PMID- 42955285 OWN - NLM STAT- Publisher LR - 20261029 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) DP - 2026 Oct 29 TI - DNA methylation analysis in urinary samples is associated with recurrence and grade progression in selected patients with pT1 low-grade urothelial bladder carcinoma. LID - 10.1007/s00428-026-04626-8 [doi] AB - Low-grade urothelial carcinoma (LGUC) has a lower risk of recurrence and grade progression than high-grade urothelial carcinoma (HGUC), although a subset of patients may develop recurrent disease and/or grade progression. The Bladder EpiCheck test (Nucleix Ltd) analyzes 15 DNA methylation biomarkers and provides a score, termed EpiScore. In this retrospective study, urine cytology and urinary methylation analysis were performed in 78 patients who subsequently received a histological diagnosis of LGUC. Patients were followed after treatment with cystoscopy and voided urine cytology every 6 months for 1 to 2 years. During follow-up, 31 of 78 patients (40%) developed recurrent disease, including 7 cases with progression to HGUC. No recurrence was observed in 47 of 78 patients (60%). At first diagnosis, an EpiScore >/= 60 was associated with recurrent neoplasia (p < 0.0001). Progression to HGUC was observed only among patients with an EpiScore >/= 60, although this finding should be interpreted cautiously because of the limited number of progression events and the absence of events in the EpiScore < 60 group. In conclusion, urinary methylation analysis may identify a subgroup of patients with LGUC associated with recurrence and grade progression to HGUC. These findings are exploratory and require prospective validation in larger and more heterogeneous cohorts. CI - (c) 2026. The Author(s). FAU - Pierconti, Francesco AU - Pierconti F AUID- ORCID: 0000-0001-9111-0165 AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. francesco.pierconti@unicatt.it. FAU - Fiorentino, Vincenzo AU - Fiorentino V AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Pathology Section, University of Messina, Messina, Italy. FAU - Larocca, Luigi Maria AU - Larocca LM AD - Unicamillus, International Medical University in Rome, Roma, Italy. FAU - Merenda, Elisabetta AU - Merenda E AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Zhang, Qianqian AU - Zhang Q AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Pizzimenti, Cristina AU - Pizzimenti C AD - Azienda Ospedaliera Papardo, Contrada Papardo, Messina, 98158, Italy. FAU - Pepe, Ludovica AU - Pepe L AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Pathology Section, University of Messina, Messina, Italy. FAU - Rossi, Esther Diana AU - Rossi ED AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Granitto, Alessia AU - Granitto A AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Molinario, Clelia AU - Molinario C AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Benvenuto, Roberta AU - Benvenuto R AD - Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome, 00168, Italy. FAU - Carlino, Angela AU - Carlino A AD - Unicamillus, International Medical University in Rome, Roma, Italy. FAU - Sacco, Emilio AU - Sacco E AD - Division of Urology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AD - Division of Urology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. FAU - Totaro, Angelo AU - Totaro A AD - Division of Urology, Agostino Gemelli School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. FAU - Martini, Maurizio AU - Martini M AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Pathology Section, University of Messina, Messina, Italy. LA - eng PT - Journal Article DEP - 20261029 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM OTO - NOTNLM OT - Bladder carcinoma OT - Methylation OT - Progression OT - Recurrence COIS- Declarations. Ethical approval: All clinicopathologic investigations were conducted according to the principles of the Declaration of Helsinki, and all information regarding the human material used in this study was managed using anonymous numerical codes. The study was approved by the local ethics committee of Messina (Prot. 24-25, 22/02/2024, AOU "G. Martino"). Informed consent: Informed consent was obtained from all subjects involved in the study. Conflict of interest: The authors declare no conflicts of interest that are directly or indirectly related to the work submitted for publication. Esther Diana Rossi, MD, PhD, is a member of the Editorial Board and discloses this relationship in accordance with journal policy. EDAT- 2026/10/29 17:36 MHDA- 2026/10/29 17:36 CRDT- 2026/10/29 12:13 PHST- 2025/09/26 00:00 [received] PHST- 2026/06/18 00:00 [accepted] PHST- 2026/05/08 00:00 [revised] PHST- 2026/10/29 17:36 [medline] PHST- 2026/10/29 17:36 [pubmed] PHST- 2026/10/29 12:13 [entrez] AID - 10.1007/s00428-026-04626-8 [pii] AID - 10.1007/s00428-026-04626-8 [doi] PST - aheadofprint SO - Virchows Arch. 2026 Oct 29. doi: 10.1007/s00428-026-04626-8. PMID- 42946445 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261027 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 46 IP - 11 DP - 2026 Nov TI - High Ubiquitin-like Protein 3 Expression Is Associated With Prolonged Recurrence-free Survival in Non-muscle-invasive Bladder Cancer. PG - 6249-6263 LID - 10.21873/anticanres.18454 [doi] AB - BACKGROUND/AIM: Current clinicopathological factors inadequately capture the biological heterogeneity of non-muscle-invasive bladder cancer (NMIBC). This study investigated the prognostic significance of ubiquitin-like protein 3 (UBL3), a molecule involved in extracellular vesicle sorting and immune regulation, in NMIBC. MATERIALS AND METHODS: Following an exploratory analysis of public RNA-sequencing databases, we evaluated tissue samples from patients who underwent transurethral resection for primary NMIBC. A discovery cohort (n=37) was assessed for UBL3 mRNA via qRT-PCR and protein expression via immunohistochemistry (IHC) quantified using digital H-scores (QuPath). A separate internal validation cohort (n=192) was subsequently evaluated by IHC. The primary endpoint was recurrence-free survival (RFS). RESULTS: The database analysis indicated that high UBL3 expression was associated with longer RFS in early-stage bladder cancer. In the discovery cohort, higher UBL3 mRNA levels were associated with prolonged RFS [hazard ratio (HR)=0.33, p=0.004]. mRNA levels also were associated with digital H-scores (rho=0.39, p=0.018). In the separate internal validation cohort, elevated UBL3 protein expression was associated with a reduced risk of recurrence. A multivariable Cox regression confirmed that a higher UBL3 H-score (HR=0.95 per 10-point increase, p=0.023), alongside a negative preoperative urine cytology and immediate intravesical chemotherapy, remained independently associated with RFS. CONCLUSION: Elevated UBL3 expression was associated with prolonged RFS in patients with NMIBC following transurethral resection of bladder tumor. While UBL3 has potential as a prognostic biomarker, establishing its definitive clinical utility will require mechanistic investigations and validation across independent, multicenter cohorts. CI - Copyright (c) 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Sano, Asuka AU - Sano A AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan; askxxx1130@gmail.com. FAU - Tamura, Keita AU - Tamura K AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Sakai, Yasuhiro AU - Sakai Y AD - Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Kahyo, Tomoaki AU - Kahyo T AD - Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Hirayama, Shoshiro AU - Hirayama S AD - Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Sekihara, Keigo AU - Sekihara K AD - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Takanashi, Yusuke AU - Takanashi Y AD - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Watanabe, Shunsuke AU - Watanabe S AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Watanabe, Kyohei AU - Watanabe K AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Watanabe, Hiromitsu AU - Watanabe H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. AD - Department of Developed Studies for Advanced Robotic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Motoyama, Daisuke AU - Motoyama D AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. AD - Department of Developed Studies for Advanced Robotic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Otsuka, Atsushi AU - Otsuka A AD - Department of Urology, Iwata City Hospital, Iwata, Japan. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Setou, Mitsutoshi AU - Setou M AD - Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Biomarkers, Tumor) RN - 0 (Ubiquitins) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/pathology/mortality/metabolism/surgery MH - Female MH - Male MH - Prognosis MH - Aged MH - *Biomarkers, Tumor/genetics/metabolism MH - Transurethral Resection of Bladder MH - *Neoplasm Recurrence, Local/genetics/pathology MH - Middle Aged MH - Disease-Free Survival MH - *Ubiquitins/genetics/metabolism MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Gene Expression Regulation, Neoplastic OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - UBL3 OT - immunohistochemistry OT - prognostic biomarker OT - recurrence-free survival EDAT- 2026/10/27 23:28 MHDA- 2026/10/27 23:29 CRDT- 2026/10/27 21:04 PHST- 2026/08/13 00:00 [received] PHST- 2026/09/08 00:00 [revised] PHST- 2026/09/16 00:00 [accepted] PHST- 2026/10/27 23:29 [medline] PHST- 2026/10/27 23:28 [pubmed] PHST- 2026/10/27 21:04 [entrez] AID - 46/11/6249 [pii] AID - 10.21873/anticanres.18454 [doi] PST - ppublish SO - Anticancer Res. 2026 Nov;46(11):6249-6263. doi: 10.21873/anticanres.18454. PMID- 42927820 OWN - NLM STAT- Publisher LR - 20261028 IS - 1873-3913 (Electronic) IS - 0898-6568 (Linking) VI - 150 DP - 2026 Oct 25 TI - Elevated GANAB fuels PD-1/PD-L1 checkpoint-mediated immune escape by maintaining PD-L1 stability in bladder cancer. PG - 112937 LID - S0898-6568(26)00597-8 [pii] LID - 10.1016/j.cellsig.2026.112937 [doi] AB - BACKGROUND: Bladder cancer (BCa) is one of the most common malignancies of the urinary system, with limited treatment options and extremely poor prognosis in advanced stages. Although immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have been approved for clinical use, the objective response rate remains low (15%-25%), and acquired resistance frequently develops. The molecular mechanisms underlying PD-L1-mediated immune evasion in bladder cancer remain incompletely understood. Post-translational modification of PD-L1, particularly N-glycosylation, stabilizes the protein and enhances its immunosuppressive function; however, the specific enzymes regulating this process have not been systematically identified in BCa. METHODS: We analyzed single-cell sequencing data from public databases to identify malignant epithelial subpopulations and constructed prognostic models using high-dimensional weighted gene co-expression network analysis (hdWGCNA), LASSO regression, and machine learning. Crucially, we performed extensive experimental validation beyond bioinformatics prediction: Ganab was stably knocked down in MB49 bladder cancer cells using lentivirus-mediated shRNA, and the effects on cell proliferation and migration were assessed by CCK-8 and wound healing assays. An orthotopic bladder cancer model was established in C57BL/6 mice by intravesical inoculation of MB49-luciferase cells, with tumor growth monitored by live bioluminescence imaging. Tumor tissues were subjected to single-cell RNA sequencing to dissect the tumor immune microenvironment (TIME) at single-cell resolution. Mechanistically, Western blotting, PNGase F deglycosylation, immunofluorescence, and bidirectional co-immunoprecipitation were employed to elucidate how GANAB regulates PD-L1 glycosylation. Flow cytometry and CellChat analysis were used to evaluate T-cell subset remodeling and PD-L1/PD-1 signaling attenuation. RESULTS: We identified a malignant epithelial subpopulation (Epi_3) characterized by high tumor stemness scores and extensive copy number variations. A 15-gene prognostic signature was successfully constructed, in which GANAB exhibited the highest predictive weight. GANAB protein expression progressively increased along the pseudotime trajectory of tumor progression. Experimentally, inhibition of Ganab significantly suppressed MB49 cell proliferation and migration in vitro, and markedly inhibited orthotopic tumor growth in vivo. Mechanistically, GANAB regulated PD-L1 N-glycosylation, yielding two distinct PD-L1 bands: a 45 kDa glycosylated form (Gly-PD-L1) and a 33 kDa non-glycosylated form (Non-gly-PD-L1). Co-immunoprecipitation confirmed that GANAB specifically interacted with non-glycosylated PD-L1 (33 kDa) but not with glycosylated PD-L1 (45 kDa), indicating that GANAB interacts with non-glycosylated PD-L1 and may facilitate its entry into the ER glycosylation pathway. Single-cell analysis of shGanab tumor tissues revealed profound remodeling of the TIME: exhausted T cells (Tex) were reduced, effector memory T cells (Tem) were increased, and PD-L1/PD-1 signaling between tumor cells and T-cell subsets was attenuated. SCENIC analysis identified Stat1 as a key upstream transcription factor, and IMvigor210 cohort analysis confirmed positive correlations among GANAB, STAT1, PD-L1, and CD8A expression. Patients with high GANAB expression exhibited poorer immunotherapeutic responses and worse prognosis. CONCLUSIONS: Our findings establish a robust prognostic model for BCa patients through integrated single-cell and bulk transcriptome analysis. More importantly, we demonstrate through both in vitro and in vivo experiments that the core gene GANAB promotes bladder cancer progression and immune evasion by regulating PD-L1 N-glycosylation along the PD-1/PD-L1 axis, thereby remodeling the tumor immune microenvironment. In the TCGA cohort, GANAB expression correlated strongly with the T-cell-inflamed gene expression profile (TEP; Spearman R = 0.85, P < 2.2e-16), indicating that GANAB-high tumors represent an inflamed yet immunotherapy-resistant phenotype. We acknowledge that the relationship between GANAB and other established biomarkers, including tumor mutation burden and PD-L1 combined positive score, as well as its expression profile across normal tissues, remains to be characterized. Furthermore, specific GANAB inhibitors are currently unavailable, and the ubiquitous expression of GANAB as a housekeeping endoplasmic reticulum enzyme raises potential on-target safety concerns that preclude immediate therapeutic targeting. Therefore, rather than advocating direct GANAB inhibition, we propose that GANAB serves as a candidate stratification biomarker and mechanistic node for glycosylation-mediated checkpoint resistance. Its clinical utility should be evaluated alongside emerging modalities such as ferroptosis-targeted nanomedicines and antibody-drug conjugates, with future efforts focused on biomarker validation and the development of tumor-specific delivery strategies before any therapeutic application can be considered. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Jin, Xuanxuan AU - Jin X AD - Department of Urology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Xu, Yi AU - Xu Y AD - Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China. FAU - Ling, Keyu AU - Ling K AD - Department of Coloproctology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Li, Haoyu AU - Li H AD - Department of Urology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Wang, Jianzhe AU - Wang J AD - Department of Urology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Liu, Jieyu AU - Liu J AD - Department of General Surgery, Lishui Second People's Hospital, Lishui, Zhejiang Province, 323000, China. FAU - Yang, Xiangchou AU - Yang X AD - Department of Hematology and Medical Oncology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: yangxiangchou@163.com. FAU - Mu, Haiqi AU - Mu H AD - Department of Urology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address: muhaiqi8877@163.com. LA - eng PT - Journal Article DEP - 20261025 PL - England TA - Cell Signal JT - Cellular signalling JID - 8904683 SB - IM OTO - NOTNLM OT - Bladder cancer OT - GANAB OT - Glycosylation OT - Immune checkpoint OT - PD-L1 OT - Single-cell RNA sequencing OT - Tumor immune microenvironment COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/25 23:29 MHDA- 2026/10/25 23:29 CRDT- 2026/10/25 20:22 PHST- 2026/07/29 00:00 [received] PHST- 2026/09/26 00:00 [revised] PHST- 2026/10/07 00:00 [accepted] PHST- 2026/10/25 23:29 [pubmed] PHST- 2026/10/25 23:29 [medline] PHST- 2026/10/25 20:22 [entrez] AID - S0898-6568(26)00597-8 [pii] AID - 10.1016/j.cellsig.2026.112937 [doi] PST - aheadofprint SO - Cell Signal. 2026 Oct 25;150:112937. doi: 10.1016/j.cellsig.2026.112937. PMID- 42923499 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261024 LR - 20261025 IS - 1792-1015 (Electronic) IS - 1792-0981 (Print) IS - 1792-0981 (Linking) VI - 32 IP - 5 DP - 2026 Nov TI - Assessment of muscularis propria invasion in urothelial bladder carcinoma using continuous-time random walk and stretched-exponential models: Comparison with VI-RADS and apparent diffusion coefficient. PG - 321 LID - 10.3892/etm.2026.13316 [doi] LID - 321 AB - Accurate assessment of muscle layer invasion in bladder cancer is required to distinguish muscle-invasive bladder cancer (MIBC) from non-MIBC (NMIBC). The present prospective study evaluated continuous-time random-walk (CTRW) and stretched-exponential model (SEM) diffusion parameters against conventional apparent diffusion coefficient (ADC) and vesical imaging-reporting and data system (VI-RADS) scores. A total of 106 patients (62 MIBC and 44 NMIBC) who underwent 3.0T multiparametric magnetic resonance imaging, including multi-b-value diffusion-weighted imaging, at The Second Affiliated Hospital of Kunming Medical University (Kunming, China) were analyzed. CTRW and SEM parameters were extracted, and VI-RADS scores were assigned. Significant differences were found between groups for VI-RADS >/=4, SEM-ADC, CTRW-alpha and CTRW-beta (P<0.05). Multivariate logistic regression identified VI-RADS >/=4 and CTRW-beta as independent predictors of muscle invasion. While VI-RADS alone achieved an area under the curve (AUC) of 0.85, the combined model incorporating SEM-ADC, CTRW-alpha and VI-RADS achieved the highest overall performance (AUC=0.91; 95% CI: 0.86-0.96), significantly outperforming VI-RADS alone (raw P=0.002, Bonferroni-corrected P=0.004). Additionally, diffusion kurtosis was positively correlated with invasion depth (r=0.62). These findings indicate that advanced diffusion parameters, particularly CTRW-alpha and SEM-ADC, effectively differentiate MIBC from NMIBC. When integrated with VI-RADS, they significantly enhance diagnostic accuracy compared with VI-RADS alone (AUC: 0.91 vs. 0.85; P=0.030). Decision curve analysis confirmed clinical utility, with the combined model providing a mean net benefit gain of 0.10 (95% CI: 0.06-0.14) across the clinically relevant threshold range, corresponding with 10 additional correct diagnoses per 100 patients. These quantitative diffusion metrics represent promising non-invasive biomarkers for guiding therapeutic decisions. CI - Copyright: (c) 2026 Wu et al. FAU - Wu, Yangying AU - Wu Y AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Zhu, Xiaofang AU - Zhu X AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Zhou, Xiaolong AU - Zhou X AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Liu, Canli AU - Liu C AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Guo, Li AU - Guo L AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Hao, Jingang AU - Hao J AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. FAU - Shang, Yunyun AU - Shang Y AD - Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China. LA - eng PT - Journal Article DEP - 20260929 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC13688612 OTO - NOTNLM OT - VI-RADS OT - apparent diffusion coefficient OT - bladder cancer OT - continuous-time random walk OT - stretched-exponential model OT - vesical imaging-reporting and data system COIS- The authors declare that they have no competing interests. EDAT- 2026/10/25 03:36 MHDA- 2026/10/25 03:37 PMCR- 2026/09/29 CRDT- 2026/10/24 11:05 PHST- 2026/02/25 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/10/25 03:37 [medline] PHST- 2026/10/25 03:36 [pubmed] PHST- 2026/10/24 11:05 [entrez] PHST- 2026/09/29 00:00 [pmc-release] AID - ETM-32-5-13316 [pii] AID - 10.3892/etm.2026.13316 [doi] PST - epublish SO - Exp Ther Med. 2026 Sep 29;32(5):321. doi: 10.3892/etm.2026.13316. eCollection 2026 Nov. PMID- 42923287 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261024 LR - 20261025 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Research progress and clinical translation prospects of multiple urinary biomarkers in non-invasive diagnosis of urothelial carcinoma. PG - 1984066 LID - 10.3389/fonc.2026.1984066 [doi] LID - 1984066 AB - Urothelial carcinoma is a common urinary malignancy with high incidence, recurrence, and mortality. Early diagnosis is pivotal for improving patient outcomes. Current standards have important limitations: cystoscopy, although the cornerstone of diagnosis and surveillance, is invasive and costly, while cytology has limited sensitivity for low-grade or early-stage lesions. Urine, as a liquid biopsy, offers a non-invasive and repeatable approach for sampling urogenital pathology, with the potential for longitudinal monitoring through serial collection. The review covers urinary multi-omics biomarkers, including cfDNA/methylation, miRNAs, extracellular vesicles (EVs), and proteomic/metabolomic signatures. We summarize their performance in early detection, staging, and postoperative monitoring. Integrated multi-analyte models, including true multi-omics assays and multiplex single-omics panels, generally outperform single biomarkers, with some panels achieving >90% sensitivity and >95% specificity in prospective cohorts. Despite progress, several challenges remain: standardization, large-scale prospective validation, and regulatory/reimbursement barriers. We conclude that urinary multi-omics diagnostics are promising complementary tools that may optimize surveillance and risk stratification. Still, limited prospective validation, lack of standardization, and the persistent risk of false-negative results constrain adoption. On current evidence, they are not positioned to replace cystoscopy, which remains the cornerstone of diagnosis and surveillance, particularly in non-muscle-invasive bladder cancer (NMIBC). However, their most realistic and immediate clinical role is as a triage tool to optimize the selective use of cystoscopy-particularly for risk-stratifying patients with hematuria, adjudicating equivocal cytology, and potentially reducing the frequency of invasive surveillance in low-risk NMIBC patients. CI - Copyright (c) 2026 Li, Wang and Gao. FAU - Li, Shuxin AU - Li S AD - Department of Urology, The First Hospital of Jilin University, Changchun, China. FAU - Wang, Lei AU - Wang L AD - Department of Urology, The First Hospital of Jilin University, Changchun, China. FAU - Gao, Baoshan AU - Gao B AD - Department of Urology, The First Hospital of Jilin University, Changchun, China. LA - eng PT - Journal Article PT - Review DEP - 20261008 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13688251 OTO - NOTNLM OT - DNA methylation OT - cell-free DNA OT - exosomes OT - liquid biopsy OT - microRNA OT - multi-omics OT - urinary biomarkers OT - urothelial carcinoma COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/25 03:36 MHDA- 2026/10/25 03:37 PMCR- 2026/10/08 CRDT- 2026/10/24 10:55 PHST- 2026/08/31 00:00 [received] PHST- 2026/09/17 00:00 [revised] PHST- 2026/09/25 00:00 [accepted] PHST- 2026/10/25 03:37 [medline] PHST- 2026/10/25 03:36 [pubmed] PHST- 2026/10/24 10:55 [entrez] PHST- 2026/10/08 00:00 [pmc-release] AID - 10.3389/fonc.2026.1984066 [doi] PST - epublish SO - Front Oncol. 2026 Oct 8;16:1984066. doi: 10.3389/fonc.2026.1984066. eCollection 2026. PMID- 42910392 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261023 LR - 20261024 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 42 IP - 4 DP - 2026 Oct-Dec TI - Deciphering the clinical significance of Beclin-1 and Bcl-2 in urothelial carcinoma of bladder. PG - 287-299 LID - 10.4103/iju.iju_77_26 [doi] AB - BACKGROUND: Considering an important interplay of Beclin-1 and Bcl-2 in autophagy, where Bcl-2 inhibits autophagy by binding and inhibiting Beclin-1, evaluation of their expressions may provide insights into the tumor biology of the clinically distinct non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MATERIALS AND METHODS: Beclin-1 and Bcl-2 expressions were examined by real-time quantitative polymerase chain reaction, Western hybridization, and immunohistochemical staining (IHC) in 47 NMIBC and 37 MIBC patients. Their expressions were evaluated in relation to patients' demographics. Autophagic vesicles (AVs)/autophagy were examined by transmission electron microscopy (TEM). RESULTS: Fold change expressions of Beclin-1 and Bcl-2, at the gene level, were observed to be asymmetrical/skewed. Significances of expressions at the mRNA level with tumor stage (P = 0.0415), grade (P = 0.0488), and size (0.0451) in the NMIBC cohort were observed, whereas Bcl-2 expression exhibited significances with stage (P = 0.0328) and tumor type (P = 0.0499) in NMIBC and MIBC (P = 0.0474) patients. Western blotting and IHC showed decreased Beclin-1 and increased Bcl-2 immunostaining with an increase in the tumor stage and grade. TEM micrographs recorded an increase in AVs/autophagy in a tumor stage and grade-dependent manner. Tumor size was identified as a predictor of short progression-free survival (P = 0.031) in NMIBC patients. The Kaplan-Meier test could not identify Beclin-1 and Bcl-2 as the predictors of survival outcomes. CONCLUSION: Beclin-1 downregulation, Bcl-2 upregulation, and increased autophagy in tumor stage and grade-dependent manner suggest their role in aggressiveness of the bladder cancer. CI - Copyright: (c) 2026 Indian Journal of Urology. FAU - Niharika AU - Niharika AD - Department of Biochemistry, University of Lucknow, Lucknow, Uttar Pradesh, India. FAU - Tripathi, Shreyansh AU - Tripathi S AD - Department of Biochemistry, University of Lucknow, Lucknow, Uttar Pradesh, India. FAU - Singhai, Atin AU - Singhai A AD - Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Goel, Apul AU - Goel A AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Kumar, Niraj AU - Kumar N AD - Centre for Biodesign and Diagnostics, Translational Health Science and Technology Institute, Faridabad, Haryana, India. FAU - Garg, Minal AU - Garg M AD - Department of Biochemistry, University of Lucknow, Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article DEP - 20260929 PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC13686718 COIS- There are no conflicts of interest. EDAT- 2026/10/23 18:31 MHDA- 2026/10/23 18:32 PMCR- 2026/10/01 CRDT- 2026/10/23 12:06 PHST- 2026/02/14 00:00 [received] PHST- 2026/05/28 00:00 [revised] PHST- 2026/06/28 00:00 [accepted] PHST- 2026/10/23 18:32 [medline] PHST- 2026/10/23 18:31 [pubmed] PHST- 2026/10/23 12:06 [entrez] PHST- 2026/10/01 00:00 [pmc-release] AID - IJU-42-287 [pii] AID - 10.4103/iju.iju_77_26 [doi] PST - ppublish SO - Indian J Urol. 2026 Oct-Dec;42(4):287-299. doi: 10.4103/iju.iju_77_26. Epub 2026 Sep 29. PMID- 42909595 OWN - NLM STAT- Publisher LR - 20261023 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) DP - 2026 Oct 23 TI - Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. PG - 101097UPJ0000000000001109 LID - 10.1097/UPJ.0000000000001109 [doi] AB - INTRODUCTION: Adequate bacillus Calmette-Guerin (BCG) therapy, as defined by the U.S. Food and Drug Administration (FDA), is widely used in clinical trial eligibility criteria and regulatory frameworks, yet its prognostic relevance in real-world practice remains incompletely understood. We evaluated the association between time-dependent completion of adequate BCG therapy and oncologic outcomes in patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC). METHODS: This retrospective cohort study included 188 patients with treatment-naive HR NMIBC treated with BCG. Adequate BCG therapy was defined according to FDA criteria, and patients were categorized according to the timing of achieving adequate BCG therapy. In a landmark analysis, Cox regression models were used to evaluate the effect of clinicopathologic characteristics and timing of adequate BCG therapy completion on conditional high-grade recurrence-free survival (HG-RFS). RESULTS: The proportion of patients completing adequate BCG therapy increased over time, reaching 61.7% by 6 months from induction initiation. Among patients included in the landmark analysis (n = 140), completion of adequate BCG therapy between 4 and 5 months after initiation of induction BCG was associated with significantly improved HG-RFS compared with completion by 4 months (hazard ratio 0.31, 95% confidence interval 0.12-0.79). CONCLUSIONS: Among patients who met FDA-defined adequate BCG criteria, completion of therapy between 4 and 5 months was associated with the most favorable oncologic outcomes observed in this cohort. These findings provide real-world context for current definitions of adequate BCG exposure and suggest that the temporal pattern of treatment delivery may be an important consideration when evaluating BCG-related outcomes. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Health Care, Iowa, USA. FAU - Myers, Amanda A AU - Myers AA AD - Department of Urology, University of Iowa Health Care, Iowa, USA. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Hopitaux Universitaires Henri Mondor, Assistance Publique - Hopitaux de Paris, Universite Paris-Est Creteil, Creteil, Paris, France. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA. FAU - Barbosa, Fernando Maciel AU - Barbosa FM AD - Department of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA. FAU - Hofland, Jackson AU - Hofland J AD - Carver College of Medicine, University of Iowa, Iowa City. FAU - Gao, Jason AU - Gao J AD - Carver College of Medicine, University of Iowa, Iowa City. FAU - Najdawi, Kenan AU - Najdawi K AD - Carver College of Medicine, University of Iowa, Iowa City. FAU - Alshare, Faris AU - Alshare F AD - Department of Urology, University of Iowa Health Care, Iowa, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Health Care, Iowa, USA. LA - eng PT - Journal Article DEP - 20261023 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - Adequate BCG OT - BCG maintenance. OT - Non-muscle invasive bladder cancer OT - Recurrence EDAT- 2026/10/23 18:31 MHDA- 2026/10/23 18:31 CRDT- 2026/10/23 11:13 PHST- 2026/10/23 18:31 [medline] PHST- 2026/10/23 18:31 [pubmed] PHST- 2026/10/23 11:13 [entrez] AID - 10.1097/UPJ.0000000000001109 [doi] PST - aheadofprint SO - Urol Pract. 2026 Oct 23:101097UPJ0000000000001109. doi: 10.1097/UPJ.0000000000001109. PMID- 42908741 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261023 LR - 20261024 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Population-specific molecular features and clinical significance of urinary tumor DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive bladder cancer. PG - 1914617 LID - 10.3389/fonc.2026.1914617 [doi] LID - 1914617 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by high recurrence rates, highlighting the need for effective, non-invasive diagnostic and risk stratification tools. Although urinary biomarkers are increasingly used worldwide, molecular data specific to Chinese NMIBC populations remain limited. This study explores the potential utility of TERT promoter and FGFR3 hotspot mutations detected in urinary tumor DNA (utDNA) in a prospective Chinese cohort. METHODS: We prospectively enrolled 106 newly diagnosed NMIBC patients between February 2023 and August 2023 at Fudan University Shanghai Cancer Center (ChiCTR2300076543). First-morning urine samples were collected prior to TURBT. A PCR-based UI-Seek assay was employed to detect hotspot mutations in the promoter region (M1: c.-146 C>T, C250T; M2: c.-124 C>T, C228T) and FGFR3 gene (M1: c.742 C>T, p.R248C; M2: c.746 C>G, p.S249C). RESULTS: The overall mutation rates for TERT promoter and FGFR3 were 49.06% and 15.09%, respectively, with a combined sensitivity of 55.66%. Compared with published study cohorts from Western countries and Japan, Chinese NMIBC patients showed differences in molecular mutation profiles. Notably, the TERT-M2 mutation was associated with tumor aggressiveness, with significant correlations observed for T1 stage (P = 0.011), high-grade tumors (P = 0.011), and high/very high EAU risk categories (P < 0.001). In the subgroup of patients with rapid recurrence within 12 months, TERT promoter mutations (particularly M2), high-grade histology, T1 stage, and high/very high EAU risk categories were significantly enriched. Conversely, FGFR3 mutations showed no significant correlation with clinicopathological parameters. Patients were stratified into early recurrence (24 months, n = 40) groups. T1 stage, high tumor grade, high/very high-risk stratification, and TERT mutations (especially the TERT-M2 subtype) were significantly associated with early recurrence (P < 0.05), whereas sex, tumor multiplicity, presence of CIS, and FGFR3 mutations showed no significant correlation with recurrence timing (P > 0.05). CONCLUSION: This study characterizes the mutational landscape of urinary tumor DNA (utDNA) in Chinese patients with non-muscle invasive bladder cancer (NMIBC). Our findings suggest that utDNA-based detection of TERT promoter mutations, particularly the M2 subtype, and FGFR3 mutations may provide complementary molecular information for recurrence risk assessment. Larger prospective multicenter studies are warranted to validate these findings and evaluate the clinical potential of utDNA as a non-invasive molecular tool in NMIBC management. CI - Copyright (c) 2026 Sun, Xie, Pan, Zhu, Shen, Gu, Ma, Jin, Wang, Ye, Zhu and Wu. FAU - Sun, Zugang AU - Sun Z AD - Department of Urology, Guangyuan Central Hospital of Sichuan Province, Guangyuan, China. AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. FAU - Xie, Run AU - Xie R AD - Department of Nursing, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Pan, Jian AU - Pan J AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Zhu, Yiping AU - Zhu Y AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Shen, Yijun AU - Shen Y AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Gu, Chengyuan AU - Gu C AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Ma, Chunguang AU - Ma C AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Jin, Shengming AU - Jin S AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Wang, Huina AU - Wang H AD - Acornmed Biotechnology Co., Ltd, Beijing, China. FAU - Ye, Dingwei AU - Ye D AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Zhu, Yao AU - Zhu Y AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. FAU - Wu, Junlong AU - Wu J AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Shanghai Medical College, Fudan University, Shanghai, China. LA - eng PT - Journal Article DEP - 20261007 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13683090 OTO - NOTNLM OT - Chinese population OT - FGFR3 mutations OT - TERT promoter mutations OT - non-muscle-invasive bladder cancer OT - qPCR OT - urinary liquid biopsy COIS- Author HW was employed by Acornmed Biotechnology Co., Ltd. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/23 05:33 MHDA- 2026/10/23 05:34 PMCR- 2026/10/07 CRDT- 2026/10/23 03:16 PHST- 2026/06/20 00:00 [received] PHST- 2026/09/18 00:00 [revised] PHST- 2026/09/21 00:00 [accepted] PHST- 2026/10/23 05:34 [medline] PHST- 2026/10/23 05:33 [pubmed] PHST- 2026/10/23 03:16 [entrez] PHST- 2026/10/07 00:00 [pmc-release] AID - 10.3389/fonc.2026.1914617 [doi] PST - epublish SO - Front Oncol. 2026 Oct 7;16:1914617. doi: 10.3389/fonc.2026.1914617. eCollection 2026. PMID- 42903929 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261022 LR - 20261022 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 79 IP - 3 DP - 2026 TI - FGFR3 mRNA expression in urothelial bladder cancer: Associations with tumor phenotype without prognostic impact. PG - 295-302 LID - 10.5173/ceju.2025.0236 [doi] AB - INTRODUCTION: FGFR3 (fibroblast growth factor receptor 3) is frequently altered in urothelial carcinoma and has been associated with less aggressive disease, but its prognostic relevance remains uncertain. We evaluated tumor FGFR3 mRNA expression levels in relation to clinicopathological phenotype and outcomes in bladder cancer. MATERIAL AND METHODS: Fresh-frozen tumor tissue from 80 urothelial carcinomas (54 non-muscle-invasive, 26 muscle-invasive) was used for RNA extraction and quantitative PCR. FGFR3 expression levels were normalized to pooled controls and log(10)-transformed. Associations with invasiveness, grade, and survival were assessed using logistic and Cox regression, with discrimination quantified by the area under the curve (AUC) and calibration by the Brier score. RESULTS: Higher FGFR3 expression was independently associated with non-muscle-invasive disease (OR 6.35, 95% CI: 2.14-18.83; p <0.001; AUC 0.74; Brier 0.180) and low grade (OR 5.99, 1.78-20.13; p = 0.004; AUC 0.74; Brier 0.189). FGFR3 was not associated with overall survival (HR 0.52, 95% CI: 0.25-1.06; p = 0.072). In the NMIBC subset, FGFR3 was not associated with recurrence-free survival (HR 1.09, 0.37-3.20; p = 0.880). Age (HR 1.03, 0.98-1.09; p = 0.191) and grade (HR 2.16, 0.78-5.94; p = 0.137) were also non-significant. CONCLUSIONS: Tumor FGFR3 mRNA expression was strongly associated with a less aggressive phenotype but showed no independent prognostic value for survival in this cohort. FGFR3 may support phenotypic assessment at diagnosis, while its prognostic role warrants validation in larger studies. CI - Copyright by Polish Urological Association. FAU - Pakovski, Kiril AU - Pakovski K AD - Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Markova, Marija AU - Markova M AD - Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Janchulev, Josif AU - Janchulev J AD - University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Ambardjieva, Martina AU - Ambardjieva M AD - PHI University Clinic for Surgical Diseases St. Naum Ohridski, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University, North Macedonia. FAU - Gavrilovska-Brzanov, Aleksandra AU - Gavrilovska-Brzanov A AD - University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Josifovska, Slavica AU - Josifovska S AD - Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Saidi, Skender AU - Saidi S AD - University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia. FAU - Panov, Sasho AU - Panov S AD - Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, North Macedonia. LA - eng PT - Journal Article DEP - 20260509 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC13682537 OTO - NOTNLM OT - FGFR3 OT - biomarkers OT - bladder cancer OT - gene expression OT - prognosis OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2026/10/22 17:33 MHDA- 2026/10/22 17:34 PMCR- 2026/01/01 CRDT- 2026/10/22 14:50 PHST- 2025/10/01 00:00 [received] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/10/22 17:34 [medline] PHST- 2026/10/22 17:33 [pubmed] PHST- 2026/10/22 14:50 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - CEJU-79-03-0236 [pii] AID - 10.5173/ceju.2025.0236 [doi] PST - ppublish SO - Cent European J Urol. 2026;79(3):295-302. doi: 10.5173/ceju.2025.0236. Epub 2026 May 9. PMID- 42903705 OWN - NLM STAT- MEDLINE DCOM- 20261022 LR - 20261027 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Reprogramming innate immune memory in bladder cancer: the proposed bone marrow-bladder axis and next-generation BCG-based immunotherapies. PG - 1945559 LID - 10.3389/fimmu.2026.1945559 [doi] LID - 1945559 AB - Intravesical Bacillus Calmette-Guerin (BCG) remains the standard adjuvant treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), yet the mechanisms underlying its durable clinical benefit and treatment resistance remain incompletely understood. Although BCG has traditionally been regarded as a local immunotherapy, emerging clinical and preclinical evidence suggests that intravesical BCG can induce trained-immunity-associated systemic immune changes, including alterations in circulating innate immune responses and hematopoietic programming. In this Review, we propose the bone marrow-bladder axis as a hypothesis-generating conceptual framework linking local microbial sensing with systemic hematopoietic responses that may contribute to sustained myeloid and adaptive antitumor immunity. Building upon this framework, we further introduce the Failure-to-Train (FTT) model, which proposes that selected immune-training-related mechanisms may contribute to heterogeneous patterns of BCG failure through disruption of productive immune training at distinct stages of the proposed immune-training circuit. Finally, we discuss the implications of this framework for biomarker development, experimental validation and mechanism-guided immunotherapy. By considering systemic immune training as a potential contributor to BCG responses, this Review provides a conceptual framework for investigating treatment response and resistance and for developing testable strategies for next-generation immunotherapy. CI - Copyright (c) 2026 Yang, Guo, Shen, Sun, Ma and Tang. FAU - Yang, Meng AU - Yang M AD - Department of Geriatric, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. FAU - Guo, Yu AU - Guo Y AD - Department of Colorectal and Anal Surgery, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. FAU - Shen, Yu-Zhao AU - Shen YZ AD - Department of Urology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. FAU - Sun, Yan-Li AU - Sun YL AD - Department of General Practice, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. FAU - Ma, Dai-Ju AU - Ma DJ AD - Department of Emergency, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. FAU - Tang, Yuan-Jia AU - Tang YJ AD - Department of Urology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20261006 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Immunity, Innate MH - *BCG Vaccine/immunology/therapeutic use/administration & dosage MH - *Immunotherapy/methods MH - Animals MH - *Urinary Bladder Neoplasms/immunology/therapy MH - *Immunologic Memory MH - Trained Immunity MH - *Bone Marrow/immunology MH - *Urinary Bladder/immunology MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC13681358 OTO - NOTNLM OT - BCG immunotherapy OT - BCG resistance OT - bladder cancer OT - precision immunotherapy OT - trained immunity COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/22 17:33 MHDA- 2026/10/22 17:34 PMCR- 2026/10/06 CRDT- 2026/10/22 14:11 PHST- 2026/07/22 00:00 [received] PHST- 2026/08/31 00:00 [revised] PHST- 2026/09/07 00:00 [accepted] PHST- 2026/10/22 17:34 [medline] PHST- 2026/10/22 17:33 [pubmed] PHST- 2026/10/22 14:11 [entrez] PHST- 2026/10/06 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1945559 [doi] PST - epublish SO - Front Immunol. 2026 Oct 6;17:1945559. doi: 10.3389/fimmu.2026.1945559. eCollection 2026. PMID- 42901828 OWN - NLM STAT- Publisher LR - 20261020 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 Oct 20 TI - Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis. LID - S2588-9311(26)00275-0 [pii] LID - 10.1016/j.euo.2026.10.001 [doi] AB - BACKGROUND: Clinical T1 micropapillary urothelial carcinoma of the bladder is an aggressive variant histology for which early radical cystectomy (RC) is commonly recommended. However, there remain conflicting data on whether conditions in carefully selected patients may be managed with initial bladder-sparing approaches without compromising oncologic outcomes. OBJECTIVE: The objective is to systematically review and synthesize the available literature comparing bladder-sparing approaches, such as Bacillus Calmette-Guerin (BCG) therapy, and early RC outcomes in clinical stage 1 primary tumor (cT1) micropapillary carcinoma of the bladder. DESIGN, SETTING, AND PARTICIPANTS: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and Cochrane Handbook for Systematic Reviews of Interventions. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: The primary end points were overall survival (OS) and cancer-specific survival (CSS). The included articles were descriptively assessed and time-to-event analysis was performed for select endpoints. RESULTS AND LIMITATIONS: Among 461 identified reports, nine retrospective studies met the criteria for quantitative analysis, encompassing 9402 patients of whom 9287 (99%) had non-muscle-invasive bladder cancer (NMIBC) and 1033 (11%) had a micropapillary subtype. A total of 625 patients (62%) underwent bladder-sparing approaches, whereas 392 (39%) underwent early RC. Of the bladder-sparing approaches, 88% of patients received intravesical BCG therapy. For a bladder-sparing approach for cT1 disease with a micropapillary component, pooled unadjusted hazard ratios were not statistically significant for CSS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 0.60-2.88, p = 0.5) and OS (HR 0.85, 95% CI 0.68-1.07, p = 0.16) compared with early RC. Data evaluating bladder-sparing strategies beyond BCG were limited. CONCLUSIONS: NMIBC with micropapillary features is an aggressive disease conventionally managed with early RC. In retrospective cohorts of selected patients with micropapillary cT1, available unadjusted data did not provide clear evidence of statistically significant differences in CSS or OS between initial bladder-sparing approaches and early RC. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Patel, Sagar R AU - Patel SR AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Rauf, Mikael AU - Rauf M AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Geng, Yimin AU - Geng Y AD - Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hinojosa-Gonzalez, David AU - Hinojosa-Gonzalez D AD - Department of Urology, Baylor College of Medicine, Houston, TX, USA. FAU - Black, Joseph B AU - Black JB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lee, Taeweon AU - Lee T AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Myers, Amanda A AU - Myers AA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Guo, Charles AU - Guo C AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Li, Roger AU - Li R AD - Department of Urology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University, Chicago, IL, USA. FAU - Agarwal, Piyush AU - Agarwal P AD - Department of Urology, University of Chicago, Chicago, IL, USA. FAU - Williams, Stephen AU - Williams S AD - Department of Surgery, Division of Urology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Alhalabi, Omar AU - Alhalabi O AD - Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Molinette Hospital, Turin, Italy. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article DEP - 20261020 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Bladder-sparing therapy OT - Micropapillary OT - Radical cystectomy EDAT- 2026/10/20 23:29 MHDA- 2026/10/20 23:29 CRDT- 2026/10/20 21:56 PHST- 2026/02/22 00:00 [received] PHST- 2026/09/01 00:00 [revised] PHST- 2026/10/01 00:00 [accepted] PHST- 2026/10/20 23:29 [medline] PHST- 2026/10/20 23:29 [pubmed] PHST- 2026/10/20 21:56 [entrez] AID - S2588-9311(26)00275-0 [pii] AID - 10.1016/j.euo.2026.10.001 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 Oct 20:S2588-9311(26)00275-0. doi: 10.1016/j.euo.2026.10.001. PMID- 42898355 OWN - NLM STAT- MEDLINE DCOM- 20261020 LR - 20261022 IS - 1532-2807 (Electronic) IS - 1219-4956 (Print) IS - 1219-4956 (Linking) VI - 32 DP - 2026 TI - Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity. PG - 1612553 LID - 10.3389/pore.2026.1612553 [doi] LID - 1612553 AB - AIMS: Grade heterogeneity is one of the most debated issues in the grading of urothelial carcinomas. The 2022 WHO classification states that approximately one-third of urothelial carcinomas exhibit grade heterogeneity and suggests that the presence of >/=5% high-grade component may justify classification as high-grade. Nevertheless, the need for further evidence was also emphasized. This study aimed to evaluate the prognostic impact of the high-grade component in urothelial carcinomas with grade heterogeneity and to determine a threshold value for high-grade proportion that is clinically meaningful for grading. METHODS: This retrospective study included 180 cases of non-muscle-invasive urothelial carcinoma with grade heterogeneity, diagnosed between January 2019 and August 2022 on TUR specimens, with available clinical data. Recurrence and survival time were assessed. Cases with >90% high-grade component were excluded. RESULTS: Recurrence was observed in 26.7% of cases. The two-year survival rate was 73.3%. While no significant association was found between recurrence and the proportion of high-grade component, survival time significantly decreased as the proportion of high-grade component increased. ROC curve analysis identified 27.5% as the cut-off value associated with adverse prognosis. CONCLUSION: In non-muscle-invasive urothelial carcinomas, the proportion of high-grade component showed a strong association with survival. Together with literature findings, our results suggest that a threshold higher than 5% may be more appropriate for assigning tumors to the high-grade category. Nonetheless, risk stratification incorporating tumor size and extent remains essential for prognostic evaluation. CI - Copyright (c) 2026 Alkan, Dogan, Turk Alkan and Onder. FAU - Alkan, Gokhan Veli AU - Alkan GV AD - Department of Pathology, Faculty of Medicine, Ordu University, Ordu, Turkiye. FAU - Dogan, Kutsal AU - Dogan K AD - Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye. FAU - Turk Alkan, Meltem AU - Turk Alkan M AD - Department of Pathology, Faculty of Medicine, Ordu University, Ordu, Turkiye. FAU - Onder, Evrim AU - Onder E AD - Department of Pathology, Ankara Etlik City Hospital, Ankara, Turkiye. LA - eng PT - Journal Article DEP - 20261005 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 SB - IM MH - Humans MH - Prognosis MH - Female MH - Neoplasm Grading MH - Retrospective Studies MH - Male MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery MH - Non-Muscle Invasive Bladder Neoplasms MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality MH - Neoplasm Recurrence, Local/pathology MH - Aged MH - Survival Rate MH - Middle Aged MH - Aged, 80 and over PMC - PMC13677559 OTO - NOTNLM OT - bladder cancer OT - grading OT - heterogeneity OT - invasion OT - uro-oncology COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/20 11:33 MHDA- 2026/10/20 11:34 PMCR- 2026/10/05 CRDT- 2026/10/20 07:31 PHST- 2026/07/15 00:00 [received] PHST- 2026/09/16 00:00 [revised] PHST- 2026/09/21 00:00 [accepted] PHST- 2026/10/20 11:34 [medline] PHST- 2026/10/20 11:33 [pubmed] PHST- 2026/10/20 07:31 [entrez] PHST- 2026/10/05 00:00 [pmc-release] AID - 1612553 [pii] AID - 10.3389/pore.2026.1612553 [doi] PST - epublish SO - Pathol Oncol Res. 2026 Oct 5;32:1612553. doi: 10.3389/pore.2026.1612553. eCollection 2026. PMID- 42891336 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261017 LR - 20261019 IS - 2996-9514 (Electronic) IS - 2996-9506 (Print) IS - 2996-9514 (Linking) VI - 3 IP - 1 DP - 2026 Mar TI - Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation. PG - e70081 LID - 10.1002/imo2.70081 [doi] LID - e70081 AB - Bladder cancer (BCa) ranks among the most frequently diagnosed malignancies worldwide. The advent of high-throughput sequencing technologies has revealed distinct urinary microbial signatures that differentiate healthy individuals from BCa patients. While growing evidence implicates microbiota dysbiosis in the pathogenesis, progression, and therapeutic response of BCa, establishing a direct causal relationship remains challenging due to methodological heterogeneity across studies. This review summarizes the current knowledge of the human urinary microbiome (urobiome) in both health and disease states. It critically examines the evidence for microbiome involvement in BCa and discusses potential mechanisms, such as chronic inflammation, immune modulation, and genotoxin production, through which the microbiota may influence carcinogenesis. Furthermore, we explore the translational potential of urinary microbiota profiling as a biomarker for risk stratification and for predicting responses to intravesical therapies and immunotherapy in BCa patients. Unraveling the complexities of host-microbe interactions in BCa is essential for developing novel strategies for its prevention and personalized treatment. CI - (c) 2026 The Author(s). iMetaOmics published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science. FAU - Xu, Haoxiang AU - Xu H AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Li, Zhibiao AU - Li Z AUID- ORCID: 0000-0003-2669-7451 AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Yang, Lin AU - Yang L AUID- ORCID: 0009-0007-4275-1135 AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Zheng, Jun AU - Zheng J AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Li, Weijia AU - Li W AUID- ORCID: 0009-0005-9665-8206 AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Liao, Rulin AU - Liao R AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Huang, Wenxue AU - Huang W AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Sun, Boyuan AU - Sun B AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Li, Zhuohang AU - Li Z AUID- ORCID: 0009-0005-6852-2790 AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Ma, Cunzhen AU - Ma C AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Yang, Xunguo AU - Yang X AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. FAU - Wang, Zongwei AU - Wang Z AD - Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA. FAU - Zhao, Jie AU - Zhao J AD - NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening School of Pharmaceutical Sciences, Southern Medical University Guangzhou China. FAU - Cheng, Bisheng AU - Cheng B AUID- ORCID: 0009-0005-2300-3583 AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. AD - Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA. AD - Department of Clinical Oncology, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China. AD - Department of Clinical Oncology The University of Hong Kong-Shenzhen Hospital Shenzhen China. FAU - Wu, Peng AU - Wu P AD - Department of Urology Nanfang Hospital, Southern Medical University Guangzhou China. LA - eng PT - Journal Article PT - Review DEP - 20260214 PL - Australia TA - IMetaOmics JT - iMetaOmics JID - 9919033199506676 PMC - PMC13674431 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - carcinogenesis OT - dysbiosis OT - immunotherapy OT - personalized medicine OT - urinary microbiome COIS- The authors declare no conflicts of interest. EDAT- 2026/10/17 23:38 MHDA- 2026/10/17 23:39 PMCR- 2026/02/14 CRDT- 2026/10/17 21:47 PHST- 2025/12/24 00:00 [received] PHST- 2026/01/26 00:00 [revised] PHST- 2026/01/28 00:00 [accepted] PHST- 2026/10/17 23:39 [medline] PHST- 2026/10/17 23:38 [pubmed] PHST- 2026/10/17 21:47 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - IMO270081 [pii] AID - 10.1002/imo2.70081 [doi] PST - epublish SO - IMetaOmics. 2026 Feb 14;3(1):e70081. doi: 10.1002/imo2.70081. eCollection 2026 Mar. PMID- 42889172 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261017 LR - 20261019 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 10 DP - 2026 Oct TI - NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in non-high-risk non-muscle invasive bladder cancer surveillance. PG - e70283 LID - 10.1002/bco2.70283 [doi] LID - e70283 AB - OBJECTIVE: This study aimed to quantify discrepancies in non-high-risk non-muscle-invasive bladder cancer (NMIBC) stratification between the National Institute for Health and Care Excellence (NICE) and the European Association of Urology (EAU) guidelines, compare discriminative performance for predicting recurrence, estimate potentially missed recurrences under shorter surveillance and calculate per-patient surveillance costs. PATIENTS AND METHODS: This is a retrospective cohort study of patients undergoing transurethral resection of bladder tumour (TURBT) at a UK tertiary centre (2018-2020). Patients with low- or intermediate-risk NMIBC who completed 5-year follow-up or experienced recurrence were included. Each patient was stratified according to both NICE and EAU (WHO 1973) guidelines. Outcomes included recurrence rate, discriminative accuracy (Harrell's C-index), proportion of recurrences occurring beyond NICE discharge timepoints and surveillance cost based on NHS reference prices. RESULTS: Of the 158 eligible patients (78% male; mean age 68 years), 40% were assigned different risk categories depending on guideline applied. NICE classified significantly more patients as low risk than EAU (31.1% vs. 12.7%; p < 0.001). Overall, 5-year recurrence was 48.7%, with no significant difference in recurrence rates between corresponding risk groups under each guideline. NICE demonstrated superior discrimination (C-index 0.605 vs. 0.511; p = 0.006). Among NICE low-risk patients, 45% of recurrences occurred between Years 2 and 5-beyond the recommended 1-year discharge point. Mean per-patient surveillance cost was pound1412 under NICE versus pound3525 under EAU, representing a 60% reduction. CONCLUSIONS: NICE can reduce cost with comparable discrimination efficiency to EAU guidelines, but risks missed recurrences; a hybrid NICE-EAU approach may offer the optimal balance. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Ibrahim, Youssef AU - Ibrahim Y AUID- ORCID: 0000-0003-0931-9707 AD - Guy's Hospital London UK. FAU - Ribeiro, Luis AU - Ribeiro L AUID- ORCID: 0000-0003-1828-2117 AD - St George's Hospital London UK. FAU - Heelan, Michelle AU - Heelan M AD - Guy's Hospital London UK. FAU - Spazzapam, Martina AU - Spazzapam M AUID- ORCID: 0000-0003-1153-5249 AD - Guy's Hospital London UK. AD - Centre for Transplantation, Urology and Kidney Disease King's College London UK. FAU - Macaskill, Findlay AU - Macaskill F AD - Guy's Hospital London UK. FAU - Fernando, Kiyara AU - Fernando K AD - Guy's Hospital London UK. FAU - Ahmed, Adham AU - Ahmed A AUID- ORCID: 0000-0003-1745-3025 AD - Addenbrooke's Hospital Cambridge UK. FAU - Hussien, Ahmed AU - Hussien A AD - St George's Hospital London UK. FAU - Gad, Mohammed AU - Gad M AUID- ORCID: 0000-0003-0969-5067 AD - Guy's Hospital London UK. FAU - Chakravarti, Soumitra AU - Chakravarti S AD - Guy's Hospital London UK. FAU - Mokbel, Sara AU - Mokbel S AD - Guy's Hospital London UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's Hospital London UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Guy's Hospital London UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's Hospital London UK. FAU - Abughanem, Yasmin AU - Abughanem Y AD - Guy's Hospital London UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's Hospital London UK. LA - eng PT - Journal Article DEP - 20261014 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC13669066 OTO - NOTNLM OT - EAU guidelines OT - NICE guidelines OT - NMIBC OT - cost-effectiveness OT - non-muscle-invasive bladder cancer OT - recurrence OT - risk stratification OT - surveillance COIS- The authors declare no conflicts of interest. EDAT- 2026/10/17 23:13 MHDA- 2026/10/17 23:14 PMCR- 2026/10/14 CRDT- 2026/10/17 08:31 PHST- 2026/07/12 00:00 [received] PHST- 2026/08/23 00:00 [revised] PHST- 2026/09/09 00:00 [accepted] PHST- 2026/10/17 23:14 [medline] PHST- 2026/10/17 23:13 [pubmed] PHST- 2026/10/17 08:31 [entrez] PHST- 2026/10/14 00:00 [pmc-release] AID - BCO270283 [pii] AID - 10.1002/bco2.70283 [doi] PST - epublish SO - BJUI Compass. 2026 Oct 14;7(10):e70283. doi: 10.1002/bco2.70283. eCollection 2026 Oct. PMID- 42889117 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261017 LR - 20261019 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer. PG - 1861461 LID - 10.3389/fonc.2026.1861461 [doi] LID - 1861461 AB - BACKGROUND: Recurrence remains common after initial transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC). This study aimed to identify routinely available clinicopathological, treatment-related, and inflammatory factors associated with recurrence and to characterize recurrence-free survival (RFS). METHODS: This retrospective cohort included patients with pathologically confirmed Ta, T1, or primary carcinoma in situ (CIS) who underwent initial TURBT between January 2017 and December 2023. Multivariable logistic regression was used as the primary analysis to evaluate factors associated with documented recurrence during follow-up. Cox proportional hazards regression was performed as a complementary analysis incorporating recurrence timing and censoring. Kaplan-Meier analysis, sensitivity analyses, restricted cubic spline analysis, time-dependent receiver operating characteristic analysis, and bootstrap-corrected model evaluation were also performed. RESULTS: Among 605 patients, 237 (39.2%) experienced recurrence during a median follow-up of 34.0 months. Multiple tumors were associated with higher recurrence odds and hazard (adjusted odds ratio [OR], 1.88; 95% confidence interval [CI], 1.27-2.78; adjusted hazard ratio [HR], 1.62; 95% CI, 1.25-2.10). Higher recurrence odds and hazards were also associated with increasing tumor diameter, T1 or primary CIS, high-grade pathology, concomitant CIS, and higher baseline neutrophil-to-lymphocyte ratio. Maintenance intravesical therapy was inversely associated with recurrence (adjusted OR, 0.49; 95% CI, 0.34-0.72; adjusted HR, 0.62; 95% CI, 0.47-0.81). Estimated RFS rates were 81.5%, 63.8%, and 54.1% at 1, 3, and 5 years, respectively. The bootstrap-corrected area under the curve was 0.769 for the logistic model, and the bootstrap-corrected Harrell's C-index was 0.739 for the Cox model. CONCLUSIONS: Recurrence after initial TURBT was associated with greater tumor burden, adverse pathological characteristics, concomitant CIS, and higher baseline neutrophil-to-lymphocyte ratio. Maintenance intravesical therapy showed an inverse observational association with recurrence. These routinely available factors may support postoperative risk stratification and risk-adapted surveillance. CI - Copyright (c) 2026 Yuan, Li, Zhang and Gao. FAU - Yuan, Fang AU - Yuan F AD - Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. FAU - Li, Xiong AU - Li X AD - Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. FAU - Zhang, Jing AU - Zhang J AD - Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. FAU - Gao, Jian-Yong AU - Gao JY AD - Department of Urology, Panzhihua Central Hospital, Panzhihua, Sichuan, China. LA - eng PT - Journal Article DEP - 20261001 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13668579 OTO - NOTNLM OT - carcinoma in situ OT - intravesical therapy OT - neutrophil-to-lymphocyte ratio OT - non-muscle-invasive bladder cancer OT - recurrence OT - transurethral resection of bladder tumor COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/17 23:13 MHDA- 2026/10/17 23:14 PMCR- 2026/10/01 CRDT- 2026/10/17 07:39 PHST- 2026/04/21 00:00 [received] PHST- 2026/07/31 00:00 [revised] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/10/17 23:14 [medline] PHST- 2026/10/17 23:13 [pubmed] PHST- 2026/10/17 07:39 [entrez] PHST- 2026/10/01 00:00 [pmc-release] AID - 10.3389/fonc.2026.1861461 [doi] PST - epublish SO - Front Oncol. 2026 Oct 1;16:1861461. doi: 10.3389/fonc.2026.1861461. eCollection 2026. PMID- 42885914 OWN - NLM STAT- Publisher LR - 20261016 IS - 1437-4331 (Electronic) IS - 1434-6621 (Linking) DP - 2026 Oct 19 TI - Enhanced detection of bladder cancer using machine learning analysis of routine urinary sediment data. LID - 10.1515/cclm-2026-1514 [doi] AB - OBJECTIVES: Bladder cancer (BC) has a high recurrence rate, requiring invasive procedures such as cystoscopy and histopathological examination. Existing non-invasive methods, including urine cytology, fluorescence in situ hybridization (FISH), and tumor markers like nuclear matrix protein 22 (NMP22), have limited sensitivity and specificity. This study assessed the potential of low-cost, non-invasive urine sediment data for BC detection using a machine learning model. METHODS: Urine sediment data from 1,341 patients (577 with BC and 764 with benign conditions) were obtained using a fully automated urinary particle analyzer (UF-5000). One preoperative sample per patient was included. A soft-voting ensemble model combining random forest and logistic regression was developed. Class imbalance was addressed using the Synthetic Minority Oversampling Technique, and feature selection was guided by the variance inflation factor. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), balanced accuracy, sensitivity, and specificity, with 95 % confidence intervals estimated via bootstrapping. Model stability was evaluated using fivefold cross-validation. RESULTS: The ensemble model achieved an AUC of 0.89, with a sensitivity of 0.80 and specificity of 0.88. Balanced accuracy was 0.84, and cross-validation demonstrated stable performance (accuracy 0.80). Feature importance analysis identified atypical cells and red blood cells as the most influential predictors, particularly of non-muscle-invasive BC. CONCLUSIONS: This urine sediment-based, non-invasive approach shows promise for the early detection and monitoring of BC. Its integration into routine clinical workflows may enhance screening efficiency without additional costs. CI - (c) 2026 Walter de Gruyter GmbH, Berlin/Boston. FAU - Okuyama, Rikiya AU - Okuyama R AUID- ORCID: 0000-0002-9904-3451 AD - Department of Clinical Laboratory, NTT Medical Center Tokyo, Tokyo, Japan. FAU - Horiuchi, Hajime AU - Horiuchi H AD - Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan. AD - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan. FAU - Nakamura, Masaki AU - Nakamura M AD - Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan. FAU - Muroya, Mitsuaki AU - Muroya M AD - Department of Clinical Laboratory, NTT Medical Center Tokyo, Tokyo, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20261019 PL - Germany TA - Clin Chem Lab Med JT - Clinical chemistry and laboratory medicine JID - 9806306 SB - IM OTO - NOTNLM OT - atypical cells OT - bladder cancer OT - cost-effective screening OT - machine learning OT - urinary sediment EDAT- 2026/10/16 11:38 MHDA- 2026/10/16 11:38 CRDT- 2026/10/16 09:04 PHST- 2026/09/09 00:00 [received] PHST- 2026/09/29 00:00 [accepted] PHST- 2026/10/16 11:38 [medline] PHST- 2026/10/16 11:38 [pubmed] PHST- 2026/10/16 09:04 [entrez] AID - cclm-2026-1514 [pii] AID - 10.1515/cclm-2026-1514 [doi] PST - aheadofprint SO - Clin Chem Lab Med. 2026 Oct 19. doi: 10.1515/cclm-2026-1514. PMID- 42881413 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261019 IS - 1475-2867 (Print) IS - 1475-2867 (Electronic) IS - 1475-2867 (Linking) VI - 26 IP - 1 DP - 2026 Jul 22 TI - Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development. LID - 10.1186/s12935-026-04424-x [doi] LID - 340 AB - Bladder cancer is a prevalent global urological malignancy characterized by significant gender differences in incidence and prognosis, ranging from indolent non-muscle invasive bladder cancer with high recurrence rates to lethal muscle invasive subtypes accompanied by distant metastasis and poor survival outcomes. Despite advances in molecular biology and therapy, the treatment options for bladder cancer remain limited. Recent advancements have shed light on the promising potential of bladder cancer organoids (BCOs) as a tool to bridge the gap between basic science, clinical therapeutics, and drug development. By modeling tumor heterogeneity, tumor microenvironment (TME) and dynamic responses to treatment, BCOs have emerged as a transformative platform in cancer research. This narrative review systematically discusses the translational potential of BCOs, focusing on their establishment and culture protocols, as well as applications in basic science, clinical therapeutics and drug development. At present, however, the clinical translation of BCOs is still constrained by multiple challenges, including absence of standardized culture protocols, inter-patient biological variability, incomplete reconstruction of the native TME, complex operational procedures and insufficient clinical validation. Addressing these limitations in the future will be critical to fully unlock the clinical potential of BCOs and accelerate their widespread use in translational research. CI - (c) 2026. The Author(s). FAU - Zhong, Xuesong AU - Zhong X AD - Department of Urology, Chuxiong Yi Autonomous Prefecture People's Hospital & The Fourth Affiliated Hospital of Dali University, Chuxiong, 675000, Yunnan, China. FAU - Wang, Gang AU - Wang G AD - Department of Urology, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, 315101, Zhejiang, China. FAU - Zhang, Honghan AU - Zhang H AD - Precision Medicine Center, Chuxiong Yi Autonomous Prefecture People's Hospital & The Fourth Affiliated Hospital of Dali University, Chuxiong, 675000, Yunnan, China. FAU - Shi, Yongjing AU - Shi Y AD - Postdoctoral Research Workstation of Hefei Industrial Investment Holding (Group) Co., LTD, Hefei, 230071, Anhui, China. FAU - Xiong, Zeyi AU - Xiong Z AD - Radiation Oncology Department, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, China. schxiong2024@163.com. FAU - Han, Jian AU - Han J AUID- ORCID: 0009-0005-5022-2239 AD - Precision Medicine Center, Chuxiong Yi Autonomous Prefecture People's Hospital & The Fourth Affiliated Hospital of Dali University, Chuxiong, 675000, Yunnan, China. hanjian2025@163.com. LA - eng GR - No.: 2024ZK01/National Clinical Key Specialty Construction Project of Cardiovascular Medicine at Chuxiong People's Hospital/ GR - No.: 2021YYXM01/Scientific Research Project of Chuxiong Medical College/ PT - Journal Article PT - Review DEP - 20260722 PL - England TA - Cancer Cell Int JT - Cancer cell international JID - 101139795 PMC - PMC13673677 OTO - NOTNLM OT - Bladder cancer organoids OT - Drug development OT - Immune microenvironment OT - Precision medicine COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/10/16 05:33 MHDA- 2026/10/16 05:34 PMCR- 2026/07/22 CRDT- 2026/10/16 00:23 PHST- 2025/12/31 00:00 [received] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/10/16 05:34 [medline] PHST- 2026/10/16 05:33 [pubmed] PHST- 2026/10/16 00:23 [entrez] PHST- 2026/07/22 00:00 [pmc-release] AID - 10.1186/s12935-026-04424-x [pii] AID - 4424 [pii] AID - 10.1186/s12935-026-04424-x [doi] PST - epublish SO - Cancer Cell Int. 2026 Jul 22;26(1):340. doi: 10.1186/s12935-026-04424-x. PMID- 42880421 OWN - NLM STAT- Publisher LR - 20261022 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) DP - 2026 Oct 15 TI - Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study. LID - S0090-4295(26)00668-0 [pii] LID - 10.1016/j.urology.2026.10.010 [doi] AB - OBJECTIVE: To evaluate whether diet quality around the time of diagnosis is associated with risks of recurrence and progression among individuals with non-muscle invasive bladder cancer (NMIBC). METHODS: We conducted a prospective cohort study within a large integrated healthcare system. A total of 1,143 adults with newly diagnosed primary NMIBC were enrolled between 2015 and 2019. Dietary intake 12 months prior was assessed using food frequency questionnaires. Four diet quality indices were calculated-American Cancer Society guidelines, alternative Healthy Eating Index, 2020 Healthy Eating Index (HEI), Healthy Plant-Based Dietary Index-and then categorized into quartiles (Q). Recurrence and progression were determined through chart review approximately 2 years after diagnosis. Kaplan-Meier curves visualized recurrence-free survival, and multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) were estimated, with analyses stratified by treatment. RESULTS: Among the 1,143 participants, 325 (28.4%) experienced recurrence and 52 (4.5%) had progression over 2 years. Higher diet quality was associated with lower recurrence risk for the HEI (Q4 vs Q1: HR=0.72; 95% CI, 0.52-0.99). In stratified analyses, lower recurrence risk was more pronounced among patients who did not receive intravesical chemotherapy mitomycin C (Q4 vs Q1 HR=0.60; 95% CI, 0.41-0.90). No associations were observed for progression. CONCLUSIONS: Of the four diet quality indices, the highest HEI quartile was associated with lower NMIBC recurrence risk, particularly among patients not treated with mitomycin C. Diet quality may be an important modifiable risk factor in NMIBC survivorship. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. Electronic address: isaac.j.ergas@kp.org. FAU - Zimbalist, Alexa AU - Zimbalist A AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. FAU - Haque, Reina AU - Haque R AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California USA. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California USA. FAU - Wang, Zinian AU - Wang Z AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York USA. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, Downey, California USA. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente South San Francisco Medical Center, Oakland, California USA. FAU - Quesenberry, Charles P Jr AU - Quesenberry CP Jr AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York USA. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA USA. LA - eng GR - R01 CA172855/CA/NCI NIH HHS/United States GR - R01 CA257480/CA/NCI NIH HHS/United States GR - U01 CA280991/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20261015 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/15 23:30 MHDA- 2026/10/15 23:30 CRDT- 2026/10/15 20:22 PHST- 2026/03/31 00:00 [received] PHST- 2026/08/31 00:00 [revised] PHST- 2026/10/07 00:00 [accepted] PHST- 2026/10/15 23:30 [medline] PHST- 2026/10/15 23:30 [pubmed] PHST- 2026/10/15 20:22 [entrez] AID - S0090-4295(26)00668-0 [pii] AID - 10.1016/j.urology.2026.10.010 [doi] PST - aheadofprint SO - Urology. 2026 Oct 15:S0090-4295(26)00668-0. doi: 10.1016/j.urology.2026.10.010. PMID- 42869744 OWN - NLM STAT- Publisher LR - 20261013 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) DP - 2026 Oct 13 TI - Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study. LID - S2405-4569(26)00221-X [pii] LID - 10.1016/j.euf.2026.09.008 [doi] AB - OBJECTIVE: To investigate the oncological and patient-reported outcomes (PROs) of patients receiving sequential gemcitabine/docetaxel (Gem/Doce) for Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). DESIGN, SETTING, AND PARTICIPANTS: Patients enrolled in prospective databases at two academic medical institutions who received Gem/Doce -for BCG-unresponsive NMIBC between January 2021 and January 2026 were included. The primary outcome was the 3-mo and 12-mo high-grade recurrence-free survival (HGRFS). Secondary outcomes included progression-free survival (PFS), radical treatment-free survival (RTFS), cancer-specific survival (CSS) and overall survival (OS). Subgroup analyses compared BCG refractory versus early-relapsing and carcinoma in situ (CIS) +/- papillary versus papillary-only disease. Adverse events were reported with the common terminology criteria for adverse events version 6.0. PRO assessments were performed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and NMIBC24 questionnaires. RESULTS AND LIMITATIONS: Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively. PFS at 12 mo was 90.1% (82.0-98.9%), RTFS 89.1% (80.5-98.7%), CSS 98.0% (94.3-100.0%), and OS 90.6% (80.9-100.0%). The BCG-refractory subgroup was associated with a higher risk of high-grade recurrence compared with early-relapsing (hazard ratio 2.44, 95% CI = 1.01-5.94, p = 0.048), whereas no difference was observed between CIS +/- papillary and papillary-only subgroup (p = 0.20). Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported. Urinary symptom burden, global function, and functional outcomes remained stable during treatment. CONCLUSIONS: In this multi-institutional prospective study, intravesical Gem/Doce demonstrated favorable intermediate oncological outcomes for BCG-unresponsive NMIBC. Gem/Doce was well tolerated with few reported side effects and preserved PROs. CI - Copyright (c) 2026 European Association of Urology. All rights reserved. FAU - Tan, Yu Guang AU - Tan YG AD - Department of Urology, Singapore General Hospital, Singapore; Department of Urology, Duke University Medical Center, Durham, USA. Electronic address: yuguangtan90@gmail.com. FAU - Dudinec, J AU - Dudinec J AD - Department of Urology, Duke University Medical Center, Durham, USA. FAU - Kamat, A M AU - Kamat AM AD - University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Lim, B J H AU - Lim BJH AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Ghoreifi, A AU - Ghoreifi A AD - Department of Urology, Duke University Medical Center, Durham, USA. FAU - Yuen, J S P AU - Yuen JSP AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Chen, K AU - Chen K AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Kanesvaran, R AU - Kanesvaran R AD - National Cancer Center Singapore, Singapore. FAU - Chan, J AU - Chan J AD - National Cancer Center Singapore, Singapore. FAU - Shah, A M AU - Shah AM AD - Department of Urology, Duke University Medical Center, Durham, USA. FAU - Tay, K J AU - Tay KJ AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Abern, M R AU - Abern MR AD - Department of Urology, Duke University Medical Center, Durham, USA. LA - eng PT - Journal Article DEP - 20261013 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM OTO - NOTNLM OT - BCG-unresponsive OT - Bladder sparing therapies OT - Non-muscle-invasive bladder cancer EDAT- 2026/10/13 23:36 MHDA- 2026/10/13 23:36 CRDT- 2026/10/13 22:03 PHST- 2026/06/02 00:00 [received] PHST- 2026/08/11 00:00 [revised] PHST- 2026/09/29 00:00 [accepted] PHST- 2026/10/13 23:36 [medline] PHST- 2026/10/13 23:36 [pubmed] PHST- 2026/10/13 22:03 [entrez] AID - S2405-4569(26)00221-X [pii] AID - 10.1016/j.euf.2026.09.008 [doi] PST - aheadofprint SO - Eur Urol Focus. 2026 Oct 13:S2405-4569(26)00221-X. doi: 10.1016/j.euf.2026.09.008. PMID- 42866931 OWN - NLM STAT- MEDLINE DCOM- 20261013 LR - 20261025 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 33 IP - 10 DP - 2026 Oct TI - Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer. PG - e70656 LID - e70656 [pii] LID - 10.1111/iju.70656 [doi] AB - OBJECTIVE: To examine the clinical usefulness of EphA2 detected on urinary extracellular vesicles (uEphA2) for bladder cancer detection and for estimating the risk of intravesical recurrence after transurethral resection of bladder tumor (TURBT). METHODS: An enzyme-linked immunosorbent assay was established to measure EphA2-positive urinary extracellular vesicles. The diagnostic cohort comprised 191 participants, including 120 patients with bladder cancer and 71 controls. RESULTS: uEphA2 concentrations were higher in patients with bladder cancer than in controls. Receiver operating characteristic analysis yielded an area under the curve of 0.679, with 46.7% sensitivity and 87.3% specificity. Among patients evaluable for post-TURBT recurrence, high uEphA2 levels were associated with shorter intravesical recurrence-free survival. This association remained significant in multivariable Cox regression analysis after adjustment for the EORTC risk score and age. CONCLUSIONS: uEphA2 showed modest diagnostic accuracy but high specificity and was independently associated with intravesical recurrence. These results support its potential use as a non-invasive urinary marker for post-TURBT risk stratification. CI - (c) 2026 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Hashimoto, Mamoru AU - Hashimoto M AUID- ORCID: 0000-0002-4137-942X AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Tomiyama, Eisuke AU - Tomiyama E AD - Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Inoki, Lan AU - Inoki L AUID- ORCID: 0009-0004-1633-5654 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Miki, Koji AU - Miki K AUID- ORCID: 0009-0007-5755-0467 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Nakayama, Takahito AU - Nakayama T AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Fujimoto, Saizo AU - Fujimoto S AUID- ORCID: 0000-0002-4004-6287 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Toyoda, Shingo AU - Toyoda S AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Kikuchi, Takashi AU - Kikuchi T AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Ukekawa, Ryo AU - Ukekawa R AD - FUJIFILM Wako Pure Chemical Corporation, Hyogo, Japan. FAU - Yamamoto, Yutaka AU - Yamamoto Y AUID- ORCID: 0000-0002-7555-6295 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Minami, Takafumi AU - Minami T AUID- ORCID: 0000-0002-6934-3760 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Yoshimura, Kazuhiro AU - Yoshimura K AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Fujita, Kazutoshi AU - Fujita K AUID- ORCID: 0000-0002-6774-7497 AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. LA - eng PT - Journal Article PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, EphA2) RN - 0 (EPHA2 protein, human) SB - IM MH - Humans MH - Female MH - *Neoplasm Recurrence, Local/urine/diagnosis MH - *Biomarkers, Tumor/urine MH - *Urinary Bladder Neoplasms/surgery/urine/pathology/diagnosis MH - Aged MH - *Receptor, EphA2/analysis/metabolism/urine MH - Male MH - Transurethral Resection of Bladder MH - *Extracellular Vesicles/metabolism MH - Middle Aged MH - Case-Control Studies MH - Enzyme-Linked Immunosorbent Assay MH - ROC Curve MH - Urinary Bladder/pathology/surgery MH - Disease-Free Survival MH - Sensitivity and Specificity PMC - PMC13659636 OTO - NOTNLM OT - EphA2 OT - bladder cancer OT - extracellular vesicles OT - recurrence OT - urinary biomarker COIS- Ryo Ukekawa is an employee of FUJIFILM Wako Pure Chemical Corporation. The other authors declare no conflicts of interest. EDAT- 2026/10/13 17:37 MHDA- 2026/10/13 17:38 PMCR- 2026/10/13 CRDT- 2026/10/13 15:07 PHST- 2026/09/06 00:00 [revised] PHST- 2026/05/13 00:00 [received] PHST- 2026/09/24 00:00 [accepted] PHST- 2026/10/13 17:38 [medline] PHST- 2026/10/13 17:37 [pubmed] PHST- 2026/10/13 15:07 [entrez] PHST- 2026/10/13 00:00 [pmc-release] AID - e70656 [pii] AID - IJU70656 [pii] AID - 10.1111/iju.70656 [doi] PST - ppublish SO - Int J Urol. 2026 Oct;33(10):e70656. doi: 10.1111/iju.70656. PMID- 42866795 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261013 LR - 20261013 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 9 DP - 2026 Sep 30 TI - An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation. PG - 341 LID - 10.21037/tau-2026-0557 [doi] LID - 341 AB - BACKGROUND: Recurrence remains a major clinical challenge in non-muscle-invasive bladder cancer (NMIBC), highlighting the need for interpretable tools for individualized risk assessment. This study aimed to develop a transparent model that estimates recurrence risk in patients with NMIBC after transurethral resection of bladder tumor (TURBT) and intravesical instillation. METHODS: We reviewed 200 patients with NMIBC who received TURBT and postoperative intravesical instillation at the Department of Urology, The Affiliated Hospital of Xuzhou Medical University, from January to December 2020. Recurrence status was determined from follow-up records. We collected baseline variables, preoperative laboratory results, and clinicopathological data. Patients were divided into training and validation sets (7:3). We screened predictors with multivariate Cox regression, least absolute shrinkage and selection operator (LASSO)-Cox regression, and Boruta analysis before building the nomogram. Model performance was checked with receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). Shapley additive explanations (SHAP) analysis was used for interpretation, and an R Shiny application was built. RESULTS: Of the 200 patients, recurrence was observed in 90 cases. The final identified predictors were smoking, hypertension, hemoglobin (Hb), and serum Na. The nomogram showed stable performance, with time-dependent areas under the curves (AUCs) of 0.862, 0.918, and 0.948 in the training set and 0.725, 0.870, and 0.919 in the validation set at 12, 36, and 60 months, respectively. SHAP analysis ranked Hb as the main contributor; higher Hb and serum Na indicated lower recurrence risk, while smoking and hypertension indicated higher risk. CONCLUSIONS: This model provided internally validated recurrence-risk estimates; external validation and usability testing are required before clinical use. CI - (c) AME Publishing Company. FAU - Li, Bingjie AU - Li B AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Ji, Guangyun AU - Ji G AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Wang, Wenting AU - Wang W AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Guo, Lina AU - Guo L AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. LA - eng PT - Journal Article DEP - 20260811 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13657710 OTO - NOTNLM OT - Intravesical instillation OT - interpretable prediction model OT - non-muscle-invasive bladder cancer (NMIBC) OT - recurrence COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2026-0557/coif). The authors have no conflicts of interest to declare. EDAT- 2026/10/13 18:26 MHDA- 2026/10/13 18:27 PMCR- 2026/09/30 CRDT- 2026/10/13 14:55 PHST- 2026/06/15 00:00 [received] PHST- 2026/08/04 00:00 [accepted] PHST- 2026/10/13 18:27 [medline] PHST- 2026/10/13 18:26 [pubmed] PHST- 2026/10/13 14:55 [entrez] PHST- 2026/09/30 00:00 [pmc-release] AID - tau-15-9-341 [pii] AID - 10.21037/tau-2026-0557 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Sep 30;15(9):341. doi: 10.21037/tau-2026-0557. Epub 2026 Aug 11. PMID- 42863296 OWN - NLM STAT- Publisher LR - 20261012 IS - 1873-4367 (Electronic) IS - 0927-7765 (Linking) VI - 270 DP - 2026 Oct 8 TI - Ultrasound-controlled therapeutics for bladder cancer: Mechanisms, recent advances, and future perspectives. PG - 116248 LID - S0927-7765(26)00836-2 [pii] LID - 10.1016/j.colsurfb.2026.116248 [doi] AB - Bladder cancer remains a significant clinical challenge, characterised by a high recurrence rate and substantial healthcare costs. Although advances in surgery, systemic therapy, and intravesical treatment have improved clinical outcomes, treatment-related toxicity, therapeutic resistance, and the persistently poor prognosis of advanced disease highlight the need for more effective therapeutic strategies. Ultrasound-based micro/nanotherapeutics offer a promising approach that combines deep tissue penetration with high focal precision in a non-invasive, externally controllable manner. This review summarises recent advances in ultrasound-mediated therapeutic strategies for bladder cancer, including ultrasound-mediated drug and gene delivery, sonodynamic therapy (SDT), and high-intensity focused ultrasound (HIFU) ablation. It describes how ultrasound, often in combination with microbubbles or nanobubbles, enhances the delivery of chemotherapeutic drugs and therapeutic genes through cavitation-induced permeabilisation of biological barriers. It then examines the mechanisms underlying SDT-induced reactive oxygen species generation and its integration with chemodynamic therapy, chemotherapy, immunotherapy, and imaging, alongside tumour microenvironment (TME) modulation strategies such as hypoxia relief and antioxidant depletion that augment SDT efficacy. Finally, it discusses HIFU ablation, including nanoparticle-assisted strategies that enhance tumour destruction through combined thermal and mechanical effects. The limitations of each modality and future directions for clinical translation, including standardisation of ultrasound devices and exposure parameters, optimisation of nanoplatform design, and integration of artificial intelligence-based predictive models, are also discussed. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Loke, Yean Leng AU - Loke YL AD - Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia. FAU - Lim, Xin Yun AU - Lim XY AD - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. FAU - Beishenaliev, Adilet AU - Beishenaliev A AD - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Goh, Sook Jing AU - Goh SJ AD - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. FAU - Dian, Zhang AU - Dian Z AD - Department of Immunology, Xi'an Medical University, Xi'an, 710021, China. FAU - Leo, Bey Fen AU - Leo BF AD - Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Center of Excellence for Innovative Medical Devices, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Nanotechnology & Catalysis Research Centre (NANOCAT), Institute for Advanced Studies, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Universiti Malaya Research Centre for Biopharmaceuticals and Advanced Therapeutics (UBAT), Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Kah, James Chen Yong AU - Kah JCY AD - Department of Biomedical Engineering, National University of Singapore, Singapore, 117583, Singapore. FAU - Misran, Misni AU - Misran M AD - Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Nagai, Takashi AU - Nagai T AD - Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. FAU - Imae, Toyoko AU - Imae T AD - Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan; Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan. FAU - Chik, Zamri AU - Chik Z AD - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Universiti Malaya Research Centre for Biopharmaceuticals and Advanced Therapeutics (UBAT), Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Chung, Lip Yong AU - Chung LY AD - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Teo, Yin Yin AU - Teo YY AD - Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. FAU - Ong, Teng Aik AU - Ong TA AD - Department of Surgery, Universiti Malaya Medical Centre, Kuala Lumpur, 50603, Malaysia. Electronic address: taong@um.edu.my. FAU - Hwang, Dennis W AU - Hwang DW AD - Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan; Biomedical Translation Research Center, Academia Sinica, Taipei, 11529, Taiwan. Electronic address: dwhwang@ibms.sinica.edu.tw. FAU - Kiew, Lik Voon AU - Kiew LV AD - Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Center of Excellence for Innovative Medical Devices, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Universiti Malaya Research Centre for Biopharmaceuticals and Advanced Therapeutics (UBAT), Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; Department of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu, 30068, Taiwan. Electronic address: lvkiew@um.edu.my. LA - eng PT - Journal Article PT - Review DEP - 20261008 PL - Netherlands TA - Colloids Surf B Biointerfaces JT - Colloids and surfaces. B, Biointerfaces JID - 9315133 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Drug delivery OT - High-intensity focused ultrasound (HIFU) OT - Sonodynamic therapy (SDT) OT - Ultrasound COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/13 00:16 MHDA- 2026/10/13 00:16 CRDT- 2026/10/12 18:09 PHST- 2026/09/06 00:00 [received] PHST- 2026/09/30 00:00 [revised] PHST- 2026/10/08 00:00 [accepted] PHST- 2026/10/13 00:16 [medline] PHST- 2026/10/13 00:16 [pubmed] PHST- 2026/10/12 18:09 [entrez] AID - S0927-7765(26)00836-2 [pii] AID - 10.1016/j.colsurfb.2026.116248 [doi] PST - aheadofprint SO - Colloids Surf B Biointerfaces. 2026 Oct 8;270:116248. doi: 10.1016/j.colsurfb.2026.116248. PMID- 42860325 OWN - NLM STAT- Publisher LR - 20261011 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) DP - 2026 Oct 11 TI - Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence. LID - 10.1111/bju.70488 [doi] AB - OBJECTIVES: To review prognostic and treatment-response biomarkers for non-muscle-invasive bladder cancer (NMIBC), with particular attention to biological function, specimen type, assay method, statistical evidence, and possible clinical use. METHODS: We conducted a focused narrative search of PubMed, Web of Science, and the Cochrane Library for English-language human studies published from January 2015 to August 2026, supplemented by earlier pivotal studies and reference-list screening. Priority was given to NMIBC cohorts reporting recurrence, progression, survival, or response to intravesical therapy. We considered cohort specificity, sample size, multivariable analysis, testing in an independent population, and assay standardisation. RESULTS: Tumour-tissue markers such as stromal antigen 2 (STAG2), fibroblast growth factor receptor 3 (FGFR3), fibroblast activation protein-alpha, the urokinase plasminogen activator system, and cadherins are linked to chromosomal stability, growth-factor signalling, stromal remodelling, extracellular-matrix invasion, and epithelial-mesenchymal transition. Urinary RNAs and plasma circulating tumour DNA permit non-invasive sampling, although results depend on specimen handling and assay conditions. Blood-derived inflammatory indices are inexpensive but non-specific. Most evidence comes from retrospective single-cohort studies; reported effects and cut-offs are not always consistent, and few markers materially improve clinicopathological models. CONCLUSIONS: None of the biomarkers reviewed can currently replace guideline-based risk stratification or cystoscopic surveillance. Future studies should define assays and thresholds prospectively, test them in independent cohorts, and show that adding a biomarker improves prediction and patient management at an acceptable cost. CI - (c) 2026 BJU International. FAU - Wang, Jinghong AU - Wang J AUID- ORCID: 0009-0006-5535-8001 AD - Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. AD - Postgraduate Training Base Alliance of Zhejiang Provincial People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Zhao, Yitao AU - Zhao Y AD - Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China. FAU - Ye, Yushan AU - Ye Y AD - Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China. FAU - Qi, Xiaolong AU - Qi X AD - Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. FAU - Zhang, Dahong AU - Zhang D AD - Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. AD - Postgraduate Training Base Alliance of Zhejiang Provincial People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Duan, Shiwei AU - Duan S AUID- ORCID: 0000-0001-7682-2877 AD - Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China. FAU - Wei, Haibin AU - Wei H AUID- ORCID: 0000-0001-6255-922X AD - Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. LA - eng GR - ZCLMS25H0501/Zhejiang Provincial Natural Science Foundation of China/ GR - 2025HY0102/Medical and Health Science Program of Zhejiang Province/ PT - Journal Article PT - Review DEP - 20261011 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM OTO - NOTNLM OT - BCG OT - biomarkers OT - liquid biopsy OT - non-muscle-invasive bladder cancer OT - prognosis OT - progression OT - recurrence EDAT- 2026/10/11 23:30 MHDA- 2026/10/11 23:30 CRDT- 2026/10/11 21:52 PHST- 2026/10/11 23:30 [medline] PHST- 2026/10/11 23:30 [pubmed] PHST- 2026/10/11 21:52 [entrez] AID - 10.1111/bju.70488 [doi] PST - aheadofprint SO - BJU Int. 2026 Oct 11. doi: 10.1111/bju.70488. PMID- 42859100 OWN - NLM STAT- Publisher LR - 20261010 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) DP - 2026 Oct 10 TI - Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience. LID - S1078-1439(26)00737-4 [pii] LID - 10.1016/j.urolonc.2026.09.006 [doi] AB - OBJECTIVE: To describe our 20-year experience with second look Transurethral Resection of Bladder Tumor (SL-TURBT) for high-risk non muscle invasive bladder cancer (NMIBC), and whether it was associated with better response to adjuvant intravesical therapy (IVT) and prognosis. METHODS: Retrospective review of our quality assurance TURBT database between 2000 and 2024. All patients with high risk NMIBC who received IVT were included in the study. SL-TURBT was defined as TURBT within 8 weeks of the initial TURBT or if labelled by the clinician as such. Patients were divided into those who received SL-TURBT vs. those who did not. Patients were followed with cystoscopy and urine cytology every 3 months for the first 2 years, then every 6 months for years 3 to 5, then annually thereafter. Annual upper tract imaging was also performed. Kaplan-Meier method was used to depict high grade recurrence (HGRFS) and progression-free (PFS) survival. RESULTS: Of 853 patients were included in the study, 41% received SL-TURBT. Median time between initial and re-TURBT was 5.9 weeks (IQR 4.0-7.1 weeks). Indications for SL-TURBT included absence of detrusor in specimen (35%), T1 high grade disease (32%), Ta high grade (13%), incomplete resection (16%) and CIS (4%). Patients who received IVT exhibited improved 3 years' HGRFS with SL-TURBT (58% compared to 40% without SL-TURBT, log rank P = 0.008). There was no significant difference in PFS. CONCLUSION: Patients with high risk NMIBC who received a SL-TURBT prior to IVT exhibited improved HGRFS compared to those who received IVT without SL-TURBT. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Klugman, Yakov AU - Klugman Y AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Cordero, Nicholas M AU - Cordero NM AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Harrington, Grace AU - Harrington G AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Khan, Mohammad AU - Khan M AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Metherell, Joshua AU - Metherell J AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Giangrasso, Ava AU - Giangrasso A AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Carlson, Jordan E AU - Carlson JE AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Tariq, Rafay AU - Tariq R AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Abd-Elhamid, Mariam AU - Abd-Elhamid M AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Rehman, Saffa AU - Rehman S AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Clark, Collin AU - Clark C AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Jing, Zhe AU - Jing Z AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Webster, Bradley AU - Webster B AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Li, Qiang AU - Li Q AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Guru, Khurshid A AU - Guru KA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Hussein, Ahmed A AU - Hussein AA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ahmed.aly@roswellpark.org. LA - eng PT - Journal Article DEP - 20261010 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM OTO - NOTNLM OT - Intravesical therapy OT - NMIBC OT - Non-muscle invasive bladder cancer OT - Recurrence OT - Repeat resection OT - Second look TURBT COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/11 04:08 MHDA- 2026/10/11 04:08 CRDT- 2026/10/10 21:58 PHST- 2026/04/17 00:00 [received] PHST- 2026/07/24 00:00 [revised] PHST- 2026/09/12 00:00 [accepted] PHST- 2026/10/11 04:08 [medline] PHST- 2026/10/11 04:08 [pubmed] PHST- 2026/10/10 21:58 [entrez] AID - S1078-1439(26)00737-4 [pii] AID - 10.1016/j.urolonc.2026.09.006 [doi] PST - aheadofprint SO - Urol Oncol. 2026 Oct 10:S1078-1439(26)00737-4. doi: 10.1016/j.urolonc.2026.09.006. PMID- 42858596 OWN - NLM STAT- Publisher LR - 20261010 IS - 1365-229X (Electronic) IS - 0009-9260 (Linking) VI - 103 DP - 2025 Dec 9 TI - MRI morphometric features and apparent diffusion coefficients predict muscle invasion in VI-RADS 3 bladder cancers. PG - 107206 LID - S0009-9260(25)00411-8 [pii] LID - 10.1016/j.crad.2025.107206 [doi] AB - AIM: The present study investigated the clinical value of tumor MRI morphometric features and apparent diffusion coefficient (ADC) for predicting muscle invasion in bladder cancer of the vesical imaging reporting and data system (VI-RADS) 3. MATERIALS AND METHODS: Patients with VI-RADS 3 urothelial carcinoma of the bladder who had undergone radical cystectomy (RC) or partial cystectomy (PC) at our hospital between January 2018 and December 2024 were included. Two radiologists independently quantified tumor morphometrics and ADC parameters under expert supervision. RESULTS: A total of 96 patients were included, with 52 and 44 in the non-muscle invasive bladder cancer (NMIBC) group and muscle invasive bladder cancer (MIBC) group, respectively. Variables screened in the least absolute shrinkage and selection operator (LASSO) regression were the vertical diameter of the tumors, ADC(min) of the tumors, ADC(mean) of the tumors, and ADC(mean) of the tumors' bases. Logistic multifactorial analysis showed that ADC(min) of the tumors emerged as the sole independent predictor of MIBC (p<0.001) [OR=0.361 (95%CI: 0.21-0.62), p<0.001], with each 0.1 x 10(-3) mm(2)/s increment reducing MIBC risk by 63.9 %. The area under the ROC curve for diagnosing MIBC and NMIBC with ADC(min) of the tumor was 0.946 (95%CI: 0.904-0.988), achieving 88.6 % sensitivity and 90.4 % specificity at the cut off value of 0.854 x 10(-3) mm(2)/s. CONCLUSIONS: The ADC(min) of the tumor is the sole MRI-derived biomarker for predicting muscle invasion in VI-RADS 3 bladder cancer and is a valuable adjunct in the diagnosis. CI - Copyright (c) 2025. Published by Elsevier Ltd. FAU - Wang, Z AU - Wang Z AD - The First Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Jiang, H AU - Jiang H AD - The First Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Hu, C AU - Hu C AD - The First Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Zhang, H AU - Zhang H AD - Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Zhu, R AU - Zhu R AD - Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Zhang, J AU - Zhang J AD - Department of Case Management, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Zhu, Y AU - Zhu Y AD - The First Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. FAU - Zhang, Y AU - Zhang Y AD - Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. Electronic address: sinvye@163.com. FAU - Li, J AU - Li J AD - The First Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. Electronic address: lijun@kmmu.edu.cn. LA - eng PT - Journal Article DEP - 20251209 PL - England TA - Clin Radiol JT - Clinical radiology JID - 1306016 SB - IM COIS- Conflict of interest The authors declare no conflict of interest. EDAT- 2026/10/11 04:08 MHDA- 2026/10/11 04:08 CRDT- 2026/10/10 19:20 PHST- 2025/04/11 00:00 [received] PHST- 2025/10/21 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2026/10/11 04:08 [medline] PHST- 2026/10/11 04:08 [pubmed] PHST- 2026/10/10 19:20 [entrez] AID - S0009-9260(25)00411-8 [pii] AID - 10.1016/j.crad.2025.107206 [doi] PST - aheadofprint SO - Clin Radiol. 2025 Dec 9;103:107206. doi: 10.1016/j.crad.2025.107206. PMID- 42857447 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261010 LR - 20261012 IS - 2090-6900 (Print) IS - 2090-6919 (Electronic) IS - 2090-6919 (Linking) VI - 2026 DP - 2026 TI - Late Penile Urethral Involvement of Urothelial Carcinoma After Radical Cystectomy: Diagnostic Challenge in Distinguishing Urethral Recurrence From Metastatic Disease. PG - 4918822 LID - 10.1155/cris/4918822 [doi] LID - 4918822 AB - Penile involvement of urothelial carcinoma is a rare clinical entity typically arising from primary pelvic tumours and is usually associated with advanced disease and poor prognosis. However, distinguishing between true penile metastasis and late urethral recurrence is challenging, particularly in patients with urethral preservation after radical cystectomy (RC). We report the case of a 77-year-old male with a history of high-grade invasive urothelial carcinoma (pT2a N0) with concomitant carcinoma in situ (CIS), treated with RC and uretero-ileal urinary diversion with urethral preservation. Ten years after surgery, the patient presented with a painful mass at the base of the penis accompanied by solid urethral discharge. Biopsy of the urethral content confirmed high-grade papillary urothelial carcinoma (G3) with invasion of the lamina propria. Multimodal imaging studies demonstrated a solid tumour involving the proximal third of the penile urethra with extension into the corpus spongiosum and tunica albuginea, alongside a suspicious left inguinal lymph node. The patient underwent radical penectomy and left laparoscopic inguinal lymphadenectomy. Histopathological examination confirmed high-grade invasive urothelial carcinoma of the penile urethra, invading the corpus spongiosum and tunica albuginea (pT2 N0), with free surgical margins. Immunohistochemical profiling was not performed due to limited archival material, preventing definitive distinction between urethral recurrence and metastatic disease. No adjuvant systemic therapy was administered. At 2 years of follow-up, the patient remains disease-free on surveillance imaging. This case highlights the unusual late presentation of urothelial carcinoma involving the penis and underscores the diagnostic challenge in distinguishing urethral recurrence from true metastatic disease in the absence of molecular data. Long-term surveillance, including thorough physical examination, is essential even many years after initial treatment. CI - Copyright (c) 2026 Vanessa Talavera Cobo et al. Case Reports in Surgery published by John Wiley & Sons Ltd. FAU - Talavera Cobo, Vanessa AU - Talavera Cobo V AUID- ORCID: 0009-0000-2425-9795 AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Tapia Tapia, Mario Daniel AU - Tapia Tapia MD AUID- ORCID: 0000-0002-9040-3828 AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Calva Lopez, Andres AU - Calva Lopez A AUID- ORCID: 0009-0006-2503-9368 AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Munoz Bastidas, Carmina Alejandra AU - Munoz Bastidas CA AUID- ORCID: 0009-0000-1175-5706 AD - Urology Department Clinica Universidad de Navarra St. Marquesado de Santa Marta 1 Madrid 28027 Spain cun.es. FAU - Labairu Huerta, Luis AU - Labairu Huerta L AUID- ORCID: 0000-0002-3882-4203 AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Sanchez Zalabardo, Daniel AU - Sanchez Zalabardo D AUID- ORCID: 0009-0003-1803-580X AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Robles Garcia, Jose Enrique AU - Robles Garcia JE AUID- ORCID: 0000-0001-5698-641X AD - Urology Department Clinica Universidad de Navarra Avenue Pio XII, 36 Pamplona 31008 Navarra Spain cun.es. FAU - Minana Lopez, Bernardino AU - Minana Lopez B AUID- ORCID: 0000-0001-7745-5650 AD - Urology Department Clinica Universidad de Navarra St. Marquesado de Santa Marta 1 Madrid 28027 Spain cun.es. LA - eng PT - Journal Article DEP - 20261009 PL - United States TA - Case Rep Surg JT - Case reports in surgery JID - 101580191 PMC - PMC13650596 OTO - NOTNLM OT - late recurrence OT - metastasis OT - penectomy OT - perineal mass OT - tunica albuginea OT - urethral recurrence OT - urothelial cancer COIS- The authors declare no conflicts of interest. EDAT- 2026/10/11 05:07 MHDA- 2026/10/11 05:08 PMCR- 2026/10/09 CRDT- 2026/10/10 15:42 PHST- 2025/07/26 00:00 [received] PHST- 2026/08/01 00:00 [revised] PHST- 2026/09/03 00:00 [accepted] PHST- 2026/10/11 05:08 [medline] PHST- 2026/10/11 05:07 [pubmed] PHST- 2026/10/10 15:42 [entrez] PHST- 2026/10/09 00:00 [pmc-release] AID - CRIS4918822 [pii] AID - 10.1155/cris/4918822 [doi] PST - epublish SO - Case Rep Surg. 2026 Oct 9;2026:4918822. doi: 10.1155/cris/4918822. eCollection 2026. PMID- 42853326 OWN - NLM STAT- Publisher LR - 20261009 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Oct 9 TI - Institutional adherence, complication rates, and intravesical recurrence with intraoperative mitomycin C during radical nephroureterectomy. LID - 10.1007/s11255-026-05434-4 [doi] AB - PURPOSE: We evaluated institutional adherence, complication rates, and intravesical recurrence (iVR) with intraoperative intravesical mitomycin C (MMC) instillation immediately after bladder cuff closure during radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). METHODS: This retrospective single-centre study included patients with UTUC who underwent RNU at Zealand University Hospital (2017-2023). The primary endpoint was adherence to the intraoperative intravesical MMC protocol following its implementation in 2018. Secondary endpoints were 90-day postoperative complications (Clavien-Dindo classification [CDC]) and iVR within 24 months. Cumulative incidence functions accounted for death as a competing event, and multivariable Fine-Gray regression was performed. RESULTS: Among 140 patients who underwent RNU, 101 received intraoperative intravesical MMC while one received it postoperatively. The institutional adherence cohort comprised 116 patients treated after protocol implementation, of whom 99 (85.3%) received MMC. Among the 17 who did not, reasons were bladder leakage (8, 47.1%), previous bladder cancer (3, 17.6%), and undocumented rationale (6, 35.3%). Major postoperative complications (CDC >/= III) did not differ significantly between groups (9.8% MMC vs 7.9% no-MMC, p = 1.0). The 24-month cumulative incidence of iVR was lower with MMC (25.0% vs 45.0%; p = 0.013). In multivariable competing-risk analysis, MMC remained independently associated with reduced iVR (subdistribution hazard ratio 0.40, 95% CI 0.20-0.78). CONCLUSION: Intraoperative MMC instillation after bladder cuff closure achieved high institutional adherence with no significant increase in major postoperative complications and achieved a low 24-month incidence of iVR. As the comparison group was non-contemporaneous, the oncological findings are exploratory. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Reeler, Stine H AU - Reeler SH AUID- ORCID: 0000-0002-8285-4020 AD - Department of Urology, Copenhagen University Hospital, Zealand University Hospital Roskilde, Sygehusvej 10, 4000, Roskilde, Denmark. sfhe@regionsjaelland.dk. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. sfhe@regionsjaelland.dk. FAU - Nadler, Naomi AU - Nadler N AUID- ORCID: 0000-0002-1416-2153 AD - Department of Urology, Copenhagen University Hospital, Zealand University Hospital Roskilde, Sygehusvej 10, 4000, Roskilde, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Laursen, Rose B AU - Laursen RB AUID- ORCID: 0009-0000-5161-5302 AD - Department of Urology, Copenhagen University Hospital, Zealand University Hospital Roskilde, Sygehusvej 10, 4000, Roskilde, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AUID- ORCID: 0000-0002-4347-739X AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Thomsen, Frederik F AU - Thomsen FF AUID- ORCID: 0000-0001-8865-6968 AD - Department of Urology, Copenhagen University Hospital, Zealand University Hospital Roskilde, Sygehusvej 10, 4000, Roskilde, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Vasquez, Juan L AU - Vasquez JL AUID- ORCID: 0009-0001-8005-3545 AD - Department of Urology, Copenhagen University Hospital, Zealand University Hospital Roskilde, Sygehusvej 10, 4000, Roskilde, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20261009 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Intravesical chemotherapy OT - MMC adherence OT - Mitomycin C OT - Nephroureterectomy OT - Upper urinary tract urothelial carcinoma EDAT- 2026/10/09 17:34 MHDA- 2026/10/09 17:34 CRDT- 2026/10/09 11:08 PHST- 2026/09/01 00:00 [received] PHST- 2026/10/05 00:00 [accepted] PHST- 2026/10/09 17:34 [medline] PHST- 2026/10/09 17:34 [pubmed] PHST- 2026/10/09 11:08 [entrez] AID - 10.1007/s11255-026-05434-4 [pii] AID - 10.1007/s11255-026-05434-4 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Oct 9. doi: 10.1007/s11255-026-05434-4. PMID- 42850079 OWN - NLM STAT- Publisher LR - 20261008 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) DP - 2026 Oct 8 TI - Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns. LID - S1078-1439(26)00713-1 [pii] LID - 10.1016/j.urolonc.2026.08.020 [doi] AB - BACKGROUND: Solid organ transplant recipients face an increased risk of bladder cancer and require lifelong immunosuppression, which may alter the natural history and treatment response of nonmuscle-invasive bladder cancer (NMIBC). Balancing cancer control with allograft preservation complicates clinical decision-making, yet outcome data in this population remain scarce. METHODS: A retrospective study of transplant recipients diagnosed with NMIBC post-transplant was conducted. The index date was NMIBC diagnosis. NMIBC recurrence was the primary endpoint, with death before recurrence as a competing event. Recurrence-free survival was estimated using Kaplan-Meier methods, and cumulative incidence of recurrence and competing mortality using the Aalen-Johansen estimator. Cox models evaluated predictors of recurrence. RESULTS: Fifty-nine transplant recipients met inclusion criteria (median age 68 years; 89.8% male), with high-risk disease present in 40/59 (67.8%). High-grade disease was present in 38/59 patients (64.4%), with T1 stage in 20/59 (33.9%) and concomitant carcinoma in situ in 13/59 (22.0%). Over a median follow-up of 37.4 months, 11/59 patients (18.6%) experienced recurrence at a median of 15.1 months, all among those receiving Bacillus Calmette-Guerin (BCG) induction. The 5-year cumulative incidence for recurrence was 20.4%, compared with 40.5% for competing mortality. Progression to advanced disease (>/=pT2 and/or nodal involvement) occurred in 3/59 (5.1%) overall, predominantly within the high-grade subcohort. All-cause mortality was 36/59 (61.0%), with a bladder cancer-specific mortality of 5/59 (8.5%). In univariable models, tumor size >3 cm (HR 19.53, P = 0.005) and increasing age (HR 1.10, P = 0.066) were associated with recurrence. Granular information on specific non-BCG intravesical regimens was limited, precluding analysis of comparative efficacy among alternative agents in this population. CONCLUSION: In this single-institution transplant cohort, competing mortality exceeded recurrence risk. Traditional prognostic factors like tumor size predicted recurrence, yet survival was driven by transplant-related comorbidities. These findings support the use of competing-risk methodologies for accurate outcome estimation and highlight the need for individualized, multidisciplinary management in this complex population. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Guzman, Taeris AU - Guzman T AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - McSweeney, Sean AU - McSweeney S AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Aydogdu, Can AU - Aydogdu C AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Diaz, Gabriela AU - Diaz G AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Baer, Mikayla AU - Baer M AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Weight, Christopher AU - Weight C AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Almassi, Nima AU - Almassi N AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Krishnamurthi, Venkakesh AU - Krishnamurthi V AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Eltemamy, Mohamed AU - Eltemamy M AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Campbell, Rebecca AU - Campbell R AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Sindhani, Mohit AU - Sindhani M AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: bukavil2@ccf.org. LA - eng PT - Journal Article DEP - 20261008 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Immunosuppression OT - NMIBC OT - Recurrence OT - Risk stratification OT - Transplant COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2026/10/08 23:31 MHDA- 2026/10/08 23:31 CRDT- 2026/10/08 21:58 PHST- 2026/04/01 00:00 [received] PHST- 2026/08/19 00:00 [revised] PHST- 2026/08/22 00:00 [accepted] PHST- 2026/10/08 23:31 [medline] PHST- 2026/10/08 23:31 [pubmed] PHST- 2026/10/08 21:58 [entrez] AID - S1078-1439(26)00713-1 [pii] AID - 10.1016/j.urolonc.2026.08.020 [doi] PST - aheadofprint SO - Urol Oncol. 2026 Oct 8:S1078-1439(26)00713-1. doi: 10.1016/j.urolonc.2026.08.020. PMID- 42840653 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261007 LR - 20261008 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 17 DP - 2026 TI - Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence. PG - 1921622 LID - 10.3389/fphar.2026.1921622 [doi] LID - 1921622 AB - Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrence and prolonged surveillance. Traditional Chinese medicine (TCM) has been investigated as an adjunct to standard NMIBC management, but its syndrome characteristics and pharmacological evidence remain heterogeneous. This review combined a scoping review of TCM syndrome-related evidence with a critical narrative synthesis of pharmacological and mechanistic studies. The scoping review included 59 sources and identified 155 syndrome-element occurrences. Deficiency (23.9%), dampness (21.3%), heat (20.6%), stasis (16.8%), and toxin (14.8%) were most frequently reported. Among 59 composite-pattern occurrences, Dampness-Heat (30.5%) and Stasis-Toxin (18.6%) predominated. These results reflect literature-level reporting patterns rather than patient-level prevalence. Mechanistic evidence involved tumor-cell survival and death, inflammatory and immune regulation, angiogenesis, invasion, migration, extracellular-matrix remodeling, and tumor-cell reimplantation. However, much of this evidence derives from broader bladder cancer experimental models or predictive analyses, and direct evidence for reducing NMIBC recurrence or progression remains limited. Overall, TCM syndrome characteristics in NMIBC can be described systematically, but mechanistic findings should be interpreted according to their disease context and evidence relevance. Future studies should emphasize standardized syndrome reporting, reproducible intervention characterization, NMIBC-relevant models, and clinically meaningful recurrence-related outcomes. CI - Copyright (c) 2026 Zhang, Xiang, Yang, Li, Zheng and Qian. FAU - Zhang, Xi-Zhe AU - Zhang XZ AD - Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. AD - Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, China. FAU - Xiang, Jiong-Ao AU - Xiang JA AD - Beijing Friendship Hospital, Capital Medical University, Beijing, China. FAU - Yang, Li-Chang AU - Yang LC AD - Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. AD - Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, China. FAU - Li, Yao-Dong AU - Li YD AD - Medical Affairs Department, The Fourth People's Hospital of Shunde, Foshan (Wu Zhongpei Memorial Hospital of Shunde, Foshan), Foshan, Guangdong, China. FAU - Zheng, Xia AU - Zheng X AD - Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. FAU - Qian, Jun AU - Qian J AD - Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. LA - eng PT - Journal Article PT - Review DEP - 20260922 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC13639432 OTO - NOTNLM OT - non-muscle-invasive bladder cancer OT - pharmacological evidence OT - scoping review OT - syndrome element OT - syndrome pattern OT - traditional Chinese medicine COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/07 11:32 MHDA- 2026/10/07 11:33 PMCR- 2026/09/22 CRDT- 2026/10/07 09:21 PHST- 2026/06/27 00:00 [received] PHST- 2026/08/21 00:00 [revised] PHST- 2026/09/04 00:00 [accepted] PHST- 2026/10/07 11:33 [medline] PHST- 2026/10/07 11:32 [pubmed] PHST- 2026/10/07 09:21 [entrez] PHST- 2026/09/22 00:00 [pmc-release] AID - 1921622 [pii] AID - 10.3389/fphar.2026.1921622 [doi] PST - epublish SO - Front Pharmacol. 2026 Sep 22;17:1921622. doi: 10.3389/fphar.2026.1921622. eCollection 2026. PMID- 42834313 OWN - NLM STAT- Publisher LR - 20261005 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Oct 5 TI - Validation of BIAS and IBCG criteria for predicting high-grade recurrence in low-grade NMIBC eligible for active surveillance. LID - 10.1007/s11255-026-05411-x [doi] AB - PURPOSE: We evaluated the performance of two scoring systems-the Bladder Cancer Italian Active Surveillance (BIAS) criteria and the International Bladder Cancer Group (IBCG) score-for predicting high-grade (HG) disease at recurrence in patients with primary low-grade (LG) non-muscle-invasive bladder cancer eligible for active surveillance (AS). METHODS: We retrospectively included patients with primary LG-NMIBC (2013-2022), eligible for AS according to BIAS criteria at time of diagnosis. All subsequent recurrences were managed with TURBT, allowing histopathological confirmation of tumor grade across 383 recurrences. Clinical data necessary to assess IBCG criteria and adherence to BIAS protocol were systematically collected at each recurrence, and their diagnostic performance in predicting HG progression was evaluated using C-statistics. Multivariable logistic regression was used to assess which individual BIAS and IBCG criteria were most predictive of progression. RESULTS: At a median (IQR) follow-up of 55 (18-83) months, HG progression occurred in 45/383 (12%) of recurrences. BIAS criteria were met in 59% (226/383) of recurrences, of which 5.3% showed upgrading to HG. Conversely, only 16% (62/383) of recurrences had 0 IBCG risk factors, of which 8 (13%) upgraded. BIAS showed higher discriminative ability than IBCG (C-statistics 0.68 vs. 0.47, p<0.001) and higher negative predictive value (95% vs. 87%). CONCLUSION: In patients with primary LG-NMIBC initially eligible for AS, adherence to BIAS criteria at recurrence identifies a subgroup with a lower prevalence of HG disease at immediate TURBT and may help inform shared decision-making regarding surveillance versus immediate intervention. CI - (c) 2026. The Author(s). FAU - Finati, Marco AU - Finati M AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. marco.finati@gmail.com. AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. marco.finati@gmail.com. FAU - Schiavone, Nicola AU - Schiavone N AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Ricapito, Anna AU - Ricapito A AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - d'Altilia, Nicola AU - d'Altilia N AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Fanelli, Antonio AU - Fanelli A AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Giannoccaro, Nicolo AU - Giannoccaro N AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Pandolfo, Savio Domenico AU - Pandolfo SD AD - Department of Urology, University of L'Aquila, L'Aquila, Italy. AD - Department of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. AD - Department of Clinical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. AD - Urology Unit, IRCCS Policlinico San Matteo Fondazione, Pavia, Italy. FAU - Naspro, Richard AU - Naspro R AD - School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Roscigno, Marco AU - Roscigno M AD - School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Da Pozzo, Luigi Filippo AU - Da Pozzo LF AD - School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Urology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. AD - Department of Pathology, University of Foggia, Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology, Ospedale Generale Regionale Francesco Miulli, 70021, Acquaviva Delle Fonti, Italy. AD - Medicine and Surgery Department, LUM University, 70010, Casamassima, Italy. FAU - Bettocchi, Carlo AU - Bettocchi C AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. LA - eng PT - Journal Article DEP - 20261005 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Active surveillance OT - International Bladder Cancer Group OT - Non-muscle-invasive bladder neoplasms OT - Urinary bladder neoplasms COIS- Declarations. Approval of the research protocol by an Institutional Reviewer Board: The study was approved by the Ethical Committee of Policlinico Riuniti of Foggia on March 15, 2022 (Approval Code 31/CE/2022). Conflicts of interest: None of the authors have any relevant disclosures, and none of the authors have any financial or non-financial interests that may be relevant to the submitted work. Informed consent: An institutional waiver of informed consent was granted due to the retrospective nature of the registry. EDAT- 2026/10/06 05:29 MHDA- 2026/10/06 05:29 CRDT- 2026/10/05 23:48 PHST- 2026/07/21 00:00 [received] PHST- 2026/09/24 00:00 [accepted] PHST- 2026/10/06 05:29 [medline] PHST- 2026/10/06 05:29 [pubmed] PHST- 2026/10/05 23:48 [entrez] AID - 10.1007/s11255-026-05411-x [pii] AID - 10.1007/s11255-026-05411-x [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Oct 5. doi: 10.1007/s11255-026-05411-x. PMID- 42832769 OWN - NLM STAT- Publisher LR - 20261005 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) DP - 2026 Oct 5 TI - Predicting Recurrence and Progression in Contemporary Patients with NMIBC Undergoing Blue Light Cystoscopy-Aided Transurethral Resection of Bladder Tumor. PG - 101097UPJ0000000000001103 LID - 10.1097/UPJ.0000000000001103 [doi] AB - BACKGROUND: Although blue light cystoscopy (BLC) is recommended by clinical practice guidelines to improve cancer detection, predictive models for patients undergoing BLC are lacking. We therefore evaluated the associations of clinicopathologic features with recurrence and progression in a contemporary cohort of patients treated with BLC to develop a risk prediction model. METHODS: We identified patients aged 18-89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-aided TURBT between 2014-2023. Associations of baseline characteristics with recurrence and progression were evaluated using Cox regression, and predictive models were developed using lasso regression. RESULTS: 1040 patients underwent BLC-TURBT. Tumor stage was Ta in 578 (56%), T1 in 166 (16%), and pure CIS in 190 (18%) patients. On multivariable analysis, HGTa (HR 1.60, 95%CI 1.10-2.35) and HGT1 (HR 1.94, 95%CI 1.25-3.02) tumors were associated with increased risk of recurrence. HGT1 (HR 12.4, 95%CI 4.52-34.0), HGTa (HR 3.08, 95% CI 1.03-9.18), pure CIS (HR 4.51, 95% CI 1.44-14.1), Ta+CIS (HR 4.98, 95%CI 1.17-21.1), and T1+CIS (HR 7.65, 95%CI 1.97-29.7) tumors, as well as lymphovascular invasion (HR 3.27, 95%CI 1.22-8.83) were associated with increased risk of progression. In contrast, adjuvant BCG was associated with decreased risk of progression (HR 0.40, 95%CI 0.22-0.72). Model discrimination was 0.64 for RFS and 0.73 for PFS. CONCLUSIONS: Using a multi-institutional cohort, we developed predictive models for recurrence and progression in patients undergoing BLC-TURBT. Although they require external validation, these models reflect to contemporary treatment paradigms and can inform personalized, risk-adapted management of NMIBC. FAU - Perez-Londono, Agustin AU - Perez-Londono A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Almohtasib, Jamil AU - Almohtasib J AUID- ORCID: 0000-0002-5055-674X AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Kaul, Sumedh AU - Kaul S AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Fleishman, Aaron AU - Fleishman A AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Konety, Badrinath AU - Konety B AD - Allina Health Cancer Institute, Minneapolis, MN. FAU - Pohar, Kamal AU - Pohar K AD - Department of Urology, Ohio State University, Columbus, OH. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - Department of Urology, University of Kansas, Kansas City, KS. FAU - Taylor, John AU - Taylor J AD - Department of Urology, University of Kansas, Kansas City, KS. FAU - Kates, Max AU - Kates M AD - The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Willard, Brian AU - Willard B AD - Lexington Medical Center, Lexington, SC. FAU - Taylor, Jennifer M AU - Taylor JM AD - Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX. FAU - Liao, Joseph C AU - Liao JC AD - VA Palo Alto Health Care System, Palo Alto, CA. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California San Francisco, San Francisco, CA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, Rush University, Chicago, IL. FAU - Tyson, Mark D AU - Tyson MD AD - Department of Urology, Mayo Clinic Hospital, Phoenix, AZ. FAU - Lotan, Yair AU - Lotan Y AD - UT Southwestern Medical Center, Dallas, TX. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. LA - eng PT - Journal Article DEP - 20261005 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - bladder cancer OT - blue light cystoscopy OT - outcome prediction OT - progression OT - recurrence EDAT- 2026/10/05 17:31 MHDA- 2026/10/05 17:31 CRDT- 2026/10/05 16:33 PHST- 2026/10/05 17:31 [medline] PHST- 2026/10/05 17:31 [pubmed] PHST- 2026/10/05 16:33 [entrez] AID - 10.1097/UPJ.0000000000001103 [doi] PST - aheadofprint SO - Urol Pract. 2026 Oct 5:101097UPJ0000000000001103. doi: 10.1097/UPJ.0000000000001103. PMID- 42832464 OWN - NLM STAT- Publisher LR - 20261005 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) DP - 2026 Oct 5 TI - Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated with Adjuvant Nivolumab. PG - 1 LID - 10.1159/uin/aewag032 [doi] AB - BACKGROUND: Adjuvant nivolumab prolongs disease-free survival (DFS) after radical surgery for high-risk urothelial carcinoma (UC), yet recurrence remains common. We investigated the prognostic impact of clinical and systemic inflammatory factors in these patients. METHODS: We retrospectively analyzed 127 patients who received adjuvant nivolumab following radical surgery at six institutions between April 2022 and January 2026. Prognostic factors for DFS were evaluated using Cox proportional hazards regression models. RESULTS: The median follow-up was 12.0 months, and DFS events occurred in 43.3% of patients. In the multivariable analysis, advanced pathological T stage (pT3-4 vs. pT1-2) (HR [hazard ratio], 2.525; 95% CI [confidence interval], 1.067-5.979) and baseline neutrophil-to-lymphocyte ratio (NLR) (HR, 1.216 per 1 unit increase; 95% CI, 1.034-1.430; p = 0.018) emerged as independent predictors of inferior DFS. Additionally, female sex showed an independent association with shorter DFS (HR, 0.275; 95% CI, 0.152-0.495; p < 0.001, though this finding warrants cautious interpretation given baseline characteristics and the small proportion of female patients. CONCLUSIONS: Baseline NLR and advanced pT stage serve as valuable independent prognostic factors for patients receiving adjuvant nivolumab. Although interpreted with caution regarding specific subgroups and retrospective limitations, these findings highlight key risk factors in this setting and provide a rationale for larger prospective validation. CI - (c) The Author(s) 2026. Published by S. Karger AG. FAU - Sano, Asuka AU - Sano A FAU - Oishi, Yuya AU - Oishi Y FAU - Ishikawa, Gaku AU - Ishikawa G FAU - Watanabe, Shunsuke AU - Watanabe S FAU - Watanabe, Shinya AU - Watanabe S FAU - Tsuchiya, Yoshihiro AU - Tsuchiya Y FAU - Maenosono, Ryoichi AU - Maenosono R FAU - Yoshikawa, Yuki AU - Yoshikawa Y FAU - Nishio, Kyosuke AU - Nishio K FAU - Morinaka, Hirofumi AU - Morinaka H FAU - Saruta, Masanobu AU - Saruta M FAU - Fukuokaya, Wataru AU - Fukuokaya W FAU - Watanabe, Kyohei AU - Watanabe K FAU - Watanabe, Hiromitsu AU - Watanabe H FAU - Tamura, Keita AU - Tamura K FAU - Motoyama, Daisuke AU - Motoyama D FAU - Yanagisawa, Takafumi AU - Yanagisawa T FAU - Takahara, Kiyoshi AU - Takahara K FAU - Yamamoto, Yutaka AU - Yamamoto Y FAU - Fujita, Kazutoshi AU - Fujita K FAU - Inamoto, Teruo AU - Inamoto T LA - eng PT - Journal Article DEP - 20261005 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM EDAT- 2026/10/05 17:31 MHDA- 2026/10/05 17:31 CRDT- 2026/10/05 13:37 PHST- 2026/07/16 00:00 [received] PHST- 2026/09/18 00:00 [accepted] PHST- 2026/10/05 17:31 [medline] PHST- 2026/10/05 17:31 [pubmed] PHST- 2026/10/05 13:37 [entrez] AID - 000554573 [pii] AID - 10.1159/uin/aewag032 [doi] PST - aheadofprint SO - Urol Int. 2026 Oct 5:1. doi: 10.1159/uin/aewag032. PMID- 42832054 OWN - NLM STAT- MEDLINE DCOM- 20261005 LR - 20261016 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Oct 5 TI - The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice. LID - 10.1007/s00345-026-06839-7 [doi] LID - 725 AB - BACKGROUND: Ureteral stenting in patients with bladder cancer involving the ureteral orifice may increase the rate of metachronous upper tract urothelial carcinoma (UTUC). Nevertheless, evidence on the matter is scarce and often contradictory. MATERIALS AND METHODS: We performed an observational study comparing ureteral stenting versus no stenting with respect to the risk of developing metachronous UTUC in patients who underwent transurethral resection of bladder tumors (TURBT) involving the ureteral orifice between January 2015 and December 2024. We performed time-to-event analyses to estimate hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs). RESULTS: We included 151 patients with a median age of 73 years. 37 (25%) underwent ureteral stenting during TURBT. Patients undergoing stenting had higher BMI (p = 0.014), more aggressive tumors (p = 0.003), underwent prior intravesical therapy more often (p = 0.008), higher preoperative creatinine values (p = 0.007), and longer hospitalization duration (p = 0.002) compared to those who did not undergo stenting. After a median follow-up of 25 months, 8 patients developed metachronous UTUC (2 in the stenting group and 6 in the non-stenting group). Ureteral stenting was not associated with statistically significantly higher rates of metachronous UTUC (HR: 1.2, 95%CI: 0.31-5.6, p > 0.9). During follow-up, 49 (33%) patients developed recurrence in the bladder, 43 (28%) underwent cystectomy, and 24 (16%) died. The HRs did not significantly differ between the two groups. CONCLUSIONS: The present study did not demonstrate an increased risk of metachronous UTUC after stenting during TURBT with urothelial cancer involving the ureteral orifice. Moreover, stenting was not statistically significantly associated with increased recurrences in the urinary bladder, higher cystectomy rates, or worse mortality. CI - (c) 2026. The Author(s). FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Engelmann, Patrick AU - Engelmann P AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Puhr-Westerheide, Daniel AU - Puhr-Westerheide D AD - Department of Radiology, University Hospital, LMU Munich, Munich, Germany. FAU - Ebner, Benedikt AU - Ebner B AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Kidess, Marc AU - Kidess M AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Semmler, Marie AU - Semmler M AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Keller, Patrick AU - Keller P AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Stief, Christian AU - Stief C AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Volz, Yannic AU - Volz Y AUID- ORCID: 0000-0002-5468-9398 AD - Department of Urology, LMU University Hospital, Marchioninistrasse 15, 81377, Munich, Germany. yannic.volz@med.uni-muenchen.de. LA - eng PT - Journal Article PT - Observational Study DEP - 20261005 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - *Stents/adverse effects MH - *Ureteral Neoplasms/epidemiology MH - *Neoplasms, Second Primary/epidemiology MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Transurethral Resection of Bladder MH - *Carcinoma, Transitional Cell/epidemiology/surgery MH - *Ureter/surgery MH - *Kidney Neoplasms/epidemiology MH - Middle Aged MH - Aged, 80 and over MH - Retrospective Studies PMC - PMC13638760 OTO - NOTNLM OT - Hydronephrosis OT - TURBT OT - Upper tract urothelial cell carcinoma OT - Ureteral stent OT - Urothelial cell carcinoma COIS- Declarations. Conflict of interest: None declared. Ethical approval: The study was approved by the local ethics committee of the LMU University Hospital (approval number: 23-0586). All procedures were conducted in accordance with the Declaration of Helsinki and applicable institutional and national ethical standards. EDAT- 2026/10/05 17:31 MHDA- 2026/10/05 17:32 PMCR- 2026/10/05 CRDT- 2026/10/05 11:16 PHST- 2026/04/26 00:00 [received] PHST- 2026/09/27 00:00 [accepted] PHST- 2026/10/05 17:32 [medline] PHST- 2026/10/05 17:31 [pubmed] PHST- 2026/10/05 11:16 [entrez] PHST- 2026/10/05 00:00 [pmc-release] AID - 10.1007/s00345-026-06839-7 [pii] AID - 6839 [pii] AID - 10.1007/s00345-026-06839-7 [doi] PST - epublish SO - World J Urol. 2026 Oct 5;44(1):725. doi: 10.1007/s00345-026-06839-7. PMID- 42827132 OWN - NLM STAT- Publisher LR - 20261002 IS - 1546-170X (Electronic) IS - 1078-8956 (Linking) DP - 2026 Oct 2 TI - Urine cell-free RNA for bladder cancer detection and treatment response prediction. LID - 10.1038/s41591-026-04673-3 [doi] AB - Urine biomarkers promise to improve noninvasive detection and molecular characterization of genitourinary malignancies. Here we describe urine random priming and affinity capture of cell-free RNA (cfRNA) fragments for enrichment analysis by sequencing (uRARE-seq), a liquid biopsy method for urine cfRNA profiling, and apply it to 683 urine samples from patients with cancer and controls. Urine cfRNA contained transcripts from genitourinary tissues and, in patients with prostate, kidney or bladder cancer, tumor-derived transcripts. uRARE-seq demonstrated 95% sensitivity at 90% specificity for detecting localized bladder cancer. The method outperformed urine tumor DNA analysis and was unaffected by the presence of field-effect mutations. Urine cfRNA analysis also sensitively detected minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical Bacillus Calmette-Guerin (BCG). Pretreatment urine from complete responders to BCG was enriched for T cell and other immune signatures, suggesting a preexisting antitumor immune response, whereas nonresponders showed higher expression of proliferation-related genes. In pretreatment urine from 114 patients, this biological difference enabled development of a biomarker predicting likelihood of response to BCG versus chemotherapy (area under the curve 0.93) that was strongly associated with risk of recurrence. Urine cfRNA analysis is therefore a promising biomarker approach for bladder cancer and potentially other urologic malignancies, although prospective studies are needed to assess its clinical utility. CI - (c) 2026. The Author(s). FAU - Liu, Kevin J AU - Liu KJ AUID- ORCID: 0000-0003-3836-3213 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Program in Cancer Biology, Stanford University, Stanford, CA, USA. FAU - Shi, William Y AU - Shi WY AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Program in Cancer Biology, Stanford University, Stanford, CA, USA. FAU - Nesselbush, Monica C AU - Nesselbush MC AD - Resero Bio, San Carlos, CA, USA. FAU - Phillips, Nick A AU - Phillips NA AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Program in Cancer Biology, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Mach, Kathleen E AU - Mach KE AD - Department of Urology, Stanford University, Stanford, CA, USA. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Luca, Bogdan AU - Luca B AD - Department of Pathology, Stanford University, Stanford, CA, USA. FAU - Bajpai, Ravi K AU - Bajpai RK AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Jabara, Isabel AU - Jabara I AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Cheng, Jordan C AU - Cheng JC AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Sugio, Takeshi AU - Sugio T AUID- ORCID: 0000-0002-4270-1943 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Shukla, Navika AU - Shukla N AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Shen, Emily C AU - Shen EC AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Program in Cancer Biology, Stanford University, Stanford, CA, USA. FAU - Koh, Ivy Lee AU - Koh IL AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Wu, Douglas J AU - Wu DJ AD - Department of Pathology, Stanford University, Stanford, CA, USA. FAU - Liu, Chih-Long AU - Liu CL AUID- ORCID: 0000-0002-6577-5427 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Almanza, Diego AU - Almanza D AUID- ORCID: 0000-0003-1222-9366 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Program in Cancer Biology, Stanford University, Stanford, CA, USA. FAU - Jun, Soyeong AU - Jun S AUID- ORCID: 0000-0001-8419-7098 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Tian, Feng AU - Tian F AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Hamilton, Emily G AU - Hamilton EG AUID- ORCID: 0000-0001-7955-6244 AD - Resero Bio, San Carlos, CA, USA. FAU - Hoerner, Christian R AU - Hoerner CR AUID- ORCID: 0000-0002-8685-1126 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Canary Center at the Stanford School of Medicine, Stanford University, Stanford, CA, USA. AD - Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Wang, Rui AU - Wang R AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Esfahani, Mohammad S AU - Esfahani MS AUID- ORCID: 0000-0002-0950-3937 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Hui, Angela AU - Hui A AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - La, Vinh AU - La V AD - Department of Urology, Stanford University, Stanford, CA, USA. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Holton, Grace AU - Holton G AD - Department of Urology, Stanford University, Stanford, CA, USA. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Rodriguez, Gabriela AU - Rodriguez G AD - Department of Urology, Stanford University, Stanford, CA, USA. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Lee, Timothy J AU - Lee TJ AD - Department of Urology, Stanford University, Stanford, CA, USA. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Ling, Xi AU - Ling X AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Kalahasti, Nikitha AU - Kalahasti N AUID- ORCID: 0000-0002-4304-2265 AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Vallamkonda, Spoorthi AU - Vallamkonda S AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Mullane, Patrick AU - Mullane P AD - Department of Pathology, Stanford University, Stanford, CA, USA. FAU - Chen, Simon B AU - Chen SB AD - Department of Pathology, Stanford University, Stanford, CA, USA. FAU - Shkolyar, Eugene AU - Shkolyar E AD - Department of Urology, Stanford University, Stanford, CA, USA. FAU - Prado, Kris AU - Prado K AUID- ORCID: 0000-0002-3987-7892 AD - Department of Urology, Stanford University, Stanford, CA, USA. FAU - Khaki, Ali Raza AU - Khaki AR AUID- ORCID: 0000-0002-4655-4426 AD - Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Chan, Emily AU - Chan E AD - Department of Pathology, Stanford University, Stanford, CA, USA. FAU - Buyyounouski, Mark K AU - Buyyounouski MK AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. FAU - Fan, Alice C AU - Fan AC AUID- ORCID: 0000-0002-4813-5444 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. AD - Canary Center at the Stanford School of Medicine, Stanford University, Stanford, CA, USA. AD - Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. FAU - Skinner, Eila C AU - Skinner EC AD - Department of Urology, Stanford University, Stanford, CA, USA. FAU - Alizadeh, Ash A AU - Alizadeh AA AUID- ORCID: 0000-0002-5153-5625 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. arasha@stanford.edu. AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu. AD - Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu. AD - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. arasha@stanford.edu. FAU - Liao, Joseph C AU - Liao JC AUID- ORCID: 0000-0003-2448-5463 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. jliao@stanford.edu. AD - Department of Urology, Stanford University, Stanford, CA, USA. jliao@stanford.edu. AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. jliao@stanford.edu. FAU - Diehn, Maximilian AU - Diehn M AUID- ORCID: 0000-0003-2032-0581 AD - Stanford Cancer Institute, Stanford University, Stanford, CA, USA. diehn@stanford.edu. AD - Department of Radiation Oncology, Stanford University, Stanford, CA, USA. diehn@stanford.edu. AD - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. diehn@stanford.edu. LA - eng GR - R01 CA254179/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R01 CA244526/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - T32 CA930245/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - K00 CA264398/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R01 CA254179/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R01 CA244526/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R01 CA244526/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ PT - Journal Article DEP - 20261002 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 SB - IM COIS- Competing interests: K.J.L., W.Y.S., M.C.N. and E.G.H. report ownership interest or stock options in Resero Bio. M.S.E. and E.G.H. report consultancy for Foresight Diagnostics. M.C.N. and E.G.H. are employees of Resero Bio. A.A.A. has received research support from Celgene and Bristol Myers Squibb; reports consultancy for AstraZeneca, Arima, Natera, Roche, Genentech, Celgene, Bristol Myers Squibb, Forty Seven, Gilead, ADCT, Janssen, CARGO, Foresight Diagnostics, Adaptive Biotech and Chugai; has served on the Scientific Advisory Board for CiberMed and Foresight Diagnostics; and reports ownership interest in CiberMed, Resero Bio, Arima, Forty Seven, CARGO and Natera. J.C.L. reports consultancy for VPIX and UroViu and ownership interest or stock options in Resero Bio. M.D. reports current or past research support from AstraZeneca, Illumina and Varian; honoraria from Bristol Myers Squibb, Chugai and Novartis; consultancy to AstraZeneca, BioNTech, Boehringer Ingelheim, CiberMed, Foresight Diagnostics, Genentech, Gritstone Bio, Illumina, Natera, Perception Medicine, RefleXion, Regeneron, Resero Bio and Roche; patents licensed to Foresight Diagnostics, Natera, Resero Bio and Roche; and ownership interest or stock options in CiberMed, Foresight Diagnostics, Gritstone Bio, Natera, Perception Medicine and Resero Bio. K.J.L., W.Y.S., M.C.N., A.A.A., J.C.L. and M.D. also report patent filings related to urine cfRNA. The other authors declare no competing interests. EDAT- 2026/10/03 05:33 MHDA- 2026/10/03 05:33 CRDT- 2026/10/02 23:18 PHST- 2026/02/24 00:00 [received] PHST- 2026/08/25 00:00 [accepted] PHST- 2026/10/03 05:33 [medline] PHST- 2026/10/03 05:33 [pubmed] PHST- 2026/10/02 23:18 [entrez] AID - 10.1038/s41591-026-04673-3 [pii] AID - 10.1038/s41591-026-04673-3 [doi] PST - aheadofprint SO - Nat Med. 2026 Oct 2. doi: 10.1038/s41591-026-04673-3. PMID- 42824830 OWN - NLM STAT- MEDLINE DCOM- 20261002 LR - 20261003 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies. PG - 1920567 LID - 10.3389/fimmu.2026.1920567 [doi] LID - 1920567 AB - Bladder cancer (BC), a highly prevalent malignancy of the urinary tract, imposes a considerable clinical burden because of its high recurrence rates and a substantial risk of disease progression. Accumulating evidence suggests that microbiome dysbiosis is associated with the initiation and progression of BC through potentially bidirectional interactions. Recent advances in high-throughput sequencing technologies have facilitated a more comprehensive characterization of the urinary microbiome, thereby revealing its potential involvement in the pathogenesis of BC. This review summarizes the proposed mechanisms through which microbial communities may contribute to BC carcinogenesis, including chronic inflammation, microbial metabolite production, and epigenetic regulation. We further critically evaluate the established mechanisms of Bacillus Calmette-Guerin (BCG) immunotherapy-a standard intravesical immunotherapy for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)-and examine the emerging application of microbiome profiling as a source of candidate noninvasive biomarkers and potential correlates or modulators of immune checkpoint inhibitor (ICI) response. Additionally, we elucidate the associations between microbiota heterogeneity and immunotherapy response, offering novel insights into microbiome-targeted therapeutic strategies for BC. CI - Copyright (c) 2026 Wu, Fu, Shi, Gong, Chen, Zhang, Jiang and Wang. FAU - Wu, Songhong AU - Wu S AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Fu, Shi AU - Fu S AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Shi, Hongjin AU - Shi H AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Gong, Yicheng AU - Gong Y AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Chen, Peng AU - Chen P AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Zhang, Xiaoyue AU - Zhang X AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Jiang, Enyan AU - Jiang E AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Wang, Haifeng AU - Wang H AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. LA - eng PT - Journal Article PT - Review DEP - 20260917 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Microbiota/immunology MH - *Urinary Bladder Neoplasms/immunology/microbiology/therapy MH - Animals MH - Immunotherapy/methods MH - Epigenesis, Genetic MH - Non-Muscle Invasive Bladder Neoplasms MH - Dysbiosis/immunology MH - Immune Checkpoint Inhibitors/therapeutic use MH - BCG Vaccine/therapeutic use PMC - PMC13628173 OTO - NOTNLM OT - bladder cancer OT - epigenetic regulation OT - immune interactions OT - microbiota OT - therapeutic strategy COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/02 13:37 MHDA- 2026/10/02 13:38 PMCR- 2026/09/17 CRDT- 2026/10/02 06:48 PHST- 2026/06/26 00:00 [received] PHST- 2026/09/06 00:00 [revised] PHST- 2026/09/07 00:00 [accepted] PHST- 2026/10/02 13:38 [medline] PHST- 2026/10/02 13:37 [pubmed] PHST- 2026/10/02 06:48 [entrez] PHST- 2026/09/17 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1920567 [doi] PST - epublish SO - Front Immunol. 2026 Sep 17;17:1920567. doi: 10.3389/fimmu.2026.1920567. eCollection 2026. PMID- 42820048 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261001 LR - 20261001 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 93 DP - 2026 Nov TI - Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer. PG - 3-11 LID - 10.1016/j.euros.2026.07.009 [doi] AB - BACKGROUND: Patients with bladder cancer (BC) may receive intravesical or systemic chemotherapy, but predictive biomarkers to guide treatment selection are lacking. Consequently, some patients receive ineffective treatment, resulting in unnecessary toxicity and an increased risk of tumor progression. OBJECTIVE: To evaluate the feasibility of ex vivo micro-tumor testing for predicting chemotherapy response in patients with BC. DESIGN SETTING AND PARTICIPANTS: In this prospective study, 65 patients with BC were enrolled (Institutional Review Board no. MEC-2022-0233). Tumor samples were collected during transurethral resection or radical cystectomy. BC was confirmed by uropathological review, supported by the detection of BC-associated mutations in hTERT, FGFR3, and PIK3CA. Patient-derived micro-tumors were exposed ex vivo to anticancer drugs, and responses were assessed using image-based measurements of viability and morphology. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was successful completion of ex vivo drug testing within 14 days of tissue collection. The secondary outcome was concordance between ex vivo sensitivity and clinical response to platinum-based chemotherapy. Clinical response data were available for nine patients. RESULTS AND LIMITATIONS: Ex vivo drug testing was successful for 48 of 65 patients (74%), with all successful results generated within 14 days of tissue collection. Among the nine patients with evaluable clinical outcomes following platinum-based chemotherapy, ex vivo responses corresponded with observed treatment responses. The main limitations were the small clinical correlation cohort and the limited number of drugs evaluated. CONCLUSIONS: Ex vivo micro-tumor drug testing is feasible for BC within a clinically relevant timeframe. The observed correspondence between ex vivo and clinical responses to platinum-based chemotherapy supports further investigation of this approach for personalized treatment selection in BC. CI - (c) 2026 The Authors. FAU - Scholtes, Mathijs P AU - Scholtes MP AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Koedoot, Esmee AU - Koedoot E AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - Ceton, Lieke J AU - Ceton LJ AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - Sijsenaar, Timothy J P AU - Sijsenaar TJP AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - Montero, Marta G AU - Montero MG AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - Roeland, Caithlyn Z AU - Roeland CZ AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - van Soest, Robert J AU - van Soest RJ AD - Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. FAU - Leijte, Joost AU - Leijte J AD - Urology, Amphia Ziekenhuis-location Molengracht, Breda, The Netherlands. FAU - Roshani, Hossein AU - Roshani H AD - Urology, Haga teaching hospital, The Hague, The Netherlands. FAU - Korthorst, Ruben AU - Korthorst R AD - Urology, Medisch Spectrum Twente, Enschede, The Netherlands. FAU - van der Meer, Dieudonne J AU - van der Meer DJ AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - van Leenders, Geert J L H AU - van Leenders GJLH AD - Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Vader, Willemijn AU - Vader W AD - R&D, VitroScan B.V., Leiden, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20260918 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC13625894 OTO - NOTNLM OT - Bladder cancer OT - Drug sensitivity profiling OT - Ex vivo OT - Precision medicine EDAT- 2026/10/02 03:10 MHDA- 2026/10/02 03:11 PMCR- 2026/09/18 CRDT- 2026/10/01 17:39 PHST- 2026/07/22 00:00 [accepted] PHST- 2026/10/02 03:11 [medline] PHST- 2026/10/02 03:10 [pubmed] PHST- 2026/10/01 17:39 [entrez] PHST- 2026/09/18 00:00 [pmc-release] AID - S2666-1683(26)00667-1 [pii] AID - 10.1016/j.euros.2026.07.009 [doi] PST - epublish SO - Eur Urol Open Sci. 2026 Sep 18;93:3-11. doi: 10.1016/j.euros.2026.07.009. eCollection 2026 Nov. PMID- 42809033 OWN - NLM STAT- MEDLINE DCOM- 20260929 LR - 20261015 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 34 IP - 10 DP - 2026 Sep 29 TI - Longitudinal data on health-related quality of life and its association with time to readmission in bladder perfusion patients. LID - 1032 [pii] LID - 10.1007/s00520-026-11243-3 [doi] AB - PURPOSE: To examine the relationship between health-related quality of life (HRQoL) and time to readmission in patients undergoing bladder perfusion, to explore the association of longitudinal changes and patterns of HRQoL at readmission, and to generate hypotheses for future interventions to prolong time to readmission. METHODS: This prospective observational study included 267 patients who underwent bladder perfusion at Shanghai General Hospital from August 2021 to January 2024. The SF-36 questionnaire was used to measure patients' health-related quality of life (HRQoL) at 1 week (T0) and 8 weeks (T1) after induction of bladder perfusion and to record information on readmission within 14 months. Cox proportional hazards regression models were constructed for readmission times at T0, T1, and T0-T1 change scores to analyze the ability of each HRQoL dimension to predict time to readmission. RESULTS: A total of 131 readmissions occurred, with an incidence rate of 49.1% and a median readmission time of 7.2 (IQR, 4.2-10.9) months. Physiological indicator dimensions were associated with time to readmission in the T0, T1, and T0-T1 models, and the strength of association for physiological indicators was significantly greater than that for psychological indicators (P = 0.023, < 0.001, and 0.017, respectively). In the T0 model, four of the ten SF-36 domains (Physical Component Summary [PCS], physical functioning, role-physical, and general health) showed statistically significant associations with time to readmission (all P < 0.05). In the T1 model, eight domains (all except bodily pain and mental health) were significantly associated. In the T0-T1 change model, six domains (PCS, physical functioning, role-physical, general health, role-emotional, and social functioning) were significantly associated. The number of significant domains varied across models because the strength of association between HRQoL and readmission time depends on the timing of assessment: post-treatment (T1) HRQoL showed the strongest associations, followed by change in HRQoL (T0-T1), while pre-treatment (T0) HRQoL showed the fewest significant associations. The HRQoL information collected at T1 had the strongest associations with readmission time, followed by change, and then T0 HRQoL information. Physiological indicators (PCS and its component domains) showed stronger associations than psychological indicators (MCS and its component domains). CONCLUSION: Health-related quality of life and its longitudinal changes are associated with time to readmission, with physiological and post-treatment indicators showing stronger associations. Longitudinal HRQoL information can be used to improve patient prognosis. Collecting HRQoL data during bladder perfusion may help guide interventions that prolong the interval to readmission. In light of these limitations, our results should be considered hypothesis-generating rather than definitive. The strong associations observed between HRQoL and readmission time warrant further investigation in studies with more comprehensive clinical data. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Zhang, Mingming AU - Zhang M AD - Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 543201002@qq.com. FAU - Chen, Zhimei AU - Chen Z AD - Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Chen, Yingping AU - Chen Y AD - Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zhou, Yi AU - Zhou Y AD - Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Observational Study DEP - 20260929 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - *Quality of Life MH - Humans MH - *Patient Readmission/statistics & numerical data MH - Prospective Studies MH - Female MH - Male MH - Longitudinal Studies MH - Time Factors MH - Aged MH - Middle Aged MH - *Urinary Bladder Neoplasms/therapy MH - Surveys and Questionnaires MH - Proportional Hazards Models MH - China MH - Perfusion/methods OTO - NOTNLM OT - Bladder perfusion OT - Health-related quality of life OT - Non-muscle-invasive bladder cancer (NMIBC) OT - Readmission COIS- Declarations. Ethical approval: This study was approved by the Ethics Committee of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (approval number: 2022-394). Patients provided informed consent. The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2400091061, Registration Date:2024.9.20). Consent for publication: Not applicable, as the study did not involve identifiable human images or personal data. Competing interests: The authors declare no competing interests. EDAT- 2026/09/29 19:04 MHDA- 2026/09/29 19:05 CRDT- 2026/09/29 11:08 PHST- 2025/05/29 00:00 [received] PHST- 2026/09/15 00:00 [accepted] PHST- 2026/09/29 19:05 [medline] PHST- 2026/09/29 19:04 [pubmed] PHST- 2026/09/29 11:08 [entrez] AID - 10.1007/s00520-026-11243-3 [pii] AID - 10.1007/s00520-026-11243-3 [doi] PST - epublish SO - Support Care Cancer. 2026 Sep 29;34(10):1032. doi: 10.1007/s00520-026-11243-3. PMID- 42808394 OWN - NLM STAT- MEDLINE DCOM- 20260929 LR - 20260929 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 27 IP - 9 DP - 2026 Sep 1 TI - Evaluation of GATA3 and HER-2 Immunohistochemical Expression as Prognostic Markers in Urothelial Carcinoma of the Urinary Bladder. PG - 3273-3279 LID - 92368 [pii] LID - 10.31557/APJCP.2026.27.9.3273 [doi] AB - OBJECTIVE: Urothelial carcinoma (UC) of the bladder remains a significant clinical challenge due to its high rates of recurrence and progression. Reliable biomarkers to predict tumor behaviour are still needed. GATA3 and HER2 have gained attention in this context, but their combined prognostic value has not been fully established. This study aims to evaluate the immunohistochemical expression of GATA3 and HER2 in bladder UC and to examine their association with key pathological parameters and patient outcomes. METHODS: One hundred archival UC specimens (2018-2022) were reviewed. Immunohistochemical staining for GATA3 and HER2 was performed and scored using a semi-quantitative H-score. Clinicopathological data and 3-year follow-up information were analysed to assess correlations with recurrence, progression, and survival. RESULTS: GATA3 expression was detected in 80% of tumors, while HER2 was positive in 25%. Both markers were significantly associated with low-grade histology and non-muscle-invasive disease. Tumors co-expressing GATA3 and HER2 showed the most favorable outcomes, including lower recurrence and improved 3-year disease-free survival. In multivariate analysis, GATA3 retained independent prognostic significance (HR 0.45, p=0.006). HER2 demonstrated a favorable trend that did not reach statistical significance after adjustment for grade and stage (HR 0.60, p=0.12), suggesting its prognostic signal is partially mediated by tumor differentiation. CONCLUSION: In multivariate analysis, GATA3 retained independent prognostic significance (HR 0.45, 95% CI 0.25-0.80, p=0.006), while HER2 did not (HR 0.60, 95% CI 0.35-1.03, p=0.12). However, combined GATA3/HER2 positivity identified a luminal subgroup with significantly better outcomes, supporting the utility of this marker panel for prognostic stratification in early-stage bladder UC. FAU - Mohammed, Mona Saeed AU - Mohammed MS AUID- ORCID: 0000-0002-7743-7222 AD - Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Abouhashim, Nehal Selim AU - Abouhashim NS AUID- ORCID: 0000-0001-7242-5671 AD - Pathological Sciences Department- MBBS Program, Fakeeh College for Medical Science, Jeddah 21461, Saudi Arabia. FAU - Elfeky, Mariem Ahmed AU - Elfeky MA AUID- ORCID: 0009-0000-9392-0364 AD - Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article DEP - 20260901 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (GATA3 Transcription Factor) RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 protein, human) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *GATA3 Transcription Factor/metabolism MH - *Biomarkers, Tumor/metabolism MH - Female MH - *Urinary Bladder Neoplasms/pathology/metabolism/surgery MH - Prognosis MH - *Erb-b2 Receptor Tyrosine Kinases/metabolism MH - *Carcinoma, Transitional Cell/pathology/metabolism/surgery MH - Male MH - Middle Aged MH - Immunohistochemistry MH - Aged MH - *Neoplasm Recurrence, Local/pathology/metabolism MH - Follow-Up Studies MH - Survival Rate MH - Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies OTO - NOTNLM OT - GATA3 OT - HER2 OT - Prognosis OT - Urothelial carcinoma OT - immunohistochemistry EDAT- 2026/09/29 12:28 MHDA- 2026/09/29 12:29 CRDT- 2026/09/29 08:02 PHST- 2025/12/11 00:00 [received] PHST- 2026/09/29 12:29 [medline] PHST- 2026/09/29 12:28 [pubmed] PHST- 2026/09/29 08:02 [entrez] AID - 92368 [pii] AID - 10.31557/APJCP.2026.27.9.3273 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2026 Sep 1;27(9):3273-3279. doi: 10.31557/APJCP.2026.27.9.3273. PMID- 42803329 OWN - NLM STAT- Publisher LR - 20260928 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) DP - 2026 Sep 28 TI - Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025). PG - 3915603261483766 LID - 10.1177/03915603261483766 [doi] AB - INTRODUCTION: Bladder cancer research has experienced a rapid increase in publication output with the emergence of new themes in diagnosis and treatment. The expanding literature makes it challenging to identify overarching trends and key developments. Therefore, a bibliometric analysis is warranted to systematically evaluate global research patterns, thematic evolution, and influential contributions within this dynamic field. METHODS: A bibliometric analysis was conducted using the Scopus database to retrieve articles and reviews on bladder cancer published between 2016 and December 2025. The search was performed in titles, abstracts, and keywords using predefined bladder cancer-related terms. Data were analyzed using VOSviewer and the Bibliometrix package in R. RESULTS: Between 2016 and 2025, a total of 49,014 publications related to bladder cancer, limited to Articles and Reviews indexed in Scopus, were included in the bibliometric analyses. The most frequent terms in bladder cancer research over the past 10 years were urothelial carcinoma, cancer immunotherapy, prognosis, biomarkers, chemotherapy, and radical cystectomy. The most cited terms included survival, cancer immunotherapy, and tumor microenvironment, and trending topics were tumor microenvironment, immune checkpoint inhibitors, and muscle-invasive bladder cancer. Thematic mapping identified one motor theme (urothelial carcinoma, chemotherapy, radical cystectomy) and two niche themes, including "cell cycle," "metastasis," and "apoptosis," and "mortality," "upper urinary tract urothelial carcinoma," and "meta-analysis." CONCLUSIONS: Frequent keywords such as biomarkers, prognosis, non-muscle invasive bladder cancer, chemotherapy, and radical cystectomy, together with highly cited and recently prominent terms including tumor microenvironment and immune checkpoint inhibitors, reflect areas of substantial research activity and evolving scientific interest. Thematic evolution analyses further indicate changing patterns in keyword co-occurrence over time, particularly for non-muscle invasive bladder cancer, upper urinary tract urothelial carcinoma, and meta-analysis. The translation of these trends into clinical practice requires further evidence synthesis, clinical trials, guideline evaluation, and broader stakeholder input. FAU - Heer, Rakesh AU - Heer R AD - Department of Surgery and Cancer, Imperial College London, London, UK. AD - Department of Urology, Imperial College Healthcare National Health Service (NHS) Trust, London, UK. FAU - Farrokhi, Mehrdad AU - Farrokhi M AUID- ORCID: 0000-0002-1559-2323 AD - Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20260928 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM OTO - NOTNLM OT - bibliometrics OT - immunotherapy OT - muscle invasive bladder cancer OT - non-muscle invasive bladder neoplasms OT - urinary bladder neoplasms EDAT- 2026/09/28 11:40 MHDA- 2026/09/28 11:40 CRDT- 2026/09/28 07:24 PHST- 2026/09/28 11:40 [medline] PHST- 2026/09/28 11:40 [pubmed] PHST- 2026/09/28 07:24 [entrez] AID - 10.1177/03915603261483766 [doi] PST - aheadofprint SO - Urologia. 2026 Sep 28:3915603261483766. doi: 10.1177/03915603261483766. PMID- 42794919 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 18 DP - 2026 Sep 12 TI - The Role of Circulating Extracellular DNA in Patients with Bladder Cancer: Clinical Associations and Exploratory Links with Heart Rate Variability. LID - 10.3390/cancers18182952 [doi] LID - 2952 AB - BACKGROUND: Extracellular DNA (extracellular DNA) is a promising biomarker for tumor burden and systemic inflammation. However, its clinical significance in urothelial carcinoma remains unclear. This study evaluated plasma extracellular DNA (nuclear and mitochondrial fractions) and DNase activity in patients with bladder cancer (BC) in comparison to healthy controls, and explored their associations with tumor stage, survival, and heart rate variability (HRV) as a non-invasive marker of autonomic regulation. METHODS: We prospectively analyzed 84 subjects: 63 patients with urothelial carcinoma (52 non-muscle-invasive [NMIBC]; 11 muscle-invasive [MIBC]) and 21 healthy controls. Plasma extracellular DNA was quantified fluorometrically, while ncDNA and mtDNA fractions were assessed via quantitative real-time PCR. DNase activity was determined using the single radial enzyme diffusion assay. Clinical associations were evaluated through group comparisons, multivariable logistic regression, survival analysis, and correlation with HRV parameters. RESULTS: Patients with BC exhibited slightly but significantly higher extracellular DNA compared to healthy controls (by 9%); ncDNA showed a similar trend. Regarding disease progression, ncDNA demonstrated a stronger association with tumor stage than total extracellular DNA, with the highest concentrations observed in patients with MIBC. In multivariable logistic regression models adjusted for age, BMI, sex, smoking, and alcohol consumption, extracellular DNA remained independently associated with BC status (OR 5.99, 95% CI 1.43-25.12, p = 0.015). Log-transformed ncDNA was also associated with BC status, although the model was constrained by missing data. No significant differences in overall survival were observed when stratified by cutoff values of extracellular DNA, ncDNA, mtDNA, or DNase activity. Notably, while extracellular DNA correlated significantly with several HRV parameters in healthy individuals (after FDR correction), this physiological coupling was absent in patients with BC. CONCLUSIONS: Circulating extracellular DNA and ncDNA are independently associated with BC, with ncDNA showing a stronger correlation with tumor stage. While prognostic value regarding survival was not confirmed in this cohort, the absence of extracellular DNA-HRV correlations in patients, despite significant associations in healthy controls, suggests the loss of physiological coupling between circulating DNA and autonomic regulation. Further longitudinal studies are needed to validate the clinical utility and biological interpretation of these markers. FAU - Palacka, Patrik AU - Palacka P AUID- ORCID: 0000-0003-4505-0952 AD - 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia. AD - Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia. FAU - Kovacova Ilijew, Hana AU - Kovacova Ilijew H AD - Institute of Immunology, Faculty of Medicine, Comenius University, Odborarske Namestie 14, 811 08 Bratislava, Slovakia. FAU - Mikolaskova, Iveta AU - Mikolaskova I AUID- ORCID: 0000-0003-4443-9069 AD - Institute of Immunology, Faculty of Medicine, Comenius University, Odborarske Namestie 14, 811 08 Bratislava, Slovakia. FAU - Suchankova, Magda AU - Suchankova M AD - Institute of Immunology, Faculty of Medicine, Comenius University, Odborarske Namestie 14, 811 08 Bratislava, Slovakia. FAU - Paulovicova, Maria AU - Paulovicova M AD - 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia. FAU - Rondzikova, Beata AU - Rondzikova B AD - 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia. FAU - Kollarik, Boris AU - Kollarik B AD - 2nd Department of Urology, Faculty of Medicine and Bory Hospital, Comenius University, Ivana Kadlecika 2, 841 03 Bratislava, Slovakia. FAU - Celec, Peter AU - Celec P AD - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia. AD - Institute of Pathophysiology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia. FAU - Hunakova, Luba AU - Hunakova L AD - Institute of Immunology, Faculty of Medicine, Comenius University, Odborarske Namestie 14, 811 08 Bratislava, Slovakia. LA - eng GR - VEGA 1/0090/22/Ministry of Education, Science, Research and Sport of the Slovak Republic/ GR - APVV-22-0231, APVV-22-0554/Slovak Research and Development Agency/ GR - UK/1364/2025/Comenius University Bratislava/ GR - NA/OncoReSearch/ PT - Journal Article DEP - 20260912 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13604709 OTO - NOTNLM OT - bladder cancer OT - extracellular DNA OT - mitochondrial DNA OT - nuclear DNA OT - nuclease COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/09/12 CRDT- 2026/09/26 01:09 PHST- 2026/08/14 00:00 [received] PHST- 2026/09/06 00:00 [revised] PHST- 2026/09/11 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:09 [entrez] PHST- 2026/09/12 00:00 [pmc-release] AID - cancers18182952 [pii] AID - cancers-18-02952 [pii] AID - 10.3390/cancers18182952 [doi] PST - epublish SO - Cancers (Basel). 2026 Sep 12;18(18):2952. doi: 10.3390/cancers18182952. PMID- 42792838 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 14 IP - 9 DP - 2026 Sep 17 TI - Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/biomedicines14092098 [doi] LID - 2098 AB - Intravesical Bacillus Calmette-Guerin (BCG) remains the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. However, 30-50% of patients fail to respond or experience recurrence within two years, while clinical and pathological risk models have limited accuracy in predicting individual response. This narrative review summarizes molecular classifications and candidate biomarkers associated with BCG response and assesses their potential clinical utility, based on a focused search of PubMed, Scopus, and Web of Science through July 2026, supplemented by ClinicalTrials.gov, regulatory documents, and current guidelines. Transcriptomic classifications, including UROMOL2021, BCG Response Subtypes (BRS), MSP888, and subtypes defined in stage T1 disease, identify tumor phenotypes associated with differences in recurrence, progression, and outcomes after BCG. BRS3 is characterized by basal-squamous and immunosuppressive features and is associated with shorter recurrence-free and progression-free survival. Genomic alterations, including FGFR3 and TERT promoter mutations and APOBEC signatures; DNA methylation markers such as GATA2, TBX3, and GPR158; and tumor microenvironment features, including regulatory T cells, exhausted CD8+ T cells, and PD-L1 expression, have been associated with outcomes in individual cohorts but remain unvalidated as treatment-specific predictors. Bladder-preserving options for BCG-unresponsive disease include pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system. Randomized trials adding checkpoint inhibition to BCG in BCG-naive disease have reported inconsistent results. No molecular biomarker is currently validated for treatment selection. Molecular profiling remains investigational and may complement, but not replace, established clinical risk assessment. Clinical implementation requires prospective biomarker-stratified trials with standardized definitions, assays, and endpoints. FAU - Bilyalov, Airat AU - Bilyalov A AUID- ORCID: 0000-0002-8888-8395 AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. AD - Life Improvement by Future Technologies (LIFT) Center, 121205 Moscow, Russia. FAU - Kotov, Andrey AU - Kotov A AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. FAU - Bodunova, Natalia AU - Bodunova N AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. FAU - Zingerenko, Maxim AU - Zingerenko M AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. FAU - Khatkov, Igor AU - Khatkov I AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. FAU - Zhukova, Ludmila AU - Zhukova L AD - Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia. LA - eng PT - Journal Article PT - Review DEP - 20260917 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC13604516 OTO - NOTNLM OT - BCG-unresponsive disease OT - Bacillus Calmette-Guerin OT - bladder-preserving therapy OT - immune checkpoint inhibitors OT - molecular classification OT - non-muscle-invasive bladder cancer OT - predictive biomarkers OT - tumor microenvironment COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/09/17 CRDT- 2026/09/26 01:02 PHST- 2026/08/25 00:00 [received] PHST- 2026/09/11 00:00 [revised] PHST- 2026/09/15 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:02 [entrez] PHST- 2026/09/17 00:00 [pmc-release] AID - biomedicines14092098 [pii] AID - biomedicines-14-02098 [pii] AID - 10.3390/biomedicines14092098 [doi] PST - epublish SO - Biomedicines. 2026 Sep 17;14(9):2098. doi: 10.3390/biomedicines14092098. PMID- 42774854 OWN - NLM STAT- MEDLINE DCOM- 20260923 LR - 20260924 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era. PG - 1853633 LID - 10.3389/fimmu.2026.1853633 [doi] LID - 1853633 AB - Urothelial carcinoma (UC) remains a persistent clinical challenge in the post-Bacillus Calmette-Guerin (BCG) era, particularly because a substantial proportion of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) experience recurrence or progression despite standard intravesical immunotherapy. Although immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have expanded the therapeutic armamentarium, widely studied biomarkers such as tumor mutational burden (TMB) and PD-L1 expression show limited and inconsistent predictive performance in UC, which may partly reflect their inability to capture the spatial organization and functional states of the tumor immune microenvironment (TIME). Tertiary lymphoid structures (TLS), ectopic lymphoid aggregates that develop in non-lymphoid tissues at sites of chronic inflammation or cancer, have emerged as candidate mediators and spatial markers of local adaptive immunity. In UC, TLS appear to exhibit spatial heterogeneity and may exist across a maturation continuum from early, disorganized lymphoid aggregates to mature, germinal center-containing follicles; their localization within the lamina propria, tumor stroma, or invasive front may be associated with distinct immune contexts and clinical outcomes. This review provides a urology-centric perspective on TLS biology in UC, emphasizing how the anatomical and immunological niche of the bladder, including urinary exposure, the urinary microbiome, BCG-associated inflammation, and stromal remodeling, may shape the conditions under which TLS develop and function. We critically discuss TLS maturation status as a potential spatial biomarker, while emphasizing that its relationship with BCG failure and subsequent response to PD-1/PD-L1 blockade or enfortumab vedotin (EV)-based therapy remains largely correlative and requires prospective validation. Furthermore, we explore emerging strategies that may modulate TLS-associated immune architecture, including STING agonist instillation and LTbetaR pathway modulation, and discuss how TLS could be tested as an adjunctive biomarker in future bladder-preservation studies for high-risk T1 disease. By synthesizing current evidence and methodological advances in spatial transcriptomics, we underscore the translational imperative of viewing UC as a malignancy with heterogeneous local immune architecture, including candidate tertiary lymphoid structures. At present, TLS should not be used as a stand-alone biomarker for selecting bladder preservation, radical cystectomy, intravesical therapy continuation, or systemic treatment switching. CI - Copyright (c) 2026 Wei, Pei and Yu. FAU - Wei, Xin AU - Wei X AD - Department of Urology, China-Japan Union Hospital, Jilin University, Changchun, China. FAU - Pei, Xin AU - Pei X AD - Department of Urology, China-Japan Union Hospital, Jilin University, Changchun, China. FAU - Yu, Shanshan AU - Yu S AD - Department of Anaesthesiology, China-Japan Union Hospital, Jilin University, Changchun, China. LA - eng PT - Journal Article PT - Review DEP - 20260908 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Tertiary Lymphoid Structures/immunology/pathology MH - Tumor Microenvironment/immunology MH - Non-Muscle Invasive Bladder Neoplasms MH - Animals MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *Urinary Bladder Neoplasms/immunology/pathology/therapy MH - Immunotherapy/methods MH - *Carcinoma, Transitional Cell/immunology/pathology/therapy MH - Biomarkers, Tumor PMC - PMC13595574 OTO - NOTNLM OT - BCG OT - bladder cancer OT - immunotherapy OT - spatial transcriptomics OT - tertiary lymphoid structures OT - tumor microenvironment COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/09/23 11:50 MHDA- 2026/09/23 11:51 PMCR- 2026/09/08 CRDT- 2026/09/23 06:55 PHST- 2026/04/12 00:00 [received] PHST- 2026/08/22 00:00 [revised] PHST- 2026/08/27 00:00 [accepted] PHST- 2026/09/23 11:51 [medline] PHST- 2026/09/23 11:50 [pubmed] PHST- 2026/09/23 06:55 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1853633 [doi] PST - epublish SO - Front Immunol. 2026 Sep 8;17:1853633. doi: 10.3389/fimmu.2026.1853633. eCollection 2026. PMID- 42759922 OWN - NLM STAT- MEDLINE DCOM- 20261006 LR - 20261007 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 660 DP - 2026 Nov 1 TI - Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study. PG - 218853 LID - S0304-3835(26)00617-8 [pii] LID - 10.1016/j.canlet.2026.218853 [doi] AB - Accurate non-invasive tools for bladder cancer detection and preoperative assessment of muscle invasion remain limited. We developed a plasma cell-free DNA (cfDNA) fragmentomics assay to support two clinically related tasks: detection of bladder cancer and preoperative estimation of muscle-invasive risk. Using low-pass whole-genome sequencing, we extracted fragment size coverage, copy-number variation, and nucleosome positioning features. The multicenter cohort included 656 participants and an external extension of 31 cancer cases (total, 687). An integrated classifier was first trained for cancer detection. Subsequently, a separate non-muscle-invasive bladder cancer (NMIBC) versus muscle-invasive bladder cancer (MIBC) classifier was developed using definitively staged cases from the training cohort with internal threshold selection and independent external validation. For cancer detection, the model achieved AUCs of 0.9484 (training), 0.9446 (internal validation), and 0.9390 (external validation). At the locked threshold of 0.592, selected in the internal validation cohort, sensitivities were 81.0%, 80.0%, and 84.3%, with specificities of 95.0%, 94.7%, and 91.8% against healthy controls and 93.3% and 91.1% against benign disease controls in internal and external validation, respectively. For invasion stratification, the NMIBC/MIBC classifier achieved AUCs of 0.9254, 0.9004, and 0.8845 in the training, internal validation, and expanded external validation cohorts, respectively, with 90.3% sensitivity and 77.4% specificity for MIBC detection externally. The assay demonstrated high reproducibility across storage conditions and sequencing batches. This blood-based framework supports multicenter bladder cancer detection and preoperative stratification of muscle invasion as an adjunctive translational approach, while prospective validation in defined clinical use settings remains necessary. CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Liu, Kaihua AU - Liu K AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Bao, Hua AU - Bao H AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Li, Guangqi AU - Li G AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Ran, Wenwen AU - Ran W AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Yang, Ping AU - Yang P AD - Department of Pathology, Yantai Yuhuangding Hospital, Yantai, Shandong, China. FAU - Zhang, Zongliang AU - Zhang Z AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Li, Wenxian AU - Li W AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Li, Ningyou AU - Li N AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Ren, Minhui AU - Ren M AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Ding, Tao AU - Ding T AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - He, Peng AU - He P AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Yang, Shanshan AU - Yang S AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Hong, Xinyue AU - Hong X AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China. FAU - Wang, Ke AU - Wang K AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: wangke@qdu.edu.cn. FAU - Xing, Xiaoming AU - Xing X AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: xiaoming.xing@qdu.edu.cn. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260918 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 RN - 0 (Biomarkers, Tumor) RN - 0 (Cell-Free Nucleic Acids) SB - IM MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/blood/genetics/diagnosis/pathology/surgery MH - Aged MH - Male MH - *Biomarkers, Tumor/blood/genetics MH - Middle Aged MH - Non-Muscle Invasive Bladder Neoplasms MH - Risk Assessment/methods MH - *Cell-Free Nucleic Acids/blood/genetics MH - Whole Genome Sequencing MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder cancer OT - Early detection OT - Liquid biopsy OT - Muscle invasion OT - cfDNA fragmentomics COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kaihua Liu, Hua Bao, Ningyou Li, Minhui Ren, Tao Ding, Peng He, Shanshan Yang, and Xinyue Hong are employees of Nanjing Geneseeq Technology Inc. The other authors declare no competing interests. EDAT- 2026/09/18 23:36 MHDA- 2026/10/06 23:29 CRDT- 2026/09/18 19:23 PHST- 2026/04/17 00:00 [received] PHST- 2026/08/30 00:00 [revised] PHST- 2026/09/18 00:00 [accepted] PHST- 2026/10/06 23:29 [medline] PHST- 2026/09/18 23:36 [pubmed] PHST- 2026/09/18 19:23 [entrez] AID - S0304-3835(26)00617-8 [pii] AID - 10.1016/j.canlet.2026.218853 [doi] PST - ppublish SO - Cancer Lett. 2026 Nov 1;660:218853. doi: 10.1016/j.canlet.2026.218853. Epub 2026 Sep 18. PMID- 42755601 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260918 LR - 20260919 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer. PG - 1921569 LID - 10.3389/fonc.2026.1921569 [doi] LID - 1921569 AB - OBJECTIVES: To characterize recurrence heterogeneity among patients with VI-RADS 2 non-muscle-invasive bladder cancer (NMIBC) and to develop and internally validate a recurrence-free survival (RFS) prediction model incorporating quantitative MRI features. METHODS: This retrospective study included 342 patients with pathologically confirmed VI-RADS 2 NMIBC, who were randomly divided into training and internal validation cohorts. Clinical and quantitative MRI variables were evaluated using Cox regression, least absolute shrinkage and selection operator regression, Boruta, and recursive feature elimination. Six survival prediction algorithms were developed and compared. The selected model was further compared with a clinical Cox model and the European Association of Urology (EAU) risk stratification system using the concordance index (C-index), time-dependent area under the curve (AUC), calibration, Brier score, and decision curve analysis. RESULTS: Among 342 patients, 111 (32.5%) experienced recurrence. Six predictors were retained: tumor number, maximum tumor vertical distance, maximum tumor diameter, maximum tumor-base contact length, mean apparent diffusion coefficient (ADC) at the tumor base, and minimum ADC within the tumor. The random survival forest (RSF) model achieved C-index values of 0.832 and 0.757 in the training and validation cohorts, respectively. In the validation cohort, the corresponding C-index values were 0.417 for the clinical Cox model and 0.534 for the EAU risk stratification system. The RSF model also yielded higher time-dependent AUCs than both reference models and greater net benefit at the 60-month horizon. RSF-derived risk groups showed significantly different RFS in both cohorts; in the validation cohort, the hazard ratio for the high-risk versus low-risk group was 5.30 (95% confidence interval, 2.39-11.76). CONCLUSIONS: Within this single-center cohort, recurrence risk varied substantially among patients with VI-RADS 2 NMIBC. An RSF model incorporating quantitative MRI features and tumor number showed better internal discrimination than the clinical Cox model and the EAU risk stratification system and separated patients into distinct risk groups. These findings suggest that quantitative MRI features may complement conventional clinical assessment in this imaging-defined subgroup. Prospective multicenter external validation with longer follow-up is required before the model can be considered for clinical use. CI - Copyright (c) 2026 Sun, Wang, Yang, Tan, Sun, Pang, Dai, Wang, Zhang, Ma, Cao and Yang. FAU - Sun, Junpeng AU - Sun J AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Wang, Ziyong AU - Wang Z AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Yang, Maofa AU - Yang M AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Tan, Zijian AU - Tan Z AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Sun, Hong AU - Sun H AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Pang, Xusong AU - Pang X AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Dai, Longguo AU - Dai L AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Wang, Siting AU - Wang S AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Zhang, Kun AU - Zhang K AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Ma, Tenglu AU - Ma T AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Cao, Zhao AU - Cao Z AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. FAU - Yang, Hong AU - Yang H AD - Department of Urology I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China. LA - eng PT - Journal Article DEP - 20260903 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13581660 OTO - NOTNLM OT - bladder neoplasms OT - machine learning OT - magnetic resonance imaging OT - prognosis OT - recurrence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/09/18 12:26 MHDA- 2026/09/18 12:27 PMCR- 2026/09/03 CRDT- 2026/09/18 05:24 PHST- 2026/06/27 00:00 [received] PHST- 2026/08/06 00:00 [revised] PHST- 2026/08/24 00:00 [accepted] PHST- 2026/09/18 12:27 [medline] PHST- 2026/09/18 12:26 [pubmed] PHST- 2026/09/18 05:24 [entrez] PHST- 2026/09/03 00:00 [pmc-release] AID - 10.3389/fonc.2026.1921569 [doi] PST - epublish SO - Front Oncol. 2026 Sep 3;16:1921569. doi: 10.3389/fonc.2026.1921569. eCollection 2026. PMID- 42751608 OWN - NLM STAT- MEDLINE DCOM- 20260917 LR - 20260918 IS - 1844-3117 (Electronic) IS - 1844-122X (Print) IS - 1844-122X (Linking) VI - 19 IP - 7 DP - 2026 Jul TI - Preoperative predictors of adverse pathological outcomes following radical cystectomy for muscle-invasive bladder cancer in a tertiary referral center. PG - 578-582 LID - 10.25122/jml-2026-0088 [doi] AB - Accurate preoperative identification of non-organ-confined disease in patients with muscle-invasive bladder cancer could guide patient selection for bladder-sparing strategies. We evaluated the association between available preoperative clinical variables linked to worse oncologic outcomes and pathologic upstaging (>/=T3) at radical cystectomy in patients with muscle-invasive bladder cancer. We reviewed our cohort of patients with clinical T2 bladder cancer who underwent radical cystectomy at the Municipal Hospital of Cluj-Napoca, Romania, between 2017 and 2026. Univariable and multivariable logistic regression analyses were used to evaluate the association between preoperative clinical variables: tumor size > 3 cm at transurethral resection (TUR), chronic kidney disease (CKD), hydronephrosis, lymphovascular invasion (LVI), and non-organ-confined disease (>/=pT3) at radical cystectomy. The final cohort consisted of 129 patients who underwent radical cystectomy and were included in the analysis. Lymphovascular invasion was independently associated with non-organ-confined disease on multivariable analysis across the entire cohort (OR = 6.99; 95% CI, 2.83-18.5; P < 0.001), among patients who received neoadjuvant chemotherapy (OR = 10.5; 95% CI, 2.62-53.1; P = 0.002), and among those who did not (OR = 5.13; 95% CI, 1.41-21.2; P = 0.017). Hydronephrosis was associated with non-organ-confined disease on univariable analysis but did not remain significant on multivariable analysis in the overall cohort (OR = 1.77; 95% CI, 0.71-4.36; P = 0.2). Chronic kidney disease and tumor size greater than 3 cm were associated with non-organ-confined disease on univariable but not multivariable analysis. Lymphovascular invasion was the most consistent independent predictor of pathologic upstaging at radical cystectomy. Further research in larger cohorts is needed to validate these findings. CI - (c) 2026 The Author(s). FAU - Buzoianu, Matei Maximilian AU - Buzoianu MM AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Andras, Iulia AU - Andras I AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Giurgiu, Lorin AU - Giurgiu L AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Medan, Paul AU - Medan P AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Medan, Stefana AU - Medan S AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Popa, Andrei AU - Popa A AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Cata, Emanuel AU - Cata E AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Ionutas, Emanuela AU - Ionutas E AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Apetrei, Marius AU - Apetrei M AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Coman, Ioan AU - Coman I AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Crisan, Nicolae AU - Crisan N AD - Urology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. LA - eng PT - Journal Article PL - Romania TA - J Med Life JT - Journal of medicine and life JID - 101477617 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Cystectomy/methods/adverse effects MH - Female MH - Male MH - Aged MH - *Tertiary Care Centers MH - Neoplasm Invasiveness MH - Middle Aged MH - Treatment Outcome MH - Transurethral Resection of Bladder MH - Preoperative Period PMC - PMC13580513 OTO - NOTNLM OT - lymphovascular invasion OT - non-organ confined disease OT - radical cystectomy COIS- The authors declare no conflict of interest. EDAT- 2026/09/17 15:39 MHDA- 2026/09/17 15:40 PMCR- 2026/07/01 CRDT- 2026/09/17 07:13 PHST- 2026/06/19 00:00 [received] PHST- 2026/07/09 00:00 [accepted] PHST- 2026/09/17 15:40 [medline] PHST- 2026/09/17 15:39 [pubmed] PHST- 2026/09/17 07:13 [entrez] PHST- 2026/07/01 00:00 [pmc-release] AID - JMedLife-19-578 [pii] AID - 10.25122/jml-2026-0088 [doi] PST - ppublish SO - J Med Life. 2026 Jul;19(7):578-582. doi: 10.25122/jml-2026-0088. PMID- 42751111 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260917 LR - 20260918 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Immunotherapy role in bladder cancer treatment: a review of literature. PG - 1908307 LID - 10.3389/fonc.2026.1908307 [doi] LID - 1908307 AB - Immunotherapy has changed the landscape of bladder cancer treatment in recent years, both for localized and metastatic bladder cancer. While bacillus Calmette-Guerin (BCG) remains the gold standard for high-risk non-muscle-invasive bladder cancer, the development of checkpoint inhibitors continues to increase treatment options for patients who are intolerant or unresponsive to BCG. In the setting of muscle-invasive bladder cancer, perioperative checkpoint blockade has shown promising pathologic response rates and survival signals, especially in PDL1/CPS enriched populations. In metastatic bladder cancer, anti-PD-1/PD-L1 therapy can lead to durable responses in a subset of patients, and combination strategies, sequences of therapy, and biomarkers are all being explored to help guide patient selection and improve clinical outcomes. Herein, we review evidence supporting the use of immunotherapy in non-muscle invasive, muscle invasive, and metastatic bladder cancer including the newer immunotherapy combination approaches. CI - Copyright (c) 2026 Thalambedu, Vasipalli, Sampath Kumar, Vellanki, Trikannad, Gullapalli, Tu and Kunthur. FAU - Thalambedu, Nishanth AU - Thalambedu N AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. FAU - Vasipalli, Krishna AU - Vasipalli K AD - Department of Internal Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States. FAU - Sampath Kumar, Nikhila AU - Sampath Kumar N AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. FAU - Vellanki, Sruthi AU - Vellanki S AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. FAU - Trikannad, Anup Kumar AU - Trikannad AK AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. FAU - Gullapalli, Manoja AU - Gullapalli M AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. FAU - Tu, Shi Ming AU - Tu SM AD - Department of Hematology and Oncology, Renown Medical Group, Reno, NV, United States. FAU - Kunthur, Anuradha AU - Kunthur A AD - Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States. LA - eng PT - Journal Article PT - Review DEP - 20260902 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13579257 OTO - NOTNLM OT - CtDNA OT - antibody drug conjugate (ADC) OT - artificial intelligence OT - bladder cancer OT - immunotherapies COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/09/17 15:39 MHDA- 2026/09/17 15:40 PMCR- 2026/09/02 CRDT- 2026/09/17 05:55 PHST- 2026/06/13 00:00 [received] PHST- 2026/07/28 00:00 [revised] PHST- 2026/08/10 00:00 [accepted] PHST- 2026/09/17 15:40 [medline] PHST- 2026/09/17 15:39 [pubmed] PHST- 2026/09/17 05:55 [entrez] PHST- 2026/09/02 00:00 [pmc-release] AID - 10.3389/fonc.2026.1908307 [doi] PST - epublish SO - Front Oncol. 2026 Sep 2;16:1908307. doi: 10.3389/fonc.2026.1908307. eCollection 2026. PMID- 42749990 OWN - NLM STAT- Publisher LR - 20260916 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Sep 16 TI - Segmental ureterectomy versus radical nephroureterectomy for middle and distal ureteral tumors associated with hydronephrosis: a comparative analysis of oncological outcomes and postoperative renal function. LID - 10.1007/s11255-026-05384-x [doi] AB - BACKGROUND: Radical nephroureterectomy (RNU) is the standard for high-risk upper tract urothelial carcinoma but causes inevitable renal functional decline. We evaluated the oncological outcomes and renal preservation of segmental ureterectomy (SU) versus RNU specifically for middle and distal ureteral tumors associated with hydronephrosis. METHODS: We retrospectively reviewed 139 patients (55 SU, 84 RNU) with middle or distal ureteral tumors and hydronephrosis treated between 2014 and 2024. Endpoints included overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and intravesical recurrence-free survival (IVRFS). Perioperative renal function was evaluated using estimated glomerular filtration rate (eGFR). RESULTS: During a median follow-up of 40.6 months, baseline characteristics were well balanced between the SU and RNU groups after overlap weighting. Despite a high proportion of high-risk disease (77.9% >/= T2, 59.2% high-grade), no significant differences existed between SU and RNU in OS (P = 0.969), CSS (P = 0.840), RFS (P = 0.957), or IVRFS (P = 0.941). Weighted Cox proportional hazards confirmed survival was dictated by tumor characteristics (stage, grade, length, lymph node involvement, surgical margins, vascular invasion and tumor necrosis), not surgical modality. Longitudinal mixed-effects analysis demonstrated that SU was associated with significantly higher postoperative eGFR compared with RNU across all follow-up intervals (P < 0.001). CONCLUSIONS: For middle and distal ureteral tumors presenting with hydronephrosis, no statistically significant differences in long-term oncological outcomes were observed between SU and RNU within the current cohort. SU demonstrated higher postoperative eGFR values, suggesting a potential nephron-sparing advantage in carefully selected patients. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Jiang, Sina AU - Jiang S AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Yao, Nianyuan AU - Yao N AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Lu, Yongliang AU - Lu Y AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Xu, Chunhui AU - Xu C AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Xiao, Yi AU - Xiao Y AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Zhang, Guohui AU - Zhang G AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. FAU - Yin, Xiaotao AU - Yin X AD - Department of Urology, The Fourth Medical Center of PLA General Hospital, Beijing, China. yxtfwy@163.com. LA - eng PT - Journal Article DEP - 20260916 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Oncological outcomes OT - Radical nephroureterectomy OT - Renal function OT - Segmental ureterectomy OT - Upper tract urothelial carcinoma COIS- Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of The Fourth Medical Center of PLA General Hospital (Date: September 11, 2025/No. 2025KY011-HS001). Consent to participate: The requirement for informed consent was waived by the Ethics Committee of The Fourth Medical Center of PLA General Hospital due to the retrospective nature of the study. Consent for publication: Not applicable. EDAT- 2026/09/17 05:35 MHDA- 2026/09/17 05:35 CRDT- 2026/09/16 23:48 PHST- 2026/04/28 00:00 [received] PHST- 2026/09/04 00:00 [accepted] PHST- 2026/09/17 05:35 [medline] PHST- 2026/09/17 05:35 [pubmed] PHST- 2026/09/16 23:48 [entrez] AID - 10.1007/s11255-026-05384-x [pii] AID - 10.1007/s11255-026-05384-x [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Sep 16. doi: 10.1007/s11255-026-05384-x. PMID- 42744708 OWN - NLM STAT- Publisher LR - 20260915 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) DP - 2026 Sep 15 TI - Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy. LID - S1078-1439(26)00695-2 [pii] LID - 10.1016/j.urolonc.2026.08.005 [doi] AB - BACKGROUND AND OBJECTIVE: The European Organization for Research and Treatment of Cancer (EORTC) and the Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk prediction models are established tools for predicting recurrence and progression in non-muscle invasive bladder cancer. However, their performance in patients undergoing TURBT with blue light cystoscopy (BLC-TURBT), which reduces disease recurrence, has not been examined. We, therefore, evaluated the performance of these models in a contemporary cohort of patients undergoing BLC-TURBT. METHODS: We identified patients aged 18 to 89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-TURBT between 2014 and 2023. We predicted disease recurrence- and progression-free survival estimates using the EORTC and CUETO models, and estimated observed recurrence-free (RFS) and progression-free (PFS) survival using the Kaplan-Meier method. RESULTS: A total of 899 patients were included. Tumor stage was Ta in 658 (73%) and T1 in 241 (27%) patients. EORTC risk score groups were associated with a statistically significant difference in RFS, whereas CUETO risk score groups were not. Observed RFS and PFS estimates were generally higher than that predicted by the EORTC risk score, while observed RFS and PFS were inconsistently related to that predicted by the CUETO risk score. The c-statistics for RFS and PFS by risk score group were 0.59 and 0.67 for EORTC, and 0.53 and 0.72 for CUETO, respectively. CONCLUSIONS: In a contemporary cohort of patients undergoing BLC-TURBT, the EORTC and CUETO models demonstrated poor performance in predicting RFS and PFS. These results underscore the need for development of more accurate predictive models to guide the risk-adapted management of patients undergoing BLC-TURBT. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Perez-Londono, Agustin AU - Perez-Londono A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Kaul, Sumedh AU - Kaul S AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Fleishman, Aaron AU - Fleishman A AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Konety, Badrinath AU - Konety B AD - Allina Health Cancer Institute, Minneapolis, MN. FAU - Pohar, Kamal AU - Pohar K AD - Department of Urology, Ohio State University, Columbus, OH. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - Department of Urology, University of Kansas, Kansas City, KS. FAU - Taylor, John AU - Taylor J AD - Department of Urology, University of Kansas, Kansas City, KS. FAU - Kates, Max AU - Kates M AD - The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Willard, Brian AU - Willard B AD - Lexington Medical Center, Lexington, SC. FAU - Taylor, Jennifer M AU - Taylor JM AD - Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX. FAU - Liao, Joseph C AU - Liao JC AD - VA Palo Alto Health Care System, Palo Alto, CA. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California San Francisco, San Francisco, CA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, Rush University, Chicago, IL. FAU - Tyson, Mark D AU - Tyson MD AD - Department of Urology, Mayo Clinic Hospital, Phoenix, AZ. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: bgershma@bidmc.harvard.edu. LA - eng PT - Journal Article DEP - 20260915 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Blue light cystoscopy OT - CUETO OT - EORTC OT - Outcome prediction OT - Progression OT - Recurrence COIS- Declaration of competing interest All study sites received research funding related to the Blue Light Cystoscopy with Cysview Registry. Additional related disclosures are listed below: Agustin Perez-Londono: None. Sumedh Kaul: None. Aaron Fleishman: None. Badrinath Konety: None. Kamal Pohar: None. Jeffrey M. Holzbeierlein: None. John Taylor: None. Max Kates: None. Brian Willard: None. Jennifer M. Taylor: None. Joseph C. Liao, Hristos Z. Kaimakliotis: None. Sima P. Porten: None. Gary D. Steinberg: None. Mark D. Tyson: None. Yair Lotan: Consultant (Photocure). Siamak Daneshmand: Consultant (Photocure). Boris Gershman: Consultant (Photocure). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/09/15 23:34 MHDA- 2026/09/15 23:34 CRDT- 2026/09/15 21:57 PHST- 2026/03/04 00:00 [received] PHST- 2026/06/15 00:00 [revised] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/09/15 23:34 [medline] PHST- 2026/09/15 23:34 [pubmed] PHST- 2026/09/15 21:57 [entrez] AID - S1078-1439(26)00695-2 [pii] AID - 10.1016/j.urolonc.2026.08.005 [doi] PST - aheadofprint SO - Urol Oncol. 2026 Sep 15:S1078-1439(26)00695-2. doi: 10.1016/j.urolonc.2026.08.005. PMID- 42740896 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260915 LR - 20260916 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 92 DP - 2026 Oct TI - Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database. PG - 28-35 LID - 10.1016/j.euros.2026.08.005 [doi] AB - BACKGROUND: Data on longitudinal bladder cancer (BC) costs are scarce. OBJECTIVE: To assess the economic burden of non-muscle-invasive bladder cancer (NMIBC) by progression risk groups in France over a 1-yr and 5-yr time horizon after initial diagnosis. DESIGN SETTING AND PARTICIPANTS: We used data from the French national prospective COhort to study BLAdder CancEr (COBLAnCE) cohort. A total of 1101 patients diagnosed with a primary NMIBC between 2012 and 2018 were linked with the French National Healthcare System Database. Patients were classified into four risk groups according to the 2021 European Association of Urology risk stratification. Resources used included all BC-related hospitalizations, follow-up visits to urology and oncology clinics and related prescriptions, BC-related imaging procedures, transportation, and sick leaves. Costs were estimated from the perspective of the French health care system over the 5 yr after BC diagnosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Across risk groups, mean per-patient cost ranged from euro5838 to euro20 678 and euro11 697 to euro40 519 over 1 yr and 5 yr, respectively. Surgical hospital stays accounted for 60% of costs in the first year. Over 5 yr, intravesical treatments, surveillance visits, and imaging were major cost drivers, especially among patients at lower risk of progression. RESULTS AND LIMITATIONS: Although claims databases are comprehensive, the economic burden of NMIBC may be underestimated owing to potential incomplete coding. CONCLUSIONS: To our knowledge, this is the first national cohort study to provide robust cost estimates for patients with NMIBC stratified according to progression risk groups. These real-world data are particularly awaited for the economic evaluation of emerging treatments in patients with NMIBC. CI - (c) 2026 The Author(s). FAU - Fraslin, Alderic M AU - Fraslin AM AD - Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France. AD - Oncostat U1018, INSERM, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France. FAU - Benhamou, Simone AU - Benhamou S AD - Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France. AD - Oncostat U1018, INSERM, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France. FAU - Lebret, Thierry AU - Lebret T AD - Urology, Foch Hospital, Universite Versailles St-Quentin en Yvelines, Suresnes, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Urology, Foch Hospital, Universite Versailles St-Quentin en Yvelines, Suresnes, France. FAU - Droupy, Stephane AU - Droupy S AD - Urology, University Hospital Center Caremeau, Nimes, France. FAU - Poinas, Gregoire AU - Poinas G AD - Urology, Clinique Beausoleil, Montpellier, France. FAU - Vordos, Dimitri AU - Vordos D AD - Urology, University Hospital Center Henri Mondor, Creteil, France. FAU - Guy, Laurent AU - Guy L AD - Urology, University Hospital Center Gabriel Montpied, Clermont-Ferrand, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology, Claude Huriez Hospital, CHU Lille F-59000 Lille, France. AD - UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Institut Pasteur de Lille, Universite de Lille, CNRS, Inserm, CHU Lille F-59000 Lille, France. FAU - Schneider, Marc AU - Schneider M AD - Urology, Pasteur Hospital, Colmar, France. FAU - Coloby, Patrick AU - Coloby P AD - Urology, NOVO Hospital, Pontoise, France. FAU - Monges, Arnaud AU - Monges A AD - Urology, Private Hospital of Provence, Aix-en-Provence, France. FAU - Mejean, Arnaud AU - Mejean A AD - Urology, European Hospital Georges Pompidou, Paris, France. FAU - Potiron, Eric AU - Potiron E AD - Urology, Atlantis Clinic, Saint-Herblain, France. FAU - Descotes, Jean-Luc AU - Descotes JL AD - Urology, University Hospital Center Michallon, Grenoble, France. FAU - Eschwege, Pascal AU - Eschwege P AD - Urology, CHRU Nancy-Brabois, UMR 7039 CRAN CNRS, Vandoeuvre-les-Nancy, France. FAU - Loison, Guillaume AU - Loison G AD - Urology, la Croix du Sud Clinic, Quint Fonsegrives, France. FAU - Krucker, Clementine AU - Krucker C AD - Integrative Molecular Pathology and Pre-clinical Testing, Inserm U1353, CNRS UMR9029, Institut Curie, Universite Versailles St-Quentin en Yvelines, Paris, France. FAU - Mangin, Anthony AU - Mangin A AD - Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France. FAU - Radvanyi, Francois AU - Radvanyi F AD - Department of Pathology, Institut Curie, UMR 144 CNRS, Universite Paris-Saclay, UVSQ, Paris, France. FAU - Allory, Yves AU - Allory Y AD - Integrative Molecular Pathology and Pre-clinical Testing, Inserm U1353, CNRS UMR9029, Institut Curie, Universite Versailles St-Quentin en Yvelines, Paris, France. FAU - Karimi, Maryam AU - Karimi M AD - Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France. AD - Oncostat U1018, INSERM, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France. FAU - Bonastre, Julia AU - Bonastre J AD - Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France. AD - Oncostat U1018, INSERM, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France. LA - eng PT - Journal Article DEP - 20260904 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC13571974 OTO - NOTNLM OT - Claims databases OT - Cohort OT - Economic burden OT - French National Healthcare System Database OT - Health care costs OT - Non-muscle-invasive bladder cancer OT - Urothelial carcinoma EDAT- 2026/09/15 05:36 MHDA- 2026/09/15 05:37 PMCR- 2026/09/04 CRDT- 2026/09/15 04:56 PHST- 2026/08/21 00:00 [accepted] PHST- 2026/09/15 05:37 [medline] PHST- 2026/09/15 05:36 [pubmed] PHST- 2026/09/15 04:56 [entrez] PHST- 2026/09/04 00:00 [pmc-release] AID - S2666-1683(26)01179-1 [pii] AID - 10.1016/j.euros.2026.08.005 [doi] PST - epublish SO - Eur Urol Open Sci. 2026 Sep 4;92:28-35. doi: 10.1016/j.euros.2026.08.005. eCollection 2026 Oct. PMID- 42739239 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260915 LR - 20260916 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 17 DP - 2026 Sep 1 TI - Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review. LID - 10.3390/diagnostics16172810 [doi] LID - 2810 AB - Urinary biomarkers are promising tools in urological oncology because urine can be collected non-invasively and repeatedly during diagnosis, treatment, and surveillance. Despite extensive biomarker discovery, their adoption in routine practice remains limited. Biomarker performance depends not only on analytical accuracy but also on the clinical decision, anatomical route into urine, biological source of the signal, specimen fraction, and timing and conditions of sampling. This review evaluates urinary biomarkers across bladder cancer, upper-tract urothelial carcinoma, prostate cancer, and renal cell carcinoma using a biologically grounded, decision-oriented framework. It considers tumor-derived nucleic acids, epigenetic alterations, proteins, immune and inflammatory mediators, extracellular vesicles, metabolites, microbiome-associated signals, and multiparametric models. Bladder cancer represents the most anatomically direct and clinically mature setting, with potential applications in hematuria evaluation, cystoscopy triage, recurrence surveillance, molecular residual disease assessment, and monitoring of response to bacillus Calmette-Guerin therapy. In upper-tract urothelial carcinoma, distinguishing voided from selectively collected urine is essential because dilution, transit, obstruction, and limited localization affect interpretation. Prostate urine assays are best positioned for biopsy triage and refinement of active surveillance rather than general population screening. Renal cell carcinoma biomarkers remain exploratory because the sources and mechanisms of urinary signal release are insufficiently resolved. Clinical translation should be assessed using decision-specific outcomes, including incremental value, calibration, net clinical benefit, procedures avoided, significant cancers missed, reproducibility, and feasibility, rather than diagnostic accuracy or area under the receiver operating characteristic curve alone. FAU - Nurmukhanbetova, Aliya AU - Nurmukhanbetova A AUID- ORCID: 0000-0001-7981-8603 AD - General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan. FAU - Sultanbekov, Kassymkhan AU - Sultanbekov K AD - Department of Public Health and Healthcare, South Kazakhstan Medical Academy, Shymkent 160019, Kazakhstan. FAU - Umurzakov, Khussan AU - Umurzakov K AD - Urooncology Center, Kazakh Institute of Oncology and Radiology, Almaty 050022, Kazakhstan. FAU - Gassanov, Zie AU - Gassanov Z AD - Urooncology Center, Kazakh Institute of Oncology and Radiology, Almaty 050022, Kazakhstan. FAU - Duisenbayeva, Altyn AU - Duisenbayeva A AD - Department of General Medical Practice No. 2, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan. FAU - Talas, Alimkhan AU - Talas A AD - Department of General Medical Practice No. 2, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan. FAU - Shaikenova, Lazzat AU - Shaikenova L AD - Department of Clinical Disciplines, University of International Business Named After Kenzhegali Sagadiev, Almaty 050010, Kazakhstan. FAU - Bolatov, Aidos AU - Bolatov A AUID- ORCID: 0000-0002-5390-4623 AD - Shenzhen University Medical School, Shenzhen University, Shenzhen 518037, China. AD - Department of Science, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan. LA - eng PT - Journal Article PT - Review DEP - 20260901 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13565365 OTO - NOTNLM OT - biomarker validation OT - bladder cancer OT - liquid biopsy OT - precision oncology OT - prostate cancer OT - renal cell carcinoma OT - upper-tract urothelial carcinoma OT - urinary biomarkers COIS- The authors declare no conflicts of interest. EDAT- 2026/09/15 05:36 MHDA- 2026/09/15 05:37 PMCR- 2026/09/01 CRDT- 2026/09/15 03:24 PHST- 2026/07/10 00:00 [received] PHST- 2026/08/15 00:00 [revised] PHST- 2026/08/24 00:00 [accepted] PHST- 2026/09/15 05:37 [medline] PHST- 2026/09/15 05:36 [pubmed] PHST- 2026/09/15 03:24 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - diagnostics16172810 [pii] AID - diagnostics-16-02810 [pii] AID - 10.3390/diagnostics16172810 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Sep 1;16(17):2810. doi: 10.3390/diagnostics16172810. PMID- 42733765 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260914 LR - 20260915 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 11 IP - 12 DP - 2026 Dec TI - Dose-Escalated Radiation Therapy for Muscle-Invasive Bladder Cancer: A Retrospective Analysis. PG - 102156 LID - 10.1016/j.adro.2026.102156 [doi] LID - 102156 AB - PURPOSE: Patients managed with trimodal therapy (TMT) for muscle-invasive bladder cancer remain at risk of intravesical recurrences. This retrospective analysis evaluates the efficacy and safety of dose escalation compared with standard-dose radiation therapy, with differentiation between invasive and noninvasive local control. METHODS AND MATERIALS: A multicenter retrospective analysis was conducted on patients with muscle-invasive bladder cancer who underwent TMT with contemporary radiation therapy techniques from 2015 to 2025. Patients in the standard-dose cohort received either 55 Gy in 20 fractions or 64 Gy in 32 fractions. In the dose-escalation cohort, a simultaneous integrated boost approach was undertaken to deliver up to 60 Gy in 20 fractions or 70 Gy in 32 fractions to the primary lesion. The effect of dose escalation compared with standard dose on 2-year local control for invasive and noninvasive disease, metastasis-free survival, overall survival, bladder preservation, and toxicity was investigated. RESULTS: The cohort consisted of 107 patients with a median follow-up of 23 months. Dose escalation was significantly associated with improved local control of invasive disease (subdistribution hazard ratio 0.20 [0.05, 0.89], P = .035) compared with standard dosing, after adjusting for T stage. There were no differences in local control for noninvasive disease (P = .8), metastasis-free survival (P = .8), and overall survival (P = .5). Both groups tolerated radiation therapy well, with no difference in grade 2 or greater genitourinary and gastrointestinal toxicity (P = .8, P = .9, respectively). No patients receiving dose escalation required salvage cystectomy for invasive disease recurrence, compared with 2 patients who received standard dosing. CONCLUSIONS: Preliminary evidence suggests efficacy of dose escalation with good tolerability, high rates of bladder preservation, and potentially lower rates of invasive recurrences compared with standard-dose radiation therapy. This study's findings support the need for further prospective studies to evaluate dose escalation as a technique to maximize the efficacy of TMT. CI - (c) 2026 The Authors. FAU - Chan, Li AU - Chan L AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. FAU - Anzela, Anzela AU - Anzela A AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. FAU - Do, Viet AU - Do V AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. FAU - Wong, Karen AU - Wong K AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. FAU - Roncolato, Felicia AU - Roncolato F AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. FAU - Descallar, Joseph AU - Descallar J AD - Ingham Institute, Sydney, Australia. AD - South West Sydney clinical campuses, School of Clinical Medicine, University of New South Wales Sydney, Liverpool, New South Wales, Australia. FAU - Stanowski, Matthew AU - Stanowski M AD - Department of Urology, Liverpool Hospital, Sydney, Australia. FAU - Sved, Paul AU - Sved P AD - Department of Urology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Sidhom, Mark AU - Sidhom M AD - Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia. AD - South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. LA - eng PT - Journal Article DEP - 20260729 PL - United States TA - Adv Radiat Oncol JT - Advances in radiation oncology JID - 101677247 PMC - PMC13571918 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/09/14 05:35 MHDA- 2026/09/14 05:36 PMCR- 2026/07/29 CRDT- 2026/09/14 04:17 PHST- 2026/02/02 00:00 [received] PHST- 2026/07/16 00:00 [accepted] PHST- 2026/09/14 05:36 [medline] PHST- 2026/09/14 05:35 [pubmed] PHST- 2026/09/14 04:17 [entrez] PHST- 2026/07/29 00:00 [pmc-release] AID - S2452-1094(26)00163-6 [pii] AID - 102156 [pii] AID - 10.1016/j.adro.2026.102156 [doi] PST - epublish SO - Adv Radiat Oncol. 2026 Jul 29;11(12):102156. doi: 10.1016/j.adro.2026.102156. eCollection 2026 Dec. PMID- 42732768 OWN - NLM STAT- Publisher LR - 20260915 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) DP - 2026 Sep 13 TI - Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer. LID - 10.1111/cas.70534 [doi] AB - Human epidermal growth factor receptor 2 (HER2) has emerged as a potential therapeutic target in bladder cancer (BC), particularly with the advent of next-generation antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd). However, the complex relationship between HER2 protein expression, genetic status, and clinical outcomes remains incompletely understood. We conducted an integrated multi-omics analysis of 445 BC cases (306 muscle-invasive [MIBC] and 139 non-muscle-invasive [NMIBC]) from the OMPU-NCC cohort, a uniform Japanese clinical database. The study utilized whole-exome sequencing, RNA sequencing, and refined HER2 immunohistochemistry (IHC) scoring. HER2 IHC positivity (1+/2+/3+) was identified in 30.1% of the cohort. An additional 8.5% exhibited faint membrane staining despite being IHC 0, indicating that detectable HER2 membrane staining was present in approximately 38.5% of cases. HER2 IHC scores showed no prognostic value, whereas ERBB2 amplification, detected in 7.8% of cases, was associated with poorer survival and remained an independent adverse prognostic factor in multivariable analysis (HR, 1.76; 95% CI: 1.08-2.87). ERBB2 amplification was accompanied by frequent co-amplification of genes within the 17q12 amplicon, including GRB7, MIEN1, and PGAP3. Molecular subtyping revealed that ERBB2 amplification was enriched in the Luminal Unstable (LumU) subtype. In contrast, detectable HER2 membrane staining significantly correlated with high NECTIN4 expression, indicating an overlap between tumors expressing these two ADC targets. HER2 protein expression and ERBB2 amplification represent distinct features of BC. Their integrated assessment may improve molecular stratification and guide future biomarker-driven studies. CI - (c) 2026 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. FAU - Hirosuna, Kensuke AU - Hirosuna K AUID- ORCID: 0000-0002-9263-4929 AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. AD - Department of Cancer Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Nishimura, Kazuki AU - Nishimura K AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. FAU - Sakamoto, Moritoshi AU - Sakamoto M AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. FAU - Tokushige, Satoshi AU - Tokushige S AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Nakamori, Keita AU - Nakamori K AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Matsunaga, Tomohisa AU - Matsunaga T AUID- ORCID: 0000-0001-5238-2598 AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Yoshikawa, Yuki AU - Yoshikawa Y AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Tsutsumi, Takeshi AU - Tsutsumi T AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Maenosono, Ryoichi AU - Maenosono R AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. FAU - Tsujino, Takuya AU - Tsujino T AUID- ORCID: 0000-0003-1559-1889 AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. FAU - Ajiro, Masahiko AU - Ajiro M AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan. FAU - Yoshimi, Akihide AU - Yoshimi A AUID- ORCID: 0000-0002-0664-7281 AD - Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan. AD - Department of Cancer Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Kawasaki Medical School, Okayama, Japan. LA - eng GR - Canon Foundation for Scientific Research/ GR - Takeda Science Foundation/ GR - JP26ak0101263/Japan Agency for Medical Research and Development/ GR - JP26ck0106906/Japan Agency for Medical Research and Development/ GR - JP26gm7010010/Japan Agency for Medical Research and Development/ GR - 21H04828/Ministry of Education, Culture, Sports, Science and Technology/ GR - 26H02447/Ministry of Education, Culture, Sports, Science and Technology/ PT - Journal Article DEP - 20260913 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 SB - IM PMC - PMC13571850 OTO - NOTNLM OT - 17q12 amplicon OT - HER2/ERBB2 OT - antibody-drug conjugates (ADC) OT - bladder cancer OT - precision medicine COIS- Akihide Yoshimi received research funding from Daiichi Sankyo, Chugai Pharmaceutical, Eisai, and xFOREST Therapeutics unrelated to this study; Akihide Yoshimi serves as a scientific advisor of xFOREST Therapeutics unrelated to this study; Akihide Yoshimi received honoraria from Chordia Therapeutics, Otsuka Pharmaceutical, MSD, Kyowa Kirin, Daiichi Sankyo, Sanofi, Sumitomo Dainippon Pharma, Life Technologies Japan, Amgen, Bayer, and Oxford Nanopore. Akihide Yoshimi is an Associate Editor of Cancer Science. Akihide Yoshimi was not involved in the editorial evaluation or decision-making process for this manuscript. The other authors declare no conflicts of interest. EDAT- 2026/09/13 23:34 MHDA- 2026/09/13 23:34 PMCR- 2026/09/13 CRDT- 2026/09/13 18:32 PHST- 2026/09/01 00:00 [revised] PHST- 2026/08/01 00:00 [received] PHST- 2026/09/04 00:00 [accepted] PHST- 2026/09/13 23:34 [medline] PHST- 2026/09/13 23:34 [pubmed] PHST- 2026/09/13 18:32 [entrez] PHST- 2026/09/13 00:00 [pmc-release] AID - CAS70534 [pii] AID - 10.1111/cas.70534 [doi] PST - aheadofprint SO - Cancer Sci. 2026 Sep 13:10.1111/cas.70534. doi: 10.1111/cas.70534. PMID- 42731680 OWN - NLM STAT- Publisher LR - 20260916 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) DP - 2026 Sep 12 TI - Risk of Subsequent Recurrences and Progression in Non-muscle Invasive Bladder Cancer Patients With Early Recurrence. LID - S0090-4295(26)00580-7 [pii] LID - 10.1016/j.urology.2026.09.005 [doi] AB - OBJECTIVE: To investigate how the timing of the first non-muscle invasive bladder cancer (NMIBC) recurrence influences the risk of subsequent recurrences and progression. Furthermore, to examine the relationship between multiple recurrences in NMIBC. METHODS: Using nationwide Danish health registers, we identified NMIBC patients diagnosed between 2009 and 2020 who experienced at least one recurrence. Patients were categorized by timing of first recurrence: early (12 months). We estimated cumulative incidences of subsequent recurrences and progression. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) for early vs late recurrence, adjusting for age, sex, primary T-stage, and grade. The Prentice-Williams-Peterson (PWP) Total Time model estimated the hazard of subsequent recurrences when accounting for previous recurrences. RESULTS: Among 6886 patients with recurrence, 3898 were early and 2988 late. The 1-year cumulative incidence of subsequent recurrence was 47% (95% CI 45-49) for early vs 26% (95% CI 24-28) for late recurrence. Corresponding 1-year progression incidences were 10% (95% CI 9.5-11) and 4.0% (95% CI 3.4-4.8). Adjusted HRs for subsequent recurrence were 1.73 (95% CI 1.63-1.85; P < .001) in Cox models and 1.19 (95% CI 1.12-1.25; P < .001) in the PWP model. For progression, the adjusted HR was 1.75 (95% CI 1.55-1.98; P < .001). CONCLUSION: Early recurrence after primary NMIBC diagnosis was associated with significantly higher risks of subsequent recurrence and progression. Timing of the first recurrence may serve as a clinically relevant prognostic marker and could influence future follow-up strategies. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Hjort, Peter B AU - Hjort PB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. Electronic address: petehj@rm.dk. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Greenland Centre for Health Research, Institute for Health and Nature, Ilisimatusarfik/University of Greenland, Nuuk, Greenland. FAU - Ernst, Andreas AU - Ernst A AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. LA - eng PT - Journal Article DEP - 20260912 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM COIS- Declaration of Competing Interest JBJ has received research grants from Photocure ASA and Ferring on behalf of the Department of Urology Research Unit. Further, he has received consulting fees from Cepheid, Medac and Cystotech, and participated in Advisory Boards for Johnson&Johnson, Roche, Cepheid and Medac. None of the disclosures is related to the manuscript. The remaining authors have no disclosures. EDAT- 2026/09/13 00:50 MHDA- 2026/09/13 00:50 CRDT- 2026/09/12 19:15 PHST- 2026/04/09 00:00 [received] PHST- 2026/08/26 00:00 [revised] PHST- 2026/09/08 00:00 [accepted] PHST- 2026/09/13 00:50 [pubmed] PHST- 2026/09/13 00:50 [medline] PHST- 2026/09/12 19:15 [entrez] AID - S0090-4295(26)00580-7 [pii] AID - 10.1016/j.urology.2026.09.005 [doi] PST - aheadofprint SO - Urology. 2026 Sep 12:S0090-4295(26)00580-7. doi: 10.1016/j.urology.2026.09.005. PMID- 42728121 OWN - NLM STAT- Publisher LR - 20260911 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) DP - 2026 Sep 11 TI - Incidental bladder cancer detected by routine cystoscopy before robot-assisted radical prostatectomy: A multicenter retrospective study. LID - S1078-1439(26)00709-X [pii] LID - 10.1016/j.urolonc.2026.08.018 [doi] AB - INTRODUCTION: To evaluate the role of routine cystoscopy before robot-assisted radical prostatectomy (RARP) in detecting incidental bladder cancer (BC) and to identify clinical factors associated with BC detection. METHODS: In this retrospective study conducted at 2 institutions, we included 918 patients who underwent routine cystoscopy before RARP between August 2014 and March 2025. We assessed incidental BC detection, detection of intermediate- or high-risk nonmuscle-invasive BC (NMIBC), and cystoscopy-related events, including urinary tract infection (UTI) and changes in planned prostate cancer (CaP) treatment. RESULTS: Incidental BC was detected in 18 of 918 patients (1.96%), including 8 cases of intermediate- or high-risk NMIBC. Increasing age was significantly associated with BC detection (odds ratio [OR] per 1-year increase, 1.13; 95% confidence interval [CI], 1.02-1.25). Patients aged >/=70 years had a higher BC detection rate (3.2%; OR, 3.96; 95% CI, 1.29-12.1). Nine patients switched to alternative CaP treatments, including radiotherapy and/or androgen deprivation therapy. Among the 9 patients who underwent RARP after bladder tumor resection, the median interval from cystoscopy to RARP was 10.8 months, with no clinically evident CaP progression before RARP. During a median follow-up of 34.6 months, no BC recurrence or dissemination-suggestive recurrence was identified. UTI occurred in 6 patients (0.7%). CONCLUSION: Routine cystoscopy before RARP identified previously unrecognized BC, including clinically significant lesions. Older age was associated with BC detection; however, this finding should be regarded as hypothesis-generating. Further prospective studies are needed to determine whether age-based or risk-adapted cystoscopy strategies are appropriate before RARP. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Nozaki, Masakazu AU - Nozaki M AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan; Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Nakagawa, Ryunosuke AU - Nakagawa R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Kadono, Yoshifumi AU - Kadono Y AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. Electronic address: yskkadono@yahoo.co.jp. FAU - Koketsu, Yoshiki AU - Koketsu Y AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan; Department of Urology, Ichinomiyanishi Hospital, Ichinomiya, Aichi, Japan. FAU - Kamijima, Taiki AU - Kamijima T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Kano, Hiroshi AU - Kano H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Makino, Tomoyuki AU - Makino T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Naito, Renato AU - Naito R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Iwamoto, Hiroaki AU - Iwamoto H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Yaegashi, Hiroshi AU - Yaegashi H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Shigehara, Kazuyoshi AU - Shigehara K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Nohara, Takahiro AU - Nohara T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Izumi, Kouji AU - Izumi K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. FAU - Nishikawa, Takao AU - Nishikawa T AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Shinagawa, Tomochika AU - Shinagawa T AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Yamauchi, Hiroki AU - Yamauchi H AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Takata, Masayuki AU - Takata M AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Kono, Masanori AU - Kono M AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Komatsu, Kazuto AU - Komatsu K AD - Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. LA - eng PT - Journal Article DEP - 20260911 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM OTO - NOTNLM OT - Age OT - Bladder cancer OT - Cystoscopy OT - Prostate cancer OT - Risk factors OT - Robot-assisted radical prostatectomy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2026/09/11 23:36 MHDA- 2026/09/11 23:36 CRDT- 2026/09/11 21:56 PHST- 2026/05/08 00:00 [received] PHST- 2026/08/12 00:00 [revised] PHST- 2026/08/22 00:00 [accepted] PHST- 2026/09/11 23:36 [medline] PHST- 2026/09/11 23:36 [pubmed] PHST- 2026/09/11 21:56 [entrez] AID - S1078-1439(26)00709-X [pii] AID - 10.1016/j.urolonc.2026.08.018 [doi] PST - aheadofprint SO - Urol Oncol. 2026 Sep 11:S1078-1439(26)00709-X. doi: 10.1016/j.urolonc.2026.08.018. PMID- 42723872 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260911 LR - 20260912 IS - 2296-861X (Print) IS - 2296-861X (Electronic) IS - 2296-861X (Linking) VI - 13 DP - 2026 TI - Association of dietary practice, rather than knowledge or attitude, with health-related quality of life in elderly NMIBC survivors: a cross-sectional study. PG - 1918491 LID - 10.3389/fnut.2026.1918491 [doi] LID - 1918491 AB - BACKGROUND: Health-related quality of life (HRQoL) is a critical concern in elderly non-muscle-invasive bladder cancer (NMIBC) survivors, but modifiable dietary factors remain underexplored. Using a cross sectional design, this study aimed to investigate the association between dietary knowledge-attitude-practice (KAP) scores and HRQoL in recurrence-free elderly NMIBC patients 12 months after TURBT, and to identify which KAP dimension shows the strongest independent association. METHODS: We enrolled 106 patients (aged >/=60 years) recurrence-free at 12 months post-TURBT who completed intravesical therapy. Dietary KAP was assessed using a culturally adapted questionnaire, analyzed both continuously and dichotomized at the median (42) for descriptive purposes. HRQoL was measured with the FACT-Bl total and Trial Outcome Index (TOI). Multivariable linear regression adjusted for age, sex, education, smoking, tumor stage, and therapy type. RESULTS: The High-KAP group (n = 53) had significantly higher FACT-Bl total (115.4 vs. 94.2) and TOI (84.1 vs. 68.5, both p < 0.001) as compared with Low-KAP group. In continuous analyses, each 1-point KAP increase was associated with a 0.58-point higher FACT-Bl (95% CI: 0.42-0.74) and 0.62-point higher TOI (0.48-0.76). Among subdomains, only practice remained significant (beta = 1.24 and 1.31, both p < 0.001); while knowledge and attitude were not. CONCLUSION: Higher dietary KAP strongly is associated with better HRQoL, and this association appears primarily attributable to actual practice, not knowledge or attitude. These findings support behavior-focused, culturally tailored dietary support in survivorship care, although causality cannot be inferred due to the cross sectional design. CI - Copyright (c) 2026 Qing, Huang and Gao. FAU - Qing, Xiaodong AU - Qing X AD - Department of Surgery, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. FAU - Huang, Jiawen AU - Huang J AD - Department of Urology, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. FAU - Gao, Wenbo AU - Gao W AD - Department of Urology, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. LA - eng PT - Journal Article DEP - 20260827 PL - Switzerland TA - Front Nutr JT - Frontiers in nutrition JID - 101642264 PMC - PMC13557947 OTO - NOTNLM OT - bladder cancer OT - dietary knowledge-attitude-practice OT - health-related quality of life OT - intravesical chemotherapy OT - non-muscle-invasive bladder cancer COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/09/11 11:38 MHDA- 2026/09/11 11:39 PMCR- 2026/08/27 CRDT- 2026/09/11 06:36 PHST- 2026/06/24 00:00 [received] PHST- 2026/08/07 00:00 [revised] PHST- 2026/08/13 00:00 [accepted] PHST- 2026/09/11 11:39 [medline] PHST- 2026/09/11 11:38 [pubmed] PHST- 2026/09/11 06:36 [entrez] PHST- 2026/08/27 00:00 [pmc-release] AID - 10.3389/fnut.2026.1918491 [doi] PST - epublish SO - Front Nutr. 2026 Aug 27;13:1918491. doi: 10.3389/fnut.2026.1918491. eCollection 2026. PMID- 42722596 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261028 IS - 1471-6771 (Electronic) IS - 0007-0912 (Linking) VI - 137 IP - 5 DP - 2026 Nov TI - Drug allergy labels and complications after surgery: a prospective multicentre cohort study. PG - 1514-1522 LID - S0007-0912(26)00592-1 [pii] LID - 10.1016/j.bja.2026.07.035 [doi] AB - BACKGROUND: One in four surgical patients carries a drug allergy label, of which an estimated 90% are incorrect. Avoidance of first-choice drug therapies can lead to worse postoperative outcomes. We sought to determine the nature and extent of any association between drug allergy labels and postoperative complications. METHODS: A multicentre observational study was performed in 21 UK National Health Service hospitals. Eligible patients were >/=18 yr of age and undergoing common surgical procedures: primary hip or knee replacement, internal fixation of closed long bone fracture, colorectal resection, transurethral resection of prostate or bladder tumour, Caesarean delivery, or hysterectomy. Exclusion criteria were the use of antibiotics in the two weeks before surgery or previous participation in the study. The primary outcome was postoperative complications within 30 days after surgery, a composite outcome comprising all postoperative infections, anastomotic leak, acute respiratory distress syndrome, myocardial infarction, postoperative bleeding, pulmonary embolism, stroke, antimicrobial side-effects, and death. RESULTS: Among 13 646 patients, 3924 (29%) carried >/=1 drug allergy label. Labelled patients were more likely to develop postoperative complications (989/3924 [25%] vs 1926/9722 [20%]; odds ratio [OR] 1.21 [1.10-1.34]; P<0.001). They were more likely to develop surgical site infections (337/3924 [9%] vs 760/9722 [8%]; OR 1.19 [1.03-1.38]; P<0.018), and any postoperative infection (750/3924 [19%] vs 1472/9722 [15%]; OR 1.24 [1.11-1.38]; P<0.001). Labelled patients experienced an increased risk of allergic drug reactions (31/3924 [0.01%] vs 29/9722 [<0.01%]; OR 3.00 [1.77-5.09]; P<0.001), but no increase in mortality. CONCLUSIONS: Drug allergy labels are common, but often incorrect. Patients with drug allergy labels experience worse postoperative outcomes, including infective and noninfective complications and an increased risk of allergic drug reactions. TRIAL REGISTRATION: ISRCTN Registry (ISRCTN15775657). CI - Crown Copyright (c) 2026. Published by Elsevier Ltd. All rights reserved. FAU - Savic, Louise C AU - Savic LC AD - Anaesthetic Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: louise.savic@nhs.net. FAU - Dias, Priya AU - Dias P AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Vairale, Jai AU - Vairale J AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Begum, Salma AU - Begum S AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Khan, Kamran AU - Khan K AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Fowler, Alexander J AU - Fowler AJ AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Kaura, Vikas AU - Kaura V AD - Anaesthetic Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Watson, Sarah-Louise AU - Watson SL AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Littlejohns, Anna AU - Littlejohns A AD - Anaesthetic Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Pearse, Rupert M AU - Pearse RM AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Abbott, Tom E F AU - Abbott TEF AD - William Harvey Research Institute, Queen Mary University of London, London, UK. CN - SAPPHIRE study investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260911 PL - England TA - Br J Anaesth JT - British journal of anaesthesia JID - 0372541 SB - IM MH - Humans MH - *Drug Hypersensitivity/epidemiology MH - Female MH - *Postoperative Complications/epidemiology MH - Male MH - Aged MH - Prospective Studies MH - Middle Aged MH - *Drug Labeling MH - United Kingdom/epidemiology MH - Aged, 80 and over MH - Adult MH - Cohort Studies OTO - NOTNLM OT - antimicrobial allergy OT - drug allergy OT - penicillin OT - perioperative complications OT - surgical site infection COIS- Declarations of interest AJF holds a UK National Institute for Health and Care Research (NIHR) Doctoral Research fellowship (DRF-2018-11-ST2-062). RP is an NIHR senior investigator. TA is supported by an NIHR Development and Skills Enhancement award (NIHR305701); has received research funding from NIHR (CL-2021-19-501), Barts Charity, the Academy of Medical Sciences, The Royal College of Anaesthetists, and the British Journal of Anaesthesia; has received honoraria from MSD, Edwards Life Sciences, and Elsevier; and is a social media editor of the British Journal of Anaesthesia. All other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 yr and no other relationships or activities that could seem to have influenced the submitted work. EDAT- 2026/09/10 23:35 MHDA- 2026/10/28 23:26 CRDT- 2026/09/10 21:59 PHST- 2026/02/03 00:00 [received] PHST- 2026/05/30 00:00 [revised] PHST- 2026/07/06 00:00 [accepted] PHST- 2026/10/28 23:26 [medline] PHST- 2026/09/10 23:35 [pubmed] PHST- 2026/09/10 21:59 [entrez] AID - S0007-0912(26)00592-1 [pii] AID - 10.1016/j.bja.2026.07.035 [doi] PST - ppublish SO - Br J Anaesth. 2026 Nov;137(5):1514-1522. doi: 10.1016/j.bja.2026.07.035. Epub 2026 Sep 11. PMID- 42717258 OWN - NLM STAT- MEDLINE DCOM- 20260910 LR - 20260921 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 33 IP - 9 DP - 2026 Sep TI - Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients. PG - e70634 LID - 10.1111/iju.70634 [doi] LID - e70634 AB - OBJECTIVES: To evaluate perioperative safety, pathological outcomes, and oncological outcomes of en bloc resection of bladder tumor (ERBT) in a large multicenter real-world cohort. METHODS: We retrospectively analyzed 668 patients who underwent ERBT at five institutions. Perioperative and pathological outcomes were assessed in the overall cohort. Recurrence-free survival (RFS) was evaluated in patients with pathologically confirmed non-muscle-invasive bladder cancer (NMIBC) without a history of upper tract urothelial carcinoma (n = 551). Clinicopathological prognosticators of recurrence were identified using Cox proportional hazards regression. RESULTS: The median age was 73 years, and the median maximum tumor diameter was 15 mm. The median operative time and postoperative catheterization period were 48 min and 3 days, respectively. Perioperative complications occurred in 60 patients (9.0%), including eight (1.2%) with Clavien-Dindo Grade III or higher complications. Detrusor muscle was identified in 77.2% of evaluable specimens. Final pathology showed pTa, pT1, pTis, and pT2 disease in 377 (56.4%), 239 (35.8%), 16 (2.4%), and 25 patients (3.7%), respectively. With a median follow-up of 42 months, the estimated 1-, 2-, and 5-year RFS rates were 80.9%, 73.2%, and 57.1%, respectively. RFS did not differ significantly between pTa and pT1 disease (log-rank p = 0.39). Patients presenting with recurrent tumors had a significantly higher risk of subsequent intravesical recurrence than those with primary tumors (HR 2.06, 95% CI 1.38-3.07; p < 0.001). CONCLUSIONS: ERBT demonstrated favorable perioperative safety and acceptable oncological outcomes in this large multicenter cohort. Post-ERBT recurrence remained strongly influenced by prior recurrence history, highlighting the importance of risk-adapted postoperative management. CI - (c) 2026 The Japanese Urological Association. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AUID- ORCID: 0000-0002-3324-762X AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan. FAU - Okada, Yohei AU - Okada Y AUID- ORCID: 0000-0001-9050-471X AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Kubota, Risa AU - Kubota R AUID- ORCID: 0000-0001-7736-8207 AD - Department of Urology, National Hospital Organization Okayama Medical Center, Okayama, Japan. FAU - Kamikubo, Kiichi AU - Kamikubo K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Taneda, Yuki AU - Taneda Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kondo, Hirotaka AU - Kondo H AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Ito, Kagenori AU - Ito K AUID- ORCID: 0000-0002-4970-1727 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. CN - Japanese En bloc TUR (JET) Study Group LA - eng PT - Journal Article PT - Multicenter Study PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/epidemiology MH - Non-Muscle Invasive Bladder Neoplasms/surgery/pathology MH - Aged, 80 and over MH - Disease-Free Survival MH - Transurethral Resection of Bladder MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Middle Aged MH - *Postoperative Complications/epidemiology/etiology MH - Operative Time MH - Urinary Bladder/pathology/surgery MH - *Cystectomy/methods/adverse effects PMC - PMC13558457 OTO - NOTNLM OT - bladder cancer OT - en bloc resection OT - non-muscle-invasive bladder cancer OT - recurrence-free survival OT - transurethral resection COIS- The authors declare no conflicts of interest. EDAT- 2026/09/10 05:36 MHDA- 2026/09/10 05:37 PMCR- 2026/09/10 CRDT- 2026/09/10 04:32 PHST- 2026/08/22 00:00 [revised] PHST- 2026/08/05 00:00 [received] PHST- 2026/09/01 00:00 [accepted] PHST- 2026/09/10 05:37 [medline] PHST- 2026/09/10 05:36 [pubmed] PHST- 2026/09/10 04:32 [entrez] PHST- 2026/09/10 00:00 [pmc-release] AID - IJU70634 [pii] AID - 10.1111/iju.70634 [doi] PST - ppublish SO - Int J Urol. 2026 Sep;33(9):e70634. doi: 10.1111/iju.70634. PMID- 42716474 OWN - NLM STAT- Publisher LR - 20260930 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 36 IP - 12 DP - 2026 Sep 9 TI - Risk stratification in non-muscle-invasive bladder cancer in the era of expanding therapeutic options: Are current classifications still adequate? PG - 103200 LID - S2950-3930(26)00131-2 [pii] LID - 10.1016/j.fjurol.2026.103200 [doi] AB - BACKGROUND: NMIBC risk classifications from AFU, EAU, AUA/SUO and NCCN were derived decades ago to estimate recurrence and progression, but the therapeutic landscape has since expanded, gene therapy, an IL-15 superagonist, systemic immunotherapy, and BCG-combination regimens, raising the question of whether these classifications remain adequate to guide treatment selection. OBJECTIVE: To determine whether contemporary NMIBC risk classifications remain adequate for treatment selection, or function as prognostic instruments applied beyond their original purpose. DATA SOURCES: PubMed/MEDLINE, AFU/EAU/AUA-SUO/NCCN guideline portals, FDA/EMA databases, and ClinicalTrials.gov, searched from January 2000 to August 2026. STUDY SELECTION: Narrative review prioritizing original derivation and validation studies of risk models, pivotal randomized trials, and current guideline texts over secondary or conference-only sources, flagged as such throughout. RESULTS: AFU, EAU, AUA/SUO and NCCN diverge architecturally, producing discordant classifications for identical patients, most sharply for low-burden Ta high-grade disease and T1 disease with concomitant CIS. Four agents now hold FDA approval for BCG-unresponsive disease, and two of three recent phase III trials in BCG-naive high-risk disease (CREST, POTOMAC) were positive, but eligibility depends on treatment-exposure definitions outside baseline risk labels; real-world adherence to adequate BCG is below 50%. MRI/VI-RADS shows strong accuracy for muscle invasion but remains unvalidated for risk stratification. We propose a seven-axis, treatment-oriented framework, reassessed at clinical checkpoints, illustrated with two worked examples. LIMITATIONS: Narrative, not systematic, review; some evidence is conference-sourced pending peer-reviewed publication, and the framework is not yet validated. CONCLUSION: Current classifications remain necessary but insufficient alone; treatment selection increasingly requires a dynamic, multi-axial framework reassessed at defined checkpoints rather than fixed at diagnosis. CI - Copyright (c) 2026 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, centre hospitalier universitaire Henri-Mondor, Creteil, France. Electronic address: igor.duquesne@aphp.fr. FAU - Chakra, Mohamad Abou AU - Chakra MA AD - Department of Urology, University of Iowa Health Care, Iowa, United States. FAU - de la Taille, Alexandre AU - de la Taille A AD - Department of Urology, centre hospitalier universitaire Henri-Mondor, Creteil, France. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Health Care, Iowa, United States. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology 2, Paoli-Calmettes Institut, Marseille, France. LA - eng PT - Journal Article DEP - 20260909 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM OTO - NOTNLM OT - BCG OT - Classification systems OT - Immunotherapy OT - Non-muscle-invasive bladder cancer OT - Risk stratification COIS- Disclosure of interest Igor Duquesne reports a relationship with Merck & Co Inc that includes: speaking and lecture fees. Igor Duquesne reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/09/09 23:36 MHDA- 2026/09/09 23:36 CRDT- 2026/09/09 19:16 PHST- 2026/09/01 00:00 [received] PHST- 2026/09/05 00:00 [accepted] PHST- 2026/09/09 23:36 [pubmed] PHST- 2026/09/09 23:36 [medline] PHST- 2026/09/09 19:16 [entrez] AID - S2950-3930(26)00131-2 [pii] AID - 10.1016/j.fjurol.2026.103200 [doi] PST - aheadofprint SO - Fr J Urol. 2026 Sep 9;36(12):103200. doi: 10.1016/j.fjurol.2026.103200. PMID- 42704540 OWN - NLM STAT- MEDLINE DCOM- 20260907 LR - 20261008 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 53 IP - 1 DP - 2026 Sep 7 TI - Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. LID - 1544 [pii] LID - 10.1007/s11033-026-12697-8 [doi] AB - BACKGROUND: Urothelial bladder carcinoma (UBC) is the ninth most common malignancy worldwide and ranks thirteenth in cancer-related mortality. A significant challenge in managing non-muscle-invasive UBC (NMIBC) is the high recurrence rate, compounded by a paucity of robust prognostic biomarkers. Given that evasion of apoptosis is a hallmark of carcinogenesis, the apoptosis regulator BCL-2 oncogene plays a critical role by negatively regulating the intrinsic apoptotic pathway, often leading to protein overexpression and malignant cell immortalization. METHODS AND RESULTS: This study evaluated the BCL-2 allelic variants rs2279115 (G > T) and rs3943258 (T > C), including their haplotype structures, in association with BCL-2 immunohistochemical expression in UBC patients. Genetic and immunostaining data were analyzed alongside prognostic factors, environmental exposure, and clinical history. Furthermore, we sought to exhibit BCL-2 immunohistochemical staining patterns via immunofluorescence in selected samples. Our findings revealed that the rs2279115 variant is significantly associated with BCL-2 positive expression. Specifically, the TT genotype in the genotypic model (p = 0.035) and the GT genotype in the overdominant model (p = 0.045) were linked to protein status. Additionally, the CT haplotype was independently associated with high-grade tumors. CONCLUSIONS: The presence of the CT haplotype - in either homozygosity or heterozygosity - exerted a risk effect of high-grade (p = 0.020). In conclusion, these findings suggest that BCL-2 variants, haplotype structures, and immunohistochemical expression may offer relevant insights into the molecular characteristics of urothelial bladder cancer. Further prospective validation is needed to determine whether BCL-2 profiling can serve as a useful complementary tool for risk assessment in clinical practice. CI - (c) 2026. The Author(s). FAU - Kawasaki, Julia Ayumi Ikeda AU - Kawasaki JAI AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. FAU - de Souza, Ariane Pereira AU - de Souza AP AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. FAU - Pontes, Joao Pedro Rocha AU - Pontes JPR AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. FAU - Serpeloni, Juliana Mara AU - Serpeloni JM AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. FAU - de Oliveira, Janaina Nicolau AU - de Oliveira JN AD - Laboratory of Molecular Genetics and Immunology, Department of Immunology, Parasitology and General Pathology, Londrina, PR, Brazil. FAU - Vanzela, Andre Luis Laforga AU - Vanzela ALL AD - Laboratory of Cytogenetics and Plant Diversity, Department of General Biology, Londrina, PR, Brazil. FAU - Terziotti, Fernando AU - Terziotti F AD - Londrina Cancer Hospital - HCL, Londrina, PR, Brazil. FAU - Martinez-Lopez, Wilner AU - Martinez-Lopez W AD - Genetics Department and Biodosimetry Service, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay. FAU - de Oliveira, Karen Brajao AU - de Oliveira KB AD - Laboratory of Molecular Genetics and Immunology, Department of Immunology, Parasitology and General Pathology, Londrina, PR, Brazil. FAU - Guembarovski, Roberta Losi AU - Guembarovski RL AUID- ORCID: 0000-0002-6291-8621 AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. robertalosi@uel.br. LA - eng PT - Journal Article DEP - 20260907 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (BCL2 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Proto-Oncogene Proteins c-bcl-2/genetics/metabolism MH - Female MH - Male MH - *Urinary Bladder Neoplasms/genetics/metabolism/pathology MH - Polymorphism, Single Nucleotide/genetics MH - Non-Muscle Invasive Bladder Neoplasms MH - Prognosis MH - Aged MH - Genotype MH - Middle Aged MH - Haplotypes/genetics MH - Alleles MH - Genetic Predisposition to Disease MH - Gene Expression Regulation, Neoplastic MH - Biomarkers, Tumor/genetics MH - Immunohistochemistry MH - Apoptosis/genetics OTO - NOTNLM OT - Haplotype structures OT - Immunohistochemistry OT - Single nucleotide polymorphism OT - Tumor recurrence OT - Urothelial bladder carcinoma COIS- Declarations. Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethics Approval: This study was approved by the Institutional Ethics Committee Involving Humans at State University of Londrina, Londrina - Parana (PR), Brazil (CAAE 88883625.5.0000.5231 ), in accordance with Resolution 466/12 of the National Research Ethics Commission. Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2026/09/07 17:36 MHDA- 2026/09/07 17:37 CRDT- 2026/09/07 11:20 PHST- 2026/04/27 00:00 [received] PHST- 2026/08/26 00:00 [accepted] PHST- 2026/09/07 17:37 [medline] PHST- 2026/09/07 17:36 [pubmed] PHST- 2026/09/07 11:20 [entrez] AID - 10.1007/s11033-026-12697-8 [pii] AID - 10.1007/s11033-026-12697-8 [doi] PST - epublish SO - Mol Biol Rep. 2026 Sep 7;53(1):1544. doi: 10.1007/s11033-026-12697-8. PMID- 42703096 OWN - NLM STAT- Publisher LR - 20260909 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) DP - 2026 Sep 7 TI - Predictive and prognostic biomarkers of Bacillus Calmette-Guerin therapy failure in bladder cancer patients: A systematic review. LID - 10.1002/1878-0261.70329 [doi] AB - High-risk non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy with a high propensity for recurrence (30-40% of patients) despite treatment with Bacillus Calmette-Guerin (BCG) instillations. Identifying patients who are likely to respond or not to BCG therapy before treatment initiation may significantly improve patient outcomes and minimise unnecessary treatments. This systematic review critically assessed the existing literature on the potential of non-invasive biomarkers to predict BCG failure in NMIBC patients. A comprehensive bibliographic search on PubMed, Scopus and Medline databases was conducted to identify relevant studies published up to July 7, 2025. After a thorough screening and selection process, 72 studies were included in the final analysis, 58 of which focused on prognostic markers, 6 on predictive markers, and 8 examined both. Moreover, 55 studies focused on tissue, while 28 studied liquid biopsy-derived biomarkers, showcasing their ability to reflect the dynamic characteristics of the tumour and its microenvironment. The most frequently studied biomarkers comprised p53, Ki-67 and pRB. Furthermore, several immunological markers were also explored, highlighting the current challenge of BCG therapy prediction biomarkers. Despite its valuable insights, this systematic review faced limitations within the included studies, such as issues related to reproducibility, feasibility, and small sample sizes. Nonetheless, the findings indicate that a wide array of molecules show potential as prognostic and/or predictive markers for BCG failure, which may improve the clinical management of this complex disease. CI - (c) 2026 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Ribeiro-Pereira, Rui AU - Ribeiro-Pereira R AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Master Programme in Oncology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal. FAU - Teixeira-Marques, Ana AU - Teixeira-Marques A AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Doctoral Programme in Biomedical Sciences, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal. FAU - Freitas, Rui AU - Freitas R AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Department of Urology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. FAU - Carvalho, Joao A AU - Carvalho JA AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Department of Urology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. FAU - Monteiro-Reis, Sara AU - Monteiro-Reis S AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. FAU - Russo, Giorgio I AU - Russo GI AD - Urology Section, Department of Surgery, University of Catania, Catania, Italy. FAU - Henrique, Rui AU - Henrique R AUID- ORCID: 0000-0003-3171-4666 AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal. FAU - Jeronimo, Carmen AU - Jeronimo C AUID- ORCID: 0000-0003-4186-5345 AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal. AD - RISE - Associate Laboratory (Health Research Network), Porto, Portugal. AD - Porto.CCC - Porto Comprehensive Cancer Centre Raquel Seruca, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal. LA - eng GR - 2023.01232.BD/Fundacao para a Ciencia e a Tecnologia/ GR - UCIPredict-10.54499/TRANSCAN3/0001/2021/Transcan/ GR - PI 27-CI-IPOP-27-2016/Research Center of the Portuguese Oncology Institute of Porto/ PT - Journal Article PT - Review DEP - 20260907 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 SB - IM PMC - PMC13548025 OTO - NOTNLM OT - BCG therapy OT - Bladder Cancer OT - PRISMA OT - molecular marker OT - predictive biomarkers OT - prognosis biomarkers COIS- The authors declare that they have no competing interests. EDAT- 2026/09/07 05:35 MHDA- 2026/09/07 05:35 PMCR- 2026/09/07 CRDT- 2026/09/07 03:13 PHST- 2026/07/20 00:00 [revised] PHST- 2026/04/30 00:00 [received] PHST- 2026/08/27 00:00 [accepted] PHST- 2026/09/07 05:35 [medline] PHST- 2026/09/07 05:35 [pubmed] PHST- 2026/09/07 03:13 [entrez] PHST- 2026/09/07 00:00 [pmc-release] AID - MOL270329 [pii] AID - 10.1002/1878-0261.70329 [doi] PST - aheadofprint SO - Mol Oncol. 2026 Sep 7:10.1002/1878-0261.70329. doi: 10.1002/1878-0261.70329. PMID- 42696081 OWN - NLM STAT- Publisher LR - 20260904 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Sep 4 TI - Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis. LID - 10.1007/s11255-026-05373-0 [doi] AB - PURPOSE: Three phase 3 trials (CREST, POTOMAC, ALBAN) adding an immune checkpoint inhibitor (ICI) to Bacillus Calmette-Guerin (BCG) in BCG-naive high-risk non-muscle-invasive bladder cancer (NMIBC) reported different results. We used reconstructed individual patient-level data (rIPD) to examine the overall event-free survival (EFS) effect and its change over time. METHODS: This post hoc analysis used data reconstructed from published Kaplan-Meier curves rather than original trial datasets, harmonized as EFS. A trial-stratified Cox model estimated the pooled hazard ratio (HR). Two-parameter Weibull models described the timing of events (scale, beta) and the temporal pattern of risk (shape, alpha), with proportional hazards assessed by Schoenfeld residuals and log-log plots. The trials differed in agent, endpoint definition, and BCG schedule. RESULTS: Reconstructed event counts and HRs closely matched reported values. The pooled EFS HR was 0.76 (95% confidence interval [CI] 0.63-0.91), and 0.68 (95% CI 0.54-0.85) after excluding ALBAN. Weibull-based cumulative HRs suggested differing time patterns: the fitted cumulative HR decreased over time in CREST, remained broadly stable in POTOMAC, and approached 1 in ALBAN. Model-based 5-year EFS differences (11.5%, 8.4%, and 0.4%) were exploratory, relying on extrapolation in CREST and sparse tail data in ALBAN. CONCLUSION: ICI plus BCG was associated with improved EFS, mainly reflecting CREST and POTOMAC. A single-pooled HR may obscure regimen-level differences in how the benefit evolves over time. Given the reconstructed data, between-trial differences, and restriction to efficacy, these findings are hypothesis-clarifying rather than practice-changing. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Yajima, Shugo AU - Yajima S AUID- ORCID: 0000-0003-2300-8446 AD - Department of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. shuyajim@east.ncc.go.jp. FAU - Yoshida, Soichiro AU - Yoshida S AUID- ORCID: 0000-0003-2757-8083 AD - Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. s-yoshida.uro@tmd.ac.jp. FAU - Chen, Wei AU - Chen W AD - Department of Urology, Zigong Fourth People's Hospital, School of Medicine, Sichuan University of Science & Engineering, Zigong, Sichuan, China. FAU - Fukushima, Hiroshi AU - Fukushima H AD - Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. FAU - Sato, Hiroyuki AU - Sato H AD - Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Hirakawa, Akihiro AU - Hirakawa A AD - Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - Department of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. LA - eng PT - Journal Article DEP - 20260904 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - BCG OT - Immune checkpoint inhibitor OT - Non-muscle-invasive bladder cancer OT - Parametric survival analysis OT - Proportional hazards OT - Reconstructed individual patient data COIS- Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: This analysis used previously published, de-identified data reconstructed from published figures and did not involve new human participants; ethics approval was not required. Consent to participate: Not applicable. Consent for publication: Not applicable. Use of AI tools: A large language model-based AI assistant was used to support language editing and to assist with checking analysis code. All analyses were run, reviewed, and verified by the authors, who take full responsibility for the content of this article. EDAT- 2026/09/04 17:40 MHDA- 2026/09/04 17:40 CRDT- 2026/09/04 12:26 PHST- 2026/06/30 00:00 [received] PHST- 2026/08/31 00:00 [accepted] PHST- 2026/09/04 17:40 [medline] PHST- 2026/09/04 17:40 [pubmed] PHST- 2026/09/04 12:26 [entrez] AID - 10.1007/s11255-026-05373-0 [pii] AID - 10.1007/s11255-026-05373-0 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Sep 4. doi: 10.1007/s11255-026-05373-0. PMID- 42694772 OWN - NLM STAT- MEDLINE DCOM- 20260904 LR - 20260905 IS - 2235-2988 (Electronic) IS - 2235-2988 (Linking) VI - 16 DP - 2026 TI - Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential. PG - 1890640 LID - 10.3389/fcimb.2026.1890640 [doi] LID - 1890640 AB - Bladder cancer is a prevalent urinary malignancy with high global incidence and mortality. Despite advances in diagnosis and treatment, challenges persist, particularly due to high recurrence rates and unpredictable progression. Recent evidence highlights the role of urinary tract microbiota in BC initiation, progression, and recurrence. The urinary tract, once thought sterile, is now recognized as a complex microbial environment influencing local immunity and carcinogenesis. Differences in microbiota composition between cancer patients and controls, as well as variations by gender, age, and lifestyle factors like smoking, have been observed. The microbiota may impact tumor staging, grading, recurrence, and treatment responses, particularly to Bacillus Calmette-Guerin therapy. Mechanisms include immune modulation, inflammation, and epithelial barrier disruption. This review synthesizes current research on urinary microbiota's role in BC, emphasizing its potential as a biomarker and therapeutic target. Large-scale studies are needed to better understand these associations and develop microbiota-based strategies for improved BC management. CI - Copyright (c) 2026 Sheng, Zhu, Sun, Zeng, Ding and Zhang. FAU - Sheng, Zhaoyang AU - Sheng Z AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. AD - Department of Urology, The 904th Hospital, Joint Logistics Support Force, Wuxi, China. FAU - Zhu, Jinpeng AU - Zhu J AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Sun, Jianming AU - Sun J AD - Department of Urology, The 904th Hospital, Joint Logistics Support Force, Wuxi, China. FAU - Zeng, ShuXiong AU - Zeng S AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Ding, Jun AU - Ding J AD - Department of Urology, The 904th Hospital, Joint Logistics Support Force, Wuxi, China. FAU - Zhang, ZhenSheng AU - Zhang Z AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. LA - eng PT - Journal Article PT - Review DEP - 20260820 PL - Switzerland TA - Front Cell Infect Microbiol JT - Frontiers in cellular and infection microbiology JID - 101585359 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/diagnosis/microbiology/pathology MH - *Microbiota MH - *Urinary Tract/microbiology PMC - PMC13539508 OTO - NOTNLM OT - BCG OT - bladder cancer OT - mechanism OT - microbiota OT - treatment COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/09/04 11:39 MHDA- 2026/09/04 11:40 PMCR- 2026/08/20 CRDT- 2026/09/04 10:22 PHST- 2026/05/25 00:00 [received] PHST- 2026/07/29 00:00 [revised] PHST- 2026/08/10 00:00 [accepted] PHST- 2026/09/04 11:40 [medline] PHST- 2026/09/04 11:39 [pubmed] PHST- 2026/09/04 10:22 [entrez] PHST- 2026/08/20 00:00 [pmc-release] AID - 10.3389/fcimb.2026.1890640 [doi] PST - epublish SO - Front Cell Infect Microbiol. 2026 Aug 20;16:1890640. doi: 10.3389/fcimb.2026.1890640. eCollection 2026. PMID- 42694519 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260904 LR - 20260905 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 18 DP - 2026 Jan-Dec TI - Biomarker-guided selection of intravesical therapy in high-risk non-muscle invasive bladder cancer: A contemporary review. PG - 17562872261485770 LID - 10.1177/17562872261485770 [doi] LID - 17562872261485770 AB - High-risk non-muscle invasive bladder cancer poses therapeutic challenges, with significant rates of recurrence and progression with standard intravesical bacillus Calmette-Guerin (BCG) therapy. Current surveillance strategies lack accurate risk stratification models to predict individual treatment response and personalized treatment options. Simultaneously, there are no well-validated alternatives to replace the current gold-standard approach based on clinical and pathologic features. This review examines emerging biomarkers and advanced technologies with the potential to enhance patient selection and personalize intravesical therapy in HR-NMIBC. Artificial intelligence(AI)-driven histopathologic tools, such as the computer histological AI biomarker, have demonstrated the ability to identify non-responders to standard therapy using whole-slide digital pathology images. In parallel, radiomics-enhanced imaging has shown promise in assessing tumor biology and immune microenvironment features predictive of BCG responsiveness. Liquid biopsy, especially urine tumor DNA analysis, is now available in the arsenal to detect minimal residual disease, stratify recurrence risk, and predict treatment response even before clinical or radiographic evidence of recurrence. Tissue-based genomic profiling has also revealed molecular alterations associated with treatment resistance, though additional validation is needed. Together, these next-generation biomarkers may represent a pivotal shift toward precision oncology in bladder cancer and their incorporation into NMIBC future clinical guidelines is both anticipated and necessary. CI - (c) The Author(s) 2026. FAU - Ito, Willian AU - Ito W AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Tachibana, Isamu AU - Tachibana I AUID- ORCID: 0000-0002-0950-1296 AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20260902 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC13539006 OAB - High-risk non-muscle invasive bladder cancer often comes back even after the gold-standard therapy, the so called intravesical BCG. Today, doctors can only learn whether BCG will work after a patient has already received it, which means some patients lose valuable time on a treatment that is unlikely to help them. Researchers are developing new biomarkers, which are tests that can give early clues about how tumors might behave. These tests may help doctors choose the right treatment sooner and avoid delays in care. This article reviews several promising types of biomarkers. One is an artificial-intelligence tool that studies tumor tissue under the microscope. It can spot patterns that suggest whether BCG is likely to work. Another approach uses advanced imaging-like special MRI or CT scans-to measure features inside and around the tumor that humans cannot see. These features may reveal how aggressive a tumor is or how it might respond to BCG. Scientists are also studying liquid biopsy, which looks for tumor DNA in urine. Because bladder tumors shed DNA directly into urine, this test may show early signs of cancer returning-even before symptoms or imaging changes appear. Tissue-based genetic testing is another area of progress, helping identify gene changes that may predict resistance to treatment. Together, these new tools could help doctors match each patient with the therapy that is most likely to work for them. Although more research is still needed, the growing evidence suggests that biomarker-guided care may soon become an important part of improving outcomes for people with high-risk bladder cancer. OABL- eng OTO - NOTNLM OT - BCG-unresponsive disease OT - artificial intelligence OT - biomarkers OT - liquid biopsy OT - non-muscle invasive bladder cancer COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/09/04 11:39 MHDA- 2026/09/04 11:40 PMCR- 2026/09/02 CRDT- 2026/09/04 09:08 PHST- 2025/12/04 00:00 [received] PHST- 2026/07/09 00:00 [revised] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/09/04 11:40 [medline] PHST- 2026/09/04 11:39 [pubmed] PHST- 2026/09/04 09:08 [entrez] PHST- 2026/09/02 00:00 [pmc-release] AID - 10.1177_17562872261485770 [pii] AID - 10.1177/17562872261485770 [doi] PST - epublish SO - Ther Adv Urol. 2026 Sep 2;18:17562872261485770. doi: 10.1177/17562872261485770. eCollection 2026 Jan-Dec. PMID- 42689553 OWN - NLM STAT- Publisher LR - 20260903 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) DP - 2026 Sep 4 TI - 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. PG - 101097JU0000000000005280 LID - 10.1097/JU.0000000000005280 [doi] AB - PURPOSE: The survival rate for the majority of patients with non-muscle invasive bladder cancer (NMIBC) is favorable; however, the rates of recurrence and progression to muscle-invasive bladder cancer are important surrogate endpoints for overall prognosis, as these are major determinants of long-term outcome. The recurrence and progression probability rates depend on several clinical and pathologic factors. Therefore, the ability to predict risk of recurrence and progression and treating the disease appropriately is important. This Guideline provides a risk-stratified clinical framework for the management of NMIBC. MATERIALS AND METHODS: During the 2025 update, a modified version of the Guideline search strategy was used to conduct a systematic search of Ovid MEDLINE and Embase for new evidence published between May 2023 and December 2025. The modified search added keywords for newly added therapeutic agents in accordance with the updated populations, interventions, comparators, and outcomes. The systematic search identified 2933 studies, of which 71 studies met inclusion criteria following title and abstract screening. Full-text review resulted in 38 studies being included in the final evidence base. RESULTS: Updates were made to NMIBC risk stratification and statements on biomarkers, subtype histologies, transurethral resection, intravesical therapy, Bacillus Calmette-Guerin maintenance, enhanced cystoscopy, and future directions. Revisions were made to the methodology and reference sections as appropriate. CONCLUSIONS: The Guideline updates herein seek to improve clinicians' ability to evaluate and treat patients with NMIBC based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care. FAU - Clark, Peter E AU - Clark PE AD - Department of Urology, Atrium Health/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina. FAU - Holzbeierlein, Jeffrey AU - Holzbeierlein J AD - Department of Urology, University of Kansas Health System, Kansas City, Kansas. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Djaladat, Hooman AU - Djaladat H AD - Department of Urology, University of Southern California, Los Angeles, California. FAU - Kim, Sennett K AU - Kim SK AD - American Urological Association, Linthicum, Maryland. FAU - Kirkby, Erin AU - Kirkby E AD - American Urological Association, Linthicum, Maryland. FAU - Kukreja, Janet B AU - Kukreja JB AD - Department of Urology, University of Colorado, Denver, Colorado. FAU - Souter, Lesley H AU - Souter LH AD - Nomadic E.B.M. Methodology, Smithville, Canada. LA - eng PT - Journal Article DEP - 20260904 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - intravesical chemotherapy OT - lymphovascular invasion OT - resection OT - risk stratification OT - surveillance OT - transurethral resection of bladder tumor OT - urine marker EDAT- 2026/09/03 17:36 MHDA- 2026/09/03 17:36 CRDT- 2026/09/03 11:26 PHST- 2026/09/03 17:36 [medline] PHST- 2026/09/03 17:36 [pubmed] PHST- 2026/09/03 11:26 [entrez] AID - 10.1097/JU.0000000000005280 [doi] PST - aheadofprint SO - J Urol. 2026 Sep 4:101097JU0000000000005280. doi: 10.1097/JU.0000000000005280. PMID- 42683856 OWN - NLM STAT- MEDLINE DCOM- 20260902 LR - 20260913 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 67 IP - 5 DP - 2026 Sep TI - Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial. PG - 441-451 LID - 10.4111/icu.20260135 [doi] AB - PURPOSE: To evaluate the long-term outcomes and molecular correlates of response after immediate preoperative intravesical chemotherapy (IPeIC) with mitomycin-C (MMC) in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: In this single-center, open-label, randomized phase II trial, 33 patients received two split doses of IPeIC/MMC (40 mg/20 mL), whereas 38 patients underwent transurethral resection of bladder tumor (TURBT) alone. The primary endpoint was 3-year recurrence-free survival (RFS), and secondary endpoints included progression-free survival (PFS). Exploratory RNA sequencing was performed on IPeIC-treated patients (three with recurrence, 25 without) using a Monte Carlo-based resampling strategy. RESULTS: The median follow-up durations were comparable between the intervention (60.0 months) and control arms (60.4 months). IPeIC/MMC reduced recurrence risk by 76.8% versus TURBT alone (p=0.024), yielding a 3-year RFS rate of 90.7% versus 78.6%. On multivariable analysis, IPeIC/MMC independently improved RFS (hazard ratio [HR] 0.266, p=0.044). IPeIC was associated with superior PFS, with 3-year and 5-year rates of 100% versus 92.1% and 85.8%, respectively, in the controls (HR 0.078, p=0.014). Exploratory transcriptomics identified low Glutathione S-transferase Mu 1 (GSTM1) expression as the factor most strongly associated with recurrence. CONCLUSIONS: IPeIC/MMC is associated with improved long-term oncological outcomes compared with TURBT alone and represents a safe prophylactic option for patients with NMIBC who are unable to receive standard immediate postoperative intravesical chemotherapy because of safety concerns or practical constraints. The GSTM1 findings are hypothesis-generating and support future biomarker-driven validation studies. CI - (c) The Korean Urological Association. FAU - Lee, Hye Won AU - Lee HW AUID- ORCID: 0000-0002-0303-4658 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Song, Geehyun AU - Song G AUID- ORCID: 0000-0001-7486-4520 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Lee, Hyung Ho AU - Lee HH AUID- ORCID: 0000-0003-4160-0216 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Jung, Eui Hyun AU - Jung EH AUID- ORCID: 0009-0001-6704-0221 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Kim, Seo-Young AU - Kim SY AUID- ORCID: 0000-0002-8258-0090 AD - Biostatistics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea. FAU - Kim, Hanbyeol AU - Kim H AUID- ORCID: 0000-0001-5149-220X AD - Bioinformatics Branch, National Cancer Center, Goyang, Korea. FAU - Park, Weon Seo AU - Park WS AUID- ORCID: 0000-0002-0035-1455 AD - Department of Pathology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Kwon, Joonha AU - Kwon J AUID- ORCID: 0000-0002-6607-0277 AD - Bioinformatics Branch, National Cancer Center, Goyang, Korea. AD - Department of Public Health & AI, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AUID- ORCID: 0000-0003-2601-1093 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. AD - Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Korea. AD - Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. seohk@ncc.re.kr. LA - eng GR - NCC-2411870/NCC/ PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Administration, Intravesical MH - *Antibiotics, Antineoplastic/administration & dosage MH - Follow-Up Studies MH - *Mitomycin/administration & dosage MH - Neoadjuvant Therapy MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/mortality/surgery MH - Transurethral Resection of Bladder MH - Treatment Outcome PMC - PMC13563139 OTO - NOTNLM OT - Biomarkers OT - Mitomycin-C OT - Neoadjuvant therapy OT - Non-muscle-invasive bladder cancer OT - Sequence analysis COIS- The authors have nothing to disclose. EDAT- 2026/09/02 11:39 MHDA- 2026/09/02 18:40 PMCR- 2026/09/01 CRDT- 2026/09/02 10:38 PHST- 2026/03/03 00:00 [received] PHST- 2026/04/09 00:00 [revised] PHST- 2026/04/13 00:00 [accepted] PHST- 2026/09/02 18:40 [medline] PHST- 2026/09/02 11:39 [pubmed] PHST- 2026/09/02 10:38 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - 67.441 [pii] AID - 10.4111/icu.20260135 [doi] PST - ppublish SO - Investig Clin Urol. 2026 Sep;67(5):441-451. doi: 10.4111/icu.20260135. PMID- 42683855 OWN - NLM STAT- MEDLINE DCOM- 20260902 LR - 20260913 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 67 IP - 5 DP - 2026 Sep TI - Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context. PG - 431-440 LID - 10.4111/icu.20250430 [doi] AB - PURPOSE: To evaluate the safety, toxicity, efficacy, and health-economic context of intravesical gemcitabine (GEM) in patients with non-muscle-invasive bladder cancer (NMIBC), and compare outcomes with Bacillus Calmette-Guerin (Onco-BCG; Cipla Ltd.), particularly during shortages. MATERIALS AND METHODS: This prospective observational study included 128 patients with intermediate- or high-risk NMIBC. Sixty-six received intravesical GEM after transurethral resection of bladder tumor (TURBT), while 62 received Onco-BCG. GEM was administered according to the GUBGEM protocol. Safety was assessed through clinical, laboratory, I-PSS (International Prostate Symptom Score), and CTCAE (Common Terminology Criteria for Adverse Events) v5.0 grading. Efficacy was evaluated by recurrence-free survival (RFS), progression rates, and Kaplan-Meier analysis. RESULTS: Baseline demographic and pathological characteristics were similar. GEM demonstrated a favorable safety profile, with 90.9% experiencing none or grade 1 adverse events. Urinary tract infection (20.0%), dysuria (17.3%), and musculoskeletal pain (10.8%) were the most common symptoms. No severe systemic toxicities were observed. Recurrence occurred in 34.8% of GEM patients versus 16.1% with Onco-BCG (p=0.016). Median RFS was 32 months for GEM and 60 for Onco-BCG. Log-rank analysis showed significantly lower RFS with GEM (p=0.017), confirmed by Cox regression (hazard ratio 2.92, 95% confidence interval 1.30-6.54; p=0.009). Most recurrences occurred within the first 12 months. CONCLUSIONS: Intravesical GEM was safe, well tolerated, and associated with high adherence. Although recurrence prevention was inferior to Onco-BCG-particularly within the first 12 months, with no difference in progression-GEM represents a pragmatic, budget-sensitive alternative during Onco-BCG shortages or intolerance. CI - (c) The Korean Urological Association. FAU - Costa, Tiago Mestriner AU - Costa TM AUID- ORCID: 0000-0002-2476-5660 AD - Department of Medicine, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. tgcosta888@gmail.com. FAU - Demartino, Giovanni AU - Demartino G AUID- ORCID: 0000-0002-6627-2549 AD - Department of Urology, Rede D'Or Sao Luiz, Rio de Janeiro, Brazil. FAU - de Toledo, Luis Gustavo Morato AU - de Toledo LGM AUID- ORCID: 0000-0003-2304-9336 AD - Department of Urology, Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil. FAU - Vetorazzi, Gabriela Dias AU - Vetorazzi GD AUID- ORCID: 0009-0004-5672-7986 AD - Department of Medicine, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Albano, Felipe Falero AU - Albano FF AUID- ORCID: 0009-0005-8018-8772 AD - Department of Urology, Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil. FAU - de Andrade, Vinicius Alves AU - de Andrade VA AUID- ORCID: 0009-0009-7912-6979 AD - Department of Urology, Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil. FAU - Moreira, Rafael Bali AU - Moreira RB AUID- ORCID: 0009-0008-4128-1757 AD - Department of Urology, Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil. FAU - Fernandes, Roni de Carvalho AU - Fernandes RC AUID- ORCID: 0000-0002-2533-1610 AD - Department of Urology, Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (BCG Vaccine) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Adjuvants, Immunologic/administration & dosage/economics/supply & distribution/therapeutic use MH - Administration, Intravesical MH - *Antimetabolites, Antineoplastic/administration & dosage/adverse effects/economics MH - *BCG Vaccine/supply & distribution/administration & dosage/economics/therapeutic use MH - *Gemcitabine/administration & dosage/adverse effects/economics MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/mortality/pathology/surgery MH - Prospective Studies MH - Transurethral Resection of Bladder MH - Treatment Outcome PMC - PMC13563136 OTO - NOTNLM OT - BCG vaccine OT - Gemcitabine OT - Urinary bladder neoplasms COIS- The authors have nothing to disclose. EDAT- 2026/09/02 11:39 MHDA- 2026/09/02 18:40 PMCR- 2026/09/01 CRDT- 2026/09/02 10:38 PHST- 2025/08/28 00:00 [received] PHST- 2025/12/16 00:00 [revised] PHST- 2026/04/05 00:00 [accepted] PHST- 2026/09/02 18:40 [medline] PHST- 2026/09/02 11:39 [pubmed] PHST- 2026/09/02 10:38 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - 67.431 [pii] AID - 10.4111/icu.20250430 [doi] PST - ppublish SO - Investig Clin Urol. 2026 Sep;67(5):431-440. doi: 10.4111/icu.20250430. PMID- 42682372 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260902 LR - 20260903 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 112 IP - 7 DP - 2026 Jul TI - A commentary on "CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study". PG - 13273-13274 LID - 10.1097/JS9.0000000000005108 [doi] FAU - Liu, Chungan AU - Liu C AD - Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China. FAU - Yu, Lan AU - Yu L AD - Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China. FAU - Zhang, Xiaotao AU - Zhang X AD - Department of Radiation Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China. LA - eng PT - Journal Article DEP - 20260318 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 PMC - PMC13336706 COIS- The authors declare that they have no conflicts of interest. EDAT- 2026/09/02 05:36 MHDA- 2026/09/02 05:37 PMCR- 2026/07/06 CRDT- 2026/09/02 04:54 PHST- 2026/01/24 00:00 [received] PHST- 2026/02/18 00:00 [accepted] PHST- 2026/09/02 05:37 [medline] PHST- 2026/09/02 05:36 [pubmed] PHST- 2026/09/02 04:54 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - IJS-D-26-01259 [pii] AID - 10.1097/JS9.0000000000005108 [doi] PST - epublish SO - Int J Surg. 2026 Mar 18;112(7):13273-13274. doi: 10.1097/JS9.0000000000005108. eCollection 2026 Jul. PMID- 42682041 OWN - NLM STAT- MEDLINE DCOM- 20260902 LR - 20260902 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 33 IP - 4 DP - 2026 Aug 21 TI - Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review. PG - 735-752 LID - 10.32604/cju.2026.074820 [doi] AB - Bladder cancer (BCa) diagnosis relies heavily on cystoscopy and imaging. Both have limited sensitivity and accuracy, particularly for muscle-invasive disease. Artificial intelligence (AI) has emerged as a promising tool for improving detection, grading, and staging by extracting imaging features that exceed human perception. We conducted a narrative review of peer-reviewed, English-language studies published between 2015 and 2025. We identified 75 articles and synthesized data from 35 key studies retrieved via PubMed, Google Scholar, Scopus, and Embase. Data were synthesized narratively, emphasizing diagnostic performance, clinical relevance, and study limitations. In cystoscopy, AI models achieved high accuracy in tumour detection and grading, including carcinoma in situ, and in some studies reduced missed lesions by >20% compared with expert urologists; CystoNet-T reported an average precision of 91.4%. Performance varied across studies, with inconsistencies driven by methodological factors: endoscopic acquisition conditions (illumination quality; white-light vs. enhanced imaging), variation in ground truth and annotation (histopathology vs. expert-labelled frames), dataset size and class imbalance, model architecture and preprocessing pipelines, and validation strategy (internal splits vs. external testing). Most evidence remains limited by retrospective, single-center datasets, which restrict generalizability. In imaging, AI applications showed modality-dependent performance. CT-based radiomic and deep-learning models demonstrated the most consistent improvements for grading, staging, and recurrence prediction across several studies. MRI and radiogenomic models demonstrated proof-of-concept associations between imaging features and molecular profiles. However, clinical readiness is limited by small cohorts and a lack of prospective validation. Results were also affected by scanner heterogeneity and reader dependence. Evidence for PET/CT remains sparse and preliminary. Many approaches outperformed conventional clinical models, including a vision transformer (ViT)-based MRI model for muscle invasiveness prediction (AUC = 0.872). Methodological heterogeneity restricted generalisability. AI shows potential to reduce diagnostic variability and improve initial treatment planning in BCa. Nonetheless, prospective multicentre trials with standardised methodology are essential before clinical integration. In parallel, regulatory approval of AI as medical software, real-time workflow integration within cystoscopy suites and radiology systems, data governance and patient privacy, and ongoing post-deployment performance monitoring must be addressed to ensure safe and effective clinical use. CI - Copyright (c) 2026 The Authors. Published by Tech Science Press. FAU - Khalid, Usman AU - Khalid U AD - Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria. FAU - Shah, Nikhil AU - Shah N AD - Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria. FAU - Kavia, Rajesh AU - Kavia R AD - Department of Urology, London North West University Healthcare NHS Trust, Watford Road, Harrow, London, UK. FAU - Batura, Deepak AU - Batura D AD - Department of Urology, London North West University Healthcare NHS Trust, Watford Road, Harrow, London, UK. LA - eng PT - Journal Article PT - Review DEP - 20260821 PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Humans MH - *Artificial Intelligence MH - *Cystoscopy/methods MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology OTO - NOTNLM OT - Bladder cancer OT - artificial intelligence OT - cystoscopy OT - imaging OT - machine learning COIS- The authors declare no conflicts of interest. EDAT- 2026/09/02 05:36 MHDA- 2026/09/02 05:37 CRDT- 2026/09/02 03:13 PHST- 2025/10/18 00:00 [received] PHST- 2026/02/18 00:00 [accepted] PHST- 2026/09/02 05:37 [medline] PHST- 2026/09/02 05:36 [pubmed] PHST- 2026/09/02 03:13 [entrez] AID - 10.32604/cju.2026.074820 [doi] PST - epublish SO - Can J Urol. 2026 Aug 21;33(4):735-752. doi: 10.32604/cju.2026.074820. PMID- 42679916 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261028 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 227 DP - 2026 Nov TI - Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis. PG - 105560 LID - S1040-8428(26)00447-6 [pii] LID - 10.1016/j.critrevonc.2026.105560 [doi] AB - Circulating tumor DNA (ctDNA) increasingly guides adjuvant therapy and surveillance in urothelial carcinoma (UC), yet whether its prognostic effect is adequately summarized by a single pooled hazard ratio (HR), which assumes proportional hazards (PH), has not been formally evaluated. We searched five sources for studies reporting ctDNA prognostic associations across non-muscle-invasive, muscle-invasive (MIBC), upper-tract and metastatic UC. HRs for unfavorable versus favorable ctDNA were pooled by Bayesian random-effects meta-analysis, with subgroups by stage and assay strategy. Where individual patient data could be reconstructed, PH was tested under four decision rules and restricted mean survival time (RMST), a PH-independent estimand, estimated at 12, 24 and 36 months. Twenty-five studies were synthesized qualitatively and 17 quantitatively. The pooled HR was 3.85 (95% credible interval 2.92-5.26; I(2) = 50.7%; prediction interval 1.67-9.38), and was higher in MIBC (4.89) than metastatic UC (2.52; p = 0.034) and for tumor-informed (5.46) than tumor-agnostic (2.68) assays (p = 0.009); neither survived multiplicity adjustment, and the latter is confounded with setting and sponsorship. PH was not supported in 5 of 11 cohorts under the pre-specified rule (2-5 across rules); pooled RMST loss in the unfavorable stratum was 2.2, 6.6 and 12.2 months at 12, 24 and 36 months (11, 8 and 5 cohorts), with certainty falling as the horizon lengthened. Unfavorable ctDNA was consistently associated with worse survival, particularly in perioperative MIBC, but non-proportional hazards in many cohorts indicate that its prognostic value should be reported with time-axis estimands alongside HRs. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Yajima, Shugo AU - Yajima S AD - Department of Urology, National Cancer Center Hospital East, Chiba, Japan; Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Electronic address: shuyajim@east.ncc.go.jp. FAU - Okumura, Gaku AU - Okumura G AD - Department of Urology, National Cancer Center Hospital East, Chiba, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Electronic address: s-yoshida.uro@tmd.ac.jp. FAU - Chen, Wei AU - Chen W AD - Department of Urology, Zigong Fourth People's Hospital, School of Medicine, Sichuan University of Science & Engineering, Zigong, Sichuan, China. FAU - Fukushima, Hiroshi AU - Fukushima H AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Sato, Hiroyuki AU - Sato H AD - Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Hirakawa, Akihiro AU - Hirakawa A AD - Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - Department of Urology, National Cancer Center Hospital East, Chiba, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20260901 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Prognosis MH - *Circulating Tumor DNA/blood MH - *Biomarkers, Tumor/blood MH - *Urologic Neoplasms/diagnosis/mortality/genetics/blood MH - *Urinary Bladder Neoplasms/diagnosis/genetics OTO - NOTNLM OT - Circulating tumor DNA OT - Meta-analysis OT - Proportional hazards OT - Restricted mean survival time OT - Urothelial carcinoma COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/09/01 23:34 MHDA- 2026/10/27 23:27 CRDT- 2026/09/01 19:12 PHST- 2026/06/16 00:00 [received] PHST- 2026/08/19 00:00 [revised] PHST- 2026/08/21 00:00 [accepted] PHST- 2026/10/27 23:27 [medline] PHST- 2026/09/01 23:34 [pubmed] PHST- 2026/09/01 19:12 [entrez] AID - S1040-8428(26)00447-6 [pii] AID - 10.1016/j.critrevonc.2026.105560 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2026 Nov;227:105560. doi: 10.1016/j.critrevonc.2026.105560. Epub 2026 Sep 1. PMID- 42671925 OWN - NLM STAT- Publisher LR - 20260831 IS - 2326-6074 (Electronic) IS - 2326-6066 (Linking) DP - 2026 Aug 31 TI - A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non-Muscle-Invasive Bladder Cancer. LID - 10.1158/2326-6066.CIR-26-0104 [doi] AB - Tertiary lymphoid structures (TLS) have emerged as critical immune niches within the tumor microenvironment across various cancers. However, their structural organization and functional roles in non-muscle-invasive bladder cancer (NMIBC) remain poorly characterized. In this study, we comprehensively characterized TLS in NMIBC using en bloc resected primary diagnostic specimens, which enabled high-resolution spatial mapping and quantitative histological assessment across a large cohort of primary tumors (97 patients). Compared with TLS in inflammation-driven cystitis, tumor-associated TLS showed heterogeneous spatial organization, altered immune composition, and disrupted follicular dendritic cell (FDC) networks with reduced high endothelial venules density. TLS density increased with NMIBC grade and stage and correlated with higher recurrence risk and shorter progression-free survival in multivariable analysis. Paired analysis of primary and recurrent tumors showed a reduction in FDC density and a shift from M1 to M2 differentiation in tumor recurrences, suggesting the development of an immunosuppressive microenvironment. Single-cell RNA sequencing of TLS from NMIBC and cystitis samples revealed impaired germinal center activity in tumor-associated TLS, with asynchronous B-cell maturation and reduced B-cell interactions with both T follicular helper cells and FDC. Tumor-associated TLS also showed increased myeloid infiltration and altered dendritic-cell function, including reduced MHC class II antigen presentation and downregulation of co-stimulatory (CD86-CD28) and migration-related (CD99) pathways compared to TLS from cystitis samples. Overall, we found that NMIBC-associated TLS are structurally and functionally impaired, which may limit effective local immune responses and suggests they may be relevant as biomarkers and targets for immunomodulatory therapy in bladder cancer. FAU - Pericart, Sarah AU - Pericart S AUID- ORCID: 0000-0001-8148-2950 AD - Centre Hospitalier Universitaire de Toulouse Toulouse France. ROR: https://ror.org/017h5q109 FAU - Tosolini, Marie AU - Tosolini M AUID- ORCID: 0000-0001-5278-5952 AD - INSERM Toulouse France. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology and Renal Transplantation, Toulouse University Hospital ; Institut Universitaire du Cancer de Toulouse, Oncopole Toulouse France. FAU - Saint, Axelle AU - Saint A AUID- ORCID: 0009-0004-5181-6496 AD - Institut universitaire du cancer de Toulouse Oncopole France. ROR: https://ror.org/014hxhm89 FAU - Largeaud, Laetitia AU - Largeaud L AUID- ORCID: 0000-0001-5341-5427 AD - Institut universitaire du cancer de Toulouse Oncopole Toulouse France. ROR: https://ror.org/014hxhm89 FAU - Gravelle, Pauline AU - Gravelle P AUID- ORCID: 0000-0002-0462-5652 AD - CHU Toulouse Toulouse, France France. FAU - Van Acker, Nathalie AU - Van Acker N AUID- ORCID: 0000-0003-0420-5081 AD - CHU, Institut Universitaire du Cancer Toulouse Toulouse France. FAU - Brousset, Pierre AU - Brousset P AUID- ORCID: 0000-0002-8629-3291 AD - Institut universitaire du cancer de Toulouse Oncopole Toulouse France. ROR: https://ror.org/014hxhm89 FAU - Malavaud, Bernard AU - Malavaud B AUID- ORCID: 0000-0003-2793-9459 AD - Institut universitaire du cancer de Toulouse Oncopole France. FAU - Laurent, Camille AU - Laurent C AUID- ORCID: 0000-0002-5375-7512 AD - Institut universitaire du cancer de Toulouse Oncopole toulouse France. ROR: https://ror.org/014hxhm89 LA - eng PT - Journal Article DEP - 20260831 PL - United States TA - Cancer Immunol Res JT - Cancer immunology research JID - 101614637 SB - IM EDAT- 2026/08/31 19:42 MHDA- 2026/08/31 19:42 CRDT- 2026/08/31 12:52 PHST- 2026/08/28 00:00 [accepted] PHST- 2026/01/21 00:00 [received] PHST- 2026/06/04 00:00 [revised] PHST- 2026/08/31 19:42 [medline] PHST- 2026/08/31 19:42 [pubmed] PHST- 2026/08/31 12:52 [entrez] AID - 787756 [pii] AID - 10.1158/2326-6066.CIR-26-0104 [doi] PST - aheadofprint SO - Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0104. PMID- 42669104 OWN - NLM STAT- Publisher LR - 20260830 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Aug 30 TI - Prognostic factors for mortality and recurrence after radical nephroureterectomy for UTUC: a Brazilian cohort study. LID - 10.1007/s11255-026-05345-4 [doi] AB - PURPOSE: To evaluate the risk factors associated with mortality and recurrence following nephroureterectomy for upper tract urothelial carcinoma (UTUC) in a large Brazilian cohort. METHODS: This retrospective study analyzed 126 patients who underwent nephroureterectomy for UTUC between 2009 and 2023 at a single institution in Brazil. Cox regression and Kaplan-Meier analyses were performed to identify factors associated with mortality and recurrence. RESULTS: The median follow-up duration was 38 months. In multivariate analysis, positive surgical margins (HR 3.45, 95% CI 1.52-7.69, p=0.003), presence of carcinoma in situ (HR 2.63, 95% CI 1.27-5.56, p=0.009), and systemic recurrence (HR 3.33, 95% CI 1.32-9.09, p=0.01) were independently associated with increased mortality. The laparoscopic approach was not associated with worse outcomes than open surgery. CONCLUSION: This large Brazilian cohort study identified several prognostic factors for mortality and recurrence after nephroureterectomy in patients with UTUC. Achieving negative surgical margins and identifying high-risk pathological features are critical for optimizing the outcomes. The laparoscopic approach was not associated with worse oncological outcomes in this cohort. These findings may help guide patient management and follow-up strategies. CI - (c) 2026. The Author(s). FAU - Gentile, Guilherme AU - Gentile G AUID- ORCID: 0009-0002-8830-6065 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. guile.gentile@gmail.com. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. guile.gentile@gmail.com. FAU - Morgan, Henri Luiz AU - Morgan HL AUID- ORCID: 0000-0002-1793-1931 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - Zorzo, Joao Victor Cagol AU - Zorzo JVC AUID- ORCID: 0000-0003-2496-4229 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - de Campos, Vinicius Daniel Faris AU - de Campos VDF AUID- ORCID: 0009-0009-8569-2440 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - Santos, Francisco Valdez AU - Santos FV AUID- ORCID: 0000-0002-7478-2186 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. FAU - Gallucci, Fabio Pescarmona AU - Gallucci FP AUID- ORCID: 0000-0001-7434-113X AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - Filho, Leopoldo Alves Ribeiro AU - Filho LAR AUID- ORCID: 0000-0001-9732-6557 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - Cordeiro, Mauricio Dener AU - Cordeiro MD AUID- ORCID: 0000-0001-8439-3283 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. FAU - Nahas, William Carlos AU - Nahas WC AUID- ORCID: 0000-0002-7395-8370 AD - Divisao de Uro-Oncologia, Instituto do Cancer do Estado de Sao Paulo - ICESP, Avenida Dr. Arnaldo, 251, Sao Paulo, SP, CEP 01246-000, Brasil. AD - Divisao de Urologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brasil. LA - eng PT - Journal Article DEP - 20260830 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Mortality OT - Nephroureterectomy OT - Prognostic factors OT - Upper tract urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare that they have no competing interests related to this study. Ethical approval: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Cancer Institute of Sao Paulo. Consent to participate: Due to its retrospective nature, the requirement for informed consent was waived. Consent to publish: Not applicable. EDAT- 2026/08/30 17:36 MHDA- 2026/08/30 17:36 CRDT- 2026/08/30 11:03 PHST- 2026/06/22 00:00 [received] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/08/30 17:36 [medline] PHST- 2026/08/30 17:36 [pubmed] PHST- 2026/08/30 11:03 [entrez] AID - 10.1007/s11255-026-05345-4 [pii] AID - 10.1007/s11255-026-05345-4 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Aug 30. doi: 10.1007/s11255-026-05345-4. PMID- 42665512 OWN - NLM STAT- In-Process LR - 20261023 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 5 DP - 2026 Oct TI - Re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9:652-9. PG - 1191 LID - S2588-9311(26)00235-X [pii] LID - 10.1016/j.euo.2026.07.022 [doi] FAU - Scarpa, Roberto Mario AU - Scarpa RM AD - Department of Urology, Fondazione Policlinico Campus Bio-Medico, via Alvaro del Portillo 200, 00128 Roma, Italy. LA - eng PT - Journal Article DEP - 20260828 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM EDAT- 2026/08/28 23:34 MHDA- 2026/08/28 23:34 CRDT- 2026/08/28 21:53 PHST- 2026/07/10 00:00 [received] PHST- 2026/07/15 00:00 [revised] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/08/28 23:34 [pubmed] PHST- 2026/08/28 23:34 [medline] PHST- 2026/08/28 21:53 [entrez] AID - S2588-9311(26)00235-X [pii] AID - 10.1016/j.euo.2026.07.022 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Oct;9(5):1191. doi: 10.1016/j.euo.2026.07.022. Epub 2026 Aug 28. PMID- 42665429 OWN - NLM STAT- MEDLINE DCOM- 20260828 LR - 20260903 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 40 IP - 5 DP - 2026 Sep-Oct TI - TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival. PG - 3137-3145 LID - 10.21873/invivo.14462 [doi] AB - BACKGROUND/AIM: TROP2 has become a therapeutic target in urothelial carcinoma following the approval of TROP2-directed antibody-drug conjugates (ADCs), yet its expression in transurethral resection (TURBT) material remains poorly characterized. This study aimed to evaluate TROP2 protein expression using immunohistochemistry (IHC) in bladder TURBT samples and to investigate its association with histological grade, tumor stage, lymphovascular invasion (LVI), carcinoma in situ (CIS), recurrence, and survival outcomes. MATERIALS AND METHODS: A total of 79 bladder TURBT specimens were included. Histological grading was performed according to the WHO/ISUP two-tier classification system (low grade / high grade) and pathological staging was based on the AJCC/UICC TNM Classification, 8th edition. TROP2 expression was assessed using IHC and quantified using the H-score method. Statistical analyses were performed using the chi-square test, Fisher's exact test, Mann-Whitney U and Kruskal-Wallis tests, Spearman's correlation analysis, receiver operating characteristic analysis, Kaplan-Meier estimates with log-rank tests, and Cox proportional hazards regression. RESULTS: Mean age was 65.87+/-11.46 years (91.1% male). Mean TROP2 H-score was 173.99+/-48.15 (median 160.0; range 30-280). A significant negative correlation was identified between TROP2 and histological grade (rho=-0.410; p=0.0003); median H-scores were 200.0 in low-grade versus 150.0 in high-grade tumors. Receiver operating characteristic analysis yielded an area under the curve (AUC) of 0.736 (sensitivity 92.3%, specificity 45.0%; cut-off 200). No significant association was found with pT stage, LVI, CIS, recurrence, disease-free survival (log-rank p=0.886), or overall survival (log-rank p=0.752). Cox regression confirmed no independent prognostic effect on survival. CONCLUSION: TROP2 inversely correlates with histological grade in bladder TURBT specimens (AUC=0.736) and may guide pathologists in diagnostically challenging cases - limited tissue, cautery artifact, or incomplete resection - where a low H-score suggests high-grade disease. TROP2 may complement WHO/ISUP grading and serve as a candidate predictive biomarker for TROP2-targeted ADC therapies. CI - Copyright (c) 2026, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Gundogar, Ozgecan AU - Gundogar O AD - Department of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye; ozgecankarahan@hotmail.com. FAU - Bektas, Sibel AU - Bektas S AD - Department of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. FAU - Arslan, Burak AU - Arslan B AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. FAU - Akbas, Pelin AU - Akbas P AD - Department of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 RN - 0 (TACSTD2 protein, human) RN - 0 (Cell Adhesion Molecules) RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Transurethral Resection of Bladder MH - *Cell Adhesion Molecules/genetics/metabolism MH - *Antigens, Neoplasm/genetics/metabolism MH - Female MH - Aged MH - Neoplasm Grading MH - Male MH - Immunohistochemistry MH - *Urinary Bladder Neoplasms/pathology/surgery/metabolism/mortality/genetics MH - Neoplasm Staging MH - Biomarkers, Tumor MH - Middle Aged MH - Prognosis MH - Kaplan-Meier Estimate MH - Urinary Bladder/pathology/metabolism/surgery MH - Neoplasm Recurrence, Local/pathology PMC - PMC13531141 OTO - NOTNLM OT - TROP2 OT - bladder cancer OT - immunohistochemistry OT - sacituzumab govitecan OT - transurethral resection OT - urothelial carcinoma COIS- The Authors declare that they have no conflicts of interest in relation to this study. EDAT- 2026/08/28 23:34 MHDA- 2026/08/28 23:35 PMCR- 2026/08/28 CRDT- 2026/08/28 21:23 PHST- 2026/06/15 00:00 [received] PHST- 2026/07/07 00:00 [revised] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/08/28 23:35 [medline] PHST- 2026/08/28 23:34 [pubmed] PHST- 2026/08/28 21:23 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - 40/5/3137 [pii] AID - 10.21873/invivo.14462 [doi] PST - ppublish SO - In Vivo. 2026 Sep-Oct;40(5):3137-3145. doi: 10.21873/invivo.14462. PMID- 42663909 OWN - NLM STAT- Publisher LR - 20260828 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Aug 28 TI - Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients. LID - 10.1007/s11255-026-05316-9 [doi] AB - PURPOSE: To evaluate the efficacy and safety of disitamab vedotin (DV) plus a PD-1 inhibitor combined with different local intensification strategies for the bladder-preserving management of muscle-invasive bladder cancer (MIBC). METHODS: This single-center retrospective cohort study enrolled patients with MIBC who underwent maximal transurethral resection of bladder tumor (TURBT), followed by DV plus a PD-1 inhibitor between January 1, 2023, and September 30, 2025. According to the local intensification strategy, patients were classified into three groups: group A, maximal TURBT followed by DV plus a PD-1 inhibitor; group B, maximal TURBT followed by DV plus a PD-1 inhibitor combined with intravesical Bacillus Calmette-Guerin (BCG); and group C, maximal TURBT followed by DV plus a PD-1 inhibitor combined with radiotherapy. Treatment selection was based on multidisciplinary evaluation of patients' clinical characteristics and treatment accessibility; because treatment allocation was nonrandomized, between-group comparisons were considered exploratory. The primary endpoint was bladder-intact event-free survival (BI-EFS). Secondary endpoints included clinical complete response (cCR), progression-free survival (PFS), overall survival (OS), bladder preservation rate, salvage or delayed radical cystectomy (RC) rate, and safety. Patient-level reasons for not receiving RC, conventional TMT, or radiotherapy were not uniformly documented, limiting assessment of treatment-selection bias. RESULTS: A total of 81 patients were included, comprising 41 in group A, 30 in group B, and 10 in group C. The median follow-up duration was 18.5 months (IQR, 13.7-26.6). The 12-month BI-EFS rates were 58.5%, 93.1%, and 90.0% in groups A, B, and C, respectively (P = 0.025). Compared with group A, group B showed improved BI-EFS (P = 0.002). In multivariable Cox regression analysis, group B was associated with a lower risk of BI-EFS events than group A (adjusted HR, 0.35; 95% CI 0.14-0.89; P = 0.027), while group C had a favorable but imprecise point estimate (adjusted HR, 0.31; 95% CI 0.07-1.40; P = 0.128). The cCR rates were 39.0%, 80.0%, and 60.0% in groups A, B, and C, respectively (P = 0.002), while the bladder preservation rates at the last follow-up were 75.6%, 100.0%, and 80.0%, respectively (P = 0.005). The 12-month PFS rates were 82.7%, 90.0%, and 100.0%, and the 12-month OS rates were 90.1%, 93.3%, and 100.0%, respectively. Any-grade and grade >/= 3 adverse events occurred in 92.6% and 4.9% of patients, respectively; all four grade >/= 3 events resulted in permanent discontinuation of ongoing DV plus PD-1 inhibitor therapy. CONCLUSION: DV plus a PD-1 inhibitor combined with local intensification strategies was feasible for the bladder-preserving management of MIBC and demonstrated an acceptable overall safety profile. The addition of intravesical BCG was associated with improved bladder-intact outcomes. Group C also showed favorable 12-month BI-EFS, PFS, and OS estimates; however, its small sample size and wide confidence intervals preclude firm conclusions, and non-significance should not be interpreted as evidence of no radiotherapy benefit. These findings should be regarded as hypothesis-generating. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Chen, Yan AU - Chen Y AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - An, Wenqiang AU - An W AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Qu, Ruonan AU - Qu R AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Chen, Chao AU - Chen C AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Wang, Zhong AU - Wang Z AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Yu, Fangqiu AU - Yu F AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Li, Yixuan AU - Li Y AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - He, Shenbao AU - He S AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. FAU - Yue, Zhongjin AU - Yue Z AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China. yuezhongjin@sina.cn. FAU - Wang, Wei AU - Wang W AD - Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China. wangwei2011@lzu.edu.cn. AD - Shenzhen School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China. wangwei2011@lzu.edu.cn. LA - eng GR - lzujbky-2025-ytA07/the Central Universities Young Talent Support Program, Class A/ GR - 2025QNTD18/the Provincial Talent (Young Team) Program of the Organization Department of the CPC Gansu Provincial Committee/ GR - 25JRRA1267/the General Project of the Joint Fund of the Gansu Provincial Department of Science and Technology/ PT - Journal Article DEP - 20260828 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Bladder preservation OT - Disitamab vedotin OT - Intravesical BCG OT - Muscle-invasive bladder cancer OT - PD-1 inhibitor OT - Radiotherapy COIS- Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: This retrospective study was approved by the Ethics Committee of Lanzhou University Second Hospital (Approval No. 2026A-097). All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent to participate: The requirement for written informed consent was waived by the Ethics Committee of Lanzhou University Second Hospital because of the retrospective nature of the study and the use of de-identified data. Consent for publication: Not applicable. EDAT- 2026/08/28 18:06 MHDA- 2026/08/28 18:06 CRDT- 2026/08/28 11:27 PHST- 2026/06/12 00:00 [received] PHST- 2026/07/28 00:00 [accepted] PHST- 2026/08/28 18:06 [medline] PHST- 2026/08/28 18:06 [pubmed] PHST- 2026/08/28 11:27 [entrez] AID - 10.1007/s11255-026-05316-9 [pii] AID - 10.1007/s11255-026-05316-9 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Aug 28. doi: 10.1007/s11255-026-05316-9. PMID- 42660692 OWN - NLM STAT- Publisher LR - 20260827 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) DP - 2026 Aug 27 TI - Therapeutic landscape of upper tract urothelial carcinoma: Intraluminal agents, perioperative chemotherapy, and immunotherapy. LID - S1078-1439(26)00696-4 [pii] LID - 10.1016/j.urolonc.2026.08.002 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is an uncommon genitourinary malignancy with distinct anatomical and clinical challenges. Historically, treatment strategies have been extrapolated from bladder cancer, leaving gaps in evidence for UTUC-specific management. Recent advances in intraluminal drug delivery and systemic therapy have presented new options across localized, locally advanced, and metastatic disease. METHODS: We reviewed prospective trials, retrospective cohort studies, and ongoing studies evaluating intraluminal chemo-ablative agents, perioperative chemotherapy, immunotherapy, and targeted therapies for UTUC. Outcomes of efficacy, safety, and innovation in drug delivery systems were synthesized. RESULTS: Kidney-sparing approaches for localized UTUC have advanced with intraluminal chemoablation. UGN-101, a mitomycin-C containing reverse-thermal gel, demonstrated meaningful complete response rates and durable remission, while mitomycin-C (aqueous) and Bacillus Calmette-Guerin-based regimens showed variable efficacy. Novel delivery systems, including reverse-thermal gels and biodegradable drug-eluting stents, aim to improve drug dwell time and reduce recurrence. For high-risk localized disease, adjuvant platinum-based chemotherapy significantly improved disease-free survival and is now standard of care. Neoadjuvant chemotherapy offers long-term survival benefits and preserves eligibility for cisplatin. Immunotherapy has emerged perioperatively, with adjuvant checkpoint inhibitors improving disease-free survival and ongoing trials exploring chemo-immunotherapy combinations. In metastatic UTUC, antibody-drug conjugates combined with immunotherapy have demonstrated superior progression-free and overall survival compared with chemotherapy. Targeted therapies, such as FGFR inhibitors, provide additional options for biomarker-selected patients. CONCLUSIONS: UTUC management is evolving towards stage-specific strategies integrating chemoablation, systemic therapy, and molecularly guided approaches. Future priorities include randomized trials, optimized drug delivery, and long-term safety evaluation. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Manivasagam, Sri Saran AU - Manivasagam SS AD - Department of Urology, Penn State Health Milton S Hershey Medical Center, Hershey, PA. FAU - Raman, Jay D AU - Raman JD AD - Department of Urology, Penn State Health Milton S Hershey Medical Center, Hershey, PA. Electronic address: jraman@pennstatehealth.psu.edu. LA - eng PT - Journal Article PT - Review DEP - 20260827 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM OTO - NOTNLM OT - Intraluminal agents OT - Neoadjuvant chemotherapy OT - Systemic therapy OT - Upper tract urothelial cancer OT - Urothelial carcinoma COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/28 11:40 MHDA- 2026/08/28 11:40 CRDT- 2026/08/27 21:52 PHST- 2026/01/11 00:00 [received] PHST- 2026/06/16 00:00 [revised] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/08/28 11:40 [medline] PHST- 2026/08/28 11:40 [pubmed] PHST- 2026/08/27 21:52 [entrez] AID - S1078-1439(26)00696-4 [pii] AID - 10.1016/j.urolonc.2026.08.002 [doi] PST - aheadofprint SO - Urol Oncol. 2026 Aug 27:S1078-1439(26)00696-4. doi: 10.1016/j.urolonc.2026.08.002. PMID- 42654506 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260909 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 62 IP - 8 DP - 2026 Aug 21 TI - Outcomes and Predictive Factors for Gynecologic Organ Involvement in Radical Cystectomy for Female Bladder Cancer Patients: A Multicenter Retrospective Cohort Study. LID - 10.3390/medicina62081609 [doi] LID - 1609 AB - Background and Objectives: Radical cystectomy (RC) is standard treatment for muscle-invasive bladder cancer, but the role of gynecologic organ preservation in women remains uncertain. We primarily evaluated the prevalence and predictors of pathological gynecologic organ involvement and secondarily assessed survival and developed a prediction model. Materials and Methods: This multicenter retrospective study included 232 women undergoing RC at 13 tertiary centers. Of the 232 women, 182 had clinical T2 disease and 50 had BCG-unresponsive or very-high-risk Ta/T1 non-muscle-invasive bladder cancer. Overall survival (OS) was the primary endpoint; CSS and RFS were secondary outcomes. Multivariable logistic regression was used to identify predictors and develop preoperative prediction models. Results: Pathological gynecologic organ involvement was identified in 26 patients (11.2%): uterine in 15 (6.5%), vaginal in 11 (4.7%), ovarian in five (2.2%), and adnexal in 21 (9.1%). The median OS was shorter in patients with involvement than in those without (19.0 vs. 48.0 months; p = 0.048). Vaginal and ovarian involvement were associated with shorter OS (both p < 0.001), whereas uterine and adnexal involvement were not. Pathological T stage was associated with organ involvement (p = 0.001), with the highest frequency in pT4 disease. Model 2 showed an AUC of 0.898 and an optimism-corrected AUC of 0.872. A risk score of 0 classified 31.0% as low risk, with an NPV of 97.2% and a sensitivity of 92.3%. Conclusions: Pathological gynecologic organ involvement was uncommon but associated with poorer survival. These findings may support preoperative risk stratification, although the oncologic safety of organ-preserving surgery cannot be established from pathological involvement data alone. FAU - Arikan, Mehmet Gurkan AU - Arikan MG AUID- ORCID: 0000-0002-9707-596X AD - Department of Urology, School of Medicine, Cukurova University, Adana 01330, Turkiye. FAU - Arda, Ersan AU - Arda E AD - Department of Urology, School of Medicine, Trakya University, Edirne 22030, Turkiye. FAU - Izol, Volkan AU - Izol V AD - Department of Urology, Cukurova Urology Center, Adana 01170, Turkiye. FAU - Yilmaz, Hasan AU - Yilmaz H AD - Department of Urology, School of Medicine, Kocaeli University, Kocaeli 41001, Turkiye. FAU - Suer, Evren AU - Suer E AUID- ORCID: 0000-0003-4093-5436 AD - Department of Urology, School of Medicine, Ankara University, Ankara 06230, Turkiye. FAU - Akgul, Murat AU - Akgul M AD - Department of Urology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkiye. FAU - Yazici, Sertac AU - Yazici S AUID- ORCID: 0000-0001-9616-3776 AD - Department of Urology, School of Medicine, Hacettepe University, Ankara 06800, Turkiye. FAU - Bolat, Deniz AU - Bolat D AUID- ORCID: 0000-0001-7338-8737 AD - Department of Urology, Izmir City Hospital, Izmir 35540, Turkiye. FAU - Aslan, Guven AU - Aslan G AD - Department of Urology, School of Medicine, Dokuz Eylul University, Izmir 35220, Turkiye. FAU - Akan, Serkan AU - Akan S AD - Department of Urology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul 34752, Turkiye. FAU - Turkeri, Levent AU - Turkeri L AD - Department of Urology, Acibadem Mehmet Ali Aydinlar University Hospital, Istanbul 34638, Turkiye. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260821 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Middle Aged MH - Aged MH - Cohort Studies MH - Treatment Outcome MH - Aged, 80 and over MH - Logistic Models PMC - PMC13515190 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - organ preservation OT - pathological gynecologic organ involvement OT - radical cystectomy OT - survival outcomes COIS- The authors declare no conflicts of interest. EDAT- 2026/08/27 05:35 MHDA- 2026/08/27 05:36 PMCR- 2026/08/21 CRDT- 2026/08/27 01:10 PHST- 2026/07/07 00:00 [received] PHST- 2026/08/17 00:00 [revised] PHST- 2026/08/19 00:00 [accepted] PHST- 2026/08/27 05:36 [medline] PHST- 2026/08/27 05:35 [pubmed] PHST- 2026/08/27 01:10 [entrez] PHST- 2026/08/21 00:00 [pmc-release] AID - medicina62081609 [pii] AID - medicina-62-01609 [pii] AID - 10.3390/medicina62081609 [doi] PST - epublish SO - Medicina (Kaunas). 2026 Aug 21;62(8):1609. doi: 10.3390/medicina62081609. PMID- 42640415 OWN - NLM STAT- Publisher LR - 20260825 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Aug 25 TI - LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study. LID - 10.1007/s11255-026-05351-6 [doi] AB - BACKGROUND: Despite recent therapeutic advances, platinum-based chemotherapy still remains a cornerstone in the treatment of muscle invasive bladder cancer (MIBC). We investigated the association between leucine-rich-repeat-containing 8A (LRRC8A) expression, a protein with a potential mechanistic role in platinum-sensitivity, and clinical outcomes following neoadjuvant chemotherapy in MIBC. METHODS: We histologically characterized transurethral resection of bladder tumor (TUR-B) and cystectomy MIBC samples. We analyzed membranous and cytoplasmic tumor expression levels of LRRC8A, correlating results with clinical outcomes. RESULTS: We analyzed clinical data from 35 MIBC patients treated at the University Hospital of Bern between September 2017 and March 2023. Immunohistochemistry (IHC) expression was assessed for 17 patients with paired TUR-B and cystectomy samples. High membranous LRRC8A expression was observed more frequently in patients achieving a complete pathologic response (tumor regression grade [TRG] 1) than in those with TRG2 or TRG3 (3/5 [60%] vs. 2/12 [16.7%]); however, this difference did not reach statistical significance. Kaplan-Meier survival analysis showed no statistically significant difference in overall survival (OS) between patients with negative/low versus high membranous LRRC8A. CONCLUSIONS: Our data suggest a potential association of LRRC8A expression levels with cisplatin sensitivity in MIBC. Given the limited sample size and retrospective nature of the study, these findings should be considered preliminary, exploratory and hypothesis-generating. Further validation in larger, independent cohorts, as well as functional studies, will be needed. CI - (c) 2026. The Author(s). FAU - Rytz, Michele Alina AU - Rytz MA AD - Department of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. FAU - Hussung, Saskia AU - Hussung S AD - Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, 8091, Zurich, Switzerland. FAU - Frehner, Lorenz AU - Frehner L AD - Department of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. FAU - Beyer, Jorg AU - Beyer J AD - Department of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. FAU - Scheidewind, Laila AU - Scheidewind L AD - Department of Urology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. FAU - Roth, Beat AU - Roth B AD - Department of Urology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. FAU - Widmer, Carmen AU - Widmer C AD - Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland. AD - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. AD - Bern Center for Precision Medicine, Inselspital, University Hospital of Bern, 3008, Bern, Switzerland. FAU - Baaral, Aavash AU - Baaral A AD - Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland. FAU - Francica, Paola AU - Francica P AD - Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland. AD - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. AD - Bern Center for Precision Medicine, Inselspital, University Hospital of Bern, 3008, Bern, Switzerland. FAU - Rubin, Mark A AU - Rubin MA AD - Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland. AD - Bern Center for Precision Medicine, Inselspital, University Hospital of Bern, 3008, Bern, Switzerland. FAU - Rottenberg, Sven AU - Rottenberg S AD - Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland. AD - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. AD - Bern Center for Precision Medicine, Inselspital, University Hospital of Bern, 3008, Bern, Switzerland. FAU - Rodriguez-Calero, Antonio AU - Rodriguez-Calero A AD - Institute of Tissue Medicine and Pathology, University of Bern, 3008, Bern, Switzerland. FAU - Akhoundova, Dilara AU - Akhoundova D AD - Department of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. dilara.akhoundovasanoyan@insel.ch. LA - eng PT - Journal Article DEP - 20260825 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Cisplatin OT - LRRC8A OT - Muscle-invasive bladder cancer (MIBC) OT - Neoadjuvant chemotherapy (NAC) OT - Tumor regression grade (TRG) COIS- Declarations. Ethics approval and consent to participate: The study received approval from the local ethics committee (BASEC 2023-00976, approved on the 19th of June 2023, Kantonale Ethikkomission Bern, Switzerland). General consent was signed by all enrolled patients. Consent for publication: Not applicable. Conflict of interests: M.R and the rest of the authors declare no conflicts of interest. EDAT- 2026/08/25 17:35 MHDA- 2026/08/25 17:35 CRDT- 2026/08/25 11:12 PHST- 2026/06/26 00:00 [received] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/08/25 17:35 [medline] PHST- 2026/08/25 17:35 [pubmed] PHST- 2026/08/25 11:12 [entrez] AID - 10.1007/s11255-026-05351-6 [pii] AID - 10.1007/s11255-026-05351-6 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Aug 25. doi: 10.1007/s11255-026-05351-6. PMID- 42639117 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260825 LR - 20260826 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 12 IP - 3 DP - 2026 Jul-Sep TI - Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study. PG - 23523735261475431 LID - 10.1177/23523735261475431 [doi] LID - 23523735261475431 AB - BACKGROUND: Guidelines recommend intravesical Bacillus Calmette-Guerin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. OBJECTIVE: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. METHODS: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan-Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. RESULTS: Sixty-five patients were included. Median follow-up was 38 months (IQR 21-55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). CONCLUSIONS: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting. CI - (c) The Author(s) 2026. FAU - Arnold, Nicolas AU - Arnold N AUID- ORCID: 0009-0006-4122-8249 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Blanc, Julien AU - Blanc J AUID- ORCID: 0000-0001-7537-2763 AD - Department of Urology, Lausanne University Hospital, Lausanne, Switzerland. RINGGOLD: 30635 FAU - Lucca, Ilaria AU - Lucca I AUID- ORCID: 0009-0000-4532-7961 AD - Department of Urology, Lausanne University Hospital, Lausanne, Switzerland. RINGGOLD: 30635 FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AUID- ORCID: 0000-0002-0359-8517 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 AD - The Institution Organizing University Doctoral Studies (I.O.S.U.D.), Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj-Napoca, Romania. FAU - Schneidewind, Laila AU - Schneidewind L AUID- ORCID: 0000-0002-3409-8654 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Giudici, Nicola AU - Giudici N AUID- ORCID: 0009-0005-9844-1799 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Rothlisberger, Raphael AU - Rothlisberger R AUID- ORCID: 0000-0002-3685-3203 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Thalmann, George N AU - Thalmann GN AUID- ORCID: 0000-0002-1908-3286 AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Kiss, Bernhard AU - Kiss B AUID- ORCID: 0000-0002-4691-556X AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 FAU - Roth, Beat AU - Roth B AUID- ORCID: 0000-0002-7369-650X AD - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. RINGGOLD: 27252 LA - eng PT - Journal Article DEP - 20260810 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC13500795 OTO - NOTNLM OT - BCG failure OT - bladder cancer OT - cystectomy OT - epirubicin OT - hyperthermic intravesical chemotherapy (HIVEC) OT - progression OT - recurrence COIS- The authors declare no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/25 11:38 MHDA- 2026/08/25 11:39 PMCR- 2026/08/10 CRDT- 2026/08/25 06:11 PHST- 2026/05/06 00:00 [received] PHST- 2026/07/17 00:00 [revised] PHST- 2026/07/22 00:00 [accepted] PHST- 2026/08/25 11:39 [medline] PHST- 2026/08/25 11:38 [pubmed] PHST- 2026/08/25 06:11 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - 10.1177_23523735261475431 [pii] AID - 10.1177/23523735261475431 [doi] PST - epublish SO - Bladder Cancer. 2026 Aug 10;12(3):23523735261475431. doi: 10.1177/23523735261475431. eCollection 2026 Jul-Sep. PMID- 42639047 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20260904 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. PG - 1929760 LID - 10.3389/fimmu.2026.1929760 [doi] LID - 1929760 AB - OBJECTIVE: PD-1 based immunochemotherapy has improved bladder cancer (BC) outcomes, yet individual responses remain heterogeneous. Low-cost, non-invasive predictive biomarkers are urgently needed. Urinary protein semi-quantification (UPSQ) correlates with BC tumor load, but its predictive value during PD-1 based immunochemotherapy remains unclear. We conducted a post-hoc analysis of the TRUCE-01 (NCT04730219) and TRUCE-02 (NCT04730232) trials to explore the association between UPSQ and clinical outcomes. METHODS: 104 patients received 3 cycles of tislelizumab plus nab-paclitaxel. UPSQ at baseline (UP-B) and 60 +/- 7 days (UP-60) after treatment initiation, urinary red blood cell (URBC) and urinary white blood cell (UWBC) were dynamically detected. Dynamic indices (UPDV score, UPV risk stratification) were defined to evaluate UPSQ changes. The primary endpoint was clinical complete response (cCR), and the secondary endpoints included overall survival (OS), cancer-specific survival (CSS), and events-free survival (EFS). Bulk RNA-seq transcriptomic analysis was performed in 22 MIBC patients. RESULTS: UPSQ decreased significantly at 60 days in the overall cohort and subgroups (all p < 0.05). Baseline URBC and UWBC were positively correlated with UPSQ, while tumor size was positively associated with UPSQ in MIBC patients. In regression analyses, several indicators reached nominal significance (unadjusted p < 0.05), but failed to remain significant (adjusted p > 0.05) after Benjamini-Hochberg correction due to limited sample size. Low UPV risk was correlated with a significantly higher cCR rate in both MIBC (OR 12.5, unadjusted p = 0.003, adjusted p = 0.055) and VHR-NMIBC (OR 3.47, unadjusted p = 0.031, adjusted p = 0.177) subgroups. UP-B grade showed a trend toward an inverse association with cCR (OR 0.48, unadjusted p = 0.028, adjusted p = 0.085) and OS (HR 1.70, unadjusted p = 0.045, adjusted p = 0.181) in the MIBC subgroup after multivariate adjustment. Transcriptomic analysis suggested that MIBC patients with high UP-B grade may exhibit a more aggressive tumor phenotype. CONCLUSIONS: UPSQ was linked to the clinical outcomes of patients receiving PD-1-based immunochemotherapy for BC. In MIBC, lower baseline UPSQ grade may be associated with a tumor transcriptomic phenotype contributing to better cCR and OS. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov, identifier NCT04730219; https://clinicaltrials.gov, identifier NCT04730232. CI - Copyright (c) 2026 Chen, Lin, Xue, Qie, Wu, Liu, Huang, Jia, Yang, Zhang, Li, Li, Liu, Shen and Hu. FAU - Chen, Houyuan AU - Chen H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Lin, Yuda AU - Lin Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Xue, Zihan AU - Xue Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Qie, Yunkai AU - Qie Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liu, Kangkang AU - Liu K AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Huang, Shiwang AU - Huang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Jia, Kaipeng AU - Jia K AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Yang, Shaobo AU - Yang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Zhang, Zhe AU - Zhang Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Li, Peng AU - Li P AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Li, Xiaohua AU - Li X AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liu, Liwei AU - Liu L AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Shen, Chong AU - Shen C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. LA - eng SI - ClinicalTrials.gov/NCT04730232 SI - ClinicalTrials.gov/NCT04730219 PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260810 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Biomarkers, Tumor/urine MH - Immunotherapy MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/urine/drug therapy/mortality/therapy PMC - PMC13500580 OTO - NOTNLM OT - PD-1 immune checkpoint inhibitors OT - bladder cancer OT - clinical outcomes OT - immunochemotherapy OT - nab-paclitaxel OT - urinary protein semi-quantification COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/25 11:38 MHDA- 2026/08/25 11:39 PMCR- 2026/08/10 CRDT- 2026/08/25 06:03 PHST- 2026/07/06 00:00 [received] PHST- 2026/07/22 00:00 [revised] PHST- 2026/07/24 00:00 [accepted] PHST- 2026/08/25 11:39 [medline] PHST- 2026/08/25 11:38 [pubmed] PHST- 2026/08/25 06:03 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1929760 [doi] PST - epublish SO - Front Immunol. 2026 Aug 10;17:1929760. doi: 10.3389/fimmu.2026.1929760. eCollection 2026. PMID- 42632232 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260921 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 7 DP - 2026 Oct TI - Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy. PG - 102638 LID - S1558-7673(26)00138-2 [pii] LID - 10.1016/j.clgc.2026.102638 [doi] AB - INTRODUCTION: Immune checkpoint inhibitors (ICI) have demonstrated meaningful activity as neoadjuvant therapy in muscle-invasive bladder cancer (MIBC). Identifying patients most likely to respond to ICI-based neoadjuvant strategies remains an unmet need. MATERIALS AND METHODS: Tumor mutational burden (TMB) from baseline transurethral resection of bladder (TURB) tumor samples of MIBC patients treated with neoadjuvant ICI across PURE-01 (NCT02736266), SURE-02 (NCT05535218), and NURE-Combo (NCT04876313) trials was analyzed. Probabilities of complete response ( CR; yT0N0‑x at radical cystectomy or re-TURB tumor), event‑free survival, and overall survival were assessed across different TMB cutoffs. Logistic regression models evaluated predictors of CR. RESULTS: 202 patients (85% male, median age 66) were included. 57% had cT2 disease. Median TMB was 10.5 mut/Mb; 88 patients (44%) achieved CR. Optimal TMB threshold for CR was 13 mut/Mb with a predicted probability (PP) of 43% (95% confidence interval [CI]: 36.6-50.6); higher TMB showed incremental PP. At TMB >/= 20 threshold, PP was 54% (95% CI: 43.7-63.1), with significant association with CR at multivariable analysis (AUC: 0.65). No significant effect by therapeutic regimen was observed. With a median follow-up of 63 months (interquartile range 25-77), 60m-event‑free survival for TMB >/= 20 pts was 97% (95% CI: 90.4-100) versus 73% (95% CI: 65.6-80.7), P=0.03, and 60m-overall survival was 100% versus 78.8% (95% CI: 71.9-86.4), P = .01. CONCLUSIONS: Our analysis support TMB as a clinically informative biomarker in MIBC patients treated with neoadjuvant ICI, identifying a subset of exceptional responders associated with higher TMB levels. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Mercinelli, Chiara AU - Mercinelli C AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: mercinelli.chiara@hsr.it. FAU - Basile, Giuseppe AU - Basile G AD - Urology Department, The Royal Free London Foundation Trust, London, UK; Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Pastorino, Giovanni L AU - Pastorino GL AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Cigliola, Antonio AU - Cigliola A AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Maiorano, Brigida A AU - Maiorano BA AD - Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Tateo, Valentina AU - Tateo V AD - Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Piacentini, Michela AU - Piacentini M AD - Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Serafin, Debora AU - Serafin D AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Guandalini, Gualtiero AU - Guandalini G AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Lacava, Roberta AU - Lacava R AD - Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Latini, Gaia AU - Latini G AD - Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AD - Universita Vita-Salute San Raffaele, Milan, Italy; Department of Pathology and Laboratory Medicine, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Universita Vita-Salute San Raffaele, Milan, Italy; Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Universita Vita-Salute San Raffaele, Milan, Italy; Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Pavlick, Dean AU - Pavlick D AD - Foundation Medicine Inc, Cambridge, MA. FAU - Ross, Jeffrey S AU - Ross JS AD - Foundation Medicine Inc, Cambridge, MA; Upstate Medical University, Syracuse, NY. FAU - Necchi, Andrea AU - Necchi A AD - Universita Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20260730 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Biomarkers, Tumor/genetics MH - Cystectomy MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology MH - Mutation MH - *Neoadjuvant Therapy/methods MH - Pathologic Complete Response MH - Prognosis MH - Transurethral Resection of Bladder MH - Treatment Outcome MH - Tumor Burden MH - *Urinary Bladder Neoplasms/genetics/drug therapy/pathology/mortality/therapy MH - Clinical Trials, Phase II as Topic OTO - NOTNLM OT - TMB OT - bladder cancer OT - immunotherapy OT - precision medicine OT - predictive biomarkers COIS- Disclosure D. Pavlick and J.S. Ross are employees at Foundation Medicine Inc. All other authors have stated that they have no conflicts of interest. EDAT- 2026/08/22 23:43 MHDA- 2026/09/18 23:36 CRDT- 2026/08/22 18:04 PHST- 2026/05/03 00:00 [received] PHST- 2026/07/18 00:00 [revised] PHST- 2026/07/27 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/22 23:43 [pubmed] PHST- 2026/08/22 18:04 [entrez] AID - S1558-7673(26)00138-2 [pii] AID - 10.1016/j.clgc.2026.102638 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Oct;24(7):102638. doi: 10.1016/j.clgc.2026.102638. Epub 2026 Jul 30. PMID- 42632153 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260918 IS - 1878-3252 (Electronic) IS - 0946-672X (Linking) VI - 97 DP - 2026 Oct TI - Relationship between concentration of heavy metals in bladder cancer tissue and molecular types using luminal GATA3 and basal cytokeratin 5/6 markers. PG - 127944 LID - S0946-672X(26)00130-6 [pii] LID - 10.1016/j.jtemb.2026.127944 [doi] AB - INTRODUCTION AND OBJECTIVES: Data on molecular sub-typing of bladder cancer (BC) associated with heavy metals (HMTE) are lacking. Clinical significance of luminal (GATA3) and basal (cytokeratin 5/6) markers in BC is controversial. Therefore, objective is to use these markers to characterize BC associated with HMTE into luminal and basal, and to investigate their clinical significance. METHODS: Study included 143 patients undergoing radical cystectomy (RC) for urothelial carcinoma. Two fresh samples were obtained from cancerous and non-cancerous RC specimens to measure [aluminum-Al, cadmium-Cd, cobalt-Co, chromium-Cr, copper-Cu, iron-Fe, nickel-Ni, lead-Pb, zinc-Zn] concentration and GATA3,CK5,CK6, by ICP-OES and RT-PCR, respectively. Also, histopathology and immunohistochemistry for GATA3/CK5/6 were performed. RESULTS: Stage was pT1/pT2/pT3/pT4 in 36/17/75/15 and grade was G1/G2/G3 in 26/32/85 patients, respectively. High Cd, Co, Cr, Ni, and/or Pb concentration in BC tissue was associated with high CK5/6 and lower GATA3 expression. High GATA3 was associated with low stages, low grade and negative lymph nodes (LN), while high CK5/6 expression was associated with the reverse. Cu had antagonistic effects to (Cd, Co, Cr, Ni, Pb) regarding both markers. No significant association was found between Fe or Zn and GATA3or CK5/6 expression. CONCLUSIONS: High BC tissue concentration of Cd, Co, Cr, Ni, and/or Pb has been proved to be associated with high expression of the basal Cytokeratin 5/6 and lower expression of luminal marker GATA3. High GATA3 and CK5/6 expression are associated with favorable (low stages, low grade, negative LN) and aggressive BC, respectively. However, data on cancer specific survival are awaited. CI - Copyright (c) 2026 Elsevier GmbH. All rights reserved. FAU - Ali-El-Dein, Bedeir AU - Ali-El-Dein B AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Electronic address: balieldein@yahoo.com. FAU - Abdelgawad, Mahmoud AU - Abdelgawad M AD - Toshka Urology and Endoscopy center, Mansoura, Egypt. FAU - Abdel-Rahim, Mona AU - Abdel-Rahim M AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Gomaa, Islam M AU - Gomaa IM AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Elnaggar, Islam I AU - Elnaggar II AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Zahran, Faten AU - Zahran F AD - Department of Biochemistry, Faculty of science, Zagazig University, Egypt. FAU - Salama, Afrah F AU - Salama AF AD - Department of Biochemistry, Faculty of science, Tanta University, Egypt. FAU - Keshta, Akaber T AU - Keshta AT AD - Department of Biochemistry, Faculty of science, Zagazig University, Egypt. FAU - Mohamed, Amro E AU - Mohamed AE AD - Department of Biochemistry, Faculty of science, Tanta University, Egypt. FAU - Saleh, Hazem H AU - Saleh HH AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Mortada, Wael I AU - Mortada WI AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Attia, Afaf M AU - Attia AM AD - Forensic and Toxicology Department, Faculty of Medicine, Mansoura University, Egypt. FAU - Elkady, Manar E AU - Elkady ME AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20260820 PL - Germany TA - J Trace Elem Med Biol JT - Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) JID - 9508274 RN - 0 (GATA3 Transcription Factor) RN - 0 (Metals, Heavy) RN - 0 (GATA3 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Keratin-6) RN - 0 (Keratin-5) SB - IM MH - Humans MH - *GATA3 Transcription Factor/metabolism/genetics MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - *Metals, Heavy/analysis/metabolism MH - *Biomarkers, Tumor/metabolism/genetics MH - *Keratin-6/metabolism/genetics MH - *Keratin-5/metabolism/genetics MH - Male MH - Female MH - Aged MH - Middle Aged MH - Aged, 80 and over OTO - NOTNLM OT - Bladder cancer OT - Cytokeratin OT - GATA3 OT - Heavy metals OT - Molecular types COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Bedeir Ali-El-Dein reports financial support was provided by Egyptian Science and Technology Development Fund. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/22 23:43 MHDA- 2026/09/18 23:36 CRDT- 2026/08/22 18:00 PHST- 2026/05/22 00:00 [received] PHST- 2026/07/30 00:00 [revised] PHST- 2026/08/17 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/22 23:43 [pubmed] PHST- 2026/08/22 18:00 [entrez] AID - S0946-672X(26)00130-6 [pii] AID - 10.1016/j.jtemb.2026.127944 [doi] PST - ppublish SO - J Trace Elem Med Biol. 2026 Oct;97:127944. doi: 10.1016/j.jtemb.2026.127944. Epub 2026 Aug 20. PMID- 42632045 OWN - NLM STAT- Publisher LR - 20260822 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) DP - 2026 Aug 22 TI - Stage-specific prognostic impact and recurrence patterns according to tumor location in upper tract urothelial carcinoma following radical nephroureterectomy: a propensity score-matched analysis. LID - hyag139 [pii] LID - 10.1093/jjco/hyag139 [doi] AB - BACKGROUND: The prognostic significance of the location of the primary tumor in upper tract urothelial carcinoma (UTUC) remains controversial. We evaluated the impact of ureteral urothelial carcinoma (UUC) versus renal pelvic urothelial carcinoma (RPUC) on oncological outcomes and recurrence patterns following radical nephroureterectomy (RNU). METHODS: We retrospectively analysed 779 patients with UTUC who underwent RNU between 2012 and 2021 within the JIKEI-YAYOI Collaborative Group. Propensity score matching (PSM) was performed to balance clinicopathological characteristics between UUC and RPUC. The primary endpoints were non-urothelial tract recurrence-free survival (NUTRFS) and overall survival (OS). Cancer-specific survival (CSS), intravesical recurrence-free survival (IVRFS), and recurrence patterns were also evaluated. RESULTS: After PSM, 309 matched pairs were analysed. Compared to RPUC, UUC was associated with significantly shorter NUTRFS (3-year rate: 68.9% vs. 77.6%, P = 0.048), OS (76.4% vs. 83.3%, P = 0.021), and CSS (80.0% vs. 88.1%, P = 0.009). No significant difference was observed in IVRFS (P = 0.90). Stage-specific analyses demonstrated that the adverse prognostic impact of UUC was primarily confined to patients with pT3/4 disease. Among node-negative pT3/4 patients, UUC was associated with significantly worse NUTRFS, OS, and CSS. Recurrence pattern analyses revealed higher rates of local recurrence and regional lymph node recurrence in pT3/4 UUC, whereas pulmonary metastasis was more frequent in RPUC. CONCLUSION: Primary tumor location was significantly associated with oncological outcomes in UTUC. The prognostic disadvantage of UUC is mainly observed in locally advanced disease and appears to be driven by an increased risk of locoregional recurrence. Tumor location may provide additional prognostic information for postoperative risk stratification and surveillance planning. CI - (c) The Author(s) 2026. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Ogihara, Yue AU - Ogihara Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AUID- ORCID: 0000-0002-2599-8183 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University West Medical Center, Tokyo, Japan. FAU - Kubo, Masataka AU - Kubo M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University West Medical Center, Tokyo, Japan. FAU - Uchida, Naoki AU - Uchida N AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Saitama Northern Medical Center, Saitama, Japan. FAU - Kagawa, Hirokazu AU - Kagawa H AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Fuji City General Hospital, Shizuoka, Japan. FAU - Hashimoto, Masaki AU - Hashimoto M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Koike, Yuhei AU - Koike Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. FAU - Iwamoto, Yuya AU - Iwamoto Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Atsugi City Hospital, Kanagawa, Japan. FAU - Kawano, Shota AU - Kawano S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Tokyo-Kita Medical Center, Tokyo, Japan. FAU - Ishikawa, Mimu AU - Ishikawa M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. FAU - Kayano, Sotaro AU - Kayano S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Ota Memorial Hospital, Gumma, Japan. FAU - Nakano, Juria AU - Nakano J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, JR Tokyo General Hospital, Tokyo, Japan. FAU - Inaba, Yuzo AU - Inaba Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Fuji City General Hospital, Shizuoka, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Imai, Yu AU - Imai Y AUID- ORCID: 0000-0003-0971-4205 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Nakazono, Minoru AU - Nakazono M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Kameda Medical Center, Chiba, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Tashiro, Kojiro AU - Tashiro K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Atsugi City Hospital, Kanagawa, Japan. FAU - Murakami, Masaya AU - Murakami M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Fuji City General Hospital, Shizuoka, Japan. FAU - Sasaki, Takaya AU - Sasaki T AD - Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AUID- ORCID: 0000-0001-6164-4684 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. CN - JIKEI-YAYOI Collaborative Group LA - eng PT - Journal Article DEP - 20260822 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM OTO - NOTNLM OT - prognosis OT - radical nephroureterectomy OT - recurrence pattern OT - renal pelvic urothelial carcinoma OT - upper tract urothelial carcinoma OT - ureteral urothelial carcinoma EDAT- 2026/08/22 22:40 MHDA- 2026/08/22 22:40 CRDT- 2026/08/22 13:53 PHST- 2026/07/17 00:00 [received] PHST- 2026/08/05 00:00 [revised] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/08/22 22:40 [medline] PHST- 2026/08/22 22:40 [pubmed] PHST- 2026/08/22 13:53 [entrez] AID - 8768763 [pii] AID - 10.1093/jjco/hyag139 [doi] PST - aheadofprint SO - Jpn J Clin Oncol. 2026 Aug 22:hyag139. doi: 10.1093/jjco/hyag139. PMID- 42629308 OWN - NLM STAT- In-Process LR - 20261023 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 5 DP - 2026 Oct TI - Reply to Simone Sforza's Letter to the Editor re: Mehdi Kardoust Parizi, David D'Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients. In press. http://dx.doi.org/10.1016/j.euo.2026.06.001. PG - 1189-1190 LID - S2588-9311(26)00231-2 [pii] LID - 10.1016/j.euo.2026.08.002 [doi] FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: m-kardoust@sina.tums.ac.ir. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medicine, New York, NY, USA; Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA; College of Medical Health Technologies, Al-Turath University, Mansour, Baghdad, Iraq; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article DEP - 20260822 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM EDAT- 2026/08/21 23:37 MHDA- 2026/08/21 23:37 CRDT- 2026/08/21 21:54 PHST- 2026/07/23 00:00 [received] PHST- 2026/08/05 00:00 [accepted] PHST- 2026/08/21 23:37 [pubmed] PHST- 2026/08/21 23:37 [medline] PHST- 2026/08/21 21:54 [entrez] AID - S2588-9311(26)00231-2 [pii] AID - 10.1016/j.euo.2026.08.002 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Oct;9(5):1189-1190. doi: 10.1016/j.euo.2026.08.002. Epub 2026 Aug 22. PMID- 42627386 OWN - NLM STAT- MEDLINE DCOM- 20260821 LR - 20260928 IS - 1436-6215 (Electronic) IS - 1436-6207 (Print) IS - 1436-6207 (Linking) VI - 65 IP - 6 DP - 2026 Aug 21 TI - Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer. LID - 10.1007/s00394-026-04079-4 [doi] LID - 237 AB - PURPOSE: Fruit and vegetable consumption may decrease bladder cancer risk, but research on its relation to outcomes of non-muscle-invasive bladder cancer (NMIBC) is scarce. We investigated the association of (changes in) pre- and postdiagnosis fruit and vegetable consumption, as well as postdiagnosis dietary and plasma carotenoids, with risks of recurrence and progression in patients with NMIBC. METHODS: Data from patients with newly diagnosed NMIBC between 2014 and 2021 from the prospective multi-centre cohort UroLife was used. Patients reported prediagnosis diet (n = 1396), and diet at 3 and 15 months postdiagnosis (n = 1270). Plasma carotenoid concentrations were measured at 3 and 15 months postdiagnosis (n = 910). Multivariable proportional hazards regression analyses were performed to assess associations with risks of first recurrence, multiple recurrences, and progression. RESULTS: Median follow-up time was 4.7 years, 466 patients had at least one recurrence, 139 had multiple recurrences, and 153 showed progression. Total fruit and vegetable consumption at 3 months postdiagnosis as well as pre-to-postdiagnosis increases in consumption were inversely associated with first recurrence risk (per 100 g/day: hazard ratio [HR] = 0.91, 95% confidence interval ([95%CI] 0.85-0.99 and HR = 0.90, 95%CI 0.81-0.99, respectively). Results were attenuated at 15 months after diagnosis. Total and individual dietary and plasma carotenoids were not associated with first recurrence risk. No associations with multiple recurrences and progression, and for prediagnosis fruit and vegetable consumption were found. CONCLUSION: Higher postdiagnosis fruit and vegetable consumption may have a beneficial role in NMIBC recurrence but not progression risk while no associations for dietary and plasma carotenoids were found. CI - (c) 2026. The Author(s). FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - IQ Health Science Department (HP 160), Radboud University Medical Center, Kapittelweg 54, 6525 EP, Nijmegen, The Netherlands. Alina.Vrieling@radboudumc.nl. AD - Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands. Alina.Vrieling@radboudumc.nl. FAU - Kiebach, Joann AU - Kiebach J AUID- ORCID: 0009-0002-1480-1362 AD - IQ Health Science Department (HP 160), Radboud University Medical Center, Kapittelweg 54, 6525 EP, Nijmegen, The Netherlands. FAU - Balvers, Michiel AU - Balvers M AUID- ORCID: 0000-0003-4308-3160 AD - Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands. FAU - Aben, Katja K AU - Aben KK AUID- ORCID: 0000-0002-0214-2147 AD - IQ Health Science Department (HP 160), Radboud University Medical Center, Kapittelweg 54, 6525 EP, Nijmegen, The Netherlands. AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AUID- ORCID: 0000-0002-8839-8601 AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kampman, Ellen AU - Kampman E AUID- ORCID: 0000-0002-8606-7075 AD - Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AUID- ORCID: 0000-0002-2368-1326 AD - IQ Health Science Department (HP 160), Radboud University Medical Center, Kapittelweg 54, 6525 EP, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng GR - KUN 2013-5926/KWF Kankerbestrijding/ PT - Journal Article PT - Multicenter Study DEP - 20260821 PL - Germany TA - Eur J Nutr JT - European journal of nutrition JID - 100888704 RN - 36-88-4 (Carotenoids) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carotenoids/blood MH - *Diet/methods/statistics & numerical data MH - Disease Progression MH - Follow-Up Studies MH - *Fruit MH - *Neoplasm Recurrence, Local/blood/epidemiology/prevention & control MH - *Non-Muscle Invasive Bladder Neoplasms/epidemiology/blood MH - Prospective Studies MH - Risk Factors MH - *Vegetables PMC - PMC13498472 OTO - NOTNLM OT - Biomarkers OT - Carotenoids OT - Fruit and vegetables OT - Patients with non-muscle invasive bladder cancer OT - Progression OT - Recurrence COIS- Declarations. Conflict of interest: The authors declare no conflict of interest. EDAT- 2026/08/21 17:37 MHDA- 2026/08/21 17:38 PMCR- 2026/08/21 CRDT- 2026/08/21 11:03 PHST- 2026/02/12 00:00 [received] PHST- 2026/07/29 00:00 [accepted] PHST- 2026/08/21 17:38 [medline] PHST- 2026/08/21 17:37 [pubmed] PHST- 2026/08/21 11:03 [entrez] PHST- 2026/08/21 00:00 [pmc-release] AID - 10.1007/s00394-026-04079-4 [pii] AID - 4079 [pii] AID - 10.1007/s00394-026-04079-4 [doi] PST - epublish SO - Eur J Nutr. 2026 Aug 21;65(6):237. doi: 10.1007/s00394-026-04079-4. PMID- 42617714 OWN - NLM STAT- MEDLINE DCOM- 20261003 LR - 20261003 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 61 DP - 2026 Oct TI - Fluorescence-guided local therapy for bladder and upper urinary tract cancer: a narrative review. PG - 105617 LID - S1572-1000(26)00284-X [pii] LID - 10.1016/j.pdpdt.2026.105617 [doi] AB - Fluorescence-guided surgery using photodynamic diagnosis (PDD) has reshaped the local management of urothelial cancer by overcoming the limitations of white light endoscopy. Leveraging tumor-selective protoporphyrin IX accumulation after 5-aminolevulinic acid (ALA) or hexaminolevulinate (HAL) administration, PDD reliably highlights flat and subtle lesions that are frequently missed under white light, particularly carcinoma in situ. This narrative review synthesized randomized trials, patient-level meta-analyses, multicenter cohorts, and real-world studies to assess the diagnostic and therapeutic potential of PDD across the bladder and upper urinary tract. In non-muscle-invasive bladder cancer, PDD-assisted transurethral resection of bladder tumor improves resection completeness, reduces residual tumor, but its impact on recurrence remains inconsistent. In upper tract disease, integrating PDD into ureteroscopic assessment and laser ablation enhances margin definition and early oncologic control, complementing nephron-sparing strategies. Although Japanese experience with oral ALA and European experience with intravesical ALA or HAL collectively highlight the clinical utility of PDD, differences in their safety profiles, particularly in terms of the risk of hypotension associated with oral ALA administration, underscore the need for careful perioperative risk stratification. Fluorescence-guided local therapy represents a pragmatic, organ-preserving advancement in urothelial oncology and a template for the broader adoption of optical molecular guidance in cancer surgery. Thus, it serves as a bridge between molecular imaging and minimally invasive oncology. CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Yamamoto, Shinkuro AU - Yamamoto S AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan; Center for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Fukata, Satoshi AU - Fukata S AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. Electronic address: jm-fukatas@kochi-u.ac.jp. FAU - Kurano, Yoshitaka AU - Kurano Y AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Morishita, Yusuke AU - Morishita Y AD - Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Pustimbara, Anantya AU - Pustimbara A AD - Center for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Shigehisa, Ryu AU - Shigehisa R AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Fukuhara, Hideo AU - Fukuhara H AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan; Center for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Shimizu, Nobutaka AU - Shimizu N AD - Pelvic Floor Center, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. FAU - Ogura, Shun-Ichiro AU - Ogura SI AD - Center for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan; School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan; Center for Photodynamic Medicine, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan; Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, 783-8505, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260819 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) RN - 0 (Protoporphyrins) SB - IM MH - Humans MH - Aminolevulinic Acid/analogs & derivatives/administration & dosage/therapeutic use MH - *Photosensitizing Agents/administration & dosage/therapeutic use MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/drug therapy MH - *Photochemotherapy/methods MH - Non-Muscle Invasive Bladder Neoplasms MH - *Optical Imaging/methods MH - Protoporphyrins MH - Fluorescence MH - Transurethral Resection of Bladder MH - Laser Therapy/methods OTO - NOTNLM OT - 5-aminolevulinic acid OT - Bladder cancer OT - Fluorescence guided surgery OT - Laser ablation OT - Photodynamic diagnosis OT - TURBT OT - Upper tract urothelial carcinoma COIS- Declaration of competing interest The authors declare that they have no conflicts of interest directly related to this review article. However, the Department of Urology, Kochi Medical School, has received research funding and collaborative research support from SBI Pharmaceuticals Co., Ltd. related to photodynamic diagnosis. The sponsor had no role in the design, interpretation, or writing of this review. EDAT- 2026/08/19 23:42 MHDA- 2026/10/04 00:33 CRDT- 2026/08/19 19:11 PHST- 2026/06/16 00:00 [received] PHST- 2026/08/13 00:00 [revised] PHST- 2026/08/17 00:00 [accepted] PHST- 2026/10/04 00:33 [medline] PHST- 2026/08/19 23:42 [pubmed] PHST- 2026/08/19 19:11 [entrez] AID - S1572-1000(26)00284-X [pii] AID - 10.1016/j.pdpdt.2026.105617 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2026 Oct;61:105617. doi: 10.1016/j.pdpdt.2026.105617. Epub 2026 Aug 19. PMID- 42613292 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260918 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 7 DP - 2026 Oct TI - The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer. PG - 102627 LID - S1558-7673(26)00127-8 [pii] LID - 10.1016/j.clgc.2026.102627 [doi] AB - INTRODUCTION: Radical cystectomy (RC) remains the most effective treatment for high-grade non-muscle invasive bladder cancer (HG NMIBC) with high-risk features or after failed bladder preservation. Yet, utilization varies and understanding contemporary treatment patterns can help guide personalized care, especially amid expanding bladder-sparing options. This study assessed national trends and outcomes in HG NMIBC management with RC from 2010 to 2022. PATIENTS AND METHODS: The National Cancer Database (NCDB) was queried for clinically localized HG NMIBC. Determinants of RC use, time to RC, pathologic upstaging, and all-cause mortality were analyzed using multivariable linear, logistic, or Cox proportional hazards models. As a covariate, RC timing used 90- and 180-day cutoffs. RESULTS: Across 220,672 HG NMIBC patients, RC use has declined since 2010. Black race had lower odds of RC use (odds ratios [OR] 0.89, P < .01), whereas variant histology (OR 4.88, P < .01) and treatment at academic centers (OR 3.47, P < .01) predicted higher odds. Among 9360 patients who underwent RC, time to surgery has increased. A total of 42% of RC patients had advanced upstaging, which was associated with RC performed 180 days after diagnosis (OR 1.2, P = .018), female sex (OR 1.14, P = .012), Black race (OR 1.2, P = .047), and variant histology (OR 1.94, P < .01). Treatment at academic centers (OR 0.73, P < .01) had lower upstaging risk. Improved all-cause mortality was linked to academic centers (hazard ratios 0.87, P < .01), with no significant difference by RC timing beyond 90 or 180 days (P > .05). CONCLUSION: RC use for HG NMIBC has declined, while time to RC has increased. Longer time to RC was not uniformly associated with greater upstaging or all-cause mortality among RC patients. These findings highlight evolving practice patterns and need for long-term studies to optimize timing and integration of RC among emerging therapies. Limitations include lack of NCDB granularity to compare intentionally early versus deferred RC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Iranmahboub, Parsa AU - Iranmahboub P AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Dave, Priya AU - Dave P AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Levine, Joshua AU - Levine J AD - Albert Einstein College of Medicine, Bronx, NY. FAU - Wang, Shu AU - Wang S AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Xu, Helen AU - Xu H AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Blum, Kyle A AU - Blum KA AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Angulo-Lozano, Juan C AU - Angulo-Lozano JC AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Wahba, Brandon Malik AU - Wahba BM AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Suzman, Evan AU - Suzman E AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. FAU - Scherr, Douglas S AU - Scherr DS AD - Department of Urology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. Electronic address: dss2001@med.cornell.edu. LA - eng PT - Journal Article DEP - 20260724 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Cystectomy/methods/trends/statistics & numerical data MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Aged MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Treatment Outcome OTO - NOTNLM OT - Early cystectomy OT - National cancer database OT - National practice patterns OT - Pathologic upstaging OT - Timing of cystectomy COIS- Disclosure The authors declare no financial or non-financial competing interests relevant to this work. EDAT- 2026/08/18 23:36 MHDA- 2026/09/18 23:36 CRDT- 2026/08/18 21:54 PHST- 2026/05/04 00:00 [received] PHST- 2026/07/13 00:00 [revised] PHST- 2026/07/14 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/18 23:36 [pubmed] PHST- 2026/08/18 21:54 [entrez] AID - S1558-7673(26)00127-8 [pii] AID - 10.1016/j.clgc.2026.102627 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Oct;24(7):102627. doi: 10.1016/j.clgc.2026.102627. Epub 2026 Jul 24. PMID- 42607565 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260918 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 10 DP - 2026 Oct TI - Intravesical recurrence is associated with increased T(reg) and exhausted CD8(+) T cells in upper tract urothelial carcinoma. PG - 598-606 LID - S1078-1439(26)00621-6 [pii] LID - 10.1016/j.urolonc.2026.07.028 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) includes renal pelvic and ureteral carcinoma, and radical nephroureterectomy (RNU) is the standard surgical treatment for nonmetastatic disease. Despite complete resection, postoperative intravesical recurrence (IVR) occurs in 22% to 47% of patients. It is generally recognized that ureteral tumor exhibits a higher incidence of IVR compared with renal pelvic tumor. However, the immunological mechanisms underlying this difference remain poorly understood. MATERIAL AND METHODS: A total of 26 patients with UTUC without variant histology who underwent laparoscopic RNU at Kyushu University Hospital were classified according to tumor location (Renal pelvic group: n = 15; Ureteral group: n = 11). Clinical characteristics and the spatial distribution of immune cells in UTUC were analyzed and compared between the 2 groups using multiplex immunohistochemistry (mIHC). RESULTS: IVR occurred more frequently in the Ureteral group than in the Renal pelvic group. mIHC analysis revealed significantly higher infiltration of regulatory T (T(reg)) cells and programmed cell death (PD)-1(+) T(reg) cells in the ureteral group. Furthermore, the infiltration of exhausted CD8(+) T cells co-expressing T cell immunoglobulin and ITIM domain (TIGIT) and PD-1 were significantly enriched in the Ureteral group. Across the entire cohort, patients who developed IVR exhibited higher densities of these T-cell subsets compared with those without IVR. CONCLUSIONS: Ureteral tumors demonstrate increased infiltration of T(reg) cells, PD-1(+) T(reg) cells, and TIGIT(+)PD-1(+)CD8(+) T cells, suggesting an immunosuppressive TME that may contribute to the higher risk of IVR after RNU. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Ito, Daisuke AU - Ito D AD - Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tanegashima, Tokiyoshi AU - Tanegashima T AD - Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: tanegashima.tokiyoshi.271@m.kyushu-u.ac.jp. FAU - Fukuchi, Genshiro AU - Fukuchi G AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Kobayashi, Satoshi AU - Kobayashi S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Matsumoto, Takashi AU - Matsumoto T AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Okumura, Genki AU - Okumura G AD - Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Immunogenomic Medicine, Research Institute, National Cancer Center Japan, Tokyo, Japan. FAU - Itahashi, Kota AU - Itahashi K AD - Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan. FAU - Oda, Yoshinao AU - Oda Y AD - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Koyama, Shohei AU - Koyama S AD - Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan; Department of Immunogenomic Medicine, Research Institute, National Cancer Center Japan, Tokyo, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article DEP - 20260817 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Female MH - *T-Lymphocytes, Regulatory/immunology MH - *CD8-Positive T-Lymphocytes/immunology MH - Male MH - *Neoplasm Recurrence, Local/immunology/pathology MH - Aged MH - T-Cell Exhaustion MH - *Ureteral Neoplasms/immunology/pathology/surgery MH - Middle Aged MH - *Carcinoma, Transitional Cell/immunology/pathology/surgery MH - Nephroureterectomy OTO - NOTNLM OT - Exhausted CD8(+) T cell OT - Intravesical recurrence OT - Regulatory T cell OT - Tumor microenvironment OT - Upper tract urothelial carcinoma COIS- Declaration of competing interest Tokiyoshi Tanegashima has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, and Takeda Pharmaceutical. Takashi Matsumoto has received honoraria for lectures from Astellas Pharma, Johnson and Johnson Innovative Medicine, Ono Pharmaceutical, Merck Biopharma, and MSD. M. Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer and research funding support from Astellas Pharma. Kota Itahashi has received honoraria from MSD and Chugai Pharmaceutical; and consulting fees from AbbVie; research funding from AbbVie, all outside the submitted work. Shohei Koyama has received research funding from Otsuka Pharmaceutical, Shionogi Pharmaceutical, and Chugai Pharmaceutical; received honoraria (lecture fee) from Chugai Pharmaceutical, MSD, and Merck; and advisory fees from Shionogi Pharmaceutical, Kaken Pharmaceutical outside of this study. M. Eto received honoraria from Astellas Pharma, AstraZeneca, Eisai, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Bayer, Pfizer Japan, Bristol-Myers Squibb, Merck Biopharma, Janssen Pharmaceutical, and research funding support from MSD. EDAT- 2026/08/17 23:39 MHDA- 2026/09/18 23:36 CRDT- 2026/08/17 18:07 PHST- 2026/02/20 00:00 [received] PHST- 2026/07/13 00:00 [revised] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/17 23:39 [pubmed] PHST- 2026/08/17 18:07 [entrez] AID - S1078-1439(26)00621-6 [pii] AID - 10.1016/j.urolonc.2026.07.028 [doi] PST - ppublish SO - Urol Oncol. 2026 Oct;44(10):598-606. doi: 10.1016/j.urolonc.2026.07.028. Epub 2026 Aug 17. PMID- 42606609 OWN - NLM STAT- MEDLINE DCOM- 20260817 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Aug 17 TI - Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER. LID - 575 [pii] LID - 10.1007/s00345-026-06683-9 [doi] AB - PURPOSE: To compare treatment trends and survival between bladder‑preserving (BP) therapy and radical cystectomy (RC) in patients with T2N0M0 muscle‑invasive bladder cancer (MIBC) using a large population‑based cohort. METHODS: This retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER) database (2010‑2022) to identify 10,495 patients with T2N0M0 MIBC. Temporal trends in treatment modalities (RC, trimodality therapy [TMT], partial cystectomy with chemotherapy [PC + CT], etc.) were analyzed. The primary outcomes were overall survival (OS) and cancer‑specific mortality (CSM). Propensity score matching (PSM) was used to compare OS and CSM between treatment groups. Fine‑Gray competing risk regression generated cumulative incidence curves and estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CSM. Kaplan‑Meier estimation with log‑rank tests and multivariable Cox regression were also performed. All comparative survival results are reported with complete 95% CIs to quantify statistical uncertainty and avoid overinterpretation of non-significant findings. RESULTS: From 2010 to 2022, the use of multimodal therapy increased. Specifically, TMT rose from 11.9% to 26.2%, and RC + CT increased from 8.9% to 23.9%, while monotherapies declined. After PSM, RC demonstrated superior 5-year OS compared to TMT (62.6% vs. 36.7%, p < 0.001). Notably, PC + CT showed no statistically significant 5-year survival differences relative to RC (OS: p = 0.893,HR = 0.97,95%CI(0.59-1.58); CSM: p = 0.902,HR = 1.04,95%CI(0.55-1.94)). Chemotherapy significantly improved survival for patients undergoing transurethral resection of bladder tumor (TURBT) and PC, but not RC. Multivariable analysis confirmed older age, female sex, and higher T-stage as risk factors, while chemotherapy and surgery (RC/PC) were protective. CONCLUSION: This study reveals a significant shift towards multimodal therapy for T2N0M0 MIBC. Although RC remains associated with the best overall survival, PC + CT showed no statistically significant difference in OS or CSM compared with RC, supporting its potential as a BP option for carefully selected patients. Nevertheless, these findings are constrained by the limited sample size of the PC + CT cohort, the absence of functional and quality-of-life outcomes, and residual confounding inherent in the SEER database. The inferior survival of TMT in real-world practice underscores the critical importance of stringent patient selection for bladder preservation strategies. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - He, Qiuming AU - He Q AD - Department of Urology, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical college, Jiangxi Clinical Research Center for Cancer, Nanchang, 330000, Jiangxi, China. FAU - Jiang, Zhenzhen AU - Jiang Z AD - VIP ward, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical college, Jiangxi Clinical Research Center for Cancer, Nanchang, 330000, Jiangxi, China. FAU - Jiang, Chao AU - Jiang C AD - Department of Urology, Poyang County People's Hospital, Poyang, Shangrao, China. FAU - Tu, Xinhua AU - Tu X AD - Department of Urology, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical college, Jiangxi Clinical Research Center for Cancer, Nanchang, 330000, Jiangxi, China. tuxinhua2020@163.com. FAU - Huang, Ji AU - Huang J AD - Department of Urology, Jiangxi Cancer Hospital and Institute, The Second Affiliated Hospital of Nanchang Medical college, Jiangxi Clinical Research Center for Cancer, Nanchang, 330000, Jiangxi, China. huangji@ncmc.edu.cn. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260817 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/mortality/surgery/pathology MH - Female MH - Retrospective Studies MH - Male MH - SEER Program MH - Aged MH - *Organ Sparing Treatments MH - Survival Rate MH - Middle Aged MH - Neoplasm Staging MH - Treatment Outcome OTO - NOTNLM OT - Bladder preservation OT - Muscle-invasive bladder cancer OT - Propensity score matching OT - Radical cystectomy OT - SEER program OT - Trimodality therapy COIS- Declarations. Conflict of interest: The authors declare that they have no competing interests. EDAT- 2026/08/17 17:45 MHDA- 2026/08/17 17:46 CRDT- 2026/08/17 11:07 PHST- 2026/05/31 00:00 [received] PHST- 2026/08/08 00:00 [accepted] PHST- 2026/08/17 17:46 [medline] PHST- 2026/08/17 17:45 [pubmed] PHST- 2026/08/17 11:07 [entrez] AID - 10.1007/s00345-026-06683-9 [pii] AID - 10.1007/s00345-026-06683-9 [doi] PST - epublish SO - World J Urol. 2026 Aug 17;44(1):575. doi: 10.1007/s00345-026-06683-9. PMID- 42605566 OWN - NLM STAT- MEDLINE DCOM- 20261012 LR - 20261014 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 138 IP - 5 DP - 2026 Nov TI - Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review. PG - 786-797 LID - 10.1111/bju.70404 [doi] AB - OBJECTIVES: To systematically identify, appraise and synthesise artificial intelligence (AI) and machine-learning (ML) models that predict treatment response and clinical outcomes after intravesical bacillus Calmette-Guerin (BCG) in non-muscle-invasive bladder cancer (NMIBC), a setting in which current risk calculators underperform, and identifying non-responders has become urgent as alternatives to BCG enter practice. METHODS: PubMed, EMBASE and Web of Science were searched through April 2026 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines (International Prospective Register of Systematic Reviews [PROSPERO] number CRD420261376808). Studies developing or validating AI/ML models for BCG-associated outcomes with a quantitative performance metric were included. Risk of bias was assessed with the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Evidence was synthesised along a clinically oriented framework: AI as a perceptual tool (extracting signal from histology or imaging) or integrative tool (re-weighting clinicopathological, molecular, or urinary variables). RESULTS: A total of 15 studies (>24 900 patients) were included: seven perceptual, eight integrative. By input data, six used digital pathology, two radiomics, two genomics/transcriptomics, four clinicopathological markers, and one urinary biomarkers. The digital-pathology Computational Histology Artificial Intelligence (CHAI) platform, validated across 12 international centres, stratified high-grade recurrence (hazard ratio [HR] 2.08), progression (HR 3.87) and BCG-unresponsive disease (HR 2.31), and was the only model providing a first signal of predictive value, demonstrating a significant BCG vs gemcitabine/docetaxel interaction (P = 0.029). Integrative models PROGRxN-BCa (concordance index [C-index] 0.79) and DeepSurv (C-index 0.881) outperformed standard calculators but with modest gains (DeltaC-index 0.05-0.10). Only 40% of studies performed external validation, none prospectively; five were at high risk of bias. CONCLUSION: Perceptual AI, particularly digital pathology, has the highest external validation and provides the only biomarker with a first signal of predictive value for BCG vs alternatives, increasingly relevant in the context of the global BCG shortage. Integrative models such as PROGRxN-BCa and DeepSurv outperform standard calculators with incremental gains and are freely accessible. Prospective validation, systematic calibration reporting and treatment-by-biomarker interaction analyses, ideally embedded in trials such as the BRIDGE trial (ClinicalTrials.gov identifier: NCT05538663), remain priorities before clinical adoption. CI - (c) 2026 BJU International. FAU - Cella, Ludovica AU - Cella L AUID- ORCID: 0009-0009-0399-2395 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Urology Department, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Naples, Italy. FAU - Paciotti, Marco AU - Paciotti M AUID- ORCID: 0000-0002-8456-6495 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AUID- ORCID: 0000-0001-6155-5964 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Uleri, Alessandro AU - Uleri A AUID- ORCID: 0000-0002-2392-2775 AD - Department of Urology, Josep Trueta University Hospital, Girona, Spain. FAU - Avolio, Pier Paolo AU - Avolio PP AUID- ORCID: 0000-0002-7497-265X AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, La Croix du Sud Hopital, Quint Fonsegrives, France. FAU - Perdona, Sisto AU - Perdona S AD - Urology Department, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Naples, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AUID- ORCID: 0000-0003-3939-4521 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AUID- ORCID: 0000-0001-9978-8587 AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. LA - eng SI - ClinicalTrials.gov/NCT05538663 PT - Journal Article PT - Systematic Review DEP - 20260817 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *Artificial Intelligence MH - *BCG Vaccine/therapeutic use MH - Machine Learning MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Predictive Learning Models MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Clinical Trials as Topic OTO - NOTNLM OT - BCG OT - artificial intelligence OT - machine learning OT - non-muscle-invasive bladder cancer OT - prediction EDAT- 2026/08/17 05:38 MHDA- 2026/10/12 05:32 CRDT- 2026/08/17 04:23 PHST- 2026/10/12 05:32 [medline] PHST- 2026/08/17 05:38 [pubmed] PHST- 2026/08/17 04:23 [entrez] AID - 10.1111/bju.70404 [doi] PST - ppublish SO - BJU Int. 2026 Nov;138(5):786-797. doi: 10.1111/bju.70404. Epub 2026 Aug 17. PMID- 42601890 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260815 LR - 20260816 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study. PG - 1856699 LID - 10.3389/fonc.2026.1856699 [doi] LID - 1856699 AB - OBJECTIVE: To evaluate the association of adjuvant intravesical Bacillus Calmette-Guerin (BCG) immunotherapy after transurethral resection of bladder tumor (TURBT) with bladder mucosal apoptosis index, recurrence-related outcomes, progression-free survival, and 12-month quality of life in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: A retrospective analysis was conducted on 114 NMIBC patients who underwent TURBT at our hospital from January 2022 to December 2024, including 57 patients receiving postoperative intravesical BCG immunotherapy (BCG group) and 57 patients receiving TURBT alone without postoperative adjuvant intravesical therapy (control group). Tumor recurrence rates, progression-free survival (PFS), bladder mucosal apoptosis index, and quality of life (QOL-BREF) scores were compared between groups. RESULTS: Baseline characteristics of both groups were balanced via propensity score matching (PSM) (P>0.05). The BCG group exhibited a significantly higher bladder mucosal apoptosis index (32. 13 +/- 5.61) compared to the control group (18.72 +/- 4.29) (P<0.001). Six-month and one-year recurrence rates were markedly lower in the BCG group (2 cases, 3.51%; 8 cases, 14.04%) versus the control group (9 cases, 15.79%; 21 cases, 36.84%) (P<0.001), with median PFS extended to 25 months (control group: 13 months, P<0.001). Pearson correlation analysis showed a positive correlation between apoptosis index and PFS (r=0.61, P<0.001), and multivariable Cox regression further indicated that a higher apoptosis index was independently associated with a lower risk of recurrence or progression. Preoperative QOL-BREF scores showed no significant difference between groups (54. 11 +/- 5.96 vs. 54.03 +/- 6.27, P>0.05), while postoperative scores were significantly higher in the BCG group (71.95 +/- 8.23 vs. 63.47 +/- 8.22) (P<0.001). CONCLUSION: In this retrospective propensity-score-matched cohort, adjuvant intravesical BCG immunotherapy after TURBT was associated with a higher bladder mucosal apoptosis index, lower recurrence risk, longer progression-free survival, and better 12-month QOL-BREF scores. These findings support the clinical relevance of apoptosis index and QOL assessment in postoperative NMIBC management. CI - Copyright (c) 2026 Zhu, Tan and Liu. FAU - Zhu, Hui AU - Zhu H AD - Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China. FAU - Tan, ShuBin AU - Tan S AD - Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China. FAU - Liu, XianGen AU - Liu X AD - Department of Urology, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China. LA - eng PT - Journal Article DEP - 20260731 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13472817 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - apoptosis OT - non-muscle-invasive bladder cancer OT - prognostic survival OT - transurethral resection of bladder tumor COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/15 05:36 MHDA- 2026/08/15 05:37 PMCR- 2026/07/31 CRDT- 2026/08/15 04:41 PHST- 2026/04/15 00:00 [received] PHST- 2026/07/08 00:00 [revised] PHST- 2026/07/13 00:00 [accepted] PHST- 2026/08/15 05:37 [medline] PHST- 2026/08/15 05:36 [pubmed] PHST- 2026/08/15 04:41 [entrez] PHST- 2026/07/31 00:00 [pmc-release] AID - 10.3389/fonc.2026.1856699 [doi] PST - epublish SO - Front Oncol. 2026 Jul 31;16:1856699. doi: 10.3389/fonc.2026.1856699. eCollection 2026. PMID- 42594670 OWN - NLM STAT- MEDLINE DCOM- 20260910 LR - 20260910 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 246 DP - 2026 Oct 5 TI - Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification. PG - 116987 LID - S0959-8049(26)00768-9 [pii] LID - 10.1016/j.ejca.2026.116987 [doi] AB - BACKGROUND: Bladder cancer (BlCa) surveillance requires lifelong invasive monitoring, imposing substantial patient burden and healthcare costs. This underscores the need for minimally-invasive precision medicine approaches. Herein, we investigated the circulating miRNome of BlCa patients to assess its clinical and translational utility. METHODS: miRNA-seq was performed on tumors and matched plasma samples from 15 patient-derived xenograft (PDX) mouse models. The screening cohort of the study consisted of 216 patients, and circulating miRNAs were quantified by RT-qPCR following 3'-end poly(A)-tailing. Cox regression models were used to develop liquid biopsy-based miRNA risk-scores (miRisk-scores), for non-muscle invasive (NMIBC) and muscle invasive BlCa (MIBC). RESULTS: miRNA-seq identified six miRNAs (miR-100, miR-1246, miR-1290, miR-193b, miR-375, miR-4488) that were concurrently upregulated in tumors and plasma, and correlated with advanced stage/grade and early progression in PDX mouse models. In our screening cohort, elevated miR-375 and miR-4488 were associated with poorer NMIBC prognosis, whereas miR-1290 and miR-193b with worse survival in MIBC. Higher miRisk-scores were associated with short-term relapse and progression in NMIBC, while miRisk score-fitted multivariate models improved TaT1 risk-stratification. Moreover, higher miRisk-scores correlated with worse clinical outcomes in MIBC, and enhanced the prognostic performance of clinical markers. CONCLUSION: Overall, liquid biopsy miRNA signatures offer a minimally-invasive tool to complement biopsy-based assessments and refine BlCa risk-stratification and prognosis. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Pilala, Katerina-Marina AU - Pilala KM AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Panoutsopoulou, Konstantina AU - Panoutsopoulou K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Soureas, Konstantinos AU - Soureas K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. FAU - Giagkos, Georgios-Christos AU - Giagkos GC AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kanaki, Zoi AU - Kanaki Z AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Loules, Gedeon AU - Loules G AD - CeMIA SA, Larissa, Greece. FAU - Zamanakou, Maria AU - Zamanakou M AD - CeMIA SA, Larissa, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Klinakis, Apostolos AU - Klinakis A AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. Electronic address: mavgeris@med.uoa.gr. FAU - Scorilas, Andreas AU - Scorilas A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. LA - eng PT - Journal Article DEP - 20260809 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (Circulating MicroRNA) SB - IM MH - Humans MH - Animals MH - *Urinary Bladder Neoplasms/genetics/pathology/blood MH - Liquid Biopsy/methods MH - Prognosis MH - Female MH - *Biomarkers, Tumor/genetics/blood MH - Mice MH - Non-Muscle Invasive Bladder Neoplasms/genetics MH - Male MH - *MicroRNAs/genetics/blood MH - Aged MH - Middle Aged MH - Risk Assessment MH - Risk Factors MH - *Circulating MicroRNA/genetics/blood MH - Heterografts OTO - NOTNLM OT - Circulating miRNAs OT - Circulating tumor markers OT - Liquid biopsy OT - Non-coding RNAs OT - PDXs OT - Patient-derived xenografts OT - Tumor markers OT - miRNA-risk score OT - miRNA-seq OT - miRNAs COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/13 23:36 MHDA- 2026/09/10 23:35 CRDT- 2026/08/13 18:07 PHST- 2026/06/24 00:00 [received] PHST- 2026/08/05 00:00 [revised] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/09/10 23:35 [medline] PHST- 2026/08/13 23:36 [pubmed] PHST- 2026/08/13 18:07 [entrez] AID - S0959-8049(26)00768-9 [pii] AID - 10.1016/j.ejca.2026.116987 [doi] PST - ppublish SO - Eur J Cancer. 2026 Oct 5;246:116987. doi: 10.1016/j.ejca.2026.116987. Epub 2026 Aug 9. PMID- 42585880 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260921 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 10 DP - 2026 Oct TI - Impact of divergent differentiation and histological subtypes on oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. PG - 565-574 LID - S1078-1439(26)00611-3 [pii] LID - 10.1016/j.urolonc.2026.07.018 [doi] AB - BACKGROUND: Divergent differentiation (DD) and histological subtypes (HS) represent rare but clinically meaningful forms of upper tract urothelial carcinoma (UTUC), but their prognostic impact remains incompletely understood. We assessed the incidence, clinicopathological characteristics, and oncologic outcomes associated with DD-HS in a large multi-institutional cohort of patients undergoing radical nephroureterectomy (RNU) for non-metastatic UTUC. METHODS: We retrospectively analyzed 3,441 patients treated between 1985 and 2022 across 22 institutions. Tumors were classified as pure urothelial carcinoma (PUC), DD, and HS. Clinicopathological features and survival outcomes-including recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS)-were compared using the Kaplan-Meier estimator, stratified by pathological stage (organ-confined [OC: /=pT3 or >/=pN1]) and multivariable Cox regression. RESULTS: DD-HS were present in 201 patients (5.8%), with DD comprising 139 (69%). Compared to PUC, DD-HS were associated with more advanced T/N stages, higher rates of lymphovascular invasion (40% vs. 20%), multifocality (35% vs. 27%), and concomitant carcinoma in situ (21% vs. 14%) (all P < 0.05). While outcomes for DD were similar to stage-matched PUC, HS showed significantly worse stage-matched RFS (OC: 38% vs. 83%; NOC: 25% vs. 46%) and OS (OC: 44% vs. 75%; all P < 0.01), and remained independently associated with poorer outcomes on multivariable analyses. Limitations include the retrospective design and lack of centralized pathology review. CONCLUSIONS: UTUC with DD-HS represents a biologically heterogeneous population with distinct oncologic outcomes compared with PUC. Further investigation into subtype-specific tumor biology and rigorous pathological characterization is warranted to better define the clinical relevance of individual histological entities and to guide future treatment strategies. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Pallauf, Maximilian AU - Pallauf M AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. FAU - Bronimann, Stephan AU - Bronimann S AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Fletcher, Sean A AU - Fletcher SA AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Rezaee, Michael E AU - Rezaee ME AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - McConkey, David J AU - McConkey DJ AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Potretzke, Aaron M AU - Potretzke AM AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Paris, France. FAU - Djaladat, Hooman AU - Djaladat H AD - Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA. FAU - Ghoreifi, Alireza AU - Ghoreifi A AD - Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Campi, Riccardo AU - Campi R AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Department of Oncology, Unit of Urology and Renal Transplantation, Careggi University Hospital, Florence, Italy. FAU - Granata, Salvatore AU - Granata S AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Department of Oncology, Unit of Urology and Renal Transplantation, Careggi University Hospital, Florence, Italy. FAU - Khene, Zine-Eddine AU - Khene ZE AD - Department of Urology, University of Rennes, Rennes, France. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Boormans, Joost AU - Boormans J AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France. FAU - Singla, Nirmish AU - Singla N AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: nsingla2@jhmi.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260812 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Treatment Outcome MH - Middle Aged MH - Prognosis MH - Cell Differentiation MH - *Kidney Neoplasms/surgery/pathology/mortality MH - *Ureteral Neoplasms/surgery/pathology/mortality OTO - NOTNLM OT - Divergent differentiation OT - Histological subtypes OT - RNU OT - Radical nephroureterectomy OT - UTUC OT - Upper tract urothelial cancer OT - Variant histology COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Maximilian Pallauf reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory. Maximilian Pallauf reports a relationship with AstraZeneca Kabushiki Kaisha that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Maximilian Pallauf reports a relationship with Johnson and Johnson SA that includes: speaking and lecture fees and travel reimbursement. Maximilian Pallauf reports a relationship with Astellas Pharma GmbH that includes: consulting or advisory. Stephen A Boorjian reports a relationship with Ferring that includes: consulting or advisory. Stephen A Boorjian reports a relationship with ArTara that includes: consulting or advisory. Stephen A Boorjian reports a relationship with Prokarium that includes: consulting or advisory. Stephen A Boorjian reports a relationship with Johnson & Johnson that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/12 23:34 MHDA- 2026/09/18 23:36 CRDT- 2026/08/12 18:06 PHST- 2026/02/17 00:00 [received] PHST- 2026/05/26 00:00 [revised] PHST- 2026/07/12 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/12 23:34 [pubmed] PHST- 2026/08/12 18:06 [entrez] AID - S1078-1439(26)00611-3 [pii] AID - 10.1016/j.urolonc.2026.07.018 [doi] PST - ppublish SO - Urol Oncol. 2026 Oct;44(10):565-574. doi: 10.1016/j.urolonc.2026.07.018. Epub 2026 Aug 12. PMID- 42584515 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260815 IS - 1534-6285 (Electronic) IS - 1527-2737 (Print) IS - 1527-2737 (Linking) VI - 27 IP - 1 DP - 2026 Aug 12 TI - Intravesical Recurrence of Upper Tract Urothelial Carcinoma: Strategies for Prevention. LID - 10.1007/s11934-026-01331-6 [doi] LID - 37 AB - PURPOSE OF REVIEW: This review focuses on intravesical recurrence (IVR) of upper tract urothelial carcinoma (UTUC). RECENT FINDINGS: We explore epidemiology, risk factors, mechanisms of tumor cell seeding, molecular pathways, genetic predispositions, and related factors of UTUC. Diagnostic techniques, strategies managing disease and reducing recurrence, as well as controversies and challenges in UTUC management are discussed. By synthesizing the latest research findings, this review aims to provide a comprehensive understanding of UTUC IVR which can guide clinical practice and future research efforts. CI - (c) 2026. The Author(s). FAU - Song, Lingmin AU - Song L AD - Department of Urology, Ningbo Hospital of Integrated Tranditional Chinese and Western Medicine, Zhejiang, China. FAU - Meagher, Margaret AU - Meagher M AD - Department of Urology, University of California San Diego, San Diego, CA, USA. FAU - Saidian, Ava AU - Saidian A AD - Department of Urology, University of Tennessee Health Sciences System, Memphis, TN, USA. FAU - Salmasi, Amirali AU - Salmasi A AD - Department of Urology, University of California San Diego, San Diego, CA, USA. FAU - Azari, Sarah AU - Azari S AD - Department of Urology, University of California San Diego, San Diego, CA, USA. FAU - Dabbas, Mai AU - Dabbas M AD - Department of Urology, University of California San Diego, San Diego, CA, USA. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Department of Urology, University of California San Diego, San Diego, CA, USA. bagrodia@health.ucsd.edu. LA - eng PT - Journal Article PT - Review DEP - 20260812 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology MH - *Carcinoma, Transitional Cell/prevention & control/therapy/secondary MH - *Urinary Bladder Neoplasms/prevention & control MH - *Ureteral Neoplasms/pathology MH - Risk Factors MH - *Kidney Neoplasms/pathology MH - Neoplasm Seeding PMC - PMC13468967 OTO - NOTNLM OT - Bladder recurrence OT - Seeding OT - Urothelial carcinoma COIS- Declarations. Human/Animals Study: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing Interests: The authors declare no competing interests. EDAT- 2026/08/12 17:35 MHDA- 2026/08/12 17:36 PMCR- 2026/08/12 CRDT- 2026/08/12 11:06 PHST- 2025/11/11 00:00 [received] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/08/12 17:36 [medline] PHST- 2026/08/12 17:35 [pubmed] PHST- 2026/08/12 11:06 [entrez] PHST- 2026/08/12 00:00 [pmc-release] AID - 10.1007/s11934-026-01331-6 [pii] AID - 1331 [pii] AID - 10.1007/s11934-026-01331-6 [doi] PST - epublish SO - Curr Urol Rep. 2026 Aug 12;27(1):37. doi: 10.1007/s11934-026-01331-6. PMID- 42578982 OWN - NLM STAT- Publisher LR - 20260811 IS - 2326-6074 (Electronic) IS - 2326-6066 (Linking) DP - 2026 Aug 11 TI - The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer. LID - 10.1158/2326-6066.CIR-25-1445 [doi] AB - Bacillus Calmette-Guerin (BCG) is the standard adjuvant therapy for early-stage bladder cancer (BCa), based on its immunostimulatory activity. However, over half of patients experience BCG failure and subsequent recurrence. The heterogeneity of the tumor microenvironment may influence BCG response, however this relationship is currently not well-established. We found that BCG response did not correlate with the number of tumor-infiltrating T cells but was determined by the pre-treatment immunosuppressive microenvironment. We identified a subset of cancer-associated fibroblasts characterized by microfibrillar-associated protein 2 (MFAP2+ CAF), which impaired BCG-induced antitumoral immunity by interacting with both individual T cells and tertiary lymphoid structures/lymphoid aggregates. This study also revealed a potential stepwise activation of cancer immune evasion factors based on cross-sectional analysis, from increasing MFAP2+ CAF to activation of PD-L1 and then LAG3 on T cells, during early-stage BCa development. These findings have the potential to enable accurate prediction of BCG response. This approach may also be applicable to the investigation of other human cancers. FAU - Guo, Yufeng AU - Guo Y AUID- ORCID: 0009-0006-0580-0236 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Ren, Xuezhao AU - Ren X AUID- ORCID: 0009-0006-4426-5344 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Zhang, Ze AU - Zhang Z AUID- ORCID: 0000-0001-6335-6491 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Cheng, Hui AU - Cheng H AUID- ORCID: 0009-0009-2417-202X AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Ma, Jin-Peng AU - Ma JP AUID- ORCID: 0009-0005-5403-9845 AD - Harbin Medical University Harbin, Heilongjiang Province China. ROR: https://ror.org/05jscf583 FAU - Yan, Hong AU - Yan H AUID- ORCID: 0009-0009-9296-5777 AD - Lanzhou University Second Hospital Lanzhou China. ROR: https://ror.org/02erhaz63 FAU - Niu, Qian AU - Niu Q AUID- ORCID: 0009-0003-6832-5987 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Zhang, Xinyu AU - Zhang X AUID- ORCID: 0000-0002-6270-4623 AD - Nantong University Nantong China. ROR: https://ror.org/02afcvw97 FAU - Zhang, Luyang AU - Zhang L AUID- ORCID: 0000-0001-6765-1252 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Tian, Junqiang AU - Tian J AUID- ORCID: 0000-0002-4529-4650 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Dong, Zhilong AU - Dong Z AUID- ORCID: 0009-0001-8862-4445 AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 FAU - Wang, Hanzhang AU - Wang H AUID- ORCID: 0009-0002-3558-7668 AD - Brown University United States. ROR: https://ror.org/05gq02987 FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0009-0004-2260-6254 AD - Brown University Warren Alpert Medical School China. FAU - Lu, Yong-Jie AU - Lu YJ AUID- ORCID: 0000-0001-6174-6621 AD - Barts Cancer Institute, Queen Mary University of London London United Kingdom. FAU - Wang, Zhiping AU - Wang Z AUID- ORCID: 0000-0002-8140-591X AD - Lanzhou University Second Hospital Lanzhou, Gansu Province China. ROR: https://ror.org/02erhaz63 LA - eng PT - Journal Article DEP - 20260811 PL - United States TA - Cancer Immunol Res JT - Cancer immunology research JID - 101614637 SB - IM EDAT- 2026/08/11 12:37 MHDA- 2026/08/11 12:37 CRDT- 2026/08/11 11:03 PHST- 2026/08/07 00:00 [accepted] PHST- 2025/11/14 00:00 [received] PHST- 2026/05/14 00:00 [revised] PHST- 2026/08/11 12:37 [medline] PHST- 2026/08/11 12:37 [pubmed] PHST- 2026/08/11 11:03 [entrez] AID - 787392 [pii] AID - 10.1158/2326-6066.CIR-25-1445 [doi] PST - aheadofprint SO - Cancer Immunol Res. 2026 Aug 11. doi: 10.1158/2326-6066.CIR-25-1445. PMID- 42575840 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260923 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 44 IP - 10 DP - 2026 Oct TI - Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer. PG - 728-738 LID - S1078-1439(26)00601-0 [pii] LID - 10.1016/j.urolonc.2026.07.017 [doi] AB - BACKGROUND: Patients with muscle-invasive bladder cancer (MIBC) have heterogeneous outcomes following transurethral resection of bladder tumor (TURBT). We used a computational histopathology artificial intelligence (CHAI)-based platform to develop and validate a digital image-only MIBC prognostic biomarker. METHODS: The CHAI platform extracts histologic features from pre-treatment TURBT specimen H&E-stained whole slide images. The Cancer Genome Atlas was used for development to construct a signature of features associated with the primary endpoint of recurrence-free survival (RFS). A continuous risk score was dichotomized into favorable and unfavorable groups. For validation, the performance of the locked model was then assessed in an independent, held-out, retrospective, pooled real-world data cohort of patients from NCI-Designated Cancer Centers with cT2N0M0 urothelial carcinoma who underwent radical cystectomy with/without neoadjuvant chemotherapy (NAC). RESULTS: A total of 178 patients were included: 44 in development and 134 in validation, of whom 50% received NAC. In validation, those classified as unfavorable risk by the CHAI biomarker (N = 67) had worse RFS (HR 3.1 [1.7-5.7], P < 0.001), cancer-specific survival (CSS) (3.5 [1.5-7.8], P = 0.003), and overall survival (OS) (3.0, [1.5-5.7], P = 0.001) vs. favorable risk (N = 67). Three-year RFS was 40% vs. 74% for disease classified as unfavorable and favorable risk, respectively (P < 0.001). After adjusting for prognostic clinical variables, including receipt of NAC, the biomarker remained associated with RFS, CSS, and OS (P < 0.01). Exploratory analysis found a significant interaction between the biomarker and NAC for RFS (P = 0.02). CONCLUSIONS: We developed and validated an image-only AI-based biomarker from pre-treatment H&E TURBT specimens associated with clinical outcomes in cT2 MIBC. While future development and validation work is warranted, these hypothesis-generating retrospective findings support the potential of this approach to advancing precision medicine in MIBC. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Woldu, Solomon AU - Woldu S AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Allison, Derek AU - Allison D AD - Department of Pathology, University of Kentucky, Lexington, KY. FAU - Kim, Joon Kyung AU - Kim JK AD - Department of Urology, University of Kentucky, Lexington, KY. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Cleveland Clinic, Cleveland, OH. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Krishna, Vrishab AU - Krishna V AD - Valar Labs, Palo Alto, CA. FAU - Kaul, Gaurav AU - Kaul G AD - Valar Labs, Palo Alto, CA. FAU - Neema, Akshay AU - Neema A AD - Valar Labs, Palo Alto, CA. FAU - Zhang, Haochen AU - Zhang H AD - Valar Labs, Palo Alto, CA. FAU - Royce, Trevor J AU - Royce TJ AD - Valar Labs, Palo Alto, CA; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: trevor.royce@mail.harvard.edu. FAU - Krishna, Viswesh AU - Krishna V AD - Valar Labs, Palo Alto, CA. FAU - Joshi, Anirudh AU - Joshi A AD - Valar Labs, Palo Alto, CA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, MD Anderson Cancer Center, Houston, TX. FAU - Li, Roger AU - Li R AD - Urology, Moffitt Cancer Center, Tampa, FL. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky, Lexington, KY. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P30 CA177558/CA/NCI NIH HHS/United States PT - Journal Article PT - Validation Study DEP - 20260810 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Female MH - *Artificial Intelligence MH - Male MH - Retrospective Studies MH - *Biomarkers, Tumor MH - Aged MH - Transurethral Resection of Bladder MH - Middle Aged MH - Neoplasm Invasiveness PMC - PMC13527431 MID - NIHMS2199868 OTO - NOTNLM OT - Artificial intelligence OT - Biomarker OT - Muscle-invasive bladder cancer OT - Oncology OT - Urothelial carcinoma COIS- Declaration of competing interest Trevor J. Royce reports financial support was provided by Valar Labs Inc. Trevor J. Royce reports a relationship with Valar Labs Inc that includes: employment and equity or stocks. Yair Lotan: Stock and Other Ownership Interests: Vessi Medical, CAPs Medical, Nanorobotics, Phinomics, UroViu, Virtuoso Therapeutics, Vesica Health, Trigone Pharma. Consulting or Advisory Role: Photocure, Pacific Edge, Vessi Medical, Merck, AstraZeneca, Nucleix, UroGen Pharma, BMS, FerGene, AbbVie, Cleveland Diagnostics, Nanorobotics, Nanogen Biopharmaceutical, Caps Medical, Ambu, Seagen, Verity Pharmaceuticals, Virtuoso Surgical, Stimit, xCures, Aura Biosciences, Convergent Genomics, Phinomics, UroViu, Trigone Pharma, NRx Pharmaceuticals, ImmunityBio, Janssen. Research Funding: Abbott Molecular (Inst), Pacific Edge (Inst), Cepheid (Inst), GenomeDx (Inst), MDxHealth (Inst), Pacific Edge, Cepheid, Augmenix, BioCancell (Inst), Photocure (Inst), Storz (Inst). Vitaly Margulis: Honoraria: Johnson & Johnson, Merck, Blue Earth Diagnostics, Progenics, Steba Biotech. Solomon Woldu: Consulting or Advisory Role: UroGen Pharma. Laura Bukavina: Leadership: Urology Times, European Urology. Consulting or Advisory Role: Charite, ImmunityBio, Pfizer. Research Funding: BCAN, American Urological Association, Kidney Cancer Association. No other potential conflicts of interest were reported. Sam Chang: Honoraria: Merck, UroGen Pharma, Janssen Oncology, Nonagen Bioscience, Pacific Edge Biotechnology, Prokarium, Lantheus Medical Imaging, Tu Therapeutics, Pfizer, Ferring, ImmunityBio, Johnson & Johnson/Janssen. Consulting or Advisory Role: Merck, Photocure, UroGen pharma, Janssen Oncology, Pfizer, NantBioScience, UroToday, virtuoso Surgical, CG Oncology, Tu Therapeutics. Research Funding: NantCell (Inst). Vrishab Krishna: Employment: Valar Labs. Stock and Other Ownership Interests: Valar Labs. Patents, Royalties, Other Intellectual Property: Valar Labs patents. Gaurav Kaul: Employment: Valar Labs. Stock and Other Ownership Interests: Valar Labs. Patents, Royalties, Other Intellectual Property: Valar Labs patents. Akshay Neema: Employment: Valar Labs. Stock and Other Ownership Interests: Valar Labs. Patents, Royalties, Other Intellectual Property: Valar Labs patents. Haochen Zhang: Employment: Valar Labs. Stock and Other Ownership Interests: Revolution Medicines, Lilly, Moderna Therapeutics, Valar Labs. Trevor J. Royce: Employment: Flatiron Health, ArteraAI, Valar Labs. Stock and Other Ownership Interests: Roche, Lumata Health, VitriVax, SonoVascular, mPATH, Deep Blue Medical, Galaxy Diagnostics. Consulting or Advisory Role: Agilix Health. Viswesh Krishna: Employment: Valar Labs. Leadership: Valar Labs. Stock and Other Ownership Interests: Valar Labs. Patents, Royalties, Other Intellectual Property: Valar Labs patents. Anirudh A. Joshi: Employment: Valar Labs, Intuitive Surgical (I). Leadership: Valar Labs. Stock and Other Ownership Interests: Valar Labs. Patents, Royalties, Other Intellectual Property: Valar Labs patents under review. Travel, Accommodations, Expenses: Valar Labs. Ashish Kamat: Leadership: International Bladder Cancer Group (IBCG), World Bladder Cancer Patient Coalition, American Urological Association. Consulting or Advisory Role: Merck, Janssen, Astellas Pharma, Cystotech, Imvax, ImmunityBio, Vivet Therapeutics, enGene, CG Oncology, Ferring, Genentech, Nonagen Bioscience, Pfizer, Seagen, Theralase, Valar Labs, Aspira Women's Health (I), Atonco Pharma, Biological Dynamics, Bristol Myers Squibb, Eisai, Imagin Medical, Incyte, Medac, Photocure, Protara Therapeutics, Roche, Sesen Bio, UroGen Pharma, US Biotest. Research Funding: FKD Therapies (Inst), Photocure (Inst), SWOG (Inst), Patient-Centered Outcomes Research Institute (PCORI) (Inst), enGene (Inst), Arquer Diagnostics (Inst), Seagen (Inst). Patents, Royalties, Other Intellectual Property: Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center. Other Relationship: European Urology Oncology, Journal of Urology, UroToday. Roger Li: Stock and Other Ownership Interests: Beam Therapeutics, Intellia Therapeutics, Lilly, CRISPR Therapeutics. Honoraria: UroToday, IBCG, MashupMD. Consulting or Advisory Role: Bristol Myers Squibb, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson/Janssen, AstraZeneca, enGene, UroGen pharma, Valar Labs, Ferring, Photocure. Speakers' Bureau: Johnson & Johnson/Janssen. Research Funding: CG Oncology, Predicine, Valar Labs. Travel, Accommodations, Expenses: CG Oncology, Predicine. Other Relationship: Predicine. Patrick Hensley: Consulting or Advisory Role: Johnson & Johnson/Janssen, Ferring. Speakers' Bureau: Johnson & Johnson/Janssen, Ferring. The remaining authors have nothing to disclose. EDAT- 2026/08/11 00:35 MHDA- 2026/09/18 23:36 PMCR- 2026/09/01 CRDT- 2026/08/10 22:00 PHST- 2026/05/18 00:00 [received] PHST- 2026/06/20 00:00 [revised] PHST- 2026/07/11 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/08/11 00:35 [pubmed] PHST- 2026/08/10 22:00 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - S1078-1439(26)00601-0 [pii] AID - 10.1016/j.urolonc.2026.07.017 [doi] PST - ppublish SO - Urol Oncol. 2026 Oct;44(10):728-738. doi: 10.1016/j.urolonc.2026.07.017. Epub 2026 Aug 10. PMID- 42572829 OWN - NLM STAT- Publisher LR - 20260810 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) DP - 2026 Aug 10 TI - Hybrid grading systems improve progression risk stratification in non-invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression. LID - 10.1111/his.70260 [doi] AB - OBJECTIVE: Histological grading is a key predictor of progression in non-muscle-invasive bladder cancer (NMIBC). The WHO 1973 three-tier system is limited by heterogeneity within the G2 category, whereas the WHO 2004/2016 binary classification reduces prognostic resolution by grouping biologically diverse tumours into broad low-grade (LG) and high-grade (HG) categories. We aimed to evaluate the prognostic performance of hybrid grading systems compared with WHO 2004/2016, while further characterizing the histomorphological continuum of non-invasive papillary urothelial carcinoma. METHODS: Non-invasive papillary urothelial carcinomas (2012-2023; n = 472) were reviewed and reclassified by two urological pathologists according to WHO 2004/2016, hybrid three-tier and four-tier systems, and an investigational five-tier framework (Grades I, IIA, IIB, IIIA, IIIB) integrating architectural, cytological and proliferative features. Primary endpoints were recurrence, grade progression and T1+ stage progression, assessed using ROC analysis, Cox proportional hazards regression and model-performance metrics (AIC, BIC, C-index). RESULTS: Increasing morphological atypia was associated with larger tumour size, greater multifocality and progressively higher progression risk, with events concentrated in Grades IIIA and IIIB. All systems showed limited recurrence discrimination (C-index 0.54-0.56). For T1+ progression, discrimination improved with increasing stratification (AUC 0.754 for WHO 2004/2016 vs. 0.815, 0.828 and 0.827 for the hybrid three-tier, four-tier and five-tier systems, respectively; all P < 0.001). The Hybrid 3-Tier model achieved the most favourable AIC and BIC, while the five-tier model yielded the highest C-index (0.818). CONCLUSIONS: Hybrid grading systems improve progression-risk stratification in non-invasive papillary urothelial carcinoma compared with WHO 2004/2016, with most benefit achieved by the Hybrid 3-Tier framework. These findings support the concept of a histomorphological continuum of progression risk and favour continued refinement of biologically informed hybrid grading for NMIBC risk stratification. CI - (c) 2026 The Author(s). Histopathology published by John Wiley & Sons Ltd. FAU - Nguyen, Jane K AU - Nguyen JK AUID- ORCID: 0000-0002-1653-4942 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Toscano, Marcello P AU - Toscano MP AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Li, Jianbo AU - Li J AD - Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Williamson, Sean R AU - Williamson SR AUID- ORCID: 0000-0002-3898-1460 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Przybycin, Christopher G AU - Przybycin CG AUID- ORCID: 0000-0001-9426-7272 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Kao, Chia-Sui AU - Kao CS AUID- ORCID: 0000-0001-6609-2567 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Myles, Jonathan L AU - Myles JL AUID- ORCID: 0000-0003-3130-5475 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Pivovarcikova, Kristyna AU - Pivovarcikova K AUID- ORCID: 0000-0002-9553-0105 AD - Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic. AD - Bioptical Laboratory, Pilsen, Czech Republic. FAU - Svajdler, Marian AU - Svajdler M AUID- ORCID: 0000-0001-8052-4741 AD - Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic. AD - Bioptical Laboratory, Pilsen, Czech Republic. FAU - Brousil, Marek AU - Brousil M AD - Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic. AD - Bioptical Laboratory, Pilsen, Czech Republic. FAU - Eltemamy, Mohamed AU - Eltemamy M AUID- ORCID: 0000-0003-2947-179X AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Bukavina, Laura AU - Bukavina L AUID- ORCID: 0000-0001-7129-6230 AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Krishnamurthi, Venkatesh AU - Krishnamurthi V AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Weight, Christopher AU - Weight C AUID- ORCID: 0000-0001-9381-959X AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Campbell, Rebecca A AU - Campbell RA AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Almassi, Nima AU - Almassi N AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Alaghehbandan, Reza AU - Alaghehbandan R AUID- ORCID: 0000-0002-6708-5032 AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. LA - eng PT - Journal Article DEP - 20260810 PL - England TA - Histopathology JT - Histopathology JID - 7704136 SB - IM OTO - NOTNLM OT - grading OT - histomorphological continuum OT - hybrid grading OT - non-muscle-invasive bladder cancer OT - papillary urothelial carcinoma OT - prognostic stratification EDAT- 2026/08/10 06:36 MHDA- 2026/08/10 06:36 CRDT- 2026/08/10 04:13 PHST- 2026/07/31 00:00 [revised] PHST- 2026/06/16 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/08/10 06:36 [medline] PHST- 2026/08/10 06:36 [pubmed] PHST- 2026/08/10 04:13 [entrez] AID - 10.1111/his.70260 [doi] PST - aheadofprint SO - Histopathology. 2026 Aug 10. doi: 10.1111/his.70260. PMID- 42567736 OWN - NLM STAT- In-Process LR - 20261023 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 5 DP - 2026 Oct TI - Re: Parizi MK, D'Andrea D, Pradere B, et al. Prognostic factors for recurrence and survival after radical cystectomy for non-muscle invasive bladder cancer: a multicenter analysis of 1032 patients. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.06.001: Prognostic Factors After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: From Prognostication to Patient Selection. PG - 1187-1188 LID - S2588-9311(26)00200-2 [pii] LID - 10.1016/j.euo.2026.07.010 [doi] FAU - Sforza, Simone AU - Sforza S AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Oncologic, Minimally-Invasive Robotic Urology and Andrology, Careggi Hospital, Florence, Italy. Electronic address: simone.sforza1988@gmail.com. FAU - Lubbersmeyer, Felix AU - Lubbersmeyer F AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Oncologic, Minimally-Invasive Robotic Urology and Andrology, Careggi Hospital, Florence, Italy. Electronic address: andreamari08@gmail.com. LA - eng PT - Journal Article DEP - 20260808 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM EDAT- 2026/08/08 00:37 MHDA- 2026/08/08 00:37 CRDT- 2026/08/07 21:54 PHST- 2026/07/07 00:00 [received] PHST- 2026/07/11 00:00 [revised] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/08/08 00:37 [pubmed] PHST- 2026/08/08 00:37 [medline] PHST- 2026/08/07 21:54 [entrez] AID - S2588-9311(26)00200-2 [pii] AID - 10.1016/j.euo.2026.07.010 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Oct;9(5):1187-1188. doi: 10.1016/j.euo.2026.07.010. Epub 2026 Aug 8. PMID- 42567092 OWN - NLM STAT- Publisher LR - 20260807 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 6 DP - 2026 Jul 10 TI - The Prognostic Role of HER2 Expression in Patients With Non-Muscle-Invasive Bladder Cancer. PG - 102624 LID - S1558-7673(26)00124-2 [pii] LID - 10.1016/j.clgc.2026.102624 [doi] AB - BACKGROUND/OBJECTIVES: The available risk stratification models used to predict the prognosis of non-muscle-invasive bladder cancer (NMIBC) are not efficient enough. The research focused on assessing the relationship between HER2 expression status and recurrence in NMIBC. METHODS: The retrospective study consisted of 217 NMIBC patients who were treated by transurethral resection of bladder tumor. Immunohistochemistry (IHC) was used to evaluate HER2 expression as being high (IHC 2(+)/3(+)) or low (IHC 0/1(+)). The relationship between the clinicopathological characteristics and the recurrence-free survival (RFS) was examined through the use of both univariate and multivariate Cox proportional hazards regression. The additional predictive utility of HER2 to the European Organization for Research and Treatment of Cancer (EORTC) and Club Urologico Espanol de Tratamiento Oncologico (CUETO) models was determined based on the concordance index (C-index) and time-dependent area under the receiver operating characteristic curve (t-AUC). RESULTS: The patients who had high HER2 expression (n = 96) had significantly increased rates of pT1 stage (39.6% vs. 18.2%, P < .001), high-grade tumor (75.0% vs. 44.6%, P < .001), and recurrent tumor (29.2% vs. 13.2%, P = .004) when compared to the low-expression group. Multivariate analysis identified high HER2 expression as an independent predictor of recurrence (HR 2.58, 95% CI, 1.41-4.73; P = .002). HER2-high patients had significantly worse RFS. Subgroup analyses showed worse RFS for HER2-overexpressing tumors across intravesical instillation subgroups and within the European Association of Urology (EAU) intermediate- and high-risk groups (all P < .05). Integrating HER2 status significantly improved the predictive performance of both the EORTC (C-index: 0.703-0.730) and CUETO models (C-index: 0.687-0.716). CONCLUSION: High HER2 expression is an independent risk predictor of recurrence in NMIBC patients. It provides significant incremental prognostic value beyond EORTC and CUETO risk scores and enhances risk stratification within intermediate- and high-risk EAU groups. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Yang, Xuejian AU - Yang X AD - Department of Urology, Jiangsu Province (Suqian) Hospital, Suqian, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Chenghao AU - Wang C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Tan, Zhengye AU - Tan Z AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Chen, Chang AU - Chen C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Tao, Yiran AU - Tao Y AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhang, Yuheng AU - Zhang Y AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Bao, Meiling AU - Bao M AD - Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Ruan, Yashi AU - Ruan Y AD - The Affiliated Taizhou People's Hospital of Nanjing Medical University, Nanjing, China. Electronic address: yashi.ruan@njmu.edu.cn. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: doctorlvqiang@njmu.edu.cn. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: yangxiao2915@163.com. LA - eng PT - Journal Article DEP - 20260710 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM OTO - NOTNLM OT - HER2 OT - Immunohistochemistry OT - Prognostic biomarker OT - Recurrence-free survival (RFS) OT - Risk stratification COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2026/08/08 00:37 MHDA- 2026/08/08 00:37 CRDT- 2026/08/07 18:08 PHST- 2026/03/01 00:00 [received] PHST- 2026/07/02 00:00 [revised] PHST- 2026/07/03 00:00 [accepted] PHST- 2026/08/08 00:37 [medline] PHST- 2026/08/08 00:37 [pubmed] PHST- 2026/08/07 18:08 [entrez] AID - S1558-7673(26)00124-2 [pii] AID - 10.1016/j.clgc.2026.102624 [doi] PST - aheadofprint SO - Clin Genitourin Cancer. 2026 Jul 10;24(6):102624. doi: 10.1016/j.clgc.2026.102624. PMID- 42565671 OWN - NLM STAT- Publisher LR - 20260807 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) DP - 2026 Aug 7 TI - Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guerin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group). LID - hyag124 [pii] LID - 10.1093/jjco/hyag124 [doi] AB - BACKGROUND: The prognostic significance of non-muscle-invasive bladder cancer (NMIBC) recurrence after a prolonged disease-free interval following intravesical Bacillus Calmette-Guerin (BCG) therapy remains unclear. This multicenter study evaluated the impact of late recurrence after BCG therapy on oncological outcomes. METHODS: This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence >/=1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1-2 years and >/= 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox proportional hazards analyses. RESULTS: During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1-2-year and >/= 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence >/=2 years was associated with significantly worse CSS than recurrence at 1-2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02-62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence >/=2 years. CONCLUSIONS: NMIBC recurrence occurring >/=2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted. CI - (c) The Author(s) 2026. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Ikehata, Yoshinori AU - Ikehata Y AUID- ORCID: 0000-0001-5079-2171 AD - Department of Urology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijocho, Kashihara, Nara, 634-8521, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, 840 Shijocho, Kashihara, Nara, 634-8521, Japan. FAU - Yuki, Kita AU - Yuki K AD - Department of Urology, Kyoto University Graduate School of Medicine, Yoshidakonoecho, Sakyo-ku, Kyoto, Kyoto, 606-8501, Japan. FAU - Shimura, Soichiro AU - Shimura S AD - Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan. FAU - Inoue, Yuta AU - Inoue Y AD - Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajii‑cho, Kamigyo‑ku, Kyoto, 602‑0841, Japan. FAU - Matsumoto, Takashi AU - Matsumoto T AUID- ORCID: 0000-0003-1570-6340 AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3‑1‑1 Maidashi, Higashi‑ku, Fukuoka 812‑8582, Japan. FAU - Yajima, Shugo AU - Yajima S AUID- ORCID: 0000-0003-2300-8446 AD - Department of Urology, National Cancer Center Hospital East, 6‑5‑1 Kashiwanoha, Kashiwa, Chiba 277‑8577, Japan. FAU - Nagumo, Yoshiyuki AU - Nagumo Y AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1‑1‑1 Tennodai, Tsukuba, Ibaraki 305‑8577, Japan. FAU - Morizane, Shuichi AU - Morizane S AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, 86 Nishimachi, Yonago, Tottori 683‑8503, Japan. FAU - Sato, Takuma AU - Sato T AD - Department of Urology, Tohoku University, 2‑1 Seiryo‑cho, Aoba‑ku, Sendai 980‑8575, Japan. FAU - Fujii, Masato AU - Fujii M AD - Department of Urology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake‑cho, Miyazaki, Miyazaki 889‑1692, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AUID- ORCID: 0000-0002-8902-7853 AD - Department of Urology, Chiba University Graduate School of Medicine, 1‑8‑1 Inohana, Chuo‑ku, Chiba, Chiba 260‑8670, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu‑cho, Hirosaki, Aomori 036‑8562, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AUID- ORCID: 0000-0002-3031-7258 AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, 160 Kou Minami‑Umemoto‑cho, Matsuyama, Ehime 791‑0280, Japan. FAU - Yamagishi, Atsushi AU - Yamagishi A AD - Department of Urology, Yamagata University Faculty of Medicine, 2‑2‑2 Iida‑Nishi, Yamagata 990‑9585, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, 1750‑1 Ikedo, Miki‑cho, Kida‑gun, Kagawa 761‑0793, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo 104‑0045, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijocho, Kashihara, Nara, 634-8521, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1‑1‑1 Tennodai, Tsukuba, Ibaraki 305‑8577, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, 3‑19‑18 Nishi‑Shimbashi, Minato‑ku, Tokyo 105‑8471, Japan. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, 3‑19‑18 Nishi‑Shimbashi, Minato‑ku, Tokyo 105‑8471, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. CN - Japanese Urological Oncology Group LA - eng PT - Journal Article DEP - 20260807 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM OTO - NOTNLM OT - intravesical bacillus Calmette-Guerin (BCG) therapy OT - late recurrence OT - non-muscle-invasive bladder cancer EDAT- 2026/08/07 12:39 MHDA- 2026/08/07 12:39 CRDT- 2026/08/07 09:53 PHST- 2026/05/15 00:00 [received] PHST- 2026/07/16 00:00 [revised] PHST- 2026/07/17 00:00 [accepted] PHST- 2026/08/07 12:39 [medline] PHST- 2026/08/07 12:39 [pubmed] PHST- 2026/08/07 09:53 [entrez] AID - 8754026 [pii] AID - 10.1093/jjco/hyag124 [doi] PST - aheadofprint SO - Jpn J Clin Oncol. 2026 Aug 7:hyag124. doi: 10.1093/jjco/hyag124. PMID- 42559128 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260825 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Decoding the temporal dimension of innate immunity in intravesical BCG therapy. PG - 1904049 LID - 10.3389/fimmu.2026.1904049 [doi] LID - 1904049 AB - Innate immune signals encode functional instructions through temporal patterns such as oscillation frequency and duration-a principle validated at the single-cell level. Yet clinical evaluation of host responses in tumor immunotherapy remains dominated by "how strongly" the immune system is activated, while the waveform of the response-how it unfolds and when it resolves-is largely overlooked. This disconnect raises unresolved questions: why can tumor progression persist despite intense inflammation, and why is fixed-interval maintenance not universally effective? Intravesical BCG instillation offers a way forward: each instillation is a controlled stimulus, voided urine provides a noninvasive sampling window, and oncological plus bladder-function outcomes form a "controlled stimulus-noninvasive sampling-dual-endpoint" closed loop. Using this model, we propose a hypothesis organized around two observation levels. The fundamental unit is the single-instillation single-cytokine waveform-the complete concentration-time curve of one cytokine following one BCG dose; the second is the longitudinal waveform trajectory, which captures how such waveforms evolve across repeated instillations. Both levels reside at a mesoscopic interface between single-cell signaling dynamics and macro-scale clinical outcomes. Our central hypothesis is that temporal features of a single-instillation single-cytokine waveform-time-to-peak, elimination half-life, and decay morphology-carry predictive information independent of peak amplitude. Distinct waveform shapes may differentially instruct adaptive immune quality, while the decay phase defines the time window for immune homeostasis restoration, thus providing a biological rationale for individualized instillation timing. If validated, this framework would expand the evaluation paradigm for intravesical immunotherapy from an "amplitude" dimension to a dual "amplitude + waveform" paradigm. CI - Copyright (c) 2026 Diao, Che, Zhai, Shao and Tang. FAU - Diao, Xuewen AU - Diao X AD - The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China. AD - Department of Urology and Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. FAU - Che, Bangwei AU - Che B AD - The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China. AD - Department of Urology and Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. FAU - Zhai, Jiancheng AU - Zhai J AD - The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China. AD - Department of Urology and Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. FAU - Shao, Bo AU - Shao B AD - The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China. AD - Department of Urology and Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. FAU - Tang, Kaifa AU - Tang K AD - The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China. AD - Department of Urology and Andrology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China. LA - eng PT - Journal Article DEP - 20260722 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Cytokines) SB - IM MH - Animals MH - Humans MH - Administration, Intravesical MH - *BCG Vaccine/administration & dosage/immunology MH - Cytokines/metabolism MH - *Immunity, Innate MH - Immunotherapy/methods MH - *Urinary Bladder Neoplasms/immunology/drug therapy/therapy PMC - PMC13439578 OTO - NOTNLM OT - BCG OT - bladder cancer OT - immunotherapy OT - innate immunity OT - kinetic profile COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/06 12:37 MHDA- 2026/08/06 12:38 PMCR- 2026/07/22 CRDT- 2026/08/06 06:59 PHST- 2026/06/09 00:00 [received] PHST- 2026/07/05 00:00 [revised] PHST- 2026/07/08 00:00 [accepted] PHST- 2026/08/06 12:38 [medline] PHST- 2026/08/06 12:37 [pubmed] PHST- 2026/08/06 06:59 [entrez] PHST- 2026/07/22 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1904049 [doi] PST - epublish SO - Front Immunol. 2026 Jul 22;17:1904049. doi: 10.3389/fimmu.2026.1904049. eCollection 2026. PMID- 42557383 OWN - NLM STAT- Publisher LR - 20260805 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) DP - 2026 Aug 5 TI - Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group. LID - 10.1038/s41585-026-01179-y [doi] AB - Crucial unmet needs for standardization and clinical integration of actionable biomarkers persist across the bladder cancer disease spectrum. To address these gaps, the International Bladder Cancer Group (IBCG) convened a global multidisciplinary panel to develop evidence-based consensus recommendations on biomarker use in bladder cancer. Recommendations were formulated across the disease spectrum using a modified Delphi process. In patients with asymptomatic microhaematuria, biomarker use should be guided by a risk-stratified approach. For patients with established non-muscle-invasive bladder cancer, no biomarker prospectively validated is available to guide intravesical therapy selection, although approved commercial tests might aid in adjudicating equivocal cytology or cystoscopy findings in patients with high-grade disease. In muscle-invasive bladder cancer, no validated biomarkers exist to guide the choice between bladder preservation and radical cystectomy, or to inform the choice of neoadjuvant therapy. Circulating tumour DNA is prognostic following neoadjuvant therapy and radical cystectomy, and provides predictive value for selecting patients who are most likely to benefit from adjuvant treatment with approved immunotherapy regimens. In addition, circulating tumour DNA has prognostic value in patients with metastatic urothelial carcinoma. The IBCG recommends assessing FGFR3 genomic alterations and HER2 immunohistochemistry in patients with locally advanced and/or metastatic bladder cancer to inform therapeutic selection. The IBCG consensus recommendations provide practical, stage-specific guidance on the use of biomarkers for diagnosis, risk stratification and treatment selection in patients with bladder cancer and define priorities for future validation and trial design. CI - (c) 2026. Springer Nature Limited. FAU - Hensley, Patrick J AU - Hensley PJ AD - Departments of Urology and Pathology, University of Kentucky Markey Cancer Center, Lexington, KY, USA. FAU - Teoh, Jeremy Y C AU - Teoh JYC AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Gupta, Shilpa AU - Gupta S AUID- ORCID: 0000-0002-8775-503X AD - Department of Genitourinary Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Mouw, Kent W AU - Mouw KW AUID- ORCID: 0000-0001-7939-7343 AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. FAU - Lobo, Niyati AU - Lobo N AUID- ORCID: 0000-0002-6505-8399 AD - Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. FAU - Maiorano, Brigida Anna AU - Maiorano BA AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Department of Urology, Yale School of Medicine, New Haven, CT, USA. AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Agarwal, Piyush AU - Agarwal P AD - Department of Surgery, Section of Urology, University of Chicago, Chicago, IL, USA. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AUID- ORCID: 0000-0002-2938-6627 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI, USA. FAU - Flaig, Thomas W AU - Flaig TW AUID- ORCID: 0000-0001-6145-9040 AD - Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Center, Aurora, CO, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Horowitz, Amir AU - Horowitz A AUID- ORCID: 0000-0003-3100-2810 AD - Department of Immunology and Immunotherapy, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Surgery (Urology), McGill University Health Center, Montreal, Quebec, Canada. FAU - Kates, Max R AU - Kates MR AD - Johns Hopkins University, Baltimore, MD, USA. FAU - Konety, Badrinath R AU - Konety BR AD - Allina Health Cancer Institute, Minneapolis, MN, USA. FAU - Kukreja, Janet B AU - Kukreja JB AD - Division of Urology, Department of Surgery, University of Colorado Anschutz Medical Center, Aurora, CO, USA. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. FAU - Mir, Maria Carmen AU - Mir MC AUID- ORCID: 0000-0002-1391-1378 AD - Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, NY, USA. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology, Unit of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AUID- ORCID: 0000-0002-3007-2756 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Oualla, Karima AU - Oualla K AD - Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco. FAU - Packiam, Vignesh T AU - Packiam VT AD - Division of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Schmidt, Bogdana AU - Schmidt B AD - Department of Surgery, Division of Urology, University of Utah, Salt Lake City, UT, USA. FAU - Buckley, Roger J AU - Buckley RJ AD - Division of Urology, North York General Hospital, Toronto, Ontario, Canada. FAU - Kamat, Ashish M AU - Kamat AM AUID- ORCID: 0000-0003-3546-9928 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. akamat@mdanderson.org. LA - eng PT - Journal Article PT - Review DEP - 20260805 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 SB - IM COIS- Competing interests: P.J.H. has acted as adviser/consultant for Ferring, ImmunityBio, Johnson & Johnson and UroGen Pharma. R.L. has received research support from Predicine, Valar Labs and Johnson & Johnson; has acted as adviser/consultant for BMS, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Ferring and Valar Labs; has received honoraria from UroToday, IBCG, MashUP Media and MJH Lifesciences; and has received travel support from Predicine, CG Oncology and Johnson & Johnson. S.G. has acted as consultant for AstraZeneca, Natera, BMS, Merck, Bayer, Foundation Medicine, Gilead Sciences, Pfizer and Novartis; has been a speaker for BMS; and received research funding from Novartis, Exelixis, Merck, BMS, Tyra Biosciences, Flare Therapeutics and Roche. L.B. has acted as consultant for Charite, ImmunityBio, Ferring Pharmaceuticals, Pfizer, Aura Biosciences, Merck and Janssen; has received honoraria from Johnson & Johnson Clinical Immersion Program and PeerView Bladder Cancer Symposium; has stock options from Tempus AI; and has been on the Editorial Board for European Urology and Urology Times. K.W.M. has acted as an adviser/ consultant for EMD Serono, Pfizer, UroGen, Riva Therapeutics, Natera and Astellas; has received research support from Pfizer and Novo Ventures; has equity in Riva Therapeutics and Illudent Therapeutics; has received writer/speaking fees from UpToDate and OncLive; has patents filed for mutational signatures of DNA repair deficiency; has a leadership role in the International Bladder Cancer Network; and is an editorial board member at Science Advances. W.S.T. has served as consultant/adviser to Ferring. P.A. has served as consultant/speaker for Urogen and Ferring; and consultant for ImmunityBio. H.A.A. has consulted for AstraZeneca, Paige.AI, Pfizer and Janssen. T.J.B. has received honoraria from Ferring, Janssen and UroGen; and served as consultant/adviser to UroGen Pharma. T.W.F. has leadership positions in Aurora Oncology, University of Colorado/UC Health and CPC-Clinical Research and Community Health; holds stock or ownership in Aurora Oncology; has received research funding from Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol Myers Squibb, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, SOTIO, Tokai Pharmaceuticals, AstraZeneca/MedImmune, Lilly, Astellas Pharma, Agensys, Seagen, La Roche-Posay, Merck, Myovant Sciences and Criterium; and has two patents with The University of Colorado related to early-stage bladder cancer treatment and detection (neither is commercialized or in active clinical development currently). W.K. has acted as consultant/adviser for Ferring, AstraZeneca, Merck, Janssen, Bayer, Pfizer, EMD Serono, Photocure, CG Oncology, enGene, Knighttx and Accord. M.R.K. has a consulting or advisory role for Nanology, UroGen Pharma, Pfizer, Johnson & Johnson/Janssen, Aura Biosciences and ImmunityBio. B.R.K. has served as a consultant/ adviser for Valar Labs, Photocure, Asieris Pharmaceuticals, Ferring Pharmaceuticals, Illumina and Abbott; and has ownership/investment interest in Astrin Biosciences and Styx Biotechnologies. J.B.K. has served as consultant/adviser to Intuitive Surgical. Y.L. has acted as consultant/adviser for Photocure, AstraZeneca, Merck, Fergene, Nucleix, Ambu, Seattle Genetics, Virtuoso Surgical, Stimit, Urogen, Vessi Medical, CAPs Medical, Nonagen, Aura Biosciences, Convergent Genomics, Pacific Edge, Pfizer, Phinomics, CG Oncology, Uroviu, Promis Diagnostics, Valar Labs, Uroessentials, NRx Pharmaceuticals, Vesica Health, Janssen, ImmunityBio, Trigone Pharma and Relmada; and has stock/stock options in Vessi, CAPs Medical, Relmada, Phinomics, Uroviu, Valar Labs, Vesica Health and Trigone Pharma. D.J.M. reports consulting roles for CG Oncology and Owkin; research support from Janssen and Convergent Genomics; leadership roles for SWOG GU Committee and the Bladder Cancer Advocacy Network scientific advisory board; and an inventor interest in pending patent PCT/US2022/019757 on the use of B8T as a prognostic and predictive biomarker in cancer. L.S.M. has acted as consultant for Johnson & Johnson and Merck. M.M. has acted as an adviser for Photocure, Janssen, Medac and Pfizer. A.N. reports institutional research funding from AstraZeneca and Merck Sharp & Dohme; grants/contracts from Bristol Myers Squibb, Gilead Sciences and Ipsen; consulting/advisory fees from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Daiichi-Sankyo, F. Hoffman-La Roche, Ferring, Gilead Sciences, GlaxoSmithKline, Incyte, Janssen Cilag EMA, Merck Sharp & Dohme, Rainier Therapeutics, Roche and Seattle Genetics/Astellas; honoraria from AstraZeneca, Bristol Myers Squibb, Foundation Medicine, Janssen, Merck and Roche; support for other professional activities from Bayer; support for travel from AstraZeneca, Janssen, Merck Sharp & Dohme, Rainier Therapeutics and Roche; and stock and other ownership interests in Bayer outside the submitted work. K.O. has served on consulting or advisory boards for Roche, MSD, Pfizer, Janssen, Astellas, AstraZeneca, Mylan, Ipsen, Novartis, Hikma, Sothema and SunPharma; has received research funding from Roche. V.T.P. serves as a consultant/speaker for Valar Labs, Veracyte, Photocure, Ferring and Johnson & Johnson; and has a joint provisional patent related to the DRIFT device. B.S. reports relationships with Ferring, Janssen, ImmunityBio and Urogen Pharma. R.J.B. received honoraria from Tersera, Knight, Astellas and Tolmar. A.M.K. has received research funding from FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics and SWOG; has acted as adviser/consultant for Astellas Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, Urogen Pharma, US Biotest, Valar Labs and Vivet Therapeutics; holds a joint patent with MD Anderson Cancer Center for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); and has held a leadership role in the International Bladder Cancer Group (IBCG), European Urology Oncology, the Journal of Urology, UroToday, American Urological Association (AUA) and World Bladder Cancer Patient Coalition. The other authors declare no competing interests. EDAT- 2026/08/06 11:36 MHDA- 2026/08/06 11:36 CRDT- 2026/08/05 23:57 PHST- 2026/07/22 00:00 [accepted] PHST- 2026/08/06 11:36 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/05 23:57 [entrez] AID - 10.1038/s41585-026-01179-y [pii] AID - 10.1038/s41585-026-01179-y [doi] PST - aheadofprint SO - Nat Rev Urol. 2026 Aug 5. doi: 10.1038/s41585-026-01179-y. PMID- 42556596 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261028 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 227 DP - 2026 Nov TI - Bacillus Calmette-Guerin (BCG) with or without immune checkpoint blockade in BCG-naive high-risk non-muscle-invasive bladder cancer: A systematic review and reconstructed individual patient data meta-analysis. PG - 105510 LID - S1040-8428(26)00397-5 [pii] LID - 10.1016/j.critrevonc.2026.105510 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) accounts for 75% of bladder cancers. Despite standard treatment with transurethral resection followed by BCG instillation, 30-40% of patients relapse. We conducted a meta-analysis evaluating immune checkpoint inhibitor (ICI) plus BCG versus BCG alone in BCG-naive high-risk NMIBC. METHODS: We performed a systematic review and reconstructed individual patient data (rIPD) meta-analysis of phase 3 randomized controlled trials (RCTs). Individual patient data were reconstructed from published Kaplan-Meier curves using the IPDfromKM method. The primary endpoint was event-free survival (EFS) for ICI plus BCG induction and maintenance (I+M) versus BCG I + M alone. Secondary endpoints included EFS for ICI plus BCG induction only, overall survival, subgroup analyses (age, sex, BCG strain, concomitant CIS), and safety. RESULTS: Three phase 3 trials (CREST, POTOMAC, ALBAN; n = 2590) were included. ICI plus BCG I + M significantly improved EFS versus BCG alone (HR 0.77, 95% CI 0.64-0.93; p = 0.006), corroborated by pooled aggregate-data analysis (HR 0.77, 95% CI 0.60-0.97; I(2)=40%). ICI plus BCG induction only conferred no benefit (HR 1.03, 95% CI 0.85-1.25; p = 0.754). Overall survival data were immature (HR 0.90; p = 0.36). Grade >/= 3 adverse events were more frequent with combination therapy (24.5% vs 6.1%). CONCLUSION: ICI combined with full BCG maintenance significantly improves EFS in BCG-naive high-risk NMIBC. This benefit is contingent on BCG maintenance; induction-only BCG provides no synergistic effect. Incremental toxicity warrants careful patient selection and biomarker-stratified validation before universal adoption. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Saad, Mohammed Amine AU - Saad MA AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. Electronic address: mohammedamine_saad@um5.ac.ma. FAU - Antari, Abdelkarim AU - Antari A AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Taleb, Imad AU - Taleb I AD - Medical Oncology Department - Moulay Ismail Military Hospital, Meknes, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - El Omri, Sofia AU - El Omri S AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Traore, Hamadoun AU - Traore H AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Chahbounia, Imane AU - Chahbounia I AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Sella, Imane AU - Sella I AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Poudiougou, Abdoulkarim AU - Poudiougou A AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Sano, Faman Douaya AU - Sano FD AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Omri, Loubna AU - Omri L AD - Medical Oncology Department - National Institute of Oncology, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Elm'hadi, Choukri AU - Elm'hadi C AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Hassan II University, Casablanca, Morocco. FAU - Lamine, Saida AU - Lamine S AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Mokhlis, Mohammed Anouar AU - Mokhlis MA AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Hassan II University, Casablanca, Morocco. FAU - Aalaoui, Lamia AU - Aalaoui L AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Debbagh, Adil AU - Debbagh A AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Khmamouche, Mohamed Reda AU - Khmamouche MR AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Sidi Mohamed Ben Abdellah University, Fez, Morocco. FAU - Slimani, Khaoula Alaoui AU - Slimani KA AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Sbitti, Yassir AU - Sbitti Y AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Mahfoud, Tarik AU - Mahfoud T AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - University, Marrakesh, Morocco. FAU - Errihani, Hassan AU - Errihani H AD - Medical Oncology Department - National Institute of Oncology, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. FAU - Tanz, Rachid AU - Tanz R AD - Medical Oncology Department - Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy - Mohammed V University, Rabat, Morocco. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20260805 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *Immune Checkpoint Inhibitors/therapeutic use MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Clinical Trials, Phase III as Topic OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Immune Checkpoint Inhibitors OT - Meta-Analysis OT - Non-Muscle-Invasive Urothelial Carcinoma COIS- Declaration of Competing Interest The authors declare that there are no conflicts of interest related to this work. EDAT- 2026/08/06 11:36 MHDA- 2026/10/27 23:27 CRDT- 2026/08/05 19:18 PHST- 2026/06/22 00:00 [received] PHST- 2026/07/17 00:00 [revised] PHST- 2026/07/30 00:00 [accepted] PHST- 2026/10/27 23:27 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/05 19:18 [entrez] AID - S1040-8428(26)00397-5 [pii] AID - 10.1016/j.critrevonc.2026.105510 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2026 Nov;227:105510. doi: 10.1016/j.critrevonc.2026.105510. Epub 2026 Aug 5. PMID- 42556054 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20260909 IS - 1873-1244 (Electronic) IS - 0899-9007 (Linking) VI - 151 DP - 2026 Nov TI - Lifestyle and dietary inflammation scores and risks of recurrence and progression among patients with non-muscle invasive bladder cancer. PG - 113354 LID - S0899-9007(26)00262-5 [pii] LID - 10.1016/j.nut.2026.113354 [doi] AB - A healthy lifestyle and diet may improve outcomes of patients with non-muscle invasive bladder cancer (NMIBC), potentially through reducing systemic inflammation. Therefore, this study investigated the association of a post-diagnosis Lifestyle (LIS) and Dietary Inflammation Score (DIS), and high-sensitivity C-reactive protein (hsCRP) with the risks of NMIBC recurrence and progression. Patients with newly diagnosed NMIBC between 2014 and 2021 were recruited for the prospective multi-center cohort UroLife. Lifestyle (n = 1334) and/or diet (n = 1306) were self-reported at 3 months post-diagnosis using lifestyle and food frequency questionnaires. The LIS and DIS were calculated to capture the inflammatory potential of lifestyle and diet; higher scores indicate more pro-inflammatory exposures. Plasma hsCRP was measured at 3 months postdiagnosis. The association of LIS and DIS with hsCRP was ascertained in multivariable linear regression models. The association of the LIS, DIS, and hsCRP with risks of first or multiple recurrence(s), and stage and/or grade progression was assessed using multivariable Cox proportional hazards models. Over a median follow-up time of 4.7 years, 466 patients had at least one recurrence, and 155 had progression. Each 1-point increment in LIS and DIS was associated with a 43% (95% CI 29%-58%) and 6% (95% CI 3%-10%) increase in hsCRP, respectively. Higher LIS, DIS, and hsCRP were not associated with risks of first or multiple recurrence(s), and progression. In conclusion, a pro-inflammatory lifestyle and diet, and systemic inflammation, as measured by hsCRP, were not associated with NMIBC outcomes in our cohort. Yet, contributions from specific inflammatory processes or other biomarkers cannot be excluded. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Kiebach, Joann AU - Kiebach J AD - IQ Health science department, Radboud university medical center, Nijmegen, the Netherlands. FAU - Kamps, Claire S A D AU - Kamps CSAD AD - Department Primary & Community Care, Radboud university medical center, Nijmegen, the Netherlands. FAU - Wesselink, Evertine AU - Wesselink E AD - Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - IQ Health science department, Radboud university medical center, Nijmegen, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud university medical center, Nijmegen, the Netherlands. FAU - van Duijnhoven, Franzel J B AU - van Duijnhoven FJB AD - Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, the Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - IQ Health science department, Radboud university medical center, Nijmegen, the Netherlands; Department of Urology, Radboud university medical center, Nijmegen, the Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - IQ Health science department, Radboud university medical center, Nijmegen, the Netherlands; Department Primary & Community Care, Radboud university medical center, Nijmegen, the Netherlands. Electronic address: Alina.Vrieling@radboudumc.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260805 PL - United States TA - Nutrition JT - Nutrition (Burbank, Los Angeles County, Calif.) JID - 8802712 RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Female MH - Male MH - *Inflammation MH - Disease Progression MH - C-Reactive Protein/analysis MH - Middle Aged MH - *Neoplasm Recurrence, Local/epidemiology MH - Prospective Studies MH - Aged MH - *Diet/adverse effects MH - *Life Style MH - Risk Factors MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Diet OT - Inflammation OT - Lifestyle OT - Non-muscle invasive bladder cancer OT - Progression OT - Recurrence COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alina Vrieling reports financial support was provided by World Cancer Research Fund Netherlands. Alina Vrieling reports financial support was provided by KWF Dutch Cancer Society. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/06 11:36 MHDA- 2026/08/25 23:33 CRDT- 2026/08/05 18:02 PHST- 2026/04/17 00:00 [received] PHST- 2026/07/03 00:00 [revised] PHST- 2026/07/08 00:00 [accepted] PHST- 2026/08/25 23:33 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/05 18:02 [entrez] AID - S0899-9007(26)00262-5 [pii] AID - 10.1016/j.nut.2026.113354 [doi] PST - ppublish SO - Nutrition. 2026 Nov;151:113354. doi: 10.1016/j.nut.2026.113354. Epub 2026 Aug 5. PMID- 42542426 OWN - NLM STAT- Publisher LR - 20260801 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) DP - 2026 Aug 1 TI - En-bloc Resection of Bladder Tumor Versus Conventional Transurethral Resection of Bladder Tumor: Long-term Oncological Outcomes from a Single-center Prospective Trial. LID - S2405-4569(26)00154-9 [pii] LID - 10.1016/j.euf.2026.07.008 [doi] AB - Prior randomized trials have shown that en bloc transurethral resection of bladder tumor (ERBT) is noninferior to conventional transurethral resection of bladder tumor (cTURBT) for pathological staging. To address gaps in long-term oncologic outcomes, we conducted a post hoc analysis of a single-center randomized trial including 219 of the 248 patients treated between 2018 and 2021, evaluating overall survival (OS), cancer-specific survival (CSS), and cumulative incidence of urothelial recurrence with a median follow-up of 60 mo (interquartile range = 53-79). ERBT was performed in 124 patients (57%) and cTURBT in 95 (43%). Overall, 77 patients experienced recurrence. With updated follow-up, 60-mo cumulative urothelial recurrence rates ranged from 8% (95% confidence interval [CI] = 2-14) for cTURBT to 10% (95% CI = 5-18) for ERBT. Even after competing-risk multivariable adjustment for overall mortality, as well as age, sex, tumor stage and grade, comorbidities (hypertension and diabetes mellitus), prior bladder tumor, and adjuvant therapy, recurrence rates did not differ between ERBT and cTURBT. Rates of upgrading (low grade to high grade) and upstaging (Tx/Ta/T1-T2) were also similar between groups. During follow-up, 41 patients died, including 5 bladder cancer-related deaths; 60-month OS was 76% (95% CI = 68-86) for cTURBT and 83% (95% CI = 76-90) for ERBT, with no difference in 60-mo CSS (97% vs 97%). CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Di Bello, Francesco AU - Di Bello F AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. Electronic address: fran.dibello12@gmail.com. FAU - Diana, Pietro AU - Diana P AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain; Department of Urology, Uros Associats, Barcelona, Spain. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. FAU - Territo, Angelo AU - Territo A AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain. FAU - Rodriguez-Faba, Oscar AU - Rodriguez-Faba O AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain. FAU - Gaya, Josep M AU - Gaya JM AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Huguet, Jordi AU - Huguet J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Belarmino, Andre R AU - Belarmino AR AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Lopez, Marta AU - Lopez M AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Avesani, Giulio AU - Avesani G AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Graps, Giorgio AU - Graps G AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Urology Unit, Universita degli Studi di Milano Statale, Milan, Italy. FAU - Algaba, Ferran AU - Algaba F AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain; Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. LA - eng PT - Journal Article DEP - 20260801 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM OTO - NOTNLM OT - Bladder tumor OT - ERBT OT - Recurrence OT - Survival OT - TURBT OT - Trial EDAT- 2026/08/02 00:50 MHDA- 2026/08/02 00:50 CRDT- 2026/08/01 21:57 PHST- 2026/03/17 00:00 [received] PHST- 2026/06/22 00:00 [revised] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/08/02 00:50 [medline] PHST- 2026/08/02 00:50 [pubmed] PHST- 2026/08/01 21:57 [entrez] AID - S2405-4569(26)00154-9 [pii] AID - 10.1016/j.euf.2026.07.008 [doi] PST - aheadofprint SO - Eur Urol Focus. 2026 Aug 1:S2405-4569(26)00154-9. doi: 10.1016/j.euf.2026.07.008. PMID- 42539921 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260801 LR - 20260813 IS - 2692-3114 (Electronic) IS - 2692-3114 (Linking) VI - 7 DP - 2026 TI - Transurethral laser ablation using 980-nm diode laser for recurrent non-muscle invasive bladder cancer. PG - 1002386 LID - 10.37349/etat.2026.1002386 [doi] LID - 1002386 AB - AIM: Transurethral laser ablation (TULA) for recurrent bladder cancer is a less invasive treatment method for patients. We report here our initial clinical experience with TULA for recurrent bladder cancer. METHODS: This retrospective study analyzed 48 patients. Twenty-four cases were treated with TULA and another 24 cases were treated with transurethral resection of bladder tumor (TURBT) from Feb 2024 to Mar 2025 at Kochi Medical School Hospital. Intraoperative and postoperative outcomes and recurrence-free survival (RFS) were analyzed between TULA and TURBT. RESULTS: This study showed that TULA using a 980-nm diode laser was significantly shorter than TURBT in terms of perioperative results: operative time, hospital stay, catheterization, bladder irrigation, and postoperative hospital stay. Regarding the occurrence of complications, TULA was observed to be less prevalent than TURBT in all cases. Kaplan-Meier curves showed that TULA was significantly associated with longer RFS compared to TURBT (hazard ratio 4.739; 95% confidence interval, 1.272-17.65; p = 0.02039). CONCLUSIONS: Our preliminary results showed that TULA for recurrent bladder cancer is feasible and safe. CI - (c) The Author(s) 2026. FAU - Fukuhara, Hideo AU - Fukuhara H AUID- ORCID: 0000-0002-9079-0995 AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Shimasaki, Syo AU - Shimasaki S AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Yamashita, Erika AU - Yamashita E AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Kurano, Yoshitaka AU - Kurano Y AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Atagi, Kaya AU - Atagi K AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Shigehisa, Ryu AU - Shigehisa R AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Takemori, Daigo AU - Takemori D AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Yamamoto, Shinkuro AU - Yamamoto S AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Osakabe, Hiroto AU - Osakabe H AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Nao, Tomoya AU - Nao T AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Shimamoto, Tsutomu AU - Shimamoto T AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Fukata, Satoshi AU - Fukata S AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Ashida, Shingo AU - Ashida S AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Japan. LA - eng PT - Journal Article DEP - 20260728 PL - United States TA - Explor Target Antitumor Ther JT - Exploration of targeted anti-tumor therapy JID - 101770662 PMC - PMC13424799 OTO - NOTNLM OT - non-muscle invasive bladder cancer OT - transurethral laser ablation OT - transurethral resection of bladder tumor COIS- The authors declare that they have no conflicts of interest. EDAT- 2026/08/02 00:30 MHDA- 2026/08/02 00:31 PMCR- 2026/07/28 CRDT- 2026/08/01 06:20 PHST- 2026/03/01 00:00 [received] PHST- 2026/06/01 00:00 [accepted] PHST- 2026/08/02 00:31 [medline] PHST- 2026/08/02 00:30 [pubmed] PHST- 2026/08/01 06:20 [entrez] PHST- 2026/07/28 00:00 [pmc-release] AID - 10.37349/etat.2026.1002386 [doi] PST - epublish SO - Explor Target Antitumor Ther. 2026 Jul 28;7:1002386. doi: 10.37349/etat.2026.1002386. eCollection 2026. PMID- 42538173 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 12 IP - 5 DP - 2026 Oct TI - Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection. PG - 931-938 LID - S2405-4569(26)00097-0 [pii] LID - 10.1016/j.euf.2026.06.002 [doi] AB - BACKGROUND AND OBJECTIVE: Patients with high-risk non-muscle invasive bladder cancer (NMIBC) experience high recurrence rates and potential understaging, supporting guideline recommendations for repeat transurethral resection (reTUR). However, identifying patients best suited for reTUR remains challenging. Here, we analyze urine tumor DNA (utDNA) for mutations associated with urothelial cancer in a cohort of patients undergoing reTUR. METHODS: Retrospective evaluation of urine samples from 43 patients with pathologically confirmed high-grade NMIBC who were undergoing reTUR. Urine was collected immediately prior to reTUR and evaluated using UroAmp. The primary objective of this study was to compare utDNA disease classification with pathological staging from reTUR. Prognostic (high/low-risk) and minimal residual disease (MRD) (positive/negative) classifications were evaluated. KEY FINDINGS AND LIMITATIONS: The stage distribution from reTUR was 32% T0 (no residual disease), 29% Ta +/-CIS, 28% T1 +/-CIS, and 11% T2. Prognostic risk classification had 97% sensitivity (95% confidence interval [CI] 86-100) and 89% negative predictive value (95% CI 59-99). MRD classification had 80% specificity (95% CI 56-94) and 88% positive predictive value (95% CI 72-97). When long-term recurrence outcomes were considered, positive predictive value increased to 92% (95% CI 78-98) for both classification algorithms. Among T0 samples, utDNA high-risk patients had recurrence-free survival of 36%, compared to 100% for utDNA low-risk patients (p = 0.006). CONCLUSIONS AND CLINICAL IMPLICATIONS: utDNA testing identifies residual disease prior to reTUR. utDNA can serve as an adjunct following initial transurethral resection, aiding in the assessment of resection completeness, determining the need and timing of repeat resection, and stratifying risk of future recurrence. CI - Published by Elsevier B.V. FAU - Ogunkeye, Jay AU - Ogunkeye J AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Shkolyar, Eugene AU - Shkolyar E AD - Department of Urology, Stanford University, Palo Alto, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Mach, Kathleen E AU - Mach KE AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Prendiville, Sophia AU - Prendiville S AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Prado, Kris AU - Prado K AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Skinner, Eila C AU - Skinner EC AD - Department of Urology, Stanford University, Palo Alto, CA, USA. FAU - Fischer, Daniel S AU - Fischer DS AD - Convergent Genomics, South San Francisco, CA, USA. FAU - Phillips, Kevin G AU - Phillips KG AD - Convergent Genomics, South San Francisco, CA, USA. FAU - Bicocca, Vincent T AU - Bicocca VT AD - Convergent Genomics, South San Francisco, CA, USA. FAU - Levin, Trevor G AU - Levin TG AD - Convergent Genomics, South San Francisco, CA, USA. FAU - Liao, Joseph C AU - Liao JC AD - Department of Urology, Stanford University, Palo Alto, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. LA - eng PT - Journal Article DEP - 20260731 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (DNA, Neoplasm) SB - IM MH - Humans MH - Transurethral Resection of Bladder/methods MH - *Non-Muscle Invasive Bladder Neoplasms/urine/surgery/pathology MH - Female MH - Retrospective Studies MH - Male MH - Aged MH - *DNA, Neoplasm/urine MH - *Urinary Bladder Neoplasms/surgery/pathology/urine MH - Middle Aged MH - Neoplasm Recurrence, Local/urine MH - Neoplasm, Residual MH - Neoplasm Staging MH - Prognosis MH - Neoplasm Grading MH - Aged, 80 and over OTO - NOTNLM OT - Bladder cancer OT - Minimal residual disease OT - Risk assessment OT - Transurethral resection OT - Urine biomarker OT - Urine tumor DNA EDAT- 2026/08/01 00:36 MHDA- 2026/10/29 23:28 CRDT- 2026/07/31 21:54 PHST- 2025/11/13 00:00 [received] PHST- 2026/04/27 00:00 [revised] PHST- 2026/06/01 00:00 [accepted] PHST- 2026/10/29 23:28 [medline] PHST- 2026/08/01 00:36 [pubmed] PHST- 2026/07/31 21:54 [entrez] AID - S2405-4569(26)00097-0 [pii] AID - 10.1016/j.euf.2026.06.002 [doi] PST - ppublish SO - Eur Urol Focus. 2026 Oct;12(5):931-938. doi: 10.1016/j.euf.2026.06.002. Epub 2026 Jul 31. PMID- 42526369 OWN - NLM STAT- MEDLINE DCOM- 20260926 LR - 20260926 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 204 DP - 2026 Nov TI - VI-RADS and beyond in bladder MRI: a pictorial review of quality control, response assessment, and artificial intelligence. PG - 113114 LID - S0720-048X(26)00462-6 [pii] LID - 10.1016/j.ejrad.2026.113114 [doi] AB - Management of bladder cancer changes markedly once a tumor invades the muscularis propria, making reliable separation of non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC) a key clinical decision point. Multiparametric MRI (mpMRI), interpreted with the Vesical Imaging-Reporting and Data System (VI-RADS), standardizes local staging by integrating T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps, and dynamic contrast-enhanced MRI (DCE-MRI). As evidence has matured, the central challenge has shifted from diagnostic accuracy alone to implementation and clinical utility: ensuring interpretable image quality across scanners and workflows, reducing inter-reader variability, and translating VI-RADS categories into appropriate clinical pathways. Bladder MRI is also being evaluated for treatment response assessment after neoadjuvant systemic therapy and bladder-preserving approaches, supported by emerging post-therapy scoring systems such as nacVI-RADS, quantitative biomarkers, and machine-learning methods. The VI-RADS Quality Score and related quality-control concepts may help separate technically inadequate examinations from biologically equivocal cases. Near-term artificial intelligence applications are likely to be most useful for scan acceleration, automated quality auditing, semi-automated segmentation, and reader support for equivocal lesions. This narrative review synthesizes acquisition and interpretation essentials, diagnostic performance, recurrent pitfalls, and scalable solutions for VI-RADS implementation, response assessment, radiomics, and artificial intelligence. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Aslan, Serdar AU - Aslan S AD - Department of Radiology, Faculty of Medicine, Giresun University, Gazipasa Yerleskesi, Debboy Mevkii, Merkez, Giresun 28200, Turkey. FAU - Eryuruk, Uluhan AU - Eryuruk U AD - Department of Radiology, Faculty of Medicine, Giresun University, Gazipasa Yerleskesi, Debboy Mevkii, Merkez, Giresun 28200, Turkey; Department of Radiology, Dinar State Hospital, Dinar, Afyonkarahisar 03400, Turkey. FAU - Park, Sung Yoon AU - Park SY AD - Department of Radiology, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA. FAU - Arita, Yuki AU - Arita Y AD - Department of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Urology, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8519, Japan; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: yuarita@health.ucsd.edu. LA - eng PT - Journal Article PT - Review DEP - 20260725 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/therapy MH - *Artificial Intelligence MH - *Magnetic Resonance Imaging/standards/methods MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Quality Control MH - *Image Interpretation, Computer-Assisted/methods/standards MH - Treatment Outcome MH - *Radiology Information Systems/standards MH - Multiparametric Magnetic Resonance Imaging/standards MH - Radiomics OTO - NOTNLM OT - Artificial intelligence OT - Magnetic resonance imaging OT - Neoplasm invasiveness OT - Radiomics OT - Treatment outcome OT - Urinary bladder neoplasms OT - VI-RADS COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yuki Arita serves as an Editor for the European Journal of Radiology. Given his role as Editor, he had no involvement in the peer review or editorial handling of this manuscript and has no access to information regarding its peer review. Full responsibility for the editorial process for this manuscript was delegated to another journal editor. All authors declare no other financial or personal conflicts of interest regarding this work. EDAT- 2026/07/30 00:38 MHDA- 2026/09/26 05:34 CRDT- 2026/07/29 18:09 PHST- 2026/06/02 00:00 [received] PHST- 2026/07/21 00:00 [revised] PHST- 2026/07/23 00:00 [accepted] PHST- 2026/09/26 05:34 [medline] PHST- 2026/07/30 00:38 [pubmed] PHST- 2026/07/29 18:09 [entrez] AID - S0720-048X(26)00462-6 [pii] AID - 10.1016/j.ejrad.2026.113114 [doi] PST - ppublish SO - Eur J Radiol. 2026 Nov;204:113114. doi: 10.1016/j.ejrad.2026.113114. Epub 2026 Jul 25. PMID- 42521520 OWN - NLM STAT- Publisher LR - 20260728 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) DP - 2026 Jul 28 TI - Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. LID - S2405-4569(26)00155-0 [pii] LID - 10.1016/j.euf.2026.07.009 [doi] AB - BACKGROUND: Radical cystectomy with pelvic lymph node dissection (PLND) remains the standard treatment for muscle-invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) improves survival, and recent immunochemotherapy trials have reported complete pathological responses in up to 60% of patients, increasing interest in bladder-sparing strategies. However, the ability to accurately identify patients without residual pelvic lymph node metastases after NAC remains limited. OBJECTIVE: To evaluate the association between pathological response in the bladder and pelvic lymph node status after NAC in patients with MIBC undergoing radical cystectomy (RC) and PLND. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multi-institutional cohort study included 751 patients with MIBC treated with NAC followed by RC and PLND between 2000 and 2021 across 26 institutions. INTERVENTION: Neoadjuvant chemotherapy followed by RC and PLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was residual lymph node involvement (ypN+). Multivariable logistic regression was used to identify factors associated with ypN+. RESULTS AND LIMITATIONS: Overall, 175 patients (23%) achieved a complete pathological response in the bladder (ypT0), 102 (14%) were downstaged to non-muscle-invasive disease (ypTa/ypTis/ypT1), and 185 (25%) had residual lymph node involvement. On multivariable analysis, cN+ disease before NAC was associated with higher odds of ypN+ (OR 1.97, 95% CI 1.32-2.94), whereas ypT0 (OR 0.11, 95% CI 0.05-0.21) and ypTa/ypTis/ypT1 (OR 0.24, 95% CI 0.12-0.47) were associated with lower odds of ypN+. Notably, 5% of ypT0 and 10% of downstaged patients harboured residual lymph node metastases. Limitations include potential selection bias and centre-level variability in surgical and pathological assessment, which may affect the generalizability of the findings. CONCLUSIONS: Current clinical and radiological variables cannot reliably exclude residual pelvic lymph node disease, even in patients achieving ypT0-1. Novel imaging techniques and liquid biomarkers require validation before bladder-sparing approaches can be safely expanded. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Antonelli, Luca AU - Antonelli L AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy; Department of Urology, Luzerner Kantonsspital, University of Lucerne, Switzerland. Electronic address: luca.antonelli.md@gmail.com. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Kantonsspital Aarau, Aarau, Switzerland. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy. FAU - Bologna, Eugenio AU - Bologna E AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy. FAU - Esperto, Francesco AU - Esperto F AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Chierigo, Francesco AU - Chierigo F AD - Department of Urology, Department of Health Science, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr University, Bochum, Germany. FAU - Umari, Paolo AU - Umari P AD - St. George's University Hospital, London, United Kingdom. FAU - Albisinni, Simone AU - Albisinni S AD - Service d'Urologie, Hopital Universitaire de Bruxelles, Universite Libre de Bruxelles, Brussels, Belgium; Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology - Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Claps, Francesco AU - Claps F AD - Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy; Oncological Urology, Veneto Institute of Oncology IRCCS, Padua, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Clinique Pasteur, Toulouse, France. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, LMU Munich, Germany. FAU - Orecchia, Luca AU - Orecchia L AD - Urology Unit, Policlinico Tor Vergata Foundation, Rome, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany. FAU - Campi, Riccardo AU - Campi R AD - Unit of Urology and Renal Transplantation, Oncology Department, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Mertens, Laura AU - Mertens L AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands. FAU - Culpan, Meftun AU - Culpan M AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Lavallee, Luke T AU - Lavallee LT AD - Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Canada. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Fankhauser, Christian Daniel AU - Fankhauser CD AD - Faculty of Health Sciences and Medicine, University of Lucerne, Switzerland; Clinic for Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland; Clinic for Urology, Kantonsspital Winterthur, Winterthur, Switzerland; University of Zurich, Zurich, Switzerland. CN - EAU YAU urothelial carcinoma working group LA - eng PT - Journal Article DEP - 20260728 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Pelvic lymph node metastasis EDAT- 2026/07/29 00:35 MHDA- 2026/07/29 00:35 CRDT- 2026/07/28 21:56 PHST- 2026/03/24 00:00 [received] PHST- 2026/06/23 00:00 [revised] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/07/29 00:35 [medline] PHST- 2026/07/29 00:35 [pubmed] PHST- 2026/07/28 21:56 [entrez] AID - S2405-4569(26)00155-0 [pii] AID - 10.1016/j.euf.2026.07.009 [doi] PST - aheadofprint SO - Eur Urol Focus. 2026 Jul 28:S2405-4569(26)00155-0. doi: 10.1016/j.euf.2026.07.009. PMID- 42520639 OWN - NLM STAT- MEDLINE DCOM- 20260817 LR - 20260817 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 202 DP - 2026 Sep TI - Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification. PG - 119807 LID - S0753-3322(26)00843-7 [pii] LID - 10.1016/j.biopha.2026.119807 [doi] AB - Bladder cancer (BC) is the eleventh most diagnosed malignancy worldwide for both sexes and the sixth in men, representing a significant public health concern. It is a heterogeneous disease classified according to tumor invasion into the bladder wall, currently requiring invasive procedures (such as transurethral resection and biopsy) for accurate tumor-node-metastasis (TNM) cancer staging. Muscle-invasive bladder cancer (MIBC), defined by tumor infiltration into the muscularis propria, represents the most aggressive non-metastatic form. The standard of care for MIBC includes neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and lymphadenectomy. However, the absence of reliable, non-invasive methods to assess treatment response results in all patients undergoing surgery, regardless of whether a pathological response (pR) has been achieved, heavily compromising their quality of life. Therefore, predictive biomarkers of NAC response are critically needed to guide clinical decisions and personalize therapy. Given the increasing relevance of liquid biopsies, particularly urine-based assays for BC, this review examines the current landscape of urinary biomarkers studied for MIBC stratification and NAC response prediction. Furthermore, we highlight the existing gaps in the field and emphasize the necessity of expanding research into non-invasive urinary biomarkers to enable their future translation into clinical practice. CI - Copyright (c) 2026 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - de Miguel-Garcia, Gisela AU - de Miguel-Garcia G AD - REMAR-IGTP Group Germans Trias i Pujol Research Institute (IGTP) & Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus Badalona (Barcelona) Catalonia, Spain; Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona (UAB), Bellaterra, Spain. FAU - Ruiz de Porras, Vicenc AU - Ruiz de Porras V AD - GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona 08028, Spain. FAU - Font-Moron, Miriam AU - Font-Moron M AD - REMAR-IGTP Group Germans Trias i Pujol Research Institute (IGTP) & Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus Badalona (Barcelona) Catalonia, Spain. FAU - Font, Albert AU - Font A AD - Badalona Applied Research Group in Oncology (B.ARGO), Catalan Institute of Oncology, Cami de les Escoles, s/n, Badalona 08916, Spain; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cami de les Escoles, s/n, Badalona 08916, Spain; Medical Oncology Department, Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona 08916, Spain. FAU - Borras, Francesc E AU - Borras FE AD - REMAR-IGTP Group Germans Trias i Pujol Research Institute (IGTP) & Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus Badalona (Barcelona) Catalonia, Spain; Department of Cell Biology, Physiology and Immunology Universitat de Barcelona (UB) Barcelona, Spain. Electronic address: feborras@igtp.cat. FAU - Clos-Sansalvador, Marta AU - Clos-Sansalvador M AD - REMAR-IGTP Group Germans Trias i Pujol Research Institute (IGTP) & Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus Badalona (Barcelona) Catalonia, Spain. Electronic address: mclos@debiosdx.com. LA - eng PT - Journal Article PT - Review DEP - 20260728 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/drug therapy/pathology MH - *Neoadjuvant Therapy/methods MH - *Biomarkers, Tumor/urine MH - Neoplasm Invasiveness MH - Treatment Outcome OTO - NOTNLM OT - Liquid biopsy OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy response OT - Non-invasive diagnostics OT - Patient stratification OT - Urinary biomarkers COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marta Clos-Sansalvador reports a relationship with Dual Dynamics Influence SL that includes: equity or stocks. Francesc E. Borras reports a relationship with Dual Dynamics Influence SL that includes: equity or stocks. Gisela de Miguel-Garcia reports a relationship with Dual Dynamics Influence SL that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/29 00:35 MHDA- 2026/08/17 23:39 CRDT- 2026/07/28 18:07 PHST- 2026/04/14 00:00 [received] PHST- 2026/07/21 00:00 [revised] PHST- 2026/07/23 00:00 [accepted] PHST- 2026/08/17 23:39 [medline] PHST- 2026/07/29 00:35 [pubmed] PHST- 2026/07/28 18:07 [entrez] AID - S0753-3322(26)00843-7 [pii] AID - 10.1016/j.biopha.2026.119807 [doi] PST - ppublish SO - Biomed Pharmacother. 2026 Sep;202:119807. doi: 10.1016/j.biopha.2026.119807. Epub 2026 Jul 28. PMID- 42515859 OWN - NLM STAT- MEDLINE DCOM- 20260908 LR - 20260916 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 4 DP - 2026 Oct TI - INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. PG - 607-619 LID - 10.1111/bju.70387 [doi] AB - BACKGROUND: High-risk non-muscle-invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette-Guerin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease. Treatments overcoming these limitations are needed to improve HRNMIBC outcomes. Many novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), but long-term efficacy is unknown. Given advanced bladder cancer findings, we believe direct intravesical administration of atezolizumab may aid with managing HRNMIBC or muscle-invasive bladder cancer in patients who are ineligible for cisplatin-based neoadjuvant chemotherapy. STUDY DESIGN: The INtraVESical immunoTherapy (INVEST) trial is a UK-based, open-label, non-randomised, single-centre, Phase Ib dose escalation, window of opportunity study exploring atezolizumab administration via intravesical routes (passive instillation and direct injection [sub-urothelial]) in patients with bladder cancer with all stages undergoing RC. For both routes, an initial dose confirmation stage will determine toxicity and recommended atezolizumab dosage, followed by a dose expansion stage to further evaluate safety and toxicity at the recommended dose. ENDPOINTS: We aim to investigate safety (primary) and preliminary activity (secondary) of intravesical atezolizumab delivered by passive instillation and direct injection into the tumour/bladder wall in patients with bladder urothelial cell carcinoma prior to RC. Primary endpoints include dose limiting toxicities and adverse events. Secondary endpoints include progression-free survival, pathological complete response rate and treatment compliance. Exploratory endpoints include pharmacokinetic profile (assessed by serum and urine concentrations at prespecified timepoints), spatial analysis of atezolizumab distribution within RC tissue by imaging mass spectrometry and overall survival. PATIENTS AND METHODS: Atezolizumab will be administered intravesically by either passive instillation or direct injection into the tumour/bladder wall. Cohorts will receive either 600 mg or 1200 mg doses administered as a single dose or as multiple doses (weekly for 3-6 weeks). TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number: ISRCTN15842444, registered 2 December 2022. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Lister-Whelan, Ruby AU - Lister-Whelan R AUID- ORCID: 0000-0003-4389-8685 AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Senior, Ethan AU - Senior E AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Kendall, Jessica AU - Kendall J AUID- ORCID: 0000-0003-2884-4849 AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Oughton, Jamie B AU - Oughton JB AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Collinson, Fiona AU - Collinson F AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Griffin, Jon AU - Griffin J AUID- ORCID: 0000-0003-3969-7637 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Hubbard, Rachel AU - Hubbard R AD - Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Kennish, Steven AU - Kennish S AD - Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Noon, Aidan AU - Noon A AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Rosario, Derek J AU - Rosario DJ AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Riaz, Irbaz B AU - Riaz IB AD - Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA. FAU - Telliez, Julie AU - Telliez J AD - F. Hoffmann-La Roche Ltd., Basel, Switzerland. FAU - Catto, James W F AU - Catto JWF AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Hussain, Syed A AU - Hussain SA AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Oncology, Weston Park Cancer and Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. LA - eng SI - ISRCTN/ISRCTN-15842444 SI - EudraCT/[EudraCT] number 2021-006537-19 GR - MO43103/Roche/ PT - Journal Article DEP - 20260727 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 52CMI0WC3Y (atezolizumab) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - *Cystectomy MH - Administration, Intravesical MH - *Antibodies, Monoclonal, Humanized/administration & dosage MH - Non-Muscle Invasive Bladder Neoplasms MH - *Immunotherapy/methods MH - *Urinary Bladder Neoplasms/therapy/drug therapy MH - Clinical Trials, Phase I as Topic MH - *Antineoplastic Agents, Immunological/administration & dosage PMC - PMC13550807 OTO - NOTNLM OT - Atezolizumab OT - Phase I OT - Tecentriq OT - bladder cancer OT - dose escalation OT - intravesical immunotherapy OT - protocol OT - radical cystectomy OT - window of opportunity EDAT- 2026/07/28 06:37 MHDA- 2026/09/08 05:36 PMCR- 2026/09/08 CRDT- 2026/07/28 01:33 PHST- 2026/09/08 05:36 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:33 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - BJU70387 [pii] AID - 10.1111/bju.70387 [doi] PST - ppublish SO - BJU Int. 2026 Oct;138(4):607-619. doi: 10.1111/bju.70387. Epub 2026 Jul 27. PMID- 42513387 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 14 DP - 2026 Jul 13 TI - Obturator Nerve Block Is Associated with Improved Histopathological Specimen Quality and Fewer Perioperative Complications During TURBT for Lateral Bladder Wall Tumors. LID - 10.3390/jcm15145473 [doi] LID - 5473 AB - Background/Objectives: Transurethral resection of bladder tumors (TURBT) is the standard for diagnosing and treating non-muscle-invasive bladder cancer. For lateral bladder wall tumors, obturator nerve stimulation can trigger sudden adductor contractions, raising the risk of perforation, hemorrhage, incomplete resection, and poor specimen quality. We evaluated the impact of obturator nerve block (ONB) on specimen quality and perioperative complications. Methods: In this single-center retrospective study, patients with lateral wall tumors treated by TURBT between October 2022 and December 2024 were divided into an ONB group (spinal anesthesia plus ONB) and a non-ONB group (spinal anesthesia alone). Specimen quality, perioperative complications, and 12-month recurrence were analyzed. Results: In this retrospective cohort of 219 patients (135 ONB, 84 non-ONB), high-quality specimens were more frequent with ONB (71.1% vs. 35.7%, p < 0.001). No perforations occurred with ONB versus 5 (6.0%) without (p = 0.008); hematuria (11.1% vs. 28.6%, p = 0.002) and 12-month recurrence (4.4% vs. 16.7%, p = 0.005) were also lower. Conclusions: ONB added to spinal anesthesia during TURBT for lateral wall tumors was associated with improved specimen quality and fewer perioperative complications. The lower recurrence rate should be considered hypothesis-generating, given the retrospective design and the small number of recurrence events; prospective studies are needed. FAU - Vasile, Dragos Florin AU - Vasile DF AD - Department of Urology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Calina, Nelu Vivi AU - Calina NV AD - Department of Anesthesiology and Intensive Care, Clinical County Emergency Hospital of Craiova, 200349 Craiova, Romania. FAU - Mesina, Mihnea AU - Mesina M AD - Department of Urology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Radu, Mihai Alexandru AU - Radu MA AUID- ORCID: 0009-0009-1971-8729 AD - Department of Urology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Mitroi, George G AU - Mitroi GG AD - Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Stepan, Alex Emilian AU - Stepan AE AUID- ORCID: 0000-0002-6875-1041 AD - Department of Pathology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Obleaga, Cosmin Vasile AU - Obleaga CV AD - Department of Surgical Oncology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Popa, Dragos George AU - Popa DG AD - Department of Plastic Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Doru, Stan Marius AU - Doru SM AD - Department of Urology, Clinical County Emergency Hospital of Constanta, 900591 Constanta, Romania. FAU - Mitroi, George F AU - Mitroi GF AD - Department of Urology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. LA - eng PT - Journal Article DEP - 20260713 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13412207 OTO - NOTNLM OT - bladder cancer OT - detrusor muscle OT - non-muscle-invasive bladder cancer OT - obturator nerve block OT - specimen quality OT - transurethral resection of bladder tumor COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/13 CRDT- 2026/07/28 01:14 PHST- 2026/06/11 00:00 [received] PHST- 2026/07/02 00:00 [revised] PHST- 2026/07/09 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:14 [entrez] PHST- 2026/07/13 00:00 [pmc-release] AID - jcm15145473 [pii] AID - jcm-15-05473 [pii] AID - 10.3390/jcm15145473 [doi] PST - epublish SO - J Clin Med. 2026 Jul 13;15(14):5473. doi: 10.3390/jcm15145473. PMID- 42512334 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 14 DP - 2026 Jul 15 TI - Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review. LID - 10.3390/cancers18142269 [doi] LID - 2269 AB - T1 high-grade (T1HG) urothelial carcinoma of the bladder presents a persistent clinical challenge: despite uniform high-risk classification under EAU guidelines, BCG failure and disease progression rates range from 10% to 40% across published series. Standard clinicopathological variables do not adequately explain this heterogeneity. Three pathological parameters evaluable from routine TURBT specimens-T1 substaging by lamina propria invasion depth, tumour budding at the invasion front, and E-cadherin (CDH1) immunohistochemistry-share a common mechanistic basis in CDH1-driven partial epithelial-to-mesenchymal transition and may refine escalation-oriented risk stratification without requiring additional tissue or molecular testing. We conducted a narrative critical review of PubMed/MEDLINE (January 2000-February 2026; 28 included studies) to evaluate the quantitative evidence for each parameter, with emphasis on reproducibility and BCG-specific outcome data. T1 substaging carries the strongest evidence: pooled progression HR 3.29 (95% CI 2.39-4.51) across 36 studies (n = 6781), with BCG failure of 41% vs. 21% in a centralised BCG-treated registry cohort of 264 patients on multivariable analysis. Tumour budding shows consistent adverse associations in BCG-treated pT1 NMIBC; zero progression was observed in the low-budding subgroup in the only available BCG-specific full-text cohort. CDH1 IHC is directionally supportive but limited by scoring heterogeneity (I(2) = 63%). All three parameters are mechanistically coherent and assessable from routine TURBT slides. Prospective validation with pre-specified thresholds and standardised scoring protocols is required before clinical implementation can be recommended. FAU - Sala-Gonzalez, Nuria AU - Sala-Gonzalez N AD - Catalan Institute of Oncology, Avenida Francia, s/n, 17007 Girona, Spain. FAU - Chekhun, Sviatoslav AU - Chekhun S AUID- ORCID: 0009-0008-0397-3779 AD - Catalan Institute of Oncology, Avenida Francia, s/n, 17007 Girona, Spain. FAU - Fina, Claudia AU - Fina C AD - Catalan Institute of Oncology, Avenida Francia, s/n, 17007 Girona, Spain. FAU - Vilaseca, Marina AU - Vilaseca M AUID- ORCID: 0000-0002-3462-4984 AD - Girona Biomedical Research Institute, 17007 Girona, Spain. FAU - Rossylna, Olha AU - Rossylna O AD - Institute of Economic and Legal Research, National Academy of Sciences of Ukraine, 01001 Kyiv, Ukraine. FAU - Boix, Roger AU - Boix R AUID- ORCID: 0000-0002-4808-0279 AD - Josep Trueta University Hospital, 17007 Girona, Spain. FAU - Bella-Burgos, Berta AU - Bella-Burgos B AUID- ORCID: 0000-0003-2897-0335 AD - Josep Trueta University Hospital, 17007 Girona, Spain. FAU - Comet, Josep AU - Comet J AUID- ORCID: 0000-0003-0853-5926 AD - Josep Trueta University Hospital, 17007 Girona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20260715 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13407352 OTO - NOTNLM OT - BCG failure OT - CDH1 OT - E-cadherin OT - T1 high-grade OT - T1 substaging OT - lamina propria invasion OT - non-muscle-invasive bladder cancer OT - radical cystectomy OT - risk stratification OT - tumour budding COIS- The authors declare no competing interests. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/15 CRDT- 2026/07/28 01:11 PHST- 2026/05/22 00:00 [received] PHST- 2026/07/05 00:00 [revised] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:11 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - cancers18142269 [pii] AID - cancers-18-02269 [pii] AID - 10.3390/cancers18142269 [doi] PST - epublish SO - Cancers (Basel). 2026 Jul 15;18(14):2269. doi: 10.3390/cancers18142269. PMID- 42509410 OWN - NLM STAT- MEDLINE DCOM- 20260919 LR - 20260919 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 10 DP - 2026 Oct TI - Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non-Muscle-Invasive Bladder Cancer? PG - 9517-9525 LID - 10.1245/s10434-026-20268-1 [doi] AB - BACKGROUND: This study aimed to determine the rates and predictors of residual tumor and pathologic upstaging among patients undergoing a second transurethral resection of bladder tumors (TURBT). METHODS: This retrospective study investigated patients who underwent a second TURBT within 2-6 weeks after an initial complete TURBT for non-muscle-invasive bladder cancer. A second TURBT was performed in cases of T1 tumors, high-grade Ta tumors, and absence of the detrusor muscle in the initial specimen. Patients were initially categorized by the presence of residual tumor, and those with residual disease were further stratified according to their pathologic upstaging status. Potential predictors, including patient demographics, tumor characteristics, surgical team consistency, and complications, were analyzed using logistic regression. RESULTS: Among 728 patients who underwent TURBT, 284 met the inclusion criteria and were included in the analysis. Residual tumor was detected in 144 patients (50.7%). Multivariable analysis showed that multifocality, tumor size >/= 3 cm, resection from both the primary and additional sites, complications, and female sex were independently associated with residual tumor (all p < 0.05). Pathologic upstaging was observed in 20 (13.9%) of the 144 patients with residual tumor. Primary tumor morphology was the only independent predictor of pathologic upstaging, with solid (odds ratio [OR], 7.72; p = 0.013) and papillosolid (OR, 4.07; p = 0.020) morphologies associated with a higher risk than papillary morphology. CONCLUSION: A second TURBT remains an important reassessment step for residual tumor and upstaging. Risk assessment for patients undergoing a second TURBT should incorporate initial pathology, tumor burden, endoscopic appearance, and tumor morphology. CI - (c) 2026. Society of Surgical Oncology. FAU - Ugur, Ramazan AU - Ugur R AUID- ORCID: 0000-0002-0593-8589 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. rugur23@gmail.com. FAU - Demiriz, Berke AU - Demiriz B AUID- ORCID: 0000-0002-0419-1786 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Nisli, Onuralp AU - Nisli O AUID- ORCID: 0009-0003-1146-2251 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Keskin, Emin Taha AU - Keskin ET AUID- ORCID: 0000-0002-1222-6424 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Sahin, Suleyman AU - Sahin S AUID- ORCID: 0000-0002-6043-6354 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Baytekin, Halil Firat AU - Baytekin HF AUID- ORCID: 0000-0002-7086-4758 AD - Department of Pathology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Canat, Halil Lutfi AU - Canat HL AUID- ORCID: 0000-0001-6481-7907 AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20260727 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - Female MH - *Neoplasm, Residual/pathology/surgery MH - *Transurethral Resection of Bladder MH - Male MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery MH - Neoplasm Staging MH - Follow-Up Studies MH - Aged MH - Prognosis MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Risk Factors MH - Neoplasm Invasiveness MH - Neoplasm Grading OTO - NOTNLM OT - Bladder cancer OT - Residual tumor OT - Second TURBT OT - Surgical quality OT - Upstaging COIS- Disclosure: There are no conflicts of interest. EDAT- 2026/07/28 00:35 MHDA- 2026/09/19 05:39 CRDT- 2026/07/27 23:28 PHST- 2026/06/16 00:00 [received] PHST- 2026/07/08 00:00 [accepted] PHST- 2026/09/19 05:39 [medline] PHST- 2026/07/28 00:35 [pubmed] PHST- 2026/07/27 23:28 [entrez] AID - 10.1245/s10434-026-20268-1 [pii] AID - 10.1245/s10434-026-20268-1 [doi] PST - ppublish SO - Ann Surg Oncol. 2026 Oct;33(10):9517-9525. doi: 10.1245/s10434-026-20268-1. Epub 2026 Jul 27. PMID- 42507049 OWN - NLM STAT- MEDLINE DCOM- 20260727 LR - 20261010 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 53 IP - 1 DP - 2026 Jul 27 TI - Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP. LID - 1281 [pii] LID - 10.1007/s11033-026-12476-5 [doi] AB - BACKGROUND: Bladder cancer (BC) is considered one of the most prevalent malignant cancers of the urinary system. Recently, autophagy was found to be involved in tumor development. OBJECTIVES: Investigating the link between BC and autophagy, highlighting the role of ER stress in tumor growth and invasiveness. METHODS: Sixty urothelial carcinoma patients recruited to this study were divided into 2 groups: Low-grade BC (LGBC) and High-grade BC (HGBC), which were further classified as muscle-invasive (HGMI) or non-muscle-invasive (HGNMI). Control tissue samples were collected from the safety margin. Levels of ATG5 and caspase 3 were determined using qRT-PCR; CHOP levels by ELISA; and malondialdehyde using the lipid peroxide assay kit. LC3A expression was detected by immunohistochemistry. RESULTS: Significant upregulation of tissue levels of ATG5, CHOP, MDA and LC3A was observed in tumor tissue samples from all groups compared to control, and in MIBC compared to NMIBC, with significant relations between their levels and LN involvement. Caspase-3 was significantly downregulated in HGBC compared to LGBC. Levels of ATG5, CHOP and LC3A can discriminate between normal and malignant urothelial tissue and between invasive and non-invasive bladder cancer. CONCLUSION: Expression of tissue autophagy biomarkers is associated with aggressive clinicopathological features (muscle invasion) in bladder cancer. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Ali, Maha AU - Ali M AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut, Egypt. AD - Department of Pathology, College of Medicine, Qassim University, Qassim, 51452, Saudi Arabia. FAU - Soliman, Shimaa E AU - Soliman SE AUID- ORCID: 0000-0003-3919-3818 AD - Department of Pathology, College of Medicine, Qassim University, Qassim, 51452, Saudi Arabia. S.saad@qu.edu.sa. FAU - Eldeeb, Thoraya S AU - Eldeeb TS AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Aboeleuon, Ebrahim AU - Aboeleuon E AD - Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. FAU - Shaban, Shimaa H AU - Shaban SH AD - Oncologic Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. FAU - Mahran, Dalia G AU - Mahran DG AD - Department of Public Health and Community Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Abdelhafez, M F AU - Abdelhafez MF AD - Department of Urology, Urology and Nephrology Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Ata, Shaimaa R AU - Ata SR AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Ata, Hesham S AU - Ata HS AD - Department of Pathology, College of Medicine, Qassim University, Qassim, 51452, Saudi Arabia. FAU - Radwan, Eman AU - Radwan E AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut, Egypt. AD - Department of Biochemistry, Sphinx University, Assiut, Egypt. LA - eng GR - 2017/08/27-004-R1/Assiut University/ PT - Journal Article DEP - 20260727 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Microtubule-Associated Proteins) RN - 0 (MAP1LC3A protein, human) RN - 0 (Autophagy-Related Protein 5) RN - 147336-12-7 (Transcription Factor CHOP) RN - 0 (DDIT3 protein, human) RN - 0 (ATG5 protein, human) RN - EC 3.4.22.- (Caspase 3) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism MH - *Microtubule-Associated Proteins/genetics/metabolism MH - Female MH - Male MH - *Autophagy-Related Protein 5/genetics/metabolism MH - *Transcription Factor CHOP/genetics/metabolism MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Autophagy/genetics MH - Gene Expression Regulation, Neoplastic MH - Non-Muscle Invasive Bladder Neoplasms MH - Caspase 3/metabolism/genetics MH - Biomarkers, Tumor/genetics OTO - NOTNLM OT - Autophagy OT - Biomarkers OT - Cancer OT - Malignant neoplasm OT - Muscle invasion COIS- Declarations. Ethics approval: The study was approved by the Faculty of Medicine, Assiut university-ethics committee and was performed in agreement with the guidelines of the declaration of Helsinki. (IRB no.17100311). The study was registered on ClinicalTrials.gov a service of the U.S. national institutes of health, with a ClinicalTrials.gov Identifier (ClinicalTrials.gov ID: NCT03254888). Consent to participate: Informed consent was obtained from all subjects involved in the study. Competing interests: The authors declare no competing interests. EDAT- 2026/07/27 12:36 MHDA- 2026/07/27 12:37 CRDT- 2026/07/27 11:05 PHST- 2026/03/28 00:00 [received] PHST- 2026/07/21 00:00 [accepted] PHST- 2026/07/27 12:37 [medline] PHST- 2026/07/27 12:36 [pubmed] PHST- 2026/07/27 11:05 [entrez] AID - 10.1007/s11033-026-12476-5 [pii] AID - 10.1007/s11033-026-12476-5 [doi] PST - epublish SO - Mol Biol Rep. 2026 Jul 27;53(1):1281. doi: 10.1007/s11033-026-12476-5. PMID- 42501246 OWN - NLM STAT- Publisher LR - 20260725 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Jul 25 TI - A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer. LID - 10.1007/s11255-026-05275-1 [doi] AB - OBJECTIVE: Bladder-preserving multimodal therapy has gained increasing recognition for the management of muscle-invasive bladder cancer (MIBC). This study aims to compare the efficacy and safety of disitamab vedotin combined with anti-PD-1 agents (RC48 + PD-1) versus gemcitabine plus cisplatin chemotherapy combined with anti-PD-1 agents (GC + PD-1) among MIBC patients receiving bladder-preserving multimodal therapy. METHODS: This was a single-center real-world retrospective cohort study. Patients diagnosed with MIBC who received bladder-preserving multimodal therapy at our hospital between January 2021 and September 2024 were enrolled. Participants were stratified into two groups according to their systemic treatment regimens: RC48 + PD-1 group and GC + PD-1 group. Propensity score matching (PSM) was performed to adjust baseline clinical characteristics and mitigate potential selection bias. Primary comparative endpoints between the two cohorts included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). RESULTS: A total of 143 patients with MIBC were initially enrolled, including 68 patients receiving RC48 + PD-1 inhibitor and 75 patients treated with GC + PD-1 inhibitor. After 1:1 PSM to balance baseline characteristics, a matched cohort consisting of 104 patients (52 patients per group) was generated for final analyses. Analysis of the matched cohort revealed that the ORR was significantly higher in the RC48 + PD-1 group than in the GC + PD-1 group (p = 0.013), whereas no statistically significant intergroup difference was observed in DCR. The median follow-up duration was 20 months (range, 8-56 months). Disease progression occurred in 43 patients (41.3%) across the entire matched cohort, with a median time to progression of 14 months (range, 2-45 months); 30 progression events were recorded in the GC + PD-1 group and 13 in the RC48 + PD-1 group. Multivariable Cox proportional hazards regression analysis revealed three independent predictors of PFS:receipt of repeated TURBT, and RC48 + PD-1 treatment were independent favorable prognostic factors, whereas HER2-positivity independently increased the risk of disease progression. Kaplan-Meier survival analysis demonstrated significantly superior PFS in patients receiving RC48 + PD-1 compared with those treated with GC + PD-1 (p < 0.05), while OS was comparable between the two arms (p = 0.42). Subgroup analysis, excluding HER2-negative patients, yielded consistent survival patterns with those observed in the overall matched cohort. In terms of safety, neither severe hypersensitivity reactions nor treatment-related deaths were documented in either group. The incidence of grade 3-4 TRAEs was 7.7% in the RC48 + PD-1 group versus 19.2% in the GC + PD-1 group, without a statistically significant between-group difference (p = 0.149). CONCLUSIONS: Whether HER2-negative patients were excluded or retained in the analysis, treatment with RC48 combined with immunotherapy yielded superior ORR and prolonged PFS, with no statistically significant intergroup difference in OS. This regimen demonstrates favorable antitumor efficacy and tolerability and may serve as an alternative clinical strategy for bladder-preserving multimodal therapy in patients with MIBC. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Zhang, Biao AU - Zhang B AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. FAU - Wang, Cheng AU - Wang C AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. FAU - Yang, Shujun AU - Yang S AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. FAU - Li, Xuan AU - Li X AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. FAU - Li, Can AU - Li C AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. FAU - Chang, Hong AU - Chang H AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. changh2010@sina.cn. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. changh2010@sina.cn. FAU - Zhang, Su AU - Zhang S AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. zhangsu1215@163.com. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. zhangsu1215@163.com. FAU - Shang, Panfeng AU - Shang P AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. shangpf@lzu.edu.cn. AD - Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou, Gansu, China. shangpf@lzu.edu.cn. LA - eng GR - CYXZPT2025-05/Cuiying Student Research Training Program/ GR - CY2024-MS-B10/Cuiying Science and Technology Innovation Project/ GR - GSWSKY2025-47/Gansu Province Health Sector Planning Projects/ PT - Journal Article DEP - 20260725 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Bladder-preserving multimodal therapy OT - Gemcitabine-cisplatin OT - Immunotherapy OT - Muscle-invasive bladder cancer OT - Prognosis OT - RC48 COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and informed consent: This study was conducted according to the guidelines of the Declaration of Helsinki. This research is a retrospective study and involves research in humans. The study passed the ethical review of the Lanzhou University Second Hospital (2025A-600). EDAT- 2026/07/25 23:59 MHDA- 2026/07/25 23:59 CRDT- 2026/07/25 11:07 PHST- 2026/04/03 00:00 [received] PHST- 2026/07/11 00:00 [accepted] PHST- 2026/07/25 23:59 [medline] PHST- 2026/07/25 23:59 [pubmed] PHST- 2026/07/25 11:07 [entrez] AID - 10.1007/s11255-026-05275-1 [pii] AID - 10.1007/s11255-026-05275-1 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275-1. PMID- 42499711 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260725 LR - 20260813 IS - 2296-634X (Print) IS - 2296-634X (Electronic) IS - 2296-634X (Linking) VI - 14 DP - 2026 TI - The 2025 paradigm shift in urothelial carcinoma pharmacotherapy: from chemotherapy to ADCs and ICIs. PG - 1904484 LID - 10.3389/fcell.2026.1904484 [doi] LID - 1904484 AB - The pharmacotherapy of urothelial carcinoma (UC) has undergone a paradigm shift from conventional chemotherapy and BCG to novel agent-based strategies, including immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), moving from later-line to frontline, monotherapy to combination, and systemic to locoregional-systemic synergy. In non-muscle-invasive bladder cancer, ICI-BCG combinations and ADC-BCG regimens improve treatment responses and patient outcomes, while the intravesical delivery system TAR-200 also shows therapeutic potential. For muscle-invasive bladder cancer, ADC/ICI-based perioperative strategies alongside biomarker-guided approaches have shown significantly improved survival. In upper tract urothelial carcinoma, ADC/ICI-based combinations show promise in neoadjuvant, kidney-sparing, and adjuvant settings. For advanced or metastatic UC, first-line enfortumab vedotin plus pembrolizumab demonstrates superior survival over chemotherapy, and various clinical trials of novel agent-based strategies are ongoing. Challenges include optimizing patient selection, determining ideal treatment duration, managing treatment-related adverse events, and preserving organ function. Future directions emphasize precision-oriented, function-preserving, and biomarker-driven individualized management. CI - Copyright (c) 2026 Liang, Zhaxi, Fu and Hu. FAU - Liang, Yong AU - Liang Y AD - Department of Urology, Lhasa People's Hospital, Lhasa, Xizang, China. FAU - Zhaxi, Duoji AU - Zhaxi D AD - Department of Urology, Lhasa People's Hospital, Lhasa, Xizang, China. FAU - Fu, Meng AU - Fu M AD - Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. FAU - Hu, Junjie AU - Hu J AD - Department of Urology, Lhasa People's Hospital, Lhasa, Xizang, China. LA - eng PT - Journal Article PT - Review DEP - 20260710 PL - Switzerland TA - Front Cell Dev Biol JT - Frontiers in cell and developmental biology JID - 101630250 PMC - PMC13395938 OTO - NOTNLM OT - antibody-drug conjugate OT - bladder cancer OT - immune checkpoint inhibitor OT - upper tract urothelial carcinoma OT - urothelial carcinoma COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/25 06:36 MHDA- 2026/07/25 06:37 PMCR- 2026/07/10 CRDT- 2026/07/25 04:58 PHST- 2026/06/09 00:00 [received] PHST- 2026/06/18 00:00 [revised] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/07/25 06:37 [medline] PHST- 2026/07/25 06:36 [pubmed] PHST- 2026/07/25 04:58 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 1904484 [pii] AID - 10.3389/fcell.2026.1904484 [doi] PST - epublish SO - Front Cell Dev Biol. 2026 Jul 10;14:1904484. doi: 10.3389/fcell.2026.1904484. eCollection 2026. PMID- 42493403 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260819 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 9 DP - 2026 Sep TI - Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study. PG - 388-393 LID - S1078-1439(26)00570-3 [pii] LID - 10.1016/j.urolonc.2026.06.012 [doi] AB - BACKGROUND: Bladder cancer (BCa) lacks reliable non-invasive diagnostic tools. Urinary volatile organic compounds (VOCs) have emerged as potential discriminative biomarkers. We evaluated the diagnostic performance of an electronic nose (eNose) platform for BCa detection. METHODS: In this prospective single-center study, 192 patients with histologically confirmed BCa and 143 healthy controls were included. Consecutive patients with suspected primary or recurrent BCa were prospectively screened, and first-morning urine samples were collected in a sterile fashion before Trans-urethral resection of bladder tumor (TURBT) or radical cystectomy. Healthy controls were recruited at the institutional outpatient clinic after exclusion of neoplasia and urinary infection. Patients with ongoing gross hematuria or concomitant urinary infection were not enrolled. Urine samples were analyzed using a 32-sensor eNose (Cyranose C320). Principal component analysis (PCA) and canonical discriminant analysis (CDA) were applied. Cross-validated accuracy (CVA) was calculated using the leave-one-out method. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis. RESULTS: The eNose achieved a cross-validated accuracy of 87.5% (P < 0.001). Sensitivity and specificity were 81.8% and 95.1%, respectively. The area under the ROC curve (AUC) was 0.926. Reproducibility was confirmed in serial urine samples obtained from the same patients (CVA 87.2%, AUC 0.90). Positive and negative likelihood ratios were 16.69 and 0.19, respectively. CONCLUSIONS: Urinary volatilome profiling using an eNose demonstrates high diagnostic accuracy in discriminating BCa patients from healthy individuals. These findings support eNose-based VOC analysis as a promising non-invasive adjunct tool for BCa detection and clinical triage in selected risk-enriched settings, warranting external validation in multicenter studies. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Filianoti, Alessio AU - Filianoti A AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy; Department of Urology, San Filippo Neri Hospital, Rome, Italy. Electronic address: alessio.filianoti@aslroma1.it. FAU - Costantini, Manuela AU - Costantini M AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Rosca, Valeriu AU - Rosca V AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Ghezzo, Nicola AU - Ghezzo N AD - Department of Urology, Sant'Andrea Hospital, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. LA - eng PT - Journal Article DEP - 20260723 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Volatile Organic Compounds) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Electronic Nose MH - *Urinary Bladder Neoplasms/urine/diagnosis MH - Male MH - *Volatile Organic Compounds/urine MH - Prospective Studies MH - Middle Aged MH - Aged MH - Case-Control Studies MH - *Biomarkers, Tumor/urine MH - Adult MH - ROC Curve MH - Aged, 80 and over OTO - NOTNLM OT - Bladder cancer OT - Electronic nose OT - Gas sensor array OT - Tumor biomarkers OT - Urinary volatilome OT - Volatile organic compounds COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/24 00:37 MHDA- 2026/08/19 23:42 CRDT- 2026/07/23 21:54 PHST- 2026/02/16 00:00 [received] PHST- 2026/05/16 00:00 [revised] PHST- 2026/06/13 00:00 [accepted] PHST- 2026/08/19 23:42 [medline] PHST- 2026/07/24 00:37 [pubmed] PHST- 2026/07/23 21:54 [entrez] AID - S1078-1439(26)00570-3 [pii] AID - 10.1016/j.urolonc.2026.06.012 [doi] PST - ppublish SO - Urol Oncol. 2026 Sep;44(9):388-393. doi: 10.1016/j.urolonc.2026.06.012. Epub 2026 Jul 23. PMID- 42488113 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260723 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy. PG - 1887794 LID - 10.3389/fonc.2026.1887794 [doi] LID - 1887794 AB - BACKGROUND: Antibody-drug conjugates (ADCs) have redefined the treatment of urothelial carcinoma (UC). However, the spatiotemporal heterogeneity and co-expression landscapes of these targets across diverse anatomical sites and pathological stages remain poorly understood. This study aimed to map these patterns and explore their clinical implications for personalized ADC therapy. METHODS: A cohort of 118 UC specimens was analyzed, including matched pairs of primary tumors with adjacent normal tissues (n=60), carcinoma in situ (CIS, n=8), and lymph node (LN) metastases (n=12). Expression levels were evaluated via immunohistochemistry (IHC). Statistical analyses included the Wilcoxon signed-rank test, Mann-Whitney U test, and multivariable logistic regression. A novel Deltascore (tumor score - normal score) was introduced to quantify target "net gain." RESULTS: High expression (IHC 2+ or higher) of at least one target occurred in 90.7 percent of patients, with 56.8 percent showing multi-target co-expression. HER2 and Trop-2 were significantly upregulated during the transition from CIS to invasive carcinoma (P = 0.034 and P = 0.039). While primary tumors and metastases showed global stability (P greater than 0.05), Nectin-4 tended to downregulate in metastases (negative ranks in 50 percent of pairs). Trop-2 expression was significantly higher in the lower than the upper urinary tract (P = 0.042), whereas HER2 and Nectin-4 were uniformly distributed. Furthermore, a high Delta-Trop-2 was independently associated with muscle invasion, lymphovascular invasion, and metastasis. CONCLUSIONS: In the "post-EV+P" era, our findings reveal significant antigenic drift and anatomical expression biases during disease progression, advocating for dynamic, multi-site molecular profiling over static primary-site assessment. This provides a translational blueprint to optimize ADC sequencing and overcome heterogeneity-driven resistance. Finally, we introduce the novel Deltascore as a new metric for further testing in quantifying net antigenic gain and predicting aggressive phenotypes. CI - Copyright (c) 2026 Qin, Dai, Hu, Wang, Zhang, Yang, Liu and Ma. FAU - Qin, Shaobo AU - Qin S AD - Department of Clinical Medicine, Shandong Second Medical University, Weifang, China. FAU - Dai, Zhicheng AU - Dai Z AD - The First Clinical Medical College, Ningxia Medical University, Yinchuan, China. FAU - Hu, Zhenxing AU - Hu Z AD - The First Clinical Medical College, Ningxia Medical University, Yinchuan, China. FAU - Wang, Xiaohui AU - Wang X AD - Department of Pain Treatment, Weifang People's Hospital, Weifang, China. FAU - Zhang, Huiyan AU - Zhang H AD - Department of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Yang, Haotian AU - Yang H AD - The First Clinical Medical College, Ningxia Medical University, Yinchuan, China. FAU - Liu, Jie AU - Liu J AD - Department of Urology, Linyi People's Hospital, Linyi, China. FAU - Ma, Lianghong AU - Ma L AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, China. LA - eng PT - Journal Article DEP - 20260708 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13388169 OTO - NOTNLM OT - HER2 OT - Trop-2 OT - antibody-drug conjugates OT - co-expression OT - heterogeneity OT - nectin-4 OT - urothelial carcinoma COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/23 06:39 MHDA- 2026/07/23 06:40 PMCR- 2026/07/08 CRDT- 2026/07/23 04:48 PHST- 2026/05/21 00:00 [received] PHST- 2026/06/22 00:00 [revised] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/07/23 06:40 [medline] PHST- 2026/07/23 06:39 [pubmed] PHST- 2026/07/23 04:48 [entrez] PHST- 2026/07/08 00:00 [pmc-release] AID - 10.3389/fonc.2026.1887794 [doi] PST - epublish SO - Front Oncol. 2026 Jul 8;16:1887794. doi: 10.3389/fonc.2026.1887794. eCollection 2026. PMID- 42462321 OWN - NLM STAT- Publisher LR - 20260716 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 6 DP - 2026 Jun 17 TI - Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC). PG - 102599 LID - S1558-7673(26)00099-6 [pii] LID - 10.1016/j.clgc.2026.102599 [doi] AB - BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by bladder-sparing trimodality therapy (TMT) is an emerging treatment option for selected patients with muscle-invasive bladder cancer (MIBC), but long-term outcome data remain limited. PATIENTS AND METHODS: MIBC patients treated with 3-4 cycles of cisplatin-based NAC followed by TMT (maximal TURBT and concurrent radiation with weekly cisplatin) at 2 Canadian cancer centers from 2008 to 2017 were retrospectively reviewed. This updated analysis assessed median disease-free survival (DFS), overall survival (OS), bladder-intact DFS (BI-DFS), and metastasis-free survival (MFS) using Kaplan-Meier methods. RESULTS: The study cohort included 56 patients (79% male; median age 72 [range, 45-87]) with stage II (59%), stage III (36%), and node-positive disease (13%); 38% had mixed histology. At baseline, 24% had eGFR < 60 mL/min/1.73 m(2), and 25% had hydronephrosis. NAC completion rate was 95%. All patients completed radiotherapy, and 88% received > 60% of planned concurrent cisplatin. After a median follow-up of 91 months, 23 patients (41%) recurred, including 11 local recurrences (20%), 8 requiring salvage cystectomy (14%), and 12 distant recurrences (21%). Median DFS was 48.9 months (95% CI, 25.3-73.4), and median OS was 96.5 months (95% CI, 56.6-126.4). Patients without residual tumor on post-NAC cystoscopy (31/43 patients) had numerically longer median DFS (73 months) and OS (126 months). CONCLUSIONS: Cisplatin-based NAC followed by TMT can provide durable disease control in selected patients with MIBC, including those with high-risk features downstaged by NAC. Prospective studies integrating novel systemic therapies and biomarkers, including ctDNA and urinary tumor DNA, may further optimize bladder-sparing approaches. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Mahoney, Meghan E AU - Mahoney ME AD - Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Jiang, Di Maria AU - Jiang DM AD - Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Diaz-Mejia, Nely AU - Diaz-Mejia N AD - Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Atenafu, Eshetu G AU - Atenafu EG AD - Division of Biostatistics, Department of Biostatistics, University Health Network, DLSPH, University of Toronto, Toronto, ON. FAU - Chung, Peter AU - Chung P AD - Division of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Zlotta, Alexandre AU - Zlotta A AD - Division of Urology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Alimohamed, Nimira AU - Alimohamed N AD - Arthur Child Cancer Centre, University of Calgary, Calgary, AB. FAU - Fleshner, Neil AU - Fleshner N AD - Division of Urology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Lo, Gregory AU - Lo G AD - Medical Oncology, Durham Regional Cancer Centre, Oshawa, ON. FAU - Zalewski, Pawel AU - Zalewski P AD - Medical Oncology, Durham Regional Cancer Centre, Oshawa, ON. FAU - Kay, Amin AU - Kay A AD - Medical Oncology, Durham Regional Cancer Centre, Oshawa, ON. FAU - Kulkarni, Girish AU - Kulkarni G AD - Division of Urology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Berlin, Alejandro AU - Berlin A AD - Division of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. FAU - Sridhar, Srikala S AU - Sridhar SS AD - Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON. Electronic address: srikala.sridhar@uhn.ca. LA - eng PT - Journal Article DEP - 20260617 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM OTO - NOTNLM OT - Concurrent Chemoradiation OT - Multidisciplinary Care OT - Organ Preservation OT - Platinum-based OT - Urothelial Cancer COIS- Disclosure The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Di Maria Jiang: Advisory: Pfizer, Astra Zeneca, Merck, Janssen. Peter Chung: Advisory: Pfizer, TerSera, Bayer, Knight, Elekta, Tolmar. Alex Zlotta; Advisory Board: Janssen, Verity Pharmaceuticals, Ferring, mIR Scientific, Tolmar, and Theralase; and Consulting Fees: Janssen, Verity Pharmaceuticals, Ferring, mIR Scientific, Tolmar, and Theralase. Nimira Alimohamed has held advisory/consultancy roles: Abbvie, AstraZeneca, Bayer, BMS, EMD Serono, Gilead, Janssen, Merck, Pfizer; and has received research funding (institution) from AstraZeneca and EMD Serono. Neil Fleshner: Consulting fees: Amgen, Sanofi, Janssen, AbbVie, Astellas, Ferring, and Bayer. Girish Kulkarni - Advisory: Verit, TerSera, Astra Zeneca, Photocure, Merck, J&J, Ferring, Merck, Pfizer, AAA/Novartis. Speakers Bureau: Merck, EMD Serono, Pfizer, BMS, Theralase, J&J, AAA/Novartis, Ferring, Astellas, Verity, Knight Therapeutics, Tolmar, Abbvie, enGene, Protara Therapeutics, CG Oncology. Srikala S. Sridhar: Advisory: Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BMS, EMD Serono, Gilead, Janssen, Merck, Pfizer. Other authors report no conflicts of interest relevant to this publication. EDAT- 2026/07/16 22:01 MHDA- 2026/07/16 22:01 CRDT- 2026/07/16 18:00 PHST- 2026/03/30 00:00 [received] PHST- 2026/06/10 00:00 [revised] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/07/16 22:01 [medline] PHST- 2026/07/16 22:01 [pubmed] PHST- 2026/07/16 18:00 [entrez] AID - S1558-7673(26)00099-6 [pii] AID - 10.1016/j.clgc.2026.102599 [doi] PST - aheadofprint SO - Clin Genitourin Cancer. 2026 Jun 17;24(6):102599. doi: 10.1016/j.clgc.2026.102599. PMID- 42457481 OWN - NLM STAT- Publisher LR - 20260715 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) DP - 2026 Jul 15 TI - Novel BCG Combination or Modified BCG Regimens in BCG-Naive High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. LID - S2405-4569(26)00115-X [pii] LID - 10.1016/j.euf.2026.06.019 [doi] AB - BACKGROUND AND OBJECTIVE: Despite Bacillus Calmette-Guerin (BCG) remaining the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), novel combination strategies are being actively investigated. Comparative evidence on the efficacy and tolerability of these regimens in BCG-naive patients remains limited. The objective of this study was to synthesize and compare the efficacy and safety of treatments for BCG-naive HR-NMIBC evaluated in randomized controlled trials (RCTs). METHODS: A systematic search of PubMed, Embase, and Web of Science was performed through October 20, 2025, following a registered protocol (PROSPERO CRD420251079219). Eligible studies were phase III RCTs enrolling adults with BCG-naive HR-NMIBC that reported recurrence-free survival (RFS), event-free survival (EFS), disease-free survival (DFS), and common terminology criteria for adverse events (CTCAE)-graded AEs. Two independent reviewers extracted data following PRISMA guidelines. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Random-effects meta-analyses and a frequentist network meta-analysis (NMA) were performed. Primary outcomes were tumor recurrences, with secondary outcomes including EFS and DFS, AEs, and subgroup analyses. KEY FINDINGS: Five phase III RCTs (n = 3486) met inclusion criteria. Pooled analyses showed 1-yr and 2-yr EFS/DFS for combination therapy of 87% (95% CI 85-89) and 82% (95% CI 79-85) versus 84% (95% CI 82-87) and 78% (95% CI 75-81) with BCG (induction + maintenance [I + M]). In trials with centrally-adjudicated high-grade recurrence, ICI + BCG (I + M) reduced HG-recurrence (RR 0.63; 95% CI 0.41-0.98). Including ALBAN attenuated the effect (RR 0.75; 95% CI 0.50-1.12). Subgroup analyses favored ICI + BCG (I + M) in CIS and T1 disease (HR 0.68; 95% CI 0.50-0.92). Grade >/=3 treatment-related AEs occurred in 25% of combination-treated patients versus 6% with BCG alone. LIMITATIONS: Interpretation is limited by heterogeneity in treatment regimens, diagnostic definitions, and incomplete reporting of key prognostic factors, including variant histology, lymphovascular invasion, programmed cell death ligand 1 status, and transurethral resection of bladder tumor quality, contributing to between-study variability. CONCLUSION AND CLINICAL IMPLICATIONS: The modest, heterogeneity-sensitive recurrence benefit of adding systemic ICI to BCG (I + M), set against a marked increase in toxicity and no demonstrated survival gain, does not justify routine systemic intensification in unselected BCG-naive HR-NMIBC. Its use should instead be individualized to higher-risk subgroups pending biomarker-driven selection and mature survival data. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Pattou, Maxime AU - Pattou M AD - Urology Department, Foch Hospital, Suresnes, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 PredictiveOnco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Kamat, Ashish AU - Kamat A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Gontero, Paolo AU - Gontero P AD - Urology Clinic - A.O.U. "Cittadella Salute e della Scienza"- Molinette Hospital, University of Turin, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: david.dandrea@muv.ac.at. LA - eng PT - Journal Article PT - Review DEP - 20260715 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM OTO - NOTNLM OT - BCG OT - Immunotherapy OT - Meta-analysis OT - Non-muscle-invasive Bladder Cancer EDAT- 2026/07/16 00:35 MHDA- 2026/07/16 00:35 CRDT- 2026/07/15 21:52 PHST- 2025/12/09 00:00 [received] PHST- 2026/06/02 00:00 [revised] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/07/16 00:35 [medline] PHST- 2026/07/16 00:35 [pubmed] PHST- 2026/07/15 21:52 [entrez] AID - S2405-4569(26)00115-X [pii] AID - 10.1016/j.euf.2026.06.019 [doi] PST - aheadofprint SO - Eur Urol Focus. 2026 Jul 15:S2405-4569(26)00115-X. doi: 10.1016/j.euf.2026.06.019. PMID- 42457459 OWN - NLM STAT- MEDLINE DCOM- 20261006 LR - 20261007 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 90 IP - 4 DP - 2026 Oct TI - EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update. PG - 389-412 LID - S0302-2838(26)02111-1 [pii] LID - 10.1016/j.eururo.2026.04.009 [doi] AB - BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation. METHODS: For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette-Guerin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAIVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice. PATIENT SUMMARY: The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients. CI - Copyright (c) 2026 European Association of Urology. All rights reserved. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France. FAU - Rai, Bhavan P AU - Rai BP AD - Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Liedberg, Fredrik AU - Liedberg F AD - Institute of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Birtle, Alison AU - Birtle A AD - Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom. FAU - Botha, Maresa AU - Botha M AD - EAU Guidelines Office, Arnhem, the Netherlands. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Fiorini, Edoardo AU - Fiorini E AD - Associazione PaLiNUro, Milan, Italy. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Smith, Emma J AU - Smith EJ AD - EAU Guidelines Office, Arnhem, the Netherlands. Electronic address: e.smith@uroweb.org. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Wood, Robert AU - Wood R AD - EAU Guidelines Office, Arnhem, the Netherlands. FAU - Xylinas, Evanguelos N AU - Xylinas EN AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20260715 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Carcinoma in Situ/therapy/diagnosis/pathology MH - *Carcinoma, Transitional Cell/therapy/pathology/diagnosis MH - *Non-Muscle Invasive Bladder Neoplasms/therapy/diagnosis MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Urology OTO - NOTNLM OT - BCG unresponsive OT - Bacillus Calmette-Guerin (BCG) OT - Bladder cancer OT - Classification OT - Cystoscopy OT - Diagnosis OT - Follow-up OT - Guidelines OT - Intravesical chemotherapy OT - Prognosis OT - Radical cystectomy OT - Transurethral resection (TUR) OT - Urothelial carcinoma EDAT- 2026/07/16 00:34 MHDA- 2026/10/06 23:29 CRDT- 2026/07/15 21:52 PHST- 2026/03/05 00:00 [received] PHST- 2026/04/07 00:00 [accepted] PHST- 2026/10/06 23:29 [medline] PHST- 2026/07/16 00:34 [pubmed] PHST- 2026/07/15 21:52 [entrez] AID - S0302-2838(26)02111-1 [pii] AID - 10.1016/j.eururo.2026.04.009 [doi] PST - ppublish SO - Eur Urol. 2026 Oct;90(4):389-412. doi: 10.1016/j.eururo.2026.04.009. Epub 2026 Jul 15. PMID- 42452659 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 13 DP - 2026 Jul 3 TI - Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies. LID - 10.3390/jcm15135199 [doi] LID - 5199 AB - Background/Objectives: Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates despite appropriate treatment and surveillance. Identifying inexpensive and readily available biomarkers capable of improving risk stratification remains an important clinical challenge. The platelet-to-lymphocyte ratio (PLR), a marker of systemic inflammation, has emerged as a potential prognostic indicator in several malignancies. This study aimed to evaluate the association between preoperative PLR, tumor recurrence, and recurrence-free survival (RFS) in NMIBC patients treated with intravesical Bacillus Calmette-Guerin (BCG) or thermochemotherapy. Methods: This retrospective study included 153 patients diagnosed with NMIBC between January 2020 and January 2024. All patients underwent transurethral resection of bladder tumor (TURBT) followed by intravesical BCG (n = 123) or thermochemotherapy (n = 30). Preoperative PLR was calculated from complete blood counts obtained before surgery. Receiver operating characteristic (ROC) analysis was used to determine the optimal PLR cut-off value. Recurrence-free survival was evaluated using Kaplan-Meier survival analysis and Cox proportional hazards regression models. Results: During a mean follow-up period of approximately 19 months, recurrence was observed in 35.8% of patients treated with BCG and 30% of those treated with thermochemotherapy. ROC analysis demonstrated good discriminatory ability for recurrence prediction (AUC = 0.831, 95% CI: 0.761-0.901, p < 0.001) and identified an optimal PLR threshold of 120. Patients with elevated PLR values demonstrated higher recurrence rates and shorter recurrence-free survival. Kaplan-Meier analysis revealed a clear separation of survival curves according to PLR status. In multivariable Cox regression analysis, PLR > 120 remained independently associated with recurrence-free survival in the BCG group (HR = 2.703, 95% CI: 1.118-6.534, p = 0.027), whereas only a borderline association was observed in the thermochemotherapy group (HR = 23.265, 95% CI: 0.952-568.336, p = 0.054). Conclusions: Elevated preoperative PLR was associated with recurrence and recurrence-free survival in patients with NMIBC. The prognostic value of PLR appeared to be more pronounced in patients receiving intravesical BCG therapy. Given its low cost, accessibility, and ease of calculation, PLR may serve as a useful adjunctive biomarker for clinical risk stratification when used alongside established clinicopathological prognostic factors. Further prospective multicenter studies are required to validate these findings. FAU - Ozturk, Muhammet Ihsan AU - Ozturk MI AUID- ORCID: 0000-0002-0687-5954 AD - Alaca State Hospital, Corum 19600, Turkey. FAU - Ekici, Musa AU - Ekici M AD - Department of Urology, Faculty of Medicine, Hitit University, Corum 19040, Turkey. FAU - Aydin, Cemil AU - Aydin C AD - Department of Urology, Faculty of Medicine, Hitit University, Corum 19040, Turkey. FAU - Caglayan, Mustafa Serdar AU - Caglayan MS AD - Department of Urology, Faculty of Medicine, Hitit University, Corum 19040, Turkey. FAU - Dogan, Mucahit AU - Dogan M AD - Mengucek Gazi Training and Research Hospital, Erzincan 24100, Turkey. FAU - Baykam, Mehmet Murat AU - Baykam MM AD - Department of Urology, Faculty of Medicine, Hitit University, Corum 19040, Turkey. LA - eng PT - Journal Article DEP - 20260703 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13363068 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - inflammation markers OT - intravesical therapy OT - non-muscle invasive bladder cancer OT - platelet-to-lymphocyte ratio OT - recurrence OT - recurrence-free survival OT - thermochemotherapy OT - uro-oncology COIS- The authors declare no conflicts of interest. EDAT- 2026/07/15 06:37 MHDA- 2026/07/15 06:38 PMCR- 2026/07/03 CRDT- 2026/07/15 01:10 PHST- 2026/04/29 00:00 [received] PHST- 2026/06/08 00:00 [revised] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/07/15 06:38 [medline] PHST- 2026/07/15 06:37 [pubmed] PHST- 2026/07/15 01:10 [entrez] PHST- 2026/07/03 00:00 [pmc-release] AID - jcm15135199 [pii] AID - jcm-15-05199 [pii] AID - 10.3390/jcm15135199 [doi] PST - epublish SO - J Clin Med. 2026 Jul 3;15(13):5199. doi: 10.3390/jcm15135199. PMID- 42452641 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 13 DP - 2026 Jul 2 TI - Urinary Biomarkers and Their Role in the Management of Urothelial Carcinoma: A Narrative Review. LID - 10.3390/jcm15135183 [doi] LID - 5183 AB - Background: Urothelial carcinoma requires frequent surveillance because of its high recurrence rate, particularly in patients with non-muscle-invasive disease. Although cystoscopy remains the standard method for diagnosis and follow-up, it is invasive, costly, and associated with patient discomfort. Urinary biomarkers have emerged as potential tools for improving surveillance and reducing unnecessary cystoscopies. Methods: We performed a narrative review of studies published between 2017 and 2026 evaluating urinary biomarkers in urothelial carcinoma. Particular attention was given to assay mechanisms, diagnostic performance, clinical applications, and integration into surveillance techniques. Results: The most extensively studied biomarkers were Xpert Bladder Cancer Monitor, Bladder EpiCheck, ADXBLADDER, and Cxbladder. Most molecular assays demonstrated higher sensitivity than urinary cytology, particularly for the detection of high-grade recurrence. Reported negative predictive values frequently exceeded 95%, suggesting potential utility in identifying patients at low risk of clinically significant recurrence. Xpert Bladder Cancer Monitor and Bladder EpiCheck were supported by the largest body of surveillance evidence, whereas Cxbladder and mutation-enhanced platforms showed promise for risk stratification and individualized follow-up. Evidence supports the use of urinary biomarkers as adjuncts to cystoscopy rather than replacements. Conclusions: Modern urinary biomarkers provide clinically useful information during the surveillance of urothelial carcinoma, especially for excluding high-grade recurrence and assisting the interpretation of equivocal findings. Future biomarker-guided surveillance strategies may reduce the burden of cystoscopy while maintaining oncological safety. Further studies are required to improve specificity and sensitivity in order to fully integrate these biomarkers into diagnostic and follow-up protocols. FAU - Tichil, Bogdan-Petru AU - Tichil BP AUID- ORCID: 0009-0000-6793-0016 AD - Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", 400349 Cluj-Napoca, Romania. AD - Deva Emergency County Hospital, 330004 Deva, Romania. FAU - Besleaga, Anamaria AU - Besleaga A AUID- ORCID: 0000-0002-8504-8032 AD - Deva Emergency County Hospital, 330004 Deva, Romania. AD - Department of Otorhinolaryngology, University of Medicine and Pharmacy "Iuliu Hatieganu", 400349 Cluj-Napoca, Romania. FAU - Vica Matei, Mihaela Laura AU - Vica Matei ML AUID- ORCID: 0000-0003-0811-0821 AD - Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", 400349 Cluj-Napoca, Romania. FAU - Florea, Adrian AU - Florea A AUID- ORCID: 0000-0002-0898-7626 AD - Department of Cell and Molecular Biology, Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", 400349 Cluj-Napoca, Romania. LA - eng GR - 1032/69/13.01.2021/Iuliu Hatieganu University of Medicine and Pharmacy/ PT - Journal Article PT - Review DEP - 20260702 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13362743 OTO - NOTNLM OT - ADXBLADDER OT - Bladder EpiCheck OT - Cxbladder OT - Xpert Bladder Cancer Monitor OT - bladder cancer OT - methylation OT - non-muscle-invasive bladder cancer OT - surveillance OT - urinary biomarkers OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2026/07/15 06:35 MHDA- 2026/07/15 06:36 PMCR- 2026/07/02 CRDT- 2026/07/15 01:10 PHST- 2026/05/23 00:00 [received] PHST- 2026/06/25 00:00 [revised] PHST- 2026/06/30 00:00 [accepted] PHST- 2026/07/15 06:36 [medline] PHST- 2026/07/15 06:35 [pubmed] PHST- 2026/07/15 01:10 [entrez] PHST- 2026/07/02 00:00 [pmc-release] AID - jcm15135183 [pii] AID - jcm-15-05183 [pii] AID - 10.3390/jcm15135183 [doi] PST - epublish SO - J Clin Med. 2026 Jul 2;15(13):5183. doi: 10.3390/jcm15135183. PMID- 42452561 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 13 DP - 2026 Jun 30 TI - Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. LID - 10.3390/jcm15135101 [doi] LID - 5101 AB - Bladder preservation has emerged as an established treatment option for selected patients with muscle-invasive bladder cancer (MIBC), offering durable oncologic control with the potential to maintain native bladder function and quality of life. Over the past several decades, prospective trials and large institutional experiences have refined trimodality therapy (TMT)-maximal transurethral resection followed by definitive radiation therapy with concurrent radiosensitizing systemic therapy-and clarified principles of patient selection, treatment delivery, surveillance, and salvage. Randomized evidence supports combined-modality therapy as the backbone of bladder preservation, and contemporary comparative analyses suggest outcomes comparable to radical cystectomy in appropriately selected populations. This review synthesizes the clinical foundations of bladder preservation, including radiobiologic considerations, advances in radiation technique, and patterns of recurrence following TMT. We discuss outcomes in higher-risk populations, including locally advanced and node-positive disease, and examine the evolving integration of systemic therapies. The emergence of immune checkpoint inhibitors and antibody-drug conjugates in urothelial carcinoma has reshaped the systemic treatment landscape and raises important questions regarding patient selection, sequencing, and the potential expansion of organ-preserving strategies. Finally, we outline future directions-including response-adaptive approaches, advances in image-guided and adaptive radiotherapy, and ctDNA-enabled risk stratification-while emphasizing the need for prospective validation and multidisciplinary collaboration to refine and optimize bladder-preserving care. FAU - Carriere, Patrick P AU - Carriere PP AD - Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Hassanzadeh, Comron J AU - Hassanzadeh CJ AD - Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20260630 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13362832 OTO - NOTNLM OT - bladder preservation OT - muscle-invasive bladder cancer OT - radiation therapy OT - trimodality therapy COIS- The authors declare no conflicts of interest. EDAT- 2026/07/15 10:10 MHDA- 2026/07/15 10:11 PMCR- 2026/06/30 CRDT- 2026/07/15 01:09 PHST- 2026/03/23 00:00 [received] PHST- 2026/04/27 00:00 [revised] PHST- 2026/05/26 00:00 [accepted] PHST- 2026/07/15 10:11 [medline] PHST- 2026/07/15 10:10 [pubmed] PHST- 2026/07/15 01:09 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - jcm15135101 [pii] AID - jcm-15-05101 [pii] AID - 10.3390/jcm15135101 [doi] PST - epublish SO - J Clin Med. 2026 Jun 30;15(13):5101. doi: 10.3390/jcm15135101. PMID- 42449730 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 13 DP - 2026 Jun 23 TI - Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer. LID - 10.3390/diagnostics16131948 [doi] LID - 1948 AB - Bladder cancer is a common malignancy with high recurrence rates and significant morbidity, necessitating accurate diagnostic and prognostic tools. Although cystoscopy and transurethral resection of bladder tumor (TURBT) remain reference standards, these approaches are invasive and limited by sampling errors and understaging. Consequently, there is growing interest in non-invasive biomarkers, including urine-based assays, blood-based markers, and imaging-derived parameters. Among these biomarkers, multiparametric magnetic resonance imaging (mpMRI), particularly with the Vesical Imaging Reporting and Data System (VI-RADS), has emerged as a robust non-invasive imaging biomarker for local staging and risk stratification. Recent evidence suggests that mpMRI plays a role in predicting treatment response and recurrence, particularly in the context of neoadjuvant therapy. This review provides a comprehensive overview of current non-invasive diagnostic and prognostic biomarkers in bladder cancer, with a particular emphasis on imaging biomarkers. We discuss their clinical utility, limitations, and future integration into multimodal decision-making frameworks. FAU - Sim, Ki Choon AU - Sim KC AUID- ORCID: 0000-0002-3344-8018 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Kim, Min Ju AU - Kim MJ AUID- ORCID: 0000-0003-0979-9835 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Sung, Deuk Jae AU - Sung DJ AUID- ORCID: 0000-0002-5025-3052 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Park, Beom Jin AU - Park BJ AUID- ORCID: 0000-0002-7289-3683 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Han, Na Yeon AU - Han NY AUID- ORCID: 0000-0001-8537-8165 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Han, Yeo Eun AU - Han YE AUID- ORCID: 0000-0002-3922-9326 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. FAU - Cha, Seung Ha AU - Cha SH AUID- ORCID: 0000-0002-4609-9769 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. LA - eng GR - K2327211/Korea University/ GR - RS-2024-00353205/National Research Foundation of Korea/ GR - RS-2022-KH129263/Korea Human Resource Development Institute for Health and Welfare/ PT - Journal Article PT - Review DEP - 20260623 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13359991 OTO - NOTNLM OT - VI-RADS OT - artificial intelligence OT - biomarker OT - bladder cancer OT - liquid biopsy OT - multiparametric MRI OT - non-invasive biomarkers OT - radiomics OT - treatment response OT - urine cytology COIS- The authors declare no conflicts of interest. EDAT- 2026/07/15 06:37 MHDA- 2026/07/15 06:38 PMCR- 2026/06/23 CRDT- 2026/07/15 01:00 PHST- 2026/04/17 00:00 [received] PHST- 2026/05/08 00:00 [revised] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/07/15 06:38 [medline] PHST- 2026/07/15 06:37 [pubmed] PHST- 2026/07/15 01:00 [entrez] PHST- 2026/06/23 00:00 [pmc-release] AID - diagnostics16131948 [pii] AID - diagnostics-16-01948 [pii] AID - 10.3390/diagnostics16131948 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Jun 23;16(13):1948. doi: 10.3390/diagnostics16131948. PMID- 42449600 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 13 DP - 2026 Jun 24 TI - Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers18132054 [doi] LID - 2054 AB - BACKGROUND/OBJECTIVES: Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) is a standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), yet baseline tools to refine prognostic stratification remain limited. We aimed to develop and internally validate a clinicopathological nomogram integrating the neutrophil-to-lymphocyte ratio (NLR) to estimate event-free survival (EFS) in patients with MIBC treated with NAC. METHODS: We retrospectively analyzed 210 patients with cT2-T4aN0-1M0 MIBC treated with cisplatin-based NAC at two Spanish institutions between 2010 and 2021. Candidate predictors included demographic, clinicopathological, and routine laboratory variables. A multivariable Cox model with backward selection based on the Akaike information criterion (AIC) was used to derive the final model, and internal validation was performed using 1000 bootstrap resamples. RESULTS: Sex, age, prior non-muscle-invasive bladder cancer (NMIBC), and NLR were retained in the final nomogram. The model showed moderate discrimination, with a Harrell's c-index of 0.60 and an optimism-corrected c-index of 0.58. The nomogram stratified patients into low-, intermediate-, and high-risk groups, with median EFS not reached, 47.5 months, and 18.0 months, respectively. High-risk patients also showed lower pathological complete response (pCR) rates. CONCLUSIONS: This exploratory nomogram integrates an accessible systemic inflammatory marker with baseline clinical variables to identify patients with poorer outcomes despite NAC. External validation in contemporary cohorts is warranted before clinical implementation. FAU - Figols, Mariona AU - Figols M AUID- ORCID: 0000-0001-7563-3812 AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. AD - PhD Programme in Medicine and Biomedical Sciences, Doctoral School, University of Vic-Central University of Catalonia (UVic-UCC), C/Dr. Junyent 1, 08500 Vic, Spain. AD - Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann Ctra de Roda 70, 08500 Vic, Spain. FAU - Gonzalez, Andrea AU - Gonzalez A AUID- ORCID: 0009-0005-4236-0199 AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Fernandez-Saorin, Maria AU - Fernandez-Saorin M AD - CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - Badalona Applied Research Group in Oncology (B.ARGO), Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Bautista, Ana AU - Bautista A AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Etxaniz, Olatz AU - Etxaniz O AUID- ORCID: 0000-0002-8856-5596 AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - Badalona Applied Research Group in Oncology (B.ARGO), Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Ruz, Ester AU - Ruz E AD - Urology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Gago, Jose Luis AU - Gago JL AUID- ORCID: 0009-0002-1639-8386 AD - Urology Department, University Hospital Germans Trias i Pujol, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Gomez-Diaz, Daniela AU - Gomez-Diaz D AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Pardo, Juan Carlos AU - Pardo JC AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - Badalona Applied Research Group in Oncology (B.ARGO), Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Gali, Marta AU - Gali M AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Bernal, Sergi AU - Bernal S AD - Urology Department, University Hospital Germans Trias i Pujol, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Camps, Cristina AU - Camps C AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Rifa, Lorena AU - Rifa L AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Domenech, Montserrat AU - Domenech M AD - Medical Oncology Department, Althaia Xarxa Assistencial Universitaria de Manresa, C/Dr. Joan Soler 1-3, 08243 Manresa, Spain. FAU - Ruiz de Porras, Vicenc AU - Ruiz de Porras V AUID- ORCID: 0000-0002-4352-1784 AD - GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain. FAU - Esteve, Anna AU - Esteve A AUID- ORCID: 0000-0002-1962-971X AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. FAU - Font, Albert AU - Font A AD - Medical Oncology Department, Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cami de les Escoles, s/n, 08916 Badalona, Spain. AD - Badalona Applied Research Group in Oncology (B.ARGO), Catalan Institute of Oncology, Cami de les Escoles, s/n, 08916 Badalona, Spain. LA - eng PT - Journal Article DEP - 20260624 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13359792 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - neoadjuvant therapy OT - nomogram OT - prognosis OT - risk assessment OT - survival analysis COIS- The authors declare no conflicts of interest. EDAT- 2026/07/15 10:10 MHDA- 2026/07/15 10:11 PMCR- 2026/06/24 CRDT- 2026/07/15 01:00 PHST- 2026/05/29 00:00 [received] PHST- 2026/06/22 00:00 [revised] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/07/15 10:11 [medline] PHST- 2026/07/15 10:10 [pubmed] PHST- 2026/07/15 01:00 [entrez] PHST- 2026/06/24 00:00 [pmc-release] AID - cancers18132054 [pii] AID - cancers-18-02054 [pii] AID - 10.3390/cancers18132054 [doi] PST - epublish SO - Cancers (Basel). 2026 Jun 24;18(13):2054. doi: 10.3390/cancers18132054. PMID- 42448544 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260819 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 9 DP - 2026 Sep TI - Network meta-analysis of immune checkpoint inhibitors in BCG-naive, high-risk non-muscle-invasive bladder cancer. PG - 369-376 LID - S1078-1439(26)00565-X [pii] LID - 10.1016/j.urolonc.2026.06.007 [doi] AB - PURPOSE: Bacillus Calmette-Guerin (BCG) remains the standard first-line therapy for BCG-naive high-risk non-muscle-invasive bladder cancer (NMIBC), yet recurrence and progression remain clinically significant. Multiple phase III trials have evaluated immune checkpoint inhibitors (ICIs) combined with BCG, but the relative efficacy of individual agents and the influence of carcinoma in situ (CIS) remain unclear. We performed a network meta-analysis (NMA) to compare ICI-based regimens and assess treatment ranking, with CIS stratification. METHODS: A frequentist NMA was performed using phase III randomized trials comparing ICI plus BCG vs. BCG alone in BCG-naive high-risk NMIBC. Included trials were ALBAN (atezolizumab plus BCG), Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment (CREST) (sasanlimab plus BCG), and POTOMAC (durvalumab plus BCG). The primary endpoint was event-based disease control, defined as event-free survival (EFS) or disease-free survival (DFS), which were analyzed jointly given their comparable definitions across trials. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted using BCG as the reference comparator. Treatments were ranked using P-scores. Sensitivity and CIS-stratified analyses were conducted. RESULTS: Durvalumab plus BCG (HR 0.68; 95% CI 0.50-0.93) and sasanlimab plus BCG (HR 0.68; 95% CI 0.49-0.94) significantly improved event-based outcomes compared with BCG alone, whereas atezolizumab plus BCG did not (HR 0.98; 95% CI 0.71-1.36). Durvalumab and sasanlimab ranked highest by P-score (0.81 each), whereas atezolizumab (0.22) approximated BCG alone (0.16). CIS-stratified analyses were hypothesis-generating and revealed differences in event-based rankings, with durvalumab ranking highest in CIS-absent disease and sasanlimab ranking highest in CIS-present disease. Results were consistent across sensitivity analyses. Grade >/=3 TRAEs were more frequent with ICI plus BCG than BCG alone (21%-29% vs. 3.8%-8.8%), while CREST and POTOMAC reported no clinically meaningful decline in health-related quality of life with combination therapy. CONCLUSIONS: In this NMA, durvalumab plus BCG and sasanlimab plus BCG significantly reduced events vs. BCG alone (HR 0.68 each), whereas atezolizumab plus BCG did not (HR 0.98; 95% CI 0.71-1.36). Pairwise indirect comparisons between active regimens were not statistically significant; point estimates and P-scores are consistent with a 2-tier efficacy pattern but do not establish between-agent differences. CIS-stratified subgroup analyses are exploratory and require confirmation. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - McGrath, Joseph AU - McGrath J AD - Department of Urology, University of Florida College of Medicine, Jacksonville, FL. FAU - Banerjee, Indraneel AU - Banerjee I AD - Department of Urology, University of Florida College of Medicine, Jacksonville, FL. FAU - Ishiyama, Yudai AU - Ishiyama Y AD - Department of Urology, University of Florida College of Medicine, Jacksonville, FL. FAU - Balaji, K C AU - Balaji KC AD - Department of Urology, University of Florida College of Medicine, Jacksonville, FL. Electronic address: kc.balaji@jax.ufl.edu. LA - eng PT - Journal Article PT - Network Meta-Analysis DEP - 20260714 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology MH - *BCG Vaccine/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Carcinoma in situ OT - Disease-free survival OT - Immunotherapy OT - Urinary bladder neoplasms COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/15 04:09 MHDA- 2026/08/19 23:42 CRDT- 2026/07/14 21:52 PHST- 2026/02/24 00:00 [received] PHST- 2026/05/21 00:00 [revised] PHST- 2026/06/10 00:00 [accepted] PHST- 2026/08/19 23:42 [medline] PHST- 2026/07/15 04:09 [pubmed] PHST- 2026/07/14 21:52 [entrez] AID - S1078-1439(26)00565-X [pii] AID - 10.1016/j.urolonc.2026.06.007 [doi] PST - ppublish SO - Urol Oncol. 2026 Sep;44(9):369-376. doi: 10.1016/j.urolonc.2026.06.007. Epub 2026 Jul 14. PMID- 42441309 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260713 LR - 20260813 IS - 2391-5463 (Print) IS - 2391-5463 (Electronic) VI - 21 IP - 1 DP - 2026 Jan TI - Analysis of the relationship between serum LAMC2, TROAP and clinical stages and prognosis of non-muscle invasive bladder cancer. PG - 20261481 LID - 10.1515/med-2026-1481 [doi] LID - 20261481 AB - OBJECTIVES: To investigate the relationship between serum LAMC2 and TROAP levels and clinical stage and prognosis in non-muscle invasive bladder cancer (NMIBC) patients. METHODS: Serum LAMC2 and TROAP levels were measured in 102 NMIBC patients and 104 healthy controls. NMIBC patients were followed up and grouped by survival status. Correlations, prognostic factors, and diagnostic value were analyzed. RESULTS: The serum levels of LAMC2 and TROAP in the research group were higher than those in the control group, and the two were positively correlated (r=0.303, p=0.002). The proportion of patients with high serum expression of LAMC2 and TROAP in stages III-IV was higher than that in patients with low expression (p<0.05). The 3-year survival rate of patients with high expression of LAMC2 and TROAP was lower than that of patients with low expression of both (p<0.05). Elevated levels of serum LAMC2 and TROAP, as well as TNM stages III-IV, were risk factors for mortality in NMIBC patients (p<0.05). The combined diagnosis of serum LAMC2 and TROAP showed better AUC than single diagnosis (Z=2.234, 2.864, p<0.05). CONCLUSIONS: Elevated serum LAMC2 and TROAP are linked to advanced stage and poor prognosis in NMIBC. Their combination improves prognostic diagnostic value. CI - (c) 2026 the author(s), published by De Gruyter, Berlin/Boston. FAU - He, Xiaolong AU - He X AUID- ORCID: 0009-0005-1238-2426 AD - Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, 341000, Ganzhou City, China. FAU - Zhu, Haiqin AU - Zhu H AUID- ORCID: 0009-0004-3649-7116 AD - Department of Personnel, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, 341000, Ganzhou City, China. FAU - Huang, Yongming AU - Huang Y AUID- ORCID: 0009-0006-5225-1380 AD - Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, 341000, Ganzhou City, China. FAU - Deng, Xiaolin AU - Deng X AUID- ORCID: 0009-0008-7374-9609 AD - Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, 341000, Ganzhou City, China. FAU - Huang, Jianrong AU - Huang J AUID- ORCID: 0009-0001-2117-8831 AD - Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, 341000, Ganzhou City, China. LA - eng PT - Journal Article DEP - 20260706 PL - Poland TA - Open Med (Wars) JT - Open medicine (Warsaw, Poland) JID - 101672167 PMC - PMC13336265 OTO - NOTNLM OT - Laminin gamma2 OT - bladder cancer OT - clinical stage OT - prognosis OT - trophinin-associated protein COIS- Conflict of interest: The authors state no conflict of interest. EDAT- 2026/07/13 22:51 MHDA- 2026/07/13 22:52 PMCR- 2026/07/06 CRDT- 2026/07/13 12:49 PHST- 2025/06/13 00:00 [received] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/07/13 22:52 [medline] PHST- 2026/07/13 22:51 [pubmed] PHST- 2026/07/13 12:49 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - med-2026-1481 [pii] AID - 10.1515/med-2026-1481 [doi] PST - epublish SO - Open Med (Wars). 2026 Jul 6;21(1):20261481. doi: 10.1515/med-2026-1481. eCollection 2026 Jan. PMID- 42440727 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260713 LR - 20260926 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics. PG - 1845015 LID - 10.3389/fonc.2026.1845015 [doi] LID - 1845015 AB - Urinary bladder cancer (UBC) remains a major global health burden, with high recurrence rates and limited therapeutic options for patients who fail standard intravesical and systemic treatments. In recent years, Living Cancer Therapeutics (LCTs)-including bacteria-, virus-, and microbiome-based oncobiotics-emerged as innovative biological strategies capable of overcoming key limitations of conventional cancer therapies. This article is a narrative review aimed at mapping the mechanistic landscape, historical development, and translational progress of LCTs in UBC. Five interrelated mechanisms were identified through which oncobiotics exert therapeutic effects: (i) direct tumor destruction via bacterial colonization, cytolysis, and metabolic deprivation; (ii) immune system modulation through innate and adaptive immune activation; (iii) engineered drug delivery and synthetic biology enabling programmable, tumor-restricted payload release; (iv) oncolytic virotherapy combining selective tumor lysis with immune priming; and (v) microbiome-driven immune modulation influencing treatment responsiveness. Although conceptually distinct, these mechanisms frequently overlap in practice, reflecting the multifunctional nature of living therapeutics. Clinical translation has progressed furthest for immune-mediated approaches such as Bacillus Calmette-Guerin (BCG) and selected oncolytic viral platforms, particularly in BCG-unresponsive UBC, although current evidence remains limited by small studies, heterogeneous endpoints, and insufficient long-term follow-up. Advances in genetic engineering and synthetic biology have enabled the development of increasingly sophisticated investigational platforms, including engineered oncolytic viruses, programmable bacterial vectors, and microbiome-based therapeutic strategies; however, most remain at an early preclinical or translational stage. UBC may represent a favorable setting for LCT development due to the accessibility of the bladder and the established use of intravesical therapies, although delivery efficiency and therapeutic durability remain important challenges. Despite encouraging early findings, significant limitations persist, including biological delivery barriers, host immune neutralization, interpatient heterogeneity, biosafety concerns, regulatory complexity, and the scarcity of late-phase randomized clinical data. Further translational research, biomarker development, and long-term clinical evaluation will therefore be required to determine the future role of LCTs in UBC management. CI - Copyright (c) 2026 Abuhasanein. FAU - Abuhasanein, Suleiman AU - Abuhasanein S AD - Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Department of Surgery, Urology section, NAL and Uddevalla (NU)-Hospital Group, Uddevalla, Region Vastra Gotaland, Sweden. AD - Department of Research and Development, NU-Hospital Group, Trollhattan, Region Vastra Gotaland, Sweden. LA - eng PT - Journal Article PT - Review DEP - 20260622 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 EIN - Front Oncol. 2026 Sep 10;16:1951323. doi: 10.3389/fonc.2026.1951323. PMID: 42787474 PMC - PMC13333517 OTO - NOTNLM OT - bacteria OT - bladder cancer OT - immunotherapy OT - living cancer therapeutics OT - oncobiotics OT - oncolytic viruses OT - probiotics COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/13 22:43 MHDA- 2026/07/13 22:44 PMCR- 2026/06/22 CRDT- 2026/07/13 12:24 PHST- 2026/04/01 00:00 [received] PHST- 2026/05/26 00:00 [revised] PHST- 2026/06/01 00:00 [accepted] PHST- 2026/07/13 22:44 [medline] PHST- 2026/07/13 22:43 [pubmed] PHST- 2026/07/13 12:24 [entrez] PHST- 2026/06/22 00:00 [pmc-release] AID - 10.3389/fonc.2026.1845015 [doi] PST - epublish SO - Front Oncol. 2026 Jun 22;16:1845015. doi: 10.3389/fonc.2026.1845015. eCollection 2026. PMID- 42436789 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260712 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 6 DP - 2026 Jun 30 TI - Impact of age on the effectiveness of intravesical Bacillus Calmette‑Guerin and gemcitabine/docetaxel in treatment-naive high-risk non‑muscle‑invasive bladder cancer. PG - 215 LID - 10.21037/tau-2026-0216 [doi] LID - 215 AB - BACKGROUND: Intravesical Bacillus Calmette‑Guerin (BCG) has long been the standard therapy for high‑risk non‑muscle‑invasive bladder cancer (HR‑NMIBC), yet treatment response may vary with age. Sequential intravesical gemcitabine/docetaxel (Gem/Doce) has emerged as a well‑tolerated and effective alternative, particularly during periods of BCG shortage, contributing to its increasing global adoption. However, the influence of age on oncologic outcomes with either regimen remains unclear, with prior studies reporting heterogeneous results, especially within BCG‑treated cohorts. This study evaluated the impact of age on the effectiveness of intravesical BCG and Gem/Doce in treatment‑naive patients with HR‑NMIBC. METHODS: We retrospectively reviewed data on treatment naive HR-NMIBC patients treated with BCG or sequential Gem/Doce from 2011-2024. The BCG cohort received a 6‑week induction course followed by maintenance at 3, 9, and 15 months. Gem/Doce consisted of six weekly induction instillations, followed by monthly maintenance for up to 24 months in patients who responded to induction. Age groups were defined as <60, 60-69, 70-79, and >/=80 years. Recurrence‑free survival (RFS) and high‑grade RFS (HG‑RFS) were estimated using Kaplan-Meier analysis, and age‑related recurrence risk was evaluated using univariate Cox regression. RESULTS: A total of 401 patients were included (BCG =192; Gem/Doce =209), with median follow-up of 84 months [interquartile range (IQR), 54-127 months] and 44 months (IQR, 28-62 months), respectively. Age was not significantly associated with RFS or HG-RFS in either cohort (BCG: for RFS, continuous age P=0.13 and categorical age P=0.15; for HG‑RFS, continuous age P=0.07 and categorical age P=0.12; Gem/Doce: for RFS, continuous age P=0.62 and categorical age P=0.44; for HG‑RFS, continuous age P=0.51 and categorical age P=0.68). In the BCG cohort, descriptive analyses showed a progressive decline in RFS and HG-RFS with advancing age, particularly among patients >/=70 years, who demonstrated lower 12- and 24-month outcomes (e.g., 24-month RFS: 64% for <60 years vs. 58% for 70-79 years and 59% for >/=80 years). In contrast, age‑related differences in the Gem/Doce cohort were smaller and primarily evident during early follow‑up (12 months); patients aged 70-79 and >/=80 years maintained stable outcomes at later time points (24 and 36 months) and did not exhibit lower outcomes (e.g., 24-month RFS: 73% for <60 years vs. 80% for 70-79 years and 76% for >/=80 years). CONCLUSIONS: Age was not a statistically significant predictor of HG‑RFS following either BCG or Gem/Doce therapy when controlling for known clinicopathologic risk factors. Although not statistically significant, a trend toward lower recurrence outcomes in older BCG‑treated patients was observed and warrants further investigation. CI - (c) AME Publishing Company. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Myers, Amanda A AU - Myers AA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Marchetti, Kathryn A AU - Marchetti KA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Zakharia, Yousef AU - Zakharia Y AD - Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. LA - eng PT - Journal Article DEP - 20260616 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13355279 OTO - NOTNLM OT - Bacillus Calmette-Guerin-naive (BCG-naive) OT - Non-muscle-invasive bladder cancer (NMIBC) OT - age OT - docetaxel OT - gemcitabine COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2026-0216/coif). M.A.C. serves as an unpaid editorial board member of Translational Andrology and Urology from August 2025 to June 2027. M.A.O. has received consulting fees from Fidia Farmaceuticals, Theralase, and Urogen; received honoraria from Merck; and serves on the data safety monitoring board for Combat Medical. The other authors have no conflicts of interest to declare. EDAT- 2026/07/12 10:09 MHDA- 2026/07/12 10:10 PMCR- 2026/06/30 CRDT- 2026/07/12 04:05 PHST- 2026/03/06 00:00 [received] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/07/12 10:10 [medline] PHST- 2026/07/12 10:09 [pubmed] PHST- 2026/07/12 04:05 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - tau-15-06-215 [pii] AID - 10.21037/tau-2026-0216 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Jun 30;15(6):215. doi: 10.21037/tau-2026-0216. Epub 2026 Jun 16. PMID- 42436788 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260712 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 6 DP - 2026 Jun 30 TI - Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances. PG - 221 LID - 10.21037/tau-2026-0342 [doi] LID - 221 AB - BACKGROUND AND OBJECTIVE: Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates and heterogeneous progression risk, making accurate diagnosis, risk stratification, and personalized management challenging. Conventional clinical scoring systems provide general guidance but often fail to fully capture tumor complexity and interpatient variability. This review summarizes current applications of artificial intelligence (AI) in NMIBC, focusing on diagnosis, prognostic, and clinical decision-making. METHODS: A comprehensive literature search was conducted in PubMed, Google Scholar, Embase and Scopus. Keywords related to AI and NMIBC including machine learning, deep learning, imaging, cystoscopy, radiomics, and computational pathology were used. Studies were independently screened, followed by full-text assessment for eligibility. A total of 35 English-language studies, published between January 2019 and March 2026, were included in the final qualitative synthesis. KEY CONTENT AND FINDINGS: AI applications in NMIBC span cystoscopy, imaging, histopathology, and prognostic modeling, demonstrating high diagnostic and predictive performance. In cystoscopy, deep learning models achieve sensitivities ranging from 88% to 97% and specificities from 92% to 99%, with area under the curves (AUCs) up to 0.98-0.99. Real-time segmentation reports Dice coefficients between 74% and 93%, with processing times approximately 6-7 ms per image. In imaging, AI-based radiomics and deep learning applied to magnetic resonance imaging (MRI) and computed tomography (CT) provide AUCs ranging from 0.82 to 0.99, often outperforming conventional models. Multiparametric MRI achieves AUCs of 0.88-0.91 for recurrence prediction, while CT-based models reach up to 0.997 for differentiating NMIBC from muscle-invasive disease. Prognostic models using machine learning, including random survival forests and neural networks, demonstrate improved discrimination compared to traditional scores, with concordance indices up to 0.79-0.88, enabling more granular risk stratification. In histopathology, AI-driven analysis of whole-slide images achieves accuracies of 74-90% for recurrence prediction and AUCs up to 0.86, while identifying patients at significantly higher risk of progression or treatment failure. CONCLUSIONS: AI enhances NMIBC management by enabling more precise, reproducible, and individualized diagnosis and risk assessment. The integration of multimodal data may improve clinical decision-making and support personalized treatment strategies, although further validation and standardization are required before widespread clinical implementation. CI - (c) AME Publishing Company. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AUID- ORCID: 0009-0000-5263-1398 AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. AD - Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Ingles, John Cris AU - Ingles JC AD - Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Zhu, Alec AU - Zhu A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Horowitz, Amir AU - Horowitz A AD - Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20260624 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13355248 OTO - NOTNLM OT - Non-muscle-invasive bladder cancer (NMIBC) OT - artificial intelligence (AI) OT - deep learning OT - precision medicine OT - risk stratification COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2026-0342/coif). The authors have no conflicts of interest to declare. EDAT- 2026/07/12 10:09 MHDA- 2026/07/12 10:10 PMCR- 2026/06/30 CRDT- 2026/07/12 04:05 PHST- 2026/04/10 00:00 [received] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/07/12 10:10 [medline] PHST- 2026/07/12 10:09 [pubmed] PHST- 2026/07/12 04:05 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - tau-15-06-221 [pii] AID - 10.21037/tau-2026-0342 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Jun 30;15(6):221. doi: 10.21037/tau-2026-0342. Epub 2026 Jun 24. PMID- 42436677 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260712 LR - 20260813 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 90 DP - 2026 Aug TI - Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study. PG - 92-100 LID - 10.1016/j.euros.2026.06.011 [doi] AB - BACKGROUND AND OBJECTIVE: Substaging of T1 bladder cancer (BC) was implemented in Denmark in 2010 based on depth of lamina propria invasion-pT1a (superficial) and pT1b (deep)-with bladder-sparing therapy recommended for pT1a and early cystectomy for pT1b. This study evaluated outcomes of this substage-guided approach in a nationwide cohort. METHODS: In this nationwide register-based study (2012-2018), all patients diagnosed with T1 BC were identified from the Danish Bladder Cancer Database. Patients were stratified by substage (pT1a, pT1b, unspecified pT1). Overall survival was estimated using Kaplan-Meier analysis; intravesical recurrence and progression were analysed using the Aalen-Johansen estimator, treating death as a competing risk; hazard ratios (HRs) were calculated using Cox models adjusted for sex, age, and comorbidities. KEY FINDINGS AND LIMITATIONS: Among 3086 patients (pT1a: 1,542; pT1b: 1,195; unspecified pT1: 349), the 5-yr overall survival (OS) was 67% for pT1a, 53% for pT1b, and 53% for unspecified pT1 (p < 0.001). The 5-yr cumulative incidence of intravesical recurrence was 19% (95% CI: 17-22), 28% (95% CI: 24-32), and 29% (95% CI: 24-35), respectively (p < 0.001). Cause-specific HRs for recurrence and progression were significantly higher for pT1b and unspecified pT1 versus pT1a. As treatment was stratified by substage, outcomes reflect both tumour biology and management. Main limitations relate to the register-based design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Nationwide T1 substaging was feasible and retained prognostic value. pT1b disease was associated with worse outcomes, and one in five patients with pT1b who underwent cystectomy had muscle-invasive disease. These findings support substage-based management while warranting prospective evaluation accounting for treatment selection. CI - (c) 2026 The Author(s). FAU - Nielsen, Ninna K AU - Nielsen NK AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Urology, Godstrup Regional Hospital, Godstrup, Denmark. FAU - Hjort, Peter B AU - Hjort PB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Hansen, Erik B AU - Hansen EB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Graugaard-Jensen, Charlotte AU - Graugaard-Jensen C AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Urology, Godstrup Regional Hospital, Godstrup, Denmark. FAU - Jakobsen, Jakob K AU - Jakobsen JK AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Kingo, Pernille S AU - Kingo PS AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Greenland Centre for Health Research, Institute for Health and Nature, Ilisimatusarfik/University of Greenland, Nuuk, Greenland. LA - eng PT - Journal Article DEP - 20260706 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC13355817 OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive bladder cancer OT - Pathological substaging OT - T1 substaging EDAT- 2026/07/12 06:38 MHDA- 2026/07/12 06:39 PMCR- 2026/07/06 CRDT- 2026/07/12 04:03 PHST- 2026/06/21 00:00 [accepted] PHST- 2026/07/12 06:39 [medline] PHST- 2026/07/12 06:38 [pubmed] PHST- 2026/07/12 04:03 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - S2666-1683(26)00649-X [pii] AID - 10.1016/j.euros.2026.06.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2026 Jul 6;90:92-100. doi: 10.1016/j.euros.2026.06.011. eCollection 2026 Aug. PMID- 42435772 OWN - NLM STAT- MEDLINE DCOM- 20261019 LR - 20261020 IS - 1474-5488 (Electronic) IS - 1470-2045 (Linking) VI - 27 IP - 8 DP - 2026 Aug TI - Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. PG - 973-982 LID - S1470-2045(26)00130-0 [pii] LID - 10.1016/S1470-2045(26)00130-0 [doi] AB - BACKGROUND: A previous phase 2 trial of single, postoperative intravesical instillation of pirarubicin after radical nephroureterectomy for upper tract urothelial carcinoma showed promising results in reducing the risk of bladder recurrence. We aimed to further evaluate the efficacy and adverse events of pirarubicin in this setting compared with the standard-of-care treatment of no intravesical instillation. METHODS: We did a multicentre, open-label, randomised, phase 3 trial (JCOG1403) with a two-stage registration at 44 institutes in the Urologic Oncology Study Group of the Japan Clinical Oncology Group. Eligible patients aged 20-80 years with previously untreated, clinical stage 0a-III upper tract urothelial carcinoma, and Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled in the first registration before radical nephroureterectomy. After surgery, patients underwent a second registration and were randomly assigned (1:1) to either pirarubicin (30 mg in 30 mL via intravesical instillation, received within 24 h after surgery) or observation using a central web-based minimisation method, stratified by institution, clinical T stage, and urine cytology results. Patients with pT3/T4 or pN+ status received adjuvant chemotherapy. The primary endpoint was relapse-free survival, analysed in the intention-to-treat population (all patients included in the second registration). Patients without an event were censored at the last date they were known to be alive and relapse-free; no imputation was performed. Adverse events were systematically assessed in the safety analysis population. The trial is registered with the Japan Registry of Clinical Trials, jRCTs031180121, and is complete. FINDINGS: Between Oct 3, 2016, and June 12, 2020, 352 participants were enrolled at the first registration. Of 348 patients who had a radical nephroureterectomy, 153 were randomly assigned to the pirarubicin group and 151 to the observation group at second registration. 226 (74%) patients were male and 78 (26%) were female. Median follow-up was 4.3 years (IQR 3.4-5.1). 3-year relapse-free survival was 60.0% (95% CI 51.7-67.3) in the pirarubicin group and 47.0% (38.7-54.9) in the observation group (hazard ratio 0.67 [90.96% CI 0.50-0.88]; p=0.0066). The most common grade 3-4 adverse event was haematuria, which occurred in four (3%) patients in the pirarubicin group and none in the observation group. No treatment-related serious adverse events or deaths were observed. INTERPRETATION: A single, postoperative pirarubicin instillation after radical nephroureterectomy is an efficacious treatment with manageable adverse events to reduce recurrence in patients with upper tract urothelial carcinoma. FUNDING: Japan Agency for Medical Research and Development and National Cancer Centre Research and Development Fund, Japan. CI - Copyright (c) 2026 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: akihiro.ito.c5@tohoku.ac.jp. FAU - Arai, Yoichi AU - Arai Y AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Kakehi, Yoshiyuki AU - Kakehi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Yokoyama, Masayuki AU - Yokoyama M AD - Japan Clinical Oncology Group Data Center, Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Sasaki, Keita AU - Sasaki K AD - Japan Clinical Oncology Group Data Center, Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Takahashi, Atsushi AU - Takahashi A AD - Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Nishimura, Kazuo AU - Nishimura K AD - Department of Urology, Osaka International Cancer Institute, Osaka, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Institution of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan. FAU - Yoshimura, Koji AU - Yoshimura K AD - Department of Urology, Shizuoka General Hospital, Shizuoka, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Hospital, Kyoto, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Kyushu University Hospital, Fukuoka, Japan. FAU - Igawa, Tsukasa AU - Igawa T AD - Department of Urology, Kurume University School of Medicine, Kurume, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Mochizuki, Takanori AU - Mochizuki T AD - Department of Urology, University of Yamanashi Faculty of Medicine, Chuo, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Department of Urology, Hara Sanshin Hospital, Fukuoka, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. FAU - Sato, Takuma AU - Sato T AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Institution of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. CN - Urologic Oncology Study Group of the Japan Clinical Oncology Group LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260711 PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Young Adult MH - Administration, Intravesical MH - *Antineoplastic Agents/administration & dosage/adverse effects MH - *Carcinoma, Transitional Cell/pathology/surgery/drug therapy MH - *Doxorubicin/analogs & derivatives/administration & dosage/adverse effects/analogs & derivatives MH - Japan MH - *Kidney Neoplasms/pathology/surgery MH - Neoplasm Recurrence, Local/prevention & control/pathology MH - *Nephroureterectomy/adverse effects MH - *Ureteral Neoplasms/pathology/surgery MH - *Urinary Bladder Neoplasms/prevention & control/pathology COIS- Declaration of interests ME reports research funding from MSD and honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Janssen Pharmaceutical, Merck Biopharma, Novartis, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical. MS reports honoraria for lectures from AstraZeneca and Bayer. KS reports institutional grants from the Japan Agency for Medical Research and Development. All other authors declare no competing interests. EDAT- 2026/07/12 00:56 MHDA- 2026/10/19 11:36 CRDT- 2026/07/11 18:52 PHST- 2025/11/27 00:00 [received] PHST- 2026/02/28 00:00 [revised] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/10/19 11:36 [medline] PHST- 2026/07/12 00:56 [pubmed] PHST- 2026/07/11 18:52 [entrez] AID - S1470-2045(26)00130-0 [pii] AID - 10.1016/S1470-2045(26)00130-0 [doi] PST - ppublish SO - Lancet Oncol. 2026 Aug;27(8):973-982. doi: 10.1016/S1470-2045(26)00130-0. Epub 2026 Jul 11. PMID- 42431961 OWN - NLM STAT- Publisher LR - 20260710 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) DP - 2026 Jul 15 TI - Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer. LID - 10.1038/s41598-026-60910-2 [doi] AB - Response to intravesical Bacillus Calmette-Guerin (BCG) varies among patients with intermediate/high-risk non-muscle-invasive bladder cancer (NMIBC). We investigated whether tumor-infiltrating memory B cells (MBCs) and tertiary lymphoid structures (TLSs) are associated with BCG response. RNA-sequencing data from GSE176178 served as the discovery cohort for identifying immune-cell subsets associated with BCG response via CIBERSORT deconvolution. In an independent validation cohort of 79 BCG-treated NMIBC patients, pre-BCG transurethral resection of bladder tumor (TURBT) specimens were evaluated by hematoxylin and eosin staining and multiplex immunohistochemistry to quantify MBC infiltration and TLS features. Paired post-BCG recurrent TURBT specimens from 16 non-responders were used for exploratory analyses of immune changes after BCG failure. Pretreatment intratumoral MBC abundance was higher in responders than in non-responders (P = 0.0009), as was TLS density (P = 0.0026). In paired samples from non-responders, post-BCG recurrent tumors showed reduced MBC levels (P = 0.0250) and a numerical increase in primary follicle-like TLSs. Higher MBC proportion and the presence of secondary follicle-like TLSs (S-TLSs) were associated with longer recurrence-free survival (RFS), with the optimal response observed when MBCs were spatially embedded within S-TLSs. In multivariable analyses, T1 stage, high MBC infiltration, and S-TLS presence independently predicted RFS. Enrichment of MBCs within mature S-TLSs is associated with improved BCG responsiveness and longer RFS in NMIBC, supporting MBC/S-TLS features as candidate biomarkers to predict BCG benefit and refine patient stratification. CI - (c) 2026. The Author(s). FAU - Wang, Haitao AU - Wang H AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Ji, Ying-Ang AU - Ji YA AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Luo, Weiming AU - Luo W AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Xie, Qiubo AU - Xie Q AD - Department of Urology, Chinese PLA General Hospital of Central Theater Command, Wuhan, Hubei, People's Republic of China. FAU - Ao, Yangkun AU - Ao Y AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Zhang, Jian AU - Zhang J AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Wang, Yapeng AU - Wang Y AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Ran, Qiang AU - Ran Q AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Zhang, Junying AU - Zhang J AD - Chongqing Medical and Pharmaceutical College, Chongqing, People's Republic of China. FAU - Xu, Jing AU - Xu J AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Zhang, Jun AU - Zhang J AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. FAU - Wang, Luofu AU - Wang L AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. wangluofu@163.com. AD - Department of Urology, Daping Hospital, Army Medical University, at 10#, Changjiang Zhilu, Yuzhong District, Chongqing, 400042, People's Republic of China. wangluofu@163.com. FAU - Jiang, Jun AU - Jiang J AD - Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China. jiangjun_64@163.com. FAU - Liu, Qiuli AU - Liu Q AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. liuqiuli900827@163.com. AD - Department of Urology, Daping Hospital, Army Medical University, at 10#, Changjiang Zhilu, Yuzhong District, Chongqing, 400042, People's Republic of China. liuqiuli900827@163.com. FAU - Lan, Weihua AU - Lan W AUID- ORCID: 0000-0003-1186-195X AD - Department of Urology, Army Medical Center of PLA, Army Medical University, Chongqing, People's Republic of China. doclan@yeah.net. AD - Department of Urology, Daping Hospital, Army Medical University, at 10#, Changjiang Zhilu, Yuzhong District, Chongqing, 400042, People's Republic of China. doclan@yeah.net. LA - eng GR - no. CSTB2022NSCQ-MSX0189/Chongqing Natural Science Foundation/ GR - nos. 82372758 and 82573508/National Natural Science Foundation of China/ GR - CSTB2024NSCQ-KJFZZDX0008/Key Project of Chongqing Natural Science Foundation/ GR - no. CSTB2024NSCQ-KJFZZDX0007/Key Project of Chongqing Natural Science Foundation/ GR - no. CSTB2025NSCQ-JQX0003/Chongqing Distinguished Young Scholars Program/ PT - Journal Article DEP - 20260715 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Memory B cells OT - Non-muscle-invasive bladder cancer OT - Responsiveness OT - Tertiary lymphoid structure COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval and informed consent: This study was approved by the Ethics Committee of the Army Medical Center (Approval No. 202517). Given its retrospective design, informed consent was waived by the Ethics Committee of the Army Medical Center. EDAT- 2026/07/11 05:37 MHDA- 2026/07/11 05:37 CRDT- 2026/07/10 23:18 PHST- 2026/02/10 00:00 [received] PHST- 2026/06/30 00:00 [accepted] PHST- 2026/07/11 05:37 [medline] PHST- 2026/07/11 05:37 [pubmed] PHST- 2026/07/10 23:18 [entrez] AID - 10.1038/s41598-026-60910-2 [pii] AID - 10.1038/s41598-026-60910-2 [doi] PST - aheadofprint SO - Sci Rep. 2026 Jul 15. doi: 10.1038/s41598-026-60910-2. PMID- 42425881 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260922 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 44 IP - 9 DP - 2026 Sep TI - Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer. PG - 377-387 LID - S1078-1439(26)00568-5 [pii] LID - 10.1016/j.urolonc.2026.06.010 [doi] AB - BACKGROUND: Sequential intravesical gemcitabine and docetaxel (Gem/Doce) are increasingly used for nonmuscle-invasive bladder cancer (NMIBC), especially in the setting of Bacillus Calmette-Guerin (BCG) shortage or failure. However, the contribution of docetaxel to gemcitabine remains unquantified. We compared the effectiveness of gemcitabine alone vs. Gem/Doce in high-risk NMIBC. METHODS: We conducted a retrospective study of 296 patients treated with gemcitabine (n = 173) or Gem/Doce (n = 123) at 3 Mayo Clinic sites between 2018 and 2023. The primary outcome was high-grade recurrence-free survival (HGRFS). Secondary outcomes included recurrence-free, progression-free, cystectomy-free, cancer-specific, and overall survival and adverse events. Analyses included Kaplan-Meier and Cox regression with 2-stage residual inclusion to adjust for confounding. RESULTS: Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P = 0.25]). Among patients with BCG-unresponsive carcinoma in situ (n = 49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P = 0.12]). No significant differences were observed for secondary outcomes. In the 2-stage residual inclusion analysis, Gem/Doce was not associated with improved HGRFS (hazard ratio [HR], 1.09; 95% CI, 0.65-1.82; P = 0.80), including among patients with BCG-unresponsive disease (HR, 2.24; 95% CI, 0.96-5.24 [P = .06]). Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P = 0.19]), but grade >/=3 adverse events were rare (2.3% vs. 2.4%). Limitations included imbalances in maintenance utilization (gemcitabine: 19%; Gem/Doce: 40%), baseline characteristics, gemcitabine dosing, and follow-up duration between cohorts. CONCLUSIONS: In this multicenter study, Gem/Doce was not associated with improved outcomes compared with gemcitabine alone. Prospective trials are needed to quantify the specific contribution of docetaxel in NMIBC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Moyer, Jacob A AU - Moyer JA AD - Department of Urology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Scottsdale, Arizona. FAU - Ashraf, Mahnoor AU - Ashraf M AD - Department of Urology, Mayo Clinic, Phoenix, Arizona. FAU - Mi, Lanyu AU - Mi L AD - Division of Clinical Trials and Biostatistics, Mayo Clinic, Scottsdale, Arizona. FAU - Zganjar, Andrew J AU - Zganjar AJ AD - Department of Urology, Mayo Clinic, Jacksonville, Florida. FAU - Lyon, Timothy D AU - Lyon TD AD - Department of Urology, Mayo Clinic, Jacksonville, Florida. FAU - Shah, Paras H AU - Shah PH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tyson, Mark D 2nd AU - Tyson MD 2nd AD - Department of Urology, Mayo Clinic, Phoenix, Arizona. Electronic address: Tyson.Mark@mayo.edu. LA - eng GR - P30 CA015083/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20260709 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) SB - IM MH - Humans MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/therapeutic use/administration & dosage/pharmacology MH - *Docetaxel/administration & dosage/therapeutic use/pharmacology MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Administration, Intravesical MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy MH - Aged, 80 and over PMC - PMC13360992 MID - NIHMS2189019 OTO - NOTNLM OT - Comparative effectiveness research OT - Docetaxel OT - Gemcitabine OT - Intravesical therapy OT - Nonmuscle-invasive bladder neoplasms COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/10 00:35 MHDA- 2026/08/19 23:42 PMCR- 2026/07/14 CRDT- 2026/07/09 21:53 PHST- 2026/02/02 00:00 [received] PHST- 2026/06/05 00:00 [revised] PHST- 2026/06/13 00:00 [accepted] PHST- 2026/08/19 23:42 [medline] PHST- 2026/07/10 00:35 [pubmed] PHST- 2026/07/09 21:53 [entrez] PHST- 2026/07/14 00:00 [pmc-release] AID - S1078-1439(26)00568-5 [pii] AID - 10.1016/j.urolonc.2026.06.010 [doi] PST - ppublish SO - Urol Oncol. 2026 Sep;44(9):377-387. doi: 10.1016/j.urolonc.2026.06.010. Epub 2026 Jul 9. PMID- 42420157 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260901 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. PG - 986-996 LID - S2588-9311(26)00182-3 [pii] LID - 10.1016/j.euo.2026.06.012 [doi] AB - CONTEXT: Bladder cancer ranks among the most common malignancies worldwide, with urothelial carcinoma as the predominant histological type. Its development from normal urothelium to non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) is driven by complex molecular events, including chromosomal aberrations, somatic mutations, and epigenetic dysregulation. Advances in next-generation sequencing (NGS) and transcriptomic profiling have transformed the understanding of urothelial tumor biology and opened new perspectives for precision oncology. OBJECTIVE: To provide an updated synthesis of molecular profiling in urothelial bladder cancer across disease stages and to discuss its diagnostic, prognostic, and therapeutic relevance. EVIDENCE ACQUISITION: We conducted a targeted narrative review based on a structured PubMed search of studies published between January 2000 and February 2026 using the keywords "genomic," "epigenetic," "transcriptomic," and "urothelial bladder cancer." Eligible publications included original research articles, reviews, and meta-analyses in English. Evidence was synthesized across NMIBC, MIBC, and metastatic disease, focusing on molecular alterations and their clinical relevance. EVIDENCE SYNTHESIS: Both NMIBC and MIBC present frequent TERT promoter mutations. NMIBC is further characterized by frequent FGFR3 and PIK3CA mutations, loss of chromosome 9, and widespread chromatin-remodeling gene alterations. MIBC displays high genomic instability, with recurrent mutations in TP53, RB1, and chromatin modifiers, as well as frequent alterations in the RTK/RAS/PI3K pathway. Consensus transcriptomic classifications identify reproducible molecular subtypes (luminal, basal/squamous, stroma rich, and neuroendocrine like), each with distinct biological and clinical behaviors. In metastatic disease, NGS and whole-exome analyses reveal strong concordance with localized tumors, with frequent TP53, ARID1A, KMT2D, RB1, and FGFR3 alterations and APOBEC mutational signatures. Transcriptomic profiling shows subtype heterogeneity and therapy-induced remodeling. Clinically, only FGFR3 alterations currently guide therapy, with erdafitinib approved by the US Food and Drug Administration and the European Medicines Agency for FGFR3-altered metastatic disease. Beyond tumor testing, circulating tumor DNA assays show promise for molecular residual disease detection and adjuvant treatment stratification. CONCLUSIONS: Molecular profiling has deepened the understanding of bladder cancer biology and identified potential biomarkers for diagnosis, prognosis, and treatment. However, clinical implementation remains limited, and prospective biomarker-driven trials are needed to establish the role of genomic and transcriptomic alterations in therapeutic decision-making. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Thibault, Constance AU - Thibault C AD - Department of Medical Oncology, Hopital Europeen Georges Pompidou, AP-HP, Paris Cite University, Paris, France; Institut du Cancer Paris CARPEM, AP-HP Centre, Paris Cite University, Paris, France; INSERM UMR-S 1147, University of Paris Cite, Centre de Recherche des Cordeliers, Paris, France. Electronic address: constance.thibault@aphp.fr. FAU - Blons, Helene AU - Blons H AD - Institut du Cancer Paris CARPEM, AP-HP Centre, Paris Cite University, Paris, France; INSERM UMR-S 1147, University of Paris Cite, Centre de Recherche des Cordeliers, Paris, France; Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hopital Europeen Georges Pompidou, AP-HP, Paris Cite University, Paris, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Institut Curie, PSL Research University, Paris, France. FAU - Harba, Alia AU - Harba A AD - Department of Medical Oncology, Hopital Europeen Georges Pompidou, AP-HP, Paris Cite University, Paris, France; Institut du Cancer Paris CARPEM, AP-HP Centre, Paris Cite University, Paris, France; INSERM UMR-S 1147, University of Paris Cite, Centre de Recherche des Cordeliers, Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Clinique Pasteur, Toulouse, France. FAU - Seisen, Thomas AU - Seisen T AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Hopital Pitie-Salpetriere, Sorbonne University, Paris, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. FAU - Leon, Priscilla AU - Leon P AD - UROSUD Urology Department, Clinique Croix Du Sud, Quint-Fonsegrives, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Hopital Saint-Louis AP-HP, Universite Paris Cite, Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - UROSUD Urology Department, Clinique Croix Du Sud, Quint-Fonsegrives, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique - Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Prost, Doriane AU - Prost D AD - Department of Urology, Hopital Saint-Louis AP-HP, Universite Paris Cite, Paris, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique - Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Laurent-Puig, Pierre AU - Laurent-Puig P AD - Institut du Cancer Paris CARPEM, AP-HP Centre, Paris Cite University, Paris, France; INSERM UMR-S 1147, University of Paris Cite, Centre de Recherche des Cordeliers, Paris, France; Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hopital Europeen Georges Pompidou, AP-HP, Paris Cite University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Hopital Pitie-Salpetriere, Sorbonne University, Paris, France. FAU - Audenet, Francois AU - Audenet F AD - INSERM UMR-S 1147, University of Paris Cite, Centre de Recherche des Cordeliers, Paris, France; Department of Urology, Hopital Europeen Georges Pompidou, AP-HP, Paris Cite University, Paris, France; Institut du Cancer Paris CARPEM, AP-HP Centre, Paris Cite University, Paris, France. CN - Cancer Committee of The French Association of Urology (CC-AFU) LA - eng PT - Journal Article PT - Review DEP - 20260708 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/therapy MH - *Clinical Decision-Making MH - *Carcinoma, Transitional Cell/genetics/pathology MH - Non-Muscle Invasive Bladder Neoplasms MH - *Gene Expression Profiling OTO - NOTNLM OT - Biomarkers OT - Gene expression profiling OT - Genomics OT - Metastatic urothelial carcinoma OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer OT - Transcriptomic classification OT - Urothelial bladder cancer EDAT- 2026/07/09 00:40 MHDA- 2026/09/01 23:34 CRDT- 2026/07/08 21:54 PHST- 2026/02/23 00:00 [received] PHST- 2026/06/05 00:00 [revised] PHST- 2026/06/18 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/07/09 00:40 [pubmed] PHST- 2026/07/08 21:54 [entrez] AID - S2588-9311(26)00182-3 [pii] AID - 10.1016/j.euo.2026.06.012 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):986-996. doi: 10.1016/j.euo.2026.06.012. Epub 2026 Jul 8. PMID- 42420156 OWN - NLM STAT- Publisher LR - 20260708 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 Jul 8 TI - MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. LID - S2588-9311(26)00154-9 [pii] LID - 10.1016/j.euo.2026.05.014 [doi] AB - OBJECTIVE: For patients with muscle-invasive bladder cancer (MIBC), accurate assessment of neoadjuvant therapy response may allow for bladder-sparing strategies, emphasizing the need for accurate, noninvasive response assessment. Multi-parametric magnetic resonance imaging (mpMRI) has emerged as a promising imaging modality, but its reproducibility and diagnostic performance following neoadjuvant immunotherapy remain underexplored. METHODS: We analyzed data from 115 patients across three prospective trials (NABUCCO, TURANDOT, and PURE-01). Patients underwent mpMRI after transurethral resection of bladder tumor and before neoadjuvant immunotherapy, and after neoadjuvant immunotherapy prior to radical cystectomy. Multiple radiologists assessed the radiological response using qualitative (AJCC Staging, nacVI-RADS, Visual Response, and RECIST 1.1) and quantitative (diameter, volumetric) criteria. Using Fleiss' kappa, Krippendorff's alpha, and intraclass-correlation coefficient (ICC), we assessed inter-radiologist variability. ROC-AUC (Receiver operator characteristic-area under the curve) assessed the diagnostic accuracy for pathological complete response (pCR) of the primary tumor, with correlations explored for circulating tumor (ctDNA) and tumor cell density. RESULTS: Visual assessment demonstrated high inter-radiologist agreement among qualitative methods (alpha = 0.79, 95% CI: [0.68-0.87]), while semi-automatic volumetric analysis showed high reproducibility and accuracy quantitatively (ICC = 0.93, 95% CI: [0.83-0.95], AUC = 0.8-0.98). Volumetric measurements showed moderate correlation with ctDNA and tumor cell density. All methods exhibited strong predictive performance for pCR, but longitudinal volume changes showed a good combination of reproducibility and accuracy. CONCLUSIONS: Semi-automatic volumetric mpMRI assessment is a reproducible and accurate tool for evaluating local response to neoadjuvant immunotherapy in MIBC. Despite focusing on the primary tumor, these findings support its potential as an imaging biomarker and foundation for future response criteria. However, confirming its role in clinical decision-making requires prospective validation. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Greidanus, Joyce AU - Greidanus J AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School for Oncology and Reproduction, Maastricht University, Masstricht, The Netherlands. Electronic address: joyce.greidanus@maastrichtuniversity.nl. FAU - van Dijk-de Haan, Margriet C AU - van Dijk-de Haan MC AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Messina, Antonella AU - Messina A AD - Department of Radiology, Fondazione IRCSS istituto Nazionale tumori, Milan, Italy; Department of Medical oncology, Fondazione IRCSS istituto Nazionale tumori, Milan, Italy. FAU - Calareso, Giuseppina AU - Calareso G AD - Department of Radiology, Fondazione IRCSS istituto Nazionale tumori, Milan, Italy; Department of Medical oncology, Fondazione IRCSS istituto Nazionale tumori, Milan, Italy. FAU - Bruining, Annemarie AU - Bruining A AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Westerink, Bram AU - Westerink B AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Dehghanpour, Ailin AU - Dehghanpour A AD - Department of Radiology, Sapienza University of Romeh Biostatistics Centre, Netherlands Cancer Institute. FAU - Tissier, Renaud AU - Tissier R AD - Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. FAU - van Dorp, Jeroen AU - van Dorp J AD - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Stockem, Chantal F AU - Stockem CF AD - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Pipinikas, Christodoulos AU - Pipinikas C AD - NeoGenomics Laboratories Inc. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - van der Poel, Henk G AU - van der Poel HG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. FAU - Beets-Tan, Regina G H AU - Beets-Tan RGH AD - GROW School for Oncology and Reproduction, Maastricht University, Masstricht, The Netherlands; Netherlands Cancer Institute, Amsterdam, The Netherlands; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Giannatempo, Patrizia AU - Giannatempo P AD - Department of Medical oncology, Fondazione IRCSS istituto Nazionale tumori, Milan, Italy. FAU - van der Heijden, Michiel S AU - van der Heijden MS AD - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Trebeschi, Stefano AU - Trebeschi S AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School for Oncology and Reproduction, Maastricht University, Masstricht, The Netherlands. FAU - Boellaard, Thierry N AU - Boellaard TN AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20260708 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Multiparametric MRI OT - Muscle-invasive bladder cancer OT - Neoadjuvant immunotherapy OT - Response assessment OT - Volumetric criteria EDAT- 2026/07/09 00:39 MHDA- 2026/07/09 00:39 CRDT- 2026/07/08 21:54 PHST- 2025/10/21 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/19 00:00 [accepted] PHST- 2026/07/09 00:39 [medline] PHST- 2026/07/09 00:39 [pubmed] PHST- 2026/07/08 21:54 [entrez] AID - S2588-9311(26)00154-9 [pii] AID - 10.1016/j.euo.2026.05.014 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 Jul 8:S2588-9311(26)00154-9. doi: 10.1016/j.euo.2026.05.014. PMID- 42419127 OWN - NLM STAT- MEDLINE DCOM- 20260909 LR - 20260909 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 85 DP - 2026 Dec TI - Determinants of nucleic acid quality in formalin-fixed paraffin-embedded bladder urothelial carcinoma specimens: effects of specimen type, fixation conditions, and storage time. PG - 152681 LID - S1092-9134(26)00077-8 [pii] LID - 10.1016/j.anndiagpath.2026.152681 [doi] AB - Formalin-fixed paraffin-embedded (FFPE) tissue is the principal substrate for cancer genomic profiling, yet pre-analytical factors affect nucleic acid quality. In our workflow, transurethral resection (TUR) specimens of bladder urothelial carcinoma are fixed promptly but exposed to electrocautery, whereas robot-assisted radical cystectomy specimens are refrigerated overnight before fixation; we compared nucleic acid quality between these specimen types. We analyzed 56 FFPE primary bladder urothelial carcinoma specimens (33 TUR, 23 cystectomy). DNA quality was assessed by the DNA Integrity Number (DIN) and short-to-long cycle threshold ratio (S/L Ct ratio), and RNA quality by the RNA Integrity Number (RIN) and percentage of RNA fragments >/=200 nucleotides (DV200), with group comparisons, Spearman correlations, and multivariable regression (specimen type, fixation duration, storage time). The median DIN (4.4 vs. 3.8, p = 0.004) and S/L Ct ratio (0.943 vs. 0.894, p < 0.001) were higher in TUR than cystectomy specimens; the RIN was also higher (1.9 vs. 1.7, p = 0.040), though low in both groups, and DV200 did not differ (50.3% vs. 47.7%, p = 0.934). In multivariable analysis, TUR specimen type independently predicted higher DIN (beta = +0.460, p = 0.040) and S/L Ct ratio (beta = +0.442, p = 0.009), whereas longer storage time independently decreased the S/L Ct ratio (beta = -0.513, p < 0.001) and RIN (beta = -0.352, p = 0.010). In our institutional workflow, TUR specimens showed higher DNA quality metrics than robot-assisted radical cystectomy specimens subjected to overnight refrigerated pre-fixation delay, whereas this workflow-associated advantage did not clearly extend to DV200-defined RNA fragment-length quality. Storage time was associated with selected aspects of nucleic acid deterioration. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Yuguchi, Shu AU - Yuguchi S AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Okubo, Yoichiro AU - Okubo Y AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. Electronic address: yoichiro0207@hotmail.com. FAU - Kasajima, Rika AU - Kasajima R AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Nakaigawa, Noboru AU - Nakaigawa N AD - Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Hiroshima, Yukihiko AU - Hiroshima Y AD - Department of Cancer Genome Medicine, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan; Advanced Cancer Therapeutics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Hasegawa, Chie AU - Hasegawa C AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Washimi, Kota AU - Washimi K AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Sato, Shinya AU - Sato S AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Yokose, Tomoyuki AU - Yokose T AD - Department of Pathology, Odawara Municipal Medical Center, 46 Kuno, Odawara, Kanagawa, 250-8558, Japan. FAU - Juichi, Tatsuma AU - Juichi T AD - Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Suzuki, Atsuto AU - Suzuki A AD - Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. FAU - Usui, Kimitsugu AU - Usui K AD - Department of Urology, Yokosuka Kyosai Hospital, 1-16 Yonegahama-dori, Yokosuka, Kanagawa, 238-8558, Japan. FAU - Miyagi, Yohei AU - Miyagi Y AD - Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. LA - eng PT - Journal Article DEP - 20260702 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 RN - 1HG84L3525 (Formaldehyde) RN - 0 (Nucleic Acids) RN - 9007-49-2 (DNA) RN - 0 (Fixatives) SB - IM MH - Humans MH - Paraffin Embedding/methods MH - *Urinary Bladder Neoplasms/pathology/genetics/surgery MH - Formaldehyde MH - Tissue Fixation/methods MH - *Specimen Handling/methods MH - *Nucleic Acids MH - Female MH - *Carcinoma, Transitional Cell/pathology/genetics MH - Time Factors MH - Cystectomy/methods MH - Transurethral Resection of Bladder MH - Male MH - DNA MH - Aged MH - Fixatives OTO - NOTNLM OT - Bladder urothelial carcinoma OT - DIN OT - DV200 OT - FFPE OT - Nucleic acid quality OT - Transurethral resection COIS- Declaration of competing interest The authors declare that they have no competing interests. EDAT- 2026/07/09 04:10 MHDA- 2026/09/09 23:36 CRDT- 2026/07/08 18:08 PHST- 2026/06/16 00:00 [received] PHST- 2026/06/29 00:00 [revised] PHST- 2026/06/30 00:00 [accepted] PHST- 2026/09/09 23:36 [medline] PHST- 2026/07/09 04:10 [pubmed] PHST- 2026/07/08 18:08 [entrez] AID - S1092-9134(26)00077-8 [pii] AID - 10.1016/j.anndiagpath.2026.152681 [doi] PST - ppublish SO - Ann Diagn Pathol. 2026 Dec;85:152681. doi: 10.1016/j.anndiagpath.2026.152681. Epub 2026 Jul 2. PMID- 42411237 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260813 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 41 IP - 26 DP - 2026 Jul 6 TI - Correlation Between the Natural Course and Magnetic Resonance Imaging Features of Bacillus Calmette-Guerin-Related Granulomatous Prostatitis in Patients With Bladder Cancer. PG - e178 LID - 10.3346/jkms.2026.41.e178 [doi] LID - e178 AB - BACKGROUND: To evaluate magnetic resonance imaging features and the natural course of granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy in patients with bladder cancer. METHODS: Using a radiologic report keyword search program, data were collected from magnetic resonance images between March 2018 and August 2023. A total of 241 baseline or follow-up magnetic resonance images of 64 patients with pathologically or clinically confirmed Bacillus Calmette-Guerin-related granulomatous prostatitis were retrospectively included. We investigated intravesical Bacillus Calmette-Guerin history, lesion size changes, and serum prostate-specific antigen changes through a chart review. Lesion imaging features were assessed on T1-. T2-, diffusion-, and contrast-enhanced T1-weighted images and classified based on enhancement degree and presence of diffusion restriction. RESULT: The completely improved group (n = 12), incompletely improved group (n = 26), and recurrent inflammation group (n = 13) were identified according to temporal magnetic resonance imaging changes of granulomatous prostatitis. Patients who underwent radical cystectomy or were lost to follow-up were excluded due to unknown outcomes (n = 13). Among 64 patients, subtle increased T1 signal intensity with granulomatous inflammation was observed in 57 (89.1%). The baseline prostate-specific antigen level in the recurrent inflammation group was 2.00 +/- 1.26 ng/mL, which was higher than the 1.0-1.1 ng/mL levels in the other groups (P = 0.050). Even if the lesion completely improved on magnetic resonance imaging, the serum prostate-specific antigen level increased by approximately 2.0 times compared to the baseline level. Lesion peak size (26.0 +/- 15.0 mm) in the incompletely improving group was significantly larger than that in the other groups (14.8 +/- 5.8 and 17.0 +/- 9.1 mm) (P = 0.006). Among the 77 initial magnetic resonance images, type A (n = 30, strong enhancement and diffusion restriction), type B (n = 25, rim enhancement with diffusion restriction), and mixed type (n = 19) were the most common. In the last 50 magnetic resonance images, type C (n = 34; no enhancement or diffusion restriction) was predominant. CONCLUSION: In patients who underwent intravesical Bacillus Calmette-Guerin therapy, bladder magnetic resonance imaging frequently revealed subtle T1-hyperintense lesion in the prostate with diffuse or rim-like enhancement accompanied by markedly restricted diffusion, which is highly suggestive of Bacillus Calmette-Guerin-related granulomatous prostatitis and tends to spontaneously regress on follow-up imaging. Even with radiological improvement, prostate-specific antigen levels may remain elevated and should not be mistaken for malignancy. CI - (c) 2026 The Korean Academy of Medical Sciences. FAU - Sim, Ki Choon AU - Sim KC AUID- ORCID: 0000-0002-3344-8018 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Sung, Deuk Jae AU - Sung DJ AUID- ORCID: 0000-0002-5025-3052 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. urorad@korea.ac.kr. FAU - Han, Na Yeon AU - Han NY AUID- ORCID: 0000-0001-8537-8165 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Han, Yeo Eun AU - Han YE AUID- ORCID: 0000-0002-3922-9326 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Park, Beom Jin AU - Park BJ AUID- ORCID: 0000-0002-7289-3683 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Kim, Min Ju AU - Kim MJ AUID- ORCID: 0000-0003-0979-9835 AD - Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article DEP - 20260706 PL - Korea (South) TA - J Korean Med Sci JT - Journal of Korean medical science JID - 8703518 RN - 0 (BCG Vaccine) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Humans MH - Male MH - *Prostatitis/diagnostic imaging/etiology/pathology MH - *Urinary Bladder Neoplasms/drug therapy/complications MH - *Magnetic Resonance Imaging MH - Middle Aged MH - Aged MH - *BCG Vaccine/adverse effects/therapeutic use/administration & dosage MH - Retrospective Studies MH - Prostate-Specific Antigen/blood MH - Administration, Intravesical MH - *Granuloma/diagnostic imaging MH - Aged, 80 and over PMC - PMC13338471 OTO - NOTNLM OT - Bacillus Calmette-Guerin Vaccine OT - Granulomatous Prostatitis OT - Intravesical Instillation OT - Magnetic Resonance Imaging OT - Prostatic Neoplasm OT - Urinary Bladder Neoplasm COIS- The authors have no potential conflicts of interest to disclose. EDAT- 2026/07/07 06:38 MHDA- 2026/07/07 13:10 PMCR- 2026/04/21 CRDT- 2026/07/07 04:13 PHST- 2025/05/26 00:00 [received] PHST- 2025/10/22 00:00 [accepted] PHST- 2026/07/07 13:10 [medline] PHST- 2026/07/07 06:38 [pubmed] PHST- 2026/07/07 04:13 [entrez] PHST- 2026/04/21 00:00 [pmc-release] AID - 41.e178 [pii] AID - 10.3346/jkms.2026.41.e178 [doi] PST - epublish SO - J Korean Med Sci. 2026 Jul 6;41(26):e178. doi: 10.3346/jkms.2026.41.e178. PMID- 42411043 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260903 IS - 1097-0339 (Electronic) IS - 8755-1039 (Print) IS - 1097-0339 (Linking) VI - 54 IP - 10 DP - 2026 Oct TI - Clinical and Cytopathological Significance of Intracytoplasmic Lumina and Immunohistochemical Mucin Expression in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. PG - 764-772 LID - 10.1002/dc.70178 [doi] AB - BACKGROUND: Intracytoplasmic lumina (ICL) are mucin-containing structures identified in histological and cytological specimens of urothelial carcinoma and are associated with high-grade tumors and poor prognosis. However, their biological significance remains unclear. This study investigated mucin expression in ICL and its association with clinical, cytopathological, and prognostic features in non-muscle-invasive urothelial carcinoma of the bladder. METHODS: A total of 105 cases of non-muscle-invasive urothelial carcinoma of the bladder diagnosed were examined. Immunohistochemical staining for MUC1, MUC2, MUC4, MUC5AC, and MUC6 was performed in 47 cases in which ICL were identified histologically, and the staining patterns of ICL and tumor cells were evaluated. The presence of ICL in urine cytology specimens was assessed, and its associations with tumor-specific survival and recurrence were analyzed statistically. RESULTS: ICL were identified in 47 cases histologically and in 33 cases cytologically. ICL-positive tumors were more frequently observed in high-grade histology and were more often diagnosed as malignant or suspicious for malignancy in urine cytology. Immunohistochemically, MUC1 was the most frequently expressed mucin, with localization along the microvilli of the ICL lumen and within luminal mucin. Increased expression of MUC4 and MUC5AC showed a trend toward decreased survival. CONCLUSION: ICL in non-muscle-invasive urothelial carcinoma is more frequently observed in high-grade tumors and shows characteristic mucin expression patterns, particularly MUC1 localization within ICL structures. Increased expression of MUC4 and MUC5AC may be associated with unfavorable clinical outcomes. These findings suggest that combined evaluation of ICL and mucin expression may provide additional prognostic information in urothelial carcinoma. CI - (c) 2026 Wiley Periodicals LLC. FAU - Terauchi, Toshie AU - Terauchi T AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. FAU - Nguyen, Thao Thanh AU - Nguyen TT AUID- ORCID: 0009-0009-6782-7479 AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. AD - Department of Pathology, Kanazawa Medical University Hospital, Kahoku, Ishikawa, Japan. FAU - Takata, Mao AU - Takata M AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. FAU - Shimizu, Ryo AU - Shimizu R AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. FAU - Tsubata, Yumi AU - Tsubata Y AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. FAU - Okanemasa, Yoshiiku AU - Okanemasa Y AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. FAU - Miyazawa, Katsuhito AU - Miyazawa K AUID- ORCID: 0000-0002-0331-3753 AD - Department of Urology, Kanazawa Medical University Hospital, Kahoku, Ishikawa, Japan. FAU - Yamada, Sohsuke AU - Yamada S AUID- ORCID: 0000-0003-2662-0024 AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. AD - Department of Pathology, Kanazawa Medical University Hospital, Kahoku, Ishikawa, Japan. FAU - Shioya, Akihiro AU - Shioya A AUID- ORCID: 0000-0002-1863-5368 AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan. AD - Department of Pathology, Kanazawa Medical University Hospital, Kahoku, Ishikawa, Japan. LA - eng GR - H2021-9/the Kanazawa Medical University Hospital Grant-in-Aid for Allied Health Professionals/ PT - Journal Article DEP - 20260706 PL - United States TA - Diagn Cytopathol JT - Diagnostic cytopathology JID - 8506895 RN - 0 (Mucins) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Mucins/metabolism MH - Male MH - Non-Muscle Invasive Bladder Neoplasms/pathology MH - Aged MH - Immunohistochemistry MH - *Biomarkers, Tumor/metabolism MH - *Urinary Bladder Neoplasms/pathology/metabolism MH - Middle Aged MH - Aged, 80 and over MH - Prognosis MH - *Carcinoma, Transitional Cell/pathology/metabolism MH - Adult PMC - PMC13532627 OTO - NOTNLM OT - bladder cancer OT - immunohistochemistry OT - intracytoplasmic lumina OT - mucin expression OT - prognostic marker OT - urine cytology OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2026/07/07 10:10 MHDA- 2026/09/01 17:39 PMCR- 2026/09/01 CRDT- 2026/07/07 02:43 PHST- 2026/06/17 00:00 [revised] PHST- 2026/05/11 00:00 [received] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/09/01 17:39 [medline] PHST- 2026/07/07 10:10 [pubmed] PHST- 2026/07/07 02:43 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - DC70178 [pii] AID - 10.1002/dc.70178 [doi] PST - ppublish SO - Diagn Cytopathol. 2026 Oct;54(10):764-772. doi: 10.1002/dc.70178. Epub 2026 Jul 6. PMID- 42410426 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261003 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 24 IP - 1 DP - 2026 Jul 6 TI - A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers. LID - 10.1186/s12967-026-08570-8 [doi] LID - 1224 AB - BACKGROUND: Lipid metabolism reprogramming is a hallmark of cancer, yet its systemic manifestations and functional implications in bladder cancer (BC) remain poorly understood. This study aimed to identify plasma lipidomic profiles with diagnostic, staging, and prognostic value in BC, and to explore their associations with thromboinflammatory mechanisms, particularly NETosis and thrombin generation. METHODS: Plasma lipidomics was characterized by ultra-high-performance liquid chromatography high-resolution mass spectrometry from 87 BC patients (non-muscle-invasive BC, NMIBC, and muscle-invasive BC, MIBC) and 30 controls. NETosis markers, active DNaseI concentration, C-reactive protein, fibrinogen, IL-6, prothrombin F1+2, thrombin-antithrombin (TAT) complexes, and thrombin generation tests (TGT) were assessed in parallel. Statistical analyses in R included PCA, ROC curve analysis, elastic net penalized logistic regression, Cox regression, natural cubic spline modeling for survival analyses, and pathway enrichment analyses. RESULTS: BC patients exhibited increased total lipid load and distinct lipidomic signatures. Phosphatidylcholine (PC) levels decreased with disease severity and were independently associated with poor overall survival (up to 85% reduction in MIBC). Multivariable elastic net models integrating lipidomic and clinical variables achieved high diagnostic accuracy for discriminating BC patients from controls (AUC = 0.943) and for distinguishing MIBC from NMIBC (AUC = 0.860). BC patients displayed increased NETosis, inflammation, and thrombin formation, while decreased active DNaseI. Potentially diagnostic lipids correlated with NETosis, inflammatory markers and TAT, and inversely with active DNaseI and TGT parameters. Given the cross-sectional and observational design, these findings should be interpreted as hypothesis-generating and do not allow causal inference. CONCLUSIONS: Plasma lipidomic profiling identifies biomarkers with diagnostic and prognostic potential in BC and reveals associations with NETosis, active DNaseI dysfunction, and thrombin generation. While causality cannot be inferred from this exploratory study, these findings support lipidomics as a minimally invasive tool for BC stratification and as a window into cancer-associated immunothrombosis, providing a rationale for future longitudinal and mechanistic studies targeting lipid-neutrophil interactions. CI - (c) 2026. The Author(s). FAU - Oto, Julia AU - Oto J AUID- ORCID: 0000-0003-3963-8661 AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. FAU - Herreros-Pomares, Alejandro AU - Herreros-Pomares A AUID- ORCID: 0000-0003-3838-097X AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. FAU - Verger, Patricia AU - Verger P AUID- ORCID: 0009-0002-8768-331X AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. FAU - Herranz, Raquel AU - Herranz R AUID- ORCID: 0000-0002-0894-2946 AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. FAU - Plana, Emma AU - Plana E AUID- ORCID: 0000-0002-8457-6984 AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. AD - Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, Valencia, Spain. FAU - Roca, Marta AU - Roca M AD - Analytical Unit Platform, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. FAU - Perez-Ardavin, Javier AU - Perez-Ardavin J AD - Urology Service, La Fe University and Polytechnic Hospital, Valencia, Spain. FAU - Vera-Donoso, Cesar D AU - Vera-Donoso CD AD - Urology Service, La Fe University and Polytechnic Hospital, Valencia, Spain. FAU - Martinez-Sarmiento, Manuel AU - Martinez-Sarmiento M AD - Urology Service, La Fe University and Polytechnic Hospital, Valencia, Spain. FAU - Bonanad, Santiago AU - Bonanad S AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. AD - Thrombosis and Haemostasis Unit, Haematology Service, La Fe University and Polytechnic Hospital, Valencia, Spain. FAU - Medina, Pilar AU - Medina P AUID- ORCID: 0000-0001-9637-5998 AD - Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain. medina_pil@gva.es. AD - Research Center, Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, La Fe University and Polytechnic Hospital, Health Research Institute La Fe (IIS La Fe), Valencia, Spain. medina_pil@gva.es. LA - eng PT - Journal Article DEP - 20260706 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - EC 3.4.21.5 (Thrombin) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Thrombin/metabolism/biosynthesis MH - *Urinary Bladder Neoplasms/blood/complications/pathology MH - *Lipidomics MH - Female MH - *Inflammation/blood/complications/pathology MH - Male MH - *Biomarkers, Tumor/blood MH - Middle Aged MH - Aged MH - *Extracellular Traps/metabolism MH - *Thrombosis/blood/complications MH - ROC Curve MH - Case-Control Studies PMC - PMC13628971 OTO - NOTNLM OT - Bladder cancer OT - Ceramide OT - DNaseI OT - Immunothrombosis OT - Lipidomics OT - Lipids OT - Neutrophil extracellular traps (NETs) OT - Phosphatidylcholine OT - Plasma biomarkers OT - Thrombin generation test COIS- Declarations. Ethics approval and consent to participate: The study was approved by the institutional ethics committee of La Fe University and Polytechnic Hospital (refs. 2014/0314 and 2020-101-1). Written informed consent was obtained from all participants. The study was conducted in accordance with the principles of the Declaration of Helsinki (Edinburgh amendment, 2000). Consent for publication: Not applicable. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/07 04:11 MHDA- 2026/10/01 05:30 PMCR- 2026/07/06 CRDT- 2026/07/06 23:57 PHST- 2025/11/10 00:00 [received] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/10/01 05:30 [medline] PHST- 2026/07/07 04:11 [pubmed] PHST- 2026/07/06 23:57 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - 10.1186/s12967-026-08570-8 [pii] AID - 8570 [pii] AID - 10.1186/s12967-026-08570-8 [doi] PST - epublish SO - J Transl Med. 2026 Jul 6;24(1):1224. doi: 10.1186/s12967-026-08570-8. PMID- 42406147 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jul 6 TI - Interpretable machine learning model of contrast-enhanced CT radiomics for predicting post-BCG recurrence in high-grade non-muscle-invasive bladder cancer. LID - 486 [pii] LID - 10.1007/s00345-026-06595-8 [doi] AB - BACKGROUND AND PURPOSE: While intravesical Bacillus Calmette-Guerin Vaccine (BCG) instillation remains standard adjuvant therapy for high-grade non-muscle-invasive bladder cancer (NMIBC) post-resection, marked interpatient response heterogeneity complicates recurrence prediction. This study develops a contrast-enhanced computed tomography (CT) radiomics-based machine learning model to quantify tumor heterogeneity and noninvasively predict 5-year recurrence in high-grade NMIBC. PATIENTS AND METHODS: This retrospective study included 136 patients with histopathologically confirmed high-grade NMIBC from our institution and an external cohort of 51 patients from an independent testing center. All patients underwent transurethral resection of bladder tumor (TURBT) followed by BCG instillation therapy. The internal cohort was randomly partitioned into a training set (n = 95) and a validation set (n = 41) at a 7:3 ratio, with an independent external test set (n = 51) used for external validation. All patients received contrast-enhanced CT prior to treatment. Independent clinicopathological predictors were identified through univariate and multivariate logistic regression analyses. Radiomics features were selected using the Least Absolute Shrinkage and Selection Operator (LASSO) regression, and a radiomics score (Radscore) was constructed. Four machine learning models-Gradient Boosting Decision Tree (GBDT), Support Vector Machine (SVM), Extreme Gradient Boosting (XGBoost), and Random Forest (RF)-were developed. Model performance was comprehensively evaluated via the area under the receiver operating characteristic curve (AUC), accuracy, precision, F1 score, confusion matrix, calibration curve, and decision curve analysis (DCA). Additionally, the interpretability of the models was assessed using Shapley Additive Explanations (SHAP). RESULTS: Multivariate logistic regression analysis identified tumor size (OR = 3.11, 95% CI: 1.16-8.34, p = 0.024), number of lesions (OR = 4.56, 95% CI: 1.52-13.70, p = 0.007), and tumor calcification (OR = 3.41, 95% CI: 1.15-10.15, p = 0.027) as independent clinical predictors of 5-year recurrence following BCG instillation. A total of 4,738 radiomic features were extracted from contrast-enhanced CT images, and the top 20 most discriminative features were selected via LASSO regression to construct the Radscore. Among the four machine learning models developed by combining clinical factors and Radscore, SVM demonstrated the superior performance, with an AUC of 0.816 (95% CI: 0.774-0.858), accuracy of 73.2%, precision of 74.3%, and F1 score of 0.734. This performance was significantly better than that of XGBoost (AUC = 0.727, 95% CI: 0.683-0.770; accuracy 65.9%, precision 65.4%, F1 score 0.655), RF (AUC = 0.717, 95% CI: 0.675-0.752; accuracy 68.3%, precision 67.9%, F1 score 0.677), and GBDT (AUC = 0.685, 95% CI: 0.633-0.740; accuracy 70.7%, precision 71.4%, F1 score 0.709). External validation using independent test sets confirmed these. RESULTS: SHAP analysis revealed that the number of lesions and Radscore were the most influential predictors in the SVM model. Calibration curves and DCA demonstrated that the SVM model exhibited robust stability and provided substantial clinical benefit. CONCLUSION: We developed an interpretable machine learning model derived from contrast-enhanced CT radiomics, integrating clinicopathological characteristics and quantitative radiomic features to accurately predict the 5-year recurrence risk in patients with high-grade NMIBC following BCG instillation. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Zou, Xin Chang AU - Zou XC AD - The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China. FAU - Yu, Zhan Jiang AU - Yu ZJ AD - The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China. FAU - Yuan, Yu Yang AU - Yuan YY AD - Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330008, China. FAU - Chao, Hai Chao AU - Chao HC AD - Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China. FAU - Zeng, Xian Jun AU - Zeng XJ AD - Department of Radiology, First Affiliated Hospital of Nanchang University, Nanchang, 330008, China. FAU - Zeng, Tao AU - Zeng T AD - Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China. taozeng40709@sina.com. LA - eng GR - 82260598/National Natural Science Foundation of China/ GR - 20225BCJ22009/Jiangxi Provincial Academic and Technical Leader Training Program in Major Disciplines/ PT - Journal Article DEP - 20260706 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Contrast Media) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Radiomics MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - *Machine Learning MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/epidemiology MH - Male MH - *Tomography, X-Ray Computed/methods MH - *BCG Vaccine/therapeutic use MH - Female MH - Predictive Learning Models MH - Contrast Media MH - Aged MH - Neoplasm Grading MH - *Adjuvants, Immunologic/therapeutic use MH - Transurethral Resection of Bladder MH - Predictive Value of Tests MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging MH - Boosting Machine Learning Algorithms MH - Random Forest OTO - NOTNLM OT - BCG OT - Machine learning OT - Non-muscle invasive bladder cancer OT - Radiomics OT - Recurrence COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and consent to participate: This study and its associated projects have been approved by the Biomedical Research Ethics Committee of the Second Affiliated Hospital of Nanchang University and the Ethics Committee of the First Affiliated Hospital of Nanchang University, with the requirement for informed consent waived by these committees. All procedures were conducted in accordance with relevant guidelines and regulations. Consent for publication: All authors have read and agreed to submit this manuscript for publication. EDAT- 2026/07/06 12:41 MHDA- 2026/07/06 12:42 CRDT- 2026/07/06 11:17 PHST- 2025/08/07 00:00 [received] PHST- 2026/07/01 00:00 [accepted] PHST- 2026/07/06 12:42 [medline] PHST- 2026/07/06 12:41 [pubmed] PHST- 2026/07/06 11:17 [entrez] AID - 10.1007/s00345-026-06595-8 [pii] AID - 10.1007/s00345-026-06595-8 [doi] PST - epublish SO - World J Urol. 2026 Jul 6;44(1):486. doi: 10.1007/s00345-026-06595-8. PMID- 42403953 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260706 LR - 20260926 IS - 2090-696X (Print) IS - 2090-6978 (Electronic) IS - 2090-6978 (Linking) VI - 2026 DP - 2026 TI - Rare Early Coexistence of Classic Urothelial and Small Cell Carcinoma of the Urinary Bladder. PG - 2064505 LID - 10.1155/criu/2064505 [doi] LID - 2064505 AB - INTRODUCTION: Small cell carcinoma of the bladder (SCCB) is a rare aggressive cancer, representing less than 1% of bladder cancers. Similar to small cell lung cancer (SCLC), it progresses rapidly, metastasizes early, and has a poor prognosis, complicating treatment. Unlike more common bladder cancers, SCCB often resists localized treatments and responds better to chemotherapy. However, its management generally relies on protocols for SCLC due to limited specific research. CASE PRESENTATION: A 47-year-old male from Bangladesh presented with intermittent painless hematuria, weak urinary stream, and incomplete voiding for 2 months. His medical history includes diabetes mellitus, chronic kidney disease, hypothyroidism, adrenal adenoma, and coronary artery disease. His physical examination was unremarkable. His blood work up showed hypochromic microcytic anemia and elevated creatinine. Urine cytology revealed atypical degenerated urothelial cells, polymorphonuclear leukocytes, and red blood cells. He underwent flexible cystoscopy, which showed a nodular tumor with a wide base at the left lateral bladder wall measuring less than 3 cm. He had a CT scan, which revealed irregular thickening in the left posterolateral bladder wall, suggesting muscle-invasive carcinoma extending into the perivesical fat. He had an MRI scan which confirmed a 4 x 4.5 - cm mass with extravesical involvement. Histopathology examination from his transurethral resection of bladder tumor specimens showed mixed carcinoma, comprising both classic invasive urothelial carcinoma (UC) and SCCB. The small cell component exhibited scant cytoplasm, high nuclear-to-cytoplasmic ratio, hyperchromatic nuclei, and numerous mitotic figures, with synaptophysin and weak chromogranin positivity; UC cells were GATA-3 positive. Surgical resection removed most of the tumor. The patient tolerated the procedure well, with no complications. After four chemotherapy cycles, he had a follow-up PET CT, which showed significant tumor regression. CONCLUSION: This case highlights the unusual early coexistence of SCCB with classic UC in the bladder, emphasizing the importance of comprehensive histopathological and immunohistochemical evaluation for accurate diagnosis and treatment planning. Further research on SCCB could improve diagnosis, treatment strategies, and identification of molecular targets, potentially enhancing survival rates and patient quality of life. CI - Copyright (c) 2026 Mohannad N. AbuHaweeleh et al. Case Reports in Urology published by John Wiley & Sons Ltd. FAU - AbuHaweeleh, Mohannad N AU - AbuHaweeleh MN AUID- ORCID: 0000-0002-6121-5158 AD - College of Medicine, Qatar University, Doha, Qatar, qu.edu.qa. AD - Department of Urology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Elfaieg, Amro AU - Elfaieg A AD - Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Alhyari, Abdelkareem AU - Alhyari A AD - Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Abuhayeh, Nada AU - Abuhayeh N AD - College of Pharmacy, Qatar University, Doha, Qatar, qu.edu.qa. FAU - Khalil, Ibrahim A AU - Khalil IA AUID- ORCID: 0000-0003-1237-5099 AD - Department of Urology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Mahmood, Nabil AU - Mahmood N AD - Department of Radiology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Akhtar, Mohammed AU - Akhtar M AUID- ORCID: 0000-0002-0722-7967 AD - Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. FAU - Al-Rumaihi, Khalid AU - Al-Rumaihi K AD - Department of Urology, Hamad Medical Corporation, Doha, Qatar, hamad.qa. LA - eng PT - Journal Article DEP - 20260703 PL - United States TA - Case Rep Urol JT - Case reports in urology JID - 101580193 PMC - PMC13332126 OTO - NOTNLM OT - bladder small cell cancer OT - bladder tumor OT - neuroendocrine tumor COIS- The authors declare no conflicts of interest. EDAT- 2026/07/06 06:31 MHDA- 2026/07/06 06:32 PMCR- 2026/07/03 CRDT- 2026/07/06 05:29 PHST- 2025/03/13 00:00 [received] PHST- 2026/02/17 00:00 [revised] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/07/06 06:32 [medline] PHST- 2026/07/06 06:31 [pubmed] PHST- 2026/07/06 05:29 [entrez] PHST- 2026/07/03 00:00 [pmc-release] AID - CRIU2064505 [pii] AID - 10.1155/criu/2064505 [doi] PST - epublish SO - Case Rep Urol. 2026 Jul 3;2026:2064505. doi: 10.1155/criu/2064505. eCollection 2026. PMID- 42403007 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 33 IP - 7 DP - 2026 Jul TI - Long-Term Oncologic Outcomes After Laparoscopic Radical Nephroureterectomy: A Contemporary Analysis From a Japanese Multicenter Cohort. PG - e70566 LID - 10.1111/iju.70566 [doi] LID - e70566 AB - OBJECTIVES: To evaluate long-term oncologic outcomes and recurrence patterns after laparoscopic radical nephroureterectomy (LRNU) performed more than five years earlier. PATIENTS AND METHODS: We retrospectively analyzed patients who underwent LRNU before 2020 at nine Japanese institutions. Nonurothelial recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were estimated using the Kaplan-Meier method. Cox proportional hazard models were applied to identify prognostic factors. Initial recurrence sites were assessed, with particular focus on disseminated recurrence. RESULTS: A total of 1102 patients were included, with a median follow-up of 57 months. Clinically locally advanced disease was observed in 212 patients (19%), including 178 (16%) with cT3-4 tumors and 64 (6%) with cN-positive disease. Lymphadenectomy was performed in 557 cases (51%). The 5-year RFS rates for pT < 1, pT1, pT2, pT3, and pT4 were 92%, 87%, 70%, 48%, and 20%, respectively. The corresponding CSS rates were 96%, 94%, 81%, 61%, and 21%, and the corresponding OS rates were 84%, 78%, 71%, 53%, and 15%. Older age at surgery and advanced pathological features were independent predictors of poorer RFS, CSS, and OS. Regarding recurrence patterns, distant recurrence occurred in 203 patients (18%), local recurrence in 127 (11%), and urothelial recurrence in 489 (45%). Disseminated recurrence was rare, occurring in 25 patients (2%), including 18 with retroperitoneal carcinomatosis and 3 (0.3%) with port-site recurrence. CONCLUSIONS: Our findings suggest that LRNU provides favorable long-term oncologic outcomes with low disseminated recurrence rates, appearing comparable to historical outcomes of open surgery. CI - (c) 2026 The Japanese Urological Association. FAU - Kanno, Toru AU - Kanno T AUID- ORCID: 0000-0001-9445-4035 AD - Department of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. FAU - Saito, Ryoichi AU - Saito R AUID- ORCID: 0000-0002-3163-8723 AD - Department of Urology, Hyogo Medical University, Hyogo, Japan. FAU - Kita, Yuki AU - Kita Y AD - Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kansai Medical University, Osaka, Japan. FAU - Koterazawa, Shigeki AU - Koterazawa S AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Takahashi, Toshifumi AU - Takahashi T AD - Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. FAU - Hattori, Yuto AU - Hattori Y AUID- ORCID: 0000-0002-1488-9811 AD - Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. FAU - Kobori, Go AU - Kobori G AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Fukui, Tomohiro AU - Fukui T AUID- ORCID: 0000-0002-1904-0884 AD - Department of Urology, Toyooka Hospital, Toyooka, Japan. FAU - Akao, Toshiya AU - Akao T AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Hatano, Shotaro AU - Hatano S AD - Department of Urology, Osaka Red Cross Hospital, Osaka, Japan. FAU - Sumiyoshi, Takayuki AU - Sumiyoshi T AD - Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. FAU - Masui, Kimihiko AU - Masui K AUID- ORCID: 0000-0002-7841-1104 AD - Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. FAU - Goto, Takayuki AU - Goto T AD - Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. CN - Daimonji Clinical Application Database Group LA - eng PT - Journal Article PT - Multicenter Study PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality MH - Disease-Free Survival MH - Follow-Up Studies MH - Japan/epidemiology MH - *Kidney Neoplasms/surgery/mortality/pathology MH - *Laparoscopy/adverse effects MH - Lymph Node Excision/statistics & numerical data MH - *Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - *Nephroureterectomy/methods/adverse effects MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - *Ureteral Neoplasms/surgery/mortality/pathology PMC - PMC13334230 OTO - NOTNLM OT - laparoscopic radical nephroureterectomy OT - long-term oncologic outcomes OT - upper tract urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2026/07/06 06:31 MHDA- 2026/07/06 06:32 PMCR- 2026/07/06 CRDT- 2026/07/06 02:54 PHST- 2026/05/20 00:00 [revised] PHST- 2026/03/09 00:00 [received] PHST- 2026/07/01 00:00 [accepted] PHST- 2026/07/06 06:32 [medline] PHST- 2026/07/06 06:31 [pubmed] PHST- 2026/07/06 02:54 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - IJU70566 [pii] AID - 10.1111/iju.70566 [doi] PST - ppublish SO - Int J Urol. 2026 Jul;33(7):e70566. doi: 10.1111/iju.70566. PMID- 42400747 OWN - NLM STAT- Publisher LR - 20260704 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) DP - 2026 Jul 4 TI - Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort. LID - 10.1007/s11255-026-05244-8 [doi] AB - BACKGROUND: Repeat transurethral resection of bladder tumour (re-TURBT) is recommended in high-risk non-muscle-invasive bladder cancer (NMIBC) to improve staging and identify residual disease. Nevertheless, whether it should be performed routinely in current practice remains uncertain. We examined the findings of re-TURBT in a multicentre cohort and assessed factors associated with residual tumour and later recurrence. METHODS: This retrospective multicentre study included 567 patients with high-grade NMIBC who underwent re-TURBT after primary resection between 2018 and 2024. Clinicopathological variables and oncological outcomes were reviewed. Logistic regression analysis was used to evaluate predictors of residual tumour, and Cox regression analysis was used to assess factors associated with recurrence. RESULTS: Residual tumour was found in 152 patients (26.8%), and 34 patients (6.0%) were upstaged to muscle-invasive disease. Sessile morphology (OR 1.9, 95%CI 1.3-2.6), multifocal tumours (OR 2.3, 95%CI 1.7-3.2), concomitant carcinoma in situ (OR 2.6, 95%CI 1.9-3.7), and lymphovascular invasion (OR 1.7, 95%CI 1.1-2.4) were independently associated with residual disease. Absence of detrusor muscle in the initial specimen was associated with a higher risk of residual tumour (p < 0.001). Patients with residual tumour had poorer recurrence-free survival. On multivariable Cox analysis, residual tumour (HR 1.95, 95%CI 1.42-2.70), multifocality (HR 2.10, 95% CI 1.55-2.85), carcinoma in situ (HR 1.78, 95%CI 1.30-2.42), and tumour size >/= 3 cm (HR 1.45, 95%CI 1.05-2.02) were independently associated with recurrence. The overall complication rate was 4.2%, and no major perioperative complications at re-TURBT were recorded. CONCLUSIONS: Residual tumour after initial TURBT remains frequent in patients with high-grade NMIBC. Repeat resection improves staging, detects occult muscle-invasive disease, and helps identify patients at greater risk of recurrence. These findings support an ongoing role for re-TURBT, particularly in carefully selected high-risk patients. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Jaabou, Mohammad AU - Jaabou M AD - Department of Urology, Hamah National Hospital, Hamah, Syrian Arab Republic. abojabo91@gmail.com. FAU - Dovey, Zachary AU - Dovey Z AD - Mount Sinai Hospital, New York, NY, USA. FAU - Zaytoun, Osama AU - Zaytoun O AD - Mount Sinai Hospital, New York, NY, USA. FAU - Awan, Modassar AU - Awan M AD - Mount Sinai Hospital, New York, NY, USA. FAU - Hildebrand, Brooke AU - Hildebrand B AD - . George's University, Grenada, USA. FAU - Bada, Maida AU - Bada M AD - Clinica Sagrada Familia, Barcelona, Spain. FAU - Signore, Stefano AU - Signore S AD - Sant Eugenio Hospital, Rome, Italy. FAU - Falavolti, Cristina AU - Falavolti C AD - San Filippo Neri Hospital, Rome, Italy. FAU - Di Marco, Massimiliano AU - Di Marco M AD - Cristo Re Hospital, Rome, Italy. FAU - Martini, Alberto AU - Martini A AD - University of Cincinnati, Cincinnati, OH, USA. FAU - Papalia, Rocco AU - Papalia R AD - University Campus Biomedica, Rome, Italy. FAU - Bellido, Jose AU - Bellido J AD - Clinica Sagrada Familia, Barcelona, Spain. FAU - Rabie, Ahmad AU - Rabie A AD - Northwell Health, New York, NY, USA. FAU - Buscarini, Maurizio AU - Buscarini M AD - Mount Sinai Hospital, New York, NY, USA. LA - eng PT - Journal Article DEP - 20260704 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM OTO - NOTNLM OT - Bladder cancer OT - NMIBC OT - Re-TURBT OT - Recurrence OT - Residual tumour COIS- Declarations. Conflict of interest: The authors report no conflicts of interest related to this study. EDAT- 2026/07/05 01:10 MHDA- 2026/07/05 01:10 CRDT- 2026/07/04 11:06 PHST- 2026/05/03 00:00 [received] PHST- 2026/06/11 00:00 [accepted] PHST- 2026/07/05 01:10 [medline] PHST- 2026/07/05 01:10 [pubmed] PHST- 2026/07/04 11:06 [entrez] AID - 10.1007/s11255-026-05244-8 [pii] AID - 10.1007/s11255-026-05244-8 [doi] PST - aheadofprint SO - Int Urol Nephrol. 2026 Jul 4. doi: 10.1007/s11255-026-05244-8. PMID- 42400296 OWN - NLM STAT- MEDLINE DCOM- 20260908 LR - 20260916 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 4 DP - 2026 Oct TI - Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC. PG - 640-649 LID - 10.1111/bju.70375 [doi] AB - OBJECTIVES: To compare the oncologic outcomes and safety profiles of Bacillus Calmette-Guerin (BCG) versus gemcitabine/docetaxel (Gem/Doce) maintenance following BCG induction in treatment-naive non-muscle-invasive bladder cancer (NMIBC). METHODS: We identified patients with treatment-naive NMIBC who received induction BCG followed by maintenance BCG per the Southwest Oncology Group Cancer Research Network protocol or Gem/Doce monthly for 1 year (2016-2026). Oncological outcomes included recurrence-free survival (RFS), high-grade RFS, progression-free survival, and metastasis-free survival. Adverse events were systematically assessed to evaluate treatment tolerability. RESULTS: Overall, 128 patients received BCG induction followed by either BCG maintenance (n = 98; 76.6%) or Gem/Doce maintenance (n = 30; 23.4%). After a median follow-up of 75.0 months (interquartile range [IQR] 66.7-86.5) in the BCG group and 22.5 months (IQR 14.8-42.9) in the Gem/Doce group (P < 0.001), 3-year RFS (80.0% vs. 83.8%; P = 0.8), 3-year high-grade RFS (83.4% vs. 92.2%; P = 0.7), 3-year progression-free survival (90.0% vs. 96.6%; P = 0.4), and 3-year metastasis-free survival (96.8% vs. 100.0%; P = 0.3) were comparable between the BCG and Gem/Doce maintenance groups, respectively. Multivariable Cox regression analysis confirmed that Gem/Doce versus BCG maintenance was not associated with disease recurrence (hazard ratio 1.04; 95% confidence interval 0.39-2.83; P > 0.9). Overall, Gem/Doce maintenance was better tolerated, with fewer patients reporting adverse events (6.7% vs. 28%, P = 0.02) and no severe events observed during the maintenance phase. Limitations of the study include its retrospective design and the relatively small sample size of the Gem/Doce cohort. CONCLUSION: Sequential Gem/Doce maintenance following BCG induction achieved oncologic outcomes comparable to those with BCG maintenance, with improved tolerability, highlighting its feasibility as an alternative in cases of BCG intolerance or shortage. CI - (c) 2026 BJU International. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Zhu, Alec AU - Zhu A AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Karim, Christopher G AU - Karim CG AD - Rutgers New Jersey Medical School, Newark, NJ, USA. FAU - Eraky, Ahmed AU - Eraky A AUID- ORCID: 0000-0001-6879-6058 AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Gupta, Raghav AU - Gupta R AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Ben-David, Reuben AU - Ben-David R AD - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Mehrazin, Reza AU - Mehrazin R AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260704 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Gemcitabine MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *Deoxycytidine/analogs & derivatives/therapeutic use/administration & dosage MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *Docetaxel/therapeutic use/administration & dosage MH - Female MH - Male MH - Aged MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Treatment Outcome MH - Retrospective Studies MH - Induction Chemotherapy MH - *Adjuvants, Immunologic/therapeutic use PMC - PMC13550786 OTO - NOTNLM OT - BCG OT - docetaxel OT - gemcitabine OT - induction OT - maintenance OT - non-muscle invasive bladder cancer EDAT- 2026/07/04 06:31 MHDA- 2026/09/08 05:36 PMCR- 2026/09/08 CRDT- 2026/07/04 03:53 PHST- 2026/09/08 05:36 [medline] PHST- 2026/07/04 06:31 [pubmed] PHST- 2026/07/04 03:53 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - BJU70375 [pii] AID - 10.1111/bju.70375 [doi] PST - ppublish SO - BJU Int. 2026 Oct;138(4):640-649. doi: 10.1111/bju.70375. Epub 2026 Jul 4. PMID- 42399473 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260703 LR - 20260814 IS - 2397-768X (Print) IS - 2397-768X (Electronic) IS - 2397-768X (Linking) VI - 10 IP - 1 DP - 2026 Jul 3 TI - Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. LID - 10.1038/s41698-026-01588-7 [doi] LID - 258 AB - Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) has been the standard care for muscle-invasive bladder cancer (MIBC) for two decades. One third of NAC-treated patients achieve pathologic complete response (pT0N0), a proxy for improved survival after RC. Predicting response already at transurethral resection of bladder tumor (TUR-BT) would enable selective use of NAC, minimizing exposure to ineffective therapy. We aimed to identify tumor mRNAs associated with response across multiple transcriptomic studies, prioritizing subsequent biomarkers for validation. Three NAC-treated cohort with tumor transcriptomic profiles were included. Differential mRNA-expression analysis and subtype classification according to the Lund Taxonomy were performed. Within each cohort and subtype, genes were ranked by differential expression, and integrated into a meta rank-score. Survival associations of top genes in the NAC-cohorts were used to select candidate biomarkers for protein validation. Proliferation/late cell-cycle gene predicted response in Urothelial-like subtype and cytotoxic T- and NK-cell-related genes predicted response in Basal/Squamous tumors. These findings were validated by immunostainings for CCNB1 and NKG7, respectively. This integrative framework suggests a complex picture in which two NAC-predictive signals identify responders in a subtype dependent manner. The framework can be updated as new datasets become available, providing dynamic exploration of NAC-predictive biomarkers in MIBC. CI - (c) 2026. The Author(s). FAU - Zadoroznyj, Aymeric AU - Zadoroznyj A AD - Department of Translational Medicine, Lund University, Malmo, Sweden. aymeric.zadoroznyj@med.lu.se. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. aymeric.zadoroznyj@med.lu.se. FAU - Eriksson, Pontus AU - Eriksson P AD - Division of Oncology, Department of clinical sciences, Lund University, Lund, Sweden. FAU - Bernardo, Carina AU - Bernardo C AD - Division of Oncology, Department of clinical sciences, Lund University, Lund, Sweden. FAU - Tran, Lena AU - Tran L AD - Division of Oncology, Department of clinical sciences, Lund University, Lund, Sweden. FAU - Mattsson, Carl-Adam AU - Mattsson CA AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Flaig, Thomas W AU - Flaig TW AD - Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Seiler, Roland AU - Seiler R AD - Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland; Department of Urology, Hospital Center Biel, Spitalzentrum Biel, Biel, Switzerland. FAU - Tangen, Catherine M AU - Tangen CM AD - SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. FAU - Black, Peter C AU - Black PC AD - University of British Columbia, Vancouver, BC, Canada. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology, Department of clinical sciences, Lund University, Lund, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Department of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. LA - eng GR - U10 CA180819/CA/NCI NIH HHS/United States GR - CAN 2022/1971/Swedish Cancer Society/ GR - 847583/European Union's Horizon 2020 research and innovation programme/ PT - Journal Article DEP - 20260703 PL - England TA - NPJ Precis Oncol JT - NPJ precision oncology JID - 101708166 PMC - PMC13332042 COIS- Competing interests: P.C.B. and R.S. share a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). The other authors do not have a competing interest. EDAT- 2026/07/04 00:33 MHDA- 2026/07/04 00:34 PMCR- 2026/07/03 CRDT- 2026/07/03 23:23 PHST- 2026/01/09 00:00 [received] PHST- 2026/06/25 00:00 [accepted] PHST- 2026/07/04 00:34 [medline] PHST- 2026/07/04 00:33 [pubmed] PHST- 2026/07/03 23:23 [entrez] PHST- 2026/07/03 00:00 [pmc-release] AID - 10.1038/s41698-026-01588-7 [pii] AID - 1588 [pii] AID - 10.1038/s41698-026-01588-7 [doi] PST - epublish SO - NPJ Precis Oncol. 2026 Jul 3;10(1):258. doi: 10.1038/s41698-026-01588-7. PMID- 42391300 OWN - NLM STAT- MEDLINE DCOM- 20261023 LR - 20261023 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 13 IP - 6 DP - 2026 Nov TI - National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma. PG - 663-670 LID - 10.1097/UPJ.0000000000001053 [doi] AB - INTRODUCTION: Intravesical chemotherapy (IC) administered perioperatively after nephroureterectomy (NUx) for upper tract urothelial carcinoma reduces intravesical recurrence based on 2 randomized trials and is endorsed by contemporary practice guidelines. However, real-world adoption of this intervention remains poorly defined. We evaluated national utilization trends and identified predictors of perioperative IC use after NUx. METHODS: Using the National Cancer Database, we identified patients with nonmetastatic upper tract urothelial carcinoma who underwent NUx between 2013 and 2022. Perioperative IC was defined as chemotherapy administered within 48 hours of surgery. Temporal trends were assessed using the Cochran-Armitage test. Multivariable logistic regression was used to identify factors independently associated with IC receipt. RESULTS: Among 14,808 eligible patients, only 1032 (7.0%) received perioperative IC. Utilization increased significantly over time, from 1.1% in 2013 to 16.6% in 2022 (P < .001). On multivariable analysis, treatment at an academic (odds ratio [OR] 2.47, 95% CI 2.09-2.91) or comprehensive cancer program (OR 2.24, 95% CI 1.86-2.69), later year of diagnosis (OR 1.37 per year, 95% CI 1.33-1.41), and ureteral tumor location (OR 1.22, 95% CI 1.06-1.40) were associated with higher odds of IC use. Hispanic ethnicity (OR 0.39, 95% CI 0.26-0.59), higher clinical T stage, and open surgical approach were associated with significantly lower odds of IC receipt. CONCLUSIONS: Despite level 1 evidence and guideline endorsement, perioperative IC after NUx remains infrequently used in the United States. Persistent disparities in adoption highlight a substantial evidence-to-practice gap and underscore opportunities for targeted implementation strategies to improve equitable delivery of guideline-supported care. FAU - Wang, Shu AU - Wang S AUID- ORCID: 0000-0001-7347-4707 AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. FAU - Blum, Kyle A AU - Blum KA AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. FAU - Iranmahboub, Parsa AU - Iranmahboub P AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. FAU - Xu, Helen AU - Xu H AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. FAU - Dave, Priya AU - Dave P AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. FAU - Scherr, Douglas S AU - Scherr DS AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. LA - eng PT - Journal Article DEP - 20260724 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 RN - 0 (Antineoplastic Agents) SB - IM CIN - Urol Pract. 2026 Nov;13(6):663-670. doi: 10.1097/UPJ.0000000000001056. PMID: 42531519 MH - Humans MH - *Nephroureterectomy MH - Female MH - Administration, Intravesical MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/drug therapy/surgery MH - *Ureteral Neoplasms/surgery/drug therapy MH - Middle Aged MH - United States MH - *Kidney Neoplasms/surgery/drug therapy MH - *Antineoplastic Agents/administration & dosage MH - Perioperative Care MH - *Practice Patterns, Physicians'/statistics & numerical data OTO - NOTNLM OT - National Cancer Database OT - bladder recurrence OT - intravesical chemotherapy OT - nephroureterectomy OT - upper tract urothelial carcinoma EDAT- 2026/07/02 18:32 MHDA- 2026/10/23 18:30 CRDT- 2026/07/02 13:53 PHST- 2026/10/23 18:30 [medline] PHST- 2026/07/02 18:32 [pubmed] PHST- 2026/07/02 13:53 [entrez] AID - 10.1097/UPJ.0000000000001053 [doi] PST - ppublish SO - Urol Pract. 2026 Nov;13(6):663-670. doi: 10.1097/UPJ.0000000000001053. Epub 2026 Jul 24. PMID- 42391037 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260923 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 32 IP - 18 DP - 2026 Sep 15 TI - Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer. PG - 4075-4083 LID - 10.1158/1078-0432.CCR-26-1407 [doi] AB - PURPOSE: More than 50% of patients with non-muscle-invasive bladder cancer experience recurrence, requiring lifelong surveillance with repeated cystoscopy. Given the invasive nature and cost of cystoscopy, accurate noninvasive tools are needed to support risk-adapted monitoring. We evaluated the ability of Oncuria-Monitor, a multiplex urine biomarker assay, to detect recurrent bladder cancer during surveillance. PATIENTS AND METHODS: Between February 2017 and August 2020, six medical centers in the United States and Japan prospectively enrolled 300 patients with a history of bladder cancer, generating 1,248 serial urine samples. Participants were divided into training and validation cohorts. At each surveillance visit over 2 years, urine samples were analyzed in a blinded manner using Oncuria-Monitor and BladderChek, alongside urine cytology. Test performance was compared with cystoscopy and histopathology-confirmed recurrence. RESULTS: Recurrent bladder cancer was identified in 31% (93/300) of participants, with 143 total recurrences during follow-up, including 90 tumors in the validation cohort. In the validation cohort, Oncuria-Monitor achieved a sensitivity of 85.6% [95% confidence interval (CI), 78.1%-92.2%] and a negative predictive value (NPV) of 93% (95% CI, 89.2%-96.4%). In comparison, BladderChek demonstrated a sensitivity of 20.0% and an NPV of 88%, whereas urine cytology showed a sensitivity of 36.9% and an NPV of 91.6%. The number needed to evaluate to detect one recurrence was 3 for both cystoscopy and Oncuria-Monitor, compared with 15 for BladderChek and 8 for cytology. CONCLUSIONS: In this large prospective longitudinal study, Oncuria-Monitor demonstrated clinically actionable performance, enabling a rule-out strategy that could safely reduce cystoscopy in approximately 25% of surveillance visits. These findings support a paradigm shift toward biomarker-guided, risk-adapted surveillance in bladder cancer that reduces unnecessary invasive procedures while maintaining oncologic safety. CI - (c)2026 The Authors; Published by the American Association for Cancer Research. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - Department of Urology, University of Texas Southwestern, Dallas, Texas. FAU - Luu, Michael AU - Luu M AUID- ORCID: 0000-0002-7968-7313 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Liu, Menghan AU - Liu M AUID- ORCID: 0009-0000-7436-3056 AD - Fred Hutchinson Cancer Center , Seattle, Washington. ROR: https://ror.org/007ps6h72 FAU - Tikhonekov, Sergei AU - Tikhonekov S AUID- ORCID: 0009-0009-1060-0206 AD - Translational and Clinical Research Program, University of Hawaii Cancer Center, Honolulu, Hawaii. ROR: https://ror.org/00kt3nk56 AD - Island Urology, Honolulu, Hawaii. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University, Kyoto, Japan. ROR: https://ror.org/02kpeqv85 FAU - Ahdoot, Michael AU - Ahdoot M AUID- ORCID: 0000-0002-5373-1283 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Kim, Hyung Lae AU - Kim HL AUID- ORCID: 0000-0003-2085-6140 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Porten, Sima AU - Porten S AUID- ORCID: 0000-0002-3948-4968 AD - Department of Urology, University of California San Francisco, San Francisco, California. ROR: https://ror.org/043mz5j54 FAU - Peers, Garry AU - Peers G AUID- ORCID: 0009-0004-5026-7296 AD - Aloha Urology, Honolulu, Hawaii. FAU - Kita, Yuki AU - Kita Y AUID- ORCID: 0000-0002-6942-9695 AD - Department of Urology, Kyoto University, Kyoto, Japan. ROR: https://ror.org/02kpeqv85 FAU - Daskivich, Timothy AU - Daskivich T AUID- ORCID: 0000-0002-7540-3272 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Murakami, Kaoru AU - Murakami K AUID- ORCID: 0000-0002-4226-3867 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Sakatani, Toru AU - Sakatani T AUID- ORCID: 0009-0004-4994-1503 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Pagano, Ian AU - Pagano I AUID- ORCID: 0000-0002-6248-0113 AD - Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, Hawaii. ROR: https://ror.org/00kt3nk56 FAU - Zheng, Yingye AU - Zheng Y AUID- ORCID: 0000-0002-3078-4200 AD - Fred Hutchinson Cancer Center , Seattle, Washington. ROR: https://ror.org/007ps6h72 FAU - Zhang, Zhen AU - Zhang Z AUID- ORCID: 0000-0002-3627-2572 AD - Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Furuya, Hideki AU - Furuya H AUID- ORCID: 0000-0002-9536-8662 AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 FAU - Rosser, Charles J AU - Rosser CJ AUID- ORCID: 0000-0002-6052-4223 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. ROR: https://ror.org/02pammg90 AD - Nonagen Bioscience Corp., Los Angeles, California. LA - eng GR - R01 CA277810/CA/NCI NIH HHS/United States GR - R01 CA198887/CA/NCI NIH HHS/United States GR - R01 CA277810/National Cancer Institute (NCI)/ GR - UH3 CA271377/CA/NCI NIH HHS/United States GR - U54 CA274375-01/National Cancer Institute (NCI)/ GR - U54 CA274375/CA/NCI NIH HHS/United States GR - UH3 CA271377/National Cancer Institute (NCI)/ GR - R01 CA1988887/National Cancer Institute (NCI)/ PT - Journal Article PT - Multicenter Study PT - Validation Study PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Neoplasm Recurrence, Local/urine/diagnosis/pathology MH - *Biomarkers, Tumor/urine MH - Male MH - Aged MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology MH - Prospective Studies MH - Middle Aged MH - Cystoscopy MH - Non-Muscle Invasive Bladder Neoplasms MH - Aged, 80 and over PMC - PMC13575556 COIS- Y. Lotan reports grants and personal fees from Nonagen Bioscience during the conduct of the study, as well as grants and personal fees from Pacific Edge, Nucleix, and Convergent Genomics and personal fees from Promis Diagnostics, Vesica Health, and Cleancard outside the submitted work. M. Ahdoot is a consultant for Oncuria. S. Porten reports grants from Cedar Sinai during the conduct of the study, as well as personal fees from Vesica Health, Stryker, J&J, and Pacific Edge and grants from Photocure outside the submitted work. H. Furuya reports other support from Nonagen Bioscience Corp. during the conduct of the study, as well as other support from Nonagen Therapeutics Corp. outside the submitted work. C.J. Rosser reports grants from the NIH during the conduct of the study, as well as nonfinancial support from Nonagen Bioscience outside the submitted work; C.J. Rosser also reports a patent for Nonagen Bioscience issued. No disclosures were reported by the other authors. EDAT- 2026/07/02 18:33 MHDA- 2026/09/15 11:37 PMCR- 2026/09/15 CRDT- 2026/07/02 12:54 PHST- 2026/04/13 00:00 [received] PHST- 2026/05/21 00:00 [revised] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/09/15 11:37 [medline] PHST- 2026/07/02 18:33 [pubmed] PHST- 2026/07/02 12:54 [entrez] PHST- 2026/09/15 00:00 [pmc-release] AID - 786377 [pii] AID - CCR-26-1407 [pii] AID - 10.1158/1078-0432.CCR-26-1407 [doi] PST - ppublish SO - Clin Cancer Res. 2026 Sep 15;32(18):4075-4083. doi: 10.1158/1078-0432.CCR-26-1407. PMID- 42389921 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260817 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 3 DP - 2026 Sep TI - Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer. PG - 491-500 LID - 10.1111/bju.70376 [doi] AB - OBJECTIVES: To evaluate whether longitudinal tumour-informed circulating tumour DNA (ctDNA) testing identifies patients at increased risk of upstaging and recurrence in high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A cohort of 52 patients with high-risk NMIBC underwent serial plasma ctDNA testing using a personalised tumour-informed assay. The ctDNA was obtained at initial presentation and at approximately 3-month surveillance intervals during appropriate routine clinical NMIBC therapy and follow-up. A subset of tumours underwent tumour-normal whole-exome sequencing to evaluate genomic alterations associated with ctDNA detection and clinical progression. RESULTS: Circulating tumour DNA was detectable in 17 of 52 patients (33%), including eight of 29 who were Bacillus Calmette-Guerin (BCG)-naive (28%) and nine of 23 who were BCG-exposed/BCG-unresponsive patients (39%). Most patients received intravesical therapy, including BCG or salvage intravesical chemotherapy, and a subset underwent radical cystectomy. Clinical upstaging occurred in 10 of 17 ctDNA-positive patients vs five of 35 ctDNA-negative patients (59% vs 14%, P = 0.002). Among the 21 patients undergoing cystectomy, pathological upstaging occurred in seven of nine ctDNA-positive patients and one of 12 ctDNA-negative patients (78% vs 8%, P = 0.002). Distant recurrence occurred in three of 17 (18%) ctDNA-positive patients and in none of ctDNA-negative patients. TP53 alterations were enriched in ctDNA-positive tumours, whereas fibroblast growth factor receptor (FGFR3) alterations were more frequent in ctDNA-negative tumours. Limitations include the small cohort and limited follow-up. CONCLUSION: Longitudinal ctDNA testing in high-risk NMIBC identifies a subgroup with higher risk of clinical and pathological upstaging and distant recurrence, often without corresponding cystoscopic or radiographic evidence. ctDNA-positivity reflects aggressive tumour biology and may help identify patients unlikely to benefit from continued intravesical salvage therapy. These findings support further evaluation of ctDNA as a potential risk stratification tool and motivate prospective studies of ctDNA-guided management. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Aydogdu, Can AU - Aydogdu C AUID- ORCID: 0009-0003-1486-183X AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Department of Urology, LMU University Hospital, Ludwig-Maximilians-University Munchen, Munich, Germany. FAU - Wang, Betty AU - Wang B AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - McSweeney, Sean Thomas AU - McSweeney ST AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Diaz, Gabriela AU - Diaz G AUID- ORCID: 0000-0002-7931-252X AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Guzman, Taeris AU - Guzman T AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Dewala, Sahab Ram AU - Dewala SR AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Arya, Rakesh AU - Arya R AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Baer, Mikayla AU - Baer M AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Nizam, Amanda AU - Nizam A AD - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Wee, Christopher AU - Wee C AD - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Moningi, Shalini AU - Moningi S AD - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Pieretti, Alberto AU - Pieretti A AD - Department of Urology, Cleveland Clinic Florida, Weston Hospital, Weston, FL, USA. FAU - Weight, Christopher J AU - Weight CJ AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA. FAU - Campbell, Rebecca AU - Campbell R AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Sindhani, Mohit AU - Sindhani M AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kaouk, Jihad AU - Kaouk J AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Abouassaly, Robert AU - Abouassaly R AD - Department of Urology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA. LA - eng PT - Journal Article DEP - 20260702 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Circulating Tumor DNA) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/blood/genetics MH - Female MH - *Neoplasm Recurrence, Local/blood/pathology/genetics MH - Male MH - Aged MH - *Circulating Tumor DNA/blood MH - Middle Aged MH - Neoplasm Staging MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor/blood MH - *Urinary Bladder Neoplasms/pathology/blood MH - Administration, Intravesical PMC - PMC13458655 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - biomarker OT - circulating tumour DNA OT - molecular residual disease OT - non-muscle-invasive bladder cancer OT - unresponsive OT - urothelial carcinoma EDAT- 2026/07/02 13:10 MHDA- 2026/08/11 06:35 PMCR- 2026/08/11 CRDT- 2026/07/02 06:12 PHST- 2026/08/11 06:35 [medline] PHST- 2026/07/02 13:10 [pubmed] PHST- 2026/07/02 06:12 [entrez] PHST- 2026/08/11 00:00 [pmc-release] AID - BJU70376 [pii] AID - 10.1111/bju.70376 [doi] PST - ppublish SO - BJU Int. 2026 Sep;138(3):491-500. doi: 10.1111/bju.70376. Epub 2026 Jul 2. PMID- 42375996 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260630 LR - 20260926 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 7 DP - 2026 Jul TI - When disease travels downstream: The effect of intravesical recurrences in patients treated for upper tract urothelial carcinoma. PG - e70225 LID - 10.1002/bco2.70225 [doi] LID - e70225 AB - BACKGROUND: Treatment of upper tract urothelial carcinoma (UTUC) depends on risk stratification and tumour characteristics. Kidney-sparing surgery (KSS) is preferred for low-risk disease, whereas radical nephroureterectomy (RNU) is the standard for high-risk UTUC. Intravesical recurrences (IVR) are common after both treatment modalities, but their impact on survival remains unclear. OBJECTIVE: To assess the IVR rate and cumulative hazard following UTUC treatment and oncological outcomes based on the presence of IVR during follow-up. Second, the relation between UTUC and IVR tumour grade in patients treated with endoscopic KSS (eKSS). METHODS: A single-centre study, including non-metastatic UTUC patients treated between 2010 and 2023. Analysis was performed in a cohort of patients without a history of bladder cancer. RESULTS: In total 164 patients were selected; 85 treated with eKSS, 79 by RNU. Overall, 91 patients (55%) developed an IVR, 53 (62%) after eKSS and 38 (48%) after RNU, during a median follow-up of 33 months (IQR 11-72). eKSS-treated patients showed a significantly higher cumulative hazard for IVR (HR 0.6, 95% CI 0.42-0.95, p = 0.02). The CSS and MFS were comparable between patients with or without IVR during follow-up. In patients treated by eKSS, we found IVR upgrading in 24% of patients treated with eKSS. CONCLUSIONS: Patients treated by eKSS showed a higher cumulative hazard of IVR, without an impact on oncological outcomes. These findings support the use of kidney-sparing approaches in well-selected cases and highlight the need for proper follow-up including the bladder and evaluate IVR preventive measures as intravesical instillations. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Figaroa, Orlane J A AU - Figaroa OJA AD - Department of Urology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. AD - Department of Medical Oncology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. AD - Cancer Center Amsterdam Amsterdam UMC Amsterdam The Netherlands. FAU - Jonker, Sanne J AU - Jonker SJ AUID- ORCID: 0009-0002-8439-4571 AD - Department of Urology Amsterdam UMC, VU Amsterdam The Netherlands. FAU - Fris, Felix J AU - Fris FJ AD - Faculty of medicine University of Amsterdam Amsterdam The Netherlands. FAU - Kamphuis, Guido M AU - Kamphuis GM AD - Department of Urology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. AD - Cancer Center Amsterdam Amsterdam UMC Amsterdam The Netherlands. FAU - Bins, Adriaan D AU - Bins AD AD - Department of Medical Oncology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. AD - Cancer Center Amsterdam Amsterdam UMC Amsterdam The Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology Amsterdam UMC, VU Amsterdam The Netherlands. FAU - Baard, Joyce AU - Baard J AUID- ORCID: 0000-0002-5509-0213 AD - Department of Urology, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. AD - Cancer Center Amsterdam Amsterdam UMC Amsterdam The Netherlands. LA - eng PT - Journal Article DEP - 20260629 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC13311729 OTO - NOTNLM OT - intravesical recurrences OT - radial nephroureterectomy OT - survival outcomes OT - upper tract urothelial cancer OT - ureteroscopy COIS- Author J. B. reports speaker fees and consultancy fees from Olympus, Coloplast, Boston Scientific, TSC Life and Storz. All other authors declare no conflicts of interest. EDAT- 2026/06/30 10:09 MHDA- 2026/06/30 10:10 PMCR- 2026/06/29 CRDT- 2026/06/30 05:22 PHST- 2026/02/10 00:00 [received] PHST- 2026/04/20 00:00 [revised] PHST- 2026/04/20 00:00 [accepted] PHST- 2026/06/30 10:10 [medline] PHST- 2026/06/30 10:09 [pubmed] PHST- 2026/06/30 05:22 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - BCO270225 [pii] AID - 10.1002/bco2.70225 [doi] PST - epublish SO - BJUI Compass. 2026 Jun 29;7(7):e70225. doi: 10.1002/bco2.70225. eCollection 2026 Jul. PMID- 42375735 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260630 LR - 20260813 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 79 IP - 2 DP - 2026 TI - Is the albumin/globulin ratio a predictor of response to neoadjuvant chemotherapy before cystectomy for muscle-invasive bladder cancer? PG - 103-110 LID - 10.5173/ceju.2025.0244 [doi] AB - INTRODUCTION: The objective of this study is to ascertain whether the albumin-to-globulin ratio (AGR) can predict the response to neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer and pure urothelial carcinoma histology who have undergone NAC prior to cystectomy. MATERIAL AND METHODS: The study population comprised patients who underwent diagnostic biopsy with complete transurethral resection of a bladder tumor in our hospital, and for whom the pathology result was muscle-invasive pure urothelial cell carcinoma (pT2), and who received a minimum of three courses of cisplatin-based NAC. Patients were divided into two groups, responders and non-responders, according to their chemotherapy response. RESULTS: A response was observed in 81 (54%) patients. The most significant difference between the two groups was found in the AGR scores. The median AGR was 1.7 (1.1-3.2) in the responders and 1.4 (0.7-2.4) in the non-responders (p = 0.001). Using ROC analysis, the optimal cut-off value of AGR for predicting chemotherapy response was determined to be 1.61. Multivariate analysis demonstrated that elevated AGR values (>1.61) exhibited a more substantial impact on response in comparison to other parameters. When the parameters that had a significant effect on survival were investigated with Cox regression analysis, a high AGR with chemotherapy response was found to have more significant effect on survival. CONCLUSIONS: We think that, in conjunction with established clinicopathological factors, AGR can be utilized for the selection of patients for NAC. CI - Copyright by Polish Urological Association. FAU - Ozcan, Levent AU - Ozcan L AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Boylu, Ahmet AU - Boylu A AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Polat, Emre Can AU - Polat EC AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Culha, Mehmet Gokhan AU - Culha MG AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Erkoc, Mustafa AU - Erkoc M AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Bozkurt, Muammer AU - Bozkurt M AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Danis, Eyyup AU - Danis E AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. FAU - Otunctemur, Alper AU - Otunctemur A AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20260326 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC13312166 OTO - NOTNLM OT - albumin-to-globulin ratio OT - muscle-invasive bladder cancer OT - neoadjuvant chemotherapy COIS- The authors declare no conflict of interest. EDAT- 2026/06/30 06:30 MHDA- 2026/06/30 06:31 PMCR- 2026/01/01 CRDT- 2026/06/30 05:19 PHST- 2025/10/05 00:00 [received] PHST- 2026/01/04 00:00 [accepted] PHST- 2026/06/30 06:31 [medline] PHST- 2026/06/30 06:30 [pubmed] PHST- 2026/06/30 05:19 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - CEJU-79-02-0244 [pii] AID - 10.5173/ceju.2025.0244 [doi] PST - ppublish SO - Cent European J Urol. 2026;79(2):103-110. doi: 10.5173/ceju.2025.0244. Epub 2026 Mar 26. PMID- 42372917 OWN - NLM STAT- MEDLINE DCOM- 20260820 LR - 20260923 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 302 IP - 8 DP - 2026 Aug TI - Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression. PG - 113302 LID - S0021-9258(26)02174-5 [pii] LID - 10.1016/j.jbc.2026.113302 [doi] LID - 113302 AB - Alterations in DNA methylation represent one of the earliest molecular events in bladder tumorigenesis and are strongly associated with treatment efficacy and prognosis. Herein, we investigated DNA methylation landscape of MIR141 promoter and elucidated its clinical relevance in bladder cancer (BlCa) patients. miRNA-seq was performed to analyze miRNA profile in bladder tumors. Expression analysis of miR-141-3p and methylation profiling of MIR141 promoter were performed in 15 patient-derived xenografts (PDXs) mouse models, and in our screening patients' cohort (n = 133). TCGA-BLCA (n = 412) was used as independent validation cohort. Survival analysis was performed employing tumor relapse/progression as clinical endpoints in non-muscle-invasive BlCa (NMIBC; TaT1), and mortality in muscle-invasive BlCa (MIBC; T2-T4) patients. Internal validation was conducted through bootstrap analysis, and the clinical benefit of the findings was evaluated using decision curve analysis. miRNA-seq highlighted miR-141-3p as one of the most significantly downregulated miRNAs in muscle-invasive and high-grade tumors, while PDXs, TCGA-BLCA and screening cohort revealed its robust epigenetic regulation through MIR141 core promoter methylation. Consistent with miR-141-3p loss, hypermethylation of MIR141 core promoter was associated with advanced stage and high-grade tumors, reduced survival in PDXs, and significantly higher risk of TaT1 patients for short-term progression to muscle-invasive disease. Multivariate models highlighted MIR141 promoter hypermethylation as independent predictor for NMIBC short-term progression, displaying superior clinical benefit in patients' prognostication. Overall, MIR141 core promoter methylation results in miR-141-3p loss in bladder tumors and correlates with patients' poor treatment outcome, offering improved risk-stratification and addressing prognostic heterogeneity beyond traditional markers. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Pilala, Katerina-Marina AU - Pilala KM AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Papadimitriou, Artemis-Melina AU - Papadimitriou AM AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Panoutsopoulou, Konstantina AU - Panoutsopoulou K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Giagkos, Georgios-Christos AU - Giagkos GC AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kanaki, Zoi AU - Kanaki Z AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Vassilacopoulou, Dido AU - Vassilacopoulou D AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Klinakis, Apostolos AU - Klinakis A AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mavgeris@med.uoa.gr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260629 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (MicroRNAs) RN - 0 (MIRN141 microRNA, human) SB - IM MH - *MicroRNAs/genetics/metabolism MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - *Promoter Regions, Genetic/genetics MH - *DNA Methylation/genetics MH - Animals MH - *Epigenesis, Genetic/genetics MH - Disease Progression MH - Female MH - Mice MH - Male MH - Middle Aged MH - *Gene Silencing MH - Aged PMC - PMC13427651 OTO - NOTNLM OT - DNA OT - MIR141 promoter OT - PDXs OT - methylation epigenetics OT - miRNA OT - non-coding RNAs OT - patient-derived xenografts OT - prognosis OT - small RNA-seq OT - tumor promoter COIS- Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article. EDAT- 2026/06/30 00:32 MHDA- 2026/08/20 23:35 PMCR- 2026/06/29 CRDT- 2026/06/29 19:30 PHST- 2026/01/14 00:00 [received] PHST- 2026/06/19 00:00 [revised] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/08/20 23:35 [medline] PHST- 2026/06/30 00:32 [pubmed] PHST- 2026/06/29 19:30 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - S0021-9258(26)02174-5 [pii] AID - 113302 [pii] AID - 10.1016/j.jbc.2026.113302 [doi] PST - ppublish SO - J Biol Chem. 2026 Aug;302(8):113302. doi: 10.1016/j.jbc.2026.113302. Epub 2026 Jun 29. PMID- 42372080 OWN - NLM STAT- MEDLINE DCOM- 20260629 LR - 20260730 IS - 1943-7722 (Electronic) IS - 0002-9173 (Linking) VI - 165 IP - 6 DP - 2026 Jun 4 TI - Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity. LID - aqag072 [pii] LID - 10.1093/ajcp/aqag072 [doi] AB - OBJECTIVES: Surface low-grade papillary urothelial carcinoma with an invasive phenotype represents an understudied entity with its clinical behavior, therapeutic responses, and long-term outcomes remaining poorly defined. METHODS: We evaluated 17 patients from a single institution with histologically confirmed surface low-grade papillary urothelial carcinoma with an invasive phenotype, followed by longitudinal clinicopathologic analysis to delineate disease trajectories and treatment outcomes. RESULTS: Surface components of all tumors in this cohort demonstrated a low-grade papillary urothelial carcinoma phenotype. At the initial presentation, 53% of patients had invasive disease, while 47% were diagnosed with noninvasive disease. During follow-up, 37% of those with noninvasive disease appeared to progress to invasive disease within 1 year. At the point when invasive disease was diagnosed, pT1 disease was observed in 77% cases, and pT2-4 was observed in 23%. During subsequent follow-up, 77% of patients experienced recurrences, with 41% requiring therapeutic escalation to intravesical Bacillus Calmette-Guerin or systemic chemotherapy for disease progression. High-grade recurrence was identified in 23% patients. Distant metastases developed in 18% of patients, preferentially involving the lungs and bone. The median survival of the cohort was 66 months, and 1 patient died of disease. CONCLUSIONS: These findings underscore the variable and unpredictable course of this disease phenotype, emphasizing its potential for aggressive evolution despite surface low-grade tumor histology. Vigilant surveillance and early consideration of definitive treatment may be a prudent strategy to mitigate progression risks in this rare subset of patients. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Mahapatra, Somnath AU - Mahapatra S AUID- ORCID: 0000-0001-9490-6353 AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. FAU - Humble, Robert M AU - Humble RM AUID- ORCID: 0000-0002-0509-9674 AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. FAU - Cordeiro-Rudnisky, Fernanda AU - Cordeiro-Rudnisky F AD - Department of Pathology, University of Florida College of Medicine, Gainesville, FL, United States. FAU - Hafez, Khaled S AU - Hafez KS AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Vaishampayan, Ulka N AU - Vaishampayan UN AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. AD - Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. AD - Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States. FAU - Chinnaiyan, Arul M AU - Chinnaiyan AM AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. AD - Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, United States. FAU - Gupta, Akriti AU - Gupta A AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. FAU - Kunju, Laxmi P AU - Kunju LP AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Udager, Aaron M AU - Udager AM AUID- ORCID: 0000-0002-8254-5404 AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. FAU - Salami, Simpa S AU - Salami SS AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Morgan, Todd M AU - Morgan TM AUID- ORCID: 0000-0002-1140-0603 AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Kaffenberger, Samuel D AU - Kaffenberger SD AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Montgomery, Jeffrey S AU - Montgomery JS AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Singhal, Udit AU - Singhal U AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Urology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. FAU - Mehra, Rohit AU - Mehra R AUID- ORCID: 0000-0002-6955-8884 AD - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. AD - Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States. LA - eng PT - Journal Article PL - England TA - Am J Clin Pathol JT - American journal of clinical pathology JID - 0370470 SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/pathology/therapy MH - *Carcinoma, Papillary/pathology MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Aged, 80 and over MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - Neoplasm Grading MH - Disease Progression OTO - NOTNLM OT - cystectomy OT - grade OT - neoplasm invasiveness OT - nephroureterectomy OT - nested OT - papillary OT - prognosis OT - urothelial carcinoma EDAT- 2026/06/29 18:43 MHDA- 2026/06/29 18:44 CRDT- 2026/06/29 14:32 PHST- 2026/03/19 00:00 [received] PHST- 2026/05/14 00:00 [accepted] PHST- 2026/06/29 18:44 [medline] PHST- 2026/06/29 18:43 [pubmed] PHST- 2026/06/29 14:32 [entrez] AID - 8721646 [pii] AID - 10.1093/ajcp/aqag072 [doi] PST - ppublish SO - Am J Clin Pathol. 2026 Jun 4;165(6):aqag072. doi: 10.1093/ajcp/aqag072. PMID- 42369179 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260813 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 18 DP - 2026 Jan-Dec TI - Complete pathological response in patients with bladder cancer: predictors and outcomes. PG - 17562872261458110 LID - 10.1177/17562872261458110 [doi] LID - 17562872261458110 AB - Pathologic complete response (pCR) in bladder cancer, most often defined as pT0N0 at radical cystectomy (RC) following transurethral resection of the bladder tumor with/without neoadjuvant therapy, has emerged as a powerful prognostic marker. Predicting pCR before RC and understanding its prognostic nuances are increasingly important as perioperative chemotherapy and immunotherapy evolve. In this study, we reviewed the contemporary evidence regarding definitions and clinical contexts of pCR in bladder cancer; clinical, pathological, imaging, molecular, and liquid-biopsy predictors of pCR; and outcomes and recurrence patterns in patients achieving pCR. We found out that pCR rates vary widely according to treatment regimen, patient selection, and underlying tumor biology, ranging from 5%-15% after transurethral resection alone, 25%-35% with cisplatin-based chemotherapy, and up to 40% with combination chemoimmunotherapy. However, regardless of upfront treatment modality, pCR correlates with significantly improved overall survival and recurrence-free survival. A growing body of evidence has identified predictors of pCR spanning clinical and histopathologic features, molecular and genomic alterations, particularly DNA damage response gene mutations, immune biomarkers (e.g., tumor mutational burden and immune gene expression signatures), advanced imaging with multiparametric magnetic resonance imaging and vesical imaging reporting and data system-based assessment, and circulating tumor DNA dynamics. Among these, circulating tumor DNA clearance during neoadjuvant therapy has demonstrated particularly strong predictive and prognostic value. Despite the favorable outcomes associated with pCR, recurrence risk is not negligible, especially among ypT0 patients, highlighting the importance of risk-adapted postoperative surveillance. In parallel, bladder-preserving strategies for carefully selected patients achieving a clinical complete response remain investigational, limited by imperfect concordance between clinical and pathologic response and requiring rigorous multimodal assessment and close follow-up. Collectively, contemporary data indicate that no single biomarker is sufficient to reliably predict pCR; rather, integrated multimodal models offer the greatest potential to refine neoadjuvant treatment selection, inform bladder preservation, and individualize surveillance while maintaining oncologic safety. CI - (c) The Author(s), 2026. FAU - Ghoreifi, Alireza AU - Ghoreifi A AUID- ORCID: 0000-0002-7368-7240 AD - Duke University Department of Urology and Duke Cancer Institute, 40 Duke Medicine Circle, White Zone Room 1562, Durham, NC 27710, USA. FAU - Dudinec, John V AU - Dudinec JV AD - Department of Urology, Duke University Medical Center, Durham, NC, USA. FAU - Refugia, Justin M AU - Refugia JM AD - Department of Urology, Duke University Medical Center, Durham, NC, USA. FAU - Zahir, Mazyar AU - Zahir M AD - Institute of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Nabavizadeh, Reza AU - Nabavizadeh R AD - Department of Urology, Duke University Medical Center, Durham, NC, USA. FAU - Shah, Ankeet M AU - Shah AM AD - Department of Urology, Duke University Medical Center, Durham, NC, USA. FAU - Abern, Michael R AU - Abern MR AD - Department of Urology, Duke University Medical Center, Durham, NC, USA. LA - eng PT - Journal Article PT - Review DEP - 20260619 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC13305378 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - neoadjuvant therapy OT - pathologic complete response OT - surveillance OT - tumor biomarkers COIS- The authors declare that there is no conflict of interest. EDAT- 2026/06/29 12:33 MHDA- 2026/06/29 12:34 PMCR- 2026/06/19 CRDT- 2026/06/29 06:55 PHST- 2026/01/02 00:00 [received] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/06/29 12:34 [medline] PHST- 2026/06/29 12:33 [pubmed] PHST- 2026/06/29 06:55 [entrez] PHST- 2026/06/19 00:00 [pmc-release] AID - 10.1177_17562872261458110 [pii] AID - 10.1177/17562872261458110 [doi] PST - epublish SO - Ther Adv Urol. 2026 Jun 19;18:17562872261458110. doi: 10.1177/17562872261458110. eCollection 2026 Jan-Dec. PMID- 42362411 OWN - NLM STAT- MEDLINE DCOM- 20261006 LR - 20261008 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 90 IP - 4 DP - 2026 Oct TI - Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. PG - 377-388 LID - S0302-2838(26)02209-8 [pii] LID - 10.1016/j.eururo.2026.05.030 [doi] AB - BACKGROUND AND OBJECTIVE: Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. METHODS: We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. KEY FINDINGS AND LIMITATIONS: Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current "one-size-fits-all" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies. CI - Copyright (c) 2026 European Association of Urology. All rights reserved. FAU - Aydogdu, Can AU - Aydogdu C AD - Cleveland Clinic Glickman Urologic Institute & Lerner College of Medicine, Cleveland, OH, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Cleveland Clinic Glickman Urologic Institute & Lerner College of Medicine, Cleveland, OH, USA. FAU - Cheng, Liang AU - Cheng L AD - Brown University/Lifespan Medical Center, Providence, RI, USA. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AD - Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Alhalabi, Omar AU - Alhalabi O AD - The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Brown, Jason R AU - Brown JR AD - University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - University of Cordoba, Cordoba, Spain. FAU - Grivas, Petros AU - Grivas P AD - Fred Hutch Cancer Center, University of Washington, Seattle, WA, USA. FAU - Hwang, Clara AU - Hwang C AD - Henry Ford Health, Detroit, MI, USA. FAU - Grass, G Daniel AU - Grass GD AD - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - The University of Texas MD Anderson Cancer Center, Houston TX, USA. FAU - Chatzkel, Jonathan AU - Chatzkel J AD - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. FAU - Mian, Omar AU - Mian O AD - Fred Hutch Cancer Center, University of Washington, Seattle, WA, USA. FAU - Necchi, Andrea AU - Necchi A AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Ross, Jeff AU - Ross J AD - SUNY Upstate Medical University, Syracuse, NY, USA. FAU - Apolo, Andrea B AU - Apolo AB AD - Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. FAU - Spiess, Philippe E AU - Spiess PE AD - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. FAU - Li, Roger AU - Li R AD - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Electronic address: Roger.Li@moffitt.org. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - ZIA BC011928/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Review DEP - 20260627 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/therapy MH - Genomics MH - *Carcinoma, Transitional Cell/pathology/genetics/therapy MH - Cell Differentiation MH - Biomarkers, Tumor/genetics PMC - PMC13336308 MID - NIHMS2184303 OTO - NOTNLM OT - Divergent differentiation OT - Histologic subtypes OT - Molecular genomics OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Systemic therapy OT - Urothelial carcinoma OT - Variant histology COIS- Financial disclosures: Roger Li certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Petros Grivas has received consulting fees from Merck Sharp & Dohme (MSD), Bristol Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, AbbVie, Bicycle Therapeutics, Replimune, Daiichi Sankyo, Foundation Medicine, Eli Lilly, Urogen, Tyra Biosciences, and Natera. Research funding was provided by MSD, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, and Genentech to the author's institution. Jason Brown has served on scientific advisory boards for AstraZeneca, EMD Serono, Johnson and Johnson, and Pfizer. The author has received honoraria from Ipsen and Johnson and Johnson. Research funding was provided by Pfizer, Roche, Novita Pharmaceutics, and Indaptus Therapeutics to the author's institution. Jeff Ross is an employee of Foundation Medicine. He holds equity in Roche Holdings and Tango Therapeutics and has pending equity in One Bioscience. Phillipe Spiess reports nonfinancial roles, including serving as president of the Global Society of Rare Genitourinary Tumors and as Vice Chair of the NCCN bladder and penile cancer panel. Jon Chatzkel's institution received research funding from Aveo, MSD, Genentech, Exelixis, Eisai, Prometheus, Arsenal Biosciences, Inc, and Allogene Therapeutics. Travel, accommodation, and related expenses were provided directly to the author by Signatera and DAVA Oncology. All remaining authors have nothing to disclose. EDAT- 2026/06/27 04:10 MHDA- 2026/10/06 23:29 PMCR- 2026/07/07 CRDT- 2026/06/26 21:55 PHST- 2026/02/20 00:00 [received] PHST- 2026/05/10 00:00 [revised] PHST- 2026/05/28 00:00 [accepted] PHST- 2026/10/06 23:29 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:55 [entrez] PHST- 2026/07/07 00:00 [pmc-release] AID - S0302-2838(26)02209-8 [pii] AID - 10.1016/j.eururo.2026.05.030 [doi] PST - ppublish SO - Eur Urol. 2026 Oct;90(4):377-388. doi: 10.1016/j.eururo.2026.05.030. Epub 2026 Jun 27. PMID- 42362302 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 53 IP - 3 DP - 2026 Aug TI - Management of High-Risk Non-Muscle-Invasive Bladder Cancer. PG - 441-452 LID - S0094-0143(26)00034-0 [pii] LID - 10.1016/j.ucl.2026.03.008 [doi] AB - High-risk non-muscle-invasive bladder cancer represents a biologically heterogeneous disease with wide variation in recurrence and progression risk, creating persistent challenges in diagnosis, risk stratification, and management. Current guidelines rely on well-described clinicopathologic features to define risk; however, these factors alone often incompletely predict individual patient outcomes and efforts to refine prognostication using molecular profiling and advanced imaging techniques such as multiparametric MRI are under active investigation. Complete transurethral resection (TUR), including restaging TUR in appropriate patients, remains essential for both diagnosis and management. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Tallman, Jacob E AU - Tallman JE AD - Department of Surgery, Section of Urology, University of Chicago, Chicago, IL, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Goh, Alvin C AU - Goh AC AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: goha@mskcc.org. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy/pathology/diagnosis MH - Transurethral Resection of Bladder MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Risk Assessment MH - Prognosis MH - Neoplasm Staging MH - Neoplasm Recurrence, Local OTO - NOTNLM OT - Bladder cancer OT - Early cystectomy OT - Intravesical therapy OT - Radical cystectomy OT - Transurethral resection COIS- Disclosure A.C. Goh: Consultant for Medtronic. J.E. Tallman: Nothing to disclose. EDAT- 2026/06/27 04:10 MHDA- 2026/06/27 18:39 CRDT- 2026/06/26 21:00 PHST- 2026/06/27 18:39 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:00 [entrez] AID - S0094-0143(26)00034-0 [pii] AID - 10.1016/j.ucl.2026.03.008 [doi] PST - ppublish SO - Urol Clin North Am. 2026 Aug;53(3):441-452. doi: 10.1016/j.ucl.2026.03.008. Epub 2026 Apr 29. PMID- 42362301 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 53 IP - 3 DP - 2026 Aug TI - Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer. PG - 429-440 LID - S0094-0143(26)00033-9 [pii] LID - 10.1016/j.ucl.2026.03.007 [doi] AB - Nonmuscle-invasive bladder cancer (NMIBC) is a clinically heterogeneous disease, characterized by a high recurrence rate and a progression risk that are challenging to predict. Although traditional risk models based on histopathology and clinical staging are widely used, their ability to inform personalized treatment remains limited. Recent advances in molecular profiling have provided a more comprehensive understanding of NMIBC biology. This article synthesizes current evidence regarding the molecular determinants, highlighting their roles in enhancing prognostication and informing personalized therapy. Integrating these molecular insights into contemporary risk stratification frameworks is enabling treatment strategies that align with tumor biology to optimize patient outcomes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Nolazco, Jose I AU - Nolazco JI AD - Department of Urology, Mass General Brigham, Harvard Medical School, Boston, MA 02114, USA; Servicio de Urologia, Hospital Universitario Austral, Universidad Austral, Pilar, Argentina. FAU - Yim, Kendrick AU - Yim K AD - Department of Urology, Mass General Brigham, Harvard Medical School, Boston, MA 02114, USA; Department of Urology, Moffitt Cancer Center, Tampa, FL 33612, USA. FAU - Salari, Keyan AU - Salari K AD - Department of Urology, Mass General Brigham, Harvard Medical School, Boston, MA 02114, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: ksalari@mgh.harvard.edu. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/therapy/pathology MH - *Precision Medicine/methods MH - Biomarkers, Tumor/genetics MH - *Urinary Bladder Neoplasms/genetics/therapy/pathology MH - Prognosis OTO - NOTNLM OT - Biomarkers OT - Genomics OT - Molecular subtypes OT - Non-Muscle-Invasive Bladder Cancer OT - Precision oncology EDAT- 2026/06/27 04:10 MHDA- 2026/06/28 00:38 CRDT- 2026/06/26 21:00 PHST- 2026/06/28 00:38 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:00 [entrez] AID - S0094-0143(26)00033-9 [pii] AID - 10.1016/j.ucl.2026.03.007 [doi] PST - ppublish SO - Urol Clin North Am. 2026 Aug;53(3):429-440. doi: 10.1016/j.ucl.2026.03.007. Epub 2026 Apr 29. PMID- 42362300 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 53 IP - 3 DP - 2026 Aug TI - Bacillus Calmette-Guerin Therapy: Optimizing Outcomes amid Challenges. PG - 413-427 LID - S0094-0143(26)00032-7 [pii] LID - 10.1016/j.ucl.2026.03.006 [doi] AB - Bacillus Calmette-Guerin (BCG) remains the cornerstone adjuvant therapy for intermediate-risk and high-risk non--muscle invasive bladder cancer, yet its clinical utility is increasingly challenged by supply shortages, treatment intolerance, and variable oncologic response. This article summarizes the immunologic basis, efficacy, and limitations of BCG, examines evidence for alternative administration strategies, evaluates combination and biomarker-based approaches to optimize patient selection, and outlines emerging therapies for BCG-unresponsive disease. Practical, evidence-driven recommendations are provided to guide contemporary management during periods of constrained supply and evolving therapeutic landscapes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Tazegul, Tutku E AU - Tazegul TE AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA 52242, USA. FAU - O'Donnell, Michael AU - O'Donnell M AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA 52242, USA. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA 52242, USA. Electronic address: hhougen@uiowa.edu. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Non-Muscle Invasive Bladder Neoplasms MH - Administration, Intravesical MH - Treatment Outcome OTO - NOTNLM OT - BCG shortage OT - BCG-Unresponsive disease OT - Bacillus Calmette-Guerin COIS- Disclosure H.Y. Hougen: Consultant for Natera. M. O'Donnell: Consulting relationships with Abbott, Photocure, Fidia, Merck, Theralase, and Urogen. EDAT- 2026/06/27 04:10 MHDA- 2026/06/27 18:37 CRDT- 2026/06/26 21:00 PHST- 2026/06/27 18:37 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:00 [entrez] AID - S0094-0143(26)00032-7 [pii] AID - 10.1016/j.ucl.2026.03.006 [doi] PST - ppublish SO - Urol Clin North Am. 2026 Aug;53(3):413-427. doi: 10.1016/j.ucl.2026.03.006. Epub 2026 Apr 29. PMID- 42362297 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 53 IP - 3 DP - 2026 Aug TI - Transurethral Resection of Bladder Tumors: Evolving Standards of Care-Optimizing Resection, Staging Accuracy, and Recurrence Reduction. PG - 365-376 LID - S0094-0143(26)00029-7 [pii] LID - 10.1016/j.ucl.2026.03.003 [doi] AB - Transurethral resection of bladder tumor (TURBT) remains the foundation of nonmuscle invasive bladder cancer (NMIBC) diagnosis and treatment. The article covers preop evaluation (history, imaging, vesical imaging-reporting and data system, multiparametric MRI, office cystoscopy, and biomarkers), anesthesia/energy choices to limit obturator reflex/perforation, and operative technique using enhanced cystoscopy and selective en bloc resection (EBRT). It stresses meticulous specimen handling, immediate use of intravesical chemotherapy, and indications for second-look TURBT. Despite progress, incomplete resection and understaging are frequent; and broader use of visualization technologies, EBRT in selected cases, and quality programs are key to reducing recurrence and progression of NMIBC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Filon, Mikolaj AU - Filon M AD - Division of Urology, Department of Surgery, University of Utah, Salt Lake City, UT 84112, USA. FAU - Kabra, Shivesh AU - Kabra S AD - Division of Urology, Department of Surgery, Washington University in St. Louis School of Medicine, Saint Louis, MO 63110, USA. Electronic address: https://twitter.com/shivkab. FAU - Smelser, Woodson AU - Smelser W AD - Division of Urology, Department of Surgery, Washington University in St. Louis, St Louis, MO 63110, USA. Electronic address: https://twitter.com/WSmelser. FAU - Schmidt, Bogdana AU - Schmidt B AD - Division of Urology, Department of Surgery, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. Electronic address: Bogdana.schmidt@hci.utah.edu. LA - eng PT - Journal Article PT - Review DEP - 20260520 PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 SB - IM MH - *Transurethral Resection of Bladder/methods/standards MH - Humans MH - *Neoplasm Recurrence, Local/prevention & control MH - Neoplasm Staging MH - Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Standard of Care MH - Cystoscopy/methods OTO - NOTNLM OT - NMIBC OT - Reresection OT - TURBT OT - en bloc COIS- Disclosure B. Schmidt has served on the advisory boards of ImmunityBio, Urogen Pharma, Ferring Pharmaceuticals, Janssen, and Natera. None of these are relevant to this publication. W. Smelser has served on advisory boards of Ferring Pharmaceuticals and Janssen. These disclosures are not relevant to this publication. M. Filon: No conflicts or disclosures. S. Kabra: No conflicts or disclosures. EDAT- 2026/06/27 04:10 MHDA- 2026/06/28 00:38 CRDT- 2026/06/26 21:00 PHST- 2026/06/28 00:38 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:00 [entrez] AID - S0094-0143(26)00029-7 [pii] AID - 10.1016/j.ucl.2026.03.003 [doi] PST - ppublish SO - Urol Clin North Am. 2026 Aug;53(3):365-376. doi: 10.1016/j.ucl.2026.03.003. Epub 2026 May 20. PMID- 42362295 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260628 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 53 IP - 3 DP - 2026 Aug TI - Epidemiology and Risk Factors for Non-Muscle-Invasive Bladder Cancer: Insights into Prevalence, Risk Stratification, and Implications for Early Diagnosis. PG - 343-352 LID - S0094-0143(26)00027-3 [pii] LID - 10.1016/j.ucl.2026.03.001 [doi] AB - Bladder cancer is the 6thth most common type of cancer in the United States and tobacco smoke remains the leading environmental risk factor of the disease. Non-muscle invasive bladder cancer (NMIBC) makes up the majority of bladder cancer cases and is a subtype of bladder cancer that has a high heterogenicity in rates of recurrence and prognosis. The aim of this article is to dive into the prevalence of NMIBC, review the literature and guidelines on how NMIBC is risk stratified, and discuss the utility of early diagnosis of this disease and ways this can be achieved. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Akinsola, Olutiwa AU - Akinsola O AD - Department of Urology, University of Washington, 1959 Northwest Pacific Street, Box 356510, Seattle, WA 98195, USA. FAU - Bharadwaj, Maheetha AU - Bharadwaj M AD - Department of Urology, University of Washington, 1959 Northwest Pacific Street, Box 356510, Seattle, WA 98195, USA. FAU - Psutka, Sarah P AU - Psutka SP AD - Department of Urology, University of Washington, 1959 Northwest Pacific Street, Box 356510, Seattle, WA 98195, USA. Electronic address: spsutka@uw.edu. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/epidemiology/diagnosis MH - Risk Factors MH - Prevalence MH - *Early Detection of Cancer MH - Risk Assessment MH - *Urinary Bladder Neoplasms/epidemiology/diagnosis/pathology MH - Prognosis OTO - NOTNLM OT - Early diagnosis OT - Hematuria OT - Non-Muscle-Invasive Bladder Cancer (NMIBC) OT - Risk stratification COIS- Disclosure None. EDAT- 2026/06/27 04:10 MHDA- 2026/06/28 13:04 CRDT- 2026/06/26 21:00 PHST- 2026/06/28 13:04 [medline] PHST- 2026/06/27 04:10 [pubmed] PHST- 2026/06/26 21:00 [entrez] AID - S0094-0143(26)00027-3 [pii] AID - 10.1016/j.ucl.2026.03.001 [doi] PST - ppublish SO - Urol Clin North Am. 2026 Aug;53(3):343-352. doi: 10.1016/j.ucl.2026.03.001. Epub 2026 Apr 29. PMID- 42360231 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1540-9538 (Electronic) IS - 0022-1007 (Linking) VI - 223 IP - 7 DP - 2026 Jul 6 TI - Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models. LID - e20250699 [pii] LID - 10.1084/jem.20250699 [doi] AB - Intravesical therapies are the mainstay of bladder cancer (BCa) management, but their efficacy is limited by toxicities and recurrences. While CAR T cell therapy has shown promise in hematologic malignancies, its application in solid tumors is limited by poor trafficking and on-target off-tumor toxicities. Here, we identify and validate MUC16 as a clinically relevant target for BCa, noting enriched expression in tumors recalcitrant to existing therapies. We engineered a second-generation mesothelin-based CAR (MSLN-28z) and demonstrated robust activity across multiple BCa cell lines and patient-derived tumor organoids. Intravesical delivery of MSLN-28z CAR T cells in xenograft BCa models conferred superior tumor control compared with intravenous transfer, while attenuating systemic T cell engraftment. Intravesical adoptive transfer uncouples local antitumor efficacy from potential systemic toxicity-a feature conserved across several T cell immunotherapies with on-target off-tumor activity. Collectively, these findings substantiate MUC16 as a therapeutic candidate and validate intravesical delivery as a platform for T cell immunotherapies in the management of organ-confined BCa. CI - (c) 2026 Abrahimi et al. FAU - Abrahimi, Parwiz AU - Abrahimi P AUID- ORCID: 0000-0003-1636-6579 AD - Departments of Urology and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Khan, Jonathan F AU - Khan JF AUID- ORCID: 0000-0002-3444-8108 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. FAU - Duren-Lubanski, Alyssa AU - Duren-Lubanski A AUID- ORCID: 0000-0001-5988-3205 AD - Englander Institute for Precision Medicine, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Cai, Winson AU - Cai W AUID- ORCID: 0000-0001-7121-0986 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Marouf, Yacine AU - Marouf Y AUID- ORCID: 0000-0002-4621-1407 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. FAU - Chen, Nan AU - Chen N AUID- ORCID: 0009-0000-2371-512X AD - Sanavia Oncology, New York, NY, USA. FAU - Hirschhorn, Daniel AU - Hirschhorn D AUID- ORCID: 0000-0003-0467-7687 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. FAU - Mammone, Renata AU - Mammone R AUID- ORCID: 0000-0003-1814-2392 AD - Memorial-Sloan Kettering Cancer Center , New York, NY, USA. ROR: https://ror.org/02yrq0923 FAU - Miranda, Ileana C AU - Miranda IC AUID- ORCID: 0000-0003-3168-0515 AD - Memorial-Sloan Kettering Cancer Center , New York, NY, USA. ROR: https://ror.org/02yrq0923 FAU - Tallman, Jacob E AU - Tallman JE AUID- ORCID: 0000-0002-9930-6493 AD - Memorial-Sloan Kettering Cancer Center , New York, NY, USA. ROR: https://ror.org/02yrq0923 AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. FAU - Vela-Moreno, Alejandra AU - Vela-Moreno A AUID- ORCID: 0009-0008-9651-6955 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. FAU - Hamieh, Mohamad AU - Hamieh M AUID- ORCID: 0000-0003-2146-4755 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. AD - Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Faltas, Bishoy M AU - Faltas BM AUID- ORCID: 0000-0002-6432-1693 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Englander Institute for Precision Medicine, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Carroll, Thomas M AU - Carroll TM AUID- ORCID: 0000-0001-9753-2385 AD - Numen, San Francisco, CA, USA. FAU - Everitt, Micaela L AU - Everitt ML AUID- ORCID: 0000-0002-5343-2443 AD - Numen, San Francisco, CA, USA. FAU - Subramanian, Hari K K AU - Subramanian HKK AUID- ORCID: 0000-0003-2956-9279 AD - Numen, San Francisco, CA, USA. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AUID- ORCID: 0000-0002-2938-6627 AD - Memorial-Sloan Kettering Cancer Center , New York, NY, USA. ROR: https://ror.org/02yrq0923 FAU - Elemento, Olivier AU - Elemento O AUID- ORCID: 0000-0002-8061-9617 AD - Englander Institute for Precision Medicine, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Hopkins, Benjamin D AU - Hopkins BD AUID- ORCID: 0000-0002-7970-6430 AD - Englander Institute for Precision Medicine, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Scherr, Douglas S AU - Scherr DS AUID- ORCID: 0000-0002-0008-0771 AD - Department of Urology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Brentjens, Renier J AU - Brentjens RJ AUID- ORCID: 0000-0002-3364-5388 AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ROR: https://ror.org/0499dwk57 FAU - Wolchok, Jedd D AU - Wolchok JD AUID- ORCID: 0000-0001-6718-2222 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. AD - Englander Institute for Precision Medicine, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Department of Medicine, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 FAU - Merghoub, Taha AU - Merghoub T AUID- ORCID: 0000-0002-1518-5111 AD - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine , New York, NY, USA. ROR: https://ror.org/02r109517 AD - Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. ROR: https://ror.org/02r109517 AD - Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. LA - eng GR - New York Academy of Medicine/ GR - Swim Across America/ GR - Ludwig Institute for Cancer Research/ GR - C-04306/Parker Institute for Cancer Immunotherapy/ PT - Journal Article DEP - 20260626 PL - United States TA - J Exp Med JT - The Journal of experimental medicine JID - 2985109R RN - J27WDC343N (Mesothelin) RN - 0 (CA-125 Antigen) RN - 0 (MUC16 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Receptors, Chimeric Antigen) RN - 0 (GPI-Linked Proteins) RN - 0 (MSLN protein, human) RN - 0 (Msln protein, mouse) SB - IM MH - Animals MH - *Urinary Bladder Neoplasms/therapy/immunology/pathology MH - Humans MH - Mesothelin MH - *CA-125 Antigen/immunology MH - Mice MH - *Immunotherapy, Adoptive/methods MH - Cell Line, Tumor MH - *Membrane Proteins/immunology MH - Female MH - *Receptors, Chimeric Antigen/immunology MH - *T-Lymphocytes/immunology MH - Xenograft Model Antitumor Assays MH - Administration, Intravesical MH - *GPI-Linked Proteins/immunology EDAT- 2026/06/27 00:51 MHDA- 2026/06/27 06:45 CRDT- 2026/06/26 10:22 PHST- 2025/04/01 00:00 [received] PHST- 2025/11/28 00:00 [revised] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/06/27 06:45 [medline] PHST- 2026/06/27 00:51 [pubmed] PHST- 2026/06/26 10:22 [entrez] AID - 282767 [pii] AID - 10.1084/jem.20250699 [doi] PST - ppublish SO - J Exp Med. 2026 Jul 6;223(7):e20250699. doi: 10.1084/jem.20250699. Epub 2026 Jun 26. PMID- 42351435 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 12 DP - 2026 Jun 9 TI - PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer. LID - 10.3390/diagnostics16121776 [doi] LID - 1776 AB - Backgrounds: As one of the important liquid biopsy methods in recent years, circulating tumor cells (CTCs) have been proven to be valuable in judging metastasis and prognosis in various tumors. With the advent of immunotherapy, the expression of programmed death-ligand 1 (PD-L1) on CTCs has also attracted researchers' attention, but its value in bladder cancer has not been fully explored. Methods: This study enrolled patients diagnosed with urothelial carcinoma who were treated in the Department of Urology, The First Affiliated Hospital of Nanjing Medical University from 2020 to 2023. Peripheral blood samples of the patients were collected to detect PD-L1+ CTCs. Meanwhile, the patients' basic clinical characteristics, pathological data, and follow-up information were collected. The Kaplan-Meier method was used to estimate the overall survival (OS) and progression-free survival (PFS) of the patients, and the log-rank test was employed to evaluate the statistical differences. COX regression analysis and Firth penalized Cox regression analysis were adopted to assess the risk factors. Finally, according to the clinical or pathological characteristics, the effects of PD-L1+/PD-L1- CTCs on different subgroups of the population were evaluated, respectively. Results: According to the inclusion and exclusion criteria, a total of 109 patients were finally enrolled in this study, including 95 males and 16 females, with a median age of 68 years. The expression of PD-L1 on CTC was as follows: 19 patients were PD-L1+ CTC and 90 patients were PD-L1- CTCs. The results showed that the pathological grade of patients with PD-L1+ CTCs was significantly higher than that of patients with PD-L1- CTCs (p = 0.003). With a median follow-up time of 48 months (IQR: 45.8-49.5), prognostic analysis indicated that PD-L1+ CTCs were a risk factor for OS in bladder cancer patients (HR = 4.696 (1.477-13.596), p = 0.011). Subgroup analysis revealed that in patients with non-muscle-invasive bladder cancer (NMIBC) and in the subgroup of patients with high pathological grade, those with PD-L1+ CTCs exhibited significantly poorer prognosis in terms of PFS and OS compared with patients with PD-L1- CTCs. Conclusions: The presence of PD-L1+ CTCs in patients with bladder carcinoma may be closely associated with high-grade disease and poor OS. FAU - Feng, Tianshuo AU - Feng T AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Jiang, Linjing AU - Jiang L AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Yang, Xiao AU - Yang X AUID- ORCID: 0000-0002-5429-9162 AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Yang, Haiwei AU - Yang H AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. FAU - Lu, Qiang AU - Lu Q AUID- ORCID: 0000-0003-3589-2507 AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing 210029, China. LA - eng GR - 2024ZD0525700/Noncommunicable Chronic Diseases-National Science and Technology Major Project/ GR - 82273152, 82503879/the National Natural Science Foundation of China/ GR - 2024M761211/China Postdoctoral Science Foundation funded project/ GR - 2024BHS210/Nanjing Postdoctoral Science Foundation funded project/ GR - BK20241128/Natural Science Foundation of Jiangsu Province/ GR - 320.6750.2025-26-45/Special Research Fund of the Wu Jieping Medical Foundation/ PT - Journal Article DEP - 20260609 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13298106 OTO - NOTNLM OT - PD-L1 OT - bladder cancer OT - circulating tumor cells OT - prognosis COIS- The authors declare no conflicts of interest. EDAT- 2026/06/26 10:10 MHDA- 2026/06/26 10:11 PMCR- 2026/06/09 CRDT- 2026/06/26 01:00 PHST- 2026/03/01 00:00 [received] PHST- 2026/06/05 00:00 [revised] PHST- 2026/06/06 00:00 [accepted] PHST- 2026/06/26 10:11 [medline] PHST- 2026/06/26 10:10 [pubmed] PHST- 2026/06/26 01:00 [entrez] PHST- 2026/06/09 00:00 [pmc-release] AID - diagnostics16121776 [pii] AID - diagnostics-16-01776 [pii] AID - 10.3390/diagnostics16121776 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Jun 9;16(12):1776. doi: 10.3390/diagnostics16121776. PMID- 42348111 OWN - NLM STAT- MEDLINE DCOM- 20260917 LR - 20260917 IS - 1559-0283 (Electronic) IS - 1085-9195 (Linking) VI - 84 IP - 3 DP - 2026 Sep TI - Association of Epithelial-to-Mesenchymal Transition Related Markers With Clinical Outcome in Non-Muscle Invasive and Muscle Invasive Bladder Cancer Patients. PG - 4089-4103 LID - 10.1007/s12013-026-02106-z [doi] AB - Clinical significance of epithelial-to-mesenchymal transition (EMT)-related markers was evaluated in a cohort of NMIBC (non-muscle invasive bladder cancer) and MIBC (muscle invasive bladder cancer) patients. Real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical (IHC) staining were carried out in 100 tumor specimens [59 NMIBC and 41 MIBC]. The expressions of the epithelial marker, mesenchymal markers and EMT-activating transcription factors (EMT-ATFs) were determined at mRNA and protein level followed by their statistical associations with clinicohistopathological variables of the patients. Expression of E-cadherin at mRNA level exhibited significant association with tumor type in NMIBC cohort and with age of MIBC patients. Association of mRNA levels of N-cadherin was reported with smoking/tobacco chewing status (S/TC) of NMIBC patients and with tumor type in MIBC cohort. Membranous expression of Vimentin protein showed significance with age of MIBC patients. Gene expression of Snail showed relevance with tumor type and S/TC status of NMIBC patients whereas its protein (nuclear) expression exhibited significance with tumor grade in NMIBC cohort. Nuclear expression of Slug showed significance with S/TC status of NMIBC patients. The study reported significances of gene levels of Twist with tumor stage and age of MIBC patients while its protein (nuclear) expression with tumor grade in NMIBC cohort. Zeb-1 mRNA levels exhibited statistical relevance with tumor stage while its protein (nuclear) expression with tumor grade in NMIBC patients. Survival analysis identified Vimentin as the predictor of short progression free survival (PFS) and short overall survival (OS) in MIBC patients. Study established altered EMT profile as an independent predictor of short recurrence free survival (RFS) in NMIBC patients and of short PFS and OS in MIBC patients. Observed significances of EMT-related markers with patients' clinicohistopathological variables as well as with their survival outcome may strengthen risk stratification and hence could be of importance in the clinical management of bladder cancer patients. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Singh, R AU - Singh R AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. FAU - Up, Singh AU - Up S AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India. FAU - Garg, Minal AU - Garg M AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. garg_minal@lkouniv.ac.in. LA - eng GR - SR/SO/HS-0113/2010/Department of Science and Technology, Govt. of India/ PT - Journal Article DEP - 20260625 PL - United States TA - Cell Biochem Biophys JT - Cell biochemistry and biophysics JID - 9701934 RN - 0 (Biomarkers, Tumor) RN - 0 (Cadherins) RN - 0 (Vimentin) RN - 0 (RNA, Messenger) RN - 0 (Snail Family Transcription Factors) RN - 0 (Zinc Finger E-box-Binding Homeobox 1) SB - IM MH - Humans MH - *Epithelial-Mesenchymal Transition MH - Female MH - Male MH - *Biomarkers, Tumor/metabolism/genetics MH - Middle Aged MH - Non-Muscle Invasive Bladder Neoplasms/pathology MH - Aged MH - *Urinary Bladder Neoplasms/pathology/metabolism MH - Cadherins/metabolism/genetics MH - Vimentin/metabolism/genetics MH - RNA, Messenger/metabolism MH - Snail Family Transcription Factors/metabolism/genetics MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Prognosis MH - Disease-Free Survival MH - Adult MH - Zinc Finger E-box-Binding Homeobox 1/metabolism/genetics OTO - NOTNLM OT - Bladder cancer OT - Epithelial-to-mesenchymal transition OT - Markers OT - Prognosis OT - Survival probabilities COIS- Declarations. Ethics Approval: Studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Ethical clearance was obtained from Bioethics Cell, Institutional Ethics Committee (IEC) SGPGIMS, Lucknow, India (Reference no. 2014-166-CP-80). Consent to Participate: Analysis used anonymous data that were obtained after each patient agreed to participate in the study. A written informed consent was taken from each patient or immediate family member. Conflict of Interests: The authors declare no competing interests. EDAT- 2026/06/25 12:38 MHDA- 2026/09/17 18:32 CRDT- 2026/06/25 11:18 PHST- 2026/06/10 00:00 [accepted] PHST- 2026/09/17 18:32 [medline] PHST- 2026/06/25 12:38 [pubmed] PHST- 2026/06/25 11:18 [entrez] AID - 10.1007/s12013-026-02106-z [pii] AID - 10.1007/s12013-026-02106-z [doi] PST - ppublish SO - Cell Biochem Biophys. 2026 Sep;84(3):4089-4103. doi: 10.1007/s12013-026-02106-z. Epub 2026 Jun 25. PMID- 42342497 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260902 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis. PG - 946-957 LID - S2588-9311(26)00173-2 [pii] LID - 10.1016/j.euo.2026.06.005 [doi] AB - BACKGROUND: Dedicated tools estimating the risk of Bacillus Calmette-Guerin (BCG) failure among patients with high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) are lacking. OBJECTIVE: To develop a risk model predicting the development of BCG-unresponsive disease (defined according to the International Bladder Cancer Group and European Association of Urology [EAU] guidelines) or progression in patients with HG NMIBC receiving adequate BCG therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective multicenter study included 2211 patients who were BCG naive with HG Ta/T1 NMIBC (+/-carcinoma in situ [CIS]) treated with adequate BCG therapy between January 2003 and December 2024 at 13 academic centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was time to BCG-unresponsive disease or progression to muscle-invasive/metastatic cancer. Multivariable Cox regression identified independent predictors, and a weighted clinical risk score stratified patients into four risk groups. RESULTS AND LIMITATIONS: Independent risk factors included T1 stage (adjusted hazard ratio [aHR] 1.52, 95% confidence interval [CI] 1.10-2.11), persistent HG or T1 tumor at restaging transurethral resection (aHR 2.51, 95% CI 2.06-3.06), multifocality (aHR 1.46, 95% CI 1.22-1.74), concomitant CIS (aHR 1.46, 95% CI 1.21-1.77), and World Health Organization 1973/2004/2016 HG/grade 3 (aHR 1.56, 95% CI 1.24-1.94). Internal validation via 1000 bootstrap samples revealed minimal optimism (0.01) and good calibration. The model demonstrated superior discrimination compared with the European Organization for Research and Treatment of Cancer progression score and EAU 2021 stratification (Harrell concordance index 0.68 vs 0.61 vs 0.56); 5-yr BCG-unresponsive-free survival was 88%, 79%, 60%, and 49%, respectively, across increasing risk groups. CONCLUSIONS: We developed a risk stratification model for patients with HG Ta/T1 treated with adequate BCG therapy. This tool enables individualized assessment of BCG failure risk and may support clinical decision-making. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Electronic address: slusarczyk.aleksander@gmail.com. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Claps, Francesco AU - Claps F AD - Oncological Urology, Veneto Institute of Oncology, Padua, Italy. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Clinica Universidad de Navarra, Cancer Center, Pamplona, Spain. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Garbas, Karolina AU - Garbas K AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Del Olmo Duran, Pedro AU - Del Olmo Duran P AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Lijnen, Renee A G AU - Lijnen RAG AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Fertitta, Giorgia AU - Fertitta G AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Reynard, Maxence AU - Reynard M AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Katzendorn, Olga AU - Katzendorn O AD - Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal, Infant, and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, University of Florence, Careggi Hospital, Florence, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Aarau Kantonsspital, Aarau, Switzerland. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Unit, Department of Surgical Sciences, Policlinico Tor Vergata, Tor Vergata University, Roma, Italy. FAU - Amodeo, Antonio AU - Amodeo A AD - Oncological Urology, Veneto Institute of Oncology, Padua, Italy. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. CN - European Association of Urology-Young Academic Urologists (EAU-YAU) CN - Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260625 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/therapeutic use MH - Female MH - Retrospective Studies MH - Male MH - Aged MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Neoplasm Grading MH - Treatment Failure MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Disease Progression MH - Risk Assessment OTO - NOTNLM OT - BCG therapy OT - BCG-unresponsive tumor OT - Progression OT - Recurrence OT - Risk stratification OT - Survival OT - Urinary neoplasm of the bladder OT - Urothelial cancer EDAT- 2026/06/25 00:33 MHDA- 2026/09/01 23:34 CRDT- 2026/06/24 21:55 PHST- 2025/12/14 00:00 [received] PHST- 2026/04/24 00:00 [revised] PHST- 2026/06/10 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/06/25 00:33 [pubmed] PHST- 2026/06/24 21:55 [entrez] AID - S2588-9311(26)00173-2 [pii] AID - 10.1016/j.euo.2026.06.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):946-957. doi: 10.1016/j.euo.2026.06.005. Epub 2026 Jun 25. PMID- 42341207 OWN - NLM STAT- MEDLINE DCOM- 20260909 LR - 20260915 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 216 IP - 4 DP - 2026 Oct TI - Oncological Outcomes of Nonmuscle-Invasive Bladder Cancer in Patients Aged 45 Years and Younger: A Retrospective Matched Cohort Study. PG - 551-558 LID - 10.1097/JU.0000000000005183 [doi] AB - PURPOSE: Most bladder cancers are diagnosed as nonmuscle invasive (NMIBC), with 90% after the age of 55 years. Although the incidence of several malignancies is increasing among younger adults in whom more aggressive behavior is observed, our knowledge about NMIBC in young patients remains limited. We compared oncological outcomes in patients with NMIBC aged 45 years and younger with a cohort of older patients. MATERIALS AND METHODS: This is a retrospective study of NMIBC diagnosed at age 45 years or younger (2005-2022) from 4 Canadian centers. End points included cancer-specific mortality, risk of metastasis, progression to muscle invasion, NMIBC progression (eg, Ta/carcinoma in situ to T1), grade progression, and recurrence. Competing risk analysis and Kaplan-Meier estimates were used. Hazard ratios were calculated using Fine and Gray regression. Propensity-score matching (3:1) was used with patients older than 45 years. Scores were estimated using a logistic regression model incorporating sex, carcinoma in situ, stage, grade, tumor size, and number and year of transurethral resection of bladder tumor. RESULTS: Among 158 patients, the median age was 39 years (IQR 32-42) and median follow-up 6.0 years (IQR 2.9-9.8). The majority were male (66%), with solitary (78%), low-grade (64%), Ta (82%) tumors. After 3:1 matching, 124 younger patients were compared with 350 older patients (median age 76 years, IQR 69-82). Recurrence rates were higher in older patients (HR 1.53, 95% CI 1.09-2.14, P = .013). Cancer-specific mortality, grade progression, and progression to muscle invasion or metastasis were not significantly different (all P > .05) between groups. CONCLUSIONS: NMIBC exhibits similar behavior in patients younger than 45 years compared with older patients but with a lower recurrence rate. FAU - St-Laurent, Marie-Pier AU - St-Laurent MP AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Din, Shayan AU - Din S AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Moryousef, Joseph AU - Moryousef J AD - Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Lajkosz, Katherine AU - Lajkosz K AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Kwong, Jethro C C AU - Kwong JCC AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Chan, Amy AU - Chan A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. FAU - Kim, Jaehoon AU - Kim J AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Taborek, Afton AU - Taborek A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. FAU - Chadee, Avesh AU - Chadee A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. FAU - Sadri, Iman AU - Sadri I AD - Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Reznik, Gabrielle AU - Reznik G AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Tin, Caris AU - Tin C AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20260624 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2026 Oct;216(4):558. doi: 10.1097/JU.0000000000005201. PMID: 42713899 MH - Humans MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/pathology MH - Female MH - Male MH - Age Factors MH - Middle Aged MH - Transurethral Resection of Bladder MH - Adult MH - Disease Progression MH - *Neoplasm Recurrence, Local/epidemiology MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Neoplasm Invasiveness MH - Canada/epidemiology MH - Treatment Outcome OTO - NOTNLM OT - disease progression OT - early-onset OT - nonmuscle-invasive bladder neoplasms OT - recurrence OT - young age EDAT- 2026/06/24 18:35 MHDA- 2026/09/09 11:38 CRDT- 2026/06/24 15:23 PHST- 2026/09/09 11:38 [medline] PHST- 2026/06/24 18:35 [pubmed] PHST- 2026/06/24 15:23 [entrez] AID - 10.1097/JU.0000000000005183 [doi] PST - ppublish SO - J Urol. 2026 Oct;216(4):551-558. doi: 10.1097/JU.0000000000005183. Epub 2026 Jun 24. PMID- 42339693 OWN - NLM STAT- MEDLINE DCOM- 20260624 LR - 20260701 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 132 IP - 13 DP - 2026 Jul 1 TI - Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel. PG - e70498 LID - 10.1002/cncr.70498 [doi] AB - BACKGROUND: Patients with very high-risk (VHR), nonmuscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy face limited treatment options. Immune checkpoint inhibitor-based regimens have demonstrated promise but lack reliable biomarkers to guide patient selection. The objective of this study was to identify magnetic resonance imaging-derived radiomic phenotypes predictive of treatment response to immune checkpoint inhibitor-based therapy. METHODS: The authors retrospectively analyzed two prospective cohorts of patients with extensive VHR NMIBC: a single-center derivation cohort from the TRUCE-02 trial (n = 59) and a multicenter validation cohort from the TRUCE-22 trial (n = 37). All patients received tislelizumab and nanoparticle albumin-bound paclitaxel every 3 weeks. Complete response (CR) was assessed at 3 months. Radiomic features were extracted from baseline, T2-weighted images, and a hybrid framework integrating supervised feature selection with unsupervised clustering was used to identify imaging phenotypes. Associations with CR, progression-free and overall survival, and immune-related transcriptional signatures were evaluated. RESULTS: Three radiomic clusters were identified: immune-excluded (cluster 0), immune-intermediate (cluster 1), and immune-inflamed (cluster 2). In the derivation cohort, cluster 2 had a significantly higher CR rate (82.8%) than cluster 0 (21.4%; p = .001), a pattern that was validated in TRUCE-22 (83.3% vs. 22.2%; p = .008). The cluster-only model achieved the highest predictive performance for CR in both the derivation (area under the receiver operating characteristic curve, 0.77) and validation (area under the receiver operating characteristic curve, 0.78) cohorts. Cluster 2 had better progression-free and overall survival. Transcriptomic and immunofluorescence analyses revealed functional immune suppression in cluster 0, including reduced CD8-positive, phosphorylated STAT1-positive T cells. CONCLUSIONS: In patients with very high-risk NMIBC, magnetic resonance imaging-derived radiomic phenotypes can be used to stratify responses to immunochemotherapy and capture functional immune states. Noninvasive radiomic profiling may guide precision treatment selection in patients who are unfit for radical cystectomy, and prospective validation is warranted before clinical adoption. CI - (c) 2026 American Cancer Society. FAU - Huang, Shiwang AU - Huang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Jia, Kaipeng AU - Jia K AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liang, Shan AU - Liang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Ma, Boyue AU - Ma B AD - Department of Medical Imaging Technology, Tianjin Medical University, Tianjin, China. FAU - Chen, Huitong AU - Chen H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Zhang, Zhe AU - Zhang Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Kang, Ning AU - Kang N AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Lin, Yuda AU - Lin Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Li, Peng AU - Li P AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Xue, Zihan AU - Xue Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Chen, Houyuan AU - Chen H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Zhao, Yang AU - Zhao Y AD - Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Guo, Jianing AU - Guo J AD - Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Li, Changping AU - Li C AD - Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin, China. FAU - Chai, Wang AU - Chai W AD - Department of Urology, Yellow River Hospital, Tianjin, China. FAU - Cui, Jingmin AU - Cui J AD - Department of Urology, Tangshan Workers Hospital, Hebei Province, China. FAU - Xu, Guoping AU - Xu G AD - Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Qie, Yunkai AU - Qie Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Shen, Chong AU - Shen C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Hu, Hailong AU - Hu H AUID- ORCID: 0000-0001-8675-5524 AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. LA - eng GR - 2024ZD0525700/Noncommunicable Chronic Diseases-National Science and Technology Major Project/ GR - 2023YFC2507003/National Key R&D Program of China/ GR - 82403319/National Natural Science Foundation of China/ GR - 25JCLMJC00330/Project of Science and Technology Plan of Tianjin City/ GR - 25JCLZJC00270/Project of Science and Technology Plan of Tianjin City/ GR - 2024XKZXY05/Ascent Plan of Tianjin Medical University Disciplines-Integrated Chinese and Western Medicine/ GR - 2023203/Scientific Research Project of Tianjin Municipal Health Commission/ GR - MYSRC202310/Tianjin Institute of Urology Talent Funding Program/ GR - MYSRC202402/Tianjin Institute of Urology Talent Funding Program/ GR - MYSRC202409/Tianjin Institute of Urology Talent Funding Program/ GR - 2023LC03/Clinical Medicine Research Project of the Second Hospital of Tianjin Medical University/ GR - 2024KJ192/Scientific Research Project of Tianjin Municipal Education Commission/ PT - Journal Article PT - Multicenter Study PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Albumin-Bound Paclitaxel) SB - IM MH - Humans MH - Radiomics MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/immunology/diagnostic imaging MH - Female MH - *Magnetic Resonance Imaging/methods MH - Aged MH - Retrospective Studies MH - Male MH - Phenotype MH - *Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use MH - *Albumin-Bound Paclitaxel/administration & dosage MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/immunology/diagnostic imaging MH - Nanoparticles OTO - NOTNLM OT - biomarker OT - immune microenvironment OT - immunochemotherapy OT - nonmuscle-invasive bladder cancer OT - radiomics OT - treatment response EDAT- 2026/06/24 12:36 MHDA- 2026/06/24 18:35 CRDT- 2026/06/24 06:42 PHST- 2026/05/09 00:00 [revised] PHST- 2025/09/18 00:00 [received] PHST- 2026/05/25 00:00 [accepted] PHST- 2026/06/24 18:35 [medline] PHST- 2026/06/24 12:36 [pubmed] PHST- 2026/06/24 06:42 [entrez] AID - 10.1002/cncr.70498 [doi] PST - ppublish SO - Cancer. 2026 Jul 1;132(13):e70498. doi: 10.1002/cncr.70498. PMID- 42336158 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260827 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 214 DP - 2026 Aug TI - A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder. PG - 35-40 LID - S0090-4295(26)00412-7 [pii] LID - 10.1016/j.urology.2026.06.031 [doi] AB - OBJECTIVE: To evaluate whether high-frequency ultrasound (HF-US) and ultrasound-guided core needle biopsy (CNB) can accurately detect muscle-invasive bladder cancer (MIBC) in an ex-vivo setting. METHODS: In this prospective study, patients undergoing radical cystectomy (RC) for urothelial carcinoma underwent ex-vivo HF-US of the extirpated bladder to assess depth of tumor invasion (ultrasound stage, usT). In a subset, HF-US guided CNB of the opened bladder targeted the deepest region of tumor invasion (cnbT). Ultrasound images and biopsy specimens were interpreted by a blinded GU-radiologist and pathologist, respectively and were compared with RC pathologic stage (pT). Co-primary endpoints were accuracy of HF-US and CNB in identifying MIBC. RESULTS: Among 54 patients, 48 underwent HF-US and 32 underwent CNB. HF-US demonstrated an accuracy of 89.6% for detecting MIBC, with sensitivity 95.0%, specificity 85.7%, and negative predictive value (NPV) 96.0%. CNB accuracy was 90.6%, with specificity and positive predictive value of 100%. In patients undergoing both modalities (n=25), a combined approach demonstrated 92.0% accuracy, 100% sensitivity, and 100% NPV. Conventional clinical staging had significantly lower accuracy (55.6%), particularly following neoadjuvant systemic therapy (40.0%). Diagnostic performance of HF-US and CNB remained high in patients treated with neoadjuvant systemic or intravesical therapy. CONCLUSION: HF-US and ultrasound-guided CNB were highly accurate in determining MIBC and specifically demonstrated excellent NPV. These findings support further investigation of in-vivo endoscopic ultrasound and CNB staging to improve risk stratification and treatment selection in bladder cancer. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Roberson, Daniel S AU - Roberson DS AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Wang, Michael K AU - Wang MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - McLeay Ii, Matthew T AU - McLeay Ii MT AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Wei, Nancy AU - Wei N AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Potretzke, Theodora A AU - Potretzke TA AD - Department of Radiology, Rochester, MN. FAU - Gupta, Sounak AU - Gupta S AD - Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN. FAU - Cheville, John C AU - Cheville JC AD - Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN. FAU - Kern, Ryan AU - Kern R AD - Department of Pulmonology Mayo Clinic, Rochester, MN. FAU - Lomas, Derek AU - Lomas D AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Mynderse, Lance AU - Mynderse L AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Khanna, Abhinav AU - Khanna A AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Shah, Paras H AU - Shah PH AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Jeffrey Karnes, R AU - Jeffrey Karnes R AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Sharma.Vidit@mayo.edu. LA - eng PT - Journal Article DEP - 20260623 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - Neoplasm Staging/methods MH - Pilot Projects MH - Male MH - Prospective Studies MH - Female MH - Aged MH - Biopsy, Large-Core Needle MH - Middle Aged MH - Ultrasonography/methods MH - Neoplasm Invasiveness MH - *Carcinoma, Transitional Cell/pathology/diagnostic imaging COIS- Declaration of Competing Interest Vidit Sharma (VS) owns common stock in ImmunityBio worth <$5000 and participated in a scientific advisory board meeting for which he was remunerated $3000. R Jeffrey Karnes (RJK) serves on the advisory board of Ferring. Stephen A Boorjian (SAB) is a consultant for Ferring and Johnson and Johnson in the non-muscle invasive bladder cancer space. No other authors have relevant conflicts of interest to disclose. EDAT- 2026/06/24 00:46 MHDA- 2026/08/28 11:40 CRDT- 2026/06/23 19:33 PHST- 2026/02/01 00:00 [received] PHST- 2026/05/18 00:00 [revised] PHST- 2026/06/16 00:00 [accepted] PHST- 2026/08/28 11:40 [medline] PHST- 2026/06/24 00:46 [pubmed] PHST- 2026/06/23 19:33 [entrez] AID - S0090-4295(26)00412-7 [pii] AID - 10.1016/j.urology.2026.06.031 [doi] PST - ppublish SO - Urology. 2026 Aug;214:35-40. doi: 10.1016/j.urology.2026.06.031. Epub 2026 Jun 23. PMID- 42332658 OWN - NLM STAT- MEDLINE DCOM- 20260904 LR - 20260911 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Jun 22 TI - A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management. LID - 10.1186/s12885-026-16361-z [doi] LID - 1048 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high recurrence rate requiring lifelong cystoscopic surveillance. Existing urine-based molecular assays mainly rely on mutations or methylation, which fail to capture large-scale genomic instability. Copy number variation (CNV) profiling offers complementary information on tumor evolution and aggressiveness, but its application in urinary diagnosis remains limited. We aimed to integrate CNV and DNA methylation signals from urinary DNA to establish a noninvasive and biologically informed stratified diagnostic model for NMIBC recurrence surveillance and risk stratification. METHODS: Urine samples were prospectively collected from 91 patients (75 evaluable) between June 2021 and August 2023. Shallow whole-genome sequencing (sWGS) was used to detect CNVs at chromosomal arm and focal gene levels, while ONECUT2 promoter methylation was quantified by qPCR. Diagnostic and prognostic performance was evaluated by ROC analysis, Kaplan-Meier survival, and stratified recurrence assessment. RESULTS: We evaluated a stratified diagnostic model combining CNV and ONECUT2 methylation testing in a cohort of 79 patients. CNV analysis alone showed high specificity (0.923) for NMIBC diagnosis. A combined model, using CNV as an initial screen followed by ONECUT2 methylation testing in CNV-positive cases, achieved a sensitivity of 0.783, specificity of 0.981, and a negative predictive value (NPV) of 0.911. This approach reduced the number of required ONECUT2 tests by 35% and identified a high proportion of true-negative patients (98.1%), which may help reduce unnecessary cystoscopy procedures. The model also demonstrated significant prognostic value, with the molecularly defined high-risk group showing significantly shorter recurrence-free survival (RFS) than the low-risk group (median RFS: 4.33 months vs. not reached; p < 0.001). Additional, in patients with initially negative cystoscopy after urine sample collection, the model demonstrated a predictive accuracy of 0.922 for recurrence, with molecular positivity observed a median of 9.6 months prior to clinical diagnosis. CONCLUSIONS: Integrating CNV and DNA methylation profiling from urinary DNA provides a powerful and noninvasive molecular framework for NMIBC surveillance. By combining early epigenetic changes with genomic instability signals, this approach enhances recurrence risk assessment and enables earlier detection compared with conventional cystoscopy. It offers a practical route toward personalized and adaptive post-treatment monitoring of NMIBC. TRIAL REGISTRATION: NCT04994197. CI - (c) 2026. The Author(s). FAU - Yi, Liqi AU - Yi L AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Ma, Zhiyang AU - Ma Z AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Zhang, Jianhua AU - Zhang J AD - Genetron Health (Beijing) Co. Ltd., Beijing, 102206, China. FAU - Zhan, Ying AU - Zhan Y AD - Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xiao, Hanqing AU - Xiao H AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Dai, Kaihan AU - Dai K AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Liu, Yulai AU - Liu Y AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Gao, Yi AU - Gao Y AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. FAU - Yang, Xiaoqun AU - Yang X AD - Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Cao, Dandan AU - Cao D AD - Genetron Health (Beijing) Co. Ltd., Beijing, 102206, China. caodandan11111@163.com. FAU - Xu, Danfeng AU - Xu D AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xdf12036@rjh.com.cn. FAU - Huang, Hai AU - Huang H AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. hh12295@rjh.com.cn. AD - Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai JiaoTong University School of Medicine, Shanghai, China. hh12295@rjh.com.cn. AD - Department of Urology, Sanming First Hospital Affiliated to Fujian Medical University, Sanming, Fujian province, China. hh12295@rjh.com.cn. LA - eng SI - ClinicalTrials.gov/NCT04994197 GR - 82573884/the National Nature Science Foundation of China/ GR - 82173045/the National Nature Science Foundation of China/ GR - 82573308/the National Nature Science Foundation of China/ GR - No.24ZR1446700/the Natural Science Foundation of the Science and Technology Innovation Action Plan of Shanghai/ PT - Journal Article DEP - 20260622 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/urine/genetics/diagnosis MH - DNA Copy Number Variations MH - DNA Methylation MH - Prognosis MH - Female MH - *Biomarkers, Tumor/urine/genetics MH - Aged MH - Male MH - Neoplasm Recurrence, Local/genetics/diagnosis/urine MH - Middle Aged MH - Prospective Studies MH - *Urinary Bladder Neoplasms/genetics/urine/diagnosis MH - Aged, 80 and over PMC - PMC13543633 OTO - NOTNLM OT - Copy number variation OT - DNA methylation OT - NMIBC OT - Recurrence surveillance OT - Risk stratification OT - Urinary biomarker COIS- Declarations. Ethics approval and consent to participate: the present study was approved by the Institutional Ethical Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine (Approval No.: 2021/158), according to the Declaration of Helsinki. The trial was registered on ClinicalTrials.gov (NCT04994197) on July, 2021. The participants provided their written informed consent to participate in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/06/23 11:37 MHDA- 2026/09/04 05:36 PMCR- 2026/06/22 CRDT- 2026/06/23 01:08 PHST- 2026/01/22 00:00 [received] PHST- 2026/06/11 00:00 [accepted] PHST- 2026/09/04 05:36 [medline] PHST- 2026/06/23 11:37 [pubmed] PHST- 2026/06/23 01:08 [entrez] PHST- 2026/06/22 00:00 [pmc-release] AID - 10.1186/s12885-026-16361-z [pii] AID - 16361 [pii] AID - 10.1186/s12885-026-16361-z [doi] PST - epublish SO - BMC Cancer. 2026 Jun 22;26(1):1048. doi: 10.1186/s12885-026-16361-z. PMID- 42328282 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260622 LR - 20260813 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 19 DP - 2026 TI - Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. PG - 614003 LID - 10.2147/OTT.S614003 [doi] LID - 614003 AB - Bacillus Calmette Guerin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) remains a difficult clinical setting in which radical cystectomy offers the most reliable oncologic control but is not feasible or acceptable for many patients. This review examines contemporary bladder-preserving strategies, with emphasis on biologic intravesical platforms, device-assisted drug-delivery systems, systemic immunotherapy, and pragmatic intravesical chemotherapy alternatives. These approaches should not be viewed as interchangeable. Biologic platforms seek to restore or intensify local antitumor immunity, whereas device-assisted strategies aim to overcome the pharmacokinetic limitations of conventional intravesical therapy by improving residence time, exposure, or tissue penetration. Across platforms, clinically meaningful activity has been reported, but current evidence remains constrained by single-arm study designs, heterogeneous eligibility criteria, non-equivalent endpoints, and variable follow-up maturity. As a result, available data support expansion of bladder-preserving options but do not establish a definitive treatment hierarchy. In clinical practice, differences in durability, toxicity, treatment burden, BCG dependence, device requirements, access, and biomarker eligibility may be as important as initial response rates. The central challenge is therefore shifting from whether bladder preservation is possible to how available options should be selected, sequenced, and integrated for individual patients. More harmonized comparative evidence, mature post-failure data, and clinically deployable biomarker frameworks will be needed to guide future treatment allocation. CI - (c) 2026 Zhang and Ren. FAU - Zhang, Kaiyuan AU - Zhang K AD - Department of Urology, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Ren, Yanche AU - Ren Y AD - Department of Urology, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. LA - eng PT - Journal Article PT - Review DEP - 20260615 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC13281876 OTO - NOTNLM OT - Bacillus Calmette Guerin OT - Bacillus Calmette Guerin-unresponsive OT - bladder preservation OT - device-assisted drug delivery OT - intravesical therapy OT - non-muscle-invasive bladder cancer COIS- The authors declare no competing interests. EDAT- 2026/06/22 13:43 MHDA- 2026/06/22 13:44 PMCR- 2026/06/15 CRDT- 2026/06/22 07:23 PHST- 2026/04/02 00:00 [received] PHST- 2026/06/05 00:00 [accepted] PHST- 2026/06/22 13:44 [medline] PHST- 2026/06/22 13:43 [pubmed] PHST- 2026/06/22 07:23 [entrez] PHST- 2026/06/15 00:00 [pmc-release] AID - 614003 [pii] AID - 10.2147/OTT.S614003 [doi] PST - epublish SO - Onco Targets Ther. 2026 Jun 15;19:614003. doi: 10.2147/OTT.S614003. eCollection 2026. PMID- 42325814 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260622 LR - 20260813 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 89 DP - 2026 Jul TI - Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer. PG - 77-88 LID - 10.1016/j.euros.2026.05.017 [doi] AB - BACKGROUND AND OBJECTIVE: Despite available therapies, patients with non-muscle-invasive bladder cancer (NMIBC) are impacted by recurrence and progression risk. Bel-sar (belzupacap sarotalocan) is a first-in-class virus-like drug conjugate composed of a tumor-targeting virus-like particle linked to a photoactivatable dye, inducing proimmunogenic tumor cell death and antitumor immune response. We report clinical and exploratory immune biomarker data from a phase 1 study in intermediate-risk and high-risk NMIBC. METHODS: Seventeen participants received focally injected bel-sar (100-200 microg) without (n = 5) or with (n = 12) light activation, followed by transurethral resection of bladder tumor (TURBT; 7-12 d later). Safety, feasibility, tolerability, and preliminary efficacy were assessed. Multiplex immunofluorescence was performed on paired tumor specimens from five responders receiving light-activated bel-sar. KEY FINDINGS AND LIMITATIONS: Bel-sar was well tolerated, with only grade 1 adverse events, and no grade >/=2, serious, or dose-limiting toxicities. Among 10 efficacy-evaluable patients receiving light activation, four of five low-grade tumors achieved complete response. Responses were also observed in high-grade and untreated tumors, suggesting a urothelial field effect. Immune profiling demonstrated conversion of immune-cold or exhausted tumors into immunogenically primed tumors, with tertiary lymphoid structure formation, expansion of cytotoxic and memory CD4+ T cells, and marked natural killer cells and eosinophils recruitment. Limitations include the small sample size and short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: Bel-sar demonstrated focal administration feasibility, a favorable safety profile, and encouraging preliminary efficacy in NMIBC, with robust immune activation in treated and untreated tumors. These findings support bel-sar's continued development as a therapy combining local tumor eradication with durable immune surveillance. CI - (c) 2026 The Author(s). FAU - Linehan, Jennifer AU - Linehan J AD - John Wayne Cancer Institute, Santa Monica, USA. FAU - Agarwal, Piyush K AU - Agarwal PK AD - University of Chicago, Chicago, USA. FAU - Penny, Xianne AU - Penny X AD - Aura Biosciences, Boston, USA. FAU - Kates, Max AU - Kates M AD - Johns Hopkins School of Medicine, Baltimore, USA. FAU - Jacob, Joseph AU - Jacob J AD - SUNY Upstate Medical University, Syracuse, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Baylor College of Medicine, Houston, USA. FAU - Kines, Rhonda C AU - Kines RC AD - Aura Biosciences, Boston, USA. AD - Laboratory of Cellular Oncology, NCI, NIH, Bethesda, USA. FAU - Schiller, John T AU - Schiller JT AD - Aura Biosciences, Boston, USA. AD - Laboratory of Cellular Oncology, NCI, NIH, Bethesda, USA. FAU - de Los Pinos, Elisabet AU - de Los Pinos E AD - Aura Biosciences, Boston, USA. FAU - Shore, Neal D AU - Shore ND AD - START Carolinas/Carolina Urologic Research Center, Myrtle Beach, USA. FAU - Hopkins, Jill AU - Hopkins J AD - Aura Biosciences, Boston, USA. FAU - McQuaid, Joseph AU - McQuaid J AD - Aura Biosciences, Boston, USA. FAU - Brookman-May, Sabine D AU - Brookman-May SD AD - Aura Biosciences, Boston, USA. AD - University of Munich, LMU, Munich, Germany. LA - eng PT - Journal Article DEP - 20260613 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC13279200 OTO - NOTNLM OT - Belzupacap sarotalocan OT - Immunogenic cell death OT - Non-muscle-invasive bladder cancer OT - Photoimmunotherapy OT - Tertiary lymphoid structures OT - Tumor microenvironment OT - Urothelial carcinoma OT - Virus-like drug conjugate EDAT- 2026/06/22 13:43 MHDA- 2026/06/22 13:44 PMCR- 2026/06/13 CRDT- 2026/06/22 07:00 PHST- 2026/05/20 00:00 [accepted] PHST- 2026/06/22 13:44 [medline] PHST- 2026/06/22 13:43 [pubmed] PHST- 2026/06/22 07:00 [entrez] PHST- 2026/06/13 00:00 [pmc-release] AID - S2666-1683(26)00517-3 [pii] AID - 10.1016/j.euros.2026.05.017 [doi] PST - epublish SO - Eur Urol Open Sci. 2026 Jun 13;89:77-88. doi: 10.1016/j.euros.2026.05.017. eCollection 2026 Jul. PMID- 42324366 OWN - NLM STAT- MEDLINE DCOM- 20260919 LR - 20260920 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 33 IP - 10 DP - 2026 Oct TI - Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer. PG - 9475-9482 LID - 10.1245/s10434-026-20022-7 [doi] AB - BACKGROUND: This study aimed to evaluate whether pre-surgical tumor-informed circulating tumor DNA (ctDNA) predicts pathologic nodal status at radical cystectomy and its potential role in risk stratification for future biomarker-guided surgical strategies. METHODS: The study prospectively analyzed 40 patients with non-muscle-invasive and muscle-invasive bladder cancer who underwent radical cystectomy with pelvic lymph node dissection (LND) and pre-surgical tumor-informed ctDNA testing. Compared with pathologic nodal findings, ctDNA status was classified as positive or negative. Diagnostic performance metrics with 95 % confidence intervals (CIs) were calculated. To assess reproducibility, data from a published cohort meeting comparable inclusion criteria were integrated for pooled descriptive analysis. RESULTS: Of 40 patients, 27 (68 %) were ctDNA-negative and 13 (32 %) were ctDNA-positive before cystectomy. Pathologic nodal metastases were identified in seven patients (18 %). For nodal metastases, ctDNA demonstrated a sensitivity of 86 % (95 % CI, 49-97 %), a specificity of 79 % (95 % CI, 62-89 %), and negative predictive value of 96 % (95 % CI, 82-99 %). In pooled descriptive analysis including 149 patients, the negative predictive value remained high at 92 % (95 % CI, 84-97 %). A simulated ctDNA-guided omission strategy may have avoided LND for 27 patients (68 %), with one false-negative case (3.7 %) that subsequently had recurrence. CONCLUSION: Pre-surgical tumor-informed ctDNA showed high negative predictive value for nodal metastases at radical cystectomy. These findings supported prospective validation of ctDNA as a biomarker to identify patients at low risk of nodal metastases and inform future trials of biomarker-guided surgical strategies. CI - (c) 2026. The Author(s). FAU - Aydogdu, Can AU - Aydogdu C AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Department of Urology, LMU University Hospital Munich, Munich, Germany. FAU - Wang, Betty AU - Wang B AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - McSweeney, Sean AU - McSweeney S AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Pieretti, Alberto AU - Pieretti A AD - Department of Urology, Weston Hospital, Cleveland Clinic Florida, Weston, FL, USA. FAU - Weight, Christopher J AU - Weight CJ AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kaouk, Jihad AU - Kaouk J AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. bukavil2@ccf.org. AD - Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA. bukavil2@ccf.org. LA - eng PT - Journal Article DEP - 20260621 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Cystectomy MH - Female MH - *Urinary Bladder Neoplasms/surgery/pathology/genetics/blood MH - *Circulating Tumor DNA/genetics/blood MH - Lymphatic Metastasis MH - *Biomarkers, Tumor/genetics/blood MH - Male MH - Prospective Studies MH - Aged MH - Prognosis MH - Lymph Node Excision MH - Follow-Up Studies MH - Middle Aged MH - Preoperative Care MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC13585835 OTO - NOTNLM OT - Bladder cancer OT - Circulating tumor DNA OT - Molecular residual disease OT - Nodal metastasis OT - Pelvic lymph node dissection OT - Precision surgery OT - Radical cystectomy OT - Risk stratification COIS- Funding: This study received no funding EDAT- 2026/06/22 00:44 MHDA- 2026/09/19 07:24 PMCR- 2026/06/21 CRDT- 2026/06/21 23:23 PHST- 2026/03/30 00:00 [received] PHST- 2026/06/09 00:00 [accepted] PHST- 2026/09/19 07:24 [medline] PHST- 2026/06/22 00:44 [pubmed] PHST- 2026/06/21 23:23 [entrez] PHST- 2026/06/21 00:00 [pmc-release] AID - 10.1245/s10434-026-20022-7 [pii] AID - 20022 [pii] AID - 10.1245/s10434-026-20022-7 [doi] PST - ppublish SO - Ann Surg Oncol. 2026 Oct;33(10):9475-9482. doi: 10.1245/s10434-026-20022-7. Epub 2026 Jun 21. PMID- 42323256 OWN - NLM STAT- Publisher LR - 20260620 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 Jun 20 TI - Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients. LID - S2588-9311(26)00168-9 [pii] LID - 10.1016/j.euo.2026.06.001 [doi] AB - BACKGROUND AND OBJECTIVE: Outcomes after radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC) are generally favorable, but a subset experiences recurrence and cancer-specific mortality (CSM). Tools to identify high-risk patients remain limited. This study aimed to identify predictors of recurrence and cancer-specific and overall mortality in pathological NMIBC treated with RC. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort of 1032 patients with pTis/pTa/pT1 N0 R0 disease who underwent RC (2000-2015) at nine centers. No patient received perioperative therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using Cox and competing-risks regression. Discrimination assessed by Harrell's C-index. RESULTS AND LIMITATIONS: Median follow-up 45.2 mo. Lymphovascular invasion (LVI), present in 39 patients (3.8%), was independently associated with RFS (hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.29-4.38; p = 0.006) and CSS (HR, 2.59; 95% CI, 1.31-5.10; p = 0.006). Pathological stage was not associated with RFS (p = 0.074). Age predicted OS (HR 1.06; p < 0.001). LVI-positive patients had higher 10-yr CSM (35.3% vs 13.7%; p = 0.002). Discrimination was modest (C-index 0.59). Limitations include retrospective design and low LVI prevalence. CONCLUSIONS: In patients undergoing RC for pathological NMIBC, LVI identifies a small subgroup at increased risk of recurrence and CSM, while pathological stage adds little. These findings support LVI-guided surveillance and trial enrichment, but no treatment recommendations can be drawn. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Parizi, Mehdi Kardoust AU - Parizi MK AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: kardoustparizi.m@gmail.com. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chlosta, Piotr AU - Chlosta P AD - Department of Urology, Jagiellonian University Medical College, Krakow, Poland. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Division of Urology, School of Medicine, The University of Jordan, Amman, Jordan. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Reis, Leonardo Oliveira AU - Reis LO AD - UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, Sao Paulo, Brazil; Pontifical Catholic University of Campinas, PUC-Campinas, Sao Paulo, Brazil. FAU - Oberneder, Katherina AU - Oberneder K AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Bronimann, Stephan AU - Bronimann S AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Austrian Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medicine, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, Texas, USA; College of Medical Health Technologies, Al-Turath University, Mansour, Baghdad, Iraq; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article DEP - 20260620 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Non-muscle-invasive bladder cancer OT - Prognostic factors OT - Radical cystectomy OT - Recurrence OT - Survival EDAT- 2026/06/21 22:30 MHDA- 2026/06/21 22:30 CRDT- 2026/06/20 21:56 PHST- 2026/04/27 00:00 [received] PHST- 2026/05/25 00:00 [revised] PHST- 2026/06/06 00:00 [accepted] PHST- 2026/06/21 22:30 [medline] PHST- 2026/06/21 22:30 [pubmed] PHST- 2026/06/20 21:56 [entrez] AID - S2588-9311(26)00168-9 [pii] AID - 10.1016/j.euo.2026.06.001 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 Jun 20:S2588-9311(26)00168-9. doi: 10.1016/j.euo.2026.06.001. PMID- 42321663 OWN - NLM STAT- MEDLINE DCOM- 20260830 LR - 20260902 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Jun 20 TI - ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer. LID - 10.1186/s12885-026-16314-6 [doi] LID - 1033 AB - OBJECTIVE: Tumor recurrence is a major clinical challenge in low-risk non-muscle invasive bladder cancer (NMIBC). Molecular studies have identified two main subtypes with distinct genetic pathways: papillary, low-grade tumors, often with FGFR3 mutations and favorable outcomes, and nonpapillary, high-grade tumors, which are linked to higher rates of progression and muscle invasion. This study evaluates the prognostic value of immunohistochemical (IHC) markers- cluster of differentiation 44 (CD44), cytokeratin 5/6 (CK5/6), cytokeratin 20 (CK20), GATA-binding protein 3 (GATA3), human epidermal growth factor receptor 2 (Cerb-B2), E74-like factor 3 (ELF-3), and tuberous sclerosis complex 1 (TSC-1)-for recurrence in patients with low-risk NMIBC. MATERIALS AND METHODS: This retrospective study evaluated 40 patients with NMIBC selected from 320 individuals who underwent transurethral resection of bladder tumors (TUR-BT) between 2011 and 2019. Patients were categorized into two groups: recurrence (n = 20), defined as tumor recurrence following TUR-BT, and nonrecurrence (n = 20), those with no recurrence during follow-up. Tissues were reevaluated and stained for the following markers using IHC methods: CK5/6, CK20, CD44, GATA3, Cerb-B2, ELF-3, and TSC-1. Statistical analysis was performed to assess associations between clinicopathological variables and recurrence. RESULTS: Recurrence was significantly correlated with tumor number (p = 0.036), whereas age, sex, smoking status, and tumor size showed no significant association (p > 0.05). CD44 positivity was predominantly observed in nonrecurrent cases (p = 0.022), whereas TSC-1 positivity was strongly associated with recurrence (p = 0.003). ELF-3 expression was uniformly positive in all cases and did not predict recurrence. Multivariate regression revealed that CD44 positivity reduced the recurrence risk (OR = 0.142, 95% CI: [0.028-0.714]), while TSC-1 positivity increased it more than 21-fold (OR = 21.871, 95% CI: [2.125-115.15]). Tumors located at the ureteral orifice were associated with increased recurrence risk (OR = 10.231, 95% CI: [1.121-93.341]). CONCLUSION: This study suggests that low CD44 expression and high TSC-1 expression in patients with low-risk NMIBC may serve as prognostic markers for tumor recurrence. Assessing these markers can facilitate earlier identification of at-risk patients, enabling strict surveillance and timely management of treatment strategies. CI - (c) 2026. The Author(s). FAU - Altin, Enes AU - Altin E AUID- ORCID: 0000-0002-5723-0793 AD - Department of Urology, Tavas State Hospital, Denizli, Turkey. FAU - Dogan, Cagri AU - Dogan C AUID- ORCID: 0000-0001-9681-2473 AD - Faculty of Medicine Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkey. drcagridogan@gmail.com. FAU - Arslan, Aysegul Isal AU - Arslan AI AUID- ORCID: 0000-0001-8558-6378 AD - , Tekirdag, Turkey. FAU - Topkac, Erdem Can AU - Topkac EC AUID- ORCID: 0009-0002-5479-7599 AD - Faculty of Medicine Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkey. FAU - Yazici, Cenk Murat AU - Yazici CM AUID- ORCID: 0000-0001-6140-5181 AD - Faculty of Medicine Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkey. FAU - Ozcan, Ridvan AU - Ozcan R AUID- ORCID: 0000-0002-2083-3216 AD - Faculty of Medicine Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkey. FAU - Akgul, Haci Murat AU - Akgul HM AUID- ORCID: 0000-0001-6187-1940 AD - Department of Urology, Istanbul Umraniye Training and Research Hospital, Istanbul, Turkey. FAU - Sahin, Mehmet Fatih AU - Sahin MF AUID- ORCID: 0000-0002-0926-3005 AD - Faculty of Medicine Department of Urology, Tekirdag Namik Kemal University, Tekirdag, Turkey. LA - eng GR - NKUBAP.02.TU.22.361/Tekirdag Namik Kemal University Scientific Research Projects Committee/ PT - Journal Article DEP - 20260620 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Tuberous Sclerosis Complex 1 Protein) RN - 0 (Biomarkers, Tumor) RN - 0 (TSC1 protein, human) RN - 0 (Transcription Factors) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery/metabolism MH - Female MH - *Tuberous Sclerosis Complex 1 Protein/metabolism/analysis MH - Male MH - *Neoplasm Recurrence, Local/metabolism/pathology MH - *Biomarkers, Tumor/metabolism MH - Aged MH - Transurethral Resection of Bladder MH - Retrospective Studies MH - Prognosis MH - Middle Aged MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/pathology/surgery MH - *Transcription Factors/metabolism MH - Immunohistochemistry PMC - PMC13528065 OTO - NOTNLM OT - Bladder cancer OT - CD44 OT - ELF-3 OT - NMIBC OT - Non-muscle invasive OT - TSC-1 COIS- Declarations. Ethics approval and consent to participate: A written informed consent was obtained from participants to participate in the study. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal studies were carried out by the authors for this article. This study protocol was reviewed and approved by [Tekirdag Namik Kemal University, Non-interventional Clinical Trials Ethical Committee], approval number [2021.227.09.13]. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/06/20 00:37 MHDA- 2026/08/31 19:42 PMCR- 2026/06/20 CRDT- 2026/06/19 23:44 PHST- 2026/02/04 00:00 [received] PHST- 2026/06/04 00:00 [accepted] PHST- 2026/08/31 19:42 [medline] PHST- 2026/06/20 00:37 [pubmed] PHST- 2026/06/19 23:44 [entrez] PHST- 2026/06/20 00:00 [pmc-release] AID - 10.1186/s12885-026-16314-6 [pii] AID - 16314 [pii] AID - 10.1186/s12885-026-16314-6 [doi] PST - epublish SO - BMC Cancer. 2026 Jun 20;26(1):1033. doi: 10.1186/s12885-026-16314-6. PMID- 42320430 OWN - NLM STAT- MEDLINE DCOM- 20260824 LR - 20260824 IS - 2210-7762 (Print) VI - 306-307 DP - 2026 Sep TI - Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer. PG - 106-115 LID - S2210-7762(26)00072-4 [pii] LID - 10.1016/j.cancergen.2026.06.004 [doi] AB - BACKGROUND: Patients with non-muscle invasive bladder cancer (NMIBC) frequently experience recurrence and may progress to muscle-invasive disease. Although several common germline variants associated with bladder cancer risk have been identified, their prognostic value in NMIBC remains unclear. We performed an updated genome-wide association study (GWAS), incorporating additional cohorts and analysing multiple NMIBC recurrences, to identify germline genetic variants associated with recurrence and progression. METHODS: We analysed eight cohorts (N = 5009) from the Netherlands, UK, Canada, and Spain. Cohort-specific GWAS were conducted using Cox regression for recurrence-free survival (RFS) and progression-free survival (PFS), including recurrent-event analysis and gene-based analyses. Analyses included chromosome X and were stratified by sex and Bacillus Calmette-Guerin (BCG) treatment. Previously reported variants for bladder cancer risk and prognosis were also evaluated. RESULTS: We observed 4237 recurrences, of which 2145 were first recurrences, and 742 cases of progression in stage and/or grade. No genome-wide significant associations were identified in the overall population, chromosome X, or sex-stratified analyses. In BCG-treated patients, two loci reached genome-wide significance for RFS, with the strongest signal for rs72744118, an intron variant in DISP-1 (HR = 0.43; 95% CI (0.32, 0.56), p = 5.8 x 10(-10)). Gene prioritization identified 101 candidate genes from SNP associations (p < 1 x 10(-6)) and colocalization analyses, of which 16 genes showed nominally significant association between gene expression and NMIBC outcome in UROMOL. CONCLUSIONS: In the largest GWAS of NMIBC prognosis to date, we prioritized a set of 16 genes. Future research should independently validate the prognostic and functional roles of identified genes. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Hof, Jasper P AU - Hof JP AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands; Aarhus University, Center for Quantitative Genetics and Genomics, Aarhus, Denmark. Electronic address: jasper.hof@qgg.au.dk. FAU - Galesloot, Tessel E AU - Galesloot TE AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands; Netherlands Comprehensive Cancer Organization, Department of Research and Development, Nijmegen, the Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Department of Cancer & Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK; Bladder Cancer Research Centre, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Cheng, Kar K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - Conroy, Samantha AU - Conroy S AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Fleshner, Neil E AU - Fleshner NE AD - Department of Urology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Radboud university medical center, Department of Urology, Nijmegen, the Netherlands. FAU - James, Nicholas D AU - James ND AD - Department of Cancer & Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Mengual, Lourdes AU - Mengual L AD - Department and Laboratory of Urology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. FAU - Uunk, Florine M AU - Uunk FM AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands. FAU - Verhaegh, Gerald AU - Verhaegh G AD - Radboud university medical center, Department of Urology, Nijmegen, the Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, the Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands; Radboud university medical center, Department of Urology, Nijmegen, the Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - Radboud university medical center, IQ Health science department, Nijmegen, the Netherlands. LA - eng PT - Journal Article DEP - 20260613 PL - United States TA - Cancer Genet JT - Cancer genetics JID - 101539150 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/pathology MH - *Genome-Wide Association Study MH - Female MH - Male MH - *Neoplasm Recurrence, Local/genetics/pathology MH - Disease Progression MH - Aged MH - Prognosis MH - Polymorphism, Single Nucleotide MH - Middle Aged MH - *Urinary Bladder Neoplasms/genetics/pathology OTO - NOTNLM OT - Genome-wide association study (GWAS) OT - Germline genetic variants OT - Non-muscle invasive bladder cancer (NMIBC) OT - Progression OT - Recurrence COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Richard T. Bryan reports a relationship with Action Bladder Cancer UK that includes: non-financial support. Richard T. Bryan reports a relationship with National Institute for Health and Care Research that includes: funding grants. Richard T. Bryan reports a relationship with Cancer Research UK that includes: funding grants. Richard T. Bryan reports a relationship with Janssen Pharmaceuticals Inc that includes: funding grants. Richard T. Bryan reports a relationship with Nonacus Ltd that includes: consulting or advisory. Richard T. Bryan reports a relationship with Cystotech ApS that includes: consulting or advisory. Richard T. Bryan reports a relationship with AstraZeneca Pharmaceuticals LP that includes: speaking and lecture fees. Katja K.H. Aben reports a relationship with Astellas Pharma US Inc that includes: funding grants. Katja K.H. Aben reports a relationship with Merck & Co Inc that includes: funding grants. Katja K.H. Aben reports a relationship with MSD that includes: funding grants. Katja K.H. Aben reports a relationship with Janssen Pharmaceuticals Inc that includes: funding grants. Katja K.H. Aben reports a relationship with AstraZeneca Pharmaceuticals LP that includes: funding grants. Richard T. Bryan has patent #GB2581967 issued to University of Birmingham. Richard T. Bryan has patent #WO2020070491A1 issued to University of Birmingham. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/20 00:38 MHDA- 2026/08/24 23:34 CRDT- 2026/06/19 18:09 PHST- 2026/05/05 00:00 [received] PHST- 2026/06/09 00:00 [revised] PHST- 2026/06/12 00:00 [accepted] PHST- 2026/08/24 23:34 [medline] PHST- 2026/06/20 00:38 [pubmed] PHST- 2026/06/19 18:09 [entrez] AID - S2210-7762(26)00072-4 [pii] AID - 10.1016/j.cancergen.2026.06.004 [doi] PST - ppublish SO - Cancer Genet. 2026 Sep;306-307:106-115. doi: 10.1016/j.cancergen.2026.06.004. Epub 2026 Jun 13. PMID- 42320108 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260819 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 9 DP - 2026 Sep TI - Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Guerin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled cohort clinical study. PG - 195-210 LID - S1078-1439(26)00551-X [pii] LID - 10.1016/j.urolonc.2026.05.026 [doi] AB - BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG) is the standard adjuvant therapy for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Toll-like receptors (TLRs) modulate the BCG immune response. Myeloid differentiation factor 88 (MyD88) is a canonical adapter for TLR signaling pathways, which ultimately activates the nuclear factor kappa-B (NF-kappaB) transcription factor, triggering cytokine expression and immune activation. Validated biomarkers to detect recurrences or progression of T1G3 bladder cancer (BC) are lacking. PURPOSE: Our study aimed to analyze the role of TLRs, MyD88, and NF-kappaB in predicting the response to BCG immunotherapy in HR-NMIBC. METHODS: The study enrolled 100 T1G3 NMIBC patients and 50 controls. TLR2, TLR4, MyD88, and NF-kappaB gene expression were evaluated, along with TLR4 and MyD88 immunohistochemical (IHC) assays. Gene expression levels were compared between BCG responders and BCG non-responders. Univariate and multivariate logistic regression analyses identified both dependent and independent predictors of BCG non-response. Cox proportional-hazard regression was used for analyses of recurrence and progression-free survival. RESULTS: In our cohort, 42 patients developed recurrence only, 16 experienced progression only, and 4 progressed after an initial recurrence; they were considered BCG non-responders. BCG responders exhibited significantly elevated TLR2, TLR4, MyD88, and NF-kappaB gene expression, alongside significantly higher TLR4 and MyD88 protein expression. Low NF-kappaB gene expression as well as diminished expression of the TLR4 gene and protein were significant independent predictors of high recurrence and progression. CONCLUSION: TLR2, TLR4, MyD88, and NF-kappaB expressions can be considered beneficial markers for predicting BCG response in HR-NMIBC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Zahran, Aya A AU - Zahran AA AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Electronic address: farouf1988@man.edu.eg. FAU - Serria, Mohamed Saad AU - Serria MS AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Awadalla, Amira AU - Awadalla A AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - El-Gamal, Randa AU - El-Gamal R AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Elshabrawy, Iman AU - Elshabrawy I AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Baiomy, Amina A AU - Baiomy AA AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20260618 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Myeloid Differentiation Factor 88) RN - 0 (NF-kappa B) RN - 0 (BCG Vaccine) RN - 0 (Toll-Like Receptors) RN - 0 (MYD88 protein, human) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *Myeloid Differentiation Factor 88/metabolism MH - Female MH - Male MH - *NF-kappa B/metabolism MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - *Toll-Like Receptors/metabolism MH - Predictive Value of Tests MH - Cohort Studies MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Adjuvants, Immunologic/therapeutic use OTO - NOTNLM OT - BCG OT - MyD88 OT - NF-kappaB OT - NMIBC OT - Toll-like receptors COIS- Declaration of competing interest The authors declare no conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/19 18:37 MHDA- 2026/08/19 23:42 CRDT- 2026/06/19 18:00 PHST- 2025/12/22 00:00 [received] PHST- 2026/04/19 00:00 [revised] PHST- 2026/05/25 00:00 [accepted] PHST- 2026/08/19 23:42 [medline] PHST- 2026/06/19 18:37 [pubmed] PHST- 2026/06/19 18:00 [entrez] AID - S1078-1439(26)00551-X [pii] AID - 10.1016/j.urolonc.2026.05.026 [doi] PST - ppublish SO - Urol Oncol. 2026 Sep;44(9):195-210. doi: 10.1016/j.urolonc.2026.05.026. Epub 2026 Jun 18. PMID- 42315458 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260818 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 5 DP - 2026 Aug TI - Clinicopathological Predictors of Survival After Radical Nephroureterectomy for UTUC: A Propensity Score-Matched Multicenter Analysis. PG - 102587 LID - S1558-7673(26)00087-X [pii] LID - 10.1016/j.clgc.2026.102587 [doi] AB - INTRODUCTION: Upper tract urothelial carcinoma (UTUC) is characterized by heterogeneous outcomes and high recurrence risk. We aimed to identify independent predictors of survival and intravesical recurrence using a bias-adjusted statistical framework. PATIENTS AND METHODS: We retrospectively analyzed 503 patients undergoing radical nephroureterectomy (RNU). Beyond Multivariable Cox regression, propensity score matching (PSM) was used to evaluate the impact of adjuvant chemotherapy. Perioperative estimated glomerular filtration rate (eGFR) changes and cisplatin eligibility were quantified. Sensitivity analyses excluding NX patients and a 90-day landmark analysis were performed. RESULTS: At a median follow-up of 31.6 months, estimated 3-year Overall Survival (OS), Cancer-Specific Survival, Disease-Free Survival (DFS), and Intravesical Recurrence-Free Survival were 75.8%, 91.5%, 73.1%, and 63.7%, respectively. Advanced pathologic stage (>/=pT3), nodal involvement, and variant/squamous differentiation independently predicted mortality. Intravesical recurrence was associated with ureteral location, multifocality, carcinoma in situ, and diagnostic ureterorenoscopy. Postoperatively, 49.7% of patients had eGFR < 60 mL/min/1.73 m(2), and 35.4% of preoperatively eligible patients (preop eGFR >/= 60, n = 336) experienced a decline below the cisplatin threshold. Following PSM (n = 222; 111 per arm), no statistically significant survival difference was observed for OS (hazard ratio [HR]: 1.31, 95% confidence intervals [CI]: 0.87-1.98; P = .199), CSS (HR: 1.50, P = .302), or DFS (HR: 1.36, P = .135), including in high-risk patients (>/=pT3/pN+). Post-hoc power analysis confirmed the study was substantially underpowered to detect a clinically meaningful treatment effect (power < 37% for a 30% hazard reduction). CONCLUSION: UTUC outcomes are primarily driven by tumor biology, while intravesical recurrence reflects multifocality and procedure-related factors. Postoperative renal decline was common following RNU, potentially limiting cisplatin candidacy in real-world practice. The present study was substantially underpowered and could neither confirm nor exclude a survival benefit from adjuvant chemotherapy; prospective evaluation of neoadjuvant strategies is warranted. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Ok, Fesih AU - Ok F AD - Department of Urology, Adana City Hospital, Adana, Turkey. Electronic address: drfesihok@gmail.com. FAU - Izol, Volkan AU - Izol V AD - Department of Urology, Cukurova University Faculty of Medicine, Adana, Turkey. FAU - Akpinar, Cagri AU - Akpinar C AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Gulsen, Murat AU - Gulsen M AD - Department of Urology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey. FAU - Ozen, Ata AU - Ozen A AD - Department of Urology, Osmangazi University Faculty of Medicine, Eskisehir, Turkey. FAU - Sozen, Sinan AU - Sozen S AD - Department of Urology, Gazi University Faculty of Medicine, Ankara, Turkey. FAU - Vural, Ahmet AU - Vural A AD - Department of Urology, Cerrahpasa University Faculty of Medicine, Istanbul, Turkey. FAU - Muezzinoglu, Talha AU - Muezzinoglu T AD - Department of Urology, Celal Bayar University Faculty of Medicine, Manisa, Turkey. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260527 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - *Nephroureterectomy/mortality/methods MH - Female MH - Propensity Score MH - Retrospective Studies MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Cisplatin/therapeutic use MH - Chemotherapy, Adjuvant MH - Disease-Free Survival MH - Glomerular Filtration Rate MH - *Ureteral Neoplasms/surgery/mortality/pathology MH - Prognosis OTO - NOTNLM OT - Adjuvant chemotherapy OT - Prognostic factors OT - Propensity score matching OT - Renal function decline OT - Upper urinary tract urothelial carcinoma EDAT- 2026/06/19 00:36 MHDA- 2026/07/14 12:35 CRDT- 2026/06/18 21:59 PHST- 2026/03/30 00:00 [received] PHST- 2026/05/21 00:00 [revised] PHST- 2026/05/23 00:00 [accepted] PHST- 2026/07/14 12:35 [medline] PHST- 2026/06/19 00:36 [pubmed] PHST- 2026/06/18 21:59 [entrez] AID - S1558-7673(26)00087-X [pii] AID - 10.1016/j.clgc.2026.102587 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Aug;24(5):102587. doi: 10.1016/j.clgc.2026.102587. Epub 2026 May 27. PMID- 42307354 OWN - NLM STAT- MEDLINE DCOM- 20260617 LR - 20260813 IS - 1806-9282 (Electronic) IS - 0104-4230 (Print) IS - 0104-4230 (Linking) VI - 72 IP - 3 DP - 2026 TI - Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis. PG - e20251628 LID - S0104-42302026000302211 [pii] LID - 10.1590/1806-9282.20251628 [doi] LID - e20251628 AB - OBJECTIVE: Non-muscle invasive bladder cancer is a common urological malignancy characterized by high recurrence and progression rates. There is a critical need for non-invasive biomarkers to support early detection and disease monitoring. Raftlin, a lipid raft-associated scaffold protein involved in immune regulation and signal transduction, has recently gained attention in cancer biology. The aim of this study was to investigate serum Raftlin levels and the rs690037 polymorphism of the Raftlin gene in non-muscle invasive bladder cancer patients. METHODS: A case-control study was conducted, including 30 patients diagnosed with non-muscle invasive bladder cancer and 50 healthy controls. Serum Raftlin levels were measured using enzyme-linked immunosorbent assay, and the rs690037 polymorphism was analyzed using real-time polymerase chain reaction. Gender-stratified analysis and receiver operating characteristic curve analysis were performed. Clinical and pathological characteristics including tumor stage, grade, and European Organisation for Research and Treatment of Cancer risk groups, were analyzed. RESULTS: Serum Raftlin levels were significantly elevated in non-muscle invasive bladder cancer patients compared to healthy controls (p<0.001). Gender-stratified analysis confirmed this association was independent of gender (males: p<0.001; females: p<0.001). Receiver operating characteristic curve analysis demonstrated an area under the curve of 0.987 (95%CI 0.966-1.000), with an optimal cut-off of 5.28 ng/mL providing 96.7% sensitivity and 98.0% specificity. Trends toward higher Raftlin levels were observed in more aggressive disease features. No significant association was found between the rs690037 polymorphism and disease presence. CONCLUSION: This pilot study suggests that serum Raftlin levels are significantly elevated in non-muscle invasive bladder cancer and show high discriminatory ability. While preliminary findings suggest potential as a non-invasive biomarker, validation in larger, independent cohorts is required before clinical implementation. FAU - Balci, Senay AU - Balci S AUID- ORCID: 0000-0002-7498-604X AD - Mersin University, Faculty of Medicine, Department of Biochemistry - Mersin, Turkey. FAU - Tanriverdi, Rojda AU - Tanriverdi R AUID- ORCID: 0000-0002-7004-790X AD - Mersin University, Faculty of Medicine, Department of Biochemistry - Mersin, Turkey. FAU - Nebioglu, Ali AU - Nebioglu A AUID- ORCID: 0000-0001-6325-1534 AD - Mersin City Training and Research Hospital, Department of Urology - Mersin, Turkey. FAU - Yildirim, Didem Derici AU - Yildirim DD AUID- ORCID: 0000-0001-7709-6133 AD - Mersin University, Faculty of Medicine, Department of Biostatistics and Medical Informatics - Mersin, Turkey. FAU - Gulum, Cemil AU - Gulum C AUID- ORCID: 0000-0002-0535-9966 AD - Mersin University, Department of Chemistry - Mersin, Turkey. FAU - Bozlu, Murat AU - Bozlu M AUID- ORCID: 0000-0002-8624-0149 AD - Mersin University, Department of Urology - Mersin, Turkey. FAU - Tamer, Lulufer AU - Tamer L AUID- ORCID: 0000-0002-0997-0260 AD - Mersin University, Faculty of Medicine, Department of Biochemistry - Mersin, Turkey. LA - eng PT - Journal Article DEP - 20260615 PL - Brazil TA - Rev Assoc Med Bras (1992) JT - Revista da Associacao Medica Brasileira (1992) JID - 9308586 RN - 0 (Biomarkers, Tumor) RN - 0 (Membrane Proteins) SB - IM MH - Humans MH - Female MH - Male MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/blood MH - Case-Control Studies MH - Middle Aged MH - Aged MH - Biomarkers, Tumor/blood/genetics MH - Enzyme-Linked Immunosorbent Assay MH - Genotype MH - *Membrane Proteins/blood/genetics MH - ROC Curve MH - *Urinary Bladder Neoplasms/blood/genetics/pathology MH - Real-Time Polymerase Chain Reaction MH - Neoplasm Staging MH - Polymorphism, Single Nucleotide MH - Polymorphism, Genetic MH - Risk Factors PMC - PMC13268625 COIS- Conflicts of interest: the authors declare there is no conflicts of interest. EDAT- 2026/06/17 13:28 MHDA- 2026/06/17 13:29 PMCR- 2026/06/15 CRDT- 2026/06/17 09:23 PHST- 2026/01/29 00:00 [received] PHST- 2026/03/03 00:00 [accepted] PHST- 2026/06/17 13:29 [medline] PHST- 2026/06/17 13:28 [pubmed] PHST- 2026/06/17 09:23 [entrez] PHST- 2026/06/15 00:00 [pmc-release] AID - S0104-42302026000302211 [pii] AID - 10.1590/1806-9282.20251628 [doi] PST - epublish SO - Rev Assoc Med Bras (1992). 2026 Jun 15;72(3):e20251628. doi: 10.1590/1806-9282.20251628. eCollection 2026. PMID- 42301343 OWN - NLM STAT- MEDLINE DCOM- 20260616 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jun 16 TI - Long-term outcomes of upper tract urothelial carcinoma in kidney transplant recipients: efficacy of bilateral radical nephroureterectomy and prognostic comparison of unilateral nephroureterectomy with non-transplant patients. LID - 432 [pii] LID - 10.1007/s00345-026-06522-x [doi] AB - BACKGROUND: The incidence of upper tract urothelial carcinoma (UTUC) is significantly elevated in kidney transplant (KT) recipients, yet the optimal surgical strategy-unilateral radical nephroureterectomy (URNU) versus bilateral radical nephroureterectomy (BRNU)-remains debated, and prognostic comparisons between KT recipients undergoing URNU and non-transplant (NKT) patients are lacking. METHODS: This retrospective study analyzed KT recipients with native-system UTUC treated at a single institution (2001-2023). Patients were stratified into BRNU or URNU groups. Propensity score matching (PSM, 1:2) was performed between KT recipients who underwent URNU and NKT patients. Survival outcomes including overall survival (OS), cancer-specific survival (CSS), intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), contralateral recurrence-free survival (CRFS), and progression-free survival (PFS) were compared using Kaplan-Meier and log-rank tests. RESULTS: Among KT patients, the BRNU group exhibited significantly better OS (p = 0.01), CSS (p = 0.02), DFS (p < 0.001), and PFS (p < 0.001) than the URNU group, despite longer operative time. In unilateral UTUC patients, BRNU still demonstrated superior DFS and PFS (both p < 0.001). After PSM, survival outcomes did not differ significantly between the URNU-KT and NKT groups across all indices (OS, CSS, IVRFS, DFS, CRFS, PFS; all p > 0.05). The 5-year survival rates were 70.0% in the KT (URNU) group and 65.0% in the NKT group. CONCLUSION: BRNU provides significant survival advantages over URNU in KT recipients with UTUC. After 1:2 PSM of patients treated with URNU, KT patients achieved comparable survival to NKT patients, underscoring that standardized management, including appropriate surgical selection and vigilant surveillance, can yield favorable prognoses in this population. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yang, Xinji AU - Yang X AD - Department of Urology, Peking University Third Hospital, Beijing, 100191, China. FAU - Zhang, Qiming AU - Zhang Q AD - Department of Urology, Peking University Third Hospital, Beijing, 100191, China. FAU - Ma, Lulin AU - Ma L AD - Department of Urology, Peking University Third Hospital, Beijing, 100191, China. FAU - Zhang, Shudong AU - Zhang S AD - Department of Urology, Peking University Third Hospital, Beijing, 100191, China. zhangshudong@bjmu.edu.cn. FAU - Hou, Xiaofei AU - Hou X AD - Department of Urology, Peking University Third Hospital, Beijing, 100191, China. houxf12@163.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260616 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Retrospective Studies MH - Male MH - *Kidney Transplantation MH - Female MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery/mortality MH - *Ureteral Neoplasms/surgery/mortality MH - Middle Aged MH - Treatment Outcome MH - *Kidney Neoplasms/surgery/mortality MH - Time Factors MH - Aged OTO - NOTNLM OT - Bilateral resection OT - Kidney transplantation OT - Radical nephroureterectomy OT - Survival outcomes OT - Upper tract urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2026/06/16 13:32 MHDA- 2026/06/16 13:33 CRDT- 2026/06/16 11:05 PHST- 2026/03/02 00:00 [received] PHST- 2026/05/30 00:00 [accepted] PHST- 2026/06/16 13:33 [medline] PHST- 2026/06/16 13:32 [pubmed] PHST- 2026/06/16 11:05 [entrez] AID - 10.1007/s00345-026-06522-x [pii] AID - 10.1007/s00345-026-06522-x [doi] PST - epublish SO - World J Urol. 2026 Jun 16;44(1):432. doi: 10.1007/s00345-026-06522-x. PMID- 42299040 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260817 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 3 DP - 2026 Sep TI - Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists. PG - 449-455 LID - 10.1111/bju.70354 [doi] AB - OBJECTIVES: To evaluate current adoption of guidelines for low- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC) in the UK and to assess clinicians' ability to apply their chosen guideline consistently to real-world clinical scenarios. PATIENTS AND METHODS: This study is a cross-sectional survey distributed to clinicians involved in the management of NMIBC in the UK. Respondents reported their unit-level and personal guideline adoption (National Institute for Health and Care Excellence [NICE] vs European Association of Urology [EAU]) and completed three case-based real-life scenarios derived from NMIBC cases with discordant risk stratification between NICE and EAU guidelines. Cases were randomly selected from a local database using a computer-generated random number function in Microsoft Excel. Concordance between respondents' decisions and their stated guideline was assessed for risk stratification and surveillance duration. RESULTS: A total of 174 eligible responses were analysed. Most units (38%) followed NICE guidelines, but individual clinicians most frequently reported that they were following EAU guidelines (39%). Those who followed NICE guidelines demonstrated significantly higher compliance with the duration of follow-up as recommended in the guidelines than did those who followed EAU guidelines (78.9% vs 49.2%, P < 0.001). Deviations from the guidelines for those who followed NICE were predominantly in duration of surveillance, which was longer than recommended. Conversely, those following EAU guidelines frequently opted for shorter-than-recommended follow-up (P < 0.001). Consistent guideline-based risk stratification was achieved in 77.1% of those following NICE guidelines and 34.1% of those following EAU guidelines (P < 0.001). Acceptable recurrence risk at discharge did not differ between guideline groups (P = 0.278). CONCLUSIONS: Substantial variation exists in NMIBC guideline adherence and real-world application in the UK. NICE guidance was associated with greater consistency and utility compared with EAU guidance for low- and intermediate-risk disease. These findings highlight the need for clearer, unified recommendations to promote equitable care and rational use of surveillance resources. CI - (c) 2026 BJU International. FAU - Ibrahim, Youssef AU - Ibrahim Y AUID- ORCID: 0000-0003-0931-9707 AD - Urology Department, Guy's Hospital, London, UK. FAU - Ribeiro, Luis AU - Ribeiro L AD - Urology Department, Guy's Hospital, London, UK. AD - Urology Department, St George's Hospital, London, UK. FAU - Spazzapan, Martina AU - Spazzapan M AUID- ORCID: 0000-0003-1153-5249 AD - Urology Department, Guy's Hospital, London, UK. AD - King's College University, London, UK. FAU - Gad, Mohammed AU - Gad M AD - Urology Department, Guy's Hospital, London, UK. FAU - Macaskill, Findlay AU - Macaskill F AUID- ORCID: 0000-0001-9973-7368 AD - Urology Department, Guy's Hospital, London, UK. FAU - O'Kelly, John AU - O'Kelly J AD - Urology Department, Guy's Hospital, London, UK. FAU - Khan, Muhammed Shamim AU - Khan MS AD - Urology Department, Guy's Hospital, London, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Urology Department, Guy's Hospital, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Urology Department, Guy's Hospital, London, UK. FAU - Mensah, Elsie AU - Mensah E AD - Urology Department, Guy's Hospital, London, UK. FAU - Ghanem, Yasmin Abu AU - Ghanem YA AD - Urology Department, Guy's Hospital, London, UK. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260615 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - Cross-Sectional Studies MH - United Kingdom MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - *Practice Guidelines as Topic MH - *Guideline Adherence/statistics & numerical data MH - Risk Assessment MH - *Urology/standards MH - *Urologists MH - Surveys and Questionnaires MH - Female MH - *Urinary Bladder Neoplasms/therapy PMC - PMC13458657 OTO - NOTNLM OT - EAU OT - NICE OT - NMIBC OT - bladder cancer OT - guidelines OT - surveillance EDAT- 2026/06/16 06:35 MHDA- 2026/08/11 06:35 PMCR- 2026/08/11 CRDT- 2026/06/16 03:04 PHST- 2026/08/11 06:35 [medline] PHST- 2026/06/16 06:35 [pubmed] PHST- 2026/06/16 03:04 [entrez] PHST- 2026/08/11 00:00 [pmc-release] AID - BJU70354 [pii] AID - 10.1111/bju.70354 [doi] PST - ppublish SO - BJU Int. 2026 Sep;138(3):449-455. doi: 10.1111/bju.70354. Epub 2026 Jun 15. PMID- 42294298 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - TURBT versus RC in T1N0M0 non-urothelial bladder cancer: a population-based study. PG - 1802962 LID - 10.3389/fonc.2026.1802962 [doi] LID - 1802962 AB - OBJECTIVES: This study aims to compare overall survival (OS) and cancer-specific survival (CSS) between transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) in patients with T1N0M0 non-urothelial bladder cancer (NUBC). Additionally, it seeks to identify prognostic factors that can guide individualized treatment for this rare malignancy. PATIENTS AND METHODS: We conducted a retrospective analysis of patients with pathologically confirmed T1N0M0 NUBC using the SEER database (2004-2017). Patients were categorized by their most definitive surgical treatment: TURBT alone or RC. A 1:3 nearest-neighbor propensity score matching (PSM) without replacement was performed to balance baseline covariates between the two groups. OS and CSS were then compared between the matched cohorts. RESULTS: Among 828 eligible patients (698 TURBT, 130 RC), significant differences in histology and treatment were observed. Following PSM, 496 patients (366 TURBT, 130 RC) were analyzed. The RC group demonstrated significantly superior 1-, 3-, and 5-year OS and CSS rates (OS: P<0.001; CSS: P=0.002). Multivariable Cox analysis identified neuroendocrine carcinoma, squamous cell carcinoma, and TURBT as independent risk factors for poorer prognosis, while RC was associated with improved survival (OS: HR=0.56, 95% CI 0.42-0.74, P<0.001; CSS: HR=0.48, 95% CI 0.32-0.72, P<0.001). Neuroendocrine and squamous cell carcinomas were associated with poorer OS than adenocarcinoma (P=0.002 and P<0.001, respectively). Married patients exhibited superior OS compared to single, divorced, widowed, or separated (SDWS) patients (P=0.003). Subgroup analyses generally favored RC, although survival differences were not statistically significant in specific subsets. For OS, these included patients aged <65 (P=0.120), male (P=0.071), low/intermediate grade (P=0.400), married (P=0.064), other histology (P=0.700), and SDWS (P=0.066). For CSS, these included patients aged <65 (P=0.120), low/intermediate grade (P=0.420), high grade (P=0.080), squamous cell carcinoma (P=0.170), other histology (P=0.690), SDWS (P=0.051), and non-first primary tumor (P=0.970). CONCLUSION: For patients with T1N0M0 NUBC, RC is associated with significantly improved survival outcomes compared to TURBT as definitive surgical management, with the greatest benefit observed in high-risk subtypes such as neuroendocrine and squamous cell carcinoma. However, this survival advantage must be carefully weighed against the substantial morbidity of RC and the potential for overtreatment. These findings support a risk-adapted, shared decision-making approach within a multidisciplinary framework, rather than a universal recommendation for RC in all T1N0M0 NUBC patients. CI - Copyright (c) 2026 He, Chen, Zhang, Sheng and Huang. FAU - He, Qiuming AU - He Q AD - Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. FAU - Chen, Yuqi AU - Chen Y AD - Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. AD - Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. FAU - Zhang, Tao AU - Zhang T AD - Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. AD - Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. FAU - Sheng, Wei AU - Sheng W AD - Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. AD - Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. FAU - Huang, Ji AU - Huang J AD - Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China. LA - eng PT - Journal Article DEP - 20260529 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13259815 OTO - NOTNLM OT - NUBC OT - bladder cancer OT - histological subtype OT - radical cystectomy OT - transurethral resection of bladder tumor COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/15 12:50 MHDA- 2026/06/15 12:51 PMCR- 2026/05/29 CRDT- 2026/06/15 07:44 PHST- 2026/02/03 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/13 00:00 [accepted] PHST- 2026/06/15 12:51 [medline] PHST- 2026/06/15 12:50 [pubmed] PHST- 2026/06/15 07:44 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.3389/fonc.2026.1802962 [doi] PST - epublish SO - Front Oncol. 2026 May 29;16:1802962. doi: 10.3389/fonc.2026.1802962. eCollection 2026. PMID- 42293220 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2296-861X (Print) IS - 2296-861X (Electronic) IS - 2296-861X (Linking) VI - 13 DP - 2026 TI - Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study. PG - 1842495 LID - 10.3389/fnut.2026.1842495 [doi] LID - 1842495 AB - BACKGROUND: The influence of long-term dietary habits on bladder cancer (BC) recurrence beyond the first postoperative year remains unclear, particularly in populations with distinct dietary traditions. This study investigated the associations between dietary knowledge, attitudes, and practices (KAP) and late recurrence (>/=12 months after transurethral resection of bladder tumor, TURBT) in a coastal Zhejiang population. METHODS: This retrospective case-control study included 264 patients with non-muscle-invasive bladder cancer (NMIBC), comprising 85 cases with recurrence >/=12 months post-TURBT and 179 recurrence-free controls who were frequency-matched for age, sex, tumor stage, and follow-up duration. Tumor grade was not a matching criterion but was adjusted for in multivariable analyses. Dietary KAP was assessed using a structured questionnaire, and habitual dietary intake was evaluated using a culturally adapted food frequency questionnaire (FFQ). Multivariable logistic regression was used to identify independent dietary factors associated with recurrence. RESULTS: Patients in the recurrence group had significantly lower dietary knowledge scores (5.9 vs. 7.3, p < 0.001) and less favorable attitudes (28.7 +/- 5.8 vs. 32.4 +/- 4.9, p = 0.003) than controls. High consumption of preserved seafood (>/=1/week: aOR = 2.15, 95% CI: 1.28-3.62), low intake of cruciferous vegetables (<1 serving/week: aOR = 2.41, 95% CI: 1.42-4.10), and inadequate daily water intake (<1.0 L/day: aOR = 2.58, 95% CI: 1.38-4.82) were independently associated with increased recurrence risk, with significant dose-response trends (all p-for trend <0.05). Higher knowledge scores correlated significantly with adherence to protective dietary practices. CONCLUSION: In this coastal Zhejiang population, poor dietary knowledge, unfavorable attitudes, and specific dietary patterns- particularly high preserved seafood intake, low cruciferous vegetable consumption and inadequate hydration- were independently associated with late BC recurrence. These findings support incorporating culturally tailored dietary education into routine survivorship care for patients with BC. CI - Copyright (c) 2026 Wu, Qing and Gao. FAU - Wu, Qiquan AU - Wu Q AD - Department of Urology, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. FAU - Qing, Xiaodong AU - Qing X AD - Department of Surgery, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. FAU - Gao, Wenbo AU - Gao W AD - Department of Urology, Ningbo Integrated Traditional Chinese and Western Medicine Hospital, Ningbo, Zhejiang, China. LA - eng PT - Journal Article DEP - 20260529 PL - Switzerland TA - Front Nutr JT - Frontiers in nutrition JID - 101642264 PMC - PMC13259901 OTO - NOTNLM OT - bladder cancer OT - cruciferous vegetables OT - diet OT - hydration OT - knowledge-attitude-practice OT - preserved seafood OT - recurrence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/15 12:51 MHDA- 2026/06/15 12:52 PMCR- 2026/05/29 CRDT- 2026/06/15 07:36 PHST- 2026/03/30 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/19 00:00 [accepted] PHST- 2026/06/15 12:52 [medline] PHST- 2026/06/15 12:51 [pubmed] PHST- 2026/06/15 07:36 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.3389/fnut.2026.1842495 [doi] PST - epublish SO - Front Nutr. 2026 May 29;13:1842495. doi: 10.3389/fnut.2026.1842495. eCollection 2026. PMID- 42292383 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer. PG - 1860957 LID - 10.3389/fimmu.2026.1860957 [doi] LID - 1860957 AB - Bladder cancer remains one of the most common malignancies of the urinary tract. Although the treatment landscape has expanded rapidly in recent years, gemcitabine still occupies a central position in intravesical treatment for non-muscle-invasive bladder cancer, in perioperative systemic therapy for muscle-invasive disease, and in platinum-based first-line regimens for advanced urothelial carcinoma. Yet the long-term benefit of gemcitabine is frequently curtailed by primary non-response or acquired resistance. In practice, this problem is often recognized only after radiographic progression or clear clinical deterioration has occurred. This review summarizes recent progress in bladder cancer therapy and translational research, with a particular emphasis on the biological basis and hierarchical evolution of gemcitabine resistance. We establish a 3-stage operational model of resistance, distinguishing: (1) early pharmacologic resistance driven by impaired drug uptake/activation or enhanced inactivation; (2) intermediate resistance driven by enhanced DNA damage repair, replication stress tolerance, and pro-survival autophagy signaling; and (3) late adaptive resistance driven by epithelial-mesenchymal transition (EMT), stemness maintenance, metabolic reprogramming, non-coding RNA-mediated epigenetic regulation, inflammatory microenvironmental remodeling, and extracellular vesicle-based intercellular transmission. These layers function as an interactive network, with sequential emergence under treatment pressure and parallel activation in context-dependent clinical settings. We stratify key mechanistic nodes (including the HYAL4-V1/CD44/JAK2-STAT3/CDA axis, AKR1C3, AP1M2-RAD54B, PRPF19-DDB1, AKT/mTOR signaling, Beclin-1-dependent autophagy, the MINCR/ZEB1/PHGDH axis, and IL-6-associated inflammatory states) by their clinical evidence quality and translational readiness, explicitly distinguishing preclinical discovery from clinically validated findings. Critically, most mechanistic findings remain at the preclinical or retrospective validation stage, with no markers yet approved for routine clinical use. Future work must prioritize longitudinal paired clinical samples, standardized analytic assays for dynamic biomarkers, and the integration of functional models (organoids, microfluidic systems), multi-omics technologies (single-cell sequencing, spatial transcriptomics), and liquid-biopsy approaches to translate mechanistic discoveries into clinically actionable predictive tools and therapeutic strategies. CI - Copyright (c) 2026 Jin, Cai, Bu, Liu and Zhang. FAU - Jin, Ming AU - Jin M AD - Heilongjiang University of Chinese Medicine, Harbin, China. FAU - Cai, Zhenzhen AU - Cai Z AD - Qiqihar Medical University, Qiqihar, China. FAU - Bu, Ming AU - Bu M AD - Qiqihar Medical University, Qiqihar, China. FAU - Liu, Jicheng AU - Liu J AD - Qiqihar Medical University, Qiqihar, China. FAU - Zhang, Xiaojie AU - Zhang X AD - Heilongjiang University of Chinese Medicine, Harbin, China. LA - eng PT - Journal Article PT - Review DEP - 20260529 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - *Drug Resistance, Neoplasm/genetics MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/therapeutic use/pharmacology MH - *Urinary Bladder Neoplasms/drug therapy/genetics/metabolism/pathology MH - Animals MH - *Antimetabolites, Antineoplastic/therapeutic use/pharmacology MH - Translational Research, Biomedical MH - Signal Transduction MH - Epithelial-Mesenchymal Transition PMC - PMC13260718 OTO - NOTNLM OT - DNA damage repair OT - biomarker OT - bladder cancer OT - gemcitabine OT - resistance COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/15 12:53 MHDA- 2026/06/15 12:54 PMCR- 2026/05/29 CRDT- 2026/06/15 07:28 PHST- 2026/04/20 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/06/15 12:54 [medline] PHST- 2026/06/15 12:53 [pubmed] PHST- 2026/06/15 07:28 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1860957 [doi] PST - epublish SO - Front Immunol. 2026 May 29;17:1860957. doi: 10.3389/fimmu.2026.1860957. eCollection 2026. PMID- 42288906 OWN - NLM STAT- MEDLINE DCOM- 20260820 LR - 20260822 IS - 1477-3155 (Electronic) IS - 1477-3155 (Linking) VI - 24 IP - 1 DP - 2026 Jun 13 TI - Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy. LID - 10.1186/s12951-026-04635-4 [doi] LID - 780 AB - Bladder cancer (BCa) management is challenged by high recurrence rates, therapeutic resistance, and the lack of integrated strategies for early diagnosis and effective treatment. Although nanotechnology has been widely explored in oncology, existing reviews largely discuss diagnostic and therapeutic applications separately, with limited attention to how nanomaterial design governs biological performance in the bladder-specific microenvironment. Here, we present a materials-oriented and problem-driven review that systematically connects nanomaterial design with functional outcomes across the diagnostic-therapeutic continuum in BCa. We highlight how tunable physicochemical properties, such as size, surface chemistry, and interfacial behavior enable enhanced urinary biomarker detection, high-resolution imaging, and efficient intravesical drug delivery under dynamic physiological conditions. Particular emphasis is placed on integrated nanotheranostic platforms that combine diagnosis, imaging, and therapy within unified systems, enabling real-time feedback and synergistic treatment. We further discuss key advances in nanocarrier-based chemotherapy, phototherapy, immunomodulation, and gene delivery, with a focus on overcoming bladder-specific barriers including urothelial impermeability, rapid urine-induced clearance, and tumor heterogeneity. In contrast to prior descriptive reviews, this work also addresses translational challenges such as biosafety, reproducibility, and scalable manufacturing, and outlines emerging directions including AI-assisted nanomaterial design and nano-enabled liquid biopsy. Overall, this review provides a conceptual framework linking nanomaterial engineering with clinical needs in BCa, aiming to guide the rational development of next-generation precision nanomedicine. CI - (c) 2026. The Author(s). FAU - Xiao, Kaiwen AU - Xiao K AD - Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China. FAU - Zhou, Bailing AU - Zhou B AD - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China. FAU - Feng, Dechao AU - Feng D AD - Division of Surgery & Interventional Science, University College London, London, W1W 7TS, UK. FAU - Yang, Shangsong AU - Yang S AD - Jiangxi Key Laboratory of Neurological Diseases, Department of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, P.R. China. FAU - Lei, Sibei AU - Lei S AD - Department of Pharmacy, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, P.R. China. FAU - Wusiman, Dilinaer AU - Wusiman D AD - Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA. FAU - Jiang, Zhixuan AU - Jiang Z AD - College of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, Zhejiang, P.R. China. FAU - Li, Fei AU - Li F AD - School of Materials and Energy, University of Electronic Science and Technology of China, Chengdu, P.R. China. feili@uestc.edu.cn. FAU - Liu, Mohan AU - Liu M AD - Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P.R. China. liumohan199606@163.com. LA - eng GR - 20253BAC280035/Natural Science Foundation of Jiangxi Province/ GR - YFYPY202519/Young Scholar Project of the First Affiliated Hospital of Nanchang University/ PT - Journal Article PT - Review DEP - 20260613 PL - England TA - J Nanobiotechnology JT - Journal of nanobiotechnology JID - 101152208 RN - 0 (Biomarkers, Tumor) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/therapy/drug therapy MH - Animals MH - *Nanotechnology/methods MH - *Precision Medicine/methods MH - Drug Delivery Systems MH - Theranostic Nanomedicine/methods MH - Nanomedicine MH - Nanostructures/chemistry MH - Biomarkers, Tumor MH - Antineoplastic Agents/therapeutic use PMC - PMC13491625 OTO - NOTNLM OT - Bladder cancer OT - Intravesical drug delivery OT - Nanomedicine OT - Nanotheranostics OT - Tumor microenvironment COIS- Declarations. Ethics approval and consent to participate: The authors have nothing to report. Competing interests: The authors declare no competing interests. EDAT- 2026/06/15 11:34 MHDA- 2026/08/20 05:43 PMCR- 2026/06/13 CRDT- 2026/06/13 23:38 PHST- 2026/01/19 00:00 [received] PHST- 2026/05/25 00:00 [accepted] PHST- 2026/08/20 05:43 [medline] PHST- 2026/06/15 11:34 [pubmed] PHST- 2026/06/13 23:38 [entrez] PHST- 2026/06/13 00:00 [pmc-release] AID - 10.1186/s12951-026-04635-4 [pii] AID - 4635 [pii] AID - 10.1186/s12951-026-04635-4 [doi] PST - epublish SO - J Nanobiotechnology. 2026 Jun 13;24(1):780. doi: 10.1186/s12951-026-04635-4. PMID- 42287324 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jun 13 TI - Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma. LID - 425 [pii] LID - 10.1007/s00345-026-06534-7 [doi] AB - PURPOSE: Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is frequent, but postoperative recurrence risk is heterogeneous. We developed and multicohort-validated an interpretable postoperative model for IVR risk stratification after RNU. METHODS: We included 813 patients with pathologically confirmed UTUC treated with RNU across four predefined cohorts: retrospective development (n = 400), retrospective external validation (n = 173), internal prospective validation (n = 166), and external prospective validation (n = 74). Missing data were handled using cohort-specific multiple imputation. A Cox model integrating clinicopathological factors and neutrophil-to-lymphocyte ratio (NLR) was developed and locked in the development cohort, then transported unchanged to validation cohorts. Bootstrap confidence intervals, competing-risk analyses, benchmark comparisons, and sensitivity analyses were performed. RESULTS: The locked Cox + NLR model retained tumor location, ureteroscopic manipulation, hydronephrosis, pathological stage, surgical margin status, lymphovascular/perineural invasion, history of bladder cancer, and NLR. Harrell's C-indices were 0.709, 0.746, 0.868, and 0.811 across the four cohorts. At the primary 12-month horizon, AUCs were 0.739, 0.771, 0.953, and 0.791, respectively. Low-risk and high-risk groups remained separated under the competing-risk framework. More complex survival machine-learning models did not show a consistent transportability advantage. The 24-month estimates and surveillance simulation were considered exploratory because prospective follow-up was limited. CONCLUSION: This interpretable postoperative Cox + NLR model showed favorable multicohort performance for IVR risk stratification after RNU. It may support postoperative risk assessment, but prospective implementation studies are needed before surveillance schedules are changed. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Wang, Cheng AU - Wang C AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - He, Shuaipeng AU - He S AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Zhang, Biao AU - Zhang B AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Zhang, Su AU - Zhang S AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Fan, Ning AU - Fan N AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Chang, Hong AU - Chang H AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Wu, Gongjin AU - Wu G AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Yue, Zhongjin AU - Yue Z AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Dai, Yu AU - Dai Y AD - Department of Urology, Baoji People's Hospital, Baoji, 721000, Shaanxi, China. FAU - Li, Hengping AU - Li H AD - Department of Urology, Gansu Provincial Hospital, Lanzhou, Gansu, China. FAU - Wan, Jianghou AU - Wan J AD - Department of Urology, Lanzhou University First Hospital, Lanzhou, Gansu, China. FAU - Ma, Junhai AU - Ma J AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. junhaiurology@163.com. FAU - Shang, Panfeng AU - Shang P AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. shangpf@lzu.edu.cn. LA - eng GR - Project No. CY2024-MS-B10/Cuiying Science and Technology Innovation Project/ PT - Journal Article PT - Validation Study DEP - 20260613 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Neoplasm Recurrence, Local/epidemiology MH - *Ureteral Neoplasms/surgery/pathology MH - Retrospective Studies MH - Female MH - *Kidney Neoplasms/surgery/pathology MH - Male MH - Aged MH - Risk Assessment MH - Middle Aged MH - Prospective Studies MH - *Urinary Bladder Neoplasms/epidemiology MH - Postoperative Period OTO - NOTNLM OT - Cox model OT - Intravesical recurrence OT - Postoperative prediction OT - Radical nephroureterectomy OT - Surveillance OT - Upper tract urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethical approval: This study was conducted under institutional ethics oversight at the Second Hospital of Lanzhou University and in accordance with the Declaration of Helsinki and relevant national regulations. The current approval/update record is archived under No. 2026 A-533. Informed consent: The requirement for written informed consent was waived by the institutional ethics committee because this observational study involved only the collection and analysis of anonymized clinical data and did not alter routine treatment or introduce additional interventions. EDAT- 2026/06/15 11:35 MHDA- 2026/06/15 11:36 CRDT- 2026/06/13 11:03 PHST- 2026/04/27 00:00 [received] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/06/15 11:36 [medline] PHST- 2026/06/15 11:35 [pubmed] PHST- 2026/06/13 11:03 [entrez] AID - 10.1007/s00345-026-06534-7 [pii] AID - 10.1007/s00345-026-06534-7 [doi] PST - epublish SO - World J Urol. 2026 Jun 13;44(1):425. doi: 10.1007/s00345-026-06534-7. PMID- 42285342 OWN - NLM STAT- MEDLINE DCOM- 20260908 LR - 20260921 IS - 1873-3492 (Electronic) IS - 0009-8981 (Linking) VI - 592 DP - 2027 Jan 1 TI - Xpert(R) bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial. PG - 121169 LID - S0009-8981(26)00351-7 [pii] LID - 10.1016/j.cca.2026.121169 [doi] AB - Cystoscopy and urinary cytology are the gold standard tools for monitoring non-muscle-invasive bladder cancer (NMIBC). A new biomarker-based test (Xpert(R) Bladder Cancer Monitor) has been developed to be used as a non-invasive aid to monitor bladder cancer recurrence in patients with NMIBC. To evaluate the diagnostic performance of the Xpert(R) Bladder Cancer Monitor test for monitoring patients with NMIBC. In this prospective, non-interventional, monocentric, blinded study, 304 follow-up visits were performed (corresponding to 193 patients) over a period of 18 months. Cystoscopy and cytology or Xpert(R) Bladder Cancer Monitor test were performed as part of the NMIBC surveillance. During the study period, histologically proven NMIBC recurrence was detected in 24 cases out of 221 tested, among whom 20 had a positive Xpert(R) Bladder Cancer Monitor test and 8 had positive urine cytology. The Xpert(R) Bladder Cancer Monitor test sensitivity was significantly higher than that of cytology (83.3% vs 33.3%; p = 0.0015 with continuity correction). The positive and negative predictive values of the Xpert(R) Bladder Cancer Monitor test were 27.78% [95% confidence interval (CI): 17.43%-38.12%] and 97.32% (95% CI: 94.72%-99.91%), respectively. The Xpert(R) Bladder Cancer Monitor test is a reliable and sensitive tool for monitoring patients with NMIBC. It performs better than urine cytology with higher sensitivity, and it appears to be more effective in detecting low- and high-grade NMIBC. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Trabelssi, Mohamed AU - Trabelssi M AD - Service d'urologie. Institut Mutualiste Montpellierain - Clinique Beausoleil, 178 rue de la Taillade, 34070 Montpellier, France. FAU - Lamy, Pierre-Jean AU - Lamy PJ AD - Institut d'Analyse Genomique, IMAGENOME, 168 rue de la Taillade, 34070 Montpellier, France; Nouvelles technologies. Institut Mutualiste Montpellierain - Clinique Beausoleil, 178 rue de la Taillade, 34070 Montpellier, France. Electronic address: Pierre-Jean.Lamy@inovie.fr. FAU - Daures, Jean-Pierre AU - Daures JP AD - Nouvelles technologies. Institut Mutualiste Montpellierain - Clinique Beausoleil, 178 rue de la Taillade, 34070 Montpellier, France. FAU - Perriard, Francoise AU - Perriard F AD - Nouvelles technologies. Institut Mutualiste Montpellierain - Clinique Beausoleil, 178 rue de la Taillade, 34070 Montpellier, France. FAU - Poinas, Gregoire AU - Poinas G AD - Service d'urologie. Institut Mutualiste Montpellierain - Clinique Beausoleil, 178 rue de la Taillade, 34070 Montpellier, France. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20260612 PL - Netherlands TA - Clin Chim Acta JT - Clinica chimica acta; international journal of clinical chemistry JID - 1302422 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Prospective Studies MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms/urine/diagnosis MH - Male MH - Aged MH - Middle Aged MH - *Biomarkers, Tumor/urine MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/13 00:40 MHDA- 2026/09/08 23:35 CRDT- 2026/06/12 19:34 PHST- 2025/05/05 00:00 [received] PHST- 2026/06/07 00:00 [revised] PHST- 2026/06/08 00:00 [accepted] PHST- 2026/09/08 23:35 [medline] PHST- 2026/06/13 00:40 [pubmed] PHST- 2026/06/12 19:34 [entrez] AID - S0009-8981(26)00351-7 [pii] AID - 10.1016/j.cca.2026.121169 [doi] PST - ppublish SO - Clin Chim Acta. 2027 Jan 1;592:121169. doi: 10.1016/j.cca.2026.121169. Epub 2026 Jun 12. PMID- 42279316 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260612 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 11 DP - 2026 May 26 TI - Expect the Unexpected: Frequency, Predictors, and Survival Impact of Pathological Upstaging from Non-Muscle-Invasive to Muscle-Invasive Bladder Cancer Following Radical Cystectomy. LID - 10.3390/cancers18111733 [doi] LID - 1733 AB - Background and Objectives: Pathological upstaging from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive disease (MIBC) at radical cystectomy (RC) compromises preoperative risk stratification and may deprive patients of the survival benefit conferred by neoadjuvant chemotherapy. This study aimed to define the frequency and independent predictors of pathological upstaging in a contemporary single-institution cohort, and to characterise its impact on recurrence-free, disease-specific, and overall survival. Materials and Methods: We conducted a retrospective review of a prospectively maintained database of all patients who underwent RC and pelvic lymphadenectomy for urothelial bladder cancer at our institution between January 2009 and December 2023. Upstaging was defined as the final pathological stage >/= pT2 or pN+ from a clinical stage of /=T2) in 448 (54.2%) and NMIBC (/=3). Competing-risk analyses assessed recurrence and progression. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were recurrence and progression. Competing-risk analyses were used to evaluate associations between risk groups. RESULTS AND LIMITATIONS: A total of 2822 patients with IR NMIBC were included: 1143 (41%) IR-low, 1535 (54%) IR-intermediate, and 144 (5%) IR-high. At 3 years, we observed stepwise increases in recurrence (12% vs 38% vs 77%) and stage progression (1% vs 3% vs 7%) across the IR-low, IR-intermediate, and IR-high groups. Fine-Gray models confirmed significantly increased hazards of recurrence and progression with higher risk categories (all p<0.001). Limitations include the retrospective design and variability in treatment administration. CONCLUSIONS: We present the largest validation to date of the IBCG stratification model for IR NMIBC. Our findings confirm that patients with IR NMIBC can be reliably classified into 3 distinct prognostic groups with significantly different outcomes. These data provide robust external validation of the IBCG scoring system and support its integration into clinical practice and future guideline development. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Siva, Jayant AU - Siva J AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Jonnalagadda, Rishi AU - Jonnalagadda R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Aydogdu, Can AU - Aydogdu C AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Diaz, Gabriela M AU - Diaz GM AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Heller, Nicholas AU - Heller N AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Campbell, Rebecca AU - Campbell R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - McSweeney, Sean AU - McSweeney S AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Patel, Sahil AU - Patel S AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Olivares, Ruben AU - Olivares R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Almassi, Nima AU - Almassi N AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Kaouk, Jihad AU - Kaouk J AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Weight, Christopher J AU - Weight CJ AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: bukavil2@ccf.org. LA - eng PT - Journal Article DEP - 20260611 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - External validation OT - Intermediate risk OT - International Bladder Cancer Group OT - Non-muscle-invasive bladder cancer OT - Substratification EDAT- 2026/06/12 00:37 MHDA- 2026/06/12 00:37 CRDT- 2026/06/11 23:01 PHST- 2025/12/23 00:00 [received] PHST- 2026/05/18 00:00 [revised] PHST- 2026/05/26 00:00 [accepted] PHST- 2026/06/12 00:37 [medline] PHST- 2026/06/12 00:37 [pubmed] PHST- 2026/06/11 23:01 [entrez] AID - S2588-9311(26)00157-4 [pii] AID - 10.1016/j.euo.2026.05.017 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 Jun 11:S2588-9311(26)00157-4. doi: 10.1016/j.euo.2026.05.017. PMID- 42274003 OWN - NLM STAT- MEDLINE DCOM- 20260614 LR - 20260730 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 6 IP - 6 DP - 2026 Jun 11 TI - Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. PG - CD013776 LID - 10.1002/14651858.CD013776.pub3 [doi] LID - CD013776 AB - RATIONALE: Disease recurrence and progression remain major challenges in the treatment of non-muscle invasive bladder cancer (NMIBC). Blue light-enhanced transurethral resection of bladder cancer (TURBT) is an approach to improve staging and achieve a complete resection of NMIBC. Since the first version of this review was published in 2021, new evidence on this topic has become available. OBJECTIVES: To assess the effects of blue light-enhanced TURBT compared to white light-based TURBT in the treatment of non-muscle invasive bladder cancer. SEARCH METHODS: We searched several medical literature databases, including the Cochrane Library, MEDLINE, and Embase, as well as two trial registers, with no restrictions on language of publication or publication status, until March 2026. ELIGIBILITY CRITERIA: We included randomized controlled trials using blue light versus white light TURBT. Included participants (older than 18 years) had a high level of suspicion based on imaging or 'visible diagnosis' for primary urothelial carcinoma of the bladder or recurrent urothelial carcinoma of the bladder upon cytoscopy. We excluded studies in which blue light was used in a surveillance setting. OUTCOMES: Critical outcomes (primary outcomes) of this review were time to disease recurrence, time to disease progression and serious surgical complications. Important outcomes (secondary outcomes) were time to death from bladder cancer, any adverse events and non-serious surgical complications. The thresholds for clinical relevance of the outcomes were determined through consensus among all authors. RISK OF BIAS: We assessed the risk of bias using RoB 1. Two review authors independently assessed the risk of bias of each included study. Any disagreements were resolved by consensus or by consultation with a third review author. SYNTHESIS METHODS: Two review authors independently performed data extraction and risk of bias assessment. We synthesized results for each outcome using meta-analysis where possible (using a random-effects model with the Mantel-Haenszel method for dichotomous outcomes and the generic inverse-variance method for time-to-event outcomes). Where this was not possible due to the nature of the data, we synthesized results using a narrative approach. We rated the certainty of evidence using the GRADE approach. INCLUDED STUDIES: We included 17 randomized controlled trials involving a total of 4890 participants in the review (1 study with 533 eligible participants was new to this update). The studies compared blue light versus white light TURBT for treatment of NMIBC. SYNTHESIS OF RESULTS: Critical outcomes Blue light TURBT may have little to no effect on the risk of recurrence in people at low risk, but may reduce the risk of recurrence in those at intermediate and high risk (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.56 to 0.82; low-certainty evidence). For participants with low-, intermediate-, and high-risk NMIBC, this corresponds to 45 (63 fewer to 25 fewer), 102 (145 fewer to 56 fewer), and 137 (200 fewer to 72 fewer) fewer recurrences per 1000 participants when compared to white light TURBT, respectively. Blue light TURBT probably has little to no effect on the risk of progression in people at low risk, may have little or no effect on the risk of progression in people at intermediate risk, but may reduce the risk of progression in those at high risk (HR 0.70, 95% CI 0.55 to 0.90; low- to moderate-certainty evidence). For participants with low-, intermediate-, and high-risk NMIBC, this corresponds to 1 (1 fewer to 0 fewer), 15 (22 fewer to 5 fewer), and 48 (73 fewer to 16 fewer) fewer progressions per 1000 participants when compared to white light TURBT, respectively. Blue light TURBT may have little to no effect on serious surgical complications (risk ratio (RR) 0.84, 95% CI 0.30 to 2.29; 2 RCTS, 951 participants; low-certainty evidence). This corresponds to three fewer (13 fewer to 24 more) surgical complications per 1000 participants with blue light TURBT. Important outcomes Blue light TURBT may have little to no effect on the risk of death from bladder cancer over time (HR 0.84, 95% CI 0.42 to 1.68; 2 RCTs, 833 participants; low-certainty evidence). This corresponds to 22 deaths per 1000 participants with white light TURBT and three fewer (12 fewer to 14 more) deaths per 1000 participants with blue light TURBT. Blue light TURBT may have little to no effect on adverse events of any grade (RR 1.07, 95% CI 0.89 to 1.29; 4 RCTs, 1801 participants; low-certainty evidence). This corresponds to 22 more (35 fewer to 92 more) adverse events of any grade per 1000 participants with blue light TURBT. Blue light TURBT may have little to no effect on non-serious surgical complications (RR 0.90, 95% CI 0.63 to 1.28; 1 RCT; 426 participants; low-certainty evidence). This corresponds to 24 fewer (87 fewer to 66 more) surgical complications per 1000 participants with blue light TURBT. AUTHORS' CONCLUSIONS: Blue light-enhanced TURBT for the treatment of non-muscle invasive bladder cancer compared to white light-based TURBT may reduce the risk of disease recurrence and disease progression over time, depending on baseline risk. There may be little or no effect on serious surgical complications. Blue light TURBT may have little to no effect on the time to death from bladder cancer, adverse events or non-serious surgical complications, respectively. The certainty of evidence for our findings was mostly low, meaning that future studies are likely to change the reported estimates of effect. Frequent issues that led us to downgrade the certainty of the evidence were study limitations, inconsistency, and imprecision. FUNDING: The update of this review had no dedicated funding. REGISTRATION: Protocol (2020): DOI: 10.1002/14651858.CD013776 Original review (2021): DOI: 10.1002/14651858.CD013776.pub2. CI - Copyright (c) 2026 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Maisch, Philipp AU - Maisch P AUID- ORCID: 0000-0001-8104-167X AD - Department of Urology and Pediatric Urology, University of Ulm, Ulm, Germany. FAU - Hamidi Madani, Mohammad AU - Hamidi Madani M AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Koziarz, Alex AU - Koziarz A AD - Diagnostic Radiology, McMaster University, Hamilton, Canada. FAU - Narayan, Vikram M AU - Narayan VM AD - Department of Urology, Emory University, Atlanta, Georgia, USA. FAU - Kim, Myung Ha AU - Kim MH AD - Yonsei Wonju Medical Library, Yonsei University Wonju College of Medicine, Wonju, Korea, South. FAU - Dahm, Philipp AU - Dahm P AD - Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. AD - Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260611 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2021 Dec 1;12:CD013776. doi: 10.1002/14651858.CD013776.pub2. PMID: 34850382 MH - *Transurethral Resection of Bladder/methods MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/surgery MH - *Blue Light MH - Randomized Controlled Trials as Topic MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Disease Progression PMC - PMC13255099 COIS- PM, AK, MHM, VMN, MHK, and PD report no conflicts of interest. MHM and PD work as urologists and sometimes use this treatment in some patients. PD is the Co-ordinating Editor of Cochrane Urology and a Sign-off Editor with the Cochrane Central Editorial Service. He was not involved in the editorial process for this review. EDAT- 2026/06/11 12:40 MHDA- 2026/06/15 11:34 PMCR- 2027/06/11 CRDT- 2026/06/11 07:02 PHST- 2026/06/15 11:34 [medline] PHST- 2026/06/11 12:40 [pubmed] PHST- 2026/06/11 07:02 [entrez] PHST- 2027/06/11 00:00 [pmc-release] AID - CD013776.pub3 [pii] AID - 10.1002/14651858.CD013776.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2026 Jun 11;6(6):CD013776. doi: 10.1002/14651858.CD013776.pub3. PMID- 42271085 OWN - NLM STAT- MEDLINE DCOM- 20261023 LR - 20261026 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 58 IP - 11 DP - 2026 Nov TI - A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy. PG - 4791-4798 LID - 10.1007/s11255-026-05234-w [doi] AB - PURPOSE: To analyze the prevalence of variant histology bladder cancer subtypes and compare survival and oncological outcomes following radical cystectomy, in urothelial and variant histology cohorts, at a high-volume Australian center. METHOD: A five-year retrospective cohort study, including 82 patients at a tertiary center in Queensland, Australia. Inclusion criteria comprised patients over 18 years old with localized high-risk bladder cancer and who underwent open cystectomy plus ileal conduit, with curative intent. Exclusion criteria included metastatic disease, an indication other than malignancy and treatment with palliative intent. Statistical analysis was performed using R version 4.4.1, with statistical significance reported at p < 0.05. RESULTS: Variant histology comprised 26% of the study cohort with a greater proportion of highly aggressive VH subtypes observed in the data compared to current literature. On multivariable analysis, VH was not associated with a higher risk of mortality. However, muscle-invasive disease and positive lymph nodes were independently associated with a significant risk of mortality (P = 0.009 and P = 0.048, respectively). Within the VH bladder cancer group, there was a greater proportion (62%) found to be stage > T1 post-cystectomy, compared to the urothelial group (41%). CONCLUSION: This is the only Australian study examining outcomes post-radical cystectomy across multiple VH subtypes. Highly aggressive subtypes (micropapillary, plasmacytoid, sarcomatoid) were over-represented in our cohort. Improved recognition of VH guides multidisciplinary decision-making while a standard of care is yet to be established. Multicentered Australian registries with long-term follow-up are needed to enhance statistical analysis and evaluate the impact of variant histology on treatment outcomes. CI - (c) 2026. The Author(s). FAU - McMaster, Thomas AU - McMaster T AUID- ORCID: 0000-0002-8558-7028 AD - Department of Urology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. tom.mac.1996@outlook.com. FAU - Hoskin, Gabrielle AU - Hoskin G AD - Department of Pathology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Homewood, David AU - Homewood D AUID- ORCID: 0000-0002-6072-6191 AD - Department of Urology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Attwell-Heap, Abigail AU - Attwell-Heap A AD - Department of Urology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Perry-Keene, Joanna AU - Perry-Keene J AD - Department of Pathology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Harrison, Vanessa AU - Harrison V AD - Department of Pathology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Perumalla, Chandrasekhar AU - Perumalla C AD - Department of Urology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. FAU - Chopra, Sam AU - Chopra S AD - Department of Urology, Sunshine Coast University Hospital, Birtinya, QLD, Australia. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260610 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Female MH - Male MH - Retrospective Studies MH - Aged MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Middle Aged MH - Neoplasm Staging MH - Survival Rate MH - Neoplasm Invasiveness MH - Aged, 80 and over PMC - PMC13694323 OTO - NOTNLM OT - Bladder cancer OT - Oncological outcomes OT - Overall survival OT - Radical cystectomy OT - Variant histology COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This is a retrospective observational study. The Gold Coast Hospital and Health Service Research Ethics Committee has confirmed that no ethical approval is required (EX/2025/QGC/115759). Consent to participate: Not applicable. EDAT- 2026/06/11 05:41 MHDA- 2026/10/23 18:30 PMCR- 2026/06/10 CRDT- 2026/06/10 23:34 PHST- 2026/02/23 00:00 [received] PHST- 2026/06/02 00:00 [accepted] PHST- 2026/10/23 18:30 [medline] PHST- 2026/06/11 05:41 [pubmed] PHST- 2026/06/10 23:34 [entrez] PHST- 2026/06/10 00:00 [pmc-release] AID - 10.1007/s11255-026-05234-w [pii] AID - 5234 [pii] AID - 10.1007/s11255-026-05234-w [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Nov;58(11):4791-4798. doi: 10.1007/s11255-026-05234-w. Epub 2026 Jun 10. PMID- 42271019 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260813 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jun 10 TI - Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes. LID - 10.1007/s00345-026-06520-z [doi] LID - 419 AB - AIM: (I) To determine clinicopathological determinants of metachronous Upper Tract Urothelial Carcinoma (UTUC) requiring Radical Nephroureterectomy (RNU) after Radical Cystectomy (RC). (II) To evaluate long-term survival of patients who underwent RC + RNU compared with matched RC only controls. METHODS: Patients undergoing RNU for metachronous UTUC were extracted from a multi-institutional RC database. A 1:2 Propensity Score Match (PSM) was performed based on age, gender, BMI, CCI, Smoking Status, and cT stage between RC only and RC + RNU patients. Simon-Makuch plots, landmark analyses and Multivariable Cox regressions were adopted to compare survival outcomes. RESULTS: Of 1804 RC patients, 85 (4.7%) underwent subsequent RNU. At multivariate regression, younger age, smoking history, BCG exposure, NMIBC, CIS and positive ureteric margins were identified as positive predictors of upper tract recurrence. After PSM, 81 RC + RNU patients were matched to 157 RC only controls. Median time from RC to RNU was 29 (18-47) months, with the majority of UTUC diagnosed at a muscle-invasive stage (70.9%). Simon-Makuch curves demonstrated worse Cancer Specific Survival (CSS) of the RC + RNU cohort (HR: 6.41, 95% CI 3.16-13.04). At landmark analyses, RNU was consistently associated with an increased mortality risk from the 24th month onward. Multivariable Cox regression identified RNU and pN + as the only significant predictors of worse CSS (respectively, HR: 6.55, 95% CI 2.93-14.64 and HR: 8.45, 95% CI 3.24-21.99). CONCLUSIONS: The worse survival outcomes and high rates of locally advanced disease found at RNU underscore the need for standardized, risk-stratified, long-term follow-up of the remnant urinary tract following RC. CI - (c) 2026. The Author(s). FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. va.santarelli@uniroma1.it. AD - Orsi Academy, Melle, Belgium. va.santarelli@uniroma1.it. AD - Department of Urology, Stanford University School of Medicine, Stanford, USA. va.santarelli@uniroma1.it. FAU - Asero, Vincenzo AU - Asero V AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - Corvino, Roberta AU - Corvino R AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - Basile, Giuseppe AU - Basile G AD - Department of Urology, Royal Free London Foundation Trust, London, UK. FAU - Abu-Ghanem, Yasmin AU - Abu-Ghanem Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St. Thomas' Hospital, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St. Thomas' Hospital, London, UK. FAU - Khan, Muhamad Shamin AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St. Thomas' Hospital, London, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St. Thomas' Hospital, London, UK. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556, Wroclaw, Poland. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556, Wroclaw, Poland. FAU - Albisinni, Simone AU - Albisinni S AD - Unit of Urology, Department of Surgical Sciences, Tor Vergata University, Rome, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. AD - Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Reynard, Maxence AU - Reynard M AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Clinical and Experimental Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Soria, Francesco AU - Soria F AD - Surgical Sciences, University of Turin and Citta della Salute e della Scienza, Turin, Italy. FAU - Teoh, Jeremy AU - Teoh J AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, Hong Kong. FAU - Claps, Francesco AU - Claps F AD - Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. FAU - Amodeo, Antonio AU - Amodeo A AD - Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria, Universidad de Alcala, Madrid, Spain. FAU - Tully, Karl H AU - Tully KH AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Bochum, Germany. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Centre Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Bertolo, Riccardo AU - Bertolo R AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Ditonno, Francesco AU - Ditonno F AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Hospital, IRCCS, Milano, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, University Hospital Augsburg, Augsburg, Germany. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Humanitas Gavazzeni, 24125, Bergamo, Italy. FAU - Marino, Filippo AU - Marino F AD - Department of Urology, Humanitas Gavazzeni, 24125, Bergamo, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Rocco, Bernardo Maria Cesare AU - Rocco BMC AD - Department of Urology, 'A. Gemelli' Hospital Foundation, IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Sighinolfi, Chiara AU - Sighinolfi C AD - Department of Urology, 'A. Gemelli' Hospital Foundation, IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Vittori, Luigi AU - Vittori L AD - Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - De Angelis, Mario AU - De Angelis M AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Scillipoti, Pietro AU - Scillipoti P AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - De Groote, Ruben AU - De Groote R AD - Orsi Academy, Melle, Belgium. AD - Azorg Hospital, Aalst, Belgium. FAU - De Naeyer, Geert AU - De Naeyer G AD - Orsi Academy, Melle, Belgium. AD - Azorg Hospital, Aalst, Belgium. FAU - Mottrie, Alexandre AU - Mottrie A AD - Orsi Academy, Melle, Belgium. AD - Azorg Hospital, Aalst, Belgium. FAU - Pavan, Nicola AU - Pavan N AD - Department Me.Pre.Cc, Precision Medicine in Medical, Surgical, and Critical Areas, Section of Urology, University of Palermo, Palermo, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, USA. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, USA. CN - European Association of Urology -Young Academic Urologists (EAU -YAU), Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260610 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality MH - *Cystectomy/methods MH - *Kidney Neoplasms/surgery/mortality MH - Neoplasm Recurrence, Local/surgery/mortality MH - *Neoplasms, Second Primary/surgery/mortality/pathology MH - *Nephroureterectomy/methods MH - Propensity Score MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - *Ureteral Neoplasms/surgery/mortality MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality PMC - PMC13253654 OTO - NOTNLM OT - Bladder cancer OT - Radical Nephroureterectomy OT - Radical cystectomy OT - Upper tract urothelial carcinoma OT - Urothelial recurrence COIS- Declarations. Conflict of interest: The authors declare no competing interests. Human ethics and consent to participate: This study is a retrospective observational study conducted in compliance with the European General Data Protection Regulation (EU GDPR 2016/679) and applicable local regulations. The study involved only the analysis of fully anonymized data and did not affect patient care. All procedures were conducted in accordance with the ethical principles of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and followed local institutional guidelines at each participating center. Before study initiation, data-transfer agreement and Institutional Review Boards (IRB) approval from each of the included centers were obtained. EDAT- 2026/06/11 05:43 MHDA- 2026/06/12 18:42 PMCR- 2026/06/10 CRDT- 2026/06/10 23:32 PHST- 2026/04/12 00:00 [received] PHST- 2026/05/30 00:00 [accepted] PHST- 2026/06/12 18:42 [medline] PHST- 2026/06/11 05:43 [pubmed] PHST- 2026/06/10 23:32 [entrez] PHST- 2026/06/10 00:00 [pmc-release] AID - 10.1007/s00345-026-06520-z [pii] AID - 6520 [pii] AID - 10.1007/s00345-026-06520-z [doi] PST - epublish SO - World J Urol. 2026 Jun 10;44(1):419. doi: 10.1007/s00345-026-06520-z. PMID- 42270010 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260823 IS - 1530-0285 (Electronic) IS - 0893-3952 (Linking) VI - 39 IP - 8 DP - 2026 Aug TI - Intratubular Spread in Renal Pelvic Urothelial Carcinoma: Prognostic Significance and Staging Implications. PG - 101022 LID - S0893-3952(26)00065-7 [pii] LID - 10.1016/j.modpat.2026.101022 [doi] AB - Intratubular spread of renal pelvic urothelial carcinoma refers to tumor extension along preexisting collecting ducts and/or renal tubules with preservation of the tubular basement membrane at the involved profiles. Although recognized as noninvasive for staging purposes, its prognostic role remains incompletely defined. We conducted a single-center retrospective cohort study of consecutive patients who underwent radical nephroureterectomy for renal pelvic urothelial carcinoma between April 2002 and April 2023, with blinded central slide review and American Joint Committee on Cancer eighth edition harmonization. The prespecified primary endpoint was non-urinary tract recurrence-free survival (NUTRFS), defined as recurrence outside the urinary tract (local/regional recurrence outside the urinary tract, lymph node metastasis, or distant metastasis) or death from any cause; urothelial tract recurrences were not counted as NUTRFS events. The key secondary endpoint was cancer-specific survival (CSS); disease-free survival and overall survival were additional endpoints. After exclusions, 158 patients were analyzed (median follow-up, 95.7 months), and intratubular spread was identified in 58 patients (36.7%). Within pT1/pT2 disease, the presence of intratubular spread strongly stratified NUTRFS (log-rank test, P < .001) and CSS (P = .0015), and outcomes for pT1/pT2 tumors with intratubular spread approximated those of pT3 tumors (NUTRFS, P = .938; CSS, P = .868). Within pT3, the presence of intratubular spread stratified NUTRFS (P = .043) but not CSS (P = .133). In prespecified multivariable Cox models restricted to invasive tumors with known nodal status and excluding pTa/pTis and pT4 (n = 71), the presence of intratubular spread remained independently associated with worse NUTRFS (hazard ratio, 2.85; 95% CI, 1.34-6.09; P = .0066) and CSS (hazard ratio, 2.98; 95% CI, 1.28-6.95; P = .0116) after adjustment for pT3 subclass and nodal status, with no evidence of interaction by pT3 subclass. Intratubular spread is a noninvasive but clinically relevant, stage-adjacent histologic feature in renal pelvic urothelial carcinoma that is best captured by NUTRFS and supported by concordant CSS findings, with particular utility for identifying high-risk pT1/pT2 disease. CI - Copyright (c) 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. FAU - Oga, Kazuki AU - Oga K AD - Faculty of Medicine, Kyoto University, Kyoto, Japan. FAU - Teramoto, Yuki AU - Teramoto Y AD - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. Electronic address: tera1980@kuhp.kyoto-u.ac.jp. FAU - Kita, Yuki AU - Kita Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Haga, Hironori AU - Haga H AD - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. LA - eng PT - Journal Article DEP - 20260610 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 SB - IM MH - Humans MH - Female MH - Aged MH - *Kidney Neoplasms/pathology/mortality/surgery MH - Retrospective Studies MH - Neoplasm Staging MH - *Carcinoma, Transitional Cell/pathology/mortality/surgery MH - *Kidney Pelvis/pathology MH - Prognosis MH - Middle Aged MH - Male MH - Aged, 80 and over MH - Nephroureterectomy MH - Disease-Free Survival OTO - NOTNLM OT - intratubular carcinoma OT - intratubular spread OT - pathologic staging OT - prognosis OT - renal pelvis OT - upper tract urothelial carcinoma EDAT- 2026/06/11 05:42 MHDA- 2026/08/19 23:42 CRDT- 2026/06/10 19:59 PHST- 2026/01/20 00:00 [received] PHST- 2026/05/03 00:00 [revised] PHST- 2026/05/29 00:00 [accepted] PHST- 2026/08/19 23:42 [medline] PHST- 2026/06/11 05:42 [pubmed] PHST- 2026/06/10 19:59 [entrez] AID - S0893-3952(26)00065-7 [pii] AID - 10.1016/j.modpat.2026.101022 [doi] PST - ppublish SO - Mod Pathol. 2026 Aug;39(8):101022. doi: 10.1016/j.modpat.2026.101022. Epub 2026 Jun 10. PMID- 42262988 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260730 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 132 IP - 12 DP - 2026 Jun 15 TI - The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration. PG - e70448 LID - 10.1002/cncr.70448 [doi] AB - Urothelial carcinoma (UC) is a significant global health challenge with heterogeneous clinical presentations from nonmuscle-invasive to metastatic disease. Circulating tumor DNA (ctDNA) has emerged as promising noninvasive biomarker for risk classification, treatment monitoring and recurrence detection. Systematic searches of PubMed identified 390 articles; 61 met inclusion criteria for plasma ctDNA analysis in UC. Independent dual screening, Joanna Briggs Institute assessment, and stratification by disease stage (nonmuscle-invasive bladder cancer [NMIBC], muscle-invasive bladder cancer [MIBC], metastatic urothelial carcinoma [mUC], and upper tract urothelial carcinoma [UTUC]) were performed. Simple pooled detection rates were calculated. ctDNA detection rates increased with disease advancement: NMIBC (53.2%), MIBC (47.6%), mUC (85.9%), and UTUC (50.5%). TERT promoter mutations predominated, followed by genomic alterations in TP53. Assays varied widely across studies with next-generation sequencing (22.4%) being most common. In NMIBC, ctDNA enabled risk stratification and recurrence detection. In MIBC, IMvigor010 demonstrated patients with positive ctDNA had worse overall survival (OS) (hazard ratio, 6.3); IMvigor011 showed that patients with negative ctDNA managed without adjuvant therapy had excellent outcomes (98% OS at 18 months). Post-surgical monitoring achieved 94%-100% sensitivity for recurrence with 96- to 131-day lead times. In mUC, KEYNOTE-361 showed ctDNA reductions at 6 weeks predicted improved OS (p < 10(-4)), whereas fibroblast growth factor receptor 3 mutations tracked resistance. Preoperative ctDNA fraction >2% in UTUC predicted worse OS (p < 10(-3)). ctDNA is a critical precision oncology tool in UC management, with TERT mutations as the predominant alteration. Stage-tailored strategies are emerging, including risk assessment in NMIBC, refining adjuvant decisions in MIBC, and treatment monitoring in mUC. Integration of ctDNA-guided approaches should proceed alongside prospective validation to ensure safe and effective adoption. CI - (c) 2026 American Cancer Society. FAU - Mehta, Sanchit AU - Mehta S AUID- ORCID: 0009-0006-7110-3527 AD - B.J. Medical College and Civil Hospital, Ahmedabad, India. FAU - Weinfeld, Michael AU - Weinfeld M AUID- ORCID: 0000-0002-0933-3747 AD - Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA. FAU - Hobeika, Charbel AU - Hobeika C AUID- ORCID: 0009-0009-3157-027X AD - Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA. FAU - Reizine, Natalie AU - Reizine N AUID- ORCID: 0000-0001-9240-9943 AD - Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA. FAU - Tawagi, Karine AU - Tawagi K AUID- ORCID: 0009-0001-3416-3786 AD - Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA. LA - eng PT - Journal Article PT - Systematic Review PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Humans MH - *Circulating Tumor DNA/blood/genetics MH - *Biomarkers, Tumor/blood/genetics MH - *Carcinoma, Transitional Cell/genetics/blood/pathology/diagnosis MH - Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/genetics/blood/pathology MH - Mutation MH - Neoplasm Recurrence, Local/genetics/blood MH - *Urologic Neoplasms/genetics/blood/pathology MH - Telomerase/genetics MH - Prognosis OTO - NOTNLM OT - ctDNA OT - liquid biopsy OT - molecular residual disease OT - precision oncology OT - prognostic biomarker OT - urothelial carcinoma EDAT- 2026/06/09 18:43 MHDA- 2026/06/12 00:37 CRDT- 2026/06/09 13:04 PHST- 2026/02/26 00:00 [revised] PHST- 2025/12/22 00:00 [received] PHST- 2026/04/10 00:00 [accepted] PHST- 2026/06/12 00:37 [medline] PHST- 2026/06/09 18:43 [pubmed] PHST- 2026/06/09 13:04 [entrez] AID - 10.1002/cncr.70448 [doi] PST - ppublish SO - Cancer. 2026 Jun 15;132(12):e70448. doi: 10.1002/cncr.70448. PMID- 42260513 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261029 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 26 IP - 1 DP - 2026 Jun 8 TI - Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances. LID - 10.1186/s12894-026-02209-y [doi] LID - 263 AB - BACKGROUND: Bladder cancer poses significant morbidity, mortality, and healthcare burdens globally. While non-muscle-invasive bladder cancer often initially responds to intravesical Bacillus Calmette-Guerin, many patients become unresponsive to Bacillus Calmette-Guerin, resulting in recurrence or progression. Emerging immunotherapies, including checkpoint inhibitors (Pembrolizumab, Atezolizumab, Durvalumab), intravesical gene therapies (Nadofaragene Firadenovec, Cretostimogene Grenadenorepvec), and novel cytokine-based therapies, present promising alternatives. This systematic review thoroughly synthesizes existing clinical evidence from phase 2 and 3 trials, critically assessing immunotherapeutic options for bladder cancer treatment. METHODS: A comprehensive search was systematically conducted across four databases: PubMed, Cochrane, Web of Science and Scopus strictly adhering to PRISMA guidelines and retrospectively registered. Included studies evaluated immunotherapies in non-muscle-invasive bladder cancer and selected muscle-invasive bladder cancer populations. Two reviewers independently performed study screening, data extraction, and risk-of-bias assessments using the Cochrane Risk-of-Bias tool. Results were synthesized qualitatively, incorporating detailed comparative analyses and robust statistical descriptions. RESULTS: A total of 778 studies were initially identified. Intravesical Cretostimogene Grenadenorepvec demonstrated the highest complete response [1] rate (75.2%), with impressive durability (83% maintaining response >/= 12 months). Intravesical Nadofaragene Firadenovec also exhibited notable efficacy (CR 53.4%, median duration 9.69 months). Nogapendekin Alfa Inbakicept combined with Bacillus Calmette-Guerin achieved a robust CR (71%) and a remarkably sustained response (median 26.6 months). Systemic Pembrolizumab showed moderate efficacy (43.5% 12-month disease-free survival) but raised significant toxicity concerns (14% grade >/= 3 adverse events). Intravesical therapies consistently provided superior cystectomy avoidance (>/= 89% at 12 months) compared to systemic treatments. Safety profiles significantly favored intravesical therapies, which had predominantly mild (grade 1-2) adverse events, while systemic therapies reported notable severe toxicities and treatment-related fatalities. CONCLUSIONS: Intravesical immunotherapies, particularly Nogapendekin Alfa Inbakicept and Bacillus Calmette-Guerin and Nadofaragene, demonstrate superior efficacy, significant response durability, and favorable safety profiles in treating bladder cancer compared to systemic checkpoint inhibitors, which display moderate efficacy and notable safety concerns. These findings strongly support prioritizing intravesical therapies in non-muscle-invasive bladder cancer management, especially for patients who are unresponsive to Bacillus Calmette-Guerin. Future research should focus on head-to-head randomized controlled trials and biomarker-driven patient selection to optimize clinical outcomes. CI - (c) 2026. The Author(s). FAU - Alasker, Ahmed AU - Alasker A AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Alghafees, Mohammad AU - Alghafees M AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. alghafees687@gmail.com. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. alghafees687@gmail.com. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. alghafees687@gmail.com. FAU - Nammor, Talah AU - Nammor T AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Alanazi, Naif AU - Alanazi N AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Alferayan, Turki AU - Alferayan T AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Almanie, Abdulaziz AU - Almanie A AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Alrashed, Mohammed AU - Alrashed M AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Almarzouq, Yousef AU - Almarzouq Y AD - College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - Department of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Alammari, Abdullah AU - Alammari A AD - King Abdullah International Medical Research Centre (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260608 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Immunotherapy/methods/trends MH - *Urinary Bladder Neoplasms/therapy MH - Clinical Trials as Topic MH - Non-Muscle Invasive Bladder Neoplasms MH - Immune Checkpoint Inhibitors/therapeutic use PMC - PMC13711737 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Intravesical immunotherapy OT - Systemic checkpoint inhibitors COIS- Declarations. Ethics approval and consent to participate: This study is a systematic review of previously published clinical trials and did not involve the collection of new data from human participants or animals. Therefore, ethical approval and informed consent were not required. All included studies reported compliance recognized ethical standards, and obtained appropriate institutional review board (IRB) approvals. Data privacy and confidentiality were maintained through the process and no individual-level data was accessed or disclosed. This review was retrospectively registered ensuring transparency and adherence to best practices for systematic reviews. Consent for publication: All authors have reviewed and approved the final version of the manuscript and consent to its publication. No individual patient data or identifiable personal information is included in this manuscript. Competing interests: The authors declare no competing interests. EDAT- 2026/06/09 06:36 MHDA- 2026/10/28 05:28 PMCR- 2026/06/08 CRDT- 2026/06/09 00:10 PHST- 2025/04/15 00:00 [received] PHST- 2026/05/28 00:00 [accepted] PHST- 2026/10/28 05:28 [medline] PHST- 2026/06/09 06:36 [pubmed] PHST- 2026/06/09 00:10 [entrez] PHST- 2026/06/08 00:00 [pmc-release] AID - 10.1186/s12894-026-02209-y [pii] AID - 2209 [pii] AID - 10.1186/s12894-026-02209-y [doi] PST - epublish SO - BMC Urol. 2026 Jun 8;26(1):263. doi: 10.1186/s12894-026-02209-y. PMID- 42256644 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260813 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 6 DP - 2026 Jun TI - Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care. PG - e70233 LID - 10.1002/bco2.70233 [doi] LID - e70233 AB - OBJECTIVES: To investigate the potential of the Haematuria Cancer Risk Score (HCRS) to improve the real-world investigation pathway for suspected bladder cancer. MATERIALS AND METHODS: Data were retrospectively analysed for all consecutive patients referred with suspected urinary tract cancer on a faster diagnostic pathway to five UK institutions between January and April 2025. The HCRS cut-off score of >/=82 was used to define a 'HCRS high risk' population. The co-primary outcomes were the ability to calculate HCRS in the referred population from the information provided by primary care and the cancer detection rate. RESULTS: In total, 1944 referrals were received, median age of 71 years (IQR 61-78), 1186/1944 (61%) were male, and 1586/1944 (82%) had sufficient information to calculate the HCRS. Of the cohort with HCRS scores, overall 165/1586 (10%) had bladder cancer. The HCRS was >/=82 in 176/437 (40%) of those with non-visible haematuria (NVH); in total, 6/176 (3%) had bladder cancer; and using HCRS in the NVH group alone, no case of muscle-invasive bladder cancer (MIBC) would have been missed. The HCRS was >/=82 in 1062/1149 (92%) with visible haematuria (VH), of whom 150/1062 (14%) had bladder cancer. Adopting a strategy of using HCRS and upper tract imaging in combination for the whole cohort would have resulted in two cases of NMIBC being missed for the NVH cohort and one case of NMIBC being missed for the VH cohort. No cases of MIBC or upper tract urothelial cancer would have been missed. CONCLUSION: HCRS is a simple innovation, which demonstrates clear potential when combined with upper tract imaging to improve current UK risk stratification to determine which patients referred with haematuria need flexible cystoscopy. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Malik, Tom AU - Malik T AUID- ORCID: 0000-0002-6302-8209 AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. AD - Population Health Sciences, Bristol Medical School University of Bristol Bristol UK. FAU - Denfhy, Jonathan AU - Denfhy J AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. FAU - Theinkha Lin, Hpone AU - Theinkha Lin H AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. FAU - Mohammed, Lubna AU - Mohammed L AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. FAU - Aung Han, Lin AU - Aung Han L AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. FAU - Babureddy, Kirthana AU - Babureddy K AD - Department of Urology Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK. FAU - Pankhurst, Amber AU - Pankhurst A AD - Department of Urology Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK. FAU - Tudor, Edward AU - Tudor E AD - Department of Urology Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK. FAU - Buba, Amina AU - Buba A AD - Department of Urology Royal United Hospitals NHS Foundation Trust Bath UK. FAU - Waley, Laura AU - Waley L AD - Department of Urology Royal United Hospitals NHS Foundation Trust Bath UK. FAU - Bali, Aashna AU - Bali A AD - Department of Urology Royal United Hospitals NHS Foundation Trust Bath UK. FAU - Shaw, Gemma AU - Shaw G AD - Department of Urology Royal United Hospitals NHS Foundation Trust Bath UK. FAU - Jefferies, Edward AU - Jefferies E AD - Department of Urology Royal United Hospitals NHS Foundation Trust Bath UK. FAU - Head, Jessica AU - Head J AD - Department of Urology Somerset Foundation Trust Taunton UK. FAU - Smith, Tirion AU - Smith T AD - Department of Urology Somerset Foundation Trust Taunton UK. FAU - Brown, Jade AU - Brown J AD - Department of Urology Somerset Foundation Trust Taunton UK. FAU - Trent, Neil AU - Trent N AD - Department of Urology Somerset Foundation Trust Taunton UK. FAU - Dudley, Sian AU - Dudley S AD - Department of Urology Great Western Hospitals NHS Foundation Trust Swindon UK. FAU - Mathur, Sunil AU - Mathur S AD - Department of Urology Great Western Hospitals NHS Foundation Trust Swindon UK. FAU - Aning, Jonathan AU - Aning J AUID- ORCID: 0000-0001-6189-4720 AD - Bristol Urological Institute, North Bristol NHS Trust Bristol UK. AD - Population Health Sciences, Bristol Medical School University of Bristol Bristol UK. LA - eng PT - Journal Article DEP - 20260529 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC13239896 OTO - NOTNLM OT - bladder cancer OT - haematuria OT - radical cystectomy OT - transurethral resection of bladder tumour COIS- Tom Malik, Jonathan Denfhy, Hpone Theinkha Lin, Lubna Mohammed, Lin Aung Han, Kirthana Babureddy, Amber Pankhurst, Edward Tudor, Amina Buba, Laura Waley, Aashna Bali, Gemma Shaw, Edward Jefferies Jessica Head, Tirion Smith, Jade Brown, Neil Trent, Sian Dudley and Sunil Mathur declare no conflicts of interest. Jonathan Aning has received research funding from Nonacus and honoraria from Astellas, AstraZeneca, Bayer, J&J Innovative Medicine, Merck and Nonacus. EDAT- 2026/06/08 12:39 MHDA- 2026/06/08 12:40 PMCR- 2026/05/29 CRDT- 2026/06/08 07:42 PHST- 2026/03/31 00:00 [received] PHST- 2026/05/06 00:00 [revised] PHST- 2026/05/08 00:00 [accepted] PHST- 2026/06/08 12:40 [medline] PHST- 2026/06/08 12:39 [pubmed] PHST- 2026/06/08 07:42 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - BCO270233 [pii] AID - 10.1002/bco2.70233 [doi] PST - epublish SO - BJUI Compass. 2026 May 29;7(6):e70233. doi: 10.1002/bco2.70233. eCollection 2026 Jun. PMID- 42252958 OWN - NLM STAT- MEDLINE DCOM- 20260916 LR - 20261006 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 50 IP - 10 DP - 2026 Oct 1 TI - Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features. PG - 1184-1194 LID - 10.1097/PAS.0000000000002576 [doi] AB - Giant cell urothelial carcinoma (GCUC) is an exceedingly rare histologic subtype with 50+ reported cases. To date, 3 case series have been reported. Scant chemotherapy and immunotherapy responses were reported with variable results. We report the largest GCUC series, including 27 GCUC and 27 matched control urothelial carcinoma (CoUC) patients, most (>90%) of whom had more than 5 years of follow-up, including neoadjuvant and adjuvant therapy status. We further characterized the nuclear size ratio of giant tumor cells to background tumor cells and analyzed urothelial differentiation markers (GATA3, CK5/6), p53, tumor-infiltrating lymphocytes (CD19 and CD3), and therapeutic targets (TROP2, Nectin4, PDL1, and HER2). Morphometric analysis of giant tumor cells demonstrated that they were, on average, 12 times larger than surrounding nongiant tumor cells. GCUC showed many histologic and immunophenotypic features similar to CoUC. GCUC was enriched for higher stages (T3/4 and metastatic disease) than CoUC and showed a trend toward worse OS than conventional urothelial carcinoma, but was similar to urothelial carcinoma with variant histology. GCUC included 3 low-stage (T1/2) patients, who had significantly worse OS than low-stage CoUC, suggesting early extensive workup and oncologic intervention. Chemotherapy slightly improved OS in both GCUC and CoUC patients without statistical significance. Compared with CoUC, GCUC appeared to have more tumor-infiltrating T cells, but without statistical significance. There were no expression differences in TROP2, Nectin4, PDL1, and HER2. However, a subset of GCUC patients might benefit from target therapies (PDL1, Nectin4), warranting more cohort studies. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Li, Huili AU - Li H AD - Department of Pathology, Johns Hopkins University, Baltimore, MD. FAU - Akbari, Amir AU - Akbari A AD - Department of Pathology, Johns Hopkins University, Baltimore, MD. FAU - Schuler, Matthew AU - Schuler M AD - Department of Oncology, The Johns Hopkins University, Baltimore, MD. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Salgado Esteves, Rodrigo AU - Salgado Esteves R AD - Department of Pathology, Johns Hopkins University, Baltimore, MD. FAU - Pienta, Kenneth J AU - Pienta KJ AD - Department of Oncology, The Johns Hopkins University, Baltimore, MD. AD - Department of Urology, Johns Hopkins University, Baltimore, MD. FAU - Johnson Iii, Burles A AU - Johnson Iii BA AD - Department of Oncology, The Johns Hopkins University, Baltimore, MD. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, Johns Hopkins University, Baltimore, MD. FAU - Baraban, Ezra AU - Baraban E AD - Department of Pathology, Johns Hopkins University, Baltimore, MD. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Matoso, Andres AU - Matoso A AUID- ORCID: 0000-0003-0990-1115 AD - Department of Pathology, Johns Hopkins University, Baltimore, MD. AD - Department of Oncology, The Johns Hopkins University, Baltimore, MD. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, Johns Hopkins University, Baltimore, MD. LA - eng PT - Journal Article DEP - 20260608 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - Biomarkers, Tumor/analysis MH - Male MH - Middle Aged MH - Aged, 80 and over MH - Aged MH - Lymphocytes, Tumor-Infiltrating/pathology/immunology MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy/immunology MH - *Urothelium/pathology/immunology/chemistry MH - Immunohistochemistry MH - Neoplasm Staging MH - Time Factors MH - *Carcinoma/mortality/therapy/pathology MH - *Carcinoma, Transitional Cell/mortality/pathology/therapy OTO - NOTNLM OT - PDL1 OT - TROP2 OT - giant cell urothelial carcinoma OT - nectin-4 OT - survival COIS- Conflicts of Interest and Source of Funding: The authors disclose that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2026/06/08 06:36 MHDA- 2026/09/16 05:36 CRDT- 2026/06/08 04:13 PHST- 2026/03/07 00:00 [received] PHST- 2026/05/09 00:00 [accepted] PHST- 2026/09/16 05:36 [medline] PHST- 2026/06/08 06:36 [pubmed] PHST- 2026/06/08 04:13 [entrez] AID - 00000478-990000000-00679 [pii] AID - 10.1097/PAS.0000000000002576 [doi] PST - ppublish SO - Am J Surg Pathol. 2026 Oct 1;50(10):1184-1194. doi: 10.1097/PAS.0000000000002576. Epub 2026 Jun 8. PMID- 42247594 OWN - NLM STAT- MEDLINE DCOM- 20260805 LR - 20260828 IS - 1465-3621 (Electronic) IS - 0368-2811 (Print) IS - 0368-2811 (Linking) VI - 56 IP - 8 DP - 2026 Aug 5 TI - Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan. PG - 984-992 LID - 10.1093/jjco/hyag063 [doi] AB - OBJECTIVE: We aimed to evaluate real-world clinical outcomes and prognostic factors of definitive chemoradiotherapy (CRT) for bladder cancer in Japan. METHODS: Patients with bladder cancer treated with definitive CRT between 2010 and 2023 at seven Japanese institutions were retrospectively analyzed. Overall survival (OS) was estimated using the Kaplan-Meier method, whereas cause-specific survival (CSS) and bladder preservation were analyzed using competing risk methods. Univariable analyses were performed using the log-rank and Gray's tests, and multivariable analyses were performed using Cox and Fine-Gray models with Bayesian Information Criterion-based stepwise selection. RESULTS: A total of 175 patients were included. Maximal transurethral resection of the bladder tumor (TUR-Bt) was performed in 55% of patients, and 49% were deemed ineligible for radical cystectomy (RC). The 5-year OS, CSS, and bladder preservation rate were 52% (95% CI, 42-60%), 73% (95% CI, 66-80%), and 69% (95% CI, 61-77%), respectively. In multivariable analyses, poorer performance status remained associated with worse OS (P = .003), whereas advanced clinical T stage was associated with worse CSS (P = .018) and maximal TUR-Bt was associated with improved bladder preservation (P = .024). Although patients ineligible for RC demonstrated inferior OS (P < .001) and CSS (P = .007) in univariable analyses, bladder preservation was comparable to those treated by patient preference. CONCLUSIONS: This multi-institutional retrospective study demonstrates acceptable real-world outcomes of definitive CRT for bladder cancer in Japan. Patient-related factors influenced OS, whereas tumor burden and local tumor control were associated with CSS and bladder preservation. CI - (c) The Author(s) 2026. Published by Oxford University Press. FAU - Sugahara, Daichi AU - Sugahara D AD - Department of Radiology, The University of Tokyo Hospital,113-8655, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan. FAU - Murofushi, Keiko Nemoto AU - Murofushi KN AD - Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-8677, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, Japan. FAU - Yamashita, Hideomi AU - Yamashita H AUID- ORCID: 0000-0001-9394-9490 AD - Department of Radiology, The University of Tokyo Hospital,113-8655, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan. FAU - Ogo, Etsuyo AU - Ogo E AUID- ORCID: 0000-0002-4909-0217 AD - Radiation Oncology Center, Kurume University, 830-0011, 67, Asahi-cho, Kurume, Fukuoka, Japan. FAU - Kikuchi, Koyo AU - Kikuchi K AUID- ORCID: 0000-0002-4840-8481 AD - Department of Radiation Oncology, Iwate Medical University Hospital, 028-3695, 2-1-1, Idai-dori, Yahaba-cho, Shiwa-gun, Iwate, Japan. FAU - Saito, Anneyuko I AU - Saito AI AD - Division of Radiation Oncology, Department of Radiology, Juntendo University Urayasu Hospital, 279-0021, 2-1-1, Tomioka, Urayasu, Chiba, Japan. FAU - Komiyama, Takafumi AU - Komiyama T AD - Department of Radiology, University of Yamanashi, 409-3898, 1110, Shimokato, Chuo, Yamanashi, Japan. FAU - Imano, Nobuki AU - Imano N AUID- ORCID: 0000-0002-7668-1506 AD - Department of Radiation Oncology, Hiroshima University Hospital, 734-8551, 1-2-3, Kasumi, Minami-ku, Hiroshima, Japan. FAU - Igarashi, Ataru AU - Igarashi A AUID- ORCID: 0000-0001-6307-6916 AD - School of Data Science, Yokohama City University School of Medicine, 236-0027, 22-2, Seto, Kanazawa-ku, Kanagawa, Japan. FAU - Ohno, Sayaka AU - Ohno S AD - School of Data Science, Yokohama City University School of Medicine, 236-0027, 22-2, Seto, Kanazawa-ku, Kanagawa, Japan. FAU - Onishi, Hiroshi AU - Onishi H AUID- ORCID: 0000-0002-3512-1166 AD - Department of Radiology, University of Yamanashi, 409-3898, 1110, Shimokato, Chuo, Yamanashi, Japan. LA - eng GR - Japanese Society for Radiation Oncology/ PT - Journal Article PT - Multicenter Study PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Retrospective Studies MH - Female MH - Aged MH - Japan MH - *Chemoradiotherapy/methods MH - Male MH - Middle Aged MH - Treatment Outcome MH - Aged, 80 and over MH - Prognosis MH - Transurethral Resection of Bladder MH - Cystectomy PMC - PMC13440125 OTO - NOTNLM OT - Chemoradiotherapy OT - organ preservation OT - urinary bladder neoplasms COIS- None declared. EDAT- 2026/06/05 18:35 MHDA- 2026/08/05 17:37 PMCR- 2026/06/05 CRDT- 2026/06/05 15:02 PHST- 2025/12/30 00:00 [received] PHST- 2026/03/26 00:00 [revised] PHST- 2026/03/30 00:00 [accepted] PHST- 2026/08/05 17:37 [medline] PHST- 2026/06/05 18:35 [pubmed] PHST- 2026/06/05 15:02 [entrez] PHST- 2026/06/05 00:00 [pmc-release] AID - 8703154 [pii] AID - hyag063 [pii] AID - 10.1093/jjco/hyag063 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2026 Aug 5;56(8):984-992. doi: 10.1093/jjco/hyag063. PMID- 42244999 OWN - NLM STAT- MEDLINE DCOM- 20260610 LR - 20260813 IS - 1838-7640 (Electronic) IS - 1838-7640 (Linking) VI - 16 IP - 12 DP - 2026 TI - Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment. PG - 6892-6910 LID - 10.7150/thno.129729 [doi] AB - RATIONALE: High-grade T1 (HGT1) Non-Muscle Invasive Bladder Cancer (NMIBC) is a clinically heterogeneous disease characterized by unpredictable treatment responses and limited tools for recurrence prediction. Despite advances in molecular classification, patient stratification still relies mainly on clinicopathological features, providing limited precision. METHODS: In this study, we integrated bulk chromatin profiling with single-nuclei RNA-seq, immunohistochemistry, and spatial transcriptomics to define epigenetic subtypes of HGT1, characterize their heterogeneity, and explore tumor-microenvironment interactions. RESULTS: We identified distinct chromatin landscapes distinguishing urothelial (URO) and micropapillary (MP) histological variants of high-risk HGT1. Three main epigenetic states emerged: luminal-like inflammatory (LLI) and basal-like (BL) subtypes within URO tumors, and a separate signature unique to MP tumors. Single-cell and spatial analyses confirmed intratumoral heterogeneity and revealed subtype-specific microenvironmental contexts.Approximately 40% of URO tumors exhibited spatially distinct coexisting LLI and BL components. BL regions, enriched for angiogenesis and hypoxia pathways, were preferentially located near vascular stroma, whereas LLI regions were situated at the tumor core. MP tumors displayed a markedly different microenvironment with abundant cancer-associated fibroblasts (CAFs) and M2-polarized macrophages intermingled with tumor cells, suggesting an immunosuppressive niche that may underlie their poor prognosis. In contrast, URO tumors showed a more immune-excluded phenotype. CONCLUSION: These findings provide a detailed molecular and spatial map of HGT1 heterogeneity, linking epigenetic states to tumor architecture and microenvironmental interactions. They underscore the need for subtype-specific therapeutic strategies to effectively address the biological diversity already present in HGT1 bladder cancer. CI - (c) The author(s). FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Xie, Yingtian AU - Xie Y AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Juanpere, Nuria AU - Juanpere N AD - Department of Pathology, Hospital del Mar, Barcelona, Spain. FAU - Munoz, Miguel Gomez AU - Munoz MG AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Kukreja, Shweta AU - Kukreja S AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Veiga, Sonsoles Liria AU - Veiga SL AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Li, Rong AU - Li R AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Qiu, Xintao AU - Qiu X AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Jiang, Yijia AU - Jiang Y AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Font-Tello, Alba AU - Font-Tello A AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Duarte, Marie Nunez AU - Duarte MN AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Epstein, Ilana AU - Epstein I AD - Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Hernandez-Llodra, Silvia AU - Hernandez-Llodra S AD - Department of Pathology, Hospital del Mar, Barcelona, Spain. AD - Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Lorenzo, Marta AU - Lorenzo M AD - Department of Pathology, Hospital del Mar, Barcelona, Spain. FAU - Menendez, Silvia AU - Menendez S AD - Department of Pathology, Hospital del Mar, Barcelona, Spain. FAU - Choueiri, Toni AU - Choueiri T AD - Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Brown, Myles AU - Brown M AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Long, Henry W AU - Long HW AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. FAU - Cejas, Paloma AU - Cejas P AD - Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. AD - Translational Oncology Laboratory, Hospital La Paz Institute for Health Research, (IdiPAZ), Madrid, Spain. LA - eng PT - Journal Article DEP - 20260518 PL - Australia TA - Theranostics JT - Theranostics JID - 101552395 SB - IM MH - Female MH - Humans MH - Male MH - *Epigenesis, Genetic/genetics MH - Gene Expression Regulation, Neoplastic MH - *Non-Muscle Invasive Bladder Neoplasms/genetics MH - *Tumor Microenvironment/genetics PMC - PMC13232474 COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2026/06/05 06:36 MHDA- 2026/06/11 05:42 PMCR- 2026/05/18 CRDT- 2026/06/05 04:59 PHST- 2025/12/10 00:00 [received] PHST- 2026/04/15 00:00 [accepted] PHST- 2026/06/11 05:42 [medline] PHST- 2026/06/05 06:36 [pubmed] PHST- 2026/06/05 04:59 [entrez] PHST- 2026/05/18 00:00 [pmc-release] AID - thnov16p6892 [pii] AID - 10.7150/thno.129729 [doi] PST - epublish SO - Theranostics. 2026 May 18;16(12):6892-6910. doi: 10.7150/thno.129729. eCollection 2026. PMID- 42240105 OWN - NLM STAT- MEDLINE DCOM- 20260608 LR - 20260609 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 33 IP - 6 DP - 2026 Jun TI - Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study. PG - e70526 LID - 10.1111/iju.70526 [doi] AB - OBJECTIVES: Non-muscle-invasive bladder cancer (NMIBC) commonly recurs despite intravesical Bacillus Calmette-Guerin (BCG) therapy. Host factors that modify the effectiveness of BCG have not been completely defined. We evaluated whether sarcopenia is associated with outcomes after BCG in Japanese patients. METHODS: We conducted a retrospective single-center cohort study (2010-2023) including high-grade (HG) NMIBC patients treated with BCG (n = 139) and those not receiving BCG (n = 100). Sarcopenia was defined a priori using sex- and BMI-specific skeletal muscle index (SMI) and psoas muscle index (PMI) cutoffs derived from baseline L3 computed tomography and validated in Asian adults. The endpoints were intravesical recurrence-free survival (IVRFS), high-grade recurrence-free survival (HGRFS), progression-free survival (PFS), and overall survival (OS). Feature selection used LASSO-Cox with cross-validation; performance was assessed using time-dependent ROC. Within the BCG cohort, we conducted a 1:1 propensity score matching. RESULTS: In the BCG cohort, 93/139 (66.9%) and 69/139 (49.6%) patients were classified as sarcopenic according to SMI and PMI, respectively. One- and two-year apparent AUCs for intravesical recurrence were 0.75 and 0.79 (validation AUCs 0.68 and 0.71). Kaplan-Meier analyses revealed no differences in outcomes by sarcopenia in the non-BCG cohort but worse outcomes across endpoints in the BCG cohort. After matching, SMI-based sarcopenia was associated with shorter IVRFS, whereas PMI-based sarcopenia was associated with shorter IVRFS, HGRFS, PFS, and OS. CONCLUSIONS: Patients with sarcopenia were less likely to benefit from BCG. The incorporation of computed tomography-based muscle indices into pre-BCG decision-making may improve risk stratification and supportive care. CI - (c) 2026 The Japanese Urological Association. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iwao, Tomoharu AU - Iwao T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Oda, Yuki AU - Oda Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Tane General Hospital, Osaka, Japan. FAU - Tomizawa, Mitsuru AU - Tomizawa M AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Onishi, Kenta AU - Onishi K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AUID- ORCID: 0000-0001-7142-5901 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AUID- ORCID: 0000-0002-6056-3820 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AUID- ORCID: 0000-0002-7579-0372 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AUID- ORCID: 0000-0001-9242-7877 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. LA - eng PT - Journal Article PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Japan MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - *Non-Muscle Invasive Bladder Neoplasms/complications/drug therapy/pathology MH - Retrospective Studies MH - *Sarcopenia/complications MH - Tomography, X-Ray Computed MH - Treatment Outcome OTO - NOTNLM OT - bacillus Calmette-Guerin OT - bladder cancer OT - psoas muscle index OT - sarcopenia OT - skeletal muscle index EDAT- 2026/06/04 12:42 MHDA- 2026/06/08 06:35 CRDT- 2026/06/04 07:03 PHST- 2026/04/24 00:00 [revised] PHST- 2026/01/29 00:00 [received] PHST- 2026/05/20 00:00 [accepted] PHST- 2026/06/08 06:35 [medline] PHST- 2026/06/04 12:42 [pubmed] PHST- 2026/06/04 07:03 [entrez] AID - 10.1111/iju.70526 [doi] PST - ppublish SO - Int J Urol. 2026 Jun;33(6):e70526. doi: 10.1111/iju.70526. PMID- 42239882 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260604 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Single versus maintenance intravesical instillation of chemotherapy for intravesical recurrence after radical nephroureterectomy in distal ureteral upper tract urothelial carcinoma: a multicenter retrospective study from China. PG - 1784342 LID - 10.3389/fonc.2026.1784342 [doi] LID - 1784342 AB - INTRODUCTION: Intravesical recurrence (IVR) is a common event after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Distal ureteral tumors are of particular clinical interest because they are associated with a relatively high risk of IVR. To reduce heterogeneity related to tumor location and pathological stage, this study focused specifically on patients with pathologically confirmed pT2 distal ureteral tumors. However, whether maintenance intravesical chemotherapy (MIC) provides additional benefit over single intravesical chemotherapy (SIC) in this subgroup remains uncertain. METHODS: We retrospectively analyzed patients with pathologically confirmed pT2 distal ureteral UTUC who underwent RNU at multiple centers between 2018 and 2023. Patients were classified into the SIC and MIC groups according to their postoperative intravesical instillation strategy. Intravesical recurrence-free survival (IVRFS) was the primary endpoint. Inverse probability of treatment weighting (IPTW), Kaplan-Meier analysis, and Cox regression were used to evaluate the association between instillation strategy and IVR. RESULTS: Among 532 patients (183 SIC, 349 MIC), IPTW achieved good baseline balance. MIC was associated with longer IVRFS than SIC on IPTW-weighted Kaplan-Meier analysis. In IPTW-weighted Cox model, MIC was associated with a lower risk of IVR (HR 0.71, 95% CI 0.501-0.989, P = 0.043). Tumor size, multifocality, preoperative ureteroscopy, and lymphovascular invasion were independent predictors of IVR. CONCLUSIONS: In this multicenter retrospective study of patients with pT2 distal ureteral UTUC, MIC was associated with a lower risk of IVR compared with SIC. However, because of the retrospective and non-randomized study design, potential residual confounding, and heterogeneity in maintenance regimens across centers, these findings should be interpreted as hypothesis-generating rather than definitive evidence of treatment superiority. Further prospective randomized studies are warranted to validate these results. CI - Copyright (c) 2026 Dai, Shi, Liu, Ma, Zhu, Fan, Yang and Pei. FAU - Dai, Shengnian AU - Dai S AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. AD - The First Clinical Medical College of Xi'an Jiaotong University Health Science Center, Xi'an, China. FAU - Shi, Xinyu AU - Shi X AD - The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Liu, Jianzhou AU - Liu J AD - Baoji Central Hospital, Baoji, China. FAU - Ma, Zhenkun AU - Ma Z AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhu, Guodong AU - Zhu G AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Fan, Junjie AU - Fan J AD - Baoji Central Hospital, Baoji, China. FAU - Yang, Tao AU - Yang T AD - General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Pei, Xinqi AU - Pei X AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Journal Article DEP - 20260519 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13226104 OTO - NOTNLM OT - bladder instillation OT - intravesical recurrence OT - inverse probability of treatment weighting OT - radical nephroureterectomy OT - upper urinary tract carcinoma COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/04 06:34 MHDA- 2026/06/04 06:35 PMCR- 2026/05/19 CRDT- 2026/06/04 05:44 PHST- 2026/01/09 00:00 [received] PHST- 2026/04/30 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/06/04 06:35 [medline] PHST- 2026/06/04 06:34 [pubmed] PHST- 2026/06/04 05:44 [entrez] PHST- 2026/05/19 00:00 [pmc-release] AID - 10.3389/fonc.2026.1784342 [doi] PST - epublish SO - Front Oncol. 2026 May 19;16:1784342. doi: 10.3389/fonc.2026.1784342. eCollection 2026. PMID- 42237315 OWN - NLM STAT- MEDLINE DCOM- 20260808 LR - 20260813 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 24 IP - 1 DP - 2026 Jun 4 TI - Bridging the evidence gap: three-year BCG maintenance therapy shows enhanced protection over one-year regimen in Chinese NMIBC. LID - 10.1186/s12957-026-04412-5 [doi] LID - 326 AB - BACKGROUND AND OBJECTIVE: The current recommendation of BCG therapy in China is a 1-year regimen, based on local strain variations and the absence of evidence for a 3-year instillation protocol. Our aim was to compare the protective efficacy of the 3-year BCG regimen versus a 1-year regimen in Chinese NMIBC patients. METHODS: We collected 140 patients followed by BCG monotherapy at our center from 2017 to 2024. All patients had >/= 1 year of follow-up. Participants were allocated based on clinical practice into a standard three-year instillation group (n = 72) and a modified one-year group (n = 68). Kaplan-Meier survival analysis evaluated the impact of both regimens, while Cox regression identified factors for recurrence. Subgroup analyses and interaction tests were performed for all categorical variables. The prognostic role of instillation regimens across different risk stratifications was assessed via interaction and subgroup analyses. KEY FINDINGS AND LIMITATIONS: Kaplan-Meier analysis demonstrated superior RFS in the three-year group (HR 0.31; 95% CI 0.14-0.67). Multivariate Cox regression confirmed the three-year regimen as an independent protective factor against recurrence (p = 0.006, HR 0.282; 95% CI 0.114-0.697). The protective effect remained significant in high-risk subgroups. Adverse events were numerically fewer in the three-year group, though this comparison should be interpreted cautiously. This study is limited by its retrospective design, the marked imbalance in treatment completion between groups (25% vs. 51.5%), and the small number of recurrence events (n = 27), all of which preclude causal interpretation and require cautious reading of the hazard ratio estimates. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings suggest that the standard 3-year regimen may offer superior recurrence risk reduction compared to the 1-year regimen in Chinese high-risk NMIBC patients. Given the retrospective design and limited sample size, these results should be considered hypothesis-generating and warrant confirmation in prospective studies. A 3-year BCG regimen may offer better protection than a 1-year regimen for Chinese high-risk NMIBC patients. CI - (c) 2026. The Author(s). FAU - Du, Xiang AU - Du X AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. FAU - Deng, Zhenggen AU - Deng Z AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. FAU - Shi, Yonghao AU - Shi Y AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. FAU - Ding, Jiayang AU - Ding J AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. FAU - Guo, Hongqian AU - Guo H AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. dr.ghq@nju.edu.cn. FAU - Yang, Rong AU - Yang R AD - Department of Urology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. yangr@nju.edu.cn. LA - eng PT - Journal Article DEP - 20260604 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - Chinese people SB - IM MH - Humans MH - Female MH - *BCG Vaccine/administration & dosage/therapeutic use MH - China/epidemiology MH - Male MH - Prognosis MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology/pathology MH - Middle Aged MH - Retrospective Studies MH - Aged MH - Follow-Up Studies MH - *Maintenance Chemotherapy/methods MH - Survival Rate MH - *Adjuvants, Immunologic/administration & dosage MH - Time Factors MH - Kaplan-Meier Estimate MH - East Asian People PMC - PMC13449506 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Instillation regimen OT - Intravesical therapy OT - Non-muscle invasive bladder cancer COIS- Declarations. Ethics approval and consent to participate: The protocol for this research project was approved by the institutional review board of Nanjing Drum Tower Hospital. Owing to the retrospective nature of the study, informed consent was waived. Competing interests: The authors declare no competing interests. EDAT- 2026/06/04 06:33 MHDA- 2026/08/08 09:15 PMCR- 2026/06/04 CRDT- 2026/06/04 00:39 PHST- 2025/10/23 00:00 [received] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/08/08 09:15 [medline] PHST- 2026/06/04 06:33 [pubmed] PHST- 2026/06/04 00:39 [entrez] PHST- 2026/06/04 00:00 [pmc-release] AID - 10.1186/s12957-026-04412-5 [pii] AID - 4412 [pii] AID - 10.1186/s12957-026-04412-5 [doi] PST - epublish SO - World J Surg Oncol. 2026 Jun 4;24(1):326. doi: 10.1186/s12957-026-04412-5. PMID- 42236415 OWN - NLM STAT- Publisher LR - 20260603 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 Jun 3 TI - Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. LID - S2588-9311(26)00131-8 [pii] LID - 10.1016/j.euo.2026.05.004 [doi] AB - BACKGROUND AND OBJECTIVE: Smoking is the strongest modifiable risk factor for the development of bladder cancer. The benefits of smoking abstinence following a bladder cancer diagnosis are uncertain. Our objective was to determine the association of smoking abstinence with survival following the diagnosis of bladder cancer compared with continued smoking. METHODS: A subset of 169 patients from the Tobacco Research and Treatment Program (TRTP) was identified following a diagnosis of urothelial bladder cancer between 2006 and 2022. Individualized tobacco treatment strategies were employed, and self-reported abstinence information was collected at 3, 6, and 9 mo following consultation. The primary outcome was overall survival (OS), analyzed according to smoking abstinence status. Secondary outcomes included cancer-specific survival (CSS), recurrence-free survival (RFS), and metastasis-free survival (MFS). KEY FINDINGS AND LIMITATIONS: Smoking abstinence rates were 43%, 44%, and 38% at the 3-, 6-, and 9-mo assessments, respectively. After a median follow-up of 5.7 yr, abstinence at 3, 6, and 9 mo was independently associated with superior OS (adjusted hazard ratios were 0.56, 0.45, and 0.51, respectively). CSS and RFS were likewise significantly improved whenever abstinence was achieved at any follow-up point. Limitations include the predominantly White, male cohort, which may limit generalizability to more diverse populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Smoking abstinence following the diagnosis of bladder cancer was associated with improved survival in our prospective cohort. Smoking cessation should be strongly encouraged in all patients with bladder cancer. IRB protocol number: DR07-0884 (Institutional Review Board at The University of Texas MD Anderson Cancer Center). CI - Copyright (c) 2026. Published by Elsevier B.V. FAU - MacDonald, Landan P AU - MacDonald LP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kypriotakis, George AU - Kypriotakis G AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Karam-Hage, Maher AU - Karam-Hage M AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Minnix, Jennifer A AU - Minnix JA AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Beneventi, Diane AU - Beneventi D AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Cui, Yong AU - Cui Y AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Blalock, Janice A AU - Blalock JA AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Robinson, Jason D AU - Robinson JD AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Alhalabi, Omar AU - Alhalabi O AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hassanazadeh, Comron J AU - Hassanazadeh CJ AD - Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lee, Byron H AU - Lee BH AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Cinciripini, Paul M AU - Cinciripini PM AD - Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: kbree@mdanderson.org. LA - eng PT - Journal Article DEP - 20260603 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer OT - Smoking abstinence OT - Smoking cessation EDAT- 2026/06/04 00:41 MHDA- 2026/06/04 00:41 CRDT- 2026/06/03 22:57 PHST- 2025/11/11 00:00 [received] PHST- 2026/04/28 00:00 [revised] PHST- 2026/05/06 00:00 [accepted] PHST- 2026/06/04 00:41 [medline] PHST- 2026/06/04 00:41 [pubmed] PHST- 2026/06/03 22:57 [entrez] AID - S2588-9311(26)00131-8 [pii] AID - 10.1016/j.euo.2026.05.004 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 Jun 3:S2588-9311(26)00131-8. doi: 10.1016/j.euo.2026.05.004. PMID- 42230748 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260908 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Jun 2 TI - A machine-learning approach to predict additional treatment after Bacillus Calmette-Guerin induction in non-muscle-invasive bladder cancer. LID - 10.1038/s41598-026-55917-8 [doi] LID - 25051 AB - Non-muscle invasive bladder cancer (NMIBC) comprises ~ 75% of newly diagnosed bladder cancer, with high-risk NMIBC associated with high rates of recurrence and progression. Nearly 40% of patients experience a lack of efficacy with gold standard Bacillus Calmette-Guerin (BCG) therapy and current methods for predicting BCG response are limited. This multicentre real-world study developed and evaluated machine learning (ML) models using data (April 2008-March 2024) from the Japan Medical Data Vision database to predict whether patients with NMIBC who received BCG induction would require additional treatment (cystectomy). In total, 7962 patients were identified based on NMIBC diagnosis and BCG. After processing, 1524 patients with 56 features were used for ML model development. Each ML model employed distinct feature selection, classification algorithms, and class imbalance strategies. Final ML models used either a nine-feature set plus repeat transurethral resection of bladder tumour (TURBT) obtained using a data-driven approach, or a clinically-informed eight-feature set plus repeat TURBT chosen for clinical relevance. Subsequent model performance suggested that factors other than feature selection, such as data imbalance, were key limitations. These findings demonstrate the feasibility of assembling a real-world dataset and performing exploratory ML modelling, although clinically meaningful prediction remains limited. CI - (c) 2026. The Author(s). FAU - Pinton, Philippe AU - Pinton P AD - Ferring Pharmaceuticals A/S, Kastrup, Denmark. Philippe.pinton@shiroito.co.jp. AD - Shiroito Co. Ltd., Health and Life Sciences, Tokyo, Japan. Philippe.pinton@shiroito.co.jp. FAU - Kawano, Haruna AU - Kawano H AD - Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan. FAU - Patschan, Oliver AU - Patschan O AD - Ferring Pharmaceuticals A/S, Kastrup, Denmark. FAU - Ravi, Arjun AU - Ravi A AD - Ferring Pharmaceuticals A/S, Kastrup, Denmark. FAU - Nakano, Atsushi AU - Nakano A AD - Ferring Pharmaceuticals Co., Ltd., Tokyo, Japan. FAU - Auvaro, Philippe AU - Auvaro P AD - Medical Data Vision Co., Ltd., Tokyo, Japan. FAU - Mukherjee, Apurba AU - Mukherjee A AD - Ferring Pharmaceuticals Co., Ltd, Singapore, Singapore. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260602 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *BCG Vaccine/therapeutic use MH - *Machine Learning MH - Female MH - Male MH - Transurethral Resection of Bladder MH - Aged MH - Predictive Learning Models MH - *Urinary Bladder Neoplasms/drug therapy MH - Middle Aged MH - Treatment Outcome MH - Cystectomy MH - Classification Algorithms MH - Japan PMC - PMC13462318 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Clinical decision support OT - Machine learning OT - Non-muscle invasive bladder cancer (NMIBC) OT - Real-world data OT - Treatment response prediction COIS- Declarations. Competing interests: All authors except H.K. and P.A. are employees of Ferring Pharmaceuticals or were at the time of the study. P.P. is CEO and shareholder of Shiroito Co. Ltd, is a member of PharmaBiome Board of Directors and owns stocks in Takeda Pharmaceutical Co., Ltd. H. K. serves as a consultant for Ferring Pharmaceuticals and receives consulting fees. A.N. is a shareholder of GlaxoSmithKline. P.A. is an employee of Medical Data Vision Co., Ltd. EDAT- 2026/06/03 00:41 MHDA- 2026/08/12 06:05 PMCR- 2026/06/02 CRDT- 2026/06/02 23:38 PHST- 2026/02/18 00:00 [received] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/08/12 06:05 [medline] PHST- 2026/06/03 00:41 [pubmed] PHST- 2026/06/02 23:38 [entrez] PHST- 2026/06/02 00:00 [pmc-release] AID - 10.1038/s41598-026-55917-8 [pii] AID - 55917 [pii] AID - 10.1038/s41598-026-55917-8 [doi] PST - epublish SO - Sci Rep. 2026 Jun 2;16(1):25051. doi: 10.1038/s41598-026-55917-8. PMID- 42226062 OWN - NLM STAT- MEDLINE DCOM- 20260804 LR - 20260813 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 24 IP - 1 DP - 2026 Jun 1 TI - Robotic segmental ureterectomy for upper tract urothelial carcinoma: comparable short-term oncological outcomes and improved postoperative recovery compared to open approach. LID - 10.1186/s12957-026-04422-3 [doi] LID - 323 AB - BACKGROUND: Segmental ureterectomy (SU) is an established kidney-sparing strategy for upper tract urothelial carcinoma (UTUC), yet few studies have compared the standard open approach to the emerging robotic modality. METHODS: We performed a clinical outcome and safety evaluation of robotic-assisted SU compared to the traditional open approach. In this retrospective study of 53 patients (40 open, 13 robotic) treated between 2008 and 2025, we assessed perioperative, functional, and oncological parameters. RESULTS: Regarding safety endpoints, robotic SU demonstrated a favorable profile with no significant difference in postoperative complication rates compared to open surgery (15.4% vs. 26.5%, p = 0.7). While the robotic approach involved longer operative times (351 vs. 285 min, p = 0.01), it resulted in a significantly shorter median hospital stay (4 vs. 12 days, p < 0.001). Utilizing Firth's penalized Cox regression to account for sparse events, no significant differences were observed in overall survival (HR 1.25, 95% CI 0.13-6.17, p = 0.815) or disease-free survival (HR 1.22, 95% CI 0.31-3.63, p = 0.75). Similarly, secondary endpoints including intraluminal recurrence-free (p = 0.188), intravesical recurrence-free (p = 0.581), and metastasis-free survival (p = 0.997) did not differ significantly. Postoperatively, functional evaluation revealed a trend toward improved renal function in the robotic cohort (+ 22.94 vs. +7.46 mL/min/1.73 m(2), p = 0.08). CONCLUSIONS: Robotic SU appears feasible and was not associated with an apparent compromise in short-term oncological outcomes during the available follow-up period, while offering the benefits of minimally invasive recovery. Given the limited follow-up and small sample size of the robotic cohort, these results provide preliminary evidence of safety. Further multi-institutional, large-scale studies with extended follow-up are required to establish definitive long-term non-inferiority. CI - (c) 2026. The Author(s). FAU - Lasmanovich, Rinat AU - Lasmanovich R AUID- ORCID: 0000-0002-7605-4684 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. Rinat.Lasmanovich@sheba.health.gov.il. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. Rinat.Lasmanovich@sheba.health.gov.il. FAU - Chepeliuk, Oleksandr AU - Chepeliuk O AUID- ORCID: 0009-0006-1651-2344 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Fihman, May AU - Fihman M AUID- ORCID: 0009-0004-0286-6067 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Shvero, Asaf AU - Shvero A AUID- ORCID: 0000-0002-3688-5133 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Kleinmann, Nir AU - Kleinmann N AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Fridman, Eddie AU - Fridman E AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Pathology, Sheba Medical Center, Ramat Gan, Israel. FAU - Portnoy, Orith AU - Portnoy O AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Diagnostic Radiology, Sheba Medical Center, Ramat Gan, Israel. FAU - Laufer, Menahem AU - Laufer M AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Zilberman, Dorit E AU - Zilberman DE AUID- ORCID: 0000-0002-2092-4732 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Rosenzweig, Barak AU - Rosenzweig B AUID- ORCID: 0000-0002-3824-5148 AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. FAU - Dotan, Zohar A AU - Dotan ZA AD - Gray Faculty of Medical and health sciences, Tel Aviv University, Tel Aviv, Israel. AD - Department of Urology, Sheba Medical Center, Sheba Road 1st, Ramat Gan, Israel. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260601 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - Male MH - *Robotic Surgical Procedures/methods MH - Follow-Up Studies MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Survival Rate MH - Aged MH - *Ureteral Neoplasms/surgery/pathology MH - *Postoperative Complications MH - Middle Aged MH - Length of Stay/statistics & numerical data MH - Neoplasm Staging MH - *Kidney Neoplasms/surgery/pathology MH - *Ureter/surgery PMC - PMC13435790 COIS- Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the institutional review board of Sheba Medical Center (SMC-4146; last update 4 June 2025). Consent was waived per local regulations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/06/02 06:35 MHDA- 2026/08/04 06:37 PMCR- 2026/06/01 CRDT- 2026/06/02 00:03 PHST- 2026/02/28 00:00 [received] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/08/04 06:37 [medline] PHST- 2026/06/02 06:35 [pubmed] PHST- 2026/06/02 00:03 [entrez] PHST- 2026/06/01 00:00 [pmc-release] AID - 10.1186/s12957-026-04422-3 [pii] AID - 4422 [pii] AID - 10.1186/s12957-026-04422-3 [doi] PST - epublish SO - World J Surg Oncol. 2026 Jun 1;24(1):323. doi: 10.1186/s12957-026-04422-3. PMID- 42220482 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data. PG - 1797389 LID - 10.3389/fimmu.2026.1797389 [doi] LID - 1797389 AB - BACKGROUND: Bladder cancer (BLCA) exhibits a poor prognosis, highlighting the urgent need for reliable prognostic genes. Although succinylation is linked to tumor progression, its role in BLCA remains understudied. This study aimed to identify and validate prognostic succinylation-related genes (SRGs) in BLCA and elucidate their impact on the tumor microenvironment (TME). METHODS: SRGs were initially identified through transcriptomic sequencing of 15 paired BLCA and adjacent normal tissues (Soochow-BLCA cohort) and further refined by integrating single-cell and bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. A prognostic risk model was developed using LASSO and multivariable Cox regression, incorporating clinical factors for nomogram construction. Mechanistic insights were obtained through functional enrichment, immune profiling, somatic mutation, and drug sensitivity analyses. The Scissor algorithm mapped bulk transcriptome risk signatures to single-cell resolution, enabling identification of high-risk cell subpopulations. Pseudotime and cell-cell communication analyses characterized dynamic expression patterns of the core genes. Finally, the expression profiles and functional roles of the core genes were validated using RT-qPCR and CCK-8 proliferation assays in vitro. RESULTS: KCTD16, CD3D and GSDMB were identified as prognostic genes. The risk score derived from these genes, in combination with age and N stage, was incorporated into a risk model that exhibited robust predictive accuracy (AUC > 0.7). Expression of these genes differed significantly between non-muscle-invasive and muscle-invasive subtypes. The high-risk group displayed enhanced immune evasion (higher TIDE score, p < 0.001), while the TME appeared to be in an "inflamed yet dysfunctional" state. Single-cell analysis indicated epithelial cells as key subpopulations, with additional involvement of T cells and fibroblasts. Scissor(+) cells were correlated with the high-risk phenotype and exhibited pseudotime-dependent expression patterns. RT-qPCR revealed significant upregulation of GSDMB and downregulation of KCTD16 and CD3D in BLCA (p < 0.05). Functionally, knockdown of GSDMB and KCTD16 significantly promoted T24 cell proliferation, supporting their tumor-suppressive roles. CONCLUSIONS: The succinylation-related prognostic model accurately predicts outcomes in BLCA, reveals links to immune escape and TME, and highlights the pivotal role of epithelial cells, offering potential targets for individualized therapy. CI - Copyright (c) 2026 Yang, You, Mo, Pu, Shen and Miao. FAU - Yang, Jiajian AU - Yang J AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. FAU - You, Zhengyao AU - You Z AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. FAU - Mo, Haojie AU - Mo H AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. FAU - Pu, Jinxian AU - Pu J AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. FAU - Shen, Gang AU - Shen G AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. FAU - Miao, Zhijun AU - Miao Z AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. LA - eng PT - Journal Article DEP - 20260515 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/metabolism/pathology/mortality MH - Tumor Microenvironment/genetics/immunology MH - Gene Expression Regulation, Neoplastic MH - *Transcriptome MH - Prognosis MH - *Biomarkers, Tumor/genetics MH - Gene Expression Profiling MH - Single-Cell Analysis MH - Single-Cell Gene Expression Analysis MH - Nomograms PMC - PMC13218921 OTO - NOTNLM OT - bladder cancer OT - prognostic model OT - single-cell analysis OT - succinylation OT - transcriptomic OT - tumor microenvironment COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/01 08:04 MHDA- 2026/06/01 14:26 PMCR- 2026/05/15 CRDT- 2026/06/01 05:56 PHST- 2026/01/27 00:00 [received] PHST- 2026/04/23 00:00 [revised] PHST- 2026/04/24 00:00 [accepted] PHST- 2026/06/01 14:26 [medline] PHST- 2026/06/01 08:04 [pubmed] PHST- 2026/06/01 05:56 [entrez] PHST- 2026/05/15 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1797389 [doi] PST - epublish SO - Front Immunol. 2026 May 15;17:1797389. doi: 10.3389/fimmu.2026.1797389. eCollection 2026. PMID- 42218654 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260818 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 44 IP - 21 DP - 2026 Jul 20 TI - Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. PG - 2017-2028 LID - 10.1200/JCO-26-00142 [doi] AB - PURPOSE: To evaluate neoadjuvant sacituzumab govitecan (SG), followed by radical cystectomy (RC), in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for/refuse neoadjuvant chemotherapy (NAC). We report the results of the primary analysis and biomarker analyses of the phase II SURE-01 trial (ClinicalTrials.gov identifier: NCT05226117). PATIENTS AND METHODS: Patients were age 18 years and older, had Eastern Cooperative Oncology Group performance status 0-1, had histologically confirmed cT2-T4aN0M0 MIBC, were ineligible/refusing NAC, and were scheduled for RC received four cycles of SG 10 mg/kg on day 1 and day 8, once every 3 weeks, followed by RC. The primary outcome measure was the pathologic complete response (pT0N0) rate. Transcriptome-wide analyses and comprehensive genomic profiling assays were performed on baseline tumor samples. RESULTS: From March 2022 to July 2025, 44 patients were treated and efficacy evaluable. After the initial eight patients enrolled, the protocol was amended with a SG dose of 7.5 mg/kg, with primary prophylaxis for neutropenia, due to the occurrence of two deaths (one treatment-related). Subsequent grade 3-4 treatment-related adverse-events occurred in 5 patients (13.9%). Twenty-six patients (59.1%) had a cT3-4 stage and 20 (45.5%) had a variant histology. Fourteen patients (31.8%) refused to undergo RC, accounting for 12 repeating a transurethral resection of the bladder tumor and two undergoing active surveillance. The median follow-up was 22 months (IQR, 15-26). In the intention-to-treat population, although the protocol-defined ypT0N0 rate was 9.1% (95% CI, 2.5 to 21.7), the overall ypT0N0-x rate was 29.5% (95% CI, 16.7 to 45.2), with an enrichment of ypT0 responses in nonluminal subtypes (46% v 14% of luminal). The 24-month event-free survival (EFS) rate was 71.4% (95% CI, 58 to 87.8), with longer EFS for participants with lower TOP1-expressing tumors. CONCLUSION: Neoadjuvant SG, at the reduced dose of 7.5 mg/kg, was active with a manageable safety profile, corroborating TROP2 as a suitable target for MIBC. FAU - Necchi, Andrea AU - Necchi A AUID- ORCID: 0000-0002-3007-2756 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Maiorano, Brigida A AU - Maiorano BA AUID- ORCID: 0000-0001-5423-3158 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Proudfoot, James A AU - Proudfoot JA AD - Veracyte Inc, San Francisco, CA. FAU - Basile, Giuseppe AU - Basile G AUID- ORCID: 0000-0002-7227-7821 AD - Department of Urology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Cigliola, Antonio AU - Cigliola A AUID- ORCID: 0009-0005-7109-2429 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Mercinelli, Chiara AU - Mercinelli C AUID- ORCID: 0000-0003-1165-1776 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Tateo, Valentina AU - Tateo V AUID- ORCID: 0000-0002-1199-2338 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Piacentini, Michela AU - Piacentini M AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Crupi, Emanuele AU - Crupi E AUID- ORCID: 0000-0002-3379-2644 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Pastorino, Giovanni L AU - Pastorino GL AUID- ORCID: 0009-0005-7359-3112 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Latini, Gaia AU - Latini G AUID- ORCID: 0009-0007-7884-9150 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Tomasi, Enrico AU - Tomasi E AD - Pharmacy Unit, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Davicioni, Elai AU - Davicioni E AD - Veracyte Inc, San Francisco, CA. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Brembilla, Giorgio AU - Brembilla G AUID- ORCID: 0000-0002-9690-8624 AD - Department of Radiology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AUID- ORCID: 0000-0003-1914-0743 AD - Department of Pathology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - de Cobelli, Francesco AU - de Cobelli F AUID- ORCID: 0000-0003-4014-3711 AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Radiology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Ross, Jeffrey S AU - Ross JS AUID- ORCID: 0000-0001-8494-2596 AD - Departments of Pathology, Medicine (Oncology), and Urology, Upstate Medical University, Syracuse, NY. AD - Foundation Medicine, Inc, Boston, MA. FAU - Madison, Russell AU - Madison R AUID- ORCID: 0000-0002-7838-2526 AD - Foundation Medicine, Inc, Boston, MA. FAU - Tambaoan, Candice Francheska B AU - Tambaoan CFB AUID- ORCID: 0000-0001-7736-1902 AD - Foundation Medicine, Inc, Boston, MA. FAU - Briganti, Alberto AU - Briganti A AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Urology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Urology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy. LA - eng SI - ClinicalTrials.gov/NCT05226117 PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study DEP - 20260531 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics/surgery MH - Female MH - Neoadjuvant Therapy MH - Male MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Pathologic Complete Response MH - Cystectomy EDAT- 2026/05/31 13:50 MHDA- 2026/07/15 12:37 CRDT- 2026/05/31 08:02 PHST- 2026/07/15 12:37 [medline] PHST- 2026/05/31 13:50 [pubmed] PHST- 2026/05/31 08:02 [entrez] AID - 10.1200/JCO-26-00142 [doi] PST - ppublish SO - J Clin Oncol. 2026 Jul 20;44(21):2017-2028. doi: 10.1200/JCO-26-00142. Epub 2026 May 31. PMID- 42216552 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 2768-6698 (Electronic) IS - 2768-6698 (Linking) VI - 31 IP - 5 DP - 2026 Apr 30 TI - Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer. PG - 47606 LID - 10.31083/FBL47606 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) accounts for roughly 75% of all bladder cancer cases. For patients with intermediate- and high-risk disease, intravesical Bacillus Calmette-Guerin (BCG) remains the standard treatment, yet it fails in up to 40% of cases. While radical cystectomy is the most effective salvage option, it carries significant morbidity and long-term quality-of-life consequences, highlighting the urgent need for bladder-sparing alternatives. Advancing such therapies requires a deep understanding of the immunologic mechanisms within the tumor microenvironment (TME). This review offers a concise overview of the immunologic mechanisms underlying BCG therapy, along with a detailed examination of the multifactorial immune evasion mechanisms that contribute to its failure in NMIBC. Within the TME, ten principal mechanisms of immune suppression have been identified. These include the activity of myeloid-derived suppressor cells, tumor-associated macrophages, regulatory T cells, and tolerogenic dendritic cells, as well as signaling pathways such as programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1), the natural killer group 2A/human leukocyte antigen-E (NKG2A/HLA-E) checkpoint, and the release of immunomodulatory molecules within the TME. Further contributors to immune evasion include cluster of differentiation 6/activated leukocyte cell adhesion molecule (CD6-ALCAM) signaling, effector T cell exhaustion, and cancer-associated fibroblasts. Collectively, these mechanisms disrupt antigen presentation, suppress cytotoxic immune responses, and facilitate tumor progression, ultimately undermining the efficacy of BCG therapy. In parallel, we highlight emerging intravesical immunotherapies for BCG-unresponsive NMIBC with carcinoma in situ, including nadofaragene firadenovec (Adstiladrin), nogapendekin alfa inbakicept-pmln (Anktiva), cretostimogene grenadenorepvec (CG0070), and detalimogene voraplasmid (EG-70). These agents employ diverse platforms, including gene therapy, cytokine stimulation, oncolytic virotherapy, and plasmid-based immune activation, to enhance antitumor responses. While early and late-phase clinical trials have shown promising response rates and favorable safety profiles for these novel agents, direct comparisons remain limited due to the reliance on single-arm study designs. The lack of comparative data, coupled with the absence of predictive biomarkers of response, complicates treatment selection. Our review underscores that developing effective therapies for BCG-unresponsive disease will require combination strategies targeting multiple immune escape mechanisms that shape immune dynamics within the TME. CI - (c) 2026 The Author(s). Published by IMR Press. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Health Care, Iowa City, IA 52242, USA. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Henri Mondor University Hospitals, Assistance Publique-Hopitaux de Paris, 94000 Creteil, France. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA 52242, USA. LA - eng PT - Journal Article PT - Review PL - Singapore TA - Front Biosci (Landmark Ed) JT - Frontiers in bioscience (Landmark edition) JID - 101612996 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/immunology/drug therapy/therapy MH - Tumor Microenvironment/immunology/drug effects MH - *BCG Vaccine/therapeutic use MH - Tumor Escape MH - *Urinary Bladder Neoplasms/immunology/pathology MH - Immunotherapy MH - Animals OTO - NOTNLM OT - BCG unresponsive disease OT - Bacillus Calmette-Guerin OT - immune evasion OT - immunotherapy OT - non muscle invasive bladder cancer OT - tumor microenvironment OT - urinary bladder neoplasms EDAT- 2026/05/30 06:36 MHDA- 2026/05/30 06:37 CRDT- 2026/05/30 03:23 PHST- 2025/10/23 00:00 [received] PHST- 2026/01/13 00:00 [revised] PHST- 2026/01/21 00:00 [accepted] PHST- 2026/05/30 06:37 [medline] PHST- 2026/05/30 06:36 [pubmed] PHST- 2026/05/30 03:23 [entrez] AID - S2768-6701(26)01997-0 [pii] AID - 10.31083/FBL47606 [doi] PST - ppublish SO - Front Biosci (Landmark Ed). 2026 Apr 30;31(5):47606. doi: 10.31083/FBL47606. PMID- 42216175 OWN - NLM STAT- MEDLINE DCOM- 20260730 LR - 20260824 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 24 IP - 1 DP - 2026 May 29 TI - Distal ureterectomy versus radical nephroureterectomy for nonmetastatic distal ureteral urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis of comparative studies. LID - 10.1186/s12957-026-04438-9 [doi] LID - 313 AB - BACKGROUND: The oncologic adequacy of distal ureterectomy (DU) versus radical nephroureterectomy (RNU) for nonmetastatic distal ureteral urothelial carcinoma remains debated, particularly in patients for whom renal preservation is clinically desirable. METHODS: A systematic review and meta-analysis of comparative studies was performed. PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library were searched from inception to February 27, 2026. A total of 229 records were identified, 14 full-text articles were assessed, and 6 studies were included. The primary outcome was a positive surgical margin. Secondary outcomes included intravesical recurrence, cancer-specific survival, lymph node metastasis, muscle-invasive disease (>/= pT2), and high-grade pathologic disease burden as a marker of baseline oncologic risk and treatment-selection balance. Random-effects models were used. Risk of bias was assessed with ROBINS-I, and certainty of evidence was evaluated using GRADE. RESULTS: A total of 6 comparative studies comprising 1,247 patients were included, of whom 588 underwent distal ureterectomy, and 659 underwent radical nephroureterectomy. DU was not associated with a significant difference in positive surgical margin compared with RNU (RR 1.24, 95% CI 0.64-2.43). Cancer-specific survival was also comparable (HR 0.97, 95% CI 0.72-1.29). No significant differences were observed for lymph node metastasis (RR 0.85, 95% CI 0.40-1.80), muscle-invasive disease (RR 0.96, 95% CI 0.86-1.08), or high-grade disease (RR 0.97, 95% CI 0.86-1.09). Intravesical recurrence was not significantly different in the primary pooled analysis (HR 1.36, 95% CI 0.89-2.07), although sensitivity analysis suggested a higher recurrence hazard after DU. Most outcomes were supported by very low to low certainty evidence. CONCLUSIONS: In selected patients with nonmetastatic distal ureteral urothelial carcinoma, DU appears to preserve oncologic adequacy relative to RNU while offering a kidney-sparing surgical alternative. The main trade-off may be a higher risk of intravesical recurrence, underscoring the need for careful surveillance and individualized surgical decision-making. CI - (c) 2026. The Author(s). FAU - Mirza, Wajahat AU - Mirza W AUID- ORCID: 0009-0001-9811-7754 AD - Shifa College of Medicine, Shifa Tameer-e-Millat University, Sector H-8/4, Islamabad, Pakistan. wajahatmirza.clinicalresearch@gmail.com. FAU - Hussain, Khalid AU - Hussain K AD - Consultant Urologist, Gujranwala Teaching Hospital, Gujranwala, Pakistan. FAU - Khalid, Maria AU - Khalid M AD - Consultant Urologist, Gujranwala Teaching Hospital, Gujranwala, Pakistan. FAU - Ali, Rao Nouman AU - Ali RN AD - Consultant Urologist, DHQ Hospital, Khanewal, Pakistan. FAU - Moeen-Ud-Din, Muhammad Bilal AU - Moeen-Ud-Din MB AD - Department of Surgery, University of Cincinnati, Cincinnati, Ohio, USA. FAU - Hadhoud, Abdalla M AU - Hadhoud AM AD - Department of Surgery, University of Cincinnati, Cincinnati, Ohio, USA. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260529 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Ureteral Neoplasms/surgery/pathology/mortality MH - *Ureter/surgery MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis PMC - PMC13411953 OTO - NOTNLM OT - Cancer-specific survival OT - Distal ureteral urothelial carcinoma OT - Distal ureterectomy OT - Intravesical recurrence OT - Kidney-sparing surgery OT - Meta-analysis OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma COIS- Declarations. Ethics approval and consent to participate: Not applicable, as this study was a systematic review and meta-analysis of previously published studies. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/05/30 00:32 MHDA- 2026/07/30 12:43 PMCR- 2026/05/29 CRDT- 2026/05/29 23:44 PHST- 2026/03/09 00:00 [received] PHST- 2026/05/25 00:00 [accepted] PHST- 2026/07/30 12:43 [medline] PHST- 2026/05/30 00:32 [pubmed] PHST- 2026/05/29 23:44 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.1186/s12957-026-04438-9 [pii] AID - 4438 [pii] AID - 10.1186/s12957-026-04438-9 [doi] PST - epublish SO - World J Surg Oncol. 2026 May 29;24(1):313. doi: 10.1186/s12957-026-04438-9. PMID- 42215586 OWN - NLM STAT- MEDLINE DCOM- 20260810 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 May 29 TI - Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer. LID - 10.1038/s41598-026-55438-4 [doi] LID - 24596 AB - Non-muscle-invasive bladder cancer (NMIBC) has high rates of recurrence and progression, yet its molecular landscape across different ethnicities remains poorly defined. We assembled a meta-cohort of 202 Asian NMIBC transcriptomes and identified three novel molecular subtypes (AC0, AC1, AC2) using non-negative matrix factorization clustering. These subtypes, each associated with distinct biological pathways and clinical outcomes, were externally validated across 22 datasets. Subtype-specific biomarkers (RABL6, MYBL2, RAD54L, and FAM64A) were confirmed by immunohistochemistry in an independent Asian cohort (n = 210), enabling the development of a machine-learning-based risk stratification model. AC1, characterized by aggressive features and enrichment of cell cycle and oncogenic signaling pathways, exhibited the poorest prognosis. Notably, after adjustment for T-stage and grade, the combined risk model was independently prognostic in Asian cohorts but not in European cohorts, underscoring ethnic differences in NMIBC biology. Our findings delineate distinct molecular subtypes and introduce a clinically applicable, ethnicity-specific prognostic model for Asian patients with NMIBC. This study emphasizes the importance of incorporating ethnic diversity into precision oncology frameworks and provides a foundation for personalized therapeutic and surveillance strategies in underrepresented populations. CI - (c) 2026. The Author(s). FAU - Jung, Minsun AU - Jung M AD - Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Park, Sangyong AU - Park S AD - Department of Statistics, Seoul National University, Seoul, Republic of Korea. FAU - Jang, Insoon AU - Jang I AD - Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. AD - Blood Transfusion Research Institute, Korean Red Cross, Wonju, Gangwon-do, Republic of Korea. FAU - Han, Dohyun AU - Han D AD - Department of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovative Technology, Seoul National University Hospital, Seoul, Republic of Korea. AD - Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Cho, Yong Mee AU - Cho YM AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Kim, Kwangsoo AU - Kim K AD - Department of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovative Technology, Seoul National University Hospital, Seoul, Republic of Korea. kksoo716@gmail.com. AD - Department of Medicine, Seoul National University, Seoul, Republic of Korea. kksoo716@gmail.com. FAU - Moon, Kyung Chul AU - Moon KC AD - Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. blue7270@snu.ac.kr. AD - Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea. blue7270@snu.ac.kr. LA - eng PT - Journal Article DEP - 20260529 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/pathology/ethnology MH - *Machine Learning MH - Female MH - *Asian People/genetics MH - Biomarkers, Tumor/genetics/metabolism MH - Prognosis MH - Male MH - Middle Aged MH - Aged MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Transcriptome MH - Gene Expression Profiling PMC - PMC13454192 OTO - NOTNLM OT - Cluster Analysis OT - Ethnicity OT - Machine Learning OT - Non-Muscle Invasive Bladder Neoplasms OT - Tumor Biomarkers COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/05/30 00:33 MHDA- 2026/08/10 06:37 PMCR- 2026/05/29 CRDT- 2026/05/29 23:19 PHST- 2025/05/13 00:00 [received] PHST- 2026/05/25 00:00 [accepted] PHST- 2026/08/10 06:37 [medline] PHST- 2026/05/30 00:33 [pubmed] PHST- 2026/05/29 23:19 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.1038/s41598-026-55438-4 [pii] AID - 55438 [pii] AID - 10.1038/s41598-026-55438-4 [doi] PST - epublish SO - Sci Rep. 2026 May 29;16(1):24596. doi: 10.1038/s41598-026-55438-4. PMID- 42215335 OWN - NLM STAT- MEDLINE DCOM- 20260704 LR - 20260811 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 3 DP - 2026 Jun TI - Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. PG - 652-659 LID - S2588-9311(26)00134-3 [pii] LID - 10.1016/j.euo.2026.05.007 [doi] AB - BACKGROUND AND OBJECTIVE: The overall objective of this modified Delphi panel study was to develop a consensus of European expert clinical opinion on unmet need, clinical evidence generation, and appropriate trial endpoints in Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). METHODS: A panel of European clinical experts participated (N = 12, n = 9 at consensus meeting). Consensus statements and topics were developed and tested in online surveys conducted in January-February and April-May 2023, before discussion in a consensus meeting in August 2023. Consensus was defined as agreement by >/=80% of the panelists. KEY FINDINGS AND LIMITATIONS: Panelists agreed that there is a significant unmet need within the BCG-unresponsive NMIBC population, particularly among patients who are unfit to undergo radical cystectomy (RC). In many cases, RC may not be feasible due to medical complications, or the risk associated with comorbidities, and patients may also be unwilling to undergo surgery. This highlights the urgent need for effective nonsurgical alternatives. While randomized controlled trials (RCTs) were considered feasible, panelists acknowledged unresolved ethical and technical barriers to their implementation in this setting. Technical challenges identified include difficulties with recruiting an adequate number of patients overall, difficulties with recruiting a sufficiently homogeneous population to generate reliable results, and difficulties with objectively defining unfitness for surgery. In contrast, single-arm trials (SATs) were viewed as an appropriate and ethical approach under these constraints. Panelists agreed that the following endpoints should be measured within a randomized or single-arm clinical trial in this indication: complete response, duration of response, and safety. CONCLUSIONS AND CLINICAL IMPLICATIONS: While conducting RCTs in this area was considered feasible and acceptable, ethical and technical challenges still appeared to be unresolved, suggesting a need for evidence generated through other means. Data from SATs may be considered an acceptable alternative. These findings therefore suggest a way forward to address this unmet need. PATIENT SUMMARY: European experts agree there is a substantial treatment gap for people with bladder cancer that no longer responds to Bacillus Calmette-Guerin, especially those too unwell for bladder removal surgery, or who do not wish to have this surgery-so effective, safer sparing therapies are urgently needed. Because large randomized trials are difficult to conduct fairly in this population, the experts support simpler study designs that assess whether the cancer responds, how long the response is maintained, and how safe the treatment is. CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, University of Turin School of Medicine, Italy. Electronic address: paolo.gontero@unito.it. FAU - Perry, Richard AU - Perry R AD - Adelphi Values PROVE, Bollington, UK. FAU - Bridge, Daisy AU - Bridge D AD - Adelphi Values PROVE, Bollington, UK. FAU - Delattre, Diane Dalila AU - Delattre DD AD - Ferring Pharmaceuticals, Kastrup, Denmark. FAU - Vosgerau, Sebastian AU - Vosgerau S AD - Ferring Pharmaceuticals, Kastrup, Denmark. FAU - Wyn, Robin AU - Wyn R AD - Adelphi Values PROVE, Bollington, UK. FAU - Stone, Medi AU - Stone M AD - Adelphi Values PROVE, Bollington, UK. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, 2nd Faculty of Medicine, Charles University, University Hospital Motol and Homolka, Prague, Czech Republic. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260530 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *BCG Vaccine/therapeutic use MH - Delphi Technique MH - Cystectomy MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Clinical trial OT - Expert opinion OT - Randomized controlled trial OT - Single-arm trial EDAT- 2026/05/30 00:32 MHDA- 2026/07/05 00:37 CRDT- 2026/05/29 21:56 PHST- 2025/12/12 00:00 [received] PHST- 2026/04/08 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/07/05 00:37 [medline] PHST- 2026/05/30 00:32 [pubmed] PHST- 2026/05/29 21:56 [entrez] AID - S2588-9311(26)00134-3 [pii] AID - 10.1016/j.euo.2026.05.007 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Jun;9(3):652-659. doi: 10.1016/j.euo.2026.05.007. Epub 2026 May 30. PMID- 42209926 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260813 IS - 1863-2491 (Electronic) IS - 1863-2483 (Print) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 May 29 TI - Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease. LID - 10.1007/s11701-026-03455-w [doi] LID - 549 AB - Minimally invasive radical nephroureterectomy (RNU) has been increasingly adopted for upper tract urothelial carcinoma (UTUC); however, direct comparisons between laparoscopic and robot-assisted approaches remain limited. We retrospectively analyzed consecutive patients treated with minimally invasive RNU with bladder cuff excision between August 2014 and July 2025. Patients were stratified into laparoscopic (LNU) and robot-assisted (RANU) groups. Perioperative outcomes and oncologic endpoints, including intravesical recurrence (IVR), disease-free survival (DFS) as well as overall survival (OS), were evaluated. Fine-Gray competing risk regression was applied to assess cancer-specific mortality and IVR. A total of 287 patients were enrolled, comprising 152 in the LNU group and 135 in the RANU group. Perioperative outcomes were comparable between groups, with no significant differences in estimated blood loss, theater time, or major complication rates. During follow-up, no remarkable differences were identified in DFS or OS. Competing risk analysis demonstrated that surgical platform was not significantly correlated with cancer-specific mortality or IVR in the overall cohort. In the subgroup of patients with pathological T3 disease, IVR occurred less frequently in the robotic group compared with the laparoscopic group (7.3% vs. 27.3%, p = 0.016). In exploratory multivariable analysis, robot-assisted surgery was associated with a decreased likelihood of IVR (sHR 0.275, p = 0.041). This finding should be interpreted cautiously in light of the limited sample size and the post-hoc nature of the analysis. Overall, robot-assisted RNU demonstrated perioperative and oncologic outcomes comparable to laparoscopic surgery. The observed difference in IVR in patients with locally advanced disease is hypothesis-generating and warrants further validation in prospective studies. CI - (c) 2026. The Author(s). FAU - Chen, I-Hsuan Alan AU - Chen IA AD - Division of Transplant Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. AD - Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan. AD - School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Luo, Hao-Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chu, Chi-Hsiang AU - Chu CH AD - Institute of Statistics, National University of Kaohsiung, Kaohsiung, Taiwan. FAU - Yu, Chia-Cheng AU - Yu CC AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Lin, Tzu-Ping AU - Lin TP AD - Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan. AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Yang, Chih-Yu AU - Yang CY AD - Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan. cyyang3@vghtpe.gov.tw. AD - Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. cyyang3@vghtpe.gov.tw. AD - Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan. cyyang3@vghtpe.gov.tw. AD - Stem Cell Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. cyyang3@vghtpe.gov.tw. AD - International Medical Service Center, Taipei Veterans General Hospital, Taipei, Taiwan. cyyang3@vghtpe.gov.tw. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260529 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Robotic Surgical Procedures/methods MH - *Laparoscopy/methods MH - Female MH - Retrospective Studies MH - Male MH - Treatment Outcome MH - Neoplasm Recurrence, Local/epidemiology MH - Aged MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Middle Aged MH - *Ureteral Neoplasms/surgery/pathology MH - Disease-Free Survival MH - Urinary Bladder Neoplasms PMC - PMC13219172 OTO - NOTNLM OT - Carcinoma OT - Competing risks OT - Intravesical recurrence OT - Laparoscopy OT - Robotic surgical procedures OT - Transitional cell OT - Ureteral neoplasms COIS- Declarations. Consent for publication: Not applicable. Conflict of interest: No conflicts of interest relevant to this study were declared by the authors. Ethics Approval: This study was approved by the Institutional Review Board (IRB) of Kaohsiung Veterans General Hospital (IRB No. VGHKS14-CT3-06) and carried out in accordance with the Declaration of Helsinki. The need for informed consent was waived by the IRB. EDAT- 2026/05/29 15:45 MHDA- 2026/05/29 15:46 PMCR- 2026/05/29 CRDT- 2026/05/28 23:33 PHST- 2026/04/03 00:00 [received] PHST- 2026/04/21 00:00 [accepted] PHST- 2026/05/29 15:46 [medline] PHST- 2026/05/29 15:45 [pubmed] PHST- 2026/05/28 23:33 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.1007/s11701-026-03455-w [pii] AID - 3455 [pii] AID - 10.1007/s11701-026-03455-w [doi] PST - epublish SO - J Robot Surg. 2026 May 29;20(1):549. doi: 10.1007/s11701-026-03455-w. PMID- 42209909 OWN - NLM STAT- MEDLINE DCOM- 20261023 LR - 20261027 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 11 DP - 2026 Nov TI - Two-step enucleation combined with needle electrode: a modified TURBT technique to enhance detrusor muscle detection. PG - 4739-4750 LID - 10.1007/s11255-026-05211-3 [doi] AB - PURPOSE: To evaluate the safety and efficacy of a modified two-step needle-electrode enucleation technique for improving detrusor muscle (DM) detection in transurethral resection of bladder tumor (TURBT). METHODS: This retrospective study included 103 patients undergoing bipolar TURBT between 2019 and 2023, assigned to Two-step enucleation (n = 37), En bloc enucleation (n = 32), or Conventional TURBT (cTURBT) (n = 34). Inverse probability of treatment weighting (IPTW) was applied to mitigate selection bias. Weighted comparisons used survey-design-adjusted methods, including Rao-Scott chi-square tests and weighted regression models. Outcomes included DM detection, operation time, complications, recovery metrics, and short-term recurrence. RESULTS: After IPTW, the Two-Step group demonstrated a higher DM detection rate than the cTURBT group (95.8% vs. 69.4%; adjusted p = 0.03), with an odds ratio of 12.40 (95%CI 1.17-131.92; p = 0.04). No significant difference was observed between the Two-Step and En bloc groups. The Two-Step procedure required a longer operation time than En bloc enucleation (27.7% increase; 95% CI 3.1-58.2%; p = 0.03) and was associated with a longer hospital stay than cTURBT (16.6% increase; 95% CI 2.9-32.2%; p = 0.02). No other statistically significant differences were found among the three groups. CONCLUSION: Two-step enucleation with a needle electrode improves DM detection compared with cTURBT. The procedure time is slightly longer than that of En bloc enucleation. Larger prospective studies are warranted to validate these findings, the perioperative safety, and the long-term oncological outcomes. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Gao, Fan AU - Gao F AD - School of Medicine, Nankai University, Tianjin, 300071, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. FAU - Chen, Xin AU - Chen X AD - Department of Pathology, The First Medical Center of Chinese, PLA General Hospital, Beijing, 100853, China. FAU - Gao, Wenfeng AU - Gao W AD - School of Medicine, Nankai University, Tianjin, 300071, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. FAU - Cheng, Qiang AU - Cheng Q AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. AD - People's Liberation Army Medical College, Beijing, 100853, China. FAU - Jiang, Bin AU - Jiang B AD - School of Medicine, Nankai University, Tianjin, 300071, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. FAU - Lu, Yin AU - Lu Y AD - School of Medicine, Nankai University, Tianjin, 300071, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. FAU - Zou, Nanxin AU - Zou N AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. AD - People's Liberation Army Medical College, Beijing, 100853, China. FAU - Ai, Qing AU - Ai Q AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. aiqing301@foximail.com. FAU - Li, Hongzhao AU - Li H AD - School of Medicine, Nankai University, Tianjin, 300071, China. lihongzhao301@126.com. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. lihongzhao301@126.com. FAU - Zhu, Jie AU - Zhu J AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, 100039, China. zhu_xiaocen@163.com. LA - eng GR - 92459303/National Natural Science Foundation of China/ GR - 2024YB14/Central Healthcare Research Project of China/ PT - Journal Article DEP - 20260528 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Transurethral Resection of Bladder/methods MH - Female MH - Retrospective Studies MH - Male MH - Middle Aged MH - Electrodes MH - Aged MH - *Urinary Bladder Neoplasms/surgery MH - Needles MH - *Muscle, Smooth OTO - NOTNLM OT - Detrusor muscle OT - En bloc OT - NMIBC OT - Needle electrode OT - TURBT OT - Two-step enucleation COIS- Declarations. Conflict of interest: The authors declare that there are no competing interests. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Chinese PLA General Hospital (protocol code S202371201 and date of approval 30 November 2023). Informed consent: Informed consent was obtained from all subjects involved in the study. EDAT- 2026/05/29 15:45 MHDA- 2026/10/23 18:30 CRDT- 2026/05/28 23:33 PHST- 2026/03/31 00:00 [received] PHST- 2026/05/20 00:00 [accepted] PHST- 2026/10/23 18:30 [medline] PHST- 2026/05/29 15:45 [pubmed] PHST- 2026/05/28 23:33 [entrez] AID - 10.1007/s11255-026-05211-3 [pii] AID - 10.1007/s11255-026-05211-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Nov;58(11):4739-4750. doi: 10.1007/s11255-026-05211-3. Epub 2026 May 28. PMID- 42209313 OWN - NLM STAT- Publisher LR - 20260528 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 May 28 TI - Oncological Outcomes of Different Managements of the Distal Ureter in Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. LID - S2588-9311(26)00135-5 [pii] LID - 10.1016/j.euo.2026.05.008 [doi] AB - BACKGROUND: The optimal management of the distal ureter and bladder cuff during radical nephroureterectomy (RNU) for patients with upper tract urothelial carcinoma (UTUC) is uncertain. Endoscopic techniques are less invasive but may compromise oncological control. OBJECTIVE: To compare oncological outcomes of formal transvesical/extravesical (Tr/Ex) bladder cuff excision versus endoscopic distal ureter management in patients undergoing RNU for UTUC. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective analysis of patients included in the Clinical Research Office of the Endourological Society (CROES) UTUC registry, which prospectively collects data from participating centers worldwide. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was recurrence-free survival (RFS); secondary endpoints were intravesical recurrence (IVR) and overall survival (OS). RFS and OS were assessed using Kaplan-Meier methods and Cox regression, whereas IVR was analyzed using competing-risk methods, including Gray's test and Fine-Gray regression. Multivariable adjustment was applied for the primary endpoint RFS. In the matched cohort, an exploratory interaction analysis was performed by adding a treatment-by-primary-tumor-location interaction term to the multivariable Cox model. RESULTS AND LIMITATIONS: Of 1255 patients, 1109 underwent Tr/Ex resection and 146 received endoscopic management. Propensity score matching yielded 258 matched patients (129/group) with good balance in measured baseline covariates, representing a restricted overlap subset. In the matched cohort, Kaplan-Meier analysis showed better RFS with Tr/Ex than with endoscopic management (log-rank p = 0.034). Univariable Cox analysis yielded a hazard ratio (HR) for recurrence of 0.47 (95% confidence interval [CI], 0.23-0.96; p = 0.039), whereas the adjusted Cox model showed a similar but nonsignificant association (HR, 0.49; 95% CI, 0.22-1.10; p = 0.085). OS was similar between groups (HR, 0.96; 95% CI, 0.32-2.89; p > 0.9). In competing-risk analyses treating death without prior IVR as a competing event, the cumulative incidence of IVR did not differ significantly between groups (Gray's test p = 0.064). Fine-Gray regression likewise showed a nonsignificant association between treatment group and IVR (Tr/Ex vs endoscopic: subdistribution hazard ratio [sHR], 0.48, 95% CI, 0.22-1.05; p = 0.067). In an exploratory interaction analysis, the estimated HR for Tr/Ex versus endoscopic management was 0.64 (95% CI, 0.23-1.75; p = 0.382) in renal pelvic tumors and 0.39 (95% CI, 0.09-1.71; p = 0.212) in ureteral tumors; however, no statistically significant treatment-by-location interaction was observed (HR for interaction, 0.61; 95% CI, 0.10-3.68; p = 0.590). CONCLUSION: In the matched cohort, Tr/Ex management was associated with longer RFS on Kaplan-Meier analysis, but the adjusted HR favored Tr/Ex without reaching statistical significance. For intravesical recurrence, competing-risk analyses showed no statistically significant difference between groups. No significant interaction by primary tumor location was observed. REGISTRATION: NCT02281188. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong; Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China. FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong; Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong; Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China. FAU - de la Rosette, Jean AU - de la Rosette J AD - Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Turkey; Bashkir State Medical University, Ufa, Russia. FAU - Laguna, Pilar AU - Laguna P AD - Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Turkey. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong; Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: jeremyteoh@surgery.cuhk.edu.hk. LA - eng SI - ClinicalTrials.gov/NCT02281188 PT - Journal Article DEP - 20260528 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Distal ureter OT - Nephroureterectomy OT - Outcome assessment OT - Urothelial carcinoma EDAT- 2026/05/29 15:45 MHDA- 2026/05/29 15:45 CRDT- 2026/05/28 21:58 PHST- 2025/11/27 00:00 [received] PHST- 2026/04/27 00:00 [revised] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/05/29 15:45 [medline] PHST- 2026/05/29 15:45 [pubmed] PHST- 2026/05/28 21:58 [entrez] AID - S2588-9311(26)00135-5 [pii] AID - 10.1016/j.euo.2026.05.008 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 May 28:S2588-9311(26)00135-5. doi: 10.1016/j.euo.2026.05.008. PMID- 42206900 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260817 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 2 DP - 2026 Aug TI - Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel. PG - 306-314 LID - 10.1111/bju.70319 [doi] AB - OBJECTIVES: To evaluate whether extracellular volume (ECV) fraction derived from contrast-enhanced computed tomography (CT) is associated with recurrence risk in patients with treatment-naive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) receiving intravesical gemcitabine/docetaxel (Gem/Doce) therapy. PATIENTS AND METHODS: This retrospective cohort study, conducted at a tertiary referral centre, included 103 patients with HR-NMIBC treated with intravesical Gem/Doce between 2012 and 2024. All patients underwent pre-resection contrast-enhanced CT with an equilibrium phase (~3 min post-injection). Tumour ECV fraction (%) was calculated using the formula: ECV = (DeltaHUtumour/DeltaHUaorta) x (1 - haematocrit) x 100, where Delta Hounsfield units (HU) represents the change in attenuation between non-contrast and equilibrium phases. Regions of interest were manually placed in the tumour and abdominal aorta, and haematocrit values obtained within +/-10 days were used. Associations between clinical variables, ECV, and recurrence were evaluated using Cox proportional hazards models, with discrimination assessed by Uno's C-statistic. RESULTS: The median (interquartile range) follow-up was 17 (10-25) months. High-grade recurrence-free survival (HG-RFS) was 76% at 12 months and 69% at 24 months. CT-derived ECV was the only variable significantly associated with HG-RFS (hazard ratio 1.05, 95% confidence interval 1.03-1.08), demonstrating strong discrimination (C-statistic, 0.81; P < 0.01). A 15% threshold offered the best sensitivity-specificity trade-off (~70% each) for predicting HG-RFS at 12 and 24 months. Patients with ECV 15% at 24 months (88% vs 41%). CONCLUSIONS: The CT-derived ECV is a practical, first-of-its-kind imaging biomarker associated with recurrence risk and useful for risk stratification in patients with HR-NMIBC treated with intravesical Gem/Doce, a regimen increasingly used in the setting of global Bacillus Calmette-Guerin shortages and intolerance. ECV can be rapidly quantified from routine contrast-enhanced CT using standard picture archiving and communication system (PACS) tools, without additional imaging or proprietary software, making it a feasible metric for integration into risk-adapted management pending large-scale validation with extended follow-up. CI - (c) 2026 BJU International. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Alsamarah, Issa AU - Alsamarah I AD - Department of Radiology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Zakharia, Yousef AU - Zakharia Y AD - Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA. FAU - Brown, James A AU - Brown JA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Myers, Amanda A AU - Myers AA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Marchetti, Kathryn A AU - Marchetti KA AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Henning, Grant M AU - Henning GM AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. FAU - Duquesne, Igor AU - Duquesne I AUID- ORCID: 0000-0002-6716-6473 AD - Department of Urology, Hopitaux Universitaires Henri Mondor, Assistance Publique - Hopitaux de Paris, Universite Paris-Est Creteil, Creteil, Paris, France. FAU - Buhas, Bogdan Adrian AU - Buhas BA AUID- ORCID: 0000-0002-5981-3802 AD - Department of Urology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France. FAU - O'Donnell, Michael A AU - O'Donnell MA AUID- ORCID: 0000-0001-7202-6427 AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. LA - eng PT - Journal Article DEP - 20260528 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) SB - IM MH - Humans MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/diagnostic imaging/pathology MH - *Docetaxel/administration & dosage/therapeutic use MH - Female MH - Retrospective Studies MH - *Tomography, X-Ray Computed/methods MH - Administration, Intravesical MH - Male MH - *Neoplasm Recurrence, Local/pathology/diagnostic imaging MH - Aged MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/diagnostic imaging/pathology MH - Aged, 80 and over PMC - PMC13371862 OTO - NOTNLM OT - BCG-naive OT - CT-derived biomarker OT - ECV fraction OT - intravesical gemcitabine and docetaxel OT - non-muscle-invasive bladder cancer EDAT- 2026/05/28 12:35 MHDA- 2026/07/15 12:37 PMCR- 2026/07/15 CRDT- 2026/05/28 09:23 PHST- 2026/07/15 12:37 [medline] PHST- 2026/05/28 12:35 [pubmed] PHST- 2026/05/28 09:23 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - BJU70319 [pii] AID - 10.1111/bju.70319 [doi] PST - ppublish SO - BJU Int. 2026 Aug;138(2):306-314. doi: 10.1111/bju.70319. Epub 2026 May 28. PMID- 42200262 OWN - NLM STAT- MEDLINE DCOM- 20261018 LR - 20261018 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 4 DP - 2026 Nov TI - A prospective cohort study to assess the diagnostic accuracy of VI-RADS score in a tertiary center in central India. PG - 682-687 LID - 10.1177/03915603261450690 [doi] AB - PURPOSE: Accurate preoperative differentiation between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is critical for selecting appropriate therapy. We prospectively evaluated the diagnostic performance of multiparametric MRI (mpMRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for predicting pathological muscle invasion in patients with suspected bladder tumors. METHODS: In this prospective cohort study, 102 consecutive adults with suspected bladder mass were enrolled; 53 patients formed the final analytic cohort (24 MIBC, 29 NMIBC). mpMRI was performed on a 3T scanner; the highest VI-RADS score was used for patients with multiple lesions. Two blinded radiologists assigned VI-RADS scores. The reference standard was histopathology obtained after Transurethral resection of bladder tumor. Diagnostic performance metrics were calculated with 95% confidence intervals, and area under curve (AUC) analysis was performed. RESULTS: All mpMRI scans were interpretable, with no serious adverse events. Muscle invasion was observed in 37.5% of VI-RADS 4 lesions and 94.7% of VI-RADS 5 lesions. At VI-RADS ⩾ 3, sensitivity was 100% and specificity 37.9% (accuracy 66.0%; AUC 0.69). At VI-RADS ⩾ 4, sensitivity remained 100% with improved specificity 62.1% (accuracy 79.2%; AUC 0.81). Using VI-RADS 5 as positive yielded specificity 96.6% with sensitivity 75% (accuracy 86.8%; AUC 0.86). CONCLUSION: VI-RADS on mpMRI demonstrated excellent sensitivity for ruling out MIBC at lower thresholds, while higher thresholds improved specificity for ruling in muscle invasion. These findings support VI-RADS-guided preoperative risk stratification, with larger multicenter validation warranted. FAU - Yadav, Sagar AU - Yadav S AUID- ORCID: 0009-0007-4048-6884 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India. FAU - Madhavan, Kumar AU - Madhavan K AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India. FAU - Yadav, Aakash AU - Yadav A AD - Department of General Surgery, Sharda University, Greater Noida, India. FAU - Khurana, Udit AU - Khurana U AUID- ORCID: 0009-0008-2588-9041 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India. FAU - Yadav, Manoj AU - Yadav M AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India. FAU - Bais, Shubham Singh AU - Bais SS AUID- ORCID: 0009-0007-5408-3656 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India. LA - eng PT - Journal Article DEP - 20260527 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - Prospective Studies MH - Female MH - India MH - Male MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging MH - Tertiary Care Centers MH - Middle Aged MH - Neoplasm Invasiveness MH - Aged MH - Non-Muscle Invasive Bladder Neoplasms/diagnostic imaging/pathology MH - *Multiparametric Magnetic Resonance Imaging MH - Cohort Studies MH - Adult MH - Diagnosis, Differential OTO - NOTNLM OT - Vesical Imaging-Reporting and Data System (VI-RADS) OT - diagnostic accuracy OT - magnetic resonance imaging OT - muscle-invasive bladder cancer OT - transurethral resection of bladder tumor (TURBT) OT - urinary bladder neoplasms COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/05/27 06:41 MHDA- 2026/10/18 05:37 CRDT- 2026/05/27 04:53 PHST- 2026/10/18 05:37 [medline] PHST- 2026/05/27 06:41 [pubmed] PHST- 2026/05/27 04:53 [entrez] AID - 10.1177/03915603261450690 [doi] PST - ppublish SO - Urologia. 2026 Nov;93(4):682-687. doi: 10.1177/03915603261450690. Epub 2026 May 27. PMID- 42195383 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 16 IP - 5 DP - 2026 May 16 TI - Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics. LID - 10.3390/life16050828 [doi] LID - 828 AB - BACKGROUND/OBJECTIVES: Bladder cancer remains one of the most frequently diagnosed malignancies worldwide and is characterized by high recurrence rates requiring long-term surveillance. Conventional white-light cystoscopy (WLC) remains the standard diagnostic method; however, it may fail to detect flat lesions such as carcinoma in situ or small papillary tumors. In recent years, enhanced imaging techniques, including fluorescence cystoscopy and autofluorescence-based systems, have been introduced to improve diagnostic accuracy. The aim of this study is to evaluate the usefulness of fluorescence-based diagnostic techniques and autofluorescence imaging supported by numerical color value (NCV) analysis in the detection and assessment of bladder lesions. METHODS: The study was conducted at the Center of Photodynamic Diagnostics and Therapy, Department of Internal Medicine, Angiology and Physical Medicine, Medical University of Silesia in Bytom. Bladder mucosa was assessed using the Onco-LIFE optical imaging system, which enables visualization under both white-light and autofluorescence conditions. The study included 30 patients diagnosed with non-muscle-invasive bladder cancer or suspected bladder lesions, who underwent cystoscopic evaluation using white-light cystoscopy and autofluorescence imaging. From this cohort, three representative cases were selected for detailed qualitative presentation to illustrate different pathological conditions of the bladder mucosa. In selected cases, photodynamic diagnosis (PDD) using intravesical administration of 5-aminolevulinic acid (ALA) was performed prior to cystoscopic examination. Autofluorescence signals were analyzed using red and green fluorescence channels, and tissue characteristics were evaluated using the numerical color value parameter. RESULTS: Representative cases of non-muscle-invasive bladder lesions were analyzed and compared using conventional white-light cystoscopy and autofluorescence imaging. The use of fluorescence-based imaging enabled improved visualization of suspicious mucosal changes compared with standard WLC. Differences in fluorescence patterns were observed between malignant lesions, inflammatory changes, and carcinoma in situ. NCV analysis allowed quantitative assessment of fluorescence signals and supported differentiation of pathological tissue from normal bladder mucosa. CONCLUSIONS: Fluorescence cystoscopy and autofluorescence-based imaging systems represent valuable tools for improving the detection of bladder lesions during endoscopic examination. The integration of enhanced optical imaging techniques with quantitative fluorescence analysis may increase diagnostic sensitivity and support targeted biopsy and tumor resection. Continued technological development and clinical experience may further expand the role of fluorescence diagnostics in the early detection and management of bladder cancer. FAU - Godlewski, Dominik AU - Godlewski D AD - Medical Centre in Lancut, 37-100 Lancut, Poland. FAU - Aebisher, David AU - Aebisher D AUID- ORCID: 0000-0002-2661-6570 AD - Department of Photomedicine and Physical Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-959 Rzeszow, Poland. FAU - Bartusik-Aebisher, Dorota AU - Bartusik-Aebisher D AUID- ORCID: 0000-0002-5557-5464 AD - Department of Biochemistry and General Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-959 Rzeszow, Poland. FAU - Dynarowicz, Klaudia AU - Dynarowicz K AUID- ORCID: 0000-0001-6851-5869 AD - Department of Biochemistry and General Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-959 Rzeszow, Poland. FAU - Smolak, Barbara AU - Smolak B AD - Department of Diagnostic Imaging and Nuclear Medicine, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-310 Rzeszow, Poland. FAU - Krupka-Olek, Magdalena AU - Krupka-Olek M AUID- ORCID: 0000-0003-4177-8102 AD - Department of Internal Medicine, Angiology, and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Batorego Street 15, 41-902 Bytom, Poland. FAU - Kawczyk-Krupka, Aleksandra AU - Kawczyk-Krupka A AD - Department of Internal Medicine, Angiology, and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Batorego Street 15, 41-902 Bytom, Poland. LA - eng PT - Journal Article DEP - 20260516 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC13208817 OTO - NOTNLM OT - NBI OT - PDD OT - TURBT OT - biomarkers OT - bladder cancer OT - fluorescence cystoscopy OT - molecular diagnostics COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:33 MHDA- 2026/05/27 06:34 PMCR- 2026/05/16 CRDT- 2026/05/27 01:13 PHST- 2026/03/06 00:00 [received] PHST- 2026/04/21 00:00 [revised] PHST- 2026/05/14 00:00 [accepted] PHST- 2026/05/27 06:34 [medline] PHST- 2026/05/27 06:33 [pubmed] PHST- 2026/05/27 01:13 [entrez] PHST- 2026/05/16 00:00 [pmc-release] AID - life16050828 [pii] AID - life-16-00828 [pii] AID - 10.3390/life16050828 [doi] PST - epublish SO - Life (Basel). 2026 May 16;16(5):828. doi: 10.3390/life16050828. PMID- 42195381 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 16 IP - 5 DP - 2026 May 16 TI - Systems Biology and Multi-Omics Determinants of Response to Bladder-Preserving Trimodality Therapy in Muscle-Invasive Bladder Cancer. LID - 10.3390/life16050826 [doi] LID - 826 AB - Trimodality therapy (TMT)-maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy-can offer oncologic outcomes comparable to radical cystectomy (RC) in carefully selected muscle-invasive bladder cancer (MIBC) patients while preserving the bladder and, possibly, the quality of life. Systematic reviews and long-term series support durable bladder-intact survival in responders, yet there is still a significant percentage of patients who exhibit incomplete response or invasive intravesical recurrence requiring salvage RC. This review covers computational genomics, transcriptomics, immune contexture, radiogenomics, and digital pathology approaches for predicting response in order to avoid preventable TMT failures. We discuss clinically relevant endpoints (complete response, invasive recurrence, bladder-intact survival, and salvage RC), patient selection (carcinoma in situ, hydronephrosis, debulking feasibility, and histology), and DNA damage response (DDR) biology-highlighting ERCC2 and related pathways as determinants of chemo-radiation sensitivity. We then review reproducible transcriptomic subtype classifiers and immune deconvolution methods, emphasizing translational constraints and reporting standards. Finally, we propose an integrated hypothetical modeling framework (calibration, external validation, and decision-curve thresholds) to guide recommendations for upfront RC versus bladder preservation with intensified surveillance and timely salvage RC. FAU - Schitcu, Vlad-Horia AU - Schitcu VH AUID- ORCID: 0000-0002-6735-8889 AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. FAU - Munteanu, Vlad Cristian AU - Munteanu VC AUID- ORCID: 0000-0003-3808-2446 AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. AD - Department of Anatomy and Embryology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Borz, Mihnea Bogdan AU - Borz MB AUID- ORCID: 0000-0002-7361-7031 AD - Department of Urology, Targu Mures County Clinical Hospital, 540136 Targu Mures, Romania. AD - Department of Anatomy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. FAU - Cojocaru, Ion AU - Cojocaru I AUID- ORCID: 0000-0002-5107-614X AD - Department of Urology, Galati County Emergency Hospital, 800578 Galati, Romania. FAU - Morari, Octavia AU - Morari O AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. FAU - Girbovan, Mircea AU - Girbovan M AD - Department of Urology, Targu Mures County Clinical Hospital, 540136 Targu Mures, Romania. FAU - Tise, Andrei-Ionut AU - Tise AI AUID- ORCID: 0009-0008-9062-8593 AD - Department of Urology, Alba County Emergency Hospital, 711325 Alba-Iulia, Romania. LA - eng PT - Journal Article PT - Review DEP - 20260516 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC13208507 OTO - NOTNLM OT - DNA damage response OT - ERCC2 OT - bladder preservation OT - chemoradiation OT - digital pathology OT - immune contexture OT - interpretable machine learning OT - molecular subtypes OT - radiomics OT - salvage cystectomy OT - trimodality therapy COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:36 MHDA- 2026/05/27 06:37 PMCR- 2026/05/16 CRDT- 2026/05/27 01:13 PHST- 2026/03/06 00:00 [received] PHST- 2026/04/23 00:00 [revised] PHST- 2026/05/14 00:00 [accepted] PHST- 2026/05/27 06:37 [medline] PHST- 2026/05/27 06:36 [pubmed] PHST- 2026/05/27 01:13 [entrez] PHST- 2026/05/16 00:00 [pmc-release] AID - life16050826 [pii] AID - life-16-00826 [pii] AID - 10.3390/life16050826 [doi] PST - epublish SO - Life (Basel). 2026 May 16;16(5):826. doi: 10.3390/life16050826. PMID- 42194851 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 10 DP - 2026 May 18 TI - Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Gemcitabine in Treatment-Naive Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis. LID - 10.3390/jcm15103890 [doi] LID - 3890 AB - Background/Objectives: Although intravesical Bacillus Calmette-Guerin (BCG) is an established adjuvant therapy for non-muscle-invasive bladder cancer (NMIBC), chronic global shortages and adverse events (AEs) can occur. Thus, intravesical gemcitabine has been used as an alternative. We compared the long-term oncological outcomes and safety profiles of BCG and gemcitabine in treatment-naive patients with intermediate- and high-risk NMIBC. Methods: Patients with intermediate- and high-risk NMIBC (n = 477) received adjuvant intravesical induction and maintenance therapy with intravesical BCG (n = 361) or gemcitabine (n = 116) and their data were collected retrospectively. Results: Compared with the gemcitabine group, the BCG group had significantly higher proportions of patients with T1 stage, high-grade tumors, high-risk tumors, and longer median follow-up duration. Over a median 36-month observation period, the BCG group exhibited significantly better recurrence-free survival (RFS) and high-grade RFS (HG-RFS) than the gemcitabine group. In the propensity score-matched high-risk population, BCG also outperformed gemcitabine in RFS and HG-RFS. BCG therapy was identified as a potent protective predictor, reducing the risk of recurrence and high-grade recurrence by 65% and 66%, respectively, in the total cohort, and by 69% and 71%, respectively, in the propensity score-matched high-risk subgroup. No significant differences were observed in the frequency of grade >/= 3 AEs between BCG and gemcitabine. Conclusions: Intravesical BCG is strongly associated with superior oncological outcomes over gemcitabine in intermediate- and high-risk NMIBC. The results of this study offer pivotal practice-based insights to guide clinical strategies for managing NMIBC. FAU - Kim, Kyung Hwan AU - Kim KH AUID- ORCID: 0000-0001-7162-6527 AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea. AD - Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea. FAU - Kang, Byeong Jin AU - Kang BJ AUID- ORCID: 0000-0003-4498-5895 AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea. AD - Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea. FAU - Lee, Chan Ho AU - Lee CH AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Kim, Soodong AU - Kim S AD - Department of Urology, Dong-A University College of Medicine, Busan 49201, Republic of Korea. FAU - Ku, Ja Yoon AU - Ku JY AUID- ORCID: 0000-0003-3460-9386 AD - Department of Urology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea. FAU - Ha, Hong Koo AU - Ha HK AUID- ORCID: 0000-0002-8240-7765 AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea. AD - Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea. LA - eng PT - Journal Article DEP - 20260518 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13207305 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - adjuvant therapy OT - adverse effects OT - gemcitabine OT - non-muscle-invasive bladder cancer OT - progression-free survival OT - recurrence-free survival COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:36 MHDA- 2026/05/27 06:37 PMCR- 2026/05/18 CRDT- 2026/05/27 01:11 PHST- 2026/03/15 00:00 [received] PHST- 2026/05/07 00:00 [revised] PHST- 2026/05/13 00:00 [accepted] PHST- 2026/05/27 06:37 [medline] PHST- 2026/05/27 06:36 [pubmed] PHST- 2026/05/27 01:11 [entrez] PHST- 2026/05/18 00:00 [pmc-release] AID - jcm15103890 [pii] AID - jcm-15-03890 [pii] AID - 10.3390/jcm15103890 [doi] PST - epublish SO - J Clin Med. 2026 May 18;15(10):3890. doi: 10.3390/jcm15103890. PMID- 42194790 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 10 DP - 2026 May 15 TI - Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. LID - 10.3390/jcm15103830 [doi] LID - 3830 AB - Intravesical Bacillus Calmette-Guerin (BCG) is a recommended therapy approach for non-muscle invasive bladder cancer (NMIBC) to prevent disease progression and eliminate tumor cells. Nevertheless, some patients have shown resistance to BCG therapy, exhibiting disease recurrence and progression to MIBC, thereby necessitating radical cystectomy as the best-recommended treatment option. However, radical cystectomy greatly affects postoperative morbidity and quality of life, rendering many patients hesitant or surgically unsuitable for this invasive therapy. The concept of bladder preservation has emerged as an alternative, employing a diverse array of therapeutic agents and interventions to improve therapeutic efficacy to retain the bladder for as long as possible. In this review, we explore various established therapeutic agents and ongoing clinical trials involving new potential agents and interventions. This study was undertaken to determine the advantage of each agent and their combined therapeutic regimens in improving prognostic efficacy, offering an alternative to radical cystectomy for BCG-unresponsive NMIBC. FAU - Kim, Sung Han AU - Kim SH AUID- ORCID: 0000-0002-1689-5203 AD - Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. FAU - Gudlavalleti, Haarika AU - Gudlavalleti H AD - Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. FAU - Lerner, Seth P AU - Lerner SP AUID- ORCID: 0000-0002-6379-2581 AD - Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20260515 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13208041 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - non-muscle-invasive OT - radical cystectomy OT - recurrence COIS- S.P.L.: Clinical trials-Aura Bioscience, Ferring, JBL (SWOG), Genentech (SWOG), Merck (Alliance), Surge Therapeutics, Tyra Bioscience, and Vaxiion; consultant/advisory board-Aura Bioscience, BMS, Ferring, Immunity Bio, Incyte, Gilead, Pfizer/EMD Serono, Protara, Surge Therapeutics, Tyra Biosciences, UroGen, Vaxiion, and Verity; patent-TCGA classifier; honoraria-Digital Science Press, Grand Rounds Urology, UroToday. SH.K. has no conflicts of interest to declare. H.G. has no conflicts of interest to declare. EDAT- 2026/05/27 06:35 MHDA- 2026/05/27 06:36 PMCR- 2026/05/15 CRDT- 2026/05/27 01:11 PHST- 2026/03/03 00:00 [received] PHST- 2026/04/19 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/05/27 06:36 [medline] PHST- 2026/05/27 06:35 [pubmed] PHST- 2026/05/27 01:11 [entrez] PHST- 2026/05/15 00:00 [pmc-release] AID - jcm15103830 [pii] AID - jcm-15-03830 [pii] AID - 10.3390/jcm15103830 [doi] PST - epublish SO - J Clin Med. 2026 May 15;15(10):3830. doi: 10.3390/jcm15103830. PMID- 42193009 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 10 DP - 2026 May 20 TI - Real-World Evaluation of Uromonitor((R)) for Bladder Cancer Detection and Surveillance. LID - 10.3390/cancers18101650 [doi] LID - 1650 AB - BACKGROUND: Surveillance of non-muscle-invasive bladder cancer (NMIBC) relies on cystoscopy and urine cytology, both of which have well-recognised limitations. Molecular urine assays have been developed to reduce the burden of invasive surveillance, yet their real-world clinical utility remains uncertain. Uromonitor((R)) is a quantitative PCR-based assay targeting hotspot variants in the TERT promoter, FGFR3, and KRAS, which are frequently altered in urothelial carcinoma. We evaluated the performance of Uromonitor((R)) in routine clinical practice and assessed its technical reproducibility. METHODS: Uromonitor((R)) diagnostic test accuracy was retrospectively calculated from samples from patients undergoing investigation for suspected bladder cancer (n = 64) or surveillance (n = 30) following a prior diagnosis at a tertiary referral centre between 2021 and 2023. Uromonitor((R)) results were compared with histology where available (n = 49, 52%), or with contemporaneous cystoscopy and urine cytology findings (n = 45, 48%). This pragmatic dual reference standard reflects routine clinical practice but may introduce some heterogeneity in diagnostic accuracy verification. A prospective in-house verification cohort was used to assess inter-laboratory reproducibility. Discordant cases underwent orthogonal next-generation sequencing (NGS) analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated for the Uromonitor((R)) against the standard of care. RESULTS: Ninety-four patients were included in the clinical performance analysis. Overall sensitivity, specificity, PPV, NPV and overall accuracy for Uromonitor((R)) were 38%, 88%, 63%, 72% and 70%, respectively. Sensitivity was higher in the diagnostic setting (47%; 95% CI 27.3-68.3%) than during surveillance (23%; 95% CI 8.2-50.2%). Several false-negative cases in the verification cohort harboured variants either detectable by NGS at variant allele frequencies below or slightly above the assay's limit of detection or variants not covered by the assay hotspot design. Inter-laboratory reproducibility was excellent, with 100% concordance observed in the verification cohort. CONCLUSIONS: In a real-world clinical setting, Uromonitor((R)) demonstrated high specificity but limited sensitivity for detection of bladder cancer, particularly during surveillance. A negative result does not reliably exclude recurrence. Assay sensitivity thresholds and restricted variant coverage appear to be key contributors to false-negative results. These findings highlight the need for cautious clinical integration of Uromonitor((R)). It is unclear whether this approach has sufficient sensitivity in surveillance to safely reduce cystoscopy frequency. This underscores the need for further refinement of urine-based molecular assays, including a need for enhanced sensitivity and broader mutational coverage before routine clinical adoption. FAU - Newman, Amy AU - Newman A AD - Cancer Genetics, Guy's Hospital, Synnovis, London SE1 9RT, UK. FAU - Hansel, Sasha AU - Hansel S AD - Cancer Genetics, Guy's Hospital, Synnovis, London SE1 9RT, UK. FAU - Gerrard, Gareth AU - Gerrard G AD - Cancer Genetics, Guy's Hospital, Synnovis, London SE1 9RT, UK. AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Orton, Llwyd AU - Orton L AUID- ORCID: 0000-0002-8578-2296 AD - Neurophysiology, Manchester Metropolitan University, Manchester M15 6BX, UK. FAU - Chandra, Ashish AU - Chandra A AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Ibrahim, Youssef AU - Ibrahim Y AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. FAU - Abu Ghanem, Yasmin AU - Abu Ghanem Y AD - Guy's Hospital, GSTT NHS Foundation Trust, London SE1 7EH, UK. LA - eng PT - Journal Article DEP - 20260520 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13204559 OTO - NOTNLM OT - FGFR3 OT - KRAS OT - TERT OT - biomarker OT - non-muscle-invasive bladder cancer OT - sensitivity OT - specificity OT - surveillance COIS- The authors declare no conflict of interest. EDAT- 2026/05/27 06:38 MHDA- 2026/05/27 06:39 PMCR- 2026/05/20 CRDT- 2026/05/27 01:05 PHST- 2026/04/06 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/05/14 00:00 [accepted] PHST- 2026/05/27 06:39 [medline] PHST- 2026/05/27 06:38 [pubmed] PHST- 2026/05/27 01:05 [entrez] PHST- 2026/05/20 00:00 [pmc-release] AID - cancers18101650 [pii] AID - cancers-18-01650 [pii] AID - 10.3390/cancers18101650 [doi] PST - epublish SO - Cancers (Basel). 2026 May 20;18(10):1650. doi: 10.3390/cancers18101650. PMID- 42191068 OWN - NLM STAT- MEDLINE DCOM- 20260831 LR - 20260914 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 50 IP - 7 DP - 2026 Sep TI - Improving long-term monitoring in NMIBC: Digital Uromonitor(R) (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification. PG - 501994 LID - S2173-5786(26)00105-8 [pii] LID - 10.1016/j.acuroe.2026.501994 [doi] AB - OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and requires intensive long-term surveillance. Existing clinical risk models offer limited prognostic accuracy. Molecular urine-based assays may improve prognostic assessment accuracy of future recurrence. This study evaluated whether Digital Uromonitor(R) (dUM), detecting TERT and FGFR3 mutations via ddPCR, enhances prognostic assessment of two-year recurrence beyond cystoscopy and cytology in a prospective multicenter cohort. METHODS: This prospective, multicenter observational study (EVALUATION-CUETO; NCT05864599) enrolled consecutive NMIBC patients from 26 institutions. Eligible participants had an index tumor diagnosed 3 months-2 years before recruitment and completed two years of follow-up with sufficient DNA for dUM analysis. Clinical, pathological, and biomarker variables (cystoscopy, cytology, dUM) were collected. Recurrence rate was defined as events per year and classified as high (R > 0.5) or low (R 0.05). The funnel plot revealed no notable publication bias. In conclusion, the present meta-analysis confirmed the effectiveness of low-dose BCG treatment for patients with NMIBC and highlighted its potentially notable advantage in managing adverse events in patients with NMIBC in the future. CI - Copyright: (c) Liu and Bao. FAU - Liu, Xiaoxi AU - Liu X AD - Operating Room, West China Hospital, Sichuan University Chengdu, Sichuan 610041, P.R. China. AD - West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P.R. China. FAU - Bao, Yige AU - Bao Y AD - Operating Room, West China Hospital, Sichuan University Chengdu, Sichuan 610041, P.R. China. AD - West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P.R. China. LA - eng PT - Journal Article DEP - 20260508 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC13184816 OTO - NOTNLM OT - Bacillus Calmette-Guerin vaccine OT - bladder cancer OT - dose OT - meta-analysis COIS- The authors declare that they have no competing interests. EDAT- 2026/05/21 06:32 MHDA- 2026/05/21 06:33 PMCR- 2026/05/08 CRDT- 2026/05/21 04:41 PHST- 2025/06/30 00:00 [received] PHST- 2026/03/26 00:00 [accepted] PHST- 2026/05/21 06:33 [medline] PHST- 2026/05/21 06:32 [pubmed] PHST- 2026/05/21 04:41 [entrez] PHST- 2026/05/08 00:00 [pmc-release] AID - OL-32-1-15643 [pii] AID - 10.3892/ol.2026.15643 [doi] PST - epublish SO - Oncol Lett. 2026 May 8;32(1):288. doi: 10.3892/ol.2026.15643. eCollection 2026 Jul. PMID- 42164394 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260521 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 4 DP - 2026 Apr 27 TI - Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study. PG - 119 LID - 10.21037/tau-2025-1-962 [doi] LID - 119 AB - BACKGROUND: Transurethral resection of bladder tumor (TURBT) remains the standard surgical approach for non-muscle invasive bladder cancer (NMIBC). However, whether newer laser-based/en bloc techniques translate into durable oncologic benefits beyond perioperative and specimen-quality advantages remains controversial, and population-level evidence on recurrence and progression-particularly among patients who subsequently recur-is limited. This study compared oncologic outcomes between TURBT and transurethral laser excision of bladder tumor (TULBT) in patients with NMIBC using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: In this SEER retrospective cohort, we identified first primary NMIBC [stage 0a/0is/I according to the American Joint Committee on Cancer (AJCC) 8th edition] with urothelial histologies (ICD-O-3: 8120/3, 8130/3, 8131/3) treated with TURBT or TULBT (SEER surgery codes 14, 24-25, 27). Variables included recurrence-free survival (RFS), demographics, tumor AJCC stage, tumor progression, and overall survival (OS). RFS was defined as the time from index diagnosis to a subsequent primary bladder cancer (BCA) under SEER multiple-primary rules; progression was defined as muscle-invasive bladder cancer (MIBC) (AJCC II-IV) at recurrence. As the primary analysis, multivariable logistic regression and Cox proportional hazards models were performed in the full cohort to evaluate tumor progression and OS, with 1:3 propensity score matching (PSM) used for sensitivity analyses. RESULTS: A total of 682 patients were included (TULBT, n=56; TURBT, n=626). In the raw cohort, MIBC at recurrence was more frequent after TULBT (46.4% vs. 31.8%; P=0.03) and RFS was longer (median 38.5 vs. 11.0 months; P<0.001). In full-cohort multivariable models, treatment modality was not independently associated with progression to MIBC [adjusted odds ratio (OR) for TURBT vs. TULBT, 0.489; 95% confidence interval (CI), 0.119-2.006; P=0.32] or OS [adjusted hazard ratio (HR) for TULBT vs. TURBT, 0.644; 95% CI, 0.355-1.166; P=0.15]. Longer RFS was independently associated with improved OS (HR, 0.975; P<0.001), whereas older age (HR, 1.055; P<0.001) and recurrent MIBC stage (HR, 2.860; P<0.001) predicted poorer OS. Sensitivity analyses in the PSM cohort showed consistent results. CONCLUSIONS: TULBT is associated with longer RFS than TURBT in NMIBC, albeit with no clear benefit in tumor progression. Its survival advantage likely stems from delaying recurrence. These findings are exploratory and hypothesis-generating and warrant validation in prospective multicenter studies. CI - (c) AME Publishing Company. FAU - Xia, Yu AU - Xia Y AUID- ORCID: 0000-0002-4829-260X AD - Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ma, Binbin AU - Ma B AD - Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Huang, Tao AU - Huang T AD - Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Liu, Xi AU - Liu X AD - Department of Urology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20260324 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13184183 OTO - NOTNLM OT - Non-muscle invasive bladder cancer (NMIBC) OT - Surveillance, Epidemiology, and End Results (SEER) OT - transurethral laser excision of bladder tumor (TULBT) OT - transurethral resection of bladder tumor (TURBT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-1-962/coif). The authors have no conflicts of interest to declare. EDAT- 2026/05/21 06:32 MHDA- 2026/05/21 06:33 PMCR- 2026/04/27 CRDT- 2026/05/21 04:40 PHST- 2025/12/15 00:00 [received] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/05/21 06:33 [medline] PHST- 2026/05/21 06:32 [pubmed] PHST- 2026/05/21 04:40 [entrez] PHST- 2026/04/27 00:00 [pmc-release] AID - tau-15-04-119 [pii] AID - 10.21037/tau-2025-1-962 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Apr 27;15(4):119. doi: 10.21037/tau-2025-1-962. Epub 2026 Mar 24. PMID- 42164370 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260521 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 4 DP - 2026 Apr 27 TI - Efficacy analysis of transurethral en bloc resection for bladder tumors >/=3 cm. PG - 121 LID - 10.21037/tau-2025-1-981 [doi] LID - 121 AB - BACKGROUND: En bloc resection of bladder tumors (ERBT) is a surgical treatment for non-muscle-invasive bladder cancer (NMIBC). However, data on the efficacy and safety of ERBT for tumors >/=3 cm are limited. This study aimed to investigate the technical characteristics and clinical application of beta-electrode ERBT in the treatment of bladder tumors >/=3 cm and analyze its feasibility and short-term safety. METHODS: Retrospective data were collected from patients with bladder cancer (BC) who underwent beta-electrode ERBT between 2021 and 2024. Surgical Procedure: A mark was made 0.5 cm from the tumor margin. The knife tip was inserted into the submucosal layer at the marked site and retracted away from the bladder wall. The tumor was completely resected using a combination of hook dissection and blunt separation, followed by removal. For larger tumors, en bloc resection was also performed, after resecting most of the tumor base, a small portion was left attached to the bladder wall (to suspend the tumor on the bladder wall and prevent it from becoming free-floating). Subsequently, the tumor crown was crushed and aspirated using a tissue morcellator, while the preserved tumor base was removed en bloc for pathological examination. The primary endpoints recorded were recurrence-free survival (RFS) and progression-free survival (PFS), with secondary endpoints including detrusor muscle (DM) presence rate (presence of muscularis propria in specimens) and safety (intraoperative and postoperative complications). RESULTS: This study enrolled 102 patients with tumor size >/=3 cm. The median operative time was 50.0 (IQR: 34.5, 90.0) minutes, with 73 (71.6%) cases involving DM. No obturator nerve reflex occurred intraoperatively in any patient. Postoperative complications were observed in 10 patients, among which urinary tract infection was the most common (n=5). During a median follow-up of 22.5 (IQR: 14.0, 29.3) months, 10 recurrences and 4 progressions were recorded. The 2-year RFS and 2-year PFS were 90.2% and 96.9%, respectively. CONCLUSIONS: beta-electrode ERBT is a selective surgical approach for bladder tumors >/=3 cm, demonstrating favorable short-term efficacy with minimal intraoperative and postoperative complications, and a good short-term oncological prognosis after surgery. CI - (c) AME Publishing Company. FAU - Zhan, Tianpeng AU - Zhan T AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. FAU - Yang, Shujun AU - Yang S AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. FAU - Kang, Le AU - Kang L AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Wang, Cheng AU - Wang C AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Zhang, Biao AU - Zhang B AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Lai, Xinyue AU - Lai X AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Li, Xuan AU - Li X AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Guo, Shun AU - Guo S AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. FAU - Huang, Shuang AU - Huang S AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. FAU - Zhang, Xu AU - Zhang X AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. FAU - Shang, Panfeng AU - Shang P AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. FAU - Sun, Shengkun AU - Sun S AD - Department of Urology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. LA - eng PT - Journal Article DEP - 20260324 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13184294 OTO - NOTNLM OT - Non-muscle invasive bladder cancer (NMIBC) OT - en bloc resection OT - transurethral resection of bladder tumor (TURBT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-1-981/coif). The authors have no conflicts of interest to declare. EDAT- 2026/05/21 06:33 MHDA- 2026/05/21 06:34 PMCR- 2026/04/27 CRDT- 2026/05/21 04:40 PHST- 2025/12/20 00:00 [received] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/05/21 06:34 [medline] PHST- 2026/05/21 06:33 [pubmed] PHST- 2026/05/21 04:40 [entrez] PHST- 2026/04/27 00:00 [pmc-release] AID - tau-15-04-121 [pii] AID - 10.21037/tau-2025-1-981 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Apr 27;15(4):121. doi: 10.21037/tau-2025-1-981. Epub 2026 Mar 24. PMID- 42164356 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260521 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 4 DP - 2026 Apr 27 TI - Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer patients. PG - 110 LID - 10.21037/tau-2025-1-904 [doi] LID - 110 AB - BACKGROUND: Current guidelines recommend intravesical Bacillus Calmette-Guerin (BCG) instillation as the first-line treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, a substantial proportion of BCG-refractory patients progress to muscle-invasive bladder cancer (BCa), and effective bladder-sparing therapeutic options remain scarce for this population. This study aims to develop a transcriptome-based predictive model for identifying HR-NMIBC patients who may benefit from human epidermal growth factor receptor 2 (HER2)-targeted therapy following BCG treatment failure, and to validate its clinical feasibility. METHODS: We conducted a retrospective analysis of HR-NMIBC cases treated with BCG over the past decade at our institution to investigate the association between HER2 expression and clinical outcomes. Public databases were interrogated to elucidate the mechanisms underlying BCG failure in HER2-overexpressing NMIBC. A HER2-related prognostic score (HRS) model was developed using bioinformatics approaches, with subsequent exploration of transcriptomic disparities between high-risk and low-risk subgroups. The therapeutic potential of HER2-targeted agents was further validated through in vitro experiments using human BCa cell lines and in vivo murine orthotopic BCa models. RESULTS: Real-world retrospective analysis revealed HER2 overexpression as an independent predictor of BCG failure in NMIBC patients. The HRS prognostic model, constructed through Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression analysis of HER2-high versus HER2-low subgroups, demonstrated superior clinical outcomes for low-risk patients via Kaplan-Meier analysis. Progression-free survival-time-dependent-receiver operating characteristic (PFS-time-dependent-ROC) curves exhibited robust sensitivity and specificity at 1-, 3-, and 5-year intervals. Preclinical validations in cellular and animal models showed promising therapeutic efficacy of HER2-targeted interventions. CONCLUSIONS: HER2 overexpression serves as an independent prognostic biomarker for BCG failure in HR-NMIBC. The HRS prognostic model effectively stratifies high-risk patients who may derive clinical benefit from HER2-targeted therapeutic strategies. CI - (c) AME Publishing Company. FAU - Zhan, Wenhao AU - Zhan W AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. AD - Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - An, Dongxin AU - An D AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Lei, Jiahao AU - Lei J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Un, Hiocheng AU - Un H AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Lin, Renxuan AU - Lin R AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Chen, Junxing AU - Chen J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Liu, Ren AU - Liu R AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Wang, Zongren AU - Wang Z AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. LA - eng PT - Journal Article DEP - 20260327 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC13184188 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Non-muscle invasive bladder cancer (NMIBC) OT - bladder-sparing therapy OT - human epidermal growth factor receptor 2 (HER2) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-1-904/coif). All authors declare that this study was supported by Guangdong Provincial Clinical Research Center for Urological Diseases (No. 2020B1111170006). The authors have no other conflicts of interest to declare. EDAT- 2026/05/21 06:31 MHDA- 2026/05/21 06:32 PMCR- 2026/04/27 CRDT- 2026/05/21 04:40 PHST- 2025/11/27 00:00 [received] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/05/21 06:32 [medline] PHST- 2026/05/21 06:31 [pubmed] PHST- 2026/05/21 04:40 [entrez] PHST- 2026/04/27 00:00 [pmc-release] AID - tau-15-04-110 [pii] AID - 10.21037/tau-2025-1-904 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Apr 27;15(4):110. doi: 10.21037/tau-2025-1-904. Epub 2026 Mar 27. PMID- 42161743 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260902 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study. PG - 868-882 LID - S2588-9311(26)00132-X [pii] LID - 10.1016/j.euo.2026.05.005 [doi] AB - BACKGROUND: In non-muscle-invasive bladder cancer (NMIBC), the occurrence of a high-grade (HG) recurrence following Bacillus Calmette-Guerin (BCG) treatment identifies a disease category that is associated with a particularly poor prognosis and for which radical cystectomy (RC) is the gold standard. The latest definition of European Association of Urology (EAU) BCG-unresponsive disease has been endorsed by the United States Food and Drug Administration for clinical trials and adopted by EAU guidelines, despite limited clinical data supporting it. OBJECTIVE: To provide a clinical validation of the current EAU definitions of BCG failure. DESIGN, SETTING, AND PARTICIPANTS: This is an international retrospective multicenter study. Patients with NMIBC treated with at least five out of six BCG induction instillations after January 2000 and presenting with disease recurrence were included. The minimum allowed follow-up was 6 mo. Patients presenting with disease progression at 3 mo and those receiving RC prior to the first follow-up cystoscopy were excluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The main objective of the study was to validate the prognostic value of the different categories of BCG failure, focusing on the EAU definitions of BCG-refractory, BCG-relapsing and BCG-unresponsive disease. The primary endpoint was the time to progression to muscle-invasive disease, the development of nodal disease or distant metastases. Patients were classified according to the EAU definitions of BCG failure, which were applied a priori and subsequently evaluated for their association with disease progression. RESULTS AND LIMITATIONS: Overall, 776 patients with recurrence after BCG were included. Of these, 448 (58%) experienced a HG recurrence. The BCG-refractory subgroups displayed the highest progression rates, the worst being represented by HG recurrence at 6 mo during BCG maintenance (46% progression at 5 yr), followed by T1HG recurrence at 3 mo (30% at 5 yr). BCG-relapsing disease showed a marginally more favorable outcome. Notably, early BCG recurrences included in the definition of BCG-unresponsive disease conveyed progression-free survival similar to BCG-refractory (35% at 5 yr), thus supporting their inclusion in this disease category. CONCLUSION: We have provided the first clinical validation of the EAU definitions of BCG failure/unresponsive disease. They are prognostically informative and can be used to support clinical decision-making. CI - Copyright (c) 2026 European Association of Urology. All rights reserved. FAU - Gontero, P AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della salute e della Scienza di Torino, Torino School of Medicine, Corso Bramante, Torino, Italy. Electronic address: paolo.gontero@unito.it. FAU - Soria, F AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della salute e della Scienza di Torino, Torino School of Medicine, Corso Bramante, Torino, Italy. FAU - Babjuk, M AU - Babjuk M AD - Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Burger, M AU - Burger M AD - Department of Urology, St. Josef Medical Center University of Regensburg, Regensburg, Germany. FAU - Palou Redorta, J AU - Palou Redorta J AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - D'Andrea, D AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Pradere, B AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Moschini, M AU - Moschini M AD - Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Birtle, A AU - Birtle A AD - Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston; University of Manchester, Manchester; University of Central Lancashire, Preston, UK. FAU - Comperat, E M AU - Comperat EM AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Dominguez-Escrig, J L AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Liedberg, F AU - Liedberg F AD - Institution of Translational Medicine, Lund University; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Mariappan, P AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, University of Edinburgh, Western General Hospital, Edinburgh, UK. FAU - van Rhijn, B W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Seisen, T AU - Seisen T AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Shariat, S F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Teoh, J AU - Teoh J AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Xylinas, E AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Capoun, O AU - Capoun O AD - Department of Urology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Rai, B P AU - Rai BP AD - Department of Urology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Soukup, V AU - Soukup V AD - Department of Urology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Faba, O R AU - Faba OR AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Cohen, D AU - Cohen D AD - Department of Urology, Royal Free Hospital, London, UK. FAU - Foster, L AU - Foster L AD - Department of Urology, Royal Free Hospital, London, UK. FAU - Beaud, N AU - Beaud N AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Girtner, F AU - Girtner F AD - Department of Urology, St. Josef Medical Center University of Regensburg, Regensburg, Germany. FAU - Breyer, J AU - Breyer J AD - Department of Urology, St. Josef Medical Center University of Regensburg, Regensburg, Germany. FAU - Hornak, J AU - Hornak J AD - Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Einerhand, S M H AU - Einerhand SMH AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Anract, J AU - Anract J AD - Department of Urology, St. Louis Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Bobjer, J AU - Bobjer J AD - Institution of Translational Medicine, Lund University; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Linares, E AU - Linares E AD - Department of Urology, Hospital La Paz, Madrid, Spain. FAU - Rodriguez-Serranos, A AU - Rodriguez-Serranos A AD - Department of Urology, Hospital La Paz, Madrid, Spain. FAU - Cathomas, R AU - Cathomas R AD - Department of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland. FAU - Saba, K AU - Saba K AD - Department of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland. FAU - Hernandez, V AU - Hernandez V AD - Urology Department, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Lorente, C AU - Lorente C AD - Urology Department, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Rouanne, M AU - Rouanne M AD - Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Lebret, T AU - Lebret T AD - Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Masson-Lecomte, A AU - Masson-Lecomte A AD - Department of Urology, St. Louis Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Roupret, M AU - Roupret M AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Sylvester, R J AU - Sylvester RJ AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20260520 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Treatment Failure MH - Adjuvants, Immunologic/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Middle Aged MH - *Neoplasm Recurrence, Local MH - Prognosis MH - *Carcinoma, Transitional Cell/drug therapy/pathology OTO - NOTNLM OT - BCG failure OT - Individual patient data validation OT - International OT - Multicenter OT - Non-muscle invasive bladder cancer OT - Prognosis EDAT- 2026/05/21 05:33 MHDA- 2026/09/01 23:34 CRDT- 2026/05/20 21:59 PHST- 2025/11/17 00:00 [received] PHST- 2026/04/28 00:00 [revised] PHST- 2026/05/06 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/05/21 05:33 [pubmed] PHST- 2026/05/20 21:59 [entrez] AID - S2588-9311(26)00132-X [pii] AID - 10.1016/j.euo.2026.05.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):868-882. doi: 10.1016/j.euo.2026.05.005. Epub 2026 May 20. PMID- 42160635 OWN - NLM STAT- MEDLINE DCOM- 20260807 LR - 20260925 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 216 IP - 3 DP - 2026 Sep TI - Urine Tumor DNA Testing Identifies Recurrence and Monitors Therapy Response in Patients With High-Risk Nonmuscle-Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guerin. PG - 388-399 LID - 10.1097/JU.0000000000005130 [doi] AB - PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) is the preferred treatment for high-risk nonmuscle-invasive bladder cancer. However, many patients recur within the first year despite optimal therapy. Urine tumor DNA (utDNA) offers promise in stratifying therapy response to identify patients who may benefit from treatment intensification or de-escalation. Our study aimed to validate utDNA testing in a multicenter cohort of patients receiving BCG. MATERIALS AND METHODS: Pretreatment/posttreatment urine from patients undergoing BCG for nonmuscle-invasive bladder cancer was analyzed by utDNA testing (UroAmp). utDNA disease classification (positive/negative) and genomic disease burden were determined according to previously established tumor-naive algorithms. Kaplan-Meier recurrence-free survival (RFS) analyses were conducted to compare groups and Cox proportional hazards assessed. RESULTS: Forty percent (23/57) of patients were utDNA positive before the first BCG treatment. utDNA-positive patients had a 12-month RFS of 61% compared with 85% for negative patients (HR = 3.2, P = .04). Post-BCG, 19% (8/43) of clinically negative patients were utDNA positive. These patients had a 12-month RFS of 25% compared with 91% for utDNA-negative patients (HR = 10.0, P < .001). Among future recurrences, 33% were identified by utDNA when clinical surveillance was negative, providing a median lead time (time between molecular detection and clinical diagnosis) of 4.1 months over standard of care. Sixty-seven percent of lead time cases went on to radical cystectomy, and 33% progressed to muscle-invasive disease. CONCLUSIONS: utDNA analysis reliably stratifies risk of recurrence in patients receiving BCG and shows promise to identify early recurrence enabling personalized treatment. FAU - Bahlburg, Henning AU - Bahlburg H AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Maas, Moritz AU - Maas M AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Contreras-Sanz, Alberto AU - Contreras-Sanz A AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Othman, Dalia AU - Othman D AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - St-Laurent, Marie-Pier AU - St-Laurent MP AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Nikkola, Jussi AU - Nikkola J AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Chai, Shoujie AU - Chai S AUID- ORCID: 0000-0002-5621-8725 AD - Convergent Genomics Inc, South San Francisco, California. FAU - Phillips, Kevin G AU - Phillips KG AUID- ORCID: 0000-0003-1062-3802 AD - Convergent Genomics Inc, South San Francisco, California. FAU - Hamlington, Barbara AU - Hamlington B AD - Convergent Genomics Inc, South San Francisco, California. FAU - Lentz, Peter S AU - Lentz PS AD - Convergent Genomics Inc, South San Francisco, California. FAU - Lumbres, Nicolai P AU - Lumbres NP AD - Convergent Genomics Inc, South San Francisco, California. FAU - Bicocca, Vincent T AU - Bicocca VT AUID- ORCID: 0000-0002-5702-4586 AD - Convergent Genomics Inc, South San Francisco, California. FAU - Jalanko, Tuomas AU - Jalanko T AD - Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Levin, Trevor G AU - Levin TG AUID- ORCID: 0000-0003-1323-1126 AD - Convergent Genomics Inc, South San Francisco, California. FAU - Lange, Dirk AU - Lange D AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260520 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) RN - 0 (DNA, Neoplasm) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - J Urol. 2026 Sep;216(3):397. doi: 10.1097/JU.0000000000005140. PMID: 42258822 CIN - J Urol. 2026 Sep;216(3):398-399. doi: 10.1097/JU.0000000000005145. PMID: 42261878 CIN - J Urol. 2026 Sep;216(3):399. doi: 10.1097/JU.0000000000005166. PMID: 42318906 MH - Humans MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Neoplasm Recurrence, Local/urine/diagnosis MH - Non-Muscle Invasive Bladder Neoplasms/urine/drug therapy MH - Female MH - Male MH - Aged MH - Administration, Intravesical MH - *DNA, Neoplasm/urine MH - *Adjuvants, Immunologic/administration & dosage/therapeutic use MH - *Urinary Bladder Neoplasms/urine/drug therapy/pathology MH - Treatment Outcome MH - Middle Aged MH - Risk Assessment PMC - PMC13456551 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - bladder cancer OT - minimal residual disease OT - urine biomarker OT - urine tumor DNA EDAT- 2026/05/20 18:33 MHDA- 2026/08/07 12:39 PMCR- 2026/08/10 CRDT- 2026/05/20 15:33 PHST- 2026/08/07 12:39 [medline] PHST- 2026/05/20 18:33 [pubmed] PHST- 2026/05/20 15:33 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - JU-25-1558 [pii] AID - 10.1097/JU.0000000000005130 [doi] PST - ppublish SO - J Urol. 2026 Sep;216(3):388-399. doi: 10.1097/JU.0000000000005130. Epub 2026 May 20. PMID- 42157474 OWN - NLM STAT- MEDLINE DCOM- 20260719 LR - 20260802 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 78 IP - 7 DP - 2026 TI - The Prognostic Nutritional Index Serves as a Novel and Independent Predictor of Recurrence in Patients with Non-Muscle-Invasive Bladder Cancer. PG - 487-496 LID - 10.1080/01635581.2026.2674944 [doi] AB - This study aimed to evaluate the prognostic significance of preoperative inflammation-based biomarkers, with a particular focus on the Prognostic Nutritional Index (PNI), in predicting recurrence-free survival (RFS) in patients with non-muscle-invasive bladder cancer (NMIBC). We conducted a retrospective analysis of 210 patients with primary NMIBC diagnosed between January 2019 and June 2020. Various inflammatory indices were calculated from preoperative laboratory data, including PNI, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), neutrophil-to-platelet ratio (NPR), and albumin-to-globulin ratio (AGR). The optimal PNI cutoff was determined using receiver operating characteristic (ROC) curve analysis for 2-year recurrence. Univariable and multivariable Cox proportional hazards models were employed to identify independent prognostic factors for RFS. Survival curves were generated using the Kaplan-Meier method and compared with the log-rank test. A restricted cubic spline (RCS) model was used to examine the dose-response relationship between PNI and recurrence risk. The optimal PNI cutoff for recurrence was 47.5, with an area under the curve (AUC) of 0.816. Multivariable analysis identified high pathological grade (adjusted hazard ratio [HR]: 2.57; 95% confidence interval [CI]: 1.37-4.81; p = 0.003) and low PNI (/= 90 were more likely to present high/very-high risk NMIBC or MIBC (OR = 1.93; 95% CI: 1.01-3.67; p = 0.046), >/=T1 stage (OR = 2.00; 95% CI: 1.09-3.71; p = 0.026) and HG tumours (OR = 2.59; 95% CI: 1.27-5.29; p = 0.008). CONCLUSIONS: During initial diagnosis of BC, BE showed higher SN with similar SP compared with urine cytology. Diagnostic performance of BE increased gradually across EAU prognostic NMIBC factor risk classification, outperforming cytology in all risk groups. Moreover, EpiScore values are able to identify high risk BC patients, >/=T1 tumours and HG tumours. CI - (c) 2026. The Author(s). FAU - Figueras, Marcel AU - Figueras M AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. AD - Genetics and Urological Tumours, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. AD - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain. FAU - Ingelmo-Torres, Mercedes AU - Ingelmo-Torres M AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. AD - Genetics and Urological Tumours, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. FAU - Roldan, Fiorella L AU - Roldan FL AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. AD - Genetics and Urological Tumours, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. FAU - Goma, Emma AU - Goma E AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Galve, Pilar AU - Galve P AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Mercader, Claudia AU - Mercader C AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Peri, Lluis AU - Peri L AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Franco, Agustin AU - Franco A AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Asiain, Ignacio AU - Asiain I AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. AD - Genetics and Urological Tumours, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. AD - Department of Surgery and Medical Specialities, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain. FAU - Mengual, Lourdes AU - Mengual L AUID- ORCID: 0000-0001-7418-9422 AD - Department and Laboratory of Urology, Hospital Clinic Barcelona, Barcelona, Spain. lmengual@ub.edu. AD - Genetics and Urological Tumours, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. lmengual@ub.edu. AD - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain. lmengual@ub.edu. AD - Department of Biomedical Sciences, Laboratory of Urology, Centre de Recerca Biomedica CELLEX, University of Barcelona, C/Casanova 143, Barcelona, 08036, Spain. lmengual@ub.edu. LA - eng GR - Nucleix/Nucleix/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260518 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/pathology/urine MH - Female MH - Male MH - Aged MH - Non-Muscle Invasive Bladder Neoplasms MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/pathology MH - Case-Control Studies PMC - PMC13359573 OTO - NOTNLM OT - Bladder EpiCheck OT - Bladder cancer OT - Diagnosis OT - Methylation OT - Urinary biomarker COIS- Declarations. Ethics approval and consent to participate: All methods were carried out in accordance with relevant guidelines and regulations. All participants provided written informed consent (HCB/2013/8753) before being included in this study. The study methodologies conformed to the standards set by Declaration of Helsinki and were approved by the Clinical Research Ethics Committee of the Hospital Clinic of Barcelona (HCB/2018/0746; HCB2021/1168; HCB/2022/0557). Consent for publication: Not applicable. Competing interests: Lourdes Mengual certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: L. Mengual is a consultant for Nucleix. A. Antonio Alcaraz has received honorarium as speaker or part of advisory boards from the following companies: Astellas, Janssen, Ipsen, Bayer, Sanofi, Olympus and Intuitive Surgical. The remaining authors have nothing to disclose. EDAT- 2026/05/19 06:30 MHDA- 2026/07/13 00:32 PMCR- 2026/05/18 CRDT- 2026/05/19 00:16 PHST- 2026/03/12 00:00 [received] PHST- 2026/04/30 00:00 [accepted] PHST- 2026/07/13 00:32 [medline] PHST- 2026/05/19 06:30 [pubmed] PHST- 2026/05/19 00:16 [entrez] PHST- 2026/05/18 00:00 [pmc-release] AID - 10.1186/s12967-026-08249-0 [pii] AID - 8249 [pii] AID - 10.1186/s12967-026-08249-0 [doi] PST - epublish SO - J Transl Med. 2026 May 18;24(1):889. doi: 10.1186/s12967-026-08249-0. PMID- 42151936 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 24 IP - 1 DP - 2026 May 18 TI - LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1. LID - 10.1186/s12957-026-04391-7 [doi] LID - 285 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high postoperative recurrence rate. LncRNAs have emerged as key regulators in cancer progression. The clinical relevance and mechanistic role of HMGA2-AS1 in NMIBC recurrence remain unclear. METHODS: Clinical samples contained paired adjacent and tumor tissues from 110 NMIBC patients. HMGA2-AS1 expression was examined using qRT-PCR, and its association with clinicopathological features and recurrence-free survival (RFS) was analyzed. Kaplan-Meier and Cox regression analyses were performed to evaluate prognostic value. Functional assays, including CCK-8, migration, and stemness- and epithelial-mesenchymal transition-related gene expression analyses, were conducted in RT4 and 5637 cells. RNA interaction analyses were performed using a dual-luciferase reporter assay. RESULTS: HMGA2-AS1 was elevated in NMIBC tissues and was closely associated with adverse clinicopathological characteristics (tumor grade and stage), and shorter RFS. HMGA2-AS1 is an independent risk factor for postoperative recurrence. Functionally, HMGA2-AS1 silencing suppressed cell proliferation, migration, stemness, and EMT in vitro. HMGA2-AS1 acted as a molecular sponge for miR-367-3p, thereby relieving repression of YAP1. Rescue experiments confirmed that inhibition of miR-367-3p or restoration of YAP1 expression reversed the influence of HMGA2-AS1 knockdown. CONCLUSION: HMGA2-AS1 is upregulated in NMIBC. HMGA2-AS1 promotes NMIBC progression through the miR-367-3p/YAP1 axis. CI - (c) 2026. The Author(s). FAU - Wang, Yingjie AU - Wang Y AD - Department of Oncology, Tongxiang First People's Hospital, Jiaxing, 314500, Zhejiang Province, People's Republic of China. FAU - Nai, Zhen AU - Nai Z AD - Department of Reproductive Medicine, The First People's Hospital of Yunnan Province, Kunming, Yunnan, 650000, China. AD - The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China. FAU - Zhang, Jianbin AU - Zhang J AD - Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, Zhigongxincun, Xinghualing District, Taiyuan, Shanxi, 030001, China. jianbinzhangdr@163.com. LA - eng PT - Journal Article DEP - 20260518 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 RN - 0 (MicroRNAs) RN - 0 (YAP1 protein, human) RN - 0 (YAP-Signaling Proteins) RN - 0 (Transcription Factors) RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (MIRN367 microRNA, human) RN - 0 (RNA, Long Noncoding) RN - 0 (Biomarkers, Tumor) RN - 0 (HMGA2 Protein) RN - 0 (HMGA2 protein, human) SB - IM MH - Humans MH - *MicroRNAs/genetics/metabolism MH - Female MH - *Neoplasm Recurrence, Local/pathology/genetics/metabolism MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology/genetics MH - Male MH - YAP-Signaling Proteins MH - Prognosis MH - Gene Expression Regulation, Neoplastic MH - *Transcription Factors/metabolism/genetics MH - *Adaptor Proteins, Signal Transducing/metabolism/genetics MH - Cell Proliferation MH - Middle Aged MH - Cell Movement MH - *RNA, Long Noncoding/genetics/metabolism MH - Biomarkers, Tumor/genetics/metabolism MH - Epithelial-Mesenchymal Transition MH - Tumor Cells, Cultured MH - *Urinary Bladder Neoplasms/pathology/surgery/genetics MH - HMGA2 Protein/genetics MH - Survival Rate MH - Cell Line, Tumor MH - Follow-Up Studies MH - Aged PMC - PMC13352868 OTO - NOTNLM OT - HMGA2-AS1 OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - YAP1 OT - miR-367-3p COIS- Declarations. Ethics approval and consent to participate: The authors state that they have obtained Tongxiang First People's Hospital review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved. Consent for publication: All patients provided written informed consent. Competing interests: The authors declare no competing interests. EDAT- 2026/05/19 06:30 MHDA- 2026/07/11 04:10 PMCR- 2026/05/18 CRDT- 2026/05/19 00:09 PHST- 2026/02/26 00:00 [received] PHST- 2026/05/02 00:00 [accepted] PHST- 2026/07/11 04:10 [medline] PHST- 2026/05/19 06:30 [pubmed] PHST- 2026/05/19 00:09 [entrez] PHST- 2026/05/18 00:00 [pmc-release] AID - 10.1186/s12957-026-04391-7 [pii] AID - 4391 [pii] AID - 10.1186/s12957-026-04391-7 [doi] PST - epublish SO - World J Surg Oncol. 2026 May 18;24(1):285. doi: 10.1186/s12957-026-04391-7. PMID- 42141426 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260904 IS - 1528-3658 (Electronic) IS - 1076-1551 (Print) IS - 1076-1551 (Linking) VI - 32 IP - 1 DP - 2026 May 15 TI - Transcriptomic profiling across stages of non-muscle-invasive bladder cancer identifies fibroblast activation protein-alpha as a stromal biomarker associated with progression. LID - 10.1186/s10020-026-01497-2 [doi] LID - 136 AB - BACKGROUND: T1 non-muscle-invasive bladder cancer (NMIBC) represents a biologically aggressive subgroup with substantial heterogeneity in recurrence and progression risk. Current clinicopathological risk stratification tools lack sufficient precision to identify patients at the highest risk of progression to muscle-invasive bladder cancer (MIBC). OBJECTIVE: To characterize transcriptomic differences between T1 and < T1 (Ta/Tis) NMIBC and to explore the association of fibroblast activation protein-alpha (FAP) gene expression with disease progression. METHODS: Transcriptomic profiling was performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue from 66 patients with primary, treatment-naive NMIBC and 5 patients with T2 disease (included for exploratory comparisons). Analyses included differential gene expression, gene set enrichment analysis (GSEA), molecular subtyping, immune cell deconvolution, and evaluation of FAP expression in relation to recurrence and progression. External validation of FAP was conducted in three independent NMIBC cohorts. RESULTS: T1 tumors demonstrated a distinct transcriptomic profile compared with < T1 tumors, characterized by enrichment of cell cycle-related and metabolic pathways and a higher prevalence of aggressive molecular subtypes. Despite these molecular differences, no statistically significant differences in recurrence-free, progression-free, cancer-specific, and overall survival were observed, likely reflecting limited event numbers. Among recurrent tumors, early recurrences (70 years (PFS: HR (Q5 vs Q1)= 1.51, 95% CI: 1.06-2.17; OS: HR (Q5 vs Q1)= 1.99, 95% CI: 1.26-3.13). Post-treatment EDIP alone showed no significant associations with BC prognosis. However, in non-muscle-invasive BC (NMIBC) patients, a shift from low to high post-treatment EDIP increased poor PFS risk (HR(Low/High)= 1.57, 95% CI: 1.06-2.32), and persistently high EDIP elevated poor OS risk (HR(High/High)= 2.02, 95% CI: 1.03-3.97) versus consistently low EDIP. No significant EDIP-related associations with CSS were observed. CONCLUSION: Pro-inflammatory diets at diagnosis may worsen PFS and OS in MIBC patients and those aged >70 years. Dynamic post-treatment EDIP changes may impact NMIBC prognosis, highlighting the need for personalized dietary strategies tailored to BC subtype and age to improve survival. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Dai, Ya-Nan AU - Dai YN AD - Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht 6229ER, the Netherlands. FAU - Tura, Benjamin AU - Tura B AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Yu, Evan Yi-Wen AU - Yu EY AD - Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China; Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht 6229ER, the Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Wesselius, Anke AU - Wesselius A AD - Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht 6229ER, the Netherlands. Electronic address: anke.wesselius@maastrichtuniversity.nl. LA - eng PT - Journal Article DEP - 20260504 PL - England TA - Clin Nutr JT - Clinical nutrition (Edinburgh, Scotland) JID - 8309603 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality MH - Female MH - Male MH - *Diet/adverse effects MH - Aged MH - Prognosis MH - *Inflammation MH - Middle Aged OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Diet OT - Dietary inflammatory potential OT - Overall survival OT - Progression-free survival COIS- Conflict of interest Y.D. is a PhD fellow at Maastricht University, under the supervision of A.W., E.Y.W.Y., and M.P.Z. All authors express their own views, which do not necessarily reflect those of their funders or employers. The authors have no further competing interests to declare that are relevant to the content of this article. EDAT- 2026/05/16 00:37 MHDA- 2026/06/16 00:33 CRDT- 2026/05/15 18:04 PHST- 2026/02/08 00:00 [received] PHST- 2026/04/21 00:00 [revised] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/06/16 00:33 [medline] PHST- 2026/05/16 00:37 [pubmed] PHST- 2026/05/15 18:04 [entrez] AID - S0261-5614(26)00106-8 [pii] AID - 10.1016/j.clnu.2026.106679 [doi] PST - ppublish SO - Clin Nutr. 2026 Jul;62:106679. doi: 10.1016/j.clnu.2026.106679. Epub 2026 May 4. PMID- 42139181 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261001 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 26 IP - 10 DP - 2026 Oct TI - Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art. PG - 1269-1284 LID - 10.1080/14737140.2026.2673109 [doi] AB - INTRODUCTION: Despite major advances in the management of bladder cancer over the past decade, including practice-changing studies with immune checkpoint inhibitors and antibody drug conjugates (ADC), patients continue to desire treatment strategies that not only improve survival but also allow them to retain their bladder. Trimodal therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT), radiation, and chemotherapy, remains an important option for appropriately selected patients. AREAS COVERED: We discuss the current standard of care for the management of localized bladder cancer with a focus on TMT including chemotherapy regimens used in TMT, the role of maximal TURBT, potential biomarkers, and the effect of histologic subtype on outcomes. We also provide updates on important upcoming trials that will hopefully translate into new treatment options. EXPERT OPINION: In appropriately selected patients, TMT is an alternative to radical cystectomy in the management of muscle invasive bladder cancer (MIBC). All patients with MIBC should be evaluated by a multidisciplinary team consisting of urology, medical oncology, and radiation oncology to determine the best treatment plan for an individual patient. Ongoing trials are studying new regimens to provide additional options for bladder preservation. FAU - Fahey, Catherine AU - Fahey C AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. AD - Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill, NC, USA. FAU - Sud, Shivani AU - Sud S AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. AD - Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA. FAU - Remella, Anvitha AU - Remella A AD - Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Milowsky, Matthew AU - Milowsky M AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. AD - Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill, NC, USA. LA - eng PT - Journal Article PT - Review DEP - 20260515 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Transurethral Resection of Bladder/methods MH - Combined Modality Therapy MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/methods MH - Patient Selection MH - Cystectomy/methods MH - Survival Rate MH - Biomarkers, Tumor/metabolism MH - Standard of Care OTO - NOTNLM OT - Bladder cancer OT - biomarkers OT - bladder preservation OT - chemoradiation OT - chemotherapy regimens OT - histologic subtype OT - trimodal therapy EDAT- 2026/05/15 18:33 MHDA- 2026/10/01 23:29 CRDT- 2026/05/15 13:22 PHST- 2026/10/01 23:29 [medline] PHST- 2026/05/15 18:33 [pubmed] PHST- 2026/05/15 13:22 [entrez] AID - 10.1080/14737140.2026.2673109 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2026 Oct;26(10):1269-1284. doi: 10.1080/14737140.2026.2673109. Epub 2026 May 15. PMID- 42135441 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260730 LR - 20260824 IS - 2730-664X (Electronic) IS - 2730-664X (Linking) VI - 6 IP - 1 DP - 2026 May 14 TI - Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction. LID - 10.1038/s43856-026-01596-5 [doi] LID - 417 AB - BACKGROUND: Bladder cancer (BC) is the tenth most common cancer and the ninth leading cause of cancer death worldwide. BC has high rates of treatment failure, so alternate approaches are needed to personalise treatments to individual patients in order to improve outcomes from this disease. One method that could provide actionable results to influence clinical decisions on alternative treatments is ex vivo drug screening. METHODS: We explored the feasibility of using ex vivo drug screening directly on patient tumour tissue from transurethral resection of the bladder tumours (TURBT) and cystectomies. We screened 38 BC patients investigating drug sensitivities to 15 agents, including standard of care treatments and some more exploratory compounds. In addition, we investigated ex vivo sensitivity and resistance over the 15 compounds and annotated common mutational profiles. We saw high methodological success (41/54 samples, 75.9%), in clinically useful timeframes (4 days) and identified distinct drug and tumour clusters. RESULTS: Here, we show that drug resistance is associated with aggressive clinical features, mutation burden, and differs with individual gene mutations. Cross-resistance between agents is common. Cisplatin-resistant tumours differ by mutational profiles and include those with multi-drug resistance and those sensitive to alternative agents. Observed clinical responses match our ex vivo response (5/6 patients, 83.3%). Proliferative responses are observed to some receptor tyrosine kinase inhibitors, cautioning against their unselected widespread use. CONCLUSIONS: Ex vivo drug screening identifies drug clusters of patients' tumours that could potentially respond to standard of care and alternative therapies. Our approach offers a platform to potentially individualise treatments, especially in drug-resistant tumours. CI - (c) 2026. The Author(s). FAU - Conroy, S AU - Conroy S AUID- ORCID: 0000-0001-7167-4908 AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. FAU - Gagg, H AU - Gagg H AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. FAU - Quayle, L A AU - Quayle LA AUID- ORCID: 0000-0002-6394-4186 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - School of Computing and Digital Technologies, Sheffield Hallam University, Sheffield, UK. FAU - Adams, J A AU - Adams JA AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. FAU - Williams, S T AU - Williams ST AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Helleday, T AU - Helleday T AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden. FAU - Hussain, S A AU - Hussain SA AUID- ORCID: 0000-0003-1552-511X AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Griffin, J AU - Griffin J AUID- ORCID: 0000-0003-3969-7637 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Allen, R AU - Allen R AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. FAU - Rantala, J K AU - Rantala JK AUID- ORCID: 0000-0002-4999-5585 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. AD - Misvik Biology Ltd, Karjakatu, Turku, Finland. FAU - Danson, S J AU - Danson SJ AUID- ORCID: 0000-0002-3593-2890 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. s.danson@sheffield.ac.uk. AD - Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. s.danson@sheffield.ac.uk. FAU - Catto, Jwf AU - Catto J AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. j.catto@sheffield.ac.uk. AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. j.catto@sheffield.ac.uk. FAU - Wells, G AU - Wells G AUID- ORCID: 0000-0002-1337-9836 AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. g.wells@sheffield.ac.uk. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20260514 PL - England TA - Commun Med (Lond) JT - Communications medicine JID - 9918250414506676 PMC - PMC13408482 OAB - Bladder cancer is the ninth leading cause of cancer death worldwide and has high rates of treatment failure. Therefore, alternative approaches are needed to personalise treatments to individual patients to improve outcomes. In this study, we investigate the feasibility of using cancer drugs directly on patient tumour cells removed from the body to identify which drugs may or may not work. To test this, we investigated 15 cancer treatments on 38 patient tumour samples. We investigated both established drugs and cutting-edge treatments. We found that drug resistance was higher in patients with aggressive cancers and that 5 out of 6 patients showed the same response to drug treatment as their tumour cells did outside their body. We identify different subtypes of bladder cancer patients who could respond to different medicines. Screening drugs outside of the body has shown that it can be used to identify effective medicines prior to the patient undergoing treatment and identify different treatments. This could be used in the future to identify the best cancer medicine specific to the patient. OABL- eng COIS- Competing interests: S.C. has received speaker fees from InMed. S.A.H has received research funding from Cancer Research UK, MRC/NIHR, UHB charities, CCC charities, North-West Cancer Research, Yorkshire Cancer Research, Weston Park Cancer Charity, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly, Roche, and has received advisory board/consultancy fees from Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Merck, Pierre Fabre, Sotio, Gilead. JG has received research funding from Roche and in-kind research support from Owkin and has received honoraria from ISSECAM. JKR is the founder of Misvik Biology Ltd and has received research funding from AstraZeneca and Boehringer Ingelheim. SJD has received consulting fees from Orion Therapeutics, Oxcia and Incanthera. JWFC has received consulting fees from AstraZeneca, Ferring, Ipsen, Roche, and Janssen; has received speaker fees from Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Janssen, Astellas, Nucleix, InMed, and Roche; has received honoraria for membership in advisory boards from Ferring, Roche, Gilead, Photocure, Pfizer, Bristol Myers Squibb, QED Therapeutics, and Janssen; and has received research funding from Roche. HG, LAQ, STW, TH, RA, and GW have declared no conflicts of interest. EDAT- 2026/05/15 00:31 MHDA- 2026/05/15 00:32 PMCR- 2026/05/14 CRDT- 2026/05/14 23:18 PHST- 2025/06/18 00:00 [received] PHST- 2026/04/07 00:00 [accepted] PHST- 2026/05/15 00:32 [medline] PHST- 2026/05/15 00:31 [pubmed] PHST- 2026/05/14 23:18 [entrez] PHST- 2026/05/14 00:00 [pmc-release] AID - 10.1038/s43856-026-01596-5 [pii] AID - 1596 [pii] AID - 10.1038/s43856-026-01596-5 [doi] PST - epublish SO - Commun Med (Lond). 2026 May 14;6(1):417. doi: 10.1038/s43856-026-01596-5. PMID- 42128947 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 May 13 TI - Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer. LID - 358 [pii] LID - 10.1007/s00345-026-06446-6 [doi] AB - PURPOSE: Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease, with Ta tumors accounting for about 70% of cases. Prognosis varies widely, especially among high-grade (HG) tumors, and current predictive systems remain imperfect. This study aimed to provide an external validation of the EAU 2021 classification for Ta HG tumors. METHODS: A retrospective European multicenter study was conducted in 316 TaHG NMIBC. According to the presence or absence of risk factors (age > 70 years, multifocality, tumor size > 3 cm), we categorized TaHG between intermediate-risk (IR) and high-risk (HR) NMIBC. Oncological outcomes included overall and HG recurrence-free survival (RFS), progression free-survival (PFS), cystectomy free-survival (CFS), cancer specific survival (CSS) and overall survival (OS). Uni- and multivariable Cox regression analyses were used to identify the independent predictors of disease recurrence and progression. RESULTS: Overall, 197 (62%) and 119 (38%) patients had IR and HR HG Ta NMIBC, respectively. All patients received endovesical instillations (BCG or chemotherapy). After a median follow-up of 36.0 [32.0; 42.0] months, IR was significantly associated with a higher 3-yr overall RFS (78.6% vs. 66.5%; p = 0.01), 3-yr HG RFS (79.9% vs. 69.2%; p = 0.03) and 3-yr PFS (97.2% vs. 91.5%; p = 0.02). CFS, CSS and OS were similar between IR and HR (all p > 0.05). Multivariable Cox regression analysis confirmed that HR vs. IR group was significantly associated with overall disease recurrence (HR = 1.69; p = 0.03), HG disease recurrence; (HR = 1.58; p = 0.04) and disease progression (HR = 2.33; p = 0.05). CONCLUSION: The European classification of TaHG NMIBC offers useful prognostic insight, especially concerning disease recurrence and progression. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Cournede, Manon AU - Cournede M AD - Department of Urology, Amiens University Hospital, 80054, Amiens, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. pierre-etienne.gabriel@aphp.fr. FAU - Lottin, Marine AU - Lottin M AD - Department of Oncology, Amiens University Hospital, 80054, Amiens, France. FAU - Moschini, Marco AU - Moschini M AD - Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - College of Medical Health Technologies, Al-Turath University, Syndicates (Al-Niqabat Street), Mansour, Baghdad, Iraq. FAU - Budowski, Alexandra AU - Budowski A AD - Department of Anesthesiology, University Hospital Zurich, University of Zurich, 8091, Zurich, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, Stadtspital Triemli, 8063, Zurich, Switzerland. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Clinique Pasteur, Toulouse, France. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Instituto de Investigacion Sanitaria La Paz (IdiPAZ), Madrid, Spain. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, Gianfranco Soldera Prostate Cancer Laboratory, Division of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Veerman, Hans AU - Veerman H AD - Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Di Bona, Carlo AU - Di Bona C AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Thenault, Ronan AU - Thenault R AD - Service d'urologie, Department of Urology, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Service d'urologie, Department of Urology, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. LA - eng PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20260513 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cystectomy MH - Europe/epidemiology MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - *Non-Muscle Invasive Bladder Neoplasms/classification/mortality/pathology MH - Retrospective Studies MH - Risk Assessment/methods MH - *Urinary Bladder Neoplasms/classification/mortality/pathology OTO - NOTNLM OT - Bladder cancer OT - High-grade OT - Non-muscle invasive OT - Progression OT - Recurrence OT - Stage Ta COIS- Declarations. Conflict of interest: The authors declare no competing interests. Informed consent: For this study, oral consent was obtained for every patient. EDAT- 2026/05/14 00:31 MHDA- 2026/05/14 00:32 CRDT- 2026/05/13 23:16 PHST- 2026/02/10 00:00 [received] PHST- 2026/04/27 00:00 [accepted] PHST- 2026/05/14 00:32 [medline] PHST- 2026/05/14 00:31 [pubmed] PHST- 2026/05/13 23:16 [entrez] AID - 10.1007/s00345-026-06446-6 [pii] AID - 10.1007/s00345-026-06446-6 [doi] PST - epublish SO - World J Urol. 2026 May 13;44(1):358. doi: 10.1007/s00345-026-06446-6. PMID- 42128773 OWN - NLM STAT- Publisher LR - 20260513 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 May 13 TI - Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials. LID - S2588-9311(26)00127-6 [pii] LID - 10.1016/j.euo.2026.04.017 [doi] AB - BACKGROUND AND OBJECTIVE: Historic prediction models overestimate the risk of recurrence and progression for intermediate risk (IR) non-muscle-invasive bladder cancer (NMIBC). We report outcomes for patients with IR-NMIBC and the appropriateness of surveillance cystoscopy protocol using contemporaneous clinical trials. METHODS: Pooled individual IR-NMIBC patient data from four randomized controlled trials (RCT) were analyzed: HIVEC-II, PHOTO, BOXIT, and CALIBER. Patients with IR-NMIBC underwent complete tumor resection and were recommended to receive 6 weekly instillations of mitomycin C. Kaplan-Meier analyses were performed for oncological endpoints. Noncumulative distribution of recurrence was evaluated to determine the appropriateness of surveillance cystoscopy. KEY FINDING: A total of 578 patients with IR-NMIBC, with a median follow-up of 34 mo (interquartile range: 25-55 mo) were included for analysis. There was no meaningful increase in recurrence from 36 to 60 mo: overall recurrence-free rates at 12, 24, 36, and 60 mo were 73%, 61%, 56%, and 54%, respectively. In the multivariable model, the risk of recurrence was higher in patients with prior recurrences (hazard ratio [HR]: 1.75, 95% confidence interval [CI]: 1.16-2.64, p = 0.008), multifocality (HR: 1.49, 95% CI: 1.13-1.95, p = 0.004), and cancer grade (HR: 1.57, 95% CI: 1.08-2.28, p = 0.018). Grade or stage progression was uncommon (<5%), and cancer-specific survival (CSS) was 99% at 60 mo. The noncumulative risk of recurrences at 36 and 60 mo were 17% and <5%, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with IR-NMIBC have a high recurrent risk within 36 mo, but grade/stage progression remains low. Patients could consider terminating/reducing the frequency of cystoscopy after 60 mo because of a low risk of subsequent recurrence. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, Yale School of Medicine, New Haven, CT, USA; Division of Surgery & Interventional Science, University College London, London, UK. Electronic address: weishen.tan@yale.edu. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lewis, Rebecca AU - Lewis R AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Porta, Nuria AU - Porta N AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Ackerman, Charlotte AU - Ackerman C AD - Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. FAU - Vadiveloo, Thenmalar AU - Vadiveloo T AD - Centre for Healthcare Randomized Trials, University of Aberdeen, Aberdeen, UK. FAU - Penegar, Steven AU - Penegar S AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, University of Cincinnati, Cincinnati, OH, USA. FAU - Vale, Luke AU - Vale L AD - Health Economics Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK. FAU - Mostafid, Hugh AU - Mostafid H AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - MacLennan, Graeme AU - MacLennan G AD - Centre for Healthcare Randomized Trials, University of Aberdeen, Aberdeen, UK. FAU - Hall, Emma AU - Hall E AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Heer, Rakesh AU - Heer R AD - Division of Surgery, Imperial College London, London, UK. FAU - Kelly, John D AU - Kelly JD AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals, London, UK. LA - eng PT - Journal Article DEP - 20260513 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Intermediate risk OT - Low grade OT - Non-muscle-invasive bladder cancer OT - Risk classification EDAT- 2026/05/14 00:31 MHDA- 2026/05/14 00:31 CRDT- 2026/05/13 21:53 PHST- 2025/08/25 00:00 [received] PHST- 2026/03/30 00:00 [revised] PHST- 2026/04/27 00:00 [accepted] PHST- 2026/05/14 00:31 [medline] PHST- 2026/05/14 00:31 [pubmed] PHST- 2026/05/13 21:53 [entrez] AID - S2588-9311(26)00127-6 [pii] AID - 10.1016/j.euo.2026.04.017 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 May 13:S2588-9311(26)00127-6. doi: 10.1016/j.euo.2026.04.017. PMID- 42127592 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260716 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 284 DP - 2026 Aug TI - Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights. PG - 156517 LID - S0344-0338(26)00170-6 [pii] LID - 10.1016/j.prp.2026.156517 [doi] AB - Flat urothelial lesions represent a diagnostically challenging and clinically significant spectrum in bladder pathology. Distinguishing urothelial carcinoma in situ (CIS) from precursor lesions such as dysplasia remains problematic due to overlapping morphologic features, marked interobserver variability, and unresolved questions about biological behavior and progression risk. These challenges pose a substantial risk of underdiagnosis of neoplastic lesions-misclassified as reactive or benign-or overtreatment of precursors overcalled as CIS. As a result, intermediary lesions-particularly dysplasia-remain controversial and marginally addressed in major guidelines, including the 2022 WHO classification. Recent molecular studies, including next-generation sequencing and proteogenomics, have uncovered defining genomic alterations in flat lesions-such as prevalent TERT promoter mutations across the intraurothelial neoplasia spectrum, alongside variable TP53, FGFR3, and chromatin-remodeling gene changes-that help better define biological behavior and refine diagnostic categories. This review synthesizes recent molecular profiling data within the framework of established urothelial carcinogenesis pathways, offering insights into the biology and progression of flat lesions. It examines evolving classification systems, ongoing challenges in diagnostic reproducibility, and clinical implications. Ancillary modalities, including immunohistochemistry (e.g., CK20, p53, CD44) and emerging molecular tests, are appraised for their utility and constraints. Finally, the review highlights emerging computational tools-particularly artificial intelligence-based analysis of histopathology slides, which shows considerable promise in enhancing diagnostic accuracy-and concludes with evidence-based recommendations aimed to optimize the management of flat urothelial lesions. CI - Copyright (c) 2026 Elsevier GmbH. All rights reserved. FAU - Musangile, Fidele Y AU - Musangile FY AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Matsuzaki, Ibu AU - Matsuzaki I AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Nishikawa, Toui AU - Nishikawa T AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Kojima, Fumiyoshi AU - Kojima F AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Murata, Shin-Ichi AU - Murata SI AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. Electronic address: smurata@wakayama-med.ac.jp. LA - eng PT - Journal Article PT - Review DEP - 20260511 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/diagnosis MH - *Urothelium/pathology MH - *Precancerous Conditions/pathology/genetics/diagnosis MH - *Carcinoma in Situ/pathology/genetics/diagnosis MH - Biomarkers, Tumor/genetics MH - *Carcinoma, Transitional Cell/pathology/genetics OTO - NOTNLM OT - Bladder cancer OT - CIS OT - Flat lesions OT - Molecular landscape OT - Urothelial dysplasia COIS- Declaration of Competing Interest All the authors declare that they have no conflicting financial interests or personal relationships that may have influenced the research presented in this paper EDAT- 2026/05/14 00:31 MHDA- 2026/05/25 06:31 CRDT- 2026/05/13 18:08 PHST- 2026/01/23 00:00 [received] PHST- 2026/04/14 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/05/25 06:31 [medline] PHST- 2026/05/14 00:31 [pubmed] PHST- 2026/05/13 18:08 [entrez] AID - S0344-0338(26)00170-6 [pii] AID - 10.1016/j.prp.2026.156517 [doi] PST - ppublish SO - Pathol Res Pract. 2026 Aug;284:156517. doi: 10.1016/j.prp.2026.156517. Epub 2026 May 11. PMID- 42120270 OWN - NLM STAT- Publisher LR - 20260512 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2026 May 12 TI - Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. LID - S2588-9311(26)00119-7 [pii] LID - 10.1016/j.euo.2026.04.010 [doi] AB - Patients with non-muscle-invasive bladder cancer (NMIBC) have a significant risk of recurrence after trans-urethral resection of bladder tumor (TURBT). The use of neoadjuvant intravesical therapy prior to TURBT has been investigated previously as a possible treatment alternative, but the prospective evidence remains fragmented and heterogeneous. OBJECTIVES: This systematic review and meta-analysis aimed to synthesize the literature and assess whether outcomes differ compared with upfront TURBT. EVIDENCE ACQUISITION: We performed a comprehensive search in PubMed, Scopus, Embase, and Web of Science for prospective studies investigating recurrence-free survival (RFS) among patients with primary or recurrent NMIBC who received neoadjuvant intravesical treatment before TURBT. Only studies with an interventional treatment arm that used neoadjuvant treatment with subsequent TURBT were included in the meta-analysis. Cochrane Q test was used to assess heterogeneity of estimates across studies. EVIDENCE SYNTHESIS: Overall, eight studies were eligible for systematic review and six for meta-analysis with RFS as outcome. Estimates of 1-, 2- and 3-yr RFS were 96% (Confidence Interval [CI]: 92-100%), 82% (95% CI: 60-100%), and 77% (95% CI: 56-97%) for patients who received any neoadjuvant treatment (intravesical mitomycin C [MMC], electromotive drug administration MMC, and hyperthermic intravesical chemotherapy MMC) followed by TURBT, whereas for patients who received upfront TURBT the 1-, 2- and 3-yr RFS estimates were 76% (95% CI: 61-91%), 55% (95% CI: 32-77%), and 54% (95% CI: 31-78%), respectively. The use of neoadjuvant intravesical therapy provided benefit in terms of RFS compared with upfront TURBT (Hazard Ratio: 0.42, 95% CI: 0.29-0.61, p < 0.001). No grade 3-5 adverse events (AEs) were observed in patients treated with neoadjuvant intravesical therapy across different studies. CONCLUSIONS: The use of neoadjuvant intravesical therapy before TURBT results in higher short-term RFS compared with upfront TURBT in patients with NMIBC without causing grade 3-5 AEs. These findings support the need for adequately powered randomized trials to define patient selection, optimal regimens, and the durability of any observed benefit before routine clinical adoption. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Zaurito, Paolo AU - Zaurito P AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Birtle, Alison AU - Birtle A AD - Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. FAU - Makaroff, Lydia AU - Makaroff L AD - Fight Bladder Cancer, Chinnor, UK; World Bladder Cancer Patient Coalition, Brussels, Belgium. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Liedberg, Fredrik AU - Liedberg F AD - Institute of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, The University of Edinburgh, Edinburgh, UK. FAU - Masson-Leconmte, Alexandra AU - Masson-Leconmte A AD - Department of Urology, AP-HP, Saint Louis Hospital, Universite de Paris, Paris, France. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Rai, Bhavan P AU - Rai BP AD - Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Seisen, Thomas AU - Seisen T AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Wood, Robert AU - Wood R AD - EAU Guidelines Office, Arnhem, The Netherlands. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: moschini.marco@hsr.it. CN - European Association of Urology (EAU) Guidelines Panel on Non-muscle-invasive Bladder Cancer LA - eng PT - Journal Article PT - Review DEP - 20260512 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Mitomycin C OT - NMIBC OT - Neoadjuvant treatment OT - Non-muscle-invasive bladder cancer OT - Oncological outcomes OT - Trans-urethral resection of bladder tumor EDAT- 2026/05/13 00:29 MHDA- 2026/05/13 00:29 CRDT- 2026/05/12 21:53 PHST- 2025/10/30 00:00 [received] PHST- 2026/04/08 00:00 [revised] PHST- 2026/04/17 00:00 [accepted] PHST- 2026/05/13 00:29 [medline] PHST- 2026/05/13 00:29 [pubmed] PHST- 2026/05/12 21:53 [entrez] AID - S2588-9311(26)00119-7 [pii] AID - 10.1016/j.euo.2026.04.010 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2026 May 12:S2588-9311(26)00119-7. doi: 10.1016/j.euo.2026.04.010. PMID- 42118290 OWN - NLM STAT- Publisher LR - 20260512 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) DP - 2026 May 12 TI - Clinicopathological characteristics and prognostic outcomes of bladder urothelial neoplasms in patients under 40 years of age: a multicenter retrospective study. LID - 10.1007/s00428-026-04567-2 [doi] AB - Bladder cancer is rare in patients under 40 years of age, and its clinicopathological behavior in this demographic remains a subject of debate. This study aimed to evaluate the histopathological features and prognosis of bladder tumors in patients under the age of 40. This multicenter retrospective study included bladder transurethral resection, biopsy, and cystectomy samples obtained from patients younger than 40 years of age across 20 centers in Turkiye between 2010 and 2025. Among 1,555 biopsies, 445 patients were diagnosed as urothelial neoplasms. After exclusion of 45 patients lacking hematoxylin and eosin stained slides for re-evaluation, 400 urothelial neoplasms were included in the final cohort. All patients were centrally reviewed by three genitourinary pathologists to establish a consensus diagnosis. Demographic characteristics, clinical presentation, tumor localization, pathological stage, and histological subtypes were analyzed. Follow-up data were available for 206 patients and were used to evaluate clinical outcomes. Statistical analyses were performed using chi-square tests with post-hoc analysis based on adjusted standardized residuals. Low-grade papillary urothelial carcinoma (LGPUC) was the most frequent diagnosis, accounting for 233/400 patients (58.3%), followed by papillary urothelial neoplasm of low malignant potential (PUNLMP) in 55/400 patients (13.8%) and high-grade papillary urothelial carcinoma (HGPUC) in 32/400 patients (8.0%). Overall, 340/400 tumors (85.0%) were non-invasive, whereas 60/400 tumors (15.0%) were invasive. Hematuria was the most common presenting symptom, observed in 197/400 patients (49.3%). Diagnostic revisions after central review were identified in 127/400 patients (31.8%), most commonly involving reclassification between PUNLMP and LGPUC. Age-group analysis demonstrated that urothelial neoplasms occurred most frequently in the 31-40-year age group, which showed a significantly higher proportion of HGPUC and invasive tumors (p < 0.001). Subtype histology or divergent differentiation was identified in 4/60 invasive tumors (6.7%). Among the 206 patients with available follow-up data, remission was observed in 159/206 patients (77.2%), recurrence in 41/206 (19.9%), progression in 2/206 (1.0%), and death in 4/206 patients (1.9%). Adverse clinical outcomes were largely confined to invasive tumors. Bladder tumors in patients under 40 years of age typically exhibit low-grade, low-stage characteristics with a favorable prognosis. Consistent with the literature, the 31-40 age group appears to be a biological transition zone with increased risks of high-grade and invasive carcinoma. Long-term follow-up remains essential due to the potential for recurrence and progression in specific subtypes. CI - (c) 2026. The Author(s). FAU - Baycelebi, Deniz AU - Baycelebi D AD - Department of Pathology, School of Medicine, Ondokuz Mayis University, Samsun, Turkiye. FAU - Icoz, Abdurrahman Taner AU - Icoz AT AD - Department of Pathology, School of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye. FAU - Yildirim, Nazif Alperen AU - Yildirim NA AD - Department of Pathology, Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkiye. FAU - Okur, Seda Nur AU - Okur SN AD - Department of Pathology, School of Medicine, Ondokuz Mayis University, Samsun, Turkiye. FAU - Kabul, Selva AU - Kabul S AD - Department of Pathology, School of Medicine, Bursa Uludag University, Bursa, Turkiye. FAU - Simsek, Gulcin Guler AU - Simsek GG AD - Department of Pathology, Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkiye. FAU - Seday, Suheda Zeynep AU - Seday SZ AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkiye. FAU - Gunes, Begum AU - Gunes B AD - Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkiye. FAU - Tasligedik, Atilla AU - Tasligedik A AD - Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkiye. FAU - Melemezoglu, Damla AU - Melemezoglu D AD - Department of Pathology, School of Medicine, Mersin University, Mersin, Turkiye. FAU - Koc Sahin, Seda AU - Koc Sahin S AD - Department of Pathology, School of Medicine, Samsun University, Samsun, Turkiye. FAU - Aksoy Khurami, Fatma AU - Aksoy Khurami F AD - Department of Pathology, School of Medicine, Suleyman Demirel University, Isparta, Turkiye. FAU - Cevik Kaya, Fatma AU - Cevik Kaya F AD - Department of Pathology, Kayseri City Hospital, Kayseri, Turkiye. FAU - Coban, Ganime AU - Coban G AD - Department of Pathology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkiye. FAU - Ordu, Melike AU - Ordu M AD - Department of Pathology, School of Medicine, Aksaray University, Aksaray, Turkiye. FAU - Yilmaz, Burcu Sanal AU - Yilmaz BS AD - Department of Pathology, School of Medicine, Karamanoglu Mehmetbey University, Karaman, Turkiye. FAU - Sener, Ebru AU - Sener E AD - Department of Pathology, School of Medicine, Ataturk University, Erzurum, Turkiye. FAU - Bolova Bicak, Tugcem AU - Bolova Bicak T AD - Department of Pathology, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkiye. FAU - Kiran, Merve Meryem AU - Kiran MM AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Sungu, Nuran AU - Sungu N AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. AD - Department of Pathology, School of Medicine, Ankara Yildirim Beyazit Universty, Ankara, Turkiye. FAU - Tok, Birgul AU - Tok B AD - Department of Pathology, School of Medicine, Giresun University, Giresun, Turkiye. FAU - Kokenek Unal, Tuba Dilay AU - Kokenek Unal TD AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. AD - Department of Pathology, School of Medicine, Ankara Yildirim Beyazit Universty, Ankara, Turkiye. FAU - Colak, Aysel AU - Colak A AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Hakkoymaz, Zeynep Ruken AU - Hakkoymaz ZR AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Yazgan, Aylin AU - Yazgan A AD - Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Altindag, Sultan Deniz AU - Altindag SD AD - Department of Pathology, School of Medicine, Bandirma Onyedi Eylul University, Balikesir, Turkiye. FAU - Bahcivan, Atike AU - Bahcivan A AD - Department of Pathology, Gemlik State Hospital, Bursa, Turkiye. FAU - Gokalp Satici, Fadime Eda AU - Gokalp Satici FE AD - Department of Pathology, Tarsus State Hospital, Mersin, Turkiye. FAU - Gumuskaya, Berrak AU - Gumuskaya B AD - Department of Pathology, School of Medicine, Lokman Hekim University, Ankara, Turkiye. FAU - Arslan, Gozde AU - Arslan G AD - Department of Pathology, Kastamonu Training and Research Hospital, Kastamonu, Turkiye. FAU - Yuyucu Karabulut, Yasemin AU - Yuyucu Karabulut Y AD - Department of Pathology, School of Medicine, Mersin University, Mersin, Turkiye. FAU - Kosemehmetoglu, Kemal AU - Kosemehmetoglu K AD - Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkiye. FAU - Yaprak Bayrak, Busra AU - Yaprak Bayrak B AUID- ORCID: 0000-0002-0537-3127 AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkiye. bsr2004_86@hotmail.com. FAU - Akgul, Mahmut AU - Akgul M AD - Department of Pathology, School of Medicine, Atlas University, Istanbul, Turkiye. AD - Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20260512 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Early-onset bladder cancer OT - Urothelial carcinoma OT - Young patients COIS- Declarations. Ethical approval: The study protocol was approved by the Ethical Committee of Non-invasive Clinical Research of Kocaeli University (GOKAEK-2025/573). Competing interests: The authors declare that they have no competing interests. EDAT- 2026/05/12 12:36 MHDA- 2026/05/12 12:36 CRDT- 2026/05/12 11:14 PHST- 2026/03/23 00:00 [received] PHST- 2026/05/02 00:00 [accepted] PHST- 2026/04/12 00:00 [revised] PHST- 2026/05/12 12:36 [medline] PHST- 2026/05/12 12:36 [pubmed] PHST- 2026/05/12 11:14 [entrez] AID - 10.1007/s00428-026-04567-2 [pii] AID - 10.1007/s00428-026-04567-2 [doi] PST - aheadofprint SO - Virchows Arch. 2026 May 12. doi: 10.1007/s00428-026-04567-2. PMID- 42116836 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260512 LR - 20260813 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 18 DP - 2026 TI - Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights. PG - 511428 LID - 10.2147/RRU.S511428 [doi] LID - 511428 AB - Upper tract urothelial carcinoma (UTUC) is a relatively uncommon urologic malignancy that has historically a worse prognosis than urothelial carcinoma of the bladder due to higher rate of invasion and worse morbidity in patients. However, recent developments in treatment possess great potential for improved outcomes in these patients. This review compiles the most recent practices in treating this disease, and avenues for future modalities. Risk stratification of UTUC guides treatment and surveillance, with neoadjuvant chemotherapy employed in higher stage, to improve oncologic outcome. Surgical management for UTUC includes endoscopic management (EM) and kidney-sparing surgery (KSS) for low risk (LR) disease, and radical nephroureterectomy (RNU) for high risk (HR) disease. EM may follow a retrograde or antegrade approach, preserving renal function at the cost of increased risk of recurrence. Topical therapies provide great potential for low-cost, outpatient procedures for LR disease, but their efficacy is poorly characterized. While RNU remains the gold standard, robot-assisted nephroureterectomy is the dominant modality, with lower rates of perioperative complications while maintaining comparable outcomes with respect to the open approach. Perioperative intravesical therapy is universally incorporated to reduce the risk of intravesical recurrence. The POUT trial demonstrated improved disease-free survival with adjuvant platinum-based chemotherapy following RNU, establishing it as standard of care in locally advanced disease, while enfortumab vedotin in combination with pembrolizumab has demonstrated significant improvements in progression-free and overall survival in the metastatic setting. Future implementation of biomarker technologies discloses the potential for improved screening and surveillance at low-cost. Treatment strategies for UTUC are rapidly expanding due to advances in diagnostic technologies and the emergence of novel systemic agents, including antibody-drug conjugates and immune checkpoint inhibitors. Proper management requires accurate risk stratification, with EM suitable for LR disease and RNU for HR disease. CI - (c) 2026 Dadabhoy et al. FAU - Dadabhoy, Anosh S AU - Dadabhoy AS AUID- ORCID: 0009-0003-1578-4901 AD - Department of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Basin, Michael F AU - Basin MF AD - Department of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Shete, Kanha C AU - Shete KC AD - Department of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Djaladat, Hooman AU - Djaladat H AD - Department of Urology, University of Southern California, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260506 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC13157846 OTO - NOTNLM OT - carcinoma OT - chemotherapy OT - endoscopic OT - immunotherapy OT - nephroureterectomy OT - upper tract urothelial carcinoma OT - ureteral neoplasms OT - urothelial COIS- The author(s) report no conflicts of interest in this work. EDAT- 2026/05/12 06:36 MHDA- 2026/05/12 06:37 PMCR- 2026/05/06 CRDT- 2026/05/12 03:53 PHST- 2025/11/19 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/05/12 06:37 [medline] PHST- 2026/05/12 06:36 [pubmed] PHST- 2026/05/12 03:53 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 511428 [pii] AID - 10.2147/RRU.S511428 [doi] PST - epublish SO - Res Rep Urol. 2026 May 6;18:511428. doi: 10.2147/RRU.S511428. eCollection 2026. PMID- 42116792 OWN - NLM STAT- MEDLINE DCOM- 20260909 LR - 20260909 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 56 IP - 9 DP - 2026 Sep 9 TI - Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma. PG - 1103-1110 LID - 10.1093/jjco/hyag078 [doi] AB - INTRODUCTION: Seeding and implantation are major mechanisms of intravesical recurrence (IVR) following the radical nephroureterectomy (RNU) of upper tract urothelial carcinoma (UTUC). We herein hypothesized that bladder biopsies (BB) may increase the IVR risk by promoting implantation in injured bladder mucosa. PATIENTS AND METHODS: This retrospective study included 172 patients with UTUC with no history of bladder UC who underwent RNU between January 2010 and December 2024 at two institutions. The primary endpoint was the association between BB and IVR-free survival (IVRFS) after RNU. A directed acyclic graph (DAG) was generated to identify potential confounders and guide multivariable analysis, and sensitivity analyses using propensity score matching were performed. RESULTS: Eighteen (10%) patients underwent BB prior to RNU due to a positive voided urine cytology finding and/or the presence of erythematous mucosa. Patients receiving BB had significantly shorter IVRFS than those without BB (3-year IVRFS rate: 14% vs. 69%; P < .001). On both DAG-guided and stepwise multivariable models, BB was independently associated with an increased IVR risk (hazard ratio: 2.55 and 4.00, respectively; both P < .005). In the propensity score-matched cohort, BB was also associated with a shorter IVRFS. Notably, IVR developed at the BB sites in 60% of the cases of IVR following BB. CONCLUSIONS: BB is likely to increase the IVR risk in patients undergoing RNU for UTUC by promoting tumor cell implantation. Avoiding BB may be prudent unless both urine cytology and cystoscopic findings are highly suspicious for bladder carcinoma. CI - (c) The Author(s) 2026. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Kanagawa, Tomonori AU - Kanagawa T AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Yonese, Ichiro AU - Yonese I AUID- ORCID: 0009-0001-2607-1013 AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Nakamura, Takehiro AU - Nakamura T AD - Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minami-Ohtsuka, Toshima-ku, Tokyo 170-8476, Japan. FAU - Shimizu, Mai AU - Shimizu M AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Tanaka, Rie AU - Tanaka R AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Kido, Hajime AU - Kido H AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Shinoda, Tsukasa AU - Shinoda T AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Sekiya, Ken AU - Sekiya K AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Soma, Takahiko AU - Soma T AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Toide, Masahiro AU - Toide M AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Ito, Masaya AU - Ito M AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. FAU - Takazawa, Ryoji AU - Takazawa R AD - Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minami-Ohtsuka, Toshima-ku, Tokyo 170-8476, Japan. FAU - Koga, Fumitaka AU - Koga F AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - Biopsy/adverse effects MH - *Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Urinary Bladder/pathology MH - Neoplasm Seeding OTO - NOTNLM OT - bladder biopsy OT - intravesical tumor recurrence OT - radical nephroureterectomy OT - upper tract urothelial carcinoma OT - ureteral catheterization EDAT- 2026/05/12 06:35 MHDA- 2026/09/09 17:47 CRDT- 2026/05/12 03:34 PHST- 2026/03/09 00:00 [received] PHST- 2026/04/19 00:00 [revised] PHST- 2026/04/22 00:00 [accepted] PHST- 2026/09/09 17:47 [medline] PHST- 2026/05/12 06:35 [pubmed] PHST- 2026/05/12 03:34 [entrez] AID - 8676261 [pii] AID - 10.1093/jjco/hyag078 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2026 Sep 9;56(9):1103-1110. doi: 10.1093/jjco/hyag078. PMID- 42108360 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260730 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 8 DP - 2026 Aug TI - Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee. PG - 7790-7800 LID - 10.1245/s10434-026-19439-x [doi] AB - BACKGROUND: The purpose of this study was to evaluate the oncological and perioperative outcomes of robot-assisted bladder cuff excision (RA-BCE) versus open bladder cuff excision (O-BCE) after radical nephroureterectomy (RNU) for patients with upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: We conducted a multicenter study including all consecutive patients who underwent RA-BCE or O-BCE in eight French academic institutions from 2014 to 2023. Kaplan-Meier curves were used to illustrate survival outcomes, while uni- and multivariable Cox regression analyses were conducted to identify independent predictors of survival by calculating hazard (HRs) ratios with their corresponding 95% confidence intervals (CIs). RESULTS: Overall, 487 patients underwent either RA-BCE (n = 182; 37.4%) or O-BCE (n = 305; 62.6%). The median follow up was 30.1 (26.9-36) months. Kaplan-Meier analyses showed that the use of RA-BCE versus O-BCE was associated with similar 3-year intravesical recurrence-free survival (RFS) (68.9% vs. 59.7%; p = 0.1), 3-year extravesical RFS (69.2 vs. 63.8%; p = 0.2), 3-year cancer-specific survival (CSS) (85.5% vs. 76.2%; p = 0.08), and 3-year overall survival (OS) (76% vs. 67.6%; p = 0.1). Multivariable Cox regression analyses confirmed that the use of RA-BCE versus O-BCE was associated with similar 3-year intravesical recurrence (HR 0.83; 95% CI 0.55-1.26; p = 0.4), as well as similar 3-year extravesical recurrence (p = 0.8), 3-year CSS (p = 0.3), and 3-year OS (p = 0.3). Among 340 patients (69.8%) assessed, RA-BCE was associated with a lower rate of overall 90-day complications (p = 0.02), fewer major complications (p = 0.02), and a shorter length of stay (p < 0.01). CONCLUSIONS: Our multicenter study supports the effectiveness of RA-BCE versus O-BCE in the treatment of UTUC with comparable 3-year oncological outcomes. CI - (c) 2026. Society of Surgical Oncology. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. pierre.etienne.aphp@gmail.com. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Duquesne, Hugo AU - Duquesne H AD - Urology Department, Claude Huriez Hospital, CHU Lille, University Lille, CNRS, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, Inserm, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, University Lille, CNRS, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, Inserm, France. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Hopital Cochin, AP-HP, Universite de Paris, Paris, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. FAU - Mercier, Jeremy AU - Mercier J AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. FAU - Pradere, Benjamin AU - Pradere B AD - UROSUD Urology Department, Clinique Croix Du Sud, Quint-Fonsegrives, France. FAU - Duffaut, Louise AU - Duffaut L AD - GRC n degrees 20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hopital Tenon, Sorbonne Universite, Paris, France. FAU - Panthier, Frederic AU - Panthier F AD - GRC n degrees 20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hopital Tenon, Sorbonne Universite, Paris, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Institut Curie, Universite Paris Saclay, Saint-Cloud, France. FAU - Audenet, Francois AU - Audenet F AD - Department of Urology, Hopital Europeen Georges-Pompidou AP-HP Centre, Universite Paris Cite, Paris, France. FAU - Leon, Priscilla AU - Leon P AD - Urology Department, Clinique Pasteur, Royan, France. FAU - Thibault, Constance AU - Thibault C AD - Medical Oncology Department, Hopital europeen Georges-Pompidou AP-HP Centre, Universite Paris Cite, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Clinique Pasteur, Toulouse, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260511 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Follow-Up Studies MH - France MH - Neoplasm Recurrence, Local/pathology/surgery MH - *Nephroureterectomy/mortality/methods MH - Prognosis MH - Retrospective Studies MH - *Robotic Surgical Procedures/mortality/methods MH - Survival Rate MH - *Ureteral Neoplasms/surgery/pathology MH - *Urinary Bladder/surgery/pathology MH - *Urinary Bladder Neoplasms/surgery/pathology OTO - NOTNLM OT - Bladder cuff excision OT - Distal ureter OT - Open OT - Radical nephroureterectomy OT - Robotic OT - Upper tract urothelial carcinoma COIS- Disclosure: Constance Thibault reports relevant financial activities outside the submitted work from Amgen, AstraZenenca, AdaCap, Astellas, Bayer, BMS, Gilead, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, and Seagen. Morgan Roupret reports being on the advisory board of Intuitive. Yves Allory reports grants from the French national institute of Cancer (INCa); being an invited speaker for the following pharmaceutical companies: AstraZeneca, Bristol-Myers-Squib, Johnson and Johnson, and MSD; and being a consultant for Pfizer and Johnson and Johnson. EDAT- 2026/05/11 00:30 MHDA- 2026/07/07 16:09 CRDT- 2026/05/10 23:17 PHST- 2025/11/06 00:00 [received] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/07/07 16:09 [medline] PHST- 2026/05/11 00:30 [pubmed] PHST- 2026/05/10 23:17 [entrez] AID - 10.1245/s10434-026-19439-x [pii] AID - 10.1245/s10434-026-19439-x [doi] PST - ppublish SO - Ann Surg Oncol. 2026 Aug;33(8):7790-7800. doi: 10.1245/s10434-026-19439-x. Epub 2026 May 11. PMID- 42104689 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260810 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 79 IP - 3 DP - 2026 Apr TI - Current Evidence on the Use of Cystoscopy in the Follow-up of Non-Muscle-Invasive Bladder Cancer: Are We Overusing It? Systematic Review of the Literature. PG - 362-370 LID - 10.56434/j.arch.esp.urol.20267903.43 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) accounts for the majority of bladder cancers. Its follow-up entails high costs and significant impact on quality of life. Cystoscopy is the standard method, although uncertainties remain regarding the optimal frequency and duration. The aim was to review the available evidence on surveillance schedules and their impact on recurrence and progression. METHODS: A systematic review was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses). Searches in PubMed, Web of Science and Scopus included clinical and observational studies published between 2004 and 2024. After applying inclusion criteria and assessment with QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies), 8 articles were selected out of a total of 3679. RESULTS: The studies included a total of 30,600 patients. With regard to the first cystoscopy, performing it within 3-4 months after transurethral resection of the bladder showed better outcomes, whereas excessively early or delayed procedures increased the risk of recurrence and progression. In low-risk patients, some studies support discontinuing surveillance after 5 years without recurrence, while others recommend prolonging it in patients with risk factors such as smoking or multiple tumours. In high-risk patients, across the different surveillance schedules analysed, no differences were found in terms of mortality or progression. No conclusive studies were identified for the intermediate-risk group. CONCLUSIONS: The first cystoscopy should be performed within 3-4 months after the initial surgery. Although risk-stratified recommendations exist, current evidence is limited and sometimes contradictory. Prospective and long-term studies are required to define optimal surveillance schedules, with the aim of optimising resources and reducing the burden on patients. CI - (c) 2026 The Author(s). FAU - Baudet Leon, Javier AU - Baudet Leon J AD - Department of Urology, Hospital General Universitario Nuestra Senora del Prado, 45600 Talavera de la Reina, Toledo, Spain. FAU - Cano Velasco, Jorge AU - Cano Velasco J AD - Department of Urology, Clinica Universidad de Navarra, 31008 Pamplona, Navarra, Spain. FAU - Polanco Pujol, Lucia AU - Polanco Pujol L AD - Department of Urology, Clinica Universidad de Navarra, 31008 Pamplona, Navarra, Spain. FAU - Artero Fullana, Silvia AU - Artero Fullana S AD - Department of Urology, Hospital General Universitario Gregorio Maranon, 28009 Madrid, Spain. FAU - Pastor Rodenas, Beatriz AU - Pastor Rodenas B AD - Department of Urology, Hospital General Universitario Nuestra Senora del Prado, 45600 Talavera de la Reina, Toledo, Spain. FAU - Subiela Henriquez, Jose Daniel AU - Subiela Henriquez JD AD - Department of Urology, Hospital General Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Garcia Martin, Luis Alberto AU - Garcia Martin LA AD - Department of Urology, Hospital General Universitario Nuestra Senora del Prado, 45600 Talavera de la Reina, Toledo, Spain. FAU - Hernandez Fernandez, Carlos AU - Hernandez Fernandez C AD - Department of Urology, Hospital General Universitario Gregorio Maranon, 28009 Madrid, Spain. FAU - Bielsa Carrillo, Alejandro AU - Bielsa Carrillo A AD - Department of Urology, Hospital General Universitario Nuestra Senora del Prado, 45600 Talavera de la Reina, Toledo, Spain. LA - eng PT - Journal Article PT - Systematic Review PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - *Cystoscopy MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Disease Progression MH - Follow-Up Studies MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology MH - Transurethral Resection of Bladder OTO - NOTNLM OT - cystoscopy OT - non-muscle-invasive bladder cancer OT - surveillance COIS- The authors declare no conflict of interest. EDAT- 2026/05/09 06:33 MHDA- 2026/05/09 06:34 CRDT- 2026/05/09 02:53 PHST- 2026/05/09 06:34 [medline] PHST- 2026/05/09 06:33 [pubmed] PHST- 2026/05/09 02:53 [entrez] AID - 10.56434/j.arch.esp.urol.20267903.43 [doi] PST - ppublish SO - Arch Esp Urol. 2026 Apr;79(3):362-370. doi: 10.56434/j.arch.esp.urol.20267903.43. PMID- 42101641 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 May 8 TI - Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey. LID - 10.1007/s00345-026-06451-9 [doi] LID - 351 AB - PURPOSE: To evaluate the pathological adequacy of morcellated ERBT specimens using a two-round Delphi methodology and to establish expert consensus among leading pathologists worldwide. METHODS: Core pathological parameters relevant for ERBT specimens were predefined, and representative high-quality digital slides of morcellated ERBT specimens were selected. These images were reviewed by an international panel of expert uropathologists with extensive experience in bladder cancer. A two-round Delphi survey was conducted, in which panelists rated the importance of predefined pathological parameters on a 5-point Likert scale. The items on which a consensus was not reached during the first round, were reviewed and rephrased for the second round involving the same responders. Consensus was defined as > 75% agreement among participants. RESULTS: 10 responders took part in the survey. During the initial Delphi round, agreement was achieved on six points, covering aspects such as tumor grading and staging (including lympho-vascular invasion, perineural invasion, detrusor muscle presence, grading adequacy, and histological classification). A broader statement also reached consensus, indicating that morcellation following ERBT provides specimen of appropriate quality. After revising the statements, the second round resulted in consensus on three more items: morcellated specimens allow for precise staging, evaluation of detrusor muscle invasion, and identification of carcinoma in situ. CONCLUSION: Tissue acquired after ERBT through morcellation permits dependable pathological evaluation, encompassing grading, staging, and identification of critical prognostic indicators such as carcinoma in situ, detrusor muscle, lymph vascular and perineural invasion. Morcellation is not perceived to compromise pathological evaluation based on expert consensus. CI - (c) 2026. The Author(s). FAU - Ventura, Yossi AU - Ventura Y AD - Department of Urology, Rabin Medical Center, Hasharon Hospital, Petah Tikva, Israel. FAU - Morozov, Andrey AU - Morozov A AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Chan, Ronald AU - Chan R AD - Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Combat Faria Tavares, Marcelo AU - Combat Faria Tavares M AD - Pathologic Anatomy Laboratory, Federal University of Minas Gerais (UFMG), Brazilian Company of Hospital Services, Clinical Hospital, Belo Horizonte, MG, Brazil. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, S. H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Tenon Hospital, Sorbonne University, Paris, France. AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI, USA. FAU - Fridman, Eddie AU - Fridman E AD - Department of Diagnostic Pathology, Sheba Medical Center, Ramat Gan, Israel. AD - Gray Faculty of Medical and Health Sciences, Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801, Israel. FAU - Lerner, Julia AU - Lerner J AD - Institute for Clinical Morphology and Digital Pathology, Sechenov University, Moscow, Russia. FAU - Baraban, Ezra AU - Baraban E AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Yakimov, Max AU - Yakimov M AD - Pathology Department, Rabin Medical Center, Petah Tikva, Israel. FAU - Lokshin, Konstantin AU - Lokshin K AD - Kent and Canterbury Hospital, East Kent Hospitals University Foundation, Canterbury, UK. FAU - Lifshitz, David AU - Lifshitz D AD - Department of Urology, Rabin Medical Center, Hasharon Hospital, Petah Tikva, Israel. AD - Gray Faculty of Medical and Health Sciences, Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801, Israel. FAU - Golan, Shay AU - Golan S AD - Department of Urology, Rabin Medical Center, Hasharon Hospital, Petah Tikva, Israel. AD - Gray Faculty of Medical and Health Sciences, Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801, Israel. FAU - Gauhar, Vineet AU - Gauhar V AD - Ng Teng Fong General Hospital (NUHS), Singapore, Singapore. AD - Asian Institute of nephrourology (AINU), Chennai, India. FAU - Herrmann, Thomas R W AU - Herrmann TRW AD - Department of Urology, Spital Thurgau AG, Kantonspital Frauenfeld, Frauenfeld, Switzerland. AD - Division of Urology, Department of Surgical Sciences, Stellenbosch University, Western Cape, Stellenbosch, South Africa. AD - Hannover Medical School, Hannover, Germany. FAU - Shariat, Shahrokh AU - Shariat S AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Urology, Rabin Medical Center, Hasharon Hospital, Petah Tikva, Israel. dvenikeev@gmail.com. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. dvenikeev@gmail.com. AD - Gray Faculty of Medical and Health Sciences, Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801, Israel. dvenikeev@gmail.com. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. dvenikeev@gmail.com. LA - eng PT - Journal Article DEP - 20260508 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Delphi Technique MH - *Urinary Bladder Neoplasms/pathology/surgery MH - *Morcellation MH - *Transurethral Resection of Bladder/methods MH - Neoplasm Staging MH - Consensus MH - Neoplasm Grading MH - *Carcinoma, Transitional Cell/pathology/surgery PMC - PMC13156192 OTO - NOTNLM OT - Bladder tumour OT - Delphi survey OT - ERBT OT - Morcellation OT - Pathology OT - Piece-meal OT - TURBT COIS- Declarations. Conflict of interest: all the authors declare no conflict of interest. EDAT- 2026/05/08 12:37 MHDA- 2026/05/08 12:38 PMCR- 2026/05/08 CRDT- 2026/05/08 11:13 PHST- 2026/03/13 00:00 [received] PHST- 2026/04/29 00:00 [accepted] PHST- 2026/05/08 12:38 [medline] PHST- 2026/05/08 12:37 [pubmed] PHST- 2026/05/08 11:13 [entrez] PHST- 2026/05/08 00:00 [pmc-release] AID - 10.1007/s00345-026-06451-9 [pii] AID - 6451 [pii] AID - 10.1007/s00345-026-06451-9 [doi] PST - epublish SO - World J Urol. 2026 May 8;44(1):351. doi: 10.1007/s00345-026-06451-9. PMID- 42097920 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20260617 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 7 DP - 2026 Jul TI - Sex-based prognostic differences in upper tract urothelial carcinoma: A multicenter cohort study from Taiwan. PG - 323-332 LID - S1078-1439(26)00203-6 [pii] LID - 10.1016/j.urolonc.2026.04.004 [doi] AB - OBJECTIVE: To investigate sex-based differences in oncologic outcomes and prognostic factors in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU) in a large multicenter cohort from Taiwan. METHODS: We retrospectively analyzed 1,337 patients with UTUC (565 men and 772 women) who underwent RNU with bladder cuff excision across 21 hospitals in Taiwan. Survival outcomes, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and bladder recurrence-free survival (BRFS), were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Overlap weighting based on propensity scores was applied to balance baseline characteristics between sexes. Sex-stratified multivariable analyses were further performed to identify prognostic factors in men and women separately. RESULTS: There were no significant sex-based differences in OS, CSS, or DFS. In contrast, female patients had significantly better BRFS than male patients on Kaplan-Meier analysis (P < 0.001), and this association remained significant after overlap weighting adjustment. In multivariable analysis, female sex was independently associated with a lower risk of bladder recurrence after RNU (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.46-0.71; P < 0.001). Established adverse prognostic factors for survival outcomes included poor Eastern Cooperative Oncology Group performance status, advanced pathological stage, lymphovascular invasion, and positive surgical margins. Sex-stratified analyses further showed differences in prognostic profiles between men and women across survival endpoints. CONCLUSIONS: In this large multicenter Taiwanese cohort, sex was not associated with OS, CSS, or DFS after RNU for UTUC. However, female patients had a significantly lower risk of intravesical recurrence, independent of clinicopathological factors. These findings suggest that sex-specific biological or clinical factors may influence bladder recurrence after RNU and support consideration of sex-informed postoperative surveillance strategies. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Chang, Hao-Han AU - Chang HH AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Tsai, Yao-Chou AU - Tsai YC AD - Department of surgery, Taipei Tzu chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan; Department of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei City, Taiwan. FAU - Yu, Chih-Chin AU - Yu CC AD - Department of surgery, Taipei Tzu chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan. FAU - Lin, Wun-Rong AU - Lin WR AD - Department of Urology, MacKay Memorial Hospital Taipei, Taipei, Taiwan; Mackay Medical College Taipei, New Taipei City, Taiwan. FAU - Chen, Marcelo AU - Chen M AD - Department of Urology, MacKay Memorial Hospital Taipei, Taipei, Taiwan; Mackay Medical College Taipei, New Taipei City, Taiwan; Mackay junior College of Medicine, Nursing, and Management, Taipei, Taiwan. FAU - Huang, Chi-Ping AU - Huang CP AD - Department of Urology, China Medical University and Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Tang, Tsz-Yi AU - Tang TY AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Lee, Hsiang Ying AU - Lee HY AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: ashum1009@hotmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260507 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Female MH - Male MH - Taiwan MH - Prognosis MH - Aged MH - Retrospective Studies MH - Sex Factors MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Middle Aged MH - Nephroureterectomy MH - Cohort Studies MH - Disease-Free Survival MH - Neoplasm Recurrence, Local MH - Kaplan-Meier Estimate MH - *Urologic Neoplasms/surgery OTO - NOTNLM OT - Gender OT - Oncologic outcome OT - UTUC COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/08 00:32 MHDA- 2026/06/15 11:32 CRDT- 2026/05/07 21:52 PHST- 2025/11/05 00:00 [received] PHST- 2026/03/05 00:00 [revised] PHST- 2026/04/05 00:00 [accepted] PHST- 2026/06/15 11:32 [medline] PHST- 2026/05/08 00:32 [pubmed] PHST- 2026/05/07 21:52 [entrez] AID - S1078-1439(26)00203-6 [pii] AID - 10.1016/j.urolonc.2026.04.004 [doi] PST - ppublish SO - Urol Oncol. 2026 Jul;44(7):323-332. doi: 10.1016/j.urolonc.2026.04.004. Epub 2026 May 7. PMID- 42092764 OWN - NLM STAT- MEDLINE DCOM- 20260619 LR - 20260813 IS - 1689-1392 (Electronic) IS - 1425-8153 (Print) IS - 1425-8153 (Linking) VI - 31 IP - 1 DP - 2026 May 6 TI - CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion. LID - 10.1186/s11658-026-00936-6 [doi] LID - 84 AB - BACKGROUND: Bladder cancer (BC) can be characterized clinically as either non-muscle-invasive (NMIBC) or muscle-invasive (MIBC). While NMIBC generally has a favorable prognosis, MIBC is characterized by high morbidity and mortality. Understanding the molecular determinants of tumor invasion is critical, yet research is hampered by the limitations of current experimental models. Standard assays such as the Boyden chamber lack physiological complexity, while porcine bladder models suffer from tissue contamination and genetic variability. There is an urgent need for reliable models that mimic the intact tissue architecture. METHODS: We established a unique ex vivo tissue invasion model (EXTIM) to evaluate the invasive capacity of BC cells within a largely intact tissue context, using freshly prepared bladders from mice. The invasiveness of human BC cells (RT4, T24, UMUC3) and the immortal urothelial cell strain (Y235T) was comparably evaluated using EXTIM, the Boyden chamber, and porcine models. Gene knockdown or ectopic expression of GJB3 or ORP3 indicated the suitability of EXTIM to investigate the impact of specific factors on tumor cell invasion. To identify novel genetic regulators of cell invasion, we combined EXTIM with a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 knockout screen. Additionally, we utilized the EXTIM to perform a pharmacological screen of a small molecule library comprising 90 substances to identify compounds capable of suppressing BC cell dissemination. RESULTS: Importantly, by combining EXTIM with genomewide CRISPR-Cas9 screening, we identified several candidate genes involved in BC progression. Notably, discoidin domain receptor tyrosine kinase 1 (DDR1) was identified as a functional inhibitor of tumor cell invasion. Furthermore, the small-molecule screen revealed that PD-156707, a selective antagonist of the endothelin receptor A (ETA), significantly suppresses cancer cell invasion within the EXTIM environment. CONCLUSIONS: EXTIM serves as a robust and physiologically relevant tool for assessing tumor cell invasion and migration under ex vivo conditions. EXTIM can be used to identify factors involved in the progression of invasive BC by high-throughput genetic screenings in an ex vivo organ culture system, by culturing cells after transmigration through the bladder tissue. Moreover, the impact of specific genetic factors in the process of tumor cell dissemination can be assessed by placing bladders from genetically modified mice into the EXTIM. CI - (c) 2026. The Author(s). FAU - Liu, Junnan AU - Liu J AD - Department of Urology, Ulm University Hospital, Ulm, Germany. AD - Department of Urology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. FAU - Jiang, Wencheng AU - Jiang W AD - Department of Urology, Ulm University Hospital, Ulm, Germany. AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA. FAU - Wang, Xue AU - Wang X AD - Department of Urology, Ulm University Hospital, Ulm, Germany. AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA. AD - Mol. Pharmacology and Exp. Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. FAU - Azoitei, Anca AU - Azoitei A AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Liu, Hengchuan AU - Liu H AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Najjar, Gregoire AU - Najjar G AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Liu, Kuangzheng AU - Liu K AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Melzer, Michael Karl AU - Melzer MK AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Stilgenbauer, Stephan AU - Stilgenbauer S AD - Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. FAU - Elati, Mohamed AU - Elati M AD - CANTHER, ONCOLille Institute, University of Lille, CNRS UMR 1277, Inserm U9020, Lille, France. FAU - Burkhalter, Martin D AU - Burkhalter MD AD - Department of Experimental and Clinical Pharmacology and Pharmacogenomics, Section of Pharmacogenomics, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Philipp, Melanie AU - Philipp M AD - Department of Experimental and Clinical Pharmacology and Pharmacogenomics, Section of Pharmacogenomics, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Wezel, Felix AU - Wezel F AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Zengerling, Friedemann AU - Zengerling F AD - Department of Urology, Ulm University Hospital, Ulm, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, Ulm University Hospital, Ulm, Germany. Christian.Bolenz@uniklinik-ulm.de. FAU - Gunes, Cagatay AU - Gunes C AD - Department of Urology, Ulm University Hospital, Ulm, Germany. Cagatay.Guenes@uni-ulm.de. LA - eng PT - Journal Article DEP - 20260506 PL - England TA - Cell Mol Biol Lett JT - Cellular & molecular biology letters JID - 9607427 RN - 0 (Small Molecule Libraries) SB - IM MH - Animals MH - Humans MH - Mice MH - Cell Line, Tumor MH - Cell Movement/drug effects MH - *CRISPR-Cas Systems/genetics MH - Neoplasm Invasiveness MH - *Non-Muscle Invasive Bladder Neoplasms MH - Small Molecule Libraries/pharmacology MH - Swine MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism PMC - PMC13277066 OTO - NOTNLM OT - Bladder cancer OT - CRISPR-Cas9 screening OT - Ex vivo tissue model OT - Invasion OT - MIBC OT - Metastasis OT - NMIBC OT - Small-compound library COIS- Declarations. Ethics approval and consent to participate: All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments. The studies were conducted with the patients' written consent and with the local research ethics committee's approval (approval no. 274/24). Mouse experiments were performed in accordance with the Basel Declaration and have been approved by Ulm University Animal Welfare Committee and adherence to strict German and EU laws (TierSchVersV, 3Rs principles). Consent for publication: Not applicable. Competing interests: All authors disclose no actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within that could inappropriately influence (bias) our work. EDAT- 2026/05/07 06:37 MHDA- 2026/06/19 07:58 PMCR- 2026/05/06 CRDT- 2026/05/07 00:33 PHST- 2025/12/01 00:00 [received] PHST- 2026/04/14 00:00 [accepted] PHST- 2026/06/19 07:58 [medline] PHST- 2026/05/07 06:37 [pubmed] PHST- 2026/05/07 00:33 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 10.1186/s11658-026-00936-6 [pii] AID - 936 [pii] AID - 10.1186/s11658-026-00936-6 [doi] PST - epublish SO - Cell Mol Biol Lett. 2026 May 6;31(1):84. doi: 10.1186/s11658-026-00936-6. PMID- 42088216 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260506 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience. PG - 1683009 LID - 10.3389/fonc.2026.1683009 [doi] LID - 1683009 AB - OBJECTIVE: To evaluate the feasibility, safety, and early oncological outcomes of office-based transurethral laser ablation (TULA) for recurrent non-muscle invasive bladder cancer (NMIBC). METHODS: We retrospectively reviewed 53 patients undergoing their first TULA for recurrent NMIBC at the University Hospital Centre Zagreb from March 2024 to February 2025. Inclusion criteria comprised histologically confirmed NMIBC recurrence suitable for outpatient laser ablation. Exclusion criteria included carcinoma in situ, muscle-invasive disease, prior intravesical therapy, or tumors >3 cm. Procedures were performed under local anesthesia using a holmium-YAG laser. Clinical, procedural, and oncological outcomes were analyzed, with predictors of recurrence assessed via multivariate logistic regression. RESULTS: The median patient age was 68 years, and 54.7% were male. Most tumors were pTa (94.3%) and low-grade (92.5%); 90.6% measured <1 cm. TULA was completed successfully in 94.3% of cases, with minimal peri-procedural complications (1.9%). At 3 months, the recurrence rate was 38.8%. Univariate analysis linked recurrence with older age, higher Charlson Comorbidity Index, and male gender. In multivariate analysis, male gender remained the only independent predictor (aOR 4.29; p=0.034). No patient progressed to muscle-invasive disease. CONCLUSIONS: Office-based TULA is a highly feasible, safe, and cost-effective alternative for selected patients with small recurrent low-grade NMIBC, offering significant procedural and economic advantages over transurethral resection. Although early recurrence rates are notable in this high-risk cohort, oncological safety appears acceptable. Male gender may predict early recurrence, warranting further investigation in larger prospective studies. CI - Copyright (c) 2026 Zimak, Vidovic, Kulis, Hauptman, Hudolin, Bakula and Kastelan. FAU - Zimak, Zoran AU - Zimak Z AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Vidovic, Dominic AU - Vidovic D AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Kulis, Tomislav AU - Kulis T AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia. FAU - Hauptman, Dinko AU - Hauptman D AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia. FAU - Hudolin, Tvrtko AU - Hudolin T AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia. FAU - Bakula, Mirko AU - Bakula M AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia. FAU - Kastelan, Zeljko AU - Kastelan Z AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia. AD - Hrvatska akademija znanosti i umjetnosti, Zagreb, Croatia. LA - eng PT - Journal Article DEP - 20260420 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13135936 OTO - NOTNLM OT - holmium-YAG laser OT - non-muscle invasive bladder cancer OT - outpatient surgery OT - recurrence OT - transurethral laser ablation COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/05/06 06:38 MHDA- 2026/05/06 06:39 PMCR- 2026/04/20 CRDT- 2026/05/06 04:58 PHST- 2025/08/10 00:00 [received] PHST- 2026/03/25 00:00 [revised] PHST- 2026/03/31 00:00 [accepted] PHST- 2026/05/06 06:39 [medline] PHST- 2026/05/06 06:38 [pubmed] PHST- 2026/05/06 04:58 [entrez] PHST- 2026/04/20 00:00 [pmc-release] AID - 10.3389/fonc.2026.1683009 [doi] PST - epublish SO - Front Oncol. 2026 Apr 20;16:1683009. doi: 10.3389/fonc.2026.1683009. eCollection 2026. PMID- 42087419 OWN - NLM STAT- MEDLINE DCOM- 20260910 LR - 20260910 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 20 IP - 9 DP - 2026 Sep TI - Clinical performance of the urine-based TERT promoter AbsoluteQ Digital PCR for non-invasive detection of bladder cancer. PG - 2163-2174 LID - 10.1002/1878-0261.70262 [doi] AB - Bladder cancer (BC) is the ninth most common cancer worldwide, with urothelial carcinoma accounting for approximately 90% of all cases and presenting predominantly as non-muscle-invasive disease. Due to its high recurrence rate and the need for long-term surveillance, BC is associated with the highest lifetime treatment costs per patient among all cancers, making its effective management a significant clinical and economic challenge. The most frequently identified variants in the TERT gene promoter are c.-124C>T (C228T) and c.-146C>T (C250T), located within a region characterized by high guanine-cytosine (GC) content, which makes amplification challenging. We aimed to validate the AbsoluteQ Digital PCR assay for the detection of urine-based TERT promoter variants for the diagnosis of urothelial bladder cancer and to assess its diagnostic performance in comparison with standard methods. Urine samples were collected from patients with histopathologically confirmed bladder cancer (n = 58) and compared with a control group (n = 55). The C228T and C250T variants were tested using the AbsoluteQ Digital PCR assay. Sensitivity, specificity, and predictive values were calculated to evaluate the performance of the assessed method. The AbsoluteQ Digital PCR demonstrated superior diagnostic performance compared to conventional Sanger sequencing for detecting TERT promoter variants, achieving a sensitivity of 89.65% (95% CI: 78.16-95.72) and a specificity of 100% (95% CI: 91.87-100), with no false positives observed. Given its robustness and clinical relevance, AbsoluteQ Digital PCR is emerging as a promising tool for non-invasive molecular diagnostics targeting TERT promoter variants. CI - (c) 2026 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Nykel, Anna AU - Nykel A AUID- ORCID: 0000-0003-1479-334X AD - Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. FAU - Kubiak, Izabela AU - Kubiak I AD - Laboratory of Medical Genetics, R&D Division, GENOS Sp. z o.o., Lodz, Poland. FAU - Rutkowska, Lena AU - Rutkowska L AUID- ORCID: 0000-0003-2120-9842 AD - Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. FAU - Kasprzyk, Zaneta AU - Kasprzyk Z AD - Laboratory of Medical Genetics, R&D Division, GENOS Sp. z o.o., Lodz, Poland. FAU - Kepczynski, Lukasz AU - Kepczynski L AD - Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. FAU - Bednarek, Michal AU - Bednarek M AD - Laboratory of Medical Genetics, R&D Division, GENOS Sp. z o.o., Lodz, Poland. FAU - Sobieraj, Dariusz AU - Sobieraj D AD - Department of Urology and Urological Oncology, John Paul II Podkarpackie Province Hospital in Krosno, Poland. FAU - Wilkosz, Jacek AU - Wilkosz J AD - Second Department of Urology, Medical University of Lodz, Poland. FAU - Kania, Piotr AU - Kania P AD - Department of Urology and Urologic Oncology, Saint John Paul II Mazovian Regional Hospital in Siedlce, Poland. FAU - Jedrzejczyk, Adam AU - Jedrzejczyk A AD - Department of Urology, District Hospital, Radomsko, Poland. FAU - Kaluzewski, Bogdan AU - Kaluzewski B AD - Laboratory of Medical Genetics, R&D Division, GENOS Sp. z o.o., Lodz, Poland. FAU - Gach, Agnieszka AU - Gach A AD - Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. FAU - Kaluzewski, Tadeusz AU - Kaluzewski T AUID- ORCID: 0000-0001-6118-696X AD - Department of Genetics, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. LA - eng GR - RPLD.01.02.01-10-0018/19/European Regional Development Fund/ GR - RPLD.01.02.02-10-0130/19/European Regional Development Fund/ GR - Polish Mother's Memorial Hospital - Research Institute (PMMH-RI)/ PT - Journal Article DEP - 20260505 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 RN - EC 2.7.7.49 (Telomerase) RN - EC 2.7.7.49 (TERT protein, human) SB - IM MH - Humans MH - *Telomerase/genetics/urine MH - *Promoter Regions, Genetic/genetics MH - *Polymerase Chain Reaction/methods MH - *Urinary Bladder Neoplasms/diagnosis/urine/genetics MH - Female MH - Male MH - Aged MH - Middle Aged MH - Sensitivity and Specificity PMC - PMC13398350 OTO - NOTNLM OT - TERT promoter variants OT - bladder cancer OT - digital PCR OT - non-invasive diagnostics COIS- The authors declare no conflicts of interests. EDAT- 2026/05/06 06:38 MHDA- 2026/09/10 11:53 PMCR- 2026/05/05 CRDT- 2026/05/06 01:23 PHST- 2026/02/02 00:00 [revised] PHST- 2025/10/14 00:00 [received] PHST- 2026/04/21 00:00 [accepted] PHST- 2026/09/10 11:53 [medline] PHST- 2026/05/06 06:38 [pubmed] PHST- 2026/05/06 01:23 [entrez] PHST- 2026/05/05 00:00 [pmc-release] AID - MOL270262 [pii] AID - 10.1002/1878-0261.70262 [doi] PST - ppublish SO - Mol Oncol. 2026 Sep;20(9):2163-2174. doi: 10.1002/1878-0261.70262. Epub 2026 May 5. PMID- 42086443 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20260912 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 7 DP - 2026 Jul TI - A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable survival prediction models. PG - 258-271 LID - S1078-1439(26)00113-4 [pii] LID - 10.1016/j.urolonc.2026.03.003 [doi] AB - This systematic review aimed to identify robust clinicopathologic predictors of overall (OS), cancer-specific (CSS), and recurrence-free survival (RFS) following radical cystectomy (RC) from published prediction models. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) recommendations were followed, and the study was registered in PROSPERO (CRD42024509410). MEDLINE (Ovid) and Embase (Elsevier) were searched from inception to January 2024 for studies developing or validating multivariable prediction models in patients undergoing RC for non-metastatic bladder cancer. Data were extracted following the CHARMS checklist, and risk of bias was assessed using the PROBAST (Prediction model Risk Of Bias Assessment) tool. Pooled hazard ratios (HRs) were estimated with DerSimonian-Laird random-effects models. Seventy-seven studies involving survival models met the inclusion criteria: 36 for OS, 44 for CSS, and 26 for RFS. For OS, adverse predictors included advanced age (HR 1.03, 95% confidence interval [CI] 1.02-1.04), gender (female) (HR 1.08, 95% CI 1.01-1.14), higher pathologic T stage, lymph node involvement (HR 1.91, 95% CI 1.70-2.14), lymphovascular invasion (LVI) (HR 1.49, 95% CI 1.40-1.58), positive surgical margins (HR 1.74, 95% CI 1.46-2.06), and concomitant carcinoma in situ (HR 1.09, 95% CI 1.03-1.16). Neoadjuvant (HR 0.66, 95% CI 0.47-0.93) and adjuvant chemotherapy (HR 0.74, 95% CI 0.71-0.76) and compliance with pentafecta criteria (HR 0.49, 95% CI 0.30-0.79) were associated with improved OS. CSS displayed similar prognostic patterns, with additional associations for lymph node density, hydronephrosis, sarcopenia, and elevated neutrophil-lymphocyte ratio. This meta-analysis identified consistent clinicopathologic predictors of adverse oncological outcomes after RC for bladder cancer. Systematic assessment of these variables allows more accurate postoperative prognostic stratification and supports clinical decision-making regarding adjuvant treatment selection, surveillance intensification, and patient counseling. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Artiles Medina, Alberto AU - Artiles Medina A AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. Electronic address: alberc.artiles@gmail.com. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Muriel Garcia, Alfonso AU - Muriel Garcia A AD - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), CIBERESP, University of Alcala, Madrid, Spain. FAU - Dominguez Gutierrez, Ana AU - Dominguez Gutierrez A AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Gomez Dos Santos, Victoria AU - Gomez Dos Santos V AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Alvarez Diaz, Noelia AU - Alvarez Diaz N AD - Library, Hospital Universitario Ramon Y Cajal (IRYCIS), Madrid, Spain. FAU - Tagalos Munoz, Ana AU - Tagalos Munoz A AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Lopez Curtis, David AU - Lopez Curtis D AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Minguez Ojeda, Cesar AU - Minguez Ojeda C AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - de la Parra Sanchez, Irene AU - de la Parra Sanchez I AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Crespo, Luis AU - Crespo L AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Coloma Del Peso, Almudena AU - Coloma Del Peso A AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Burgos Revilla, Francisco Javier AU - Burgos Revilla FJ AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260505 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Transl Androl Urol. 2026 Aug 31;15(8):260. doi: 10.21037/tau-2026-0481. PMID: 42729131 MH - Humans MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - *Cystectomy/methods MH - Prognosis OTO - NOTNLM OT - Cystectomy OT - Nomograms OT - Prognosis OT - Survival OT - Urinary bladder neoplasms COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/06 00:33 MHDA- 2026/06/13 06:38 CRDT- 2026/05/05 21:53 PHST- 2026/01/16 00:00 [received] PHST- 2026/03/08 00:00 [revised] PHST- 2026/03/22 00:00 [accepted] PHST- 2026/06/13 06:38 [medline] PHST- 2026/05/06 00:33 [pubmed] PHST- 2026/05/05 21:53 [entrez] AID - S1078-1439(26)00113-4 [pii] AID - 10.1016/j.urolonc.2026.03.003 [doi] PST - ppublish SO - Urol Oncol. 2026 Jul;44(7):258-271. doi: 10.1016/j.urolonc.2026.03.003. Epub 2026 May 5. PMID- 42086351 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260820 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 33 IP - 2 DP - 2026 Apr 15 TI - Overweight status predicts improved overall survival after radical nephroureterectomy for upper tract urothelial carcinoma. PG - 325-337 LID - 10.32604/cju.2025.069390 [doi] AB - INTRODUCTION: Upper urinary tract urothelial carcinoma (UTUC) is a rare malignancy, particularly in the ureter, and is associated with high rates of recurrence and metastasis. Although body mass index (BMI) has been associated with prognosis in multiple cancer types, its role as a predictive factor in UTUC is still debated. This study aimed to investigate how BMI influences survival outcomes in patients with UTUC treated with radical nephroureterectomy (RNU). METHODS: This multi-center retrospective analysis by the Taiwan UTUC Collaboration Group involved 2503 patients who underwent treatment across 19 hospitals from 1988 to 2022. Patients were categorized into normal (18.5 /= 27) groups. Demographic, clinical, and pathological data were analyzed. Overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IVRFS) were assessed using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: The median follow-up period was 44.2 months. In multivariable analysis, overweight patients demonstrated significantly better OS compared with normal-weight patients (p = 0.033), and the obesity group showed a favorable, though not statistically significant, trend toward better OS. However, BMI was not an independent predictor of CSS, DFS, or IVRFS. Independent predictors of worse outcomes included older age, end-stage renal disease, ureteral tumor location, tumor size >/=3 cm, and high-grade urothelial carcinoma. Tumor stage and grade were comparable across BMI groups. CONCLUSIONS: Overweight status was associated with better OS in patients with UTUC treated with RNU, while BMI had no significant impact on CSS, DFS, or IVRFS. These findings suggest a potential protective effect of higher BMI on OS, warranting further investigation in prospective studies. However, BMI alone should not guide clinical decisions and may instead reflect broader patient health characteristics. CI - Copyright (c) 2026 The Authors. Published by Tech Science Press. FAU - Wu, Shu-Yu AU - Wu SY AD - Department of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan. AD - Department of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. FAU - Huang, Kuan-Hua AU - Huang KH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, 710, Taiwan. AD - Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan, 711, Taiwan. FAU - Liu, Chien-Liang AU - Liu CL AD - Division of Urology, Division of Urological Oncology, Department of Surgery, Chi-Mei Medical Center, Tainan, 710, Taiwan. AD - Chia Nan University of Pharmacy and Science, Tainan, 717, Taiwan. FAU - Wang, Shian-Shiang AU - Wang SS AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, 407, Taiwan. AD - Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan. AD - Department of Applied Chemistry, National Chi Nan University, Nantou, 545, Taiwan. FAU - Li, Jian-Ri AU - Li JR AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, 407, Taiwan. AD - Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan. FAU - Weng, Han-Yu AU - Weng HY AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. FAU - Tai, Ta-Yao AU - Tai TY AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. FAU - Chen, Pi-Che AU - Chen PC AD - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, 600, Taiwan. FAU - Cheong, Ian-Seng AU - Cheong IS AD - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, 600, Taiwan. FAU - Tsai, Chung-You AU - Tsai CY AD - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan. AD - Department of Electrical Engineering, Yuan Ze University, Taoyuan, 320, Taiwan. FAU - Cheng, Pai-Yu AU - Cheng PY AD - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan. AD - Department of Biomedical Engineering, National Taiwan University, Taipei, 106, Taiwan. FAU - Hong, Jian-Hua AU - Hong JH AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, 106, Taiwan. AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan. FAU - Chen, Chung-Hsin AU - Chen CH AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan. FAU - Tseng, Jen-Shu AU - Tseng JS AD - Department of Urology, MacKay Memorial Hospital, Taipei, 104, Taiwan. AD - Mackay Medical College, Taipei, 252, Taiwan. AD - Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. FAU - Lin, Wun-Rong AU - Lin WR AD - Department of Urology, MacKay Memorial Hospital, Taipei, 104, Taiwan. AD - Mackay Medical College, Taipei, 252, Taiwan. FAU - Jiang, Yuan-Hong AU - Jiang YH AD - Department of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan. AD - Department of Urology, Hualien Tzu Chi Hospital, Tzu Chi Medical Foundation, Hualien, 970, Taiwan. FAU - Lee, Yu-Khun AU - Lee YK AD - Department of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan. AD - Department of Urology, Hualien Tzu Chi Hospital, Tzu Chi Medical Foundation, Hualien, 970, Taiwan. FAU - Lin, Po-Hung AU - Lin PH AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan. AD - Graduate Institute of Clinical Medical Science, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan. AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan. FAU - Pang, See-Tong AU - Pang ST AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan. FAU - Chen, Yung-Tai AU - Chen YT AD - Department of Urology, Taiwan Adventist Hospital, Taipei, 105, Taiwan. FAU - Chen, Wei-Chieh AU - Chen WC AD - Department of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan. FAU - Wu, Chia-Chang AU - Wu CC AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 235, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan. AD - TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei, 110, Taiwan. FAU - Hsueh, Thomas Y AU - Hsueh TY AD - Division of Urology, Department of Surgery, Taipei City Hospital, Taipei, 103, Taiwan. AD - Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. FAU - Huang, Hsu-Che AU - Huang HC AD - Division of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City, 231, Taiwan. AD - Department of Life Science, College of Science, National Taiwan Normal University, Taipei, 106, Taiwan. FAU - Lin, Wei-Yu AU - Lin WY AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, 613, Taiwan. AD - Chang Gung University of Science and Technology, Chiayi, 613, Taiwan. AD - Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan. FAU - Yu, Chia-Cheng AU - Yu CC AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, 813, Taiwan. FAU - Fang, Jen-Kai AU - Fang JK AD - Department of Urology, China Medical University Hospital, Taichung, 404, Taiwan. FAU - Yu, Chih-Chin AU - Yu CC AD - Department of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan. AD - Department of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan. FAU - Tsai, Yao-Chou AU - Tsai YC AD - Department of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan. AD - Department of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan. AD - Department of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan. LA - eng GR - TCMF-JCT-113-09/Buddhist Tzu Chi Medical Foundation/ GR - TCRD-TPE-112-12/Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation/ GR - TCRD-TPE-113-32/Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation/ PT - Journal Article PT - Multicenter Study DEP - 20260415 PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Female MH - Male MH - *Ureteral Neoplasms/surgery/mortality/complications MH - Retrospective Studies MH - *Overweight/complications MH - *Carcinoma, Transitional Cell/surgery/mortality/complications MH - Aged MH - *Kidney Neoplasms/surgery/mortality/complications MH - Body Mass Index MH - Middle Aged MH - Survival Rate MH - Prognosis MH - Taiwan/epidemiology OTO - NOTNLM OT - Urothelial cancer OT - body mass index OT - oncological outcomes OT - radical nephroureterectomy OT - upper urinary tract urothelial carcinoma COIS- The authors declare no conflicts of interest to report. EDAT- 2026/05/06 00:35 MHDA- 2026/05/06 00:36 CRDT- 2026/05/05 21:33 PHST- 2025/06/22 00:00 [received] PHST- 2025/12/16 00:00 [accepted] PHST- 2026/05/06 00:36 [medline] PHST- 2026/05/06 00:35 [pubmed] PHST- 2026/05/05 21:33 [entrez] AID - 10.32604/cju.2025.069390 [doi] PST - epublish SO - Can J Urol. 2026 Apr 15;33(2):325-337. doi: 10.32604/cju.2025.069390. PMID- 42086287 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 1365-2559 (Electronic) IS - 0309-0167 (Print) IS - 0309-0167 (Linking) VI - 89 IP - 2 DP - 2026 Aug TI - Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E-cadherin, P120, HER2 and TRPS1. PG - 338-346 LID - 10.1111/his.70172 [doi] AB - AIMS: Plasmacytoid urothelial carcinoma (PUC) is an aggressive morphological subtype characterized by discohesive single-cell infiltration and frequent loss of epithelial adhesion. Although p63 is widely regarded as a reliable urothelial lineage marker in conventional urothelial carcinoma, its expression may be reduced or absent in plasmacytoid tumours, creating an important diagnostic pitfall. This multi-institutional study aimed to characterize the clinicopathological and immunohistochemical profile of PUC, with particular emphasis on p63 immunoreactivity and its relationship to adhesion-related markers and other diagnostically relevant immunophenotypes. METHODS AND RESULTS: A total of 93 cases initially diagnosed as PUC were retrospectively reviewed across multiple centres. After histopathological re-evaluation, 70 confirmed cases were included. Immunohistochemical analysis was performed for p63, e-cadherin, p120 catenin, TRPS1, HER2/Neu. The cohort comprised 70 patients with a median age of 66.5 years (IQR, 59.8-72.0) and a strong male predominance of 85.7% (60/70). Most specimens were obtained from transurethral resections (64.3%, 45/70) and radical cystectomy specimens (34.3%, 24/70). The median tumour size was 3.0 cm (IQR, 1.0-5.0), and the median proportion of plasmacytoid differentiation was 80% (IQR, 20-100). Morphologically, tumours were classified as classic plasmacytoid in 65.7% (46/70), pleomorphic in 22.9% (16/70) and desmoplastic in 11.4% (8/70). Concurrent variant histology was identified in 21.4% (15/70), most commonly micropapillary (12.9%, 9/70) and sarcomatoid (7.1%, 5/70) components. Lymphovascular invasion was present in 51.4% (36/70), and concomitant carcinoma in situ was detected in 35.7% (25/70). Immunohistochemically, p63 expression was retained in only 10.0% of tumours (7/70). HER2 membranous overexpression was observed in 58.6% (41/70), while loss of E-cadherin expression was highly prevalent (84.3%, 59/70). Aberrant p120 catenin expression was common, with cytoplasmic localization in 72.9% (51/70) and complete loss in 17.1% (12/70). TRPS1 immunostaining was available in 54 tumours and was negative in 92.6% of evaluable cases (50/54). CONCLUSION: PUC demonstrates a distinctive immunophenotype characterized by frequent loss of p63 and disruption of the e-cadherin/p120 adhesion complex. Recognition of p63 attenuation, together with adhesion-related markers and HER2 status, provides a useful diagnostic framework for distinguishing this aggressive subtype from conventional urothelial carcinoma and its mimickers. CI - (c) 2026 The Author(s). Histopathology published by John Wiley & Sons Ltd. FAU - Yaprak Bayrak, Busra AU - Yaprak Bayrak B AUID- ORCID: 0000-0002-0537-3127 AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Kosemehmetoglu, Kemal AU - Kosemehmetoglu K AUID- ORCID: 0000-0002-7747-0460 AD - Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkey. FAU - Ozbek, Busra AU - Ozbek B AUID- ORCID: 0000-0002-4221-0845 AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Simsek, Sercan AU - Simsek S AUID- ORCID: 0000-0002-9875-8228 AD - Department of Pathology, Kutahya Evliya Celebi Research and Training Hospital, Kutahya, Turkey. FAU - Oktay, Murat AU - Oktay M AUID- ORCID: 0000-0002-0893-4444 AD - Department of Pathology, Memorial Sisli Hospitals Group, Istanbul, Turkey. FAU - Coban, Ganime AU - Coban G AUID- ORCID: 0000-0002-5779-6797 AD - Department of Pathology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkey. FAU - Arslan Kahraman, Dilara Irem AU - Arslan Kahraman DI AUID- ORCID: 0000-0003-0251-9597 AD - Department of Pathology, Ankara Etlik City Hospital, Ankara, Turkey. FAU - Akincioglu, Egemen AU - Akincioglu E AUID- ORCID: 0000-0003-1973-1279 AD - Department of Pathology, Gulhane Research and Training Hospital, Ankara, Turkey. FAU - Buyukgok, Melek AU - Buyukgok M AUID- ORCID: 0009-0007-0156-0105 AD - Department of Pathology, School of Medicine, Dokuz Eylul University, Izmir, Turkey. FAU - Colak, Selin AU - Colak S AUID- ORCID: 0009-0002-2395-8206 AD - Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkey. FAU - Dogan, Hatice Nese AU - Dogan HN AUID- ORCID: 0009-0009-7411-6720 AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Gurel, Burak AU - Gurel B AUID- ORCID: 0009-0001-7281-6039 AD - Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Kabul, Selva AU - Kabul S AUID- ORCID: 0000-0001-7864-6694 AD - Department of Pathology, School of Medicine, Bursa Uludag University, Bursa, Turkey. FAU - Karaca, Kerem AU - Karaca K AUID- ORCID: 0009-0000-5672-4743 AD - Department of Pathology, School of Medicine, Akdeniz University, Antalya, Turkey. FAU - Ozsagir, Elif AU - Ozsagir E AUID- ORCID: 0000-0002-9851-9227 AD - Department of Pathology, Sakarya Research and Training Hospital, Sakarya, Turkey. FAU - Ozturk, Ece AU - Ozturk E AUID- ORCID: 0000-0001-6051-057X AD - Department of Pathology, School of Medicine, Acibadem University, Ankara, Turkey. FAU - Toru, Havva Serap AU - Toru HS AUID- ORCID: 0000-0002-4438-0434 AD - Department of Pathology, School of Medicine, Akdeniz University, Antalya, Turkey. FAU - Turan, Gupse AU - Turan G AUID- ORCID: 0000-0002-4207-2833 AD - Department of Pathology, Kocaeli City Hospital, Kocaeli, Turkey. FAU - Yildirim, Nazif Alperen AU - Yildirim NA AUID- ORCID: 0009-0007-8803-5468 AD - Department of Pathology, Gulhane Research and Training Hospital, Ankara, Turkey. FAU - Yildiz, Ozlem Nur AU - Yildiz ON AUID- ORCID: 0009-0003-0881-5677 AD - Department of Pathology, Kocaeli State Hospital, Kocaeli, Turkey. FAU - Karabulut, Yasemin Yuyucu AU - Karabulut YY AUID- ORCID: 0000-0001-6619-6868 AD - Department of Pathology, School of Medicine, Mersin University, Mersin, Turkey. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Providence, Rhode Island, USA. FAU - Akgul, Mahmut AU - Akgul M AUID- ORCID: 0000-0003-0929-0940 AD - Department of Pathology, School of Medicine, Atlas University, Istanbul, Turkey. AD - Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260505 PL - England TA - Histopathology JT - Histopathology JID - 7704136 RN - 0 (Cadherins) RN - 0 (Biomarkers, Tumor) RN - 0 (Catenins) RN - 0 (Delta Catenin) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - 0 (CTNND1 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Transcription Factors) RN - 0 (CKAP4 protein, human) RN - 0 (DNA-Binding Proteins) SB - IM MH - Humans MH - Male MH - Female MH - Cadherins/metabolism/biosynthesis MH - Aged MH - Middle Aged MH - *Biomarkers, Tumor/analysis/metabolism MH - Immunohistochemistry MH - Catenins/metabolism/biosynthesis MH - *Carcinoma, Transitional Cell/pathology/metabolism MH - *Urinary Bladder Neoplasms/pathology/metabolism MH - Delta Catenin MH - Erb-b2 Receptor Tyrosine Kinases/metabolism/biosynthesis MH - Retrospective Studies MH - *Membrane Proteins/metabolism MH - Transcription Factors MH - DNA-Binding Proteins/metabolism PMC - PMC13341038 OTO - NOTNLM OT - HER2 OT - TRPS1 OT - e-cadherin OT - immunohistochemistry OT - p120 catenin OT - p63 OT - plasmacytoid urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2026/05/06 00:32 MHDA- 2026/07/08 12:56 PMCR- 2026/07/07 CRDT- 2026/05/05 20:52 PHST- 2026/03/06 00:00 [revised] PHST- 2026/02/11 00:00 [received] PHST- 2026/04/27 00:00 [accepted] PHST- 2026/07/08 12:56 [medline] PHST- 2026/05/06 00:32 [pubmed] PHST- 2026/05/05 20:52 [entrez] PHST- 2026/07/07 00:00 [pmc-release] AID - HIS70172 [pii] AID - 10.1111/his.70172 [doi] PST - ppublish SO - Histopathology. 2026 Aug;89(2):338-346. doi: 10.1111/his.70172. Epub 2026 May 5. PMID- 42083993 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260505 LR - 20260813 IS - 2980-1478 (Electronic) IS - 2980-1478 (Linking) VI - 52 DP - 2026 Apr 10 TI - Targeting Human Epidermal Growth Factor Receptor 2 in Bladder Cancer: Evaluating Its Role as a More Robust Clinicopathological Biomarker Compared to Programmed Death Ligand 1 Expression. PG - 1-6 LID - 10.5152/tud.2026.25061 [doi] LID - e25061 AB - Objective: This retrospective cross-sectional analytical study evaluated the clinicopathological associations of programmed death ligand 1 (PD-L1) and human epidermal growth factor receptor 2 (HER2/neu) expression in 250 patients with urothelial carcinoma of the urinary bladder, with particular emphasis on their relationship to tumor stage and lymph node involvement. METHODS: A retrospective observational study was conducted on 250 patients with urothelial carcinoma who underwent immunohistochemical evaluation of PD-L1, using a tumor proportion score (TPS) of >/=1%, and HER2/neu with 3+ considered positive. Formalin-fixed paraffin-embedded tissue from transurethral resection of bladder tumor and cystectomy specimens was analyzed by immunohistochemistry. The HER2/ neu was scored using a standard 0-3+ system, and PD-L1 expression was assessed by TPS. Associations were tested using chi-square or Fisher's exact tests. Multivariable logistic regression evaluated whether HER2/neu independently predicted nodal involvement after adjustment for age, sex, tumor stage, and morphology. Statistical significance was set at P < .05. RESULTS: The HER2/neu 3+ positivity was present in 100/250 patients (40%) and was significantly associated with nodal involvement (P = .019). On multivariable logistic regression, HER2/neu is independently associated with nodal involvement, reflecting aggressive tumor biology (adjusted OR 2.41; 95% CI 1.33-4.36; P = .004). Among node-negative patients (N0, n = 200), 35.5% were HER2/neu positive, rising stepwise to 50.0% in N1, 54.5% in N2, and 71.4% in N3 disease, supporting a relationship between HER2/ neu overexpression and nodal progression. In contrast, PD-L1 positivity (TPS >/=1%) was observed in 129/250 patients (51.6%) and was not significantly associated with age, sex, tumor stage, nodal status, grade, multiplicity, or morphology (all P > .05). CONCLUSION: The HER2/neu was an independent clinicopathological biomarker associated with nodal involvement and aggressive tumor biology in urothelial carcinoma. PD-L1 showed limited clinicopathological utility in this cohort, though it retains predictive value for immune checkpoint inhibitor therapy. Cite this article as: Mittal A, Malhotra K, Panwar V, Kishore S, Taher M, Singhal A. Targeting human epidermal growth factor receptor 2 in bladder cancer: evaluating its role as a more robust clinicopathological biomarker compared to programmed death ligand 1 expression. Urol Res Pract. 2026, 52, 0061, doi: 10.5152/tud.2026.25061. FAU - Mittal, Ankur AU - Mittal A AD - Department of Urology, AIIMS Rishikesh, India. FAU - Malhotra, Kunal AU - Malhotra K AD - Department of Urology, AIIMS Rishikesh, India. FAU - Panwar, Vikas AU - Panwar V AD - Department of Urology, AIIMS Rishikesh, India. FAU - Kishore, Sanjeev AU - Kishore S AD - Department of Pathology, AIIMS Rishikesh, India. FAU - Taher, Mohammed AU - Taher M AD - Department of Urology, AIIMS Rishikesh, India. FAU - Singhal, Avin AU - Singhal A AD - Department of Urology, AIIMS Rishikesh, India. LA - eng PT - Journal Article DEP - 20260410 PL - Turkey TA - Urol Res Pract JT - Urology research & practice JID - 9918608789006676 PMC - PMC13174960 COIS- Declaration of Interests: The authors have no conflicts of interest to declare. EDAT- 2026/05/05 12:36 MHDA- 2026/05/05 12:37 PMCR- 2026/04/10 CRDT- 2026/05/05 06:23 PHST- 2026/04/10 00:00 [received] PHST- 2026/05/05 12:37 [medline] PHST- 2026/05/05 12:36 [pubmed] PHST- 2026/05/05 06:23 [entrez] PHST- 2026/04/10 00:00 [pmc-release] AID - urp-52-1-25061 [pii] AID - 10.5152/tud.2026.25061 [doi] PST - epublish SO - Urol Res Pract. 2026 Apr 10;52:1-6. doi: 10.5152/tud.2026.25061. PMID- 42081487 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260813 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 136 IP - 12 DP - 2026 Jun 15 TI - Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guerin vaccine in high-risk bladder cancer. LID - 10.1172/JCI200442 [doi] LID - e200442 AB - BACKGROUNDPrimary therapy for high-risk bladder cancer (BCa) is repeated instillations of the tuberculosis vaccine Bacillus Calmette-Guerin (BCG). Although BCG reduces the risk of recurrence by more than half, the mechanisms underlying its immune-activating effects remain unknown. Our objective was to investigate how the immune response differs between BCG responders and nonresponders and to compare systemic and local immune responses.METHODSWe performed scRNA-seq of isolated immune cells adjacent to high-risk bladders in BCG responders and nonresponders before and after BCG. We also compared concurrent scRNA-seq profiles of circulating immune cell populations with those of bladder immune cells.RESULTSWe observed an increase in Th17-like Th1 cells in BCG responders, characterized by greater expression of proinflammatory cytokines. By contrast, nonresponders showed increased CD8+ T cell exhaustion and Treg cells. We found that the primary mechanism driving divergent T cell activity is altered polarization and immunosuppressive signaling with myeloid cells. Using a machine learning-based approach, we identified that Th17-like Th1 cytokines, such as IL-17, IL-21, and IL-26, are predictive of response, which was subsequently validated in a separate BCG-treated BCa cohort.CONCLUSIONTogether, these findings suggest that dynamic regulation of myeloid-T cell interactions can be critical for outcomes of BCG-treated BCa.FUNDINGBX005599 and BX003692 (Veterans Health Administration), HT94252410507 (Department of Defense), R01CA298333 (National Cancer Institute), and Robert H. Lurie Comprehensive Cancer Center H Foundation Core Facility Pilot Project Award. FAU - Brown, Ryan J AU - Brown RJ AD - Department of Microbiology and Immunology and. AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. AD - Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. FAU - Khan, Mairah T AU - Khan MT AD - Department of Urology and. AD - Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Houston, Andrew J AU - Houston AJ AD - Department of Urology and. AD - Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Niu, Hongshen AU - Niu H AD - Department of Microbiology and Immunology and. AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Podojil, Joseph R AU - Podojil JR AD - Department of Microbiology and Immunology and. FAU - Choy, Bonnie AU - Choy B AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Cui, Weiguo AU - Cui W AD - Department of Microbiology and Immunology and. AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology and. AD - Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. AD - Jesse Brown Department of Veterans Affairs Medical Center, Chicago, Illinois, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260421 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/pathology/therapy MH - *BCG Vaccine/administration & dosage/immunology MH - *Macrophages/immunology/pathology MH - Female MH - *T-Lymphocytes, Regulatory/immunology/pathology MH - Male MH - *Th1 Cells/immunology/pathology MH - *Th17 Cells/immunology/pathology MH - Aged PMC - PMC13262731 OTO - NOTNLM OT - Adaptive immunity OT - Immunology OT - Oncology OT - Tuberculosis OT - Urology COIS- JJM participated in a Data and Safety Monitoring Board for Medscape and advisory boards or consulting for Merck, AstraZeneca, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring, CG Oncology, Immunity Bio, Protara, and Photocure. EDAT- 2026/05/04 18:33 MHDA- 2026/06/15 12:52 PMCR- 2026/04/21 CRDT- 2026/05/04 13:33 PHST- 2025/09/19 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/06/15 12:52 [medline] PHST- 2026/05/04 18:33 [pubmed] PHST- 2026/05/04 13:33 [entrez] PHST- 2026/04/21 00:00 [pmc-release] AID - 200442 [pii] AID - 10.1172/JCI200442 [doi] PST - epublish SO - J Clin Invest. 2026 Apr 21;136(12):e200442. doi: 10.1172/JCI200442. eCollection 2026 Jun 15. PMID- 42077394 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260922 IS - 2768-2811 (Electronic) IS - 2768-2811 (Linking) VI - 5 IP - 5 DP - 2026 May TI - Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis. PG - e70141 LID - 10.1002/jex2.70141 [doi] LID - e70141 AB - Bladder cancer (BCa) exhibits molecular heterogeneity that complicates early diagnosis and prognosis, and drives confounding clinical outcomes. Non-muscle invasive and muscle-invasive subtypes, especially for intermediate to high grade, carry a 25%-50% progression-free survival rate, underscoring the need for high-precision prognostic strategy. Urinary extracellular vesicles (uEVs) are promising carriers of tumour-derived RNAs and proteins. However, significant challenges in studying uEVs arise from the diverse cellular origin of uEVs associated with the dynamic composition of urine, which presents roadblocks for developing the clinical utility of uEVs. We developed an AI-driven EV liquid biopsy pipeline that integrates (1) standardised EV isolation via NanoPom magnetic beads, (2) transcriptomic profiling for molecular subtyping and (3) prognostic scoring algorithm. In a discovery cohort of 16 BCa patients including both muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), we compared NanoPom isolated uEVs with ExoEasy and Fujifilm MagCapture isolated uEVs, for identifying BCa subtype-specific gene signatures, and externally validated them using UCSC Xena. The result outperformed currently reported BCa diagnostic biomarkers from assays including Galeas, CxBladder and Xpert. In a validation cohort composed of seven individuals with MIBC, NMIBC and healthy individuals, we confirmed with plasma-derived EVs for correlating with uEV biomarkers from NGS sequencing. The prognostic score stratified patients into low-, intermediate- and high-grade risk groups based on Xena's BCa survival outcomes. Our AI-driven uEV liquid biopsy pipeline proves the concept for high precision BCa subtyping and prognosis, which could potentially facilitate treatment decision and lead to advanced profiling of bladder tumour biology using uEV liquid biopsy. CI - (c) 2026 The Author(s). Journal of Extracellular Biology published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles. FAU - Greenberg, Zachary F AU - Greenberg ZF AUID- ORCID: 0000-0001-9626-2694 AD - Department of Pharmaceutics College of Pharmacy University of Florida Gainesville Florida USA. FAU - Hutchinson, Tarun AU - Hutchinson T AD - Department of Pediatrics College of Medicine University of Florida Gainesville Florida USA. FAU - Kahn, Jonathan AU - Kahn J AD - Department of Computer and Information Science and Engineering Herbert Wertheim College of Engineering University of Florida Gainesville Florida USA. FAU - Graim, Kiley S AU - Graim KS AD - Department of Computer and Information Science and Engineering Herbert Wertheim College of Engineering University of Florida Gainesville Florida USA. FAU - O'Malley, Padraic AU - O'Malley P AD - Department of Urology College of Medicine University of Florida Gainesville Florida USA. AD - University of Florida Health Cancer Institute Gainesville Florida USA. FAU - He, Mei AU - He M AUID- ORCID: 0000-0001-5316-9326 AD - Department of Pharmaceutics College of Pharmacy University of Florida Gainesville Florida USA. AD - University of Florida Health Cancer Institute Gainesville Florida USA. LA - eng GR - R01 CA265907/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20260430 PL - United States TA - J Extracell Biol JT - Journal of extracellular biology JID - 9918382980506676 UOF - medRxiv. 2025 Oct 17:2025.10.14.25338041. doi: 10.1101/2025.10.14.25338041. PMID: 41282769 PMC - PMC13132343 OTO - NOTNLM OT - bladder cancer OT - liquid biopsy OT - subtype OT - urinary extracellular vesicles COIS- The authors declare no conflicts of interest. EDAT- 2026/05/04 12:34 MHDA- 2026/05/04 12:35 PMCR- 2026/04/30 CRDT- 2026/05/04 06:15 PHST- 2025/09/28 00:00 [received] PHST- 2026/02/12 00:00 [revised] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/05/04 12:35 [medline] PHST- 2026/05/04 12:34 [pubmed] PHST- 2026/05/04 06:15 [entrez] PHST- 2026/04/30 00:00 [pmc-release] AID - JEX270141 [pii] AID - 10.1002/jex2.70141 [doi] PST - epublish SO - J Extracell Biol. 2026 Apr 30;5(5):e70141. doi: 10.1002/jex2.70141. eCollection 2026 May. PMID- 42075575 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 62 IP - 4 DP - 2026 Apr 7 TI - Positron Emission Tomography/Computed Tomography in Bladder Cancer: The Role of [(18)F]FDG and Non-FDG Radiotracers. LID - 10.3390/medicina62040703 [doi] LID - 703 AB - Background and Objectives: Bladder cancer is one of the most common malignancies of the urinary tract and poses a significant clinical challenge due to its biological heterogeneity and high rates of recurrence and progression. Urothelial carcinoma represents the predominant histological subtype, ranging from non-muscle-invasive disease with relatively favorable outcomes to aggressive muscle-invasive and metastatic forms associated with poor prognosis. Accurate diagnosis, staging, prognostic stratification, and assessment of treatment response are therefore essential for optimal patient management. The objective of this review is to summarize and critically evaluate the current evidence on the role of positron emission tomography/computed tomography (PET/CT) in bladder cancer, with particular emphasis on [(18)F]FDG PET/CT and non-FDG radiotracers. Materials and Methods: A narrative review of the available literature was performed, focusing on clinical studies, review articles, and guideline documents addressing the use of PET/CT in bladder cancer. The literature search included articles published between 2000 and 2025, while earlier landmark studies were selectively included if considered historically important for understanding the development of PET/CT imaging in bladder cancer. The initial search yielded over 500 records; after screening titles and abstracts, more than 100 articles were selected for full-text evaluation. The analyzed evidence encompasses the clinical applications of [(18)F]FDG PET/CT and alternative radiotracers, including choline-, acetate-, methionine-, and sodium fluoride-based tracers, and fibroblast activation protein inhibitors (FAPI), across different stages of disease and clinical settings. Results: Conventional imaging modalities, such as computed tomography and magnetic resonance imaging, provide important anatomical information but remain limited in the evaluation of lymph node involvement, early metastatic disease, treatment response, and disease recurrence. Despite limitations related to physiological urinary excretion, [(18)F]FDG PET/CT has demonstrated clinical value in selected scenarios, particularly for staging, prognostic assessment, detection of recurrence, and response evaluation. To overcome FDG-related constraints, several non-FDG radiotracers have been investigated. Among these, FAPI PET/CT has emerged as a promising modality due to its ability to target the tumor stroma, potentially improving lesion detectability and tumor-to-background contrast. Conclusions: This review summarizes and critically evaluates current evidence on the role of PET/CT in bladder cancer, with a focus on [(18)F]FDG PET/CT and non-FDG radiotracers. The discussed studies highlight their applications in primary diagnosis, staging, prognostic assessment, detection of recurrence, and evaluation of treatment response, as well as their respective advantages and limitations. Furthermore, potential future directions for PET/CT imaging in clinical practice are outlined, emphasizing the need for further research to clarify the optimal use of established and emerging radiotracers. FAU - Falinska, Hanna AU - Falinska H AD - Military Institute of Medicine-National Research Institute, Department of Nuclear Medicine, Szaserow 128, 04-141 Warsaw, Poland. AD - Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland. FAU - Witkowska-Patena, Ewa AU - Witkowska-Patena E AD - Military Institute of Medicine-National Research Institute, Department of Nuclear Medicine, Szaserow 128, 04-141 Warsaw, Poland. AD - Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland. FAU - Krzyzanowska, Karolina AU - Krzyzanowska K AD - Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland. FAU - Dziuk, Miroslaw AU - Dziuk M AD - Military Institute of Medicine-National Research Institute, Department of Nuclear Medicine, Szaserow 128, 04-141 Warsaw, Poland. AD - Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20260407 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - *Positron Emission Tomography Computed Tomography/methods/standards MH - *Urinary Bladder Neoplasms/diagnostic imaging MH - *Fluorodeoxyglucose F18/therapeutic use MH - Radiopharmaceuticals/therapeutic use MH - Prognosis MH - Neoplasm Staging/methods PMC - PMC13117931 OTO - NOTNLM OT - FAPI OT - PET/CT OT - [18F]FDG PET/CT OT - bladder cancer COIS- Author Hanna Falinska, Ewa Witkowska-Patena, Karolina Krzyzanowska and Miroslaw Dziuk were employed by the company Affidea Poland. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/05/04 06:32 MHDA- 2026/05/04 06:33 PMCR- 2026/04/07 CRDT- 2026/05/04 01:18 PHST- 2026/01/25 00:00 [received] PHST- 2026/03/14 00:00 [revised] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/05/04 06:33 [medline] PHST- 2026/05/04 06:32 [pubmed] PHST- 2026/05/04 01:18 [entrez] PHST- 2026/04/07 00:00 [pmc-release] AID - medicina62040703 [pii] AID - medicina-62-00703 [pii] AID - 10.3390/medicina62040703 [doi] PST - epublish SO - Medicina (Kaunas). 2026 Apr 7;62(4):703. doi: 10.3390/medicina62040703. PMID- 42074918 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 8 DP - 2026 Apr 19 TI - The Burden of Worry: Fear of Cancer Recurrence Across Bladder Cancer Survivorship Phases-A Cross-Sectional Analysis. LID - 10.3390/jcm15083116 [doi] LID - 3116 AB - Objective: To characterize the distribution of FCR severity across survivorship time intervals in bladder cancer survivors. Methods: A cross-sectional study of 79 patients utilized the validated 9-item FCR Inventory-Short Form (FCRI-SF) to assess overall FCR severity. Primary analysis employed Spearman's correlation coefficient to evaluate the relationship between time elapsed since the first procedure and total FCR scores. Patients were stratified into four temporal groups (<1, 1-2, 2-5, and >5 years). Inter-group variability in FCR scores was assessed using Levene's test for equality of variances. Subgroup analyses compared FCR scores across clinical subgroups, including tumor grade and smoking history, using the Mann-Whitney U test. Multivariate logistic regression identified independent predictors of clinically significant FCR (total score >/=13). Results: Median patient age was 72.0 years (IQR 66.0-78.0), with a median of 24.0 months post-diagnosis. Clinically significant FCR (score >/=13) was prevalent in 55.7% of the cohort. Spearman correlation analysis revealed no significant relationship between months elapsed and FCR severity (rho = 0.068, p = 0.552). Patients in the 12-24 month window exhibited the highest variability (Levene's test, p = 0.058), representing a period of clinical divergence. High-Grade disease and smoking cessation motivated by diagnosis were associated with higher FCR scores. In the multivariate logistic regression model, history of tumor recurrence was the sole independent predictor of clinically significant FCR (aOR 3.28, 95% CI 1.11-9.68, p = 0.031), whereas age and gender were not significantly associated. Conclusions: FCR severity did not demonstrate a significant association with time elapsed since diagnosis in this cross-sectional sample. The 1-2 year interval demonstrated greater inter-individual variability in FCR scores. Findings highlight the need for long-term, structured survivorship support, particularly targeting the 12-24 month post-diagnosis window. FAU - Golomb, Dor AU - Golomb D AUID- ORCID: 0000-0002-9957-0390 AD - Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel. FAU - Simard, Sebastien AU - Simard S AUID- ORCID: 0000-0001-7493-4672 AD - Department of Health Sciences, Universite du Quebec a Chicoutimi, Saguenay, QC G7H 2B1, Canada. FAU - Eisner, Alon AU - Eisner A AD - Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel. FAU - Avda, Yuval AU - Avda Y AD - Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel. FAU - Atamna, Fahed AU - Atamna F AD - Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel. FAU - Raz, Orit AU - Raz O AD - Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel. LA - eng PT - Journal Article DEP - 20260419 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13116715 OTO - NOTNLM OT - bladder cancer OT - fear of cancer recurrence (FCR) OT - non-muscle invasive bladder cancer (NMIBC) OT - survivorship COIS- The authors declare no conflicts of interest. EDAT- 2026/05/04 06:32 MHDA- 2026/05/04 06:33 PMCR- 2026/04/19 CRDT- 2026/05/04 01:16 PHST- 2026/03/28 00:00 [received] PHST- 2026/04/14 00:00 [revised] PHST- 2026/04/16 00:00 [accepted] PHST- 2026/05/04 06:33 [medline] PHST- 2026/05/04 06:32 [pubmed] PHST- 2026/05/04 01:16 [entrez] PHST- 2026/04/19 00:00 [pmc-release] AID - jcm15083116 [pii] AID - jcm-15-03116 [pii] AID - 10.3390/jcm15083116 [doi] PST - epublish SO - J Clin Med. 2026 Apr 19;15(8):3116. doi: 10.3390/jcm15083116. PMID- 42074229 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260926 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 8 DP - 2026 Apr 17 TI - Serum Trimethylamine-N-Oxide and Its Precursors as a Diagnostic Biomarker Panel for Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/ijms27083591 [doi] LID - 3591 AB - Non-muscle-invasive bladder cancer (NMIBC) is characterized by high recurrence rates and necessitates lifelong cystoscopic surveillance, underscoring the need for minimally invasive biomarkers to improve early detection and risk stratification. Therefore, this study aimed to investigate the role of trimethylamine-N-oxide (TMAO) and its precursors as diagnostic biomarkers for NMIBC. A total of 50 male patients with NMIBC (25 pTa and 25 pT1) were included in this study. Additionally, 52 age-matched healthy individuals were included as controls. Serum TMAO and its dietary precursors were quantified using liquid chromatography-tandem mass spectrometry. Group differences were analyzed using nonparametric tests, associations were assessed using Spearman's correlation, and diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Multivariate logistic regression was performed to identify independent predictors, and a composite risk score was generated. Serum TMAO, carnitine, and choline levels were significantly higher in patients with NMIBC than in controls (p /= 0.05). The pathological stage (pTa vs. pT1) showed the strongest correlation with TMAO levels. The ROC analysis revealed that TMAO had the highest individual diagnostic accuracy (area under the curve [AUC] = 0.875, 95% confidence interval [CI] 0.812-0.939), whereas carnitine and choline provided complementary diagnostic performance. In multivariate models, TMAO, carnitine, and choline remained independent predictors of NMIBC (p /= 3, sensitivity was 70.4% and specificity was 59.4%. In multivariable analysis, only invasion depth at initial TURBT independently predicted repeat TURBT. CONCLUSIONS: VI-RADS was associated with pathological tumor severity and with repeat TURBT status, but it did not independently predict undergoing repeat TURBT. These findings support VI-RADS as an adjunctive preoperative tool rather than a stand-alone determinant for repeat resection decisions. CI - (c) 2026. The Author(s). FAU - Aghayev, Anar AU - Aghayev A AD - Department of Urology, Isparta Meddem Hospital, Isparta, Turkiye. FAU - Durak, Huseyin Mert AU - Durak HM AD - Department of Urology, Ankara Etlik City Hospital, Ankara, Turkiye. hmertdurak@gmail.com. FAU - Hepsen, Emre AU - Hepsen E AD - Department of Urology, Ankara Etlik City Hospital, Ankara, Turkiye. FAU - Dinc, Engin AU - Dinc E AD - Department of Radiology, Ankara Etlik City Hospital, Ankara, Turkiye. FAU - Karabacak, Osman Raif AU - Karabacak OR AD - Department of Urology, Ankara Etlik City Hospital, Ankara, Turkiye. LA - eng PT - Journal Article PT - Observational Study DEP - 20260501 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - Female MH - Prospective Studies MH - Male MH - Aged MH - Middle Aged MH - Predictive Value of Tests MH - Reoperation MH - Multiparametric Magnetic Resonance Imaging MH - Aged, 80 and over PMC - PMC13285616 COIS- Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Diskapi Yildirim Beyazit Training and Research Hospital (Decision No: 146/31; Date: 12 September 2022). Written informed consent was obtained from all participants prior to mpMRI. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/05/02 00:33 MHDA- 2026/06/22 13:43 PMCR- 2026/05/01 CRDT- 2026/05/01 23:26 PHST- 2026/01/29 00:00 [received] PHST- 2026/03/25 00:00 [accepted] PHST- 2026/06/22 13:43 [medline] PHST- 2026/05/02 00:33 [pubmed] PHST- 2026/05/01 23:26 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - 10.1186/s12894-026-02131-3 [pii] AID - 2131 [pii] AID - 10.1186/s12894-026-02131-3 [doi] PST - epublish SO - BMC Urol. 2026 May 1;26(1):145. doi: 10.1186/s12894-026-02131-3. PMID- 42066506 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260723 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 4 DP - 2026 Jun TI - Comparative Analysis of Risk Stratifications for Non-Muscle-Invasive Bladder Cancer According to the Classifications Provided by the National Comprehensive Cancer Network, European Association of Urology, and Japanese Urological Association Guidelines. PG - 102560 LID - S1558-7673(26)00060-1 [pii] LID - 10.1016/j.clgc.2026.102560 [doi] AB - INTRODUCTION: Risk stratification systems for non-muscle-invasive bladder cancer (NMIBC) differ among the National Comprehensive Cancer Network (NCCN)/American Urological Association (AUA), European Association of Urology (EAU), and Japanese Urological Association (JUA) guidelines, and their comparative ability to predict clinical outcomes in real-world practice remains unclear. PATIENTS AND METHODS: We retrospectively analyzed 591 patients who underwent transurethral resection of bladder tumor and classified them into risk categories according to the NCCN, EAU, and JUA guidelines, comparing recurrence and progression outcomes among classifications. RESULTS: During median follow-up of 64.1 months, intravesical recurrence (32.1%), T stage progression (4.5%), grade progression (2.5%), undergoing radical nephroureterectomy (2.7%), and radical cystectomy (5.3%) were observed, respectively. Grade progression from low-grade to high-grade disease was significantly associated with increasing EAU risk (P = .026) but not with NCCN or JUA classifications. Among pTa tumors, progression to >/= pT1 occurred more frequently in higher risk groups across all classifications (all, P < .05), whereas progression from pT1 to pT2 was not significantly stratified by any system. Early intravesical recurrence increased with higher risk in all classifications (all, P < .05), with the strongest discrimination observed for the NCCN system. In multivariable Cox proportional hazards analyses, the NCCN classification demonstrated the highest discriminative performance for predicting intravesical recurrence. CONCLUSIONS: The NCCN, EAU, and JUA risk classifications are all clinically relevant for NMIBC, but their predictive performance varies by endpoint, indicating the importance of selecting the classification according to the specific outcome of interest. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Shimoda, Moeto AU - Shimoda M AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Ito, Hiroki AU - Ito H AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: hiroki22@yokohama-cu.ac.jp. FAU - Aoki, Tetsuya AU - Aoki T AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Karibe, Jurii AU - Karibe J AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Shibata, Yosuke AU - Shibata Y AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Imano, Masashi AU - Imano M AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Otake, Shinji AU - Otake S AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Inoue, Masahiro AU - Inoue M AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. FAU - Makiyama, Kazuhide AU - Makiyama K AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Kobayashi, Kazuki AU - Kobayashi K AD - Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260403 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - Japanese people SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology/classification MH - Female MH - Retrospective Studies MH - Male MH - Aged MH - Practice Guidelines as Topic MH - Risk Assessment/methods MH - *Neoplasm Recurrence, Local/epidemiology MH - Cystectomy MH - Disease Progression MH - Middle Aged MH - Transurethral Resection of Bladder MH - Japan MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Neoplasm Grading MH - Neoplasm Staging MH - East Asian People OTO - NOTNLM OT - NCCN guidelines OT - Progression OT - Radical cystectomy OT - Radical nephrectomy OT - Recurrence EDAT- 2026/05/02 00:33 MHDA- 2026/05/17 06:29 CRDT- 2026/05/01 18:04 PHST- 2026/01/22 00:00 [received] PHST- 2026/03/11 00:00 [revised] PHST- 2026/03/22 00:00 [accepted] PHST- 2026/05/17 06:29 [medline] PHST- 2026/05/02 00:33 [pubmed] PHST- 2026/05/01 18:04 [entrez] AID - S1558-7673(26)00060-1 [pii] AID - 10.1016/j.clgc.2026.102560 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Jun;24(4):102560. doi: 10.1016/j.clgc.2026.102560. Epub 2026 Apr 3. PMID- 42065660 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260819 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 67 IP - 3 DP - 2026 May TI - Impact of carcinoma in situ of bladder at transurethral resection and radical cystectomy on survival: Retrospective multicenter study. PG - 246-253 LID - 10.4111/icu.20250455 [doi] AB - PURPOSE: Carcinoma in situ (CIS) of the bladder is a high-grade, non-invasive lesion known to increase the risk of recurrence and progression. However, the prognostic significance of CIS identified at transurethral resection of bladder tumor (TURB) versus radical cystectomy (RC) remains controversial. This study aimed to evaluate the impact of CIS at different treatment stages on recurrence-free survival (RFS) and cancer-specific survival (CSS). MATERIALS AND METHODS: A retrospective multicenter study was conducted using data from 2,553 patients who underwent TURB followed by RC between 2010 and 2019 across eleven Korean institutions. Kaplan-Meier survival curves and Cox proportional hazards models were used to assess the association of CIS at TURB and RC with RFS and CSS, adjusting for clinicopathological variables. RESULTS: CIS was identified in 731 TURB specimens (28.6%) and 821 RC specimens (32.2%). Patients with CIS at TURB had significantly higher RFS (p<0.001) and CSS (p=0.002) compared to those without. In multivariate analysis, CIS at TURB was independently associated with better RFS (hazard ratio [HR] 0.787, p=0.001) but not CSS (HR 0.989, p=0.905). CIS at RC showed no significant association with either RFS or CSS. Independent predictors of poor survival included advanced stage, lymph node involvement, lymphovascular invasion, and positive surgical margins. Adjuvant therapy was associated with improved CSS. CONCLUSIONS: CIS at TURB is associated with a lower recurrence risk following RC, whereas CIS in RC specimens has limited prognostic impact. These findings suggest CIS at TURB may carry different prognostic implications than traditionally assumed, warranting careful clinical interpretation. CI - (c) The Korean Urological Association. FAU - Heo, Ji Eun AU - Heo JE AUID- ORCID: 0000-0002-4184-8468 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Kim, Jongchan AU - Kim J AUID- ORCID: 0000-0002-0022-6689 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Jang, Won Sik AU - Jang WS AUID- ORCID: 0000-0002-9082-0381 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Sung, Hyun Hwan AU - Sung HH AUID- ORCID: 0000-0001-9845-3742 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lim, Bumjin AU - Lim B AUID- ORCID: 0000-0001-7065-020X AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AUID- ORCID: 0000-0002-8076-3643 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Oh, Jong Jin AU - Oh JJ AUID- ORCID: 0000-0003-0448-5992 AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. FAU - Song, Geehyun AU - Song G AUID- ORCID: 0000-0001-7486-4520 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AUID- ORCID: 0000-0003-2601-1093 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Kim, Tae-Hwan AU - Kim TH AUID- ORCID: 0000-0003-4924-4826 AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Ha, Yun-Sok AU - Ha YS AUID- ORCID: 0000-0003-3732-9814 AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Nam, Wook AU - Nam W AUID- ORCID: 0000-0002-1424-9339 AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. FAU - Kim, Kyung Hwan AU - Kim KH AUID- ORCID: 0000-0001-7162-6527 AD - Department of Urology, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea. FAU - Nam, Jong Kil AU - Nam JK AUID- ORCID: 0000-0002-3424-2417 AD - Department of Urology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan, Korea. FAU - Noh, Tae Il AU - Noh TI AUID- ORCID: 0000-0002-5278-7672 AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Kang, Seok Ho AU - Kang SH AUID- ORCID: 0000-0002-1524-5233 AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AUID- ORCID: 0000-0002-5399-2184 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Ham, Won Sik AU - Ham WS AUID- ORCID: 0000-0003-2246-8838 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. uroham@yuhs.ac. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - *Cystectomy/methods MH - Humans MH - Transurethral Resection of Bladder MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Female MH - Male MH - *Carcinoma in Situ/surgery/mortality/pathology MH - Aged MH - Middle Aged MH - Survival Rate MH - Prognosis PMC - PMC13145770 OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Radical cystectomy OT - Survival OT - Transurethral resection of bladder tumor COIS- The authors have nothing to disclose. EDAT- 2026/05/01 12:36 MHDA- 2026/05/01 12:37 PMCR- 2026/05/01 CRDT- 2026/05/01 10:02 PHST- 2025/09/14 00:00 [received] PHST- 2025/12/14 00:00 [revised] PHST- 2025/12/23 00:00 [accepted] PHST- 2026/05/01 12:37 [medline] PHST- 2026/05/01 12:36 [pubmed] PHST- 2026/05/01 10:02 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - 67.246 [pii] AID - 10.4111/icu.20250455 [doi] PST - ppublish SO - Investig Clin Urol. 2026 May;67(3):246-253. doi: 10.4111/icu.20250455. PMID- 42065659 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260820 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 67 IP - 3 DP - 2026 May TI - Association of initial transurethral resection staging on survival in radical cystectomy patients. PG - 237-245 LID - 10.4111/icu.20250573 [doi] AB - PURPOSE: Muscle-invasive bladder cancer (MIBC) is highly aggressive and presents complex treatment challenges. This study aimed to determine if the stage found during the initial transurethral resection of bladder tumor (TURBT) significantly impacts the prognosis of patients undergoing subsequent radical cystectomy (RC). MATERIALS AND METHODS: We retrospectively analyzed a multi-institutional database of 3,258 RC patients treated between January 2010 and December 2019, with confirmed survival data. The analysis included 68 variables such as baseline characteristics, initial and highest TURBT pathology, and final pathology. Patients were categorized into four groups based on initial T stage: pTa, pT1, pT2, and Tis (carcinoma in situ). RESULTS: The mean follow-up was 46.6+/-38.7 months. There were no significant differences in demographic variables between the groups. Overall survival (OS) rates differed significantly across the four groups (p=0.017). Crucially, the Tis group demonstrated the most favorable long-term outcomes, with an OS rate over 60% at 150 months. The initial pTa, pT1, and pT2 groups did not show significant OS differences among themselves. CONCLUSIONS: The initial TURBT stage is associated with the prognosis of patients undergoing RC for bladder cancer. Patients with carcinoma in situ (Tis) is associated with more favorable outcomes from earlier cystectomy, leading to markedly improved long-term survival. For patients with more advanced initial stages (pT1, pT2), however, final pathology and lymph node status are more predictive of survival than the initial TURBT findings. CI - (c) The Korean Urological Association. FAU - Choi, Joongwon AU - Choi J AUID- ORCID: 0000-0001-5978-8179 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Song, Wan AU - Song W AUID- ORCID: 0000-0003-0971-1805 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Nam, Jong Kil AU - Nam JK AUID- ORCID: 0000-0002-3424-2417 AD - Department of Urology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan, Korea. FAU - Lim, Bumjin AU - Lim B AUID- ORCID: 0000-0001-7065-020X AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Nam, Wook AU - Nam W AUID- ORCID: 0000-0002-1424-9339 AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. FAU - Oh, Jong Jin AU - Oh JJ AUID- ORCID: 0000-0003-0448-5992 AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AUID- ORCID: 0000-0002-8076-3643 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kang, Seok Ho AU - Kang SH AUID- ORCID: 0000-0002-1524-5233 AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Kim, Tae-Hwan AU - Kim TH AUID- ORCID: 0000-0003-4924-4826 AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Heo, Ji Eun AU - Heo JE AUID- ORCID: 0000-0002-4184-8468 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Ham, Won Sik AU - Ham WS AUID- ORCID: 0000-0003-2246-8838 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Song, Geehyun AU - Song G AUID- ORCID: 0000-0001-7486-4520 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AUID- ORCID: 0000-0003-2601-1093 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Lee, Chung Un AU - Lee CU AUID- ORCID: 0000-0002-3030-0405 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Lee, Yong Seong AU - Lee YS AUID- ORCID: 0000-0003-0611-4554 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Choi, Se Young AU - Choi SY AUID- ORCID: 0000-0002-4615-0966 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Kim, Kyung Hwan AU - Kim KH AUID- ORCID: 0000-0001-7162-6527 AD - Department of Urology, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AUID- ORCID: 0000-0002-5399-2184 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bc2.jung@samsung.com. LA - eng GR - RS-2024-00342763/NRF/ PT - Journal Article PT - Multicenter Study PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Transurethral Resection of Bladder MH - Neoplasm Staging MH - *Cystectomy/methods MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - Survival Rate MH - Middle Aged MH - Prognosis PMC - PMC13145776 OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Cystectomy COIS- The authors have nothing to disclose. EDAT- 2026/05/01 12:38 MHDA- 2026/05/01 12:39 PMCR- 2026/05/01 CRDT- 2026/05/01 10:02 PHST- 2025/11/05 00:00 [received] PHST- 2025/12/24 00:00 [revised] PHST- 2026/01/01 00:00 [accepted] PHST- 2026/05/01 12:39 [medline] PHST- 2026/05/01 12:38 [pubmed] PHST- 2026/05/01 10:02 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - 67.237 [pii] AID - 10.4111/icu.20250573 [doi] PST - ppublish SO - Investig Clin Urol. 2026 May;67(3):237-245. doi: 10.4111/icu.20250573. PMID- 42063735 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260501 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Proteogenomic detection of tumor-specific somatic mutant proteins in urinary extracellular vesicles for non-invasive monitoring of bladder cancer. PG - 1808671 LID - 10.3389/fonc.2026.1808671 [doi] LID - 1808671 AB - BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is characterized by frequent recurrence, requiring repeated cystoscopic surveillance that is invasive and burdensome for patients. Although liquid biopsy approaches have been explored, clinically applicable non-invasive biomarkers that directly reflect tumor burden remain limited. As a proof-of-concept, we investigated whether somatic mutant proteins derived from bladder cancer cells can be detected and quantified in urinary extracellular vesicles (EVs) using a proteogenomic strategy. METHODS: Tumor tissues, cultured tissue-derived EVs, and urinary EVs were collected from five patients with bladder cancer. Whole-exome sequencing was performed to generate patient-specific mutation databases. Deep proteomic profiling by LC/MS was conducted for each specimen type, followed by a proteogenomic pipeline to identify somatic mutant proteins. To explore clinical feasibility, selected mutant proteins were further evaluated by targeted mass spectrometry with absolute quantification in prospectively collected urine samples. RESULTS: Comprehensive proteomic analyses identified 11, 207 proteins in tumor tissues, 9, 809 in tissue-derived EVs, and 5, 828 in urinary EVs. Across these matched sample sets, 39, 32, and 4 somatic mutant proteins were detected, respectively, demonstrating that tumor-specific mutant proteins are incorporated into EVs and released into urine. Importantly, absolute quantification of selected mutant proteins (LCP1_D321H, TKT_K102N, and PLCD1_R639H) revealed a clear association between urinary EV mutant protein levels and cystoscopic tumor burden, supporting their potential utility for non-invasive disease monitoring. CONCLUSION: This proof-of-concept study provides the first evidence that somatic mutant proteins can be directly detected and quantified in urinary EVs using a proteogenomic approach. Our findings establish a conceptual framework for mutation-informed, protein-level liquid biopsy and suggest that urinary EV-associated mutant proteins may serve as highly specific, non-invasive biomarkers for monitoring bladder cancer recurrence. CI - Copyright (c) 2026 Hakozaki, Sugimoto, Yamada, Danno, Hashimoto, Shinchi, Kume and Ueda. FAU - Hakozaki, Yuji AU - Hakozaki Y AD - Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Sugimoto, Kazuma AU - Sugimoto K AD - Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Yamada, Yuta AU - Yamada Y AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Danno, Tetsuya AU - Danno T AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Hashimoto, Kenichi AU - Hashimoto K AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Shinchi, Hiroki AU - Shinchi H AD - Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. FAU - Ueda, Koji AU - Ueda K AD - Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20260415 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13124499 OTO - NOTNLM OT - bladder cancer OT - extracellular vesicles OT - liquid biopsy OT - proteogenomics OT - somatic mutant protein COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author KU declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2026/05/01 06:34 MHDA- 2026/05/01 06:35 PMCR- 2026/04/15 CRDT- 2026/05/01 05:07 PHST- 2026/02/11 00:00 [received] PHST- 2026/03/25 00:00 [revised] PHST- 2026/03/27 00:00 [accepted] PHST- 2026/05/01 06:35 [medline] PHST- 2026/05/01 06:34 [pubmed] PHST- 2026/05/01 05:07 [entrez] PHST- 2026/04/15 00:00 [pmc-release] AID - 10.3389/fonc.2026.1808671 [doi] PST - epublish SO - Front Oncol. 2026 Apr 15;16:1808671. doi: 10.3389/fonc.2026.1808671. eCollection 2026. PMID- 42053403 OWN - NLM STAT- MEDLINE DCOM- 20261018 LR - 20261018 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 4 DP - 2026 Nov TI - Tumor site as predictors of pathologic progression in high-grade T1 bladder cancer. PG - 669-673 LID - 10.1177/03915603261444890 [doi] AB - OBJECTIVE: To evaluate the association between tumor location and progression or recurrence after initial transurethral resection of bladder tumor (TURBT) in patients with high grade (HG) T1 urothelial carcinoma. METHODS: This retrospective cohort analysis included patients diagnosed with HG-T1 bladder cancer from 2020 to 2024. Patients were stratified by tumor location: anterior/posterior wall, lateral walls, bladder neck, trigone, dome. Residual disease or upstaging at restaging TURBT was assessed via follow-up restaging TURBT. Associations were tested using chi-square, univariate, and multivariate models. RESULTS: A total of 80 patients with high-grade T1 urothelial carcinoma were included. The median age was 73 years (range 45-89) and 92.8% (77) were male. The mean tumor size was 2.6 cm, and 91.3% of tumors were completely resected. Tumors were most commonly located in the lateral wall (36.3%) and posterior wall (31.3%). Worsening on restaging TURBT was most frequent in posterior wall (48.4%) and bladder neck tumors (50%). Lateral wall tumors worsened in 37.0%, anterior wall in 23.1%, and none from the trigone. Posterior wall tumors showed higher odds of worsening versus dome tumors in univariate analysis (OR 2.50, p = 0.34), though not statistically significant. Multivariable analysis adjusting for clinical and tumor factors also found non-significant increased odds for posterior wall tumors versus lateral wall and dome (OR 1.26, p = 0.71). CONCLUSION: Posterior wall and bladder neck tumors showed the highest descriptive rates of residual disease or upstaging at restaging TURBT, but multivariable analysis did not demonstrate statistically significant independent associations. These findings may warrent closer surveillance or earlier intervention in select cases. FAU - Golomb, Dor AU - Golomb D AUID- ORCID: 0000-0002-9957-0390 AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Atamna, Fahed AU - Atamna F AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Avda, Yuval AU - Avda Y AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Leonov Polak, Mia AU - Leonov Polak M AD - Department of Pathology, Samson Assuta Ashdod University Hospital, Israel. FAU - Raz, Orit AU - Raz O AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. LA - eng PT - Journal Article DEP - 20260429 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - Disease Progression MH - Male MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Female MH - Aged MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Transurethral Resection of Bladder MH - Neoplasm Staging MH - Neoplasm Grading MH - Middle Aged MH - Non-Muscle Invasive Bladder Neoplasms MH - Cohort Studies MH - Neoplasm Recurrence, Local OTO - NOTNLM OT - age groups OT - bladder cancer OT - high-grade T1 OT - pathologic progression OT - risk factors OT - tumor location COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/29 12:41 MHDA- 2026/10/18 05:37 CRDT- 2026/04/29 09:52 PHST- 2026/10/18 05:37 [medline] PHST- 2026/04/29 12:41 [pubmed] PHST- 2026/04/29 09:52 [entrez] AID - 10.1177/03915603261444890 [doi] PST - ppublish SO - Urologia. 2026 Nov;93(4):669-673. doi: 10.1177/03915603261444890. Epub 2026 Apr 29. PMID- 42042542 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260813 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 16 IP - 4 DP - 2026 Mar 24 TI - Recurrence Rate After Post-Operative Two-Hour Continuous Bladder Irrigation for Primary Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. LID - 10.3390/jpm16040175 [doi] LID - 175 AB - Background: High recurrence rates for non-muscle-invasive bladder cancer (NMIBC) remain a clinical challenge. Recommended post-operative treatments are underutilized, highlighting the need for alternative strategies. Given the variability in bladder cancer prognosis, personalized treatment approaches are highly relevant. In this study, we evaluated post-operative two-hour continuous sterile water bladder irrigation (CSWBI) regarding recurrence and safety, as a potential addition to the treatment arsenal for bladder cancer. Method: In 2018, two-hour CSWBI was implemented as routine treatment after all transurethral resection procedures of the bladder (TURB), at the urology department of Sundsvall Hospital. All patients who underwent TURBs four years prior (control group) and four years after the implementation of CSWBI (intervention group) were analyzed. Primary NMIBC were included, MIBC and CIS were excluded. Data were collected retrospectively from patient records, including baseline characteristics, adverse events, and recurrence rates within 12 months follow-up. Statistical analyses included Chi-squared test, Wilcoxon rank-sum test, univariate and multivariate logistic regression analyses, Kaplan-Meier curves and log-rank test. Results: A total of 168 patients were included (control group n = 90, irrigation group n = 78). Median age was 73 years, 23% were female, 77% were male, and 74% were active or previous smokers. The recurrence rate within twelve months for the intervention group vs. the control group was: 27% vs. 21% (p = 0.4) respectively. CSWBI had no statistically significant impact on recurrence (OR 1.25, 95% CI 0.58-2.68, p = 0.6). Adverse effects were limited and equal between groups. Conclusions: Post-operative two-hour CSWBI did not significantly reduce NMIBC recurrence within twelve months in this cohort. FAU - Sterner, Patrick AU - Sterner P AUID- ORCID: 0009-0006-7256-4624 AD - Centre for Clinical Research Vastmanland, Uppsala University, 72189 Vasteras, Sweden. AD - Department of Urology, Vastmanland Hospital Vasteras, 72189 Vasteras, Sweden. FAU - Gimbergsson, Sanna AU - Gimbergsson S AD - Department of Diagnostics and Intervention, Urology and Andrology, Umea University, 90187 Umea, Sweden. FAU - Johansson, Markus AU - Johansson M AD - Department of Urology, Sundsvall Hospital, 85643 Sundsvall, Sweden. FAU - Alamdari, Farhood AU - Alamdari F AUID- ORCID: 0000-0003-3589-7789 AD - Centre for Clinical Research Vastmanland, Uppsala University, 72189 Vasteras, Sweden. AD - Department of Urology, Vastmanland Hospital Vasteras, 72189 Vasteras, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Diagnostics and Intervention, Urology and Andrology, Umea University, 90187 Umea, Sweden. FAU - Chabok, Abbas AU - Chabok A AUID- ORCID: 0000-0001-9662-5045 AD - Centre for Clinical Research Vastmanland, Uppsala University, 72189 Vasteras, Sweden. AD - Department of Surgery, Danderyd Hospital, Region Stockholm, 18288 Danderyd, Sweden. FAU - Styrke, Johan AU - Styrke J AUID- ORCID: 0000-0001-8455-2010 AD - Department of Diagnostics and Intervention, Urology and Andrology, Umea University, 90187 Umea, Sweden. AD - Department of Urology, Sundsvall Hospital, 85643 Sundsvall, Sweden. LA - eng GR - N/A/Stiftelsen SCUR/ GR - N/A/Vastmanland Cancerfond/ GR - N/A/Centre for clinical research Region Vastmanland/ PT - Journal Article DEP - 20260324 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC13117165 OTO - NOTNLM OT - local neoplasm recurrence OT - non-randomized controlled trials OT - non-muscle-invasive bladder cancer OT - personalized treatment OT - retrospective studies OT - therapeutic irrigation OT - urinary bladder neoplasms COIS- The authors declare no conflicts of interest. EDAT- 2026/04/27 12:34 MHDA- 2026/04/27 12:35 PMCR- 2026/03/24 CRDT- 2026/04/27 09:29 PHST- 2025/08/15 00:00 [received] PHST- 2026/02/22 00:00 [revised] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/04/27 12:35 [medline] PHST- 2026/04/27 12:34 [pubmed] PHST- 2026/04/27 09:29 [entrez] PHST- 2026/03/24 00:00 [pmc-release] AID - jpm16040175 [pii] AID - jpm-16-00175 [pii] AID - 10.3390/jpm16040175 [doi] PST - epublish SO - J Pers Med. 2026 Mar 24;16(4):175. doi: 10.3390/jpm16040175. PMID- 42038393 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers. PG - 1767712 LID - 10.3389/fonc.2026.1767712 [doi] LID - 1767712 AB - The application of circulating tumor DNA (ctDNA) has advanced in the treatment of multiple cancer types, including urothelial cancer (UC). While ctDNA currently plays a limited role in non-muscle-invasive bladder cancer (NMIBC), its relevance is expanding in muscle-invasive bladder cancer (MIBC), as evidenced by recent positive results from the IMvigor011 trial. This study demonstrated that a ctDNA-guided approach to adjuvant atezolizumab therapy enhances disease-free survival. Furthermore, ctDNA is well-established as a tool for monitoring treatment response and assessing minimal residual disease (MRD) in metastatic urothelial cancer (mUC). This narrative review explores the current data on the clinical utility of ctDNA in various disease states within UC to help guide clinicians in the appropriate setting and application of ctDNA based on retrospective, current, and emerging data. CI - Copyright (c) 2026 Aragon-Ching, Urabe and Yajima. FAU - Aragon-Ching, Jeanny B AU - Aragon-Ching JB AD - Genitourinary (GU) Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, United States. AD - Department of Medical Education, University of Virginia, Charlottesville, VA, United States. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, The Jikei University West Medical Center, Tokyo, Japan. FAU - Yajima, Shugo AU - Yajima S AD - Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260410 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13106067 OTO - NOTNLM OT - circulating tumor DNA (ctDNA) OT - immune checkpoint inhibitors OT - locally advanced urothelial cancer OT - metastatic urothelial cancer OT - urothelial cancer COIS- JA-C has served on the Speakers' Bureau of BMS, Astellas, SeaGen, EMD Serono, and the Advisory Board of Merck, Pfizer, EMD Serono, and AZD. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/04/27 12:33 MHDA- 2026/04/27 12:34 PMCR- 2026/04/10 CRDT- 2026/04/27 06:50 PHST- 2025/12/15 00:00 [received] PHST- 2026/02/21 00:00 [revised] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/04/27 12:34 [medline] PHST- 2026/04/27 12:33 [pubmed] PHST- 2026/04/27 06:50 [entrez] PHST- 2026/04/10 00:00 [pmc-release] AID - 10.3389/fonc.2026.1767712 [doi] PST - epublish SO - Front Oncol. 2026 Apr 10;16:1767712. doi: 10.3389/fonc.2026.1767712. eCollection 2026. PMID- 42033426 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1941-837X (Electronic) IS - 1369-6998 (Linking) VI - 29 IP - 1 DP - 2026 Dec TI - Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer. PG - 1341-1354 LID - 10.1080/13696998.2026.2661553 [doi] AB - INTRODUCTION: Standard economic models, which have been developed to reflect typical data availability for pharmaceutical products, often struggle with non-pharmaceutical interventions like diagnostics and medical devices, where clinical trial data is more likely to be short-term or non-comparative. This paper explores methodological challenges in evaluating Photodynamic Diagnosis (PDD) via blue light cystoscopy (BLC) versus Narrow Band Imaging (NBI) for non-muscle invasive bladder cancer (NMIBC). METHODS: A semi-Markov state-transition cost-utility model was developed for a health technology appraisal (HTA) by the Danish Treatment Council. The basis of the model was a differential effect of the two technologies on the risk of early local cancer recurrence. Due to a lack of direct comparative trials, an indirect hazard-function-based approach was used. Using TreeAge Pro software, baseline hazard curves were derived from ten-year survival data for conventional white light cystoscopy. Hazard ratios (HRs) from meta-analyses were then applied to these curves to derive simulated time-to-event curves for BLC and NBI. RESULTS: The base-case analysis yielded an incremental cost-effectiveness ratio (ICER) of DKK 70,707/QALY for BLC-TURBT versus NBI-TURBT. Sensitivity analyses confirmed results remained robust and well below the DKK 500,000/QALY willingness-to-pay threshold. The model was most sensitive to HRs for time to first recurrence. Scenario analyses, including traditional parametric extrapolation, yielded consistent ICERs between DKK 36,775 and DKK 215,965/QALY. DISCUSSION: The hazard-based workflow effectively integrated survival data from disparate sources, using a software-based method was quicker, simpler and more intuitive to use than conventional statistical methods. The approach used is equally applicable to a partitioned survival structure. The alignment between hazard-based and traditional parametric methods suggests this is a valid, efficient alternative for developing models in the face of evidence gaps. CONCLUSIONS: A hazard-function approach provides a transparent, practical solution for building robust economic models when clinical data is limited or incompatible with standard approaches. FAU - Belsey, Jonathan AU - Belsey J AUID- ORCID: 0000-0001-7283-327X AD - JB Medical Ltd, London, UK. FAU - Chrosny, Wojciech AU - Chrosny W AUID- ORCID: 0009-0002-9816-9893 AD - TreeAge Software LLC, Williamstown, MA, USA. FAU - Lapon, Jane AU - Lapon J AUID- ORCID: 0009-0002-3713-2405 AD - Photocure ASA, Oslo, Norway. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260425 PL - England TA - J Med Econ JT - Journal of medical economics JID - 9892255 RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/diagnostic imaging/diagnosis MH - *Cystoscopy/methods/economics MH - Cost-Benefit Analysis MH - *Narrow Band Imaging/economics/methods MH - *Models, Economic MH - Markov Chains MH - Quality-Adjusted Life Years MH - *Urinary Bladder Neoplasms/diagnosis MH - Blue Light MH - Aminolevulinic Acid/analogs & derivatives MH - Cost-Effectiveness Analysis MH - Neoplasm Recurrence, Local MH - Denmark OTO - NOTNLM OT - C18 OT - Health economics OT - I19 OT - blue light cystoscopy OT - hexaminolevulinate OT - narrow band imaging OT - non-muscle-invasive bladder cancer OT - photodynamic diagnosis OT - survival analysis EDAT- 2026/04/26 05:11 MHDA- 2026/04/26 05:12 CRDT- 2026/04/25 10:23 PHST- 2026/04/26 05:12 [medline] PHST- 2026/04/26 05:11 [pubmed] PHST- 2026/04/25 10:23 [entrez] AID - 10.1080/13696998.2026.2661553 [doi] PST - ppublish SO - J Med Econ. 2026 Dec;29(1):1341-1354. doi: 10.1080/13696998.2026.2661553. Epub 2026 Apr 25. PMID- 42032498 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260813 IS - 1471-2342 (Electronic) IS - 1471-2342 (Linking) VI - 26 IP - 1 DP - 2026 Apr 24 TI - Predicting muscle-invasive bladder cancer with dual-layer detector spectral CT-derived extracellular volume fraction. LID - 10.1186/s12880-026-02342-y [doi] LID - 290 AB - OBJECTIVES: To evaluate the diagnostic performance of dual-layer detector spectral CT (DLCT)-derived extracellular volume fraction (ECV) for pre-operatively distinguishing muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: This retrospective study included 116 patients with pathologically confirmed urothelial carcinoma who underwent preoperative DLCT. Pathological results from transurethral resection or cystectomy served as the reference standard, classifying patients into MIBC (n = 57) and NMIBC (n = 59) groups. Two radiologists independently measured morphological features and spectral CT parameters, including iodine density and ECV. Statistical analyses involved univariate comparisons, multivariable logistic regression, and receiver operating characteristic (ROC) analysis. RESULTS: Multivariable analysis identified the longest tumor contact length (CL) >/= 3 cm (Odds Ratio [OR] = 5.827; p = 0.006) and ECV (OR = 1.378 per 1% increment; p < 0.001) as independent predictors of MIBC. The area under the ROC curve (AUC) for ECV (0.886) was significantly superior to that of CL >/= 3 cm (0.726) (DeLong test, p = 0.040). A combined model (ECV + CL) achieved an AUC of 0.869, which was not significantly better than ECV alone (p = 0.146). At the optimal cut-off of 72.3%, ECV predicted MIBC with 84.2% sensitivity and 88.1% specificity. Excellent inter-reader agreement was observed for all quantitative measurements (ICC >/= 0.86). CONCLUSION: DLCT-derived ECV is a robust, non-invasive, and reproducible quantitative biomarker that outperforms conventional morphological assessment for the pre-operative prediction of MIBC, offering significant potential for improving clinical decision-making and personalized treatment planning. FAU - Lv, Jian AU - Lv J AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Yang, Pianpian AU - Yang P AD - Department of Radiology, Laibin Municipal People's Hospital, Laibin, 546100, China. FAU - Zheng, Wei AU - Zheng W AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Huang, Danyi AU - Huang D AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Feng, Yuling AU - Feng Y AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Huang, Bingqin AU - Huang B AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. AD - Graduate School, Guilin Medical University, Guilin, 541002, China. FAU - Mu, Ronghua AU - Mu R AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Dai, Siyu AU - Dai S AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. AD - Graduate School, Guilin Medical University, Guilin, 541002, China. FAU - Li, Peijia AU - Li P AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Yang, Peng AU - Yang P AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Li, Xin AU - Li X AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. FAU - Zhu, Xiqi AU - Zhu X AD - Department of Radiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China. xiqi.zhu@163.com. AD - Life Science and Clinical Medicine Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China. xiqi.zhu@163.com. FAU - Qin, Xiaoyan AU - Qin X AD - Department of Radiology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541004, China. qinxiaoyan2013@163.com. LA - eng PT - Journal Article DEP - 20260424 PL - England TA - BMC Med Imaging JT - BMC medical imaging JID - 100968553 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Female MH - Retrospective Studies MH - *Tomography, X-Ray Computed/methods MH - Male MH - Aged MH - Neoplasm Invasiveness MH - Middle Aged MH - Non-Muscle Invasive Bladder Neoplasms MH - Transurethral Resection of Bladder MH - Sensitivity and Specificity MH - Aged, 80 and over MH - ROC Curve PMC - PMC13245017 OTO - NOTNLM OT - Bladder cancer OT - Dual-layer spectral CT OT - Extracellular volume fraction OT - Muscle invasion OT - Quantitative imaging COIS- Declarations. Ethics approval and consent to participate: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of Nanxishan Hospital of Guangxi Zhuang Autonomous Region [NO.2023 (KY-E-006)], which waived the requirement for written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/04/25 00:34 MHDA- 2026/06/28 06:35 PMCR- 2026/04/24 CRDT- 2026/04/24 23:44 PHST- 2025/11/07 00:00 [received] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/06/28 06:35 [medline] PHST- 2026/04/25 00:34 [pubmed] PHST- 2026/04/24 23:44 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - 10.1186/s12880-026-02342-y [pii] AID - 2342 [pii] AID - 10.1186/s12880-026-02342-y [doi] PST - epublish SO - BMC Med Imaging. 2026 Apr 24;26(1):290. doi: 10.1186/s12880-026-02342-y. PMID- 42031924 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Apr 24 TI - Hydronephrosis modifies the association between ureteroscopy and intravesical recurrence risk after radical nephroureterectomy for upper tract urothelial carcinoma. LID - 10.1038/s41598-026-49123-9 [doi] LID - 18820 AB - This study investigates whether ureteroscopy (URS) increases intravesical recurrence (IVR) risk following radical nephroureterectomy for upper tract urothelial carcinoma and identifies vulnerable patient subgroups. Previous studies did not fully clarify the impact of URS and biopsy on IVR risk, or whether the risk is elevated in specific subgroups. We retrospectively analyzed 1,483 patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma at nine institutions between January 2001 and April 2024. Cox proportional hazards models identified risk factors for IVR. Subgroup analyses determined characteristics increasing recurrence susceptibility. Inverse probability of treatment weighting validated subgroup analyses results. The median follow-up period was 45.1 (IQR 21.1-79.4) months. Multivariable analysis revealed that male sex, lower clinical T stage, concomitant bladder cancer, and pathological node-negative status were significantly associated with shorter IVR-free survival and confirmed URS as an independent risk factor for recurrence (HR = 1.30, 95% CI: 1.10-1.53, P < 0.001). URS-associated recurrence risk varied most by the presence of hydronephrosis. In weight-adjusted cohorts, IVR-free survival was significantly shorter with URS compared to non-URS among patients without hydronephrosis (HR = 1.73, 95% CI: 1.35-2.21, P < 0.001), whereas no significant differences were observed among patients with hydronephrosis (HR = 1.11, 95% CI: 0.88-1.40, P = 0.4). URS was an independent risk factor for IVR, but was not associated with increased risk among patients with hydronephrosis, whereas significantly increased risk was observed in patients without hydronephrosis. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Ikeda, Junichi AU - Ikeda J AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Yoshida, Takashi AU - Yoshida T AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Nakamoto, Takahiro AU - Nakamoto T AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Motoki, Yusuke AU - Motoki Y AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Yoshida, Ryuichi AU - Yoshida R AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Takahashi, Toshifumi AU - Takahashi T AD - Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. FAU - Hattori, Yuto AU - Hattori Y AD - Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. FAU - Yamasaki, Toshinari AU - Yamasaki T AD - Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. FAU - Imamura, Masaaki AU - Imamura M AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Kobori, Go AU - Kobori G AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Watanabe, Jun AU - Watanabe J AD - The Department of Urology, Toyooka Hospital, Toyooka, Japan. FAU - Ito, Noriyuki AU - Ito N AD - Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. FAU - Akao, Toshiya AU - Akao T AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Hatano, Shotaro AU - Hatano S AD - Department of Urology, Osaka Red Cross Hospital Osaka, Osaka, Japan. FAU - Koterazawa, Shigeki AU - Koterazawa S AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Fukui, Tomohiro AU - Fukui T AD - The Department of Urology, Toyooka Hospital, Toyooka, Japan. FAU - Murakami, Kaoru AU - Murakami K AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. FAU - Sumiyoshi, Takayuki AU - Sumiyoshi T AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. FAU - Kita, Yuki AU - Kita Y AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. FAU - Masui, Kimihiko AU - Masui K AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. FAU - Goto, Takayuki AU - Goto T AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. FAU - Kinoshita, Hidefumi AU - Kinoshita H AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Kanno, Toru AU - Kanno T AD - The Department of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, 606-8507, Kyoto, Japan. selecao@kuhp.kyoto-u.ac.jp. FAU - Saito, Ryoichi AU - Saito R AUID- ORCID: 0000-0002-3163-8723 AD - Department of Urology, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Hyogo, Japan. rsaito@kuhp.kyoto-u.ac.jp. LA - eng PT - Journal Article DEP - 20260424 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Male MH - *Nephroureterectomy/adverse effects/methods MH - *Ureteroscopy/adverse effects MH - Female MH - *Neoplasm Recurrence, Local/pathology/etiology MH - *Hydronephrosis/complications/pathology MH - Retrospective Studies MH - Aged MH - Risk Factors MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Urinary Bladder Neoplasms/pathology/surgery MH - *Ureteral Neoplasms/surgery PMC - PMC13272906 OTO - NOTNLM OT - Hydronephrosis OT - Nephroureterectomy OT - Recurrence OT - Ureteroscopy OT - Urothelial carcinoma COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval: This study was approved by the Institutional Review Board of Kyoto University (Approval number: R1581-4). This study follows the principles of the Declaration of Helsinki and its subsequent amendments. Due to the retrospective nature of the study, the requirement for informed consent was waived by the Institutional Review Board, with an opt-out method employed. EDAT- 2026/04/25 00:34 MHDA- 2026/06/27 18:37 PMCR- 2026/04/24 CRDT- 2026/04/24 23:22 PHST- 2025/10/20 00:00 [received] PHST- 2026/04/13 00:00 [accepted] PHST- 2026/06/27 18:37 [medline] PHST- 2026/04/25 00:34 [pubmed] PHST- 2026/04/24 23:22 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - 10.1038/s41598-026-49123-9 [pii] AID - 49123 [pii] AID - 10.1038/s41598-026-49123-9 [doi] PST - epublish SO - Sci Rep. 2026 Apr 24;16(1):18820. doi: 10.1038/s41598-026-49123-9. PMID- 42027190 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 61 DP - 2026 Apr 24 TI - Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette-Guerin immunotherapy. PG - 148-155 LID - 10.2340/sju.v61.45539 [doi] AB - OBJECTIVE: To determine whether asymptomatic bacteriuria (ABU) prior to Bacillus Calmette-Guerin (BCG) immunotherapy has an impact on the oncological results and overall tolerability of BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We analyzed retrospectively all patients who received >/= 1 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009-2018. Patients submitted urine specimen 1-7 days prior to the initiation of BCG therapy. ABU was classified as having any positive urine culture but no dysuria or fever. Our primary endpoints were 5-yr recurrence-free survival and progression-free survival. Discontinuation rate of BCG therapy was a secondary endpoint. RESULTS: We identified 795 patients, of whom 154 (19%) had ABU prior to the first BCG instillation. The 5-yr recurrence-free survival rates in the uninfected and bacteriuric groups were 63% (95% confidence interval [CI]: 59-67%) vs. 69% (95% CI: 62-78%), respectively (hazard ratio [HR] 0.83, 95% CI 0.60-1.14). The 5-yr progression-free survival rates were 88% (95% CI: 86-90%) vs. 89% (95% CI: 84-94%), respectively (HR 0.86, 95% CI 0.50-1.49). The 3-yr discontinuation-free survival rates were 51% (95% CI: 47-54%) vs. 51% (95% CI: 44-60%), respectively (HR 0.98, 95% CI 0.75-1.28). CONCLUSION: ABU did not significantly affect BCG immunotherapy outcomes. Intravesical BCG during ABU is safe, with similar discontinuation rates, indicating very similar treatment tolerability. FAU - Nummi, Antti AU - Nummi A AD - Department of Urology, Helsinki University Hospital, Helsinki, Finland. antti.nummi@hus.fi. FAU - Nurminen, Pertti AU - Nurminen P AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Kesti, Olli AU - Kesti O AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Hogerman, Mikael AU - Hogerman M AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Ettala, Otto AU - Ettala O AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Kaipia, Antti AU - Kaipia A AD - Department of Urology, Tampere University Hospital, Tampere, Finland. FAU - Sairanen, Jukka AU - Sairanen J AD - Department of Urology, Helsinki University Hospital, Helsinki, Finland. FAU - Jarvinen, Riikka AU - Jarvinen R AD - Department of Urology, Helsinki University Hospital, Helsinki, Finland. LA - eng PT - Journal Article DEP - 20260424 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - *Bacteriuria/complications MH - Non-Muscle Invasive Bladder Neoplasms MH - *Immunotherapy MH - Aged MH - Treatment Outcome MH - *Adjuvants, Immunologic/therapeutic use MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/complications MH - *Asymptomatic Infections MH - Administration, Intravesical MH - Progression-Free Survival EDAT- 2026/04/24 06:33 MHDA- 2026/04/24 06:34 CRDT- 2026/04/24 04:43 PHST- 2025/10/31 00:00 [received] PHST- 2026/01/21 00:00 [accepted] PHST- 2026/04/24 06:34 [medline] PHST- 2026/04/24 06:33 [pubmed] PHST- 2026/04/24 04:43 [entrez] AID - 10.2340/sju.v61.45539 [doi] PST - epublish SO - Scand J Urol. 2026 Apr 24;61:148-155. doi: 10.2340/sju.v61.45539. PMID- 42024907 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 0971-5916 (Print) IS - 0971-5916 (Linking) VI - 163 IP - 3 DP - 2026 Mar TI - Expression levels of miRNA 22-5p and miRNA 337-5p in bladder cancer. PG - 290-294 LID - 10.25259/IJMR_2226_2025 [pii] AB - Background and objectives MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression at the post-transcriptional level and play critical roles in tumour development and progression. Bladder cancer requires reliable molecular biomarkers for diagnosis and prognosis; the roles of certain miRNAs remain insufficiently explored. This study aimed to investigate the expression profiles of miR-22-5p and miR-337-5p in bladder cancer and to evaluate their associations with clinicopathological characteristics. Methods Paired tumour and adjacent non-tumorous bladder tissue samples were collected from 50 patients undergoing transurethral resection of bladder tumour. Quantitative PCR was performed using RNA U6 as the reference gene. Expression differences were analysed, and correlations with clinicopathological features were assessed. Results Both miR-22-5p and miR-337-5p were downregulated in tumour tissues compared to normal tissues. miR-22-5p expression showed a marked reduction in bladder cancer, while miR-337-5p downregulation reached borderline statistical significance. Correlation analyses revealed no association between miR-22-5p expression and clinical variables; however, miR-337-5p expression was significantly correlated with patient age and disease duration. Interpretation and conclusions Altered expression of miR-22-5p and miR-337-5p may contribute to bladder cancer pathogenesis. miR-22-5p appears as a potential tumour suppressor, while miR-337-5p expression is influenced by clinical parameters such as age and disease duration, highlighting their potential roles as prognostic and therapeutic biomarkers. FAU - Dagdeviren, Mehmet Aydin AU - Dagdeviren MA AD - 1, Department of Biology, Health Services, Gaziantep University, Gaziantep, Turkey. FAU - Oguzkan, Sibel Bayil AU - Oguzkan SB AD - 2, Department of Medical Services and Techniques, Health Services, Gaziantep University, Gaziante, Turkey. FAU - Ozaslan, Mehmet AU - Ozaslan M AD - 1, Department of Biology, Health Services, Gaziantep University, Gaziantep, Turkey. FAU - Erturhan, Mehmet Sakip AU - Erturhan MS AD - 3, Department of Urology, Gaziantep University Medical Faculty Research Hospital, Gaziantep, Turkey. LA - eng PT - Journal Article PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *MicroRNAs/genetics MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - *Biomarkers, Tumor/genetics MH - Male MH - Middle Aged MH - Prognosis MH - Aged PMC - PMC13126542 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Microrna OT - Mir-22-5p OT - Mir-337-5p OT - Prognosis COIS- None. EDAT- 2026/04/23 18:34 MHDA- 2026/04/23 18:35 PMCR- 2026/03/01 CRDT- 2026/04/23 17:22 PHST- 2025/08/20 00:00 [received] PHST- 2025/12/11 00:00 [accepted] PHST- 2026/04/23 18:35 [medline] PHST- 2026/04/23 18:34 [pubmed] PHST- 2026/04/23 17:22 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - 10.25259/IJMR_2226_2025 [pii] AID - 10.25259/IJMR_2226_2025 [doi] PST - ppublish SO - Indian J Med Res. 2026 Mar;163(3):290-294. doi: 10.25259/IJMR_2226_2025. PMID- 42024120 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260817 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 2 DP - 2026 Aug TI - Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis. PG - 257-266 LID - 10.1111/bju.70297 [doi] AB - OBJECTIVE: To provide insight into real-world surveillance practices for patients with low-risk (LR), intermediate-risk (IR), and (very) high-risk (HR) non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Cystoscopy surveillance patterns were analysed using real-world data from two population-based cohort studies in the Netherlands, comparing practices to guideline recommendations by risk group. As bladder cancer-related symptoms may prompt diagnostic investigations beyond routine follow-up, we evaluated the occurrence of such symptoms and the use of various diagnostics including cystoscopy in a subset of patients with available data. RESULTS: In total, 2791 primary and recurrent tumours were included in the analyses. Among patients with LR NMIBC, 37.6% were monitored more intensively than recommended. The average number of cystoscopies in the first follow-up year was 1.3 (range 0-4). IR NMIBCs were generally monitored in accordance with guideline recommendations. However, adherence declined over the years following diagnosis, dropping from 78.1% to 59.3%. The proportion of patients with IR NMIBCs who were monitored less than recommended increased from 21.7% to 39.8%. Most HR NMIBCs (88.2%) were monitored less than recommended, though adherence improved over time. In-depth analysis of 204 tumours revealed that next to cystoscopy, cytology was frequently employed, increasing with risk group (LR: 50.0%, IR: 52.3%, HR: 88.9%). Imaging (25-65%) and biopsies (25-85%) were also commonly performed. Surveillance patterns varied especially among IR NMIBCs. Symptoms were reported in approximately one third of bladder tumours during follow-up but did not appear to affect surveillance patterns. CONCLUSION: Our findings demonstrate substantial deviations from recommended NMIBC surveillance practices, with cystoscopy overuse in LR disease and underuse in HR cases. Surveillance of IR NMIBC was particularly heterogenous, using varying diagnostic investigations. These insights highlight the need to refine NMIBC surveillance schedules to improve patient outcomes and optimise healthcare resource allocation. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - van Hoogstraten, Lisa M C AU - van Hoogstraten LMC AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Hof, Jasper P AU - Hof JP AUID- ORCID: 0000-0002-7461-6364 AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Center for Quantitative Genetics and Genomics, Aarhus University, Aarhus, Denmark. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng GR - KWF Kankerbestrijding/ GR - KUN 2013-5926/KWF Dutch Cancer Society/Alpe d'HuZes/ GR - 2017-2/11179/KWF Dutch Cancer Society/ PT - Journal Article DEP - 20260423 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/epidemiology/diagnosis MH - Female MH - Male MH - Cystoscopy/statistics & numerical data MH - Aged MH - Netherlands/epidemiology MH - Middle Aged MH - Guideline Adherence/statistics & numerical data MH - Aged, 80 and over MH - Population Surveillance MH - Risk Assessment MH - *Urinary Bladder Neoplasms/pathology MH - Risk Factors PMC - PMC13371837 OTO - NOTNLM OT - bladder cancer OT - guideline adherence OT - non-muscle invasive bladder cancer OT - practice patterns OT - real-world data OT - surveillance EDAT- 2026/04/23 12:52 MHDA- 2026/07/15 18:39 PMCR- 2026/07/15 CRDT- 2026/04/23 10:43 PHST- 2026/07/15 18:39 [medline] PHST- 2026/04/23 12:52 [pubmed] PHST- 2026/04/23 10:43 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - BJU70297 [pii] AID - 10.1111/bju.70297 [doi] PST - ppublish SO - BJU Int. 2026 Aug;138(2):257-266. doi: 10.1111/bju.70297. Epub 2026 Apr 23. PMID- 42023750 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 78 IP - 2 DP - 2026 Apr TI - Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center. PG - 249-256 LID - 10.23736/S2724-6051.26.06722-4 [doi] AB - BACKGROUND: Radical cystectomy (RC) is the gold standard for muscle-invasive and recurrent high-risk non-muscle-invasive bladder cancer (BCa). Over time, robot-assisted radical cystectomy (RARC) has gained adoption. Despite technological advancements, survival differences may persist between patients treated in earlier versus recent years. This study examines temporal variations in overall survival (OS) among patients undergoing robotic-assisted radical cystectomy (RARC) at a high-volume tertiary robotic center, comparing a historical cohort (2003-2016) with a contemporary one (2017-2024). METHODS: Data from patients undergoing RARC at AZORG Hospital (Aalst, Belgium) between July 2003 and March 2024 were analyzed. Three experienced surgeons performed all procedures. Baseline characteristics were compared, Kaplan-Meier plots illustrated OS, and Cox regression models evaluated overall mortality (OM). An 18-month landmark analysis minimized immortal time bias. RESULTS: Overall, 358 BCa patients underwent RARC (53% historical vs. 47% contemporary). The 3-year OS was 85% for the historical cohort vs. 93% for the contemporary cohort (P=0.001). Multivariable Cox regression showed that treatment in the contemporary cohort was an independent predictor of lower OM (hazard ratio [HR]: 0.52, 95% CI: 0.34-0.83; P=0.006), with further reduction after the 18-month landmark analysis (HR: 0.42, 95% CI: 0.19-0.92; P=0.03). Higher pathological T stage (pT3-4) was associated with increased OM before (HR: 3.9, 95% CI: 2.19-6.95; P<0.001) and after landmark analysis (HR: 2.25, 95% CI: 1.08-4.68; P=0.03). Grade 3-4 Clavien-Dindo complications predicted higher OM before (HR: 2.02, 95% CI: 1.27-3.22; P=0.003), but not after landmark analysis (HR: 2.04; 95% CI: 0.99-4.18; P=0.052). CONCLUSIONS: Patients treated between 2017-2024 had significantly lower OM, with a 50% reduction in mortality risk compared to 2003-2016. Advancements in surgical techniques and perioperative care likely contributed to improved OS. However, pathological T stage remained a strong predictor of OM, highlighting the need for enhanced early detection and disease management despite technological progress. FAU - Resca, Stefano AU - Resca S AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Morra, Simone AU - Morra S AD - Department of Urology, AZORG Hospital, Aalst, Belgium - simonemorra@outlook.com. AD - ORSI Academy, Ghent, Belgium. AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, School of Medicine, University of Naples Federico II, Naples, Italy. FAU - Frego, Nicola AU - Frego N AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Department of Urology, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. FAU - Tamburini, Sara AU - Tamburini S AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Ticonosco, Marco AU - Ticonosco M AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, School of Medicine, University of Naples Federico II, Naples, Italy. FAU - Pissavini, Alessandro AU - Pissavini A AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Mourullo, Andrea N AU - Mourullo AN AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - UROINTEC Urologia, Innovacion, Tecnologia, Gran Canaria, Spain. FAU - Barletta, Francesco AU - Barletta F AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. AD - Division of Oncology/Unit of Urology (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Lambert, Edward AU - Lambert E AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - D'Hondt, Frederiek AU - D'Hondt F AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - DE Groote, Ruben AU - DE Groote R AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - DE Naeyer, Geert AU - DE Naeyer G AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - Mottrie, Alexandre AU - Mottrie A AD - Department of Urology, AZORG Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. LA - eng PT - Journal Article PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 SB - IM MH - Humans MH - *Cystectomy/methods/mortality MH - *Robotic Surgical Procedures MH - *Urinary Bladder Neoplasms/surgery/mortality MH - Male MH - Female MH - Aged MH - Tertiary Care Centers MH - Time Factors MH - Treatment Outcome MH - Survival Rate MH - Middle Aged MH - Hospitals, High-Volume MH - Retrospective Studies MH - Non-Muscle Invasive Bladder Neoplasms MH - Belgium/epidemiology EDAT- 2026/04/23 12:53 MHDA- 2026/04/23 12:54 CRDT- 2026/04/23 08:11 PHST- 2026/04/23 12:54 [medline] PHST- 2026/04/23 12:53 [pubmed] PHST- 2026/04/23 08:11 [entrez] AID - S2724-6051.26.06722-4 [pii] AID - 10.23736/S2724-6051.26.06722-4 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2026 Apr;78(2):249-256. doi: 10.23736/S2724-6051.26.06722-4. PMID- 42023708 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260819 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 4 IP - 4 DP - 2026 Apr 23 TI - Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy. PG - CD013336 LID - 10.1002/14651858.CD013336.pub2 [doi] LID - CD013336 AB - RATIONALE: We are currently uncertain of the benefits and harms of standard pelvic lymph node dissection (PLND) compared to extended PLND in the treatment of urothelial carcinoma of the bladder. OBJECTIVES: To assess the effects of extended versus standard PLND in people undergoing cystectomy to treat muscle-invasive (cT2 and cT4a) and treatment-refractory, non-muscle-invasive (cT1 with or without carcinoma in situ) urothelial carcinoma of the bladder. SEARCH METHODS: We conducted a comprehensive literature search using multiple databases (CENTRAL, PubMed, Embase, Web of Science, and LILACS), trial registries, and conference proceedings published up to 24 September 2025, with no restrictions on language or publication status. ELIGIBILITY CRITERIA: We included randomized controlled trials (RCTs) in which participants underwent radical cystectomy for muscle-invasive or therapy-refractory non-muscle-invasive urothelial carcinoma of the bladder with either an extended PLND with an upper extent reaching as far as the inferior mesenteric artery, or a standard PLND up to the bifurcation of the internal and external iliac artery, with otherwise the same anatomical boundaries. OUTCOMES: Critical outcomes were time to death from any cause (assessed at five years), time to death from bladder cancer (assessed at five years), and Clavien-Dindo classification of surgical complications grade III-V (assessed up to 90 days' postoperatively). Important outcomes were time to recurrence (assessed at five years), Clavien-Dindo I-II complications (assessed up to 90 days' postoperatively), and disease-specific quality of life. RISK OF BIAS: We used the Cochrane RoB 2 tool to assess the risk of bias in the included studies. SYNTHESIS METHODS: We conducted statistical analyses according to the guidance in the Cochrane Handbook for Systematic Reviews of Interventions. We combined the results for each outcome using a meta-analysis with a random-effects model. We employed GRADE to evaluate the certainty of the evidence. INCLUDED STUDIES: We included two RCTs with 993 randomized participants (extended PLND 490, standard PLND 503). Both studies were published in full text. The median age of both groups was similar, ranging from 67 to 69 years for the extended group and 68 years for the standard group. All participants had locally completely resectable, invasive urothelial bladder cancer. SYNTHESIS OF RESULTS: Overall, the certainty of evidence for most outcomes was moderate to low, primarily downgraded due to imprecision. Time to death from any cause Extended PLND may result in little to no difference in time to death from any cause as compared to standard PLND (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.75 to 1.30; 2 studies, 993 participants; low-certainty evidence). Based on the control event risk of 43.0% at five-year follow-up, this corresponds to 3 fewer deaths from any cause (95% CI 86 fewer to 88 more) per 1000 participants. Time to death from bladder cancer Extended PLND likely extends the time to death from bladder cancer as compared to standard PLND (HR 0.65, 95% CI 0.44 to 0.97; 1 study, 401 participants; moderate-certainty evidence). Based on the control event risk of 35.0% at five-year follow-up, this corresponds to 106 fewer deaths from bladder cancer (95% CI 177 fewer to 8 fewer) per 1000 participants. Clavien-Dindo grade >/= 3 complications (up to 90 days) Extended PLND likely increases Clavien-Dindo grade >/= 3 complications as compared to standard PLND (risk ratio [RR] 1.22, 95% CI 1.06 to 1.41; 2 studies; 993 participants; moderate-certainty evidence). Based on the control event risk of 39.0% at 90-day follow-up, this corresponds to 86 more complications (95% CI 23 more to 160 more) per 1000 participants. Time to recurrence Extended PLND may result in little to no difference in time to recurrence as compared to standard PLND (HR 0.96, 95% CI 0.71 to 1.31; 2 studies, 993 participants; low-certainty evidence). Based on the control event risk of 40.0% at five-year follow-up, this corresponds to 12 fewer recurrences (95% CI 96 fewer to 88 more) per 1000 participants. Clavien-Dindo grade /= 3), while likely showing similar rates of minor complications (grade /= T2 (p = 0.006, p = 0.006, and p = 0.001, respectively). Multivariable analysis identified T stage as an independent risk factor for PFS, CSS, and OS, irrespective of age, treatment modality, and VH type (HR: 5.45, p = 0.01; HR: 3.67, p = 0.006; and HR: 2.68, p = 0.01, respectively). While tumor stage remains a key prognostic factor in VH, our findings suggest that TMT may be a viable alternative to RC. CI - (c) The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Demirci, Aykut AU - Demirci A AUID- ORCID: 0000-0001-8921-4571 AD - University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Urology, Ankara, Turkey. ROR: https://ror.org/02nj8cq30 FAU - Uzel, Tuncel AU - Uzel T AD - University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Urology, Ankara, Turkey. ROR: https://ror.org/02nj8cq30 LA - eng PT - Journal Article DEP - 20250805 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC13096458 OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Non-muscle invasive bladder cancer OT - Radical cystectomy OT - Radiotherapy OT - Squamous cell carcinoma COIS- Conflict of interestThe authors declare no conflict of interest. EDAT- 2026/04/23 06:32 MHDA- 2026/04/23 06:33 PMCR- 2027/04/01 CRDT- 2026/04/23 05:19 PHST- 2024/12/05 00:00 [received] PHST- 2025/07/23 00:00 [accepted] PHST- 2026/04/23 06:33 [medline] PHST- 2026/04/23 06:32 [pubmed] PHST- 2026/04/23 05:19 [entrez] PHST- 2027/04/01 00:00 [pmc-release] AID - 2394 [pii] AID - 10.1007/s13193-025-02394-6 [doi] PST - ppublish SO - Indian J Surg Oncol. 2026 Apr;17(4):721-727. doi: 10.1007/s13193-025-02394-6. Epub 2025 Aug 5. PMID- 42022227 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260423 LR - 20260813 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 4 DP - 2026 Apr TI - Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naive non-muscle invasive bladder cancer: Systematic review and meta-analysis. PG - e70194 LID - 10.1002/bco2.70194 [doi] LID - e70194 AB - OBJECTIVE: The objective of this study is to assess the efficacy, safety and change in quality of life associated with ICI-BCG (I + M) compared to BCG (I + M) in patients with BCG-naive HR-NMIBC. MATERIAL AND METHODS: A systematic search was run on PubMed, Embase and CENTRAL from inception to 29 October 2025. Phase 3 randomized controlled trials comparing safety, efficacy and quality of life (QOL) for patients with BCG-naive HR-NMIBC receiving ICI-BCG (I + M) versus BCG (I + M): hazard ratios (HR) and 95% confidence interval (95% CI) for HG-RFS (high-grade recurrence free survival), odds ratio (OR) and 95% CI for Grade >/=3 treatment-related adverse events (G3 + TRAEs), and mean difference (MD) and 95% CI for changes in quality of life (QOL measured using EORTC QLQ C30). A priori defined subgroups included presence of CIS, presence of papillary tumours, age <65 or >/=65 years, male/female, and BCG strain. RESULTS: Pooled results indicated that ICI-BCG (I + M) was not associated with a reduction in HG-RFS (HR: 0.78; 95% CI: 0.59-1.02). However, on sensitivity analysis excluding ALBAN (for differences in trial design and patients included), ICI-BCG (I + M) was associated with a reduction in HG-RFS (HR: 0.68; 95% CI: 0.54-0.85) with an absolute risk reduction of 4.4-7.3% in 36-month HG-RFS. ICI-BCG (I + M) was associated with an increased risk of G3 + TRAEs (OR: 4.76; 95% CI: 3.01-7.53). ICI-BCG (I + M) was associated with a non-clinically significant decline in QOL (MD: -3.25; 95% CI: -5.11 to -1.39). Heterogeneity between trials was minimal (tau (2) < 1). Risk of bias was low in all included studies. CONCLUSION: This pooled analysis provides data for patient-specific counselling on the use of ICI-BCG (I + M) for BCG-naive HR-NMIBC. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Titus, Renil S AU - Titus RS AUID- ORCID: 0000-0002-5486-749X AD - Department of Urology Houston Methodist Hospital Houston Texas USA. FAU - Riveros, Carlos AU - Riveros C AD - Department of Urology Houston Methodist Hospital Houston Texas USA. FAU - Velasquez, Eusebio Luna AU - Velasquez EL AD - Department of Urology Houston Methodist Hospital Houston Texas USA. FAU - Nguyen, David-Dan AU - Nguyen DD AD - Division of Urology, Department of Surgery University of Toronto Toronto Ontario Canada. FAU - Somawardana, Suran AU - Somawardana S AD - Rice University Houston Texas USA. FAU - Singh, Amar AU - Singh A AD - Southwestern University Georgetown Texas USA. FAU - Kaushik, Dharam AU - Kaushik D AD - Department of Urology Houston Methodist Hospital Houston Texas USA. FAU - Sonpavde, Guru AU - Sonpavde G AD - Advent Health Cancer Institute Orlando Florida USA. FAU - Zlotta, Alexandre AU - Zlotta A AD - Division of Urology, Department of Surgery University of Toronto Toronto Ontario Canada. AD - Division of Urology Mount Sinai Hospital Toronto Ontario Canada. AD - Division of Urology, Department of Surgery University Health Network Toronto Ontario Canada. FAU - Kulkarni, Girish AU - Kulkarni G AD - Division of Urology, Department of Surgery University of Toronto Toronto Ontario Canada. AD - Division of Urology, Department of Surgery University Health Network Toronto Ontario Canada. FAU - Sridhar, Srikala S AU - Sridhar SS AD - Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network University of Toronto Toronto Ontario Canada. FAU - Wallis, Christopher J D AU - Wallis CJD AUID- ORCID: 0000-0002-5990-4026 AD - Division of Urology, Department of Surgery University of Toronto Toronto Ontario Canada. AD - Division of Urology Mount Sinai Hospital Toronto Ontario Canada. AD - Division of Urology, Department of Surgery University Health Network Toronto Ontario Canada. FAU - Satkunasivam, Raj AU - Satkunasivam R AD - Department of Urology Houston Methodist Hospital Houston Texas USA. LA - eng PT - Journal Article PT - Review DEP - 20260331 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC13098361 OTO - NOTNLM OT - BCG naive OT - immune checkpoint inhibition OT - non-muscle invasive bladder cancer OT - urothelial carcinoma COIS- Christopher J.D. Wallis has received consulting fees from Johnson & Johnson Innovative Medicine and Nanostics Inc.; honoraria/travel from AbbVie, Astellas, Astra Zeneca, Bayer, Johnson & Johnson Innovative Medicine, Knight Therapeutics, Intuitive Surgical, MashUP Media, Merck, Pfizer, Science & Medicine Canada, Sumitomo Pharmaceuticals, TerSera Canada, and Tolmar Pharmaceuticals Canada; and research funding from Astellas, Bayer, Knight Therapeutics, Sunnybrook HSC AFP, and Tolmar Pharmaceuticals. Srikala S. Sridhar has received consulting fees from AstraZeneca, Bayer, Bicycle Therapeutics, BMS, Daiichi Sankyo, EMD Serono, Gilead, Janssen, Merck, and Pfizer and research funding (institution) from Pfizer, Bayer, and EMD Serono. Raj Satkunasivam has received research funding or support to institution from Pfizer, Merck, UroGen, enGene, Photocure, Janssen, ProTARA, and CG Oncology and consulting fees from Pfizer (2022-2025), Intuitive Surgical (Proctor, 2019; 2023), and Ferring (2025). EDAT- 2026/04/23 06:32 MHDA- 2026/04/23 06:33 PMCR- 2026/03/31 CRDT- 2026/04/23 05:09 PHST- 2026/01/02 00:00 [received] PHST- 2026/02/13 00:00 [revised] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/04/23 06:33 [medline] PHST- 2026/04/23 06:32 [pubmed] PHST- 2026/04/23 05:09 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - BCO270194 [pii] AID - 10.1002/bco2.70194 [doi] PST - epublish SO - BJUI Compass. 2026 Mar 31;7(4):e70194. doi: 10.1002/bco2.70194. eCollection 2026 Apr. PMID- 42012493 OWN - NLM STAT- MEDLINE DCOM- 20261015 LR - 20261015 IS - 2366-0058 (Electronic) VI - 51 IP - 11 DP - 2026 Nov TI - Habitat-based radiomics-clinical analysis for early prediction of bladder cancer recurrence: a retrospective cohort study. PG - 5589-5600 LID - 10.1007/s00261-026-05516-y [doi] AB - PURPOSE: A high recurrence rate is a serious problem in the bladder cancer (BC) treatment. To develop a habitat-based radiomics-clinical model for noninvasive recurrence prediction in BC patients undergoing transurethral resection of bladder tumor (TURBT) or radical cystectomy (RC). METHODS: We retrospectively enrolled 294 BC patients who underwent TURBT or RC at our Hospital. Tumor regions of interest (ROIs) were automatically segmented and manually checked. Voxel-wise radiomic features were extracted. The K-means clustering algorithm was applied to perform cluster analysis on the extracted features. The Calinski-Harabasz (CH) index was calculated to determine the optimal number of clusters (the one yielding the highest CH value). Subsequently, features from these subregions were extracted and further filtered using the t-test and Pearson correlation analysis. The final feature set was selected through the least absolute shrinkage and selection operator regression. The dataset was randomly divided into the training (n = 235) and validation (n = 59) sets (8:2 ratio) for model training and evaluation. The habitat-based radiomics model based on Support Vector Machine (SVM) was developed based on the final feature set. Additionally, we combined clinical risk factors to establish and validate a radiomics-clinical model. RESULTS: We divided the tumor ROIs into three subregions. The Areas Under the Curve (AUCs) for the habitat-based radiomics-model were 0.870 (95% confidence interval [CI]: 0.825-0.914) and 0.865 (95% CI: 0.774-0.956) in the training and validation set. The radiomics-clinical model, incorporating tumor grades and intravesical therapy, achieved AUCs of 0.883 (95% CI: 0.842-0.924) and 0.956 (95% CI: 0.912-1.000) in the training and validation sets, respectively. CONCLUSIONS: The habitat-based radiomics-clinical model demonstrated superior performance in predicting BC recurrence. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Yang, Yanjie AU - Yang Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Gong, Bingxin AU - Gong B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Kong, Xiangchuang AU - Kong X AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Guo, Yusheng AU - Guo Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Lou, Jie AU - Lou J AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Fu, Xiaona AU - Fu X AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Liu, Weiwei AU - Liu W AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. FAU - Feng, Qingmin AU - Feng Q AD - Institute of Biomedical Engineering, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. qingmin_feng@hust.edu.cn. FAU - Yang, Lian AU - Yang L AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. yanglian@hust.edu.cn. AD - Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China. yanglian@hust.edu.cn. AD - Hubei Key Laboratory of Molecular Imaging, Wuhan, China. yanglian@hust.edu.cn. LA - eng GR - 2022BCA025/Key Research and Development Plan of Hubei Province/ GR - 82472058 and 82172034/National Natural Science Foundation of China/ PT - Journal Article DEP - 20260421 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - *Radiomics MH - Humans MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery/pathology MH - *Neoplasm Recurrence, Local/diagnostic imaging MH - Female MH - Male MH - Aged MH - Transurethral Resection of Bladder MH - Cystectomy MH - Middle Aged MH - *Tomography, X-Ray Computed/methods MH - Predictive Value of Tests OTO - NOTNLM OT - Bladder cancer OT - Habitat analysis OT - Medical image OT - Radiomics COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval: This retrospective study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Hospital (IRB No.0361-01). Consent to participate: The study was conducted in accordance with the Declaration of Helsinki. The Ethics Committee waived the requirement for written informed consent due to the retrospective nature of the study. Consent for publication: Not applicable. EDAT- 2026/04/21 18:34 MHDA- 2026/10/15 23:30 CRDT- 2026/04/21 11:02 PHST- 2026/02/10 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/10/15 23:30 [medline] PHST- 2026/04/21 18:34 [pubmed] PHST- 2026/04/21 11:02 [entrez] AID - 10.1007/s00261-026-05516-y [pii] AID - 10.1007/s00261-026-05516-y [doi] PST - ppublish SO - Abdom Radiol (NY). 2026 Nov;51(11):5589-5600. doi: 10.1007/s00261-026-05516-y. Epub 2026 Apr 21. PMID- 42004060 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260420 LR - 20260813 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 16 IP - 3 DP - 2026 TI - Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis. PG - 771-795 LID - 10.62347/VSXB5813 [doi] AB - High-grade Ta bladder cancer, although anatomically confined to the mucosa, exhibits aggressive biological behavior with high recurrence rate and progression risks. The role of repeat transurethral resection of bladder tumor (Re-TURBT) in this specific population remains controversial. This retrospective cohort study aimed to evaluate the therapeutic and prognostic value of Re-TURBT for high-grade Ta non-muscle-invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. A total of 324 patients with pathologically confirmed high-grade Ta urothelial carcinoma who underwent initial TURBT from January 2014 to June 2023 were included in this study. Among them, 196 underwent Re-TURBT within 2-6 weeks, whereas 128 did not. PSM was performed in a 1:1 ratio using a caliper width of 0.10, resulting in 70 matched pairs with comparable baseline characteristics. Recurrence-free survival (RFS) was defined as primary outcome. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the residual tumor detection rate. In the Re-TURBT group, residual tumor was detected in 29.6% of patients, with pathological upstaging observed in 8.6% of cases (7.1% to T1 and 1.5% to T2). The Re-TURBT group showed significantly lower recurrence rates (14.3% vs. 50.0%; P<0.001) and progression rates (4.3% vs. 15.7%; P=0.024). Cox regression identified Re-TURBT as an independent protective factor for RFS (HR=0.217, 95% CI: 0.107-0.439, P<0.001) and PFS (HR=0.253, 95% CI: 0.070-0.906, P=0.023); however, Re-TURBT was not significantly associated with OS (P=0.854). Subgroup analyses revealed that the benefits of Re-TURBT were particularly pronounced in patients with larger tumors (>3.2 cm) and those not receiving BCG maintenance therapy. The overall complication rate was 6.12%. All complications were mild to moderate and were managed conservatively. To sum up, in patients with high grade Ta bladder cancer, Re-TURBT significantly reduces the risks of recurrence and progression and should be considered an integral component of high-risk NMIBC management, particularly for patients with larger tumors or suboptimal BCG maintenance therapy. CI - AJCR Copyright (c) 2026. FAU - Zhang, Xiaoxi AU - Zhang X AD - Department of Urology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology Wuhan 430000, Hubei, China. FAU - Wang, Lei AU - Wang L AD - Department of Pathology, Pu'er People's Hospital Pu'er 665000, Yunnan, China. FAU - Sun, Wenjun AU - Sun W AD - Department of Endocrine Genetic Metabolism in Children, Maternal and Child Hospital of Hubei Province Tongji Medical College Huazhong University of Science and Technology Wuhan 430000, Hubei, China. FAU - Yang, Xiangli AU - Yang X AD - Department of Urology, Geriatric Hospital Affiliated to Wuhan University of Science and Technology Wuhan 430000, Hubei, China. LA - eng PT - Journal Article DEP - 20260315 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC13090488 OTO - NOTNLM OT - Bladder cancer OT - high-grade Ta OT - prognosis OT - propensity score matching OT - repeat transurethral resection COIS- None. EDAT- 2026/04/20 13:10 MHDA- 2026/04/20 13:11 PMCR- 2026/03/15 CRDT- 2026/04/20 07:26 PHST- 2026/01/09 00:00 [received] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/04/20 13:11 [medline] PHST- 2026/04/20 13:10 [pubmed] PHST- 2026/04/20 07:26 [entrez] PHST- 2026/03/15 00:00 [pmc-release] AID - 10.62347/VSXB5813 [doi] PST - epublish SO - Am J Cancer Res. 2026 Mar 15;16(3):771-795. doi: 10.62347/VSXB5813. eCollection 2026. PMID- 42003978 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260421 LR - 20260813 IS - 2692-3114 (Electronic) IS - 2692-3114 (Linking) VI - 7 DP - 2026 TI - Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC. PG - 1002365 LID - 10.37349/etat.2026.1002365 [doi] LID - 1002365 AB - AIM: Intravesical Bacillus Calmette-Guerin (BCG) is the standard therapy for non-muscle invasive bladder cancer (NMIBC); however, many patients experience recurrence or progression. We examined how urinary immune signals and the urinary microbiome change across BCG and are related to outcomes. METHODS: In this single-center prospective cohort study, adults with NMIBC underwent transurethral resection of bladder tumor (TURBT), followed by BCG induction. Urine was collected before TURBT, before BCG, after BCG induction, and three months later. Urine sediment mRNA (PD-L1, PD-L2, CD33, and CD204) was quantified using TaqMan DeltaCt. The urinary microbiome was profiled using 16S rRNA gene sequencing, and diversity, composition, and taxon balance were evaluated using nonparametric tests, PERMANOVA, repeated-measures correlations, and mixed-effects models. We analyzed the relationship between the urinary microbiome and prognosis. RESULTS: Twenty-three patients were analyzed; ten recurrences, eight progressions, and three deaths were observed. Relative to baseline, CD33 increased after BCG and after three months; PD-L2 increased immediately after BCG and returned to baseline by three months; PD-L1 and CD204 increased after BCG. Shannon alpha-diversity was unchanged, but total read count was higher at three months, with stable beta-diversity and dispersion. Higher PD-L1 expression was associated with lower Actinobacteria abundance in the bladder cancer microenvironment. A higher post-BCG Firmicutes/Bacteroidetes ratio was associated with worse prognosis, with the clearest signal for progression-free survival (PFS) observed in the univariate Cox models. Higher post-BCG Corynebacterium and Enterobacteriaceae abundance was associated with better PFS. CONCLUSIONS: BCG was associated with higher urinary PD-L1/PD-L2 and myeloid marker transcripts, while overall community structure remained stable. These exploratory data support that pre-BCG microbial features may be related to early response, and post-BCG profiles may reflect durability and survival. Urine immune-microbiome profiling could be a feasible, noninvasive adjunct for monitoring and risk stratification in NMIBC. CI - (c) The Author(s) 2026. FAU - Oda, Yuki AU - Oda Y AUID- ORCID: 0000-0003-3909-1133 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AUID- ORCID: 0009-0000-1150-1298 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Iida, Kota AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Nakai, Yasushi AU - Nakai Y AUID- ORCID: 0000-0002-7579-0372 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AUID- ORCID: 0000-0001-9242-7877 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, Kashihara 634-8521, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. LA - eng PT - Journal Article DEP - 20260413 PL - United States TA - Explor Target Antitumor Ther JT - Exploration of targeted anti-tumor therapy JID - 101770662 PMC - PMC13087446 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) therapy OT - Firmicutes/Bacteroidetes ratio OT - non-muscle invasive bladder cancer OT - progression-free survival OT - urinary immune profiling OT - urinary microbiome dynamics COIS- Yuki Oda and Makito Miyake, who are the Guest Editors of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or review process of this manuscript. The other authors declare no conflicts of interest. EDAT- 2026/04/20 13:10 MHDA- 2026/04/20 13:11 PMCR- 2026/04/13 CRDT- 2026/04/20 07:25 PHST- 2025/11/29 00:00 [received] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/04/20 13:11 [medline] PHST- 2026/04/20 13:10 [pubmed] PHST- 2026/04/20 07:25 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.37349/etat.2026.1002365 [doi] PST - epublish SO - Explor Target Antitumor Ther. 2026 Apr 13;7:1002365. doi: 10.37349/etat.2026.1002365. eCollection 2026. PMID- 42002631 OWN - NLM STAT- In-Process LR - 20260921 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Apr 20 TI - A molecular landscape tracking the progression of non-muscle invasive bladder cancer. LID - 10.1007/s00345-026-06406-0 [doi] LID - 320 AB - PURPOSE: We aim to report transcriptomic biomarkers derived from available open-access studies that can reliably monitor the progression of bladder tumors from non-invasive (non-muscle-invasive bladder cancer, NMIBC) to invasive stages (muscle-invasive bladder cancer, MIBC) of bladder cancer, as well as within the different stages of NMIBC. These biomarkers hold exciting potential for use in clinical settings, offering valuable insights for both diagnosis and prognosis. METHODS: A comprehensive literature review on bladder cancer studies was conducted in primary bibliographic databases, selecting gene expression studies that illustrate bladder tumor progression, either alone or within gene-set datasets. RESULTS: A plethora of dysregulated gene expression signatures guide the evolution of bladder cancer through its progressive forms and predict the oncological outcomes for cancer patients. The oncotarget genes and abnormalities in the mitotic spindle play a significant role in promoting tumor development and progression. At the cellular level, substantial tumor morphological changes in the urothelium and extracellular matrix support this process. CONCLUSION: The molecular snapshot of biomarkers reflects the heterogeneity of bladder tumors during their progression. Despite this relevance, none of these biomarkers has yet been implemented in the clinical management of bladder cancer. However, this evidence supports their potential future clinical utility for stratifying bladder cancer patients and aiding the development of targeted drug therapies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-026-06406-0. FAU - Cesta, Giuseppe AU - Cesta G AD - Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). FAU - Zolfanelli, Cinzia AU - Zolfanelli C AD - Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). FAU - Lauciello, Vincenzo AU - Lauciello V AD - Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). FAU - Lorusso, Vincenzo AU - Lorusso V AD - Department of Urology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). FAU - Di Giacomo, Ferdinando AU - Di Giacomo F AD - Department of Urology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). FAU - Mazzone, Pellegrino AU - Mazzone P AD - Biogem S.c.a.r.l., Istituto Di Ricerche Genetiche 'Gaetano Salvatore', Avellino (AV), 83031, Ariano Irpino, Italy. FAU - D'Amore, Teresa AU - D'Amore T AD - Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB). AD - Department of Food Safety, Nutrition and Veterinary Public Health Istituto Superiore di Sanita (Italian National Institute of Health), Viale Regina Elena 299, 00161, Rome, Italy. FAU - Di Paola, Giuseppina AU - Di Paola G AD - Biogem S.c.a.r.l., Istituto Di Ricerche Genetiche 'Gaetano Salvatore', Avellino (AV), 83031, Ariano Irpino, Italy. FAU - Bravoco, Daniele AU - Bravoco D AD - Biogem S.c.a.r.l., Istituto Di Ricerche Genetiche 'Gaetano Salvatore', Avellino (AV), 83031, Ariano Irpino, Italy. AD - Department of Public Health, University of Naples Federico II, 80147, Naples, Italy. FAU - Falco, Geppino AU - Falco G AD - Department of Biology, University of Naples Federico II, 80147, Naples, Italy. FAU - Sabato, Claudia AU - Sabato C AUID- ORCID: 0000-0001-7533-4660 AD - Laboratory of Preclinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), . claudia.sabato@crob.it. LA - eng PT - Journal Article PT - Review DEP - 20260420 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM PMC - PMC13092541 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Bladder progression OT - Gene signature OT - Non-muscle-invasive bladder cancer COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and consent to participate: Not applicable. Consent to publication: Not applicable. EDAT- 2026/04/20 07:10 MHDA- 2026/04/20 07:10 PMCR- 2026/04/20 CRDT- 2026/04/19 23:15 PHST- 2025/10/01 00:00 [received] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/04/20 07:10 [medline] PHST- 2026/04/20 07:10 [pubmed] PHST- 2026/04/19 23:15 [entrez] PHST- 2026/04/20 00:00 [pmc-release] AID - 10.1007/s00345-026-06406-0 [pii] AID - 6406 [pii] AID - 10.1007/s00345-026-06406-0 [doi] PST - epublish SO - World J Urol. 2026 Apr 20;44(1):320. doi: 10.1007/s00345-026-06406-0. PMID- 42000298 OWN - NLM STAT- MEDLINE DCOM- 20260704 LR - 20260717 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 3 DP - 2026 Jun TI - Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer. PG - 705-709 LID - S2588-9311(26)00096-9 [pii] LID - 10.1016/j.euo.2026.04.001 [doi] AB - BACKGROUND AND OBJECTIVE: Patients with T1 nonmuscle-invasive bladder cancer (NMIBC) face substantial risks of recurrence and progression to muscle-invasive disease. However, current risk stratification tools rely on retrospective data with significant heterogeneity in the reporting of adverse pathological features. The ROGUE-1 registry was designed to address the unmet need for a clean, prospective dataset on primary T1 bladder cancer to enable accurate risk stratification and guide clinical decision-making. METHODS: ROGUE-1 is a multicentric, international, prospective registry enrolling 700 patients with a pathologically confirmed primary diagnosis of T1 bladder cancer across 18 urology centers in Europe and North America. All patients must have T1 disease confirmed at second-look transurethral resection of bladder tumor (TURB). Clinical, pathological, and epidemiological data are prospectively collected using an electronic case report form on the Castor electronic data capture platform. Central pathology review by expert genitourinary pathologists is performed for all specimens. An optional molecular component includes transcriptome analysis of formalin-fixed paraffin-embedded tumor specimens. The primary endpoints are therapy failure rates (recurrence, high-grade recurrence, and progression to muscle-invasive disease). Follow-up data are collected at 3-mo intervals. KEY FINDINGS AND LIMITATIONS: This is a protocol paper; no clinical results are reported. A key limitation is the observational design, which precludes treatment standardization across centers. The optional molecular component may result in variable specimen availability. CONCLUSIONS AND CLINICAL IMPLICATIONS: ROGUE-1 will provide a prospective, multi-institutional dataset to improve risk stratification in T1 NMIBC and identify patients who may benefit from early aggressive treatment versus conservative management. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05792033). CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: david.dandrea@meduniwien.ac.at. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, F-75013 Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. CN - ROGUE-1 Investigators LA - eng SI - ClinicalTrials.gov/NCT05792033 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260418 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Female MH - Humans MH - Male MH - Europe MH - Neoplasm Recurrence, Local/epidemiology MH - *Non-Muscle Invasive Bladder Neoplasms/pathology MH - Prospective Studies MH - *Registries MH - Risk Assessment MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Non-muscle-invasive bladder cancer OT - Prospective registry OT - ROGUE-1 OT - Risk stratification OT - T1 FIR - D'Andrea, David IR - D'Andrea D IRAD- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FIR - Ofner, Heidemarie IR - Ofner H IRAD- Medical University of Vienna, Vienna, Austria. FIR - Oberneder, Katharina IR - Oberneder K IRAD- Medical University of Vienna, Vienna, Austria. FIR - Shariat, Shahrokh F IR - Shariat SF IRAD- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FIR - Soria, Francesco IR - Soria F IRAD- Division of Urology, Department of Surgical Sciences, University of Turin, Turin, Italy. FIR - Gontero, Paolo IR - Gontero P IRAD- Division of Urology, Department of Surgical Sciences, University of Turin, Turin, Italy. FIR - Roupret, Morgan IR - Roupret M IRAD- GRC 5 Predictive Onco-Uro, AP-HP, Urology, Sorbonne University, Pitie-Salpetriere Hospital, Paris, France. FIR - Pellegrino, Antony IR - Pellegrino A IRAD- Sorbonne University, Pitie-Salpetriere Hospital, Paris, France. FIR - Zaurito, Paolo IR - Zaurito P IRAD- Sorbonne University, Pitie-Salpetriere Hospital, Paris, France. FIR - Xylinas, Evanguelos IR - Xylinas E IRAD- Department of Urology, Universite de Paris Cite, Bichat-Claude Bernard Hospital, AP-HP, Paris, France. FIR - Gabriel, Pierre-Etienne IR - Gabriel PE IRAD- Bichat-Claude Bernard Hospital, AP-HP, Paris, France. FIR - Moschini, Marco IR - Moschini M IRAD- Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. FIR - Re, Chiara IR - Re C IRAD- San Raffaele Hospital Milan, IRCCS Ospedale San Raffaele, Milan, Italy. FIR - de Angelis, Mario IR - de Angelis M IRAD- San Raffaele Hospital Milan, IRCCS Ospedale San Raffaele, Milan, Italy. FIR - Hurle, Rodolfo IR - Hurle R IRAD- Humanitas Rozzano, Milan, Italy. FIR - Mancon, Stefano IR - Mancon S IRAD- IEO Milano, Milan, Italy. FIR - Pignot, Geraldine IR - Pignot G IRAD- Marseille Paoli-Calmette, Institut Paoli-Calmettes, Marseille, France. FIR - Richter, Konstantin IR - Richter K IRAD- Marseille Paoli-Calmette, Institut Paoli-Calmettes, Marseille, France. FIR - Yildirim, Asif IR - Yildirim A IRAD- Istanbul Medeniyet University, Istanbul, Turkey. FIR - Culpan, Meftun IR - Culpan M IRAD- Istanbul Medeniyet University, Istanbul, Turkey. FIR - Pradere, Benjamin IR - Pradere B IRAD- Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Neuenschwander, Anne IR - Neuenschwander A IRAD- La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Ploussard, Guillaume IR - Ploussard G IRAD- La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Combes, Laure IR - Combes L IRAD- La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Mavier, Loubna IR - Mavier L IRAD- La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Ghijselings, Lynn IR - Ghijselings L IRAD- La Croix Du Sud Hospital, Quint-Fonsegrives, France. FIR - Leistmann, Conrad IR - Leistmann C IRAD- Medical University of Graz, Graz, Austria. FIR - Koll, Florestan IR - Koll F IRAD- Medical University of Graz, Graz, Austria. FIR - Leistmann, Marianne IR - Leistmann M IRAD- Medical University of Graz, Graz, Austria. FIR - Giudice, Francesco Del IR - Giudice FD IRAD- Policlinico Umberto I Hospital, Rome, Italy. FIR - Oswald, David IR - Oswald D IRAD- Salzburger Universitatsklinik, Salzburg, Austria. FIR - Olesch, Kathrin IR - Olesch K IRAD- Salzburger Universitatsklinik, Salzburg, Austria. FIR - Lusuardi, Lukas IR - Lusuardi L IRAD- Salzburger Universitatsklinik, Salzburg, Austria. FIR - Pallauf, Maximilian IR - Pallauf M IRAD- Salzburger Universitatsklinik, Salzburg, Austria. FIR - Kluth, Luis IR - Kluth L IRAD- Universitatsklinik Frankfurt, Frankfurt, Germany. FIR - Wenzel, Mike IR - Wenzel M IRAD- Universitatsklinik Frankfurt, Frankfurt, Germany. FIR - Banek, Severine IR - Banek S IRAD- Universitatsklinik Frankfurt, Frankfurt, Germany. FIR - Gibb, Ewan IR - Gibb E IRAD- University of British Columbia, Vancouver, Canada. FIR - Cormio, Angelo IR - Cormio A IRAD- University of Foggia, Foggia, Italy. FIR - Martino, Beatrice IR - Martino B IRAD- University of Foggia, Foggia, Italy. FIR - Kielb, Pawel IR - Kielb P IRAD- Wroclaw Medical University, Wroclaw, Poland. FIR - Krajewski, Wojciech IR - Krajewski W IRAD- Wroclaw Medical University, Wroclaw, Poland. FIR - Yilmaz, Ahmet IR - Yilmaz A IRAD- Ankara City Hospital, Ankara, Turkey. FIR - Tuncel, Altug IR - Tuncel A IRAD- Ankara City Hospital, Ankara, Turkey. FIR - Yazgan, Aylin IR - Yazgan A IRAD- Ankara City Hospital, Ankara, Turkey. EDAT- 2026/04/19 13:11 MHDA- 2026/07/05 00:37 CRDT- 2026/04/18 22:08 PHST- 2026/03/25 00:00 [received] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/07/05 00:37 [medline] PHST- 2026/04/19 13:11 [pubmed] PHST- 2026/04/18 22:08 [entrez] AID - S2588-9311(26)00096-9 [pii] AID - 10.1016/j.euo.2026.04.001 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Jun;9(3):705-709. doi: 10.1016/j.euo.2026.04.001. Epub 2026 Apr 18. PMID- 41995346 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 61 DP - 2026 Apr 17 TI - Early recurrence after primary TURBT for non-muscle-invasive bladder cancer in Iceland: the critical role of surgical quality. PG - 131-137 LID - 10.2340/sju.v61.45711 [doi] AB - INTRODUCTION: Transurethral resection of bladder tumor (TURBT) is the standard treatment for non-muscle-invasive bladder cancer (NMIBC), but early recurrences remain frequent. The objective of this study was to standardize TURBT management at our institution through the implementation of a treatment protocol designed to reduce early recurrence after primary TURBT. MATERIAL AND METHODS: All patients with newly diagnosed NMIBC who underwent primary TURBT at Landspitali University Hospital between 2013-2015 (control) and 2017-2019 (intervention) were included. The treatment protocol restricted procedures to four surgeons, mandated blue-light cystoscopy, routine postoperative bladder irrigation, and guideline-based instillation therapy. The primary endpoint was recurrence rate at first follow-up cystoscopy; secondary endpoints included adherence to protocol measures and recurrence-free survival. RESULTS: A total of 133 control and 138 intervention patients were included. Baseline characteristics were comparable. After implementation, bladder irrigation increased from 46 to 90%, blue-light cystoscopy was used in 59% of intervention cases, and instillation therapy rates rose (Mitomycin-C: 0-49% in intermediate-risk; Bacillus Calmette-Guerin (BCG):35-63% in high-risk patients). Early recurrence rates remained comparable (15% vs. 16%). Early recurrence varied markedly between surgeons (11-40%) and correlated strongly with detrusor muscle presence. No significant difference in recurrence-free survival was observed, though a trend toward lower recurrence was seen in the intervention group after adjusting for risk factors. CONCLUSION: Implementation of a standardized TURBT protocol improved adherence to recommended measures but did not reduce early recurrence. Marked inter-surgeon variability highlights surgical quality as the key determinant of early recurrence in non-muscle-invasive bladder cancer. FAU - Bjornsson, Oddur AU - Bjornsson O AD - Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. oddur.bjornsson@vgregion.se. FAU - Geirsson, Guethmundur AU - Geirsson G AD - Department of Urology, Landspitali University Hospital, Reykjavik, Iceland. FAU - Leifsson, Arni Stefan AU - Leifsson AS AD - Department of Urology, Landspitali University Hospital, Reykjavik, Iceland. FAU - Nikulasson, Sigfus Thornor AU - Nikulasson SThorn AD - Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland. FAU - Guethjonsson, Sigurethur AU - Guethjonsson S AD - Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Urology, Landspitali University Hospital, Reykjavik, Iceland. LA - eng PT - Journal Article DEP - 20260417 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Transurethral Resection of Bladder/standards MH - *Non-Muscle Invasive Bladder Neoplasms/surgery MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Female MH - Male MH - Aged MH - Cystoscopy MH - Iceland MH - Middle Aged MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Mitomycin/therapeutic use MH - BCG Vaccine/therapeutic use MH - Antibiotics, Antineoplastic/therapeutic use MH - Blue Light EDAT- 2026/04/17 13:25 MHDA- 2026/04/17 13:26 CRDT- 2026/04/17 09:05 PHST- 2025/11/24 00:00 [received] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/04/17 13:26 [medline] PHST- 2026/04/17 13:25 [pubmed] PHST- 2026/04/17 09:05 [entrez] AID - 10.2340/sju.v61.45711 [doi] PST - epublish SO - Scand J Urol. 2026 Apr 17;61:131-137. doi: 10.2340/sju.v61.45711. PMID- 41995252 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 61 DP - 2026 Apr 17 TI - Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer. PG - 127-130 LID - 10.2340/sju.v61.45712 [doi] AB - The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013-2014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size < 3 cm) and intermediate-risk (multiple and/or tumour size >/= 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence interval [CI]: 15-23) and 41% (95% CI: 35-46), versus 27% (95% CI: 22-31) and 45% (95% CI: 40-50) in the intermediate-risk group. In a sensitivity analysis including only patients receiving serial adjuvant instillations (n = 152) the corresponding probabilities at 1 and 3 years were 19% (95% CI: 10-28) and 33% (95% CI: 22-43) versus 15% (95% CI: 7-23) and 31% (95% CI: 20-41), respectively. Thus, no clinically meaningful difference in recurrence-free survival was observed between International Bladder Cancer Group low- and intermediate-risk groups in this population-based primary non-muscle invasive bladder cancer setting. FAU - Mesinovic, Denis AU - Mesinovic D AD - Department of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology Skane University Hospital, Malmo, Sweden. denis.mesinovic@med.lu.se. FAU - Bobjer, Johannes AU - Bobjer J AD - Department of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology Skane University Hospital, Malmo, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Urology, Danderyd Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, Sweden. FAU - Kjolhede, Henrik AU - Kjolhede H AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Oncology, Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom. FAU - Haggstrom, Christel AU - Haggstrom C AD - Northern Register Centre, Oncology, Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology Skane University Hospital, Malmo, Sweden. LA - eng PT - Journal Article DEP - 20260417 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/therapy/mortality MH - Female MH - Disease-Free Survival MH - Aged MH - Male MH - *Neoplasm Recurrence, Local/epidemiology MH - Risk Assessment MH - Middle Aged MH - Sweden/epidemiology MH - *Urinary Bladder Neoplasms/pathology MH - Aged, 80 and over MH - Prognosis EDAT- 2026/04/17 13:26 MHDA- 2026/04/17 13:27 CRDT- 2026/04/17 08:34 PHST- 2025/11/23 00:00 [received] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/04/17 13:27 [medline] PHST- 2026/04/17 13:26 [pubmed] PHST- 2026/04/17 08:34 [entrez] AID - 10.2340/sju.v61.45712 [doi] PST - epublish SO - Scand J Urol. 2026 Apr 17;61:127-130. doi: 10.2340/sju.v61.45712. PMID- 41994582 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260417 LR - 20260813 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 12 IP - 2 DP - 2026 Apr-Jun TI - Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients. PG - 23523735261438727 LID - 10.1177/23523735261438727 [doi] LID - 23523735261438727 AB - BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy (NACT-RC) is the prevailing standard of care for muscle-invasive bladder cancer (MIBC), but trimodality treatment (TMT) using chemoradiation after transurethral resection of bladder tumor (TURBT) is an effective alternative in select patients. OBJECTIVE: This study examined patterns of care and impact of social determinants of health on the overall survival (OS) using the National Cancer Database (NCDB). METHODS: Data on patients aged >/=18 years with stage II-IIIA MIBC treated with TMT or NACT-RC during 2014-2021 were analyzed with propensity score matching. Logistic and Cox regression were used to evaluate the association of social determinants of health with patterns of care and OS. RESULTS: Among 18,072 cases (mean age 68.3 years), 77.1% received NACT-RC. TMT use increased from 18.4% in 2014 to 27.1% in 2021 (p < 0.001). The odds for receiving NACT-RC were higher for patients with stage IIIA (odds ratio (OR) = 1.21, 95% confidence interval (CI) 1.09-1.34). However, older patients (OR 0.86, 95% CI 0.87-0.88), those treated at comprehensive community cancer programs (OR 0.51, 95% CI: 0.46-0.55), or used Medicaid (OR = 0.48, 95% CI 0.39-0.61) had lower odds for receiving NACT-RC. In propensity score matching analysis, NACT-RC was associated with lower mortality compared to TMT (Hazard ratio (HR) = 0.66, 95% CI:0.59-0.73). Medicaid users receiving NACT-RC had the highest mortality risk (HR = 1.47, 95% CI:1.28-1.68, p(interaction)=0.001). CONCLUSION: TMT for MIBC has increased in recent years. Selection between NACT-RC and TMT was influenced by age, stage, diagnosis year, comorbidities, travel distance, facility, and insurance type, highlighting disparities in MIBC treatment. CATEGORIES: Radiation Oncology, Oncology. CI - (c) The Author(s) 2026. FAU - Mai, Megan AU - Mai M AD - School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. RINGGOLD: 12343 FAU - Tran, Vivie AU - Tran V AD - School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. RINGGOLD: 12343 FAU - Zhu, Albert AU - Zhu A AD - Department of Computer Science, Rice University, Houston, TX, USA. RINGGOLD: 3990 FAU - Appiah, Duke AU - Appiah D AD - Julia Jones Matthews School of Population and Public Health, Texas Tech University Health Sciences Center, Lubbock, TX, USA. RINGGOLD: 12343 FAU - Shi, Zheng AU - Shi Z AD - School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. RINGGOLD: 12343 AD - Radiation Oncology Clinic, University Medical Center Cancer Center, Lubbock, TX, USA. LA - eng PT - Journal Article DEP - 20260413 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC13080124 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - radical cystectomy OT - social determinants of health OT - trimodality treatment COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/17 13:26 MHDA- 2026/04/17 13:27 PMCR- 2026/04/13 CRDT- 2026/04/17 05:34 PHST- 2025/09/10 00:00 [received] PHST- 2026/03/08 00:00 [accepted] PHST- 2026/04/17 13:27 [medline] PHST- 2026/04/17 13:26 [pubmed] PHST- 2026/04/17 05:34 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.1177_23523735261438727 [pii] AID - 10.1177/23523735261438727 [doi] PST - epublish SO - Bladder Cancer. 2026 Apr 13;12(2):23523735261438727. doi: 10.1177/23523735261438727. eCollection 2026 Apr-Jun. PMID- 41990886 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 213 DP - 2026 Jul TI - Long-term Outcomes of Partial Cystectomy for Urothelial Carcinoma in the Era of Bladder Preservation. PG - 131-140 LID - S0090-4295(26)00244-X [pii] LID - 10.1016/j.urology.2026.04.011 [doi] AB - OBJECTIVE: To compare perioperative complications, oncologic outcomes, and patient-reported outcomes between partial cystectomy (PC) and radical cystectomy (RC). METHODS: We queried a prospectively maintained database to identify patients undergoing PC and RC for UCB between 1980-2020. Multivariable logistic regression compared 90-day major complications. Multivariable Cox regression examined oncologic outcomes. Quality of life (QoL), urinary symptoms, and decisional regret were assessed in survivors using validated survey instruments. RESULTS: Among 277 PC patients and 3474 RC patients, PC was associated with fewer 90-day major complications (16.2% vs 33%, P < .01) and readmissions (5.8% vs 16.1%, P < .01) After PC, the 5-year intravesical recurrence risk was 40% and 5-year salvage cystectomy risk was 21%. PC did not compromise metastasis-free (HR 1.06, P = .59) or cancer-specific survival (HR 1.13, P = .21). Survey response rates were 43% (35/81) for PC and 18% (217/1176) for RC. QoL (P = .88) and decisional regret (P = .217) were similar between groups. PC patients had less financial difficulty (6% vs 24%, P = .01) and were less likely to feel less physically attractive (30% vs 51%, P = .04). Male PC patients reported less difficulty with erection (58% vs 87%, P < .001) and ejaculation (35% vs 78%, P < .001). CONCLUSION: Well-selected PC provides similar oncologic outcomes to RC with less perioperative morbidity and improved QoL. While intravesical recurrence and salvage cystectomy remain risks, guidelines should incorporate PC with adequate postoperative monitoring as an option for select patients with muscle-invasive UCB. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Martin, Austin AU - Martin A AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Shi, Chloe AU - Shi C AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Martinez, Gianni Morales AU - Martinez GM AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Britton, Cameron AU - Britton C AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Thapa, Prabin AU - Thapa P AD - Department of Health Sciences Research, Mayo Clinic, Rochester, MN. FAU - Khanna, Abhinav AU - Khanna A AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Shah, Paras AU - Shah P AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Jeffrey Karnes, Robert AU - Jeffrey Karnes R AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Sharma.Vidit@mayo.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260415 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Humans MH - *Cystectomy/methods/adverse effects MH - Male MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Female MH - Aged MH - Quality of Life MH - Treatment Outcome MH - *Postoperative Complications/epidemiology/etiology MH - Middle Aged MH - *Organ Sparing Treatments/methods MH - Time Factors MH - Patient Reported Outcome Measures MH - Neoplasm Recurrence, Local/epidemiology MH - Retrospective Studies COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stephen A Boorjian - consultant for Ferring and Johnson & Johnson. Vidit Sharma - owns personal stock <$10,000 in ImmunityBio and has served on their advisory board. The other authors have no conflict of interest to declare. EDAT- 2026/04/17 13:25 MHDA- 2026/07/15 18:41 CRDT- 2026/04/16 19:12 PHST- 2026/01/27 00:00 [received] PHST- 2026/03/19 00:00 [revised] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/07/15 18:41 [medline] PHST- 2026/04/17 13:25 [pubmed] PHST- 2026/04/16 19:12 [entrez] AID - S0090-4295(26)00244-X [pii] AID - 10.1016/j.urology.2026.04.011 [doi] PST - ppublish SO - Urology. 2026 Jul;213:131-140. doi: 10.1016/j.urology.2026.04.011. Epub 2026 Apr 15. PMID- 41989781 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260822 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 9 IP - 4 DP - 2026 Apr 1 TI - Clinical Outcomes in Bacillus Calmette-Guerin-Exposed Non-Muscle-Invasive Bladder Cancer. PG - e267470 LID - 10.1001/jamanetworkopen.2026.7470 [doi] LID - e267470 AB - IMPORTANCE: Bacillus Calmette-Guerin (BCG) therapy is the standard of care for non-muscle-invasive bladder cancer (NMIBC), yet many patients experience recurrence and progression, and clinical adherence to recommended regimens is low. OBJECTIVE: To examine the clinical burden, treatment patterns, and outcomes of patients with BCG-exposed NMIBC in the US. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study examined Optum's deidentified Market Clarity Data (Optum Market Clarity), linking US electronic health records and insurance claims from January 1, 2007, to June 30, 2024. Eligible patients were identified by diagnostic codes consistent with bladder cancer and were required to have received at least 1 full course of BCG. Subgroups were defined by adequacy of induction and maintenance therapy. EXPOSURE: Bacillus Calmette-Guerin therapy classified as adequate or inadequate induction and maintenance according to regulatory definitions. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrence within 24 months. Secondary outcomes were progression and cystectomy, and survival was an exploratory outcome. Rates of recurrence, progression, and radical cystectomy were compared between patients with BCG-exposed and BCG-unresponsive NMIBC. RESULTS: The study included 26 876 patients with NMIBC (median [IQR] age at BCG initiation, 73 [65-77] years; 79.5% male), including 9639 patients with carcinoma in situ; baseline demographic and clinical characteristics were similar across induction and maintenance subgroups. Adequate BCG maintenance therapy was uncommon; only 24.9% (4951 of 19 889) of patients across all risk groups received maintenance therapy. Of 5271 patients with carcinoma in situ-containing tumors and sufficient follow-up, 3134 (59.3%) experienced recurrence within 24 months, of whom 2604 (83.1%) were BCG exposed and 530 (16.9%) were BCG unresponsive. Among patients with recurrence, those who were BCG exposed accounted for 83.0% (366 of 441) of disease progression and 87.8% (337 of 384) of cystectomy cases. Most patients with BCG-exposed NMIBC (2442 [93.8%]) had received inadequate maintenance therapy, and progression and cystectomy outcomes were disproportionately concentrated among those with incomplete BCG exposure (330 of 366 [90.2%] and 327 of 337 [97.0%], respectively). CONCLUSIONS AND RELEVANCE: This retrospective cohort study found that patients with BCG-exposed NMIBC represented a large, underserved population and the majority of those who experienced progression and cystectomy. These findings highlight an urgent need for new therapeutic strategies and clinical trial designs targeting this group. FAU - Giatsoglou, Maria AU - Giatsoglou M AD - Pfizer Artificial Intelligence, Data and Analytics Research and Development AI and Data Science, Thessaloniki, Greece. FAU - Chatzistavrou, Dimitrios AU - Chatzistavrou D AD - Pfizer Artificial Intelligence, Data and Analytics Research and Development AI and Data Science, Thessaloniki, Greece. FAU - Sopczynski, Joan Mazzarelli AU - Sopczynski JM AD - Pfizer Artificial Intelligence, Data, and Analytics Research and Development AI and Data Science, Collegeville, Pennsylvania. FAU - Feng, Gang AU - Feng G AD - Pfizer Oncology, Cambridge, Massachusetts. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida. AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260401 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM EIN - JAMA Netw Open. 2026 May 1;9(5):e2618475. doi: 10.1001/jamanetworkopen.2026.18475. PMID: 42189550 MH - Humans MH - Female MH - *BCG Vaccine/therapeutic use MH - Male MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Treatment Outcome MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Cystectomy/statistics & numerical data MH - Disease Progression MH - *Urinary Bladder Neoplasms/drug therapy MH - United States/epidemiology MH - Aged, 80 and over MH - Administration, Intravesical PMC - PMC13087816 COIS- Conflict of Interest Disclosures: Drs Giatsoglou and Feng and Mr Chatzistavrou reported owning shares in Pfizer Inc outside the submitted work. Dr Li reported receiving personal fees from Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Valar Labs, Predicine, and Ferring during the conduct of the study and receiving research support from Predicine, Valar Labs, and Johnson & Johnson; serving as scientific advisor or consultant for Bristol Myers Squibb, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Valar Labs, and Ferring; receiving honoraria from UroToday, International Bladder Cancer Group, MashUP Media, and MJH Lifesciences; and receiving travel expenses from Predicine, CG Oncology, and Johnson & Johnson. No other disclosures were reported. EDAT- 2026/04/17 13:25 MHDA- 2026/04/17 13:26 PMCR- 2026/04/16 CRDT- 2026/04/16 11:33 PHST- 2026/04/17 13:26 [medline] PHST- 2026/04/17 13:25 [pubmed] PHST- 2026/04/16 11:33 [entrez] PHST- 2026/04/16 00:00 [pmc-release] AID - 2847804 [pii] AID - zoi260245 [pii] AID - 10.1001/jamanetworkopen.2026.7470 [doi] PST - epublish SO - JAMA Netw Open. 2026 Apr 1;9(4):e267470. doi: 10.1001/jamanetworkopen.2026.7470. PMID- 41986174 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy. PG - 86-97 LID - S1078-1439(26)00106-7 [pii] LID - 10.1016/j.urolonc.2026.111095 [doi] AB - BACKGROUND: Concordance of NECTIN-4 gene and protein expression and clinic-pathologic associations in matched bladder cancer (BC) triplets, defined as histological specimens from transurethral resection of the bladder (TUR-B), radical cystectomy (RC), and lymphadenectomy (LA) from the same patient, remains unknown. With Enfortumab Vedotin (EV) potentially moving into earlier treatment settings, understanding expression of NECTIN-4 and other targets in archival tissue samples is important. This study characterized protein expression of NECTIN-4 and gene expression of NECTIN4, TACSTD2, ERBB2, PD-L1 and PD1 in matched BC triplet specimens and correlated findings with survival endpoints. METHODS: This retrospective study analyzed NECTIN-4 protein expression and gene expression of 6 target genes using immunohistochemistry and quantitative real-time polymerase chain reaction in matched TUR-B, RC, and LA tissue samples from 27 patients with BC. NECTIN-4 was validated in 3 independent BC cohorts. Protein and gene expression were correlated with clinic-pathologic characteristics. Prognostic associations with survival were analyzed using Kaplan-Meier estimates, log-rank tests and Cox proportional hazard models. RESULTS: Median NECTIN-4 protein expression differed significantly across tissues types with highest levels in TUR-B, lower levels in RC, and intermediate levels in LA specimens Quantitative analysis confirmed significant differences in H-scores across specimens. Expression of NECTIN-4, TACSTD2, PD-L1 and ERBB2 varied significantly across triplets. NECTIN-4 protein expression was not associated with overall or progression-free survival, whereas NECTIN-4 gene expression showed significant but contradictory survival associations in different BC cohorts. CONCLUSION: NECTIN-4 expression differs by tissue type, limiting prognostic value and supporting site-specific biomarker assessment in BC. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Uysal, Daniel AU - Uysal D AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: daniel.uysal@umm.de. FAU - Reible, Bruno AU - Reible B AD - Institute of Pathology, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Wildner, Lukas AU - Wildner L AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Steidler, Annette AU - Steidler A AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Stoth, Manuel AU - Stoth M AD - Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Wurzburg University Hospital, Wurzburg, Germany. FAU - Wessels, Frederik AU - Wessels F AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Nientiedt, Malin AU - Nientiedt M AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Worst, Thomas Stefan AU - Worst TS AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Egen, Luisa AU - Egen L AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Nitschke, Katja AU - Nitschke K AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Brochhausen, Christoph AU - Brochhausen C AD - Institute of Pathology, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Michel, Maurice Stephan AU - Michel MS AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Nuhn, Philipp AU - Nuhn P AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Department of Urology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. FAU - Kowalewski, Karl-Friedrich AU - Kowalewski KF AD - Department of Urology and Urological Surgery, University Medical Centre Mannheim, University Hospital Heidelberg - UK Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; German Cancer Research Center (DKFZ) Heidelberg, Division of Intelligent Systems and, Robotics in Urology (ISRU), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, University Hospital Heidelberg - UK Mannheim. Theodor-Kutzer-Ufer 1-3, Mannheim, Germany. LA - eng PT - Journal Article DEP - 20260414 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (NECTIN4 protein, human) RN - 0 (Nectins) RN - 0 (Cell Adhesion Molecules) RN - 0 (Immune Checkpoint Inhibitors) RN - DLE8519RWM (enfortumab vedotin) RN - 0 (Biomarkers, Tumor) RN - 0 (Antibodies, Monoclonal) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology MH - *Cystectomy/methods MH - Female MH - Retrospective Studies MH - Prognosis MH - Transurethral Resection of Bladder/methods MH - Male MH - *Lymph Node Excision/methods MH - Nectins MH - Aged MH - Middle Aged MH - Cell Adhesion Molecules/metabolism MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology MH - Biomarkers, Tumor MH - Aged, 80 and over MH - Antibodies, Monoclonal OTO - NOTNLM OT - Bladder cancer OT - Immunohistochemistry OT - NECTIN-4 OT - Radical cystectomy, matched bladder cancer triplets COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/16 00:32 MHDA- 2026/05/10 05:19 CRDT- 2026/04/15 21:54 PHST- 2025/09/25 00:00 [received] PHST- 2026/02/02 00:00 [revised] PHST- 2026/03/16 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2026/04/16 00:32 [pubmed] PHST- 2026/04/15 21:54 [entrez] AID - S1078-1439(26)00106-7 [pii] AID - 10.1016/j.urolonc.2026.111095 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):86-97. doi: 10.1016/j.urolonc.2026.111095. Epub 2026 Apr 14. PMID- 41981124 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2397-768X (Print) IS - 2397-768X (Electronic) IS - 2397-768X (Linking) VI - 10 IP - 1 DP - 2026 Apr 14 TI - Spatial transcriptomics of en bloc transurethral resection of bladder tumor specimens defines an invasive-front gene expression signature. LID - 10.1038/s41698-026-01417-x [doi] LID - 224 AB - Bladder cancer is classified by depth of invasion into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). Because some NMIBC cases progress to MIBC, it is important to elucidate the mechanisms of invasion. Spatial transcriptomics is a powerful tool for characterizing the tumor microenvironment. We applied Visium to seven high-grade NMIBC tumors using en bloc transurethral resection of bladder tumor (ERBT) specimens that preserve three-dimensional tumor architecture. Malignant regions were divided into the tumor-upper and tumor-boundary regions, and seven cases were further stratified by pathological subgroup based on the muscularis mucosae. We identified 15 genes with boundary-enriched expression in the higher-risk subgroup. These genes were enriched for epithelial-mesenchymal transition and myogenesis features. To assess the generalizability of this finding, we analyzed public bulk RNA-seq datasets and found that higher expression of the 15-gene signature was associated with worse overall survival, suggesting potential utility for prognostic stratification and therapeutic decision-making. CI - (c) 2026. The Author(s). FAU - Yoshihara, Kentaro AU - Yoshihara K AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. furabe0809@gmail.com. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. furabe0809@gmail.com. FAU - Umemori, Miyaka AU - Umemori M AD - Department of Clinical Laboratory Technology, Faculty of Medicine Science, Juntendo University, Chiba, Japan. FAU - Suzuki, Hironori AU - Suzuki H AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. FAU - Ito, Kagenori AU - Ito K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sekine, Keisuke AU - Sekine K AD - Laboratory of Cancer Cell Systems, National Cancer Center Research Institute, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yamamoto, Yusuke AU - Yamamoto Y AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. yuyamamo@ncc.go.jp. LA - eng GR - JHP2023-06/Japan Health Research Promotion Bureau (JH) Project Fund/ GR - 23K17397, 24K12448, and 25K02414/JSPS KAKENHI Grant/ GR - JP21km0908001/Japan Agency for Medical Research and Development/ PT - Journal Article DEP - 20260414 PL - England TA - NPJ Precis Oncol JT - NPJ precision oncology JID - 101708166 PMC - PMC13269820 COIS- Competing interests: The authors declare no competing interests. EDAT- 2026/04/15 00:33 MHDA- 2026/04/15 00:34 PMCR- 2026/04/14 CRDT- 2026/04/14 23:24 PHST- 2025/11/20 00:00 [received] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/04/15 00:34 [medline] PHST- 2026/04/15 00:33 [pubmed] PHST- 2026/04/14 23:24 [entrez] PHST- 2026/04/14 00:00 [pmc-release] AID - 10.1038/s41698-026-01417-x [pii] AID - 1417 [pii] AID - 10.1038/s41698-026-01417-x [doi] PST - epublish SO - NPJ Precis Oncol. 2026 Apr 14;10(1):224. doi: 10.1038/s41698-026-01417-x. PMID- 41967989 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin. PG - 31-40 LID - S1078-1439(26)00096-7 [pii] LID - 10.1016/j.urolonc.2026.111085 [doi] AB - INTRODUCTION: Age >70 years is considered an adverse prognostic factor in the current EAU NMIBC risk stratification. Whether poorer outcomes in older adults reflect differences in tumor biology or reduced access to guideline-concordant Bacillus Calmette-Guerin (BCG) therapy remains unclear. We evaluated the relationship between age, BCG adherence, and oncological outcomes in a contemporary multicenter cohort. METHODS: We retrospectively analyzed 1,741 patients with intermediate-, high-, or very high-risk non-muscle-invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) at European tertiary referral centers between 2005 and 2024. Adequate BCG was defined according to International Bladder Cancer Group (IBCG) criteria. Multivariable linear, logistic, Cox, and Fine-Gray competing-risk regression models assessed the association between age and (1) BCG delivery and (2) recurrence, high-grade recurrence, progression, and cancer-specific mortality (CSM) among adequately treated patients, adjusting for standard clinicopathologic variables. RESULTS: Among 1,317 (77%) patients with >/=1 year of follow-up and no early high-grade recurrence, increasing age was associated with lower BCG delivery (per 10 years: beta -0.83 for number of instillations; OR 0.76 for adequate treatment; OR 0.87 for 1-year completion; all P < 0.05). Findings were similar when dichotomizing age at 70 years. No significant interaction was observed between age and BCG adequacy for oncological endpoints. Median follow-up was 40 months (IQR: 21-70). Among adequately treated patients (n = 1,296, 74%), 5-year risks for 70 years were comparable for any recurrence (28% vs. 30%; aHR: 1.12, 95% CI: 0.91-1.37), high-grade recurrence (22% vs. 25%; aHR: 1.27, 95% CI: 0.93-1.52), progression (11% vs. 13%; aHR: 1.04, 95% CI: 0.67-1.63), and CSM (5% vs. 8%; aHR: 1.90, 95% CI: 0.95-3.79). CONCLUSIONS: Older age was associated with reduced adherence to BCG schedules, but not with worse oncological outcomes when adequate BCG was delivered. These findings indicate that age itself does not appear to diminish BCG effectiveness. Efforts to optimize treatment adherence, rather than age-based de-escalation, should be prioritized in the management of older NMIBC patients. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Occhi, Angelo AU - Occhi A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Disabato, Natasha AU - Disabato N AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Barracco, Silvio AU - Barracco S AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Gallioli, Andrea AU - Gallioli A AD - Fundacio Puigvert, Department of Urology, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Sant Quinti 77-79, Barcelona, 08041, Spain. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Unit, Department of Surgical Sciences, University of Tor Vergata, Rome, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Elena, Jose Luis Rodriguez AU - Elena JLR AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Clinica Universidad De Navarra, Pamplona, Spain. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Nazionale Tumori IRCCS, "Fondazione G. Pascale", Naples, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS Rozzano, Milan, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: moschini.marco@hsr.it. CN - European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260412 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *BCG Vaccine/therapeutic use MH - Aged MH - Female MH - Male MH - Retrospective Studies MH - Age Factors MH - Aged, 80 and over MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - Adequate BCG OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Oncological outcomes OT - Survival COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/13 00:31 MHDA- 2026/05/10 05:19 CRDT- 2026/04/12 21:54 PHST- 2026/01/16 00:00 [received] PHST- 2026/03/01 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2026/04/13 00:31 [pubmed] PHST- 2026/04/12 21:54 [entrez] AID - S1078-1439(26)00096-7 [pii] AID - 10.1016/j.urolonc.2026.111085 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):31-40. doi: 10.1016/j.urolonc.2026.111085. Epub 2026 Apr 12. PMID- 41956941 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis. PG - 119-127 LID - S1078-1439(26)00102-X [pii] LID - 10.1016/j.urolonc.2026.111091 [doi] AB - INTRODUCTION: Emerging evidence suggests that metachronous non-muscle invasive bladder cancer (m-NMIBC) recurrence after prior upper tract urothelial carcinoma (UTUC) treatment is distinct from primary NMIBC (p-NMIBC). Correspondingly, their disease trajectories and treatment responses may differ vastly. This systematic review aims to evaluate the differences in Bacillus Calmette-Guerin (BCG) response between m-NMIBC and p-NMIBC. METHODS: A comprehensive literature search (PubMed, Embase, and Scopus) was performed to identify relevant studies that reported BCG outcomes for p-NMIBC and m-NIMBC. Endpoints analyzed were high-grade recurrence-free survival (HG-RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS). This study followed the PRISMA guidelines. Both one-stage and two-stage meta-analyses were performed. RESULTS: Six cohort studies with 1,292 patients were identified. Three studies utilized propensity-matched scoring to account for differences in baseline clinical characteristics. BCG prescription was observed in 89% of the whole cohort, with 4 studies treating all included patients with BCG. Patients with m-NMIBC demonstrated worse HG-RFS (one-stage meta-analysis: HR 0.47, 95% CI 0.38-0.59, P < 0.001; two-stage meta-analysis: HR 0.44, 95% CI 0.38-0.50, P < 0.001, I(2) = 0%). M-NMNIBC also demonstrated worse PFS compared to p-NMIBC (one-stage meta-analysis: HR 0.54, 95% CI 0.35-0.83, P = 0.005; two-stage meta-analysis: HR 0.45, 95% CI 0.22-0.90, P = 0.035, I(2) = 0%). There were no significant differences for CSS (one-stage meta-analysis: HR 0.53, 95% CI 0.24-1.17, P = 0.116) and OS (one-stage meta-analysis: HR 1.24, 95% CI 0.64-2.42, P = 0.520). Overall risk of bias was moderate across the included studies. CONCLUSIONS: This review observed that m-NMIBC exhibits a poorer response to BCG compared to p-NMIBC, with significantly higher rates of HG-recurrence and disease progression. These observations reflect a potential biological distinction between the 2 entities, and highlight important implications in clinical trial design and risk stratification. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Tan, Yu Guang AU - Tan YG AD - Department of Urology, Singapore General Hospital, Singapore; Department of Urology, Duke University School of Medicine, Durham, NC. Electronic address: tan.yu.guang@singhealth.com.sg. FAU - Fong, Khi Yung AU - Fong KY AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Abern, Michael R AU - Abern MR AD - Department of Urology, Duke University School of Medicine, Durham, NC. FAU - Lim, Benjamin Jia Han AU - Lim BJH AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Leow, Jeffrey Jj AU - Leow JJ AD - Department of Urology, Tan Tock Seng Hospital, Singapore. FAU - Chong, Tsung Wen AU - Chong TW AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Tay, Kae Jack AU - Tay KJ AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Chen, Kenneth AU - Chen K AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Yuen, John Sp AU - Yuen JS AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Chan, Johan AU - Chan J AD - National Cancer Centre Singapore, Singapore. FAU - Chan, Jason Ys AU - Chan JY AD - National Cancer Centre Singapore, Singapore. FAU - Hussain, Syed A AU - Hussain SA AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Teoh, Jeremy Yc AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong. FAU - Kamat, Ashish M AU - Kamat AM AD - University of Texas MD Anderson Cancer Centre, Houston, TX. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260409 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *BCG Vaccine/therapeutic use/pharmacology MH - *Neoplasms, Second Primary/drug therapy/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - High-grade non-muscle invasive bladder cancer OT - Metachronous non-muscle invasive bladder cancer OT - Upper tract urothelial cancer COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/10 00:33 MHDA- 2026/05/10 05:19 CRDT- 2026/04/09 21:54 PHST- 2025/11/05 00:00 [received] PHST- 2026/03/09 00:00 [revised] PHST- 2026/03/12 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2026/04/10 00:33 [pubmed] PHST- 2026/04/09 21:54 [entrez] AID - S1078-1439(26)00102-X [pii] AID - 10.1016/j.urolonc.2026.111091 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):119-127. doi: 10.1016/j.urolonc.2026.111091. Epub 2026 Apr 9. PMID- 41955422 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1943-7730 (Electronic) IS - 0007-5027 (Linking) VI - 57 IP - 3 DP - 2026 Apr 3 TI - Expression of lncRNA-ATB and miR-200c in patients with bladder cancer: a pilot study. LID - lmag011 [pii] LID - 10.1093/labmed/lmag011 [doi] AB - INTRODUCTION: Bladder cancer is prevalent worldwide; however, the detailed mechanisms underlying its initiation and progression remain incompletely understood. This study aimed to investigate the expression levels of long noncoding RNA activated by transforming growth factor-beta (lncRNA-ATB) and microRNA-200c (miR-200c) in tumor tissues of patients with bladder cancer and to explore their association with clinicopathologic features. METHODS: The study cohort consisted of 50 patients diagnosed with non-muscle-invasive bladder cancer. Tumor tissues and adjacent normal tissues were obtained during transurethral resection of bladder tumor. The relative expression levels of lncRNA-ATB and miR-200c were determined using quantitative reverse transcriptase-polymerase chain reaction. RESULTS: LncRNA-ATB expression was substantially higher in tumor tissues than in adjacent normal tissues. Conversely, miR-200c was upregulated in tumor tissues but showed lower expression in high-grade tumors compared with low-grade tumors. A receiver operating characteristic curve analysis indicated that lncRNA-ATB (72% sensitivity, 68% specificity) and miR-200c (68% sensitivity, 64% specificity) could distinguish tumor from normal tissues. DISCUSSION: This study is the first to concurrently evaluate lncRNA-ATB and miR-200c expression in non-muscle-invasive bladder cancer. Even in early-stage bladder cancer, alterations in the lncATB/miR-200c axis appear to be associated with tumor grade and may potentially serve as an indicator of metastatic potential. CI - (c) The Author(s) (2026). Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Kaytaz, Murat AU - Kaytaz M AUID- ORCID: 0000-0001-8355-8285 AD - Department of Biochemistry, Bogazliyan State Hospital, Yozgat, Turkey. AD - Istanbul Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey. FAU - Degirmenci, Mehmet Enes AU - Degirmenci ME AD - Department of Urology, Florence Nightingale Hospital, Istanbul, Turkey. FAU - Kucukgergin, Canan AU - Kucukgergin C AD - Istanbul Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey. FAU - Aydin, Abdurrahman Fatih AU - Aydin AF AD - Istanbul Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey. FAU - Sanli, Oner AU - Sanli O AD - Istanbul Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey. FAU - Erdem, Selcuk AU - Erdem S AD - Istanbul Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey. FAU - Ozcan, Faruk AU - Ozcan F AD - Istanbul Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey. FAU - Ozluk, Yasemin AU - Ozluk Y AD - Istanbul Faculty of Medicine, Department of Pathology, Istanbul University, Istanbul, Turkey. FAU - Dogru Abbasoglu, Semra AU - Dogru Abbasoglu S AD - Istanbul Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey. LA - eng GR - TTU-2022-38859/Istanbul University Scientific Research Projects Unit/ PT - Journal Article PL - England TA - Lab Med JT - Laboratory medicine JID - 0250641 RN - 0 (MicroRNAs) RN - 0 (MIRN200 microRNA, human) RN - 0 (RNA, Long Noncoding) RN - 0 (long non-coding RNA ATB, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *MicroRNAs/genetics/metabolism MH - *RNA, Long Noncoding/genetics/metabolism/analysis MH - Male MH - Female MH - *Urinary Bladder Neoplasms/genetics/pathology/metabolism/diagnosis MH - Pilot Projects MH - Aged MH - Middle Aged MH - Gene Expression Regulation, Neoplastic MH - Biomarkers, Tumor/genetics OTO - NOTNLM OT - bladder cancer OT - lncRNA-ATB OT - mir-200c OT - noncoding RNA EDAT- 2026/04/09 18:31 MHDA- 2026/04/09 18:32 CRDT- 2026/04/09 14:34 PHST- 2026/04/09 18:32 [medline] PHST- 2026/04/09 18:31 [pubmed] PHST- 2026/04/09 14:34 [entrez] AID - 8644237 [pii] AID - 10.1093/labmed/lmag011 [doi] PST - ppublish SO - Lab Med. 2026 Apr 3;57(3):lmag011. doi: 10.1093/labmed/lmag011. PMID- 41954652 OWN - NLM STAT- Publisher LR - 20260409 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) DP - 2026 Apr 9 TI - Stage-dependent prognostic impact of GATA3/FOXA1-defined luminal-like subtype in upper tract urothelial carcinoma. LID - 10.1007/s00428-026-04503-4 [doi] AB - Upper tract urothelial carcinoma (UTUC) exhibits poorly defined molecular heterogeneity and lacks reliable biomarkers for subtype classification. We investigated the prognostic impact of luminal-like UTUC defined by GATA3 and FOXA1 immunohistochemistry in 245 surgically resected UTUC cases. The cohort included 183 non-muscle-invasive (NMI) and 62 muscle-invasive (MI) tumors. The Kaplan-Meier and Cox analyses demonstrated that the luminal-like subtype had opposite prognostic implications depending on muscle invasiveness: poorer outcomes in NMI-UTUC but more favorable outcomes in MI-UTUC. To provide biological context, we additionally analyzed independent RNA-seq datasets stratified by GATA3 and FOXA1 expression. Luminal-like tumors showed consistent upregulation of cell growth and developmental pathways, whereas non-luminal-like tumors, particularly in MI cases, were enriched for immune-related signatures such as antigen presentation and T-cell recruitment. Exploratory biomarker screening also identified one luminal-like gene and three non-luminal-like genes with survival implications. Using a large cohort of patients with UTUC, we establish GATA3 and FOXA1 as robust surrogate IHC biomarkers for luminal-like UTUC. Their prognostic value is dependent on muscle invasiveness, with transcriptomic analyses providing complementary mechanistic insights. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ahn, ByungSoo AU - Ahn B AD - Department of Pathology, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea. FAU - Jung, Minsun AU - Jung M AUID- ORCID: 0000-0002-8701-4282 AD - Department of Pathology, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea. jjunglammy@gmail.com. FAU - Moon, Kyung Chul AU - Moon KC AD - Department of Pathology, Seoul National University College of Medicine, 101, Daehak-Ro, Jongno-Gu, Seoul, Republic of Korea. AD - Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea. LA - eng GR - RS-2024-00341570/Ministry of Science and ICT, South Korea/ GR - RS-2025-02223506/Ministry of Health and Welfare/ PT - Journal Article DEP - 20260409 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM OTO - NOTNLM OT - FOXA1 OT - GATA3 OT - Molecular subtype OT - Transcriptomic analysis OT - Upper tract urothelial carcinoma COIS- Declarations. Ethics approval: This study was conducted in accordance with ethical guidelines and regulations for research involving human samples. Tissue samples were obtained from Seoul National University Hospital, following approval by the Institutional Review Board of Seoul National University Hospital (IRB H-2201-049-1288). The research adhered to the principles of the Declaration of Helsinki, ensuring data confidentiality and participant anonymity throughout the study. No animal subjects were involved in this research. Competing interests: The authors declare no competing interests. EDAT- 2026/04/09 12:45 MHDA- 2026/04/09 12:45 CRDT- 2026/04/09 11:04 PHST- 2025/12/18 00:00 [received] PHST- 2026/03/26 00:00 [accepted] PHST- 2026/02/23 00:00 [revised] PHST- 2026/04/09 12:45 [medline] PHST- 2026/04/09 12:45 [pubmed] PHST- 2026/04/09 11:04 [entrez] AID - 10.1007/s00428-026-04503-4 [pii] AID - 10.1007/s00428-026-04503-4 [doi] PST - aheadofprint SO - Virchows Arch. 2026 Apr 9. doi: 10.1007/s00428-026-04503-4. PMID- 41945867 OWN - NLM STAT- MEDLINE DCOM- 20260629 LR - 20260813 IS - 2198-3844 (Electronic) IS - 2198-3844 (Linking) VI - 13 IP - 36 DP - 2026 Jun TI - NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer. PG - e23605 LID - 10.1002/advs.202523605 [doi] LID - e23605 AB - T1 high-grade (T1HG) bladder cancer represents an aggressive subset of non-muscle-invasive bladder cancer (NMIBC) with frequent Bacillus Calmette-Guerin (BCG) failure and a high risk of progression, yet current models inadequately guide treatment selection between early cystectomy and bladder preservation. Integrative multi-omics profiling of 147 tumors identifies two clinically distinct subtypes. A high-risk subtype (T1HG1) is defined by coupled anoikis resistance and immune evasion, exhibiting markedly increased progression rates (>80% vs. <20%), poor BCG responsiveness, and a higher likelihood of cystectomy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is identified as a central regulator linking tumor-intrinsic survival to suppression of macrophage-T cell crosstalk. Elevated NQO1 promotes anoikis resistance and reprograms macrophages toward an immunosuppressive phenotype, limiting CXCL9-mediated T cell recruitment and facilitating immune escape. Pharmacologic inhibition of NQO1 using skullcapflavone II restores apoptotic sensitivity and enhances cisplatin efficacy, resulting in significant tumor suppression with favorable tolerability in preclinical models. A multi-omic machine learning framework for T1HG UCB, termed T1HG-UCBguider, integrating clinical, transcriptomic, and methylation features, enables individualized risk stratification and treatment guidance. Validation across seven independent cohorts, demonstrates robust performance in identifying patients at risk of progression and BCG failure. These findings establish a biologically grounded framework for precision management of T1HG bladder cancer. CI - (c) 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH. FAU - Guo, Bin AU - Guo B AD - China National Center for Bioinformation, Beijing, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Xu, Chunru AU - Xu C AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Fu, Shufan AU - Fu S AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Cheng, Qiang AU - Cheng Q AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. FAU - Li, Juan AU - Li J AD - Chinese Institutes for Medical Research, Beijing, China. FAU - Shang, Linkuo AU - Shang L AD - Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, Guangdong, China. FAU - Li, Gaojie AU - Li G AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Yang, Yang AU - Yang Y AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Wang, Ying AU - Wang Y AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Gong, Yanqing AU - Gong Y AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Xiong, Shengwei AU - Xiong S AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Fan, Jian AU - Fan J AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Yuan, Changwei AU - Yuan C AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Zhang, Mei AU - Zhang M AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. FAU - Zuo, Yifan AU - Zuo Y AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Papaleo, Elena AU - Papaleo E AD - Technical University of Denmark, Department of Health and Technology, Section for Bioinformatics, Cancer Systems Biology, Lyngby, Denmark. AD - Danish Cancer Institute, Cancer Structural Biology, Copenhagen, Denmark. FAU - Shi, Yue AU - Shi Y AD - China National Center for Bioinformation, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. FAU - Liang, Yuan AU - Liang Y AD - Institute for Regenerative Biology and Medicine, Chinese Institutes for Medical Research, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Li, Hongzhao AU - Li H AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. FAU - Ci, Weimin AU - Ci W AUID- ORCID: 0000-0002-4111-5360 AD - China National Center for Bioinformation, Beijing, China. AD - Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. AD - Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. LA - eng GR - 2023YFC2507002/National Key R&D Program of China/ GR - 2023YFC3402704/National Key R&D Program of China/ GR - 2022CR72/National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital)/ GR - 82341030/National Natural Science Foundation of China/ GR - 82173061/National Natural Science Foundation of China/ GR - 82273350/National Natural Science Foundation of China/ GR - U23A20460/National Natural Science Foundation of China/ GR - 82103426/National Natural Science Foundation of China/ PT - Journal Article DEP - 20260407 PL - Germany TA - Adv Sci (Weinh) JT - Advanced science (Weinheim, Baden-Wurttemberg, Germany) JID - 101664569 RN - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone)) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/immunology/pathology MH - *Anoikis/genetics MH - *NAD(P)H Dehydrogenase (Quinone)/genetics/metabolism MH - Animals MH - Non-Muscle Invasive Bladder Neoplasms MH - Multiomics MH - *Immune Evasion/genetics MH - Precision Medicine/methods MH - Mice PMC - PMC13317658 OTO - NOTNLM OT - NQO1 OT - T1 high-grade bladder cancer OT - anoikis resistance OT - bladder-preserving therapy OT - immune evasion OT - multi-omics OT - risk stratification COIS- The authors declare no conflicts of interest. EDAT- 2026/04/07 18:32 MHDA- 2026/06/29 18:43 PMCR- 2026/04/07 CRDT- 2026/04/07 15:53 PHST- 2026/03/27 00:00 [revised] PHST- 2025/11/19 00:00 [received] PHST- 2026/03/28 00:00 [accepted] PHST- 2026/06/29 18:43 [medline] PHST- 2026/04/07 18:32 [pubmed] PHST- 2026/04/07 15:53 [entrez] PHST- 2026/04/07 00:00 [pmc-release] AID - ADVS75148 [pii] AID - 10.1002/advs.202523605 [doi] PST - ppublish SO - Adv Sci (Weinh). 2026 Jun;13(36):e23605. doi: 10.1002/advs.202523605. Epub 2026 Apr 7. PMID- 41943689 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260819 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 79 IP - 2 DP - 2026 Mar TI - Efficacy and Safety of Keyhole Limpet Hemocyanin in Bacillus Calmette-Guerin Unresponsive Non-muscle Invasive Bladder Cancer. PG - 219-223 LID - 10.56434/j.arch.esp.urol.20267902.26 [doi] AB - BACKGROUND: Despite undergoing transurethral resection and appropriate Bacillus Calmette-Guerin (BCG) administration for high-risk non-muscle invasive bladder cancer (NMIBC), the non-responder rate is approximately 25%. Although radical cystectomy is the gold standard of treatment recommended by various international guidelines, many patients are either unwilling or ineligible for this therapeutic option. In Argentina, keyhole limpet hemocyanin (immunocyanin KLH) is approved for those patients. The primary objectives of this study were to evaluate the overall treatment response, defined as disease-free survival (recurrence and/or local or distant progression), and adverse events. METHODS: A retrospective, two-centre, single-arm clinical study with a quantitative exploratory and documentary approach was designed. Seventy patients diagnosed with NMIBC who were non-responders to appropriate BCG were evaluated between January 2001 and August 2022, with a minimum follow-up duration of one year. All patients completed an induction regimen of KLH and at least three maintenance treatments, which involved the intravesical administration of 20 mg of KLH in 60 mL of physiological saline weekly for six weeks during the induction phase, followed by monthly maintenance with the same dose. Cystoscopic controls were performed every three months during the first year and every three to four months in the second and third years. All suspicious lesions were completely resected, and cytological samples were systematically collected. RESULTS: The mean age of the patients was 69.1 years (SD: 8.1). The mean follow-up duration from the first KLH dose was 60.9 months, with a median of 53 months. The estimated one-, two- and three-year disease-free survival rates were 57.1%, 33.5% and 30.1% (95% CI: 45.5-68.7, 22.3-44.7 and 19.1-41.1), respectively, with a median disease-free survival of 14 months (95% CI: 10.4-17.6). Multifocality, pT1 classification and lymphovascular invasion were identified as adverse factors in multivariate analysis. Toxicity was well tolerated, with six patients (8.6%) experiencing mild urinary infections during treatment (adverse event grade 2). CONCLUSIONS: The use of KLH in patients with NMIBC who are non-responders to BCG therapy shows favourable outcomes in terms of disease-free survival and exhibits an excellent safety profile. These findings support KLH as a potential treatment option for this challenging patient population. CI - (c) 2026 The Author(s). FAU - Chernobilsky, Victor AU - Chernobilsky V AD - CDU Urology Center, Autonomous City of Buenos Aires, 1190 Buenos Aires, Argentina. FAU - Gonzalez, Ignacio Tobia AU - Gonzalez IT AD - CDU Urology Center, Autonomous City of Buenos Aires, 1190 Buenos Aires, Argentina. AD - Department of Urology, Hospital Italiano de Buenos Aires, 1199 Buenos Aires, Argentina. FAU - Favre, Gabriel AU - Favre G AD - Department of Urology, Hospital Italiano de Buenos Aires, 1199 Buenos Aires, Argentina. LA - eng PT - Clinical Study PT - Journal Article PT - Multicenter Study PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 9013-72-3 (Hemocyanins) RN - FV4Y0JO2CX (keyhole-limpet hemocyanin) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - *Hemocyanins/therapeutic use/adverse effects MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - BCG-unresponsive OT - bladder cancer OT - keyhole limpet hemocyanin COIS- The authors declare no conflict of interest. EDAT- 2026/04/07 06:31 MHDA- 2026/04/07 06:32 CRDT- 2026/04/07 03:44 PHST- 2026/04/07 06:32 [medline] PHST- 2026/04/07 06:31 [pubmed] PHST- 2026/04/07 03:44 [entrez] AID - 10.56434/j.arch.esp.urol.20267902.26 [doi] PST - ppublish SO - Arch Esp Urol. 2026 Mar;79(2):219-223. doi: 10.56434/j.arch.esp.urol.20267902.26. PMID- 41941336 OWN - NLM STAT- MEDLINE DCOM- 20260611 LR - 20260818 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 138 IP - 1 DP - 2026 Jul TI - Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urologico Espanol de Tratamiento Oncologico Group' (EVALUATION-CUETO) study. PG - 75-84 LID - 10.1111/bju.70230 [doi] AB - OBJECTIVE: To compare the performance of a new digital Uromonitor(R) (dUM; U-Monitor, Porto, Portugal) against the previous quantitative polymerase chain reaction (qPCR) version and cytology in the follow-up of non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: This retrospective (post hoc) molecular analysis of a prospectively collected multicentre cohort re-analysed stored urine DNA samples from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urologico Espanol de Tratamiento Oncologgico Group' (EVALUATION-CUETO) study (ClinicalTrials.gov identifier: NCT05864599). Samples, previously tested with Uromonitor-version 2, were analysed using dUM (QX200 Droplet Digital PCR System) for TERT and FGFR3 hotspot mutations. Performance metrics (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], area under the curve [AUC]) for detecting recurrence were calculated against cystoscopy/histology and compared to qPCR and cytology. The study received approval from the Ethical Committee at the University Hospital of Vall d'Hebron (Barcelona). RESULTS: Analysis of 271 samples revealed dUM had superior sensitivity to qPCR (72% vs 36%) and cytology (72% vs 34%), while preserving high specificity (88%) and NPV (93%). The AUC for dUM was 0.80 vs 0.66 for qPCR. Performance was consistent across tumour grades and risk groups. Crucially, combining a positive/suspicious cystoscopy with a positive dUM result significantly increased the PPV to 94% (from 79% for cystoscopy alone). CONCLUSION: The dUM significantly outperformed its qPCR predecessor and cytology in sensitivity for detecting NMIBC recurrence in a real-world setting, without compromising specificity. Its high NPV supports its potential for reducing unnecessary cystoscopies. Furthermore, its combination with cystoscopy drastically increased the PPV, suggesting a role as an adjunctive tool to improve diagnostic confidence and potentially reduce unnecessary transurethral resections of bladder tumour, pending favourable cost-effectiveness. CI - (c) 2026 BJU International. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AUID- ORCID: 0000-0001-6615-4641 AD - Hospital VITHAS 9 de Octubre, Urology, Valencia, Spain. FAU - Guerrero Ramos, Felix AU - Guerrero Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Hospital 12 de Octubre, Urology, Madrid, Spain. FAU - Mercade Sanchez, Asier AU - Mercade Sanchez A AUID- ORCID: 0000-0003-0192-2704 AD - Hospital Clinic, Urology, Barcelona, Spain. FAU - Bezana Abadia, Ines AU - Bezana Abadia I AD - Complejo Hospitalario de Navarra, Urology, Pamplona, Spain. FAU - Martin Rodriguez, Ruth AU - Martin Rodriguez R AD - Hospital 12 de Octubre, Urology, Madrid, Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Hospital Clinic, Urology, Barcelona, Spain. FAU - Miqueleiz Legaz, Maite AU - Miqueleiz Legaz M AUID- ORCID: 0000-0003-4062-307X AD - Complejo Hospitalario de Navarra, Urology, Pamplona, Spain. FAU - Lozano, Fernando AU - Lozano F AD - Hospital Universitario Valle Hebron, Urology, Barcelona, Spain. FAU - Arrabal Martin, Miguel AU - Arrabal Martin M AD - Hospital Universitario San Cecilio, Urology, Granada, Spain. FAU - Luis Cardo, Adrian AU - Luis Cardo A AD - Complejo Hospitalario de Toledo, Urology, Toledo, Spain. FAU - Gonzalo Rodriguez, Victoria AU - Gonzalo Rodriguez V AD - Complejo Asistencial Universitario de Burgos, Urology, Burgos, Spain. FAU - Cano Velasco, Jorge AU - Cano Velasco J AD - Hospital General Universitario Gregorio Maranon, Urology, Madrid, Spain. FAU - Serrano Liesa, Miriam AU - Serrano Liesa M AD - Hospital Universitario La Paz, Urology, Madrid, Spain. FAU - Ferreiro Pareja, Cristina AU - Ferreiro Pareja C AUID- ORCID: 0000-0003-1702-2225 AD - Hospital Universitari Bellvitge, Urology, Barcelona, Spain. FAU - Espilez Ortiz, Raquel AU - Espilez Ortiz R AD - Hospital Universitario Miguel Servet, Urology, IIS Aragon, Zaragoza, Spain. FAU - Gonzalez-Valcarcel de Torres, Ignacio AU - Gonzalez-Valcarcel de Torres I AD - Hospital Universitario Infanta Sofia, Urology, Madrid, Spain. FAU - Sanchez Zalabardo, Daniel AU - Sanchez Zalabardo D AD - Clinica Universitaria de Navarra, Urology, Pamplona, Spain. FAU - Guijarro, Ana AU - Guijarro A AD - Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Mengual, Lourdes AU - Mengual L AD - Hospital Clinic, Genetics, University of Barcelona, Barcelona, Spain. FAU - Borque-Fernando, Angel AU - Borque-Fernando A AD - Hospital Universitario Miguel Servet, Urology, IIS Aragon, Zaragoza, Spain. FAU - Esteban Escano, Luis Mariano AU - Esteban Escano LM AD - Escuela Universitaria Politecnica de la Almunia, Matematica Aplicada, Almunia de Dona Godina, Spain. FAU - Palou Redorta, Joan AU - Palou Redorta J AD - Fundacio Puigvert, Urology, Barcelona, Spain. FAU - Witjes, Fred AU - Witjes F AD - University of Nijmegen, Urology, Nijmegen, The Netherlands. FAU - Martinez Pineiro, Luis AU - Martinez Pineiro L AD - Hospital Universitario La Paz, Urology, Madrid, Spain. LA - eng SI - ClinicalTrials.gov/NCT05864599 GR - Spanish Association of Urology/ PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20260406 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (Telomerase) RN - EC 2.7.7.49 (TERT protein, human) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Biomarkers, Tumor/urine/genetics MH - *Non-Muscle Invasive Bladder Neoplasms/urine/genetics/pathology/diagnosis MH - Polymerase Chain Reaction/methods MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Retrospective Studies MH - Sensitivity and Specificity MH - Telomerase/genetics OTO - NOTNLM OT - FGFR3 OT - KRAS OT - TERT OT - NMIBC (non-muscle-invasive bladder cancer) OT - biomarker OT - bladder cancer OT - cystoscopy OT - follow-up OT - molecular diagnostics OT - urine-based diagnostic tests EDAT- 2026/04/06 18:32 MHDA- 2026/06/11 18:35 CRDT- 2026/04/06 13:03 PHST- 2026/06/11 18:35 [medline] PHST- 2026/04/06 18:32 [pubmed] PHST- 2026/04/06 13:03 [entrez] AID - 10.1111/bju.70230 [doi] PST - ppublish SO - BJU Int. 2026 Jul;138(1):75-84. doi: 10.1111/bju.70230. Epub 2026 Apr 6. PMID- 41936844 OWN - NLM STAT- MEDLINE DCOM- 20260617 LR - 20260906 IS - 1530-0285 (Electronic) IS - 0893-3952 (Linking) VI - 39 IP - 6 DP - 2026 Jun TI - Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System. PG - 100997 LID - S0893-3952(26)00040-2 [pii] LID - 10.1016/j.modpat.2026.100997 [doi] AB - Bladder cancer is a heterogeneous malignancy with diverse clinical outcomes, and conventional pathological assessment alone is insufficient to capture its underlying biology. Gene expression profiling can stratify tumors into molecular subtypes with prognostic and predictive potential, but the reliability of transcriptomic classification and its clinical utility remains to be established. The translational/observational UROSCANSEQ study (ISRCTN15459149) prospectively evaluates RNA-based Lund Taxonomy (LundTax) molecular subtype classification in a clinical setting. Among 784 consecutive biopsies collected between 2018 and 2022, RNA sequencing was successful for 90% of all biopsies, encompassing 662 bladder cancer patients with a stage distribution of 48% Ta, 27% T1, 24% >/=T2, and 1% CIS. We demonstrate that the LundTax subtype classification algorithm, applied to individual samples, accurately identifies cancer cell phenotypes with characteristic gene and protein expression patterns in a manner robust to RNA quality, data preprocessing strategies, and batch effects, supporting its clinical feasibility across both non-muscle-invasive and muscle-invasive disease. We further extend the LundTax framework by incorporating single-sample molecular risk scores reflecting tumor grade, proliferation, and progression risk, as well as tumor microenvironment signatures. Both risk scores and overall immune and stromal content in biopsies were significantly associated with an increased risk of clinical progression in noninvasive disease. In a separate analysis of the relative cellular composition of the tumor microenvironment, however, only the fraction of natural killer cells remained significant. Together, the expanded LundTax system provides a comprehensive molecular portrait of individual tumor biopsies. By explicitly separating cancer cell-intrinsic phenotypes, prognostic indexes, and microenvironmental signals, the framework minimizes biological confounding and establishes a strong foundation for future studies evaluating clinical outcomes and treatment responses. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Eriksson, Pontus AU - Eriksson P AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: pontus.eriksson@med.lu.se. FAU - Cotillas, Elena Aramendia AU - Cotillas EA AD - Endocrine Regulatory Genomics, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain. FAU - Mattsson, Carl-Adam AU - Mattsson CA AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Zadoroznyj, Aymeric AU - Zadoroznyj A AD - Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden. FAU - Bernardo, Carina AU - Bernardo C AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden. FAU - Edsjo, Anders AU - Edsjo A AD - Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Office for Medical Services, Skane University Hospital, Region Skane, Lund, Sweden. FAU - Heidenblad, Markus AU - Heidenblad M AD - Center for Translational Genomics, Lund University, Lund, Sweden; Clinical Genomics Lund, SciLifeLab, Lund, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260403 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/classification MH - Female MH - Biopsy MH - *Carcinoma, Transitional Cell/pathology/genetics/classification MH - Male MH - Gene Expression Profiling MH - Aged MH - Middle Aged MH - Biomarkers, Tumor/genetics MH - Neoplasm Staging OTO - NOTNLM OT - Lund Taxonomy OT - RNA sequencing OT - UROSCANSEQ OT - bladder cancer OT - molecular subtypes OT - urothelial carcinoma EDAT- 2026/04/06 00:31 MHDA- 2026/06/18 00:32 CRDT- 2026/04/05 23:18 PHST- 2025/10/02 00:00 [received] PHST- 2026/03/19 00:00 [revised] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/06/18 00:32 [medline] PHST- 2026/04/06 00:31 [pubmed] PHST- 2026/04/05 23:18 [entrez] AID - S0893-3952(26)00040-2 [pii] AID - 10.1016/j.modpat.2026.100997 [doi] PST - ppublish SO - Mod Pathol. 2026 Jun;39(6):100997. doi: 10.1016/j.modpat.2026.100997. Epub 2026 Apr 3. PMID- 41936674 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Apr 5 TI - Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer. LID - 10.1038/s41598-026-46649-w [doi] LID - 16338 AB - Owing to the rarity of radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC), information regarding oncological outcomes is limited. The aim was to conduct a comprehensive analysis of risk factors and survival outcomes following RC. This retrospective study included 435 patients who underwent RC for clinically diagnosed NMIBC at multiple institutions in Japan. The 5-year cancer-specific survival (CSS) rates were 97.4% for cTa, 93.3% for cTis, and 85.4% for cT1, respectively. Among 351 patients with cTa and cT1 disease, multivariable Cox proportional hazards analyses identified upstaging to >/=pT2 or pN+ disease as the most impactful risk factor associated with cancer-specific mortality (hazard ratio = 6.53; p < 0.001). Neither neoadjuvant chemotherapy nor lymph node dissection (LND) exhibited a survival benefit in terms of CSS in this cohort; however, LND was occasionally indicative of pN+ disease, suggesting potential diagnostic value. The multivariable logistic regression analysis of preoperative variables identified tumour size (>/= 3 cm) as the lone risk factor associated with upstaging (odds ratio = 1.90; p = 0.03). In the sensitivity analyses, tumour size >/= 3 cm still trended toward an increased upstaging risk, without a statistically significant association. Although the prediction of upstaging remains highly challenging, RC should not be delayed when clinically indicated, even for patients diagnosed with NMIBC, particularly in those with large tumours. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe , Kita-gun, Miki-cho, 761-0793, Kagawa, Japan. taoka.rikiya@kagawa-u.ac.jp. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. AD - Department of Urology, Hyogo Medical University, Nishinomiya, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Matsuda, Ayumu AU - Matsuda A AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. AD - Department of Urology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan. FAU - Kato, Minoru AU - Kato M AD - Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Hospital, Tokyo, Japan. FAU - Kashima, Soki AU - Kashima S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Naito, Hirohito AU - Naito H AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. AD - Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan. FAU - Murakami, Yoji AU - Murakami Y AD - Department of Urology, Graduate School of Life Science, Kumamoto University, Kumamoto, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Daizumoto, Kei AU - Daizumoto K AD - Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Hayashi, Takuji AU - Hayashi T AD - Department of Urology, Osaka International Cancer Institute, Osaka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. AD - Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. FAU - Sugino, Yusuke AU - Sugino Y AD - Department of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin General Hospital, Fukuoka, Japan. FAU - Yamaguchi, Noriya AU - Yamaguchi N AD - Department of Urology, Faculty of Medicine, Tottori University, Tottori, Japan. FAU - Yamamoto, Shingo AU - Yamamoto S AD - Department of Urology, Hyogo Medical University, Nishinomiya, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Katsushika Medical Center, Tokyo, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Nakanishi, Shotaro AU - Nakanishi S AD - Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. FAU - Fujii, Masato AU - Fujii M AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Nishihara, Kiyoaki AU - Nishihara K AD - Department of Urology, Kurume University School of Medicine, Kurume, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Tatarano, Shuichi AU - Tatarano S AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Wada, Koichiro AU - Wada K AD - Department of Urology, Faculty of Medicine, Shimane University, Izumo, Japan. FAU - Sekito, Sho AU - Sekito S AD - Department of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan. AD - Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan. FAU - Maruyama, Ryo AU - Maruyama R AD - Department of Urology, Niigata University Graduate School of Medicine, Niigata, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. CN - Japan Urological Oncology Group LA - eng PT - Journal Article DEP - 20260405 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology/mortality MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - Treatment Outcome MH - Middle Aged MH - Risk Factors MH - Lymph Node Excision MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Aged, 80 and over MH - Neoplasm Staging MH - Proportional Hazards Models MH - Japan PMC - PMC13212721 OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Lymph node dissection OT - Neoadjuvant chemotherapy OT - Non-muscle-invasive bladder cancer OT - Radical cystectomy COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/04/06 00:31 MHDA- 2026/06/27 12:39 PMCR- 2026/04/05 CRDT- 2026/04/05 23:15 PHST- 2025/07/07 00:00 [received] PHST- 2026/03/26 00:00 [accepted] PHST- 2026/06/27 12:39 [medline] PHST- 2026/04/06 00:31 [pubmed] PHST- 2026/04/05 23:15 [entrez] PHST- 2026/04/05 00:00 [pmc-release] AID - 10.1038/s41598-026-46649-w [pii] AID - 46649 [pii] AID - 10.1038/s41598-026-46649-w [doi] PST - epublish SO - Sci Rep. 2026 Apr 5;16(1):16338. doi: 10.1038/s41598-026-46649-w. PMID- 41936003 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20261008 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 9 DP - 2026 Sep TI - Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients. PG - 3557-3566 LID - 10.1007/s11255-026-05079-3 [doi] AB - BACKGROUND: Urothelial carcinoma is a common malignancy with a substantial burden, including in Egypt. Although Ki-67 and EMT-related markers such as vimentin have been previously studied, region-specific validation and practical cutoff performance remain relevant.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Also, kindly confirm the details in the metadata are correct. We have made the requested corrections. In addition, we would like to change the author order so that Deema Abu Al-Teen is listed as author number 4, and Abdulhadi Samman is moved to author number 8 in her place, with the same affiliation as currently shown related to each author, Samman (Jeddah) and Abu Al-Teen (Amman). METHODS: This cross-sectional study included 60 archival conventional UC cases diagnosed at university hospitals during 2024. Tumors were re-reviewed to confirm grade and stage and categorized as NMIBC or MIBC. Immunohistochemistry was performed for vimentin and Ki-67 (MIB-1). Vimentin was considered positive when >/= 10% of tumor cells showed convincing cytoplasmic staining. The Ki-67 labeling index was assessed in hotspots by counting >/= 500 tumor nuclei and categorized as low (< 30%) versus high (>/= 30%) using a predefined pragmatic cutoff. Multivariable logistic regression was used to identify independent predictors of high-grade disease. RESULTS: Vimentin positivity was detected in 18/60 cases (30.0%), and high Ki-67 index was present in 37/60 (61.7%). High Ki-67 independently predicted high-grade carcinoma (OR = 5.601, p = 0.009) and was significantly associated with high grade (p = 0.011), non-papillary pattern (p < 0.001), and muscle invasion (p = 0.001), but not lymphovascular invasion (p = 0.405). Vimentin showed no significant associations and was not an independent predictor; Ki-67 and vimentin were not significantly correlated. CONCLUSION: In this Egyptian cohort, Ki-67 >/= 30% was strongly associated with adverse pathological features and independently predicted high-grade disease, supporting its use as a practical ancillary marker and providing regional validation of prior reports. Vimentin was not significantly associated with the studied parameters in this dataset. Future studies should assess alternative cutoffs within the same cohort and validate outcome-linked thresholds in longitudinal datasets. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Youssef, Heba M K AU - Youssef HMK AD - Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Ibrahim, Eman Hassan AU - Ibrahim EH AD - Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman, United Arab Emirates. dr.eman@gmu.ac.ae. AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. dr.eman@gmu.ac.ae. FAU - Hasan, Abdulkarim AU - Hasan A AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt. abdulkarim.hasan@azhar.edu.eg. FAU - Samman, Abdulhadi AU - Samman A AD - Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. FAU - Abdelwahed, Mohammed S AU - Abdelwahed MS AD - Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. FAU - Baloush, Razan A AU - Baloush RA AD - Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. FAU - Noorwali, Hussain AU - Noorwali H AD - Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. FAU - Abu Al-Teen, Deema AU - Abu Al-Teen D AD - Department of Basic Dental Sciences, Faculty of Dentistry, Al-Ahliyya Amman University, Amman, Jordan. FAU - El Bostany, Mona Zakaria AU - El Bostany MZ AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. FAU - Nasr, Amira AU - Nasr A AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. FAU - Samir, Mahmoud AU - Samir M AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt. FAU - Mandour, Essam AU - Mandour E AD - Pathology Department, School of Medicine, Badr University in Cairo (BUC), Cairo, Egypt. FAU - Rabie, Ahmed AU - Rabie A AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt. FAU - Shokery, Sara Ehab M AU - Shokery SEM AD - Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. LA - eng PT - Journal Article DEP - 20260405 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Vimentin) RN - 0 (Ki-67 Antigen) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Vimentin/biosynthesis/analysis MH - *Ki-67 Antigen/analysis/biosynthesis/metabolism MH - Female MH - Egypt MH - Immunohistochemistry MH - Middle Aged MH - *Carcinoma, Transitional Cell/metabolism/pathology/chemistry MH - Cross-Sectional Studies MH - Male MH - Aged MH - *Urinary Bladder Neoplasms/pathology/metabolism/chemistry MH - Biomarkers, Tumor MH - Cell Proliferation MH - Non-Muscle Invasive Bladder Neoplasms MH - Adult OTO - NOTNLM OT - Bladder cancer OT - Immunohistochemistry OT - Ki-67 OT - Urothelial carcinoma OT - Vimentin COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: Provided from Al-Azhar Assiut faculty of medicine IRB.ID: RESEARCH/AZ.AST/PAT005/7/244/5/2025. Informed consent: NA and waived from the ethical committee. EDAT- 2026/04/05 15:43 MHDA- 2026/08/25 17:35 CRDT- 2026/04/05 11:03 PHST- 2025/12/22 00:00 [received] PHST- 2026/02/28 00:00 [accepted] PHST- 2026/08/25 17:35 [medline] PHST- 2026/04/05 15:43 [pubmed] PHST- 2026/04/05 11:03 [entrez] AID - 10.1007/s11255-026-05079-3 [pii] AID - 10.1007/s11255-026-05079-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Sep;58(9):3557-3566. doi: 10.1007/s11255-026-05079-3. Epub 2026 Apr 5. PMID- 41935944 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study. PG - 70-79 LID - S1078-1439(26)00101-8 [pii] LID - 10.1016/j.urolonc.2026.111090 [doi] AB - BACKGROUND: Real-world data on the costs and outcomes of blue light cystoscopy (BLC) for non-muscle-invasive bladder cancer (NMIBC) are limited. We compared healthcare costs and oncologic outcomes associated with BLC versus white light cystoscopy only (WLC) in patients with NMIBC. METHODS: We performed a retrospective cohort study of NMIBC patients treated in the Veterans Affairs (VA) healthcare system between January 1, 1997 and December 31, 2021. Patients exposed to BLC after diagnosis were compared with WLC-only patients. Propensity score matching (1:1) identified 311 BLC-exposed and 311 WLC-only patients. Outcomes included 5-year total and category-specific healthcare costs, NMIBC recurrence, and recurrence-related cost offsets. RESULTS: Among 622 matched patients (311 BLC; 311 WLC), median age was 71 years, and 378 (61%) had high-risk disease. BLC-exposed patients were more likely to receive intravesical BCG (190 [61%] vs. 133 [43%]; p < 0.01) and intravesical chemotherapy (149 [49%] vs. 86 [28%]; p < 0.01). Unadjusted 5-year total costs were higher with BLC ($108,411 vs. $66,734; p < 0.01), primarily due to outpatient costs ($90,788 vs. $55,529; p < 0.01). BLC was associated with decreased risk of recurrence (HR 0.62, 95% CI 0.45 - 0.86). After accounting for recurrence-related cost offsets, the adjusted 5-year cost difference was $721 per patient. CONCLUSIONS: In an equal-access setting, BLC exposure was associated with higher 5-year costs, largely driven by outpatient care. However, lower recurrence rates reduced the net cost difference, resulting in near cost neutrality. These findings highlight the trade-off between higher upfront costs and improved recurrence outcomes when incorporating BLC into NMIBC management. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Nasrallah, Ali A AU - Nasrallah AA AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX. FAU - Evans, Claire AU - Evans C AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC. FAU - Gu, Lin AU - Gu L AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC; Duke Cancer Institute Biostatistics Shared Resource, Durham, NC. FAU - Parrish, Joshua A AU - Parrish JA AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC. FAU - De Hoedt, Amanda M AU - De Hoedt AM AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC. FAU - Lapon, Jane AU - Lapon J AD - Medical Affairs, Photocure Inc, Princeton, NJ. FAU - McKee, Chad AU - McKee C AD - Medical Affairs, Photocure Inc, Princeton, NJ. FAU - Aronson, William AU - Aronson W AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA; Greater Los Angeles Veterans Affair, Los Angeles, CA; Department of Urology, University of California-Los Angeles, Los Angeles, CA. FAU - Freedland, Stephen J AU - Freedland SJ AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX. Electronic address: stbwilli@utmb.edu. LA - eng PT - Journal Article DEP - 20260403 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Cystoscopy/economics/methods MH - Blue Light MH - Retrospective Studies MH - Female MH - Male MH - Non-Muscle Invasive Bladder Neoplasms/economics MH - Aged MH - *Health Care Costs/statistics & numerical data MH - *Urinary Bladder Neoplasms/economics MH - Middle Aged MH - Neoplasm Recurrence, Local/economics OTO - NOTNLM OT - Bladder cancer OT - Blue light OT - Cost analysis OT - Hexaminolevulinate OT - Oncologic outcomes, cystoscopy OT - Recurrence COIS- Declaration of competing interest Stephen B. Williams is a consultant for Photocure. Chad McKee is the Head of Medical Affairs North America at Photocure. Jane Lapon is the Head of Global Market Access at Photocure. All other authors declare no competing interests. EDAT- 2026/04/05 06:36 MHDA- 2026/05/10 05:19 CRDT- 2026/04/05 06:02 PHST- 2026/01/13 00:00 [received] PHST- 2026/02/27 00:00 [revised] PHST- 2026/03/12 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2026/04/05 06:36 [pubmed] PHST- 2026/04/05 06:02 [entrez] AID - S1078-1439(26)00101-8 [pii] AID - 10.1016/j.urolonc.2026.111090 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):70-79. doi: 10.1016/j.urolonc.2026.111090. Epub 2026 Apr 3. PMID- 41934023 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Adequate Bacillus Calmette-Guerin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study. PG - 53-60 LID - S1078-1439(26)00098-0 [pii] LID - 10.1016/j.urolonc.2026.111087 [doi] AB - OBJECTIVE: To evaluate the impact of Bacillus Calmette-Guerin (BCG) maintenance therapy intensity on outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and identify the critical period of maintenance efficacy. PATIENTS AND METHODS: This retrospective cohort study involved 150 patients with high-risk NMIBC who received BCG induction therapy between January 2010 and September 2022. The patients were classified by maintenance intensity within 1 year: adequate maintenance (AM; 5-9 of 9 planned instillations) or inadequate maintenance (IM; 0-4 instillations). The primary endpoint was conditional recurrence-free survival (CRFS), assessed at baseline (0 months) and at 6, 12, 18, and 24 months postinduction. CRFS was estimated, and multivariable Cox regression identified predictors of recurrence at each conditional time point. RESULTS: Of 150 patients, 77 (51.3%) received AM and 73 (48.7%) received IM. AM patients showed significantly better RFS, with 5-year rates of 85.9% vs. 63.9% for IM. The 5-year CRFS rates for AM remained consistently higher than IM at all time points (0, 6, 12, 18, and 24 months). In the multivariable analysis, IM was the only significant predictor of poorer RFS at baseline, 6, and 12 months, with this association diminishing at 18 and 24 months. CONCLUSION: Adequate BCG maintenance-defined as at least five instillations within the first year-significantly reduces early recurrence in high-risk NMIBC. The benefit of maintenance intensity is most pronounced during the first 12 months, underscoring the importance of adherence to an adequate BCG regimen to optimize outcomes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Bando, Yukari AU - Bando Y AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: ykrbando@med.kobe-u.ac.jp. FAU - Teishima, Jun AU - Teishima J AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Tobe, Taisuke AU - Tobe T AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Ueki, Hideto AU - Ueki H AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Wakita, Naoto AU - Wakita N AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Okamura, Yasuyoshi AU - Okamura Y AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Suzuki, Kotaro AU - Suzuki K AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Hara, Takuto AU - Hara T AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Terakawa, Tomoaki AU - Terakawa T AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Chiba, Koji AU - Chiba K AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. LA - eng PT - Journal Article DEP - 20260402 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/drug therapy MH - Female MH - Retrospective Studies MH - Male MH - Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Middle Aged MH - Disease-Free Survival MH - Neoplasm Recurrence, Local MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/drug therapy/mortality MH - Maintenance Chemotherapy OTO - NOTNLM OT - Bacille Calmette-Guerin OT - Maintenance therapy OT - Non-muscle-invasive bladder cancer COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/04 06:34 MHDA- 2026/05/10 05:18 CRDT- 2026/04/04 02:11 PHST- 2025/10/31 00:00 [received] PHST- 2026/02/18 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/05/10 05:18 [medline] PHST- 2026/04/04 06:34 [pubmed] PHST- 2026/04/04 02:11 [entrez] AID - S1078-1439(26)00098-0 [pii] AID - 10.1016/j.urolonc.2026.111087 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):53-60. doi: 10.1016/j.urolonc.2026.111087. Epub 2026 Apr 2. PMID- 41934021 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study. PG - 61-69 LID - S1078-1439(26)00100-6 [pii] LID - 10.1016/j.urolonc.2026.111089 [doi] AB - BACKGROUND AND OBJECTIVE: The oncological risk of patients with Ta high-grade (TaHG) non-muscle-invasive bladder cancer (NMIBC) remains uncertain. We aimed to evaluate the oncological outcomes of TaHG patients treated with Bacillus Calmette-Guerin (BCG) by applying the 2021 European Association of Urology (EAU) and the American Association of Urology (AUA) risk stratifications and assessing the prognostic value of individual risk factors. METHODS: We identified 529 TaHG patients without carcinoma in situ (CIS) treated with BCG from 16 tertiary centers between 2003 and 2024. BCG failure was defined as the development of BCG-unresponsive status, BCG relapsing status or identification of muscle invasive bladder cancer during follow-up. TaHG patients were stratified according to the number of EAU and AUA risk factors in three groups (0, 1, 2-3 risk factors), and in intermediate risk (IR-TaHG) and high-risk (HR-TaHG) according to both EAU and AUA risk stratifications. Cumulative incidence analyses and Cox regression models analyzed the 5-yr risk of HG-recurrence, progression and BCG failure among TaHG patients stratified according to the number of EAU and AUA risk factors. KEY FINDINGS: At a median follow-up of 40 months (IQR: 37-42), 114 (22%) TaHG patients experienced a HG-recurrence, 49 (9%) patients had progression and 107 (20%) had BCG failure. No differences in the risk of HG-recurrence, progression and rates of BCG failure were detected in TaHG patients stratified according to the number of EAU or AUA risk factors (all P < 0.05). No differences in the risk of 5-year HG-recurrence were observed between IR-TaHG and HR-TaHG patients according to both EAU (26% vs. 31%, P = 0.10) and AUA risk stratifications (24% vs. 29%, P = 0.07). Similarly, no differences in the 5-yr risk of progression were detected among IR-TaHG and HR-TaHG according to EAU (13% vs. 15%, P = 0.3) and AUA risk stratifications (12% vs. 15%, P = 0.2). No differences in the risk of BCG failure were observed between IR-TaHG and HR-TaHG according to both EAU and AUA risk stratifications (all P > 0.05). CONCLUSION AND CLINICAL IMPLICATIONS: We observed no differences in HG-recurrence, progression, or BCG failure rates among patients with TaHG NMIBC, regardless of the number of EAU or AUA risk factors harbored. These findings may speculatively support the increasing need for BCG-adapted risk stratification and the consideration of all TaHG tumors without CIS as a homogenous population with a similar oncological risk, regardless of individual risk factors. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Viti, Alessandro AU - Viti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Elena, Jose Luis Rodriguez AU - Elena JLR AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS Rozzano, Milan, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: moschini.marco@hsr.it. CN - European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260402 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *BCG Vaccine/therapeutic use MH - Cohort Studies MH - Neoplasm Grading MH - *Non-Muscle Invasive Bladder Neoplasms/pathology MH - Prognosis MH - Risk Assessment MH - Risk Factors OTO - NOTNLM OT - Bacillus-Calmette Guerin OT - Bladder cancer OT - Non-muscle-invasive bladder cancer OT - Risk stratification OT - Ta high-grade COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/04 06:33 MHDA- 2026/05/10 05:18 CRDT- 2026/04/04 02:11 PHST- 2025/11/06 00:00 [received] PHST- 2026/02/27 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/05/10 05:18 [medline] PHST- 2026/04/04 06:33 [pubmed] PHST- 2026/04/04 02:11 [entrez] AID - S1078-1439(26)00100-6 [pii] AID - 10.1016/j.urolonc.2026.111089 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):61-69. doi: 10.1016/j.urolonc.2026.111089. Epub 2026 Apr 2. PMID- 41934020 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Recurrence patterns in primary urethral carcinoma: Prognostic impact of inguinal and pelvic lymphadenectomy. PG - 41-52 LID - S1078-1439(26)00097-9 [pii] LID - 10.1016/j.urolonc.2026.111086 [doi] AB - PURPOSE: Primary urethral carcinoma (PUC) is a rare, aggressive malignancy with limited evidence to guide management. This study aimed to characterize recurrence patterns and identify clinicopathological predictors of recurrence-free survival (RFS), focusing on nodal management. METHODS: We retrospectively analyzed adults treated for PUC at 2 academic centers. Patients with concurrent bladder cancer, upper tract urothelial carcinoma, or urethral involvement from another malignancy were excluded. Management included transurethral resection, partial or radical urethrectomy (with or without cystectomy), and selective inguinal and/or pelvic lymph node dissection (ILND/PLND). Some patients received radiotherapy or systemic therapy. The primary endpoint was RFS, defined as the interval from initial treatment to first recurrence. Kaplan-Meier and Cox regression identified independent predictors. RESULTS: Fifty patients were included (median age 68.5 years; 78% male): 44 treated at University Hospital Tubingen and 6 at Fundeni Clinical Institute. Histology comprised urothelial carcinoma (50%), squamous cell carcinoma (20%), and others (30%). At diagnosis, 28% were cN+ and 12% cM1. ILND and PLND were performed in 28% and 36% of cases, respectively. Overall, 48% developed recurrence (12% local, 12% regional, 24% distant) at a median of 14.5 months. RFS was 71% at 12 months and 23% at 36 months. On multivariable analysis, age >/= 70 years (HR 0.07; P = 0.01) was independently associated with a reduced risk of recurrence. PLND demonstrated a protective trend (HR 0.08; P = 0.07), and a similar tendency was observed for ILND (HR 0.23; P = 0.053). In contrast, posterior tumor location was associated with an increased risk of overall recurrence (P = 0.023), and grade 3 tumors with a higher risk of local recurrence (P = 0.047). The retrospective design and small sample limit generalizability. CONCLUSIONS: Recurrence after PUC treatment is frequent and early. PLND and older age predict improved RFS, supporting risk-adapted, multimodal management and extended follow-up at expert centers. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Garaz, Radion AU - Garaz R AD - Department of Urology, University Hospital Tubingen, Tubingen, Germany. Electronic address: Radion.Garaz@med.uni-tuebingen.de. FAU - Rausch, Steffen AU - Rausch S AD - Department of Urology, University Hospital Tubingen, Tubingen, Germany. FAU - Mirvald, Cristian AU - Mirvald C AD - Department of Urology, Fundeni Clinical Institute, Bucharest, Romania; University of Medicine and Pharmacy, 'Carol Davila' Bucharest, Bucharest, Romania. FAU - Schurch, Christian M AU - Schurch CM AD - Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tubingen, Tubingen, Germany; Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, University of Tubingen, Tubingen, Germany. FAU - Maas, Moritz AU - Maas M AD - Department of Urology, University Hospital Tubingen, Tubingen, Germany. FAU - Lauer, Henrik AU - Lauer H AD - Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Klinik Tubingen, University of Tubingen, Tubingen, Germany. FAU - Surcel, Cristian AU - Surcel C AD - Department of Urology, Fundeni Clinical Institute, Bucharest, Romania; University of Medicine and Pharmacy, 'Carol Davila' Bucharest, Bucharest, Romania. FAU - Tsaur, Igor AU - Tsaur I AD - Department of Urology, University Hospital Tubingen, Tubingen, Germany. LA - eng PT - Journal Article DEP - 20260402 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Male MH - *Urethral Neoplasms/pathology/surgery/mortality MH - *Lymph Node Excision/methods MH - Aged MH - Retrospective Studies MH - Prognosis MH - *Neoplasm Recurrence, Local/pathology MH - Female MH - Middle Aged MH - Pelvis MH - Inguinal Canal MH - Aged, 80 and over OTO - NOTNLM OT - Lymph nodes OT - Pelvic lymphadenectomy OT - Prognostic factors OT - Surveillance OT - Urethral neoplasms COIS- Declaration of competing interest The authors declare that they have no known competing personal relationships or financial interests that may have influenced the study reported in this paper. EDAT- 2026/04/04 06:34 MHDA- 2026/05/10 05:18 CRDT- 2026/04/04 02:11 PHST- 2025/11/01 00:00 [received] PHST- 2026/02/23 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/05/10 05:18 [medline] PHST- 2026/04/04 06:34 [pubmed] PHST- 2026/04/04 02:11 [entrez] AID - S1078-1439(26)00097-9 [pii] AID - 10.1016/j.urolonc.2026.111086 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):41-52. doi: 10.1016/j.urolonc.2026.111086. Epub 2026 Apr 2. PMID- 41930190 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260403 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Chromosomal instability as a predictive biomarker for recurrence risk following transurethral resection of NMIBC. PG - 1752078 LID - 10.3389/fonc.2026.1752078 [doi] LID - 1752078 AB - OBJECTIVE: To investigate chromosomal instability (CIN) in tumor tissues from transurethral resection of bladder tumor (TURBT) and evaluate its feasibility as a molecular biomarker for prognostic stratification in non-muscle-invasive bladder cancer (NMIBC). METHODS: In this retrospective single-center cohort study, DNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples of 50 BC patients using the Qiagen nucleic acid extraction kit. The recurrence defined in this study refers to cystoscopically visible recurrence confirmed by biopsy or surgical pathology. All patients underwent follow-up until January 2025 in strict accordance with the protocol established by the EAU guidelines for NMIBC. Low-coverage whole-genome sequencing (LC-WGS) was performed to analyze CIN in bladder tumors. Time-dependent Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive efficacy of CIN values for post-TURBT outcomes. Survival analysis was conducted using the Kaplan-Meier method (log-rank test), and associations between variables and recurrence-free survival (RFS) were assessed via Cox proportional hazards models. RESULTS: Recurrent bladder cancer patients exhibited significant copy number alterations (CNAs) differences in 67 gene segments versus non-recurrent patients. Time-dependent ROC analysis demonstrates that CIN values exhibit good predictive performance between the 2nd and 5th years. High CIN was significantly associated with tumor recurrence, higher tumor grade, with high-CIN patients exhibiting poorer prognosis (median RFS: 22 months vs. unreached in the low-CIN group, p = 0.009). Multivariate analysis confirmed high CIN as an independent predictor of recurrence (HR = 5.22, 95% CI: 1.52-17.93, P = 0.009). Patients with single-chromosome copy number abnormalities also showed worse outcomes (median RFS: 16-23 months) compared to those without such abnormalities. No significant difference in RFS was detected between Ta and T1 stages (P = 0.577). CONCLUSION: High CIN exhibits a correlation with bladder tumor recurrence, higher tumor grade. High CIN or the presence of specific chromosomal abnormalities are indicative of an adverse prognosis. CIN may serve as a prognostic biomarker for predicting recurrence following TURBT, particularly between the 2nd and 5th years post-surgery. CI - Copyright (c) 2026 Ding, Zhu, Fan, Wang, Jin, Cao, Shi, Fan, Tu and Li. FAU - Ding, Qi AU - Ding Q AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Zhu, Hailiang AU - Zhu H AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Fan, Bo AU - Fan B AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Wang, Lisheng AU - Wang L AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Jin, Xiaohua AU - Jin X AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Cao, Cheng AU - Cao C AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Shi, Ying AU - Shi Y AD - Department of Gastroenterology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Fan, Zhijiang AU - Fan Z AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Tu, Wenjian AU - Tu W AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. FAU - Li, Feng AU - Li F AD - Department of Urology, The First People's Hospital of Changshu, The Changshu Hospital Affiliated to Soochow University, Changshu, China. LA - eng PT - Journal Article DEP - 20260311 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13040361 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - chromosomal instability OT - low-coverage whole genome sequencing OT - recurrence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/04/03 06:30 MHDA- 2026/04/03 06:31 PMCR- 2026/03/11 CRDT- 2026/04/03 05:05 PHST- 2025/11/22 00:00 [received] PHST- 2026/02/14 00:00 [revised] PHST- 2026/02/24 00:00 [accepted] PHST- 2026/04/03 06:31 [medline] PHST- 2026/04/03 06:30 [pubmed] PHST- 2026/04/03 05:05 [entrez] PHST- 2026/03/11 00:00 [pmc-release] AID - 10.3389/fonc.2026.1752078 [doi] PST - epublish SO - Front Oncol. 2026 Mar 11;16:1752078. doi: 10.3389/fonc.2026.1752078. eCollection 2026. PMID- 41927709 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Apr 2 TI - Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer. LID - 10.1038/s41598-026-43393-z [doi] LID - 15796 AB - High-risk non-muscle invasive bladder cancer (HR-NMIBC) presents a significant therapeutic challenge due to its high recurrence and progression rates, particularly in patients with human epidermal growth factor receptor 2 (HER2) expression who are unresponsive to or ineligible for Bacillus Calmette-Guerin (BCG) therapy. This study aimed to evaluate the efficacy and safety of the HER2-targeted antibody-drug conjugate (ADC), Disitamab Vedotin (RC48), alone or in combination with PD-1 inhibitors, as a systemic bladder-sparing approach in a real-world HR-NMIBC cohort. We conducted a multicenter, retrospective, real-world study involving 32 patients with HR-NMIBC who received RC48 alone (n = 3) or in combination with PD-1 inhibitors (n = 29) between June 2022 and December 2024. Eligibility criteria included BCG-unresponsive (n = 7) or BCG-ineligible (n = 25). Data were collected on demographics, clinical characteristics, treatment responses, and adverse events. The primary endpoint was complete response rate (CRR). Secondary endpoints included event-free survival (EFS), duration of complete response (DoCR), 6-month bladder preservation rate, and safety. At a median follow-up of 13.3 months, the overall CRR was 71.9% (23/32; 95% CI: 53.3%-86.3%). In the BCG-unresponsive and BCG-ineligible subgroups, CRRs were 85.7% (6/7) and 68.0% (17/25), respectively. The median EFS for the overall cohort was 22.1 months (95% CI: 16.7-27.4), with no significant difference between the BCG subgroups (P = 0.98). Among the 23 responders, the median DoCR was 16.9 months (95% CI: 13.1-20.7). Treatment-related adverse events (TRAEs) occurred in 53.1% of patients, primarily Grade 1-2 peripheral neuropathy (21.9%) and rash (21.9%). Grade >/= 3 TRAEs were rare (6.3%). In this real-world study, RC48-based systemic therapy, particularly in combination with PD-1 inhibitors, demonstrates promising preliminary activity and a manageable safety profile in BCG-unresponsive or BCG-ineligible HR-NMIBC. Large prospective trials are required to confirm long-term durability and the optimal role of this systemic approach. FAU - Guo, Xuanjun AU - Guo X AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Wang, Shuoyu AU - Wang S AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Ma, Yechi AU - Ma Y AD - Peking University Health Science Centre, Beijing, 100191, China. FAU - Chen, Yuke AU - Chen Y AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Du, Yicong AU - Du Y AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Wang, Qian AU - Wang Q AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Yang, Kaiwei AU - Yang K AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Tang, Qi AU - Tang Q AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Fan, Yu AU - Fan Y AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Hao, Han AU - Hao H AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Yu, Wei AU - Yu W AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - He, Zhisong AU - He Z AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Gong, Yanqing AU - Gong Y AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. yqgong@bjmu.edu.cn. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. yqgong@bjmu.edu.cn. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. yqgong@bjmu.edu.cn. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. yqgong@bjmu.edu.cn. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. yqgong@bjmu.edu.cn. FAU - Zhang, Cuijian AU - Zhang C AD - Department of Urology, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. zhangcj@bjmu.edu.cn. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034 , China. zhangcj@bjmu.edu.cn. AD - Institute of Urology, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. zhangcj@bjmu.edu.cn. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. zhangcj@bjmu.edu.cn. AD - National Urological Cancer Center, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. zhangcj@bjmu.edu.cn. LA - eng GR - No. 82273347/National Natural Science Foundation of China/ GR - No. 2023HQ6/Clinical Research Foundation of Central High-level Hospital (Peking University First Hospital Research Fund Program)/ PT - Journal Article PT - Multicenter Study DEP - 20260402 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Immune Checkpoint Inhibitors) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Immunoconjugates) RN - 0 (PDCD1 protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Female MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects/administration & dosage MH - Retrospective Studies MH - Aged MH - Male MH - Middle Aged MH - Erb-b2 Receptor Tyrosine Kinases/antagonists & inhibitors/metabolism MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors MH - *Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use/administration & dosage MH - *Immunoconjugates/therapeutic use/adverse effects/administration & dosage MH - Treatment Outcome MH - Aged, 80 and over MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC13194773 OTO - NOTNLM OT - Bladder-sparing therapy OT - Disitamab Vedotin (RC48) OT - HER2 expression OT - High-risk non-muscle-invasive bladder cancer OT - PD-1 inhibitor COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval: The study protocol was approved by the Ethics Committee of Peking University First Hospital (Approval No.: 2025R0556). The requirement for informed consent was waived by the ethics committee given the participants could not be contacted due to the retrospective nature of the research. EDAT- 2026/04/03 00:31 MHDA- 2026/06/28 13:04 PMCR- 2026/04/02 CRDT- 2026/04/02 23:22 PHST- 2025/11/17 00:00 [received] PHST- 2026/03/04 00:00 [accepted] PHST- 2026/06/28 13:04 [medline] PHST- 2026/04/03 00:31 [pubmed] PHST- 2026/04/02 23:22 [entrez] PHST- 2026/04/02 00:00 [pmc-release] AID - 10.1038/s41598-026-43393-z [pii] AID - 43393 [pii] AID - 10.1038/s41598-026-43393-z [doi] PST - epublish SO - Sci Rep. 2026 Apr 2;16(1):15796. doi: 10.1038/s41598-026-43393-z. PMID- 41924954 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260818 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 2 DP - 2026 Aug TI - Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach. PG - 244-249 LID - 10.1111/bju.70269 [doi] AB - OBJECTIVES: To evaluate whether a simplified risk model preserves the prognostic performance of the International Bladder Cancer Group (IBCG) five-factor risk stratification model in intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We performed a multicentre retrospective analysis of 2822 patients with IR NMIBC treated with transurethral resection of bladder tumour and intravesical therapy between 2005 and 2025. Multivariable Cox regression identified independent predictors of recurrence and progression. A simplified risk model was constructed using significant variables and compared with the full IBCG model using recurrence and progression rates, area under the curve analysis, and likelihood ratio testing. RESULTS: A total of 2822 patients with IR NMIBC were included. When classified using the full IBCG model, 1143 (41%) were in the IR-low, 1535 (54%) IR-intermediate, and 144 (5%) IR-high-risk groups. On multivariable analysis, only multifocality, early recurrence, and failure of intravesical therapy independently predicted oncological outcomes. Using these factors, patients were stratified as IR-low (no factors), IR-intermediate (one factor), or IR-high (two or more factors). Under the simplified model, 1535 (54%) patients were classified as IR-low, 906 (32%) as IR-intermediate, and 381 (14%) as IR-high. The 3-year recurrence and progression rates increased stepwise across simplified risk groups. Discriminative performance of the simplified model was comparable to the full model across all metrics, with no meaningful loss of discrimination. CONCLUSION: Three variables captured the most prognostic signal in this cohort without loss of discrimination compared with the full model. This simplified model is an internally validated refinement, with planned external validation to confirm generalisability and to ensure that simplified thresholds do not alter the clinically important IR-high subgroup used in care and trials. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Siva, Jayant AU - Siva J AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Aydogdu, Can AU - Aydogdu C AUID- ORCID: 0009-0003-1486-183X AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Heller, Nicholas AU - Heller N AUID- ORCID: 0000-0001-8516-8707 AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Jonnalagadda, Rishi AU - Jonnalagadda R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Diaz, Gabriela M AU - Diaz GM AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - McSweeney, Sean AU - McSweeney S AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Campbell, Rebecca AU - Campbell R AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Almassi, Nima AU - Almassi N AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Alaghehbandan, Reza AU - Alaghehbandan R AD - Department of Pathology, Cleveland Clinic, Cleveland, OH, USA. FAU - Weight, Christopher J AU - Weight CJ AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urology, Cleveland Clinic, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260402 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - Transurethral Resection of Bladder MH - Risk Assessment/methods MH - Neoplasm Recurrence, Local MH - Middle Aged MH - Prognosis MH - Disease Progression MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Administration, Intravesical MH - Aged, 80 and over PMC - PMC13371396 OTO - NOTNLM OT - IBCG OT - NMIBC OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - urothelial cancer EDAT- 2026/04/02 12:37 MHDA- 2026/07/15 12:37 PMCR- 2026/07/15 CRDT- 2026/04/02 06:03 PHST- 2026/07/15 12:37 [medline] PHST- 2026/04/02 12:37 [pubmed] PHST- 2026/04/02 06:03 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - BJU70269 [pii] AID - 10.1111/bju.70269 [doi] PST - ppublish SO - BJU Int. 2026 Aug;138(2):244-249. doi: 10.1111/bju.70269. Epub 2026 Apr 2. PMID- 41923172 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260627 LR - 20260910 IS - 2049-3002 (Print) IS - 2049-3002 (Electronic) IS - 2049-3002 (Linking) VI - 14 IP - 1 DP - 2026 Apr 1 TI - Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer. LID - 10.1186/s40170-026-00427-4 [doi] LID - 8 AB - BACKGROUND: Untargeted metabolomics has emerged as a powerful approach to uncover metabolic dysregulation associated with cancer progression. When integrated with a machine learning strategy it facilitates the discovery of key metabolic pathways and predictive biomarkers with high diagnostic and prognostic value. METHODS: In this study, we employed liquid chromatography coupled to high-resolution Tribrid Orbitrap mass spectrometry to perform comprehensive metabolic profiling of bladder cancer (BLCA) as well as predict invasiveness of the disease. RESULTS: By leveraging both in-house retention time-based MS/MS spectral libraries and commercial databases, we robustly identify over 2000 metabolites. In addition, this platform allows identification of novel pathways highlighting metabolic vulnerabilities in BLCA. The application of machine learning algorithms and advanced computational modeling uncovered metabolic signatures that differentiate BLCA from adjacent normal/benign samples and distinguish muscle-invasive from non-muscle-invasive bladder cancer. Our integrative analytical pipeline addresses key challenges in metabolomics-including high dimensionality, metabolite annotation, and biological variability-through feature selection and predictive modeling. We identify candidate metabolic markers with strong potential for early detection and characterize invasiveness of the disease and identify potential therapeutic target pathways. CONCLUSIONS: This work highlights the power of combining untargeted metabolomics with machine learning to map the metabolic landscape of BLCA and to accelerate the development of precision diagnostics and future therapeutic strategies. FAU - Kamal, Abu Hena Mostafa AU - Kamal AHM AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. FAU - Putluri, Vasanta AU - Putluri V AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. FAU - Gandhi, Tanmay AU - Gandhi T AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. AD - Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. FAU - Ambati, Chandra Shekar R AU - Ambati CSR AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. FAU - Amara, Chandra Sekhar AU - Amara CS AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Kami Reddy, Karthik Reddy AU - Kami Reddy KR AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Spradlin, Meredith Lauren AU - Spradlin ML AD - Department of Surgery, Baylor College of Medicine, Houston, TX, USA. FAU - Koirala, Amrit AU - Koirala A AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. AD - Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. AD - Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA. FAU - Jorvekar, Sachin B AU - Jorvekar SB AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Grimm, Sandra L AU - Grimm SL AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. AD - Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. AD - Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA. FAU - Fu, Dexue AU - Fu D AD - Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Parsawar, Krishna AU - Parsawar K AD - Analytical and Biological Mass Spectrometry Core, University of Arizona, Tucson, AZ, USA. FAU - Jong, Felice de AU - Jong F AD - IROA Technologies, Chapel Hill, NC, USA. FAU - Beecher, Chris AU - Beecher C AD - IROA Technologies, Chapel Hill, NC, USA. FAU - Sen, Subrata AU - Sen S AD - Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. FAU - Siddiqui, M Minhaj AU - Siddiqui MM AD - Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Eberlin, Livia S AU - Eberlin LS AD - Department of Surgery, Baylor College of Medicine, Houston, TX, USA. FAU - Sreekumar, Arun AU - Sreekumar A AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Coarfa, Cristian AU - Coarfa C AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. coarfa@bcm.edu. AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. coarfa@bcm.edu. AD - Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. coarfa@bcm.edu. AD - Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA. coarfa@bcm.edu. FAU - Putluri, Nagireddy AU - Putluri N AD - Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA. putluri@bcm.edu. AD - Advanced Technology Cores, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. putluri@bcm.edu. LA - eng GR - R01 CA282282/CA/NCI NIH HHS/United States GR - S10 OD032218/OD/NIH HHS/United States GR - U54 CA274321/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20260401 PL - England TA - Cancer Metab JT - Cancer & metabolism JID - 101607582 PMC - PMC13040883 OTO - NOTNLM OT - Bladder cancer OT - Machine learning OT - Orbitrap IQ-X OT - Untargeted metabolomics COIS- Declarations. Ethics approval and consent to participate: All human tissue samples were collected from tumor bank from UTSW, UMB and de-identified samples were analysed under protocols approved by the Institutional Review Board: protocol H-35808 (BCM) from UTSW, UMB. De-identified samples from CHTN were obtained by Dr. Eberlin (under MTA) and trasnsfered to Dr. Putluri lab (under MTA) for metabolomics analysis. Consent for publication: All the authors have read and approved the submission of the current version of the manuscript. Competing interests: AS is Scientific Advisor to Karkinos Health Care Pvt Ltd., India, and is an unpaid visiting faculty to Sri Sathya Sai Institute for Higher Learning, India. EDAT- 2026/04/02 06:31 MHDA- 2026/04/02 06:32 PMCR- 2026/04/01 CRDT- 2026/04/02 00:13 PHST- 2025/06/17 00:00 [received] PHST- 2026/03/11 00:00 [accepted] PHST- 2026/04/02 06:32 [medline] PHST- 2026/04/02 06:31 [pubmed] PHST- 2026/04/02 00:13 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - 10.1186/s40170-026-00427-4 [pii] AID - 427 [pii] AID - 10.1186/s40170-026-00427-4 [doi] PST - epublish SO - Cancer Metab. 2026 Apr 1;14(1):8. doi: 10.1186/s40170-026-00427-4. PMID- 41919786 OWN - NLM STAT- MEDLINE DCOM- 20260611 LR - 20260818 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 138 IP - 1 DP - 2026 Jul TI - Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial. PG - 92-99 LID - 10.1111/bju.70266 [doi] AB - OBJECTIVE: To assess whether improvements in transurethral resection of bladder tumour (TURBT) quality achieved during the RESECT international study (ClinicalTrials.gov identifier: NCT05154084) were sustained over time following completion of the programme at our institution and to investigate their effect on disease recurrence. PATIENTS AND METHODS: We conducted a prospective, observational monocentric cohort study at a tertiary university hospital. A total of 128 consecutive patients undergoing TURBT between March 2023 and June 2025 and meeting RESECT eligibility criteria were analysed. Four pre-defined surgical quality indicators-detrusor muscle sampling, completeness of resection, accuracy of operative documentation, and administration of single immediate intravesical chemotherapy (SI-IVC)-were compared across three institutional phases: pre-audit, prospective audit and post-audit RESECT periods. Recurrence-free survival (RFS) at follow-up was evaluated by cystoscopy and histological confirmation with TURBT. RESULTS: Detrusor muscle presence improved from 61.9% in the pre-audit phase to 70.7% during the prospective audit and 85.9% post-audit (P < 0.001). Completeness of resection documentation increased from 88.4% to 96.3% and 97.6%, respectively (P < 0.001), while documentation accuracy remained high across all phases (93.2%, 96.3%, and 96.1%). SI-IVC use rose from 0% in the first two phases to 25% after audit closure. Despite these improvements, RFS did not differ significantly between phases. CONCLUSION: Participation in a service-wide audit and feedback programme resulted in sustained improvements in TURBT surgical quality indicators after programme completion. This did not yield a detectable reduction in recurrence, highlighting the multifactorial nature of oncological outcomes in non-muscle-invasive bladder cancer. Further studies are required to identify which quality metrics most strongly influence long-term prognosis. CI - (c) 2026 BJU International. FAU - Orecchia, Luca AU - Orecchia L AUID- ORCID: 0000-0001-8376-5380 AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. AD - Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Gerardi, Marco AU - Gerardi M AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. FAU - Colalillo, Gaia AU - Colalillo G AUID- ORCID: 0000-0001-8703-5975 AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. AD - Urology Department, Policlinico San Marco Hospital, Bergamo, Italy. FAU - Leonardis, Federico De AU - Leonardis F AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. FAU - Rosato, Eleonora AU - Rosato E AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. FAU - Asimakopoulos, Anastasios D AU - Asimakopoulos AD AUID- ORCID: 0000-0002-7230-579X AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. FAU - Gallagher, Kevin M AU - Gallagher KM AD - Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. AD - Department of Urology, Western General Hospital, Edinburgh, UK. AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Bhatt, Nikita AU - Bhatt N AUID- ORCID: 0000-0002-8554-4335 AD - Department of Urology, St Vincent's University Hospital, Dublin, Ireland. FAU - Khadhouri, Sinan AU - Khadhouri S AUID- ORCID: 0000-0002-1836-8992 AD - Department of Urology, School of Medicine, University of St Andrews, St Andrews, UK. FAU - Kasivisvanathan, Veeru AU - Kasivisvanathan V AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Finazzi Agro, Enrico AU - Finazzi Agro E AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. AD - Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Miano, Roberto AU - Miano R AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. AD - Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Urology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. AD - Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. LA - eng SI - ClinicalTrials.gov/NCT05154084 PT - Journal Article PT - Observational Study DEP - 20260401 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Transurethral Resection of Bladder/standards MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Female MH - Male MH - Prospective Studies MH - Aged MH - Neoplasm Recurrence, Local MH - Middle Aged MH - *Medical Audit MH - Feedback OTO - NOTNLM OT - audit OT - non-muscle-invasive bladder cancer OT - quality OT - recurrence-free survival OT - transurethral resection of bladder tumour COIS- Kevin M. Gallagher has had unrestricted grants for research related to the RESECT study from Karl Storz, Photocure and Medac Pharma. The other authors report no conflicts of interest. EDAT- 2026/04/01 12:32 MHDA- 2026/06/11 18:36 CRDT- 2026/04/01 08:43 PHST- 2026/06/11 18:36 [medline] PHST- 2026/04/01 12:32 [pubmed] PHST- 2026/04/01 08:43 [entrez] AID - 10.1111/bju.70266 [doi] PST - ppublish SO - BJU Int. 2026 Jul;138(1):92-99. doi: 10.1111/bju.70266. Epub 2026 Apr 1. PMID- 41907065 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260330 LR - 20260813 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 18 DP - 2026 TI - Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups. PG - 584499 LID - 10.2147/RRU.S584499 [doi] LID - 584499 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) accounts for the majority of newly diagnosed bladder cancer cases and is characterized by high rates of recurrence and progression. Intravesical Bacillus Calmette-Guerin (BCG) remains the standard of care for high-risk disease; however, treatment intolerance, failure, and global supply shortages have prompted investigation of alternative intravesical therapies. OBJECTIVE: To summarize and critically appraise the existing clinical evidence evaluating sequential intravesical gemcitabine and docetaxel (Gem/Doce) in NMIBC, across different clinical contexts. METHODS: We performed a narrative review of published clinical studies assessing sequential intravesical Gem/Doce in patients with BCG-unresponsive, BCG-exposed, and selected treatment-naive NMIBC. Reported oncologic outcomes, including recurrence-free survival, progression, cystectomy rates, and treatment-related adverse events, were reviewed. Emerging exploratory approaches, including biomarker-based risk stratification, were also described. RESULTS: Across multiple retrospective and prospective studies, Gem/Doce has demonstrates favorable recurrence-free survival, and acceptable safety profiles, particularly in patients with BCG-unresponsive or previously treated high-risk NMIBC. Reported rates of progression and cystectomy are generally low, and treatment discontinuation due to toxicity is uncommon. Exploratory studies have evaluated AI-assisted histologic biomarkers as potential tools for risk stratification and hypothesis-generating treatment selection; however, these approaches remain investigational and require prospective validation. CONCLUSION: Current evidence suggests that sequential intravesical Gem/Doce is a well-tolerated bladder-sparing option with encouraging oncologic outcomes, particularly in patients with recurrent or BCG-unresponsive NMIBC. While early data have explored its use in treatment-naive settings, definitive conclusions regarding its role as first-line therapy require validation in prospective randomized trials. CI - (c) 2026 Hemmati Ghavshough et al. FAU - Hemmati Ghavshough, Mahdi AU - Hemmati Ghavshough M AUID- ORCID: 0000-0002-2145-0778 AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Fu, Melinda Z AU - Fu MZ AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Islam, Raeesa AU - Islam R AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Patel, Disha AU - Patel D AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. LA - eng PT - Journal Article PT - Review DEP - 20260127 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC13017178 OTO - NOTNLM OT - docetaxel OT - gemcitabine OT - naive OT - refractory OT - treatment failure OT - untreated OT - urinary bladder neoplasms COIS- Vignesh Packiam reports personal fees from Valar Labs, personal fees from Veracyte, personal fees from Photocure, personal fees from Ferring, personal fees from Jannsen, personal fees from Urogen, outside the submitted work. The authors report no other conflicts of interest in this work. EDAT- 2026/03/30 12:49 MHDA- 2026/03/30 12:50 PMCR- 2026/01/27 CRDT- 2026/03/30 06:14 PHST- 2025/12/02 00:00 [received] PHST- 2026/01/23 00:00 [accepted] PHST- 2026/03/30 12:50 [medline] PHST- 2026/03/30 12:49 [pubmed] PHST- 2026/03/30 06:14 [entrez] PHST- 2026/01/27 00:00 [pmc-release] AID - 584499 [pii] AID - 10.2147/RRU.S584499 [doi] PST - epublish SO - Res Rep Urol. 2026 Jan 27;18:584499. doi: 10.2147/RRU.S584499. eCollection 2026. PMID- 41905878 OWN - NLM STAT- MEDLINE DCOM- 20260805 LR - 20260805 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 3 DP - 2026 Aug TI - Bladder Urothelial Neoplasms Profile in Dr. Soetomo General Academic Hospital Surabaya: Retrospective Study during 2013-2023. PG - 384-388 LID - 10.1177/03915603261434799 [doi] AB - BACKGROUND: Bladder urothelial neoplasms were the most common type of tumor in the urinary tract. These tumors often recur and are progressive. Therefore, it is necessary to analyze the patient's profile. The aim is to examine the clinicopathologic character with a retrospective study. METHOD: This is a descriptive study with retrospective approach. Data were collected from the histopathological diagnosis of urothelial neoplasms at Laboratory of Anatomical Pathology in Dr. Soetomo General Academic Hospital, Surabaya, from 2013 to 2023. RESULT: There were 618 people with bladder urothelial neoplasms. Males predominate in this research (87.5%), and 32% occur between the ages of 51 and 60. Procedure used for diagnosing was 46.6% by TURB. High-grade tumors constituted 81% and 92.6% were already invasive, with 58.4% being MIBC. DISCUSSION: This study exhibits a higher prevalence of urothelial neoplasms in males, likely due to smoking and androgen receptor influence. Most individuals were diagnosed after 50 years old. The majority of them already have high-grade, muscle-invasive tumors, which may have worse prognosis than low-grade, NMIBC tumors. CONCLUSION: There was male predominance in urothelial bladder neoplasms. Most ages were after 50 years. The majority of tumors were high grade and already muscle invasive (at least pT2). FAU - Ilmiah, Khafidhotul AU - Ilmiah K AUID- ORCID: 0000-0002-3820-360X AD - Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Parengkuan, Irene Lingkan AU - Parengkuan IL AUID- ORCID: 0000-0002-7407-9052 AD - Department of Anatomical Pathology, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia. FAU - Rahaju, Anny Setijo AU - Rahaju AS AUID- ORCID: 0000-0001-8392-3350 AD - Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Mastutik, Gondo AU - Mastutik G AUID- ORCID: 0000-0002-1681-0222 AD - Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Djatisoesanto, Wahjoe AU - Djatisoesanto W AUID- ORCID: 0000-0002-7579-5608 AD - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. AD - Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. LA - eng PT - Journal Article DEP - 20260329 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - Male MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/epidemiology/pathology MH - Middle Aged MH - Female MH - Aged MH - Adult MH - *Carcinoma, Transitional Cell/epidemiology/pathology MH - Time Factors MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms MH - Academic Medical Centers OTO - NOTNLM OT - TURB OT - bladder cancer OT - cancer OT - grade OT - pathological T stage OT - radical cystectomy COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/03/30 00:29 MHDA- 2026/08/05 17:37 CRDT- 2026/03/29 22:02 PHST- 2026/08/05 17:37 [medline] PHST- 2026/03/30 00:29 [pubmed] PHST- 2026/03/29 22:02 [entrez] AID - 10.1177/03915603261434799 [doi] PST - ppublish SO - Urologia. 2026 Aug;93(3):384-388. doi: 10.1177/03915603261434799. Epub 2026 Mar 29. PMID- 41905815 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 6 DP - 2026 Jun TI - Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer? PG - 23-30 LID - S1078-1439(26)00091-8 [pii] LID - 10.1016/j.urolonc.2026.111080 [doi] AB - OBJECTIVE: To study the impact of complete transurethral resection of bladder tumor (TURBT) on survival outcomes for patients of muscle-invasive bladder carcinoma (MIBC) undergoing upfront or post-NACT (neo-adjuvant chemotherapy) radical cystectomy (RC) and to identify the factors that contribute to achieving a complete TURBT (cTURBT). METHODS: A retrospective analysis of 244 cases of bladder cancer that underwent RC at our institute between 2013 and 2019 was undertaken. Univariate logistic regression analysis was used to identify factors that could affect the performance of cTURBT. The factors significant on univariate analysis were further subjected to multivariate logistic analysis. Survival univariate analysis was performed using the Kaplan-Meier curve analysis method. Cox regression analysis was used to identify the factors that affected cancer specific survival (CSS). RESULTS: In multivariate logistic analysis, tumor sizes of 3 to 5 cm (HR 3.5) and greater than 5 cm (HR 11.2) were significantly linked to residual tumor at TURBT, as was clinical T-stage greater than 3 (HR 5.2). Hydroureteronephrosis (HUN) (HR 2.9), variant histology (HR 2.2), incomplete TURBT (icTURBT) (HR 1.7), pathological T-stage (HR 1.2), pathological N-stage (HR 2.0), and NACT (HR 0.2) were identified as independent predictors of CSS in Cox survival analysis. cTURBT improved CSS (36 months) compared to icTURBT (17 months) in patients who did not receive NACT (log-rank test P = 0.001). No survival difference was observed when NACT was administered. CONCLUSION: Tumor size > 3 cm and T-stage >/ = cT3 were significantly associated with icTURBT. cTURBT improved CSS in patients subjected to upfront cystectomy but not in patients subjected to NACT before RC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Patel, Keval N AU - Patel KN AD - Department of Surgical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. Electronic address: drkevalpatel@yahoo.com. FAU - Yalla, Poojitha AU - Yalla P AD - Department of Surgical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. FAU - Panchal, Harsha AU - Panchal H AD - Department of Medical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. FAU - Pandya, Shashank J AU - Pandya SJ AD - Department of Surgical Oncology, The Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. LA - eng PT - Journal Article DEP - 20260329 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Transurethral Resection of Bladder/methods MH - Male MH - Female MH - Retrospective Studies MH - *Cystectomy/methods MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness OTO - NOTNLM OT - Cancer specific survival OT - Carcinoma bladder OT - Complete TURBT OT - NACT OT - Radical cystectomy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/30 00:29 MHDA- 2026/05/10 05:19 CRDT- 2026/03/29 21:55 PHST- 2025/10/05 00:00 [received] PHST- 2026/02/23 00:00 [revised] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2026/03/30 00:29 [pubmed] PHST- 2026/03/29 21:55 [entrez] AID - S1078-1439(26)00091-8 [pii] AID - 10.1016/j.urolonc.2026.111080 [doi] PST - ppublish SO - Urol Oncol. 2026 Jun;44(6):23-30. doi: 10.1016/j.urolonc.2026.111080. Epub 2026 Mar 29. PMID- 41902493 OWN - NLM STAT- MEDLINE DCOM- 20260611 LR - 20260818 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 1 DP - 2026 Jul TI - Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer. PG - 125-132 LID - 10.1111/bju.70267 [doi] AB - OBJECTIVE: To describe the recurrence and progression trends of non-muscle-invasive bladder cancer (NMIBC) during a 14-year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5-year recurrence-free interval (RFI). PATIENTS AND METHODS: We conducted a nationwide cohort study of all patients diagnosed with NMIBC in Denmark between 2009 and 2022, linking data from population-based registries (N = 21 037). Recurrence was defined as a new bladder tumour >/=90 days after transurethral resection of bladder tumour, and progression followed the criteria set out by Lamm et al. or cystectomy. Cumulative incidence and Cox regression analyses described risks of recurrence and progression within 5 years after primary diagnosis. A landmark analysis assessed late recurrences with or without progression among patients who were recurrence-free for >/=5 years. RESULTS: We identified 21 037 patients with NMIBC (median age 72 years; 76% male). The 1- and 5-year cumulative incidence of recurrence was 24% (95% confidence interval [CI] 24-25%) and 44% (95% CI 43-45%), while progression risks were 4.4% (95% CI 4.1-4.7%) and 10% (95% CI 9.7-11%). Among the 6583 patients who were recurrence-free for 5 years, the subsequent 5-year cumulative incidence was 9.8% (95% CI 9.0-11%) for recurrence and 1.5% (95% CI 1.2-1.9%) for progression, with one-third progressing to MIBC. CONCLUSION: Our study confirmed previous findings that most recurrences in patients with NMIBC occur within the first years after primary diagnosis. Furthermore, we found improved recurrence-free rates over the past 14 years. Our analysis suggests the risk of recurrence and progression persists after a 5-year RFI; however, only in a limited proportion of patients. Future studies should identify specific risk factors able to predict patients' long-term risk, to tailor potential long-term follow-up schemes for patients with NMIBC. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Hjort, Peter B AU - Hjort PB AUID- ORCID: 0000-0002-3931-9727 AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. FAU - Ernst, Andreas AU - Ernst A AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. LA - eng GR - PhD-student salary/ PT - Journal Article DEP - 20260328 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cohort Studies MH - Denmark/epidemiology MH - Disease Progression MH - Incidence MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - *Non-Muscle Invasive Bladder Neoplasms/epidemiology/pathology MH - Registries MH - Time Factors MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/epidemiology/pathology PMC - PMC13244915 OTO - NOTNLM OT - follow-up OT - late recurrence OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - recurrence-free survival OT - treatment EDAT- 2026/03/28 06:39 MHDA- 2026/06/11 18:35 PMCR- 2026/06/08 CRDT- 2026/03/28 04:03 PHST- 2026/06/11 18:35 [medline] PHST- 2026/03/28 06:39 [pubmed] PHST- 2026/03/28 04:03 [entrez] PHST- 2026/06/08 00:00 [pmc-release] AID - BJU70267 [pii] AID - 10.1111/bju.70267 [doi] PST - ppublish SO - BJU Int. 2026 Jul;138(1):125-132. doi: 10.1111/bju.70267. Epub 2026 Mar 28. PMID- 41899627 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 6 DP - 2026 Mar 22 TI - Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer. LID - 10.3390/cancers18061026 [doi] LID - 1026 AB - Background: Urothelial bladder cancer (UBC) is a molecularly heterogeneous disease, and most sequencing studies have relied on bladder-specific or solid tumor-restricted panels. Whether broader pan-cancer assays provide additional clinically relevant information remains unclear. Methods: We performed targeted next-generation sequencing using an extended gene panel on tumor samples from 100 patients with UBC treated at a tertiary center. Somatic single-nucleotide variants, small insertions/deletions, copy-number alterations, and gene co-occurrence patterns were analyzed and correlated with clinicopathological features, disease-free survival (DFS), and overall survival (OS). Results: Recurrent alterations were identified in FGFR3 ( approximately 50%), TP53 ( approximately 35%), STAG2 ( approximately 25%), and PIK3CA ( approximately 20%), consistent with established molecular pathways in UBC. Less frequent but potentially actionable alterations, including mutations in BRCA1 and ALK, were also detected, reflecting the extended coverage of the panel. TP53 mutations were independently associated with worse OS, whereas STAG2 alterations were associated with improved OS, particularly in tumors without concurrent TP53 mutations. FGFR3 mutations showed a favorable but non-independent trend. No gene retained independent prognostic significance for DFS. Co-occurrence analysis revealed an FGFR3/PIK3CA-associated pathway and relative mutual exclusivity between FGFR3 and TP53. Copy-number alterations were modest overall. Comparison with TCGA data demonstrated a higher frequency of FGFR3 alterations in our cohort, likely reflecting the larger proportion of non-muscle-invasive tumors. Conclusions: Pan-cancer targeted sequencing provided a comprehensive genomic landscape of UBC, capturing canonical drivers and additional alterations that may be overlooked by bladder-restricted assays. The identification of TP53 and STAG2 as prognostic markers highlights the potential value of broader genomic profiling for biologically informed risk stratification in urothelial bladder cancer. FAU - Ugrinovski, Dimitar AU - Ugrinovski D AD - Laboratory for Molecular Biology and Genomics, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. AD - PathoNext GmbH, 04103 Leipzig, Germany. FAU - Saidi, Skender AU - Saidi S AD - University Clinic for Urology, Clinical Center, Medical Faculty, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. FAU - Stankov, Viktor AU - Stankov V AD - University Clinic for Urology, Clinical Center, Medical Faculty, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. FAU - Ambardjieva, Martina AU - Ambardjieva M AUID- ORCID: 0009-0008-7770-220X AD - PHI University Clinic for Surgical Diseases St. Naum Ohridski, Skopje, Medical Faculty, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. FAU - Josifovska, Slavica AU - Josifovska S AUID- ORCID: 0000-0003-2551-0368 AD - Laboratory for Molecular Biology and Genomics, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. FAU - Koehler, Anne-Katrin AU - Koehler AK AD - PathoNext GmbH, 04103 Leipzig, Germany. FAU - Gabert, Joerg AU - Gabert J AD - PathoNext GmbH, 04103 Leipzig, Germany. FAU - Panov, Sasho AU - Panov S AUID- ORCID: 0000-0001-6742-5212 AD - Laboratory for Molecular Biology and Genomics, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. LA - eng PT - Journal Article DEP - 20260322 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13025778 OTO - NOTNLM OT - FGFR3 OT - STAG2 OT - TP53 OT - bladder cancer OT - next-generation sequencing OT - pan-cancer panel OT - prognosis OT - urothelial carcinoma COIS- Authors Dimitar Ugrinovski, Anne-Katrin Koehler and Joerg Gabert were employed by the company PathoNext GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/03/28 06:40 MHDA- 2026/03/28 06:41 PMCR- 2026/03/22 CRDT- 2026/03/28 01:26 PHST- 2026/02/13 00:00 [received] PHST- 2026/03/12 00:00 [revised] PHST- 2026/03/20 00:00 [accepted] PHST- 2026/03/28 06:41 [medline] PHST- 2026/03/28 06:40 [pubmed] PHST- 2026/03/28 01:26 [entrez] PHST- 2026/03/22 00:00 [pmc-release] AID - cancers18061026 [pii] AID - cancers-18-01026 [pii] AID - 10.3390/cancers18061026 [doi] PST - epublish SO - Cancers (Basel). 2026 Mar 22;18(6):1026. doi: 10.3390/cancers18061026. PMID- 41899592 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 6 DP - 2026 Mar 18 TI - Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guerin for Bladder Cancer: A Systematic Review and Meta-Analysis. LID - 10.3390/cancers18060990 [doi] LID - 990 AB - Background/Objectives: The present study aimed to compare the efficacy and safety of intravesical gemcitabine versus Bacillus Calmette-Guerin administered after transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer. Methods: A comprehensive literature search was conducted using PubMed, Embase, and the Cochrane Library databases up to September 2025. Studies were eligible for inclusion if they were comparative studies evaluating intravesical gemcitabine versus Bacillus Calmette-Guerin following transurethral resection of bladder tumor. The primary outcomes were recurrence-free survival, progression-free survival, and incidence of adverse events. Pooled hazard ratios were calculated using a random-effects model based on log hazard ratios and standard error values. Results: Seven studies comprising approximately 774 patients were included in this analysis. The pooled hazard ratio was 0.80 (95% confidence interval, 0.42-1.53) for recurrence-free survival and 0.76 (95% confidence interval, 0.46-1.26) for progression-free survival, indicating no significant difference between gemcitabine and Bacillus Calmette-Guerin. However, gemcitabine was associated with a significantly lower incidence of adverse events, with a pooled odds ratio of approximately 0.48 (95% confidence interval, 0.27-0.86). Risk-of-bias assessment revealed that most randomized trials had "some concerns" based on the Risk of Bias 2 tool, whereas non-randomized studies were rated as having "moderate to serious" risk of bias according to the Risk of Bias in Non-randomized Studies of Interventions tool. Conclusions: Gemcitabine demonstrated an oncologic efficacy comparable to that of Bacillus Calmette-Guerin in terms of recurrence and progression outcomes while showing a substantially lower incidence of treatment-related toxicities. FAU - Kim, Do Kyung AU - Kim DK AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. FAU - Jeon, Jinhyung AU - Jeon J AUID- ORCID: 0000-0001-8663-1310 AD - Department of Urology, Yongin Severance Hospital, College of Medicine, Yonsei University, Yongin 16995, Republic of Korea. FAU - Kwon, Jong Kyou AU - Kwon JK AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. FAU - Bang, Sungun AU - Bang S AUID- ORCID: 0000-0001-7298-756X AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. FAU - Lee, Kwang Suk AU - Lee KS AUID- ORCID: 0000-0002-7961-8393 AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. FAU - Koo, Kyo Chul AU - Koo KC AUID- ORCID: 0000-0001-7303-6256 AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. FAU - Cho, Kang Su AU - Cho KS AUID- ORCID: 0000-0002-3500-8833 AD - Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Urological Science Institute, College of Medicine, Yonsei University, Seoul 06273, Republic of Korea. AD - Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul 03722, Republic of Korea. LA - eng PT - Journal Article PT - Review DEP - 20260318 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13024882 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - gemcitabine OT - intravesical OT - meta-analysis COIS- The authors declare no conflicts of interest. EDAT- 2026/03/28 06:39 MHDA- 2026/03/28 06:40 PMCR- 2026/03/18 CRDT- 2026/03/28 01:26 PHST- 2026/02/13 00:00 [received] PHST- 2026/03/06 00:00 [revised] PHST- 2026/03/11 00:00 [accepted] PHST- 2026/03/28 06:40 [medline] PHST- 2026/03/28 06:39 [pubmed] PHST- 2026/03/28 01:26 [entrez] PHST- 2026/03/18 00:00 [pmc-release] AID - cancers18060990 [pii] AID - cancers-18-00990 [pii] AID - 10.3390/cancers18060990 [doi] PST - epublish SO - Cancers (Basel). 2026 Mar 18;18(6):990. doi: 10.3390/cancers18060990. PMID- 41899563 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 6 DP - 2026 Mar 16 TI - Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature. LID - 10.3390/cancers18060961 [doi] LID - 961 AB - BACKGROUND/OBJECTIVES: The standard surgical treatment of muscle-invasive bladder cancer (MIBC) comprises neoadjuvant systemic therapy followed by radical cystectomy (RC). However, a notable number of patients achieve a favorable response to neoadjuvant systemic therapy, a finding associated with improved outcomes, and questioning the necessity of RC in this subset of patients. The objective of this review is to summarize the available evidence regarding the feasibility, efficacy and toxicity of bladder-preserving chemoradiotherapy (CRT) following clinical response (CR) to neoadjuvant systemic therapy in patients with MIBC. METHODS: A literature search was performed using the PubMed database to identify studies evaluating the use of CRT for bladder preservation in MIBC patients with CR following neoadjuvant therapy. RESULTS: Clinical complete response (cCR) rates to neoadjuvant systemic treatment ranged from 31% to 87.5%, with subsequent CRT enabling 50-97% of responders to retain their bladder. Long-term outcomes were favorable for cCR patients, with 3- to 5-year overall survival (OS) ranging from 65% to 89%, disease-free survival (DFS) of 64-86%, and bladder-intact survival up to 80%. Achievement of cCR, T2 tumor stage, absence of concomitant carcinoma in situ or hydronephrosis, and complete transurethral resection of the bladder tumor (TURBT) were prognostic factors for improved oncologic outcomes. Treatment-related toxicity was generally acceptable, concerning mainly hematological and gastrointestinal events, while severe late toxicity was uncommon. CONCLUSIONS: Bladder-preserving CRT is a promising, effective, and well-tolerated option for MIBC patients achieving CR to neoadjuvant systemic therapy. While further prospective validation and longer follow-up are required before it can universally replace radical cystectomy in this subset of patients, advances in neoadjuvant treatments, imaging and molecular biomarkers may improve response assessment and patient selection for bladder preservation. FAU - Ntoumas, Georgios Nikiforos AU - Ntoumas GN AUID- ORCID: 0000-0002-8770-7142 AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Kougioumtzopoulou, Andromachi AU - Kougioumtzopoulou A AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Desse, Dimitra AU - Desse D AUID- ORCID: 0000-0002-9074-2395 AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Fragkoulis, Charalambos AU - Fragkoulis C AD - Department of Urology, General Hospital of Athens "G. Gennimatas", 115 27 Athens, Greece. FAU - Papadopoulos, Georgios AU - Papadopoulos G AD - Department of Urology, General Hospital of Athens "G. Gennimatas", 115 27 Athens, Greece. FAU - Kostouros, Efthymios AU - Kostouros E AD - 3rd Department of Internal Medicine, General Hospital of Athens "G. Gennimatas", 115 27 Athens, Greece. FAU - Michaletou, Dimitra AU - Michaletou D AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Kouloulias, Vassileios AU - Kouloulias V AUID- ORCID: 0000-0003-2082-7323 AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Zygogianni, Anna AU - Zygogianni A AD - Department of Clinical Radiation Oncology, Medical School, ATTIKON University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece. FAU - Georgakopoulos, Ioannis AU - Georgakopoulos I AUID- ORCID: 0000-0002-6354-9805 AD - Radiotherapy Unit, 1st Department of Radiology, Medical School, Aretaieion University Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260316 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13025384 OTO - NOTNLM OT - bladder preservation OT - chemoradiotherapy OT - complete response OT - muscle-invasive bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2026/03/28 06:40 MHDA- 2026/03/28 06:41 PMCR- 2026/03/16 CRDT- 2026/03/28 01:26 PHST- 2026/01/25 00:00 [received] PHST- 2026/03/09 00:00 [revised] PHST- 2026/03/13 00:00 [accepted] PHST- 2026/03/28 06:41 [medline] PHST- 2026/03/28 06:40 [pubmed] PHST- 2026/03/28 01:26 [entrez] PHST- 2026/03/16 00:00 [pmc-release] AID - cancers18060961 [pii] AID - cancers-18-00961 [pii] AID - 10.3390/cancers18060961 [doi] PST - epublish SO - Cancers (Basel). 2026 Mar 16;18(6):961. doi: 10.3390/cancers18060961. PMID- 41899544 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 6 DP - 2026 Mar 13 TI - Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers18060938 [doi] LID - 938 AB - Background/Objectives: High recurrence rates and intensive lifelong surveillance make bladder cancer among the costliest malignancies to treat. Although Bacillus Calmette-Guerin (BCG) immunotherapy is the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), up to 50% of patients fail to respond, and predictive biomarkers are lacking. Molecular profiling has established three BCG response subtypes (BRS1-3), with BRS3 characterized by an immunosuppressive, BCG-resistant phenotype; however, these features have not been validated at single-cell spatial resolution. Methods: We applied imaging mass cytometry (IMC) to 82 BCG-treated high-risk NMIBC samples and performed (i) single-cell IMC with unsupervised clustering to identify phenotypic cell clusters and quantify cluster abundances and (ii) a convolutional neural network-based gated attention multiple instance learning model trained on IMC images (IMC-GA-MIL) to predict BCG response. Cluster abundances were summarized using II (immune composition within the immune compartment), TT (tumor phenotypic composition), and IT (immune/stromal abundance relative to tumor cells) indices. Results: Single-cell IMC identified 18 distinct phenotypic cell clusters. In BCG responders, immune cells localized within the tumor compartment were enriched and independently protective (HR 0.67, 95% CI 0.49-0.92). BCG nonresponse was associated with a higher abundance of fibroblast-dominant clusters relative to tumor cells (IT index). Plasma cell-dominant clusters were the strongest predictors of progression (II index HR 2.28, 95% CI 1.37-3.79; IT index HR 1.25, 95% CI 1.06-1.48). The IMC-GA-MIL model predicted BCG response with 90% accuracy (9/10) and identified myeloid- and T-cell-associated marker patterns involving CD14, CD11b, CD68, CD8, and FOXP3 as the most informative contributors. Conclusions: Spatial single-cell profiling and IMC-GA-MIL identify spatial immune and stromal features associated with BCG failure. However, findings from both analyses should be considered exploratory and will require validation in larger, independent cohorts. FAU - Lillesand, Melinda AU - Lillesand M AUID- ORCID: 0000-0001-8898-1330 AD - Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway. FAU - Austdal, Marie AU - Austdal M AD - Section for Biostatistics, Department of Research, Stavanger University Hospital, 4011 Stavanger, Norway. FAU - Mroz, Jakub AU - Mroz J AD - Department of Electrical Engineering and Computer Science, University of Stavanger, 4021 Stavanger, Norway. FAU - Skaland, Ivar AU - Skaland I AD - Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. FAU - Gudlaugsson, Einar AU - Gudlaugsson E AD - Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. FAU - Jong, Florus C de AU - Jong FC AUID- ORCID: 0000-0001-6853-5982 AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands. FAU - Engan, Kjersti AU - Engan K AUID- ORCID: 0000-0002-8970-0067 AD - Department of Electrical Engineering and Computer Science, University of Stavanger, 4021 Stavanger, Norway. FAU - Janssen, Emiel A M AU - Janssen EAM AUID- ORCID: 0000-0002-7760-5396 AD - Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway. LA - eng GR - F-12320-D10192/Folke Hermansen Foundation/ GR - F-12593-D11698/Western Norway Regional Health Authority/ PT - Journal Article DEP - 20260313 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC13024979 OTO - NOTNLM OT - BCG response subtypes OT - Bacillus Calmette-Guerin OT - biomarkers OT - high-risk non-muscle-invasive bladder cancer OT - imaging mass cytometry OT - progression OT - risk stratification OT - spatial proteomics OT - treatment response OT - tumor microenvironment COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2026/03/28 06:39 MHDA- 2026/03/28 06:40 PMCR- 2026/03/13 CRDT- 2026/03/28 01:26 PHST- 2026/02/01 00:00 [received] PHST- 2026/03/03 00:00 [revised] PHST- 2026/03/11 00:00 [accepted] PHST- 2026/03/28 06:40 [medline] PHST- 2026/03/28 06:39 [pubmed] PHST- 2026/03/28 01:26 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - cancers18060938 [pii] AID - cancers-18-00938 [pii] AID - 10.3390/cancers18060938 [doi] PST - epublish SO - Cancers (Basel). 2026 Mar 13;18(6):938. doi: 10.3390/cancers18060938. PMID- 41899387 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 6 DP - 2026 Mar 23 TI - Early Recurrence Following Complete Initial Resection Predicts Adverse Oncological Outcomes in NMIBC. LID - 10.3390/jcm15062463 [doi] LID - 2463 AB - Background/Objectives: Early recurrence after complete initial transurethral resection of bladder tumor (TUR-BT) may indicate biologically aggressive non-muscle-invasive bladder cancer (NMIBC). This study aimed to identify clinicopathological predictors of ER and its independent impact on progression and survival outcomes. Methods: Clinical data of 335 primary NMIBC patients who underwent TUR-BT between 2012 and 2024 were retrospectively analyzed. Patients with non-primary tumors, incomplete resection, or follow-up <6 months were excluded from the study. Patients were categorized into recurrence-free, early recurrence, and late recurrence groups. Logistic regression was used to identify predictors of early recurrence. Progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression. A 36-month landmark analysis was conducted to adjust for heterogeneity in follow-up duration. Results: Early recurrence occurred in 118 patients (35.2%). Independent predictors of early recurrence were tumor size (OR = 1.012, p = 0.038), T1 stage (OR = 2.57, p = 0.004), high-grade pathology (OR = 1.933, p = 0.030), and absence of single-dose intravesical chemotherapy (IVC) (OR = 3.642, p = 0.025). Additionally, adjuvant IVC (OR = 0.279, p = 0.015) and intravesical BCG (OR = 0.427, p = 0.006) independently reduced the risk of early recurrence. Early recurrence independently predicted worse PFS (HR = 6.053), CSS (HR = 2.052), and OS (HR = 1.961) (all p < 0.001). The landmark analysis confirmed these results (all p < 0.05). Conclusions: Early recurrence after initial and complete TUR-BT is an independent predictor of adverse oncological outcomes. Identifying high-risk patients and applying early intravesical therapy may improve outcomes by preventing early recurrence. FAU - Aydin, Yavuz Mert AU - Aydin YM AUID- ORCID: 0000-0002-6287-6767 AD - Department of Urology, Zonguldak Bulent Ecevit University, Kozlu, 67639 Zonguldak, Turkiye. FAU - Mungan, Necmettin Aydin AU - Mungan NA AD - Department of Urology, Zonguldak Bulent Ecevit University, Kozlu, 67639 Zonguldak, Turkiye. LA - eng PT - Journal Article DEP - 20260323 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13027191 OTO - NOTNLM OT - early recurrence OT - non-muscle-invasive bladder cancer (NMIBC) OT - oncological outcomes OT - prognostic factors OT - transurethral resection of bladder tumor (TUR-BT) COIS- The authors declare no conflicts of interest. EDAT- 2026/03/28 06:40 MHDA- 2026/03/28 06:41 PMCR- 2026/03/23 CRDT- 2026/03/28 01:25 PHST- 2026/02/10 00:00 [received] PHST- 2026/03/18 00:00 [revised] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/03/28 06:41 [medline] PHST- 2026/03/28 06:40 [pubmed] PHST- 2026/03/28 01:25 [entrez] PHST- 2026/03/23 00:00 [pmc-release] AID - jcm15062463 [pii] AID - jcm-15-02463 [pii] AID - 10.3390/jcm15062463 [doi] PST - epublish SO - J Clin Med. 2026 Mar 23;15(6):2463. doi: 10.3390/jcm15062463. PMID- 41895764 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260713 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 46 IP - 4 DP - 2026 Apr TI - Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy. PG - 2077-2086 LID - 10.21873/anticanres.18096 [doi] AB - BACKGROUND/AIM: The clinical course and clinicopathological characteristics of primary non-muscle-invasive bladder cancer (NMIBC) have been well characterized; however, those of NMIBC secondary to radical nephroureterectomy (RNU) remain unclear. We aimed to compare these parameters between NMIBC following RNU and primary NMIBC. PATIENTS AND METHODS: The records of patients who underwent transurethral resection of bladder tumor and were later diagnosed with NMIBC between January 2009 and December 2016 were retrospectively analyzed. Patients who underwent RNU for upper tract urinary carcinoma (UTUC) and subsequently developed NMIBC were included in the UTUC-NMIBC group. Patients who were newly diagnosed with NMIBC were included in the primary NMIBC group. The clinicopathological characteristics and recurrence-free survival rates in patients were compared between the groups using Pearson's chi-squared test and the Kaplan-Meier method with the log-rank test, respectively. Further, the predictors of recurrence-free survival were identified using Cox proportional hazards regression analysis. RESULTS: A total of 59 and 1,019 patients were included in the UTUC-NMIBC and primary NMIBC groups, respectively. Significant differences were observed between the groups in tumor stage, grade, largest tumor size, and presence of carcinoma in situ. Additionally, patients in the UTUC-NMIBC group exhibited significantly poorer recurrence-free survival than those in the primary NMIBC group (p=0.0035). Univariate and multivariate Cox regression analysis revealed differences in the predictors of recurrence-free survival between the patients in both groups. CONCLUSION: NMIBC secondary to RNU exhibits distinct tumor characteristics and recurrence-free survival compared with primary NMIBC. Further studies are needed to clarify the mechanisms underlying these differences. CI - Copyright (c) 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Sato, Takuma AU - Sato T AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan; takuma.sato.a4@tohoku.ac.jp. AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Adachi, Hisanobu AU - Adachi H AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Miyagi Cancer Center, Natori, Japan. FAU - Ikeda, Yoshihiro AU - Ikeda Y AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Osaki Citizen Hospital, Osaki, Japan. FAU - Takemoto, Jun AU - Takemoto J AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Kesennuma City Hospital, Kesennuma, Japan. FAU - Myoen, Shingo AU - Myoen S AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Hachinohe City Hospital, Hachinohe, Japan. FAU - Mitsuzuka, Koji AU - Mitsuzuka K AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan. FAU - Kyan, Atsushi AU - Kyan A AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Shirakawa Kosei General Hospital, Shirakawa, Japan. FAU - Aoki, Hiroshi AU - Aoki H AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Sendai Red Cross Hospital, Sendai, Japan. FAU - Tokuyama, Satoru AU - Tokuyama S AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, Iwaki City Medical Center, Iwaki, Japan. FAU - Saito, Hideo AU - Saito H AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. AD - Department of Urology, National Hospital Organization Sendai Medical Center, Sendai, Japan. FAU - Yamashita, Shinichi AU - Yamashita S AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. FAU - Arai, Yoichi AU - Arai Y AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. AD - Tohoku Urological Evidence-Based Medicine Study Group, Sendai, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/etiology/surgery MH - *Nephroureterectomy/adverse effects MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Transurethral Resection of Bladder MH - Disease-Free Survival MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Kaplan-Meier Estimate OTO - NOTNLM OT - Clinical outcome OT - intravesical recurrence OT - non-muscle-invasive bladder cancer OT - radical nephroureterectomy OT - upper tract urinary carcinoma EDAT- 2026/03/28 00:42 MHDA- 2026/03/28 00:43 CRDT- 2026/03/27 20:52 PHST- 2026/01/27 00:00 [received] PHST- 2026/02/24 00:00 [revised] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/03/28 00:43 [medline] PHST- 2026/03/28 00:42 [pubmed] PHST- 2026/03/27 20:52 [entrez] AID - 46/4/2077 [pii] AID - 10.21873/anticanres.18096 [doi] PST - ppublish SO - Anticancer Res. 2026 Apr;46(4):2077-2086. doi: 10.21873/anticanres.18096. PMID- 41884949 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260806 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 61 DP - 2026 Mar 26 TI - Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study. PG - 72-79 LID - 10.2340/sju.v61.45602 [doi] AB - BACKGROUND: Muscle invasive bladder cancer (MIBC) is an aggressive disease with a high mortality rate. Radical cystectomy (RC) is the standard treatment for MIBC and selected non-muscle invasive bladder -cancer (NMIBC) cases. The NorCys-study (NCT04523038, NCT04537221 and NCT04523025) aims to validate biomarkers predicting RC outcomes. This report describes RC practice patterns across the Nordic countries. MATERIALS AND METHODS: This prospective, multi-institutional study included bladder cancer patients undergoing RC with or without preoperative chemotherapy in all five Nordic countries from 5/2020 to 1/2025. Clinical and pathological data were collected prospectively into REDCap database and analysed using descriptive statistics, Wilcoxon rank sum and Pearson's Chi-squared tests. RESULTS: A total of 1,642 patients from 15 centres were enrolled. Of these, 35% (531) had clinical NMIBC (T1-Tis-Ta), and 65% (999) had cT2-4 disease. Preoperative chemotherapy was administered to 398/929 (43%) cT2-4 or node-positive patients. The most common neoadjuvant chemotherapy (NAC) regimens were gemcitabine - cisplatin (GC) (275/475 [58%]) and dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) (144/475 [30%]). Robot-assisted RC was the most common surgical approach administered in 886 of 1,472 (60%) cases, with variation between centres. Ileal conduit was the predominant diversion method in 1,375 out of 1,465 cases (94%). Median surgical time was 322 min, blood loss was 300 mL and hospital stay was 9 days. Final pathology demonstrated pT0 in 29%, >/=pT2 in 43% and lymph node metastases 203 (17%). CONCLUSION: This study reports current RC practices amongst Nordic countries. Patient cohorts did not differ between countries, and although the practices were generally similar, some differences were noted in chemotherapy regimens, the use of robotic-assisted surgery and rates of early RC. FAU - Venhomaa, Tiia AU - Venhomaa T AD - Department of Urology, Turku University Hospital, Turku, Finland. timati@utu.fi. FAU - Nikulainen, Ilkka AU - Nikulainen I AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Bobjer, Johannes AU - Bobjer J AD - Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Blackberg, Mats AU - Blackberg M AD - Department of Urology, Helsingborgs Hospital, Helsingborg, Sweden. FAU - Bro, Lasse AU - Bro L AD - Department of Urology, University Hospital of Southern Denmark, Esbjerg, Denmark. FAU - Brandt, Simone Buchardt AU - Brandt SB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Ettala, Otto AU - Ettala O AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Fabrin, Knud AU - Fabrin K AD - Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Gudjonsson, Sigurdur AU - Gudjonsson S AD - Department of Urology, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. FAU - Haug, Erik Skaaheim AU - Haug ES AD - Department of Urology, Vestfold Hospital Trust, Vestfold, Norway; Department of Clinical Medicine, University of Bergen, Norway. FAU - Hogerman, Mikael AU - Hogerman M AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Hyldgaard, Josephine M AU - Hyldgaard JM AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, School of Medical Sciences, Orebro University, Orebro, Sweden. FAU - Kirrander, Peter AU - Kirrander P AD - Department of Urology, School of Medical Sciences, Orebro University, Orebro, Sweden. FAU - Koskinen, Ilmari AU - Koskinen I AD - Department of Urology, Helsinki University Hospital, Helsinki, Finland. FAU - Lam, Gitte AU - Lam G AD - Department of Urology, Herlev Hospital, Herlev, Denmark. FAU - Leskinen, Markku J AU - Leskinen MJ AD - Department of Urology, Seinajoki Central Hospital, Seinajoki, Finland. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Livbjerg, Astrid Helene AU - Livbjerg AH AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Seikkula, Heikki AU - Seikkula H AD - Department of Urology, Central Hospital of Jyvaskyla, Jyvaskyla, Finland. FAU - Skovhus, Katharina AU - Skovhus K AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Tuckus, Grazvydas AU - Tuckus G AD - Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Virta, Ville AU - Virta V AD - Department of Urology, Oulu University Hospital, Oulu, Finland. FAU - Vrang, Marie-Louise AU - Vrang ML AD - Department of Urology, Herlev Hospital, Herlev, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260326 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - *Cystectomy/methods MH - Prospective Studies MH - Female MH - Scandinavian and Nordic Countries MH - Male MH - *Urinary Bladder Neoplasms/surgery/pathology/drug therapy MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Aged MH - Middle Aged MH - Neoadjuvant Therapy MH - Non-Muscle Invasive Bladder Neoplasms MH - Aged, 80 and over MH - Chemotherapy, Adjuvant EDAT- 2026/03/26 07:09 MHDA- 2026/03/26 13:30 CRDT- 2026/03/26 05:12 PHST- 2025/06/05 00:00 [received] PHST- 2026/02/10 00:00 [accepted] PHST- 2026/03/26 13:30 [medline] PHST- 2026/03/26 07:09 [pubmed] PHST- 2026/03/26 05:12 [entrez] AID - 10.2340/sju.v61.45602 [doi] PST - epublish SO - Scand J Urol. 2026 Mar 26;61:72-79. doi: 10.2340/sju.v61.45602. PMID- 41876828 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20261008 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 9 DP - 2026 Sep TI - Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis. PG - 3359-3377 LID - 10.1007/s11255-026-05110-7 [doi] AB - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression is an established oncogenic driver and therapeutic target in several malignancies, but its clinical significance in urothelial carcinoma (UC) of the bladder remains controversial due to disease heterogeneity and lack of standardized assessment. OBJECTIVE: To synthesize evidence on the stage-specific associations of HER2 overexpression with clinicopathological features in bladder UC through a systematic review and meta-analysis. METHODS: We conducted a PRISMA-compliant systematic review and meta-analysis, searching PubMed, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) up to November 6, 2025. Included studies were retrospective observational cohorts of treatment-naive bladder UC patients with HER2 assessed by immunohistochemistry (IHC). Data on HER2 positivity (various IHC thresholds) stratified by clinicopathological variables were extracted. Random-effects models calculated pooled risk differences (RD) with 95% CI (confidence intervals), stratified by non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive/metastatic bladder cancer (MIBC/mUC). Heterogeneity was assessed via I(2), and subgroup analyses explored IHC thresholds. RESULTS: 19 studies were included (9 on NMIBC, 10 on MIBC/mUC), comprising a total of 2799 patients (NMIBC: 1751; MIBC/mUC: 1048). In NMIBC, HER2 overexpression was significantly associated with higher T stage (RD: 0.11, 95% CI: 0.08-0.15), higher grade (RD: 0.22, 95% CI: 0.16-0.28), multifocality (RD: 0.10, 95% CI: 0.05-0.15), recurrence (RD: 0.22, 95% CI: 0.10-0.35), and progression (RD: 0.31, 95% CI: 0.23-0.39). In MIBC/mUC, significant association was observed only with lymph node metastasis (RD: 0.11, 95% CI: 0.03-0.19). Associations were consistent across IHC thresholds. CONCLUSIONS: HER2 overexpression exhibits stage-specific patterns, strongly linked to aggressive features and progression risk in NMIBC but primarily to lymphatic spread in MIBC/mUC. These findings provide preliminary evidence supporting HER2 as a stage-specific biomarker, with implications for risk stratification and emerging targeted therapies. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Guo, Citing AU - Guo C AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. FAU - Wei, Jinchang AU - Wei J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. FAU - Wang, Yajie AU - Wang Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. FAU - Zhang, Lei AU - Zhang L AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Medical Ethics Committee, Peking University Cancer Hospital & Institute, Beijing, 100142, China. FAU - Wu, Xiaowen AU - Wu X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. FAU - Sheng, Xinan AU - Sheng X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China. doctor_sheng@126.com. LA - eng GR - L244024/Beijing Natural Science Foundation/ GR - G202512054/the Beijing High-Level Innovation and Entrepreneurship Talent Support Program leading talent projects/ GR - 82473199/the National Natural Science Foundation of China/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260325 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Erb-b2 Receptor Tyrosine Kinases/genetics/biosynthesis/metabolism MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism MH - Neoplasm Staging MH - *Carcinoma, Transitional Cell/pathology/genetics MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - HER2 receptors OT - Immunohistochemistry OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer OT - Risk stratification OT - Urothelial carcinoma COIS- Declarations. Conflict of interests: The authors declare no competing interests. Consent for publication: All authors approved the manuscript for publication. EDAT- 2026/03/25 07:09 MHDA- 2026/08/25 17:35 CRDT- 2026/03/25 00:28 PHST- 2026/02/01 00:00 [received] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/08/25 17:35 [medline] PHST- 2026/03/25 07:09 [pubmed] PHST- 2026/03/25 00:28 [entrez] AID - 10.1007/s11255-026-05110-7 [pii] AID - 10.1007/s11255-026-05110-7 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Sep;58(9):3359-3377. doi: 10.1007/s11255-026-05110-7. Epub 2026 Mar 25. PMID- 41872009 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260713 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 5 DP - 2026 May TI - Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy. PG - 111076 LID - S1078-1439(26)00087-6 [pii] LID - 10.1016/j.urolonc.2026.111076 [doi] AB - BACKGROUND: Current guidelines recommend trimodal therapy (TMT) for muscle-invasive bladder cancer when complete visible transurethral resection is feasible, but no specific tumor size cutoff is defined. We evaluated the impact of tumor size on cancer-specific mortality (CSM) in T2N0M0 urothelial bladder cancer treated with TMT. METHODS: Using the Surveillance, Epidemiology, and End Results database (2004-2022), pT2N0M0 urothelial bladder cancer patients treated with TMT were identified. Sequential testing of tumor size cutoffs of 3, 4, 5, 6, and 7 cm were applied. Propensity score matching and multivariable competing risks regression (CRR) models were used. RESULTS: Among 3,014 included pT2N0M0 urothelial bladder cancer patients treated with TMT, tumor size ranged from 0.3 to 10.0 cm (median 4.0 cm). In multivariable CRR models, each tested cutoff independently predicted higher CSM, except for at 3 cm. Multivariable CRR-derived hazard ratios (HR) for cutoffs of 4, 5, 6, and 7 cm were respectively 1.23, 1.28, 1.72, and 2.22 (all P < 0.05). Applying established and recommended noninferiority margins in oncology trials of up to 30% suggests that tumor size cutoff of 6 cm (HR 1.72) could represent a clinically meaningful criterion used in patient selection for TMT. Limitations include retrospective design and lack of data on comorbidities and treatment specifics. CONCLUSION: Tumor size is directly proportional to CSM rate in pT2N0M0 urothelial bladder cancer treated with TMT. A tumor size cutoff of 6 cm (HR 1.72) could represent a clinically meaningful criterion used in patient selection for TMT when the intent of avoiding excess CSM represents the endpoint of interest. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Lee, Nick J AU - Lee NJ AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: nick.lee@umontreal.ca. FAU - Polverino, Federico AU - Polverino F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Quarta, Leonardo AU - Quarta L AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy. FAU - Filzmayer, Maximilian AU - Filzmayer M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany. FAU - Petix, Michele AU - Petix M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Urology, Universitadegli Studi di Milano, Milan, Italy. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Longo, Nicola AU - Longo N AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, New York; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20260322 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy MH - Aged MH - Male MH - Middle Aged MH - SEER Program MH - Neoplasm Staging MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/mortality/therapy/pathology MH - Tumor Burden MH - Aged, 80 and over MH - Combined Modality Therapy MH - Transurethral Resection of Bladder OTO - NOTNLM OT - Bladder cancer OT - SEER OT - Trimodal therapy OT - Tumor size OT - Urothelial carcinoma of the bladder COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/24 00:30 MHDA- 2026/04/21 18:34 CRDT- 2026/03/23 22:50 PHST- 2025/12/31 00:00 [received] PHST- 2026/02/23 00:00 [revised] PHST- 2026/02/24 00:00 [accepted] PHST- 2026/04/21 18:34 [medline] PHST- 2026/03/24 00:30 [pubmed] PHST- 2026/03/23 22:50 [entrez] AID - S1078-1439(26)00087-6 [pii] AID - 10.1016/j.urolonc.2026.111076 [doi] PST - ppublish SO - Urol Oncol. 2026 May;44(5):111076. doi: 10.1016/j.urolonc.2026.111076. Epub 2026 Mar 22. PMID- 41871219 OWN - NLM STAT- Publisher LR - 20260611 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) DP - 2026 Mar 23 TI - Perioperative Management of Upper Tract Urothelial Carcinoma: Current Evidence and Future Directions. PG - 1-15 LID - 10.1159/000551611 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare but aggressive malignancy characterized by high rates of muscle-invasive and non-organ-confined disease at diagnosis, substantial postoperative renal function decline, and frequent intravesical recurrence. These clinical features complicate the use of cisplatin-based chemotherapy and limit the development of robust, disease-specific evidence. Most perioperative recommendations remain extrapolated from bladder cancer, and considerable uncertainty persists regarding the optimal integration of chemotherapy, immunotherapy, and emerging biomarkers. This review aims to synthesize contemporary evidence on neoadjuvant and adjuvant systemic therapy in UTUC, identify persistent gaps in clinical practice, and outline future research priorities in the era of biomarker-driven treatment. SUMMARY: Neoadjuvant platinum-based chemotherapy has been evaluated in prospective phase II studies, which suggest potential benefits in terms of pathological downstaging and survival, with manageable toxicity profiles. Observational and propensity-adjusted studies reinforce these benefits, particularly in responders, and real-world data confirm expanding adoption in advanced and node-positive disease. Neoadjuvant immunotherapy as monotherapy has shown limited activity, while recent data from the iNDUCT trial indicate that early chemo-immunotherapy combinations are feasible but have not yet met primary efficacy endpoints. Findings from the POUT trial show a significant improvement in disease-free survival with adjuvant chemotherapy; however, overall survival data remain immature at the time of premature study closure. Adjuvant immunotherapy trials, including IMvigor010, CheckMate 274, and AMBASSADOR, have not shown a definitive benefit in UTUC subgroup analyses, a finding that may reflect limited statistical power. Persistent challenges include inaccurate preoperative staging, limited use of lymphadenectomy, uncertain management of variant histology and clinically node-positive disease, and the unresolved role of carboplatin. Emerging biomarkers such as circulating tumor DNA and urine tumor DNA show promise for refining risk stratification and minimal residual disease assessment but remain investigational and require UTUC-specific prospective validation. KEY MESSAGES: Neoadjuvant platinum-based chemotherapy is gaining acceptance as a perioperative strategy in UTUC, supported by prospective phase II data demonstrating pathological downstaging and manageable safety profiles. Neoadjuvant immunotherapy as monotherapy has demonstrated limited activity to date, whereas chemo-immunotherapy combinations remain under evaluation, with early feasibility but immature efficacy results. Adjuvant chemotherapy, as shown in the POUT trial, significantly improves disease-free survival; however, overall survival benefit remains uncertain due to premature study closure and immature follow-up. Evidence for adjuvant immunotherapy in UTUC remains inconclusive as subgroup analyses from IMvigor010, CheckMate 274, and AMBASSADOR have not demonstrated clear benefit (likely influenced by limited statistical power) highlighting the need for UTUC-specific randomized trials. Emerging biomarkers, including predictive models and circulating tumor DNA, may help refine perioperative treatment selection and guide future individualized strategies. CI - (c) 2026 S. Karger AG, Basel. FAU - Albers Acosta, Eduardo AU - Albers Acosta E AD - Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain, eduardo.albers@salud.madrid.org. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYSIS, Universidad de Alcala, Madrid, Spain, jdsubiela@gmail.com. FAU - Pelari-Mici, Lira AU - Pelari-Mici L AD - Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Saavedra Centeno, Manuel AU - Saavedra Centeno M AD - Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Lopez-Fando Lavalle, Luis AU - Lopez-Fando Lavalle L AD - Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Toquero Diez, Patricia AU - Toquero Diez P AD - Department of Medical Oncology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Romero-Laorden, Nuria AU - Romero-Laorden N AD - Department of Medical Oncology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - San-Jose Manso, Luis AU - San-Jose Manso L AD - Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autonoma de Madrid, Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20260323 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM OTO - NOTNLM OT - Adjuvant immunotherapy OT - Neoadjuvant chemotherapy OT - Perioperative therapy OT - Upper tract urothelial carcinoma OT - ctDNA EDAT- 2026/03/23 19:54 MHDA- 2026/03/23 19:54 CRDT- 2026/03/23 14:44 PHST- 2026/01/07 00:00 [received] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/03/23 19:54 [pubmed] PHST- 2026/03/23 19:54 [medline] PHST- 2026/03/23 14:44 [entrez] AID - 000551611 [pii] AID - 10.1159/000551611 [doi] PST - aheadofprint SO - Urol Int. 2026 Mar 23:1-15. doi: 10.1159/000551611. PMID- 41869746 OWN - NLM STAT- In-Process LR - 20260813 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 2 DP - 2026 Aug TI - Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications. PG - 229-231 LID - 10.1111/bju.70247 [doi] FAU - Ye, Tian AU - Ye T AUID- ORCID: 0000-0003-2740-0955 AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. AD - Department of Urology, Guizhou Provincial People's Hospital, Guiyang, China. FAU - Tura, Benjamin AU - Tura B AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Abbotts, Ben AU - Abbotts B AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer Research, London, UK. FAU - Bryan, Richard T AU - Bryan RT AUID- ORCID: 0000-0003-2853-4293 AD - Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. LA - eng GR - University of Birmingham/ GR - Birmingham and the Black Country Comprehensive Local Research Network/ GR - CRUK_/Cancer Research UK/United Kingdom PT - Journal Article DEP - 20260323 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM PMC - PMC13371793 OTO - NOTNLM OT - BCG OT - Bacillus Calmette-Guerin OT - European Association of Urology OT - Non-muscle-invasive bladder cancer OT - clincial outcomes OT - progression OT - risk stratification EDAT- 2026/03/23 13:04 MHDA- 2026/03/23 13:04 PMCR- 2026/07/15 CRDT- 2026/03/23 06:13 PHST- 2026/03/23 13:04 [pubmed] PHST- 2026/03/23 13:04 [medline] PHST- 2026/03/23 06:13 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - BJU70247 [pii] AID - 10.1111/bju.70247 [doi] PST - ppublish SO - BJU Int. 2026 Aug;138(2):229-231. doi: 10.1111/bju.70247. Epub 2026 Mar 23. PMID- 41869400 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260813 IS - 1178-2013 (Electronic) IS - 1176-9114 (Print) IS - 1176-9114 (Linking) VI - 21 DP - 2026 TI - Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms. PG - 575926 LID - 10.2147/IJN.S575926 [doi] LID - 575926 AB - BACKGROUND: Bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC), poses significant clinical challenges due to its high recurrence rate. Traditional diagnostic approaches such as cystoscopy and urine cytology have limitations, including invasiveness and insufficient sensitivity. Gold nanoparticles (AuNPs) offer unique opportunities to address these challenges with their surface plasmon resonance effect, biocompatibility, and ease of functionalization. METHODS: Through critical review of recent literature, this paper outlines the application principles, achievements, and mechanisms of AuNPs in bladder cancer, including in vitro diagnostics, multimodal molecular imaging, photothermal therapy, targeted drug delivery, radiotherapy sensitization, and tumor immune microenvironment remodeling. MAIN FINDINGS: AuNPs are driving a paradigm shift in bladder cancer management. In diagnostics, AuNP-based biosensors enable ultra-sensitive detection of urinary biomarkers. In imaging, they serve as effective contrast agents for enhanced visualization. For therapy, AuNP-mediated photothermal therapy enables precise tumor ablation, and as drug carriers, they help overcome chemoresistance. Additionally, AuNPs demonstrate potential in remodeling the immunosuppressive microenvironment through modulation of signaling pathways and tumor-associated macrophages. CONCLUSION: Gold nanoparticles are transforming bladder cancer toward precision, minimally invasive, and personalized treatment models. However, it is important to acknowledge that most current findings remain in the preclinical stage, and significant translational barriers-particularly long-term biosafety and standardized production-must be addressed before widespread clinical adoption. CI - (c) 2026 Zhang et al. FAU - Zhang, Xuwei AU - Zhang X AD - Department of Urology, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. FAU - Wu, Xiaochui AU - Wu X AD - Department of Urology, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. FAU - Du, Jiancheng AU - Du J AD - Department of Intensive Care Unit, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. FAU - Mei, Jianfeng AU - Mei J AD - Department of General Surgery, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. FAU - Chen, Fei AU - Chen F AD - Department of General Surgery, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. FAU - Lou, Kecheng AU - Lou K AD - Department of Urology, Lanxi People's Hospital, Jinhua, Zhejiang, People's Republic of China. LA - eng PT - Journal Article PT - Review DEP - 20260120 PL - New Zealand TA - Int J Nanomedicine JT - International journal of nanomedicine JID - 101263847 RN - 7440-57-5 (Gold) SB - IM MH - *Gold/chemistry/therapeutic use MH - Humans MH - *Metal Nanoparticles/chemistry/therapeutic use MH - *Theranostic Nanomedicine/methods MH - *Urinary Bladder Neoplasms/diagnosis/therapy/diagnostic imaging MH - Tumor Microenvironment MH - Animals MH - Drug Delivery Systems MH - Photothermal Therapy/methods MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC13003781 OTO - NOTNLM OT - bladder cancer OT - drug delivery OT - gold nanoparticles OT - nanomedicine OT - non-invasive diagnosis OT - tumor microenvironment COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/23 06:32 MHDA- 2026/03/23 13:04 PMCR- 2026/01/20 CRDT- 2026/03/23 06:01 PHST- 2025/10/21 00:00 [received] PHST- 2026/01/16 00:00 [accepted] PHST- 2026/03/23 13:04 [medline] PHST- 2026/03/23 06:32 [pubmed] PHST- 2026/03/23 06:01 [entrez] PHST- 2026/01/20 00:00 [pmc-release] AID - 575926 [pii] AID - 10.2147/IJN.S575926 [doi] PST - epublish SO - Int J Nanomedicine. 2026 Jan 20;21:575926. doi: 10.2147/IJN.S575926. eCollection 2026. PMID- 41864769 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260908 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. PG - 833-840 LID - S2588-9311(26)00066-0 [pii] LID - 10.1016/j.euo.2026.03.008 [doi] AB - BACKGROUND AND OBJECTIVE: Transurethral resection of bladder tumors (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC) but is associated with procedural risks and health care burden. Chemoresection using intravesical mitomycin C (MMC) has emerged as a minimally invasive alternative. This randomized controlled trial presents 5-yr follow-up data evaluating long-term outcomes of MMC chemoresection versus standard surgical management in patients with intermediate-risk NMIBC. METHODS: From 2018 to 2024, 120 patients with recurrent Ta low-grade or high-grade NMIBC and >1 papillary tumor <2 cm were randomized 1:1 to receive either short-term, intensive chemoresection (6 MMC instillations over 2 wk) or standard care with TURBT/biopsy followed by adjuvant instillations with a 5-yr follow-up. Primary end points were the number of procedures (TURBT or biopsy/fulguration) and recurrence-free survival (RFS). KEY FINDINGS AND LIMITATIONS: Fewer patients in the intervention group underwent TURBT (64% vs 89%, p = 0.003), and more patients avoided procedures entirely (17% vs 0%, p = 0.002). Nonresponders shifted from TURBT to office procedures (p = 0.029). At 5 yr, RFS was 14% vs 28% (p = 0.3), with no statistically significant between-group difference (hazard ratio = 1.32, 95% confidence interval 0.86-2.01). Patients with fewer baseline tumors had better RFS (p = 0.012). Findings are limited by a few high-grade tumors at baseline. CONCLUSIONS AND CLINICAL IMPLICATIONS: Chemoresection reduces the need for surgical procedures in patients with recurrent NMIBC without compromising long-term oncological outcomes. These findings support its integration as a less-invasive treatment option in selected patients. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Klingenberg, Soren AU - Klingenberg S AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark. Electronic address: soekli@rm.dk. FAU - Lindgren, Maria S AU - Lindgren MS AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark; Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Jakobsen, Jakob K AU - Jakobsen JK AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark. FAU - Kingo, Pernille S AU - Kingo PS AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20260320 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 50SG953SK6 (Mitomycin) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Mitomycin/administration & dosage/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Administration, Intravesical MH - Female MH - Follow-Up Studies MH - *Neoplasm Recurrence, Local/drug therapy MH - *Antibiotics, Antineoplastic/administration & dosage/therapeutic use MH - Transurethral Resection of Bladder MH - Male MH - Aged MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - Bladder cancer OT - Chemoablation OT - Chemoresection OT - Intermediate risk OT - Mitomycin C OT - Neodjuvant OT - Non-muscle-invasive bladder cancer (NMIBC) OT - Randomized controlled trial OT - Recurrence OT - Recurrence-free survival EDAT- 2026/03/22 06:07 MHDA- 2026/09/01 23:34 CRDT- 2026/03/21 22:52 PHST- 2025/10/10 00:00 [received] PHST- 2026/02/03 00:00 [revised] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/03/22 06:07 [pubmed] PHST- 2026/03/21 22:52 [entrez] AID - S2588-9311(26)00066-0 [pii] AID - 10.1016/j.euo.2026.03.008 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):833-840. doi: 10.1016/j.euo.2026.03.008. Epub 2026 Mar 20. PMID- 41862762 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260723 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 8 DP - 2026 Aug TI - Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer. PG - 7732-7745 LID - 10.1245/s10434-026-19476-6 [doi] AB - BACKGROUND: We aimed to evaluate the impact of bladder tumor location on oncological outcomes in high-grade non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: The testing cohort included 1796 patients with high-grade NMIBC treated with transurethral resection of bladder tumor (TURBT) and adjuvant Bacillus Calmette-Guerin (BCG). The primary endpoints were high-grade recurrence-free survival (HG-RFS) and progression-free survival (PFS). Propensity score matching (PSM) was used to adjust for clinicopathological confounders between patients with and without trigone/bladder neck involvement. External validation included 20,249 high-grade NMIBC from the Surveillance, Epidemiology, and End Results (SEER) database, with overall and cancer-specific survival (CSS) as endpoints. Cumulative incidence functions and competing-risk regression models were used for survival analyses. RESULTS: Our multicenter cohort included 1796 patients, of whom, 1351 (75%) had high-grade T1, 869 (48%) had multiple tumors, and 637 (35%) had tumors arising from bladder neck or trigone. On multivariable analysis, trigone or bladder neck involvement (hazard ratio, HR: 1.24, 95% confidence interval, CI 1.02-1.49) was independently associated with worse HG-RFS. This was confirmed in a PSM analysis, which also showed worse PFS (HR: 1.45, 95% CI 1.00-2.09) and HG-RFS (HR: 1.40, 95% CI 1.08-1.82). In the SEER cohort, trigone (HR: 1.22, 95% CI 1.09-1.38) and bladder neck (HR:1.37, 95% CI 1.19-1.58) tumors were independently associated with worse CSS compared with other locations. CONCLUSIONS: Involvement of the bladder trigone or neck is an independent prognostic factor for worse oncological outcomes in high-grade NMIBC. Further studies are needed to elucidate underlying mechanisms and determine the clinical implications for treatment decision-making. CI - (c) 2026. Society of Surgical Oncology. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. slusarczyk.aleksander@gmail.com. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Cano Velasco, Jorge AU - Cano Velasco J AD - Department of Urology, Clinica Universidad de Navarra, Cancer Center, Pamplona, Spain. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Garbas, Karolina AU - Garbas K AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Del Olmo Duran, Pedro AU - Del Olmo Duran P AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Claps, Francesco AU - Claps F AD - Oncological Urology, Veneto Institute of Oncology, Padua, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Domanski, Piotr AU - Domanski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Lijnen, Renee A G AU - Lijnen RAG AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Fertitta, Giorgia AU - Fertitta G AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, University of Florence, Careggi Hospital, Florence, Italy. FAU - Amodeo, Antonio AU - Amodeo A AD - Oncological Urology, Veneto Institute of Oncology, Padua, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Aarau Kantonsspital, Aarau, Switzerland. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Surgical Sciences, Urology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. CN - European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260320 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - BCG Vaccine/therapeutic use MH - Follow-Up Studies MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/pathology MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/therapy/mortality MH - Prognosis MH - SEER Program MH - Survival Rate MH - Transurethral Resection of Bladder/mortality MH - *Urinary Bladder/pathology OTO - NOTNLM OT - BCG OT - Bladder neck OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Survival OT - Trigone OT - Tumor location COIS- Disclosures: Gautier Marcq-speaker for a pharmaceutical company: BMS, Merck, Johnson and Johnson, Astellas, and Engene; support from a pharmaceutical company for participation in a national or international congress: Bouchara Recordati, BMS, Merck, Johnson and Johnson, Ipsen, Astellas, and Photocure; consultant: Johnson and Johnson, BMS, Merck, and Merck Serono; principal investigator of a pharmaceutical industry trial: Merck, Johnson and Johnson, Fidia, Steba Biotech, and Engene. EDAT- 2026/03/21 06:30 MHDA- 2026/07/07 18:54 CRDT- 2026/03/21 00:27 PHST- 2026/01/07 00:00 [received] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/07/07 18:54 [medline] PHST- 2026/03/21 06:30 [pubmed] PHST- 2026/03/21 00:27 [entrez] AID - 10.1245/s10434-026-19476-6 [pii] AID - 10.1245/s10434-026-19476-6 [doi] PST - ppublish SO - Ann Surg Oncol. 2026 Aug;33(8):7732-7745. doi: 10.1245/s10434-026-19476-6. Epub 2026 Mar 20. PMID- 41862336 OWN - NLM STAT- MEDLINE DCOM- 20260704 LR - 20260730 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 3 DP - 2026 Jun TI - Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective. PG - 690-704 LID - S2588-9311(26)00065-9 [pii] LID - 10.1016/j.euo.2026.03.005 [doi] AB - BACKGROUND AND OBJECTIVE: Urothelial bladder cancer (UBC) carries significant mortality and treatment morbidity. Conventional diagnostic and monitoring methods, including cystoscopy and biopsy, are invasive and limited in sensitivity. Circulating tumor DNA (ctDNA), a minimally-invasive "liquid biopsy," has emerged as a promising tool for real-time disease assessment. This study aimed to systematically evaluate the diagnostic, prognostic, and predictive value of plasma and urine ctDNA in localized, locally advanced, and metastatic UBC. METHODS: A systematic review was conducted according to PRISMA guidelines using PubMed, MEDLINE, and Web of Science databases (January 2016-October 2025). Eligible studies evaluated plasma and urine ctDNA. Main outcomes included diagnostic performance, correlation with tissue mutations, disease monitoring, and prognostic or predictive value. Data synthesis focused on ctDNA detection methods, timing relative to treatment, and survival outcomes. KEY FINDINGS AND LIMITATIONS: ctDNA showed strong concordance with tumor tissue mutations and high potential for real-time monitoring of tumor burden. Data are more robust in muscle-invasive bladder cancer (MIBC) than non-muscle-invasive bladder cancer (NMIBC). Postcystectomy ctDNA positivity was an independent predictor of recurrence-free, progression-free, and overall survival. ctDNA clearance correlated with response to neoadjuvant chemotherapy and immune checkpoint inhibitors. In metastatic disease, high ctDNA mutation burden was associated with shorter overall survival and resistance mechanisms, such as PIK3CA-mediated fibroblast growth factor receptor inhibitor resistance. Limitations included heterogeneous methodologies, variable assay sensitivity, and small patient cohorts. CONCLUSIONS AND CLINICAL IMPLICATIONS: ctDNA represents a powerful non-invasive biomarker for diagnosis, surveillance, and treatment guidance in UBC. Ongoing phase III trials (IMvigor011, TOMBOLA, MODERN) may establish its clinical utility as a standard tool for personalized disease management. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Urology, Henri Mondor University Hospital, Assistance Publique-Hopitaux de Paris, Creteil, France; Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France. FAU - Epelbaum, Isabelle AU - Epelbaum I AD - Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Prost, Doriane AU - Prost D AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France; Department of Urology, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Haberstich, Mathilde AU - Haberstich M AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France; Department of Medical Oncology, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Suartz, Caio Vinicius AU - Suartz CV AD - Department of Urology, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Blons, Helene AU - Blons H AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France. FAU - Taly, Valerie AU - Taly V AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France. FAU - Laurent-Puig, Pierre AU - Laurent-Puig P AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France. FAU - Horowitz, Amir AU - Horowitz A AD - Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Thibault, Constance AU - Thibault C AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France; Department of Medical Oncology, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Audenet, Francois AU - Audenet F AD - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite Paris Cite, Personalized Medicine, Phamacogenomics and Therapeutic Optimization, Paris, France; Institut du Cancer Paris CARPEM, APHP, Centre, Department of Biology, Hopital Europeen Georges Pompidou, Paris, France; Department of Urology, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. Electronic address: francois.audenet@aphp.fr. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260319 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Circulating Tumor DNA/urine/blood MH - *Urinary Bladder Neoplasms/blood/urine/genetics/diagnosis MH - Biomarkers, Tumor/urine/blood MH - Prognosis MH - Liquid Biopsy MH - *Carcinoma, Transitional Cell/urine/blood/genetics OTO - NOTNLM OT - Circulating tumor DN OT - Diagnostic biomarker OT - Liquid biopsy OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Non-muscle-invasive bladder cancer OT - Urothelial bladder cancer EDAT- 2026/03/21 00:34 MHDA- 2026/07/05 00:37 CRDT- 2026/03/20 22:54 PHST- 2025/10/09 00:00 [received] PHST- 2026/01/30 00:00 [revised] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/07/05 00:37 [medline] PHST- 2026/03/21 00:34 [pubmed] PHST- 2026/03/20 22:54 [entrez] AID - S2588-9311(26)00065-9 [pii] AID - 10.1016/j.euo.2026.03.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Jun;9(3):690-704. doi: 10.1016/j.euo.2026.03.005. Epub 2026 Mar 19. PMID- 41861349 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 1473-6586 (Electronic) IS - 0963-0643 (Print) IS - 0963-0643 (Linking) VI - 36 IP - 3 DP - 2026 May 1 TI - The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents. PG - 244-249 LID - 10.1097/MOU.0000000000001388 [doi] AB - PURPOSE OF REVIEW: The treatment landscape for advanced and non-muscle-invasive urothelial carcinoma (UC) is rapidly evolving beyond platinum chemotherapy and immune checkpoint inhibitors. This review is timely and relevant as it synthesizes recent, impactful data from 2024-2025 early-phase trials, highlighting agents poised to redefine clinical standards. RECENT FINDINGS: Recent studies showcase promising novel strategies. These include next-generation targeted therapies like sapanisertib, novel antibody-drug conjugates (ADCs) and bicycle toxin conjugates (BTCs) such as zelenectide pevedotin (BT8009) and dual-ADC combinations with high response rates, and the approved immunomodulator N-803 for BCG-unresponsive disease. Furthermore, innovative intravesical therapies, including ADCs (disitamab vedotin) and immune checkpoint inhibitors, show transformative potential for localized disease with favorable safety. SUMMARY: The findings indicate a shift towards more effective and tailored treatments. Future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances into practice and improve patient outcomes. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Lee, Yan Hiu Athena AU - Lee YHA AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital. FAU - Wong, Chris Ming-Ho AU - Wong CM AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital. FAU - Liu, Alex Qinyang AU - Liu AQ AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital. AD - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong. AD - Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review DEP - 20260317 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Antineoplastic Agents) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Immunoconjugates) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Antineoplastic Agents/therapeutic use MH - Molecular Targeted Therapy/trends MH - Immune Checkpoint Inhibitors/therapeutic use MH - Immunoconjugates/therapeutic use MH - Clinical Trials as Topic MH - Forecasting PMC - PMC13048309 OTO - NOTNLM OT - antibody-drug conjugates OT - clinical trials OT - immunotherapy OT - targeted therapy OT - urothelial carcinoma COIS- There are no conflicts of interest. EDAT- 2026/03/20 18:37 MHDA- 2026/03/31 12:32 PMCR- 2026/04/03 CRDT- 2026/03/20 16:34 PHST- 2026/03/31 12:32 [medline] PHST- 2026/03/20 18:37 [pubmed] PHST- 2026/03/20 16:34 [entrez] PHST- 2026/04/03 00:00 [pmc-release] AID - 00042307-990000000-00322 [pii] AID - MOU360303 [pii] AID - 10.1097/MOU.0000000000001388 [doi] PST - ppublish SO - Curr Opin Urol. 2026 May 1;36(3):244-249. doi: 10.1097/MOU.0000000000001388. Epub 2026 Mar 17. PMID- 41858138 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260918 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 6 DP - 2026 Jun TI - Refining BCG-failure classifications in non-muscle-invasive bladder cancer. PG - 1076-1087 LID - 10.1111/bju.70231 [doi] AB - OBJECTIVE: To validate International Bladder Cancer Group (IBCG) definitions of Bacillus Calmette-Guerin (BCG)-unresponsive and BCG-exposed non-muscle-invasive bladder cancer (NMIBC) and assess prognostic heterogeneity across various BCG-failure types. PATIENTS AND METHODS: From a multicentre international cohort of 3806 BCG-treated patients, 591 who developed high-grade NMIBC recurrence following BCG between 2003 and 2024 were included. Progression-free survival (PFS) was the primary endpoint; cancer-specific (CSM) and overall mortality (OM) were secondary endpoints. Cumulative incidence functions, competing-risk models and multivariable Cox regression were used. RESULTS: Patients with BCG-unresponsive and BCG-exposed disease showed similar PFS, CSM, and OM (all P > 0.05). When stratified into five subgroups, prognosis varied: 5-year progression rates were 29% for BCG-unresponsive, 32.5% for late relapse (between 6 and 24 months) after adequate BCG, 30% for BCG-exposed with inadequate BCG (<24 months from induction), 6.2% for BCG-resistant, and 14% for very late relapse (>24 months since last BCG) (P < 0.01). In multivariable analysis, BCG-exposed after inadequate BCG (subdistribution hazard ratio [sHR] 3.42, 95% confidence interval [CI] 1.33-8.84), late relapse (sHR 3.74, 95% CI 1.59-8.78), and BCG-unresponsive (sHR 2.34, 95% CI 1.00-5.44) were associated with higher progression risks compared to very late relapse. Limitations include retrospective design and treatment heterogeneity. CONCLUSIONS: Under IBCG definitions, BCG-unresponsive and BCG-exposed NMIBC have similarly poor outcomes. A refined classification reveals prognostic heterogeneity, with late relapses after adequate BCG demonstrating outcomes comparable to BCG-unresponsive, and very late relapses conferring better prognosis. CI - (c) 2026 BJU International. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Claps, Francesco AU - Claps F AUID- ORCID: 0000-0003-2812-5553 AD - Oncological Urology, Veneto Institute of Oncology IRCCS, Padua, Italy. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Clinica Universidad de Navarra, Cancer Center, Pamplona, Spain. FAU - Tully, Karl AU - Tully K AUID- ORCID: 0000-0002-9499-0169 AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Duran, Pedro Del Olmo AU - Duran PDO AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Lijnen, Renee A G AU - Lijnen RAG AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Aarau Kantonsspital, Aarau, Switzerland. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Urology Unit, Department of Surgical Sciences, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. CN - European Association of Urology-Young Academic Urologists (EAU-YAU) CN - Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260319 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/mortality MH - *BCG Vaccine/therapeutic use MH - Female MH - Male MH - Aged MH - Prognosis MH - Neoplasm Recurrence, Local MH - *Adjuvants, Immunologic/therapeutic use MH - Treatment Failure MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/mortality/pathology MH - Progression-Free Survival MH - Retrospective Studies OTO - NOTNLM OT - BCG failure OT - BCG therapy OT - BCG-unresponsive tumour OT - NMIBC OT - progression OT - survival OT - urinary neoplasm of the bladder OT - urothelial cancer COIS- Aleksander Slusarczyk certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Prof. Boorjian is a consultant for Ferring and Johnson & Johnson. The remaining authors have no disclosures relevant to this project. Funding This was a zero-cost study, and no funding was granted for the project. Other support: Aleksander Slusarczyk is supported by the Foundation for Polish Science under the START Programme. EDAT- 2026/03/20 07:10 MHDA- 2026/05/13 06:32 CRDT- 2026/03/20 02:53 PHST- 2026/05/13 06:32 [medline] PHST- 2026/03/20 07:10 [pubmed] PHST- 2026/03/20 02:53 [entrez] AID - 10.1111/bju.70231 [doi] PST - ppublish SO - BJU Int. 2026 Jun;137(6):1076-1087. doi: 10.1111/bju.70231. Epub 2026 Mar 19. PMID- 41850565 OWN - NLM STAT- MEDLINE DCOM- 20260831 LR - 20260914 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 50 IP - 7 DP - 2026 Sep TI - Prognostic factors and oncological outcomes after trimodality bladder-preserving therapy for muscle-invasive bladder cancer: A multicenter real-world study. PG - 501967 LID - S2173-5786(26)00082-X [pii] LID - 10.1016/j.acuroe.2026.501967 [doi] AB - INTRODUCTION: Trimodality therapy (TMT), consisting of maximal transurethral resection of the bladder tumor followed by concurrent chemoradiotherapy, is an established bladder-preserving option for selected patients with muscle-invasive bladder cancer (MIBC). However, contemporary multicenter real-world data are needed to better define oncological outcomes and prognostic factors in routine clinical practice. METHODS: We conducted a retrospective multicenter cohort study including 369 patients with cT2-T4aN0M0 MIBC treated with definitive TMT between 2010 and 2022. Time-to-event outcomes were measured from radiotherapy completion and estimated using the Kaplan-Meier method. Endpoints included overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), and progression-free survival (PFS). Bladder-preservation outcomes included complete local response (CLR) at first assessment and salvage cystectomy. Prognostic factors were evaluated using multivariable Cox proportional hazards regression. RESULTS: Median age was 76 years (IQR 66.5-81.0), and 85.1% of patients were male. After a median follow-up of 27.4 months, OS at 1, 2, and 3 years was 85.8%, 75.7%, and 65.7%, respectively, while CSS was 90.5%, 84.7%, and 79.9%. MFS rates at 1, 2, and 3 years were 85.8%, 83.1%, and 80.6%, and corresponding PFS rates were 82.9%, 75.4%, and 71.6%. A complete local response was achieved in 63.7% of patients, and salvage cystectomy was required in 9.7%. On multivariable analysis, increasing age, poorer ECOG performance status, and lymphovascular invasion were independently associated with worse outcomes, whereas the use of modern radiotherapy techniques (IMRT/VMAT) was associated with improved survival compared with three-dimensional conformal radiotherapy. CONCLUSIONS: In this large contemporary real-world cohort, trimodality therapy achieved effective cancer control with durable bladder preservation and a low salvage cystectomy rate. While overall survival was influenced by baseline patient fitness, cancer-specific and metastasis-free outcomes remained favourable. These findings support TMT as a robust bladder-preserving strategy in routine clinical practice, provided that appropriate patient selection and high-quality radiotherapy delivery are ensured. CI - Copyright (c) 2026 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Feltes Benitez, N AU - Feltes Benitez N AD - Servicio de Oncologia Radioterapica, Hospital Universitario de Terrassa (CST), Terrassa, Spain. Electronic address: Nicofeltes_81@hotmail.com. FAU - Counago, F AU - Counago F AD - Servicio de Oncologia Radioterapica, Hospital La Milagrosa, Madrid, Spain; Servicio de Oncologia Radioterapica, Hospital San Francisco de Asis, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Salud y Deporte, Universidad Europea de Madrid, Madrid, Spain. FAU - Paredes-Rubio, S AU - Paredes-Rubio S AD - Servicio de Oncologia Radioterapica, Hospital Universitario de Terrassa (CST), Terrassa, Spain. FAU - Peleteiro Higuero, P AU - Peleteiro Higuero P AD - Servicio de Oncologia Radioterapica, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. FAU - Molina Osorio, J G AU - Molina Osorio JG AD - Servicio de Oncologia Radioterapica, Institut Catala d'Oncologia (ICO) Badalona, Barcelona, Spain. FAU - Folgar Torres, A AU - Folgar Torres A AD - Servicio de Oncologia Radioterapica, Complexo Hospitalario Universitario de Lugo, Lugo, Spain. FAU - Aissati, A AU - Aissati A AD - Servicio de Oncologia Radioterapica, Hospital Universitario Dr. Josep Trueta, Girona, Spain. FAU - Mera, A AU - Mera A AD - Servicio de Oncologia Radioterapica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. FAU - Pastor Peidro, J R AU - Pastor Peidro JR AD - Servicio de Oncologia Radioterapica, ASCIRES Grupo Biomedico, Valencia, Spain. FAU - Garrido Botella, M I AU - Garrido Botella MI AD - Servicio de Oncologia Radioterapica, Hospital La Milagrosa, Madrid, Spain. FAU - Gonzalez de Duenas, M AU - Gonzalez de Duenas M AD - Servicio de Oncologia Radioterapica, Hospital La Milagrosa, Madrid, Spain; Servicio de Oncologia Radioterapica, Hospital San Francisco de Asis, Madrid, Spain. FAU - Duque-Santana, V AU - Duque-Santana V AD - Departamento de Medicina, Facultad de Medicina, Salud y Deporte, Universidad Europea de Madrid, Madrid, Spain; Servicio de Oncologia Radioterapica, Hospital Universitario Quironsalud Madrid, Madrid, Spain. FAU - Torices Caballero, J AU - Torices Caballero J AD - Servicio de Oncologia Radioterapica, Hospital Quironsalud Barcelona, Barcelona, Spain. FAU - Pons Sanchez, A AU - Pons Sanchez A AD - Servicio de Urologia, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain. FAU - Andreescu Yague, J AU - Andreescu Yague J AD - Servicio de Oncologia Radioterapica, GenesisCare Cordoba, Cordoba, Spain. FAU - Rodriguez Perez, A AU - Rodriguez Perez A AD - Servicio de Oncologia Radioterapica, Hospital Ruber Internacional, Madrid, Spain. FAU - Guardado Gonzalez, S AU - Guardado Gonzalez S AD - Servicio de Oncologia Radioterapica, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Fernandez Alonso, S AU - Fernandez Alonso S AD - Servicio de Oncologia Radioterapica, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Lazo-Prados, A AU - Lazo-Prados A AD - Servicio de Oncologia Radioterapica, Hospital Universitario Virgen de la Victoria, Malaga, Spain. FAU - Gaztanaga Boronat, M AU - Gaztanaga Boronat M AD - Servicio de Oncologia Radioterapica, Hospital Clinico San Carlos, Madrid, Spain. FAU - Moreno Lopez, S AU - Moreno Lopez S AD - Servicio de Oncologia Radioterapica, Hospital Clinic Barcelona, Barcelona, Spain. FAU - Mendez Villamon, A AU - Mendez Villamon A AD - Servicio de Oncologia Radioterapica, Hospital Universitario Miguel Servet, Zaragoza, Spain. FAU - Garcia Gomez, R AU - Garcia Gomez R AD - Servicio de Oncologia Radioterapica, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Gil Restrepo, C AU - Gil Restrepo C AD - Servicio de Oncologia Radioterapica, Complejo Asistencial de Zamora, Zamora, Spain. FAU - Alonso Martinez, P AU - Alonso Martinez P AD - Servicio de Oncologia Radioterapica, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Mesa Lopez, F AU - Mesa Lopez F AD - Servicio de Oncologia Radioterapica, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Ibanez Villoslada, C AU - Ibanez Villoslada C AD - Servicio de Oncologia Radioterapica, Hospital Gomez Ulla, Madrid, Spain. FAU - Willisch Santamaria, P AU - Willisch Santamaria P AD - Servicio de Oncologia Radioterapica, Hospital Meixoeiro, Vigo, Spain. FAU - Ribeiro, I AU - Ribeiro I AD - Servicio de Oncologia Radioterapica, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain. FAU - Nicolas Boluda, C AU - Nicolas Boluda C AD - Servicio de Oncologia Radioterapica, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. FAU - Fernandez Lopez, J AU - Fernandez Lopez J AD - Servicio de Oncologia Radioterapica, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Lopez Campos, F AU - Lopez Campos F AD - Servicio de Oncologia Radioterapica, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Sargos, P AU - Sargos P AD - Servicio de Radioterapia, Institut Bergonie, Bordeaux, France. FAU - Gonzalez Del Portillo, E AU - Gonzalez Del Portillo E AD - Servicio de Oncologia Radioterapica, Hospital Rey Juan Carlos, Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Multicenter Study DEP - 20260316 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Retrospective Studies MH - Male MH - *Organ Sparing Treatments MH - Prognosis MH - Neoplasm Invasiveness MH - Female MH - Treatment Outcome MH - Aged, 80 and over MH - Aged MH - Transurethral Resection of Bladder MH - Combined Modality Therapy MH - Cystectomy MH - Chemoradiotherapy MH - Cohort Studies OTO - NOTNLM OT - Arcoterapia volumetrica modulada OT - Bladder preservation OT - Chemoradiotherapy OT - Cancer de vejiga musculo invasivo OT - Evidencia del mundo real OT - Muscle-invasive bladder cancer OT - Preservacion vesical OT - Quimiorradioterapia OT - Radioterapia OT - Radiotherapy OT - Real-world evidence OT - Terapia trimodal OT - Trimodality therapy OT - Volumetric Modulated Arc Therapy COIS- Declaration of competing interest The authors declare no conflicts of interest related to this work. EDAT- 2026/03/19 01:32 MHDA- 2026/08/31 23:43 CRDT- 2026/03/18 20:15 PHST- 2025/10/28 00:00 [received] PHST- 2026/01/26 00:00 [revised] PHST- 2026/01/28 00:00 [accepted] PHST- 2026/08/31 23:43 [medline] PHST- 2026/03/19 01:32 [pubmed] PHST- 2026/03/18 20:15 [entrez] AID - S2173-5786(26)00082-X [pii] AID - 10.1016/j.acuroe.2026.501967 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2026 Sep;50(7):501967. doi: 10.1016/j.acuroe.2026.501967. Epub 2026 Mar 16. PMID- 41850129 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260805 IS - 1879-4076 (Electronic) IS - 1879-4068 (Linking) VI - 17 IP - 4 DP - 2026 May TI - Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults. PG - 102939 LID - S1879-4068(26)00093-7 [pii] LID - 10.1016/j.jgo.2026.102939 [doi] AB - INTRODUCTION: We aimed to evaluate population-based outcomes of chemoradiation therapy (CRT) for muscle-invasive bladder cancer given a lack of population-based data, particularly in older adults. MATERIALS AND METHODS: We conducted observational analyses using SEER-Medicare based on the CRT protocol in the control arm of SWOG/NRG 1806. We included adults aged 66-89 years with T2-T4a N0 M0 urothelial bladder cancer treated with radiation and concurrent chemotherapy (cisplatin, gemcitabine, or 5-FU + mitomycin C) within 90 days of transurethral resection of bladder tumor (TURBT) from 2000 to 2017. We examined progression-free (PFS), cancer-specific (CSS), and overall survival (OS) using claims-based proxies and the Kaplan-Meier method. Associations of baseline characteristics with outcomes were evaluated using Cox regression. RESULTS: A total of 283 patients were included. Median age was 78 years (IQR 73-82), and tumor stage was T2 in 247 (87%) patients. Median follow-up was 26.0 months. At five years, PFS was 47%, CSS was 53%, and OS was 35%. On multivariable analysis, female sex (HR 1.74) was associated with increased risk of cancer-specific mortality (CSM), while higher education level (HR 0.37 for <14% without high school education versus >29%) was associated with reduced CSM. DISCUSSION: Notwithstanding the limitations of SEER-Medicare, in observational analyses designed to evaluate outcomes of a hypothetical single-arm trial, CRT was associated with lower CSS and OS than reported in prior clinical trials. Additional studies are required to determine if this is related to the efficacy or completeness of CRT in population-based practices or differences between trial and non-trial populations. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Bahar, Piroz AU - Bahar P AD - University of Michigan Medical School, Ann Arbor, MI, United States of America. FAU - Perez-Londono, Agustin AU - Perez-Londono A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Kaul, Sumedh AU - Kaul S AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Efstathiou, Jason AU - Efstathiou J AD - Department of Radiation Oncology, Mass General Brigham, Boston, MA, United States of America. FAU - Williams, Stephen B AU - Williams SB AD - University of Texas Medical Branch, Galveston, TX, United States of America. FAU - Shan, Yong AU - Shan Y AD - University of Texas Medical Branch, Galveston, TX, United States of America. FAU - Chang, Peter AU - Chang P AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Wagner, Andrew AU - Wagner A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Fleishman, Aaron AU - Fleishman A AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Olumi, Aria AU - Olumi A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. Electronic address: bgershma@bidmc.harvard.edu. LA - eng PT - Journal Article PT - Observational Study DEP - 20260317 PL - Netherlands TA - J Geriatr Oncol JT - Journal of geriatric oncology JID - 101534770 RN - Q20Q21Q62J (Cisplatin) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) RN - 50SG953SK6 (Mitomycin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Humans MH - Aged MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Female MH - Male MH - *Chemoradiotherapy/methods MH - Aged, 80 and over MH - SEER Program MH - Cisplatin/therapeutic use/administration & dosage MH - United States/epidemiology MH - Transurethral Resection of Bladder MH - Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - Treatment Outcome MH - Gemcitabine MH - Mitomycin/therapeutic use/administration & dosage MH - Neoplasm Invasiveness MH - Medicare MH - *Carcinoma, Transitional Cell/therapy/pathology MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Fluorouracil/therapeutic use/administration & dosage MH - Neoplasm Staging MH - Sex Factors MH - Progression-Free Survival OTO - NOTNLM OT - Bladder cancer OT - Chemoradiation OT - Older adults OT - Outcomes OT - Trimodality COIS- Declaration of competing interest The authors report no conflicts of interest. EDAT- 2026/03/19 01:32 MHDA- 2026/05/01 00:31 CRDT- 2026/03/18 19:17 PHST- 2025/10/10 00:00 [received] PHST- 2026/01/30 00:00 [revised] PHST- 2026/03/03 00:00 [accepted] PHST- 2026/05/01 00:31 [medline] PHST- 2026/03/19 01:32 [pubmed] PHST- 2026/03/18 19:17 [entrez] AID - S1879-4068(26)00093-7 [pii] AID - 10.1016/j.jgo.2026.102939 [doi] PST - ppublish SO - J Geriatr Oncol. 2026 May;17(4):102939. doi: 10.1016/j.jgo.2026.102939. Epub 2026 Mar 17. PMID- 41843887 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260711 IS - 1548-8756 (Electronic) IS - 1548-8748 (Linking) VI - 46 IP - 2 DP - 2026 Feb TI - Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer. PG - e515984 LID - 10.1200/EDBK-26-515984 [doi] AB - Muscle-invasive bladder cancer (MIBC) has historically been managed with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC), a strategy associated with substantial morbidity and long-term quality-of-life implications. As systemic therapies achieve increasingly deep responses, interest has intensified in bladder-preserving approaches that maintain oncologic efficacy while minimizing treatment-related burden. This review examines the evolving landscape of bladder preservation in MIBC, spanning radiation-based trimodality therapy (TMT), partial cystectomy, and emerging response-adapted strategies after neoadjuvant therapy. We summarize long-term oncologic outcomes of TMT, which, in carefully selected patients, provides disease-specific and overall survival (OS) results comparable with RC outcomes with durable bladder preservation in many long-term survivors. We review patient selection criteria, the role of maximal transurethral resection, and optimal radiosensitizing regimens, as well as ongoing efforts to integrate immunotherapy into definitive chemoradiation. Beyond radiation-based strategies, we highlight growing interest in active surveillance after clinical complete response (CR) to neoadjuvant chemotherapy or chemo-immunotherapy, an approach enabled by unprecedented pathologic CR rates achieved with modern regimens, including enfortumab vedotin plus pembrolizumab. A central challenge to response-adapted bladder preservation remains the accurate identification of patients with true eradication of local and systemic disease. We discuss limitations of conventional clinical restaging and review advances in multiparametric magnetic resonance imaging, fluorodeoxyglucose positron emission tomography/computed tomography, circulating tumor DNA, and urinary tumor DNA as complementary tools for response assessment, risk stratification, and early detection of recurrence. Finally, we outline future directions focused on integrating molecular biomarkers, advanced imaging, and multidisciplinary decision making to safely expand bladder preservation while preserving metastasis-free survival and OS. FAU - Li, Joy AU - Li J AD - Fox Chase Cancer Center, Philadelphia, PA. FAU - Ballas, Leslie AU - Ballas L AD - Cedars-Sinai Medical Center in Los Angeles, Los Angeles, CA. FAU - Ghatalia, Pooja AU - Ghatalia P AD - Fox Chase Cancer Center, Philadelphia, PA. LA - eng PT - Journal Article PT - Review DEP - 20260317 PL - United States TA - Am Soc Clin Oncol Educ Book JT - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting JID - 101233985 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Neoplasm Invasiveness MH - *Organ Sparing Treatments/methods MH - Neoadjuvant Therapy MH - Combined Modality Therapy MH - Cystectomy MH - Treatment Outcome MH - Transurethral Resection of Bladder MH - Urinary Bladder/pathology EDAT- 2026/03/18 13:41 MHDA- 2026/03/18 13:42 CRDT- 2026/03/17 16:03 PHST- 2026/03/18 13:42 [medline] PHST- 2026/03/18 13:41 [pubmed] PHST- 2026/03/17 16:03 [entrez] AID - 10.1200/EDBK-26-515984 [doi] PST - ppublish SO - Am Soc Clin Oncol Educ Book. 2026 Feb;46(2):e515984. doi: 10.1200/EDBK-26-515984. Epub 2026 Mar 17. PMID- 41843343 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20261008 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 9 DP - 2026 Sep TI - Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population. PG - 3491-3502 LID - 10.1007/s11255-026-05067-7 [doi] AB - BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG) is the standard adjuvant therapy for intermediate/high-risk non-muscle-invasive bladder cancer (NMIBC) but is limited by failure, toxicity, and global supply constraints. Sequential Intravesical gemcitabine-docetaxel (Gem/Doce) can offer a rational chemotherapy alternative. METHODS: In this prospective randomized, parallel-arm interventional study comparing efficacy and safety of Gem/Doce versus BCG in BCG-naive intermediate/high-risk NMIBC, patients aged 18-80 years with complete TURBT of primary localised bladder lesion(s) were included. Gem/Doce induction comprised weekly gemcitabine (1000 mg) and docetaxel (40 mg) Intravesical instillations for 6 weeks, with monthly maintenance per risk group. BCG induction (weekly 80 mg OncoBCG for 6 weeks) was followed by risk-based maintenance as per SWOG protocol. Outcomes (RFS, high-grade RFS, PFS, CSS, OS) were evaluated post-induction, and at 6 and 12 months. Adverse events were graded by CTCAE v5.0. RESULTS: 91 patients (Gem/Doce n = 43; BCG n = 48) were evaluated. At 6 and 12 months, RFS was 95.35% and 90.71% in Gem/Doce versus 83.33% and 77.08% in BCG. Intermediate-risk category had higher 12 month RFS with Gem/Doce (93.55% vs 81.82%, p = 0.041). High-grade RFS was higher with Gem/Doce (97.67% and 93.02%) than BCG (93.75% and 89.58%). At 12 months, PFS, CSS, and OS were superior with Gem/Doce: PFS 97.67% vs 95.83%, CSS 100% vs 97.92%, and OS 100% vs 95.83%. Fewer patients reported AEs with Gem/Doce (13.95% vs 35.42%), with fewer Grade 1-2 events (p < 0.01) and no Grade >/= 3 events vs. three in BCG. Dysuria, bladder spasm, and frequency were higher with BCG. CONCLUSIONS: Sequential Gem/Doce is an effective and better-tolerated alternative to BCG in BCG-naive NMIBC, demonstrating superior intermediate-risk RFS and comparable survival outcomes. Long-term validation through larger multi-centre studies is warranted. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Srivastava, Aviral AU - Srivastava A AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Trivedi, Sameer AU - Trivedi S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Singh, Yashasvi AU - Singh Y AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. yashasvisingh075@gmail.com. FAU - Kumar, Ujwal AU - Kumar U AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Lalit AU - Kumar L AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Data, Sahil AU - Data S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Anil AU - Kumar A AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Sankhwar, Satya Narayan AU - Sankhwar SN AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20260317 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *Deoxycytidine/analogs & derivatives/administration & dosage/adverse effects MH - Gemcitabine MH - Middle Aged MH - Female MH - *BCG Vaccine/administration & dosage/therapeutic use/adverse effects MH - *Docetaxel/administration & dosage/adverse effects MH - Prospective Studies MH - Administration, Intravesical MH - Aged MH - Male MH - Adult MH - Aged, 80 and over MH - India MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage/adverse effects MH - Treatment Outcome MH - Chemotherapy, Adjuvant MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Adjuvants, Immunologic/administration & dosage MH - Young Adult MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Adolescent OTO - NOTNLM OT - BCG OT - Docetaxel OT - Gemcitabine OT - NMIBC OT - TURBT OT - Urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare no conflict of interests. EDAT- 2026/03/18 13:41 MHDA- 2026/08/25 17:35 CRDT- 2026/03/17 12:24 PHST- 2025/11/28 00:00 [received] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/08/25 17:35 [medline] PHST- 2026/03/18 13:41 [pubmed] PHST- 2026/03/17 12:24 [entrez] AID - 10.1007/s11255-026-05067-7 [pii] AID - 10.1007/s11255-026-05067-7 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Sep;58(9):3491-3502. doi: 10.1007/s11255-026-05067-7. Epub 2026 Mar 17. PMID- 41843048 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260925 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 216 IP - 1 DP - 2026 Jul TI - Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. PG - 34-45 LID - 10.1097/JU.0000000000005034 [doi] AB - PURPOSE: We sought to assess if precystectomy circulating tumor DNA (ctDNA) status predicts recurrence-free survival (RFS) and correlates with disease upstaging in patients with high-risk nonmuscle-invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC). MATERIALS AND METHODS: We conducted a bicenter analysis of patients with high-risk NMIBC (cN0M0) who underwent RC between 2021 and 2023 and had prospective serial tumor-informed ctDNA analyses performed before and after RC. The molecular residual disease window was defined as the initial 90 days after RC. The primary end point RFS was analyzed with the Kaplan-Meier method. RESULTS: A total of 56 patients with NMIBC with a median follow-up time of 14 months (IQR 6-18) and a median age of 67 years (IQR 62-72) were included; among them, 45 patients had pre-RC ctDNA available, 15 patients (33.3%) had detectable, and 30 patients (66.7%) had undetectable ctDNA. Twelve patients had bacillus Calmette-Guerin-unresponsive disease (26.8%). The most common pre-RC pathology was T1HG (60%) and T1HG + carcinoma in situ (28.9%). Detectable pre-RC ctDNA cases were more commonly upstaged (>/=pT2) 66.7% vs 13.3%, and 33.3% vs 0% had pN+ (odds ratio = 13.0 [3.13-66.1], P < .001). Among patients with undetectable ctDNA, 20% had pT0 and none had >/= pT3 or pN+ disease. On survival analysis, detectable pre-RC ctDNA had worse RFS than undetectable ctDNA (log-rank, P < .0001, HR = 11 [2.27-53.8]), with worse 6-month RFS of 64.3% (43.5-95) vs 100% and 12-month RFS of 38.6% (17.1-87.2) vs 95.7% (87.7-100), respectively. Detectable molecular residual disease ctDNA was associated with worse RFS than undetectable ctDNA (log-rank, P < .0001, HR = 14.1 [3.12-63.7], P = .001). CONCLUSIONS: Detectable ctDNA for high-risk NMIBC pre-RC was associated with worse RFS, increased risk of pathological upstaging, and locally advanced disease with lymph node metastasis. FAU - Ben-David, Reuben AU - Ben-David R AUID- ORCID: 0000-0001-7946-7145 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. AD - Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel. FAU - Raizenne, Brendan L AU - Raizenne BL AUID- ORCID: 0000-0002-1710-8224 AD - Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. FAU - Eraky, Ahmed AU - Eraky A AUID- ORCID: 0000-0001-6879-6058 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Duquesne, Igor AU - Duquesne I AUID- ORCID: 0000-0002-6716-6473 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Wiklund, Peter AU - Wiklund P AUID- ORCID: 0000-0001-6497-4697 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Mehrazin, Reza AU - Mehrazin R AUID- ORCID: 0009-0007-8648-0410 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Chu, Carissa AU - Chu C AUID- ORCID: 0000-0003-3065-389X AD - Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. FAU - Odisho, Anobel Y AU - Odisho AY AUID- ORCID: 0000-0003-0975-0812 AD - Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. FAU - Porten, Sima AU - Porten S AUID- ORCID: 0000-0002-3948-4968 AD - Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. FAU - Sfakianos, John P AU - Sfakianos JP AUID- ORCID: 0000-0002-3101-0266 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. LA - eng PT - Journal Article DEP - 20260317 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Circulating Tumor DNA) SB - IM CIN - J Urol. 2026 Jul;216(1):43-44. doi: 10.1097/JU.0000000000005045. PMID: 41945765 CIN - J Urol. 2026 Jul;216(1):44. doi: 10.1097/JU.0000000000005047. PMID: 41955103 MH - Humans MH - *Cystectomy/methods MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/blood/pathology MH - *Neoplasm Recurrence, Local/blood/diagnosis/epidemiology MH - Female MH - Male MH - Aged MH - *Circulating Tumor DNA/blood MH - Neoplasm Staging MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery/pathology/blood MH - Risk Assessment MH - Prospective Studies MH - Preoperative Period OTO - NOTNLM OT - bladder cancer OT - circulating tumor DNA OT - non-muscle-invasive bladder cancer OT - radical cystectomy OT - tumor biomarkers EDAT- 2026/03/17 14:25 MHDA- 2026/06/13 00:38 CRDT- 2026/03/17 12:06 PHST- 2026/06/13 00:38 [medline] PHST- 2026/03/17 14:25 [pubmed] PHST- 2026/03/17 12:06 [entrez] AID - 10.1097/JU.0000000000005034 [doi] PST - ppublish SO - J Urol. 2026 Jul;216(1):34-45. doi: 10.1097/JU.0000000000005034. Epub 2026 Mar 17. PMID- 41839747 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260818 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 138 IP - 2 DP - 2026 Aug TI - Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis. PG - 186-195 LID - 10.1111/bju.70214 [doi] AB - OBJECTIVE: To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle-invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder-sparing strategies. METHODS: In this prospectively registered systematic review and meta-analysis (CRD420251066540), we searched MEDLINE, EMBASE, and Web of Science in June 2025 for studies reporting clinical and pathological complete response rates in patients with MIBC undergoing neoadjuvant therapy followed by radical cystectomy (RC). Pooled concordance was estimated via random-effects meta-analysis. Risk-of-bias was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I). RESULTS: Out of 1947 individual records, 10 (n = 894) retrospective and three (n = 181) prospective studies comprising 1075 patients were included. Restaging modalities for cCR assessment included transurethral resection of the bladder (TURB; n = 188, two studies), computed tomography (n = 221, two studies), magnetic resonance imaging (MRI; n = 122, two studies), and fluorodeoxyglucose positron emission tomography (n = 45). One study (n = 56) used perioperative cystoscopy, while the remaining five studies (n = 499) combined imaging with cystoscopy or TURB. The concordance (n = 779, nine studies) between cCR and pCR was 0.51 (95% confidence interval [CI] 0.42-0.60), the concordance (n = 536, seven studies) between non-cCR and non-pCR was 0.84 (95% CI 0.70-0.92). Most studies were rated as having moderate concerns regarding bias, and one as serious due to examiner-dependent bias of cystoscopy-based cCR assessment. CONCLUSION: Current evidence does not support relying on the current definition of cCR alone, which poorly predicts pCR, to guide treatment decisions. Ongoing trials assessing the combination of MRI plus TURB with urine and/or blood based circulating tumour DNA may help refine cCR evaluation and support the sole introduction of bladder-sparing approaches in patients with MIBC who respond to neoadjuvant systemic therapy. CI - (c) 2026 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Roessler, Navid AU - Roessler N AUID- ORCID: 0009-0008-2792-9828 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Collegium Medicum, Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Dematteis, Alessandro AU - Dematteis A AUID- ORCID: 0009-0006-4125-3874 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Miyajima, Keiichiro AU - Miyajima K AUID- ORCID: 0000-0002-7799-669X AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Inoue, Shota AU - Inoue S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Schuettfort, Victor M AU - Schuettfort VM AUID- ORCID: 0000-0002-7114-0508 AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Szabados, Bernadett AU - Szabados B AD - Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. AD - Department of Urology, University College London Hospital NHS Foundation Trust, London, UK. FAU - Rajwa, Pawel AU - Rajwa P AUID- ORCID: 0000-0003-4073-6584 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260316 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Pathologic Complete Response MH - Cystectomy MH - Transurethral Resection of Bladder MH - Neoadjuvant Therapy MH - Prognosis PMC - PMC13371391 OTO - NOTNLM OT - bladder-sparing strategies OT - clinical complete response OT - muscle-invasive bladder cancer OT - neoadjuvant systemic therapy OT - pathological complete response EDAT- 2026/03/17 00:33 MHDA- 2026/07/15 12:35 PMCR- 2026/07/15 CRDT- 2026/03/16 23:33 PHST- 2026/07/15 12:35 [medline] PHST- 2026/03/17 00:33 [pubmed] PHST- 2026/03/16 23:33 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - BJU70214 [pii] AID - 10.1111/bju.70214 [doi] PST - ppublish SO - BJU Int. 2026 Aug;138(2):186-195. doi: 10.1111/bju.70214. Epub 2026 Mar 16. PMID- 41836594 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260806 LR - 20260920 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 18 DP - 2026 TI - Methylation and Expression Analysis of POU4F2, HOXA9, RBM46, and TSGA10 Genes in Bladder Cancer Using Methyl-Sensitive Restriction Enzyme PCR (MSRE-PCR). PG - 557943 LID - 10.2147/CMAR.S557943 [doi] LID - 557943 AB - PURPOSE: Bladder cancer is a prevalent malignancy, with high recurrence rates for non-muscle invasive cases and significant progression risks. Traditional diagnostic methods, such as cystoscopy and urine cytology, are limited by their invasiveness and low sensitivity for detecting low-grade tumors, respectively. Advances in non-invasive diagnostics focus on biomarkers such as cfDNA and DNA methylation, offering promising tools for early detection. PATIENTS AND METHODS: This study investigated methylation and expression changes in POU4F2, HOXA9, RBM46, and TSGA10 genes in bladder cancer. A total of 22 patients and 30 controls were enrolled, with urine and plasma samples collected for analysis. cfDNA and total RNA were extracted using commercial kits. Methylation was assessed via MSRE-PCR, and gene expression was evaluated with Real-Time PCR. Statistical analysis was performed using GraphPad Prism software, with an unpaired t-test and ANOVA to compare the differences between the cancer and control groups. A p-value of less than 0.05 was considered statistically significant. RESULTS: Urine cfDNA from bladder cancer patients showed significantly higher promoter methylation of POU4F2, HOXA9, RBM46, and TSGA10 compared with controls (approximately 2.2-, 9.0-, 3.6- and 6.1-fold increases; all p < 0.0001), with smaller but still significant differences in plasma (p = 0.0005-0.0278). ROC analysis of urine methylation yielded AUCs of 0.97 for POU4F2, 0.95 for HOXA9, 0.88 for RBM46 and 0.98 for TSGA10 (sensitivities 95-100%, specificities 80-100%; all p < 0.0001). A PCA-derived composite methylation score further improved discrimination (AUC = 0.993, 95% CI 0.974-1.000; sensitivity 100%, specificity 95%; p < 0.001). Consistently, gene expression analysis in urine showed significant downregulation of POU4F2 and HOXA9 ( approximately 7- and 9-fold decreases; p = 0.0099 and p = 0.025) and upregulation of RBM46 and TSGA10 ( approximately 2.5- and 2.3-fold increases; p = 0.0037 and p = 0.0114) in patients versus controls. CONCLUSION: The results indicate that these methylation and expression profiles can be used as non-invasive biomarkers for the early diagnosis of bladder cancer. The use of these methods provides both greater sensitivity and accuracy than traditional methods and can pave the way for the development of more effective screening tests. CI - (c) 2026 Mahdipour et al. FAU - Mahdipour, Shadi AU - Mahdipour S AUID- ORCID: 0000-0002-9016-5655 AD - Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Modarressi, Mohammad Hossein AU - Modarressi MH AD - Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. FAU - Noruzinia, Mehrdad AU - Noruzinia M AD - Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. LA - eng PT - Journal Article DEP - 20260106 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC12988434 OTO - NOTNLM OT - DNA methylation OT - PCR-based methods OT - bladder cancer OT - cell-free DNA OT - non-invasive biomarkers COIS- The author(s) report no conflicts of interest in this work. EDAT- 2026/03/16 21:58 MHDA- 2026/03/16 21:59 PMCR- 2026/01/06 CRDT- 2026/03/16 06:08 PHST- 2025/08/19 00:00 [received] PHST- 2025/12/26 00:00 [accepted] PHST- 2026/03/16 21:58 [pubmed] PHST- 2026/03/16 21:59 [medline] PHST- 2026/03/16 06:08 [entrez] PHST- 2026/01/06 00:00 [pmc-release] AID - 557943 [pii] AID - 10.2147/CMAR.S557943 [doi] PST - epublish SO - Cancer Manag Res. 2026 Jan 6;18:557943. doi: 10.2147/CMAR.S557943. eCollection 2026. PMID- 41832109 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260711 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 5 DP - 2026 May TI - Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence. PG - 111047 LID - S1078-1439(26)00058-X [pii] LID - 10.1016/j.urolonc.2026.111047 [doi] AB - Over the past 2 decades, risk stratification in non-muscle-invasive bladder cancer (NMIBC) has evolved considerably, progressing from simple clinico-pathologic scoring systems to sophisticated, molecular, and artificial intelligence (AI)-driven frameworks. This review summarizes evidence from peer-reviewed studies that evaluate prognostic models incorporating clinical, pathological, molecular, radiomic, or AI-derived variables to predict recurrence, progression, or response to BCG. Although traditional models, such as the EORTC and CUETO tables, are widely used, they demonstrate modest discrimination and limited calibration in contemporary cohorts. Molecular systems, including the 12-gene PCR score and the UROMOL21 classifier, offer deeper biological insight and improved prognostic accuracy. However, they require specialized platforms and lack prospective demonstration of clinical utility. More recent AI-based approaches, including machine learning applied to clinico-pathologic data, deep learning from whole-slide images, and MRI radiomics, have been shown to consistently outperform historical risk tables. These approaches offer improved patient stratification. However, challenges remain regarding reproducibility, interpretability, and integration into clinical pathways. Overall, no single prognostic tool currently fulfills all criteria for broad adoption. Future progress will depend on the development of rigorously validated, multimodal models that integrate clinical, molecular, imaging, and digital pathology data to enable more precise surveillance and treatment decisions for patients with NMIBC. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Mardelli, Celine AU - Mardelli C AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Bertail, Theophile AU - Bertail T AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Tachibana, Isamu AU - Tachibana I AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, GRC 5 Predictive Onco-Uro, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. FAU - Bensalah, Karim AU - Bensalah K AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. FAU - Khene, Zine-Eddine AU - Khene ZE AD - Department of Urology, Rennes University Hospital, Rennes, France; Department of Urology, UT Southwestern Medical Center, Dallas, TX. Electronic address: zineddine.khene@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260314 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology MH - *Artificial Intelligence MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology MH - Radiomics OTO - NOTNLM OT - Artificial intelligence OT - Molecular classifiers OT - Non-muscle-invasive bladder cancer OT - Prognostic models OT - Risk stratification COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/15 05:36 MHDA- 2026/04/21 17:57 CRDT- 2026/03/14 22:54 PHST- 2026/01/12 00:00 [received] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/04/21 17:57 [medline] PHST- 2026/03/15 05:36 [pubmed] PHST- 2026/03/14 22:54 [entrez] AID - S1078-1439(26)00058-X [pii] AID - 10.1016/j.urolonc.2026.111047 [doi] PST - ppublish SO - Urol Oncol. 2026 May;44(5):111047. doi: 10.1016/j.urolonc.2026.111047. Epub 2026 Mar 14. PMID- 41828460 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 5 DP - 2026 Feb 27 TI - Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer. LID - 10.3390/ijms27052237 [doi] LID - 2237 AB - Bladder cancer (BC) is the most common malignancy of the urinary tract. Approximately 75% of cases are non-muscle-invasive BC (NMIBC), while muscle-invasive BC (MIBC) and advanced tumors account for most cancer-specific mortality. Accurate assessment of tumor invasion is essential, as staging variability may lead to inappropriate treatments. Tumor invasion involves several mechanisms including extracellular matrix (ECM) remodeling mediated by metalloproteinases, angiogenesis, and cell adhesions. Masson's trichrome staining (MTS) provides relevant information on ECM composition. This study evaluated the application of machine learning to MTS-stained bladder biopsies to predict muscle invasion. A retrospective analysis of bladder biopsy images obtained from transurethral resections and cystectomies (2022-2024). A total of 702 histological images were analyzed. A convolutional neural network (CNN) was trained to classify tumors as MIBC or NMIBC and model outputs were correlated with clinical variables. The CNN achieved an accuracy of 95.2% in the training set and 90.1% in validation. Model-derived probabilities were significantly associated with tumor grade, lesion size, and muscle invasion. Logistic regression demonstrated a strong association with invasive disease (OR = 0.07, p = 0.017). CNN-based analysis of MTS-stained bladder biopsy images enable accurate prediction of muscle invasion, with potential to improve diagnostic precision. FAU - Parrao, Diego AU - Parrao D AUID- ORCID: 0000-0003-0411-0672 AD - School of Medicine, Universidad de O'Higgins, Rancagua 2820000, Chile. FAU - Gallegos, Hector AU - Gallegos H AUID- ORCID: 0000-0002-1339-4358 AD - Department of Urology, Hospital Sotero del Rio, Santiago 8207257, Chile. FAU - Ruz, Karin AU - Ruz K AD - Department of Pathology, Hospital Dr. Franco Ravera Zunino, Rancagua 2820000, Chile. FAU - Lay, Roman AU - Lay R AD - School of Medicine, Universidad de O'Higgins, Rancagua 2820000, Chile. FAU - Saavedra, Catalina AU - Saavedra C AUID- ORCID: 0009-0002-9271-8070 AD - School of Medicine, Universidad de O'Higgins, Rancagua 2820000, Chile. FAU - Guerrero, Renata AU - Guerrero R AD - School of Medicine, Universidad de O'Higgins, Rancagua 2820000, Chile. FAU - Larranaga, Matias AU - Larranaga M AUID- ORCID: 0009-0006-2146-5677 AD - Department of Urology, Hospital Dr. Franco Ravera Zunino, Rancagua 2820000, Chile. FAU - Lindsay, Carolina B AU - Lindsay CB AD - Research Department, Hospital Dr. Franco Ravera Zunino, Rancagua 2820000, Chile. FAU - Bravo, Juan Cristobal AU - Bravo JC AUID- ORCID: 0000-0001-8581-7658 AD - Department of Urology, Hospital Dr. Franco Ravera Zunino, Rancagua 2820000, Chile. LA - eng PT - Journal Article DEP - 20260227 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (trichrome stain) RN - TDQ283MPCW (Eosine Yellowish-(YS)) RN - 82-94-0 (Methyl Green) RN - 0 (Azo Compounds) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Invasiveness MH - *Artificial Intelligence MH - Convolutional Neural Networks MH - Female MH - Non-Muscle Invasive Bladder Neoplasms MH - *Eosine Yellowish-(YS) MH - *Methyl Green MH - Male MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Neural Networks, Computer MH - Staining and Labeling/methods MH - Azo Compounds PMC - PMC12984275 OTO - NOTNLM OT - Masson's trichrome staining OT - bladder cancer OT - convolutional neural network OT - muscle invasive COIS- The authors declare no conflicts of interest. EDAT- 2026/03/14 06:33 MHDA- 2026/03/14 06:34 PMCR- 2026/02/27 CRDT- 2026/03/14 01:05 PHST- 2025/12/20 00:00 [received] PHST- 2026/01/15 00:00 [revised] PHST- 2026/02/05 00:00 [accepted] PHST- 2026/03/14 06:34 [medline] PHST- 2026/03/14 06:33 [pubmed] PHST- 2026/03/14 01:05 [entrez] PHST- 2026/02/27 00:00 [pmc-release] AID - ijms27052237 [pii] AID - ijms-27-02237 [pii] AID - 10.3390/ijms27052237 [doi] PST - epublish SO - Int J Mol Sci. 2026 Feb 27;27(5):2237. doi: 10.3390/ijms27052237. PMID- 41828319 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 5 DP - 2026 Feb 24 TI - Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma. LID - 10.3390/ijms27052089 [doi] LID - 2089 AB - Urothelial carcinoma (UC) of the bladder exhibits low- and high-grade papillary forms with distinct prognoses. High mobility group proteins (HMGA1, HMGA2, HMGB1) and miR-106a-5p are involved in tumor progression, but their interplay in UC remains incompletely understood. The aim of this study was to compare the expression of these parameters in low- and high-grade papillary UC. Tissue samples from 80 patients (40 low-grade and 40 high-grade) undergoing transurethral resection or cystectomy were analyzed, with control samples consisting of tumor-adjacent tissues without histopathological alterations obtained from the same patients. HMGA1, HMGA2, and HMGB1 protein expression was assessed immunohistochemically. Gene expression was quantified by real-time PCR, and miR-106a-5p levels were measured by droplet digital PCR. Statistical analysis was conducted using Statistica 13.3, applying one-way ANOVA with Tukey's post hoc test and correlation analysis, with p < 0.05 considered significant. Expression of HMGA1 and HMGB1 was reduced in low-grade papillary urothelial carcinoma compared to control tissues, whereas both proteins were significantly increased in high-grade lesions. HMGA2 expression was minimal in low-grade tumors but partially restored in high-grade tumors. Analysis revealed the highest levels of miR-106a-5p in normal urothelium, slightly decreased in low-grade tumors, and significantly reduced in high-grade cancers. HMG proteins and miR-106a-5p demonstrate distinct expression patterns in low- versus high-grade papillary UC, which correlates with tumor aggressiveness. These molecules may serve as diagnostic and prognostic biomarkers. Their potential as therapeutic targets requires further mechanistic and translational investigation. FAU - Domian, Natalia AU - Domian N AD - Department of Histology and Cytophysiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Smereczanska, Magdalena AU - Smereczanska M AD - Department of Histology and Cytophysiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Mrugacz, Malgorzata AU - Mrugacz M AUID- ORCID: 0000-0002-4296-2203 AD - Laboratory of Eye Rehabilitation, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Mlynarczyk, Grzegorz AU - Mlynarczyk G AUID- ORCID: 0000-0002-1453-8501 AD - Department of Urology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Kasacka, Irena AU - Kasacka I AUID- ORCID: 0000-0003-2954-942X AD - Department of Histology and Cytophysiology, Medical University of Bialystok, 15-089 Bialystok, Poland. LA - eng GR - Statutory funds/Medical University of Bialystok/ PT - Comparative Study PT - Journal Article DEP - 20260224 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (MicroRNAs) RN - 0 (MIRN106 microRNA, human) RN - 0 (HMGB1 Protein) RN - 124544-67-8 (HMGA1a Protein) RN - 0 (HMGA2 Protein) RN - 0 (HMGB1 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (HMGA1 protein, human) RN - 0 (HMGA2 protein, human) SB - IM MH - Humans MH - *MicroRNAs/genetics/metabolism MH - Male MH - Female MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Aged MH - Middle Aged MH - Neoplasm Grading MH - *HMGB1 Protein/genetics/metabolism MH - *Carcinoma, Papillary/pathology/genetics/metabolism MH - Non-Muscle Invasive Bladder Neoplasms MH - *HMGA1a Protein/genetics/metabolism MH - *HMGA2 Protein/genetics/metabolism MH - Biomarkers, Tumor/genetics/metabolism PMC - PMC12984743 OTO - NOTNLM OT - HMGA1 OT - HMGA2 OT - HMGB1 OT - bladder cancer OT - miR-106a-5p OT - tumor grading OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2026/03/14 06:34 MHDA- 2026/03/14 06:35 PMCR- 2026/02/24 CRDT- 2026/03/14 01:05 PHST- 2026/01/22 00:00 [received] PHST- 2026/02/13 00:00 [revised] PHST- 2026/02/19 00:00 [accepted] PHST- 2026/03/14 06:35 [medline] PHST- 2026/03/14 06:34 [pubmed] PHST- 2026/03/14 01:05 [entrez] PHST- 2026/02/24 00:00 [pmc-release] AID - ijms27052089 [pii] AID - ijms-27-02089 [pii] AID - 10.3390/ijms27052089 [doi] PST - epublish SO - Int J Mol Sci. 2026 Feb 24;27(5):2089. doi: 10.3390/ijms27052089. PMID- 41826518 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260807 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 6 DP - 2026 Jun TI - HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients. PG - 5470-5477 LID - 10.1245/s10434-026-19268-y [doi] AB - BACKGROUND: Urinary bladder cancer (UBC) is a leading cause of cancer-related morbidity and mortality worldwide, but current diagnostic methods are invasive and prone to false-negatives. This study aimed to evaluate the diagnostic and prognostic value of HMGB1 protein expression in urothelial carcinoma of the bladder using three distinct methods (serum ELISA, tissue IHC, and mRNA expression) via reverse transcription polymerase chain reaction (RT-PCR) and establishing their correlation. METHODS: This single-center prospective observational study enrolled adults planned for transurethral resection of bladder tumor (TURBT) from March 2023 to April 2025 at Banaras Hindu University, India. The study enrolled 64 UBC patients and 21 control subject. For analysis, 5 ml of blood and cystoscopic guided tumor tissue were retrieved from UBC patients undergoing TURBT and normal bladder urothelium, and 5 mL blood was retrieved from noncancerous subjects (controls) undergoing cystoscopy for various reasons. Clinicopathologic features including tumor stage (T), grade, risk group, and imaging data also were analyzed with respect to their correlation with HMGB1 expression. RESULTS: Levels of HMGB1 were significantly elevated in the UBC patients compared with the control patients (serum ELISA [p < 0.001], mRNA [p = 0.002], IHC [p = 0.013]). Expression of HMGB1 correlated significantly with tumor stage (T) and grade, with higher levels observed in muscle-invasive bladder cancer (MIBC) than in non-muscle-invasive bladder cancer (NMIBC). Notably, HMGB1 expression was highest in very-high-risk NMIBC patients. However, correlations with age, sex, MRI-VIRADS score, tumor size, and number of growths were statistically insignificant. CONCLUSIONS: Elevated levels of HMGB1 correlated with advanced tumor stage, high grade, and MIBC, suggesting its utility in early detection and risk stratification, making it a non-invasive diagnostic and prognostic biomarker for UBC. CI - (c) 2026. Society of Surgical Oncology. FAU - Data, Sahil AU - Data S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Trivedi, Sameer AU - Trivedi S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Singh, Yashasvi AU - Singh Y AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. yashasvisingh075@gmail.com. FAU - Kumar, Ujwal AU - Kumar U AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Lalit AU - Kumar L AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Shankhwar, S N AU - Shankhwar SN AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Srivastava, Aviral AU - Srivastava A AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Anil AU - Kumar A AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kar, Amrita Ghosh AU - Kar AG AD - Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Singh, Rajesh AU - Singh R AD - Department of Molecular and Human Genetics, Institute of Sciences, Banaras Hindu University, Varanasi, India. FAU - Zarekar, Rupesh AU - Zarekar R AD - Department of Molecular and Human Genetics, Institute of Sciences, Banaras Hindu University, Varanasi, India. LA - eng PT - Journal Article PT - Observational Study DEP - 20260313 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Biomarkers, Tumor) RN - 0 (HMGB1 Protein) RN - 0 (HMGB1 protein, human) SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Biomarkers, Tumor/metabolism/genetics/blood MH - *Carcinoma, Transitional Cell/surgery/diagnosis/pathology/metabolism MH - Case-Control Studies MH - Follow-Up Studies MH - *HMGB1 Protein/metabolism/genetics/blood MH - Prognosis MH - Prospective Studies MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/genetics/metabolism/pathology/surgery OTO - NOTNLM OT - NMIBC OT - HMGB1 OT - MIBC OT - Non-invasive diagnostic markers OT - Urinary bladder carcinoma (UBC) OT - Urothelial carcinoma (UC) COIS- Disclosure: There are no conflicts of interest. EDAT- 2026/03/14 06:34 MHDA- 2026/05/19 06:30 CRDT- 2026/03/14 00:23 PHST- 2025/08/27 00:00 [received] PHST- 2026/02/04 00:00 [accepted] PHST- 2026/05/19 06:30 [medline] PHST- 2026/03/14 06:34 [pubmed] PHST- 2026/03/14 00:23 [entrez] AID - 10.1245/s10434-026-19268-y [pii] AID - 10.1245/s10434-026-19268-y [doi] PST - ppublish SO - Ann Surg Oncol. 2026 Jun;33(6):5470-5477. doi: 10.1245/s10434-026-19268-y. Epub 2026 Mar 13. PMID- 41825577 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 222 DP - 2026 Jun TI - Advances in intravesical therapy for non-muscle-invasive bladder cancer. PG - 105271 LID - S1040-8428(26)00158-7 [pii] LID - 10.1016/j.critrevonc.2026.105271 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) accounts for roughly 75% of newly diagnosed bladder cancer and associates with high risk of recurrence and progression. Intravesical therapy remains the cornerstone of NMIBC management following transurethral resection of bladder tumor (TURBT). For low-risk NMIBC, immediate single instillation of chemotherapy after TURBT effectively reduces recurrence. Intermediate-risk patients could benefit from either intravesical chemotherapy or Bacillus Calmette-Guerin (BCG) instillation, with emerging therapies such as UGN-102 chemoablation showing promise. For high/very high-risk NMIBC, full-dose, 3-year BCG instillation remains the standard of care, However, global BCG shortages and treatment failures have prompted the need for alternative strategies. Optimization of BCG regimens, such as two induction courses, may preserve efficacy while improving feasibility. Moreover, alternative agents such as sequential gemcitabine and docetaxel instillation have demonstrated favorable outcomes in both BCG-naive and BCG-unresponsive patients. For those with BCG failure, a number of novel therapies are under active investigation. Gene therapy (nadofaragene firadenovec), oncolytic viral therapy (CG0070), interleukin-15 superagonist (Nogapendekin alfa-inbakicept), and innovative drug delivery systems (TAR-200) have shown encouraging clinical potential in this population. This review provides an overview of current intravesical treatment strategies for NMIBC across different risk groups and highlights promising new approaches aimed at overcoming the limitations of BCG therapy. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Tang, Yanfeng AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. FAU - Wang, Ling AU - Wang L AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. FAU - Liu, Haoyang AU - Liu H AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. FAU - Zhu, Qiyu AU - Zhu Q AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. FAU - Xu, Chenhao AU - Xu C AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. FAU - Zeng, Hao AU - Zeng H AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. Electronic address: kucaizeng@163.com. FAU - Chen, Junru AU - Chen J AD - Department of Urology, Institute of Urology, West China Hospital,, Sichuan University, Chengdu, Sichuan, PR China. Electronic address: jrchen@scu.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20260311 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - 0 (BCG Vaccine) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - Administration, Intravesical MH - Genetic Therapy MH - Transurethral Resection of Bladder MH - BCG Vaccine/therapeutic use/administration & dosage MH - *Urinary Bladder Neoplasms/therapy/pathology MH - *Antineoplastic Agents/administration & dosage/therapeutic use OTO - NOTNLM OT - BCG-unresponsive OT - Immune checkpoint inhibitor OT - Intravesical chemotherapy OT - Non-muscle-invasive bladder cancer OT - Novel intravesical therapies COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/14 00:31 MHDA- 2026/05/13 00:29 CRDT- 2026/03/13 20:12 PHST- 2025/06/07 00:00 [received] PHST- 2026/02/21 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/05/13 00:29 [medline] PHST- 2026/03/14 00:31 [pubmed] PHST- 2026/03/13 20:12 [entrez] AID - S1040-8428(26)00158-7 [pii] AID - 10.1016/j.critrevonc.2026.105271 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2026 Jun;222:105271. doi: 10.1016/j.critrevonc.2026.105271. Epub 2026 Mar 11. PMID- 41824818 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 105 IP - 11 DP - 2026 Mar 13 TI - Impact of physiological ability and surgical stress score on postoperative complications in patients undergoing surgery for non-muscle-invasive bladder cancer. PG - e47699 LID - 10.1097/MD.0000000000047699 [doi] LID - e47699 AB - This study aims to evaluate the predictive value of the physiological ability and surgical stress (E-PASS) scoring system for postoperative complications in patients undergoing surgery for non-muscle-invasive bladder cancer (NMIBC). This retrospective study included patients with NMIBC who underwent transurethral resection of bladder tumor. The E-PASS score was calculated for each patient. Postoperative in-hospital complications were recorded and graded according to the Clavien-Dindo classification. Logistic regression analysis was used to identify independent risk factors, and receiver operating characteristic curves were constructed to assess predictive performance. Significant differences were observed between the two groups in intraoperative blood loss, tumor differentiation grade, and the E-PASS scores (all P < .05). Multivariate analysis identified poor differentiation grade (odds ratio [OR] = 1.625), greater intraoperative blood loss (OR = 1.239), preoperative risk score (OR = 1.442), surgical stress score (OR = 1.376), and comprehensive risk score (CRS; OR = 1.272) as independent risk factors for in-hospital complications (all P < .05). Receiver operating characteristic analysis demonstrated high predictive accuracy for the E-PASS components: the area under the curve was 0.926 for preoperative risk score (sensitivity 85.71%, specificity 85.77%), 0.915 for surgical stress score (sensitivity 71.43%, specificity 89.29%), and 0.942 for CRS (sensitivity 78.57%, specificity 89.29%). Furthermore, at 24 and 36 months post-surgery, the recurrence rate was significantly lower in the non-complication group compared to the complication group (P < .05). The E-PASS scoring system, particularly the CRS, is a useful tool for predicting postoperative complications in patients undergoing surgery for NMIBC. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Bai, Junchao AU - Bai J AUID- ORCID: 0009-0009-7359-7868 AD - Urology Department, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Jinhua, Zhejiang, China. LA - eng GR - Y202045823/Study on the Polymorphisms of the Renal Interstitial Inflammation Genes CSF-1 and CD44 and the Susceptibility to Renal Calcium Oxalate Stones/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Postoperative Complications/epidemiology/etiology MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms/surgery MH - Male MH - Retrospective Studies MH - Transurethral Resection of Bladder MH - Risk Factors MH - Aged MH - ROC Curve MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery MH - *Stress, Physiological MH - Blood Loss, Surgical PMC - PMC12991610 OTO - NOTNLM OT - complication OT - non-muscle-invasive bladder cancer OT - physiological ability OT - predictor OT - surgical stress score COIS- The author has no funding and conflicts of interest to disclose. EDAT- 2026/03/13 19:31 MHDA- 2026/03/13 19:32 PMCR- 2026/03/13 CRDT- 2026/03/13 15:13 PHST- 2025/11/13 00:00 [received] PHST- 2026/01/27 00:00 [accepted] PHST- 2026/03/13 19:32 [medline] PHST- 2026/03/13 19:31 [pubmed] PHST- 2026/03/13 15:13 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - 00005792-202603130-00014 [pii] AID - MD-D-25-16100 [pii] AID - 10.1097/MD.0000000000047699 [doi] PST - ppublish SO - Medicine (Baltimore). 2026 Mar 13;105(11):e47699. doi: 10.1097/MD.0000000000047699. PMID- 41823129 OWN - NLM STAT- MEDLINE DCOM- 20260805 LR - 20260805 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 3 DP - 2026 Aug TI - Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in bladder cancer: Insight from a prospective tertiary care study. PG - 364-369 LID - 10.1177/03915603261429445 [doi] AB - BACKGROUND: Multiparametric magnetic resonance imaging (mp-MRI) has emerged as a promising technique for evaluating the extent of bladder cancer, particularly for assessing muscle invasion. The Vesical Imaging Reporting and Data System (VI-RADS), introduced in 2018, aims to standardize the interpretation of mp-MRI for staging bladder tumors. This study investigates the diagnostic accuracy of VI-RADS in predicting detrusor muscle involvement preoperatively. OBJECTIVE: To assess the diagnostic performance of VI-RADS scoring in determining muscle invasion in bladder cancer patients prior to surgical intervention. METHODS: This prospective study enrolled 62 patients between June 2021 and April 2023 who presented with bladder masses. Each underwent mp-MRI followed by surgical treatment, including either TURBT or radical cystectomy. Two radiologists independently evaluated images using VI-RADS scoring. The results were compared with final histopathological findings to determine diagnostic accuracy. RESULTS: VI-RADS scores of 4 and 5 were observed in 10 (16%) and 19 (30.6%) patients respectively; scores of 3, 2, and 1 were assigned to 3 (4.8%), 25 (40.3%), and 5 (8.0%) patients, respectively. Histopathological evaluation confirmed muscle invasion in 29 patients (46.77%) and non-muscle-invasive disease in 33 (53.22%). The mp-MRI demonstrated a sensitivity of 93.10%, specificity of 93.94%, and an overall accuracy of 93.54% in detecting muscle invasion. CONCLUSION: Mp-MRI interpreted using the VI-RADS system offers more than 90% sensitivity and specificity for detecting muscle invasion in bladder cancer. VI-RADS may serves as a valuable tool for preoperative staging, potentially optimizing treatment planning and reducing unnecessary restaging TURBT. FAU - Shukla, Anupam AU - Shukla A AUID- ORCID: 0009-0008-3277-6977 AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Hiralal AU - Hiralal AD - Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Raj, Himanshu AU - Raj H AUID- ORCID: 0009-0004-5481-9860 AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Surekha, Sanjoy AU - Surekha S AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Singh, Uday Pratap AU - Singh UP AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. LA - eng PT - Journal Article DEP - 20260313 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - Neoplasm Invasiveness MH - Female MH - Male MH - Middle Aged MH - Aged MH - *Multiparametric Magnetic Resonance Imaging MH - Reproducibility of Results MH - *Muscle, Smooth/pathology/diagnostic imaging MH - Transurethral Resection of Bladder MH - Magnetic Resonance Imaging MH - Non-Muscle Invasive Bladder Neoplasms MH - Data Systems OTO - NOTNLM OT - MIBC : Muscle invasive bladder cancer OT - NMIBC : Non muscle invasive bladder cancer OT - TURBT: Transurethral resection of bladder tumor OT - VI-RADS: Vesical imaging reporting and data system OT - mp-MRI: Multiparametric magnetic resonance imaging COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/03/13 12:41 MHDA- 2026/08/05 17:37 CRDT- 2026/03/13 06:42 PHST- 2026/08/05 17:37 [medline] PHST- 2026/03/13 12:41 [pubmed] PHST- 2026/03/13 06:42 [entrez] AID - 10.1177/03915603261429445 [doi] PST - ppublish SO - Urologia. 2026 Aug;93(3):364-369. doi: 10.1177/03915603261429445. Epub 2026 Mar 13. PMID- 41821902 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260313 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Tertiary lymphoid structures in genitourinary cancers: a comprehensive review. PG - 1787200 LID - 10.3389/fonc.2026.1787200 [doi] LID - 1787200 AB - Tertiary lymphoid structures (TLSs) are lymphoid cell clusters that form in non-lymphoid tissues in response to chronic inflammation and function as sites for localized, antigen-specific immune responses, potentially enhancing anti-tumor immunity. This review examines TLS presence, composition, and clinical significance across genitourinary (GU) cancers to evaluate their potential as prognostic and therapeutic targets. In prostate cancer, TLSs are infrequently found due to a typically immunologically inactive tumor microenvironment (TME), but when present, they correlate with improved outcomes and reduced recurrence, especially when structurally mature with active germinal centers (GCs). Bladder cancer, in contrast, demonstrates increased TLS activity, particularly in high-grade disease, with high TLS density associated with superior responses to Bacillus Calmette-Guerin (BCG) therapy and anti-PD-L1 treatment. In testicular seminomas, TLSs have been associated with a more favorable prognosis, whereas non-seminomatous germ cell tumors demonstrate TLS suppression driven by SERPINB9-mediated downregulation of chemokines that promote their development. In clear cell renal cell carcinoma (ccRCC), TLSs correlate with improved survival and enhanced immunotherapy responses, although elevated CXCL13 expression may paradoxically signal more aggressive disease. Unlike ccRCC, TLSs are infrequent in papillary and chromophobe RCC, reflecting a less-inflamed TME that likely contributes to reduced immunotherapy responsiveness and prognostic value. TLSs in penile squamous cell carcinomas show enhanced immune infiltration and improved overall survival (OS) independent of stage. Notably, mature TLSs are key for effective anti-tumor immunity, whereas immature TLSs may fail to generate an adequate response. Collectively, these findings highlight TLSs as prognostic biomarkers with prognostic value and therapeutic potential in GU malignancies. CI - Copyright (c) 2026 Abreu, Viera Plasencia, Iribarren, Wegner, Nuraj, Davicioni, Bahmad and Shahait. FAU - Abreu, Alvaro AU - Abreu A AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. FAU - Viera Plasencia, Alejandra AU - Viera Plasencia A AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. FAU - Iribarren, Mercy AU - Iribarren M AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. FAU - Wegner, Carter AU - Wegner C AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. FAU - Nuraj, Joana AU - Nuraj J AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. FAU - Davicioni, Elai AU - Davicioni E AD - Veracyte, Inc., South San Francisco, CA, United States. FAU - Bahmad, Hisham F AU - Bahmad HF AD - Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, United States. FAU - Shahait, Mohammed AU - Shahait M AD - Department of Urology, University of California, Irvine, Irvine, CA, United States. LA - eng PT - Journal Article PT - Review DEP - 20260225 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12975446 OTO - NOTNLM OT - bladder cancer OT - genitourinary cancers OT - kidney tumors OT - penile cancer OT - prostate cancer OT - review OT - tertiary lymphoid structures OT - testicular cancer COIS- Author ED was employed by Veracyte, Inc. The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author MS declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2026/03/13 06:52 MHDA- 2026/03/13 06:53 PMCR- 2026/02/25 CRDT- 2026/03/13 04:46 PHST- 2026/01/13 00:00 [received] PHST- 2026/02/07 00:00 [revised] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/03/13 06:53 [medline] PHST- 2026/03/13 06:52 [pubmed] PHST- 2026/03/13 04:46 [entrez] PHST- 2026/02/25 00:00 [pmc-release] AID - 10.3389/fonc.2026.1787200 [doi] PST - epublish SO - Front Oncol. 2026 Feb 25;16:1787200. doi: 10.3389/fonc.2026.1787200. eCollection 2026. PMID- 41817750 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Mar 12 TI - Prognostic value of pathological T stage and independent survival benefit of adjuvant chemotherapy for upper tract urothelial carcinoma: real-world data from a high-volume Vietnamese center. LID - 233 [pii] LID - 10.1007/s00345-026-06331-2 [doi] AB - PURPOSE: This study evaluated oncological outcomes after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) at a high-volume tertiary center in Vietnam. METHODS: We performed a retrospective analysis of 134 consecutive patients with UTUC who underwent open or laparoscopic RNU at Cho Ray Hospital from 2017 to 2023. The primary outcome was overall survival (OS); secondary outcomes were metastasis-free survival (MFS) and the effect of adjuvant chemotherapy (AC) in patients with >/=pT2 and/or node-positive disease. Survival was assessed using Kaplan-Meier methods, and independent prognostic factors were identified with multivariate Cox regression. RESULTS: The median age was 65 years, and 60.4% were male. Advanced disease was common, with 78.4% of patients presenting with >/=pT2 tumors. Lymph node metastasis was identified in 9.7% of cases. OS rates at 1 and 3 years were 82.7% and 59.1%, respectively; corresponding MFS rates were 77.8% and 58.8%. Pathological T stage independently predicted both OS and MFS. Compared with pT1 disease, mortality risk increased markedly in pT2 (HR 5.95, 95% CI 1.31-27.04) and >/=pT3 (HR 19.20, 95% CI 4.29-85.48). AC provided a significant independent survival benefit, reducing the risk of death by more than half (HR 0.49, 95% CI 0.25-0.95) and decreasing metastatic risk (HR 0.25, 95% CI 0.11-0.55). CONCLUSION: Pathological T stage remains a powerful independent prognostic factor after RNU. AC was associated with significant improvements in both survival and metastasis-free outcomes in advanced-stage UTUC. These findings offer robust real-world evidence from a major center in a low- to middle-income country and support current international guideline recommendations. FAU - Thai, Kinh Luan AU - Thai KL AD - University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. thaikinhluan@ump.edu.vn. AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. thaikinhluan@ump.edu.vn. FAU - Le, Nho Tinh AU - Le NT AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Do, Hoang Tung AU - Do HT AD - University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. FAU - Vu, Duc Huy AU - Vu DH AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Tiong, Ho Yee AU - Tiong HY AD - National University Hospital, Singapore, Singapore. FAU - Nguyen, David-Dan AU - Nguyen DD AD - University of Toronto, Toronto, ON, Canada. FAU - Nguyen, Tuan Thanh AU - Nguyen TT AD - University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Ngo, Xuan Thai AU - Ngo XT AD - University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Thai, Sam Minh AU - Thai SM AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. LA - eng PT - Journal Article DEP - 20260312 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Male MH - Chemotherapy, Adjuvant MH - Vietnam MH - Prognosis MH - *Carcinoma, Transitional Cell/pathology/mortality/drug therapy/surgery MH - Retrospective Studies MH - *Ureteral Neoplasms/pathology/mortality/drug therapy/surgery MH - Neoplasm Staging MH - *Kidney Neoplasms/pathology/mortality/drug therapy/surgery MH - Aged MH - Nephroureterectomy MH - Female MH - Survival Rate MH - Middle Aged OTO - NOTNLM OT - Adjuvant chemotherapy OT - Radical nephroureterectomy OT - Survival outcomes OT - Upper tract urothelial carcinoma OT - Vietnam COIS- Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethical approval and consent to participate: This research was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the University of Medicine and Pharmacy at Ho Chi Minh City, with Approval No. 1218/HDDD-DHYD, dated December 11, 2023. The Institutional Review Board of the University of Medicine and Pharmacy at Ho Chi Minh City waived the need for individual informed consent as this was a retrospective study using anonymized data. Consent for publication: Not applicable. EDAT- 2026/03/12 18:53 MHDA- 2026/06/27 12:36 CRDT- 2026/03/12 12:16 PHST- 2025/11/16 00:00 [received] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/12 18:53 [pubmed] PHST- 2026/03/12 12:16 [entrez] AID - 10.1007/s00345-026-06331-2 [pii] AID - 10.1007/s00345-026-06331-2 [doi] PST - epublish SO - World J Urol. 2026 Mar 12;44(1):233. doi: 10.1007/s00345-026-06331-2. PMID- 41815372 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260312 LR - 20260813 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 13 IP - 1 DP - 2026 Jan TI - A multiregional study of presentation and outcomes in upper tract urothelial cancer: Data from East Asia and Europe. PG - 67-75 LID - 10.1016/j.ajur.2025.03.015 [doi] AB - OBJECTIVE: Clinical features of upper tract urothelial carcinoma (UTUC) vary widely across countries. We aimed to provide clinical observations and compare oncological outcomes among regions in East Asia and Europe. METHODS: This retrospective study (March 2000 to July 2020) included 664 UTUC patients undergoing radical nephroureterectomy in China, Japan, the Republic of Korea, and Germany. Cohorts from China comprised patients from the Hong Kong Special Administrative Region and the Taiwan region, respectively. Demographic and clinicopathological parameters were analyzed. Continuous variables were analyzed using the Student's t-test, and categorical variables were assessed using the Pearson's chi-square test. The Cox proportional hazards model was employed to evaluate overall survival (OS), cancer-specific survival (CSS), and bladder recurrence-free survival across regions and various parameters. RESULTS: Females had a higher proportion of patients than males only in Taiwan, China. Few patients received preoperative ureteroscopic biopsy prior to radical surgery in Seoul, the Republic of Korea. In the multivariate analysis, patients' regional origin was not associated with worse OS and CSS. Older age, multifocal tumors, high pT stage (pT4), positive lymphovascular invasion, and distant metastasis were associated with worse OS. High pT stage (pT4) and distant metastasis were independent factors leading to worse CSS. Patients' regional origin (Seoul, the Republic of Korea; Schleswig-Holstein, Germany; and Chiba, Japan) was associated with worse bladder recurrence-free survival. The preoperative ureteroscopic biopsy did not increase the intravesical recurrence. CONCLUSION: This international observational study revealed variations in the epidemiological distributions and practice patterns among UTUC patients in China, Japan, the Republic of Korea, and Germany. Cohorts from China comprised patients from the Hong Kong Special Administrative Region and the Taiwan region, respectively. However, ethnic and regional differences did not affect OS and CSS after radical nephroureterectomy. CI - (c) 2026 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V. FAU - Chiu, Tai-Hua AU - Chiu TH AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China. FAU - Wei, Tzu-Chun AU - Wei TC AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, China. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Kashiwa Hospital, Chiba, Japan. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Yee, Chi Hang AU - Yee CH AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, the Republic of Korea. FAU - Cho, Sung Yong AU - Cho SY AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, the Republic of Korea. FAU - Kramer, Mario Wolfgang AU - Kramer MW AD - Department of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Lubeck, Germany. FAU - Ho, Pei-Shan AU - Ho PS AD - Department of Oral Hygiene, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China. AD - School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China. AD - Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China. FAU - Huang, Yu-Ting AU - Huang YT AD - Division of Medical Statistics and Bioinformatics, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China. FAU - Lee, Hsiang-Ying AU - Lee HY AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China. LA - eng PT - Journal Article DEP - 20250607 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC12974158 OTO - NOTNLM OT - Epidemiology OT - Ethnicity OT - Nephroureterectomy OT - Prognostic factors OT - Survival OT - Upper tract urothelial cancer OT - Ureteroscopy COIS- The authors declare no conflict of interest. EDAT- 2026/03/12 07:03 MHDA- 2026/03/12 07:04 PMCR- 2025/06/07 CRDT- 2026/03/12 05:06 PHST- 2024/10/31 00:00 [received] PHST- 2025/03/18 00:00 [accepted] PHST- 2026/03/12 07:04 [medline] PHST- 2026/03/12 07:03 [pubmed] PHST- 2026/03/12 05:06 [entrez] PHST- 2025/06/07 00:00 [pmc-release] AID - S2214-3882(25)00061-X [pii] AID - 10.1016/j.ajur.2025.03.015 [doi] PST - ppublish SO - Asian J Urol. 2026 Jan;13(1):67-75. doi: 10.1016/j.ajur.2025.03.015. Epub 2025 Jun 7. PMID- 41815366 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260312 LR - 20260813 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 13 IP - 1 DP - 2026 Jan TI - Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review. PG - 11-23 LID - 10.1016/j.ajur.2024.12.008 [doi] AB - OBJECTIVE: This review aims to explore the risk factors for recurrence of non-muscle-invasive bladder cancer (NMIBC) and evaluate current prevention strategies to provide valuable insights for future clinical management. By systematically analyzing various clinical and pathological characteristics, this review examines their relationship with NMIBC recurrence and proposes effective preventive measures for these factors. METHODS: A systematic literature search was conducted through PubMed and Web of Science to identify studies that focus on the risk factors for NMIBC recurrence. A systematic review was conducted to evaluate the statistical significance of various factors influencing recurrence, such as age, sex, body mass index (BMI), diabetes, smoking, surgical techniques, and tumor-specific characteristics. Additionally, current preventive strategies and treatments, such as intravesical drug instillation, adjuvant chemotherapy, and immunotherapy, were assessed. RESULTS: The following factors significantly influence the recurrence risk of NMIBC: age (older patients have a higher recurrence risk due to weakened immune responses and more comorbidities), sex (women tend to experience more aggressive forms and a poorer prognosis following recurrence), BMI and diabetes (obesity and diabetes worsen immune responses and increase inflammation, contributing to higher recurrence rates), smoking (smokers face a higher recurrence risk due to carcinogenic exposure, but quitting significantly reduces the risk), surgical techniques (incomplete transurethral resection of bladder tumor or inadequate postoperative treatments, e.g., Bacillus Calmette-Guerin [BCG], increase recurrence), tumor characteristics (high-grade and large tumors [especially multifocal] have a higher risk of recurrence), immunotherapy and chemotherapy (BCG is standard for high-risk patients, while newer treatments, such as immune checkpoint inhibitors [e.g., pembrolizumab] and chemotherapy [e.g., gemcitabine with docetaxel], are emerging for BCG-unresponsive cases), and biomarkers (biomarkers like tumor DNA in urine or circulating tumor DNA in blood can facilitate early detection of recurrence and help predict recurrence risk). CONCLUSION: NMIBC recurrence is a complex process influenced by multiple factors. Identifying the risk factors associated with recurrence, such as age, sex, BMI, diabetes, smoking, and surgical techniques, allows for personalized treatment strategies. BCG treatment remains the standard for preventing recurrence, but new immunotherapies and chemotherapy combinations provide hope for BCG-unresponsive patients. Early detection, effective postoperative treatment, and individualized management strategies are key to reducing recurrence and improving patient quality of life. Future research should continue exploring new treatment methods, molecular biomarkers, and the role of immunotherapy in mitigating NMIBC recurrence. CI - (c) 2026 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V. FAU - Liu, Wuhao AU - Liu W AD - Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Xiao, Jiafu AU - Xiao J AD - Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Zou, Junrong AU - Zou J AD - Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - He, Zhihua AU - He Z AD - Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20250524 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC12974208 OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - Prevention OT - Recurrence OT - Risk factors COIS- The authors declare no conflict of interest. EDAT- 2026/03/12 07:03 MHDA- 2026/03/12 07:04 PMCR- 2025/05/24 CRDT- 2026/03/12 05:06 PHST- 2024/09/23 00:00 [received] PHST- 2024/12/25 00:00 [accepted] PHST- 2026/03/12 07:04 [medline] PHST- 2026/03/12 07:03 [pubmed] PHST- 2026/03/12 05:06 [entrez] PHST- 2025/05/24 00:00 [pmc-release] AID - S2214-3882(25)00052-9 [pii] AID - 10.1016/j.ajur.2024.12.008 [doi] PST - ppublish SO - Asian J Urol. 2026 Jan;13(1):11-23. doi: 10.1016/j.ajur.2024.12.008. Epub 2025 May 24. PMID- 41809805 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260311 LR - 20260813 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 2 DP - 2026 Feb 28 TI - Derivation and validation of the SLNA score: a tumor size-location-number-apperance model to predict transurethral resection of bladder tumor (TURBT) complexity. PG - 58 LID - 10.21037/tau-2025-736 [doi] LID - 58 AB - BACKGROUND: Transurethral resection of bladder tumor (TURBT) is the core surgical procedure for the diagnosis and treatment of bladder cancer, with significant variations in its surgical complexity that directly affect the difficulty of surgical operation, the risk of perioperative complications, and the efficacy of postoperative management. This study aimed to develop a scoring system to evaluate the complexity of TURBT and provide a reference for preoperative assessment and postoperative management of bladder cancer patients. METHODS: A retrospective analysis was performed on 388 patients who underwent TURBT from January 2022 to June 2023. The complexity of TURBT was defined based on serious complications (Clavien-Dindo >/=3), operation time >50 minutes, and incomplete resection. A nomogram was constructed to predict complexity based on factors such as tumor size, number of tumors, tumor location, and recurrence. The entire cohort (n=388) was randomly partitioned into: a development/training set (70%, n=272) for model construction and an internal validation/testing set (30%, n=116) for performance assessment. Statistical analysis was conducted using univariate and multivariate logistic regression, and the accuracy was assessed using the receiver operating characteristic (ROC) curve. RESULTS: Of the 388 patients, 276 were classified as having non-complex TURBT, and 112 as complex. Factors significantly associated with complexity included larger tumor size, tumor location, age and gender. The nomogram achieved an area under the curve (AUC) of 0.92 [95% confidence interval (CI): 0.89-0.96] in the training set and 0.87 (95% CI: 0.78-0.96) in the validation set. CONCLUSIONS: The proposed nomogram effectively predicts the complexity of TURBT using preoperative clinical data. This scoring system can aid surgeons in preoperative planning and improve patient outcomes by standardizing the assessment of TURBT complexity across institutions. CI - (c) AME Publishing Company. FAU - Zhang, Hui AU - Zhang H AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. AD - Department of Urology, General Hospital of Southern Theater Command, Joint Logistics Support Force, Guangzhou, China. FAU - Zhang, Chen AU - Zhang C AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Xu, Jinshan AU - Xu J AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Wang, Maoyu AU - Wang M AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Sheng, Chaoyang AU - Sheng C AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Xu, Yang AU - Xu Y AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Zhu, Jinpeng AU - Zhu J AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. LA - eng PT - Journal Article DEP - 20260211 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC12968924 OTO - NOTNLM OT - Transurethral resection of bladder tumor (TURBT) OT - bladder cancer OT - complexity score OT - surgical outcomes COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-736/coif). The authors have no conflicts of interest to declare. EDAT- 2026/03/11 12:12 MHDA- 2026/03/11 12:13 PMCR- 2026/02/28 CRDT- 2026/03/11 05:24 PHST- 2025/09/26 00:00 [received] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/03/11 12:13 [medline] PHST- 2026/03/11 12:12 [pubmed] PHST- 2026/03/11 05:24 [entrez] PHST- 2026/02/28 00:00 [pmc-release] AID - tau-15-02-58 [pii] AID - 10.21037/tau-2025-736 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Feb 28;15(2):58. doi: 10.21037/tau-2025-736. Epub 2026 Feb 11. PMID- 41807571 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Mar 10 TI - Diagnostic uncertainty of clinical T2 disease and its impact on treatment stratification in upper tract urothelial carcinoma: a multicenter retrospective study. LID - 10.1038/s41598-026-42876-3 [doi] LID - 12848 AB - Accurate clinical staging of upper tract urothelial carcinoma (UTUC) remains challenging, and discrepancies between clinical and pathological T stages may result in missed opportunities for appropriate treatment. This study aimed to elucidate real-world discrepancies between clinical and pathological T staging in UTUC, emphasizing the diagnostic uncertainty associated with clinical T2 (cT2) disease. A retrospective analysis was conducted involving 739 patients with cTa-4N0M0 UTUC who underwent radical nephroureterectomy (RNU) at multiple institutions. Patients who received neoadjuvant therapy or had missing pathological T stage data were excluded. Discrepancies between clinical and pathological staging, treatment patterns, and survival outcomes were evaluated. Among 739 patients, substantial discrepancies between clinical and pathological T stages were observed, with an overall diagnostic concordance rate of 44.7%. Only 16% of cT2 cases were pathologically confirmed as pathological T2 (pT2), whereas most were either down-staged to /=pT3, indicating marked diagnostic uncertainty. Clinical heterogeneity within the cT2 group resulted in marked survival differences based on pathological stage, as pT3 patients had significantly worse outcomes than pT2 patients. Within the pT3 subgroup, lymphovascular invasion independently correlated with poor prognosis, whereas adjuvant therapy improved survival. However, only approximately one-third of patients with pT3 disease received adjuvant therapy, indicating a treatment gap in this high-risk population. This multicenter study identified real-world discrepancies between clinical and pathological staging in UTUC. cT2 disease represents a heterogeneous and diagnostically uncertain category, requiring careful interpretation for appropriate treatment planning. FAU - Shiga, Masanobu AU - Shiga M AD - Department of Urology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Kandori, Shuya AU - Kandori S AD - Department of Urology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. shuya79@md.tsukuba.ac.jp. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kobayashi, Mizuki AU - Kobayashi M AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Ikarashi, Daiki AU - Ikarashi D AD - Department of Urology, Iwate Medical University, Morioka, Japan. FAU - Fukuhara, Hiroki AU - Fukuhara H AD - Department of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan. FAU - Sato, Takuma AU - Sato T AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Myoen, Shingo AU - Myoen S AD - Department of Urology, Miyagi Cancer Center, Natori, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Division of Urology, Fukushima Medical University, Fukushima, Japan. FAU - Inoue, Takamitsu AU - Inoue T AD - Department of Renal and Urological Surgery, International University of Health and Welfare Narita Hospital, Narita, Japan. FAU - Oikawa, Masaaki AU - Oikawa M AD - Division of Urology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. FAU - Kaiho, Yasuhiro AU - Kaiho Y AD - Division of Urology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. FAU - Miyazaki, Jun AU - Miyazaki J AD - Department of Renal and Urological Surgery, International University of Health and Welfare Narita Hospital, Narita, Japan. FAU - Kojima, Yoshiyuki AU - Kojima Y AD - Division of Urology, Fukushima Medical University, Fukushima, Japan. FAU - Adachi, Hisanobu AU - Adachi H AD - Department of Urology, Miyagi Cancer Center, Natori, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Tsuchiya, Norihiko AU - Tsuchiya N AD - Department of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University, Morioka, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. LA - eng GR - 25K20057/Japan Society for the Promotion of Science/ GR - 23K24469/Japan Society for the Promotion of Science/ PT - Journal Article PT - Multicenter Study DEP - 20260310 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Retrospective Studies MH - Neoplasm Staging MH - Female MH - Male MH - Aged MH - Prognosis MH - Middle Aged MH - Nephroureterectomy MH - *Urologic Neoplasms/diagnosis/pathology/therapy/mortality MH - Aged, 80 and over PMC - PMC13096306 OTO - NOTNLM OT - Radical nephroureterectomy OT - Stage discrepancy OT - Upper urinary tract OT - Urothelial carcinoma COIS- Declarations. Competing interests: Competing interestsShingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. Hiroyuki Nishiyama received honoraria from Astellas, BMS, Janssen, MSD, Ono, and Pfizer, and a grant from Chugai and Astellas. The other authors have no conflicts of interest to declare. Tomonori Habuchi received honoraria from Janssen Pharmaceutical K.K., Nippon Kayaku Co., LTD., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., Novartis Pharmaceuticals and Bayer AG. Tomonori Habuchi also received research funding supports from Mochida Pharmaceutical Co., Novartis Pharmaceuticals Co, LTD., Pharmaceuticals Co, LTD. and Sysmex Co. Wataru Obara received honoraria from Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Merck Biopharma. Norihiko Tsuchiya received honoraria from Janssen Pharmaceutical K.K., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., Ono Pharmaceuticals Co., Ltd., MSD K.K., Merk & Co., Inc. Other authors have no conflicts of interest to declare. Ethical approval: This retrospective, multi-institutional study was approved by the Institutional Review Boards or Ethics Committees of all participating centers, based on the central approval granted by the Ethics Committee of the Hirosaki University School of Medicine (approval number: 2023-063-1), which served as the central ethics committee for this study. The requirement for informed consent was waived by the Ethics Committee of the Hirosaki University School of Medicine due to the retrospective nature of the study, and information was disclosed to patients using an opt-out approach. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki and institutional policies for human research. Consent to participate: The need for informed consent to participate was waived by the Institutional Review Board of the University of Tsukuba Hospital and all participating hospitals. Written informed consent was not obtained from individual patients due to the use of an opt-out approach. Consent to publish: All authors approved for the publication. EDAT- 2026/03/11 06:56 MHDA- 2026/06/27 12:38 PMCR- 2026/03/10 CRDT- 2026/03/11 00:24 PHST- 2025/12/04 00:00 [received] PHST- 2026/02/27 00:00 [accepted] PHST- 2026/06/27 12:38 [medline] PHST- 2026/03/11 06:56 [pubmed] PHST- 2026/03/11 00:24 [entrez] PHST- 2026/03/10 00:00 [pmc-release] AID - 10.1038/s41598-026-42876-3 [pii] AID - 42876 [pii] AID - 10.1038/s41598-026-42876-3 [doi] PST - epublish SO - Sci Rep. 2026 Mar 10;16(1):12848. doi: 10.1038/s41598-026-42876-3. PMID- 41804641 OWN - NLM STAT- MEDLINE DCOM- 20260803 LR - 20260803 IS - 1699-5848 (Electronic) IS - 0213-3911 (Linking) VI - 41 IP - 9 DP - 2026 Sep TI - Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications. PG - 1483-1491 LID - 10.14670/HH-25-058 [doi] AB - Inverted urothelial papilloma (IUP) is a rare benign tumor of the urinary tract, most commonly arising in the bladder and characterized by an endophytic growth pattern. IUP primarily affects middle-aged and older men and typically presents with painless hematuria. IUP was first described in 1927 and recognized as an independent entity by the World Health Organization in 1973. It can be difficult to distinguish from urothelial carcinoma (UC), which can result in misdiagnosis and overtreatment. Genetic analyses have confirmed the benign nature of IUP. Activating mutations in RAS family genes (HRAS, KRAS, NRAS) are frequent in IUP, whereas mutations typical of UC, such as FGFR3, TP53, and TERT promoter alterations, are rare. Macroscopically, lesions are generally small, solitary, and broad-based. Histologically, IUP exhibits two architectural patterns: trabecular and glandular, which both show minimal atypia and low mitotic activity. Differentiating IUP from UC with inverted growth and benign mimickers, such as florid von Brunn's nests or cystitis cystica/glandularis, is challenging, particularly when specimen size is limited. Immunohistochemistry (KRT20, TP53, and Ki-67) may support the diagnosis but does not reliably distinguish IUP from UC in difficult cases. The standard treatment is complete transurethral resection, and recurrence rates are low. The superficial urothelial cells overlying IUP may also harbor RAS mutations, challenging the long-held assumption that these cells are morphologically and genetically normal. Future studies should investigate whether similar genetic alterations in morphologically normal urothelium occur in other urothelial tumors. This could refine understanding of early tumorigenesis and guide improved detection and risk assessment. CI - (c)The Author(s) 2026. Open Access. This article is licensed under a Creative Commons CC-BY International License. FAU - Kitahama, Keiichiro AU - Kitahama K AD - Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan. AD - Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Inamura, Kentaro AU - Inamura K AD - Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. AD - Division of Tumor Pathology, Jichi Medical University, Shimotsuke, Japan. inamura-tky@umin.ac.jp. LA - eng GR - JP22H02930/JSPS KAKENHI/ GR - JP23K18246/JSPS KAKENHI/ GR - JP25K22581/JSPS KAKENHI/ PT - Journal Article PT - Review DEP - 20260310 PL - Spain TA - Histol Histopathol JT - Histology and histopathology JID - 8609357 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Papilloma, Inverted/diagnosis/pathology/genetics MH - *Urinary Bladder Neoplasms/pathology/diagnosis/genetics MH - Biomarkers, Tumor/genetics/analysis MH - Mutation MH - Urothelium/pathology MH - Diagnosis, Differential EDAT- 2026/03/10 07:00 MHDA- 2026/08/03 12:42 CRDT- 2026/03/10 04:53 PHST- 2026/08/03 12:42 [medline] PHST- 2026/03/10 07:00 [pubmed] PHST- 2026/03/10 04:53 [entrez] AID - HH-25-058 [pii] AID - 10.14670/HH-25-058 [doi] PST - ppublish SO - Histol Histopathol. 2026 Sep;41(9):1483-1491. doi: 10.14670/HH-25-058. Epub 2026 Mar 10. PMID- 41799330 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260309 LR - 20260926 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 3 DP - 2026 Mar TI - Standardized care pathway reshaped the diagnostic and therapeutic landscape of urinary bladder cancer. A 15-year population-based study. PG - e70179 LID - 10.1002/bco2.70179 [doi] LID - e70179 AB - OBJECTIVES: This work aimed to evaluate the long-term impact of standardized care pathway (SCP) implementation for urinary bladder cancer (UBC) on tumour characteristics, diagnostic and treatment intervals and guideline adherence. MATERIALS AND METHODS: A retrospective cohort study was conducted including all patients with newly diagnosed UBC at the NU Hospital Group, Sweden, between 2010 and 2024. Patients were grouped into pre-SCP (2010-2015) and during-SCP (2016-2024) cohorts. Patient demographics, tumour characteristics, adherence to guideline-recommended care and diagnostic and treatment time intervals were analysed. Overall survival was assessed using Kaplan-Meier analysis and Cox proportional hazards regression. RESULTS: Following SCP implementation, emergency presentations declined significantly (15% pre-SCP to 10% SCP, p = 0.003). Tumour characteristics shifted towards earlier-stage disease, with increased detection of small tumours 18 days were independently associated with worse overall survival. Kaplan-Meier analysis revealed a temporal shift: Early rapid TURBT was associated with poorer survival in 2010-2015 but conferred a survival benefit in 2016-2024 (log-rank chi (2) = 13.66, p = 0.003). CONCLUSIONS: SCP implementation was associated with earlier detection, improved guideline adherence and sustained reductions in diagnostic delays. However, increasing delays to definitive treatment for muscle-invasive disease highlight emerging system-level constraints, underscoring the need to optimize downstream capacity to fully realize the benefits of early diagnosis. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Istamulov, Mansour AU - Istamulov M AD - Department of Urology, Institute of Clinical Science, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden. FAU - Eriksson, Hanna AU - Eriksson H AD - Department of Surgery, Urology Section NU-Hospital Group Uddevalla Region Vastra Gotaland Sweden. FAU - Abuhasanein, Suleiman AU - Abuhasanein S AUID- ORCID: 0000-0003-3756-0397 AD - Department of Urology, Institute of Clinical Science, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden. AD - Department of Surgery, Urology Section NU-Hospital Group Uddevalla Region Vastra Gotaland Sweden. AD - Department of Research and Development NU-Hospital Group Trollhattan Region Vastra Gotaland Sweden. LA - eng PT - Journal Article DEP - 20260304 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12960746 OTO - NOTNLM OT - diagnostic delay OT - guideline adherence OT - haematuria OT - healthcare delivery OT - resection of tumour OT - standardized care pathway OT - survival analysis OT - treatment intervals OT - urinary bladder cancer COIS- The authors have no conflict of interest to declare. EDAT- 2026/03/09 17:37 MHDA- 2026/03/09 17:38 PMCR- 2026/03/04 CRDT- 2026/03/09 06:17 PHST- 2026/01/08 00:00 [received] PHST- 2026/02/03 00:00 [revised] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/03/09 17:38 [medline] PHST- 2026/03/09 17:37 [pubmed] PHST- 2026/03/09 06:17 [entrez] PHST- 2026/03/04 00:00 [pmc-release] AID - BCO270179 [pii] AID - 10.1002/bco2.70179 [doi] PST - epublish SO - BJUI Compass. 2026 Mar 4;7(3):e70179. doi: 10.1002/bco2.70179. eCollection 2026 Mar. PMID- 41795740 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Mar 8 TI - Immediate Vs. Delayed single post-operative intravesical instillation of chemotherapy in reducing bladder recurrence rate in upper tract urothelial carcinoma patients after radical nephroureterectomy. LID - 226 [pii] LID - 10.1007/s00345-026-06326-z [doi] AB - OBJECTIVE: To evaluate the impact of immediate single dose intravesical instillation after operation on bladder recurrence in upper tract urothelial carcinoma patients after radical nephroureterectomy. METHODS: A retrospective analysis was performed on clinical data of upper tract urothelial carcinoma patients who underwent radical nephroureterectomy at our center from December 2013 to December 2023. All patients undergo single-dose intravesical instillation (The instillation agent were pirarubicin or epirubicin) after surgery. Patients were divided into two groups based on the time of undergoing single dose postoperative intravesical instillation: the immediate instillation group (within 24 h after the operation) and the delayed group (2-10days after the operation). The primary observation indicator was postoperative bladder recurrence-free survival. Baseline characteristics of the two groups were balanced using propensity score matching (PSM). The Kaplan-Meier method was used to plot survival curves, and the Log-rank test was applied to compare differences between groups. Cox proportional hazards regression model was used to analyze risk factors for postoperative bladder recurrence. RESULTS: A total of 418 patients were included (115 in the immediate instillation group and 303 in the delayed instillation group). After propensity score matching (PSM), 101 patients were successfully matched in each group. The 2-year bladder recurrence-free survival rate was significantly higher in the immediate instillation group (84.2%) than in the delayed instillation group (77.2%, P = 0.004). Subgroup analysis showed: among patients who underwent preoperative ureteroscopy, the bladder recurrence-free survival rate was 76.7% in the immediate instillation group vs. 48.0% in the delayed instillation group (P = 0.035); among patients without preoperative ureteroscopy, the bladder recurrence-free survival rate was 87.3% in the immediate instillation group vs. 73.7% in the delayed instillation group (P = 0.029). There was no difference in instillation-related adverse events between the two groups. CONCLUSION: Whether ureteroscopy is performed preoperatively or not, a single immediate bladder instillation after operation can effectively reduce the bladder recurrence rate in upper tract urothelial carcinoma patients after radical nephroureterectomy compared with delayed instillation. FAU - Liu, Yiwen AU - Liu Y AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. AD - Graduate School of Xuzhou Medical University, Xuzhou, China. FAU - Song, Yun AU - Song Y AD - Feng Xian People's Hospital, Xuzhou, China. FAU - Qi, Nienie AU - Qi N AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Han, Chong AU - Han C AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. AD - Graduate School of Xuzhou Medical University, Xuzhou, China. FAU - Lu, Meng AU - Lu M AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. FAU - Zhang, Meng AU - Zhang M AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. AD - Graduate School of Xuzhou Medical University, Xuzhou, China. FAU - Wen, Rumin AU - Wen R AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. wenrumin163@163.com. FAU - Jiang, Xiaoxiao AU - Jiang X AD - Yancheng No.1 People's Hospital, Yancheng, China. 401774138@qq.com. FAU - Li, Hailong AU - Li H AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. justinlee719@163.com. LA - eng GR - WSW-064/Six Talent Peaks Project in Jiangsu Province/ GR - 2021K447C/Post-doctoral Research Funding Project in Jiangsu Province/ GR - 81502193/National Nature Science Foundation of China Youth Project/ GR - LCZX202407/Construction Project of High Level Hospital of Jiangsu Province/ GR - SRYKTH202402/Jiangsu Province Postdoctoral Innovation Practice Base Medical Science and Technology Innovation Project/ GR - CXCYYB202413/Innovation and entrepreneurship projects at the Xuzhou Medical University Science and Technology Park/ GR - FXJDBF2024104/Research project on the "Pairing Assistance" initiative at the Affiliated Hospital of Xuzhou Medical University/ GR - K2024040/Key Medical Research Projects of Jiangsu Provincial Health Commission/ GR - 2024104192/Advanced Program of The Affiliated Hospital of Xuzhou Medical University/ PT - Comparative Study PT - Journal Article DEP - 20260308 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - D58G680W0G (pirarubicin) RN - 80168379AG (Doxorubicin) RN - 0 (Antineoplastic Agents) RN - 3Z8479ZZ5X (Epirubicin) SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Administration, Intravesical MH - Female MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/surgery/drug therapy MH - *Ureteral Neoplasms/surgery MH - *Doxorubicin/analogs & derivatives/administration & dosage MH - *Kidney Neoplasms/surgery MH - *Urinary Bladder Neoplasms/prevention & control/epidemiology MH - Time Factors MH - *Antineoplastic Agents/administration & dosage MH - *Epirubicin/administration & dosage MH - Middle Aged MH - Postoperative Care/methods OTO - NOTNLM OT - Intravesical instillation OT - Intravesical recurrence OT - Radical nephroureterectomy OT - Upper urinary tract urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This retrospective single- institutional study was approved by the ethics committee of the Affiliated Hospital of Xuzhou Medical University. All patients provided written informed consent EDAT- 2026/03/08 19:23 MHDA- 2026/06/28 00:36 CRDT- 2026/03/08 12:04 PHST- 2025/10/30 00:00 [received] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/06/28 00:36 [medline] PHST- 2026/03/08 19:23 [pubmed] PHST- 2026/03/08 12:04 [entrez] AID - 10.1007/s00345-026-06326-z [pii] AID - 10.1007/s00345-026-06326-z [doi] PST - epublish SO - World J Urol. 2026 Mar 8;44(1):226. doi: 10.1007/s00345-026-06326-z. PMID- 41792072 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260721 IS - 1681-7168 (Electronic) IS - 1022-386X (Linking) VI - 36 IP - 1 DP - 2026 Jan TI - Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following Repeat Transurethral Resection: A Meta-Analysis. PG - 87-94 LID - 10.29271/jcpsp.2026.01.87 [doi] AB - To systematically evaluate the risk factors associated with positive pathology results following second transurethral resection (re-TUR) in patients with non-muscle invasive bladder cancer (NMIBC), a thorough database search, including PubMed, Embase, Cochrane Library, and CNKI, was performed, limited to studies published up to January 2023. Researchers independently conducted literature screening, data extraction, and meta-analysis using RevMan 5.3, incorporating 15 studies with 1,877 patients. Based on the results, positive pathology results after re-TUR were associated with the following factors: higher pathological grade (OR = -0.24, 95% CI: -0.31-0.17; p <0.001), tumour size >/=3 cm (OR = 0.40, 95% CI: 0.22-0.72; p = 0.003), multiple tumours (OR = 0.47, 95% CI: 0.37-0.61, p <0.001), absence of muscularis propria in the initial resection specimen (OR = 0.19, 95% CI: 0.09-0.39; p <0.001), concurrent carcinoma in situ (CIS, OR = 2.99, 95% CI: 1.52-5.87; p = 0.002), a history of bladder cancer recurrence (OR = 2.32, 95% CI: 1.30-4.13; p = 0.004), and treatment at different medical institutions for the first and second resections (OR = 0.23, 95% CI: 0.12-0.45; p <0.001). This study indicates that higher pathological grade, tumour size >/=3 cm, multiple tumours, the absence of muscularis propria in the initial resection specimen, and concurrent CIS are risk factors for positive pathology results after re-TUR in NMIBC patients. Key Words: Non-muscle invasive bladder cancer, Repeat transurethral resection, Tumour residual, Risk factors, Meta-analysis. FAU - Li, Jiashuo AU - Li J AD - Department of Urology, First People's Hospital of Fuzhou, Fuzhou, China. AD - Department of Basic Medical Sciences, Fuzhou Medical College, Fuzhou, China. FAU - He, Yidi AU - He Y FAU - Wu, Shuai AU - Wu S AD - Department of Urology, First People's Hospital of Fuzhou, Fuzhou, China. AD - Department of Basic Medical Sciences, Fuzhou Medical College, Fuzhou, China. LA - eng PT - Journal Article PT - Meta-Analysis PL - Pakistan TA - J Coll Physicians Surg Pak JT - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP JID - 9606447 SB - IM MH - Humans MH - Transurethral Resection of Bladder MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology MH - *Neoplasm, Residual/pathology MH - Risk Factors MH - Reoperation MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Grading EDAT- 2026/03/07 01:37 MHDA- 2026/03/08 01:38 CRDT- 2026/03/06 22:48 PHST- 2024/10/25 00:00 [received] PHST- 2025/08/12 00:00 [accepted] PHST- 2026/03/08 01:38 [medline] PHST- 2026/03/07 01:37 [pubmed] PHST- 2026/03/06 22:48 [entrez] AID - 040579197 [pii] AID - 10.29271/jcpsp.2026.01.87 [doi] PST - ppublish SO - J Coll Physicians Surg Pak. 2026 Jan;36(1):87-94. doi: 10.29271/jcpsp.2026.01.87. PMID- 41786089 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 36 IP - 3 DP - 2026 Apr TI - Real-world data on neoadjuvant chemotherapy for localized muscle-invasive bladder cancer (2015-2024): A single-center retrospective study. PG - 103093 LID - S2950-3930(26)00024-0 [pii] LID - 10.1016/j.fjurol.2026.103093 [doi] AB - INTRODUCTION: The aim of this study was to evaluate the real-world effectiveness of neoadjuvant chemotherapy (NAC) regimens for muscle-invasive bladder cancer (MIBC) and to identify factors that may influence treatment response. METHODS: We conducted a retrospective, single-center study from 2015 to 2024, analyzing real-world data on patients diagnosed with localized MIBC who received NAC prior to radical cystectomy. Patient demographics, pathological response rates and toxicities were recorded. Statistical analyses were performed to compare the outcomes between the two chemotherapy regimens and to identify factors affecting the pathologic response. RESULTS: Eighty-nine patients were included, with 39 in the dose-dense MVAC (ddMVAC) group and 50 in the gemcitabine-cisplatin (GC) group. Twenty-five percent of the patients had a history of non-muscle-invasive bladder cancer (NMIBC). Patients treated with GC had a higher prevalence of cardiovascular disease (62 vs. 38% in the ddMVAC group) and lower glomerular filtration rates (84 vs. 92mL/min in the ddMVAC group). Dose reductions occurred in 38% of the GC group mainly due to thrombocytopenia and 13% in the MVAC group. There was no significant difference in postoperative complications between the two groups, although more severe complications (Clavien>2) occurred in the GC group. The complete response rate (ypT0N0) was similar in both groups with 56% for ddMVAC and 47% for GC. Multivariate analysis identified incomplete macroscopic transurethral resection of the bladder tumor and a history of NMIBC as factors negatively affecting the complete pathologic response rate. CONCLUSION: In this real-world study, incomplete TURBT and a history of NMIBC were independently associated with a lower pathological response to NAC, highlighting the importance of thorough initial tumor management. After 2022, favorable adherence to ddMVAC was observed without an apparent increase in severe toxicities in our cohort. CI - Copyright (c) 2026 Elsevier Masson SAS. All rights reserved. FAU - Maurice, Tanguy AU - Maurice T AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: tanguymaurice@hotmail.fr. FAU - Pillet, Armelle AU - Pillet A AD - Department of Oncology, Poitiers University Hospital, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: Armelle.PILLET@chu-poitiers.fr. FAU - Emambux, Sheik AU - Emambux S AD - Department of Oncology, Poitiers University Hospital, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: Sheik.EMAMBUX@chu-poitiers.fr. FAU - Isambert, Nicolas AU - Isambert N AD - Department of Oncology, Poitiers University Hospital, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: Nicolas.ISAMBERT@chu-poitiers.fr. FAU - Chapelle, Caroline AU - Chapelle C AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: chapelle.caroline07@gmail.com. FAU - Bernardeau, Simon AU - Bernardeau S AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: simon.bernardeau@gmail.com. FAU - Abi Abdallah, Mikael AU - Abi Abdallah M AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: mikael.Abiabdallah@Hotmail.Com. FAU - Vallee, Maxime AU - Vallee M AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France; Unite Inserm U1070, PHAR2, universite de Poitiers, 86000 Poitiers, France. Electronic address: maxime.vallee1786@gmail.com. FAU - Kutchukian, Stessy AU - Kutchukian S AD - Departement d'urologie et de transplantation renale, centre hospitalier universitaire, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: stessy.kutchukian@gmail.com. LA - eng PT - Journal Article DEP - 20260303 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 RN - Q20Q21Q62J (Cisplatin) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) RN - 80168379AG (Doxorubicin) SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - *Urinary Bladder Neoplasms/pathology/drug therapy/surgery MH - *Neoadjuvant Therapy MH - Male MH - Aged MH - Cisplatin/administration & dosage MH - Neoplasm Invasiveness MH - Deoxycytidine/analogs & derivatives/administration & dosage MH - Gemcitabine MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects MH - Cystectomy MH - Treatment Outcome MH - Chemotherapy, Adjuvant MH - Doxorubicin/administration & dosage OTO - NOTNLM OT - Cisplatin OT - Cystectomy OT - Dose-dense methotrexate OT - Doxorubicin OT - Gemcitabine and cisplatin OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Vinblastine COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2026/03/06 08:59 MHDA- 2026/04/28 00:35 CRDT- 2026/03/05 19:13 PHST- 2025/10/25 00:00 [received] PHST- 2026/02/05 00:00 [revised] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/04/28 00:35 [medline] PHST- 2026/03/06 08:59 [pubmed] PHST- 2026/03/05 19:13 [entrez] AID - S2950-3930(26)00024-0 [pii] AID - 10.1016/j.fjurol.2026.103093 [doi] PST - ppublish SO - Fr J Urol. 2026 Apr;36(3):103093. doi: 10.1016/j.fjurol.2026.103093. Epub 2026 Mar 3. PMID- 41784671 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1591-9528 (Electronic) IS - 1591-8890 (Print) IS - 1591-8890 (Linking) VI - 26 IP - 1 DP - 2026 Mar 5 TI - Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines. LID - 10.1007/s10238-026-02098-3 [doi] LID - 184 AB - Bladder cancer (BC), primarily urothelial carcinoma, remains one of the most common and lethal genitourinary malignancies worldwide, with limited long-term outcomes from standard treatments such as chemotherapy and radical cystectomy. These conventional modalities often fail to achieve durable responses and can severely affect patients' quality of life, underscoring the need for more effective and targeted therapeutic strategies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTsLA-4) have revolutionized BC therapy by restoring antitumor immune function. Nevertheless, treatment resistance, immune-related adverse events, and patient heterogeneity continue to limit their universal efficacy. This review provides an in-depth overview of ICI mechanisms and highlights evolving therapeutic approaches, including combination strategies with chemotherapy, radiotherapy, Bacillus Calmette-Guerin (BCG), and antibody-drug conjugates (ADCs). It also discusses emerging biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and DNA damage repair (DDR) deficiency as predictive tools for treatment selection. Overall, this study underscores the pivotal role of immunotherapy in reshaping bladder cancer management and outlines future directions toward safe, personalized, and biomarker-driven therapeutic paradigms. FAU - Ajalli, Mohammad Mahdi AU - Ajalli MM AD - School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. FAU - Sansebli, Yalda AU - Sansebli Y AD - Department of Laboratory Sciences, School of Paramedical Sciences, Golestan University of Medical Sciences, Gorgan, Iran. FAU - Ekrami, Davood AU - Ekrami D AD - Department of Chemistry, Sharif University of Technology, Tehran, Iran. FAU - Alaeenejad, Fatemeh AU - Alaeenejad F AD - Department of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. FAU - Abbasi, Ainaz AU - Abbasi A AD - Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Eini, Pooya AU - Eini P AD - Shaheed Rajaei Cardiovascular Medical and Research Center, Tehran, Iran. FAU - Hassanzadeh, Farnaz AU - Hassanzadeh F AD - First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia. farnaz78h@gmail.com. FAU - Bahrami, Nastaran AU - Bahrami N AD - Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. nastaran.bahrami@srbiau.ac.ir. AD - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. nastaran.bahrami@srbiau.ac.ir. LA - eng PT - Journal Article PT - Review DEP - 20260305 PL - Italy TA - Clin Exp Med JT - Clinical and experimental medicine JID - 100973405 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology MH - *Urinary Bladder Neoplasms/therapy/drug therapy/immunology MH - Combined Modality Therapy MH - Immunotherapy/methods MH - B7-H1 Antigen/antagonists & inhibitors MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors MH - Biomarkers, Tumor PMC - PMC12999821 OTO - NOTNLM OT - Bladder cancer OT - Combination therapy OT - Immune checkpoint inhibitors OT - Immunotherapy resistance OT - Tumor microenvironment OT - Urothelial carcinoma COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. AI tools: The authors declare that generative AI tools (ChatGPT, Grammarly) were used only for language editing and grammar improvement. The authors take full responsibility for the content of this publication. EDAT- 2026/03/05 12:49 MHDA- 2026/06/28 00:36 PMCR- 2026/03/05 CRDT- 2026/03/05 11:05 PHST- 2025/11/03 00:00 [received] PHST- 2026/02/10 00:00 [accepted] PHST- 2026/06/28 00:36 [medline] PHST- 2026/03/05 12:49 [pubmed] PHST- 2026/03/05 11:05 [entrez] PHST- 2026/03/05 00:00 [pmc-release] AID - 10.1007/s10238-026-02098-3 [pii] AID - 2098 [pii] AID - 10.1007/s10238-026-02098-3 [doi] PST - epublish SO - Clin Exp Med. 2026 Mar 5;26(1):184. doi: 10.1007/s10238-026-02098-3. PMID- 41783444 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260305 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Comparative analysis of oncologic outcomes: kidney-sparing surgery versus radical nephroureterectomy for localized high-risk upper tract urothelial carcinoma. PG - 1753148 LID - 10.3389/fonc.2026.1753148 [doi] LID - 1753148 AB - BACKGROUND: The kidney-sparing surgery (KSS) technique for upper tract urothelial carcinoma (UTUC) shows potential, yet its efficacy in treating high-risk UTUC is a topic of debate. This study seeks to assess and compare the impact of KSS versus radical nephroureterectomy (RNU) on renal function and long-term oncological outcomes in patients with localized high-risk UTUC. METHODS: This study retrospectively analyzed 115 patients diagnosed with high-risk UTUC and treated with KSS or RNU in the First Affiliated Hospital of Chongqing Medical University from January 2018 to June 2024. The primary endpoint of this study was overall survival (OS). Secondary endpoints included disease-free survival (DFS), metastasis-free survival (MFS), intravesical recurrence-free survival (IVRFS), and postoperative renal function changes. Additionally, predictors of OS, DFS, MFS, and IVRFS were evaluated through Cox regression models. RESULTS: There were no significant differences in the 3-year OS (88.1% vs 78.5%), DFS (60.3% vs 53.9%), MFS (82.1% vs 71.9%), and IVRFS (80.2% vs 69.3%) rates between the KSS and RNU groups, which included 29 and 86 patients, respectively. 6 months after intervention, renal function decreased significantly in RNU group, but not in KSS group. In univariate Cox regression analysis, the surgical procedure did not exhibit significant associations with OS, DFS, MFS, or IVRFS. Subsequent multivariable Cox regression analysis revealed that preoperative creatinine levels, pathological stage, and intraoperative bleeding emerged as independent predictors of OS. Moreover, pathological stage was also an independent predictor for DFS and MFS. CONCLUSIONS: KSS exhibits similar oncological efficacy as RNU in managing localized high-risk UTUC, with less damage to patients and benefit of better preservation of renal function. Adverse factors such as elevated preoperative creatinine levels, advanced pathological stage, and increased intraoperative blood loss may correlate with inferior overall survival. Additional prospective research is necessary to confirm the validity of our findings. CI - Copyright (c) 2026 Zhang, Tan, He, Zhang and He. FAU - Zhang, Hongyu AU - Zhang H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Tan, Qi AU - Tan Q AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - He, Yutao AU - He Y AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhang, Tong AU - Zhang T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - He, Yunfeng AU - He Y AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20260217 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12953131 OTO - NOTNLM OT - kidney-sparing surgery OT - radical nephroureterectomy OT - renal function OT - survival OT - upper tract urothelial carcinoma COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/03/05 07:09 MHDA- 2026/03/05 07:10 PMCR- 2026/02/17 CRDT- 2026/03/05 04:53 PHST- 2025/11/24 00:00 [received] PHST- 2026/01/24 00:00 [revised] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/03/05 07:10 [medline] PHST- 2026/03/05 07:09 [pubmed] PHST- 2026/03/05 04:53 [entrez] PHST- 2026/02/17 00:00 [pmc-release] AID - 10.3389/fonc.2026.1753148 [doi] PST - epublish SO - Front Oncol. 2026 Feb 17;16:1753148. doi: 10.3389/fonc.2026.1753148. eCollection 2026. PMID- 41777952 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260304 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 1 DP - 2026 Jan TI - Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis. PG - e102672 LID - 10.7759/cureus.102672 [doi] LID - e102672 AB - AIM: To investigate immunogenic cell death (ICD) induced by platinum-based neoadjuvant chemotherapy (NAC) and its impact on survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC). METHODS: This study included 45 patients with MIBC who underwent RC with (n = 25) or without NAC (n = 20). Induction of ICD in MIBC was assessed by comparing immunohistochemical analyses of two ICD-related proteins, high-mobility group box 1 (HMGB1) and calreticulin, between transurethral resection (TUR) and matched RC specimens. Clinicopathologic data, including the upregulation of ICD-related proteins, were correlated with survival outcomes after RC. RESULTS: Upregulation of HMGB1 and calreticulin from TUR to matched RC specimens was observed in 11 (44%) and 12 (48%) of 25 NAC-treated patients, respectively, whereas it was detected in only two (8%) and one (4%) patients without NAC (P = 0.03 and P = 0.01, respectively). Upregulation of HMGB1 was significantly associated with longer cancer-specific survival (CSS) and overall survival (P < 0.01 and P = 0.02, respectively). Upregulation of HMGB1 and histological subtype (P = 0.03 and P = 0.05, respectively) were independent prognostic factors for CSS. Furthermore, among NAC-treated patients with recurrent disease, upregulation of HMGB1 tended to correlate with a better response to subsequent immune checkpoint inhibitor therapy and longer survival (P = 0.07). CONCLUSIONS: Our findings suggest that platinum-based NAC induces ICD in MIBC. Upregulation of HMGB1 may serve as a marker of chemotherapy-induced ICD and as a potential prognostic biomarker after RC. CI - Copyright (c) 2026, Miyamoto et al. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Oda, Yuki AU - Oda Y AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, Kashihara, JPN. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, JPN. LA - eng PT - Journal Article DEP - 20260130 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12950619 OTO - NOTNLM OT - calreticulin OT - high-mobility group box 1 OT - immunogenic tumor cell death OT - muscle-invasive bladder cancer OT - neoadjuvant chemotherapy COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. The Ethics Committee of Nara Medical University issued approval 2891. This retrospective, single-center study was conducted in accordance with the ethical principles of the Declaration of Helsinki (2013). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/03/04 07:15 MHDA- 2026/03/04 07:16 PMCR- 2026/01/30 CRDT- 2026/03/04 04:32 PHST- 2026/01/30 00:00 [accepted] PHST- 2026/03/04 07:16 [medline] PHST- 2026/03/04 07:15 [pubmed] PHST- 2026/03/04 04:32 [entrez] PHST- 2026/01/30 00:00 [pmc-release] AID - 10.7759/cureus.102672 [doi] PST - epublish SO - Cureus. 2026 Jan 30;18(1):e102672. doi: 10.7759/cureus.102672. eCollection 2026 Jan. PMID- 41775643 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260730 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 3 DP - 2026 Apr TI - Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 102514 LID - S1558-7673(26)00014-5 [pii] LID - 10.1016/j.clgc.2026.102514 [doi] AB - This meta-analysis evaluated the oncological outcomes and safety profile of intravesical gemcitabine and docetaxel (Gem/Doce) in patients with non-muscle-invasive bladder cancer (NMIBC). Additionally, efficacy comparison to Bacillus Calmette-Guerin (BCG) therapy was aimed only for BCG-naive NMIBC. A systematic review and meta-analysis were conducted following PRISMA guidelines. Studies evaluating Gem/Doce for NMIBC were identified through PubMed, Web of Science, and Scopus databases. The primary outcome was recurrence-free survival (RFS). Secondary outcomes were high-grade RFS (HG-RFS), progression-free survival (PFS) and risk of adverse events (AEs). A subgroup analysis was performed according to the European Association of Urology (EAU) 2021 risk stratification and previous BCG exposure. A total of 14 studies, involving 1634 NMIBC patients (999 Gem/Doce and 635 BCG), were included. In high-risk BCG-naive and BCG-treated (BCG-exposed/-unresponsive) NMIBC, Gem/Doce resulted in 24-month RFS of 78% (95% confidence intervals [CI] 70%-84%) and 41% (95% CI: 34%-47%), and 24-month PFS of 97% (95% CI: 69%-100%) and 85% (95% CI: 63%-95%), respectively. Five studies, including BCG-naive intermediate to very-high-risk NMIBC, directly compared Gem/Doce and BCG, and demonstrated significant heterogeneity and no significant difference in RFS (Hazard ratio: 0.87, 95% CI: 0.51-1.50) and risk of AEs (odds ratio: 0.58, 95% CI: 0.21-1.60). Grade >/= 3 AEs were found in 3.6% of Gem/Doce cohorts. Across Gem/Doce cohorts, higher maintenance utilization was associated with significantly improved RFS at 24 months (p = .004). However, maintenance effects were derived from between-study comparisons and should be interpreted cautiously due to heterogeneity in maintenance protocols and adherence. Gem/Doce provided acceptable RFS and PFS at 2 years among BCG-naive patients and those who previously experienced recurrence after BCG. Gem/Doce demonstrated RFS and HG-RFS comparable to BCG in BCG-naive NMIBC and had an acceptable safety profile. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Domanski, Piotr AU - Domanski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland; Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, Warsaw, Poland. FAU - Hanusz, Karolina AU - Hanusz K AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shah, Paras AU - Shah P AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Electronic address: slusarczyk.aleksander@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260211 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Gemcitabine) RN - 15H5577CQD (Docetaxel) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/mortality MH - Gemcitabine MH - *Docetaxel/administration & dosage/adverse effects MH - *Deoxycytidine/analogs & derivatives/administration & dosage/adverse effects MH - *Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use MH - Administration, Intravesical MH - Treatment Outcome MH - BCG Vaccine/administration & dosage MH - *Urinary Bladder Neoplasms/drug therapy MH - Progression-Free Survival OTO - NOTNLM OT - Docetaxel OT - Gemcitabine OT - Intravesical therapy OT - Non-muscle-invasive bladder cancer OT - Recurrence COIS- Disclosure S. Boorjian has a consultant role for Ferring, ArTara, Prokarium, and Johnson & Johnson. Other authors have nothing to disclose. The authors have stated that they have no conflicts of interest. EDAT- 2026/03/04 01:17 MHDA- 2026/03/19 01:32 CRDT- 2026/03/03 21:55 PHST- 2025/12/02 00:00 [received] PHST- 2026/01/25 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/03/19 01:32 [medline] PHST- 2026/03/04 01:17 [pubmed] PHST- 2026/03/03 21:55 [entrez] AID - S1558-7673(26)00014-5 [pii] AID - 10.1016/j.clgc.2026.102514 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Apr;24(3):102514. doi: 10.1016/j.clgc.2026.102514. Epub 2026 Feb 11. PMID- 41775134 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260728 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 5 DP - 2026 May TI - Perioperative and oncologic outcomes of extirpative surgery for upper tract urothelial cancer in octogenarians. PG - 111041 LID - S1078-1439(26)00052-9 [pii] LID - 10.1016/j.urolonc.2026.111041 [doi] AB - BACKGROUND AND OBJECTIVE: Upper tract urothelial carcinoma (UTUC) predominantly affects older patients. We evaluated whether advanced age influences perioperative and oncologic outcomes following radical surgery for UTUC. METHODS: We analyzed a multi-institutional cohort of 2,380 patients treated for UTUC with radical nephroureterectomy or partial ureterectomy between 2006 and 2023. Patients were stratified by age: <60 (n = 380), 60 to 70 (n = 741), 70 to 80 (n = 849), and >80 years (n = 410). Outcomes assessed included perioperative complications, pathologic features, and survival metrics across each age group and were compared using Kruskal-Wallis rank sum test. Cox proportional hazards models were used to evaluate factors associated with recurrence, metastasis, and mortality. In addition, Fit and Gray competing risk model was used to assess cancer-specific mortality. KEY FINDINGS AND LIMITATIONS: Elderly patients demonstrated higher American Society of Anesthesiologists scores, comorbidity burden, and decreased renal function (all P < 0.001). While clinical stage was similar among age groups, older patients more frequently exhibited advanced pathologic T-stage (P = 0.04), higher grade (P = 0.007), nodal involvement (P = 0.002), and lymphovascular invasion (P = 0.004). While overall complications increased with age (P < 0.001), rates of major complications (>/=Clavien-Dindo III) remained similar (P = 0.19). Perioperative chemotherapy utilization declined with age (P < 0.001). On univariate Cox regression analysis, advanced age (>80 years) was associated with increased risk of intravesical recurrence, metastasis, overall mortality, and cancer-specific mortality; however, on multivariable analysis, age >80 years remained independently associated with increased risk of metastasis and overall mortality but not intravesical recurrence or cancer-specific mortality. CONCLUSIONS: Advanced age alone should not contraindicate surgical intervention for UTUC. Elderly patients exhibit more aggressive UTUC pathologies but with similar cancer-specific survival and comparable rates of major complications postoperatively compared to their younger counterparts. Results support individualized treatment selection based on comprehensive patient assessment rather than age alone. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Li, Taibo AU - Li T AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MA. FAU - Bronimann, Stephan AU - Bronimann S AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MA; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Eraky, Ahmed AU - Eraky A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Lopez, Carlos Rivera AU - Lopez CR AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MA. FAU - Cheaib, Joseph AU - Cheaib J AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MA. FAU - Bignante, Gabriele AU - Bignante G AD - Department of Urology, Rush University Medical Center, Chicago, IL. FAU - Wu, Zhenjie AU - Wu Z AD - Department of Urology, Naval Medical Hospital, Shanghai, China. FAU - Wang, Linhui AU - Wang L AD - Department of Urology, Naval Medical Hospital, Shanghai, China. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. FAU - Decobelli, Ottavio AU - Decobelli O AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. FAU - Sundaram, Chandru P AU - Sundaram CP AD - Department of Urology, Indiana University, Indianapolis, IN. FAU - Sidhom, Daniel AU - Sidhom D AD - Department of Urology, Indiana University, Indianapolis, IN. FAU - Yoshida, Takashi AU - Yoshida T AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. FAU - Perdona, Sisto AU - Perdona S AD - Urology Department, Istituto Nazionale Tumori Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Tufano, Antonio AU - Tufano A AD - Urology Department, Istituto Nazionale Tumori Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Fu, Melinda AU - Fu M AD - Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Shah, Ankeet AU - Shah A AD - Duke Cancer Institute and Duke University Medical Center, Durham, NC. FAU - Ghoreifi, Alireza AU - Ghoreifi A AD - Duke Cancer Institute and Duke University Medical Center, Durham, NC. FAU - Porter, James AU - Porter J AD - Swedish Medical Center, Seattle, WA. FAU - Correa, Andres F AU - Correa AF AD - Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA. FAU - Rais-Bahrami, Soroush AU - Rais-Bahrami S AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL. FAU - Moon, Sol C AU - Moon SC AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL. FAU - Derweesh, Ithaar H AU - Derweesh IH AD - Department of Urology, UC San Diego School of Medicine, La Jolla, CA. FAU - Puri, Dhruv AU - Puri D AD - Department of Urology, UC San Diego School of Medicine, La Jolla, CA. FAU - Meagher, Margaret F AU - Meagher MF AD - Department of Urology, UC San Diego School of Medicine, La Jolla, CA. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Lambertini, Luca AU - Lambertini L AD - Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy. FAU - Amparore, Daniele AU - Amparore D AD - Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy. FAU - Checcucci, Enrico AU - Checcucci E AD - Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Faliknativ, Omri AU - Faliknativ O AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Taylor, Jacob AU - Taylor J AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Cusmano, Nicholas B AU - Cusmano NB AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Abdollah, Firas AU - Abdollah F AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Ditonno, Francesco AU - Ditonno F AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Moghaddam, Farshad S AU - Moghaddam FS AD - Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Rush University Medical Center, Chicago, IL. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Singla, Nirmish AU - Singla N AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MA; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: nsingla2@jhmi.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260302 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Female MH - Male MH - Aged, 80 and over MH - Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Treatment Outcome MH - Age Factors MH - Middle Aged MH - *Ureteral Neoplasms/surgery/mortality/pathology MH - *Nephroureterectomy MH - *Kidney Neoplasms/surgery/mortality/pathology MH - Retrospective Studies OTO - NOTNLM OT - Age-related outcomes OT - Cancer-specific survival OT - Upper tract urothelial carcinoma COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2026/03/04 01:17 MHDA- 2026/04/21 17:55 CRDT- 2026/03/03 18:06 PHST- 2025/10/30 00:00 [received] PHST- 2026/01/27 00:00 [revised] PHST- 2026/02/09 00:00 [accepted] PHST- 2026/04/21 17:55 [medline] PHST- 2026/03/04 01:17 [pubmed] PHST- 2026/03/03 18:06 [entrez] AID - S1078-1439(26)00052-9 [pii] AID - 10.1016/j.urolonc.2026.111041 [doi] PST - ppublish SO - Urol Oncol. 2026 May;44(5):111041. doi: 10.1016/j.urolonc.2026.111041. Epub 2026 Mar 2. PMID- 41773726 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260918 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 5 DP - 2026 May TI - Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups. PG - 866-876 LID - 10.1111/bju.70207 [doi] AB - OBJECTIVE: To evaluate the prognostic impact of T-stage at re-transurethral resection of bladder (TURB) and its utility for refining risk stratification across European Association of Urology 2021 (EAU21) risk groups in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette-Guerin (BCG). PATIENTS AND METHODS: Retrospective multicentre study including patients with primary or secondary T1HG NMIBC treated with TURB, re-TURB, and adequate BCG between 2007 and 2020 across 28 European academic centres. Patients were stratified according to re-TURB pathological stage (T0, Ta, Tis, T1) and EAU21 risk groups. Kaplan-Meier, Cox regression, and competing-risk methods were used to evaluate recurrence-free survival (RFS), HG-RFS, progression-free survival (PFS), and cancer-specific mortality (CSM). A mixture cure model estimated statistical cure fractions for the overall cohort. RESULTS: Among 1403 patients, residual disease at re-TURB was identified in 38.8%, including 17.7% with persistent T1. Residual T1 was consistently associated with worse outcomes. Compared with T0/Ta, persistent T1 at re-TURB showed substantially lower 5-year HG-RFS and PFS, with high-grade recurrence in over half of patients and 5-year progression up to 48% in high- and very high-risk groups. The 5-year CSM rose from 6-7% (T0/Ta) to 23% (T1). On multivariable analysis, residual T1 was independently associated with worse HG-RFS (hazard ratio 2.40), PFS (hazard ratio 3.10), and CSM (hazard ratio 3.00). Cure modelling showed lower cure fractions for residual T1 compared with T0/Ta. CONCLUSION: Residual T1 at re-TURB is strongly associated with adverse long-term oncological outcomes in BCG-treated T1HG NMIBC and markedly reduces the likelihood of statistical cure. High- and very high-risk patients with persistent T1 represent a biologically adverse subgroup in whom standard BCG may be insufficient. CI - (c) 2026 BJU International. FAU - Fernandez-Mardomingo, Ana AU - Fernandez-Mardomingo A AUID- ORCID: 0009-0000-7149-0578 AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Artiles Medina, Alberto AU - Artiles Medina A AUID- ORCID: 0000-0003-0930-0344 AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - van Creij, Nils C H AU - van Creij NCH AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - de la Estella Lucena, Maria de la Palma AU - de la Estella Lucena MP AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - de la Parra, Irene AU - de la Parra I AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Minguez Ojeda, Cesar AU - Minguez Ojeda C AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Coloma, Almudena AU - Coloma A AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Crespo Martinez, Luis AU - Crespo Martinez L AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Del Olmo Duran, Pedro AU - Del Olmo Duran P AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Gonzalez-Padilla, Daniel A AU - Gonzalez-Padilla DA AUID- ORCID: 0000-0002-5853-8845 AD - Department of Urology, Clinica Universidad de Navarra, Madrid, Spain. FAU - Villacampa, Felipe AU - Villacampa F AD - Department of Urology, Clinica Universidad de Navarra, Madrid, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Mostoles, Madrid, Spain. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Cano-Velasco, Jorge AU - Cano-Velasco J AD - Department of Urology, Clinica Universidad de Navarra, Pamplona, Spain. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Acosta, Eduardo Albers AU - Acosta EA AD - Department of Urology, La Princesa University Hospital, IIS Princesa, Autonomous University of Madrid, Madrid, Spain. FAU - Ajami, Tarek AU - Ajami T AUID- ORCID: 0000-0002-3505-8232 AD - Department of Urology, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Department of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Urology Unit, Department of Surgical Sciences, University of Tor Vergata, Rome, Italy. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Tully, Karl AU - Tully K AUID- ORCID: 0000-0002-9499-0169 AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Unit of Oncologic Minimally-Invasive Urology and Andrology - Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Departament of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - ROC Clinic, Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Anagua Melendres, Franklin AU - Anagua Melendres F AD - Department of Urology, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Buisan, Oscar AU - Buisan O AD - Department of Urology, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Gajate, Pablo AU - Gajate P AD - Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. FAU - Guerrero, Patricia AU - Guerrero P AD - Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. FAU - Saiz, Ana AU - Saiz A AUID- ORCID: 0000-0001-7110-450X AD - Pathology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Burgos Revilla, Francisco Javier AU - Burgos Revilla FJ AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. CN - Young Academic Urologist: Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260303 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Transurethral Resection of Bladder MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery MH - Retrospective Studies MH - Neoplasm Staging MH - Female MH - Male MH - Europe MH - Risk Assessment MH - Aged MH - BCG Vaccine/therapeutic use MH - Middle Aged MH - Prognosis MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - Neoplasm Grading MH - Reoperation OTO - NOTNLM OT - cure fraction OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - re-TURB staging COIS- The authors declare no conflicts of interest. EDAT- 2026/03/03 12:31 MHDA- 2026/04/13 06:32 CRDT- 2026/03/03 08:03 PHST- 2026/04/13 06:32 [medline] PHST- 2026/03/03 12:31 [pubmed] PHST- 2026/03/03 08:03 [entrez] AID - 10.1111/bju.70207 [doi] PST - ppublish SO - BJU Int. 2026 May;137(5):866-876. doi: 10.1111/bju.70207. Epub 2026 Mar 3. PMID- 41770416 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1863-2491 (Electronic) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 Mar 2 TI - Global research trends in robot-assisted nephroureterectomy for upper tract urothelial carcinoma: a visualized bibliometric analysis. LID - 305 [pii] LID - 10.1007/s11701-026-03283-y [doi] AB - Objectives: This study applied bibliometric methods to depict the global research profile of robot-assisted nephroureterectomy (RANU) for upper tract urothelial carcinoma (UTUC). We examined temporal changes in publication and citation output, outlined the main contributing countries, institutions, authors and journals, characterised prevailing research themes and key references, and pinpointed domains in which clinical evidence is still too sparse to provide firm guidance for routine practice. Materials and methods: Publications on RANU in patients with UTUC, appearing between 1 January 2001 and 31 December 2025, were retrieved from the Web of Science Core Collection database. Only records written in English and categorised as articles or reviews were eligible. Titles, abstracts and, when required, full texts were screened in sequence, yielding 249 publications (215 original research papers and 34 review articles) that met the inclusion criteria. Bibliographic information was exported into Microsoft Excel for data cleaning, descriptive summarisation of key variables and preparation of time-trend plots. CiteSpace 6.3 and VOSviewer 1.6.17 were then employed to construct and visualise collaboration and co-citation networks for countries/regions, institutions, authors, journals, keywords and references, and to conduct clustering, timeline and thematic-evolution analyses. Results: Between 2001 and 2025, we identified 249 publications on RANU for UTUC, which together received 3,165 citations, giving an average of 12.71 citations per article. Research output was sparse before 2010, then increased gradually and rose steeply during 2021-2025, a period in which 157 papers were published and annual citation counts peaked. The United States was the dominant contributor with 110 articles, while China and Italy ranked second and third. Several other European and East Asian countries produced fewer papers but achieved relatively high mean citation counts. High-volume centres located in North America and Europe occupied central positions within the international collaboration network, and a small group of surgeons contributed a large share of the highly cited literature. Publications were primarily disseminated through specialist journals, notably Journal of Endourology, BJU International, Cancers, World Journal of Urology and Journal of Robotic Surgery. Keyword co-occurrence and thematic analyses pointed to a shift from early feasibility and initial minimally invasive experience toward comparative-effectiveness research, optimisation of bladder cuff techniques, prevention of intravesical recurrence and guideline-based risk stratification. Conclusions: Research activity on RANU for UTUC has grown rapidly over the past decade and is now predominantly concentrated in high-volume centres in North America, Europe and East Asia, supported by a limited number of specialist journals and core authors. Robotic approaches are increasingly employed for complex UTUC scenarios and for refining techniques of bladder cuff excision and reconstruction. Nevertheless, evidence on long-term oncological outcomes, recurrence patterns, integration with systemic therapies and cost-effectiveness remains sparse. Future investigations should emphasise prospective multicentre registries and rigorously designed comparative studies with standardised reporting, refined risk-stratification schemes and formal health-economic assessment, to ensure that the potential benefits of RANU are more consistently translated into real-world practice across diverse healthcare systems. FAU - Ma, Longtu AU - Ma L AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China. AD - Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China. FAU - Yue, Chuanchao AU - Yue C AD - The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Feng, Biao AU - Feng B AD - The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Huang, Xiaoyu AU - Huang X AD - The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Lu, Rui AU - Lu R AD - The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Wang, Xingliang AU - Wang X AD - The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. mnwkyswxl@126.com. FAU - Dong, Zhilong AU - Dong Z AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China. dzl19780829@163.com. AD - Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China. dzl19780829@163.com. LA - eng GR - 82160148/National Natural Science Foundation of China/ GR - lzujbky-2023-ct06/Fundamental Research Funds for Central Universities/ GR - 23JRRA1509/Gansu Province Joint Research Fund/ GR - 24ZDFA007/Gansu Province Major Science and Technology Special Project/ GR - 2023RCXM42/Gansu Province Key Talent Program/ GR - CY2024-LC-A01/Cuiying Science and Technology Innovation Program/ PT - Journal Article DEP - 20260302 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - *Bibliometrics MH - Humans MH - *Nephroureterectomy/methods/trends MH - *Robotic Surgical Procedures/methods/trends MH - *Carcinoma, Transitional Cell/surgery MH - *Urologic Neoplasms/surgery MH - *Kidney Neoplasms/surgery OTO - NOTNLM OT - Bibliometric analysis OT - CiteSpace OT - Radical nephroureterectomy OT - Robot-assisted nephroureterectomy OT - Upper tract urothelial carcinoma OT - VOSviewer COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study relies exclusively on aggregated data from previously published articles and involves no direct research on human participants; therefore, institutional ethics approval and individual informed consent were not required. EDAT- 2026/03/02 13:17 MHDA- 2026/06/28 00:37 CRDT- 2026/03/02 11:16 PHST- 2026/01/25 00:00 [received] PHST- 2026/02/18 00:00 [accepted] PHST- 2026/06/28 00:37 [medline] PHST- 2026/03/02 13:17 [pubmed] PHST- 2026/03/02 11:16 [entrez] AID - 10.1007/s11701-026-03283-y [pii] AID - 10.1007/s11701-026-03283-y [doi] PST - epublish SO - J Robot Surg. 2026 Mar 2;20(1):305. doi: 10.1007/s11701-026-03283-y. PMID- 41766662 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260926 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 136 IP - 5 DP - 2026 Mar 2 TI - The changing landscape of urothelial carcinoma: on the edge of a paradigm shift. LID - 10.1172/JCI202079 [doi] LID - e202079 AB - Urothelial cancers of the urinary tract are the fourth most common malignancy in men, with a shifting demographic affecting younger patients and an increasing incidence in females. In this Review, we discuss recent discoveries and paradigm-shifting clinical trials that impact all stages of urothelial cancer. New therapeutics and drug-delivery devices have led to multiple approvals for treatments of non-muscle invasive bladder cancer. The addition of chemotherapy, immunotherapy, and antibody-drug conjugates is transforming perioperative treatment for patients with muscle-invasive bladder cancer. The use of liquid biomarkers, circulating tumor DNA, and urinary tumor DNA is aiding the identification of patients at risk for local recurrence and possibly those who can avoid systemic therapy. Finally, integrating biomarkers and systemic treatments is creating a paradigm that could lead to the successful treatment of bladder cancer without requiring bladder removal. Overall, these advancements in biomarkers and novel therapeutics are likely to dramatically improve survival for bladder cancer. FAU - Meeks, Joshua J AU - Meeks JJ AD - Departments of Urology and. AD - Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. AD - Jesse Brown VA Medical Center, Department of Veterans Affairs, Chicago, Illinois, USA. LA - eng PT - Journal Article PT - Review DEP - 20260302 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Biomarkers, Tumor) RN - 0 (Circulating Tumor DNA) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Biomarkers, Tumor MH - Female MH - Non-Muscle Invasive Bladder Neoplasms MH - Male MH - Circulating Tumor DNA MH - Immunotherapy PMC - PMC12948436 COIS- Conflict of interest: JJM has received consulting or speaking fees from Merck, AstraZeneca, Janssen, Bristol Myers Squibb, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferringn Pharmaceuticals, CG Oncology, Immunity Bio, Protara Therapuetics, and Photocure. EDAT- 2026/03/02 13:16 MHDA- 2026/03/07 06:38 PMCR- 2026/03/02 CRDT- 2026/03/02 06:03 PHST- 2026/03/07 06:38 [medline] PHST- 2026/03/02 13:16 [pubmed] PHST- 2026/03/02 06:03 [entrez] PHST- 2026/03/02 00:00 [pmc-release] AID - 202079 [pii] AID - 10.1172/JCI202079 [doi] PST - epublish SO - J Clin Invest. 2026 Mar 2;136(5):e202079. doi: 10.1172/JCI202079. eCollection 2026 Mar 2. PMID- 41764455 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Feb 28 TI - Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection. LID - 10.1186/s12885-026-15797-7 [doi] LID - 445 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate, necessitating rigorous surveillance primarily reliant on invasive cystoscopy. While urine cytology offers high specificity, its sensitivity for low-grade tumors is unacceptably low. CellDetect is a novel histochemical staining test based on differential metabolic activity between normal and malignant cells, which is often referred to as the Warburg effect. This study aimed to evaluate its real-world diagnostic performance for detecting NMIBC recurrence. METHODS: This retrospective cohort study included 243 patients under surveillance after transurethral resection of bladder tumor (TURBT). All patients underwent both the CellDetect test and cystoscopy within 24 months post-operatively. Using cystoscopy and histopathology as the reference standard, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of CellDetect were evaluated. Subgroup analyses were performed based on tumor grade, stage, and European Organization for Research and Treatment of Cancer (EORTC) risk category. RESULTS: Among the 52 patients (21.4%) with histologically confirmed recurrence, the overall sensitivity of the CellDetect test was 76.9%, specificity was 78.0%, PPV was 52.6%, NPV was 91.2%, and overall accuracy was 77.8%. Sensitivity was significantly higher for high-grade (HG) tumors (93.8%) than for low-grade (LG) tumors (69.4%). In the high-risk EORTC subgroup, sensitivity was 88.9% and NPV was 95.2%. Furthermore, among 18 patients with "discordant" findings (positive CellDetect/ negative cystoscopy), 6 (33.3%) were subsequently diagnosed with recurrence upon random biopsy. CONCLUSION: In this retrospective analysis, the CellDetect test demonstrated encouraging diagnostic performance in the post-TURBT surveillance setting, particularly its high NPV and sensitivity for HG tumors. "Discordant" results may hold predictive value for imminent recurrence. Further prospective validation is warranted. CellDetect represents a potential tool for developing a more personalized, risk-adapted, and patient-friendly follow-up strategy for NMIBC. FAU - Gao, Wen-Bo AU - Gao WB AD - Department of Urology, Ningbo Urology and Nephrology Hospital, Ningbo City, Zhejiang Province, PR China. gwbmdoc@foxmail.com. FAU - Yu, Jing-Jing AU - Yu JJ AD - Department of Pathology, Ningbo Urology and Nephrology Hospital, Ningbo City, Zhejiang Province, PR China. LA - eng PT - Journal Article DEP - 20260228 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - Transurethral Resection of Bladder MH - Female MH - *Neoplasm Recurrence, Local/diagnosis/pathology MH - Retrospective Studies MH - Male MH - Non-Muscle Invasive Bladder Neoplasms MH - Aged MH - Cystoscopy MH - *Urinary Bladder Neoplasms/surgery/pathology/diagnosis MH - Middle Aged MH - Sensitivity and Specificity MH - Aged, 80 and over MH - Predictive Value of Tests MH - Neoplasm Grading PMC - PMC13059172 OTO - NOTNLM OT - Bladder cancer OT - CellDetect OT - Diagnostic Performance OT - Surveillance OT - Transurethral resection of bladder tumor COIS- Declarations. Ethics approval and consent to participate: This study was conducted in compliance with the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of Ningbo Urology and Nephrology Hospital. Informed consent was obtained from all individual participants included in the study. Patient data were anonymized to ensure confidentiality. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/03/01 13:37 MHDA- 2026/06/27 12:39 PMCR- 2026/02/28 CRDT- 2026/03/01 07:33 PHST- 2025/12/27 00:00 [received] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/06/27 12:39 [medline] PHST- 2026/03/01 13:37 [pubmed] PHST- 2026/03/01 07:33 [entrez] PHST- 2026/02/28 00:00 [pmc-release] AID - 10.1186/s12885-026-15797-7 [pii] AID - 15797 [pii] AID - 10.1186/s12885-026-15797-7 [doi] PST - epublish SO - BMC Cancer. 2026 Feb 28;26(1):445. doi: 10.1186/s12885-026-15797-7. PMID- 41763905 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260901 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity. PG - 814-821 LID - S2588-9311(26)00057-X [pii] LID - 10.1016/j.euo.2026.02.020 [doi] AB - BACKGROUND AND OBJECTIVE: Low-grade, stage Ta (TaLG) non-muscle-invasive bladder cancer (NMIBC) is generally nonaggressive; yet, some patients experience recurrence or progression. We previously identified long noncoding RNA cluster 2 (LC2) as an aggressive TaLG subgroup via consensus clustering, which required a cohort-level analysis. We developed a single-sample transcriptome classifier for patient-level LC2 identification. METHODS: Using the UROMOL cohort (n = 276) for training/testing and the Hurst (Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep Med 2021;2:100472) cohort (n = 72) for validation, we performed feature selection via median absolute deviation and nested cross-validation. An elastic net regression model (alpha = 0.5) was trained using ten-fold cross-validation. Performance was evaluated through a pathway analysis, with prognostic significance assessed by Kaplan-Meier and univariable Cox regression. KEY FINDINGS AND LIMITATIONS: Biological characterization revealed that LC2 tumors exhibited higher proliferation (G2M/E2F signatures), elevated FGFR3 pathway activity, and reduced sonic hedgehog signaling and immune activity (p < 0.001). The classifier identified 7/72 LC2 tumors in the Hurst cohort. LC2-TaLG patients had significantly worse recurrence-free survival (log-rank p < 0.001). On univariable Cox regression analysis, LC2 status was strongly associated with recurrence (hazard ratio 4.52, 95% confidence interval 1.78-11.5; p = 0.001). LC2-predicted tumors in the Hurst cohort showed similar biological patterns. CONCLUSIONS AND CLINICAL IMPLICATIONS: We developed a single-sample transcriptomic classifier identifying aggressive TaLG NMIBC, demonstrating reproducibility across platforms. If validated, this model has the potential to support clinical decision-making. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Thu Phung, Tran Anh AU - Thu Phung TA AD - Vancouver Prostate Centre, M. H. Mohseni Institute of Urologic Sciences, Vancouver, BC, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Weng, Rachel AU - Weng R AD - Vancouver Prostate Centre, M. H. Mohseni Institute of Urologic Sciences, Vancouver, BC, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Centre, M. H. Mohseni Institute of Urologic Sciences, Vancouver, BC, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Gibb, Ewan A AU - Gibb EA AD - Vancouver Prostate Centre, M. H. Mohseni Institute of Urologic Sciences, Vancouver, BC, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. Electronic address: ewan.gibb@ubc.ca. LA - eng PT - Journal Article DEP - 20260228 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (RNA, Long Noncoding) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) SB - IM MH - Humans MH - *RNA, Long Noncoding/genetics MH - *Receptor, Fibroblast Growth Factor, Type 3/metabolism/genetics MH - Non-Muscle Invasive Bladder Neoplasms/genetics MH - Female MH - Male MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Neoplasm Grading MH - Aged MH - Middle Aged MH - Prognosis OTO - NOTNLM OT - Biomarkers OT - Gene expression profiling OT - Long noncoding RNA OT - Non-muscle-invasive bladder cancer OT - Single-sample classifier OT - Ta bladder cancer EDAT- 2026/03/01 00:35 MHDA- 2026/09/01 23:34 CRDT- 2026/02/28 21:51 PHST- 2025/11/20 00:00 [received] PHST- 2026/02/04 00:00 [revised] PHST- 2026/02/13 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/03/01 00:35 [pubmed] PHST- 2026/02/28 21:51 [entrez] AID - S2588-9311(26)00057-X [pii] AID - 10.1016/j.euo.2026.02.020 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):814-821. doi: 10.1016/j.euo.2026.02.020. Epub 2026 Feb 28. PMID- 41751537 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260813 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 17 IP - 2 DP - 2026 Jan 29 TI - Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction. LID - 10.3390/genes17020153 [doi] LID - 153 AB - Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 70% of newly diagnosed bladder cancer cases but exhibits significant clinical heterogeneity in treatment response and progression risk. While intravesical bacillus Calmette-GuerinCa (BCG) therapy remains the gold standard for high-risk disease, approximately 30-50% of patients experience BCG failure, creating a critical decision point between additional bladder-sparing therapy (BST) and early radical cystectomy (RC). Recent clinical data from the CISTO study suggest that, in appropriately selected patients, RC may be associated with higher 12-month recurrence-free survival while maintaining comparable cancer-specific survival and physical functioning. In this narrative review, we synthesize contemporary evidence on NMIBC genomic and transcriptomic subtypes, immune contexture, and clinicopathologic features associated with BCG response and progression risk, with emphasis on clinically oriented classification systems such as BCG Response Subtypes (BRS1-3) and UROMOL21. We highlight how tumor-intrinsic biology (e.g., EMT-associated programs), immune phenotypes (inflamed vs. immune-cold microenvironments), and genomic alterations may help refine risk stratification beyond traditional clinicopathologic models. To facilitate clinical integration, we propose a conceptual decisional framework that combines molecular subtype assignment, immune profiling, key pathologic risk factors, and patient considerations to generate probabilistic risk tiers that support selection among early RC, BST, and clinical trial strategies. Standardized multicenter cohorts and prospective evaluation are needed to validate integrated models and define their clinical utility for the precision timing of cystectomy in BCG-unresponsive NMIBC. FAU - Schitcu, Vlad-Horia AU - Schitcu VH AUID- ORCID: 0000-0002-6735-8889 AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. FAU - Munteanu, Vlad Cristian AU - Munteanu VC AUID- ORCID: 0000-0003-3808-2446 AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. FAU - Borz, Mihnea Bogdan AU - Borz MB AUID- ORCID: 0000-0002-7361-7031 AD - Department of Urology, Targu Mures County Emergency Clinical Hospital, 540136 Targu Mures, Romania. FAU - Cojocaru, Ion AU - Cojocaru I AUID- ORCID: 0000-0002-5107-614X AD - Department of Urology, Galati County Emergency Hospital, 800578 Galati, Romania. FAU - Morari, Octavia AU - Morari O AD - Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuta" Cluj-Napoca, 400015 Cluj-Napoca, Romania. FAU - Girbovan, Mircea AU - Girbovan M AD - Department of Urology, Targu Mures County Emergency Clinical Hospital, 540136 Targu Mures, Romania. FAU - Tise, Andrei-Ionut AU - Tise AI AD - Department of Urology, Alba County Emergency Hospital, 711325 Alba-Iulia, Romania. LA - eng PT - Journal Article PT - Review DEP - 20260129 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/genetics MH - *Cystectomy/methods MH - *BCG Vaccine/therapeutic use MH - *Biomarkers, Tumor/genetics MH - Genomics/methods MH - *Urinary Bladder Neoplasms/genetics PMC - PMC12940329 OTO - NOTNLM OT - BCG response prediction OT - genomic subtypes OT - molecular biomarkers OT - non-muscle-invasive bladder cancer OT - precision oncology OT - radical cystectomy OT - timing of surgery COIS- The authors declare no conflict of interest. EDAT- 2026/02/27 06:32 MHDA- 2026/03/06 09:10 PMCR- 2026/01/29 CRDT- 2026/02/27 01:08 PHST- 2026/01/13 00:00 [received] PHST- 2026/01/20 00:00 [revised] PHST- 2026/01/23 00:00 [accepted] PHST- 2026/03/06 09:10 [medline] PHST- 2026/02/27 06:32 [pubmed] PHST- 2026/02/27 01:08 [entrez] PHST- 2026/01/29 00:00 [pmc-release] AID - genes17020153 [pii] AID - genes-17-00153 [pii] AID - 10.3390/genes17020153 [doi] PST - epublish SO - Genes (Basel). 2026 Jan 29;17(2):153. doi: 10.3390/genes17020153. PMID- 41749876 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260227 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 4 DP - 2026 Feb 14 TI - Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers18040623 [doi] LID - 623 AB - Non-muscle-invasive bladder cancer (NMIBC) comprises approximately 75% of new bladder cancer cases and generally carries a favorable prognosis, yet high rates of recurrence and progression necessitate close surveillance with frequent cystoscopies and repeated transurethral resections. Upfront treatment for high-risk disease is typically Bacillus Calmette-Guerin (BCG), although combinations with immune checkpoint inhibitors have reported results. Patients with BCG-unresponsive, intolerant, or refractory disease represent a subset of patients with high risk of progression, with early radical cystectomy being the standard approach for this setting. Global BCG shortages and the substantial impact of cystectomy on quality of life underscore the need for therapeutic alternatives. Over the past decade, investigational trials in immunotherapy have expanded treatment options for BCG-unresponsive NMIBC with CIS, leading to FDA approval of intravesical nadofaragene firadenovec, nogapendekin alfa-inbakicept, and systemic pembrolizumab. This narrative review summarizes developments in intravesical and systemic immunotherapies for NMIBC, highlights ongoing trials, and addresses controversies in trial design, treatment sequencing, comparative efficacy, and safety. FAU - Grier, Abby L AU - Grier AL AUID- ORCID: 0000-0002-5199-8670 AD - School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. FAU - Zhong, Jeffrey Y AU - Zhong JY AD - Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. FAU - Basourakos, Spyridon AU - Basourakos S AUID- ORCID: 0000-0002-7458-4593 AD - Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. FAU - Calaway, Adam AU - Calaway A AD - Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. FAU - Singh, Parminder AU - Singh P AUID- ORCID: 0000-0002-8548-6948 AD - Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Zakharia, Yousef AU - Zakharia Y AUID- ORCID: 0000-0001-9480-2626 AD - Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Lucien, Fabrice AU - Lucien F AUID- ORCID: 0000-0001-6149-345X AD - Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Shah, Paras AU - Shah P AD - Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Costello, Brian A AU - Costello BA AD - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Pagliaro, Lance C AU - Pagliaro LC AD - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Orme, Jacob J AU - Orme JJ AUID- ORCID: 0000-0002-0319-0239 AD - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. FAU - Brown, Jason R AU - Brown JR AUID- ORCID: 0000-0001-6225-7555 AD - Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. AD - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA. FAU - Jang, Albert AU - Jang A AUID- ORCID: 0000-0002-0461-6174 AD - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. AD - Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. AD - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA. LA - eng PT - Journal Article PT - Review DEP - 20260214 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12938786 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - immune checkpoint inhibitor OT - immunotherapy OT - intravesical therapy OT - non-muscle-invasive bladder cancer OT - transurethral resection of bladder tumors COIS- A.C. is a key opinion leader for Fortec medical and reports honoraria from the AUA, Pfizer, and OncLive. P. Singh reports advisory board membership with Genetech, Gilead Sciences, Bicycle Therapeutics, Astellas, and Pfizer. P. Singh also reports speaking fees from Curio, IBCU, Target Oncology, and GatherEd. R.J.K reports a one-time advisory panel (December 2025) from Ferring Pharm. V.S. owns stock in ImmunityBio, Macrogenics, and United. J.J.O. receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23). Current clinical trial support from Janux Therapeutics. J.J.O. has received support from NaNotics, NEXUS Global, Genentech, Johnson & Johnson, and Partner Therapeutics. J.J.O. reports support and/or research and consulting support from the Prostate Cancer Foundation, NaNotics, Nexus Global, Genentech, and Partner Therapeutics. J.R.B. reports honoraria from AstraZeneca, EMD Serono, Ipsen, Johnson and Johnson, and Pfizer. A.J. reports personal fees from RealTimeCase; honoraria from MJH Life Sciences and Curio Science; and travel/housing/accommodation from MECC Inc. and the Binaytara Foundation. Other authors declare no relevant conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the review. EDAT- 2026/02/27 06:31 MHDA- 2026/02/27 06:32 PMCR- 2026/02/14 CRDT- 2026/02/27 01:03 PHST- 2025/12/31 00:00 [received] PHST- 2026/02/03 00:00 [revised] PHST- 2026/02/05 00:00 [accepted] PHST- 2026/02/27 06:32 [medline] PHST- 2026/02/27 06:31 [pubmed] PHST- 2026/02/27 01:03 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - cancers18040623 [pii] AID - cancers-18-00623 [pii] AID - 10.3390/cancers18040623 [doi] PST - epublish SO - Cancers (Basel). 2026 Feb 14;18(4):623. doi: 10.3390/cancers18040623. PMID- 41749284 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260914 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 24 IP - 1 DP - 2026 Feb 27 TI - Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy. LID - 10.1186/s12916-026-04745-8 [doi] LID - 196 AB - BACKGROUND: High-frequency recurrence (HfR, >/= 2 recurrences) in non-muscle-invasive bladder cancer (NMIBC) poses a significant clinical burden. Current risk models, such as the European Organization for Research and Treatment of Cancer (EORTC), the European Association of Urology (EAU), and the UROMOL classification, offer limited predictive accuracy for identifying patients at risk for frequent recurrence despite appropriate treatment. METHODS: A 75-gene high-frequency recurrence index (HfRI) was constructed by selecting recurrence-associated genes using differential expression and Cox regression analyses. The HfRI was computed as a weighted sum of normalized gene expression values. The model was trained on a discovery cohort and validated in multiple cohorts (n = 1379) using machine-learning approaches. Clinical relevance was assessed using recurrence-free survival (RFS) and Cox models, and predictive performance was compared with that of the EORTC, EAU, and UROMOL classifications using the area under the curve (AUC) and the concordance index (c-index). RESULTS: The HfRI robustly stratified patients into high-risk and low-risk groups across six independent NMIBC cohorts. Patients classified as HfRI-high had a significantly greater likelihood of experiencing >/= 2 recurrences (chi(2), p = 0.001) and showed markedly reduced RFS (log-rank test, p < 0.001). The adverse prognostic effect of the HfRI persisted even among patients treated with BCG therapy (log-rank test, p = 0.02). Multivariate analysis revealed that the HfRI was an independent predictor of HfR (HR = 2.82, 95% CI = 1.89-4.20, p < 0.001). Compared with established clinical risk classifiers, the HfRI demonstrated superior predictive performance (AUC = 0.736, c-index = 0.673) in terms of the EORTC (AUC = 0.594), EAU (AUC = 0.557) risk groups, and UROMOL2021 (AUC = 0.596) classification. Pathway analysis revealed that HfRI-high tumors were characterized by upregulation of cell cycle progression and DNA replication pathways, accompanied by suppression of immune signaling pathways. These biological features provide a mechanistic explanation for the reduced responsiveness to intravesical BCG therapy, underscoring the role of HfRI not only as a predictor of recurrence risk but also as a biomarker capable of identifying patients unlikely to benefit from standard BCG treatment. CONCLUSIONS: HfRI represents a robust, transcriptome-based tool for predicting frequent recurrence in NMIBC patients. The HfRI supports earlier identification of patients at risk of high-frequency recurrence, thereby supporting personalized treatment strategies. CI - (c) 2026. The Author(s). FAU - Baek, Seung-Woo AU - Baek SW AD - Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. FAU - Seo, Jee-Woo AU - Seo JW AD - Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. AD - Department of Bioscience, University of Science and Technology, Daejeon, Republic of Korea. FAU - Jeong, Il-San AU - Jeong IS AD - Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. AD - Department of Bioscience, University of Science and Technology, Daejeon, Republic of Korea. FAU - Kamarov, Otabek AU - Kamarov O AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. FAU - Moon, Seongmin AU - Moon S AD - Department of Urology, Chungbuk National University Hospital, Cheongju, Republic of Korea. FAU - Kim, Kyeong AU - Kim K AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, Hankook General Hospital, Cheongju, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, Republic of Korea. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biochemistry, Dong-Eui University College of Korean Medicine, Busan, Republic of Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food and Nutrition, Chung-Ang University, Anseong, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Institute of Urotech, Cheongju, Republic of Korea. FAU - Choi, Young Deuk AU - Choi YD AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Seon-Young AU - Kim SY AD - Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. AD - Department of Bioscience, University of Science and Technology, Daejeon, Republic of Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. seonkyu@kribb.re.kr. AD - Department of Bioscience, University of Science and Technology, Daejeon, Republic of Korea. seonkyu@kribb.re.kr. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Chungbuk, 28644, Republic of Korea. sjyun@chungbuk.ac.kr. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, Republic of Korea. sjyun@chungbuk.ac.kr. AD - Cancer Research Center, Chungbuk National University, Cheongju, Republic of Korea. sjyun@chungbuk.ac.kr. LA - eng SI - GEO/GSE294703[16] SI - GEO/GSE294705[17] SI - GEO/GSE5479[12, 20] SI - GEO/GSE13507[13, 14, 21] SI - GEO/GSE120736[11, 22] SI - GEO/GSE163209[8, 23] GR - 2022R1A6A3A01087141/Ministry of Education/ GR - RS-2023-00245919/Ministry of Education/ GR - 2120240615350/Ministry of Education/ GR - BK21 program (2024)/Chungbuk National University/ GR - RS-2024-00342111/Ministry of Science and ICT, South Korea/ GR - NRF-2021M3H9A2096953/Ministry of Science and ICT, South Korea/ GR - RS-2025-19922981/Ministry of Science and ICT, South Korea/ GR - KGM5192531/Korea Research Institute of Bioscience and Biotechnology/ PT - Journal Article DEP - 20260227 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/genetics/drug therapy MH - Female MH - *Neoplasm Recurrence, Local/genetics MH - Male MH - Aged MH - *Transcriptome MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/genetics MH - Gene Expression Profiling MH - Adjuvants, Immunologic/therapeutic use MH - Prognosis PMC - PMC13040970 OTO - NOTNLM OT - BCG therapy OT - Frequent recurrence OT - High-frequency recurrence index OT - NMIBC COIS- Declarations. Ethics approval and consent to participate: All patient-derived tissues were collected after surgery at Chungbuk National University Hospital (CBNUH) in accordance with institutional procedures. The study was approved by the Institutional Review Board of Chungbuk National University and CBNUH (IRB approval numbers: CBNU-202309-BR-0201 and GR2010-12-010, respectively), and written informed consent was obtained from all participants prior to enrollment. Specimens were provided by CBNUH, a member of the National Biobank of Korea supported by the Ministry of Health, Welfare and Family Affairs, and all biobank samples were obtained under IRB-approved protocols with informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/27 00:33 MHDA- 2026/04/02 06:30 PMCR- 2026/02/27 CRDT- 2026/02/26 23:49 PHST- 2025/09/03 00:00 [received] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/04/02 06:30 [medline] PHST- 2026/02/27 00:33 [pubmed] PHST- 2026/02/26 23:49 [entrez] PHST- 2026/02/27 00:00 [pmc-release] AID - 10.1186/s12916-026-04745-8 [pii] AID - 4745 [pii] AID - 10.1186/s12916-026-04745-8 [doi] PST - epublish SO - BMC Med. 2026 Feb 27;24(1):196. doi: 10.1186/s12916-026-04745-8. PMID- 41744892 OWN - NLM STAT- In-Process LR - 20260813 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 33 IP - 2 DP - 2026 Feb 22 TI - BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG. LID - 10.3390/curroncol33020128 [doi] LID - 128 AB - Evidence on modifiable post-diagnosis factors influencing outcomes after intravesical Bacillus Calmette-Guerin (BCG) therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) is limited. In this exploratory, feasibility-focused prospective multicenter cohort (March 2023-November 2024), BCG-naive patients completed repeated interviewer-administered 24 h dietary recalls; prespecified food groups, selected foods, and nutrients were screened for associations with 1-year intravesical recurrence using Firth's penalized logistic regression adjusted a priori for age, sex, and total energy intake, with false discovery rate control within each exposure family. Forty-six patients were enrolled; 41 had evaluable recurrence status, including 8 recurrences (19.5%). Participants were predominantly overweight (mean body mass index (BMI) 28.4 kg/m(2)) and had low adherence to a Mediterranean dietary pattern (median Mediterranean Adequacy Index 2.25). No dietary exposure met the within-family false discovery rate threshold; the smallest q-value was 0.361. Nominal inverse associations were observed for leafy green vegetables (OR per 1 SD 0.385; 95% CI 0.101-0.972) and for energy-adjusted zinc (OR 0.280; 95% CI 0.069-0.802) and magnesium intakes (OR 0.260; 95% CI 0.045-0.872), but these did not remain significant after FDR adjustment. These exploratory signals warrant replication in larger, biomarker-informed cohorts incorporating dietary biomarkers and immune profiling during BCG. Given the limited sample size and low number of recurrence events, these findings are strictly hypothesis-generating and should not be interpreted as evidence of definitive protective or risk dietary factors. FAU - Buonerba, Carlo AU - Buonerba C AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. AD - Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. FAU - Baio, Raffaele AU - Baio R AUID- ORCID: 0000-0002-3157-0845 AD - Department of Urology, Umberto I, Nocera Inferiore, 84014 Salerno, Italy. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Urology and Andrology Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Bruzzese, Dario AU - Bruzzese D AUID- ORCID: 0000-0001-9911-4646 AD - Department of Public Health, University of Naples Federico II, 80131 Naples, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Nacchia, Antonio AU - Nacchia A AUID- ORCID: 0000-0002-3985-1991 AD - Sant'Andrea Hospital, 00189 Rome, Italy. FAU - Chiancone, Francesco AU - Chiancone F AUID- ORCID: 0000-0001-8648-3557 AD - Department of Urology, A.O.R.N. Antonio Cardarelli Hospital, 80131 Naples, Italy. FAU - Ingenito, Concetta AU - Ingenito C AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. FAU - Strianese, Oriana AU - Strianese O AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. FAU - Verde, Antonio AU - Verde A AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. AD - Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. FAU - Costabile, Ferdinando AU - Costabile F AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. AD - Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. FAU - Scafuri, Luca AU - Scafuri L AUID- ORCID: 0000-0002-7410-8300 AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. AD - Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. FAU - Sanseverino, Roberto AU - Sanseverino R AD - Department of Urology, Umberto I, Nocera Inferiore, 84014 Salerno, Italy. FAU - Sorrentino, Elena AU - Sorrentino E AUID- ORCID: 0000-0002-3570-7642 AD - Department of Agricultural, Environmental and Food Sciences (DiAAA), University of Molise, Via Francesco de Sanctis snc, 86100 Campobasso, Italy. FAU - Riccio, Vittorio AU - Riccio V AD - P.O. "Santissima Maria della Pieta" Hospital, 80026 Casoria, Italy. FAU - Carino, Dalila AU - Carino D AUID- ORCID: 0009-0007-4043-6625 AD - Department of Maternal-Infant and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Bertoni, Margherita AU - Bertoni M AD - Department of Maternal-Infant and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Monaco, Federica AU - Monaco F AUID- ORCID: 0000-0002-5986-3594 AD - Department of Anesthesia, San Paolo Hospital ASL Napoli 1 Centro, 80125 Naples, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy. FAU - Di Lauro, Teresa AU - Di Lauro T AD - S.C. Oncologia Clinica Sperimentale Uro-Ginecologica, IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale", 80131 Naples, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Urology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy. FAU - Manfredi, Celeste AU - Manfredi C AD - Unit of Urology, Department of Woman Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. FAU - Ruffo, Antonio AU - Ruffo A AD - Dipartimento di Medicina e di Scienze della Salute "Vincenzo Tiberio", 86100 Campobasso, Italy. FAU - Barbato, Gabriele AU - Barbato G AD - Department of Anesthesia and Intensive Care, "Anastasia Guerriero" Hospital, Caserta Local Health Authority, Marcianise, 81100 Caserta, Italy. FAU - Rizzano, Serena AU - Rizzano S AD - Fondazione "Peppino Scoppa", Angri, 84012 Salerno, Italy. FAU - Rizzano, Sara AU - Rizzano S AD - Fondazione "Peppino Scoppa", Angri, 84012 Salerno, Italy. FAU - Pisapia, Armando AU - Pisapia A AD - Fondazione "Peppino Scoppa", Angri, 84012 Salerno, Italy. FAU - Pisapia, Marina AU - Pisapia M AD - Fondazione "Peppino Scoppa", Angri, 84012 Salerno, Italy. FAU - Di Trolio, Rossella AU - Di Trolio R AD - Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, 80131 Naples, Italy. FAU - Sergianni, Emanuela AU - Sergianni E AD - School of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Romeo, Giuseppe AU - Romeo G AD - Department of Urology, A.O.R.N. Antonio Cardarelli Hospital, 80131 Naples, Italy. FAU - Cappuccio, Francesca AU - Cappuccio F AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. FAU - Sosto, Gennaro AU - Sosto G AD - General Directorate, ASL Salerno, 84134 Salerno, Italy. FAU - Di Lorenzo, Giuseppe AU - Di Lorenzo G AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. AD - Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. AD - School of Medicine, UniCamillus "Saint Camillus International" University of Health Sciences, 00131 Rome, Italy. LA - eng GR - (Protocol No. 2203159/23)/liberal grant from the Bank of Italy (Banca d'Italia Eurosystem)/ GR - (Protocol No. 1100/15/10/2020)/AstraZeneca (Italy)/ GR - (Grant No. 302/2023)/Fondazione Peppino Scoppa/ PT - Journal Article DEP - 20260222 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM PMC - PMC12939331 OTO - NOTNLM OT - 24 h dietary recall OT - FOODCONS OT - Firth logistic regression OT - Mediterranean Adequacy Index OT - diet OT - intravesical BCG OT - non-muscle-invasive bladder cancer OT - nutrient density OT - recurrence COIS- The authors declare no conflicts of interest. EDAT- 2026/02/26 13:40 MHDA- 2026/02/26 13:40 PMCR- 2026/02/22 CRDT- 2026/02/26 09:05 PHST- 2026/01/15 00:00 [received] PHST- 2026/02/15 00:00 [revised] PHST- 2026/02/20 00:00 [accepted] PHST- 2026/02/26 13:40 [medline] PHST- 2026/02/26 13:40 [pubmed] PHST- 2026/02/26 09:05 [entrez] PHST- 2026/02/22 00:00 [pmc-release] AID - curroncol33020128 [pii] AID - curroncol-33-00128 [pii] AID - 10.3390/curroncol33020128 [doi] PST - epublish SO - Curr Oncol. 2026 Feb 22;33(2):128. doi: 10.3390/curroncol33020128. PMID- 41743958 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260226 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer. PG - 1724968 LID - 10.3389/fonc.2026.1724968 [doi] LID - 1724968 AB - BACKGROUND: The prognostic value of the preoperative gamma-glutamyl transferase to lymphocyte ratio (GLR), an established marker in many solid tumors, remains unclear in non-muscle-invasive bladder cancer (NMIBC). This study aimed to investigate the significance of GLR for predicting recurrence in NMIBC patients after transurethral resection of bladder tumor (TURBt). METHODS: We retrospectively analyzed 254 patients with primary NMIBC who underwent TURBt from 2013 to 2024. Preoperative GLR was calculated from blood tests performed within one week of surgery. The primary endpoint was recurrence-free survival (RFS). The optimal GLR cutoff was determined using receiver operating characteristic (ROC) curve analysis. Kaplan-Meier method, log-rank tests, and Cox proportional hazards models were used to assess survival outcomes and identify independent prognostic factors. A novel prognostic nomogram for RFS was constructed and its performance was evaluated by concordance index (C-index), calibration curves, time-dependent ROC, and decision curve analysis (DCA). RESULTS: The optimal GLR cutoff was identified as 11.71. Patients with high GLR (> 11.71) had significantly poorer RFS (P < 0.001). On multivariate analysis, a high GLR was an independent predictor of postoperative recurrence (Hazard Ratio (HR) = 2.822, 95% Confidence Interval (CI): 1.651-4.824, P < 0.001). A nomogram incorporating GLR and established clinicopathological factors was developed. The inclusion of GLR significantly improved the model's predictive accuracy, increasing the C-index from 0.745 to 0.785. The nomogram demonstrated good calibration and discrimination (3-year Area Under the Curve (AUC) = 0.72) and provided superior net clinical benefit in DCA. The prognostic value of GLR remained robust across all clinicopathological subgroups. CONCLUSION: Preoperative GLR is a simple, cost-effective, and reliable independent biomarker for predicting recurrence in NMIBC patients following TURBt. The GLR-based nomogram integrates systemic inflammation with clinical risk factors, offering a more precise tool for individualized risk stratification. This model can help guide personalized follow-up strategies and adjuvant treatment decisions, holding significant potential for clinical application. CI - Copyright (c) 2026 Zhang, Su, Liu, Song, Cui, Cao, Li, Li, He, Kang and Zhang. FAU - Zhang, Xueqiao AU - Zhang X AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Su, Shiqiang AU - Su S AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Liu, Lizhe AU - Liu L AD - Institute of Medicine and Health, Hebei Medical University, Shijiazhuang, China. FAU - Song, Feifan AU - Song F AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Cui, Xiongjie AU - Cui X AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Cao, Yunpeng AU - Cao Y AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Li, Chao AU - Li C AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Li, Shen AU - Li S AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - He, Hanxing AU - He H AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Kang, Yuanhui AU - Kang Y AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Zhang, Jin AU - Zhang J AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. LA - eng PT - Journal Article DEP - 20260210 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12929151 OTO - NOTNLM OT - gamma-glutamyl transferase to lymphocyte ratio OT - non-muscle-invasive bladder cancer OT - predictive indicator OT - prognosis OT - tumor recurrence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/26 13:41 MHDA- 2026/02/26 13:42 PMCR- 2026/02/10 CRDT- 2026/02/26 04:45 PHST- 2025/10/21 00:00 [received] PHST- 2026/01/19 00:00 [revised] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/02/26 13:42 [medline] PHST- 2026/02/26 13:41 [pubmed] PHST- 2026/02/26 04:45 [entrez] PHST- 2026/02/10 00:00 [pmc-release] AID - 10.3389/fonc.2026.1724968 [doi] PST - epublish SO - Front Oncol. 2026 Feb 10;16:1724968. doi: 10.3389/fonc.2026.1724968. eCollection 2026. PMID- 41742675 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260918 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 5 DP - 2026 May TI - Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer. PG - 821-828 LID - 10.1111/bju.70182 [doi] AB - OBJECTIVE: To examine the impact of specific Bacillus Calmette-Guerin (BCG) failure phenotypes on treatment outcomes with intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer (HR-NMIBC). PATIENTS AND METHODS: A BCG failure was classified according to the United States Food and Drug Administration (FDA)/International Bladder Cancer Group (IBCG) definitions and analysed as early refractory BCG failure, early non-refractory BCG failure, or late BCG relapse. Kaplan-Meier methods were used to estimate recurrence-free survival (RFS), high-grade RFS (HG-RFS), and progression-free survival (PFS). Multivariable Cox proportional hazards models, adjusted for histology, multifocality, and tumour size, were used to assess the association between BCG failure patterns and oncological outcomes. RESULTS: Among the 143 patients included, 72 had early non-refractory BCG failure, 36 had early refractory BCG failure, and 35 experienced late BCG relapse. The median follow-up was 12 months. At 12 months, the RFS was 67% (95% confidence interval [CI] 55-82%) in early non-refractory BCG failure, 54% (95% CI 36-82%) in early refractory BCG failure, and 84% (95% CI 70-100%) in late BCG relapse (P < 0.05). Corresponding HG-RFS rates were 75% (95% CI 64-88%), 58% (95% CI 39-87%), and 87% (95% CI 75-100%), respectively (P < 0.05). The PFS remained >90% across all groups at 12 months. On multivariable analysis, both early non-refractory BCG failure (adjusted hazard ratio [aHR] 3.20, 95% CI 1.31-7.82; P = 0.011) and early refractory BCG failure (aHR 3.59, 95% CI 1.28-10.1; P = 0.015) were associated with a significantly higher risk of recurrence compared with late BCG relapse, with consistent findings for HG recurrence. CONCLUSIONS: Gemcitabine/docetaxel demonstrated meaningful activity across all BCG failure types, with late BCG relapsing patients achieving the most favourable outcomes and refractory disease showing the poorest control. These findings underscore the clinical relevance of distinguishing BCG failure subtypes when selecting candidates for post-BCG intravesical gemcitabine/docetaxel and designing future prospective trials. CI - (c) 2026 BJU International. FAU - Scilipoti, Pietro AU - Scilipoti P AUID- ORCID: 0009-0007-6126-9889 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AUID- ORCID: 0009-0005-8050-9388 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AUID- ORCID: 0009-0001-9363-682X AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Occhi, Angelo AU - Occhi A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Dutto, Daniele AU - Dutto D AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Katzendorn, Olga AU - Katzendorn O AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Elena, Jose Luis Rodriguez AU - Elena JLR AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Lucena, Palma Estella AU - Lucena PE AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Fernandez, Ana AU - Fernandez A AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Szostek, Aleksandra AU - Szostek A AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Bazan, Alfredo Aguilera AU - Bazan AA AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Klatte, Tobias AU - Klatte T AUID- ORCID: 0000-0002-4392-6861 AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. AD - Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Neuruppin, Brandenburg, Germany. FAU - du Biest, Albane Massiet AU - du Biest AM AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Ferrando, Valentina AU - Ferrando V AD - Department of Urology, Hospital Universitari de Bellvitge, Barcelona, Spain. FAU - Buisan, Oscar AU - Buisan O AD - Department of Urology, Hospital Universitari de Bellvitge, Barcelona, Spain. FAU - Lopez, Angela Villares AU - Lopez AV AD - Department of Urology, University Hospital of Toledo, Toledo, Spain. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - D Andrea, David AU - D Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. FAU - Colecchia, Maurizio AU - Colecchia M AUID- ORCID: 0000-0003-1914-0743 AD - Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. CN - European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators LA - eng PT - Journal Article DEP - 20260225 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology MH - Female MH - *Docetaxel/administration & dosage MH - Male MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Administration, Intravesical MH - Aged MH - Treatment Failure MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Treatment Outcome OTO - NOTNLM OT - BCG failure OT - Bacillus Calmette-Guerin OT - docetaxel OT - gemcitabine OT - non-muscle-invasive bladder cancer COIS- Nothing is declared. EDAT- 2026/02/26 15:21 MHDA- 2026/04/13 06:32 CRDT- 2026/02/26 01:53 PHST- 2026/04/13 06:32 [medline] PHST- 2026/02/26 15:21 [pubmed] PHST- 2026/02/26 01:53 [entrez] AID - 10.1111/bju.70182 [doi] PST - ppublish SO - BJU Int. 2026 May;137(5):821-828. doi: 10.1111/bju.70182. Epub 2026 Feb 25. PMID- 41741147 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260908 IS - 1880-2206 (Electronic) IS - 1347-3182 (Print) IS - 1347-3182 (Linking) VI - 25 IP - 3 DP - 2026 Jul 1 TI - Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions. LID - 10.2463/mrms.rev.2025-0213 [doi] LID - 2025-0213 AB - Bladder cancer carries one of the highest lifetime costs among malignancies, and accurate distinction between non-muscle-invasive and muscle-invasive disease is essential for appropriate treatment selection. Multiparametric MRI (mpMRI) and the Vesical Imaging-Reporting and Data System (VI-RADS) have emerged as key tools for standardizing local staging of bladder cancer; however, their clinical uptake in Japan remains limited. This non-systematic narrative review summarizes the fundamentals and current evidence of VI-RADS, outlines Japan-specific barriers to its implementation, and proposes practical solutions and future perspectives. It describes patient preparation and VI-RADS-compliant mpMRI protocols, sequence-specific criteria for estimating muscle invasion, and the diagnostic performance and reproducibility reported in recent meta-analyses. It also evaluates VI-RADS within the context of major international and Japanese guidelines, highlighting the current gap between imaging-based risk stratification and transurethral resection of bladder tumor (TURBT)-centered decision-making. Particular focus is placed on challenges arising from Japan's healthcare structure, heterogeneous MRI quality, and shortage of subspecialized radiologists, as well as common diagnostic pitfalls related to technical, reader, and tumor factors. Recent diagnostic advances-including deep learning-based image reconstruction, improved diffusion and dynamic contrast techniques, and qualitative or quantitative adjunct biomarkers, such as peritumoral enhancement, tumor contact length, diffusion kurtosis metrics, radiomics, and artificial intelligence-based prediction models-are reviewed as promising avenues to enhance diagnostic confidence and inter-reader agreement. Finally, the review discusses MRI-first and MRI-guided clinical pathways under investigation, in which VI-RADS-based risk stratification informs the selective use of TURBT, and facilitates more timely, tailored, definitive therapy. In the future, sustained educational efforts, protocol standardization, quality monitoring, and outcome-based prospective trials will be crucial for establishing bladder MRI and VI-RADS as integral components of personalized bladder cancer care in Japan. FAU - Takeuchi, Mitsuru AU - Takeuchi M AUID- ORCID: 0000-0002-3005-8487 AD - Radiolonet Tokai, Nagoya, Aichi, Japan. AD - Department of Radiology, Kawasaki Medical School, Kurashiki, Okayama, Japan. FAU - Tamada, Tsutomu AU - Tamada T AUID- ORCID: 0000-0003-2521-9570 AD - Department of Radiology, Kawasaki Medical School, Kurashiki, Okayama, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260226 PL - Japan TA - Magn Reson Med Sci JT - Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine JID - 101153368 SB - IM MH - Humans MH - Japan MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - *Multiparametric Magnetic Resonance Imaging MH - *Magnetic Resonance Imaging/methods MH - Reproducibility of Results MH - Transurethral Resection of Bladder MH - Neoplasm Staging MH - *Radiology Information Systems PMC - PMC13546798 OTO - NOTNLM OT - Japan OT - Vesical Imaging-Reporting and Data System OT - bladder cancer OT - clinical application OT - magnetic resonance imaging COIS- Conflicts of Interest: The authors declare that they have no conflicts of interest. EDAT- 2026/02/26 15:24 MHDA- 2026/07/02 00:34 PMCR- 2026/02/26 CRDT- 2026/02/25 21:13 PHST- 2026/07/02 00:34 [medline] PHST- 2026/02/26 15:24 [pubmed] PHST- 2026/02/25 21:13 [entrez] PHST- 2026/02/26 00:00 [pmc-release] AID - mrms-25-0213 [pii] AID - 10.2463/mrms.rev.2025-0213 [doi] PST - ppublish SO - Magn Reson Med Sci. 2026 Jul 1;25(3):2025-0213. doi: 10.2463/mrms.rev.2025-0213. Epub 2026 Feb 26. PMID- 41740229 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260813 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 125 DP - 2026 Mar TI - Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription. PG - 106182 LID - S2352-3964(26)00063-0 [pii] LID - 10.1016/j.ebiom.2026.106182 [doi] LID - 106182 AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is an uncommon but aggressive malignancy. Muscle invasion is strongly associated with poor prognosis and limited treatment options. Revealing the molecular basis of muscle invasiveness in UTUC is crucial. METHODS: We characterised somatic structural variants (SSVs) from 162 patients with UTUC and integrated these data with bulk RNA-seq, single cell RNA-seq and spatial transcriptomics, with selected SSVs validated by single-molecule sequencing. Furthermore, functional validation experiments, including dual-luciferase reporter assays, wound healing, and invasion/migration assays, were conducted on both the SSV region upstream of TPX2 and the TPX2 gene itself in the 5637 cell line. FINDINGS: We found that SSVs were enriched in muscle-invasive (MI) -UTUC compared with non-muscle-invasive (NMI)-UTUC, and were associated with gene expression changes independent of copy-number variation. TPX2 emerged as a representative target, with TPX2-associated SSVs linked to TPX2 over expression and patient poorer progression-free and overall survival. Functional study indicated that a TPX2-upstream SSV region enhances TPX2 expression through promoter regulation, leading to increased invasiveness of 5637 cells. Single cell analyses revealed that TPX2-positive cycling epithelial cells exhibited heightened proliferative signalling and distinct ligand-receptor interactions, particularly involving EGFR- and EPHA2-related pathways. Spatial transcriptomics further localised TPX2-positive spots to epithelial mesenchymal transition (EMT) -enriched neighbourhoods with elevated EGFR/EPHA2 associated ligands, and showed markedly higher abundance in MI-UTUC. INTERPRETATION: SSVs drive transcriptional reprogramming, disease aggressiveness and microenvironmental remodelling in UTUC. The signatures of SSVs could classify UTUC into classes with different prognosis. Furthermore, SSVs of TPX2 might be a potential biomarker and candidate therapeutic vulnerability. FUNDING: Stated in acknowledgements section of manuscript. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Xu, Zhe AU - Xu Z AD - Science and Technology Research Centre, Harbin Medical University Cancer Hospital, Harbin, 150080, China; Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China; College of Life Sciences, University of Chinese Academy of Science, Beijing, 100049, China. FAU - Lv, Wei AU - Lv W AD - Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. FAU - He, Rongzhang AU - He R AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, 423000, China. FAU - Li, Yue AU - Li Y AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. FAU - Peng, Xi AU - Peng X AD - College of Life Sciences, University of Chinese Academy of Science, Beijing, 100049, China; Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. FAU - He, Chunxiao AU - He C AD - Scientific Research Center, Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. FAU - Lin, Ling AU - Lin L AD - College of Life Sciences, University of Chinese Academy of Science, Beijing, 100049, China. FAU - Lan, Linxiang AU - Lan L AD - Scientific Research Center, Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. FAU - Sui, Xiaolong AU - Sui X AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. FAU - Liu, Xin AU - Liu X AD - College of Life Sciences, University of Chinese Academy of Science, Beijing, 100049, China. FAU - Dong, Wei AU - Dong W AD - Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. FAU - Yang, Huanming AU - Yang H AD - Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. FAU - Yuan, Zhennan AU - Yuan Z AD - Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: yuanzhennan123@hrbmu.edu.cn. FAU - Fan, Guangyi AU - Fan G AD - College of Life Sciences, University of Chinese Academy of Science, Beijing, 100049, China. Electronic address: fanguangyi@genomics.cn. FAU - Lin, Chunhua AU - Lin C AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. Electronic address: chunhua.lin@qdu.edu.cn. FAU - Xiang, Xi AU - Xiang X AD - Scientific Research Center, Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. Electronic address: xiangx25@mail.sysu.edu.cn. FAU - Han, Peng AU - Han P AD - Science and Technology Research Centre, Harbin Medical University Cancer Hospital, Harbin, 150080, China; Lars Bolund Institute of Regenerative Medicine, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China; Scientific Research Center, Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. Electronic address: hanpeng@sysush.com. LA - eng PT - Journal Article DEP - 20260224 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (TPX2 protein, human) RN - 0 (Microtubule-Associated Proteins) RN - 0 (Cell Cycle Proteins) SB - IM MH - Humans MH - *Microtubule-Associated Proteins/genetics/metabolism MH - *Cell Cycle Proteins/genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Cell Line, Tumor MH - Neoplasm Invasiveness MH - *Transcription, Genetic MH - Promoter Regions, Genetic MH - Cell Movement/genetics MH - Female MH - Cell Proliferation PMC - PMC12955098 OTO - NOTNLM OT - Complex structrual variant OT - Somatic structural variant OT - TPX2 OT - Tumour microenvironment OT - Upper tract urothelial carcinoma COIS- Declaration of interests The authors declare no competing interests. EDAT- 2026/02/26 15:21 MHDA- 2026/03/14 00:32 PMCR- 2026/02/24 CRDT- 2026/02/25 18:03 PHST- 2025/07/07 00:00 [received] PHST- 2026/02/05 00:00 [revised] PHST- 2026/02/06 00:00 [accepted] PHST- 2026/03/14 00:32 [medline] PHST- 2026/02/26 15:21 [pubmed] PHST- 2026/02/25 18:03 [entrez] PHST- 2026/02/24 00:00 [pmc-release] AID - S2352-3964(26)00063-0 [pii] AID - 106182 [pii] AID - 10.1016/j.ebiom.2026.106182 [doi] PST - ppublish SO - EBioMedicine. 2026 Mar;125:106182. doi: 10.1016/j.ebiom.2026.106182. Epub 2026 Feb 24. PMID- 41733191 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260717 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 36 IP - 3 DP - 2026 May 1 TI - Navigating bladder preservation in Bacillus Calmette-Guerin-unresponsive disease: how much risk is too much? PG - 235-243 LID - 10.1097/MOU.0000000000001371 [doi] AB - PURPOSE OF REVIEW: Management of Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer (BCG-unresponsive NMIBC) is rapidly evolving, with an expanding range of bladder-sparing therapies challenging the traditional paradigm of early radical cystectomy. This review is timely given the growing need to balance oncologic safety with quality-of-life considerations in patients who are unfit for or unwilling to undergo cystectomy. RECENT FINDINGS: Recent studies have demonstrated clinically meaningful response rates with several bladder-sparing strategies, including intravesical chemotherapy combinations, gene therapy, immune-modulating agents, and systemic immunotherapy. Although durability varies and cross-trial comparisons are limited, emerging data suggest that, in carefully selected patients, an initial bladder-sparing approach followed by timely salvage cystectomy - if required - may achieve oncologic outcomes comparable to upfront cystectomy, provided progression to muscle-invasive disease is avoided. SUMMARY: Bladder preservation in BCG-unresponsive NMIBC should be framed as a preference-sensitive decision that integrates individual progression risk, feasibility of delayed cystectomy, and patient-valued functional outcomes. Rather than a fixed threshold, acceptable oncologic risk represents a negotiated balance, with the urologist acting as a navigator who defines safety boundaries while supporting informed, patient-centered decision-making. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Aliaga, Alfredo AU - Aliaga A AD - Department of Urology, Faculty of Medicine, Clinica Alemana Universidad del Desarrollo. AD - Department of Urology, National Cancer Institute, Santiago, Chile. FAU - Avila, Cristobal AU - Avila C AD - Department of Urology, Faculty of Medicine, University of Chile. FAU - Fernandez, Mario I AU - Fernandez MI AD - Department of Urology, Faculty of Medicine, Clinica Alemana Universidad del Desarrollo. LA - eng PT - Journal Article PT - Review DEP - 20260220 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - *BCG Vaccine/therapeutic use MH - *Cystectomy/adverse effects/methods MH - *Organ Sparing Treatments/methods/adverse effects MH - Administration, Intravesical MH - Salvage Therapy/methods MH - Immunotherapy/methods MH - Quality of Life MH - Risk Assessment MH - Urinary Bladder/surgery/pathology MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Disease Progression OTO - NOTNLM OT - Bacillus Calmette-Guerin-unresponsive OT - bladder-sparing therapy OT - non-muscle-invasive bladder cancer OT - radical cystectomy OT - risk stratification EDAT- 2026/02/24 18:46 MHDA- 2026/03/31 12:32 CRDT- 2026/02/24 07:33 PHST- 2026/03/31 12:32 [medline] PHST- 2026/02/24 18:46 [pubmed] PHST- 2026/02/24 07:33 [entrez] AID - 00042307-990000000-00309 [pii] AID - 10.1097/MOU.0000000000001371 [doi] PST - ppublish SO - Curr Opin Urol. 2026 May 1;36(3):235-243. doi: 10.1097/MOU.0000000000001371. Epub 2026 Feb 20. PMID- 41726849 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260223 LR - 20260813 IS - 2577-171X (Electronic) IS - 2577-171X (Linking) VI - 9 IP - 2 DP - 2026 Mar TI - A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab. PG - e70149 LID - 10.1002/iju5.70149 [doi] LID - e70149 AB - INTRODUCTION: Upper tract urothelial carcinoma with neuroendocrine differentiation (UC-NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin-4-targeted therapy. CASE PRESENTATION: A 61-year-old man was diagnosed with UC-NE of the renal pelvis. Laparoscopic nephroureterectomy revealed invasive UC-NE with lymphatic invasion (pT1, G2) and carcinoma in situ of the ureter (pTis, G1). Immunohistochemistry showed strong nectin-4 expression in the urothelial component but only weak to moderate expression in the neuroendocrine component. Ten months after surgery, para-aortic and bilateral pelvic lymph node recurrence developed. Treatment with enfortumab vedotin (EV) plus pembrolizumab achieved a complete response after 3 cycles, and remission was maintained with continued therapy. CONCLUSION: This case suggests that EV plus pembrolizumab may be effective for UC-NE and highlights the importance of evaluating nectin-4 and the tumor immune microenvironment when considering treatment strategies for this rare subtype. CI - (c) 2026 The Author(s). IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. FAU - Taniguchi, Kosei AU - Taniguchi K AUID- ORCID: 0009-0002-0890-6598 AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Hashimoto, Mamoru AU - Hashimoto M AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Nakayama, Takahito AU - Nakayama T AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Fujimoto, Saizo AU - Fujimoto S AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Toyoda, Shingo AU - Toyoda S AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Kikuchi, Takashi AU - Kikuchi T AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Velasco, Marco Antonio De AU - Velasco MA AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Maenishi, Osamu AU - Maenishi O AD - Department of Pathology Kindai University Faculty of Medicine Osaka Japan. FAU - Minami, Takafumi AU - Minami T AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. FAU - Fujita, Kazutoshi AU - Fujita K AUID- ORCID: 0000-0002-6774-7497 AD - Department of Urology Kindai University Faculty of Medicine Osaka Japan. LA - eng PT - Journal Article DEP - 20260219 PL - Australia TA - IJU Case Rep JT - IJU case reports JID - 101764958 PMC - PMC12920264 OTO - NOTNLM OT - Enfortumab vedotin OT - Nectin-4 OT - neuroendocrine differentiation OT - pembrolizumab OT - upper tract urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2026/02/23 13:06 MHDA- 2026/02/23 13:07 PMCR- 2026/02/19 CRDT- 2026/02/23 06:27 PHST- 2025/12/11 00:00 [received] PHST- 2026/01/19 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/02/23 13:07 [medline] PHST- 2026/02/23 13:06 [pubmed] PHST- 2026/02/23 06:27 [entrez] PHST- 2026/02/19 00:00 [pmc-release] AID - IJU570149 [pii] AID - 10.1002/iju5.70149 [doi] PST - epublish SO - IJU Case Rep. 2026 Feb 19;9(2):e70149. doi: 10.1002/iju5.70149. eCollection 2026 Mar. PMID- 41724981 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 45 IP - 1 DP - 2026 Feb 23 TI - Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models. LID - 10.1186/s13046-026-03677-8 [doi] LID - 79 AB - BACKGROUND: Bladder cancer (BC) remains a major clinical challenge owing to its high recurrence, limited treatment options, and molecular heterogeneity. Despite recent therapeutic advances, prognosis remains poor and resistance to treatment is common, underscoring the need for improved experimental models to study tumorigenesis and therapeutic response. A critical obstacle in advanced BC research is the scarcity of in vivo models that accurately replicate invasive and metastatic behavior and serve as robust preclinical tools for evaluating new therapies, especially in immunocompetent settings. METHODS: To assess how the cell of origin and specific driver genes influence bladder tumorigenesis and subtype specification, we engineered four genetically modified mouse models of advanced BC. Two combinations of tumor suppressor genes-either Pten and Trp53, or Pten, Trp53, Rb1, and Rbl1- were targeted either basal or suprabasal urothelial cells via intravesical Cre-adenovirus delivery. From tumors arising in these models, we derived multiple cell lines and established syngeneic graft models. Both genetically engineered mouse models and derived mouse cell lines were extensively characterized and transcriptionally compared with advanced human BC and human BC cell lines, and were further utilized as preclinical platforms to evaluate therapeutic responses. RESULTS: Loss of the retinoblastoma gene family reduced cancer-specific survival and was associated with more differentiated carcinomas. In both genetic backgrounds, luminal-derived tumors appeared earlier but displayed fewer metastatic events. Histopathological and transcriptomic analyses revealed that these tumors resemble human basal-squamous and stroma-rich subtypes, sharing regulatory networks and activated signaling pathways with human invasive BC. Tumors lacking retinoblastoma family genes exhibited enhanced immune infiltration, reinforcing their value for diverse preclinical applications. To overcome detection and latency limitations, we established syngeneic graft models from tumor-derived cell lines. These models were validated as preclinical platforms, exhibiting therapeutic responses to CDK4/6 inhibition and anti-PD-L1 immunotherapy. CONCLUSIONS: These novel mouse models faithfully recapitulate key molecular, histological, and immune features of human invasive BC. They represent versatile and clinically relevant preclinical models for dissecting disease progression mechanisms and evaluating emerging therapeutic strategies within an intact immune environment. FAU - Munera-Maravilla, Ester AU - Munera-Maravilla E AUID- ORCID: 0000-0002-2494-7587 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Perez-Escavy, Mercedes AU - Perez-Escavy M AUID- ORCID: 0000-0002-1884-3773 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Rubio, Carolina AU - Rubio C AUID- ORCID: 0000-0003-0098-2297 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Segovia, Cristina AU - Segovia C AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Lodewijk, Iris AU - Lodewijk I AUID- ORCID: 0000-0002-5208-8249 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Nunes, Sandra P AU - Nunes SP AUID- ORCID: 0000-0003-4466-037X AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal. FAU - Martin de Bernardo, Alvaro AU - Martin de Bernardo A AUID- ORCID: 0009-0001-1626-3978 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. FAU - A Reina, Ignacio AU - A Reina I AUID- ORCID: 0000-0003-3661-2503 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Montesinos, Esther AU - Montesinos E AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. FAU - Morales, Lucia AU - Morales L AUID- ORCID: 0000-0001-5253-1442 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Martinez, Victor G AU - Martinez VG AUID- ORCID: 0000-0002-5515-0626 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Alvarez-Prada, Ainara AU - Alvarez-Prada A AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. FAU - Martinez-Fernandez, Monica AU - Martinez-Fernandez M AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Duenas, Marta AU - Duenas M AUID- ORCID: 0000-0003-0857-9726 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Paramio, Jesus M AU - Paramio JM AUID- ORCID: 0000-0001-7520-3177 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. jesusm.paramio@ciemat.es. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. jesusm.paramio@ciemat.es. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. jesusm.paramio@ciemat.es. FAU - Suarez-Cabrera, Cristian AU - Suarez-Cabrera C AUID- ORCID: 0000-0003-1897-1596 AD - Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. cristian.suarez@ciemat.es. AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Madrid, Spain. cristian.suarez@ciemat.es. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. cristian.suarez@ciemat.es. LA - eng GR - BES- 2016-078288/European Regional Development Fund for Science and Innovation/ GR - PRE2020-093423/European Regional Development Fund for Science and Innovation/ GR - SAF2015-66015-R and PID2019-110758RB-I00 and PID2023-147517OB-I00/European Regional Development Fund for Science and Innovation/ GR - FERP-2022-79/Fundacion Eugenio Rodriguez Pascual/ GR - PRDMA19024LODE/Fundacion Cientifica Asociacion Espanola Contra el Cancer/ GR - POSTD19036MORA/Fundacion Cientifica Asociacion Espanola Contra el Cancer/ GR - INVES222946GARC/Fundacion Cientifica Asociacion Espanola Contra el Cancer/ GR - TRNSC213883DUEN and Transcan-3 JTC2022/Fundacion Cientifica Asociacion Espanola Contra el Cancer/ GR - SFRH/BD/144241/2019/FCT-Fundacao para a Ciencia e Tecnologia Grant/ GR - AC22/00015/Instituto de Salud Carlos III/ GR - CIBERONC no. CB16/12/00228/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20260223 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 SB - IM MH - Animals MH - *Urinary Bladder Neoplasms/genetics/pathology/drug therapy MH - Mice MH - Humans MH - Disease Models, Animal MH - Female MH - Cell Line, Tumor PMC - PMC13032214 OTO - NOTNLM OT - Advaced bladder cancer OT - Molecular subtypes OT - Preclincal models OT - Therapy response OT - Tumor suppressor genes OT - Tumor-initiating cells COIS- Declarations. Ethics approval and consent to participate: All animal studies were approved by the Institutional Animal Care and Use Committee of Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT) and the competent regional authority (Animal Welfare Department of the Comunidad de Madrid; PROEX 088/15 and 150.8/21), in compliance with Directive 2010/63/EU and Spanish national regulations (RD 53/2013) for the protection of animals used for scientific purposes. All procedures were conducted in accordance with institutional guidelines to minimize animal suffering. The maximal tumor size permitted in adult mice was approximately 1.5 cm(3), and we confirmed that this limit was not exceeded. Cages were randomized to experimental groups to minimize environmental bias, and all observers were blinded to the experimental conditions. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/23 01:34 MHDA- 2026/06/27 06:47 PMCR- 2026/02/23 CRDT- 2026/02/22 23:24 PHST- 2025/08/26 00:00 [received] PHST- 2026/02/18 00:00 [accepted] PHST- 2026/06/27 06:47 [medline] PHST- 2026/02/23 01:34 [pubmed] PHST- 2026/02/22 23:24 [entrez] PHST- 2026/02/23 00:00 [pmc-release] AID - 10.1186/s13046-026-03677-8 [pii] AID - 3677 [pii] AID - 10.1186/s13046-026-03677-8 [doi] PST - epublish SO - J Exp Clin Cancer Res. 2026 Feb 23;45(1):79. doi: 10.1186/s13046-026-03677-8. PMID- 41720695 OWN - NLM STAT- MEDLINE DCOM- 20260704 LR - 20260704 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 3 DP - 2026 Jun TI - Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes. PG - 619-627 LID - S2588-9311(26)00042-8 [pii] LID - 10.1016/j.euo.2026.02.005 [doi] AB - BACKGROUND AND OBJECTIVE: Adherence to European Association of Urology (EAU) guideline-recommended management of non-muscle-invasive bladder cancer (NMIBC) is essential for optimal outcomes. We quantified real-world adherence to early instillation (EI), second-look transurethral resection of bladder tumor (re-TURBT), and risk-adapted intravesical therapy, and assessed their impact on oncological outcomes. METHODS: We retrospectively analyzed 2194 consecutive NMIBC patients treated with TURBT at six European tertiary centers (2014-2021). Eligibility for EI, re-TURBT, and intravesical instillations was defined using the EAU criteria. Adherence was evaluated through Sankey plots. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier analyses with inverse probability of treatment weighting and compared by adherence status. Cox regression models were also fitted. KEY FINDINGS AND LIMITATIONS: Tumor stage distribution was as follows: 63% Ta, 32% T1, and 5.4% Tis stage; 60% were of high grade. Risk distribution was as follows: 22% low, 27% intermediate, 38% high, and 13% very high. EI was recommended in 1333 patients and performed in 290 (22%) patients. Re-TURBT was indicated in 1006 patients and performed in 445 (44%) patients. Intravesical instillations were recommended in 1713 patients and initiated in 497 (29%) patients. Adherence to EI (79% vs 61%; hazard ratio [HR] 0.60), re-TURBT (70% vs 54%; HR 0.53), and instillations (72% vs 53%; HR 0.49) was associated with superior RFS; re-TURBT (94% vs 87%; HR 0.41) and instillations (95% vs 89%; HR 0.47) also improved PFS (all p < 0.001). Nonadherence reasons were not reported. CONCLUSIONS AND CLINICAL IMPLICATIONS: In real-world practice, adherence to EAU-recommended NMIBC management remains low; yet, it is associated with more favorable outcomes. Improving delivery of guideline-based care through standardized pathways should be a priority in NMIBC management. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - De Angelis, Mario AU - De Angelis M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Uro-oncology Program, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Uro-oncology Program, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Lonati, Chiara AU - Lonati C AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Suardi, Nazareno AU - Suardi N AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, Lille, France. FAU - Szostek, Aleksandra AU - Szostek A AD - Department of Urology, Claude Huriez Hospital, Lille, France. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Lafuente Puentedura, Alfonso AU - Lafuente Puentedura A AD - Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Del Olmo Duran, Pedro AU - Del Olmo Duran P AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC no. 5, Predictive Onco-Urology, Hopital Pitie-Salpetriere, AP-HP, Sorbonne Universite, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: marco.moschini87@gmail.com. CN - European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group LA - eng PT - Journal Article DEP - 20260219 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - Female MH - Retrospective Studies MH - *Guideline Adherence/statistics & numerical data MH - Transurethral Resection of Bladder MH - Male MH - Aged MH - Administration, Intravesical MH - Europe MH - Evidence-Based Practice MH - Middle Aged MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Urology/standards OTO - NOTNLM OT - Adherence OT - Bladder cancer OT - Early instillation OT - Guidelines OT - Intravesical instillations OT - Second look EDAT- 2026/02/21 00:40 MHDA- 2026/07/05 04:10 CRDT- 2026/02/20 21:58 PHST- 2025/10/15 00:00 [received] PHST- 2026/01/19 00:00 [revised] PHST- 2026/02/04 00:00 [accepted] PHST- 2026/07/05 04:10 [medline] PHST- 2026/02/21 00:40 [pubmed] PHST- 2026/02/20 21:58 [entrez] AID - S2588-9311(26)00042-8 [pii] AID - 10.1016/j.euo.2026.02.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Jun;9(3):619-627. doi: 10.1016/j.euo.2026.02.005. Epub 2026 Feb 19. PMID- 41711555 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260708 IS - 2040-3372 (Electronic) IS - 2040-3364 (Linking) VI - 18 IP - 11 DP - 2026 Mar 19 TI - Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects. PG - 5727-5740 LID - 10.1039/d5nr04072h [doi] AB - Bladder cancer persists as a formidable clinical challenge due to its high recurrence rate, intrinsic chemoresistance, and suboptimal immunotherapy response. Copper-based nanomaterials have emerged as promising therapeutic platforms leveraging distinctive copper redox biology and tumor vulnerabilities to copper-induced cell death mechanisms-particularly cuproptosis. This review systematically analyzes dysregulated copper metabolism in bladder cancer and its mechanistic roles in mediating oxidative stress, ferroptosis, and cuproptosis, while classifying four principal nanomaterial categories: metallic Cu structures, copper-based polymers, copper-based compounds, and copper composites-highlighting their synthesis strategies, physicochemical properties, and therapeutic applications. These platforms facilitate photothermal, photodynamic and chemo-/immunotherapeutic synergies through precise modulation of redox homeostasis and tumor immunity. Despite these advances, key clinical translation barriers including biosafety concerns, pharmacokinetic variability, targeting inefficiency, immune unpredictability, and regulatory hurdles are critically examined. Future directions propose physics-informed material design, biomarker-guided patient stratification, and integrated therapy-monitoring platforms, demonstrating copper-based nanomedicine's significant potential to redefine precision intravesical therapy through mechanistically tailored, translationally optimized strategies. FAU - Zhang, Pu AU - Zhang P AD - Department of Urology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Xiong, Wei AU - Xiong W AD - Department of Urology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Wang, Kai AU - Wang K AD - School of Materials Science and Engineering, Xihua University, Chengdu 610039, China. zhaoxl@mail.xhu.edu.cn. FAU - Zhao, Xiaoli AU - Zhao X AD - School of Materials Science and Engineering, Xihua University, Chengdu 610039, China. zhaoxl@mail.xhu.edu.cn. FAU - Liu, Xiaoying AU - Liu X AUID- ORCID: 0000-0003-4621-2722 AD - Army Logistics Academy of PLA, Chongqing 401331, China. lxy_ctbu@163.com. FAU - Huang, Ming AU - Huang M AUID- ORCID: 0000-0002-9188-4619 AD - Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 611731, China. huangming@uestc.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20260319 PL - England TA - Nanoscale JT - Nanoscale JID - 101525249 RN - 789U1901C5 (Copper) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Copper/chemistry/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/metabolism/therapy/pathology MH - Animals MH - Cuproptosis MH - Nanomedicine MH - *Metal Nanoparticles/chemistry/therapeutic use MH - Oxidative Stress/drug effects MH - Antineoplastic Agents/chemistry/therapeutic use EDAT- 2026/02/19 17:35 MHDA- 2026/03/19 21:44 CRDT- 2026/02/19 10:03 PHST- 2026/03/19 21:44 [medline] PHST- 2026/02/19 17:35 [pubmed] PHST- 2026/02/19 10:03 [entrez] AID - 10.1039/d5nr04072h [doi] PST - epublish SO - Nanoscale. 2026 Mar 19;18(11):5727-5740. doi: 10.1039/d5nr04072h. PMID- 41696654 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260216 LR - 20260925 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 7 IP - 2 DP - 2026 Feb TI - Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer. PG - e70135 LID - 10.1002/bco2.70135 [doi] LID - e70135 AB - OBJECTIVE: To identify factors associated with decreased adherence to the national risk-stratified surveillance cystoscopy schedule for non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A retrospective, IRB-approved review was conducted at a single academic institution to identify patients diagnosed with NMIBC who underwent cystoscopy. Patient demographics were collected and driving distance to the urology clinic was calculated. Area Deprivation Index (ADI) and Distressed Communities Index (DCI) were used as proxies for socio-economic status (SES). Clinical data included year of diagnosis, cancer stage, risk stratification per national guidelines, pathology results and surveillance cystoscopy dates. The primary outcome was 12-month adherence to surveillance cystoscopy. Stepwise model selection using logistic regression identified factors associated with adherence. RESULTS: Of 591 patients identified, 351 had a confirmed pathological diagnosis and complete follow-up data. After excluding 57 patients who experienced recurrence, 112/294 (38.1%) were found to be compliant with the one-year surveillance schedule. Adherence was inversely associated with travel time to the clinic (OR 0.99, 95% CI 0.99-1.00; p = 0.015), while ADI and DCI were not statistically significant in relation to adherence. Other significant predictors included diagnosis before the 2016 guideline update where patients diagnosed pre-2016 were much more likely to adhere (OR 4.36, 95% CI 2.32-8.55; p < 0.001), risk stratification where patients of intermediate- and high-risk were much less likely to adhere than those of low-risk (intermediate: OR 0.48, CI 0.26-0.88; p = 0.018, high risk: OR 0.14, CI 0.04-0.40; p < 0.001), and smokers were much more likely to adhere than non-smokers (OR 1.91, CI 1.08-3.43; p = 0.028). CONCLUSIONS: Travel time emerged as a significant barrier to adherence to NMIBC surveillance guidelines, whereas patients' SES did not appear to influence compliance. These findings suggest that logistical obstacles may play a more prominent role than socio-economic factors. Incorporating telehealth solutions and local partnerships may improve adherence and outcomes for NMIBC patients. CI - (c) 2026 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Chen, Katherina Y AU - Chen KY AD - Department of Urology University of Virginia Charlottesville Virginia USA. FAU - Jones, Marieke K AU - Jones MK AD - Department of Public Health Sciences, School of Medicine University of Virginia Charlottesville Virginia USA. FAU - Ghosal, Soutik AU - Ghosal S AD - Department of Public Health Sciences, School of Medicine University of Virginia Charlottesville Virginia USA. FAU - Ignozzi, Grace P AU - Ignozzi GP AD - Department of Urology University of Virginia Charlottesville Virginia USA. FAU - Culp, Stephen H AU - Culp SH AD - Department of Urology University of Virginia Charlottesville Virginia USA. FAU - Krupski, Tracey L AU - Krupski TL AD - Department of Urology University of Virginia Charlottesville Virginia USA. FAU - Lobo, Jennifer M AU - Lobo JM AUID- ORCID: 0000-0001-8375-2475 AD - Department of Urology University of Virginia Charlottesville Virginia USA. AD - Department of Public Health Sciences, School of Medicine University of Virginia Charlottesville Virginia USA. LA - eng PT - Journal Article DEP - 20260211 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12894418 OTO - NOTNLM OT - adherence OT - cystoscopy OT - health services OT - non-muscle invasive bladder cancer OT - surveillance COIS- Dr Krupski and Dr Lobo's work on this project was supported by an American Cancer Society Research Investigator Grant (Grant No. RSG-16-161-01, PI: Dr Krupski). Dr Krupski has subsequently consulted with UROVIU on the development of a prototype remote controlled cystoscope. All other authors report no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. EDAT- 2026/02/16 12:30 MHDA- 2026/02/16 12:31 PMCR- 2026/02/11 CRDT- 2026/02/16 06:58 PHST- 2025/10/24 00:00 [received] PHST- 2025/11/23 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2026/02/16 12:31 [medline] PHST- 2026/02/16 12:30 [pubmed] PHST- 2026/02/16 06:58 [entrez] PHST- 2026/02/11 00:00 [pmc-release] AID - BCO270135 [pii] AID - 10.1002/bco2.70135 [doi] PST - epublish SO - BJUI Compass. 2026 Feb 11;7(2):e70135. doi: 10.1002/bco2.70135. eCollection 2026 Feb. PMID- 41695338 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260216 LR - 20260218 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study. PG - 1728821 LID - 10.3389/fonc.2026.1728821 [doi] LID - 1728821 AB - BACKGROUND: This study investigated the prognostic value of the preoperative red cell distribution width to lymphocyte ratio (RLR) for recurrence-free survival (RFS) and overall survival (OS) in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing transurethral resection of bladder tumor (TURBT). METHODS: A retrospective analysis was performed on data from 239 patients who received TURBT. The optimal RLR cutoff was determined using time-dependent receiver operating characteristic (ROC) curve analysis. Survival outcomes were assessed using Kaplan-Meier curves and univariate/multivariate Cox regression. An RFS prognostic nomogram incorporating independent factors was developed and evaluated via the concordance index (C-index), calibration plots, time-dependent ROC, and decision curve analysis (DCA). Subgroup analyses assessed the consistency of the RLR-RFS association.Results: Elevated preoperative RLR was an independent prognostic factor for worse RFS and OS. Moreover, compared to the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), RLR demonstrated relatively higher predictive performance for 1-year and 3-year RFS. The novel nomogram incorporating the RLR parameter demonstrated improved predictive accuracy and a trend toward greater net clinical benefit compared to the conventional model based solely on the EORTC recurrence risk classification. Subgroup analysis indicated a stronger relationship between high RLR and poor RFS in patients with pTaN0M0 compared to those with pT1N0M0. CONCLUSION: Preoperative RLR represents a potential independent prognostic indicator for tumor recurrence in NMIBC patients following TURBT. The RLR-based nomogram may improve recurrence risk prediction in this population. CI - Copyright (c) 2026 Song, Su, Zhang, Cao, Cui, Zhang, Li, Li, Tian and Liu. FAU - Song, Feifan AU - Song F AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Su, Shiqiang AU - Su S AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Zhang, Xueqiao AU - Zhang X AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Cao, Yunpeng AU - Cao Y AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Cui, Xiongjie AU - Cui X AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Zhang, Lili AU - Zhang L AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Li, Chao AU - Li C AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Li, Shen AU - Li S AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Tian, Shuo AU - Tian S AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Liu, Lizhe AU - Liu L AD - Institute of Medicine and Health, Hebei Medical University, Shijiazhuang, China. LA - eng PT - Journal Article DEP - 20260129 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12893947 OTO - NOTNLM OT - lymphocyte count OT - nomogram OT - non-muscle-invasive bladder cancer OT - prognosis OT - red cell distribution width COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/16 12:31 MHDA- 2026/02/16 12:32 PMCR- 2026/01/29 CRDT- 2026/02/16 06:48 PHST- 2025/10/20 00:00 [received] PHST- 2026/01/01 00:00 [revised] PHST- 2026/01/09 00:00 [accepted] PHST- 2026/02/16 12:32 [medline] PHST- 2026/02/16 12:31 [pubmed] PHST- 2026/02/16 06:48 [entrez] PHST- 2026/01/29 00:00 [pmc-release] AID - 10.3389/fonc.2026.1728821 [doi] PST - epublish SO - Front Oncol. 2026 Jan 29;16:1728821. doi: 10.3389/fonc.2026.1728821. eCollection 2026. PMID- 41692624 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 3 DP - 2026 Apr TI - TNM Stage-Stratified Comparison Between Urachal and Nonurachal Adenocarcinomas of the Bladder: A Single-Center Retrospective Cohort Study. PG - 102509 LID - S1558-7673(26)00009-1 [pii] LID - 10.1016/j.clgc.2026.102509 [doi] AB - BACKGROUND: Among patients with adenocarcinoma of the urinary bladder (ADKUB), prognostic analysis of urachal ADKUB is relatively limited, and there is no unified staging system. To investigate the impact of tumor location (urachal vs. nonurachal) on ADKUB, we evaluated the survival outcomes of urachal ADKUB and conducted a comparative analysis with nonurachal ADKUB after stage-stratified. METHODS: We retrospectively collected clinicopathological and survival data from 82 patients with bladder adenocarcinoma treated at a single center, including 31 with urachal ADKUB and 51 with nonurachal ADKUB. To compare the survival outcomes with nonurachal ADKUB, a unified TNM staging system was first applied to urachal ADKUB. Subsequently, both cohorts were grouped into pT1-T2 and pT3-T4 categories for stage-stratified survival analysis. RESULTS: Urachal ADKUB patients were younger and less likely to harbor comorbidities, with 24 patients (77.4%) receiving partial cystectomy and 7 patients (22.6%) receiving radical cystectomy. Urachal ADKUB was more likely to be Mucinous ADKUB (48.4% vs. 15.7%). The 5-year cancer-specific survival (CSS) and recurrence-free survival (RFS) were similar between the 2 groups (60.9% and 47.4% in urachal ADKUB vs. 52.2% and 40.7% in nonurachal ADKUB, respectively). When applying the unified TNM-based staging system, urachal ADKUB showed a possible trend toward better cancer-specific survival, which was more pronounced in patients with locally advanced and metastatic disease (pT3-T4 or higher; P = .048). On multivariate analysis, pathologic T stage (hazard ratio [HR], 4.721) and cardiovascular diseases (HR, 2.616) remained significantly associated with CSS in all patients. Poorly differentiated tumor (HR, 2.039) remained significantly associated with RFS. CONCLUSIONS: Compared with nonurachal ADKUB, urachal ADKUB is relatively rare and shows a distinct histological distribution and clinicopathological features. Urachal ADKUB has a prognosis broadly comparable to nonurachal ADKUB, with a possible survival advantage in advanced disease that warrants further validation. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Zhu, Jianhang AU - Zhu J AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Ma, Xiaocheng AU - Ma X AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Xie, Fei AU - Xie F AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Wang, Yonghua AU - Wang Y AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. Electronic address: wangyonghua@qdu.edu.cn. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260122 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - Urachal adenocarcinoma SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - Neoplasm Staging MH - Male MH - *Adenocarcinoma/pathology/surgery/mortality MH - Aged MH - Middle Aged MH - Prognosis MH - Cystectomy MH - Survival Analysis MH - Aged, 80 and over OTO - NOTNLM OT - Clinicopathological feature OT - Prognosis OT - Survival analysis OT - TNM classification OT - Urinary bladder neoplasms COIS- Disclosure The authors declare that they have no conflict of interest. EDAT- 2026/02/16 00:31 MHDA- 2026/03/19 01:31 CRDT- 2026/02/15 21:58 PHST- 2025/11/26 00:00 [received] PHST- 2026/01/17 00:00 [revised] PHST- 2026/01/18 00:00 [accepted] PHST- 2026/03/19 01:31 [medline] PHST- 2026/02/16 00:31 [pubmed] PHST- 2026/02/15 21:58 [entrez] AID - S1558-7673(26)00009-1 [pii] AID - 10.1016/j.clgc.2026.102509 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Apr;24(3):102509. doi: 10.1016/j.clgc.2026.102509. Epub 2026 Jan 22. PMID- 41690465 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 50 IP - 3 DP - 2026 Apr TI - The role of systemic inflammatory and prognostic indices in diabetic patients with non-muscle invasive bladder cancer receiving BCG therapy. PG - 501925 LID - S2173-5786(26)00031-4 [pii] LID - 10.1016/j.acuroe.2026.501925 [doi] AB - INTRODUCTION: Systemic inflammatory and prognostic indices are emerging biomarkers in bladder cancer. Diabetes mellitus (DM), a chronic inflammatory disease, and Bacillus Calmette-Guerin (BCG) therapy may influence these indices in non-muscle invasive bladder cancer (NMIBC). OBJECTIVE: To evaluate the impact of DM and BCG therapy on inflammatory and prognostic indices in patients with NMIBC. MATERIAL AND METHOD: A retrospective study of 156 NMIBC patients was conducted. Patients were stratified by DM and BCG status (DM+/DM-; BCG+/BCG-), and into four subgroups (DM-/BCG-, DM+/BCG+, DM-/BCG+, DM+/BCG-). Laboratory and clinical parameters were compared using standard statistical tests (t-test, Chi-square, ANOVA). A P-value <.05 was considered significant. RESULTS: DM+ patients had significantly higher glucose (P = .001), HbA1c (P = .017), GKR (P = .014), and lower PNI (P = .014). Tumor recurrence was more common in DM+ (P = .021). In the BCG comparison, albumin (P = .002) and PNI (P = .009) differed. Four-group analysis showed significant differences in tumor grade, tumor recurrence, HbA1c, albumin, PNI, and MPR (all P < .05), especially between DM+/BCG+ and DM-/BCG+. CONCLUSION: DM and BCG therapy are associated with systemic inflammatory and prognostic indices in NMIBC. GKR and PNI may serve as practical, cost-effective markers for recurrence risk stratification. CI - Copyright (c) 2026 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Tuncekin, A AU - Tuncekin A AD - Usak Training and Research Hospital, Urology Department, Usak, Turkey; Usak University, Faculty of Medicine, Urology Department, Usak, Turkey. Electronic address: adem.tuncekin@usak.edu.tr. FAU - Aktas, Y AU - Aktas Y AD - Usak Training and Research Hospital, Urology Department, Usak, Turkey; Usak University, Faculty of Medicine, Urology Department, Usak, Turkey. LA - eng LA - spa PT - Journal Article DEP - 20260212 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/blood/complications/drug therapy MH - Prognosis MH - *BCG Vaccine/therapeutic use MH - Female MH - Retrospective Studies MH - Male MH - Aged MH - Inflammation/blood MH - *Adjuvants, Immunologic/therapeutic use MH - *Diabetes Complications/blood MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy/pathology/complications/blood OTO - NOTNLM OT - BCG therapy OT - Cancer de vejiga no musculo invasor OT - Diabetes mellitus OT - Glucose-to-potassium ratio OT - Neutrophil-to-lymphocyte ratio OT - Non-muscle invasive bladder cancer OT - Prognostic nutritional index OT - Ratio glucosa/potasio OT - Ratio neutrofilos/linfocitos OT - Terapia con BCG OT - Indice pronostico nutricional COIS- Declaration of competing interest All authors declare that there are no conflicts of interest relevant to the content of this manuscript. EDAT- 2026/02/15 00:31 MHDA- 2026/04/03 00:31 CRDT- 2026/02/14 19:12 PHST- 2025/09/25 00:00 [received] PHST- 2025/10/28 00:00 [revised] PHST- 2025/10/30 00:00 [accepted] PHST- 2026/04/03 00:31 [medline] PHST- 2026/02/15 00:31 [pubmed] PHST- 2026/02/14 19:12 [entrez] AID - S2173-5786(26)00031-4 [pii] AID - 10.1016/j.acuroe.2026.501925 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2026 Apr;50(3):501925. doi: 10.1016/j.acuroe.2026.501925. Epub 2026 Feb 12. PMID- 41688839 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1534-6285 (Electronic) IS - 1527-2737 (Print) IS - 1527-2737 (Linking) VI - 27 IP - 1 DP - 2026 Feb 14 TI - Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum. PG - 13 LID - 10.1007/s11934-026-01322-7 [doi] LID - 13 AB - PURPOSE OF REVIEW: This review aims to synthesize recent evidence and accounts evaluating the utility of blue light cystoscopy (BLC) across the disease spectrum of bladder cancer, including its diagnostic, surveillance, and post-treatment uses, as well as its outpatient applications, economic impact, patient perspectives, and future directions. RECENT FINDINGS: While initial studies on BLC suggested an advantage over traditional cystoscopy in terms of diagnostic power and recurrence rates for non-muscle invasive bladder cancer, recent studies are more equivocal on its benefits and suggest that the utilization of blue-light cystoscopy is more nuanced. Evidence is lacking on a clear superiority of blue light for all bladder cancer patients. Cost, logistics, and accuracy concerns indicate certain patients may benefit from this procedure more than others. BLC can be a valuable adjunct to white light cystoscopy in the management of bladder cancer. It provides high diagnostic sensitivity but there are questions surrounding its cost-effectiveness, positive predictive value, and its role in effective surveillance and reduction of tumor recurrence require further longitudinal and standardized investigation. FAU - Wan, Ethan AU - Wan E AUID- ORCID: 0000-0003-3043-6115 AD - Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Wade, Caroline AU - Wade C AUID- ORCID: 0000-0001-9135-3773 AD - Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Sathe, Aditya AU - Sathe A AUID- ORCID: 0000-0003-1366-0510 AD - Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Ferguson, James E 3rd AU - Ferguson JE 3rd AUID- ORCID: 0000-0001-9073-9615 AD - Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Peyton, Charles C AU - Peyton CC AUID- ORCID: 0009-0008-8778-9759 AD - Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. cpeyton@uabmc.edu. AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. cpeyton@uabmc.edu. LA - eng PT - Journal Article PT - Review DEP - 20260214 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Humans MH - *Cystoscopy/methods/economics MH - Blue Light MH - *Urinary Bladder Neoplasms/diagnosis/diagnostic imaging MH - Non-Muscle Invasive Bladder Neoplasms MH - Aminolevulinic Acid/analogs & derivatives MH - Transurethral Resection of Bladder PMC - PMC12904949 OTO - NOTNLM OT - Bladder cancer OT - Blue-light cystoscopy OT - Hexaminolevulinate OT - Photodynamic diagnosis OT - Transurethral resection of bladder tumor COIS- Declarations. Disclosure and Human and Animal Rights: This article does not contain any studies with human or animal subjects performed by any of the authors. All images included are fully deidentified clinical examples used for illustrative purposes only. Competing interests: The authors declare no competing interests. EDAT- 2026/02/14 05:30 MHDA- 2026/06/27 18:39 PMCR- 2026/02/14 CRDT- 2026/02/13 23:32 PHST- 2025/10/10 00:00 [received] PHST- 2026/02/01 00:00 [accepted] PHST- 2026/06/27 18:39 [medline] PHST- 2026/02/14 05:30 [pubmed] PHST- 2026/02/13 23:32 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - 10.1007/s11934-026-01322-7 [pii] AID - 1322 [pii] AID - 10.1007/s11934-026-01322-7 [doi] PST - epublish SO - Curr Urol Rep. 2026 Feb 14;27(1):13. doi: 10.1007/s11934-026-01322-7. PMID- 41684950 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260215 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 18 DP - 2026 Jan-Dec TI - Digital twins in urology: a vision for the future of urological practice. PG - 17562872261419592 LID - 10.1177/17562872261419592 [doi] LID - 17562872261419592 AB - Digital twins, dynamic, patient-specific virtual replicas of physical systems are gaining momentum across various medical fields. Their capacity to simulate and predict biological behavior offers unprecedented opportunities for personalized care. While their utility has been demonstrated in oncology, their application in urology remains nascent, and there is still a significant gap in literature findings. This review explores the theoretical framework, current evidence, and future potential of digital twins technology in managing urological conditions such as urolithiasis, benign prostatic hyperplasia (BPH), and nonmuscle invasive bladder cancer. A narrative literature review, guided by SANRA criteria, was conducted using PubMed and Scopus databases to identify relevant studies on the application of digital twins in healthcare, with a focus on urology and related fields. Additional sources from AI, imaging, and computational modelling were incorporated to support technological and theoretical concepts. Real-world use cases and clinical scenarios were constructed to illustrate the conceptual application of digital twins in endourology. Although limited in number, preliminary studies have shown promising results in uro-oncology, particularly for prostate and renal cancers. No models have yet been developed for benign urological diseases. Hypothetical applications in endourology include personalized procedural planning, dynamic follow-up, prediction of obstruction or recurrence, and real-time intraoperative guidance. Integration of imaging, functional data, and AI algorithms could create continuously adaptive simulations to support decision-making and improve treatment outcomes. However, barriers such as data complexity, cost, lack of validation frameworks, and clinician trust persist. Digital twins hold transformative potential for the future of urology, promising to personalize care across diagnosis, treatment, and surveillance. While the path to clinical integration is challenged by technical, ethical, and infrastructural hurdles, collaborative efforts and real-world validation studies are critical to realizing their full potential in clinical practice. CI - (c) The Author(s), 2026. FAU - Nedbal, Carlotta AU - Nedbal C AD - Department of Urology, IRCCS San Gerardo dei Tintori, Monza, Italy. FAU - Madaan, Sanjeev AU - Madaan S AUID- ORCID: 0000-0003-4220-5613 AD - Department of Urology, Darrent Valley Hospital, Dartford, UK. FAU - Nabi, Ghulam AU - Nabi G AD - Department of Urology, University of Dundee, Dundee, UK. FAU - Somani, Bhaskar Kumar AU - Somani BK AUID- ORCID: 0000-0002-6248-6478 AD - Department of Urology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO166YD, UK. LA - eng PT - Journal Article PT - Review DEP - 20260210 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC12891402 OAB - Digital twin in urology Digital twins consist in a virtual computer model of a real patient, created using medical scans, test results, and clinical information. It can be updated as new data become available. In urology, digital twins could help doctors plan operations, predict whether kidney stones will return, estimate how prostate treatments will work, or determine which bladder cancer patients need more frequent monitoring. Although digital twins are increasingly used in engineering and some medical fields, they are still new in urology and require further research. OABL- eng OTO - NOTNLM OT - artificial intelligence OT - digital twins OT - machine learning OT - oncology OT - personalized medicine OT - urology COIS- Authors Carlotta Nedbal, Sanjeev Madaan, Ghulam Nabi, and Bhaskar Kumar Somani are reviewers or members of the Editorial Board of Therapeutic Advances in Urology. The authors did not take part in the peer-review or decision-making process for this submission and have no further conflicts to declare. EDAT- 2026/02/13 06:32 MHDA- 2026/02/13 06:33 PMCR- 2026/02/10 CRDT- 2026/02/13 04:30 PHST- 2025/10/25 00:00 [received] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/02/13 06:33 [medline] PHST- 2026/02/13 06:32 [pubmed] PHST- 2026/02/13 04:30 [entrez] PHST- 2026/02/10 00:00 [pmc-release] AID - 10.1177_17562872261419592 [pii] AID - 10.1177/17562872261419592 [doi] PST - epublish SO - Ther Adv Urol. 2026 Feb 10;18:17562872261419592. doi: 10.1177/17562872261419592. eCollection 2026 Jan-Dec. PMID- 41682003 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 3 DP - 2026 Feb 6 TI - High Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder. LID - 10.3390/cancers18030532 [doi] LID - 532 AB - Background: In high-risk non-muscle-invasive bladder cancer (NMIBC), adjuvant therapies, such as intravesical Bacillus Calmette-Guerin (BCG) instillation, are widely employed; however, BCG treatment poses challenges due to potential adverse effects and ongoing supply limitations. This study aimed to evaluate treatment patterns, therapeutic efficacy, incidence of adverse events, and clinical predictors of recurrence and progression in patients with high-grade pT1 urothelial carcinoma (HG-T1 UC) of the bladder. Methods: This retrospective cohort study included 204 patients diagnosed with HG-pT1 UC who underwent transurethral resection of bladder tumor (TURBT) at Toho University Sakura Medical Center between 2010 and 2021. Clinical data encompassing treatment modalities (BCG or intravesical chemotherapy), complications, and oncological outcomes were collected. Recurrence-Free Survival (RFS), Progression-Free Survival, and Cancer-Specific Survival were analyzed using Kaplan-Meier analyses and multivariate regression models. Results: Maintenance BCG therapy was significantly associated with prolonged RFS compared to other treatments, including among 'very high-risk' patients. However, 52.4% of patients receiving BCG maintenance experienced adverse events, with dose reductions required in 59% of cases. Notably, recurrence rates did not significantly differ based on dose reduction or the total number of BCG instillations. Tumor multiplicity emerged as an independent risk factor for recurrence. Conclusions: Although maintenance BCG therapy remains essential for managing HG-T1 UC, especially in high-risk patients, treatment should be individualized due to concerns about tolerability and availability. The study results support the importance of personalized strategies based on risk stratification as outlined in clinical guidelines for preventing recurrence in NMIBC. FAU - Noro, Takahide AU - Noro T AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Kamiya, Naoto AU - Kamiya N AUID- ORCID: 0000-0002-4183-2490 AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Ishitsuka, Naoki AU - Ishitsuka N AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Ikeda, Rino AU - Ikeda R AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Suzuki, Yuta AU - Suzuki Y AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Iijima, Syota AU - Iijima S AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Sugizaki, Yuka AU - Sugizaki Y AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Somoto, Takatoshi AU - Somoto T AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Oka, Ryo AU - Oka R AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Utsumi, Takanobu AU - Utsumi T AUID- ORCID: 0000-0002-9423-7361 AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Endo, Takumi AU - Endo T AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Hiruta, Nobuyuki AU - Hiruta N AD - Department of Surgical Pathology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. FAU - Suzuki, Hiroyoshi AU - Suzuki H AUID- ORCID: 0000-0001-5838-114X AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan. LA - eng PT - Journal Article DEP - 20260206 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12896884 OTO - NOTNLM OT - bladder cancer OT - high-grade T1 OT - intravesical BCG therapy OT - intravesical chemotherapy COIS- The authors declare no conflicts of interest. EDAT- 2026/02/13 06:32 MHDA- 2026/02/13 06:33 PMCR- 2026/02/06 CRDT- 2026/02/13 01:04 PHST- 2026/01/06 00:00 [received] PHST- 2026/02/03 00:00 [revised] PHST- 2026/02/04 00:00 [accepted] PHST- 2026/02/13 06:33 [medline] PHST- 2026/02/13 06:32 [pubmed] PHST- 2026/02/13 01:04 [entrez] PHST- 2026/02/06 00:00 [pmc-release] AID - cancers18030532 [pii] AID - cancers-18-00532 [pii] AID - 10.3390/cancers18030532 [doi] PST - epublish SO - Cancers (Basel). 2026 Feb 6;18(3):532. doi: 10.3390/cancers18030532. PMID- 41681972 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 3 DP - 2026 Feb 3 TI - Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions. LID - 10.3390/cancers18030500 [doi] LID - 500 AB - Introduction: Conservative or upfront radical management for high- and very high-risk non-muscle-invasive bladder cancer continues to be debated, particularly for cases with adverse pathological features. We aimed to compare survival outcomes among NMIBC patients treated with transurethral resection of bladder tumour (TURBT) followed by either Bacillus Calmette-Guerin (BCG), sequential BCG plus electromotive administration of mitomycin C (EMDA-MMC), or upfront radical cystectomy (RC). Materials and Methods: High- and- very high-risk NMIBC cases undergoing TURBT followed by BCG, BCG plus EMDA-MMC, or RC at two international tertiary referral centres between 2009 and 2024 were retrospectively reviewed. Recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methods. Multivariable Cox regression models were applied to identify factors independently associated with survival outcomes. Results: A total of 1178 patients were included: 852 received BCG, 249 received BCG/EMDA-MMC, and 77 underwent upfront RC. Kaplan-Meier analysis revealed no significant differences in RFS or PFS between the BCG and BCG/EMDA-MMC groups, nor in OS between the three treatment strategies. According to multivariable analysis, concomitant carcinoma in situ (CIS) and increasing T stage at TURBT were independently associated with poorer RFS (HR 1.39; 95% CI 1.05-1.85), PFS (HR 1.95; 95% CI 1.36-2.82), and OS (HR 2.28; 95% CI 1.60-3.25). A second resection conferred a protective effect on PFS (HR 0.72; 95% CI 0.54-0.95). Treatment modality (BCG, BCG/EMDA-MMC, or upfront RC) was not significantly associated with any survival endpoint. Conclusions: In this large multicentre series of patients with high- and very high-risk NMIBC undergoing TURBT, survival outcomes were primarily influenced by clinical-pathological characteristics rather than the adjuvant treatment of choice. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, Palo Alto, CA 94305, USA. AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Khan, Amir AU - Khan A AUID- ORCID: 0000-0003-1074-7290 AD - Division of Urology, Department of Surgery, University of Maryland, Baltimore, MD 21201, USA. FAU - Gad, Mohamed AU - Gad M AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Spurna, Katarina AU - Spurna K AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Kirmani, Syed Ghazi Ali AU - Kirmani SGA AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Bhatti, Noor Huda AU - Bhatti NH AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Chatterton, Kathryn AU - Chatterton K AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Amery, Suzanne AU - Amery S AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Challacombe, Benjamin AU - Challacombe B AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Ibrahim, Youssef AU - Ibrahim Y AUID- ORCID: 0000-0003-0931-9707 AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy. FAU - Basile, Giuseppe AU - Basile G AD - Department of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Corvino, Roberta AU - Corvino R AUID- ORCID: 0009-0003-3168-1435 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Razeto, Eleonora AU - Razeto E AUID- ORCID: 0009-0008-8951-517X AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Verde, Matilde AU - Verde M AUID- ORCID: 0009-0000-9024-9640 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Asero, Vincenzo AU - Asero V AUID- ORCID: 0000-0001-5293-9253 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Garaffa, Giulio AU - Garaffa G AD - The Institute of Urology, University College London Hospitals, London NW1 2BU, UK. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Claps, Francesco AU - Claps F AUID- ORCID: 0000-0003-2812-5553 AD - Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, Palo Alto, CA 94305, USA. FAU - Thuraraja, Ramesh AU - Thuraraja R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - O'Brien, Timothy AU - O'Brien T AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Abu-Ghanem, Yasmin AU - Abu-Ghanem Y AUID- ORCID: 0000-0003-3682-5963 AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. LA - eng PT - Journal Article DEP - 20260203 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12896385 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - bladder cancer (BC) OT - non-muscle-invasive bladder cancer (NMIBC) OT - radical cystectomy (RC) OT - transurethral resection of bladder tumour (TURBT) COIS- The authors declare no conflict of interest. EDAT- 2026/02/13 06:32 MHDA- 2026/02/13 06:33 PMCR- 2026/02/03 CRDT- 2026/02/13 01:04 PHST- 2025/12/19 00:00 [received] PHST- 2026/01/27 00:00 [revised] PHST- 2026/01/29 00:00 [accepted] PHST- 2026/02/13 06:33 [medline] PHST- 2026/02/13 06:32 [pubmed] PHST- 2026/02/13 01:04 [entrez] PHST- 2026/02/03 00:00 [pmc-release] AID - cancers18030500 [pii] AID - cancers-18-00500 [pii] AID - 10.3390/cancers18030500 [doi] PST - epublish SO - Cancers (Basel). 2026 Feb 3;18(3):500. doi: 10.3390/cancers18030500. PMID- 41679343 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 210 DP - 2026 Apr TI - Association Between Photodynamic Diagnosis and Risk of Recurrence and Progression in Bacillus Calmette-guerin-treated Nonmuscle Invasive Bladder Cancer Patients: A Nationwide Follow-up Study. PG - 99-104 LID - S0090-4295(26)00091-9 [pii] LID - 10.1016/j.urology.2026.02.004 [doi] AB - OBJECTIVE: To investigate whether photodynamic diagnosis (PDD) influences recurrence and progression risk in patients with nonmuscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG). METHODS: We performed a nationwide cohort study using Danish health registries. Patients with a first-time diagnosis of nonmuscle invasive bladder cancer who received BCG between 2009 and 2022 were included. Patients were followed until death, cystectomy, or December 31, 2023. Exposure was PDD at primary transurethral resection of the bladder. We estimated cumulative incidences and relative risks for recurrence and progression, anid calculated crude and adjusted odds ratios for BCG response according to PDD status. RESULTS: A total of 4318 patients were included, of whom 2388 (55%) underwent PDD-assisted diagnosis. At 1 year, the age-adjusted relative risk for recurrence was 0.85 (95% CI, 0.76-0.96) in the PDD group compared with the non-PDD group. At 5 years, the relative risk was 0.94 (95% CI, 0.87-1.03). No significant differences were observed in BCG response among adequately treated patients between the PDD and non-PDD groups. CONCLUSION: This large registry-based cohort study found no evidence that the use of PDD was associated with differences in BCG treatment outcomes. While PDD was associated with a modest reduction in recurrence risk at 1 year, no long-term benefit was observed regarding recurrence, progression, or BCG response. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Hjort, Peter B AU - Hjort PB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. Electronic address: petehj@rm.dk. FAU - Hyldgaard, Josephine M AU - Hyldgaard JM AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Young-Halvorsen, Kristine AU - Young-Halvorsen K AD - Clinical Development & Medical Affairs, Photocure ASA, Oslo, Norway. FAU - Husch, Tanja AU - Husch T AD - Clinical Development & Medical Affairs, Photocure ASA, Oslo, Norway; Department of Urology and Pediatric Urology, University Medical Center of Johannes-Gutenberg University, Mainz, Germany. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Ernst, Andreas AU - Ernst A AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. LA - eng PT - Journal Article DEP - 20260210 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - Female MH - Male MH - Disease Progression MH - *Neoplasm Recurrence, Local/epidemiology/diagnosis MH - Non-Muscle Invasive Bladder Neoplasms MH - Aged MH - Follow-Up Studies MH - Denmark/epidemiology MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Transurethral Resection of Bladder MH - Risk Assessment MH - *Urinary Bladder Neoplasms/diagnosis/pathology MH - Cohort Studies MH - Registries MH - Administration, Intravesical COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kristine Young-Halvorsen, employee of Photocure ASA, (Sponsor). Dr Tanja Husch, employee of Photocure ASA, (Sponsor). Dr Jorgen Bjerggard Jensen, recipient of Photocure Grant. EDAT- 2026/02/13 01:26 MHDA- 2026/04/10 00:34 CRDT- 2026/02/12 19:10 PHST- 2025/09/11 00:00 [received] PHST- 2026/01/23 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/04/10 00:34 [medline] PHST- 2026/02/13 01:26 [pubmed] PHST- 2026/02/12 19:10 [entrez] AID - S0090-4295(26)00091-9 [pii] AID - 10.1016/j.urology.2026.02.004 [doi] PST - ppublish SO - Urology. 2026 Apr;210:99-104. doi: 10.1016/j.urology.2026.02.004. Epub 2026 Feb 10. PMID- 41671709 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1879-3320 (Electronic) IS - 0960-7404 (Linking) VI - 65 DP - 2026 Apr TI - HALP score as an independent prognostic biomarker for recurrence and progression in non-muscle-invasive bladder cancer: A retrospective cohort study. PG - 102357 LID - S0960-7404(26)00008-3 [pii] LID - 10.1016/j.suronc.2026.102357 [doi] AB - OBJECTIVE: This study aimed to evaluate the prognostic utility of the HALP (Hemoglobin-Albumin-Lymphocyte-Platelet) score in predicting tumor recurrence in patients with non-metastatic bladder cancer (NMIBC) without muscle invasion. METHODS: A retrospective cohort analysis was conducted involving 428 NMIBC patients followed for at least five years. HALP scores were calculated using preoperative hemoglobin, albumin, lymphocyte, and platelet measurements. Tumor recurrence was defined as the appearance of new lesions during follow-up, while muscle invasion was classified as progression. Determinants of recurrence were investigated using multivariate logistic regression and Cox proportional hazards models. The discriminative performance of the HALP score was evaluated using ROC analysis, and recurrence-free survival was compared according to the median HALP threshold using Kaplan-Meier methodology. RESULTS: The mean HALP score was significantly higher in patients without recurrence compared to those with recurrence (5.9 +/- 1.3 vs. 4.6 +/- 1.4; p < 0.001). HALP score, along with tumor size and grade, remained an independent predictor of recurrence in multivariate analyses (HR approximately 0.825; p < 0.001). ROC analysis showed acceptable discrimination, and Kaplan-Meier curves showed significantly shorter recurrence-free survival in patients with lower HALP scores (log-rank p < 0.005). Additionally, HALP values were significantly lower in patients with progression compared to those without (p = 0.006). CONCLUSION: HALP score is a simple, cost-effective biomarker reflecting immune nutrition status and is significantly associated with recurrence and progression in NMIBC. Inclusion of HALP in risk stratification models can improve individualized follow-up strategies and clinical decision-making processes in patients with non-invasive bladder cancer. STRUCTURED ABSTRACT: Recurrence and progression remain major clinical challenges in non-muscle-invasive bladder cancer (NMIBC), highlighting the need for reliable and cost-effective prognostic biomarkers. This retrospective cohort study included 428 patients with NMIBC who were followed for at least five years to evaluate the prognostic value of the hemoglobin-albumin-lymphocyte-platelet (HALP) score. The HALP score was calculated using preoperative laboratory parameters, and recurrence and progression were analyzed using multivariable logistic regression, Cox proportional hazards models, receiver operating characteristic analysis, and Kaplan-Meier survival analysis. Patients with recurrence exhibited significantly lower HALP scores compared with those without recurrence, and the HALP score remained an independent predictor of recurrence in multivariable analyses (HR approximately 0.83; p < 0.001). ROC analysis demonstrated acceptable discriminatory performance (AUC = 0.78), while Kaplan-Meier analysis showed significantly shorter recurrence-free survival in patients with low HALP scores. Additionally, HALP values were significantly lower in patients who developed disease progression. These findings suggest that the HALP score is a simple, inexpensive, and independent prognostic biomarker that may enhance risk stratification and support personalized surveillance strategies in patients with NMIBC. CI - Copyright (c) 2026 Elsevier Ltd. All rights reserved. FAU - Utlu, Adem AU - Utlu A AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: drademu@gmail.com. FAU - Aksakalli, Tugay AU - Aksakalli T AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: tugay_daydreamer@hotmail.com. FAU - Celik, Feyzullah AU - Celik F AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: drfeyzcelik@gmail.com. FAU - Cinislioglu, Ahmet Emre AU - Cinislioglu AE AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: emrecinisli@hotmail.com. FAU - Altay, Mehmet Sefa AU - Altay MS AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: memsefaaltay@gmail.com. FAU - Bedir, Fevzi AU - Bedir F AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: fevzibedir84@gmail.com. FAU - Kocaturk, Huseyin AU - Kocaturk H AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: kocaturk78@hotmail.com. FAU - Karabulut, Ibrahim AU - Karabulut I AD - University of Health Sciences, Erzurum City Hospital, Department of Urology, Erzurum, Turkey. Electronic address: karabulutibrahim36@gmail.com. LA - eng PT - Journal Article DEP - 20260205 PL - Netherlands TA - Surg Oncol JT - Surgical oncology JID - 9208188 RN - 0 (Biomarkers, Tumor) RN - 0 (Hemoglobins) RN - 0 (Serum Albumin) SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - *Neoplasm Recurrence, Local/pathology/blood/diagnosis MH - Male MH - Prognosis MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/blood MH - *Biomarkers, Tumor MH - Disease Progression MH - Aged MH - Follow-Up Studies MH - Survival Rate MH - *Hemoglobins/analysis/metabolism MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Middle Aged MH - *Blood Platelets/pathology MH - *Serum Albumin/analysis MH - *Lymphocytes/pathology OTO - NOTNLM OT - Bladder cancer OT - HALP score OT - Immune nutrition index OT - Prognosis OT - Recurrence COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/12 00:47 MHDA- 2026/03/13 00:50 CRDT- 2026/02/11 18:03 PHST- 2025/12/22 00:00 [received] PHST- 2026/01/21 00:00 [revised] PHST- 2026/01/28 00:00 [accepted] PHST- 2026/03/13 00:50 [medline] PHST- 2026/02/12 00:47 [pubmed] PHST- 2026/02/11 18:03 [entrez] AID - S0960-7404(26)00008-3 [pii] AID - 10.1016/j.suronc.2026.102357 [doi] PST - ppublish SO - Surg Oncol. 2026 Apr;65:102357. doi: 10.1016/j.suronc.2026.102357. Epub 2026 Feb 5. PMID- 41669338 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260211 LR - 20260213 IS - 2223-8956 (Electronic) IS - 1016-3190 (Print) IS - 1016-3190 (Linking) VI - 38 IP - 1 DP - 2026 Jan-Mar TI - Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan. PG - 83-89 LID - 10.4103/tcmj.tcmj_78_25 [doi] AB - OBJECTIVES: This study aimed to identify the prognostic factors that influence the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancerr (NMIBC) based on data from the Hualien Tzu Chi Hospital, Taiwan. MATERIALS AND METHODS: A retrospective cohort study enrolled patients with NMIBC diagnosed between 2005 and 2022 who underwent transurethral resection of bladder tumor (TUR-BT). Demographic, clinical, and pathological data, along with recurrence outcomes, were collected. Cox proportional hazard regression models were used to analyze the factors associated with recurrence, progression to muscle-invasive disease, and risk for multiple recurrences. RESULTS: Overall, 199 patients were included, with a mean follow-up duration of 4.6 years. Tumors recurred in 53.8% of the patients, which further progressed to muscle-invasive bladder cancer (MIBC) in 13.1%. Multivariate Cox regression analysis identified betel nut chewing, multiple tumors, high-grade tumors, and lack of bacillus Calmette-Guerin (BCG) therapy as significant predictors of recurrence. Age, high-grade tumors, and recurrence within 3 months after the initial TUR-BT were the significant predictors of progression. Multiple tumors and early recurrence occurring within 3 months after the initial TUR-BT were significantly associated with the risk of experiencing multiple recurrences. CONCLUSION: This study identified multiple tumors, high-grade tumors, and BCG therapy as the significant factors associated with NMIBC recurrence, with a potential link also observed for betel nut chewing. Age, tumor grade, and early recurrence emerged as the key predictors of progression to MIBC. In addition, multiple tumors and early recurrence were linked to an increased risk of experiencing multiple recurrences. CI - Copyright: (c) 2025 Tzu Chi Medical Journal. FAU - Kung, Ti-Chia AU - Kung TC AD - Department of Medical Education, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. FAU - Jiang, Yuan-Hong AU - Jiang YH AD - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan. FAU - Kuo, Hann-Chorng AU - Kuo HC AD - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan. LA - eng PT - Journal Article DEP - 20251013 PL - India TA - Tzu Chi Med J JT - Tzu chi medical journal JID - 101770275 PMC - PMC12885465 OTO - NOTNLM OT - Bladder cancer OT - Nonmuscle invasive OT - Risk factors OT - Tumor recurrence COIS- Dr. Hann-Chorng Kuo and Dr. Yuan-Hong Jiang, the editorial board members at Tzu Chi Medical Journal, had no role in the peer review process of or decision to publish this article. The other author declared no conflicts of interest in writing this paper. EDAT- 2026/02/11 06:31 MHDA- 2026/02/11 06:32 PMCR- 2025/10/13 CRDT- 2026/02/11 04:40 PHST- 2025/02/14 00:00 [received] PHST- 2025/05/01 00:00 [revised] PHST- 2025/05/29 00:00 [accepted] PHST- 2026/02/11 06:32 [medline] PHST- 2026/02/11 06:31 [pubmed] PHST- 2026/02/11 04:40 [entrez] PHST- 2025/10/13 00:00 [pmc-release] AID - TCMJ-38-83 [pii] AID - 10.4103/tcmj.tcmj_78_25 [doi] PST - epublish SO - Tzu Chi Med J. 2025 Oct 13;38(1):83-89. doi: 10.4103/tcmj.tcmj_78_25. eCollection 2026 Jan-Mar. PMID- 41663990 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Feb 9 TI - Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing. LID - 10.1186/s12885-026-15666-3 [doi] LID - 361 AB - BACKGROUND: Bladder cancer (BC) is significantly more prevalent in men than in women, yet female patients often experience higher recurrence rates and poorer prognosis. METHODS: Our study aimed to investigate sex-specific gene expression differences in early-stage BC using whole-transcriptome sequencing. A total of 51 patients diagnosed with low-grade Ta stage non-muscle-invasive bladder cancer were recruited. Paired tissue samples from tumor lesions and adjacent healthy bladder mucosa (BM) were analyzed to identify differentially expressed genes (DEGs). RESULTS: Among the top 100 most significant DEGs for each gender, overwhelmingly more upregulated in BC comparing with BM were in male than female tissues (90% vs. 19%). The most significantly altered expression in female BC tissues included MT-ND6, ARL4C, ASGR1, MYBL1, and SCAMP5, whereas in males, ONECUT2, SPEG, CTSE, GJB2, and SYNM. Notably, 753 DEGs were unique to female patients, while 3989 were specific to males, with 1633 shared between both sexes. Functional annotation revealed that female-unique DEGs were significantly enriched in immune-related pathways, including regulation of leukocyte activation and cell-cell adhesion, and lymphocyte differentiation. Whereas male-unique DEGs were predominantly associated with pathways related to cell cycle regulation, mitochondrial function, and androgen receptor signaling. Immune-related gene expression indicated that female-specific DEGs were involved in leukocyte activation and antigen receptor signaling, whereas male-specific DEGs were linked to B-cell activation and neutrophil-mediated immune responses. A two-factor interaction model identified S100A14 as the only protein-coding gene whose expression exhibited a significant sex-dependent pattern, with four additional genes (GJB2, DSC2, TM4SF and ALOX15B) showing a probable interaction effect. CONCLUSIONS: These findings provide preliminary evidence supporting further investigation of sex-specific approaches to BC management. FAU - Zeber-Lubecka, Natalia AU - Zeber-Lubecka N AD - Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781, Warsaw, Poland. AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. FAU - Bilski, Konrad AU - Bilski K AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Prof. W. Orlowski, 00-416, Warsaw, Poland. FAU - Dabrowska, Michalina AU - Dabrowska M AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. FAU - Goryca, Krzysztof AU - Goryca K AD - Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781, Warsaw, Poland. AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. FAU - Ziemska-Legiecka, Joanna AU - Ziemska-Legiecka J AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. FAU - Ostrowski, Jerzy AU - Ostrowski J AD - Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781, Warsaw, Poland. AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Prof. W. Orlowski, 00-416, Warsaw, Poland. jdobruch@cmkp.edu.pl. FAU - Hennig, Ewa E AU - Hennig EE AD - Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781, Warsaw, Poland. ehennig@cmkp.edu.pl. AD - Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. ehennig@cmkp.edu.pl. LA - eng GR - 2019/33/B/NZ5/02447/Narodowe Centrum Nauki/ PT - Journal Article DEP - 20260209 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - Male MH - Gene Expression Profiling/methods MH - *Gene Expression Regulation, Neoplastic MH - *Urinary Bladder Neoplasms/genetics/pathology MH - *Transcriptome MH - Non-Muscle Invasive Bladder Neoplasms MH - Sex Factors MH - Middle Aged MH - Aged MH - Neoplasm Staging MH - *Biomarkers, Tumor/genetics PMC - PMC12998147 OTO - NOTNLM OT - Grade stage; differentially expressed genes OT - Invasive bladder cancer; early OT - Muscle OT - Non OT - Related; low OT - Stage cancer; sex COIS- Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Local Ethics Committee at Centre of Postgraduate Medical Education (No: 77/PB/2017) for studies involving humans. Written informed consent was obtained from all participants prior to the examination. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/10 01:29 MHDA- 2026/06/27 06:43 PMCR- 2026/02/09 CRDT- 2026/02/09 23:58 PHST- 2025/08/13 00:00 [received] PHST- 2026/01/28 00:00 [accepted] PHST- 2026/06/27 06:43 [medline] PHST- 2026/02/10 01:29 [pubmed] PHST- 2026/02/09 23:58 [entrez] PHST- 2026/02/09 00:00 [pmc-release] AID - 10.1186/s12885-026-15666-3 [pii] AID - 15666 [pii] AID - 10.1186/s12885-026-15666-3 [doi] PST - epublish SO - BMC Cancer. 2026 Feb 9;26(1):361. doi: 10.1186/s12885-026-15666-3. PMID- 41661209 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260813 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 32 IP - 9 DP - 2026 May 1 TI - Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer. PG - 1755-1765 LID - 10.1158/1078-0432.CCR-25-3395 [doi] AB - PURPOSE: To determine whether carcinoma in situ (CIS) is a sufficient measure of minimal residual disease (MRD) in non-muscle-invasive bladder cancer (NMIBC) and evaluate alternative measures of MRD. EXPERIMENTAL DESIGN: We evaluated the concordance of CIS on transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) to determine eradication rates of clinical CIS (cCIS) by TURBT alone and rates of occult pathologic CIS (pCIS) seen only in RC specimens. We studied a prospective cohort of patients with BCG-naive high-grade NMIBC to evaluate pretreatment urinary cytology and urinary tumor (ut)DNA as alternative biomarkers. RESULTS: Eradication of CIS was seen in 20% of patients (78/383). Positive urinary cytology, but not cCIS, was associated with pCIS. In our prospective cohort (n = 173), abnormal pre-BCG urine cytology, but not pre-BCG cCIS, had worse high-grade recurrence-free survival [HG-RFS; hazard ratio, 3.56; 95% confidence interval (CI), 1.74-7.31, P < 0.001]. The median follow-up was 1.8 years (95% CI, 1.3-2.2). Among those with utDNA available, 84% (56/67) had sufficient DNA for genomic profiling. The 2-year HG-RFS rate in patients without an oncogenic alteration (n = 17) in their pre-BCG urine was 100% versus 60% (95% CI, 46%-78%) in patients with detectable oncogenic alterations (n = 38; P = 0.004). Area under the curve values for predicting 2-year HG-RFS were 0.52 for cCIS, 0.68 for cytology, and 0.74 for utDNA. CONCLUSIONS: We found approximately 20% eradication of cCIS from TURBT alone. cCIS was a poor metric of MRD, performing worse than abnormal pretreatment urinary cytology and utDNA. These urine biomarkers are more objective MRD measures than cCIS for NMIBC risk stratification and treatment assessment. CI - (c)2026 American Association for Cancer Research. FAU - Katims, Andrew B AU - Katims AB AUID- ORCID: 0000-0003-2254-0334 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 AD - Department of Urology, Westchester Medical Center, New York Medical College, Valhalla, New York. ROR: https://ror.org/03dkvy735 FAU - White, Charlie AU - White C AUID- ORCID: 0000-0003-1671-3155 AD - Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Alam, Syed Muneeb AU - Alam SM AUID- ORCID: 0000-0001-7854-2967 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 AD - Department of Urology, Yale University, New Haven, Connecticut. FAU - Farha, Mark AU - Farha M AUID- ORCID: 0000-0002-3511-2630 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 AD - Department of Urology, Weill Cornell Medicine, New York, New York. ROR: https://ror.org/02r109517 FAU - Sepehri, Sadra AU - Sepehri S AUID- ORCID: 0009-0003-9620-4699 AD - Brady Urologic Institute, Johns Hopkins Medicine, Baltimore, Maryland. FAU - De Jesus Escano, Manuel AU - De Jesus Escano M AUID- ORCID: 0000-0001-6347-4148 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 AD - Urology Institute, DHR Health, Edinburg, Texas. FAU - D'Souza, Neeta AU - D'Souza N AUID- ORCID: 0009-0008-7972-8278 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 AD - Department of Anesthesia, SUNY Downstate Medical Center, Brooklyn, New York. ROR: https://ror.org/0041qmd21 FAU - Gokturk Ozcan, Gamze AU - Gokturk Ozcan G AUID- ORCID: 0000-0003-4758-2020 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Basar, Merve AU - Basar M AUID- ORCID: 0000-0002-7737-2430 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Martinez Benitez, Anthony AU - Martinez Benitez A AUID- ORCID: 0009-0006-9471-9922 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - McCarter, Melissa AU - McCarter M AUID- ORCID: 0009-0005-7859-8588 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Tomberlin, Morgan AU - Tomberlin M AUID- ORCID: 0009-0000-9979-0556 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Solit, David B AU - Solit DB AUID- ORCID: 0000-0002-6614-802X AD - Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Iyer, Gopa AU - Iyer G AUID- ORCID: 0000-0002-5093-6099 AD - Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Du, Pan AU - Du P AUID- ORCID: 0000-0002-4561-6883 AD - Predicine, Inc., Hayward, California. FAU - Jia, Shidong AU - Jia S AUID- ORCID: 0000-0001-5854-819X AD - Predicine, Inc., Hayward, California. FAU - Goh, Alvin C AU - Goh AC AUID- ORCID: 0000-0003-3092-9024 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Donahue, Timothy F AU - Donahue TF AUID- ORCID: 0000-0002-0932-2968 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Sarungbam, Judy AU - Sarungbam J AUID- ORCID: 0000-0002-7443-8123 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Bochner, Bernard H AU - Bochner BH AUID- ORCID: 0000-0003-0846-0848 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Kates, Max AU - Kates M AUID- ORCID: 0000-0003-1166-7225 AD - Brady Urologic Institute, Johns Hopkins Medicine, Baltimore, Maryland. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AUID- ORCID: 0000-0003-1783-0070 AD - Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AUID- ORCID: 0000-0002-2938-6627 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Lin, Oscar AU - Lin O AUID- ORCID: 0000-0003-2089-6118 AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 FAU - Pietzak, Eugene J AU - Pietzak EJ AUID- ORCID: 0000-0002-5121-5701 AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ROR: https://ror.org/02yrq0923 LA - eng GR - Sidney Kimmel Center for Prostate and Urologic Cancers (Sidney Kimmel Center)/ GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - R37 CA276946/CA/NCI NIH HHS/United States GR - R37CA276946/Center for Cancer Research (CCR)/ PT - Journal Article PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/urine/pathology/surgery MH - *Neoplasm, Residual/urine/pathology/diagnosis MH - Female MH - *Biomarkers, Tumor/urine MH - Male MH - Aged MH - Transurethral Resection of Bladder MH - Middle Aged MH - Prospective Studies MH - *Carcinoma in Situ/urine/pathology/surgery MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/urine/pathology/surgery MH - Cystectomy MH - Neoplasm Recurrence, Local/urine/pathology PMC - PMC13312225 MID - NIHMS2176494 COIS- Conflict of Interest Statement: Eugene J. Pietzak: Honoraria: UpToDate; Consulting or Advisory Role: Merck, QED Therapeutics, Janssen, Urogen Pharma; Research Funding: Janssen, Merck David Solit: Consulted/received honoraria from Pfizer, Fog Pharma, PaigeAI, BridgeBio, Scorpion Therapeutics, FORE Therapeutics, Function Oncology, Pyramid, Elsie Biotechnologies, Inc, and Meliora Therapeutics, Inc. Alvin C. Goh: Consultant for Medtronic Oscar Lin: Consultant for Janssen and Hologic Judy Sarungbam Consultant for Janssen Research & Development, LLC EDAT- 2026/02/09 12:54 MHDA- 2026/05/01 06:34 PMCR- 2026/06/29 CRDT- 2026/02/09 11:03 PHST- 2025/09/06 00:00 [received] PHST- 2025/11/15 00:00 [revised] PHST- 2026/02/05 00:00 [accepted] PHST- 2026/05/01 06:34 [medline] PHST- 2026/02/09 12:54 [pubmed] PHST- 2026/02/09 11:03 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - 774232 [pii] AID - 10.1158/1078-0432.CCR-25-3395 [doi] PST - ppublish SO - Clin Cancer Res. 2026 May 1;32(9):1755-1765. doi: 10.1158/1078-0432.CCR-25-3395. PMID- 41661092 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260213 IS - 2056-5623 (Print) IS - 2056-5623 (Electronic) IS - 2056-5623 (Linking) VI - 12 IP - 1 DP - 2026 Dec TI - Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer. PG - 2622297 LID - 10.1080/20565623.2026.2622297 [doi] LID - 2622297 AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) accounts for over 75% of bladder cancer cases worldwide and is associated with high recurrence rates and significant surveillance costs. Advances in diagnostic modalities, risk stratification, and bladder-preserving therapies have transformed management strategies. AREAS COVERED: This narrative review synthesizes evidence from 70 key publications identified through a comprehensive search of PubMed, MEDLINE, Embase, Scopus, and Google Scholar (2005-2025). Topics include clinical presentation, diagnostic innovations such as enhanced cystoscopy and urinary biomarkers, contemporary risk stratification models, and evolving treatment paradigms including intravesical therapy, immunotherapy, and gene therapy. NMIBC management is shifting toward precision-based, multimodal approaches that integrate molecular biomarkers, immunotherapy, and novel drug delivery systems. While early-phase trials show promise, large-scale studies and real-world data are essential to validate these strategies. Personalized surveillance using circulating and urinary tumor DNA may reduce procedural burden and improve outcomes, marking a paradigm shift toward adaptive, patient-centered care. FAU - Manivasagam, Sri Saran AU - Manivasagam SS AD - Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. FAU - Kassim, Amar AU - Kassim A AD - Pennsylvania State University College of Medicine, Hershey, PA, USA. FAU - Raman, Jay D AU - Raman JD AD - Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260209 PL - England TA - Future Sci OA JT - Future science OA JID - 101665030 PMC - PMC12893692 OAB - Over three-quarters of bladder cancers present as non-muscle invasive bladder cancer (NMIBC), a disease characterized by frequent recurrences and substantial long-term surveillance costs.Advances in diagnostic tools, particularly blue light cystoscopy and evolving urinary biomarker assays, enhance detection accuracy and lower recurrence rates compared with conventional white-light cystoscopy.Updated risk classification systems (AUA/SUO, EAU, and AI-driven models such as PROGRxN-BCa) are improving estimation of recurrence and progression risk, enabling more individualized care.Intravesical treatment remains central to NMIBC management, with BCG continuing as the primary therapy for high-risk disease; during BCG shortages, sequential chemotherapy and novel heat-based delivery systems serve as alternatives.Emerging bladder-preserving therapies, including checkpoint inhibitors, gene-based therapeutics, and controlled-release intravesical platforms, demonstrate encouraging activity in patients with BCG-unresponsive disease.Novel molecular surveillance approaches (ctDNA, utDNA, and urine-derived biomarkers) are poised to shift follow-up toward adaptive, biomarker-guided protocols, potentially reducing procedural burden and improving patient-centered outcomes. OABL- eng OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - biomarkers OT - diagnosis OT - guidelines OT - immunotherapy OT - intravesical therapy OT - risk stratification OT - surveillance COIS- The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 PMCR- 2026/02/09 CRDT- 2026/02/09 10:14 PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 10:14 [entrez] PHST- 2026/02/09 00:00 [pmc-release] AID - 2622297 [pii] AID - 10.1080/20565623.2026.2622297 [doi] PST - ppublish SO - Future Sci OA. 2026 Dec;12(1):2622297. doi: 10.1080/20565623.2026.2622297. Epub 2026 Feb 9. PMID- 41660878 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 2515-4184 (Electronic) IS - 2515-4184 (Linking) VI - 22 IP - 2 DP - 2026 Mar 6 TI - Urinary metabolomics identifies lactate as a biomarker for bladder cancer detection and progression. LID - aaiag004 [pii] LID - 10.1093/molecular-omics/aaiag004 [doi] AB - Bladder cancer (BC) is the ninth most prevalent malignancy worldwide. It remains a significant clinical burden due to high recurrence rates and the need for reliable, non-invasive diagnostic tools. Metabolomics is a powerful strategy for non-invasive cancer detection, with urine representing an ideal biofluid for biomarker discovery, given its direct contact with the urinary tract and its rich diversity of metabolites. This study aimed to identify urinary metabolites showing significant differences in urinary levels between BC patients and controls, and to evaluate their potential for diagnosis and disease monitoring. Beyond identifying metabolites differentiating BC patients from controls, we also assessed whether urinary metabolic patterns could distinguish BC subtypes [non-muscle invasive BC (NMIBC) versus muscle-invasive BC (MIBC)]. Following chemical derivatization, urinary samples were analysed by gas chromatography-mass spectrometry, and the resulting datasets were evaluated using univariate and multivariate statistical approaches. Among the 32 metabolites identified (e.g. amino acids, organic acids, alcohols, and sugar-derivatives), lactate was identified as significantly upregulated in BC versus controls, particularly in MIBC cases. Receiver operating characteristic analysis demonstrated a good performance for overall BC detection and in discriminating between MIBC and NMIBC cases. These results, independent of smoking status and sex, position lactate as a promising non-invasive biomarker for invasive BC. CI - (c) The Author(s) 2026. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Carapito, Angela AU - Carapito A AUID- ORCID: 0000-0003-1396-4485 AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. FAU - Vieira de Sousa, Tiago AU - Vieira de Sousa T AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. FAU - Teixeira-Marques, Ana AU - Teixeira-Marques A AD - Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal. FAU - Henrique, Rui AU - Henrique R AD - Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal. FAU - Jeronimo, Carmen AU - Jeronimo C AD - Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal. FAU - Roque, Ana Cecilia A AU - Roque ACA AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, 2829-516 Caparica, Portugal. FAU - Carvalho, Felix AU - Carvalho F AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. FAU - Pinto, Joana AU - Pinto J AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. FAU - Guedes de Pinho, Paula AU - Guedes de Pinho P AUID- ORCID: 0000-0002-7395-5700 AD - Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. AD - UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. LA - eng GR - FCT-Fundacao para a Ciencia e a Tecnologia/ GR - UIDP/04378/2020/Research Unit on Applied Molecular Biosciences-UCIBIO/ GR - UIDB/04378/2020/Research Unit on Applied Molecular Biosciences-UCIBIO/ GR - LA/P/0140/2020/Associate Laboratory Institute for Health and Bioeconomy - i4HB/ GR - 2021.05844.BD/FCT/ GR - NORTE2030-FEDER-02707400/Cancer Diagnosis, Therapies and Lifestyle - Strategies to Overcome Chemotherapy Resistance and Long-Term Adverse Effects'/ GR - European Regional Development Fund/ GR - NORTE2030/Northern Regional Programme 2021-2027/ PT - Journal Article PL - England TA - Mol Omics JT - Molecular omics JID - 101713384 RN - 0 (Biomarkers, Tumor) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Humans MH - *Biomarkers, Tumor/urine MH - *Metabolomics/methods MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology/metabolism MH - Male MH - Female MH - *Lactic Acid/urine MH - Disease Progression MH - Gas Chromatography-Mass Spectrometry MH - Middle Aged MH - Aged MH - ROC Curve MH - Non-Muscle Invasive Bladder Neoplasms MH - Case-Control Studies MH - Metabolome EDAT- 2026/02/09 12:53 MHDA- 2026/03/07 06:38 CRDT- 2026/02/09 08:23 PHST- 2025/10/10 00:00 [received] PHST- 2025/12/03 00:00 [revised] PHST- 2026/01/20 00:00 [accepted] PHST- 2026/03/07 06:38 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 08:23 [entrez] AID - 8469216 [pii] AID - 10.1093/molecular-omics/aaiag004 [doi] PST - ppublish SO - Mol Omics. 2026 Mar 6;22(2):aaiag004. doi: 10.1093/molecular-omics/aaiag004. PMID- 41659728 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260211 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Preoperative fibrinogen-to-lymphocyte ratio as a prognostic biomarker for non-muscle-invasive bladder cancer. PG - 1707696 LID - 10.3389/fonc.2026.1707696 [doi] LID - 1707696 AB - OBJECTIVE: Although the fibrinogen-to-lymphocyte ratio (FLR) is an established prognostic biomarker in various solid tumors, its role in non-muscle-invasive bladder cancer (NMIBC) remains poorly defined. This study aimed not only to investigate the predictive value of preoperative FLR for overall survival (OS) in NMIBC patients undergoing transurethral resection of bladder tumor (TURBt), but also to develop and validate a novel FLR-based nomogram as a practical clinical tool. METHODS: This retrospective study enrolled 304 NMIBC patients who underwent TURBt at the Shijiazhuang People's Hospital between November 2013 and January 2024, with OS as the primary endpoint. The optimal prognostic cutoff for FLR was determined by maximizing the Youden index via receiver operating characteristic (ROC) curve analysis. Propensity score matching (1:2) was employed to balance baseline confounders. The dose-response relationship between continuous FLR and mortality risk was evaluated using restricted cubic splines (RCS), which confirmed a linear association. Subsequently, independent prognostic factors identified through Cox proportional hazards regression were integrated to construct a nomogram. The model's predictive accuracy and clinical utility were then comprehensively evaluated using the concordance index (C-index), calibration curves, time-dependent ROC curves, and decision curve analysis (DCA). RESULTS: The optimal FLR cutoff was identified as 2.91. Patients in the high-FLR group (FLR >/= 2.91) exhibited significantly poorer OS (P < 0.001) and cancer-specific survival (CSS; P = 0.004). RCS analysis confirmed a significant positive linear association between increasing FLR levels and all-cause mortality risk. Critically, multivariate Cox regression validated FLR as an independent predictor for both OS (Hazard Ratio (HR): 1.520, 95% Confidence Interval (CI): 1.149-2.010) and CSS (HR: 1.536, 95% CI: 1.033-2.284). Integrating FLR into a baseline model improved the C-index for OS prediction from 0.739 to 0.772. The resulting nomogram demonstrated robust discrimination (C-index: 0.772), excellent calibration, and superior net clinical benefit in DCA. CONCLUSION: Preoperative FLR is an independent predictor of overall survival in NMIBC, characterized by a robust linear dose-response relationship with mortality risk. This cost-effective biomarker, integrated into our validated nomogram, enhances risk stratification to guide personalized postoperative management. CI - Copyright (c) 2026 Zhang, Su, Liu, Song, Cui, Cao, Li, Li, He, Kang and Zhang. FAU - Zhang, Xueqiao AU - Zhang X AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Su, Shiqiang AU - Su S AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Liu, Lizhe AU - Liu L AD - Institute of Medicine and Health, Hebei Medical University, Shijiazhuang, China. FAU - Song, Feifan AU - Song F AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Cui, Xiongjie AU - Cui X AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Cao, Yunpeng AU - Cao Y AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Li, Chao AU - Li C AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Li, Shen AU - Li S AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - He, Hanxing AU - He H AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Kang, Yuanhui AU - Kang Y AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. FAU - Zhang, Jin AU - Zhang J AD - Department of Urology, The People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China. LA - eng PT - Journal Article DEP - 20260122 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12872508 OTO - NOTNLM OT - fibrinogen-to-lymphocyte ratio OT - linear OT - non-muscle-invasive bladder cancer OT - predictive indicator OT - prognosis COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 PMCR- 2026/01/22 CRDT- 2026/02/09 06:54 PHST- 2025/09/17 00:00 [received] PHST- 2026/01/02 00:00 [revised] PHST- 2026/01/05 00:00 [accepted] PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 06:54 [entrez] PHST- 2026/01/22 00:00 [pmc-release] AID - 10.3389/fonc.2026.1707696 [doi] PST - epublish SO - Front Oncol. 2026 Jan 22;16:1707696. doi: 10.3389/fonc.2026.1707696. eCollection 2026. PMID- 41658461 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260211 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 15 IP - 1 DP - 2026 Jan 31 TI - Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions. PG - 29 LID - 10.21037/tau-2025-717 [doi] LID - 29 AB - BACKGROUND AND OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy poses a significant clinical challenge, as the standard intervention of radical cystectomy (RC) is associated with substantial morbidity. Immune checkpoint inhibitors (ICIs) have emerged as a promising strategy that may enable bladder preservation. This review critically evaluates current evidence regarding the efficacy and safety of ICIs in this high-risk patient population, aiming to inform clinical decision-making and guide future research. METHODS: A comprehensive literature search was conducted in PubMed and Web of Science up to July 2025. The search strategy combined keywords and Medical Subject Headings (MeSH) terms related to bladder cancer, ICIs, and BCG treatment failure. Only studies published in English were included. KEY CONTENT AND FINDINGS: This review integrates findings from key clinical trials evaluating ICIs, such as pembrolizumab and atezolizumab, used alone or alongside BCG, emphasizing their capacity to elicit sustained therapeutic benefits. It also examines the significance of predictive biomarkers, including programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and characteristics of the tumor microenvironment. In addition, the review outlines current approaches for detecting and managing immune-related adverse events (irAEs). CONCLUSIONS: ICIs represent a promising therapeutic avenue for patients with BCG-unresponsive NMIBC, supporting a shift toward bladder-preserving management strategies. Future research should focus on biomarker-guided patient selection and explore combination regimens to optimize clinical outcomes, thereby informing both clinical practice and investigational priorities. CI - (c) AME Publishing Company. FAU - Zhao, Liang AU - Zhao L AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. AD - Gansu Province Clinical Research Center for Urology, Lanzhou, China. FAU - Yang, Jian-Wei AU - Yang JW AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. AD - Gansu Province Clinical Research Center for Urology, Lanzhou, China. FAU - Chen, Si-Yu AU - Chen SY AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. AD - Gansu Province Clinical Research Center for Urology, Lanzhou, China. FAU - Wang, Li AU - Wang L AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. AD - Gansu Province Clinical Research Center for Urology, Lanzhou, China. FAU - Lin, Peiting AU - Lin P AD - Department of Plastic Surgery, Gansu Provincial Hospital, Lanzhou, China. FAU - Chai, Jin AU - Chai J AD - Health Examination Center, The First Hospital of Lanzhou University, Lanzhou, China. FAU - Yang, Li AU - Yang L AD - Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. AD - Gansu Province Clinical Research Center for Urology, Lanzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20260113 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC12877674 OTO - NOTNLM OT - Bacillus Calmette-Guerin resistance mechanisms (BCG resistance mechanisms) OT - immune checkpoint inhibitors (ICIs) OT - non-muscle-invasive bladder cancer (NMIBC) OT - personalized immunotherapy OT - predictive biomarkers COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-717/coif). L.Z., J.W.Y., S.Y.C., L.W., P.L., and L.Y. report that this work was supported by the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (No. CY2023-BJ-04); Lanzhou Science and Technology Plan Project (No. 2023-ZD-23); and Cuiying Student Research Program of Lanzhou University Second Hospital (No. CYXZ2024-20). The other author has no conflicts of interest to declare. EDAT- 2026/02/09 12:54 MHDA- 2026/02/09 12:55 PMCR- 2026/01/31 CRDT- 2026/02/09 06:45 PHST- 2025/09/21 00:00 [received] PHST- 2025/12/02 00:00 [accepted] PHST- 2026/02/09 12:55 [medline] PHST- 2026/02/09 12:54 [pubmed] PHST- 2026/02/09 06:45 [entrez] PHST- 2026/01/31 00:00 [pmc-release] AID - tau-15-01-29 [pii] AID - 10.21037/tau-2025-717 [doi] PST - ppublish SO - Transl Androl Urol. 2026 Jan 31;15(1):29. doi: 10.21037/tau-2025-717. Epub 2026 Jan 13. PMID- 41657613 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260211 IS - 0973-2063 (Print) IS - 0973-2063 (Electronic) IS - 0973-2063 (Linking) VI - 21 IP - 11 DP - 2025 TI - Impact of lifestyle factors on recurrence rates in non-muscle invasive bladder cancer: A case-control study. PG - 4025-4027 LID - 10.6026/973206300214025 [doi] AB - Recurrence of non-muscle invasive bladder cancer (NMIBC) remains a major clinical challenge despite advances in diagnosis and treatment. Hence, this case-control study evaluated the influence of lifestyle factors on NMIBC recurrence among 120 patients. Dietary habits, smoking, alcohol consumption, and physical activity were analyzed using structured questionnaires. Patients with recurrence showed higher rates of smoking, sedentary lifestyle, and processed meat intake. Multivariate analysis identified these factors as independent predictors, suggesting that targeted lifestyle modification may help reduce recurrence risk. CI - (c) 2025 Biomedical Informatics. FAU - Ranjith, Navaneeth AU - Ranjith N AD - Department of Urology, Caritas hospital, Thellakom, Kottayam, Kerala, India. FAU - Khan, Pathan Ameer AU - Khan PA AD - Department of Medicine, Sri Balaji Hospital, Telangana, India. FAU - Koppolu, Shanmukha AU - Koppolu S AD - Department of Trauma and Orthopaedics, Barts NHS Trust, London, England, UK. FAU - Pavani, Saggurthi AU - Pavani S AD - Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India. FAU - Bhat, Satya Sudhakara AU - Bhat SS AD - Department of Trauma and Orthopaedics, Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK. FAU - Saikumar, Godaba Govardhana AU - Saikumar GG AD - Department of General Medicine, District Medical and Health Office, Vizianagaram, Andhra Pradesh, India. LA - eng PT - Journal Article DEP - 20251115 PL - Singapore TA - Bioinformation JT - Bioinformation JID - 101258255 PMC - PMC12880137 OTO - NOTNLM OT - Bladder cancer OT - case-control study OT - diet OT - lifestyle factors OT - physical activity OT - recurrence OT - smoking EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 PMCR- 2025/11/15 CRDT- 2026/02/09 06:37 PHST- 2025/11/01 00:00 [received] PHST- 2025/11/15 00:00 [revised] PHST- 2025/11/15 00:00 [accepted] PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 06:37 [entrez] PHST- 2025/11/15 00:00 [pmc-release] AID - 973206300214025 [pii] AID - 10.6026/973206300214025 [doi] PST - epublish SO - Bioinformation. 2025 Nov 15;21(11):4025-4027. doi: 10.6026/973206300214025. eCollection 2025. PMID- 41655456 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260813 IS - 1760-4788 (Electronic) IS - 1279-7707 (Print) IS - 1279-7707 (Linking) VI - 30 IP - 4 DP - 2026 Apr TI - Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach. PG - 100805 LID - S1279-7707(26)00036-9 [pii] LID - 10.1016/j.jnha.2026.100805 [doi] LID - 100805 AB - BACKGROUND: Sarcopenia and altered body composition are established prognostic markers in several malignancies, but their relevance in non-muscle-invasive bladder cancer (NMIBC) remains unclear. This study evaluated associations between body composition indices-body mass index (BMI), skeletal muscle index (SMI), and psoas muscle index (PMI)-and recurrence risk in high-risk NMIBC patients treated with intravesical Bacillus Calmette-Guerin (BCG). METHODS: Body composition was assessed on computed tomography at primary diagnosis. Sarcopenia was defined using published sex-specific cut-offs. Recurrence-free survival (RFS) was analyzed using Kaplan-Meier estimates, Cox regression with linear and spline terms, and a gradient boosted machine (GBM) model. RESULTS: A total of 118 patients (median age 71 years; 78% male) were included. Tumor stages were pTa (40%), pT1 (54%), and primary carcinoma in situ (CIS) in 6%. During a mean follow-up of 32 months, 30 patients (25.4%) developed recurrence. Median BMI was 26 kg/m(2). SMI and PMI were higher in men and declined with age, whereas BMI remained stable. Sarcopenia prevalence varied widely across definitions (6-66%) with low-to-moderate concordance (Cohen's kappa: 0-0.58). No sarcopenia definition independently predicted recurrence. In the GBM model, BCG maintenance, tumor stage, CIS, age, BMI, SMI, and PMI were important predictors. Spline Cox models demonstrated nonlinear U-shaped associations between BMI, SMI, PMI, and recurrence risk, with increased risk at both low and high values. CONCLUSIONS: Body composition shows nonlinear associations with recurrence in high-risk NMIBC. Both low and excessive body and muscle mass may adversely affect disease control. The heterogeneity and limited prognostic value of current sarcopenia definitions highlight the need for standardized, multiparametric, and nonlinear risk modeling approaches. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Klinglmair, Gerald AU - Klinglmair G AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Lutz, Maximilian AU - Lutz M AD - Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Telia, Tatia AU - Telia T AD - Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria. FAU - van Creij, Nils C H AU - van Creij NCH AD - Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Wafa, Hamed AU - Wafa H AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Tymoszuk, Piotr AU - Tymoszuk P AD - Data Analysis Service Tirol, Worgl, Austria. FAU - Heim, Beatrice AU - Heim B AD - Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Niedersuess-Beke, Dora AU - Niedersuess-Beke D AD - Department of Internal Medicine I., Centre for Oncology and Haematology, Vienna Healthcare Group, Ottakring, Vienna, Austria. FAU - Terbuch, Angelika AU - Terbuch A AD - Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), University of Alcala, Madrid, Spain. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, University of Augsburg, Augsburg, Germany. FAU - Luger, Anna AU - Luger A AD - Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: Renate.Pichler@i-med.ac.at. LA - eng PT - Journal Article DEP - 20260208 PL - France TA - J Nutr Health Aging JT - The journal of nutrition, health & aging JID - 100893366 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Male MH - *Sarcopenia/complications/epidemiology MH - Aged MH - Female MH - *Neoplasm Recurrence, Local/epidemiology MH - Non-Muscle Invasive Bladder Neoplasms MH - Body Mass Index MH - Body Composition MH - Muscle, Skeletal MH - Risk Factors MH - *Urinary Bladder Neoplasms/pathology/complications/drug therapy MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Proportional Hazards Models MH - Middle Aged MH - Kaplan-Meier Estimate MH - Prognosis MH - Disease-Free Survival MH - Nonlinear Dynamics PMC - PMC12907225 OTO - NOTNLM OT - BCG OT - BMI OT - Bladder cancer OT - PMI OT - Recurrence OT - SMI OT - Sarcopenia COIS- Declaration of competing interest The authors have no conflict of interest to declare. EDAT- 2026/02/09 00:29 MHDA- 2026/04/10 00:33 PMCR- 2026/02/08 CRDT- 2026/02/08 18:05 PHST- 2025/11/27 00:00 [received] PHST- 2026/01/17 00:00 [revised] PHST- 2026/02/04 00:00 [accepted] PHST- 2026/04/10 00:33 [medline] PHST- 2026/02/09 00:29 [pubmed] PHST- 2026/02/08 18:05 [entrez] PHST- 2026/02/08 00:00 [pmc-release] AID - S1279-7707(26)00036-9 [pii] AID - 100805 [pii] AID - 10.1016/j.jnha.2026.100805 [doi] PST - ppublish SO - J Nutr Health Aging. 2026 Apr;30(4):100805. doi: 10.1016/j.jnha.2026.100805. Epub 2026 Feb 8. PMID- 41651177 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1873-3913 (Electronic) IS - 0898-6568 (Linking) VI - 142 DP - 2026 Jun TI - ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance. PG - 112398 LID - S0898-6568(26)00048-3 [pii] LID - 10.1016/j.cellsig.2026.112398 [doi] AB - Tumor-associated fibroblast-mediated matrix remodeling is an important feature of invasive immune-rejection bladder cancer, but its pathogenic mechanism and potential therapeutic targets are still unclear. The matrix and immune interaction network and core related genes in bladder cancer were systematically investigated by combining single-cell transcriptome data analysis and fibroblast GWAS data with TCGA and GEO data deconvolution, WGCNA, drug response prediction, multiplex immunofluorescence, and in vitro and in vivo validation experiments of cells and animals. ADAM12's functional validation. The findings demonstrated that the tumor-associated fibroblast ECM-CAF subgroup infiltration was evident in bladder cancer and was substantially associated with the upregulation of the core genes ADAM12 and TP53-biased basal-like program. These were characterized by the deposition of dense matrix, the upregulation of numerous immune checkpoints, the rejection and dysfunction of T cells, and a decrease in immunogenicity. Multiplex immunofluorescence localization of bladder cancer and normal bladder tissue showed that ADAM12 was significantly associated with the progression of non-muscle invasive bladder cancer to muscle invasive bladder cancer and the infiltration of ECM-CAF. Knockdown of ADAM12 inhibited the proliferation, migration, and invasion of bladder cancer cells, reduced the activation of the PI3K-AKT-mTOR pathway, and inhibited bladder cancer xenograft growth and lung metastasis. ADAM12 overexpression triggered the PI3K-AKT-mTOR pathway, enhanced the development and lung metastasis of bladder cancer xenografts, and markedly increased the invasion, migration, and proliferation of bladder cancer cells. The above results indicate that ADAM12, as a matrix-driven factor, links matrix remodeling, PI3K-AKT signaling pathway and bladder cancer immunosuppression, and has good prognostic and therapeutic stratification potential, providing new ideas for precision targeted intervention and treatment of bladder cancer. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Song, Tianbao AU - Song T AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - He, Wenlin AU - He W AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - Yuan, Qin AU - Yuan Q AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - Xia, Sihan AU - Xia S AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - Yi, Qin AU - Yi Q AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - He, Yipeng AU - He Y AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. FAU - Yu, Weimin AU - Yu W AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. Electronic address: 1025931346@qq.com. FAU - Cheng, Fan AU - Cheng F AD - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China. Electronic address: urology1969@aliyun.com. LA - eng PT - Journal Article DEP - 20260205 PL - England TA - Cell Signal JT - Cellular signalling JID - 8904683 RN - EC 3.4.24.- (ADAM12 Protein) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 3.4.24.- (ADAM12 protein, human) SB - IM MH - Humans MH - *ADAM12 Protein/metabolism/genetics MH - *Urinary Bladder Neoplasms/pathology/immunology/metabolism/genetics/drug therapy MH - *Proto-Oncogene Proteins c-akt/metabolism MH - *Phosphatidylinositol 3-Kinases/metabolism MH - Animals MH - *Tumor Microenvironment MH - *Extracellular Matrix/metabolism MH - Cell Line, Tumor MH - Signal Transduction MH - *Cancer-Associated Fibroblasts/metabolism/pathology MH - Disease Progression MH - *Drug Resistance, Neoplasm MH - Mice MH - Cell Proliferation OTO - NOTNLM OT - ADAM12 OT - Cancer-associated fibroblasts OT - Extracellular matrix remodeling OT - PI3K-AKT signaling OT - Tumor microenvironment COIS- Declaration of competing interest The writers assert that they possess no recognized conflicting monetary concerns or personal associations that may have seemed to impact the research documented in this article. EDAT- 2026/02/07 00:30 MHDA- 2026/03/09 07:41 CRDT- 2026/02/06 19:16 PHST- 2025/11/05 00:00 [received] PHST- 2026/01/14 00:00 [revised] PHST- 2026/01/27 00:00 [accepted] PHST- 2026/03/09 07:41 [medline] PHST- 2026/02/07 00:30 [pubmed] PHST- 2026/02/06 19:16 [entrez] AID - S0898-6568(26)00048-3 [pii] AID - 10.1016/j.cellsig.2026.112398 [doi] PST - ppublish SO - Cell Signal. 2026 Jun;142:112398. doi: 10.1016/j.cellsig.2026.112398. Epub 2026 Feb 5. PMID- 41649780 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260730 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 5 DP - 2026 May TI - Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer. PG - 4858-4872 LID - 10.1245/s10434-025-19064-0 [doi] AB - BACKGROUND: The oncological safety of bladder preservation therapy (BPT) versus standard radical cystectomy (RC) in elderly patients with muscle-invasive bladder cancer (MIBC) remains controversial. MATERIALS AND METHODS: Adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) guidelines, we conducted a systematic literature review of publications indexed in the PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) databases through July 2025. This meta-analysis evaluated the oncological safety of BPT compared with that of RC for the treatment of elderly patients with MIBC. The outcomes were overall survival (OS) rates at 1, 5, and 10 years; cancer-specific survival (CSS) rates at 1 and 5 years; and mortality rates. RESULTS: Our analysis included 8 studies with a total of 4888 patients, comprising 2534 patients undergoing BPT and 2354 undergoing RC. BPT and RC did not differ significantly in 1-year OS (odds ratio [OR]) 0.81; 95% confidence interval [CI] 0.46, 1.41; p = 0.45), 5-year OS (OR 0.83; 95% CI 0.51, 1.36; p = 0.46), 10-year OS (OR 1.09; 95% CI 0.24, 4.89; p = 0.91), and 1-year CSS (OR 0.80; 95% CI 0.61, 1.04; p = 0.10). However, BPT was inferior in terms of 5-year CSS (OR 0.51; 95% CI 0.42, 0.63; p < 0.00001) and exhibited a higher mortality rate (OR 2.06; 95% CI 1.24, 3.42; p = 0.005). CONCLUSIONS: BPT was proven more favorable for elderly patients when contrasted with those of unstratified age groups. Indirect comparisons within BPT sub-analyses suggest that combining transurethral resection of bladder tumors (TURBT) with chemoradiotherapy (CRT) might yield greater benefits than either treatment alone or in dual combination. Due to high heterogeneity and the retrospective design of included studies, the results should be interpreted with caution. CI - (c) 2026. Society of Surgical Oncology. FAU - Mehmud, Irfan AU - Mehmud I AD - Department of Urology, Medical School, South China Hospital, Shenzhen University, Shenzhen, Guangdong, China. AD - Motor Robotics Institute (MRI), Medical School, South China Hospital, Shenzhen University, Shenzhen, China. FAU - Zhang, Yi AU - Zhang Y AD - Motor Robotics Institute (MRI), Medical School, South China Hospital, Shenzhen University, Shenzhen, China. AD - Department of Urology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China. FAU - Wu, Song AU - Wu S AD - Department of Urology, Medical School, South China Hospital, Shenzhen University, Shenzhen, Guangdong, China. wusong@szu.edu.cn. FAU - Zhang, Shaohua AU - Zhang S AD - Department of Urology, Medical School, South China Hospital, Shenzhen University, Shenzhen, Guangdong, China. 22zsh@163.com. AD - Motor Robotics Institute (MRI), Medical School, South China Hospital, Shenzhen University, Shenzhen, China. 22zsh@163.com. LA - eng GR - XMHT20220104016/Shenzhen Engineering Research Center/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260206 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality/therapy MH - *Organ Sparing Treatments/mortality/methods MH - *Cystectomy/mortality MH - Aged MH - Survival Rate MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder preservation therapy OT - Elderly patients OT - Meta-analysis OT - Muscle-invasive bladder cancer OT - Radical cystectomy COIS- Funding: This work was supported by the Shenzhen Engineering Research Center; project approval number: XMHT20220104016. Disclosure: The authors declare that they have no financial conflict of interest with regard to the content of this report. EDAT- 2026/02/06 14:37 MHDA- 2026/04/19 17:44 CRDT- 2026/02/06 11:26 PHST- 2025/08/26 00:00 [received] PHST- 2025/12/30 00:00 [accepted] PHST- 2026/04/19 17:44 [medline] PHST- 2026/02/06 14:37 [pubmed] PHST- 2026/02/06 11:26 [entrez] AID - 10.1245/s10434-025-19064-0 [pii] AID - 10.1245/s10434-025-19064-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2026 May;33(5):4858-4872. doi: 10.1245/s10434-025-19064-0. Epub 2026 Feb 6. PMID- 41645782 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 98 IP - 1 DP - 2026 Mar 31 TI - Results of rotational thromboelastometry confirm venous thromboembolic risk prediction in urologic patients. PG - 14624 LID - 10.4081/aiua.2026.14624 [doi] AB - PURPOSE: Venous thromboembolic (VTE) complications contribute substantially to perioperative morbidity and mortality. The decision for mechanical and/or chemo-prophylaxis is currently based on VTE risk assessment models since conventional laboratory assays of coagulation usually fail to detect changes indicating hypercoagulability. Rotational thromboelastometry is a novel assay of coagulation, that it could potentially be used in objectively selecting patients at risk for VTE, who should indisputably undergo prophylaxis. We evaluated the association of conventional and novel assays of coagulation and VTE risk. METHODS: VTE risk was preoperatively assessed in 45 patients scheduled for endoscopic, open and laparoscopic urologic surgery, including transurethral resection of prostate, transurethral resection of bladder tumor, endoscopic vesical or ureteral stone lithotripsy, open prostatectomy, open cystectomy and urinary diversion, open or laparoscopic radical or partial nephrectomy, between March 2021 and October 2022, using three different risk assessment models (RAMs): the European Association of Urology (EAU) RAM, the American Urological Association (AUA) RAM, and the Caprini model. Patients under antiplatelet or anticoagulation agents were excluded. Patients' coagulation profile was determined by measuring PT, fibrinogen, aPTT, and rotational thromboelastometry analysis. For rotational thromboelastometry analysis, extrinsic rotational thromboelastometry and fibrinogen rotational thromboelastometry were examined in every patient. Statistical analysis was performed with ANOVA test and chi2 test. RESULTS: Mean values of all rotational thromboelastometry variables did not vary significantly among different EAU VTE categories. In extrinsic rotational thromboelastometry assessment, a significant difference was observed in the mean values of the Clotting time (CT) between the different risk groups based on AUA RAM. In the comparison between the risk groups defined based on the Caprini score, statistically significant differences were observed in the extrinsic rotational thromboelastometry clot formation time (CFT). In fibrinogen rotational thromboelastometry analysis, significant differences were identified in the clot amplitude after five minutes (A5) and maximum clot firmness (MCF) indices between the AUA risk groups, along with a significant difference in the mean clot formation rate (CFR) value between the risk groups defined based on the Caprini score. CONCLUSIONS: Rotational thromboelastometry can provide a detailed evaluation of the hemostatic status in patients undergoing urologic surgery that can be used as an adjunct to the VTE risk assessment models and thus, help to offer prophylaxis on a rather personalized basis. Future studies should assess the utility of thromboelastometry in identifying patients at high risk for VTE after major urological procedures. FAU - Douroumis, Konstantinos AU - Douroumis K AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Kotrotsios, Konstantinos AU - Kotrotsios K AD - Department of General Surgery, Elpis General Hospital of Athens. FAU - Moulavasilis, Napoleon AU - Moulavasilis N AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Fragkiadis, Evangelos AU - Fragkiadis E AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Stratigopoulou, Panagiota AU - Stratigopoulou P AD - Anesthesiology Department, Laikon General Hospital of Athens. FAU - Adamakis, Ioannis AU - Adamakis I AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Anastasiou, Ioannis AU - Anastasiou I AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, National and Kapodistrian University of Athens. FAU - Mitropoulos, Dionysios AU - Mitropoulos D AD - First Department of Urology, National and Kapodistrian University of Athens. LA - eng PT - Journal Article DEP - 20260206 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Humans MH - *Thrombelastography/methods MH - Male MH - *Venous Thromboembolism/etiology/prevention & control/diagnosis MH - *Urologic Surgical Procedures/methods/adverse effects MH - Risk Assessment/methods MH - Aged MH - Middle Aged MH - Female MH - Risk Factors MH - *Postoperative Complications/prevention & control OTO - NOTNLM OT - Venous thromboembolism OT - rotational thromboelastometry OT - urologic surgery EDAT- 2026/02/06 06:41 MHDA- 2026/03/31 12:33 CRDT- 2026/02/06 04:03 PHST- 2025/11/03 00:00 [received] PHST- 2025/12/23 00:00 [accepted] PHST- 2026/03/31 12:33 [medline] PHST- 2026/02/06 06:41 [pubmed] PHST- 2026/02/06 04:03 [entrez] AID - 10.4081/aiua.2026.14624 [doi] PST - ppublish SO - Arch Ital Urol Androl. 2026 Mar 31;98(1):14624. doi: 10.4081/aiua.2026.14624. Epub 2026 Feb 6. PMID- 41633899 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260716 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 5 DP - 2026 May TI - Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PG - 446-453 LID - S0302-2838(26)00015-1 [pii] LID - 10.1016/j.eururo.2026.01.009 [doi] AB - BACKGROUND AND OBJECTIVE: Intravesical bacillus Calmette-Guerin (BCG) plus mitomycin (MM) had not been compared rigorously with BCG alone in BCG-naive, non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: Participants with BCG-naive NMIBC (high-grade pTa or any grade pT1; concurrent carcinoma in situ [CIS] allowed) were assigned randomly (1:1) to either the BCG + MM or the BCG-alone group after maximal transurethral resection. The primary endpoint was disease-free survival (DFS); the secondary endpoints included a complete response on cystoscopy at 3 mo (CR3mos), recurrence, progression, adverse events (AEs), and deaths from any cause. KEY FINDINGS AND LIMITATIONS: We randomised 501 participants (249 to BCG + MM and 252 to BCG alone), with pTa in 53%, pT1 in 47%, and concurrent CIS in 28%. The median follow-up was 48 mo. DFS was not superior for BCG + MM versus BCG alone (2-yr DFS rate: 75% vs 71%; hazard ratio 0.87, 95% confidence interval 0.65-1.16; p = 0.3). The numbers of events for BCG + MM versus BCG alone were as follows: 214 versus 210 (CR3mos), 79 versus 86 (recurrence), 28 versus 44 (progression), and 26 versus 23 (death). Those assigned BCG + MM had more instillations (4033 vs 3383) but fewer doses of BCG (total 2056 vs 3383; median nine vs 16) than BCG alone. Grade 3-5 AEs occurred in 43 assigned BCG + MM versus 37 assigned BCG alone. A higher number of participants assigned BCG + MM than those assigned BCG alone had >/=75% of their planned doses (78% vs 68%, p = 0.02). CONCLUSIONS AND CLINICAL IMPLICATIONS: BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations. These findings support consideration of BCG + MM as a pragmatic alternative to BCG alone, which could mitigate the global shortage of BCG. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Hayne, Dickon AU - Hayne D AD - UWA Medical School, University of Western Australia, Perth, WA, Australia. Electronic address: dickon.hayne@uwa.edu.au. FAU - Zhang, Alison Y AU - Zhang AY AD - NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. FAU - Thomas, Hayley AU - Thomas H AD - NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. FAU - Krieger, Laurence AU - Krieger L AD - Department of Medical Oncology, Northern Cancer Institute, St Leonards, Sydney, NSW, Australia. FAU - Ischia, Joseph AU - Ischia J AD - Department of Urology, Austin Health, Melbourne, Victoria, Australia. FAU - Anderson, Paul AU - Anderson P AD - Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. FAU - Srivastav, Ratnesh K AU - Srivastav RK AD - Department of Medical Oncology, Tweed Valley Hospital, Cudgen, NSW, Australia. FAU - Green, William AU - Green W AD - Department of Urology, Nottingham University Hospital, Nottingham, UK. FAU - Grummet, Jeremy AU - Grummet J AD - Department of Urology, The Alfred Hospital, Melbourne, Victoria, Australia. FAU - Bastick, Patricia A AU - Bastick PA AD - Department of Medical Oncology, Southside Cancer Care Centre, Sydney, NSW, Australia. FAU - Beardsley, Emma K AU - Beardsley EK AD - Department of Medical Oncology, Frankston Hospital, Melbourne, Victoria, Australia. FAU - Blatt, Alison AU - Blatt A AD - Department of Urology, John Hunter Hospital, Newcastle, NSW, Australia. FAU - Patel, Manish AU - Patel M AD - Department of Urology, Westmead Hospital, Sydney, NSW, Australia. FAU - Chan, Lewis AU - Chan L AD - Department of Urology, Concord Repatriation General Hospital, Sydney, NSW, Australia. FAU - Mitterdorfer, Andrew AU - Mitterdorfer A AD - Department of Urology, Concord Repatriation General Hospital, Sydney, NSW, Australia. FAU - Roberts, Matthew AU - Roberts M AD - Department of Urology, Redcliffe Hospital, Redcliffe, Queensland, Australia. FAU - Sengupta, Shomik AU - Sengupta S AD - Department of Urology, Epworth HealthCare - Richmond, Melbourne, Victoria, Australia. FAU - Winter, Matthew AU - Winter M AD - Department or Urology, Nepean Hospital, Sydney, NSW, Australia. FAU - Marx, Gavin AU - Marx G AD - SAN Clinical Trials Unit, Sydney Adventist Hospital, Sydney, NSW, Australia. FAU - Bishop, Conrad AU - Bishop C AD - Department of Urology, Footscray Hospital, Melbourne, Victoria, Australia. FAU - Cheung, Leanna AU - Cheung L AD - NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. FAU - Hawks, Cynthia AU - Hawks C AD - Department of Urology, Fiona Stanley Hospital, Perth, WA, Australia. FAU - Martin, Andrew AU - Martin A AD - ULTRA The University of Queensland Clinical Trials Capability, Centre for Clinical Research, Queensland, Australia. FAU - McCombie, Steve P AU - McCombie SP AD - Department of Urology, Footscray Hospital, Melbourne, Victoria, Australia. FAU - Redfern, Andrew D AU - Redfern AD AD - Department of Oncology, UWA Medical School, Perth, WA, Australia. FAU - Davis, Ian D AU - Davis ID AD - Monash University Eastern Health Clinical School, Melbourne, Australia. FAU - Stockler, Martin R AU - Stockler MR AD - NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Department of Urology, Concord Repatriation General Hospital, Sydney, NSW, Australia. LA - eng PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260202 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Mitomycin/administration & dosage/adverse effects MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/administration & dosage/adverse effects MH - Female MH - Aged MH - Administration, Intravesical MH - Male MH - Transurethral Resection of Bladder MH - Middle Aged MH - Disease-Free Survival MH - *Antibiotics, Antineoplastic/administration & dosage/adverse effects MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *Adjuvants, Immunologic/administration & dosage/adverse effects MH - Neoplasm Recurrence, Local MH - Aged, 80 and over OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Intravesical instillation OT - Mitomycin OT - Non-muscle invasive OT - Randomised controlled trial EDAT- 2026/02/04 05:06 MHDA- 2026/05/07 00:32 CRDT- 2026/02/03 21:53 PHST- 2025/10/02 00:00 [received] PHST- 2025/12/21 00:00 [revised] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/05/07 00:32 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 21:53 [entrez] AID - S0302-2838(26)00015-1 [pii] AID - 10.1016/j.eururo.2026.01.009 [doi] PST - ppublish SO - Eur Urol. 2026 May;89(5):446-453. doi: 10.1016/j.eururo.2026.01.009. Epub 2026 Feb 2. PMID- 41633898 OWN - NLM STAT- MEDLINE DCOM- 20260702 LR - 20260715 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 90 IP - 1 DP - 2026 Jul TI - Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. PG - 7-12 LID - S0302-2838(26)00022-9 [pii] LID - 10.1016/j.eururo.2026.01.015 [doi] AB - The PURE-01 trial evaluated three cycles of pembrolizumab 200 mg followed by radical cystectomy (RC) in patients with cT2-3b N0 M0 muscle-invasive bladder cancer (MIBC) ineligible for or refusing cisplatin. A total of 155 patients were treated. We report survival outcomes after median follow-up of >60 mo and associations with pathological response rates and biomarker levels. In the intention-to-treat population, the 5-yr event-free survival rate was 68% and the 5-yr overall survival (OS) rate was 77%. In the RC cohort, the 5-yr recurrence-free survival (RFS) rate was 77%. Pathological response categories were significantly associated with survival, with a 5-yr OS rate of approximately 90% in the group achieving a complete or major response (p < 0.001). The 5-yr cumulative risk of recurrence was 19%, with three of 31 relapses occurring beyond 5 yr after RC. Eight patients refused RC and underwent transurethral resection; seven remain alive and disease-free. Transcriptome-wide profiling of pretreatment tissue was available for 102 patients. Stratification by genomic subtyping classifier showed that the claudin-low subtype (n = 14) had the highest 5-yr RFS rate, with a 5-yr OS rate of 93%. At long-term follow-up, PURE-01 demonstrates sustained survival outcomes and confirms the prognostic relevance of pathological response and molecular subtypes. These results support further investigation of single-agent immunotherapy as a potential de-escalation strategy in selected patients. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tateo, Valentina AU - Tateo V AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: tateo.valentina@hsr.it. FAU - Basile, Giuseppe AU - Basile G AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Giannatempo, Patrizia AU - Giannatempo P AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands. FAU - Proudfoot, James A AU - Proudfoot JA AD - Veracyte, Inc., South San Francisco, CA, USA. FAU - Maiorano, Brigida A AU - Maiorano BA AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Cigliola, Antonio AU - Cigliola A AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Mercinelli, Chiara AU - Mercinelli C AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Davicioni, Elai AU - Davicioni E AD - Veracyte, Inc., South San Francisco, CA, USA. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Rota, Simone AU - Rota S AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Brembilla, Giorgio AU - Brembilla G AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Radiology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - De Cobelli, Francesco AU - De Cobelli F AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Radiology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. LA - eng PT - Clinical Trial, Phase II PT - Journal Article DEP - 20260203 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antibodies, Monoclonal, Humanized) RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - *Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects MH - *Cystectomy MH - Neoadjuvant Therapy MH - Female MH - Male MH - Aged MH - Neoplasm Invasiveness MH - Middle Aged MH - *Antineoplastic Agents, Immunological/therapeutic use/adverse effects MH - Time Factors MH - Pathologic Complete Response MH - Survival Rate MH - Treatment Outcome OTO - NOTNLM OT - Molecular subtypes OT - Muscle-invasive bladder cancer OT - Neoadjuvant immunotherapy OT - Pembrolizumab EDAT- 2026/02/04 05:06 MHDA- 2026/07/03 00:30 CRDT- 2026/02/03 21:53 PHST- 2025/09/09 00:00 [received] PHST- 2026/01/05 00:00 [revised] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/07/03 00:30 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 21:53 [entrez] AID - S0302-2838(26)00022-9 [pii] AID - 10.1016/j.eururo.2026.01.015 [doi] PST - ppublish SO - Eur Urol. 2026 Jul;90(1):7-12. doi: 10.1016/j.eururo.2026.01.015. Epub 2026 Feb 3. PMID- 41624768 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260202 LR - 20260204 IS - 2296-889X (Print) IS - 2296-889X (Electronic) IS - 2296-889X (Linking) VI - 12 DP - 2025 TI - A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer. PG - 1722809 LID - 10.3389/fmolb.2025.1722809 [doi] LID - 1722809 AB - BACKGROUND: Cancer-associated fibroblasts (CAFs) are key drivers of tumor progression in bladder cancer (BLCA), yet their molecular heterogeneity and prognostic utility remain incompletely characterized. Single-cell studies have revealed distinct CAF subpopulations with divergent clinical impacts, necessitating refined prognostic frameworks that capture CAF-mediated progression. METHODS: We analyzed single-cell RNA sequencing data (GSE267718) from 8 BLCA patients to identify CAF populations and define progression-associated gene signatures. Using 359 TCGA-BLCA samples as the training cohort, we performed non-negative matrix factorization (NMF) consensus clustering on 85 prognostically significant CAF genes, identifying two molecular clusters with distinct survival outcomes. Through LASSO-Cox regression and stepwise selection, we constructed a four-gene Tumor-Progressing Fibroblast Riskscore model comprising FOXA1, TBX3, LRIG1, and RNF11. Model performance was validated in the E-MTAB-4321 cohort (n = 476). Functional validation of RNF11 was performed using shRNA-mediated knockdown in T24 and 5637 bladder cancer cell lines, followed by proliferation, migration, invasion assays, and transcriptomic profiling. RESULTS: Single-cell analysis identified 557 differentially expressed genes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer CAFs. NMF clustering stratified TCGA patients into 2 clusters with significantly different overall survival. The TPFR model showed consistent prognostic performance in both training and validation cohorts, with high-risk patients showing significantly worse survival. Functional enrichment analysis revealed that TPFR scores correlated with ECM-receptor interaction, focal adhesion, and cytoskeletal regulation pathways. Stratified analysis revealed superior model performance in elderly (>60 years), male, and early-stage patients. In particular, RNF11 knockdown significantly reduced proliferation, migration, and invasion in 5637 and T24 cells, while transcriptomic analysis revealed alterations in tumors after RNF11 knockdown including TNF and MAPK signaling pathway, indicating a potential mechanism by which RNF11 regulates bladder cancer progression. CONCLUSION: We established a CAF-based prognostic model that integrates single-cell insights with bulk transcriptomics for robust risk stratification in BLCA. The TPFR model shows clinical utility particularly in elderly and early-stage patients. Functional characterization showed that RNF11 regulates proliferation and migration of bladder cancer. These findings highlight the prognostic value of CAF signatures and provide a framework for precision medicine approaches in bladder cancer management. CI - Copyright (c) 2026 Zhang, Lin, Xu, Su, Zeng, Zhong, Su, Chen, Cao, Yu and Zhuo. FAU - Zhang, Miaoyu AU - Zhang M AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Lin, Liangbin AU - Lin L AD - Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China. AD - Obesity and Metabolism Medicine-Engineering Integration Laboratory, Department of General Surgery, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China. AD - The Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Xu, He AU - Xu H AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. AD - Department of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. FAU - Su, Xu AU - Su X AD - Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China. FAU - Zeng, Kui AU - Zeng K AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Zhong, Fangyang AU - Zhong F AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Su, Xianchao AU - Su X AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Chen, Jie AU - Chen J AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. FAU - Cao, Min AU - Cao M AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. AD - Department of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. FAU - Yu, Hui AU - Yu H AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. AD - Department of Urology, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. FAU - Zhuo, Hui AU - Zhuo H AD - Department of Urology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China. LA - eng PT - Journal Article DEP - 20260115 PL - Switzerland TA - Front Mol Biosci JT - Frontiers in molecular biosciences JID - 101653173 PMC - PMC12851964 OTO - NOTNLM OT - RNF11 OT - bladder cancer OT - cancer-associated fibroblasts OT - prognostic model OT - single-cell RNA sequence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/02 18:13 MHDA- 2026/02/02 18:14 PMCR- 2026/01/15 CRDT- 2026/02/02 06:47 PHST- 2025/10/11 00:00 [received] PHST- 2025/12/14 00:00 [revised] PHST- 2025/12/29 00:00 [accepted] PHST- 2026/02/02 18:14 [medline] PHST- 2026/02/02 18:13 [pubmed] PHST- 2026/02/02 06:47 [entrez] PHST- 2026/01/15 00:00 [pmc-release] AID - 1722809 [pii] AID - 10.3389/fmolb.2025.1722809 [doi] PST - epublish SO - Front Mol Biosci. 2026 Jan 15;12:1722809. doi: 10.3389/fmolb.2025.1722809. eCollection 2025. PMID- 41622133 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Feb 2 TI - Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor. LID - 10.1186/s12885-026-15658-3 [doi] LID - 319 AB - BACKGROUND: We have previously reported urine laminin-gamma2 monomer (Lm-gamma2m) as a diagnostic biomarker for patients with non-muscle-invasive bladder cancer (NMIBC). However, Lm-gamma2m has not been evaluated as a prognostic biomarker for patients with NMIBC after transurethral resection of bladder tumor (TURBT). This study aimed to clarify whether urine Lm-gamma2m offers a useful prognostic biomarker for patients with NMIBC after TURBT. METHODS: Participants comprised 41 patients with NMIBC. Urine Lm-gamma2m was prospectively measured before and 3 months after TURBT and values were compared. Traditional urine tumor markers such as urine nuclear matrix protein 22 and cytology were also evaluated before and after TURBT. Patients were stratified by the presence of recurrence within 1 year after TURBT and values of urine Lm-gamma2m before and after TURBT were analyzed. RESULTS: Mean urine Lm-gamma2m values were significantly decreased after TURBT compared to before surgery. Mean urine Lm-gamma2m before and after TURBT were higher in patients with recurrence within 1 year after surgery than in patients without recurrence. Urine Lm-gamma2m before TURBT was also important to predict prognosis in patients with NMIBC treated using TURBT. CONCLUSIONS: These results suggest urine Lm-gamma2m as a potentially useful biomarker for NMIBC before and after TURBT. FAU - Osaka, Kimito AU - Osaka K AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. AD - Department of Urology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Kishida, Takeshi AU - Kishida T AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Umemoto, Susumu AU - Umemoto S AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. AD - Yokohama Futamatagawa Umemoto Urology Clinic, Yokohama, Japan. FAU - Karashima, Takashi AU - Karashima T AUID- ORCID: 0000-0001-7338-8059 AD - Department of Urology, Kochi Medical School, Nankoku, Japan. karasima@kochi-u.ac.jp. FAU - Nakagawa, Masatoshi AU - Nakagawa M AD - Diagnostic Division, Abbott Japan LLC, Chiba, Japan. FAU - Yoshida, Eisaku AU - Yoshida E AD - Diagnostic Division, Abbott Japan LLC, Chiba, Japan. FAU - Yoshimura, Toru AU - Yoshimura T AD - Diagnostic Division, Abbott Japan LLC, Chiba, Japan. FAU - Sakaguchi, Masahiko AU - Sakaguchi M AD - Integrated Center for Advanced Medical Technologies, Kochi Medical School, Nankoku, Japan. AD - Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - Department of Engineering Informatics, Faculty of Information and Communication Engineering, Osaka Electro-Communication University, Neyagawa, Japan. AD - Unit of Cancer Education, Kanagawa Cancer Center Research Institute, Yokohama, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nankoku, Japan. FAU - Koshikawa, Naohiko AU - Koshikawa N AD - Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Japan. AD - Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Seiki, Motoharu AU - Seiki M AD - Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Shuin, Taro AU - Shuin T AD - Department of Urology, Kochi Medical School, Nankoku, Japan. LA - eng GR - 5lm0103002j0004 (B29)/Japan Agency for Medical Research and Development/ PT - Journal Article DEP - 20260202 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Laminin) RN - 0 (Biomarkers, Tumor) RN - 0 (LAMC2 protein, human) SB - IM MH - Humans MH - Transurethral Resection of Bladder MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms/urine/surgery/pathology MH - Male MH - *Laminin/urine MH - Aged MH - *Biomarkers, Tumor/urine MH - Middle Aged MH - Prognosis MH - Neoplasm Recurrence, Local/urine MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/surgery/urine/pathology PMC - PMC12958644 OTO - NOTNLM OT - Bladder cancer, non OT - Invasive bladder cancer, laminin OT - Muscle OT - gamma2 monomer, biomarker OT - gamma2, urine laminin COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by our institutional review board (Kochi Medical School Hospital: ERB-106289; Kanagawa Cancer Center: 2019-22). Consent for publication: All patients provided written informed consent and consented to publication. Competing interests: T. Yoshimura, E. Yoshida and M. Nakagawa are employees of Abbott Japan LLC. K. Inoue received patent royalties and research funds from SBI Pharmaceuticals Co., Ltd., honoraria from Chugai Pharmaceutical Co., Ltd., and endowments from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., MC Medical Inc. and Ono Pharmaceutical Co., Ltd. M. Seiki and N. Koshikawa received research funds from Tokyo University. N. Koshikawa, T. Karashima and T. Shuin received research funds from Abbott Japan LLC. None of the other authors have any potential conflicts of interest. EDAT- 2026/02/02 00:29 MHDA- 2026/06/27 12:38 PMCR- 2026/02/02 CRDT- 2026/02/01 23:12 PHST- 2025/02/25 00:00 [received] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/06/27 12:38 [medline] PHST- 2026/02/02 00:29 [pubmed] PHST- 2026/02/01 23:12 [entrez] PHST- 2026/02/02 00:00 [pmc-release] AID - 10.1186/s12885-026-15658-3 [pii] AID - 15658 [pii] AID - 10.1186/s12885-026-15658-3 [doi] PST - epublish SO - BMC Cancer. 2026 Feb 2;26(1):319. doi: 10.1186/s12885-026-15658-3. PMID- 41618669 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260628 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 23 IP - 2 DP - 2026 Jun 20 TI - Clinical Features and Treatment Outcomes of Large Bladder Tumors Nearly Filling the Bladder. PG - 48-53 LID - 10.22037/uj.v23i00.8655 [doi] AB - PURPOSE: The prognosis and clinical management of bladder tumors nearly occupying the entire bladder cavity remain poorly defined due to limited available data. This study aimed to evaluate the clinical features and treatment outcomes of patients presenting with bladder tumors nearly filling the bladder at initial diagnosis. MATERIALS AND METHODS: After obtaining ethical approval, a retrospective analysis was conducted on 51 patients diagnosed between 2017 and 2024 with primary bladder tumors nearly filling the bladder. All underwent transurethral resection of bladder tumor (TURBT). The clinical and pathological data were analyzed using descriptive statistics and multivariable logistic regression. RESULTS: The mean age was 76.24 +/- 11.7 years, with a median follow-up of 9.73 months (range: 3-84 months). Hematuria was the most frequent symptom (74.5%). Muscle-invasive disease was identified in 43.1% of cases at initial diagnosis, exceeding the 25% generally reported in newly diagnosed bladder cancer cohorts (p < .001). Complete resection was achieved in 68.6%, while 31.4% required repeat TURBT (re-TURBT). Among patients initially diagnosed with non-muscle-invasive tumors, 31.1% were found to have muscle invasion upon second resection. Treatments comprised intravesical immunotherapy (48.6%), radical cystectomy (25.7%), chemoradiation (14.3%), and systemic chemotherapy (11.4%). CONCLUSION: Bladder tumors nearly filling the bladder cavity are associated with high rates of muscle invasion and pose significant challenges in treatment and management. Larger, prospective multicenter studies are warranted to validate these findings and optimize management in this high-risk population. FAU - Akarken, Ilker AU - Akarken I AD - Mugla Sitki Kocman University, School of Medicine, Department of Urology, Turkey. FAU - Tarhan, Huseyin AU - Tarhan H AD - Mugla Sitki Kocman University, School of Medicine, Department of Urology, Turkey. FAU - Karaoz, Fatih AU - Karaoz F AD - Bismil State Hospital, Department of Urology, Turkey. FAU - Deliktas, Hasan AU - Deliktas H AD - Mugla Sitki Kocman University, School of Medicine, Department of Urology, Turkey. FAU - Dere, Yelda AU - Dere Y AD - Mugla Sitki Kocman University, School of Medicine, Department of Pathology, Turkey. FAU - Sahin, Hayrettin AU - Sahin H AD - Mugla Sitki Kocman University, School of Medicine, Department of Urology, Turkey. LA - eng PT - Journal Article DEP - 20260620 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/diagnosis MH - Female MH - Retrospective Studies MH - Transurethral Resection of Bladder MH - Male MH - Treatment Outcome MH - Aged MH - Cystectomy/methods MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Invasiveness MH - Middle Aged EDAT- 2026/01/31 06:31 MHDA- 2026/06/28 13:04 CRDT- 2026/01/31 03:22 PHST- 2026/06/28 13:04 [medline] PHST- 2026/01/31 06:31 [pubmed] PHST- 2026/01/31 03:22 [entrez] AID - 8655 [pii] AID - 10.22037/uj.v23i00.8655 [doi] PST - epublish SO - Urol J. 2026 Jun 20;23(2):48-53. doi: 10.22037/uj.v23i00.8655. PMID- 41618515 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 33 IP - 2 DP - 2026 Feb TI - Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis. PG - e70365 LID - 10.1111/iju.70365 [doi] AB - OBJECTIVES: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease. In this study, we aimed to evaluate the efficacy of photodynamic diagnosis (PDD)-assisted transurethral resection of the bladder (TURBT) using the recently validated International Bladder Cancer Group (IBCG) risk stratification model for IR-NMIBC. METHODS: We conducted a single-center retrospective analysis of 193 patients with IR-NMIBC who underwent either PDD-assisted with oral 5-aminolevulinic acid (n = 69) or white-light (WL) TURBT (n = 126) between 2009 and 2023. We performed 1:1 propensity score matching (PSM) to balance baseline characteristics. Recurrence-free survival (RFS) was compared between the groups using the Kaplan-Meier method with subgroup analyses based on IBCG risk strata (IR-low, IR-intermediate/high). RESULTS: After PSM, 69 patients with well-balanced characteristics remained in each group. PDD was associated with a significantly improved RFS compared with WL-TURBT in the overall cohort (p = 0.016). Using subgroup analysis, this benefit was most pronounced in the IR-low risk group (p = 0.025), whereas no significant difference was found in the IR-intermediate/high-risk group (p = 0.14). Regarding multivariate analysis, PDD was an independent predictor of improved RFS in both the entire IR cohort (hazard ratio [HR]: 0.421, p = 0.009) and IR-low subgroup (HR: 0.361, p = 0.047). CONCLUSIONS: PDD-assisted TURBT significantly improved the recurrence outcomes in patients with IR-NMIBC, with the greatest benefit observed in the IR-low risk subgroup. These findings support a stratified approach in which PDD is a cornerstone of management of IR-low patients, while highlighting the need for further research to optimize treatment strategies for IR-intermediate/high patients. CI - (c) 2026 The Japanese Urological Association. FAU - Abe, Yohei AU - Abe Y AUID- ORCID: 0000-0002-4826-4043 AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kaji, Asuka AU - Kaji A AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Harada, Satoshi AU - Harada S AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Fujiwara, Kengo AU - Fujiwara K AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kohashiguchi, Kana AU - Kohashiguchi K AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Naito, Hirohito AU - Naito H AUID- ORCID: 0000-0002-1045-1978 AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Tohi, Yoichiro AU - Tohi Y AUID- ORCID: 0000-0003-3884-8915 AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kato, Takuma AU - Kato T AUID- ORCID: 0000-0003-2047-496X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Okazoe, Homare AU - Okazoe H AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Ueda, Nobufumi AU - Ueda N AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AUID- ORCID: 0000-0001-9266-782X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. LA - eng PT - Journal Article PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/diagnosis/surgery MH - Propensity Score MH - Transurethral Resection of Bladder MH - Retrospective Studies MH - Female MH - Aminolevulinic Acid/administration & dosage MH - Male MH - Aged MH - Risk Assessment/methods MH - Photosensitizing Agents/administration & dosage MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Middle Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - *Urinary Bladder Neoplasms/diagnosis/pathology/surgery MH - Urinary Bladder/surgery/pathology/diagnostic imaging MH - Kaplan-Meier Estimate OTO - NOTNLM OT - aminolevulinic acid OT - disease progression OT - non-muscle-invasive bladder neoplasms OT - risk assessment OT - urinary bladder EDAT- 2026/01/31 06:30 MHDA- 2026/01/31 06:31 CRDT- 2026/01/31 00:53 PHST- 2026/01/08 00:00 [revised] PHST- 2025/08/31 00:00 [received] PHST- 2026/01/20 00:00 [accepted] PHST- 2026/01/31 06:31 [medline] PHST- 2026/01/31 06:30 [pubmed] PHST- 2026/01/31 00:53 [entrez] AID - 10.1111/iju.70365 [doi] PST - ppublish SO - Int J Urol. 2026 Feb;33(2):e70365. doi: 10.1111/iju.70365. PMID- 41598326 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 16 IP - 1 DP - 2026 Jan 21 TI - Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network. LID - 10.3390/life16010169 [doi] LID - 169 AB - BACKGROUND: Bladder cancer (BC) predominantly affects older patients, and their multidisciplinary treatment often includes surgical intervention. Frailty can influence treatment decisions and is associated with poorer outcomes. This study analyses trends in demographics, treatment patterns and frailty in a large, nationwide, real-world inpatient cohort in Germany. METHODS: This retrospective observational study included a total of 49,139 consecutive patients, who received inpatient care for BC at all HELIOS hospitals in Germany between 2016 and 2022. Frailty was assessed using the Hospital Frailty Risk Score (HFRS) and categorised as low (<5), intermediate (5-15), or high (>15). Trends in HFRS, treatment modalities, and demographic variables were analysed using regression models and compared between the periods 2016-2019 and 2020-2022. RESULTS: Of the 49,139 patients, 27,979 were treated between 2016-2019 and 21,160 between 2020-2022. Patients treated in the later period were slightly older but had a lower comorbidity index. The proportion of patients with low frailty increased (73.4% vs. 75.5%, p < 0.01), intermediate frailty decreased (23.5% vs. 21.5%, p < 0.01) and the proportion of highly frail patients remained stable at 3.0% (p = 0.95). Rates of transurethral resection declined over time, whereas rates of RC remained stable (p = 0.12). The use of systemic therapy increased (p = 0.003), particularly among low frailty elderly patients. Early intravesical chemotherapy following transurethral resection declined significantly in 2020-2022 (p < 0.001), particularly among elderly patients with high frailty. Mean length of hospital stay decreased by one day, while ICU admission rates and in-hospital mortality remained stable across time periods. CONCLUSIONS: This study shows frailty-specific changes in hospitalisation patterns and inpatient management of BC in Germany, underscoring the value of frailty assessment in population-based research. The proportion of patients classified as having low frailty increased over time. Significant changes in the use of intravesical chemotherapy and systemic therapy were associated with frailty. The decline in early intravesical chemotherapy may have implications for recurrence risk and downstream healthcare utilisation. FAU - Klatte, Tobias AU - Klatte T AUID- ORCID: 0000-0002-4392-6861 AD - Department of Urology, Helios Klinikum Bad Saarow, 15526 Bad Saarow, Germany. AD - Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg, Germany. FAU - Bold, Frederic AU - Bold F AD - Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg, Germany. AD - Department of Anaesthesiology and Intensive Care Medicine, Helios Klinikum Bad Saarow, 15526 Bad Saarow, Germany. FAU - Dengler, Julius AU - Dengler J AUID- ORCID: 0000-0002-6698-8600 AD - Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg, Germany. AD - Department of Neurosurgery, Helios Klinikum Bad Saarow, 15526 Bad Saarow, Germany. FAU - de Martino, Michela AU - de Martino M AD - Department of Urology, Helios Klinikum Bad Saarow, 15526 Bad Saarow, Germany. FAU - Hohenstein, Sven AU - Hohenstein S AUID- ORCID: 0000-0002-9708-1593 AD - Real World Evidence and Health Technology Assessment, Helios Health Institute, 13125 Berlin, Germany. FAU - Kuhlen, Ralf AU - Kuhlen R AD - Real World Evidence and Health Technology Assessment, Helios Health Institute, 13125 Berlin, Germany. FAU - Bollmann, Andreas AU - Bollmann A AUID- ORCID: 0000-0002-5441-3906 AD - Real World Evidence and Health Technology Assessment, Helios Health Institute, 13125 Berlin, Germany. FAU - Steiner, Thomas AU - Steiner T AD - Department of Urology, Helios Klinikum Erfurt, 99089 Erfurt, Germany. FAU - Dengler, Nora F AU - Dengler NF AD - Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg, Germany. AD - Department of Neurosurgery, Helios Klinikum Bad Saarow, 15526 Bad Saarow, Germany. LA - eng PT - Journal Article DEP - 20260121 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12843476 OTO - NOTNLM OT - bladder cancer OT - chemotherapy OT - frailty OT - prognosis COIS- The authors declare no conflict of interest. EDAT- 2026/01/28 07:48 MHDA- 2026/01/28 07:49 PMCR- 2026/01/21 CRDT- 2026/01/28 01:17 PHST- 2025/12/28 00:00 [received] PHST- 2026/01/12 00:00 [revised] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/01/28 07:49 [medline] PHST- 2026/01/28 07:48 [pubmed] PHST- 2026/01/28 01:17 [entrez] PHST- 2026/01/21 00:00 [pmc-release] AID - life16010169 [pii] AID - life-16-00169 [pii] AID - 10.3390/life16010169 [doi] PST - epublish SO - Life (Basel). 2026 Jan 21;16(1):169. doi: 10.3390/life16010169. PMID- 41597336 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 62 IP - 1 DP - 2025 Dec 26 TI - Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis. LID - 10.3390/medicina62010051 [doi] LID - 51 AB - Background and Objectives: To evaluate the prognostic significance of preoperative complete blood count parameters in patients with non-muscle-invasive bladder cancer (NMIBC), to determine optimal cutoff values, and to explore their potential integration into existing risk stratification systems. Materials and Methods: In this retrospective cohort study, 551 patients with NMIBC treated between January 2007 and December 2024 were analyzed. Complete blood count parameters obtained within 30 days prior to transurethral resection were collected. The primary endpoints were disease recurrence and progression. Statistical analyses included the Mann-Whitney U test, Kaplan-Meier survival analysis, Cox proportional hazards regression, and receiver operating characteristic (ROC) curve analysis. Results: Complete data were available for 548 patients (mean age 66.3 +/- 11.3 years, 70.3% male). Disease recurrence occurred in 203 patients (37.0%) and progression in 60 patients (10.9%). Compared with the non-recurrence group, patients with recurrence had lower hemoglobin (11.8 +/- 2.3 vs. 13.2 +/- 2.4 g/dL, p < 0.001), higher lymphocyte counts (2.4 +/- 3.3 vs. 2.1 +/- 2.9 x10(3)/microL, p = 0.025), and lower neutrophil counts (5.3 +/- 3.0 vs. 6.1 +/- 3.4 x 10(3)/microL, p < 0.001). In multivariable analysis, hemoglobin (HR 0.75, 95% CI 0.68-0.83, p < 0.001), age (HR 1.02, 95% CI 1.00-1.03, p = 0.023), and carcinoma in situ (HR 1.69, 95% CI 1.13-2.53, p = 0.011) were independent predictors of recurrence. Hemoglobin yielded the highest AUC for predicting recurrence (0.692). Conclusions: Routinely available hematologic indices-particularly hemoglobin concentration-exhibit independent prognostic value in patients with NMIBC. Incorporating these parameters into established risk stratification models may enhance personalized treatment strategies. FAU - Nebioglu, Ali AU - Nebioglu A AUID- ORCID: 0000-0001-6325-1534 AD - Urology Clinic, Mersin City Training and Research Hospital, Mersin 33240, Turkiye. FAU - Turhan, Ahmet AU - Turhan A AUID- ORCID: 0009-0008-4933-0808 AD - Department of Urology, Faculty of Medicine, Mersin University, Mersin 33343, Turkiye. FAU - Basaranoglu, Mert AU - Basaranoglu M AUID- ORCID: 0000-0002-9873-4920 AD - Department of Urology, Faculty of Medicine, Mersin University, Mersin 33343, Turkiye. FAU - Bozlu, Murat AU - Bozlu M AUID- ORCID: 0000-0002-8624-0149 AD - Department of Urology, Faculty of Medicine, Mersin University, Mersin 33343, Turkiye. FAU - Akbay, Erdem AU - Akbay E AUID- ORCID: 0000-0001-7669-414X AD - Department of Urology, Faculty of Medicine, Mersin University, Mersin 33343, Turkiye. LA - eng PT - Journal Article DEP - 20251226 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0 (Hemoglobins) SB - IM MH - Humans MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms/blood MH - Prognosis MH - Female MH - Male MH - Aged MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Blood Cell Count/methods MH - Proportional Hazards Models MH - ROC Curve MH - Kaplan-Meier Estimate MH - *Urinary Bladder Neoplasms/blood MH - Hemoglobins/analysis MH - Transurethral Resection of Bladder PMC - PMC12842641 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - complete blood count OT - prognosis COIS- The authors declare no conflicts of interest, financial or otherwise. This research received no specific grant from any funding agency. EDAT- 2026/01/28 07:47 MHDA- 2026/01/28 19:21 PMCR- 2025/12/26 CRDT- 2026/01/28 01:13 PHST- 2025/10/19 00:00 [received] PHST- 2025/12/02 00:00 [revised] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/01/28 19:21 [medline] PHST- 2026/01/28 07:47 [pubmed] PHST- 2026/01/28 01:13 [entrez] PHST- 2025/12/26 00:00 [pmc-release] AID - medicina62010051 [pii] AID - medicina-62-00051 [pii] AID - 10.3390/medicina62010051 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Dec 26;62(1):51. doi: 10.3390/medicina62010051. PMID- 41595169 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 2 DP - 2026 Jan 14 TI - Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study. LID - 10.3390/cancers18020249 [doi] LID - 249 AB - Background/Objectives: Non-muscle invasive bladder cancer (NMIBC) management is increasingly complex due to conflicting guideline-based risk classifications, ongoing Bacillus Calmette-Guerin (BCG) shortages, and emerging alternative therapies. Computational Histology Artificial Intelligence (CHAI) tests are clinically available, providing insights from tumor specimens including predicting BCG responsiveness and individualized recurrence and progression risks, which may support precision medicine. This technology features biomarkers purpose-built for clinically unmet needs and has practical advantages including a fast turnaround time and no need for consumption of tissue or other specimens. We assessed the impact of such tests on physicians' decision-making in routine, real-world NMIBC management. Methods: Physicians at six centers ordered CHAI tests (Vesta Bladder) at their discretion during routine NMIBC care. Tumor specimens were processed by a CLIA/CAP-accredited laboratory (Valar Labs, Houston, TX, USA) where H&E-stained slides were analyzed with the CHAI assay to extract histomorphic features of the tumor and microenvironment, which were algorithmically assessed to generate biomarker test results. For each case from 24 June 2024 to 18 July 2025, ordering physicians were surveyed to assess pre- and post-test management plans and post-test result usefulness. Results: Among 105 high-grade NMIBC cases with complete survey results available, primary management changed in 67% (70/105). Changes included modality shifts (n = 7; three to radical cystectomy with high prognostic risk scores; four avoiding cystectomy with low scores) and intravesical agent change (n = 63). Surveillance was intensified in 7%, predominantly among those with >/=90th percentile risk scores. The therapeutic agent changed in 80% (40/50) of predictive biomarker-present (indicative of poor response to BCG) tumors vs. 48% (23/48) of biomarker-absent tumors. Conclusions: In two thirds of cases, CHAI biomarker results influenced clinical decision-making during routine care. BCG predictive biomarker results frequently guided intravesical agent selection. These results have implications for optimizing clinical outcomes, especially in the setting of ongoing BCG shortages. Prognostic risk stratification results guided treatment escalation vs. de-escalation, including surveillance intensification and surgical vs. bladder-sparing decisions. CHAI biomarkers are currently utilized in routine clinical care and informing precision NMIBC management. FAU - Packiam, Vignesh T AU - Packiam VT AUID- ORCID: 0000-0001-8397-7797 AD - Rutgers Cancer Institute, New Brunswick, NJ 08901, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AUID- ORCID: 0000-0001-8901-0210 AD - Rutgers Cancer Institute, New Brunswick, NJ 08901, USA. FAU - Konety, Badrinath R AU - Konety BR AD - Allina Health, Minneapolis, MN 55407, USA. FAU - Ahmadi, Hamed AU - Ahmadi H AD - Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Agarwal, Gautum AU - Agarwal G AD - Mercy Clinic, St. Louis, MO 63141, USA. FAU - Kiedrowski, Lesli A AU - Kiedrowski LA AUID- ORCID: 0000-0001-5081-2005 AD - Valar Labs, Palo Alto, CA 94306, USA. FAU - Krishna, Viswesh AU - Krishna V AD - Valar Labs, Palo Alto, CA 94306, USA. FAU - Joshi, Anirudh AU - Joshi A AD - Valar Labs, Palo Alto, CA 94306, USA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, Division of Urology, University of Texas Medical Branch, Galveston, TX 77555, USA. FAU - Smith, Armine K AU - Smith AK AD - Brady Urological Institute, Johns Hopkins University, Washington, DC 21218, USA. LA - eng PT - Journal Article DEP - 20260114 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12839055 OTO - NOTNLM OT - Artificial Intelligence OT - Bacillus Calmette-Guerin OT - Computational Histology OT - decision impact OT - non-muscle invasive bladder cancer OT - precision medicine OT - risk stratification COIS- V.T.P., B.R.K., and S.B.W. have received consulting fees from Valar Labs. L.A.K., V.K., and A.J. are employees with equity interest in Valar Labs. EDAT- 2026/01/28 07:48 MHDA- 2026/01/28 07:49 PMCR- 2026/01/14 CRDT- 2026/01/28 01:05 PHST- 2025/12/20 00:00 [received] PHST- 2026/01/05 00:00 [revised] PHST- 2026/01/08 00:00 [accepted] PHST- 2026/01/28 07:49 [medline] PHST- 2026/01/28 07:48 [pubmed] PHST- 2026/01/28 01:05 [entrez] PHST- 2026/01/14 00:00 [pmc-release] AID - cancers18020249 [pii] AID - cancers-18-00249 [pii] AID - 10.3390/cancers18020249 [doi] PST - epublish SO - Cancers (Basel). 2026 Jan 14;18(2):249. doi: 10.3390/cancers18020249. PMID- 41591483 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 75 IP - 2 DP - 2026 Jan 27 TI - Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns. PG - 41 LID - 10.1007/s00262-025-04254-2 [doi] LID - 41 AB - BACKGROUND: The association between the tumor immune microenvironment (TiME) in upper tract urothelial carcinoma (UTUC) and its prognosis remains unclear. We investigated the relationship between TiME and UTUC recurrence patterns. METHODS: We evaluated 90 patients who underwent nephroureterectomy for UTUC and divided them into nonrecurrence, distant metastasis, and intravesical recurrence-only groups. We assessed the association of the TiME with clinicopathological factors using surgical tissues and the prognosis of the three groups via multiplex fluorescence immunohistochemistry. RESULTS: The median age was 71 years (44-89), and 58 (64%) were male. Intratumoral CD4(+) T cell density was significantly higher in the nonrecurrence group (p = 0.0004) than the other groups, whereas intra- and peritumoral regulatory T cell (Treg; CD3(+)CD4(+)FoxP3(+) cell) density was higher in the distant metastases group than the intravesical recurrence-only group (p = 0.0025). In the multivariate analysis, pathological T stage and CD4(+) T cells, and pathological T stage and Treg were independent predictors of recurrence-free survival (p = 0.045, p = 0.017) and metastatic-free survival (p = 0.027, p = 0.011), respectively. CONCLUSIONS: Our study demonstrated that CD4(+) T cells and Tregs in the TiME of patients with UTUC were independent predictors of high-risk recurrence together with high pathological stage. The analysis of TiME in surgical specimens may provide an objective indicator of the efficacy of adjuvant therapy in UTUC. CI - (c) 2025. The Author(s). FAU - Takahashi, Kenta AU - Takahashi K AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Ikarashi, Daiki AU - Ikarashi D AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. AD - Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. AD - Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. FAU - Kitano, Shigehisa AU - Kitano S AUID- ORCID: 0000-0002-4041-8298 AD - Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp. AD - Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp. FAU - Tamura, Daichi AU - Tamura D AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Abe, Masakazu AU - Abe M AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Ito, Ayato AU - Ito A AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Shiomi, Ei AU - Shiomi E AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Maekawa, Shigekatsu AU - Maekawa S AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Kato, Renpei AU - Kato R AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Kanehira, Mitsugu AU - Kanehira M AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Yanagawa, Naoki AU - Yanagawa N AD - Department of Pathology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. LA - eng PT - Journal Article DEP - 20260127 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 SB - IM MH - Humans MH - Male MH - *Tumor Microenvironment/immunology MH - Aged MH - Female MH - *Neoplasm Recurrence, Local/immunology/pathology MH - Prognosis MH - Aged, 80 and over MH - Middle Aged MH - T-Lymphocytes, Regulatory/immunology MH - Adult MH - *Carcinoma, Transitional Cell/immunology/pathology MH - *Urologic Neoplasms/immunology/pathology MH - Lymphocytes, Tumor-Infiltrating/immunology PMC - PMC12847598 OTO - NOTNLM OT - Distant metastasis OT - Nephroureterectomy OT - Regulatory T cell OT - Tumor immune microenvironment OT - Upper tract urothelial carcinoma COIS- Declarations. Conflict of interest: Dr. Kitano reports grants and personal fees from Astra Zeneca, grants and personal fees from Pfizer, grants and personal fees from Nippon Boehringer Ingelheim, personal fees from Taiho, personal fees from Novartis, grants and personal fees from MSD, personal fees from Sumitomo Pharma, grants and personal fees from Eisai, grants from Astellas, grants and personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from Rakuten Medical, grants from Takara Bio Inc., grants and personal fees from GSK, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Chugai, grants from Incyte, personal fees from ImmuniT Research Inc., grants and personal fees from Merck KGaA, grants and personal fees from Takeda, personal fees from United Immunity, grants from Eli Lilly /LOXO Oncology, grants from Abbvie, grants from Kyowa Kirin, grants from Syneos Healthe Clinical, grants from ModernaEth personal fees from PMDA(Pharmaceuticals and Medical Devices Agency), outside the submitted work; Other authors do not have competing interest. Ethics approval and consent to participate: The study was conducted following the principles of the Declaration of Helsinki. The human ethics board of each institution approved this study, and written informed consent was obtained from all patients before enrollment (Iwate Medical University; protocol no. HM2022-121, The Cancer Institute Hospital of Japanese Foundation for Cancer Research; protocol No. 2021-GA-1096). Informed consent: Informed consent was obtained from participants or from the families of deceased patients using the opt-out method through publicly accessible websites. EDAT- 2026/01/27 12:59 MHDA- 2026/01/27 19:17 PMCR- 2026/01/27 CRDT- 2026/01/27 11:15 PHST- 2025/08/30 00:00 [received] PHST- 2025/11/25 00:00 [accepted] PHST- 2026/01/27 19:17 [medline] PHST- 2026/01/27 12:59 [pubmed] PHST- 2026/01/27 11:15 [entrez] PHST- 2026/01/27 00:00 [pmc-release] AID - 10.1007/s00262-025-04254-2 [pii] AID - 4254 [pii] AID - 10.1007/s00262-025-04254-2 [doi] PST - epublish SO - Cancer Immunol Immunother. 2026 Jan 27;75(2):41. doi: 10.1007/s00262-025-04254-2. PMID- 41590518 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260127 LR - 20260131 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 16 IP - 1 DP - 2026 Jan 5 TI - Emerging Molecular and Computational Biomarkers in Urothelial Carcinoma: Innovations in Diagnosis, Prognosis, and Therapeutic Response Prediction. LID - 10.3390/jpm16010025 [doi] LID - 25 AB - Bladder cancer (BC) represents a major global health issue with high recurrence and significant mortality rates in cases of advanced disease. Currently, the development of molecular profiling, liquid biopsy technologies, and artificial intelligence (AI) software has resulted in unprecedented opportunities to improve diagnosis, prognostic assessment, and treatment selection. Recent multicenter studies have identified emerging metabolomic, proteomic, and genomic biomarkers with high sensitivity and specificity that may help replace or complement invasive approaches. AI-driven models that combine multi-omics datasets with radiomics and clinical parameters have demonstrated improved accuracy for predicting both therapeutic response and long-term outcomes, compared to standard approaches for risk stratification. Additionally, the incremental clinical usefulness of liquid biopsy platforms has been demonstrated for the monitoring of non-muscle-invasive bladder cancer and minimal disease detection. As these innovations converge, they herald the advent of a new era of personalized management of urothelial carcinoma; however, broad-based clinical implementation will require large-scale validation, standardization, regulatory harmonization, and economic analyses. Background: Bladder cancer continues to be a global health problem, particularly in the advanced disease setting where treatment options are limited, and mortality remains high. The exciting advances in precision medicine, including breakthrough molecular profiling techniques, liquid biopsy, and opportunities to apply AI to interpret these molecular data, hold unprecedented promise in improving the accuracy of diagnosis, prognostic stratification, and therapeutic decision-making. FAU - Alberca-Del Arco, Fernando AU - Alberca-Del Arco F AD - Department of Urology, Hospital Universitario Virgen de la Victoria (HUVV), 29010 Malaga, Spain. AD - Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), 29590 Malaga, Spain. AD - Genitourinary Alliance for Research and Development (GUARD Consortium). FAU - Santos-Perez de la Blanca, Rocio AU - Santos-Perez de la Blanca R AD - Department of Urology, Hospital Universitario Virgen de la Victoria (HUVV), 29010 Malaga, Spain. AD - Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), 29590 Malaga, Spain. AD - Genitourinary Alliance for Research and Development (GUARD Consortium). FAU - Matas-Rico, Elisa Maria AU - Matas-Rico EM AUID- ORCID: 0000-0003-0640-5511 AD - Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), 29590 Malaga, Spain. AD - Department of Cell Biology, Genetics and Physiology, Universidad de Malaga (UMA), 29071 Malaga, Spain. FAU - Herrera-Imbroda, Bernardo AU - Herrera-Imbroda B AUID- ORCID: 0000-0002-6235-4897 AD - Department of Urology, Hospital Universitario Virgen de la Victoria (HUVV), 29010 Malaga, Spain. AD - Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), 29590 Malaga, Spain. AD - Genitourinary Alliance for Research and Development (GUARD Consortium). AD - Department of Surgical Specialties, Biochemistry and Immunology, Universidad de Malaga (UMA), 29071 Malaga, Spain. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Genitourinary Alliance for Research and Development (GUARD Consortium). AD - Department of Urology, Hospital Universitario 12 de Octubre, Avda. Cordoba s/n, 28041 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20260105 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC12843400 OTO - NOTNLM OT - artificial machine learning OT - biomarkers OT - bladder cancer OT - immune checkpoint inhibitors OT - liquid biopsy OT - multi-omics OT - tumor microenvironment OT - urothelial carcinoma COIS- The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2026/01/27 12:59 MHDA- 2026/01/27 13:00 PMCR- 2026/01/05 CRDT- 2026/01/27 09:33 PHST- 2025/10/01 00:00 [received] PHST- 2025/11/18 00:00 [revised] PHST- 2025/12/10 00:00 [accepted] PHST- 2026/01/27 13:00 [medline] PHST- 2026/01/27 12:59 [pubmed] PHST- 2026/01/27 09:33 [entrez] PHST- 2026/01/05 00:00 [pmc-release] AID - jpm16010025 [pii] AID - jpm-16-00025 [pii] AID - 10.3390/jpm16010025 [doi] PST - epublish SO - J Pers Med. 2026 Jan 5;16(1):25. doi: 10.3390/jpm16010025. PMID- 41587934 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260727 IS - 1535-3907 (Electronic) IS - 1535-3893 (Linking) VI - 25 IP - 2 DP - 2026 Feb 6 TI - Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk. PG - 903-919 LID - 10.1021/acs.jproteome.5c00486 [doi] AB - Nonmuscle invasive bladder cancer (NMIBC) represents a significant clinical challenge due to its high recurrence and progression rates. We aimed to characterize proteomic differences between matched pairs of tumor and control bladder tissues in NMIBC to identify potential biomarkers and underlying molecular mechanisms. Methods: Data-independent analysis proteomics experiments were conducted in paired samples from 45 patients with NMIBC, comprising 45 tumor and 45 control tissues. Tumor and nontumor results were compared using a paired Student's t test. Proteins detected in at least 50% of the samples were used. Results: A total of 188 differentially abundant detected proteins were identified, along with 11 proteins exclusively detected in tumor tissues, including SPINT1, TXNDC12, GTF2F1, COPZ1, RS25, PTK2, LSR, SNRNP40, NCOA5, SEC63, and CD2AP. The protein interaction network analysis among this set of proteins revealed AGR2, FLNA, TPM1, and CALD1. Additionally, CNDP2 and CTSD expression were inversely correlated with tumor recurrence and progression risk respectively, while EPS8L2 and KRT7 levels were associated with tumor staging. Conclusions: Our study identified specific proteins as potential NMIBC biomarkers and drug targets. The identified proteins, particularly those linked to tumor recurrence and staging, warrant further validation to assess their clinical utility in NMIBC diagnosis, prognosis, and treatment strategies. FAU - Silva, Tiago Aparecido AU - Silva TA AUID- ORCID: 0000-0001-6796-3491 AD - Department of Surgery, Division of Urology, Federal University of Sao Paulo, Rua Botucatu, 740 horizontal line Vila Clementino, Sao Paulo 04023062, Brazil. FAU - Viana, Luciana Godoy AU - Viana LG AD - Research and Development Division, Fleury Group, Avenue Gal Valdomiro de Lima, 508 horizontal line Jabaquara, Sao Paulo 04344-903, Brazil. FAU - Carvalho, Valdemir Melechco AU - Carvalho VM AUID- ORCID: 0000-0002-9816-8615 AD - Research and Development Division, Fleury Group, Avenue Gal Valdomiro de Lima, 508 horizontal line Jabaquara, Sao Paulo 04344-903, Brazil. FAU - Bertolla, Ricardo Pimenta AU - Bertolla RP AD - Department of Surgery, Division of Urology, Federal University of Sao Paulo, Rua Botucatu, 740 horizontal line Vila Clementino, Sao Paulo 04023062, Brazil. AD - Wayne State University CS Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, Detroit, Michigan 48201-1405, United States. FAU - Antoniassi, Mariana Pereira AU - Antoniassi MP AUID- ORCID: 0000-0001-8340-3435 AD - Department of Surgery, Division of Urology, Federal University of Sao Paulo, Rua Botucatu, 740 horizontal line Vila Clementino, Sao Paulo 04023062, Brazil. FAU - Azevedo, Hatylas AU - Azevedo H AD - Department of Surgery, Division of Urology, Federal University of Sao Paulo, Rua Botucatu, 740 horizontal line Vila Clementino, Sao Paulo 04023062, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260126 PL - United States TA - J Proteome Res JT - Journal of proteome research JID - 101128775 RN - 0 (Biomarkers, Tumor) RN - 0 (Proteome) SB - IM MH - Humans MH - *Biomarkers, Tumor/metabolism/genetics MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/metabolism MH - *Proteomics/methods MH - Female MH - Disease Progression MH - Male MH - Middle Aged MH - Aged MH - *Neoplasm Recurrence, Local/pathology/metabolism/genetics MH - *Urinary Bladder Neoplasms/pathology/metabolism MH - Protein Interaction Maps MH - *Proteome/metabolism/genetics OTO - NOTNLM OT - biomarker OT - bladder cancer OT - bladder tissue OT - networks OT - nonmuscle invasive cancer OT - progression risk OT - protein interaction OT - proteomic OT - recurrence risk OT - urothelial carcinoma EDAT- 2026/01/27 00:52 MHDA- 2026/02/06 06:42 CRDT- 2026/01/26 22:43 PHST- 2026/02/06 06:42 [medline] PHST- 2026/01/27 00:52 [pubmed] PHST- 2026/01/26 22:43 [entrez] AID - 10.1021/acs.jproteome.5c00486 [doi] PST - ppublish SO - J Proteome Res. 2026 Feb 6;25(2):903-919. doi: 10.1021/acs.jproteome.5c00486. Epub 2026 Jan 26. PMID- 41587110 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260831 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 32 IP - 8 DP - 2026 Apr 15 TI - ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer. PG - 1522-1527 LID - 10.1158/1078-0432.CCR-25-3712 [doi] AB - PURPOSE: Trimodality therapy (TMT) is a bladder-sparing treatment approach for patients with muscle-invasive bladder cancer (MIBC). Although plasma circulating tumor DNA (ctDNA) is correlated with treatment response and outcomes following cystectomy for MIBC, the association of plasma ctDNA with clinical outcomes in patients treated with TMT is poorly characterized. EXPERIMENTAL DESIGN: Patients with MIBC who received TMT at Dana-Farber/Brigham and Women's Cancer Center or Massachusetts General Hospital were consented to a research protocol and underwent ctDNA evaluation at baseline and at regular intervals following TMT using the commercially available Signatera assay. All patients also underwent routine post-TMT surveillance including cross-sectional imaging and cystoscopic evaluation. The association between ctDNA status and clinical disease status was assessed. RESULTS: Eighty-four patients had at least one ctDNA result. Fifty-nine patients had a ctDNA test performed prior to chemoradiotherapy (CRT), and 19 (32%) had detectable ctDNA. Forty-six patients had paired pre- and post-CRT ctDNA results available: nearly all (29/31, 94%) patients with undetectable ctDNA prior to CRT also had undetectable ctDNA at the first post-CRT assessment, whereas 11 of 15 (73%) patients with detectable ctDNA prior to CRT converted to undetectable ctDNA following CRT. Sixteen (19%) patients developed metastatic disease, and detectable ctDNA following CRT was strongly correlated with metastatic recurrence (P < 0.0001). Conversely, no patients with an isolated muscle-invasive (n = 5) or non-muscle invasive (n = 7) bladder recurrence had a post-TMT test demonstrating detectable ctDNA prior to recurrence. CONCLUSIONS: ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patients with MIBC following TMT. CI - (c)2026 The Authors; Published by the American Association for Cancer Research. FAU - Epstein, Ilana B AU - Epstein IB AUID- ORCID: 0009-0003-1085-7817 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Odogiyon, Adetolani AU - Odogiyon A AUID- ORCID: 0009-0000-6137-432X AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Berg, Stephanie AU - Berg S AUID- ORCID: 0000-0001-6193-5350 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Otani, Yukako AU - Otani Y AUID- ORCID: 0009-0006-4422-2782 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Mantia, Charlene AU - Mantia C AUID- ORCID: 0000-0001-7672-3131 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Pompa, Isabella R AU - Pompa IR AUID- ORCID: 0000-0003-1376-1653 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Mossanen, Matthew AU - Mossanen M AUID- ORCID: 0000-0001-5444-2515 AD - Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. ROR: https://ror.org/04b6nzv94 FAU - Wan, Joshua AU - Wan J AUID- ORCID: 0009-0007-5701-2167 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Saraf, Anurag AU - Saraf A AUID- ORCID: 0000-0001-8199-2782 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Preston, Mark AU - Preston M AUID- ORCID: 0000-0003-1010-8464 AD - Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. ROR: https://ror.org/04b6nzv94 FAU - Ravi, Arvind AU - Ravi A AUID- ORCID: 0000-0003-2461-3533 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Carvalho, Filipe AU - Carvalho F AUID- ORCID: 0000-0003-2378-6512 AD - Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. ROR: https://ror.org/04b6nzv94 FAU - Herberts, Cameron AU - Herberts C AUID- ORCID: 0000-0002-9929-8374 AD - Natera, Inc., Austin, Texas. ROR: https://ror.org/02anzyy56 FAU - ElNaggar, Adam AU - ElNaggar A AUID- ORCID: 0000-0003-3409-583X AD - Natera, Inc., Austin, Texas. ROR: https://ror.org/02anzyy56 FAU - Clinton, Timothy AU - Clinton T AUID- ORCID: 0000-0002-0616-6840 AD - Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. ROR: https://ror.org/04b6nzv94 FAU - Roberts, Daniel AU - Roberts D AUID- ORCID: 0000-0001-6467-7238 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Peng, Luke AU - Peng L AUID- ORCID: 0000-0002-5678-1251 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - McGregor, Bradley AU - McGregor B AUID- ORCID: 0000-0002-8298-0289 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Bellmunt, Joaquim AU - Bellmunt J AUID- ORCID: 0000-0003-2328-3421 AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 FAU - Kamran, Sophia C AU - Kamran SC AUID- ORCID: 0000-0001-9283-6515 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Berchuck, Jacob E AU - Berchuck JE AUID- ORCID: 0000-0002-7607-2428 AD - Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia. ROR: https://ror.org/03czfpz43 FAU - Efstathiou, Jason A AU - Efstathiou JA AUID- ORCID: 0000-0003-0996-0350 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Miyamoto, David T AU - Miyamoto DT AUID- ORCID: 0000-0003-3692-8823 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. FAU - Mouw, Kent W AU - Mouw KW AUID- ORCID: 0000-0001-7939-7343 AD - Department of Radiation Oncology, Massachusetts General Brigham, Boston, Massachusetts. AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ROR: https://ror.org/02jzgtq86 LA - eng GR - R01CA259007/Center for Cancer Research (CCR)/ GR - R01CA289304/Center for Cancer Research (CCR)/ GR - R01 CA279221/CA/NCI NIH HHS/United States GR - R01 CA272657/CA/NCI NIH HHS/United States GR - R01 CA259007/CA/NCI NIH HHS/United States GR - R01CA272657/Center for Cancer Research (CCR)/ GR - R01 CA289304/CA/NCI NIH HHS/United States GR - ROI2021-9151/Radiation Oncology Institute (ROI)/ GR - R01CA279221/Center for Cancer Research (CCR)/ PT - Journal Article PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/therapy/genetics/blood/pathology MH - *Neoplasm Recurrence, Local/genetics/blood/pathology MH - Aged MH - Male MH - Middle Aged MH - *Circulating Tumor DNA/blood/genetics MH - Combined Modality Therapy MH - *Organ Sparing Treatments/methods MH - *Biomarkers, Tumor/blood/genetics MH - Cystectomy MH - Aged, 80 and over MH - Chemoradiotherapy MH - Treatment Outcome MH - Prognosis PMC - PMC13080314 COIS- S. Berg reports other support from Natera, Inc. outside the submitted work. C. Mantia reports personal fees from Synthekine, Nextech, Cogent Biosciences, and EMD Serono and other support from Bristol Myers Squibb outside the submitted work. M. Preston reports grants from Merck and personal fees from Janssen, Bayer, and Pfizer outside the submitted work. C. Herberts reports other support from Natera, Inc. outside the submitted work, as well as full-time employment with Natera, Inc. with stocks or option to own stocks in the company. A. ElNaggar reports other support from Natera, Inc. outside the submitted work. T. Clinton reports other support from Intuitive Surgical and Olympus outside the submitted work. L. Peng reports personal fees and other support from Stratifind outside the submitted work. B. McGregor reports personal fees from Arcus, AstraZeneca, Eisai, Genmab, Hexagon, and Eli Lilly and Company and grants and personal fees from Aveo Oncology, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Gilead Sciences, and Pfizer outside the submitted work. J. Bellmunt reports stock or other ownership in Rainer Therapeutics; honoraria from UpToDate; consulting or advisory role for Astra Zeneca/MedImmune, Bristol-Myers Squibb, EMD Serono/Merck, Merck, Novartis, Pfizer, and Pierre Fabre; research funding from Pfizer/EMD Serono, Pfizer/Gilead; patents, royalties, and other intellectual property from UpToDate Bladder Cancer; and travel, accommodations, expenses from Genentech/Roche and Ipsen. J.E. Berchuck reports grants and personal fees from Guardant Health, other support from Genome Medical, Oncotect, Tracer Biotechnologies, and Musculo, and grants and other support from Precede Biosciences outside the submitted work. J.A. Efstathiou reports personal fees from Blue Earth Diagnostics, Boston Scientific, Clarity Pharmaceuticals, Elekta, IBA, Genentech, Pfizer, Astellas Pharma, Myovant Sciences, Janssen, Johnson & Johnson, Bayer Healthcare, Progenics Pharmaceuticals, Lantheus, Angiodynamics, BioProtect, mdxHealth, and Gilead Sciences outside the submitted work. D.T. Miyamoto reports grants from NIH and Radiation Oncology Institute during the conduct of the study, as well as grants from NIH outside the submitted work. K.W. Mouw reports grants from NCI during the conduct of the study, as well as personal fees from EMD Serono, UroGen, Natera, Astellas Pharma, UpToDate, and OncLive, grants and personal fees from Pfizer, and other support from Riva Therapeutics, Illudent Therapeutics, and Science Advances outside the submitted work. No disclosures were reported by the other authors. EDAT- 2026/01/26 18:28 MHDA- 2026/04/15 06:29 PMCR- 2026/04/15 CRDT- 2026/01/26 12:52 PHST- 2025/10/07 00:00 [received] PHST- 2025/12/19 00:00 [revised] PHST- 2026/01/22 00:00 [accepted] PHST- 2026/04/15 06:29 [medline] PHST- 2026/01/26 18:28 [pubmed] PHST- 2026/01/26 12:52 [entrez] PHST- 2026/04/15 00:00 [pmc-release] AID - 771978 [pii] AID - CCR-25-3712 [pii] AID - 10.1158/1078-0432.CCR-25-3712 [doi] PST - ppublish SO - Clin Cancer Res. 2026 Apr 15;32(8):1522-1527. doi: 10.1158/1078-0432.CCR-25-3712. PMID- 41586998 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260922 IS - 2589-0409 (Electronic) IS - 1110-0362 (Print) IS - 1110-0362 (Linking) VI - 38 IP - 1 DP - 2026 Jan 26 TI - Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study. PG - 2 LID - 10.1186/s43046-026-00340-3 [doi] LID - 2 AB - BACKGROUND: Bladder cancer ranks among the most prevalent genitourinary malignancies globally, demanding comprehensive management strategies. Bacille Calmette-Guerin (BCG) therapy, a standard for Non-Muscle Invasive Bladder Cancer (NMIBC), is integral to treatment, yet debates persist regarding its optimal application. AIM: This research aims to elucidate potential correlations and implications for BCG immunotherapy. Moreover, explores the impact of BCG-induced localized and systemic side effects on NMIBC outcome, addressing the need for a nuanced understanding of its therapeutic and adverse effects. PATIENTS AND METHODS: Patients' data was sourced from NMIBC patient files at The National Cancer Institute-Cairo University, comprising a total of 150 patients' files. Demographic and pathological data, BCG side effects, performance status (PS), recurrences and progression were recorded. The European Organization for Research and Treatment of Cancer (EORTC) score guided risk assessment was employed. ALP, urea and creatinine levels were also assessed at baseline and after the 1st, 3rd, and 6th dose of BCG to establish correlations with the number of BCG doses administered. RESULTS: An association emerges, indicating that the dosage of BCG therapy significantly influences recurrence-free survival. Remarkably, patients receiving more than 10 doses showed significantly lower recurrence-free survival (RFS) compared to those administered fewer than 10 doses (p = 0.001). Univariate analysis showed that patients who received >/= 10 BCG doses had worse RFS compared to those who received < 10 BCG doses (Hazard Ratio (HR): 4 [95% confidence interval (CI): 2.4-6.7]), p < 0.001. The study reveals a remarkable correlation between the elevation of ALP, urea, and creatinine levels and the number of BCG doses administered. On multivariate analysis, the only independent factor that significantly affects the RFS was number of doses of BCG. Patients who received >/= 10 doses had worse RFS compared to those who received < 10 doses (HR: 3.8 [95%CI: 1.8-8.1]), p = 0.001. Cardiac comorbidity negatively impacted the PFS with P-value (0.016). The only significant pathological parameter impacting OS was grade of tumor, P-value (0.025). Moreover, size of tumor influenced RFS, P-value (0.001). Clear relation between diabetes mellitus and tumor size was observed; where larger tumor size was more prevalent in diabetic patients and reflected as shorter RFS. Significant localized adverse effects included increased frequency of urination, pus in urine, and urgency. Pus in urine doubled the risk of recurrence-free survival (RFS). 6.1% reported vomiting and 23.5% experienced fever. Performance status tended to decline post BCG doses. Patients who had vomiting episodes had worse outcome (p = 0.01). CONCLUSION: The current findings suggest that cardiac comorbidity, high tumor grade and large size might be evaluated as independent poor prognostic factors for Egyptian NMIBC patients. Performance status decline correlated with BCG therapy; tuberculosis-like symptoms were undetected in the currently studied cohort due to the mass vaccination program implemented in Egypt. The research also highlights the impact of the number of BCG doses and ALP baseline on patients' outcome, providing valuable insights into the sophisticated relationship between treatment intensity and key biomarkers in NMIBC management. FAU - Karkeet, Riham M AU - Karkeet RM AD - Cairo University, Giza, Egypt. Riham.karkeet@nci.cu.edu.eg. AD - NewGiza University, Giza, Egypt. Riham.karkeet@nci.cu.edu.eg. AD - School of Medicine, Badya University, Badya city, Giza, Egypt. Riham.karkeet@nci.cu.edu.eg. FAU - Sayed-Ahmed, Mohamed M AU - Sayed-Ahmed MM AD - Cairo University, Giza, Egypt. FAU - Ghaly, Shahenda AU - Ghaly S AD - NewGiza University, Giza, Egypt. FAU - Farouk, Mayar AU - Farouk M AD - NewGiza University, Giza, Egypt. FAU - Yasser, Nourhan AU - Yasser N AD - NewGiza University, Giza, Egypt. FAU - Hany, Nada AU - Hany N AD - NewGiza University, Giza, Egypt. FAU - Atta, Malak AU - Atta M AD - NewGiza University, Giza, Egypt. FAU - Amer, Ahmed M AU - Amer AM AD - Cairo University, Giza, Egypt. FAU - Abdelbary, Ahmed AU - Abdelbary A AD - Cairo University, Giza, Egypt. LA - eng PT - Journal Article DEP - 20260126 PL - England TA - J Egypt Natl Canc Inst JT - Journal of the Egyptian National Cancer Institute JID - 9424566 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology/mortality MH - Female MH - Male MH - *BCG Vaccine/adverse effects/administration & dosage/therapeutic use MH - Retrospective Studies MH - Middle Aged MH - Egypt/epidemiology MH - Aged MH - Treatment Outcome MH - Neoplasm Recurrence, Local/pathology/epidemiology MH - Adult MH - *Urinary Bladder Neoplasms/pathology/drug therapy/mortality MH - *Adjuvants, Immunologic/adverse effects/administration & dosage/therapeutic use PMC - PMC13262385 OTO - NOTNLM OT - Alkaline phosphatase OT - Bacille Calmette-Guerin (BCG) OT - Creatinine OT - Diabetes Mellitus OT - Non-Muscle Invasive Bladder Cancer (NMIBC) OT - Pathological parameters OT - Performance status OT - Side effects OT - Urea COIS- Declarations. Ethics approval and consent to participate: The ethics approval was obtained from the research ethical committee for experimental and clinical studies at School of Pharmacy, New Giza University with number CP-0035. Consent for publication: Not applicable. Competing interests: Prof Mohamed M. Sayed-Ahmed is a co-author and the Managing Editor of the Journal of the Egyptian National Cancer Institute. However, he was not involved in the editorial handling or decision-making process for this manuscript. The rest of the authors have no competing interests to declare. EDAT- 2026/01/26 13:03 MHDA- 2026/06/27 06:43 PMCR- 2026/01/26 CRDT- 2026/01/26 11:18 PHST- 2025/03/06 00:00 [received] PHST- 2026/01/03 00:00 [accepted] PHST- 2026/06/27 06:43 [medline] PHST- 2026/01/26 13:03 [pubmed] PHST- 2026/01/26 11:18 [entrez] PHST- 2026/01/26 00:00 [pmc-release] AID - 10.1186/s43046-026-00340-3 [pii] AID - 340 [pii] AID - 10.1186/s43046-026-00340-3 [doi] PST - epublish SO - J Egypt Natl Canc Inst. 2026 Jan 26;38(1):2. doi: 10.1186/s43046-026-00340-3. PMID- 41586981 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 2211-3436 (Electronic) IS - 2211-3428 (Print) IS - 2211-3428 (Linking) VI - 49 IP - 1 DP - 2026 Jan 26 TI - SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression. PG - 30 LID - 10.1007/s13402-026-01163-z [doi] LID - 30 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of all bladder cancer cases and is characterized by a high recurrence rate, requiring long-term surveillance and repeated treatments that impose substantial clinical burdens. While aberrant fibroblast growth factor receptor 3 (FGFR3) signaling is a well-established driver in the majority of NMIBC cases, the precise molecular mechanisms regulating FGFR3 plasma membrane stability and trafficking remain poorly defined, limiting targeted therapeutic development. This study aims to elucidate the molecular pathway sustaining FGFR3 at the plasma membrane and its clinical relevance. METHODS: RAB11A expression was analyzed in NMIBC datasets and correlated with survival. In FGFR3-high RT4 cells, RAB11A was knocked down to assess effects on proliferation, apoptosis, and FGFR3 membrane localization via functional assays and immunoblotting. Mechanistic interactions were examined through co-immunoprecipitation and promoter-reporter assays. A phase-separation-defective SREBP2 mutant (F178A) was used to validate transcriptional activation. In vivo tumor growth and FGFR3 membrane localization were evaluated in xenograft models following RAB11A or ZDHHC20 knockdown. Statistical analyses included Student's t-test and log-rank test. RESULTS: RAB11A was significantly up-regulated in NMIBC, correlated with FGFR3 mRNA expression, and predicted poorer recurrence-free survival. RAB11A knockdown suppressed proliferation, induced apoptosis, and reduced membrane FGFR3 without altering transcript levels. RAB11A acted as a scaffold recruiting ZDHHC20 to promote FGFR3 palmitoylation and inhibit FGFR3 degradation. SREBP2 directly activated RAB11A transcription, dependent on its liquid-liquid phase separation capability. In vivo, knockdown of RAB11A or ZDHHC20 attenuated tumor growth and reduced membrane FGFR3. CONCLUSIONS: We identify a novel SREBP2-RAB11A-ZDHHC20 axis essential for FGFR3 palmitoylation, membrane retention, and oncogenic signaling in NMIBC. Targeting this pathway may offer a therapeutic strategy for FGFR3-driven bladder cancer. FAU - Zhang, Wen-Wen AU - Zhang WW AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Qu, Hao-Ran AU - Qu HR AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Du, Xuan-Shuang AU - Du XS AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Sun, Su-Juan AU - Sun SJ AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Chen, Pin-Ru AU - Chen PR AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Deng, Zi-Han AU - Deng ZH AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Pan, Qin AU - Pan Q AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Luo, Feng-Ling AU - Luo FL AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. FAU - Wu, Hong-Yan AU - Wu HY AD - Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yi-chang, Hubei Province, 443002, China. AD - School of Basic Medicine, China Three Gorges University, Yi-chang, Hubei Province, 443002, China. FAU - Song, Chao AU - Song C AD - Department of Urology and Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. FAU - Liu, Min AU - Liu M AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology Wuhan University Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Donghu Road 185#, Wuhan, Hubei Province, 430071, China. mliu@whu.edu.cn. LA - eng GR - 82272978/National Natural Science Foundation of China/ GR - 2021CFB484/Natural Science Foundation Project of Hubei Province/ GR - 2024KZL07/Open Foundation of Hubei Province Key Laboratory of Tumor Microenvironment and Immunotherapy/ PT - Journal Article DEP - 20260126 PL - Netherlands TA - Cell Oncol (Dordr) JT - Cellular oncology (Dordrecht, Netherlands) JID - 101552938 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 3.6.5.2 (rab GTP-Binding Proteins) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 3.6.5.2 (rab11 GTP-Binding Proteins) RN - EC 2.3.- (Acyltransferases) SB - IM MH - Humans MH - *Receptor, Fibroblast Growth Factor, Type 3/metabolism/genetics MH - Animals MH - Cell Line, Tumor MH - *rab GTP-Binding Proteins/metabolism/genetics MH - *Urinary Bladder Neoplasms/pathology/metabolism/genetics MH - *Cell Membrane/metabolism MH - Cell Proliferation/genetics MH - rab11 GTP-Binding Proteins MH - Lipoylation MH - *Disease Progression MH - *Acyltransferases/metabolism/genetics MH - Signal Transduction MH - Mice, Nude MH - Apoptosis/genetics MH - Gene Expression Regulation, Neoplastic MH - Non-Muscle Invasive Bladder Neoplasms MH - Female PMC - PMC12835112 OTO - NOTNLM OT - Bladder cancer OT - FGFR3 OT - Membrane trafficking OT - Palmitoylation OT - RAB11A OT - SREBP2 OT - ZDHHC20 COIS- Declarations. Ethical approval: The use of human samples in this study was approved by the Ethics Committee of the Life Sciences Medical Ethics Committee of Wuhan University (Approval No. 20220007). All patients gave written informed consent before inclusion in this study. All animal experiments were approved by the Ethics Committee of the Life Sciences Medical Ethics Committee of Wuhan University and were performed in accordance with the guidelines approved by Wuhan University Institutional Animal Care and Use Committee (IACUC) (approval number WAEF-2024-0035). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/26 14:54 MHDA- 2026/06/27 10:10 PMCR- 2026/01/26 CRDT- 2026/01/26 11:17 PHST- 2025/10/19 00:00 [received] PHST- 2026/01/07 00:00 [accepted] PHST- 2026/06/27 10:10 [medline] PHST- 2026/01/26 14:54 [pubmed] PHST- 2026/01/26 11:17 [entrez] PHST- 2026/01/26 00:00 [pmc-release] AID - 10.1007/s13402-026-01163-z [pii] AID - 1163 [pii] AID - 10.1007/s13402-026-01163-z [doi] PST - epublish SO - Cell Oncol (Dordr). 2026 Jan 26;49(1):30. doi: 10.1007/s13402-026-01163-z. PMID- 41586967 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 8 DP - 2026 Aug TI - Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning. PG - 2917-2927 LID - 10.1007/s11255-026-05021-7 [doi] AB - AIM: This study aimed to develop a machine learning (ML)-assisted model to predict the risk of upstaging (subsequent higher stage on repeat pathology) in non-muscle-invasive bladder cancer (NMIBC). METHODS: A retrospective cohort study was conducted on 380 patients with NMIBC. Comprehensive data on demographics, comorbidities, frailty (modified frailty index, mFI), nutritional status (nutritional risk index, NRI), inflammatory indices, and detailed histopathological features were collected. The primary outcome was pathological upstaging, defined as a diagnosis of a higher T stage (from Ta to >/= T1 or from T1 to >/= T2) on a subsequent procedure. Multivariate logistic regression and six machine learning models were developed and evaluated using tenfold cross-validation, and their performances in predicting upstaging were directly compared. RESULTS: Pathological upstaging occurred in 84 patients (22.1%). Multivariate logistic regression identified initial T1 stage (OR: 13.54), high tumor grade (OR: 4.60), lymphovascular invasion (LVI) (OR: 3.67), frailty (mFI >/= 2, OR: 2.68), and lower estimated glomerular filtration rate (eGFR) as factors independently associated with upstaging (AUC: 0.702). Machine learning models, particularly the support vector machine (SVM), demonstrated superior predictive performance (AUC: 0.796). Analysis using supervised learning algorithms confirmed tumor grade as the strongest associated factor, followed by initial T stage, the presence of lymphovascular invasion on initial TURBT (transurethral resection of the bladder tumor), frailty, eGFR, and occupational exposure. CONCLUSIONS: This study demonstrates that artificial intelligence models provide a superior framework for predicting subsequent pathological upstaging in NMIBC compared to traditional multivariate logistic regression. The ML-driven analysis adequately validated established clinical risk factors associated with upstaging. Among all variables evaluated, high tumor grade emerged as the most powerful and clinically significant factor associated with upstaging. Thus, ML-assisted tools may feasibly be integrated into clinical practice to enhance risk stratification. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Ozden, Sami Berk AU - Ozden SB AD - Department of Urology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Cd. No: 53, Fatih, 34098, Istanbul, Turkey. s.berkozden@gmail.com. FAU - Bulbul, Emre AU - Bulbul E AD - Department of Urology, Trabzon Vakfikebir State Hospital, Trabzon, Turkey. FAU - Ilki, Yavuz AU - Ilki Y AD - Department of Urology, Gulhane Training and Research Hospital, Ankara, Turkey. FAU - Vural, Ahmet AU - Vural A AD - Department of Urology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Cd. No: 53, Fatih, 34098, Istanbul, Turkey. FAU - Ozturk, Admir AU - Ozturk A AD - Department of Urology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Cd. No: 53, Fatih, 34098, Istanbul, Turkey. FAU - Demirdag, Cetin AU - Demirdag C AD - Department of Urology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Cd. No: 53, Fatih, 34098, Istanbul, Turkey. FAU - Citgez, Sinharib AU - Citgez S AD - Department of Urology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Kocamustafapasa Cd. No: 53, Fatih, 34098, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20260126 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/complications MH - Female MH - Retrospective Studies MH - Male MH - *Frailty/complications MH - *Machine Learning MH - Neoplasm Staging MH - Aged MH - Predictive Learning Models MH - Middle Aged MH - Cohort Studies MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Invasiveness MH - Aged, 80 and over OTO - NOTNLM OT - Frailty OT - Machine learning OT - Non-muscle-invasive bladder cancer OT - Upstaging COIS- Declarations. Conflict of interests: The authors declare no competing interests. Ethical approval: This study was approved by the Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine Ethics Committee (Date: 18.06.2025, No: E-74555795-050.04-1337608) and conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all participants for urodynamic testing, cystoscopy, and bladder biopsy as part of standard clinical care. The ethics committee waived the requirement for additional informed consent for the retrospective analysis of anonymized patient data. Patient confidentiality was strictly maintained. Consent for study and publication: Not applicable, as the manuscript does not contain identifiable personal data, images, or details of individual participants. EDAT- 2026/01/26 12:54 MHDA- 2026/07/16 12:40 CRDT- 2026/01/26 11:17 PHST- 2025/12/13 00:00 [received] PHST- 2026/01/15 00:00 [accepted] PHST- 2026/07/16 12:40 [medline] PHST- 2026/01/26 12:54 [pubmed] PHST- 2026/01/26 11:17 [entrez] AID - 10.1007/s11255-026-05021-7 [pii] AID - 10.1007/s11255-026-05021-7 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Aug;58(8):2917-2927. doi: 10.1007/s11255-026-05021-7. Epub 2026 Jan 26. PMID- 41582286 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260813 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 33 IP - 5 DP - 2026 May TI - Preliminary Experience of Transurethral Thulium Laser En Bloc Resection of Paraganglioma of the Urinary Bladder. PG - 4806-4811 LID - 10.1245/s10434-025-18692-w [doi] AB - BACKGROUND: The use of thulium laser en bloc resection (TmLER) for treating bladder tumor has gained increasing attention in recent years. This study aims to share our preliminary clinical experience with respect to the safety and efficacy of TmLER in treating paraganglioma of the urinary bladder (PUB). PATIENTS AND METHODS: The clinical and pathological data of eight patients with PUB who underwent TmLER under general anesthesia at our urology center between January 2020 and April 2024 were retrospectively collected and analyzed. Detailed documentation was maintained regarding intraoperative blood pressure fluctuations, the incidence of perioperative complications, changes in postoperative catecholamine hormone levels, and tumor recurrence rates. RESULTS: Eight patients successfully underwent TmLER without the need for conversion to conventional transurethral resection. The operation duration ranged from 25 to 37 min, with an average of 28.9 min. During TmLER, systolic blood pressure fluctuated between 8 and 20 mmHg, averaging 13.5 mmHg. No significant perioperative complications were observed. Postoperatively, bladder irrigation was discontinued on average after 18.75 h, and the urinary catheter was removed after 3-5 days. Hospital stays ranged from 4 to 6 days, with an average of 4.91 days. At the 1-month follow-up, there was no significant fluctuation in systolic blood pressure before and after urination, and plasma catecholamine hormone levels had normalized. Furthermore, no tumor recurrence was detected at the 12-month follow-up. CONCLUSIONS: For the treatment of PUB, the TmLER technique can effectively reduce intraoperative bleeding and blood pressure fluctuations, and it is a safe and efficient minimally invasive surgical option. CI - (c) 2026. The Author(s). FAU - Yang, Yongjun AU - Yang Y AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. FAU - Wu, Ye AU - Wu Y AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. FAU - Yang, Kehao AU - Yang K AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. FAU - Song, Guangqing AU - Song G AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. FAU - Liu, Zhe AU - Liu Z AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. 7562122@qq.com. FAU - Li, Yuanwei AU - Li Y AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, People's Republic of China. liywurology@163.com. LA - eng GR - Z2023088/National Key Clinical Specialty Scientific Research Project/ GR - 2020SK50902/Hunan Provincial Inclusive Policy and Innovative Environment Construction Plan/ PT - Journal Article DEP - 20260125 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 8RKC5ATI4P (Thulium) SB - IM MH - Humans MH - *Thulium/therapeutic use MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Retrospective Studies MH - Female MH - *Paraganglioma/surgery/pathology MH - *Laser Therapy/methods MH - Middle Aged MH - Transurethral Resection of Bladder MH - Adult MH - Prognosis MH - Follow-Up Studies MH - Neoplasm Recurrence, Local/surgery/pathology MH - Aged MH - *Lasers, Solid-State/therapeutic use PMC - PMC13083330 OTO - NOTNLM OT - Bladder OT - Blood pressure fluctuations OT - Catecholamine OT - En bloc resection OT - Paraganglioma OT - Thulium laser COIS- Disclosure: The authors declare no competing interests. EDAT- 2026/01/26 00:33 MHDA- 2026/04/17 04:10 PMCR- 2026/01/25 CRDT- 2026/01/25 23:17 PHST- 2025/04/22 00:00 [received] PHST- 2025/10/25 00:00 [accepted] PHST- 2026/04/17 04:10 [medline] PHST- 2026/01/26 00:33 [pubmed] PHST- 2026/01/25 23:17 [entrez] PHST- 2026/01/25 00:00 [pmc-release] AID - 10.1245/s10434-025-18692-w [pii] AID - 18692 [pii] AID - 10.1245/s10434-025-18692-w [doi] PST - ppublish SO - Ann Surg Oncol. 2026 May;33(5):4806-4811. doi: 10.1245/s10434-025-18692-w. Epub 2026 Jan 25. PMID- 41579061 OWN - NLM STAT- MEDLINE DCOM- 20260124 LR - 20260926 IS - 1097-0142 (Electronic) IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 132 IP - 3 DP - 2026 Feb 1 TI - Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases. PG - e70220 LID - 10.1002/cncr.70220 [doi] LID - e70220 AB - BACKGROUND: Event-free survival (EFS) and complete response rate (CRR) are recommended as primary endpoints in bladder cancer trials to enable timely assessment of therapeutic benefit. However, their surrogacy relationship with overall survival (OS) in high-risk non-muscle-invasive bladder cancer (HR NMIBC) remains unclear. This meta-analysis evaluated EFS and CRR as surrogate endpoints for OS in bacillus Calmette-Guerin (BCG)-naive or -remote HR NMIBC. METHODS: A systematic literature review identified trials enrolling BCG-naive or -remote HR NMIBC patients and reporting EFS, CRR, and OS. Weighted linear regression models estimated trial-level associations between the hazard ratio (HR) for EFS and HR for OS, odds ratio for CRR and HR for OS, and arm-level association between median EFS and median OS. Strength of association was quantified using the correlation coefficient (R) and coefficient of determination (R(2)). Sensitivity analyses evaluated consistency across EFS definitions, publication year, and BCG treatment history. RESULTS: Ten eligible trials were identified for surrogacy analyses of EFS and CRR. Strong correlations were observed between EFS and OS at the trial level (R = 0.85; R(2) = 0.72) and arm level (R = 0.90; R(2) = 0.82). Trial-level associations between CRR and OS were weaker (R(2) = 0.36 for 3-month CRR; R(2) = 0.30 for 6-month CRR). Sensitivity analyses confirmed robustness of the primary results. CONCLUSION: In BCG-naive or -remote HR NMIBC, EFS shows strong correlation with OS at the trial and arm levels, supporting its potential as a surrogate endpoint. Further validation incorporating additional trials across varied therapeutic modalities is warranted. CI - (c) 2026 Merck & Co and The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. FAU - Bhattacharya, Rituparna AU - Bhattacharya R AD - Merck & Co., Inc, Rahway, New Jersey, USA. FAU - Kponee-Shovein, Kale AU - Kponee-Shovein K AD - Analysis Group Inc, Boston, Massachusetts, USA. FAU - Gao, Yipeng AU - Gao Y AUID- ORCID: 0000-0001-5917-1005 AD - Analysis Group Inc, Boston, Massachusetts, USA. FAU - Song, Yan AU - Song Y AD - Analysis Group Inc, Boston, Massachusetts, USA. FAU - Liu, Jingyi AU - Liu J AD - Analysis Group Inc, Boston, Massachusetts, USA. FAU - Wei, Katherine AU - Wei K AD - Analysis Group Inc, Boston, Massachusetts, USA. FAU - Kapadia, Ekta AU - Kapadia E AD - Merck & Co., Inc, Rahway, New Jersey, USA. FAU - Li, Haojie AU - Li H AD - Merck & Co., Inc, Rahway, New Jersey, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. LA - eng GR - Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/drug therapy/pathology MH - *BCG Vaccine/therapeutic use MH - Disease-Free Survival MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12831502 OTO - NOTNLM OT - bacillus Calmette-Guerin-naive or -remote bladder cancer OT - complete response rate OT - event-free survival OT - non-muscle-invasive bladder cancer OT - overall survival OT - surrogate endpoints COIS- Rituparna Bhattacharya reports fees for professional activities from Merck & Co., Inc. Yipeng Gao reports fees for professional activities from Merck Sharp & Dohme. Ashish M. Kamat reports consulting fees from Astellas Pharma, Atonco Pharma, Biological Dynamics, Bristol-Myers Squibb, Carisma Therapeutics, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, Immunity Bio, Imvax, Incyte Corporation, Janssen Biotech, Medac Pharma, Inc, Merck, Nonagen Bioscience, Pfizer, Protara Therapeutics, Roche, Theralase, Urogen Pharma, Inc, US Biotest, Valar Labs, and Vivet Therapeutics; fees for professional activities from World Bladder Cancer Patient Coalition; participation as a fiduciary officer for International Bladder Cancer Group; and grant and/or contract funds from Arquer Diagnostics, Patient-Centered Outcomes Research Institute, Photocure Inc, Seagen Inc, and SWOG Cancer Research Network; Editorial Board copyrights; and a patent "CyPRIT (Cytokine Predictors of Response to Intravesical Therapy)" with MD Anderson Cancer Center. Kale Kponee-Shovein reports consulting fees from Analysis Group. Haojie Li reports stock options with Merck & Co., Inc. Yan Song reports consulting fees from Merck & Co., Inc and Novo Nordisk. Katherine Wei reports consulting fees from Merck Sharp & Dohme. The other authors declare no conflicts of interest. EDAT- 2026/01/24 12:32 MHDA- 2026/01/24 12:33 PMCR- 2026/01/24 CRDT- 2026/01/24 09:12 PHST- 2025/11/12 00:00 [revised] PHST- 2025/05/30 00:00 [received] PHST- 2025/11/13 00:00 [accepted] PHST- 2026/01/24 12:33 [medline] PHST- 2026/01/24 12:32 [pubmed] PHST- 2026/01/24 09:12 [entrez] PHST- 2026/01/24 00:00 [pmc-release] AID - CNCR70220 [pii] AID - 10.1002/cncr.70220 [doi] PST - ppublish SO - Cancer. 2026 Feb 1;132(3):e70220. doi: 10.1002/cncr.70220. PMID- 41577610 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260902 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 4 DP - 2026 Aug TI - Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study. PG - 777-785 LID - S2588-9311(25)00343-8 [pii] LID - 10.1016/j.euo.2025.12.016 [doi] AB - BACKGROUND AND OBJECTIVE: Muscle-invasive bladder cancer (MIBC) may present de novo (primary MIBC [pMIBC]) or progress from non-muscle-invasive disease (secondary MIBC [sMIBC]). While sMIBC has been associated with adverse outcomes after radical cystectomy, its prognostic impact in patients undergoing trimodal therapy (TMT) is unclear. We aimed to compare the outcomes between pMIBC and sMIBC in a multicenter cohort treated with bladder-preserving TMT. METHODS: We conducted a retrospective study including patients with MIBC treated with curative-intent TMT. Eligible patients had stage >/=T2 disease and completed TMT without discontinuation. Patients were classified as those having pMIBC (>/=T2 at diagnosis) or sMIBC (progression after prior non-muscle-invasive bladder cancer [NMIBC]). The primary endpoint was recurrence-free survival; the secondary endpoints were metastasis-free survival, cancer-specific survival (CSS), overall survival, and treatment-related toxicity. Survival was assessed using Kaplan-Meier methods and multivariable Cox regression. KEY FINDINGS AND LIMITATIONS: Among 294 patients (234 with pMIBC and 60 with sMIBC), the median age was 77 yr. The median follow-up was 34 mo for pMIBC and 24 mo for sMIBC. The 3-yr CSS rate was 78% for pMIBC and 79% for sMIBC. After adjustment for clinical covariates, sMIBC was not associated with an increased risk of recurrence (hazard ratio [HR] 1.35, 95% confidence interval [CI] 0.85-2.13) and cancer-specific death (HR 0.88, 95% CI 0.44-1.76). Toxicities were mostly of grade 1-2; grade >/=3 events were rare. Limitations include the retrospective design, a smaller sMIBC subgroup, and a relatively short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: Outcomes after TMT were broadly similar between pMIBC and sMIBC, although overall survival was lower in patients with secondary disease. A prior NMIBC history should therefore not preclude consideration of bladder-preserving therapy in appropriately selected patients. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Mezepo, Garvey AU - Mezepo G AD - Department of Urology, Andrology, and Kidney Transplantation, University of Franche-Comte, Jean Minjoz University Hospital, Besancon, France. FAU - Khene, Zine-Eddine AU - Khene ZE AD - Department of Urology, University of Rennes, Rennes, France; Image and Signal Processing Laboratory, Inserm U1099, University of Rennes, Rennes, France; Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Boustani, Jihane AU - Boustani J AD - Department of Radiation Oncology, Jean Minjoz University Hospital, Marie and Louis Pasteur University, Besancon, France. FAU - Kleinclauss, Francois AU - Kleinclauss F AD - Department of Urology, Andrology, and Kidney Transplantation, Jean Minjoz University Hospital, Nanomedicine Lab, Imagery and Therapeutics (EA 4662), University of Franche-Comte, Besancon, France. FAU - Quivrin, Magali AU - Quivrin M AD - Department of Radiation Oncology, Georges-Francois Leclerc Center, Dijon, France. FAU - Neftah, Yasmine AU - Neftah Y AD - Department of Radiation Oncology, Jean Minjoz University Hospital, Marie and Louis Pasteur University, Besancon, France. FAU - Mercier, Jeremy AU - Mercier J AD - Department of Urology, University of Toulouse, Rangueil Hospital, Toulouse, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Department of Urology, University of Toulouse, Rangueil Hospital, Toulouse, France. FAU - Mardelli, Celine AU - Mardelli C AD - Department of Urology, University of Rennes, Rennes, France; Image and Signal Processing Laboratory, Inserm U1099, University of Rennes, Rennes, France; Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, University of Vienna, Vienna, Austria; Department of Urology, Hopital de La Croix du Sud, Quint-Fonsegrives, France. FAU - Seisen, Thomas AU - Seisen T AD - Department of Urology, Predictive ONCO-URO, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Hammoud, Yasser AU - Hammoud Y AD - Department of Radiation Oncology, Mittan Center, Montbeliard, France. FAU - Bouvier, Elodie AU - Bouvier E AD - Clinical Research Unit, Nord Franche-Comte Hospital, Trevenans, France. FAU - Jacquey, Hugo AU - Jacquey H AD - Department of Urology, Andrology, and Kidney Transplantation, University of Franche-Comte, Jean Minjoz University Hospital, Besancon, France. FAU - Choffel, Loic AU - Choffel L AD - Department of Urology, Andrology, and Kidney Transplantation, University of Franche-Comte, Jean Minjoz University Hospital, Besancon, France. FAU - Palkowski, Thomas AU - Palkowski T AD - Department of Urology, Andrology, and Kidney Transplantation, University of Franche-Comte, Jean Minjoz University Hospital, Besancon, France. FAU - Khalifa, Jonathan AU - Khalifa J AD - Department of Radiation Oncology, Claudius Rigaud Institute, Toulouse University Cancer Institute - Oncopole, Toulouse, France. FAU - Benyoucef, Ahmed AU - Benyoucef A AD - Department of Radiation Oncology, Henri Becquerel Center, Rouen, France. FAU - Pasquier, David AU - Pasquier D AD - Department of Radiation Oncology, Oscar Lambret Center, Lille, France; CRISTAL UMR 9189, University of Lille, Lille, France. FAU - Brassart, Carroline AU - Brassart C AD - Department of Radiation Oncology, Oscar Lambret Center, Lille, France. FAU - Marcq, Gauthier AU - Marcq G AD - Department of Urology, Lille University Hospital, Henri Warembourg University, Lille, France. FAU - Khalladi, Nazim AU - Khalladi N AD - Department of Radiation Oncology, Francois Baclesse Center, Caen, France. FAU - Coutte, Alexandre AU - Coutte A AD - Department of Radiation Oncology, Amiens University Hospital, Amiens, France. FAU - Sargos, Paul AU - Sargos P AD - Department of Radiation Oncology, Bergonie Institute, Bordeaux, France. FAU - Huck, Constance AU - Huck C AD - Department of Radiation Oncology, Bergonie Institute, Bordeaux, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Predictive ONCO-URO, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Pasteur Clinic, Toulouse, France. CN - French Committee of Urologic Oncology (CCAFU) LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20260122 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Female MH - Male MH - Aged MH - Treatment Outcome MH - Neoplasm Invasiveness MH - Middle Aged MH - Combined Modality Therapy MH - Cystectomy OTO - NOTNLM OT - Bladder preservation OT - Chemoradiotherapy OT - Muscle-invasive bladder cancer OT - Oncological outcomes OT - Primary muscle-invasive bladder cancer OT - Secondary muscle-invasive bladder cancer OT - Trimodal therapy EDAT- 2026/01/24 00:32 MHDA- 2026/09/01 23:34 CRDT- 2026/01/23 21:55 PHST- 2025/09/07 00:00 [received] PHST- 2025/11/19 00:00 [revised] PHST- 2025/12/29 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/01/24 00:32 [pubmed] PHST- 2026/01/23 21:55 [entrez] AID - S2588-9311(25)00343-8 [pii] AID - 10.1016/j.euo.2025.12.016 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Aug;9(4):777-785. doi: 10.1016/j.euo.2025.12.016. Epub 2026 Jan 22. PMID- 41577500 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 12 IP - 2 DP - 2026 Mar TI - The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management. PG - 162-164 LID - S2405-4569(26)00004-0 [pii] LID - 10.1016/j.euf.2026.01.005 [doi] AB - The management of non-muscle-invasive bladder cancer (NMIBC) is undergoing a major paradigm shift driven by molecular biomarkers, artificial intelligence (AI), and a better understanding of the tumor microenvironment and bladder microbiome. Traditional risk stratification based on stage and grade fails to capture the biological heterogeneity of NMIBC and its variable clinical behavior. Recent evidence highlights the prognostic and dynamic value of urinary and circulating tumor DNA for detecting aggressive disease, anticipating recurrence, and guiding treatment escalation. In parallel, AI-based models that integrate clinicopathological variables and computational histology significantly outperform current guideline-based risk calculators and thus allow refined patient stratification. Furthermore, emerging data demonstrate that immune infiltration patterns and microbiome composition influence response to intravesical therapies, particularly bacillus Calmette-Guerin. Together, these advances support a unified molecular-digital framework that integrates biomarkers, AI, and immunomicrobial profiling to personalize surveillance and treatment strategies. This evolving approach hold promise for optimizing bladder preservation and improving oncological outcomes in NMIBC. PATIENT SUMMARY: Combining tumor DNA tests, artificial intelligence tools, and analysis of the immune and microbial environment in the bladder may improve assessment of risk for patients with non-muscle-invasive bladder cancer. This approach could allow more personalized treatment and follow-up. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Bichat Claude-Bernard Hospital, AP-HP, University Paris Cite, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, AP-HP, University Paris Cite, Paris, France. Electronic address: evanguelos.xylinas@aphp.fr. LA - eng PT - Journal Article PT - Review DEP - 20260123 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy/diagnosis/genetics MH - Artificial Intelligence MH - *Precision Medicine/methods/trends MH - Biomarkers, Tumor MH - Tumor Microenvironment MH - Microbiota MH - Prognosis MH - *Urinary Bladder Neoplasms/therapy/pathology OTO - NOTNLM OT - Artificial intelligence OT - Computational pathology OT - Microbiome OT - Microenvironment OT - Non-muscle-invasive bladder cancer OT - Tumor DNA EDAT- 2026/01/24 00:32 MHDA- 2026/03/20 00:59 CRDT- 2026/01/23 21:51 PHST- 2025/12/26 00:00 [received] PHST- 2025/12/30 00:00 [revised] PHST- 2026/01/12 00:00 [accepted] PHST- 2026/03/20 00:59 [medline] PHST- 2026/01/24 00:32 [pubmed] PHST- 2026/01/23 21:51 [entrez] AID - S2405-4569(26)00004-0 [pii] AID - 10.1016/j.euf.2026.01.005 [doi] PST - ppublish SO - Eur Urol Focus. 2026 Mar;12(2):162-164. doi: 10.1016/j.euf.2026.01.005. Epub 2026 Jan 23. PMID- 41575494 OWN - NLM STAT- MEDLINE DCOM- 20260721 LR - 20260813 IS - 2366-0058 (Electronic) IS - 2366-004X (Print) VI - 51 IP - 8 DP - 2026 Aug TI - Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer. PG - 4037-4049 LID - 10.1007/s00261-026-05389-1 [doi] AB - PURPOSE: To compare whole-lesion apparent diffusion coefficient (ADC) histogram analysis with representative ADC value for assessing muscle invasion in bladder cancer, and to build a decision tree model that combines bi-parametric Vesical Imaging Reporting and Data System (bp VI-RADS) with ADC values. METHODS: This retrospective study included 82 patients with bladder cancer who underwent 3T MRI and transurethral resection. The bp VI-RADS was scored using T2-weighted and diffusion-weighted imaging, and ADC maps. For histogram analysis, tumors were segmented on all ADC slices to obtain ADC percentiles. For a representative ADC, three regions of interest were placed in visually lowest ADC areas and averaged to obtain the minimum mean ADC. ADC parameters were compared between muscle invasive (MIBC) and non-muscle invasive (NMIBC) disease. Diagnostic performance was assessed using receiver operating characteristic curve analysis with area under the curve (AUC), and combination models were constructed using logistic regression and decision tree analysis. RESULTS: Among histogram-derived parameters, the 25th percentile ADC achieved the highest AUC, and the minimum mean ADC was strongly correlated with it. As single parameters, bp VI-RADS, the 25th percentile and the minimum mean ADC showed similar accuracy (0.74-0.76). Logistic regression models combining bp VI-RADS with the 25th percentile or the minimum mean ADC achieved higher accuracy (0.88 and 0.87). Decision tree models using bp VI-RADS and ADC reached accuracy of 0.82 and 0.80. In both decision tree models, ADC provided additional stratification primarily for bp VI-RADS 4 lesions, using cutoffs of 1,183 x 10((-)6) mm(2)/s (25th percentile ADC) and 1,100 x 10((-)6) mm(2)/s (minimum mean ADC). CONCLUSION: The 25th percentile and the minimum mean ADC showed similar diagnostic performance for predicting muscle invasion. A decision tree combining bp VI-RADS with ADC measurements may provide an interpretable and clinically applicable approach, particularly for bp VI-RADS 4 lesions. CI - (c) 2026. The Author(s). FAU - Sugawara, Daichi AU - Sugawara D AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Hatakeyama, Kento AU - Hatakeyama K AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Konno, Motoko AU - Konno M AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Tozawa, Tomoki AU - Tozawa T AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Sato, Tomochika AU - Sato T AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Murata, Toshiki AU - Murata T AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Murasawa, Emika AU - Murasawa E AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Narita, Shintaro AU - Narita S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Nanjo, Hiroshi AU - Nanjo H AD - Department of pathology, Akita University Hospital, Akita, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Mori, Naoko AU - Mori N AD - Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan. naokomori7127@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260123 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - *Decision Trees MH - Female MH - Retrospective Studies MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Male MH - Aged MH - *Diffusion Magnetic Resonance Imaging/methods MH - Middle Aged MH - Transurethral Resection of Bladder MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms MH - Image Interpretation, Computer-Assisted/methods MH - Predictive Value of Tests MH - *Magnetic Resonance Imaging/methods PMC - PMC13388427 OTO - NOTNLM OT - Apparent diffusion coefficient OT - Bladder cancer OT - Decision tree models OT - Magnetic resonance imaging OT - Vesical imaging reporting and data system COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/01/23 13:05 MHDA- 2026/07/21 12:35 PMCR- 2026/01/23 CRDT- 2026/01/23 11:13 PHST- 2025/12/15 00:00 [received] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/01/11 00:00 [revised] PHST- 2026/07/21 12:35 [medline] PHST- 2026/01/23 13:05 [pubmed] PHST- 2026/01/23 11:13 [entrez] PHST- 2026/01/23 00:00 [pmc-release] AID - 10.1007/s00261-026-05389-1 [pii] AID - 5389 [pii] AID - 10.1007/s00261-026-05389-1 [doi] PST - ppublish SO - Abdom Radiol (NY). 2026 Aug;51(8):4037-4049. doi: 10.1007/s00261-026-05389-1. Epub 2026 Jan 23. PMID- 41571573 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 5 DP - 2026 May TI - Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. PG - 437-445 LID - S0302-2838(26)00014-X [pii] LID - 10.1016/j.eururo.2026.01.008 [doi] AB - BACKGROUND AND OBJECTIVE: We evaluated the noninferiority of active surveillance (AS) in comparison to intravesical bacillus Calmette-Guerin (BCG) in terms of recurrence and progression for patients with high-grade T1 (HG T1) bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB. METHODS: After initial evaluation, participants diagnosed with HG T1 bladder cancer who had undergone complete eradication of visible tumors underwent a second TURB. Those with specimens showing T0 were randomized to either AS or to intravesical BCG for 8 wk without maintenance therapy. The primary endpoint was invasive relapse-free survival (iRFS). KEY FINDINGS AND LIMITATIONS: In total, 513 participants were enrolled in the initial evaluation. After second TURB, 263 participants were enrolled and randomized. AS was noninferior to BCG in terms of iRFS (hazard ratio 0.69, 90% confidence interval 0.44-1.08; p = 0.001). Rates of adverse events were 50% and 90% for any grade, and in 3.1% and 3.8% for grade >/=3 events in the AS and BCG arms, respectively. The protocol treatment in the control arm was not the current standard. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this highly selected patient population, AS was noninferior to eight-dose intravesical BCG induction therapy in terms of iRFS for T1 disease or deeper intravesical and/or extravesical recurrence. The safety profile of AS was better than that of BCG. These findings indicate that AS represents a potentially viable therapeutic strategy for selected patients with HG T1 bladder cancer for whom second TURB demonstrates the absence of residual disease. CI - Copyright (c) 2026 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. Electronic address: hkitamur@med.u-toyama.ac.jp. FAU - Tsukamoto, Taiji AU - Tsukamoto T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kakehi, Yoshiyuki AU - Kakehi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Mizusawa, Junki AU - Mizusawa J AD - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Shibata, Taro AU - Shibata T AD - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Sasaki, Keita AU - Sasaki K AD - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Tanikawa, Toshiki AU - Tanikawa T AD - Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Takahashi, Atsushi AU - Takahashi A AD - Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Adachi, Hisanobu AU - Adachi H AD - Department of Urology, Miyagi Cancer Center, Miyagi, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. CN - Urologic Oncology Study Group of the Japan Clinical Oncology Group LA - eng PT - Clinical Trial, Phase III PT - Comparative Study PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260121 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/administration & dosage/adverse effects MH - Female MH - Transurethral Resection of Bladder MH - Administration, Intravesical MH - Aged MH - Male MH - *Urinary Bladder Neoplasms/pathology/therapy/surgery MH - *Watchful Waiting MH - Middle Aged MH - *Adjuvants, Immunologic/administration & dosage/adverse effects MH - Neoplasm Recurrence, Local MH - Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Grading MH - Neoplasm Staging MH - Disease Progression MH - Treatment Outcome MH - Aged, 80 and over OTO - NOTNLM OT - Active surveillance OT - Bacillus Calmette-Guerin OT - High grade OT - Non-muscle-invasive bladder cancer OT - Phase 3 OT - Stage T1 EDAT- 2026/01/23 00:26 MHDA- 2026/05/07 00:32 CRDT- 2026/01/22 21:58 PHST- 2025/08/04 00:00 [received] PHST- 2025/12/27 00:00 [revised] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/05/07 00:32 [medline] PHST- 2026/01/23 00:26 [pubmed] PHST- 2026/01/22 21:58 [entrez] AID - S0302-2838(26)00014-X [pii] AID - 10.1016/j.eururo.2026.01.008 [doi] PST - ppublish SO - Eur Urol. 2026 May;89(5):437-445. doi: 10.1016/j.eururo.2026.01.008. Epub 2026 Jan 21. PMID- 41569182 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260813 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 27 IP - 1 DP - 2026 Jan 1 TI - Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis. PG - 151-156 LID - 92015 [pii] LID - 10.31557/APJCP.2026.27.1.151 [doi] AB - OBJECTIVE: To investigate the association between tumor morphology and muscle-invasive bladder cancer (MIBC) in patients with newly diagnosed bladder cancer (BC). METHODS: This retrospective study included 416 patients who underwent transurethral resection of a bladder tumor for newly diagnosed BC between January 2018 and December 2023 at a tertiary hospital in Vietnam. Multivariable logistic regression analysis was applied to assess the adjusted association between the sessile morphology of BC on cystoscopy and the risk of muscle invasion. Age, sex, tumor size, number of tumors, and pathological grade were considered confounders. Stratified analysis by tumor size and number of tumors was performed to clarify the effect modification. RESULTS: Patients with MIBC had a significantly higher prevalence of sessile morphology (68.8% vs. 28.4%, p<0.001). After controlling for confounders, patients with sessile tumors were three times more likely to have MIBC than those with papillary tumors (OR = 3.1, 95% CI = [1.8-5.3], p < 0.001). The association of sessile tumor with MIBC was higher in patients with tumor 3 tumors (about 64%, OR = 5.1, 95% CI = [2.1-12.4]). CONCLUSIONS: Sessile morphology is associated with the risk of MIBC in patients newly diagnosed with BC. This association was more pronounced in patients with tumor 3 tumors. FAU - Do, Ngoc-The AU - Do NT AUID- ORCID: 0000-0003-3525-6906 AD - Urology and Andrology Center, 108 Military Central Hospital, Hanoi, Vietnam. FAU - Nguyen Tung, Lam AU - Nguyen Tung L AUID- ORCID: 0009-0002-8730-3460 AD - Urology and Andrology Center, 108 Military Central Hospital, Hanoi, Vietnam. FAU - Nguyen Cong, Dinh AU - Nguyen Cong D AUID- ORCID: 0009-0007-8388-169X AD - Urology and Andrology Center, 108 Military Central Hospital, Hanoi, Vietnam. FAU - Do, Minh-Tung AU - Do MT AUID- ORCID: 0000-0003-4936-5660 AD - Department of Surgery, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam. LA - eng PT - Journal Article DEP - 20260101 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Female MH - Male MH - Retrospective Studies MH - Risk Factors MH - Neoplasm Invasiveness MH - Aged MH - Middle Aged MH - Transurethral Resection of Bladder MH - Prognosis MH - Follow-Up Studies MH - *Muscle Neoplasms/pathology PMC - PMC13380869 OTO - NOTNLM OT - Urinary Bladder Neoplasms OT - muscle invasive OT - risk factor OT - tumor morphology COIS- The authors declare no conflicts of interest regarding the publication of this article. EDAT- 2026/01/22 13:30 MHDA- 2026/01/22 13:31 PMCR- 2026/03/01 CRDT- 2026/01/22 10:24 PHST- 2025/05/04 00:00 [received] PHST- 2026/01/22 13:31 [medline] PHST- 2026/01/22 13:30 [pubmed] PHST- 2026/01/22 10:24 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - 92015 [pii] AID - 10.31557/APJCP.2026.27.1.151 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2026 Jan 1;27(1):151-156. doi: 10.31557/APJCP.2026.27.1.151. PMID- 41565702 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Jan 22 TI - Training and external validation of machine learning supervised prognostic models of upper tract urothelial cancer (UTUC) after nephroureterectomy. PG - 2847 LID - 10.1038/s41598-025-29043-w [doi] LID - 2847 AB - The European association of Urology (EAU) suggests a prognostic stratification of Upper Tract Urothelial Cancer (UTUC) based on high and low risk patients, with Radical nephroureterectomy (RNU) and bladder cuff resection being the gold standard for the treatment of non-metastatic High risk UTUC. However, no consensus on post-operative patient management or tools that predict who would benefit the most from a close follow-up rather than adjuvant chemotherapy regimen exist. in Machine Learning (ML) is gaining interest in Urology providing models for prognostic prediction purpose; It's role in UTUC has not yet been investigated. We aim to develop and validate multiple supervised ML models based on patient- and tumor- related features to predict prognosis in patients with preoperative Histological or Imaging proved UTUC treated with RNU within a multiethnic large cohort. Data from an international multicenter large cohort of histologically proven UTUC patients from Asia and Europe treated with RNU were retrospectively collected. Twenty different ML-supervised predictive models were first trained and then external validate with two separate set. Nomograms were constructed based on 8 independent prognostic factors (age, gender, grading, pT, pN, presence of Carcinoma in Situ (CIS), multifocality and Lymphovascular invasion(LVI)) to predict 6 Outcomes (Overall Survival (OS), Cancer Specific Survival (CSS) and Disease Free Survival (DFS) at 3 and 5 year). Performances were compared using Area-under-curve (AUC) of Receiver-Operating Characteristics (ROC). A total of 3129 patients were enrolled: 637 Asian Patients (training cohort) and 2492 European patients (validation cohort). Upon training assessment, LR models achieved the best results, being the best model for prediction of 4/6 outcomes, with the best result in CSS both at 3 and 5 years (AUC: 0.85, 0.84, 0.81 for CSS-3y, CSS-5y and DFS-3y respectively). Upon external validation, LR(CSL) models achieve the best results, being the number 1 model for prediction of 3/6 outcomes (AUC: 0.84, 0.79, 0.77 for CSS-3y, OS-3y and OS-5y respectively). ML is a promising technology in the field of UTUC. Our model achieve favorable results in terms of prediction of prognosis after RNU, especially in terms of CSS at 3 and 5 years, moreover is the first model of prognosis taking into account the differences in epidemiology existing between European and Asian patients. Further clinical validation and verification of its reliability for the case selection of adjuvant therapy are needed to assess its use in clinical practice linked to clinical decision making. ML is an advancing technology in the field of medicine and urology, which can also be applied to the definition of the prognosis of patients with UTUC undergoing RNU. Our study represents the first experience investigating this potential. FAU - Nicoletti, Rossella AU - Nicoletti R AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Ho, Nick AU - Ho N AD - The Hong Kong Polytechnic University, Hung Hom, Hong Kong. FAU - Lee, Hsiang-Ying AU - Lee HY AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Spatafora, Pietro AU - Spatafora P AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. FAU - Ko, Ivan Ching-Ho AU - Ko IC AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. FAU - Leung, Chi-Ho AU - Leung CH AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. FAU - Giannarini, Gianluca AU - Giannarini G AD - Unit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy. FAU - Vasdev, Nikhil AU - Vasdev N AD - Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, UK. AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. FAU - Gontero, Paolo AU - Gontero P AD - AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. FAU - Li, Ching-Chia AU - Li CC AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Ke, Hung-Lung AU - Ke HL AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Yeh, Hsin-Chih AU - Yeh HC AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Campi, Riccardo AU - Campi R AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Serni, Sergio AU - Serni S AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Gacci, Mauro AU - Gacci M AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Shariat, Shahrokh AU - Shariat S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, USA. AD - Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Salt, Jordan. FAU - Choi, Thomas AU - Choi T AD - The Hong Kong Polytechnic University, Hung Hom, Hong Kong. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong. jeremyteoh@surgery.cuhk.edu.hk. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. jeremyteoh@surgery.cuhk.edu.hk. LA - eng PT - Journal Article DEP - 20260122 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Nephroureterectomy MH - Prognosis MH - Female MH - Male MH - Aged MH - Predictive Learning Models MH - *Machine Learning MH - Retrospective Studies MH - *Ureteral Neoplasms/surgery/pathology MH - Nomograms MH - *Urologic Neoplasms/surgery/pathology PMC - PMC12827265 OTO - NOTNLM OT - Machine learning OT - Nephroureterectomy OT - Upper tract urothelial cancer COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/01/22 01:09 MHDA- 2026/06/27 06:43 PMCR- 2026/01/22 CRDT- 2026/01/21 23:17 PHST- 2024/04/17 00:00 [received] PHST- 2025/11/13 00:00 [accepted] PHST- 2026/06/27 06:43 [medline] PHST- 2026/01/22 01:09 [pubmed] PHST- 2026/01/21 23:17 [entrez] PHST- 2026/01/22 00:00 [pmc-release] AID - 10.1038/s41598-025-29043-w [pii] AID - 29043 [pii] AID - 10.1038/s41598-025-29043-w [doi] PST - epublish SO - Sci Rep. 2026 Jan 22;16(1):2847. doi: 10.1038/s41598-025-29043-w. PMID- 41562639 OWN - NLM STAT- Publisher LR - 20260121 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) DP - 2026 Jan 20 TI - Comment on Yu et al. "CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study". LID - 10.1097/JS9.0000000000004844 [doi] FAU - Wan, Bangbei AU - Wan B AUID- ORCID: 0000-0002-9557-4095 AD - Reproductive Medical Center, Hainan Women and Children's Medical Center, Haikou, China. AD - Department of Urology, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China. LA - eng PT - Journal Article DEP - 20260120 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM EDAT- 2026/01/21 12:59 MHDA- 2026/01/21 12:59 CRDT- 2026/01/21 09:13 PHST- 2025/12/19 00:00 [received] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/01/21 12:59 [medline] PHST- 2026/01/21 12:59 [pubmed] PHST- 2026/01/21 09:13 [entrez] AID - 01279778-990000000-04481 [pii] AID - 10.1097/JS9.0000000000004844 [doi] PST - aheadofprint SO - Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004844. PMID- 41561769 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260123 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer. PG - 1716324 LID - 10.3389/fonc.2025.1716324 [doi] LID - 1716324 AB - BACKGROUND: Bladder cancer (BCA) shows significant prognostic differences between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) forms. While NMIBC frequently recurs and can progress to invasive disease, reliable biomarkers to monitor this transition are lacking. Extracellular matrix (ECM) remodeling is a critical factor influencing tumor aggressiveness, yet the key regulators of ECM changes across BCA stages remain unclear. In this study, we investigate the role of COL1A2 in ECM-related tumor biology and its potential as a prognostic biomarker for BCA progression. METHODS: We utilized a multi-step bioinformatics pipeline, analyzing RNA-seq data from TCGA and GEO datasets to identify molecular differences between NMIBC and MIBC. Prognostic markers were prioritized via differential expression analysis, Cox regression, and Kaplan-Meier survival analysis. The regulatory network was explored using protein-protein interaction analysis, and ECM-related activity was quantified through ssGSEA. Cell-type-specific insights were gained through single-cell RNA-seq analysis, and intercellular communication was deciphered using CellChat. Functional validation was performed through in vitro knockdown experiments in BCA cell lines. RESULTS: COL1A2 emerged as a key prognostic ECM-related gene associated with MIBC. Single-cell RNA-seq analysis revealed that COL1A2 and ECM components were predominantly enriched in matrix cancer-associated fibroblasts (CAFs), with PTK2 (FAK, focal adhesion kinase) upregulated in epithelial cells undergoing epithelial-mesenchymal transition (EMT). CellChat analysis uncovered a dominant COL1A2-mediated signaling axis from matrix CAFs to EMT epithelial cells via COL1A1/2-SDC1/4 ligand-receptor interactions. Functional assays confirmed that COL1A2 knockdown significantly impaired MIBC cell invasion and migration by suppressing ECM remodeling and EMT. CONCLUSION: Our results suggest that the COL1A2-ECM-FAK signaling axis plays a critical role in MIBC progression, and COL1A2 could serve as a potential biomarker and therapeutic target for muscle-invasive bladder cancer. CI - Copyright (c) 2026 Li, Liu, Xue, Lu, Chen, Zhang, Chen, Zhao, Wang and Feng. FAU - Li, Menglu AU - Li M AD - Department of Urology, Jiangnan University Medical Center, Wuxi, China. AD - Institute of Urology, Wuxi School of Medicine, Jiangnan University, Wuxi, China. AD - Department of Urology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Nanjing, China. AD - Department of Urology, Wuxi Medical Center, Nantong University, Nantong, China. FAU - Liu, Xinwei AU - Liu X AD - Department of Urology, Jiangnan University Medical Center, Wuxi, China. AD - Institute of Urology, Wuxi School of Medicine, Jiangnan University, Wuxi, China. FAU - Xue, Yuhui AU - Xue Y AD - Department of Urology, Jiangnan University Medical Center, Wuxi, China. AD - Institute of Urology, Wuxi School of Medicine, Jiangnan University, Wuxi, China. FAU - Lu, Yichen AU - Lu Y AD - Department of Urology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Nanjing, China. FAU - Chen, Zhiqiang AU - Chen Z AD - Department of Urology, Jiangnan University Medical Center, Wuxi, China. AD - Institute of Urology, Wuxi School of Medicine, Jiangnan University, Wuxi, China. FAU - Zhang, Yuwei AU - Zhang Y AD - Department of Urology, Wuxi Medical Center, Nantong University, Nantong, China. FAU - Chen, Weiguo AU - Chen W AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Zhao, Shan-Chao AU - Zhao SC AD - Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China. FAU - Wang, Ke AU - Wang K AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Feng, Ninghan AU - Feng N AD - Department of Urology, Jiangnan University Medical Center, Wuxi, China. AD - Institute of Urology, Wuxi School of Medicine, Jiangnan University, Wuxi, China. AD - Department of Urology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Nanjing, China. AD - Department of Urology, Wuxi Medical Center, Nantong University, Nantong, China. LA - eng PT - Journal Article DEP - 20260105 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12812713 OTO - NOTNLM OT - COL1A2 OT - extracellular matrix OT - focal adhesion kinase OT - muscle-invasive bladder cancer OT - non-muscle-invasive bladder cancer COIS- The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/21 06:32 MHDA- 2026/01/21 06:33 PMCR- 2026/01/05 CRDT- 2026/01/21 05:02 PHST- 2025/10/02 00:00 [received] PHST- 2025/12/08 00:00 [revised] PHST- 2025/12/09 00:00 [accepted] PHST- 2026/01/21 06:33 [medline] PHST- 2026/01/21 06:32 [pubmed] PHST- 2026/01/21 05:02 [entrez] PHST- 2026/01/05 00:00 [pmc-release] AID - 10.3389/fonc.2025.1716324 [doi] PST - epublish SO - Front Oncol. 2026 Jan 5;15:1716324. doi: 10.3389/fonc.2025.1716324. eCollection 2025. PMID- 41561745 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260123 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study. PG - 1710047 LID - 10.3389/fonc.2025.1710047 [doi] LID - 1710047 AB - BACKGROUND: The prognostic utility of the red cell distribution width-to-albumin ratio (RAR) in non-muscle-invasive bladder cancer (NMIBC) has not been established. This study aimed to evaluate the associations between preoperative RAR and both recurrence-free survival (RFS) and overall survival (OS) in patients with NMIBC. METHODS: A retrospective review was performed for 240 individuals with NMIBC having undergone transurethral resection of bladder tumor (TURBT) at Shijiazhuang People's Hospital from November 2013 to January 2024. Demographic characteristics, hematological parameters, pathological data, and information on instillation therapy were collected. The optimal RAR cutoff was identified by applying receiver operating characteristic (ROC) analysis. Survival curves were generated via the Kaplan-Meier method. The relationships of RAR with both RFS and OS were examined using univariate and multivariate Cox proportional hazards regression models. A nomogram was created using the identified independent prognostic factors from multivariate analysis to predict RFS. The discriminative ability and clinical usefulness of the nomogram were assessed by the concordance index (C-index), the calibration plots, time-dependent ROC analysis, and decision curve analysis (DCA). RESULTS: Patients with higher preoperative RAR showed significantly poorer RFS and OS. Multivariate analysis identified high RAR as an independent prognostic factor for both RFS (HR: 1.731, 95% CI: 1.012 - 2.959) and OS (HR: 3.425, 95% CI: 1.196 - 9.806) in NMIBC patients. Based on these findings, RAR was incorporated into a nomogram model for predicting RFS. Compared to the baseline model without RAR, the new model exhibited an improved C-index (from 0.704 to 0.728). The calibration plots demonstrated excellent consistency of the nomogram-predicted probabilities for 1-, 3-, and 5-year RFS with the actual survival rates. The time-dependent ROC analysis revealed that the areas under the curve (AUC) values for RFS predictions at 1-, 3-, and 5- years were 0.806, 0.797 and 0.806. DCA validated that the nomogram yielded a superior net benefit within threshold probability ranges of 10% to 45% when compared to traditional staging systems. CONCLUSIONS: The findings suggest that preoperative RAR serves as a novel and independent prognostic factor for predicting RFS and OS in NMIBC cases. CI - Copyright (c) 2026 Song, Su, Zhang, Cao, Cui, Zhang, Li and Li. FAU - Song, Feifan AU - Song F AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Su, Shiqiang AU - Su S AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Zhang, Xueqiao AU - Zhang X AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Cao, Yunpeng AU - Cao Y AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Cui, Xiongjie AU - Cui X AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. AD - Graduate School of Hebei Medical University, Shijiazhuang, China. FAU - Zhang, Lili AU - Zhang L AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Li, Chao AU - Li C AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. FAU - Li, Shen AU - Li S AD - Department of Urology, Shijiazhuang People's Hospital, Shijiazhuang, China. LA - eng PT - Journal Article DEP - 20260105 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12812645 OTO - NOTNLM OT - albumin OT - non-muscle-invasive bladder cancer OT - overall survival OT - recurrence-free survival OT - red cell distribution width COIS- The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/21 06:30 MHDA- 2026/01/21 06:31 PMCR- 2026/01/05 CRDT- 2026/01/21 05:01 PHST- 2025/09/21 00:00 [received] PHST- 2025/11/30 00:00 [revised] PHST- 2025/12/08 00:00 [accepted] PHST- 2026/01/21 06:31 [medline] PHST- 2026/01/21 06:30 [pubmed] PHST- 2026/01/21 05:01 [entrez] PHST- 2026/01/05 00:00 [pmc-release] AID - 10.3389/fonc.2025.1710047 [doi] PST - epublish SO - Front Oncol. 2026 Jan 5;15:1710047. doi: 10.3389/fonc.2025.1710047. eCollection 2025. PMID- 41559463 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 33 IP - 5 DP - 2026 May TI - Intratumoral and Peritumoral Fat CT‑Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study. PG - 4795-4805 LID - 10.1245/s10434-025-18981-4 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence, and multiple surgeries increase the disease burden on patients. Using computed tomography (CT)-based machine learning, this study established a pre-treatment recurrence prediction model incorporating tumor and peritumoral fat characteristics. This approach may guide early clinical interventions. METHODS: In this retrospective study, 208 NMIBC patients who underwent enhanced CT before transurethral resection of bladder tumor (TURBT) with intravesical chemotherapy were collected from two hospitals. The radiomics features were extracted from the intratumoral region and peritumoral fat region (5 mm), followed by least absolute shrinkage and selection operator (LASSO) selection. Three radiomics models were developed: intratumoral, peritumoral-fat, and combined intratumoral-peritumoral model. Kaplan-Meier analysis assessed the association between radiomics features and recurrence-free survival. Cox analyses identified clinical risk factors integrated with radiomics score into a clinical-radiomics nomogram. Time-dependent ROC assessed the nomogram's predictive performance, and decision curve analysis evaluated its clinical utility. RESULTS: The combined model based on logistic regression demonstrated superior discrimination, with area under the curve (AUC) values of 0.88 in the test set and 0.82 in the external validation set. The clinical-radiomics nomogram exhibited optimal performance in predicting early recurrence for NMIBC, with time-AUC values of 0.86 and 0.84 in the test and external validation sets, respectively. The nomogram showed better calibration and reclassification than the clinical model (net reclassification improvement, 0.736; p < 0.05). CONCLUSIONS: The integrated radiomics-clinical model enhances the predictive capability compared with individual models, demonstrating significant value in predicting early recurrence of NMIBC. This approach offers a novel predictive strategy for assessing NMIBC recurrence risk. CI - (c) 2026. Society of Surgical Oncology. FAU - Jiang, Meng AU - Jiang M AD - Department of Nuclear Medicine, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Chen, Siji AU - Chen S AD - Department of Nuclear Medicine, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Ma, Han AU - Ma H AD - Department of Radiology, People's Hospital of China Medical University, Shenyang, China. AD - Department of Radiology, The People's Hospital of Liaoning Province, Shenyang, China. FAU - Shi, Yunfei AU - Shi Y AD - Department of Nuclear Medicine, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Zhu, Hehe AU - Zhu H AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Liu, Bitian AU - Liu B AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Pan, Shen AU - Pan S AD - Department of Nuclear Medicine, Shengjing Hospital of China Medical University, Shenyang, China. panshencmu@163.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260120 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Radiomics MH - *Neoplasm Recurrence, Local/diagnostic imaging/pathology MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Retrospective Studies MH - *Tomography, X-Ray Computed/methods MH - Male MH - *Nomograms MH - Follow-Up Studies MH - Aged MH - Prognosis MH - Transurethral Resection of Bladder MH - Survival Rate MH - *Adipose Tissue/diagnostic imaging/pathology MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging MH - Risk Factors MH - ROC Curve COIS- Disclosure: There are no conflicts of interest. EDAT- 2026/01/21 01:48 MHDA- 2026/04/19 17:42 CRDT- 2026/01/20 23:35 PHST- 2025/08/12 00:00 [received] PHST- 2025/12/17 00:00 [accepted] PHST- 2026/04/19 17:42 [medline] PHST- 2026/01/21 01:48 [pubmed] PHST- 2026/01/20 23:35 [entrez] AID - 10.1245/s10434-025-18981-4 [pii] AID - 10.1245/s10434-025-18981-4 [doi] PST - ppublish SO - Ann Surg Oncol. 2026 May;33(5):4795-4805. doi: 10.1245/s10434-025-18981-4. Epub 2026 Jan 20. PMID- 41553526 OWN - NLM STAT- MEDLINE DCOM- 20260721 LR - 20260820 IS - 2366-0058 (Electronic) VI - 51 IP - 8 DP - 2026 Aug TI - Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer. PG - 4018-4029 LID - 10.1007/s00261-025-05365-1 [doi] AB - PURPOSE: To evaluate the diagnostic value of synthetic MRI (SyMRI)-derived T1 and T2 values in predicting muscle-invasive bladder cancer (MIBC), and assess the feasibility of integrating them into the biparametric MRI Vesical Imaging-Reporting and Data System (bpVI-RADS). METHODS: This prospective dual-center study included 42 patients (mean age: 71.90 +/- 9.70 years, 90.5% male, 23.8% MIBC) with histologically confirmed urothelial carcinoma who underwent bladder MRI. Two radiologists independently assigned bpVI-RADS scores based on T2-weighted and diffusion-weighted images, blinded to pathological, with consensus reached through consultation with a senior radiologist. Tumor volumes were manually delineated on SyMRI-derived maps to extract T1 and T2 values. Two modified models (bpVI-RADS + T1 and bpVI-RADS + T2) were created by adjusting bpVI-RADS scores according to optimal T1 or T2 cutoff values determined via receiver operating characteristic (ROC) curve analysis. Diagnostic performance was assessed with ROC analysis, and AUCs were compared using the DeLong test. RESULTS: MIBC lesions showed significantly lower T1 and T2 values than non-muscle-invasive bladder cancer (NMIBC). Optimal cutoff values for T1 and T2 to differentiate MIBC from NMIBC were 1370 msec and 115 msec, respectively. The bpVI-RADS + T2 achieved significantly higher AUC (0.994 vs. 0.881, P = 0.021) than bpVI-RADS at a cutoff score of >/= 4. The bpVI-RADS + T1 showed slightly improved diagnostic performance than bpVI-RADS (0.913 vs. 0.881, P = 0.605). CONCLUSION: SyMRI-derived T1 and T2 values could help distinguish muscle invasion in bladder cancer. Incorporating T2 values into the bpVI-RADS framework significantly enhances diagnostic performance for predicting MIBC. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Zhao, Zihui AU - Zhao Z AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Zhao, Zhen AU - Zhao Z AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Bu, Xuefeng AU - Bu X AD - Nanjing Lishui People's Hospital, Southeast University, Nanjing, China. FAU - Wang, Min AU - Wang M AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Zhao, Tonglei AU - Zhao T AD - Southeast University School of Medicine, Nanjing, China. FAU - Fu, Lin AU - Fu L AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Cui, Ying AU - Cui Y AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Jiang, Yang AU - Jiang Y AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Yang, Wenjun AU - Yang W AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Xu, Jiajia AU - Xu J AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. FAU - Peng, Xin-Gui AU - Peng XG AD - Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. 101011887@seu.edu.cn. AD - Nanjing Lishui People's Hospital, Southeast University, Nanjing, China. 101011887@seu.edu.cn. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260119 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Male MH - Aged MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Prospective Studies MH - Female MH - *Magnetic Resonance Imaging/methods MH - Predictive Value of Tests MH - Feasibility Studies MH - Middle Aged MH - Aged, 80 and over MH - Radiology Information Systems MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Multiparametric magnetic resonance imaging OT - Neoplasm staging OT - Urinary bladder neoplasms OT - Vesical imaging reporting and data system COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2026/01/19 12:51 MHDA- 2026/07/21 12:35 CRDT- 2026/01/19 11:14 PHST- 2025/11/10 00:00 [received] PHST- 2025/12/26 00:00 [accepted] PHST- 2025/12/08 00:00 [revised] PHST- 2026/07/21 12:35 [medline] PHST- 2026/01/19 12:51 [pubmed] PHST- 2026/01/19 11:14 [entrez] AID - 10.1007/s00261-025-05365-1 [pii] AID - 10.1007/s00261-025-05365-1 [doi] PST - ppublish SO - Abdom Radiol (NY). 2026 Aug;51(8):4018-4029. doi: 10.1007/s00261-025-05365-1. Epub 2026 Jan 19. PMID- 41552893 OWN - NLM STAT- MEDLINE DCOM- 20260423 LR - 20260826 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 4 DP - 2026 Apr TI - Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer. PG - 690-697 LID - 10.1111/bju.70149 [doi] AB - OBJECTIVES: To compare oncological outcomes between intravesical bacillus Calmette-Guerin (BCG) and gemcitabine/docetaxel (Gem/Doce) in patients with primary high-grade (HG) Ta non-muscle-invasive bladder cancer (NMIBC) and assess the prognostic utility of the American Urological Association (AUA) risk stratification system, which classifies these tumours as intermediate risk (IR) or high risk (HR). PATIENTS AND METHODS: Retrospective cohort of 128 treatment-naive patients with HG Ta NMIBC treated from January 2011 to December 2024 was analysed. After resection, patients received intravesical therapy with either BCG (n = 65) or Gem/Doce (n = 63), with Gem/Doce on a 24-month maintenance schedule and BCG at 3, 9, and 15 months. Cox regression models evaluated the impact of patient, disease, and treatment characteristics on oncological outcomes. RESULTS: The follow-up was longer in the BCG group (median [interquartile range, IQR] 81 [44-113] months) than in the Gem/Doce group (median [IQR] 37 [26-55] months). Recurrence-free survival (RFS) at 12 and 24 months was 80% and 76% for Gem/Doce, and 76% and 70% for BCG, respectively. HG-RFS at 12 and 24 months was 82% and 78% for Gem/Doce, and 79% and 75% for BCG, respectively. The 24-month progression-free survival was 100% for Gem/Doce and 91% for BCG. There were no significant associations between AUA risk classification (IR vs HR; hazard ratio 1.05, P = 0.89 for RFS; hazard ratio 1.12, P = 0.75 for HG-RFS) or treatment type (BCG vs Gem/Doce; hazard ratio 1.19, P = 0.60 for RFS; hazard ratio 1.02, P = 0.96 for HG-RFS) and recurrence outcomes. Adverse events were less frequent with Gem/Doce than BCG (40% vs 46%), with no Grade III events in the Gem/Doce group. CONCLUSION: Treatment with Gem/Doce is a well-tolerated, effective alternative to BCG for HG Ta NMIBC. In this subset, AUA risk stratification (IR vs HR) was not significantly associated with recurrence outcomes, warranting prospective validation. CI - (c) 2026 BJU International. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. FAU - McElree, Ian M AU - McElree IM AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AUID- ORCID: 0000-0001-7202-6427 AD - Department of Urology, University of Iowa Health Care, Iowa City, IA, USA. LA - eng GR - John and Carol Walter Family Foundation/ PT - Comparative Study PT - Journal Article DEP - 20260119 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Gemcitabine) RN - 15H5577CQD (Docetaxel) SB - IM MH - Societies, Medical MH - Urology MH - *BCG Vaccine/administration & dosage MH - *Gemcitabine/administration & dosage MH - *Docetaxel/administration & dosage MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/therapy MH - Risk Assessment MH - Humans MH - Male MH - Female MH - Administration, Intravesical MH - *Antineoplastic Combined Chemotherapy Protocols MH - Aged MH - Aged, 80 and over MH - Retrospective Studies MH - Progression-Free Survival MH - Neoplasm Recurrence, Local/epidemiology MH - United States OTO - NOTNLM OT - BCG OT - BCG-naive OT - Ta OT - docetaxel OT - gemcitabine OT - high grade OT - non-muscle-invasive bladder cancer COIS- None declared. EDAT- 2026/01/19 12:51 MHDA- 2026/03/08 01:38 CRDT- 2026/01/19 06:34 PHST- 2026/03/08 01:38 [medline] PHST- 2026/01/19 12:51 [pubmed] PHST- 2026/01/19 06:34 [entrez] AID - 10.1111/bju.70149 [doi] PST - ppublish SO - BJU Int. 2026 Apr;137(4):690-697. doi: 10.1111/bju.70149. Epub 2026 Jan 19. PMID- 41552287 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260119 LR - 20260926 IS - 1943-8141 (Print) IS - 1943-8141 (Electronic) IS - 1943-8141 (Linking) VI - 17 IP - 12 DP - 2025 TI - Efficacy of a pubic superior ramus approach versus a distal approach for obturator nerve block in transurethral bladder tumor resection: a randomized controlled trial. PG - 9811-9829 LID - 10.62347/FEWQ7776 [doi] AB - OBJECTIVE: This study aimed to compare the clinical efficacy and safety of a modified pubic superior ramus (PSS) approach for pericapsular nerve group block against the conventional distal technique in obturator nerve blockade during transurethral resection of bladder tumor (TURBT), with a focus on preventing intraoperative obturator nerve reflex. METHODS: We conducted a prospective, randomized, single-blind trial involving 70 patients scheduled for TURBT under general anesthesia. Participants were randomly assigned to one of two groups: Group P (n = 34) received ultrasound-guided obturator nerve block via the pubic superior ramus approach, while Group O (n = 34) underwent blockade via the distal approach. The primary outcome measures were the incidence and severity of obturator nerve reflex. Secondary outcomes encompassed block performance time and success rate, postoperative pain profiles (assessed by VAS scores), recovery quality, perioperative inflammatory biomarker levels, hemodynamic fluctuations, functional recovery metrics, as well as long-term bladder function and oncological outcomes evaluated at 6 and 12 months postoperatively. RESULTS: Group P demonstrated significantly faster onset and greater reduction in adductor muscle strength at all measured time points (P < 0.05), with shorter block performance times (175.5 +/- 34.2 vs. 223.7 +/- 39.6 seconds, P < 0.001) and fewer needle passes (P < 0.001). While the incidence of the obturator reflex was similar between the groups, Group P had superior postoperative analgesia with lower pain scores, reduced morphine consumption (15.2 +/- 4.8 vs. 24.5 +/- 6.1 mg, P < 0.001), and a longer time to first analgesia. The quality of recovery scores was significantly greater in Group P at 24 and 48 hours (P < 0.001), along with an attenuated systemic inflammatory and neurochemical stress response (e.g., IL-6, Substance P, and c-Fos), improved hemodynamic stability, faster quadriceps recovery, and better short- and long-term bladder function. At the 12-month follow-up, Group P exhibited superior urodynamic parameters (Qmax and PVR, P < 0.01) and a trend towards lower tumor recurrence (94.1% vs. 85.3% recurrence-free survival, P = 0.218). CONCLUSION: Compared with the distal approach, the pubic superior ramus approach for obturator nerve block provides more efficient blockade and superior multidimensional perioperative benefits, making it an optimal technique for TURBT within enhanced recovery protocols. CI - AJTR Copyright (c) 2025. FAU - Zhang, Jian AU - Zhang J AD - Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University Nanjing 210006, Jiangsu, China. FAU - Wei, Jie AU - Wei J AD - Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University Nanjing 210006, Jiangsu, China. FAU - Han, Liu AU - Han L AD - Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University Nanjing 210006, Jiangsu, China. LA - eng PT - Journal Article DEP - 20251215 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC12808052 OTO - NOTNLM OT - Obturator nerve block OT - PENG block OT - bladder tumor OT - transurethral resection OT - ultrasound-guided COIS- None. EDAT- 2026/01/19 12:51 MHDA- 2026/01/19 12:52 PMCR- 2025/12/15 CRDT- 2026/01/19 06:24 PHST- 2025/10/22 00:00 [received] PHST- 2025/11/30 00:00 [accepted] PHST- 2026/01/19 12:52 [medline] PHST- 2026/01/19 12:51 [pubmed] PHST- 2026/01/19 06:24 [entrez] PHST- 2025/12/15 00:00 [pmc-release] AID - 10.62347/FEWQ7776 [doi] PST - epublish SO - Am J Transl Res. 2025 Dec 15;17(12):9811-9829. doi: 10.62347/FEWQ7776. eCollection 2025. PMID- 41550467 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260119 LR - 20260926 IS - 2688-2663 (Electronic) IS - 2688-2663 (Linking) VI - 7 IP - 2 DP - 2026 Feb TI - Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study. PG - e70592 LID - 10.1002/mco2.70592 [doi] LID - e70592 AB - Conventional approaches for the detection and surveillance of non-muscle invasive bladder cancer (NMIBC) remain invasive, burdensome, and costly. The utLIFE-UC assay, designed to identify mutations and large copy number variations in urine, has demonstrated high accuracy in detecting urothelial carcinoma. Here, we assessed its efficacy in early detection of NMIBC, identifying minimal residual disease, and monitoring recurrence. Among 108 consecutive NMIBC patients evaluated, utLIFE-UC exhibited a sensitivity of 90.5% in diagnosing NMIBC, with comparable performance in detecting both de novo and recurrent NMIBC. For patients undergoing repeat transurethral resection of bladder tumor (Re-TURBT), the assay accurately identified all cases with residual tumor, achieving a 100% negative predictive value. Positive postoperative utLIFE-UC results before the first follow-up cystoscopy predicted a higher risk of future relapse. A positive test result at any time following TURBT was correlated with poorer recurrence-free survival, whereas sustained negative test results indicated recurrence-free status. Moreover, utLIFE-UC could predict recurrence with a median lead time of 73.5 days prior to clinical confirmation. As the first prospective, longitudinal analysis of urinary tumor DNA in NMIBC, this study highlights the potential of utLIFE-UC to enable earlier recurrence detection and improve risk stratification, potentially obviating unnecessary Re-TURBT and surveillance cystoscopies. CI - (c) 2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. FAU - Wu, Junlong AU - Wu J AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Jin, Shengming AU - Jin S AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Bai, Qianming AU - Bai Q AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. AD - Department of Pathology Fudan University Shanghai Cancer Center Shanghai China. AD - Institute of Pathology Fudan University Shanghai China. FAU - Wang, Huina AU - Wang H AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Cheng, Huanqing AU - Cheng H AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Zhou, Xiaoyan AU - Zhou X AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. AD - Department of Pathology Fudan University Shanghai Cancer Center Shanghai China. AD - Institute of Pathology Fudan University Shanghai China. FAU - Shen, Yijun AU - Shen Y AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Ma, Chunguang AU - Ma C AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Gu, Chengyuan AU - Gu C AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Chen, Hui AU - Chen H AD - Department of Urology Harbin Medical University Cancer Hospital Harbin China. FAU - Zhang, Yafeng AU - Zhang Y AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Chen, Libin AU - Chen L AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology Comprehensive Cancer Center Medical University Vienna Vienna Austria. AD - Institute For Urology and Reproductive Health Sechenov University Moscow Russia. AD - Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA. AD - Department of Urology Weill Cornell Medical College New York New York USA. AD - Division of Urology Department of Special Surgery University of Jordan Amman Jordan. AD - Research Center for Evidence Medicine Urology Department Tabriz University of Medical Sciences Tabriz Iran. FAU - Lou, Feng AU - Lou F AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Cao, Shanbo AU - Cao S AD - Acornmed Biotechnology Co., Ltd Beijing China. FAU - Zhu, Yiping AU - Zhu Y AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. FAU - Ye, Dingwei AU - Ye D AD - Department of Urology Fudan University Shanghai Cancer Center Shanghai China. AD - Department of Oncology Shanghai Medical College Fudan University Shanghai China. LA - eng PT - Journal Article DEP - 20260115 PL - China TA - MedComm (2020) JT - MedComm JID - 101769925 PMC - PMC12805463 OTO - NOTNLM OT - early detection OT - minimal residual disease OT - non-muscle-invasive bladder cancer OT - recurrence monitoring OT - urine tumor DNA COIS- H.W., H.C., Y.Z., L.C., F.L., and S.C. are employees of Acornmed Biotechnology Co., Ltd. The other authors declare that they have no conflicts of interest. EDAT- 2026/01/19 12:51 MHDA- 2026/01/19 12:52 PMCR- 2026/01/15 CRDT- 2026/01/19 06:09 PHST- 2025/02/10 00:00 [received] PHST- 2025/10/24 00:00 [revised] PHST- 2025/12/15 00:00 [accepted] PHST- 2026/01/19 12:52 [medline] PHST- 2026/01/19 12:51 [pubmed] PHST- 2026/01/19 06:09 [entrez] PHST- 2026/01/15 00:00 [pmc-release] AID - MCO270592 [pii] AID - 10.1002/mco2.70592 [doi] PST - epublish SO - MedComm (2020). 2026 Jan 15;7(2):e70592. doi: 10.1002/mco2.70592. eCollection 2026 Feb. PMID- 41549273 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 26 IP - 1 DP - 2026 Jan 19 TI - Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer. PG - 278 LID - 10.1186/s12885-026-15554-w [doi] LID - 278 AB - BACKGROUND AND PURPOSE: Repeat transurethral resection (ReTUR) is essential for reducing residual and recurrent non-muscle-invasive bladder cancer (NMIBC). Pathological upstaging after ReTUR significantly influences prognosis. This study aimed to develop an interpretable machine learning model using CT radiomics to predict the risk of pathological upstaging following ReTUR in NMIBC patients. PATIENTS AND METHODS: We retrospectively analyzed 104 NMIBC patients who underwent ReTUR at the Second Affiliated Hospital of Nanchang University from March 2019 to July 2022. Data were split 7:3 into training and internal validation sets. An external validation set included 40 patients from two other hospitals. Radiomic features were extracted from preoperative CT scans. Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate logistic regression were used to identify predictors of pathological upstaging. Four machine learning models, including Extreme Gradient Boosting (XGBoost), Gradient Boosting Decision Tree (GBDT), Random Forest (RF), and Linear Discriminant Analysis (LDA), were constructed and evaluated using AUC, accuracy, precision, F1 score, calibration curves, and decision curve analysis (DCA). The best model was interpreted via SHapley Additive exPlanations (SHAP) to identify key predictive features. RESULTS: Tumor grade (OR = 7.02, 95% CI: 1.17-42.21), tumor size (OR = 5.83, 95% CI: 1.21-28.15), and tumor number (OR = 6.83, 95% CI: 1.18-39.52) were independent risk factors. From 4,738 radiomic features, nine were selected. The XGBoost model outperformed others, with an AUC of 0.804 (95% CI: 0.756-0.862), accuracy of 77.4%, precision of 82.7%, and F1 score of 0.701 in internal validation. External validation confirmed its robustness. SHAP analysis highlighted Wavelet_LLH_firstorder_Maximum.1, Gradient_ngtdm_Complexity, and tumor grade as top predictors. The model showed good calibration and clinical utility on DCA. CONCLUSION: An interpretable CT radiomics-based machine learning model integrating clinical and imaging features was developed to accurately predict pathological upstaging risk after ReTUR in NMIBC patients. This tool may support clinical decision-making for individualized treatment after multicenter validation. FAU - Rao, Xue Peng AU - Rao XP AD - The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China. FAU - Zou, Xin Chang AU - Zou XC AD - The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China. FAU - Yu, Zhan Jiang AU - Yu ZJ AD - The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, China. FAU - Yuan, Yu Yang AU - Yuan YY AD - Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, 330008, China. FAU - Chao, Hai Chao AU - Chao HC AD - Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China. FAU - Huang, Jian Biao AU - Huang JB AD - Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital & Institute, The Second Affiliat ed Hospital of Nanchang Medical College, Nanchang, 330008, China. 1292238757@qq.com. FAU - Zeng, Tao AU - Zeng T AD - Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, 330008, China. taozeng40709@sina.com. LA - eng GR - 20225BCJ22009/Jiangxi Provincial Academic and Technical Leader Training Program in Major Disciplines/ GR - 202610361/Jiangxi Provincial Health Commission project/ PT - Journal Article DEP - 20260119 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - Radiomics MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery/diagnostic imaging MH - Female MH - Retrospective Studies MH - *Machine Learning MH - Male MH - *Tomography, X-Ray Computed/methods MH - Aged MH - Boosting Machine Learning Algorithms MH - Middle Aged MH - Predictive Learning Models MH - Transurethral Resection of Bladder MH - Random Forest MH - Prognosis MH - Neoplasm Staging MH - Neoplasm Grading MH - *Urinary Bladder Neoplasms/pathology/surgery/diagnostic imaging PMC - PMC12918572 OTO - NOTNLM OT - Explainable machine learning OT - Non-Muscle-Invasive bladder cancer OT - Pathological upgrading OT - Radiomics OT - Repeat transurethral resection COIS- Declarations. Ethics approval and consent to participate: This study and related projects have been approved by the Biomedical Research Ethics Committees of the Second Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hospital, and the First Affiliated Hospital of Nanchang University, with all committees waiving the requirement for informed consent. All procedures were conducted in accordance with relevant guidelines and regulations. This study fully complies with the Declaration of Helsinki ( https://www.wma.net/policies-post/wma-declaration-of-helsinki/ ). Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/19 01:03 MHDA- 2026/06/27 06:45 PMCR- 2026/01/19 CRDT- 2026/01/18 23:14 PHST- 2025/10/27 00:00 [received] PHST- 2026/01/05 00:00 [accepted] PHST- 2026/06/27 06:45 [medline] PHST- 2026/01/19 01:03 [pubmed] PHST- 2026/01/18 23:14 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - 10.1186/s12885-026-15554-w [pii] AID - 15554 [pii] AID - 10.1186/s12885-026-15554-w [doi] PST - epublish SO - BMC Cancer. 2026 Jan 19;26(1):278. doi: 10.1186/s12885-026-15554-w. PMID- 41548434 OWN - NLM STAT- MEDLINE DCOM- 20260130 LR - 20260626 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 172 DP - 2026 Mar 1 TI - Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study. PG - 116186 LID - S1567-5769(26)00029-9 [pii] LID - 10.1016/j.intimp.2026.116186 [doi] AB - OBJECTIVE: Recurrence is not rare for high-risk non-muscle invasive bladder cancer (HR-NMIBC) after bacillus Calmette-Guerin (BCG) immunotherapy. We aimed to introduce disitamab vedotin (DV) to BCG and evaluate its efficacy. METHODS: Consecutive BCG-naive patients with HER2-expressing HR-NMIBC receiving transurethral resection followed by BCG alone or combined with intravenous DV (BCG + DV) were enrolled in this retrospective study. Relationship with recurrence-free survival (RFS) was analyzed using log-rank and Cox regression analyses. Given the differences in baseline patient characteristics, propensity score matching (PSM) was also implemented to address the heterogeneity. RESULTS: A total of 117 patients with a median follow-up of 19 months were finally evaluated (BCG: 85, BCG + DV: 32). Compared with BCG group, BCG + DV group had significantly higher proportions of multifocal lesions (81.2%/57.6%), HER2 2+/3+ tumors (87.6%/51.8%), very-high-risk (VHR) disease (31.3%/14.1%) and tumor residue after initial resection (40.6%/21.2%). The 3-month complete response rates of BCG + DV and BCG groups were 100% and 91.8%, respectively (p = 0.187). BCG + DV yielded superior RFS (1-year: 92.3%, 2-year: 86.5%) versus BCG (1-year: 80.0%, 2-year: 64.6%; p = 0.041), and this advantage was pronounced in HER2 2+/3+, VHR and residual disease subgroups. Independent risk factors of recurrence after BCG monotherapy included large tumor, HER2 2+/3+ and residual disease. Combination treatment emerged as the strongest predictor of improved RFS for the entire cohort. After PSM, BCG + DV still rendered significantly better RFS in both entire matched cohort and aforementioned subgroups. CONCLUSION: Addition of DV to BCG provided favorable early response and superior intermediate-term RFS for BCG-naive HER2-expressing HR-NMIBC, highlighting its prospect in HR-NMIBC management. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Xu, Tianyuan AU - Xu T AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. Electronic address: xvtianyuan@126.com. FAU - Wang, Keyi AU - Wang K AD - Department of Urology, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 200032, China. FAU - Chen, Yifan AU - Chen Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Yu, Yang AU - Yu Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Shen, Danjing AU - Shen D AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Zhang, Jingcheng AU - Zhang J AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Geng, Jiang AU - Geng J AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Peng, Bo AU - Peng B AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. FAU - Yan, Yang AU - Yan Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. Electronic address: 13564368328@163.com. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. Electronic address: yaoxdtj@163.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260117 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (BCG Vaccine) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - 0 (Adjuvants, Immunologic) RN - 0 (disitamab vedotin) RN - 0 (Antibodies, Monoclonal) RN - 0 (Oligopeptides) SB - IM MH - Humans MH - Female MH - *BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Aged MH - Retrospective Studies MH - Middle Aged MH - Male MH - *Immunotherapy/methods MH - *Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms MH - Treatment Outcome MH - Aged, 80 and over MH - Antibodies, Monoclonal MH - Oligopeptides OTO - NOTNLM OT - Antibody-drug conjugate OT - Bacillus Calmette-Guerin OT - Disitamab vedotin OT - Human epidermal growth factor receptor 2 OT - Non-muscle invasive bladder cancer OT - RC48 OT - Recurrence COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/19 01:03 MHDA- 2026/01/31 00:29 CRDT- 2026/01/18 18:06 PHST- 2025/10/18 00:00 [received] PHST- 2026/01/05 00:00 [revised] PHST- 2026/01/07 00:00 [accepted] PHST- 2026/01/31 00:29 [medline] PHST- 2026/01/19 01:03 [pubmed] PHST- 2026/01/18 18:06 [entrez] AID - S1567-5769(26)00029-9 [pii] AID - 10.1016/j.intimp.2026.116186 [doi] PST - ppublish SO - Int Immunopharmacol. 2026 Mar 1;172:116186. doi: 10.1016/j.intimp.2026.116186. Epub 2026 Jan 17. PMID- 41540431 OWN - NLM STAT- MEDLINE DCOM- 20260211 LR - 20260917 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 24 IP - 1 DP - 2026 Jan 16 TI - Comparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China. PG - 88 LID - 10.1186/s12916-026-04632-2 [doi] LID - 88 AB - BACKGROUND: This study aimed to compare radical nephroureterectomy (RNU) and distal ureterectomy (DU) in managing high-risk distal ureteral urothelial carcinoma (UC), focusing on renal function, adjuvant chemotherapy (AC), and oncologic outcomes. METHODS: A retrospective analysis was conducted on 758 patients initially identified with high-risk distal ureteral cancer treated from 2008 to 2021 at two national centers in Beijing and Guangzhou, China. After selection, 554 patients were included: 371 in the RNU group and 183 in the DU group. Propensity score matching (PSM) was applied, resulting in 176 patients in each group. Primary outcomes included intravesical recurrence-free survival (IVRFS), extravesical recurrence-free survival (EVRFS), overall survival (OS), and cancer-specific survival (CSS). Secondary outcomes assessed associations between eGFR, AC, and survival. RESULTS: After PSM, RNU provided better recurrence control, showing significantly higher IVRFS, particularly in T1/N- and low-grade cases, and in patients with eGFR >/= 50 mL/min/1.73 m(2). DU, however, demonstrated superior renal function preservation across all postoperative time points (p < 0.01). Higher postoperative eGFR was associated with increased AC administration and improved OS (p = 0.0010) and CSS (p = 0.0003). In advanced-stage (T2-4/N +) tumors, AC was linked to better OS (p = 0.0399) and a trend toward improved CSS. Additionally, variant histology (VH) and positive surgical margins were confirmed as significant negative prognostic factors for survival. CONCLUSIONS: RNU is preferred for early-stage, low-grade cases due to its superior recurrence control, particularly for IVRFS. DU offers comparable outcomes in advanced-stage or high-grade cases, with the added advantage of renal preservation, supporting chemotherapy eligibility. Individualized treatment strategies based on patient-specific factors remain essential for optimizing outcomes in high-risk distal ureteral UC. CI - (c) 2026. The Author(s). FAU - Xie, Junyi AU - Xie J AUID- ORCID: 0000-0003-2474-9262 AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Department of Urology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, 510120, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Liu, Zhenhua AU - Liu Z AUID- ORCID: 0000-0002-3152-1007 AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Zhou, Peimin AU - Zhou P AUID- ORCID: 0009-0007-7925-0908 AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Ye, Jingwei AU - Ye J AUID- ORCID: 0009-0005-9324-6652 AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Ye, Yunlin AU - Ye Y AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. AD - Cancer Center Gansu Hospital, Lanzhou, Gansu Province, People's Republic of China. FAU - Li, Zhiyong AU - Li Z AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Li, Xiangdong AU - Li X AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Sun, Zhoujie AU - Sun Z AUID- ORCID: 0009-0007-2548-9980 AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Xu, Chunru AU - Xu C AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - He, Zhisong AU - He Z AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - The Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Hao, Han AU - Hao H AUID- ORCID: 0000-0002-7221-0192 AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. haohan1122@vip.sina.com. AD - The Institution of Urology, Peking University, Beijing, 100034, China. haohan1122@vip.sina.com. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. haohan1122@vip.sina.com. AD - National Urological Cancer Center, Beijing, 100034, China. haohan1122@vip.sina.com. FAU - Liu, Zhuowei AU - Liu Z AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. liuzhw@sysucc.org.cn. AD - Guangzhou Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. liuzhw@sysucc.org.cn. AD - Cancer Center Gansu Hospital, Lanzhou, Gansu Province, People's Republic of China. liuzhw@sysucc.org.cn. FAU - Yu, Wei AU - Yu W AUID- ORCID: 0000-0002-0938-0308 AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. yuweipku@bjmu.edu.cn. AD - The Institution of Urology, Peking University, Beijing, 100034, China. yuweipku@bjmu.edu.cn. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. yuweipku@bjmu.edu.cn. AD - National Urological Cancer Center, Beijing, 100034, China. yuweipku@bjmu.edu.cn. AD - Urothelial Cancer Center, Peking University First Hospital, Beijing, 100034, China. yuweipku@bjmu.edu.cn. LA - eng GR - 7232179/Beijing Natural Science Foundation/ PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20260116 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 SB - IM MH - Humans MH - Female MH - China MH - Retrospective Studies MH - *Nephroureterectomy/methods MH - *Ureteral Neoplasms/surgery/mortality MH - Male MH - Middle Aged MH - Aged MH - Treatment Outcome MH - *Ureter/surgery MH - *Carcinoma, Transitional Cell/surgery/mortality PMC - PMC12892482 OTO - NOTNLM OT - Distal ureteral urothelial carcinoma OT - Propensity score matching OT - Renal function OT - Surgery OT - Survival COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Peking University First Hospital (2023-895). All authors contributed in final approval of manuscript and accountable for all aspects of the work. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/16 17:21 MHDA- 2026/02/11 06:31 PMCR- 2026/01/16 CRDT- 2026/01/16 00:32 PHST- 2025/03/24 00:00 [received] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/02/11 06:31 [medline] PHST- 2026/01/16 17:21 [pubmed] PHST- 2026/01/16 00:32 [entrez] PHST- 2026/01/16 00:00 [pmc-release] AID - 10.1186/s12916-026-04632-2 [pii] AID - 4632 [pii] AID - 10.1186/s12916-026-04632-2 [doi] PST - epublish SO - BMC Med. 2026 Jan 16;24(1):88. doi: 10.1186/s12916-026-04632-2. PMID- 41535603 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20261010 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 23 IP - 7 DP - 2026 Jul TI - A multi-modal approach for decision making in bladder cancer. PG - 444-467 LID - 10.1038/s41585-025-01122-7 [doi] AB - Bladder cancer remains a major global health challenge, characterized by diagnostic uncertainty, substantial treatment costs and high recurrence rates. Current diagnostic and treatment modalities, including cystoscopy, transurethral resection of bladder tumour and standard histopathology, have limitations, including the inability to detect flat lesions, frequent understaging and interobserver variability, highlighting a crucial need for improved approaches. Advances in artificial intelligence (AI), blue-light cystoscopy, narrow-band imaging, cytology and urinary markers show promise in enhancing early detection and diagnosis. Developments in multiparametric MRI, radiomics, genomics and AI-driven algorithms for histopathological analyses have demonstrated considerable improvements in staging and risk stratification of bladder tumours, enabling personalized therapy selection and prognostication. Despite these promising developments, challenges remain regarding standardization, external validation, cost-effectiveness and ethical considerations in clinical implementation. Future research should prioritize addressing these barriers through collaborative, multi-institutional studies and robust validation frameworks. Ultimately, adopting a comprehensive multimodal strategy, such as proposed, novel, multimodal decision-making frameworks in which these advances and technologies are integrated, promises to considerably advance precision oncology in bladder cancer, improving patient outcomes and reducing health care burdens. CI - (c) 2026. Springer Nature Limited. FAU - Al-Sattar, Hasan AU - Al-Sattar H AUID- ORCID: 0000-0002-6830-2051 AD - School of Medicine and Biomedical Sciences, University of Oxford, Oxford, UK. FAU - Ding, Hao AU - Ding H AD - Faculty of Medicine, Imperial College London, London, UK. FAU - Okoli, Oluchi AU - Okoli O AUID- ORCID: 0009-0009-3869-7185 AD - School of Clinical Medicine, University of Cambridge, Cambridge, UK. FAU - Okoli, Somto AU - Okoli S AUID- ORCID: 0000-0002-2905-2889 AD - University of Bristol Medical School, Bristol, UK. FAU - Ghose, Aruni AU - Ghose A AD - Department of Medical Oncology, Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Banna, Giuseppe Luigi AU - Banna GL AUID- ORCID: 0000-0003-0764-3650 AD - Portsmouth Hospitals University NHS Trust, Portsmouth, UK. AD - Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. FAU - Wan, Simon AU - Wan S AD - Institute of Nuclear Medicine, University College London, London, UK. FAU - Haroon, Athar AU - Haroon A AD - Department of Medical Oncology, Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Wong, Jonathan AU - Wong J AD - London School of Hygiene & Tropical Medicine, London, UK. FAU - Teoh, Jeremy AU - Teoh J AUID- ORCID: 0000-0002-9361-2342 AD - Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Vasdev, Nikhil AU - Vasdev N AD - Department of Urology, Lister Hospital, ENHT Teaching NHS Trust, Stevenage, UK. AD - Hertfordshire Medical School, University of Hertfordshire, Hatfield, UK. FAU - Efstathiou, Eleni AU - Efstathiou E AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. AD - Houston Methodist Cancer Center, Houston, TX, USA. FAU - Boussios, Stergios AU - Boussios S AUID- ORCID: 0000-0002-2512-6131 AD - Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, UK. AD - Faculty of Life Sciences and Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK. FAU - Adeleke, Sola AU - Adeleke S AUID- ORCID: 0000-0002-4388-8754 AD - School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. olusola.adeleke@kcl.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20260114 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/diagnosis/pathology MH - *Clinical Decision-Making/methods MH - Cystoscopy MH - Transurethral Resection of Bladder MH - Artificial Intelligence COIS- Competing interests: G.L.B. reports receiving personal fees from advisory boards for Accord, AstraZeneca, Amgen and Merck; and from speaker bureaus for Astellas, AstraZeneca, Amgen, Bayer, Merck, Novartis and Pfizer. G.L.B. holds four patents with ST Microelectronics and has received travel and accommodation support for scientific conferences from Accord, Merck and Janssen. J.T. reports receiving honoraria for lectures from Astellas, Boston Scientific, Combat Medical, Ferring, Ipsen, Janssen, Olympus and Sanofi; consultancy or advisory board fees from Astellas, Aulea Medical, CMR Robotics, Combat Medical, EQT, Ferring, Illumicell AI, Janssen, MRI PRO, MedTech Syndicates, Merck Sharp & Dohme, Phase Scientific and Procept BioRobotics; and research grant support from Baxter, Bristol-Myers Squibb, Ferring, Janssen, Merck Sharp & Dohme, Karl Storz and Olympus. The other authors declare no competing interests. EDAT- 2026/01/15 08:04 MHDA- 2026/07/07 18:54 CRDT- 2026/01/14 23:29 PHST- 2025/12/15 00:00 [accepted] PHST- 2026/07/07 18:54 [medline] PHST- 2026/01/15 08:04 [pubmed] PHST- 2026/01/14 23:29 [entrez] AID - 10.1038/s41585-025-01122-7 [pii] AID - 10.1038/s41585-025-01122-7 [doi] PST - ppublish SO - Nat Rev Urol. 2026 Jul;23(7):444-467. doi: 10.1038/s41585-025-01122-7. Epub 2026 Jan 14. PMID- 41533243 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261009 IS - 1863-2491 (Electronic) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 Jan 14 TI - Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type. PG - 173 LID - 10.1007/s11701-025-03059-w [doi] AB - To compare early and late complications rates after robot-assisted radical cystectomy for muscle invasive bladder tumors and certain high-risk non-muscle-invasive tumors according to the type of reconstruction. We conducted a single-center retrospective study including 109 patients who underwent robot-assisted radical cystectomy between 2008 and 2022. Patients were divided into two groups based on urinary diversion: extracorporeal Bricker ileal conduit (n = 74) or orthotopic neobladder (n = 35). Complications were graded by the Clavien-Dindo classification. Multivariate analysis identified independent risk factors for morbidity and mortality. Operative time was significantly longer for neobladder reconstruction (320 vs. 291 min, p = 0.047), as was hospital stay (14 vs. 10 days, p < 0.001). Early complications (< 30 days) occurred in 59.6% of patients, with a higher rate of minor complications in the neobladder group (57.1% vs. 28.4%, p = 0.006). There was no significant difference in major complications (Clavien III-V) or late complications (> 30 days), which affected 47.7% of patients. Operative time was an independent risk factor for major complications (OR = 1.15 per additional 15 min). Neobladder reconstruction was associated with increased early morbidity, mainly minor, without impact on late morbidity or mortality. Urinary diversion choice should be guided by patient profile and expected functional benefits. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Deniaud, Corentin AU - Deniaud C AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. corentin.deniaud@chu-nantes.fr. FAU - Mesnard, Benoit AU - Mesnard B AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. FAU - Bobet, Soline AU - Bobet S AD - Department of Clinical Database, University Hospital of Nantes, Nantes, France. FAU - Perrouin-Verbe, Marie-Aimee AU - Perrouin-Verbe MA AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. FAU - Branchereau, Julien AU - Branchereau J AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. FAU - De Vergie, Stephane AU - De Vergie S AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. FAU - Rigaud, Jerome AU - Rigaud J AD - Department of Urology, University Hospital of Nantes, 1, Place Alexis- Ricordeau, Nantes Cedex 1, 44093, France. LA - eng PT - Journal Article DEP - 20260114 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - Humans MH - *Cystectomy/methods/mortality/adverse effects MH - *Robotic Surgical Procedures/methods/mortality/adverse effects MH - *Urinary Diversion/methods/mortality/adverse effects MH - *Urinary Bladder Neoplasms/surgery/mortality MH - Female MH - Male MH - Retrospective Studies MH - *Postoperative Complications/epidemiology/mortality MH - Middle Aged MH - Aged MH - Operative Time MH - Risk Factors MH - Length of Stay OTO - NOTNLM OT - Bladder cancer OT - Morbidity, mortality, urinary diversion OT - Robotic-assisted radical cystectomy COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/01/14 12:31 MHDA- 2026/01/14 12:32 CRDT- 2026/01/14 11:20 PHST- 2025/11/02 00:00 [received] PHST- 2025/12/08 00:00 [accepted] PHST- 2026/01/14 12:32 [medline] PHST- 2026/01/14 12:31 [pubmed] PHST- 2026/01/14 11:20 [entrez] AID - 10.1007/s11701-025-03059-w [pii] AID - 10.1007/s11701-025-03059-w [doi] PST - epublish SO - J Robot Surg. 2026 Jan 14;20(1):173. doi: 10.1007/s11701-025-03059-w. PMID- 41528510 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jan 13 TI - Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder. PG - 91 LID - 10.1007/s00345-025-06178-z [doi] AB - PURPOSE: Repeat transurethral resection (re-TURBT) is recommended for all patients with high-risk bladder cancer to improve staging and oncologic outcomes. However, contemporary evidence on the role of re-TURBT is lacking. We therefore examined the contemporary rates of upstaging at re-TURBT and the association of re-TURBT with disease recurrence and progression. MATERIALS AND METHODS: We identified patients with an incident diagnosis of high-grade Ta, low-grade T1 and high-grade T1 urothelial carcinoma of the bladder between 2010 and 2022. The association of re-TURBT with disease recurrence and progression was evaluated using Cox regression. Rates and predictors of residual tumor and upstaging at re-TURBT were evaluated using univariable logistic regression. RESULTS: A total of 328 patients were included, of whom 88 (27%) underwent re-TURBT. Among those who underwent re-TURBT, 9 (10%) were upstaged to >/= T2, while 39 (44%) were found to have residual non-muscle invasive disease. Median follow-up time was 13 and 24 months for RFS and PFS, respectively. In a multivariable analysis, re-TURBT was not associated with a significant difference in disease recurrence or progression compared with no re-TURBT. In unadjusted analysis, a higher Charlson index was associated with an increased risk of upstaging and residual tumors. A greater number of tumors was associated with increased risks of residual tumor at re-TURBT. CONCLUSIONS: In a contemporary cohort of patients with bladder cancer, the rate of upstaging at re-TURBT was 10%, lower than historical studies. The rate of residual non-muscle invasive disease remains high at 44%. Re-TURBT was not associated with a statistically significant difference in disease recurrence or progression. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Perez-Londono, Agustin AU - Perez-Londono A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Kaul, Sumedh AU - Kaul S AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Fleishman, Aaron AU - Fleishman A AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Korets, Ruslan AU - Korets R AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Rayala, Heidi AU - Rayala H AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Chang, Peter AU - Chang P AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Wagner, Andrew A AU - Wagner AA AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Olumi, Aria F AU - Olumi AF AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA. bgershma@bidmc.harvard.edu. LA - eng PT - Journal Article DEP - 20260113 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Transurethral Resection of Bladder MH - *Non-Muscle Invasive Bladder Neoplasms/surgery/pathology MH - Female MH - *Reoperation MH - Male MH - Aged MH - Neoplasm Recurrence, Local/epidemiology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Disease Progression MH - Neoplasm Staging MH - Retrospective Studies MH - Treatment Outcome MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Neoplasm, Residual OTO - NOTNLM OT - Re-TURBT OT - Bladder cancer OT - Progression OT - Re-resection OT - Recurrence OT - Residual tumor OT - Upstaging COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2026/01/13 13:15 MHDA- 2026/01/13 13:16 CRDT- 2026/01/13 11:17 PHST- 2025/06/29 00:00 [received] PHST- 2025/12/28 00:00 [accepted] PHST- 2026/01/13 13:16 [medline] PHST- 2026/01/13 13:15 [pubmed] PHST- 2026/01/13 11:17 [entrez] AID - 10.1007/s00345-025-06178-z [pii] AID - 10.1007/s00345-025-06178-z [doi] PST - epublish SO - World J Urol. 2026 Jan 13;44(1):91. doi: 10.1007/s00345-025-06178-z. PMID- 41526868 OWN - NLM STAT- MEDLINE DCOM- 20260210 LR - 20260626 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 26 IP - 1 DP - 2026 Jan 12 TI - Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer. PG - 38 LID - 10.1186/s12894-026-02045-0 [doi] LID - 38 AB - BACKGROUND: This study aimed to systematically compare the most recent guidelines from the European Association of Urology (EAU, 2025), American Urological Association (AUA, 2024), and National Comprehensive Cancer Network (NCCN, 2025) for the management of non-muscle invasive bladder cancer (NMIBC). The primary objective was to assess the degree of concordance and identify sources of divergence across 32 predefined clinical decision domains. MATERIALS AND METHODS: This guideline concordance study was conducted according to PRISMA 2020 recommendations, evaluating full-text versions of the latest EAU, AUA, and NCCN guidelines. Thirty-two clinical domains encompassing the diagnostic, therapeutic, and follow-up aspects of NMIBC management were pre-defined based on literature review and expert consensus. Two independent reviewers classified each domain for each guideline as full concordance, partial concordance, or discordance, with discrepancies resolved by a third reviewer. Inter-guideline agreement was quantified using Cohen's and Fleiss' kappa coefficients. RESULTS: Among the 32 domains analyzed, full concordance was identified in 19 domains (59.4%), partial concordance in 12 domains (37.5%), and discordance in 1 domain (3.1%). Inter-guideline reliability was high, with Cohen's kappa values ranging from 0.83 to 0.94 across pairs and an overall Fleiss' kappa of 0.74, indicating substantial agreement among the three guidelines. Clinically meaningful differences were mainly related to risk-stratification criteria, the management of BCG-unresponsive disease, the selective use of urinary biomarkers, and the endorsement of conservative strategies for recurrent low-grade tumors. CONCLUSION: Current international guidelines for NMIBC are highly consistent across the majority of clinical decision domains, providing a strong framework for evidence-based care. Residual differences reflect evolving evidence, regulatory environments, and the pace of integration of new diagnostics and therapeutics. Continued harmonization efforts and regular guideline updates are necessary to further optimize global NMIBC management. CI - (c) 2026. The Author(s). FAU - Aydin, Mehmet Erhan AU - Aydin ME AUID- ORCID: 0000-0002-3567-9987 AD - Department of Urology, University of Health Sciences Eskisehir City Health Application and Research Center, Eskisehir City Hospital, 71 Evler Neighborhood, Cavdarlar Street, Odunpazari/Eskisehir, Turkey. FAU - Aykac, Aykut AU - Aykac A AUID- ORCID: 0000-0001-7078-0135 AD - Department of Urology, University of Health Sciences Eskisehir City Health Application and Research Center, Eskisehir City Hospital, 71 Evler Neighborhood, Cavdarlar Street, Odunpazari/Eskisehir, Turkey. aykut.aykac@sbu.edu.tr. FAU - Kaya, Coskun AU - Kaya C AUID- ORCID: 0000-0002-7445-2304 AD - Department of Urology, University of Health Sciences Eskisehir City Health Application and Research Center, Eskisehir City Hospital, 71 Evler Neighborhood, Cavdarlar Street, Odunpazari/Eskisehir, Turkey. FAU - Sungur, Mustafa AU - Sungur M AUID- ORCID: 0000-0001-8602-1723 AD - Department of Urology, University of Health Sciences Eskisehir City Health Application and Research Center, Eskisehir City Hospital, 71 Evler Neighborhood, Cavdarlar Street, Odunpazari/Eskisehir, Turkey. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260112 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - Humans MH - *Practice Guidelines as Topic MH - Societies, Medical MH - Urology MH - Europe MH - United States MH - *Urinary Bladder Neoplasms/therapy/pathology PMC - PMC12888563 OTO - NOTNLM OT - AUA OT - Artificial intelligence OT - BCG-unresponsive OT - Biomarkers OT - Concordance OT - EAU OT - Guideline comparison OT - Molecular profiling OT - NCCN OT - Non-muscle invasive bladder cancer COIS- Declarations. Ethics approval and consent to participate: Ethics committee approval was not required for this study as it did not involve human participants, or identifiable patient information. Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. EDAT- 2026/01/13 00:25 MHDA- 2026/02/10 06:31 PMCR- 2026/01/12 CRDT- 2026/01/12 23:47 PHST- 2025/06/18 00:00 [received] PHST- 2026/01/02 00:00 [accepted] PHST- 2026/02/10 06:31 [medline] PHST- 2026/01/13 00:25 [pubmed] PHST- 2026/01/12 23:47 [entrez] PHST- 2026/01/12 00:00 [pmc-release] AID - 10.1186/s12894-026-02045-0 [pii] AID - 2045 [pii] AID - 10.1186/s12894-026-02045-0 [doi] PST - epublish SO - BMC Urol. 2026 Jan 12;26(1):38. doi: 10.1186/s12894-026-02045-0. PMID- 41526608 OWN - NLM STAT- MEDLINE DCOM- 20260112 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jan 13 TI - Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer. PG - 84 LID - 10.1007/s00345-025-06170-7 [doi] AB - OBJECTIVE: To evaluate the oncological outcomes of second-look transurethral resection of bladder tumor (TURBT) in patients with a high grade (HG) Ta non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We conducted a real-life multicenter study including all consecutive patients with HG Ta NMIBC, with or without second TURBT. Oncological outcomes included disease recurrence and progression. Multivariable Cox regression analyses were used to identify the independent predictors of bladder recurrence and progression. RESULTS: Of the 447 patients with HG Ta NMIBC, 240 (53.7%) underwent a second TURBT, while 207 (46.3%) did not. After a median follow-up of 30 [15-54] months, Kaplan Meier curves showed that a second TURBT was associated with significantly higher 5-year recurrence-free survival (RFS) rate but similar 5-year progression-free survival (PFS) rate. Multivariable Cox regression analysis reported that a second TURBT was not significantly associated with RFS (HR = 0.76; 95% CI=[0.50-1.16]; p = 0.2) and PFS (HR = 0.76; 95% CI=[0.37-1.56]; p = 0.4). Among the 240 patients underwent second TURBT, 151 (63%) had no residual disease. The 5-year RFS and 5-year PFS were significantly higher in patients without residual tumor at second TURBT. Multivariable Cox regression analysis confirmed that residual bladder tumor at second TURBT was the only independent predictor of bladder recurrence (HR = 1.28; p = 0.02) and progression (HR = 1.38; p = 0.03). CONCLUSION: Based on the results of our multicenter retrospective study, a systematic second TURBT in HG Ta NMIBC does not significantly improve oncologic outcomes. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Regnier, Sophie AU - Regnier S AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Budowski, Alexandra AU - Budowski A AD - Department of Anesthesiology, University of Zurich, University Hospital Zurich, Zurich, 8091, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Clinique Pasteur, Toulouse, France. FAU - Maestro, Mario Alvarez AU - Maestro MA AD - Servicio Urologia, Hospital Universitario La Paz, Madrid, Spain. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Veerman, Hans AU - Veerman H AD - Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Di Bona, Carlo AU - Di Bona C AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy. FAU - Thenault, Ronan AU - Thenault R AD - Department of Urology, Service d'urologie, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, Service d'urologie, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Gontero, Paolo AU - Gontero P AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. evanguelos.xylinas@aphp.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260113 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - *Cystectomy/methods MH - Retrospective Studies MH - Neoplasm Grading MH - *Second-Look Surgery/methods MH - Urethra MH - Neoplasm Recurrence, Local/epidemiology MH - Aged, 80 and over MH - Disease Progression MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Detrusor muscle OT - High-grade OT - Non-muscle invasive bladder cancer OT - Second look OT - Ta COIS- Declarations. Conflict of interest: The authors declare no conflict of interest. Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2026/01/13 00:25 MHDA- 2026/01/13 00:26 CRDT- 2026/01/12 23:29 PHST- 2025/10/07 00:00 [received] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/01/13 00:26 [medline] PHST- 2026/01/13 00:25 [pubmed] PHST- 2026/01/12 23:29 [entrez] AID - 10.1007/s00345-025-06170-7 [pii] AID - 10.1007/s00345-025-06170-7 [doi] PST - epublish SO - World J Urol. 2026 Jan 13;44(1):84. doi: 10.1007/s00345-025-06170-7. PMID- 41524744 OWN - NLM STAT- MEDLINE DCOM- 20260423 LR - 20260626 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 78 IP - 2 DP - 2026 Apr TI - Machine learning methods for predicting early recurrence in Ta stage bladder cancer and comparison with conventional statistical methods. PG - 232-240 LID - 10.23736/S2724-6051.25.06385-2 [doi] AB - BACKGROUND: Predicting whether recurrence will occur during follow-up in bladder cancer cases confined to the mucosa (Ta-stage) is one of the crucial aspects of management. In this study, we aimed to compare the models obtained by conventional statistical methods and machine learning (ML) methods in order to predict the development of recurrence in the 2-year postoperative period in Ta stage Non-Muscle Invasive Bladder Cancers. METHODS: The data of patients who underwent complete transurethral resection of the bladder and were found to have Ta pathologies due to primary bladder cancer between 2018-2021 was retrospectively screened. Patients with no recurrence during the two-year follow-up were classified as Group 1 (N.=107, 58.2%), and those with recurrence were classified as Group 2 (N.=77, 41.8%). The demographic, clinical, imaging and pathological data were recorded. These parameters were analyzed using a conventional statistical method and ML methods to construct prediction models. RESULTS: Body Mass Index, American Society of Anesthesiologists (ASA) score, and the presence of macroscopic hematuria were found to be significant variables to predict early recurrence (P<0.05). The prediction model created by Cox-regression analysis was determined to have a sensitivity of 65%, specificity of 63.6%, and an area under the curve (AUC) value of 66%, while the AUC values achieved by the ML methods, namely random forest, logistic regression, and k-nearest neighbors, were calculated to be 0.75, 0.87 and 0.74, respectively. CONCLUSIONS: Models developed using ML can provide more accurate predictions than conventional statistical methods in predicting the recurrence of Ta bladder cancer. FAU - Sungur, Ubeyd AU - Sungur U AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye - ubeydsungur@gmail.com. FAU - Bitkin, Alper AU - Bitkin A AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. FAU - Eksi, Mithat AU - Eksi M AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. FAU - Polat, Hakan AU - Polat H AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. FAU - Tasci, Ali I AU - Tasci AI AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkiye. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260112 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/diagnosis/epidemiology MH - Female MH - Retrospective Studies MH - Male MH - *Machine Learning MH - Non-Muscle Invasive Bladder Neoplasms MH - Predictive Learning Models MH - Aged MH - Transurethral Resection of Bladder MH - Neoplasm Staging MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Random Forest MH - Prediction Algorithms MH - Classification Algorithms EDAT- 2026/01/12 13:14 MHDA- 2026/04/23 12:52 CRDT- 2026/01/12 11:02 PHST- 2026/04/23 12:52 [medline] PHST- 2026/01/12 13:14 [pubmed] PHST- 2026/01/12 11:02 [entrez] AID - S2724-6051.25.06385-2 [pii] AID - 10.23736/S2724-6051.25.06385-2 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2026 Apr;78(2):232-240. doi: 10.23736/S2724-6051.25.06385-2. Epub 2026 Jan 12. PMID- 41521375 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jan 11 TI - Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study. PG - 82 LID - 10.1007/s00345-025-06179-y [doi] AB - INTRODUCTION: Patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) face a high risk of disease progression. While radical cystectomy (RC) remains the recommended standard of care, many patients are unfit for or unwilling to undergo radical surgery, leading to bladder-sparing strategies spreading in real-world practice. This study aims to describe the oncological outcomes of patients diagnosed with BCG-unresponsive NMIBC treated with gemcitabine/docetaxel (Gem/Doce), electromotive drug administration of mitomycin C (EMDA/MMC), further BCG, or upfront RC. METHODS: We included patients diagnosed with BCG-unresponsive NMIBC treated across 21 European centers (2009-2024) with either intravesical Gem/Doce, EMDA/MMC, further BCG, or upfront RC. Cumulative incidence curves were used to estimate the risk of recurrence, high-grade recurrence, progression, cancer-specific and overall mortality. Multivariable Cox regression models were used to assess the association between treatment type and the risk of recurrence and progression. RESULTS: Of the 361 patients, 104 (28%) received Gem/Doce, 58 (16%) EMDA/MMC, 150 (42%) further BCG, and 49 (14%) underwent RC. Overall median follow-up was 73 months. Recurrence and high-grade recurrence rates were comparable between Gem/Doce and EMDA/MMC (adjusted HR: 1.30 and 0.40, respectively; both p > 0.5). The 2-year risk of progression was 15% with Gem/Doce, 20% with EMDA/MMC, and 30% with further BCG (p < 0.001). In multivariable analysis, Gem/Doce was associated with a significantly lower risk of progression compared to further BCG (adjusted HR: 0.19, 95% CI 0.09-0.43; p < 0.001). The 2-year cancer-specific mortality was 0% for both Gem/Doce and EMDA/MMC, 4% for BCG, and 7% for RC, with corresponding other-cause mortality rates of 3%, 8%, 11%, and 8%, respectively. CONCLUSIONS: In real-world practice, our study indicates that both Gem/Doce and EMDA/MMC represent viable treatment bladder-sparing options for patients with BCG-unresponsive NMIBC who refuse or are unfit for RC. For patients eligible and consenting to surgery, RC remains the guideline-endorsed standard. Prospective trials are warranted to define the optimal therapeutic algorithm for this challenging patient population. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Cosenza, Andrea AU - Cosenza A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Gabriel, Pierre Etienne AU - Gabriel PE AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Dutto, Daniele AU - Dutto D AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Katzendorn, Olga AU - Katzendorn O AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Elena, Jose Luis Rodriguez AU - Elena JLR AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Clinica Universidad De Navarra, Pamplona, Spain. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Fernandez, Ana AU - Fernandez A AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Szostek, Aleksandra AU - Szostek A AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Uro-Oncology Program, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Uro-Oncology Program, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Bazan, Alfredo Aguilera AU - Bazan AA AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. AD - Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany. FAU - du Biest, Albane Massiet AU - du Biest AM AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Ferrando, Valentina AU - Ferrando V AD - Department of Urology, Hospital Universitari de Bellvitge, Barcelona, Spain. FAU - Buisan, Oscar AU - Buisan O AD - Department of Urology, Hospital Universitari de Bellvitge, Barcelona, Spain. FAU - Lopez, Angela Villares AU - Lopez AV AD - Department of Urology, University Hospital of Toledo, Toledo, Spain. FAU - Zazzara, Michele AU - Zazzara M AD - Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", Acquaviva Delle Fonti, Italy. FAU - Ludovico, Giuseppe Mario AU - Ludovico GM AD - Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", Acquaviva Delle Fonti, Italy. FAU - Carando, Roberto AU - Carando R AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - Sant'Anna Clinic, Swiss Medical Group, Sorengo, Switzerland. AD - Belegarzt Fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. moschini.marco@hsr.it. AD - Vita-Salute San Raffaele University, Milan, Italy. moschini.marco@hsr.it. CN - European Association of Urology -Young Academic Urologists (EAU-YAU) CN - Urothelial carcinoma working group CN - EuroGemDoce Study Group Collaborators LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260111 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 50SG953SK6 (Mitomycin) RN - 15H5577CQD (Docetaxel) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/therapy MH - *BCG Vaccine/therapeutic use MH - Female MH - Male MH - Aged MH - Treatment Outcome MH - *Organ Sparing Treatments/methods MH - Gemcitabine MH - Deoxycytidine/analogs & derivatives/administration & dosage MH - Middle Aged MH - Cystectomy MH - Retrospective Studies MH - Mitomycin/administration & dosage/therapeutic use MH - Docetaxel/administration & dosage MH - Disease Progression MH - *Urinary Bladder Neoplasms/pathology/drug therapy OTO - NOTNLM OT - BCG-unresponsive OT - Bacillus Calmette-Guerin OT - Bladder-sparing therapy OT - EMDA OT - Gemcitabine and Docetaxel OT - Non-muscle invasive bladder cancer OT - Oncological outcomes OT - Survival COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. EDAT- 2026/01/12 00:37 MHDA- 2026/06/27 06:43 CRDT- 2026/01/11 23:16 PHST- 2025/10/21 00:00 [received] PHST- 2025/12/28 00:00 [accepted] PHST- 2026/06/27 06:43 [medline] PHST- 2026/01/12 00:37 [pubmed] PHST- 2026/01/11 23:16 [entrez] AID - 10.1007/s00345-025-06179-y [pii] AID - 10.1007/s00345-025-06179-y [doi] PST - epublish SO - World J Urol. 2026 Jan 11;44(1):82. doi: 10.1007/s00345-025-06179-y. PMID- 41520313 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 7 DP - 2026 Jul TI - Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis. PG - 2355-2364 LID - 10.1007/s11255-026-05008-4 [doi] AB - OBJECTIVE: To systematically evaluate the comparative efficacy and safety of hyperthermic intravesical chemotherapy (HIVEC) versus bacillus Calmette-Guerin (BCG) instillation in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: A systematic literature search was conducted across PubMed, Embase, the Cochrane Library, and CBM from inception to June 30, 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420251075299. Randomized controlled trials and cohort studies comparing HIVEC with BCG in NMIBC patients were included. Primary outcomes were 24-month recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included adverse events. Risk ratios (RRs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using fixed- or random-effects models. RESULTS: Seven studies involving 820 patients were included. The meta-analysis showed no significant differences between HIVEC and BCG in 24-month RFS (RR = 1.01, 95% CI: 0.90-1.12), PFS (RR = 1.00, 95% CI: 0.95-1.05), or OS (RR = 0.99, 95% CI: 0.91-1.09). However, BCG was associated with a significantly higher incidence of dysuria (RR = 1.38, 95% CI: 0.57-3.37). No significant differences were observed in other adverse events such as urinary tract infection, hematuria, or pain. CONCLUSION: HIVEC demonstrates comparable oncological efficacy to BCG in terms of 24-month RFS, PFS, and OS for NMIBC patients, while offering a better tolerability profile with a significantly lower risk of dysuria. These findings support HIVEC as a valuable alternative treatment option, particularly in the context of BCG shortages or for BCG-intolerant patients. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Chai, Yucong AU - Chai Y AD - School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Zhou, YinXiong AU - Zhou Y AD - School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Peng, Hao AU - Peng H AD - School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Jiang, Yuqi AU - Jiang Y AD - Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Qingyang District, Chengdu, 610072, China. FAU - Dai, Junzhe AU - Dai J AD - Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Qingyang District, Chengdu, 610072, China. FAU - Liu, Jing AU - Liu J AD - Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Qingyang District, Chengdu, 610072, China. liujingmn@med.uestc.edu.cn. LA - eng GR - 2023YFS0257/Science & Technology Department of Sichuan Province/ PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260111 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Hyperthermia, Induced MH - Administration, Intravesical MH - Treatment Outcome MH - *Adjuvants, Immunologic/administration & dosage MH - *Urinary Bladder Neoplasms/pathology/therapy OTO - NOTNLM OT - BCG Instillation Therapy OT - Bladder Cancer OT - Microbiota-Immune Interactions OT - Multi-omics Integration OT - Treatment Resistance OT - Urinary Microbiome COIS- Declarations. Conflicts of interest: The authors declare no competing interests. EDAT- 2026/01/11 17:49 MHDA- 2026/06/27 00:57 CRDT- 2026/01/11 11:04 PHST- 2025/11/03 00:00 [received] PHST- 2026/01/05 00:00 [accepted] PHST- 2026/06/27 00:57 [medline] PHST- 2026/01/11 17:49 [pubmed] PHST- 2026/01/11 11:04 [entrez] AID - 10.1007/s11255-026-05008-4 [pii] AID - 10.1007/s11255-026-05008-4 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Jul;58(7):2355-2364. doi: 10.1007/s11255-026-05008-4. Epub 2026 Jan 11. PMID- 41516353 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 1 DP - 2026 Jan 2 TI - Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers. LID - 10.3390/ijms27010476 [doi] LID - 476 AB - Neoadjuvant chemotherapy (NACT) is the standard treatment for muscle-invasive bladder carcinoma (MIBC), but its efficacy varies significantly among patients. The aim of this study is the identification of biomarkers and biological processes related to the response to neoadjuvant chemotherapy (NACT) in muscle-invasive bladder carcinoma (MIBC). Fifty-eight transurethral resection (TURBT) samples and thirty cystectomy samples from NACT non-responders were analyzed using mass spectrometry. Samples were classified with sparse k-means and consensus clustering. Protein networks were built using probabilistic graphical models, grouped into functional nodes, and analyzed for activity differences. Gene set enrichment analysis was applied to identify resistance mechanisms, and results were validated using The Cancer Genome Atlas (TCGA) cohort. Proteomic analysis revealed two independent classifications in TURBT samples. The first (Layer1) divided tumors into three groups, including one NACT non-responder subtype not aligned with traditional luminal or basal classifications but characterized by high expression of targetable markers NECTIN4 and Her2. The second (Layer3) separated luminal-papillary tumors from luminal-infiltrated/luminal and basal tumors. While Layer3 groups did not differ in NACT response, they showed distinct disease-free survival outcomes. Importantly, complete response to NACT was linked to improved survival in luminal subgroups but not in basal tumors, suggesting subtype-specific prognostic implications. Finally, analysis of cystectomy samples identified unique mechanisms of resistance for each subgroup, suggesting tailored therapeutic approaches. Two classification systems were defined as follows: one identified a proteomics-based non-responder group with actionable targets, and the other linked tumor subtype to prognosis. Distinct resistance mechanisms suggest opportunities for subtype-specific therapies, supporting improved management and treatment development for MIBC patients. FAU - Trilla-Fuertes, Lucia AU - Trilla-Fuertes L AUID- ORCID: 0000-0002-4452-3474 AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Pedregosa-Barbas, Jorge AU - Pedregosa-Barbas J AD - Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Garcia-Fernandez, Eugenia AU - Garcia-Fernandez E AUID- ORCID: 0000-0002-3850-1906 AD - Department of Pathology, La Paz University Hospital-IdiPAZ, UAM, 28046 Madrid, Spain. FAU - Zambrana, Francisco AU - Zambrana F AUID- ORCID: 0000-0003-2815-7731 AD - Medical Oncology Department, Infanta Sofia University Hospital, 28702 Madrid, Spain. FAU - Martinez-Salas, Imanol AU - Martinez-Salas I AD - Medical Oncology Department, IIS-FJD, University Hospital Fundacion Jimenez Diaz, 28040 Madrid, Spain. FAU - Gajate, Pablo AU - Gajate P AUID- ORCID: 0000-0001-5156-7080 AD - Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Becerril-Gomez, Fernando AU - Becerril-Gomez F AUID- ORCID: 0009-0007-3726-050X AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Lalanda-Delgado, Pedro AU - Lalanda-Delgado P AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Dittmann, Antje AU - Dittmann A AUID- ORCID: 0000-0002-2570-5192 AD - Functional Genomics Center Zurich, University of Zurich/ETH Zurich, 8057 Zurich, Switzerland. FAU - Lopez-Vacas, Rocio AU - Lopez-Vacas R AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Kunz, Laura AU - Kunz L AD - Functional Genomics Center Zurich, University of Zurich/ETH Zurich, 8057 Zurich, Switzerland. FAU - Rubio, Gustavo AU - Rubio G AD - Medical Oncology Department, Infanta Sofia University Hospital, 28702 Madrid, Spain. FAU - Nieto-Torrero, Sandra AU - Nieto-Torrero S AD - IdiPAZ Biobank, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain. FAU - Pertejo, Ana AU - Pertejo A AD - Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Gonzalez-Peramato, Pilar AU - Gonzalez-Peramato P AD - Department of Pathology, La Paz University Hospital-IdiPAZ, UAM, 28046 Madrid, Spain. FAU - Fresno Vara, Juan Angel AU - Fresno Vara JA AUID- ORCID: 0000-0003-1527-1252 AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. AD - Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, 28029 Madrid, Spain. FAU - Gamez-Pozo, Angelo AU - Gamez-Pozo A AUID- ORCID: 0000-0002-8931-0624 AD - Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. AD - Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, 28029 Madrid, Spain. FAU - Pinto-Marin, Alvaro AU - Pinto-Marin A AUID- ORCID: 0000-0002-4719-053X AD - Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain. LA - eng GR - 823839/European Proteomics Infrastructure Consortium/ PT - Journal Article DEP - 20260102 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/metabolism/genetics MH - *Neoadjuvant Therapy MH - *Biomarkers, Tumor/metabolism/genetics MH - Proteomics/methods MH - Transurethral Resection of Bladder MH - Female MH - Male MH - Aged MH - Prognosis MH - Neoplasm Invasiveness PMC - PMC12787041 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - proteomics subtype OT - response to neoadjuvant chemotherapy OT - targetable biomarkers COIS- The authors declare no conflicts of interest. EDAT- 2026/01/10 06:31 MHDA- 2026/01/10 06:32 PMCR- 2026/01/02 CRDT- 2026/01/10 01:10 PHST- 2025/11/18 00:00 [received] PHST- 2025/12/19 00:00 [revised] PHST- 2025/12/31 00:00 [accepted] PHST- 2026/01/10 06:32 [medline] PHST- 2026/01/10 06:31 [pubmed] PHST- 2026/01/10 01:10 [entrez] PHST- 2026/01/02 00:00 [pmc-release] AID - ijms27010476 [pii] AID - ijms-27-00476 [pii] AID - 10.3390/ijms27010476 [doi] PST - epublish SO - Int J Mol Sci. 2026 Jan 2;27(1):476. doi: 10.3390/ijms27010476. PMID- 41514644 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260110 LR - 20260113 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 1 DP - 2025 Dec 31 TI - Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers18010136 [doi] LID - 136 AB - INTRODUCTION: Prompt diagnosis and differentiation between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) are essential in the treatment of bladder cancer. Inflammation-based biomarkers have recently emerged as potential tools for improving cancer diagnostics and prognostication. This study aims to evaluate the potential value of the Systemic Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), Pan-immune Inflammation Value (PIV), and Platelet-to-Lymphocyte Ratio (PLR) as predictors of muscle-invasive disease. MATERIALS AND METHODS: Analyzed data included 310 bladder tumors. The SII, SIRI, PIV, and PLR were calculated from pre-TURBT complete blood-count results. Differences in inflammatory markers between pathological stages (pTa-pT4) were examined using ANOVA with Tukey's post hoc testing. Optimal cutoff values for distinguishing NMIBC from MIBC were identified using ROC curve analysis and Youden's J statistic. Logistic regression models incorporating age, sex, the number of recurrences, and each inflammatory index were developed to evaluate their predictive performance in patients treated with curative intent. RESULTS: All investigated inflammation indices significantly differed across tumor stages (p < 0.001), with lower values observed in pTa tumors compared with muscle-invasive disease. Determined cutoff values for muscle-invasive disease were 865.63 for SII, 2.02 for SIRI, 579.28 for PIV, and 166.35 for PLR. Logistic regression models demonstrated promising diagnostic performance, achieving AUC values of 0.812 (SII), 0.816 (SIRI), 0.821 (PIV), and 0.795 (PLR); sensitivity and specificity were 76% and 75% for SII, 79% and 77% for SIRI, 80% and 72% for PIV, and 88% and 59% for PLR. DISCUSSION: The presented results indicate that inflammation-based indices vary meaningfully between bladder cancer stages and may be utilized in early identification of muscle-invasive disease. As inexpensive and widely available biomarkers, they offer potential value in the evaluation of suspected MIBC before the final pathology report and could enhance the diagnostic process. FAU - Jaromin, Maciej AU - Jaromin M AUID- ORCID: 0009-0008-9825-2543 AD - 1st Urology Department, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Kutwin, Piotr AU - Kutwin P AUID- ORCID: 0000-0002-6681-3982 AD - 1st Urology Department, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Konecki, Tomasz AU - Konecki T AD - 1st Urology Department, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Popiela, Dariusz AU - Popiela D AD - 1st Urology Department, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Kamecki, Mateusz AU - Kamecki M AD - Department of Chemotherapy, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Kurowski, Marcin AU - Kurowski M AUID- ORCID: 0000-0002-0653-7533 AD - Department of Immunology and Allergy, Medical University of Lodz, 90-419 Lodz, Poland. LA - eng PT - Journal Article DEP - 20251231 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12784776 OTO - NOTNLM OT - MICB OT - NMICB OT - PIV OT - PLR OT - SII OT - SIRI OT - bladder cancer OT - diagnostics OT - inflammation index OT - inflammation indices OT - prediction model COIS- The authors declare no conflicts of interest. EDAT- 2026/01/10 06:31 MHDA- 2026/01/10 06:32 PMCR- 2025/12/31 CRDT- 2026/01/10 01:02 PHST- 2025/11/15 00:00 [received] PHST- 2025/12/23 00:00 [revised] PHST- 2025/12/27 00:00 [accepted] PHST- 2026/01/10 06:32 [medline] PHST- 2026/01/10 06:31 [pubmed] PHST- 2026/01/10 01:02 [entrez] PHST- 2025/12/31 00:00 [pmc-release] AID - cancers18010136 [pii] AID - cancers-18-00136 [pii] AID - 10.3390/cancers18010136 [doi] PST - epublish SO - Cancers (Basel). 2025 Dec 31;18(1):136. doi: 10.3390/cancers18010136. PMID- 41501950 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1470-7330 (Electronic) IS - 1740-5025 (Print) IS - 1470-7330 (Linking) VI - 26 IP - 1 DP - 2026 Jan 7 TI - Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study. PG - 21 LID - 10.1186/s40644-025-00984-9 [doi] LID - 21 AB - BACKGROUND: Accurate preoperative evaluation of lymph node (LN) status is crucial for guiding precise treatment. Although several methods have been developed for preoperative evaluation of LN status, accurate evaluation remains a challenge. OBJECTIVE: To develop and validate MRI-based clinical prediction models for the preoperative assessment of lymph node metastasis (LNM) in patients with very high risk non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MATERIALS AND METHODS: A total of 468 eligible patients with very high risk NMIBC and MIBC who underwent radical cystectomy and pelvic lymph node dissection from four hospitals were enrolled (derivation cohort, n=247; internal validation cohort, n=106; external validation cohort, n=115). Preoperative clinical characteristics were reviewed to identify significant predictors for constructing a nomogram and an integer-based model. The diagnostic performance of the nomogram and the integer-based model was compared using accuracy, sensitivity, specificity, and area under the curve (AUC). Kaplan-Meier survival curves were conducted to analyze the prognosis of patients. RESULTS: Multivariable analysis revealed that Node-RADS score and VI-RADS score were independent predictive factors for LNM. The nomogram based on these variables achieved an AUC of 0.885 for predicting LNM. An integer-based scoring system (NV score) was established, with an AUC of 0.883. Delong's test indicated no significant difference between two models (P=0.535). The NV score demonstrated excellent discrimination in both internal (AUC: 0.930) and external (AUC: 0.924) validation cohorts. The optimal cutoff value of the NV score for predicting LNM in all patients was determined to be >3. Patients with high-LNM risk had significantly worse overall survival (HR=3.473) and recurrence-free survival (HR=4.400). CONCLUSION: The MRI-based NV score can preoperatively assess LNM status and predict postoperative prognosis in BCa patients. FAU - Bai, Rongjie AU - Bai R AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. AD - Department of Urology, Wuxi Medical Center of Nanjing Medical University, Wuxi, 214043, China. FAU - Jiang, Meihua AU - Jiang M AD - Department of Radiology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, 210029, China. FAU - Wang, Chenghao AU - Wang C AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Tan, Zhengye AU - Tan Z AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Jiang, Xuping AU - Jiang X AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. AD - Department of Urology, Yixing People's Hospital, Wuxi, 214200, China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Tian, Wei AU - Tian W AD - Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. FAU - Wu, Chenjiang AU - Wu C AD - Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. FAU - Liu, Xiaotong AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450002, China. FAU - Liang, Bo AU - Liang B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. yangxiao2915@163.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital with Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Nanjing City, 210029, China. doctorlvqiang@njmu.edu.cn. LA - eng PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20260107 PL - England TA - Cancer Imaging JT - Cancer imaging : the official publication of the International Cancer Imaging Society JID - 101172931 SB - IM MH - Humans MH - *Lymphatic Metastasis/diagnostic imaging MH - Female MH - *Magnetic Resonance Imaging/methods MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - Male MH - Aged MH - Middle Aged MH - Nomograms MH - Lymph Node Excision MH - Prognosis MH - Cystectomy MH - Lymph Nodes/pathology/diagnostic imaging MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12870397 OTO - NOTNLM OT - Bladder cancer OT - Lymph node metastasis OT - Magnetic resonance imaging COIS- Declarations. Ethics approval and consent to participate: This study is a retrospective analysis and has received ethical approval from the Institutional Review Board (Approval Number: 2021-SR-409) of The First Affiliated Hospital of Nanjing Medical University. The study was conducted in strict accordance with the ethical principles outlined in the Declaration of Helsinki. Given the retrospective nature of the study, the requirement for informed consent was waived by the ethics committee. Consent to participate: Written informed consent was obtained from patients for the use of their relevant information. Competing interests: The authors declare no competing interests. EDAT- 2026/01/08 07:13 MHDA- 2026/06/27 06:44 PMCR- 2026/01/07 CRDT- 2026/01/08 00:12 PHST- 2025/09/11 00:00 [received] PHST- 2025/12/18 00:00 [accepted] PHST- 2026/06/27 06:44 [medline] PHST- 2026/01/08 07:13 [pubmed] PHST- 2026/01/08 00:12 [entrez] PHST- 2026/01/07 00:00 [pmc-release] AID - 10.1186/s40644-025-00984-9 [pii] AID - 984 [pii] AID - 10.1186/s40644-025-00984-9 [doi] PST - epublish SO - Cancer Imaging. 2026 Jan 7;26(1):21. doi: 10.1186/s40644-025-00984-9. PMID- 41492078 OWN - NLM STAT- MEDLINE DCOM- 20260224 LR - 20261009 IS - 1759-4782 (Electronic) IS - 1759-4774 (Linking) VI - 23 IP - 3 DP - 2026 Mar TI - Advances in the management of localized bladder cancers. PG - 158-179 LID - 10.1038/s41571-025-01104-z [doi] AB - Bladder cancer remains a substantial global health burden. Localized, non-metastatic bladder cancer encompasses a spectrum from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Advances in risk stratification, biomarker discovery and therapeutic innovation are reshaping the management of localized bladder cancers. Regarding NMIBC, enhanced cystoscopy techniques, en bloc transurethral resection and a multitude of novel systemic or intravesical treatment strategies, including immunomodulatory, viral, molecularly targeted and/or cytotoxic therapies as well as novel drug delivery mechanisms and chemoablation, are expanding treatment options, particularly for patients with Bacillus Calmette-Guerin-unresponsive disease. For patients with MIBC, refinements in surgical techniques and new neoadjuvant and/or adjuvant systemic therapies, particularly perioperative immunotherapy and potentially antibody-drug conjugates, continue to improve oncological outcomes. Bladder-preserving approaches such as trimodal therapy or even active surveillance following neoadjuvant therapy are also gaining clinical traction, offering selected patients with MIBC an alternative to radical cystectomy. Advances in the identification and application of circulating tumour DNA-based and tumour tissue-based biomarkers will help to further support personalized treatment and follow-up strategies. In this Review, we discuss progress and changes in the management of localized bladder cancer over the past decade and highlight ongoing innovations and future research directions that will shape clinical practice in the coming decade. CI - (c) 2026. Springer Nature Limited. FAU - St-Laurent, Marie-Pier AU - St-Laurent MP AUID- ORCID: 0000-0002-7823-4857 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. mst-laurent@prostatecentre.com. FAU - Nikkola, Jussi AU - Nikkola J AUID- ORCID: 0000-0002-5077-2012 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Tomiyama, Eisuke AU - Tomiyama E AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Black, Peter C AU - Black PC AUID- ORCID: 0000-0002-2919-7068 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Review DEP - 20260105 PL - England TA - Nat Rev Clin Oncol JT - Nature reviews. Clinical oncology JID - 101500077 RN - 0 (Biomarkers, Tumor) SB - IM EIN - Nat Rev Clin Oncol. 2026 Mar;23(3):230. doi: 10.1038/s41571-026-01121-6. PMID: 41554966 MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Neoadjuvant Therapy MH - Cystectomy/methods MH - Biomarkers, Tumor MH - Immunotherapy/methods COIS- Competing interests: The authors declare no competing interests. EDAT- 2026/01/06 13:05 MHDA- 2026/02/25 00:30 CRDT- 2026/01/06 11:43 PHST- 2025/11/03 00:00 [accepted] PHST- 2026/02/25 00:30 [medline] PHST- 2026/01/06 13:05 [pubmed] PHST- 2026/01/06 11:43 [entrez] AID - 10.1038/s41571-025-01104-z [pii] AID - 10.1038/s41571-025-01104-z [doi] PST - ppublish SO - Nat Rev Clin Oncol. 2026 Mar;23(3):158-179. doi: 10.1038/s41571-025-01104-z. Epub 2026 Jan 5. PMID- 41491719 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260730 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2026 Jan 5 TI - First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis. PG - 76 LID - 10.1007/s00345-025-06180-5 [doi] LID - 76 AB - PURPOSE: To evaluate novel intravesical and systemic combination therapies for improving outcomes in BCG-naive patients with non-muscle invasive bladder cancer (NMIBC), this systematic review and meta-analysis assessed first-line treatment strategies, including combinations with systemic immune-checkpoint inhibitors (ICIs). METHODS: In this prospectively registered review (CRD420251163026), MEDLINE, Embase, Web of Science, and the ESMO 2025 abstract book were searched for randomized controlled trials (RCTs) evaluating first-line therapies in BCG-naive NMIBC. Meta-analyses estimated HRs for recurrence-related time-to-event outcomes (disease-free and event-free survival). Grade >/= 3 treatment-related adverse events were pooled as relative risks (RRs). Risk of bias was assessed using the Cochrane RoB 2 tool. RESULTS: Out of 5202 records screened, six RCTs including 3485 patients were eligible. Modifications to intravesical BCG alone (three trials, n = 895) did not significantly improve recurrence-related outcomes. Systemic ICIs given additional to intravesical BCG significantly reduced recurrence-related events compared to BCG alone (HR 0.77, 95%CI 0.6-0.97, n = 1899; number needed to treat at two years: 25), but increased grade >/= 3 treatment-related adverse events by a statistically and clinically significant margin (RR 3.97, 95% CI 2.53-6.22, n = 1879; number needed to treat to harm one patient: 5). Sensitivity analysis using the ALBAN alternative endpoint of high-grade recurrence-free survival yielded HR 0.78 (95% CI 0.59-1.02), not reaching statistical significance. Limitations included heterogeneity in trial design and endpoint definitions. CONCLUSION: In BCG-naive NMIBC, systemic ICIs combined with intravesical BCG improve recurrence-related outcomes but are offset by a substantially increased risk of severe treatment-related adverse events. These findings highlight the need for careful, risk-based, biomarker-guided patient selection to balance over- and undertreatment within a shared decision-making process. FAU - Roessler, Navid AU - Roessler N AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. FAU - Maiorano, Brigida A AU - Maiorano BA AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Collegium Medicum, Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Miyajima, Keiichiro AU - Miyajima K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Inoue, Shota AU - Inoue S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, Medical University Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, Medical University Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, Department of Urology, AP-HP, Pitie Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology UROSUD, La Croix du Sud Hopital, Quint Fonsegrives, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, University of Torino School of Medicine, Citta della Salute e della Scienza, Torino, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, H2X 0A9, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260105 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Immune Checkpoint Inhibitors/therapeutic use MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/pathology/drug therapy PMC - PMC12769649 OTO - NOTNLM OT - Bacillus calmette guerin OT - Immune checkpoint inhibitors OT - Immunotherapy OT - Treatment outcome OT - Urinary bladder neoplasms COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and consent to participate: Not applicable. EDAT- 2026/01/06 13:06 MHDA- 2026/06/27 00:57 PMCR- 2026/01/05 CRDT- 2026/01/06 11:26 PHST- 2025/12/08 00:00 [received] PHST- 2025/12/28 00:00 [accepted] PHST- 2026/06/27 00:57 [medline] PHST- 2026/01/06 13:06 [pubmed] PHST- 2026/01/06 11:26 [entrez] PHST- 2026/01/05 00:00 [pmc-release] AID - 10.1007/s00345-025-06180-5 [pii] AID - 6180 [pii] AID - 10.1007/s00345-025-06180-5 [doi] PST - epublish SO - World J Urol. 2026 Jan 5;44(1):76. doi: 10.1007/s00345-025-06180-5. PMID- 41478781 OWN - NLM STAT- Publisher LR - 20260101 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2025 Dec 31 TI - Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival Free from Ipsilateral UTUC Recurrence. LID - S2588-9311(25)00328-1 [pii] LID - 10.1016/j.euo.2025.12.002 [doi] AB - BACKGROUND AND OBJECTIVE: Distal ureterectomy (DU) is a kidney-sparing option for low-risk upper tract urothelial carcinoma (UTUC) and may be considered for selected high-risk cases. Long-term outcomes and recurrence predictors remain poorly defined. Our aim was to evaluate oncological outcomes of DU and identify preoperative predictors of disease recurrence, with a particular focus on ipsilateral upper tract recurrence (iUTR). METHODS: This retrospective multicentre study included 450 patients with nonmetastatic UTUC in the distal ureter treated with DU and bladder cuff excision between 2010 and 2023. The primary endpoint was iUTR-free survival (iUTRFS). Secondary endpoints were intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), cancer-specific survival (CSS), overall survival (OS), and perioperative outcomes. Survival outcomes were visualised using Kaplan-Meier curves, and multivariable Cox regression analyses were performed. KEY FINDINGS AND LIMITATIONS: The 5-yr survival estimates were 82% for iUTRFS, 49% for IVRFS, 81% for RFS, 89% for CSS, and 72% for OS. IVRFS, iUTRFS, CSS, and OS did not significantly differ between the low-risk and high-risk groups. iUTR occurred in 16% of patients, with one in four of these cases arising after 5 yr. Salvage radical nephroureterectomy was performed in 10% of patients. Preoperative double-J stenting (hazard ratio [HR] 2.85, 95% confidence interval [CI] 1.11-7.30), tumour size (HR 1.04, 95% CI 1.01-1.07) and endoscopic bladder cuff management (HR 9.73, 95% CI 1.66-56.89) were independent predictors of iUTR. Perioperative complications were rare, with only 7% graded as high grade within 90 d. Limitations include the retrospective design, lack of centralised pathology review, and variability in surgical technique. CONCLUSIONS AND CLINICAL IMPLICATIONS: DU provides favourable perioperative and long-term oncological outcomes and may also be appropriate for selected high-risk cases. iUTR is not uncommon, and prolonged upper tract follow-up is essential. Avoidance of preoperative stenting and endoscopic bladder cuff management may reduce the risk of iUTR. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. Electronic address: francesco.soria@unito.it. FAU - Liedberg, Frederik AU - Liedberg F AD - Institution of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Stahl, Elin AU - Stahl E AD - Institution of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Centre, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Teoh, Jeremy Y-C AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Rai, Bhavan P AU - Rai BP AD - Department of Urology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Birtle, Alison AU - Birtle A AD - Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University of Manchester, Manchester, UK; University of Central Lancashire, Preston, UK. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Mariappan, Param AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, University of Edinburgh, Western General Hospital, Edinburgh, UK. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Seisen, Thomas AU - Seisen T AD - GRC 5 Predictive Onco-Uro, Sorbonne University, Paris, France; Department of Urology, Pitie-Salpetriere Hospital, AP-HP, Paris, France. FAU - Xylinas, Evanguelos N AU - Xylinas EN AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Centre, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Hourani Centre, Al-Ahliyya Amman University, Amman, Jordan. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, St. Louis Hospital, AP-HP, Universite de Paris, Paris, France. LA - eng PT - Journal Article DEP - 20251231 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Distal ureterectomy OT - Ipsilateral upper tract recurrence OT - Preoperative predictors OT - Survival OT - Upper tract urothelial carcinoma EDAT- 2026/01/02 00:33 MHDA- 2026/01/02 00:33 CRDT- 2026/01/01 22:00 PHST- 2025/08/25 00:00 [received] PHST- 2025/11/15 00:00 [revised] PHST- 2025/12/03 00:00 [accepted] PHST- 2026/01/02 00:33 [medline] PHST- 2026/01/02 00:33 [pubmed] PHST- 2026/01/01 22:00 [entrez] AID - S2588-9311(25)00328-1 [pii] AID - 10.1016/j.euo.2025.12.002 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328-1. doi: 10.1016/j.euo.2025.12.002. PMID- 41478774 OWN - NLM STAT- MEDLINE DCOM- 20260222 LR - 20260804 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 3 DP - 2026 Mar TI - Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials. PG - 204-209 LID - S0302-2838(25)04877-8 [pii] LID - 10.1016/j.eururo.2025.12.022 [doi] AB - Intravesical bacillus Calmette-Guerin (BCG) therapy remains the cornerstone for high-risk non-muscle-invasive bladder cancer (NMIBC), but up to 40% of patients experience disease recurrence or progression within 2 yr. We conducted a systematic review and meta-analysis of three phase 3 randomized trials POTOMAC, CREST, and ALBAN; n = 2590) in BCG-naive high-risk NMIBC disease treated with a combination of BCG and an immune checkpoint inhibitor (ICI). Overall risk of bias was low for all studies. Combination therapy with BCG maintenance was associated with better event-free survival (EFS) in comparison to BCG alone (pooled hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.60-0.99; Q = 3.29, p = 0.2). Using the HR for high-grade recurrence from ALBAN, the pooled estimate was directionally consistent, but not statistically significant (HR 0.78, 95% CI 0.58-1.04; Q = 3.94, p = 0.1). Overall survival was comparable between groups (HR 0.92, 95% CI 0.67-1.26). Grade >/=3 treatment-related adverse events were more frequent with combination therapy (risk ratio [RR] 3.66, 95% CI 2.56-5.24 for BCG induction only; RR 3.97, 95% CI 2.54-6.21 for BCG induction + maintenance). There was a moderate decline in patient-reported quality of life in the ICI + BCG maintenance arms. These findings are supported by moderate-certainty evidence for EFS. BCG monotherapy remains the benchmark for BCG-naive high-risk NMIBC. ICI addition improves EFS but increases high-grade toxicity, which should prompt cautious and individualized adoption pending mature survival data. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AD - Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Mercinelli, Chiara AU - Mercinelli C AD - Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy. FAU - Maiorano, Brigida AU - Maiorano B AD - Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: moschini.marco@hsr.it. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20251231 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Adjuvants, Immunologic) SB - IM EIN - Eur Urol. 2026 Aug;90(2):184. doi: 10.1016/j.eururo.2026.02.001. PMID: 41708452 MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Humans MH - *BCG Vaccine/administration & dosage/adverse effects/therapeutic use MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects/administration & dosage MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Randomized Controlled Trials as Topic MH - *Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Clinical Trials, Phase III as Topic MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder-sparing therapy OT - Checkpoint inhibitor OT - High-risk non-muscle-invasive bladder cancer OT - Immunotherapy OT - PD-1 blockade OT - PD-L1 inhibition OT - Treatment-naive EDAT- 2026/01/02 00:33 MHDA- 2026/02/23 01:34 CRDT- 2026/01/01 22:00 PHST- 2025/10/21 00:00 [received] PHST- 2025/12/15 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/02/23 01:34 [medline] PHST- 2026/01/02 00:33 [pubmed] PHST- 2026/01/01 22:00 [entrez] AID - S0302-2838(25)04877-8 [pii] AID - 10.1016/j.eururo.2025.12.022 [doi] PST - ppublish SO - Eur Urol. 2026 Mar;89(3):204-209. doi: 10.1016/j.eururo.2025.12.022. Epub 2025 Dec 31. PMID- 41478226 OWN - NLM STAT- MEDLINE DCOM- 20260304 LR - 20260304 IS - 1879-3320 (Electronic) IS - 0960-7404 (Linking) VI - 64 DP - 2026 Feb TI - Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights. PG - 102344 LID - S0960-7404(25)00159-8 [pii] LID - 10.1016/j.suronc.2025.102344 [doi] AB - INTRODUCTION: Bladder cancer is a major global health concern, and urothelial carcinoma (UC) often presents with diverse histologic subtypes and differentiations associated with aggressive behavior and poorer survival with no standardized treatment recommendations. This study aimed to compare clinicopathologic characteristics and survival outcomes between patients with histologic/divergent UC subtypes and those with pure UC at initial presentation. PATIENTS AND METHODS: We retrospectively analyzed 506 patients with de novo UC identified at initial transurethral resection of the bladder (TUR-BT) between 2015 and 2023. Demographic and clinical characteristics, pathologic features, treatment strategies, and survival outcomes were compiled and compared between groups. Treatment strategies, including radical cystectomy and neoadjuvant chemotherapy, were also evaluated to examine how histologic subtypes influenced clinical decision-making. RESULTS: Median follow-up period was 71 months (95 % CI, 68.0-74.0). Patients with histologic subtypes and divergent differentiations demonstrated significantly more aggressive tumor features at diagnosis, including higher rates of muscle invasion (46.1 % vs. 28.8 %, p < 0.001) and lymphovascular invasion (LVI) (38 % vs. 13.5 %, p < 0.001). Both overall survival (OS) and metastasis-free survival (MFS) were significantly worse in the UC with histologic subtype and differentiation group (five-year OS: 48.1 % vs. 73.1 %, p < 0.001; five-year MFS: 58.3 % vs. 87.4 %, p < 0.001). In multivariate analyses, presence of histologic subtypes and LVI were independently associated with poorer OS and MFS across all models. Age remained a significant factor for OS in all categories. ASA score >/=2 and surgical margin positivity were also associated with OS in the overall and muscle invasive patient cohorts. CONCLUSION: Histologic subtypes of UC are associated with more aggressive clinicopathologic features and significantly worse survival outcomes. Early and accurate recognition of these subtypes and divergent differentiations at initial TUR-BT is critical, highlighting the need for tailored management strategies to improve patient prognosis. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Sahin, Kadir Can AU - Sahin KC AD - Istanbul Bayrampasa State Hospital, Department of Urology, Turkey. Electronic address: sahinkadircan@gmail.com. FAU - Simsekoglu, Muhammed Fatih AU - Simsekoglu MF AD - Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Urology, Turkey. FAU - Ozden, Sami Berk AU - Ozden SB AD - Osmaniye State Hospital, Department of Urology, Turkey. FAU - Ercili, Birgi AU - Ercili B AD - Memorial Diyarbakir Hospital, Department of Urology, Turkey. FAU - Vural, Ahmet AU - Vural A AD - Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Urology, Turkey. FAU - Gurses, Iclal AU - Gurses I AD - Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Pathology, Turkey. FAU - Demirdag, Cetin AU - Demirdag C AD - Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Urology, Turkey. LA - eng PT - Journal Article DEP - 20251223 PL - Netherlands TA - Surg Oncol JT - Surgical oncology JID - 9208188 SB - IM MH - Retrospective Studies MH - Prognosis MH - *Urothelium/pathology/surgery MH - *Carcinoma, Transitional Cell/diagnosis/mortality/pathology/therapy MH - Follow-Up Studies MH - *Urinary Bladder/pathology/surgery MH - *Urinary Bladder Neoplasms/diagnosis/mortality/pathology/therapy MH - Treatment Outcome MH - Survival Rate MH - Neoplasm Invasiveness/pathology MH - Age Factors MH - Cell Differentiation MH - Cystectomy/mortality MH - Humans MH - Male MH - Female MH - Adult MH - Middle Aged MH - Aged MH - Aged, 80 and over OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Cystectomy OT - Diagnosis OT - Prognosis EDAT- 2026/01/02 00:33 MHDA- 2026/02/22 05:35 CRDT- 2026/01/01 18:15 PHST- 2025/09/18 00:00 [received] PHST- 2025/11/16 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/02/22 05:35 [medline] PHST- 2026/01/02 00:33 [pubmed] PHST- 2026/01/01 18:15 [entrez] AID - S0960-7404(25)00159-8 [pii] AID - 10.1016/j.suronc.2025.102344 [doi] PST - ppublish SO - Surg Oncol. 2026 Feb;64:102344. doi: 10.1016/j.suronc.2025.102344. Epub 2025 Dec 23. PMID- 41469902 OWN - NLM STAT- MEDLINE DCOM- 20251231 LR - 20260708 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 67 IP - 1 DP - 2026 Jan TI - Artificial intelligence-based personalized oncological outcome prediction model for upper urinary tract urothelial carcinoma after radical nephroureterectomy: A development and multicenter validation. PG - 15-23 LID - 10.4111/icu.20250385 [doi] AB - PURPOSE: To develop and validate an artificial intelligence (AI)-based personalized outcome prediction model for upper-urinary tract urothelial carcinoma patients undergoing radical nephroureterectomy. MATERIALS AND METHODS: Data from patients who underwent radical nephroureterectomy between 2010 and 2020 across three hospitals were retrospectively analyzed. A model was developed using one tertiary center's data and externally validated with data from two other hospitals. An AI model using XGBoost as risk estimator and bootstrapped Weibull Accelerated Failure Time model for 10-year survival probability was employed. Hyperparameter tuning used Optuna method. Model efficacy was assessed using concordance index, average Brier score, D-calibration, and six-month interval time-dependent area under the curve (AUC). RESULTS: Of 1,039 patients, 627 qualified after excluding 50 with neoadjuvant chemotherapy. Model development used 564 patients (507 training, 57 test) with 9:1 stratified random split, plus 63 for internal validation and 362 for external validation. Significant parameters included preoperative glomerular filtration rate (p<0.001), hydroureteronephrosis (p=0.013), pathological N stage (p<0.001), concurrent carcinoma in situ (p<0.001), disease progression (p<0.001), and survival rate (p<0.001). Disease-free survival (DFS) model's concordance index: internal validation 0.789, external validations 0.734 and 0.771. Overall survival (OS) model's concordance index: internal validation 0.819, external validations 0.780 and 0.771. Mean time-dependent AUC was 0.66-0.77 for DFS and 0.67-0.80 for OS during 10-year periods. CONCLUSIONS: AI-based model effectively predicts disease-free and OS outcomes for upper-urinary tract urothelial carcinoma patients with post-radical nephroureterectomy, showcasing robust performance across multicenter settings. CI - (c) The Korean Urological Association. FAU - Lee, Hyun Young AU - Lee HY AUID- ORCID: 0000-0002-6706-3554 AD - Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. FAU - Kim, Hwanik AU - Kim H AUID- ORCID: 0000-0001-5201-2490 AD - Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. FAU - Lim, Bumjin AU - Lim B AUID- ORCID: 0000-0001-7065-020X AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - You, Dalsan AU - You D AUID- ORCID: 0000-0001-8152-847X AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Song, Cheryn AU - Song C AUID- ORCID: 0000-0002-1823-4281 AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Jeong, In Gab AU - Jeong IG AUID- ORCID: 0000-0003-4093-832X AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Jun Hyuk AU - Hong JH AUID- ORCID: 0000-0003-2705-0481 AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Bumsik AU - Hong B AUID- ORCID: 0000-0003-1991-1229 AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Ahn, Hanjong AU - Ahn H AUID- ORCID: 0000-0001-7608-5352 AD - Department of Urology, Kangwon National University Hospital, Chuncheon, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AUID- ORCID: 0000-0002-8076-3643 AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. kuuro70@snu.ac.kr. FAU - Suh, Jungyo AU - Suh J AUID- ORCID: 0000-0002-3867-4778 AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. uro_jun@amc.seoul.kr. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PT - Validation Study PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Artificial Intelligence MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Kidney Neoplasms/surgery/pathology/mortality MH - *Ureteral Neoplasms/surgery/pathology/mortality MH - Middle Aged MH - Treatment Outcome PMC - PMC12792390 OTO - NOTNLM OT - Artificial Intelligence OT - Nephroureterectomy OT - Transitional cell carcinoma COIS- The authors have nothing to disclose. EDAT- 2025/12/31 07:37 MHDA- 2025/12/31 07:38 PMCR- 2026/01/01 CRDT- 2025/12/31 00:03 PHST- 2025/08/10 00:00 [received] PHST- 2025/10/05 00:00 [revised] PHST- 2025/11/01 00:00 [accepted] PHST- 2025/12/31 07:38 [medline] PHST- 2025/12/31 07:37 [pubmed] PHST- 2025/12/31 00:03 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - 67.15 [pii] AID - 10.4111/icu.20250385 [doi] PST - ppublish SO - Investig Clin Urol. 2026 Jan;67(1):15-23. doi: 10.4111/icu.20250385. PMID- 41463635 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260102 IS - 2306-5354 (Print) IS - 2306-5354 (Electronic) IS - 2306-5354 (Linking) VI - 12 IP - 12 DP - 2025 Dec 8 TI - Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion. LID - 10.3390/bioengineering12121338 [doi] LID - 1338 AB - Background: The Vesical Imaging-Reporting and Data System (VI-RADS) has limited diagnostic accuracy in distinguishing non-muscle-invasive bladder cancer (NMIBC) within VI-RADS categories 2 and 3, despite its value for overall NMIBC assessment. Dynamic contrast-enhanced MRI (DCE-MRI), which reflects tumor vascularity, holds promise for improving these challenging cases but remains underutilized due to unexploited spatiotemporal information. Methods: We developed a deep learning model to comprehensively quantify spatiotemporal features from multiphase DCE-MRI in 184 patients with VI-RADS 2 or 3 (training: n = 115, validation: n = 20, testing: n = 49). The model integrated multiscale feature extraction and contextual attention mechanisms to enhance diagnostic performance. Results: The model outperformed established benchmarks (e.g., VGG, ResNet) and the conventional VI-RADS /=5% high-grade component (%HGc) as a criterion to label non-invasive papillary urothelial carcinomas as high-grade (pTaHG). It also suggested that tumours with minor high-grade component behave more indolently and are better labelled as mixed low- and high-grade papillary carcinomas. METHODS AND RESULTS: We investigated the prognostic value of %HGc along with other clinical and morphological parameters. 130 pTaHGs and 96 pTaLGs were included. 9% and 12% of pTaHGs had 0.05). There was no significant interaction between the occurrence of prior NMIBC and the impact of NAC on pCR, pOR, RFS, CSS, and OS (all p(interaction) > 0.05). The study is limited by its retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our real-world data suggest that the occurrence of prior NMIBC could limit the access to NAC, while not predicting its effectiveness in patients treated with RC for localized MIBC. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Urology, GRC 5, Predictive Onco-Urology, Pitie-Salpetriere Hopital, APHP, Sorbonne University, Paris, France; Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Diamant, Elliott AU - Diamant E AD - Department of Urology, Henri Mondor Hospital, University of Paris Est Creteil, Creteil, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Urology, GRC 5, Predictive Onco-Urology, Pitie-Salpetriere Hopital, APHP, Sorbonne University, Paris, France. FAU - De Olivera, Alexandre AU - De Olivera A AD - Departement d'urologie, CHU-IUCT Toulouse, Toulouse, France. FAU - Harber, Theo AU - Harber T AD - Department of Urology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, Lyon, France. FAU - Colombel, Marc AU - Colombel M AD - Department of Urology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, Lyon, France. FAU - Hanquiez, Paul AU - Hanquiez P AD - Service d'urologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France. FAU - Chatain, Vera AU - Chatain V AD - Service d'urologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France. FAU - Vordos, Dimitri AU - Vordos D AD - Department of Urology, Henri Mondor Hospital, University of Paris Est Creteil, Creteil, France. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Cochin Hospital, Paris Cite Universite, APHP, Paris, France. FAU - Borz, Mihnea Bogdan AU - Borz MB AD - Department of Urology, Cochin Hospital, Paris Cite Universite, APHP, Paris, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, University of Rennes, Rennes, France. FAU - De Varennes, Anne Mauger AU - De Varennes AM AD - Department of Urology, University of Rennes, Rennes, France. FAU - Surlemont, Louis AU - Surlemont L AD - Service d'urologie, CHU Rouen, Rouen, France. FAU - Ghenassia, Marion AU - Ghenassia M AD - Service d'urologie, CHU Rouen, Rouen, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Service d'urologie, Hopital Saint-Louis, Universite Paris-Cite, Paris, France. FAU - Peyrottes, Arthur AU - Peyrottes A AD - Service d'urologie, Hopital Saint-Louis, Universite Paris-Cite, Paris, France. FAU - Lebacle, Cedric AU - Lebacle C AD - Urology Department, University Hospital of Bicetre-Paris Sud-Saclay University, Le Kremlin Bicetre, Paris, France. FAU - Beniac, Peter AU - Beniac P AD - Urology Department, University Hospital of Bicetre-Paris Sud-Saclay University, Le Kremlin Bicetre, Paris, France. FAU - Leon, Priscilla AU - Leon P AD - Service d'urologie, Clinique Pasteur, Royan, France. FAU - Larre, Stephane AU - Larre S AD - Service d'Urologie, CHU de Reims, Reims, France. FAU - Taha, Fayek AU - Taha F AD - Service d'Urologie, CHU de Reims, Reims, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Szostek, Aleksandra AU - Szostek A AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France. FAU - Calleris, Giorgio AU - Calleris G AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France; Department of Surgical Sciences, University of Turin, Turin, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, Universite Paris Cite, Paris, France. FAU - Allory, Yves AU - Allory Y AD - UMR 144 CNRS, Institut Curie, Paris, France. FAU - Bajeot, Anne-Sophie AU - Bajeot AS AD - Departement d'urologie, CHU-IUCT Toulouse, Toulouse, France. FAU - Prost, Doriane AU - Prost D AD - Department of Urology, Paris Saint-Joseph Hospital, Paris, France. FAU - Audenet, Francois AU - Audenet F AD - Service d'Urologie, Hopital Europeen Georges Pompidou, APHP, Universite Paris Cite, Paris, France. FAU - Thibault, Constance AU - Thibault C AD - Service d'oncologie medicale, Hopital Europeen Georges-Pompidou, APHP Centre, Institut du Cancer Paris CARPEM, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC 5, Predictive Onco-Urology, Pitie-Salpetriere Hopital, APHP, Sorbonne University, Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Clinique Pasteur Toulouse, Toulouse, France. FAU - Seisen, Thomas AU - Seisen T AD - Urology, GRC 5, Predictive Onco-Urology, Pitie-Salpetriere Hopital, APHP, Sorbonne University, Paris, France. Electronic address: thomas.seisen@aphp.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251218 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/surgery MH - *Neoadjuvant Therapy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Cystectomy MH - Cohort Studies MH - Retrospective Studies MH - Treatment Outcome MH - Chemotherapy, Adjuvant MH - Predictive Value of Tests MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Non-muscle-invasive bladder cancer OT - Progressive disease OT - Radical cystectomy EDAT- 2025/12/20 00:41 MHDA- 2026/02/05 00:30 CRDT- 2025/12/19 22:03 PHST- 2025/08/08 00:00 [received] PHST- 2025/11/01 00:00 [revised] PHST- 2025/11/11 00:00 [accepted] PHST- 2026/02/05 00:30 [medline] PHST- 2025/12/20 00:41 [pubmed] PHST- 2025/12/19 22:03 [entrez] AID - S2588-9311(25)00294-9 [pii] AID - 10.1016/j.euo.2025.11.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Feb;9(1):116-124. doi: 10.1016/j.euo.2025.11.006. Epub 2025 Dec 18. PMID- 41419363 OWN - NLM STAT- MEDLINE DCOM- 20260731 LR - 20260821 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 12 IP - 3 DP - 2026 Jun TI - Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PG - 486-496 LID - S2405-4569(25)00364-5 [pii] LID - 10.1016/j.euf.2025.12.010 [doi] AB - BACKGROUND AND OBJECTIVE: Trimodal therapy (TMT)-comprising transurethral resection of the bladder tumor, chemotherapy, and radiotherapy-offers a bladder-preserving alternative to radical cystectomy for selected patients with muscle-invasive bladder cancer (MIBC). However, the optimal criteria for patient selection and prognostication remain inadequately defined. A systematic review and meta-analysis was conducted to optimize the selection of MIBC patients who are likely to have better survival outcomes from TMT. METHODS: A systematic literature search was conducted in MEDLINE, Embase, and Web of Science in February 2025. Eligible studies examined prognostic factors for overall or cancer-specific survival in patients with MIBC undergoing TMT. To reduce the impact of confounding, only multivariable-adjusted estimates were included in the meta-analysis. Pooled hazard ratios (HRs) were calculated using a random-effect model. The risk of bias was evaluated using the Quality In Prognosis Studies (QUIPS) tool (CRD42025641514). KEY FINDINGS AND LIMITATIONS: A total of 31 studies, including 9416 patients treated with TMT for MIBC, met the inclusion criteria. Older age (per year increase; HR: 1.03, 95% confidence interval [CI]: 1.01-1.05), poor performance status (Eastern Cooperative Oncology Group >/=2 vs 0-1; HR: 2.47, 95% CI: 1.78-3.43), impaired renal function (HR: 1.47, 95% CI: 1.12-1.92), presence of hydronephrosis (HR: 1.65, 95% CI: 1.17-2.34), advanced T stage (HR: 1.47, 95% CI: 1.23-1.77), nodal involvement (HR: 1.90, 95% CI: 1.10-3.30), and concomitant carcinoma in situ (HR: 1.81, 95% CI: 1.02-3.20) were independently associated with worse overall survival. Limitations included heterogeneity in treatment protocols and potential residual confounding across studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: Specific patient- and tumor-related factors are significantly associated with prognosis in patients undergoing TMT for MIBC. These findings may aid in refining patient selection and risk stratification for TMT-based bladder-preserving approaches. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Miyajima, Keiichiro AU - Miyajima K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Anatomy, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Anatomy, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Roessler, Navid AU - Roessler N AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Inoue, Shota AU - Inoue S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Nishimura, Shingo AU - Nishimura S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Alqahtani, Abdulrahman S AU - Alqahtani AS AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Ministry of Health, Second Health Cluster, Riyadh, KSA. FAU - Alfarhan, Ahmed R AU - Alfarhan AR AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Prince Saud Bin Jalawi Hospital, Al Ahsa Health Cluster, Al Ahsa, the Kingdom of Saudi Arabia. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Reis, Leonardo Oliveira AU - Reis LO AD - UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, Sao Paulo, Brazil; Pontifical Catholic University of Campinas, PUC-Campinas, Sao Paulo, Brazil. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20251218 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Prognosis MH - Transurethral Resection of Bladder MH - Neoplasm Invasiveness MH - Combined Modality Therapy MH - Cystectomy OTO - NOTNLM OT - Bladder preservation OT - Meta-analysis OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Prognostic factors OT - Trimodal therapy EDAT- 2025/12/20 00:40 MHDA- 2026/08/01 00:36 CRDT- 2025/12/19 22:01 PHST- 2025/08/04 00:00 [received] PHST- 2025/11/08 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2026/08/01 00:36 [medline] PHST- 2025/12/20 00:40 [pubmed] PHST- 2025/12/19 22:01 [entrez] AID - S2405-4569(25)00364-5 [pii] AID - 10.1016/j.euf.2025.12.010 [doi] PST - ppublish SO - Eur Urol Focus. 2026 Jun;12(3):486-496. doi: 10.1016/j.euf.2025.12.010. Epub 2025 Dec 18. PMID- 41417076 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260707 IS - 2366-0058 (Electronic) VI - 51 IP - 7 DP - 2026 Jul TI - CT-derived tumor extracellular volume fraction for predicting recurrence in non-muscle-invasive bladder cancer. PG - 3563-3572 LID - 10.1007/s00261-025-05327-7 [doi] AB - PURPOSE: To investigate the predictive value of CT-derived tumor extracellular volume fraction (ECV) for recurrence in non-muscle-invasive bladder cancer (NMIBC) and to develop a comprehensive clinical prediction model. METHODS: This retrospective study included 97 patients with pathologically confirmed NMIBC treated between July 2017 and December 2022. All patients underwent pre-treatment contrast-enhanced CT scans, including unenhanced and delayed phases. Tumor ECV was independently measured by two radiologists. Clinical variables were retrieved from medical records. The primary outcome was tumor recurrence, confirmed by cystoscopy or imaging during follow-up. Univariable analysis identified candidate predictors (P < 0.1), and correlation testing was used to exclude multicollinearity. A logistic regression model was developed using 5-fold stratified cross-validation. Model performance was assessed using the area under the ROC curve (AUC), calibration curves, and recurrence-free survival estimated by Kaplan-Meier analysis. RESULTS: The recurrence rate was 34.0% over a median follow-up of 38.8 months. ECV values were significantly higher in recurrent cases (35.1 +/- 11.4%) than in non-recurrent cases (30.7 +/- 7.1%, P = 0.024). ECV independently predicted recurrence (OR = 1.072, 95% CI: 1.008-1.140; P = 0.028). Five variables-gender, tumor location, ECV, resection type, and intravesical chemotherapy-were identified as significant predictors. The model achieved an AUC of 0.722 +/- 0.051 with good calibration. Cox proportional hazards regression demonstrated that higher ECV was significantly associated with recurrence-free survival in transurethral resection of bladder tumor patients (HR = 1.031, 95% CI: 1.002-1.061, P = 0.036). CONCLUSION: CT-derived ECV is a promising imaging biomarker for recurrence prediction in NMIBC. The integrated model provides potential risk stratification and supports personalized clinical decision-making. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Wang, Lin AU - Wang L AD - Department of Radiology, Suining Municipal Hospital of TCM, Suining, China. FAU - Wang, Zhimin AU - Wang Z AD - Department of Critical Care Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Ziyu AU - Liu Z AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhou, Yin AU - Zhou Y AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Siyi AU - Li S AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Yong AU - Chen Y AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. shaoer.cy@gmail.com. LA - eng PT - Journal Article DEP - 20251219 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 RN - 0 (Contrast Media) SB - IM MH - Humans MH - Female MH - Male MH - *Neoplasm Recurrence, Local/diagnostic imaging/pathology MH - *Tomography, X-Ray Computed/methods MH - *Non-Muscle Invasive Bladder Neoplasms/diagnostic imaging/pathology MH - Retrospective Studies MH - Aged MH - Predictive Value of Tests MH - Contrast Media MH - Middle Aged MH - Tumor Burden MH - Aged, 80 and over MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology OTO - NOTNLM OT - Bladder cancer OT - Computed tomography OT - Extracellular volume fraction OT - Recurrence prediction COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/12/19 15:02 MHDA- 2026/06/15 12:51 CRDT- 2025/12/19 11:13 PHST- 2025/10/26 00:00 [received] PHST- 2025/11/30 00:00 [accepted] PHST- 2025/11/27 00:00 [revised] PHST- 2026/06/15 12:51 [medline] PHST- 2025/12/19 15:02 [pubmed] PHST- 2025/12/19 11:13 [entrez] AID - 10.1007/s00261-025-05327-7 [pii] AID - 10.1007/s00261-025-05327-7 [doi] PST - ppublish SO - Abdom Radiol (NY). 2026 Jul;51(7):3563-3572. doi: 10.1007/s00261-025-05327-7. Epub 2025 Dec 19. PMID- 41412840 OWN - NLM STAT- Publisher LR - 20251218 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) DP - 2025 Dec 17 TI - Clinical Evaluation of a Novel Deintensified Surveillance Protocol for Low-risk Non-muscle-invasive Bladder Cancer: A Prospective Study in 250 Patients. LID - S2588-9311(25)00292-5 [pii] LID - 10.1016/j.euo.2025.11.004 [doi] AB - BACKGROUND AND OBJECTIVE: Recent Edinburgh-based research demonstrated high negative predictive value (NPV) for urinary dipstick testing for haematuria (UDH) in low-risk bladder cancer surveillance. This enabled a new protocol where flexible cystoscopy in surveillance years 2 and 4 is performed only if UDH is positive. Adopted across Scotland and included as aspirational in European Association of Urology guidelines, this protocol has yet to be validated in real-world settings. This study aims to evaluate the clinical outcomes of low-risk bladder cancer with the implementation of the new surveillance protocol. METHODS: The protocol began in December 2018. All patients with low-risk bladder cancer on initial transurethral resection of bladder tumour were included from January 2019 to February 2025. General practitioners conducted UDH in surveillance years 2 and 4; cystoscopy followed if positive. Patient and clinical data were prospectively recorded using a standardised institutional pro forma. This study performed the first clinical evaluation of the deintensified low-risk protocol. The study evaluated the recurrence and progression rates, NPV of UDH throughout surveillance, and number of check cystoscopies performed. The statistical analysis used Stata-BE version 19.0 for Mac. KEY FINDINGS AND LIMITATIONS: A total of 250 patients were observed with a recurrence rate of 14.4% and a progression rate of 1.6%, similar to preprotocol outcomes. The NPV of UDH remained above 94% throughout surveillance. Flexible cystoscopy use declined by 18.2%, saving at least pound51 000. Limitations included a lack of randomisation, modest cohort sizes at 4 and 5 yr of surveillance, and absence of patient-reported outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: The deintensified protocol appears safe, maintaining clinical outcomes whilst reducing procedural use and costs in low-risk bladder cancer. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Shah, Chandrarajan Premal AU - Shah CP AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Gray, Jennifer AU - Gray J AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Lord-McKenzie, Tanya AU - Lord-McKenzie T AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK; The University of Edinburgh, Edinburgh, UK. Electronic address: param.mariappan@nhs.scot. LA - eng PT - Journal Article DEP - 20251217 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Efficiency OT - Haematuria OT - Low-grade cancer OT - Noninvasive cancer OT - Non-muscle-invasive bladder cancer OT - Surveillance OT - Ta cancer OT - Urinary dipstick EDAT- 2025/12/19 01:45 MHDA- 2025/12/19 01:45 CRDT- 2025/12/18 22:38 PHST- 2025/08/09 00:00 [received] PHST- 2025/10/16 00:00 [revised] PHST- 2025/11/07 00:00 [accepted] PHST- 2025/12/19 01:45 [medline] PHST- 2025/12/19 01:45 [pubmed] PHST- 2025/12/18 22:38 [entrez] AID - S2588-9311(25)00292-5 [pii] AID - 10.1016/j.euo.2025.11.004 [doi] PST - aheadofprint SO - Eur Urol Oncol. 2025 Dec 17:S2588-9311(25)00292-5. doi: 10.1016/j.euo.2025.11.004. PMID- 41409365 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251218 LR - 20251220 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 12 DP - 2025 Dec TI - Effectiveness of Simulation-Based Training in Urology: A Systematic Review of Educational Outcomes and Clinical Skill Transfer. PG - e98641 LID - 10.7759/cureus.98641 [doi] LID - e98641 AB - Urology is a technically demanding specialty, where training opportunities can be limited by patient safety, working hours, and case availability. Simulation-based medical education (SBME) is being increasingly integrated into urology training, offering opportunities for deliberate practice in a structured, reproducible, and risk-free environment. The effectiveness of modern simulation modalities and the extent of clinical skill transfer, however, remain variably reported. This review aims to evaluate the educational outcomes, validity evidence, and clinical skill transfer associated with contemporary simulation-based training in urology. A systematic review was conducted in accordance with PRISMA guidelines. PubMed/MEDLINE, EMBASE, Cochrane CENTRAL, and SCOPUS were searched for studies published between 1st January 2015 and 10th November 2025. Eligible designs included randomized trials, cohort studies, and prospective or retrospective evaluations involving urology trainees or consultants. Outcomes of interest were educational performance, technical skill acquisition, and transfer of skills to clinical practice. Risk of bias was assessed using ROBINS-I and the Cochrane Risk of Bias tool. Owing to the heterogeneity of interventions and outcomes, a narrative synthesis was undertaken. Fifteen studies involving 475 participants met the inclusion criteria. Simulation modalities included virtual reality (VR) platforms, multimodal endourological curricula, laparoscopic simulators, and patient-specific 3D-printed or hydrogel models. High-fidelity simulators demonstrated strong face, content, and construct validity, consistently distinguishing between novice and experienced surgeons. Short-format and proficiency-based progression curricula yielded significant improvements in technical skills. Several studies demonstrated predictive validity, showing that VR-trained participants achieved superior operative performance in procedures such as transurethral resection of bladder tumor, ureteroscopy, and laparoscopic nephrectomy. Patient-specific rehearsal models enhanced anatomical understanding and influenced operative planning for complex cases. Common limitations included small sample sizes, single-center designs, and limited reporting of long-term patient outcomes. Modern SBME is an effective and validated tool for developing technical proficiency in urology and demonstrates meaningful transferability to clinical practice. Further multicenter studies using standardized outcomes are required to assess long-term patient impact and evaluate the cost-effectiveness of advanced simulation technologies. CI - Copyright (c) 2025, Bhardwaj et al. FAU - Bhardwaj, Maanya AU - Bhardwaj M AD - Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GBR. FAU - Singhal, Abhinav AU - Singhal A AD - Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR. FAU - Bhardwaj, Gaurika AU - Bhardwaj G AD - Urology, Chelsea Westminster Hospital NHS Foundation Trust, London, GBR. FAU - Sur, Hariom AU - Sur H AD - Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR. LA - eng PT - Journal Article PT - Review DEP - 20251207 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12707426 OTO - NOTNLM OT - augmented reality OT - educational outcomes OT - simulation OT - simulation training OT - simulation-based training OT - skills training OT - urology resident OT - urology trainee OT - virtual reality OT - vr COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/12/18 07:20 MHDA- 2025/12/18 07:21 PMCR- 2025/12/07 CRDT- 2025/12/18 04:32 PHST- 2025/12/07 00:00 [accepted] PHST- 2025/12/18 07:21 [medline] PHST- 2025/12/18 07:20 [pubmed] PHST- 2025/12/18 04:32 [entrez] PHST- 2025/12/07 00:00 [pmc-release] AID - 10.7759/cureus.98641 [doi] PST - epublish SO - Cureus. 2025 Dec 7;17(12):e98641. doi: 10.7759/cureus.98641. eCollection 2025 Dec. PMID- 41396440 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 44 IP - 1 DP - 2025 Dec 15 TI - A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives. PG - 44 LID - 10.1007/s00345-025-06151-w [doi] AB - OBJECTIVE: BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) represents a major therapeutic challenge, given the high risk of disease progression and the absence of validated bladder-sparing strategies. In this context, gene-mediated therapy has emerged as a promising bladder-sparing approach. METHODS: A systematic review of the literature available on Medline and Google Scholar was conducted to report the main oncological evidence, safety profile and future perspectives on gene therapies in BCG-unresponsive NMIBC. A total of 3157 records were screened and 13 references were included in our result section, including 8 articles from PubMed and 5 unpublished studies presented at conferences between 2023 and 2025. RESULTS: Gene-mediated therapies are emerging as a promising therapeutic strategy, with complete responses rates ranging from 53.4% to 82.9% at 3 months and from 24.4% to 57.1% at 12 months. Median duration of response rate ranging from 9,7 to 28 months. The safety profile is promising, with overall adverse events ranging from 47% to 91%, including grade >/= 3 adverse events in 4% to 14% of cases, and no treatment-related deaths. The recent Food and Drug Administration approval of Nadofaragene firadenovec, is expected to provide relevant real-world clinical data. However, precise patient selection, the lack of predictive biomarkers for response or monitoring, and the cost-related challenges of these treatments remain major limitations. CONCLUSIONS: Gene therapies represent a novel and promising therapeutic approach for BCG-unresponsive NMIBC, with significant oncological efficacy and a favorable safety profile. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Bertrand, Constance AU - Bertrand C AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Hospital Universitario 12 de Octubre, Madrid, Spain. AD - ROC Clinic, Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, 59000, France. AD - Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, 59000, France. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, Paris, France. pierre-etienne.gabriel@aphp.fr. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251215 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Urinary Bladder Neoplasms/therapy/pathology MH - *Genetic Therapy/methods MH - Forecasting MH - Adjuvants, Immunologic/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG-unresponsive OT - Cretostimogene grenadenorepvec OT - Detalimogene voraplasmid OT - Gene therapy OT - Nadofaragene firadenovec OT - Non-muscle invasive bladder cancer COIS- Declarations. Conflict of interest: The authors declare no competing interests. Other authors declare no conflict of interest. Ethical approval and consent to participate: Not applicable. EDAT- 2025/12/15 13:10 MHDA- 2025/12/15 19:18 CRDT- 2025/12/15 11:30 PHST- 2025/11/09 00:00 [received] PHST- 2025/12/07 00:00 [accepted] PHST- 2025/12/15 19:18 [medline] PHST- 2025/12/15 13:10 [pubmed] PHST- 2025/12/15 11:30 [entrez] AID - 10.1007/s00345-025-06151-w [pii] AID - 10.1007/s00345-025-06151-w [doi] PST - epublish SO - World J Urol. 2025 Dec 15;44(1):44. doi: 10.1007/s00345-025-06151-w. PMID- 41395572 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251215 LR - 20260909 IS - 2192-3183 (Electronic) IS - 2192-3183 (Linking) VI - 14 IP - 4 DP - 2025 Oct TI - Small cell bladder carcinoma with a high tumor mutational burden responding to sequential cisplatin-etoposide and pembrolizumab: a case report. PG - 440-445 LID - 10.1007/s13691-025-00788-5 [doi] AB - Small cell carcinoma of the urinary bladder (SCCB) is a rare and aggressive malignancy with limited treatment options and a poor prognosis. We present the case of a 63-year-old man who was initially diagnosed to have non-metastatic high-grade non-muscle invasive urothelial carcinoma with sarcomatoid subtype and later developed bone metastases. A bone biopsy confirmed small cell carcinoma, and retrospective review of the original tumor revealed mixed histology comprising small cell, sarcomatoid-like, and conventional urothelial carcinoma components. The patient was treated with six cycles of cisplatin and etoposide, during which genomic profiling identified a high tumor mutational burden (22 mutations/megabase). Based on this finding, pembrolizumab was administered sequentially as monotherapy. The patient achieved a complete response that lasted for more than 1 year, but subsequently developed lymph node metastases and recurrences in bone. This case highlights the role of genomic profiling test for clinical decision-making as tumor mutational burden predicts the efficacy of immune checkpoint inhibitor therapy in SCCB. This case also underscores the urgent need for novel treatment approaches for SCCB. CI - (c) The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Ohtsu, Akira AU - Ohtsu A AUID- ORCID: 0009-0007-4757-4633 AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Fujizuka, Yuji AU - Fujizuka Y AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Arai, Seiji AU - Arai S AUID- ORCID: 0000-0002-9514-735X AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Shimizu, Takanori AU - Shimizu T AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Ozawa, Yuki AU - Ozawa Y AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Imanari, Shun AU - Imanari S AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Yamaguchi, Masakazu AU - Yamaguchi M AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Agata, Tomohiro AU - Agata T AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Onose, Mai AU - Onose M AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Nomura, Masashi AU - Nomura M AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Sekine, Yoshitaka AU - Sekine Y AUID- ORCID: 0000-0002-8094-4524 AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Koike, Hidekazu AU - Koike H AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Matsui, Hiroshi AU - Matsui H AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 FAU - Ohtake, Nobuaki AU - Ohtake N AD - Department of Urology, Hidaka Hospital, Nakao-machi, Takasaki, Gunma 886370-0001 Japan. ROR: https://ror.org/01cxg6q60. GRID: grid.440411.4. ISNI: 0000 0004 0642 4832 FAU - Suzuki, Kazuhiro AU - Suzuki K AUID- ORCID: 0000-0002-1448-7273 AD - Department of Urology, Gunma University Hospital, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 Japan. ROR: https://ror.org/05kq1z994. GRID: grid.411887.3. ISNI: 0000 0004 0595 7039 LA - eng PT - Journal Article DEP - 20250908 PL - Singapore TA - Int Cancer Conf J JT - International cancer conference journal JID - 101734231 PMC - PMC12696199 OTO - NOTNLM OT - Case report OT - Chemotherapy OT - Immune checkpoint inhibitor OT - Pembrolizumab OT - Small cell bladder carcinoma OT - Tumor mutational burden COIS- Conflict of interestThe authors declare that they have no competing interests. EDAT- 2025/12/15 13:09 MHDA- 2025/12/15 13:10 PMCR- 2026/09/08 CRDT- 2025/12/15 06:33 PHST- 2025/06/12 00:00 [received] PHST- 2025/07/24 00:00 [accepted] PHST- 2025/12/15 13:10 [medline] PHST- 2025/12/15 13:09 [pubmed] PHST- 2025/12/15 06:33 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - 788 [pii] AID - 10.1007/s13691-025-00788-5 [doi] PST - epublish SO - Int Cancer Conf J. 2025 Sep 8;14(4):440-445. doi: 10.1007/s13691-025-00788-5. eCollection 2025 Oct. PMID- 41390999 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20251214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 1 DP - 2026 Jan TI - The changing landscape of urinary diversion post cystectomy: A 15-year analysis of the NSQIP database. PG - 63.e13-63.e20 LID - S1078-1439(25)00385-0 [pii] LID - 10.1016/j.urolonc.2025.09.013 [doi] AB - BACKGROUND: Radical cystectomy (RC) with urinary diversion is the standard of care for high-risk non-muscle-invasive and muscle-invasive bladder cancer. While continent urinary diversions offer potential quality-of-life benefits, their adoption over time remains poorly defined. OBJECTIVE: To evaluate national trends in the use of continent versus incontinent urinary diversion following RC and identify demographic and clinical factors associated with diversion type. METHODS: We analyzed data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) from 2008 to 2022. Patients undergoing RC with urinary diversion were identified using CPT codes. Diversion type, temporal trends, and associated demographic and clinical variables were assessed using descriptive statistics and multivariable Firth logistic regression models. RESULTS: Among 26,587 patients, 85.1% received incontinent diversion and 14.9% received continent diversion. The use of continent diversion declined significantly over time, particularly among males, patients under 75 years old, and White patients. No significant trends were observed among female, Black or Asian patients. CONCLUSION: Continent urinary diversions have declined over the past decade despite surgical advancements, with notable variation by age, sex, and race. These findings highlight the influence of clinical and sociodemographic factors on diversion selection. The extent to which these findings reflect practice patterns beyond NSQIP remains uncertain. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Zein, Marwan AU - Zein M AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. FAU - Sebai, Towfik AU - Sebai T AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. FAU - AlJardali, Baraa AU - AlJardali B AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. FAU - Ghandour, Yara AU - Ghandour Y AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. FAU - Alameddine, Bilal AU - Alameddine B AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. FAU - Hajj, Albert El AU - Hajj AE AD - Department of Surgery, Division of Urology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: ae67@aub.edu.lb. LA - eng PT - Journal Article DEP - 20251025 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Diversion/methods/trends/statistics & numerical data MH - *Cystectomy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery MH - Databases, Factual OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Trends OT - Urinary diversion OT - Urinary reservoirs COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/14 15:52 MHDA- 2025/12/14 15:53 CRDT- 2025/12/14 08:04 PHST- 2025/02/24 00:00 [received] PHST- 2025/08/31 00:00 [revised] PHST- 2025/09/20 00:00 [accepted] PHST- 2025/12/14 15:53 [medline] PHST- 2025/12/14 15:52 [pubmed] PHST- 2025/12/14 08:04 [entrez] AID - S1078-1439(25)00385-0 [pii] AID - 10.1016/j.urolonc.2025.09.013 [doi] PST - ppublish SO - Urol Oncol. 2026 Jan;44(1):63.e13-63.e20. doi: 10.1016/j.urolonc.2025.09.013. Epub 2025 Oct 25. PMID- 41386721 OWN - NLM STAT- MEDLINE DCOM- 20260123 LR - 20260127 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 33 IP - 1 DP - 2026 Jan TI - Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer. PG - e70314 LID - 10.1111/iju.70314 [doi] AB - OBJECTIVE: To compare survival outcomes between Japanese patients receiving radical cystectomy (RC) and intravesical Bacillus Calmette-Guerin (BCG) for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). METHODS: This study was conducted within the Japanese Urological Oncology Group (JUOG) framework using two nationwide, multi-institutional databases: JUOG-UC-2021-RC, comprising 2674 patients with bladder cancer who underwent RC, and JUOG-UC-1901-BCG, comprising 3226 patients who received intravesical BCG. Patients were classified according to the Japanese Urological Association guideline (version 2023) risk stratification model into three cohorts: BCG-naive standard HR-NMIBC (without aggressive factors), BCG-naive highest-risk NMIBC (an aggressive subgroup), and BCG-unresponsive NMIBC. Metastasis-free survival (MFS) and overall survival (OS) were compared between the two interventions. Propensity score matching was applied to create well-balanced groups (BCG vs RC). RESULTS: In the adjusted BCG-naive standard HR-NMIBC subcohort, both MFS and OS were longer in the BCG-treated group than in the RC group (p = 0.15 and p = 0.027, respectively). However, no significant differences in MFS or OS were observed in the adjusted BCG-naive highest-risk NMIBC subcohort (p = 0.20 and p = 0.47, respectively). In the adjusted BCG-unresponsive NMIBC cohort, no differences in MFS or OS were detected (p = 0.76 and p = 0.35, respectively), although long-term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group. CONCLUSIONS: Our findings demonstrated that the RC group had worse outcomes than the BCG group in the BCG-naive standard HR-NMIBC subcohort but not in the highest-risk or BCG-unresponsive cohorts. Accumulating evidence is essential to guide physicians in counseling patients with HR-NMIBC and BCG-unresponsive NMIBC. REGISTRY AND THE REGISTRATION NO. OF THE STUDY/TRIAL: The authors have nothing to report. CI - (c) 2025 The Japanese Urological Association. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Saito, Ryoichi AU - Saito R AUID- ORCID: 0000-0002-3163-8723 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. AD - Department of Urology, Hyogo College of Medicine, Hyogo, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AUID- ORCID: 0000-0003-1044-912X AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Daizumoto, Kei AU - Daizumoto K AD - Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AUID- ORCID: 0000-0002-8159-9793 AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Hayashi, Takuji AU - Hayashi T AUID- ORCID: 0000-0003-2030-3087 AD - Department of Urology, Osaka International Cancer Institute, Osaka, Japan. AD - Department of Urology, Osaka Graduate School of Medicine, Osaka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. AD - Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. FAU - Sugino, Yusuke AU - Sugino Y AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin General Hospital, Fukuoka, Japan. FAU - Yamaguchi, Noriya AU - Yamaguchi N AD - Department of Urology, Faculty of Medicine, Tottori University, Tottori, Japan. FAU - Yamamoto, Shingo AU - Yamamoto S AD - Department of Urology, Hyogo College of Medicine, Hyogo, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, Jikei University Katsushika Medical Center, Tokyo, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Nara, Japan. CN - Japanese Urological Oncology Group LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20251212 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Cystectomy/methods MH - Male MH - Female MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - Adjuvants, Immunologic/administration & dosage MH - Neoplasm Invasiveness MH - Japan/epidemiology MH - Treatment Outcome MH - Retrospective Studies MH - Risk Assessment MH - Propensity Score MH - Aged, 80 and over MH - Urinary Bladder/pathology/surgery MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - cystectomy OT - prognosis OT - risk OT - urinary bladder neoplasms EDAT- 2025/12/13 00:32 MHDA- 2026/01/23 06:29 CRDT- 2025/12/12 20:24 PHST- 2025/11/12 00:00 [revised] PHST- 2025/10/09 00:00 [received] PHST- 2025/12/03 00:00 [accepted] PHST- 2026/01/23 06:29 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 20:24 [entrez] AID - 10.1111/iju.70314 [doi] PST - ppublish SO - Int J Urol. 2026 Jan;33(1):e70314. doi: 10.1111/iju.70314. Epub 2025 Dec 12. PMID- 41386348 OWN - NLM STAT- MEDLINE DCOM- 20260131 LR - 20260131 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 36 IP - 1 DP - 2026 Jan TI - Interim analysis of the IRMAA study: Concordance between MRI and histopathological analysis of bladder cancer. PG - 103065 LID - S2950-3930(25)00212-8 [pii] LID - 10.1016/j.fjurol.2025.103065 [doi] AB - INTRODUCTION: Bladder cancer are common, and their management and prognosis depend on the stage of tumor infiltration, particularly the involvement of the muscular layer. MRI appears to be an effective tool for assessing this infiltration, but its role remains to be determined. The aim of our study was to evaluate the concordance between the VIRADS score established on MRI and the histopathological examination of TURBT samples to access the staging T of bladder cancer. METHODS: We conducted an interim analysis on patients enrolled in the prospective, single-center IRMAA study (NCT05464576). All patients underwent bladder MRI prior to surgery. The VIRADS score on MRI was blindly compared to the histopathological results of TURBT samples for tumor staging T. We secondarily evaluated the concordance between the VIRADS score and the histopathological analysis of cystectomy as well as the efficacy of neoadjuvant chemotherapy. RESULTS: A total of 85 patients were included. 109 lesions were jointly identified on MRI and TURBT, of which 11 were discordant lesions. The concordance rate is 89.91% with a Cohen's Kappa coefficient of 0.74. Sensitivity is 100%, specificity is 87.4%, positive predictive value is 66.7% and negative predictive value is 100%. CONCLUSION: MRI is a promising tool for discrimination between NMIBC and MIBC. This interim analysis allowed us to identify discordant cases in order to refine future MRI interpretations for the final analysis of the IRMAA study. CI - Copyright (c) 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Mollot-Granger, Stephanie AU - Mollot-Granger S AD - Service d'urologie, Centre Hospitalo-Universitaire Gabriel-Montpied, 58,rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address: smollot-granger@chu-clermontferrand.fr. FAU - Chabrot, Pascal AU - Chabrot P AD - Service de radiologie, Centre Hospitalo-Universitaire Gabriel-Montpied, 58,n rue Montalembert, 63000 Clermont-Ferrand, France. FAU - Xardel, Vincent AU - Xardel V AD - Service d'urologie, Medipole de Savoie, 73190 Challes-Les-Eaux, France. FAU - Charbonnel, Cyril AU - Charbonnel C AD - Service d'urologie, Clinique Bon Secours, 43000 Le-Puy-en-Velay, France. FAU - Valli, Marie-Pierre AU - Valli MP AD - Recherche clinique, Centre Hospitalo-Universitaire Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France. FAU - Guandalino, Marlene AU - Guandalino M AD - Service d'urologie, Clinique Bon Secours, 43000 Le-Puy-en-Velay, France. FAU - Guy, Laurent AU - Guy L AD - Service d'urologie, Centre Hospitalo-Universitaire Gabriel-Montpied, 58,rue Montalembert, 63000 Clermont-Ferrand, France. LA - eng PT - Journal Article DEP - 20251210 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/therapy MH - *Magnetic Resonance Imaging MH - Prospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - Neoplasm Staging MH - Cystectomy MH - Neoadjuvant Therapy MH - Sensitivity and Specificity OTO - NOTNLM OT - Anatomopathologie OT - Bladder cancer OT - Histopathology OT - IRM OT - MRI OT - Tumeur vessie OT - VIRADS COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/12/13 00:32 MHDA- 2026/02/01 00:44 CRDT- 2025/12/12 19:31 PHST- 2025/06/29 00:00 [received] PHST- 2025/10/27 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2026/02/01 00:44 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 19:31 [entrez] AID - S2950-3930(25)00212-8 [pii] AID - 10.1016/j.fjurol.2025.103065 [doi] PST - ppublish SO - Fr J Urol. 2026 Jan;36(1):103065. doi: 10.1016/j.fjurol.2025.103065. Epub 2025 Dec 10. PMID- 41384865 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260615 IS - 2162-402X (Electronic) IS - 2162-4011 (Print) IS - 2162-4011 (Linking) VI - 14 IP - 1 DP - 2025 Dec 31 TI - HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer. PG - 2598920 LID - 10.1080/2162402X.2025.2598920 [doi] LID - 2598920 AB - Bacille Calmette-Guerin (BCG) is the immunotherapy of choice for high-risk non-muscle invasive bladder cancer (BC), although recurrence eventually occurs in 50% of patients and 20% progress to advanced stages. This study evaluates the predictive value of human leukocyte antigen class-I (HLA-I) genotyping to guide BCG immunotherapy. HLA-I genotyping and expression of NK cell receptors in circulating T and NK lymphocytes was evaluated at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 with other therapies), 648 patients with other cancers and 23,250 healthy controls. Proliferation, cytotoxicity, and production of cytokines and intracellular nitric oxide (icNO) was assessed in peripheral blood mononuclear cells from these donors, selected based on their Bw4 genotype, after stimulation in vitro with anti-CD3/CD28 or BCG. HLA-A*11, HLA-B*07 and HLA-B*18 allotypes were associated with favorable outcomes after BCG therapy (longer progression-free and overall survival), whereas HLA-B*44 and other KIR3DL1 Bw4 ligands were associated with unfavorable outcomes. Although Bw4 ligands were associated with better NK cell education in vivo (CD226-upregulation, KIR3DL1 downregulation and stronger NK cytotoxic capacity), they were also associated with weaker NK cell proliferation, and lower IL-1beta, IL-6, and icNO production after BCG stimulation in vitro, revealing an inhibitory role of KIR3DL1. Mechanisms by which KIR3DL1/Bw4 interaction interferes with BCG-induced NK cell proliferation and the production of cytokines and icNO, warrant further investigation. HLA-I genotyping should be investigated as a useful biomarker to personalize BCG immunotherapy in BC. FAU - Ruiz-Lorente, Inmaculada AU - Ruiz-Lorente I AUID- ORCID: 0009-0009-2433-8755 AD - Immunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Gimeno, Lourdes AU - Gimeno L AD - Immunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. AD - Human Anatomy Department, Universidad de Murcia and Campus Mare Nostrum, Murcia, Spain. FAU - Lopez-Abad, Alicia AU - Lopez-Abad A AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Cubillana, Pedro Lopez AU - Cubillana PL AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Aparicio, Tomas Fernandez AU - Aparicio TF AD - Urology Service, Morales Meseguer Hospital, Murcia, Spain. FAU - Egea, Lucas Jesus Asensio AU - Egea LJA AD - Urology Service, De la Vega Lorenzo Guirao Hospital, Murcia, Spain. FAU - Aviles, Juan Moreno AU - Aviles JM AD - Urology Service, Santa Lucia Hospital, Murcia, Spain. FAU - Iniguez, Gloria Donate AU - Iniguez GD AD - Urology Service, Los Arcos Hospital, Murcia, Spain. FAU - Martinez-Valls, Pablo Luis Guzman AU - Martinez-Valls PLG AD - Urology Service, Reina Sofia Hospital, Murcia, Spain. FAU - Server, Gerardo AU - Server G AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Ferri, Belen AU - Ferri B AD - Pathology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Campillo, Jose Antonio AU - Campillo JA AD - Immunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Galindo, Francisco AU - Galindo F AD - Department of Inorganic and Organic Chemistry, Universitat Jaume I, Av. V. Sos Baynat s/n, Castellon, Spain. FAU - Martinez-Sanchez, Maria Victoria AU - Martinez-Sanchez MV AD - Immunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. FAU - Minguela, Alfredo AU - Minguela A AUID- ORCID: 0000-0003-2472-5893 AD - Immunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Murcia, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251212 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 RN - 0 (BCG Vaccine) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Cytokines) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/immunology/therapy/drug therapy/mortality/pathology MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Aged MH - *Immunotherapy/methods MH - Middle Aged MH - Killer Cells, Natural/immunology/metabolism MH - Genotype MH - Precision Medicine/methods MH - *Histocompatibility Antigens Class I/genetics/immunology MH - Aged, 80 and over MH - Cytokines/metabolism MH - Adult PMC - PMC12710922 OTO - NOTNLM OT - Bacille Calmette-Guerin OT - Bladder cancer OT - HLA OT - NK cells OT - immunotherapy COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/12/12 17:54 MHDA- 2025/12/12 17:55 PMCR- 2025/12/12 CRDT- 2025/12/12 10:23 PHST- 2025/12/12 17:55 [medline] PHST- 2025/12/12 17:54 [pubmed] PHST- 2025/12/12 10:23 [entrez] PHST- 2025/12/12 00:00 [pmc-release] AID - 2598920 [pii] AID - 10.1080/2162402X.2025.2598920 [doi] PST - ppublish SO - Oncoimmunology. 2025 Dec 31;14(1):2598920. doi: 10.1080/2162402X.2025.2598920. Epub 2025 Dec 12. PMID- 41379263 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260114 LR - 20260117 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 17 IP - 1 DP - 2025 Dec 11 TI - Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report. PG - 96 LID - 10.1007/s12672-025-04209-0 [doi] LID - 96 AB - With the advancement of medical technology and improvements in living standards, the survival time of many cancer patients has been prolonged. However, a significant proportion of these patients develop multiple primary cancers (MPC), which indicates a poorer prognosis. Currently, there are no specific guidelines for managing MPC. This article reports a rare case of an elderly male patient who, during a six-year follow-up period, was diagnosed with four primary tumors in different organs including prostate cancer (first manifestation), renal cancer, bladder cancer, and lung cancer. Genetic testing of tumor tissues revealed an EGFR mutation in the lung cancer tissue and BAP1 gene deletion in the renal cancer tissue. Over the six-year follow-up, the patient underwent radical prostatectomy, partial nephrectomy, transurethral resection of bladder tumor, and radical left lung resection, with good postoperative recovery. This case represents MPC involving three urogenital system tumors and highlights the rare coexistence of EGFR mutation and BAP1 gene deletion across different organ-specific cancers. It underscores the necessity of genetic testing for MPC patients and demonstrates that aggressive management of primary tumors can improve the patient's quality of life. This case provides valuable insights for clinical research and treatment strategies for MPC. CI - (c) 2025. The Author(s). FAU - Yang, Kai AU - Yang K AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, People's Republic Of China. FAU - Zhou, Jiatong AU - Zhou J AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, People's Republic Of China. 1324088@zju.edu.cn. LA - eng GR - 82504016/National Natural Science Foundation for Young Scientists of China/ PT - Journal Article DEP - 20251211 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC12804532 OTO - NOTNLM OT - BAP1 loss OT - EGFR mutation OT - Multiple primary cancers COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee at Institute of The First Affiliated Hospital, Zhejiang University School of Medicine. A written informed consent for study participation from this patient was obtained. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication: Patients signed informed consent regarding publishing their data and photographs. Competing interests: The authors declare no competing interests. EDAT- 2025/12/11 13:04 MHDA- 2025/12/11 13:05 PMCR- 2025/12/11 CRDT- 2025/12/11 11:06 PHST- 2025/05/01 00:00 [received] PHST- 2025/11/27 00:00 [accepted] PHST- 2025/12/11 13:05 [medline] PHST- 2025/12/11 13:04 [pubmed] PHST- 2025/12/11 11:06 [entrez] PHST- 2025/12/11 00:00 [pmc-release] AID - 10.1007/s12672-025-04209-0 [pii] AID - 4209 [pii] AID - 10.1007/s12672-025-04209-0 [doi] PST - epublish SO - Discov Oncol. 2025 Dec 11;17(1):96. doi: 10.1007/s12672-025-04209-0. PMID- 41377897 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251213 IS - 1970-5565 (Print) IS - 1970-5557 (Electronic) IS - 1970-5557 (Linking) VI - 19 DP - 2025 TI - DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. PG - 1679974 LID - 10.3389/or.2025.1679974 [doi] LID - 1679974 AB - INTRODUCTION: Early prognostication in non-muscle-invasive bladder cancer (NMIBC) is essential for optimizing therapy and follow-up. Epigenetic mechanisms, particularly DNA methylation, have emerged as promising biomarkers for predicting disease outcome. MATERIALS AND METHODS: A systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate the prognostic significance of promoter DNA methylation in NMIBC. Comprehensive searches of PubMed, Web of Science, Embase, MEDLINE, and the Cochrane Library (January 2010-October 2022) identified eligible studies. The Newcastle-Ottawa scale was used for quality assessment, and pooled hazard ratios with 95% confidence intervals were calculated using random-effects models. RESULTS: Eleven studies with 3,065 NMIBC patients were analyzed. Promoter methylation was significantly associated with poor progression-free survival (pooled hazard ratios (HR) = 2.88; 95% CI = 2.03-4.09; p < 0.0001) and recurrence-free survival (pooled HR = 2.65; 95% CI = 1.93-3.63; p < 0.0001). Although overall survival showed pathway-specific variation (pooled HR = 0.96; 95% CI = 0.36-2.60; p = 0.94), methylation of adhesion and apoptosis-related genes exhibited the strongest associations. Subgroup analyses revealed a greater prognostic impact in Asian cohorts (p < 0.0001), suggesting regional differences in epigenetic susceptibility. CONCLUSION: Promoter DNA methylation constitutes a robust prognostic biomarker for recurrence and progression in NMIBC, with stronger effects in Asian populations. Standardization of validated gene panels, assay thresholds, and cross-regional prospective validation will be essential for clinical translation. Integrating methylation-based classifiers into risk stratification models could improve individualized management and long-term outcomes in NMIBC. CI - Copyright (c) 2025 Singh, Singh, Kumar, Shrivastava, Sahu, Jain and Pandey. FAU - Singh, Vishwajeet AU - Singh V AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Singh, Mukul Kumar AU - Singh MK AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Kumar, Anil AU - Kumar A AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Shrivastava, Ashutosh AU - Shrivastava A AD - Centre for Advance Research, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Sahu, Dinesh Kumar AU - Sahu DK AD - Central Research Facility, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India. FAU - Jain, Mayank AU - Jain M AD - Department of Thoracic Surgery, King George's Medical University, Lucknow, India. FAU - Pandey, Anuj Kumar AU - Pandey AK AD - Department of Biochemistry, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251125 PL - Switzerland TA - Oncol Rev JT - Oncology reviews JID - 101519906 PMC - PMC12685936 OTO - NOTNLM OT - DNA methylation biomarkers OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - predictive factor OT - prognostic markers COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/12/11 07:43 MHDA- 2025/12/11 07:44 PMCR- 2025/11/25 CRDT- 2025/12/11 05:28 PHST- 2025/08/05 00:00 [received] PHST- 2025/10/30 00:00 [revised] PHST- 2025/10/31 00:00 [accepted] PHST- 2025/12/11 07:44 [medline] PHST- 2025/12/11 07:43 [pubmed] PHST- 2025/12/11 05:28 [entrez] PHST- 2025/11/25 00:00 [pmc-release] AID - 1679974 [pii] AID - 10.3389/or.2025.1679974 [doi] PST - epublish SO - Oncol Rev. 2025 Nov 25;19:1679974. doi: 10.3389/or.2025.1679974. eCollection 2025. PMID- 41376810 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251213 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 83 DP - 2026 Jan TI - Impact of H1 Antihistamines on Bacillus Calmette-Guerin-treated Non-muscle-invasive Bladder Cancer. PG - 23-29 LID - 10.1016/j.euros.2025.11.001 [doi] AB - BACKGROUND AND OBJECTIVE: Concomitant H1 antihistamine (H1-AH) administration is associated with better survival outcomes for patients with metastatic urothelial carcinoma receiving immunotherapy. However, the role of H1-AHs among patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacillus Calmette-Guerin (BCG) immunotherapy has not been explored. Our aim was to investigate the impact of H1-AH use on survival outcomes for patients with BCG-treated NMIBC. METHODS: We conducted a territory-wide retrospective observational study. Patients with NMIBC who received intravesical immunotherapy with a single BCG strain in Hong Kong from 2001 to 2020 were identified. H1-AH prescription data were recorded. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) outcomes were compared between H1-AH and control groups using the Kaplan-Meier method and multivariable Cox regression. KEY FINDINGS AND LIMITATIONS: Our analysis included 2028 patients with NMIBC who received intravesical BCG immunotherapy. Of these, 1539 patients (76%) had a H1-AH prescription at baseline and 489 (24%) never received any H1-AH prescription during the study period. Median follow-up was 11.0 yr. Kaplan-Meier analysis revealed that the H1-AH group had better CSS (p = 0.017) and PFS (p = 0.001). Subgroup analysis by H1-AH timing (before or during BCG therapy) showed that concomitant H1-AH treatment during intravesical BCG immunotherapy was associated with better CSS (p = 0.002) and PFS (p = 0.005). Multivariable Cox regression results demonstrated that concomitant H1-AH treatment was associated with better OS (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.58-0.82), CSS (HR 0.44, 95% CI 0.30-0.65), RFS (HR 0.81, 95% CI 0.67-0.98), and PFS (HR 0.64, 95% CI 0.45-0.91). CONCLUSIONS AND CLINICAL IMPLICATIONS: Concomitant H1-AH treatment was associated with better OS, CSS, RFS, and PFS for patients with NMIBC receiving adjuvant intravesical BCG. PATIENT SUMMARY: The treatment for non-muscle-invasive bladder cancer (NMIBC) typically includes a solution of BCG (bacillus Calmette-Guerin) instilled into the bladder. We found better survival outcomes (overall survival, cancer-specific survival, recurrence-free survival, and progression-free survival) for patients who took a H1 antihistamine during their BCG treatment for intermediate-risk or high-risk NMIBC. More research is needed to confirm our results. CI - (c) 2025 The Author(s). FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Liu, Alex Qinyang AU - Liu AQ AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. AD - Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China. AD - Center for Translational Urological Research, Shenzhen Research Institute, Chinese University of Hong Kong, Shenzhen, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20251125 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC12689218 OTO - NOTNLM OT - Cancer-specific survival OT - H1 antihistamines OT - Non-muscle-invasive bladder cancer OT - Overall survival OT - Progression-free survival OT - Recurrence-free survival EDAT- 2025/12/11 07:44 MHDA- 2025/12/11 07:45 PMCR- 2025/11/25 CRDT- 2025/12/11 05:16 PHST- 2025/11/05 00:00 [accepted] PHST- 2025/12/11 07:45 [medline] PHST- 2025/12/11 07:44 [pubmed] PHST- 2025/12/11 05:16 [entrez] PHST- 2025/11/25 00:00 [pmc-release] AID - S2666-1683(25)01956-1 [pii] AID - 10.1016/j.euros.2025.11.001 [doi] PST - epublish SO - Eur Urol Open Sci. 2025 Nov 25;83:23-29. doi: 10.1016/j.euros.2025.11.001. eCollection 2026 Jan. PMID- 41375830 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251214 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 23 DP - 2025 Dec 1 TI - Diagnostic and Prognostic Implications of FGFR3, TP53 Mutation and Urinary Biomarkers in Urothelial Carcinoma in Pakistani Cohort. LID - 10.3390/jcm14238526 [doi] LID - 8526 AB - Background: Urothelial carcinoma (UC) presents with clinically heterogeneous disease. There is an emerging need to explore the prognosis of non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Therefore, we aimed to explore the prognostic value of FGFR3 and TP53 mutations and protein expression and to investigate the diagnostic utility of urine cytology and Xpert bladder cancer monitor (BCM) assay in UC. Materials and Methods: A prospective cross-sectional study was conducted in a cohort of 73 Pakistani patients. Cystoscopy, biopsy, tissue diagnosis, UC grade, and stage followed by immunohistochemistry (IHC) and genotyping were recorded. Voided urine samples were also collected for urine cytology and Xpert BCM. Statistical analysis was performed using SPSS version 26.0. A p-value 80-100 mL) and moderate to severe lower urinary tract symptoms (LUTS) were consistently associated with higher NMIBC recurrence rates, independent of tumor stage and grade, in heterogeneous cohorts. Retention correlated with reduced efficacy of Bacillus Calmette-Guerin (BCG) and mitomycin C, likely via uneven drug distribution and a chronically inflamed urothelium. Mechanistic data support a plausible link between BOO-related inflammation, barrier dysfunction, and tumor biology, although direct biomarker correlations with PVR or pharmacokinetic studies are lacking. HoLEP provides durable relief of BOO, reduces PVR, and improves LUTS. Limited retrospective data suggest an association between HoLEP and lower recurrence, but these observations are confounded and should be viewed as hypothesis-generating. CONCLUSIONS: Chronic urinary retention and BOO appear to be modifiable functional factors that may influence NMIBC recurrence and intravesical therapy performance. HoLEP is a promising option to optimize bladder emptying in carefully selected patients, but its oncologic impact remains unproven and should be considered hypothesis-generating pending prospective, risk-adjusted studies. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Marino, Filippo AU - Marino F AUID- ORCID: 0000-0002-2908-6907 AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. FAU - De Marchi, Davide AU - De Marchi D AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. FAU - Giampaoli, Marco AU - Giampaoli M AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. FAU - D'Agostino, Daniele AU - D'Agostino D AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. FAU - Simonetti, Francesca AU - Simonetti F AUID- ORCID: 0009-0006-8387-8290 AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. FAU - Ragonese, Mauro AU - Ragonese M AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli"-IRCCS, 00144 Rome, Italy. FAU - Amodeo, Antonio AU - Amodeo A AUID- ORCID: 0009-0009-2730-0402 AD - Department of Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, 35128 Padua, Italy. FAU - Corsi, Paolo AU - Corsi P AD - Department of Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, 35128 Padua, Italy. FAU - Claps, Francesco AU - Claps F AD - Department of Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, 35128 Padua, Italy. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AUID- ORCID: 0000-0002-0564-7415 AD - Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251201 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12691192 OTO - NOTNLM OT - BCG therapy OT - benign prostatic hyperplasia (BPH) OT - bladder cancer recurrence OT - bladder compliance OT - bladder outlet obstruction (BOO) OT - chronic urinary retention OT - functional urology OT - holmium laser enucleation of the prostate (HoLEP) OT - intravesical therapy OT - lower urinary tract symptoms (LUTS) OT - mitomycin C OT - non-muscle-invasive bladder cancer (NMIBC) OT - oncological outcomes OT - postvoid residual (PVR) OT - urodynamic dysfunction COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/12/11 07:44 MHDA- 2025/12/11 07:45 PMCR- 2025/12/01 CRDT- 2025/12/11 01:08 PHST- 2025/10/19 00:00 [received] PHST- 2025/11/24 00:00 [revised] PHST- 2025/11/25 00:00 [accepted] PHST- 2025/12/11 07:45 [medline] PHST- 2025/12/11 07:44 [pubmed] PHST- 2025/12/11 01:08 [entrez] PHST- 2025/12/01 00:00 [pmc-release] AID - cancers17233864 [pii] AID - cancers-17-03864 [pii] AID - 10.3390/cancers17233864 [doi] PST - epublish SO - Cancers (Basel). 2025 Dec 1;17(23):3864. doi: 10.3390/cancers17233864. PMID- 41374349 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251214 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 23 DP - 2025 Nov 22 TI - A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer. LID - 10.3390/diagnostics15232968 [doi] LID - 2968 AB - Background/Objectives: The Vesical Imaging-Reporting and Data System (VI-RADS) provides high diagnostic accuracy for muscle-invasive bladder cancer; however, its prognostic value remains limited. We propose serum cytokeratin 19 fragment (CYFRA 21-1) and tumor contact length (TCL) as complementary prognostic factors. We aimed to construct a composite risk score integrating VI-RADS, CYFRA 21-1, and TCL for prognostic stratification. Methods: We retrospectively analyzed data from 101 patients with bladder cancer (BC) who underwent transurethral resection of bladder tumor (TURBT), magnetic resonance imaging, and postoperative serum CYFRA 21-1 measurement. For each factor, cut-off values were determined using receiver operating characteristic (ROC) analysis; meeting each threshold contributed one point (score range, 0-3). Overall survival (OS) was assessed using Kaplan-Meier and Cox regression analyses. Results: ROC analysis identified cut-offs of VI-RADS >/= 3 (area under the curve [AUC] 0.779), TCL >/= 40 mm (AUC 0.817), and CYFRA 21-1 >/= 2.1 ng/mL (AUC 0.875). Based on these, patients were stratified into low- (0-1, n = 81), intermediate- (2, n = 12), and high-risk (3, n = 8) groups with 3-year OS rates of 95.1%, 75.0%, and 25.0%, respectively (p < 0.001). In univariate Cox regression, all factors significantly predicted poor OS: VI-RADS >/= 3 (hazard ratio [HR], 6.51; p = 0.015), TCL >/= 40 mm (HR, 8.36; p < 0.001), and CYFRA 21-1 >/= 2.1 ng/mL (HR, 14.02; p < 0.001). In multivariate analysis, only CYFRA 21-1 remained independently significant (HR, 11.80; p < 0.001). Conclusions: A composite risk score combining VI-RADS, TCL, and CYFRA 21-1 effectively stratified patients with BC into distinct groups using minimally invasive, peri-TURBT assessments. Prospective multicenter validation is warranted. FAU - Ikuma, Shunsuke AU - Ikuma S AUID- ORCID: 0009-0006-0570-8173 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Akatsuka, Jun AU - Akatsuka J AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kaneko, Godai AU - Kaneko G AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Takeda, Hayato AU - Takeda H AUID- ORCID: 0000-0002-4556-6601 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Endo, Yuki AU - Endo Y AUID- ORCID: 0009-0002-0787-9321 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kimura, Go AU - Kimura G AUID- ORCID: 0000-0003-0088-9324 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kondo, Yukihiro AU - Kondo Y AUID- ORCID: 0000-0003-4141-9230 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. LA - eng GR - 25K20053/the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research/ PT - Journal Article DEP - 20251122 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12691414 OTO - NOTNLM OT - Vesical Imaging-Reporting and Data System OT - bladder cancer OT - cytokeratin 19 fragment OT - magnetic resonance imaging OT - reporting and data system OT - tumor contact length COIS- The authors declare no conflicts of interest. EDAT- 2025/12/11 07:43 MHDA- 2025/12/11 07:44 PMCR- 2025/11/22 CRDT- 2025/12/11 01:05 PHST- 2025/10/15 00:00 [received] PHST- 2025/11/19 00:00 [revised] PHST- 2025/11/21 00:00 [accepted] PHST- 2025/12/11 07:44 [medline] PHST- 2025/12/11 07:43 [pubmed] PHST- 2025/12/11 01:05 [entrez] PHST- 2025/11/22 00:00 [pmc-release] AID - diagnostics15232968 [pii] AID - diagnostics-15-02968 [pii] AID - 10.3390/diagnostics15232968 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Nov 22;15(23):2968. doi: 10.3390/diagnostics15232968. PMID- 41372117 OWN - NLM STAT- MEDLINE DCOM- 20260131 LR - 20260712 IS - 1744-8352 (Electronic) IS - 1473-7159 (Linking) VI - 26 IP - 1 DP - 2026 Jan TI - Unlocking the potential of long non-coding RNAs in bladder cancer. PG - 9-12 LID - 10.1080/14737159.2025.2603407 [doi] AB - INTRODUCTION: Bladder cancer (BC) is a prevalent urinary tract malignancy, characterized by high recurrence rates and heterogeneous disease progression. Non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) present distinct clinical challenges, and conventional clinicopathological parameters are often insufficient to predict recurrence or progression accurately. Long non-coding RNAs (lncRNAs) have emerged as key regulators of tumor biology, influencing proliferation, migration, epithelial-mesenchymal transition, and therapy resistance, with potential in risk stratification, prognostic prediction and guidance of therapy de-escalation or intensification. AREAS COVERED: This narrative review examines the role of lncRNAs in BC, focusing on their biological functions, prognostic significance, and potential to guide personalized treatment strategies. We discuss lncRNA involvement in NMIBC and MIBC, highlight molecular profiling studies enabling risk stratification and molecular subtyping for guiding treatment de-escalation or intensification. Finally, we address the challenges and future directions for integrating lncRNA profiling into routine clinical practice. EXPERT OPINION: LncRNAs offer a promising approach for precision oncology in bladder cancer, providing insights beyond traditional clinical parameters. Integrating lncRNA profiling into routine practice could optimize risk stratification, guide therapy intensity, and reduce overtreatment. Although current evidence is encouraging, large-scale prospective trials are needed to validate lncRNA signatures and fully realize their potential in personalized bladder cancer management. FAU - Tomassen, Yoran L AU - Tomassen YL AD - Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Gibb, Ewan A AU - Gibb EA AD - Department of Urologic Sciences, Vancouver Prostate Centre, Vancouver, Canada. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20251213 PL - England TA - Expert Rev Mol Diagn JT - Expert review of molecular diagnostics JID - 101120777 RN - 0 (RNA, Long Noncoding) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/diagnosis/therapy/pathology MH - *RNA, Long Noncoding/genetics MH - *Biomarkers, Tumor/genetics MH - Prognosis MH - Gene Expression Regulation, Neoplastic MH - Epithelial-Mesenchymal Transition/genetics OTO - NOTNLM OT - Bladder cancer OT - biomarker OT - long non-coding RNA OT - molecular subtyping OT - urothelial carcinoma EDAT- 2025/12/11 01:22 MHDA- 2026/01/31 06:31 CRDT- 2025/12/10 23:13 PHST- 2026/01/31 06:31 [medline] PHST- 2025/12/11 01:22 [pubmed] PHST- 2025/12/10 23:13 [entrez] AID - 10.1080/14737159.2025.2603407 [doi] PST - ppublish SO - Expert Rev Mol Diagn. 2026 Jan;26(1):9-12. doi: 10.1080/14737159.2025.2603407. Epub 2025 Dec 13. PMID- 41372083 OWN - NLM STAT- MEDLINE DCOM- 20260118 LR - 20260118 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 2 DP - 2026 Feb TI - Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis. PG - 119.e7-119.e16 LID - S1078-1439(25)00452-1 [pii] LID - 10.1016/j.urolonc.2025.11.005 [doi] AB - BACKGROUND AND OBJECTIVE: Accurate prediction of recurrence and progression risk in non-muscle invasive bladder cancer (NMIBC) is essential for patient counseling and risk-adapted management. However, conventional models fail to account for the decrease in baseline risk over time. We therefore examined the conditional survival free of recurrence and progression in older adults with NMIBC to develop a dynamic risk prediction model. METHODS: We identified patients 66 to 89 years with Ta/Tis/T1 cN0 cM0 urothelial bladder cancer treated with transurethral resection of bladder tumor (TURBT) between 2000 and 2017 in SEER-Medicare. Conditional recurrence-free (RFS) and progression-free (PFS) survival were estimated using the Kaplan-Meier method. The associations of baseline characteristics with RFS and PFS at prespecified landmark times were evaluated using Cox-proportional hazards models. KEY FINDINGS AND LIMITATIONS: A total of 39,862 patients were included. Of these, 26,339 (66%) had Ta, 11,758 (29%) had T1, and 1,765 (4%) had Tis-disease. Median follow-up was 65 months. The 60-month RFS and PFS increased from 0.39 and 0.85 at baseline to 0.73 and 0.89 at 24-months event-free survival. Conditional RFS rapidly improved within the first 24 months before plateauing. Patients with T1-disease demonstrated the greatest improvement in conditional RFS. On multivariable analyses, T stage and tumor grade were less predictive of RFS with longer landmark times. Limitations include measurement error and risk heterogeneity within grade and stage subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: Among patients with NMIBC, recurrence and progression risks decrease with longer event-free intervals, particularly among patients at highest risk of each event as reflected by tumor stage and grade. A dynamic risk prediction model can improve patient counseling and support risk-adapted management during follow-up. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Chang, Jenny Chia-Chen AU - Chang JC AD - Georgetown University School of Medicine, Washington, DC. FAU - Perez-Londono, Agustin AU - Perez-Londono A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Kaul, Sumedh AU - Kaul S AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Almohtasib, Jamil AU - Almohtasib J AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Fleishman, Aaron AU - Fleishman A AD - Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Korets, Ruslan AU - Korets R AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Chang, Peter AU - Chang P AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Wagner, Andrew AU - Wagner A AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. FAU - Olumi, Aria F AU - Olumi AF AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: bgershma@bidmc.harvard.edu. LA - eng PT - Journal Article DEP - 20251209 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery MH - Aged MH - Male MH - Female MH - United States MH - SEER Program MH - Medicare/statistics & numerical data MH - Aged, 80 and over MH - Prognosis MH - Progression-Free Survival MH - *Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Conditional survival OT - Non-muscle invasive bladder cancer OT - Predictive model OT - Progression OT - Recurrence COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Boris Gershman reports the following relationships: Photocure (Consultant; Investigator), Ferring (Consultant; Investigator), Surge Therapeutics (Investigator). If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/11 01:22 MHDA- 2026/01/19 01:03 CRDT- 2025/12/10 22:27 PHST- 2025/09/08 00:00 [received] PHST- 2025/10/24 00:00 [revised] PHST- 2025/11/03 00:00 [accepted] PHST- 2026/01/19 01:03 [medline] PHST- 2025/12/11 01:22 [pubmed] PHST- 2025/12/10 22:27 [entrez] AID - S1078-1439(25)00452-1 [pii] AID - 10.1016/j.urolonc.2025.11.005 [doi] PST - ppublish SO - Urol Oncol. 2026 Feb;44(2):119.e7-119.e16. doi: 10.1016/j.urolonc.2025.11.005. Epub 2025 Dec 9. PMID- 41365723 OWN - NLM STAT- MEDLINE DCOM- 20260118 LR - 20260118 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 2 DP - 2026 Feb TI - Evaluation of kynurenine and tryptophan metabolism in bladder cancer: Diagnostic and prognostic implications of IDO1 polymorphism. PG - 119.e17-119.e25 LID - S1078-1439(25)00475-2 [pii] LID - 10.1016/j.urolonc.2025.11.011 [doi] AB - OBJECTIVE: The tryptophan-kynurenine (TRP-KYN) pathway, regulated by indoleamine 2,3-dioxygenase 1 (IDO1), plays a pivotal role in tumor immune escape. Altered TRP catabolism and IDO1 gene polymorphisms may influence bladder cancer (BC) behavior through immune metabolic mechanisms. To evaluate the diagnostic and prognostic value of plasma and urinary KYN/TRP ratios and the IDO1 rs10089084 (G > C) polymorphism in patients with BC. METHODS: In this case-control study, plasma and urine samples were obtained from 58 patients with BC and 70 healthy controls before diagnostic cystoscopy. TRP and KYN levels were quantified by high-performance liquid chromatography. IDO1 rs10089084 genotypes were determined via PCR-RFLP. Diagnostic accuracy was assessed by ROC analysis, and recurrence risk was analyzed using Cox regression. RESULTS: Plasma KYN/TRP ratios were significantly higher in BC patients than in controls (P = 0.011; AUC = 0.617). Among BC cases, the urinary KYN/TRP ratio discriminated patients with a visible bladder mass (AUC = 0.879; 95% CI 0.774-0.984; cut-off = 0.0895; sensitivity = 100%; specificity = 70.8%). In recurrence analysis, the IDO1 rs10089084 C allele independently predicted recurrence risk (HR = 7.51; 95% CI 1.70-33.10; P = 0.008). No association was found with progression. CONCLUSIONS: Combined metabolic and genetic profiling implicates the IDO1-TRP-KYN axis in BC pathophysiology. Urinary KYN/TRP ratio offers a noninvasive, biologically grounded marker for intravesical tumor activity, while the IDO1 rs10089084 variant provides complementary prognostic information. These findings support the integration of immunometabolic biomarkers into risk-adapted surveillance strategies. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Kayar, Kemal AU - Kayar K AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Uskudar, Istanbul. Electronic address: kemal.kayar@hotmail.com. FAU - Kayar, Ridvan AU - Kayar R AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Uskudar, Istanbul. FAU - Sonmez, Dilara AU - Sonmez D AD - Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye. FAU - Hakan, Mehmet Tolgahan AU - Hakan MT AD - Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye. FAU - Horozoglu, Cem AU - Horozoglu C AD - Department of Biochemistry, Faculty of Medicine, Halic University, Eyupsultan, Istanbul, Turkey. FAU - Yucebas, Omer Ergin AU - Yucebas OE AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Uskudar, Istanbul. FAU - Yaylim, Ilhan AU - Yaylim I AD - Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye. FAU - Verim, Levent AU - Verim L AD - Departmen of Urology, Yalova University Medical School, Yalova, Turkiye. LA - eng PT - Journal Article DEP - 20251208 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 8DUH1N11BX (Tryptophan) RN - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase) RN - 343-65-7 (Kynurenine) RN - 0 (IDO1 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/metabolism/diagnosis/blood MH - *Tryptophan/metabolism/blood/urine MH - *Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics/metabolism MH - *Kynurenine/metabolism/blood/urine MH - Male MH - Female MH - Prognosis MH - Case-Control Studies MH - Middle Aged MH - Aged MH - Biomarkers, Tumor MH - Polymorphism, Single Nucleotide MH - Neoplasm Recurrence, Local MH - Genotype OTO - NOTNLM OT - Bladder cancer OT - IDO1 OT - Kynurenine OT - Rs10089084 OT - Tryptophan COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/10 01:47 MHDA- 2026/01/19 01:03 CRDT- 2025/12/09 22:02 PHST- 2025/03/06 00:00 [received] PHST- 2025/10/31 00:00 [revised] PHST- 2025/11/14 00:00 [accepted] PHST- 2026/01/19 01:03 [medline] PHST- 2025/12/10 01:47 [pubmed] PHST- 2025/12/09 22:02 [entrez] AID - S1078-1439(25)00475-2 [pii] AID - 10.1016/j.urolonc.2025.11.011 [doi] PST - ppublish SO - Urol Oncol. 2026 Feb;44(2):119.e17-119.e25. doi: 10.1016/j.urolonc.2025.11.011. Epub 2025 Dec 8. PMID- 41363059 OWN - NLM STAT- MEDLINE DCOM- 20260123 LR - 20260126 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 33 IP - 1 DP - 2026 Jan TI - Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer. PG - e70293 LID - 10.1111/iju.70293 [doi] LID - e70293 AB - OBJECTIVES: Considering the high frequency of intravesical recurrence in bladder urothelial carcinoma (UBC), accurate non-invasive biomarkers for recurrence prediction are needed for better management after transurethral surgery. This pilot study examined the usefulness of urine DNA for detecting and predicting intravesical recurrence in UBC. METHODS: Patients with primary nonmuscle-invasive UBC were prospectively enrolled just after initial transurethral surgery. Genomic profiles were evaluated in resected specimens of the original tumor and in urine during follow-up. Urine DNA, urine cytology, and cystoscopy were all evaluated at 3-month intervals until 1 year postoperatively. Upon centrifuging urine samples into precipitation and supernatant fractions, we retrospectively evaluated urine DNA using a genomic panel established in our previous report. RESULTS: In the 19 patients enrolled, intravesical recurrent tumors were detected in six patients by cystoscopy. Urine DNA was positive in all of the recurrence cases before or at the time of cystoscopic or cytological detection, whereas urine cytology did not test positive before cystoscopic recurrence. Both urine precipitation and supernatant samples tested positive in 5 of 6 recurrence cases, indicating no obvious differences in the fraction used. Urine DNA was positive in 4 of the 13 nonrecurrence cases, among which three tested negative following Bacille Calmette-Guerin therapy. CONCLUSIONS: Urine DNA as screened by our genomic panel may be useful for predicting and detecting intravesical recurrence in UBC. The simultaneous evaluation of urine precipitation and supernatant may enhance the clinical utility of urine DNA during surveillance for intravesical recurrence in UBC patients. CI - (c) 2025 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Shiozaki, Masashi AU - Shiozaki M AUID- ORCID: 0000-0001-9063-782X AD - Department of Urology, Shinshu University School of Medicine, Nagano, Japan. AD - Department of Urology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. FAU - Minagawa, Tomonori AU - Minagawa T AUID- ORCID: 0000-0002-5910-2808 AD - Department of Urology, Shinshu University School of Medicine, Nagano, Japan. FAU - Yokoyama, Hitoshi AU - Yokoyama H AD - Department of Urology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. FAU - Hirotsu, Yosuke AU - Hirotsu Y AUID- ORCID: 0000-0002-8002-834X AD - Genomic Analysis Center, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. FAU - Oyama, Toshio AU - Oyama T AD - Department of Pathology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. FAU - Omata, Masao AU - Omata M AUID- ORCID: 0000-0001-7977-1497 AD - Department of Urology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. AD - Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan. AD - The University of Tokyo, Tokyo, Japan. FAU - Akiyama, Yoshiyuki AU - Akiyama Y AUID- ORCID: 0000-0003-1439-5640 AD - Department of Urology, Shinshu University School of Medicine, Nagano, Japan. LA - eng GR - This study was supported by a Grant-in-Aid for the Genome Research Project from Yamanashi Prefecture (to M.O. and Y.H.), the Japan Society for the Promotion of Science (JSPS) KAKENHI Early-Career Scientists JP18K16292 (to Y.H.), a Grant-in-Aid for Scientific Research (B) 20H03668 and 23K27646 (to Y.H.), a Research Grant for Young Scholars (to Y.H.), the YASUDA Medical Foundation (to Y.H.), the Uehara Memorial Foundation (to Y.H.), and medical research grants from the Takeda Science Foundation (t/ PT - Journal Article DEP - 20251209 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Biomarkers, Tumor) RN - 0 (DNA, Neoplasm) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/surgery/pathology/genetics/diagnosis MH - Male MH - Aged MH - Female MH - *Neoplasm Recurrence, Local/urine/diagnosis/genetics MH - Pilot Projects MH - Middle Aged MH - Cystoscopy MH - *Carcinoma, Transitional Cell/urine/surgery/pathology/genetics MH - Retrospective Studies MH - *Biomarkers, Tumor/urine MH - Aged, 80 and over MH - Prospective Studies MH - Predictive Value of Tests MH - Urinary Bladder/pathology/surgery MH - Follow-Up Studies MH - *DNA, Neoplasm/urine MH - Cystectomy PMC - PMC12830168 OTO - NOTNLM OT - intravesical recurrence OT - urine DNA OT - urine cytology OT - urothelial bladder cancer COIS- Approval of the Research Protocol by an Institutional Reviewer Board: The protocol for this research project has been approved by the Institutional Review Board of Yamanashi Central Hospital (no. G-2018-1). This study conforms to the provisions outlined in the Declaration of Helsinki. Registry and the Registration No. of the Study/Trial: UMIN000058060. Animal Studies (If Not Applicable Please Write N/A.): Not applicable. Tomonori Minagawa and Yoshiyuki Akiyama are the Editorial Board members of the International Journal of Urology and the co-authors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. EDAT- 2025/12/09 07:38 MHDA- 2026/01/24 00:32 PMCR- 2026/01/24 CRDT- 2025/12/09 05:42 PHST- 2025/11/03 00:00 [revised] PHST- 2025/06/09 00:00 [received] PHST- 2025/11/06 00:00 [accepted] PHST- 2026/01/24 00:32 [medline] PHST- 2025/12/09 07:38 [pubmed] PHST- 2025/12/09 05:42 [entrez] PHST- 2026/01/24 00:00 [pmc-release] AID - IJU70293 [pii] AID - 10.1111/iju.70293 [doi] PST - ppublish SO - Int J Urol. 2026 Jan;33(1):e70293. doi: 10.1111/iju.70293. Epub 2025 Dec 9. PMID- 41354695 OWN - NLM STAT- MEDLINE DCOM- 20260108 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2025 Dec 7 TI - Preferred surgical strategies for bladder diverticular carcinoma. PG - 917 LID - 10.1038/s41598-025-30477-5 [doi] LID - 917 AB - To investigate the safety and efficacy of laparoscopic partial cystectomy in the treatment of bladder diverticular carcinoma. A retrospective analysis was performed on the clinical data of 12 patients diagnosed with bladder diverticular carcinoma who were treated at Quanzhou First Hospital Affiliated to Fujian Medical University between January 2016 and May 2023. All patients underwent laparoscopic partial cystectomy. The study assessed surgical parameters (e.g., operation time, intraoperative blood loss), pathological findings (tumor grade, stage, surgical margin status), postoperative complications, adjuvant treatment regimens, and long-term follow-up outcomes (tumor recurrence, survival status). All 12 operations were completed successfully without major intraoperative complications. Postoperative pathology confirmed bladder urothelial carcinoma in all cases, with negative surgical margins in all patients. Postoperatively, all patients received regular intravesical instillation chemotherapy. Additionally, 5 patients underwent systemic intravenous chemotherapy, and 1 patient received intra-arterial chemotherapy as adjuvant treatment to reduce the risk of tumor recurrence. The median follow-up duration was 16-49 months. During follow-up, 11 patients remained free of tumor recurrence, while 1 patient developed recurrent bladder cancer at 15 months postoperatively (subsequently managed with transurethral resection of bladder tumor and adjuvant radiotherapy, achieving long-term survival). Laparoscopic partial cystectomy is a safe and effective therapeutic option for bladder diverticular carcinoma, characterized by low postoperative complication rates and favorable tumor control. Larger-sample, multi-center studies with longer follow-up are needed to further validate its long-term prognostic benefits. CI - (c) 2025. The Author(s). FAU - Ye, Yanle AU - Ye Y AD - Department of Urology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, No. 1028, Anji Road, Quanzhou, 362000, Fujian, China. FAU - Chen, Qingxia AU - Chen Q AD - Department of Urology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, No. 1028, Anji Road, Quanzhou, 362000, Fujian, China. FAU - Huang, Zhiyang AU - Huang Z AD - Department of Urology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, No. 1028, Anji Road, Quanzhou, 362000, Fujian, China. FAU - Huang, Qi AU - Huang Q AD - Department of Urology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, No. 1028, Anji Road, Quanzhou, 362000, Fujian, China. 15980271958@163.com. LA - eng GR - No. Quanke [2021] No. 150/The project was funded by the Quanzhou Science and Technology Program/ PT - Journal Article DEP - 20251207 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - Bladder Diverticulum SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Middle Aged MH - Retrospective Studies MH - *Cystectomy/methods MH - Laparoscopy/methods MH - *Diverticulum/surgery/pathology MH - Treatment Outcome MH - *Urinary Bladder/surgery/pathology/abnormalities MH - Neoplasm Recurrence, Local MH - Postoperative Complications PMC - PMC12783667 OTO - NOTNLM OT - Bladder cancer OT - Bladder diverticular carcinoma OT - Laparoscopic partial cystectomy COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study protocol was approved by the Institutional Review Board of the First Affiliated Hospital of Quanzhou, Fujian Medical University (IRB: Quanyi Ethics [2021] No. 292). Informed consent was obtained from all participants prior to the start of the study. Consent for publication: All authors read the final manuscript and agreed to publish it. EDAT- 2025/12/08 01:37 MHDA- 2026/01/09 00:26 PMCR- 2025/12/07 CRDT- 2025/12/07 23:06 PHST- 2024/12/29 00:00 [received] PHST- 2025/11/25 00:00 [accepted] PHST- 2026/01/09 00:26 [medline] PHST- 2025/12/08 01:37 [pubmed] PHST- 2025/12/07 23:06 [entrez] PHST- 2025/12/07 00:00 [pmc-release] AID - 10.1038/s41598-025-30477-5 [pii] AID - 30477 [pii] AID - 10.1038/s41598-025-30477-5 [doi] PST - epublish SO - Sci Rep. 2025 Dec 7;16(1):917. doi: 10.1038/s41598-025-30477-5. PMID- 41354277 OWN - NLM STAT- MEDLINE DCOM- 20260208 LR - 20260208 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 208 DP - 2026 Feb TI - Clinical Characteristics, Recurrence, and Survival for Children and Young Adults With Urothelial Cancer: A Systematic Review. PG - 135-141 LID - S0090-4295(25)01331-7 [pii] LID - 10.1016/j.urology.2025.11.242 [doi] AB - OBJECTIVE: To perform a systematic review of available data among children and young adults and propose a risk-based surveillance protocol. It was hypothesized that this population had favorable outcomes, with low rates of recurrence and death. METHODS: Medline was searched for peer-reviewed reports of pediatric and young adult (aged 21 years or below) urothelial cancer through July 2023. Demographic, clinical, and oncologic variables were extracted, with clinicopathological outcomes and survival described. RESULTS: Overall, 256 patients from 118 papers were included. There was a 2:1 male predominance, and the median age at diagnosis was 13 (IQR 10-16) years. 3.1% of patients had a known genetic syndrome and 78.5% presented with gross hematuria. 76% of patients had either papillary urothelial neoplasm of low malignant potential or low-grade urothelial carcinoma (UC), while 9% had high-grade UC. Regarding staging, 84% had non-muscle invasive and 5.1% had muscle invasive disease. Tumor recurrence was seen in 9% of patients with localized disease at presentation. Median time to recurrence after initial resection was 12 (IQR 6-21) months. The patients were followed for a median of 36 months (IQR 12-69). CONCLUSION: Children and young adult urothelial cancer patients have an excellent prognosis, but up to 10% can recur. The authors recommend long-term follow-up for these patients and herein suggest a risk-based protocol that balances the morbidity and costs of surveillance with the risk of recurrence and/or progression. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Aponte-Colon, Diana A AU - Aponte-Colon DA AD - Department of Urology, Duke University, Durham, NC. Electronic address: daa42@duke.edu. FAU - Wilcox Vanden Berg, Rand AU - Wilcox Vanden Berg R AD - Department of Urology, Duke University, Durham, NC. FAU - Tua-Caraccia, Rafael AU - Tua-Caraccia R AD - Department of Urology, Duke University, Durham, NC. FAU - Kim, Joshua K AU - Kim JK AD - Duke University School of Medicine, Durham, NC. FAU - Kaplan, Samantha AU - Kaplan S AD - Duke University Medical Library, Durham, NC. FAU - Routh, Jonathan C AU - Routh JC AD - Department of Urology, Duke University, Durham, NC. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251205 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/epidemiology MH - Child MH - Adolescent MH - *Urinary Bladder Neoplasms/mortality/pathology/diagnosis/therapy MH - *Carcinoma, Transitional Cell/mortality/pathology/diagnosis/therapy MH - Young Adult MH - Survival Rate MH - Male MH - Prognosis COIS- Declaration of Competing Interest Authors report no competing interests. EDAT- 2025/12/08 01:36 MHDA- 2026/02/09 00:29 CRDT- 2025/12/07 19:35 PHST- 2025/06/17 00:00 [received] PHST- 2025/11/19 00:00 [revised] PHST- 2025/11/26 00:00 [accepted] PHST- 2026/02/09 00:29 [medline] PHST- 2025/12/08 01:36 [pubmed] PHST- 2025/12/07 19:35 [entrez] AID - S0090-4295(25)01331-7 [pii] AID - 10.1016/j.urology.2025.11.242 [doi] PST - ppublish SO - Urology. 2026 Feb;208:135-141. doi: 10.1016/j.urology.2025.11.242. Epub 2025 Dec 5. PMID- 41346430 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251205 LR - 20260925 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 12 DP - 2025 Dec TI - Haematuria cancer risk score as a predictor of muscle-invasive bladder cancer. PG - e70125 LID - 10.1002/bco2.70125 [doi] LID - e70125 AB - OBJECTIVE: To evaluate the prognostic performance of the Haematuria Cancer Risk Score (HCRS) for predicting muscle-invasive bladder cancer (MIBC) in patients presenting with haematuria. METHODS: This retrospective study analysed newly diagnosed urothelial carcinoma cases identified during haematuria evaluations between 2018 and 2023. Pathological staging was based on the highest grade or stage from TUR or re-TUR specimens. HCRS was calculated using age, sex, haematuria type, and smoking status. The primary outcome was muscle-invasive disease (>/=T2). Associations were examined using univariate logistic regression, and discriminatory performance was evaluated with ROC analysis and bootstrap-derived 95% confidence intervals. RESULTS: Among 162 patients, 45 (27.8%) had MIBC. The median HCRS was higher in patients with MIBC than in those with non-muscle-invasive disease (6.49 [6.08-6.96] vs. 6.16 [5.44-6.94]; p = 0.04). Univariate analysis showed a significant association between HCRS and MIBC (odds ratio = 1.78; 95% CI 1.03-3.06; p = 0.039). ROC analysis demonstrated limited discriminative performance (AUC = 0.60; 95% CI 0.53-0.67). At the Youden cut-off of 6.04, sensitivity was 77.8% and specificity 48.3%. An integer threshold of HCRS >/=6 yielded comparable performance, supporting clinical applicability. CONCLUSIONS: Higher HCRS values were modestly associated with muscle invasion, although predictive performance was limited. The HCRS may support risk stratification in haematuria pathways by flagging patients at higher risk of muscle invasion-particularly when interpreted together with cystoscopy and imaging findings. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Turan, Serdar AU - Turan S AUID- ORCID: 0000-0003-4894-4441 AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. FAU - Gezmis, Cem Tugrul AU - Gezmis CT AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. FAU - Cilesiz, Nusret Can AU - Cilesiz NC AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. FAU - Uzut, Mehmet AU - Uzut M AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. FAU - Satilmisoglu, Mustafa AU - Satilmisoglu M AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. AD - Department of Urology, Istanbul Faculty of Medicine Istanbul University Istanbul Turkiye. FAU - Ergul, Rifat Burak AU - Ergul RB AUID- ORCID: 0000-0001-6262-9582 AD - Department of Urology, Istanbul Faculty of Medicine Istanbul University Istanbul Turkiye. FAU - Balci, Mustafa Bahadir Can AU - Balci MBC AD - Department of Urology Taksim Training and Research Hospital Istanbul Turkiye. LA - eng PT - Journal Article DEP - 20251203 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12673275 OTO - NOTNLM OT - Haematuria Cancer Risk Score OT - bladder cancer OT - muscle-invasive bladder cancer OT - prognostic factors OT - risk stratification COIS- The authors declare no conflicts of interest. EDAT- 2025/12/05 06:27 MHDA- 2025/12/05 06:28 PMCR- 2025/12/03 CRDT- 2025/12/05 04:25 PHST- 2025/11/11 00:00 [received] PHST- 2025/11/15 00:00 [accepted] PHST- 2025/12/05 06:28 [medline] PHST- 2025/12/05 06:27 [pubmed] PHST- 2025/12/05 04:25 [entrez] PHST- 2025/12/03 00:00 [pmc-release] AID - BCO270125 [pii] AID - 10.1002/bco2.70125 [doi] PST - epublish SO - BJUI Compass. 2025 Dec 3;6(12):e70125. doi: 10.1002/bco2.70125. eCollection 2025 Dec. PMID- 41337691 OWN - NLM STAT- In-Process LR - 20260813 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 44 IP - 7 DP - 2026 Mar TI - Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. PG - 586-597 LID - 10.1200/JCO-25-02382 [doi] AB - PURPOSE: Standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant cisplatin-based chemotherapy (NAC). However, many patients are ineligible for or refuse cisplatin. SunRISe-4 (ClinicalTrials.gov identifier: NCT04919512) is an open-label, multicenter, parallel-cohort phase II study assessing neoadjuvant gemcitabine intravesical system (TAR-200/gem-iDRS) plus cetrelimab or cetrelimab monotherapy in patients with MIBC. METHODS: Adults with Eastern Cooperative Oncology Group performance status 0-1, cT2-T4a N0M0, ineligible/refusing NAC, and planned for RC were randomly assigned 5:3, stratified by transurethral resection of bladder tumor completeness (residual tumor 70, size >3 cm, multiple lesions). High-grade (HG) Ta can be categorized as intermediate-risk (IR) or high-risk (HR). However, the 2021 EAU stratification is based on non-BCG-treated patients. This study investigated the predictive value of EAU risk groups and factors in TaHG treated with BCG. METHODS: We retrospectively reviewed NMIBC patients treated with BCG from 2005 to 2022. Patients were stratified by EAU 2021 risk groups. The primary endpoint was HG recurrence-free survival (RFS). RESULTS: Among 163 TaHG patients, 84 (54%) had one risk factor, 40 (23%) two, and 8 (4%) three. According to EAU 2021, 71% (115) were IR and 29% (48) HR. Median follow-up was 37 months (IQR 19-64). Three patients progressed to MIBC or M+. Three-year HG RFS was 84% (95% CI: 69-96), 80% (95% CI: 68-87), 83% (95% CI: 66-92), and 87% (95% CI: 38-98) for patients with 0, 1, 2, and 3 risk factors, respectively (P = 0.85). For IR and HR groups, 3-year HG RFS was 81% (95% CI: 76-90) and 84% (95% CI: 68-92) (P = 0.97). At Cox regression analysis, neither the number of risk factors nor HR classification was a predictor of HG recurrence (P = 0.9). CONCLUSIONS: Progression to MIBC was rare in our real-world cohort of BCG-treated TaHG NMIBC, while HG recurrence rates mirrored those of T1HG cases. Neither the EAU 2021 risk groups nor individual clinical RFs predicted HG recurrence effectively. Development of recurrence-based risk models for TaHG NMIBC is therefore warranted. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Finocchiaro, Alessio AU - Finocchiaro A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Piccolini, Andrea AU - Piccolini A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Brin, Pietro AU - Brin P AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Moretto, Stefano AU - Moretto S AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Dagnino, Filippo AU - Dagnino F AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Aljoulani, Muhannad AU - Aljoulani M AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Uleri, Alessandro AU - Uleri A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Avolio, Pierpaolo AU - Avolio P AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Beatrici, Edoardo AU - Beatrici E AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Mancon, Stefano AU - Mancon S AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Buffi, Nicolo AU - Buffi N AD - Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. Electronic address: Massimo.lazzeri@humanitas.it. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. LA - eng PT - Journal Article DEP - 20251127 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Risk Assessment MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Grading OTO - NOTNLM OT - AUA OT - BCG OT - Bladder cancer OT - EAU 2021 guidelines OT - High-grade OT - IBCG OT - NMIBC OT - Risk categories OT - Ta COIS- Declaration of competing interest None of the authors have any relevant disclosures, and none have any financial or nonfinancial interests pertinent to the submitted work. EDAT- 2025/11/29 02:21 MHDA- 2026/01/19 01:03 CRDT- 2025/11/28 21:53 PHST- 2025/07/04 00:00 [received] PHST- 2025/09/18 00:00 [revised] PHST- 2025/11/02 00:00 [accepted] PHST- 2026/01/19 01:03 [medline] PHST- 2025/11/29 02:21 [pubmed] PHST- 2025/11/28 21:53 [entrez] AID - S1078-1439(25)00447-8 [pii] AID - 10.1016/j.urolonc.2025.11.003 [doi] PST - ppublish SO - Urol Oncol. 2026 Feb;44(2):119.e1-119.e6. doi: 10.1016/j.urolonc.2025.11.003. Epub 2025 Nov 27. PMID- 41314851 OWN - NLM STAT- MEDLINE DCOM- 20251128 LR - 20251219 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 11 DP - 2025 Nov 28 TI - Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial. PG - e107824 LID - 10.1136/bmjopen-2025-107824 [doi] LID - e107824 AB - INTRODUCTION: The impact of anaesthesia modality on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) remains uncertain. Emerging evidence suggests that anaesthetic agents and techniques may influence tumour biology and recurrence through immunomodulatory and neuroendocrine pathways. However, prospective randomised trials comparing spinal and general anaesthesia in this population are lacking. METHODS AND ANALYSIS: This single-centre, prospective, parallel-arm randomised controlled trial will enrol 370 patients with clinically suspected high-risk NMIBC undergoing transurethral resection of bladder tumour. Participants will be randomised 1:1 to receive either spinal or general anaesthesia. The primary endpoint is time to recurrence over a 104-week follow-up period. Secondary endpoints include time to progression, Bacillus Calmette-Guerin (BCG) unresponsiveness and a composite oncological event. Additional secondary outcomes include postoperative opioid consumption (morphine equivalents), obturator jerk occurrence, acute urinary retention and tolerance to immediate intravesical chemotherapy. Safety outcomes will include treatment-emergent adverse events, Clavien-Dindo graded surgical complications, haemorrhagic events and anaesthesia-related risks. Exploratory endpoints involve perioperative biomarker analyses. Data will be analysed on an intention-to-treat basis. ETHICS AND DISSEMINATION: Recruitment has not yet started. It is expected to begin in December 2025 and to be completed by June 2029. The planned follow-up period for each participant is 104 weeks. This manuscript is based on protocol V.1.0, dated March 2025. Results will be disseminated through peer-reviewed journals and conference presentations TRIAL REGISTRATION NUMBER: NCT06982690. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Fang, Chu-Wen AU - Fang CW AUID- ORCID: 0009-0000-3170-4869 AD - Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua City, Taiwan. AD - Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan. FAU - Shau, Wen-Yi AU - Shau WY AD - Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan cm007abao@gmail.com jeffchueh@gmail.com wyshau@msn.com wen-yi.shau@pfizer.com. FAU - Fan, Shou-Zen AU - Fan SZ AD - Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan. AD - Department of Anesthesiology, National Taiwan University College of Medicine, Taipei City, Taiwan. FAU - Chueh, Jeff S AU - Chueh JS AUID- ORCID: 0009-0003-9540-9932 AD - Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan cm007abao@gmail.com jeffchueh@gmail.com wyshau@msn.com wen-yi.shau@pfizer.com. AD - Department of Urology, National Taiwan University Hospital, Taipei City, Taiwan. LA - eng SI - ClinicalTrials.gov/NCT06982690 PT - Clinical Trial Protocol PT - Journal Article DEP - 20251128 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Female MH - Humans MH - *Anesthesia, General/methods MH - *Anesthesia, Spinal/methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Non-Muscle Invasive Bladder Neoplasms/surgery MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/surgery PMC - PMC12666151 OTO - NOTNLM OT - Anaesthesia in oncology OT - Anaesthesia in urology OT - Cancer OT - Treatment Outcome OT - Urological tumours COIS- Competing interests: None declared. EDAT- 2025/11/29 02:21 MHDA- 2025/11/29 02:22 PMCR- 2025/11/28 CRDT- 2025/11/28 21:43 PHST- 2025/11/29 02:22 [medline] PHST- 2025/11/29 02:21 [pubmed] PHST- 2025/11/28 21:43 [entrez] PHST- 2025/11/28 00:00 [pmc-release] AID - bmjopen-2025-107824 [pii] AID - 10.1136/bmjopen-2025-107824 [doi] PST - epublish SO - BMJ Open. 2025 Nov 28;15(11):e107824. doi: 10.1136/bmjopen-2025-107824. PMID- 41313232 OWN - NLM STAT- MEDLINE DCOM- 20260401 LR - 20260730 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 26 IP - 4 DP - 2026 Apr TI - From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors. PG - 463-477 LID - 10.1080/14737140.2025.2597526 [doi] AB - INTRODUCTION: Residual lesions after transurethral resection of bladder tumor (TURBT) are a major contributor to recurrence in bladder cancer. Advances in diagnostic technology are shifting postoperative management from conventional macroscopic evaluation toward molecular-level assessment. AREAS COVERED: A systematic search of PubMed, Web of Science and Embase from January 2000 to September 2025 identified studies on postoperative residual disease detection in non-muscle invasive bladder cancer (NMIBC). At the macroscopic level, enhanced cystoscopic modalities and artificial intelligence have improved visualization and recognition of subtle urothelial abnormalities. At the microscopic level, liquid biopsy approaches such as urinary tumor DNA, plasma circulating tumor DNA and exosome-based biomarkers enable more sensitive detection of minimal residual disease and dynamic molecular risk stratification beyond traditional cystoscopy and cytology. Integration of imaging findings with molecular profiling provides a more comprehensive basis for individualized surveillance and early therapeutic intervention in NMIBC. EXPERT OPINION: Future priorities include standardizing diagnostic workflows, improving multi-omics integration and validating MRD-guided strategies in prospective studies. These developments may refine risk stratification, reduce recurrence, and support more personalized postoperative management in bladder cancer. FAU - Zhang, Yalong AU - Zhang Y AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, China. FAU - Yan, Rui AU - Yan R AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, China. FAU - Wang, Hao AU - Wang H AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, China. FAU - Man, Jiangwei AU - Man J AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, China. FAU - Yang, Li AU - Yang L AD - Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251202 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/diagnosis MH - Neoplasm, Residual/diagnosis MH - Cystoscopy/methods MH - Biomarkers, Tumor/metabolism MH - Neoplasm Recurrence, Local MH - Liquid Biopsy/methods MH - Artificial Intelligence MH - Risk Assessment OTO - NOTNLM OT - Bladder cancer OT - liquid biopsy OT - minimal residual disease OT - molecular probe OT - postoperative residual disease EDAT- 2025/11/28 13:30 MHDA- 2026/04/01 12:32 CRDT- 2025/11/28 09:52 PHST- 2026/04/01 12:32 [medline] PHST- 2025/11/28 13:30 [pubmed] PHST- 2025/11/28 09:52 [entrez] AID - 10.1080/14737140.2025.2597526 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2026 Apr;26(4):463-477. doi: 10.1080/14737140.2025.2597526. Epub 2025 Dec 2. PMID- 41308254 OWN - NLM STAT- MEDLINE DCOM- 20260122 LR - 20260122 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 1 DP - 2026 Feb TI - Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer. PG - 102464 LID - S1558-7673(25)00164-8 [pii] LID - 10.1016/j.clgc.2025.102464 [doi] AB - AIM: Patients with NMIBC frequently experience recurrences. Yet, the timing and characteristics of subsequent recurrences are understudied. We aim to describe subsequent recurrences in a large, contemporary, population-based cohort. METHODS: We included 1915 patients from the UroLife study and the Nijmegen Bladder Cancer Study, diagnosed with primary NMIBC between 2011 and 2021. The conditional 1-, 3- and 5-year risks of first to fourth recurrence were calculated using Kaplan-Meier risks, stratified by clinicopathological factors. Patterns of subsequent tumors were described and visualized. RESULTS: We observed 671 first recurrences and 400 subsequent recurrences. The 3-year conditional recurrence risks for first, second and third recurrence were 31%, 45%, and 54%, respectively, and were similar for NMIBC risk groups. Recurrence after a low-, intermediate- or high-risk tumor (either primary or recurrent) was again of low-, intermediate- or high-risk in 74%, 62% and 44% of cases, respectively. Ten patients with low/intermediate-risk NMIBC and 89 patients with high-risk NMIBC progressed to MIBC or mBC. Seven out of these ten (70%) and 13 out of these 89 (15%) patients had a high-risk recurrence before progression. This study was limited to a patient cohort from The Netherlands. CONCLUSIONS: Our study provides reliable estimates of recurrence rates and patterns in NMIBC from a large, contemporary, population-based cohort. Recurring NMIBC tumors often exhibit similar clinicopathological characteristics, and patients with primary low- or intermediate-risk NMIBC that progresses to MIBC/mBC often have a high-risk recurrence before progression. These results can inform research into NMIBC recurrences and surveillance schedules. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Hof, Jasper P AU - Hof JP AD - IQ Health Science Department, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - IQ Health Science Department, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands; Department of Urology, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - IQ Health Science Department, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization, PO Box 19079, 3501DB, Utrecht, the Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - IQ Health Science Department, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - IQ Health Science Department, Radboud University Medical Center, PO Box 9101, 6500GB, Nijmegen, the Netherlands. Electronic address: sita.vermeulen@radboudumc.nl. LA - eng PT - Journal Article DEP - 20251104 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/epidemiology MH - Male MH - Female MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Aged MH - Middle Aged MH - Aged, 80 and over MH - Cohort Studies MH - Neoplasm Invasiveness MH - Kaplan-Meier Estimate MH - Risk Factors MH - Disease Progression MH - Netherlands/epidemiology MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Observational study OT - Outcome OT - Recurring tumors OT - Risk stratification OT - Urothelial carcinoma COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2025/11/27 18:28 MHDA- 2026/01/23 00:26 CRDT- 2025/11/27 18:01 PHST- 2025/08/20 00:00 [received] PHST- 2025/10/27 00:00 [revised] PHST- 2025/11/02 00:00 [accepted] PHST- 2026/01/23 00:26 [medline] PHST- 2025/11/27 18:28 [pubmed] PHST- 2025/11/27 18:01 [entrez] AID - S1558-7673(25)00164-8 [pii] AID - 10.1016/j.clgc.2025.102464 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Feb;24(1):102464. doi: 10.1016/j.clgc.2025.102464. Epub 2025 Nov 4. PMID- 41300366 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251127 LR - 20260925 IS - 2079-7737 (Print) IS - 2079-7737 (Electronic) IS - 2079-7737 (Linking) VI - 14 IP - 11 DP - 2025 Nov 11 TI - Phase Separation Competent TIA1 Couples Glycolytic Shutdown to CD8(+) T-Cell Activation and Shapes the Efficacy of Intravesical BCG in Bladder Cancer. LID - 10.3390/biology14111576 [doi] LID - 1576 AB - Metabolic immune evasion is a major factor limiting the long-term efficacy of intravesical Bacillus Calmette-Guerin (BCG) therapy in non-muscle-invasive bladder cancer (NMIBC). TIA1 is a stress granule RNA-binding protein with liquid-liquid phase separation (LLPS) capacity. Its role in tumor metabolism and immunotherapy response has been unclear. Here, we demonstrated that high TIA1 expression was independently associated with favorable survival across multiple cohorts. Full-length TIA1 formed cytoplasmic condensates, repressed LDHA/PKM2/HK2, reduced lactate, and lowered extracellular acidification. A condensate-defective DeltaLCD (deletion of the low-complexity domain) mutant was inactive. TIA1 showed physical association with these glycolytic mRNAs in human cells, consistent with mRNA-linked control. Condensate-competent TIA1 promoted CD8(+) T-cell proliferation, increased CD69 and Granzyme-B, and reduced PD-1 in co-culture. TIMER (Tumor Immune Estimation Resource) and spatial-omics supported co-localization with tumoral CD8A. BCG induced this metabolic-immune signature in cell lines, murine models, and patient explants, but the effects were abolished by TIA1 knock-down. Conversely, TIA1 over-expression alone limited tumor growth and recapitulated BCG-mediated glycolytic restraint and T-cell activation. Together, these results support an LLPS-linked, mRNA-associated regulation of tumor glycolysis. BCG-driven glycolytic suppression and CD8(+) T cell activation track with the condensate-forming capacity of TIA1. TIA1 emerges as a prognostic biomarker and a potential therapeutic axis to improve intravesical immunotherapy in NMIBC. FAU - Zhang, Wenwen AU - Zhang W AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China. FAU - Zhou, Kailiang AU - Zhou K AD - The Eighth Hospital of Wuhan, Wuhan 430010, China. FAU - Chen, Pinru AU - Chen P AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China. FAU - Du, Xuanshuang AU - Du X AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China. FAU - Liu, Min AU - Liu M AUID- ORCID: 0000-0001-7095-1344 AD - Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China. LA - eng GR - 2024KZL07/Open Foundation of Hubei Province Key Laboratory of Tumor Microenvironment and Immunotherapy/ GR - 82272978/National Natural Science Foundation of China grants/ GR - 2021CFB484/Natural Science Foundation Project of Hubei Province/ PT - Journal Article DEP - 20251111 PL - Switzerland TA - Biology (Basel) JT - Biology JID - 101587988 PMC - PMC12649904 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - CD8+ T cells OT - TIA1 OT - bladder cancer OT - glycolysis OT - liquid-liquid phase separation COIS- The authors declare no conflicts of interest. EDAT- 2025/11/27 06:28 MHDA- 2025/11/27 06:29 PMCR- 2025/11/11 CRDT- 2025/11/27 01:02 PHST- 2025/09/28 00:00 [received] PHST- 2025/11/04 00:00 [revised] PHST- 2025/11/07 00:00 [accepted] PHST- 2025/11/27 06:29 [medline] PHST- 2025/11/27 06:28 [pubmed] PHST- 2025/11/27 01:02 [entrez] PHST- 2025/11/11 00:00 [pmc-release] AID - biology14111576 [pii] AID - biology-14-01576 [pii] AID - 10.3390/biology14111576 [doi] PST - epublish SO - Biology (Basel). 2025 Nov 11;14(11):1576. doi: 10.3390/biology14111576. PMID- 41289654 OWN - NLM STAT- MEDLINE DCOM- 20260130 LR - 20260130 IS - 1532-3072 (Electronic) IS - 0040-8166 (Linking) VI - 99 DP - 2026 Apr TI - Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients. PG - 103240 LID - S0040-8166(25)00522-1 [pii] LID - 10.1016/j.tice.2025.103240 [doi] AB - Impaired autophagy could contribute to genetic heterogeneity, differential cellular response to drugs and disease relapse in bladder cancer. Among key autophagy related genes, ATG4B, cleaves pro- microtubule-associated protein1 light chain 3 (LC3) to LC3-I, enabling its conjugation to phosphatidylethanolamine (PE) to form membrane-bound LC3-II. LC3-II binds to adaptor protein p62 which facilitates autophagic degradation in lysosomes. Current study determined clinical implications of autophagic markers in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients. Gene and immuno-expressions of ATG4B, LC3B and p62 were examined by RT-qPCR, western and immunohistochemical staining and their associations with clinicohistopathological characteristics and survival outcomes of 47 NMIBC and 37 MIBC patients. Transmission electron microscopy (TEM) evaluated autophagy/ autophagic vesicles in tumor stage/grade-dependent manner. Observed higher LC3 mRNA showed significances with smoking status and tumor size in MIBC cohort. Increased cytoplasmic LC3-II/LC3-I exhibited significances with tumor type in NMIBC and MIBC and size in MIBC patients. Study reported reduction in gene and protein levels of ATG4B and p62 with increase in tumor stage and grade. TEM studies examined increase in autophagic vesicles with tumor stage and grade. Cox regression identified tumor size and cytoplasmic LC3 as predictors of short PFS and RFS respectively in NMIBC patients. Kaplan Meier analysis established LC3 as an independent predictor of short RFS in NMIBC patients. To the best of our knowledge, this is the first study exploring the clinical implications of ATG4B, LC3 and p62 in urothelial tumorigenesis. Studies are required to validate their relevances in larger cohort. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Niharika AU - Niharika AD - Department of Biochemistry, University of Lucknow, Lucknow 226007, India. FAU - Tripathi, Shreyansh AU - Tripathi S AD - Department of Biochemistry, University of Lucknow, Lucknow 226007, India. FAU - Singhai, Atin AU - Singhai A AD - Department of Pathology, King George's Medical University, Lucknow 226003, India. FAU - Goel, Apul AU - Goel A AD - Department of Urology, King George's Medical University, Lucknow 226003, India. FAU - Singh, Rita AU - Singh R AD - Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, Haryana 121001, India. FAU - Kumar, Niraj AU - Kumar N AD - Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO box #04, Faridabad, Haryana 121001, India. FAU - Garg, Minal AU - Garg M AD - Department of Biochemistry, University of Lucknow, Lucknow 226007, India. Electronic address: garg_minal@lkouniv.ac.in. LA - eng PT - Journal Article DEP - 20251121 PL - Scotland TA - Tissue Cell JT - Tissue & cell JID - 0214745 RN - 0 (Microtubule-Associated Proteins) RN - 0 (Autophagy-Related Proteins) RN - EC 3.4.22.- (ATG4B protein, human) RN - 0 (MAP1LC3A protein, human) RN - EC 3.4.22.- (Cysteine Endopeptidases) RN - 0 (Biomarkers, Tumor) RN - 0 (Sequestosome-1 Protein) RN - 0 (MAP1LC3B protein, human) RN - 0 (P62 protein, human) RN - 0 (SQSTM1 protein, human) RN - 0 (RNA-Binding Proteins) SB - IM MH - Humans MH - *Microtubule-Associated Proteins/metabolism/genetics/biosynthesis MH - *Urinary Bladder Neoplasms/pathology/metabolism/genetics MH - *Autophagy-Related Proteins/metabolism/genetics/biosynthesis MH - *Autophagy/genetics MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Cysteine Endopeptidases/metabolism/genetics/biosynthesis MH - *Biomarkers, Tumor/metabolism/genetics MH - *Sequestosome-1 Protein/metabolism/genetics MH - RNA-Binding Proteins OTO - NOTNLM OT - ATG4B, LC3 and p62 OT - Autophagy OT - Clinical relevance OT - NMIBC and MIBC patients COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/11/26 00:27 MHDA- 2026/01/31 00:29 CRDT- 2025/11/25 18:01 PHST- 2025/09/15 00:00 [received] PHST- 2025/11/17 00:00 [revised] PHST- 2025/11/19 00:00 [accepted] PHST- 2026/01/31 00:29 [medline] PHST- 2025/11/26 00:27 [pubmed] PHST- 2025/11/25 18:01 [entrez] AID - S0040-8166(25)00522-1 [pii] AID - 10.1016/j.tice.2025.103240 [doi] PST - ppublish SO - Tissue Cell. 2026 Apr;99:103240. doi: 10.1016/j.tice.2025.103240. Epub 2025 Nov 21. PMID- 41284039 OWN - NLM STAT- MEDLINE DCOM- 20251124 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Nov 24 TI - Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis. PG - 718 LID - 10.1007/s00345-025-06102-5 [doi] AB - OBJECTIVES: To compare rates of 30-day post-operative complications after transurethral resection of bladder tumors (TURBT) in octogenarians versus younger patients. METHODS: We conducted a review of the NSQIP database from 2012 to 2022. We included patients undergoing TURBT as the principal procedure, and excluded patients with disseminated cancer, pre-operative sepsis, or who were ventilator-dependent. We conducted multivariate logistic regression modeling to evaluate the association of age (>/= 80 vs. < 80 years) with 30-day post-operative complications, adjusting for confounders. We report adjusted odds ratios (aOR) and 95% confidence intervals (CI). RESULTS: We identified 78,665 reports of TURBT, of which 21,627 (27.5%) were performed on patients aged >/= 80. In multivariate analysis, age >/= 80 was significantly associated with septic shock (aOR 2.29; 95% CI 1.44-3.66), receipt of blood transfusion /= 1 day (aOR 1.50; 95% CI 1.43-1.57), unplanned related readmission (aOR 1.26; 95% CI 1.15-1.38), and death (aOR 2.74; 95% CI 2.15-3.52). Octogenarians had greater rates of readmission for hematuria (0.7% vs. 0.5%) but not reoperation for hematuria (0.7% vs. 0.8%). Octogenarians were also more frequently readmitted for severe complications (31.8% vs. 26.3% CD grades 3-5). CONCLUSIONS: Octogenarians who underwent TURBT experienced higher rates of several serious 30-day complications. While TURBT in octogenarians has a low rate of complications overall, clinicians should remain mindful of increased risk of complications for pre-operative counseling and discharge preparation. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Song, Jonathan J AU - Song JJ AD - Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Zhou, Maya T AU - Zhou MT AD - Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Lee, Samuel Z AU - Lee SZ AD - Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Jones, James McAndrew AU - Jones JM AD - Department of Urology, Boston Medical Center, 725 Albany Street, Suite 3B, Boston, MA, 02118, USA. FAU - Katz, Mark H AU - Katz MH AD - Department of Urology, Boston Medical Center, 725 Albany Street, Suite 3B, Boston, MA, 02118, USA. FAU - Wang, David S AU - Wang DS AD - Department of Urology, Boston Medical Center, 725 Albany Street, Suite 3B, Boston, MA, 02118, USA. david.wang@bmc.org. LA - eng PT - Comparative Study PT - Journal Article DEP - 20251124 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - Aged, 80 and over MH - Male MH - Female MH - *Postoperative Complications/epidemiology MH - *Cystectomy/methods/adverse effects MH - Age Factors MH - Aged MH - Retrospective Studies MH - Databases, Factual MH - Middle Aged MH - Urethra MH - Transurethral Resection of Bladder OTO - NOTNLM OT - NSQIP OT - Octogenarian OT - Post-operative complications OT - TURBT COIS- Declarations. Conflict of interest: None. EDAT- 2025/11/24 12:39 MHDA- 2025/11/24 18:38 CRDT- 2025/11/24 11:14 PHST- 2025/06/16 00:00 [received] PHST- 2025/11/16 00:00 [accepted] PHST- 2025/11/24 18:38 [medline] PHST- 2025/11/24 12:39 [pubmed] PHST- 2025/11/24 11:14 [entrez] AID - 10.1007/s00345-025-06102-5 [pii] AID - 10.1007/s00345-025-06102-5 [doi] PST - epublish SO - World J Urol. 2025 Nov 24;43(1):718. doi: 10.1007/s00345-025-06102-5. PMID- 41281745 OWN - NLM STAT- MEDLINE DCOM- 20251124 LR - 20260901 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 21 IP - 15 DP - 2025 TI - Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma. PG - 6649-6673 LID - 10.7150/ijbs.114618 [doi] AB - Muscle-invasive (MI) urothelial carcinoma (UC) is a clinically challenging malignancy with a poor prognosis. Understanding the cellular dynamics that drive UC progression is critical for the development of optimized therapeutic strategies. Through integrative analysis of large-scale single-cell transcriptomic datasets from non-muscle-invasive (NMI) and MI tumours and validation with spatial transcriptomic datasets, we systematically characterized immune cell dynamics and cancer cell plasticity during UC progression. Our analysis revealed an immunosuppressive tumour microenvironment and a subset of cancer cells with upregulated major histocompatibility complex II (MHC-II) expression in MI tumours. Notably, MHC-II(+) cancer cells were induced by interferon-gamma signalling, as confirmed through in vitro experiments, and exhibited phenotypic alterations characterized by enhanced proliferative and migratory capacities. Furthermore, MHC-II(+) cancer cells spatially colocalized with CD8(+) T cells, regulatory T cells, and SPP1(+) macrophages, where they engaged with inhibitory receptors on these immune cells, promoted CD8(+) T cell exhaustion and facilitated immune evasion. CI - (c) The author(s). FAU - Xiong, Shengwei AU - Xiong S AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Fan, Jian AU - Fan J AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Huang, Cong AU - Huang C AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - He, Shiming AU - He S AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Liang, Yuan AU - Liang Y AD - China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. FAU - Zhang, Qi AU - Zhang Q AD - China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. FAU - Guo, Bin AU - Guo B AD - China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. FAU - Wu, Yucai AU - Wu Y AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Xia, Mancheng AU - Xia M AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Zhao, Fangzhou AU - Zhao F AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Ci, Weimin AU - Ci W AD - Department of Urology, Chinese PLA General Hospital, Beijing 100039, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Gong, Yanqing AU - Gong Y AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing, 100034, China. AD - Institution of Urology, Peking University, Beijing, 100034, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, 100034, China. AD - National Urological Cancer Center, Beijing, 100034, China. LA - eng SI - GEO/GSE171351 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251020 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 RN - 0 (Histocompatibility Antigens Class II) SB - IM MH - Humans MH - Single-Cell Analysis MH - Tumor Microenvironment MH - Gene Expression Profiling MH - Transcriptome/genetics MH - *Urinary Bladder Neoplasms/metabolism/genetics MH - Cell Line, Tumor MH - *Histocompatibility Antigens Class II/metabolism/genetics MH - CD8-Positive T-Lymphocytes/metabolism PMC - PMC12631105 OTO - NOTNLM OT - Cellular heterogeneity OT - Immunosuppressive microenvironment OT - MHC-II molecules OT - Muscle invasion OT - Single-cell RNA sequencing OT - Urothelial carcinoma COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2025/11/24 12:39 MHDA- 2025/11/24 18:38 PMCR- 2025/10/20 CRDT- 2025/11/24 09:07 PHST- 2025/03/28 00:00 [received] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/11/24 18:38 [medline] PHST- 2025/11/24 12:39 [pubmed] PHST- 2025/11/24 09:07 [entrez] PHST- 2025/10/20 00:00 [pmc-release] AID - ijbsv21p6649 [pii] AID - 10.7150/ijbs.114618 [doi] PST - epublish SO - Int J Biol Sci. 2025 Oct 20;21(15):6649-6673. doi: 10.7150/ijbs.114618. eCollection 2025. PMID- 41280976 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251124 LR - 20251126 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 10 DP - 2025 Oct TI - Short-Term Morbidity and Mortality in Patients Undergoing Radical Cystectomy at a Tertiary Care Center: A Prospective Observational Study. PG - e95183 LID - 10.7759/cureus.95183 [doi] LID - e95183 AB - BACKGROUND: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC) but is associated with significant perioperative morbidity and mortality. This study evaluates short-term (90-day) morbidity and mortality outcomes following RC at Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, to identify complications and risk factors. METHODS: This prospective observational study, conducted from February 2023 to July 2025, included 173 patients undergoing RC for MIBC or high-risk non-MIBC (NMIBC) at SKIMS. Patients underwent RC with ileal conduit (IC) or orthotopic neobladder (NB) diversion. Complications within 90 days were graded using the Clavien-Dindo classification. Data on preoperative, operative, and postoperative variables were analyzed using IBM SPSS Statistics for Windows, version 24, with associations tested at a 5% significance level (P < 0.05). RESULTS: Of 173 patients (86.7% male, mean age 59.9 years), 52.6% (91/173) experienced complications, with 15.6% (27/173) classified as major (Grades 3-5). The most frequent complications were superficial wound infections (9.8%), postoperative blood transfusions (8.7%), and subacute intestinal obstruction (5.8%). The 90-day mortality rate was 3.4% (6/173), primarily due to septic shock and cardiovascular events. Predictors of complications included diabetes mellitus, advanced disease stage, higher American Society of Anesthesiologists (ASA) score, low preoperative hemoglobin, low serum albumin, longer operative time, and increased blood loss. Orthotopic NB patients had longer operative times and hospital stays but fewer complications due to selective patient criteria. CONCLUSION: RC at SKIMS carries a 52.6% complication rate and 3.4% mortality rate within 90 days. Optimizing patient selection, surgical techniques, and perioperative care is critical to reducing morbidity and improving outcomes in this high-risk procedure. CI - Copyright (c) 2025, Verma et al. FAU - Verma, Saundarya Kumar AU - Verma SK AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Wani, Saleem AU - Wani S AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Khawaja, Abdul Rouf AU - Khawaja AR AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Malik, Sajad A AU - Malik SA AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Para, Sajjad A AU - Para SA AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Hamid, Arif AU - Hamid A AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Mehdi, Saqib AU - Mehdi S AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Tantray, Mudasir Ahmad AU - Tantray MA AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. FAU - Khan, Tufeel Ahmad AU - Khan TA AD - Department of Urology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND. LA - eng PT - Journal Article DEP - 20251022 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12638069 OTO - NOTNLM OT - clavien-dindo classification OT - ileal conduit OT - muscle-invasive bladder cancer OT - radical cystectomy OT - urinary diversion COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Ethical Committee of Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar issued approval SIMS 131/IEC-SKIMS/2024-126. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/11/24 18:21 MHDA- 2025/11/24 12:39 PMCR- 2025/10/22 CRDT- 2025/11/24 09:00 PHST- 2025/10/22 00:00 [accepted] PHST- 2025/11/24 12:39 [medline] PHST- 2025/11/24 18:21 [pubmed] PHST- 2025/11/24 09:00 [entrez] PHST- 2025/10/22 00:00 [pmc-release] AID - 10.7759/cureus.95183 [doi] PST - epublish SO - Cureus. 2025 Oct 22;17(10):e95183. doi: 10.7759/cureus.95183. eCollection 2025 Oct. PMID- 41277127 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20260127 IS - 1752-0371 (Electronic) IS - 1752-0363 (Print) IS - 1752-0363 (Linking) VI - 19 IP - 22 DP - 2025 Nov TI - A CT-based deep learning radiomics model for predicting HER2 expression and prognosis in non-muscle-invasive bladder cancer. PG - 1117-1126 LID - 10.1080/17520363.2025.2590778 [doi] AB - OBJECTIVE: This study aimed to extract radiomics (Rad) and deep learning (DL) features from preoperative CT of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) and develop models incorporating clinical characteristics to assess Human-Epidermal-Growth-Factor-Receptor-2 (HER2) expression status and prognosis in these patients. METHODS: From January 2019 to December 2024, 181 patients with NMIBC were retrospectively enrolled in this study. A deep learning radio-clinical signature model (DLCS) was created by integrating DL score, Rad score, and clinicopathologic features to predict HER2 expression in NMIBC and compared with a deep learning model, a radiomic model, and a Clinical model. An additional model was built to predict Recurrence-Free Survival (RFS) in NMIBC patients. RESULTS: 181 patients with NMIBC were divided into a training cohort (n = 126) and a test cohort (n = 55). The DLCS model achieved the highest area under the curve (AUC) for HER2 prediction in the test cohort (AUC = 0.894 (95% CI: 0.814-0.974)). The univariate and multivariate Cox regression analyses identified both the DL score and Rad score as independent risk factors for RFS (p < 0.05). CONCLUSION: The DLCS model demonstrates good diagnostic performance in predicting HER2 expression, and the prognosis model can stratify the risk of tumor recurrence in patients with NMIBC. FAU - Jin, Tian AU - Jin T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Huanrui AU - Liu H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Senlin AU - Li S AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Haonan AU - Chen H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Shi, Tenglin AU - Shi T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhan, Yue AU - Zhan Y AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Haotian AU - Liu H AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Xinyuan AU - Li X AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Gou, Xin AU - Gou X AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20251123 PL - England TA - Biomark Med JT - Biomarkers in medicine JID - 101312535 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/metabolism/genetics MH - Female MH - *Deep Learning MH - *Erb-b2 Receptor Tyrosine Kinases/metabolism/genetics MH - Male MH - Prognosis MH - Middle Aged MH - *Tomography, X-Ray Computed/methods MH - Aged MH - Retrospective Studies MH - Biomarkers, Tumor/metabolism MH - Non-Muscle Invasive Bladder Neoplasms MH - Radiomics PMC - PMC12674324 OTO - NOTNLM OT - HER2 OT - Non-muscle invasive bladder cancer OT - deep learning OT - radiomics OT - recurrence-free survival COIS- The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2025/11/24 06:27 MHDA- 2025/12/02 12:56 PMCR- 2026/11/23 CRDT- 2025/11/24 02:13 PHST- 2025/12/02 12:56 [medline] PHST- 2025/11/24 06:27 [pubmed] PHST- 2025/11/24 02:13 [entrez] PHST- 2026/11/23 00:00 [pmc-release] AID - 2590778 [pii] AID - 10.1080/17520363.2025.2590778 [doi] PST - ppublish SO - Biomark Med. 2025 Nov;19(22):1117-1126. doi: 10.1080/17520363.2025.2590778. Epub 2025 Nov 23. PMID- 41272562 OWN - NLM STAT- MEDLINE DCOM- 20251230 LR - 20260101 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Nov 22 TI - Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients. PG - 1900 LID - 10.1186/s12885-025-15284-5 [doi] LID - 1900 AB - BACKGROUND: Muscle-invasive urothelial carcinoma (MIUC) poses higher risks of recurrence and metastasis compared with non-muscle-invasive urothelial carcinoma (NMIUC). However, difficulties in early detection and the invasive nature of current diagnostic procedures. Using next-generation sequencing (NGS), we aimed to profile comprehensive surveillance of urinary microRNAs (miRNAs) as a promising non-invasive tool for assessing urothelial carcinoma (UC) and identify differentially expressed miRNAs (DEmiRNAs) in patients with MIUC or NMIUC, providing insights into UC progression and molecular mechanisms in Taiwanese patients. We analyzed the clinical differences between patients with MIUC or NMIUC in treatment-naive patients. METHODS: Urinary miRNAs were profiled using NGS. DEmiRNAs were identified with DESeq2, and target prediction was performed using TarBase-v9.0 and DIANA-microT. Enrichment analysis was conducted with the miEAA tool to link DEmiRNAs to biological pathways and processes, focusing on the KEGG pathways and Gene Ontology (GO) annotations. RESULTS: Among the 52 participants, significantly more patients with MIUC used herbal medicines compared with the NMIUC group (p = 0.027). A total of 1,967 DEmiRNAs were detected comprehensively, with 691 upregulated and 232 downregulated in MIUC versus NMIUC. Notably, hsa-miR-3168 exhibited the highest upregulation (10.2-fold), while hsa-miR-511-3p was the most downregulated (9.32-fold). KEGG analysis revealed that upregulated DEmiRNAs were most enriched in amino acid biosynthesis pathways, while downregulated DEmiRNAs were associated with the Hedgehog signaling pathway. CONCLUSIONS: This study highlights urinary DEmiRNAs detected via NGS as a potential non-invasive diagnostic tool. Pathway analyses of DEmiRNAs provided valuable insights into UC progression and offers opportunities for future therapeutic development. CI - (c) 2025. The Author(s). FAU - Yang, I-Ning AU - Yang IN AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. AD - Department of Pharmaceutical Science and Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan. FAU - Liang, Chun-An AU - Liang CA AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. AD - School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Wu, Chia-Chun AU - Wu CC AD - Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. FAU - Xu, Qian-Sheng AU - Xu QS AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Lin, Shang-Wen AU - Lin SW AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Wang, Ming-Cheng AU - Wang MC AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chen, Ming-Jenn AU - Chen MJ AD - Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Hsueh, Yuan-Shuo AU - Hsueh YS AD - School of Post Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. yshsueh@kmu.edu.tw. AD - Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan. yshsueh@kmu.edu.tw. AD - Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. yshsueh@kmu.edu.tw. FAU - Chang, Hui Hua AU - Chang HH AD - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. huihua@ncku.edu.tw. AD - School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan. huihua@ncku.edu.tw. AD - Department of Pharmacy, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan. huihua@ncku.edu.tw. AD - Department of Pharmacy, National Cheng Kung University Hospital, Dou- Liou Branch, Douliu, Yunlin, Taiwan. huihua@ncku.edu.tw. LA - eng GR - CMNCKU11207/Chi-Mei/ National Cheng Kung University/ GR - NSTC 114-2314-B-384-001/National Science and Technology Council/ GR - NSTC 114-2320-B-075B-002/National Science and Technology Council/ GR - NSTC 111-2314-B-309-001, and NSTC 113-2320-B-037-025/National Science and Technology Council/ GR - NSTC 111-2628-B-006-010-MY3/National Science and Technology Council/ GR - KMU-Q113010, 113CM-KMU-10, KMU-TC113A04, and KMU-Q114011/Kaohsiung Medical University/ PT - Journal Article DEP - 20251122 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *MicroRNAs/urine/genetics MH - Male MH - Female MH - Taiwan MH - Middle Aged MH - Aged MH - High-Throughput Nucleotide Sequencing MH - *Urinary Bladder Neoplasms/genetics/urine/pathology/diagnosis MH - *Biomarkers, Tumor/genetics/urine MH - Sequence Analysis, RNA MH - Gene Expression Regulation, Neoplastic MH - Neoplasm Invasiveness MH - *Carcinoma, Transitional Cell/genetics/urine/pathology/diagnosis MH - Gene Expression Profiling PMC - PMC12752029 OTO - NOTNLM OT - Early detection OT - MicroRNA OT - Muscle-invasive urothelial carcinoma OT - Urothelial cancer COIS- Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the ethical standards of the institutional and national research committees, and the 1964 Helsinki Declaration and its later amendments. The study protocol was approved by the Institutional Review Board of Chi Mei Medical Center, Taiwan (approval number: 10612-015). Informed consent was obtained from all study participants. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/22 06:29 MHDA- 2025/12/30 13:08 PMCR- 2025/11/22 CRDT- 2025/11/22 00:10 PHST- 2025/04/08 00:00 [received] PHST- 2025/10/30 00:00 [accepted] PHST- 2025/12/30 13:08 [medline] PHST- 2025/11/22 06:29 [pubmed] PHST- 2025/11/22 00:10 [entrez] PHST- 2025/11/22 00:00 [pmc-release] AID - 10.1186/s12885-025-15284-5 [pii] AID - 15284 [pii] AID - 10.1186/s12885-025-15284-5 [doi] PST - epublish SO - BMC Cancer. 2025 Nov 22;25(1):1900. doi: 10.1186/s12885-025-15284-5. PMID- 41266607 OWN - NLM STAT- MEDLINE DCOM- 20251120 LR - 20251123 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Nov 20 TI - Small cell size circulating tumor cells predict the prognosis of high-risk non-muscle invasive bladder cancer patients. PG - 40909 LID - 10.1038/s41598-025-16000-w [doi] LID - 40909 AB - The study aimed to explore the distribution of circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and their subtypes in non-cancer and bladder cancer individuals, focusing on their prognostic value in high-risk non-muscle invasive bladder cancer (NMIBC). Researchers analyzed 59 fresh peripheral blood samples using subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH). Samples were collected from healthy individuals (n = 18), patients with benign urinary conditions (n = 2), newly diagnosed bladder cancer patients (n = 20), and NMIBC patients after repeated transurethral resection of bladder tumor (R-TURBT) (n = 19). NMIBC patients had significantly higher total CTCs. In newly diagnosed bladder cancer patients, large CTCs constituted 58.8%. The most common karyotype was >/= pentaploid CTCs (61.2%). In the non-cancer group, large CTCs constituted 83.0%, with >/= pentaploid CTCs comprising 72.3% of aneuploid CTCs. For NMIBC patients after R-TURBT, those without recurrence had 16% small CTCs. Conversely, the recurrence group had 71% small CTCs, where tetraploid CTCs were predominant (40%). By performing logistic ridge repression, the >/= pentaploid small CTC is noted as an important indicator of recurrence. The presence and proportion of small CTCs can serve as a prognostic marker in NMIBC patients following R-TURBT, potentially guiding patient management and surveillance strategies. CI - (c) 2025. The Author(s). FAU - Wen, Yuheng AU - Wen Y AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Ming, Zhihao AU - Ming Z AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Xiong, Yichen AU - Xiong Y AD - Xiangya School of Stomatology, Central South University, Changsha, China. FAU - Li, Hong AU - Li H AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Zhu, Shuai AU - Zhu S AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Cao, Jian AU - Cao J AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Ye, Mingji AU - Ye M AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Gan, Tian AU - Gan T AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Yin, Bangwen AU - Yin B AD - The Second People's Hospital of Huaihua, Huaihua, Hunan, China. FAU - She, Xiangqun AU - She X AD - The Second People's Hospital of Huaihua, Huaihua, Hunan, China. FAU - Zeng, Yong AU - Zeng Y AD - Clinical Translational Research Center, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. 47537511@qq.com. FAU - Xie, Yu AU - Xie Y AD - Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. xieyu420@sina.com. LA - eng GR - NCC201818A55/National Cancer Center Clinical Research in "Climbing" Foundation of China/ GR - 2021JJ70030/Natural Science Foundation Health Union Foundation of Hunan Province, China/ PT - Journal Article DEP - 20251120 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Neoplastic Cells, Circulating/pathology MH - *Urinary Bladder Neoplasms/pathology/blood/surgery MH - Male MH - Female MH - Prognosis MH - Middle Aged MH - Aged MH - In Situ Hybridization, Fluorescence MH - Biomarkers, Tumor MH - Adult MH - Neoplasm Recurrence, Local/pathology MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12635209 OTO - NOTNLM OT - Circulating tumor cells OT - Non-muscle invasive bladder cancer OT - Prognosis OT - SE-iFISH OT - TURBT COIS- Declarations. Competing interests: The authors declare no competing interests. Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee) of Hunan Cancer Hospital (IRB number: KYJJ-2023-127). Informed consent: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper. EDAT- 2025/11/21 00:27 MHDA- 2025/11/21 00:28 PMCR- 2025/11/20 CRDT- 2025/11/20 23:38 PHST- 2025/04/17 00:00 [received] PHST- 2025/08/12 00:00 [accepted] PHST- 2025/11/21 00:28 [medline] PHST- 2025/11/21 00:27 [pubmed] PHST- 2025/11/20 23:38 [entrez] PHST- 2025/11/20 00:00 [pmc-release] AID - 10.1038/s41598-025-16000-w [pii] AID - 16000 [pii] AID - 10.1038/s41598-025-16000-w [doi] PST - epublish SO - Sci Rep. 2025 Nov 20;15(1):40909. doi: 10.1038/s41598-025-16000-w. PMID- 41264026 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260706 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Nov 20 TI - Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomy. PG - 705 LID - 10.1007/s00345-025-06089-z [doi] LID - 705 AB - PURPOSE: The prognostic value of histopathological grade in muscle-invasive urothelial carcinoma (MIBC) to predict disease-specific survival (DSS) is understudied. While grading systems like WHO1973 and WHO2004 are established in non-muscle-invasive bladder cancer (NMIBC), their relevance in MIBC remains controversial. This study assessed the prognostic impact of histopathological grade on DSS in a multicenter cohort. METHODS: We included 1,123 cN0M0 MIBC patients treated with upfront radical cystectomy (1987-2020) at nine centers. Tumors were graded using WHO1973 (G1 + G2 combined as G1/2 due to low numbers vs. G3), WHO2004 (low-grade [LG] vs. high-grade [HG]), and a hybrid three-tier system. Slides were locally reviewed by uro-pathologists. DSS was analyzed using Kaplan-Meier and Cox models, adjusting for age, stage, lympho-vascular invasion, surgical margins, lymph-node status, adjuvant chemotherapy, treatment center, and era of cystectomy. RESULTS: Among all cases, 74 (6.6%) were G1/2 and 1,049 (93.4%) G3; 27 (2.4%) were LG and 1,096 (97.6%) HG. Median follow-up was 5.3 years (IQR 2.9-8.5). Univariable analyses showed significantly better DSS for LG and G1/2 tumors across grading systems. However, multivariable models showed no independent association between grade and DSS. CONCLUSION: Although LG and G1/2 MIBC tumors demonstrated superior DSS in univariable analyses, the lack of independent prognostic significance in multivariable models questions the relevance of histopathological grade in MIBC. Further studies should explore the clinical utility of grade, define new grading schemes including features of epithelial-mesenchymal transition or tumor microenvironment, and explore alternative prognostic (bio)markers. FAU - Rinderknecht, Emily AU - Rinderknecht E AUID- ORCID: 0009-0002-7283-5237 AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. emily.rinderknecht@ukr.de. FAU - Claps, Francesco AU - Claps F AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Molecular Oncology team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, F-75005, France. AD - Department of Urology, Hopital Foch, UVSQ-Paris-Saclay University, Suresnes, 92150, France. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Trombetta, Carlo AU - Trombetta C AD - Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Lijnen, Renee A G AU - Lijnen RAG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Bussani, Rossana AU - Bussani R AD - Department of Pathology, University of Trieste, Trieste, Italy. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. FAU - van Leenders, Geert J L H AU - van Leenders GJLH AD - Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen- Nurnberg, Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Pavan, Nicola AU - Pavan N AD - Department of Precision Medicine in Medical, Surgical and Critical Care, Urological Clinic, University of Palermo, Palermo, Italy. FAU - Pouessel, Damien AU - Pouessel D AD - Department of Medical Oncology, Oncopole Claudius Regaud, Toulouse University Cancer Center (IUCT) Oncopole, Toulouse, F-31000, France. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Toronto and Laboratory Medicine and Pathobiology, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Allory, Yves AU - Allory Y AD - Molecular Oncology team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, F-75005, France. AD - Department of Pathology, Institut Curie, Paris, F-75005, France. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. AD - Department of Urology, University of Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251120 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality MH - Female MH - Neoplasm Grading MH - Male MH - Neoplasm Invasiveness MH - Disease-Free Survival MH - Aged MH - Prognosis MH - Middle Aged MH - Retrospective Studies PMC - PMC12634793 OTO - NOTNLM OT - Histopathological grade OT - Radical cystectomy OT - Urothelial carcinoma OT - Urothelial neoplasm OT - WHO1973 classification OT - WHO2004 classification COIS- Declarations. Conflict of interest: The authors have no financial or non-financial conflicts of interest to declare that are relevant to the content of this article. Ethical approval: The study complies with the ethical standards described in the latest declaration of Helsinki; it was approved by the institutional ethics review board of the respective institutions. Site specific approval and protocol numbers: Amsterdam: The Institutional Review Board of the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital (CFMPB-160 & IRBd18126). Trieste: The University of Trieste Ethical Committee; Trieste (ID 113/2021). Regensburg: Medical ethical board of the University of Regensburg (16-101-0218). Paris: The regional ethics board of Ile-de-France IX - Comite de protection des personnes - Ile-de-France IX - Creteil (11-052). Toronto: The regional ethics board of the University Health Network, Toronto (02-0515-C, 08-0263-T, 09-0826-CE and 09-0556-TE). Turku: Ethical committee of the hospital district of South-West Finland, No: ETMK 6/2006. Erlangen: The ethical and translational boards, Erlangen (217_18 Bc and 329_16-B). Dallas: The Institutional Review Board for the Protection of Human Subjects at University of Texas Southwestern Medical School: STU 102014-008. Rotterdam: The medical-ethical board of Erasmus MC, Rotterdam (MEC 168.922/1998/55). EDAT- 2025/11/20 13:38 MHDA- 2026/06/27 00:54 PMCR- 2025/11/20 CRDT- 2025/11/20 11:17 PHST- 2025/10/05 00:00 [received] PHST- 2025/11/08 00:00 [accepted] PHST- 2026/06/27 00:54 [medline] PHST- 2025/11/20 13:38 [pubmed] PHST- 2025/11/20 11:17 [entrez] PHST- 2025/11/20 00:00 [pmc-release] AID - 10.1007/s00345-025-06089-z [pii] AID - 6089 [pii] AID - 10.1007/s00345-025-06089-z [doi] PST - epublish SO - World J Urol. 2025 Nov 20;43(1):705. doi: 10.1007/s00345-025-06089-z. PMID- 41260885 OWN - NLM STAT- MEDLINE DCOM- 20260216 LR - 20260827 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 137 IP - 3 DP - 2026 Mar TI - Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer. PG - 502-508 LID - 10.1111/bju.70085 [doi] AB - OBJECTIVE: To determine the risk and timing of metachronous upper tract urothelial carcinoma (UTUC) after non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: In this multi-institutional retrospective cohort study involving academic and community hospitals, clinicopathological data were collected from patients with NMIBC treated between 2005 and 2022. Patients with prior or synchronous UTUC at NMIBC diagnosis were excluded. The primary outcome was time to metachronous UTUC, confirmed on pathology or upper tract imaging. Secondary objectives included determining the cumulative incidence of UTUC stratified by the European Association of Urology risk groups and UTUC risk factors identified using Fine and Gray regression, with all-cause mortality as a competing risk. RESULTS: Among 3003 patients, 1158 (39%) were low-risk, 650 (22%) intermediate-risk, 944 (31%) high-risk, and 251 (8%) very high-risk. During a median (interquartile range) follow-up of 4.9 (2.7-8.4) years, 104 patients developed UTUC. On multivariable analysis, multiple tumours were an independent predictor of UTUC (subdistribution hazard ratio 1.86, 95% confidence interval 1.24-2.80; P = 0.003). The 10-year cumulative incidence was 2.2% for low-risk, 4.4% for intermediate-risk, and 6.3% for high- and very high-risk patients. Routine imaging detected UTUC in 40% of low-risk, 58% of intermediate-risk, and 53% of high- and very high-risk patients. High-grade UTUC was found in 36% of low-risk, 63% of intermediate-risk, and 64% of high- and very high-risk patients. The majority of UTUC cases (77%) occurred within 5 years of NMIBC. CONCLUSIONS: The contemporary risk of metachronous UTUC may be lower than historical data. Our findings demonstrate that UTUC incidence is low in patients with low- and intermediate-risk NMIBC and increases in the high- and very high-risk groups. These results support current guideline recommendations to omit routine upper tract imaging in low-risk NMIBC and question its utility in intermediate-risk disease. In high-risk patients, routine imaging remains warranted, although the optimal frequency and duration are yet to be determined. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Pace, Keiran J C AU - Pace KJC AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Kwong, Jethro C C AU - Kwong JCC AUID- ORCID: 0000-0003-4728-1025 AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Randhawa, Harkanwal AU - Randhawa H AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Ringa, Maximiliano AU - Ringa M AD - Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada. AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Al-Daqqaq, Zizo AU - Al-Daqqaq Z AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Chelliahpillai, Yashan AU - Chelliahpillai Y AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Lee, Soomin AU - Lee S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Kim, Kellie AU - Kim K AUID- ORCID: 0000-0003-4682-6409 AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Haile, Samuel AU - Haile S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Ali, Amna AU - Ali A AD - Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Wettstein, Marian AU - Wettstein M AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Chan, Amy AU - Chan A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. FAU - Perlis, Nathan AU - Perlis N AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Lee, Jason AU - Lee J AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Hamilton, Robert AU - Hamilton R AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Fleshner, Neil AU - Fleshner N AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Finelli, Antonio AU - Finelli A AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Jamal, Munir AU - Jamal M AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Papanikolaou, Frank AU - Papanikolaou F AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Short, Thomas AU - Short T AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Feifer, Andrew AU - Feifer A AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Kulkarni, Girish AU - Kulkarni G AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251119 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/epidemiology MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - *Neoplasms, Second Primary/epidemiology/pathology MH - Middle Aged MH - *Carcinoma, Transitional Cell/epidemiology/pathology MH - *Ureteral Neoplasms/epidemiology/pathology MH - Risk Factors MH - *Kidney Neoplasms/epidemiology/pathology MH - Incidence MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12907774 OTO - NOTNLM OT - non-muscle-invasive bladder cancer OT - recurrence OT - risk stratification OT - surveillance imaging OT - upper tract urothelial carcinoma EDAT- 2025/11/20 00:29 MHDA- 2026/02/16 06:30 PMCR- 2026/02/16 CRDT- 2025/11/19 21:03 PHST- 2026/02/16 06:30 [medline] PHST- 2025/11/20 00:29 [pubmed] PHST- 2025/11/19 21:03 [entrez] PHST- 2026/02/16 00:00 [pmc-release] AID - BJU70085 [pii] AID - 10.1111/bju.70085 [doi] PST - ppublish SO - BJU Int. 2026 Mar;137(3):502-508. doi: 10.1111/bju.70085. Epub 2025 Nov 19. PMID- 41257657 OWN - NLM STAT- MEDLINE DCOM- 20251119 LR - 20251124 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 Nov 19 TI - Investigation on the current status of secondary transurethral resection for bladder cancer among Chinese urologists and construction of an acceptance prediction model. PG - 292 LID - 10.1186/s12894-025-01977-3 [doi] LID - 292 AB - OBJECTIVE: Through the investigation of the current situation of bladder cancer secondary electrotomy performed by urologists in China, it provides reference for further improvement and improvement of diagnosis and treatment norms. METHODS: From September 3, 2023 to October 7, 2023, questionnaires compiled by researchers were distributed and collected from urologists across the country in the form of electronic questionnaires through the questionnaire Star platform; The questionnaire data were exported online using SPSS 26.0 software (SPSS Inc, Chicago, IL, USA) and R language (R Foundation for Statistical Computing, Vienna, Austria, Austria). Version 4.2.1) for data analysis. Count data were described by percentages, and comparisons between groups were made by chi-square test or Fisher's exact test. Logistic regression was used to screen out the influencing factors related to the status of secondary electrotomy for bladder cancer performed by Chinese urologists and to construct a predictive model for the column-line diagram. ROC curves, calibration curves, and DCA curves were plotted to evaluate the model and validate its efficacy. RESULTS: A total of 514 valid questionnaires were returned. 77.2% (397/514) of the physicians interviewed were from tertiary care hospitals. 21.2% (109/514) were from secondary care hospitals. The acceptance rate of secondary electrosurgical resection of bladder cancer among Chinese urologists was 87.74%, with 12.26% still opposed to the procedure.The majority of respondents believed that secondary electroresection could be performed if the indications recommended by the guidelines were met (75%), while a significant number felt that the initial electroresection was complete and did not require a second (37.74%), or they decided whether to perform a secondary electroresection based on their clinical experience (40.27%). CONCLUSION: Survey results indicate that secondary transurethral resection enhances staging accuracy, eliminates residual lesions, and decreases recurrence and progression rates. However, it serves as a means to compensate for shortcomings in the initial resection. Advances in NMIBC treatment techniques assist in reducing or avoiding the need for secondary transurethral resection in bladder cancer cases. This study is the first to develop a predictive model for Chinese urologists' acceptance of secondary transurethral resection for bladder cancer and analyzes their perspectives on the procedure, offering a reference for future research. CI - (c) 2025. The Author(s). FAU - Liu, Xianjun AU - Liu X AD - Department of Urology, Chinese PLA General Hospital, Beijing, 100853, China. AD - Department of Urology, Liaocheng Third People's Hospital, Liaocheng, Shandong, 252000, China. FAU - Sun, Shengkun AU - Sun S AD - Department of Urology, Chinese PLA General Hospital, Beijing, 100853, China. sunshengkun@301hospital.org. FAU - Wang, Hengen AU - Wang H AD - Department of Urology, Chinese PLA General Hospital, Beijing, 100853, China. FAU - Yang, Shujun AU - Yang S AD - Department of Urology, Chinese PLA General Hospital, Beijing, 100853, China. LA - eng PT - Journal Article DEP - 20251119 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - Chinese people SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - China MH - Male MH - *Urologists/statistics & numerical data MH - Female MH - Surveys and Questionnaires MH - Middle Aged MH - *Electrosurgery/statistics & numerical data/methods MH - *Practice Patterns, Physicians'/statistics & numerical data MH - East Asian People PMC - PMC12628868 OTO - NOTNLM OT - Bladder cancer OT - Current status survey OT - Predictive modeling OT - Questionnaire survey OT - Re-TURBT OT - Secondary transurethral resection COIS- Declarations. Ethics approval and consent to participate: The study was approved by the Research Ethics Committee of the General Hospital of the Chinese People's Liberation Army (Ethics No. S2022-303-01), which certified that the study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments or similar ethical standards.All study participants signed a written informed consent form. Consent for publication: As this study does not involve identifable images or personal/clinical details that could compromise participant anonymity, the"Consent for Publication"is not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/19 12:28 MHDA- 2025/11/19 12:29 PMCR- 2025/11/19 CRDT- 2025/11/19 08:16 PHST- 2025/05/29 00:00 [received] PHST- 2025/10/22 00:00 [accepted] PHST- 2025/11/19 12:29 [medline] PHST- 2025/11/19 12:28 [pubmed] PHST- 2025/11/19 08:16 [entrez] PHST- 2025/11/19 00:00 [pmc-release] AID - 10.1186/s12894-025-01977-3 [pii] AID - 1977 [pii] AID - 10.1186/s12894-025-01977-3 [doi] PST - epublish SO - BMC Urol. 2025 Nov 19;25(1):292. doi: 10.1186/s12894-025-01977-3. PMID- 41253084 OWN - NLM STAT- MEDLINE DCOM- 20260122 LR - 20260122 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 1 DP - 2026 Feb TI - Metastasis Profile and Survival Outcomes of Metastatic Non-Muscle Invasive Bladder Cancer: A National Cancer Database Analysis. PG - 102462 LID - S1558-7673(25)00162-4 [pii] LID - 10.1016/j.clgc.2025.102462 [doi] AB - INTRODUCTION: Metastatic non-muscle invasive bladder cancer (mNMIBC) is a condition in which bladder cancer patients develop metastasis in the absence of muscle invasion. The nature of mNMIBC is understudied due to its recent increased recognition. The study aimed to analyze the baseline characteristics, metastatic patterns, and survival outcomes of this condition. METHODS: A retrospective analysis of the National Cancer Database (NCDB) (2004-2021) was done to identify NMIBC patients who presented with distant metastasis at diagnosis, as defined in the NCDB. The patient characteristics, metastatic trends, and survival outcomes were analyzed. Multivariable logistic regression was performed to identify the variables associated with mNMIBC. Cox proportional hazards regression and Kaplan-Meier analysis were used to analyze the survival outcomes (overall survival). RESULTS: Among the 537,674 patients diagnosed with NMIBC, 3982 (0.74%) patients had metastasis. The most common sites of metastasis were the bone (15.3%), followed by the lung (13.6%), liver (7.1%), and brain (0.9%). Furthermore, 15.1% of patients had multiple metastases. The median overall survival (OS) for mNMIBC was 6.54 months (95% Confidence Interval [CI]: 6.04-7.03). The OS was poorer among patients with metastasis to multiple sites (median OS: 3.55 months; 95% CI, 3.05-4.04) compared to those with metastasis to a single site. The best OS in isolated metastasis was seen in lung metastasis (median OS: 8.48 months; 95% CI, 6.68-10.27), and the worst OS was seen in liver metastasis (median OS: 3.70 months; 95% CI, 2.80-4.56). Older age, higher Charlson comorbidity score, and non-urothelial histology were associated with worse OS (P < .05). CONCLUSION: mNMIBC is an uncommon condition with poor OS. Metastases to multiple sites have a poorer prognosis than metastases to a single site. Among the single-site metastases, the most common metastatic site was bone, and the best OS was seen in lung metastasis. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Raja Iyub, Mohamed Javid AU - Raja Iyub MJ AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. Electronic address: mohamedjavid.rajaiyub@baptisthealth.net. FAU - Prabhakar, Pushan AU - Prabhakar P AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. FAU - Sakthivel, Deerush Kannan AU - Sakthivel DK AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. FAU - Chandrasekaran, Aditi AU - Chandrasekaran A AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. FAU - Ozambela, Manuel Jr AU - Ozambela M Jr AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL. FAU - Manoharan, Murugesan AU - Manoharan M AD - Department of Urologic Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Department of Urology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL. LA - eng PT - Journal Article DEP - 20251026 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - Middle Aged MH - Databases, Factual MH - Prognosis MH - Neoplasm Invasiveness MH - *Lung Neoplasms/secondary MH - United States/epidemiology MH - *Bone Neoplasms/secondary MH - Aged, 80 and over MH - *Liver Neoplasms/secondary MH - Kaplan-Meier Estimate MH - Survival Rate MH - Neoplasm Metastasis MH - *Brain Neoplasms/secondary MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Metastatic NMIBC OT - Metastatic bladder cancer OT - NMIBC OT - NMIBC with metastasis OT - Urothelial cancer COIS- Disclosure The authors declare that they have no competing interests. EDAT- 2025/11/19 00:26 MHDA- 2026/01/23 00:26 CRDT- 2025/11/18 18:10 PHST- 2025/08/15 00:00 [received] PHST- 2025/10/22 00:00 [revised] PHST- 2025/10/25 00:00 [accepted] PHST- 2026/01/23 00:26 [medline] PHST- 2025/11/19 00:26 [pubmed] PHST- 2025/11/18 18:10 [entrez] AID - S1558-7673(25)00162-4 [pii] AID - 10.1016/j.clgc.2025.102462 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Feb;24(1):102462. doi: 10.1016/j.clgc.2025.102462. Epub 2025 Oct 26. PMID- 41250764 OWN - NLM STAT- MEDLINE DCOM- 20251118 LR - 20261022 IS - 2167-8359 (Electronic) IS - 2167-8359 (Linking) VI - 13 DP - 2025 TI - The CD8(+)/Foxp3(+) ratio, but not the number of OX40(+) TILs, is an independent predictor of tumor recurrence in non-muscle-invasive bladder cancer: a retrospective study. PG - e20322 LID - 10.7717/peerj.20322 [doi] LID - e20322 AB - Non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progresses into an aggressive and lethal entity within five years. The clinical management of recurrent tumors remains limited. Therefore, identifying individual patients who are at a high risk of recurrence is crucial for early clinical monitoring and appropriate medical intervention, which may lead to improved outcomes. OX40 is a dual modulator that stimulates effector T cells and suppresses Tregs. It appears to be an ideal molecule for predicting survival outcomes, surpassing the predictive power of single or combined T cell signatures. It has been shown to act as an independent tumor prognostic predictor in various cancers, including non-small cell lung cancer, melanoma, and colorectal cancer. However, its potential as a prognostic tool for tumor recurrence in NMIBC has yet to be investigated. The present study aimed to investigate the potential value of OX40 as a predictor of recurrence risk in patients with NMIBC. Additionally, its downstream effectors, Foxp3 and CD8, were also evaluated. Tissue samples were collected from a cohort of 110 patients diagnosed with NMIBC. Immunohistochemistry was performed to assess the density of stromal OX40(+), Foxp3(+), and CD8(+) tumor infiltrating lymphocytes (TILs). Following survival analysis using the Kaplan-Meier method and log-rank test, we found that tumor recurrence was associated with a decreased density of OX40(+) and CD8(+) TILs, an elevated density of Foxp3(+) TILs, and lower ratios of OX40(+)/Foxp3(+) and CD8(+)/Foxp3(+) TILs. However, after adjustment, multivariate COX regression analysis indicated that only the ratio of CD8(+)/Foxp3(+) was an independent predictor of recurrence risk. The prediction power was assessed by a receiver operating characteristic (ROC) curve analysis. The results demonstrated that the AUC value for the CD8(+)/Foxp3(+) ratio was better than the other predictive markers. Although the expression of OX40 in TILs was associated with tumor recurrence, our results suggest that the predictive efficacy of a combination of CD8 and Foxp3 was more robust after adjustment. Future research utilizing advanced immunotyping techniques is necessary to validate these findings in larger cohorts. CI - (c)2025 Han et al. FAU - Han, Ke AU - Han K AD - Department of Pathology, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong Province, China. FAU - Wang, Fenghou AU - Wang F AD - Department of Pathology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, Shandong Province, China. FAU - Wang, Rong AU - Wang R AD - Department of Clinical Laboratory, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong Province, China. FAU - Kong, Qingnuan AU - Kong Q AD - Department of Pathology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, Shandong Province, China. LA - eng GR - Qingdao Key Medical and Health Discipline Project and the Qingdao Shinan District Science and Technology Plan/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251113 PL - United States TA - PeerJ JT - PeerJ JID - 101603425 RN - 0 (Forkhead Transcription Factors) RN - 0 (FOXP3 protein, human) RN - 0 (Receptors, OX40) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/immunology MH - *Forkhead Transcription Factors/metabolism MH - Male MH - Female MH - *Neoplasm Recurrence, Local/immunology/pathology MH - Retrospective Studies MH - Aged MH - *Lymphocytes, Tumor-Infiltrating/immunology MH - Middle Aged MH - *Receptors, OX40/metabolism MH - Prognosis MH - *CD8-Positive T-Lymphocytes/immunology MH - Biomarkers, Tumor MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12619943 OTO - NOTNLM OT - CD8 OT - Foxp3 OT - Non-muscle-invasive bladder cancer OT - OX40 OT - Tumor infiltrating lymphocytes COIS- The authors declare there are no competing interests. EDAT- 2025/11/18 12:14 MHDA- 2025/11/18 12:15 PMCR- 2025/11/13 CRDT- 2025/11/18 03:45 PHST- 2025/05/28 00:00 [received] PHST- 2025/10/10 00:00 [accepted] PHST- 2025/11/18 12:15 [medline] PHST- 2025/11/18 12:14 [pubmed] PHST- 2025/11/18 03:45 [entrez] PHST- 2025/11/13 00:00 [pmc-release] AID - 20322 [pii] AID - 10.7717/peerj.20322 [doi] PST - epublish SO - PeerJ. 2025 Nov 13;13:e20322. doi: 10.7717/peerj.20322. eCollection 2025. PMID- 41246593 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251117 LR - 20251120 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 10 DP - 2025 Oct TI - Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours. PG - e94455 LID - 10.7759/cureus.94455 [doi] LID - e94455 AB - INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) is characterised by a high recurrence rate, necessitating frequent intervention. While conventional transurethral resection of bladder tumour (TURBT) under general anaesthesia is standard, it carries inherent risks. Transurethral laser ablation (TULA) performed under local anaesthesia in an outpatient setting presents a viable, minimally invasive alternative, yet robust comparative efficacy data remain limited. This study aimed to compare the effectiveness of TULA and TURBT in preventing early tumour recurrence and to provide practical insights for implementing an outpatient TULA service. METHODS: This retrospective cohort study included patients with recurrent NMIBC treated with either TULA or TURBT. Patient selection for the comparative analysis was restricted to those with recurrent lesions sized less than 1 cm. The TULA procedures were performed under local anaesthesia using a holmium:yttrium-aluminium-garnet (Ho:YAG) laser (Cook Medical, Ireland) and a compatible fibre. Key outcomes included the tumour recurrence rate at the first follow-up cystoscopy. Complications were assessed retrospectively over a 30-day period. RESULTS: A total of 97 patients were included (TULA: 51; TURBT: 46). Baseline characteristics (age, sex, and risk stratification) were comparable between the groups (p>0.05). No statistically significant difference in tumour recurrence rates was observed at the first follow-up cystoscopy: 30 patients (58.8%) in the TULA group and 27 patients (58.7%) in the TURBT group exhibited no recurrence. Furthermore, TULA demonstrated no immediate post-procedure complications requiring hospital admission. Implementation of the outpatient TULA service, prioritising staff training, safety, and a robust governance framework, proved successful in our centre. CONCLUSION: TULA performed under local anaesthesia demonstrates possible comparable efficacy to TURBT in preventing early tumour recurrence, underscoring its potential as a reasonable alternative for managing small, recurrent NMIBC, particularly for patients at higher risk of complications from general anaesthesia. Successful establishment of an outpatient TULA service, guided by clear operational and safety protocols, enhances efficiency. Larger prospective multicentre trials with longer follow-up are warranted to fully validate these findings. CI - Copyright (c) 2025, Srour et al. FAU - Srour, Mahmoud D AU - Srour MD AD - Urology, Great Western Hospitals NHS Foundation Trust, Swindon, GBR. FAU - Mohamed, Ali AU - Mohamed A AD - Urology, Great Western Hospitals NHS Foundation Trust, Swindon, GBR. FAU - Mathur, Sunil AU - Mathur S AD - Urology, Great Western Hospitals NHS Foundation Trust, Swindon, GBR. LA - eng PT - Journal Article DEP - 20251013 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12612793 OTO - NOTNLM OT - non-muscle-invasive bladder cancer OT - outpatient tula service OT - recurrent superficial bladder tumours OT - transurethral laser ablation (tula) OT - transurethral resection of bladder tumour (turbt) COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/11/17 17:30 MHDA- 2025/11/17 17:31 PMCR- 2025/10/13 CRDT- 2025/11/17 06:30 PHST- 2025/10/13 00:00 [accepted] PHST- 2025/11/17 17:31 [medline] PHST- 2025/11/17 17:30 [pubmed] PHST- 2025/11/17 06:30 [entrez] PHST- 2025/10/13 00:00 [pmc-release] AID - 10.7759/cureus.94455 [doi] PST - epublish SO - Cureus. 2025 Oct 13;17(10):e94455. doi: 10.7759/cureus.94455. eCollection 2025 Oct. PMID- 41244924 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251117 LR - 20251120 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Explainable machine learning model predicts response to adjuvant therapy after radical cystectomy in bladder cancer. PG - 1664965 LID - 10.3389/fonc.2025.1664965 [doi] LID - 1664965 AB - PURPOSE: Radical cystectomy (RC) is the standard treatment for muscle-invasive and select high-risk non-muscle-invasive bladder cancer. Despite definitive surgery, recurrence and progression remain major clinical concerns. Adjuvant chemotherapy and immunotherapy may improve outcomes, but therapeutic response varies due to tumor heterogeneity. Robust predictive models are needed to guide individualized treatment strategies. METHODS: This study retrospectively analyzed bladder cancer patients undergoing RC. Data included tumor morphology (e.g., vascular and perineural invasion), demographic variables (e.g., age, sex), and molecular markers (e.g., PD-L1, HER2, GATA3). LASSO regression identified key features, followed by model development using nine machine learning algorithms, including XGBoost and LightGBM. Model performance was assessed via area under the ROC curve (AUC), and Shapley Additive Explanations (SHAP) were used for model interpretability. RESULTS: The random forest model achieved the highest predictive performance (AUC = 0.92 in training; 0.74 in testing). SHAP analysis identified vascular invasion, perineural invasion, and PD-L1/HER2 expression as major contributors. Decision curve analysis showed favorable net benefit within a moderate-risk threshold. CONCLUSIONS: A machine learning model integrating pathological, demographic, and molecular features demonstrates promising potential to predict response to adjuvant therapy post-RC in bladder cancer. Decreased performance in the external test cohort highlights the need for further validation. Prospective studies incorporating multi-center and longitudinal data are warranted to enhance model generalizability and clinical applicability. CI - Copyright (c) 2025 Hou, Ding, Feng, Wang, Tao, Li, Qin, Liang, Gu and Liu. FAU - Hou, Jian AU - Hou J AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Ding, Yi AU - Ding Y AD - Department of Urology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Feng, Runlin AU - Feng R AD - Department of Pathology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Wang, Yumin AU - Wang Y AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Tao, Yanping AU - Tao Y AD - Department of Emergency Medicine, Kunming Third People's Hospital, Kunming, Yunnan, China. FAU - Li, Junxiong AU - Li J AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Qin, Jingbo AU - Qin J AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Liang, Pinyao AU - Liang P AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Gu, Peng AU - Gu P AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. FAU - Liu, Xiaodong AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. LA - eng PT - Journal Article DEP - 20251031 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12615217 OTO - NOTNLM OT - adjuvant therapy OT - bladder cancer OT - machine learning OT - molecular markers OT - predictive model OT - radical cystectomy OT - shap COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/11/17 17:29 MHDA- 2025/11/17 17:30 PMCR- 2025/10/31 CRDT- 2025/11/17 06:13 PHST- 2025/07/13 00:00 [received] PHST- 2025/10/13 00:00 [accepted] PHST- 2025/11/17 17:30 [medline] PHST- 2025/11/17 17:29 [pubmed] PHST- 2025/11/17 06:13 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - 10.3389/fonc.2025.1664965 [doi] PST - epublish SO - Front Oncol. 2025 Oct 31;15:1664965. doi: 10.3389/fonc.2025.1664965. eCollection 2025. PMID- 41241655 OWN - NLM STAT- MEDLINE DCOM- 20260430 LR - 20260730 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 9 IP - 2 DP - 2026 Apr TI - Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PG - 459-471 LID - S2588-9311(25)00286-X [pii] LID - 10.1016/j.euo.2025.10.012 [doi] AB - BACKGROUND AND OBJECTIVE: Different substaging methods have been proposed for risk stratification of T1 non-muscle-invasive bladder cancer; however, no consensus exists. This systematic review and meta-analysis evaluates the prognostic value of various T1 substaging systems. METHODS: A systematic literature search was conducted using the PubMed/Medline, Embase, Scopus, and Web of Science databases to identify reports published until January 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The primary outcomes were disease recurrence and progression. A subgroup analysis evaluated histoanatomical and micrometric substaging within the same population. KEY FINDINGS AND LIMITATIONS: Fifty-seven studies met the inclusion criteria. Muscularis mucosae invasion was associated with progression (hazard ratio [HR]: 2.65, 95% confidence interval [CI]: 1.79-3.92, p < 0.001) but not with recurrence (HR: 1.19, 95% CI: 0.88-1.61, p = 0.3). Micrometric substaging (T1m/T1e, 0.5 mm cutoff) correlated with both recurrence (HR: 2.01, 95% CI: 1.53-2.64, p < 0.001) and progression (HR: 3.33, 95% CI: 2.47-4.49, p < 0.001). Considering the substaging systems applied to the same population, the pooled risk ratio (RR) for T1a versus T1b/c was 0.60 (95% CI: 0.45-0.80, p < 0.001), while the RR for T1m versus T1e was 0.39 (95% CI: 0.29-0.52, p < 0.001). The main limitation was heterogeneity in postsurgery management. CONCLUSIONS AND CLINICAL IMPLICATIONS: Histoanatomical substaging significantly associate with progression but not with recurrence. Micrometric substaging demonstrated an association with both recurrence and progression, potentially enhancing patient stratification. Rete Oncologica Lombarda substaging shows some promising results in stratifying patients. These results may support a global pathological consensus on the optimal T1 substaging system. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Piccolini, Andrea AU - Piccolini A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Moretto, Stefano AU - Moretto S AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. Electronic address: vittorio.fasulo@humanitas.it. FAU - Uleri, Alessandro AU - Uleri A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS, Fondazione "G. Pascale", Napoli, Italy. FAU - Finocchiaro, Alessio AU - Finocchiaro A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Cella, Ludovica AU - Cella L AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Dagnino, Filippo AU - Dagnino F AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Avolio, Pier Paolo AU - Avolio PP AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Valeri, Marina AU - Valeri M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20251114 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Disease Progression MH - *Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Neoplasm Staging/methods MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - Oncological outcomes OT - Staging OT - T1 substage OT - Urothelial carcinoma EDAT- 2025/11/16 00:27 MHDA- 2026/05/01 00:31 CRDT- 2025/11/15 21:54 PHST- 2025/04/10 00:00 [received] PHST- 2025/10/06 00:00 [revised] PHST- 2025/10/24 00:00 [accepted] PHST- 2026/05/01 00:31 [medline] PHST- 2025/11/16 00:27 [pubmed] PHST- 2025/11/15 21:54 [entrez] AID - S2588-9311(25)00286-X [pii] AID - 10.1016/j.euo.2025.10.012 [doi] PST - ppublish SO - Eur Urol Oncol. 2026 Apr;9(2):459-471. doi: 10.1016/j.euo.2025.10.012. Epub 2025 Nov 14. PMID- 41235065 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251114 LR - 20260925 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 11 DP - 2025 Nov TI - Assessing EAU criteria for high-risk upper tract urothelial carcinoma. PG - e70044 LID - 10.1002/bco2.70044 [doi] LID - e70044 AB - BACKGROUND AND OBJECTIVE: Preoperative EAU guideline criteria stratify Upper tract urinary carcinomas (UTUC) into low- and high-risk groups. Depending on this classification, high-risk patients may receive simultaneous lymphadenectomy (LAD) during robot-assisted radical nephroureterectomy (RANU). This study examines the reliability of such stratification, focusing on oncological outcomes. METHODS: In 60 patients with UTUC who underwent RANU, 38 were stratified as low-risk (63%) and 22 as high-risk (37%) based on preoperative EAU guideline criteria. LAD was performed solely in the high-risk group. RESULTS: In the low-risk group, 19 patients (50%) had non-muscle-invasive (Ta, Tis-T1) disease, 7 (18%) had muscle-invasive, locally confined (T2) disease and 12 (32%) had locally advanced (T3/4) disease. In the high-risk group, results were 11 (50%), 3 (14%) and 8 (36%), with no statistical differences observed. Follow-up (6 to 60 months) showed no significant differences in cancer-specific (p = 0.3) and overall survival (p = 0.8) between groups. Limitations: the small sample size and the retrospective nature. Conclusions and Clinical Implications: The current EAU guideline-based preoperative criteria for UTUC risk stratification demonstrated limited accuracy in identifying high-risk patients undergoing RANU, potentially excluding some patients from receiving LAD. PATIENT SUMMARY: We think that improved preoperative staging and risk stratification tools are needed to better manage patients with upper urinary tract urothelial carcinoma undergoing surgical treatment. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Farzat, Mahmoud AU - Farzat M AUID- ORCID: 0000-0003-1989-2187 AD - Department of Urology, Pediatric Urology, and Andrology Justus-Liebig University of Giessen Giessen Germany. AD - Department of Urology and Robotic Urology Diakonie Klinikum Siegen Siegen Germany. FAU - Leyh-Bannurah, Sami-Ramzi AU - Leyh-Bannurah SR AUID- ORCID: 0000-0002-6156-2117 AD - Department of University Medical Center Hamburg - Eppendorf Department of Urology Hamburg Germany. FAU - Kachanov, Mykyta AU - Kachanov M AD - Institute of Human Genetics University Medical Center Hamburg-Eppendorf Germany. FAU - Wagenlehner, Florian M AU - Wagenlehner FM AUID- ORCID: 0000-0002-2909-0797 AD - Department of Urology, Pediatric Urology, and Andrology Justus-Liebig University of Giessen Giessen Germany. LA - eng PT - Journal Article DEP - 20251111 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12605949 OTO - NOTNLM OT - LAD OT - RANU OT - upper urinary tract carcinoma (UTUC) COIS- The authors declare no conflicts of interests. EDAT- 2025/11/14 06:28 MHDA- 2025/11/14 06:29 PMCR- 2025/11/11 CRDT- 2025/11/14 04:42 PHST- 2025/05/21 00:00 [received] PHST- 2025/05/22 00:00 [accepted] PHST- 2025/11/14 06:29 [medline] PHST- 2025/11/14 06:28 [pubmed] PHST- 2025/11/14 04:42 [entrez] PHST- 2025/11/11 00:00 [pmc-release] AID - BCO270044 [pii] AID - 10.1002/bco2.70044 [doi] PST - epublish SO - BJUI Compass. 2025 Nov 11;6(11):e70044. doi: 10.1002/bco2.70044. eCollection 2025 Nov. PMID- 41234472 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251114 LR - 20251116 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 17 DP - 2025 TI - Fear of Cancer Recurrence and Its Associated Factors in Bladder Cancer Patients of Different Age Stages: A Cross-Sectional Study. PG - 2653-2664 LID - 10.2147/CMAR.S556758 [doi] AB - OBJECTIVE: To investigate the level of fear of cancer recurrence (FCR) in bladder cancer patients across different age groups and to identify associated sociodemographic, clinical, and psychosocial factors. This study aims to provide an evidence base for developing age-specific psychological interventions. METHODS: A cross-sectional survey was conducted among 322 bladder cancer patients primarily diagnosed with non-muscle invasive bladder cancer (NMIBC) at Hebei General Hospital between January 2020 and December 2022. Patients were categorized into a younger group (18-59 years) and an older group (>/=60 years). Data were collected using a general information questionnaire, the Fear of Progression Questionnaire-Short Form (FoP-Q-SF), the Social Support Rating Scale (SSRS), and the Simplified Coping Style Questionnaire (SCSQ). Descriptive statistics, t-tests, ANOVA, Pearson correlation, and multiple linear regression analyses were performed. RESULTS: The mean FCR scores were significantly higher in the younger group (33.46 +/- 7.62) compared to the older group (28.93 +/- 8.58) (P<0.001). Multiple linear regression analysis (R(2)=0.500, F=31.075, P<0.001) identified several significant predictors of FCR: younger age (beta=-0.100, P=0.022), lower per capita monthly family income (beta=-0.171, P<0.001), advanced tumor TNM stage (beta=0.207, P<0.001), poorer doctor-patient communication (beta=0.112 for "General" vs "Very Satisfied", P=0.013), more tumor recurrences (beta=0.100, P=0.023), less use of positive coping strategies (beta=-0.100, P=0.029), more use of negative coping strategies (beta=0.241, P<0.001), and lower social support (beta=-0.232, P<0.001). CONCLUSION: Bladder cancer patients experience considerable FCR, with younger patients exhibiting significantly higher levels than older patients. Factors such as age, socioeconomic status, disease severity, communication, coping styles, and social support are crucial determinants of FCR. Early identification of these factors and the implementation of tailored, age-appropriate interventions are recommended to alleviate FCR in this population. CI - (c) 2025 Li et al. FAU - Li, Jingpo AU - Li J AD - Department of Urology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China. FAU - Bai, Lijie AU - Bai L AD - Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China. FAU - Yan, Shuaijiang AU - Yan S AD - Graduate School, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. FAU - Niu, Jinzhi AU - Niu J AD - Nursing School, Hebei University of Chinese Medicine, Shijiazhuang, People's Republic of China. FAU - Li, Shoubin AU - Li S AD - Department of Urology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China. FAU - Ning, Xiaohui AU - Ning X AD - Department of Nursing, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China. LA - eng PT - Journal Article DEP - 20251108 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC12607745 OTO - NOTNLM OT - age groups OT - bladder cancer OT - coping styles OT - fear of cancer recurrence OT - influencing factors OT - psychosocial oncology OT - social support COIS- The authors declare that they have no competing interests. EDAT- 2025/11/14 06:28 MHDA- 2025/11/14 06:29 PMCR- 2025/11/08 CRDT- 2025/11/14 04:36 PHST- 2025/07/28 00:00 [received] PHST- 2025/10/15 00:00 [accepted] PHST- 2025/11/14 06:29 [medline] PHST- 2025/11/14 06:28 [pubmed] PHST- 2025/11/14 04:36 [entrez] PHST- 2025/11/08 00:00 [pmc-release] AID - 556758 [pii] AID - 10.2147/CMAR.S556758 [doi] PST - epublish SO - Cancer Manag Res. 2025 Nov 8;17:2653-2664. doi: 10.2147/CMAR.S556758. eCollection 2025. PMID- 41231336 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251116 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 16 IP - 1 DP - 2025 Nov 13 TI - Role of microRNA-183 based theranostics through targeting TPM1 in bladder cancer. PG - 2100 LID - 10.1007/s12672-025-03829-w [doi] LID - 2100 AB - BACKGROUND: MicroRNA-183 (miR-183-5p), a noncoding RNA, is upregulated in bladder carcinoma (BC). Although it has been implicated in oncogenesis, its precise regulatory effects and biological functions remain unclear. Tropomyosin-1 (TPM1) was shown to be downregulated in solid tumors and was previously identified as a novel tumor suppressor gene. OBJECTIVES: Our study focuses on the prognostic, diagnostic, and therapeutic potential of miR-183-5p in bladder carcinoma and assess TPM1 gene targets and their modulatory functions. METHODS: Urine cytology, cystectomy and transurethral resection (TUR) biopsies from 148 BC patients were collected. TPM1 protein and miR-183-5p expressions were assessed through immunohistochemistry (IHC) and real-time PCR respectively. In vitro assay investigated the effect of miR-183-5p on TPM1mRNA in bladder carcinoma cell lines, then confirmed by comparing miR-183-5p mimics in non-cancerous and urothelial carcinoma cell lines. Concomitant TPM1 gene expression was examined, and the theranostic miR-183-5p potential was evaluated. RESULTS: Upregulation of miR-183-5p expression in BC tissue biopsies and urine cytologies was noted, contrasting the downregulation of TPM1 protein expression in the high-grade, high-stage, lymph node metastatic BC tissues (in comparison to non-cancerous, low-grade, low-stage non-lymph node metastasizing BCs). Moreover, the miR-183-5p oncogenic influence was responsive in targeting TPM1 gene at 3'UTR region, and miR‑183‑5p.1 restricted TPM1 expression in T24 cells. CONCLUSION: This study provides the first illustration of the miR-183-5p-TPM1 axis in bladder carcinoma, supporting the theranostic role of miR-183-5p as an onco-miR in BC progression, diagnosis, and prognostication. CI - (c) 2025. The Author(s). FAU - Mamdouh, Samah AU - Mamdouh S AD - Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt. FAU - Aboushousha, Tarek AU - Aboushousha T AD - Pathology Department, Theodor Bilharz Research Institute, Giza, Egypt. FAU - Hemida, Eman AU - Hemida E AD - Biochemistry Department, Obstetrics and Gynecology Hospital, Faculty of Science, Ain Shams University, Cairo, Egypt. FAU - El-Araby, Rady E AU - El-Araby RE AD - Department of Basic and Clinical Translation Sciences, Tufts University School of Dental Medicine, Boston, MA, 02111, USA. AD - Central Lab, Theodor Bilharz Research Institute, Giza, Egypt. FAU - Elesaily, Khaled AU - Elesaily K AD - Urology Department, Theodor Bilharz Research Institute, Giza, Egypt. FAU - Hammad, Gehan AU - Hammad G AUID- ORCID: 0000-0002-3333-5005 AD - Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt. gmhammad@msa.edu.eg. FAU - Magdy, Mona AU - Magdy M AD - Pathology Department, Theodor Bilharz Research Institute, Giza, Egypt. LA - eng PT - Journal Article DEP - 20251113 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC12615872 OTO - NOTNLM OT - Biopsy OT - Bladder carcinomas OT - MicroRNA OT - TPM1 OT - Theranostic OT - Urine cytology OT - miR-183-5p COIS- Declarations. Ethics approval and consent to participate: This research was approved by the TBRI ethics committee, under the Federal Wide Assurance No. FWA00010609, in Cairo, Egypt, according to the 18th WMA General Assembly, Helsinki, Finland, June 1964, regulations. Informed consent was acquired from all participants in writing prior to sample collection. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/13 12:31 MHDA- 2025/11/13 12:32 PMCR- 2025/11/13 CRDT- 2025/11/13 11:05 PHST- 2025/06/17 00:00 [received] PHST- 2025/10/07 00:00 [accepted] PHST- 2025/11/13 12:32 [medline] PHST- 2025/11/13 12:31 [pubmed] PHST- 2025/11/13 11:05 [entrez] PHST- 2025/11/13 00:00 [pmc-release] AID - 10.1007/s12672-025-03829-w [pii] AID - 3829 [pii] AID - 10.1007/s12672-025-03829-w [doi] PST - epublish SO - Discov Oncol. 2025 Nov 13;16(1):2100. doi: 10.1007/s12672-025-03829-w. PMID- 41230142 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251115 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 14 IP - 10 DP - 2025 Oct 31 TI - Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence. PG - 3402-3412 LID - 10.21037/tau-2025-483 [doi] AB - Bladder spasms and irritative lower urinary tract symptoms (LUTS) are a common complication following urologic procedures, causing significant discomfort and potentially compromising therapeutic outcomes. Intravesical therapy, which enables localized drug delivery and limits systemic toxicity, relies on the urinary bladder as a reservoir accessible via urethral catheterization. However, direct mucosal exposure to chemotherapeutic and immunotherapeutic agents frequently provokes irritative LUTS, ranging from dysuria and discomfort to bladder spasms. In patients receiving intravesical therapy for non-muscle-invasive bladder cancer (NMIBC), spasms may lead to premature drug expulsion, severe cystitis symptoms or discontinuation of therapy. This concern is of particular relevance given the recent approval of several novel intravesical agents for the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC, including nadofaragene firadenovec and nogapendekin alfa inbakicept. While evidence for managing adverse urinary symptoms with these newer agents remains limited, various management strategies, such as anticholinergics, beta3-adrenergic agonists, and adjunctive therapies, have been explored for similar presentations. In this review, we evaluate the etiology of bladder spasms and irritative LUTS associated with currently approved intravesical therapies for bladder cancer and current approaches to preventing and managing them. By synthesizing available evidence and clinical practice insights, we aim to provide practical recommendations to optimize intravesical therapy for bladder cancer outcomes. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Albakr, Ahmed AU - Albakr A AUID- ORCID: 0000-0001-5321-1707 AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. FAU - Narayan, Vikram M AU - Narayan VM AD - Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. AD - Winship Cancer Institute of Emory University, Atlanta, GA, USA. FAU - Tyson, Mark AU - Tyson M AD - Department of Urology, Mayo Clinic, Phoenix, AZ, USA. FAU - Shoskes, Daniel AU - Shoskes D AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. AD - Ferring Pharmaceuticals, Inc., Parsippany, NJ, USA. FAU - Vasavada, Sandip AU - Vasavada S AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Review DEP - 20251028 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC12603835 OTO - NOTNLM OT - Non-muscle-invasive bladder cancer (NMIBC) OT - bladder spasms OT - detrusor muscle spasms OT - intravesical therapy OT - lower urinary tract symptom (LUTS) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-483/coif). All authors report administrative support for this manuscript was provided by Ferring Pharmaceuticals. V.M.N. has served as a consultant or received research funding from Ciox Health. M.T. has received royalties or licenses from Endoluxe and honoraria for roles on the steering committees for POTOPSCO (AstraZeneca) and LEGEND (enGene); he gave a bladder cancer lecture to the commercial team and holds stock/stock options at ImmunityBio; he has participated in a scientific advisory board for Protara Therapeutics. D.S. is an employee of Ferring Pharmaceuticals, Inc. S.V. has served as a consultant for Medtronic and BlueWind. The authors have no other conflicts of interest to declare. EDAT- 2025/11/13 06:29 MHDA- 2025/11/13 06:30 PMCR- 2025/10/31 CRDT- 2025/11/13 04:41 PHST- 2025/07/09 00:00 [received] PHST- 2025/09/14 00:00 [accepted] PHST- 2025/11/13 06:30 [medline] PHST- 2025/11/13 06:29 [pubmed] PHST- 2025/11/13 04:41 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - tau-14-10-3402 [pii] AID - 10.21037/tau-2025-483 [doi] PST - ppublish SO - Transl Androl Urol. 2025 Oct 31;14(10):3402-3412. doi: 10.21037/tau-2025-483. Epub 2025 Oct 28. PMID- 41228348 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251116 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 21 DP - 2025 Nov 2 TI - Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives. LID - 10.3390/cancers17213555 [doi] LID - 3555 AB - BACKGROUND/OBJECTIVES: Systemic immunotherapy, previously used mainly for advanced urothelial carcinoma, now plays an important role in the treatment of non-muscle invasive bladder cancer (NMIBC), either alone or combined with intravesical BCG instillations. METHODS: We conducted a collaborative, comprehensive review to summarize the key evidence and future perspectives on therapeutic intensification strategies involving immune checkpoint inhibitors in NMIBC. A total of 51 references published between 2000 and 2025 were included. RESULTS: Four phase II studies evaluated pembrolizumab, atezolizumab, durvalumab, and cetrelimab as monotherapy in 28 to 132 BCG-unresponsive NMIBC patients. They reported complete response rates ranging from 12% to 43% after 3 to 12 months of treatment, with a durable response rate ranging from 49% to 57.4% at 12 months. To improve these results, a phase II trial launched this year tests a new systemic combination targeting both the PD-1/PD-L1 axis and the emerging HLA-E/NKG2A pathway. Regarding BCG-naive high-risk (HR) NMIBC, four phase III studies are evaluating BCG instillations combined with systemic immunotherapy: sasanlimab (CREST), durvalumab (POTOMAC), atezolizumab (ALBAN), and pembrolizumab (KEYNOTE-676), with significant results reported for the CREST and POTOMAC trials. The key challenge remains selecting patients most likely to benefit from this combination therapy while avoiding overtreatment. Identifying predictive biomarkers of tumor aggressiveness and response to immunotherapy also represents a major future challenge. CONCLUSIONS: Therapeutic intensification using systemic immunotherapy applies to both BCG-unresponsive NMIBC, with a new target pathway (HLA-E/NKG2A), and BCG-naive HR NMIBC, where the combination of BCG instillations and immunotherapy represents a major breakthrough. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, 75018 Paris, France. FAU - Horowitz, Amir AU - Horowitz A AD - Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Department of Urology, 12 de Octubre University Hospital, Av Cordoba s/n, 28041 Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, 10126 Torino, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, San Raffaele Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 20132 Milan, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, La Croix Du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Claude-Bernard Hospital, Assistance Publique-Hopitaux de Paris Nord, University Paris Cite, 75018 Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20251102 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12609815 OTO - NOTNLM OT - BCG-naive OT - BCG-unresponsive OT - HLA-E OT - NKG2A OT - PD-1 OT - PD-L1 OT - high-risk OT - immunotherapy OT - non-muscle invasive bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2025/11/13 06:30 MHDA- 2025/11/13 06:31 PMCR- 2025/11/02 CRDT- 2025/11/13 01:11 PHST- 2025/09/25 00:00 [received] PHST- 2025/10/31 00:00 [revised] PHST- 2025/10/31 00:00 [accepted] PHST- 2025/11/13 06:31 [medline] PHST- 2025/11/13 06:30 [pubmed] PHST- 2025/11/13 01:11 [entrez] PHST- 2025/11/02 00:00 [pmc-release] AID - cancers17213555 [pii] AID - cancers-17-03555 [pii] AID - 10.3390/cancers17213555 [doi] PST - epublish SO - Cancers (Basel). 2025 Nov 2;17(21):3555. doi: 10.3390/cancers17213555. PMID- 41224545 OWN - NLM STAT- MEDLINE DCOM- 20260122 LR - 20260122 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 24 IP - 1 DP - 2026 Feb TI - Trends in Treatment Patterns and Outcomes Among Patients Diagnosed With Nonmuscle-Invasive Bladder Cancer in the United States. PG - 102424 LID - S1558-7673(25)00124-7 [pii] LID - 10.1016/j.clgc.2025.102424 [doi] AB - INTRODUCTION: Heterogeneity in disease presentation in nonmuscle invasive bladder cancer (NMIBC) creates significant variability in treatment patterns and outcomes across risk and clinical subgroups. METHODS: A descriptive analysis of NMIBC patients diagnosed between 2004 and 2017 using the National Cancer Database (NCDB), examined trends and patterns in treatment practices, postradical cystectomy (RC) outcomes, and survival overall and by subgroups. The American Urological Association/Society of Urologic Oncology risk stratification guideline was used to categorize patients into low-intermediate (LIR) and high-risk groups. RESULTS: Among newly diagnosed NMIBC patients (N = 324,646), 78.6% received TURBT without BCG, and 17.4% received BCG as part of their first course of treatment. Treatment patterns differed by risk groups. The high-risk group had lower TURBT without BCG than LIR (64.7% vs. 90.8%), but higher BCG (28.3% vs. 8.0%) and RC (5.5% vs. 0.5%). In the high-risk group, BCG and RC rates were higher in cT1/cTs than cTa patients. Over time, from 2004-2008 to 2013-2017, the use of BCG (12.6%-21.3%) and RC (2.2%-3.0%) increased, while TURBT-without BCG (84.3%-74.5%) decreased. Post-RC 90-day mortality was higher in high-risk than in LIR patients (4.6% vs. 2.8%). Five-year survival probabilities were unchanged over time. A post-hoc analysis revealed that 14% of patients received postoperative intravesical chemotherapy, with no notable differences in patient characteristics between this subgroup and the overall population. CONCLUSION: Unmet medical needs for NMIBC patients persist, as many high-risk patients do not receive guideline-recommended care, and survival outcomes remain largely unchanged. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Davies-Teye, Bernard Bright AU - Davies-Teye BB AD - Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD. FAU - Seo, Dominique AU - Seo D AD - Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD. Electronic address: dseo@umaryland.edu. FAU - Johnson, Abree AU - Johnson A AD - Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD. FAU - Stuart, Jennifer AU - Stuart J AD - Merck & Co., Inc., Rahway, NJ. FAU - Burcu, Mehmet AU - Burcu M AD - Merck & Co., Inc., Rahway, NJ. FAU - Hanna, Nader AU - Hanna N AD - University of Maryland School of Medicine, Baltimore, MD; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA. FAU - Onukwugha, Eberechukwu AU - Onukwugha E AD - Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD. FAU - Siddiqui, M Minhaj AU - Siddiqui MM AD - University of Maryland School of Medicine, Baltimore, MD. LA - eng PT - Journal Article DEP - 20250829 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/mortality/pathology MH - Male MH - Female MH - Aged MH - United States/epidemiology MH - *Cystectomy/trends/statistics & numerical data MH - BCG Vaccine/therapeutic use/administration & dosage MH - Middle Aged MH - Treatment Outcome MH - *Practice Patterns, Physicians'/trends/statistics & numerical data MH - Aged, 80 and over MH - Neoplasm Invasiveness OTO - NOTNLM OT - Cystectomy radical OT - Health Outcomes OT - Intravesical BCG OT - NMIBC OT - Urinary bladder neoplasm COIS- Disclosure Jennifer Stuart, ScD, MSc and Mehmet Burcu, PhD, MS, FISPE are salaried employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and own stocks in Merck & Co., Inc., Rahway, NJ, USA. EDAT- 2025/11/13 00:29 MHDA- 2026/01/23 00:26 CRDT- 2025/11/12 21:52 PHST- 2025/03/10 00:00 [received] PHST- 2025/08/12 00:00 [revised] PHST- 2025/08/21 00:00 [accepted] PHST- 2026/01/23 00:26 [medline] PHST- 2025/11/13 00:29 [pubmed] PHST- 2025/11/12 21:52 [entrez] AID - S1558-7673(25)00124-7 [pii] AID - 10.1016/j.clgc.2025.102424 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2026 Feb;24(1):102424. doi: 10.1016/j.clgc.2025.102424. Epub 2025 Aug 29. PMID- 41219575 OWN - NLM STAT- MEDLINE DCOM- 20260427 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 5 DP - 2026 May TI - Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis. PG - 1735-1743 LID - 10.1007/s11255-025-04907-2 [doi] AB - BACKGROUND: Metastasis development in bladder cancer patients without any evidence of muscle invasion is known as metastatic non-muscle invasive bladder cancer (mNMIBC). Given its recent recognition, this condition is largely underexplored. The objective of our study was to analyze the baseline characteristics, metastatic patterns, and survival outcomes of this condition based on different histology subtypes. METHODS: Data from patients with mNMIBC were analyzed across different histology subtypes. Demographic and clinical variables were compared using Chi-square and Fisher's exact analysis. Kaplan-Meier analysis was performed to compare survival outcomes between the various types of histology. RESULTS: Among the 537,674 patients diagnosed with NMIBC, 3982 had distant metastasis. The most common histopathology type was urothelial carcinoma [UC] (86.2%), followed by small cell carcinoma [SCC] (3.2%), squamous cell carcinoma [SqCC] (2.6%), adenocarcinoma (1.6%), and other variants (6.4%). The median overall survival (OS) of mNMIBC was 6.54 months. Among the various histopathology types, adenocarcinoma had the best OS (median OS: 12.71 months), followed by SCC (median OS: 8.87 months), UC (median OS: 6.83 months), and SqCC (median OS: 3.48 months). All results were statistically significant (p = 0.002). The common sites of metastasis were bone in UC (15.8%), lungs in SqCC (18.1%) and adenocarcinoma (16.9%), and liver in SCC (22%). CONCLUSION: mNMIBC is an uncommon (0.74% of NMIBC) condition with a poor prognosis. The most common and least common subtypes were urothelial carcinoma and adenocarcinoma, respectively. In comparison with the other subtypes, adenocarcinoma had the best prognosis, and squamous cell carcinoma had the worst prognosis. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Raja Iyub, Mohamed Javid AU - Raja Iyub MJ AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. mohamedjavid.rajaiyub@baptisthealth.net. FAU - Prabhakar, Pushan AU - Prabhakar P AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. FAU - Sakthivel, Deerush Kannan AU - Sakthivel DK AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. FAU - Chandrasekaran, Aditi AU - Chandrasekaran A AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. FAU - Ozambela, Manuel Jr AU - Ozambela M Jr AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. FAU - Manoharan, Murugesan AU - Manoharan M AD - Miami Cancer Institute, Baptist Health South Florida, 8900 N Kendal Drive, Miami, FL, 33176, USA. AD - Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. LA - eng PT - Journal Article DEP - 20251111 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Databases, Factual MH - *Carcinoma, Transitional Cell/secondary/mortality/pathology MH - *Carcinoma, Small Cell/secondary/mortality MH - Survival Rate MH - *Carcinoma, Squamous Cell/secondary/mortality MH - *Adenocarcinoma/secondary/mortality MH - Aged, 80 and over MH - Retrospective Studies MH - Kaplan-Meier Estimate MH - Adult MH - *Liver Neoplasms/secondary MH - *Lung Neoplasms/secondary MH - United States/epidemiology MH - Prognosis MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Metastatic non-muscle invasive bladder cancer OT - Non-muscle invasive bladder cancer OT - Urothelial Carcinoma COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: Not Applicable. EDAT- 2025/11/12 00:26 MHDA- 2026/04/27 12:34 CRDT- 2025/11/11 23:36 PHST- 2025/10/20 00:00 [received] PHST- 2025/11/08 00:00 [accepted] PHST- 2026/04/27 12:34 [medline] PHST- 2025/11/12 00:26 [pubmed] PHST- 2025/11/11 23:36 [entrez] AID - 10.1007/s11255-025-04907-2 [pii] AID - 10.1007/s11255-025-04907-2 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 May;58(5):1735-1743. doi: 10.1007/s11255-025-04907-2. Epub 2025 Nov 11. PMID- 41216726 OWN - NLM STAT- MEDLINE DCOM- 20260410 LR - 20260410 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 2 DP - 2026 May TI - A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer. PG - 170-176 LID - 10.1177/03915603251388204 [doi] AB - INTRODUCTION: Intravesical therapy following transurethral resection of bladder tumor (TURBT) remains the standard of care for non-muscle invasive bladder cancer (NMIBC). However, the global shortage of Bacillus Calmette-Guerin (BCG) and its notable side effect profile have driven interest in alternative agents such as gemcitabine and hyperthermic intravesical chemotherapy (HIVEC), both of which have shown promising results. MATERIALS AND METHODS: A total of 100 consenting patients with intermediate- and high-risk NMIBC, as per EAU 2020 risk stratification, were enrolled at a single institution between January 2021 and July 2022. Patients were electronically randomized in a 2:1:1 ratio into three groups: gemcitabine (n = 50), HIVEC (n = 25), and BCG (n = 25). Follow-up included cystoscopy and urine cytology every 3 months. Adverse events were assessed and graded using the Modified Clavien-Dindo Classification System. RESULTS: At 12 months, recurrence-free survival (RFS) was 94% in the gemcitabine group, 84% in the HIVEC group, and 92% in the BCG group (p = 0.675, intention-to-treat analysis). No cases of grade or stage progression were observed. Most recurrences (88.9%) occurred in the high-risk subgroup. Treatment-related side effects were significantly more frequent in the BCG group, while gemcitabine was the most well-tolerated during both induction and maintenance phases. The most common adverse events included lower urinary tract symptoms (LUTS), dysuria, and urinary tract infections (UTIs). CONCLUSION: Preliminary findings indicate that intravesical gemcitabine is non-inferior to BCG and HIVEC in terms of short-term efficacy, with a significantly better safety and tolerability profile. These results position gemcitabine as a viable alternative in the management of NMIBC. However, the study's limited sample size and short follow-up period necessitate larger, long-term studies to validate these outcomes. FAU - Michael, Shreyas Nellamkuziyil AU - Michael SN AUID- ORCID: 0000-0001-6516-2834 AD - Department of Urology and Renal Transplant, Father Muller Medical College Hospital, Mangaluru, Dakshina Kannada, Karnataka, India. AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Makkar, Arun AU - Makkar A AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Nagaraju, Supreeth AU - Nagaraju S AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Sood, Rajeev AU - Sood R AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Goel, Hemant Kumar AU - Goel HK AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Sharma, Umesh AU - Sharma U AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Singla, Anurag AU - Singla A AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. FAU - Sahoo, Shivaprasad AU - Sahoo S AD - Department of Urology and Renal Transplant, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20251111 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - 0 (Gemcitabine) RN - 50SG953SK6 (Mitomycin) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Gemcitabine MH - *Urinary Bladder Neoplasms/pathology/therapy/drug therapy MH - Administration, Intravesical MH - Male MH - Female MH - *Mitomycin/administration & dosage MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Aged MH - Middle Aged MH - *BCG Vaccine/administration & dosage MH - Neoplasm Invasiveness MH - Treatment Outcome MH - *Hyperthermia, Induced MH - *Antibiotics, Antineoplastic/administration & dosage MH - Risk Assessment MH - *Adjuvants, Immunologic/administration & dosage MH - Combined Modality Therapy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Gemcitabine OT - HIVEC OT - Mitomycin C OT - bladder cancer COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/11/11 06:31 MHDA- 2026/04/10 12:59 CRDT- 2025/11/11 05:13 PHST- 2026/04/10 12:59 [medline] PHST- 2025/11/11 06:31 [pubmed] PHST- 2025/11/11 05:13 [entrez] AID - 10.1177/03915603251388204 [doi] PST - ppublish SO - Urologia. 2026 May;93(2):170-176. doi: 10.1177/03915603251388204. Epub 2025 Nov 11. PMID- 41214597 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20251114 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Nov 10 TI - TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study. PG - 1735 LID - 10.1186/s12885-025-15079-8 [doi] LID - 1735 AB - BACKGROUND: Although non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progresses despite BCG therapy, cellular mechanisms behind this remain unclear. Understanding the dynamics within the tumor microenvironment (TME) and identifying pathways associated with BCG resistance are crucial for improving NMIBC treatment. METHODS: To elucidate transcriptional dynamics and key cellular interactions in the TME, we performed longitudinal single-nucleus RNA sequencing of 9 NMIBC cases with three pairs of treatment-naive and disease progression samples. The resulting 58,037 nuclei were subject to cell type and subtyping annotations along with cell-cell interaction analyses. RESULTS: Our analysis revealed marked interpatient heterogeneity in malignant cells, accompanied by copy number alterations associated with disease progression. TGF-beta signaling emerged as a key pathway, showing gradual enrichment from pre-treatment to post-progression samples. Within the tumor microenvironment, we identified distinct subtypes including LAMP3 + dendritic cells and iCAF fibroblasts that followed unique pseudotime trajectories linked to progression. Cell-cell interaction analysis further highlighted critical ligand-receptor pairs such as DSC2-DSG2 and ENG-BMPR2, which were associated with poor clinical outcomes. These interactions may represent hypothesis-generating candidates that warrant further validation. CONCLUSIONS: This study highlights key cellular and molecular mechanisms underlying bladder cancer progression Post-BCG treatment. Through single-nucleus RNA sequencing, we identified critical TME subtypes, TGF-beta signaling involvement, and crucial ligand-receptor interactions such as DSC2-DSG2 and ENG-BMPR2, which may serve as preliminary biomarkers requiring confirmation in larger independent cohorts. These findings offer valuable insights into enhancement of treatment strategies and patient outcomes. CI - (c) 2025. The Author(s). FAU - Lee, Seo-Young AU - Lee SY AD - Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. AD - Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Lee, Yun-Hee AU - Lee YH AD - Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Kim, Tae-Min AU - Kim TM AD - Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. tmkim@catholic.ac.kr. AD - Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. tmkim@catholic.ac.kr. AD - Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul, Republic of Korea. tmkim@catholic.ac.kr. FAU - Ha, U-Syn AU - Ha US AD - Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ushamd@catholic.ac.kr. AD - Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ushamd@catholic.ac.kr. LA - eng GR - 2018R1D1A1B07049542, 2019R1A5A2027588, and 2019M3E5D3073104/National Research Foundation of Korea/ PT - Journal Article DEP - 20251110 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Transforming Growth Factor beta) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/genetics/metabolism MH - *Tumor Microenvironment/genetics MH - *Transforming Growth Factor beta/metabolism/genetics MH - Disease Progression MH - Signal Transduction MH - *BCG Vaccine/therapeutic use MH - RNA-Seq MH - Longitudinal Studies MH - Female MH - Male MH - Gene Expression Regulation, Neoplastic MH - Single-Cell Analysis PMC - PMC12599029 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Fibroblast OT - Macrophage OT - Single-cell sequencing OT - TGF- beta signaling COIS- Declarations. Ethics approval and consent to participate: All procedures were conducted with informed consent from patients and approved by the Institutional Review Board of Seoul St. Mary's Hospital. Consent for publication: All authors reviewed the final version of the manuscript and approved it for publication. Competing interests: The authors declare no competing interests. EDAT- 2025/11/11 06:31 MHDA- 2025/11/13 06:28 PMCR- 2025/11/10 CRDT- 2025/11/11 00:16 PHST- 2025/03/10 00:00 [received] PHST- 2025/09/19 00:00 [accepted] PHST- 2025/11/13 06:28 [medline] PHST- 2025/11/11 06:31 [pubmed] PHST- 2025/11/11 00:16 [entrez] PHST- 2025/11/10 00:00 [pmc-release] AID - 10.1186/s12885-025-15079-8 [pii] AID - 15079 [pii] AID - 10.1186/s12885-025-15079-8 [doi] PST - epublish SO - BMC Cancer. 2025 Nov 10;25(1):1735. doi: 10.1186/s12885-025-15079-8. PMID- 41211449 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251112 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis. PG - 1707657 LID - 10.3389/fonc.2025.1707657 [doi] LID - 1707657 AB - BACKGROUND: Bladder cancer (BC) prognosis remains challenging to predict accurately with conventional tools. Systemic immune-inflammation index (SII) has emerged as a promising biomarker reflecting the tumor microenvironment. However, existing studies are limited by small sample sizes, heterogeneous designs, and inconsistent endpoints. This updated meta-analysis aims to comprehensively evaluate the association between high SII and key survival outcomes in BC patients. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane up to August 2025. Cohort studies reporting hazard ratios (HRs) for overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS) comparing high vs. low SII groups in histologically confirmed BC were included. Study quality was assessed using the Newcastle-Ottawa Scale. Pooled HRs with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses by pathological type (NMIBC vs. MIBC) and sensitivity analyses were performed. Publication bias was evaluated via funnel plots and Egger's test. RESULTS: Sixteen cohort studies involving 2,352 patients were analyzed. Meta-analysis revealed that elevated SII was significantly associated with worse OS (HR=1.66, 95% CI: 1.30-2.12, P < 0.0001) and RFS (HR=1.50, 95% CI: 1.28-1.76, P < 0.00001), with substantial heterogeneity (OS: I(2) = 81%; RFS: I(2) = 59%). Subgroup analysis showed significant predictive value of SII for RFS in both NMIBC (HR=1.55, 95% CI: 1.27-1.89, P < 0.0001; heterogeneity reduced to I(2) = 37%) and MIBC (HR=1.13, 95% CI: 1.01-1.26, P=0.03). However, OS subgroup associations for NMIBC (HR=1.15, P=0.50) and MIBC (HR=1.92, P=0.07) were non-significant. No significant associations were found for PFS (HR=1.55, 95% CI: 0.92-2.60, P=0.10, I(2) = 68%) or CSS (HR=1.50, 95% CI: 0.95-2.37, P=0.08, I(2) = 69%), likely due to limited study numbers (4 and 3, respectively). Significant publication bias was detected for OS and RFS. CONCLUSION: Elevated SII is significantly associated with poorer overall and recurrence-free survival in bladder cancer patients, particularly highlighting its potential predictive value for recurrence risk in NMIBC. However, significant heterogeneity, publication bias, and retrospective design limitations necessitate caution in interpretation. Future large-scale, prospective studies with standardized SII measurement and dynamic monitoring are crucial to validate its clinical utility and define optimal cut-offs for integration into risk-stratified management strategies. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145769, Prospero identifier, CRD420251145769. CI - Copyright (c) 2025 Bai, Huang, Chen, Ran, Jian, Li, Chen, Wei, Cao and Liu. FAU - Bai, Jingxing AU - Bai J AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Huang, Yin AU - Huang Y AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Chen, Bo AU - Chen B AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Ran, Biao AU - Ran B AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Jian, Shibo AU - Jian S AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Li, Jinze AU - Li J AD - Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine, Deyang, China. FAU - Chen, Jie AU - Chen J AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Wei, Qian AU - Wei Q AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Cao, Dehong AU - Cao D AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Liangren AU - Liu L AD - Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251024 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12591970 OTO - NOTNLM OT - bladder cancer OT - overall survival OT - prognostic indicators OT - recurrence-free survival OT - systemic immune-inflammation index COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/11/10 18:15 MHDA- 2025/11/10 18:16 PMCR- 2025/10/24 CRDT- 2025/11/10 06:17 PHST- 2025/09/17 00:00 [received] PHST- 2025/10/09 00:00 [accepted] PHST- 2025/11/10 18:16 [medline] PHST- 2025/11/10 18:15 [pubmed] PHST- 2025/11/10 06:17 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - 10.3389/fonc.2025.1707657 [doi] PST - epublish SO - Front Oncol. 2025 Oct 24;15:1707657. doi: 10.3389/fonc.2025.1707657. eCollection 2025. PMID- 41194083 OWN - NLM STAT- MEDLINE DCOM- 20251106 LR - 20251211 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Nov 5 TI - Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study. PG - 1719 LID - 10.1186/s12885-025-15028-5 [doi] LID - 1719 AB - PURPOSE: We conducted an assessment to investigate the impact of prostate volume on the recurrence of patients with non-muscle invasive bladder cancer (NMIBC). Subsequently, we developed and validated nomograms to accurately evaluate recurrence in NMIBC patients. Additionally, we examined the potential improvement in predictive capability achieved by introducing prostate volume as a variable in the model. METHODS: We conducted a retrospective analysis, enrolling 555 eligible patients from seven independent medical institutions across China. We first evaluate recurrence-free survival outcomes in patients with varying prostate volumes. Subsequently, we divided patients into a training cohort and an external validation cohort. Univariate and multivariate Cox regression analyses were conducted within the training cohort. Accordingly, two nomogram models with and without prostate volumes were developed. Their performance was compared by concordance index, calibration curves, receiver operating characteristics curves, and decision curve analysis. Furthermore, a risk classification model utilizing the nomogram incorporating prostate volume was developed. RESULTS: The 3-year recurrence-free survival was markedly lower in patients with large prostate volumes (> 30 ml) compared to those with relatively small prostate volumes (< 30 ml) (p < 0.001). The AUC for the model incorporating prostate volume at 3 years in the training cohort and external validation cohort was 0.828 and 0.811, surpassing the AUC for the model excluding prostate volume at the corresponding intervals, which was 0.796 and 0.778. The 1- and 2-year AUC for the two models also exhibited similar differences. The decision curve analysis results demonstrated the significant superiority of the nomogram incorporating prostate volume over the one without it. CONCLUSION: Our investigation revealed that prostate volume significantly influences recurrence in patients with NMIBC. We successfully developed a more accurate nomogram by introducing prostate volume as a variable and provided new insights to further guide clinical management and individualized treatment of NMIBC patients. CI - (c) 2025. The Author(s). FAU - Hu, Dichao AU - Hu D AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. FAU - Liu, He AU - Liu H AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. FAU - Li, Mingyang AU - Li M AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. FAU - Wu, Wenbo AU - Wu W AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. FAU - Ma, Chenxu AU - Ma C AD - Department of Urology, Shandong Second Medical University, No. 7166 Baotong West Street, Weifang City, Shandong, 261053, China. FAU - Chen, Lujie AU - Chen L AD - Department of Urology, Shandong Second Medical University, No. 7166 Baotong West Street, Weifang City, Shandong, 261053, China. FAU - Lin, Yunqiao AU - Lin Y AD - Department of Urology, The School of Clinical Medicine, Ningde Municipal Hospital of Ningde Normal University, Fujian Medical University, Ningde City, Fujian, 352100, China. FAU - Li, Peng AU - Li P AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. AD - Department of Urology, The School of Clinical Medicine, Ningde Municipal Hospital of Ningde Normal University, Fujian Medical University, Ningde City, Fujian, 352100, China. FAU - Du, Yiheng AU - Du Y AD - Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, 215028, China. FAU - Shao, Zhiqiang AU - Shao Z AD - Department of Urology, Linyi People's Hospital, Linyi, Shandong, 276000, China. FAU - Qiao, Liang AU - Qiao L AD - Department of Urology, Weifang People's Hospital, No. 150, Guangwen Road , Kuiwen, Weifang city, Shandong, 261041, China. Lqiaotj@126.com. FAU - Wang, Yongchuan AU - Wang Y AD - Department of Urology, Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University Affiliated Traditional Chinese Medicine Hospital, Weifang City, Shandong, 261041, China. chinayc@hotmail.com. FAU - Liu, Haitao AU - Liu H AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100, Haining Road, Shanghai, 200080, China. doctorlht69@163.com. LA - eng GR - 81972371/National Natural Science Foundation of China/ GR - 21SJKJGG97/Shanghai Songjiang District Medical and Health Science and Technology Research Project/ PT - Journal Article PT - Multicenter Study DEP - 20251105 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - Male MH - *Nomograms MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/mortality MH - *Neoplasm Recurrence, Local/pathology/epidemiology MH - Prognosis MH - Aged MH - Retrospective Studies MH - *Prostate/pathology MH - Neoplasm Invasiveness MH - Organ Size MH - ROC Curve MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12590736 OTO - NOTNLM OT - Nomogram OT - Non-muscle invasive bladder cancer OT - Prostate volume OT - Recurrence COIS- Declarations. Ethics approval and consent to participate: This retrospective study was approved by the Shanghai General Hospital Institutional Review Board (20240909073949417). Consent for publication: All authors have agreed to the publication of this work and have reviewed the manuscript prior to submission. Competing interests: The authors declare no competing interests. EDAT- 2025/11/06 00:27 MHDA- 2025/11/06 06:29 PMCR- 2025/11/05 CRDT- 2025/11/05 23:47 PHST- 2024/07/12 00:00 [received] PHST- 2025/09/10 00:00 [accepted] PHST- 2025/11/06 06:29 [medline] PHST- 2025/11/06 00:27 [pubmed] PHST- 2025/11/05 23:47 [entrez] PHST- 2025/11/05 00:00 [pmc-release] AID - 10.1186/s12885-025-15028-5 [pii] AID - 15028 [pii] AID - 10.1186/s12885-025-15028-5 [doi] PST - epublish SO - BMC Cancer. 2025 Nov 5;25(1):1719. doi: 10.1186/s12885-025-15028-5. PMID- 41192830 OWN - NLM STAT- MEDLINE DCOM- 20260307 LR - 20260307 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 40 IP - 1 DP - 2026 Jan TI - The Role of Holmium Laser Enucleation of the Prostate in Reducing the Risk of Bladder Cancer Recurrence and Progression. PG - 90-99 LID - 10.1177/08927790251390869 [doi] AB - BACKGROUND: Bladder outlet obstruction (BOO) and urinary retention were recognized contributing factors to bladder cancer (BCa) recurrence and progression due to prolonged urothelial exposure to carcinogens, chronic inflammation, and incomplete bladder emptying. Holmium laser enucleation of prostate (HoLEP) is a minimally invasive and highly effective procedure that completely removes obstructive prostatic tissue, thus resolving BOO. To explore the HoLEP impact on BCa recurrence and progression by improving voiding dynamics and reducing post-void residual (PVR). MATERIALS AND METHODS: We carried out a retrospective case-control study, based on a multicenter prospectively maintained database, on 100 consecutive male patients (cases) with a first diagnosis of non-muscle-invasive bladder cancer, with BOO and urinary retention and treated with HoLEP (in case of at least 3-months of timor-free status). The cases were compared with 200 patients (controls) with same baseline characteristics but not treated with HoLEP. We evaluated PVR, International Prostatic Symptoms Score-IPSS, BCa recurrence and progression rates. The t-Test, chi2-test, logistic correlations, multivariate analysis were applied to evaluate the association between the BOO resolution and urinary retention by HoLEP and BCa recurrence and progression. RESULTS: Patients treated with HoLEP showed a significant PVR reduction compared with controls (p < 0.01). The HoLEP group demonstrated statistically significant improvements in IPSS scores, indicating better urinary symptom control. The rates of recurrence and progression were significantly lower in the HoLEP-treated group (p < 0.01). Multivariate analysis identified the BOO resolution by HoLEP as an independent predictor of reduced BCa recurrence (odds ratio 0.65, 95% CI 0.45-0.85, p < 0.001). The control group exhibited persistently elevated PVR and higher rates of BCa recurrence and progression. CONCLUSIONS: Urinary retention could represent a prognostic factor of treatment response, and its active treatment by HoLEP should be considered as an important therapeutic step in the clinical management of patients with BCa. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. AD - Department of Biomedical Sciences Humanitas University, Pieve Emanuele Humanitas University, Rozzano, Italy. FAU - Marino, Filippo AU - Marino F AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. FAU - Marchi, Davide De AU - Marchi D AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. FAU - Giampaoli, Marco AU - Giampaoli M AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. FAU - Simonetti, Francesca AU - Simonetti F AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Renal Transplantation, University of Foggia, Policlinico Riuniti, Ospedali Riuniti di Foggia University of Foggia, Foggia, Italy. FAU - Amodeo, Antonio AU - Amodeo A AD - Department of Urology, Veneto Institute of Oncology, Castelfranco Veneto, Italy. FAU - Corsi, Paolo AU - Corsi P AD - Department of Urology, Veneto Institute of Oncology, Castelfranco Veneto, Italy. FAU - Claps, Francesco AU - Claps F AD - Department of Urology, Veneto Institute of Oncology, Castelfranco Veneto, Italy. FAU - Crestani, Alessandro AU - Crestani A AD - Department of Urology, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy. FAU - D'Agostino, Daniele AU - D'Agostino D AD - Department of Urology, Ospedale Villa Salus, Mestre, Italy. FAU - Romagnoli, Daniele AU - Romagnoli D AD - Department of Urology, Policlinico Abano Terme, Abano Terme, Italy. FAU - Prontera, Pier Paolo AU - Prontera PP AD - Department of Urology, Ospedale SS. Annunziata, Taranto, Italy. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AD - Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy. LA - eng PT - Journal Article DEP - 20251107 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Humans MH - Male MH - *Lasers, Solid-State/therapeutic use MH - *Urinary Bladder Neoplasms/pathology/surgery/prevention & control MH - Disease Progression MH - *Neoplasm Recurrence, Local/prevention & control/pathology MH - Aged MH - *Prostate/surgery MH - Middle Aged MH - Case-Control Studies MH - Risk Factors MH - Urinary Bladder Neck Obstruction/surgery MH - *Laser Therapy MH - Urinary Retention MH - Retrospective Studies MH - Multivariate Analysis OTO - NOTNLM OT - bladder cancer recurrence OT - bladder outlet obstruction (BOO) OT - holmium laser enucleation of the prostate (HoLEP) OT - non-muscle invasive bladder cancer (NMIBC) OT - post-void residual (PVR) OT - urothelial carcinogenesis COIS- Author Disclosure StatementThe authors declare no conflicts of interest. EDAT- 2025/11/06 00:27 MHDA- 2026/03/08 01:38 CRDT- 2025/11/05 19:53 PHST- 2026/03/08 01:38 [medline] PHST- 2025/11/06 00:27 [pubmed] PHST- 2025/11/05 19:53 [entrez] AID - 10.1177/08927790251390869 [doi] PST - ppublish SO - J Endourol. 2026 Jan;40(1):90-99. doi: 10.1177/08927790251390869. Epub 2025 Nov 7. PMID- 41187894 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251211 IS - 1876-7737 (Electronic) IS - 1874-3919 (Linking) VI - 323 DP - 2026 Jan 20 TI - Decoding bladder cancer aggressiveness: A proteomic, phosphoproteomic and metabolomic approach. PG - 105553 LID - S1874-3919(25)00180-0 [pii] LID - 10.1016/j.jprot.2025.105553 [doi] AB - BACKGROUND: Bladder cancer (BC) is the most common malignancy of the urinary system. However, the median survival of patients with metastatic bladder cancer remains limited. Thus, there is an urgent imperative to develop novel biomarkers for BC-targeted therapies and to conduct in-depth investigations into BC pathogenesis leveraging multi-omics technologies. RESULTS: Our results revealed that proteins co-upregulated in both proteomic and phosphoproteomic analysis, such as SLC4A7 and MYO9B, demonstrated potential utility in distinguishing MIBC from NMIBC. Upregulation of CPT2 and palmitic acid in MIBC patients highlighted the dysregulation of physiological control mechanisms and enhanced pro-tumorigenic effects of lipid metabolic pathways. CONCLUSIONS: Integrated multi-omics analysis reveals that key regulatory proteins such as SLC4A7 and MYO9B play pivotal roles in mediating the aggressive phenotypes of MIBC. Aberrant upregulation of CPT2 protein and metabolites like palmitic acid may drive malignant transformation from NMIBC to MIBC by promoting lipid metabolic reprogramming. SIGNIFICANCE: This study utilized LC-MS/MS to systematically profile the proteomic, phosphoproteomic, and metabolomic characteristics of MIBC, NMIBC, and adjacent noncancerous tissues, with the aim of identifying key molecules and metabolites driving bladder cancer progression. Our findings indicate that aberrant phosphorylation of regulatory proteins such as SLC4A7 and MYO9B may play a critical role in mediating the invasive phenotype of MIBC. In parallel, the upregulation of CPT2 and its associated metabolites (e.g., palmitic acid) suggests that lipid metabolic reprogramming, including enhanced beta-oxidation and membrane phospholipid synthesis, may contribute to the malignant transition from NMIBC to MIBC. Overall, this study not only reveals potential molecules and metabolites driving bladder cancer progression but also provides a valuable reference for further exploration of pathways associated with bladder cancer invasiveness. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Feng, Zhihui AU - Feng Z AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. FAU - Zhang, Biao AU - Zhang B AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. FAU - Liu, Yi AU - Liu Y AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. FAU - Yang, Fei AU - Yang F AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. FAU - Lei, Yinping AU - Lei Y AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. FAU - Liao, Songbai AU - Liao S AD - Department of Urology, The Nanxishan Hospital of Guangxi Zhuang Autonomous Region, 541002, China. Electronic address: 1182194916@qq.com. FAU - Hou, Xianliang AU - Hou X AD - Laboratory Central, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. Electronic address: houxl115@126.com. LA - eng PT - Journal Article DEP - 20251102 PL - Netherlands TA - J Proteomics JT - Journal of proteomics JID - 101475056 RN - 0 (Phosphoproteins) RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) SB - IM MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - Humans MH - *Proteomics/methods MH - *Metabolomics/methods MH - *Phosphoproteins/metabolism MH - Female MH - Male MH - *Biomarkers, Tumor/metabolism MH - *Neoplasm Proteins/metabolism OTO - NOTNLM OT - Bladder cancer OT - Metabolomics OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer OT - Phosphoproteomic OT - Proteomic COIS- Declaration of competing interest The authors declare no competing financial interest. EDAT- 2025/11/05 00:27 MHDA- 2025/12/12 03:30 CRDT- 2025/11/04 19:11 PHST- 2025/07/12 00:00 [received] PHST- 2025/10/05 00:00 [revised] PHST- 2025/10/28 00:00 [accepted] PHST- 2025/12/12 03:30 [medline] PHST- 2025/11/05 00:27 [pubmed] PHST- 2025/11/04 19:11 [entrez] AID - S1874-3919(25)00180-0 [pii] AID - 10.1016/j.jprot.2025.105553 [doi] PST - ppublish SO - J Proteomics. 2026 Jan 20;323:105553. doi: 10.1016/j.jprot.2025.105553. Epub 2025 Nov 2. PMID- 41186595 OWN - NLM STAT- MEDLINE DCOM- 20260224 LR - 20260224 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 112 IP - 2 DP - 2026 Feb 1 TI - The prognostic value of circadian syndrome in non-muscle-invasive bladder cancer: a retrospective cohort study. PG - 3948-3961 LID - 10.1097/JS9.0000000000003740 [doi] AB - PURPOSE: Investigating the impact of circadian syndrome (CircS) on the prognosis of non-muscle-invasive bladder cancer (NMIBC), identifying potential indicators affecting prognosis, and explaining NMIBC prognosis from the perspective of circadian rhythm disruption to provide a preventable risk factor. MATERIALS AND METHODS: A total of 438 patients with NMIBC who received intravesical Bacillus Calmette-Guerin immunotherapy after transurethral resection of bladder tumor were selected for retrospective analysis by retrieving medical records. The primary outcomes were recurrence-free survival (RFS) and progression-free survival (PFS). The secondary endpoints were safety parameters. Least absolute shrinkage and selection operator (LASSO) regression was used to screen variables for COX regression. Subgroup analysis and sensitivity analyses were used to validate the robustness of the results. Bootstrap and K-fold cross-validations were used to validate the robustness of the models. All adverse events (AEs) were further quantified for association strength using a logistic regression analysis. RESULTS: This retrospective study screened 406 patients who met the inclusion criteria for further analysis. Survival analysis demonstrated significantly lower RFS in patients with CircS compared to the non-CircS cohort [Log-rank P = 0.018; hazard ratio (HR) = 1.58, 95% confidence interval (CI): 1.08-2.31]. Multivariable analysis of LASSO-selected variables identified CircS (HR = 1.72, 95% CI: 1.09-2.73, P = 0.021), male gender (HR = 2.04, 95% CI: 1.12-3.72, P = 0.02), recurrence history (HR = 1.79, 95% CI: 1.17-2.73, P = 0.007), and tumor diameter >3 cm (HR = 1.88, 95% CI: 1.24-2.87, P = 0.003) as independent predictors of inferior RFS in NMIBC. Notably, elevated serum albumin levels exhibited protective effects (HR = 0.91, 95% CI: 0.85-0.98, P = 0.008). The prognostic significance of CircS remained robust across multiple RFS validation models, though no significant association was observed with PFS. In the analysis of AEs, patients with CircS showed significantly higher odds, such as lower urinary tract symptoms (OR = 1.64, 95% CI: 1.02-2.63, P = 0.041), hematuria (OR = 2.94, 95% CI: 1.55-5.50, P < 0.001), dysuria (OR = 4.26, 95% CI: 1.67-11.08, P = 0.002), lower abdominal pain (OR = 4.28, 95% CI: 1.59-11.73, P = 0.004), fatigue (OR = 3.86, 95% CI: 1.60-9.34, P = 0.002), and arthralgia or flu-like symptoms (OR = 7.30, 95% CI: 1.40-53.31, P = 0.023). CONCLUSION: CircS may serve as a potential risk factor affecting the prognosis of NMIBC, manifesting as worse RFS and AEs. Along with gender, tumor size, and recurrence history, it constitutes a high-risk factor for RFS. This finding provides clues for exploring potential causal relationships between clinical syndromes caused by circadian rhythm disruption and bladder tumor prognosis, while also reshaping the understanding of connections between chronic non-neoplastic diseases and neoplastic diseases. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Ren, Jun-Wei AU - Ren JW AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Ye, Jun-Jiang AU - Ye JJ AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Bai, Yun-Jin AU - Bai YJ AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Ping AU - Han P AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20251104 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/therapy/complications/pathology/diagnosis MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Prognosis MH - Middle Aged MH - BCG Vaccine/therapeutic use/administration & dosage MH - *Chronobiology Disorders/complications MH - Aged, 80 and over MH - Risk Factors MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - NMIBC OT - circadian syndrome OT - cohort study OT - prognosis EDAT- 2025/11/04 12:27 MHDA- 2026/02/24 06:34 CRDT- 2025/11/04 10:53 PHST- 2025/06/04 00:00 [received] PHST- 2025/10/10 00:00 [accepted] PHST- 2026/02/24 06:34 [medline] PHST- 2025/11/04 12:27 [pubmed] PHST- 2025/11/04 10:53 [entrez] AID - 01279778-990000000-03565 [pii] AID - 10.1097/JS9.0000000000003740 [doi] PST - ppublish SO - Int J Surg. 2026 Feb 1;112(2):3948-3961. doi: 10.1097/JS9.0000000000003740. Epub 2025 Nov 4. PMID- 41184144 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20260711 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 6 DP - 2025 Nov TI - The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer. PG - 509-515 LID - 10.4111/icu.20250111 [doi] AB - PURPOSE: This study aimed to evaluate whether the pathological findings from repeat transurethral resection of bladder (re-TURB) predict Bacillus Calmette-Guerin (BCG) response in patients with T1 high-grade bladder cancer. MATERIALS AND METHODS: We analyzed patients with bladder cancer enrolled in the prospective patient registry system of Seoul National University, SUPER-UC, from March 2016 to May 2022. Patients with T1 high-grade cancer who underwent re-TURB and BCG instillation were identified. Re-TURB pathology and its relationship with BCG response were analyzed. RESULTS: Out of a total of 2,673 patients with bladder cancer, 539 had T1 high-grade bladder cancer. Among these, 251 patients underwent subsequent re-TURB and BCG instillation. Of the 251 patients, 210 (83.7%) were male, and TURB was performed as the initial procedure in 232 cases (92.4%). In the TURB specimens of T1 high-grade cancer, concomitant carcinoma in situ (CIS), lymphovascular invasion, and variant histology were observed in 27 (10.8%), 54 (21.5%), and 29 (11.6%) cases, respectively. However, these factors were not associated with BCG failure after re-TURB. Re-TURB pathology showed chronic inflammation (51.8%), CIS (17.5%), Ta (15.5%), and T1 (15.1%). These findings were significantly correlated with BCG responsiveness. Notably, BCG failure was reported in 20.8% of patients with chronic inflammation, which showed the best response, compared to patients with T1 pathology, where BCG failure was observed in 47.4% of cases (p=0.011). CONCLUSIONS: The pathological results of re-TURB play a critical role in determining the BCG response in patients with T1 high-grade bladder cancer. CI - (c) The Korean Urological Association. FAU - Lee, Hyomyoung AU - Lee H AUID- ORCID: 0009-0002-0715-6609 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - So, Sang Won AU - So SW AUID- ORCID: 0000-0002-9428-4272 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Han, Jang Hee AU - Han JH AUID- ORCID: 0000-0003-4942-4632 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AUID- ORCID: 0000-0002-5874-9167 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AUID- ORCID: 0000-0002-2200-5019 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AUID- ORCID: 0000-0002-1987-2111 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AUID- ORCID: 0000-0002-8076-3643 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. 11shjeong@snu.ac.kr. LA - eng GR - SNU/ GR - HI23C1575/Korea Health Industry Development Institute/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/surgery/therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Aged MH - Neoplasm Staging MH - Middle Aged MH - Neoplasm Grading MH - *Adjuvants, Immunologic/therapeutic use MH - *Cystectomy/methods MH - Prospective Studies MH - Treatment Outcome MH - Aged, 80 and over MH - Administration, Intravesical MH - Reoperation PMC - PMC12599427 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - NMIBC OT - Pathology OT - Transurethral resection of bladder COIS- The authors have nothing to disclose. EDAT- 2025/11/04 00:28 MHDA- 2025/11/04 00:29 PMCR- 2025/11/01 CRDT- 2025/11/03 21:43 PHST- 2025/06/21 00:00 [received] PHST- 2025/07/18 00:00 [revised] PHST- 2025/08/14 00:00 [accepted] PHST- 2025/11/04 00:29 [medline] PHST- 2025/11/04 00:28 [pubmed] PHST- 2025/11/03 21:43 [entrez] PHST- 2025/11/01 00:00 [pmc-release] AID - 66.509 [pii] AID - 10.4111/icu.20250111 [doi] PST - ppublish SO - Investig Clin Urol. 2025 Nov;66(6):509-515. doi: 10.4111/icu.20250111. PMID- 41184141 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20260711 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 6 DP - 2025 Nov TI - Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review. PG - 482-490 LID - 10.4111/icu.20250262 [doi] AB - PURPOSE: Urinary biomarkers have been proposed to play an integral role in detecting recurrent non-muscle invasive bladder carcinoma (NMIBC). This review delineates the diagnostic accuracy of such biomarkers and management strategies in the event of discordance between biomarker findings and flexible cystoscopy, the current gold standard for NMIBC surveillance. MATERIALS AND METHODS: In accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement, literature searches were conducted across PubMed, Embase, Scopus, and CENTRAL (Cochrane Central Register of Controlled Trials), focusing on studies comparing urinary biomarkers to cystoscopy. The inclusion criteria were based on the PICOS (Patient Intervention Comparison Outcome Study type) model. The quality of included studies was assessed using the QUADAS-2 tool. RESULTS: A total of 23 studies were included, encompassing 21 types of urinary biomarkers. The analysis revealed significant variability in diagnostic performance. Sensitivity ranged from 14.8% to 94.3%, specificity from 33.3% to 99.2%, positive predictive value from 9.9% to 100%, and negative predictive value from 35.3% to 98.8%. Heterogeneity was observed across studies, indicating variability in different biomarker performance. Genetic biomarkers demonstrated higher diagnostic accuracy compared to protein-based markers. However, their clinical utility needs further validation. CONCLUSIONS: Urinary biomarkers could complement, rather than replace cystoscopy, in the surveillance of NMIBC, potentially reducing the frequency of invasive procedures. In cases of discordance, an algorithm focusing on shared decision-making and tailored surveillance strategies can be undertaken. Large-scale multicentric studies are needed to confirm their efficacy and establish standardized clinical protocols. CI - (c) The Korean Urological Association. FAU - Ramasamy, Reena Prhiya AU - Ramasamy RP AUID- ORCID: 0009-0004-3393-9740 AD - Urology Unit, Department of Surgery, University Malaya Medical Centre, Kuala Lumpur, Malaysia. FAU - Chai, Chu Ann AU - Chai CA AUID- ORCID: 0000-0001-8915-3617 AD - Urology Unit, Department of Surgery, University Malaya Medical Centre, Kuala Lumpur, Malaysia. chu.ann@ummc.edu.my. FAU - Cormio, Angelo AU - Cormio A AUID- ORCID: 0000-0002-6897-7040 AD - Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy. AD - Department of Urology, Faculty of Medicine, Universita Politecnica delle Marche, Ancona, Italy. FAU - Rajandram, Retnagowri AU - Rajandram R AUID- ORCID: 0000-0001-5247-2817 AD - Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Castellani, Daniele AU - Castellani D AUID- ORCID: 0000-0001-7354-9190 AD - Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy. FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Department of Urology, Yale School of Medicine, New Haven, CT, USA. AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Gauhar, Vineet AU - Gauhar V AUID- ORCID: 0000-0002-3740-7141 AD - Department of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore. FAU - Pang, See Tong AU - Pang ST AUID- ORCID: 0000-0002-2064-0828 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Mariappan, Paramananthan AU - Mariappan P AUID- ORCID: 0000-0001-8221-4640 AD - Department of Urology, Edinburgh Bladder Cancer Surgery, The University of Edinburgh, Western General Hospital, Edinburgh, UK. FAU - Teoh, Jeremy Yuen Chun AU - Teoh JYC AUID- ORCID: 0000-0002-9361-2342 AD - SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Ong, Teng Aik AU - Ong TA AUID- ORCID: 0000-0002-0207-8966 AD - Urology Unit, Department of Surgery, University Malaya Medical Centre, Kuala Lumpur, Malaysia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology MH - *Biomarkers, Tumor/urine MH - Neoplasm Invasiveness MH - Cystoscopy PMC - PMC12599468 OTO - NOTNLM OT - Biomarkers OT - Cystoscopy OT - Non-muscle invasive bladder cancer OT - Systematic review OT - Urine COIS- The authors have nothing to disclose. EDAT- 2025/11/04 00:28 MHDA- 2025/11/04 00:29 PMCR- 2025/11/01 CRDT- 2025/11/03 21:43 PHST- 2025/06/12 00:00 [received] PHST- 2025/08/26 00:00 [revised] PHST- 2025/09/08 00:00 [accepted] PHST- 2025/11/04 00:29 [medline] PHST- 2025/11/04 00:28 [pubmed] PHST- 2025/11/03 21:43 [entrez] PHST- 2025/11/01 00:00 [pmc-release] AID - 66.482 [pii] AID - 10.4111/icu.20250262 [doi] PST - ppublish SO - Investig Clin Urol. 2025 Nov;66(6):482-490. doi: 10.4111/icu.20250262. PMID- 41181941 OWN - NLM STAT- MEDLINE DCOM- 20260128 LR - 20260128 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 93 IP - 1 DP - 2026 Feb TI - Cumulative smoking exposure correlates with progression in high-grade T1 bladder cancer. PG - 74-78 LID - 10.1177/03915603251390744 [doi] AB - OBJECTIVE: To evaluate the relationship between cumulative smoking exposure, measured in pack-years, and pathologic progression in patients with transitional cell carcinoma (TCC) of the bladder staged as high-grade T1 (HG-T1). PATIENT AND METHODS: We conducted a retrospective cohort study of patients diagnosed with HG-T1 urothelial carcinoma between 2020 and 2024. Clinical and pathological data were extracted, including age, gender, BMI, comorbidities, tumor size/location, completeness of resection, and presence of variant histology. Pathologic progression was defined based on worsening histology or stage on follow-up restaging transurethral resection of bladder tumor (TURBT). A pearson correlation and multivariate logistic regression were used to assess associations. RESULTS: Among the 80 patients analyzed, increasing cumulative smoking exposure, measured in pack-years, demonstrated a weak negative correlation with favorable pathology outcomes (r = -0.13). Neither tumor size nor completeness of resection showed a significant association with pathology change. Pathologic worsening was observed in 29.0% of smokers compared to 5.6% of non-smokers, with this difference approaching statistical significance (p = 0.057; OR = 7.0). When comparing non-smokers specifically to heavy smokers (⩾30 pack-years), the difference was statistically significant, with 34.4% of heavy smokers experiencing pathologic progression versus 5.6% of non-smokers (p = 0.036; OR = 8.9), indicating a strong association between heavy smoking exposure and adverse pathology. CONCLUSION: Cumulative smoking exposure is an independent predictor of pathologic progression in patients with HG-T1 bladder cancer. These findings support the incorporation of smoking history into risk stratification models and underscore the importance of smoking cessation counseling in this population. FAU - Golomb, Dor AU - Golomb D AUID- ORCID: 0000-0002-9957-0390 AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Atamna, Fahed AU - Atamna F AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Leonov Polak, Mia AU - Leonov Polak M AD - Department of Pathology, Samson Assuta Ashdod University Hospital, Israel. FAU - Avda, Yuval AU - Avda Y AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. FAU - Raz, Orit AU - Raz O AD - Department of Urology, Samson Assuta Ashdod University Hospital, Israel. LA - eng PT - Journal Article DEP - 20251103 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Retrospective Studies MH - Disease Progression MH - Male MH - Female MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Aged MH - Middle Aged MH - *Smoking/adverse effects/epidemiology MH - Neoplasm Staging MH - Neoplasm Grading MH - Cohort Studies OTO - NOTNLM OT - bladder cancer OT - pathologic progression OT - risk stratification OT - smoking COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/11/03 13:42 MHDA- 2026/01/28 19:21 CRDT- 2025/11/03 08:03 PHST- 2026/01/28 19:21 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 08:03 [entrez] AID - 10.1177/03915603251390744 [doi] PST - ppublish SO - Urologia. 2026 Feb;93(1):74-78. doi: 10.1177/03915603251390744. Epub 2025 Nov 3. PMID- 41179078 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20251105 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Exploring the Need for a Consensus Guideline for the Management of Non-Muscle-Invasive Bladder Cancer: A Scoping Review. PG - e93553 LID - 10.7759/cureus.93553 [doi] LID - e93553 AB - Non-muscle-invasive bladder cancers (NMIBC) are a heterogeneous subclass of bladder cancers consisting of carcinoma in situ, stage Ta disease, and stage T1 disease. Despite treatment by tumor resection, they have a high rate of recurrence and progression, which present unique management challenges. This scoping review discusses the management of NMIBC, including risk stratification, intravesical therapy, surveillance protocols, and developing treatments. A systematic search in different databases (PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science) was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Publications in English, from January 2010 to April 2025, were included. The final search was conducted on May 5, 2025. A total of 16 studies that met our inclusion criteria were reviewed. Different themes emerged, which include risk stratification and diagnosis, tumor resection, intravesical therapy, surveillance and follow-up, patient factors, and novel therapies. Substantial differences were found in clinical practice. Immediate postoperative chemotherapy was not adequately used, and the schedules of surveillance varied. Newer therapies, such as immune checkpoint inhibitors and novel intravesical agents, are promising. The role of enhanced cystoscopy and urinary biomarkers is also increasing for non-invasive disease monitoring. Despite this advancement, therapy standardization or a patient-centered view is still lacking. This review highlights the need for harmonized guidelines, wider access to innovative therapies, and collaborative research to improve outcomes in patients living with NMIBC. CI - Copyright (c) 2025, Enemoh et al. FAU - Enemoh, Obinna AU - Enemoh O AD - General Surgery, Chesterfield Royal Hospital, Chesterfield, GBR. FAU - Adefehinti, Mayowa AU - Adefehinti M AD - Urology, Peterborough City Hospital, Peterborough, GBR. FAU - Sanni, Quadri A AU - Sanni QA AD - Urology, South Warwickshire University NHS Foundation Trust, West Midlands, GBR. FAU - Ogunbadejo, Hykmat A AU - Ogunbadejo HA AD - Surgery, Lagos University Teaching Hospital, Lagos, NGA. AD - Urology, College of Medicine, University of Lagos, Lagos, NGA. FAU - Brabi, Daniel AU - Brabi D AD - Surgery, University of Health and Allied Sciences, Ho, GHA. AD - Surgery, Surgery Interest Group of Africa, Lagos, NGA. FAU - Iwunna, Obichukwu AU - Iwunna O AD - General Practice, NHS Health Education England East Midlands, Mansfield, GBR. AD - Emergency Medicine, Mid Cheshire Hospitals NHS Foundation Trust, Crewe, GBR. FAU - Agboro, Stephen O AU - Agboro SO AD - General Surgery, University Hospital Lewisham, London, GBR. FAU - Chukwumah, Bernard AU - Chukwumah B AD - General Practice, New Cross Hospital, Wolverhampton, GBR. FAU - Akintayo, Abiodun AU - Akintayo A AD - Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, GBR. FAU - Njeakor, Henry I AU - Njeakor HI AD - Urology, Hafar al-Batin Central Hospital, Hafar al-Batin, SAU. FAU - Uwaoma, Gentle C AU - Uwaoma GC AD - Internal Medicine, College of Medicine, University of Nigeria, Enugu, NGA. LA - eng PT - Journal Article PT - Review DEP - 20250930 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12576360 OTO - NOTNLM OT - bladder cancer OT - cancer chemotherapy OT - muscle-invasive bladder cancer OT - nmibc OT - nmibc treatment OT - non-muscle-invasive bladder cancer OT - onco-urology COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/09/30 CRDT- 2025/11/03 06:55 PHST- 2025/09/29 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 06:55 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - 10.7759/cureus.93553 [doi] PST - epublish SO - Cureus. 2025 Sep 30;17(9):e93553. doi: 10.7759/cureus.93553. eCollection 2025 Sep. PMID- 41178915 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20251105 IS - 2218-4333 (Print) IS - 2218-4333 (Electronic) IS - 2218-4333 (Linking) VI - 16 IP - 10 DP - 2025 Oct 24 TI - Human epidermal growth factor receptor 2 overexpression is associated with high-grade tumors in upper tract urothelial carcinoma. PG - 110047 LID - 10.5306/wjco.v16.i10.110047 [doi] LID - 110047 AB - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) plays pivotal roles in cellular proliferation, survival, and differentiation of several malignancies. Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy. The clinical and molecular significance of HER2 expression level in UTUC remains poorly characterized vs bladder cancer. AIM: To comprehensively evaluate HER2 expression patterns and their association with UTUC patients' clinicopathological features. METHODS: Data were retrospectively collected from patients diagnosed with UTUC at The First Affiliated Hospital of Guangxi Medical University between January 2023 and December 2024. HER2 status was evaluated by immunohistochemistry in 145 UTUC patients who met the inclusion criteria. Its associations with tumor grade, tumor stage, and other clinicopathological parameters were assessed. The chi (2) test or Fisher's exact test, along with univariate and multivariate logistic regression analyses, were performed to determine the influences of clinicopathological factors on HER2 expression. RESULTS: HER2 positivity was significantly associated with high tumor grade (P = 0.003), while other variables, including sex, anatomical tumor location, pathological T stage, Ki-67 proliferation index, nodal metastasis status, lymphovascular invasion, and tumor laterality failed to demonstrate statistically significant correlations. These findings were further substantiated through univariate logistic regression modeling, yielding an odds ratio of 3.56 [95% confidence interval (CI): 1.30-9.75; P = 0.013] for the association between high tumor grade and HER2 positivity. Importantly, this relationship remained robust (hazard ratio = 3.42, 95%CI: 1.22-9.60; P = 0.019) even after implementing multivariate logistic regression analysis. With a median follow-up time of 8 months (interquartile range, 4-14) months, 14 patients experienced intravesical recurrence after radical nephroureterectomy. Certain patient characteristics, such as HER2-negative, male sex, high-grade tumors, and luminal phenotype, were associated with a higher risk of intravesical recurrence. CONCLUSION: In UTUC, HER2 overexpression is closely associated with tumor dedifferentiation (high grade), while it does not correlate with conventional indicators of disease progression, indicating that HER2 may serve a distinct biological function in this cancer type. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Huang, Lin AU - Huang L AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China. FAU - He, Juan AU - He J AD - Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China. hejuan@stu.gxmu.edu.cn. LA - eng PT - Journal Article PL - United States TA - World J Clin Oncol JT - World journal of clinical oncology JID - 101549149 PMC - PMC12576524 OTO - NOTNLM OT - Clinicopathological features OT - Human epidermal growth factor receptor 2 OT - Relationship OT - Tumor grade OT - Upper tract urothelial carcinoma COIS- Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/10/24 CRDT- 2025/11/03 06:54 PHST- 2025/06/07 00:00 [received] PHST- 2025/07/15 00:00 [revised] PHST- 2025/09/25 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 06:54 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - 10.5306/wjco.v16.i10.110047 [doi] PST - ppublish SO - World J Clin Oncol. 2025 Oct 24;16(10):110047. doi: 10.5306/wjco.v16.i10.110047. PMID- 41175231 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20260917 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Nov 1 TI - Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data. PG - 661 LID - 10.1007/s00345-025-06025-1 [doi] LID - 661 AB - PURPOSE: To assess the epidemiology, treatment patterns, and Bacillus Calmette-Guerin (BCG) instillations in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients to evaluate guidelines compliance and effectiveness of adherence on real-world outcomes. METHODS: NMIBC patients with BCG-treatment were identified in a retrospective cohort study using German health claims data. The first BCG prescription was defined as index date. Crude and standardized annual incidence were calculated. Subsequent treatment regimens were described based on prescriptions to assess adherence. BCG-maintenance adherents were compared with non-adherents using a landmark time approach and Cox proportional hazard model. RESULTS: The annual standardized incidence per 100,000 for intermediate- and high-risk NMIBC patients ranged from 7.6 to 10.4 in males and 1.2 to 1.9 in females from 2017 to 2021. The main cohort consisted of 817 patients (mean age: 72.5; male: 78%). Most patients (98%) received transurethral resection of bladder tumor (TURBT) as initial treatment followed by BCG, with a median number of 13 BCG instillations per patient (IQR: 8-21). 28% continued BCG in the maintenance phase at 24 months post-induction and 62% received at least one Re-TURBT post-index. BCG maintenance-adherent patients showed lower risk compared with non-adherent patients: adjusted hazard ratio (aHR): 0.92 [0.73-1.18] for all-cause death; aHR: 0.49 [0.36-0.67] for advanced treatment; aHR: 0.65 [0.53-0.80] for disease progression. CONCLUSION: Real-world compliance with clinical guidelines may require improvement based on BCG maintenance duration and adherence to treatment schedules. The benefits of BCG adherence in improving oncology-relevant outcomes support guidelines recommendations for sufficient BCG maintenance. CI - (c) 2025. The Author(s). FAU - Luna, Jaime AU - Luna J AUID- ORCID: 0000-0002-5990-7534 AD - Cytel Inc, Real World and Advanced Analytics, Berlin, Germany. jaime.luna@cytel.com. FAU - Kampe, Eveline Otte Im AU - Kampe EOI AUID- ORCID: 0000-0002-9741-1193 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Aga-Barfknecht, Heja AU - Aga-Barfknecht H AUID- ORCID: 0000-0002-8765-9881 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Lehne, Moritz AU - Lehne M AUID- ORCID: 0000-0001-8435-1374 AD - Cytel Inc, Real World and Advanced Analytics, Berlin, Germany. FAU - Kunk, Leonie AU - Kunk L AUID- ORCID: 0000-0001-5305-9805 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Hansel, Ivonne AU - Hansel I AUID- ORCID: 0009-0008-6368-0791 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Trescher, Saskia AU - Trescher S AUID- ORCID: 0000-0002-0726-8590 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Mevius, Antje AU - Mevius A AUID- ORCID: 0000-0002-9556-6693 AD - IPAM e.V., University of Wismar, Wismar, Germany. FAU - Kisser, Agnes AU - Kisser A AUID- ORCID: 0009-0009-1486-8795 AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Kroeger, Nils AU - Kroeger N AUID- ORCID: 0000-0001-6659-1374 AD - Department of Urology, University Medicine Greifswald, Greifswald, Germany. AD - Praxis Urologie Altstadtquartier, Magdeburg, Germany. FAU - De Santis, Maria AU - De Santis M AUID- ORCID: 0000-0003-4969-0877 AD - Department of Urology, Charite - University Medicine Berlin, Berlin, Germany. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20251101 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/epidemiology/pathology/drug therapy/therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - Germany/epidemiology MH - *Guideline Adherence/statistics & numerical data MH - *Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Middle Aged MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Aged, 80 and over MH - Cohort Studies MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12579700 OTO - NOTNLM OT - Adherence OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Real-world evidence COIS- Declarations. Conflict of interest: EO, HAB AK, ST, IH, LK are all employees of Pfizer Pharma GmbH in Germany, the sponsor of this study and may hold stocks or stock options. JL and ML participated in this study as staff members of Cytel, the work of IPAM and Cytel in this study was funded by Pfizer. NK received honoraria from Pfizer, Astellas, BMS, MSD, Merck, Janssen, Johnson&Johnson, Eisai, Bayer, Apogepha. MDS received honoraria and travel support from AAA, AbbVie, Amgen, Astellas, AstraZeneca, Basilea, Bayer, BMS, Daiichi Sankyo, EISAI, Ferring, Gilead, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, SeaGen, Thermosome. Ethical approval: The study protocol was approved by a Scientific Committee, consisting of external experts, the cooperating sickness funds, the research sponsor, Cytel and IPAM. As the study analyzed retrospective anonymized claims data, the use of such data is not subject to ethics committee approval and no informed consent was required according to German laws ( section sign 75 SGB X, Tenth Social Code Book). The work on the dataset conformed to all social security data protection requirements. The study followed all the dictates of the Declaration of Helsinki. EDAT- 2025/11/01 21:22 MHDA- 2025/11/01 21:23 PMCR- 2025/11/01 CRDT- 2025/11/01 12:13 PHST- 2025/04/23 00:00 [received] PHST- 2025/10/17 00:00 [accepted] PHST- 2025/11/01 21:23 [medline] PHST- 2025/11/01 21:22 [pubmed] PHST- 2025/11/01 12:13 [entrez] PHST- 2025/11/01 00:00 [pmc-release] AID - 10.1007/s00345-025-06025-1 [pii] AID - 6025 [pii] AID - 10.1007/s00345-025-06025-1 [doi] PST - epublish SO - World J Urol. 2025 Nov 1;43(1):661. doi: 10.1007/s00345-025-06025-1. PMID- 41169868 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251031 LR - 20251102 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 12 DP - 2025 TI - Analysis of risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor in paraureteral bladder cancer. PG - 1680837 LID - 10.3389/fsurg.2025.1680837 [doi] LID - 1680837 AB - BACKGROUND: This study explores the risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor (TURBT) in patients with paraureteral bladder cancer, aiming to provide references for clinicians in their treatment practices. METHODS: A retrospective analysis was conducted on 164 patients with paraureteral bladder cancer who underwent TURBT from April 2017 to July 2024, among whom 133 patients had complete clinical data and follow-up data. Univariate and multivariate logistic regression analyses were used to identify the risk factors for ureteral stricture and tumor recurrence after TURBT in paraureteral bladder cancer. RESULTS: The incidence of ureteral stricture after TURBT in patients with paraureteral bladder cancer was 11.28% (15/133), and the recurrence rate of bladder cancer within 1 year after surgery was 21.80% (29/133). Multivariate logistic regression analysis showed that diabetes mellitus (p = 0.021) and tumor diameter (p = 0.002) were independent risk factors for ureteral stricture within 1 year after TURBT. Additionally, multivariate logistic regression analysis revealed that sex (p = 0.021), diabetes mellitus (p = 0.008), and pathological T stage (p = 0.002) were independent risk factors for bladder tumor recurrence within 1 year after TURBT. CONCLUSION: Diabetes mellitus and tumor diameter are independent risk factors for ureteral stricture within 1 year after TURBT in patients with paraureteral bladder cancer. Sex, diabetes mellitus, and pathological T stage are independent risk factors for bladder tumor recurrence within 1 year after TURBT in these patients. CI - (c) 2025 Meng, Han and Zhai. FAU - Meng, Rui AU - Meng R AD - Department of Urology, YuQuan Hospital, Tsinghua University, Beijing, China. FAU - Han, Yu AU - Han Y AD - Department of Urology, YuQuan Hospital, Tsinghua University, Beijing, China. FAU - Zhai, Zhipeng AU - Zhai Z AD - Department of Urology, YuQuan Hospital, Tsinghua University, Beijing, China. LA - eng PT - Journal Article DEP - 20251015 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC12568671 OTO - NOTNLM OT - TURBT OT - diabetes mellitus OT - paraureteral bladder cancer OT - tumor recurrence OT - ureteral stricture COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/31 06:26 MHDA- 2025/10/31 06:27 PMCR- 2025/10/15 CRDT- 2025/10/31 04:51 PHST- 2025/08/06 00:00 [received] PHST- 2025/09/22 00:00 [accepted] PHST- 2025/10/31 06:27 [medline] PHST- 2025/10/31 06:26 [pubmed] PHST- 2025/10/31 04:51 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - 10.3389/fsurg.2025.1680837 [doi] PST - epublish SO - Front Surg. 2025 Oct 15;12:1680837. doi: 10.3389/fsurg.2025.1680837. eCollection 2025. PMID- 41166647 OWN - NLM STAT- MEDLINE DCOM- 20260209 LR - 20260812 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 215 IP - 3 DP - 2026 Mar TI - Outcomes Among Rural and Urban Patients With High-Risk Nonmuscle-Invasive Bladder Cancer: Results From the Canadian Bladder Cancer Information System. PG - 286-293 LID - 10.1097/JU.0000000000004836 [doi] AB - PURPOSE: Patients with high-risk nonmuscle-invasive bladder cancer (NMIBC) require frequent surveillance and adjuvant intravesical therapy, which may be less accessible in rural areas. Using the Statistics Canada Remoteness Index, we sought to investigate the effect of rurality/remoteness on the presentation, management, and surveillance of high-risk NMIBC and cancer-specific outcomes such as survival and rate of progression. MATERIALS AND METHODS: The Canadian Bladder Cancer Information System database was used to identify all patients diagnosed with high-risk NMIBC (defined as high-grade [HG] Ta, any T1 disease, CIS) on initial transurethral resection of bladder tumor. Using the manual classification method, rural areas were defined as a Remoteness Index >/= 0.15. Exclusion criteria included patients with nonurothelial histology, unknown T stage, or evidence of nodal or distant metastases at the time of diagnosis. RESULTS: Among 2838 high-risk NMIBC patients, 71% were urban and 30% rural. Rural patients were more likely than urban patients to present with HG T1 tumors (42% vs 37%, P = .059). Repeat transurethral resection of bladder tumor was performed within 90 days for HG T1 disease in 29% of urban and 23% of rural patients (P = .04). Rural patients were less likely than urban patients to receive induction bacillus Calmette-Guerin (52% vs 69%, P < .0001). Five-year progression-free survival to muscle-invasive bladder cancer was significantly lower among rural patients (80% vs 85%; P = .048). CONCLUSIONS: Rural patients with high-risk NMIBC were significantly less likely to meet quality indicator benchmarks for guideline-concordant surveillance and management, although overall rates are low indicating a potential area of quality improvement efforts. FAU - Chung, D AU - Chung D AUID- ORCID: 0000-0002-7813-0986 AD - Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Kassouf, W AU - Kassouf W AD - Division of Urology, McGill University Health Center, Montreal, Quebec, Canada. FAU - Agnihotram, R AU - Agnihotram R AD - Research Institute, McGill University Health Center, Montreal, Quebec, Canada. FAU - Alday, H AU - Alday H AD - University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Tajzler, C AU - Tajzler C AD - Research Institute, McGill University Health Center, Montreal, Quebec, Canada. FAU - Eskandari, A AU - Eskandari A AD - Department of Surgical Oncology/Urology, University Health Network, Toronto, Ontario, Canada. FAU - Breau, R AU - Breau R AD - Division of Urology, Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada. FAU - Kulkarni, G AU - Kulkarni G AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Chung, P AU - Chung P AD - Department of Radiation Oncology, University Health Network, Toronto, Ontario, Canada. FAU - Fairey, A AU - Fairey A AD - Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada. FAU - Lodde, M AU - Lodde M AD - Department of Urology, University of Laval, Quebec City, Quebec, Canada. FAU - Hyndman, E AU - Hyndman E AD - Division of Urology, Department of Surgery, Section of Urology, University of Calgary, Calgary, Alberta, Canada. FAU - Alimohamed, N AU - Alimohamed N AD - Division of Medical Oncology, University of Calgary, Calgary, Alberta, Canada. FAU - Rendon, R AU - Rendon R AD - Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada. FAU - Black, P AU - Black P AD - Division of Urology, Department of Surgery, Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Nayak, J G AU - Nayak JG AD - Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada. LA - eng SI - ClinicalTrials.gov/NCT02298998 PT - Journal Article DEP - 20251030 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM CIN - Transl Androl Urol. 2026 Jul 31;15(7):227. doi: 10.21037/tau-2026-0412. PMID: 42582623 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality/epidemiology MH - Male MH - Female MH - Canada/epidemiology MH - Aged MH - *Rural Population/statistics & numerical data MH - Neoplasm Invasiveness MH - *Urban Population/statistics & numerical data MH - Middle Aged MH - BCG Vaccine MH - Aged, 80 and over MH - Disease Progression MH - Survival Rate MH - Risk Assessment MH - Neoplasm Staging MH - Cystectomy OTO - NOTNLM OT - bladder cancer OT - disparity OT - rural EDAT- 2025/10/30 18:26 MHDA- 2026/02/09 12:53 CRDT- 2025/10/30 15:33 PHST- 2026/02/09 12:53 [medline] PHST- 2025/10/30 18:26 [pubmed] PHST- 2025/10/30 15:33 [entrez] AID - 10.1097/JU.0000000000004836 [doi] PST - ppublish SO - J Urol. 2026 Mar;215(3):286-293. doi: 10.1097/JU.0000000000004836. Epub 2025 Oct 30. PMID- 41166099 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20251112 IS - 1936-086X (Electronic) IS - 1936-0851 (Linking) VI - 19 IP - 44 DP - 2025 Nov 11 TI - An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer. PG - 38305-38317 LID - 10.1021/acsnano.5c09883 [doi] AB - Bladder cancer is a common malignancy with high rates of recurrence and progression. Chemotherapy is employed at various stages of treatment to improve patient outcomes and survival; however, it is sometimes ineffective and often associated with significant side effects. Moreover, growing evidence suggests that chemotherapy may paradoxically enhance tumor invasiveness and metastatic potential in certain cancer types. These concerns underscore the need to better understand the impact of chemotherapy and to develop personalized prognostic strategies for managing bladder cancer. Here, we present an organoid biosensing platform designed to evaluate chemotherapy-induced effects in a patient-specific manner. Freshly isolated tumor organoids and self-assembled microtumors derived from transurethral resection of bladder tumors are cultured within a tumor-on-gel biomimetic microenvironment. By integrating live single cell nanobiosensors with 3D time-lapse microscopy, the platform enables real-time detection of molecular biomarkers and rapid assessment of tumor invasiveness. We demonstrate the platform's capability to evaluate cisplatin-induced invasion in bladder cancer organoids at the individual patient level. These findings highlight the potential of this organoid biosensing system to investigate patient-specific risks of chemotherapy-induced invasion and to guide more personalized approaches to bladder cancer treatment. FAU - Yan, Yue AU - Yan Y AD - Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States. FAU - Ahmed, Mona AU - Ahmed M AD - Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States. FAU - Mach, Kathleen E AU - Mach KE AD - Department of Urology, Stanford University School of Medicine, Stanford, California 94305, United States. FAU - Liao, Joseph C AU - Liao JC AUID- ORCID: 0000-0003-2448-5463 AD - Department of Urology, Stanford University School of Medicine, Stanford, California 94305, United States. FAU - Wong, Pak Kin AU - Wong PK AUID- ORCID: 0000-0001-7388-2110 AD - Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States. AD - Department of Mechanical Engineering and Department of Surgery, The Pennsylvania State University, University Park, Pennsylvania 16802, United States. LA - eng PT - Journal Article DEP - 20251030 PL - United States TA - ACS Nano JT - ACS nano JID - 101313589 RN - Q20Q21Q62J (Cisplatin) RN - 0 (Antineoplastic Agents) SB - IM MH - *Urinary Bladder Neoplasms/diagnosis/pathology/drug therapy MH - Humans MH - *Organoids/pathology/drug effects MH - *Biosensing Techniques/methods MH - *Precision Medicine MH - Prognosis MH - Cisplatin/pharmacology MH - Antineoplastic Agents/pharmacology MH - Cell Line, Tumor OTO - NOTNLM OT - cancer OT - chemo-induced invasion OT - chemotherapy OT - nanobiosensors OT - organoids OT - precision medicine EDAT- 2025/10/30 18:26 MHDA- 2025/11/13 00:31 CRDT- 2025/10/30 12:42 PHST- 2025/11/13 00:31 [medline] PHST- 2025/10/30 18:26 [pubmed] PHST- 2025/10/30 12:42 [entrez] AID - 10.1021/acsnano.5c09883 [doi] PST - ppublish SO - ACS Nano. 2025 Nov 11;19(44):38305-38317. doi: 10.1021/acsnano.5c09883. Epub 2025 Oct 30. PMID- 41165824 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Oct 30 TI - Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes. PG - 647 LID - 10.1007/s00345-025-06008-2 [doi] AB - BACKGROUND: Robot-assisted radical cystectomy (RARC) use for bladder cancer (BC) treatment is increasing, offering similar oncologic outcomes to open radical cystectomy (ORC) with better perioperative results. We assessed factors driving RARC selection, predictors of conversion to open surgery, and impacts on mortality and morbidity. METHODS: We retrospectively analyzed the National Cancer Database (NCDB) (2010-2021) for patients with localized BC undergoing RARC versus ORC. Proportions in approach use were assessed, and multivariable logistic regression identified predictors of approach selection. RARC conversion rates and conversion predictors were analyzed. 30-/90-day mortality and 30-day readmission were compared between converted and non-converted cases using adjusted odds ratios (aOR) and 95% confidence intervals (CI). RESULTS: Among 29,215 patients with localized BC, 9,954 (34.1%) underwent RARC. Usage rose from 18.1% in 2010 to 48.7% in 2021 (p < 0.001), highest in non-muscle invasive BC (NMIBC) (36.0%; p < 0.001). Predictors of RARC adoption over ORC included NMIBC diagnosis (aOR 1.22, 95% CI 1.10-1.35), neoadjuvant chemotherapy (1.49, 1.34-1.66), and private insurance (1.68, 1.32-2.16). RARC usage was less likely for cN2-3 (0.73, 0.61-0.86) and prior radiation (0.60, 0.43-0.85). Among RARC cases, 288 (2.9%) required intraoperative conversion to open surgery. Low-volume centers (< 10 cases: 2.33, 1.66-3.28; 10-19 cases: 1.89, 1.26-2.83) had higher conversion risk. Converted cases had significantly higher 90-day (11.9% vs. 5.1%; 2.53, 1.72-3.72) mortality and 30-day readmission (14.3% vs. 8.5%; 1.79, 1.28-2.51). CONCLUSIONS: RARC use increased, especially in NMIBC cases. Its adoption was driven by NMIBC diagnosis, neoadjuvant chemotherapy, and insurance; low caseload predicted conversion to open surgery and worse outcomes, informing patient selection. FAU - Dagnino, Filippo AU - Dagnino F AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Beatrici, Edoardo AU - Beatrici E AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Qian, Zhiyu AU - Qian Z AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Stelzl, Daniel AU - Stelzl D AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Zurl, Hanna AU - Zurl H AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Korn, Stephan AU - Korn S AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Pohl, Klara AU - Pohl K AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Piccolini, Andrea AU - Piccolini A AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Garcia, Guilherme AU - Garcia G AD - Department of Urology, University of Sao Paulo, Sao Paulo, Brazil. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Buffi, Nicolo M AU - Buffi NM AD - Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Kibel, Adam S AU - Kibel AS AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Cole, Alexander P AU - Cole AP AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Department of Urology, University of Pittsburgh, UPMC, Pittsburgh, PA, USA. FAU - Clinton, Timothy N AU - Clinton TN AD - Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. tclinton1@bwh.harvard.edu. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. tclinton1@bwh.harvard.edu. AD - Department of Urology, Brigham and Women's Hospital, 45 Francis St, ASB II-3, Boston, MA, 02115, USA. tclinton1@bwh.harvard.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20251030 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Retrospective Studies MH - Female MH - *Robotic Surgical Procedures MH - Male MH - Treatment Outcome MH - Aged MH - *Conversion to Open Surgery/statistics & numerical data MH - Middle Aged OTO - NOTNLM OT - Bladder cancer OT - Conversion OT - Open approach OT - Radical cystectomy OT - Robotic approach COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This study was deemed exempt by IRB because it did not include direct identifiable patient information. EDAT- 2025/10/30 18:26 MHDA- 2026/06/27 00:50 CRDT- 2025/10/30 12:15 PHST- 2025/04/26 00:00 [received] PHST- 2025/10/15 00:00 [accepted] PHST- 2026/06/27 00:50 [medline] PHST- 2025/10/30 18:26 [pubmed] PHST- 2025/10/30 12:15 [entrez] AID - 10.1007/s00345-025-06008-2 [pii] AID - 10.1007/s00345-025-06008-2 [doi] PST - epublish SO - World J Urol. 2025 Oct 30;43(1):647. doi: 10.1007/s00345-025-06008-2. PMID- 41151860 OWN - NLM STAT- MEDLINE DCOM- 20251028 LR - 20251102 IS - 1790-6245 (Electronic) IS - 1109-6535 (Print) IS - 1109-6535 (Linking) VI - 22 IP - 6 DP - 2025 Nov-Dec TI - Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer as Independent Prognosticators. PG - 850-862 LID - 10.21873/cgp.20542 [doi] AB - BACKGROUND/AIM: Cross-talk between forkhead box O1 (FOXO1), a transcriptional factor known to function as a tumor suppressor via the PI3K/AKT pathway, and glucocorticoid receptor (GR) has been implied in non-urothelial cells. The present study aimed to investigate the association of FOXO1 and GR expression in bladder cancer and its prognostic significance. MATERIALS AND METHODS: Immunohistochemical staining for GR, FOXO1, and p-FOXO1 (a phosphorylated/inactivated form) was performed in a set of bladder cancer tissue microarray comprising 50 low-grade non-invasive tumors, 28 high-grade non-muscle-invasive tumors, and 51 high-grade muscle-invasive tumors. Western blotting for FOXO1 and p-FOXO1 was also conducted in human bladder cancer cells. RESULTS: GR expression was detected in 109 [84.5%; 39 (30.2%) weakly positive (1+), 39 (30.2%) moderately positive (2+), 31 (24.0%) strongly positive (3+)] tumors, whereas FOXO1 and p-FOXO1 were immunoreactive in 17 [13.2%; 16 (12.4%) 1+, 1 (0.8%) 2+] and 71 [55.0%; 57 (44.2%) 1+, 14 (10.9%) 2+] tumors, respectively. The expression levels of GR were positively and negatively correlated with those of FOXO1 (p=0.003) and p-FOXO1 (p=0.009), respectively. GR(0/1+)/FOXO1(0) and GR(0/1+)/p-FOXO1(1+/2+) were significantly more often observed in high-grade (vs. low-grade) or muscle-invasive (vs. non-muscle-invasive) tumors. Both univariate and multivariate analyses revealed that GR(0/1+)/FOXO1(0) and GR(0/1+)/p-FOXO1(1+/2+) were associated with a significantly higher risk for the recurrence of non-invasive disease or progression of muscle-invasive disease. In 2 GR-positive bladder cancer lines, glucocorticoids (i.e., dexamethasone, prednisone) and a GR antagonist (i.e., RU486) induced the levels of FOXO1 and p-FOXO1 expression, respectively. CONCLUSION: The expression levels of GR and FOXO1 or p-FOXO1 were strongly correlated in bladder cancer. Specific GR/FOXO1 and GR/p-FOXO1 expression profiles served as independent predictors of disease recurrence or progression. CI - Copyright (c) 2025, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Ide, Hiroki AU - Ide H AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A. AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Najafi, Mohammad Amin Elahi AU - Najafi MAE AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, U.S.A. FAU - Matsukawa, Takuo AU - Matsukawa T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, U.S.A. FAU - Tatenuma, Tomoyuki AU - Tatenuma T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, U.S.A. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.; hiroshi_miyamoto@urmc.rochester.edu. AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, U.S.A. AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, U.S.A. LA - eng PT - Journal Article PL - Greece TA - Cancer Genomics Proteomics JT - Cancer genomics & proteomics JID - 101188791 RN - 0 (Forkhead Box Protein O1) RN - 0 (Receptors, Glucocorticoid) RN - 0 (FOXO1 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/genetics/mortality MH - *Forkhead Box Protein O1/metabolism/genetics MH - *Receptors, Glucocorticoid/metabolism/genetics MH - Prognosis MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Biomarkers, Tumor/metabolism MH - Aged, 80 and over MH - Adult MH - Phosphorylation PMC - PMC12577604 OTO - NOTNLM OT - Bladder cancer OT - FOXO1 OT - glucocorticoid receptor OT - immunohistochemistry OT - phospho-FOXO1 COIS- The Authors declare that they have no conflicts of interest interests or financial ties related to this study. EDAT- 2025/10/29 00:26 MHDA- 2025/10/29 00:27 PMCR- 2025/10/28 CRDT- 2025/10/28 21:26 PHST- 2025/07/21 00:00 [received] PHST- 2025/08/15 00:00 [revised] PHST- 2025/08/25 00:00 [accepted] PHST- 2025/10/29 00:27 [medline] PHST- 2025/10/29 00:26 [pubmed] PHST- 2025/10/28 21:26 [entrez] PHST- 2025/10/28 00:00 [pmc-release] AID - 22/6/850 [pii] AID - 10.21873/cgp.20542 [doi] PST - ppublish SO - Cancer Genomics Proteomics. 2025 Nov-Dec;22(6):850-862. doi: 10.21873/cgp.20542. PMID- 41150018 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251028 LR - 20251030 IS - 2313-433X (Electronic) IS - 2313-433X (Linking) VI - 11 IP - 10 DP - 2025 Oct 1 TI - Radiomics-Based Preoperative Assessment of Muscle-Invasive Bladder Cancer Using Combined T2 and ADC MRI: A Multicohort Validation Study. LID - 10.3390/jimaging11100342 [doi] LID - 342 AB - Accurate preoperative staging of bladder cancer on MRI remains challenging because visual reads vary across observers. We investigated a multiparametric MRI (mpMRI) radiomics approach to predict muscle invasion (>/=T2) and prospectively tested it on a validation cohort. Eighty-four patients with urothelial carcinoma underwent 1.5-T mpMRI per VI-RADS (T2-weighted imaging and DWI-derived ADC maps). Two blinded radiologists performed 3D tumor segmentation; 37 features per sequence were extracted (LifeX) using absolute resampling. In the training cohort (n = 40), features that differed between non-muscle-invasive and muscle-invasive tumors (Mann-Whitney p < 0.05) underwent ROC analysis with cut-offs defined by the Youden index. A compact descriptor combining GLRLM-LRLGE from T2 and GLRLM-SRLGE from ADC was then fixed and applied without re-selection to a prospective validation cohort (n = 44). Histopathology within 6 weeks-TURBT or cystectomy-served as the reference. Eleven T2-based and fifteen ADC-based features pointed to invasion; DWI texture features were not informative. The descriptor yielded AUCs of 0.934 (training) and 0.871 (validation) with 85.7% sensitivity and 96.2% specificity in validation. Collectively, these findings indicate that combined T2/ADC radiomics can provide high diagnostic accuracy and may serve as a useful decision support tool, after multicenter, multi-vendor validation. FAU - Kabanov, Dmitry AU - Kabanov D AUID- ORCID: 0000-0003-3550-0139 AD - Department of Computed Tomography and Magnetic Resonance Imaging, P. Hertsen Moscow Oncology Research Institute (MORI), 125284 Moscow, Russia. FAU - Rubtsova, Natalia AU - Rubtsova N AUID- ORCID: 0000-0001-8378-4338 AD - Department of Computed Tomography and Magnetic Resonance Imaging, P. Hertsen Moscow Oncology Research Institute (MORI), 125284 Moscow, Russia. FAU - Golbits, Aleksandra AU - Golbits A AD - Department of Computed Tomography and Magnetic Resonance Imaging, N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology (SRIUIR), 105425 Moscow, Russia. FAU - Kaprin, Andrey AU - Kaprin A AD - Department of Computed Tomography and Magnetic Resonance Imaging, P. Hertsen Moscow Oncology Research Institute (MORI), 125284 Moscow, Russia. AD - Department of Oncology and Radiology, Institute of Medicine, Peoples' Friendship University of Russia-RUDN University, 117198 Moscow, Russia. FAU - Sinitsyn, Valentin AU - Sinitsyn V AUID- ORCID: 0000-0002-5649-2193 AD - Radiology Department of University Medical Center, Lomonosov Moscow State University, 119991 Moscow, Russia. FAU - Potievskiy, Mikhail AU - Potievskiy M AUID- ORCID: 0000-0002-8514-8295 AD - Center for Clinical Trials of Center for Innovative Radiological and Regenerative Technologies, Federal State Budgetary Institution National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 249031 Obninsk, Russia. LA - eng PT - Journal Article DEP - 20251001 PL - Switzerland TA - J Imaging JT - Journal of imaging JID - 101698819 PMC - PMC12565562 OTO - NOTNLM OT - LifeX OT - MIBC OT - MRI OT - bladder cancer OT - muscle invasion OT - radiomics OT - staging OT - texture analysis COIS- The authors declare no conflicts of interest. EDAT- 2025/10/28 18:27 MHDA- 2025/10/28 18:28 PMCR- 2025/10/01 CRDT- 2025/10/28 12:46 PHST- 2025/08/09 00:00 [received] PHST- 2025/09/22 00:00 [revised] PHST- 2025/09/25 00:00 [accepted] PHST- 2025/10/28 18:28 [medline] PHST- 2025/10/28 18:27 [pubmed] PHST- 2025/10/28 12:46 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - jimaging11100342 [pii] AID - jimaging-11-00342 [pii] AID - 10.3390/jimaging11100342 [doi] PST - epublish SO - J Imaging. 2025 Oct 1;11(10):342. doi: 10.3390/jimaging11100342. PMID- 41149454 OWN - NLM STAT- MEDLINE DCOM- 20260316 LR - 20260316 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 32 IP - 10 DP - 2025 Sep 24 TI - Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study. LID - 10.3390/curroncol32100534 [doi] LID - 534 AB - BACKGROUND: Urothelial carcinoma of the bladder (UCB) demonstrates considerable heterogeneity, with markedly varying outcomes between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The pan-immune-inflammation value (PIV), derived from routine hematological parameters, has emerged as a novel biomarker reflecting systemic inflammation and immune dysregulation. This pilot, exploratory analysis evaluated the prognostic relevance of the PIV in UCB and contextualized PIV against other inflammation-based indices. METHODS: We retrospectively analyzed 119 patients with histologically confirmed UCB who were treated between 2019 and 2024. PIV was calculated as (neutrophils x platelets x monocytes) / lymphocytes. Additional indices included the NLR, SII, SIRI, and PLR. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier analysis, and prognostic factors were assessed using Cox regression. RESULTS: Among 119 patients (median age, 72 years; 88% male), 68 were diagnosed with NMIBC and 51 with MIBC. Elevated PIV levels were significantly associated with NMIBC progression to MIBC (p = 0.028) and strongly correlated with NLR, SII, SIRI, and PLR. Patients with high PIV exhibited shorter OS (24 vs. 45 months) and PFS (20 vs. 35 months) than those with low patients (p < 0.001). Although the prognostic value was evident in the univariate analyses, PIV did not retain significance in multivariate models. CONCLUSION: Elevated PIV levels predict adverse survival outcomes and progression in UCB, underscoring its potential as a cost-effective and accessible biomarker for risk stratification. Prospective validation in larger cohorts is warranted to confirm its role in personalized patient management. FAU - Eren, Ali Erhan AU - Eren AE AD - Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Aydin, Asim Armagan AU - Aydin AA AUID- ORCID: 0000-0001-8749-9825 AD - Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Aksaray, Eren Erdi AU - Aksaray EE AUID- ORCID: 0000-0003-1074-1016 AD - Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Durak, Arda AU - Durak A AUID- ORCID: 0009-0008-0159-2497 AD - Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Unlu, Ahmet AU - Unlu A AUID- ORCID: 0000-0001-6654-3815 AD - Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Islamoglu, Mahmut Ekrem AU - Islamoglu ME AUID- ORCID: 0000-0003-0693-0666 AD - Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Ozturk, Banu AU - Ozturk B AD - Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. FAU - Yildiz, Mustafa AU - Yildiz M AD - Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. LA - eng PT - Journal Article DEP - 20250924 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Pilot Projects MH - *Urinary Bladder Neoplasms/blood/immunology/mortality/pathology MH - Prognosis MH - *Carcinoma, Transitional Cell/blood/immunology/mortality/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - Progression-Free Survival MH - Disease Progression MH - *Inflammation/blood/diagnosis/immunology MH - Kaplan-Meier Estimate MH - Retrospective Studies MH - Follow-Up Studies MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - Aged, 80 and over PMC - PMC12564454 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - muscle invasive OT - non-muscle invasive OT - pan-immune-inflammation value OT - prognosis OT - survival OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2025/10/28 18:27 MHDA- 2025/10/28 18:28 PMCR- 2025/09/24 CRDT- 2025/10/28 12:37 PHST- 2025/08/23 00:00 [received] PHST- 2025/09/20 00:00 [revised] PHST- 2025/09/23 00:00 [accepted] PHST- 2025/10/28 18:28 [medline] PHST- 2025/10/28 18:27 [pubmed] PHST- 2025/10/28 12:37 [entrez] PHST- 2025/09/24 00:00 [pmc-release] AID - curroncol32100534 [pii] AID - curroncol-32-00534 [pii] AID - 10.3390/curroncol32100534 [doi] PST - epublish SO - Curr Oncol. 2025 Sep 24;32(10):534. doi: 10.3390/curroncol32100534. PMID- 41135713 OWN - NLM STAT- MEDLINE DCOM- 20260205 LR - 20260817 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 124 IP - 3 DP - 2026 Mar 1 TI - The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer. PG - 726-732 LID - S0360-3016(25)06329-1 [pii] LID - 10.1016/j.ijrobp.2025.09.056 [doi] AB - PURPOSE: Radical cystectomy (RC) is a standard of care for muscle-invasive bladder cancer (MIBC). Although radiation therapy (RT) offers bladder preservation with comparable survival, 20%-30% of patients require salvage RC. Neoadjuvant chemotherapy (NAC) is given to patients prior to RC, but with modest benefit and considerable toxicity. Among tumor immune microenvironment features, tertiary lymphoid structures (TLS) have emerged as prognostic and predictive biomarkers. Here, we investigate the association between TLS and response to RT and NAC in MIBC. METHODS AND MATERIALS: We evaluated TLS in pre-treatment transurethral resection of bladder tumor specimens from MIBC patients given RT or NAC. Multiplex immunohistochemistry defined TLS presence, density, and maturation, including germinal center and immune subset markers. Associations with treatment response and survival were analyzed separately for RT and NAC cohorts. RESULTS: TLS were detected in 83% of RT patients. Although the presence was not prognostic, higher density and maturation correlated with response and with improved overall and cancer-specific survival. Furthermore, TLS density correlated with B cells and regulatory T cells (Tregs) in responders and inversely with cytotoxic T cells in nonresponders. In the NAC cohort, TLS presence, density, or maturation were not associated with response or survival. CONCLUSIONS: These exploratory findings suggest that TLS density and maturation may be associated with improved RT outcomes in MIBC and warrant prospective validation as biomarkers. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Hassan, Nour AU - Hassan N AD - Department of Surgery, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. FAU - Michaud, Eva AU - Michaud E AD - Department of Surgery, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. FAU - Mansure, Jose Joao AU - Mansure JJ AD - Department of Surgery, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. FAU - Farag, Mina AU - Farag M AD - Division of Pathology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Kool, Ronald AU - Kool R AD - Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Alessa, Mohanned AU - Alessa M AD - Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Sadri, Erfan AU - Sadri E AD - Department of Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. FAU - Cury, Fabio AU - Cury F AD - Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Brimo, Fadi AU - Brimo F AD - Division of Pathology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Koti, Madhuri AU - Koti M AD - Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada; Department of Urology, Queen's University, Kingston, Ontario, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Surgery, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada; Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: wassim.kassouf.med@ssss.gouv.qc.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251022 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/immunology/therapy/radiotherapy MH - Male MH - *Tertiary Lymphoid Structures/pathology/immunology MH - Aged MH - Female MH - Neoplasm Invasiveness MH - Cystectomy MH - Middle Aged MH - Neoadjuvant Therapy MH - Tumor Microenvironment/immunology MH - Aged, 80 and over MH - Treatment Outcome MH - B-Lymphocytes/immunology MH - T-Lymphocytes, Regulatory/immunology MH - Prognosis MH - Clinical Relevance EDAT- 2025/10/25 00:30 MHDA- 2026/02/06 00:31 CRDT- 2025/10/24 19:37 PHST- 2025/05/05 00:00 [received] PHST- 2025/08/19 00:00 [revised] PHST- 2025/09/21 00:00 [accepted] PHST- 2026/02/06 00:31 [medline] PHST- 2025/10/25 00:30 [pubmed] PHST- 2025/10/24 19:37 [entrez] AID - S0360-3016(25)06329-1 [pii] AID - 10.1016/j.ijrobp.2025.09.056 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):726-732. doi: 10.1016/j.ijrobp.2025.09.056. Epub 2025 Oct 22. PMID- 41132345 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251024 LR - 20251027 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 14 IP - 9 DP - 2025 Sep 30 TI - En bloc transurethral resection versus conventional transurethral resection for non-muscle invasive bladder cancer: a systematic review and meta-analysis. PG - 2593-2605 LID - 10.21037/tau-2025-329 [doi] AB - BACKGROUND: The gold standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor (TURBT). En bloc transurethral resection is a new method for non-muscle invasive bladder cancer that may improve some shortcomings of TURBT. The aim of this systematic review and meta-analysis was to compare the perioperative and prognostic outcomes of en bloc transurethral resection and TURBT for NMIBC. METHODS: Literature searches were conducted using PubMed, Embase, Cochrane Library, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), WanFang Data (WanFang) and VIP Information Network (VIP). We only included randomized controlled trials (RCTs). We used the Cochrane risk of bias 2.0 tool and modified Jadad scale to assess the quality of the literature. Statistical analyses were conducted using Review Manager 5.3 software (RevMan) and Stata SE software. RESULTS: We included 16 RCTs comprising 1,505 patients (experimental group: 827; control group: 678). There were no significant differences between en bloc transurethral resection and TURBT in operation time [standard mean difference (SMD) =-0.21, 95% confidence interval (CI): -0.70 to -0.28, P=0.40] and 3-month recurrence rate [relative risk (RR) =0.14, 95% CI: 0.02-1.08, P=0.06]. Compared with TURBT, en bloc transurethral resection significantly decreased 6-month recurrence rate (RR =0.43, 95% CI: 0.26-0.69, P<0.001), 1-year recurrence rate (RR =0.36, 95% CI: 0.25-0.53, P<0.001), positive number of the biopsy at the tumor base (RR =0.17, 95% CI: 0.07-0.43, P<0.001), vesical perforation (RR =0.22, 95% CI: 0.11-0.43, P<0.001), obturator nerve reflex (RR =0.39, 95% CI: 0.18-0.83, P=0.01), postoperative complications (RR =0.10, 95% CI: 0.02-0.41, P=0.002), hemorrhage (SMD =-2.13, 95% CI: -2.89 to -1.37, P<0.001), hospital stay [mean difference (MD) =-2.14, 95% CI: -2.81 to -1.47, P<0.001], bladder irrigation time (SMD =-2.80, 95% CI: -3.36 to -2.24, P<0.001), and catheterization period (SMD =-1.77, 95% CI: -2.63 to -0.91, P<0.001). CONCLUSIONS: Compared with TURBT, en bloc transurethral resection appears to be a better treatment option for NMIBC. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Lv, Lingdong AU - Lv L AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Wang, Jing AU - Wang J AD - Department of Pathology, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Li, Lu AU - Li L AD - Department of Pathology, General Hospital of Ningxia Medical University, Yinchuan, China. LA - eng PT - Journal Article DEP - 20250926 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC12541490 OTO - NOTNLM OT - Non-muscle invasive bladder cancer (NMIBC) OT - en bloc transurethral resection OT - transurethral resection OT - transurethral resection of the bladder tumor (TURBT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-329/coif). The authors have no conflicts of interest to declare. EDAT- 2025/10/24 06:26 MHDA- 2025/10/24 06:27 PMCR- 2025/09/30 CRDT- 2025/10/24 04:45 PHST- 2025/05/08 00:00 [received] PHST- 2025/08/04 00:00 [accepted] PHST- 2025/10/24 06:27 [medline] PHST- 2025/10/24 06:26 [pubmed] PHST- 2025/10/24 04:45 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - tau-14-09-2593 [pii] AID - 10.21037/tau-2025-329 [doi] PST - ppublish SO - Transl Androl Urol. 2025 Sep 30;14(9):2593-2605. doi: 10.21037/tau-2025-329. Epub 2025 Sep 26. PMID- 41132341 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251024 LR - 20251027 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 14 IP - 9 DP - 2025 Sep 30 TI - Mechanistic study of GALNT16 promoting malignant progression and metastasis in bladder cancer: functional analysis and experimental validation. PG - 2481-2497 LID - 10.21037/tau-2025-133 [doi] AB - BACKGROUND: Bladder cancer is highly malignant, but specific biomarkers and molecular targets are lacking. The aim of this study was to screen bladder cancer progression-related differential genes based on those associated with tumor-node-metastasis (TNM) staging, and to validate them by in vitro and in vivo experiments. METHODS: Common genes were screened and prognostically analyzed by cross-analyzing differential genes in The Cancer Genome Atlas (TCGA) database for bladder cancer stages T1-2 and T3-4, N1 and N2, and M0 and M1. The functions were further identified by enrichment analysis, and the biological functions of the differential genes in bladder cancer were verified using in vivo and in vitro experiments. RESULTS: The shared gene polypeptide N-acetylgalactosaminyltransferase 16 (GALNT16) was identified by cross-analysis of differential genes between T1-2 and T3-4 stages, N1 and N2 stages, and M0 and M1 stages. Further analysis showed that GALNT16 was involved in a variety of signaling pathways and biological functions, especially related to tumor metastasis, and correlated with immune cell infiltration status. In addition, ex vivo and in vivo functional experiments demonstrated that GALNT16 was able to influence the expression of epithelial-mesenchymal transition (EMT) pathway-related proteins, thereby promoting the proliferation, migration and invasive ability of bladder cancer. CONCLUSIONS: GALNT16 can promote malignant progression of bladder cancer and may be a valuable diagnostic and prognostic marker and potential therapeutic target for bladder cancer. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Ben, Liangliang AU - Ben L AD - Department of Urology, Nantong Rehabilitation Hospital (Nantong Second People's Hospital), Nantong, China. FAU - Wang, Jian AU - Wang J AD - Department of Urology, Nantong Rehabilitation Hospital (Nantong Second People's Hospital), Nantong, China. FAU - Wu, Peng AU - Wu P AD - Department of Urology, Nantong Rehabilitation Hospital (Nantong Second People's Hospital), Nantong, China. LA - eng PT - Journal Article DEP - 20250926 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC12541496 OTO - NOTNLM OT - Bladder cancer OT - N-acetylgalactosaminyltransferase 16 (GALNT16) OT - biomarker OT - tumor-node-metastasis (TNM) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-133/coif). The authors have no conflicts of interest to declare. EDAT- 2025/10/24 06:26 MHDA- 2025/10/24 06:27 PMCR- 2025/09/30 CRDT- 2025/10/24 04:45 PHST- 2025/02/21 00:00 [received] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/10/24 06:27 [medline] PHST- 2025/10/24 06:26 [pubmed] PHST- 2025/10/24 04:45 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - tau-14-09-2481 [pii] AID - 10.21037/tau-2025-133 [doi] PST - ppublish SO - Transl Androl Urol. 2025 Sep 30;14(9):2481-2497. doi: 10.21037/tau-2025-133. Epub 2025 Sep 26. PMID- 41126111 OWN - NLM STAT- MEDLINE DCOM- 20251023 LR - 20251027 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 Oct 22 TI - Diagnostic value of serum DR-70 levels, a new fibrin-related biomarker, in bladder cancer patients. PG - 264 LID - 10.1186/s12894-025-01964-8 [doi] LID - 264 AB - BACKGROUND: Bladder cancer has high morbidity and mortality rates when it is diagnosed at an advanced stage. The aim of our study is to determine the effect of the DR-70 protein in the diagnosis of bladder cancer and to evaluate its relationship with the grade of the disease. METHODS: Serum samples from 60 patients with bladder cancer and 24 control patients with macroscopic hematuria of benign etiology were included in the study. DR-70 levels were compared between the bladder cancer group and the control group. Additionally, a comparison was made between patients with non-muscle invasive bladder cancer and those with muscle invasive disease. RESULTS: The median DR-70 level in the bladder cancer group was 1.08 U/mL (0.48-8.5), whereas it was 0.89 U/mL (0.29-1.76) in the control group. The DR-70 level was significantly greater in the bladder cancer group than in the control group (p = 0.012). DR-70 had a sensitivity of 73.3% and a specificity of 66.7% in detecting bladder cancer. On the other hand, the median DR-70 level was 1.06 U/mL (0.48-4.09) in patients with non-muscle-invasive bladder cancer (Ta, T1) and 2.66 U/mL (0.57-8.5) in patients with invasive bladder cancer (T2). DR-70 levels were significantly greater in patients with invasive bladder cancer than in those with non-muscle invasive bladder cancer (p = 0.021). Additionally, DR-70 had 72.7% sensitivity and 63.3% specificity in detecting muscle invasive bladder cancer. CONCLUSIONS: Compared with that in the control group, the protein level of DR-70 significantly increased in patients with bladder cancer and was greater in the group with muscle invasion. CI - (c) 2025. The Author(s). FAU - Karakanli, Musab Umeyir AU - Karakanli MU AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. musabkarakanli@gmail.com. FAU - Kutluturk, Eren Gorkem AU - Kutluturk EG AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. FAU - Polat, Emre Can AU - Polat EC AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. FAU - Otunctemur, Alper AU - Otunctemur A AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. FAU - Merder, Erkan AU - Merder E AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. FAU - Dursun, Murat AU - Dursun M AD - Faculty of Medicine, Istanbul University, Urology Clinic, Istanbul, Turkey. FAU - Ozcan, Levent AU - Ozcan L AD - Prof. Dr. Cemil Tascioglu City Hospital, Urology Clinic, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20251022 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/diagnosis/pathology MH - Male MH - Female MH - *Biomarkers, Tumor/blood MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Adult MH - Sensitivity and Specificity PMC - PMC12542430 OTO - NOTNLM OT - Bladder cancer OT - DR-70 OT - Fibrin degradation products OT - Hematuria COIS- Declarations. Ethics approval and consent to participate: This study was performed in accordance with the Declaration of Helsinki. This human study was approved by Prof. Dr. Cemil Tascioglu City Hospital - approval: 2023-92. All adult participants provided written informed consent to participate in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/10/23 00:26 MHDA- 2025/10/23 06:28 PMCR- 2025/10/22 CRDT- 2025/10/22 23:48 PHST- 2025/07/03 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/10/23 06:28 [medline] PHST- 2025/10/23 00:26 [pubmed] PHST- 2025/10/22 23:48 [entrez] PHST- 2025/10/22 00:00 [pmc-release] AID - 10.1186/s12894-025-01964-8 [pii] AID - 1964 [pii] AID - 10.1186/s12894-025-01964-8 [doi] PST - epublish SO - BMC Urol. 2025 Oct 22;25(1):264. doi: 10.1186/s12894-025-01964-8. PMID- 41123570 OWN - NLM STAT- MEDLINE DCOM- 20260107 LR - 20260107 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 97 IP - 4 DP - 2025 Dec 24 TI - Survival outcomes and prognostic factors in muscle-invasive bladder cancer: a retrospective cohort study from a Saudi Arabian tertiary center. PG - 14119 LID - 10.4081/aiua.2025.14119 [doi] AB - BACKGROUND: Bladder cancer (BC) exhibits a wide range of clinical behaviors, with survival outcomes depending on tumor biology, treatment choices, and patient characteristics. This study measured survival across different stages of the disease, compared the effectiveness of treatments, and identified prognostic factors in BC patients at a Tertiary Center. PATIENTS AND METHOD: We reviewed 65 patients diagnosed with BC at the King Khaled Hospital in Najran, Saudi Arabia, from September 2014 to February 2025. Data on demographics, clinical presentation, pathology, treatment, and survival outcomes were collected. We used the Kaplan-Meier method to generate survival estimates and identified independent prognostic factors using multivariate Cox proportional hazards regression. RESULTS: The median overall survival (OS) was 23.4 months (95% confidence interval [CI], 19.8 to 27.1), with significant differences in survival based on disease stage: localized (median OS, 36 months; 95% CI, 30.2 to 41.8), locally advanced (22 months; 95% CI, 18.5 to 25.5), and metastatic (8 months; 95% CI, 6.2 to 9.8) (log-rank p < 0.001). The 1-year and 3-year OS rates were 72% (95% CI, 63-81%) and 41% (95% CI, 31-51%), respectively. Radical cystectomy provided the best survival outcomes (3-year OS, 64% compared to 38% for TURBT alone; adjusted hazard ratio [HR] 2.10, 95% CI 1.21 to 3.62). Multivariate analysis identified metastatic disease (adjusted hazard ratio [HR] 4.12, 95% CI 2.48 to 6.85), ECOG performance status >/=2 (HR 3.21, 95% CI 1.82 to 5.66), and lack of radical treatment (HR 1.97, 95% CI 1.19 to 3.27) as independent predictors of mortality. CONCLUSIONS: Survival in BC is closely linked to disease stage, treatment type, and patient performance status. Radical cystectomy remains the main treatment for curing the disease, whereas cisplatin-based chemotherapy is the preferred option for advanced cases. These findings encourage personalized treatment strategies that consider performance status to improve outcomes. FAU - Badheeb, Ahmed M AU - Badheeb AM AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Alkhanbash, Omar AU - Alkhanbash O AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Alzubaidi, Qasim AU - Alzubaidi Q AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Al Asmari, Abdulla AU - Al Asmari A AD - Internal Medicine, King Khalid Hospital, Najran. FAU - Eltohamie, Doaa Abdallah AU - Eltohamie DA AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Ahmed, Faisal AU - Ahmed F AD - Department of Urology, Faculty of Medicine, Ibb University, Ibb. FAU - Ben Yahya, Esam Ali AU - Ben Yahya EA AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Alkarak, Samer AU - Alkarak S AD - Cardiothoracic Surgery, King Khalid Hospital, Najran. FAU - Baslasel, Omar S AU - Baslasel OS AD - Oncology Centre, King Khalid Hospital, Najran. FAU - Aman, Abdelaziz AU - Aman A AD - Internal Medicine/Endocrinology and Diabetes, King Khalid Hospital, Najran. FAU - Seada, Islam AU - Seada I AD - Internal Medicine/Endocrinology and Diabetes, King Khalid Hospital, Najran. FAU - Abubakar, Abdullah AU - Abubakar A AD - Department of Ophthalmology, King Khalid Hospital, Najran. FAU - Badheeb, Mohamed AU - Badheeb M AD - Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport,CT. LA - eng PT - Journal Article DEP - 20251022 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - Saudi Arabia MH - Male MH - Female MH - Retrospective Studies MH - Middle Aged MH - Prognosis MH - Tertiary Care Centers MH - Aged MH - Survival Rate MH - Neoplasm Invasiveness MH - Cohort Studies MH - Neoplasm Staging MH - Aged, 80 and over MH - Cystectomy/methods MH - Kaplan-Meier Estimate MH - Adult MH - Proportional Hazards Models OTO - NOTNLM OT - Eastern Cooperative Oncology Group OT - Muscle-invasive bladder cancer OT - Saudi Arabia OT - prognostic factors OT - radical cystectomy OT - survival analysis OT - systemic chemotherapy EDAT- 2025/10/22 12:31 MHDA- 2026/01/07 06:30 CRDT- 2025/10/22 10:43 PHST- 2025/07/05 00:00 [received] PHST- 2025/08/27 00:00 [accepted] PHST- 2026/01/07 06:30 [medline] PHST- 2025/10/22 12:31 [pubmed] PHST- 2025/10/22 10:43 [entrez] AID - 10.4081/aiua.2025.14119 [doi] PST - ppublish SO - Arch Ital Urol Androl. 2025 Dec 24;97(4):14119. doi: 10.4081/aiua.2025.14119. Epub 2025 Oct 22. PMID- 41122023 OWN - NLM STAT- MEDLINE DCOM- 20251210 LR - 20260916 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 1 DP - 2026 Jan TI - Impact of ureteroscopy on nephroureterectomy and standards of care compliance in upper tract urothelial carcinoma: the BAUS UK I-DUNC audit. PG - 120-128 LID - 10.1111/bju.70013 [doi] AB - OBJECTIVES: To evaluate diagnostic practices in the United Kingdom (UK) prior to radical nephroureterectomy (RNU) for suspected upper tract urothelial carcinoma (UTUC) and assess their impact on early oncological outcomes. The audit examined compliance post-operative intravesical Mitomycin C (MMC) instillation and adjuvant chemotherapy for >/=pT2 disease. MATERIALS AND METHODS: This national audit, by the British Association of Urological Surgeons (BAUS), invited all NHS hospitals performing RNU for non-metastatic UTUC. Retrospective anonymised data were collected. Outcomes included time from imaging to RNU, use of MMC, adjuvant chemotherapy, bladder recurrence, surgical margins, extravesical metastasis, and final histology. Statistical analysis used Mann-Whitney U, Chi-square/Fisher's exact test, and multivariate logistic regression. RESULTS: A total of 877 patients who underwent RNU across 70 hospitals were analysed (median 10 cases per hospital). Diagnostic ureteroscopy (d-URS) was performed in 61.3% of cases, delaying RNU by a median of 53 days (130 vs 77 days; P < 0.01). Voided urine cytology was recorded in 34.3%. Among patients with high-grade and/or >/= pT1 disease, 89% had positive cytology. MMC was administered in 45.1% of >/=pT2 cases and adjuvant chemotherapy in 46%. Bladder recurrence was significantly higher in patients undergoing d-URS (26.6% vs 12.3%; P < 0.01), as were positive margins in >/=pT2 tumours (24% vs 14%; P = 0.03). Although not statistically significant, d-URS was associated with more metastases (27.2% vs 19.2%) and fewer non-UTUC diagnoses (5.5% vs 8.6%). Multivariate analysis showed that d-URS independently predicted bladder recurrence and margin positivity in >/=pT2 disease. CONCLUSIONS: Our audit showed that d-URS is associated with significant treatment delays, increased rates of metachronous bladder cancer recurrence, and higher surgical positive margin rates in patients with >/=pT2 disease. Compliance with MMC therapy and adjuvant chemotherapy was low. This national audit highlights the need for risk-stratified diagnostic pathways, multidisciplinary expertise, and establishment of quality performance indicators to improve care and outcomes in UTUC management in the UK. CI - (c) 2025 BJU International. FAU - Rai, Bhavan Prasad AU - Rai BP AUID- ORCID: 0000-0002-6323-7246 AD - Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Geraghty, Robert AU - Geraghty R AUID- ORCID: 0000-0002-9128-5173 AD - Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Walton, Thomas AU - Walton T AD - Department of Urology, Nottingham University Hospitals NHS Trust, Nottingham, UK. FAU - Calvert, Robert AU - Calvert R AD - Department of Urology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Philip, Joe AU - Philip J AUID- ORCID: 0000-0003-1330-8883 AD - Department of Urology, Bristol Urology Institute, Southmead Hospital, Bristol, UK. FAU - Aning, Jonathan AU - Aning J AUID- ORCID: 0000-0001-6189-4720 AD - Department of Urology, Bristol Urology Institute, Southmead Hospital, Bristol, UK. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Hanchanale, Vishwanath AU - Hanchanale V AD - Department of Urology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Laird, Alexander AU - Laird A AUID- ORCID: 0000-0002-7296-025X AD - Western General Hospital, Edinburgh, UK. AD - Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK. FAU - Armitage, James AU - Armitage J AUID- ORCID: 0000-0003-1379-0964 AD - Department of Urology, Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. LA - eng PT - Evaluation Study PT - Journal Article PT - Multicenter Study DEP - 20251022 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 50SG953SK6 (Mitomycin) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/diagnosis MH - Chemotherapy, Adjuvant MH - *Guideline Adherence MH - *Kidney Neoplasms/surgery MH - Medical Audit MH - Mitomycin/administration & dosage MH - *Nephroureterectomy/standards/methods MH - Retrospective Studies MH - *Standard of Care MH - United Kingdom MH - *Ureteral Neoplasms/surgery/diagnosis MH - *Ureteroscopy OTO - NOTNLM OT - bladder recurrence OT - nephroureterectomy OT - transitional cell carcinoma OT - upper tract OT - ureteroscopy OT - urothelial carcinoma EDAT- 2025/10/22 06:33 MHDA- 2025/12/10 06:28 CRDT- 2025/10/22 03:42 PHST- 2025/12/10 06:28 [medline] PHST- 2025/10/22 06:33 [pubmed] PHST- 2025/10/22 03:42 [entrez] AID - 10.1111/bju.70013 [doi] PST - ppublish SO - BJU Int. 2026 Jan;137(1):120-128. doi: 10.1111/bju.70013. Epub 2025 Oct 22. PMID- 41115436 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20260922 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 406 IP - 10516 DP - 2025 Nov 8 TI - Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PG - 2221-2234 LID - S0140-6736(25)01897-5 [pii] LID - 10.1016/S0140-6736(25)01897-5 [doi] AB - BACKGROUND: Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) often have recurrence or progression after transurethral resection of bladder tumour (TURBT) and subsequent BCG therapy. We aimed to evaluate whether 1 year of durvalumab with BCG could improve outcomes versus BCG alone for these patients. METHODS: This randomised, open-label, phase 3 trial enrolled patients aged 18 years or older with BCG-naive, high-risk NMIBC who underwent TURBT. Patients were randomly allocated (1:1:1) to receive intravenous durvalumab (every 4 weeks for 13 cycles) plus intravesical BCG induction (weekly for 6 weeks) and maintenance (three doses at weekly intervals at 3, 6, 12, 18, and 24 months), durvalumab plus BCG induction, or BCG induction and maintenance (comparison group). The primary endpoint was investigator-assessed disease-free survival in the durvalumab plus BCG induction and maintenance group versus the comparison group in the intention-to-treat population. This study is registered at ClinicalTrials.gov (NCT03528694) and EudraCT (2017-002979-26) and is ongoing but is no longer enrolling patients. FINDINGS: Between June 18, 2018, and Oct 2, 2020, 1350 patients were assessed for eligibility, among whom 1018 patients were randomly allocated: 339 to the durvalumab plus BCG induction and maintenance group (of whom 336 [99%] initiated and 180 [53%] completed treatment), 339 to the durvalumab plus BCG induction group (337 [99%] initiated and 239 [71%] completed treatment), and 340 to the comparison group (339 [>99%] initiated and 182 [54%] completed treatment). At a median follow-up of 60.7 months (IQR 51.5-66.5), there were 67 (20%) disease-free survival events in the durvalumab plus BCG induction and maintenance group and 98 (29%) events in the comparison group, resulting in a 32% reduction in the risk of recurrence of high-risk disease or death by any cause with durvalumab plus BCG induction and maintenance versus the comparison group (hazard ratio 0.68 [95% CI 0.50-0.93]; log-rank p=0.015). Among patients who received at least one dose of study treatment, grade 3 or 4 treatment-related adverse events occurred in 71 (21%) of 336 patients in the durvalumab plus BCG induction and maintenance group, 52 (15%) in the durvalumab plus BCG induction only group, and 13 (4%) of 339 patients in the comparison group. No treatment-related adverse events led to death. INTERPRETATION: Among patients with BCG-naive, high-risk NMIBC, 1 year of durvalumab combined with BCG induction and maintenance therapy showed a statistically significant and clinically meaningful improvement in disease-free survival versus BCG induction and maintenance alone. The combination had a manageable safety profile, consistent with that of the individual therapies. These results support 1 year of durvalumab in combination with BCG induction and maintenance therapy as a potential new treatment for this patient population. FUNDING: AstraZeneca. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. FAU - De Santis, Maria AU - De Santis M AD - Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Palou Redorta, Joan AU - Palou Redorta J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba, Ibaraki, Japan. FAU - Krawczynski, Michal AU - Krawczynski M AD - Clinical Research Center, Poznan, Poland. FAU - Seyitkuliev, Artur AU - Seyitkuliev A AD - Saint Petersburg Hospital of the Russian Academy of Sciences, Saint Petersburg, Russia. FAU - Novikov, Andrey AU - Novikov A AD - North-Western State Medical University, Saint Petersburg, Russia. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Zukov, Ruslan AU - Zukov R AD - Krasnoyarsk State Medical University, Krasnoyarsk Regional Clinical Cancer Center, Krasnoyarsk, Russia. FAU - Kato, Minoru AU - Kato M AD - Department of Urology, Osaka Metropolitan University, Osaka, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Goeman, Lieven AU - Goeman L AD - Department of Development and Regeneration, University Hospitals Leuven, Leuven, Belgium. FAU - Puente, Javier AU - Puente J AD - Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain. FAU - Hellmis, Eva AU - Hellmis E AD - Urologicum-Duisburg, Duisburg, Germany. FAU - Powles, Thomas AU - Powles T AD - Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, Barts Health NHS Trust, London, UK. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Vasey, Paul AU - Vasey P AD - Icon Cancer Centre Wesley, Auchenflower, QLD, Australia. FAU - Bigot, Pierre AU - Bigot P AD - Department of Urology, Angers University Hospital, Angers, France. FAU - Fradet, Yves AU - Fradet Y AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec, Universite Laval, Quebec City, QC, Canada. FAU - Hunting, Jarmo AU - Hunting J AD - Department of Medical Oncology, St Antonius Hospital, Utrecht, Netherlands. FAU - Armstrong, Jon AU - Armstrong J AD - Oncology Biometrics, AstraZeneca, Cambridge, UK. FAU - Boulos, Suliman AU - Boulos S AD - Late-stage Development Oncology R&D, AstraZeneca, Cambridge, UK. FAU - Hois, Stephan AU - Hois S AD - Late-stage Development Oncology R&D, AstraZeneca, Gaithersburg, MD, USA. FAU - Shore, Neal D AU - Shore ND AD - START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: shore@auclinics.com. CN - POTOMAC Investigators LA - eng SI - ClinicalTrials.gov/NCT03528694 PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20251017 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (BCG Vaccine) RN - 28X28X9OKV (durvalumab) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - *Antibodies, Monoclonal/administration & dosage/therapeutic use/adverse effects MH - *Antineoplastic Agents, Immunological/administration & dosage/therapeutic use MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality/surgery COIS- Declaration of interests MDS reports consulting roles for AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, Bristol Myers Squibb, Eisai, Ferring, Gilead Sciences, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, SeaGen, and Thermosome; honoraria from AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, Bristol Myers Squibb, Eisai, Ferring, Gilead Sciences, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and SeaGen; support for attending meetings and/or travel from AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, Bristol Myers Squibb, Eisai, Ferring, Gilead Sciences, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and SeaGen; unpaid participation on data safety monitoring boards or advisory boards for Thermosome Hyperthermia trial, GUSTO DMEC (academic trial Sheffield), and AURORA (academic trial Southampton); and unpaid leadership or fiduciary role in ESMO bladder cancer CPG and German S3 bladder cancer guidelines. JPR reports consulting roles for AstraZeneca, Fidia, Jemedis, Olympus, and Pfizer; and participation on advisory boards for AstraZeneca, Fidia, and Pfizer. HN reports grants or contracts from Chugai Pharma and Astellas; consulting roles for Ono Pharmaceutical, AstraZeneca, Janssen, and Merck Sharp & Dohme; and honoraria for speakers bureaus from Astellas, Merck Sharp & Dohme, Nippon Kayaku, Merck Biopharma, AstraZeneca, Ono Pharmaceutical, Bristol Myers Squibb, and Pfizer. AN reports honoraria from Eisai; and travel, accommodations, and expenses from Biocad. FG-R reports consulting roles for Johnson & Johnson, Pfizer, Merck, Roche, Taris, Combat Medical, AstraZeneca, MSD, Bristol Myers Squibb, enGene, and Nanobots Therapeutics; honoraria from or participation in speakers bureaus for Janssen, Nucleix, MSD, Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, Palex, Combat Medical, Johnson & Johnson, and Recordati; expert testimony for Nucleix and Menarini Diagnostics; travel, accommodations, and expenses from Pfizer, Recordati, Ipsen, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia, and Johnson & Johnson; patents planned, issued or pending from Danae UroGenomics; participation on a data safety monitoring board or advisory board for MDS and enGene; and holding stocks in CG Oncology, Johnson & Johnson, and Pfizer. RZ reports honoraria from Astellas Pharma, AstraZeneca, Johnson & Johnson, Merck, Novartis, Pfizer, Aegean, Roche, and Biocad; research funding from AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, MSD, Novartis, and Roche. MKa reports honoraria from or participation in speakers bureaus for Pfizer, Merck, Astellas, MSD, Janssen, Ono Pharmaceutical, Bristol Myers Squibb, MC Medical, Nippon Kayaku, and AstraZeneca; and participation on a data safety monitoring board or advisory board for Astellas, MSD, AstraZeneca, Merck, and Janssen. JP reports consulting roles from Pfizer and Roche; honoraria for lectures from AstraZeneca, Eisai, Janssen, MSD, Pfizer, Bristol Myers Squibb, and Merck; travel for attending meetings from Janssen, Pfizer, and Merck; and participation in advisory boards for AstraZeneca, Janssen, MSD, Pfizer, Bristol Myers Squibb, and Merck. TP reports grants or contracts from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai; consulting roles for AstraZeneca, Exelixis, Ipsen, Novartis, Bristol Myers Squibb, Incyte, Merck/MSD, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, Mashup, and Gilead Sciences; honoraria from AstraZeneca, Exelixis, Ipsen, Novartis, Bristol Myers Squibb, Incyte, Merck/MSD, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, Mashup, and Gilead Sciences; payment for expert testimony from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai; support for attending meetings and/or travel from Roche, Pfizer, MSD, AstraZeneca, Ipsen, Gilead Sciences, and Astellas. PR reports grants or contracts from AstraZeneca. KMG reports grants or contracts from Bristol Myers Squibb (paid to institution); consulting roles for Astellas, AstraZeneca, Bristol Myers Squibb, Cepheid, Ferring, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, and Roche; honoraria or participation in speakers bureaus for Astellas, AstraZeneca, Bristol Myers Squibb, Cepheid, Ferring, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, and Roche; travel, accommodations, and expenses from Allergan, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Pierre Fabre, and Roche; participation on a data safety monitoring board or advisory board for Astellas, AstraZeneca, Bristol Myers Squibb, Cepheid, Ferring, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, and Roche; and leadership or fiduciary role in the Austrian Uro-Oncology Working Group (unpaid). YF reports grants or contracts from Merck and TerSera. JH reports consulting roles for Novartis. JA, SB, and SH report holding stocks in and being an employee of AstraZeneca. NDS reports consulting roles for Alessa, Amgen, Asieris Pharmaceuticals, Astellas, AstraZeneca, Aura Biosciences, Bayer, BioProtect, Bristol Myers Squibb, CG Oncology, Clarity, Dendreon, Exact Imaging, Ferring, Fize Medical, Glytherix, Immunity Bio, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Minomic, Myriad, Novartis, Nusano, Pfizer, Photocure, Promaxo, Protara, Sumitomo, Telix, Tolmar, Tutelix, and UroGen. All other authors declare no competing interests. FIR - Anderson, Paul IR - Anderson P FIR - Brungs, Daniel IR - Brungs D FIR - Davis, Ian IR - Davis I FIR - Glasgow, Amanda IR - Glasgow A FIR - Harris, Carole IR - Harris C FIR - Parente, Phillip IR - Parente P FIR - Patel, Manish IR - Patel M FIR - Vasey, Paul IR - Vasey P FIR - Vela, Ian IR - Vela I FIR - Zielinski, Robert IR - Zielinski R FIR - Buchegger, Johannes IR - Buchegger J FIR - Gust, Kilian IR - Gust K FIR - Horninger, Wolfgang IR - Horninger W FIR - Hutterer, Georg IR - Hutterer G FIR - Loidl, Wolfgang IR - Loidl W FIR - Luger, Ferdinand IR - Luger F FIR - Lusuardi, Lukas IR - Lusuardi L FIR - Pichler, Renate IR - Pichler R FIR - Ameye, Filip IR - Ameye F FIR - Goeman, Lieven IR - Goeman L FIR - Joniau, Steven IR - Joniau S FIR - Roumeguere, Thierry IR - Roumeguere T FIR - Fradet, Yves IR - Fradet Y FIR - Izard, Jason IR - Izard J FIR - Kulkarni, Girish IR - Kulkarni G FIR - Paradis, Jean-Benoit IR - Paradis JB FIR - Saad, Fred IR - Saad F FIR - Rahmene Azzouzi, Abdel IR - Rahmene Azzouzi A FIR - Barthelemy, Philippe IR - Barthelemy P FIR - Bigot, Pierre IR - Bigot P FIR - Colombel, Marc IR - Colombel M FIR - Deturmeny, Julien IR - Deturmeny J FIR - Lebret, Thierry IR - Lebret T FIR - Robert, Gregoire IR - Robert G FIR - Saint, Fabien IR - Saint F FIR - Topart, Delphine IR - Topart D FIR - Bogemann, Martin IR - Bogemann M FIR - Casuscelli, Jozefina IR - Casuscelli J FIR - De Santis, Maria IR - De Santis M FIR - Feyerabend, Susan IR - Feyerabend S FIR - Garcia-Schurmann, Miguel IR - Garcia-Schurmann M FIR - Hatiboglu, Gencay IR - Hatiboglu G FIR - Hegele, Axel IR - Hegele A FIR - Hellmis, Eva IR - Hellmis E FIR - Keil, Christian IR - Keil C FIR - Klier, Jorg IR - Klier J FIR - Pulte, Thomas IR - Pulte T FIR - Pursche, Lars IR - Pursche L FIR - Schmitz-Drager, Bernd IR - Schmitz-Drager B FIR - Schutz, Viktoria IR - Schutz V FIR - Spiegelhalder, Philipp IR - Spiegelhalder P FIR - Stagge, Elke IR - Stagge E FIR - Tosev, Georgi IR - Tosev G FIR - von Klot, Christoph IR - von Klot C FIR - Arai, Gaku IR - Arai G FIR - Bekku, Kensuke IR - Bekku K FIR - Etani, Toshiki IR - Etani T FIR - Hashine, Katsuyoshi IR - Hashine K FIR - Inokuchi, Junichi IR - Inokuchi J FIR - Izumi, Koji IR - Izumi K FIR - Izumi, Kouji IR - Izumi K FIR - Kamoto, Toshiyuki IR - Kamoto T FIR - Kandori, Shuya IR - Kandori S FIR - Kato, Minoru IR - Kato M FIR - Kawahara, Takashi IR - Kawahara T FIR - Kawai, Noriyasu IR - Kawai N FIR - Kikuchi, Eiji IR - Kikuchi E FIR - Kimura, Tomokazu IR - Kimura T FIR - Kitamura, Hiroshi IR - Kitamura H FIR - Kobayashi, Yasuyuki IR - Kobayashi Y FIR - Kondo, Yukihiro IR - Kondo Y FIR - Masumori, Naoya IR - Masumori N FIR - Matsuo, Tomohiro IR - Matsuo T FIR - Miyata, Yasuyoshi IR - Miyata Y FIR - Mizuno, Ryuichi IR - Mizuno R FIR - Mukai, Shoichiro IR - Mukai S FIR - Mutaguchi, Jun IR - Mutaguchi J FIR - Naiki, Taku IR - Naiki T FIR - Nishimura, Kazuo IR - Nishimura K FIR - Ohyama, Chikara IR - Ohyama C FIR - Okamoto, Teppei IR - Okamoto T FIR - Saito, Kazutaka IR - Saito K FIR - Sakai, Hideki IR - Sakai H FIR - Sugimoto, Mikio IR - Sugimoto M FIR - Takamoto, Atsushi IR - Takamoto A FIR - Tamada, Satoshi IR - Tamada S FIR - Tanaka, Nobuyuki IR - Tanaka N FIR - Yonese, Junji IR - Yonese J FIR - Yoshimura, Kazuhiro IR - Yoshimura K FIR - De Reijke, Theo IR - De Reijke T FIR - Hunting, Jarmo IR - Hunting J FIR - Oddens, Jorg IR - Oddens J FIR - Westgeest, Hans IR - Westgeest H FIR - Demkow, Tomasz IR - Demkow T FIR - Korozan, Magdalena IR - Korozan M FIR - Kozlowski, Robert IR - Kozlowski R FIR - Krawczynski, Michal IR - Krawczynski M FIR - Kwiatkowski, Mariusz IR - Kwiatkowski M FIR - Maslowski, Michal IR - Maslowski M FIR - Radziszewski, Piotr IR - Radziszewski P FIR - Sadowska, Urszula IR - Sadowska U FIR - Tupikowski, Krzysztof IR - Tupikowski K FIR - Zaucha, Renata IR - Zaucha R FIR - Zdrojowy, Romuald IR - Zdrojowy R FIR - Atduev, Vagif IR - Atduev V FIR - Karyakin, Oleg IR - Karyakin O FIR - Kislov, Nikolay IR - Kislov N FIR - Kopyltsov, Evgeny IR - Kopyltsov E FIR - Komyakov, Boris IR - Komyakov B FIR - Novikov, Andrey IR - Novikov A FIR - Orlov, Igor IR - Orlov I FIR - Semenov, Andrey IR - Semenov A FIR - Severtsev, Alexey IR - Severtsev A FIR - Seyitkuliev, Artur IR - Seyitkuliev A FIR - Smirnov, Roman IR - Smirnov R FIR - Topuzov, Timur IR - Topuzov T FIR - Vasiliev, Aleksandr IR - Vasiliev A FIR - Zukov, Ruslan IR - Zukov R FIR - Alvarez-Maestro, Mario IR - Alvarez-Maestro M FIR - Alcaraz, Antonio IR - Alcaraz A FIR - Almagro-Casado, Elena IR - Almagro-Casado E FIR - Bonfill, Teresa IR - Bonfill T FIR - Caballero Diaz, Cristina IR - Caballero Diaz C FIR - Cecchini Rosell, Lluis IR - Cecchini Rosell L FIR - Delgado Mingorance, Juan Ignacio IR - Delgado Mingorance JI FIR - Gonzalez Caliz, Carlos IR - Gonzalez Caliz C FIR - Guerrero-Ramos, Felix IR - Guerrero-Ramos F FIR - Hannaoui Hadi, Naim IR - Hannaoui Hadi N FIR - Herrera Imbroda, Bernardo IR - Herrera Imbroda B FIR - Hevia Suare, Miguel IR - Hevia Suare M FIR - Moyano Calvo, Jose Luis IR - Moyano Calvo JL FIR - Pascual Piedrola, Juan Ignacio IR - Pascual Piedrola JI FIR - Puente, Javier IR - Puente J FIR - Raventos Busquets, Carles Xavier IR - Raventos Busquets CX FIR - Rico Lopez, Javier IR - Rico Lopez J FIR - Rodriguez-Faba, Oscar IR - Rodriguez-Faba O FIR - Torres Roca, Marcos IR - Torres Roca M FIR - Vazquez Mazon, Federico Jose IR - Vazquez Mazon FJ FIR - Virizuela Echaburu, Juan IR - Virizuela Echaburu J FIR - Douglas, James IR - Douglas J FIR - Enting, Deborah IR - Enting D FIR - Jones, Robert IR - Jones R FIR - Linch, Mark IR - Linch M FIR - Mostafid, Hugh IR - Mostafid H FIR - Noon, Aidan IR - Noon A FIR - Patel, Keval IR - Patel K FIR - Patel, Prashant IR - Patel P FIR - Powles, Thomas IR - Powles T FIR - Sephton, Matthew IR - Sephton M FIR - Varughese, Mohini IR - Varughese M EDAT- 2025/10/21 00:28 MHDA- 2025/11/12 23:29 CRDT- 2025/10/20 18:52 PHST- 2025/08/11 00:00 [received] PHST- 2025/09/05 00:00 [revised] PHST- 2025/09/14 00:00 [accepted] PHST- 2025/11/12 23:29 [medline] PHST- 2025/10/21 00:28 [pubmed] PHST- 2025/10/20 18:52 [entrez] AID - S0140-6736(25)01897-5 [pii] AID - 10.1016/S0140-6736(25)01897-5 [doi] PST - ppublish SO - Lancet. 2025 Nov 8;406(10516):2221-2234. doi: 10.1016/S0140-6736(25)01897-5. Epub 2025 Oct 17. PMID- 41111641 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251020 LR - 20251022 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Evaluating the Long-Term Utility and Cost-Effectiveness of Computed Tomography (CT) Surveillance Beyond Five Years After Radical Cystectomy: A 10-Year Follow-Up Study. PG - e92501 LID - 10.7759/cureus.92501 [doi] LID - e92501 AB - Introduction While computed tomography (CT) imaging is crucial for the early detection of recurrence after radical cystectomy, the clinical value and cost-effectiveness of routine surveillance beyond five years remain unclear. This study evaluates the diagnostic yield and economic justification of CT scans performed at seven and 10 years postoperatively. Methodology This retrospective study included 46 patients who underwent radical cystectomy for bladder cancer in 2013-2014, ensuring a minimum follow-up of 10 years. Clinical and pathological variables were analysed for correlation with recurrence or metastasis. The diagnostic utility of CT scans at seven and 10 years was assessed. Statistical analysis included the chi-squared test, Mann-Whitney U test, and logistic regression using IBM SPSS Statistics for Windows, V. 27.0 (IBM Corp., Armonk, NY, USA). Results At 10 years, 19 patients (41.3%) were alive. All metastases (n=14) occurred within the first two years post-surgery; no positive findings were detected on CT scans at seven or 10 years. Metastasis was significantly associated with the presence of carcinoma in situ (CIS) (p=0.02), positive surgical margins (p=0.004), and fewer dissected lymph nodes (p<0.001). Logistic regression identified positive margins as an independent predictor of metastasis (OR: 9.33; p=0.008). Conclusion Routine CT surveillance beyond five years post-cystectomy shows minimal clinical benefit in unselected patients. A risk-adapted approach, focusing on pathological factors such as surgical margin status and CIS, may optimize follow-up strategies and resource utilization. CI - Copyright (c) 2025, Elsandoby et al. FAU - Elsandoby, Omar AU - Elsandoby O AD - Urology, Royal Surrey County Hospital, Guildford, GBR. FAU - Akroush, Rahaf AU - Akroush R AD - Urology, Royal Surrey County Hospital, Guildford, GBR. FAU - Roodhouse, Alison AU - Roodhouse A AD - Urology, Royal Surrey County Hospital, Guildford, GBR. FAU - Kusuma, Venkata Ramana Murthy AU - Kusuma VRM AD - Urology, Royal Surrey County Hospital, Guildford, GBR. FAU - Perry, Matthew AU - Perry M AD - Urology, Royal Surrey County Hospital, Guildford, GBR. LA - eng PT - Journal Article DEP - 20250916 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12535421 OTO - NOTNLM OT - bladder cancer OT - cost-effectiveness OT - ct surveillance OT - follow-up OT - radical cystectomy COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/20 12:30 MHDA- 2025/10/20 12:31 PMCR- 2025/09/16 CRDT- 2025/10/20 06:55 PHST- 2025/09/16 00:00 [accepted] PHST- 2025/10/20 12:31 [medline] PHST- 2025/10/20 12:30 [pubmed] PHST- 2025/10/20 06:55 [entrez] PHST- 2025/09/16 00:00 [pmc-release] AID - 10.7759/cureus.92501 [doi] PST - epublish SO - Cureus. 2025 Sep 16;17(9):e92501. doi: 10.7759/cureus.92501. eCollection 2025 Sep. PMID- 41111372 OWN - NLM STAT- MEDLINE DCOM- 20251020 LR - 20251020 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 78 IP - 8 DP - 2025 Sep TI - Qualitative Interferon-gamma Release Assay for Predicting Response to BCG Instillations in Bladder Cancer. PG - 1015-1021 LID - 10.56434/j.arch.esp.urol.20257808.133 [doi] AB - BACKGROUND: This study aims to investigate the potential use of qualitative interferon-gamma release assay, specifically T-spot testing focusing on culture filtrate protein 10 (CFP-10) positivity, in predicting the response of patients with high-risk non-muscle invasive bladder cancer (NMIBC) to intracavitary Bacillus Calmette-Guerin (BCG) vaccine instillation. METHODS: Patients diagnosed with high-risk NMIBC were retrospectively identified from an institutional database and subsequently underwent prospective T-spot testing. Following the completion of an adequate course of BCG instillation, patients who were unresponsive to BCG were assigned to the study group. By contrast, those who remained recurrence free for at least one year post-treatment were assigned to the control group. RESULTS: In this cohort of 42 patients with high-risk NMIBC, the median age was 67, and 40.0% were unresponsive to BCG. The distribution comprised 50.0% pTa and 81% high-grade cases. Over a median follow-up of 18 months, the positive BCG response varied between pTa (81%) and pT1 (38%; p = 0.005), and T-spot testing revealed positivity in 75.0% of the control group and 92% in BCG-unresponsive patients (p = 0.235). Notably, CFP-10 positivity was significantly more prevalent in the BCG-unresponsive group, observed in 91.7% of the patients, in contrast to 35.7% in the control group (p = 0.004). CONCLUSIONS: T-spot test or more specifically CFP-10 positivity is a potential marker for predicting response to BCG instillation in patients with NMIBC. CI - (c) 2025 The Author(s). FAU - Koseoglu, Hikmet AU - Koseoglu H AD - Department of Urology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul Health Practice and Research Center, 34668 Istanbul, Turkey. FAU - Yalcin, Berrin AU - Yalcin B AD - Department of Radiation Oncology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul Health Practice and Research Center, 34668 Istanbul, Turkey. FAU - Eroglu, Tolga AU - Eroglu T AD - Department of Urology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul Health Practice and Research Center, 34668 Istanbul, Turkey. FAU - Yucetas, Ugur AU - Yucetas U AD - Department of Urology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul Health Practice and Research Center, 34668 Istanbul, Turkey. FAU - Mungan, Ugur AU - Mungan U AD - Department of Urology, Faculty of Medicine, Dokuz Eylul University, 35210 Izmir, Turkey. LA - eng PT - Journal Article PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - *Interferon-gamma Release Tests MH - Middle Aged MH - Predictive Value of Tests MH - Administration, Intravesical MH - Treatment Outcome MH - Aged, 80 and over OTO - NOTNLM OT - BCG OT - Interferon-gamma release assay OT - TURBT OT - bladder OT - cancer COIS- The authors declare no conflict of interest. It was presented as poster in the 10th Online Eurasian Uro-oncology Congress, Istanbul, 27-28 June 2020. EDAT- 2025/10/20 06:29 MHDA- 2025/10/20 12:30 CRDT- 2025/10/20 05:45 PHST- 2025/10/20 12:30 [medline] PHST- 2025/10/20 06:29 [pubmed] PHST- 2025/10/20 05:45 [entrez] AID - 1760425528007-327893190 [pii] AID - 10.56434/j.arch.esp.urol.20257808.133 [doi] PST - ppublish SO - Arch Esp Urol. 2025 Sep;78(8):1015-1021. doi: 10.56434/j.arch.esp.urol.20257808.133. PMID- 41110692 OWN - NLM STAT- MEDLINE DCOM- 20251220 LR - 20260625 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 37 IP - 1 DP - 2026 Jan TI - ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). PG - 44-52 LID - S0923-7534(25)04787-8 [pii] LID - 10.1016/j.annonc.2025.09.017 [doi] AB - BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guerin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure. PATIENTS AND METHODS: The ALBAN trial is an international, 1 : 1 randomized, open-label phase III trial comparing the combination of atezolizumab (an anti-PD-L1 antibody) and BCG (arm B) versus BCG alone (arm A) for BCG-naive patients with high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS). Key secondary endpoints included high-grade recurrence-free survival, complete response rate, and duration of response in patients with carcinoma in situ disease, as well as overall survival. RESULTS: In total, 255 patients were randomly assigned to arm A and 262 to arm B. The trial did not meet its primary endpoint; there was no significant difference in EFS between arms, with a hazard ratio of 0.98 (95% confidence interval 0.71-1.36, P = 0.9106). EFS results were consistent across all prespecified subgroups. The safety profile of the treatment combination was consistent with that of the individual agents but showed higher rates of treatment-related adverse events (TRAEs) and grade >/=3 TRAEs than BCG alone. CONCLUSION: This phase III trial in BCG-naive patients with high-risk NMIBC did not demonstrate an EFS benefit from the addition of atezolizumab to 1-year BCG therapy, in contrast to positive EFS results reported with another PD-(L)1 agent, suggesting that any benefit from checkpoint-BCG therapy may be context- and agent-specific rather than a class effect. Future research should focus on biomarker-driven patient selection and optimization of the timing, duration, and route of checkpoint delivery relative to BCG. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Roupret, M AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. Electronic address: morgan.roupret@aphp.fr. FAU - Bertaut, A AU - Bertaut A AD - Biostatistics, Centre Georges-Francois Leclerc (CGFL), Dijon, France. FAU - Pignot, G AU - Pignot G AD - Surgical Oncology Department, Institut Paoli-Calmettes (IPC), Marseille, France. FAU - Neuzillet, Y AU - Neuzillet Y AD - Urology, Hopital Foch, Paris-Saclay - UVSQ University, Suresnes, France. FAU - Houede, N AU - Houede N AD - Department of Oncology, CHU Nimes, University Montpellier, Nimes, France. FAU - Mathieu, R AU - Mathieu R AD - Urology, CHU de Rennes - Hopital Pontchaillou, Rennes, France. FAU - Corbel, L AU - Corbel L AD - Urology, Hopital Prive des Cotes d'Armor, Plerin, France. FAU - Besson, D AU - Besson D AD - Medical Oncology, Hopital Prive des Cotes d'Armor, Plerin, France. FAU - Seisen, T AU - Seisen T AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Jaffrelot, L AU - Jaffrelot L AD - Sorbonne University, AP-HP, Medical Oncology, Pitie-Salpetriere Hospital, Paris, France. FAU - Lebacle, C AU - Lebacle C AD - Urology, Hopital Bicetre, Le Kremlin-Bicetre, France. FAU - Champiat, S AU - Champiat S AD - Drug Development Department (DITEP), Institut Gustave Roussy, Villejuif, France. FAU - Lebdai, S AU - Lebdai S AD - Urology, CHU Angers, Angers, France. FAU - Timsit, M-O AU - Timsit MO AD - Department of Urology, Georges-Pompidou European Hospital, AP-HP, Universite Paris Cite, Paris, France. FAU - Thibault, C AU - Thibault C AD - Department of Medical Oncology, Hopital Europeen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Universite de Paris Cite, Paris, France. FAU - Goeman, L AU - Goeman L AD - Urology, AZ Delta, Roeselare, Belgium. FAU - Juarez Soto, A AU - Juarez Soto A AD - Urology, Hospitales Universitarios de Jerez de la Frontera y Punta de Europa, Cadiz, Spain. FAU - La, C AU - La C AD - Research and Development, Unicancer, Paris, France. FAU - Leger, C AU - Leger C AD - Research and Development, Unicancer, Paris, France. FAU - Loriot, Y AU - Loriot Y AD - Departement de Medecine Oncologique et Departement des Essais Precoces, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20251017 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - 52CMI0WC3Y (atezolizumab) RN - 0 (BCG Vaccine) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - *BCG Vaccine/administration & dosage/adverse effects MH - *Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects MH - Male MH - Female MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/administration & dosage MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - NMIBC OT - immunotherapy OT - transurethral resection OT - urothelial carcinoma EDAT- 2025/10/20 00:27 MHDA- 2025/12/21 01:48 CRDT- 2025/10/19 19:36 PHST- 2025/09/05 00:00 [received] PHST- 2025/09/24 00:00 [accepted] PHST- 2025/12/21 01:48 [medline] PHST- 2025/10/20 00:27 [pubmed] PHST- 2025/10/19 19:36 [entrez] AID - S0923-7534(25)04787-8 [pii] AID - 10.1016/j.annonc.2025.09.017 [doi] PST - ppublish SO - Ann Oncol. 2026 Jan;37(1):44-52. doi: 10.1016/j.annonc.2025.09.017. Epub 2025 Oct 17. PMID- 41107105 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260127 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 6 DP - 2025 Dec TI - Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing Strategy. PG - 1607-1616 LID - S2588-9311(25)00250-0 [pii] LID - 10.1016/j.euo.2025.09.015 [doi] AB - BACKGROUND AND OBJECTIVE: Kidney-sparing treatment (KST) is an emerging alternative to radical nephroureterectomy for selected patients with upper tract urothelial carcinoma (UTUC), particularly those with imperative indications. Our aim was to evaluate the efficacy and safety of a novel KST approach combining endoscopic thulium laser ablation (TLA) with perioperative systemic therapy (disitamab vedotin [DV] and an immune checkpoint inhibitor [ICI]; toripalimab or tislelizumab) in a carefully selected cohort of patients with localized high-risk UTUC. METHODS: This single-center prospective pilot study conducted from June 2021 to February 2024 and enrolled patients with localized high-risk UTUC with HER2 expression. Patients underwent multimodal treatment comprising sequential induction therapy, endoscopic TLA, consolidation therapy, and maintenance therapy. Co-primary endpoints were local recurrence-free survival (LRFS) and conversion-free survival (CFS). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), intravesical recurrence-free survival (IVRFS), renal function benefits, and therapy-related adverse events (TRAEs). KEY FINDINGS AND LIMITATIONS: A total of 33 patients were enrolled. Median follow-up was 23 mo for those without death or salvage surgery. LRFS rates were 67% at 1 yr and 64% at 2 yr. HER2 positivity was identified as a candidate protective factor for local recurrence within the first year (odds ratio 0.12, 95% confidence interval 0.01-0.95; p = 0.042). The 2-yr survival rates were 94% for CFS, 88% for IVRFS,100% for MFS, 94% for OS, and 100% for CSS. A renal function benefit was observed within the first year after ablation. The 1-yr ureteral stricture rate was 12% and no grade >3 TRAEs were observed. CONCLUSIONS AND CLINICAL IMPLICATIONS: The combination of endoscopic TLA with perioperative systemic therapy demonstrated promising efficacy and manageable safety in selected patients with localized high-risk UTUC. Our results suggest that there is potential for a paradigm shift in the management of this challenging patient population. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Ye, Jianjun AU - Ye J AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Chen, Zeyu AU - Chen Z AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liao, Xinyang AU - Liao X AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Shiyu AU - Zhang S AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Tu, Xiang AU - Tu X AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Qihao AU - Wang Q AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Zheng, Lei AU - Zheng L AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Chen, Kai AU - Chen K AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Liao, Banghua AU - Liao B AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Mengni AU - Zhang M AD - Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. FAU - Shen, Yali AU - Shen Y AD - Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Jiyan AU - Liu J AD - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Shuang AU - Zhang S AD - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Hanmei AU - Zhang H AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zeng, Hao AU - Zeng H AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Xiang AU - Li X AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: weiqiang933@126.com. FAU - Bao, Yige AU - Bao Y AD - Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: yige.bao@scu.edu.cn. LA - eng PT - Journal Article DEP - 20251016 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 8RKC5ATI4P (Thulium) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (disitamab vedotin) RN - 0 (Antibodies, Monoclonal) RN - 0 (Oligopeptides) SB - IM MH - Humans MH - Pilot Projects MH - Female MH - Male MH - Prospective Studies MH - Aged MH - *Thulium/therapeutic use MH - Middle Aged MH - *Kidney Neoplasms/therapy/pathology/drug therapy MH - *Laser Therapy/methods MH - *Ureteral Neoplasms/therapy/pathology/drug therapy MH - *Carcinoma, Transitional Cell/therapy/drug therapy/pathology MH - *Organ Sparing Treatments/methods MH - *Immunotherapy/methods MH - Aged, 80 and over MH - Immune Checkpoint Inhibitors/therapeutic use MH - Combined Modality Therapy MH - Antibodies, Monoclonal MH - Oligopeptides OTO - NOTNLM OT - Disitamab vedotin OT - High risk OT - Immunotherapy, Kidney-sparing strategy OT - Thulium laser OT - Upper tract urothelial carcinoma EDAT- 2025/10/18 00:29 MHDA- 2025/12/13 00:32 CRDT- 2025/10/17 21:59 PHST- 2025/02/03 00:00 [received] PHST- 2025/09/09 00:00 [revised] PHST- 2025/09/19 00:00 [accepted] PHST- 2025/12/13 00:32 [medline] PHST- 2025/10/18 00:29 [pubmed] PHST- 2025/10/17 21:59 [entrez] AID - S2588-9311(25)00250-0 [pii] AID - 10.1016/j.euo.2025.09.015 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Dec;8(6):1607-1616. doi: 10.1016/j.euo.2025.09.015. Epub 2025 Oct 16. PMID- 41103949 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251017 LR - 20251019 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Management of bladder cancer recurrence following the trimodality therapy. PG - 1672431 LID - 10.3389/fonc.2025.1672431 [doi] LID - 1672431 AB - Trimodality therapy (TMT), including transurethral resection (TUR), chemotherapy (CT), and radiotherapy (RT), offers the bladder-preserving treatment option for patients with muscle-invasive bladder cancer (MIBC). TMT, once indicated, has demonstrated effective and favorable local tumor control in MIBC, with complete response rates ranging between 50% and 80%. However, residual tumor is identified on follow-up TUR in approximately 20-30% of patients, and tumor recurrence occurs in a similar proportion. In both situations, the prognosis becomes unfavorable. This manuscript reviews the current evidence regarding recurrence patterns after TMT, differentiating between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) relapses. NMIBC recurrences after TMT are often manageable with conservative treatments like repeat TURBT and intravesical BCG, without negatively impacting survival. In contrast, MIBC recurrences typically require salvage cystectomy in fit patients, offering outcomes similar to primary surgery. For those unfit for or who continue to decline cystectomy, treatment remains uncertain due to the absence of clear guidelines, and systemic therapies used in metastatic urothelial carcinoma seem commonly applied by extrapolation. CI - Copyright (c) 2025 Damaj, Naim, Saad, Kattan and Kattan. FAU - Damaj, Nahed AU - Damaj N AD - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine-Saint Joseph University of Beirut, Beirut, Lebanon. FAU - Naim, Nabih AU - Naim N AD - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine-Saint Joseph University of Beirut, Beirut, Lebanon. FAU - Saad, Ahmad AU - Saad A AD - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine-Saint Joseph University of Beirut, Beirut, Lebanon. FAU - Kattan, Clarisse AU - Kattan C AD - Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. FAU - Kattan, Joseph AU - Kattan J AD - Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine-Saint Joseph University of Beirut, Beirut, Lebanon. LA - eng PT - Journal Article PT - Review DEP - 20251001 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12520969 OTO - NOTNLM OT - chemotherapy OT - cystectomy OT - muscle invasive bladder cancer OT - radiotherapy OT - trimodality therapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/17 06:29 MHDA- 2025/10/17 06:30 PMCR- 2025/10/01 CRDT- 2025/10/17 04:53 PHST- 2025/07/24 00:00 [received] PHST- 2025/09/17 00:00 [accepted] PHST- 2025/10/17 06:30 [medline] PHST- 2025/10/17 06:29 [pubmed] PHST- 2025/10/17 04:53 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - 10.3389/fonc.2025.1672431 [doi] PST - epublish SO - Front Oncol. 2025 Oct 1;15:1672431. doi: 10.3389/fonc.2025.1672431. eCollection 2025. PMID- 41097639 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251016 LR - 20251019 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 19 DP - 2025 Sep 24 TI - Contemporary Trends and Predictors of pT0 in Radical Cystectomy Specimens Among Non-Muscle and Muscle-Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom. LID - 10.3390/cancers17193110 [doi] LID - 3110 AB - Introduction: Absence of residual cancer in radical cystectomy (RC) specimens is a well-known positive prognostic factor for non-muscle and muscle-invasive bladder cancer (NMIBC and MIBC) in patients with or without neoadjuvant chemotherapy (NAC). Understanding the clinical and pathological features associated with a final pT0 status can provide valuable prognostic insights, serve as a surrogate marker for survival outcomes, and help identify candidates suitable for bladder-sparing strategies. Methods: Temporal trends and clinical/demographic characteristics across clinically high-/very-high-risk NMIBC or MIBC RC patients from 2009 to 2024 were explored. Subsequently, RC pT0 patients were propensity score-matched (PSM, 1:1 ratio) with the >pT0 population based on age-adjusted CCI and preoperative clinical stage (cTis-T1 vs. cT2). Multivariable regression modelling was applied to explore predictors of pT0 status stratified according to clinical NMIBC or MIBC status. Results: A total of 655 RCs performed with curative intent were included (43% for MIBC, 57% for NMIBC). Of these, 117 were pT0 at final pathological assessment (68 NMIBC and 49 MIBC). Subsequently, 228 PSM patients (114 pT0 vs. 114 >pT0) were extracted from the original cohort and stratified according to preoperative clinical stage (MIBC vs. NMIBC). In multivariable analysis, male gender was associated with an increased likelihood of pT0 status in the NMIBC cohort (adjusted odds ratio [aOR] 2.89, 95% CI 1.13-7.90). Conversely, BCG failure and concomitant CIS independently reduced the chances of achieving pT0 status (aOR: 0.40, 95% CI 0.19-0.99; aOR: 0.16, 95% CI 0.03-0.97). For MIBC patients, as expected, NAC more than doubled the chances of achieving pT0 status (aOR: 2.20, 95% CI 1.01-6.82). On the other hand, the concomitant presence of CIS reduced the likelihood of pT0 achievement (aOR 0.22, 95% CI, 0.06-0.80). In both cohorts, the presence of variant histology (VH) demonstrated a negative association with pT0 achievement; however, the estimated effect did not reach statistical significance (p = 0.09 and p = 0.08). Conclusions: Our findings suggest potentially raising the threshold for RC consideration in high-risk or very-high-risk NMIBC patients with a favourable risk profile. MIBC patients without additional risk factors (CIS and VH) are more likely to achieve a tumour-free status, particularly when adequately receiving NAC. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94304, USA. AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Spurna, Katarina AU - Spurna K AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Ali Kirmani, Syed Ghazi AU - Ali Kirmani SG AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Bhatti, Noor Huda AU - Bhatti NH AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Abu-Ghanem, Yasmin AU - Abu-Ghanem Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Challacombe, Benjamin AU - Challacombe B AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Davies, Samuel J AU - Davies SJ AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Hegazy, Mohammad AU - Hegazy M AUID- ORCID: 0000-0003-3051-3918 AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Ibrahim, Youssef AU - Ibrahim Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Gad, Mohammed AU - Gad M AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Khan, Amir AU - Khan A AUID- ORCID: 0000-0003-1074-7290 AD - Division of Urology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. FAU - Corvino, Roberta AU - Corvino R AUID- ORCID: 0009-0003-3168-1435 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - University Centre of Excellence in Urology, Wroclaw Medical University, 50367 Wroclaw, Poland. FAU - Rocco, Bernardo AU - Rocco B AD - Department of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00136 Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94304, USA. FAU - Thuraraja, Ramesh AU - Thuraraja R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Khan, Muhammad Shamin AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. LA - eng PT - Journal Article DEP - 20250924 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12523908 OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - downstaging OT - radical cystectomy COIS- The authors have no conflicts of interest to disclose. EDAT- 2025/10/16 06:30 MHDA- 2025/10/16 06:31 PMCR- 2025/09/24 CRDT- 2025/10/16 01:17 PHST- 2025/08/09 00:00 [received] PHST- 2025/09/16 00:00 [revised] PHST- 2025/09/19 00:00 [accepted] PHST- 2025/10/16 06:31 [medline] PHST- 2025/10/16 06:30 [pubmed] PHST- 2025/10/16 01:17 [entrez] PHST- 2025/09/24 00:00 [pmc-release] AID - cancers17193110 [pii] AID - cancers-17-03110 [pii] AID - 10.3390/cancers17193110 [doi] PST - epublish SO - Cancers (Basel). 2025 Sep 24;17(19):3110. doi: 10.3390/cancers17193110. PMID- 41090495 OWN - NLM STAT- MEDLINE DCOM- 20260121 LR - 20260121 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 33 IP - 1 DP - 2026 Jan TI - Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer. PG - e70254 LID - 10.1111/iju.70254 [doi] AB - OBJECTIVES: The glucocorticoid receptor beta (GRbeta) not only inhibits the function of the glucocorticoid receptor but also possesses unique transcriptional activity. Whereas the role of GRbeta varies among different cancer types, its significance in bladder cancer remains unclear. This study aimed to investigate the clinical significance of GRbeta expression in bladder cancer. METHODS: Immunohistochemical analysis was performed on tissue samples obtained from 106 patients who underwent surgery for bladder cancer. The immunoreactivity of GRbeta was evaluated using the labeling index (0%-100%). The association between GRbeta expression and clinical parameters obtained from medical records was analyzed. RESULTS: GRbeta expression was significantly lower in muscle-invasive bladder cancer (>/= pT2) compared with non-muscle-invasive cases (75% agreement. KEY FINDINGS AND LIMITATIONS: The IBCG recommends inclusion of only low-grade (LG; G1 and G2) tumors in the IR-NMIBC category, risk stratified using the IBCG IR-NMIBC risk scoring system. Given the relatively indolent course and treatment burden of IR-NMIBC, therapeutic deintensification with active surveillance or office-based ablation is appropriate for select patients. Morbidity related to transurethral resection of a bladder tumor can be mitigated by forgoing restaging resection in completely resected LG tumors and not mandating muscularis propria sampling. Perioperative chemotherapy reduces recurrences, and additional adjuvant intravesical treatment should be risk stratified. Clinical trials evaluating novel IR-NMIBC therapies, including adjuvant and ablative designs, should incorporate patient-reported outcomes and risk-stratified controls. Ablative trials, as proof-of-concept studies for efficacy, require randomized controlled studies in the adjuvant setting to confirm superiority over the standard of care. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance for clinical care and clinical trial design for patients with IR-NMIBC. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky, Lexington, KY, USA. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Second Faculty of Medicine, Charles University, Hospital Motol, Prague, Czech Republic. FAU - Bukavina, Laura AU - Bukavina L AD - Department of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Psutka, Sarah P AU - Psutka SP AD - Department of Urology, University of Washington Fred Hutchinson Cancer Center, Seattle, WA, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Department of Urology, Baylor College of Medicine, Houston, TX, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Redorta, Joan Palou AU - Redorta JP AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA. FAU - Lee, Byron H AU - Lee BH AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, The University of Edinburgh Western General Hospital, Edinburgh, UK. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Soloway, Mark S AU - Soloway MS AD - Department of Urologic Oncology, Memorial Hospital, Hollywood, FL, USA. FAU - Svatek, Robert S AU - Svatek RS AD - Division of Urologic Oncology, Department of Urology, University of Texas Health Science Center, San Antonio, TX, USA. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, Yale School of Medicine, New Haven, CT, USA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, Division of Urology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Gupta, Shilpa AU - Gupta S AD - Department of Genitourinary Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Buckley, Roger AU - Buckley R AD - York General Hospital, Toronto, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article PT - Review DEP - 20251010 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Humans MH - Risk Assessment MH - Clinical Trials as Topic MH - Neoplasm Invasiveness MH - Research Design MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Ablative therapies OT - Adjuvant intravesical therapy OT - Bladder cancer OT - Clinical trial design OT - Intermediate-risk non-muscle-invasive bladder cancer OT - Intravesical therapy OT - Risk stratification EDAT- 2025/10/12 00:33 MHDA- 2025/12/13 00:32 CRDT- 2025/10/11 21:59 PHST- 2025/05/13 00:00 [received] PHST- 2025/07/09 00:00 [revised] PHST- 2025/08/08 00:00 [accepted] PHST- 2025/12/13 00:32 [medline] PHST- 2025/10/12 00:33 [pubmed] PHST- 2025/10/11 21:59 [entrez] AID - S2588-9311(25)00223-8 [pii] AID - 10.1016/j.euo.2025.08.003 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Dec;8(6):1685-1695. doi: 10.1016/j.euo.2025.08.003. Epub 2025 Oct 10. PMID- 41073500 OWN - NLM STAT- MEDLINE DCOM- 20251010 LR - 20251013 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Oct 10 TI - Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer. PG - 35415 LID - 10.1038/s41598-025-14974-1 [doi] LID - 35415 AB - Intravesical bacillus Calmette-Guerin (BCG) therapy reduces recurrence in non-muscle invasive bladder cancer (NMIBC). Various scoring models have been developed to predict recurrence, and this study aims to improve them by analyzing hematologic parameters and urinary immune cells. This study involved 88 bladder cancer patients treated with BCG between January 2022 and January 2023. Preoperative hematological parameters were recorded from two separate blood samples. Urine samples were collected before and after the first and sixth BCG instillations and analyzed by flow cytometry to determine the proportions of T cells, neutrophils, and myeloid-derived suppressor cells (MDSCs). Results were compared based on recurrence status and within-group changes. Six patients died from non-cancer causes, and five were excluded due to irregular follow-ups or external monitoring. Of the remaining 77 patients, followed for an average of 30 months, 12 experienced recurrence, and 65 did not. No significant differences were found in clinical or histopathological factors. Urine analysis revealed a higher Neutrophil/T cell ratio in patients with recurrence, while the T/MDSCs ratio increased significantly in the non-recurrent group post-BCG. Additionally, the MDSCs/Total Cell ratio significantly decreased post-treatment in the non-recurrent group. Peripheral blood analysis showed no significant differences in Neutrophil-Lymphocyte Ratio (NLR) and Lymphocyte-Monocyte Ratio (LMR). The results suggest a T cell-dominant immune response may prevent recurrence, while an MDSCs-dominant environment increases the risk. Changes in urinary T/MDSCs, MDSCs/Total Cell, and Neutrophil/T cell ratios may serve as potential biomarkers for predicting recurrence risk shortly after induction therapy. CI - (c) 2025. The Author(s). FAU - Celik, Mecit AU - Celik M AUID- ORCID: 0000-0003-1334-3451 AD - Department of Urology, Ergani State Hospital, Adnan Menderes, Ergani, 21950, Diyarbakir, Turkey. mecitcelik44@gmail.com. FAU - Polat, Muhammed Emin AU - Polat ME AD - Department of Urology, Ankara Bilkent City Hospital, Ankara, Turkey. FAU - Karaaslan, Mustafa AU - Karaaslan M AD - Department of Urology, Bayindir Kavaklidere Hospital, Ankara, Turkey. FAU - Odabas, Oner AU - Odabas O AD - Department of Urology, Ankara Bilkent City Hospital, Ankara, Turkey. FAU - Yilmaz, Fatma Meric AU - Yilmaz FM AD - Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20251010 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/drug therapy/blood/pathology MH - Female MH - Male MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Aged MH - *Neoplasm Recurrence, Local/urine/blood MH - Middle Aged MH - Administration, Intravesical MH - Neutrophils MH - *Biomarkers, Tumor/urine/blood MH - T-Lymphocytes MH - Aged, 80 and over MH - Myeloid-Derived Suppressor Cells PMC - PMC12514065 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Flow cytometry OT - Immunology OT - Non-Muscle invasive bladder cancer OT - Recurrence COIS- Declarations. Consent for publication: All co-authors agreed to publication of the acquired data. Competing interests: The authors declare no competing interests. EDAT- 2025/10/11 00:31 MHDA- 2025/10/11 00:32 PMCR- 2025/10/10 CRDT- 2025/10/10 23:24 PHST- 2025/04/25 00:00 [received] PHST- 2025/08/05 00:00 [accepted] PHST- 2025/10/11 00:32 [medline] PHST- 2025/10/11 00:31 [pubmed] PHST- 2025/10/10 23:24 [entrez] PHST- 2025/10/10 00:00 [pmc-release] AID - 10.1038/s41598-025-14974-1 [pii] AID - 14974 [pii] AID - 10.1038/s41598-025-14974-1 [doi] PST - epublish SO - Sci Rep. 2025 Oct 10;15(1):35415. doi: 10.1038/s41598-025-14974-1. PMID- 41072608 OWN - NLM STAT- MEDLINE DCOM- 20260121 LR - 20260126 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 123 DP - 2026 Feb TI - Clinical Characteristics and Management of Infective Native Arterial Aneurysms Associated with BCG Therapy for Bladder Cancer. PG - 222-232 LID - S0890-5096(25)00659-4 [pii] LID - 10.1016/j.avsg.2025.09.053 [doi] AB - BACKGROUND: Intravesical Bacille Calmette-Guerin (BCG) immunotherapy is a well-established treatment for bladder cancer. Although generally safe, rare but severe complications such as Mycobacterium bovis-induced infected native arterial aneurysms (INAAs) can occur. These complications present diagnostic and therapeutic challenges due to their delayed onset and nonspecific symptoms. This systematic review aims to evaluate the causes, clinical presentation, diagnostic strategies, and management of BCG-induced INAA and to report an additional clinical case from the present institution. METHODS: A systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. PubMed was searched for English-language case reports published up to March 2025, describing arterial aneurysms as complications of intravesical BCG immunotherapy. Inclusion criteria required documented BCG treatment, no prior aneurysm, and microbiological or clinical confirmation of INAA. RESULTS: A total of 56 case reports involving 58 patients were included. Most patients were male (98%) with a mean age of 72.2 years (standard deviation (SD) +/- 7.7). Abdominal aortic aneurysms were most frequent (70.4%), followed by thoracic and peripheral aneurysms. The median interval between BCG instillations and INAA diagnosis was 12 months (interquartile range (IQR): 7.5-27.5). Treatment included open surgical repair (69%), endovascular repair (24.1%), and conservative management (3.5%). The median duration of antimicrobial treatment was 9 months (IQR 8-12). Overall mortality was 15.7%, and the complication rate was 33.3%. CONCLUSION: BCG-induced INAA is a rare but life-threatening complication, and early recognition is critical. Optimal management involves targeted antimicrobial therapy and timely surgical intervention, either open or endovascular, based on the patient's condition and aneurysm characteristics. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Colonna, Giulia AU - Colonna G AD - Departments of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Vascular and Endovascularvascular Surgery Unit, Sant'Andrea Hospital of Rome, Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Rome, Italy. Electronic address: giulia.colonna@uniroma1.it. FAU - Liesker, David AU - Liesker D AD - Departments of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Wouthuyzen-Bakker, M AU - Wouthuyzen-Bakker M AD - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Taurino, Maurizio AU - Taurino M AD - Vascular and Endovascularvascular Surgery Unit, Sant'Andrea Hospital of Rome, Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Rome, Italy. FAU - Zeebregts, Clark J AU - Zeebregts CJ AD - Departments of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Saleem, Ben R AU - Saleem BR AD - Departments of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251008 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Administration, Intravesical MH - *Aneurysm, Infected/microbiology/therapy/diagnostic imaging/diagnosis MH - *BCG Vaccine/adverse effects/administration & dosage MH - *Endovascular Procedures/adverse effects/mortality MH - *Mycobacterium bovis/pathogenicity MH - Risk Factors MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy MH - Case Reports as Topic EDAT- 2025/10/11 00:31 MHDA- 2026/01/22 01:09 CRDT- 2025/10/10 19:33 PHST- 2025/08/01 00:00 [received] PHST- 2025/09/12 00:00 [revised] PHST- 2025/09/13 00:00 [accepted] PHST- 2026/01/22 01:09 [medline] PHST- 2025/10/11 00:31 [pubmed] PHST- 2025/10/10 19:33 [entrez] AID - S0890-5096(25)00659-4 [pii] AID - 10.1016/j.avsg.2025.09.053 [doi] PST - ppublish SO - Ann Vasc Surg. 2026 Feb;123:222-232. doi: 10.1016/j.avsg.2025.09.053. Epub 2025 Oct 8. PMID- 41065838 OWN - NLM STAT- MEDLINE DCOM- 20251210 LR - 20260109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Oct 9 TI - Second opinions and pathological review impact the clinical management of patients with muscle-invasive bladder cancer. PG - 602 LID - 10.1007/s00345-025-05861-5 [doi] LID - 602 AB - PURPOSE: Studies evaluating inter-institutional discrepancies in muscle-invasive bladder cancer diagnosis, particularly when radical cystectomy is recommended, are scarce. In this study, we aimed to examine the inter-institutional concordance rate of pathological stages in patients diagnosed with muscle-invasive bladder cancer. METHODS: We reviewed tissue samples from patients pathologically diagnosed with muscle-invasive bladder cancer at other hospitals who subsequently sought a second opinion at our hospital between January 1, 2013 and December 31, 2023. Data were acquired retrospectively by retrieving clinical data from medical records. We investigated the inter-institutional concordance rate of pathological stages assigned to each patient and examined the tumor characteristics and prognoses of patients with pathological stage discrepancies. RESULTS: Of the 170 patients evaluated, 22 (12.9%) were downstaged upon pathological examination at our hospital. The tumor characteristics of stage discrepancy cases were small tumor size, solitary lesions, and vesical imaging reporting data system score < 3. Eleven patients were treated for non-muscle-invasive bladder cancer based on the re-evaluation findings. Eight patients had no evidence of disease, two patients had Ta bladder recurrence, and one patient had lung metastasis despite no bladder recurrence. CONCLUSION: This study highlights the importance of pathological re-evaluation of patients diagnosed with muscle-invasive bladder cancer. The significant discrepancy rate and its impact on the treatment decisions are noteworthy. Standardization of diagnostic practices is essential to mitigate variability among pathologists and facilities and to ensure optimal care for patients with muscle-invasive bladder cancer. CI - (c) 2025. The Author(s). FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. tkawahar@md.tsukuba.ac.jp. FAU - Nitta, Satoshi AU - Nitta S AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Shiga, Masanobu AU - Shiga M AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Nagumo, Yoshiyuki AU - Nagumo Y AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Kandori, Shuya AU - Kandori S AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Negoro, Hiromitsu AU - Negoro H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. FAU - Sakamoto, Noriaki AU - Sakamoto N AD - Department of Diagnostic Pathology, University of Tsukuba, 1-1-1 Tennodai, Ibaraki, 305-8575, Tsukuba, Japan. FAU - Matsubara, Daisuke AU - Matsubara D AD - Department of Diagnostic Pathology, University of Tsukuba, 1-1-1 Tennodai, Ibaraki, 305-8575, Tsukuba, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. LA - eng PT - Journal Article DEP - 20251009 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - *Urinary Bladder Neoplasms/diagnosis/pathology/therapy MH - *Urinary Bladder/pathology MH - *Referral and Consultation/standards/statistics & numerical data MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Neoplasm Staging/statistics & numerical data MH - Cystectomy/standards/statistics & numerical data MH - Clinical Decision-Making MH - Humans PMC - PMC12511233 OTO - NOTNLM OT - Muscle invasive bladder cancer OT - Tumor staging OT - Urinary bladder OT - Urinary bladder neoplasms COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and consent to participant: This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the University of Tsukuba Hospital, Japan (approval number: H29-030). Informed consent was obtained using an opt-out method via the hospital website. Patients who declined participation were excluded from the study. EDAT- 2025/10/09 12:30 MHDA- 2025/10/09 12:31 PMCR- 2025/10/09 CRDT- 2025/10/09 11:15 PHST- 2024/07/30 00:00 [received] PHST- 2025/07/26 00:00 [accepted] PHST- 2025/10/09 12:31 [medline] PHST- 2025/10/09 12:30 [pubmed] PHST- 2025/10/09 11:15 [entrez] PHST- 2025/10/09 00:00 [pmc-release] AID - 10.1007/s00345-025-05861-5 [pii] AID - 5861 [pii] AID - 10.1007/s00345-025-05861-5 [doi] PST - epublish SO - World J Urol. 2025 Oct 9;43(1):602. doi: 10.1007/s00345-025-05861-5. PMID- 41062389 OWN - NLM STAT- MEDLINE DCOM- 20260201 LR - 20260202 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 2 DP - 2026 Feb TI - Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. PG - 165-173 LID - S0302-2838(25)04702-5 [pii] LID - 10.1016/j.eururo.2025.09.4152 [doi] AB - BACKGROUND AND OBJECTIVE: High-risk (HR) or intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) carries a high probability of recurrence and/or progression. We present the final analysis results of erdafitinib in HR- or IR-NMIBC with fibroblast growth factor receptor 3/2 alterations (FGFR3/2alt) from the phase 2 THOR-2 study. METHODS: Cohort 1 (HR-NMIBC papillary only) with prior bacillus Calmette-Guerin was randomized 2:1 to erdafitinib or intravesical chemotherapy. Cohorts 2 (carcinoma in situ +/- papillary) and 3 (IR-NMIBC) received erdafitinib. The primary endpoint was recurrence-free survival (RFS) for cohort 1. Exploratory endpoints included complete response (CR) rate and duration of response (DoR) for cohorts 2 and 3. KEY FINDINGS AND LIMITATIONS: In cohort 1 (n = 73), median RFS was not reached (NR) for erdafitinib (95% confidence interval [CI] 28.6 mo-not estimable [NE]) and 11.6 mo (95% CI 5.3-NE) for intravesical chemotherapy (hazard ratio 0.28 [95% CI 0.13-0.61; nominal p = 0.0007]; median follow-up, 18.5 and 16.6 mo, respectively). In cohort 2 (n = 16), CR rates were 94% (95% CI 70-100%) and 81% (95% CI 54-96%) at 8 and 32 wk, respectively; the median DoR (mDoR) was 23.3 mo (95% CI 10.0-NE; n = 15). In cohort 3 (n = 18), the CR rate was 89% (95% CI 65-99%) and mDoR was NR (95% CI 13.4 mo-NE). Most common treatment-related adverse event in pooled erdafitinib cohorts (N = 83) was hyperphosphatemia (76%). Limitations include early termination in cohort 1 and small sample size that precluded prespecified hypothesis testing. CONCLUSIONS AND CLINICAL IMPLICATIONS: Oral erdafitinib demonstrated high efficacy in FGFR3/2alt HR-/IR-NMIBC, with a manageable safety profile. CI - Copyright (c) 2025 Janssen Global Services LLC. Published by Elsevier B.V. All rights reserved. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: daneshma@med.usc.edu. FAU - Zaucha, Renata AU - Zaucha R AD - Department of Clinical Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Catto, James W F AU - Catto JWF AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. FAU - Tran, Ben AU - Tran B AD - Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. FAU - Master, Viraj AU - Master V AD - Department of Urology, Emory University, Atlanta, GA, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France. FAU - Tubaro, Andrea AU - Tubaro A AD - Department of Urology, Sant'Andrea Hospital, Rome, Italy. FAU - Shimizu, Nobuaki AU - Shimizu N AD - Department of Urology, Gunma Prefectural Cancer Center, Gunma, Japan. FAU - Vasdev, Nikhil AU - Vasdev N AD - Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertford, Hatfield, UK. FAU - Lee, Eugene K AU - Lee EK AD - Department of Urology, University of Kansas Health System, Kansas City, KS, USA. FAU - Procopio, Giuseppe AU - Procopio G AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. FAU - Galanternik, Fernando AU - Galanternik F AD - Servicio de Oncologia Clinica, Centro de Educacion Medica e Investigaciones Clinicas, Buenos Aires, Argentina. FAU - Crow, Lauren AU - Crow L AD - Johnson & Johnson Spring House, PA, USA. FAU - Deprince, Kris AU - Deprince K AD - Johnson & Johnson, Beerse, Belgium. FAU - Naini, Vahid AU - Naini V AD - Johnson & Johnson, San Diego, CA, USA. FAU - Triantos, Spyros AU - Triantos S AD - Johnson & Johnson, Raritan, NJ, USA. FAU - Baig, Mahadi AU - Baig M AD - Johnson & Johnson Spring House, PA, USA. FAU - Zhu, Wei AU - Zhu W AD - Johnson & Johnson, Raritan, NJ, USA. FAU - Maranchie, Jodi K AU - Maranchie JK AD - Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20251007 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 890E37NHMV (erdafitinib) RN - 0 (Quinoxalines) RN - 0 (Pyrazoles) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics MH - Female MH - Male MH - Aged MH - Middle Aged MH - *Quinoxalines/therapeutic use/adverse effects/administration & dosage MH - *Pyrazoles/therapeutic use/adverse effects/administration & dosage MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Aged, 80 and over MH - *Protein Kinase Inhibitors/adverse effects/therapeutic use MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Erdafitinib OT - Fibroblast growth factor receptor alterations OT - High-risk non-muscle-invasive bladder cancer OT - Intermediate-risk non-muscle-invasive bladder cancer EDAT- 2025/10/09 00:30 MHDA- 2026/02/02 00:29 CRDT- 2025/10/08 21:59 PHST- 2025/05/16 00:00 [received] PHST- 2025/09/09 00:00 [revised] PHST- 2025/09/18 00:00 [accepted] PHST- 2026/02/02 00:29 [medline] PHST- 2025/10/09 00:30 [pubmed] PHST- 2025/10/08 21:59 [entrez] AID - S0302-2838(25)04702-5 [pii] AID - 10.1016/j.eururo.2025.09.4152 [doi] PST - ppublish SO - Eur Urol. 2026 Feb;89(2):165-173. doi: 10.1016/j.eururo.2025.09.4152. Epub 2025 Oct 7. PMID- 41062388 OWN - NLM STAT- MEDLINE DCOM- 20260506 LR - 20260507 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 5 DP - 2026 May TI - Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer. PG - 404-413 LID - S0302-2838(25)04688-3 [pii] LID - 10.1016/j.eururo.2025.09.4145 [doi] AB - BACKGROUND AND OBJECTIVE: Current non-muscle-invasive bladder cancer (NMIBC) tools perform suboptimally in predicting progression risk to potentially lethal muscle-invasive disease. We aimed to improve risk assessment using artificial intelligence approaches (PROGression Risk assessment in NMIBC [PROGRxN-BCa]). METHODS: PROGRxN-BCa was trained using 14 clinicopathological features on 3324 NMIBC patients treated from 2005 to 2022 at four Canadian institutions. External testing was performed on 9335 patients treated from 2005 to 2023 across 30 North American and European institutions. The primary outcome was time to progression (muscle-invasive or metastatic disease). PROGRxN-BCa was compared with the European Association of Urology (EAU) risk calculator. Performance was characterised using concordance index (c-index), calibration plots, instability assessments, decision curve analysis, and an algorithmic audit. KEY FINDINGS AND LIMITATIONS: During a median follow-up of 3.3 yr (interquartile range 1.6-5.8), 1405 of 12659 patients progressed. In the external testing cohort, PROGRxN-BCa had significantly higher c-index (0.79, 95% confidence interval [CI] 0.77-0.80) and net benefit overall and across different subgroups compared with the EAU risk calculator (0.71, 95% CI 0.70-0.73, p < 0.001). This improvement was consistent regardless of treatment with bacillus Calmette-Guerin, adherence to guideline-concordant care, and World Health Organization 1973 or 2004/2022 grading system, and was consistent among patients with at least 5 yr of follow-up. It also outperformed other guideline-endorsed tools and a previously published artificial intelligence model. Compared with guideline recommendations, PROGRxN-BCa improved substratification of intermediate-risk patients into distinct risk tertiles, with estimated 5-yr progression risks of 2%, 7%, and 15%-the latter in line with high-risk NMIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: PROGRxN-BCa outperformed current tools in the largest NMIBC cohort of its kind. Its integration into guidelines could improve risk stratification and patient management. CI - Copyright (c) 2025. Published by Elsevier B.V. FAU - Kwong, Jethro C C AU - Kwong JCC AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada; Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, Canada. FAU - Al-Daqqaq, Zizo AU - Al-Daqqaq Z AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. FAU - Chelliahpillai, Yashan AU - Chelliahpillai Y AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. FAU - Lee, Soomin AU - Lee S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. FAU - Kim, Kellie AU - Kim K AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. FAU - Ringa, Maximiliano AU - Ringa M AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Canada. FAU - Feifer, Andrew AU - Feifer A AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada; Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Canada. FAU - Lajkosz, Katherine AU - Lajkosz K AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Canada. FAU - Wettstein, Marian S AU - Wettstein MS AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada. FAU - Chan, Amy AU - Chan A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Canada. FAU - Lee, Taeweon AU - Lee T AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nguyen, Myky AU - Nguyen M AD - Department of Urology, Jules Bordet Institute-Erasme Hospital, Hopital Universitaire de Bruxelles, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Urology, McGill University Health Centre, Montreal, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Breau, Rodney H AU - Breau RH AD - Division of Urology, Department of Surgery, The Ottawa Hospital Research Institute, Ottawa, Canada. FAU - Lodde, Michele AU - Lodde M AD - Division of Urology, Department of Surgery, CHU de Quebec-Universite Laval, Quebec City, Canada. FAU - Fairey, Adrian AU - Fairey A AD - Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada. FAU - Lattouf, Jean-Baptiste AU - Lattouf JB AD - Division of Urology, Department of Surgery, Centre Hospitalier de l'Universite de Montreal, Montreal, Canada. FAU - Jeldres, Claudio AU - Jeldres C AD - Division of Urology, Department of Surgery, Universite de Sherbrooke, Sherbrooke, Canada. FAU - Rendon, Ricardo AU - Rendon R AD - Department of Urology, Dalhousie University, Halifax, Canada. FAU - Alimohamed, Nimira AU - Alimohamed N AD - Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada. FAU - Diamand, Romain AU - Diamand R AD - Department of Urology, Jules Bordet Institute-Erasme Hospital, Hopital Universitaire de Bruxelles, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Sylvester, Richard J AU - Sylvester RJ AD - Department of Biostatistics, European Organization for Research and Treatment of Cancer, Brussels, Belgium. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Johnson, Alistair E W AU - Johnson AEW AD - Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; Vector Institute, Toronto, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada; Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada; Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, Canada. Electronic address: girish.kulkarni@uhn.ca. CN - PROGRxN-BCa Consortium LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251007 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Risk Assessment/methods MH - Disease Progression MH - Male MH - *Artificial Intelligence MH - Female MH - Aged MH - Neoplasm Invasiveness MH - Middle Aged MH - Neoplasm Grading MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Artificial intelligence OT - Machine learning OT - Non-muscle-invasive bladder cancer OT - Progression OT - Risk stratification EDAT- 2025/10/09 00:30 MHDA- 2026/05/07 00:32 CRDT- 2025/10/08 21:59 PHST- 2025/05/01 00:00 [received] PHST- 2025/09/04 00:00 [revised] PHST- 2025/09/16 00:00 [accepted] PHST- 2026/05/07 00:32 [medline] PHST- 2025/10/09 00:30 [pubmed] PHST- 2025/10/08 21:59 [entrez] AID - S0302-2838(25)04688-3 [pii] AID - 10.1016/j.eururo.2025.09.4145 [doi] PST - ppublish SO - Eur Urol. 2026 May;89(5):404-413. doi: 10.1016/j.eururo.2025.09.4145. Epub 2025 Oct 7. PMID- 41058365 OWN - NLM STAT- MEDLINE DCOM- 20260320 LR - 20260321 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 4 DP - 2026 Apr TI - Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems. PG - 346-352 LID - S0302-2838(25)04677-9 [pii] LID - 10.1016/j.eururo.2025.09.4138 [doi] AB - BACKGROUND AND OBJECTIVE: High-risk bladder cancer recurs in 30% of cases and causes fatal outcomes in 10% within 2 yr despite surgical resection, endoscopic surveillance, and bacillus Calmette-Guerin (BCG) immunotherapy. The global shortage of BCG highlights the urgent need for alternative or complementary strategies. This study aimed to identify molecular subtypes and develop a precision framework to predict recurrence risk and guide treatment. METHODS: Transcriptomic profiling and targeted genomic sequencing were performed with validation by single-cell RNA sequencing and spatial transcriptomics. A machine learning model incorporating genomic and transcriptomic features was developed to predict recurrence risk. KEY FINDINGS AND LIMITATIONS: Four subtypes were identified, and an inflamed tumor subtype with high endogenous retroelement expression and increased commensal bacterial presence demonstrated the highest responsiveness to BCG therapy. The predictive model achieved high accuracy (area under the curve = 0.87, 95% confidence interval: 0.72-1.0) for recurrence risk. Findings are limited by sample size, necessitating validation in larger cohorts. CONCLUSIONS AND CLINICAL IMPLICATIONS: We describe a new conceptual framework for T1 tumors. Those with increased immune cells (subtype 2) have a better response to BCG, which may be secondary to enhanced baseline immune activity. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Meghani, Khyati AU - Meghani K AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Yu, Yanni AU - Yu Y AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Frydenlund, Noah AU - Frydenlund N AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Li, Erik Z AU - Li EZ AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Choy, Bonnie AU - Choy B AD - Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Abdulkadir, Sarki A AU - Abdulkadir SA AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: joshua.meeks@northwestern.edu. LA - eng GR - I01 BX003692/BX/BLRD VA/United States GR - I01 BX005599/BX/BLRD VA/United States GR - R01 CA298333/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20251007 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/drug therapy/immunology/microbiology/therapy MH - *Gene Expression Profiling MH - *Tumor Microenvironment/genetics MH - BCG Vaccine/therapeutic use MH - Male MH - Female MH - *Transcriptome MH - Aged MH - Neoplasm Recurrence, Local/genetics MH - Genomics MH - Middle Aged MH - Risk Assessment OTO - NOTNLM OT - High risk OT - Multiomics OT - Therapeutics EDAT- 2025/10/08 06:29 MHDA- 2026/03/21 00:34 CRDT- 2025/10/08 03:37 PHST- 2025/01/09 00:00 [received] PHST- 2025/08/23 00:00 [revised] PHST- 2025/09/04 00:00 [accepted] PHST- 2026/03/21 00:34 [medline] PHST- 2025/10/08 06:29 [pubmed] PHST- 2025/10/08 03:37 [entrez] AID - S0302-2838(25)04677-9 [pii] AID - 10.1016/j.eururo.2025.09.4138 [doi] PST - ppublish SO - Eur Urol. 2026 Apr;89(4):346-352. doi: 10.1016/j.eururo.2025.09.4138. Epub 2025 Oct 7. PMID- 41050687 OWN - NLM STAT- MEDLINE DCOM- 20251006 LR - 20251008 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - The miRNA-immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision. PG - 1639334 LID - 10.3389/fimmu.2025.1639334 [doi] LID - 1639334 AB - INTRODUCTION: Bladder cancer (BC) is a complex disease with patients showing widely variable responses to treatment. While immunotherapy has recently emerged as a promising alternative to the standard platinum-based chemotherapy, especially for platinum-resistant tumors, clinicians still lack reliable biomarkers to predict which patients will truly benefit from immunotherapy. AIM: This systematic review aimed to explore whether miRNAs could help decode the immune landscape of BC and serve as predictive biomarkers for immunotherapy response. METHODS: A total of 3,272 articles were systematically screened on medical databases and narrowed down to 37 studies that examined the relationship between miRNAs, immune cell infiltration, and patient outcomes in BC. To further strengthen and validate our findings, we analyzed large-scale genomic data from The Cancer Genome Atlas (TCGA-BLCA). RESULTS: A total of 104 different miRNAs appeared to shape the BC immune microenvironment. Some studies also linked miRNA expression with clinical outcomes such as BCG therapy response and prognosis, while others dissected the molecular pathways. Further analyses established miR-155, miR-142, and miR-146b as key factors for CD4(+) memory T-cell and M1 macrophage infiltration. Notably, 49 miRNAs showed stage-specific expression differences in TCGA data, with 25 of them also significantly associated with progression-free interval or overall survival. CONCLUSION: miRNAs are emerging as powerful regulators of the immune microenvironment of BC. However, despite growing evidence, to date, no studies have directly explored miRNA profiles in driving immunotherapeutic decisions. Our findings highlight the need for prospective studies to translate these molecular insights into personalized treatment strategies. CI - Copyright (c) 2025 Dulf, Ravegnini, Giorgi, Burnar, Gorini, De Leo, Lutichievici, Oprita, Todirut, Ciuleanu and Coada. FAU - Dulf, Daniel-Vasile AU - Dulf DV AD - 10th Department - Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Clinical Municipal Hospital Cluj-Napoca, Cluj-Napoca, Romania. FAU - Ravegnini, Gloria AU - Ravegnini G AD - Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy. AD - Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Giorgi, Federico Manuel AU - Giorgi FM AD - Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy. FAU - Burnar, Anamaria Larisa AU - Burnar AL AD - Institute of Oncology "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania. FAU - Gorini, Francesca AU - Gorini F AD - Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy. FAU - De Leo, Antonio AU - De Leo A AD - Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. FAU - Lutichievici, Harisa AU - Lutichievici H AD - Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. FAU - Oprita, Constantin-Lucian AU - Oprita CL AD - Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. FAU - Todirut, Cezar-Nicolae AU - Todirut CN AD - Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. FAU - Ciuleanu, Tudor-Eliade AU - Ciuleanu TE AD - 10th Department - Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Institute of Oncology "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania. FAU - Coada, Camelia Alexandra AU - Coada CA AD - Department of Morpho-functional Sciences, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250919 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/therapy/genetics MH - *MicroRNAs/genetics/immunology MH - *Immunotherapy/methods MH - Tumor Microenvironment/immunology/genetics MH - *Biomarkers, Tumor/genetics MH - Precision Medicine MH - Gene Expression Regulation, Neoplastic MH - Prognosis PMC - PMC12491296 OTO - NOTNLM OT - PD-L1 OT - immune checkpoint inhibitor OT - immunotherapy OT - microRNA OT - personalized therapy OT - prognosis OT - tumor immune infiltration OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/06 12:31 MHDA- 2025/10/06 12:32 PMCR- 2025/09/19 CRDT- 2025/10/06 07:37 PHST- 2025/06/01 00:00 [received] PHST- 2025/08/18 00:00 [accepted] PHST- 2025/10/06 12:32 [medline] PHST- 2025/10/06 12:31 [pubmed] PHST- 2025/10/06 07:37 [entrez] PHST- 2025/09/19 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1639334 [doi] PST - epublish SO - Front Immunol. 2025 Sep 19;16:1639334. doi: 10.3389/fimmu.2025.1639334. eCollection 2025. PMID- 41049840 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251006 LR - 20251008 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer. PG - 1646723 LID - 10.3389/fonc.2025.1646723 [doi] LID - 1646723 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) presents a variable prognosis, with a significant risk of recurrence and progression. Traditional clinicopathological factors provide limited prognostic accuracy, necessitating additional biomarkers. This study aimed to evaluate the prognostic role of the systemic inflammatory response index (SIRI) and traditional risk factors in predicting outcomes in NMIBC patients. METHODS: We retrospectively analyzed 158 NMIBC patients who underwent transurethral resection of bladder tumor (TURBT) between January 2021 and October 2023. Patients were stratified into recurrence/non-recurrence and progression/non-progression groups. Clinical and pathological characteristics were compared using Chi-square tests, t-tests, or Fisher's exact tests as appropriate. Receiver operating characteristic (ROC) analysis identified the optimal SIRI cutoff, which was used for Kaplan-Meier survival analysis and Cox regression to assess independent prognostic factors for progression-free survival (PFS). RESULTS: The optimal SIRI cutoff value for predicting progression was 0.716 (area under the curve [AUC] = 0.689, sensitivity = 0.689, specificity = 0.718). Patients with SIRI >/= 0.716 exhibited significantly higher progression risk (P = 0.012) and poorer PFS (Log-rank P < 0.05). Multivariate Cox regression confirmed tumor count (HR = 3.273, 95% CI: 1.003-10.691, P = 0.049), primary diagnosis status (HR = 2.563, 95% CI: 1.012-7.214, P = 0.045), and high SIRI (HR = 2.979, 95% CI: 1.110-8.027, P = 0.031) as independent predictors of PFS. Recurrence analysis further revealed that high SIRI was associated with markedly increased recurrence rates in both Ta (50.0% vs. 6.2%, P < 0.001) and T1 subgroups (73.9% vs. 32.3%, P < 0.001). CONCLUSIONS: SIRI is a significant predictor of disease progression in NMIBC, although it is not associated with RFS. When combined with clinicopathological factors such as tumor stage, grade, count, and primary diagnosis status, SIRI can enhance risk stratification in NMIBC, aiding personalized management. CI - Copyright (c) 2025 Gui, Guo, Liu, Wen and Jiao. FAU - Gui, Qi AU - Gui Q AD - Department of Urology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, Henan, China. FAU - Guo, Hongwei AU - Guo H AD - College of Biological and Food Engineering, Huanghuai University, Zhumadian, Henan, China. FAU - Liu, Taiyang AU - Liu T AD - Department of Urology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, Henan, China. FAU - Wen, Xiuhua AU - Wen X AD - Department of Urology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, Henan, China. FAU - Jiao, Xiang AU - Jiao X AD - Department of Urology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, Henan, China. LA - eng PT - Journal Article DEP - 20250918 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12488455 OTO - NOTNLM OT - non-muscle-invasive bladder cancer OT - prognostic factors OT - progression-free survival OT - recurrence-free survival OT - systemic inflammatory response index COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/06 12:31 MHDA- 2025/10/06 12:32 PMCR- 2025/09/18 CRDT- 2025/10/06 07:27 PHST- 2025/06/13 00:00 [received] PHST- 2025/08/29 00:00 [accepted] PHST- 2025/10/06 12:32 [medline] PHST- 2025/10/06 12:31 [pubmed] PHST- 2025/10/06 07:27 [entrez] PHST- 2025/09/18 00:00 [pmc-release] AID - 10.3389/fonc.2025.1646723 [doi] PST - epublish SO - Front Oncol. 2025 Sep 18;15:1646723. doi: 10.3389/fonc.2025.1646723. eCollection 2025. PMID- 41048480 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251006 LR - 20251008 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 17 DP - 2025 TI - Influencing Factors and Risk Prediction Model Construction of Urinary Tract Infections in Patients with Bladder Cancer. PG - 383-399 LID - 10.2147/RRU.S545001 [doi] AB - PURPOSE: Urinary tract infections (UTI) are a common complication in patients with bladder cancer (BLCA). This study investigated the role of stearoyl-CoA desaturase-1 (SCD1) in BLCA progression and assessed its potential as a biomarker for predicting UTI risk in BLCA patients. PATIENTS AND METHODS: SCD1 expression profiles were evaluated in BLCA patients with concurrent UTI. Receiver operating characteristic curve analysis was used to assess the diagnostic value of SCD1 for predicting UTI risk. In vitro assays were conducted to explore the functional role of SCD1 in lipopolysaccharide (LPS)-associated BLCA progression. RESULTS: SCD1 expression was significantly higher in the UTI group compared with the non-UTI group (p = 0.000 and 0.011, respectively). The combination of SCD1, immune-inflammation index, and C-reactive protein demonstrated strong predictive value for UTI risk in BLCA patients (non-muscle invasive BLCA patients: area under the curve (AUC) = 0.887; 95% CI: 0.821-0.935; muscle-invasive BLCA patients: AUC = 0.861; 95% CI: 0.767-0.927). Functional experiments revealed that lipopolysaccharide (LPS)-induced SCD1 expression promoted autophagy and enhanced malignant phenotypes, whereas SCD1 inhibition or treatment with an autophagosome inhibitor reversed these effects. CONCLUSION: SCD1 promotes LPS-associated BLCA progression by regulating autophagy and may serve as a valuable biomarker for predicting UTI risk in BLCA patients. CI - (c) 2025 Di et al. FAU - Di, Yancheng AU - Di Y AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People's Republic of China. FAU - Zhang, Lingling AU - Zhang L AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People's Republic of China. FAU - Zhao, Linlin AU - Zhao L AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People's Republic of China. FAU - Yin, Lei AU - Yin L AUID- ORCID: 0009-0002-3166-6211 AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People's Republic of China. LA - eng PT - Journal Article DEP - 20250930 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC12495926 OTO - NOTNLM OT - autophagy OT - biomarker OT - bladder cancer OT - stearoyl-CoA desaturase 1 OT - urinary tract infections COIS- The authors have no relevant financial or non-financial interests to disclose for this work. EDAT- 2025/10/06 12:31 MHDA- 2025/10/06 12:32 PMCR- 2025/09/30 CRDT- 2025/10/06 07:08 PHST- 2025/06/05 00:00 [received] PHST- 2025/09/15 00:00 [accepted] PHST- 2025/10/06 12:32 [medline] PHST- 2025/10/06 12:31 [pubmed] PHST- 2025/10/06 07:08 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - 545001 [pii] AID - 10.2147/RRU.S545001 [doi] PST - epublish SO - Res Rep Urol. 2025 Sep 30;17:383-399. doi: 10.2147/RRU.S545001. eCollection 2025. PMID- 41046347 OWN - NLM STAT- MEDLINE DCOM- 20260319 LR - 20260921 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 20 IP - 3 DP - 2026 Mar TI - Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. PG - 823-837 LID - 10.1002/1878-0261.70140 [doi] AB - Bladder cancer incidence has recently risen, making it the ninth most diagnosed cancer, highlighting an urgent need for novel and effective diagnostic and therapeutic strategies to improve patient outcomes. Here, we report on a secreted glycoprotein, Galectin-3-binding protein (LGALS3BP), as a potential biomarker and therapeutic target for bladder cancer. We found a significantly elevated LGALS3BP expression in bladder cancer tissues, correlating with disease progression. Moreover, urinary and serum levels of LGALS3BP were significantly higher in patients compared to healthy individuals, with a strong correlation observed between elevated urinary protein levels and tumor grade. Of note, LGALS3BP produced by tumor cells treated with a mannosidase I inhibitor, Kifunensine, exhibited increased reactivity to a therapeutic antibody (denoted as "1959"), suggesting that glycosylation of LGALS3BP may influence antibody recognition and protein function. Furthermore, administration of 1959-sss/DM4 antibody-drug conjugate in two xenograft mouse models of human bladder cancer resulted in complete inhibition of tumor growth. In summary, findings presented here highlight LGALS3BP as a promising candidate for further investigation into its potential as a urinary biomarker and a therapeutic target for bladder cancer. CI - (c) 2025 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Pece, Asia AU - Pece A AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Lovato, Giulio AU - Lovato G AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Cela, Ilaria AU - Cela I AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Mercatelli, Arianna AU - Mercatelli A AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Ferro, Benedetta AU - Ferro B AD - Diagnostic Molecular Pathology, Unit of Anatomic Pathology, SS Annunziata Hospital, Chieti, 66100, Italy. FAU - Nikkola, Jussi AU - Nikkola J AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada. AD - Vancouver Prostate Centre, Vancouver, V6H 3Z6, BC, Canada. FAU - Pagotto, Sara AU - Pagotto S AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Department of Medical Oral Science and Biotechnology, G. d'Annunzio University, Chieti, 66100, Italy. FAU - Grottola, Tommaso AU - Grottola T AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Diagnostic Molecular Pathology, Unit of Anatomic Pathology, SS Annunziata Hospital, Chieti, 66100, Italy. AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada. AD - Vancouver Prostate Centre, Vancouver, V6H 3Z6, BC, Canada. AD - Department of Medical Oral Science and Biotechnology, G. d'Annunzio University, Chieti, 66100, Italy. AD - Unit of Surgical Oncology, Casa di Cura Pierangeli, Pescara, 65100, Italy. FAU - De Laurenzi, Vincenzo AU - De Laurenzi V AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Cicchetti, Rossella AU - Cicchetti R AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio University', Chieti, 66100, Italy. FAU - Marchetti, Antonio AU - Marchetti A AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Diagnostic Molecular Pathology, Unit of Anatomic Pathology, SS Annunziata Hospital, Chieti, 66100, Italy. FAU - Schips, Luigi AU - Schips L AD - Department of Medical Oral Science and Biotechnology, G. d'Annunzio University, Chieti, 66100, Italy. AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio University', Chieti, 66100, Italy. FAU - Lattanzio, Rossano AU - Lattanzio R AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. FAU - Iacobelli, Stefano AU - Iacobelli S AD - MediaPharma s.r.l., Via Colonnetta 50/A, Chieti, 66100, Italy. FAU - Capone, Emily AU - Capone E AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Department of Science, 'G. d'Annunzio University', Chieti, Italy. FAU - Black, Peter AU - Black P AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada. AD - Vancouver Prostate Centre, Vancouver, V6H 3Z6, BC, Canada. FAU - Daugaard, Mads AU - Daugaard M AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada. AD - Vancouver Prostate Centre, Vancouver, V6H 3Z6, BC, Canada. FAU - Marchioni, Michele AU - Marchioni M AD - Department of Medical Oral Science and Biotechnology, G. d'Annunzio University, Chieti, 66100, Italy. AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio University', Chieti, 66100, Italy. FAU - Sala, Gianluca AU - Sala G AUID- ORCID: 0000-0002-4494-915X AD - Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. AD - Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, 66100, Italy. LA - eng GR - GR026025/Terry Fox Foundation/ GR - IG 2021 id 25696/Associazione Italiana per la Ricerca sul Cancro/ PT - Journal Article DEP - 20251005 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 RN - 0 (LGALS3BP protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Carrier Proteins) RN - 0 (Glycoproteins) RN - 0 (Antigens, Neoplasm) RN - 0 (Extracellular Matrix Proteins) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/metabolism/blood MH - Animals MH - *Biomarkers, Tumor/urine/metabolism/blood MH - Cell Line, Tumor MH - Glycosylation MH - Mice MH - Female MH - *Carrier Proteins/urine/metabolism/blood MH - Male MH - *Glycoproteins/urine/metabolism/blood MH - *Antigens, Neoplasm/metabolism/urine/blood MH - Middle Aged MH - Xenograft Model Antitumor Assays MH - Aged MH - Extracellular Matrix Proteins PMC - PMC13042393 OTO - NOTNLM OT - LGALS3BP OT - bladder cancer OT - glycosylation OT - non-muscle-invasive bladder cancer OT - urinary biomarker COIS- G.S. and S.I. are shareholders of Mediapharma s.r.l. and the other authors declare no conflict of interest in this study. EDAT- 2025/10/05 06:35 MHDA- 2026/03/19 15:12 PMCR- 2025/10/05 CRDT- 2025/10/05 05:52 PHST- 2025/07/29 00:00 [revised] PHST- 2025/06/16 00:00 [received] PHST- 2025/09/24 00:00 [accepted] PHST- 2026/03/19 15:12 [medline] PHST- 2025/10/05 06:35 [pubmed] PHST- 2025/10/05 05:52 [entrez] PHST- 2025/10/05 00:00 [pmc-release] AID - MOL270140 [pii] AID - 10.1002/1878-0261.70140 [doi] PST - ppublish SO - Mol Oncol. 2026 Mar;20(3):823-837. doi: 10.1002/1878-0261.70140. Epub 2025 Oct 5. PMID- 41045389 OWN - NLM STAT- MEDLINE DCOM- 20251004 LR - 20260917 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Oct 4 TI - Risk stratification of high-risk muscle invasive upper urinary tract urothelial carcinoma: multi-institutional study. PG - 594 LID - 10.1007/s00345-025-05915-8 [doi] LID - 594 AB - PURPOSE: This study aimed to analyze a large multi-institutional UTUC database to identify prognostic factors in patients with organ-confined and non-organ-confined disease, and to further stratify pT2 patients using a nomogram to identify high-risk subgroups who may benefit from adjuvant therapy. METHODS: The records of patients diagnosed with UCTC who underwent nephroureterectomy from 1988 to 2022 at 15 hospitals in Taiwan were retrospectively reviewed. The outcomes evaluated were overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and bladder recurrence-free survival (BRFS) after nephroureterectomy. RESULTS: A total of 2635 patients were included: 1935 with organ-confined (pTis/pTa/pT1/pT2 stage) disease, and 700 with non-organ confined (pT3/pT4 stage) disease. Significant risk factors for poor survival in patients with organ-confined disease were age >/= 70 years, ureter involvement, high pathological T stage (pT2), multiplicity, lymphovascular invasion, and eGFR /= 70 years, ureter involvement, high pathological T stage (pT4), multiplicity, eGFR 115 had significantly worse OS (P < 0.0001) and CSS (P = 0.025) compared to those with a score /=18 with a diagnosis of bladder cancer (BC) who underwent BCG therapy in 2007-2021, were identified in the Merative(TM) Marketscan(R) Research Commercial and Medicare databases. Multivariable Cox proportion hazard regressions adjusted by relevant confounders were performed to investigate the influence of immunosuppression on the events associated with progression and recurrence of BC, both in the unmatched cohort and after 1:2 propensity score matching (PSM). Also, subgroup analysis on progression in patients without cancer other than BC was conducted. RESULTS: Immunocompromised and immunocompetent patients had similar rates of disseminated BCG infection after intravesical immunotherapy. However, immunocompromised patients had shorter progression-free survival and higher probability of progression (aHR: 1.23, 95% CI: 1.11-1.38), as well as shorter recurrence-free survival and a higher probability of recurrence (aHR: 1.13, 95% CI: 1.05-1.20). Similar significant associations were observed in the PSM cohort. A subgroup analysis of patients without any additional oncological diagnoses beyond BC confirmed a higher likelihood of progression in the immunocompromised group (aHR: 1.34, 95% CI: 1.15-1.56). CONCLUSIONS: BCG immunotherapy is safe in immunocompromised patients. Nevertheless, the efficacy of intravesical BCG in these patients might be suboptimal thus advocating the need for appropriate counselling and a possible lower threshold to consider radical treatment. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy; Department of Urology, Stanford University School of Medicine, Stanford, CA; Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. Electronic address: francesco.delgiudice@uniroma1.it. FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Li, Shufeng AU - Li S AD - Department of Urology, Stanford University School of Medicine, Stanford, CA; Department of Dermatology, Stanford University School of Medicine, Stanford, CA. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Ferro, Matteo AU - Ferro M AD - Department of Life Sciences, University of Milan, Milan, Italy, Urologic Unit, ASST Santi Paolo and Carlo, Milan, Italy. FAU - Rocco, Bernardo AU - Rocco B AD - Department of Urology, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Barone, Biagio AU - Barone B AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Buonerba, Carlo AU - Buonerba C AD - Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Mari, Andrea AU - Mari A AD - Urological Robotic Surgery and Renal Transplantation Unit, Careggi Hospital, University of Florence, Firenze, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Jo, Jung Ki AU - Jo JK AD - Department of Urology, College of Medicine, Hanyang University, Seoul , Republic of Korea. FAU - Gad, Mohamed AU - Gad M AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Challacombe, Ben AU - Challacombe B AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Abu-Ghanem, Yasmin AU - Abu-Ghanem Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guys and St Thomas' Hospital, London, UK. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, CA. CN - Young Academic Urology (YAU) Urothelial Working Gourp LA - eng PT - Journal Article DEP - 20250919 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery/drug therapy/therapy/immunology MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - *Neoplasm Recurrence, Local MH - Aged MH - *Cystectomy/methods MH - *Immunocompromised Host MH - Middle Aged MH - United States MH - Administration, Intravesical MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Progression-Free Survival MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Transurethral Resection of Bladder OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Bladder cancer (BC) OT - Immunodepression OT - Transurethral resection of bladder tumor (TURBT) COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/21 00:29 MHDA- 2025/11/14 00:28 CRDT- 2025/09/20 21:58 PHST- 2025/02/28 00:00 [received] PHST- 2025/05/03 00:00 [revised] PHST- 2025/07/07 00:00 [accepted] PHST- 2025/11/14 00:28 [medline] PHST- 2025/09/21 00:29 [pubmed] PHST- 2025/09/20 21:58 [entrez] AID - S1078-1439(25)00254-6 [pii] AID - 10.1016/j.urolonc.2025.07.005 [doi] PST - ppublish SO - Urol Oncol. 2025 Dec;43(12):693.e9-693.e18. doi: 10.1016/j.urolonc.2025.07.005. Epub 2025 Sep 19. PMID- 40970394 OWN - NLM STAT- MEDLINE DCOM- 20251001 LR - 20260706 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 35 IP - 6 DP - 2025 Nov 1 TI - Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation. PG - 666-673 LID - 10.1097/MOU.0000000000001345 [doi] AB - PURPOSE OF REVIEW: Gene therapy has emerged as an attractive bladder-sparing strategy for patients with high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC), addressing a therapeutic gap for those ineligible for or declining radical cystectomy. This review aims to describe the recent advances in gene-mediated therapies for BCG-unresponsive NMIBC. RECENT FINDINGS: The bladder's unique anatomy with direct intravesical access and capacity for high local exposure with minimal systemic absorption provides an ideal context for gene delivery. Advances in barrier modulation with Syn3 and vector engineering have enabled efficient delivery. Adenoviral vectors as illustrated by the FDA-approved nadofaragene firadenovec (Adstiladrin), and other platforms, such as the conditionally replicating oncolytic adenoviruses (cretostimogene, CG0070), are maturing. Combination regimens of gene therapy and immune checkpoint inhibitors have shown additive or synergistic activity, deepening durability of gene therapy. Novel advancements including urinary and plasma tumor DNA are emerging as predictive biomarkers to guide patient selection, monitor minimal residual disease, and trigger early salvage. SUMMARY: Gene-mediated therapy is gradually advancing NMIBC care, with expanding indications and potent combinations positing itself to improve bladder preservation and long-term outcomes. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong. FAU - Leung, David Ka-Wai AU - Leung DK AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong. AD - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong. AD - Center for Translational Urological Research, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review DEP - 20250918 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/genetics MH - *Genetic Therapy/methods MH - BCG Vaccine/therapeutic use MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Immune Checkpoint Inhibitors/therapeutic use MH - Cystectomy MH - Urinary Bladder/pathology MH - Genetic Vectors MH - Treatment Outcome MH - Organ Sparing Treatments/methods MH - Combined Modality Therapy/methods OTO - NOTNLM OT - Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer OT - adenoviral vectors (nadofaragene firadenovec) OT - intravesical gene therapy OT - nonviral plasmid therapy (detalimogene voraplasmid/EG-70) OT - oncolytic adenovirus (cretostimogene/CG0070) EDAT- 2025/09/19 12:51 MHDA- 2025/10/01 12:30 CRDT- 2025/09/19 06:03 PHST- 2025/10/01 12:30 [medline] PHST- 2025/09/19 12:51 [pubmed] PHST- 2025/09/19 06:03 [entrez] AID - 00042307-990000000-00289 [pii] AID - 10.1097/MOU.0000000000001345 [doi] PST - ppublish SO - Curr Opin Urol. 2025 Nov 1;35(6):666-673. doi: 10.1097/MOU.0000000000001345. Epub 2025 Sep 18. PMID- 40967188 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251113 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 19 IP - 11 DP - 2025 Nov TI - Impact of bladder cuff management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma A systematic review and meta-analysis. PG - E404-E413 LID - 10.5489/cuaj.9145 [doi] AB - INTRODUCTION: Bladder cuff excision (BCE) is an integral component of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). While many approaches have been described, the optimal technique for BCE to provide maximal oncologic control remains unanswered. We performed a systematic review and meta-analysis to compare oncologic outcomes of different BCE techniques. METHODS: The Ovid MEDLINE, Embase, CENTRAL, and Web of Science databases were searched for studies comparing oncologic outcomes of RNU for UTUC based on different BCE approaches. Techniques for BCE were categorized as intravesical, extravesical, or endoscopic. Our primary outcomes were intravesical recurrence rate (IVR) and intravesical recurrence-free survival (IVRFS). Secondary outcomes included recurrence-free survival (RFS) and cancer-specific survival (CSS). Meta-analysis was performed to compare the recurrence rates and survival outcomes associated with different BCE techniques. RESULTS: Forty studies assessing a total of 17 168 patients were identified for inclusion. Open intravesical BCE was associated with superior univariate IVRFS (hazard ratio [HR] 1.27, 95% confidence interval [CI] 1.13-1.42, p=0.04, I(2)=43%), multivariate IVRFS (HR 1.44, 95% CI 1.16-1.80, p<0.0001, I(2)=75%), univariate RFS (HR 2.30, 95% CI 1.04-5.10, p=0.0002, I(2)=71%), and multivariate CSS (HR 1.62, 95% CI 1.22-2.15, p=0.33, I(2)=14%) when compared to non-intravesical techniques. Subgroup analysis revealed that this difference was primarily driven by the inferiority of the open extravesical approach. Endoscopic and non-endoscopic BCE demonstrated equivalent univariate and multivariate IVRFS, RFS, and CSS. CONCLUSIONS: Open intravesical BCE is associated with superior oncologic outcomes when compared to non-intravesical techniques. This difference is primarily driven by the open intravesical approach's superiority to the open extravesical approach. Endoscopic BCE showed equivalent outcomes when compared to non-endoscopic approaches. Prospective randomized trials can shed further light on the optimal approach to BCE. FAU - Kim, John AU - Kim J AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Alrumaih, Abdullah AU - Alrumaih A AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Millan, Braden AU - Millan B AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Uy, Michael AU - Uy M AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Britt, Deron AU - Britt D AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Tang, Jennifer AU - Tang J AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Bansal, Rahul AU - Bansal R AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. AD - McMaster Institute of Urology, St. Joseph's Hospital, Hamilton, ON, Canada. LA - eng PT - Journal Article PT - Review PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC12604920 COIS- COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work. EDAT- 2025/09/19 00:36 MHDA- 2025/09/19 00:37 PMCR- 2025/11/01 CRDT- 2025/09/18 18:22 PHST- 2025/09/19 00:37 [medline] PHST- 2025/09/19 00:36 [pubmed] PHST- 2025/09/18 18:22 [entrez] PHST- 2025/11/01 00:00 [pmc-release] AID - cuaj.9145 [pii] AID - cuaj-11-404 [pii] AID - 10.5489/cuaj.9145 [doi] PST - ppublish SO - Can Urol Assoc J. 2025 Nov;19(11):E404-E413. doi: 10.5489/cuaj.9145. PMID- 40967126 OWN - NLM STAT- MEDLINE DCOM- 20251216 LR - 20260127 IS - 1532-3072 (Electronic) IS - 0040-8166 (Linking) VI - 98 DP - 2026 Feb TI - Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma profiling. PG - 103137 LID - S0040-8166(25)00419-7 [pii] LID - 10.1016/j.tice.2025.103137 [doi] AB - Bacillus Calmette-Guerin (BCG) immunotherapy remains the cornerstone of adjuvant treatment for high-risk non-muscle invasive bladder cancer (NMIBC); however, therapeutic failure is particularly frequent in pT1 disease, resulting in early recurrence and progression to muscle-invasive cancer. Identifying biomarkers to anticipate BCG failure is a current clinical priority to improve patient stratification and enable risk-adapted, bladder-sparing interventions. We retrospectively analyzed a cohort of 48 patients with histologically confirmed pT1 NMIBC treated with standard intravesical BCG at two tertiary centers. The median age was 67 years (range: 41-93), 79.2 % were male, 81.2 % had high-grade tumors, 70.8 % had multifocal lesions, and 75.0 % presented tumors > 3 cm. Formalin-fixed, paraffin-embedded tumor samples were obtained prior to BCG and, when available, at recurrence or progression. Immunohistochemical expression of HER-2, SERBP1, HABP4, and IFN-gamma was quantified using semi-quantitative scoring and H-scores. Associations with recurrence-free survival (RFS) and progression-free survival (PFS) were evaluated using Kaplan-Meier survival analysis and Cox regression. HER-2 and SERBP1 were significantly overexpressed in BCG-refractory tumors, with high immunorectivities conferring markedly reduced RFS (HER-2: 7.78 vs. 11.71 months, p < 0.001; SERBP1: 7.64 vs. 11.52 months, p < 0.0001) and inferior PFS (p < 0.05). In contrast, high HABP4 and IFN-gamma immunorectivities were strongly associated with sustained recurrence- and progression-free survival (both p < 0.0001). Hazard ratios for recurrence and progression exceeded 5.0 for HER-2/SERBP1-high and IFN-gamma/HABP4-low profiles. These findings define two molecular phenotypes-immune-evasive versus immune-active-that may inform precision risk stratification, early intervention, and personalized therapeutic decision-making in high-risk NMIBC. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Alonso, Joao Carlos Cardoso AU - Alonso JCC AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil; Paulinia Municipal Hospital, Paulinia, Sao Paulo, Brazil. Electronic address: jocaalonso1@gmail.com. FAU - Goncalves, Juliana Mattoso AU - Goncalves JM AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - de Arruda Camargo, Gabriela Cardoso AU - de Arruda Camargo GC AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - de Oliveira, Gabriela AU - de Oliveira G AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - da Silva Santos, Andre AU - da Silva Santos A AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - Cintra, Adriano Angelo AU - Cintra AA AD - Paulinia Municipal Hospital, Paulinia, Sao Paulo, Brazil. FAU - Guimaraes, Fabio AU - Guimaraes F AD - Paulinia Municipal Hospital, Paulinia, Sao Paulo, Brazil. FAU - de Freitas, Leandro Luiz Lopes AU - de Freitas LLL AD - Pathology Department, Medical School, Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - Bottene, Martim Correa AU - Bottene MC AD - Sao Vicente de Paulo Charity Hospital, Jundiai, Sao Paulo, Brazil. FAU - Lestingi, Jean Felipe Prodocimo AU - Lestingi JFP AD - Sao Vicente de Paulo Charity Hospital, Jundiai, Sao Paulo, Brazil; Division of Urology, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil. FAU - Kobarg, Jorg AU - Kobarg J AD - Laboratory of Signal Mechanisms, School of Pharmaceutical Sciences (FCF), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - Favaro, Wagner Jose AU - Favaro WJ AD - Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIN), Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: favarowj@unicamp.br. LA - eng PT - Journal Article DEP - 20250915 PL - Scotland TA - Tissue Cell JT - Tissue & cell JID - 0214745 RN - 0 (BCG Vaccine) RN - 82115-62-6 (Interferon-gamma) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/immunology MH - Female MH - Male MH - Aged MH - Middle Aged MH - *BCG Vaccine/therapeutic use MH - Adult MH - Aged, 80 and over MH - *Interferon-gamma/metabolism MH - *Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Neoplasm Invasiveness MH - *Drug Resistance, Neoplasm MH - Retrospective Studies MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Biomarkers OT - HABP4 OT - HER-2 OT - Interferon-gamma OT - Non-muscle-invasive bladder cancer OT - SERBP1 COIS- Declaration of Competing Interest The authors declare no known competing financial interests or personal relationships that could have influenced the work reported in this paper. EDAT- 2025/09/19 00:36 MHDA- 2025/12/16 06:29 CRDT- 2025/09/18 18:11 PHST- 2025/07/22 00:00 [received] PHST- 2025/09/02 00:00 [revised] PHST- 2025/09/13 00:00 [accepted] PHST- 2025/12/16 06:29 [medline] PHST- 2025/09/19 00:36 [pubmed] PHST- 2025/09/18 18:11 [entrez] AID - S0040-8166(25)00419-7 [pii] AID - 10.1016/j.tice.2025.103137 [doi] PST - ppublish SO - Tissue Cell. 2026 Feb;98:103137. doi: 10.1016/j.tice.2025.103137. Epub 2025 Sep 15. PMID- 40963137 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260807 IS - 1472-6750 (Electronic) IS - 1472-6750 (Linking) VI - 25 IP - 1 DP - 2025 Sep 17 TI - Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models. PG - 102 LID - 10.1186/s12896-025-01039-4 [doi] LID - 102 AB - PURPOSE: Urinary bladder cancer remains a significant global health challenge, with effective early preventive strategies urgently needed to reduce incidence and progression. This study explores the prophylactic potential of artemisinin against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced early-stage urothelial carcinoma in a mouse model. METHODS: A multidisciplinary approach was used to evaluate artemisinin's molecular and physiological effects. Techniques included protein-protein interaction (PPI) network analysis, molecular docking, gene expression profiling, histopathological evaluation, and systemic biomarker assessment. RESULTS: PPI analysis revealed FGFR3, HRAS, and TP53 as central oncogenic drivers. Molecular docking confirmed strong binding affinities of artemisinin to these targets. Prophylactic artemisinin administration significantly downregulated FGFR3 and HRAS while upregulating TP53, indicating early correction of carcinogenic signaling. These molecular changes were associated with preserved bladder and renal histoarchitecture, normalized kidney function markers, and restored hematological profiles, reflecting systemic protection against BBN-induced toxicity. CONCLUSIONS: Artemisinin effectively intercepts bladder carcinogenesis at multiple levels, modulating key genetic pathways and mitigating systemic damage. These findings provide compelling preclinical evidence supporting artemisinin as a promising prophylactic agent for bladder cancer prevention in high-risk populations. FAU - Botrous, Silvia AU - Botrous S AD - Department of Genetics, Faculty of Agriculture, Alexandria University, Alexandria, Egypt. silviamorcous136@gmail.com. FAU - Elmaghraby, Ayaat AU - Elmaghraby A AD - Department of Nucleic Acids Research, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt. FAU - Achy, Samar El AU - Achy SE AD - Department of Surgical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Mustafa, Yehia AU - Mustafa Y AD - Department of Genetics, Faculty of Agriculture, Alexandria University, Alexandria, Egypt. FAU - Abdel-Rahman, Salah AU - Abdel-Rahman S AD - Department of Nucleic Acids Research, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt. salahmaa@gmail.com. LA - eng PT - Journal Article DEP - 20250917 PL - England TA - BMC Biotechnol JT - BMC biotechnology JID - 101088663 RN - 0 (Artemisinins) RN - 0 (Tumor Suppressor Protein p53) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - 3817-11-6 (Butylhydroxybutylnitrosamine) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - 9RMU91N5K2 (artemisinin) RN - EC 3.6.5.2 (Hras protein, mouse) RN - 0 (Trp53 protein, mouse) SB - IM MH - Animals MH - Mice MH - *Artemisinins/pharmacology MH - *Tumor Suppressor Protein p53/metabolism/genetics MH - *Proto-Oncogene Proteins p21(ras)/metabolism/genetics MH - *Urinary Bladder Neoplasms/chemically induced/prevention & control/metabolism/pathology MH - Butylhydroxybutylnitrosamine/toxicity MH - *Receptor, Fibroblast Growth Factor, Type 3/metabolism/genetics MH - Molecular Docking Simulation MH - Disease Models, Animal MH - Protein Interaction Maps/drug effects PMC - PMC12442291 OTO - NOTNLM OT - Artemisinin OT - Bladder carcinogenesis OT - Early-stage urothelial carcinoma (pT1) OT - FGFR3 OT - Gene expression profiling OT - HRAS OT - Molecular docking OT - N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) OT - Prophylactic agent OT - Protein-protein interaction network OT - TP53 OT - Urinary bladder cancer OT - Urothelial carcinoma COIS- Declarations. Ethical approval and consent to participate: The study was performed in accordance with the guidelines for the care and use of laboratory animals approved by Institutional Animal Care and Use Committee AU-08-22-07-24-2-96 (Faculty of Medicine, Alexandria University, Egypt). Consent for publication: All authors approved the final manuscript and the submission to the journal. Competing interests: The authors declare no competing interests. EDAT- 2025/09/18 00:30 MHDA- 2026/06/27 00:53 PMCR- 2025/09/17 CRDT- 2025/09/17 23:35 PHST- 2025/07/11 00:00 [received] PHST- 2025/09/02 00:00 [accepted] PHST- 2026/06/27 00:53 [medline] PHST- 2025/09/18 00:30 [pubmed] PHST- 2025/09/17 23:35 [entrez] PHST- 2025/09/17 00:00 [pmc-release] AID - 10.1186/s12896-025-01039-4 [pii] AID - 1039 [pii] AID - 10.1186/s12896-025-01039-4 [doi] PST - epublish SO - BMC Biotechnol. 2025 Sep 17;25(1):102. doi: 10.1186/s12896-025-01039-4. PMID- 40959077 OWN - NLM STAT- MEDLINE DCOM- 20250917 LR - 20250919 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance. PG - 1638628 LID - 10.3389/fimmu.2025.1638628 [doi] LID - 1638628 AB - Bladder cancer is one of the most common malignancies of the urogenital system, with a high incidence and mortality. The treatment of bladder cancer is diverse, with surgical treatment being the most common approach, including transurethral resection of bladder tumor and radical cystectomy. Following radical cystectomy, patients often undergo ileal neobladder reconstruction to restore urinary storage and voiding functions. However, postoperative changes in the urinary microbiota have become a major issue for bladder cancer patients. Traditionally, urine was believed to be sterile, but an increasing body of research has demonstrated the presence of a resident microbiota in urine, which is closely associated with the development of bladder diseases, postoperative complications, and patient prognosis. Dynamic changes in the urinary microbiota may lead to urinary tract infections, tumor recurrence, and other issues, severely affecting patients' recovery and quality of life. In recent years, with the advancement of high-throughput sequencing technology, research on the urinary microbiota has deepened, particularly regarding its changes and clinical significance after bladder cancer surgery. Although studies have explored the impact of urinary microbiota on recurrence and prognosis after bladder cancer surgery, research on urinary microbiota changes following ileal neobladder reconstruction is still limited. Therefore, this review aims to summarize the latest research on the dynamic changes of urinary microbiota in bladder cancer patients postoperatively, especially focusing on changes after ileal neobladder reconstruction, providing references for clinical treatment and future research directions. CI - Copyright (c) 2025 Lang, Li, He, Zhu, Wang and Li. FAU - Lang, Ye AU - Lang Y AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. FAU - Li, Pei AU - Li P AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. FAU - He, Ruixiang AU - He R AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. FAU - Zhu, Bo AU - Zhu B AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. FAU - Wang, Guang AU - Wang G AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. FAU - Li, Jiongming AU - Li J AD - Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China. LA - eng PT - Journal Article PT - Review DEP - 20250901 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/microbiology/urine MH - *Microbiota MH - *Cystectomy/adverse effects MH - Postoperative Complications/microbiology MH - Prognosis MH - Clinical Relevance PMC - PMC12434072 OTO - NOTNLM OT - bladder cancer OT - clinical significance OT - dynamic changes OT - ileal neobladder reconstruction OT - urinary microbiota COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/09/17 06:33 MHDA- 2025/09/17 06:34 PMCR- 2025/09/01 CRDT- 2025/09/17 04:48 PHST- 2025/05/31 00:00 [received] PHST- 2025/08/11 00:00 [accepted] PHST- 2025/09/17 06:34 [medline] PHST- 2025/09/17 06:33 [pubmed] PHST- 2025/09/17 04:48 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1638628 [doi] PST - epublish SO - Front Immunol. 2025 Sep 1;16:1638628. doi: 10.3389/fimmu.2025.1638628. eCollection 2025. PMID- 40958886 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250917 LR - 20250919 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 76 DP - 2025 Jun TI - Effect of a Single Intravesical Instillation of Mitomycin C on the Intravesical Recurrence Rate After Ureteroscopy for Upper Tract Urothelial Carcinoma: The SINCERE Prospective Multicenter Registry Study. PG - 17-22 LID - 10.1016/j.euros.2025.03.017 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare malignancy, accounting for 5-10% of all urothelial carcinomas (UCs). Radical nephroureterectomy (RNU) has been the standard treatment, but kidney-sparing surgery (KSS) via ureteroscopy (URS) is now recommended for low-risk cases. KSS is associated with a higher rate of intravesical recurrence (IVR). The SINCERE study is evaluating whether a single postoperative intravesical instillation of mitomycin C (SI-MMC) after URS can reduce the IVR rate. STUDY DESIGN: This is a prospective multicenter registry study enrolling patients with nonmetastatic UTUC undergoing URS followed by SI-MMC. Data will be compared to a historical control cohort without adjuvant MMC. Patients are aged >/=18 yr with no history of bladder cancer or contralateral UTUC. The study is following the principles of the Declaration of Helsinki and has received ethics approval. PRIMARY AND SECONDARY OUTCOMES: The primary outcome is total IVR and time to IVR. The secondary outcome is evaluation of predictive variables for IVR in patients with UTUC after endoscopic treatment. DISCUSSION: Given the high recurrence rate after URS, the study aim is to provide evidence regarding MMC use to reduce IVR and address the current lack of robust data for this strategy. The study has potential to change clinical practice by demonstrating the efficacy of SI-MMC in preventing IVR after URS for UTUC. CI - (c) 2025 The Authors. FAU - Figaroa, Orlane AU - Figaroa O AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Dasgupta, Ranan AU - Dasgupta R AD - Department of Urology, Imperial College Healthcare NHS Trust, London, UK. FAU - Hendriks, Nora AU - Hendriks N AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Kamphuis, Guido AU - Kamphuis G AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Oddens, Jorg AU - Oddens J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - van Moorselaar, Jeroen AU - van Moorselaar J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Bins, Adriaan AU - Bins A AD - Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20250428 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC12434985 OTO - NOTNLM OT - Intravesical recurrence OT - Mitomycin C OT - Upper tract urothelial cancer OT - Ureteroscopy EDAT- 2025/09/17 06:32 MHDA- 2025/09/17 06:33 PMCR- 2025/04/28 CRDT- 2025/09/17 04:45 PHST- 2025/03/31 00:00 [accepted] PHST- 2025/09/17 06:33 [medline] PHST- 2025/09/17 06:32 [pubmed] PHST- 2025/09/17 04:45 [entrez] PHST- 2025/04/28 00:00 [pmc-release] AID - S2666-1683(25)00106-5 [pii] AID - 10.1016/j.euros.2025.03.017 [doi] PST - epublish SO - Eur Urol Open Sci. 2025 Apr 28;76:17-22. doi: 10.1016/j.euros.2025.03.017. eCollection 2025 Jun. PMID- 40955381 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250916 LR - 20260925 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 9 DP - 2025 Sep TI - Is a second TUR necessary in patients with primary high-grade Ta NMIBC, particularly in the context of initial cases? PG - e70082 LID - 10.1002/bco2.70082 [doi] LID - e70082 AB - OBJECTIVE: To evaluate the clinical significance of a second transurethral resection of the bladder tumour (TURBT) in patients with a primary high-grade (HG) Ta non-muscle invasive bladder cancer (NMIBC), specifically selected for the initial diagnosis. PATIENTS AND METHODS: We retrospectively analysed 121 patients with primary HG Ta urothelial carcinoma treated at our institution between January 2007 and October 2024. All patients underwent an initial TURBT with the detrusor muscle present in the specimen. Patients were divided into the second TUR group (n = 48) and the non-second TUR group (n = 73). Propensity score matching was performed using age, number of tumours and Bacillus Calmette-Guerin treatment status. Outcomes included the residual tumour rate, recurrence-free survival (RFS), time to progression to muscle invasive bladder cancer (MIBC) and cancer-specific survival (CSS). RESULTS: Residual tumour at the initial resection site was identified in four patients (8.3%) who underwent a second TUR, with two patients (4.2%) being upstaged to T1. The median follow-up was 53 months. There were no significant differences between the two groups in RFS (p = 0.60), time to progression to MIBC (p = 0.63) or CSS (p = 0.18). These findings remained consistent in the matched cohort. Multivariate analysis revealed that a second TUR was not associated with improved RFS. CONCLUSIONS: This is the first study to specifically address primary HG Ta bladder cancer, and it suggests that a second TUR may be omitted in selected cases, particularly when the initial resection is complete and the detrusor muscle is adequately sampled. A risk-adapted approach may help reduce unnecessary procedures without compromising oncological safety. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Abe, Satoki AU - Abe S AUID- ORCID: 0009-0007-8612-9751 AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Fujinami, Hiroyuki AU - Fujinami H AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Yamanaka, Naoyuki AU - Yamanaka N AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Hata, Shinro AU - Hata S AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Inoue, Toru AU - Inoue T AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Ando, Tadasuke AU - Ando T AD - Organ Transplantation Promotion Project, Faculty of Medicine Oita University Yufu Oita Japan. FAU - Shin, Toshitaka AU - Shin T AD - Department of Urology, Faculty of Medicine Oita University Yufu Oita Japan. LA - eng PT - Journal Article DEP - 20250914 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12433709 OTO - NOTNLM OT - high-grade Ta tumour OT - non-muscle invasive bladder cancer OT - recurrence-free survival OT - residual tumour rate OT - second transurethral resection COIS- The authors declare no conflicts of interest. EDAT- 2025/09/16 06:37 MHDA- 2025/09/16 06:38 PMCR- 2025/09/14 CRDT- 2025/09/16 03:59 PHST- 2025/07/21 00:00 [received] PHST- 2025/08/14 00:00 [accepted] PHST- 2025/09/16 06:38 [medline] PHST- 2025/09/16 06:37 [pubmed] PHST- 2025/09/16 03:59 [entrez] PHST- 2025/09/14 00:00 [pmc-release] AID - BCO270082 [pii] AID - 10.1002/bco2.70082 [doi] PST - epublish SO - BJUI Compass. 2025 Sep 14;6(9):e70082. doi: 10.1002/bco2.70082. eCollection 2025 Sep. PMID- 40950259 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250917 IS - 1943-8141 (Print) IS - 1943-8141 (Electronic) IS - 1943-8141 (Linking) VI - 17 IP - 8 DP - 2025 TI - Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas aeruginosa effectively prevents postoperative recurrence in high-risk non-muscle-invasive bladder cancer. PG - 6619-6629 LID - 10.62347/GSYN6858 [doi] AB - OBJECTIVE: To evaluate the role of alternating intravesical instillation of Bacillus Calmette-Guerin (BCG) and Pseudomonas aeruginosa (PA) in preventing postoperative recurrence in high-risk non-muscle-invasive bladder cancer (HR-NMIBC). METHODS: We retrospectively reviewed the clinical data from 115 HR-NMIBC cases who underwent transurethral resection of bladder tumors (TURBT) at Gongli Hospital of Shanghai Pudong New Area between March 2021 and January 2023. Patients were grouped based on postoperative management: a control group (n=51) treated with standard gemcitabine instillations and an intervention group (n=64) given alternating BCG and PA instillations. This study assessed 1- and 2-year recurrence, recurrence-free survival, safety (gastrointestinal reactions, fever, bladder irritation symptoms, and hematuria), serum tumor markers, and life quality. Univariate and multivariate Cox proportional hazards analyses were applied to identify the recurrence predictors. A nomogram predictive model was further developed for postoperative recurrence risk estimation, and its performance was later validated. RESULTS: Despite an equivalent 1-year recurrence rate, the intervention group showed a lower 2-year recurrence rate, prolonged recurrence-free survival, and superior safety (fewer adverse events) than controls. The intervention group also showed decreased post-treatment serum tumor marker concentrations and greater life quality enhancement relative to the control cohort. Univariate and multivariate analyses identified tumor number >/=3 (P=0.036), high-grade tumors (P=0.040), and gemcitabine monotherapy (P=0.035) as independent predictors for 2-year recurrence. The nomogram's scoring system reliably associated elevated risk points with heightened recurrence risk, demonstrating strong discrimination and reliable calibration in medium-to-high-risk ranges. CONCLUSIONS: Alternating intravesical BCG and PA instillations markedly decreases 2-year postoperative recurrence on the premise of favorable safety in HR-NMIBC patients. CI - AJTR Copyright (c) 2025. FAU - Shao, Yiqun AU - Shao Y AD - Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area Shanghai 200135, China. FAU - Guan, Yongjun AU - Guan Y AD - Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area Shanghai 200135, China. FAU - Zhao, Jingying AU - Zhao J AD - Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area Shanghai 200135, China. FAU - Abudurexiti, Mierxiati AU - Abudurexiti M AD - Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area Shanghai 200135, China. FAU - Wang, Zhong AU - Wang Z AD - Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area Shanghai 200135, China. LA - eng PT - Journal Article DEP - 20250815 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC12432711 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - High-risk non-muscle-invasive bladder cancer OT - Pseudomonas aeruginosa OT - alternating intravesical instillation OT - postoperative recurrence COIS- None. EDAT- 2025/09/15 12:35 MHDA- 2025/09/15 12:36 PMCR- 2025/08/15 CRDT- 2025/09/15 07:53 PHST- 2025/05/18 00:00 [received] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/09/15 12:36 [medline] PHST- 2025/09/15 12:35 [pubmed] PHST- 2025/09/15 07:53 [entrez] PHST- 2025/08/15 00:00 [pmc-release] AID - 10.62347/GSYN6858 [doi] PST - epublish SO - Am J Transl Res. 2025 Aug 15;17(8):6619-6629. doi: 10.62347/GSYN6858. eCollection 2025. PMID- 40950252 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250917 IS - 1943-8141 (Print) IS - 1943-8141 (Electronic) IS - 1943-8141 (Linking) VI - 17 IP - 8 DP - 2025 TI - Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled receptors promote bladder cancer progression. PG - 6403-6413 LID - 10.62347/KFGI9710 [doi] AB - OBJECTIVES: To investigate the functional role of latrophilin-1 (LPHN1; encoded by the ADGRL1 gene) and latrophilin-2 (LPHN2; encoded by the ADGRL2 gene), members of the G protein-coupled receptor family, in relation to androgen receptor (AR) signaling, in the outgrowth of bladder cancer. METHODS: Human bladder urothelial carcinoma cell lines were subjected to real-time PCR, western blotting, chromatin immunoprecipitation, MTT assay, and wound-healing assay. Immunostaining was also performed on a set of bladder cancer tissue microarrays consisting of transurethral resection specimens. RESULTS: In bladder cancer cells with endogenous or exogenous AR expression, dihydrotestosterone markedly up-regulated ADGRL1/LPHN1 and ADGRL2/LPHN2 expression. Chromatin immunoprecipitation confirmed AR binding to the promoter regions of ADGRL1 and ADGRL2. Additionally, LPHN ligands (e.g. alpha-latrotoxin, FLRT3) induced their expression. Knockdown of LPHN1 or LPHN2 via shRNA virus infection significantly reduced cell viability and migration, while the stimulatory effects of LPHN ligands on cell viability were more significant in AR-negative or AR-knockdown lines than in corresponding AR-positive lines. Immunohistochemical analysis in surgical specimens further showed that LPHN1 overexpression (i.e. moderate/strong) in muscle-invasive tumors (n = 62) independently predicted poorer disease-specific survival following radical cystectomy (hazard ratio 2.662, P = 0.031). Analysis of The Cancer Genome Atlas (TCGA) dataset (n = 305, stage II-IV bladder cancer) also revealed that high ADGRL2 expression was associated with significantly worse overall survival. CONCLUSION: These findings suggest that LPHN1 and LPHN2 function as downstream effectors of AR and contribute to the progression of bladder cancer. CI - AJTR Copyright (c) 2025. FAU - Goto, Takuro AU - Goto T AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Akai, Taro AU - Akai T AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Teramoto, Yuki AU - Teramoto Y AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. AD - Department of Urology, University of Rochester Medical Center Rochester, NY, USA. AD - Department of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA. LA - eng PT - Journal Article DEP - 20250815 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC12432755 OTO - NOTNLM OT - ADGRL1 OT - ADGRL2 OT - LPHN1 OT - LPHN2 OT - androgen receptor OT - bladder cancer COIS- None. EDAT- 2025/09/15 12:33 MHDA- 2025/09/15 12:34 PMCR- 2025/08/15 CRDT- 2025/09/15 07:53 PHST- 2025/02/24 00:00 [received] PHST- 2025/07/05 00:00 [accepted] PHST- 2025/09/15 12:34 [medline] PHST- 2025/09/15 12:33 [pubmed] PHST- 2025/09/15 07:53 [entrez] PHST- 2025/08/15 00:00 [pmc-release] AID - 10.62347/KFGI9710 [doi] PST - epublish SO - Am J Transl Res. 2025 Aug 15;17(8):6403-6413. doi: 10.62347/KFGI9710. eCollection 2025. PMID- 40949297 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250917 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 11 IP - 3 DP - 2025 Jul-Sep TI - Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis. PG - 23523735251370645 LID - 10.1177/23523735251370645 [doi] LID - 23523735251370645 AB - PURPOSE: This study aimed to evaluate the impact of lymphovascular invasion (LVI) and histologic subtypes on prognosis following Bacillus Calmette-Guerin (BCG) therapy in high-grade non-muscle invasive bladder cancer (NMIBC). METHODS: We retrospectively analyzed 245 patients who underwent transurethral resection of bladder tumor (TURBT) for high-grade Ta, T1, or carcinoma in situ (CIS) and received BCG therapy between January 2010 and December 2020. Effects of LVI and histologic subtypes on recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. RESULTS: At median follow-up of 48.5 months, LVI was detected in 25.7% of patients and histologic subtypes in 36.3%. During follow-up, disease recurrence occurred in 98 patients (40.0%) and progression in 45 patients (18.4%). In multivariate analysis, LVI (HR: 2.28, 95% CI: 1.68-3.10, p < 0.001) and histologic subtypes >/=1% (HR: 1.95, 95% CI: 1.45-2.62, p < 0.001) were independent risk factors for recurrence. Similarly, LVI (HR: 2.85, 95% CI: 1.98-4.11, p < 0.001) and histologic subtypes >/=1% (HR: 2.34, 95% CI: 1.67-3.28, p < 0.001) were independent risk factors for progression. Patients with concurrent LVI and histologic subtypes demonstrated highest risk of progression (HR: 4.15, 95% CI: 2.85-6.05, p < 0.001) with 5-year PFS rate of 45.2%. CONCLUSION: In high-grade NMIBC patients receiving BCG therapy, LVI and histologic subtypes are strong independent risk factors for disease recurrence and progression. Patients with both factors have highest risk and may require more aggressive treatment strategies including consideration of early radical cystectomy. These findings support the importance of detailed pathological assessment in treatment selection for BCG-treated NMIBC patients. CI - (c) The Author(s) 2025. FAU - Nebioglu, Ali AU - Nebioglu A AUID- ORCID: 0000-0001-6325-1534 AD - Department of Urology, Mersin City Training and Research Hospital, Mersin, Turkey. RINGGOLD: 123648 FAU - Basaranoglu, Mert AU - Basaranoglu M AUID- ORCID: 0000-0002-9873-4920 AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. RINGGOLD: 52983 FAU - Bozlu, Murat AU - Bozlu M AUID- ORCID: 0000-0002-8624-0149 AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. RINGGOLD: 52983 FAU - Yuyucu Karabulut, Yasemin AU - Yuyucu Karabulut Y AUID- ORCID: 0000-0001-6619-6868 AD - Department of Pathology, Mersin University Faculty of Medicine, Mersin, Turkey. RINGGOLD: 52983 LA - eng PT - Journal Article DEP - 20250911 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC12426400 OTO - NOTNLM OT - BCG therapy OT - histological variants OT - lymphovascular invasion OT - non-muscle invasive bladder cancer OT - prognosis OT - progression OT - recurrence EDAT- 2025/09/15 12:33 MHDA- 2025/09/15 12:34 PMCR- 2025/09/11 CRDT- 2025/09/15 07:41 PHST- 2025/06/17 00:00 [received] PHST- 2025/08/05 00:00 [accepted] PHST- 2025/09/15 12:34 [medline] PHST- 2025/09/15 12:33 [pubmed] PHST- 2025/09/15 07:41 [entrez] PHST- 2025/09/11 00:00 [pmc-release] AID - 10.1177_23523735251370645 [pii] AID - 10.1177/23523735251370645 [doi] PST - epublish SO - Bladder Cancer. 2025 Sep 11;11(3):23523735251370645. doi: 10.1177/23523735251370645. eCollection 2025 Jul-Sep. PMID- 40948378 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20260925 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 14 IP - 18 DP - 2025 Sep TI - Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer. PG - e71243 LID - 10.1002/cam4.71243 [doi] LID - e71243 AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is the standard adjuvant therapy for high-risk non-muscle invasive bladder cancer (NMIBC), yet treatment failure occurs in 30% to 40% of patients. Those with BCG-unresponsive disease face a high risk of progression and represent a critical unmet need in urologic oncology. This review summarizes the mechanisms of BCG failure and evaluates emerging therapies for BCG-unresponsive NMIBC. METHODS: We conducted a comprehensive literature review of clinical trials and preclinical studies through August 2025, focusing on therapeutic strategies for BCG-unresponsive NMIBC. Mechanisms of BCG resistance, regulatory definitions, and results from recent Phase II/III trials were analyzed. RESULTS: Multiple novel therapies have demonstrated efficacy in BCG-unresponsive patients. Immune checkpoint inhibitors (e.g., pembrolizumab) achieved complete response (CR) rates of 41% in carcinoma in situ (CIS) patients. Gene therapies such as nadofaragene firadenovec and CG0070 induced CR rates of 51% and 75%, respectively. Device-assisted therapies including hyperthermic intravesical chemotherapy (HIVEC) showed 24-month recurrence-free survival of 57.4%. The IL-15 superagonist Anktiva (nogapendekin alfa inbakicept), recently FDA-approved, achieved a 71% CR rate with a median duration of 26.6 months when combined with BCG. CONCLUSIONS: The treatment landscape for BCG-unresponsive NMIBC is rapidly evolving, with immune checkpoint inhibitors, gene therapies, targeted agents, and advanced drug delivery systems showing promising efficacy. These innovations provide bladder-preserving options for patients ineligible for radical cystectomy. Future directions include biomarker-driven therapy selection, combination regimens, and optimized intravesical delivery platforms to improve long-term outcomes. CI - (c) 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. FAU - Huang, Xiaotong AU - Huang X AD - Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou University of Chinese Medicine, Guangzhou, China. FAU - Wang, Xuan AU - Wang X AD - Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China. FAU - He, Zihe AU - He Z AD - Xi'an Jiaotong-Liverpool University, Suzhou, China. FAU - Huang, Yishu AU - Huang Y AD - Guangdong Pharmaceutical University, Guangzhou, China. FAU - Hu, Bing AU - Hu B AD - Guangdong Pharmaceutical University, Guangzhou, China. FAU - Chen, Weiying AU - Chen W AD - Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou University of Chinese Medicine, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou, China. FAU - Du, Haifang AU - Du H AUID- ORCID: 0000-0002-5721-1779 AD - Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou University of Chinese Medicine, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China. AD - Hunan Yueyang Maternal & Child Health-Care Hospital, Yueyang, China. LA - eng GR - 2021B0909050003/High-level Innovative Research Institute/ GR - 2024A1515012150/Guangdong Basic and Applied Basic Research Foundation/ GR - 2025A03J4069/Guangzhou Municipal Science and Technology Bureau/ GR - 2023JJ40641/Natural Science Foundation of Hunan Province/ GR - 2023B1212060063/Science and Technology Planning Project of Guangdong Province/ GR - 82304703/National Natural Science Foundation of China/ PT - Journal Article PT - Review PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/drug therapy MH - *BCG Vaccine/therapeutic use MH - Clinical Trials as Topic MH - Immune Checkpoint Inhibitors/therapeutic use MH - *Drug Resistance, Neoplasm MH - Treatment Failure MH - Neoplasm Invasiveness PMC - PMC12434483 OTO - NOTNLM OT - BCG treatment OT - BCG vaccine replacement therapy OT - BCG-unresponsive treatment OT - bladder cancer OT - gene therapy OT - immune checkpoint inhibitors OT - photodynamic therapy OT - targeted therapy COIS- The authors declare no conflicts of interest. EDAT- 2025/09/15 12:34 MHDA- 2025/09/16 06:38 PMCR- 2025/09/15 CRDT- 2025/09/15 06:42 PHST- 2025/08/26 00:00 [revised] PHST- 2025/06/06 00:00 [received] PHST- 2025/09/02 00:00 [accepted] PHST- 2025/09/16 06:38 [medline] PHST- 2025/09/15 12:34 [pubmed] PHST- 2025/09/15 06:42 [entrez] PHST- 2025/09/15 00:00 [pmc-release] AID - CAM471243 [pii] AID - 10.1002/cam4.71243 [doi] PST - ppublish SO - Cancer Med. 2025 Sep;14(18):e71243. doi: 10.1002/cam4.71243. PMID- 40947805 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251211 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 32 IP - 12 DP - 2025 Dec TI - TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma. PG - 1893-1901 LID - 10.1111/iju.70220 [doi] AB - OBJECTIVES: beta3-tubulin, which is encoded by tubulin-beta3 (TUBB3), is a microtubule protein. Although previous studies have indicated that TUBB3 overexpression is associated with a poor prognosis and chemoresistance in bladder cancer (BLCA), no studies have conducted comprehensive in silico analyses of urothelial carcinoma (UC) via public databases. We aimed to analyze the role of TUBB3 in UC via immunohistochemistry (IHC) and public database analysis. METHODS: We performed IHC and in silico analyses to investigate the clinicopathological significance of TUBB3 in UC, evaluated its role in determining the molecular subtype, and examined its impact on the effectiveness of chemotherapy, BCG treatment, and immunotherapy in patients with UC using public databases. RESULTS: IHC revealed that 18 of 71 (25.4%) BLCA cases were positive for beta3-tubulin. The beta3-tubulin-positive group had a greater disease stage and poorer cancer-specific survival (CSS). In silico analysis revealed that there was significant upregulation of TUBB3 expression in BLCA, particularly in muscle-invasive bladder cancer (MIBC), relative to normal urothelium. High TUBB3 expression was associated with the basal molecular subtype and a poor prognosis. There was no association between the expression of TUBB3 and the efficacy of BCG therapy, cisplatin-based chemotherapy, or immunotherapy. The high expression of TUBB3 was also associated with aggressive features, a poor prognosis, and the basal subtype of upper-tract urothelial carcinoma (UTUC). CONCLUSIONS: TUBB3 may play an essential role in the development and progression of UC. TUBB3 was associated with the basal subtype. TUBB3 could be a potential therapeutic target and biomarker in UC. CI - (c) 2025 The Japanese Urological Association. FAU - Nomura, Naofumi AU - Nomura N AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Sekino, Yohei AU - Sekino Y AUID- ORCID: 0000-0003-1525-5463 AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Hayashi, Tetsutaro AU - Hayashi T AD - Department of Urology, Matsuyama Red Cross Hospital, Ehime, Japan. FAU - Kobayashi, Go AU - Kobayashi G AD - Laboratory of Molecular Pathology, Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan. FAU - Nakahara, Hikaru AU - Nakahara H AD - Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan. FAU - Tasaka, Ryo AU - Tasaka R AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Kohada, Yuki AU - Kohada Y AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Takemoto, Kenshiro AU - Takemoto K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Naito, Miki AU - Naito M AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Miyamoto, Shunsuke AU - Miyamoto S AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Kobatake, Kohei AU - Kobatake K AUID- ORCID: 0000-0003-2098-3916 AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Kitano, Hiroyuki AU - Kitano H AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Goto, Keisuke AU - Goto K AUID- ORCID: 0000-0002-3580-1401 AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Goriki, Akihiro AU - Goriki A AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Hieda, Keisuke AU - Hieda K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Niitsu, Hiroaki AU - Niitsu H AD - Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan. FAU - Hinoi, Takao AU - Hinoi T AD - Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan. FAU - Hinata, Nobuyuki AU - Hinata N AUID- ORCID: 0000-0001-7014-6812 AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. LA - eng PT - Journal Article DEP - 20250914 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Tubulin) RN - 0 (TUBB3 protein, human) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Tubulin/metabolism MH - Prognosis MH - Male MH - Female MH - Aged MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - Middle Aged MH - BCG Vaccine/therapeutic use MH - *Biomarkers, Tumor/metabolism MH - *Carcinoma, Transitional Cell/pathology/mortality/therapy MH - Immunohistochemistry MH - Urothelium/pathology MH - Immunotherapy MH - Aged, 80 and over MH - Up-Regulation MH - Neoplasm Staging OTO - NOTNLM OT - TUBB3 OT - bladder cancer OT - chemotherapy OT - immunotherapy OT - molecular subtype OT - urothelial carcinoma EDAT- 2025/09/15 06:32 MHDA- 2025/12/11 07:44 CRDT- 2025/09/15 02:44 PHST- 2025/08/17 00:00 [revised] PHST- 2025/06/03 00:00 [received] PHST- 2025/08/25 00:00 [accepted] PHST- 2025/12/11 07:44 [medline] PHST- 2025/09/15 06:32 [pubmed] PHST- 2025/09/15 02:44 [entrez] AID - 10.1111/iju.70220 [doi] PST - ppublish SO - Int J Urol. 2025 Dec;32(12):1893-1901. doi: 10.1111/iju.70220. Epub 2025 Sep 14. PMID- 40947536 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20261006 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 50 IP - 1 DP - 2026 Jan 1 TI - Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease. PG - 51-61 LID - 10.1097/PAS.0000000000002468 [doi] AB - Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive subtype of bladder cancer. We retrospectively analyzed 136 patients diagnosed between 1993 and 2025. Clinicopathologic features, immunophenotype, PD-L1 expression, molecular alterations, and survival outcomes were assessed, with a focus on patients presenting with local low-stage (pT1) disease. The cohort included 96 males and 40 females (median age: 72). Most tumors (77%) were mixed with conventional urothelial carcinoma (UC), and 10% demonstrated heterologous differentiation. Tumor stage, lymphovascular invasion (LVI), and nodal metastasis were significantly associated with poor overall survival (OS; P <0.05). Fifty-four cases had CK5/6 and GATA3 immunohistochemical stains available; a mixed basal-luminal phenotype (CK5/6+/GATA3+) was most common (43%), though immunophenotypic grouping did not significantly impact survival. Twenty-two patients had PD-L1 immunostain performed at diagnosis, and most patients (82%) were PD-L1(+) with a CPS >/=10. Patients with CPS >/=50 trended toward improved OS. Panel-based sequencing was available for 6 patients and revealed heterogeneous mutations with few recurrent alterations. In our cohort, 10 patients had local low-stage (LLS/pT1) SUC, which is rare in SUC. The metastatic rate was 30%, and mortality was 40%. Findings in LLS patients with poor outcomes included large tumor, extensive invasion, tumor necrosis, and heterologous elements. LLS patients who underwent radical cystectomy (RC) had longer OS compared with those treated with transurethral resection of bladder tumor (TURBT) alone ( P =0.0269). 3/6 survival LLS patients had no residual tumor at RC. Our findings highlight the variable clinical courses of SUC, and call for more attention on this unique group of patients. The absence of residual disease in several pT1 patients following RC suggests that timely RC can have a favorable outcome in a subset of patients. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Li, Huili AU - Li H AD - Departments of Pathology. FAU - Parimi, Vamsi AU - Parimi V AD - Departments of Pathology. FAU - Johnson, Burles 3rd AU - Johnson B 3rd AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Kamanda, Sonia AU - Kamanda S AD - Departments of Pathology. FAU - Baraban, Ezra AU - Baraban E AD - Departments of Pathology. FAU - Hoffman-Censits, Jean AU - Hoffman-Censits J AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, The Johns Hopkins Medical Institutions. FAU - Kates, Max AU - Kates M AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, The Johns Hopkins Medical Institutions. FAU - McConkey, David J AU - McConkey DJ AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, The Johns Hopkins Medical Institutions. FAU - Hahn, Noah M AU - Hahn NM AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, The Johns Hopkins Medical Institutions. FAU - Matoso, Andres AU - Matoso A AUID- ORCID: 0000-0003-0990-1115 AD - Departments of Pathology. AD - Oncology. AD - Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. AD - Department of Urology, The Johns Hopkins Medical Institutions. LA - eng PT - Journal Article DEP - 20250915 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology/mortality/genetics/chemistry/surgery MH - Middle Aged MH - Biomarkers, Tumor/analysis/genetics MH - Aged, 80 and over MH - Neoplasm Staging MH - B7-H1 Antigen/analysis MH - *Carcinoma, Transitional Cell/mortality/genetics/pathology/chemistry/surgery MH - Adult MH - Prognosis MH - Immunohistochemistry MH - Cystectomy OTO - NOTNLM OT - PD-L1 OT - bladder cancer OT - immunophenotype OT - pT1 OT - radical cystectomy OT - sarcomatoid urothelial carcinoma COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2025/09/15 06:31 MHDA- 2025/12/15 13:10 CRDT- 2025/09/15 00:23 PHST- 2025/12/15 13:10 [medline] PHST- 2025/09/15 06:31 [pubmed] PHST- 2025/09/15 00:23 [entrez] AID - 00000478-990000000-00575 [pii] AID - 10.1097/PAS.0000000000002468 [doi] PST - ppublish SO - Am J Surg Pathol. 2026 Jan 1;50(1):51-61. doi: 10.1097/PAS.0000000000002468. Epub 2025 Sep 15. PMID- 40947056 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20251103 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 49 IP - 9 DP - 2025 Nov TI - Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. PG - 501834 LID - S2173-5786(25)00179-9 [pii] LID - 10.1016/j.acuroe.2025.501834 [doi] AB - INTRODUCTION: The management of non-muscle invasive bladder cancer (NMIBC) failing Bacillus Calmette-Guerin (BCG) therapy remains challenging. The European Association of Urology (EAU) has standardized definitions of BCG failure. We aim to evaluate oncological outcomes in patients undergoing radical cystectomy (RC) for NMIBC following BCG failure, as defined by the EAU. METHODS: Retrospective study analyzed 93 patients with NMIBC who underwent RC between 2011 and 2021 after BCG therapy failure. Patients were stratified into 4 groups: clinical NMIBC, clinical progression, subclinical progression (understaged), and pathological NMIBC (pNMIBC) groups. Oncological outcomes included cancer-specific survival (CSS) and overall survival (OS). Kaplan-Meier and logistic regression analyses were used to evaluate outcomes and predictors of disease progression. RESULTS: Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC. Of those with clinical NMIBC, 46 (71.9%) were confirmed as pNMIBC and 18 (28.1%) had subclinical progression. Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%). cT1 with conco-mitant carcinoma in situ and prostatic urethral involvement were independent predictors of muscle-invasive disease at RC. CONCLUSIONS: Patients treated at an appropriate stage show superior survival outcomes com-pared to those with progression. These findings underscore the importance of timely surgical intervention in BCG-unresponsive NMIBC and support early RC in select high-risk patients to improve long-term prognosis. CI - Copyright (c) 2025 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Farre, A AU - Farre A AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. Electronic address: afarrealejo@gmail.com. FAU - Huguet, J AU - Huguet J AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Basile, G AU - Basile G AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Dieguez, L AU - Dieguez L AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Izquierdo, P AU - Izquierdo P AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Sanchez, R AU - Sanchez R AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Gavrilov, P AU - Gavrilov P AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Gallioli, A AU - Gallioli A AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Rodriguez Faba, O AU - Rodriguez Faba O AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Gaya, J M AU - Gaya JM AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, J AU - Palou J AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Breda, A AU - Breda A AD - Servicio de Urologia, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. LA - eng LA - spa PT - Journal Article DEP - 20250912 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/drug therapy/mortality/therapy/pathology MH - *BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Treatment Failure MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Treatment Outcome MH - Societies, Medical MH - Urology MH - Aged, 80 and over MH - Europe OTO - NOTNLM OT - BCG-unresponsive OT - Cistectomia radical OT - Intravesical therapy OT - No respondedor a BCG OT - Non-muscle-invasive bladder cancer OT - Radical cystectomy OT - Terapia intravesical OT - Tumor vesical no musculo invasivo COIS- Declaration of competing interest O. Rodriguez Faba is the Editor-in-Chief of the journal. The rest of the authors have nothing to disclose. EDAT- 2025/09/15 00:33 MHDA- 2025/11/04 00:28 CRDT- 2025/09/14 19:15 PHST- 2025/05/27 00:00 [received] PHST- 2025/06/25 00:00 [revised] PHST- 2025/07/01 00:00 [accepted] PHST- 2025/11/04 00:28 [medline] PHST- 2025/09/15 00:33 [pubmed] PHST- 2025/09/14 19:15 [entrez] AID - S2173-5786(25)00179-9 [pii] AID - 10.1016/j.acuroe.2025.501834 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2025 Nov;49(9):501834. doi: 10.1016/j.acuroe.2025.501834. Epub 2025 Sep 12. PMID- 40941651 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250916 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 17 DP - 2025 Aug 26 TI - Diagnostic, Prognostic, and Predictive Tissue Biomarkers in Urothelial Carcinoma In Situ: A Narrative Review. LID - 10.3390/diagnostics15172163 [doi] LID - 2163 AB - Urothelial carcinoma in situ (UCIS) is a high-grade non-muscle-invasive neoplasm with significant clinical implications due to its potential for progression to muscle-invasive disease. Accurate diagnosis and risk stratification are crucial for appropriate management, particularly given the variability in response to intravesical Bacillus Calmette-Guerin (BCG) therapy. While the diagnosis of UCIS primarily relies on morphological criteria, immunohistochemical (IHC) markers serve as valuable ancillary tools, particularly in challenging cases. Markers such as CK20, CD44, p53, and Ki-67 have been extensively studied, though none demonstrate complete sensitivity or specificity. Additionally, molecular classification has identified luminal and basal subtypes, with potential prognostic and therapeutic implications. Recent studies have also explored predictive biomarkers for BCG response, including PD-L1, whose expression correlates with recurrence and potential responsiveness to immune checkpoint inhibitors. Emerging targeted therapies, such as enfortumab vedotin, have shown promise, with nectin-4 overexpression observed in most UCIS cases. Despite these advancements, challenges remain, including interobserver variability in morphological assessment, heterogeneous IHC methodologies, and the need for standardized molecular testing. This review highlights the current understanding of diagnostic, prognostic, and predictive tissue biomarkers in UCIS, underscoring the potential role of molecular profiling in guiding personalized treatment strategies. Future research should focus on refining biomarker-driven classification systems to improve risk stratification and therapeutic decision-making in UCIS patients. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Angelo AU - Cormio A AD - Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universita Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy. AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Zanelli, Magda AU - Zanelli M AUID- ORCID: 0000-0002-8733-9933 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Zizzo, Maurizio AU - Zizzo M AUID- ORCID: 0000-0001-9841-7856 AD - Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Palicelli, Andrea AU - Palicelli A AUID- ORCID: 0000-0003-2299-5160 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. AD - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Milanese, Giulio AU - Milanese G AD - Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universita Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy. AD - Urology Unit, AST 5, Via degli Iris 1, 63100 Ascoli Piceno, Italy. FAU - Galosi, Andrea Benedetto AU - Galosi AB AD - Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universita Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy. FAU - Mazzucchelli, Roberta AU - Mazzucchelli R AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, United Hospitals, Universita Politecnica delle Marche, 60126 Ancona, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. AD - Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250826 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12428764 OTO - NOTNLM OT - CD44 OT - CK20 OT - Ki-67 OT - PD-L1 OT - bacillus Calmette-Guerin OT - biomarkers OT - bladder cancer OT - immunohistochemistry OT - nectin-4 OT - p53 OT - urothelial carcinoma in situ COIS- The authors declare no conflicts of interest. EDAT- 2025/09/13 06:35 MHDA- 2025/09/13 06:36 PMCR- 2025/08/26 CRDT- 2025/09/13 01:06 PHST- 2025/06/28 00:00 [received] PHST- 2025/08/16 00:00 [revised] PHST- 2025/08/25 00:00 [accepted] PHST- 2025/09/13 06:36 [medline] PHST- 2025/09/13 06:35 [pubmed] PHST- 2025/09/13 01:06 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - diagnostics15172163 [pii] AID - diagnostics-15-02163 [pii] AID - 10.3390/diagnostics15172163 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Aug 26;15(17):2163. doi: 10.3390/diagnostics15172163. PMID- 40940866 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250916 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 17 DP - 2025 Aug 25 TI - Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability. LID - 10.3390/cancers17172768 [doi] LID - 2768 AB - BACKGROUND: Despite clinical and pathological risk tools, predicting outcomes in non-muscle-invasive bladder cancer (NMIBC), particularly high-grade (HG) cases, remains challenging due to its unpredictable recurrence and progression. There is an urgent need for molecular biomarkers to enhance risk stratification and guide treatment. METHODS: We assessed the prognostic potential of eight miRNAs (miR-9, miR-143, miR-182, miR-205, miR-27a, miR-369, let-7c, and let-7g) in a cohort of ninety patients with primary bladder cancer. Expression data were retrieved from our previously published studies. Kaplan-Meier's and Cox's regression analyses were used to evaluate the associations with overall survival (OS), metastasis-free survival (MFS), and clinical outcomes. Principal component analysis (PCA) was performed to identify informative miRNA combinations. Target gene prediction, pathway enrichment (DAVID), and drug-gene interaction mapping (DGIdb) were conducted in silico. RESULTS: A high expression of let-7g and miR-9 was significantly associated with better OS in HG NMIBC and MIBC, respectively (p = 0.013 and p = 0.000). MiR-9 downregulation correlated with metastasis in MIBC (p = 0.018). Among all combinations, miR-205 and miR-27a best predicted intermediate-risk NMIBC progression and recurrence (r(2) = 0.982, p = 0.000). A functional analysis revealed that these miRNAs regulate key cancer-related pathways (MAPK, mTOR, and p53) through genes such as TP53, PTEN, and CDKN1A. Drug interaction mapping identified nine target genes (e.g., DAPK1, ATR, and MTR) associated with eight FDA-approved bladder cancer therapies, including cisplatin and gemcitabine. CONCLUSIONS: Let-7g, miR-9, miR-143, miR-182, and miR-205 emerged as promising biomarkers for outcome prediction in NMIBC. Their integration into liquid biopsy platforms could support non-invasive monitoring and personalized treatment strategies. These findings warrant validation in larger, prospective studies and through functional assays. FAU - Setti Boubaker, Nouha AU - Setti Boubaker N AUID- ORCID: 0000-0001-8342-6936 AD - UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), Biology Engineering Department, National Institute of Applied Sciences and Technology (INSAT), University of Tunis Carthage, Tunis 1080, Tunisia. FAU - Gurtner, Aymone AU - Gurtner A AUID- ORCID: 0000-0002-7661-9059 AD - UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. AD - Institute of Translational Pharmacology (IFT), National Research Council (CNR), 00133 Rome, Italy. FAU - Boussetta, Sami AU - Boussetta S AUID- ORCID: 0000-0003-3994-6701 AD - Laboratory of Genetics, Immunology and Human Pathology, Biology Department, Faculty of Science of Tunis, University of Tunis El Manar, Tunis 2092, Tunisia. FAU - Manni, Isabella AU - Manni I AUID- ORCID: 0000-0003-4823-0596 AD - UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. FAU - Saadi, Ahmed AU - Saadi A AUID- ORCID: 0000-0002-5361-9005 AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Ayed, Haroun AU - Ayed H AUID- ORCID: 0000-0002-7365-0309 AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Ronchetti, Livia AU - Ronchetti L AUID- ORCID: 0000-0002-2367-3852 AD - UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. FAU - Blel, Ahlem AU - Blel A AUID- ORCID: 0000-0001-6702-3889 AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia. FAU - Chakroun, Marouene AU - Chakroun M AUID- ORCID: 0000-0002-0385-2917 AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Mokadem, Seif AU - Mokadem S AUID- ORCID: 0000-0002-9226-610X AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Naimi, Zeineb AU - Naimi Z AUID- ORCID: 0000-0002-9511-5403 AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia. FAU - Bedoui, Mohamed Ali AU - Bedoui MA AUID- ORCID: 0000-0003-2919-1173 AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Bel Haj Kacem, Linda AU - Bel Haj Kacem L AUID- ORCID: 0000-0002-1492-9799 AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia. FAU - Meddeb, Khedija AU - Meddeb K AUID- ORCID: 0000-0002-3418-1749 AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AUID- ORCID: 0000-0003-0366-4630 AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia. FAU - Ben Slama, Mohamed Riadh AU - Ben Slama MR AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia. FAU - Ouerhani, Slah AU - Ouerhani S AUID- ORCID: 0000-0002-3651-4690 AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), Biology Engineering Department, National Institute of Applied Sciences and Technology (INSAT), University of Tunis Carthage, Tunis 1080, Tunisia. FAU - Piaggio, Giulia AU - Piaggio G AUID- ORCID: 0000-0003-2114-1892 AD - UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy. LA - eng PT - Journal Article DEP - 20250825 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12427307 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - drug interaction OT - microRNA OT - pathway enrichment OT - prognosis COIS- The authors declare no conflicts of interest. EDAT- 2025/09/13 06:32 MHDA- 2025/09/13 06:33 PMCR- 2025/08/25 CRDT- 2025/09/13 01:02 PHST- 2025/07/22 00:00 [received] PHST- 2025/08/20 00:00 [revised] PHST- 2025/08/22 00:00 [accepted] PHST- 2025/09/13 06:33 [medline] PHST- 2025/09/13 06:32 [pubmed] PHST- 2025/09/13 01:02 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - cancers17172768 [pii] AID - cancers-17-02768 [pii] AID - 10.3390/cancers17172768 [doi] PST - epublish SO - Cancers (Basel). 2025 Aug 25;17(17):2768. doi: 10.3390/cancers17172768. PMID- 40933478 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2327-2120 (Electronic) IS - 2327-2120 (Linking) VI - 12 IP - 3 DP - 2025 TI - Applications and future prospects of laser technologies in the treatment of non-muscle invasive bladder cancer. PG - e21200050 LID - 10.14440/bladder.2025.0004 [doi] LID - e21200050 AB - BACKGROUND: Bladder cancer (BCa) represents a common malignancy of the urinary system across the globe and poses significant treatment challenges. OBJECTIVE: This review comprehensively examined the application of laser technology in the treatment of BCa, including thulium (Tm) lasers (e.g., Tm-doped yttrium aluminium garnet [YAG]), GreenLight lasers (e.g., potassium titanyl phosphate-doped YAG and lead aluminum borate-doped YAG), holmium lasers (e.g., Ho-doped YAG), Tm fiber laser (TFL), and diode lasers. Studies have demonstrated that laser technology effectively improves tumor resection quality, reduces intraoperative bleeding, shortens recovery time, and lowers recurrence rates. Among these, Ho-doped YAG and Tm-doped YAG lasers have been shown to reduce tissue damage and enhance resection precision, while the TFL has attracted attention for its efficient tissue cutting and minimal thermal damage. GreenLight lasers offer advantages in preserving surrounding healthy tissues and demonstrate potential for use in outpatient settings. Diode lasers, known for their high-energy efficiency, contribute to improved overall treatment efficacy. This article further explored the benefits, drawbacks, and prospective uses of each laser technology in BCa treatment. CONCLUSION: This article thoroughly reviewed the applications of various laser technologies in BCa treatment, highlight their benefits and limitations, and assess their potential roles in future clinical practice. CI - Copyright: (c) 2025 Author(s). FAU - Liu, Yiting AU - Liu Y AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Liu, Lilong AU - Liu L AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Yao, Zhipeng AU - Yao Z AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Hou, Yaxin AU - Hou Y AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Liu, Zhenghao AU - Liu Z AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Li, Yang AU - Li Y AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Ding, Yuhong AU - Ding Y AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Shi, Pengjie AU - Shi P AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Liu, Zheng AU - Liu Z AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Chen, Ke AU - Chen K AD - Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Institute of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. LA - eng PT - Journal Article PT - Review DEP - 20250605 PL - United States TA - Bladder (San Franc) JT - Bladder (San Francisco, Calif.) JID - 101664418 PMC - PMC12417870 OTO - NOTNLM OT - Bladder cancer OT - Laser OT - Prognosis COIS- The authors declare that they have no competing interests. EDAT- 2025/09/11 18:29 MHDA- 2025/09/11 18:30 PMCR- 2025/06/05 CRDT- 2025/09/11 12:37 PHST- 2025/01/09 00:00 [received] PHST- 2025/03/15 00:00 [revised] PHST- 2025/04/25 00:00 [accepted] PHST- 2025/09/11 18:30 [medline] PHST- 2025/09/11 18:29 [pubmed] PHST- 2025/09/11 12:37 [entrez] PHST- 2025/06/05 00:00 [pmc-release] AID - 10.14440/bladder.2025.0004 [doi] PST - epublish SO - Bladder (San Franc). 2025 Jun 5;12(3):e21200050. doi: 10.14440/bladder.2025.0004. eCollection 2025. PMID- 40933472 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2327-2120 (Electronic) IS - 2327-2120 (Linking) VI - 12 IP - 3 DP - 2025 TI - Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for muscle-invasive bladder cancer. PG - e21200053 LID - 10.14440/bladder.2024.0065 [doi] LID - e21200053 AB - BACKGROUND: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). However, its high perioperative mortality and significant impact on quality of life have led many patients to opt for bladder-preserving approaches, which currently lack a standardized treatment protocol. OBJECTIVE: This study evaluated the efficacy and feasibility of bladder-preserving therapy using thulium laser maximal transurethral resection of bladder tumors (TURBT) combined with neoadjuvant therapy and immunotherapy in MIBC patients. METHODS: A retrospective analysis was conducted on 46 MIBC patients treated with neoadjuvant therapy followed by thulium laser maximal TURBT at a single center between January 2021 and October 2024. Patients had received neoadjuvant immunotherapy in combination with chemotherapy or antibody-drug conjugate before maximal thulium laser TURBT. Those who achieved a complete clinical response were allowed to pursue either bladder preservation or RC. Patients choosing bladder-preserving therapy were either given maintenance immunotherapy or put on observation. Bladder-intact disease-free survival (BIDFS) was assessed through Kaplan-Meier analysis, and Cox regression identified factors influencing BIDFS. RESULTS: Among the 46 patients, 95.7% remained alive, and 82.6% demonstrated no evidence of cancer with bladder function preserved. The estimated 2-year BIDFS rate was 84.2%, and T stage and maintenance immunotherapy were identified as two independent predictors of BIDFS. Patients receiving immunotherapy were at a significantly reduced risk of recurrence compared to their counterparts under observation. CONCLUSION: Thulium laser maximal TURBT, combined with neoadjuvant therapy and maintenance immunotherapy, is a promising bladder-preserving approach that helps MIBC patients attain favorable BIDFS and quality of life. CI - Copyright: (c) 2025 Author(s). FAU - Zhong, Honglin AU - Zhong H AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - He, Wei AU - He W AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Mo, Miao AU - Mo M AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Tong, Shiyu AU - Tong S AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Wang, Yinzhao AU - Wang Y AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Wang, Yuhang AU - Wang Y AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Liu, Xuhao AU - Liu X AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Zhu, Wenhao AU - Zhu W AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Shen, Zhengchao AU - Shen Z AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Huang, Zhongfu AU - Huang Z AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Ou, Zhenyu AU - Ou Z AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. FAU - Chen, Minfeng AU - Chen M AD - Department of Urology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China. LA - eng PT - Journal Article DEP - 20250605 PL - United States TA - Bladder (San Franc) JT - Bladder (San Francisco, Calif.) JID - 101664418 PMC - PMC12417871 OTO - NOTNLM OT - Bladder preservation therapy OT - Maintenance immunotherapy OT - Muscle-invasive bladder cancer OT - Neoadjuvant therapy OT - Thulium OT - Transurethral resection of bladder tumor COIS- The authors declare that they have no conflicts of interest. EDAT- 2025/09/11 18:29 MHDA- 2025/09/11 18:30 PMCR- 2025/06/05 CRDT- 2025/09/11 12:37 PHST- 2024/11/22 00:00 [received] PHST- 2025/02/11 00:00 [revised] PHST- 2025/04/25 00:00 [accepted] PHST- 2025/09/11 18:30 [medline] PHST- 2025/09/11 18:29 [pubmed] PHST- 2025/09/11 12:37 [entrez] PHST- 2025/06/05 00:00 [pmc-release] AID - 10.14440/bladder.2024.0065 [doi] PST - epublish SO - Bladder (San Franc). 2025 Jun 5;12(3):e21200053. doi: 10.14440/bladder.2024.0065. eCollection 2025. PMID- 40931081 OWN - NLM STAT- MEDLINE DCOM- 20251130 LR - 20261010 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 22 IP - 12 DP - 2025 Dec TI - Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. PG - 846-861 LID - 10.1038/s41585-025-01072-0 [doi] AB - Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very low, but approximately half of patients will experience recurrence within the first 5 years after diagnosis. This high propensity for recurrence, coupled with the threat of progression, mandates ongoing surveillance. However, the optimal frequency and duration of follow-up monitoring remain undefined. Current management strategies for low-grade non-muscle invasive bladder cancer rely heavily on routine office cystoscopy, with few advances in diagnostic and treatment options over the past 25 years. Our basic understanding of disease biology has substantially advanced. However, at present, considerable variations in clinical practice exist, with implications for increased financial and treatment burden for patients and health care systems. Molecular signatures and biomarker discoveries are crucial to understand disease behaviour and inform novel treatment strategies. Emerging therapies, such as advanced drug-delivery systems, immunomodulatory agents and targeted therapies, offer the potential to improve patient outcomes, streamline management and reduce the need for surveillance cystoscopies. Actionable avenues for future research in the field include prospective validation of novel biomarkers and therapies with the ultimate aim of optimizing patient care and reducing health care costs. CI - (c) 2025. Springer Nature Limited. FAU - Wen, Lexiaochuan AU - Wen L AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. LexiaochuanWen@gmail.com. FAU - Miyagi, Hiroko AU - Miyagi H AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Spiess, Philippe E AU - Spiess PE AUID- ORCID: 0000-0002-5723-1972 AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Yu, Alice AU - Yu A AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Mendelsohn, Cathy L AU - Mendelsohn CL AUID- ORCID: 0000-0002-4026-4073 AD - Department of Urology, Columbia University, New York, NY, USA. FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Department of Urology, Department of Urology, Yale School of Medicine, New Haven, CT, USA. AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Psutka, Sarah P AU - Psutka SP AD - Department of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA. FAU - Lerner, Seth P AU - Lerner SP AUID- ORCID: 0000-0002-6379-2581 AD - Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI, USA. FAU - Dyrskjot, Lars AU - Dyrskjot L AUID- ORCID: 0000-0001-7061-9851 AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Meeks, Joshua J AU - Meeks JJ AUID- ORCID: 0000-0002-5444-5510 AD - Department of Urology, Feinberg School of Medicine, Chicago, IL, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, University of Torino School of Medicine, Torino, Italy. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, NYU Langone Health, New York, NY, USA. FAU - Kamat, Ashish M AU - Kamat AM AUID- ORCID: 0000-0003-3546-9928 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. LA - eng SI - ClinicalTrials.gov/NCT02202044, NCT06319820, NCT03988309, NCT06510374, NCT06111235 , GR - I01 BX005599/BX/BLRD VA/United States PT - Journal Article PT - Review DEP - 20250910 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/genetics/diagnosis MH - Neoplasm Invasiveness MH - Neoplasm Grading MH - Non-Muscle Invasive Bladder Neoplasms COIS- Competing interests: S.P.L declares patent: TCGA classifier; clinical trials: Aura Bioscience, FKD, JBL (SWOG), Merck (Alliance), QED Therapeutics, Surge Therapeutics; advisory board/consulting fee: Aura Bioscience, Astra Zeneca, BMS, Pfizer/EMD Serono, Protara, Surge Therapeutics, Immunity Bio UroGen, Verity, Gilead, FKD, Viventa; honoraria: Grand Rounds Urology, UroToday. J.J.M. declares advisory boards/consulting: Merck, AstraZeneca, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring, CG Oncology, Calibr, Immunity Bio, Protara, Photocure. S.P.P. declares research funding: National Institute on Aging, Bladder Cancer Advocacy Network, PRIME Education, Inc, Janssen; guidelines committee: American Urological Association: Upper Tract Urothelial Carcinoma Guidelines 2023 and AUA Practice Guidelines Committee; advisory/consulting: Janssen (SunRise-4 Global Co-PI), Immunity Bio, Merck, CG Oncology, Pfizer; editorial boards: European Urology, Bladder Cancer; steering committees/leadership: Bladder Cancer Advocacy Network, KCCure/Kidney Cancer Association/International Kidney Cancer Society; educational company presentations given: PeerView, MedScape, UroToday. A.M.K. declares patent: CyPRIT (Anderson Cancer Center #00043705); grants/contracts: FKD Therapies, Patient-Centered Outcomes Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostis, SWOG; advisory board/consulting: Astellas Pharma, Atonco Pharma, Biologic Dynamics, Bristol-Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merk, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio, Theralase, urogen Pharma, US Biotest, Valar Labs, Vivet Therapeutics; boards/committee: IBCG, European Urology Oncology, Journal of Urology, UroToday, World Bladder Cancer patient Coalition, American Urological Association. L.D. declares funding agreement: 2i Genomics, Veracyte, Natera, AstraZeneca, Photocure and Ferring; advisory/consulting: Ferring, MSD, Cystotech, AstraZeneca and UroGen; honoraria: AstraZeneca, Pfizer and Roche and travel support from MSD. R.L. declares research support: Predicine; Valar labs; Johnson & Johnson; scientific adviser/consultant: BMS, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Valar Labs; honoraria: UroToday, IBCG, MashUP Media, MJH Lifesciences; travel: Predicine, CG Oncology, Johnson & Johnson. P.E.S. declares vice-chair of the NCCN bladder and penile cancer panel. All other authors declare no competing interests. EDAT- 2025/09/11 00:28 MHDA- 2025/12/01 00:30 CRDT- 2025/09/10 23:16 PHST- 2025/07/15 00:00 [accepted] PHST- 2025/12/01 00:30 [medline] PHST- 2025/09/11 00:28 [pubmed] PHST- 2025/09/10 23:16 [entrez] AID - 10.1038/s41585-025-01072-0 [pii] AID - 10.1038/s41585-025-01072-0 [doi] PST - ppublish SO - Nat Rev Urol. 2025 Dec;22(12):846-861. doi: 10.1038/s41585-025-01072-0. Epub 2025 Sep 10. PMID- 40926780 OWN - NLM STAT- In-Process LR - 20250912 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 17 DP - 2025 Jan-Dec TI - Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer. PG - 17562872251367555 LID - 10.1177/17562872251367555 [doi] LID - 17562872251367555 AB - OBJECTIVE: Many studies have stressed the necessity of repeat transurethral resection (reTURB) following the initial conventional transurethral resection of the bladder for non-muscle invasive bladder cancer (NMIBC) patients. However, there have been few studies focusing on the role of reTURB after en bloc resection of bladder tumor (ERBT) for NMIBC by far. This study aimed to evaluate whether reTURB can be avoided after ERBT. MATERIALS AND METHODS: We conducted research in PubMed, Web of Science, EMBASE, and the Cochrane Library up to November 14, 2024, to identify studies on the reTURB after initial ERBT. For data conversion and the combined calculation of the incidence rate, we utilized R software (R Foundation for Statistical Computing, Vienna, Austria) and Cochrane Review Manager 5.4 (The Cochrane Collaboration, London, UK) along with the double arcsine method. This systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under number 1082989. RESULTS: A total of 17 studies involving 1051 participants were included. The rates of residual tumor and tumor upstaging detected by reTURB or cystoscopy after ERBT were 9% (95% confidence interval (CI) = 4%-16%) and 0% (95% CI = 0%-1%). No statistically significant positive effect of reTURB after initial ERBT was exhibited in recurrence-free survival (RFS), tumor recurrence, and progression. The pooled hazard ratios of 1-year and 5-year RFS were 0.77 (95% CI = 0.41-1.44, p = 0.41) and 0.83 (95% CI = 0.58-1.20, p = 0.33). The pooled odds ratio of progression and recurrence were 1.13 (95% CI = 0.53-2.41, p = 0.75) and 0.78 (95% CI = 0.53-1.16, p = 0.23). CONCLUSION: ERBT can successfully regulate the rate of tumor upstaging and residual tumor to an acceptable level. For patients with NMIBC, subsequent reTURB may not be required following the initial ERBT. CI - (c) The Author(s), 2025. FAU - Li, Jincong AU - Li J AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Song, Yuxuan AU - Song Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Chen, Rui AU - Chen R AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Gao, Hanlin AU - Gao H AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Liu, Yang AU - Liu Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Peng, Yun AU - Peng Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Wu, Jilin AU - Wu J AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Du, Yiqing AU - Du Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Qin, Caipeng AU - Qin C AD - Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Haidian District, Beijing 100044, China. FAU - Xu, Tao AU - Xu T AUID- ORCID: 0000-0003-3899-1500 AD - Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Haidian District, Beijing 100044, China. LA - eng PT - Journal Article DEP - 20250907 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC12415345 OAB - Systematic review of reTURB after ERBT This article aimed to evaluate whether repeat transurethral resection (reTURB) can be avoided after En bloc resection of bladder tumor (ERBT) and found that reTURB may not be required following the initial ERBT in non-muscle invasive bladder cancer. OABL- eng OTO - NOTNLM OT - en bloc resection OT - non-muscle invasive bladder cancer OT - repeat transurethral resection OT - systematic review COIS- The authors declare that there is no conflict of interest. EDAT- 2025/09/10 06:29 MHDA- 2025/09/10 06:29 PMCR- 2025/09/07 CRDT- 2025/09/10 04:53 PHST- 2025/01/17 00:00 [received] PHST- 2025/07/16 00:00 [accepted] PHST- 2025/09/10 06:29 [medline] PHST- 2025/09/10 06:29 [pubmed] PHST- 2025/09/10 04:53 [entrez] PHST- 2025/09/07 00:00 [pmc-release] AID - 10.1177_17562872251367555 [pii] AID - 10.1177/17562872251367555 [doi] PST - epublish SO - Ther Adv Urol. 2025 Sep 7;17:17562872251367555. doi: 10.1177/17562872251367555. eCollection 2025 Jan-Dec. PMID- 40926363 OWN - NLM STAT- MEDLINE DCOM- 20250919 LR - 20260813 IS - 1573-4056 (Electronic) VI - 21 DP - 2025 TI - CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two Years after TURBT. PG - e15734056350444 LID - 10.2174/0115734056350444250418075406 [doi] LID - e15734056350444 AB - BACKGROUND: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment. OBJECTIVE: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT). METHODS: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed. Within the intratumoral and peritumoral regions of the venous phase images, 1316 radiomics features were extracted. Feature selection was used to identify a set of top recurrence-associated features within the training cohort. Three models were constructed to predict recurrence for a given patient using Random Forest (RF): Model 1 was based on the radiomics features set from the intratumoral region, Model 2 was based on a combination of intratumoral and peritumoral regions, and Model 3 combined the radiomics features from Model 2 and clinical factors. The three models were then independently tested on internal and external cohorts, and their performance was evaluated. We also employed the bootstrap method on the internal cohort to further validate the performance of the model. RESULTS: Combining intratumoral and peritumoral regions, Model 2 yielded a higher area under the receiver operator characteristic curves (AUC) than Model 1, with 0.826 AUCs of the training cohort. After adding clinical factors, the predictive performance of Model 3 for postoperative recurrence of NMIBC was further improved, and the AUCs of the training, internal, and external validation cohorts of Model 3 were 0.860 (95% CI: 0.829-0.954), 0.829 (0.812-0.863), and 0.805 (0.652-0.840), respectively (all p>0.05). The bootstrap value of Model 3 on the internal cohort was 0.852. Model 3 stratified patients into high- and low-risk groups with significantly different recurrence-free survival (RFS) (p<0.001). CONCLUSION: Radiomic features derived from intratumoral regions can predict the 2-year recurrence risk following TURBT in patients with NMIBC. The predictive performance is further enhanced when combined with radiomic features from peritumoral regions and clinical risk factors. FAU - Cao, Ting AU - Cao T AD - Department of Radiology, First Central Clinical College, Tianjin Medical University, Tianjin, China. AD - Department of Radiology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Li, Na AU - Li N AD - Department of Radiology, The People's Hospital of Zhangqiu Area, Jinan, China. FAU - Guo, Chuanchao AU - Guo C AD - Department of Radiology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Zhang, Hepeng AU - Zhang H AD - Department of Urology Surgery, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Chen, Lihua AU - Chen L AD - Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Jinan, China. FAU - Wu, Ke AU - Wu K AD - Department of Radiology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Liang, Lisha AU - Liang L AD - Department of Radiology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China. FAU - Wang, Ximing AU - Wang X AD - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. FAU - Shen, Wen AU - Shen W AD - Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Jinan, China. LA - eng PT - Journal Article PL - United Arab Emirates TA - Curr Med Imaging JT - Current medical imaging JID - 101762461 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery/pathology MH - Male MH - Female MH - *Neoplasm Recurrence, Local/diagnostic imaging MH - Retrospective Studies MH - *Tomography, X-Ray Computed/methods MH - Middle Aged MH - Aged MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms MH - Radiomics PMC - PMC13176758 OTO - NOTNLM OT - Bladder cancer OT - CT OT - Machine learning OT - Non-muscle-invasive bladder cancer OT - Radiomics OT - Recurrence OT - TME. OT - Transurethral resection of bladder tumor COIS- The authors declare no conflict of interest, financial or otherwise. EDAT- 2025/09/10 06:29 MHDA- 2025/09/19 06:32 PMCR- 2026/05/15 CRDT- 2025/09/10 01:03 PHST- 2024/08/11 00:00 [received] PHST- 2025/02/05 00:00 [revised] PHST- 2025/02/13 00:00 [accepted] PHST- 2025/09/19 06:32 [medline] PHST- 2025/09/10 06:29 [pubmed] PHST- 2025/09/10 01:03 [entrez] PHST- 2026/05/15 00:00 [pmc-release] AID - CMIR-EPUB-148567 [pii] AID - CMIM-21-E15734056350444 [pii] AID - 10.2174/0115734056350444250418075406 [doi] PST - ppublish SO - Curr Med Imaging. 2025;21:e15734056350444. doi: 10.2174/0115734056350444250418075406. PMID- 40923330 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20251204 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 158 IP - 3 DP - 2026 Feb 1 TI - Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients. PG - 763-774 LID - 10.1002/ijc.70147 [doi] AB - Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6-methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis. The screening cohort of the study included 213 patients. The UROMOL (n = 535) was analyzed as a validation cohort for non-muscle-invasive BlCa (NMIBC), while the TCGA-BLCA (n = 412) and Mariathasan et al. (n = 348) cohorts were analyzed for muscle-invasive BlCa (MIBC). Disease recurrence/progression and patients' mortality were assessed as clinical endpoints for NMIBC and MIBC, respectively. Internal validation of Cox regression models was conducted using bootstrap analysis, while the clinical utility for patient prognosis was evaluated through decision curve analysis. Reduced METTL3 expression was correlated with muscle-invasive disease and tumors of advanced stage. Loss of METTL3 expression at diagnosis was strongly associated with higher risk of short-term progression (HR = 2.903, 95% CI: 1.303-6.464, p = 0.006) to invasive stages in NMIBC and with worse survival of MIBC patients (HR = 1.908, 95% CI: 1.020-3.567, p = 0.042). Consistently, validation cohorts confirmed the poor treatment outcomes in patients exhibiting loss of METTL3. Finally, METTL3-fitted multivariate models improved risk stratification and offered superior clinical benefit for NMIBC and MIBC prognostication compared to clinically established disease markers. Overall, loss of METTL3 expression correlates with inferior treatment outcomes in BlCa, driving more accurate risk stratification and ameliorating patients' prognosis in BlCa. CI - (c) 2025 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Pilala, Katerina-Marina AU - Pilala KM AUID- ORCID: 0000-0002-0187-6907 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Koroneou, Stella AU - Koroneou S AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AUID- ORCID: 0000-0003-1903-8343 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Panoutsopoulou, Konstantina AU - Panoutsopoulou K AUID- ORCID: 0000-0003-2773-4883 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Soureas, Konstantinos AU - Soureas K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. AD - Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. FAU - Giagkos, Georgios-Christos AU - Giagkos GC AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Linardoutsos, Dimitrios AU - Linardoutsos D AD - First Department of Propaedeutic Surgery, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AUID- ORCID: 0000-0002-2135-9886 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. AD - Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. LA - eng GR - HFRI-3765/Hellenic Foundation for Research and Innovation/ PT - Journal Article DEP - 20250909 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - EC 2.1.1.62 (METTL3 protein, human) RN - EC 2.1.1.- (Methyltransferases) RN - K72T3FS567 (Adenosine) RN - 0 (Biomarkers, Tumor) RN - CLE6G00625 (N-methyladenosine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/mortality/therapy/enzymology MH - *Methyltransferases/genetics/metabolism MH - Male MH - Female MH - Disease Progression MH - Prognosis MH - Aged MH - Middle Aged MH - Adenosine/analogs & derivatives/metabolism MH - *Biomarkers, Tumor/genetics/metabolism MH - Treatment Outcome MH - Gene Expression Regulation, Neoplastic MH - Neoplasm Recurrence, Local/pathology/genetics PMC - PMC12670348 OTO - NOTNLM OT - N6-methyladenosine OT - RNA modifications OT - epitranscriptome OT - m6A RNA methylation OT - m6A modification COIS- The authors declare no conflicts of interest. EDAT- 2025/09/09 06:35 MHDA- 2025/12/02 12:56 PMCR- 2025/12/02 CRDT- 2025/09/09 06:04 PHST- 2025/08/20 00:00 [revised] PHST- 2025/02/05 00:00 [received] PHST- 2025/08/28 00:00 [accepted] PHST- 2025/12/02 12:56 [medline] PHST- 2025/09/09 06:35 [pubmed] PHST- 2025/09/09 06:04 [entrez] PHST- 2025/12/02 00:00 [pmc-release] AID - IJC70147 [pii] AID - 10.1002/ijc.70147 [doi] PST - ppublish SO - Int J Cancer. 2026 Feb 1;158(3):763-774. doi: 10.1002/ijc.70147. Epub 2025 Sep 9. PMID- 40915948 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 44 IP - 1 DP - 2026 Jan TI - Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer. PG - 62.e1-62.e7 LID - S1078-1439(25)00313-8 [pii] LID - 10.1016/j.urolonc.2025.08.007 [doi] AB - OBJECTIVE: To evaluate the role of Rescue BCG in the treatment of BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC), in order to inform clinical decision-making especially when access to alternative therapies is limited. METHODS: From an institutional database, patients who met the criteria of BCG-unresponsive NMIBC between 2002 and 2023 were identified and sorted into 2 cohorts: those who received additional BCG therapy immediately after BCG-unresponsive designation and those who received alternative treatments such as intravesical chemotherapy and radical cystectomy. Primary endpoint was progression-free survival (PFS). Secondary endpoints included high-grade (HG) recurrence-free survival (RFS) and overall survival (OS). RESULTS: A total of 120 patients with BCG-unresponsive NMIBC were evaluated. Of these, 66 received Rescue BCG, and 54 did not. Both cohorts were similar in demographics, although the Rescue BCG cohort had significantly more HG T1 disease. The 1-year PFS for Rescue BCG was 95.3% compared with 84.5% for No Rescue BCG (log rank, P = 0.4). Multivariable analyses showed Rescue BCG significantly reduced disease progression (HR: 0.38, 95% CI, 0.14-0.99) and improved overall survival (HR: 0.18, 95% CI, 0.04-0.79), though no difference in HG recurrence was found. Limitations include retrospective design. CONCLUSION: Use of rescue BCG was associated with reduced risk of progression and improved overall survival when compared to No Rescue BCG. There was no significant difference in PFS between the No Rescue BCG cohort and in patients who had a HG recurrence within 2 years of being treated with Rescue BCG suggesting that a trial of Rescue BCG does not compromise overall oncologic outcomes. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Bai, Ketty AU - Bai K AD - Vagelos College of Physicians and Surgeons, Columbia University, New York, NY. Electronic address: kb3253@cumc.columbia.edu. FAU - Pingle, Srinath-Reddi AU - Pingle SR AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Chung, Rainjade AU - Chung R AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Joffe, Benjamin I AU - Joffe BI AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Laplaca, Caroline AU - Laplaca C AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Decastro, G Joel AU - Decastro GJ AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Lenis, Andrew T AU - Lenis AT AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. LA - eng PT - Journal Article DEP - 20250906 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - *BCG Vaccine/therapeutic use MH - Female MH - Male MH - Aged MH - Middle Aged MH - Retrospective Studies MH - *Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG-unresponsive OT - Bacillus Calmette-Guerin OT - Bladder-sparing therapy OT - Nonmuscle-invasive bladder cancer OT - Rescue BCG COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/08 00:33 MHDA- 2025/12/12 03:30 CRDT- 2025/09/07 21:55 PHST- 2025/04/01 00:00 [received] PHST- 2025/07/07 00:00 [revised] PHST- 2025/08/04 00:00 [accepted] PHST- 2025/12/12 03:30 [medline] PHST- 2025/09/08 00:33 [pubmed] PHST- 2025/09/07 21:55 [entrez] AID - S1078-1439(25)00313-8 [pii] AID - 10.1016/j.urolonc.2025.08.007 [doi] PST - ppublish SO - Urol Oncol. 2026 Jan;44(1):62.e1-62.e7. doi: 10.1016/j.urolonc.2025.08.007. Epub 2025 Sep 6. PMID- 40910335 OWN - NLM STAT- MEDLINE DCOM- 20250905 LR - 20250916 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 32 IP - 4 DP - 2025 Aug 29 TI - Impact of COVID-19 care reorganization on the prognosis of patients with bladder urothelial carcinoma: a multicentric retrospective study. PG - 359-366 LID - 10.32604/cju.2025.066470 [doi] AB - BACKGROUND: The COVID-19 pandemic disrupted healthcare systems globally, raising concerns about delayed cancer diagnosis and treatment. In France, transurethral resection of bladder tumors (TURBT) was prioritized in national urology guidelines to ensure the timely management of urothelial carcinoma. This study aimed to assess the impact of care reorganization on tumor staging, recurrence, palliative care, and mortality in bladder cancer patients from the pre-pandemic through late-pandemic periods. METHODS: We conducted a retrospective multicenter study including all patients who underwent TURBT with histologically confirmed urothelial carcinoma between April and December of 2019 (pre-pandemic), 2020 (early pandemic), 2021 (mid-pandemic), and 2022 (late pandemic) in two French institutions. TURBT indications were categorized as diagnostic, palliative, or staging. Clinical and pathological data were compared across the four periods. Statistical analyses included Chi-square tests, Estimated Annual Percentage Change (EAPC), and multivariable logistic regression adjusted for age, sex, ASA score, and center. RESULTS: A total of 790 TURBT procedures were analyzed. The proportion of muscle-invasive bladder cancer (pT >/= 2) declined over time (18.7% in 2019 to 13.2% in 2022; p = 0.63), while superficial tumors (pTa) increased (57.2% to 65.5%). All-cause mortality significantly decreased from 38.0% in 2019 to 22.0% in 2020, 20.5% in 2021, and 19.5% in 2022 (p = 0.006). EAPC showed a significant annual decline in mortality (-24.3%, p = 0.004). In multivariable analysis, 2020, 2021, and 2022 were each associated with significantly lower odds of mortality compared to 2019. Recurrence rates remained stable across all periods (p = 0.93). Inter-hospital variation persisted in mortality and recurrence. CONCLUSIONS: Despite the pandemic, urothelial bladder cancer outcomes did not worsen through 2022. On the contrary, timely reorganization, prioritization of TURBT, and triage strategies were associated with reduced mortality and palliative care needs, highlighting the resilience of cancer care when guided by adaptive health policies. CI - Copyright Ⓒ 2025 The Authors. Published by Tech Science Press. FAU - Chaumel, Marie AU - Chaumel M AD - Department of Urology, University Hospital of Tours (CHRU Tours), 2 Boulevard Tonnelle, Tours Cedex 9, 37044, France. FAU - Brichart, Nicolas AU - Brichart N AD - Department of Urology, Centre Hospitalier Regional d'Orleans (CHR Orleans), 14 Avenue de l'Hopital, Orleans, 45100, France. FAU - Bruyere, Franck AU - Bruyere F AD - Department of Urology, University Hospital of Tours (CHRU Tours), 2 Boulevard Tonnelle, Tours Cedex 9, 37044, France. FAU - Bourgi, Ali AU - Bourgi A AD - Department of Urology, University Hospital of Tours (CHRU Tours), 2 Boulevard Tonnelle, Tours Cedex 9, 37044, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250829 PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/surgery/pathology/diagnosis MH - Retrospective Studies MH - Male MH - Female MH - *COVID-19/epidemiology MH - Aged MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology/diagnosis MH - Middle Aged MH - France/epidemiology MH - Neoplasm Staging MH - Palliative Care MH - SARS-CoV-2 MH - Aged, 80 and over MH - Neoplasm Recurrence, Local/epidemiology MH - Cystectomy OTO - NOTNLM OT - COVID-19 OT - bladder tumor OT - cancer prognosis OT - mortality OT - pandemic OT - recurrence OT - transurethral resection of bladder tumors (TURBT) OT - urothelial carcinoma COIS- The authors declare no conflicts of interest to report regarding the present study. EDAT- 2025/09/05 06:35 MHDA- 2025/09/05 12:41 CRDT- 2025/09/05 05:33 PHST- 2025/04/09 00:00 [received] PHST- 2025/08/15 00:00 [accepted] PHST- 2025/09/05 12:41 [medline] PHST- 2025/09/05 06:35 [pubmed] PHST- 2025/09/05 05:33 [entrez] AID - 10.32604/cju.2025.066470 [doi] PST - epublish SO - Can J Urol. 2025 Aug 29;32(4):359-366. doi: 10.32604/cju.2025.066470. PMID- 40906958 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20251108 IS - 1221-9118 (Print) IS - 1221-9118 (Linking) VI - 120 IP - 4 DP - 2025 Aug TI - Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer: An 18-Year Retrospective Study from Real-Life Practice. PG - 459-466 LID - 11 [pii] LID - 10.21614/chirurgia.3154 [doi] AB - Introduction: Non-muscle-invasive bladder cancer (NMIBC) is common and heterogeneous, requiring risk-adapted therapeutic strategies. BCG remains standard for intermediate- and high-risk forms, but its effectiveness is influenced by limited access, variable tolerance, treatment resistance, and healthcare system disruptions. Material and Methods: This retrospective study aimed to identify prognostic factors for survival with an additional assessment of the influence of the COVID-19 pandemic. Although we could not directly evaluate the effect of COVID- 19 pandemic due to lack of recorded variables,we hypothesize it may have contributed to the limited impact of BCG therapy in our real-world setting. A total of 100 patients were selected from an initial group of 297 diagnosed in the Urology Clinic of Tg.Mures between 2006 - 2008, followed up until 2024. Prognostic analysis included clinical variables, RecScore and ProgScore were calculated using the EORTC risk calculator. No specific cut-offs were applied; the scores were analyzed as continuous variables. Results: Age over 70 and tumor multiplicity were significantly associated with increased mortality. RecScore was significantly correlated with the risk of relapse (p=0.0464). ProgScore showed a marginal association with mortality in univariate analysis (p=0.0561), but was not significant in multivariate models (p=0,9159). BCG therapy had a marginal protective effect, but did not significantly influence survival. Although we could not directly evaluate the effect of COVID-19 pandemic due to lack of recorded variables,we hypothesize that it may have contributed to treatment discontinuities in this real-life cohort. Conclusions: The results support the need for personalized, risk-based strategies and underline the importance of integrating real-world data into NMIBC management, especially in the context of systemic disruptions. CI - Celsius. FAU - Chiujdea, Sever AU - Chiujdea S FAU - Petrut, Bogdan AU - Petrut B FAU - Martha, Orsolya AU - Martha O FAU - Chiujdea, Ariana-Lisa AU - Chiujdea AL FAU - Porav-Hodade, Daniel AU - Porav-Hodade D FAU - Rachita, Anca Ioana AU - Rachita AI FAU - Sin, Anca AU - Sin A LA - eng PT - Journal Article PL - Romania TA - Chirurgia (Bucur) JT - Chirurgia (Bucharest, Romania : 1990) JID - 9213031 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/mortality/therapy/pathology/drug therapy MH - Male MH - Aged MH - Female MH - Prognosis MH - *BCG Vaccine/therapeutic use MH - *COVID-19/epidemiology MH - Middle Aged MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Risk Factors MH - Survival Rate MH - Treatment Outcome MH - Risk Assessment MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - NMIBC OT - intravesicaltherapy OT - prognosticfactors OT - recurrence OT - survival EDAT- 2025/09/04 18:34 MHDA- 2025/09/04 18:35 CRDT- 2025/09/04 15:54 PHST- 2025/08/01 00:00 [accepted] PHST- 2025/09/04 18:35 [medline] PHST- 2025/09/04 18:34 [pubmed] PHST- 2025/09/04 15:54 [entrez] AID - 11 [pii] AID - 10.21614/chirurgia.3154 [doi] PST - ppublish SO - Chirurgia (Bucur). 2025 Aug;120(4):459-466. doi: 10.21614/chirurgia.3154. PMID- 40899324 OWN - NLM STAT- MEDLINE DCOM- 20251117 LR - 20251215 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 39 IP - 11 DP - 2025 Nov TI - Outcome and Impact of Diagnostic Ureteroscopy in Clinically Suspected Upper Urinary Tract Carcinoma in Situ. PG - 1115-1124 LID - 10.1177/08927790251374291 [doi] AB - Objectives: To clarify disease behavior and oncological outcomes as well as the need for ureteroscopy (URS) implementation in patients with clinically suspected upper tract carcinoma in situ (UT-CIS). Patients and Methods: In this multi-institutional study, we retrospectively analyzed patients who met three criteria for clinically suspected UT-CIS between 2008 and 2018: positive high-grade cytology from the upper tract, absence of a solid upper tract lesion on imaging, and negative bladder biopsy. Patients who underwent URS were compared with those who did not. Kaplan-Meier curve was used to assess the natural history of treated UT-CIS and the prognostic impact of URS. Results: In total, 48 patients with clinically suspected UT-CIS were analyzed, of whom 27 (57%) had a previous history of urothelial carcinoma. Of 28 (58%) patients who underwent URS, pathologically confirmed UT-CIS and UT-non-CIS were detected in 7 (25%) and 6 (21%), respectively. As initial treatment, 23 (48%) patients received upper tract bacillus Calmette-Guerin, while 21 (44%) underwent radical nephroureterectomy (RNU). During a median follow-up of 44.8 months, the most common site that suffered recurrence and progression was the bladder (40% and 17%), followed by the affected (15% and 6%) and contralateral (8% and 4%) upper tract, respectively. Three-year overall, cancer-specific, upper tract-specific, progression-free (PFS), and recurrence-free survival estimates were 88.2%, 94.8%, 100%, 80.8%, and 52.4%, respectively. Survival outcomes were comparable regardless of URS implementation, with the exception of PFS. However, URS implementation resulted in an earlier transition to surgical intervention in 11% and avoided unnecessary RNU in 11%. Conclusions: UT-CIS is a pan-urothelial disease and frequently shows metachronous recurrence and progression in any part of the urinary tract, necessitating long-term, meticulous follow-up. Despite the lack of a statistical difference between patients with and without URS, we found that a non-negligible number of patients benefited from URS implementation. FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Sasaki, Katsumi AU - Sasaki K AD - Department of Urology, Kagawa Prefectural Central Hospital, Kagawa, Japan. FAU - Kusumi, Norihiro AU - Kusumi N AD - Department of Urology, National Hospital Organization Okayama Medical Center, Okayama, Japan. FAU - Fujita, Osamu AU - Fujita O AD - Department of Urology, Kagawa Rosai Hospital, Kagawa, Japan. FAU - Kurose, Kyohei AU - Kurose K AD - Department of Urology, Fukuyama City Hospital, Hiroshima, Japan. FAU - Ichikawa, Takaharu AU - Ichikawa T AD - Department of Urology, National Hospital Organization Okayama Medical Center, Okayama, Japan. FAU - Takenaka, Tadasu AU - Takenaka T AD - Department of Urology, Japanese Red Cross Okayama Hospital, Okayama, Japan. FAU - Hashimoto, Hideaki AU - Hashimoto H AD - Department of Urology, Okayama Central Hospital, Okayama, Japan. FAU - Nakada, Tetsuya AU - Nakada T AD - Department of Urology, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan. FAU - Arata, Ryoji AU - Arata R AD - Department of Urology, Kochi Health Sciences Center, Kochi, Japan. FAU - Uematsu, Katsutoshi AU - Uematsu K AD - Department of Urology, Mitoyo General Hospital, Kagawa, Japan. FAU - Yamamoto, Yasuo AU - Yamamoto Y AD - Department of Urology, Kurashiki Medical Center, Okayama, Japan. FAU - Nasu, Yoshitsugu AU - Nasu Y AD - Department of Urology, Okayama Rosai Hospital, Okayama, Japan. FAU - Tsugawa, Masaya AU - Tsugawa M AD - Department of Urology, Okayama City Hospital, Okayama, Japan. FAU - Yoshida, Takashi AU - Yoshida T AD - Department of Urology, Kansai Medical University, Osaka, Japan. FAU - Sekito, Takanori AU - Sekito T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Yoshinaga, Kasumi AU - Yoshinaga K AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Yamanoi, Tomoaki AU - Yamanoi T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Tominaga, Yusuke AU - Tominaga Y AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Sadahira, Takuya AU - Sadahira T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Iwata, Takehiro AU - Iwata T AUID- ORCID: 0000-0001-6116-543X AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Nishimura, Shingo AU - Nishimura S AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Bekku, Kensuke AU - Bekku K AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Edamura, Kohei AU - Edamura K AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Kobayashi, Tomoko AU - Kobayashi T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Kobayashi, Yasuyuki AU - Kobayashi Y AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Watanabe, Toyohiko AU - Watanabe T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Araki, Motoo AU - Araki M AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. CN - Okayama Urological Research Group (OURG) LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250903 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Humans MH - *Ureteroscopy MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma in Situ/diagnosis/diagnostic imaging/surgery/pathology MH - Treatment Outcome MH - Retrospective Studies MH - *Urologic Neoplasms/diagnosis/diagnostic imaging MH - Aged, 80 and over MH - Kaplan-Meier Estimate MH - Adult OTO - NOTNLM OT - BCG OT - biopsy OT - survival OT - upper tract carcinoma in situ OT - upper urinary tract OT - ureteroscopy EDAT- 2025/09/03 06:36 MHDA- 2025/11/17 18:27 CRDT- 2025/09/03 05:14 PHST- 2025/11/17 18:27 [medline] PHST- 2025/09/03 06:36 [pubmed] PHST- 2025/09/03 05:14 [entrez] AID - 10.1177/08927790251374291 [doi] PST - ppublish SO - J Endourol. 2025 Nov;39(11):1115-1124. doi: 10.1177/08927790251374291. Epub 2025 Sep 3. PMID- 40892146 OWN - NLM STAT- MEDLINE DCOM- 20260225 LR - 20261009 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 3 DP - 2026 Mar TI - Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors. PG - 921-929 LID - 10.1007/s11255-025-04734-5 [doi] AB - PURPOSE: Postoperative bleeding is a known complication following transurethral resection of bladder tumors (TURBT). Although factors like tumor size and anticoagulant use are associated with increased bleeding risk, no validated prediction tool currently exists. This study aimed to determine predictors and develop a clinical tool for preoperative bleeding risk assessment. METHODS: We conducted a retrospective analysis of patients undergoing TURBT at the University Hospital of Zurich between January 2016 and November 2022. Bleeding events were defined by four criteria: hemoglobin drop of >/= 4 g/dl, need for transfusion, gross hematuria requiring prolonged irrigation, or surgical revision for bleeding during hospitalization or within 2 weeks after dischargement. RESULTS: During this time period, 447 TURBTs were performed, of which 54 (12.1%) were associated with a bleeding event. Univariable logistic regression identified five significant predictors (p value < 0.05): HAS-BLED score, high-risk alcohol consumption, use of oral anticoagulant and/or platelet aggregation inhibitors, and bridging therapy. In the multivariable logistic regression model, only high-risk alcohol consumption and platelet aggregation inhibitors remained statistically significant (p value < 0.05). All predictors had positive coefficients, indicating increased bleeding risk. A nomogram was developed based on these variables to assist in preoperative risk assessment. The model showed good calibration (Brier score = 0.097) and strong overall fit (Likelihood Ratio Test: chi(2) = 31.08, df = 5, p < 0.0001). CONCLUSION: We developed a predictive model for bleeding risk after TURBT. This tool may support perioperative management, by raising awareness of risk factors for bleeding complications and enabling tailored interventions for at-risk patients. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Pellegrino, Paloma AU - Pellegrino P AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. palomamina.pellegrino@gmail.com. FAU - Scherer, Thomas Paul AU - Scherer TP AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Wettstein, Marian Severin AU - Wettstein MS AD - Department of Surgery, Division of Urology, University of Toronto, Toronto, Canada. FAU - Baumgartner, Melanie AU - Baumgartner M AD - Mobiliar Lab for Analytics, Department Management, Technology, and Economics, ETH Zurich, Zurich, Switzerland. FAU - Eberli, Daniel AU - Eberli D AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, City Hospital Triemli of Zurich, Zurich, Switzerland. FAU - Bieri, Uwe AU - Bieri U AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. AD - Department of Surgery, Division of Urology, Kantonsspital Baden, Baden, Switzerland. LA - eng PT - Journal Article DEP - 20250902 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Nomograms MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery MH - Male MH - Female MH - Aged MH - *Postoperative Hemorrhage/etiology/epidemiology/diagnosis MH - Middle Aged MH - Risk Assessment/methods MH - *Cystectomy/methods/adverse effects MH - Predictive Value of Tests MH - Aged, 80 and over MH - Urethra OTO - NOTNLM OT - Bleeding risk OT - Nomogram OT - Postoperative OT - TURBT COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Cantonal Ethics Committee of Zurich (BASEC-Nr.: 2022-00988). EDAT- 2025/09/02 22:24 MHDA- 2026/02/25 13:36 CRDT- 2025/09/02 11:08 PHST- 2025/06/18 00:00 [received] PHST- 2025/08/10 00:00 [accepted] PHST- 2026/02/25 13:36 [medline] PHST- 2025/09/02 22:24 [pubmed] PHST- 2025/09/02 11:08 [entrez] AID - 10.1007/s11255-025-04734-5 [pii] AID - 10.1007/s11255-025-04734-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Mar;58(3):921-929. doi: 10.1007/s11255-025-04734-5. Epub 2025 Sep 2. PMID- 40891474 OWN - NLM STAT- MEDLINE DCOM- 20250902 LR - 20251023 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 77 IP - 4 DP - 2025 Aug TI - The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper. PG - 443-450 LID - 10.23736/S2724-6051.25.06361-X [doi] AB - Photodynamic diagnosis (PDD) significantly enhances the detection of bladder cancer (BCa) and is able to reduce the risk of disease recurrence, although it may not affect disease progression and mortality rates. Despite its advantages, widespread adoption of PDD is limited by cost considerations and the absence of unified guidelines on its application, highlighting the need for continued evaluation of its cost-effectiveness across different healthcare settings. To date, no specific recommendations for PDD in non-muscle invasive bladder cancer (NMIBC) management have been provided by the Italian Society of Urology (Societa Italiana di Urologia, SIU). Therefore, the aim of this paper is to report on the position of SIU on the role of PDD in NMIBC. According to available evidence and international guidelines (i.e., European Association of Urology, American Association of Urology, National Comprehensive Cancer Network and other national guidelines) on BCa, a Panel of twelve Italian urologists with long and renowned experience in treating BCa defined current indications for PDD in the management of NMIBC. The final document was ultimately reviewed and approved by the expert Panel prior to publication. The consensus highlighted the role of PDD during the initial transurethral resection of the bladder (TURB) to detect carcinoma in situ (CIS) and small papillary lesions that might otherwise be missed, leading to disease persistence. Additionally, in clinical scenarios such as positive urine cytology with negative cystoscopy, PDD-guided biopsies can significantly increase the detection of CIS. For cases involving larger or multifocal tumors, or atypical macroscopic features during cystoscopy, PDD is valuable for identifying subtle high-grade disease elements, thereby facilitating more precise risk stratification and targeted treatment planning. In the setting of re-TURB, aiming to detect the presence and extent of concomitant CIS and to gain all possible additional information, PDD may be used in all procedures if not already performed during initial resection. Finally, PDD may be used for disease recurrence in patients with a history of HG NMIBC and to evaluate the response of CIS to Bacillus Calmette-Guerin (BCG). This position paper of the SIU highlights the current recommendation for the use of PDD in the management of NMIBC, from initial TURB, to re-TURB and follow-up. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Citta della Salute e della Scienza, Turin, Italy - francesco.soria@unito.it. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Naspro, Richard AU - Naspro R AD - Unit of Urology, Fondazione IRCCS San Matteo Polyclinic, Pavia, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Miglioranza, Eugenio AU - Miglioranza E AD - Department of Urology, IRCCS Veneto Institute of Oncology (IOV), Headquarter of Castelfranco Veneto, Treviso, Italy. FAU - Lapini, Alberto AU - Lapini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona (AOUI-Vr), Verona, Italy. FAU - Tubaro, Andrea AU - Tubaro A AD - Department of Urology, Sapienza University, Rome, Italy. FAU - Volpe, Alessandro AU - Volpe A AD - Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carita Hospital, Novara, Italy. FAU - Bartoletti, Riccardo AU - Bartoletti R AD - Unit of Urology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Citta della Salute e della Scienza, Turin, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy. FAU - Ficarra, Vincenzo AU - Ficarra V AD - Urologic Section, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. AD - Urologic Section, Department of Oncology, AOU G. Martino, Messina, Italy. LA - eng PT - Journal Article PT - Practice Guideline PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) SB - IM CIN - Minerva Urol Nephrol. 2025 Oct;77(5):718-720. doi: 10.23736/S2724-6051.25.06711-4. PMID: 41128042 MH - Humans MH - Aminolevulinic Acid MH - Cystoscopy/methods MH - Italy MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms MH - Photosensitizing Agents MH - Societies, Medical MH - *Urinary Bladder Neoplasms/pathology/diagnosis/therapy/diagnostic imaging MH - Urology EDAT- 2025/09/02 22:21 MHDA- 2025/09/02 22:22 CRDT- 2025/09/02 06:20 PHST- 2025/09/02 22:22 [medline] PHST- 2025/09/02 22:21 [pubmed] PHST- 2025/09/02 06:20 [entrez] AID - S2724-6051.25.06361-X [pii] AID - 10.23736/S2724-6051.25.06361-X [doi] PST - ppublish SO - Minerva Urol Nephrol. 2025 Aug;77(4):443-450. doi: 10.23736/S2724-6051.25.06361-X. PMID- 40883258 OWN - NLM STAT- MEDLINE DCOM- 20260110 LR - 20260918 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 2 DP - 2026 Feb TI - Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy. PG - 270-281 LID - 10.1111/bju.16913 [doi] AB - OBJECTIVE: To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high-grade (T1HG) non-muscle-invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette-Guerin (BCG) immunotherapy. PATIENTS AND METHODS: This multi-institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed. RESULTS: Cure fractions were 41% (95% confidence interval [CI] 36%-46%) for RFS, 71% (95% CI 65%-76%) for PFS, 76% (95% CI 70%-83%) for CSS, and 38% (95% CI 28%-49%) for OS. Patients in very-high-risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%-72%]) and CSS (59% [95% CI 34-84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5-year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event-free at 5 years from diagnosis. CONCLUSIONS: We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle-invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event-free for 5 years. CI - (c) 2025 BJU International. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - de la Parra, Irene AU - de la Parra I AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Taborda, Javier AU - Taborda J AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Medina, Alberto Artiles AU - Medina AA AUID- ORCID: 0000-0003-0930-0344 AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Ojeda, Cesar Minguez AU - Ojeda CM AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Mardomingo, Ana Fernandez AU - Mardomingo AF AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Duran, Pedro Del Olmo AU - Duran PDO AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Perez, Enrique Lopez AU - Perez EL AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Gonzalez-Padilla, Daniel A AU - Gonzalez-Padilla DA AUID- ORCID: 0000-0002-5853-8845 AD - Department of Urology, Clinica Universidad de Navarra, Madrid, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Mostoles, Madrid, Spain. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Cano-Velasco, Jorge AU - Cano-Velasco J AD - Department of Urology, Hospital Universitario Gregorio Maranon, Madrid, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Hospital Universitario Gregorio Maranon, Madrid, Spain. FAU - Pujol, Lucia Polanco AU - Pujol LP AD - Department of Urology, Hospital Universitario Gregorio Maranon, Madrid, Spain. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Milan, Italy. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Institute of Health Sciences, Opole University, Opole, Poland. AD - University Clinical Hospital in Opole, Opole, Poland. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, SAR, China. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, McGill University Health Centre, Montreal, QC, Canada. AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. AD - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, Lille, France. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Tully, Karl AU - Tully K AUID- ORCID: 0000-0002-9499-0169 AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Department of Clinical and Experimental Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology - Careggi Hospital, University of Florence, Florence, Italy. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - ROC Clinic, Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Martin, Carlos Casanova AU - Martin CC AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Melendres, Franklin Anagua AU - Melendres FA AD - Department of Urology, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain. FAU - Buisan, Oscar AU - Buisan O AD - Department of Urology, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain. FAU - Lopez-Gonzalez, Jose Agustin AU - Lopez-Gonzalez JA AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Dominguez-Escrig, Jose Luis AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Elena, Jose Luis Rodriguez AU - Elena JLR AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Basile, Giuseppe AU - Basile G AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Santos, Victoria Gomez Dos AU - Santos VGD AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Acosta, Eduardo Albers AU - Acosta EA AD - Department of Urology, La Princesa University Hospital, IIS Princesa, Autonomous University of Madrid, Madrid, Spain. FAU - Palacio, Fernando Lozano AU - Palacio FL AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Puig, Albert Carrion AU - Puig AC AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Gajate, Pablo AU - Gajate P AD - Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. FAU - Saiz, Ana AU - Saiz A AUID- ORCID: 0000-0001-7110-450X AD - Pathology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Revilla, Francisco Javier Burgos AU - Revilla FJB AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. CN - From Young Academic Urologist: Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250829 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy/drug therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - *Immunotherapy/methods MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Neoplasm Grading MH - Treatment Outcome MH - Progression-Free Survival OTO - NOTNLM OT - BCG immunotherapy OT - cure fraction OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence EDAT- 2025/08/30 00:44 MHDA- 2026/01/10 06:31 CRDT- 2025/08/29 23:03 PHST- 2026/01/10 06:31 [medline] PHST- 2025/08/30 00:44 [pubmed] PHST- 2025/08/29 23:03 [entrez] AID - 10.1111/bju.16913 [doi] PST - ppublish SO - BJU Int. 2026 Feb;137(2):270-281. doi: 10.1111/bju.16913. Epub 2025 Aug 29. PMID- 40883237 OWN - NLM STAT- MEDLINE DCOM- 20250829 LR - 20250829 IS - 0126-8635 (Print) IS - 0126-8635 (Linking) VI - 47 IP - 2 DP - 2025 Aug TI - Risk stratification of pT1b urothelial carcinoma based on spatial relationships between invasive tumour and muscularis propria on TURB specimens for predicting muscle-invasive urothelial carcinoma in radical cystectomy: A new proposal. PG - 247-252 AB - INTRODUCTION: In bladder cancer, the presence of lamina propria invasion (pT1) poses a significant clinical challenge due to varied tumour behaviours and risk of disease progression. Efforts to substage pT1 urothelial carcinoma (UC) using diverse systems have been made, but challenges persist in accurately predicting disease progression. This study introduces a novel risk stratification approach focusing on pT1b UC cases based on the spatial relationship between invasive carcinoma and the muscularis propria (MP) in transurethral resection of bladder (TURB) specimens. MATERIALS AND METHODS: Retrospective analysis of pathology reports from 2017 to 2023 identified pT1 cases in TURB specimens, subcategorised using a 2-tiered approach. Exclusions were applied based on specific criteria, leading to a final cohort of 24 patients. We evaluated the tumour diameter and proximity to the MP from a "Tumour-MP (T-M) angle" perspective. A novel pT1b risk stratification method focusing on the T-M angle to differentiate low- and high-risk groups was developed, in which pT1b low-risk is defined as a T-M angle less than 180 degrees, and pT1b high-risk is defined as a T-M angle greater than 180 degrees. RESULTS: In this study of 24 pT1b UC cases, 16 were categorised as pT1b low-risk and 8 as pT1b high-risk. Notably, the high-risk group showed a higher upstaging rate to advanced tumour stages (>/=pT2) in radical cystectomy (RC) specimens compared to the low-risk group (88% vs. 56%, p = 0.015). CONCLUSION: This new risk stratification method presents promise in guiding early aggressive treatment decisions, though larger prospective studies are essential for further validation and clinical integration. FAU - Kim, J M AU - Kim JM AD - Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Department of Pathology, Seoul, Republic of Korea. FAU - Park, S AU - Park S AD - Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Department of Pathology, Seoul, Republic of Korea. spark0430@ewha.ac.kr. LA - eng PT - Journal Article PL - Malaysia TA - Malays J Pathol JT - The Malaysian journal of pathology JID - 8101177 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Cystectomy/methods MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Risk Assessment/methods MH - Neoplasm Invasiveness/pathology MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Neoplasm Staging MH - Mucous Membrane/pathology MH - Aged, 80 and over EDAT- 2025/08/30 00:44 MHDA- 2025/08/30 00:45 CRDT- 2025/08/29 22:53 PHST- 2025/08/30 00:45 [medline] PHST- 2025/08/30 00:44 [pubmed] PHST- 2025/08/29 22:53 [entrez] PST - ppublish SO - Malays J Pathol. 2025 Aug;47(2):247-252. PMID- 40870446 OWN - NLM STAT- MEDLINE DCOM- 20250828 LR - 20250831 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 8 DP - 2025 Aug 1 TI - Microbiome Shifts in Bladder Cancer: A Narrative Review of Urobiome Composition, Progression, and Therapeutic Impact. LID - 10.3390/medicina61081401 [doi] LID - 1401 AB - Background/Objectives: Bladder cancer is a common malignancy with a high rate of recurrence and progression. Recent studies have identified that the urinary microbiome can be a key factor in tumor pathogenesis, progression, and outcomes. This narrative review is designed to summarize current evidence regarding the urobiome and explore its diagnostic and therapeutic potential. Methods: Studies between 2019 and 2024 were identified through the PubMed/MEDLINE and Google Scholar databases. Case reports and non-English-language articles were excluded. Results: The main findings revealed that specific bacteria, viruses, and taxa are linked to bladder cancer presence, progression, and response to immunotherapy treatment. Urinary microbiota differ by tumor type, sex, smoking status, and occupational exposure to toxins. Conclusions: Urinary microbiome and certain types of viruses present in urine may serve as promising tools to enhance bladder cancer diagnosis and predict treatment response. However, larger longitudinal studies are needed to confirm and establish these findings. Furthermore, integration of the urinary microbiome in clinical practice and public health strategies may reduce disease-related burden. FAU - Gherasim, Raul-Dumitru AU - Gherasim RD AUID- ORCID: 0009-0002-4778-380X AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Chibelean, Calin AU - Chibelean C AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Porav-Hodade, Daniel AU - Porav-Hodade D AUID- ORCID: 0009-0003-4279-673X AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Todea-Moga, Ciprian AU - Todea-Moga C AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Tataru, Sabin-Octavian AU - Tataru SO AUID- ORCID: 0000-0001-7057-7815 AD - Institution Organizing University Doctoral Studies, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania. FAU - Reman, Tibor-Lorand AU - Reman TL AUID- ORCID: 0009-0005-8009-3482 AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Vida, Arpad-Oliver AU - Vida AO AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Ghirca, Maria-Veronica AU - Ghirca MV AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. FAU - Ferro, Matteo AU - Ferro M AD - Unit of Urology, Department of Health Science, Faculty of Medicine, University of Milan, ASST Santi Paolo and Carlo, 20122 Milan, Italy. FAU - Martha, Orsolya Katalyn Ilona AU - Martha OKI AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department of Urology, Targu Mures Clinical Hospital, P-ta Bernady Gyorgy, Nr. 6, 540072 Tirgu-Mures, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250801 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/microbiology/therapy MH - *Microbiota/physiology MH - Disease Progression PMC - PMC12388085 OTO - NOTNLM OT - bladder cancer OT - intravesical therapy OT - microbial biomarkers OT - public health burden OT - urinary microbiome COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:50 MHDA- 2025/08/30 04:51 PMCR- 2025/08/01 CRDT- 2025/08/28 01:15 PHST- 2025/06/25 00:00 [received] PHST- 2025/07/22 00:00 [revised] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/08/30 04:51 [medline] PHST- 2025/08/30 04:50 [pubmed] PHST- 2025/08/28 01:15 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - medicina61081401 [pii] AID - medicina-61-01401 [pii] AID - 10.3390/medicina61081401 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Aug 1;61(8):1401. doi: 10.3390/medicina61081401. PMID- 40868379 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2306-5354 (Print) IS - 2306-5354 (Electronic) IS - 2306-5354 (Linking) VI - 12 IP - 8 DP - 2025 Aug 12 TI - Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A Critical Review. LID - 10.3390/bioengineering12080866 [doi] LID - 866 AB - Non-muscle invasive bladder cancer (NMIBC) accounts for about 75% of new bladder cancer diagnoses. Early detection improves survival, yet routine white-light cystoscopy is invasive, costly, and can miss up to 45% of flat or small lesions. These shortcomings have prompted development of label-free diagnostic tools that read the intrinsic optical, electrical, or mechanical signatures of urinary biomarkers without added labels. This review examines recent engineering advances in such platforms for NMIBC detection, focusing on analytical performance, readiness for clinical translation, and remaining barriers to adoption. We compare each technology with conventional cytology using key metrics such as limit of detection, diagnostic accuracy, analysis time, cohort size, and stage of clinical development. Surface-enhanced Raman spectroscopy and interferometric flow cytometry offer femtomolar sensitivity and more than 98% accuracy within minutes, while compact electrochemical sensors targeting NMP22, Galectin-1, and microRNAs reach sub-picogram levels on disposable chips. Standardized sample handling, multicenter validation, and robust cost-effectiveness data are now essential for these tools to advance point-of-care NMIBC surveillance. FAU - Vera, Gabriela AU - Vera G AUID- ORCID: 0009-0008-4681-5826 AD - Servicio de Urologia, Complejo Asistencial Dr. Sotero del Rio, Santiago 8150215, Chile. FAU - Cerda-Infante, Javier AU - Cerda-Infante J AD - Environ SPA, Santiago 7750000, Chile. FAU - Fernandez, Mario I AU - Fernandez MI AUID- ORCID: 0000-0001-6424-4977 AD - Departamento de Urologia, Clinica Alemana Universidad del Desarrollo, Santiago 7610315, Chile. FAU - Sanchez-Encinas, Miguel AU - Sanchez-Encinas M AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, 28933 Madrid, Spain. AD - Facultad Ciencias de la Salud, Universidad Rey Juan Carlos, 28933 Madrid, Spain. AD - Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), 28040 Madrid, Spain. FAU - Rojas, Pablo A AU - Rojas PA AUID- ORCID: 0009-0009-1854-8334 AD - Servicio de Urologia, Complejo Asistencial Dr. Sotero del Rio, Santiago 8150215, Chile. AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, 28933 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20250812 PL - Switzerland TA - Bioengineering (Basel) JT - Bioengineering (Basel, Switzerland) JID - 101676056 PMC - PMC12383690 OTO - NOTNLM OT - Raman spectroscopy OT - SERS OT - electrochemical biosensor OT - interferometric flow cytometry OT - label-free biosensors OT - non-muscle invasive bladder cancer OT - urinary biomarkers COIS- Author Javier Cerda-Infante was employed by the company Environ SPA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/30 04:48 MHDA- 2025/08/30 04:49 PMCR- 2025/08/12 CRDT- 2025/08/28 01:08 PHST- 2025/06/26 00:00 [received] PHST- 2025/07/25 00:00 [revised] PHST- 2025/07/31 00:00 [accepted] PHST- 2025/08/30 04:49 [medline] PHST- 2025/08/30 04:48 [pubmed] PHST- 2025/08/28 01:08 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - bioengineering12080866 [pii] AID - bioengineering-12-00866 [pii] AID - 10.3390/bioengineering12080866 [doi] PST - epublish SO - Bioengineering (Basel). 2025 Aug 12;12(8):866. doi: 10.3390/bioengineering12080866. PMID- 40867253 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 16 DP - 2025 Aug 11 TI - Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells Exposed to Hypoxia. LID - 10.3390/cancers17162624 [doi] LID - 2624 AB - INTRODUCTION: Hypoxic cancers are radioresistant, but biomarkers based on expression of multiple genes can identify patients who will benefit from hypoxia modification. Most studies identifying relevant genes exposed cells in culture to 1% oxygen, which activates hypoxia-inducible factor (HIF). However, oxygen concentrations in hypoxic tumours are heterogeneous ranging from <0.1%. As lower oxygen levels would likely affect transcriptional responses, we aimed to investigate how gene selection at different oxygen levels affects the genes identified and their prognostic capability. METHODS: Four MIBC (J82, T24, UMUC3, HT1376) and two non-MIBC (RT4, RT112) bladder cancer cell lines were exposed to varying oxygen levels (20%, 1%, 0.2% and 0.1% O(2)) for 24 h and were then harvested and frozen. RNA was extracted and transcriptomes analysed using Clariom S microarrays. Differences in gene expression were investigated. Prognostic and predictive significance of a published 24-gene signature was compared with one generated from genes identified at lower oxygen levels. RESULTS: The number of upregulated genes increased with decreasing O(2) level. The number of biological pathways involved also increased. Differences between cell lines dominated those due to hypoxia. Some genes were commonly upregulated in MIBC and NMIBC cells and others increased exclusively in either MIBC or NMIBC cells. The median expression of a published 24-gene bladder cancer hypoxia-associated signature increased with decreasing oxygen levels. Seventy-seven genes were upregulated in at least three cell lines by exposure to 0.1% O(2). The median expression of the 77 genes was of borderline prognostic significance in the bladder cancer cohort in the TCGA (The Cancer Genome Atlas). Five of the seventy-seven genes upregulated by hypoxia were present in the twenty-four-gene bladder hypoxia signature. The median expression of the 5 genes demonstrated identical prognostication to the 24-gene signature but failed to predict benefit from hypoxia modification. CONCLUSIONS: The number of genes upregulated by exposure of bladder cancer cells to hypoxia increases as O(2) level is decreased from 1% to 0.2% to 0.1%. Differential upregulation of gene expression by MIBC and NMIBC cells and the associated biological pathways may be useful in understanding the genetics of bladder cancer invasiveness. Based on a search of the literature, this is the first study that assessed the expression of genes in bladder cancer using three hypoxic concentration levels to identify biomarkers for disease progression and prognosis among differentially expressed bladder cancer genes. FAU - Shabbir, Rekaya AU - Shabbir R AUID- ORCID: 0009-0000-1066-145X AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. FAU - Quiles, Conrado G AU - Quiles CG AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. FAU - Lane, Brian AU - Lane B AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. FAU - Zeef, Leo AU - Zeef L AUID- ORCID: 0000-0003-2833-7847 AD - Bioinformatics Core Facility, University of Manchester, Manchester M13 6PT, UK. FAU - Hoskin, Peter J AU - Hoskin PJ AUID- ORCID: 0000-0001-8323-9567 AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. AD - Christie Hospital NHS Trust, Manchester M20 4BX, UK. FAU - Choudhury, Ananya AU - Choudhury A AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. AD - Christie Hospital NHS Trust, Manchester M20 4BX, UK. FAU - West, Catharine M L AU - West CML AUID- ORCID: 0000-0002-0839-3449 AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. FAU - Smith, Tim A D AU - Smith TAD AUID- ORCID: 0000-0002-3945-630X AD - Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. AD - Nuclear Futures Institute, School of Computer Sciences and Engineering, Bangor LL57 1UT, UK. LA - eng GR - [KSP12018294/1440-7582-2]./Ministry of Higher Education and the Ministry of Health, Saudi Arabian Government (Riyadh, Saudi Arabia) and the Saudi Arabian Cultural Bureau (London, United Kingdom),/ PT - Journal Article DEP - 20250811 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12384837 OTO - NOTNLM OT - bladder cancer OT - hypoxia OT - signature biomarker OT - transcriptome COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:47 MHDA- 2025/08/30 04:48 PMCR- 2025/08/11 CRDT- 2025/08/28 01:02 PHST- 2025/06/26 00:00 [received] PHST- 2025/07/29 00:00 [revised] PHST- 2025/08/06 00:00 [accepted] PHST- 2025/08/30 04:48 [medline] PHST- 2025/08/30 04:47 [pubmed] PHST- 2025/08/28 01:02 [entrez] PHST- 2025/08/11 00:00 [pmc-release] AID - cancers17162624 [pii] AID - cancers-17-02624 [pii] AID - 10.3390/cancers17162624 [doi] PST - epublish SO - Cancers (Basel). 2025 Aug 11;17(16):2624. doi: 10.3390/cancers17162624. PMID- 40877645 OWN - NLM STAT- MEDLINE DCOM- 20260225 LR - 20261009 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 3 DP - 2026 Mar TI - Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer. PG - 895-903 LID - 10.1007/s11255-025-04767-w [doi] AB - PURPOSE: To evaluate different protocols to increase the efficacy and reliability of single, immediate intravesical postoperative chemotherapy (IPOC) after transurethral bladder tumour resection (TURBT). METHODS: A retrospective evaluation was made of 104 patients, who underwent TURBT between October 2020 and October 2022, and were subsequently administered IPOC. The patients were examined in two groups as infusion IPOC (n:50) and bolus IPOC (n:54). In the infusion IPOC group, 50 mg epirubicin in 100 mL saline was administered intravesically in 30 min as an infusion with gravity. In the bolus IPOC group, 50 mg epirubicin in 50 mL saline was administered intravesically as a bolus with a catheter-type syringe. Preoperative information was recorded, including age, gender, body mass index (BMI), ASA score, smoking status, primary tumour, and previous IPOC, and postoperative information, including number, size, stage, and grade of tumour, the presence of detrusor muscle in the specimen, prognostic risk group, and second TURB. The two groups were compared with respect to dysuria, urgency, pain (VAS score), IPOC discontinuation, tumour recurrence rate, and recurrence-free survival (RFS). RESULTS: No statistically significant difference was determined between the groups with respect to age, gender, BMI, ASA score, smoking status, presence of primary tumour, number and size of tumours, the presence of detrusor muscle in the specimen, stage and grade of tumour, prognostic risk group, second TURB, and previous IPOC (p > 0.05 for all). The VAS score for pain/bladder irritation was determined to be statistically significantly lower at 2.3 +/- 1.8 in the infusion IPOC group compared to 3.1 +/- 2.2 in the bolus IPOC group (p = 0.01). The discontinuation rate of 10.0% was statistically significantly lower in the infusion IPOC group compared to the 25.9% rate determined in the bolus group (p = 0.04). Although the RFS rate was higher in the infusion IPOC group in all the NMIBC patients (p = 0.4) and in the low-risk NMIBC subgroup (p = 0.1), no significant difference was found. In the low-risk NMIBC, the 3-month recurrence rate was 3.3% in the infusion IPOC group and 20.5% in the bolus group, and thus the infusion protocol was observed to have significantly reduced early recurrence (p = 0.04). CONCLUSION: The results of this study showed that an infusion IPOC protocol demonstrated reliability, efficacy, and applicability, which decreased bladder irrigation and treatment discontinuation rates while also reducing early recurrence. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Yildiz, Ali Kaan AU - Yildiz AK AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. alikaan.yildiz@sbu.edu.tr. AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. alikaan.yildiz@sbu.edu.tr. FAU - Bayraktar, Arif AU - Bayraktar A AD - Department of Urology, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Kacan, Turgay AU - Kacan T AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. FAU - Demir, Demirhan Orsan AU - Demir DO AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. FAU - Gokkurt, Yusuf AU - Gokkurt Y AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. FAU - Erbay, Omer Furkan AU - Erbay OF AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. FAU - Keseroglu, Bugra Bilge AU - Keseroglu BB AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. FAU - Ozgur, Berat Cem AU - Ozgur BC AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. AD - Department of Urology, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Doluoglu, Omer Gokhan AU - Doluoglu OG AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. AD - Department of Urology, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Karakan, Tolga AU - Karakan T AD - Department of Urology, University of Health Sciences, Ankara City Hospital, Universiteler Mahallesi 1604. Cadde No: 9 Cankaya, 06800, Ankara, Turkey. AD - Department of Urology, Ankara City Hospital, Ankara, Turkey. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250828 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 3Z8479ZZ5X (Epirubicin) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/drug therapy MH - Retrospective Studies MH - Male MH - Administration, Intravesical MH - Female MH - Aged MH - Middle Aged MH - *Epirubicin/administration & dosage MH - Neoplasm Invasiveness MH - *Cystectomy/methods MH - Chemotherapy, Adjuvant/methods MH - *Antibiotics, Antineoplastic/administration & dosage MH - Postoperative Care/methods MH - Clinical Protocols MH - Time Factors MH - Urethra MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Immediate OT - Intravesical OT - Postoperative OT - Single COIS- Declarations. Conflict of interests: The authors declare no competing interests. EDAT- 2025/08/29 00:45 MHDA- 2026/02/25 13:37 CRDT- 2025/08/28 23:41 PHST- 2025/07/07 00:00 [received] PHST- 2025/08/23 00:00 [accepted] PHST- 2026/02/25 13:37 [medline] PHST- 2025/08/29 00:45 [pubmed] PHST- 2025/08/28 23:41 [entrez] AID - 10.1007/s11255-025-04767-w [pii] AID - 10.1007/s11255-025-04767-w [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Mar;58(3):895-903. doi: 10.1007/s11255-025-04767-w. Epub 2025 Aug 28. PMID- 40865937 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260130 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 12 DP - 2025 Dec 1 TI - Comparative outcomes and prognosis in patients with ureteral upper tract urothelial carcinoma undergoing segmental ureterectomy versus radical nephroureterectomy: a multicenter cohort study. PG - 8818-8836 LID - 10.1097/JS9.0000000000003292 [doi] AB - BACKGROUND: Although radical nephroureterectomy (RNU) with bladder cuff excision remains the gold standard treatment for upper tract urothelial carcinoma (UTUC), segmental ureterectomy (SU) may offer a nephron-sparing alternative. Studies comparing oncologic outcomes and renal functional outcomes between SU and RNU have yielded controversial, often conflicting results. Furthermore, investigations specifically involving ureteral UTUC patients in northern China are scarce. METHODS: We retrospectively enrolled 546 ureteral urothelial carcinoma patients (282 SU and 264 RNU cases) from three hospitals between October 2003 and September 2024 to assess overall survival (OS) and intravesical recurrence-free survival (IV-RFS) as oncologic outcomes, and to evaluate renal functional outcomes (preoperative, postoperative [2-month] and delta change in estimated glomerular filtration rate [eGFR] and serum creatinine [Scr]). The prognostic impact of surgical approach and clinicopathological variables were evaluated using Kaplan-Meier analysis with log-rank tests and Cox regression models. Significant predictors were incorporated into a validated nomogram for personalized 3-, 4-, and 5-year OS and IV-RFS probability estimation. Furthermore, eight machine learning algorithms (Lasso Cox, random survival forest [RSF], CoxBoost, generalized boosted regression modeling [GBM], support vector machine [Survival-SVM], eXtreme Gradient Boosting [XGBoost], supervised principal components [SuperPC], and partial least squares regression for Cox [plsRcox]) were implemented for OS and IV-RFS prediction modeling. Finally, we quantitatively pooled our cohort data with literature evidence retrieved from major databases (PubMed, Cochrane, Embase, Web of Science) up to 21 May 2025, to compare survival and renal function outcomes between the two procedures using Stata 14.0. Subgroup assessments and leave-one-out sensitivity analyses were performed to address potential confounding factors related to heterogeneity. RESULTS: Firstly, the multicenter retrospective cohort study revealed that SU was associated with reduced IV-RFS and was identified as a significant independent predictor of IV-RFS (HR = 1.48; P = 0.02). Meanwhile, there was no significant difference in OS between SU and RNU. Algorithm comparison confirmed optimal discriminative performance for IV-RFS (3-year AUC: 0.771, 4-year: 0.758, 5-year: 0.761) and OS (3-year AUC: 0.739, 4-year: 0.726, 5-year: 0.710). Decision curve analysis demonstrated the excellent clinical applicability of the nomograms for OS and IV-RFS, which enhanced model precision and clinical utility. Furthermore, in the meta-analysis, 21 studies including 31 293 patients were selected for inclusion, spanning publication years from 2010 to 2025. Regarding survival outcomes, although no statistically significant differences were observed in OS risk ( P = 0.696), CSS risk ( P = 0.765), or RFS ( P = 0.072) between patients receiving SU and those undergoing RNU, SU was associated with lower IV-RFS compared to RNU (HR = 1.21, P = 0.019). Subgroup analysis stratified by geographic region revealed significantly reduced OS with SU versus RNU in European cohorts (HR = 1.24, P = 0.001). Concerning renal functional outcomes, the SU group demonstrated significantly higher postoperative eGFR (WMD, 14.16 mL/min; P < 0.001) and greater delta change in eGFR (WMD, 11.78 mL/min; P < 0.001). CONCLUSION: SU achieves cancer-specific and overall survival comparable to RNU, even in high-grade ureteral UTUC, while significantly improving postoperative renal function. However, it necessitates multidisciplinary management of intravesical recurrence risk. Validation of molecular predictors and prospective trials in advanced disease are essential to further expand and validate the therapeutic landscape of SU. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yu, Ailing AU - Yu A AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, Liaoning Province, China. AD - First Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Meng, Xianfeng AU - Meng X AD - Department of Urology, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China. FAU - Hou, Zhaonan AU - Hou Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, Liaoning Province, China. FAU - Du, Xiaochen AU - Du X AD - College of Humanities and Social Sciences, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Chen, Mengxin AU - Chen M AD - Second Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Zong, Xiaowen AU - Zong X AD - First Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Chen, Yihao AU - Chen Y AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. FAU - Wang, Minjie AU - Wang M AD - Second Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Dai, Ruihang AU - Dai R AD - Second Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Li, Yanze AU - Li Y AD - First Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Li, Zixuan AU - Li Z AD - Second Clinical College, Dalian Medical University, Dalian, Liaoning Province, China. FAU - Dong, Pei AU - Dong P AD - Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Center; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China. FAU - Fan, Bo AU - Fan B AUID- ORCID: 0000-0001-6598-3237 AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, Liaoning Province, China. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20250826 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Retrospective Studies MH - Male MH - Female MH - *Ureteral Neoplasms/surgery/mortality MH - Aged MH - Middle Aged MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery/mortality MH - *Ureter/surgery MH - Treatment Outcome MH - China/epidemiology PMC - PMC12695398 OTO - NOTNLM OT - machine learning OT - prognostic outcomes OT - radical nephroureterectomy OT - segmental ureterectomy OT - ureteral upper tract urothelial carcinoma COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. The authors declare no conflicts of interest. EDAT- 2025/08/28 00:47 MHDA- 2025/12/12 07:20 PMCR- 2025/12/10 CRDT- 2025/08/27 19:42 PHST- 2025/04/01 00:00 [received] PHST- 2025/08/12 00:00 [accepted] PHST- 2025/12/12 07:20 [medline] PHST- 2025/08/28 00:47 [pubmed] PHST- 2025/08/27 19:42 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - 01279778-202512000-00003 [pii] AID - IJS-D-25-01631 [pii] AID - 10.1097/JS9.0000000000003292 [doi] PST - ppublish SO - Int J Surg. 2025 Dec 1;111(12):8818-8836. doi: 10.1097/JS9.0000000000003292. Epub 2025 Aug 26. PMID- 40862784 OWN - NLM STAT- MEDLINE DCOM- 20250827 LR - 20250829 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 32 IP - 8 DP - 2025 Jul 24 TI - Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study. LID - 10.3390/curroncol32080415 [doi] LID - 415 AB - The Vesical Imaging Reporting and Data System (VI-RADS) is used to detect muscle-invasive bladder cancer, with emerging prognostic implications. Integrating imaging parameters with molecular biomarkers may improve risk stratification in bladder cancer. This study evaluated whether combining VI-RADS scores with serum cytokeratin fragment 19 (CYFRA 21-1) levels-a clinically relevant biomarker for bladder cancer-could improve overall survival (OS) prediction. We retrospectively analyzed 134 patients who underwent transurethral resection of bladder tumors, magnetic resonance imaging, and postoperative serum CYFRA 21-1 measurements. In total, 15 cancer-specific deaths were observed during follow-up. Receiver operating characteristic curve analysis identified optimal prognostic cut-off values: VI-RADS score >/= 4 and CYFRA 21-1 level >/= 1.8 ng/mL. The 1-, 2-, and 3-year OS in patients with both high VI-RADS scores and CYFRA 21-1 levels were 42.9%, 16.7%, and 8.3%, respectively, significantly lower than those in other groups (p < 0.001, 0.002, and 0.003, respectively). Multivariate Cox proportional hazards analysis demonstrated that such patients had the poorest OS (hazard ratio: 7.51; p = 0.002). This suggests that combining VI-RADS and CYFRA 21-1 improves prognostic accuracy in bladder cancer, demonstrating potential clinical utility by informing individualized treatment strategies; however, limitations include the retrospective study design and absence of external validation. FAU - Ikuma, Shunsuke AU - Ikuma S AUID- ORCID: 0009-0006-0570-8173 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Akatsuka, Jun AU - Akatsuka J AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kaneko, Godai AU - Kaneko G AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Takeda, Hayato AU - Takeda H AUID- ORCID: 0000-0002-4556-6601 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Endo, Yuki AU - Endo Y AUID- ORCID: 0009-0002-0787-9321 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kimura, Go AU - Kimura G AUID- ORCID: 0000-0003-0088-9324 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. FAU - Kondo, Yukihiro AU - Kondo Y AUID- ORCID: 0000-0003-4141-9230 AD - Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. LA - eng GR - 25K20053/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20250724 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Keratin-19) RN - 0 (antigen CYFRA21.1) RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Keratin-19/blood MH - *Urinary Bladder Neoplasms/blood/diagnostic imaging/pathology/mortality/surgery MH - Male MH - Female MH - Retrospective Studies MH - *Antigens, Neoplasm/blood MH - Aged MH - Prognosis MH - Middle Aged MH - Biomarkers, Tumor/blood MH - Aged, 80 and over MH - Magnetic Resonance Imaging MH - Adult PMC - PMC12384138 OTO - NOTNLM OT - bladder cancer OT - cytokeratin fragment 19 OT - magnetic resonance imaging OT - reporting and data system COIS- The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2025/08/28 04:47 MHDA- 2025/08/28 04:48 PMCR- 2025/07/24 CRDT- 2025/08/27 10:04 PHST- 2025/06/21 00:00 [received] PHST- 2025/07/22 00:00 [revised] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/08/28 04:48 [medline] PHST- 2025/08/28 04:47 [pubmed] PHST- 2025/08/27 10:04 [entrez] PHST- 2025/07/24 00:00 [pmc-release] AID - curroncol32080415 [pii] AID - curroncol-32-00415 [pii] AID - 10.3390/curroncol32080415 [doi] PST - epublish SO - Curr Oncol. 2025 Jul 24;32(8):415. doi: 10.3390/curroncol32080415. PMID- 40864529 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20251015 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 87 IP - 5 DP - 2025 Nov TI - Clinicopathologic, immunohistochemical and genomic characterization of urothelial carcinoma with myxoid and chordoid features. PG - 757-767 LID - 10.1111/his.15545 [doi] AB - AIMS: To comprehensively characterize the clinicopathologic, immunohistochemical and genomic features of urothelial carcinoma with myxoid and chordoid features (UCMC), a rare histologic subtype of urothelial carcinoma with fewer than 50 reported cases in the literature. METHODS AND RESULTS: We retrospectively identified and analysed eight cases of UCMC using clinicopathologic information, immunohistochemistry and molecular profiling by DNA next-generation sequencing. Genomic analysis revealed a heterogeneous molecular profile, with alterations previously implicated in urothelial carcinoma, including p53/Rb/cell cycle pathway genes (6/7 cases), histone modification genes (6/7 cases) and FGFR3/PIK3CA signalling pathway genes (5/7 cases). Actionable variants were present in 6/7 cases. Classification utilizing immunohistochemical surrogates for basal and luminal subtypes of urothelial carcinoma demonstrated mixed subtypes: three cases with a luminal profile, one case with a basal profile, two cases which were double negative and two cases with a non-specific profile. One case demonstrated a molecular and immunohistochemical profile consistent with plasmacytoid urothelial carcinoma, suggesting that myxoid and chordoid features may overlap with previously recognized histologic subtypes. The five-year overall survival rate was 75%, with varying stages at presentation (pT1-pT3). CONCLUSIONS: UCMC represents a rare histologic finding, which can be associated with multiple molecular subtypes of urothelial carcinoma and can pose a diagnostic dilemma when identifying potentially aggressive histologic subtypes. It is uncertain whether UCMC represents a distinct histologic subtype, or (more likely) a histologic pattern acquired during tumour evolution. Further investigation is needed to fully understand the biological and clinical significance of this histologic pattern. CI - (c) 2025 John Wiley & Sons Ltd. FAU - Zhao, Ting AU - Zhao T AUID- ORCID: 0009-0004-0768-4764 AD - Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. FAU - Akgul, Mahmut AU - Akgul M AUID- ORCID: 0000-0003-0929-0940 AD - Department of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA. FAU - Siegmund, Stephanie E AU - Siegmund SE AUID- ORCID: 0000-0003-1848-2389 AD - Department of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA. LA - eng PT - Journal Article DEP - 20250827 PL - England TA - Histopathology JT - Histopathology JID - 7704136 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology/genetics MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/pathology/genetics MH - Immunohistochemistry MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/analysis MH - Urothelium/pathology OTO - NOTNLM OT - abladder cancer OT - chordoid OT - immunohistochemistry OT - molecular OT - myxoid OT - urothelial carcinom EDAT- 2025/08/27 20:46 MHDA- 2025/10/15 12:31 CRDT- 2025/08/27 12:13 PHST- 2025/08/04 00:00 [revised] PHST- 2025/04/14 00:00 [received] PHST- 2025/08/11 00:00 [accepted] PHST- 2025/10/15 12:31 [medline] PHST- 2025/08/27 20:46 [pubmed] PHST- 2025/08/27 12:13 [entrez] AID - 10.1111/his.15545 [doi] PST - ppublish SO - Histopathology. 2025 Nov;87(5):757-767. doi: 10.1111/his.15545. Epub 2025 Aug 27. PMID- 40861834 OWN - NLM STAT- MEDLINE DCOM- 20250827 LR - 20250829 IS - 1735-3688 (Electronic) IS - 0253-0716 (Print) IS - 0253-0716 (Linking) VI - 50 IP - 8 DP - 2025 Aug TI - Clinical Predictive Factors for Reproductive Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy Cases from Two Tertiary Centers. PG - 530-538 LID - 10.30476/ijms.2025.104015.3746 [doi] AB - BACKGROUND: The preservation of reproductive organs in females with muscle-invasive bladder cancer (MIBC) might improve reproductive and sexual function. This study aimed to identify potential clinical risk factors for reproductive organ involvement (ROI) using preoperative data from transurethral resection of tumor (TURT) reports and imaging findings. METHODS: This retrospective analysis was conducted on 143 women with bladder cancer who underwent radical cystectomy (RC) at Modarres and Labafinejad Medical Centers in Tehran, Iran, between 2010 and 2019. Demographic, clinical, and pathological data, along with follow-up reports, were collected from medical records and analyzed. RESULTS: The mean age of the participants was 69.17+/-10.62 years, with an ROI rate of 16.8%. The vagina was the predominantly involved organ. Significant independent risk factors for ROI included clinical T stage (P=0.042), bladder neck or trigonal location of the tumor (P<0.001), tumor size> 5 cm (P=0.002), presence of carcinoma in situ (CIS) (P=0.014), lymphovascular invasion in TURT reports (P=0.002), and preoperative hydronephrosis in imaging (P<0.001). Patients with ROI demonstrated significantly lower 5-year survival rates than those without ROI, with overall survival rate of 20.8% versus 63.9% and cancer-specific survival rate of 19% versus 64.8%, respectively. CONCLUSION: This study represented a comprehensive analysis of preoperative TURT and imaging predictors of ROI. Clinical T stage, tumor location, maximum tumor size, concomitant CIS, presence of lymphovascular invasion, and hydronephrosis were identified as significant preoperative clinical factors associated with ROI. These findings might help guide surgical planning for organ preservation in female MIBC patients. CI - Copyright: (c) Iranian Journal of Medical Sciences. FAU - Mahmoudnejad, Nastaran AU - Mahmoudnejad N AD - Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hamidi Madani, Mohammad AU - Hamidi Madani M AD - Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Montazeri, Parham AU - Montazeri P AD - Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Vakili, Kimia AU - Vakili K AD - Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Nasri, Mohammad AU - Nasri M AD - Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Imen, Sajjad AU - Imen S AD - Clinical Research Development Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Masoumi, Navid AU - Masoumi N AD - Department of Urology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20250801 PL - Iran TA - Iran J Med Sci JT - Iranian journal of medical sciences JID - 8104374 SB - IM MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Cystectomy/methods MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Iran/epidemiology MH - Risk Factors MH - Tertiary Care Centers/statistics & numerical data MH - Neoplasm Invasiveness MH - Aged, 80 and over PMC - PMC12374062 OTO - NOTNLM OT - Carcinoma, transitional cell OT - Cystectomy OT - Genitalia, female OT - Organ preservation COIS- None declared. EDAT- 2025/08/27 20:46 MHDA- 2025/08/27 20:47 PMCR- 2025/08/01 CRDT- 2025/08/27 06:44 PHST- 2024/09/11 00:00 [received] PHST- 2024/11/26 00:00 [revised] PHST- 2024/12/20 00:00 [accepted] PHST- 2025/08/27 20:47 [medline] PHST- 2025/08/27 20:46 [pubmed] PHST- 2025/08/27 06:44 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - IJMS-50-8 [pii] AID - 10.30476/ijms.2025.104015.3746 [doi] PST - epublish SO - Iran J Med Sci. 2025 Aug 1;50(8):530-538. doi: 10.30476/ijms.2025.104015.3746. eCollection 2025 Aug. PMID- 40850212 OWN - NLM STAT- MEDLINE DCOM- 20251102 LR - 20260918 IS - 1532-2157 (Electronic) IS - 0748-7983 (Linking) VI - 51 IP - 11 DP - 2025 Nov TI - Robot-assisted radical nephroureterectomy for locally advanced upper tract urothelial carcinoma: a multicenter study by the Junior ERUS/YAU Working Group on Robot-assisted Surgery. PG - 110396 LID - S0748-7983(25)00824-8 [pii] LID - 10.1016/j.ejso.2025.110396 [doi] AB - INTRODUCTION: Aim of the study was investigate outcomes of patients affected by locally advanced (pT3-pT4 and/or pN+) upper tract urothelial carcinoma (UTUC) and treated with robot-assisted radical nephroureterectomy (RNU). MATERIALS AND METHODS: Clinical and surgical data of newly-diagnosed UTUC patients referring to 9 high-volume centres from January 2019 to March 2023 undergoing RNU were collected. RESULTS: 191 patients showed locally advanced disease. Da Vinci and Hugo RAS System were employed in 95.8 % and 4.2 % of cases, respectively. Bladder cuff removal was carried out in 161 (84.3 %) patients, by using either an intravesical and extravesical approach in 50 (31.1 %) and 111 (68.9 %) respectively. Open and robotic approaches for bladder cuff removal were preferred in 107 (66.5 %) and 54 (33.5 %) patients, respectively. Lymph node dissection was performed in 55 % of patients. Median follow up was 19 (IQR 10-23) months and 31 (16.4 %) patients experienced bladder recurrence. On multivariate analysis, in those patients receiving RNU and bladder cuff removal, the approach for bladder cuff management (extravesical vs intravesical) was the only independent predictor of bladder recurrence (hazard ratio [HR]: 1.34; 95 % confidence interval [CI] 1.12-2.11; p = 0.03). Surgical approach for bladder cuff management (open vs robot) was not independently associated with bladder recurrence or tumor progression (both p > 0.05) CONCLUSIONS: In experienced hands, the robotic approach showed satisfactory survival outcomes also for the surgical treatment of pathological locally advanced UTUC. Extravesical approach for bladder cuff management may be burdened by a higher risk for bladder recurrence in locally advanced disease. CI - Copyright (c) 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. Electronic address: fabrizio.dimaida@unifi.it. FAU - Bravi, Carlo Andrea AU - Bravi CA AD - Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK; Department of Urology, Northampton General Hospital, Northampton, UK; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium. FAU - De Groote, Ruben AU - De Groote R AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium. FAU - Piramide, Federico AU - Piramide F AD - Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy. FAU - Turri, Filippo AU - Turri F AD - Department of Urology, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy. FAU - Wenzel, Mike AU - Wenzel M AD - Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Sharma, Gopal AU - Sharma G AD - Department of Urologic Oncology, Medanta the Medicity, Gurgaon, India. FAU - Wurnschimmel, Christoph AU - Wurnschimmel C AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Andras, Iulia AU - Andras I AD - Department of Urology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Lambert, Edward AU - Lambert E AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; Department of Urology, Ghent University Hospital, Ghent, Belgium. FAU - Dell'Oglio, Paolo AU - Dell'Oglio P AD - ASST Grande Ospedale Metropolitano Niguarda Urology Department, Milan, Italy. FAU - Moschovas, Marcio Covas AU - Moschovas MC AD - AdventHealth Global Robotics Institute, Celebration, FL, USA. FAU - Campi, Riccardo AU - Campi R AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Urologic Robotic, Minimally-Invasive Surgery and Renal Transplantation, Careggi University Hospital, Florence, Italy. FAU - Grosso, Antonio Andrea AU - Grosso AA AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Liakos, Nikolaos AU - Liakos N AD - Department of Urology, Faculty of Medicine, Medical Centre of the University of Freiburg, Freiburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Carbin Joseph, Danny Darlington AU - Carbin Joseph DD AD - Department of Urology, Royal Surrey NHS Foundation Trust, Guildford, UK. FAU - Eraky, Ahmed AU - Eraky A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Urology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy. FAU - Sorce, Gabriele AU - Sorce G AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Tappero, Stefano AU - Tappero S AD - ASST Grande Ospedale Metropolitano Niguarda Urology Department, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Mottrie, Alexandre AU - Mottrie A AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Larcher, Alessandro AU - Larcher A AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. CN - Junior ERUS/EAU-YAU Working Group on Robot-assisted Surgery LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250821 PL - England TA - Eur J Surg Oncol JT - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JID - 8504356 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Robotic Surgical Procedures/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Ureteral Neoplasms/surgery/pathology MH - *Kidney Neoplasms/surgery/pathology MH - Aged, 80 and over MH - Neoplasm Staging MH - Lymph Node Excision MH - Survival Rate MH - Retrospective Studies MH - Neoplasm Recurrence, Local/epidemiology OTO - NOTNLM OT - Da vinci OT - Hugo RAS system OT - Nephroureterectomy OT - Robotic OT - Upper tract urothelial carcinoma (UTUC) OT - Urothelial neoplasm EDAT- 2025/08/25 00:44 MHDA- 2025/11/03 00:26 CRDT- 2025/08/24 18:15 PHST- 2025/05/16 00:00 [received] PHST- 2025/08/01 00:00 [revised] PHST- 2025/08/15 00:00 [accepted] PHST- 2025/11/03 00:26 [medline] PHST- 2025/08/25 00:44 [pubmed] PHST- 2025/08/24 18:15 [entrez] AID - S0748-7983(25)00824-8 [pii] AID - 10.1016/j.ejso.2025.110396 [doi] PST - ppublish SO - Eur J Surg Oncol. 2025 Nov;51(11):110396. doi: 10.1016/j.ejso.2025.110396. Epub 2025 Aug 21. PMID- 40848880 OWN - NLM STAT- MEDLINE DCOM- 20260118 LR - 20260126 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 207 DP - 2026 Jan TI - Smoking is Associated With Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer. PG - 186-192 LID - S0090-4295(25)00808-8 [pii] LID - 10.1016/j.urology.2025.08.042 [doi] AB - OBJECTIVE: To examine the oncologic outcomes in patients treated for UTUC by radical nephroureterectomy (RNU) relative to their smoking history in a contemporary cohort that includes use of neoadjuvant and intravesical chemotherapy (IVC). METHODS: We analyzed a multi-institutional cohort of patients treated with RNU for UTUC between 2000 and 2020. Patients were classified as never smokers, those with a <20 pack-year smoking history, and those with a >/=20 pack-years of smoking history. Overall survival (OS), cancer-specific survival, intravesical recurrence, contralateral upper tract recurrence, and metastasis were compared. RESULTS: One thousand seven hundred ninety-six patients were included. No significant differences in the risks of intravesical recurrence, contralateral upper tract recurrence, metastasis, or cancer-specific survival were identified based on smoking status. OS was significantly higher in the never smoking group, with hazard ratio for death of 1.38 (95% CI 1.09-1.73) for <20 pack years smoking history and 1.34 (95% CI 1.12-1.61) for >/=20 pack years smoking history (P = .002). Rates of intravesical recurrence and OS were improved among smokers who received IVC compared to those who did not. CONCLUSION: Patients with a history of RNU for UTUC with any smoking history had worse OS compared to those with no smoking history, but no differences were seen in intravesical, contralateral upper tract, and extraurothelial recurrence or in cancer-specific survival. Counseling on smoking cessation remains an important element of ongoing care to optimize health outcomes in these patients. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lehner, Kelly AU - Lehner K AD - Mayo Clinic, Rochester, MN. FAU - Li, Roger AU - Li R AD - Moffitt Cancer Center, Tampa, FL. FAU - Hensley, Patrick J AU - Hensley PJ AD - University of Kentucky, Lexington, KY. FAU - Clark, Roderick K AU - Clark RK AD - Penn State Health, Hershey, PA. FAU - Pallauf, Maximilian AU - Pallauf M AD - Johns Hopkins University, Baltimore, MD; University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. FAU - Katims, Andrew AU - Katims A AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Bingham, Nicholas AU - Bingham N AD - The University of Texas Southwestern, Dallas, TX. FAU - Thapa, Prabin AU - Thapa P AD - Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Mayo Clinic, Rochester, MN. FAU - Raman, Jay D AU - Raman JD AD - Penn State Health, Hershey, PA. FAU - Singla, Nirmish AU - Singla N AD - Johns Hopkins University, Baltimore, MD. FAU - Coleman, Jonathan AU - Coleman J AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Margulis, Vitaly AU - Margulis V AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Spiess, Philippe E AU - Spiess PE AD - Moffitt Cancer Center, Tampa, FL. FAU - Matin, Surena F AU - Matin SF AD - The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Potretzke, Aaron M AU - Potretzke AM AD - Mayo Clinic, Rochester, MN. Electronic address: potretzke.aaron@mayo.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250821 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Humans MH - *Nephroureterectomy MH - Male MH - Female MH - Aged MH - *Smoking/adverse effects/epidemiology MH - *Ureteral Neoplasms/surgery/mortality MH - Middle Aged MH - *Kidney Neoplasms/surgery/mortality/pathology MH - *Carcinoma, Transitional Cell/surgery/mortality MH - Retrospective Studies MH - Survival Rate MH - Neoplasm Recurrence, Local/epidemiology MH - Treatment Outcome COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/08/24 00:46 MHDA- 2026/01/19 01:03 CRDT- 2025/08/23 19:14 PHST- 2025/05/21 00:00 [received] PHST- 2025/07/31 00:00 [revised] PHST- 2025/08/18 00:00 [accepted] PHST- 2026/01/19 01:03 [medline] PHST- 2025/08/24 00:46 [pubmed] PHST- 2025/08/23 19:14 [entrez] AID - S0090-4295(25)00808-8 [pii] AID - 10.1016/j.urology.2025.08.042 [doi] PST - ppublish SO - Urology. 2026 Jan;207:186-192. doi: 10.1016/j.urology.2025.08.042. Epub 2025 Aug 21. PMID- 40844867 OWN - NLM STAT- MEDLINE DCOM- 20251210 LR - 20260925 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 137 IP - 1 DP - 2026 Jan TI - The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer. PG - 201-208 LID - 10.1111/bju.16905 [doi] AB - OBJECTIVE: To evaluate which subgroups of patients with intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) benefit from maintenance therapy based on the International Bladder Cancer Group (IBCG) risk stratification, as the role of a maintenance course in patients with IR-NMIBC is debated. PATIENTS AND METHODS: We relied on a prospectively maintained database of patients with IR-NMIBC who received intravesical chemotherapy or Bacillus Calmette-Guerin (BCG) (2010-2023). Patients were stratified according the IBCG prognostic algorithm (no, one to two, and three or more risk factors). All patients received at least six induction instillations after index transurethral resection of bladder tumour. We used 3-month landmark stacked cumulative incidence and multivariable Cox regression models to assess the benefit from a maintenance course in terms of risk of recurrence and progression according to the IBCG risk groups stratification. RESULTS: Among 464 patients, 205 (44%) received BCG treatment and 259 (56%) received intravesical chemotherapy. The median (interquartile range) number of maintenance instillations was 9 (5-11). Over a median follow-up of 57 months, 139 (30%) patients had a recurrence. Patients with no IBCG risk factors had a similar risk of 5-year disease recurrence according to treatment duration (7.7% vs 7.3%; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.49-1.37, for induction only vs induction plus maintenance, respectively), whereas patients with one to two (5-year risk: 16% vs 13%; HR 0.65, 95% CI 0.48-0.82) or three or more IBCG risk factors (5-year risk: 21% vs 17%; HR 0.48, 95% CI 0.25-0.85) were associated with lower hazards of recurrence if treated with an induction plus maintenance course. CONCLUSIONS: The IBCG algorithm effectively stratifies patients with IR-NMIBC by recurrence risk. In this observational cohort, maintenance therapy was associated with lower recurrence rates in patients with one to two or three or more IBCG risk factors, but not in those with no risk factors. These findings suggest that the IBCG stratification may inform risk-adapted treatment decisions in patients with IR-NMIBC. CI - (c) 2025 BJU International. FAU - Zaurito, Paolo AU - Zaurito P AUID- ORCID: 0009-0005-8050-9388 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Scilipoti, Pietro AU - Scilipoti P AUID- ORCID: 0009-0007-6126-9889 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Viti, Alessandro AU - Viti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AUID- ORCID: 0009-0001-9363-682X AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Quarta, Leonardo AU - Quarta L AUID- ORCID: 0009-0008-9523-3400 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Cosenza, Andrea AU - Cosenza A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Occhi, Angelo AU - Occhi A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Galdieri, Armando AU - Galdieri A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Disabato, Natasha AU - Disabato N AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Brancaccio, Michele AU - Brancaccio M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Burgio, Giusy AU - Burgio G AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Division of Oncology, Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AUID- ORCID: 0000-0003-1914-0743 AD - Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AUID- ORCID: 0000-0002-0595-7165 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. LA - eng PT - Journal Article DEP - 20250822 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Male MH - Female MH - Aged MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Middle Aged MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Risk Assessment MH - *Maintenance Chemotherapy MH - Neoplasm Recurrence, Local/epidemiology MH - Risk Factors MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - International Bladder Cancer Group OT - bladder cancer OT - intermediate-risk OT - intravesical chemotherapy OT - maintenance OT - non-muscle-invasive bladder cancer COIS- All authors declare no conflict of interest relative to the content of the paper. EDAT- 2025/08/22 20:45 MHDA- 2025/12/10 06:28 CRDT- 2025/08/22 12:32 PHST- 2025/12/10 06:28 [medline] PHST- 2025/08/22 20:45 [pubmed] PHST- 2025/08/22 12:32 [entrez] AID - 10.1111/bju.16905 [doi] PST - ppublish SO - BJU Int. 2026 Jan;137(1):201-208. doi: 10.1111/bju.16905. Epub 2025 Aug 22. PMID- 40841270 OWN - NLM STAT- MEDLINE DCOM- 20250915 LR - 20250915 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 5 DP - 2025 Oct TI - Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy. PG - 102405 LID - S1558-7673(25)00105-3 [pii] LID - 10.1016/j.clgc.2025.102405 [doi] AB - BACKGROUND: Occult pathological lymph node involvement in patients with clinical node-negative (cN0) bladder cancer (BC) remains a diagnostic challenge. We evaluate predictors of lymph node positivity (pN+) in patients with cT1-4N0M0 BC undergoing radical cystectomy and pelvic lymph node dissection (RC-PLND). METHODS: We included patients with cT1-4N0M0 BC undergoing RC-PLND from February 2004 through October 2020. Patients were classified as pN+ vs. pN0. Baseline characteristics were summarized using descriptive statistics. Logistic regression models and multivariable analysis estimated odds ratios (OR) for pN+ status. Kaplan Meier analysis and multivariable Cox proportional hazards models analyzed recurrence-free survival (RFS) and overall survival (OS). RESULTS: 440 patients were evaluated, of which 81% (n = 359) had pN0 and 17% (n = 74) had pN+ disease. Most were male (80%), white (88%), and had a median age of 71 years. Most had clinical T2 (55%) and T1 (25%) disease. Lymphovascular invasion (LVI) on TURBT (OR 2.62, P = .04), positive surgical margins (OR 16.77, P < .001), and >/= cT2 disease (OR 1.89, P = .04) had higher odds of pN+ status. pN+ patients were more likely to suffer recurrence (HR 7.67, P < .001) or death (HR 3.26, P < .001) compared to pN0 patients. Preoperative hydronephrosis predicted worse RFS (HR 1.76, P = .011) and OS (HR 1.55, P = .007). Positive surgical margins (HR 2.34, P = .008) and preoperative renal function (HR 1.50, P = .004) predicted worse OS. CONCLUSION: Positive surgical margins, LVI, and >/= cT2 disease strongly predict pN+ findings in patients with cT1-4N0M0 BC. Preoperative variables can inform treatment for patients with a higher risk for positive lymph node findings at surgery. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Jaime-Casas, Salvador AU - Jaime-Casas S AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Zugman, Miguel AU - Zugman M AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Barragan-Carrillo, Regina AU - Barragan-Carrillo R AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Ebrahimi, Hedyeh AU - Ebrahimi H AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Shah, Koral AU - Shah K AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Yip, Wesley AU - Yip W AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Hugen, Cory M AU - Hugen CM AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Chan, Kevin G AU - Chan KG AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Lau, Clayton S AU - Lau CS AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Yuh, Bertram E AU - Yuh BE AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Mercier, Benjamin AU - Mercier B AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Salgia, Nicholas J AU - Salgia NJ AD - Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Castro, Daniela V AU - Castro DV AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Li, Xiaochen AU - Li X AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Hsu, JoAnn AU - Hsu J AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Nguyen, Charles B AU - Nguyen CB AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Chehrazi-Raffle, Alexander AU - Chehrazi-Raffle A AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Pal, Sumanta K AU - Pal SK AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Tripathi, Abhishek AU - Tripathi A AD - Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: atripathi@coh.org. LA - eng PT - Journal Article DEP - 20250723 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - *Cystectomy/methods MH - Female MH - Aged MH - Lymph Node Excision MH - Middle Aged MH - Lymphatic Metastasis MH - *Lymph Nodes/pathology/surgery MH - Retrospective Studies MH - Neoplasm Staging MH - Prognosis MH - Aged, 80 and over MH - Kaplan-Meier Estimate OTO - NOTNLM OT - Clinical staging OT - Nodal metastasis OT - Preoperative assessment OT - Upstaging OT - Urothelial carcinoma COIS- Disclosure A.T. has received consulting fees from Deka Biosciences, Aadi Biosciences, Seattle Genetics/Astellas, Exelixis, Bayer, and Gilead Sciences and research funding from Corvus Pharmaceuticals, EMD Serono and Aravive, Inc. S.K.P. reports honoraria and a consulting/advisory role with Novartis, Astellas Pharma, Pfizer, Aveo, Myriad Pharmaceuticals, Roche/Genentech, Exelixis, Bristol-Myers Squibb, Ipsen, and Eisai and honoraria and research funding from Medivation. C.B.N has received travel funding from DAVA Oncology and honoraria from MJH Associates. EDAT- 2025/08/22 00:44 MHDA- 2025/09/16 00:33 CRDT- 2025/08/21 22:02 PHST- 2025/05/03 00:00 [received] PHST- 2025/07/20 00:00 [revised] PHST- 2025/07/21 00:00 [accepted] PHST- 2025/09/16 00:33 [medline] PHST- 2025/08/22 00:44 [pubmed] PHST- 2025/08/21 22:02 [entrez] AID - S1558-7673(25)00105-3 [pii] AID - 10.1016/j.clgc.2025.102405 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Oct;23(5):102405. doi: 10.1016/j.clgc.2025.102405. Epub 2025 Jul 23. PMID- 40838134 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 11 IP - 3 DP - 2025 Jul-Sep TI - Expression of PD-1 and PD-L1 in BCG-treated NMIBC. PG - 23523735251368683 LID - 10.1177/23523735251368683 [doi] LID - 23523735251368683 AB - BACKGROUND: The recommended treatment for high-risk non-muscle invasive bladder cancer (NMIBC) is intravesical instillations of Bacillus Calmette-Guerin (BCG). Despite completing BCG therapy, up to 40% of patients experience disease recurrence within five years. T cell exhaustion has been associated with poor outcome following treatment with BCG. OBJECTIVE: In this study, we investigated whether T cell exhaustion, characterized by tumor protein expression of PD-1 and PD-L1 in paired samples obtained before and after BCG treatment could provide further insight into BCG response and help predict outcome in patients with NMIBC. METHODS: Tumor samples from 104 patients with NMIBC were collected before and after BCG. Sections from tissue microarrays were stained using immunohistochemistry to analyze the protein expression of PD-1 and PD-L1. Data was analyzed using digital pathology software. RESULTS: High PD-1 expression was associated with higher tumor stage and grade pre-BCG (p = 0.001 and p = 0.002) and with tumor stage post-BCG (p = 0.005). PD-L1 was associated with higher tumor stage in pre- and post-BCG samples (p = 0.006 and p = 0.048). Patients with low expression of PD-1 and PD-L1 in the pre-BCG tumor had a superior high-grade recurrence-free survival (HG-RFS) compared to patients with high PD-1 (p = 0.008) and PD-L1 (p = 0.006) expression. CONCLUSION: Protein expression of the exhaustion markers PD-1 and PD-L1 in pre-BCG tumor samples were correlated to higher stage and grade as well as worse HG-RFS, indicating that T cell exhaustion may play an important role in resistance to BCG treatment. CI - (c) The Author(s) 2025. FAU - Andreasen, Tine Ginnerup AU - Andreasen TG AUID- ORCID: 0000-0002-9633-2987 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. RINGGOLD: 721996 AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. RINGGOLD: 211076 FAU - Strandgaard, Trine AU - Strandgaard T AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. RINGGOLD: 721996 AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. RINGGOLD: 211076 FAU - Raaby, Line AU - Raaby L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. RINGGOLD: 721996 AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. RINGGOLD: 211076 AD - Department of Pathology, Aarhus University Hospital, Aarhus N, Denmark. RINGGOLD: 1006 FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. RINGGOLD: 211076 AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AUID- ORCID: 0000-0001-7061-9851 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. RINGGOLD: 721996 AD - Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark. RINGGOLD: 211076 LA - eng PT - Journal Article DEP - 20250817 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC12361738 OTO - NOTNLM OT - BCG OT - bladder cancer OT - digital image analysis OT - immunohistochemistry OT - tumor microenvironment COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TGA, TS and LR report no relevant conflicts of interest. JBJ has sponsored research agreements with medac, Photocure ASA, Roche, Ferring, Olympus, Astellas, Cepheid, Nucleix, Urotech, Pfizer, AstraZenica, VingMed, Laborie, AMBU, and Cystotech and serves in an advisory/consulting role for Ferring, Roche/Genentech, Cepheid, Urotech, Olympus, AMBU, Janssen, Cystotech, and Polyceutix and has received speaker honoraria from medac, Olympus, Photocure ASA, and Conmed and is furthermore proctor for Intuitive Surgery. LD has sponsored research agreements with C2i Genomics, Veracyte, Natera, AstraZeneca, Photocure, and Ferring and serves in an advisory/consulting role for Ferring, MSD, Cystotech, and UroGen. LD has received speaker honoraria from AstraZeneca, Pfizer, and Roche. Lars Dyrskjot is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. EDAT- 2025/08/21 06:28 MHDA- 2025/08/21 06:29 PMCR- 2025/08/17 CRDT- 2025/08/21 05:25 PHST- 2025/03/13 00:00 [received] PHST- 2025/07/31 00:00 [accepted] PHST- 2025/08/21 06:29 [medline] PHST- 2025/08/21 06:28 [pubmed] PHST- 2025/08/21 05:25 [entrez] PHST- 2025/08/17 00:00 [pmc-release] AID - 10.1177_23523735251368683 [pii] AID - 10.1177/23523735251368683 [doi] PST - epublish SO - Bladder Cancer. 2025 Aug 17;11(3):23523735251368683. doi: 10.1177/23523735251368683. eCollection 2025 Jul-Sep. PMID- 40824692 OWN - NLM STAT- MEDLINE DCOM- 20251205 LR - 20251208 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 68 IP - 4 DP - 2025 Oct 1 TI - Basal subtype of invasive urothelial carcinoma of the bladder has aggressive behavior and poor prognosis: An immunohistochemistry-based study. PG - 736-743 LID - 10.4103/ijpm.ijpm_290_25 [doi] AB - INTRODUCTION: Molecular subtyping of urothelial cancer of the bladder can help in identifying aggressive subtypes and aid in the prognostication of the disease. These subtypes can be broadly identified with the help of immunohistochemistry (IHC) markers reliably. AIMS: To assess the molecular subtypes of urothelial carcinoma of the bladder using IHC markers and evaluate their association with clinicopathological characteristics and overall survival (OS). MATERIALS AND METHODS: This was a cross-sectional study done over 3 years in a tertiary care center. There were 109 cases of invasive urothelial carcinoma of the bladder. In 43 cases, radical cystectomy was performed, and 66 cases underwent transurethral resection of bladder tumor. CK5/6, and CK14 were used as markers of the basal subtype; GATA-3 and CK20 were used for the luminal subtype. Cases were classified into basal, luminal, double-positive, and double-negative subtypes. The association of molecular subtypes with clinicopathological characteristics was analyzed. OS was analyzed for the molecular subtypes. All the relevant statistical tests were performed using IBM SPSS software version 24.0. RESULTS: The most frequently occurring molecular subtype was luminal (GATA3+, CK5/6-) in 62% of cases. Tumors with the basal subtype showed a higher frequency of muscle invasion compared to nonbasal types and presented as high-grade tumors. The luminal subtype was significantly associated with conventional histology and lamina propria invasive tumors. The basal molecular subtype showed a mean OS of 15 (+/-4) months, which was significantly worse than that of nonbasal subtypes. CONCLUSION: The basal subtype of urothelial carcinoma of the bladder behaves more aggressively in terms of grade, extent of invasion, and OS. CI - Copyright (c) 2025 Indian Journal of Pathology and Microbiology. FAU - Venkatakrishnan, Swetha AU - Venkatakrishnan S AD - Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Jinkala, Sree Rekha AU - Jinkala SR AD - Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Sreerag, K S AU - Sreerag KS AD - Department of Urology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Kayal, Smita AU - Kayal S AD - Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. LA - eng PT - Journal Article DEP - 20250814 PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (Keratin-14) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnosis/classification/mortality MH - Male MH - Female MH - Immunohistochemistry MH - Middle Aged MH - Cross-Sectional Studies MH - Aged MH - Prognosis MH - Biomarkers, Tumor/analysis MH - GATA3 Transcription Factor/analysis/genetics MH - Adult MH - Aged, 80 and over MH - Urinary Bladder/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Urothelium/pathology MH - Keratin-20/analysis/genetics MH - Tertiary Care Centers MH - Keratin-5/analysis/genetics MH - Keratin-14/analysis/genetics OTO - NOTNLM OT - Basal OT - immunohistochemistry OT - luminal OT - molecular subtypes OT - urothelial carcinoma EDAT- 2025/08/18 12:33 MHDA- 2025/12/05 13:07 CRDT- 2025/08/18 11:53 PHST- 2025/03/26 00:00 [received] PHST- 2025/07/02 00:00 [accepted] PHST- 2025/12/05 13:07 [medline] PHST- 2025/08/18 12:33 [pubmed] PHST- 2025/08/18 11:53 [entrez] AID - 00004270-202510000-00009 [pii] AID - 10.4103/ijpm.ijpm_290_25 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2025 Oct 1;68(4):736-743. doi: 10.4103/ijpm.ijpm_290_25. Epub 2025 Aug 14. PMID- 40804804 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250817 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 15 DP - 2025 Jul 22 TI - Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors. LID - 10.3390/diagnostics15151840 [doi] LID - 1840 AB - Background/Objectives: Upper tract urothelial carcinoma (UTUC) is often complicated by intravesical recurrence and cancer progression following radical nephroureterectomy (RNU). Identifying reliable prognostic biomarkers remains crucial for optimizing postoperative surveillance. The goal of this study was to assess the prognostic value of the De Ritis ratio (AST/ALT) in predicting bladder recurrence and oncologic outcomes in patients with clinically localized UTUC undergoing RNU. Methods: This retrospective study analyzed 87 patients treated with RNU between 2018 and 2025. Preoperative De Ritis ratios were calculated, and an optimal cut-off value of 1.682 was determined using ROC analysis. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using the Kaplan-Meier and Cox regression methods. Logistic regression was used to identify independent predictors of bladder recurrence. Results: A high De Ritis ratio was significantly associated with increased bladder recurrence and worse RFS and CSS, but not OS. Multivariate analysis confirmed that an elevated De Ritis ratio, current smoking, positive surgical margins, and synchronous bladder cancer were the independent predictors of bladder recurrence. The De Ritis ratio demonstrated strong discriminatory performance (AUC: 0.807), with good sensitivity and specificity for predicting recurrence. Conclusions: The De Ritis ratio is a simple, cost-effective preoperative biomarker that may aid in identifying UTUC patients at higher risk for intravesical recurrence and cancer-specific mortality. Incorporating this ratio into clinical decision-making could enhance risk stratification and guide tailored follow-up strategies. FAU - Yorulmaz, Enis Mert AU - Yorulmaz EM AUID- ORCID: 0000-0003-2109-2015 AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. FAU - Donmez, Kursad AU - Donmez K AD - Department of Urology, Ataturk Research and Training Hospital, Izmir 35360, Turkey. FAU - Ozcan, Serkan AU - Ozcan S AUID- ORCID: 0000-0002-2459-139X AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. FAU - Kose, Osman AU - Kose O AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. FAU - Gorgel, Sacit Nuri AU - Gorgel SN AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. FAU - Candemir, Enes AU - Candemir E AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. FAU - Akin, Yigit AU - Akin Y AUID- ORCID: 0000-0001-7627-3476 AD - Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey. LA - eng PT - Journal Article DEP - 20250722 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12346446 OTO - NOTNLM OT - De Ritis ratio OT - intravesical recurrence OT - nephroureterectomy OT - prognostic biomarker OT - upper tract urothelial carcinoma COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2025/08/14 06:28 MHDA- 2025/08/14 06:29 PMCR- 2025/07/22 CRDT- 2025/08/14 01:01 PHST- 2025/05/03 00:00 [received] PHST- 2025/06/14 00:00 [revised] PHST- 2025/07/14 00:00 [accepted] PHST- 2025/08/14 06:29 [medline] PHST- 2025/08/14 06:28 [pubmed] PHST- 2025/08/14 01:01 [entrez] PHST- 2025/07/22 00:00 [pmc-release] AID - diagnostics15151840 [pii] AID - diagnostics-15-01840 [pii] AID - 10.3390/diagnostics15151840 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Jul 22;15(15):1840. doi: 10.3390/diagnostics15151840. PMID- 40804697 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20260829 IS - 1096-9896 (Electronic) IS - 0022-3417 (Linking) VI - 267 IP - 2 DP - 2025 Oct TI - MS4A4A-positive tumor-associated macrophages associate with poor prognosis and T-cell exhaustion in patients with urothelial carcinoma of the bladder. PG - 225-239 LID - 10.1002/path.6465 [doi] AB - Tumor-associated macrophages (TAMs) have multiple potent functions in cancer representing important therapeutic targets. MS4A4A is a functional TAM marker with controversial implications for prognosis. This study aimed to evaluate the association between MS4A4A(+) TAM infiltration and clinical outcomes in urothelial carcinoma of the bladder (UCB), as well as their impact on the immune landscape. A total of 400 UCB patients from cohorts at Sun Yat-sen Memorial Hospital were analyzed. Immunohistochemistry was used to quantify MS4A4A(+) TAMs and assess their spatial distribution alongside various immune components, evaluate the benefit of Bacillus Calmette-Guerin (BCG) immunotherapy, and analyze survival outcomes. Additionally, matched UCB tissues were examined before and after recurrence or progression. We observed that MS4A4A(+) TAMs were present at higher levels in the stromal region compared to the intratumoral region, and correlated with advanced tumor stage and poor prognosis in both regions. No significant difference was observed in the number of MS4A4A(+) TAMs before and after recurrence/progression in the same patient. Stromal MS4A4A(+) TAMs were negatively correlated with BCG efficacy and recurrence-free survival. These TAMs were positively associated with CD8(+) T cells, Foxp3(+) regulatory T cells, immune checkpoints (PD-1, LAG-3, HAVcr-2, TIGIT), and anti-inflammatory molecules (TGF-beta1, IL-4) in the same respective regions. Additionally, MS4A4A(+) TAMs expressed high levels of TGF-beta1 and HAVcr-2 in UCB tissues. In vitro, IL-4 induced MS4A4A expression in mouse bone marrow-derived macrophages, while Ms4a4a knockdown reduced the anti-inflammatory molecule Arg1 and increased pro-inflammatory molecule Nos2 expression. These findings demonstrate that MS4A4A is a reliable prognostic marker and predictor of BCG response in UCB, highlighting its role in shaping the immune landscape and immunotherapy outcomes. (c) 2025 The Pathological Society of Great Britain and Ireland. CI - (c) 2025 The Pathological Society of Great Britain and Ireland. FAU - Yang, Tenghao AU - Yang T AUID- ORCID: 0000-0001-6035-7296 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Sun, Xi AU - Sun X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Chen, Jiaming AU - Chen J AD - Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances and School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, PR China. FAU - Li, Jinqing AU - Li J AD - Division of Hematology & Oncology, Department of Geriatrics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, PR China. FAU - Liu, Chaoqun AU - Liu C AD - Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, PR China. FAU - Yu, Jingwei AU - Yu J AD - Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances and School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, PR China. FAU - Meng, Weiju AU - Meng W AD - Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances and School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, PR China. FAU - Wang, Yongqiang AU - Wang Y AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Wang, Bo AU - Wang B AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. LA - eng GR - 2020B1111170006/Guangdong Provincial Clinical Research Center for Urological Diseases/ GR - 81961128027/National Natural Science Foundation of China/ GR - 82173230/National Natural Science Foundation of China/ GR - 82473074/National Natural Science Foundation of China/ GR - 2023B1212060013/The Science and Technology Planning Project of Guangdong Province/ GR - Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to B.W./ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250813 PL - England TA - J Pathol JT - The Journal of pathology JID - 0204634 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/pathology/mortality/therapy/metabolism MH - *Tumor-Associated Macrophages/immunology/pathology/metabolism MH - Male MH - Female MH - Middle Aged MH - Aged MH - BCG Vaccine/therapeutic use MH - Prognosis MH - Tumor Microenvironment MH - *Biomarkers, Tumor/metabolism MH - *Carcinoma, Transitional Cell/immunology/pathology MH - *Lymphocytes, Tumor-Infiltrating/immunology MH - T-Cell Exhaustion OTO - NOTNLM OT - MS4A4A OT - T-cell exhaustion OT - immune checkpoint OT - macrophage OT - prognosis OT - urothelial carcinoma of the bladder EDAT- 2025/08/14 06:27 MHDA- 2025/09/16 18:32 CRDT- 2025/08/14 00:25 PHST- 2025/05/15 00:00 [revised] PHST- 2024/12/13 00:00 [received] PHST- 2025/07/18 00:00 [accepted] PHST- 2025/09/16 18:32 [medline] PHST- 2025/08/14 06:27 [pubmed] PHST- 2025/08/14 00:25 [entrez] AID - 10.1002/path.6465 [doi] PST - ppublish SO - J Pathol. 2025 Oct;267(2):225-239. doi: 10.1002/path.6465. Epub 2025 Aug 13. PMID- 40787990 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260130 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 12 DP - 2025 Dec 1 TI - CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study. PG - 9457-9470 LID - 10.1097/JS9.0000000000003140 [doi] AB - INTRODUCTION: The objective of this study is to investigate the predictive ability of abdominal fat features derived from computed tomography (CT) to predict early recurrence within a year following the initial transurethral resection of bladder tumor (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC). A predictive model is constructed in combination with clinical factors to aid in the evaluation of the risk of early recurrence among patients with NMIBC after initial TURBT. METHODS: This retrospective study enrolled 325 NMIBC patients from three centers. Machine learning-based visceral adipose tissue (VAT) radiomics models (VAT-RM) and subcutaneous adipose tissue (SAT) radiomics models (SAT-RM) were constructed to identify patients with early recurrence. A combined model integrating VAT-RM and clinical factors was established. The predictive performance of each variable and model was analyzed using the area under the receiver operating characteristic curve (AUC). The net benefit of each variable and model was presented through decision curve analysis (DCA). The calibration was evaluated utilizing the Hosmer-Lemeshow test. FINDINGS: The VAT-RM demonstrated satisfactory performance in the training cohort (AUC = 0.853; 95% CI: 0.768-0.937), test cohort 1 (AUC = 0.823; 95% CI: 0.730-0.916), and test cohort 2 (AUC = 0.808; 95% CI: 0.681-0.935). Across all cohorts, the AUC values of the VAT-RM were higher than those of the SAT-RM ( P < 0.001). The DCA curves further confirmed that the clinical net profit of the VAT-RM was superior to that of the SAT-RM. In multivariate logistic regression analysis, the VAT-RM emerged as the most significant independent predictor [odds ratio (OR) = 0.295; 95% CI: 0.141-0.508; P < 0.001]. The fusion model exhibited excellent AUC values of 0.938, 0.909, and 0.905 across three cohorts. The fusion model surpassed the traditional risk assessment frameworks in both predictive efficacy and clinical net benefit. INTERPRETATION: VAT serves as a crucial factor in early postoperative recurrence in NMIBC patients. The VAT-RM can accurately identify high-risk patients with early postoperative recurrence, offering significant advantages over SAT-RM. The new predictive model constructed by integrating the VAT-RM and clinical factors exhibits excellent predictive performance, clinical net benefits, and calibration accuracy. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yu, Nengfeng AU - Yu N AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Li, Jiali AU - Li J AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Cao, Dan AU - Cao D AD - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Chen, Xingbei AU - Chen X AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Yang, Dong AU - Yang D AD - Department of Gastrointestinal Surgery,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. FAU - Jiang, Nan AU - Jiang N AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Wu, Junhui AU - Wu J AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Zhao, Chenkai AU - Zhao C AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. FAU - Zheng, Yichun AU - Zheng Y AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Chen, Yicheng AU - Chen Y AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Jin, Xiaodong AU - Jin X AUID- ORCID: 0009-0008-5048-3262 AD - Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250805 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - *Intra-Abdominal Fat/diagnostic imaging MH - Male MH - Female MH - Retrospective Studies MH - Middle Aged MH - Aged MH - *Tomography, X-Ray Computed/methods MH - *Neoplasm Recurrence, Local/diagnostic imaging MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - Machine Learning MH - Predictive Value of Tests MH - Radiomics MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12695364 OTO - NOTNLM OT - computed tomography OT - early recurrence after initial surgery OT - non-muscle-invasive bladder cancer OT - prediction model OT - visceral adipose tissue COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. All authors declare no competing interests. EDAT- 2025/08/11 12:33 MHDA- 2025/12/12 07:20 PMCR- 2025/12/10 CRDT- 2025/08/11 09:03 PHST- 2025/04/17 00:00 [received] PHST- 2025/07/18 00:00 [accepted] PHST- 2025/12/12 07:20 [medline] PHST- 2025/08/11 12:33 [pubmed] PHST- 2025/08/11 09:03 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - 01279778-202512000-00056 [pii] AID - IJS-D-25-01875 [pii] AID - 10.1097/JS9.0000000000003140 [doi] PST - ppublish SO - Int J Surg. 2025 Dec 1;111(12):9457-9470. doi: 10.1097/JS9.0000000000003140. Epub 2025 Aug 5. PMID- 40784849 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20251002 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 11 DP - 2025 Nov TI - Does ureteral stent drainage prior to radical nephroureterectomy increase the risk of intravesical tumor recurrence? PG - 662.e1-662.e8 LID - S1078-1439(25)00273-X [pii] LID - 10.1016/j.urolonc.2025.07.012 [doi] AB - PURPOSE: To investigate whether ureteral stent drainage (USD) increases the risk of intravesical recurrence in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: This retrospective study was conducted involving 2,756 upper tract urothelial carcinoma (UTUC) patients treated with RNU between 2000 and 2022, of whom 77 had a history of USD. The primary endpoint was to assess the association between USD and post-RNU bladder recurrence-free survival (BRFS). A 1:3 propensity score-matching analysis was performed to compare patients with and without a history of USD. Kaplan-Meier analyses, along with univariate and multivariate Cox proportional hazard modeling, were employed to compare BRFS, overall survival, cancer-specific survival, and contralateral recurrence-free survival. RESULTS: Kaplan-Meier analysis demonstrated a significant difference in BRFS between patients with and without a history of USD in the entire cohort (P = 0.022). However, in the matched cohort, no significant difference in BRFS was observed. Both univariate and multivariate Cox regression analyses revealed that prior ureteroscopy with biopsy was associated with intravesical recurrence, but USD history did not increase the risk of bladder recurrence, regardless of whether ureteroscopy was performed. Further analysis demonstrated that preoperative USD significantly improved pre-RNU renal function in patients with chronic kidney disease stage 3-5. CONCLUSION: The use of USD does not increase the risk of intravesical recurrence and has minimal impact on oncologic outcomes. Additionally, preoperative USD improves renal function, thereby expanding neoadjuvant treatment options for patients with compromised kidney function. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Guan, Bao AU - Guan B AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Wang, Guoli AU - Wang G AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Zhang, Huifeng AU - Zhang H AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Department of Urology, People's Hospital of Zhongmu County, Zhongmu County, Zhengzhou, Henan, China. FAU - Xia, Mancheng AU - Xia M AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Tao, Zihao AU - Tao Z AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Tang, Qi AU - Tang Q AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Xu, Chunru AU - Xu C AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. FAU - Yang, Qian AU - Yang Q AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Ren, Hanzhen AU - Ren H AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Du, Yicong AU - Du Y AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Department of Urology, People's Hospital of Zhongmu County, Zhongmu County, Zhengzhou, Henan, China. FAU - Cao, Chao AU - Cao C AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Department of Urology, The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Shangjie Town, Minhou County, Fuzhou, Fujian, China. FAU - Luo, Kaishun AU - Luo K AD - Department of Urology, The First People's Hospital of Zhaotong, Zhaoyang District, Zhaotong City, Yunnan Province, China. FAU - Zhang, Kai AU - Zhang K AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. Electronic address: kaizhangpku@163.com. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. Electronic address: zhoulqmail@sina.com. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Xicheng District, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China. Electronic address: pineneedle@sina.com. LA - eng PT - Journal Article DEP - 20250809 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Male MH - *Nephroureterectomy/methods MH - Female MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/etiology/epidemiology MH - Aged MH - *Stents/adverse effects MH - Middle Aged MH - *Urinary Bladder Neoplasms/pathology MH - *Drainage/adverse effects/methods MH - *Ureteral Neoplasms/surgery/pathology MH - Ureter/surgery MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Kidney Neoplasms/surgery/pathology OTO - NOTNLM OT - Dupper-tract urothelial carcinoma OT - Intravesical recurrence OT - Ureteral stent drainage COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/08/11 00:26 MHDA- 2025/10/03 00:29 CRDT- 2025/08/10 22:43 PHST- 2024/12/26 00:00 [received] PHST- 2025/07/02 00:00 [revised] PHST- 2025/07/18 00:00 [accepted] PHST- 2025/10/03 00:29 [medline] PHST- 2025/08/11 00:26 [pubmed] PHST- 2025/08/10 22:43 [entrez] AID - S1078-1439(25)00273-X [pii] AID - 10.1016/j.urolonc.2025.07.012 [doi] PST - ppublish SO - Urol Oncol. 2025 Nov;43(11):662.e1-662.e8. doi: 10.1016/j.urolonc.2025.07.012. Epub 2025 Aug 9. PMID- 40783897 OWN - NLM STAT- MEDLINE DCOM- 20260225 LR - 20260813 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 58 IP - 3 DP - 2026 Mar TI - High-density lectin microarray uncovers stage-specific plasma glycoprofiling signatures for non-muscle-invasive and muscle-invasive bladder cancer. PG - 789-802 LID - 10.1007/s11255-025-04708-7 [doi] AB - OBJECTIVES: The critical need for minimally invasive biomarkers to stratify non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC) prompted our investigation into tumor-specific glycan signatures. We hypothesized that lectin-based glycoprofiling could stratify MIBC and NMIBC via stage-specific glycan remodeling. Leveraging the emerging role of lectin microarrays in glycoprofiling, the first comprehensive plasma-based analysis comparing NMIBC and MIBC glycosylation patterns using a high-density 95-lectin platform was conducted. METHODS: A pilot cohort of 48 plasma samples (22 NMIBC, 10 MIBC, 16 NL) was analyzed using RayBiotech's high-density 95-lectin microarray platform (GA-Lectin-95). Advanced bioinformatics pipelines (Limma package, R/Bioconductor) identified differentially expressed lectins (LogFC > 1.2, adj.p < 0.05) with stringent validation, including ROC analysis (Receiver Operating Characteristic, pROC package) and cross-validated AUC (Area Under the Curve) calculations. RESULTS: Stage-specific glycoarchitectural remodeling revealed profound pathophysiological divergence: NMIBC plasma exhibited global glycan depletion marked by SSA/ASA/SHA downregulation (diagnostic AUC 0.79-1.00), whereas MIBC demonstrated aggressive sialylation/fucosylation signatures dominated by VVA/WFA overexpression (AUC 0.91-0.95). A decalectin panel in DSA/ASA/STL/ABL/MNM-M/PWA/PTL-1/SSA/CAA/GAL3C-S achieved perfect stratification of NMIBC from controls (AUC = 1.00), while four invasion-associated lectin complexes GAL1-S/RCA60/MPL/LSL-N showed MIBC-specific amplification (AUC > 0.80). Notably, CAA/DSA/SSA precisely discriminated MIBC from NMIBC (AUC = 1.00). GAL2 emerged as a novel metastasis checkpoint through its dramatic suppression in invasive tumors, suggesting its role as a glycosylation gatekeeper restraining muscle invasion. CONCLUSIONS: These findings support plasma glycoprofiling as a paradigm-shifting tool for bladder cancer subtyping. The results of this study provide actionable biomarkers for clinical stratification and diagnostics applications in bladder cancer management. CI - (c) 2025. The Author(s). FAU - Xiang, Xiansheng AU - Xiang X AD - Department of Urology, Nanbu County People's Hospital, Nanbu, China. FAU - Mei, Xue AU - Mei X AD - College of Pharmacy, North Sichuan Medical College, Nanchong, China. FAU - Song, Xiaojing AU - Song X AD - College of Pharmacy, North Sichuan Medical College, Nanchong, China. FAU - Pan, Bing AU - Pan B AD - Department of Urology, Nanbu County People's Hospital, Nanbu, China. FAU - Ma, Kun AU - Ma K AD - Department of Urology, Nanbu County People's Hospital, Nanbu, China. FAU - Tan, Chunlin AU - Tan C AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. FAU - Liu, Lin AU - Liu L AD - Department of Clinical Medicine, North Sichuan Medical College, Nanchong, China. FAU - Li, Shengmao AU - Li S AD - College of Pharmacy, North Sichuan Medical College, Nanchong, China. FAU - Dong, Qiang AU - Dong Q AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China, 610041. dqiang@gmail.com. FAU - Tang, Tielong AU - Tang T AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. cdzt2004@163.com. LA - eng GR - CBY23-QDA11/Scientific Startup Foundation for Doctors of North Sichuan Medical College to Xue Mei/ GR - No. 22SXQT0162/the Nanchong Science and Technology Bureau/ PT - Journal Article DEP - 20250810 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Lectins) RN - 0 (Biomarkers, Tumor) RN - 0 (Polysaccharides) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/blood MH - *Lectins/blood MH - Male MH - Neoplasm Invasiveness MH - Female MH - Aged MH - Middle Aged MH - Glycosylation MH - Neoplasm Staging MH - Pilot Projects MH - Biomarkers, Tumor/blood MH - Microarray Analysis MH - *Polysaccharides/blood PMC - PMC12935817 OTO - NOTNLM OT - Biomarkers OT - Lectin OT - MIBC OT - NMIBC OT - Plasma glycopatterns COIS- Declarations. Conflict of interest: The authors declare that there are no competing interests. Ethical approval: Ethical approval for this study (No. 2025-88) was provided by the Ethics Committee on Biomedical Research, Nanbu County People's Hospital. Informed consent: Not applicable. EDAT- 2025/08/10 12:33 MHDA- 2026/02/25 13:35 PMCR- 2025/08/10 CRDT- 2025/08/10 11:04 PHST- 2025/05/19 00:00 [received] PHST- 2025/07/30 00:00 [accepted] PHST- 2026/02/25 13:35 [medline] PHST- 2025/08/10 12:33 [pubmed] PHST- 2025/08/10 11:04 [entrez] PHST- 2025/08/10 00:00 [pmc-release] AID - 10.1007/s11255-025-04708-7 [pii] AID - 4708 [pii] AID - 10.1007/s11255-025-04708-7 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Mar;58(3):789-802. doi: 10.1007/s11255-025-04708-7. Epub 2025 Aug 10. PMID- 40782344 OWN - NLM STAT- MEDLINE DCOM- 20250809 LR - 20260127 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 131 IP - 16 DP - 2025 Aug 15 TI - Top advances of the year: Bladder cancer. PG - e70020 LID - 10.1002/cncr.70020 [doi] AB - Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC); (2) immune checkpoint inhibition (ICI) as adjuvant and (3) perioperative therapy in MIBC; (4) circulating tumor DNA as a biomarker in MIBC; to (5) a new standard of care in first-line metastatic urothelial carcinoma. TAR-200 is a new intravesical drug-delivery system that enables controlled release of gemcitabine but may be used with other anticancer drugs to treat nonmuscle-invasive bladder cancer and MIBC. Two phase 3 studies of adjuvant ICI (nivolumab and pembrolizumab) have both reported a doubling of disease-free survival in patients with high-risk MIBC receiving therapy. Perioperative durvalumab, including neoadjuvant therapy plus gemcitabine and cisplatin before radical cystectomy followed by adjuvant durvalumab, demonstrated an improvement in event-free survival and overall survival for patients with MIBC. Circulating tumor DNA is a promising biomarker to select patients with MIBC for adjuvant ICI therapy. Finally, the combination of enfortumab vedotin, an antibody-drug conjugate, plus pembrolizumab doubled overall survival compared with standard gemcitabine plus platinum in patients with metastatic urothelial carcinoma and has been implemented in treatment guidelines in the United States, Europe, and Asia as the new standard of care in this setting, transforming the treatment landscape for bladder cancer. CI - (c) 2025 American Cancer Society. FAU - Apolo, Andrea B AU - Apolo AB AUID- ORCID: 0000-0001-9409-1836 AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Atiq, Saad AU - Atiq S AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Kydd, Andre R AU - Kydd AR AUID- ORCID: 0000-0002-5579-8457 AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Chelluri, Raju AU - Chelluri R AD - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Millan, Braden AU - Millan B AUID- ORCID: 0000-0002-4253-8568 AD - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Gurram, Sandeep AU - Gurram S AUID- ORCID: 0000-0002-6405-9269 AD - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Chandran, Elias AU - Chandran E AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Simon, Nicholas AU - Simon N AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Biomarkers, Tumor) RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Circulating Tumor DNA) RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/therapy/mortality MH - Immune Checkpoint Inhibitors/therapeutic use/administration & dosage MH - Biomarkers, Tumor/blood MH - Neoadjuvant Therapy MH - Gemcitabine MH - Deoxycytidine/analogs & derivatives/administration & dosage MH - Circulating Tumor DNA/blood MH - Chemotherapy, Adjuvant MH - *Carcinoma, Transitional Cell/drug therapy MH - Cystectomy MH - Administration, Intravesical MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Antibodies, Monoclonal, Humanized OTO - NOTNLM OT - TAR-200 OT - adjuvant therapy OT - bladder cancer OT - circulating tumor DNA (ctDNA) OT - first-line therapy OT - immune checkpoint inhibitors OT - immunotherapy OT - perioperative therapy OT - urothelial carcinoma EDAT- 2025/08/10 06:14 MHDA- 2025/08/10 06:15 CRDT- 2025/08/09 12:32 PHST- 2025/05/15 00:00 [revised] PHST- 2025/02/10 00:00 [received] PHST- 2025/06/23 00:00 [accepted] PHST- 2025/08/10 06:15 [medline] PHST- 2025/08/10 06:14 [pubmed] PHST- 2025/08/09 12:32 [entrez] AID - 10.1002/cncr.70020 [doi] PST - ppublish SO - Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. PMID- 40776775 OWN - NLM STAT- MEDLINE DCOM- 20260403 LR - 20260813 IS - 1745-7270 (Electronic) IS - 1672-9145 (Print) IS - 1672-9145 (Linking) VI - 58 IP - 3 DP - 2025 Aug 6 TI - The TCF7L2/miR-206/Cofilin1 axis promotes the metastasis of bladder cancer cells by regulating the formation of invadopodia. PG - 663-680 LID - 10.3724/abbs.2025114 [doi] AB - Bladder cancer (BCa) is one of the most common malignant tumors of the urinary system, but its pathogenesis is still unclear. T1G3 BCa is particularly invasive and relapses readily after treatment, with progression to invasive cancer or distant metastasis. Therefore, identification of the molecular mechanism by which it invades and metastasizes to guide treatment and predict patient prognosis is needed. Cofilin1 plays an important role in regulating gene expression and the invasiveness of tumors. In this study, we show that Cofilin1 is highly expressed in BCa and lymph nodes with metastasis, which is positively related to the grade of BCa, and is significantly related to clinicopathological parameters and cancer-specific survival. Phenotypic analysis reveals that Cofilin1 knockout inhibits the proliferation and migration of BCa cells, whereas Cofilin1 overexpression promotes the opposite phenotype. Cofilin1 binds to cortactin, thereby reducing the expression of F-actin and promoting the formation of invadopodia in BCa cells. Further experiments reveal that TCF7L2 can bind to the promoter of Cofilin1 and transactivate it, promoting a malignant phenotype. TCF7L2 may also reverse the inhibitory effect of miR-206 on the binding of Cofilin1 and cortactin and promote the metastasis of BCa by inhibiting the transcription maturation of miR-206. This study confirms that Cofilin1 is an oncogene in T1G3 BCa, and the TCF7L2/miR-206/Cofilin1 signaling pathway plays an important role in the formation of invadopodia in BCa. FAU - Jie, Yuzhen AU - Jie Y AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. FAU - Yang, Yinggui AU - Yang Y AD - Department of Urology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, China. FAU - Guo, Chengyan AU - Guo C AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. FAU - Wu, Qinghui AU - Wu Q AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. FAU - Ou, Zhewen AU - Ou Z AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. FAU - Wang, Weifu AU - Wang W AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. FAU - Xu, Ning AU - Xu N AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. FAU - Peng, Wei AU - Peng W AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. FAU - Wu, Yingguang AU - Wu Y AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. FAU - Peng, Jiangfan AU - Peng J AD - Department of Urology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, China. FAU - Ma, Shengchao AU - Ma S AD - NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China. FAU - Zhang, Shufang AU - Zhang S AD - Central Laboratory, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine and Haikou City Key Laboratory of Clinical Medicine, Haikou 570203, China. FAU - Wang, Fei AU - Wang F AD - Department of Urology, Affiliated Hainan Hospital of Hainan Medical University, Hainan General Hospital, Hainan Provincial Clinical Medical Center, Haikou 570311, China. AD - School of Clinical Medicine, Hainan Medical University, Haikou 571199, China. LA - eng PT - Journal Article PL - China TA - Acta Biochim Biophys Sin (Shanghai) JT - Acta biochimica et biophysica Sinica JID - 101206716 RN - 0 (MicroRNAs) RN - 0 (Cofilin 1) RN - 0 (CFL1 protein, human) RN - 0 (Cortactin) SB - IM MH - Humans MH - *MicroRNAs/metabolism/genetics MH - *Urinary Bladder Neoplasms/pathology/metabolism/genetics MH - *Cofilin 1/metabolism/genetics MH - Cell Line, Tumor MH - *Podosomes/metabolism/pathology/genetics MH - Cell Movement MH - Gene Expression Regulation, Neoplastic MH - Male MH - Female MH - Cell Proliferation MH - Neoplasm Metastasis MH - Neoplasm Invasiveness MH - Middle Aged MH - Signal Transduction MH - Cortactin/metabolism PMC - PMC13059783 OTO - NOTNLM OT - Cofilin1 OT - bladder cancer OT - invadopodia formation OT - metastasis COIS- The authors declare that they have no conflict of interest. EDAT- 2025/08/08 06:29 MHDA- 2026/04/03 13:47 PMCR- 2025/08/06 CRDT- 2025/08/08 04:03 PHST- 2026/04/03 13:47 [medline] PHST- 2025/08/08 06:29 [pubmed] PHST- 2025/08/08 04:03 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - 10.3724/abbs.2025114 [doi] PST - ppublish SO - Acta Biochim Biophys Sin (Shanghai). 2025 Aug 6;58(3):663-680. doi: 10.3724/abbs.2025114. PMID- 40763383 OWN - NLM STAT- MEDLINE DCOM- 20250915 LR - 20250915 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 5 DP - 2025 Oct TI - Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A 20-Year Nationwide Center Experience. PG - 102397 LID - S1558-7673(25)00097-7 [pii] LID - 10.1016/j.clgc.2025.102397 [doi] AB - OBJECTIVE: Bladder paraganglioma (BPGL) is a rare neuroendocrine tumor. This study evaluates the clinical characteristics, perioperative course, and long-term outcomes of BPGL treated at a nationwide center over the past 2 decades. METHODS: A retrospective review was conducted on 45 patients who underwent surgery for BPGL between January 2004 and September 2024. Demographic data, clinical features, tumor characteristics, surgical approach, intraoperative hemodynamic instability (HDI), and follow-up outcomes were assessed. RESULTS: The median age of patients was 54.0 years (IQR, 36.5, 65.0), with 66.4% being female. A preoperative diagnosis was made in 53.3% of cases. Younger patients (age 0.05). These results were corroborated on multivariable analysis with adjustment for BST type. Secondary endpoints, including cystectomy-free survival and overall survival, were comparable across time-to-treatment intervals (all p > 0.05), with findings supported by multivariable analyses. These results indicate that inclusion criteria based on time to treatment can probably be expanded, which would allow more patients to participate in clinical trials by avoiding leadtime exclusion. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Guske, Christopher AU - Guske C AD - Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Electronic address: cguske@usf.edu. FAU - Jazayeri, Seyed Behzad AU - Jazayeri SB AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Harrs, Christian AU - Harrs C AD - Morsani College of Medicine, University of South Florida, Tampa, FL, USA. FAU - Rao, Nagashree AU - Rao N AD - Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Davaro, Facundo AU - Davaro F AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Xu, Hongzhi AU - Xu H AD - Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Zemp, Logan AU - Zemp L AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Yu, Alice AU - Yu A AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Gilbert, Scott M AU - Gilbert SM AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Poch, Michael AU - Poch M AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Sexton, Wade AU - Sexton W AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Linscott, Joshua AU - Linscott J AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. LA - eng PT - Journal Article DEP - 20250715 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Cystectomy MH - Clinical Trials as Topic MH - *Time-to-Treatment MH - Adjuvants, Immunologic/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer OT - Bladder-sparing therapy OT - Clinical trial OT - Urinary bladder neoplasms EDAT- 2025/07/17 04:40 MHDA- 2025/09/19 00:36 CRDT- 2025/07/16 22:04 PHST- 2025/03/31 00:00 [received] PHST- 2025/05/15 00:00 [revised] PHST- 2025/05/28 00:00 [accepted] PHST- 2025/09/19 00:36 [medline] PHST- 2025/07/17 04:40 [pubmed] PHST- 2025/07/16 22:04 [entrez] AID - S2588-9311(25)00164-6 [pii] AID - 10.1016/j.euo.2025.05.022 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):888-892. doi: 10.1016/j.euo.2025.05.022. Epub 2025 Jul 15. PMID- 40663496 OWN - NLM STAT- MEDLINE DCOM- 20251001 LR - 20251001 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 31 IP - 19 DP - 2025 Oct 1 TI - Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy. PG - 4174-4183 LID - 10.1158/1078-0432.CCR-24-3726 [doi] AB - PURPOSE: Many patients have residual disease after neoadjuvant therapy, but their prognosis and need for adjuvant therapy are unclear. This study evaluates patient prognosis based on the molecular profiling of residual disease at cystectomy. EXPERIMENTAL DESIGN: RNA sequencing data from TURBT samples were available from N = 84 ABACUS patients, of whom N = 64 had matched radical cystectomy (RC) samples, including 10 patients with pathologic complete response (ypT0N0). Pre- and post-atezolizumab tumor gene expression data were classified into molecular subtypes using the consensus subtyping model as a benchmark. Unsupervised consensus clustering was performed to categorize RC samples de novo, and each cluster was characterized using gene expression signatures. Two RC cohorts (neoadjuvant chemotherapy, N = 133 and University of Texas Southwestern, N = 94) known to harbor a scar-like biologic cluster were used for training and testing of a single-sample transcriptomic classifier that was validated in two independent (PURE-01, N = 26 ad ABACUS, N = 64) RC cohorts after neoadjuvant immunotherapy. RESULTS: Unsupervised consensus clustering revealed four distinct post-atezolizumab clusters (scar-like, basal, luminal-stromal, and luminal). The scar-like cluster was present in 25% (16/64) of the post-atezolizumab samples and expressed genes associated with wound healing/scarring. A transcriptomic classifier trained to identify a favorable scar-like transcriptomic profile in residual bladder tumors showed robust performance in two validation cohorts, indicating a patient subgroup with favorable prognosis among neoadjuvant chemotherapy-treated, pembrolizumab-treated, and atezolizumab-treated patients with residual bladder cancer. CONCLUSIONS: This study contributes to the framework for defining molecular subtypes at RC. Residual bladder cancer with a scar-like transcriptomic profile may predict favorable patient prognosis after neoadjuvant chemotherapy and immunotherapy, identifying potential candidates for treatment deintensification. CI - (c)2025 American Association for Cancer Research. FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Erasmus MC Cancer Institute, Rotterdam, the Netherlands. AD - Maasstad Hospital, Rotterdam, the Netherlands. FAU - Reike, Moritz J AU - Reike MJ AUID- ORCID: 0009-0000-1161-4196 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. AD - Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - University of Texas Southwestern, Dallas, Texas. FAU - Seiler, Roland AU - Seiler R AUID- ORCID: 0000-0002-3529-2088 AD - Department of Urology, Hospital Center Biel, Biel, Switzerland. AD - Department of BioMedical Research, University of Bern, Bern, Switzerland. FAU - Davicioni, Elai AU - Davicioni E AUID- ORCID: 0000-0001-9136-099X AD - Veracyte Inc., San Francisco, California. FAU - Necchi, Andrea AU - Necchi A AUID- ORCID: 0000-0002-3007-2756 AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. AD - Vita-Salute San Raffaele University Milan, Milan, Italy. FAU - Powles, Thomas AU - Powles T AUID- ORCID: 0000-0001-7760-4724 AD - Barts Cancer Center, London, United Kingdom. FAU - Black, Peter C AU - Black PC AUID- ORCID: 0000-0002-2919-7068 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Szabados, Bernadett AU - Szabados B AUID- ORCID: 0000-0002-8786-0032 AD - Barts Cancer Center, London, United Kingdom. FAU - Gibb, Ewan A AU - Gibb EA AUID- ORCID: 0000-0001-9836-1434 AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. LA - eng GR - RE4782/1-2/Deutsche Forschungsgemeinschaft (DFG)/ GR - Rene Vogels Stichting (Rene Vogels Foundation)/ PT - Journal Article PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/therapy/drug therapy/mortality MH - Neoadjuvant Therapy/methods MH - Prognosis MH - *Transcriptome MH - Male MH - Female MH - Aged MH - *Biomarkers, Tumor/genetics MH - Gene Expression Profiling MH - Middle Aged MH - *Neoplasm, Residual/genetics/pathology MH - Gene Expression Regulation, Neoplastic/drug effects MH - Cystectomy MH - Neoplasm Invasiveness EDAT- 2025/07/15 18:27 MHDA- 2025/10/01 06:29 CRDT- 2025/07/15 13:23 PHST- 2024/11/18 00:00 [received] PHST- 2025/01/19 00:00 [revised] PHST- 2025/07/10 00:00 [accepted] PHST- 2025/10/01 06:29 [medline] PHST- 2025/07/15 18:27 [pubmed] PHST- 2025/07/15 13:23 [entrez] AID - 763607 [pii] AID - 10.1158/1078-0432.CCR-24-3726 [doi] PST - ppublish SO - Clin Cancer Res. 2025 Oct 1;31(19):4174-4183. doi: 10.1158/1078-0432.CCR-24-3726. PMID- 40659783 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250717 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Jul 14 TI - CENPF overexpression in bladder cancer cells enhances proliferation, migration, invasion, and apoptosis. PG - 25398 LID - 10.1038/s41598-025-10677-9 [doi] LID - 25398 AB - Bladder cancer has been considered as one of the most common urinary malignancies. Growing evidence has indicated that Centromere Protein F (CENPF) is a promising molecular biomarker for many human malignant tumors. However, the role of CENPF in bladder cancer (BC) proliferation, migration, invasion, cell cycle and apoptosis thereof remain unclear. In the present study, high-throughput sequencing technology and bioinformatics analysis were conducted to identify mRNAs profiles in 10 pairs of bladder cancer tissues and adjacent noncancerous tissues. CENPF was overexpression in bladder cancer tissues, and higher in MIBC than NMIBC. We investigated the expression of CENPF in 30 other pairs bladder cancers tissues, and the results were in accordance with the sequencing results. Furthermore, Immunohistochemical staining, showed that strong intensity of CENPF in BC tissues than normal tissues. Increased staining of CENPF was detected of tumor cells in MIBC compared with NMIBC. This suggests that CENPF might be highly expressed in aggressive and invasive tumor cells. Subsequently, in vitro functional experiments also demonstrated that the siRNA interference of CENPF expression significantly weakened the proliferation, migration, invasion and apoptosis of BC cells, and the cells were arrested in the G2/S phase in Cell cycle. Moreover, functional enrichment analyses, lncRNA-miRNA-mRNA, and protein-protein interaction networks revealed that CENPF was potentially involved in carcinogenesis and evolution of bladder cancer. Taken together, these results demonstrated that CENPF may serve as a potential biomarker of tumor occurrence, progression, and even prognosis for bladder cancer. However, further research is needed to be further clarified the pathway mechanisms of CENPF in bladder cancer. CI - (c) 2025. The Author(s). FAU - Song, Ruixiang AU - Song R AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Chen, Xin AU - Chen X AD - Department of Urology, Zhejiang Qiushi Cardiovascular Hospital, Hangzhou, China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Wang, Huiqing AU - Wang H AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Xu, Jinshan AU - Xu J AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Sheng, Zhaoyang AU - Sheng Z AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. 1113165278@qq.com. AD - Department of Urology, The 904th Hospital, Joint Logistics Support Force, Wuxi, China. 1113165278@qq.com. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. yaoxudong1967@163.com. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. yaoxudong1967@163.com. LA - eng GR - 2022YFB3804504/National Key Research and Development Program of China/ GR - Nos. 82101838, 82203367, 82203505, and 82203403/National Natural Science Foundation of China, Youth Project/ GR - No. 22140903800/Experimental Animal Fund of Shanghai Science and Technology Commission/ PT - Journal Article DEP - 20250714 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (centromere protein F) RN - 0 (Microfilament Proteins) RN - 0 (Chromosomal Proteins, Non-Histone) RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism MH - Cell Proliferation/genetics MH - *Cell Movement/genetics MH - *Apoptosis/genetics MH - Gene Expression Regulation, Neoplastic MH - Cell Line, Tumor MH - Neoplasm Invasiveness MH - *Microfilament Proteins/genetics/metabolism MH - *Chromosomal Proteins, Non-Histone/genetics/metabolism MH - Female MH - Male MH - Middle Aged MH - MicroRNAs/genetics MH - Biomarkers, Tumor/genetics MH - RNA, Long Noncoding/genetics PMC - PMC12259981 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - CENPF OT - Cell functional experiments COIS- Competing interests: The authors declare no competing interests. Ethical approval: All methods were performed in accordance with the relevant guidelines and regulations. This paper does not engage in animal experimentation or involve any animal ethics. EDAT- 2025/07/15 00:30 MHDA- 2025/07/15 00:31 PMCR- 2025/07/14 CRDT- 2025/07/14 23:26 PHST- 2025/03/20 00:00 [received] PHST- 2025/07/04 00:00 [accepted] PHST- 2025/07/15 00:31 [medline] PHST- 2025/07/15 00:30 [pubmed] PHST- 2025/07/14 23:26 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - 10.1038/s41598-025-10677-9 [pii] AID - 10677 [pii] AID - 10.1038/s41598-025-10677-9 [doi] PST - epublish SO - Sci Rep. 2025 Jul 14;15(1):25398. doi: 10.1038/s41598-025-10677-9. PMID- 40647487 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250716 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 13 DP - 2025 Jun 28 TI - Prognostic Value of PLR, SIRI, PIV, SII, and NLR in Non-Muscle Invasive Bladder Cancer: Can Inflammatory Factors Influence Pathogenesis and Outcomes? LID - 10.3390/cancers17132189 [doi] LID - 2189 AB - Background/Objectives: Given the increasing interest in the predictive role of inflammation in oncology, we aimed to assess the association between inflammatory factors (IFs) and the histopathological characteristics of bladder cancer (BC). Our objective was to correlate some of these IFs with BC progression and recurrence, identifying possible new diagnostic tools. Methods: We retrospectively analyzed 285 patients (79.8% male, 20.4% female; median age 73) who underwent transurethral resection of the bladder (TURB) between January 2016 and January 2022. The preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), systemic inflammation response index (SIRI), and standard clinical variables were collected one month before TURB and evaluated as predictors of recurrence and progression. Patients were stratified using the Youden Index and ROC analysis. Cox regression models were applied to identify independent predictors. Results: High-grade tumors were present in 74.6% of cases, and 34% were recurrent. Carcinoma in situ was found in 5%. After 72 months, 53% underwent radical cystectomy, and 13.7% died within 5 years. The optimal cutoffs were PLR 139, SIRI 1.12, PIV 248.49, NLR 2, SII 327. Smoking, primary MIBC, age, and lymph node status were significantly associated with recurrence. Elevated PLR correlated with recurrence and T2 progression (p = 0.004). Higher SIRI, PIV, and PLR levels were significantly associated with lymphovascular invasion and nodal metastasis (p < 0.05). PLR was linked to recurrence in tumors >/= 3 cm post-BCG (p = 0.004); high SIRI predicted recurrence within 48 months (p = 0.05). Conclusions: High PLR and SIRI levels were associated with recurrence. Our findings support the emerging role of IFs in predicting BC outcomes and suggest their potential inclusion in future prognostic models. FAU - Bizzarri, Francesco Pio AU - Bizzarri FP AUID- ORCID: 0000-0003-2119-9023 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. AD - Department of Urology, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. FAU - Campetella, Marco AU - Campetella M AUID- ORCID: 0000-0002-7412-1214 AD - Department of Urology, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. FAU - Russo, Pierluigi AU - Russo P AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. AD - Department of Life Science, Health, and Health Professions, University Unilink, 00165 Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AUID- ORCID: 0000-0002-3861-3545 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Moosavi, Seyed Koosha AU - Moosavi SK AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Rossi, Francesco AU - Rossi F AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - D'Amico, Lorenzo AU - D'Amico L AD - Department of Urology, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. FAU - Creti, Antonio AU - Creti A AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Gavi, Filippo AU - Gavi F AUID- ORCID: 0000-0001-9994-4316 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Panio, Enrico AU - Panio E AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Presutti, Simona AU - Presutti S AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Bellavia, Fabrizio AU - Bellavia F AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Ragonese, Mauro AU - Ragonese M AUID- ORCID: 0000-0002-1919-8729 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Ciccarese, Chiara AU - Ciccarese C AD - Department of Oncology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Iacovelli, Roberto AU - Iacovelli R AUID- ORCID: 0000-0002-1750-2117 AD - Department of Oncology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Sighinolfi, Maria Chiara AU - Sighinolfi MC AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Racioppi, Marco AU - Racioppi M AUID- ORCID: 0000-0001-9129-8479 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. FAU - Sacco, Emilio AU - Sacco E AD - Department of Urology, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. FAU - Rocco, Bernardo AU - Rocco B AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy. LA - eng PT - Journal Article DEP - 20250628 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12248968 OTO - NOTNLM OT - bladder cancer OT - inflammatory factors OT - non-muscle invasive bladder cancer COIS- The authors declare no conflicts of interest. We previously declared that our corresponding authors were the guest editors for this special issue. EDAT- 2025/07/13 03:34 MHDA- 2025/07/13 03:35 PMCR- 2025/06/28 CRDT- 2025/07/12 01:07 PHST- 2025/05/30 00:00 [received] PHST- 2025/06/23 00:00 [revised] PHST- 2025/06/25 00:00 [accepted] PHST- 2025/07/13 03:35 [medline] PHST- 2025/07/13 03:34 [pubmed] PHST- 2025/07/12 01:07 [entrez] PHST- 2025/06/28 00:00 [pmc-release] AID - cancers17132189 [pii] AID - cancers-17-02189 [pii] AID - 10.3390/cancers17132189 [doi] PST - epublish SO - Cancers (Basel). 2025 Jun 28;17(13):2189. doi: 10.3390/cancers17132189. PMID- 40645289 OWN - NLM STAT- MEDLINE DCOM- 20251003 LR - 20251003 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 49 IP - 8 DP - 2025 Oct TI - Comparison of prognosis between primary and progressive muscle-invasive bladder carcinoma: A prospective analysis of long-term outcomes after radical cystectomy. PG - 501815 LID - S2173-5786(25)00128-3 [pii] LID - 10.1016/j.acuroe.2025.501815 [doi] AB - INTRODUCTION: Up to 15% of muscle-invasive bladder cancers (MIBC) arise from the progression of a non-muscle-invasive neoplasm. Despite sharing similar treatment strategies, the literature reports differences in survival rates between these two groups. This study aims to identify differences in recurrence and survival that may influence individualized treatment approaches. MATERIAL AND METHODS: Prospective study of cystectomies performed for MIBC between 2011 and 2023, collecting demographic, diagnostic, treatment, and recurrence data (local, urothelial, or distant). A comparative and multivariate analysis was conducted. RESULTS: We did not observe significant differences in recurrence rates between primary and progressive MIBC. However, the group with progression showed better overall survival (OS) rates at 2, 5 and 10 years (100%, 90%, 55%) compared to the primary (80%, 55%, 35%; p = 0.012), as well as better cancer-specific survival (CSS) (100%, 100%, 95% vs. 85%, 77%, 65%; p = 0.033). Independent risk factors for recurrence include pN+ (OR: 3.72) and lymphovascular invasion (LVI) (OR: 5.53). Predictors of lower OS include age, nodal involvement, LVI and relapse at any level. For CSS, predictors include nodal involvement, LVI and relapse at any level. CONCLUSIONS: In our series, patients with progressive MIBC have better OS and CSS. For both groups, pN + and LVI are independent risk factors for recurrence. Nodal involvement, LVI and relapse at any level are predictors of poorer OS and CSS. CI - Copyright (c) 2025 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Juste-Alvarez, S AU - Juste-Alvarez S AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: sjustealvarez@gmail.com. FAU - Garcia-Rayo Encina, C AU - Garcia-Rayo Encina C AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Gomez Del Canizo, C AU - Gomez Del Canizo C AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Hernandez-Arroyo, M AU - Hernandez-Arroyo M AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Miranda-Utrera, N R AU - Miranda-Utrera NR AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Rodriguez-Antolin, A AU - Rodriguez-Antolin A AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Guerrero-Ramos Felix, F AU - Guerrero-Ramos Felix F AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. LA - eng LA - spa PT - Comparative Study PT - Journal Article DEP - 20250709 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Cystectomy/methods MH - Prospective Studies MH - Male MH - Female MH - Neoplasm Invasiveness MH - Aged MH - Prognosis MH - Middle Aged MH - Disease Progression MH - Time Factors MH - Neoplasm Recurrence, Local/epidemiology MH - Treatment Outcome MH - Survival Rate MH - Aged, 80 and over OTO - NOTNLM OT - Cistectomia radical OT - Cancer vesical musculo-invasivo OT - Muscle-invasive bladder cancer OT - Primario OT - Primary OT - Progresivo OT - Progressive OT - Radical cystectomy OT - Recurrence OT - Recurrencia COIS- Declaration of competing interest The authors declare that they have no conflicts of interest. EDAT- 2025/07/12 16:44 MHDA- 2025/10/04 00:30 CRDT- 2025/07/11 19:33 PHST- 2025/01/21 00:00 [received] PHST- 2025/03/11 00:00 [revised] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/10/04 00:30 [medline] PHST- 2025/07/12 16:44 [pubmed] PHST- 2025/07/11 19:33 [entrez] AID - S2173-5786(25)00128-3 [pii] AID - 10.1016/j.acuroe.2025.501815 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2025 Oct;49(8):501815. doi: 10.1016/j.acuroe.2025.501815. Epub 2025 Jul 9. PMID- 40637830 OWN - NLM STAT- MEDLINE DCOM- 20260312 LR - 20260917 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 32 IP - 12 DP - 2025 Nov TI - Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study. PG - 9432-9444 LID - 10.1245/s10434-025-17654-6 [doi] AB - BACKGROUND: The purpose of this study was to find out the impact of lymph node dissection (LND) on the prognosis of patients undergoing cystectomy for non-muscle invasive bladder cancer (NMIBC) and determine the minimum number of lymph nodes (LNs) for resection. PATIENTS AND METHODS: Patients with NMIBC undergoing cystectomy between 2004 and 2015 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching and multivariate Cox regression analyses were performed to mitigate the influence of selection bias and control for potential confounding variables. RESULTS: Of 1950 patients with NMIBC, 1353 underwent LND, of which 58 (4.2%) exhibited positive LNs. LND were associated with better prognosis in the whole cohort (P < 0.001). Patients who had positive lymph nodes were found to have the worst prognosis (P < 0.001). Restricted cubic spline (RCS) found that patients with at least 8 LNs examined show longer survival than those with nLNE < 8, which was further validated in multivariable Cox regression [HR 0.66 (0.59, 0.76)]. Subgroup analysis indicated that nLNE >/= 8 was associated with significantly improved overall survival in T1 and Tis patients both before and after PSM, while for Ta patients, the impact of LND or nLNE >/= 8 on prognosis was insignificant. Additionally, for patients with negative lymph node, nLNE >/= 8 still resulted in better prognosis [HR 0.73 (0.61, 0.87)]. Furthermore, sensitivity analyses replicated the same results in patients more than 80 years old and found that patients with nLNE >/= 8 demonstrated superior prognosis than those with less than 8 lymph nodes retrieved. CONCLUSIONS: Among patients with NMIBC, it is crucial to remove eight or more lymph node effectively during cystectomy, except in Ta subgroup. CI - (c) 2025. The Author(s). FAU - Ji, Jiaxiang AU - Ji J AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Lai, Chin-Hui AU - Lai CH AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Wang, Mingrui AU - Wang M AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Hu, Haopu AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Ni, Runfeng AU - Ni R AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Bian, Xiaolong AU - Bian X AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Hu, Hao AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. huhao@bjmu.edu.cn. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. huhao@bjmu.edu.cn. LA - eng GR - L248068/Natural Science Foundation of Beijing Municipality/ PT - Journal Article DEP - 20250710 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Lymph Node Excision/mortality MH - Female MH - Male MH - Retrospective Studies MH - Survival Rate MH - Aged MH - *Cystectomy/mortality MH - Prognosis MH - Neoplasm Invasiveness MH - Middle Aged MH - Follow-Up Studies MH - SEER Program MH - Lymphatic Metastasis MH - *Lymph Nodes/pathology/surgery MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12534230 OTO - NOTNLM OT - Cystectomy OT - Extent of lymphadenectomy OT - Non-muscle invasive bladder cancer (NMIBC) OT - Propensity score matching (PSM) OT - Threshold COIS- Disclosure: All authors claim no conflict of interests. Ethical approval: Ethical approval for this study was provided by the Ethical Committee of Peking University People's Hospital, Beijing, China. Since the SEER database is publicly accessible and patient information was anonymous, this study did not require informed consent. EDAT- 2025/07/10 12:30 MHDA- 2026/03/12 18:52 PMCR- 2025/07/10 CRDT- 2025/07/10 11:07 PHST- 2025/01/13 00:00 [received] PHST- 2025/05/27 00:00 [accepted] PHST- 2026/03/12 18:52 [medline] PHST- 2025/07/10 12:30 [pubmed] PHST- 2025/07/10 11:07 [entrez] PHST- 2025/07/10 00:00 [pmc-release] AID - 10.1245/s10434-025-17654-6 [pii] AID - 17654 [pii] AID - 10.1245/s10434-025-17654-6 [doi] PST - ppublish SO - Ann Surg Oncol. 2025 Nov;32(12):9432-9444. doi: 10.1245/s10434-025-17654-6. Epub 2025 Jul 10. PMID- 40637628 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251013 LR - 20251015 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 19 IP - 10 DP - 2025 Oct TI - A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada. PG - 302-310 LID - 10.5489/cuaj.9110 [doi] AB - INTRODUCTION: Approximately three-quarters of patients newly diagnosed with bladder cancer have non-muscle-invasive disease (NMIBC). Among these patients, those with high-risk (HR) features should be managed more aggressively in an attempt to circumvent the elevated risk of recurrence/progression. Population-based data on the incidence of HR-NMIBC and receipt of guideline-recommended care are limited. METHODS: This retrospective, observational study gathered data from multiple linked provincial (Alberta) healthcare databases to describe baseline characteristics, treatment patterns, and survival outcomes in a population of individuals diagnosed with HR-NMIBC from 2010-2020. Data for all patients aged >18 years with T1, Tis, or high-grade Ta NMIBC ("high-risk") were analyzed using basic statistics, multivariate regression analyses, and the Kaplan-Meier method. RESULTS: Of 6837 de novo NMIBC patients identified, 3874 (57%) were categorized as HR-NMIBC. The majority (82%) were male with a median age of 72 years, and approximately half had a Charlson comorbidity index score >/=1. Following initial transurethral resection of bladder tumor (TURBT), 61% of the cohort received no adjuvant bacillus Calmette-Guerin (BCG) or chemotherapy, while 36% received BCG, 3% gemcitabine, and 1% mitomycin C. Patients underwent a median of four TURBT procedures. 'Adequate BCG' (>/=5 induction doses + >/=2 maintenance doses) was received by 32% of BCG-treated and 12% of all HR-NMIBC patients. Survival was improved in patients receiving adequate BCG. CONCLUSIONS: Data from this large, real-world population highlights poor use of induction/maintenance BCG therapy following TURBT among patients with HR-NMIBC. FAU - Gotto, Geoffrey AU - Gotto G AD - Departments of Surgery and Oncology, University of Calgary, Calgary, AB, Canada. FAU - Alimohamed, Nimira S AU - Alimohamed NS AD - Division of Medical Oncology, Department of Medicine, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, Department of Surgery, McGill University Health Center, Montreal, QC, Canada. FAU - Kokorovic, Andrea AU - Kokorovic A AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. FAU - Eigl, Bernhard J AU - Eigl BJ AD - BC Cancer, Vancouver, BC, Canada. FAU - Blais, Normand AU - Blais N AD - Division of Medical Oncology and Hematology, Department of Medicine, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada. FAU - Lalani, Aly-Khan A AU - Lalani AA AD - Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. FAU - Cheung, Winson Y AU - Cheung WY AD - Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. AD - Oncology Outcomes, Calgary, AB, Canada. FAU - Stephen, Mariet AU - Stephen M AD - Oncology Outcomes, Calgary, AB, Canada. AD - Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. FAU - Osborne, Brendan J W AU - Osborne BJW AD - Janssen Inc., Toronto, ON, Canada. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Urologic Oncology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 CIN - Can Urol Assoc J. 19:311. PMC - PMC12517452 COIS- COMPETING INTERESTS: Dr. Gotto has received honoraria from Astellas, AstraZeneca, Bayer, EMD Serono, Ferring, Janssen, McKesson, Merck, Pfizer, Sanofi, and Tolmar. Dr. Alimohamed has held advisory/consultancy roles with AbbVie, AstraZeneca, Bayer, BMS, EMD Serono, Gilead, Janssen, Merck, Pfizer, and Seagen; and has received research funding (to institution) from AstraZeneca and EMD Serono. Dr. Kulkarni has served on advisory boards for AAA/Novartis, AbbVie, Astellas, BMS, EMD Serono, EnGene, Ferring, Johnson&Johnson, Knight Therapeutics, Merck, Pfizer, Theralase, and Verity; has consulted for Astra Zeneca, Johnson&Johnson, Photocure, TerSera, and Verity; and has participated in clinical trials supported by BMS, CG Oncology, EnGene, Ferring, Johnson&Johnson, Merck, Pfizer, Seagen, Theralase, and Verity. Dr. Black has been an advisory board member or equivalent for AbbVie, AstraZeneca, Astellas, Bayer, BMS, CG Oncology, Combat, EMD Serono, Ferring, Janssen, Merck, Nonagen, Nanobot, NanOlogy, Pfizer, Photocure, Prokarium, Sumitomo, TerSera, Tolmar, and Verity; a speaker's bureau member for Bayer, Janssen, Pfizer, and TerSera; has participated in clinical trials supported by CG Oncology, Genentech, Janssen, Pacific Edge, Pfizer, and Therelase; and holds a shared patent with Veracyte. Dr. Kassouf has held consultant or advisory roles with Astellas, AstraZeneca, Bayer, BMS, EMD Serono, Ferring, Janssen, Merck, Pfizer, Photocure, Roche, Seagen, and Sesen Bio; and has participated in clinical trials supported by BMS, CG Oncology, Janssen, Pfizer, Roche, and Theralase. Dr. Kokorovic has been a consultant for Astellas, Bayer, Ferring, Janssen, Knight Therapeutics, Pfizer, and Tolmar; and has received honoraria from Janssen. Dr. Eigl has received honoraria from EMD Serono, Gilead, Janssen, Pfizer, and Seagen; has received research funding from Pfizer and travel expenses from EMD Serono. Dr. Blais does not report any competing personal or financial interests related to this work. Dr. Lalani has received grants/research support from BMS (Inst), BioCanRx (Inst), EMD Serrono (Inst), Ipsen (Inst), Novartis (Inst), and Roche (Inst); and honoraria from Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, and TerSera. Dr. Cheung has received grants/research support from Janssen. Dr. Stephen has received grants/research support from Janssen. Mr. Osborne is employed by J&J Innovative Medicine. Dr. Wallis has received consulting fees from Janssen Oncology, Nanostics Inc, Precision Point Specialty LLC, SESEN Bio; honoraria/travel from AbbVie, Astellas, Astra Zeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera, and Tolmar; and research funding from Knight Therapeutics and Tolmar. EDAT- 2025/07/10 12:30 MHDA- 2025/07/10 12:31 PMCR- 2025/10/01 CRDT- 2025/07/10 10:12 PHST- 2025/07/10 12:31 [medline] PHST- 2025/07/10 12:30 [pubmed] PHST- 2025/07/10 10:12 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - cuaj.9110 [pii] AID - cuaj-10-302 [pii] AID - 10.5489/cuaj.9110 [doi] PST - ppublish SO - Can Urol Assoc J. 2025 Oct;19(10):302-310. doi: 10.5489/cuaj.9110. PMID- 40635630 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20260813 IS - 1744-8301 (Electronic) IS - 1479-6694 (Print) IS - 1479-6694 (Linking) VI - 21 IP - 19 DP - 2025 Aug TI - Intravesical interferon-alpha2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review. PG - 2429-2438 LID - 10.1080/14796694.2025.2527593 [doi] AB - Intravesical bacillus Calmette-Guerin (BCG) represents the standard of care therapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC); however, the rate of BCG-unresponsive disease remains high. Cystectomy is the most definitive treatment for patients with this disease entity but is associated with significant morbidity and quality-of-life implications. Recently, several single-arm clinical trials have been conducted to develop alternative treatment options for patients who are ineligible for or decline cystectomy based on guidance from the US Food and Drug Administration (FDA). As a result, several therapeutic options have now emerged, including nadofaragene firadenovec-vncg, an intravesical gene therapy that induces interferon (IFN)-alpha2b gene expression with resultant direct and indirect anti-tumor effects within the bladder. Today, nadofaragene firadenovec-vncg represents the first-line treatment option for patients with BCG-unresponsive disease as an alternative to cystectomy. Advances in our knowledge of the tumor microenvironment, gene therapy techniques, and tumor biology have contributed to this important discovery, with future studies aimed to optimize the efficacy of this therapy through improved patient selection, disease prognostication, and development of combination strategies. FAU - Lee, Taeweon AU - Lee T AUID- ORCID: 0000-0003-0264-6959 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Gianchandani, Ayushi AU - Gianchandani A AD - Faculty of Medicine, Imperial College London, London, UK. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Shore, Neal D AU - Shore ND AD - Carolina Urologic Research Center, Myrtle Beach, SC, USA. FAU - Narayan, Vikram M AU - Narayan VM AUID- ORCID: 0000-0003-3731-4209 AD - Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20250710 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (Interferon alpha-2) RN - 0 (BCG Vaccine) RN - 0 (Interferon-alpha2b) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/genetics/pathology/immunology MH - *Genetic Therapy/methods MH - Administration, Intravesical MH - Interferon alpha-2/genetics MH - BCG Vaccine/therapeutic use/administration & dosage MH - Tumor Microenvironment MH - Clinical Trials as Topic MH - Treatment Outcome MH - Genetic Vectors/genetics/administration & dosage PMC - PMC12330264 OAB - Nadofaragene firadenovec-vncg is a new treatment for bladder cancer that uses gene therapy. This approach delivers a gene into the bladder that helps produce a protein called interferon, which can reduce cancer growth and survival. This treatment is mainly used for patients whose cancer has returned or persisted after receiving a standard treatment called bacillus Calmette-Guerin (BCG). In this article, we review how nadofaragene firadenovec-vncg was developed, how it works, and what clinical studies have shown about its safety and effectiveness, to better understand its place in the evolving landscape of bladder cancer care. OABL- eng OTO - NOTNLM OT - BCG-unresponsive OT - Bacillus Calmette-Guerin (BCG) OT - cystectomy OT - gene therapy OT - intravesical OT - nadofaragene firadenovec-vncg OT - non-muscle invasive bladder cancer OT - rAd-IFNalpha2b/Syn3 COIS- Ashish M. Kamat (AMK) has received research funding from FKD Therapies (now Ferring), Seagen, EnGene, Arquer Diagnostics, and SWOG. AMK served as consultant to Astellas Pharma, Bristol-Myers Squibb, CG Oncology, EnGene, Ferring, Genentech, ImmunityBio, Imvax, Incyte, Janssen, Johnson & Johnson, Medac, Merck, Pfizer, Protara Therapeutics, Seagen, Theralase, Urogen Pharma, and Valar Labs. AMK holds a joint patent with the University of Texas MD Anderson Cancer Center for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy). AMK also holds/recently held leadership or fiduciary roles in the International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). Stephen A. Boorjian is a consultant for Ferring, Prokarium, ArTara, and Johnson & Johnson. Vikram M. Narayan (VMN) is a consultant for Ferring, Aura Biosciences, ImmunityBio. VMN received research funding from Merck, Johnson & Johnson Innovative Medicine, and Photocure. Colin P. N. Dinney (CPND) is a creator of intellectual property owned by the University of Texas MD Anderson Cancer Center related to the use of genetic alterations as a predictive biomarker for response to nadofaragene firadenovec-vncg. CPND owns stock options and personal compensation from CG Oncology for consulting and advisory services. CPND received personal compensation from Ferring for consulting and advisory services.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. EDAT- 2025/07/10 06:27 MHDA- 2025/08/06 12:28 PMCR- 2026/07/10 CRDT- 2025/07/10 04:34 PHST- 2025/08/06 12:28 [medline] PHST- 2025/07/10 06:27 [pubmed] PHST- 2025/07/10 04:34 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 2527593 [pii] AID - 10.1080/14796694.2025.2527593 [doi] PST - ppublish SO - Future Oncol. 2025 Aug;21(19):2429-2438. doi: 10.1080/14796694.2025.2527593. Epub 2025 Jul 10. PMID- 40631580 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20260925 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 136 IP - 5 DP - 2025 Nov TI - Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. PG - 911-919 LID - 10.1111/bju.16851 [doi] AB - OBJECTIVES: To evaluate whether computed tomography (CT) scans should be performed before or after transurethral resection of bladder tumour (TURBT) for accurate lymph node staging in clinically lymph node-positive bladder cancer (BCa). Additionally, to identify patient factors that can aid in predicting lymph node metastasis. PATIENTS AND METHODS: In this retrospective, multicentre study, we analysed patients with cN+ M0 BCa staged by CT and treated with upfront radical cystectomy (RC) and pelvic lymph node dissection. We stratified patients by the interval between TURBT and CT into three groups: (1) before TURBT; (2) within 30 days after TURBT; and (3) more than 30 days post-TURBT. Staging accuracy, defined as concordance between clinical and pathological lymph node status, was evaluated. We utilised logistic regression analyses to identify patient factors, including the optimal timing of staging, in predicting pathological lymph node status at RC. RESULTS: Among 183 patients with cN+ disease, 90 (49%) had pN0 disease at RC. Of these, 40, 36 and 14 were staged before TURBT, within 30 days after TURBT, and more than 30 days post-TURBT, respectively (P = 0.2). Pathological downstaging was most common in cN1 (22%) and cN2 (20%) disease. The overall concordance rate was 23%. The timing of staging did not correlate with pathological lymph node status on logistic regression (all P > 0.05). Lymphovascular invasion (LVI) at TURBT was associated with pN status (odds ratio 4.25, confidence interval 2.02-9.34; P < 0.001) at RC. CONCLUSION: Overall, we found no association between the timing of CT-based staging and pathological lymph node metastases in cN+ BCa. The data suggest that performing a TURBT prior to staging does not increase the finding of false-positive nodes on imaging. LVI was the only factor at the time of TURBT associated with pathological lymph node metastasis at RC. Limitations include the multicentre retrospective design and the inclusion of only patients with clinically node-positive disease. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Furrer, Marc AU - Furrer M AUID- ORCID: 0000-0001-8847-6799 AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland. AD - Department of Urology, Solothurner Spitaler AG, Olten and Solothurn, Switzerland. FAU - Bianchi, Alberto AU - Bianchi A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Maas, Moritz AU - Maas M AD - Department of Urology, Eberhard Karls University Tubingen, Tubingen, Germany. AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Tully, Karl H AU - Tully KH AUID- ORCID: 0000-0002-9499-0169 AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Longoni, Mattia AU - Longoni M AD - Department of Urology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Taylor, Jacob AU - Taylor J AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Velev, Maud AU - Velev M AD - Department of Cancer Medicine, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Klemm, Jakob AU - Klemm J AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Singla, Nirmish AU - Singla N AD - The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Antonelli, Alessandro AU - Antonelli A AUID- ORCID: 0000-0001-6067-5497 AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Kiss, Bernhard AU - Kiss B AUID- ORCID: 0000-0002-4691-556X AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. AD - Department of Urology, Weill Cornell Medical College, New York, New York, USA. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Semmelweis University, Budapest, Hungary. AD - Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Urosud, La Croix Du Sud Hospital, Quint-Fonsegrives, France. CN - CLIPOLY study group collaborators LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250709 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/diagnostic imaging MH - Male MH - Female MH - Neoplasm Staging/methods MH - Aged MH - Retrospective Studies MH - *Tomography, X-Ray Computed/methods MH - Middle Aged MH - Cystectomy/methods MH - Lymphatic Metastasis MH - Time Factors MH - Lymph Node Excision MH - Aged, 80 and over MH - *Lymph Nodes/pathology/diagnostic imaging PMC - PMC12522521 OTO - NOTNLM OT - cN+ OT - computed tomography OT - lymph node staging OT - radical cystectomy OT - template OT - urinary bladder neoplasms OT - urothelial cancer FIR - Antonelli, Luca IR - Antonelli L FIR - Bacchiani, Mara IR - Bacchiani M FIR - Flippot, Ronan IR - Flippot R FIR - Khanna, Abhinav IR - Khanna A FIR - Maier, Elisabeth IR - Maier E FIR - Marcq, Gautier IR - Marcq G FIR - Minvervini, Andrea IR - Minvervini A FIR - Mori, Keiichiro IR - Mori K FIR - Pallauf, Maximilian IR - Pallauf M FIR - Penel, Nicolas IR - Penel N FIR - Sarkis, Julien IR - Sarkis J FIR - Soria, Francesco IR - Soria F FIR - Tendijck, Guus A H IR - Tendijck GAH FIR - van Ginkel, Noor IR - van Ginkel N FIR - Woldu, Solomon IR - Woldu S EDAT- 2025/07/09 12:28 MHDA- 2025/10/15 12:30 PMCR- 2025/10/15 CRDT- 2025/07/09 07:03 PHST- 2025/10/15 12:30 [medline] PHST- 2025/07/09 12:28 [pubmed] PHST- 2025/07/09 07:03 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - BJU16851 [pii] AID - 10.1111/bju.16851 [doi] PST - ppublish SO - BJU Int. 2025 Nov;136(5):911-919. doi: 10.1111/bju.16851. Epub 2025 Jul 9. PMID- 40630945 OWN - NLM STAT- MEDLINE DCOM- 20250709 LR - 20250710 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Taurine-mediated metabolic immune crosstalk indicates and promotes immunosuppression with anti-PD-1 resistance in bladder cancer. PG - 1618439 LID - 10.3389/fimmu.2025.1618439 [doi] LID - 1618439 AB - BACKGROUND: Bladder cancer (BLCA) remains heavily dependent on bacillus Calmette-Guerin (BCG) therapy due to the profound heterogeneity of its tumor microenvironment (TME) and deregulated metabolic landscapes. Taurine metabolism (TM) is a pivotal axis in BLCA, exhibiting dual roles in tumor progression and immune evasion. Deciphering the molecular mechanisms by which TM reprogramming fosters immunosuppression is imperative for advancing BLCA immunotherapy. METHODS: This study employed an integrative approach combining single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (ST), and bulk transcriptome analyses to unravel taurine metabolic dysregulation in the BLCA TME. Computational frameworks such as Seurat and Monocle 3 were used to characterize cellular subpopulations, reconstruct differentiation trajectories, and model intercellular signaling networks. A taurine metabolic dysregulation index (TMs) was developed using TCGA cohorts, with survival modeling and machine learning methodologies deployed to assess its prognostic utility. Immuno-infiltration patterns and immunotherapeutic responsiveness were quantified via algorithms including ESTIMATE and TIDE. Mechanistic validation was achieved through co-culture systems. RESULTS: ScRNA-seq profiling revealed significant perturbations in TM scores across epithelial cells, fibroblasts, and macrophages within the BLCA TME. High TMs clusters were enriched for Notch signaling and EGFR tyrosine kinase inhibitor resistance pathways. Spatial transcriptomics analyses highlighted spatiotemporal heterogeneity in taurine metabolic gene expression. The TMs index emerged as an independent prognostic biomarker, with high TMs patients demonstrating significantly shorter overall survival and synergistic prognostic deterioration in the context of high tumor mutational burden (TMB). High TMs tumors exhibited enrichment of immunosuppressive cell compartments and elevated immune checkpoint molecule expression. Mechanistically, FAAH knockdown in cancer-associated fibroblasts (CAFs) attenuated co-cultured BLCA cell viability, potentially mediated by CCL15 secretion. CONCLUSION: This study establishes that taurine metabolic dysregulation reconfigures intercellular signaling within the BLCA TME, driving immunosuppression and tumor progression. The TMs framework enables robust patient stratification and provides a mechanistic rationale for therapeutic strategies targeting TM in conjunction with immune checkpoint inhibitors, thus paving the way for advanced precision medicine approaches in BLCA. CI - Copyright (c) 2025 Liang, Nong, Li, Chen, Zhao and Huang. FAU - Liang, Zhengfang AU - Liang Z AD - Department of Urinary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. FAU - Nong, Fengwei AU - Nong F AD - The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong, China. AD - Department of Renal Diseases, Affiliated Hospital of Youjiang Medical University for Nationalites, Baise, Guangxi, China. FAU - Li, Zhenjie AU - Li Z AD - Department of Urinary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. FAU - Chen, Runmin AU - Chen R AD - Department of Urinary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. FAU - Zhao, Haoxu AU - Zhao H AD - Department of Urinary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. FAU - Huang, Yongping AU - Huang Y AD - Department of Urinary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. AD - Key Laboratory of Tumor Molecular Pathology of Baise, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. LA - eng PT - Journal Article DEP - 20250624 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 1EQV5MLY3D (Taurine) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (PDCD1 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/metabolism/drug therapy/genetics/pathology MH - *Taurine/metabolism MH - Tumor Microenvironment/immunology MH - *Drug Resistance, Neoplasm/immunology MH - *Immune Checkpoint Inhibitors/pharmacology/therapeutic use MH - *Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology MH - Cell Line, Tumor MH - Immune Tolerance PMC - PMC12234460 OTO - NOTNLM OT - CAFs OT - anti-PD-1 OT - bladder cancer OT - spatial transcriptomics OT - taurine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/07/09 06:26 MHDA- 2025/07/09 06:27 PMCR- 2025/06/24 CRDT- 2025/07/09 05:06 PHST- 2025/04/26 00:00 [received] PHST- 2025/06/05 00:00 [accepted] PHST- 2025/07/09 06:27 [medline] PHST- 2025/07/09 06:26 [pubmed] PHST- 2025/07/09 05:06 [entrez] PHST- 2025/06/24 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1618439 [doi] PST - epublish SO - Front Immunol. 2025 Jun 24;16:1618439. doi: 10.3389/fimmu.2025.1618439. eCollection 2025. PMID- 40620890 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250708 IS - 1428-2526 (Print) IS - 1897-4309 (Electronic) IS - 1428-2526 (Linking) VI - 29 IP - 2 DP - 2025 TI - Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection - a prospective observational study. PG - 188-194 LID - 10.5114/wo.2025.151064 [doi] AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) is one of the most commonly diagnosed urogenital types of cancer with a relatively favourable prognosis. Cystoscopy stands as the most significant diagnostic and monitoring procedure, however more accessible methods are needed for diagnosis and follow-up. MATERIAL AND METHODS: A total of 285 pa-- tients with NMIBC were enrolled in this prospective study. Complete blood count (CBC) biomarkers and nutritional risk scores were evaluated for predicting cancer recurrence or progression after radical transurethral resection of bladder tumour (TURB). Additionally, the correlation between CBC biomarkers and European Organisation for Research and Treatment of Cancer (EORTC) risk scores was performed. A final study group with complete follow-up and dataset, comprised of 183. RESULTS: After a 3-month follow-up period, 104 subjects experienced cancer recurrence or progression. A group of 79 patients were tumour free. The neutrophil-to-lymphocyte ratio (NLR) showed the highest area under the curve of 0.618 (95% CI: 0.536-0.699) with p = 0.0047, for discrimination of the study outcomes. None of nutritional risk scores has predicted disease progression or recurrence. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio and derived NLR enhanced the diagnostic performance for EORTC recurrence and progression points. CONCLUSIONS: Complete blood count biomarkers can predict recurrence or progression of NMIBC after TURB, yet nutritional risk scores have demonstrated inadequate predictive value. Complete blood count biomarkers increase prognostic properties of EORTC risk score. CI - Copyright (c) 2025 Termedia. FAU - Bardowska, Klaudia AU - Bardowska K AD - Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Koscielska-Kasprzak, Katarzyna AU - Koscielska-Kasprzak K AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Bartoszek, Dorota AU - Bartoszek D AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Zabinska, Marcelina AU - Zabinska M AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krolicki, Tomasz AU - Krolicki T AD - Department of Anesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland. FAU - Krajewska, Magdalena AU - Krajewska M AD - Department of Non-Procedural Clinical Sciences, Faculty of Medicine, University of Science and Technology, Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kaminska, Dorota AU - Kaminska D AD - Department of Non-Procedural Clinical Sciences, Faculty of Medicine, University of Science and Technology, Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20250513 PL - Poland TA - Contemp Oncol (Pozn) JT - Contemporary oncology (Poznan, Poland) JID - 101233223 PMC - PMC12224241 OTO - NOTNLM OT - European Organisation for Research and Treatment of Cancer (EORTC) OT - GPS (Glasgow prognostic score) OT - MLR (monocyte-to-lymphocyte ratio) OT - NLR (neutrophil-to-lymphocyte ratio) OT - PLR (platelet-to-lymphocyte ratio) OT - PNI (prognostic nutritional index) OT - dNLR (derived neutrophil-to-lymphocyte ratio) OT - non-muscle invasive bladder cancer (NMIBC) OT - transurethral resection of bladder tumour (TURB) EDAT- 2025/07/07 06:26 MHDA- 2025/07/07 06:27 PMCR- 2025/01/01 CRDT- 2025/07/07 05:14 PHST- 2024/12/17 00:00 [received] PHST- 2025/03/09 00:00 [accepted] PHST- 2025/07/07 06:27 [medline] PHST- 2025/07/07 06:26 [pubmed] PHST- 2025/07/07 05:14 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 56069 [pii] AID - 10.5114/wo.2025.151064 [doi] PST - ppublish SO - Contemp Oncol (Pozn). 2025;29(2):188-194. doi: 10.5114/wo.2025.151064. Epub 2025 May 13. PMID- 40618210 OWN - NLM STAT- MEDLINE DCOM- 20250706 LR - 20260711 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 4 DP - 2025 Jul TI - The role of Uro-Vaxom in reducing infectious adverse effects and improving outcomes in bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer. PG - 344-351 LID - 10.4111/icu.20250060 [doi] AB - PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) instillation is a cornerstone treatment for non-muscle-invasive bladder cancer (NMIBC) but is frequently associated with significant local and systemic adverse effects. This study aimed to investigate the effects of Uro-Vaxom (UVX) on BCG-related infectious adverse events and oncologic outcomes in patients with NMIBC. MATERIALS AND METHODS: This retrospective cohort study included 251 NMIBC patients who underwent BCG induction therapy following transurethral resection of bladder tumors at a single institution. Patients were stratified into two groups: those not receiving UVX (non-UVX group, n=142) and those receiving UVX (UVX group, n=109). Clinical and oncologic parameters, including the frequency of antibiotic use, treatment discontinuation rates, and early recurrence rates following BCG therapy, were compared between the groups. RESULTS: Antibiotic use during BCG treatment was significantly lower in the UVX group compared to the non-UVX group (p<0.001). Furthermore, BCG discontinuation due to urinary tract infection (UTI) was observed exclusively in the non-UVX group (p=0.003). Although tumor recurrence rates within one year were lower in the UVX group, this difference did not reach statistical significance (p=0.212). Multivariate analysis did not identify UVX use as a significant predictor of early recurrence or bacteriuria. CONCLUSIONS: The administration of UVX during BCG therapy in NMIBC patients was associated with reduced antibiotic use and a lower BCG discontinuation rate due to UTI, thereby improving treatment adherence. These findings highlight the potential role of UVX as a valuable adjunct to BCG therapy to optimize patient outcomes. CI - (c) The Korean Urological Association. FAU - Cho, Sookyung AU - Cho S AUID- ORCID: 0009-0002-2274-9533 AD - Department of Internal Medicine, Kwangju Christian Hospital, Gwangju, Korea. FAU - Chung, Ho Seok AU - Chung HS AUID- ORCID: 0000-0001-9883-1539 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Jung, Seung Il AU - Jung SI AUID- ORCID: 0000-0003-4864-8175 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. drjsi51@gmail.com. FAU - Lim, Do Gyeong AU - Lim DG AUID- ORCID: 0000-0002-5955-0758 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Hwang, Eu Chang AU - Hwang EC AUID- ORCID: 0000-0002-2031-124X AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Kwon, Dong Deuk AU - Kwon DD AUID- ORCID: 0000-0002-4544-5420 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. LA - eng GR - HCRI 24022/Chonnam National University Hwasun Hospital Institute for Biomedical Science/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/adverse effects/administration & dosage/therapeutic use MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - *Urinary Tract Infections/prevention & control/etiology/chemically induced MH - Middle Aged MH - Administration, Intravesical MH - *Adjuvants, Immunologic/adverse effects/administration & dosage MH - Treatment Outcome MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Neoplasm Recurrence, Local MH - Anti-Bacterial Agents/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12277912 OTO - NOTNLM OT - BCG vaccine OT - Recurrence OT - Urinary bladder neoplasms OT - Urinary tract infections COIS- The authors have nothing to disclose. EDAT- 2025/07/06 07:48 MHDA- 2025/07/06 07:49 PMCR- 2025/07/01 CRDT- 2025/07/06 02:33 PHST- 2025/02/12 00:00 [received] PHST- 2025/04/14 00:00 [revised] PHST- 2025/04/29 00:00 [accepted] PHST- 2025/07/06 07:49 [medline] PHST- 2025/07/06 07:48 [pubmed] PHST- 2025/07/06 02:33 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 66.344 [pii] AID - 10.4111/icu.20250060 [doi] PST - ppublish SO - Investig Clin Urol. 2025 Jul;66(4):344-351. doi: 10.4111/icu.20250060. PMID- 40618205 OWN - NLM STAT- MEDLINE DCOM- 20250706 LR - 20260710 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 4 DP - 2025 Jul TI - Impact of regular cystoscopy on prognosis in non-muscle-invasive bladder cancer: A nationwide study. PG - 302-310 LID - 10.4111/icu.20240362 [doi] AB - PURPOSE: Transurethral resection of bladder tumors (TUR-BT) requires follow-up evaluation by cystoscopy. We sought to evaluate the prognosis of non-muscle-invasive bladder cancer (NMIBC) patients within 6 months of surgery to identify the optimal timing for the first cystoscopy after TUR-BT. MATERIALS AND METHODS: In this retrospective analysis, patients newly diagnosed with NMIBC were divided into two groups according to whether they underwent cystoscopy within 6 months after TUR-BT. We considered four outcomes: recurrence, progression, cancer-specific mortality, and all-cause mortality. Inverse probability treatment weighting (IPTW)-adjusted Kaplan-Meier analysis was performed to identify the difference in survival for each outcome stratified by cystoscopy status within 6 months after the first TUR-BT. We employed Cox regression models with IPTW to estimate the hazard ratios (HRs) of each outcome according to cystoscopy status. RESULTS: Among 40,678 patients, 11,940 (29.4%) did not undergo cystoscopy within 6 months. The risk of recurrence was higher for patients who underwent cystoscopy than those who did not (HR 1.32, 95% confidence interval [CI] 1.26-1.38, p<0.001). By contrast, the cystoscopy group had a lower risk of progression compared to the non-cystoscopy group (HR 0.70, 95% CI 0.65-0.76, p<0.001), with lower cancer-specific mortality (HR 0.62, 95% CI 0.56-0.68, p<0.001) and all-cause mortality (HR 0.58, 95% CI 0.56-0.60, p<0.001). CONCLUSIONS: Cystoscopy within 6 months was associated with a higher risk of recurrence but a lower risk of progression and death. Therefore, regular cystoscopy after the first TUR-BT for NMIBC is essential to ensure favorable survival outcomes. CI - (c) The Korean Urological Association. FAU - Kim, Jeong-Soo AU - Kim JS AUID- ORCID: 0009-0001-9811-6372 AD - Department of Applied Statistics, Chung-Ang University, Seoul, Korea. FAU - Lee, Jooyoung AU - Lee J AUID- ORCID: 0000-0002-3246-5246 AD - Department of Applied Statistics, Chung-Ang University, Seoul, Korea. FAU - Lee, Chung Un AU - Lee CU AUID- ORCID: 0000-0002-3030-0405 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Nguyen, Tuan Thanh AU - Nguyen TT AUID- ORCID: 0000-0002-4309-8082 AD - Department of Urology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. FAU - Choi, Se Young AU - Choi SY AUID- ORCID: 0000-0002-4615-0966 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. alse3025@gmail.com. LA - eng GR - NRF-2022R1A2C2008207/NRF/ GR - NRF-2023R1A2C1003830/NRF/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality/diagnosis MH - *Cystoscopy/statistics & numerical data MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Prognosis MH - Middle Aged MH - Neoplasm Invasiveness MH - Disease Progression MH - Neoplasm Recurrence, Local/epidemiology MH - Aged, 80 and over MH - Time Factors MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12277910 OTO - NOTNLM OT - Cystoscopy OT - Non-muscle-invasive bladder cancer OT - Prognosis COIS- The authors have nothing to disclose. EDAT- 2025/07/06 07:48 MHDA- 2025/07/06 07:49 PMCR- 2025/07/01 CRDT- 2025/07/06 02:33 PHST- 2024/10/14 00:00 [received] PHST- 2024/12/05 00:00 [revised] PHST- 2025/06/07 00:00 [accepted] PHST- 2025/07/06 07:49 [medline] PHST- 2025/07/06 07:48 [pubmed] PHST- 2025/07/06 02:33 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 66.302 [pii] AID - 10.4111/icu.20240362 [doi] PST - ppublish SO - Investig Clin Urol. 2025 Jul;66(4):302-310. doi: 10.4111/icu.20240362. PMID- 40618204 OWN - NLM STAT- MEDLINE DCOM- 20250706 LR - 20260710 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 4 DP - 2025 Jul TI - Predictive value of tumor invasion patterns on intravesical bacillus Calmette-Guerin response for stage T1 high-grade non-muscle-invasive bladder cancer. PG - 295-301 LID - 10.4111/icu.20250124 [doi] AB - PURPOSE: Parameters predicting intravesical bacillus Calmette-Guerin (BCG) treatment response in non-muscle-invasive bladder cancer (NMIBC) are limited. This study investigated the effectiveness of tumor invasion patterns in predicting intravesical BCG treatment response, which are known to have prognostic value for NMIBC. MATERIALS AND METHODS: Data of 167 primary, stage T1 high-grade NMIBC patients evaluated retrospectively. All transurethral resection samples were re-evaluated for confirmation of pathological variables and determination of invasion patterns. Binary logistic regression analysis applied to obtain determinants of BCG response. Kaplan-Meier curves and log-rank test used to assess relationship between variables and time to recurrence and time to progression. RESULTS: Tumor invasion pattern was nodular in 83 (49.7%), trabecular in 20 (12.0%) and infiltrative in 64 patients (38.3%). Multivariate analysis revealed multifocality (p=0.001), trabecular invasion (p=0.001) and infiltrative invasion (p=0.001) were independent predictors of poor BCG response. Log-rank test determined infiltrative invasion has higher impact on time to recurrence (p<0.001) and nodular invasion has significantly lower risk for time to progression (p=0.013), during the median follow-up period of 15 months. CONCLUSIONS: Invasion patterns are significantly correlated with BCG response. Assessment of this easily applicable parameter can differ patients who may benefit from BCG treatment and can be used as a prognostic indicator. CI - (c) The Korean Urological Association. FAU - Ulus, Ismail AU - Ulus I AUID- ORCID: 0000-0002-2005-9734 AD - Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. ismailulus06@yahoo.com. FAU - Ozsoy, Sule AU - Ozsoy S AUID- ORCID: 0000-0002-6310-1947 AD - Department of Pathology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. FAU - Cin, Selcuk AU - Cin S AUID- ORCID: 0000-0001-5097-0505 AD - Department of Pathology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. FAU - Yilmaz, Mehmet AU - Yilmaz M AUID- ORCID: 0000-0002-5780-534X AD - Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. FAU - Cil, Gokhan AU - Cil G AUID- ORCID: 0000-0001-8997-3164 AD - Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. FAU - Canitez, Ibrahim Ogulcan AU - Canitez IO AUID- ORCID: 0000-0002-2906-5452 AD - Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. FAU - Semercioz, Atilla AU - Semercioz A AUID- ORCID: 0000-0001-8688-4772 AD - Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkiye. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Male MH - Female MH - Neoplasm Invasiveness MH - Aged MH - Retrospective Studies MH - Administration, Intravesical MH - *Adjuvants, Immunologic/administration & dosage/therapeutic use MH - Middle Aged MH - Neoplasm Staging MH - Aged, 80 and over MH - Neoplasm Grading MH - Predictive Value of Tests MH - Prognosis MH - Disease Progression MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12277913 OTO - NOTNLM OT - Intravesical BCG OT - Invasion patterns OT - Non-muscle invasive bladder neoplasms COIS- The authors have nothing to disclose. EDAT- 2025/07/06 07:48 MHDA- 2025/07/06 07:49 PMCR- 2025/07/01 CRDT- 2025/07/06 02:33 PHST- 2025/03/17 00:00 [received] PHST- 2025/04/24 00:00 [revised] PHST- 2025/05/13 00:00 [accepted] PHST- 2025/07/06 07:49 [medline] PHST- 2025/07/06 07:48 [pubmed] PHST- 2025/07/06 02:33 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 66.295 [pii] AID - 10.4111/icu.20250124 [doi] PST - ppublish SO - Investig Clin Urol. 2025 Jul;66(4):295-301. doi: 10.4111/icu.20250124. PMID- 40617053 OWN - NLM STAT- MEDLINE DCOM- 20250915 LR - 20260709 IS - 1535-6345 (Electronic) IS - 0147-0272 (Linking) VI - 58 DP - 2025 Oct TI - Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillance. PG - 101222 LID - S0147-0272(25)00049-2 [pii] LID - 10.1016/j.currproblcancer.2025.101222 [doi] AB - Upper tract urothelial carcinoma (UTUC) is a rare but aggressive malignancy with increasing incidence, often diagnosed at advanced stages due to the limitations of current diagnostic tools. Conventional methods such as urinary cytology, imaging, and ureteroscopy have important drawbacks, including low sensitivity, high costs, and procedural invasiveness. As a result, there is a growing need for non-invasive, highly accurate diagnostic approaches. Epigenetic biomarkers, particularly DNA methylation-based assays, have emerged as promising alternatives for UTUC detection and surveillance. Among these, Bladder EpiCheck(R) (BE) has shown remarkable sensitivity and specificity, particularly for high-grade tumors, making it a valuable adjunct to standard diagnostic techniques. By analyzing tumor-specific methylation patterns in urine samples, BE offers a practical and non-invasive solution that could improve early detection, reduce the need for ureteroscopy, and enhance risk stratification. Several studies have demonstrated its superior diagnostic accuracy, with sensitivity reaching 97.4 % and specificity up to 100 % for high-grade UTUC. Despite these advantages, challenges remain regarding the standardization of testing protocols, validation in larger patient cohorts, and evaluation of cost-effectiveness. Moreover, the role of DNA methylation biomarkers in guiding clinical decisions and predicting disease progression requires further investigation. This review explores the current state of UTUC diagnosis, compares BE with conventional and emerging biomarkers, and discusses its clinical applications, limitations, and future perspectives. The integration of molecular biomarkers like BE into clinical practice has the potential to revolutionize UTUC diagnosis, improving patient outcomes through more precise, non-invasive detection strategies. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Ricciardi, Gabriele AU - Ricciardi G AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy; Istituto Clinico Polispecialistico C.O.T Cure Ortopediche Traumatologiche s.p.a. Messina, Italy. Electronic address: gricciardi1998@gmail.com. FAU - Tralongo, Pietro AU - Tralongo P AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. Electronic address: pietrotralongo@gmail.com. FAU - Fiorentino, Vincenzo AU - Fiorentino V AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: vincenzo.fiorentino@unime.it. FAU - Germana, Emanuela AU - Germana E AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. Electronic address: emanuela.germana@hotmail.it. FAU - Ballato, Mariagiovanna AU - Ballato M AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. Electronic address: mariagiovannaballato96@gmail.com. FAU - Giordano, Walter Giuseppe AU - Giordano WG AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. Electronic address: waltergiordano1997g@gmail.com. FAU - Pepe, Ludovica AU - Pepe L AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: ludopepe97@gmail.com. FAU - Ficarra, Vincenzo AU - Ficarra V AD - Department of Clinical and Experimental Medicine, Division of Urology, University of Messina, Messina, Italy. Electronic address: vincenzo.ficarra@unime.it. FAU - Pizzimenti, Cristina AU - Pizzimenti C AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: cristinapizzimenti86@gmail.co. FAU - Giuffre, Giuseppe AU - Giuffre G AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: giuseppe.giuffre@unime.it. FAU - Zuccala, Valeria AU - Zuccala V AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: valeria.zuccala@unime.it. FAU - Ieni, Antonio AU - Ieni A AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: antonio.ieni@unime.it. FAU - Fadda, Guido AU - Fadda G AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: guido.fadda@unime.it. FAU - Pierconti, Francesco AU - Pierconti F AD - Department of Women, Children and Public Health Sciences, Division of Pathology, Catholic University of Sacred Heart, "A. Gemelli" Hospital Foundation, IRCCS, Roma, Italy. Electronic address: francesco.pierconti@unicatt.it. FAU - Martini, Maurizio AU - Martini M AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy. Electronic address: maurizio.martini@unime.it. LA - eng PT - Journal Article PT - Review DEP - 20250704 PL - United States TA - Curr Probl Cancer JT - Current problems in cancer JID - 7702986 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Biomarkers, Tumor/genetics/urine MH - DNA Methylation MH - *Epigenesis, Genetic MH - *Urologic Neoplasms/diagnosis/genetics MH - *Carcinoma, Transitional Cell/diagnosis/genetics MH - Early Detection of Cancer/methods OTO - NOTNLM OT - -CH(3), methyl group OT - 5-ALA, 5-aminolevulinic acid OT - 5mC, 5-methylcytosine OT - BC, bladder cancer OT - BE, Bladder EpiCheck(R) OT - BTA, Bladder Tumor Antigen OT - BiomarkerList of abbreviations: UTUC, Upper tract urothelial carcinoma OT - CIS, carcinoma in situ OT - CLE, Confocal laser endomicroscopy OT - CTU, computed tomography urography OT - DNA methylation OT - DNMT, DNA methyltransferase OT - EAU, European Association of Urology OT - HG, high-grade OT - HNPCC, hereditary non-polyposis colorectal cancer OT - LG, low-grade OT - MRU, Magnetic Resonance Urography OT - NBI, Narrow-band imaging OT - NMIBC, non-muscle-invasive bladder cancer OT - NMP22, Nuclear Matrix Protein 22 OT - NPV, negative predictive value OT - OCT, Optical coherence tomography OT - PDD, Photodynamic diagnosis OT - PPV, positive predictive value OT - PpIX, protoporphyrin IX OT - TET, ten-eleven translocation OT - UC, Urothelial carcinoma OT - UUT, upper urinary tract OT - WL-URS, conventional white light ureteroscopy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/07/06 06:18 MHDA- 2025/09/16 00:32 CRDT- 2025/07/05 18:06 PHST- 2025/04/12 00:00 [received] PHST- 2025/05/15 00:00 [revised] PHST- 2025/06/24 00:00 [accepted] PHST- 2025/09/16 00:32 [medline] PHST- 2025/07/06 06:18 [pubmed] PHST- 2025/07/05 18:06 [entrez] AID - S0147-0272(25)00049-2 [pii] AID - 10.1016/j.currproblcancer.2025.101222 [doi] PST - ppublish SO - Curr Probl Cancer. 2025 Oct;58:101222. doi: 10.1016/j.currproblcancer.2025.101222. Epub 2025 Jul 4. PMID- 40607984 OWN - NLM STAT- MEDLINE DCOM- 20251018 LR - 20260110 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 10 DP - 2025 Oct 1 TI - Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China. PG - 7363-7368 LID - 10.1097/JS9.0000000000002892 [doi] AB - PURPOSE: This study aimed to evaluate the prognostic significance of synchronous and metachronous bladder cancer (BCa) in Chinese patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). MATERIALS AND METHODS: We retrospectively analyzed clinicopathological data from 2921 consecutive nonmetastatic UTUC patients who underwent RNU between 2000 and 2022. Kaplan-Meier survival analysis and Cox proportional hazards regression models were employed to assess the impact of synchronous or metachronous BCa on clinical outcomes. RESULTS: The cohort included 118 patients (4.0%) with prior non-muscle-invasive BCa (NMIBCa) only and 205 patients (7.1%) with synchronous NMIBCa. Synchronous NMIBCa showed significant associations with inferior overall survival [OS; hazard ratios (HR) = 1.709, 95% confidence interval (CI): 1.301-2.247] and cancer-specific survival (CSS; HR = 1.577, 95% CI: 1.265-1.967). Multivariate analysis confirmed synchronous NMIBCa as an independent predictor for both OS (HR = 1.709, 95% CI: 1.301-2.247, P < 0.001) and CSS (HR = 1.577, 95% CI: 1.265-1.967, P < 0.001). Neither prior NMIBCa history nor the interval from NMIBCa to UTUC diagnosis showed significant associations with OS or CSS. Of the 2598 patients without prior or synchronous BCa, 491 (18.9%) developed intravesical recurrence after RNU, including 37 (7.5%) cases of muscle-invasive BCa. Among 2598 patients without prior/synchronous BCa, 491 (18.9%) developed intravesical recurrence post-RNU, including 37 (7.5%) muscle-invasive cases. Intravesical recurrence within 1-2 years significantly predicted unfavorable OS and CSS, and muscle-invasive BCa recurrence during this period indicated particularly poor outcomes. CONCLUSIONS: Synchronous NMIBCa is an independent risk factor for worse survival in UTUC patients. Early IVR was significantly related to poor survival outcomes in UTUC patients, particularly in pTa-2 cases. Bladder-directed preventive and adjuvant therapeutic strategies may optimize clinical outcomes. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Guan, Bao AU - Guan B AD - The First Hospital of Fangshan District, Beijing, China. FAU - Zhang, Jianye AU - Zhang J AD - The First Hospital of Fangshan District, Beijing, China. FAU - Chen, Silu AU - Chen S AD - The First Hospital of Fangshan District, Beijing, China. FAU - Wang, Guoli AU - Wang G AD - The First Hospital of Fangshan District, Beijing, China. FAU - Du, Yicong AU - Du Y AD - The First Hospital of Fangshan District, Beijing, China. FAU - Tao, Zihao AU - Tao Z AD - The First Hospital of Fangshan District, Beijing, China. FAU - Xu, Chunru AU - Xu C AD - The First Hospital of Fangshan District, Beijing, China. FAU - Tang, Qi AU - Tang Q AD - The First Hospital of Fangshan District, Beijing, China. FAU - Yang, Yi AU - Yang Y AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - The First Hospital of Fangshan District, Beijing, China. FAU - Li, Xuesong AU - Li X AD - The First Hospital of Fangshan District, Beijing, China. FAU - Li, Xiaoying AU - Li X AD - Department of Radiation Oncology, Peking University First Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20250703 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - Male MH - Female MH - *Nephroureterectomy MH - Retrospective Studies MH - Aged MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Middle Aged MH - China/epidemiology MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Neoplasms, Multiple Primary/mortality/surgery MH - *Neoplasms, Second Primary/mortality MH - *Ureteral Neoplasms/surgery/mortality MH - *Kidney Neoplasms/surgery/mortality MH - Aged, 80 and over MH - Kaplan-Meier Estimate PMC - PMC12527747 OTO - NOTNLM OT - bladder cancer OT - metachronous OT - prognosis OT - synchronous OT - upper tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2025/07/03 12:31 MHDA- 2025/10/18 06:29 PMCR- 2025/10/16 CRDT- 2025/07/03 10:23 PHST- 2025/04/30 00:00 [received] PHST- 2025/06/13 00:00 [accepted] PHST- 2025/10/18 06:29 [medline] PHST- 2025/07/03 12:31 [pubmed] PHST- 2025/07/03 10:23 [entrez] PHST- 2025/10/16 00:00 [pmc-release] AID - 01279778-202510000-00068 [pii] AID - IJS-D-25-02094 [pii] AID - 10.1097/JS9.0000000000002892 [doi] PST - ppublish SO - Int J Surg. 2025 Oct 1;111(10):7363-7368. doi: 10.1097/JS9.0000000000002892. Epub 2025 Jul 3. PMID- 40605073 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250705 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 30 IP - 1 DP - 2025 Jul 2 TI - The impact of surgery and survival prediction in patients with bladder neuroendocrine carcinoma: a novel propensity score-matched population-based cohort study. PG - 564 LID - 10.1186/s40001-025-02658-5 [doi] LID - 564 AB - OBJECTIVE: To evaluate the effects of surgical interventions on individuals diagnosed with bladder neuroendocrine carcinoma (BNEC). MATERIALS AND METHODS: Data were gathered from the Surveillance, Epidemiology, and End Results (SEER) database for this retrospective analysis. No-surgery procedures included TURBT, cryotherapy, excisional biopsy, or partial cystectomy. Surgery was categorized as cystectomy, radical cystectomy, or a more complex surgical intervention, such as exenteration. A propensity score overlap weight (PSOW) analysis was performed to adjust statistical influences between the two groups. Prognostic factors related to cancer-specific survival (CSS) and overall survival (OS) were assessed using Cox proportional hazard regression. RESULTS: A total of 2,442 participants were divided into two groups: no-surgery group (n = 1860) and surgery group (n = 582). Individuals in the no-surgery cohort showed a preference for radiation therapy (29.5% compared to 6.7%), whereas individuals in the surgery cohort were more prone to receiving chemotherapy (71.5% compared to 56.6%) as part of their treatment regimen. Surgery was determined to have a strong correlation with increased rates of OS (hazard ratio (HR) = 0.564, 95% confidence interval (CI) = 0.497-0.639, P < 0.001) and CSS (HR = 0.628, 95% CI 0.539-0.732, P < 0.001) results in BNEC patients. After PSOW, 307 patients were selected for each group. Surgical intervention demonstrated a notable enhancement in OS (P < 0.001) and CSS (P < 0.001) than those patients in the no-surgery group. Among the chemotherapy population, the median survival of patients in the surgery group was significantly higher when compared to those in the no-surgery group. Furthermore, individuals diagnosed with stage I (OS, HR = 0.202, 95% CI 0.112-0.366, P < 0.001; CSS HR = 0.198, 95% CI 0.083-0.472, P < 0.001) and II (OS HR = 0.417, 95% CI 0.331-0.525, P < 0.001; CSS HR = 0.415, 95% CI 0.307-0.561, P < 0.001) tumors who underwent surgical procedures exhibited improved long-term survival rates, whereas no surgical advantage was evident in later stages. CONCLUSIONS: In the early stages of BNEC, individuals who undergo surgery experience improved survival rates. Therefore, it is important to carefully consider surgical treatment for patients with advanced BNEC. CI - (c) 2025. The Author(s). FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. ljy543760704@163.com. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, People's Republic of China. FAU - Lu, Na AU - Lu N AD - Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. FAU - Luo, Shuhang AU - Luo S AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China. AD - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. FAU - Tang, Runhua AU - Tang R AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China. AD - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. FAU - Li, Lin AU - Li L AD - National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, People's Republic of China. lilin5052@bjhmoh.cn. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China. wupengjiesan@163.com. FAU - Wang, Dongwen AU - Wang D AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. urology2007@126.com. FAU - Tian, Jun AU - Tian J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. tianjun197010@hotmail.com. AD - Department of Urology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical, Beijing, China. tianjun197010@hotmail.com. LA - eng GR - SZSM202111003/Sanming Project of Medicine in Shenzhen/ PT - Journal Article DEP - 20250702 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 SB - IM MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Propensity Score MH - *Carcinoma, Neuroendocrine/surgery/mortality/pathology MH - Aged MH - Middle Aged MH - Retrospective Studies MH - SEER Program MH - *Cystectomy MH - Prognosis MH - Survival Rate PMC - PMC12224867 OTO - NOTNLM OT - Bladder neuroendocrine carcinoma OT - Propensity score overlap weight OT - SEER OT - Surgery OT - Survival outcome COIS- Declarations. Ethics approval and consent to participate: This was a retrospective study, and clinical data were de-identified before analysis; therefore, ethical approval was not required. Informed consent: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/07/03 06:27 MHDA- 2025/07/03 06:28 PMCR- 2025/07/02 CRDT- 2025/07/03 00:47 PHST- 2024/08/19 00:00 [received] PHST- 2025/05/03 00:00 [accepted] PHST- 2025/07/03 06:28 [medline] PHST- 2025/07/03 06:27 [pubmed] PHST- 2025/07/03 00:47 [entrez] PHST- 2025/07/02 00:00 [pmc-release] AID - 10.1186/s40001-025-02658-5 [pii] AID - 2658 [pii] AID - 10.1186/s40001-025-02658-5 [doi] PST - epublish SO - Eur J Med Res. 2025 Jul 2;30(1):564. doi: 10.1186/s40001-025-02658-5. PMID- 40584958 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250702 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 17 DP - 2025 Jan-Dec TI - Impact of smoking status at diagnosis on oncological outcomes of upper-tract urothelial carcinoma. PG - 17562872251352049 LID - 10.1177/17562872251352049 [doi] LID - 17562872251352049 AB - BACKGROUND: The evidence supporting personalized surveillance strategies for upper-tract urothelial carcinoma (UTUC) remains limited. This study seeks to explore how smoking habits influence the oncological outcomes of UTUC. METHODS: Data on disease characteristics from UTUC patients were gathered prospectively. Recurrence-free survival was the primary outcome measured. Patients were stratified based on smoking status for Kaplan-Meier and multivariable Cox regression analyses. RESULTS: A total of 1952 patients were involved, including 684 (35%) patients who never smoked, 572 (29%) that were ex-smokers, and 696 (36%) that were current smokers. For female patients, most of them were nonsmokers (n = 328). Current smokers were significantly younger and had higher American Society of Anesthesiologist (ASA) scores and Charlson Comorbidity Index. A total of 19.9% (n = 236) of patients developed tumor recurrence. Kaplan-Meier analyses showed that smoking status was associated with a greater likelihood of urothelial carcinoma recurrence (p = 0.011) and intravesical recurrence (p = 0.021). The multivariable Cox regression analysis identified the smoking status as an independent risk factor for urothelial carcinoma recurrence (p = 0.046). When compared with former smokers, current smokers showed a higher urothelial carcinoma recurrence (p = 0.016) and intravesical recurrence (p = 0.006). CONCLUSION: Smoking at the time of diagnosis was significantly associated with an increased risk of tumor recurrence in the bladder but not significantly in the upper urinary tract. This study confirms that cumulative smoking exposure accelerates the risk of tumor recurrence and underlines the importance of smoking cessation. TRIAL REGISTRATION: NCT02281188. CI - (c) The Author(s), 2025. FAU - Zhao, Hongda AU - Zhao H AUID- ORCID: 0000-0003-2414-1484 AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Crisci, Alfonso AU - Crisci A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Te Slaa, Ed AU - Te Slaa E AD - Department of Urology, Isala Klinieken, Zwolle, The Netherlands. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Akand, Murat AU - Akand M AD - Department of Urology, School of Medicine, Selcuk University, Selcuklu, Turkey. FAU - Ng, Chi Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Laguna, Pilar AU - Laguna P AD - Istanbul Medipol University, Istanbul, Turkiye. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. FAU - de la Rosette, Jean AU - de la Rosette J AUID- ORCID: 0000-0002-6308-1763 AD - Istanbul Medipol University, Istanbul, Turkiye. AD - Bashkir State Medical University, Ufa, Russia. LA - eng SI - ClinicalTrials.gov/NCT02281188 PT - Journal Article DEP - 20250628 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC12206271 OAB - The influence of smoking status for patients with UTUC Based on the CROES-UTUC registry, we confirmed that both previous non-urothelial and urothelial cancers could accelerate the risk of tumour recurrence and, more personalized follow-up plans and active treatment strategies should be considered for UTUC patients. OABL- eng OTO - NOTNLM OT - oncological outcomes OT - recurrence OT - smoking OT - upper tract urothelial carcinoma COIS- The authors declare that there is no conflict of interest. EDAT- 2025/07/01 04:06 MHDA- 2025/07/01 04:07 PMCR- 2025/06/28 CRDT- 2025/06/30 06:19 PHST- 2024/09/02 00:00 [received] PHST- 2025/06/03 00:00 [accepted] PHST- 2025/07/01 04:07 [medline] PHST- 2025/07/01 04:06 [pubmed] PHST- 2025/06/30 06:19 [entrez] PHST- 2025/06/28 00:00 [pmc-release] AID - 10.1177_17562872251352049 [pii] AID - 10.1177/17562872251352049 [doi] PST - epublish SO - Ther Adv Urol. 2025 Jun 28;17:17562872251352049. doi: 10.1177/17562872251352049. eCollection 2025 Jan-Dec. PMID- 40583504 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20260827 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 157 IP - 10 DP - 2025 Nov 15 TI - Physical activity and risks of recurrence and progression among patients with non-muscle invasive bladder cancer. PG - 2049-2060 LID - 10.1002/ijc.70030 [doi] AB - Previous studies in solid tumors link high physical activity (PA) levels to lower cancer recurrence risk, but evidence is lacking for patients with non-muscle invasive bladder cancer (NMIBC). We evaluated the association between (changes in) PA (total, moderate-to-vigorous PA, leisure-time PA, and Dutch PA guideline adherence) and risks of NMIBC recurrence and progression. Patients diagnosed between 2014 and 2021 were recruited for the multi-center prospective cohort UroLife. Participants reported prediagnosis PA at 6 weeks (n = 1414) and postdiagnosis PA at 3 and 15 months after diagnosis (n = 1275). Multivariable proportional hazards models were used to assess the association of PA levels with risk of first and multiple recurrence(s) and progression. During a median total follow-up time of 4.6 years, 501 patients had >/=1 recurrence, 144 had >/=2 recurrences, and 157 had progression. Higher pre- and postdiagnosis PA levels were not significantly associated with risks of first recurrence, multiple recurrences, and progression. Pre-to-postdiagnosis increases of 10 metabolic equivalent of task hour/week in leisure-time PA, equivalent to 3-4 h/week of walking or 1 h/week of running, were significantly associated with lower progression risk (hazard ratio at 3 months: 0.94, 95% confidence interval: 0.89-0.99). The self-reported and relatively high PA levels could have limited the detection of associations. In conclusion, higher PA levels before or after NMIBC diagnosis were not significantly associated with lower recurrence or progression risk. Although pre-to-postdiagnosis increases in leisure-time PA were associated with lower progression risk, further research is necessary before specific PA recommendations can be formulated for patients with NMIBC. CI - (c) 2025 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Beeren, Ivy AU - Beeren I AUID- ORCID: 0000-0002-8424-7638 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiebach, Joann AU - Kiebach J AUID- ORCID: 0009-0002-1480-1362 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Hof, Jasper P AU - Hof JP AUID- ORCID: 0000-0002-7461-6364 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Buffart, Laurien M AU - Buffart LM AD - Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AUID- ORCID: 0000-0002-0214-2147 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AUID- ORCID: 0000-0002-8839-8601 AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AUID- ORCID: 0000-0002-2368-1326 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng GR - KUN 2013-5926/Alpe d'HuZes/Dutch Cancer Society/ GR - 2017-2/11179/Dutch Cancer Society/ PT - Journal Article PT - Multicenter Study DEP - 20250630 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/epidemiology MH - Male MH - Female MH - Disease Progression MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control/pathology MH - Aged MH - *Exercise/physiology MH - Middle Aged MH - Prospective Studies MH - Risk Factors MH - Follow-Up Studies MH - Neoplasm Invasiveness MH - Netherlands/epidemiology MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12439070 OTO - NOTNLM OT - disease management OT - lifestyle OT - longitudinal studies OT - non-muscle invasive bladder neoplasms OT - physical activity COIS- The authors declare no conflict of interest. EDAT- 2025/07/01 04:06 MHDA- 2025/09/17 00:31 PMCR- 2025/09/16 CRDT- 2025/06/30 03:33 PHST- 2025/06/17 00:00 [revised] PHST- 2025/01/13 00:00 [received] PHST- 2025/06/18 00:00 [accepted] PHST- 2025/09/17 00:31 [medline] PHST- 2025/07/01 04:06 [pubmed] PHST- 2025/06/30 03:33 [entrez] PHST- 2025/09/16 00:00 [pmc-release] AID - IJC70030 [pii] AID - 10.1002/ijc.70030 [doi] PST - ppublish SO - Int J Cancer. 2025 Nov 15;157(10):2049-2060. doi: 10.1002/ijc.70030. Epub 2025 Jun 30. PMID- 40577661 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20260819 IS - 2473-4276 (Electronic) IS - 2473-4276 (Linking) VI - 9 DP - 2025 Jun TI - Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non-Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guerin Therapy. PG - e2400249 LID - 10.1200/CCI-24-00249 [doi] LID - e2400249 AB - PURPOSE: Collecting information on clinical outcomes (recurrence/progression) from complex treatment courses in non-muscle invasive bladder cancer (NMIBC) is challenging and time-consuming. We developed a deep learning natural language processing model to assess outcomes in patients with NMIBC using vast data from electronic health records (EHRs). METHODS: This retrospective study analyzed data from Japanese adults with NMIBC who started Bacillus Calmette-Guerin (BCG) induction therapy between April 2016 and June 2022. A Bidirectional Encoder Representations from Transformers (BERT) model was trained to classify outcomes, supported by human review for past history records. The model's performance was assessed by precision, recall, and F1 scores. We compared the effectiveness of BCG therapy between completion (patients who completed therapy) and non-completion groups. RESULTS: Of 372 patients studied, 79.3% and 20.7% were in the completion group and the non-completion group, respectively. The final BERT model achieved average F1 scores of 0.91 and 0.98 for time to recurrence (TTR), and 0.74 and 0.94 for time to progression (TTP) before and after human support, respectively. The hazard ratio for TTR in BCG completion versus non-completion groups was 0.40 (95% CI, 0.26 to 0.62) by a multivariate Cox proportional hazard model and 0.41 (95% CI, 0.26 to 0.63) by inverse probability of treatment weighting. CONCLUSION: The developed model could compare the clinical outcomes between treatments in patients with NMIBC using EHRs. Human support, although required, was needed in only 10% documents and was deemed feasible. The model was able to demonstrate the difference in TTR and TTP between BCG completion and non-completion groups. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Yonemoto, Naohiro AU - Yonemoto N AUID- ORCID: 0000-0003-3637-2095 AD - Department of Biostatistics, Faculty of Medicine, University of Toyama. Toyama-shi, Toyama, Japan. FAU - Togo, Kanae AU - Togo K AUID- ORCID: 0000-0003-3964-4009 AD - Access & Value, Pfizer Japan Inc, Shibuya-ku, Tokyo, Japan. FAU - Xu, Linghua AU - Xu L AUID- ORCID: 0000-0003-0466-5993 AD - Access & Value, Pfizer Japan Inc, Shibuya-ku, Tokyo, Japan. FAU - Oguri, Tomoyo AU - Oguri T AUID- ORCID: 0000-0002-7655-1517 AD - Oncology Medical Affairs, Pfizer Japan Inc, Shibuya-ku, Tokyo, Japan. FAU - Tanaka, Masayuki AU - Tanaka M AUID- ORCID: 0000-0002-7778-6844 AD - Oncology Medical Affairs, Pfizer Japan Inc, Shibuya-ku, Tokyo, Japan. FAU - Hasegawa, Yoshiyuki AU - Hasegawa Y AUID- ORCID: 0000-0002-2105-3975 AD - System Integration Sector, NTT DATA Corporation, Koto-ku, Tokyo, Japan. FAU - Izawa, Yoshinobu AU - Izawa Y AD - System Integration Sector, NTT DATA Corporation, Koto-ku, Tokyo, Japan. FAU - Araki, Kenji AU - Araki K AD - Faculty of Medicine, University of Miyazaki Hospital, Miyazaki-shi, Miyazaki, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250627 PL - United States TA - JCO Clin Cancer Inform JT - JCO clinical cancer informatics JID - 101708809 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Deep Learning MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Natural Language Processing MH - Middle Aged MH - Administration, Intravesical MH - Electronic Health Records MH - Treatment Outcome MH - Aged, 80 and over MH - Neoplasm Recurrence, Local/pathology MH - Adjuvants, Immunologic/administration & dosage MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12233173 COIS- The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). EDAT- 2025/06/27 18:28 MHDA- 2025/06/27 18:29 PMCR- 2025/06/27 CRDT- 2025/06/27 16:03 PHST- 2025/06/27 18:29 [medline] PHST- 2025/06/27 18:28 [pubmed] PHST- 2025/06/27 16:03 [entrez] PHST- 2025/06/27 00:00 [pmc-release] AID - CCI-24-00249 [pii] AID - 10.1200/CCI-24-00249 [doi] PST - ppublish SO - JCO Clin Cancer Inform. 2025 Jun;9:e2400249. doi: 10.1200/CCI-24-00249. Epub 2025 Jun 27. PMID- 40570264 OWN - NLM STAT- MEDLINE DCOM- 20250626 LR - 20260828 IS - 2687-8941 (Electronic) IS - 2687-8941 (Linking) VI - 11 DP - 2025 Jun TI - Survival According to Source of Treatment Funding in Bladder Cancer: Analysis of a Large Public Database From Sao Paulo, Brazil. PG - e2400648 LID - 10.1200/GO-24-00648 [doi] AB - PURPOSE: Previous studies have shown differences in patient profile and outcomes depending on the source of health care funding. Here, we evaluated the overall survival (OS) of patients with bladder cancer in public and in private systems in Sao Paulo, Brazil. METHODS: We conducted a retrospective cohort study of patients with bladder cancer registered in the Registro Hospitalar de Cancer da Fundacao Oncocentro de Sao Paulo, a large state-wide database. Eligibility required a diagnosis of non-muscle-invasive or invasive bladder cancer between 2013 and 2018. The main objective was to compare OS between private and public treatment-funding sources. RESULTS: Of 21,090 patients with bladder cancer since database inception, 6,217 were eligible (82.4% with a public source of health care funding). Patients with a public source had more advanced TNM stages at diagnosis and were less likely to have noninvasive papillary transitional-cell carcinoma. Within a 5-year follow-up period, median OS was not reached in either group. Funding source was significantly associated with OS in favor of private source (hazard ratio [HR], 1.72 [95% CI, 1.51 to 1.96]; P < .001), even after adjustment for age, TNM stage, and educational level (HR, 1.41 [95% CI, 1.21 to 1.65]; P < .001). The 5-year OS rate was 68.5% (95% CI, 68.5% to 68.5%) and 53.71% (95% CI, 53.7% to 53.7%) for private and public groups, respectively. CONCLUSION: Public source of funding was associated with a lower OS for bladder cancer. Much progress is required to ensure higher standards of health care focusing on patients treated at public sources. FAU - Maluf, Fernando C AU - Maluf FC AD - Hospital Israelita Albert Einstein, Sao Paulo, Brazil. AD - Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil. FAU - de Oliveira, Cintia S K S AU - de Oliveira CSKS AUID- ORCID: 0000-0001-7385-5729 AD - Produtos Roche Quimicos e Farmaceuticos, Sao Paulo, Brazil. FAU - Ziegelmann, Patricia K AU - Ziegelmann PK AUID- ORCID: 0000-0001-8012-3761 AD - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250626 PL - United States TA - JCO Glob Oncol JT - JCO global oncology JID - 101760170 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/economics/therapy/pathology MH - Brazil/epidemiology MH - Female MH - Male MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Databases, Factual MH - Public Sector MH - Aged, 80 and over EDAT- 2025/06/26 18:35 MHDA- 2025/06/26 18:36 CRDT- 2025/06/26 16:02 PHST- 2025/06/26 18:36 [medline] PHST- 2025/06/26 18:35 [pubmed] PHST- 2025/06/26 16:02 [entrez] AID - 10.1200/GO-24-00648 [doi] PST - ppublish SO - JCO Glob Oncol. 2025 Jun;11:e2400648. doi: 10.1200/GO-24-00648. Epub 2025 Jun 26. PMID- 40569461 OWN - NLM STAT- MEDLINE DCOM- 20250626 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jun 26 TI - Prevalence and predictive factors of complicated urinary tract infections post bladder and prostate transurethral resections. PG - 398 LID - 10.1007/s00345-025-05775-2 [doi] AB - PURPOSE: Complicated urinary tract infections (UTI) after transurethral resection of bladder or prostate tumor (TURBT, TURP) are one of the most frequent and significant complications. However, recommendations for pre-operative antibiotic prophylaxis and treatment of asymptomatic bacteriuria differ greatly. This study aims to determine the prevalence of complicated UTI following TURP and TURBT. The secondary objective is to identify pre and postoperative risk factors associated with complicated UTI. METHODS: A retrospective institutional cohort study was conducted by analyzing records of patients who had either a TURP or a TURBT between January 2020 and December 2021 at the Centre integre universitaire de sante et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke (CIUSSE-CHUS). The prevalence of complicated UTI requiring hospitalization up to 30 days after surgery and associated risk factors were recorded. RESULTS: Out of the 701 patients included, 579 (82.6%) were men and the median age was 72.9 years (IQR: 67-79). In total, 505 (72.0%) patients had undergone a TURBT while 196 (28.0%) had a TURP. Readmission for a complicated UTI was necessary in 16 (2.3%) patients. American Society of Anesthesiologists scores of 3 and 4 were significantly associated with a higher prevalence of post-operative complicated UTI (OR 3.39; CI 1.21-10.8; p = 0.025). CONCLUSION: The prevalence of complicated UTI after TURBT and TURP is relatively low. However, patients with more comorbidities are at greater risk of serious post-operative infectious complications. Antibiotic regimen for patients with pre-operative asymptomatic bacteriuria should therefore be further personalized. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Souiden, Lina AU - Souiden L AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. lina.souiden@usherbrooke.ca. FAU - Tu, Le Mai AU - Tu LM AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. AD - Department of Urology, CIUSSSE-CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. FAU - Bordeleau, Maxence AU - Bordeleau M AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. AD - Department of Urology, CIUSSSE-CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. FAU - Laberge, Genevieve AU - Laberge G AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. AD - Department of Urology, CIUSSSE-CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. FAU - Richard, Patrick O AU - Richard PO AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. AD - Department of Urology, CIUSSSE-CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. FAU - Ismail, Salima AU - Ismail S AD - Faculte de Medecine et des Sciences de la Sante, Universite de Sherbrooke, Sherbrooke, QC, Canada. AD - Department of Urology, CIUSSSE-CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. LA - eng PT - Journal Article DEP - 20250626 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Male MH - Retrospective Studies MH - *Urinary Tract Infections/epidemiology/etiology MH - Prevalence MH - Aged MH - *Transurethral Resection of Prostate/adverse effects MH - *Postoperative Complications/epidemiology MH - Risk Factors MH - *Cystectomy/adverse effects/methods MH - *Prostatic Neoplasms/surgery MH - *Urinary Bladder Neoplasms/surgery MH - Cohort Studies MH - Female OTO - NOTNLM OT - Antibiotic prophylaxis OT - Complicated urinary tract infections OT - Risk factors OT - Transurethral resection of bladder tumor OT - Transurethral resection of prostate COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This study was approved by the committee of the Centre de Recherche de l'Universite de Sherbrooke. Consent for publication: Not applicable. EDAT- 2025/06/26 12:29 MHDA- 2025/06/26 12:30 CRDT- 2025/06/26 11:15 PHST- 2025/02/23 00:00 [received] PHST- 2025/06/16 00:00 [accepted] PHST- 2025/06/26 12:30 [medline] PHST- 2025/06/26 12:29 [pubmed] PHST- 2025/06/26 11:15 [entrez] AID - 10.1007/s00345-025-05775-2 [pii] AID - 10.1007/s00345-025-05775-2 [doi] PST - epublish SO - World J Urol. 2025 Jun 26;43(1):398. doi: 10.1007/s00345-025-05775-2. PMID- 40569326 OWN - NLM STAT- MEDLINE DCOM- 20250909 LR - 20260726 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 214 IP - 4 DP - 2025 Oct TI - Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer. PG - 393-399 LID - 10.1097/JU.0000000000004658 [doi] AB - PURPOSE: Nadofaragene firadenovec-vncg is a US Food and Drug Administration-approved therapy for bacillus Calmette-Guerin-unresponsive nonmuscle-invasive bladder cancer. Bladder spasms and medication leakage during intravesical instillation are common and can affect treatment efficacy. We evaluated the effect of rectal diazepam pretreatment on bladder spasm incidence, retention of instilled medication, and 3-month recurrence rates. MATERIALS AND METHODS: We retrospectively analyzed data from patients treated with nadofaragene firadenovec for bacillus Calmette-Guerin-unresponsive nonmuscle-invasive bladder cancer at Mayo Clinic from November 28, 2023, through September 30, 2024. Patients were stratified by pretreatment with rectal diazepam (10 mg) vs other strategies. Outcomes included bladder spasms, retention of instilled medication, and 3-month recurrence rates. RESULTS: Eighty-eight nadofaragene firadenovec instillations (45 patients) were evaluated. Rectal diazepam pretreatment was used for 25 instillations (28%) and associated with a 25% absolute risk reduction for nadofaragene firadenovec retention failure (4.0% vs 29% of instillations), as compared with other pretreatments (patient-level odds ratio, 0.22 [95% CI, 0.11-0.44]; P < .001). In addition, we observed a 24% absolute reduction in bladder spasm incidence (32% vs 56% of instillations) in the rectal diazepam group (patient-level odds ratio, 0.32 [95% CI, 0.13-0.82]; P = .02). Patients without medication leakage had a lower recurrence rate at 3 months (18% vs 38%), although this difference was not statistically significant (P = .3). One patient had fatigue attributable to rectal diazepam. CONCLUSIONS: Rectal diazepam pretreatment may reduce bladder spasms and improve nadofaragene firadenovec retention during intravesical instillation, thereby enhancing efficacy. Rectal diazepam could improve patient comfort and treatment outcomes, thus warranting further investigation through larger, prospective studies. FAU - Moyer, Jacob A AU - Moyer JA AD - Graduate Research Education Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science, Phoenix, Arizona. FAU - Durant, Adri M AU - Durant AM AD - Department of Urology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Scottsdale, Arizona. FAU - Nguyen, Mimi V AU - Nguyen MV AD - Department of Urology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Scottsdale, Arizona. FAU - Mi, Lanyu AU - Mi L AD - Division of Clinical Trials and Biostatistics, Mayo Clinic, Scottsdale, Arizona. FAU - Zganjar, Andrew J AU - Zganjar AJ AD - Department of Urology, Mayo Clinic, Jacksonville, Florida. FAU - Lyon, Timothy D AU - Lyon TD AD - Department of Urology, Mayo Clinic, Jacksonville, Florida. FAU - Shah, Paras H AU - Shah PH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tyson, Mark D 2nd AU - Tyson MD 2nd AD - Department of Urology, Mayo Clinic, Phoenix, Arizona. LA - eng GR - P30 CA015083/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250626 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - Q3JTX2Q7TU (Diazepam) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Retrospective Studies MH - Administration, Intravesical MH - Male MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Female MH - *Diazepam/administration & dosage MH - Aged MH - BCG Vaccine/therapeutic use/administration & dosage MH - Middle Aged MH - *Spasm/prevention & control/chemically induced MH - Administration, Rectal MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Aged, 80 and over PMC - PMC12278371 MID - NIHMS2092808 OTO - NOTNLM OT - adjuvants OT - administration OT - diazepam OT - drug therapy OT - immunologic OT - intravesical OT - non-muscle-invasive bladder neoplasms COIS- Conflict of interest: None EDAT- 2025/06/26 12:30 MHDA- 2025/09/09 12:31 PMCR- 2026/06/26 CRDT- 2025/06/26 11:04 PHST- 2025/09/09 12:31 [medline] PHST- 2025/06/26 12:30 [pubmed] PHST- 2025/06/26 11:04 [entrez] PHST- 2026/06/26 00:00 [pmc-release] AID - 10.1097/JU.0000000000004658 [doi] PST - ppublish SO - J Urol. 2025 Oct;214(4):393-399. doi: 10.1097/JU.0000000000004658. Epub 2025 Jun 26. PMID- 40563677 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 12 DP - 2025 Jun 17 TI - Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG Immunotherapy. LID - 10.3390/cancers17122027 [doi] LID - 2027 AB - Background: Statins are commonly used cholesterol-lowering drugs with evidence of additional chemoprotective and immunomodulatory effects resulting from the inhibition of DNA replication, cell proliferation, and TH1-cell inhibition. There are conflicting reports regarding the potential benefit of concurrent statin treatment on non-muscle invasive bladder cancer (NMIBC) and specifically on intravesical Bacillus Calmette-Guerin (BCG) outcomes. We therefore aimed to analyze the effects of concurrent BCG and statin use in patients with NMIBC. Methods: National Veterans Affairs databases were used to retrospectively identify men with NMIBC between 2000 and 2010 who were treated with BCG. Pharmacy data was interrogated, and patients were divided according to statin therapy status. Statins had to be given at the beginning of BCG treatments and continued for at least 6 months. Cox proportional hazard ratios after inverse propensity score-weighted and competing risks adjustments were calculated for recurrence, secondary events (e.g., progression), cancer-specific survival, and overall survival. Results: Among 8814 patients, with a median follow-up of 11.3 years, statins were used by 38% of the patients. Patients taking statins were older (71 vs. 68, p < 0.0001), had more comorbidities (Charlson Comorbidity Index (CCI > 2; 38.6% vs. 31.4%, p < 0.0001), and had a higher-grade disease (40.2% vs. 34.3%, p < 0.0001) compared to those not on statins. After adjusting for stage, grade, age, race, CCI, agent orange exposure, and year of diagnosis, Cox proportional hazard analysis revealed no association with recurrence (HR 1.05, 95% CI 0.97-1.15, p = 0.23), secondary events (HR 0.91, 95% CI 0.80-1.05, p = 0.189), or bladder cancer specific survival (HR 0.88, 95% CI 0.76-1.02, p = 0.09) of statin use. However, statins were associated with improved overall survival (HR 0.89, 95% CI 0.83-0.96, p = 0.002). Conclusions: Concurrent statin and BCG use in patients with NMIBC was associated with improved overall survival, but not recurrence, secondary events, or bladder cancer-specific survival. These results confirm the real-world well-established cardiovascular benefit of statin treatment and primary preventive care. However, this large population study did not find any association between statins and the outcomes of patients with NMIBC treated with BCG immunotherapy. FAU - Ndukwe, Estelle AU - Ndukwe E AD - University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA. FAU - Lotan, Paz AU - Lotan P AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Risk, Michael AU - Risk M AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Koehne, Elizabeth L AU - Koehne EL AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Shapiro, Daniel D AU - Shapiro DD AUID- ORCID: 0000-0002-4079-9051 AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. AD - Division of Urology, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA. FAU - Tyllo, Robert P AU - Tyllo RP AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Allen, Glenn O AU - Allen GO AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Abel, E Jason AU - Abel EJ AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Jarrard, David F AU - Jarrard DF AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Richards, Kyle A AU - Richards KA AD - Department of Urology, University of Wisconsin Madison, Madison, WI 53792, USA. AD - Division of Urology, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA. LA - eng PT - Journal Article DEP - 20250617 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12190269 OTO - NOTNLM OT - BCG immunotherapy OT - NMIBC OT - statins COIS- The authors declare no conflicts of interest. EDAT- 2025/06/26 06:27 MHDA- 2025/06/26 06:28 PMCR- 2025/06/17 CRDT- 2025/06/26 01:04 PHST- 2025/04/27 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/11 00:00 [accepted] PHST- 2025/06/26 06:28 [medline] PHST- 2025/06/26 06:27 [pubmed] PHST- 2025/06/26 01:04 [entrez] PHST- 2025/06/17 00:00 [pmc-release] AID - cancers17122027 [pii] AID - cancers-17-02027 [pii] AID - 10.3390/cancers17122027 [doi] PST - epublish SO - Cancers (Basel). 2025 Jun 17;17(12):2027. doi: 10.3390/cancers17122027. PMID- 40560260 OWN - NLM STAT- MEDLINE DCOM- 20250625 LR - 20260127 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 95 IP - 1 DP - 2025 Jun 25 TI - Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer. PG - 62 LID - 10.1007/s00280-025-04783-8 [doi] AB - INTRODUCTION: Mechanism underlying resistance to enfortumab vedotin (EV) and prognostication of Nectin-4 expression in muscle-invasive bladder cancer (MIBC) remains unclear. METHODS: We generated gemcitabine-resistant HT-1376 and cisplatin-resistant HT-1376 cells generated from parental HT1376 cells (derived from MIBC). Transcriptome analysis was conducted to explore the biological function of differentially expressed genes detected in chemoresistant HT-1376 cells compared to parental HT-1376. In 70 patients with MIBC undergoing radical cystectomy, unsupervised hierarchical clustering was performed using immunohistochemical staining pattern with GATA3, KRT20, KRT5/6, KRT14, and Nectin-4 expression derived from the gene expression-based Nectin-4-modified NanoString molecular classification: Luminal-Nec4-High, Luminal-Nec4-Low, Basal-Nec4-High, and Basal-Nec4-Low subgroups. RESULTS: We found significant downregulation of Nectin-4 expression along with epithelial-to-mesenchymal transition in chemoresistant HT-1376 cells. Exogenous expression of NECTIN4 in chemoresistant HT-1376 cells partially restored sensitivity to EV. RNA seq identified differentially expressed genes, including Nectin-4 and small proline-rich proteins, downregulated in chemoresistant HT-1376 cells. Over-representation analysis using GO and KEGG revealed upregulation of gene sets enriched for ribosome biogenesis-related pathways in chemoresistant HT-1376 cells. Nectin-4-modified molecular subtype resulted in better stratification of survival-the Luminal-Nec4-High subgroup had the best and the Basal-Nec4-Low subgroup had the worst prognosis. Comparing molecular subtypes of MIBC cells between transurethral resection specimens and matched radical cystectomy specimens revealed that 43% of neoadjuvant chemotherapy-treated patients with luminal subtype tumors showed a marked shift to the basal subtype in the cystectomy specimens. CONCLUSION: The clinical utility of Nection-4, associated molecules, and Nectin-4-modified molecular subtype need to be studied for better management strategies for MIBC. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. makitomiyake@yahoo.co.jp. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. AD - Division of Cancer Immunology, National Cancer Center Research Institute, Chuo-ku, Tsukiji, Tokyo, 104-0045, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Onishi, Sayuri AU - Onishi S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Division of Fostering Required Medical Human Resources, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan. FAU - Jinno, Cynthia N AU - Jinno CN AD - Department of Biomedical Sciences, Cedars‑Sinai Medical Center, Los Angeles, CA, USA. FAU - Furuya, Hideki AU - Furuya H AD - Department of Biomedical Sciences, Cedars‑Sinai Medical Center, Los Angeles, CA, USA. FAU - Oda, Yuki AU - Oda Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Tomizawa, Mitsuru AU - Tomizawa M AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Onishi, Kenta AU - Onishi K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Goto, Daisuke AU - Goto D AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, 840 Shijo, Kashihara, 634-8522, Nara, Japan. FAU - Miura, Noriyoshi AU - Miura N AD - Department of Urology, Ehime University Graduate School of Medicine, Ehime, 791- 0295, Japan. FAU - Kikugawa, Tadahiko AU - Kikugawa T AD - Department of Urology, Ehime University Graduate School of Medicine, Ehime, 791- 0295, Japan. FAU - Saika, Takashi AU - Saika T AD - Department of Urology, Ehime University Graduate School of Medicine, Ehime, 791- 0295, Japan. FAU - Rosser, Charles AU - Rosser C AD - Department of Urology, Cedars‑Sinai Medical Center, Los Angeles, CA, USA. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, 634- 8522, Nara, Japan. LA - eng GR - 16K20159/Japan Society for the Promotion of Science/ GR - 15K10605/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20250625 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - 0 (NECTIN4 protein, human) RN - 0 (Cell Adhesion Molecules) RN - 0 (Gemcitabine) RN - Q20Q21Q62J (Cisplatin) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Antineoplastic Agents) RN - 0 (Nectins) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics MH - *Cell Adhesion Molecules/genetics/metabolism MH - Drug Resistance, Neoplasm/genetics MH - Epithelial-Mesenchymal Transition/drug effects MH - Female MH - Male MH - Down-Regulation MH - Cell Line, Tumor MH - Gemcitabine MH - Gene Expression Regulation, Neoplastic/drug effects MH - Cisplatin/pharmacology MH - Prognosis MH - Deoxycytidine/analogs & derivatives/pharmacology MH - Middle Aged MH - Aged MH - Antineoplastic Agents/pharmacology MH - Cystectomy MH - Gene Expression Profiling MH - Clinical Relevance MH - Nectins OTO - NOTNLM OT - Bladder neoplasm OT - Chemoresistance OT - Enfortumab Vedotin OT - Molecular classification OT - RNA seq COIS- Declarations. Conflict of interest: Kiyohide Fujimoto received speaking/lecture fees and Makito Miyake received speaking/lecture and consultation/advisory fees from Astellas Pharma Inc. Other authors disclose no potential conflicts of interest. Ethics statement: Approval of the research protocol by an Institutional Reviewer Board: ID: 1256/2891. EDAT- 2025/06/25 12:28 MHDA- 2025/06/25 12:29 CRDT- 2025/06/25 11:06 PHST- 2025/04/29 00:00 [received] PHST- 2025/06/11 00:00 [accepted] PHST- 2025/06/25 12:29 [medline] PHST- 2025/06/25 12:28 [pubmed] PHST- 2025/06/25 11:06 [entrez] AID - 10.1007/s00280-025-04783-8 [pii] AID - 10.1007/s00280-025-04783-8 [doi] PST - epublish SO - Cancer Chemother Pharmacol. 2025 Jun 25;95(1):62. doi: 10.1007/s00280-025-04783-8. PMID- 40557582 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20251130 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 136 IP - 5 DP - 2025 Nov TI - Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer. PG - 882-890 LID - 10.1111/bju.16828 [doi] AB - OBJECTIVES: To compare the predictive performance of the World Health Organization (WHO) 1973, WHO 2004/2022, the three-tier (low grade [LG]/Grade 1 [G1]-G2, high grade [HG]/G2, and HG/G3), and four-tier (LG/G1, LG/G2, HG/G2, and HG/G3) hybrid grading systems in Ta non-muscle-invasive bladder cancer (NMIBC), by evaluating recurrence-free survival (RFS) and progression-free survival (PFS). PATIENTS AND METHODS: This retrospective multicentre study included 1233 patients with pTa NMIBC treated with transurethral resection of bladder tumour, eventually followed by intravesical instillations as determined by their physicians, between 2010 and 2023, across 18 Italian hospitals. Pathologists graded resected tissues using the WHO 1973, WHO 2004/2022 classifications, and hybrid three-tier (LG, HG/G2, HG/G3) and four-tier (LG/G1, LG/G2, HG/G2, HG/G3) systems. Kaplan-Meier curves estimated RFS and PFS. Discriminative performance was assessed using Harrell's concordance index (C-index). RESULTS: Among 1233 patients with pTa NMIBC, 890 were classified as LG and 343 as HG according to the WHO 2004/2022 grading system, while 586, 405, and 242 were categorised as G1, G2, and G3, respectively, under the WHO 1973 system. With a median (interquartile range) follow-up of 26 (14-48) months, 418 patients experienced recurrence, including 184 with HG recurrence and 42 who progressed to MIBC. The C-index values for RFS were 0.60, 0.56, 0.57, and 0.61 for the WHO 1973, WHO 2004/2022, hybrid three-tier, and four-tier grading systems, respectively. For progression, the C-index values were 0.80, 0.74, 0.75, and 0.81 across the same systems, underscoring the superior predictive capacity of the four-tier classification. Nonetheless, the low number of MIBC progression events limits the robustness of these analyses. CONCLUSION: Our findings highlight the superior prognostic accuracy of the four-tier hybrid classification in predicting recurrence and progression in patients with stage Ta NMIBC. By combining strengths from the WHO 1973 and 2004/2022, this hybrid model shows promise as tool for enhancing NMIBC patient management in clinical practice. CI - (c) 2025 BJU International. FAU - Ferro, Matteo AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Catellani, Michele AU - Catellani M AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Bianchi, Roberto AU - Bianchi R AUID- ORCID: 0000-0001-7011-0537 AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Fallara, Giuseppe AU - Fallara G AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Tozzi, Marco AU - Tozzi M AUID- ORCID: 0009-0004-6911-2905 AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Maggi, Martina AU - Maggi M AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Chierigo, Francesco AU - Chierigo F AUID- ORCID: 0000-0001-7357-0758 AD - Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. FAU - Uleri, Alessandro AU - Uleri A AUID- ORCID: 0000-0002-2392-2775 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Da Pozzo, Luigi Filippo AU - Da Pozzo LF AD - School of Medicine, University of Milano-Bicocca, Milan, Italy. AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Cella, Ludovica AU - Cella L AUID- ORCID: 0009-0009-0399-2395 AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Di Stasi, Mauro Savino AU - Di Stasi MS AD - Department of Surgery and Experimental Medicine, Tor Vergata University, Rome, Italy. FAU - Checcucci, Enrico AU - Checcucci E AUID- ORCID: 0000-0001-7901-5608 AD - Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Robotic and Minimally-Invasive Urology Unit, AOU Policlinico Tor Vergata, Rome, Italy. FAU - Maiorino, Francesco AU - Maiorino F AD - Robotic and Minimally-Invasive Urology Unit, AOU Policlinico Tor Vergata, Rome, Italy. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Albo, Giancarlo AU - Albo G AD - Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - De Lorenzis, Elisa AU - De Lorenzis E AD - Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Boeri, Luca AU - Boeri L AD - Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Liguori, Giovanni AU - Liguori G AD - Department of Urology, University of Trieste, Cattinara Hospital-ASUGI, Trieste, Italy. FAU - Vedovo, Francesca AU - Vedovo F AUID- ORCID: 0000-0002-9791-6888 AD - Department of Urology, University of Trieste, Cattinara Hospital-ASUGI, Trieste, Italy. FAU - Roth, Beat AU - Roth B AUID- ORCID: 0000-0002-7369-650X AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Falagario, Ugo AU - Falagario U AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AUID- ORCID: 0000-0003-3708-2209 AD - Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Madonia, Massimo AU - Madonia M AD - Dipartimento di Medicina, Chirurgia e Farmacia, Universita degli Studi di Sassari, Sassari, Italy. FAU - Tedde, Alessandro AU - Tedde A AD - Dipartimento di Medicina, Chirurgia e Farmacia, Universita degli Studi di Sassari, Sassari, Italy. FAU - Di Tonno, Pasquale AU - Di Tonno P AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AUID- ORCID: 0000-0001-7807-1229 AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Forte, Saverio AU - Forte S AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Lo Giudice, Arturo AU - Lo Giudice A AUID- ORCID: 0000-0003-1987-929X AD - Department of Urology, University of Catania, Catania, Italy. FAU - Verweij, Fabrizio AU - Verweij F AD - U.O.C. Urologia ASST, Cremona, Italy. FAU - Racioppi, Marco AU - Racioppi M AD - U.O.C. Clinica Urologica, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Bizzarri, Francesco Pio AU - Bizzarri FP AUID- ORCID: 0000-0003-2119-9023 AD - U.O.C. Clinica Urologica, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Crestani, Alessandro AU - Crestani A AUID- ORCID: 0000-0001-7443-8740 AD - Department of Urology, Santa Maria Della Misericordia Hospital, Udine, Italy. FAU - Rinaldi, Marco AU - Rinaldi M AD - Department of Urology, Santa Maria Della Misericordia Hospital, Udine, Italy. FAU - Cerruto, Maria Angela AU - Cerruto MA AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. AD - University of Verona, Verona, Italy. FAU - Claps, Francesco AU - Claps F AUID- ORCID: 0000-0003-2812-5553 AD - Urology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. FAU - Conti, Andrea AU - Conti A AD - Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. AD - Department of Urology, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy. FAU - Dal Moro, Fabrizio AU - Dal Moro F AD - Urology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy. FAU - Zattoni, Fabio AU - Zattoni F AUID- ORCID: 0000-0002-4178-373X AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Imbimbo, Ciro AU - Imbimbo C AD - Department of Urology, Humanitas Gavazzeni, Humanitas University, Bergamo, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Aveta, Achille AU - Aveta A AD - Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy. FAU - Pandolfo, Savio Domenico AU - Pandolfo SD AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Humanitas Gavazzeni, Humanitas University, Bergamo, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Carmignani, Luca AU - Carmignani L AD - Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. AD - Department of Urology, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy. FAU - De Nunzio, Cosimo AU - De Nunzio C AUID- ORCID: 0000-0002-2190-512X AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Genoa, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AUID- ORCID: 0000-0001-8567-6795 AD - Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Turin, Italy. FAU - Rocco, Bernardo AU - Rocco B AUID- ORCID: 0000-0002-9135-0035 AD - U.O.C. Clinica Urologica, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Barone, Biagio AU - Barone B AUID- ORCID: 0000-0003-4884-132X AD - Division of Urology, Department of Surgical Sciences, AORN Sant'Anna e San Sebastiano, Caserta, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale', Naples, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250625 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - *Neoplasm Grading/methods MH - Prognosis MH - Middle Aged MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Progression-Free Survival MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Ta sub-staging OT - four-tier hybrid OT - grading system OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence EDAT- 2025/06/25 06:25 MHDA- 2025/10/15 12:31 CRDT- 2025/06/25 05:33 PHST- 2025/10/15 12:31 [medline] PHST- 2025/06/25 06:25 [pubmed] PHST- 2025/06/25 05:33 [entrez] AID - 10.1111/bju.16828 [doi] PST - ppublish SO - BJU Int. 2025 Nov;136(5):882-890. doi: 10.1111/bju.16828. Epub 2025 Jun 25. PMID- 40552702 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 60 DP - 2025 Jun 24 TI - Use of Photodynamic diagnosis (PDD) at primary TURB: Potential influence on recurrence and progression rates in NMIBC: a registry-based study using a country cohort. PG - 115-123 LID - 10.2340/sju.v60.43993 [doi] AB - OBJECTIVE: To investigate whether department-level use of photodynamic diagnosis (PDD) for primary transurethral bladder resections (TURBs) is associated with recurrence and progression rates in a non-selected, national cohort. Non-muscle invasive bladder cancer (NMIBC) has high global prevalence, and is characterized by high recurrence risk and risk of progression to muscle-invasive bladder cancer. Treatment effects and long-term outcomes rely on diagnostic accuracy, which may be enhanced using PDD for TURB. PDD-use in Denmark has varied between departments. Material and Methods: We identified all Danish patients with primary NMIBC during 2011-2017 via the Danish National Patient Registry (DNPR) and divided them into four groups based on the treating department's annual PDD use. We included 8,502 patients; 76% men, median age at diagnosis: 70 years (interquartile range [IQR]: 63, 77). Primary outcomes were recurrence- and progression risk differences (RDs) at 2 and 5 years depending on the PDD-exposure group. Results were additionally stratified by baseline pathological risk group. RESULTS: The PDD-use varied from <40% of primary TURBs in group 1 to >74% in group 4. Overall 2- and 5 years recurrence risks were 39.9% [95% CI: 38.8; 41.0] and 48.1% [95% CI: 46.9; 49.3], while risks of progression were 17.5% [95% CI: 16.7; 18.4] and 22.9% [95% CI: 21.9; 23.9]. PDD-exposure groups 2-4 had lower recurrence- and progression risks compared to group 1, most pronounced for high-risk NMIBC. CONCLUSIONS: PDD-use in primary TURBs correlates with reduced 2- and 5 years recurrence- and progression risks in NMIBC. The PDD benefit was most noticeable in higher risk NMIBC. Photodynamic diagnosis, primary Trans Urethral Resection of the Bladder (TURB), progression risk, recurrence risk. FAU - Blichert-Refsgaard, Linea AU - Blichert-Refsgaard L AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. lineblic@rm.dk. FAU - Lindgren, Maria S AU - Lindgren MS AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Sundelin, Maria Ordell AU - Sundelin MO AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Graugaard-Jensen, Charlotte AU - Graugaard-Jensen C AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Norgaard, Mette AU - Norgaard M AD - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. LA - eng PT - Journal Article DEP - 20250624 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/diagnosis MH - Male MH - Aged MH - Disease Progression MH - Registries MH - Middle Aged MH - Female MH - *Neoplasm Recurrence, Local/epidemiology MH - Denmark/epidemiology MH - *Cystectomy/methods MH - Cohort Studies MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms EDAT- 2025/06/24 13:08 MHDA- 2025/06/24 18:30 CRDT- 2025/06/24 07:43 PHST- 2025/03/31 00:00 [received] PHST- 2025/05/27 00:00 [accepted] PHST- 2025/06/24 18:30 [medline] PHST- 2025/06/24 13:08 [pubmed] PHST- 2025/06/24 07:43 [entrez] AID - 10.2340/sju.v60.43993 [doi] PST - epublish SO - Scand J Urol. 2025 Jun 24;60:115-123. doi: 10.2340/sju.v60.43993. PMID- 40551001 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jun 23 TI - Utility of restaging transurethral resection in patients with primary high-grade Ta bladder cancer. PG - 387 LID - 10.1007/s00345-025-05778-z [doi] AB - PURPOSE: International guidelines present discrepancies concerning restaging transurethral resection (TURBT) for high-grade (HG) Ta bladder cancer. Recent studies with heterogeneous inclusion criteria have reported discordant results regarding its benefits. Our study aimed to assess the prognostic impact of restaging TURBT in patients with HG Ta that was fully resected during the initial TURBT. METHODS: This single-center retrospective study involved patients with HG Ta. Patients with a history of urothelial carcinoma >/= HG Ta, macroscopically incomplete resection, or the absence of detrusor muscle in the resected tissue were excluded. The decision to perform restaging TURBT was left to the discretion of the operating surgeon. Adjuvant treatment and follow-up were conducted according to established guidelines. RESULTS: A total of 181 patients were identified, with 111 included in the survival analysis. Patients who underwent restaging TURBT presented more frequently with multifocal lesions and were more likely to receive adjuvant therapy. Conversely, patients who underwent only TURBT had a higher prevalence of previous low-grade Ta tumors. The median time to restaging TURBT was 49 days. Residual tumors were detected in 36.4%, with 4.6% classified as pT1. Restaging TURBT did not impact RFS. In multivariate analysis, the use of photodynamic diagnosis PDD (HR = 0.3, p = 0.03) and adjuvant therapy (HR = 0.5, p < 0.01) were associated with a reduced risk of recurrence. Restaging TURBT did not significantly influence PFS. CONCLUSIONS: Restaging TURBT did not affect the risk of recurrence or progression in patients with HG Ta following a complete initial TURBT. These findings are consistent with recent updates in clinical guidelines. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Mebroukine, Samy AU - Mebroukine S AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. samy.mebroukine@u-bordeaux.fr. FAU - Klein, Clement AU - Klein C AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. FAU - Yacoub, Mokrane AU - Yacoub M AD - Anatomical Pathology Department, Bordeaux University Hospital, Bordeaux, France. FAU - Capon, Gregoire AU - Capon G AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. FAU - Alezra, Eric AU - Alezra E AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. FAU - Bladou, Franck AU - Bladou F AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. FAU - Bernhard, Jean-Christophe AU - Bernhard JC AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. FAU - Robert, Gregoire AU - Robert G AD - Urology Department, Bordeaux University Hospital, 1 Place Amelie Raba Leon, Bordeaux, 33000, France. LA - eng PT - Journal Article DEP - 20250623 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - *Cystectomy/methods MH - Neoplasm Staging MH - Middle Aged MH - Neoplasm Grading MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Urethra MH - Aged, 80 and over MH - Prognosis OTO - NOTNLM OT - Hexaminolevulinate OT - Non-muscle invasive bladder cancer OT - Second-look surgery OT - Transurethral resection of bladder COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/06/24 11:07 MHDA- 2025/06/24 18:30 CRDT- 2025/06/23 23:23 PHST- 2024/12/09 00:00 [received] PHST- 2025/06/16 00:00 [accepted] PHST- 2025/06/24 18:30 [medline] PHST- 2025/06/24 11:07 [pubmed] PHST- 2025/06/23 23:23 [entrez] AID - 10.1007/s00345-025-05778-z [pii] AID - 10.1007/s00345-025-05778-z [doi] PST - epublish SO - World J Urol. 2025 Jun 23;43(1):387. doi: 10.1007/s00345-025-05778-z. PMID- 40550272 OWN - NLM STAT- MEDLINE DCOM- 20251006 LR - 20251006 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 35 IP - 9 DP - 2025 Oct TI - Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach. PG - 102921 LID - S2950-3930(25)00068-3 [pii] LID - 10.1016/j.fjurol.2025.102921 [doi] AB - OBJECTIVES: Non-muscle invasive bladder cancer (NMIBC) accounts for 70-80% of all bladder cancer cases. Despite adequate Bacillus Calmette-Guerin (BCG) therapy, approximately 30% of patients fail to respond, with up to 40% recurring within a year and 20% progressing to muscle-invasive disease (MIBC). Current studies often focus on single recurrence events, failing to account for the recurrent nature of NMIBC. This study aims to identify key factors influencing recurrence and progression, utilizing advanced statistical models to capture the complexity of disease dynamics. METHODS: This monocentric retrospective study included 385 NMIBC patients treated with BCG between 2012 and 2020. Patients were stratified by EAU intermediate-risk (IR) and high-risk (HR) categories. Multi-event analyses, including Cox proportional hazards and Prentice-Williams-Peterson Total Time (PWP-TT) models, identified predictors of recurrence and progression. Multinomial logistic regression analyzed temporal recurrence dynamics across three time intervals: within 6months of BCG initiation, 6months after the last instillation, and beyond this period. RESULTS: Among 385 patients, 122 experienced recurrence, with 34.4% presenting as low-grade pTa, 23.8% as high-grade pTa, and 40.9% as advanced stages (pT1 or higher). Progression to MIBC occurred in 10.3%, predominantly in HR patients (HR: 13.1% vs. IR: 4.5%; P=0.017). Cox analysis identified multifocality (HR=2.07; P=0.001) and prior bladder cancer history (HR=1.72; P=0.008) as key predictors for any-grade recurrence. Multinomial regression showed high-risk patients had increased odds of advanced recurrence (pT2 or higher; OR=2.71, P=0.001). Late high-grade recurrences demonstrated similar progression and mortality risks to early refractory tumors. CONCLUSIONS: This study highlights the heterogeneous recurrence dynamics in NMIBC. While IR patients predominantly experience low-grade recurrences, HR patients remain at persistent risk of high-grade and advanced-stage progression. These findings advocate for tailored surveillance strategies and further exploration of personalized, bladder-preserving therapies for high-risk patients. LEVEL OF EVIDENCE: Level 3: Non-randomized controlled cohort/follow-up study (retrospective cohort). CI - Copyright (c) 2025. Published by Elsevier Masson SAS. FAU - Brouzes, Hugo AU - Brouzes H AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France; Service d'Urologie, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France. Electronic address: hugo.brouzes@chu-lyon.fr. FAU - Ourfali, Said AU - Ourfali S AD - Service d'Urologie, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France. FAU - Fassi-Fehri, Hakim AU - Fassi-Fehri H AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France. FAU - Benoit-Janin, Melanie AU - Benoit-Janin M AD - Service d'Anatomo-Cyto-Pathologie, Hopital Louis Pradel, Hospices Civils de Lyon, Bron, France. FAU - Abid, Nadia AU - Abid N AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France. FAU - Maillet, Denis AU - Maillet D AD - Service d'Urologie, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France; Service d'oncologie medicale, Hopital Lyon Sud, Pierre-Benite, France; Faculte de medecine Jacques Lisfranc, Universite Jean-Monnet, Saint-Etienne, Pierre-Benite, France. FAU - Ruffion, Alain AU - Ruffion A AD - Service d'Urologie, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France; Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon, France; Lyon Sud Medical School, University Claude-Bernard Lyon 1, Lyon, France. FAU - Colombel, Marc AU - Colombel M AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard-Herriot, Hospices Civils de Lyon, Lyon, France; Service d'Urologie, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Electronic address: marc.colombel@chu-lyon.fr. LA - eng PT - Journal Article DEP - 20250621 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Disease Progression MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - Middle Aged MH - *BCG Vaccine/therapeutic use MH - Time Factors MH - Aged, 80 and over MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Risk Assessment MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG relapsing tumor OT - BCG unresponsive tumor OT - Delay to recurrence OT - Low grade recurrence OT - Prognosis OT - Tumor recurrence characteristics (grade stage) COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/06/24 11:08 MHDA- 2025/10/07 00:29 CRDT- 2025/06/23 19:10 PHST- 2025/02/09 00:00 [received] PHST- 2025/06/10 00:00 [revised] PHST- 2025/06/19 00:00 [accepted] PHST- 2025/10/07 00:29 [medline] PHST- 2025/06/24 11:08 [pubmed] PHST- 2025/06/23 19:10 [entrez] AID - S2950-3930(25)00068-3 [pii] AID - 10.1016/j.fjurol.2025.102921 [doi] PST - ppublish SO - Fr J Urol. 2025 Oct;35(9):102921. doi: 10.1016/j.fjurol.2025.102921. Epub 2025 Jun 21. PMID- 40546393 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250624 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 77 DP - 2025 Jul TI - Potential of Urinary Mutation and Methylation Biomarkers in Selecting Candidates for Repeat Transurethral Resection of Bladder Tumor in Non-muscle-invasive Bladder Cancer: A Prospective Multicenter Study. PG - 49-57 LID - 10.1016/j.euros.2025.05.011 [doi] AB - BACKGROUND AND OBJECTIVE: The necessity of repeat transurethral resection of bladder tumor (re-TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC) remains a matter of debate. The role of liquid biopsy in predicting residual tumor status and selecting patients who can be spared re-TURBT is still undefined. The aim of our study was to assess the efficacy of the urinary OncoUrine assay for mutation and methylation markers in determining the necessity for re-TURBT in NMIBC. METHODS: We prospectively recruited patients with NMIBC who were candidates for re-TURBT. Urine samples for OncoUrine testing and exfoliated cytology analysis were collected after initial TURBT, followed by re-TURBT. KEY FINDINGS AND LIMITATIONS: Among 151 patients with NMIBC, 48 (32%) had residual tumor at re-TURBT, and 87 (58%) had detrusor muscle (DM) in their initial TURBT specimen. The OncoUrine test showed sensitivity of 77%, specificity of 78%, positive predictive value of 62%, and negative predictive value (NPV) of 88% for residual tumor, while exfoliated cytology showed corresponding values of 20%, 96%, 69%, and 72%. Stratified analyses revealed higher OncoUrine accuracy in predicting disease-free status in intermediate-risk NMIBC (NPV 98%) and in high-risk NMIBC cases with DM in the initial TURBT specimen (NPV 92%). At 18-mo follow-up for 131 patients, 20 had experienced tumor recurrence, for which OncoUrine positivity was the only independent factor predictive for the risk of recurrence (hazard ratio 3.67, 95% confidence interval 1.49-9.00; p = 0.005). CONCLUSIONS AND CLINICAL IMPLICATIONS: The OncoUrine test may identify patients who can avoid unnecessary re-TURBT, especially for intermediate-risk NMIBC cases and high-risk NMIBC cases with DM in the initial TURBT specimen. Conversely, patients with a positive OncoUrine result are at higher risk of recurrence and should undergo re-TURBT. PATIENT SUMMARY: OncoUrine is a urine test that can help in identifying patients with non-muscle-invasive bladder cancer who may be able to avoid unnecessary repeat resection of the bladder. CI - (c) 2025 The Author(s). FAU - Yang, Xiao AU - Yang X AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. AD - Department of Urology, Wuxi Medical Center of Nanjing Medical University, Wuxi, China. FAU - Xin, Yaqun AU - Xin Y AD - Hangzhou Jichenjunchuang Medical Laboratory, Hangzhou, China. FAU - Chen, Xinfeng AU - Chen X AD - Department of Urology, Nantong First People's Hospital, Nantong, China. FAU - Zheng, Bing AU - Zheng B AD - Department of Urology, Nantong First People's Hospital, Nantong, China. FAU - Han, Jie AU - Han J AD - Department of Urology, Jiangsu Province Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China. FAU - Yuan, Lin AU - Yuan L AD - Department of Urology, Jiangsu Province Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China. FAU - Yang, Xuejian AU - Yang X AD - Department of Urology, Suqian First Hospital, Suqian, China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. AD - Department of Urology, Suqian First Hospital, Suqian, China. FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Liu, Peikun AU - Liu P AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yu, Ruixi AU - Yu R AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Bai, Rongjie AU - Bai R AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Liu, Yiyang AU - Liu Y AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Ma, Tonghui AU - Ma T AD - Genecn-Biotech, Hangzhou, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article DEP - 20250610 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC12182801 OTO - NOTNLM OT - Methylation OT - Mutation OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Repeat transurethral resection of bladder tumor OT - Residual tumor OT - Urine liquid biopsy EDAT- 2025/06/23 08:42 MHDA- 2025/06/23 08:43 PMCR- 2025/06/10 CRDT- 2025/06/23 05:56 PHST- 2025/05/24 00:00 [accepted] PHST- 2025/06/23 08:43 [medline] PHST- 2025/06/23 08:42 [pubmed] PHST- 2025/06/23 05:56 [entrez] PHST- 2025/06/10 00:00 [pmc-release] AID - S2666-1683(25)00133-8 [pii] AID - 10.1016/j.euros.2025.05.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2025 Jun 10;77:49-57. doi: 10.1016/j.euros.2025.05.011. eCollection 2025 Jul. PMID- 40545490 OWN - NLM STAT- MEDLINE DCOM- 20260108 LR - 20261009 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 58 IP - 1 DP - 2026 Jan TI - Comparative efficacy of kidney-sparing surgery versus radical nephroureterectomy for high-risk middle-lower ureteral urothelial carcinoma: a retrospective analysis. PG - 33-43 LID - 10.1007/s11255-025-04618-8 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare and aggressive malignancy. The standard treatment, radical nephroureterectomy (RNU), may lead to renal function deterioration in high-risk patients. Kidney-sparing surgery (KSS) offers an alternative, but its efficacy in high-risk UTUC, especially for high-risk middle-lower ureteral urothelial carcinoma (UUC), is not well-established. METHODS: We conducted a retrospective analysis of 181 patients with high-risk middle-lower UUC treated between 2013 and 2023 at three hospitals in China. Patients were categorized into RNU (n = 155) and KSS (n = 26) groups. Propensity score matching (PSM) was used to balance baseline characteristics between groups. Perioperative outcomes and long-term survival were compared. RESULTS: After PSM, the KSS group showed significantly reduced surgery duration and blood loss compared to the RNU group. No significant differences were observed in transfusion rate, perioperative complications, resection margins, and hospitalization duration. In terms of prognosis, no significant differences were found in overall survival (OS), cancer-specific survival (CSS), intravesical recurrence-free survival (IVRFS), and metastasis-free survival (MFS) between the two groups post-PSM. Multivariate analysis identified T-stage as an independent risk factor for CSS. CONCLUSION: KSS may be a feasible alternative to RNU in selected high-risk middle-lower UUC patients, with comparable long-term survival. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Wang, Cheng AU - Wang C AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Shang, PanFeng AU - Shang P AUID- ORCID: 0009-0000-2493-6004 AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. shangpf@lzu.edu.cn. FAU - Zhang, Biao AU - Zhang B AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Kang, ZiMing AU - Kang Z AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Ou, ShuZhen AU - Ou S AD - Lanzhou University, Lanzhou, Gansu, China. FAU - Xu, WanRong AU - Xu W AD - Department of Urology, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China. FAU - Li, HengPing AU - Li H AD - Department of Urology, Gansu Provincial Hospital, Lanzhou, Gansu, China. FAU - Wan, JiangHou AU - Wan J AD - Department of Urology, Lanzhou University First Hospital, Lanzhou, Gansu, China. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20250622 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - Retrospective Studies MH - *Nephroureterectomy/methods MH - Male MH - Female MH - *Ureteral Neoplasms/surgery/pathology/mortality MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Treatment Outcome MH - *Organ Sparing Treatments/methods MH - Kidney MH - Propensity Score OTO - NOTNLM OT - High-risk patients OT - Kidney-sparing surgery OT - Radical nephroureterectomy OT - Retrospective analysis OT - Ureteral urothelial carcinoma COIS- Statements and Declarations. Ethical approval and informed consent: The study was conducted according to the guidelines of the Declaration of Helsinki. This research is a retrospective study and involves research in humans. The study passed the ethical review of the Lanzhou University Second Hospital (2023A-116). The above results are indicated in the statement at the end of the manuscript. Competing interests: The authors have no relevant financial or non-financial interests to disclose. The authors declare no competing interests. Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2025/06/23 06:13 MHDA- 2026/01/08 17:53 CRDT- 2025/06/22 23:03 PHST- 2025/04/14 00:00 [received] PHST- 2025/06/10 00:00 [accepted] PHST- 2026/01/08 17:53 [medline] PHST- 2025/06/23 06:13 [pubmed] PHST- 2025/06/22 23:03 [entrez] AID - 10.1007/s11255-025-04618-8 [pii] AID - 10.1007/s11255-025-04618-8 [doi] PST - ppublish SO - Int Urol Nephrol. 2026 Jan;58(1):33-43. doi: 10.1007/s11255-025-04618-8. Epub 2025 Jun 22. PMID- 40544234 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20260111 IS - 1748-717X (Electronic) IS - 1748-717X (Linking) VI - 20 IP - 1 DP - 2025 Jun 21 TI - Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis. PG - 104 LID - 10.1186/s13014-025-02678-9 [doi] LID - 104 AB - BACKGROUND: Radical cystectomy is the recommended treatment in muscle-invasive bladder cancer patients with hydronephrosis. However, there is no literature on the impact of chemoradiotherapy on pre-existing hydronephrosis or the development of new hydronephrosis. This study aims to assess the incidence, aetiology, and management of hydronephrosis before and after chemoradiotherapy (CRT). MATERIALS AND METHODS: Retrospective cohort study, including patients with muscle-invasive bladder cancer (MIBC) treated with CRT between 1 January 2014 and 5 December 2022. Patients with urethral urothelial carcinoma and with stage T1 were included if they received total bladder irradiation. Exclusion criteria were renal transplantation, ureteral reimplantation, sequential chemotherapy and radiotherapy, CRT as preoperative treatment, urinary diversion before CRT, transitioning to palliative radiotherapy, and sarcomatoid or signet ring cell carcinoma type. Patients were also excluded if no follow-up data was available. In this period 181 patients received CRT, after applying the exclusion criteria a total of 146 patients were eligible for evaluation. The main outcome was hydronephrosis, defined as any grade of dilatation of the renal pelvis with or without ureter dilatation, identified on any form of imaging. RESULTS: 146 patients were included, 27 with pre-existing hydronephrosis before CRT and 119 without. The mean age of the patients was 73 years (Standard deviation (SD): 8.59) and 74% was male. Hydronephrosis in patients with pre-existing hydronephrosis persisted after CRT in 74% (n = 20), with 44% (n = 12) receiving drainage. Of the patients without pre-existing hydronephrosis, 21% (n = 25) developed hydronephrosis, and 52% (n = 13) of the patients that developed hydronephrosis required drainage. Tumour was responsible for pre-existing hydronephrosis in 93% (n = 25) and for hydronephrosis after CRT in 22% (n = 6) with pre-existing hydronephrosis. In patients without pre-existing hydronephrosis, hydronephrosis was caused by a tumour in 11 out of 25 patients. CONCLUSIONS: Pre-existing hydronephrosis persists after CRT for MIBC in ~ 75% of patients and ~ 20% of patients without pre-existing hydronephrosis develops hydronephrosis after CRT. Around half of these patients receive drainage. These findings may assist in counselling patients with pre-existing hydronephrosis regarding the potential outcomes following CRT. CI - (c) 2025. The Author(s). FAU - Remmelink, Marinka J AU - Remmelink MJ AD - VUmc Department of Urology , Amsterdam University Medical Center, University of Amsterdam, Boelelaan 1117, Amsterdam, 1081HV, The Netherlands. m.j.remmelink@amsterdamumc.nl. AD - Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands. m.j.remmelink@amsterdamumc.nl. FAU - Awadly, Nader El AU - Awadly NE AD - Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Arbeel-Weening, Berber AU - Arbeel-Weening B AD - Flevoziekenhuis, Department of Urology, Almere, the Netherlands. FAU - Nadorp, Sven AU - Nadorp S AD - Amstelland Hospital, Department of Urology, Amstelveen, the Netherlands. FAU - Leter, Maicle R AU - Leter MR AD - Dijklander Hospital, Department of Urology, Hoorn, the Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - VUmc Department of Urology , Amsterdam University Medical Center, University of Amsterdam, Boelelaan 1117, Amsterdam, 1081HV, The Netherlands. AD - Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands. FAU - Bruck, Katharina AU - Bruck K AD - Department of Radiation Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Cancer Center Amsterdam, Therapy and Supportive Care, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands. AD - Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands. FAU - Bins, Adriaan D AU - Bins AD AD - Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. LA - eng GR - NA/Cure for Cancer/ PT - Journal Article DEP - 20250621 PL - England TA - Radiat Oncol JT - Radiation oncology (London, England) JID - 101265111 SB - IM EIN - Radiat Oncol. 2026 Jan 9;21(1):8. doi: 10.1186/s13014-025-02729-1. PMID: 41508013 MH - Humans MH - *Hydronephrosis/etiology/epidemiology/pathology MH - Male MH - *Urinary Bladder Neoplasms/therapy/pathology/complications MH - Retrospective Studies MH - Female MH - Aged MH - *Chemoradiotherapy/adverse effects MH - Middle Aged MH - Aged, 80 and over MH - Prognosis PMC - PMC12182687 OTO - NOTNLM OT - Bladder cancer OT - Bladder preservation OT - Bladder preserving treatment OT - Bladder-sparing treatment OT - Chemoradiotherapy OT - Concurrent chemoradiation OT - Hydronephrosis OT - Radiotherapy OT - Trimodality treatment COIS- Declarations. Ethics approval and consent to participate: Institutional ethics board approval was waived by the medical ethical committee of Amsterdam Medical Center. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/06/22 06:10 MHDA- 2025/06/24 11:10 PMCR- 2025/06/21 CRDT- 2025/06/21 23:22 PHST- 2025/02/10 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2025/06/24 11:10 [medline] PHST- 2025/06/22 06:10 [pubmed] PHST- 2025/06/21 23:22 [entrez] PHST- 2025/06/21 00:00 [pmc-release] AID - 10.1186/s13014-025-02678-9 [pii] AID - 2678 [pii] AID - 10.1186/s13014-025-02678-9 [doi] PST - epublish SO - Radiat Oncol. 2025 Jun 21;20(1):104. doi: 10.1186/s13014-025-02678-9. PMID- 40543100 OWN - NLM STAT- MEDLINE DCOM- 20250913 LR - 20250913 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 162 DP - 2025 Sep 23 TI - Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. PG - 115057 LID - S1567-5769(25)01047-1 [pii] LID - 10.1016/j.intimp.2025.115057 [doi] AB - BACKGROUND: Gemcitabine is a widely used intravesical chemotherapeutic agent for non-muscle-invasive bladder cancer (NMIBC), yet its efficacy remains suboptimal, with high recurrence rates. While traditionally considered a cytotoxic agent, emerging evidence suggests that certain chemotherapeutics may exert immunomodulatory effects. This study investigated whether gemcitabine induces immunogenic cell death (ICD) and explored the underlying mechanisms involving endoplasmic reticulum (ER) stress. METHODS: A retrospective analysis was conducted to assess the association between gemcitabine-related complications and NMIBC recurrence. In vitro assays were used to evaluate ICD hallmarks (ATP, HMGB1, CALR) and pro-inflammatory cytokines. RNA sequencing and western blotting were performed to explore ER stress pathways. Functional assays included dendritic cell (DC) maturation, phagocytosis, and CD8(+)T cell proliferation and cytotoxicity. In vivo vaccination and T cell depletion models were used to evaluate antitumor immunity. RESULTS: Clinical data revealed an inverse correlation between gemcitabine-related complications and tumor recurrence. Gemcitabine induced classical ICD markers in bladder cancer cells and elicited CD8(+)T cell-mediated antitumor immunity in vivo. Mechanistically, gemcitabine activated the PERK branch of the ER stress response, promoting CALR translocation and DAMP release. PERK overexpression enhanced DC maturation, phagocytosis, and stimulation of CD8(+)T cell proliferation and cytotoxicity, whereas PERK knockdown impaired these effects. CONCLUSIONS: This study demonstrates that short-term, high-dose gemcitabine induces PERK-dependent ICD, which enhances antitumor immune responses via DC and CD8(+)T cell activation. These findings provide a mechanistic rationale for combining gemcitabine with immunotherapy and suggest PERK as a potential biomarker and therapeutic target for ICD enhancement in bladder cancer. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Xiong, Wei AU - Xiong W AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: xiongw21@lzu.edu.cn. FAU - Liu, Yali AU - Liu Y AD - Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, China. Electronic address: wo_lyl@163.com. FAU - Yang, Haihong AU - Yang H AD - Gansu Hospital, Affiliated Cancer Hospital of Sun Yat-Sen University,Lanzhou 730000, Gansu Province, China. Electronic address: 17582812413@63.com. FAU - Zhang, Bin AU - Zhang B AD - Shanxi Provincial People's Hospital Affiliated to Shanxi Mcdical University, 030000, Shanxi Province, China. Electronic address: zhangb24@sxmu.edu.cn. FAU - Zhang, Xingxing AU - Zhang X AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: xxzhang21@lzu.edu.cn. FAU - Du, Yuelin AU - Du Y AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: docdyl@163.com. FAU - Wang, Hongbo AU - Wang H AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: drwanghongbo@163.com. FAU - Zhang, Xiaojun AU - Zhang X AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: zxj1026cc@163.com. FAU - Luo, Yao AU - Luo Y AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: 2273992710@qq.com. FAU - Ha, Hualan AU - Ha H AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: hahl21@lzu.edu.cn. FAU - Fu, Yuqiang AU - Fu Y AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: fuyq0720@163.com. FAU - Zhang, Biao AU - Zhang B AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: zhangb2023@lzu.edu.cn. FAU - Zhang, Helin AU - Zhang H AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: zhanghl2023@lzu.edu.cn. FAU - Lu, Jianzhong AU - Lu J AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Key Laboratory of Gansu Province for Urological Diseases, Lanzhou 730000, Gansu Province, China. Electronic address: lujzh@lzu.edu.cn. FAU - Shang, Panfeng AU - Shang P AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: shangpf@lzu.edu.cn. FAU - Yue, Zhongjin AU - Yue Z AD - Department of Urology, Lanzhou University, Second Hospital, Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou University, Lanzhou, 730000, Gansu Province, China; Lanzhou University, Lanzhou 730000, Gansu Province, China. Electronic address: yuezj@lzu.edu.cn. LA - eng PT - Journal Article DEP - 20250620 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - EC 2.7.11.1 (eIF-2 Kinase) RN - 0 (Antimetabolites, Antineoplastic) RN - EC 2.7.11.1 (EIF2AK3 protein, human) RN - 0 (Calreticulin) SB - IM MH - Gemcitabine MH - *Urinary Bladder Neoplasms/drug therapy/immunology/pathology MH - *Deoxycytidine/analogs & derivatives/pharmacology/therapeutic use MH - Humans MH - *Immunogenic Cell Death/drug effects MH - Animals MH - Endoplasmic Reticulum Stress/drug effects MH - Mice MH - *eIF-2 Kinase/metabolism/genetics MH - Cell Line, Tumor MH - CD8-Positive T-Lymphocytes/immunology/drug effects MH - Female MH - Retrospective Studies MH - Male MH - Dendritic Cells/immunology/drug effects MH - *Antimetabolites, Antineoplastic/therapeutic use/pharmacology MH - Calreticulin/metabolism MH - Mice, Inbred C57BL MH - Aged MH - Middle Aged OTO - NOTNLM OT - Bladder cancer OT - CD8(+)T cell OT - Endoplasmic reticulum stress OT - Gemcitabine OT - Immunogenic cell death (ICD) OT - PERK signaling COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/06/21 20:44 MHDA- 2025/09/13 12:31 CRDT- 2025/06/21 18:00 PHST- 2025/03/27 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/04 00:00 [accepted] PHST- 2025/09/13 12:31 [medline] PHST- 2025/06/21 20:44 [pubmed] PHST- 2025/06/21 18:00 [entrez] AID - S1567-5769(25)01047-1 [pii] AID - 10.1016/j.intimp.2025.115057 [doi] PST - ppublish SO - Int Immunopharmacol. 2025 Sep 23;162:115057. doi: 10.1016/j.intimp.2025.115057. Epub 2025 Jun 20. PMID- 40542947 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20260111 IS - 1534-6285 (Electronic) IS - 1527-2737 (Print) IS - 1527-2737 (Linking) VI - 26 IP - 1 DP - 2025 Jun 21 TI - Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers. PG - 51 LID - 10.1007/s11934-025-01278-0 [doi] LID - 51 AB - PURPOSE OF REVIEW: Urothelial carcinoma is a prevalent malignancy within the United States that may involve the upper and/or lower urinary tracts. Multimodal treatment is often employed, with transurethral resection and intravesical therapy standard of care for non-muscle-invasive disease; neoadjuvant systemic therapy followed by radical cystectomy or trimodal therapy for muscle-invasive disease; and combination immune checkpoint inhibitors and antibody-drug conjugates standard of care for metastatic disease. These treatments carry risks of surgical complication or treatment-associated toxicity which can impair quality of life. Predictive biomarkers of treatment tolerability are currently limited. RECENT FINDINGS: There is emerging evidence that radiological biomarkers can predict treatment outcomes among patients with urothelial carcinoma. In this review, we evaluate the existing data on radiological biomarkers evaluable from current standard-of-care imaging in predicting treatment outcome among patients with urothelial carcinoma. CI - (c) 2025. The Author(s). FAU - Harper, Shelby AU - Harper S AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA. FAU - Remer, Erick M AU - Remer EM AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA. AD - Diagnostics Institute, Cleveland Clinic, Cleveland, USA. FAU - Almassi, Nima AU - Almassi N AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA. almassn2@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20250621 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/diagnostic imaging MH - *Carcinoma, Transitional Cell/therapy/diagnostic imaging MH - *Standard of Care MH - Treatment Outcome MH - *Ureteral Neoplasms/diagnostic imaging/therapy MH - *Kidney Neoplasms/diagnostic imaging/therapy MH - Predictive Value of Tests PMC - PMC12182448 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Cystectomy OT - Neoadjuvant therapy OT - Sarcopenia OT - Treatment outcomes COIS- Declarations. Human/Animal Studies Informed Consent Statement: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing Interests: The authors declare no competing interests. EDAT- 2025/06/21 18:53 MHDA- 2025/06/24 13:16 PMCR- 2025/06/21 CRDT- 2025/06/21 11:07 PHST- 2025/05/20 00:00 [accepted] PHST- 2025/06/24 13:16 [medline] PHST- 2025/06/21 18:53 [pubmed] PHST- 2025/06/21 11:07 [entrez] PHST- 2025/06/21 00:00 [pmc-release] AID - 10.1007/s11934-025-01278-0 [pii] AID - 1278 [pii] AID - 10.1007/s11934-025-01278-0 [doi] PST - epublish SO - Curr Urol Rep. 2025 Jun 21;26(1):51. doi: 10.1007/s11934-025-01278-0. PMID- 40540048 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20250825 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 31 IP - 16 DP - 2025 Aug 14 TI - Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. PG - 3503-3511 LID - 10.1158/1078-0432.CCR-24-4312 [doi] AB - PURPOSE: Androgen and estrogen influence bladder cancer pathogenesis, but their role in modulating treatment response, especially immunotherapy, remains unclear. This post hoc analysis of the PURE-01 trial evaluated the impact of androgen and estrogen signatures on outcomes in patients with muscle-invasive bladder carcinoma treated with neoadjuvant pembrolizumab followed by radical cystectomy. EXPERIMENTAL DESIGN: Pretreatment transurethral resection of bladder tumor samples from 102 PURE-01 patients was analyzed using the Decipher Bladder whole-transcriptome assay to classify genomic subtypes. Hallmark androgen response (ARS), early estrogen response (ERS-early), and late estrogen response (ERS-late) scores were derived and visualized with boxplots. Subgroup differences were assessed using Mann-Whitney U, chi2, and Kruskal-Wallis tests. Event-free survival (EFS) was the primary endpoint, whereas pathologic response was the secondary endpoint. Cox proportional hazard models and Kaplan-Meier analyses evaluated the association of molecular scores with outcomes. Immune190 and FGFR3 signatures were also analyzed to explore their interactions with ARS and ERS. RESULTS: Luminal subtypes had the highest ARS and ERS scores across molecular classifications. Negative correlations were observed between Immune190 scores and ERS and ARS scores. ERS-late scores were highest in nonresponders and significantly associated with worse EFS. Conversely, ARS was not significantly linked to EFS. FGFR3 signature positively correlated with ARS and ERS and negatively with Immune190 scores. CONCLUSIONS: The strong association of ERS-late scores with both pathologic response and EFS suggests that this signature could guide patient stratification and treatment selection. These findings support future trials combining immunotherapy with antiestrogens in both neoadjuvant and advanced urothelial carcinoma settings. CI - (c)2025 American Association for Cancer Research. FAU - Tateo, Valentina AU - Tateo V AUID- ORCID: 0000-0002-1199-2338 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Cigliola, Antonio AU - Cigliola A AUID- ORCID: 0009-0005-7109-2429 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Maiorano, Brigida A AU - Maiorano BA AUID- ORCID: 0000-0001-5423-3158 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Mercinelli, Chiara AU - Mercinelli C AUID- ORCID: 0000-0003-1165-1776 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Crupi, Emanuele AU - Crupi E AUID- ORCID: 0000-0002-3379-2644 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Giannatempo, Patrizia AU - Giannatempo P AUID- ORCID: 0000-0002-3358-4466 AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AUID- ORCID: 0000-0003-1914-0743 AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Proudfoot, James A AU - Proudfoot JA AUID- ORCID: 0009-0008-7063-5761 AD - Veracyte Inc., South San Francisco, California. FAU - Santini, Daniele AU - Santini D AUID- ORCID: 0000-0002-9118-3337 AD - Dipartimento Scienze e Biotecnologie Medico-Chirurgiche, Medical Oncology, La Sapienza Universita di Roma, Rome, Italy. FAU - Davicioni, Elai AU - Davicioni E AUID- ORCID: 0000-0001-9136-099X AD - Veracyte Inc., South San Francisco, California. FAU - Briganti, Alberto AU - Briganti A AUID- ORCID: 0000-0002-2178-0494 AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AUID- ORCID: 0000-0002-3007-2756 AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. LA - eng GR - 27746/AIRC Investigator Grant IG 2022/ PT - Journal Article PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Estrogens) RN - 0 (Androgens) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics/mortality/metabolism MH - Neoadjuvant Therapy MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage MH - Male MH - Female MH - Aged MH - *Estrogens/metabolism MH - Middle Aged MH - *Androgens/metabolism MH - Cystectomy MH - Treatment Outcome MH - Biomarkers, Tumor/genetics MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Neoplasm Invasiveness MH - Prognosis EDAT- 2025/06/20 12:28 MHDA- 2025/08/31 20:02 CRDT- 2025/06/20 11:05 PHST- 2024/12/22 00:00 [received] PHST- 2025/02/26 00:00 [revised] PHST- 2025/06/13 00:00 [accepted] PHST- 2025/08/31 20:02 [medline] PHST- 2025/06/20 12:28 [pubmed] PHST- 2025/06/20 11:05 [entrez] AID - 763060 [pii] AID - 10.1158/1078-0432.CCR-24-4312 [doi] PST - ppublish SO - Clin Cancer Res. 2025 Aug 14;31(16):3503-3511. doi: 10.1158/1078-0432.CCR-24-4312. PMID- 40524687 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250618 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 77 DP - 2025 Jul TI - Prevalence and Prognostic Significance of Preoperative Anemia in Radical Cystectomy Patients: A Multicenter Retrospective Observational Study. PG - 10-18 LID - 10.1016/j.euros.2025.05.002 [doi] AB - BACKGROUND AND OBJECTIVE: Preoperative anemia is common in patients undergoing radical cystectomy for bladder cancer, but its prevalence and impact on outcomes remain poorly characterized across different health care settings. This study aims to assess the prevalence of preoperative anemia, evaluate its current management practices, and determine its association with postoperative and oncological outcomes in patients undergoing radical cystectomy. METHODS: We retrospectively analyzed 4886 patients with nonmetastatic bladder cancer who underwent radical cystectomy across 28 centers in 13 countries. Multivariable regression models identified the predictors of preoperative hemoglobin levels and postoperative blood transfusions. Survival outcomes were assessed using Kaplan-Meier and Cox proportional hazards regression analyses. KEY FINDINGS AND LIMITATIONS: Preoperative anemia was present in 44% of women and 48% of men. Among anemic patients, 73% received no blood management interventions. Higher hemoglobin levels before transurethral resection of a bladder tumor correlated with higher levels before cystectomy and fewer postoperative blood transfusions (odds ratio: 0.98, 95% confidence interval [CI]: 0.97-0.99, p < 0.001). Higher preoperative hemoglobin levels were associated with lower 90-d mortality rates (hazard ratio: 0.98, 95% CI: 0.97-0.99, p < 0.001) and independently predicted reduced all-cause mortality, cancer-specific mortality, and disease relapse. CONCLUSIONS AND CLINICAL IMPLICATIONS: Preoperative anemia is prevalent and undertreated in patients undergoing radical cystectomy, and is independently associated with adverse perioperative and oncological outcomes. This highlights the need for further research regarding the potential benefits of implementing systematic preoperative anemia management. PATIENT SUMMARY: This study found that low blood counts before bladder removal surgery are common, often untreated, and linked to worse outcomes. Early treatment of low blood counts before surgery could improve results for patients. CI - (c) 2025 The Author(s). FAU - Kaufmann, Ernest AU - Kaufmann E AD - Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. FAU - Antonelli, Luca AU - Antonelli L AD - Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. FAU - Asero, Vincenzo AU - Asero V AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Prata, Francesco AU - Prata F AD - Department of Urology, Fondazione Policlinico Universitario Campus BIo-Medico of Rome, Rome, Italy. FAU - Rebuffo, Silvia AU - Rebuffo S AD - IRCCS Ospedale Policlinico S. Martino, Genoa, Italy. AD - Department of Surgical and Diagnostic Integrated Sciences, University of Genoa, Genoa, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Culpan, Meftun AU - Culpan M AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr University Bochum, Bochum, Germany. FAU - Ribeiro, Luis AU - Ribeiro L AD - St. George's University Hospital, London, UK. FAU - Roumeguere, Thierry AU - Roumeguere T AD - Service d'Urologie, Hopital Universitaire de Bruxelles, Universite Libre de Bruxelles, Bruxelles, Belgium. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Lambertini, Luca AU - Lambertini L AD - Unit of Oncologic Minimally Invasive Urology and Andrology - Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Pavan, Nicola AU - Pavan N AD - Urology Clinic, Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. AD - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, CHU-IUCT, Toulouse, France. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, LMU Munich, Munich, Germany. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - AlGhamlas, Aamer AU - AlGhamlas A AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Desprez, Pierre-Emmanuel AU - Desprez PE AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Orecchia, Luca AU - Orecchia L AD - Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, Stadtspital Zurich Triemli, Zurich, Switzerland. FAU - Alrumayyan, Majed AU - Alrumayyan M AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany. FAU - Zamboni, Stefania AU - Zamboni S AD - Unit of Urology, Department of Medical and Surgical Specialities, Radiological Science and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - Montes, Maria Riaza AU - Montes MR AD - Galdakao-Usansolo Hospital, Vizcaya, Spain. FAU - Okoye, Steven AU - Okoye S AD - Department of Urology, Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Re, Mattia Lo AU - Re ML AD - Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Lavallee, Luke AU - Lavallee L AD - Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada. FAU - Wettstein, Marian Severin AU - Wettstein MS AD - Department of Uro-Oncology, University of Toronto, Toronto, ON, Canada. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Fankhauser, Christian Daniel AU - Fankhauser CD AD - Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. LA - eng PT - Journal Article DEP - 20250604 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC12169704 OTO - NOTNLM OT - Anemia OT - Bladder cancer OT - Hemoglobin OT - Patient blood management OT - Radical cystectomy OT - Survival outcomes EDAT- 2025/06/17 06:25 MHDA- 2025/06/17 06:26 PMCR- 2025/06/04 CRDT- 2025/06/17 04:14 PHST- 2025/05/07 00:00 [accepted] PHST- 2025/06/17 06:26 [medline] PHST- 2025/06/17 06:25 [pubmed] PHST- 2025/06/17 04:14 [entrez] PHST- 2025/06/04 00:00 [pmc-release] AID - S2666-1683(25)00123-5 [pii] AID - 10.1016/j.euros.2025.05.002 [doi] PST - epublish SO - Eur Urol Open Sci. 2025 Jun 4;77:10-18. doi: 10.1016/j.euros.2025.05.002. eCollection 2025 Jul. PMID- 40523218 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250703 IS - 2578-5478 (Electronic) IS - 2578-5478 (Linking) VI - 43 IP - 7 DP - 2025 Jul TI - Neoadjuvant Radiotherapy Combined with Transurethral Photoselective Vaporization of Bladder Tumors and Postoperative Adjuvant Radiotherapy and Chemotherapy for T3 Muscle-Invasive Bladder Cancer: A Retrospective Case Series Study. PG - 302-309 LID - 10.1089/photob.2024.0150 [doi] AB - Objective: To evaluate the efficacy and safety of neoadjuvant radiotherapy combined with transurethral photoselective vaporization of bladder tumors (PVBT), followed by postoperative adjuvant radiotherapy and chemotherapy, in the treatment of T3 muscle-invasive bladder cancer (MIBC). Background: Transurethral resection of bladder tumors combined with radiotherapy and chemotherapy, also known as trimodal therapy (TMT), is the recommended bladder-preserving approach for MIBC and has demonstrated favorable outcomes in T2 MIBC. However, T3 MIBC remains a challenging candidate for TMT due to its relatively poor prognosis. Therefore, optimizing the "triple therapy" strategy for T3 MIBC is essential. Methods: This was a retrospective case series. Patients with T3 MIBC who underwent preoperative neoadjuvant radiotherapy combined with PVBT, followed by postoperative adjuvant radiotherapy and chemotherapy, between January 2018 and December 2020 were included. Tumor response after neoadjuvant radiotherapy, the incidence of PVBT-related complications, and adverse effects of radiotherapy and chemotherapy were assessed. Tumor recurrence and survival outcomes were monitored through outpatient follow-ups and telephone consultations. Risk factors for recurrence were analyzed using statistical methods. Results: A total of 48 patients were included. Four weeks after neoadjuvant radiotherapy, complete response, partial response, stable disease, and disease progression were observed in 3 (6.3%), 23 (47.9%), 20 (41.7%), and 2 (4.2%) patients, respectively. The objective response rate and disease control rate were 54.2% and 95.8%, respectively. Radiation- or chemotherapy-related toxicity occurred in 23 patients (47.9%), all of whom experienced only grade I-II adverse effects, with no grade III-IV toxicity reported. During a follow-up period of 14-58 months, 22 patients (45.83%) experienced recurrence, and 3 patients died due to distant organ metastases. Multi-variate Cox regression analysis identified tumor diameter (3.0 cm) and tumor multiplicity (single vs. multiple) as significant risk factors for recurrence. Conclusions: Preoperative neoadjuvant radiotherapy combined with PVBT, followed by postoperative adjuvant radiotherapy and chemotherapy, is an effective and well-tolerated treatment for T3 MIBC. FAU - Chen, Yatong AU - Chen Y AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. AD - The First Affiliated Hospital of Nankai University, Tianjin, China. FAU - Luo, Fei AU - Luo F AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. AD - The First Affiliated Hospital of Nankai University, Tianjin, China. FAU - Li, Jian AU - Li J AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. AD - The First Affiliated Hospital of Nankai University, Tianjin, China. FAU - Zhang, Tingji AU - Zhang T AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. AD - The First Affiliated Hospital of Nankai University, Tianjin, China. LA - eng PT - Journal Article DEP - 20250616 PL - United States TA - Photobiomodul Photomed Laser Surg JT - Photobiomodulation, photomedicine, and laser surgery JID - 101734781 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Retrospective Studies MH - Male MH - Female MH - *Neoadjuvant Therapy MH - Aged MH - Middle Aged MH - Radiotherapy, Adjuvant MH - Neoplasm Invasiveness MH - Chemotherapy, Adjuvant MH - Combined Modality Therapy OTO - NOTNLM OT - bladder cancer OT - chemotherapy OT - neoadjuvant radiotherapy OT - transurethral photoselective vaporization of bladder tumors EDAT- 2025/06/16 18:25 MHDA- 2025/07/03 18:26 CRDT- 2025/06/16 16:13 PHST- 2025/07/03 18:26 [medline] PHST- 2025/06/16 18:25 [pubmed] PHST- 2025/06/16 16:13 [entrez] AID - 10.1089/photob.2024.0150 [doi] PST - ppublish SO - Photobiomodul Photomed Laser Surg. 2025 Jul;43(7):302-309. doi: 10.1089/photob.2024.0150. Epub 2025 Jun 16. PMID- 40521274 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250617 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 77 DP - 2025 Jul TI - Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer. PG - 1-9 LID - 10.1016/j.euros.2025.04.005 [doi] AB - BACKGROUND AND OBJECTIVE: Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating FGFR3 alterations and their impact on oncological outcomes across different urothelial carcinoma (UC) stages. METHODS: We retrospectively analyzed clinical data and FGFR3 results for 1509 formalin-fixed, paraffin-embedded tissue specimens. Actionable activating FGFR3 mutations were assessed using a well-established multiplex SNaPshot polymerase chain reaction approach. FGFR3 fusion testing was performed with a Qiagen Therascreen kit. KEY FINDINGS AND LIMITATIONS: In the study population of 1509 patients, 202 (13%) had stage pTa, 380 (25%) had stage pT1, 258 (17%) had localized muscle-invasive bladder cancer (MIBC), 556 (37%) had locally advanced MIBC, 91 (6.0%) had metastatic UC of the bladder (mUCB), and 22 (1.5%) had metastatic upper tract UC (mUTUC). Of the FGFR3 alterations detected in 373 patients (25%), 104 (52%) were in stage pTa, 158 (42%) were in pT1, 42 (16%) were in localized MIBC, 53 (9.5%) were in locally advanced MIBC, nine (9.9%) were in mUCB, and seven (32%) were in mUTUC. FGFR3 alterations were associated with better progression-free survival and overall survival in the overall population (p < 0.001), but not in subgroup analyses for different disease stages. Study limitations include the retrospective design and heterogeneous patient cohort. CONCLUSIONS AND CLINICAL IMPLICATIONS: FGFR3 alterations occur at a stage-dependent frequency and are more prevalent in lower tumor stages. We were unable to demonstrate an independent prognostic effect of FGFR3 alterations on oncological outcomes after adjusting for tumor stage. PATIENT SUMMARY: We analyzed a protein called fibroblast growth factor receptor 3 (FGFR3) in patients with cancer of the urinary tract. We found that more aggressive tumors had fewer genetic changes in FGFR3 in comparison to less aggressive tumors. However, genetic changes in FGFR3 were not related to survival for these patients. CI - (c) 2025 The Author(s). FAU - Haas, Maximilian AU - Haas M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. FAU - Klumper, Niklas AU - Klumper N AD - Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. AD - Institute of Experimental Oncology, University Medical Center Bonn, Bonn, Germany. AD - Center for Integrated Oncology Aachen/Bonn/Cologne/Dusseldorf, Bonn, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Pediatric Urology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Wirtz, Ralph AU - Wirtz R AD - STRATIFYER Molecular Pathology, Cologne, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology and Pediatric Urology, University of Bochum, Herne, Germany. FAU - Stohr, Robert AU - Stohr R AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. AD - Institute of Pathology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Bahlinger, Veronika AU - Bahlinger V AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. AD - Institute of Pathology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - Institute of Pathology, University Hospital Tubingen, University of Tubingen, Tubingen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. AD - Institute of Pathology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. AD - Comprehensive Cancer Center Alliance WERA, Erlangen, Germany. AD - Bavarian Cancer Research Center, Erlangen, Germany. AD - Institute of Pathology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. CN - BRIDGE Consortium e.V LA - eng PT - Journal Article DEP - 20250530 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC12162067 OTO - NOTNLM OT - FGFR3 alteration OT - Proliferation OT - Targeted therapy OT - Tumor growth OT - Urothelial carcinoma EDAT- 2025/06/16 12:28 MHDA- 2025/06/16 12:29 PMCR- 2025/05/30 CRDT- 2025/06/16 06:52 PHST- 2025/04/17 00:00 [accepted] PHST- 2025/06/16 12:29 [medline] PHST- 2025/06/16 12:28 [pubmed] PHST- 2025/06/16 06:52 [entrez] PHST- 2025/05/30 00:00 [pmc-release] AID - S2666-1683(25)00118-1 [pii] AID - 10.1016/j.euros.2025.04.005 [doi] PST - epublish SO - Eur Urol Open Sci. 2025 May 30;77:1-9. doi: 10.1016/j.euros.2025.04.005. eCollection 2025 Jul. PMID- 40520868 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250617 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 15 IP - 5 DP - 2025 TI - The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. PG - 2301-2318 LID - 10.62347/ABZG4705 [doi] AB - Membrane-bound LRRC15 facilitates communication with adjacent cells by interacting with extracellular molecules, yet its role in urothelial carcinoma remains undefined. A systematic analysis of clinicopathological transcriptome profiles of urothelial carcinoma patients reveals that dysregulated levels of LRRC15 are associated with tumor malignancy features and poor prognosis. A clinically based molecular simulation model highlights potential mechanisms whereby LRRC15 mediates urothelial carcinoma cell motility and growth, primarily through the extracellular matrix organization pathway. Further molecular interaction mapping identifies SCG5 as a novel molecule linking to LRRC15 via protein-protein interactions, positively correlating with advanced pathological features and worse prognosis in urothelial carcinoma patients. Kaplan-Meier plotter results indicate that the LRRC15/SCG5 axis can serve as a prognostic marker for low survival rates in both non-muscle invasive and muscle-invasive bladder cancer. Molecules affected by the LRRC15/SCG5 axis in bladder cancer and upper tract urothelial carcinoma contribute to signatures of poor prognosis in urothelial carcinoma. These findings support targeting the LRRC15/SCG5 axis as a potential therapeutic strategy to intervene in urothelial carcinoma progression. CI - AJCR Copyright (c) 2025. FAU - Dong, Shao-Wei AU - Dong SW AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. AD - Taipei Medical University (TMU) Research Center of Urology and Kidney, Taipei Medical University Taipei, Taiwan. FAU - Chen, Chih-Heng AU - Chen CH AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. AD - Taipei Medical University (TMU) Research Center of Urology and Kidney, Taipei Medical University Taipei, Taiwan. FAU - Tzou, Kai-Yi AU - Tzou KY AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. AD - Taipei Medical University (TMU) Research Center of Urology and Kidney, Taipei Medical University Taipei, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan. FAU - Hu, Su-Wei AU - Hu SW AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. AD - Taipei Medical University (TMU) Research Center of Urology and Kidney, Taipei Medical University Taipei, Taiwan. FAU - Wu, Chia-Chang AU - Wu CC AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. AD - Taipei Medical University (TMU) Research Center of Urology and Kidney, Taipei Medical University Taipei, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan. FAU - Li, Chien Hsiu AU - Li CH AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University New Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20250525 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC12163458 OTO - NOTNLM OT - LRRC15 OT - SCG5 OT - bioinformatics OT - bladder cancer OT - extracellular matrix protein COIS- None. EDAT- 2025/06/16 12:27 MHDA- 2025/06/16 12:28 PMCR- 2025/05/25 CRDT- 2025/06/16 06:46 PHST- 2024/09/02 00:00 [received] PHST- 2025/05/18 00:00 [accepted] PHST- 2025/06/16 12:28 [medline] PHST- 2025/06/16 12:27 [pubmed] PHST- 2025/06/16 06:46 [entrez] PHST- 2025/05/25 00:00 [pmc-release] AID - 10.62347/ABZG4705 [doi] PST - epublish SO - Am J Cancer Res. 2025 May 25;15(5):2301-2318. doi: 10.62347/ABZG4705. eCollection 2025. PMID- 40520863 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250617 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 15 IP - 5 DP - 2025 TI - Impact of immediate intravesical therapy on non-muscle invasive bladder cancer with risk factors analysis for recurrence. PG - 2275-2284 LID - 10.62347/DNBH6092 [doi] AB - OBJECTIVE: To evaluate the impact of immediate intravesical therapy (IIT) on recurrence rates in non-muscle invasive bladder cancer (NMIBC) patients and to explore the potential protective role of vitamin supplementation. METHODS: A retrospective analysis was conducted on 216 NMIBC patients treated between April 2019 and March 2023. Patients were categorized into two groups: IIT group (n = 154) and no-IIT group (n = 62). Inclusion criteria included pathologically confirmed NMIBC, initial transurethral resection of bladder tumor (TURBT), and a minimum follow-up of one year. Patients who underwent radical cystectomy, had other malignancies, or suffered from severe comorbid conditions were excluded. Recurrence within one year post-treatment was used to stratify patients into recurrence and non-recurrence groups. Statistical analyses were performed to identify factors significantly associated with recurrence. Logistic regression and receiver operating characteristic curve analyses were employed to evaluate predictive performance. RESULTS: The recurrence rate was significantly lower in the IIT group (33.12%) compared to the no-IIT group (95.16%, P < 0.001). IIT significantly reduced the risk of recurrence (P < 0.001). Among vitamin supplements, only vitamin K3 demonstrated a significant association with recurrence (P = 0.010). Logistic regression confirmed IIT as an independent protective factor (OR = 0.026, P < 0.001). The area under the curve (AUC) for individual predictors ranged from 0.587 to 0.754, while the combined model achieved an AUC of 0.877, indicating strong predictive performance. CONCLUSION: IIT and self-supplementation with vitamin K3 are associated with a reduced risk of NMIBC recurrence. These findings suggest that adjunctive strategies alongside standard transurethral resection of bladder tumor may enhance patient outcomes. Further prospective studies are warranted to confirm these associations and support their integration into clinical practice. CI - AJCR Copyright (c) 2025. FAU - Liu, Bo AU - Liu B AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. FAU - Gong, Shide AU - Gong S AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. FAU - Chen, Yongwei AU - Chen Y AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. FAU - Xiao, Bangming AU - Xiao B AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. FAU - Wang, Junlin AU - Wang J AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. FAU - Sun, Xinbo AU - Sun X AD - Department of Urology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. LA - eng PT - Journal Article DEP - 20250515 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC12163442 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - immediate intravesical therapy OT - recurrence OT - risk factors OT - vitamin self-supplementation COIS- None. EDAT- 2025/06/16 12:28 MHDA- 2025/06/16 12:29 PMCR- 2025/05/15 CRDT- 2025/06/16 06:46 PHST- 2024/12/18 00:00 [received] PHST- 2025/05/14 00:00 [accepted] PHST- 2025/06/16 12:29 [medline] PHST- 2025/06/16 12:28 [pubmed] PHST- 2025/06/16 06:46 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - 10.62347/DNBH6092 [doi] PST - epublish SO - Am J Cancer Res. 2025 May 15;15(5):2275-2284. doi: 10.62347/DNBH6092. eCollection 2025. PMID- 40518596 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20251113 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 136 IP - 6 DP - 2025 Dec TI - Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel. PG - 1028-1036 LID - 10.1111/bju.16827 [doi] AB - OBJECTIVES: To evaluate the impact of bladder neck involvement (BNI) on oncological outcomes in non-muscle-invasive bladder cancer (NMIBC) and compare outcomes between Bacillus Calmette-Guerin (BCG) and gemcitabine/docetaxel (Gem/Doce) intravesical therapies in this population. PATIENTS AND METHODS: We analysed consecutive patients with NMIBC who underwent transurethral resection of bladder tumour (TURBT) and received BCG or Gem/Doce from 2013 to 2023. BNI was defined as tumour presence at the bladder neck during TURBT. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. RESULTS: Among 474 patients, 58 (12%) had BNI. The median (interquartile range) follow-up time was 34 (12-58) months. The 2-year RFS was lower in the BNI group for any-grade (41% vs 57%, log-rank p = 0.003) and high-grade recurrence (56% vs 68%, log-rank p = 0.03). BNI independently predicted worse any-grade RFS (hazard ratio [HR] 1.59, p = 0.02), high-grade RFS (HR 1.68, p = 0.03), and PFS (HR 2.18, p = 0.03). While BCG and Gem/Doce had comparable 2-year high-grade RFS (59% vs 53%, log-rank p = 0.31) and PFS (88% vs 68%, log-rank p = 0.07), the multivariable analysis revealed significantly increased risk of any-grade recurrence (HR 1.75, p < 0.001) and progression (HR 2.72, p = 0.002). Maintenance therapy improved high-grade RFS (HR 0.43, p < 0.001) and PFS (HR 0.44, p = 0.003). Limitations include retrospective design and single-institution data. CONCLUSION: Bladder neck involvement is an independent predictor of worse outcomes in NMIBC. While unadjusted outcomes were similar, multivariable analysis showed higher recurrence and progression risk with Gem/Doce. Recognising BNI as a high-risk factor may refine risk stratification and treatment decisions. Further studies are needed to validate these findings. CI - (c) 2025 BJU International. FAU - Eraky, Ahmed AU - Eraky A AUID- ORCID: 0000-0001-6879-6058 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Ben-David, Reuben AU - Ben-David R AUID- ORCID: 0000-0001-7946-7145 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Hug, Brenda AU - Hug B AUID- ORCID: 0000-0002-9040-808X AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AUID- ORCID: 0009-0001-9525-2600 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Tillu, Neeraja AU - Tillu N AUID- ORCID: 0000-0002-4149-0486 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Wiklund, Peter AU - Wiklund P AUID- ORCID: 0000-0001-6497-4697 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250615 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/mortality/therapy MH - Male MH - Female MH - Gemcitabine MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Aged MH - *Docetaxel/administration & dosage/therapeutic use MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - Middle Aged MH - Retrospective Studies MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Treatment Outcome MH - Administration, Intravesical MH - Aged, 80 and over MH - Adjuvants, Immunologic MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - bladder neck involvement OT - gemcitabine/docetaxel OT - intravesical therapy OT - non-muscle-invasive bladder cancer EDAT- 2025/06/16 11:10 MHDA- 2025/11/13 06:30 CRDT- 2025/06/16 00:33 PHST- 2025/11/13 06:30 [medline] PHST- 2025/06/16 11:10 [pubmed] PHST- 2025/06/16 00:33 [entrez] AID - 10.1111/bju.16827 [doi] PST - ppublish SO - BJU Int. 2025 Dec;136(6):1028-1036. doi: 10.1111/bju.16827. Epub 2025 Jun 15. PMID- 40517059 OWN - NLM STAT- MEDLINE DCOM- 20250918 LR - 20250918 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 4 DP - 2025 Aug TI - Real-World Experience with a Commercial Circulating Tumor DNA Assay in Non-muscle-invasive Bladder Cancer. PG - 883-887 LID - S2588-9311(25)00165-8 [pii] LID - 10.1016/j.euo.2025.05.019 [doi] AB - Circulating tumor DNA (ctDNA) is an emerging biomarker in advanced bladder cancer, but its role in non-muscle-invasive bladder cancer (NMIBC) remains undefined. We conducted a retrospective study of 23 patients with NMIBC who underwent serial ctDNA monitoring using the commercially available Signatera assay at a single institution. ctDNA was detected in 35% of patients, with two illustrative cases highlighting its clinical utility. In one case, baseline ctDNA positivity prompted earlier reimaging that revealed locally advanced disease, leading to initiation of systemic therapy followed by planned consolidative cystectomy. In another case, ctDNA positivity following salvage intravesical therapy detected early recurrence, prompting a shift from maintenance intravesical therapy to radical cystectomy. These findings suggest that ctDNA may facilitate early detection of molecular residual disease and guide treatment decisions in NMIBC, particularly in patients with bacillus Calmette-Guerin-unresponsive disease. Prospective studies are needed to validate the role of ctDNA in risk stratification and treatment optimization for this high-risk population. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Wang, Betty AU - Wang B AD - Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Davis, Laura E AU - Davis LE AD - Case Western University Hospitals, Urology Institute, Cleveland, OH, USA. FAU - Weight, Christopher J AU - Weight CJ AD - Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Abouassaly, Robert AU - Abouassaly R AD - Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Bukavina, Laura AU - Bukavina L AD - Glickman Urologic Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: bukavil2@ccf.org. LA - eng PT - Journal Article DEP - 20250614 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/pathology/genetics/therapy MH - *Circulating Tumor DNA/blood MH - Male MH - Aged MH - Retrospective Studies MH - Female MH - Middle Aged MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Biomarkers, Tumor/blood MH - Cystectomy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Biomarker OT - Circulating tumor DNA OT - Molecular residual disease OT - Non-muscle-invasive bladder cancer OT - Unresponsive OT - Urothelial carcinoma EDAT- 2025/06/15 04:45 MHDA- 2025/09/19 00:35 CRDT- 2025/06/14 21:52 PHST- 2025/03/03 00:00 [received] PHST- 2025/05/09 00:00 [revised] PHST- 2025/05/28 00:00 [accepted] PHST- 2025/09/19 00:35 [medline] PHST- 2025/06/15 04:45 [pubmed] PHST- 2025/06/14 21:52 [entrez] AID - S2588-9311(25)00165-8 [pii] AID - 10.1016/j.euo.2025.05.019 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):883-887. doi: 10.1016/j.euo.2025.05.019. Epub 2025 Jun 14. PMID- 40514270 OWN - NLM STAT- MEDLINE DCOM- 20250716 LR - 20250721 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 4 DP - 2025 Aug TI - Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin. PG - 102378 LID - S1558-7673(25)00078-3 [pii] LID - 10.1016/j.clgc.2025.102378 [doi] AB - BACKGROUND: Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue. METHODS: In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA. RESULTS: Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; P = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; P = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all P < .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage (P < .01). CONCLUSIONS: Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Engelmann, Simon U AU - Engelmann SU AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Electronic address: sengelmann@csj.de. FAU - Pickl, Christoph AU - Pickl C AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Haas, Maximilian AU - Haas M AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Kasparbauer, Felix AU - Kasparbauer F AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Rinderknecht, Emily AU - Rinderknecht E AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Kalble, Sebastian AU - Kalble S AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Siska, Peter J AU - Siska PJ AD - Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. FAU - Decking, Sonja-Maria AU - Decking SM AD - Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany. FAU - Renner, Kathrin AU - Renner K AD - Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Guzvic, Miodrag AU - Guzvic M AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Regensburg, Germany. LA - eng PT - Journal Article PT - Observational Study DEP - 20250520 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Interleukin-6) RN - 0 (IL6 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/surgery/pathology/mortality MH - *Interleukin-6/blood/metabolism MH - Female MH - Male MH - Aged MH - Prognosis MH - Middle Aged MH - Prospective Studies MH - Cystectomy MH - *Biomarkers, Tumor/blood MH - Aged, 80 and over OTO - NOTNLM OT - Biomarker OT - Immunology OT - Interleukin OT - Tumor microenvironment OT - Urothelial cancer COIS- Disclosure The authors have no relevant financial or nonfinancial interests to disclose. EDAT- 2025/06/14 16:44 MHDA- 2025/07/17 04:42 CRDT- 2025/06/13 21:58 PHST- 2024/12/02 00:00 [received] PHST- 2025/05/12 00:00 [revised] PHST- 2025/05/17 00:00 [accepted] PHST- 2025/07/17 04:42 [medline] PHST- 2025/06/14 16:44 [pubmed] PHST- 2025/06/13 21:58 [entrez] AID - S1558-7673(25)00078-3 [pii] AID - 10.1016/j.clgc.2025.102378 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Aug;23(4):102378. doi: 10.1016/j.clgc.2025.102378. Epub 2025 May 20. PMID- 40510068 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250614 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 5 DP - 2025 May TI - Prospective Analysis of Residual Urine Volume and Its Association With Intravesical Recurrence in Patients With Non-Muscle-Invasive Bladder Cancer. PG - e84023 LID - 10.7759/cureus.84023 [doi] LID - e84023 AB - Aim This study aimed to investigate the correlation between parameters of voiding dysfunction, including residual urine volume, and bladder cancer recurrence in patients. Methods A total of 68 patients (52 males and 16 females) with primary non-muscle-invasive bladder cancer (NMIBC) were prospectively analyzed. Univariate and multivariate analyses were performed with bladder cancer recurrence as the dependent variable. Explanatory variables included patient demographics, pathological findings, residual urine volume measured by ultrasound, and voiding symptoms assessed using the International Prostate Symptom Score (IPSS), the IPSS Quality of Life Index (IPSS-QOL), and the Overactive Bladder Symptom Score (OABSS). Results Bladder cancer recurrence was found in 11 patients (8 males and 3 females). In male patients, the median residual urine volume was significantly higher in the recurrence group (24 mL, IQR 5.5-47 mL) compared to the non-recurrence group (2 mL, IQR 0-21.5 mL; p = 0.0469). Multivariate analysis identified residual urine volume as an independent risk factor for recurrence in male patients (p = 0.0276). Conclusion Increased residual urine volume may be independently associated with intravesical recurrence in male patients with NMIBC. Assessing and managing voiding dysfunction may help reduce the risk of recurrence in this population. CI - Copyright (c) 2025, Maeda et al. FAU - Maeda, Akihiro AU - Maeda A AD - Department of Urology, Faculty of Medicine Saga University, Saga, JPN. FAU - Tobu, Shohei AU - Tobu S AD - Department of Urology, Faculty of Medicine Saga University, Saga, JPN. FAU - Kawasaki, Maki AU - Kawasaki M AD - Department of Urology, Faculty of Medicine Saga University, Saga, JPN. FAU - Kakinoki, Hiroaki AU - Kakinoki H AD - Department of Urology, Faculty of Medicine Saga University, Saga, JPN. FAU - Noguchi, Mitsuru AU - Noguchi M AD - Department of Urology, Faculty of Medicine Saga University, Saga, JPN. LA - eng PT - Journal Article DEP - 20250513 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12161164 OTO - NOTNLM OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - recurrence OT - residual urine volume OT - voiding dysfunction COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. The Clinical Research Ethics Committee of the Saga University issued approval 2016-09-04. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/06/13 06:34 MHDA- 2025/06/13 06:35 PMCR- 2025/05/13 CRDT- 2025/06/13 05:04 PHST- 2025/05/13 00:00 [accepted] PHST- 2025/06/13 06:35 [medline] PHST- 2025/06/13 06:34 [pubmed] PHST- 2025/06/13 05:04 [entrez] PHST- 2025/05/13 00:00 [pmc-release] AID - 10.7759/cureus.84023 [doi] PST - epublish SO - Cureus. 2025 May 13;17(5):e84023. doi: 10.7759/cureus.84023. eCollection 2025 May. PMID- 40501280 OWN - NLM STAT- MEDLINE DCOM- 20250612 LR - 20250612 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 60 DP - 2025 Jun 12 TI - Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden. PG - 108-114 LID - 10.2340/sju.v60.43875 [doi] AB - OBJECTIVE: For patients diagnosed with muscle-invasive bladder cancer (MIBC), prognosis remains poor with high rates of progression and risk for mortality. To better understand the current treatment landscape, this study aims to describe real-world treatment patterns and clinical outcomes for MIBC patients in Sweden. MATERIALS AND METHODS: Using population-based registers and electronic medical records, patients with MIBC (T2-4aN0M0) were identified between January 2016 and December 2020 in the Skane region in Sweden. Patients with de novo MIBC and those who progressed from high-risk nonmuscle-invasive bladder cancer were included. Treatment patterns, overall survival (OS), metastatic rate, event-free survival (EFS), and bladder-intact EFS (BI-EFS) were described. Results: Among the 231 MIBC patients identified, 34% received only best supportive care (BSC) primarily due to age and comorbidity. Of the 153 patients who received curative treatment, 84 (55%) underwent radical cystectomy (RC) and 69 (45%) received bladder-sparing treatment. Patients who received bladder-sparing treatment were older, had poorer health status, and more comorbidities. Among RC-treated patients, 5-year OS and EFS were 74% (95% confidence interval [CI]: 61-83%) and 70% (95% CI: 58-79%), respectively. Among patients who received bladder-sparing treatment, 5-year OS and BI-EFS were 52% (95% CI: 38-64%) and 34% (95% CI: 21-48%), respectively. CONCLUSIONS: Old age and high rates of comorbidities among the MIBC patient population meant many patients were ineligible for recommended RC and instead received bladder-sparing treatment or BSC only. High rates of progression and poor survival were observed in both patients undergoing RC and patients who received bladder-sparing treatment. FAU - Kwok, Kelvin H M AU - Kwok KHM AD - Schain Research AB, Stockholm Sweden. kelvin@schainresearch.com. FAU - Abbadi, Ahmad AU - Abbadi A AD - Schain Research AB, Stockholm Sweden. FAU - Cote, Sarah AU - Cote S AD - Global Market Access and Health Policy, Janssen Global Services LLC, Toronto, Canada. FAU - Baculea, Simona AU - Baculea S AD - Global Market Access and Health Policy, Janssen Global Services LLC, High Wycombe, UK. FAU - Spigelman, Samuel AU - Spigelman S AD - Global Medical Affairs, Janssen Research and Development LLC, Raritan, NJ, USA. FAU - Aly, Markus AU - Aly M AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. FAU - Schain, Frida AU - Schain F AD - Schain Research AB, Stockholm Sweden. LA - eng PT - Journal Article DEP - 20250612 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality MH - Sweden MH - Male MH - Female MH - Aged MH - Neoplasm Invasiveness MH - Middle Aged MH - *Cystectomy/statistics & numerical data MH - Aged, 80 and over MH - Treatment Outcome MH - Survival Rate MH - Organ Sparing Treatments EDAT- 2025/06/12 06:30 MHDA- 2025/06/12 06:31 CRDT- 2025/06/12 04:04 PHST- 2024/11/20 00:00 [received] PHST- 2025/05/14 00:00 [accepted] PHST- 2025/06/12 06:31 [medline] PHST- 2025/06/12 06:30 [pubmed] PHST- 2025/06/12 04:04 [entrez] AID - 10.2340/sju.v60.43875 [doi] PST - epublish SO - Scand J Urol. 2025 Jun 12;60:108-114. doi: 10.2340/sju.v60.43875. PMID- 40497570 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20260514 IS - 1533-4058 (Electronic) IS - 1533-4058 (Linking) VI - 33 IP - 5 DP - 2025 Sep 1 TI - Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification. PG - 267-276 LID - 10.1097/PAI.0000000000001272 [doi] AB - Molecular subtyping, though complex and typically reliant on costly and limited accessibility techniques, remains crucial for understanding the biology of urothelial carcinoma (UC). We sought a practical alternative by categorizing UCs into immunohistochemistry (IHC) subtypes using a panel of accessible antibodies. Examining 100 UCs from 2020 to 2021, encompassing both chemotherapy-naive MIBC and NMIBC, acquired through transurethral resection or radical resection, we employed IHC with GATA3, KRT5, KRT14, and KRT20 markers on tissue microarrays. IHC luminal, IHC basal, IHC dual-positive, and IHC dual-negative subtypes were identified based on marker expressions. Positive staining criteria were established, considering >20% positive staining for specific markers. Results indicated a mean age of 64 years, with a 2.33:1 male-to-female ratio, and 60% NMIBC versus 40% MIBC. Subtypes identified were IHC luminal (55%), IHC basal (19%), IHC dual (22%), and IHC dual (4%). IHC luminal subtype demonstrated the highest overall survival rate (80%), followed by IHC dual (72.72%), IHC basal (63.15%), and IHC dual with the lowest survival (25%). KRT5-positive tumors exhibited a crude hazard ratio (HR) of 1.98 in univariate analysis, lacking statistical significance. Conversely, GATA3-positive tumors were significantly associated with lower risk in both univariate (Crude HR=0.36, P =0.01) and multivariate analysis ( P =0.01). In addition, lymphovascular invasion significantly increased risk in both univariate and multivariate analyses (adjusted HR=5.26, P <0.01). In conclusion, our study advocates for the early stratification of UC into IHC-based subtypes, facilitated by a panel of 4 markers, offering valuable insights into molecular characteristics, particularly in resource-constrained settings, and aiding clinical stratification. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Indulkar, Shreeya AU - Indulkar S AUID- ORCID: 0009-0000-8988-9747 AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana. AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute. FAU - Rao, B Vishal AU - Rao BV AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute. FAU - Das, Debasmita AU - Das D AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute. FAU - Pasam, Mohan Krishna AU - Pasam MK AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute. FAU - Kodandapani, Suseela AU - Kodandapani S AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute. FAU - Sharma, Rakesh Manilal AU - Sharma RM AD - Department of Surgical Oncology, Division of Uro-Oncology. FAU - Thammineedi, Subramanyeshwar Rao AU - Thammineedi SR AD - Department of Surgical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250611 PL - United States TA - Appl Immunohistochem Mol Morphol JT - Applied immunohistochemistry & molecular morphology : AIMM JID - 100888796 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Keratin-20) SB - IM MH - Humans MH - Male MH - Female MH - *Immunohistochemistry/economics/methods MH - Middle Aged MH - *Biomarkers, Tumor/metabolism MH - Aged MH - GATA3 Transcription Factor/metabolism MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - Cost-Benefit Analysis MH - *Urothelium/pathology/metabolism MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/metabolism MH - Keratin-20/metabolism OTO - NOTNLM OT - basal OT - immunohistochemistry (IHC) OT - luminal OT - molecular subtypes OT - urinary bladder carcinoma OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2025/06/11 12:30 MHDA- 2025/09/04 06:37 CRDT- 2025/06/11 08:03 PHST- 2024/01/20 00:00 [received] PHST- 2025/05/12 00:00 [accepted] PHST- 2025/09/04 06:37 [medline] PHST- 2025/06/11 12:30 [pubmed] PHST- 2025/06/11 08:03 [entrez] AID - 00129039-990000000-00233 [pii] AID - 10.1097/PAI.0000000000001272 [doi] PST - ppublish SO - Appl Immunohistochem Mol Morphol. 2025 Sep 1;33(5):267-276. doi: 10.1097/PAI.0000000000001272. Epub 2025 Jun 11. PMID- 40494734 OWN - NLM STAT- MEDLINE DCOM- 20250918 LR - 20250918 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 4 DP - 2025 Aug TI - Long Noncoding RNAs Identify a Subgroup of Patients with Low-grade Non-muscle-invasive Bladder Cancer with Less Favorable Outcomes. PG - 879-882 LID - S2588-9311(25)00151-8 [pii] LID - 10.1016/j.euo.2025.05.013 [doi] AB - Low-grade (LG) stage Ta non-muscle-invasive bladder cancer (NMIBC) is typically nonaggressive with low progression rates and favorable cancer-specific survival. However, frequent monitoring is required because of the risk of recurrence. In this study, we analyzed RNA sequencing data for 286 LG Ta tumors from the UROMOL consortium. Unsupervised consensus clustering of long noncoding RNA profiles identified a subgroup of patients with significantly worse recurrence-free and progression-free survival. These patients may benefit from intensified intravesical therapy or closer surveillance. Further validation of these molecular subgroups could enhance risk stratification and guide personalized treatment approaches. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - de Jong, Joep J AU - de Jong JJ AD - Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Gibb, Ewan A AU - Gibb EA AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: ewan.gibb@ubc.ca. LA - eng PT - Journal Article DEP - 20250610 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (RNA, Long Noncoding) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/mortality MH - *RNA, Long Noncoding/genetics MH - Male MH - Female MH - Neoplasm Invasiveness MH - Neoplasm Grading MH - Aged MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Biomarkers OT - Gene expression profiling OT - Low-grade Ta bladder cancer OT - Noncoding RNA OT - Non-muscle-invasive bladder cancer EDAT- 2025/06/11 00:27 MHDA- 2025/09/19 00:36 CRDT- 2025/06/10 21:57 PHST- 2025/03/10 00:00 [received] PHST- 2025/05/06 00:00 [revised] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/09/19 00:36 [medline] PHST- 2025/06/11 00:27 [pubmed] PHST- 2025/06/10 21:57 [entrez] AID - S2588-9311(25)00151-8 [pii] AID - 10.1016/j.euo.2025.05.013 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):879-882. doi: 10.1016/j.euo.2025.05.013. Epub 2025 Jun 10. PMID- 40493901 OWN - NLM STAT- MEDLINE DCOM- 20250610 LR - 20250610 IS - 2162-6537 (Electronic) IS - 0731-8898 (Linking) VI - 44 IP - 2 DP - 2025 TI - Anti-Cancer Role of Ellagic Acid by Modulating the Altered PI3K/PTEN/Akt Pathway in Bladder Cancer. PG - 57-69 LID - 10.1615/JEnvironPatholToxicolOncol.2024053383 [doi] AB - Bladder cancer (BCa) is approximately the fourth most prevalent diagnosed cancer in men and is three times less common in women. Therefore, identifying biomarkers, developing more effective therapeutic strategies, and understanding the mechanisms underlying BCa tumor growth and progression are urgently required to improve survival rates. Therefore, we aim to investigate the expression of PTEN/Akt in tissue samples of both non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) patients (n = 70) and human BCa cell lines T24 and 5637, along with the potent role of ellagic acid (EA) in the modulation of the PTEN/Akt pathway and the resulting therapeutic potential. Results showed low-intensity nuclear or cytoplasmic PTEN staining or loss of PTEN expression in tumor cells and overexpression of p-Akt (Ser-473) with high intensity in the nucleus or cytoplasm. EA treatment of T24 and 5637 cells reduced cell viability, inflammation (NF-kappaB, COX-2), invasion (MMP-9), induced the caspase (cas-3 and cas-9) cascade signaling pathway, and induced cell apoptosis along with the suppression of the PI3K/PTEN/Akt signaling pathway after 48h in a dose-dependent manner. Thus, these data suggested that the EA showed a strong potential anti-cancer effect in T24 and 5637 cells. In conclusion, the expression of PTEN/p-Akt and the inverse relation indicated an alteration of the PTEN/Akt pathway, and such cases could benefit from treatment with EA in BCa. FAU - Sahay, Satya AU - Sahay S AD - Lab-CRIB, ICMR-National Institute of Pathology, Delhi 110029, India. FAU - Trehan, Deepika AU - Trehan D AD - Lab-CRIB, ICMR-National Institute of Pathology, Delhi 110029, India; Department of Biochemistry Jamia Hamdard University, Delhi 110029, India. FAU - Kumari, Ranbala AU - Kumari R AD - Lab-CRIB, ICMR-National Institute of Pathology, Delhi 110029, India; Department of Virology and Immunology, Amity University, Noida, UP, 201303, India. FAU - Sharma, Jyoti AU - Sharma J AD - Lab-CRIB, ICMR-National Institute of Pathology, Delhi 110029, India. FAU - Vasudeva, Pawan AU - Vasudeva P AD - Department of Urology and Renal Transplant, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi 110029, India. FAU - Kumar, Niraj AU - Kumar N AD - Department of Urology and Renal Transplant, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi 110029, India. FAU - Agrawal, Usha AU - Agrawal U AD - AIPH University Bhubaneswar. LA - eng PT - Journal Article PL - United States TA - J Environ Pathol Toxicol Oncol JT - Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer JID - 8501420 RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - 19YRN3ZS9P (Ellagic Acid) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.1.3.67 (PTEN protein, human) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/metabolism/pathology MH - *PTEN Phosphohydrolase/metabolism MH - *Ellagic Acid/pharmacology MH - *Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction/drug effects MH - Cell Line, Tumor MH - *Phosphatidylinositol 3-Kinases/metabolism MH - Female MH - Male MH - Middle Aged MH - Aged MH - *Antineoplastic Agents/pharmacology MH - Cell Survival/drug effects MH - Apoptosis/drug effects EDAT- 2025/06/10 18:28 MHDA- 2025/06/10 18:29 CRDT- 2025/06/10 16:23 PHST- 2025/06/10 18:29 [medline] PHST- 2025/06/10 18:28 [pubmed] PHST- 2025/06/10 16:23 [entrez] AID - 0b717b2d411c7d59,5e0728b7452eda52 [pii] AID - 10.1615/JEnvironPatholToxicolOncol.2024053383 [doi] PST - ppublish SO - J Environ Pathol Toxicol Oncol. 2025;44(2):57-69. doi: 10.1615/JEnvironPatholToxicolOncol.2024053383. PMID- 40485741 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250611 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Inflammation as a key mediator: linking triglyceride-glucose index to prognosis in non-muscle-invasive bladder cancer. PG - 1545985 LID - 10.3389/fonc.2025.1545985 [doi] LID - 1545985 AB - BACKGROUND: Bladder carcinoma (BCa) is a prevalent urological malignancy characterised by high recurrence and progression rates, posing significant challenges in clinical management. The triglyceride-glucose (TyG) index has emerged as a promising prognostic marker for metabolic health in various cancers. This study explores the prognostic value of the TyG index in non-muscle-invasive bladder cancer (NMIBC), with a focus on its association with high-grade recurrence-free survival (RFS) and progression-free survival (PFS) and the mediating role of systemic inflammation. METHODS: A total of 230 patients diagnosed with NMIBC between October 2017 and October 2022 were included in this retrospective study. Clinical and pathological data were collected alongside follow-up treatment outcomes. Mediation analysis was conducted to quantify the role of systemic inflammation, using markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-8 (IL-8), in the relationship between the TyG index and patient prognosis. RESULTS: The TyG index was identified as a significant, non-linear prognostic factor for both RFS and PFS. An inverted U-shaped relationship was observed, with inflexion points at 9.186 and 9.168 for RFS and PFS, respectively. Below these thresholds, the TyG index was positively associated with worse outcomes (RFS: HR = 3.37, 95% CI = 1.77-6.41, P < 0.001; PFS: HR = 3.54, 95% CI = 1.65-7.58, P = 0.001). Mediation analysis revealed systemic inflammation as a critical intermediary, contributing significantly to the observed associations. CONCLUSION: These findings suggest that the TyG index could serve as a valuable tool for risk stratification and prognostic assessment in NMIBC. Its integration into clinical decision-making frameworks may improve personalised management strategies, particularly by targeting systemic inflammation as a modifiable factor. CI - Copyright (c) 2025 Zhang, Li, Shao, Jiang, Wang, Zhang, Chen, Ding, Wang, Xia and Wang. FAU - Zhang, Yan AU - Zhang Y AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Li, Zixiang AU - Li Z AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Shao, Xianfeng AU - Shao X AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Jiang, Shan AU - Jiang S AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Jiahao AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Zhang, He AU - Zhang H AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Chen, Li AU - Chen L AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Ding, Li AU - Ding L AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Kun AU - Wang K AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Xia, Wentao AU - Xia W AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. LA - eng PT - Journal Article DEP - 20250523 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12141014 OTO - NOTNLM OT - TyG index OT - bladder cancer OT - inflammation OT - metabolic syndrome OT - prognosis OT - tumour recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/06/09 12:30 MHDA- 2025/06/09 12:31 PMCR- 2025/05/23 CRDT- 2025/06/09 06:34 PHST- 2024/12/22 00:00 [received] PHST- 2025/04/29 00:00 [accepted] PHST- 2025/06/09 12:31 [medline] PHST- 2025/06/09 12:30 [pubmed] PHST- 2025/06/09 06:34 [entrez] PHST- 2025/05/23 00:00 [pmc-release] AID - 10.3389/fonc.2025.1545985 [doi] PST - epublish SO - Front Oncol. 2025 May 23;15:1545985. doi: 10.3389/fonc.2025.1545985. eCollection 2025. PMID- 40484005 OWN - NLM STAT- MEDLINE DCOM- 20260402 LR - 20260402 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 110 IP - 2 DP - 2026 TI - The Predictive Value of Urinary Twist1 Methylation and VI-RADS Score for Residual Tumor before Repeat Transurethral Resection of Bladder Tumor in NMIBC Patients. PG - 114-124 LID - 10.1159/000546718 [doi] AB - INTRODUCTION: Although cystoscopy is highly accurate in managing bladder cancer, its invasive nature and high cost underscore the need for more practical, noninvasive alternatives. Urinary Twist Family BHLH Transcription Factor 1 (Twist1) methylation, an emerging biomarker, shows great promise for early diagnosis and postsurgical monitoring. Meanwhile, the Vesical Imaging-Reporting and Data System (VI-RADS), which incorporates multiple sequences of multiparametric MRI, demonstrates excellent diagnostic performance for bladder cancer. These tools could potentially overcome the limitations in managing non-muscle invasive bladder cancer (NMIBC), particularly in predicting residual tumor burden before repeat transurethral resection of bladder tumor (re-TURBT). This study aims to evaluate a predictive model that combines VI-RADS, urinary Twist1 methylation, and hematuria to guide clinical decision-making in NMIBC management. METHODS: A prospective cohort study was conducted, including NMIBC patients who underwent re-TURBT at the Department of Urology, Zhongshan city People's Hospital, from June 2022 to May 2024. Morning urine samples were collected prior to re-TURBT to detect urinary Twist1 methylation, and a 3.0T MRI scan of the bladder was performed for VI-RADS scoring. Based on postoperative pathology results, patients were divided into residual tumor and non-residual tumor groups. Binary logistic regression was employed to identify independent predictors of residual tumor burden prior to re-TURBT. Two predictive models were subsequently developed. The diagnostic performance and clinical utility of these models were assessed using the receiver operating characteristic (ROC) curve and decision curve analysis (DCA). RESULTS: The study ultimately included 52 patients who were initially diagnosed with NMIBC based on pathology. According to the pathological results after re-TURBT, the patients were divided into two groups: the tumor residue group (n = 22) and the control group (n = 30). Binary logistic regression analysis identified the VI-RADS score and urinary Twist1 methylation as independent predictors of residual tumor burden in NMIBC patients prior to re-TURBT. A predictive model incorporating these factors, along with the presence of visible hematuria within 1 week before re-TURBT, achieved a sensitivity of 95.45% and a specificity of 83.33% for diagnosing residual tumor burden. ROC curve analysis demonstrated an area under the curve (AUC) of 0.950 (95% CI: 0.884-1.000, p < 0.001). DCA revealed that the model provided a net benefit for threshold probabilities ranging from 0.10 to 0.92. CONCLUSION: The predictive model combining VI-RADS score, urinary Twist1 methylation, and visible hematuria exhibits excellent diagnostic performance for predicting residual tumor burden in NMIBC patients, offering significant guidance for clinical practice. CI - (c) 2025 S. Karger AG, Basel. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Zhongshan City People's Hospital, Zhongshan, China. FAU - Lin, Qisheng AU - Lin Q AD - Department of Urology, Zhongshan City People's Hospital, Zhongshan, China. FAU - Li, Linfeng AU - Li L AD - Department of Urology, Zhongshan City People's Hospital, Zhongshan, China. FAU - Wei, Weiyang AU - Wei W AD - Department of Urology, Zhongshan City People's Hospital, Zhongshan, China. FAU - Yang, Hao AU - Yang H AD - Chongzhou City People's Hospital, Chengdu, China. FAU - Huang, Yaqiang AU - Huang Y AD - Department of Urology, Zhongshan City People's Hospital, Zhongshan, China, hyq128@126.com. LA - eng PT - Journal Article DEP - 20250606 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Twist-Related Protein 1) RN - 0 (TWIST1 protein, human) RN - 0 (Nuclear Proteins) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Twist-Related Protein 1/urine/genetics MH - *Urinary Bladder Neoplasms/surgery/urine/pathology/diagnostic imaging/diagnosis MH - Male MH - Female MH - Middle Aged MH - Predictive Value of Tests MH - Aged MH - Prospective Studies MH - Neoplasm, Residual MH - *Nuclear Proteins/urine MH - *Cystectomy/methods MH - Methylation MH - Biomarkers, Tumor/urine MH - Multiparametric Magnetic Resonance Imaging MH - Transurethral Resection of Bladder MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Predictive model OT - Repeat transurethral resection of bladder tumor OT - VI-RADS score EDAT- 2025/06/09 00:28 MHDA- 2026/04/02 18:31 CRDT- 2025/06/08 18:23 PHST- 2024/12/01 00:00 [received] PHST- 2025/05/24 00:00 [accepted] PHST- 2026/04/02 18:31 [medline] PHST- 2025/06/09 00:28 [pubmed] PHST- 2025/06/08 18:23 [entrez] AID - 000546718 [pii] AID - 10.1159/000546718 [doi] PST - ppublish SO - Urol Int. 2026;110(2):114-124. doi: 10.1159/000546718. Epub 2025 Jun 6. PMID- 40468309 OWN - NLM STAT- MEDLINE DCOM- 20250605 LR - 20250714 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 Jun 4 TI - Pediatric papillary urothelial neoplasm: 18-year single-center experience in diagnosis and treatment. PG - 148 LID - 10.1186/s12894-025-01831-6 [doi] LID - 148 AB - OBJECTIVE: This study outlines the diagnosis, treatment, and follow-up protocols for pediatric bladder urothelial tumors, sharing insights from clinical experience to assist pediatric surgeons. METHOD: A retrospective analysis was conducted on medical records from January 2006 to January 2024, involving 17 pediatric cases treated at our hospital. The patients were categorized into two groups: Group 1 included children diagnosed with the pathological type "urothelial papilloma" (UP), while Group 2 consisted of those with the pathological type "papillary urothelial neoplasm of low malignant potential" (PUNLMP). The primary outcomes of the study were the presence or absence of recurrence. RESULTS: The average age of the patients was 10.5 years, with all patients being male. Gross hematuria was the predominant symptom, observed in 88.2% of cases. All patients underwent a urinary ultrasound examination. Open resection of bladder tumors was performed in 82.3% of patients, while the remainder underwent transurethral resection of bladder tumors (TURBT) surgery. Pathologic findings revealed UP in 11 cases and PUNLMP in 6 cases. The median follow-up duration was 46 months. Two out of the six PUNLMP patients received postoperative chemotherapy with bladder instillation, while the remaining 4 patients did not receive this treatment. Among those not treated, one patient experienced a recurrence 25 months after the initia surgery. Subsequently, the patient underwent a second bladder tumor resection and received intravesical chemotherapy. No recurrences were noted following bladder instillation chemotherapy. CONCLUSION: Children presenting with gross hematuria should be evaluated for bladder urothelial tumors. Timely ultrasonography aids in diagnosis. The prognosis for children with this condition is favorable, although recurrence is possible. Ultrasound monitoring is crucial during follow-up, and prophylactic bladder instillation chemotherapy may be considered for children with PUNLMP to reduce recurrence risk, though further evidence is required to validate this approach. LEVELS OF EVIDENCE: Level III. CI - (c) 2025. The Author(s). FAU - Liu, Pei AU - Liu P AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Li, Xin AU - Li X AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Li, Jiayi AU - Li J AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Li, Zonghan AU - Li Z AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Yang, Yang AU - Yang Y AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Sun, Ning AU - Sun N AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Song, Hongcheng AU - Song H AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. FAU - Zhang, Weiping AU - Zhang W AD - Department of Urology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 10045, China. zhangwp59616406@126.com. LA - eng PT - Journal Article DEP - 20250604 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Male MH - Retrospective Studies MH - Child MH - *Urinary Bladder Neoplasms/diagnosis/therapy/surgery MH - Adolescent MH - Child, Preschool MH - *Papilloma/diagnosis/therapy MH - Time Factors MH - Female PMC - PMC12254994 OTO - NOTNLM OT - Bladder neoplasms OT - Intravesical chemotherapy OT - Papillary urothelial neoplasm of low malignant potential OT - Pediatric urothelial carcinoma OT - Pediatrics COIS- Declarations. Ethical approval: This retrospective study was approved by the Ethics Committee of Beijing Children's Hospital, Capital Medical University, National Center for Children's Health (Approval No. IEC-C-006-A04-V.07.1). The exemption is in line with the national regulations (Article 39 of China's Ethical Review Measures for Biomedical Research Involving Humans) that allow for waived informed consent in retrospective studies under strict confidentiality and anonymization protocols. Additionally, all patients provided written informed consent for their clinical procedures (including hospitalization and surgery) during their admission. Patient identities were completely anonymized, and no personally identifiable information was used for this study. Human ethics and consent to participate: Not applicable. Consent to publish: Not applicable. Competing interests: The authors declare no competing interests. Conflict of interest: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. EDAT- 2025/06/05 00:28 MHDA- 2025/06/05 07:07 PMCR- 2025/06/04 CRDT- 2025/06/04 23:48 PHST- 2025/02/23 00:00 [received] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/06/05 07:07 [medline] PHST- 2025/06/05 00:28 [pubmed] PHST- 2025/06/04 23:48 [entrez] PHST- 2025/06/04 00:00 [pmc-release] AID - 10.1186/s12894-025-01831-6 [pii] AID - 1831 [pii] AID - 10.1186/s12894-025-01831-6 [doi] PST - epublish SO - BMC Urol. 2025 Jun 4;25(1):148. doi: 10.1186/s12894-025-01831-6. PMID- 40467750 OWN - NLM STAT- MEDLINE DCOM- 20250605 LR - 20250610 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Jun 4 TI - Development of a machine learning-based model to predict urethral recurrence following radical cystectomy: a multicentre retrospective study and updated meta-analysis. PG - 19573 LID - 10.1038/s41598-025-04893-6 [doi] LID - 19573 AB - Urethral recurrence (UR) following radical cystectomy for bladder cancer represents an aggressive disease failure with typically poor survival outcomes. Our study aimed to assess the predictive risk factors for UR, to develop and validate an easy-to-use predictive tool of UR in our region based on machine learning algorithms and to update the meta-analysis of risk factors for UR in combination with our results to improve its accuracy and reliability. Clinicopathological data from the patients who underwent RC between 2010 and 2020 at multiple centres were collected. To confirm the independent risk factors for UR, univariate and multivariate Cox regression were applied. We conducted internal validation by randomly partitioning the dataset into train (80%) and test (20%) subsets for UR prediction model development and validation. We developed UR predictive models using ten machine learning algorithms and evaluated the model performance by the area under the ROC curve (AUC), accuracy, sensitivity, and other metrics (F1 score, Brier score, C-index). The best-performing model was selected based on these criteria. The SHapley Additive exPlanations (SHAP) method was used to calculate the contribution of each feature to the machine learning prediction with best performance and develop online calculator based on the machine model with the best performance. Moreover, to avoid bias from single-region studies for the risk factors identifications, we searched the PubMed, Embase, and Scopus databases published before April 2025 to perform a meta-analysis of patient-, tumour- and treatment-specific factors for UR. In our multi-centre study, 473 patients were analysed with a UR rate of 8.24%, concomitant CIS (HR: 2.02, p = 0.039) and tumor multifocality (HR: 2.89, p = 0.004) were demonstrated to be independent predictors for UR. Among the ten different machine learning methods, the gradient boosting machine model demonstrated the best predictive performance which reached AUC of 0.865 (95%CI: 0.805-0.926) and 0.778 (95%CI: 0.558-0.968) in train and test set respectively. Moreover, to benefit from the clinical implications of the predictive model, an easy-to-use risk calculator tool for UR was developed online ( https://zluxin.shinyapps.io/make_web/ ) based on the GBM model. In the updated meta-analysis, a history of TURBT (HR: 2.56, p = 0.019), bladder neck or trigeminal or prostate involvement (HR: 3.39, p < 0.001), tumor multifocality (HR: 2.05, p < 0.001), concomitant CIS (HR: 1.74, p = 0.006), lymphovascular invasion (HR: 1.95, p = 0.028), diversion type (HR: 0.47, p < 0.001) and receiving neoadjuvant chemotherapy or adjuvant chemotherapy (HR: 1.36, p = 0.019) were significant predictors of UR. Tumour multifocality and concomitant CIS were independent predictors for UR in the retrospective multicentre research and meta-analysis. An easy-to-use online calculator based on GBM algorithm was developed can help predict UR for patients with bladder cancer after radical cystectomy and contribute to tailor individualized follow-up management strategies. CI - (c) 2025. The Author(s). FAU - Fan, Bo AU - Fan B AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. fanbo@dmu.edu.cn. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. fanbo@dmu.edu.cn. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. fanbo@dmu.edu.cn. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. fanbo@dmu.edu.cn. FAU - Zhang, Luxin AU - Zhang L AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Cui, Hepeng AU - Cui H AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Bai, Shanshan AU - Bai S AD - Department of Ultrasound, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. FAU - Gao, Haifeng AU - Gao H AD - Department of Urology, Central Hospital of Dalian, Dalian, 116089, Liaoning Province, China. FAU - Xiang, Shengxiang AU - Xiang S AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Wang, Yuchao AU - Wang Y AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Song, Zhuwei AU - Song Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Chen, Jiaqiang AU - Chen J AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. FAU - Yu, Guanghai AU - Yu G AD - Department of Urology, Central Hospital of Dalian, Dalian, 116089, Liaoning Province, China. dlzxygh@126.com. FAU - Wang, Jianbo AU - Wang J AD - Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. wangjianbo@dmu.edu.cn. FAU - Wang, Liang AU - Wang L AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. wangldoct@sina.com. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. wangldoct@sina.com. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. wangldoct@sina.com. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. wangldoct@sina.com. FAU - Liu, Zhiyu AU - Liu Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning Province, China. lzydoct@163.com. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning Province, China. lzydoct@163.com. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning Province, China. lzydoct@163.com. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning Province, China. lzydoct@163.com. LA - eng GR - 2023-MSLH-021；2023021014-JH2/1017/the Joint Fund Project of Liaoning Provincial Science and Technology Programme/ GR - LJKQZ20222382, LJKZZ20220100/the Scientific Research Project of Ministry of Education of Liaoning Province/ GR - JCHZ2023001/the Interdisciplinary Research Cooperation Project Team Funding of Dalian Medical University Planning and research category (focusing on planning for recreation)/ GR - JCHZ2023020/the Interdisciplinary Research Cooperation Project Team Funding of Dalian Medical University Youth-specific category of free exploration/ GR - LH-JSRZ-202201/the United Foundation for Medico-engineering Cooperation from Dalian Neusoft University of Information and the Second Hospital of Dalian Medical University/ GR - 2022JCXKYB15/"1+X"Program for Clinical Competency Enhancemen-interdisciplinary Innovation Project, the Second Hospital of Dalian Medical University/ GR - dy2yhbrc202010/the Young Reserve Talent Project of the Second Hospital of Dalian Medical University/ PT - Journal Article PT - Meta-Analysis PT - Multicenter Study DEP - 20250604 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Machine Learning MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Cystectomy/adverse effects MH - Retrospective Studies MH - *Neoplasm Recurrence, Local MH - Male MH - Female MH - Middle Aged MH - Aged MH - Risk Factors MH - ROC Curve MH - *Urethra/pathology MH - Prognosis PMC - PMC12137677 OTO - NOTNLM OT - Bladder cancer OT - Machine learning OT - Meta-analysis OT - Online calculator OT - Predictive model OT - Risk factor OT - Urethral recurrence COIS- Declarations. Competing interests: The authors declare no competing interests. Consent for publication: All the authors provided the approval the publication. Ethics approval and consent to participate: The Ethics Committee of the Second Affiliated Hospital of Dalian Medical University, the First Affiliated Hospital of Dalian Medical University and the Dalian Central Hospital approved the research. All the patient provided informed consent. EDAT- 2025/06/05 00:28 MHDA- 2025/06/05 07:07 PMCR- 2025/06/04 CRDT- 2025/06/04 23:26 PHST- 2025/02/08 00:00 [received] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/06/05 07:07 [medline] PHST- 2025/06/05 00:28 [pubmed] PHST- 2025/06/04 23:26 [entrez] PHST- 2025/06/04 00:00 [pmc-release] AID - 10.1038/s41598-025-04893-6 [pii] AID - 4893 [pii] AID - 10.1038/s41598-025-04893-6 [doi] PST - epublish SO - Sci Rep. 2025 Jun 4;15(1):19573. doi: 10.1038/s41598-025-04893-6. PMID- 40467530 OWN - NLM STAT- MEDLINE DCOM- 20250708 LR - 20250708 IS - 1557-9034 (Electronic) IS - 1092-6429 (Linking) VI - 35 IP - 7 DP - 2025 Jul TI - Prospective Evaluation of the Effect of Vesical Imaging Reporting and Data System Scoring on the Identification of Candidates for Repeated Transurethral Resection. PG - 557-563 LID - 10.1089/lap.2025.0073 [doi] AB - Background: To determine the diagnostic accuracy of the Vesical Imaging Reporting and Data System (VI-RADS) scoring system in identifying candidates for second transurethral resection (reTUR-BT) and investigate the success of VI-RADS in detecting muscle-invasive bladder cancer (MIBC). Methods: Data from 186 patients who underwent primary TUR-BT for bladder cancer (BC) at our center between April 2022 and April 2023 were prospectively collected. Preoperative bladder multiparametric magnetic resonance imaging was performed for all patients to determine the VI-RADS score. A cutoff value of VI-RADS >/=4 was accepted for detecting muscle invasion. Sensitivity, specificity, positive predictive value, negative predictive value, and the area under the curve (AUC) were calculated to evaluate the performance of VI-RADS in distinguishing MIBC from non-muscle-invasive bladder cancer (NMIBC) after primary TUR-BT. In the second phase, following the application of exclusion criteria, the study proceeded with 52 patients who underwent reTUR-BT, the primary target population of the study. Preoperatively calculated VI-RADS scores were compared with reTUR-BT pathology findings. Results: VI-RADS scoring was statistically significant in distinguishing MIBC from NMIBC. However, the performance of VI-RADS in identifying persistent NMIBC and upstaged MIBC in patients undergoing reTUR-BT was statistically nonsignificant. For VI-RADS >/=4, the sensitivity was 45.4%, specificity was 90.2%, PPV was 55.5%, and NPV was 86%. The AUC was 0.67 (95% confidence interval: 0.46-0.88; P = .079). Conclusions: Histopathologic sampling via reTUR-BT remains the gold standard, and the performance of VI-RADS in identifying candidates for reTUR-BT has been found to be suboptimal. FAU - Ayten, Ali AU - Ayten A AUID- ORCID: 0000-0001-8441-1293 AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Eksi, Mithat AU - Eksi M AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. FAU - Civan, Orkun AU - Civan O AD - Department of Radiology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Colakoglu, Yunus AU - Colakoglu Y AD - Department of Urology, Bahcelievler Memorial Hospital, Istanbul, Turkey. FAU - Arikan, Yusuf AU - Arikan Y AD - Department of Urology, Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Sahin, Selcuk AU - Sahin S AD - Department of Urology, Istinye University Liv Hospital Bahcesehir, Istanbul, Turkey. FAU - Tasci, Ali Ihsan AU - Tasci AI AD - Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20250604 PL - United States TA - J Laparoendosc Adv Surg Tech A JT - Journal of laparoendoscopic & advanced surgical techniques. Part A JID - 9706293 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - Male MH - Female MH - Prospective Studies MH - Aged MH - Middle Aged MH - Aged, 80 and over MH - Reoperation MH - *Multiparametric Magnetic Resonance Imaging MH - Sensitivity and Specificity MH - Neoplasm Invasiveness MH - *Cystectomy/methods MH - Predictive Value of Tests MH - Urinary Bladder/diagnostic imaging/surgery OTO - NOTNLM OT - Vesical Imaging Reporting and Data System OT - bladder cancer OT - multiparametric MRI OT - second transurethral bladder resection EDAT- 2025/06/05 00:28 MHDA- 2025/07/08 12:52 CRDT- 2025/06/04 22:52 PHST- 2025/07/08 12:52 [medline] PHST- 2025/06/05 00:28 [pubmed] PHST- 2025/06/04 22:52 [entrez] AID - 10.1089/lap.2025.0073 [doi] PST - ppublish SO - J Laparoendosc Adv Surg Tech A. 2025 Jul;35(7):557-563. doi: 10.1089/lap.2025.0073. Epub 2025 Jun 4. PMID- 40457401 OWN - NLM STAT- MEDLINE DCOM- 20250603 LR - 20250605 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 23 IP - 1 DP - 2025 Jun 2 TI - Unsupervised learning-based quantitative analysis of CT intratumoral subregions predicts risk stratification of bladder cancer patients. PG - 328 LID - 10.1186/s12916-025-04163-2 [doi] LID - 328 AB - BACKGROUND: Preoperative diagnosis of muscle invasion and American Joint Committee on Cancer (AJCC) stage plays a crucial role in guiding treatment strategies for bladder cancer (BCa). Utilizing quantitative analysis of tumor subregions via CT imaging holds promise in identifying high-risk populations. Developing and evaluating the performance of an unsupervised clustering algorithm-based intratumoral subregion radiomics model for distinguishing between bladder muscle invasion and AJCC stage. METHODS: This retrospective study included BCa patients who underwent CT imaging prior to transurethral resection of bladder tumor (TURBT) between January 2006 and December 2022, with all cases being histologically confirmed. Utilizing an unsupervised clustering learning method, the tumor region was classified into three intratumoral subregions, and radiomics features were extracted from both the whole tumor region and each intratumoral subregion. Following feature selection and nested cross-validation, seven predictive models were developed: clinicopathological model, whole-tumor model, intratumoral subregion 1 model, intratumoral subregion 2 model, intratumoral subregion 3 model, merged intratumoral subregion model, and fusion model. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUROC). RESULTS: A total of 1017 patients were included in this study, with 778 from center A (training cohort; median age, 67 years [IQR, 69-75 years]) and 239 from center B (external validation cohort; median age, 58.5 years [IQR, 66-74 years]). In the external validation cohort, the fusion model AUROC was highest for predicting muscle invasion and AJCC stage tasks, at 0.884 (95% CI, 0.842, 0.926) and 0.832 (95% CI, 0.768, 0.897), respectively. The merged intratumoral subregion model outperformed the whole-tumor model (AUROC, muscle invasion, 0.871 vs 0.804, p = 0.004; AJCC stage, 0.832 vs 0.804, p = 0.4). CONCLUSIONS: The subregional radiomics model based on preoperative CT shows potential value in predicting muscle invasion and AJCC stage. This noninvasive risk stratification tool may offer supportive insights into surgical approaches and treatment decisions for BCa patients. CI - (c) 2025. The Author(s). FAU - Wang, Ying AU - Wang Y AD - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jing Wu Road, No. 324, Jinan, 250021, China. AD - School of Radiology, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271016, China. FAU - Wang, Hexiang AU - Wang H AD - Department of Radiology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong, China. FAU - Li, Na AU - Li N AD - Department of Radiology, The People's Hospital of Zhangqiu Area, Jinan, 250200, China. FAU - Wu, Siyu AU - Wu S AD - Department of Radiology, Shandong Provincial Hospital, No. 324, Jingwu Road, Jinan, 250021, Shandong, China. FAU - Shi, Rongchao AU - Shi R AD - Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. FAU - Sun, Kui AU - Sun K AD - Department of General Surgery, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, China. sksunkui@163.com. FAU - Wang, Ximing AU - Wang X AD - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jing Wu Road, No. 324, Jinan, 250021, China. wxming369@163.com. LA - eng GR - 82271993/National Natural Science Foundation of China/ PT - Journal Article DEP - 20250602 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Tomography, X-Ray Computed/methods MH - Middle Aged MH - Risk Assessment/methods MH - *Unsupervised Machine Learning MH - Neoplasm Staging PMC - PMC12131335 OTO - NOTNLM OT - American Joint Committee on Cancer OT - Bladder cancer OT - Muscle invasion OT - Radiomics OT - Subregion COIS- Declarations. Ethics approval and consent to participate: All participating centers' Institutional Review Board approved the study protocols (The Affiliated Hospital of Qingdao University, No. QYFY WZLL 28166; Shandong Provincial Hospital, No.2023-526). The informed consent was waived because of the two-center retrospective nature of this study and due to all procedures being part of routine care. Consent for publication: N/A. Competing interests: The authors declare no competing interests. EDAT- 2025/06/03 00:29 MHDA- 2025/06/03 06:27 PMCR- 2025/06/02 CRDT- 2025/06/02 23:42 PHST- 2024/08/11 00:00 [received] PHST- 2025/05/26 00:00 [accepted] PHST- 2025/06/03 06:27 [medline] PHST- 2025/06/03 00:29 [pubmed] PHST- 2025/06/02 23:42 [entrez] PHST- 2025/06/02 00:00 [pmc-release] AID - 10.1186/s12916-025-04163-2 [pii] AID - 4163 [pii] AID - 10.1186/s12916-025-04163-2 [doi] PST - epublish SO - BMC Med. 2025 Jun 2;23(1):328. doi: 10.1186/s12916-025-04163-2. PMID- 40457308 OWN - NLM STAT- MEDLINE DCOM- 20250603 LR - 20250606 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 Jun 2 TI - Double-J stenting during TURBT increases risk of metachronous upper tract urothelial carcinoma. PG - 146 LID - 10.1186/s12894-025-01828-1 [doi] LID - 146 AB - OBJECTIVE: The potential impact of double-J (DJ) stenting during transurethral resection of bladder tumor (TURBT) on the occurrence of metachronous upper urinary tract urothelial carcinoma (UTUC) remains a subject of debate. This study investigates the effect of DJ stenting during TURBT for bladder cancer (BC) on the incidence of metachronous UTUC. METHODS: We retrospectively analyzed the data from patients who underwent TURBT at our institution between September 2013 and September 2023. Patients were grouped based on whether DJ stents were placed during TURBT. The outcome was the occurrence of metachronous UTUC, defined by UTUC occurring 3 months after TURBT. We define UTUC in DJ group occurring 3 months to 24 months post-TURBT as stent-related metachronous UTUC. Propensity scores adjustment was computed to control the confounding factors (p < 0.05). Kaplan-Meier analyses estimated metachronous UTUC recurrence-free survival (RFS) before and after propensity scores adjustment. Cox regression analyses were used to evaluate the data. Subgroup analyses and interaction tests for all categorical variables were conducted. RESULTS: A total of 570 patients were included in this study. We identified 19 (3.33%) patients were metachronous UTUC. Among patients with metachronous UTUC, 7 patients received DJ stents, while 12 patients did not receive DJ stents. Kaplan-Meier analysis showed poorer recurrence-free survival in the DJ group during the first two years postoperatively (unadjusted p < 0.001 VS. adjusted p = 0.006) and throughout the entire follow-up period (unadjusted p < 0.001 VS. adjusted p < 0.001). Cox multivariable regression analysis revealed that the placement of DJ stent was an independent risk factor for metachronous UTUC-free survival rates within the first two years postoperatively ( p = 0.003) or during the overall follow-up period ( p < 0.001). CONCLUSIONS: Patients who underwent DJ stenting during TURBT for BC exhibited an increased risk of developing metachronous UTUC, suggesting a potential association that warrants further investigation. CI - (c) 2025. The Author(s). FAU - Wu, Zhengfeng AU - Wu Z AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. FAU - Qu, Canhui AU - Qu C AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. FAU - Liang, Guangyao AU - Liang G AD - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. FAU - Sun, Rui AU - Sun R AD - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. FAU - Lin, Nanhe AU - Lin N AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. FAU - Xie, Yun AU - Xie Y AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. FAU - Wei, Huanqing AU - Wei H AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. FAU - Guan, Jianfeng AU - Guan J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. guanjianf@mail3.sysu.edu.cn. FAU - Mo, Chengqiang AU - Mo C AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. mochengq@mail.sysu.edu.cn. LA - eng GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ GR - 2024A1515010094/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20250602 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Male MH - *Stents/adverse effects MH - Female MH - Retrospective Studies MH - Aged MH - *Urinary Bladder Neoplasms/surgery MH - *Neoplasms, Second Primary/epidemiology/etiology MH - Middle Aged MH - *Ureteral Neoplasms/epidemiology/etiology MH - *Carcinoma, Transitional Cell/epidemiology/surgery MH - *Cystectomy/methods MH - *Kidney Neoplasms/epidemiology/etiology MH - Risk Factors PMC - PMC12128326 OTO - NOTNLM OT - Bladder cancer OT - Double J stent OT - Propensity score adjustment OT - Transurethral resection of bladder tumor OT - Upper urinary tract urothelial carcinoma COIS- Declarations. Ethics approval and consent to participate: This study strictly adhered to the Declaration of Helsinki. Ethical approval was waived by the First Affiliated Hospital of Sun Yat-sen University Ethical Committee in view of the retrospective nature of the study and all the procedures being performed were part of routine care. As a retrospective study, consent for participation were not applicable to this research. Consent for publication: As this study does not involve identifiable images or personal/clinical details that could compromise participant anonymity, the"Consent for Publication"is not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/06/03 00:29 MHDA- 2025/06/03 06:27 PMCR- 2025/06/02 CRDT- 2025/06/02 23:38 PHST- 2025/01/07 00:00 [received] PHST- 2025/05/21 00:00 [accepted] PHST- 2025/06/03 06:27 [medline] PHST- 2025/06/03 00:29 [pubmed] PHST- 2025/06/02 23:38 [entrez] PHST- 2025/06/02 00:00 [pmc-release] AID - 10.1186/s12894-025-01828-1 [pii] AID - 1828 [pii] AID - 10.1186/s12894-025-01828-1 [doi] PST - epublish SO - BMC Urol. 2025 Jun 2;25(1):146. doi: 10.1186/s12894-025-01828-1. PMID- 40450141 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20251107 IS - 1546-170X (Electronic) IS - 1078-8956 (Print) IS - 1078-8956 (Linking) VI - 31 IP - 8 DP - 2025 Aug TI - Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. PG - 2806-2814 LID - 10.1038/s41591-025-03738-z [doi] AB - Bacillus Calmette-Guerin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a global, phase 3, randomized trial evaluating subcutaneous sasanlimab in combination with BCG-I+M (Arm A), sasanlimab in combination with BCG-I (Arm B) or BCG-I+M (Arm C) in BCG-naive high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS) for Arm A versus Arm C; key secondary endpoints were EFS (Arm B versus Arm C) and overall survival. Patients were randomized 1:1:1 to Arm A (N = 352), Arm B (N = 352) and Arm C (N = 351). The trial met its primary endpoint with a statistically significant and clinically meaningful prolongation of EFS (Arm A versus Arm C); hazard ratio, 0.68 (95% confidence interval: 0.49-0.94); one-sided P = 0.0095. The 36-month estimated EFS rates were 82.1% (Arm A) and 74.8% (Arm C). EFS benefit for Arm A versus Arm C was observed across prespecified subgroups, including carcinoma in situ (CIS) and T1. The safety profile of the combination was consistent with the known profiles. To our knowledge, sasanlimab is the first anti-PD-1 antibody to show a clinically meaningful prolongation of EFS when combined with BCG-I+M versus SOC in patients with BCG-naive high-risk NMIBC. Sasanlimab combined with BCG-I+M has the potential to redefine the treatment paradigm and clinical decision-making for patients with BCG-naive high-risk NMIBC. ClinicalTrials.gov identifier: NCT04165317 . CI - (c) 2025. The Author(s). FAU - Shore, Neal D AU - Shore ND AUID- ORCID: 0000-0001-5767-0548 AD - START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com. FAU - Powles, Thomas B AU - Powles TB AUID- ORCID: 0000-0001-7760-4724 AD - Barts Health Biomedical NIHR Research Centre, Queen Mary University of London, London, UK. FAU - Bedke, Jens AU - Bedke J AD - Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany. FAU - Galsky, Matthew D AU - Galsky MD AUID- ORCID: 0000-0001-7655-9378 AD - The Tisch Cancer Institute, Mount Sinai, New York, NY, USA. FAU - Palou Redorta, Joan AU - Palou Redorta J AUID- ORCID: 0000-0003-1264-5327 AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kretkowski, Michal AU - Kretkowski M AD - Clinical Research Center, Spolka z Ograniczona, Poznan, Poland. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Alekseev, Boris AU - Alekseev B AD - P. Hertsen Moscow Cancer Research Institute, Moscow, Russia. FAU - Ye, Dingwei AU - Ye D AUID- ORCID: 0000-0003-4974-3780 AD - Fudan University Shanghai Cancer Center, Shanghai, China. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer, Center University of Toronto, Toronto, ON, Canada. FAU - Brinkmann, Julia AU - Brinkmann J AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Calella, Anna-Maria AU - Calella AM AD - Pfizer SRL, Rome, Italy. FAU - Cesari, Rossano AU - Cesari R AD - Pfizer SRL, Milan, Italy. FAU - Eccleston, Anthony AU - Eccleston A AD - Pfizer Ltd., Tadworth, UK. FAU - Michelon, Elisabete AU - Michelon E AD - Pfizer Inc., New York, NY, USA. FAU - Vermette, Jennifer AU - Vermette J AUID- ORCID: 0009-0000-8729-8652 AD - Pfizer Inc., Cambridge, MA, USA. FAU - Wei, Caimiao AU - Wei C AD - Pfizer Inc., Groton, CT, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, Rush University Medical Center, Chicago, IL, USA. LA - eng SI - ClinicalTrials.gov/NCT04165317 PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20250531 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 RN - 0 (BCG Vaccine) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM EIN - Nat Med. 2025 Aug;31(8):2815. doi: 10.1038/s41591-025-03894-2. PMID: 40691368 MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/administration & dosage/therapeutic use/adverse effects MH - Male MH - Female MH - Aged MH - Middle Aged MH - Aged, 80 and over MH - *Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/therapeutic use MH - Neoplasm Invasiveness MH - Adult MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12353837 COIS- Competing interests: N.D.S. reports research/consulting: Allessa, Amgen, Artera, Astellas, AstraZeneca, Aura Biosciences, Bayer, Bristol Myers Squibb, Caris, CG Oncology, Daiichi Sankyo, Dendreon, Glytheryx, Invitae, Janssen, MDxhealth, Merck, Minomic, Novartis, Nusano, PhotoCure, Pfizer, Sumitomo, Telix, Tolmar, Tutelix and Urogen. T.B.P. reports honoraria: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; consulting or advisory role: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; research funding: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Incyte, Ipsen, Johnson & Johnson, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; and travel, accommodations or expenses: Astellas, AstraZeneca, Gilead, Ipsen, Merck Sharp & Dohme, Pfizer and Roche. J. Bedke reports financial interests from Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Ipsen, Janssen, Merck Sorono, Merck Sharp & Dohme, Pfizer, Roche, Nektar, Novartis and Seagen and membership in the European Association of Urology and the Renal Cell Carcinoma Guidelines Panel (Vice-Chairman). M.D.G. reports stock and other ownership interests: Pfizer, Merck and Gilead Sciences; research funding: Merck, Bristol Myers Squibb, Mirati Therapeutics, Seagen, Alliance Foundation Trials, Alliance for Clinical Trials in Oncology, Clovis Oncology, Arvinas, ALX Oncology, Hoosier Cancer Research Network, Novartis, Acrivon Therapeutics, Astellas, Genentech, Accuray, PCCTC, G1 Therapeutics, OncoC4, Flare Therapeutics, Loxo/Lilly, Roche and Pfizer; other relationships: Elsevier, Medscape and Research to Practice; uncompensated relationships: G1 Therapeutics and Loxo/Lilly. J.P.R. reports advisory/consultancy roles for Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Combat, Genomic Expression and Olympus; steering committee membership for AstraZeneca, Bristol Myers Squibb, Janssen and Pfizer; grant or research support from Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Cepheid, TARIS Biomedical and Nucleix; and research funding from Pfizer. J.H.K. reports research funding from Pfizer. M.K. reports research funding from Pfizer. E.X. reports consulting or advisory role: Pfizer, Ferring and Boston Scientific and research funding: Ferring and Pfizer. B.A. reports honoraria: AstraZeneca, Astellas, Eisai, Janssen, Bayer, Merck Sharp & Dohme, Merck, Pfizer, Roche and Bristol Myers Squibb; consulting or advisory role: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck, Pfizer, Merck Sharp & Dohme, Roche and Eisai; speakers' bureau: Janssen, Astellas, Pfizer, AstraZeneca, Bayer, Merck, Bristol Myers Squibb, Merck Sharp & Dohme, Eisai and Roche; research funding: AstraZeneca, Merck, Bayer, Astellas, Janssen, Bristol Myers Squibb, Pfizer, ICON Clinical Research, Eisai, Merck Sharp & Dohme and Roche; and travel, accommodations and expenses: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Pfizer and Sanofi. D.Y. reports research funding from Pfizer. F.G.-R. reports research support/principal investigator: Johnson & Johnson, Pfizer, Taris, Bristol Myers Squibb, Roche, Seagen, AstraZeneca, Combat Medical, Cepheid, Fidia, Astellas, UroGen and Merck Sharp & Dohme; employment: SERMAS (Servicio Madrileno de Salud); consultancy: Johnson & Johnson, Pfizer, Merck, Roche, Taris, Combat Medical, AstraZeneca, Merck Sharp & Dohme and Bristol Myers Squibb; stockholder: CG Oncology; speakers' bureau: Janssen, Nucleix, Merck Sharp & Dohme, Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, Palex, Combat Medical, Johnson & Johnson and Recordati; travel: Pfizer, Recordati, Ipsen, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia and Johnson & Johnson; advisory board: AstraZeneca, Bristol Myers Squibb, Combat Medical, Johnson & Johnson, Nucleix, Pfizer, Taris, Roche and Merck Sharp & Dohme; and manuscript support: Pfizer, Janssen, Combat Medical, AstraZeneca, Johnson & Johnson and Bristol Myers Squibb. A.B. reports consulting or advisory role: Astellas, Janssen-Cilag, OPKO Health, MDxHealth, Ferring, Bayer, AstraZeneca, Hauora and Pfizer; speakers' bureau: Astellas; and research funding: Sandoz-Novartis, Merck Sharp & Dohme and Pfizer. G.S.K. reports honoraria: AbbVie, Tersera, Bayer, Knight Pharmaceuticals, AstraZeneca Canada and PhotoCure; consulting or advisory role: Merck, Theralase, Janssen Oncology, Ferring, Verity Pharmaceuticals, Bristol Myers Squibb, EMD Serono, Pfizer, Novartis and enGene; research funding: Johnson & Johnson/Janssen and Pfizer. J. Brinkmann reports employment: Pfizer Pharma GmbH. A.-M.C. reports employment: Pfizer SRL. R.C. reports employment: Pfizer SRL. A.E. reports employment: Pfizer Ltd. E.M. reports employment: Pfizer Inc. J.V. reports employment: Pfizer Inc. C.W. reports employment: Pfizer Inc. G.D.S. reports advisory/consultancy roles: Heat Biologics, CG Oncology, PhotoCure, Merck, Roche/Genentech, Ciclomed, Taris Biomedical (now Janssen), MDxHealth, Fidia Farmaceutici, UroGen, Ferring, Aduro, Boston Scientific, Bristol Myers Squibb, AstraZeneca, Pfizer, Janssen, Epivax Therapeutics, Natera, FKD, EnGene Bio, Sesen Bio, BioCanCell (now Archiano), Nucleix, Ipsen, Combat Medical, Astellas, FerGene, Dendreon, AbbVie, Seagen, Verity Pharmaceuticals, Regeneron, STIMIT, Vyriad, Protara, xCures, Nonagen, Nanology and Imvax; clinical trial protocol committee membership for Bristol Myers Squibb, CG Oncology, Fidia, Janssen, Merck, Pfizer, PhotoCure, Protara and Seagen; stock/shares in CG Oncology, EnGene Bio, EpiVax Therapeutics and UroGen; and research funding from Pfizer. EDAT- 2025/06/01 00:45 MHDA- 2025/09/08 08:00 PMCR- 2025/05/31 CRDT- 2025/05/31 23:22 PHST- 2025/04/04 00:00 [received] PHST- 2025/04/29 00:00 [accepted] PHST- 2025/09/08 08:00 [medline] PHST- 2025/06/01 00:45 [pubmed] PHST- 2025/05/31 23:22 [entrez] PHST- 2025/05/31 00:00 [pmc-release] AID - 10.1038/s41591-025-03738-z [pii] AID - 3738 [pii] AID - 10.1038/s41591-025-03738-z [doi] PST - ppublish SO - Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. PMID- 40442275 OWN - NLM STAT- MEDLINE DCOM- 20250529 LR - 20250704 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 May 29 TI - Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: a multicenter retrospective study. PG - 18905 LID - 10.1038/s41598-025-03916-6 [doi] LID - 18905 AB - This multicenter, retrospective study evaluated the impact of pelvic lymph node dissection (PLND) on survival outcomes in non-muscle invasive bladder cancer (NMIBC) patients undergoing radical cystectomy (RC) and identified factors associated with upstaging. A total of 544 NMIBC patients who underwent RC with or without PLND between 2019 and 2024 were analyzed. Survival outcomes, including cancer-specific survival (CSS) and recurrence-free survival (RFS), were compared using Kaplan-Meier analysis and Cox proportional hazards models, while factors associated with upstaging were examined through logistic regression. Of the 544 patients, 509 (93.6%) were staged as cT1, and 412 (75.7%) underwent PLND. Upstaging occurred in 193 patients (35.5%), with pathological stages distributed as pT1 (50.0%), pT2 (20.8%), pT3 (11.2%), and pT4 (3.5%). Among patients who underwent PLND, 29 (7.0%) had positive lymph nodes. PLND was associated with improved RFS (5-year: 84.3% vs. 71.5%; adjusted hazard ratio [HR] = 0.33, 95% confidence interval [CI]: 0.20-0.56, p < 0.001) but did not significantly impact CSS (5-year: 86.5% vs. 81.6%; adjusted HR = 0.57, 95% CI: 0.32-1.02, p = 0.06). Lymph node positivity was linked to the worst prognosis. cT1 tumors, histological subtypes, and PLND were significant predictors of upstaging. In patients with cT1 tumors or histological subtypes, repeat transurethral resection is recommended to obtain more precise staging, which may inform further therapeutic decisions. While PLND is not routinely recommended for all NMIBC patients, it may be considered in those with high-risk features, particularly cT1 tumors or histological subtypes. CI - (c) 2025. The Author(s). FAU - Huang, Shiwang AU - Huang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Jia, Kaipeng AU - Jia K AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Cui, Jingmin AU - Cui J AD - Department of Urology, Tangshan Workers Hospital, Tangshan, Hebei Province, China. FAU - Duan, Jianfei AU - Duan J AD - Department of General Surgery, Tianjin Children's Hospital, Tianjin, China. FAU - Li, Xiaosong AU - Li X AD - Department of Psychiatry, Tianjin Rehabilitation Center of Joint Logistics Support Force, Tianjin, China. FAU - Chai, Wang AU - Chai W AD - Department of Urology, Yellow River Hospital, Tianjin, China. FAU - Shen, Chong AU - Shen C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Zhang, Zhe AU - Zhang Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Chen, Huitong AU - Chen H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liang, Shan AU - Liang S AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Han, Jingwen AU - Han J AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Guo, Jianing AU - Guo J AD - Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. Zhouliangwu2012@163.com. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. Zhouliangwu2012@163.com. FAU - Qie, Yunkai AU - Qie Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. qieyunkai@tmu.edu.cn. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. qieyunkai@tmu.edu.cn. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China. huhailong@tmu.edu.cn. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. huhailong@tmu.edu.cn. LA - eng GR - TJWJ2022XK014/the Tianjin Municipal Health Industry Key Project fund/ GR - 2022ZD069/the Scientific Research Project fund of Tianjin Municipal Education Commission/ PT - Journal Article PT - Multicenter Study DEP - 20250529 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cystectomy/methods MH - Kaplan-Meier Estimate MH - *Lymph Node Excision/methods MH - Lymph Nodes/pathology/surgery MH - Lymphatic Metastasis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/pathology/surgery MH - Pelvis/pathology/surgery MH - Prognosis MH - Retrospective Studies PMC - PMC12122790 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Outcomes OT - Pelvic lymph node dissection OT - Radical cystectomy OT - Upstaging COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/05/30 01:54 MHDA- 2025/05/30 01:55 PMCR- 2025/05/29 CRDT- 2025/05/29 23:26 PHST- 2025/01/04 00:00 [received] PHST- 2025/05/23 00:00 [accepted] PHST- 2025/05/30 01:55 [medline] PHST- 2025/05/30 01:54 [pubmed] PHST- 2025/05/29 23:26 [entrez] PHST- 2025/05/29 00:00 [pmc-release] AID - 10.1038/s41598-025-03916-6 [pii] AID - 3916 [pii] AID - 10.1038/s41598-025-03916-6 [doi] PST - epublish SO - Sci Rep. 2025 May 29;15(1):18905. doi: 10.1038/s41598-025-03916-6. PMID- 40439390 OWN - NLM STAT- MEDLINE DCOM- 20250529 LR - 20250729 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 26 IP - 5 DP - 2025 May 1 TI - The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A double Blinded Prospective Randomized Study. PG - 1767-1771 LID - 91664 [pii] LID - 10.31557/APJCP.2025.26.5.1767 [doi] AB - BACKGROUND: Transurethral resection of the bladder tumor (TURBT) followed by intravesical instillation therapy is the standard treatment for non-muscle invasive bladder cancer (NMIBC). One of the factors that may affect the risk of recurrence after TURBT is the quality of surgery that may vary between individual surgeons. While there has been a large number of studies demonstrating the ability to reduce the risk of recurrence of NMIBC with different types of the intravesical therapy, less attention was paid to the quality of TURBT in improving long-term treatment results. The aim of the study is to evaluate the effect of the quality of TURBT on the recurrence rate of NMIBC based on surgeon experience. METHODS: The study is a double blinded prospective randomized study conducted on 50 patients with NMIBC. who underwent 126 procedures (50 primary cystoscopies ,26 restaging cystoscopies and 50 check cystoscopies at three months). All Treatment-naive patients with NMIBC candidate for TURBT were included, with exclusion of patients with previous history of TURBT, previous open bladder surgery, patients with urethral stricture, patients with muscle invasive bladder cancer. And patients who lost follow up. Patients were randomized by closed envelope into two groups; Group A included 25 patients who underwent TURBT by a senior surgeon (more than 5 years' experience), and Group B included 25 patients underwent TURBT by a qualified junior surgeon (less than 5 years' experience). Restaging cystoscopy at 2-6 weeks (if indicated) and follow up cystoscopy at three months were performed by another senior surgeon (who was blinded to the name of the first surgeon). RESULTS: No statistically significant difference was found between both groups regarding the incidence of complications (urethral injury, bladder perforation, ureteric injury, obturator reflex), Group B showed a statistically significant longer operative time, postoperative irrigation time, more hemoglobin loss, longer hospital stay, and higher 3 months' recurrence rates. Moreover, senior surgeons' specimens were more likely to include detrusor muscles. CONCLUSION: surgeon's experience has significant impact on the quality of TURBT and risk of recurrence of NMIBC. With less operative time, less hemoglobin drop, and less hospital stay. FAU - Kassem, Ayman AU - Kassem A AD - Department of Urology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt. FAU - Assem, Ahmed AU - Assem A AD - Department of Urology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt. FAU - Sharawy, Ahmed AU - Sharawy A AD - Department of Urology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt. FAU - Ezz El Deen, Mohamed AU - Ezz El Deen M AD - Department of Urology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt. FAU - Emran, Ashraf AU - Emran A AD - Department of Urology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20250501 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Double-Blind Method MH - Prospective Studies MH - Female MH - *Neoplasm Recurrence, Local/pathology/surgery MH - *Cystectomy/methods MH - Aged MH - Middle Aged MH - Follow-Up Studies MH - Neoplasm Invasiveness MH - Prognosis MH - *Surgeons/standards MH - Cystoscopy MH - *Clinical Competence MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12290209 OTO - NOTNLM OT - NMIBC OT - TURBT OT - bladder cancer OT - double blinded study COIS- No disclosures or conflict of a declarable nature for financial or editorial support. EDAT- 2025/05/29 12:53 MHDA- 2025/05/29 12:54 PMCR- 2025/03/01 CRDT- 2025/05/29 08:53 PHST- 2024/12/16 00:00 [received] PHST- 2025/05/29 12:54 [medline] PHST- 2025/05/29 12:53 [pubmed] PHST- 2025/05/29 08:53 [entrez] PHST- 2025/03/01 00:00 [pmc-release] AID - 91664 [pii] AID - 10.31557/APJCP.2025.26.5.1767 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2025 May 1;26(5):1767-1771. doi: 10.31557/APJCP.2025.26.5.1767. PMID- 40438876 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250531 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 30 IP - 1 DP - 2025 Jul TI - Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons. PG - 348 LID - 10.3892/ol.2025.15094 [doi] LID - 348 AB - Bladder cancer (BC) is a significant global health concern and includes non-muscle-invasive BC (NMIBC), which poses challenges due to recurrence and progression. Immunotherapy, such as immune checkpoint inhibitors (ICIs) and Bacillus Calmette-Guerin (BCG), shows promise particularly in cases of BCG failure or BCG-unresponsive NMIBC, with ICIs emerging as a potential treatment option for these challenging cases. To the best of our knowledge, the present study is the first to systematically compare the efficacy and safety of BCG with ICIs in NMIBC. The present meta-analysis identifies response predictors and treatment outcomes, which can help in recognizing potential biomarkers such as tumor characteristics, hemoglobin levels and baseline performance status, associated with therapy response. These insights may guide future research in developing personalized treatment strategies for BCG non-responsive NMIBC cases. Following the Preferred Reporting Standards for Systematic Reviews and Meta-Analyses guidelines, a systematic literature search identified relevant studies published between January 2015 and April 2024. Randomized controlled trials and clinical trials involving patients with BCG-refractory NMIBC were included in the primary analysis. Data extraction and analysis were conducted using Review Manager version 5.4, employing a random effects model. The risk of bias assessment followed the Cochrane guidelines. The present study included 2,154 participants across 10 studies evaluating treatments for NMIBC. Primary comparisons focused on BCG vs. ICIs: Pembrolizumab significantly improved tumor control (OR, 4.67; 95% CI, 1.43-15.25; P=0.01), progression-free survival (PFS; OR, 4.85; CI, 1.58-14.85; P=0.006), and overall survival (OS; OR, 3.61; CI, 1.28-10.19; P=0.02). Atezolizumab similarly outperformed BCG in metastatic disease (OR, 0.19; CI, 0.06-0.59; P=0.004) and lymph node involvement (OR, 0.43; CI, 0.20-0.93; P=0.03). ICIs exhibited a favorable safety profile vs. BCG, with fewer incidents of anemia (OR, 2.87; P=0.001) and diarrhea (OR, 1.79; P=0.03), despite higher rates of asthenia (OR, 7.33; P<0.00001) and pyrexia (OR, 3.26; P<0.00001). Exploratory comparisons with chemotherapy revealed pembrolizumab's advantages in terms of PFS (OR, 1.36; P=0.02) and OS (OR, 1.31; P=0.005), while atezolizumab improved metastatic control (OR, 0.54; P=0.0008). Heterogeneity was low for BCG comparisons (I(2)=0%) but high for chemotherapy (I(2)=81-95%). In conclusion, ICIs, particularly pembrolizumab and atezolizumab, demonstrate superior efficacy and safety over BCG in BCG-refractory NMIBC, supporting their use as first-line alternatives. These findings advocate for a paradigm shift in managing BCG-unresponsive disease, emphasizing personalized immunotherapy. CI - Copyright: (c) 2025 Adan et al. FAU - Adan, Mohamed Mohamoud AU - Adan MM AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China. FAU - Mao, Xudong AU - Mao X AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China. FAU - Ding, Lifeng AU - Ding L AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China. FAU - Abdullahi, Khalid Mohamoud AU - Abdullahi KM AD - Zhejiang Clinical Research Center of Minimally Invasive Diagnosis and Treatment of Abdominal Diseases, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China. FAU - Li, Gonghui AU - Li G AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China. LA - eng PT - Journal Article DEP - 20250516 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC12117413 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - immune checkpoint inhibitors OT - immunotherapy OT - meta-analysis OT - non-muscle invasive bladder cancer COIS- The authors declare that they have no competing interests. EDAT- 2025/05/29 06:27 MHDA- 2025/05/29 06:28 PMCR- 2025/05/16 CRDT- 2025/05/29 04:46 PHST- 2024/08/17 00:00 [received] PHST- 2025/01/15 00:00 [accepted] PHST- 2025/05/29 06:28 [medline] PHST- 2025/05/29 06:27 [pubmed] PHST- 2025/05/29 04:46 [entrez] PHST- 2025/05/16 00:00 [pmc-release] AID - OL-30-1-15094 [pii] AID - 10.3892/ol.2025.15094 [doi] PST - epublish SO - Oncol Lett. 2025 May 16;30(1):348. doi: 10.3892/ol.2025.15094. eCollection 2025 Jul. PMID- 40434425 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20260514 IS - 2366-0058 (Electronic) VI - 50 IP - 12 DP - 2025 Dec TI - Recurrence risk prediction for non-muscle-invasive bladder urothelial carcinoma using diffusion and clinicopathology features. PG - 5903-5914 LID - 10.1007/s00261-025-05023-6 [doi] AB - PURPOSE: To investigate the prognostic value of apparent diffusion coefficient (ADC) metrics, MRI characteristics, and clinicopathological parameters in predicting non-muscle-invasive bladder urothelial carcinoma (UCB) recurrence, and to develop a novel multiparametric risk stratification framework. METHODS: This retrospective single-center study (n = 135) with histologically confirmed non-muscle-invasive UCB diagnosed between January 2015 and March 2023. ADC values, vesical imaging reporting and data system (VI-RADS) scores, and clinicopathological variables were analyzed with recurrence-free survival (RFS) as the primary endpoint. Prognostic determinants were identified using univariate and multivariate Cox proportional hazard regression models. An advanced risk stratification system was developed using independent predictors and validated against the European Association of Urology (EAU) risk classification using concordance index (C-index). RESULTS: Multivariate analysis identified three independent predictors: ADC values (HR = 0.104, 95% confidence interval (CI) 0.025-0.436), hemoglobin levels (HR = 0.463, 95% CI 0.223-0.960), and pathological grade (HR = 2.079, 95% CI 1.098-3.936). The combined model incorporating these parameters demonstrated moderate predictive accuracy (C-index = 0.724, 95% CI 0.655-0.794). Notably, VI-RADS scores showed no independent prognostic value. Risk stratification based on ADC (/=3 for T2 (muscle-invasive), sensitivity and specificity were 93.75% (79.19% to 99.23%) and 76.92% (60.67% to 88.87%), respectively. With a cut-off score of VI-RADS >/=4 for muscle invasion, sensitivity and specificity were 62.5% (43.69% to 78.90%) and 89.74% (75.78% to 97.13%), respectively. VI-RADS scores of 1 and 2 were fairly accurate for non-muscle invasion, while scores of 4 and 5 were highly predictive of muscle invasion. A VI-RADS score of 3 remained the grey zone. Conclusion It is easy to interpret the VI-RADS score and assess detrusor muscle invasion. The present study on VI-RADS shows reliability for local staging and for differentiating non-MIBC (NMIBC) and MIBC. Among the VI-RADS scores, it was found that the result was statistically significant between high-grade and low-grade cancer, with a p-value <0.001. CI - Copyright (c) 2025, Ahmad et al. FAU - Ahmad, Ahsan AU - Ahmad A AD - Department of Urology, Indira Gandhi Institute of Medical Sciences, Patna, IND. FAU - Ranjan, Nikhil AU - Ranjan N AD - Department of Urology, Indira Gandhi Institute of Medical Sciences, Patna, IND. FAU - Babelay, Gaurav AU - Babelay G AD - Department of Urology, Indira Gandhi Institute of Medical Sciences, Patna, IND. FAU - Dheeraj, Kumar AU - Dheeraj K AD - Department of Urology, Indira Gandhi Institute of Medical Sciences, Patna, IND. LA - eng PT - Journal Article DEP - 20250427 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12108148 OTO - NOTNLM OT - bladder cancer OT - mp-mri OT - mri OT - multiparametric magnetic resonance imaging OT - muscle invasive bladder cancer OT - non-muscle-invasive bladder cancer OT - virads COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Ethics Committee of Indira Gandhi Institute of Medical Sciences, Patna, India issued approval 847/IEC/IGIMS/2022. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/05/28 11:02 MHDA- 2025/05/28 11:03 PMCR- 2025/04/27 CRDT- 2025/05/28 04:44 PHST- 2025/04/26 00:00 [accepted] PHST- 2025/05/28 11:03 [medline] PHST- 2025/05/28 11:02 [pubmed] PHST- 2025/05/28 04:44 [entrez] PHST- 2025/04/27 00:00 [pmc-release] AID - 10.7759/cureus.83068 [doi] PST - epublish SO - Cureus. 2025 Apr 27;17(4):e83068. doi: 10.7759/cureus.83068. eCollection 2025 Apr. PMID- 40421535 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20261006 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 49 IP - 11 DP - 2025 Nov 1 TI - Clinicopathologic Review of Malignancies in Neobladders and Conduits Following Bladder Reconstruction. PG - 1150-1157 LID - 10.1097/PAS.0000000000002429 [doi] AB - Malignancy associated with ileal neobladders or ileal conduits in postradical cystectomy patients is rare. Yet, recurrent urothelial carcinoma or new primary cancers, such as adenocarcinoma, enteric type (EA), are potential complications that pose significant clinical challenges. This study aimed to evaluate the incidence, clinical outcomes, and management strategies for malignancies in patients with ileal neobladders or ileal conduits. A retrospective review was conducted at 3 large academic institutions, identifying 10 cases of malignant tumors arising in ileal neobladders or ileal conduits over a period of 10 years. The study cohort included 9 male and 1 female patient aged 56 to 92 years (mean age = 68.2 y). Data on clinical presentation, management, pathology, and outcomes were collected, with a focus on recurrence and disease-specific survival rates. Seven of 10 patients (all males) were initially diagnosed with invasive high-grade urothelial carcinoma (IHGUC), whereas 3 patients had a history of bladder augmentation with colonic tissue (BA) for benign etiologies. Of patients with IHGUC, 2 patients received neoadjuvant chemotherapy, 1 received a combination of chemotherapy agents, and 3 patients underwent intravesical BCG therapy. All IHGUC exhibited conventional morphology without divergent differentiation. Pathologic staging of the cystectomy for IHGUC ranged from pTa to pT3a, with 4 cases showing lymph node metastasis. IHGUC recurrence was detected in 6 of 7 patients with a latency period range of 7 months to 6.7 years (mean 37 mo) and all tumors again exhibiting conventional morphology without divergent differentiation. IHGUC recurrence demonstrated a pathologic stage ranging from pT2 to pT4, and 5 died (mean = 4.2 mo), whereas 1 patient remains alive and on surveillance. EA occurred in 4 patients, including 3 BA patients and 2 foci in 1 patient with a neobladder for IHGUC. Staging of patients with EA ranged from pTis to pT2 developing 31 to 55 years postsurgery. Three of 5 EA cases were associated with a precursor lesion including 2 tubular adenoma with high-grade dysplasia, and 1 sessile serrated lesion with dysplasia. EA patients had relatively favorable outcomes compared with IHGUC patients, with all surviving patients currently on surveillance though with one case demonstrating nodal metastasis. Although rare, malignancies in ileal neobladders or ileal conduits are a serious complication. Although IHGUC recurrence often leads to poor survival, EA patients-especially those with prior bladder augmentation-seem to be associated with better survival outcomes. The long latency period for IHGUC recurrence and the favorable prognosis for EA underscore the need for vigilant long-term surveillance. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Chen, Jacqueline AU - Chen J AD - Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Daniels, Elaina AU - Daniels E AD - Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. FAU - Mirsadraei, Leili AU - Mirsadraei L AD - Department of Pathology, New York University Grossman Long Island School of Medicine, Mineola, NY. FAU - Skala, Stephanie L AU - Skala SL AD - Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. FAU - Sun, Yue AU - Sun Y AD - Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Yilmaz, Osman AU - Yilmaz O AD - Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Mehra, Rohit AU - Mehra R AD - Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. FAU - Kopach, Pavel AU - Kopach P AD - Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250527 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy/surgery MH - Retrospective Studies MH - *Cystectomy/adverse effects MH - Aged, 80 and over MH - *Urinary Diversion/adverse effects/mortality MH - *Urinary Reservoirs, Continent/adverse effects/pathology MH - Neoplasm Recurrence, Local MH - *Carcinoma, Transitional Cell/pathology/mortality/therapy MH - Treatment Outcome MH - *Adenocarcinoma/therapy/pathology/mortality MH - Neoadjuvant Therapy MH - Chemotherapy, Adjuvant MH - Time Factors MH - *Plastic Surgery Procedures/adverse effects OTO - NOTNLM OT - and chemotherapy OT - immune checkpoint inhibitors OT - palliative radiation OT - with poor survival COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2025/05/27 06:27 MHDA- 2025/10/15 06:30 CRDT- 2025/05/27 05:03 PHST- 2025/10/15 06:30 [medline] PHST- 2025/05/27 06:27 [pubmed] PHST- 2025/05/27 05:03 [entrez] AID - 00000478-202511000-00009 [pii] AID - 10.1097/PAS.0000000000002429 [doi] PST - ppublish SO - Am J Surg Pathol. 2025 Nov 1;49(11):1150-1157. doi: 10.1097/PAS.0000000000002429. Epub 2025 May 27. PMID- 40418371 OWN - NLM STAT- MEDLINE DCOM- 20250526 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 May 26 TI - Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the "jump" of the lamina propria layer myth. PG - 324 LID - 10.1007/s00345-025-05669-3 [doi] AB - PURPOSE: To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort. METHODS: This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival. RESULTS: Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41-1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27-1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09-0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04). CONCLUSION: Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Tissot, Gabrielle AU - Tissot G AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Dubuet, Ulysse AU - Dubuet U AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Regnier, Sophie AU - Regnier S AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Anesthesiology, University of Zurich, University Hospital Zurich, Zurich, 8091, Switzerland. FAU - Budowski, Alexandra AU - Budowski A AD - Department of Anesthesiology, University of Zurich, University Hospital Zurich, Zurich, 8091, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Clinique Pasteur, Toulouse, France. FAU - Maestro, Mario Alvarez AU - Maestro MA AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Veerman, Hans AU - Veerman H AD - Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Di Bona, Carlo AU - Di Bona C AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy. FAU - Thenault, Ronan AU - Thenault R AD - Department of Urology, Service d'urologie, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, Service d'urologie, Rennes University Hospital, Hopital Pontchaillou, Rennes, France. FAU - Hermieu, Jean-Francois AU - Hermieu JF AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Assistance Publique-Hopitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cite, Paris, France. evanguelos.xylinas@aphp.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250526 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Cystectomy/methods MH - Mucous Membrane/pathology/surgery MH - *Muscle, Smooth/pathology/surgery MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality OTO - NOTNLM OT - Detrusor muscle OT - High-grade OT - Non-muscle invasive bladder cancer OT - Second look OT - pTa COIS- Declarations. Informed consent: For this study, oral consent was obtained for every patient. Competing interests: The authors declare no competing interests. EDAT- 2025/05/26 12:37 MHDA- 2025/05/26 12:38 CRDT- 2025/05/26 11:15 PHST- 2025/04/02 00:00 [received] PHST- 2025/04/25 00:00 [accepted] PHST- 2025/05/26 12:38 [medline] PHST- 2025/05/26 12:37 [pubmed] PHST- 2025/05/26 11:15 [entrez] AID - 10.1007/s00345-025-05669-3 [pii] AID - 10.1007/s00345-025-05669-3 [doi] PST - epublish SO - World J Urol. 2025 May 26;43(1):324. doi: 10.1007/s00345-025-05669-3. PMID- 40417381 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250527 IS - 2770-9183 (Electronic) IS - 2770-9191 (Print) IS - 2770-9183 (Linking) VI - 4 IP - 4 DP - 2025 Aug TI - Identification and Evaluation of the Urinary Microbiota Associated With Bladder Cancer. PG - e70012 LID - 10.1002/cai2.70012 [doi] LID - e70012 AB - BACKGROUND: Bladder cancer is a common malignancy of the genitourinary system. Recent studies have confirmed the existence of microorganisms in urine. This study aimed to characterize changes in the urinary microbiota of Chinese bladder cancer patients and determine differences between patients with muscle-invasive bladder cancer (MIBC) and those with non-muscle-invasive bladder cancer (NMIBC). METHODS: Urine samples were collected from 64 patients with bladder cancer and 94 disease-free controls using the clean catch method and sequenced by 16S rRNA gene sequencing. Sequencing reads were filtered by VSEARCH and clustered by UPARSE. RESULTS: Significant associations were found between urinary microbiota and factors such as sex, age, and disease status. After age adjustment, differences in beta diversity were observed between healthy men and women, cancer patients and healthy controls, and NMIBC and MIBC patients. The cancer patients had an increased abundance of 14 bacterial genera, including Stenotrophomonas, Propionibacterium, and Acinetobacter. Notably, Peptoniphilus spp. were enriched in high-risk MIBC patients, indicating their potential as a risk marker. Functional prediction via PICRUSt analysis suggested enriched metabolic pathways in specific disease groups. Furthermore, molecular ecological network analysis revealed differences based on sex and disease type. CONCLUSIONS: This significant microbial diversity indicates a potential correlation between urinary microbiota dysbiosis and bladder cancer, with implications for risk stratification and disease management. The identified urinary microbiota may serve as noninvasive markers for bladder cancer, warranting further validation in larger cohorts. This study provides a foundation for further research on the mechanisms of bladder cancer progression. CI - (c) 2025 The Author(s). Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press. FAU - Li, Nannan AU - Li N AUID- ORCID: 0000-0001-7799-0880 AD - College of Life Sciences University of Chinese Academy of Sciences Beijing China. AD - HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences, BGI Research Hangzhou China. AD - Guangdong Provincial Key Laboratory of Human Disease Genomics Shenzhen Key Laboratory of Genomics, BGI Research Shenzhen China. AD - BGI Genomics Harbin China. AD - BGI Shenzhen China. FAU - Wang, Lei AU - Wang L AD - Department of Urology Peking University Shougang Hospital Beijing China. AD - Peking University Wu-Jieping Urology Center, Peking University Health Science Center Beijing China. FAU - Yang, Qin AU - Yang Q AD - BGI Shenzhen China. FAU - Li, Fuqiang AU - Li F AD - Guangdong Provincial Key Laboratory of Human Disease Genomics Shenzhen Key Laboratory of Genomics, BGI Research Shenzhen China. AD - BGI Genomics Harbin China. FAU - Shi, Zhun AU - Shi Z AD - BGI Genomics Harbin China. FAU - Feng, Xiujie AU - Feng X AD - College of Life Sciences University of Chinese Academy of Sciences Beijing China. AD - HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences, BGI Research Hangzhou China. AD - Guangdong Provincial Key Laboratory of Human Disease Genomics Shenzhen Key Laboratory of Genomics, BGI Research Shenzhen China. AD - BGI Genomics Harbin China. AD - BGI Shenzhen China. FAU - Zhang, Liwei AU - Zhang L AD - Department of Urology Peking University Shougang Hospital Beijing China. AD - Peking University Wu-Jieping Urology Center, Peking University Health Science Center Beijing China. FAU - Li, Xiaojian AU - Li X AD - Department of Urology Peking University Shougang Hospital Beijing China. AD - Peking University Wu-Jieping Urology Center, Peking University Health Science Center Beijing China. FAU - Jin, Xin AU - Jin X AD - College of Life Sciences University of Chinese Academy of Sciences Beijing China. AD - BGI Shenzhen China. FAU - Zhu, Shida AU - Zhu S AD - BGI Genomics Harbin China. FAU - Wu, Kui AU - Wu K AD - College of Life Sciences University of Chinese Academy of Sciences Beijing China. AD - HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences, BGI Research Hangzhou China. AD - Guangdong Provincial Key Laboratory of Human Disease Genomics Shenzhen Key Laboratory of Genomics, BGI Research Shenzhen China. AD - BGI Genomics Harbin China. AD - BGI Shenzhen China. FAU - Li, Ningchen AU - Li N AD - Department of Urology Peking University Shougang Hospital Beijing China. AD - Peking University Wu-Jieping Urology Center, Peking University Health Science Center Beijing China. LA - eng PT - Journal Article DEP - 20250525 PL - England TA - Cancer Innov JT - Cancer innovation JID - 9918713888606676 PMC - PMC12103652 OTO - NOTNLM OT - bladder cancer OT - microbiota OT - muscle-invasive bladder cancer OT - non-muscle-invasive bladder cancer OT - urine COIS- Qin Yang, Fuqiang Li, and Zhun Shi are the Project Scientists in BGI, Xin Jin is the Chief Scientist of BGI, Shida Zhu is the Deputy General Manager of BGI, and Kui Wu is Director Scientist of BGI. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. EDAT- 2025/05/26 12:37 MHDA- 2025/05/26 12:38 PMCR- 2025/05/25 CRDT- 2025/05/26 06:14 PHST- 2024/09/23 00:00 [received] PHST- 2025/01/03 00:00 [revised] PHST- 2025/03/26 00:00 [accepted] PHST- 2025/05/26 12:38 [medline] PHST- 2025/05/26 12:37 [pubmed] PHST- 2025/05/26 06:14 [entrez] PHST- 2025/05/25 00:00 [pmc-release] AID - CAI270012 [pii] AID - 10.1002/cai2.70012 [doi] PST - epublish SO - Cancer Innov. 2025 May 25;4(4):e70012. doi: 10.1002/cai2.70012. eCollection 2025 Aug. PMID- 40415640 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250716 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 136 IP - 2 DP - 2025 Aug TI - Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk. PG - 236-244 LID - 10.1111/bju.16793 [doi] AB - OBJECTIVE: To assess whether the distribution of concomitant carcinoma in situ (CIS; unifocal or multifocal) with papillary non-muscle-invasive bladder cancer (NMIBC) impacts the risk of progression, as concomitant CIS is an established risk factor for progression in papillary NMIBC and commonly used calculators do not make this distinction. PATIENTS AND METHODS: In this multi-institutional retrospective cohort study from both academic and community hospitals, clinicopathological data were collected from patients with pTa/pT1 NMIBC treated from 2005 to 2022. Unifocal concomitant CIS was defined as CIS present in only one specimen (i.e., papillary disease with CIS at the tumour base or isolated CIS in one specimen). Multifocal concomitant CIS was characterised by CIS in multiple specimens. Progression was defined as the development of muscle-invasive or metastatic disease. Fine-Gray regression was performed to identify progression-associated factors, using all-cause mortality as a competing risk. RESULTS: Among 2923 patients, 383 (13%) progressed over a median (interquartile range) follow-up of 5.1 (3.0-8.5) years. Concomitant CIS was found in 327 patients (11%), with 233 and 94 harbouring unifocal and multifocal CIS, respectively. Recurrent tumours, T1 stage, high-grade disease, multifocal CIS, and multiple tumours were independently associated with increased progression risk (all P < 0.05). Among patients with concomitant CIS, multifocal CIS remained a significant prognosticator (sub-distribution hazard ratio 1.90, 95% confidence interval 1.18-3.05; P = 0.008) adjusting for age, sex, tumour history, stage, grade, number of tumours, tumour diameter, and Bacillus Calmette-Guerin treatment. CONCLUSIONS: Papillary NMIBC progression risk varies with concomitant CIS distribution. Only multifocal concomitant CIS is a risk factor for progression in patients with T1 NMIBC. If validated in further studies, risk calculators should consider including this CIS distinction. Submitting separate specimens at the time of transurethral resection, as recommended by guidelines, should be encouraged. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Kwong, Jethro C C AU - Kwong JCC AUID- ORCID: 0000-0003-4728-1025 AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Pace, Keiran AU - Pace K AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Al-Daqqaq, Zizo AU - Al-Daqqaq Z AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Chelliahpillai, Yashan AU - Chelliahpillai Y AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Lee, Soomin AU - Lee S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Kim, Kellie AU - Kim K AUID- ORCID: 0000-0003-4682-6409 AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Ringa, Maximiliano AU - Ringa M AD - Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Ali, Amna AU - Ali A AD - Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Wettstein, Marian AU - Wettstein M AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Chan, Amy AU - Chan A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. FAU - Lajkosz, Katherine AU - Lajkosz K AD - Department of Biostatistics, University Health Network, Toronto, Ontario, Canada. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada. FAU - Perlis, Nathan AU - Perlis N AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Lee, Jason Y AU - Lee JY AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Hamilton, Robert J AU - Hamilton RJ AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Finelli, Antonio AU - Finelli A AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Jamal, Munir AU - Jamal M AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Papanikolaou, Frank AU - Papanikolaou F AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Short, Thomas AU - Short T AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Feifer, Andrew AU - Feifer A AD - Division of Urology, Department of Surgery, Trillium Health Partners, Mississauga, Ontario, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250526 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Disease Progression MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Carcinoma in Situ/pathology/mortality MH - Middle Aged MH - Risk Factors MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12256721 OTO - NOTNLM OT - Carcinoma in situ OT - multifocal CIS OT - non-muscle-invasive bladder cancer OT - tumour progression OT - unifocal CIS EDAT- 2025/05/26 06:26 MHDA- 2025/07/14 06:26 PMCR- 2025/07/14 CRDT- 2025/05/26 04:22 PHST- 2025/07/14 06:26 [medline] PHST- 2025/05/26 06:26 [pubmed] PHST- 2025/05/26 04:22 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - BJU16793 [pii] AID - 10.1111/bju.16793 [doi] PST - ppublish SO - BJU Int. 2025 Aug;136(2):236-244. doi: 10.1111/bju.16793. Epub 2025 May 26. PMID- 40414744 OWN - NLM STAT- MEDLINE DCOM- 20250829 LR - 20260813 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 43 IP - 9 DP - 2025 Sep TI - Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate. PG - 521.e1-521.e8 LID - S1078-1439(25)00151-6 [pii] LID - 10.1016/j.urolonc.2025.04.007 [doi] AB - OBJECTIVES: To characterize the oncologic outcomes in patients with high-grade noninvasive urothelial carcinoma of the prostate (NMIUC-P) treated with intravesical therapy and assess for clinicopathologic features associated with response. SUBJECTS AND METHODS: Patients with high-grade NMIUC-P treated with intravesical Bacillus Calmette-Guerin (BCG) or chemotherapy between 2005 and 2021 were retrospectively analyzed. Survival probabilities were estimated using the Kaplan-Meier method. Cox regression was used to evaluate the effect of clinicopathologic and treatment characteristics on high-grade recurrence-free survival (HG-RFS) and progression-free survival (PFS). RESULTS: A total of 62 patients with median follow-up of 38 months (IQR 19-74) were included. NMIUC-P pathology was carcinoma in situ containing in 52 (84%), high-grade Ta in 9 (14%), and high-grade T1 in 1 (2%). Fifty (80%) patients had concomitant bladder UC. Induction regimens were BCG (44%), gemcitabine/docetaxel (42%), and other chemotherapies (14%). HG-RFS was 45%, 43%, and 38% at 1, 2, and 3 years, respectively. Seventeen patients (27%) underwent cystectomy at a median of 12 months, of whom 5 (29%) had >/=T2 and 3 (18%) had N+ disease. Among all patients, PFS was 87%, 69%, and 69% at 1, 2, and 3 years, respectively. Cystectomy-free, cancer-specific, and overall survival were 65%, 92%, and 83% at 3 years, respectively. No clinicopathologic or treatment characteristics were significantly associated with HG-RFS. CONCLUSION: In a high-risk cohort of patients with NMIUC-P, a select number of patients were able to avoid cystectomy and remain recurrence-free at 3-years after pursuing bladder-sparing intravesical treatment. However, given the high incidence of disease progression, careful patient selection is critical. Further prospective studies are needed to identify markers of response. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Martin, Alexander C AU - Martin AC AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - McElree, Ian M AU - McElree IM AD - University of Iowa Carver College of Medicine, Iowa City, IA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Electronic address: vignesh.packiam@rutgers.edu. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250524 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Gemcitabine) RN - 15H5577CQD (Docetaxel) RN - 0 (Antineoplastic Agents) SB - IM MH - Follow-Up Studies MH - Humans MH - Male MH - Aged MH - *Urothelium/pathology MH - *Prostatic Neoplasms/mortality/pathology/therapy MH - Urinary Bladder/pathology MH - *Carcinoma in Situ/mortality/pathology/therapy MH - *Organ Sparing Treatments/methods/mortality MH - Kaplan-Meier Estimate MH - Retrospective Studies MH - Treatment Outcome MH - Neoplasm Grading MH - Proportional Hazards Models MH - Survival Rate MH - Cystectomy MH - BCG Vaccine/administration & dosage MH - Adjuvants, Immunologic/administration & dosage MH - Gemcitabine/administration & dosage MH - Docetaxel/administration & dosage MH - *Antineoplastic Agents/administration & dosage MH - Administration, Intravesical PMC - PMC13218301 MID - NIHMS2174838 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Docetaxel OT - Gemcitabine OT - Prostatic urethral COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/26 00:28 MHDA- 2025/09/08 07:59 PMCR- 2026/05/28 CRDT- 2025/05/25 21:54 PHST- 2024/08/12 00:00 [received] PHST- 2025/03/28 00:00 [revised] PHST- 2025/04/14 00:00 [accepted] PHST- 2025/09/08 07:59 [medline] PHST- 2025/05/26 00:28 [pubmed] PHST- 2025/05/25 21:54 [entrez] PHST- 2026/05/28 00:00 [pmc-release] AID - S1078-1439(25)00151-6 [pii] AID - 10.1016/j.urolonc.2025.04.007 [doi] PST - ppublish SO - Urol Oncol. 2025 Sep;43(9):521.e1-521.e8. doi: 10.1016/j.urolonc.2025.04.007. Epub 2025 May 24. PMID- 40414743 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20260726 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 9 DP - 2025 Sep TI - Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer. PG - 520.e19-520.e28 LID - S1078-1439(25)00134-6 [pii] LID - 10.1016/j.urolonc.2025.04.006 [doi] AB - PURPOSE: Uncertainty exits over the best treatments for patients whom Bacillus Calmette-Guerin (BCG) has failed. We aim to contextualize novel therapies approved based on single-arm, nonrandomized trials and those supported only by retrospective data by re-analyzing oncologic outcomes achieved with intravesical gemcitabine. MATERIALS AND METHODS: Patients with non-muscle-invasive bladder cancer (NMIBC) who were treated for BCG failure with single agent intravesical gemcitabine at our institution were analyzed to compare clinical outcomes (high-grade recurrence/progression) across different BCG failure definitions. Associations between clinicopathologic variables with outcomes after gemcitabine were estimated using Cox models. RESULTS: Of the 127 patients, 57% met the historical definition of BCG-refractory NMIBC and 33% met BCG-unresponsive criteria using a 12-month cut-off. Twelve-month recurrence-free survival was similar between BCG-refractory (47%; 95% CI: 36%, 60%) and BCG-unresponsive (52%; 95% CI: 38%, 71%) definitions. BCG-unresponsive patients who received gemcitabine in a clinical trial had significantly worse recurrence-free survival compared to those receiving the same treatment outside a trial (12-month recurrence-free survival difference: 41%; P = 0.02). A positive pretreatment urine cytology was associated with increased risk of recurrence (P = 0.005) and progression (P = 0.002) and may better indicate minimal residual disease than carcinoma in-situ on pretreatment biopsies. CONCLUSIONS: Our data raise concern over US Food and Drug Administration approval based on single-arm, nonrandomized trials using expert-based BCG-unresponsive criteria and for the use of combination gemcitabine-docetaxel as a de facto standard treatment based on retrospective data alone. Improved assessments of minimal residual disease, such as pretreatment urinary cytology, are needed to improve risk stratification in NMIBC. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Escano, Manuel R De Jesus AU - Escano MRJ AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Vertosick, Emily A AU - Vertosick EA AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - D'Souza, Neeta AU - D'Souza N AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Benfante, Nicole AU - Benfante N AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Lenis, Andrew T AU - Lenis AT AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Reisz, Peter A AU - Reisz PA AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Gaffney, Christopher AU - Gaffney C AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Goh, Alvin AU - Goh A AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Donahue, Timothy F AU - Donahue TF AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Cha, Eugene AU - Cha E AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Donat, S Machele AU - Donat SM AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Herr, Harry W AU - Herr HW AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Dalbagni, Guido AU - Dalbagni G AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Bajorin, Dean AU - Bajorin D AD - Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sarungbam, Judy AU - Sarungbam J AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Bochner, Bernard H AU - Bochner BH AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sjoberg, Daniel D AU - Sjoberg DD AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: pietzake@mskcc.org. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - R37 CA276946/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250524 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - Gemcitabine MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - *BCG Vaccine/therapeutic use MH - Male MH - Administration, Intravesical MH - Female MH - Aged MH - Retrospective Studies MH - Middle Aged MH - *Antimetabolites, Antineoplastic/administration & dosage/therapeutic use MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin failure OT - Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer OT - Intravesical gemcitabine OT - clinical trial COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/26 00:28 MHDA- 2025/08/31 19:59 CRDT- 2025/05/25 21:54 PHST- 2024/12/19 00:00 [received] PHST- 2025/03/21 00:00 [revised] PHST- 2025/04/11 00:00 [accepted] PHST- 2025/08/31 19:59 [medline] PHST- 2025/05/26 00:28 [pubmed] PHST- 2025/05/25 21:54 [entrez] AID - S1078-1439(25)00134-6 [pii] AID - 10.1016/j.urolonc.2025.04.006 [doi] PST - ppublish SO - Urol Oncol. 2025 Sep;43(9):520.e19-520.e28. doi: 10.1016/j.urolonc.2025.04.006. Epub 2025 May 24. PMID- 40414077 OWN - NLM STAT- MEDLINE DCOM- 20250606 LR - 20250606 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 271 DP - 2025 Jul TI - FGFR3 immunohistochemistry as a surrogate biomarker for FGFR3 alterations in urothelial carcinoma. PG - 156028 LID - S0344-0338(25)00220-1 [pii] LID - 10.1016/j.prp.2025.156028 [doi] AB - FGFR3 alterations are common in urothelial carcinoma (UC) and have implications both in prognosis and treatment. FGFR3 analysis is the current gold standard, but limitations as cost, turnaround time or accessibility may exist. FGFR3 immunohistochemistry (IHC) could provide a faster and more cost-effective identification of FGFR3 alterations. The aim of this study was to establish the accuracy of FGFR3 IHC as a surrogate biomarker for FGFR3 variants in UC. We retrospectively reviewed 41 UC patients from an institutional database selected by stratified random sampling based on presence of muscle invasion and FGFR3 variants. FGFR3 genetic analysis had been stablished through quantitative polymerase chain reaction. FGFR3 IHC was performed using a FGFR3 mouse monoclonal antibody and blindly evaluated by three independent pathologists. Results were dichotomised into positive (membrane and cytoplasm positivity even in small foci of cells) or negative categories. The cohort included 37 patients with bladder cancer and four with upper tract urinary carcinoma (UTUC). Twenty-two patients had muscle-invasive tumours (11 without and 11 with FGFR3 variants), while the other 19 had non-muscle-invasive disease (10 without and 9 with FGFR3 variants). FGFR3 IHC exhibited 80 % sensitivity, 95 % specificity, 94 % PPV and 83 % NPV to detect FGFR3 variants. There was concordance among the three pathologists in 78 % of samples, which traduces a substantial agreement with a Fleiss' kappa statistic of 0.7. Our study suggests that FGFR3 IHC is feasible and could potentially eliminate the need for genetic testing in patients with positive immunohistochemical results. Our findings support a dichotomic evaluation for FGFR3 IHC, which has the potential to enhance reproducibility compared to more complex scoring systems. Still, further research is needed to validate this proposed diagnostic algorithm. CI - Copyright (c) 2025 Elsevier GmbH. All rights reserved. FAU - Mercader, Claudia AU - Mercader C AD - Department of Urology, Hospital Clinic of Barcelona, Barcelona, Spain; Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain; Unitat de Genetica, Departament de Biomedicina, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. Electronic address: cmercaderb.germans@gencat.cat. FAU - Lopez, Ricardo AU - Lopez R AD - Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Ferrer, Laura AU - Ferrer L AD - Department of Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Calderon, Ricard AU - Calderon R AD - Department of Urology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Ribera-Cortada, Inmaculada AU - Ribera-Cortada I AD - Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Trias, Isabel AU - Trias I AD - Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Cobo-Lopez, Sandra AU - Cobo-Lopez S AD - Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Sanchez, Samuel AU - Sanchez S AD - Institute for Bioengineering of Catalonia, Barcelona, Spain; Catalan Institute for Research and Advanced Studies, (ICREA), Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Department of Urology, Hospital Clinic of Barcelona, Barcelona, Spain; Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Mengual, Lourdes AU - Mengual L AD - Department of Urology, Hospital Clinic of Barcelona, Barcelona, Spain; Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain; Unitat de Genetica, Departament de Biomedicina, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. FAU - Rodriguez-Carunchio, Leonardo AU - Rodriguez-Carunchio L AD - Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Vilaseca, Antoni AU - Vilaseca A AD - Department of Urology, Hospital Clinic of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20250519 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Receptor, Fibroblast Growth Factor, Type 3/genetics/analysis/metabolism MH - *Biomarkers, Tumor/analysis/genetics MH - Immunohistochemistry MH - Male MH - Female MH - Aged MH - Middle Aged MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology/genetics/metabolism MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/genetics/metabolism MH - *Urologic Neoplasms/pathology/genetics/metabolism MH - Urothelium/pathology MH - Adult OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - FGFR3, Immunochemistry OT - Upper tract urothelial cancer OT - Urothelial cancer COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Samuel Sanchez reports equipment, drugs, or supplies was provided by LaCaixa Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/26 00:28 MHDA- 2025/06/07 16:45 CRDT- 2025/05/25 18:08 PHST- 2025/03/20 00:00 [received] PHST- 2025/05/11 00:00 [revised] PHST- 2025/05/18 00:00 [accepted] PHST- 2025/06/07 16:45 [medline] PHST- 2025/05/26 00:28 [pubmed] PHST- 2025/05/25 18:08 [entrez] AID - S0344-0338(25)00220-1 [pii] AID - 10.1016/j.prp.2025.156028 [doi] PST - ppublish SO - Pathol Res Pract. 2025 Jul;271:156028. doi: 10.1016/j.prp.2025.156028. Epub 2025 May 19. PMID- 40413454 OWN - NLM STAT- MEDLINE DCOM- 20250524 LR - 20250530 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 May 24 TI - The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis. PG - 135 LID - 10.1186/s12894-025-01822-7 [doi] LID - 135 AB - BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are integral components of the tumor microenvironment and have been extensively studied across various cancers. In bladder cancer, the prognostic significance of TILs remains uncertain. This study aimed to analyze the impact of muscularis mucosa invasion and TILs ratios on clinical outcomes, tumor aggressiveness, and prognosis in pT1 urothelial carcinoma of the bladder. METHODS: This retrospective study included 154 patients with pT1 bladder urothelial carcinoma, categorized into pT1a and pT1b groups based on the extent of muscularis mucosa invasion. TILs ratios were stratified into three groups: <1%, 1-5%, and > 5%. Clinical and pathological characteristics, including tumor diameter, necrosis, tumor thickness, recurrence, and progression rates, were compared. Depth of invasion and tumor features were assessed using standard histopathological methods. Recurrence and progression-free survival (PFS) were evaluated during a median follow-up of 20 months. RESULTS: By definition, pT1b tumors demonstrated significantly deeper invasion into the muscularis mucosa (p < 0.0001) compared to pT1a tumors. They were also associated with larger tumor diameter (p = 0.023), greater tumor thickness (p < 0.0001), and increased necrosis (p = 0.0012). Radical cystectomy was performed more frequently in pT1b patients (19.2%) than in pT1a patients (7.9%), although recurrence and PFS rates did not differ significantly between the groups. Higher TILs ratios were linked to increased tumor thickness (p = 0.0299) and more extensive invasion into TURBT chips (p = 0.0025), but no significant differences in recurrence or PFS rates were observed across TILs groups. CONCLUSIONS: Muscularis mucosa invasion is a defining feature of pT1b bladder cancer and serves as a key indicator of tumor aggressiveness. While TILs were associated with aggressive tumor characteristics, their prognostic role remains inconclusive. These findings highlight the need for aggressive management strategies for pT1b disease and underscore the importance of further research into the complex interplay between TILs and tumor progression in bladder cancer. CI - (c) 2025. The Author(s). FAU - Yaprak Bayrak, Busra AU - Yaprak Bayrak B AUID- ORCID: 0000-0002-0537-3127 AD - Department of Pathology, Faculty of Medicine, Kocaeli University, Kocaeli, 41380, Turkey. bsr2004_86@hotmail.com. FAU - Dogan, Hatice Nese AU - Dogan HN AUID- ORCID: 0009-0009-7411-6720 AD - Department of Pathology, Faculty of Medicine, Kocaeli University, Kocaeli, 41380, Turkey. FAU - Teke, Kerem AU - Teke K AUID- ORCID: 0000-0001-9030-4662 AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Yuvak, Hakkican AU - Yuvak H AUID- ORCID: 0009-0007-1602-0443 AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Dillioglugil, Ozdal AU - Dillioglugil O AUID- ORCID: 0000-0001-5460-4588 AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. LA - eng PT - Journal Article DEP - 20250524 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/immunology/surgery MH - Retrospective Studies MH - *Lymphocytes, Tumor-Infiltrating/pathology MH - Neoplasm Invasiveness MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/pathology/immunology/surgery MH - Neoplasm Staging MH - Aged, 80 and over MH - Prognosis PMC - PMC12102908 OTO - NOTNLM OT - Bladder Cancer OT - Clinical outcomes OT - Prognosis OT - Tumor-infiltrating lymphocytes OT - Urothelial carcinoma COIS- Declarations. Ethics approval: The study protocol was approved by the Ethical Committee of Non-invasive Clinical Research of Kocaeli University (Decision No: KU GOKAEK-2024/18.22, Project No: 2024/456). This study was conducted according to the Helsinki principles, patients signed informed consent for participation, and nothing invasive of patients' privacy was done. Written informed consent was obtained from patients for publication of this original article and all accompanying images. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/05/25 20:35 MHDA- 2025/05/25 20:36 PMCR- 2025/05/24 CRDT- 2025/05/24 23:36 PHST- 2025/01/21 00:00 [received] PHST- 2025/05/12 00:00 [accepted] PHST- 2025/05/25 20:36 [medline] PHST- 2025/05/25 20:35 [pubmed] PHST- 2025/05/24 23:36 [entrez] PHST- 2025/05/24 00:00 [pmc-release] AID - 10.1186/s12894-025-01822-7 [pii] AID - 1822 [pii] AID - 10.1186/s12894-025-01822-7 [doi] PST - epublish SO - BMC Urol. 2025 May 24;25(1):135. doi: 10.1186/s12894-025-01822-7. PMID- 40413062 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20250826 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 9 DP - 2025 Sep TI - Prognostic role of pathological substaging in high-grade pT1 bladder cancer undergoing BCG therapy: Insights on recurrence and progression. PG - 522.e9-522.e13 LID - S1078-1439(25)00174-7 [pii] LID - 10.1016/j.urolonc.2025.05.004 [doi] AB - INTRODUCTION/OBJECTIVES: Bladder cancer is a common malignancy, with pT1 tumors carrying a higher risk of recurrence and progression compared to other non-muscle-invasive bladder cancers (NMIBC). Substaging of pT1 tumors into superficial (pT1a) and deeper (pT1b) invasion into the lamina propria has shown potential prognostic value. This study investigates the impact of pT1 substaging on predicting progression and recurrence in patients with high-grade pT1 bladder cancer treated with Bacillus Calmette-Guerin (BCG) therapy. MATERIALS AND METHODS: A retrospective analysis was conducted on 99 patients with primary high-grade pT1 bladder cancer who underwent transurethral resection of the bladder tumor (TURBT) followed by BCG therapy. Patients were stratified into pT1a and pT1b subgroups based on pathological findings. Predictors of disease progression and recurrence were assessed using logistic regression, adjusting for age, tumor size, carcinoma in situ (CIS), and multiplicity. RESULTS: Of the 99 patients, 71.7% were classified as pT1a, and 28.3% as pT1b. Disease progression was significantly more frequent in pT1b cases (P < 0.001), particularly in the presence of concurrent CIS (P = 0.002). Logistic regression identified pT1b substaging (odds ratio [OR]: 28.9, 95% confidence interval [CI]: 12.4-58.7) and CIS (OR: 8.65, 95% CI: 3.21-18.8) as independent predictors of progression. DISCUSSION: Pathological substaging of pT1 bladder cancer provides critical prognostic insights. Patients with pT1b tumors, especially those with concurrent CIS, are at higher risk for disease progression and may benefit from intensified management strategies. Incorporating pT1 substaging into routine pathological evaluations can improve risk stratification and inform individualized treatment planning. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Kayar, Kemal AU - Kayar K AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. Electronic address: kemal.kayar@hotmail.com. FAU - Kayar, Ridvan AU - Kayar R AD - Department of Urology, Van Training and Research Hospital, University of Health Sciences, Van, Turkiye. FAU - Karabay, Emre AU - Karabay E AD - Department of Urology, Acibadem M.A. Aydinlar University, School of Medicine, Acibadem Hospital, Istanbul, Turkey. FAU - Ozdemir, Bugrahan Buhur AU - Ozdemir BB AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. FAU - Tosun, Cagatay AU - Tosun C AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. FAU - Gumrukcu, Gulistan AU - Gumrukcu G AD - Department of Pathology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. FAU - Ozturk, Metin Ishak AU - Ozturk MI AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. FAU - Yucebas, Omer Ergin AU - Yucebas OE AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20250523 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Disease Progression MH - Prognosis MH - Aged MH - *Neoplasm Recurrence, Local/pathology MH - *Adjuvants, Immunologic/therapeutic use MH - Middle Aged MH - Neoplasm Staging MH - Neoplasm Grading MH - Aged, 80 and over OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Carcinoma in situ OT - Pathological substaging OT - Progression OT - Recurrence OT - pT1 bladder cancer COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/25 20:35 MHDA- 2025/08/31 19:59 CRDT- 2025/05/24 22:13 PHST- 2025/01/22 00:00 [received] PHST- 2025/04/21 00:00 [revised] PHST- 2025/05/02 00:00 [accepted] PHST- 2025/08/31 19:59 [medline] PHST- 2025/05/25 20:35 [pubmed] PHST- 2025/05/24 22:13 [entrez] AID - S1078-1439(25)00174-7 [pii] AID - 10.1016/j.urolonc.2025.05.004 [doi] PST - ppublish SO - Urol Oncol. 2025 Sep;43(9):522.e9-522.e13. doi: 10.1016/j.urolonc.2025.05.004. Epub 2025 May 23. PMID- 40409440 OWN - NLM STAT- MEDLINE DCOM- 20250727 LR - 20250727 IS - 1879-0038 (Electronic) IS - 0378-1119 (Linking) VI - 963 DP - 2025 Sep 5 TI - Uncovering citron kinase as a key biomarker for predicting outcomes and therapy efficacy in non-muscle-invasive bladder cancer. PG - 149590 LID - S0378-1119(25)00379-8 [pii] LID - 10.1016/j.gene.2025.149590 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is highly heterogeneous, with frequent recurrence and progression. Identifying biomarkers can improve the prediction of therapeutic response and prognosis, guiding clinical decisions. In this study, public NMIBC databases were analyzed for differential expression, receiver operating characteristic (ROC), Cox regression, and Kaplan-Meier survival to identify and validate potential prognostic biomarkers of NMIBC. Functional enrichment analysis was conducted to reveal the potential molecular mechanisms of hub genes. Bioinformatics findings were validated through immunohistochemistry (IHC) and in vitro experiments. Immune cell infiltration and drug sensitivity analyses were performed to assess differences between low- and high-CIT expression groups. Citron kinase (CIT) was identified as a biomarker linked to aggressive tumors and poor prognosis in NMIBC patients. CIT overexpression predicts poor intravesical Bacillus Calmette-Guerin (BCG) efficacy in patients with NMIBC. Immunohistochemical staining demonstrated that the protein expression analysis of CIT was consistent with the mRNA analysis results. Functional enrichment analysis revealed that the function of CIT is associated with tumor development and progression. Furthermore, in vitro cell experiments demonstrated that CIT knockdown inhibited cell proliferation by inducing cell cycle arrest at the G2/M phase via downregulation of cyclin dependent kinase 1. Immune infiltration analysis revealed that high CIT expression contributed to BCG resistance by reducing CD8+ T cell infiltration in the NMIBC microenvironment. Additionally, drug sensitivity analysis further demonstrated that high CIT expression leads to resistance to common chemotherapy drugs, including epirubicin, gemcitabine, and cisplatin. This study identifies CIT as a promising biomarker, offering a foundation for prognostic evaluation and personalized therapeutic strategies for NMIBC patients. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Deng, Pei AU - Deng P AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Zhong, Chuanfan AU - Zhong C AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China. FAU - He, Pingkaiqi AU - He P AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Liu, Qinwei AU - Liu Q AD - Department of Urology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong 510180, China. FAU - Peng, Siqiao AU - Peng S AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Liu, Rongxin AU - Liu R AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Li, Jiaxuan AU - Li J AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Wang, Yikang AU - Wang Y AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Yin, Wenjun AU - Yin W AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Liu, Yu AU - Liu Y AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. FAU - Yang, Jingjing AU - Yang J AD - Department of Urology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong 510180, China. FAU - Zhong, Weide AU - Zhong W AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China; Department of Urology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong 510180, China; Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, 510005 Guangzhou, Guangdong, China; State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, 999078 Macau, China. Electronic address: eyweidezhong@scut.edu.cn. FAU - Lu, Jianming AU - Lu J AD - Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China; Department of Urology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong 510180, China. Electronic address: eylujianmin@scut.edu.cn. FAU - Cai, Chao AU - Cai C AD - Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou 510230, Guangdong, China. Electronic address: chaocai85@hotmail.com. LA - eng PT - Journal Article DEP - 20250521 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.1.- (citron-kinase) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/drug therapy/metabolism MH - *Biomarkers, Tumor/genetics/metabolism MH - *Protein Serine-Threonine Kinases/genetics/metabolism MH - Prognosis MH - *Intracellular Signaling Peptides and Proteins/genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Cell Line, Tumor MH - Cell Proliferation MH - Female MH - BCG Vaccine/therapeutic use MH - Male MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bioinformatics OT - CIT OT - Non-muscle-invasive bladder cancer OT - Prognosis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/24 00:46 MHDA- 2025/07/28 08:44 CRDT- 2025/05/23 19:36 PHST- 2025/03/03 00:00 [received] PHST- 2025/05/06 00:00 [revised] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/07/28 08:44 [medline] PHST- 2025/05/24 00:46 [pubmed] PHST- 2025/05/23 19:36 [entrez] AID - S0378-1119(25)00379-8 [pii] AID - 10.1016/j.gene.2025.149590 [doi] PST - ppublish SO - Gene. 2025 Sep 5;963:149590. doi: 10.1016/j.gene.2025.149590. Epub 2025 May 21. PMID- 40406869 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20250904 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 32 IP - 9 DP - 2025 Sep TI - PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PG - 1195-1202 LID - 10.1111/iju.70122 [doi] AB - OBJECTIVE: Programmed cell death ligand 1 (PD-L1) expression is considered a poor prognostic factor in patients with muscle-invasive bladder cancer (MIBC). However, the data regarding the change in PD-L1 expression before and after neoadjuvant chemotherapy (NAC) are limited. We aimed to investigate the longitudinal association between programmed death-ligand 1 (PD-L1) and Ki-67 expression before and after NAC in muscle-invasive bladder cancer (MIBC). METHODS: We retrospectively analyzed 191 patients with MIBC who underwent platinum-based NAC followed by radical cystectomy (RC) between June 2010 and March 2022. We excluded ypT0-1 cases because of the difficulty of evaluating PD-L1 and Ki-67 by immunostaining. Finally, we selected 104 patients with matched specimens from transurethral resection of bladder tumor (TURBT) and residual invasive disease in RC. We examined the relationship between PD-L1 expression and Ki-67 labeling index in TURBT and RC specimens. Additionally, we investigated the differential expression of 39 subtype-related genes before and after NAC. RESULTS: Among 104 patients who underwent NAC, the number of PD-L1-positive patients significantly increased from 16 (15.4%) in the TURBT specimens to 30 (28.8%) in the RC specimens. The median Ki-67 labeling index significantly decreased from 30.6% in the TURBT specimens to 9.9% in the RC specimens. The correlation between treatment effects and changes in gene expression was challenging to identify. CONCLUSIONS: A significant effect of NAC on PD-L1 expression and Ki-67 labeling index was observed in patients with MIBC. However, the impact of changes in gene expression on prognosis needs further study. CI - (c) 2025 The Japanese Urological Association. FAU - Sasaki, Daichi AU - Sasaki D AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Glycotechnology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Fumiya AU - Yoneyama F AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ozaki, Kai AU - Ozaki K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ozaki, Yusuke AU - Ozaki Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Miura, Yuki AU - Miura Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Fujita, Naoki AU - Fujita N AUID- ORCID: 0000-0001-8284-9582 AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Okamoto, Teppei AU - Okamoto T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Goto, Shintaro AU - Goto S AD - Department of Pathology and BioScience, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshizawa, Tadashi AU - Yoshizawa T AD - Department of Pathology and BioScience, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kurose, Akira AU - Kurose A AD - Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kijima, Hiroshi AU - Kijima H AD - Department of Pathology and BioScience, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng GR - 20K09517/Japan Society for the Promotion of Science/ GR - 21K09339/Japan Society for the Promotion of Science/ GR - 24K12501/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20250523 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Ki-67 Antigen) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/therapy MH - *Ki-67 Antigen/metabolism/analysis MH - Neoadjuvant Therapy/methods MH - Male MH - Female MH - *B7-H1 Antigen/metabolism/analysis MH - Retrospective Studies MH - Aged MH - Cystectomy MH - Middle Aged MH - Neoplasm Invasiveness MH - Chemotherapy, Adjuvant MH - Urinary Bladder/pathology/surgery MH - Prognosis MH - Aged, 80 and over OTO - NOTNLM OT - Ki-67 OT - PD-L1 OT - bladder cancer OT - cystectomy OT - prognosis EDAT- 2025/05/23 06:26 MHDA- 2025/09/04 12:38 CRDT- 2025/05/23 05:03 PHST- 2025/04/07 00:00 [revised] PHST- 2024/10/14 00:00 [received] PHST- 2025/05/13 00:00 [accepted] PHST- 2025/09/04 12:38 [medline] PHST- 2025/05/23 06:26 [pubmed] PHST- 2025/05/23 05:03 [entrez] AID - 10.1111/iju.70122 [doi] PST - ppublish SO - Int J Urol. 2025 Sep;32(9):1195-1202. doi: 10.1111/iju.70122. Epub 2025 May 23. PMID- 40405063 OWN - NLM STAT- MEDLINE DCOM- 20250523 LR - 20250525 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 May 22 TI - Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer. PG - 916 LID - 10.1186/s12885-025-14273-y [doi] LID - 916 AB - BACKGROUND: Bladder cancer represents a heterogeneous disease with distinct clinical challenges. Non-muscle invasive bladder cancer (NMIBC) typically presents as indolent and slow-growing, yet a critical clinical challenge remains: identifying which patients will progress to muscle-invasive disease requiring radical interventions. Early detection of progression propensity is essential, as once muscle invasion occurs, the risk of distant metastasis increases substantially, and treatment shifts from conservative TURBT (Transurethral Resection of Bladder Tumor) to aggressive surgical interventions with significant morbidity. Current risk stratification methods fail to adequately predict this transition in approximately 30% of cases, highlighting the urgent need for more accurate prognostic tools. OBJECTIVE: This retrospective study aimed to develop and validate a transcriptomics-based mRNA score for predicting early NMIBC recurrence, comparing its performance against traditional risk stratification methods. METHODS: We analyzed mRNA expression profiles from primary retrospective NMIBC tumor specimens (n = 25) collected between [2018-2022]. Traditional risk stratification tools, including EORTC scoring, were applied alongside our novel mRNA-based risk score to evaluate predictive accuracy for recurrence. RESULTS: The transcriptomics-based mRNA score demonstrated a median prediction accuracy of 90% across 10,000 resampling iterations for predicting early NMIBC recurrence, significantly outperforming traditional EORTC risk scores. Our comprehensive gene set identified 435 differentially expressed genes associated with recurrence. Kaplan-Meier analysis showed significantly different recurrence-free survival between high and low mRNA risk score groups (Bonferroni corrected p-value < 0.0001). CONCLUSIONS: This retrospective analysis confirms that mRNA expression-based risk stratification provides superior predictive accuracy compared to conventional clinicopathologic risk tools. Implementation of this gene signature could potentially reduce over-investigation and improve surveillance cost-effectiveness after TURBT in patients with primary high-risk NMIBC. These findings may transform the clinical management paradigm by enabling more personalized follow-up protocols based on molecular risk assessment. CI - (c) 2025. The Author(s). FAU - N, Srivatsa AU - N S AD - Department of Uro Oncology, Sri Shankara Cancer Hospital and Research Center, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Ps, Hari AU - Ps H AD - Department of Molecular Oncology, Sri Shankara National Center for Cancer Prevention and Research, Sri Shankara Cancer Foundation, Bangalore, India. FAU - P, Rahul AU - P R AD - Department of Uro Oncology, Sri Shankara Cancer Hospital and Research Center, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Paul, Lista AU - Paul L AD - Department of Surgical Oncology, Sri Shankara Cancer Hospital and Research Center, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Veeraiyan, Durgadevi AU - Veeraiyan D AD - Department of Molecular Oncology, Sri Shankara National Center for Cancer Prevention and Research, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Narikot, Ambili AU - Narikot A AD - Department of Molecular Oncology, Sri Shankara National Center for Cancer Prevention and Research, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Veldore, Vidya AU - Veldore V AD - BaseCare Pvt Ltd, Bangalore, India. FAU - Tanwar, Nishtha AU - Tanwar N AD - BaseCare Pvt Ltd, Bangalore, India. FAU - Sreekanthreddy, Peddagangannagari AU - Sreekanthreddy P AD - BaseCare Pvt Ltd, Bangalore, India. FAU - Goswami, Hitesh AU - Goswami H AD - BaseCare Pvt Ltd, Bangalore, India. FAU - Kumar, Rekha V AU - Kumar RV AD - Department of Pathology, Sri Shankara Cancer Hospital and Research Center, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Srinath, B S AU - Srinath BS AD - Department of Surgical Oncology, Sri Shankara Cancer Hospital and Research Center, Sri Shankara Cancer Foundation, Bangalore, India. FAU - Korlimarla, Aruna AU - Korlimarla A AD - Department of Molecular Oncology, Sri Shankara National Center for Cancer Prevention and Research, Sri Shankara Cancer Foundation, Bangalore, India. aruna.k@ssnccpr.org. LA - eng PT - Journal Article DEP - 20250522 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/genetics/pathology MH - Male MH - Female MH - Risk Assessment/methods MH - Aged MH - Middle Aged MH - Gene Expression Profiling/methods MH - Prognosis MH - Neoplasm Invasiveness MH - *Biomarkers, Tumor/genetics MH - Transcriptome MH - Aged, 80 and over MH - RNA, Messenger/genetics MH - Gene Expression Regulation, Neoplastic MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12096726 OTO - NOTNLM OT - Bladder Cancer OT - Classifier Signature OT - EORTC OT - Subtypes OT - Targeted therapy COIS- Declarations. Ethics approval and consent to participate: The study was conducted as per Helsinki guidelines, approved by the Institutional Ethics Committee of Sri Shankara Cancer Hospital and Research Centre, Bangalore (with Identification number- ECR/1715/Inst/KA/2022, affiliated with, Ministry of Health & Family Welfare, Government of India), which waived the requirement for individual patient informed consent due to the retrospective nature of the study using anonymized archival tissue specimens with anonymized data analysis. Consent for publication: The study was conducted as per Helsinki guidelines, approved by the Institutional Ethics Committee of Sri Shankara Cancer Hospital and Research Centre, Bangalore (with Identification number- ECR/1715/Inst/KA/2022, affiliated with, Ministry of Health & Family Welfare, Government of India), which waived the requirement for individual patient informed consent due to the retrospective nature of the study using anonymized archival tissue specimens with anonymized data analysis and consent for publishing research findings. The authors affirm that the content does not contain identifiable personal information, and all reasonable measures have been taken to maintain privacy and confidentiality. Competing interests: The authors declare no competing interests. EDAT- 2025/05/23 00:27 MHDA- 2025/05/23 07:09 PMCR- 2025/05/22 CRDT- 2025/05/22 23:34 PHST- 2024/10/26 00:00 [received] PHST- 2025/05/05 00:00 [accepted] PHST- 2025/05/23 07:09 [medline] PHST- 2025/05/23 00:27 [pubmed] PHST- 2025/05/22 23:34 [entrez] PHST- 2025/05/22 00:00 [pmc-release] AID - 10.1186/s12885-025-14273-y [pii] AID - 14273 [pii] AID - 10.1186/s12885-025-14273-y [doi] PST - epublish SO - BMC Cancer. 2025 May 22;25(1):916. doi: 10.1186/s12885-025-14273-y. PMID- 40405006 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 May 22 TI - Youth matters: a systematic review of the molecular and clinical landscape of bladder cancer in young adults. PG - 321 LID - 10.1007/s00345-025-05698-y [doi] AB - BACKGROUND: Bladder cancer is uncommon in individuals under the age of 45, and its clinical and molecular characteristics in this population differ significantly from those observed in older patients. This systematic review aims to evaluate recurrence, progression, survival outcomes, and molecular profiles of bladder cancer in young adults. METHODS: A systematic search was conducted in MEDLINE, Embase, Scopus, and CENTRAL databases for studies published between 1998 and 2024. Eligible studies included patients aged /=11 maintenance instillations). RESULTS: Of all NMIBC patients identified, 467 (24.3%) were LR vs 582 (30.3%) IR vs 739 (38.5%) HR vs 130 (6.8%) VHR. The median (interquartile range) follow-up after TURBT was 26 (12-46) months. The 5-year HG recurrence rates were 7.2% in LR vs 17.3% in IR vs 26.7% in HR vs 30.9% in VHR patients, resulting in a three-, five- and seven-fold higher risk of IR, HR and VHR, respectively, relative to LR (all P < 0.001). The 5-year progression rates were 3.9% in LR vs 5.2% in IR vs 13.6% in HR vs 31.6% in VHR patients, resulting in a six- and nine-fold higher risk for HR and VHR, respectively, relative to LR (all P < 0.001). In all, 1001 (52.2%) patients underwent intravesical instillations. Those receiving adequate instillation course (244/1001 [24.3%]) had lower HG-recurrence (hazard ratio 0.3, P < 0.001) and progression (hazard ratio 0.2, P = 0.001) risk. CONCLUSIONS: Patients with HR/VHR NMIBC face significantly higher HG recurrence and progression risks. While tailored treatment strategies are needed, adherence to adequate instillation course remains crucial for optimising oncological outcomes. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Longoni, Mattia AU - Longoni M AUID- ORCID: 0000-0002-2613-2306 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - De Angelis, Mario AU - De Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AUID- ORCID: 0009-0001-9363-682X AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Simone, Giuseppe AU - Simone G AUID- ORCID: 0000-0002-4868-9025 AD - Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AUID- ORCID: 0000-0003-3708-2209 AD - Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Lonati, Chiara AU - Lonati C AUID- ORCID: 0000-0003-0113-9920 AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Zamboni, Stefania AU - Zamboni S AUID- ORCID: 0000-0002-6244-4120 AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Suardi, Nazareno AU - Suardi N AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, Lille, France. FAU - Szostek, Aleksandra AU - Szostek A AD - Department of Urology, Claude Huriez Hospital, Lille, France. FAU - Cano Velasco, Jorge AU - Cano Velasco J AD - Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Duran, Pedro Del Olmo AU - Duran PDO AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC no. 5, Predictive Onco-Urology, Hopital Pitie-Salpetriere, AP-HP, Sorbonne Universite, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AUID- ORCID: 0000-0002-0595-7165 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. CN - European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250521 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/surgery/drug therapy MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - Administration, Intravesical MH - Middle Aged MH - Europe/epidemiology MH - *Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Invasiveness MH - BCG Vaccine/administration & dosage MH - Disease Progression MH - Mitomycin/administration & dosage MH - Treatment Outcome MH - Cystectomy MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12522524 OTO - NOTNLM OT - BCG OT - bladder cancer OT - intravesical instillations OT - non-muscle-invasive OT - oncological outcomes OT - progression OT - recurrence EDAT- 2025/05/22 06:28 MHDA- 2025/10/15 12:31 PMCR- 2025/10/15 CRDT- 2025/05/22 01:43 PHST- 2025/10/15 12:31 [medline] PHST- 2025/05/22 06:28 [pubmed] PHST- 2025/05/22 01:43 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - BJU16780 [pii] AID - 10.1111/bju.16780 [doi] PST - ppublish SO - BJU Int. 2025 Nov;136(5):826-834. doi: 10.1111/bju.16780. Epub 2025 May 21. PMID- 40399193 OWN - NLM STAT- MEDLINE DCOM- 20250918 LR - 20250918 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 4 DP - 2025 Aug TI - Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer. PG - 977-985 LID - S2588-9311(25)00104-X [pii] LID - 10.1016/j.euo.2025.04.010 [doi] AB - BACKGROUND AND OBJECTIVE: The current European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC) categorize patients into four risk groups. In 2024, a specific follow-up schedule was introduced for intermediate-risk (IR) disease. However, recommendations are based on expert opinion and restricted to patients with IR-NMIBC who have primary low-grade or high-grade/grade 2 disease. Our aim was to identify a subgroup of patients with IR-NMIBC who may require more stringent follow-up. METHODS: We conducted a retrospective analysis of 2086 patients with IR-NMIBC classified according to the World Health Organization 1973 grading scheme. Multivariable Cox-regression models were fitted to identify predictors of recurrence, which were then used to dichotomize groups with low risk of recurrence (IR-Low) versus high risk of recurrence (IR-High). Kaplan-Meier curves were plotted to estimate recurrence-free survival (RFS) and progression-free survival (PFS). Smoothed hazard estimates of first recurrence were plotted by risk group. KEY FINDINGS AND LIMITATIONS: Multifocality and tumor size >/=3 cm were significantly associated with higher risk of first recurrence and were used to define the IR-High and IR-Low (unifocal, size <3 cm; n = 1087) groups. The 3-yr RFS rate was significantly worse for the IR-High group (51%, 95% confidence interval [CI] 48-54%) than for IR-Low (68%, 95% CI 65-71%). The risk of progression was low (5-yr PFS rate 96%) with no significant difference between the IR-High and IR-Low groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: During IR-NMIBC follow-up for recurrence, tumor size and focality should be considered rather than grade. If the primary objective is to ensure prompt detection of recurrence, follow-up schedules should be tailored according to the risk of recurrence, with more stringent protocols for patients with IR-NMIBC at higher risk of recurrence. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Contieri, Roberto AU - Contieri R AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Biochemical Science, Humanitas University, Milan, Italy; Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, University of Cincinnati, Cincinnati, OH, USA. FAU - Beijert, Irene J AU - Beijert IJ AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Plass, Karin AU - Plass K AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Subiela Henriquez, Jose D AU - Subiela Henriquez JD AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Department of Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Bauerova, Lenka AU - Bauerova L AD - Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Pesl, Michael AU - Pesl M AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Maxim Bruins, H AU - Maxim Bruins H AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Runneboom, Willemien AU - Runneboom W AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Calatrava, Ana AU - Calatrava A AD - Department of Pathology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Department of Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Department of Urology, Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Ashabere, David AU - Ashabere D AD - Department of Urology, Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Huebner, Nicolai AU - Huebner N AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Seisen, Thomas AU - Seisen T AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; GRC No. 5 ONCOTYPE-URO, Department of Urology, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Claps, Francesco AU - Claps F AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Saint-Louis Hospital, AP-HP, Paris Cite University, Paris, France. FAU - Liedberg, Fredrik AU - Liedberg F AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Skaanes Universitetssjukhus, Malmo, Sweden. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, London, UK. FAU - Lunelli, Luca AU - Lunelli L AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Sheikh, Soha El AU - Sheikh SE AD - Department of Pathology, Royal Free London NHS Foundation Trust, London, UK. FAU - Volanis, Dimitrios AU - Volanis D AD - Department of Urology, Royal Free London NHS Foundation Trust, London, UK. FAU - Cote, Jean-Francois AU - Cote JF AD - Department of Pathology, Pitie Salpetriere Hospital, AP-HP and Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; GRC No. 5 ONCOTYPE-URO, Department of Urology, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Hacek, Jaromir AU - Hacek J AD - Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Evert, Matthias AU - Evert M AD - Department of Pathology, University of Regensburg, Regensburg, Germany. FAU - de Kaa, Christina A Hulsbergen-van AU - de Kaa CAH AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - IQ Health and Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Molinaro, Luca AU - Molinaro L AD - Department of Pathology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Biochemical Science, Humanitas University, Milan, Italy; Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix du Sud Hopital, Quint Fonsegrives, France. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale Tumori di Napoli G. Pascale IRCCS, Naples, Italy. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Llorente, Carlos AU - Llorente C AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - N'Dow, James AU - N'Dow J AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: b.v.rhijn@nki.nl. LA - eng PT - Journal Article DEP - 20250521 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Invasiveness MH - Follow-Up Studies MH - Aged, 80 and over MH - Risk Assessment MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Follow-up OT - Intermediate risk OT - Non-muscle-invasive bladder cancer OT - Risk OT - Stratification EDAT- 2025/05/22 00:28 MHDA- 2025/09/19 00:36 CRDT- 2025/05/21 21:56 PHST- 2024/12/02 00:00 [received] PHST- 2025/04/06 00:00 [revised] PHST- 2025/04/15 00:00 [accepted] PHST- 2025/09/19 00:36 [medline] PHST- 2025/05/22 00:28 [pubmed] PHST- 2025/05/21 21:56 [entrez] AID - S2588-9311(25)00104-X [pii] AID - 10.1016/j.euo.2025.04.010 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):977-985. doi: 10.1016/j.euo.2025.04.010. Epub 2025 May 21. PMID- 40393853 OWN - NLM STAT- MEDLINE DCOM- 20260205 LR - 20260205 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 12 IP - 1 DP - 2026 Jan TI - Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment. PG - 70-78 LID - S2405-4569(25)00111-7 [pii] LID - 10.1016/j.euf.2025.04.033 [doi] AB - BACKGROUND AND OBJECTIVE: Intravesical bacillus Calmette-Guerin (BCG) instillation is recommended for intermediate-risk (IR) and high-risk (HiR) non-muscle-invasive bladder cancer (NMIBC). There are limited comparisons of long-term outcomes between adequate and inadequate BCG. METHODS: We analyzed data from a multicenter European database (2010-2024) for 1558 patients diagnosed with IR- or HiR-NMIBC who underwent BCG treatment and received at least five BCG instillations. Adequate BCG was defined as at least five of six induction instillations and two of three maintenance doses, or two of six doses of a reinduction course. A 3-mo landmark analysis was conducted. Recurrence-free survival (RFS), high-grade RFS (HG-RFS), progression-free survival (PFS), and overall survival (OS) were estimated using inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and IPTW-adjusted multivariable Cox regression models. Cancer-specific mortality (CSM) was assessed via cumulative incidence curves and Fine-Gray competing-risks regression analysis. KEY FINDINGS AND LIMITATIONS: The cohort included 606 IR-NMIBC (39%), 840 HiR-NMIBC (54%), and 112 very HiR (VHR)-NMIBC (7.1%) cases. Adequate BCG was administered to 1226 patients (78%). Among 1239 patients (80%) with documented treatment termination reasons, 503 (41%) completed guideline-recommended treatment and 150 (12%) discontinued because of BCG intolerance. Over median follow-up of 37 mo, adequate BCG was associated with higher IPTW-adjusted 5-yr RFS (72% vs 52%; hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.31-0.85; p < 0.001), HG-RFS (83% vs 68%; HR 0.43, 95% CI 0.32-0.58; p < 0.001), PFS (92% vs 85%; HR 0.47, 95% CI 0.30-0.74; p = 0.001), and OS (88% vs 71%; HR 0.52, 95% CI 0.37-0.74; p = 0.001). CSM rates were comparable between the groups (3% vs 4.9%; p = 0.3). CONCLUSIONS AND CLINICAL IMPLICATIONS: Adequate BCG, as defined by the International Bladder Cancer Group (IBCG), was associated with significantly better RFS, PFS, and OS. These findings support use of the IBCG definition as a standardized benchmark for BCG exposure. However, further prospective validation to confirm causality is needed. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rodriguez Elena, Jose Luis AU - Rodriguez Elena JL AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, Sorbonne University, Pitie-Salpetriere Hospital, AP-HP, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: moschini.marco@hsr.it. CN - European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20250519 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Male MH - Female MH - Aged MH - Administration, Intravesical MH - *Adjuvants, Immunologic/administration & dosage/therapeutic use MH - Middle Aged MH - Treatment Outcome MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Adequate intravesical treatment OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Oncological outcomes OT - Survival EDAT- 2025/05/21 00:30 MHDA- 2026/02/06 00:30 CRDT- 2025/05/20 21:58 PHST- 2025/01/07 00:00 [received] PHST- 2025/03/31 00:00 [revised] PHST- 2025/04/30 00:00 [accepted] PHST- 2026/02/06 00:30 [medline] PHST- 2025/05/21 00:30 [pubmed] PHST- 2025/05/20 21:58 [entrez] AID - S2405-4569(25)00111-7 [pii] AID - 10.1016/j.euf.2025.04.033 [doi] PST - ppublish SO - Eur Urol Focus. 2026 Jan;12(1):70-78. doi: 10.1016/j.euf.2025.04.033. Epub 2025 May 19. PMID- 40392156 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250922 LR - 20250924 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 19 IP - 9 DP - 2025 Sep TI - Comparative effectiveness of en-bloc vs. conventional transurethral resection for non-muscle-invasive bladder cancer A systematic review and meta-analysis. PG - E328-E335 LID - 10.5489/cuaj.9070 [doi] AB - INTRODUCTION: Transurethral en-bloc resection of bladder tumor (ERBT) has emerged as an alternate technique to conventional transurethral resection of bladder tumor (cTURBT). While theoretically advantageous, the comparative effectiveness of ERBT across various technical approaches remains unclear. We performed an updated systematic review and meta-analysis to evaluate perioperative, pathologic, and oncologic outcomes of ERBT vs. cTURBT. METHODS: We systematically searched PubMed, EMBASE, Scopus, and Google Scholar for randomized controlled trials (RCTs) comparing ERBT and cTURBT. The primary outcome was recurrence-free survival (RFS). Secondary outcomes were operative time, complication rates, detrusor muscle presence, and need for repeated resection. Meta-analyses were performed, with subgroup analyses stratified by ERBT technique. RESULTS: A total of 10 RCTs with 1973 patients (1012 ERBT, 961 cTURBT) were included. Overall data favored ERBT in RFS (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.71-1.01, p=0.07, I(2)=48%), with bipolar ERBT demonstrating significantly improved RFS (HR 0.51, 95% CI 0.32-0.81, p=0.004). ERBT had longer operative times compared to cTURBT (mean difference 3.52 minutes, 95% CI 1.25-5.80, p=0.001, I(2)=71%). There were no significant differences in catheter time or hospital stay between groups. ERBT had a non-significant lower incidence of bladder perforation (odds ratio [OR] 0.41, 95% CI 0.16-1.04, p=0.06, I(2)=52%) and obturator nerve reflex (OR 0.27, 95% CI 0.10-0.74, p=0.01, I(2)=79%) compared to cTURBT. ERBT was not significantly associated with higher detrusor muscle presence (OR 2.08, 95% CI 0.94-4.58, p=0.07, I(2)=78%). CONCLUSIONS: ERBT might have oncologic and perioperative benefits, in addition to technical advantages, relative to cTURBT. Variations in resection instruments used impact the consistency of results. FAU - Hinojosa-Gonzalez, David E AU - Hinojosa-Gonzalez DE AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - Saffati, Gal AU - Saffati G AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - La, Troy AU - La T AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - Cathey, Jackson AU - Cathey J AD - Duke University School of Medicine, Durham, NC, United States. FAU - Angulo-Lozano, Juan C AU - Angulo-Lozano JC AD - Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, United States. FAU - Salgado-Garza, Gustavo AU - Salgado-Garza G AD - Oregon Health and Sciences University, Portland, OR, United States. FAU - Walsh, Jonathan AU - Walsh J AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - Slawin, Bailey AU - Slawin B AD - McGovern Medical School at UTHealth, Houston, TX, United States. FAU - Kronstedt, Shane AU - Kronstedt S AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - Lowrey, Kate AU - Lowrey K AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. FAU - Slawin, Jeremy R AU - Slawin JR AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States. AD - Michael E. DeBakey VA Medical Center, Houston, TX, United States. LA - eng PT - Journal Article PT - Review PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC12453885 COIS- COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work EDAT- 2025/05/20 17:06 MHDA- 2025/05/20 17:07 PMCR- 2025/09/01 CRDT- 2025/05/20 10:23 PHST- 2025/05/20 17:07 [medline] PHST- 2025/05/20 17:06 [pubmed] PHST- 2025/05/20 10:23 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - cuaj.9070 [pii] AID - cuaj-9-e328 [pii] AID - 10.5489/cuaj.9070 [doi] PST - ppublish SO - Can Urol Assoc J. 2025 Sep;19(9):E328-E335. doi: 10.5489/cuaj.9070. PMID- 40389638 OWN - NLM STAT- MEDLINE DCOM- 20250519 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 May 19 TI - Relationship between urinary pH and efficacy of Bacillus Calmette-Guerin treatment in patients with carcinoma in situ of the bladder. PG - 317 LID - 10.1007/s00345-025-05700-7 [doi] AB - PURPOSE: Bacillus Calmette-Guerin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response. METHODS: Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80 mg, >/= 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort). RESULTS: The median follow-up period was 45 months (interquartile range (IQR): 14-83 months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32-0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates. CONCLUSION: This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yamashita, Ryo AU - Yamashita R AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. r.yamashita@scchr.jp. FAU - Sugino, Takashi AU - Sugino T AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Notsu, Akifumi AU - Notsu A AD - Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Nakaya, Yuichiro AU - Nakaya Y AD - Division of Infectious Disease, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Ito, Kana AU - Ito K AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Sakura, Yuma AU - Sakura Y AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Shinsaka, Hideo AU - Shinsaka H AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Matsuzaki, Masato AU - Matsuzaki M AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Niwakawa, Masashi AU - Niwakawa M AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Saint Marianna University School of Medicine, Kawasaki, Japan. LA - eng PT - Journal Article DEP - 20250519 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/urine MH - *BCG Vaccine/therapeutic use MH - *Carcinoma in Situ/drug therapy/urine MH - Male MH - Female MH - Aged MH - Hydrogen-Ion Concentration MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Retrospective Studies MH - Treatment Outcome MH - Aged, 80 and over MH - Administration, Intravesical MH - Neoplasm Recurrence, Local/epidemiology MH - *Urine/chemistry MH - *Carcinoma, Transitional Cell/urine/drug therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Bladder cancer OT - Urinary pH OT - Urothelial carcinoma COIS- Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Institutional reviewer board: This single-center study was approved by the Institutional Review Board of Shizuoka Cancer Center (J2024-218-2024-1-3). Informed consent: The requirement for informed consent was waived due to the retrospective nature of the study. The study information was displayed on the hospital's homepage to provide a means of opting out. Registry and the registration no. of the study: 4766. EDAT- 2025/05/20 00:30 MHDA- 2025/05/20 00:31 CRDT- 2025/05/19 23:26 PHST- 2025/05/12 00:00 [accepted] PHST- 2025/05/20 00:31 [medline] PHST- 2025/05/20 00:30 [pubmed] PHST- 2025/05/19 23:26 [entrez] AID - 10.1007/s00345-025-05700-7 [pii] AID - 10.1007/s00345-025-05700-7 [doi] PST - epublish SO - World J Urol. 2025 May 19;43(1):317. doi: 10.1007/s00345-025-05700-7. PMID- 40385797 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250520 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 4 DP - 2025 Apr TI - Changing Clinical Spectrum and Disease Progression in Young Patients With Bladder Cancer: A Retrospective Observational Study. PG - e82516 LID - 10.7759/cureus.82516 [doi] LID - e82516 AB - Background Bladder cancer is a rare entity in young adults, and the course of the disease is not well defined. This study aims to analyze the clinical characteristics, risk factors, disease progression, and survival outcomes of bladder cancer patients aged 40 years or younger. Methods A retrospective review was conducted of 162 young bladder cancer patients treated from August 2017 to May 2024. Recurrence-free survival and overall survival were analyzed using Kaplan-Meier analysis. Results Of the 162 patients, 138 (85.2%) were male, with a mean age of 34.5 years. Key risk factors included tobacco use (80 patients, 49.4%) and occupational exposure to chemicals (50 patients, 30.9%). The predominant histology was urothelial carcinoma (159 patients, 98.1%). Muscle-invasive bladder cancer (MIBC) was observed in 42 patients (26.4%). Among patients with non-muscle-invasive bladder cancer (NMIBC), 61 (53.5%) had high-grade tumors. High-grade tumors and recurrence were frequent, with a mean recurrence-free survival of 3.7 years. Patients with muscle-invasive disease had poorer survival (mean 3.4 years) compared to those with non-muscle-invasive disease (mean 6 years). Conclusion Young bladder cancer patients exhibit a more aggressive disease course than reported in older cohorts. The findings underscore the importance of early detection, targeted treatment strategies, and tailored surveillance in young patients due to their unique risk factors and disease characteristics. CI - Copyright (c) 2025, Agarwal et al. FAU - Agarwal, Mehul AU - Agarwal M AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Kumar Panwar, Vikas AU - Kumar Panwar V AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Mittal, Ankur AU - Mittal A AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Dev, Dharam AU - Dev D AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Saxena, Siddharta AU - Saxena S AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Agrawal, Harshit AU - Agrawal H AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Singhal, Avin AU - Singhal A AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Srivastava, Nalin AU - Srivastava N AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. FAU - Malhotra, Kunal AU - Malhotra K AD - Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND. LA - eng PT - Journal Article DEP - 20250418 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12085901 OTO - NOTNLM OT - bladder cancer OT - disease progression OT - recurrence OT - survival OT - urothelial carcinoma OT - young patients COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/05/19 12:30 MHDA- 2025/05/19 12:31 PMCR- 2025/04/18 CRDT- 2025/05/19 06:16 PHST- 2025/04/16 00:00 [accepted] PHST- 2025/05/19 12:31 [medline] PHST- 2025/05/19 12:30 [pubmed] PHST- 2025/05/19 06:16 [entrez] PHST- 2025/04/18 00:00 [pmc-release] AID - 10.7759/cureus.82516 [doi] PST - epublish SO - Cureus. 2025 Apr 18;17(4):e82516. doi: 10.7759/cureus.82516. eCollection 2025 Apr. PMID- 40382482 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20260515 IS - 2366-0058 (Electronic) VI - 50 IP - 12 DP - 2025 Dec TI - Preoperative CT-based radiomics model for predicting muscle invasion in patients with upper tract urothelial carcinoma below T3 stage. PG - 5872-5882 LID - 10.1007/s00261-025-04979-9 [doi] AB - PURPOSE: To development of a preoperative CT-based radiomics model for predicting muscle invasion in patients with upper tract urothelial carcinoma below T3 stage. METHODS: 163 consecutive patients who underwent radical nephroureterectomy for stage pT1-2 UTUC were retrospectively enrolled two medical centers (116 patients in training data and 47 patients in external validation data). Lesion segmentation, extraction and selection of radiomic features on pre-surgical CT urography, development and validation of predictive models were performed. Risk stratification of UTUC was evaluated. The diagnostic performance of the radiomics model and risk stratification was analyzed. Reference standard was histopathological analysis. RESULTS: Among 163 patients (mean age, 52 years +/- 9 [standard deviation], 97 men), 61.5% had pT2 grade tumors. 1165 features with intraclass coefficients > 0.75 were retained for least absolute shrinkage and selection operator (LASSO) regression. Nine radiomic features with non-zero coefficients on LASSO regression were selected from the training dataset and used for constructing the radiomics model. Good discrimination capability of the predictive model was observed, as AUCs were 0.859 (95% CI, 0.782-0.917) in the training dataset and 0.821 (95% CI, 0.682-0.918) in the validation dataset, respectively. Based on judgement by the model, When the tumor length diameter > 3 cm, combining ureteroscopy biopsy would improve sensitivity and NPV to 0.86 (95% CI, 0.776-0.922), 0.81 (95% CI, 0.714-0.903). CONCLUSION: The preoperative radiomics model showed promising diagnostic performance in predicting UTUC muscle invasion. This could help patients receive more accurate risk classification, especially help patients avoiding radical nephroureterectomy. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Zhang, Han-Mei AU - Zhang HM AD - Department of Radiology, Sichuan University West China Hospital, Chengdu, China. FAU - Wang, Yi AU - Wang Y AD - Department of Radiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Huang, Zi-Xing AU - Huang ZX AD - Department of Radiology, Sichuan University West China Hospital, Chengdu, China. FAU - Liu, Yu-Xi AU - Liu YX AD - Department of Radiology, Sichuan University West China Tianfu Hospital, Chengdu, China. FAU - Liu, Li AU - Liu L AD - Department of Radiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China. FAU - Bao, Yi-Ge AU - Bao YG AD - Department of Urology, Sichuan University West China Hospital, Chengdu, China. FAU - Cai, Xiang AU - Cai X AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. FAU - Wu, Tao AU - Wu T AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. FAU - Xu, Qian AU - Xu Q AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. FAU - Zhu, Xiang-Lan AU - Zhu XL AD - Department of Pathology, Sichuan University West China Hospital, Chengdu, China. FAU - Yin, Hong-Kun AU - Yin HK AD - Infervision Medical Technology Co., Ltd, Beijing, China. FAU - Zhang, Hui-Ling AU - Zhang HL AD - Infervision Medical Technology Co., Ltd, Beijing, China. FAU - Yuan, Fang AU - Yuan F AD - Department of Radiology, Sichuan University West China Hospital, Chengdu, China. yf025@hotmail.com. FAU - Song, Bin AU - Song B AD - Department of Radiology, Sichuan University West China Hospital, Chengdu, China. songlab_radiology@163.com. AD - Sanya People's Hospital, Sanya, China. songlab_radiology@163.com. LA - eng GR - 2023NSFSC1534/Natural Science Foundation of Sichuan Province/ PT - Journal Article PT - Multicenter Study DEP - 20250517 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Humans MH - Male MH - Middle Aged MH - Female MH - *Tomography, X-Ray Computed/methods MH - Retrospective Studies MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Neoplasm Staging MH - *Carcinoma, Transitional Cell/pathology/diagnostic imaging/surgery MH - *Ureteral Neoplasms/pathology/diagnostic imaging/surgery MH - *Kidney Neoplasms/pathology/diagnostic imaging/surgery MH - Nephroureterectomy MH - Preoperative Care/methods MH - Adult MH - Urography/methods MH - Aged MH - Radiomics OTO - NOTNLM OT - Computed tomography OT - Diagnostic test OT - Muscle invasion OT - Radiomics OT - Urothelial carcinoma COIS- Declarations. Competing interests: Authors "Hong-Kun Yin, Hui-Ling Zhang" were employed by Infervision Medical Technology Co., Ltd, Beijing, China, and participated in analysis of the data used in this research. Authors employed by Infervision Medical Technology Co. did not have a fiduciary responsibility to this study. Job titles of these authors were researcher of institute of advanced research. EDAT- 2025/05/18 17:01 MHDA- 2025/11/12 23:30 CRDT- 2025/05/17 23:24 PHST- 2025/03/23 00:00 [received] PHST- 2025/04/29 00:00 [accepted] PHST- 2025/04/26 00:00 [revised] PHST- 2025/11/12 23:30 [medline] PHST- 2025/05/18 17:01 [pubmed] PHST- 2025/05/17 23:24 [entrez] AID - 10.1007/s00261-025-04979-9 [pii] AID - 10.1007/s00261-025-04979-9 [doi] PST - ppublish SO - Abdom Radiol (NY). 2025 Dec;50(12):5872-5882. doi: 10.1007/s00261-025-04979-9. Epub 2025 May 17. PMID- 40369748 OWN - NLM STAT- MEDLINE DCOM- 20260416 LR - 20260813 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 58 IP - 2 DP - 2026 Apr TI - Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non-muscle-Invasive Bladder Cancer. PG - 591-602 LID - 10.4143/crt.2025.100 [doi] AB - PURPOSE: This study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC). MATERIALS AND METHODS: This retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models. RESULTS: Patients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course. CONCLUSION: Our research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability. FAU - Lee, Hye Won AU - Lee HW AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jung, Eui Hyun AU - Jung EH AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Kim, Kyung Hwan AU - Kim KH AD - Department of Urology, Pusan National University Hospital, Pusan National University College of Medicine, Busan, Korea. FAU - Ha, Hong Koo AU - Ha HK AD - Department of Urology, Pusan National University Hospital, Pusan National University College of Medicine, Busan, Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Heo, Ji Eun AU - Heo JE AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Ham, Won Sik AU - Ham WS AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Hwang, Eu Chang AU - Hwang EC AD - Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. FAU - Jung, Seung Il AU - Jung SI AD - Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. FAU - Song, Wan AU - Song W AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lim, Bumjin AU - Lim B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Jeong, Byung Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. AD - Division of Tumor Immunology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. AD - Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. LA - eng GR - NCC-2211590/National Cancer Center/Republic of Korea PT - Journal Article PT - Multicenter Study DEP - 20250512 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - Gemcitabine MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - Male MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use/adverse effects MH - Female MH - Aged MH - Retrospective Studies MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Middle Aged MH - *Antimetabolites, Antineoplastic/administration & dosage/therapeutic use/adverse effects MH - Aged, 80 and over MH - Treatment Outcome MH - Neoplasm Recurrence, Local MH - Cystectomy MH - Neoplasm Invasiveness MH - Adult MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC13093033 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Failure OT - Gemcitabine OT - Intravesical administration OT - Non-muscle invasive bladder neoplasms OT - Organization and administration OT - Therapeutics COIS- Conflicts of Interest Boryung Co., Ltd. sponsored this research. The funder had no role in study design, data collection, data analysis, interpretation, or writing of the report. EDAT- 2025/05/15 06:34 MHDA- 2026/04/19 17:26 PMCR- 2026/04/01 CRDT- 2025/05/15 00:06 PHST- 2025/01/23 00:00 [received] PHST- 2025/05/11 00:00 [accepted] PHST- 2026/04/19 17:26 [medline] PHST- 2025/05/15 06:34 [pubmed] PHST- 2025/05/15 00:06 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - crt.2025.100 [pii] AID - crt-2025-100 [pii] AID - 10.4143/crt.2025.100 [doi] PST - ppublish SO - Cancer Res Treat. 2026 Apr;58(2):591-602. doi: 10.4143/crt.2025.100. Epub 2025 May 12. PMID- 40365701 OWN - NLM STAT- MEDLINE DCOM- 20250926 LR - 20260522 IS - 1751-1097 (Electronic) IS - 0031-8655 (Print) IS - 0031-8655 (Linking) VI - 101 IP - 5 DP - 2025 Sep-Oct TI - Predicting head and neck tumor nodule responses to TLD1433 photodynamic therapy using the image-guided surgery probe ABY-029. PG - 1199-1210 LID - 10.1111/php.14083 [doi] AB - Incomplete surgical resection in head and neck cancer can lead to locoregional recurrence in >35% of patients. Approaches such as image-guided surgery (IGS) and post-operative photodynamic therapy (PDT) have been proposed to reduce recurrence rates. However, the PDT doses needed to eliminate all unresected diseases are not established. This in vitro proof-of-concept study aims to predict head and neck tumor nodule viability in vitro following PDT with TLD1433 using the IGS probe ABY-029. ABY-029 is an EGFR-specific affibody-IRDye800CW conjugate that has undergone Phase 0 evaluation studies in head and neck cancer, among others. TLD1433 is a ruthenium-based photosensitizer in a Phase II trial for non-muscle invasive bladder cancer. Here, we demonstrate that decreases in fluorescence emission of ABY-029 bound to MOC1 mouse head and neck cancer nodules in vitro can be predictive of TLD1433 PDT responses. Results show that photoactivation of TLD1433 produces reactive oxygen species (ROS) that reduce MOC1 nodule fractional viability in a manner that is inversely correlated with ABY-029 fluorescence intensity (Pearson's r = -0.9148, R(2) = 0.8369, p < 0.0001). We hypothesize that this is due to ROS-mediated degradation of IRDye800CW. The findings warrant further studies using head and neck cancer nodules with heterogenous PDT responses and EGFR expression levels. If successful, the future goal would be to use ABY-029 to guide the dosimetry of intraoperative PDT of the surgical bed after IGS to eliminate all microscopic diseases, reduce recurrence rates, and prolong survival. CI - (c) 2025 American Society for Photobiology. FAU - Bhandari, Chanda AU - Bhandari C AUID- ORCID: 0000-0002-4056-4754 AD - Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. FAU - Soma, Siddharth AU - Soma S AD - Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. FAU - Quaye, Maxwell AU - Quaye M AD - Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. FAU - Talgatov, Alisher AU - Talgatov A AD - Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA. FAU - Shafirstein, Gal AU - Shafirstein G AD - Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Samkoe, Kimberley AU - Samkoe K AD - Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA. FAU - McFarland, Sherri AU - McFarland S AD - Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA. FAU - Obaid, Girgis AU - Obaid G AD - Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. LA - eng GR - R01 EB034360/EB/NIBIB NIH HHS/United States GR - R01 CA167413/CA/NCI NIH HHS/United States GR - 2400127/National Science Foundation/ GR - RP240498/Cancer Prevention and Research Institute of Texas/ GR - R01CA167413/NH/NIH HHS/United States GR - 2102459/National Science Foundation/ GR - R00CA215301/NH/NIH HHS/United States GR - R00 CA215301/CA/NCI NIH HHS/United States GR - 2503230/National Science Foundation/ GR - R01EB034360/NH/NIH HHS/United States GR - R00CA215301/NH/NIH HHS/United States GR - R01EB034360/NH/NIH HHS/United States GR - R01CA167413/NH/NIH HHS/United States PT - Journal Article DEP - 20250514 PL - United States TA - Photochem Photobiol JT - Photochemistry and photobiology JID - 0376425 RN - 0 (Photosensitizing Agents) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - *Photochemotherapy MH - Animals MH - *Head and Neck Neoplasms/drug therapy/pathology/surgery MH - Mice MH - *Photosensitizing Agents/therapeutic use/chemistry/pharmacology MH - Humans MH - Cell Line, Tumor MH - Surgery, Computer-Assisted MH - ErbB Receptors/metabolism PMC - PMC12353352 MID - NIHMS2058489 OTO - NOTNLM OT - ABY-029 OT - TLD1433 OT - head and neck cancer OT - image-guided surgery OT - photodynamic therapy COIS- CONFLICT OF INTERESTS: G.O. and C.B. acknowledge the following potential conflict of interest: patent application # 18/984,124 (2024). G.S. acknowledges the following potential conflict of interest (in the past 36 months): Applied Materials and Products Company collaborative research, in-kind contribution. G.S. acknowledges the following potential conflict of interest (in the past 36 months) outside the submitted work: Lumeda Inc. receipt of stock options, honorarium, service on scientific advisory board, in-kind contribution and grant/contract. US patent # 11,040,217, US patents # 11,344,742. Patent applications PCT US US20240198127A1 and PCT US20230173301. POP Biotechnologies, Inc. NIH/NCI grant/contract. Simphotek Inc. NIH/NCI grant/contract. Modulight Corp. in-kind contribution. Concordia Laboratories Inc. and Pinnacle Biologics, Inc. grant/contract, in-kind contribution. Lung Cancer Initiative at Johnson & Johnson grant/contract. Simphotek Inc. NCI/NIH grant/contract. Pioneer Optics Company, in-kind contribution. NH TherAguix, in-kind contribution. S.A.M. has a potential research conflict of interest due to a financial interest with Theralase Technologies, Inc. and PhotoDynamic, Inc. A management plan has been created to preserve objectivity in research in accordance with UTA policy. K.S. has no non-financial or financial interests to declare. ABY-029 was manufactured under an academic-industrial partnership with Affibody Medical, and LI-COR Biosciences, Inc. funded by the National Cancer Institute (R01CA167413). EDAT- 2025/05/14 11:41 MHDA- 2025/09/26 12:31 PMCR- 2026/05/14 CRDT- 2025/05/14 05:13 PHST- 2024/12/17 00:00 [received] PHST- 2025/01/26 00:00 [accepted] PHST- 2025/09/26 12:31 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 05:13 [entrez] PHST- 2026/05/14 00:00 [pmc-release] AID - 10.1111/php.14083 [doi] PST - ppublish SO - Photochem Photobiol. 2025 Sep-Oct;101(5):1199-1210. doi: 10.1111/php.14083. Epub 2025 May 14. PMID- 40362200 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20250516 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 26 IP - 9 DP - 2025 Apr 22 TI - Diagnostic and Prognostic Potential of SH3YL1 and NOX4 in Muscle-Invasive Bladder Cancer. LID - 10.3390/ijms26093959 [doi] LID - 3959 AB - Bladder cancer, especially muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its aggressive nature and poor prognosis, often necessitating cisplatin-based chemotherapy. While cisplatin effectively reduces tumor burden, its nephrotoxic effects, specifically cisplatin-induced acute kidney injury (AKI), limit its clinical use. This study investigates SH3YL1 as a potential biomarker for bladder cancer progression and AKI. Plasma and urine SH3YL1 levels were measured in bladder cancer patients undergoing cisplatin treatment, showing elevated baseline levels compared to controls, suggesting a link with bladder cancer pathology rather than cisplatin-induced AKI. Functional network and Gene Ontology (GO) enrichment analyses identified SH3YL1's interactions with NADPH oxidase pathways, particularly NOX family genes, and highlighted its roles in cell adhesion, migration, and cytoskeletal organization-processes critical for tumor invasiveness. Notably, SH3YL1 and NOX4 expression were significantly higher in MIBC than in non-muscle-invasive bladder cancer (NMIBC), with a strong correlation between SH3YL1 and NOX4 (r = 0.62) in MIBC, suggesting a subtype-specific interaction. Kaplan-Meier survival analysis using The Cancer Genome Atlas bladder cancer (TCGA-BLCA) data further demonstrated that low SH3YL1 expression is significantly associated with poor overall and disease-specific survival in MIBC patients, reinforcing its role as a prognostic biomarker. In conclusion, SH3YL1 is a promising biomarker for identifying the invasive characteristics of MIBC and predicting patient outcomes. These findings underscore the importance of SH3YL1-NOX4 pathways in MIBC and suggest the need for further research into targeted biomarkers for bladder cancer progression and cisplatin-induced AKI to improve patient outcomes in high-risk cases. FAU - Kim, Mingyu AU - Kim M AUID- ORCID: 0000-0001-9678-154X AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Jung, Euihyun AU - Jung E AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Song, Geehyun AU - Song G AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Joung, Jaeyoung AU - Joung J AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Chung, Jinsoo AU - Chung J AUID- ORCID: 0000-0003-2251-5331 AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Seo, Hokyung AU - Seo H AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. FAU - Lee, Hyungho AU - Lee H AUID- ORCID: 0000-0003-4160-0216 AD - Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea. LA - eng GR - NCC2510550/National Cancer Center/Republic of Korea GR - NCC23F1960/National Cancer Center/Republic of Korea GR - NCC2211590/National Cancer Center/Republic of Korea PT - Journal Article DEP - 20250422 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - EC 1.6.3.- (NADPH Oxidase 4) RN - 0 (Biomarkers, Tumor) RN - EC 1.6.3.- (NOX4 protein, human) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/pathology/drug therapy/urine/genetics/metabolism/blood MH - *NADPH Oxidase 4/metabolism/genetics MH - Prognosis MH - *Biomarkers, Tumor/urine/blood MH - Male MH - Female MH - Cisplatin/therapeutic use/adverse effects MH - Middle Aged MH - Aged MH - Neoplasm Invasiveness MH - Gene Expression Regulation, Neoplastic MH - Kaplan-Meier Estimate PMC - PMC12071612 OTO - NOTNLM OT - AKI OT - NOX4 OT - SH3YL1 OT - bladder cancer OT - cisplatin COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/04/22 CRDT- 2025/05/14 01:09 PHST- 2025/03/25 00:00 [received] PHST- 2025/04/15 00:00 [revised] PHST- 2025/04/21 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:09 [entrez] PHST- 2025/04/22 00:00 [pmc-release] AID - ijms26093959 [pii] AID - ijms-26-03959 [pii] AID - 10.3390/ijms26093959 [doi] PST - epublish SO - Int J Mol Sci. 2025 Apr 22;26(9):3959. doi: 10.3390/ijms26093959. PMID- 40361519 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 9 DP - 2025 May 7 TI - Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions. LID - 10.3390/cancers17091594 [doi] LID - 1594 AB - BACKGROUND/OBJECTIVES: Urothelial carcinoma (UC) treatment has been transformed by immunotherapy and antibody-drug conjugates (ADCs). This review evaluates the current evidence for these approaches and identifies future directions. METHODS: We conducted a structured review of clinical trials, meta-analyses, and guidelines published until early 2025. RESULTS: Immune checkpoint inhibitors have established benefits across multiple settings: post-platinum therapy (pembrolizumab, nivolumab), maintenance therapy (avelumab), adjuvant settings for high-risk muscle-invasive disease (nivolumab), and BCG-unresponsive non-muscle-invasive disease (pembrolizumab). Enfortumab vedotin (targeting Nectin-4) has proven effective in post-platinum/post-immunotherapy. Most significantly, enfortumab vedotin plus pembrolizumab has redefined first-line treatment with unprecedented survival benefits (median OS 31.5 months vs. 16.1 months with chemotherapy; HR 0.47), and nivolumab plus gemcitabine-cisplatin improved outcomes in cisplatin-eligible patients. Key challenges include managing unique toxicity profiles, optimizing treatment sequencing, and developing reliable biomarkers. CONCLUSIONS: Combination approaches offer the most promising path forward, with future research needed on resistance mechanisms, biomarker development, and expanding these therapies to earlier disease stages. FAU - Yajima, Shugo AU - Yajima S AUID- ORCID: 0000-0003-2300-8446 AD - National Cancer Center Hospital East, Department of Urology, 6-5-1 Kashiwa no ha, Kashiwa City 277-8577, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - National Cancer Center Hospital East, Department of Urology, 6-5-1 Kashiwa no ha, Kashiwa City 277-8577, Japan. LA - eng PT - Journal Article PT - Review DEP - 20250507 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12071276 OTO - NOTNLM OT - antibody-drug conjugates OT - bladder cancer OT - combination therapy OT - enfortumab vedotin OT - immune checkpoint inhibitors OT - immunotherapy OT - nivolumab OT - pembrolizumab OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/05/07 CRDT- 2025/05/14 01:04 PHST- 2025/04/12 00:00 [received] PHST- 2025/05/04 00:00 [revised] PHST- 2025/05/06 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:04 [entrez] PHST- 2025/05/07 00:00 [pmc-release] AID - cancers17091594 [pii] AID - cancers-17-01594 [pii] AID - 10.3390/cancers17091594 [doi] PST - epublish SO - Cancers (Basel). 2025 May 7;17(9):1594. doi: 10.3390/cancers17091594. PMID- 40361404 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250516 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 9 DP - 2025 Apr 27 TI - Contemporary Trends and Predictors Associated with Adverse Pathological Upstaging Among Non-Metastatic Localized Clinical T2 Muscle-Invasive Bladder Cancers Undergoing Radical Cystectomy: Outcomes from a Single Tertiary Centre in the United Kingdom. LID - 10.3390/cancers17091477 [doi] LID - 1477 AB - Introduction: Radical cystectomy (RC) is the gold standard for urothelial cT2-4a, N0, M0 muscle-invasive bladder cancer (MIBC). However, bladder-sparing strategies (BSS) such as Trimodality Therapy (TMT) have emerged as alternative treatments for a select group of localized muscle-confined (cT2) urothelial bladder cancers. Accordingly, reliable preoperative staging and a reliable risk factor assessment linked to pathological upstaging play a key role in adequate counselling and patient selection for BSS. Patients and Methods: cT2 MIBC patients undergoing RC at our institution from 2014 to 2024 were reviewed. Preoperative staging modalities, demographics, and tumour and patient characteristics were assessed. Multivariable logistic regression was applied to explore the relative effect of confounders on any pathological upstaging from robot-assisted or open RC specimens. Subgroup analysis according to the local upstaging (>pT2) or nodal dissemination (pN+) was also performed. Results: N = 275 RCs were included (73.5% males, 26.5% females). Upstaging was documented in n = 141 (51%) cases. Of these, n = 125 (45.5%) were upstaged locally (>pT2) and n = 35 (23%) yielded pN+ disease. Preoperative parameters like gender, the number of TURBTs, previous BCG exposure, and concomitant CIS did not significantly influence the risk of any kind of upstaging (p > 0.05). At multivariable analysis, neoadjuvant chemotherapy (NAC) and multi-disciplinary team (MDT) discussion were found protective (odds ratio [OR]: 0.4, 95%CI 0.2-0.7, p = 0.001 and OR: 0.51, 95%CI 0.2-0.9, p = 0.01). Preoperative FDG-PET assessment yielded higher risk for later pN upstaging (OR: 1.8, 95%CI 1-3, p = 0.05). HG/G3 features at TURBT along with mixed/pure histology variants in RC specimens were the most relevant independent predictors for both any and pT upstaging (OR: 4.3, 95%CI 1-34, p = 0.04 and OR: 2.3, 95%CI 1.1-4.6, p = 0.02 for any upstaging and OR: 5.6, 95%CI 1.3-36, p = 0.02 and OR: 2.5, 95%CI 1.3-5, p = 0.01 for pT upstaging, respectively). Conclusions: In this study, over half of the patients undergoing RC for cT2 were upstaged at the final pathology. Therefore, adequate counselling and examining the non-conventional criteria for prognosis is mandatory in the contemporary era of bladder-preservation strategies. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94304, USA. AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Abu-Ghanem, Yasmin AU - Abu-Ghanem Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Nair, Rajesh AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Mensah, Elsie AU - Mensah E AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Kam, Jonathan AU - Kam J AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Ibrahim, Youssef AU - Ibrahim Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Gad, Mohamed AU - Gad M AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Chatterton, Kathryn AU - Chatterton K AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Amery, Suzanne AU - Amery S AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Alao, Romerr AU - Alao R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Challacombe, Ben AU - Challacombe B AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Hegazy, Mohammed AU - Hegazy M AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy. FAU - Santarelli, Valerio AU - Santarelli V AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - University Center of Excellence in Urology, Wroclaw Medical University, 50367 Wroclaw, Poland. FAU - Rocco, Bernardo AU - Rocco B AD - Deptartment of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00136 Roma, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AUID- ORCID: 0000-0002-7899-8056 AD - Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Umberto I Hospital, 00185 Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94304, USA. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 7EH, UK. LA - eng PT - Journal Article DEP - 20250427 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12070980 OTO - NOTNLM OT - clinical predictors OT - muscle-invasive bladder cancer (MIBC) OT - pathological upstaging OT - radical cystectomy (RC) OT - robot-assisted radical cystectomy (RARC) COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/04/27 CRDT- 2025/05/14 01:03 PHST- 2025/02/09 00:00 [received] PHST- 2025/04/05 00:00 [revised] PHST- 2025/04/17 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:03 [entrez] PHST- 2025/04/27 00:00 [pmc-release] AID - cancers17091477 [pii] AID - cancers-17-01477 [pii] AID - 10.3390/cancers17091477 [doi] PST - epublish SO - Cancers (Basel). 2025 Apr 27;17(9):1477. doi: 10.3390/cancers17091477. PMID- 40361038 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20260127 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 May 13 TI - Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial. PG - 868 LID - 10.1186/s12885-025-14234-5 [doi] LID - 868 AB - BACKGROUND: Muscle invasive bladder cancer (MIBC) is a malignancy with high recurrence and metastasis rate. Radical cystectomy and lymph node dissection are the current standard cares for MIBC. The demand for bladder preservation in MIBC patients is growing daily; however, the recognized trimodal bladder-sparing regimen has been shown to have substantial radiation damage and inconsistent efficacy in numerous investigations. In order to address these issues, a secure and efficient bladder preservation program is desperately needed. Therefore, a novel bladder-sparing modality that employing antibody-drug conjugates and immune checkpoint inhibitors combined with pelvic lymph node dissection is worth investigating further in this setting. METHODS: In this multicenter, single-arm clinical trial, subjects who were diagnosed with muscle-invasive bladder cancer with human epidermal growth factor receptor-2 expression >/= 2 + will be enrolled. Eligible subjects will receive 12 cycles Disitamab Vedotin combined with Toripalimab treatment and pelvic lymph node dissection after completed transurethral bladder tumor resection, efficacy evaluation would be performed in all of them, patients who achieved clinical complete response will receive 1-year bladder-sparing therapy with Toripalimab immune maintenance treatment. The primary endpoint is 2-year Bladder-intact disease-free survival, and the secondary endpoints include clinical complete response rate, over survival, quality of life, safety and exploratory objectives that biomarkers will be evaluated. DISCUSSION: Disitamab Vedotin combined with Toripalimab therapy and pelvic lymph node dissection is a promising bladder-sparing treatment option that has the potential to improve the rate of bladder-intact disease-free survival and may become a novel modality of bladder-sparing regimen if the study endpoints are met. TRIAL REGISTRATION: This study was registered at Chinese Clinical Trial Registry (ldentifer: ChiCTR2400081555) on March 5, 2024. CI - (c) 2025. The Author(s). FAU - Lan, Tianhang AU - Lan T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. FAU - Zhu, Yingying AU - Zhu Y AD - Clinical Research Design Division, Clinical Research Center, Sun Yat- sen Memorial Hospital, Sun Yat-sen University, Guangdong, 510120, China. FAU - Zhong, Wenlong AU - Zhong W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, 510120, China. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, 510120, China. FAU - Tan, Qihong AU - Tan Q AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, 510120, China. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, 510120, China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. urolhj@sina.com. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, 510120, China. urolhj@sina.com. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, 510120, China. urolhj@sina.com. FAU - He, Wang AU - He W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang West Road, Guangzhou, Guangdong, 510120, China. hewang525344@126.com. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, 510120, China. hewang525344@126.com. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, 510120, China. hewang525344@126.com. LA - eng PT - Clinical Trial Protocol PT - Journal Article DEP - 20250513 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 8JXN261VVA (toripalimab) RN - 0 (Immunoconjugates) RN - 0 (disitamab vedotin) RN - 0 (Antibodies, Monoclonal) RN - 0 (Oligopeptides) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/drug therapy MH - *Lymph Node Excision/methods MH - *Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use MH - Multicenter Studies as Topic MH - Male MH - Female MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects MH - *Organ Sparing Treatments/methods MH - Middle Aged MH - Clinical Trials, Phase II as Topic MH - *Immunoconjugates/administration & dosage MH - Aged MH - Neoplasm Invasiveness MH - Pelvis MH - Cystectomy MH - Treatment Outcome MH - Adult MH - Combined Modality Therapy MH - Antibodies, Monoclonal MH - Oligopeptides PMC - PMC12076858 OTO - NOTNLM OT - Bladder-sparing treatment OT - Disitamab Vedotin OT - Muscle-invasive bladder cancer (MIBC) OT - Pelvic lymph node dissection (PLND) OT - Toripalimab OT - Transurethral bladder tumor resection (TURBT) COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by Medical Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Written informed consent will be obtained from all objects prior to enrollment. Participants will be made aware that participation is strictly voluntary. Participants may withdraw from the study at any time. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/05/14 11:42 MHDA- 2025/05/14 11:43 PMCR- 2025/05/13 CRDT- 2025/05/13 23:40 PHST- 2024/06/04 00:00 [received] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/05/14 11:43 [medline] PHST- 2025/05/14 11:42 [pubmed] PHST- 2025/05/13 23:40 [entrez] PHST- 2025/05/13 00:00 [pmc-release] AID - 10.1186/s12885-025-14234-5 [pii] AID - 14234 [pii] AID - 10.1186/s12885-025-14234-5 [doi] PST - epublish SO - BMC Cancer. 2025 May 13;25(1):868. doi: 10.1186/s12885-025-14234-5. PMID- 40357040 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250627 IS - 2296-861X (Print) IS - 2296-861X (Electronic) IS - 2296-861X (Linking) VI - 12 DP - 2025 TI - Prognostic impact of nutritional indicators based on Lasso-Cox regression for non-muscle-invasive bladder cancer. PG - 1560655 LID - 10.3389/fnut.2025.1560655 [doi] LID - 1560655 AB - BACKGROUND: There is a lack of prognostic models to predict the outcomes of non-muscle-invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guerin (BCG) immunotherapy. Existing nutritional risk indicators, such as the prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI) and Naples prognostic score (NPS), have demonstrated prognostic value in various malignancies. This study aimed to construct novel nutritional risk indexes (NRIs) using peripheral blood markers via Lasso-Cox regression and validate their prognostic value. METHODS: The electric medical records in our institution were searched and data of 525 NMIBC patients were collected. The Lasso-Cox regression was employed to screen preoperative blood biomarkers correlated with recurrence-free survival (RFS), time to BCG-treatment failure (TTF), and progression-free survival (PFS). NRIs were developed based on selected markers and validated against GNRI, PNI, NPS, and the EAU2021 risk model using Kaplan-Meier analysis, Cox regression, receiver-operating characteristic (ROC) curves, Concordance index (C-index) and Decision Curve analysis. RESULTS: Lasso-Cox regression identified distinct blood biomarkers: gamma-glutamyl transpeptidase (GGT), serum total protein (TP), albumin and cholesterol were predictive of tumor recurrence and BCG failure, while GGT, TP, and coefficient variation of red blood cell volume distribution width were linked to tumor progression. Three NRIs-NRITR (RFS), NRIBF (TTF) and NRITP (PFS)-were constructed. The NRIs exhibited prognostic value through Kaplan-Meier analysis. Multivariate Cox analysis confirmed NRITR (HR = 0.38, 95%CI:0.28-0.53), NRIBF (HR = 0.45, 95%CI: 0.30-0.67), and NRITP (HR = 0.38, 95%CI: 0.21-0.69) as independent predictors. Nomograms incorporating NRIs demonstrated superior discriminative performance in predicting RFS (AUC = 0.739, C-index = 0.673), TTF (AUC = 0.795, C-index = 0.767), and PFS (AUC = 0.796, C-index = 0.788), and could bring more net benefit for NMIBC patients. CONCLUSION: The Lasso-Cox regression may offer superior value in selecting prognostic biomarkers for NMIBC. The Lasso-Cox regression based NRIs enhance prognostic stratification for BCG-treated NMIBC, outperforming existing blood-based nutritional risk indicators and the EAU2021 model. Incorporation of blood-based nutritional indicators into clinical practice could optimization of personalized NMIBC treatment strategies and clinical decision-making. Further validation is warranted. CI - Copyright (c) 2025 Ye, Xie, Ran and Han. FAU - Ye, Junjiang AU - Ye J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Xie, Yandong AU - Xie Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Ran, Biao AU - Ran B AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20250428 PL - Switzerland TA - Front Nutr JT - Frontiers in nutrition JID - 101642264 EIN - Front Nutr. 2025 Jun 12;12:1630197. doi: 10.3389/fnut.2025.1630197. PMID: 40575391 PMC - PMC12066686 OTO - NOTNLM OT - Lasso-Cox regression OT - Naples prognostic score OT - geriatric nutritional risk index OT - non-muscle-invasive bladder cancer OT - prognostic nutritional index COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/05/13 06:32 MHDA- 2025/05/13 06:33 PMCR- 2025/04/28 CRDT- 2025/05/13 04:49 PHST- 2025/01/14 00:00 [received] PHST- 2025/04/14 00:00 [accepted] PHST- 2025/05/13 06:33 [medline] PHST- 2025/05/13 06:32 [pubmed] PHST- 2025/05/13 04:49 [entrez] PHST- 2025/04/28 00:00 [pmc-release] AID - 10.3389/fnut.2025.1560655 [doi] PST - epublish SO - Front Nutr. 2025 Apr 28;12:1560655. doi: 10.3389/fnut.2025.1560655. eCollection 2025. PMID- 40353763 OWN - NLM STAT- MEDLINE DCOM- 20250604 LR - 20260716 IS - 2767-9764 (Electronic) IS - 2767-9764 (Linking) VI - 5 IP - 6 DP - 2025 Jun 1 TI - Repurposing Amiodarone for Bladder Cancer Treatment. PG - 906-920 LID - 10.1158/2767-9764.CRC-24-0433 [doi] AB - Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing has emerged as a promising approach in cancer treatment, with various studies proposing the use of existing drugs for the treatment of bladder cancer. In this context, we previously established an in silico repurposing strategy using patient omics signatures, identifying drugs and compounds with the potential to reverse nonmuscle-invasive bladder cancer (NMIBC) to less aggressive subtypes. In the present study, we expanded our in silico approach to verify a list of compounds with potential antitumor activity against MIBC. We investigated the efficacy of the predicted candidates in a group of different bladder cancer cell lines, including NMIBC and MIBC. The most potent compound for decreasing cell viability was amiodarone, an antiarrhythmic drug widely used in the field of cardiology. Amiodarone reduced cell proliferation and colony formation capacity, with a stronger effect on the most aggressive invasive models, validating our repurposing pipeline. The drug additionally induced cell death and inhibited the activity of mTOR and its target protein S6, suggesting that the anticancer effect of the drug is, in part, mediated by inhibition of the mTOR signaling pathway. Furthermore, the administration of amiodarone in a xenograft MIBC mouse model reduced tumor growth without inducing toxicity. Altogether, we demonstrated that amiodarone is a potential repurposed drug for bladder cancer, which might be especially effective in MIBC. SIGNIFICANCE: Treatment of advanced bladder cancer remains a therapeutic challenge in urological oncology. In order to make more drugs available to patients in the future, we identified amiodarone, a repurposed drug used in cardiology as a compound that inhibits bladder cancer in vitro and in vivo. CI - (c)2025 The Authors; Published by the American Association for Cancer Research. FAU - Roa, Francisco J AU - Roa FJ AUID- ORCID: 0009-0001-3429-8955 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Roubelakis, Maria AU - Roubelakis M AUID- ORCID: 0000-0001-5790-6581 AD - Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. AD - Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Paschidis, Konstantinos AU - Paschidis K AUID- ORCID: 0009-0008-2552-6339 AD - Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. AD - Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - van Creij, Nils C H AU - van Creij NCH AUID- ORCID: 0009-0004-2208-5305 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Handle, Florian AU - Handle F AUID- ORCID: 0000-0002-7558-5635 AD - XPseq Analytics GmbH, Innsbruck, Austria. FAU - Makridakis, Manousos AU - Makridakis M AUID- ORCID: 0000-0002-0063-3559 AD - Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Narayanasamy, Shaman AU - Narayanasamy S AUID- ORCID: 0000-0002-5793-6235 AD - Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. FAU - Balaur, Irina-Afrodita AU - Balaur IA AUID- ORCID: 0000-0002-3671-895X AD - Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. FAU - Tserga, Aggeliki AU - Tserga A AUID- ORCID: 0000-0002-5531-2111 AD - Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Vlahou, Antonia AU - Vlahou A AUID- ORCID: 0000-0003-3284-5713 AD - Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Santer, Frederic R AU - Santer FR AUID- ORCID: 0000-0002-4591-6368 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Holm, Per-Sonne AU - Holm PS AUID- ORCID: 0000-0002-1196-2323 AD - Department of Oral and Maxilofacial Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Hoffmann, Michele AU - Hoffmann M AUID- ORCID: 0000-0002-6044-1671 AD - Department of Urology, Medical Faculty and University Hospital Dusseldorf, Heinrich Heine University of Dusseldorf, Dusseldorf, Germany. FAU - Puhr, Martin AU - Puhr M AUID- ORCID: 0000-0002-3858-9653 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Mokou, Marika AU - Mokou M AUID- ORCID: 0000-0002-4511-1578 AD - Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany. FAU - Frantzi, Maria AU - Frantzi M AUID- ORCID: 0000-0003-0415-0316 AD - Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany. FAU - Schneider, Reinhard AU - Schneider R AUID- ORCID: 0000-0002-8278-1618 AD - Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. FAU - Latosinska, Agnieszka AU - Latosinska A AUID- ORCID: 0000-0001-8917-2412 AD - Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany. FAU - Mischak, Harald AU - Mischak H AUID- ORCID: 0000-0003-0323-0306 AD - Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany. FAU - Satagopam, Venkata AU - Satagopam V AUID- ORCID: 0000-0002-6532-5880 AD - Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. FAU - Culig, Zoran AU - Culig Z AUID- ORCID: 0000-0002-5001-6153 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Res Commun JT - Cancer research communications JID - 9918281580506676 RN - N3RQ532IUT (Amiodarone) RN - 0 (Antineoplastic Agents) SB - IM MH - *Urinary Bladder Neoplasms/drug therapy/pathology/metabolism MH - *Drug Repositioning/methods MH - Humans MH - *Amiodarone/pharmacology/therapeutic use MH - Animals MH - Mice MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Xenograft Model Antitumor Assays MH - Cell Survival/drug effects PMC - PMC12134865 COIS- F.J. Roa reports grants from Eurostars-BMBF (Germany, 01QE2010A) and FFG during the conduct of the study. F. Handle reports personal fees from the Medical University of Innsbruck during the conduct of the study and that he is the owner and CEO of XPseq Analytics GmbH. M. Mokou reports grants from Mosaiques diagnostics during the conduct of the study as well as other support from Mosaiques diagnostics outside the submitted work and has a patent to EP4428869A1 pending. M. Frantzi reports personal fees from Mosaiques diagnostics GmbH during the conduct of the study. A. Latosinska reports personal fees from Mosaiques diagnostics GmbH and grants from BMBF (01QE2010A)/Eurostars (E! 113726) during the conduct of the study. H. Mischak reports grants from BMBF during the conduct of the study; has a patent to PCT/EP2024/055936 pending; and that he is the co-founder and co-owner of Mosaiques diagnostics. No disclosures were reported by the other authors. EDAT- 2025/05/12 12:34 MHDA- 2025/06/04 06:27 PMCR- 2025/06/04 CRDT- 2025/05/12 10:12 PHST- 2024/08/21 00:00 [received] PHST- 2024/12/06 00:00 [revised] PHST- 2025/05/07 00:00 [accepted] PHST- 2025/06/04 06:27 [medline] PHST- 2025/05/12 12:34 [pubmed] PHST- 2025/05/12 10:12 [entrez] PHST- 2025/06/04 00:00 [pmc-release] AID - 762312 [pii] AID - CRC-24-0433 [pii] AID - 10.1158/2767-9764.CRC-24-0433 [doi] PST - ppublish SO - Cancer Res Commun. 2025 Jun 1;5(6):906-920. doi: 10.1158/2767-9764.CRC-24-0433. PMID- 40349989 OWN - NLM STAT- MEDLINE DCOM- 20250525 LR - 20250525 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 158 DP - 2025 Apr TI - Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry. PG - 105788 LID - S0046-8177(25)00075-9 [pii] LID - 10.1016/j.humpath.2025.105788 [doi] AB - Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is an aggressive UC subtype characterized by infiltrating cells with plasmacytoid appearance, and somatic CDH1 mutations leading to E-cadherin loss. 32 PUC cases were found in our pathology archives from 2018 to 2024; next-generation sequencing (NGS) was available in 18 cases, and PD-L1 immunohistochemistry in all 32 cases. PD-L1 tumor proportion score (TPS) and combined positive score (CPS) were calculated. Kaplan-Meier method and log-rank test were used for survival analysis. Median patient age was 72.5 years (IQR: 64.3-78.8 years). The cohort consisted predominantly of males (29/32, 91%). 25 patients (78%) underwent radical cystectomy/cystoprostatectomy (RC), while 7 (22%) transurethral resection. Median tumor size was 5.2 cm (IQR of 3.6-8.0 cm). Most RCs (22/25, 88 %) were high-stage (pT3-4). Lymphovascular invasion was identified in 22/25 RCs (88%) and 12/23 RCs (52%) were pN1-2. 17/32 cases (53%) showed a PD-L1 TPS>/=1% (6/17 received immune-checkpoint inhibitors - ICIs), while 21/32 (66%) exhibited a CPS>/=1% (8/21 received ICIs). Recurrently mutated genes included TP53, TERT, RB1, CREBBP, and ERBB2, among others; our NGS panel does not cover CDH1. Most frequent copy number alterations were RB1, CDKN2A, and CDKN1B losses. Median tumor mutational burden (TMB) was 10.3 mut/Mb (IQR 5.4-15.73 mut/Mb). Median overall survival (OS) was 13.0 months (95% CI 4.2-21.8 months) with some evidence for superior OS among patients with PD-L1 expression. Overall, PUCs frequently exhibit high TMB and/or PD-L1 expression, suggesting a potential for intervention with ICIs. Finally, NGS is recommended to identify actionable alterations, including ERBB2 mutations. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Korentzelos, Dimitrios AU - Korentzelos D AD - Department of Pathology, Genitourinary Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, USA. Electronic address: korentzelosd@upmc.edu. FAU - Diamantopoulos, Leonidas AU - Diamantopoulos L AD - Department of Medicine, Northwell Health/Staten Island University Hospital, New York, USA. FAU - Mohebnasab, Maedeh AU - Mohebnasab M AD - Department of Pathology, Division of Molecular Genetics Pathology, University of Pittsburgh Medical Center, Pittsburgh, USA. FAU - Dhir, Rajiv AU - Dhir R AD - Department of Pathology, Genitourinary Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, USA. FAU - Quiroga-Garza, Gabriela M AU - Quiroga-Garza GM AD - Department of Pathology, Genitourinary Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, USA. LA - eng PT - Journal Article DEP - 20250509 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Male MH - *B7-H1 Antigen/analysis/metabolism MH - Aged MH - High-Throughput Nucleotide Sequencing MH - *Urinary Bladder Neoplasms/genetics/pathology/mortality MH - Middle Aged MH - Female MH - Immunohistochemistry MH - *Biomarkers, Tumor/genetics/analysis MH - *Carcinoma, Transitional Cell/genetics/pathology MH - Mutation OTO - NOTNLM OT - Bladder cancer OT - Next-generation sequencing (NGS) OT - PD-L1 OT - Plasmacytoid urothelial carcinoma OT - Tumor mutational burden (TMB) COIS- Declaration of competing interest The authors have no conflicts of interest directly relevant to the manuscript. EDAT- 2025/05/12 05:13 MHDA- 2025/05/26 00:29 CRDT- 2025/05/11 19:33 PHST- 2025/03/09 00:00 [received] PHST- 2025/05/02 00:00 [revised] PHST- 2025/05/08 00:00 [accepted] PHST- 2025/05/26 00:29 [medline] PHST- 2025/05/12 05:13 [pubmed] PHST- 2025/05/11 19:33 [entrez] AID - S0046-8177(25)00075-9 [pii] AID - 10.1016/j.humpath.2025.105788 [doi] PST - ppublish SO - Hum Pathol. 2025 Apr;158:105788. doi: 10.1016/j.humpath.2025.105788. Epub 2025 May 9. PMID- 40349568 OWN - NLM STAT- MEDLINE DCOM- 20250518 LR - 20250518 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 270 DP - 2025 Jun TI - Infiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer. PG - 155997 LID - S0344-0338(25)00189-X [pii] LID - 10.1016/j.prp.2025.155997 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) consists of tumors restricted to the bladder urothelium or lamina propria, without invasion of the muscular layer. Intravesical BCG (Bacillus Calmette-Guerin) is widely used as an adjuvant therapy for patients with intermediate or high-risk NMIBC. However, a significant proportion of these patients fail to respond to BCG or recur after treatment. Moreover, despite decades of BCG usage, there are still no clinically validated biomarkers capable of predicting which patients will benefit from this treatment. Emerging evidence suggests that the tumor immune microenvironment influences the efficacy of BCG immunotherapy. In this context, our study aimed to assess, by immunohistochemistry, whether the abundance of immune cell subpopulations - Natural Killer (NK) cells, tumor-associated macrophages (TAMs), CD4 + T, CD8 + T, and FOXP3 + regulatory T (Treg) cells, or T cell ratios (CD4 +/CD8 + and FOXP3 +/CD8 +) - in NMIBC urothelium, prior to BCG, were associated with BCG response rate (RR) and recurrence-free survival (RFS) after treatment. We demonstrated that higher pretreatment NK cell count in the NMIBC urothelium is significantly associated with improved BCG RR and prolonged RFS after BCG immunotherapy. We hypothesize these results are associated with BCG-induced trained immunity, which has been proposed to be essential for the efficacy of BCG immunotherapy in bladder cancer. Once validated and further investigated by future studies, our findings may help to improve the stratification and treatment of patients with NMIBC. CI - Copyright (c) 2025 The Authors. Published by Elsevier GmbH.. All rights reserved. FAU - Lima, Mariana Z T AU - Lima MZT AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil. Electronic address: mariana.lima@mackenzie.br. FAU - Bastos, Diogo A AU - Bastos DA AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil; Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. FAU - Mattedi, Romulo L AU - Mattedi RL AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil; Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. Electronic address: romulo.lmattedi@hsl.org.br. FAU - Dzik, Carlos AU - Dzik C AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. FAU - Jardim, Denis L F AU - Jardim DLF AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil. FAU - Coelho, Rafael AU - Coelho R AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. Electronic address: coelhouro@yahoo.com.br. FAU - Ribeiro-Filho, Leopoldo A AU - Ribeiro-Filho LA AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. Electronic address: leopoldofilho@yahoo.com.br. FAU - Cordeiro, Mauricio D AU - Cordeiro MD AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. FAU - Nahas, William C AU - Nahas WC AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. Electronic address: wnahas@uol.com.br. FAU - Mello, Evandro S AU - Mello ES AD - Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, SP, Brazil. Electronic address: esobroza@usp.br. FAU - Amano, Mariane T AU - Amano MT AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil. Electronic address: mtamano@mochsl.org.br. FAU - Inoue, Lilian T AU - Inoue LT AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil. Electronic address: lilian.tinoue@hsl.org.br. FAU - Camargo, Anamaria A AU - Camargo AA AD - Hospital Sirio-Libanes, Sao Paulo, SP, Brazil. Electronic address: anamaria.acamargo@hsl.org.br. LA - eng PT - Journal Article DEP - 20250506 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/pathology/drug therapy/therapy MH - *Killer Cells, Natural/immunology/pathology MH - *BCG Vaccine/therapeutic use MH - *Immunotherapy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - Tumor Microenvironment/immunology MH - *Lymphocytes, Tumor-Infiltrating/immunology/pathology MH - Aged, 80 and over MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Bladder cancer OT - NK cells OT - NMIBC OT - Trained immunity OT - Tumor microenvironment COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Anamaria Aranha Camargo reports financial support was provided by Ludwig Institute for Cancer Research Ltd. Diogo Assed Bastos reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Astellas Pharma US Inc that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Merck Sharp & Dohme UK Ltd that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Bristol-Myers Squibb that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Bayer Corporation that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Pfizer that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with AstraZeneca R&D Reims that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Ipsen that includes: speaking and lecture fees. Diogo Assed Bastos reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Diogo Assed Bastos reports a relationship with Astellas Pharma Inc that includes: consulting or advisory. Diogo Assed Bastos reports a relationship with Bayer Corporation that includes: consulting or advisory. Denis LF Jardim reports a relationship with Roche that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Astellas Pharma Inc that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Merck Sharp & Dohme UK Ltd that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Bristol Myers Squibb Co that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Pfizer Inc that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with AstraZeneca R&D Reims that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Libbs Pharmaceutical that includes: speaking and lecture fees. Denis LF Jardim reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Denis LF Jardim reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory. Denis LF Jardim reports a relationship with Libbs Pharmaceutical that includes: consulting or advisory. Romulo L. Mattedi reports a relationship with AstraZeneca Pharmaceuticals LP that includes: speaking and lecture fees. Anamaria Aranha Camargo reports a relationship with Roche that includes: speaking and lecture fees. Anamaria Aranha Camargo reports a relationship with Bristol Myers Squibb Co that includes: speaking and lecture fees. Anamaria Aranha Camargo reports a relationship with Illumina Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/12 05:13 MHDA- 2025/05/19 00:36 CRDT- 2025/05/11 18:05 PHST- 2024/11/14 00:00 [received] PHST- 2025/04/29 00:00 [revised] PHST- 2025/05/05 00:00 [accepted] PHST- 2025/05/19 00:36 [medline] PHST- 2025/05/12 05:13 [pubmed] PHST- 2025/05/11 18:05 [entrez] AID - S0344-0338(25)00189-X [pii] AID - 10.1016/j.prp.2025.155997 [doi] PST - ppublish SO - Pathol Res Pract. 2025 Jun;270:155997. doi: 10.1016/j.prp.2025.155997. Epub 2025 May 6. PMID- 40349488 OWN - NLM STAT- MEDLINE DCOM- 20250716 LR - 20250716 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 4 DP - 2025 Aug TI - Assessment of the Impact of Grade Heterogeneity on Survival in Ta and T1 Tumors: A Subgroup Analysis of NMIBC Cohort. PG - 102357 LID - S1558-7673(25)00058-8 [pii] LID - 10.1016/j.clgc.2025.102357 [doi] AB - INTRODUCTION: We aimed to compare the RFS and PFS of Ta-MG, Ta-HG, T1-MG and T1-HG groups with the hypothesis that MG tumors may have a better prognosis than pure HG tumors. MATERIAL AND METHODS: Patients with HG-NMIBC in the first TUR specimen between 2010 and 2020 were screened. The first TUR specimens were re-evaluated by experienced uropathologists and the percentage of LG tumor areas accompanying HG areas was determined for each case. HG tumors with accompanying LG rates ranging from 1% to 95% were evaluated as "Mixed-Grade (MG)," while tumors without any LG component (0%) were evaluated as "pure High-Grade (HG)." Survival analysis was performed using the Kaplan-Meier method. RFS and PFS were compared via the log-rank test. RESULTS: Of the 201 patients included in the study, 25 (12.4%) had Ta-MG, 45 (22.4%) had Ta-HG, 43 (21.4%) had T1-MG and 88 (43.8%) had T1-HG tumors. The median follow-up period of the patients was 36 months. The median number of BCG instillations received by the patients was 12 and a total of 102 patients (50.7%) received a minimum of 12 doses of BCG treatment. Recurrence was observed in 6 (24%), 11 (24.4%), 13 (30.2%) and 30 (34.1%) patients in the Ta-MG, Ta-HG, T1-MG and T1-HG groups, respectively. The 36-month RFS rates were 76% (CI: 59-93), 76% (CI: 63-88), 70% (CI: 56-84) and 66% (CI: 56-76), respectively (Log-Rank; P = .701). Progression was observed in 2 (8%), 3 (6.6%), 2 (4.6%) and 19 (21.6%) patients, respectively. The 36-month PFS rates for groups were 92% (CI: 82-100), 93% (CI: 86-100), 95% (CI: 89-100) and 78% (CI: 70-87), respectively. The T1-HG group was found to have a statistically significantly lower PFS (Log-Rank; P = .016). CONCLUSION: In BCG-treated NMIBC patients, those with T1-pure-HG tumors have worse PFS compared to those with T1-MG, Ta-HG, and Ta-MG tumors. The presence of pure-HG tumors may hold prognostic importance for NMIBC patients and might be crucial for patient classification and treatment options. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Karaburun, Murat Can AU - Karaburun MC AD - Department of Urology, Etlik City Hospital, Ankara, Turkey; Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. Electronic address: muratkaraburun2@gmail.com. FAU - Serbes, Ezgi Dicle AU - Serbes ED AD - Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Akpinar, Cagri AU - Akpinar C AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Obaid, Khaled AU - Obaid K AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Gogus, Cagatay AU - Gogus C AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Kiremitci, Saba AU - Kiremitci S AD - Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Enneli, Duygu AU - Enneli D AD - Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. FAU - Suer, Evren AU - Suer E AD - Department of Urology, Ankara University Faculty of Medicine, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20250414 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - Middle Aged MH - Neoplasm Grading MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - Prognosis MH - Aged, 80 and over MH - Neoplasm Staging MH - BCG Vaccine/administration & dosage/therapeutic use MH - Retrospective Studies MH - Adult MH - Kaplan-Meier Estimate MH - Follow-Up Studies MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Bladder cancer OT - high-grade OT - low-grade OT - prognosis COIS- Disclosure All authors declare that they have no conflict of interest. EDAT- 2025/05/12 05:12 MHDA- 2025/07/17 04:42 CRDT- 2025/05/11 18:03 PHST- 2024/11/05 00:00 [received] PHST- 2025/04/10 00:00 [revised] PHST- 2025/04/12 00:00 [accepted] PHST- 2025/07/17 04:42 [medline] PHST- 2025/05/12 05:12 [pubmed] PHST- 2025/05/11 18:03 [entrez] AID - S1558-7673(25)00058-8 [pii] AID - 10.1016/j.clgc.2025.102357 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Aug;23(4):102357. doi: 10.1016/j.clgc.2025.102357. Epub 2025 Apr 14. PMID- 40348729 OWN - NLM STAT- MEDLINE DCOM- 20250716 LR - 20250716 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 4 DP - 2025 Aug TI - Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. PG - 102354 LID - S1558-7673(25)00055-2 [pii] LID - 10.1016/j.clgc.2025.102354 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) has shown an increasing incidence, with intravesical recurrence (IVR) being a common postoperative challenge following radical nephroureterectomy. Although current guidelines recommend cystoscopic surveillance based on risk stratification, these recommendations are weak and may not adequately address IVR-specific risk factors or optimal surveillance intervals. METHODS: We retrospectively analyzed 700 patients who underwent radical nephroureterectomy between 2012 and 2021. Risk factors for IVR were identified using Cox proportional hazards regression models, and optimal cystoscopic intervals were evaluated through hypothetical surveillance models. Gap risk ratios were calculated to assess the risk of delayed IVR detection, stratified by the presence or absence of identified risk factors. RESULTS: The median follow-up duration was 28 months, and IVR occurred in 38.0% of patients. Significant risk factors included a history of bladder cancer, positive voided cytology, and preoperative ureteroscopy. Kaplan-Meier curves revealed significantly worse IVR-free survival in patients with 1 or more risk factors (P < .001). Gap risk ratio analysis supported frequent surveillance during the first postoperative year, with tailored intervals thereafter. For patients without risk factors, surveillance every 3 months during the first year, every 6 months during the second year, and annually thereafter was optimal. For patients with risk factors, surveillance every 3 months during the first year, every 6 months for the next 2 years, and annually thereafter was recommended. CONCLUSION: Tailored cystoscopic surveillance schedules based on IVR risk factors optimize recurrence detection while minimizing procedural burden. These findings provide an evidence-based framework for individualized surveillance strategies in patients with UTUC following nephroureterectomy. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Koike, Yuhei AU - Koike Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Electronic address: furabe0809@gmail.com. FAU - Muramoto, Katsuki AU - Muramoto K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Goto, Yuma AU - Goto Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Imai, Yu AU - Imai Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Atsuta, Mahito AU - Atsuta M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Onuma, Hajime AU - Onuma H AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Aikawa, Koichi AU - Aikawa K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tashiro, Kojiro AU - Tashiro K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Teoh, Jeremy AU - Teoh J AD - Department of Surgery, S.H. Ho Urology Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Yanada, Brendan A AU - Yanada BA AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Surgery, The University of Melbourne, Victoria, Australia. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yamamoto, Toshihiro AU - Yamamoto T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Furuta, Akira AU - Furuta A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yamada, Hiroki AU - Yamada H AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. CN - JIKEI-YAYOI Collaborative Group LA - eng PT - Journal Article DEP - 20250411 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Middle Aged MH - *Neoplasm Recurrence, Local/epidemiology/diagnosis MH - *Cystoscopy/methods/standards MH - Risk Factors MH - *Ureteral Neoplasms/surgery/pathology MH - *Kidney Neoplasms/surgery/pathology MH - *Urinary Bladder Neoplasms MH - Follow-Up Studies MH - Aged, 80 and over OTO - NOTNLM OT - Cystoscopic follow-up OT - Cystoscopic intervals OT - Intravesical recurrence OT - JIKEI-YAYOI collaborative group COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2025/05/11 18:57 MHDA- 2025/07/17 04:42 CRDT- 2025/05/10 22:33 PHST- 2024/12/05 00:00 [received] PHST- 2025/04/08 00:00 [revised] PHST- 2025/04/08 00:00 [accepted] PHST- 2025/07/17 04:42 [medline] PHST- 2025/05/11 18:57 [pubmed] PHST- 2025/05/10 22:33 [entrez] AID - S1558-7673(25)00055-2 [pii] AID - 10.1016/j.clgc.2025.102354 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Aug;23(4):102354. doi: 10.1016/j.clgc.2025.102354. Epub 2025 Apr 11. PMID- 40347426 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20261010 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 30 IP - 7 DP - 2025 Jul TI - Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study. PG - 1417-1425 LID - 10.1007/s10147-025-02778-2 [doi] AB - BACKGROUND: There is no definitive consensus on the necessity and impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer (NMIBC). This study aimed to evaluate the prognostic significance of lymph-node dissection in NMIBC and identify preoperative factors influencing non-urinary tract recurrence-free survival (NUTRFS). METHODS: We retrospectively analyzed data for 2674 cases of bladder cancer treated with radical cystectomy between January 2013 and December 2019 from a multicenter Japanese database; 410 patients were preoperatively diagnosed with NMIBC. Patients were divided into lymph-node dissection and non-lymph-node dissection groups, and NUTRFS and overall survival were compared as endpoints. Univariate and multivariate analyses were performed to determine NUTRFS prognostic factors. RESULTS: Lymph-node dissection was performed in 374/410 patients and not in 36/410. Compared with the lymph-node dissection group, the non-lymph-node dissection group was older, and had a lower proportion of a performance status of 0 and a higher proportion of clinical stage < T1 disease. The pathological lymph-node positivity rate in the lymph-node dissection group was 6.9%. However, lymph-node dissection did not provide a statistically significant prolonged survival. Results remained consistent after propensity score matching. Multivariate analysis revealed poor performance status and bladder neck tumors as independent risk factors for NUTRFS. Lymph-node dissection was not a significant prognostic factor in preoperatively diagnosed NMIBC. CONCLUSIONS: Routine lymph-node dissection may be unnecessary for all NMIBC cases; however, our findings suggest that this should be considered for NMIBC involving the bladder neck. CI - (c) 2025. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. taoka.rikiya@kagawa-u.ac.jp. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. FAU - Matsuda, Ayumu AU - Matsuda A AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. AD - Department of Urology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan. FAU - Kato, Minoru AU - Kato M AD - Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. AD - Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. AD - Department of Urology, Jikei University Hospital, Tokyo, Japan. FAU - Kashima, Soki AU - Kashima S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Naito, Hirohito AU - Naito H AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. AD - Department of Urology, Kurashiki Central Hospital, Okayama, Japan. FAU - Murakami, Yoji AU - Murakami Y AD - Department of Urology, Graduate School of Life Science, Kumamoto University, Kumamoto, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Daizumoto, Kei AU - Daizumoto K AD - Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Hayashi, Takuji AU - Hayashi T AD - Department of Urology, Osaka International Cancer Institute, Osaka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. AD - Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. FAU - Sugino, Yusuke AU - Sugino Y AD - Department of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin General Hospital, Fukuoka, Japan. FAU - Yamaguchi, Noriya AU - Yamaguchi N AD - Department of Urology, Faculty of Medicine, Tottori University, Tottori, Japan. FAU - Yamamoto, Shingo AU - Yamamoto S AD - Department of Urology, Hyogo Medical University, Hyogo, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Katsushika Medical Center, Tokyo, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. FAU - Nakanishi, Shotaro AU - Nakanishi S AD - Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan. FAU - Sawada, Atsuro AU - Sawada A AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Nishihara, Kiyoaki AU - Nishihara K AD - Department of Urology, Kurume University School of Medicine, Fukuoka, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan. FAU - Tatarano, Shuichi AU - Tatarano S AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Wada, Koichiro AU - Wada K AD - Department of Urology, Faculty of Medicine, Shimane University, Shimane, Japan. FAU - Sekito, Sho AU - Sekito S AD - Department of Urology, Aichi Cancer Center Hospital, Aichi, Japan. AD - Department of Nephro-urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. FAU - Maruyama, Ryo AU - Maruyama R AD - Department of Urology, Niigata University Graduate School of Medicine, Niigata, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. CN - Japan Urological Oncology Group LA - eng GR - 22K09494/Japan Society for the Promotion of Science/ PT - Journal Article PT - Multicenter Study DEP - 20250510 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 RN - Japanese people SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Female MH - Retrospective Studies MH - *Lymph Node Excision/methods MH - *Cystectomy/methods MH - Aged MH - Middle Aged MH - Japan MH - Prognosis MH - Lymphatic Metastasis MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Lymph Nodes/pathology/surgery MH - Non-Muscle Invasive Bladder Neoplasms MH - East Asian People OTO - NOTNLM OT - Lymph-node dissection OT - Non-muscle-invasive bladder cancer OT - Positivity rate OT - Radical cystectomy OT - Survival COIS- Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: This study was approved by the Institutional Review Board of Kagawa University (Approval No. 2021-140). The procedures used in this study adhere to the tenets of the Declaration of Helsinki and later amendments, and all methods were performed in accordance with the relevant guidelines and regulations. Informed consent: Informed consent was obtained using an opt-out method. The requirement to obtain written patient consent was waived, because this was a retrospective review of medical data for procedures that were covered by national health insurance. EDAT- 2025/05/11 00:46 MHDA- 2025/06/24 18:30 CRDT- 2025/05/10 11:27 PHST- 2025/03/13 00:00 [received] PHST- 2025/04/24 00:00 [accepted] PHST- 2025/06/24 18:30 [medline] PHST- 2025/05/11 00:46 [pubmed] PHST- 2025/05/10 11:27 [entrez] AID - 10.1007/s10147-025-02778-2 [pii] AID - 10.1007/s10147-025-02778-2 [doi] PST - ppublish SO - Int J Clin Oncol. 2025 Jul;30(7):1417-1425. doi: 10.1007/s10147-025-02778-2. Epub 2025 May 10. PMID- 40340993 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20250509 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 78 IP - 3 DP - 2025 Apr TI - Evaluation of the EMT Markers SNAIL-SLUG and TWIST in Urothelial Carcinoma of the Bladder: A Retrospective Study. PG - 289-295 LID - 10.56434/j.arch.esp.urol.20257803.39 [doi] AB - BACKGROUND: Bladder cancer, primarily urothelial carcinoma, is an important global health issue given its high recurrence and poor prognosis. Tumour invasion into the muscularis propria is a crucial prognostic indicator, distinguishing muscle-invasive bladder carcinoma (MIBC) from non-muscle-invasive carcinoma. Epithelial-mesenchymal transition (EMT) promotes tumour aggressiveness and metastasis and is marked by key transcription factors, such as SNAIL, SLUG and TWIST. This study investigates the association between the expression of EMT markers and histopathological features of bladder carcinoma. MATERIALS AND METHODS: This retrospective study included 36 newly diagnosed cases of urothelial carcinoma at a tertiary care centre. Immunohistochemistry was conducted to assess SNAIL-SLUG and TWIST expression. Scoring was performed on the basis of staining intensity and extent. Statistical analysis was conducted to evaluate the associations amongst EMT markers, tumour grade, muscle invasion and clinical stage. RESULTS: MIBC was present in 58.3% of cases, with 80.6% of cases having high-grade tumours. TWIST expression was significantly higher in MIBC (p = 0.0001) and high-grade tumours (p = 0.03), particularly in advanced T-stages, than in other tumours. SNAIL-SLUG expression was significantly associated with muscle invasion (p = 0.005) but not with tumour grade. EMT markers were not correlated with lymphovascular invasion. CONCLUSIONS: Elevated TWIST expression is correlated with high-grade and muscle-invasive urothelial carcinoma, suggesting its prognostic importance. CI - (c) 2025 The Author(s). FAU - Khan, Adil Aziz AU - Khan AA AD - Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, 110029 New Delhi, India. FAU - Ahluwalia, Charanjeet AU - Ahluwalia C AD - Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, 110029 New Delhi, India. FAU - Khurana, Ridam AU - Khurana R AD - Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, 110029 New Delhi, India. FAU - Ahuja, Sana AU - Ahuja S AD - Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, 110029 New Delhi, India. LA - eng PT - Journal Article PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Twist-Related Protein 1) RN - 0 (Snail Family Transcription Factors) RN - 0 (TWIST1 protein, human) RN - 0 (SNAI1 protein, human) RN - 0 (Nuclear Proteins) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/chemistry MH - Retrospective Studies MH - *Twist-Related Protein 1/biosynthesis/analysis MH - *Snail Family Transcription Factors/biosynthesis/analysis MH - *Epithelial-Mesenchymal Transition MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/pathology/metabolism/chemistry MH - *Nuclear Proteins/biosynthesis/analysis MH - *Biomarkers, Tumor/analysis/biosynthesis MH - Aged, 80 and over OTO - NOTNLM OT - SLUG OT - SNAIL OT - TWIST OT - epithelial-mesenchymal transition OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2025/05/09 12:36 MHDA- 2025/05/09 18:34 CRDT- 2025/05/09 11:22 PHST- 2025/05/09 18:34 [medline] PHST- 2025/05/09 12:36 [pubmed] PHST- 2025/05/09 11:22 [entrez] AID - 1745979500286-1680059286 [pii] AID - 10.56434/j.arch.esp.urol.20257803.39 [doi] PST - ppublish SO - Arch Esp Urol. 2025 Apr;78(3):289-295. doi: 10.56434/j.arch.esp.urol.20257803.39. PMID- 40340174 OWN - NLM STAT- MEDLINE DCOM- 20250918 LR - 20250922 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 4 DP - 2025 Aug TI - Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. PG - 1041-1049 LID - S2588-9311(25)00115-4 [pii] LID - 10.1016/j.euo.2025.04.020 [doi] AB - BACKGROUND AND OBJECTIVE: A growing body of evidence suggests that the intensity of current follow-up in non-muscle-invasive bladder cancer (NMIBC) patients greatly exceeds clinical necessities. The UroFollow trial investigated the diagnostic accuracy of marker-based follow-up in patients with low/intermediate-risk NMIBC against the standard of care (SOC) for noninferiority (margin: <20%). METHODS: Patients with Ta low- and high-grade (G1-2) NMIBC were randomized to the SOC or 6-monthly marker-based follow-up (algorithm comprising urine markers and ultrasound; marker-based surveillance regimen [MA]). After a negative 3-mo cystoscopy (white light cystoscopy [WLC]), only patients with a positive algorithm underwent WLC in the MA. End-of-study WLC was recommended at 3 yr to recurrence-free patients. Simultaneously, several innovative urine markers were examined. KEY FINDINGS AND LIMITATIONS: In total, 214 patients were randomized to the SOC (n = 109) and MA (n = 105). The median follow-up was 2.4 yr; 30 and 29 cases of tumor recurrence were diagnosed in the SOC and MA arms, respectively. Sensitivity was 96.5% versus 81.5% (p = 0.1), with one and five Ta low-grade tumors being overlooked in the SOC and MA patients, respectively. No tumor progressing in stage or grade was missed. A total of 589 WLC procedures were performed in the SOC and 148 in the MA arm (p < 0.001). Among five other markers (ADX-Bladder, CellDetect, Bladder EpiCheck, UBC rapid, and Xpert bladder cancer monitor [BC-M]), Bladder EpiCheck and the Xpert BC-M showed similar performance to the algorithm. CONCLUSIONS AND CLINICAL IMPLICATIONS: UroFollow is the first urine marker-based randomized trial in low/intermediate-risk NMIBC patients. We conclude that 6-monthly marker-based follow-up after negative 3-mo WLC is safe in this cohort. Results of contemporary urine markers suggest that their potential for use in marker-based surveillance, however, requires prospective confirmation. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Schmitz-Drager, Bernd J AU - Schmitz-Drager BJ AD - Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany; Urologie 24, St. Theresien Hospital, Nurnberg, Germany. Electronic address: bernd_sd@yahoo.de. FAU - Bismarck, Ekkehardt AU - Bismarck E AD - Urologie 24, St. Theresien Hospital, Nurnberg, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany. FAU - von Landenberg, Nicolas AU - von Landenberg N AD - Department of Urology, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology, Marienhospital Herne, Ruhr-University Bochum, Bochum, Germany. FAU - Jahn, Daniela AU - Jahn D AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - Kernig, Karoline AU - Kernig K AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - Hakenberg, Oliver W AU - Hakenberg OW AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - Goebell, Peter J AU - Goebell PJ AD - Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany. FAU - Hennenlotter, Jorg AU - Hennenlotter J AD - Department of Urology, Eberhard-Karls-University, Tubingen, Germany. FAU - Erne, Eva AU - Erne E AD - Department of Urology, Eberhard-Karls-University, Tubingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls-University, Tubingen, Germany. FAU - Rowinski, Maciej AU - Rowinski M AD - IGES Institute, Berlin, Germany. FAU - Schiffhorst, Guido AU - Schiffhorst G AD - IGES Institute, Berlin, Germany. FAU - Baranek, Thomas AU - Baranek T AD - Department of Clinical Research, University of Applied Sciences and Arts, Hannover, Germany; LaNova Consulting s.r.o. Jachymov, Czech Republic. FAU - Benderska-Soder, Natalya AU - Benderska-Soder N AD - Urologie 24, St. Theresien Hospital, Nurnberg, Germany. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20250507 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/diagnosis/diagnostic imaging MH - *Cystoscopy/methods MH - Male MH - Female MH - Aged MH - Prospective Studies MH - Middle Aged MH - *Biomarkers, Tumor/urine MH - Ultrasonography MH - Follow-Up Studies MH - Neoplasm Recurrence, Local/urine OTO - NOTNLM OT - Intermediate risk OT - Low risk OT - Non-muscle-invasive bladder cancer OT - Randomized controlled trial OT - Surveillance OT - Urine markers EDAT- 2025/05/09 11:47 MHDA- 2025/09/19 00:36 CRDT- 2025/05/08 22:09 PHST- 2024/12/03 00:00 [received] PHST- 2025/04/05 00:00 [revised] PHST- 2025/04/22 00:00 [accepted] PHST- 2025/09/19 00:36 [medline] PHST- 2025/05/09 11:47 [pubmed] PHST- 2025/05/08 22:09 [entrez] AID - S2588-9311(25)00115-4 [pii] AID - 10.1016/j.euo.2025.04.020 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):1041-1049. doi: 10.1016/j.euo.2025.04.020. Epub 2025 May 7. PMID- 40337218 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 5 DP - 2025 May TI - Outcomes in BCG failure: Outcome from a single centre UK experience. PG - e70025 LID - 10.1002/bco2.70025 [doi] LID - e70025 AB - OBJECTIVE: To describe real-world outcomes of patients with BCG failure undergoing bladder-sparing treatments (BSTs) vs radical cystectomy in the UK. PATIENTS AND METHODS: A single institution audit was conducted at a tertiary bladder cancer referral service (UCLH, London, UK). Patients with BCG failure treated between January 2017 and September 2022 were included. BSTs included endoscopic surveillance, hyperthermic mitomycin and further BCG. The primary outcome was event free survival (EFS). Complete response (CR) rate and duration of response (DoR) were investigated in patients undergoing BST. The secondary outcomes were 3- and 5-year cancer-specific (CSS) and overall survival (OS). RESULTS: A total of 112 patients were included: 30% (34/112), 32% (36/112) and 27% (30/112) had BCG unresponsive, exposed and intolerant disease and 11% (12/112) had progressed to muscle invasive disease (MIBC).In the BCG unresponsive and exposed groups, 79% (27/34) and 72% (26/36) underwent RC, with the remaining receiving BSTs. Comparing RC vs BST in BCG unresponsive and exposed groups combined, there was a significantly poorer EFS in the BST group (p < 0.001); 35.3% (6/17) patients transitioned to second-line BST due to recurrence or intolerance and a further 50% (3/6) transitioned a third line BST. There was no significant difference in CSS or OS rates. In BCG intolerance, the EFS rate was 90% as three patients experienced high-grade recurrence and underwent RC. There were no cancer-related deaths. In MIBC group, 5/12 presented with metastatic disease and 3- and 5-year CSS rates was 66% and 0%. CONCLUSION: This data reports real-world practice in a UK centre. BSTs in BCG unresponsive and exposed disease are supported as an alternative to RC providing the increased risk of recurrence is accepted. Additionally, consideration of formal guidance supporting BST is needed in BCG intolerance, which appears to have an excellent outcome in a cohort managed with endoscopic surveillance. Upstaging to MIBC remains a poor prognostic factor and is key to improving survival outcomes in BCG failure. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Day, Elizabeth AU - Day E AUID- ORCID: 0000-0002-3773-3836 AD - Department of Urology University College London Hospital NHS Foundation Trust London UK. FAU - Aquilina, Rachel AU - Aquilina R AD - School of Medicine University College London London UK. FAU - Tzelves, Lazaros AU - Tzelves L AUID- ORCID: 0000-0003-4619-9783 AD - 2nd Department of Urology Sismanogleio Hospital, National and Kapodistrian University of Athens Greece. FAU - Sridhar, Ashwin AU - Sridhar A AUID- ORCID: 0000-0001-8070-4822 AD - Department of Urology University College London Hospital NHS Foundation Trust London UK. FAU - Ta, Anthony AU - Ta A AD - Department of Urology St Vincent's Hospital Melbourne Australia. FAU - Kelly, John AU - Kelly J AD - Department of Urology University College London Hospital NHS Foundation Trust London UK. FAU - Szabados, Bernadett AU - Szabados B AD - Department of Urology University College London Hospital NHS Foundation Trust London UK. AD - Barts Experimental Cancer Medicine Centre, Barts Cancer Institute Queen Mary University of London London UK. LA - eng PT - Journal Article DEP - 20250506 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC12056233 OTO - NOTNLM OT - BCG failure OT - Hyperthermic Mitomycin OT - bladder cancer OT - bladder sparing treatment OT - radical cystectomy COIS- Nil from any author for the purposes of this work. EDAT- 2025/05/08 11:14 MHDA- 2025/05/08 11:15 PMCR- 2025/05/06 CRDT- 2025/05/08 05:14 PHST- 2024/12/11 00:00 [received] PHST- 2025/04/08 00:00 [revised] PHST- 2025/04/12 00:00 [accepted] PHST- 2025/05/08 11:15 [medline] PHST- 2025/05/08 11:14 [pubmed] PHST- 2025/05/08 05:14 [entrez] PHST- 2025/05/06 00:00 [pmc-release] AID - BCO270025 [pii] AID - 10.1002/bco2.70025 [doi] PST - epublish SO - BJUI Compass. 2025 May 6;6(5):e70025. doi: 10.1002/bco2.70025. eCollection 2025 May. PMID- 40325235 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 May 5 TI - The role of multiparametric MRI-based VI-RADS in predicting the need for a second TURB. PG - 271 LID - 10.1007/s00345-025-05666-6 [doi] AB - PURPOSE: To prospectively evaluate the value of Vesical Imaging Reporting and Data System (VI‑RADS) prior to initial transurethral resection of the bladder (TURB) in predicting residual tumor at second TURB and subsequent prognosis of patients. METHODS: We enrolled suspected bladder cancer patients and scheduled multiparametric magnetic resonance imaging (mpMRI) of bladder for them before initial TURB. Second TURB were conducted based on initial resection reports, with comparisons made between patients with VI-RADS scores <3 and >/=3 regarding residual tumor rate, recurrence-free survival (RFS) and progression-free survival (PFS). Predictive efficacy of VI-RADS was assessed using Chi-square tests, logistic and Cox regression analyses, ROC curves, and Kaplan-Meier analyses. RESULTS: A total of 108 patients were included, and residual tumors were detected in 25.0% (27/108) of them at second TURB, with a significant difference between patients with VI-RADS score <3 and >/=3 (8/81 vs. 19/27, p <0.001). VI-RADS >/=3 demonstrated a sensitivity of 70.4%, specificity of 90.1%, positive predictive value (PPV) of 70.4%, and negative predictive value (NPV) of 90.1%. Stratified analysis showed VI-RADS achieved a NPV of 95.2% for disease-free Ta patients, while 84.6% for T1 patients. After a median follow-up of 30 months for the 92 patients, 24 experienced tumor recurrence. VI-RADS >/=3 was found to be an independent predictor of tumor recurrence (HR = 4.297, p = 0.003). CONCLUSIONS: VI-RADS >/=3 is associated with higher residual tumor rate at second TURB and higher recurrence risk. It might be an option for omitting second TURB when VI-RADS is <3, especially for Ta patients. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Jiang, Xuping AU - Jiang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. AD - Department of Urology, Yixing People's Hospital, No. 1588 Xincheng Road, 214200, Yixing, People's Republic of China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. AD - Department of Urology, Wuxi Medical Center of Nanjing Medical University, Wuxi,, People's Republic of China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Liu, Peikun AU - Liu P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Bai, Rongjie AU - Bai R AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Liu, Xiaowu AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Wang, Chenghao AU - Wang C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. yangxiao2915@163.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing, 210029, People's Republic of China. doctorlvqiang@njmu.edu.cn. LA - eng GR - 82072832, 82273152/the National Natural Science Foundation of China/ GR - JSPH-MC-2021-15, JSPH-MA-2022-5/Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project/ GR - ZDXK202219/Jiangsu Province Capability Improvement Project through Science，Technology and Education/ PT - Journal Article DEP - 20250505 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - Aged MH - *Multiparametric Magnetic Resonance Imaging MH - Prospective Studies MH - Predictive Value of Tests MH - Neoplasm, Residual/diagnostic imaging MH - *Cystectomy/methods MH - Prognosis MH - Reoperation OTO - NOTNLM OT - Bladder cancer OT - Multiparametric MRI OT - Second TURB OT - Vesical Imaging Reporting and Data System COIS- Declarations. Ethical approval: This study was approved by the institutional ethics committee of the first affiliated hospital of Nanjing medical university (approval number: 2021-SR-409) and informed consent was obtained from each patient. Competing interests: The authors declare no competing interests. EDAT- 2025/05/06 00:30 MHDA- 2025/05/06 06:30 CRDT- 2025/05/05 23:27 PHST- 2024/12/13 00:00 [received] PHST- 2025/04/23 00:00 [accepted] PHST- 2025/05/06 06:30 [medline] PHST- 2025/05/06 00:30 [pubmed] PHST- 2025/05/05 23:27 [entrez] AID - 10.1007/s00345-025-05666-6 [pii] AID - 10.1007/s00345-025-05666-6 [doi] PST - epublish SO - World J Urol. 2025 May 5;43(1):271. doi: 10.1007/s00345-025-05666-6. PMID- 40317391 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20260109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 May 3 TI - Influence of tumour location on the survival outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. PG - 261 LID - 10.1007/s00345-024-05432-0 [doi] LID - 261 AB - OBJECTIVE: To evaluate the impact of tumour location on the survival outcomes of patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). METHOD: Patients with ureteral urothelial carcinoma (UUC) or renal pelvic urothelial carcinoma (RPUC) of the Clinical Research Office of the Endourology Society (CROES)-UTUC registry were analyzed. Study outcomes included overall survival (OS), cancer-specific survival (CSS), intravesical recurrence-free survival (IRFS), and progression-free survival (PFS), which were compared using Kaplan-Meier method with log-rank test. Propensity score matching (PSM) was performed to balance the differences in tumour features between the two groups. RESULT: The UUC and RPUC groups consisted of 309 (41.9%) and 429 (58.1%) patients, respectively. RPUC group had larger tumour size (77.9% >/= 2 cm vs 67.0% in UUC, p < 0.01), and more T3/T4 tumours (36.4% vs. 22. 0%, p < 0.01). The UUC group exhibited worse PFS compared to the RPUC group ( p = 0.029 for the initial analysis and p = 0.013 after PSM). However, there were no significant differences in OS (p = 0.088 before PSM and p = 0.255 after PSM), CSS (p = 0.106 before PSM and p = 0.101 after PSM), or IRFS (p = 0.112 before PSM and p = 0.28 after PSM) between the two groups. CONCLUSION: Patients with ureteral urothelial carcinoma exhibited worse PFS compared to those with renal pelvic urothelial carcinoma. However, no significant differences were observed in OS, CSS, or IRFS between the two tumour locations. UTUC patients should be counselled about their individualized prognosis accordingly. REGISTRATION: NCT02281188. CI - (c) 2025. The Author(s). FAU - Liu, Kang AU - Liu K AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Leung, David Ka-Wai AU - Leung DK AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ko, Ivan Ching-Ho AU - Ko IC AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Horuz, Rahim AU - Horuz R AD - International School of Medicine, Istanbul Medipol University, Istanbul, Turkey. AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, University of Turin, Turin, Italy. FAU - Laguna, Pilar AU - Laguna P AD - International School of Medicine, Istanbul Medipol University, Istanbul, Turkey. AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. FAU - de la Rosette, Jean AU - de la Rosette J AD - International School of Medicine, Istanbul Medipol University, Istanbul, Turkey. AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. jeremyteoh@surgery.cuhk.edu.hk. LA - eng SI - ClinicalTrials.gov/NCT02281188 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250503 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Kidney Neoplasms/surgery/pathology/mortality MH - *Kidney Pelvis MH - *Nephroureterectomy/methods MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - *Ureteral Neoplasms/surgery/pathology/mortality PMC - PMC12049378 OTO - NOTNLM OT - Location OT - Radical Nephroureterectomy OT - Survival OT - Upper Tract Urothelial Carcinoma COIS- Declarations. Conflicts of interest: The authors declare no competing interests. Institutional review board statement: The study was approved by the institutional review board. Informed consent: Informed consents were taken from the study subjects. EDAT- 2025/05/03 22:23 MHDA- 2025/05/03 22:24 PMCR- 2025/05/03 CRDT- 2025/05/03 11:16 PHST- 2024/09/10 00:00 [received] PHST- 2024/12/31 00:00 [accepted] PHST- 2025/05/03 22:24 [medline] PHST- 2025/05/03 22:23 [pubmed] PHST- 2025/05/03 11:16 [entrez] PHST- 2025/05/03 00:00 [pmc-release] AID - 10.1007/s00345-024-05432-0 [pii] AID - 5432 [pii] AID - 10.1007/s00345-024-05432-0 [doi] PST - epublish SO - World J Urol. 2025 May 3;43(1):261. doi: 10.1007/s00345-024-05432-0. PMID- 40312900 OWN - NLM STAT- MEDLINE DCOM- 20250502 LR - 20260710 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 3 DP - 2025 May TI - Correlation of shear wave elastography with histopathological grade, tumor stage, and microvessel density in bladder cancer. PG - 207-214 LID - 10.4111/icu.20250068 [doi] AB - PURPOSE: To evaluate the pathological correlation and prognostic significance of tissue stiffness measured by shear wave elastography (SWE) in bladder cancer. MATERIALS AND METHODS: Patients with microscopic or macroscopic hematuria diagnosed with bladder tumors were included. SWE measurements were performed using a Samsung Medison RS80A Prestige ultrasonography device, with ten valid measurements taken for each tumor. Tumor specimens were collected via transurethral resection (transurethral resection of the bladder tumor) for histopathological analysis. Microvessel density (MVD) was assessed by immunohistochemical staining with anti-CD34 antibody using the hot-spot method. Correlations between tissue stiffness, MVD and tumor stage and grade were analyzed, and receiver operating characteristic (ROC) analysis determined the optimal SWE cutoff for differentiating tumor characteristics. RESULTS: A total of 65 bladder urothelial carcinoma patients were included in the study (43 high-grade, 22 low-grade). SWE and MVD were significantly higher in the high-grade group (p=0.001, p=0.002, respectively). ROC analysis showed SWE could differentiate tumor grades (area under ROC curve=0.837, p<0.001), with a cut-off of 4.25 kPa (74% sensitivity, 86% specificity). Stiffness was also higher in recurrence (p=0.007). A strong positive correlation between SWE and MVD was found (rho=0.767, p<0.001). SWE may be a reliable, non-invasive tool for assessing tumor grade and recurrence risk. CONCLUSIONS: SWE may be a reliable, non-invasive preoperative marker for bladder cancer, aiding in tumor characterization and clinical decision-making. CI - (c) The Korean Urological Association. FAU - Sahin, Gokhan AU - Sahin G AUID- ORCID: 0000-0002-1955-2679 AD - Department of Urology, Aydin State Hospital, Aydin, Turkiye. FAU - Gemalmaz, Hakan AU - Gemalmaz H AUID- ORCID: 0000-0002-2133-841X AD - Department of Urology, Aydin Adnan Menderes University Hospital, Aydin, Turkiye. FAU - Gok, Mustafa AU - Gok M AUID- ORCID: 0000-0001-7021-0984 AD - Department of Radiology, Section of Interventional Radiology, Aydin Adnan Menderes University Hospital, Aydin, Turkiye. mustafagok@yahoo.com. LA - eng GR - TPF-21054/Aydin Adnan Menderes University/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/blood supply MH - *Elasticity Imaging Techniques/methods MH - Female MH - Male MH - Neoplasm Grading MH - Aged MH - Middle Aged MH - *Microvascular Density MH - Neoplasm Staging MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/diagnostic imaging/blood supply MH - Adult MH - Prognosis PMC - PMC12058542 OTO - NOTNLM OT - Bladder cancer OT - Microvessel density OT - Sonoelastography COIS- The authors have nothing to disclose. EDAT- 2025/05/02 06:28 MHDA- 2025/05/02 06:29 PMCR- 2025/05/01 CRDT- 2025/05/02 01:33 PHST- 2025/02/18 00:00 [received] PHST- 2025/03/08 00:00 [revised] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/05/02 06:29 [medline] PHST- 2025/05/02 06:28 [pubmed] PHST- 2025/05/02 01:33 [entrez] PHST- 2025/05/01 00:00 [pmc-release] AID - 66.207 [pii] AID - 10.4111/icu.20250068 [doi] PST - ppublish SO - Investig Clin Urol. 2025 May;66(3):207-214. doi: 10.4111/icu.20250068. PMID- 40300977 OWN - NLM STAT- MEDLINE DCOM- 20260205 LR - 20260205 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 12 IP - 1 DP - 2026 Jan TI - The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis. PG - 88-95 LID - S2405-4569(25)00102-6 [pii] LID - 10.1016/j.euf.2025.04.028 [doi] AB - BACKGROUND AND OBJECTIVE: Trimodality therapy (TMT) with transurethral resection followed by radiation of the urinary bladder and chemotherapy is associated with similar long-term survival rates to radical cystectomy (RC) for well-selected patients. Nevertheless, salvage RC may become necessary in 10% of patients receiving TMT. We aimed to assess the perioperative and long-term outcomes of salvage RC after prior TMT through a large multinational cohort study. METHODS: We included patients with pure urothelial cancer of the urinary bladder. Patients undergoing salvage RC after prior TMT due to recurrence in the urinary bladder from 13 high-volume centers were matched with a propensity score analysis in a 1:1 ratio with patients without prior TMT undergoing primary RC. The two groups were adjusted for institution, age, histological status, American Society of Anesthesiologists score, and surgical technique (open or minimally invasive RC). KEY FINDINGS AND LIMITATIONS: We included 118 patients (59 per group) with a median age of 73 yr (interquartile range [IQR]: 66-79). Seven patients (11%) developed severe, grade 4 or 5 perioperative complications during RC after prior TMT. The 30- and 90-d survival rates of salvage RC after prior TMT were 93% and 91%, respectively. RC in patients with prior TMT was associated with higher blood loss by 297 ml (95% confidence interval [CI]: 73-520, p = 0.010) and higher odds of admission to the intensive care unit (odds ratio: 2.8, 95% CI: 1.2-6.7, p = 0.017) than primary RC in matched patients. At a median follow-up of 10 mo (IQR: 5-34), 29 deaths occurred in patients requiring RC after prior TMT. Prior TMT was associated with worse overall survival than primary RC (hazard ratio: 1.9, 95% CI: 1.2-4.1, p = 0.032). CONCLUSIONS AND CLINICAL IMPLICATIONS: Salvage RC after TMT and primary RC have comparable perioperative outcomes. Patients undergoing salvage RC after TMT may have worse overall survival in the long term, likely reflecting tumor biology. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. Electronic address: nikospyrgidis@gmail.com. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. FAU - Pellegrino, Francesco AU - Pellegrino F AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. FAU - Casuscelli, Jozefina AU - Casuscelli J AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Tzelves, Lazaros AU - Tzelves L AD - Second Department of Urology, Sismanoglio General Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Katsimperis, Stamatios AU - Katsimperis S AD - Second Department of Urology, Sismanoglio General Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Ciavarella, Davide AU - Ciavarella D AD - Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University of Chieti, Urology Unit, Chieti, Italy. FAU - Mir, Maria Carmen AU - Mir MC AD - Department of Urology, Hospital Universitario La Ribera, Valencia, Spain. FAU - Sokolakis, Ioannis AU - Sokolakis I AD - Second Department of Urology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Helios Klinikum Bad Saarow, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane (MHB), Brandenburg, Germany. FAU - Belinchon, Alberto Ramos AU - Belinchon AR AD - Department of Urology, Hospital Universitario General Universitario Gregorio Maranon, Madrid, Spain. FAU - Velasco, Jorge Cano AU - Velasco JC AD - Department of Urology, Hospital Universitario General Universitario Gregorio Maranon, Madrid, Spain. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Matsumoto, Shunya AU - Matsumoto S AD - Department of Urology, Institute of Science Tokyo, Tokyo, Japan. FAU - Umari, Paolo AU - Umari P AD - St. George's University Hospital, London, UK. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ming, Chris Wong Ho AU - Ming CWH AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, St. Josef Medical Center, University Medical Center Regensburg, Regensburg, Germany. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250428 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Salvage Therapy/methods MH - *Urinary Bladder Neoplasms/therapy/mortality/surgery/pathology MH - Male MH - Female MH - Aged MH - Combined Modality Therapy/methods MH - *Neoplasm Recurrence, Local/surgery/therapy MH - Propensity Score MH - Survival Rate MH - Treatment Outcome MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/therapy/mortality MH - Matched-Pair Analysis OTO - NOTNLM OT - Bladder cancer OT - Radical cystectomy OT - Urothelial carcinoma EDAT- 2025/04/30 00:31 MHDA- 2026/02/06 00:30 CRDT- 2025/04/29 21:58 PHST- 2025/01/03 00:00 [received] PHST- 2025/03/10 00:00 [revised] PHST- 2025/04/16 00:00 [accepted] PHST- 2026/02/06 00:30 [medline] PHST- 2025/04/30 00:31 [pubmed] PHST- 2025/04/29 21:58 [entrez] AID - S2405-4569(25)00102-6 [pii] AID - 10.1016/j.euf.2025.04.028 [doi] PST - ppublish SO - Eur Urol Focus. 2026 Jan;12(1):88-95. doi: 10.1016/j.euf.2025.04.028. Epub 2025 Apr 28. PMID- 40299272 OWN - NLM STAT- MEDLINE DCOM- 20250708 LR - 20250711 IS - 2211-3436 (Electronic) IS - 2211-3428 (Print) IS - 2211-3428 (Linking) VI - 48 IP - 4 DP - 2025 Aug TI - Postoperative continuous saline bladder irrigation reduces active urinary cancer cells: a prospective study in NMIBC. PG - 991-1003 LID - 10.1007/s13402-025-01059-4 [doi] AB - PURPOSE: There is a lack of clinical evidence on whether further clinical strategies are needed after TURBT combined with immediate bladder instillation. This study intends to establish a reliable quantitative assay for active urinary cancer cells (AUCC) and to investigate the clinical efficacy of continuous saline bladder irrigation (CSBI) as a feasible option by analyzing the perioperative AUCC changes in TURBT. METHODS: An AUCC assay was developed and its reliability was verified by single-cell whole genome sequencing. Bladder cancer patients (N = 324) diagnosed by cystoscopy and pathologic biopsy and control individuals (N = 92) were included from 2021 to 2023 in the study. Enrolled patients with non-muscle invasive bladder cancer (NMIBC) underwent TURBT followed by immediate bladder instillation of epirubicin, after subgroups received CSBI or not, and AUCCs were tested on the first and fifth postoperative day. The patients were followed up for two years for postoperative recurrence. RESULTS: The AUCC assay achieved good detection accuracy, with a sensitivity of 0.821 and specificity of 0.902. AUCC increased on the first day after TURBT in combination with immediate bladder instillation, regardless of whether or not the patient received CSBI. However, AUCCs decreased more rapidly on the fifth day in patients treated with CSBI, and patients with concomitant risk factors benefited more from CSBI. The two-year follow-up results showed that high-risk patients with complex surgeries could benefit significantly from CSBI. CONCLUSIONS: We pioneered a quantitative assay for AUCC and provided laboratory evidence that TURBT causes tumor cell dissemination and CSBI can be a further clinical strategy to reduce the risk of potential recurrence. CI - (c) 2025. The Author(s). FAU - Zhang, Qi AU - Zhang Q AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Du, Yanhua AU - Du Y AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Wang, Dong AU - Wang D AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Du, Gan AU - Du G AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Cao, Chuanzhen AU - Cao C AD - Department of Urology, China-Japan Friendship Hospital, Beijing, 100021, China. FAU - Yu, Xiaomin AU - Yu X AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Zhang, Xiaoli AU - Zhang X AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Xie, Peipei AU - Xie P AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Wan, Duo AU - Wan D AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Wen, Li AU - Wen L AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Shi, Hongzhe AU - Shi H AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Guan, Youyan AU - Guan Y AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Lu, Li AU - Lu L AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Bi, Xingang AU - Bi X AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Cheng, Shujun AU - Cheng S AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Zhang, Kaitai AU - Zhang K AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. zhangkt@cicams.ac.cn. FAU - Zhang, Wen AU - Zhang W AD - Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. zhangwen@cicams.ac.cn. FAU - Shou, Jianzhong AU - Shou J AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. shoujianzhong@cicams.ac.cn. AD - Beijing Key Laboratory of Urologic Cancer Cell and Gene Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. shoujianzhong@cicams.ac.cn. LA - eng PT - Journal Article DEP - 20250429 PL - Netherlands TA - Cell Oncol (Dordr) JT - Cellular oncology (Dordrecht, Netherlands) JID - 101552938 RN - 0 (Saline Solution) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Male MH - Female MH - Prospective Studies MH - *Therapeutic Irrigation/methods MH - *Saline Solution/therapeutic use/pharmacology MH - Middle Aged MH - Aged MH - *Urinary Bladder/pathology/drug effects MH - *Postoperative Care MH - Neoplasm Recurrence, Local MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12238213 OTO - NOTNLM OT - Active urinary cancer cells OT - CSBI OT - NMIBC OT - TURBT COIS- Declarations. Ethics approval and consent to participate: The study complied with all relevant ethical regulations and was approved by the Ethical Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. NGC2022C-490). All patients provided oral and written informed consent for participation and publication. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/29 12:42 MHDA- 2025/07/08 12:54 PMCR- 2025/04/29 CRDT- 2025/04/29 11:26 PHST- 2024/11/24 00:00 [received] PHST- 2025/03/22 00:00 [accepted] PHST- 2025/07/08 12:54 [medline] PHST- 2025/04/29 12:42 [pubmed] PHST- 2025/04/29 11:26 [entrez] PHST- 2025/04/29 00:00 [pmc-release] AID - 10.1007/s13402-025-01059-4 [pii] AID - 1059 [pii] AID - 10.1007/s13402-025-01059-4 [doi] PST - ppublish SO - Cell Oncol (Dordr). 2025 Aug;48(4):991-1003. doi: 10.1007/s13402-025-01059-4. Epub 2025 Apr 29. PMID- 40293462 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Apr 28 TI - Efficacy of Bacillus Calmette-Guerin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer. PG - 255 LID - 10.1007/s00345-025-05613-5 [doi] AB - PURPOSE: Sequential gemcitabine and docetaxel (Gem/Doce) therapy is increasingly regarded as a promising substitute for Bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC). This study compares the efficacy of Gem/Doce and BCG in managing Ta high-grade (TaHG) NMIBC. METHODS: Patients with TaHG NMIBC treated with Gem/Doce or BCG therapy following transurethral resection of the bladder tumor (TURBT) were analyzed. A one-year maintenance protocol when applicable. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis, and multivariate Cox regression identified predictors for recurrence and progression. RESULTS: A total of 172 patients (99 BCG, 73 Gem/Doce) were included, with longer median follow-up in the BCG group (47 vs. 20 months, p < 0.001). Progression was more frequent in the Gem/Doce group (18% vs. 4%, p = 0.003). BCG demonstrated superior 2-year RFS for any recurrence (62.3% vs. 37.9%, p = 0.018), high-grade recurrence (72.7% vs. 61.3%, p = 0.049), and 2-year PFS (97.4% vs. 83.3%, p < 0.0001). Maintenance therapy improved high-grade RFS (p = 0.019) and PFS (p = 0.033) in the Gem/Doce group but had no significant impact in the BCG group. On multivariate analysis, Gem/Doce was an independent risk factor for any recurrence (HR = 2.03, p < 0.001), high-grade recurrence (HR = 1.95, p = 0.03), and progression (HR = 13.55, p < 0.001). CONCLUSION: BCG appears to provide superior recurrence and progression control over Gem/Doce in TaHG NMIBC with a one-year maintenance protocol. Future studies should explore extended maintenance regimens, particularly for Gem/Doce. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Eraky, Ahmed AU - Eraky A AUID- ORCID: 0000-0001-6879-6058 AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. Ahmed.Eraky@mountsinai.org. FAU - Hug, Brenda AU - Hug B AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Ben-David, Reuben AU - Ben-David R AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Waingankar, Nikhil AU - Waingankar N AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Ave, New York, NY, 10029, USA. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250428 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Gemcitabine MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Male MH - *Docetaxel/administration & dosage MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Neoplasm Grading MH - *Adjuvants, Immunologic/therapeutic use MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Gemcitabine/Docetaxel OT - Risk stratification OT - Ta high-grade COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/04/28 12:30 MHDA- 2025/04/28 12:31 CRDT- 2025/04/28 11:13 PHST- 2025/01/17 00:00 [received] PHST- 2025/03/31 00:00 [accepted] PHST- 2025/04/28 12:31 [medline] PHST- 2025/04/28 12:30 [pubmed] PHST- 2025/04/28 11:13 [entrez] AID - 10.1007/s00345-025-05613-5 [pii] AID - 10.1007/s00345-025-05613-5 [doi] PST - epublish SO - World J Urol. 2025 Apr 28;43(1):255. doi: 10.1007/s00345-025-05613-5. PMID- 40288936 OWN - NLM STAT- MEDLINE DCOM- 20251011 LR - 20260427 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 88 IP - 5 DP - 2025 Nov TI - Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma. PG - 472-481 LID - S0302-2838(25)00210-6 [pii] LID - 10.1016/j.eururo.2025.04.008 [doi] AB - BACKGROUND AND OBJECTIVE: Divergent differentiation and histologic subtypes are common findings in urothelial carcinoma (UC). Clinically relevant genomic alterations and oncogenic drivers of individual subtypes remain poorly defined. We characterized surgical outcomes and the genomic landscape of UC with aberrant histology (UCAH), with a focus on biomarkers and targetable alterations. METHODS: The clinical cohort comprised 3052 patients who underwent radical cystectomy (RC) with or without neoadjuvant chemotherapy. Targeted exon sequencing was performed for a genomic cohort of 1060 bladder tumors from RC or transurethral resection specimens. We characterized the frequency of oncogenic mutations and targetable alterations, and the tumor mutational burden (TMB) of each subtype. We defined the clonal relatedness of morphologically distinct regions of tumors with mixed histology. KEY FINDINGS AND LIMITATIONS: Patients with plasmacytoid, micropapillary, sarcomatoid, or mixed-histology tumors had worse cancer-specific survival than patients with pure urothelial histology. ERBB2, FGFR3, and PTEN alterations were most frequent in micropapillary, nested/squamous, and sarcomatoid UC, respectively. TMB was highest in plasmacytoid, neuroendocrine, and micropapillary tumors. Regions of mixed histology had shared clonal origins, but exceptions were observed. The retrospective design and potential for selection bias are limitations of our study. CONCLUSIONS AND CLINICAL IMPLICATIONS: UCAH tumors have distinct patterns of genomic alterations, which may be targetable via novel therapies and have implications for clinical trial inclusion. Biomarker-driven systemic therapy should be explored in patients with histologic subtypes that are associated with worse clinical outcomes. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Chu, Carissa E AU - Chu CE AD - Department of Urology, University of California, San Francisco, CA, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Chen, Ziyu AU - Chen Z AD - Physiology, Biophysics and Systems Biology Program, Weill Cornell Medicine, New York, NY, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Whiting, Karissa AU - Whiting K AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Lenis, Andrew T AU - Lenis AT AD - Department of Urology, Columbia University, New York, NY, USA. FAU - Clinton, Timothy N AU - Clinton TN AD - Department of Urology, Brigham and Women's Hospital, Boston, MA, USA. FAU - Rammal, Rayan AU - Rammal R AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Ozcan, Gamze Gokturk AU - Ozcan GG AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Akbulut, Dilara AU - Akbulut D AD - Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. FAU - Basar, Merve AU - Basar M AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Chen, Jie-Fu AU - Chen JF AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Chen, Ying-Bei AU - Chen YB AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Gopalan, Anuradha AU - Gopalan A AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Fine, Samson W AU - Fine SW AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Tickoo, Satish K AU - Tickoo SK AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Arcila, Maria AU - Arcila M AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Brannon, A Rose AU - Brannon AR AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Berger, Michael F AU - Berger MF AD - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Cha, Eugene K AU - Cha EK AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Goh, Alvin C AU - Goh AC AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Donahue, Timothy F AU - Donahue TF AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Bajorin, Dean F AU - Bajorin DF AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Teo, Min Yuen AU - Teo MY AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Iyer, Gopa AU - Iyer G AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Reuter, Victor E AU - Reuter VE AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Sarungbam, Judy AU - Sarungbam J AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Solit, David B AU - Solit DB AD - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: alahmadh@mskcc.org. LA - eng GR - R01 CA233899/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - T32 CA082088/CA/NCI NIH HHS/United States GR - K12 CA260225/CA/NCI NIH HHS/United States GR - P01 CA221757/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250426 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - 0 (Biomarkers, Tumor) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 3.1.3.67 (PTEN protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/therapy/mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - Mutation MH - Cystectomy MH - *Carcinoma, Transitional Cell/genetics/pathology/therapy/mortality MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - *Biomarkers, Tumor/genetics MH - Treatment Outcome MH - PTEN Phosphohydrolase/genetics MH - Genetic Heterogeneity MH - Erb-b2 Receptor Tyrosine Kinases/genetics MH - Neoadjuvant Therapy MH - Genomics MH - Retrospective Studies MH - Aged, 80 and over MH - Urothelium/pathology PMC - PMC12353162 MID - NIHMS2074106 OTO - NOTNLM OT - Divergent differentiation OT - Histologic subtype OT - Neoadjuvant chemotherapy OT - Next-generation sequencing OT - Urothelial carcinoma OT - Variant histology EDAT- 2025/04/28 00:27 MHDA- 2025/10/12 00:33 PMCR- 2026/04/26 CRDT- 2025/04/27 21:59 PHST- 2024/06/07 00:00 [received] PHST- 2025/03/05 00:00 [revised] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/10/12 00:33 [medline] PHST- 2025/04/28 00:27 [pubmed] PHST- 2025/04/27 21:59 [entrez] PHST- 2026/04/26 00:00 [pmc-release] AID - S0302-2838(25)00210-6 [pii] AID - 10.1016/j.eururo.2025.04.008 [doi] PST - ppublish SO - Eur Urol. 2025 Nov;88(5):472-481. doi: 10.1016/j.eururo.2025.04.008. Epub 2025 Apr 26. PMID- 40287765 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250429 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 23 IP - 1 DP - 2025 Apr 26 TI - Current laser application in En bloc resection of bladder tumor- a narrative literature review. PG - 165 LID - 10.1186/s12957-025-03815-0 [doi] LID - 165 AB - At present, laser en bloc resection of bladder tumor (ERBT) has attracted great interest with potential superiority to transurethral resection of bladder tumor (TURBT). It has several advantages, including complete resection, intact specimen for accurate histologic assessment, avoiding fragmentation and tumor seeding, preventing obturator nerve reflex, and reduction of inflammatory response. Several types of lasers have been studied in the application of ERBT, for example, holmium laser, green-light laser, thulium laser, diode laser. This paper reviews current literature concerning the characteristics of these types of laser, the surgical technique and procedures of laser ERBT with its advantages and limitations, and future directions in clinical development, aiming to display the status quo of these techniques in clinical practice. CI - (c) 2025. The Author(s). FAU - Gao, Wenbo AU - Gao W AD - Department of Urology, Ningbo Urology and Nephrology Hospital, N0. 999, Road Qianhe, Ningbo City, Zhejiang Province, 315100, China. gwbmdoc@foxmail.com. LA - eng PT - Journal Article PT - Review DEP - 20250426 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Laser Therapy/methods/instrumentation MH - *Cystectomy/methods MH - Prognosis MH - Lasers, Solid-State/therapeutic use PMC - PMC12034164 OTO - NOTNLM OT - Bladder cancer OT - En bloc OT - Laser resection OT - Transurethral resection COIS- Declarations. Ethics approval: Not applicable. Consent to participate: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/27 03:14 MHDA- 2025/04/27 06:28 PMCR- 2025/04/26 CRDT- 2025/04/26 23:39 PHST- 2025/03/02 00:00 [received] PHST- 2025/04/15 00:00 [accepted] PHST- 2025/04/27 06:28 [medline] PHST- 2025/04/27 03:14 [pubmed] PHST- 2025/04/26 23:39 [entrez] PHST- 2025/04/26 00:00 [pmc-release] AID - 10.1186/s12957-025-03815-0 [pii] AID - 3815 [pii] AID - 10.1186/s12957-025-03815-0 [doi] PST - epublish SO - World J Surg Oncol. 2025 Apr 26;23(1):165. doi: 10.1186/s12957-025-03815-0. PMID- 40287344 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260726 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 6 DP - 2025 Dec TI - Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer. PG - 1461-1465 LID - S2588-9311(25)00100-2 [pii] LID - 10.1016/j.euo.2025.04.006 [doi] AB - Intravesical bacillus Calmette-Guerin (BCG) is considered first-line adjuvant therapy for high-risk or high-grade non-muscle-invasive bladder cancer (NMIBC). Recently, sequential intravesical gemcitabine and docetaxel (Gem/Doce) has emerged as a promising alternative to intravesical BCG. Biomarkers to select the optimal treatment regimen could facilitate clinical decision-making. The Computational Histologic Artificial Intelligence (CHAI) platform was previously used to develop an artificial intelligence-augmented histologic assay (CHAI biomarker) that identified patients with NMIBC at an increased risk of recurrence and progression events following BCG treatment. In this study, we assessed use of the CHAI biomarker among patients with treatment-naive high-grade NMIBC who received intravesical BCG or Gem/Doce. Among patients with the presence of the CHAI biomarker, those treated with BCG had a 24-mo high-grade recurrence-free survival (HG-RFS) rate of 56% (95% confidence interval [CI] 43-73%) and those treated with Gem/Doce had an HG-RFS rate of 90% (95% CI 79-100%; hazard ratio [HR] 5.4, 95% CI 1.6-18.3, p = 0.007). Among patients with an absence of the CHAI biomarker, those treated with BCG or Gem/Doce had no significant difference in HG-RFS (HR 1.3, 95% CI 0.6-2.6, p = 0.5). The interaction term between the CHAI biomarker and the treatment type was significant (p = 0.029), indicating an association between the biomarker and the clinical outcome that is dependent on the treatment received. This study suggests that the CHAI biomarker predicts which specific high-grade NMIBC patients are less likely to benefit from BCG and may benefit from alternative treatments including, potentially, Gem/Doce. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, Rutgers Cancer Institute, New Brunswick, NJ, USA. Electronic address: vignesh.packiam@rutgers.edu. FAU - McElree, Ian M AU - McElree IM AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Department of Urology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Nimgaonkar, Vivek AU - Nimgaonkar V AD - Valar Labs, Palo Alto, CA, USA. FAU - Krishna, Viswesh AU - Krishna V AD - Valar Labs, Palo Alto, CA, USA. FAU - Kim, Joon Kyung AU - Kim JK AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Allison, Derek B AU - Allison DB AD - Department of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Richards, Jordan R AU - Richards JR AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Anand Rajan, K D AU - Anand Rajan KD AD - Department of Pathology, University of Iowa, Iowa City, IA, USA. FAU - Chen, Stephanie J AU - Chen SJ AD - Department of Pathology, University of Iowa, Iowa City, IA, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Urology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Zhang, Haochen AU - Zhang H AD - Valar Labs, Palo Alto, CA, USA. FAU - Watson, Drew AU - Watson D AD - Valar Labs, Palo Alto, CA, USA. FAU - Vrabac, Damir AU - Vrabac D AD - Valar Labs, Palo Alto, CA, USA. FAU - Abuzeid, Waleed M AU - Abuzeid WM AD - Valar Labs, Palo Alto, CA, USA. FAU - Joshi, Anirudh AU - Joshi A AD - Valar Labs, Palo Alto, CA, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States GR - P30 CA086862/CA/NCI NIH HHS/United States GR - P30 CA177558/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250425 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Biomarkers, Tumor) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Gemcitabine MH - Deoxycytidine/analogs & derivatives/administration & dosage MH - Female MH - Male MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Aged MH - Docetaxel/administration & dosage MH - *Artificial Intelligence MH - Middle Aged MH - Administration, Intravesical MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage MH - Biomarkers, Tumor MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic/administration & dosage MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12907750 MID - NIHMS2110211 OTO - NOTNLM OT - Artificial intelligence OT - Bacillus Calmette-Guerin OT - Biomarker OT - Docetaxel OT - Gemcitabine OT - Machine learning OT - Non-muscle-invasive bladder cancer EDAT- 2025/04/27 03:14 MHDA- 2025/12/13 00:32 PMCR- 2026/02/16 CRDT- 2025/04/26 21:58 PHST- 2024/11/18 00:00 [received] PHST- 2025/03/15 00:00 [revised] PHST- 2025/04/09 00:00 [accepted] PHST- 2025/12/13 00:32 [medline] PHST- 2025/04/27 03:14 [pubmed] PHST- 2025/04/26 21:58 [entrez] PHST- 2026/02/16 00:00 [pmc-release] AID - S2588-9311(25)00100-2 [pii] AID - 10.1016/j.euo.2025.04.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Dec;8(6):1461-1465. doi: 10.1016/j.euo.2025.04.006. Epub 2025 Apr 25. PMID- 40280776 OWN - NLM STAT- MEDLINE DCOM- 20250613 LR - 20260120 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 88 IP - 1 DP - 2025 Jul TI - Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. PG - 23-30 LID - S0302-2838(25)00191-5 [pii] LID - 10.1016/j.eururo.2025.03.018 [doi] AB - BACKGROUND AND OBJECTIVE: Urinary biomarker tests have long been suggested as a noninvasive alternative to current cystoscopy-based follow-up of high-grade non-muscle-invasive bladder cancer (NMIBC) to reduce both morbidity and costs. However, the clinical impact of urinary biomarker tests remains uncertain owing to a lack of randomized trials. METHODS: In this randomized noninferiority trial, we evaluated the impact of alternating a urinary biomarker test (Xpert Bladder Cancer Monitor, XBCM) with cystoscopy in the intervention arm as a method for reducing the number of cystoscopies during follow-up of patients with high-grade NMIBC. Patients in the control arm underwent cystoscopy at all follow-up visits. The primary outcome was comparison of the risk of recurrence-free survival in terms of high-grade NMIBC, muscle-invasive bladder cancer, or metastatic urothelial carcinoma between the study arms. KEY FINDINGS AND LIMITATIONS: In total, 43 high-grade recurrences were detected, 22 in the intervention arm and 21 in the control arm. The risk difference for high-grade recurrence between the study arms was 0.08% (95% confidence interval -7.2% to 7.4%). Two pTa high-grade recurrences were missed by the XBCM test. The number of cystoscopies performed was 1029 cystoscopies in the control arm and 445 in the intervention arm. An anticipatory positive effect was observed, with XBCM positivity observed before recurrences were visible on cystoscopy. The findings are limited by a lower-than-expected rate of recurrence in both study arms. CONCLUSIONS AND CLINICAL IMPLICATIONS: Alternating cystoscopy with XBCM reduced the number of follow-up cystoscopies for high-grade NMIBC without affecting detection of any recurrence. The long-term oncological safety of this strategy needs to be validated over longer follow-up. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Dreyer, Thomas AU - Dreyer T AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: thomas.dreyer@rm.dk. FAU - Brandt, Simone AU - Brandt S AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Fabrin, Knud AU - Fabrin K AD - Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Azawi, Nessn AU - Azawi N AD - Department of Urology, Zeeland University Hospital, Roskilde, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Vasquez, Juan Luis AU - Vasquez JL AD - Department of Urology, Zeeland University Hospital, Roskilde, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Ernst, Andreas AU - Ernst A AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Public Health, Aarhus University, Aarhus, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Godstrup Hospital, Godstrup, Denmark. LA - eng PT - Equivalence Trial PT - Journal Article PT - Randomized Controlled Trial DEP - 20250425 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/urine/diagnosis MH - *Cystoscopy MH - *Biomarkers, Tumor/urine MH - Male MH - Female MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/urine/diagnosis MH - Neoplasm Grading MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Cystoscopy OT - Follow-up OT - Non-muscle-invasive bladder cancer OT - Urinary biomarker test EDAT- 2025/04/26 16:17 MHDA- 2025/06/14 16:46 CRDT- 2025/04/25 22:00 PHST- 2024/09/30 00:00 [received] PHST- 2025/02/20 00:00 [revised] PHST- 2025/03/18 00:00 [accepted] PHST- 2025/06/14 16:46 [medline] PHST- 2025/04/26 16:17 [pubmed] PHST- 2025/04/25 22:00 [entrez] AID - S0302-2838(25)00191-5 [pii] AID - 10.1016/j.eururo.2025.03.018 [doi] PST - ppublish SO - Eur Urol. 2025 Jul;88(1):23-30. doi: 10.1016/j.eururo.2025.03.018. Epub 2025 Apr 25. PMID- 40278931 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20261009 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Apr 25 TI - Acidic urine as a prognostic factor after intravesical Bacillus Calmette-Guerin induction therapy for nonmuscle-invasive bladder cancer. PG - 247 LID - 10.1007/s00345-025-05648-8 [doi] AB - PURPOSE: To investigate the effect of acidic urine (pH 5.5) urine pH groups. RESULTS: Patients with acidic urine showed higher fasting plasma glucose levels (p = 0.017), higher serum uric acid level (p = 0.011), lower estimated glomerular filtration rates (p = 0.022), and higher rates of abnormal urinary cytology (p = 0.021), but no significant differences were observed in context of adverse clinicopathological features. During a median follow-up period of 56 months, the acidic urine group had a lower recurrence-free survival rate than the high urine pH group (p = 0.009). In terms of disease progression, there was no difference according to urine pH status. CONCLUSION: Acidic urine was associated with disease recurrence after intravesical BCG induction for NMIBC, despite no differences in adverse clinicopathological features according to urine acidity. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ryu, Hoyoung AU - Ryu H AD - Department of Urology, Ewha Womans University Mokdong Hospital, Seoul, Korea. FAU - Lee, Sangchul AU - Lee S AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Song, Sang Hun AU - Song SH AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Lee, Hakmin AU - Lee H AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Hong, Sung Kyu AU - Hong SK AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Byun, Seok-Soo AU - Byun SS AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Song, Byeongdo AU - Song B AD - Department of Urology, Hanyang University College of Medicine, Seoul, Korea. dreamofkgr@naver.com. AD - Department of Urology, Hanyang University Guri Hospital, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do, 11923, Republic of Korea. dreamofkgr@naver.com. LA - eng PT - Journal Article DEP - 20250425 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/drug therapy/therapy MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Male MH - Female MH - Aged MH - Administration, Intravesical MH - *Adjuvants, Immunologic/administration & dosage/therapeutic use MH - Middle Aged MH - Hydrogen-Ion Concentration MH - Prognosis MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/urine/epidemiology MH - *Urine/chemistry MH - Aged, 80 and over MH - Disease Progression OTO - NOTNLM OT - Intravesical BCG induction OT - Intravesical recurrence OT - Nonmuscle-invasive bladder cancer OT - Urine pH OT - Urothelial carcinoma COIS- Declarations. Ethical approval: The Institutional Review Board (IRB) of Seoul National University Bundang Hospital approved this study (IRB No. B-2410-933-106). Our research does not include animals as subjects. All procedures performed in studies involving human participants were according to the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Competing interests: The authors declare no competing interests. EDAT- 2025/04/25 13:45 MHDA- 2025/04/25 13:46 CRDT- 2025/04/25 11:16 PHST- 2025/01/12 00:00 [received] PHST- 2025/04/19 00:00 [accepted] PHST- 2025/04/25 13:46 [medline] PHST- 2025/04/25 13:45 [pubmed] PHST- 2025/04/25 11:16 [entrez] AID - 10.1007/s00345-025-05648-8 [pii] AID - 10.1007/s00345-025-05648-8 [doi] PST - epublish SO - World J Urol. 2025 Apr 25;43(1):247. doi: 10.1007/s00345-025-05648-8. PMID- 40274464 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20260916 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 43 IP - 8 DP - 2025 Aug TI - National complication and cost burden of transurethral resection of bladder tumor for bladder cancer. PG - 469.e1-469.e11 LID - S1078-1439(25)00085-7 [pii] LID - 10.1016/j.urolonc.2025.03.004 [doi] AB - BACKGROUND: Transurethral resection of bladder tumor (TURBT) is the gold standard for the diagnosis and treatment of bladder tumors. Although it is a widely-performed urologic surgery, the complication rate and cost burden of TURBT is poorly understood. This study aims to assess factors contributing to increased complications and healthcare cost burden of TURBT. METHODS: In this population-based cohort study using Survival Epidemiology, and End Results-Medicare (SEER-Medicare) registry, patients with bladder urothelial carcinoma (UC) who underwent a TURBT between 2004 and 2015 were queried to assess post-TURBT complications and costs. Multivariable logistic regression modeling identified factors associated with 30-day complications. Multivariable linear regression models compared overall costs between patients with and without a complication. RESULTS: In a cohort of 72,284 patients who underwent TURBT for UC, 31,459 (43.5%) of patients experienced at least one complication within 30 days. Factors associated with increased complications include male sex, larger higher grade/stage tumors, repeat TURBTs, concomitant stent placement, and post-TURBT chemotherapy. Having a complication after TURBT was significantly associated with increased overall Medicare cost after multivariable regression adjustment at 30 days ($7393 vs. $3934, P < 0.001), and at multiple time points up to 1 year. Total 30-day Medicare costs measured $207,094,382 (median cost of $2,865 per patient), of which 53% occurred in patients with complications. CONCLUSIONS: Complications after TURBT account for a significant proportion of the cost burden of bladder cancer care. A 30-day complication was associated with a 47% increase in per patient Medicare costs. Future studies are needed to reduce complications after TURBT. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Zhang, Jj H AU - Zhang JH AD - Department of Urology, UCLA Ronald Reagan Medical Center, Los Angeles, CA; Department of Surgery, Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, WA. FAU - Joyce, Daniel D AU - Joyce DD AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Shan, Yong AU - Shan Y AD - Department of Surgery, University of Texas Medical Branch, Galveston, TX. FAU - Fadel, Anthony AU - Fadel A AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Liao, Brian AU - Liao B AD - Department of Surgery, University of Texas Medical Branch, Galveston, TX. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, UCLA Ronald Reagan Medical Center, Los Angeles, CA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, University of Texas Medical Branch, Galveston, TX. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Sharma.Vidit@mayo.edu. LA - eng GR - HHSN261201800032C/CA/NCI NIH HHS/United States GR - HHSN261201800009C/CA/NCI NIH HHS/United States GR - K12 CA090625/CA/NCI NIH HHS/United States GR - HHSN261201800015I/CA/NCI NIH HHS/United States GR - U58 DP001056/DP/NCCDPHP CDC HHS/United States GR - HHSN261201800032I/CA/NCI NIH HHS/United States GR - HHSN261201800015C/CA/NCI NIH HHS/United States GR - HHSN261201800009I/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20250423 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/economics MH - Male MH - Female MH - Aged MH - *Postoperative Complications/economics/etiology/epidemiology MH - United States MH - *Cystectomy/methods/economics/adverse effects MH - Aged, 80 and over MH - *Cost of Illness MH - *Health Care Costs MH - Medicare/economics MH - Cohort Studies MH - Transurethral Resection of Bladder PMC - PMC13572987 MID - NIHMS2208898 OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Cost-effectiveness analysis OT - Financial toxicity OT - TURBT OT - Urothelial carcinoma COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Vidit Sharma reports a relationship with ImmunityBio Inc that includes: board membership and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/25 01:20 MHDA- 2025/07/12 16:44 PMCR- 2026/09/14 CRDT- 2025/04/24 21:57 PHST- 2025/01/06 00:00 [received] PHST- 2025/02/23 00:00 [revised] PHST- 2025/03/02 00:00 [accepted] PHST- 2025/07/12 16:44 [medline] PHST- 2025/04/25 01:20 [pubmed] PHST- 2025/04/24 21:57 [entrez] PHST- 2026/09/14 00:00 [pmc-release] AID - S1078-1439(25)00085-7 [pii] AID - 10.1016/j.urolonc.2025.03.004 [doi] PST - ppublish SO - Urol Oncol. 2025 Aug;43(8):469.e1-469.e11. doi: 10.1016/j.urolonc.2025.03.004. Epub 2025 Apr 23. PMID- 40268594 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20260809 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 89 IP - 1 DP - 2026 Jan TI - Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. PG - 18-28 LID - S0302-2838(25)00189-7 [pii] LID - 10.1016/j.eururo.2025.03.017 [doi] AB - BACKGROUND AND OBJECTIVE: Patient-centric management necessitates providing care aligned with patients' values, preferences, and expressed needs. Therefore, critical assessment of bladder preservation therapies (BPTs) as alternatives to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) and practical recommendations on the optimal selection of patients for BPTs are needed urgently. METHODS: A global committee of bladder cancer experts was assembled to develop BPT recommendations for MIBC. Working groups reviewed the literature and drafted recommendations, which were voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined based on discussions. Final recommendations achieved >/=75% agreement during the meeting, with further refinements through web conferences and e-mail discussions. KEY FINDINGS AND LIMITATIONS: Patients with newly diagnosed MIBC should be offered evaluation in a multidisciplinary setting for consideration of BPTs. The main alternative to RC is trimodal therapy (TMT), and favorable prognostic factors for TMT include unifocal cT2 stage, lack of hydronephrosis, and no multifocal carcinoma in situ (CIS). Other options should be reserved for very select patients who are ineligible for or who decline TMT or RC after thorough consideration of benefits versus risks. These include partial cystectomy (PC) for urachal adenocarcinoma and PC or radical transurethral resection alone for solitary tumors amenable to resection with adequate margins and without concomitant CIS or histologic subtypes. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BPTs for MIBC. CI - Copyright (c) 2025 European Association of Urology. All rights reserved. FAU - Gupta, Shilpa AU - Gupta S AD - Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Choudhury, Ananya AU - Choudhury A AD - Division of Cancer Sciences, University of Manchester, Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, England, UK. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA, USA. FAU - Faltas, Bishoy M AU - Faltas BM AD - Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York City, NY, USA. FAU - Flaig, Thomas W AU - Flaig TW AD - Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Grass, G Daniel AU - Grass GD AD - Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Grivas, Petros AU - Grivas P AD - Division of Hematology Oncology, Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. FAU - Hansel, Donna E AU - Hansel DE AD - Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hassanzadeh, Comron AU - Hassanzadeh C AD - Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University, Montreal, Quebec, Canada. FAU - Kukreja, Janet AU - Kukreja J AD - University of Colorado Anschutz Medical Campus, Denver, CO, USA. FAU - Mendoza-Valdes, Arturo AU - Mendoza-Valdes A AD - Urology Department, Hospital Medica Sur, Mexico City, Mexico. FAU - Moschini, Marco AU - Moschini M AD - Division of Oncology/Unit of Urology, URI IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Mouw, Kent W AU - Mouw KW AD - Department of Radiation Oncology, Dana-Farber Cancer Institute & Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA. FAU - Navai, Neema AU - Navai N AD - Division of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Necchi, Andrea AU - Necchi A AD - Vita-Salute San Raffaele University, Milan Italy, Department of Medical Oncology, IRCC San Raffaele Hospital, Milan, Italy. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. FAU - Ross, Jeffrey S AU - Ross JS AD - Urology and Medicine (Oncology), Upstate Medical University, Syracuse, NY, USA; Foundation Medicine, Boston, MA USA. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Taylor, John AU - Taylor J AD - University of Kansas Cancer Center, Kansas City, KS, USA. FAU - Willliams, Stephen B AU - Willliams SB AD - Division of Urology, The University of Texas Medical Branch (UTMB), Galveston, TX, USA. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, Sinai Health System, University of Toronto, Toronto, Ontario, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre, University Heath Network, University of Toronto, Toronto, Ontario, Canada. FAU - Buckley, Roger AU - Buckley R AD - North York General Hospital, Toronto, Ontario, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - Division of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20250422 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - Cystectomy MH - Neoplasm Invasiveness MH - *Organ Sparing Treatments/methods/standards MH - *Urinary Bladder Neoplasms/pathology/therapy OTO - NOTNLM OT - Bladder preservation OT - Bladder-sparing therapy OT - Clinical complete response OT - Maximal transurethral resection OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Neoadjuvant immunotherapy OT - Partial cystectomy OT - Trimodal therapy EDAT- 2025/04/24 00:27 MHDA- 2025/12/12 03:29 CRDT- 2025/04/23 22:08 PHST- 2024/11/20 00:00 [received] PHST- 2025/02/25 00:00 [revised] PHST- 2025/03/27 00:00 [accepted] PHST- 2025/12/12 03:29 [medline] PHST- 2025/04/24 00:27 [pubmed] PHST- 2025/04/23 22:08 [entrez] AID - S0302-2838(25)00189-7 [pii] AID - 10.1016/j.eururo.2025.03.017 [doi] PST - ppublish SO - Eur Urol. 2026 Jan;89(1):18-28. doi: 10.1016/j.eururo.2025.03.017. Epub 2025 Apr 22. PMID- 40268559 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 7 DP - 2025 Jul TI - BCG response and oncological outcomes in high risk nonmuscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: A propensity-matched analysis. PG - 440.e1-440.e9 LID - S1078-1439(25)00126-7 [pii] LID - 10.1016/j.urolonc.2025.03.026 [doi] AB - INTRODUCTION: Metachronous bladder recurrences after prior treatment for primary upper tract urothelial carcinoma (UTUC) can occur in approximately 3% to 50% of patients. Because UTUC demonstrated distinct molecular alterations, bladder recurrences in these patients may be molecularly and phenotypically different compared to primary bladder carcinoma. We aim to study the BCG efficacy in patients with primary high risk nonmuscle invasive bladder cancer (P-NMIBC) and metachronous bladder recurrences after previous nephroureterectomy for UTUC (M-NMIBC). METHODS: We reviewed an IRB-approved prospective uro-oncology database of patients who underwent resection followed by BCG therapy for high grade NMIBC from 2017 to 2021. Clinicopathological parameters, intravesical therapies and the oncological outcomes were analyzed. Patients in the P-NMIBC group were matched to patients in the M-NMIBC cohort (control) via propensity score matching (PSM) to adjust for potential clinicopathological confounders. Nearest-neighbor PSM targeting a 4:1 ratio of study to control subjects was performed using a caliper of 0.2, aiming for an absolute standardized mean difference of <0.1 across key covariates. Secondary outcomes were progression to distant metastasis and overall survival. Logistic and cox regression analyses were performed to elucidate independent variables associated with intravesical recurrences and disease progression. RESULTS: Of the 183 patients diagnosed with NMIBC, 35 patients were identified to have a history of UTUC with radical nephroureterectomy. EAU risk stratification revealed 50 (27.3%) intermediate risk, 107 (58.5%) high risk and 26 (14.2%) very high risk groups. P-NMIBC patients were more likely to have symptomatic presentation (79.7% vs. 23.9%), and a larger mean tumor size (25.7 mm vs. 15.4 mm) than M-NMIBC. The mean follow-up duration for the study was 34.0 months. In the unmatched analysis, M-NMIBC was associated with increased risk of HG intravesical recurrence post BCG compared to P-NMIBC (54.3% vs. 28.4%, P = 0.006, HR 2.14, 95% CI: 1.25-3.65) and increased risk of progression to MIBC (28.6% vs. 4.7%, P = 0.007, HR 4.19, 95% CI: 1.47-11.95). For the propensity-matched analysis, the control group consisted of 35 M-NMIBC matched to 123 P-NMIBC patients for similar demographics, EAU risk score and BCG doses. M-NMIBC again demonstrated a higher HG intravesical recurrence rate (54.3% vs. 22.8%, P = 0.001, HR 2.67, 95% CI: 1.50-4.77), progression to MIBC (28.6% vs. 5.7%, P = 0.022, HR 3.42, 95% CI: 1.20-9.75) and progression to distant metastasis (20.0% vs. 6.5%, P = 0.033, HR 3.02, 95% CI: 1.09-8.35). Overall survival in both groups were not significantly different in both unmatched and matched analysis. CONCLUSIONS: Our study indicates that BCG treatment may be less effective for NMIBC patients with a history of UTUC, with a higher risk of intravesical recurrences and disease progression. This is an important consideration when counselling patients for BCG treatment and overall prognostication. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lim, Benjamin J H AU - Lim BJH AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Fong, Khi Yung AU - Fong KY AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Lu, Timothy AU - Lu T AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Ong, Julene AU - Ong J AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Tan, Siying AU - Tan S AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Chong, Tsung Wen AU - Chong TW AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Cheng, Christopher W S AU - Cheng CWS AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Tay, Kae Jack AU - Tay KJ AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Yuen, John S P AU - Yuen JSP AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Chen, Kenneth AU - Chen K AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Chan, Johan AU - Chan J AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Chan, Jason Y S AU - Chan JYS AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Tan, Wei Chong AU - Tan WC AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Kanesvaran, R AU - Kanesvaran R AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Hussain, Syed A AU - Hussain SA AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Abern, Michael R AU - Abern MR AD - Department of Urology, Duke University School of Medicine, Durham, NC. FAU - Tan, Yu Guang AU - Tan YG AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. Electronic address: tan.yu.guang@singhealth.com.sg. LA - eng PT - Journal Article DEP - 20250422 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Male MH - Female MH - Aged MH - Propensity Score MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - *Ureteral Neoplasms/pathology/drug therapy/surgery MH - *Kidney Neoplasms/pathology/drug therapy/surgery MH - *Adjuvants, Immunologic/therapeutic use MH - Treatment Outcome MH - Middle Aged MH - Retrospective Studies MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local MH - Nephroureterectomy MH - Aged, 80 and over OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Non-muscle-invasive bladder cancer OT - Upper tract urothelial cancer COIS- Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/24 00:28 MHDA- 2025/05/31 00:37 CRDT- 2025/04/23 22:07 PHST- 2024/09/04 00:00 [received] PHST- 2025/02/20 00:00 [revised] PHST- 2025/03/24 00:00 [accepted] PHST- 2025/05/31 00:37 [medline] PHST- 2025/04/24 00:28 [pubmed] PHST- 2025/04/23 22:07 [entrez] AID - S1078-1439(25)00126-7 [pii] AID - 10.1016/j.urolonc.2025.03.026 [doi] PST - ppublish SO - Urol Oncol. 2025 Jul;43(7):440.e1-440.e9. doi: 10.1016/j.urolonc.2025.03.026. Epub 2025 Apr 22. PMID- 40258413 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20250903 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 49 IP - 7 DP - 2025 Sep TI - New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer. PG - 501758 LID - S2173-5786(25)00089-7 [pii] LID - 10.1016/j.acuroe.2025.501758 [doi] AB - INTRODUCCTION AND OBJECTIVE: Muscle-invasive bladder cancer (MIBC) poses significant challenges, traditionally treated with radical cystectomy, a procedure with considerable morbidity and impact on quality of life. Bladder-sparing approaches aim to preserve the bladder while maintaining oncological efficacy. This review explores emerging perspectives in bladder-sparing strategies for MIBC, focusing on patient selection criteria, molecular characterization, non-invasive treatment response assessment, systemic therapies, radiation techniques, and the role of intravesical devices. METHODS: A comprehensive narrative review provides insights into novel perspectives in bladder-sparing strategies for treating MIBC. RESULTS: Patient selection criteria for bladder preservation remain challenging. While the traditional approach focuses on selecting candidates with MIBC with fewer clinicopathological risk characteristics, some studies suggest that histological variants and the presence of hydronephrosis may not be absolute exclusion criteria. Molecular classification data shows promise but lacks sufficient evidence, while immune cell infiltration may provide insights into potential treatment response. MRI and radiomics offer the potential for non-invasive treatment response assessment. Ongoing trials investigate new systemic therapies, radiation therapy approaches, and the role of intravesical devices in bladder preservation, with some preliminary data appearing promising. CONCLUSION: Bladder-sparing strategies for MIBC are currently experiencing substantial evolution. Achieving optimal patient selection may entail the integration of clinical, radiological, histopathological, and molecular data. It is likely that shortly, multimodal approaches incorporating neoadjuvant systemic therapy, radiotherapy, intravesical devices, and possibly maintenance or adjuvant regimens guided by biomarker-driven strategies will become standard practice. CI - Copyright (c) 2025 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Subiela, J D AU - Subiela JD AD - Servicio de Urologia, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. Electronic address: jdsubiela@gmail.com. FAU - Guerrero-Ramos, F AU - Guerrero-Ramos F AD - Clinica ROC, Madrid, Spain; Servicio de Urologia, Hospital Universitario HM Sanchinarro, Madrid, Spain; Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Rodriguez-Faba, O AU - Rodriguez-Faba O AD - Servicio de Urologia, Fundacio Puigvert, Barcelona, Spain. FAU - Aumatell, J AU - Aumatell J AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Mostoles, Madrid, Spain. FAU - Gajate, P AU - Gajate P AD - Servicio de Oncologia Medica, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Lopez-Campos, F AU - Lopez-Campos F AD - Servicio de Oncologia Radioterapica, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Sevillano, E AU - Sevillano E AD - HM CIOCC (Centro Integral Oncologico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain. FAU - Hernandez-Arroyo, M AU - Hernandez-Arroyo M AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Garcia-Rojo, E AU - Garcia-Rojo E AD - Clinica ROC, Madrid, Spain; Servicio de Urologia, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Artiles Medina, A AU - Artiles Medina A AD - Servicio de Urologia, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Saenz-Calzada, D AU - Saenz-Calzada D AD - Clinica ROC, Madrid, Spain; Servicio de Urologia, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Gomez-Canizo, C AU - Gomez-Canizo C AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Romero-Otero, J AU - Romero-Otero J AD - Clinica ROC, Madrid, Spain; Servicio de Urologia, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Counago, Felipe AU - Counago F AD - GenesisCare Madrid, Madrid, Spain; Hospital San Francisco de Asis, Madrid, Spain; Hospital La Milagrosa, Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Review DEP - 20250419 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/surgery MH - *Organ Sparing Treatments/methods MH - Neoplasm Invasiveness MH - Patient Selection OTO - NOTNLM OT - Bladder cancer OT - Bladder preservation OT - Bladder-sparing OT - Chemoradiation OT - Preservacion vesical OT - Quimiorradiacion OT - Radiation therapy OT - Radioterapia OT - Terapia trimodal OT - Trimodal therapy OT - Tumor vesical COIS- Declaration of competing interest Felix Guerrero: Payment honoraria for lectures Astellas, Janssen, Pfizer, AstraZeneca, Palex, Combat Medical, Rovi. Support for attending meetings and/or travel: Pfizer, Lacer, Janssen, Ipsen, Combat Medical, Rovi, Recordati. Pablo Gajate: Consulting fees: AAA, Jannsen, Astellas. Payment honoraria for lectures: Astellas. Elena Sevillano: Payment honoraria for lectures: Roche, MSD, BMS, Janssen, Pfizer, Astellas. Travel expenses: Pfizer, Roche, BMS, Janssen. Corporate-sponsored research: Roche. Advisors: BMS. Felipe Counago: Payment honoraria for lectures: Roche, Janssen, Astellas, AztraZeneca. Support for attending meetings and/or travel: Roche, Janssen, Astellas, AztraZeneca Participation on a Data Safety Monitoring Board or Advisory Board: AztraZeneca, Jaansen. Others: Sponsored Research, Janssen. Jose Daniel Subiela, Oscar Rodriguez-Faba, Julia Aumatell, Fernando Lopez-Campos, Mario Hernandez-Arroyo, Esther Garcia-Rojo, Alberto Artiles Medina, David Saenz-Calzada, Carmen Gomez-Canizo, Javier Romero-Otero: None. EDAT- 2025/04/22 00:27 MHDA- 2025/09/04 00:36 CRDT- 2025/04/21 19:28 PHST- 2025/01/06 00:00 [received] PHST- 2025/02/24 00:00 [revised] PHST- 2025/02/25 00:00 [accepted] PHST- 2025/09/04 00:36 [medline] PHST- 2025/04/22 00:27 [pubmed] PHST- 2025/04/21 19:28 [entrez] AID - S2173-5786(25)00089-7 [pii] AID - 10.1016/j.acuroe.2025.501758 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2025 Sep;49(7):501758. doi: 10.1016/j.acuroe.2025.501758. Epub 2025 Apr 19. PMID- 40254784 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250716 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 136 IP - 2 DP - 2025 Aug TI - External validation of current quality care metrics after radical nephroureterectomy. PG - 261-270 LID - 10.1111/bju.16741 [doi] AB - OBJECTIVES: To externally validate the tetrafecta and pentafecta frameworks for assessing the quality of radical nephroureterectomy (RNU) and their correlation with oncological outcomes in patients with localised upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: This retrospective study included 545 patients who underwent RNU for localised UTUC between 2012 and 2023 at eight French university hospitals and one Lebanese university hospital. Achievement of tetrafecta required four criteria to be met: negative surgical margins, complete bladder cuff excision, lymph node dissection (if indicated), and absence of recurrence within 12 months. Pentafecta consisted of the same criteria, plus no major complications or haematological events. Oncological outcomes assessed included intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier analyses, Cox regression, and calibration plots were used to evaluate the predictive performance of the frameworks for 3-year outcomes. RESULTS: A total of 29.5% of our cohort achieved tetrafecta and 34.5% achieved pentafecta. Patients meeting either of these quality care metrics demonstrated significantly improved oncological outcomes, with higher 3-year OS rates (tetrafecta: 90.1% vs 74.2%, P < 0.001; pentafecta: 89.4% vs 73.4%, P < 0.001) and RFS rates (tetrafecta: 84.5% vs 57.6%, P < 0.001; pentafecta: 83.5% vs 56%, P < 0.001). Both metrics showed high predictive accuracy for OS (area under the curve [AUC] 0.92 for tetrafecta; 0.93 for pentafecta, P = 0.41) and CSS (AUC 0.944 for tetrafecta; 0.945 for pentafecta, P = 0.6018). Pentafecta achievement was independently associated with better OS and CSS in multivariable analysis (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.16-0.55, P < 0.001 and (HR 0.24, 95% CI 0.10-0.54, P < 0.001, respectively). CONCLUSION: Tetrafecta and pentafecta are reliable tools for assessing oncological outcomes after RNU in localised UTUC. Pentafecta demonstrated stronger prognostic value for OS, particularly in high-risk populations. These metrics offer a standardised framework to guide clinical decisions, evaluate surgical quality, and counsel patients about prognosis. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Duquesne, Igor AU - Duquesne I AUID- ORCID: 0000-0002-6716-6473 AD - Department of Urology, Henri Mondor University Hospital, Assistance Publique-Hopitaux de Paris, Creteil, France. AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. FAU - Gabriel, Pierre-Etienne AU - Gabriel PE AD - Department of Urology, Pitie Salpetriere University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Chakra, Mohamad Abou AU - Chakra MA AUID- ORCID: 0000-0002-4293-3314 AD - Department of Urology, University of Illinois at Chicago, Chicago, Illinois, USA. AD - Department of Urology, Lebanese University, Beirut, Lebanon. FAU - Moussa, Mohamad AU - Moussa M AD - Department of Urology, Lebanese University, Beirut, Lebanon. FAU - Mansour, Raymond AU - Mansour R AD - Department of Urology, Cochin University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Borz, Mihnea Bogdan AU - Borz MB AD - Department of Urology, Cochin University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Duffaut, Louise AU - Duffaut L AD - Department of Urology, Tenon University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Mesnard, Benoit AU - Mesnard B AUID- ORCID: 0000-0002-3314-1892 AD - Department of Urology, University Hospital of Nantes, Nantes, France. FAU - Ourfali, Said AU - Ourfali S AUID- ORCID: 0000-0001-7947-0395 AD - Department of Urology, Hospices Civils de Lyon, Lyon, France. FAU - Mercier, Jeremy AU - Mercier J AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - de la Taille, Alexandre AU - de la Taille A AD - Department of Urology, Henri Mondor University Hospital, Assistance Publique-Hopitaux de Paris, Creteil, France. FAU - Rigaud, Jerome AU - Rigaud J AD - Department of Urology, University Hospital of Nantes, Nantes, France. FAU - Ruffion, Alain AU - Ruffion A AD - Department of Urology, Hospices Civils de Lyon, Lyon, France. FAU - Panthier, Frederic AU - Panthier F AD - Department of Urology, Tenon University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Saint-Louis University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie Salpetriere University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - Department of Urology, Pitie Salpetriere University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology, Clinique Pasteur, Toulouse, France. CN - CCAFU LA - eng PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20250420 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Nephroureterectomy/standards/methods MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/mortality MH - *Ureteral Neoplasms/surgery/mortality MH - *Urologic Neoplasms/surgery/mortality MH - *Kidney Neoplasms/surgery/mortality MH - Aged, 80 and over PMC - PMC12256761 OTO - NOTNLM OT - quality care metrics OT - radical nephroureterectomy OT - upper tract urothelial carcinoma OT - ureter OT - ureteral neoplasms EDAT- 2025/04/21 06:26 MHDA- 2025/07/14 06:26 PMCR- 2025/07/14 CRDT- 2025/04/21 00:33 PHST- 2025/07/14 06:26 [medline] PHST- 2025/04/21 06:26 [pubmed] PHST- 2025/04/21 00:33 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - BJU16741 [pii] AID - 10.1111/bju.16741 [doi] PST - ppublish SO - BJU Int. 2025 Aug;136(2):261-270. doi: 10.1111/bju.16741. Epub 2025 Apr 20. PMID- 40254057 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250703 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 49 IP - 6 DP - 2025 Jul-Aug TI - Is the presence of lymphovascular invasion associated with recurrence and progression in bladder cancer patients that have received adequate BCG therapy? PG - 501785 LID - S2173-5786(25)00091-5 [pii] LID - 10.1016/j.acuroe.2025.501785 [doi] AB - INTRODUCTION AND OBJECTIVES: To investigate whether lymphovascular invasion (LVI) could be a factor in predicting recurrence and progression in patients with high and very high-risk non-muscle-invasive bladder cancer (NMIBC) who received Bacillus Calmette-Guerin (BCG) treatment. METHODS: Ninety-three patients with high and very high-risk NMIBC, diagnosed initially in our clinic, were treated with at least 1 year of BCG therapy, and they were followed up to assess recurrence and progression, comparing those with and without lymphovascular invasion (LVI) at the time of diagnosis. RESULTS: In the entire cohort, LVI was present in 33 (35.5%) patients while absent in 60 (64.5%) patients. Among patients with LVI, 17 (51.5%) showed recurrence, and 11 (33.3%) showed progression. Statistically significant differences were observed in both recurrence and progression in patients with LVI compared to those without LVI (p < 0.001 and 0.04, respectively). Additionally, univariate and multivariate regression analysis revealed that the presence of LVI was an independent factor predicting recurrence (p = 0.001). CONCLUSION: In our study, we demonstrated the importance of being cautious regarding recurrence and progression in patients with high and very high-risk NMIBC who also have LVI despite receiving standard treatment. We found that approximately one-third of these patients may experience recurrence within one year. CI - Copyright (c) 2025 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Aydin, U AU - Aydin U AD - Departamento de Urologia, Hospital de Formacion e Investigacion de Agri, Agri, Turkey. Electronic address: ugurr.aydinn@hotmail.com. FAU - Cetin, S AU - Cetin S AD - Departamento de Urologia, Facultad de Medicina, Universidad de Gazi, Ankara, Turkey. FAU - Koparal, M Yavuz AU - Koparal MY AD - Departamento de Urologia, Facultad de Medicina, Universidad de Gazi, Ankara, Turkey. FAU - Coskun, C AU - Coskun C AD - Departamento de Urologia, Hospital de Formacion e Investigacion de Agri, Agri, Turkey. FAU - Isik Gonul, I AU - Isik Gonul I AD - Departamento de Patologia, Facultad de Medicina, Universidad de Gazi, Ankara, Turkey. FAU - Yesil, S AU - Yesil S AD - Departamento de Urologia, Facultad de Medicina, Universidad de Gazi, Ankara, Turkey. FAU - Sozen, T S AU - Sozen TS AD - Departamento de Urologia, Facultad de Medicina, Universidad de Gazi, Ankara, Turkey. LA - eng LA - spa PT - Journal Article DEP - 20250418 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/pathology/epidemiology MH - Disease Progression MH - Middle Aged MH - Retrospective Studies MH - *Adjuvants, Immunologic/therapeutic use MH - Aged, 80 and over MH - Lymphatic Metastasis OTO - NOTNLM OT - Bladder cancer OT - Cancer de vejiga OT - Invasion linfovascular OT - Lymphovascular invasion OT - Progresion OT - Progression OT - Recurrence OT - Recurrencia EDAT- 2025/04/21 00:25 MHDA- 2025/07/04 00:27 CRDT- 2025/04/20 19:31 PHST- 2025/01/16 00:00 [received] PHST- 2025/03/03 00:00 [revised] PHST- 2025/03/04 00:00 [accepted] PHST- 2025/07/04 00:27 [medline] PHST- 2025/04/21 00:25 [pubmed] PHST- 2025/04/20 19:31 [entrez] AID - S2173-5786(25)00091-5 [pii] AID - 10.1016/j.acuroe.2025.501785 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2025 Jul-Aug;49(6):501785. doi: 10.1016/j.acuroe.2025.501785. Epub 2025 Apr 18. PMID- 40247223 OWN - NLM STAT- MEDLINE DCOM- 20250418 LR - 20250420 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Apr 17 TI - Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer. PG - 717 LID - 10.1186/s12885-025-14109-9 [doi] LID - 717 AB - BACKGROUND: Bladder cancer (BLCA) is a highly heterogeneous disease that presents challenges in predicting prognosis and treatment response. Cancer stem cells are key drivers of tumor development, progression, metastasis, and treatment resistance. The features and prognostic significance of stemness in bladder cancer need further investigation. METHODS: We used bladder cancer datasets from the TCGA and GEO databases, based on stemness gene sets from the StemChecker database, to identify stemness subtypes using the consensus clustering algorithm. We calculated the mRNA expression-based stemness index (mRNAsi) using the OCLR algorithm. We compared the differences in overall survival, genomic characteristics, tumor microenvironment, and treatment response between the stemness subtypes. We constructed the stemness subtype classifier using machine learning algorithms such as LASSO regression, random forest, and multivariate logistic regression. The function of the classifier gene was validated through experiments. RESULTS: We divided bladder cancer patients into two subtypes based on the enrichment scores of stemness gene sets. Patients within subtype 1 have a higher mRNAsi score, a better survival rate, an antitumor microenvironment, and higher sensitivity to immunotherapy, while patients within subtype 2 show higher aneuploidy scores, greater homologous recombination defects, an elevated tumor mutation burden, and increased chemotherapy sensitivity. We constructed a stemness subtype classifier based on six differentially expressed genes between the two subtypes. The classifier demonstrated good performance in predicting prognosis on three additional datasets from the GEO database and two non-muscle invasive bladder cancer datasets. Through tumor sphere formation experiments and western blotting, we found that TNFAIP6, out of the six classifier genes, maintains stemness. TNFAIP6 silencing also facilitated the chemotherapy response of cisplatin, docetaxel, and paclitaxel on bladder cancer cells. Furthermore, decreasing TNFAIP6 expression caused the immune checkpoint gene PD-L1 to downregulate. CONCLUSION: This study provided valuable insights into the heterogeneity of BLCA stemness, and the stemness subtype classifier may facilitate molecular classification and personalized treatment selection for BLCA patients. Besides, TNFAIP6 may serve as a potential future stemness target guiding bladder cancer chemotherapy and immunotherapy. CI - (c) 2025. The Author(s). FAU - Qiu, Heping AU - Qiu H AD - Department of Urology, the Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. FAU - Deng, Xiaolin AU - Deng X AD - Department of Urology, Ganzhou People's Hospital, Ganzhou, 341000, China. FAU - Zha, Jing AU - Zha J AD - No 908th hospital of Chinese PLA Joint Logistic Support Force, Nanchang, 330000, China. FAU - Wu, Lihua AU - Wu L AD - Physical Examination Center, the Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. FAU - Liu, Haonan AU - Liu H AD - Department of Urology, the Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. FAU - Lu, Yichen AU - Lu Y AD - Queen Mary School of Nanchang University, Nanchang University, Nanchang, 330000, China. 2434788521@qq.com. FAU - Zhang, Xinji AU - Zhang X AD - Department of Urology, the Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. zhangxinjimd@163.com. LA - eng GR - 20224BAB206055/Jiangxi Provincial Natural Science Foundation/ GR - 2021YNFY12029/The Second Affiliated Hospital of Nanchang University, National Natural Science Foundation incubation project/ GR - Y-2019AZQN-0018/CSCO-Pilotage Cancer Research Fund/ PT - Journal Article DEP - 20250417 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/mortality/classification/drug therapy MH - *Machine Learning MH - *Neoplastic Stem Cells/pathology/metabolism MH - Prognosis MH - Tumor Microenvironment/genetics MH - Biomarkers, Tumor/genetics MH - Gene Expression Regulation, Neoplastic MH - Gene Expression Profiling PMC - PMC12004775 OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Stemness OT - TNFAIP6 OT - Treatment response COIS- Declarations. Ethics approval and consent to participate: This study has received approval from the ethics committee of the Second Affiliated Hospital of Nanchang University. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable. EDAT- 2025/04/18 00:25 MHDA- 2025/04/18 06:25 PMCR- 2025/04/17 CRDT- 2025/04/17 23:45 PHST- 2024/12/08 00:00 [received] PHST- 2025/04/08 00:00 [accepted] PHST- 2025/04/18 06:25 [medline] PHST- 2025/04/18 00:25 [pubmed] PHST- 2025/04/17 23:45 [entrez] PHST- 2025/04/17 00:00 [pmc-release] AID - 10.1186/s12885-025-14109-9 [pii] AID - 14109 [pii] AID - 10.1186/s12885-025-14109-9 [doi] PST - epublish SO - BMC Cancer. 2025 Apr 17;25(1):717. doi: 10.1186/s12885-025-14109-9. PMID- 40247187 OWN - NLM STAT- MEDLINE DCOM- 20250418 LR - 20260914 IS - 1528-3658 (Electronic) IS - 1076-1551 (Print) IS - 1076-1551 (Linking) VI - 31 IP - 1 DP - 2025 Apr 17 TI - Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid. PG - 140 LID - 10.1186/s10020-025-01199-1 [doi] LID - 140 AB - BACKGROUND: The limited genomic data on non-muscle-invasive bladder cancer (NMIBC) hampers our understanding of its carcinogenesis and development. Specifically, Aristolochic acid (AA), a potent human carcinogenic compound from aristolochia plants and commonly found in Chinese herbal medicine, has been extensively documented as being closely associated with the onset and progression of bladder cancer. However, the field of AA-induced NMIBC remains largely unexplored in terms of its genomic and molecular characteristics, as well as clinical therapeutic strategies. METHODS: To bridge this knowledge gap, we conducted a comprehensive study using a cohort of 81 NMIBC samples. We performed whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to obtain detailed genomic and transcriptomic data. We subjected these datasets to genomic analysis and subtype analysis to gain valuable insights into NMIBC. RESULTS: By temporally dissecting mutations in NMIBC specimens, we identified a comprehensive mutational landscape of NMIBC and the associations of these mutations with recurrence-free survival. Additionally, we discerned four genomic subtypes of NMIBC: AA-like, FGFR3/HRAS, FGFR3 & chr9Del, and genome instability (GI). The AA-like subtype presented a high frequency of gene mutations along with a pronounced AA mutagenesis signature of SBS22 (Fisher test: P-value 3.5e-4, OR 25.25) even after temporal dissection. The FGFR3/HRAS subtype exhibited FGFR3 or HRAS mutations with few copy number alterations (CNAs). The FGFR3 & chr9Del subtype was characterized by the co-occurrence of chr9p and chr9q deletions as well as FGFR3 mutations, while the GI subtype showed a high frequency of CNAs. Notably, the AA-like and GI subtypes demonstrated better outcomes after immunotherapy, whereas the FGFR3/HRAS subtype showed poorer outcomes. CONCLUSIONS: Our findings provide novel perspectives on the genomics of NMIBC, unveiling four prominent genomic subtypes, each showing different outcomes following immunotherapy. TRIAL REGISTRATION: No. 2019PHB268-01 (retrospectively registered on February 14, 2020). CI - (c) 2025. The Author(s). FAU - Peng, Yun AU - Peng Y AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Song, Yuxuan AU - Song Y AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Qin, Caipeng AU - Qin C AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Ding, Mengting AU - Ding M AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Huang, Zixiong AU - Huang Z AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Wang, Fei AU - Wang F AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - HuangFu, Yuchao AU - HuangFu Y AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Yu, Luping AU - Yu L AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. FAU - Du, Yiqing AU - Du Y AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. duyiqing@bjmu.edu.cn. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, 100044, China. xutao@pkuph.edu.cn. LA - eng GR - Z191100006619010/Beijing Municipal Science & Technology Commission/ GR - 81802533/Foundation for Innovative Research Groups of the National Natural Science Foundation of China/ GR - 2018YFA0902802/National Key Research and Development Program of China/ GR - 2024ZD0525700/Noncommunicable Chronic Diseases-National Science and Technology Major Project/ PT - Journal Article DEP - 20250417 PL - England TA - Mol Med JT - Molecular medicine (Cambridge, Mass.) JID - 9501023 RN - 0 (Aristolochic Acids) RN - 94218WFP5T (aristolochic acid I) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Humans MH - *Aristolochic Acids/adverse effects MH - *Urinary Bladder Neoplasms/genetics/therapy/pathology/etiology/chemically induced MH - Male MH - Female MH - Mutation MH - *Immunotherapy/methods MH - Aged MH - Genomics/methods MH - Middle Aged MH - Exome Sequencing MH - Biomarkers, Tumor/genetics MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Clinical Decision-Making MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12004710 OTO - NOTNLM OT - Aristolochic acid OT - Bacillus Calmette-Guerin OT - Genomic subtypes OT - Immunotherapy OT - Non-muscle-invasive bladder cancer COIS- Declarations. Ethics approval and consent to participate: The ethics committee of the Peking University People's Hospital approved this retrospective study, and a waiver of consent to participate was obtained. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/04/18 00:24 MHDA- 2025/04/18 06:25 PMCR- 2025/04/17 CRDT- 2025/04/17 23:44 PHST- 2024/11/30 00:00 [received] PHST- 2025/04/04 00:00 [accepted] PHST- 2025/04/18 06:25 [medline] PHST- 2025/04/18 00:24 [pubmed] PHST- 2025/04/17 23:44 [entrez] PHST- 2025/04/17 00:00 [pmc-release] AID - 10.1186/s10020-025-01199-1 [pii] AID - 1199 [pii] AID - 10.1186/s10020-025-01199-1 [doi] PST - epublish SO - Mol Med. 2025 Apr 17;31(1):140. doi: 10.1186/s10020-025-01199-1. PMID- 40243380 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250425 IS - 2980-1478 (Electronic) IS - 2980-1478 (Linking) VI - 50 IP - 6 DP - 2025 Apr 4 TI - The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 343-350 LID - 10.5152/tud.2025.24135 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) presents substantial variability in clinical outcomes, especially in high-grade T1 cases, which exhibit high recurrence and progression rates. Circulating tumor cells (CTCs) have emerged as a potential biomarker for cancer prognosis, with evidence linking CTC positivity to poor outcomes in various cancers. In bladder cancer (BC), studies suggest that CTC presence correlates with advanced tumor stage and treatment response, but findings are inconsistent. This study aims to clarify the association between CTC positivity and recurrence and progression to muscle invasiveness in BC. A comprehensive search was conducted using PubMed, SciVerse Scopus, Google Scholar, and the World Health Organization International Clinical Trials Registry Platform databases up to August 2024. This study focuses on assessing the predictive ability of CTCs for NMIBC recurrence and upstaging after transurethral resection of bladder tumor (TURBT). A total of 5 studies were included. Four of the 5 studies found a significant relationship between CTCs and recurrence after TURBT. The hazard ratio (HR) for recurrences was available in 5 studies, and the estimated pooled odds ratio (OR) predicted the value of recurrences for CTC- positive OR = 2.68 (95% CI: 2.11-3.25; P < .001; fixed-effect). Four studies provided data on disease progression from T1 to T2 after TURBT with an overall HR of 3.36 (95% CI: 2.68-3.25). Circulating tumor cells enhance prognostic accuracy and therapeutic strategies in NMIBC, particularly in high-risk cases. Further studies should address molecular subtype stratification and evaluate systemic chemotherapy for CTC-positive patients. FAU - Zulfiqqar, Andy AU - Zulfiqqar A AD - Division of Urology, Al Huda Hospital, Banyuwangi, Indonesia. AD - Division of Urology, IHC Kaliwates Hospital, Jember, Indonesia. FAU - Liliana, Belinda AU - Liliana B AD - International Ph.D. Program in Cell Therapy and Regenerative Medicine, Taipei Medical University College of Medicine, Taipei, Taiwan. FAU - Mataho, Nurul Lantika AU - Mataho NL AD - School of Medicine, Faculty of Medicine Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta. FAU - Subekti, Eko AU - Subekti E AD - Division of Urology, Department of Surgery, Banyumas Regional General Hospital, Banyumas, Indonesia. LA - eng PT - Journal Article PL - Turkey TA - Urol Res Pract JT - Urology research & practice JID - 9918608789006676 PMC - PMC12015750 OTO - NOTNLM OT - Circulating tumor cell OT - disease progression OT - non-muscle invasive bladder cancer OT - prognosis OT - recurrence COIS- Declaration of Interests: The authors have no conflict of interest to declare. EDAT- 2025/04/17 12:26 MHDA- 2025/04/17 12:27 PMCR- 2025/04/04 CRDT- 2025/04/17 09:22 PHST- 2025/04/17 12:27 [medline] PHST- 2025/04/17 12:26 [pubmed] PHST- 2025/04/17 09:22 [entrez] PHST- 2025/04/04 00:00 [pmc-release] AID - urp-50-6-343 [pii] AID - 10.5152/tud.2025.24135 [doi] PST - ppublish SO - Urol Res Pract. 2025 Apr 4;50(6):343-350. doi: 10.5152/tud.2025.24135. PMID- 40242251 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250418 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review. PG - 1448079 LID - 10.3389/fonc.2025.1448079 [doi] LID - 1448079 AB - OBJECTIVE: Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and meta-analysis comparing the long-term oncologic and renal function outcomes of KSS with those of radical nephroureterectomy (RNU) for UTUC. MATERIALS AND METHODS: A literature search was conducted on PubMed, Embase, and Web of Science in January 2024. A meta-analysis was performed to analyze overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), intravesical recurrence-free survival (IVRFS), metastasis-free survival (MFS), and surgery-related estimated glomerular filtration rate (eGFR) variations. RESULTS: A total of 32 studies with 21615 patients were included in this meta-analysis. Patients treated with KSS were less likely to have hydronephrosis, more often had low-grade tumors, and were more frequently at a low-stage compared to those undergoing RNU. There were no significant differences between the KSS and RNU groups in terms of 5-year OS, 5-year CSS, 5-year RFS, 5-year IVRFS, 5-year MFS, and hazard ratios (HRs) for OS and CSS based on univariate or multivariable Cox regression analysis. Similar results were found in subgroup analyses comparing segmental urethrectomy (SU) with RNU. In the comparison between the endoscopic management (EM) and RNU groups, EM was associated with worse overall survival outcomes (HR,1.40; 95%CI,1.08-1.82; P=0.01) based on multivariable Cox regression analysis, and the upper tract recurrence rate (OR,39.06; 95%CI, 14.55-104.85; P<0.00001) was significantly higher in the EM group. On the other hand, in patients treated with KSS, postoperative renal function as measured by eGFR increased by 0.4ml/min/1.73 m(2), while it decreased by 11.4ml/min/1.73 m(2) in the RNU group (WMD, 11.81 ml/min/1.73 m(2); 95%CI,9.06-14.56; P<0.0001). CONCLUSION: Our meta-analysis supports similar oncological outcomes between KSS and RNU, although tumor characteristics were not equally balanced. KSS can be considered the best choice option for patients with low-risk UTUC, as it offers better preservation of renal function. In terms of kidney-sparing options, SU could be a better alternative for the treatment of ureteral tumors compared to ureteroscopy, due to the higher local recurrence rate associated with EM. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2024-5-0051/, identifier (INPLASY202450051). CI - Copyright (c) 2025 Zhou, Huang, Sun, Ning and Tang. FAU - Zhou, Leqing AU - Zhou L AD - Department of Urology, Shaoyang Hospital affiliated to University of South China, Shaoyang, China. FAU - Huang, Chuyang AU - Huang C AD - Department of Urology, Shaoyang Hospital affiliated to University of South China, Shaoyang, China. FAU - Sun, Sheng AU - Sun S AD - Department of Urology, Shaoyang Hospital affiliated to University of South China, Shaoyang, China. FAU - Ning, Keping AU - Ning K AD - Department of Urology, Shaoyang Hospital affiliated to University of South China, Shaoyang, China. FAU - Tang, Shan AU - Tang S AD - Department of Urology, Shaoyang Hospital affiliated to University of South China, Shaoyang, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250402 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11999840 OTO - NOTNLM OT - endoscopic management OT - kidney-sparing surgery OT - meta-analysis OT - renal function OT - segmental urethrectomy OT - survival outcomes OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/04/17 10:57 MHDA- 2025/04/17 10:58 PMCR- 2025/01/01 CRDT- 2025/04/17 05:01 PHST- 2024/08/02 00:00 [received] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/04/17 10:58 [medline] PHST- 2025/04/17 10:57 [pubmed] PHST- 2025/04/17 05:01 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2025.1448079 [doi] PST - epublish SO - Front Oncol. 2025 Apr 2;15:1448079. doi: 10.3389/fonc.2025.1448079. eCollection 2025. PMID- 40240255 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250530 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 3 DP - 2025 Jun TI - Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project. PG - 603-607 LID - S2588-9311(25)00080-X [pii] LID - 10.1016/j.euo.2025.03.005 [doi] AB - The standard of care (SOC) for treatment of muscle-invasive bladder cancer is neoadjuvant systemic treatment (NAT) with chemotherapy +/- immunotherapy (pending durvalumab approval for this indication) followed by cystectomy or radiochemotherapy, regardless of the extent of any tumor response. Studies have recently begun to question the pertinence of local treatment in cases with a complete clinical response after NAT. However, such a de-escalation strategy is hampered by the poor correlation between clinical evaluation of the tumor response and final pathology results for radical cystectomy specimens. The aim of the EORTC STARBURST-1 trial is to develop and validate a multimodal assessment protocol to enhance prediction of the response to systemic treatment. This will include cystoscopy, multiparametric magnetic resonance imaging of the bladder, quantification of circulating plasma and urinary tumor DNA, and measurement of urinary biomarkers. If this protocol can be validated, it will be used in STARBURST-2 to randomize patients to either SOC or to NAT, followed by local treatment or a risk-adapted strategy according to the response to NAT. This strategy involves omitting local treatment and replacing it with intravesical or systemic treatments for complete responders, or with immediate systemic escalation in nonresponders. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Urology Department, Saint Louis Hospital, AP-HP, Universite Paris Cite, Paris, France. Electronic address: alexandra.massonlecomte@aphp.fr. FAU - Grisay, Guillaume AU - Grisay G AD - CHU Helora Site Jolimont, La Louviere, Belgium. FAU - Damme, Julien Van AU - Damme JV AD - Urology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - Achard, Verane AU - Achard V AD - Department of Radiotherapy, Institut Bergonie, Bordeaux, France; University of Geneva, Geneva, Switzerland. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Boellaard, Thierry N AU - Boellaard TN AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - D'Haese, David AU - D'Haese D AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. FAU - Fournier, Beatrice AU - Fournier B AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. FAU - Govaerts, Anne-Sophie AU - Govaerts AS AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. FAU - Huddart, Robert AU - Huddart R AD - Royal Marsden Hospital, London, UK. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza, Molinette Hospital, Torino School of Medicine, Torino, Italy. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Universite Paris-Saclay, UVSQ, Institut Curie, Saint-Cloud, France. FAU - Pecoraro, Martina AU - Pecoraro M AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. FAU - Litiere, Saskia AU - Litiere S AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. FAU - Tombal, Bertrand AU - Tombal B AD - Urology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - Panebianco, Valeria AU - Panebianco V AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. FAU - Loriot, Yohann AU - Loriot Y AD - Gustave Roussy, Universite Paris-Saclay, Paris, France. LA - eng PT - Journal Article DEP - 20250416 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Neoadjuvant Therapy/methods MH - Neoplasm Invasiveness MH - Cystectomy MH - Treatment Outcome OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Neoadjuvant chemotherapy OT - Organ preservation OT - Urothelial carcinoma EDAT- 2025/04/17 00:23 MHDA- 2025/05/31 00:36 CRDT- 2025/04/16 22:00 PHST- 2025/01/28 00:00 [received] PHST- 2025/03/11 00:00 [accepted] PHST- 2025/05/31 00:36 [medline] PHST- 2025/04/17 00:23 [pubmed] PHST- 2025/04/16 22:00 [entrez] AID - S2588-9311(25)00080-X [pii] AID - 10.1016/j.euo.2025.03.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Jun;8(3):603-607. doi: 10.1016/j.euo.2025.03.005. Epub 2025 Apr 16. PMID- 40221279 OWN - NLM STAT- MEDLINE DCOM- 20250918 LR - 20250922 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 4 DP - 2025 Aug TI - Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis. PG - 1126-1139 LID - S2588-9311(25)00055-0 [pii] LID - 10.1016/j.euo.2025.03.003 [doi] AB - BACKGROUND AND OBJECTIVE: Upper tract urothelial carcinoma (UTUC) is associated with poor survival. Recent studies have evaluated whether the presence of histological subtypes or divergent differentiation (HS/DD) is associated with worse UTUC prognosis. Our aim was to assess the relationship between HS/DD and clinicopathological features and oncological outcomes for patients with UTUC undergoing radical nephroureterectomy (RNU) without investigating causal pathways. METHODS: A literature search was conducted in September 2024. Patients with UTUC who underwent RNU were included. The main outcomes were differences in clinicopathological features and oncological outcomes between HS/DD and pure urothelial carcinoma (PUC) groups. KEY FINDINGS AND LIMITATIONS: We included 22 studies involving 14 407 patients in our review. HS/DD was present in 14% of tumours. In comparison to PUC, the HS/DD group had significantly higher rates of >/=pT3 stage, high-grade tumours, lymph node invasion (LNI), lymphovascular invasion (LVI), and receipt of adjuvant chemotherapy. Pooled results revealed that the HS/DD group had significantly worse cancer-specific survival (CSS) (hazard ratio [HR] 1.65, 95% confidence interval CI] 1.39-1.96), overall survival (OS; HR 1.84, 95% CI 1.52-2.22) ,and recurrence-free survival (RFS; HR 1.64, 95% CI 1.43-1.87). Intravesical RFS (IVRFS) and urothelial RFS (URFS) were comparable between the groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings suggest that UTUC with HS/DD is associated with more advanced/aggressive features, such as higher pathological stage and grade, LNI, and LVI. HS/DD is associated with significantly worse CSS, OS, and RFS, but does not predict worse IVRFS or URFS. Therefore, HS/DD detection should prompt extensive treatment and closer follow-up. To improve the quality of recommendations and patient care, well-designed studies with central pathological review are needed. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. Electronic address: lllukasz.nowak@gmail.com. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Tomczak, Wojciech AU - Tomczak W AD - University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Gurwin, Adam AU - Gurwin A AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Subiela, Jose D AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria, Universidad de Alcala, Madrid, Spain. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Krajewska, Magdalena AU - Krajewska M AD - Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Khan, Muhammad S AU - Khan MS AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. CN - Urothelial Carcinoma Working Group of the European Association of Urology Young Academic Urologists LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250411 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality MH - *Kidney Neoplasms/pathology/surgery/mortality MH - *Nephroureterectomy/methods MH - Treatment Outcome MH - *Ureteral Neoplasms/pathology/surgery/mortality OTO - NOTNLM OT - Clinicopathological outcomes OT - Histological subtypes OT - Histological variants OT - Oncological outcomes OT - Survival OT - Upper tract urothelial carcinoma EDAT- 2025/04/13 00:44 MHDA- 2025/09/19 00:36 CRDT- 2025/04/12 21:58 PHST- 2024/10/21 00:00 [received] PHST- 2025/02/22 00:00 [revised] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/09/19 00:36 [medline] PHST- 2025/04/13 00:44 [pubmed] PHST- 2025/04/12 21:58 [entrez] AID - S2588-9311(25)00055-0 [pii] AID - 10.1016/j.euo.2025.03.003 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Aug;8(4):1126-1139. doi: 10.1016/j.euo.2025.03.003. Epub 2025 Apr 11. PMID- 40217220 OWN - NLM STAT- MEDLINE DCOM- 20250412 LR - 20260924 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 25 IP - 1 DP - 2025 Apr 11 TI - Stapled vs. manually sutured bowel anastomosis in robot-assisted radical cystectomy: a single-center retrospective analysis. PG - 85 LID - 10.1186/s12894-025-01763-1 [doi] LID - 85 AB - BACKGROUND: Radical cystectomy is the primary treatment for muscle-invasive bladder cancer and certain cases of high-risk non-muscle-invasive disease. Robot-assisted cystectomy techniques (RARC) have emerged as a minimally invasive alternative to traditional open surgery, offering enhanced precision and potentially improved recovery. Bowel anastomosis remains a critical step in these procedures, with manually sutured anastomosis offering a cost-effective alternative to the standard stapled technique. However, concerns remain regarding its impact on surgical outcomes. METHODS: We conducted a retrospective study of 92 patients who underwent RARC in our hospital between March 2021 and November 2023. Bowel anastomosis was performed using either stapled (n = 33) or manually sutured techniques (n = 59). Key outcome parameters included gastro-intestinal (GI) complications, overall complications, operation duration, length of hospital stay, readmissions, and postoperative recovery metrics. RESULTS: GI complications occurred in 23 patients (25%), with paralytic ileus being the most common (17%). The rates of GI complications were comparable between the manually sutured (27%) and stapled (21%) groups (p = 0.530, odds ratio 1.38). The mean operation duration was 300 min for the sutured group and 313 min for the stapled group (p = 0.124). The median hospital stay was similar at 8 days (p = 0.384) for both groups. Readmission rates were higher in the sutured group (25% vs. 6%, p = 0.022, odds ratio 5.28), but this was predominantly due to non-GI complications. CONCLUSION: This study indicates that outcomes are comparable between stapled and manually sutured bowel anastomosis in RARC, with no significant increase in overall complications, GI complications, operation duration or hospital stay if using a manually sutured anastomosis. Considering the low cost of manual suturing, this technique seems highly cost-effective and could be considered a viable alternative to existing stapling techniques. CI - (c) 2025. The Author(s). FAU - Hermans, Thomas AU - Hermans T AD - Department of Urology, Ziekenhuis Oost-Limburg, Synaps Park 1, Genk, 3600, Belgium. thomashermans1@gmail.com. FAU - Schevenels, Giel AU - Schevenels G AD - Department of Molecular Biology, ULB Neuroscience Institute, Universite libre de Bruxelles (ULB), 12 rue des Profs. Jeener et Brachet, Gosselies, 6041, Belgium. FAU - Motmans, Steve AU - Motmans S AD - Department of Urology, Ziekenhuis Oost-Limburg, Synaps Park 1, Genk, 3600, Belgium. FAU - De Sutter, Thomas AU - De Sutter T AD - Department of Urology, Ziekenhuis Oost-Limburg, Synaps Park 1, Genk, 3600, Belgium. FAU - Raskin, Yannic AU - Raskin Y AD - Department of Urology, Ziekenhuis Oost-Limburg, Synaps Park 1, Genk, 3600, Belgium. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250411 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Retrospective Studies MH - *Cystectomy/methods MH - Anastomosis, Surgical/methods MH - *Robotic Surgical Procedures/methods MH - Male MH - Female MH - Aged MH - *Suture Techniques MH - Middle Aged MH - *Surgical Stapling/methods MH - Postoperative Complications/epidemiology/etiology MH - *Intestines/surgery MH - *Urinary Bladder Neoplasms/surgery PMC - PMC11987437 OTO - NOTNLM OT - Bowel anastomosis OT - Cost OT - Muscle-invasive bladder cancer OT - Robot-assisted radical cystectomy OT - Stapled OT - Sutured COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Ethical Committee of Ziekenhuis Oost-Limburg (Comite Medische Ethiek ZOL Genk, ID Number Z2024049). As a retrospective, non-interventional study, the requirement for participant informed consent was waived by the committee in accordance with Belgian legislation (Law of 7 May 2004 on human experiments, relevant royal decrees, and the program law). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/12 00:42 MHDA- 2025/04/12 21:51 PMCR- 2025/04/11 CRDT- 2025/04/11 23:46 PHST- 2024/06/22 00:00 [received] PHST- 2025/03/27 00:00 [accepted] PHST- 2025/04/12 21:51 [medline] PHST- 2025/04/12 00:42 [pubmed] PHST- 2025/04/11 23:46 [entrez] PHST- 2025/04/11 00:00 [pmc-release] AID - 10.1186/s12894-025-01763-1 [pii] AID - 1763 [pii] AID - 10.1186/s12894-025-01763-1 [doi] PST - epublish SO - BMC Urol. 2025 Apr 11;25(1):85. doi: 10.1186/s12894-025-01763-1. PMID- 40215707 OWN - NLM STAT- MEDLINE DCOM- 20250505 LR - 20250515 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 187 DP - 2025 Jun TI - Contribution of lesion shape features to the VI-RADS for predicting muscle invasion in bladder tumors. PG - 112104 LID - S0720-048X(25)00190-1 [pii] LID - 10.1016/j.ejrad.2025.112104 [doi] AB - OBJECTIVE: Muscle invasion in bladder cancer is a crucial factor influencing treatment decisions and prognosis. We hypothesize that the integration of tumor shape characteristics with the VI-RADS scoring system improves the predictive accuracy for assessing muscle invasion in bladder cancer. METHODS: This prospective observational study included patients scheduled for transurethral resection of bladder tumor (TURBT) and/or cystectomy due to suspected bladder cancer between March 2022 and November 2024. All patients underwent multiparametric bladder MRI following the VI-RADS protocol. Tumor segmentation was performed using 3D Slicer to assess shape features, including sphericity, surface area, surface-volume ratio, elongation, and flatness. Mann-Whitney U tests were conducted to evaluate the association between shape features and muscle invasion, while ROC (Receiver Operating Characteristic) analysis determined threshold values. RESULTS: The study included 119 patients (98 males, 21 females; mean age 66.9 +/- 9.9 years, range 33-89). Using VI-RADS >/= 3 as the threshold, sensitivity was 100 %, with a specificity of 65.91 %. For VI-RADS >/= 4, sensitivity was 80.65 %, and specificity was 95.45 %. A significant relation was found between tumor sphericity and muscle invasion. For VI-RADS >/= 3B, sensitivity was 100 %, and specificity was 66.67 %. CONCLUSION: The VI-RADS algorithm demonstrated high predictive accuracy for muscle invasion, particularly for tumors scored VI-RADS >/= 4. Additionally, while a relation was identified between tumor sphericity and muscle invasion, its incorporation into the VI-RADS scoring system did not enhance the overall predictive performance of the algorithm. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Dogan, Mahmut Bilal AU - Dogan MB AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Radiology, Istanbul, Turkiye. Electronic address: mahmutbilaldogan@gmail.com. FAU - Gunduz, Nesrin AU - Gunduz N AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Radiology, Istanbul, Turkiye. FAU - Kazan, Huseyin Ozgur AU - Kazan HO AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology, Istanbul, Turkiye. FAU - Cakici, Mehmet Caglar AU - Cakici MC AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology, Istanbul, Turkiye. FAU - Yildirim, Asif AU - Yildirim A AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology, Istanbul, Turkiye. FAU - Erdem, Gulnur AU - Erdem G AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Radiology, Istanbul, Turkiye. LA - eng PT - Journal Article PT - Observational Study DEP - 20250409 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - Middle Aged MH - Aged MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Prospective Studies MH - Aged, 80 and over MH - Adult MH - Sensitivity and Specificity MH - *Magnetic Resonance Imaging/methods MH - *Image Interpretation, Computer-Assisted/methods MH - Imaging, Three-Dimensional MH - Reproducibility of Results OTO - NOTNLM OT - Bladder cancer OT - Multiparametric magnetic resonance imaging OT - VI-RADS COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/12 00:42 MHDA- 2025/05/05 06:27 CRDT- 2025/04/11 18:05 PHST- 2025/03/04 00:00 [received] PHST- 2025/03/31 00:00 [revised] PHST- 2025/04/06 00:00 [accepted] PHST- 2025/05/05 06:27 [medline] PHST- 2025/04/12 00:42 [pubmed] PHST- 2025/04/11 18:05 [entrez] AID - S0720-048X(25)00190-1 [pii] AID - 10.1016/j.ejrad.2025.112104 [doi] PST - ppublish SO - Eur J Radiol. 2025 Jun;187:112104. doi: 10.1016/j.ejrad.2025.112104. Epub 2025 Apr 9. PMID- 40204943 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20250514 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 151 IP - 4 DP - 2025 Apr 9 TI - Investigating the role of HMGA2 plasma level as a diagnostic marker in bladder urothelial carcinoma patients. PG - 134 LID - 10.1007/s00432-025-06192-z [doi] LID - 134 AB - BACKGROUND: Bladder Cancer (BC) is an environmental cancer caused by exposure to a globally widespread carcinogen, which is smoking, and it is characterized by high rates of recurrence and mortality. High Mobility Group A2 (HMGA2) protein is an oncofetal protein that belongs to the HMG family proteins. It is involved in various stages of carcinogenesis and cancer progression. This study investigated the presence and levels of the HMGA2 protein in bladder urothelial carcinoma patients' plasma and in healthy individuals and their association with the clinicopathological features of bladder urothelial carcinoma. METHODS: This case-control study included 80 individuals divided into two groups: a healthy group (n = 22) and a patient group with bladder urothelial carcinoma (n = 58). There were 16 patients with Muscle-Invasive Bladder Cancer (MIBC) and 42 patients with Non-Invasive Bladder Cancer (NMIBC) in the patients' cohort according to the European Association of Urology (EAU) classification. HMGA2 plasma levels were measured by Sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA). The statistical analysis was performed using IBM SPSS statistics (version 25) software. The t-test and the Mann-Whitney test were used. RESULTS: Plasma HMGA2 protein levels were higher in the BC group than in the healthy group (P < 0.001), they also were higher in MIBC (pT2-pT3) than in NMIBC (pTa-pT1) (P < 0.001). HMGA2 plasma levels were higher in high grade BC patients than in low grade BC patients (P = 0.049). CONCLUSIONS: This study confirmed that the plasma HMGA2 protein level was higher in bladder cancer patients than in healthy individuals and that its elevated plasma levels were correlated with advanced stage and grade of BC; thus, the plasma HMGA2 protein level represents a potential non-invasive marker that could be included in bladder cancer diagnosis approach. CI - (c) 2025. The Author(s). FAU - Khazem, Farah AU - Khazem F AD - Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria. farahraedkhazem@gmail.com. FAU - Zetoune, Almoutassem Billah AU - Zetoune AB AD - Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria. LA - eng PT - Journal Article DEP - 20250409 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (HMGA2 Protein) RN - 0 (Biomarkers, Tumor) RN - 0 (HMGA2 protein, human) SB - IM MH - Humans MH - *HMGA2 Protein/blood MH - *Urinary Bladder Neoplasms/blood/diagnosis/pathology MH - Female MH - Male MH - *Biomarkers, Tumor/blood MH - Case-Control Studies MH - Middle Aged MH - Aged MH - *Carcinoma, Transitional Cell/blood/diagnosis/pathology MH - Aged, 80 and over MH - Adult PMC - PMC11982150 OTO - NOTNLM OT - BC grade OT - BC stage OT - Bladder cancer OT - HMGA2 OT - MIBC OT - NMIBC OT - Plasma OT - Pyroptosis OT - Urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethics approval and consent to participate: Plasma samples were obtained after getting the ethical approval from the Biomedical Research Ethics Committee (BMREC) at Damascus University (2022/1/29) (ID number: PH-290122 -31) in accordance with the Declaration of Helsinki (1964). A written informed consent was taken from each participant. Consent for publication: Not applicable. EDAT- 2025/04/10 00:20 MHDA- 2025/04/10 00:21 PMCR- 2025/04/09 CRDT- 2025/04/09 23:26 PHST- 2025/03/12 00:00 [received] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/04/10 00:21 [medline] PHST- 2025/04/10 00:20 [pubmed] PHST- 2025/04/09 23:26 [entrez] PHST- 2025/04/09 00:00 [pmc-release] AID - 10.1007/s00432-025-06192-z [pii] AID - 6192 [pii] AID - 10.1007/s00432-025-06192-z [doi] PST - epublish SO - J Cancer Res Clin Oncol. 2025 Apr 9;151(4):134. doi: 10.1007/s00432-025-06192-z. PMID- 40199157 OWN - NLM STAT- MEDLINE DCOM- 20250516 LR - 20250516 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 3 DP - 2025 Jun TI - mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up). PG - 102333 LID - S1558-7673(25)00034-5 [pii] LID - 10.1016/j.clgc.2025.102333 [doi] AB - INTRODUCTION AND OBJECTIVES: Non-muscle-invasive bladder cancer (NMIBC) patients need a strict follow-up with cystoscopy (UCS) and voided urinary cytology (vUC) due to high rate of recurrence and progression. To reduce invasiveness and costs, a new diagnostic biomarker, namely Xpert Monitor BC(Ⓡ)-detecting 5 mRNAs in voided urine-, has been proposed. We test Xpert Monitor BC(Ⓡ) ability to detect tumor recurrence at an early point during follow-up of high risk (HR) or very high risk (VHR) NMIBC patients, aiming at evaluating reliability of this test as a single procedure. MATERIALS AND METHODS: Between September 2022 and July 2023 included, 80 HR or VHR NMIBC patients were prospectively enrolled. Both naive and previously treated patients (including Bacillus Calmette-Guerin-BCG-and/or systemic immunotherapy) were admitted. Patients with known upper urinary tract urothelial carcinoma (UTUC) were excluded. Xpert Monitor BC(Ⓡ) test was carried out on precystoscopy voided urine samples. In case of suspicious urethra-cystoscopy (UCS), a transurethral resection (TURB) or a biopsy was indicated. vUC was usually prescribed to be performed prior to UCS. Negative predictive value (NVP), positive predictive value (PPV), sensitivity (SE) and specificity (SP) of Xpert Monitor BC(Ⓡ) and vUC, were assessed and compared with UCS and secondarily with histology at TURB/bladder biopsy. Patients who proceeded with follow-up underwent a second evaluation with Xpert Monitor BC(Ⓡ) test. RESULTS: Seventy-six patients were evaluable. Median age was 70 years (interquartile range [IQR] 65-78) and 62 (81.6%) patients were male. VHR patients were 14 (18.4%), 47 (61.8%) had a history of carcinoma in situ (CIS) and 37 (49.3%) had multifocal disease while 51 patients (67.1%) had recurrent bladder cancer (BC). BC recurred in 15 patients (19.7%): in 3 of them as a muscle-invasive bladder cancer (MIBC). Xpert Monitor BC(Ⓡ) showed a NPV, PPV, SE, SP of 95.3% (41/43), 57.6% (19/33), 90.5% (19/21) and 74.5% (41/55) respectively. When available, vUC displayed a NPV of 78.9% (30/38), a PPV of 75% (3/4), a SE of 27.3% (3/11) and a SP of 96.7% (30/31). Twenty patients underwent a subsequent Xpert Monitor BC(Ⓡ) test and UCS during their follow-up, and 3 had a bladder cancer recurrence. Of note Xpert Monitor BC(Ⓡ) was positive in all those 3 patients who previously tested positive despite a negative UC. CONCLUSIONS: High NPV and SE of Xpert Monitor BC(Ⓡ) are confirmed in our HR and VHR NMIBC series. Apparent false positive tests may be regarded as suspicious for persistent/recurrent disease. Implementation of Xpert Monitor BC(Ⓡ) aiming at improving cancer detection is supported by these findings, and a single test based follow-up may be explored. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Macchi, Alberto AU - Macchi A AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: alberto.macchi@istitutotumori.mi.it. FAU - Bruniera, Martina AU - Bruniera M AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Nazzani, Sebastiano AU - Nazzani S AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Ceccato, Tommaso AU - Ceccato T AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Colbacchini, Claudia AU - Colbacchini C AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Taverna, Alessandra AU - Taverna A AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Aiello, Giuseppe AU - Aiello G AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Bernasconi, Valentina AU - Bernasconi V AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Catanzaro, Mario AU - Catanzaro M AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Torelli, Tullio AU - Torelli T AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Biasoni, Davide AU - Biasoni D AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Stagni, Silvia AU - Stagni S AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Tesone, Antonio AU - Tesone A AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Silvani, Carlo AU - Silvani C AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Claps, Melanie AU - Claps M AD - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Giannatempo, Patrizia AU - Giannatempo P AD - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Zimatore, Matteo AU - Zimatore M AD - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Bonini, Chiara AU - Bonini C AD - Laboratory Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Morelli, Daniele AU - Morelli D AD - Laboratory Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Nicolai, Nicola AU - Nicolai N AD - Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. LA - eng PT - Journal Article DEP - 20250319 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (RNA, Messenger) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology/genetics MH - Male MH - Female MH - Aged MH - Cystoscopy MH - *RNA, Messenger/urine MH - Follow-Up Studies MH - Prospective Studies MH - Middle Aged MH - *Neoplasm Recurrence, Local/urine/diagnosis MH - *Biomarkers, Tumor/urine/genetics MH - Aged, 80 and over MH - Urine/cytology MH - Neoplasm Invasiveness MH - Sensitivity and Specificity MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Active surveillance OT - Biomarkers OT - NMBIC OT - Urethro-cystoscopy OT - Voided urinary cytology OT - Xpert Monitor BC(Ⓡ) COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2025/04/09 10:13 MHDA- 2025/05/16 11:42 CRDT- 2025/04/08 18:08 PHST- 2024/09/06 00:00 [received] PHST- 2025/02/19 00:00 [revised] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/05/16 11:42 [medline] PHST- 2025/04/09 10:13 [pubmed] PHST- 2025/04/08 18:08 [entrez] AID - S1558-7673(25)00034-5 [pii] AID - 10.1016/j.clgc.2025.102333 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Jun;23(3):102333. doi: 10.1016/j.clgc.2025.102333. Epub 2025 Mar 19. PMID- 40187951 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 5 DP - 2025 May TI - Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma. PG - 330.e11-330.e17 LID - S1078-1439(25)00091-2 [pii] LID - 10.1016/j.urolonc.2025.03.008 [doi] AB - OBJECTIVE: To investigate the pattern and risk factors of local recurrence and intravesical recurrence of ureteral upper tract urothelial carcinoma (UTUC) following segmental ureterectomy (SU). METHODS: From February 2012 to August 2021, a retrospective analysis was conducted on patients following SU. Univariate and multivariate Cox regression analysis were used to evaluate the risk factors. Kaplan-Meier curves were employed to illustrate survival outcomes. RESULTS: Among 88 patients, 50 (57%) were male, with a median age of 71 (IQR: 62-77) years. The procedures of ureteral reconstruction included ureteral reimplantation in 77 (88%) cases, ureteroureteral anastomosis in 9 (10 %) cases, Boari flap ureteroplasty with psoas hitch in 1 (1%) case, and cutaneous ureterostomy in 1 (1%) case. The median follow-up time was 44.5 months. The 3-year rate of local recurrence, lymph node metastasis, ipsilateral upper urinary tract recurrence and intravesical recurrence was 31.6%, 19.0%, 22.2% and 35.7%, respectively. G3 (HR = 3.355, 95% CI 1.375-8.184, P = 0.008), and lymphatic vascular infiltration (HR = 3.127, 95% CI 1.043-9.373, P = 0.042) were independent risk factors for local recurrence. G3 (HR = 3.782, 95% CI 1.036-13.812, P = 0.044) was an independent risk factor for lymph node metastasis. Sarcomatoid differentiation (HR = 3.943, 95% CI 1.087-14.308, P = 0.037) was an independent risk factor for ipsilateral upper urinary tract recurrence. Previous or concurrent bladder cancer (HR = 3.280, 95% CI 1.667-6.453, P = 0.001) and sarcomatoid differentiation (HR = 4.442, 95% CI 1.317-14.989, P = 0.016) were independent risk factor for intravesical recurrence. The most common regions for bladder recurrence were posterior wall (21%), same lateral wall (16%) and trigon (16%). CONCLUSION: SU is a feasible treatment for selected UTUC patients, yet it is associated with a considerable risk of local and intravesical recurrence. Careful monitoring and active adjuvant therapy are essential to minimize the recurrence rate for patients with risk factors. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Guan, Bao AU - Guan B AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Chen, Silu AU - Chen S AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Tao, Zihao AU - Tao Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Jiang, Yueyuan AU - Jiang Y AD - Department of Radiation Oncology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Li, Zhenyu AU - Li Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Xu, Chunru AU - Xu C AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Tang, Qi AU - Tang Q AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Liu, Yang AU - Liu Y AD - Department of Radiation Oncology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Li, Hongzhen AU - Li H AD - Department of Radiation Oncology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Gao, Xianshu AU - Gao X AD - Department of Radiation Oncology, Peking University First Hospital, Xicheng District, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing, China. Electronic address: pineneedle@sina.com. FAU - Li, Xiaoying AU - Li X AD - Department of Radiation Oncology, Peking University First Hospital, Xicheng District, Beijing, China. Electronic address: 13716109164@139.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250404 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Male MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Female MH - Risk Factors MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Ureteral Neoplasms/surgery/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Ureter/surgery MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Intravesical recurrence OT - Local recurrence OT - Segmental ureterectomy OT - Survival analysis OT - Upper tract urothelial carcinoma COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/06 04:44 MHDA- 2025/05/13 06:32 CRDT- 2025/04/05 21:59 PHST- 2024/07/03 00:00 [received] PHST- 2025/01/11 00:00 [revised] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/05/13 06:32 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 21:59 [entrez] AID - S1078-1439(25)00091-2 [pii] AID - 10.1016/j.urolonc.2025.03.008 [doi] PST - ppublish SO - Urol Oncol. 2025 May;43(5):330.e11-330.e17. doi: 10.1016/j.urolonc.2025.03.008. Epub 2025 Apr 4. PMID- 40185662 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250729 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 8 DP - 2025 Aug TI - Prophylactic heparin does not increase clinically significant bleeding following transurethral resection of a bladder tumor. PG - 469.e13-469.e18 LID - S1078-1439(25)00114-0 [pii] LID - 10.1016/j.urolonc.2025.03.017 [doi] AB - INTRODUCTION: Transurethral resection of bladder tumor (TURBT) is a high bleeding risk procedure due to resection over a mucosal surface and is often performed in patients with risk factors for venous thromboembolism (VTE). Limited data exist to inform the risks and benefits of prophylactic heparin before TURBT. We sought to assess whether preoperative heparin was associated with clinically significant bleeding after TURBT. METHODS: We retrospectively identified 583 consecutive patients who underwent TURBT between Jan 1, 2021 and April 30, 2023. In April 2022 we began routinely administering 5,000 units of subcutaneous heparin at anesthesia induction during TURBT. The primary outcome was clinically significant bleeding within 30 days of TURBT, defined as reoperation for clot evacuation/fulguration, clot retention, blood transfusion, and/or continuous bladder irrigation. RESULTS: Among 583 patients, 220 (38%) received preoperative heparin and 363 (62%) did not. Twenty-five patients experienced a bleeding event, including 6 (2.7%) in the heparin group and 19 (5.2%) in the no heparin group (P = 0.25). After adjusting for sex and tumor size, heparin was not significantly associated with clinically significant bleeding (adjOR 0.51, 95% CI, 0.18-1.2, P = 0.16). Three patients (0.5%) experienced a 30-day VTE, including 1 (0.5%) in the heparin group and 2 (0.6%) in the group without heparin (P = 0.9). CONCLUSION: We did not observe a statistically significant difference in the rate of clinically significant bleeding within 30 days of TURBT between patients treated with and without preoperative heparin, suggesting that preoperative heparin can be considered among patients at high risk of postoperative VTE. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Regele, Eric AU - Regele E AD - Department of Urology, Mayo Clinic, Jacksonville, FL. FAU - Beran, Katherine AU - Beran K AD - Boston University, Boston, MA. FAU - Hanchate, Kunal AU - Hanchate K AD - College of Medicine, University of Florida, Gainesville, FL. FAU - Hochwald, Alex AU - Hochwald A AD - Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL. FAU - Edwards, Michael A AU - Edwards MA AD - Department of Surgery, Division of Advanced GI and Bariatric Surgery, Mayo Clinic, Jacksonville, FL. FAU - Zganjar, Andrew J AU - Zganjar AJ AD - Department of Urology, Mayo Clinic, Jacksonville, FL. FAU - Lyon, Timothy D AU - Lyon TD AD - Department of Urology, Mayo Clinic, Jacksonville, FL; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Division of Health Care Delivery Research, Mayo Clinic, Jacksonville, FL. Electronic address: Lyon.timothy@mayo.edu. LA - eng PT - Journal Article DEP - 20250403 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 9005-49-6 (Heparin) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Heparin/adverse effects/therapeutic use MH - *Urinary Bladder Neoplasms/surgery MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Postoperative Hemorrhage/chemically induced/epidemiology MH - *Anticoagulants/adverse effects/therapeutic use MH - *Cystectomy/methods/adverse effects MH - Venous Thromboembolism/prevention & control OTO - NOTNLM OT - Health care delivery OT - Hospital quality OT - Rankings and ratings OT - Urology COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. TDL has served as a consultant for ImmunityBio and UroGen Pharma. TDL has served as a consultant for ImmunityBio and UroGen Pharma. EDAT- 2025/04/05 15:57 MHDA- 2025/07/12 16:45 CRDT- 2025/04/04 21:59 PHST- 2025/01/13 00:00 [received] PHST- 2025/03/06 00:00 [revised] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/07/12 16:45 [medline] PHST- 2025/04/05 15:57 [pubmed] PHST- 2025/04/04 21:59 [entrez] AID - S1078-1439(25)00114-0 [pii] AID - 10.1016/j.urolonc.2025.03.017 [doi] PST - ppublish SO - Urol Oncol. 2025 Aug;43(8):469.e13-469.e18. doi: 10.1016/j.urolonc.2025.03.017. Epub 2025 Apr 3. PMID- 40183956 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20260823 IS - 1619-7089 (Electronic) IS - 1619-7070 (Print) IS - 1619-7070 (Linking) VI - 52 IP - 10 DP - 2025 Aug TI - Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer - Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/CT? PG - 3653-3661 LID - 10.1007/s00259-025-07240-z [doi] AB - PURPOSE: Nodal staging in patients with muscle invasive bladder cancer (MIBC) or very high risk non-muscle invasive bladder cancer (vhNMIBC) aids to predict survival. The sentinel node (SN) procedure holds the promise to identify the diagnostically relevant first tumor-draining nodes while limiting the complication rate associate with a pelvic lymph node dissection (PLND), still considered the gold standard of nodal staging. Following an initial technical feasibility study, we prospectively evaluated the clinical impact of using peri-tumoral injections with the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid for SN procedures in bladder cancer. METHODS: A total of 30 patients with vhNMIBC or MIBC, cN0M0 (with or without neo-adjuvant systemic therapy) scheduled for radical cystectomy with pelvic lymph node dissection (PLND) were enrolled in a prospective study. Patients received four to six transurethral peritumoral injections of ICG-(99m)Tc-nanocolloid into the bladder for SN tracing. Preoperative lymphoscintigraphy and Single Photon Emission Computed Tomography (SPECT)/CT was performed the day before surgery. The intraoperative detection of SNs was supported by both fluorescence (utilizing a hand-held camera or fluorescence laparoscope) and radio-guidance (using hand-held, laparoscopic or DROP-IN probe tracing). Resected specimens, comprising both SNs and PLND tissue, were analyzed by the pathologist. Complications related to the tracer injection were documented and cancer-specific survival (CSS) and overall survival (OS) were studied using Kaplan-Meier survival curves. RESULTS: SPECT/CT imaging revealed 31 SNs in 19 patients with non-visualization of SN in 11 patients (36.7%). During surgery, 4 additional SNs were identified based on fluorescent signals in 3 patients. In 1 patient who underwent open cystectomy, ex vivo evaluation of the PLND-specimen revealed an additional radioactive SN. The PLND yielded 592 lymph nodes (LNs; median 17 LNs/patient). In 5 out of 35 SNs (14.2%; no additional tumor positive LN in complementary PLND) and 3 out of 592 LNs (0.5%; 2 patients with non-visualization of SN) were identified as tumor-positive upon pathological evaluation. At mean follow up of 82 months (SD +/- 7.1 months) 17% of patients died of disease. The 2 patients with non-visualization of SN and nodal metastases (0%) did worse than SN positive patients (75%). Of the 24 patients classified as pN0 8% died. CONCLUSIONS: Preoperative SN-visualization on SPECT/CT was achieved in the majority of patients. Patients with SN non-visualization had an increased risk of nodal metastases and poorer outcome. In patients with metastases in the SN no additional nodal metastases were found in the complementary PLND. CI - (c) 2025. The Author(s). FAU - van Gennep, E J AU - van Gennep EJ AD - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands. AD - Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Pisano, G AU - Pisano G AD - Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. FAU - KleinJan, G H AU - KleinJan GH AD - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands. g.h.kleinjan@lumc.nl. AD - Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. g.h.kleinjan@lumc.nl. FAU - Rietbergen, D D D AU - Rietbergen DDD AD - Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Department of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands. FAU - Hendricksen, K AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Mertens, L S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Vd Kamp, M W AU - Vd Kamp MW AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Wit, E M K AU - Wit EMK AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - van Montfoort, M L AU - van Montfoort ML AD - Department of Pathology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Donswijk, M AU - Donswijk M AD - Department of Nuclear Medicine, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - van Rhijn, B W G AU - van Rhijn BWG AD - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands. AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - van Leeuwen, F W B AU - van Leeuwen FWB AD - Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - van der Poel, H G AU - van der Poel HG AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands. LA - eng GR - PGF2009-4344/KWF Kankerbestrijding/ PT - Clinical Trial PT - Journal Article DEP - 20250404 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 RN - IX6J1063HV (Indocyanine Green) RN - 0 (Technetium Tc 99m Aggregated Albumin) RN - 0 (Radioactive Tracers) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Aged MH - Female MH - Male MH - Middle Aged MH - *Lymph Node Excision MH - *Single Photon Emission Computed Tomography Computed Tomography MH - Prospective Studies MH - *Sentinel Lymph Node/diagnostic imaging/pathology/surgery MH - Pelvis/diagnostic imaging MH - Aged, 80 and over MH - Indocyanine Green MH - Technetium Tc 99m Aggregated Albumin MH - Lymphatic Metastasis MH - Radioactive Tracers MH - *Sentinel Lymph Node Biopsy PMC - PMC12316797 OTO - NOTNLM OT - Bladder cancer OT - Fluorescence OT - Radio-guided surgery OT - Robotic surgery OT - Sentinel lymph node COIS- Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of NKI-AvL 2014, M14HSN study protocol. Consent to participate: Informed consent was obtained from all individual participants included in the study. Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Figs. 1, 3 and 4 Competing interests: The authors have no relevant financial or non-financial interests to disclose. EDAT- 2025/04/04 12:29 MHDA- 2025/08/01 12:35 PMCR- 2025/04/04 CRDT- 2025/04/04 11:14 PHST- 2025/01/21 00:00 [received] PHST- 2025/03/24 00:00 [accepted] PHST- 2025/08/01 12:35 [medline] PHST- 2025/04/04 12:29 [pubmed] PHST- 2025/04/04 11:14 [entrez] PHST- 2025/04/04 00:00 [pmc-release] AID - 10.1007/s00259-025-07240-z [pii] AID - 7240 [pii] AID - 10.1007/s00259-025-07240-z [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2025 Aug;52(10):3653-3661. doi: 10.1007/s00259-025-07240-z. Epub 2025 Apr 4. PMID- 40182577 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250405 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 23 IP - 2 DP - 2025 TI - Nephrogenic adenoma of the urinary bladder. Clinical features, long-term follow-up and recurrence predictors. PG - 109-116 LID - 10.1080/20905998.2024.2402585 [doi] AB - OBJECTIVES: To review the clinical features of nephrogenic adenoma (NA) of the urinary bladder and assess the long-term recurrence rates. MATERIAL AND METHODS: A retrospective analysis of all diagnosed NA of the urinary bladder between 2000 and 2023 was done. All patients' demographics, symptoms, history of previous bladder surgeries, macroscopic and microscopic features of NA and coincidental pathology were reviewed. The long-term recurrence rate including malignant recurrence was assessed. Univariate and multivariate analysis of predictor of recurrence was performed. RESULTS: We identified 24 patients diagnosed with NA with a mean (SD, range) age of 56 (16, 15-73) years. Eighteen (75%) patients had previous history of bladder surgeries. Macroscopic appearance on cystoscopy looked polypoidal, flat velvety, papillary and nodular in eight, seven, five, and four patients, respectively. At a median (range) follow-up of 35 (18-145) months, 15 (63%) patients developed one recurrence including NA, non-specific cystitis and urothelial carcinoma (UC) in nine, three and three patients, respectively. Of them, five had a second recurrence, and one patient had a third recurrence. Patients with malignant recurrence had previous history of UC and two of them required radical cystectomy and urinary diversion. Previous TURBT was the only independent predictor for recurrence [OR (95% CI) = 28 (2-37), p = 0.01]. CONCLUSION: Nephrogenic adenoma is a benign disease that mimics malignant lesion clinically. It is associated with high recurrence rate. Previous resection of bladder lesion is the independent predictor of the recurrence. CI - (c) 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Zahran, Mohamed H AU - Zahran MH AUID- ORCID: 0000-0002-2897-1023 AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shehata, Mohamed AU - Shehata M AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Khater, Shery AU - Khater S AD - Pathology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Nabeeh, Hosam AU - Nabeeh H AD - Urology Department, Kafr Elsheikh University, Kafr Elsheikh, Egypt. FAU - Ali Badawy, Mohamed AU - Ali Badawy M AD - Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Mosbah, Ahmed AU - Mosbah A AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abol-Enein, Hassan AU - Abol-Enein H AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20240911 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC11963184 OTO - NOTNLM OT - Bladder cancer OT - cystoscopy OT - nephrogenic adenoma OT - recurrence OT - tumour resection COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/04/04 06:26 MHDA- 2025/04/04 06:27 PMCR- 2024/09/11 CRDT- 2025/04/04 05:12 PHST- 2025/04/04 06:27 [medline] PHST- 2025/04/04 06:26 [pubmed] PHST- 2025/04/04 05:12 [entrez] PHST- 2024/09/11 00:00 [pmc-release] AID - 2402585 [pii] AID - 10.1080/20905998.2024.2402585 [doi] PST - epublish SO - Arab J Urol. 2024 Sep 11;23(2):109-116. doi: 10.1080/20905998.2024.2402585. eCollection 2025. PMID- 40175503 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20250515 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Apr 2 TI - Perioperative and oncological outcomes of single position retroperitoneoscopic radical nephroureterectomy for upper urinary tract urothelial carcinoma. PG - 11221 LID - 10.1038/s41598-025-96261-7 [doi] LID - 11221 AB - Radical nephroureterectomy (RNU) is the gold standard therapy for patients with upper urinary tract urothelial carcinoma (UTUC). In this study, we compared the effect of two surgical techniques, single-position complete retroperitoneoscopic radical nephroureterectomy (SCRNU) and laparoscopic nephroureterectomy with open bladder cuff excision (LNOBE), on perioperative and long-term oncological outcomes in UTUC patients. We retrospectively collected information on baseline characteristics, clinicopathological characteristics, surgical approaches, perioperative data, and survival outcomes from 174 patients who underwent RNU for UTUC between January 2018 and June 2023 in our center. The data were analyzed using the Mann-Whitney test, Fisher's exact test, Chi-square test. Linear regressions were applied to explore the effect of surgery approach on the continuous outcomes. Log-rank test and Kaplan-Meier survival curves were plotted to describe the survival outcome. Univariate and Multivariate Cox regressions were conducted to explore the independent prognostic factors. To address potential selection bias, we also employed an Inverse Probability of Treatment Weighting (IPTW) strategy. Patients who underwent SCRNU had shorter operative times (p < 0.001), reduced estimated blood loss (p < 0.001), less drainage on the first postoperative day (p = 0.009), shorter hospital stays (p = 0.001), and better intravesical recurrence-free survival than those who underwent LNOBE (IVRFS, HR: 0.17, 95% CI: 0.07-0.44, p = 0.007). Moreover, SCRNU was confirmed to be a protective factor for IVRFS after IPTW-adjusted Cox regression analysis was performed (HR: 0.17, 95% CI: 0.04-0.77, p = 0.021). SCRNU not only avoids intraoperative repositioning but also improves perioperative outcomes, including the reduction of operative time, blood loss, and length of hospital stay, and is associated with better IVRFS. CI - (c) 2025. The Author(s). FAU - Chen, Jiaqiang AU - Chen J AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Zhang, Luxin AU - Zhang L AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Dai, Zhihong AU - Dai Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Chang, Cheng AU - Chang C AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Tong, Heyao AU - Tong H AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Cui, Hepeng AU - Cui H AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Song, Zhuwei AU - Song Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. FAU - Fan, Bo AU - Fan B AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. fanbo@dmu.edu.cn. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. fanbo@dmu.edu.cn. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. fanbo@dmu.edu.cn. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. fanbo@dmu.edu.cn. FAU - Liu, Zhiyu AU - Liu Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. lzydoct@163.com. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. lzydoct@163.com. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. lzydoct@163.com. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. lzydoct@163.com. FAU - Wang, Liang AU - Wang L AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, No.467, Zhongshan Road, Dalian, 116011, Liaoning, China. wangldoct@sina.com. AD - Liaoning Provincial Key Laboratory of Urological Digital Precision Diagnosis and Treatment, Dalian, 116011, Liaoning, China. wangldoct@sina.com. AD - Liaoning Engineering Research Center of Integrated Precision Diagnosis and Treatment Technology for Urological Cancer, Dalian, 116011, Liaoning, China. wangldoct@sina.com. AD - Dalian Key Laboratory of Prostate Cancer Research, Dalian, 116011, Liaoning, China. wangldoct@sina.com. LA - eng GR - JYTZD2023046/the Scientific Research Project of Ministry of Education of Liaoning Province/ PT - Journal Article DEP - 20250402 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Male MH - Female MH - *Nephroureterectomy/methods MH - Aged MH - Middle Aged MH - Retrospective Studies MH - *Laparoscopy/methods MH - Treatment Outcome MH - *Urologic Neoplasms/surgery/mortality/pathology MH - Retroperitoneal Space/surgery MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Operative Time MH - Kaplan-Meier Estimate MH - Aged, 80 and over PMC - PMC11965278 OTO - NOTNLM OT - Intravesical recurrence-free survival OT - Perioperative outcomes OT - Radical nephroureterectomy OT - Single-position OT - Upper urinary tract urothelial carcinoma COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/04/03 00:24 MHDA- 2025/04/03 18:25 PMCR- 2025/04/02 CRDT- 2025/04/02 23:24 PHST- 2024/11/30 00:00 [received] PHST- 2025/03/27 00:00 [accepted] PHST- 2025/04/03 18:25 [medline] PHST- 2025/04/03 00:24 [pubmed] PHST- 2025/04/02 23:24 [entrez] PHST- 2025/04/02 00:00 [pmc-release] AID - 10.1038/s41598-025-96261-7 [pii] AID - 96261 [pii] AID - 10.1038/s41598-025-96261-7 [doi] PST - epublish SO - Sci Rep. 2025 Apr 2;15(1):11221. doi: 10.1038/s41598-025-96261-7. PMID- 40169318 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 7 DP - 2025 Jul TI - Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Guerin and gemcitabine-docetaxel therapy. PG - 443.e1-443.e10 LID - S1078-1439(25)00105-X [pii] LID - 10.1016/j.urolonc.2025.03.009 [doi] AB - BACKGROUND AND OBJECTIVE: Sequential intravesical gemcitabine/docetaxel (Gem/Doce) is a potential alternative to bacillus Calmette-Guerin (BCG) for treating non-muscle-invasive bladder cancer (NMIBC). Intermediate-risk NMIBC group (IR-NMIBC) includes both low-grade (LG) and high-grade tumors (HG). This study investigates the response of HG and LG IR-NMIBC to Gem/Doce compared to BCG therapy. METHODS: We included patients with IR-NMIBC who received either BCG or Gem/Doce between 2013 and 2023. Maintenance regimens were administered to patients without recurrence after induction for 1 year. Follow-up cystoscopies were performed per American Urological Association (AUA) guidelines. Kaplan-Meier and Cox regression analyses were performed to evaluate recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: Among 505 NMIBC patients, 150 were IR-NMIBC: 115 with HG tumors (69 received BCG, 46 received Gem/Doce) and 35 with LG tumors (14 received BCG, 21 received Gem/Doce).With a median follow-up time of 31 months (Interquartile Range [IQR] 13-54), The overall 2-year any-grade RFS was 55%. For HG and LG groups, the 2-year any-grade RFS was 58% and 35% (P = 0.009), respectively. High-grade RFS at 2 years was 75% for HG and 94% for LG (P = 0.065). The 2-year PFS was similar between groups, at 96% for both HG and LG (P = 0.39). In HG patients, 2-year high-grade RFS was higher with BCG than Gem/Doce (81% vs. 59%, P = 0.008). In LG patients, 2-year any-grade and high-grade RFS were comparable between BCG and Gem/Doce (P = 0.067 and P = 0.37, respectively). CONCLUSIONS: Our findings suggest that BCG may offer a superior benefit in terms of high-grade RFS for HG IR-NMIBC compared to Gem/Doce, while LG tumors respond similarly to both treatments. This emphasizes the role of risk stratification in treatment selection. Prospective studies are needed to validate these findings and refine treatment strategies. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Eraky, Ahmed AU - Eraky A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Ahmed.Eraky@mountsinai.org. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Hug, Brenda AU - Hug B AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Ben-David, Reuben AU - Ben-David R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Waingankar, Nikhil AU - Waingankar N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. LA - eng PT - Journal Article DEP - 20250331 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Gemcitabine MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Male MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - *Docetaxel/therapeutic use/administration & dosage/pharmacology MH - Aged MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Gemcitabine/Docetaxel OT - Intermediate-risk OT - Risk stratification COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/02 00:25 MHDA- 2025/05/31 00:36 CRDT- 2025/04/01 21:58 PHST- 2024/11/13 00:00 [received] PHST- 2025/01/28 00:00 [revised] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/05/31 00:36 [medline] PHST- 2025/04/02 00:25 [pubmed] PHST- 2025/04/01 21:58 [entrez] AID - S1078-1439(25)00105-X [pii] AID - 10.1016/j.urolonc.2025.03.009 [doi] PST - ppublish SO - Urol Oncol. 2025 Jul;43(7):443.e1-443.e10. doi: 10.1016/j.urolonc.2025.03.009. Epub 2025 Mar 31. PMID- 40163213 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250403 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 16 IP - 1 DP - 2025 Mar 31 TI - Investigation of new autoantibodies in urothelial bladder cancer for biomarker discovery using immunoproteomics. PG - 436 LID - 10.1007/s12672-025-02167-1 [doi] LID - 436 AB - BACKGROUND: Tumor-associated antigens (TAAs) lead to the production of tumor-specific autoantibodies (anti-TAA autoantibodies) by triggering the humoral immune system which can be used as candidate biomarkers. This study aims to investigate TAAs proteins eliciting humoral responses in different stages of urothelial bladder carcinoma (UBC) using an immunoproteomics approach to find novel biomarkers for the clinical management of the disease. METHODS: Total proteins were obtained from the newly established UBC cell line, JAM-ICR, and separated by two-dimensional gel electrophoresis (2DE). These proteins were then immobilized using pooled serum samples from healthy individuals, autoimmune and UBC patients at different stages. The immunoreactive spots in UBC patient samples were identified by mass spectrometry and verified with several databases such as GEPIA and Enrichr databases. RESULTS: Through the comparison of the immunoreactivity pattern of serums, we were able to identify eight specific proteins using LC-MS. Patients with muscle invasion showed increased expression of ENO1, VDAC2, AKR1B1, SDF2L1, PRDX6, PSME1, HSPB1 and PHB1 compared to controls. In addition, non-muscle invasive patients showed overexpression of ENO1, VDAC2, AKR1B1, and PRDX6 compared to controls. In addition to their diagnostic function, PRDX6, ENO1, VDAC2, and PHB1 have been demonstrated to possess prognostic capabilities in patients with UBC. Interestingly, these proteins were mainly associated with cellular growth and anti-apoptotic activity. CONCLUSION: In this study, eight anti-TAA autoantibodies were identified that have the potential to serve as diagnostic and prognostic biomarkers. These could represent a valuable panel of biomarkers for the management of UBC. CI - (c) 2025. The Author(s). FAU - Tabaei, Samira AU - Tabaei S AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Zareinejad, Mohammadrasul AU - Zareinejad M AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Haghshenas, Mohammad Reza AU - Haghshenas MR AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Shakhssalim, Nasser AU - Shakhssalim N AD - Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Gilany, Kambiz AU - Gilany K AD - Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran. FAU - Stensballe, Allan AU - Stensballe A AD - Department of Health Science and Technology, Aalborg University, 9260, Gistrup, Denmark. AD - Clinical Cancer Research Center, Aalborg University Hospital, 9260, Gistrup, Denmark. FAU - Ghaderi, Abbas AU - Ghaderi A AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Ghaderia@sums.ac.ir. LA - eng GR - 5072-00007B/Danish National Mass Spectrometry Platform for Functional Proteomics/ GR - No26430/Beheshti University of Medical Sciences/ PT - Journal Article DEP - 20250331 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC11958914 OTO - NOTNLM OT - Biomarker OT - Diagnostic biomarkers OT - Immunoproteomics OT - Prognostic biomarkers OT - Tumor-associated antigens OT - Urothelial bladder cancer COIS- Declarations. Ethics approval and consent to participate: Approval of the research protocol by an institutional review board: This study was approved by the local Ethics Committee of Beheshti University of Medical Sciences [IR.SBMU.UNRC.REC.1399.021] under the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all participants. Consent for publication: All authors have reviewed the final version of the manuscript and approved its submission. Competing interests: The authors declare no competing interests. EDAT- 2025/03/31 21:17 MHDA- 2025/03/31 21:18 PMCR- 2025/03/31 CRDT- 2025/03/31 11:55 PHST- 2024/11/26 00:00 [received] PHST- 2025/03/18 00:00 [accepted] PHST- 2025/03/31 21:18 [medline] PHST- 2025/03/31 21:17 [pubmed] PHST- 2025/03/31 11:55 [entrez] PHST- 2025/03/31 00:00 [pmc-release] AID - 10.1007/s12672-025-02167-1 [pii] AID - 2167 [pii] AID - 10.1007/s12672-025-02167-1 [doi] PST - epublish SO - Discov Oncol. 2025 Mar 31;16(1):436. doi: 10.1007/s12672-025-02167-1. PMID- 40158236 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250513 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 77 DP - 2025 Aug TI - Clinicopathological features analysis of Paraganglioma of urinary bladder: A retrospective study. PG - 152477 LID - S1092-9134(25)00042-5 [pii] LID - 10.1016/j.anndiagpath.2025.152477 [doi] AB - Paraganglioma of urinary bladder (PUB) is a rare neuroendocrine neoplasm. This study is a retrospective analysis of clinicopathological features in 11 cases of PUB. The studied cohort included seven male and four female patients with a median age of 64 years (range 37-73 years). The maximum tumor diameter ranged from 1 to 4 cm (median: 2.5 cm). Macroscopically, most lesions appeared as smooth, polypoid intraluminal protrusions; one case exhibited a nodular mass extending into the outer bladder wall. Microscopic evaluation demonstrated tumor infiltration into the muscularis propria (6 cases) or both lamina propria and muscularis propria (5 cases). Tumor cells were arranged in nested (Zellballen) or organoid patterns. Tumor cells uniformly expressed CD56, synaptophysin, and chromogranin. The Ki-67 proliferation index was /=3, the pooled sensitivity and specificity for detecting muscle invasion were 88.2% and 80.6%, respectively. Interobserver agreement showed excellent consistency with a mean kappa value of 0.82. Individual study sensitivities ranged from 74.1% to 94.6%, while specificities varied from 43.9% to 96.5%. Conclusions: VI-RADS demonstrates high diagnostic accuracy and excellent interobserver agreement in BC staging, supporting its role as a reliable non-invasive diagnostic tool. However, it should be used as a complementary tool to, not a replacement for, histopathological confirmation. Moreover, the variability in specificity suggests the need for standardized training and interpretation protocols. Clinical correlation and adequate reader experience are essential for optimal implementation. Future integration with pathological data may further enhance its predictive value. FAU - Nesiu, Alexandru AU - Nesiu A AD - Discipline of Urology, Department of Medicine, Vasile Goldis Western University, Liviu Rebreanu Boulevard, No. 86, 310414 Arad, Romania. FAU - Novacescu, Dorin AU - Novacescu D AUID- ORCID: 0000-0002-2520-7636 AD - Department II of Microscopic Morphology, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Latcu, Silviu AU - Latcu S AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. AD - Discipline of Urology, Department XV, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Bardan, Razvan AU - Bardan R AD - Discipline of Urology, Department XV, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Cumpanas, Alin AU - Cumpanas A AD - Discipline of Urology, Department XV, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Zara, Flavia AU - Zara F AUID- ORCID: 0000-0002-5755-179X AD - Department II of Microscopic Morphology, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Buciu, Victor AU - Buciu V AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Caprariu, Radu AU - Caprariu R AD - Discipline of Radiology and Medical Imaging, Department XV, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. FAU - Cut, Talida Georgiana AU - Cut TG AUID- ORCID: 0000-0002-6567-4407 AD - Discipline of Infectious Diseases, Department XIII, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Stana, Ademir Horia AU - Stana AH AD - Discipline of Radiology, Department of Medicine, Vasile Goldis Western University, Liviu Rebreanu Boulevard, No. 86, 310414 Arad, Romania. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250307 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/diagnosis/pathology MH - Observer Variation MH - Neoplasm Staging/methods MH - Sensitivity and Specificity MH - *Multiparametric Magnetic Resonance Imaging/methods/standards PMC - PMC11943855 OTO - NOTNLM OT - bladder cancer diagnosis and staging OT - diagnostic accuracy OT - interobserver agreement OT - multiparametric magnetic resonance imaging (mp-MRI) OT - muscle-invasive bladder cancer (MIBC) OT - non-muscle-invasive bladder cancer (NMIBC) OT - systematic review OT - urologic oncology imaging OT - urothelial cancer OT - vesical imaging-reporting and data system (VI-RADS) COIS- The authors declare no conflicts of interest. EDAT- 2025/03/27 06:28 MHDA- 2025/03/27 06:29 PMCR- 2025/03/07 CRDT- 2025/03/27 01:11 PHST- 2025/02/08 00:00 [received] PHST- 2025/02/28 00:00 [revised] PHST- 2025/03/05 00:00 [accepted] PHST- 2025/03/27 06:29 [medline] PHST- 2025/03/27 06:28 [pubmed] PHST- 2025/03/27 01:11 [entrez] PHST- 2025/03/07 00:00 [pmc-release] AID - medicina61030469 [pii] AID - medicina-61-00469 [pii] AID - 10.3390/medicina61030469 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Mar 7;61(3):469. doi: 10.3390/medicina61030469. PMID- 40142190 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20250515 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 3 DP - 2025 Feb 22 TI - Intravesical BCG: A Double-Edged Sword? The Untold Story of Infection Risks. LID - 10.3390/medicina61030379 [doi] LID - 379 AB - Background and Objectives: Intravesical Bacillus Calmette-Guerin (BCG) therapy remains a cornerstone in the treatment of non-muscle-invasive bladder carcinoma due to its efficacy in reducing recurrence and progression rates. However, its use is associated with various complications-including urinary tract infections (UTIs)-which necessitates further exploration. This study aims to analyze UTIs occurring during intravesical BCG treatment, emphasizing the microbial spectrum, resistance patterns, and risk factors from an infectious diseases and clinical microbiology perspective. Materials and Methods: A retrospective analysis was conducted on 240 patients diagnosed with non-muscle-invasive bladder carcinoma who received intravesical BCG therapy between 2010 and 2021. Data were collected from hospital records, including demographic characteristics, comorbidities, number of intravesical BCG cycles, and microbiological findings. UTIs were classified based on susceptibility patterns, and statistical analyses were performed to determine associations between clinical variables and UTI risk. Results: UTIs developed in 39.1% (n = 94) of patients, with 25.8% (n = 62) caused by susceptible pathogens and 13.3% (n = 32) by resistant pathogens. The most common causative agent was Escherichia coli (80.7% in susceptible UTIs, 43.8% in resistant UTIs), followed by Pseudomonas aeruginosa and Klebsiella pneumoniae. The presence of diabetes mellitus and chronic kidney disease significantly increased the risk of developing a UTI (p < 0.05). A higher number of intravesical BCG cycles correlated with increased UTI occurrence (p < 0.001). Serum C-reactive protein (CRP) levels were significantly elevated in patients with resistant UTIs, while procalcitonin levels were not a reliable predictor of UTI occurrence. Conclusions: Intravesical BCG therapy is associated with a significant incidence of UTIs, particularly among patients with predisposing comorbidities. The increasing prevalence of antibiotic-resistant infections underscores the need for careful monitoring and targeted antimicrobial stewardship strategies. CRP may serve as a useful adjunctive marker for UTI diagnosis in this setting. Future studies should focus on optimizing infection control measures and refining diagnostic criteria to differentiate between BCG-related inflammation and infectious complications. FAU - Barkay, Orcun AU - Barkay O AUID- ORCID: 0000-0001-5347-7740 AD - Infectious Diseases and Clinical Microbiology Department, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan 24002, Turkey. FAU - Keskin, Ercument AU - Keskin E AUID- ORCID: 0000-0001-9618-8252 AD - Urology Department, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan 24002, Turkey. LA - eng PT - Journal Article DEP - 20250222 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - Male MH - *BCG Vaccine/adverse effects/therapeutic use/administration & dosage MH - Aged MH - Administration, Intravesical MH - *Urinary Tract Infections/etiology/epidemiology/microbiology MH - Middle Aged MH - *Urinary Bladder Neoplasms/drug therapy MH - Risk Factors MH - Aged, 80 and over PMC - PMC11943905 OTO - NOTNLM OT - C-reactive protein OT - chronic kidney disease OT - diabetes mellitus OT - intravesical BCG therapy OT - non-muscle-invasive bladder carcinoma OT - urinary tract infections COIS- The authors declare no conflicts of interest. EDAT- 2025/03/27 06:28 MHDA- 2025/03/27 06:29 PMCR- 2025/02/22 CRDT- 2025/03/27 01:11 PHST- 2025/02/01 00:00 [received] PHST- 2025/02/18 00:00 [revised] PHST- 2025/02/20 00:00 [accepted] PHST- 2025/03/27 06:29 [medline] PHST- 2025/03/27 06:28 [pubmed] PHST- 2025/03/27 01:11 [entrez] PHST- 2025/02/22 00:00 [pmc-release] AID - medicina61030379 [pii] AID - medicina-61-00379 [pii] AID - 10.3390/medicina61030379 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Feb 22;61(3):379. doi: 10.3390/medicina61030379. PMID- 40140488 OWN - NLM STAT- MEDLINE DCOM- 20250327 LR - 20250515 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Mar 26 TI - Development and validation of a nomogram for predicting prostatic urethral involvement in bladder cancer. PG - 10431 LID - 10.1038/s41598-025-95684-6 [doi] LID - 10431 AB - To identify risk factors for prostatic urethral involvement (PUI) in bladder cancer and develop an accurate nomogram prediction model. We retrospectively analyzed 295 male patients with bladder urothelial carcinoma undergoing transurethral prostatic biopsy. Risk factors of PUI in bladder cancer were assessed through univariate and multivariate logistic regression analyses. A nomogram model for predicting clinical outcomes was constructed based on the independent risk factors of PUI. The performance of the model was internally validated by 'leave-one-out' cross-validation (LOOCV) and calibration curve. The decision curve analysis (DCA) was applied to evaluate the clinical utility. Further evaluation of PUI and associated risk factors within the context of non-muscle-invasive bladder cancer (NMIBC) were assessed using the same methods. Multivariate analysis revealed that the tumor multiplicity (OR = 2.44, 95% CI 1.17-5.26, P = 0.019), trigonal/neck tumor location (OR = 7.42, 95% CI 4.00-14.24, P < 0.001), high-grade tumor (OR = 5.17, 95% CI 1.52-21.95, P = 0.014), and recurrent carcinoma (OR = 4.39, 95% CI 2.32-8.63, P < 0.001) were identified as independent risk factors for PUI in bladder cancer (all P < 0.05). A final prediction nomogram was established based on these four independent risk factors. After internally validated by LOOCV, the nomogram showed strong discrimination (area under the curve, AUC = 0.8, 95%CI 0.749-0.851) and excellent calibration. DCA further confirmed the model's clinical utility across a wide range of risk thresholds. Subgroup analysis in NMIBC yielded consistent results (AUC = 0.819, 95%CI 0.764-0.874). This nomogram provides a robust tool to stratify PUI risk in bladder cancer, guiding selective prostatic biopsies and personalized management. Integration into clinical workflows may reduce understaging and optimize outcomes. Further external validation is warranted. CI - (c) 2025. The Author(s). FAU - Xu, Hao AU - Xu H AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. AD - Department of Urology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. AD - Department of Urology, The Eco-City Hospital of Tianjin Fifth Central Hospital, Tianjin, 300451, China. FAU - Zhang, Zhe AU - Zhang Z AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Wang, Jian AU - Wang J AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Shen, Chong AU - Shen C AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Qie, Yunkai AU - Qie Y AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Tian, Dawei AU - Tian D AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. FAU - Liu, Shenglai AU - Liu S AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. lshlyhm@126.com. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. huhailong@tmu.edu.cn. FAU - Wu, Changli AU - Wu C AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin, 300211, China. wucl_1989@163.com. LA - eng GR - 2019BWKY026/Technology Project of Tianjin Binhai New Area Health Commission/ GR - MNRC202313/The Talents Cultivated Project of Department of Urology, the Second Hospital of Tianjin Medical University/ GR - 2022ydey15/the Youth Fund of Tianjin Medical University Second Hospital/ GR - 2022ZD069/Scientific Research Project of Tianjin Municipal Education Commission/ GR - TJWJ2022XK014/Tianjin Municipal Health Industry Key Project/ GR - ZC20119/Tianjin Health Science and Technology Project/ PT - Journal Article PT - Validation Study DEP - 20250326 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Male MH - *Nomograms MH - *Urinary Bladder Neoplasms/pathology MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Risk Factors MH - *Prostatic Neoplasms/pathology MH - *Prostate/pathology MH - Aged, 80 and over MH - *Urethra/pathology PMC - PMC11947163 OTO - NOTNLM OT - Bladder cancer OT - Nomogram OT - Prostate urethral biopsy OT - Prostatic urethral involvement OT - Risk stratification COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics statement: In accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments, the present study was approved by the Medical Ethics Committee of the Second Hospital of Tianjin Medical University (Office Address: Third floor of the Comprehensive Building, The Second Hospital of Tianjin Medical University, Tianjin, China) (ethics approval number: KY2024K207, date of approval: April 15, 2024). All patients' records were analyzed anonymously in the retrospective study, which did not affect the clinical course of any patient. Due to the retrospective nature of the study, Medical Ethics Committee of the Second Hospital of Tianjin Medical University waived the need of obtaining informed consent. EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 06:30 PMCR- 2025/03/26 CRDT- 2025/03/27 00:34 PHST- 2025/01/09 00:00 [received] PHST- 2025/03/24 00:00 [accepted] PHST- 2025/03/27 06:30 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 00:34 [entrez] PHST- 2025/03/26 00:00 [pmc-release] AID - 10.1038/s41598-025-95684-6 [pii] AID - 95684 [pii] AID - 10.1038/s41598-025-95684-6 [doi] PST - epublish SO - Sci Rep. 2025 Mar 26;15(1):10431. doi: 10.1038/s41598-025-95684-6. PMID- 40138884 OWN - NLM STAT- MEDLINE DCOM- 20250417 LR - 20250417 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 269 DP - 2025 May TI - Detection and agreement of blood- and lymph vessel invasion assessed by immunohistochemistry in matched TURBT and radical cystectomy specimens. PG - 155917 LID - S0344-0338(25)00109-8 [pii] LID - 10.1016/j.prp.2025.155917 [doi] AB - Vessel invasion (VI) in transurethral resection of bladder tumor (TURBT) usually assessed without immunohistochemistry (IHC) is associated with nodal metastases and reduced survival. Separation of blood (BVI) and lymph (LVI) vessel invasion by IHC in cystectomy (RC) suggests different prognostic trajectories and could guide management after TURBT. However, prevalence of BVI and LVI in TURBT and accuracy between TURBT and RC has not been thoroughly evaluated. We aimed to examine the prevalence of VI, BVI and LVI in TURBT using IHC, and investigate their agreement across matched TURBT and RC. We reviewed TURBT specimens from 244 patients later treated with RC with respect to VI on routine sections. On one selected block for each case D2-40/CD31 antibodies were applied. Accuracy of VI status was assessed comparing the corresponding RC results, and the differences across specimen types were assessed using McNemar s test. In TURBT, more VI was detected with IHC (43 % vs. 31 %). The prevalences were 20 % BVI and 31 % LVI. BVI was associated with higher pathological stages on RC whereas LVI was associated with more nodal metastases. LVI showed good concordance. BVI showed low concordance overall but compared well in patients with MIBC and patients clinically assessed with non-organ confined disease. Our findings indicate that IHC in TURBT is a reliable tool, enabling increased VI detection and showing concordance of VI status between matched TURBT and RC. IHC may hold an improved prognostic potential as differentiating of BVI and LVI could contribute to better risk stratification at the time of TURBT. CI - Copyright (c) 2025 The Authors. Published by Elsevier GmbH.. All rights reserved. FAU - Carlsen, Birgitte AU - Carlsen B AD - Department of Pathology, Vestfold Hospital Trust, Norway. Electronic address: birgitte.carlsen@siv.no. FAU - Klingen, Tor Audun AU - Klingen TA AD - Department of Pathology, Vestfold Hospital Trust, Norway. FAU - Andreassen, Bettina Kulle AU - Andreassen BK AD - Department of Research, Cancer Registry of Norway, Norway. FAU - Beisland, Christian AU - Beisland C AD - Department of Clinical Medicine, University of Bergen, Department of Urology, Haukeland University Hospital, Norway. FAU - Haug, Erik Skaaheim AU - Haug ES AD - Department of Clinical Medicine, University of Bergen, Norway; Institute of Cancer Genomics and Informatics, Oslo University Hospital, Norway; Department of Urology, Vestfold Hospital Trust, Norway. LA - eng PT - Journal Article DEP - 20250316 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Cystectomy/methods MH - Male MH - Female MH - Immunohistochemistry/methods MH - Aged MH - Middle Aged MH - *Lymphatic Vessels/pathology MH - Neoplasm Invasiveness/pathology MH - Aged, 80 and over MH - Lymphatic Metastasis/pathology MH - Biomarkers, Tumor/analysis MH - Adult OTO - NOTNLM OT - Bladder cancer OT - CD31 OT - Concordance OT - Cystectomy OT - D2-40 OT - Lymphovascular invasion OT - TURBT COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/03/27 16:08 MHDA- 2025/04/18 00:25 CRDT- 2025/03/26 19:05 PHST- 2024/09/18 00:00 [received] PHST- 2025/02/17 00:00 [revised] PHST- 2025/03/12 00:00 [accepted] PHST- 2025/04/18 00:25 [medline] PHST- 2025/03/27 16:08 [pubmed] PHST- 2025/03/26 19:05 [entrez] AID - S0344-0338(25)00109-8 [pii] AID - 10.1016/j.prp.2025.155917 [doi] PST - ppublish SO - Pathol Res Pract. 2025 May;269:155917. doi: 10.1016/j.prp.2025.155917. Epub 2025 Mar 16. PMID- 40138016 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20261010 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 52 IP - 1 DP - 2025 Mar 26 TI - FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in the Tunisian population. PG - 338 LID - 10.1007/s11033-025-10441-2 [doi] AB - BACKGROUND: Mutations occurring in the Fibroblast Growth Factor Receptor (FGFR3) gene are thought to be associated with the incidence and prognosis of non-muscle invasive bladder tumors (NMIBC). Yet, their prognostic significance in the Tunisian population remains unclear. Herein, we aim to investigate their prognostic impact in NMIBC in terms of recurrence, progression, and survival. METHODS AND RESULTS: It is a monocentric retrospective study including 42 NMIBC patients. DNA was isolated from formalin-fixed paraffin-embedded tissue samples. Polymerase Chain Reaction (PCR) followed by Sanger sequencing were performed for a targeted mutations' screening of the hot-spot regions of the FGFR3 gene (exons 7 and 15). Overall survival (OS) and disease-specific survival (DSS) were estimated by the Kaplan-Meier method and the corresponding curves were compared using log-rank test. Sequencing analysis revealed 15 different mutations in FGFR3 gene across 26 different tumors (68%). Among these, 9 are already reported mutations (S249C, P250R, P250S, H251Q, S249S, S249Y, S249A, T264T, Thr651) and, interestingly, 6 are new variants (P250A, H251L, A257S, P253P, I254V, R618S). FGFR3-mutated NMIBC and wild-type FGFR3 tumors were comparable in terms of clinical and endoscopic presentation. The presence of FGFR3 mutations was not statistically correlated to a decrease in OS and DSS. The main factors correlated with their presence were the solid appearance of the tumor (p = 0.04), the presence of tumor calcifications (p = 0.04), and tumor stage (p = 0.04). CONCLUSION: FGFR3 mutations were common in our series. These variations seem to be a favorable prognostic factor for NMIBC in our population. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Saidani, Bilel AU - Saidani B AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia. FAU - Boubaker, Nouha Setti AU - Boubaker NS AD - Theranostic Biomarkers LR23ES02, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, 1006, Tunisia. nouha.setti@hotmail.fr. FAU - Chakroun, Marouen AU - Chakroun M AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia. FAU - Ayed, Haroun AU - Ayed H AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia. FAU - Ksontini, Meriem AU - Ksontini M AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia. FAU - Naimi, Zeineb AU - Naimi Z AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia. FAU - Meddeb, Khedija AU - Meddeb K AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia. FAU - Saadi, Ahmed AU - Saadi A AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AD - Theranostic Biomarkers LR23ES02, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, 1006, Tunisia. AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia. FAU - Slama, Mohamed Riadh Ben AU - Slama MRB AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia. LA - eng PT - Journal Article DEP - 20250326 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) SB - IM MH - Humans MH - *Receptor, Fibroblast Growth Factor, Type 3/genetics MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Female MH - Male MH - Tunisia/epidemiology MH - Middle Aged MH - Mutation/genetics MH - Aged MH - Retrospective Studies MH - Prognosis MH - Adult MH - Aged, 80 and over MH - Kaplan-Meier Estimate MH - Neoplasm Recurrence, Local/genetics MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - FGFR3 OT - Pathway enrichment OT - Prognosis OT - Progression OT - Recurrence COIS- Declarations. Ethics approval and consent to participate: This retrospective chart study involving human participants was in accordance with the ethical standards of the Ethic committee of Charles Nicolle Hospital-Tunis-Tunisia (date of approval: 16/06/2020) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All protocols were approved by the Charles Nicolle Ethics committee and a written informed consent form was obtained from the included patients. Competing interests: The authors declare no competing interests. EDAT- 2025/03/27 16:08 MHDA- 2025/03/27 16:09 CRDT- 2025/03/26 12:17 PHST- 2025/01/31 00:00 [received] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/03/27 16:09 [medline] PHST- 2025/03/27 16:08 [pubmed] PHST- 2025/03/26 12:17 [entrez] AID - 10.1007/s11033-025-10441-2 [pii] AID - 10.1007/s11033-025-10441-2 [doi] PST - epublish SO - Mol Biol Rep. 2025 Mar 26;52(1):338. doi: 10.1007/s11033-025-10441-2. PMID- 40135788 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250715 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 136 IP - 2 DP - 2025 Aug TI - The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates. PG - 336-343 LID - 10.1111/bju.16714 [doi] AB - OBJECTIVE: To evaluate the impact of discordant histological diagnoses between transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) on cancer-specific mortality (CSM) in patients with bladder cancer (BCa). PATIENTS AND METHODS: We relied on a multi-institutional database collecting data of patients with BCa who underwent TURBT and subsequent RC from nine centres between 2000 and 2023. We tested concordance rates between TURBT and RC in detecting urothelial carcinoma of the urinary bladder (UCUB) as well as non-UCUB hystological subtypes, using RC as the reference standard. Concordance was defined as the agreement between a specific histological subtype identified both at TURBT and RC and evaluated according to Cohen's kappa coefficient. Subsequently, survival analyses consisted of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressing CSM according to concordance between TURBT and RC (namely, concordant vs discordant). RESULTS: Overall, 3160 patients were identified. Of these, 2762 (87%) harboured UCUB and 398 (13%) non-UCUB at TURBT vs 2481 (79%) UCUB and 679 (21%) non-UCUB at RC. There were 683 (21.6%) patients with a discordant diagnosis between TURBT and RC. The overall concordance in detecting non-UCUB subtypes was defined as fair concordance (Cohen's kappa coefficient: 0.32). In MCR models, a discordant diagnosis exhibited higher CSM relative to those with a concordant diagnosis (hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.1-1.6; P = 0.002). In a sensitivity analysis including patients with UCUB not exposed to neoadjuvant chemotherapy, this survival disadvantage was even higher (HR 1.5, 95% CI 1.1-1.7; P = 0.04). CONCLUSIONS: A discordant histopathological diagnosis between TURBT and RC is associated with higher CSM rates, particularly in cases initially misdiagnosed as UCUB. However, we also observed a moderate concordance between TURBT and RC in identifying non-UCUB subtypes. CI - (c) 2025 BJU International. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Lonati, Chiara AU - Lonati C AUID- ORCID: 0000-0003-0113-9920 AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AUID- ORCID: 0009-0001-9363-682X AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Viti, Alessandro AU - Viti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Pellegrino, Francesco AU - Pellegrino F AUID- ORCID: 0000-0002-7828-6876 AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - De Cobelli, Ottavio AU - De Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Department of Urology, Kantonsspital Aarau, Aarau, Switzerland. AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Simone, Giuseppe AU - Simone G AUID- ORCID: 0000-0002-4868-9025 AD - Department of Urology, "Regina Elena"_National Cancer Institute, IRCCS, Rome, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Antonelli, Alessandro AU - Antonelli A AUID- ORCID: 0000-0002-7455-8803 AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Cerruto, Maria Angela AU - Cerruto MA AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Zamboni, Stefania AU - Zamboni S AUID- ORCID: 0000-0002-6244-4120 AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Suardi, Nazareno AU - Suardi N AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Karakiewicz, Pierre AU - Karakiewicz P AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Necchi, Andrea AU - Necchi A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Mottrie, Alexandre AU - Mottrie A AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - De Naeyer, Geert AU - De Naeyer G AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium. AD - ORSI Academy, Ghent, Belgium. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Salonia, Andrea AU - Salonia A AUID- ORCID: 0000-0002-0595-7165 AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250326 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Cystectomy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality MH - Aged, 80 and over MH - Transurethral Resection of Bladder OTO - NOTNLM OT - accuracy OT - bladder cancer OT - bladder cancer histology OT - conconrdance OT - histological evaluation OT - histological subtypes OT - histological variants OT - radical cystectomy OT - survival OT - transurethral resection OT - turbt EDAT- 2025/03/26 12:30 MHDA- 2025/07/14 06:26 CRDT- 2025/03/26 08:25 PHST- 2025/07/14 06:26 [medline] PHST- 2025/03/26 12:30 [pubmed] PHST- 2025/03/26 08:25 [entrez] AID - 10.1111/bju.16714 [doi] PST - ppublish SO - BJU Int. 2025 Aug;136(2):336-343. doi: 10.1111/bju.16714. Epub 2025 Mar 26. PMID- 40127527 OWN - NLM STAT- MEDLINE DCOM- 20250418 LR - 20260709 IS - 1365-229X (Electronic) IS - 0009-9260 (Linking) VI - 84 DP - 2025 May TI - Preoperative prediction of muscle invasion in bladder cancer in the Indian population using the Vesical Imaging-Reporting and Data System (VI-RADS) score and individual multiparametric magnetic resonance imaging (MRI) characteristics. PG - 106862 LID - S0009-9260(25)00067-4 [pii] LID - 10.1016/j.crad.2025.106862 [doi] AB - AIM: This study aimed to prospectively validate the Vesical Imaging-Reporting and Data System (VI-RADS) score in the preoperative prediction of muscle invasion in bladder cancer in the Indian population. MATERIALS AND METHODS: The study prospectively reviewed patients with bladder masses who underwent 1.5T multiparametric magnetic resonance imaging between December 2018 and April 2023. Clinical and pathological data were collected, and bladder tumors were evaluated using a 5-point VI-RADS scoring system. Independent measurements of quantitative parameters (maximum tumor diameter [DMax] and tumor contact length [TCL]) were performed. These parameters and VI-RADS scores were compared to postoperative pathology to assess muscle invasion. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated using a cutoff score of 4. Receiver Operating Characteristic (ROC) analysis evaluated the diagnostic performance of quantitative values. RESULTS: A total of 55 patients were included in the analysis, of whom 36 were non-muscle invasive and 19 were muscle invasive on the final histopathological report. A VI-RADS score of >/=4 as the cutoff for muscle invasion yielded a sensitivity and specificity of 94.7% (95% CI 72.7%-99.9%) and 97.2% (95% CI 85%-99.9%), with PPV and NPV value of 94.7% and 97.2%, respectively. The receiver operating curve showed an area under the curve (AUC) of 0.958 (95% CI 0.89-1.0). The AUC of TCL and TCL/DMax values for muscle invasion were 0.811 and 0.835, respectively. CONCLUSIONS: The VI-RADS scoring system, qualitative parameters, as well as the TCL and TCL/Dmax exhibits a strong correlation with pathological staging, indicating to be an effective method for the preoperative determination of muscle invasion in bladder cancer. CI - Copyright (c) 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. FAU - Selvaraju, A AU - Selvaraju A AD - Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: anup951996@gmail.com. FAU - Patbamniya, N K AU - Patbamniya NK AD - Department of Urology, Gandhi Medical College, Bhopal, India. Electronic address: kumar.drnaveen17@gmail.com. FAU - Kumar, M AU - Kumar M AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: drmanoj1611@yahoo.com. FAU - Seth, A AU - Seth A AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: amlesh.seth@gmail.com. FAU - Kaushal, S AU - Kaushal S AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: seema.dr@gmail.com. FAU - Das, C J AU - Das CJ AD - Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: dascj@yahoo.com. LA - eng PT - Journal Article DEP - 20250225 PL - England TA - Clin Radiol JT - Clinical radiology JID - 1306016 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/diagnostic imaging/surgery MH - Male MH - Female MH - Middle Aged MH - India MH - Neoplasm Invasiveness/diagnostic imaging MH - Aged MH - *Multiparametric Magnetic Resonance Imaging/methods MH - Prospective Studies MH - Predictive Value of Tests MH - Sensitivity and Specificity MH - Adult MH - Urinary Bladder/diagnostic imaging/pathology MH - *Magnetic Resonance Imaging/methods COIS- Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/03/25 00:38 MHDA- 2025/04/19 00:56 CRDT- 2025/03/24 19:01 PHST- 2024/05/31 00:00 [received] PHST- 2025/02/09 00:00 [revised] PHST- 2025/02/20 00:00 [accepted] PHST- 2025/04/19 00:56 [medline] PHST- 2025/03/25 00:38 [pubmed] PHST- 2025/03/24 19:01 [entrez] AID - S0009-9260(25)00067-4 [pii] AID - 10.1016/j.crad.2025.106862 [doi] PST - ppublish SO - Clin Radiol. 2025 May;84:106862. doi: 10.1016/j.crad.2025.106862. Epub 2025 Feb 25. PMID- 40127243 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20250801 IS - 1557-8674 (Electronic) IS - 1096-2964 (Linking) VI - 26 IP - 6 DP - 2025 Aug TI - Is There Always a Need to Perform Urine Culture before Bacillus Calmette-Guerin Instillation for Bladder Cancer? PG - 390-394 LID - 10.1089/sur.2024.119 [doi] AB - Objectives: There are no unanimous recommendations between urology societies regarding the performance of a urine culture before Bacillus Calmette-Guerin (BCG) instillations. The management of a positive urine culture before each instillation depends on the choice of the urologist. The objective of our study was to collect urine cultures performed before instillations and to study their impact on the risk of associated urinary tract infection (UTI) and on the risk of recurrence of bladder tumors. Patients and Methods: A retrospective analysis of induction BCG files (six instillations per cycle) associated or not with maintenance BCG (three instillations per cycle) was performed between January 2022 and January 2023. A urine culture was systematically carried out a few days before each instillation. In the event of a positive urine culture, the choice of treatment depended on the referring urologist. Demographic data, tumor characteristics, risk factors for UTI, and bacteriological data (date of urine culture, leukocyturia, hematuria, polymicrobial, sterile, and antibiotic therapy given) were collected. Results: Eighty patients were included, all with non-muscle-infiltrating bladder tumors. A total of 812 urine cultures were studied, of which 88 were positive. Among all positive urine cultures, 42 did not receive antibiotics, and yet no febrile UTI was detected. A serious infectious event was reported in two patients including one death, and no risk factor for the occurrence of a positive urine culture could be identified. Bladder tumor recurrence was identified in 17 patients, 3 of whom had positive urine culture treated with antibiotics. Conclusions: Performing urine culture before BCG instillation does not seem necessary. Antibiotic therapy for a positive urine culture could expose to a higher risk of recurrence. FAU - Bourgi, Ali AU - Bourgi A AUID- ORCID: 0000-0003-0249-0739 AD - Department of Urology, Regional University Hospital of Tours, Tours, France. FAU - Ghanem, Omar AU - Ghanem O AD - Department of Urology, Regional University Hospital of Tours, Tours, France. FAU - Brocail, Camille AU - Brocail C AD - Department of Urology, Regional University Hospital of Tours, Tours, France. FAU - Bruyere, Franck AU - Bruyere F AD - Department of Urology, Regional University Hospital of Tours, Tours, France. LA - eng PT - Journal Article DEP - 20250324 PL - United States TA - Surg Infect (Larchmt) JT - Surgical infections JID - 9815642 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Middle Aged MH - *Urinary Tract Infections/prevention & control/microbiology MH - Administration, Intravesical MH - Aged, 80 and over MH - *Urine/microbiology MH - Neoplasm Recurrence, Local MH - Risk Factors OTO - NOTNLM OT - BCG OT - bladder cancer OT - instillation OT - urinary tract infection EDAT- 2025/03/24 18:30 MHDA- 2025/08/01 18:34 CRDT- 2025/03/24 14:53 PHST- 2025/08/01 18:34 [medline] PHST- 2025/03/24 18:30 [pubmed] PHST- 2025/03/24 14:53 [entrez] AID - 10.1089/sur.2024.119 [doi] PST - ppublish SO - Surg Infect (Larchmt). 2025 Aug;26(6):390-394. doi: 10.1089/sur.2024.119. Epub 2025 Mar 24. PMID- 40123630 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260813 IS - 0970-1915 (Print) IS - 0974-0422 (Electronic) IS - 0970-1915 (Linking) VI - 40 IP - 2 DP - 2025 Apr TI - Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A Comprehensive Systematic Review and Meta-Analysis. PG - 176-190 LID - 10.1007/s12291-024-01187-y [doi] AB - The prognostic biomarkers, or metabolites, have gained relevance due to their significance in predicting clinical and therapeutic outcomes and guiding informed therapy options. This systematic review and meta-analysis aimed to evaluate the prognostic significance of metabolites in non-muscle-invasive bladder cancer (NMIBC) through an array of literature. The PubMed, Web of Science, Embase, and Cochrane Library databases were comprehensively searched for eligible studies published between January 2010 and August 2022, using related keywords and MeSH terms. Two reviewers performed the extraction process, and a third reviewer settled possible controversies. The New Castle Ottawa scale (NOS) was used to determine the quality of selected studies. Pooled hazard ratios (H.R.s) with 95% confidence intervals (C.I.s) were calculated to establish the relationship of metabolites with NMIBC outcomes (recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (O.S.) to establish their prognostic roles. A total of 15 studies, with a sample size of 5491, were included and analyzed in this study. Various metabolites were found to be correlated with the outcomes of the study: PFS (pooled HR, 4.48; 95% CI, 1.70-11.80, p = 0.002), RFS (pooled HR, 2.85; 95% CI, 1.91-4.26; p = 0.00001), and OS (HR, 1.78; 95% CI, 1.07-2.98; p = 0.03). Pretreatment metabolites or markers in NMIBC patients had a relationship with recurrence prediction and disease outcomes in bladder cancer. Therefore, metabolites may equally serve as a critical, independent prognostic predictor for NMIBC patients. This could be considered in most related clinical decisions in bladder cancer. CI - (c) The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Singh, Vishwajeet AU - Singh V AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 FAU - Singh, Mukul Kumar AU - Singh MK AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 FAU - Kumar, Anil AU - Kumar A AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 FAU - Sahu, Dinesh Kumar AU - Sahu DK AD - Central Research Facility, Post Graduate Institute of Child Health, Noida, Uttar Pradesh India. FAU - Jain, Mayank AU - Jain M AD - Department of Thoracic Surgery, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 FAU - Pandey, Anuj Kumar AU - Pandey AK AD - Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 FAU - Mantasha AU - Mantasha AD - Indian Health Action Trust, Bengaluru, Karnataka India. ROR: https://ror.org/03wcw5870. GRID: grid.429013.d. ISNI: 0000 0004 6789 6219 FAU - Singh, Shubhendu AU - Singh S AD - Santosh Deemed to Be University, Ghaziabad, Uttar Pradesh India. ROR: https://ror.org/02bdf7k74. GRID: grid.411706.5. ISNI: 0000 0004 1773 9266 FAU - Verma, Ajay Kumar AU - Verma AK AD - Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh India. ROR: https://ror.org/00gvw6327. GRID: grid.411275.4. ISNI: 0000 0004 0645 6578 LA - eng PT - Journal Article PT - Review DEP - 20240209 PL - India TA - Indian J Clin Biochem JT - Indian journal of clinical biochemistry : IJCB JID - 8708303 PMC - PMC11928707 OTO - NOTNLM OT - Bladder Cancer OT - Metabolite OT - Prognostic Markers OT - Progression OT - Recurrence COIS- Conflict of interestThe authors declare that they have no competing interests. EDAT- 2025/03/24 06:30 MHDA- 2025/03/24 06:31 PMCR- 2026/04/01 CRDT- 2025/03/24 05:54 PHST- 2023/12/04 00:00 [received] PHST- 2024/01/19 00:00 [accepted] PHST- 2025/03/24 06:31 [medline] PHST- 2025/03/24 06:30 [pubmed] PHST- 2025/03/24 05:54 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - 1187 [pii] AID - 10.1007/s12291-024-01187-y [doi] PST - ppublish SO - Indian J Clin Biochem. 2025 Apr;40(2):176-190. doi: 10.1007/s12291-024-01187-y. Epub 2024 Feb 9. PMID- 40118736 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20250418 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 87 IP - 5 DP - 2025 May TI - European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. PG - 582-600 LID - S0302-2838(25)00138-1 [pii] LID - 10.1016/j.eururo.2025.02.019 [doi] AB - BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2025 European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). The aim is to provide practical recommendations on the clinical management of MMIBC with a focus on diagnosis, treatment, and follow-up. METHODS: For the 2025 guidelines, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: The key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with MMIBC. The guidelines stress the importance of a multidisciplinary approach to the treatment of MMIBC patients and the importance of shared decision-making with patients. The key changes in the 2025 muscle-invasive bladder cancer (MIBC) guidelines include the following: a new recommendation for the use of susceptible FGFR3 alterations to select patients with unresectable or metastatic urothelial carcinoma for treatment with erdafitinib; significant adaption and update of the recommendations for pre- and postoperative radiotherapy and sexual organ-preserving techniques in women; new recommendation related to radical cystectomy and extent of lymph node dissection based on the results of the SWOG trial; recommendation related to hospital volume; new recommendations for salvage cystectomy after trimodality therapy and for the management of all patients who are candidates for trimodality bladder-preserving treatment in a multidisciplinary team setting using a shared decision-making process; significant adaption and update to the recommendation for adjuvant nivolumab in selected patients with pT3/4 and/or pN+ disease not eligible for, or who declined, adjuvant cisplatin-based chemotherapy; and addition of a new recommendation for metastatic disease regarding the antibody-drug conjugate trastuzumab deruxtecan in case of HER2 overexpression; in addition, removal of the recommendations on sacituzumab govitecan as the manufacturer has withdrawn the US Food and Drug Administration approval for this product; update of the follow-up of MIBC; and full update of the management algorithms of MIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2025 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, treatment, and follow-up of MIBC patients and is designed for effective integration into clinical practice. CI - Copyright (c) 2025 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: Toine.vanderHeijden@radboudumc.nl. FAU - Bruins, Harman Max AU - Bruins HM AD - Department of Urology, Zuyderland Medisch Centrum, Sittard/Heerlen, The Netherlands. FAU - Carrion, Albert AU - Carrion A AD - Department of Urology, Vall Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain. FAU - Cathomas, Richard AU - Cathomas R AD - Department of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University Vienna, General Hospital, Vienna, Austria. FAU - Dimitropoulos, Konstantinos AU - Dimitropoulos K AD - Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Fietkau, Rainer AU - Fietkau R AD - Department of Radiation Therapy, University of Erlangen, Erlangen, Germany. FAU - Kailavasan, Mithun AU - Kailavasan M AD - Department of Urology, Victoria Hospital, London, Ontario, Canada. FAU - Lorch, Anja AU - Lorch A AD - Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, University of Cincinnati, Cincinnati, OH, USA. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Meijer, Richard P AU - Meijer RP AD - Department of Oncological Urology, University Medical Center, Utrecht, The Netherlands. FAU - Mariappan, Param AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, University of Edinburgh, Edinburgh, UK. FAU - Milowsky, Matthew I AU - Milowsky MI AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Panebianco, Valeria AU - Panebianco V AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. FAU - Saebjornsen, Saebjorn AU - Saebjornsen S AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Smith, Emma J AU - Smith EJ AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, Inselspital, University Hospital Bern, Bern, Switzerland. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Marienkrankenhaus Hamburg, Hamburg, Germany. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20250320 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - Europe MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - *Urinary Bladder Neoplasms/therapy/pathology/diagnosis MH - Urology/standards OTO - NOTNLM OT - Bladder cancer OT - Classification OT - Cystoscopy OT - Diagnosis OT - Follow-up OT - Guidelines OT - Marker prognosis OT - Radical cystectomy OT - Transurethral resection OT - Urothelial carcinoma EDAT- 2025/03/22 00:41 MHDA- 2025/04/17 00:24 CRDT- 2025/03/21 23:04 PHST- 2025/02/14 00:00 [received] PHST- 2025/02/16 00:00 [revised] PHST- 2025/02/25 00:00 [accepted] PHST- 2025/04/17 00:24 [medline] PHST- 2025/03/22 00:41 [pubmed] PHST- 2025/03/21 23:04 [entrez] AID - S0302-2838(25)00138-1 [pii] AID - 10.1016/j.eururo.2025.02.019 [doi] PST - ppublish SO - Eur Urol. 2025 May;87(5):582-600. doi: 10.1016/j.eururo.2025.02.019. Epub 2025 Mar 20. PMID- 40118680 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 7 DP - 2025 Jul TI - Bladder cuff excision at radical nephroureterectomy improved survival in upper tract urothelial carcinoma. PG - 442.e1-442.e7 LID - S1078-1439(25)00040-7 [pii] LID - 10.1016/j.urolonc.2025.02.014 [doi] AB - OBJECTIVE: To test for survival differences after radical nephroureterectomy (RNU) in pT1-T3N0 upper tract urothelial carcinoma (UTUC) patients according to bladder cuff excision (BCE) status. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified RNU patients and documented BCE status. Prior and after propensity score matching (ratio 1:1), cumulative incidence plots and competing risk regression (CRR) models addressed cancer specific mortality (CSM) and other-cause mortality (OCM). RESULTS: Of 4,426 RNU-treated patients, 3,186 (72%) patients underwent BCE and 1,240 (28%) did not. BCE rates significantly increased over time from 65.2 to 77.0% (EAPC: +1.0%, 95% CI +0.4 to +1.6%, P = 0.004) between 2004 and 2020. After 1:1 propensity score matching for T stage, 1,240 of 1,240 (100%) RNU patients without BCE and 1,240 of 3,186 (39%) RNU patients with BCE were included in subsequent analyses. Five-year CSM rates were 30% in RNU with BCE vs. 36% in RNU without BCE patients (Delta = 6%). In multivariable CRR, RNU with BCE independently predicted lower CSM (HR: 0.81, 95% CI: 0.70-0.93; P < 0.001). Conversely, BCE status did not affect OCM (P = 0.4). CONCLUSION: The rate of guideline recommended BCE at RNU increased over time. Additionally, RNU with BCE is associated with significantly lower CSM than RNU without BCE in pT1-T3N0 UTUC patients. In consequence, BCE should represent an integral part of a comprehensive RNU. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Di Bello, Francesco AU - Di Bello F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. Electronic address: fran.dibello12@gmail.com. FAU - Siech, Carolin AU - Siech C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt, Germany. FAU - de Angelis, Mario AU - de Angelis M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Rodriguez Penaranda, Natali AU - Rodriguez Penaranda N AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy. FAU - Jannello, Letizia Maria Ippolita AU - Jannello LMI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Colla Ruvolo, Claudia AU - Colla Ruvolo C AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Califano, Gianluigi AU - Califano G AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Mangiapia, Francesco AU - Mangiapia F AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt, Germany. FAU - Micali, Salvatore AU - Micali S AD - Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy. FAU - Longo, Nicola AU - Longo N AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20250320 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Male MH - Female MH - Aged MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Ureteral Neoplasms/surgery/mortality/pathology MH - *Kidney Neoplasms/surgery/mortality/pathology MH - Middle Aged MH - *Urinary Bladder/surgery MH - Survival Rate MH - Retrospective Studies MH - SEER Program OTO - NOTNLM OT - Cuff excision OT - Disease-free-survival OT - SEER OT - UTUC COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/03/22 00:41 MHDA- 2025/05/31 00:36 CRDT- 2025/03/21 23:02 PHST- 2024/11/09 00:00 [received] PHST- 2024/12/28 00:00 [revised] PHST- 2025/02/15 00:00 [accepted] PHST- 2025/05/31 00:36 [medline] PHST- 2025/03/22 00:41 [pubmed] PHST- 2025/03/21 23:02 [entrez] AID - S1078-1439(25)00040-7 [pii] AID - 10.1016/j.urolonc.2025.02.014 [doi] PST - ppublish SO - Urol Oncol. 2025 Jul;43(7):442.e1-442.e7. doi: 10.1016/j.urolonc.2025.02.014. Epub 2025 Mar 20. PMID- 40109859 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250514 IS - 1555-3906 (Electronic) IS - 0965-0407 (Print) IS - 0965-0407 (Linking) VI - 33 IP - 3 DP - 2025 TI - Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer. PG - 723-731 LID - 10.32604/or.2024.056282 [doi] AB - OBJECTIVES: Intravesical Bacillus Calmette-Guerin (BCG) therapy is a gold standard for patients with high-risk non-muscle invasive bladder cancer (NMIBC). Although a long-lasting therapeutic response is observed in most patients, BCG failure occurs in 30%-50% of patients and a progression to muscle-invasive disease is found in 10%-15%. Therefore, predicting high-risk patients who might not benefit from BCG treatment is critical. The purpose of this study was to identify, whether the presence of specific oncogenic mutations might be indicative of BCG treatment response. METHODS: Nineteen high-grade NMIBC patients who received intravesical BCG were retrospectively enrolled and divided into "responders" and "non-responders" groups. Tissue samples from transurethral resection of bladder cancer were performed before starting therapy and were examined using a multigene sequencing panel. RESULTS: Mutations in TP53, FGFR3, PIK3CA, KRAS, CTNNB1, ALK and DDR2 genes were detected. TP53 and FGFR3 were found to be the most frequently mutated genes in our cohort (31.6% and 26.3%, respectively), followed by PIK3CA (15.8%). In the BCG-responsive patient group, 90% of samples were found to have mutated genes, with almost 50% of them showing mutations in tyrosine kinase receptors and CTNNB1 genes. On the other hand, in the BCG-unresponsive group, we found mutations in 44.4% of samples, mainly in TP53 gene. CONCLUSIONS: Our findings suggest that a Next-Generation Sequencing (NGS) multigene panel is useful in predicting BCG response in patients with NMIBC. CI - (c) 2025 The Authors. FAU - Francesca, Belardinilli AU - Francesca B AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy. FAU - Meo, Michela DE AU - Meo M AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy. FAU - Scornajenghi, Carlo Maria AU - Scornajenghi CM AD - Department of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy. FAU - Gazzaniga, Paola AU - Gazzaniga P AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy. FAU - Berardinis, Ettore DE AU - Berardinis E AD - Department of Maternal-Child and Urological Sciences, Sapienza University of Rome, Rome, 00161, Italy. FAU - Marino, Luca AU - Marino L AD - Department of Mechanical and Aerospace Engineering, Sapienza University of Rome, Rome, 00161, Italy. FAU - Magliocca, Fabio Massimo AU - Magliocca FM AD - Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, 00161, Italy. FAU - Inbeh Chung, Benjamin AU - Inbeh Chung B AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, 50556, Poland. FAU - Magri, Valentina AU - Magri V AD - Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, 00161, Italy. FAU - Giannini, Giuseppe AU - Giannini G AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy. AD - Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, 00161, Italy. FAU - Nicolazzo, Chiara AU - Nicolazzo C AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, 00161, Italy. LA - eng PT - Journal Article DEP - 20250228 PL - United States TA - Oncol Res JT - Oncology research JID - 9208097 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/drug therapy/pathology MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - Aged MH - *High-Throughput Nucleotide Sequencing/methods MH - Mutation MH - Middle Aged MH - Aged, 80 and over MH - Retrospective Studies MH - Neoplasm Invasiveness MH - *Biomarkers, Tumor/genetics MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11915050 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Macropinocytosis OT - Molecular profile OT - Next-generation sequencing (NGS) OT - Non-muscle invasive bladder cancer (NMIBC) COIS- The authors declare that they have no conflicts of interest to report regarding the present study. EDAT- 2025/03/20 06:24 MHDA- 2025/03/20 06:25 PMCR- 2025/02/28 CRDT- 2025/03/20 05:10 PHST- 2024/07/18 00:00 [received] PHST- 2024/10/12 00:00 [accepted] PHST- 2025/03/20 06:25 [medline] PHST- 2025/03/20 06:24 [pubmed] PHST- 2025/03/20 05:10 [entrez] PHST- 2025/02/28 00:00 [pmc-release] AID - 56282 [pii] AID - 10.32604/or.2024.056282 [doi] PST - epublish SO - Oncol Res. 2025 Feb 28;33(3):723-731. doi: 10.32604/or.2024.056282. eCollection 2025. PMID- 40109498 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250321 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 11 IP - 1 DP - 2025 Jan-Mar TI - Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette-Guerin therapy in patients with non-muscle invasive bladder cancer. PG - 23523735251325100 LID - 10.1177/23523735251325100 [doi] LID - 23523735251325100 AB - BACKGROUND: Metabolomic research and metabolomics-based biomarkers predicting treatment outcomes in bladder cancer remain limited. OBJECTIVE: We explored the serum metabolites potentially associated with the risk of recurrence after intravesical Bacillus Calmette-Guerin (BCG) therapy. METHODS: Two independent cohorts, a discovery cohort (n = 23) and a validation cohort (n = 40), were included in this study. Blood was collected before the induction of BCG therapy (pre-BCG blood; both discovery and validation cohorts) and after six doses of BCG (post-BCG blood; only discovery cohort). Metabolome analysis of serum samples was conducted using capillary electrophoresis time-of-flight mass spectrometry. The endpoint was intravesical recurrence-free survival, which was analysed using Kaplan-Meier estimates, the log-rank test, and the Cox proportional hazard model. RESULTS: Of the 353 metabolites quantified, nine (2.5%) and four (1.1%) were significantly upregulated and downregulated, respectively. The heatmap of hierarchical clustering analysis and principal coordinate analysis for the fold changes and in serum metabolites differentiated 10 recurrent cases and 13 non-recurrent cases in the discovery cohort. A metabolome response-based scoring model using 16 metabolites, including threonine and N6,N6,N6-trimethyl-lysine effectively stratified the risk of post-BCG recurrence. Additionally, pre-BCG metabolome-based score models using six metabolites, octanoylcarnitine, S-methylcysteine-S-oxide, theobromine, carnitine, indole-3-acetic acid, and valeric acid, were developed from the discovery cohort. Univariate and multivariate analyses confirmed a high predictive accuracy in the validation and combination cohorts. CONCLUSIONS: We demonstrated that numerous types of serum metabolites were altered in response to intravesical BCG and developed high-performance score models which might effectively differentiated the risk of post-BCG tumour recurrence. CI - (c) The Author(s) 2025. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Ohnishi, Sayuri AU - Ohnishi S AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. AD - Division of Cancer Immunology, National Cancer Center, Tsukiji, Chuo-ku, Tokyo, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Division of Fostering Required Medical Human Resources, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan. FAU - Oda, Yuki AU - Oda Y AUID- ORCID: 0000-0003-3909-1133 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Ohnishi, Kenta AU - Ohnishi K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Hori, Shunta AU - Hori S AUID- ORCID: 0000-0001-9514-9964 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. LA - eng PT - Journal Article DEP - 20250318 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11921002 OTO - NOTNLM OT - BCG OT - Bacillus Calmette-Guerin OT - metabolites OT - metabolomics OT - mycobacterium bovis OT - prognosis OT - recurrence OT - serum OT - urinary bladder neoplasms COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/03/20 06:24 MHDA- 2025/03/20 06:25 PMCR- 2025/03/18 CRDT- 2025/03/20 05:06 PHST- 2024/10/13 00:00 [received] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/03/20 06:25 [medline] PHST- 2025/03/20 06:24 [pubmed] PHST- 2025/03/20 05:06 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - 10.1177_23523735251325100 [pii] AID - 10.1177/23523735251325100 [doi] PST - epublish SO - Bladder Cancer. 2025 Mar 18;11(1):23523735251325100. doi: 10.1177/23523735251325100. eCollection 2025 Jan-Mar. PMID- 40107612 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20260818 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 49 IP - 4 DP - 2025 May TI - Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database. PG - 501738 LID - S2173-5786(25)00064-2 [pii] LID - 10.1016/j.acuroe.2025.501738 [doi] AB - INTRODUCTION AND OBJECTIVES: Transurethral resection of the bladder tumor (TURBT) is a standard procedure in bladder cancer (BC), which is associated with low risk of venous thrombo-embolism (VTE). The aim of this study was to find the predictors of postoperative VTE in patients undergoing TURBT for BC. MATERIALS AND METHODS: In this retrospective cohort analysis, patients aged >/= 18 years with BC diagnosis undergoing TURBT were identified in the Merative(R) Marketscan(R) Research de-identified databases in 2007-2021. Patients with prior VTE events were excluded. Preoperative diagnostic codes and outpatient prescriptions present in at least 1% of the cohort were recorded (205 variables). Then, logistic regressions were performed including each variable separately, all variables together, as well as variables selected by stepwise and Least Absolute Shrinkage and Selection Operator (LASSO) selection methods. Adjusted odds ratios (aOR) with 95% confidence intervals (CI) were calculated. RESULTS: In total, 132,425 patients were included in this study, with 1959 (1.5%) individuals diagnosed with postoperative VTE. Various malignant neoplasms diagnosed before BC were significant risk factors of postoperative VTE, with aOR reaching up to 2.26 (95% CI: 1.96-2.61). Another strong predictor of VTE was a diagnosis of nephritis, nephrotic syndrome, and nephrosis (aOR 1.67, 95% CI: 1.48-1.87 stepwise; aOR 1.65, 95% CI: 1.46-1.85 LASSO). Also, patients with diseases of the urinary system, non-specific symptoms, diseases of the respiratory system, anemias, and other cardiovascular diseases were associated with increased VTE risk. Regarding drugs, antidiabetic agents and gastrointestinal drugs reduced the probability of VTE. CONCLUSIONS: Numerous preoperative factors have influence on the risk of VTE after TURBT. These findings might facilitate the clinical decision about the implementation of thromboprophylaxis in the appropriate patients. CI - Copyright (c) 2025 The Authors. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Laszkiewicz, J AU - Laszkiewicz J AD - Centro Universitario de Excelencia en Urologia, Universidad de Medicina de Breslavia, Breslavia, Poland. FAU - Del Giudice, F AU - Del Giudice F AD - Departamento de Urologia, Facultad de Medicina de la Universidad de Stanford, Stanford, CA, United States; Departamento de Ciencias Urologicas y Materno-Infantiles, Universidad Sapienza de Roma, Hospital Policlinico Umberto I, Roma, Italy; Guy's and St. Thomas' NHS Foundation Trust, Guy's and St Thomas' Hospital, London, United Kingdom. Electronic address: francesco.delgiudice@uniroma.it. FAU - Li, S AU - Li S AD - Departamento de Urologia, Facultad de Medicina de la Universidad de Stanford, Stanford, CA, United States; Departamento de Dermatologia, Facultad de Medicina de la Universidad de Stanford, Stanford, CA, United States. FAU - Krajewski, W AU - Krajewski W AD - Departamento de Urologia Robotica y Minimamente Invasiva, Centro Universitario de Excelencia en Urologia, Universidad de Medicina de Breslavia, Breslavia, Poland. FAU - Nowak, L AU - Nowak L AD - Departamento de Urologia Robotica y Minimamente Invasiva, Centro Universitario de Excelencia en Urologia, Universidad de Medicina de Breslavia, Breslavia, Poland. FAU - Szydelko, T AU - Szydelko T AD - Centro Universitario de Excelencia en Urologia, Universidad de Medicina de Breslavia, Breslavia, Poland. FAU - Basran, S AU - Basran S AD - Departamento de Urologia, Facultad de Medicina de la Universidad de Stanford, Stanford, CA, United States. FAU - De Berardinis, E AU - De Berardinis E AD - Departamento de Ciencias Urologicas y Materno-Infantiles, Universidad Sapienza de Roma, Hospital Policlinico Umberto I, Roma, Italy. FAU - Carino, D AU - Carino D AD - Departamento de Ciencias Urologicas y Materno-Infantiles, Universidad Sapienza de Roma, Hospital Policlinico Umberto I, Roma, Italy. FAU - Corvino, R AU - Corvino R AD - Departamento de Ciencias Urologicas y Materno-Infantiles, Universidad Sapienza de Roma, Hospital Policlinico Umberto I, Roma, Italy. FAU - Santarelli, V AU - Santarelli V AD - Departamento de Ciencias Urologicas y Materno-Infantiles, Universidad Sapienza de Roma, Hospital Policlinico Umberto I, Roma, Italy. FAU - Ferro, M AU - Ferro M AD - Unidad de Urologia, Instituto Europeo de Oncologia (IEO), IRCCS, Milan, Italy. FAU - Rocco, B AU - Rocco B AD - Departamento de Ciencias de la Vida, Universidad de Milan, Milan, Italy; Unidad de Urologia, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Sighinolfi, M C AU - Sighinolfi MC AD - Unidad de Urologia, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Crocetto, F AU - Crocetto F AD - Departamento de Neurociencias, Ciencias de la Reproduccion y Odontoestomatologia, Universidad Federico II de Napoles, Napoles, Italy. FAU - Barone, B AU - Barone B AD - Departamento de Neurociencias, Ciencias de la Reproduccion y Odontoestomatologia, Universidad Federico II de Napoles, Napoles, Italy. FAU - Dinacci, F AU - Dinacci F AD - Departamento de Neurociencias, Ciencias de la Reproduccion y Odontoestomatologia, Universidad Federico II de Napoles, Napoles, Italy. FAU - Pichler, R AU - Pichler R AD - Servicio de Urologia, Comprehensive Cancer Center Innsbruck, Universidad de Medicina de Innsbruck, Innsbruck, Austria. FAU - Subiela, J D AU - Subiela JD AD - Servicio de Urologia, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Pradere, B AU - Pradere B AD - Servicio de Urologia, Hospital La Croix Du Sud, Quint Fonsegrives, France. FAU - Moschini, M AU - Moschini M AD - Division de Oncologia Experimental, Servicio de Urologia, IRCCS Hospital San Raffaele, Milan, Italy. FAU - Mari, A AU - Mari A AD - Unidad de Cirugia Urologica Robotica y Trasplante Renal, Hospital Careggi, Universidad de Florencia, Florencia, Italy. FAU - Gallioli, A AU - Gallioli A AD - Servicio de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Mori, K AU - Mori K AD - Departamento de Urologia, Facultad de Medicina de la Universidad Jikei, Tokio, Japan; Departamento de Urologia, Universidad de Medicina de Viena, Viena, Austria. FAU - Soria, F AU - Soria F AD - Division de Urologia, Departamento de Ciencias Quirurgicas, Hospital San Giovanni Battista, Universidad de Turin, Turin, Italy. FAU - Mertens, L AU - Mertens L AD - Servicio de Urologia, Instituto Oncologico de los Paises Bajos, Hospital Antoni van Leeuwenhoek, Amsterdam, The Netherlands. FAU - Abu-Ghanem, Y AU - Abu-Ghanem Y AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's and St Thomas' Hospital, London, United Kingdom. FAU - Nair, R AU - Nair R AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's and St Thomas' Hospital, London, United Kingdom. FAU - Khan, M Shamim AU - Khan MS AD - Guy's and St. Thomas' NHS Foundation Trust, Guy's and St Thomas' Hospital, London, United Kingdom. FAU - Chung, B I AU - Chung BI AD - Departamento de Urologia, Facultad de Medicina de la Universidad de Stanford, Stanford, CA, United States. LA - eng LA - spa GR - UL1 TR003142/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20250317 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Humans MH - *Venous Thromboembolism/epidemiology/etiology MH - *Urinary Bladder Neoplasms/surgery MH - Retrospective Studies MH - Male MH - Female MH - Risk Factors MH - Middle Aged MH - *Postoperative Complications/epidemiology/etiology MH - *Cystectomy/methods/adverse effects MH - Databases, Factual MH - Aged MH - United States MH - Ambulatory Surgical Procedures MH - Insurance Claim Review MH - Adult MH - Multivariate Analysis OTO - NOTNLM OT - Bladder cancer OT - Cancer de vejiga OT - LASSO OT - RTU OT - Regresion escalonada OT - Stepwise OT - TURBT OT - Tromboembolismo venoso OT - Venous thromboembolism COIS- Declaration of competing interest Authors have no conflict of interest to disclose. EDAT- 2025/03/20 00:33 MHDA- 2025/05/04 15:36 CRDT- 2025/03/19 20:39 PHST- 2024/10/23 00:00 [received] PHST- 2025/01/15 00:00 [revised] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/05/04 15:36 [medline] PHST- 2025/03/20 00:33 [pubmed] PHST- 2025/03/19 20:39 [entrez] AID - S2173-5786(25)00064-2 [pii] AID - 10.1016/j.acuroe.2025.501738 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2025 May;49(4):501738. doi: 10.1016/j.acuroe.2025.501738. Epub 2025 Mar 17. PMID- 40104687 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250320 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 17 DP - 2025 TI - Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature. PG - 69-85 LID - 10.2147/RRU.S386026 [doi] AB - Bladder cancer management, particularly non-muscle-invasive bladder cancer (NMIBC), has evolved significantly due to advancements in imaging techniques and surgical methodologies. Enhanced tumor visualization methods, including Photodynamic Diagnosis (PDD) and Narrow-Band Imaging (NBI), offer improved detection rates for both papillary tumors and carcinoma in situ (CIS), compared to traditional white-light cystoscopy (WLC). Recent studies suggest that these technologies enhance diagnostic accuracy, reduce recurrence rates, and improve oncological outcomes. Additionally, transurethral resection of bladder tumors (TURBT), performed with advanced imaging, has demonstrated better resection quality, particularly in terms of detrusor muscle presence. Despite these innovations, challenges remain in the long-term impact on recurrence-free and progression-free survival. Artificial intelligence (AI) integration into cystoscopic imaging further promises enhanced diagnostic precision and cost-effective bladder cancer management. As personalized treatment paradigms emerge, predictive biomarkers, including genomic and pathological markers, may help stratify patients for aggressive treatment, sparing those at lower risk from unnecessary interventions. Future research should focus on validating these AI models and combining them with enhanced imaging modalities to refine treatment protocols further. These advancements collectively represent a significant leap toward precision medicine in bladder cancer care. CI - (c) 2025 Ben Muvhar et al. FAU - Ben Muvhar, Rei AU - Ben Muvhar R AD - Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. FAU - Paluch, Reem AU - Paluch R AD - Faculty of Medicine, Technion-Israel, Institute of Technology, Haifa, Israel. FAU - Mekayten, Matan AU - Mekayten M AUID- ORCID: 0000-0001-9116-960X AD - Adelson School of Medicine, Ariel University, Ariel, Israel. AD - Department of Urology, Sanz Medical Center, Laniado Hospital, Netanya, Israel. LA - eng PT - Journal Article PT - Review DEP - 20250314 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC11917164 OTO - NOTNLM OT - artificial intelligence OT - biomarkers OT - bladder neoplasms OT - narrow-band imaging OT - photodynamic therapy OT - precision medicine OT - recurrence-free survival OT - transurethral resection OT - tumor COIS- The authors report no conflicts of interest in this work. EDAT- 2025/03/19 06:21 MHDA- 2025/03/19 06:22 PMCR- 2025/03/14 CRDT- 2025/03/19 05:09 PHST- 2024/10/31 00:00 [received] PHST- 2025/02/05 00:00 [accepted] PHST- 2025/03/19 06:22 [medline] PHST- 2025/03/19 06:21 [pubmed] PHST- 2025/03/19 05:09 [entrez] PHST- 2025/03/14 00:00 [pmc-release] AID - 386026 [pii] AID - 10.2147/RRU.S386026 [doi] PST - epublish SO - Res Rep Urol. 2025 Mar 14;17:69-85. doi: 10.2147/RRU.S386026. eCollection 2025. PMID- 40104408 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250401 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 12 DP - 2025 TI - Corrigendum: A retrospective study of paraganglioma of the urinary bladder and literature review. PG - 1556161 LID - 10.3389/fsurg.2025.1556161 [doi] LID - 1556161 AB - [This corrects the article DOI: 10.3389/fsurg.2024.1348737.]. CI - (c) 2025 Zhao, Zhang, Wang, Wen, Wang, Ji, Zhang and Li. FAU - Zhao, Yi AU - Zhao Y AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Zhijun AU - Zhang Z AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, ShiJun AU - Wang S AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wen, Jin AU - Wen J AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Dong AU - Wang D AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Ji, ZhiGang AU - Ji Z AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, YuShi AU - Zhang Y AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, HanZhong AU - Li H AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Published Erratum DEP - 20250304 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 EFR - Front Surg. 2024 Apr 05;11:1348737. doi: 10.3389/fsurg.2024.1348737. PMID: 38645508 PMC - PMC11913675 OTO - NOTNLM OT - cystectomy OT - diagnosis OT - paraganglioma of the urinary bladder OT - prognosis OT - transurethral resection of bladder tumor EDAT- 2025/03/19 06:22 MHDA- 2025/03/19 06:23 PMCR- 2025/03/04 CRDT- 2025/03/19 05:05 PHST- 2025/01/06 00:00 [received] PHST- 2025/01/09 00:00 [accepted] PHST- 2025/03/19 06:23 [medline] PHST- 2025/03/19 06:22 [pubmed] PHST- 2025/03/19 05:05 [entrez] PHST- 2025/03/04 00:00 [pmc-release] AID - 10.3389/fsurg.2025.1556161 [doi] PST - epublish SO - Front Surg. 2025 Mar 4;12:1556161. doi: 10.3389/fsurg.2025.1556161. eCollection 2025. PMID- 40102029 OWN - NLM STAT- MEDLINE DCOM- 20250318 LR - 20250529 IS - 2051-1426 (Electronic) IS - 2051-1426 (Linking) VI - 13 IP - 3 DP - 2025 Mar 18 TI - Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). LID - 10.1136/jitc-2024-010572 [doi] LID - e010572 AB - BACKGROUND: Muscle-invasive urothelial cancer (UC) has a high risk of recurrence after definitive treatment. Nivolumab adjuvant to radical surgery improves disease-free survival in patients with UC with a high risk of recurrence; however, its role adjuvant to chemoradiation therapy (CRT) is unknown. METHODS: The NEXT trial is a single-arm, phase-2 study evaluating the efficacy and tolerability of nivolumab adjuvant to CRT in patients with localized or locoregional UC. The primary endpoint is failure-free survival (FFS) at 2 years. Secondary endpoints include patterns of recurrence, toxicity and quality of life (QoL). Plasma cell-free DNA (cfDNA) was subjected to shallow whole-genome sequencing to correlate with outcomes. RESULTS: 28 patients were enrolled and received 480 mg of nivolumab intravenously every 4 weeks for up to 12 cycles adjuvant to CRT. The FFS at 2 years was 33.2% (95% CI 18.5% to 59.6%). Nine (32%) patients had localized progression, and eight (29%) had distant progression. 25 (89%) had one or more high-risk features (ie, plasmacytoid differentiation, T4, N+, multiple tumors, tumors >5 cm, residual disease before CRT, carcinoma in situ, and hydronephrosis). Patients with /=26 (49.6 months vs 20.5 months, p=0.0024). Genome copy number changes indicated chromatin remodeling and tyrosine kinase pathways, among others, as oncogenic drivers implicated in progression. CONCLUSION: Nivolumab adjuvant to CRT in localized or locally advanced UC is well tolerated. Stratification by risk factors and correlation with plasma cfDNA analyses generate hypotheses for potential patient selection and putative therapeutic targets for future study. TRIAL REGISTRATION NUMBER: NCT03171025. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Galarza Fortuna, Gliceida M AU - Galarza Fortuna GM AUID- ORCID: 0000-0002-1084-953X AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Grass, Daniel AU - Grass D AD - Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA. FAU - Maughan, Benjamin L AU - Maughan BL AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Jain, Rohit K AU - Jain RK AD - Department of Medical Oncology, Weill Cornell Medicine, New York, New York, USA. FAU - Dechet, Christopher AU - Dechet C AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Beck, Julia AU - Beck J AD - Oncocyte Corporation, Irvine, California, USA. FAU - Schuetz, Ekke AU - Schuetz E AD - Oncocyte Corporation, Irvine, California, USA. FAU - Sanchez, Alejandro AU - Sanchez A AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - O'Neil, Brock AU - O'Neil B AD - Department of Surgery, Division of Urology, University of Utah Health, Salt Lake City, Utah, USA. FAU - Poch, Michael AU - Poch M AD - Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA. AD - Immunology, Moffitt Cancer Center, Tampa, Florida, USA. FAU - Li, Roger AU - Li R AD - Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA. FAU - Lloyd, Shane AU - Lloyd S AD - Department of Radiation Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Tward, Jonathan AU - Tward J AD - Department of Radiation Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Phunrab, Tenzin AU - Phunrab T AD - Department of Medical Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Hawks, Josiah Lyn AU - Hawks JL AUID- ORCID: 0000-0001-9908-4598 AD - Research Compliance Office, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Swami, Umang AU - Swami U AUID- ORCID: 0000-0003-3518-0411 AD - Department of Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA. FAU - Boucher, Kenneth M AU - Boucher KM AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA. FAU - Agarwal, Neeraj AU - Agarwal N AUID- ORCID: 0000-0003-1076-0428 AD - Department of Medical Oncology, University of Utah, Salt Lake City, Utah, USA. FAU - Gupta, Sumati AU - Gupta S AUID- ORCID: 0000-0001-6271-0831 AD - University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA Sumati.Gupta@hci.utah.edu. LA - eng SI - ClinicalTrials.gov/NCT03171025 GR - I01 BX005765/BX/BLRD VA/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study DEP - 20250318 PL - England TA - J Immunother Cancer JT - Journal for immunotherapy of cancer JID - 101620585 RN - 31YO63LBSN (Nivolumab) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - *Nivolumab/therapeutic use/pharmacology MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Chemoradiotherapy/methods MH - Aged, 80 and over MH - *Antineoplastic Agents, Immunological/therapeutic use/pharmacology MH - Chemotherapy, Adjuvant PMC - PMC11927433 OTO - NOTNLM OT - Bladder Cancer OT - Circulating tumor DNA - ctDNA OT - Immune Checkpoint Inhibitor COIS- Competing interests: DG reports consultancy to MyCarGorithm. BLM reports consultancy to Astellas, AVEO, Bavarian Nordig, Bayer, Bristo-Myers Squibb, Clovis Oncology, Exelixis, Janssen Oncology, Merck, Peloton Therapeutics, Pfizer and Tempus; and research funding from Bavarian Nordic, Bristol-Myers Squibb, and Clovis Oncology. RKJ reports consulting to AVEO, Bristo-Myers Squibb, EMD Serono and Gilead Sciences; and research funding to Bristol Myers Squibb, Gilead Sciences and the NCI. JB reports being employed by Chronix Biomedical and Oncocyte. ES reports being employed by OncoCyte. RL reports consultancy to Arquer iagnostics, Bristol-Myers Squibb, CG Oncology, FerGene, Ferring, Lucence Diagnostics, Merck and Urogen pharma; and Research funding from G Oncology, and Predicine. SL reports consultancy to Cancer Study Group. JT reports consultancy to Bayer, Blue Earth Diagnostics, Boston Scientific, Boston Scientific, Janssen Scientific Affairs, Lantheus Medical Imaging, Merck, Myovant Sciences, Myriad Genetics, Myriad Genetics, and Myriad Genetics; and Research funding from Bayer (Inst), and Myriad Genetics (Inst). US reports consultancy to Astellas, AstraZeneca, Adaptimmune, Exelixis, Gilead, Imvax, Pfizer, Seattle Genetics and Sanofi and research funding from institute from Janssen, Exelixis and Astellas/Seattle Genetics. NA reports research funding from Amgen (Inst), Arvinas (Inst), AstraZeneca (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Celldex (Inst), crispr therapeutics (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), Gilead Sciences (Inst), Immunomedics (Inst), Janssen (Inst), Lilly (Inst), Merck (Inst), Nektar (Inst), ORIC Pharmaceuticals (Inst), ORIC Pharmaceuticals (Inst), Pfizer (Inst), and Takeda (Inst). SG reports research funding from Acrotech Biopharma (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst), Clovis Oncology (Inst), Daiichi Sankyo/Lilly (Inst), Five Prime Therapeutics (Inst), Hoosier Cancer Research Network (Inst), Immunocore (Inst), Incyte (Inst), LSK BioPharma (Inst), MedImmune (Inst), Merck (Inst), Mirati Therapeutics (Inst), Novartis (Inst), Pfizer (Inst), QED Therapeutics (Inst), Rexahn Pharmaceuticals (Inst), Seagen (Inst), and Viralytics (Inst). All other authors have no pertinent interests to report. EDAT- 2025/03/19 00:36 MHDA- 2025/03/19 00:37 PMCR- 2025/03/18 CRDT- 2025/03/18 21:52 PHST- 2025/03/06 00:00 [accepted] PHST- 2025/03/19 00:37 [medline] PHST- 2025/03/19 00:36 [pubmed] PHST- 2025/03/18 21:52 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - jitc-2024-010572 [pii] AID - 10.1136/jitc-2024-010572 [doi] PST - epublish SO - J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572. PMID- 40093987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250318 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 81 DP - 2025 Mar TI - Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non-muscle-invasive bladder cancer: a retrospective, multicentre study. PG - 103125 LID - 10.1016/j.eclinm.2025.103125 [doi] LID - 103125 AB - BACKGROUND: Accurate prediction of early recurrence is essential for disease management of patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to develop and validate a deep learning-based early recurrence predictive model (ERPM) and a treatment response predictive model (TRPM) on whole slide images to assist clinical decision making. METHODS: In this retrospective, multicentre study, we included consecutive patients with pathology-confirmed NMIBC who underwent transurethral resection of bladder tumour from five centres. Patients from one hospital (Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China) were assigned to training and internal validation cohorts, and patients from four other hospitals (the Third Affiliated Hospital of Sun Yat-sen University, and Zhujiang Hospital of Southern Medical University, Guangzhou, China; the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China; Shenshan Medical Centre, Shanwei, China) were assigned to four independent external validation cohorts. Based on multi-instance and ensemble learning, the ERPM was developed to make predictions on haematoxylin and eosin (H&E) staining and immunohistochemistry staining slides. Sharing the same architecture of the ERPM, the TRPM was trained and evaluated by cross validation on patients who received Bacillus Calmette-Guerin (BCG). The performance of the ERPM was mainly evaluated and compared with the clinical model, H&E-based model, and integrated model through the area under the curve. Survival analysis was performed to assess the prognostic capability of the ERPM. FINDINGS: Between January 1, 2017, and September 30, 2023, 4395 whole slide images of 1275 patients were included to train and validate the models. The ERPM was superior to the clinical and H&E-based model in predicting early recurrence in both internal validation cohort (area under the curve: 0.837 vs 0.645 vs 0.737) and external validation cohorts (area under the curve: 0.761-0.802 vs 0.626-0.682 vs 0.694-0.723) and was on par with the integrated model. It also stratified recurrence-free survival significantly (p < 0.0001) with a hazard ratio of 4.50 (95% CI 3.10-6.53). The TRPM performed well in predicting BCG-unresponsive NMIBC (accuracy 84.1%). INTERPRETATION: The ERPM showed promising performance in predicting early recurrence and recurrence-free survival of patients with NMIBC after surgery and with further validation and in combination with TRPM could be used to guide the management of NMIBC. FUNDING: National Natural Science Foundation of China, the Science and Technology Planning Project of Guangdong Province, the National Key Research and Development Programme of China, the Guangdong Provincial Clinical Research Centre for Urological Diseases, and the Science and Technology Projects in Guangzhou. CI - (c) 2025 The Author(s). FAU - Jiang, Fan AU - Jiang F AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Hong, Guibin AU - Hong G AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Zeng, Hong AU - Zeng H AD - Department of Pathology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Lin, Zhen AU - Lin Z AD - CellsVision Medical Technology Services Co., Ltd., Guangzhou, China. FAU - Liu, Ye AU - Liu Y AD - Department of Pathology, The Fifth Affiliated Hospital, Sun Yat-sen University, Guangdong, China. FAU - Xu, Abai AU - Xu A AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangdong, China. FAU - Shen, Runnan AU - Shen R AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Xie, Ye AU - Xie Y AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Luo, Yun AU - Luo Y AD - Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Wang, Yun AU - Wang Y AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Zhu, Mengyi AU - Zhu M AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Yang, Hongkun AU - Yang H AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Wang, Haoxuan AU - Wang H AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Huang, Shuting AU - Huang S AD - CellsVision Medical Technology Services Co., Ltd., Guangzhou, China. FAU - Chen, Rui AU - Chen R AD - CellsVision Medical Technology Services Co., Ltd., Guangzhou, China. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. AD - Guangdong Provincial Clinical Research Centre for Urological Diseases, Guangdong, China. FAU - Wu, Shaoxu AU - Wu S AD - Department of Urology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. AD - Guangdong Provincial Clinical Research Centre for Urological Diseases, Guangdong, China. LA - eng PT - Journal Article DEP - 20250226 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC11909458 OTO - NOTNLM OT - Bladder cancer OT - Deep learning OT - Early recurrence OT - Multicentre study OT - Therapy response COIS- We declare no competing interests. EDAT- 2025/03/17 15:19 MHDA- 2025/03/17 15:20 PMCR- 2025/02/26 CRDT- 2025/03/17 06:40 PHST- 2024/11/03 00:00 [received] PHST- 2025/01/19 00:00 [revised] PHST- 2025/02/07 00:00 [accepted] PHST- 2025/03/17 15:20 [medline] PHST- 2025/03/17 15:19 [pubmed] PHST- 2025/03/17 06:40 [entrez] PHST- 2025/02/26 00:00 [pmc-release] AID - S2589-5370(25)00057-4 [pii] AID - 103125 [pii] AID - 10.1016/j.eclinm.2025.103125 [doi] PST - epublish SO - EClinicalMedicine. 2025 Feb 26;81:103125. doi: 10.1016/j.eclinm.2025.103125. eCollection 2025 Mar. PMID- 40087655 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250513 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Mar 14 TI - The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study. PG - 468 LID - 10.1186/s12885-025-13817-6 [doi] LID - 468 AB - BACKGROUND: Bladder cancer (BCa) is a common urinary malignancy with high recurrence rates in non-muscle invasive bladder cancer (NMIBC), posing significant clinical challenges. Emerging evidence links urinary microbiota to cancer progression; however, their role in BCa recurrence remains unclear. This study aimed to explore urinary microbiota differences between primary and recurrent BCa to identify potential microbiological markers and mechanisms associated with recurrence. METHODS: Urine samples were collected from 170 BCa patients, including 125 with primary Bca(BCa_P) and 45 with recurrent BCa (BCa_R). All samples underwent 16 S rRNA gene sequencing, and clinical data were collected, including age, sex, body mass index (BMI), smoking history, pathological grade, and other biological characteristics. Propensity score matching (1:1 ratio, caliper = 0.02) minimized baseline differences, resulting in 39 matched pairs. Microbial diversity was analyzed using alpha and beta diversity indices. Differential taxa were identified with Linear Discriminant Analysis Effect Size (LEfSe), and functional pathways were predicted using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). RESULTS: Alpha diversity was significantly higher in BCa_P than BCa_R, particularly in Chao1 indices. beta diversity revealed distinct microbial structures (ADONIS, P = 0.004, R(2) = 0.025). At the phylum level, both BCa_P and BCa_R were dominated by Firmicutes, Proteobacteria, Bacteroidetes, and Actinobacteria, with Firmicutes significantly higher and Bacteroidetes lower in BCa_R. At the genus level, BCa_P was enriched in Sphingomonas, Corynebacterium, Capnocytophaga, Massilia, and Aquabacterium, while BCa_R showed higher levels of Aeromonas, Cupriavidus, and Bradyrhizobium. Functional predictions revealed glucose metabolism and oxidative stress pathways enriched in BCa_R, while pollutant degradation and TCA cycle pathways were prominent in BCa_P. CONCLUSION: These findings reveal significant differences in urinary microbiota compositions and functional profiles between primary and recurrent BCa patients, with recurrent cases exhibiting reduced microbial diversity and enrichment of potentially pathogenic communities, highlighting their potential roles in tumor progression and recurrence. TRIAL REGISTRATION: Registered with the Chinese Clinical Trial Registry (ChiCTR2300070969) on April 27, 2023. CI - (c) 2025. The Author(s). FAU - Sheng, Zhaoyang AU - Sheng Z AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. AD - Department of Urology, The 904th Hospital, Joint Logistics Support Force, Wuxi, 214000, China. FAU - Xu, Jinshan AU - Xu J AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. FAU - Wang, Maoyu AU - Wang M AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. FAU - Xu, Xi AU - Xu X AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. FAU - Zhu, Jinpeng AU - Zhu J AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. zengshuxiong@126.com. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. chuanliang_xu@126.comor. AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China. chuanliang_xu@126.comor. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. 13761178177@163.com. LA - eng GR - 82172871/National Natural Science Foundation of China/ GR - 82272950/National Natural Science Foundation of China/ GR - 2022YQ010/Shanghai Municipal Health Commission/ GR - 2024MS013/Basic Research Project of Naval Medical University/ PT - Journal Article DEP - 20250314 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (RNA, Ribosomal, 16S) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/microbiology/urine/pathology MH - Male MH - Female MH - *Microbiota MH - *Neoplasm Recurrence, Local/microbiology/urine MH - Middle Aged MH - Aged MH - Propensity Score MH - Phylogeny MH - RNA, Ribosomal, 16S/genetics MH - Bacteria/genetics/classification/isolation & purification PMC - PMC11907829 OTO - NOTNLM OT - 16sRNA OT - BCa OT - Recurrence OT - Urinary Microbiome COIS- Declarations. Ethics approval and consent to participate: Informed written consent was obtained from all patients at the time of enrollment. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki for research involving human subjects and received approval from the Ethics Committee of Changhai Hospital, Naval Medical University (Approval No. CHEC2023-062). Consent for publication: Written informed consent was obtained from all patients. Competing interests: The authors declare no competing interests. EDAT- 2025/03/16 11:16 MHDA- 2025/03/16 11:17 PMCR- 2025/03/14 CRDT- 2025/03/15 00:40 PHST- 2024/12/29 00:00 [received] PHST- 2025/02/25 00:00 [accepted] PHST- 2025/03/16 11:17 [medline] PHST- 2025/03/16 11:16 [pubmed] PHST- 2025/03/15 00:40 [entrez] PHST- 2025/03/14 00:00 [pmc-release] AID - 10.1186/s12885-025-13817-6 [pii] AID - 13817 [pii] AID - 10.1186/s12885-025-13817-6 [doi] PST - epublish SO - BMC Cancer. 2025 Mar 14;25(1):468. doi: 10.1186/s12885-025-13817-6. PMID- 40084633 OWN - NLM STAT- MEDLINE DCOM- 20250608 LR - 20250611 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 32 IP - 6 DP - 2025 Jun TI - Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ. PG - 737-746 LID - 10.1111/iju.70044 [doi] AB - OBJECTIVES: Intravesical instillation of bacillus Calmette-Guerin (BCG) is the standard treatment for bladder carcinoma in situ (CIS); however, factors that predict its therapeutic efficacy have not been identified. We focused on immune cells infiltrating within 20 mum of tumor cells and examined factors that predict the efficacy of intravesical BCG treatment. METHODS: Formalin-fixed, paraffin-embedded tissue specimens from 82 patients with bladder CIS treated with intravesical BCG were used. Patients who relapsed after BCG treatment were grouped as non-responders, and those who did not were grouped as responders. Tissue sections were immunostained for CD4, CD8, and forkhead box P3 (FOXP3), a marker of regulatory T cells (Tregs). The number of immune cells positive for the above markers present within 20 mum of the lower edge of the basement membrane on which CIS is present was counted and compared between groups. RESULTS: Both the peritumoral Treg density and Treg+/CD4+ cell ratio were significantly greater in nonresponders than in responders. The patients were divided into high and low groups based on Treg density and Treg+/CD4+ cell ratio cut-off values; recurrence-free survival was significantly longer in the low group than in the high group (p = 0.005 and p < 0.001, respectively). CONCLUSIONS: The Treg density and Treg+/CD4+ cell ratio within 20 mum of bladder CIS may be useful predictors of therapeutic response to BCG. CI - (c) 2025 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Fukiage, Yusuke AU - Fukiage Y AD - Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. FAU - Muramoto, Akifumi AU - Muramoto A AD - Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. FAU - Terada, Naoki AU - Terada N AUID- ORCID: 0009-0005-1082-6089 AD - Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. FAU - Kobayashi, Motohiro AU - Kobayashi M AUID- ORCID: 0000-0002-7607-0801 AD - Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. LA - eng GR - Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20250314 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 0 (Forkhead Transcription Factors) RN - 0 (FOXP3 protein, human) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/drug therapy/pathology MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *T-Lymphocytes, Regulatory/immunology MH - Female MH - Male MH - Aged MH - *Carcinoma in Situ/drug therapy/immunology/pathology MH - Middle Aged MH - Administration, Intravesical MH - Aged, 80 and over MH - Treatment Outcome MH - Forkhead Transcription Factors/metabolism MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Neoplasm Recurrence, Local MH - *Lymphocytes, Tumor-Infiltrating/immunology PMC - PMC12146248 OTO - NOTNLM OT - BCG vaccine OT - carcinoma in situ OT - regulatory T cell OT - tumor microenvironment OT - urinary bladder COIS- The authors declare no financial support received for the present study. Naoki Terada is an Editorial Board member of the International Journal of Urology and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. EDAT- 2025/03/14 11:17 MHDA- 2025/06/09 00:28 PMCR- 2025/06/09 CRDT- 2025/03/14 07:03 PHST- 2025/02/25 00:00 [revised] PHST- 2024/11/01 00:00 [received] PHST- 2025/03/05 00:00 [accepted] PHST- 2025/06/09 00:28 [medline] PHST- 2025/03/14 11:17 [pubmed] PHST- 2025/03/14 07:03 [entrez] PHST- 2025/06/09 00:00 [pmc-release] AID - IJU70044 [pii] AID - 10.1111/iju.70044 [doi] PST - ppublish SO - Int J Urol. 2025 Jun;32(6):737-746. doi: 10.1111/iju.70044. Epub 2025 Mar 14. PMID- 40082801 OWN - NLM STAT- MEDLINE DCOM- 20250512 LR - 20250512 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Mar 13 TI - Long term survival in elderly patients with resectable upper tract urothelial carcinoma: analysis of hospital-based cancer registry data in Japan. PG - 464 LID - 10.1186/s12885-025-13852-3 [doi] LID - 464 AB - BACKGROUND: To clarify the long-term prognoses of elderly upper tract urothelial carcinoma (UTUC) patients after surgery. METHODS: We used a hospital-based cancer registry data in Japan to extract patients with pT1-3N0M0 UTUC diagnosed in 2009 who underwent surgery, and classified them by age group (/= 75 years old). We estimated the 10-year overall survival (OS) by a Kaplan-Meier analysis. For cancer survival estimation, we calculated the 10-year net survival (NS) by Pohar-Preme method using the Japanese life tables. RESULTS: A total of 1139 UTUC patients (564 renal pelvic cancer [RPC] and 575 ureteral cancer [UrC]) were identified. The 10-year OS rates for elderly RPC patients (>/= 75 years old) were significantly worse than for younger patients (/= 2 and no complications of grade >/= 4. High levels of patient satisfaction were reported, with 83% preferring outpatient TURB to inpatient treatment for future surgery. CONCLUSION: Outpatient TURB appears to be a safe and effective alternative to inpatient surgery for selected patients with bladder tumors 6w) to second resection were associated with a higher tumor residual rate (p < 0.05), and they were confirmed as predictors for tumor residue. Differences were not determined between patients with different tumor characteristics (e.g., Ta vs. T1). A median follow-up of 14 (3-40) months was conducted in 100 patients. Intravesical recurrence and progression were determined in 14 (14%) and 4 (4%) patients, with the 1-year recurrence-free and progression-free survivals of 86.5% and 96.9%, respectively. Maintenance BCG therapy was identified as a predictor for tumor recurrence (HR = 6.168, p < 0.05). CONCLUSIONS: A lower tumor residual rate than previously reported was achieved with acceptable short-term oncological outcomes after conventional transurethral resection of bladder tumors. The basis of second resection may need further exploration. Second resection may be prioritized for younger patients and performed within 6 weeks of the initial resection. Maintenance BCG therapy could reduce tumor recurrence after second resection. CI - (c) 2025 The Japanese Urological Association. FAU - Xu, Song AU - Xu S AUID- ORCID: 0009-0002-9284-0711 AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Institute of Urology, Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Urological Diseases, Wuhan, China. AD - Hubei Clinical Research Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. AD - Hubei Medical Quality Control Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. FAU - Shi, Hongjie AU - Shi H AD - Department of Biological Repositories, Human Genetic Resources Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Yu, Fang AU - Yu F AD - Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Lu, Mengxin AU - Lu M AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Institute of Urology, Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Urological Diseases, Wuhan, China. AD - Hubei Clinical Research Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. AD - Hubei Medical Quality Control Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. FAU - Yang, Zhonghua AU - Yang Z AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Institute of Urology, Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Urological Diseases, Wuhan, China. AD - Hubei Clinical Research Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. AD - Hubei Medical Quality Control Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. FAU - Zheng, Hang AU - Zheng H AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Institute of Urology, Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Urological Diseases, Wuhan, China. AD - Hubei Clinical Research Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. AD - Hubei Medical Quality Control Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China. LA - eng PT - Journal Article DEP - 20250310 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Cystectomy/methods MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control/pathology MH - *Reoperation/statistics & numerical data MH - Neoplasm, Residual MH - Aged, 80 and over MH - Follow-Up Studies MH - Treatment Outcome MH - BCG Vaccine/administration & dosage MH - Neoplasm Staging MH - Urinary Bladder/surgery/pathology MH - Progression-Free Survival MH - Age Factors MH - Disease Progression OTO - NOTNLM OT - local neoplasm recurrence OT - prognostic factors OT - progression-free survival OT - residual tumor OT - transurethral resection of bladder tumor EDAT- 2025/03/10 12:31 MHDA- 2025/06/09 00:28 CRDT- 2025/03/10 08:13 PHST- 2025/02/18 00:00 [revised] PHST- 2024/11/28 00:00 [received] PHST- 2025/02/26 00:00 [accepted] PHST- 2025/06/09 00:28 [medline] PHST- 2025/03/10 12:31 [pubmed] PHST- 2025/03/10 08:13 [entrez] AID - 10.1111/iju.70041 [doi] PST - ppublish SO - Int J Urol. 2025 Jun;32(6):720-726. doi: 10.1111/iju.70041. Epub 2025 Mar 10. PMID- 40057908 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 57 IP - 9 DP - 2025 Sep TI - Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study. PG - 2755-2765 LID - 10.1007/s11255-025-04446-w [doi] AB - PURPOSE: To evaluate the efficacy of integrating en bloc resection, endoscopic submucosal dissection (ESD), and submucosal injection of chemotherapeutic agents with TURBT (cESD-TURBT). METHODS: This retrospective observational study was conducted on patients diagnosed with stage cTa-T1 bladder cancer who received TURBT between December 2020 and July 2023 at Liaoning Cancer Hospital. The participants were grouped on the basis of the type of treatment they received: cESD-TURBT (n = 118) or conventional TURBT (cTURBT, n = 105). Hydroxycothecin is the chemotherapeutic agent used for submucosal injections. The primary outcome was the recurrence-free survival (RFS) of the treated patients with bladder cancer. The secondary outcomes included disease recurrence within one year, operation duration, length of postoperative hospitalization, and complication rates. Statistical analyses were performed via appropriate tests, with a threshold of P < 0.05 defined as statistically significant. RESULTS: Compared with the cTURBT cohort, the cESD-TURBT cohort demonstrated increased RFS, with a median follow-up of 775 days (interquartile range [IQR] 414-1040). The recurrence rate in the cESD-TURBT cohort was 18.6% (22/118), whereas it was 39.1% (41/105) in the cTURBT cohort, with a log-rank hazard ratio of 0.49 (95% CI 0.29-0.82; p = 0.0053). Furthermore, cESD-TURBT resulted in fewer postoperative complications than did cTURBT, markedly reducing the occurrence of complications, such as the obturator reflex (1.7% vs. 8.6%, p = 0.03). The difference in operation time was not statistically significant, with a cESD-TURBT of 49.0 +/- 21.0 min and a cTURBT of 44.3 +/- 23.8 min (p = 0.127). CONCLUSION: Our analysis revealed that, compared with cTURBT, cESD-TURBT significantly lowers recurrence rates and is associated with fewer postoperative complications. Our study revealed that cESD-TURBT is superior to cTURBT for bladder tumor removal. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Liu, Xi AU - Liu X AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Wang, Yiding AU - Wang Y AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Wang, Zhe AU - Wang Z AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Shao, Bo AU - Shao B AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Liu, Qiang AU - Liu Q AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Li, Changqi AU - Li C AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Lv, Chengcheng AU - Lv C AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Bi, Huan AU - Bi H AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Shan, Guangyi AU - Shan G AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Fu, Shui AU - Fu S AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Chen, Ang AU - Chen A AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. FAU - Zeng, Yu AU - Zeng Y AD - Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. zengyud07@foxmail.com. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study DEP - 20250309 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - Female MH - *Endoscopic Mucosal Resection/methods MH - *Urinary Bladder Neoplasms/surgery/drug therapy/pathology MH - Middle Aged MH - Aged MH - *Antineoplastic Agents/administration & dosage MH - *Cystectomy/methods MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - En bloc resection OT - Endoscopic submucosal dissection OT - Nonmuscle-invasive bladder cancer OT - Transurethral resection of the bladder COIS- Declarations. Conflict of interest: Yu Zeng certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None of which are related to the present publication. The remaining authors have nothing to disclose. EDAT- 2025/03/10 04:42 MHDA- 2025/08/31 19:51 CRDT- 2025/03/09 12:03 PHST- 2024/11/24 00:00 [received] PHST- 2025/03/01 00:00 [accepted] PHST- 2025/08/31 19:51 [medline] PHST- 2025/03/10 04:42 [pubmed] PHST- 2025/03/09 12:03 [entrez] AID - 10.1007/s11255-025-04446-w [pii] AID - 10.1007/s11255-025-04446-w [doi] PST - ppublish SO - Int Urol Nephrol. 2025 Sep;57(9):2755-2765. doi: 10.1007/s11255-025-04446-w. Epub 2025 Mar 9. PMID- 40053821 OWN - NLM STAT- MEDLINE DCOM- 20250307 LR - 20251016 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 1 DP - 2025 Jan 1 TI - Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study. PG - 920-931 LID - 10.1097/JS9.0000000000001999 [doi] AB - BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are strongly correlated with the prognosis and immunotherapy response in bladder cancer. The TIL status is typically assessed through microscopy as part of tissue pathology. Here, the authors developed Rad-TIL model, a novel radiomics model, to predict TIL status in patients with bladder cancer. MATERIAL AND METHODS: The authors enrolled 1089 patients with bladder cancer and developed the Rad-TIL model by using a machine-learning method based on computed tomography (CT) images. The authors applied a radiogenomics cohort to reveal the key pathways underlying the Rad-TIL model. Finally, the authors used an independent treatment cohort to evaluate the predictive efficacy of the Rad-TIL model for Bacillus Calmette-Guerin (BCG) immunotherapy. RESULTS: The authors developed the Rad-TIL model by integrating tumoral and peritumoral features on CT images and obtained areas under the receiver operating characteristic curves of 0.844 and 0.816 in the internal and external validation cohorts, respectively. Patients were stratified into two groups based on the predicted radiomics score of TILs (RSTIL). RSTIL exhibited prognostic significance for both overall and cancer-specific survival in each cohort (hazard ratios: 2.27-3.15, all P<0.05). Radiogenomics analysis revealed a significant association of RSTIL with immunoregulatory pathways and immune checkpoint molecules (all P<0.05). Notably, BCG immunotherapy response rates were significantly higher in high-RSTIL patients than in low-RSTIL patients (P=0.007). CONCLUSION: The Rad-TIL model, a noninvasive method for assessing TIL status, can predict clinical outcomes and BCG immunotherapy response in patients with bladder cancer. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Chen, Ke AU - Chen K AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. AD - Department of Urology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China. FAU - Li, Xiaoyang AU - Li X AD - Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Liu, Libo AU - Liu L AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Wang, Bo AU - Wang B AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Liang, Weiming AU - Liang W AD - Department of Urology, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, People's Republic of China. FAU - Chen, Junyu AU - Chen J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Gao, Mingchao AU - Gao M AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Huang, Xiaodong AU - Huang X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Liu, Bohao AU - Liu B AD - Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Sun, Xi AU - Sun X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Yang, Tenghao AU - Yang T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Zhao, Xiao AU - Zhao X AD - Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - He, Wang AU - He W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. FAU - Luo, Yun AU - Luo Y AD - Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. AD - Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou. FAU - Zhong, Wenlong AU - Zhong W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University. LA - eng SI - ClinicalTrials.gov/NCT06381895 PT - Journal Article PT - Multicenter Study DEP - 20250101 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/diagnostic imaging/therapy/immunology/drug therapy MH - *Lymphocytes, Tumor-Infiltrating/pathology MH - Male MH - Female MH - *BCG Vaccine/therapeutic use MH - *Immunotherapy/methods MH - Aged MH - Middle Aged MH - Tomography, X-Ray Computed MH - Prognosis MH - Cohort Studies MH - Aged, 80 and over MH - Adjuvants, Immunologic/therapeutic use MH - Retrospective Studies MH - Machine Learning PMC - PMC11745626 COIS- All authors declare no potential conflicts of interest. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. EDAT- 2025/03/07 18:21 MHDA- 2025/03/07 18:22 PMCR- 2025/01/20 CRDT- 2025/03/07 14:47 PHST- 2024/04/24 00:00 [received] PHST- 2024/07/15 00:00 [accepted] PHST- 2025/03/07 18:22 [medline] PHST- 2025/03/07 18:21 [pubmed] PHST- 2025/03/07 14:47 [entrez] PHST- 2025/01/20 00:00 [pmc-release] AID - 01279778-202501000-00085 [pii] AID - IJS-D-24-01680 [pii] AID - 10.1097/JS9.0000000000001999 [doi] PST - epublish SO - Int J Surg. 2025 Jan 1;111(1):920-931. doi: 10.1097/JS9.0000000000001999. PMID- 40050483 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250423 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 32 IP - 5 DP - 2025 May TI - Leveraging Deep Learning in Real-Time Intelligent Bladder Tumor Detection During Cystoscopy: A Diagnostic Study. PG - 3220-3226 LID - 10.1245/s10434-025-17015-3 [doi] AB - BACKGROUND: Accurate detection of bladder lesions during cystoscopy is crucial for early tumor diagnosis and recurrence monitoring. However, conventional visual inspection methods have low and inconsistent detection rates. This study aimed to evaluate the effectiveness of the HRNetV2 deep learning model for intelligent bladder lesion detection, focusing on its performance at different image resolutions. PATIENTS AND METHODS: We recruited 94 patients undergoing cystoscopy or transurethral resection of bladder tumor and collected 102 white-light cystoscopy videos between July 2022 and July 2023. Frames containing suspected bladder lesions were manually annotated. HRNetV2, a semantic segmentation model, was used to identify tumor-related morphological features. Images were categorized as high- or low-resolution, and the dataset was split into training and test sets (4:1 ratio). Diagnostic performance was assessed using sensitivity, precision, and mean Dice (mDice) score. RESULTS: A total of 33,657 frames were annotated. The overall sensitivity and precision for the test set were 91.6% and 91.3%, respectively, with an mDice score of 80.3%. In the high-resolution group, sensitivity and precision were 94.8% and 94.4%, while in the low-resolution group, they were 75.6% and 74.8%. The mDice scores for high- and low-resolution images were 84.7% and 56.6%, respectively. CONCLUSIONS: HRNetV2 demonstrated excellent performance, particularly with high-resolution images, offering high sensitivity and precision in bladder lesion detection. The results suggest that HRNetV2 has significant potential to improve detection accuracy in clinical practice. Future work should focus on optimizing the model further and testing it with larger, multicenter datasets. CI - (c) 2025. The Author(s). FAU - Ye, Zixing AU - Ye Z AD - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Yingjie AU - Li Y AD - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Sun, Yujiao AU - Sun Y AD - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - He, Chengqing AU - He C AD - Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - He, Guanglin AU - He G AD - Hangzhou Hikvision Digital Technology Co., Ltd., Hangzhou, China. FAU - Ji, Zhigang AU - Ji Z AD - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. jizhigang@pumch.cn. LA - eng GR - 012/China Primary Health Care Foundation/ GR - 2022-PUMCH-B-008/National High Level Hospital Clinical Research Funding/ PT - Journal Article DEP - 20250306 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/surgery MH - *Deep Learning MH - *Cystoscopy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - Follow-Up Studies MH - Prognosis PMC - PMC11976823 OTO - NOTNLM OT - Artificial intelligence OT - Bladder lesion OT - Cystoscopy OT - Deep learning OT - Transurethral resection of bladder tumor COIS- Disclosures: The authors declare that they have no competing interests Ethics Approval and Consent to Participate: This study was approved by the Ethics Committee of Peking Union Medical Hospital, Chinese Academy of Medical Sciences (I-23PJ1996). Consent for Publication: Written informed consent was obtained from the patient for publication and accompanying images. EDAT- 2025/03/07 00:21 MHDA- 2025/04/23 06:26 PMCR- 2025/03/06 CRDT- 2025/03/06 23:25 PHST- 2024/12/27 00:00 [received] PHST- 2025/01/30 00:00 [accepted] PHST- 2025/04/23 06:26 [medline] PHST- 2025/03/07 00:21 [pubmed] PHST- 2025/03/06 23:25 [entrez] PHST- 2025/03/06 00:00 [pmc-release] AID - 10.1245/s10434-025-17015-3 [pii] AID - 17015 [pii] AID - 10.1245/s10434-025-17015-3 [doi] PST - ppublish SO - Ann Surg Oncol. 2025 May;32(5):3220-3226. doi: 10.1245/s10434-025-17015-3. Epub 2025 Mar 6. PMID- 40047306 OWN - NLM STAT- MEDLINE DCOM- 20250908 LR - 20250910 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 136 IP - 4 DP - 2025 Oct TI - Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer. PG - 682-689 LID - 10.1111/bju.16697 [doi] AB - OBJECTIVE: To evaluate the performance of Bladder Epicheck(R) (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette-Guerin (BCG) failure during the first year after induction treatment. PATIENTS AND METHODS: Prospective study including 65 patients with non-muscle-invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment. RESULTS: During follow-up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high-grade recurrence) and five (31.2%) were low-grade recurrences. The median (range) time to overall recurrence was 7.3 (3.8-17.4) months. A significant association was found between the risk of tumour recurrence/BCG failure and post-BCG cystoscopy (odds ratio [OR] 10.0; P < 0.001 and OR 13.1; P < 0.001, respectively), post-BCG BE result (OR 16.9; P < 0.001 and OR 33.1; P < 0.001, respectively) and pre/post-BCG EpiScore value variation (OR 14.4; P = 0.001 and OR 7.1; P = 0.018, respectively). A nomogram including these three variables outperformed the Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk tables to predict any bladder cancer event after BCG induction (area under the curve 95.1% vs 67.1%). Result validation in a larger and independent series is needed. CONCLUSIONS: The BE post-BCG status and variations in EpiScore values can help us identify patients at higher risk of any bladder cancer event and BCG failure promptly. These data can have an impact on disease management. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Roldan, Fiorella L AU - Roldan FL AUID- ORCID: 0000-0002-9152-922X AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Ingelmo-Torres, Mercedes AU - Ingelmo-Torres M AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Mercader, Claudia AU - Mercader C AUID- ORCID: 0000-0002-5710-958X AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Figueras, Marcel AU - Figueras M AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Padulles, Bernat AU - Padulles B AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Duran, Maria Angeles AU - Duran MA AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Carrasco, Josep L AU - Carrasco JL AD - Unitat de Bioestadistica, Departament de Fonaments Clinics, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. FAU - Ribal, Maria Jose AU - Ribal MJ AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Franco, Agustin AU - Franco A AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Izquierdo, Laura AU - Izquierdo L AUID- ORCID: 0000-0001-6015-2987 AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. FAU - Mengual, Lourdes AU - Mengual L AD - Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. AD - Genetica i Tumors Urologics, Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain. AD - Unitat de Genetica, Departament de Biomedicina, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain. LA - eng GR - Nucleix/ PT - Journal Article DEP - 20250306 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/urine MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Aged MH - Prospective Studies MH - Middle Aged MH - *Neoplasm Recurrence, Local/diagnosis/urine MH - *Adjuvants, Immunologic/therapeutic use MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Treatment Failure MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12415308 OTO - NOTNLM OT - BCG response OT - Bacillus Calmette-Guerin (BCG) OT - bladder EpiCheck OT - bladder cancer OT - methylation biomarkers OT - predictive biomarkers OT - urine EDAT- 2025/03/06 12:35 MHDA- 2025/09/08 06:32 PMCR- 2025/09/08 CRDT- 2025/03/06 07:34 PHST- 2025/09/08 06:32 [medline] PHST- 2025/03/06 12:35 [pubmed] PHST- 2025/03/06 07:34 [entrez] PHST- 2025/09/08 00:00 [pmc-release] AID - BJU16697 [pii] AID - 10.1111/bju.16697 [doi] PST - ppublish SO - BJU Int. 2025 Oct;136(4):682-689. doi: 10.1111/bju.16697. Epub 2025 Mar 6. PMID- 40047124 OWN - NLM STAT- MEDLINE DCOM- 20250306 LR - 20260708 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 66 IP - 2 DP - 2025 Mar TI - Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study. PG - 114-123 LID - 10.4111/icu.20240323 [doi] AB - PURPOSE: Adjuvant chemotherapy (AC) is recommended for muscle-invasive or lymph node-positive upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). However, disease recurrences are frequently observed in pT1 disease, and AC may increase the risk of overtreatment in pT2 UTUC patients. This study aimed to validate a risk-adapted scoring model for selecting UTUC patients with /=3 patients was performed. A narrative review was also performed for various aspects of management such as pathophysiology, surgical considerations, intravesical therapy, immunosuppression and oncological surveillance. RESULTS: Bladder cancer incidence in KT recipients is 2.8-4.1 times higher than the general population, and there is a notable association with aristolochic acid nephropathy as well as BK virus oncogenesis. Regarding surgical treatment, transurethral resection is preferred for non-muscle invasive tumors, and intravesical BCG for intermediate- and high-risk patients appears to be underutilized despite its safety and associated reduction in recurrence. Radical cystectomy with limited pelvic lymph node dissection, urinary diversion, and consideration of bilateral nephroureterectomy appears to be the safest method of oncological control in muscle-invasive tumors. A switch in immunosuppressive regimens to mTOR inhibitors may be considered in lieu of its antitumor effects. Routine surveillance in KT patients with risk factors for bladder cancer is challenging and may be warranted especially in the Asian population which has a higher rate of urothelial malignancy. CONCLUSIONS: This review provides a thorough summary of management strategies for bladder cancer in the setting of previous KT. CI - (c) The Author(s) 2025. FAU - Fong, Khi Yung AU - Fong KY AUID- ORCID: 0000-0001-8194-0800 AD - Department of Surgery, Singapore General Hospital, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Lim, Ee Jean AU - Lim EJ AUID- ORCID: 0000-0002-5242-0651 AD - Department of Urology, Singapore General Hospital, Singapore. FAU - So, Wei Zheng AU - So WZ AUID- ORCID: 0000-0002-2303-0750 AD - Department of Urology, National University Hospital, Singapore. FAU - Aslim, Edwin Jonathan AU - Aslim EJ AUID- ORCID: 0000-0003-1512-3356 AD - Department of Urology, Singapore General Hospital, Singapore. FAU - Tiong, Ho Yee AU - Tiong HY AUID- ORCID: 0000-0003-0077-7904 AD - Department of Urology, National University Hospital, Singapore. AD - National University Centre for Organ Transplantation, Singapore. FAU - Gan, Valerie Huei Li AU - Gan VHL AUID- ORCID: 0000-0002-6258-3286 AD - Department of Urology, Singapore General Hospital, Singapore. AD - SingHealth Duke-NUS Transplant Centre, Singapore. LA - eng PT - Journal Article PT - Review DEP - 20250224 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11863735 OTO - NOTNLM OT - Immunotherapy OT - bladder cancer OT - kidney transplantation OT - systematic review OT - urinary diversion COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/03/04 06:23 MHDA- 2025/03/04 06:24 PMCR- 2025/02/24 CRDT- 2025/03/04 04:46 PHST- 2024/11/27 00:00 [received] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/03/04 06:24 [medline] PHST- 2025/03/04 06:23 [pubmed] PHST- 2025/03/04 04:46 [entrez] PHST- 2025/02/24 00:00 [pmc-release] AID - 10.1177_23523735251321986 [pii] AID - 10.1177/23523735251321986 [doi] PST - epublish SO - Bladder Cancer. 2025 Feb 24;11(1):23523735251321986. doi: 10.1177/23523735251321986. eCollection 2025 Jan-Mar. PMID- 40021370 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250729 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 8 DP - 2025 Aug TI - Association of metabolic syndrome and chronic kidney disease with nonmuscle invasive bladder cancer recurrence and progression. PG - 467.e13-467.e20 LID - S1078-1439(25)00032-8 [pii] LID - 10.1016/j.urolonc.2025.02.008 [doi] AB - INTRODUCTION: Metabolic syndrome (MetS) has been associated with the pathogenesis of multiple solid tumors and chronic kidney disease (CKD) is related to higher incidence of urinary tract malignancy. Both MetS and CKD are prevalent in the same population of bladder cancer patients and are potentially modifiable risk factors. However, it is unclear whether they impact nonmuscle invasive bladder cancer (NMIBC) outcomes. We aimed to assess the effect of MetS and CKD on the risk of recurrence and progression of NMIBC. METHODS: A retrospective cohort study of 500 patients with NMIBC was conducted at a single institution from 2010-2022. CKD was defined as a past medical history of CKD at the time of presentation and MetS was defined as having at least 3 of the following: BMI >/=30 kg/m(2), hypertension, diabetes and elevated triglycerides. The cohort was categorized into 4 groups: MetS alone, CKD alone, both CKD and MetS, and neither. Univariate Kaplan Meier and cox regression analysis were conducted to determine whether MetS or CKD along with known clinical predictors influenced recurrence and/or progression. RESULTS: There was no statistical difference in NMIBC time to recurrence or progression for patients with CKD alone, MetS alone, CKD+MetS and neither condition. However, hypertension was significantly associated with a shorter time to progression (P = 0.03). As expected, receipt of BCG was associated with a decreased risk of recurrence and progression over time (HR 0.50, P < 0.0001; HR 0.28, P = 0.0002 respectively). Older age was associated with an increase in progression risk (HR: 1.04, P = 0.024). CONCLUSION: While both MetS and CKD are prevalent in the same population affected by bladder cancer patients, these conditions do not impact recurrence and progression in NMIBC. Nonetheless, NMIBC patients with MetS and CKD should strive to maintain good control of their chronic conditions to avoid disruption of treatment due to end-organ damage and associated sequelae. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Egemba, Christabel AU - Egemba C AD - University of Miami, Miller School of Medicine, Miami, FL. FAU - Kapil, Sneha AU - Kapil S AD - University of Miami, Miller School of Medicine, Miami, FL. FAU - Ajami, Tarek AU - Ajami T AD - University of Miami, Department of Urology, Miami, FL. FAU - Williams, Adam AU - Williams A AD - University of Miami, Department of Urology, Miami, FL. FAU - Nahar, Bruno AU - Nahar B AD - University of Miami, Department of Urology, Miami, FL. FAU - Punnen, Sanoj AU - Punnen S AD - University of Miami, Department of Urology, Miami, FL. FAU - Parekh, Dipen J AU - Parekh DJ AD - University of Miami, Department of Urology, Miami, FL. FAU - Gonzalgo, Mark AU - Gonzalgo M AD - University of Miami, Department of Urology, Miami, FL. FAU - Ritch, Chad R AU - Ritch CR AD - University of Miami, Department of Urology, Miami, FL. Electronic address: critch@med.miami.edu. LA - eng PT - Journal Article DEP - 20250228 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/complications MH - *Metabolic Syndrome/complications/epidemiology MH - Female MH - Male MH - Disease Progression MH - Retrospective Studies MH - *Renal Insufficiency, Chronic/complications/epidemiology MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder cancer OT - Chronic kidney disease OT - Metabolic syndrome OT - Recurrence COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/03/01 14:41 MHDA- 2025/07/12 16:44 CRDT- 2025/02/28 21:56 PHST- 2024/11/22 00:00 [received] PHST- 2025/01/20 00:00 [revised] PHST- 2025/02/08 00:00 [accepted] PHST- 2025/07/12 16:44 [medline] PHST- 2025/03/01 14:41 [pubmed] PHST- 2025/02/28 21:56 [entrez] AID - S1078-1439(25)00032-8 [pii] AID - 10.1016/j.urolonc.2025.02.008 [doi] PST - ppublish SO - Urol Oncol. 2025 Aug;43(8):467.e13-467.e20. doi: 10.1016/j.urolonc.2025.02.008. Epub 2025 Feb 28. PMID- 40010639 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20250613 IS - 1530-0307 (Electronic) IS - 0023-6837 (Linking) VI - 105 IP - 5 DP - 2025 May TI - Roles for Androgen Receptor, ADAR2, and PD-L1 in Primary Urothelial Carcinoma In Situ of the Bladder Treated with Bacillus Calmette-Guerin Therapy. PG - 104120 LID - S0023-6837(25)00030-3 [pii] LID - 10.1016/j.labinv.2025.104120 [doi] AB - In this retrospective observational multicenter study, we identified tumors and immune markers that are related to each other, which could help in selecting patients with bladder primary urothelial carcinoma in situ (CIS) who responded better to Bacillus Calmette-Guerin (BCG) therapy. Seventy-three patients with primary bladder CIS who were homogeneously treated with BCG were studied. Tumor-infiltrating lymphocytes (TILs) measured as CD4/CD8 ratio, androgen receptor (AR), adenosine deaminase acting on RNA 1 (ADAR1), adenosine deaminase acting on RNA 2 (ADAR2), and programmed death ligand 1 (PD-L1) expression were analyzed using immunohistochemistry, whereas miR-200a-3p and INF-gamma were correlated with clinicopathological features and recurrence-free survival. High AR levels in CIS were significantly associated with higher ADAR1 expression, lower ADAR2 expression, higher PD-L1 TPS, higher CD4/CD8 ratio, and multifocality of CIS (P < .001). All patients with the above-mentioned characteristics had significantly worse recurrence-free survival (P < .0001). Multivariate and multiple regression analyses confirmed the predictive role of AR, ADAR2, and PD-L1, especially when all 3 parameters were combined. Additionally, we demonstrated that patients with lower AR and higher ADAR2 expressions had significantly higher levels of miR-200a-3p and INF-gamma than those with higher AR and lower ADAR2 expression (P = .0011 and P = .0002, respectively). Our findings highlight the role of AR in the response to BCG therapy by modulating PD-L1 expression and TILs through the ADAR2, miR-200a-3p, and INF-gamma pathways. Furthermore, our data provide valuable insights for optimizing BCG therapy in patients with CIS, paving the way for other possible combined treatment strategies. CI - Copyright (c) 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. FAU - Ricciardi, Gabriele AU - Ricciardi G AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy; Istituto Clinico Polispecialistico C.O.T. Cure Ortopediche Traumatologiche s.p.a., Messina, Italy. FAU - Fiorentino, Vincenzo AU - Fiorentino V AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. FAU - Pierconti, Francesco AU - Pierconti F AD - Department of Women, Children and Public Health Sciences, Division of Pathology, Catholic University of the Sacred Heart, "A. Gemelli" Hospital Foundation, IRCCS, Roma, Italy. FAU - Giordano, Walter Giuseppe AU - Giordano WG AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. FAU - Germana, Emanuela AU - Germana E AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. FAU - Ieni, Antonio AU - Ieni A AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. FAU - Palermo, Giuseppe AU - Palermo G AD - Department of Medical and Abdominal Surgery and Endocrine-Metabolic Science, Division of Urology, Catholic University of the Sacred Heart, "A. Gemelli" Hospital Foundation, IRCCS, Roma, Italy. FAU - Racioppi, Marco AU - Racioppi M AD - Department of Medical and Abdominal Surgery and Endocrine-Metabolic Science, Division of Urology, Catholic University of the Sacred Heart, "A. Gemelli" Hospital Foundation, IRCCS, Roma, Italy. FAU - Rossanese, Marta AU - Rossanese M AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Urology, University of Messina, Italy. FAU - Ficarra, Vincenzo AU - Ficarra V AD - Department of Clinical and Experimental Medicine, Division of Urology, University of Messina, Italy. FAU - Pizzimenti, Cristina AU - Pizzimenti C AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. FAU - Tuccari, Giovanni AU - Tuccari G AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. FAU - Gallo, Angela AU - Gallo A AD - Department of Onco-hematology and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, Rome, Italy. FAU - Cesarini, Valeriana AU - Cesarini V AD - Department of Biomedicine, Institute of Translational Pharmacology (IFT), National Research Council (CNR), Rome, Italy. Electronic address: valeriana.cesarini@ift.cnr.it. FAU - Fadda, Guido AU - Fadda G AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. FAU - Martini, Maurizio AU - Martini M AD - Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, Messina, Italy. Electronic address: maurizio.martini@unime.it. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250224 PL - United States TA - Lab Invest JT - Laboratory investigation; a journal of technical methods and pathology JID - 0376617 RN - EC 3.5.4.4 (Adenosine Deaminase) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (BCG Vaccine) RN - 0 (RNA-Binding Proteins) RN - 0 (Receptors, Androgen) RN - EC 3.5.4.4 (ADARB1 protein, human) RN - 0 (AR protein, human) RN - 0 (MIRN200 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Adenosine Deaminase/metabolism MH - *B7-H1 Antigen/metabolism MH - Male MH - Female MH - Aged MH - *BCG Vaccine/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/metabolism/pathology MH - Middle Aged MH - Retrospective Studies MH - *RNA-Binding Proteins/metabolism MH - *Receptors, Androgen/metabolism MH - *Carcinoma in Situ/drug therapy/metabolism/pathology MH - Aged, 80 and over MH - MicroRNAs/metabolism MH - Lymphocytes, Tumor-Infiltrating MH - Biomarkers, Tumor/metabolism OTO - NOTNLM OT - Bacillus Calmette-Guerin treatment OT - adenosine deaminase acting on RNA 2 OT - androgen receptor OT - primary in situ urothelial carcinoma OT - programmed death ligand 1 OT - tumor-infiltrating lymphocytes EDAT- 2025/02/27 05:02 MHDA- 2025/05/23 00:27 CRDT- 2025/02/26 19:28 PHST- 2024/08/12 00:00 [received] PHST- 2025/01/27 00:00 [revised] PHST- 2025/02/06 00:00 [accepted] PHST- 2025/05/23 00:27 [medline] PHST- 2025/02/27 05:02 [pubmed] PHST- 2025/02/26 19:28 [entrez] AID - S0023-6837(25)00030-3 [pii] AID - 10.1016/j.labinv.2025.104120 [doi] PST - ppublish SO - Lab Invest. 2025 May;105(5):104120. doi: 10.1016/j.labinv.2025.104120. Epub 2025 Feb 24. PMID- 40010309 OWN - NLM STAT- MEDLINE DCOM- 20250805 LR - 20250805 IS - 1423-0291 (Electronic) IS - 1015-2008 (Linking) VI - 92 IP - 4 DP - 2025 TI - Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer. PG - 202-215 LID - 10.1159/000544733 [doi] AB - INTRODUCTION: This study aimed to evaluate the prognostic significance of programmed cell death (PD)-1/PD-ligand 1 (PD-L1), PD-ligand 2 (PD-L2), and fibroblast growth factor receptor 3 (FGFR3) expression in bladder cancer (BC). METHODS: A retrospective study was conducted on BC patients who underwent transurethral resection between 2005 and 2014. Of the initial 136 patients, 31 were excluded for not meeting the inclusion criteria, leaving 105 cases for the final analysis. The mRNA levels of PD-1/PD-L1/PD-L2 and FGFR3 were assessed using quantitative reverse transcription PCR and NanoString technology. RESULTS: High expression of PD-1 and its ligands (PD-L1/PD-L2) showed a strong correlation with each other and was associated with poor clinical outcomes, including higher tumor stage, grade, and cancer-specific mortality (p < 0.001). Conversely, high FGFR3 expression was associated with improved survival and more favorable clinicopathological features. Interestingly, an inverse relationship was observed between FGFR3 and PD-1 (p = 0.032) and PD-L1 (p = 0.016) expression. High mRNA expression profiles of PD-1, PD-L1, PD-L2, and low FGFR3 expression were associated with worse cancer-specific survival (p < 0.001). Multivariate analysis revealed that advanced stage, low FGFR3 expression, and high PD-L2 expression are independent predictors of poor prognosis in BC patients. CONCLUSION: Our findings suggest that elevated levels of PD-1, PD-L1, and PD-L2, combined with reduced FGFR3 expression, may assist in identifying patients with poor outcomes and highlight their potential as prognostic biomarkers in BC. CI - (c) 2025 S. Karger AG, Basel. FAU - Blanca, Ana AU - Blanca A AD - Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain. AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain. AD - Urology Department, Reina Sofia University Hospital, UCO, IMIBIC, Cordoba, Spain. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain. FAU - Gomez-Gomez, Enrique AU - Gomez-Gomez E AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain. AD - Urology Department, Reina Sofia University Hospital, UCO, IMIBIC, Cordoba, Spain. FAU - Campos-Hernandez, Pablo AU - Campos-Hernandez P AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain. AD - Urology Department, Reina Sofia University Hospital, UCO, IMIBIC, Cordoba, Spain. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Institute of Pathological Anatomy, Department of Medical Area (DAME), University of Udine, Udine, Italy. FAU - Montironi, Rodolfo AU - Montironi R AD - Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of Marche Region, Ancona, Italy. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA. LA - eng PT - Journal Article DEP - 20250226 PL - Switzerland TA - Pathobiology JT - Pathobiology : journal of immunopathology, molecular and cellular biology JID - 9007504 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Programmed Cell Death 1 Ligand 2 Protein) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - 0 (RNA, Messenger) RN - 0 (CD274 protein, human) RN - 0 (PDCD1 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (PDCD1LG2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/mortality/diagnosis MH - Male MH - Female MH - *Receptor, Fibroblast Growth Factor, Type 3/genetics/metabolism MH - *B7-H1 Antigen/genetics/metabolism MH - Prognosis MH - Aged MH - *Programmed Cell Death 1 Receptor/genetics/metabolism MH - Retrospective Studies MH - *Programmed Cell Death 1 Ligand 2 Protein/genetics/metabolism MH - Middle Aged MH - RNA, Messenger/genetics/metabolism MH - Biomarkers, Tumor/genetics MH - Aged, 80 and over MH - Adult OTO - NOTNLM OT - Bladder cancer OT - Fibroblast growth factor receptor 3 OT - Prognostic significance OT - Programmed cell death-1 OT - Programmed cell death-ligand 1/programmed cell death-ligand 2 OT - Therapeutic strategy EDAT- 2025/02/27 05:01 MHDA- 2025/08/06 00:27 CRDT- 2025/02/26 18:33 PHST- 2024/08/12 00:00 [received] PHST- 2025/02/10 00:00 [accepted] PHST- 2025/08/06 00:27 [medline] PHST- 2025/02/27 05:01 [pubmed] PHST- 2025/02/26 18:33 [entrez] AID - 000544733 [pii] AID - 10.1159/000544733 [doi] PST - ppublish SO - Pathobiology. 2025;92(4):202-215. doi: 10.1159/000544733. Epub 2025 Feb 26. PMID- 40002790 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250228 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 2 DP - 2025 Feb 5 TI - Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression. LID - 10.3390/biomedicines13020377 [doi] LID - 377 AB - Background: Bladder cancer (BC) is a heterogeneous malignancy, and predicting response to immune checkpoint inhibitors (ICIs) remains a challenge. Herein, we investigate a high-risk bladder tumor, which developed during anti-BRAF/MEK therapy for a concurrent advanced BRAF-V600E-positive malignant melanoma (MM) and subsequently underwent complete spontaneous necrosis following Nivolumab immunotherapy, only to recur thereafter while still under the same treatment. This unique scenario provided an opportunity to investigate the roles of BRAF gene mutations in BC pathogenesis, respectively, of PD-L1 expression in immunotherapy response prediction. Methods: We retrospectively analyzed BC specimens obtained via transurethral resection at two critical time-points: prior to the complete spontaneous necrosis under Nivolumab (prenecrosis) and after tumor recurrence postnecrosis (postnecrosis). The BRAF gene mutation status was evaluated using quantitative polymerase chain reaction (qPCR). PD-L1 expression was assessed by immunohistochemistry (IHC), quantified using the combined positive score (CPS), and a cutoff of >/=10 for positivity. Results: Neither pre- nor postnecrosis BC samples harbored BRAF gene mutations. Prenecrosis PD-L1 expression (CPS = 5) indicated a minimal likelihood of response to immunotherapy. However, complete spontaneous necrosis occurred under Nivolumab, followed by recurrence with further reduced PD-L1 expression (CPS = 1). Conclusions: The complete BC regression challenges the conventional role of PD-L1 as a sole predictive biomarker for immunotherapy. This study also highlights the potential role of BRAF/MEK inhibitors in BC oncogenesis and underscores the need for alternative biomarkers, such as tumor mutation burden (TMB) and circulating tumor DNA (ctDNA), to guide treatment selection in BC better. FAU - Condoiu, Cristian AU - Condoiu C AD - Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Musta, Mihael AU - Musta M AD - Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Cumpanas, Alin Adrian AU - Cumpanas AA AUID- ORCID: 0000-0002-4071-9824 AD - Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Bardan, Razvan AU - Bardan R AUID- ORCID: 0000-0002-8288-5468 AD - Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Dema, Vlad AU - Dema V AUID- ORCID: 0009-0008-0140-701X AD - Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. AD - Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Zara, Flavia AU - Zara F AUID- ORCID: 0000-0002-5755-179X AD - Department II of Microscopic Morphology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Suciu, Cristian Silviu AU - Suciu CS AUID- ORCID: 0009-0009-2421-0137 AD - Department II of Microscopic Morphology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Dumitru, Cristina-Stefania AU - Dumitru CS AUID- ORCID: 0000-0001-8933-3060 AD - Department II of Microscopic Morphology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Ciucurita, Andreea AU - Ciucurita A AD - Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Dumache, Raluca AU - Dumache R AUID- ORCID: 0000-0003-1790-8130 AD - Department VIII, Discipline of Forensic Medicine, Bioethics, Deontology and Medical Law, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. AD - Center for Ethics in Human Genetic Identifications, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Ismail, Hossam AU - Ismail H AD - Department of Urology, Lausitz Seenland Teaching Hospital, University of Dresden, Maria-Grollmuss-Strasse, No. 10, 02977 Hoyerswerda, Germany. FAU - Novacescu, Dorin AU - Novacescu D AUID- ORCID: 0000-0002-2520-7636 AD - Department II of Microscopic Morphology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. LA - eng PT - Journal Article DEP - 20250205 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11852637 OTO - NOTNLM OT - BRAF V600E positive malignant melanoma OT - BRAF gene mutations OT - bladder cancer carcinogenesis OT - immunotherapy OT - multiple concomitant neoplasms OT - programmed death ligand 1 (PD-L1) combined positive score OT - targeted therapies OT - treatment response prediction biomarkers OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2025/02/26 06:27 MHDA- 2025/02/26 06:28 PMCR- 2025/02/05 CRDT- 2025/02/26 01:08 PHST- 2025/01/03 00:00 [received] PHST- 2025/02/03 00:00 [revised] PHST- 2025/02/03 00:00 [accepted] PHST- 2025/02/26 06:28 [medline] PHST- 2025/02/26 06:27 [pubmed] PHST- 2025/02/26 01:08 [entrez] PHST- 2025/02/05 00:00 [pmc-release] AID - biomedicines13020377 [pii] AID - biomedicines-13-00377 [pii] AID - 10.3390/biomedicines13020377 [doi] PST - epublish SO - Biomedicines. 2025 Feb 5;13(2):377. doi: 10.3390/biomedicines13020377. PMID- 39999445 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20260318 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 213 IP - 6 DP - 2025 Jun TI - A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma. PG - 739-752 LID - 10.1097/JU.0000000000004475 [doi] AB - PURPOSE: We investigated the efficacy and safety of tislelizumab as neoadjuvant therapy in patients with cisplatin-ineligible high-risk upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: In this single-arm phase 2 trial (NCT04672330), 20 patients with high-risk UTUC were enrolled. Eligibility criteria included high-risk UTUC (defined as high-grade UTUC confirmed by endoscopic biopsy or urinary cytology, radiographic evidence of invasion [cT2-T4N0-2M0], and/or hydronephrosis), an Eastern Cooperative Oncology Group performance status of 0 to 2, no previous systemic therapy, and cisplatin ineligibility. Patients received neoadjuvant tislelizumab before radical surgery. Contrast-enhanced MRI was performed before the third dose and again before surgery. The primary end point was pathological complete response rate (ypT0N0). Secondary end points included pathological response rate ( 2. Similarly, when cutoff > 3, the kappa values were 0.848, 0.811, 0.873, 0.811, and 0.873. No significant differences were observed between mp-MRI and bp-DWI (AUC: 0.916 vs. 0.912, p = 0.498), but mp-MRI and bp-DWI had higher AUCs compared to bp-DWI Plus, bp-T2WI, and bp-T2WI Plus. CONCLUSIONS: Both mp-MRI and bp-DWI demonstrate excellent performance in predicting MIBC, with bp-DWI being an alternative to mp-MRI. TRIAL REGISTRATION: retrospectively. CI - (c) 2025. The Author(s). FAU - Liu, Peikun AU - Liu P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. AD - Department of Urology, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, 214023, China. FAU - Jiang, Linjing AU - Jiang L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Chen, Haonan AU - Chen H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Bai, Kexin AU - Bai K AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Bai, Rongjie AU - Bai R AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. yangxiao2915@163.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Gulou District, Jiangsu Province, 210029, Nanjing, China. doctorlvqiang@njmu.edu.cn. LA - eng GR - 82072832/National Natural Science Foundation of China/ GR - JSPH-MA-2022-5/Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project/ GR - ZDXK202219/Jiangsu Province Capability Improvement Project through Science, Technology and Education/ PT - Comparative Study PT - Journal Article DEP - 20250224 PL - England TA - BMC Med Imaging JT - BMC medical imaging JID - 100968553 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Female MH - Male MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Multiparametric Magnetic Resonance Imaging/methods MH - Neoplasm Invasiveness/diagnostic imaging MH - *Magnetic Resonance Imaging/methods MH - Diffusion Magnetic Resonance Imaging/methods MH - Aged, 80 and over MH - Sensitivity and Specificity MH - Adult PMC - PMC11853285 OTO - NOTNLM OT - Bladder cancer, Biparametric MRI, VI-RADS OT - Diagnostic performance OT - MIBC COIS- Declarations. Human Ethics and Consent to Participate: In accordance with the Declaration of Helsinki, the Ethics Committee of Jiangsu Provincial People's Hospital (IRB) reviewed the study's design and determined that ethical approval was not required due to its retrospective nature. Consequently, the committee waived the need for formal ethics approval. Consent to Participate: Informed consent was obtained from each participant through verbal meetings or telephone follow-up. Clinical trial number: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/02/25 00:22 MHDA- 2025/02/25 06:21 PMCR- 2025/02/24 CRDT- 2025/02/24 23:55 PHST- 2024/08/12 00:00 [received] PHST- 2025/02/13 00:00 [accepted] PHST- 2025/02/25 06:21 [medline] PHST- 2025/02/25 00:22 [pubmed] PHST- 2025/02/24 23:55 [entrez] PHST- 2025/02/24 00:00 [pmc-release] AID - 10.1186/s12880-025-01595-3 [pii] AID - 1595 [pii] AID - 10.1186/s12880-025-01595-3 [doi] PST - epublish SO - BMC Med Imaging. 2025 Feb 24;25(1):60. doi: 10.1186/s12880-025-01595-3. PMID- 39982659 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 57 IP - 8 DP - 2025 Aug TI - Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years. PG - 2463-2473 LID - 10.1007/s11255-025-04413-5 [doi] AB - PURPOSE: To compare intravesical instillation of gemcitabine and anthracyclines in the treatment of primary non-muscle-invasive bladder cancer (NMIBC), and to evaluate the effect of changing intravesical chemotherapy drugs on the the second recurrence of NMIBC. METHOD: Patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) for the first time in our center from January 2014 to December 2023 were enrolled. Kaplan-Meier method was used to analyze the recurrence-free survival (RFS) and progression-free survival (PFS), and COX regression was used to analyze the risk factors for recurrence. RESULT: 464 patients were included in the study (212 in the gemcitabine group and 252 in the anthracyclines group). Anthracyclines-treated patients had superior RFS compared to gemcitabine-treated patients (p = 0.006), but PFS did not differ significantly between the two groups (p = 0.654). After the first recurrence of NMIBC, patients who changed intravesical chemotherapy drugs had better RFS than those who kept the original chemotherapy drugs (p = 0.037). In terms of safety, the incidence of adverse events of pirarubicin was significantly higher than that of gemcitabine and epirubicin (55.2% vs 26.4% vs 36.2%, p < 0.001). CONCLUSION: Anthracyclines are more effective than gemcitabine in preventing recurrence of primary NMIBC but with more adverse events. After the first recurrence of NMIBC, changing the drugs of intravesical chemotherapy can reduce the second recurrence of NMIBC. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Fan, Haobo AU - Fan H AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. AD - School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Chen, Weiwu AU - Chen W AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. AD - School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Guo, Wenhao AU - Guo W AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Han, Jiayu AU - Han J AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. AD - School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Xie, Haoze AU - Xie H AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. AD - School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China. FAU - Yu, Yanlan AU - Yu Y AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Ding, Guoqing AU - Ding G AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Chen, Yicheng AU - Chen Y AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. chenyicheng@zju.edu.cn. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250221 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Anthracyclines) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery MH - Gemcitabine MH - Retrospective Studies MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Female MH - Male MH - *Neoplasm Recurrence, Local/drug therapy MH - Administration, Intravesical MH - Aged MH - Middle Aged MH - *Anthracyclines/administration & dosage MH - Neoplasm Invasiveness MH - *Antimetabolites, Antineoplastic/administration & dosage MH - Time Factors MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Anthracyclines OT - Bladder cancer OT - Gemcitabine OT - Intravesical chemotherapy COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/02/21 12:22 MHDA- 2025/07/14 12:28 CRDT- 2025/02/21 11:21 PHST- 2025/01/16 00:00 [received] PHST- 2025/02/02 00:00 [accepted] PHST- 2025/07/14 12:28 [medline] PHST- 2025/02/21 12:22 [pubmed] PHST- 2025/02/21 11:21 [entrez] AID - 10.1007/s11255-025-04413-5 [pii] AID - 10.1007/s11255-025-04413-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2025 Aug;57(8):2463-2473. doi: 10.1007/s11255-025-04413-5. Epub 2025 Feb 21. PMID- 39980308 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20250509 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 14 IP - 4 DP - 2025 Feb TI - Transcriptomic Profiles for Elucidating Response of Bladder Intracavitary Hyperthermic Perfusion Chemotherapy in High-Risk Nonmuscular Invasive Bladder Cancer. PG - e70672 LID - 10.1002/cam4.70672 [doi] LID - e70672 AB - BACKGROUND: Bladder intracavitary hyperthermic perfusion chemotherapy (HIPEC) is a promising treatment for non-muscular invasive bladder cancer (NMIBC). However, the molecular mechanisms underlying the response to HIPEC remain poorly understood. This study aimed to elucidate the transcriptomic profiles associated with the response to HIPEC in NMIBC patients. METHODS: RNA sequencing was performed on bladder tumor samples from NMIBC patients who underwent HIPEC treatment. Differentially expressed genes (DEGs) between responders and non-responders to HIPEC were identified. Gene ontology and pathway analysis were conducted to explore the biological functions and pathways enriched in the DEGs. Additionally, the expression of specific immune-related genes was evaluated for their association with HIPEC response. The diagnostic efficiency of selected genes in predicting relapse before and after HIPEC treatment was assessed in a validation cohort. RESULTS: We assessed the expression status of differentially expressed genes (DEGs) between responders and non-responders to HIPEC. Gene ontology and pathway analysis revealed that DEGs were enriched in immune-related pathways, including cytokine-cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation. Furthermore, the expression of several immune-related genes, including ZMAP4, UPP2, and GALR1, was significantly associated with the response to HIPEC. Therefore, the immune system's reaction plays a crucial role in the response to HIPEC in patients with NMIBC. At last, a considerable diagnostic efficiency that tissue TMEFF2, KRT222, and GTSF1 in predicting relapse in NMIBC patients after HIPEC treatment, and ZMAP4, UPP2, and GALR1 in predicting relapse in NMIBC patients before HIPEC treatment in the validation cohort. CONCLUSION: Transcriptomic profiling revealed that immune-related pathways and genes play a crucial role in the response to HIPEC in NMIBC patients. These findings suggest that transcriptomic profiling could provide a valuable tool for predicting treatment outcomes and identifying therapeutic targets for NMIBC. CI - (c) 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. FAU - Huang, Zhicheng AU - Huang Z AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Zhang, Tianhui AU - Zhang T AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Magnetic Resonance Imaging, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Pan, Jinghua AU - Pan J AD - Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China. FAU - Zhang, Guihao AU - Zhang G AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Jiang, Linjun AU - Jiang L AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Jiang, Huiming AU - Jiang H AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Wan, Pei AU - Wan P AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Peng, Ying AU - Peng Y AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Zou, Wenchao AU - Zou W AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Liu, Qinghua AU - Liu Q AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Pathology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. FAU - Chen, Nanhui AU - Chen N AUID- ORCID: 0000-0001-5075-5848 AD - Shantou University Medical College Meizhou Clinical College, Meizhou, Guangdong Province, China. AD - Department of Urology, Meizhou People's Hospital, Meizhou, Guangdong Province, China. LA - eng GR - PY-C2023041, PY-C20210016/Cultivation project of Meizhou People's Hospital/ GR - 2023A1515220113/Natural Science Foundation of Guangdong Province/ GR - 2023C0301181/Meizhou science and technology plan project/ PT - Journal Article PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/therapy/pathology MH - Female MH - Male MH - *Transcriptome MH - *Hyperthermia, Induced/methods MH - Gene Expression Profiling MH - Middle Aged MH - Gene Expression Regulation, Neoplastic MH - Aged MH - Biomarkers, Tumor/genetics MH - Gene Ontology PMC - PMC11842869 OTO - NOTNLM OT - bladder cancer OT - immune response OT - intracavitary hyperthermic perfusion chemotherapy OT - resistance OT - transcriptomics COIS- The authors declare no conflicts of interest. EDAT- 2025/02/21 06:22 MHDA- 2025/02/21 06:23 PMCR- 2025/02/20 CRDT- 2025/02/21 02:33 PHST- 2025/01/25 00:00 [revised] PHST- 2023/08/26 00:00 [received] PHST- 2025/01/29 00:00 [accepted] PHST- 2025/02/21 06:23 [medline] PHST- 2025/02/21 06:22 [pubmed] PHST- 2025/02/21 02:33 [entrez] PHST- 2025/02/20 00:00 [pmc-release] AID - CAM470672 [pii] AID - 10.1002/cam4.70672 [doi] PST - ppublish SO - Cancer Med. 2025 Feb;14(4):e70672. doi: 10.1002/cam4.70672. PMID- 39980082 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20260319 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 136 IP - 3 DP - 2025 Sep TI - Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer. PG - 545-552 LID - 10.1111/bju.16686 [doi] AB - OBJECTIVE: To evaluate the 12-year survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) who underwent robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD), focusing on those upstaged to >/=pT2 or with node-positive disease. MATERIALS AND METHODS: A multicentre, prospectively maintained database (2004-2022) was reviewed to identify patients who had undergone RARC. Univariable and multivariable models were used to assess upstaging (>/=pT2, >/=pN1), and Kaplan-Meier curves were used to predict cancer-specific survival (CSS) and overall survival (OS). RESULTS: Among 355 patients with NMIBC (295 men, 60 women), 12.68% had pT2, 8.2% had pT3, 4.2% had pT4, 5.4% had pN1, and 2.8% had pN2 disease. Age >/= 83 years (odds ratio [OR] 19.7), presence of carcinoma in situ (CIS), in combination with Ta/ T1 bladder cancer (OR 2.7), squamous cell carcinoma (OR 6.6), and variant histology (OR 6.2), predicted upstaging. A body mass index >/=28 kg/m(2) (OR 0.4) and Tis alone (OR 0.1) reduced upstaging. The OS rate for the entire cohort was 93% at 1 year, 87% at 5 years and 49% at 12 years. The CSS rate was 97% at 1 year, 83% at 5 years and 76% at 12 years. At 12 years, OS was better in the non-upstaged cohort (52%, 95% confidence interval [CI] 37%-74%) vs the upstaged cohort (39%, 95% CI 26%-57%). CSS was higher in the non-upstaged cohort (79%, 95% CI 71%-88%; P < 0.001) vs the upstaged cohort (68%, 95% CI 56%-82%; P < 0.001). CONCLUSION: This study provides the longest follow-up data on RARC in NMIBC. The presence of CIS, variant histology, and pT1 on transurethral resection of the bladder tumour were predictors of upstaging, which correlated with higher recurrence and worse survival. RARC with ICUD is a minimally invasive option for NMIBC patients who need to undergo early cystectomy, offering comparable long-term outcomes. CI - (c) 2025 BJU International. FAU - Tillu, Neeraja AU - Tillu N AUID- ORCID: 0000-0002-4149-0486 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Ben-David, Reuben AU - Ben-David R AUID- ORCID: 0000-0001-7946-7145 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Skokic, Viktor AU - Skokic V AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Rich, Jordan M AU - Rich JM AUID- ORCID: 0000-0002-4434-5321 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AUID- ORCID: 0009-0001-9525-2600 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Dey, Linda AU - Dey L AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Rautiola, Juhana AU - Rautiola J AUID- ORCID: 0009-0008-7208-6321 AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Bjorklund, Johan AU - Bjorklund J AUID- ORCID: 0000-0003-3254-3993 AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Almoflihi, Mohammed AU - Almoflihi M AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Eraky, Ahmed AU - Eraky A AUID- ORCID: 0000-0001-6879-6058 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Miranda, Gus AU - Miranda G AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. FAU - Cacciamani, Giovanni AU - Cacciamani G AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. FAU - Desai, Mihir AU - Desai M AUID- ORCID: 0000-0002-3744-8234 AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250220 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM EIN - BJU Int. 2026 Oct;138(4):737. doi: 10.1111/bju.70248. PMID: 41852265 MH - Humans MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - *Cystectomy/methods MH - Male MH - *Robotic Surgical Procedures/methods MH - Female MH - Aged MH - Aged, 80 and over MH - Middle Aged MH - Neoplasm Invasiveness MH - Urinary Diversion/methods MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - cystectomy OT - ileal conduit OT - intracorporeal OT - neobladder OT - non-muscle invasive OT - robot-assisted surgery OT - urinary diversion EDAT- 2025/02/21 00:21 MHDA- 2025/08/31 19:49 CRDT- 2025/02/20 23:55 PHST- 2025/08/31 19:49 [medline] PHST- 2025/02/21 00:21 [pubmed] PHST- 2025/02/20 23:55 [entrez] AID - 10.1111/bju.16686 [doi] PST - ppublish SO - BJU Int. 2025 Sep;136(3):545-552. doi: 10.1111/bju.16686. Epub 2025 Feb 20. PMID- 39976835 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20261010 IS - 1534-6269 (Electronic) IS - 1523-3790 (Linking) VI - 27 IP - 3 DP - 2025 Mar TI - Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. PG - 236-246 LID - 10.1007/s11912-025-01645-7 [doi] AB - PURPOSE OF REVIEW: This review examines the evolving landscape of non-muscle invasive bladder cancer (NMIBC) management, focusing on risk stratification, novel therapeutic strategies, and the integration of biomarkers into clinical care. RECENT FINDINGS: Emerging genomic markers such as FGFR3 and TERT promoter mutations show promise for diagnosis and personalized treatment. Advances in immunotherapy, including the use of pembrolizumab and nadofaragene firadenovec, offer options for BCG-unresponsive NMIBC, though challenges like cost and adverse effects remain. Current guidelines emphasize stratified care based on risk, balancing treatment intensity with recurrence and progression risks. While transurethral resection with intravesical therapy remains the standard for most NMIBC, early radical cystectomy is pivotal for select high-risk cases. Future directions highlight the need for biomarker-driven models to refine treatment paradigms, reduce overtreatment, and improve long-term outcomes. Continued clinical trials are essential to validate these approaches and address unmet needs in NMIBC care. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Smani, Shayan AU - Smani S AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - DuBois, Julien AU - DuBois J AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Zhao, Kai AU - Zhao K AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Sutherland, Ryan AU - Sutherland R AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Rahman, Syed N AU - Rahman SN AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Humphrey, Peter AU - Humphrey P AD - Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. FAU - Hesse, David AU - Hesse D AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Martin, Darryl AU - Martin D AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Lokeshwar, Soum D AU - Lokeshwar SD AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. FAU - Ghali, Fady AU - Ghali F AD - Department of Urology, Yale University School of Medicine, 789 Howard Avenue FMP 300, New Haven, CT, 06520, USA. fed.ghali@yale.edu. LA - eng PT - Journal Article PT - Review DEP - 20250220 PL - United States TA - Curr Oncol Rep JT - Current oncology reports JID - 100888967 RN - 0 (Biomarkers, Tumor) RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/therapy/genetics/pathology MH - Risk Assessment MH - Immunotherapy/methods MH - Biomarkers, Tumor/genetics MH - Cystectomy MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms MH - Antibodies, Monoclonal, Humanized OTO - NOTNLM OT - Bladder neoplasms OT - Immunotherapy OT - Non-muscle invasive bladder cancer OT - Radical cystectomy OT - Risk stratification COIS- Declarations. Human and Animal Rights: All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee. Competing Interests: The authors declare no competing interests. EDAT- 2025/02/20 12:24 MHDA- 2025/03/31 21:17 CRDT- 2025/02/20 11:18 PHST- 2025/01/27 00:00 [accepted] PHST- 2025/03/31 21:17 [medline] PHST- 2025/02/20 12:24 [pubmed] PHST- 2025/02/20 11:18 [entrez] AID - 10.1007/s11912-025-01645-7 [pii] AID - 10.1007/s11912-025-01645-7 [doi] PST - ppublish SO - Curr Oncol Rep. 2025 Mar;27(3):236-246. doi: 10.1007/s11912-025-01645-7. Epub 2025 Feb 20. PMID- 39974803 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250222 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 14 IP - 1 DP - 2025 Jan 31 TI - Efficacy of cystectomy in single-site oligometastatic bladder cancer: a Surveillance, Epidemiology, and End Results (SEER) study of 1,381 patients. PG - 81-90 LID - 10.21037/tau-24-586 [doi] AB - BACKGROUND: The treatment paradigm of metastatic bladder cancer has remained largely unchanged for decades and the prognosis is extremely poor. This study aimed to evaluate the role of cystectomy in patients with single-site oligometastatic bladder cancer. METHODS: Patients with single-site distant metastasis at the time of bladder cancer diagnosis from 2010-2017 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Cohorts were defined by target organ [bone, brain, lung, liver, distant lymph nodes (DLNs)] and then stratified by local treatment received [no surgery, transurethral resection of bladder tumor (TURBT) and cystectomy]. Patients not receiving chemotherapy were excluded. Two-year cancer specific survival (CSS) was assessed using Kaplan-Meier (K-M) analysis and multivariable Cox proportional hazards analysis, adjusting for demographic, clinical and pathologic factors. RESULTS: A total of 1,381 patients met study criteria. K-M analysis indicated that cystectomy was associated with improved survival when compared to no surgery in patients with bone and DLNs metastasis. In multivariable analysis, patients with bone [hazard ratio (HR) =0.58; P=0.03] or DLNs (HR =0.51; P=0.005) metastasis who underwent cystectomy had a significant survival advantage over those receiving systemic therapy only. And patients with liver (HR =0.40; P=0.07) and lung (HR =0.84; P=0.58) who underwent cystectomy failed to exhibit superior survival than those receiving chemotherapy only. Patients with brain metastasis were omitted in subgroup analysis due to the limit of small sample size (n=20). In addition, the advent of immune checkpoint inhibitors improved the survival of patients, with HR of 0.78, indicating the reduction of death risk by 22%. CONCLUSIONS: Cystectomy in the setting of multimodality protocols may prolong survival in bladder cancer patients with single-site metastasis of the bone and DLNs. It should be considered in a multidisciplinary setting. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Ji, Jiaxiang AU - Ji J AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Lai, Chin-Hui AU - Lai CH AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Ni, Runfeng AU - Ni R AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Wang, Mingrui AU - Wang M AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Hu, Haopu AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Bian, Xiaolong AU - Bian X AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Tian, Cong AU - Tian C AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Wang, Chenlong AU - Wang C AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Hu, Hao AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. LA - eng PT - Journal Article DEP - 20250122 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC11833523 OTO - NOTNLM OT - Cystectomy OT - cancer specific survival (CSS) OT - metastatic bladder cancer OT - oligometastasis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-586/coif). The authors have no conflicts of interest to declare. EDAT- 2025/02/20 06:22 MHDA- 2025/02/20 06:23 PMCR- 2025/01/31 CRDT- 2025/02/20 05:34 PHST- 2024/10/17 00:00 [received] PHST- 2024/12/29 00:00 [accepted] PHST- 2025/02/20 06:23 [medline] PHST- 2025/02/20 06:22 [pubmed] PHST- 2025/02/20 05:34 [entrez] PHST- 2025/01/31 00:00 [pmc-release] AID - tau-14-01-81 [pii] AID - 10.21037/tau-24-586 [doi] PST - ppublish SO - Transl Androl Urol. 2025 Jan 31;14(1):81-90. doi: 10.21037/tau-24-586. Epub 2025 Jan 22. PMID- 39974795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250222 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 14 IP - 1 DP - 2025 Jan 31 TI - A novel nomogram for predicting post-operative recurrence for patients with intermediate and high-risk non-muscle invasive bladder cancer after thulium laser resection of bladder tumors or conventional transurethral resection of bladder tumors followed by intravesical bacille Calmette-Guerin immunotherapy. PG - 91-102 LID - 10.21037/tau-24-535 [doi] AB - BACKGROUND: Post-operative recurrence for patients with intermediate and high-risk non-muscular invasive bladder cancer (NMIBC) is common. This study aims to evaluate the potential factors of tumor recurrence, and construct a novel nomogram to predict the probability of tumor recurrence. METHODS: We retrospectively enrolled patients with intermediate and high-risk NMIBC who received thulium laser resection of bladder tumors (TmLRBT) or transurethral resection of the bladder tumor (TURBT) followed by intravesical bacille Calmette-Guerin (BCG) immunotherapy. The risk factors were screened by the least absolute shrinkage and selection operator (LASSO) regression method. And multivariate logistic regression was applied to recognize the independent risk factors of bladder cancer recurrence. A nomogram was established, and the recurrence probability was calculated based on the model scores. RESULTS: A total of 90 patients with intermediate and high-risk NMIBC were included in this study, of whom 53 underwent TURBT and 37 underwent TmLRBT. During the follow-up period, 22 patients (24.4%) experienced bladder cancer recurrence. Three variables were screened out in the LASSO regression. The multivariate logistic analysis suggested that surgery of TURBT [odds ratio (OR) =6.86760; 95% confidence interval (CI): 1.5048-31.34300] and previous bladder tumor (OR =14.73600; 95% CI: 2.81180-77.23000) were independent risk factors of recurrence, while more BCG treatment sessions (OR =0.26504; 95% CI: 0.12455-0.56398) was independent protective factor of recurrence. CONCLUSIONS: Patients with TURBT and previous bladder tumor history were more likely to develop recurrent bladder cancer, while more BCG treatment sessions was independent protective factor of recurrence. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Xu, Meng-Yao AU - Xu MY AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Jian-Xuan AU - Sun JX AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xiang, Yu-Xi AU - Xiang YX AD - Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hua, Zi-Jin AU - Hua ZJ AD - Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Kunming, China. FAU - Liu, Chen-Qian AU - Liu CQ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - An, Ye AU - An Y AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Jin-Zhou AU - Xu JZ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Si-Han AU - Zhang SH AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Zheng AU - Liu Z AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20250122 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC11833529 OTO - NOTNLM OT - Non-muscular invasive bladder cancer (NMIBC) OT - nomogram OT - recurrence OT - thulium laser resection of bladder tumors (TmLRBT) OT - transurethral resection of the bladder tumor (TURBT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-535/coif). The authors have no conflicts of interest to declare. EDAT- 2025/02/20 06:22 MHDA- 2025/02/20 06:23 PMCR- 2025/01/31 CRDT- 2025/02/20 05:34 PHST- 2024/09/28 00:00 [received] PHST- 2024/12/29 00:00 [accepted] PHST- 2025/02/20 06:23 [medline] PHST- 2025/02/20 06:22 [pubmed] PHST- 2025/02/20 05:34 [entrez] PHST- 2025/01/31 00:00 [pmc-release] AID - tau-14-01-91 [pii] AID - 10.21037/tau-24-535 [doi] PST - ppublish SO - Transl Androl Urol. 2025 Jan 31;14(1):91-102. doi: 10.21037/tau-24-535. Epub 2025 Jan 22. PMID- 39974639 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260107 IS - 2575-9108 (Electronic) IS - 2575-9108 (Linking) VI - 8 IP - 2 DP - 2025 Feb 14 TI - A Comprehensive Review of Current Approaches in Bladder Cancer Treatment. PG - 286-307 LID - 10.1021/acsptsci.4c00663 [doi] AB - Bladder cancer is one of the most common malignant tumors of the urinary system globally. It is also one of the most expensive cancers to manage, due to the need for extensive treatment and follow-ups that often involve invasive and costly procedures. Although there have been some improvements in treatment options, the quality of life they offer has not improved at the same rate as other cancers. Therefore, there is an urgent need to find new alternatives to ease the burden of bladder cancer on patients. Recent discoveries have opened new avenues for the diagnosis and management of bladder cancer even though the clinical approach has largely remained the same for years. The decline in bladder cancer-specific mortality in regions that promote social awareness of risk factors and reduction of carcinogenic exposure demonstrates the effectiveness of such measures. New agents have been approved for patients who have undergone radical cystectomy after Bacillus Calmette-Guerin failure. Current best practices for diagnosing and treating bladder cancer are presented in this review. The review discusses radiation therapy, photodynamic therapy, gene therapy, chemotherapy, and nanomedicine in relation to non muscle-invasive cancers and muscle-invasive bladder cancers, as well as systemic treatments. CI - (c) 2025 American Chemical Society. FAU - Kumbham, Soniya AU - Kumbham S AUID- ORCID: 0009-0009-7078-0990 AD - Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States. FAU - Md Mahabubur Rahman, Kazi AU - Md Mahabubur Rahman K AD - Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States. FAU - Foster, Barbara A AU - Foster BA AD - Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14263, United States. FAU - You, Youngjae AU - You Y AUID- ORCID: 0000-0003-0835-464X AD - Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States. LA - eng GR - R01 CA268390/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20250106 PL - United States TA - ACS Pharmacol Transl Sci JT - ACS pharmacology & translational science JID - 101721411 PMC - PMC11833730 COIS- The authors declare no competing financial interest. EDAT- 2025/02/20 06:22 MHDA- 2025/02/20 06:23 PMCR- 2026/01/06 CRDT- 2025/02/20 05:32 PHST- 2024/11/12 00:00 [received] PHST- 2024/12/19 00:00 [revised] PHST- 2024/12/26 00:00 [accepted] PHST- 2025/02/20 06:23 [medline] PHST- 2025/02/20 06:22 [pubmed] PHST- 2025/02/20 05:32 [entrez] PHST- 2026/01/06 00:00 [pmc-release] AID - 10.1021/acsptsci.4c00663 [doi] PST - epublish SO - ACS Pharmacol Transl Sci. 2025 Jan 6;8(2):286-307. doi: 10.1021/acsptsci.4c00663. eCollection 2025 Feb 14. PMID- 39967051 OWN - NLM STAT- MEDLINE DCOM- 20250604 LR - 20251125 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 136 IP - 1 DP - 2025 Jul TI - Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer. PG - 47-54 LID - 10.1111/bju.16675 [doi] AB - OBJECTIVE: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette-Guerin (BCG) instillations from a contemporary European multicentre cohort. PATIENTS AND METHODS: We conducted a retrospective analysis of 1491 patients diagnosed with HR- or VHR-NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle-invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer-specific mortality (CSM) were fitted. RESULTS: Among the 1221 patients with HR- (n = 1221 [90%]) or VHR-NMIBC (n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow-up was 2.6 years. After PSM (87 vs 87 patients), the 5-year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66-4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle-invasive bladder cancer before delayed RC. The 3-year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non-progressing patients (P = 0.3). However, patients who progressed before delayed RC had worse 3-year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13-0.83; P = 0.018). CONCLUSION: Within a European cohort of patients with HR- and VHR-NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long-term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery. CI - (c) 2025 BJU International. FAU - Scilipoti, Pietro AU - Scilipoti P AUID- ORCID: 0009-0007-6126-9889 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, 'Sapienza' University of Rome, Rome, Italy. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mastroianni, Riccardo AU - Mastroianni R AUID- ORCID: 0000-0003-3708-2209 AD - IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AUID- ORCID: 0000-0002-4868-9025 AD - IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Oberneder, Katharina AU - Oberneder K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rodriguez Elena, Jose Luis AU - Rodriguez Elena JL AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Aranda, Javier AU - Aranda J AD - Department of Urology, Hospital Universitario de Caceres, Caceres, Spain. FAU - Puentedura, Alfonso Lafuente AU - Puentedura AL AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Cano Velasco, Jorge AU - Cano Velasco J AD - Department of Urology, Gregorio Maranon University Hospital, Madrid, Spain. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AUID- ORCID: 0000-0002-0595-7165 AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. CN - European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20250218 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM EIN - BJU Int. 2026 Jun;137(6):1109. doi: 10.1111/bju.70090. PMID: 41287478 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery/therapy/drug therapy MH - *Cystectomy/methods MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Treatment Outcome MH - *Adjuvants, Immunologic/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - high risk OT - non-muscle-invasive bladder cancer OT - survival analysis OT - upfront radical cystectomy OT - very high risk EDAT- 2025/02/19 06:22 MHDA- 2025/06/04 06:27 CRDT- 2025/02/19 00:52 PHST- 2025/06/04 06:27 [medline] PHST- 2025/02/19 06:22 [pubmed] PHST- 2025/02/19 00:52 [entrez] AID - 10.1111/bju.16675 [doi] PST - ppublish SO - BJU Int. 2025 Jul;136(1):47-54. doi: 10.1111/bju.16675. Epub 2025 Feb 18. PMID- 39966479 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20260924 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Feb 18 TI - Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy. PG - 5977 LID - 10.1038/s41598-025-89525-9 [doi] LID - 5977 AB - This study was designed to evaluate the impact of upper tract urothelial carcinoma (UTUC) history on prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) receiving intravesical chemotherapy. We conducted a single center, retrospective, cohort study of 444 NMIBC patients who received intravesical chemotherapy after transurethral resection of the bladder cancer (TURBT) at Peking University People's Hospital from 2000 to 2015. Patients were divided into UTUC-NMIBC group (with UTUC history) and primary NMIBC group (without UTUC history) by presence of previous UTUC. Demographic, clinical and pathologic factors were analyzed. Kaplan-Meier curves and the log-rank test were used to depict and compare recurrence-free survival (RFS) and progression-free survival (PFS) between the two groups. Multivariable Cox regression models were constructed to determine the variables associated with RFS and PFS. Compared to the primary NMIBC group (n = 410), the UTUC-NMIBC group (n = 34) had an older median age [72.0 (65.0-81.0) vs. 66.0 (58-75) years; P = 0.007], a higher incidence of multiple tumors (52.9% vs. 33.9%; P = 0.026) and a higher recurrence rate (52.9% vs. 30.7%; P = 0.008) and worse RFS (P < 0.001). In multivariate analysis, UTUC history was an independent risk factor for recurrence (hazard ratio = 2.242; P = 0.001), but not for progression. Interestingly, subgroup analysis indicated patients with recent UTUC history ( 0) at initial transurethral resection was correlated with outcomes, primarily BCG-unresponsiveness. The impact of BCG exposure on PD-L1 expression was analyzed in patients who had sequential tumor sampling. RESULTS: Of 232 patients, 48 (21.6%) were BCG-unresponsive. PD-L1 expression was positive in 20 (9.2%) and in 5 (5.4%), 15 (14.3%), and 0 of Ta, T1, and CIS, respectively. In the US cohort, BCG-unresponsiveness occurred in 2 (14.3%) of PD-L1 positive and 36 (42.9%) of PD-L1 negative patients (P = 0.042). Tumors with baseline PD-L1 positivity were associated with a lower rate of BCG-unresponsiveness (OR 0.14; 95%CI 0.03-0.76). The predictive value of PD-L1 status in determining BCG-unresponsiveness was poor (AUC 0.57, 95%CI 0.46-0.69). Changes from PD-L1 negative to positive status after BCG exposure were observed, indicating a possible mechanism of resistance to BCG. CONCLUSIONS: While PD-L1 status was an imperfect overall biomarker for BCG unresponsiveness, there was an association between initial PD-L1 expression and BCG response. Additionally, there was an upregulation of PD-L1 expression in BCG unresponsive specimens. These findings generate a hypothesis-generating discussion regarding the tumor immune-microenvironment and its response to BCG. Further investigation is necessary to better understand this interaction and its impact on tumor biomarker profiling and patient selection for combination therapy. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Gerald, Thomas AU - Gerald T AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: thomas.s.gerald.mil@health.mil. FAU - Woldu, Solomon L AU - Woldu SL AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Halstuch, Daniel AU - Halstuch D AD - Division of Urology, Rabin Medical Center, Petah-Tikva, Israel. FAU - Ber, Yaara AU - Ber Y AD - Division of Urology, Rabin Medical Center, Petah-Tikva, Israel. FAU - Lifshitz, Karin AU - Lifshitz K AD - Division of Urology, Rabin Medical Center, Petah-Tikva, Israel. FAU - Cook, Grayden AU - Cook G AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Francis, Franto AU - Francis F AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Margel, David AU - Margel D AD - Division of Urology, Rabin Medical Center, Petah-Tikva, Israel. FAU - Jia, Liwei AU - Jia L AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. LA - eng GR - P30 CA142543/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20250215 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (CD274 protein, human) RN - 0 (Adjuvants, Immunologic) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/metabolism MH - *B7-H1 Antigen/metabolism MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Aged, 80 and over MH - Adjuvants, Immunologic/therapeutic use MH - Biomarkers, Tumor/metabolism OTO - NOTNLM OT - BCG OT - Biomarker OT - Bladder cancer OT - PD-L1 COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yair Lotan reports financial support was provided by National Cancer Institute of the National Institutes of Health. Yair Lotan reports financial support was provided by Delek Foundation Fund at the Communities Foundation of Texas. Yair Lotan reports a relationship with UTSW Simmons Comprehensive Cancer Center Tissue Management Shared Resource that includes: funding grants and nonfinancial support. Solomon Woldu. Consultant: Urogen Yair Lotan. Consultant: Nanorobotics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Nucleix, Ambu, Seattle Genetics, Hitachi, Ferring Research, verity pharmaceutics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Xcures, BMS, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc, CG oncology, Uroviu, On target lab, Promis Diagnostics, Valar labs, Uroessentials, NRx Pharmaceuticals, Vesica health, Janssen, Immunity Bio If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/02/17 00:21 MHDA- 2025/05/18 17:01 CRDT- 2025/02/16 22:16 PHST- 2024/09/02 00:00 [received] PHST- 2025/01/04 00:00 [revised] PHST- 2025/01/25 00:00 [accepted] PHST- 2025/05/18 17:01 [medline] PHST- 2025/02/17 00:21 [pubmed] PHST- 2025/02/16 22:16 [entrez] AID - S1078-1439(25)00014-6 [pii] AID - 10.1016/j.urolonc.2025.01.015 [doi] PST - ppublish SO - Urol Oncol. 2025 Jun;43(6):391.e1-391.e10. doi: 10.1016/j.urolonc.2025.01.015. Epub 2025 Feb 15. PMID- 39954010 OWN - NLM STAT- Publisher LR - 20250217 IS - 1746-045X (Electronic) IS - 1746-0441 (Linking) DP - 2025 Feb 17 TI - Recent animal models of bladder cancer and their application in drug discovery: an update of the literature. PG - 1-21 LID - 10.1080/17460441.2025.2465373 [doi] AB - INTRODUCTION: Bladder cancer presents a significant health problem worldwide, with environmental and genetic factors contributing to its incidence. Histologically, it can be classified as carcinoma in situ, non-muscle invasive and muscle-invasive carcinoma, each one with distinct genetic alterations impacting prognosis and response to therapy. While traditional transurethral resection is commonly performed in carcinoma in situ and non-muscle invasive carcinoma, it often fails to prevent recurrence or progression to more aggressive phenotypes, leading to the frequent need for additional treatment such as intravesical chemotherapy or immunotherapy. Despite the advances made in recent years, treatment options for bladder cancer are still lacking due to the complex nature of this disease. So, animal models may hold potential for addressing these limitations, because they not only allow the study of disease progression but also the evaluation of therapies and the investigation of drug repositioning. AREAS COVERED: This review discusses the use of animal models over the past decade, highlighting key discoveries and discussing advantages and disadvantages for new drug discovery. EXPERT OPINION: Over the past decade animal models have been employed to evaluate new mechanisms underlying the responses to standard therapies, aiming to optimize bladder cancer treatment. The authors propose that molecular engineering techniques and AI may hold promise for the future development of more precise and effective targeted therapies in bladder cancer. FAU - Aires, Ines AU - Aires I AUID- ORCID: 0009-0005-1411-9146 AD - Department of Chemistry, University of Aveiro, Aveiro, Portugal. AD - Department of Veterinary Sciences, University of Tras-os-Montes and Alto Douro, Vila Real, Portugal. FAU - Parada, Belmiro AU - Parada B AUID- ORCID: 0000-0002-9911-4926 AD - Coimbra Institute for Clinical and Biomedical, University of Coimbra, Coimbra, Portugal. FAU - Ferreira, Rita AU - Ferreira R AUID- ORCID: 0000-0002-6872-4051 AD - Department of Chemistry, University of Aveiro, Aveiro, Portugal. FAU - Oliveira, Paula A AU - Oliveira PA AUID- ORCID: 0000-0001-9519-4044 AD - Department of Veterinary Sciences, University of Tras-os-Montes and Alto Douro, Vila Real, Portugal. LA - eng PT - Journal Article PT - Review DEP - 20250217 PL - England TA - Expert Opin Drug Discov JT - Expert opinion on drug discovery JID - 101295755 SB - IM OTO - NOTNLM OT - Animal models OT - bladder cancer OT - carcinogenesis OT - drugs OT - genetic alterations EDAT- 2025/02/16 01:30 MHDA- 2025/02/16 01:30 CRDT- 2025/02/15 10:12 PHST- 2025/02/16 01:30 [pubmed] PHST- 2025/02/16 01:30 [medline] PHST- 2025/02/15 10:12 [entrez] AID - 10.1080/17460441.2025.2465373 [doi] PST - aheadofprint SO - Expert Opin Drug Discov. 2025 Feb 17:1-21. doi: 10.1080/17460441.2025.2465373. PMID- 39953419 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250507 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Feb 14 TI - Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients. PG - 268 LID - 10.1186/s12885-025-13705-z [doi] LID - 268 AB - PURPOSE: This study aimed to determine whether administering intravesical chemotherapy (IVC) during the Bacillus Calmette - Guerin (BCG) waiting period after the second TURBT improves the recurrence-free survival (RFS) of patients with non - muscle - invasive bladder cancer (NMIBC). METHODS: A retrospective analysis was performed on patients who had undergone a second TURBT and subsequent intravesical BCG immunotherapy (IBI) at the Affiliated Hospital of Xuzhou Medical University between January 2012 and December 2023. The patients were divided into two groups (A and B) based on whether they continued IVC during the BCG waiting period, and RFS was compared between the two groups. RESULTS: A total of 164 patients were included in this study. The log-rank test results indicated that IVC administered during the BCG waiting period was associated with a more favorable RFS for patients with NMIBC, particularly those at high risk. Multivariate analysis revealed that pathological T-stage (HR 2.084, 95% CI [1.132, 3.834], p = 0.018) and IVC received during the BCG waiting period (HR 0.261, 95% CI [0.140, 0.488], p < 0.001) were significantly correlated with patient RFS. CONCLUSIONS: Administering IVC during the BCG waiting period is recommended to prolong the time to recurrence in patients with high-risk NMIBC. Conversely, this additional treatment is unnecessary for patients at intermediate risk. CI - (c) 2025. The Author(s). FAU - Li, Zhen AU - Li Z AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Wang, Zewei AU - Wang Z AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. FAU - Wu, Jiyue AU - Wu J AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Zhang, Feilong AU - Zhang F AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Gan, Lijian AU - Gan L AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Wang, Wei AU - Wang W AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. weiwang0920@163.com. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. weiwang0920@163.com. FAU - Li, Hailong AU - Li H AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. justinlee719@163.com. FAU - Gu, Ling AU - Gu L AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. gl0710@126.com. LA - eng PT - Journal Article DEP - 20250214 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality/therapy MH - Female MH - Male MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Administration, Intravesical MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/prevention & control/pathology MH - Aged MH - Middle Aged MH - Adjuvants, Immunologic/administration & dosage MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11829350 OTO - NOTNLM OT - BCG OT - Chemotherapy OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - TURBT COIS- Declarations. Ethics approval and consent to participate: Ethics approval and consent to participate: This retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (XYFY2022-KL340). All patients provided written informed consent. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/02/15 15:11 MHDA- 2025/02/15 15:12 PMCR- 2025/02/14 CRDT- 2025/02/14 23:34 PHST- 2024/07/15 00:00 [received] PHST- 2025/02/10 00:00 [accepted] PHST- 2025/02/15 15:12 [medline] PHST- 2025/02/15 15:11 [pubmed] PHST- 2025/02/14 23:34 [entrez] PHST- 2025/02/14 00:00 [pmc-release] AID - 10.1186/s12885-025-13705-z [pii] AID - 13705 [pii] AID - 10.1186/s12885-025-13705-z [doi] PST - epublish SO - BMC Cancer. 2025 Feb 14;25(1):268. doi: 10.1186/s12885-025-13705-z. PMID- 39952876 OWN - NLM STAT- MEDLINE DCOM- 20250313 LR - 20250728 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 2 DP - 2025 Apr TI - Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 102306 LID - S1558-7673(25)00008-4 [pii] LID - 10.1016/j.clgc.2025.102306 [doi] AB - Despite currently used intravesical therapies in non-muscle-invasive bladder cancer (NMIBC), the rate of intravesical recurrence remains very high. We aimed to evaluate the effectiveness of adding nonintravesical interventions to standard intravesical therapies to prevent intravesical recurrence. In April 2024, 3 databases were queried for prospective studies evaluating nonintravesical interventions in addition to standard intravesical therapies for NMIBC (CRD42024490988). The primary outcome was intravesical recurrence-free survival (iRFS). Standard pairwise meta-analyses were performed using hazard ratios (HR) and 95% confidence intervals (95% CI) with a random-effects model. We identified 18 eligible studies (14 RCTs and 4 prospective trials) comprising 4,593 NMIBC patients, which investigated pharmacological interventions (eg, selenium, vitamins, Lactobacillus casei, celecoxib, metformin, mistletoe lectin) and lifestyle modifications (diet). The addition of Lactobacillus casei significantly improved iRFS (HR: 0.50; 95% CI: 0.34-0.73; P < .001). A high western diet pattern significantly worsened iRFS (HR:1.48, 95%CI:1.06-2.06, P = .03). The other nonintravesical interventions were not associated with iRFS. Our comprehensive review of the published literature highlights the need for further research into the efficacy of nonvesical interventions for NMIBC. While Lactobacillus was shown to improve iRFS in 2 RCTs, additional high-quality randomized studies are required to evaluate the effectiveness of other interventions. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Tsuboi, Ichiro AU - Tsuboi I AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Schulz, Robert J AU - Schulz RJ AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Mancon, Stefano AU - Mancon S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy. FAU - Fazekas, Tamas AU - Fazekas T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Cadenar, Anna AU - Cadenar A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Surgery and Interventional Science, University College London, London, UK. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Katayama, Satoshi AU - Katayama S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Iwata, Takehiro AU - Iwata T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Bekku, Kensuke AU - Bekku K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Wada, Koichiro AU - Wada K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Chlosta, Piotr AU - Chlosta P AD - Department of Urology, Jagiellonian University, Medical College, Krakow, Poland. FAU - Teoh, Jeremy AU - Teoh J AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Araki, Motoo AU - Araki M AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250123 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/prevention & control MH - *Neoplasm Recurrence, Local/prevention & control MH - Administration, Intravesical MH - Lacticaseibacillus casei OTO - NOTNLM OT - Celecoxib OT - Diet OT - Lactobacillus casei OT - Non-muscle-invasive bladder cancer OT - Vitamins COIS- Disclosure None of the authors has conflicts of interest to disclose. EDAT- 2025/02/15 15:10 MHDA- 2025/03/14 11:22 CRDT- 2025/02/14 21:58 PHST- 2024/12/15 00:00 [received] PHST- 2025/01/11 00:00 [revised] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/03/14 11:22 [medline] PHST- 2025/02/15 15:10 [pubmed] PHST- 2025/02/14 21:58 [entrez] AID - S1558-7673(25)00008-4 [pii] AID - 10.1016/j.clgc.2025.102306 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Apr;23(2):102306. doi: 10.1016/j.clgc.2025.102306. Epub 2025 Jan 23. PMID- 39945120 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250520 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 32 IP - 5 DP - 2025 May TI - Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer. PG - 567-574 LID - 10.1111/iju.70009 [doi] AB - OBJECTIVES: To evaluate the preoperative risk factors for early intravesical recurrence after radical nephroureterectomy (RNU) in patients with upper urinary tract carcinoma (UTUC) according to the history of non-muscle invasive bladder cancer (NMIBC). METHODS: We retrospectively evaluated patients who underwent RNU for UTUC between 2012 and 2022 at 14 hospitals. Early recurrence was defined as intravesical pathologically confirmed recurrence within 1 year after RNU. Patients who received single-dose immediate intravesical instillation (IVI) as prevention for intravesical recurrence were excluded. Using preoperative factors, we examined the risk factors for early intravesical recurrences in patients with and without a history of NMIBC. Death from any cause within 1 year after RNU was regarded as a competitive risk. RESULTS: We included 504 UTUC patients who were treated with RNU. Among these patients, 126 (25.0%) had a history of NMIBC, whereas 378 (75%) did not. According to multivariate analysis, the presence of macrohematuria, positive cytology in self-voided urine, and performing diagnostic ureteroscopy prior to RNU were risk factors in patients without a history of NMIBC. On the other hand, an NMIBC diagnosis within 1 year prior to RNU and an extravesical approach for bladder cuff management were risk factors in RNU-treated patients with a history of NMIBC. CONCLUSIONS: Early intravesical recurrence risk factors differ between UTUC patients with and without a history of NMIBC. Different stratification may be needed to predict intravesical recurrence risk in these two types of UTUC patients. CI - (c) 2025 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Shindo, Tetsuya AU - Shindo T AUID- ORCID: 0000-0002-4990-8330 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Ueki, Yohei AU - Ueki Y AD - Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan. FAU - Muranaka, Ippei AU - Muranaka I AD - Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan. FAU - Kobayashi, Genki AU - Kobayashi G AD - Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Miyamoto, Shintaro AU - Miyamoto S AD - Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan. FAU - Kunishima, Yasuharu AU - Kunishima Y AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan. FAU - Sato, Shunsuke AU - Sato S AD - Department of Urology, Oji General Hospital, Tomakomai, Japan. FAU - Okada, Manabu AU - Okada M AD - Department of Urology, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Japan. FAU - Kato, Shuichi AU - Kato S AD - Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan. FAU - Kato, Ryuichi AU - Kato R AD - Department of Urology, Muroran City General Hospital, Muroran, Japan. FAU - Adachi, Hideki AU - Adachi H AD - Department of Urology, Saiseikai Otaru Hospital, Otaru, Japan. FAU - Matsukawa, Masanori AU - Matsukawa M AD - Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan. FAU - Takayanagi, Akio AU - Takayanagi A AD - Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan. FAU - Ito, Naoki AU - Ito N AD - Department of Urology, NTT East Medical Center Sapporo, Sapporo, Japan. FAU - Wanifuchi, Atsushi AU - Wanifuchi A AD - Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan. FAU - Maehana, Takeshi AU - Maehana T AD - Department of Urology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan. FAU - Kyoda, Yuki AU - Kyoda Y AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Hashimoto, Kohei AU - Hashimoto K AUID- ORCID: 0000-0003-0873-4642 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kobayashi, Ko AU - Kobayashi K AUID- ORCID: 0000-0001-6995-6930 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Tanaka, Toshiaki AU - Tanaka T AUID- ORCID: 0000-0002-1199-9302 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Masumori, Naoya AU - Masumori N AUID- ORCID: 0000-0001-6324-0739 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250213 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Humans MH - *Nephroureterectomy MH - Retrospective Studies MH - Male MH - *Urinary Bladder Neoplasms/pathology/epidemiology/surgery MH - Female MH - Risk Factors MH - Aged MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Middle Aged MH - *Ureteral Neoplasms/surgery/pathology MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - *Kidney Neoplasms/surgery/pathology MH - Ureteroscopy MH - Urinary Bladder/pathology MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12022740 OTO - NOTNLM OT - intravesical recurrence OT - non-muscle invasive bladder cancer OT - radical nephroureterectomy OT - upper urinary tract carcinoma COIS- Ko Kobayashi and Naoya Masumori are the Editorial Board members of the International Journal of Urology and co-authors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. EDAT- 2025/02/13 11:01 MHDA- 2025/04/25 13:46 PMCR- 2025/04/25 CRDT- 2025/02/13 05:13 PHST- 2025/01/30 00:00 [revised] PHST- 2024/11/12 00:00 [received] PHST- 2025/02/04 00:00 [accepted] PHST- 2025/04/25 13:46 [medline] PHST- 2025/02/13 11:01 [pubmed] PHST- 2025/02/13 05:13 [entrez] PHST- 2025/04/25 00:00 [pmc-release] AID - IJU70009 [pii] AID - 10.1111/iju.70009 [doi] PST - ppublish SO - Int J Urol. 2025 May;32(5):567-574. doi: 10.1111/iju.70009. Epub 2025 Feb 13. PMID- 39944514 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250214 IS - 2327-2120 (Electronic) IS - 2327-2120 (Linking) VI - 11 IP - 4 DP - 2024 TI - Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study. PG - e21200019 LID - 10.14440/bladder.2024.0031 [doi] LID - e21200019 AB - BACKGROUND: Muscle-invasive bladder cancer (MIBC) is universally classified as high-grade urothelial carcinoma, precluding the use of histological grading alone for prognostication. However, specific morphological features of MIBC may provide useful information to guide treatment decisions. In the last decade, there has been increasing interest in genetic profiling of MIBC. OBJECTIVE: The aim of the study is to validate the use of Lund Classification in attributing phenotype to large series with extreme reliability and reproducibility compared to all histological sections in the clinical practice. METHODS: We performed a molecular profiling study on a large, consecutive cohort of MIBC cases using a straightforward immunohistochemical algorithm aligned with the Lund Classification. RESULTS: We evaluated 450 MIBC cases. In a subgroup of 103 patients, we assessed the concordance between transurethral resection of bladder tumor (TURBT) specimens and cystectomy on paired samples. Luminal tumor types showed a statistically significant association with the usual histotype, while basal and NULL types were more frequently associated with variant histotypes (p < 0.0001). A stromal lymphocytic infiltrate >/=10% was more commonly observed in basal types (p < 0.0001). Basal types also exhibited higher positive rates of human epidermal growth factor receptor-2 (HER2/neu) positivity, while luminal types were more likely to be positive for tumor suppressor protein p53. Luminal types have demonstrated longer survival compared to their basal and NULL counterparts. In the concordance analysis, tumor type assignment based on TURBT showed sensitivity, specificity, and both positive and negative predictive values of 100% for basal and NULL types. The predictive accuracy for luminal types on TURBT ranged between 89.5% and 98.2%. CONCLUSION: Our findings demonstrate the feasibility of applying the Lund Classification for molecular subtyping of MIBC in routine diagnostics. The consistency in tumor type assignment between TURBT and cystectomy samples further supports the clinical utility of this approach. Tumor types significantly influenced survival outcomes, underscoring its relevance in patient stratification and personalized treatment strategies. CI - (c) 2024 Bladder, All rights reserved. FAU - Campobasso, Davide AU - Campobasso D AD - Department of Urology, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Vezzini, Simone AU - Vezzini S AD - Pathology Unit, Department of Medical Sciences, University of Torino, AOU Citta Della Salute E Della Scienza Di Torino, Turin, 10126 Italy. FAU - Buti, Sebastiano AU - Buti S AD - Unit of Medical Oncology, Department of Medicine and Surgery, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Patera, Annalisa AU - Patera A AD - Department of Urology, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Campanini, Nicoletta AU - Campanini N AD - Unit of Pathological Anatomy, Department of Medicine & Surgery, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Ziglioli, Francesco AU - Ziglioli F AD - Department of Urology, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Thai, Elena AU - Thai E AD - Unit of Pathological Anatomy, Department of Medicine & Surgery, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Ruffini, Livia AU - Ruffini L AD - Nuclear Medicine Division, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Maestroni, Umberto AU - Maestroni U AD - Department of Urology, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. FAU - Silini, Enrico Maria AU - Silini EM AD - Unit of Pathological Anatomy, Department of Medicine & Surgery, University Hospital of Parma, Parma, Emilia-Romagna, 43126 Italy. LA - eng PT - Journal Article DEP - 20241127 PL - United States TA - Bladder (San Franc) JT - Bladder (San Francisco, Calif.) JID - 101664418 PMC - PMC11810687 OTO - NOTNLM OT - Bladder cancer OT - Immunohistochemistry OT - Lund taxonomy OT - Molecular subtype OT - Survival COIS- The authors declare no conflict of interest. EDAT- 2025/02/13 11:01 MHDA- 2025/02/13 11:02 PMCR- 2024/11/27 CRDT- 2025/02/13 04:32 PHST- 2024/08/17 00:00 [received] PHST- 2024/09/22 00:00 [revised] PHST- 2024/10/29 00:00 [accepted] PHST- 2025/02/13 11:02 [medline] PHST- 2025/02/13 11:01 [pubmed] PHST- 2025/02/13 04:32 [entrez] PHST- 2024/11/27 00:00 [pmc-release] AID - 10.14440/bladder.2024.0031 [doi] PST - epublish SO - Bladder (San Franc). 2024 Nov 27;11(4):e21200019. doi: 10.14440/bladder.2024.0031. eCollection 2024. PMID- 39941873 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 3 DP - 2025 Feb 3 TI - Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes. LID - 10.3390/cancers17030505 [doi] LID - 505 AB - OBJECTIVES: To investigate neoadjuvant chemotherapy (NAC) eligibility, utilization, and survival outcomes for muscle-invasive bladder cancer patients undergoing radical cystectomy (RC) in a Finnish population. MATERIALS AND METHODS: Data from the Finnish National Cystectomy Database (2005-2017) was combined with Finnish Cancer Registry survival data. NAC utilization rates were reported, and downstaging rates were calculated based on final pathological staging. Logistic regression analyzed NAC usage and complete response (CR) predictors. RESULTS: Since 2011, 29% of 1157 patients received NAC. Its usage remained consistent, and the number of eligible patients not receiving NAC decreased during the study period. Among NAC patients, pathology T-category was pT0 (34%), pT1-Ta-Tis (16%), pT2 (23%), pT3 (20%), and pT4 (7%) tumors, with pN0 in 82%. In the RC + NAC group, the 5-year overall survival (OS) rates were 89% for patients with no residual disease (pT0N0), 82% for those with organ-confined residual disease (pT1, Tis, Ta, T2/N0), and 49% for patients with non-organ-confined residual disease (pT3+/N+). The corresponding cancer-specific survival (CSS) rates were 93%, 86%, and 57%, respectively. Patients with organ-confined residual disease after NAC had survival outcomes comparable to those who underwent RC alone. Higher age; odds ratio (OR) 0.93, [95% Confidence Interval (CI): 0.90-0.95] and Charlson Co-morbidity Index-score [OR 0.88 (0.79-0.98)] reduced the likelihood of receiving NAC, while a smaller center size increased the probability [OR 1.82 (1.02-3.28)]. More treatment cycles [OR 0.70, (95% CI: 0.51-0.93)] and a favorable GFR [OR 0.38 (0.16-0.88)] were associated with achieving CR. CONCLUSION: We report that NAC is well-utilized across Finland, with CR rates comparable to recent trials. Additionally, our survival rates are reasonable, and even with organ-confined residual disease after NAC, survival outcomes are similar to those who underwent RC alone. FAU - Nikulainen, Ilkka AU - Nikulainen I AUID- ORCID: 0000-0002-6065-4087 AD - Department of Urology, University of Turku and Turku University Hospital, 20521 Turku, Finland. FAU - Salminen, Antti P AU - Salminen AP AD - Department of Urology, University of Turku and Turku University Hospital, 20521 Turku, Finland. FAU - Hogerman, Mikael AU - Hogerman M AUID- ORCID: 0000-0002-4287-9231 AD - Department of Urology, University of Turku and Turku University Hospital, 20521 Turku, Finland. FAU - Seikkula, Heikki AU - Seikkula H AD - Department of Surgery, Division of Urology, Central Hospital of Jyvaskyla, 40620 Jyvaskyla, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, University of Turku and Turku University Hospital, 20521 Turku, Finland. FAU - The Finnish National Cystectomy Database Research Group AU - The Finnish National Cystectomy Database Research Group LA - eng GR - 1/CX/CSRD VA/United States GR - 2/Orion Research Foundation sr./ PT - Journal Article DEP - 20250203 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11816346 OTO - NOTNLM OT - NAC OT - bladder cancer OT - muscle-invasive bladder cancer OT - neoadjuvant chemotherapy OT - radical cystectomy COIS- The authors report there are no conflicts of interests to declare. EDAT- 2025/02/13 11:00 MHDA- 2025/02/13 11:01 PMCR- 2025/02/03 CRDT- 2025/02/13 01:10 PHST- 2024/12/27 00:00 [received] PHST- 2025/01/24 00:00 [revised] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/02/13 11:01 [medline] PHST- 2025/02/13 11:00 [pubmed] PHST- 2025/02/13 01:10 [entrez] PHST- 2025/02/03 00:00 [pmc-release] AID - cancers17030505 [pii] AID - cancers-17-00505 [pii] AID - 10.3390/cancers17030505 [doi] PST - epublish SO - Cancers (Basel). 2025 Feb 3;17(3):505. doi: 10.3390/cancers17030505. PMID- 39941820 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 3 DP - 2025 Jan 28 TI - Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers17030453 [doi] LID - 453 AB - Background/Objectives: Non-muscle-invasive bladder cancer (NMIBC) is a common form of bladder cancer with a significant risk of recurrence and progression, especially in intermediate- and high-risk patients. Bacillus Calmette-Guerin (BCG) therapy has been the gold standard, but its limitations have prompted the exploration of alternative therapies. This study aims to compare the long-term effectiveness of two such alternatives-hyperthermia-induced potentiation of mitomycin C (HIVEC) and electromotive drug administration (EMDA)-in preventing recurrence and progression in NMIBC patients. Methods: A prospective observational study was conducted at a Spanish center, including patients with intermediate- and high-risk NMIBC who were treated between August 2018 and December 2024. Participants were allocated to receive either HIVEC or EMDA based on their preferences. Both treatments followed a similar protocol, with an initial induction phase and maintenance sessions. Patient follow-up included regular cystoscopy, cytology, and imaging. Results: At 36 months, the disease-free survival rate was 62.4% for the HIVEC group and 67% for the EMDA group. Statistical analysis showed no significant difference between the two groups in terms of long-term efficacy. The adjusted hazard ratio for the treatment effect was 0.95, indicating comparable outcomes. Conclusions: Both HIVEC and EMDA demonstrate similar long-term efficacy in preventing recurrence and progression in intermediate- and high-risk NMIBC. These findings suggest that both treatments show promise as potential future options for managing NMIBC, providing clinicians with additional considerations based on patient characteristics and preferences. Further studies, particularly randomized controlled trials, are needed to confirm these results and optimize treatment protocols. FAU - Melgarejo-Segura, Maria Teresa AU - Melgarejo-Segura MT AUID- ORCID: 0000-0002-4183-2060 AD - Department of Urology, San Cecilio Clinical University Hospital of Granada, Av. del Conocimiento, s/n, 18007 Granada, Spain. AD - ibs.GRANADA Biosanitary Research Institute, Av. de Madrid, 15, Beiro, 18012 Granada, Spain. FAU - Zambudio-Munuera, Alberto AU - Zambudio-Munuera A AUID- ORCID: 0009-0009-2320-5088 AD - Department of Urology, San Cecilio Clinical University Hospital of Granada, Av. del Conocimiento, s/n, 18007 Granada, Spain. FAU - Arrabal-Polo, Miguel Angel AU - Arrabal-Polo MA AD - Department of Urology, San Cecilio Clinical University Hospital of Granada, Av. del Conocimiento, s/n, 18007 Granada, Spain. AD - ibs.GRANADA Biosanitary Research Institute, Av. de Madrid, 15, Beiro, 18012 Granada, Spain. FAU - Lardelli-Claret, Pablo AU - Lardelli-Claret P AD - Faculty of Medicine, University of Granada, Avenida Doctor Jesus Candel Fabregas No. 11, 18071 Granada, Spain. FAU - Pareja-Vilchez, Manuel AU - Pareja-Vilchez M AD - Department of Urology, San Cecilio Clinical University Hospital of Granada, Av. del Conocimiento, s/n, 18007 Granada, Spain. FAU - Arrabal-Martin, Miguel AU - Arrabal-Martin M AUID- ORCID: 0000-0002-6661-1811 AD - Department of Urology, San Cecilio Clinical University Hospital of Granada, Av. del Conocimiento, s/n, 18007 Granada, Spain. AD - ibs.GRANADA Biosanitary Research Institute, Av. de Madrid, 15, Beiro, 18012 Granada, Spain. AD - Faculty of Medicine, University of Granada, Avenida Doctor Jesus Candel Fabregas No. 11, 18071 Granada, Spain. LA - eng PT - Journal Article DEP - 20250128 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11815731 OTO - NOTNLM OT - EMDA OT - HIVEC OT - bladder cancer OT - chemotherapy OT - mitomycin C OT - non-muscle-invasive bladder cancer OT - recurrence prevention COIS- The authors declare no conflicts of interest. EDAT- 2025/02/13 11:01 MHDA- 2025/02/13 11:02 PMCR- 2025/01/28 CRDT- 2025/02/13 01:10 PHST- 2024/12/20 00:00 [received] PHST- 2025/01/25 00:00 [revised] PHST- 2025/01/26 00:00 [accepted] PHST- 2025/02/13 11:02 [medline] PHST- 2025/02/13 11:01 [pubmed] PHST- 2025/02/13 01:10 [entrez] PHST- 2025/01/28 00:00 [pmc-release] AID - cancers17030453 [pii] AID - cancers-17-00453 [pii] AID - 10.3390/cancers17030453 [doi] PST - epublish SO - Cancers (Basel). 2025 Jan 28;17(3):453. doi: 10.3390/cancers17030453. PMID- 39941772 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 3 DP - 2025 Jan 25 TI - "Modernized" en Bloc Radical Cystectomy Versus Standard Radical Cystectomy: A Nationwide Multi-Institutional Propensity Score Matched Analysis. LID - 10.3390/cancers17030404 [doi] LID - 404 AB - Background: Pelvic lymph node dissection during standard radical cystectomy (stdRC) for muscle invasive bladder cancer is performed as separate templates. In the modernized en bloc radical cystectomy (mEbRC), the bladder is removed together with all its associated lymphatic tissue as one specimen. Our aim was to evaluate the oncological and surgical outcomes of mEbRC with a propensity-matched national cohort of stdRC cases. Methods: 935 patients (mEbRC: 214 and stdRC: 721) were eligible for analysis, and 1:2 propensity score matching was performed regressing mEbRC treatment on the variables age, gender, neoadjuvant chemotherapy, Charlson Comorbidity Index, lymph node metastases at final pathology, carcinoma in situ, and pT-stage. The primary outcome was recurrence-free survival (RFS). Secondary endpoints were overall survival (OS) and cancer-specific survival (CSS), survival for female patients. and perioperative measures. Results: There were no significant differences between the groups regarding complications, 30-day readmission rates, and 30- and 90-day mortality rates. In the propensity score matched groups, the 5-year RFS was 83% in the mEbRC group vs. 67% in the stdRC group (p < 0.001), the CSS was 89% and 78% (p 0.05). CONCLUSIONS: In T1 NMIBC, adequate BCG therapy and absence of residual tumor at second-look TURBT are the primary predictors of 3-year RFS. These findings emphasize the importance of quality management in TURBT procedures and patient treatment. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Guigui, Alexandre AU - Guigui A AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Gondran-Tellier, Bastien AU - Gondran-Tellier B AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Basile, Giuseppe AU - Basile G AD - Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Zattoni, Fabio AU - Zattoni F AD - Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Verri, Paolo AU - Verri P AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Lechevallier, Eric AU - Lechevallier E AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Bastide, Cyrille AU - Bastide C AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Akiki, Akram AU - Akiki A AD - Department of Urology, Aubagne Hospital, Aubagne, France. FAU - Toledano, Harry AU - Toledano H AD - Department of Urology, Martigues Hospital, Martigues, France. FAU - Moschini, Marco AU - Moschini M AD - Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Amparore, Daniele AU - Amparore D AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Pradere, Benjamin AU - Pradere B AD - Service d'Urologie, Clinique de La Croix du Sud, Toulouse, France. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Teoh, Jeremy Y C AU - Teoh JYC AD - Department of Surgery, S. H. Ho Urology Centre, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 4/F LCW Clinical Sciences Building, Shatin, Hong Kong. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Baboudjian, Michael AU - Baboudjian M AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Uleri, Alessandro AU - Uleri A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. alessandrouleri@outlook.it. AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. alessandrouleri@outlook.it. AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. alessandrouleri@outlook.it. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250211 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/therapy MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - *Neoplasm Recurrence, Local/prevention & control MH - Europe MH - BCG Vaccine/therapeutic use MH - *Cystectomy/methods MH - Neoplasm Staging OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Recurrence OT - T1 OT - Turbt COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/02/12 00:20 MHDA- 2025/07/14 12:29 CRDT- 2025/02/11 23:32 PHST- 2024/10/09 00:00 [received] PHST- 2025/02/05 00:00 [accepted] PHST- 2025/07/14 12:29 [medline] PHST- 2025/02/12 00:20 [pubmed] PHST- 2025/02/11 23:32 [entrez] AID - 10.1007/s11255-025-04416-2 [pii] AID - 10.1007/s11255-025-04416-2 [doi] PST - ppublish SO - Int Urol Nephrol. 2025 Aug;57(8):2379-2386. doi: 10.1007/s11255-025-04416-2. Epub 2025 Feb 11. PMID- 39933503 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20251002 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 109 IP - 5 DP - 2025 TI - Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date. PG - 471-477 LID - 10.1159/000543979 [doi] AB - INTRODUCTION: Outpatient transurethral resection of bladder tumors (TURBT) is not widespread, involving only 5% of patients. Our aim was to assess the feasibility of TURBT in an outpatient setting and to evaluate factors possibly associated with conversion to inpatient care. METHODS: All consecutive outpatient-TURBT performed between January 2016 and December 2022 in one academic center was retrospectively analyzed. Outpatient success was defined as the absence of conversion to conventional hospitalization as well as the absence of unscheduled care within 30 postoperative days. The quality of the resection was assessed by the presence of detrusor muscle in the surgical specimen. RESULTS: A total of 500 consecutive outpatient-TURBT were included in 376 patients. Outpatient-TURBT was performed for primary tumor diagnosis in 187 (37%) cases, second look in 66 (13%) cases and tumor relapse in 216 (43%) cases. Muscle was present in 86% of cases. Perioperative inpatient conversions occurred in 40 cases (8%). Once converted, patients stayed a median of 2 days IQR (1;3). Seventy-seven post-TURBT unscheduled care were observed (15%) with 40 emergency room visits (8%) and/or 22 rehospitalizations (4%), occurring on a median postoperative day 3 IQR (1; 4). Overall complication rate was 11% (51 cases of grade 1 and 2 complications [10%] and 6 cases of grade 3 complications [1%]). Multivariate predictors of outpatient-TURBT failure were specimen weight >/=1 g (OR = 4.35, 95% CI: 1.60-13.3, p = 0.007), surgery duration (OR = 1.03, 95% CI: 1.06-1.71), p = 0.002) and antiplatelet treatment (OR = 2.86, 95% CI: 0.864-9.17, p = 0.077). CONCLUSION: Outpatient TURBT appears to be acceptable with an 8% conversion rate, as well as safe, with an 11% complication rate. Quality of the resection was not affected by the outpatient setting. Tumor weight >/=1 g, surgery duration and absence of antiplatelet treatment were significant multivariate predictors of outpatient surgery failure. CI - (c) 2025 S. Karger AG, Basel. FAU - Pattou, Maxime AU - Pattou M AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Ochoa, Adrien AU - Ochoa A AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Goujon, Annabelle AU - Goujon A AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Verine, Jerome AU - Verine J AD - Pathology department, APHP, Saint Louis Hospital, Paris, France. FAU - Meyer, Francois AU - Meyer F AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Bebane, Sonia AU - Bebane S AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Gaudez, Francois AU - Gaudez F AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Meria, Paul AU - Meria P AD - Urology department, APHP, Saint Louis Hospital, Paris, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - Urology department, APHP, Saint Louis Hospital, Universite Paris Cite, Paris, France. FAU - Mongiat-Artus, Pierre AU - Mongiat-Artus P AD - Urology department, APHP, Saint Louis Hospital, Universite Paris Cite, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Urology department, APHP, Saint Louis Hospital, Universite Paris Cite, Paris, France. LA - eng PT - Journal Article DEP - 20250211 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Ambulatory Surgical Procedures MH - *Cystectomy/methods/adverse effects MH - Feasibility Studies MH - Treatment Outcome MH - Urethra MH - Aged, 80 and over MH - Postoperative Complications OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Hematuria OT - Outpatient care OT - Urothelial EDAT- 2025/02/12 00:20 MHDA- 2025/10/02 18:27 CRDT- 2025/02/11 18:25 PHST- 2024/08/22 00:00 [received] PHST- 2025/01/17 00:00 [accepted] PHST- 2025/10/02 18:27 [medline] PHST- 2025/02/12 00:20 [pubmed] PHST- 2025/02/11 18:25 [entrez] AID - 000543979 [pii] AID - 10.1159/000543979 [doi] PST - ppublish SO - Urol Int. 2025;109(5):471-477. doi: 10.1159/000543979. Epub 2025 Feb 11. PMID- 39930090 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20260625 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Feb 10 TI - IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment. PG - 4874 LID - 10.1038/s41598-025-89008-x [doi] LID - 4874 AB - To explore whether intravesical chemotherapy (IVC) between primary and second transurethral resection of bladder tumor (TURBT) affects the prognosis of non-muscle invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guerin (BCG) treatment. NMIBC patients who underwent a second TURBT and subsequent BCG treatment between 2012 and 2023 at the Affiliated Hospital of Xuzhou Medical University were retrospectively analyzed. These patients were divided into Group A, which received IVC between TURBT, and Group B, which did not. Recurrence-free survival (RFS) was compared among the different risk subgroups. A total of 292 NMIBC patients were included in this study. In the entire cohort, IVC treatment between the primary and second TURBT was associated with longer RFS (P = 0.009). When stratified by risk groups, in intermediate-risk patients, the difference in RFS between the groups was not statistically significant (P = 0.434). By contrast, for high-risk patients, the treated group exhibited a better prognosis compared to the non-treated group (85.6% vs. 77.6%, P = 0.007). In both univariate and multivariate COX regression analyses, after adjusting for clinical factors such as tumor stage and tumor grade, the IVC between the primary and second TURBT remained an independent prognostic factor for NMIBC patients (HR 0.571, 95% CI [0.380, 0.859], p = 0.007). IVC treatment administered between the primary and second TURBT has been demonstrated to enhance RFS of high-risk NMIBC patients undergoing BCG treatment, whereas it is not applicable to intermediate-risk patients. CI - (c) 2025. The Author(s). FAU - Li, Zhen AU - Li Z AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. AD - Institute of Urology, Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Wang, Zewei AU - Wang Z AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. FAU - Liu, Yang AU - Liu Y AD - Department of Urology, The First Hospital of Qiqihar City, Qiqihar, 221000, People's Republic of China. FAU - Yang, Lei AU - Yang L AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. FAU - Gu, Ling AU - Gu L AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. FAU - Li, Hailong AU - Li H AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. justinlee719@163.com. FAU - Wang, Wei AU - Wang W AD - Department of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, 8 Gong Ti Nan Road, Chaoyang District, Beijing, 100020, People's Republic of China. weiwang0920@163.com. LA - eng PT - Journal Article DEP - 20250210 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) SB - IM EIN - Sci Rep. 2025 Apr 23;15(1):14163. doi: 10.1038/s41598-025-98177-8. PMID: 40269133 MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/drug therapy/pathology/therapy/mortality/surgery MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Aged MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Administration, Intravesical MH - Cystectomy MH - Neoplasm Recurrence, Local MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11811208 OTO - NOTNLM OT - BCG OT - Chemotherapy OT - Non-muscle-invasive bladder cancer OT - Progression OT - Re-TURBT COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Ethics approval and consent to participate: This retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (XYFY2022-KL340). All patients provided written informed consent. Consent for publication: Not applicable. EDAT- 2025/02/11 00:18 MHDA- 2025/02/11 00:19 PMCR- 2025/02/10 CRDT- 2025/02/10 23:27 PHST- 2024/11/10 00:00 [received] PHST- 2025/02/03 00:00 [accepted] PHST- 2025/02/11 00:19 [medline] PHST- 2025/02/11 00:18 [pubmed] PHST- 2025/02/10 23:27 [entrez] PHST- 2025/02/10 00:00 [pmc-release] AID - 10.1038/s41598-025-89008-x [pii] AID - 89008 [pii] AID - 10.1038/s41598-025-89008-x [doi] PST - epublish SO - Sci Rep. 2025 Feb 10;15(1):4874. doi: 10.1038/s41598-025-89008-x. PMID- 39929768 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20260624 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 29 IP - 3 DP - 2025 Feb TI - Machine Learning Accurately Predicts Muscle Invasion of Bladder Cancer Based on Three miRNAs. PG - e70361 LID - 10.1111/jcmm.70361 [doi] LID - e70361 AB - The aim of this study was to validate the diagnostic potential of four previously identified miRNAs in two independent cohorts and to develop accurate classification models to predict invasiveness of bladder cancer. Furthermore, molecular subtypes were investigated. The miRNAs were isolated from pTa low-grade (lg) (n = 113), pT1 high-grade (hg) (n = 133) and muscle-invasive bladder cancer (MIBC) (n = 136) tumour tissue samples (FFPE) after either transurethral resection of a bladder tumour (TURB) or cystectomy (CYS). In both cohorts, the expression of miR-138-5p and miR-200a-3p was significantly lower, and the expression of miR-146b-5p and miR-155-5p was significantly higher in MIBC compared to pTa lg. A k-nearest neighbours (KNN) classifier trained to distinguish pTa lg from MIBC based on three miRNAs achieved an accuracy of 0.94. The accuracy remained at 0.91 when the classifier was applied exclusively to the TURB samples. To guarantee reliable predictions, a conformal prediction approach was applied to the KNN model, which eliminated all misclassifications on the test cohort. pT1 hg samples were classified as MIBC in 32% of cases using the KNN model. miR-146b-5p, miR-155-5p and miR-200a-3p expressions are significantly associated with particular molecular subtypes. In conclusion, we confirmed that the four miRNAs significantly distinguish MIBC from NMIBC. A classification model based on three miRNAs was able to accurately classify the phenotype of invasive tumors. This could potentially support the histopathological diagnosis in bladder cancer and therefore, the clinical decision between performing a radical cystectomy and pursuing bladder-conserving strategies, especially in pT1 hg tumors. CI - (c) 2025 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Eckhart, Lea AU - Eckhart L AD - Center for Bioinformatics, Saarland Informatics Campus, Saarland University, Saarbrucken, Germany. FAU - Rau, Sabrina AU - Rau S AD - Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Homburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. FAU - Stahl, Phillip R AU - Stahl PR AD - Institute of Pathology, Saarland University Medical Center and Saarland University, Homburg, Germany. AD - Department of Medicine, MSB Medical School, Berlin, Germany. FAU - Ayoubian, Hiresh AU - Ayoubian H AD - Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany. FAU - Heinzelbecker, Julia AU - Heinzelbecker J AD - Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Homburg, Germany. FAU - Zohari, Farzaneh AU - Zohari F AD - Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. FAU - Stockle, Michael AU - Stockle M AD - Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Homburg, Germany. FAU - Lenhof, Hans-Peter AU - Lenhof HP AD - Center for Bioinformatics, Saarland Informatics Campus, Saarland University, Saarbrucken, Germany. FAU - Junker, Kerstin AU - Junker K AUID- ORCID: 0000-0002-0873-8128 AD - Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University, Homburg, Germany. LA - eng GR - Gunther-Voges-Gesellschaft/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/diagnosis MH - *MicroRNAs/genetics MH - Neoplasm Invasiveness MH - Male MH - *Machine Learning MH - Female MH - Gene Expression Regulation, Neoplastic MH - Aged MH - Middle Aged MH - Biomarkers, Tumor/genetics PMC - PMC11810526 OTO - NOTNLM OT - machine learning algorithms OT - microRNA OT - molecular subtypes OT - muscle-invasive bladder cancer OT - pT1 high-grade tumours COIS- The authors declare no conflicts of interest. EDAT- 2025/02/11 00:19 MHDA- 2025/02/11 00:20 PMCR- 2025/02/10 CRDT- 2025/02/10 22:33 PHST- 2024/12/12 00:00 [revised] PHST- 2024/07/03 00:00 [received] PHST- 2025/01/02 00:00 [accepted] PHST- 2025/02/11 00:20 [medline] PHST- 2025/02/11 00:19 [pubmed] PHST- 2025/02/10 22:33 [entrez] PHST- 2025/02/10 00:00 [pmc-release] AID - JCMM70361 [pii] AID - 10.1111/jcmm.70361 [doi] PST - ppublish SO - J Cell Mol Med. 2025 Feb;29(3):e70361. doi: 10.1111/jcmm.70361. PMID- 39929084 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20260318 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 213 IP - 6 DP - 2025 Jun TI - Gemcitabine vs Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naive Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer. PG - 730-738 LID - 10.1097/JU.0000000000004472 [doi] AB - PURPOSE: Patients with intermediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) are recommended to receive induction intravesical chemotherapy or immunotherapy. However, the comparison between gemcitabine and bacillus Calmette-Guerin (BCG) in treatment-naive patients with low-grade IR-NMIBC remains underexplored. The aim of this study was to evaluate the efficacy of gemcitabine compared with BCG in a cohort of treatment-naive patients with IR-NMIBC. MATERIALS AND METHODS: A retrospective analysis was conducted on patients with low-grade IR-NMIBC, classified according to International Bladder Cancer Group criteria, with no history of induction intravesical treatment. Patients received either induction intravesical BCG or gemcitabine. Recurrence was defined as histologically confirmed cancer during follow-up, while progression included stage/grade progression. Kaplan-Meier estimates were used for survival analysis, and multivariable Cox analysis identified factors associated with recurrence and progression. RESULTS: Of the 151 patients with IR-NMIBC, 78 received BCG and 73 received gemcitabine. Both groups completed the 6-week induction treatment at similar rates (100%), and maintenance therapy was administered to 47% of BCG-treated patients and 53% of gemcitabine-treated patients (P = .46). The median number of maintenance doses was 6 (IQR: 3-9) in the BCG group and 8 (IQR: 4-10) in the gemcitabine group (P = .83). Median follow-up was 54 months for patients receiving BCG and 36 months for patients receiving gemcitabine. After adjusting for age, International Bladder Cancer Group subgroups, year of treatment, single postoperative instillation, and maintenance therapy, gemcitabine was associated with a higher risk of recurrence compared with BCG (P = .02), while the risk of progression remained similar between the 2 groups (P = .87). Adverse events were observed in 62% of patients treated with BCG and 38% of patients treated with gemcitabine (P = .02). CONCLUSIONS: Gemcitabine is associated with a higher risk of recurrence than BCG in treatment-naive patients with IR-NMIBC. However, both treatments show comparable efficacy in preventing disease progression. FAU - Khene, Zine-Eddine AU - Khene ZE AUID- ORCID: 0000-0002-4124-789X AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Bhanvadia, Raj AU - Bhanvadia R AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Attia, Sarah AU - Attia S AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Ito, Willian AU - Ito W AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Trevino, Ivan AU - Trevino I AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Woldu, Solomon L AU - Woldu SL AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, Texas. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250210 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Antimetabolites, Antineoplastic) SB - IM CIN - J Urol. 2025 Jun;213(6):737-738. doi: 10.1097/JU.0000000000004482. PMID: 39996507 MH - Humans MH - Gemcitabine MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - *BCG Vaccine/administration & dosage MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Retrospective Studies MH - Female MH - Administration, Intravesical MH - Male MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - *Adjuvants, Immunologic/administration & dosage MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/epidemiology MH - Disease Progression MH - Aged, 80 and over MH - Treatment Outcome MH - *Antimetabolites, Antineoplastic/administration & dosage OTO - NOTNLM OT - BCG OT - NMIBC OT - gemcitabine OT - intravesical OT - progression OT - recurrence EDAT- 2025/02/11 00:19 MHDA- 2025/05/09 12:36 CRDT- 2025/02/10 18:04 PHST- 2025/05/09 12:36 [medline] PHST- 2025/02/11 00:19 [pubmed] PHST- 2025/02/10 18:04 [entrez] AID - 10.1097/JU.0000000000004472 [doi] PST - ppublish SO - J Urol. 2025 Jun;213(6):730-738. doi: 10.1097/JU.0000000000004472. Epub 2025 Feb 10. PMID- 39928162 OWN - NLM STAT- MEDLINE DCOM- 20250210 LR - 20260109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Feb 10 TI - Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection- a prospective observational study. PG - 114 LID - 10.1007/s00345-025-05485-9 [doi] LID - 114 AB - PURPOSE: To prospectively evaluate prognostic capabilities of non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical TURB (transurethral resection of bladder tumor). METHODS: Evaluated biomarkers included blood: plasminogen activator inhibitor 1 (PAI-1), soluble urokinase plasminogen activator receptor (suPAR), interleukin 8 (IL-8) and urine: IL-8, vascular endothelial growth factor (VEGF) and apolipoprotein E (APOE). Blood and urine samples acquired before TURB for NMIBC from 223 subjects were analysed. The primary outcome was tumor recurrence or progression. RESULTS: After 3 months follow-up with cystoscopy or TURB- 92 patients were tumor free (Group 1). In 131 subjects (Group 2) a recurrence of NMIBC (n = 120) or progression to muscle invasive bladder cancer (MIBC) (n = 11) has been observed. No major clinical differences between these two groups were spotted. The group 2 has presented with significantly higher concentrations of blood IL-8 and suPAR as well as urine VEGF and APOE. The serum IL-8 and urinary VEGF showed the highest prognostic abilities with AUROC of 0.611 (95% CI: 0.534-0.687, p = 0.0044) and 0.632 (95% CI: 0.557-0.707, p = 0.0006), respectively. Multivariable machine learning models which included all investigated biomarkers and European Organisation for Research and Treatment of Cancer (EORTC) risk scores have allowed to discriminate the two patient entities with AUROC of 0.84 (95% CI: 0.73-0.95, p < 0.0001). CONCLUSIONS: The assessed biomarkers alone have shown unsatisfactory prognostic capabilities to be used for prognostication of outcomes after TURB. More complex multivariable prediction models may improve their prognostic performance. TRIAL REGISTRATION: The study was retrospectively registered at clinicaltrails.gov with National Clinical Trial number (NCT): NCT06235853. CI - (c) 2025. The Author(s). FAU - Bardowska, Klaudia AU - Bardowska K AUID- ORCID: 0000-0001-9578-0836 AD - Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland. klbardowska@gmail.com. FAU - Krajewski, Wojciech AU - Krajewski W AUID- ORCID: 0000-0003-1727-2283 AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AUID- ORCID: 0000-0003-2241-6309 AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Koscielska-Kasprzak, Katarzyna AU - Koscielska-Kasprzak K AUID- ORCID: 0000-0002-3216-438X AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Bartoszek, Dorota AU - Bartoszek D AUID- ORCID: 0000-0001-7720-7163 AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Zabinska, Marcelina AU - Zabinska M AUID- ORCID: 0000-0003-1810-3131 AD - Department of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AUID- ORCID: 0000-0001-9792-4450 AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kubacki, Filip AU - Kubacki F AD - EMO-LINK, Opole, Poland. FAU - Krolicki, Tomasz AU - Krolicki T AUID- ORCID: 0000-0002-2548-3008 AD - Department of Anesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland. FAU - Krajewska, Magdalena AU - Krajewska M AUID- ORCID: 0000-0002-2632-2409 AD - Department of Non-Procedural Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AUID- ORCID: 0000-0002-1360-0422 AD - University Centre of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kaminska, Dorota AU - Kaminska D AUID- ORCID: 0000-0003-2400-9328 AD - Department of Non-Procedural Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. LA - eng SI - ClinicalTrials.gov/NCT06235853 GR - 0073/DIA/2019/48/Polish Ministry of Science and Higher Education/ PT - Journal Article PT - Observational Study DEP - 20250210 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) RN - 0 (Interleukin-8) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (Receptors, Urokinase Plasminogen Activator) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/blood/urine MH - Male MH - Prospective Studies MH - Female MH - Aged MH - *Neoplasm Recurrence, Local/blood/urine/diagnosis/epidemiology MH - Middle Aged MH - *Biomarkers, Tumor/blood/urine MH - Interleukin-8/urine/blood MH - Neoplasm Invasiveness MH - Vascular Endothelial Growth Factor A/urine/blood MH - Prognosis MH - Plasminogen Activator Inhibitor 1/blood MH - Receptors, Urokinase Plasminogen Activator/blood MH - Cystectomy/methods MH - Cystoscopy MH - Aged, 80 and over MH - Disease Progression MH - Predictive Value of Tests MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11811479 OTO - NOTNLM OT - Biomarkers OT - Machine learning OT - Non-muscle invasive bladder cancer (NMIBC) OT - Transurethral resection of bladder tumor (TURB) COIS- Declarations. Ethics approval and consent to participate: The approval of the Bioethics Committee of the Wroclaw Medical University was obtained (approval number: KB - 692/2019; Ethical Statement Date: 22nd October 2019, Wroclaw). Every study participant has signed the informed consent form (ICF). Competing interests: The authors declare no competing interests. EDAT- 2025/02/10 12:22 MHDA- 2025/02/10 12:23 PMCR- 2025/02/10 CRDT- 2025/02/10 11:16 PHST- 2024/08/22 00:00 [received] PHST- 2025/01/24 00:00 [accepted] PHST- 2025/02/10 12:23 [medline] PHST- 2025/02/10 12:22 [pubmed] PHST- 2025/02/10 11:16 [entrez] PHST- 2025/02/10 00:00 [pmc-release] AID - 10.1007/s00345-025-05485-9 [pii] AID - 5485 [pii] AID - 10.1007/s00345-025-05485-9 [doi] PST - epublish SO - World J Urol. 2025 Feb 10;43(1):114. doi: 10.1007/s00345-025-05485-9. PMID- 39927777 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20250923 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 4 DP - 2025 Apr 1 TI - An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for nonmuscle-invasive bladder tumor. PG - 3061-3077 LID - 10.1097/JS9.0000000000002291 [doi] AB - OBJECTIVE: En bloc transurethral resection of bladder tumor (ERBT) for nonmuscular-invasive bladder tumor (NMIBC) has been used in clinical practice, but its efficacy and safety have not been conclusional. We aimed to evaluate the efficacy and safety of ERBT and conventional transurethral resection of bladder tumor (cTURBT) for NMIBC. METHODS: Randomized controlled trials (RCTs) comparing ERBT and cTURBT in the treatment of NMIBC were searched in Pubmed, Embase, Clinicaltrials.gov, and Cochrane; 12 RCTs were included for systematic review and meta-analysis using RevMan 5.4. RESULTS: A total of 12 RCTs involving 2097 patients with NMIBC were included and analyzed. The results showed the rate of identification of detrusor muscle in specimens [odds ratio (OR) 1.90; P = 0.03] was higher in ERBT group, and bladder perforation (OR 0.30; P = 0.004), obturator nerve reflex (OR 0.18; P = 0.001), catheter indwelling time (MD -0.64; P = 0.002), length of hospital stay (MD -0.58; P = 0.002), tumor recurrence rate 3 months after surgery (OR 0.42; P = 0.03), tumor recurrence rate 6 months after surgery (OR 0.21; P = 0.007), the recurrence rate of the same site 1 year after surgery (OR 0.23; P < 0.0001) and bleeding rate (OR 0.30; P = 0.0005) were significantly lower in ERBT group than that in cTURBT group. There was no significant difference in residual tumor (OR 0.62; P = 0.07), Re-TURBT (OR 0.71; P = 0.19), hemoglobin deficit (MD -0.81; P = 0.29), urethral stricture (OR 0.67; P = 0.42), resection time (MD 2.31; P = 0.16), operative time (MD 1.17; P = 0.49), 1 year (OR 0.61; P = 0.13), 2 years (OR 0.94; P = 0.76), 3-year tumor recurrence rate (OR 1.03; P = 0.86) and the risk of progression at 12 month (OR 0.68; P = 0.79) between the two groups. CONCLUSIONS: Our results showed that ERBT can improve the rate of identification of detrusor muscle in specimens and reduce the 3-month, 6-month tumor recurrence rate and recurrence rate of the same site 1 year after surgery. In addition, ERBT has fewer complications, and shorter catheter indentation time and hospital stay. The laser ERBT can also decrease tumor residual rate and re-TURBT. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Xu, Zhunan AU - Xu Z AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Wang, Qihua AU - Wang Q FAU - Li, Bing AU - Li B FAU - Hao, Xuexue AU - Hao X FAU - Ren, Congzhe AU - Ren C FAU - Chen, Xiangyu AU - Chen X FAU - Liu, Li AU - Liu L FAU - Liu, Xiaoqiang AU - Liu X LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250401 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Cystectomy/methods/adverse effects MH - Treatment Outcome MH - Randomized Controlled Trials as Topic MH - Postoperative Complications/epidemiology MH - Neoplasm Invasiveness MH - Urethra PMC - PMC12175814 OTO - NOTNLM OT - early oral feeding OT - gastrectomy OT - gastric cancer OT - meta-analysis OT - traditional oral feeding COIS- The authors declare that they have no competing interests. EDAT- 2025/02/10 12:23 MHDA- 2025/04/16 18:24 PMCR- 2025/06/18 CRDT- 2025/02/10 09:03 PHST- 2024/10/14 00:00 [received] PHST- 2025/01/12 00:00 [accepted] PHST- 2025/04/16 18:24 [medline] PHST- 2025/02/10 12:23 [pubmed] PHST- 2025/02/10 09:03 [entrez] PHST- 2025/06/18 00:00 [pmc-release] AID - 01279778-202504000-00028 [pii] AID - IJS-D-24-05691 [pii] AID - 10.1097/JS9.0000000000002291 [doi] PST - epublish SO - Int J Surg. 2025 Apr 1;111(4):3061-3077. doi: 10.1097/JS9.0000000000002291. PMID- 39920881 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20250506 IS - 1525-6049 (Electronic) IS - 0886-022X (Print) IS - 0886-022X (Linking) VI - 47 IP - 1 DP - 2025 Dec TI - Impact of dialysis on intravesical recurrence and survival outcomes in upper tract urothelial cancer patients undergoing radical nephroureterectomy. PG - 2458762 LID - 10.1080/0886022X.2025.2458762 [doi] LID - 2458762 AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) presents a significant recurrence risk following radical nephroureterectomy (RNU). Patients on dialysis may experience unique clinical trajectories due to uremic states and altered immune responses. OBJECTIVE: To evaluate the impact of dialysis on intravesical recurrence and survival outcomes in patients with UTUC undergoing RNU, and to identify predictive factors influencing prognosis. METHODS: A retrospective cohort study analyzed 402 patients with non-metastatic UTUC treated with RNU between 2001 and 2014. Patients were stratified into dialysis (n = 66) and non-dialysis (n = 336) groups. Survival and recurrence outcomes were assessed using Kaplan-Meier and Cox regression analyses. RESULTS: Dialysis patients were predominantly female, younger, and exhibited less advanced pathological tumor stages. Dialysis was associated with higher intravesical recurrence rates (p = 0.009), which were largely attributable to a history of bladder cancer (42.4% vs. 26.5%; p = 0.009). After adjustment for bladder cancer history, dialysis was not an independent predictor of bladder recurrence-free survival (BRFS). Advanced pT stages (HR: 3.9, p = 0.012) and prior bladder cancer were the primary factors influencing BRFS. CONCLUSIONS: Dialysis does not independently worsen surgical outcomes or BRFS in UTUC patients post-RNU when accounting for prior bladder cancer. Prognostic models should integrate these findings to enhance individualized surveillance and treatment strategies. FAU - Hsieh, Chi-Chun AU - Hsieh CC AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Juan, Yung-Shun AU - Juan YS AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Chien, Tsu-Ming AU - Chien TM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Postbaccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20250207 PL - England TA - Ren Fail JT - Renal failure JID - 8701128 SB - IM MH - Humans MH - Female MH - Male MH - Retrospective Studies MH - *Nephroureterectomy MH - Aged MH - Middle Aged MH - *Neoplasm Recurrence, Local/epidemiology MH - *Renal Dialysis/adverse effects MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Urinary Bladder Neoplasms/mortality/pathology/surgery MH - Prognosis MH - Aged, 80 and over MH - *Ureteral Neoplasms/surgery/mortality/pathology MH - Kaplan-Meier Estimate MH - Proportional Hazards Models MH - Neoplasm Staging PMC - PMC11809166 OTO - NOTNLM OT - Upper tract urothelial carcinoma OT - dialysis OT - end-stage renal diseases OT - intravesical recurrence OT - radical nephroureterectomy COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/02/08 00:30 MHDA- 2025/02/08 19:52 PMCR- 2025/02/07 CRDT- 2025/02/07 23:46 PHST- 2025/02/08 19:52 [medline] PHST- 2025/02/08 00:30 [pubmed] PHST- 2025/02/07 23:46 [entrez] PHST- 2025/02/07 00:00 [pmc-release] AID - 2458762 [pii] AID - 10.1080/0886022X.2025.2458762 [doi] PST - ppublish SO - Ren Fail. 2025 Dec;47(1):2458762. doi: 10.1080/0886022X.2025.2458762. Epub 2025 Feb 7. PMID- 39891954 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20250525 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 2 DP - 2025 Apr TI - Investigating the Potential to Offer Reproductive Organ Preserving Radical Cystectomy to More Female Bladder Cancer Patients. PG - 102303 LID - S1558-7673(25)00005-9 [pii] LID - 10.1016/j.clgc.2025.102303 [doi] AB - INTRODUCTION: Traditional radical cystectomy (tRC) in female bladder cancer (BC) patients includes removal of the ovaries, uterus, and anterior vaginal wall. Reproductive organ preserving radical cystectomy (ROPRC) offers less invasive surgery with comparable survival and better functional outcomes for selected patients. The objective of this study is to investigate the current number of ROPRC at our institution and the potential for increased adoption of the procedure based on precystectomy assessment criteria. PATIENTS AND METHODS: A retrospective cohort study of female patients treated with radical cystectomy between 2017 and 2021 at a single high volume academic center in Denmark. Suspicion of stage T4 was assessed based on precystectomy CT, transurethral resection of bladder tumor with bimanual palpation, and intraoperative assessment at cystectomy. Median follow-up was 36 months for both tRC and ROPRC. The primary outcome was number of ROPRC. The secondary outcome was potential for ROPRC in the tRC population. Frequencies and predictive values were calculated. RESULTS: A total of 118 female BC patients were included. Four patients underwent ROPRC, all with non-muscle-invasive BC. None had local recurrence. In tRC (n = 114), stage T4 BC was suspected in 31% (35/114) and 14% (16/114) had pT4 at final pathology. There was no suspicion of stage T4 BC in 83 patients, and 82 of these had 18%) was significantly correlated with tumor stage (P=0.001), tumor grade (P=0.014), immediate postoperative instillation (P=0.001), the expression of P53 (P=0.019) and CK20 (P=0.001). Ki67 expression greater than 18% was an independent risk factor for high recurrence rate of NMIBUC (P=0.001). Moreover, the 1-year and 3-year recurrence-free survival (RFS) of the high Ki67 group were 56.6% (95%CI 51.2%-62%) and 43.6% (95%CI 37.5%-49.7%) respectively, which were significantly lower than those in low Ki67 group which present as 92.9% (95%CI 89.0%-96.8%) and 88.3% (95%CI 82.4%-94.2%) respectively, and the difference was statistically significant (P<0.001). CONCLUSIONS: 18% is the optimal cut-off value of Ki67 for predicting recurrence of NMIBUC. Ki67>18% is an independent risk factor for high recurrence rate of NMIBUC. This cut-off value can more accurately predict the risk of recurrence and has the potential clinical value for guiding the postoperative adjuvant treatment and follow-up strategy of NMIBUC. CI - Copyright (c) 2025 Peng, Zhang, Jia, Yi, Yi, Li, Pi and Meng. FAU - Peng, Rende AU - Peng R AD - Department of Urology, Chengdu Second People's Hospital, Chengdu, China. FAU - Zhang, Yaoyu AU - Zhang Y AD - Department of Urology, The General Hospital of Western Theater Command, Chengdu, China. FAU - Jia, Mingzhu AU - Jia M AD - Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Yi, Xinping AU - Yi X AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. FAU - Yi, Xiaoyao AU - Yi X AD - Department of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Shadan AU - Li S AD - Department of Urology, The General Hospital of Western Theater Command, Chengdu, China. FAU - Pi, Jiangchuan AU - Pi J AD - Department of Urology, Chengdu Second People's Hospital, Chengdu, China. FAU - Meng, Wenjun AU - Meng W AD - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20250116 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11779619 OTO - NOTNLM OT - immunohistochemical markers OT - ki67 OT - non-muscular invasive bladder urothelial carcinoma OT - optimal cut-off value OT - prognosis OT - recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/01/31 06:17 MHDA- 2025/01/31 06:18 PMCR- 2024/01/01 CRDT- 2025/01/31 04:37 PHST- 2024/11/03 00:00 [received] PHST- 2024/12/26 00:00 [accepted] PHST- 2025/01/31 06:18 [medline] PHST- 2025/01/31 06:17 [pubmed] PHST- 2025/01/31 04:37 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1522009 [doi] PST - epublish SO - Front Oncol. 2025 Jan 16;14:1522009. doi: 10.3389/fonc.2024.1522009. eCollection 2024. PMID- 39883196 OWN - NLM STAT- MEDLINE DCOM- 20250130 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jan 30 TI - Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review. PG - 95 LID - 10.1007/s00345-025-05473-z [doi] AB - OBJECTIVE: This systematic review was conducted to synthesize current research on the role of repeated transurethral resection of the bladder (re-TURB) and the emerging use of magnetic resonance imaging (MRI) in discerning patient suitability for safely foregoing this procedure. EVIDENCE ACQUISITION: Employing a methodical literature search, we consulted several bibliographic databases including PubMed, Science Direct, Scopus, and Embase. The review process adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. EVIDENCE SYNTHESIS: We evaluated data from 667 patients (mean age 65.8 years; age range 59-75 years) who underwent MRI prior to potential re-TURB. The gap between initial TURB and MRI was reported as 42 days in one study, while the interval between MRI and subsequent cystoscopy, with or without biopsy, varied from 21 days to 3 months. Initial TURB pathology for non-muscle invasive bladder cancer (NMIBC) patients identified stage Ta in 177 (42.5%) and T1 in 246 (57.5%) patients across three studies. High-grade and low-grade pathologic classifications were reported in 377 (64.5%) and 207 (35.5%) patients respectively in two studies. The VI-RADS scoring system's sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the detection of bladder cancer recurrence were 89%, 85.5%, 82.7%, and 96%, respectively. A total of 365 patients (54.7%) underwent re-TUR. Among NMIBC patients, re-TUR pathology revealed Ta in 22 cases (5.4%) and pT1 in 179 cases (44%) with VI-RADS 1-2, while no cases of Ta (0%) and 37 cases of T1 (9%) were reported with VI-RADS 4-5, as documented in two studies. Notably, only 69 patients (10.7%) were identified as having MIBC across all studies. CONCLUSION: MRI is demonstrating reliability as a diagnostic tool for non-muscle invasive bladder cancers. The VI-RADS scoring system appears to be a promising approach in selecting patients for re-TURB. DW-MRI may serve as a primary diagnostic examination for patient follow-up post-TURB. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Saouli, A AU - Saouli A AD - Department of Urology, Centre Hospitalier Regional Moulay Youssef, Rabat, Morocco. Amine.saouli0@gmail.com. FAU - Zerda, I AU - Zerda I AD - Department of Urology B, Ibn Sina Hospital, CHU Ibn Sina, Rabat, Morocco. FAU - Elkhader, K AU - Elkhader K AD - Department of Urology B, Ibn Sina Hospital, CHU Ibn Sina, Rabat, Morocco. FAU - Durand, X AU - Durand X AD - Department of Urology, Paris Saint-Joseph Hospital, Paris, France. FAU - Ariane, M AU - Ariane M AD - Department of Urology, Clinique de la Region Mantaise, Mantes-la-Jolie, France. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Shammari, Masoud Al AU - Shammari MA AD - Department of Urology, King Fahad Hospital of University in Khobar, Al Khobar, Saudi Arabia. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, 20089, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072, Italy. FAU - Chebbi, Ala AU - Chebbi A AD - Department of Urology, Paris Saint-Joseph Hospital, Paris, France. AD - Department of Urology, Clinique de la Region Mantaise, Mantes-la-Jolie, France. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250130 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - *Magnetic Resonance Imaging MH - Feasibility Studies MH - *Cystectomy/methods MH - *Patient Selection MH - Reoperation MH - Neoplasm Invasiveness MH - Middle Aged MH - Aged MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Follow-up OT - MRI OT - Re-TURB COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/01/30 12:35 MHDA- 2025/01/30 12:36 CRDT- 2025/01/30 11:17 PHST- 2024/09/27 00:00 [received] PHST- 2025/01/17 00:00 [accepted] PHST- 2025/01/30 12:36 [medline] PHST- 2025/01/30 12:35 [pubmed] PHST- 2025/01/30 11:17 [entrez] AID - 10.1007/s00345-025-05473-z [pii] AID - 10.1007/s00345-025-05473-z [doi] PST - epublish SO - World J Urol. 2025 Jan 30;43(1):95. doi: 10.1007/s00345-025-05473-z. PMID- 39877575 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250205 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 1 DP - 2025 Jan TI - A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance. PG - e468 LID - 10.1002/bco2.468 [doi] LID - e468 AB - OBJECTIVES: Cx bladder monitor (CxM) is a urine test with a proven high sensitivity and negative predictive value in bladder cancer surveillance. The aim of this retrospective study was to report on the outcomes of our newly implemented bladder cancer surveillance program for patients eligible for yearly cystoscopy, as per the European Association of Urology (EAU) guidelines. In this program, eligible patients alternate between yearly surveillance cystoscopy and CxM, instead of the standard yearly surveillance cystoscopy. Outcomes measures were overall results of CxM and subsequent treatment patterns of patients, impact on waiting lists, cost comparison and patient satisfaction. PATIENTS AND METHODS: In 2022, 109 eligible and consenting patients were identified, with 98 commencing on the new surveillance program, starting with CxM instead of cystoscopy. A negative CxM, would result in a planned flexible cystoscopy in 12 months. If a patient had a positive CxM, they proceeded to undergo a cystoscopy, and if required, imaging. RESULTS: Of the 98 that underwent testing, 90 had a negative CxM test and 8 patients had a positive CxM test. Three of these eight were true positive (PPV 0.375). Seventy negative CxM patients had no recurrence at the time of the next cystoscopy/imaging. Of the remaining 20 negative CxM patients, 11 were found to have a recurrence at subsequent cystoscopy/imaging and 9 did not proceed with further surveillance for various reasons. All of the tumour recurrences diagnosed after a negative CxM were non-invasive, thus there was no progression to muscle-invasive disease. All suitable patients consented to continuing with the CxM protocol. The hospital surveillance cystoscopy waitlist was reduced by approximately 59% and CxM was approximately $850 AUD cheaper than a cystoscopy. CONCLUSION: CxM can be safely used in an alternating schedule with Flexible Cystoscopy for patients on annual bladder cancer surveillance. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Guduguntla, Arjun AU - Guduguntla A AUID- ORCID: 0009-0003-8439-2813 AD - Department of Urology Northern Health Victoria Australia. AD - University of Melbourne Victoria Australia. FAU - Whish-Wilson, Thomas AU - Whish-Wilson T AUID- ORCID: 0000-0002-2116-9695 AD - Department of Urology Northern Health Victoria Australia. FAU - Chandler, Lauren AU - Chandler L AD - Department of Urology Northern Health Victoria Australia. FAU - Gyomber, Dennis AU - Gyomber D AD - Department of Urology Northern Health Victoria Australia. AD - University of Melbourne Victoria Australia. LA - eng PT - Journal Article DEP - 20250115 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC11771502 OTO - NOTNLM OT - bladder cancer surveillance OT - bladder cx OT - bladder cx monitor OT - non-muscle invasive bladder cancer OT - skip cystoscopy OT - urine test COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2025/01/29 11:20 MHDA- 2025/01/29 11:21 PMCR- 2025/01/15 CRDT- 2025/01/29 04:34 PHST- 2024/08/01 00:00 [received] PHST- 2024/10/14 00:00 [revised] PHST- 2024/10/15 00:00 [accepted] PHST- 2025/01/29 11:21 [medline] PHST- 2025/01/29 11:20 [pubmed] PHST- 2025/01/29 04:34 [entrez] PHST- 2025/01/15 00:00 [pmc-release] AID - BCO2468 [pii] AID - 10.1002/bco2.468 [doi] PST - epublish SO - BJUI Compass. 2025 Jan 15;6(1):e468. doi: 10.1002/bco2.468. eCollection 2025 Jan. PMID- 39877564 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 6 IP - 1 DP - 2025 Jan TI - Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma. PG - e488 LID - 10.1002/bco2.488 [doi] LID - e488 AB - OBJECTIVE: To evaluate the correlation between ATP-binding cassette (ABC) transporter expression and therapeutic efficacy of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, in urothelial cancer, as only a few studies have been conducted on this topic. PATIENTS AND METHODS: This retrospective study included 20 patients with metastatic urothelial carcinoma (mUC), including bladder and upper urinary tract cancers, who were treated with EV at Dokkyo Medical University Hospital between 2022 and 2024. Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue samples. Progression-free survival (PFS) was estimated using the Kaplan-Meier method, and differences between subgroups (e.g., Nectin-4 and ABC transporter expression) were compared using the log-rank test. RESULTS: Immunohistochemical analysis indicated that tumours with high ABC transporter expression exhibited shorter PFS time and poorer response to EV. Furthermore, a decrease in Nectin-4 expression and an increase in ABC transporter expression were observed as the disease progressed from non-muscle-invasive to muscle-invasive and metastatic. Patients with Nectin-4-positive and ABC transporter-negative tumours had the longest PFS, underscoring the prognostic significance of these biomarkers. CONCLUSION: To our knowledge, this study is the first to show a correlation between ABC transporter expression and EV efficacy in urothelial carcinoma. Future research should focus on optimizing treatment strategies based on Nectin-4 and ABC transporter expression to improve outcomes. CI - (c) 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Kijima, Toshiki AU - Kijima T AUID- ORCID: 0000-0002-4380-9294 AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Takada-Owada, Atsuko AU - Takada-Owada A AD - Department of Diagnostic Pathology Dokkyo Medical University Tochigi Japan. FAU - Shimoda, Hiroki AU - Shimoda H AD - Department of Urology Tokyo Medical and Dental University, Dokkyo Medical University Tokyo Japan. FAU - Kokubun, Hidetoshi AU - Kokubun H AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Uematsu, Toshitaka AU - Uematsu T AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Takei, Kohei AU - Takei K AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Betsunoh, Hironori AU - Betsunoh H AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Yashi, Masahiro AU - Yashi M AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Ishida, Kazuyuki AU - Ishida K AD - Department of Diagnostic Pathology Dokkyo Medical University Tochigi Japan. FAU - Kamai, Takao AU - Kamai T AUID- ORCID: 0000-0002-7086-6964 AD - Department of Urology Dokkyo Medical University Tochigi Japan. LA - eng PT - Journal Article DEP - 20250111 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC11771482 OTO - NOTNLM OT - ABC transporters OT - Enfortumab Vedotin OT - Nectin-4 OT - drug resistance OT - metastatic urothelial carcinoma COIS- The authors declare that they have no financial or nonfinancial conflicts of interest. EDAT- 2025/01/29 06:20 MHDA- 2025/01/29 06:21 PMCR- 2025/01/11 CRDT- 2025/01/29 04:34 PHST- 2024/11/21 00:00 [received] PHST- 2024/11/28 00:00 [accepted] PHST- 2025/01/29 06:21 [medline] PHST- 2025/01/29 06:20 [pubmed] PHST- 2025/01/29 04:34 [entrez] PHST- 2025/01/11 00:00 [pmc-release] AID - BCO2488 [pii] AID - 10.1002/bco2.488 [doi] PST - epublish SO - BJUI Compass. 2025 Jan 11;6(1):e488. doi: 10.1002/bco2.488. eCollection 2025 Jan. PMID- 39874715 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 2 DP - 2025 Apr TI - Does Bladder Outlet Obstruction Releated to Recurrence In Low Risk Ta Low Grade Non Muscle Invasive Bladder Cancer? PG - 102296 LID - S1558-7673(24)00266-0 [pii] LID - 10.1016/j.clgc.2024.102296 [doi] AB - INTRODUCTION: Bladder cancer is common in men. The number of recurrences is one of the risk factors for progression and poor prognosis in nonmuscle invasive bladder cancer (NMIBC). We aimed to investigate whether bladder outlet obstruction (BOO) has an effect on bladder cancer recurrence in patients with nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Data from 207 male patients with nonmuscle invasive bladder cancer (NMIBC) diagnosed between November 2008 and March 2023, with low risk Ta Low-Grade tumors were retrospectively reviewed. Patients were divided into 2 groups as bladder outlet obstruction (n:133) and nonobstruction (n:74). We analyzed the results of the effect of obstruction on bladder cancer recurrence. RESULTS: Recurrence rates of patients with bladder outlet obstruction were found to be higher in Kaplan-Meier analysis. The log-rank test result of P = .034 was statistically significant at 5% significance level. Cox regression analysis revealed that bladder outlet obstruction had an increasing effect on recurrence (P = .049), while other variables (smoking, age, postmicturition residual [PMR]) did not create a significant difference in the risk of recurrence. CONCLUSION: The presence of bladder outlet obstruction is a factor that increases the risk of recurrence. In bladder cancer patients, early treatment of bladder outlet obstruction will not only reduce the tumor recurrence rate but also have a positive impact on the patient's quality of life. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Yentur, Serhat AU - Yentur S AD - Bagcilar Training and Research Hospital, Department of Urology, Istanbul, Turkey. Electronic address: drserhatyentur@hotmail.com. FAU - Dusunus, Yunus Emre AU - Dusunus YE AD - Bagcilar Training and Research Hospital, Department of Urology, Istanbul, Turkey. Electronic address: yunusdusunus@gmail.com. FAU - Ulus, Ismail AU - Ulus I AD - Bagcilar Training and Research Hospital, Department of Urology, Istanbul, Turkey. FAU - Kandirali, Ismail Engin AU - Kandirali IE AD - Bagcilar Training and Research Hospital, Department of Urology, Istanbul, Turkey. FAU - Sahin, Sergen AU - Sahin S AD - Esenler Maternity and Child Diseases Hospital, Department of Urology, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20241228 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Male MH - *Urinary Bladder Neoplasms/pathology/complications MH - *Urinary Bladder Neck Obstruction/complications MH - *Neoplasm Recurrence, Local/epidemiology/pathology/etiology MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Risk Factors MH - Prognosis MH - Neoplasm Grading MH - Aged, 80 and over MH - Kaplan-Meier Estimate MH - Neoplasm Invasiveness OTO - NOTNLM OT - Benign prostate hyperplasia OT - Lower urinary tract symptoms OT - Obstruction OT - Recurrence OT - Transurethral resection EDAT- 2025/01/29 00:20 MHDA- 2025/03/14 11:22 CRDT- 2025/01/28 18:04 PHST- 2024/10/04 00:00 [received] PHST- 2024/12/25 00:00 [revised] PHST- 2024/12/26 00:00 [accepted] PHST- 2025/03/14 11:22 [medline] PHST- 2025/01/29 00:20 [pubmed] PHST- 2025/01/28 18:04 [entrez] AID - S1558-7673(24)00266-0 [pii] AID - 10.1016/j.clgc.2024.102296 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Apr;23(2):102296. doi: 10.1016/j.clgc.2024.102296. Epub 2024 Dec 28. PMID- 39874333 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 77 IP - 12 DP - 2024 TI - Immunohistochemical evaluation of SOX-10 in patients with urinary bladder cancer. PG - 2481-2486 LID - 10.36740/WLek/195857 [doi] AB - OBJECTIVE: Aim: To evaluate the expression levels of SOX-10 in tissues of bladder tumor and to prove the correlation between SOX-10 expression and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion. PATIENTS AND METHODS: Materials and Methods: Forty formalin fixed paraffin embedded FFPE tissue blocks gathered by transurethral resection of bladder tumor are collected from teaching hospitals at Al-Najaf governorate. Those blocks were stained by hematoxylin and eosin. The histopathological characteristics were examined and immunostained by SOX10. RESULTS: Results: An assessment of the expression of SOX-10 in urothelial carcinoma showed that the SOX-10 test was positive in five samples of urothelial carcinoma, while the SOX-10 test was negative in thirty-five samples. The correlation of SOX-10 with other variables (age, sex, and grade) was statistically non-significant. CONCLUSION: Conclusions: SOX-10 is an immunohistochemical sensitive marker for the diagnosis of urothelial carcinoma. SOX-10 expression appeared to be non-significant relation with age, gender and histopathological parameters and its expression has been showed to be lost or decreased in substantial proportion in relation to urothelial carcinoma. This variation or down regulation of SOX-10 is correlated with higher tumor grade and stage. FAU - Hameed, Randa Saad AU - Hameed RS AD - DEPARTMENT OF BASIC SCIENCES, COLLEGE OF DENTISTRY, UNIVERSITY OF KUFA, KUFA, IRAQ. FAU - Alhussain, Ghufran Salman Abd AU - Alhussain GSA AD - DEPARTMENT OF BASIC SCIENCES, COLLEGE OF DENTISTRY, UNIVERSITY OF KUFA, KUFA, IRAQ. FAU - Almudhafar, Rihab Hameed AU - Almudhafar RH AD - DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLEGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ. FAU - Mahdi, Liwaa Hussein AU - Mahdi LH AD - DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLEGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 RN - 0 (SOXE Transcription Factors) RN - 0 (SOX10 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - Male MH - Female MH - *SOXE Transcription Factors/metabolism MH - Middle Aged MH - Aged MH - *Biomarkers, Tumor/metabolism MH - Immunohistochemistry MH - Aged, 80 and over MH - Adult OTO - NOTNLM OT - SOX-10 OT - immunohistochemistry OT - urothelial carcinoma EDAT- 2025/01/28 18:21 MHDA- 2025/01/28 18:22 CRDT- 2025/01/28 13:53 PHST- 2025/01/28 18:22 [medline] PHST- 2025/01/28 18:21 [pubmed] PHST- 2025/01/28 13:53 [entrez] AID - 10.36740/WLek/195857 [doi] PST - ppublish SO - Wiad Lek. 2024;77(12):2481-2486. doi: 10.36740/WLek/195857. PMID- 39874320 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 77 IP - 12 DP - 2024 TI - Immunohistochemical evaluation of GATA-3 in patients with urinary bladder cancer. PG - 2381-2387 LID - 10.36740/WLek/195858 [doi] AB - OBJECTIVE: Aim: To analyze expression levels of GATA-3 in bladder tumor tissues and to prove a relation between expression of GATA-3 and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion. PATIENTS AND METHODS: Materials and Methods: Forty formalin fixed paraffin embedded (FFPE) tissue blocks obtained from bladder tumor by transurethral resection are collected from teaching hospitals at Al-Najaf governorate. Those blocks are stained by using hematoxylin and eosin stain. Histopathological features were examined and then immunostained by GATA-3. RESULTS: Results: Evaluation of GATA-3 expression in urothelial carcinoma, revealed GATA-3 test was (positive) in thirty-four samples of urothelial carcinoma, while GATA-3 test was (negative) in twenty-one samples of urothelial carcinoma. Correlation of GATA-3 with other variables (age, sex, and grade) was a statistically non-significant. CONCLUSION: Conclusions: GATA-3 is an Immunohistochemical sensitive marker to diagnose urothelial carcinoma. GATA-3 expression showed non-significant relation with age, gender and histopathological parameters and its expression has been observed to be lost or reduced in substantial proportion in relation to urothelial carcinoma. This alteration or down regulation of GATA-3 is correlated with higher tumor grade and stage. FAU - Hameed, Randa Saad AU - Hameed RS AD - DEPARTMENT OF BASIC SCIENCES, COLLAGE OF DENTISTRY, UNIVERSITY OF KUFA, KUFA, IRAQ. FAU - Almudhafar, Rihab Hameed AU - Almudhafar RH AD - DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLAGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ. FAU - Mahdi, Liwaa Hussein AU - Mahdi LH AD - DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLAGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - *GATA3 Transcription Factor/metabolism MH - Female MH - Male MH - Middle Aged MH - Aged MH - Immunohistochemistry MH - *Biomarkers, Tumor/metabolism MH - Adult MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/metabolism/pathology OTO - NOTNLM OT - GATA-3 OT - urothelial carcinoma OT - immunohistochemistry EDAT- 2025/01/28 18:21 MHDA- 2025/01/28 18:22 CRDT- 2025/01/28 13:53 PHST- 2025/01/28 18:22 [medline] PHST- 2025/01/28 18:21 [pubmed] PHST- 2025/01/28 13:53 [entrez] AID - 10.36740/WLek/195858 [doi] PST - ppublish SO - Wiad Lek. 2024;77(12):2381-2387. doi: 10.36740/WLek/195858. PMID- 39873429 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20260910 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 57 IP - 1 DP - 2025 Dec TI - Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer. PG - 2458211 LID - 10.1080/07853890.2025.2458211 [doi] LID - 2458211 AB - BACKGROUND: Despite surgical and intravesical chemotherapy interventions, non-muscle invasive bladder cancer (NMIBC) poses a high risk of recurrence, which significantly impacts patient survival. Traditional clinical characteristics alone are inadequate for accurately assessing the risk of NMIBC recurrence, necessitating the development of novel predictive tools. METHODS: We analyzed microarray data of NMIBC samples obtained from the ArrayExpress and GEO databases. LASSO regression was utilized to develop the predictive signature. We combined gene signature and clinicopathological factors to construct a clinical nomogram for estimating NMIBC recurrence in a local cohort. Finally. the biological functions and potential mechanisms of SDCBP in bladder cancer were investigated experimentally in vitro and in vivo. RESULTS: An 8-gene signature was developed, and its efficiency for predicting NMIBC recurrence was evaluated using Kaplan-Meier and time-dependent ROC curves in both training and validation datasets. Immunohistochemical testing revealed elevated levels of ACTN4 and SDCBP in recurrent NMIBC tissues. We integrated the two proteins with clinical factors to develop a nomogram model, which showed superior accuracy compared to individual parameters. Gene Set Variation Analysis and Gene Set Enrichment Analysis unveiled SDCBP exerted cancer-promoting biological processes, such as angiogenesis, EMT, metastasis and proliferation. Experimental procedures demonstrated that silencing SDCBP attenuated cell growth, glucose metabolism and extracellular acidification rate, accompanied by decreased expression of p-AKT, p-ERK1/2, LDHA and Vimentin. CONCLUSIONS: The established 8-gene signature holds promise as a tool for predicting NMIBC recurrence, while targeting SDCBP may represent a potential strategy for delaying disease relapse. FAU - Zhang, Chen AU - Zhang C AD - Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, China. FAU - Yin, Hubin AU - Yin H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Tinghao AU - Li T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Junrui AU - Chen J AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - He, Weiyang AU - He W AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Ren, Ke AU - Ren K AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Bo AU - Li B AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Xudong AU - Liu X AD - Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250128 PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 RN - 0 (Syntenins) RN - 0 (SDCBP protein, human) RN - 0 (Biomarkers, Tumor) RN - 11003-00-2 (Actinin) RN - 0 (ACTN4 protein, human) SB - IM MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Humans MH - *Neoplasm Recurrence, Local/genetics/pathology MH - *Syntenins/genetics/metabolism MH - Animals MH - Biomarkers, Tumor/genetics MH - Male MH - Actinin/genetics/metabolism MH - Cell Line, Tumor MH - Nomograms MH - Gene Expression Regulation, Neoplastic MH - Female MH - Mice MH - Oncogenes MH - Gene Expression Profiling MH - Prognosis MH - Middle Aged MH - Cell Proliferation MH - Kaplan-Meier Estimate MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11776064 OTO - NOTNLM OT - NMIBC OT - SDCBP OT - cell growth OT - recurrence OT - signature COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/01/28 12:35 MHDA- 2025/01/28 12:36 PMCR- 2025/01/28 CRDT- 2025/01/28 08:13 PHST- 2025/01/28 12:36 [medline] PHST- 2025/01/28 12:35 [pubmed] PHST- 2025/01/28 08:13 [entrez] PHST- 2025/01/28 00:00 [pmc-release] AID - 2458211 [pii] AID - 10.1080/07853890.2025.2458211 [doi] PST - ppublish SO - Ann Med. 2025 Dec;57(1):2458211. doi: 10.1080/07853890.2025.2458211. Epub 2025 Jan 28. PMID- 39869192 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jan 27 TI - Predictive value of Bladder EpiCheck((R)) in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer. PG - 89 LID - 10.1007/s00345-025-05453-3 [doi] AB - PURPOSE: As Bladder EpiCheck((R)) (BE) is a promising urinary biomarker for diagnosis and follow up of non-muscle-invasive bladder cancer (NMIBC), there are no studies evaluated this tool for second transurethral resection (TUR) indication. We aim to evaluate the performance of BE in predicting residual tumor before second TUR in NMIBC and its effects on clinical decision making. METHODS: A total of 50 patients who were diagnosed with NMIBC and indicated for a second TUR were included in the study prospectively. The urine sample taken one day before the second TUR operation was evaluated with BE and the results were compared with second TUR pathologies. RESULTS: The mean age was 65.3 and 45 of the patients were male. Specificity and negative predictive value of BE in primary tumor stage Ta were 100% and 87.5% while in primary tumor stage T1 were 71.4% and 68.2%, respectively. The specificity and negative predictive value of BE were 77.8% and 75%, respectively, in patients with high grade primary tumor. When all NMIBC were evaluated, the specificity and negative predictive value of BE were found to be 78.6% and 73.3% for second TUR, respectively. As an independent predictor of residual tumor in this group, positivity rates of BE were higher in T1 (p < 0.037) and high grade (p < 0.002) tumors. CONCLUSIONS: BE may be useful in detecting residual tumor before second TUR and benefit in clinical decision making with high specificity and negative predictive value. These results encourage the use of BE to reduce number of unnecessary second TUR procedures. It may improve cost effectivity and quality of life as high numbered studies are needed to support these views and to incorporate BE into clinical practice. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Suzan, Serhat AU - Suzan S AUID- ORCID: 0000-0002-3344-464X AD - Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey. FAU - Ulus, Ismail AU - Ulus I AUID- ORCID: 0000-0002-2005-9734 AD - Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey. ismailulus06@yahoo.com. FAU - Hacibey, Ibrahim AU - Hacibey I AUID- ORCID: 0000-0002-2212-5504 AD - Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey. FAU - Muslumanoglu, Ahmet Yaser AU - Muslumanoglu AY AUID- ORCID: 0000-0002-8691-0886 AD - Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey. LA - eng PT - Journal Article DEP - 20250127 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/urine/pathology/diagnosis MH - Male MH - Aged MH - Female MH - Neoplasm, Residual/urine/diagnosis MH - Predictive Value of Tests MH - Middle Aged MH - Prospective Studies MH - Neoplasm Invasiveness MH - *Biomarkers, Tumor/urine MH - Aged, 80 and over MH - Reoperation MH - Cystectomy/methods MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Bladder epicheck OT - Second TUR OT - Urinary biomarkers COIS- Declarations. Ethics approval: The protocol for this research has been approved by Clinical Research Ethics Commitee of the University of Health Sciences, Istanbul Bagcilar Training and Research Hospital, decision number 2019.10.2.01.074. All methods were carried out in accordance with relevant guidelines and regulations of Helsinki declaration. Consent to participate: Written informed consent was obtained from the participants included in the study. Competing interests: The authors declare no competing interests. EDAT- 2025/01/27 12:26 MHDA- 2025/01/27 12:27 CRDT- 2025/01/27 11:13 PHST- 2024/11/24 00:00 [received] PHST- 2025/01/10 00:00 [accepted] PHST- 2025/01/27 12:27 [medline] PHST- 2025/01/27 12:26 [pubmed] PHST- 2025/01/27 11:13 [entrez] AID - 10.1007/s00345-025-05453-3 [pii] AID - 10.1007/s00345-025-05453-3 [doi] PST - epublish SO - World J Urol. 2025 Jan 27;43(1):89. doi: 10.1007/s00345-025-05453-3. PMID- 39867903 OWN - NLM STAT- MEDLINE DCOM- 20250127 LR - 20260605 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer. PG - 1467527 LID - 10.3389/fimmu.2024.1467527 [doi] LID - 1467527 AB - BACKGROUND: Most patients initially diagnosed with non-muscle invasive bladder cancer (NMIBC) still have frequent recurrence after urethral bladder tumor electrodesiccation supplemented with intravesical instillation therapy, and their risk of recurrence is difficult to predict. Risk prediction models used to predict postoperative recurrence in patients with NMIBC have limitations, such as a limited number of included cases and a lack of validation. Therefore, there is an urgent need to develop new models to compensate for the shortcomings and potentially provide evidence for predicting postoperative recurrence in NMIBC patients. METHODS: Clinicopathologic characteristics and follow-up data were retrospectively collected from 556 patients with NMIBC who underwent transurethral resection of bladder tumors by electrocautery (TURBT) from January 2014 to December 2023 at the Affiliated Hospital of Zunyi Medical University and 167 patients with NMIBC who underwent the same procedure from January 2018 to April 2024 at the Third Affiliated Hospital of Zunyi Medical University. Independent risk factors affecting the recurrence of NMIBC were screened using the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis. Cox risk regression models and randomized survival forest (RSF) models were developed. The optimal model was selected by comparing the area under the curve (AUC) of the working characteristics of the subjects in both and presented as a column-line graph. RESULTS: The study included data from 566 patients obtained from the affiliated hospital of Zunyi Medical University and 167 patients obtained from the third affiliated hospital of Zunyi Medical University. Tumor number, urine leukocytes, urine occult blood, platelets, and red blood cell distribution width were confirmed as independent risk factors predicting RFS by Lasso-Cox regression analysis. The Cox proportional risk regression model and RSF model were constructed based on Lasso, which showed good predictive efficacy in both training and validation sets, especially the traditional Cox proportional risk regression model. In addition, the discrimination, consistency, and clinical utility of the column-line graph were assessed using C-index, area under the curve (AUC), calibration curve, and decision curve analysis (DCA). Patients at high risk of recurrence can be identified early based on risk stratification. CONCLUSION: Internal and external validation has demonstrated that the model is highly discriminative and stable and can be used to assess the risk of early recurrence in NMIBC patients and to guide clinical decision-making. CI - Copyright (c) 2025 Tang, Fan, Huang, Yang, Yang, Liao, Zuo, Zhang and Zhang. FAU - Tang, Jiajia AU - Tang J AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Fan, Longmei AU - Fan L AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Huang, Tianyu AU - Huang T AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Yang, Rongrong AU - Yang R AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Yang, Xinqi AU - Yang X AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Liao, Yuanjian AU - Liao Y AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Zuo, Mingshun AU - Zuo M AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Zhang, Neng AU - Zhang N AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. FAU - Zhang, Jiangrong AU - Zhang J AD - School of Nursing, Zunyi Medical University, Zunyi, China. AD - Department of Urology, the Affiliated Hospital of ZunYi Medical University, Zunyi, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20250110 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/diagnosis/mortality MH - Female MH - Male MH - *Neoplasm Recurrence, Local MH - Middle Aged MH - Aged MH - Retrospective Studies MH - Risk Factors MH - Risk Assessment MH - Neoplasm Invasiveness MH - Prognosis MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11757240 OTO - NOTNLM OT - Lasso-Cox regression OT - nomogram OT - non-muscle invasive bladder cancer OT - random forest OT - recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/01/27 11:14 MHDA- 2025/01/27 12:24 PMCR- 2024/01/01 CRDT- 2025/01/27 05:58 PHST- 2024/07/20 00:00 [received] PHST- 2024/12/16 00:00 [accepted] PHST- 2025/01/27 12:24 [medline] PHST- 2025/01/27 11:14 [pubmed] PHST- 2025/01/27 05:58 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1467527 [doi] PST - epublish SO - Front Immunol. 2025 Jan 10;15:1467527. doi: 10.3389/fimmu.2024.1467527. eCollection 2024. PMID- 39865397 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20250827 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 136 IP - 3 DP - 2025 Sep TI - Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer. PG - 429-438 LID - 10.1111/bju.16665 [doi] AB - OBJECTIVES: To evaluate the association of pre- and post-diagnosis fluid intake with non-muscle-invasive bladder cancer (NMIBC) recurrence and progression risk. PATIENTS AND METHODS: Data were used from the multicentre prospective cohort study UroLife. Participants reported pre-diagnosis fluid intake at 6 weeks (food frequency questionnaire [FFQ]) (n = 1322) and post-diagnosis fluid intake at 3 and 15 months (FFQ and 4-day 24-h fluid diaries) (n = 1275) after diagnosis. Multivariable proportional hazard regression models were used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of fluid intake with risk of first and multiple recurrence(s) and progression. RESULTS: During a median overall follow-up of 4.6 years, 474 patients had one or more recurrence and 142 had progression. A higher first recurrence risk was observed for patients with the highest pre-diagnosis fluid intakes (>/=2300 vs 1500-1900 mL/day: HR 1.38, 95% CI 1.07-1.79), but not for those with the highest post-diagnosis fluid intakes. HRs were similar for multiple recurrence risk. For progression, each 150 mL/day increase in both pre- and post-diagnosis fluid intake was consistently associated with an increased risk (post-diagnosis [3 months] FFQ-based: HR 1.05, 95% CI 1.01-1.09 and diary-based: HR 1.04, 95% CI 0.99-1.09). CONCLUSION: High fluid intakes may be associated with higher NMIBC recurrence and especially progression risk. These findings lack a clear explanation but may be related to extensive expansion of the bladder wall or urinary symptoms. Further research is warranted. Meanwhile, these findings do not support recommending high(er) fluid intakes to patients with NMIBC to decrease their recurrence or progression risk. CI - (c) 2025 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Beeren, Ivy AU - Beeren I AUID- ORCID: 0000-0002-8424-7638 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Meijer, Hilde AU - Meijer H AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AUID- ORCID: 0000-0002-8839-8601 AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AUID- ORCID: 0000-0002-0214-2147 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AUID- ORCID: 0000-0002-2368-1326 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng GR - Dutch Cancer Society/ PT - Journal Article PT - Multicenter Study DEP - 20250125 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/epidemiology MH - Male MH - Female MH - *Neoplasm Recurrence, Local/epidemiology MH - Disease Progression MH - Aged MH - Middle Aged MH - *Drinking MH - Prospective Studies MH - Risk Factors MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC12343983 OTO - NOTNLM OT - beverages OT - disease management OT - drinking OT - non-muscle invasive bladder neoplasms OT - prospective studies EDAT- 2025/01/27 00:20 MHDA- 2025/09/08 07:46 PMCR- 2025/08/13 CRDT- 2025/01/26 23:30 PHST- 2025/09/08 07:46 [medline] PHST- 2025/01/27 00:20 [pubmed] PHST- 2025/01/26 23:30 [entrez] PHST- 2025/08/13 00:00 [pmc-release] AID - BJU16665 [pii] AID - 10.1111/bju.16665 [doi] PST - ppublish SO - BJU Int. 2025 Sep;136(3):429-438. doi: 10.1111/bju.16665. Epub 2025 Jan 25. PMID- 39857758 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 1 DP - 2025 Jan 13 TI - Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain. LID - 10.3390/biomedicines13010174 [doi] LID - 174 AB - OBJECTIVES: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guerin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). METHODS: A total of 273 consecutive NMIBC patients who received low-dose (40 mg) or standard-dose (80 mg) BCG intravesical instillation therapy between January 2004 and December 2023 were analyzed. Recurrence-free survival (RFS) rates were assessed using the Kaplan-Meier method with the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were used to identify independent predictors of recurrence based on the Club Urologico Espanol de Tratamiento Oncologico (CUETO) criteria. RESULTS: The log-rank test showed that older age, low BCG dose, number of tumors, and a history of recurrence increased the risk of recurrence significantly. Regarding older patients, recurrence rates were similar between the two dose groups. However, younger patients had significantly lower recurrence rates with standard-dose BCG compared to low-dose BCG. Multiple Cox regression analysis confirmed that older age, low-dose BCG, greater than three tumors, and a history of recurrence were significant predictors of recurrence. CONCLUSIONS: In this study, we found that low-dose BCG induction therapy was associated with higher relapse rates compared with standard doses, especially in younger patients. Age-related differences in the immune response to BCG may influence these relapse patterns. FAU - Isobe, Hideyuki AU - Isobe H AUID- ORCID: 0009-0001-1800-5235 AD - Department of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Shimizu, Fumitaka AU - Shimizu F AUID- ORCID: 0000-0002-4608-7645 AD - Department of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. FAU - Ieda, Takeshi AU - Ieda T AD - Department of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. FAU - Nakamura, So AU - Nakamura S AD - Department of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Takazawa, Naoko AU - Takazawa N AD - Department of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Suetsugu, Hanna AU - Suetsugu H AD - Department of Urology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Kajino, Kazunori AU - Kajino K AD - Department of Pathology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Hirai, Shu AU - Hirai S AD - Department of Pathology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075, Japan. FAU - Hirano, Hisashi AU - Hirano H AD - Department of Urology, Otakanomori Hospital, Chiba 277-0863, Japan. FAU - Yuzawa, Katsuhito AU - Yuzawa K AD - Department of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. FAU - Horie, Shigeo AU - Horie S AD - Department of Urology, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan. LA - eng PT - Journal Article DEP - 20250113 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11762364 OTO - NOTNLM OT - intravesical induction therapy OT - low-dose BCG OT - non-muscle invasive bladder cancer OT - standard-dose BCG COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:52 MHDA- 2025/01/25 13:53 PMCR- 2025/01/13 CRDT- 2025/01/25 01:07 PHST- 2024/12/20 00:00 [received] PHST- 2025/01/10 00:00 [revised] PHST- 2025/01/11 00:00 [accepted] PHST- 2025/01/25 13:53 [medline] PHST- 2025/01/25 13:52 [pubmed] PHST- 2025/01/25 01:07 [entrez] PHST- 2025/01/13 00:00 [pmc-release] AID - biomedicines13010174 [pii] AID - biomedicines-13-00174 [pii] AID - 10.3390/biomedicines13010174 [doi] PST - epublish SO - Biomedicines. 2025 Jan 13;13(1):174. doi: 10.3390/biomedicines13010174. PMID- 39857739 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 1 DP - 2025 Jan 10 TI - Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies. LID - 10.3390/biomedicines13010156 [doi] LID - 156 AB - Background: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette-Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. Methods: We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls. The proliferation and production of cytokines and cytotoxicity were evaluated in peripheral blood mononuclear cells, stimulated in vitro with anti-CD3/CD28 or BCG, from selected patients based on HLA-B -21M/T dimorphism (NKG2A ligands). Results: The HLA-B -21M/T genotype showed opposing results in BC patients treated with BCG or other therapies. The MM genotype, compared to MT and TT, was associated with a longer 75th-percentile overall survival (not reached vs. 68.0 +/- 13.7 and 52.0 +/- 8.3 months, p = 0.034) in BCG, but a shorter (8.0 +/- 2.4 vs. 21.0 +/- 3.4 and 19.0 +/- 4.9 months, p = 0.131) survival in other treatments. The HLA-B -21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, p = 0.01) and the OS (HR = 2.059, p = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. The MM genotype was associated with higher counts of circulating CD56(bright), fewer KIR2DL1/L2(+) NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. Conclusions: The HLA-B -21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients. FAU - Ruiz-Lorente, Inmaculada AU - Ruiz-Lorente I AD - Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Gimeno, Lourdes AU - Gimeno L AUID- ORCID: 0000-0002-3402-5842 AD - Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. AD - Human Anatomy Department, Universidad de Murcia and Campus Mare Nostrum, 30071 Murcia, Spain. FAU - Lopez-Abad, Alicia AU - Lopez-Abad A AUID- ORCID: 0000-0003-1190-2694 AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Lopez Cubillana, Pedro AU - Lopez Cubillana P AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Fernandez Aparicio, Tomas AU - Fernandez Aparicio T AUID- ORCID: 0000-0001-5925-4900 AD - Urology Service, Morales Meseguer Hospital, 30008 Murcia, Spain. FAU - Asensio Egea, Lucas Jesus AU - Asensio Egea LJ AD - Urology Service, De la Vega Lorenzo Guirao Hospital, 30530 Murcia, Spain. FAU - Moreno Aviles, Juan AU - Moreno Aviles J AD - Urology Service, Santa Lucia Hospital, 30202 Murcia, Spain. FAU - Donate Iniguez, Gloria AU - Donate Iniguez G AD - Urology Service, Los Arcos Hospital, 30739 Murcia, Spain. FAU - Guzman Martinez-Valls, Pablo Luis AU - Guzman Martinez-Valls PL AD - Urology Service, Reina Sofia Hospital, 30003 Murcia, Spain. FAU - Server, Gerardo AU - Server G AD - Urology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Ferri, Belen AU - Ferri B AD - Pathology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Campillo, Jose Antonio AU - Campillo JA AD - Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Martinez-Sanchez, Maria Victoria AU - Martinez-Sanchez MV AD - Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. FAU - Minguela, Alfredo AU - Minguela A AUID- ORCID: 0000-0003-2472-5893 AD - Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. LA - eng GR - PI1302297 and PI20_00161/ISCIII-FIS/ GR - 20812-PI-18/Seneca Foundation, Science and Technology Agency from Murcia Region/ GR - L.G/Robles Chillida Foundation, University of Murcia, Campus Mare Nostrum/ GR - AECC PRDMU21540RUIZ/Spanish Association Against Cancer/ PT - Journal Article DEP - 20250110 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11760850 OTO - NOTNLM OT - BCG OT - HLA-E OT - NK cells OT - NKG2A OT - bladder cancer OT - immunotherapy OT - patient outcomes COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:53 MHDA- 2025/01/25 13:54 PMCR- 2025/01/10 CRDT- 2025/01/25 01:07 PHST- 2024/11/13 00:00 [received] PHST- 2024/12/19 00:00 [revised] PHST- 2025/01/08 00:00 [accepted] PHST- 2025/01/25 13:54 [medline] PHST- 2025/01/25 13:53 [pubmed] PHST- 2025/01/25 01:07 [entrez] PHST- 2025/01/10 00:00 [pmc-release] AID - biomedicines13010156 [pii] AID - biomedicines-13-00156 [pii] AID - 10.3390/biomedicines13010156 [doi] PST - epublish SO - Biomedicines. 2025 Jan 10;13(1):156. doi: 10.3390/biomedicines13010156. PMID- 39843302 OWN - NLM STAT- MEDLINE DCOM- 20250320 LR - 20250623 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 87 IP - 4 DP - 2025 Apr TI - Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. PG - 444-452 LID - S0302-2838(24)02759-3 [pii] LID - 10.1016/j.eururo.2024.12.006 [doi] AB - BACKGROUND AND OBJECTIVE: Intravesical instillation of chemotherapy (IIC) after radical surgery for upper urinary tract urothelial carcinoma (UTUC) reduces the risk of intravesical recurrence (IVR). However, compliance is low because of possible extravesical leakage after bladder cuff excision. The aim of this study was to evaluate the efficacy of preoperative IIC in reducing the risk of IVR. METHODS: In this prospective, single-arm, multi-institutional, phase 2 clinical trial, 190 chemonaive patients with primary UTUC without prior or concurrent bladder cancer received a single intravesical instillation of mitomycin C for 1-2 hr within 3 h before surgery. The primary endpoint was the 2-yr histologically confirmed IVR rate, with a target reduction of >40% (from 33.2% according to literature data to <20%). A historical cohort of 247 patients with UTUC who did not receive perioperative IIC served as the reference. Secondary endpoints included compliance, toxicity, and IVR-free survival, which was analyzed via multivariable Cox regression and stratified by previous diagnostic ureteroscopy (d-URS). KEY FINDINGS AND LIMITATIONS: The 2-yr IVR rate was 24% (95% confidence interval [CI] 18-31%) on intention-to-treat analysis and 23% (95% CI 13-32%) on per-protocol analysis. Multivariable analysis revealed that d-URS was associated with higher IVR risk. In the REBACARE cohort, patients without d-URS had threefold lower IVR risk (hazard ratio 0.33, 95% CI 0.12-0.87) in comparison to the reference cohort. Compliance with preoperative instillation was 96% and no grade >2 toxicity occurred. CONCLUSIONS AND CLINICAL IMPLICATIONS: Preoperative IIC with mitomycin C was feasible and well tolerated and significantly reduced IVR risk for patients without d-URS. These findings suggest that preoperative IIC is a viable strategy for this subset of UTUC patients and that d-URS should be performed judiciously. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - van Doeveren, Thomas AU - van Doeveren T AD - Department of Urology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands. Electronic address: t.vandoeveren.1@erasmusmc.nl. FAU - Remmers, Sebastiaan AU - Remmers S AD - Department of Urology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands. FAU - Boeve, Egbert R AU - Boeve ER AD - Department of Urology Franciscus Gasthuis en Vlietland Rotterdam The Netherlands. FAU - Cornel, Erik B AU - Cornel EB AD - Department of Urology Ziekenhuis Groep Twente Hengelo The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology Radboud University Medical Center Nijmegen The Netherlands. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology Netherlands Cancer Institute Amsterdam The Netherlands. FAU - Cauberg, Evelyne C C AU - Cauberg ECC AD - Department of Urology Isala Medical Center Zwolle The Netherlands. FAU - Jacobs, Rens AU - Jacobs R AD - Department of Urology Zuyderland Medical Center Heerlen The Netherlands. FAU - Kroon, Bin K AU - Kroon BK AD - Department of Urology Rijnstate Medical Center Arnhem The Netherlands. FAU - Leliveld, Annemarie M AU - Leliveld AM AD - Department of Urology University Medical Center Groningen Groningen The Netherlands. FAU - Meijer, Richard P AU - Meijer RP AD - Department of Oncological Urology University Medical Center Utrecht Utrecht The Netherlands. FAU - van Melick, Harm AU - van Melick H AD - Department of Urology St. Antonius Ziekenhuis Nieuwegein The Netherlands. FAU - Merks, Bob AU - Merks B AD - Department of Urology Haaglanden Medical Center Leidschendam The Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology Amsterdam UMC University of Amsterdam Amsterdam The Netherlands. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology La Croix du Sud Hospital Quint-Fonsegrives France. FAU - Roelofs, Luc A J AU - Roelofs LAJ AD - Department of Urology Treant Zorggroep Emmen The Netherlands. FAU - Somford, Diederik M AU - Somford DM AD - Department of Urology Canisius Wilhelmina Ziekenhuis Nijmegen The Netherlands. FAU - de Vries, Peter AU - de Vries P AD - Department of Urology Zuyderland Medical Center Heerlen The Netherlands. FAU - Wijsman, Bart AU - Wijsman B AD - Department of Urology Elisabeth-Tweesteden Medical Center Tilburg The Netherlands. FAU - Windt, Willemijn A K M AU - Windt WAKM AD - Department of Urology Martini Ziekenhuis Groningen The Netherlands. FAU - Yska, Marit AU - Yska M AD - Department of Urology Maasstad Ziekenhuis Rotterdam The Netherlands. FAU - Zwaan, Peter J AU - Zwaan PJ AD - Department of Urology Gelre Ziekenhuis Apeldoorn The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department of Research and Development Netherlands Comprehensive Cancer Organization Utrecht The Netherlands; IQ Health Science Department Radboud University Medical Center Nijmegen The Netherlands. FAU - van Leeuwen, Pim J AU - van Leeuwen PJ AD - Department of Urology Netherlands Cancer Institute Amsterdam The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study DEP - 20250122 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 50SG953SK6 (Mitomycin) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - Male MH - Female MH - Administration, Intravesical MH - Aged MH - *Mitomycin/administration & dosage/adverse effects MH - Prospective Studies MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/drug therapy/pathology MH - *Ureteral Neoplasms/surgery/drug therapy/pathology MH - *Kidney Neoplasms/surgery/drug therapy/pathology MH - *Antibiotics, Antineoplastic/administration & dosage/adverse effects MH - *Neoplasm Recurrence, Local/prevention & control OTO - NOTNLM OT - Diagnostic ureteroscopy OT - Intravesical instillation OT - Intravesical recurrence OT - Phase 2 trial OT - Treatment OT - Upper urinary tract urothelial carcinoma EDAT- 2025/01/23 05:15 MHDA- 2025/03/21 00:22 CRDT- 2025/01/22 21:56 PHST- 2024/08/08 00:00 [received] PHST- 2024/12/09 00:00 [revised] PHST- 2024/12/16 00:00 [accepted] PHST- 2025/03/21 00:22 [medline] PHST- 2025/01/23 05:15 [pubmed] PHST- 2025/01/22 21:56 [entrez] AID - S0302-2838(24)02759-3 [pii] AID - 10.1016/j.eururo.2024.12.006 [doi] PST - ppublish SO - Eur Urol. 2025 Apr;87(4):444-452. doi: 10.1016/j.eururo.2024.12.006. Epub 2025 Jan 22. PMID- 39839785 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses. PG - 1509362 LID - 10.3389/fonc.2024.1509362 [doi] LID - 1509362 AB - BACKGROUND: Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current prediction tools for NMIBC recurrence rely on scoring systems that often overestimate risk and lack accuracy. Machine learning (ML) and artificial intelligence (AI) are transforming oncological urology by leveraging molecular and clinical data to enhance predictive precision. METHODS: This comprehensive review critically examines ML-based frameworks for predicting NMIBC recurrence. A systematic literature search was conducted, focusing on the statistical robustness and algorithmic efficacy of studies. These were categorised by data modalities (e.g., radiomics, clinical, histopathological, genomic) and types of ML models, such as neural networks, deep learning, and random forests. Each study was analysed for strengths, weaknesses, performance metrics, and limitations, with emphasis on generalisability, interpretability, and cost-effectiveness. RESULTS: ML algorithms demonstrate significant potential, with neural networks achieving accuracies of 65-97.5%, particularly with multi-modal datasets, and support vector machines averaging around 75%. Models combining multiple data types consistently outperformed single-modality approaches. However, challenges include limited generalisability due to small datasets and the "black-box" nature of advanced models. Efforts to enhance explainability, such as SHapley Additive ExPlanations (SHAP), show promise but require refinement for clinical use. CONCLUSION: This review illuminates the nuances, complexities and contexts that influence the real-world advancement and adoption of these AI-driven techniques in precision oncology. It equips researchers with a deeper understanding of the intricacies of the ML algorithms employed. Actionable insights are provided for refining algorithms, optimising multimodal data utilisation, and bridging the gap between predictive accuracy and clinical utility. This rigorous analysis serves as a roadmap to advance real-world AI applications in oncological care, highlighting the collaborative efforts and robust datasets necessary to translate these advancements into tangible benefits for patient management. CI - Copyright (c) 2025 Abbas, Shafik, Soomro, Heer and Adhikari. FAU - Abbas, Saram AU - Abbas S AD - School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom. FAU - Shafik, Rishad AU - Shafik R AD - School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom. FAU - Soomro, Naeem AU - Soomro N AD - Department of Urology, Freeman Hospital, Newcastle upon Tyne, United Kingdom. FAU - Heer, Rakesh AU - Heer R AD - Division of Surgery, Imperial College London, London, United Kingdom. AD - Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Adhikari, Kabita AU - Adhikari K AD - School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250107 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11746116 OTO - NOTNLM OT - NMIBC OT - artificial intelligence OT - machine learning OT - non-muscle-invasive bladder cancer OT - prediction OT - recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/01/22 06:26 MHDA- 2025/01/22 06:27 PMCR- 2024/01/01 CRDT- 2025/01/22 04:54 PHST- 2024/10/10 00:00 [received] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/22 06:27 [medline] PHST- 2025/01/22 06:26 [pubmed] PHST- 2025/01/22 04:54 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1509362 [doi] PST - epublish SO - Front Oncol. 2025 Jan 7;14:1509362. doi: 10.3389/fonc.2024.1509362. eCollection 2024. PMID- 39835617 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250520 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 32 IP - 5 DP - 2025 May TI - The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association. PG - 508-515 LID - 10.1111/iju.15683 [doi] AB - OBJECTIVES: To evaluate the role of neoadjuvant chemotherapy in the final treatment plan and its impact on survival in bladder cancer patients who were diagnosed with variant histology in the radical cystectomy specimen and whose diagnostic accuracy was achieved with the previous transurethral resection of the bladder specimen. METHODS: In this retrospective multicenter study, data from 221 patients across 9 centers were analyzed between January 2012 and January 2022. The primary endpoint was overall, cancer-specific, recurrence-free, and metastasis-free survival rates among patients with and without neoadjuvant chemotherapy, and the secondary endpoint was to identify independent predictors of survival. The Kaplan-Meier method was used to estimate overall survival, cancer-specific survival, recurrence-free survival, and metastasis-free survival, and multivariate analyses were performed using the Cox-regression model. RESULTS: Kaplan-Meier estimates of overall, cancer-specific, recurrence-free, and metastasis-free survival demonstrated no significant difference between two groups. Cox multifactorial analysis revealed that the age (HR 1.030, 95% CI 1.003-1.057, p = 0.027), presence of pT4 tumor stage (HR 3.861, 95% CI 1.303-11.494, p = 0.015), and pN+ (HR 2.288, 95% CI 1.475-3.550, p < 0.001) at radical cystectomy histopathology were independent predictors of overall survival; presence of pT4 tumor stage and pN+ at radical cystectomy histopathology were independent predictors of cancer-specific survival (HR 8.245, 95% CI 1.873-36.292, p = 0.005 and HR 1.792, 95% CI 1.049-3.061, p = 0.033) and metastasis-free survival (HR 9.957, 95% CI 1.286-77.073, p = 0.028 and HR 2.949, 95% CI 1.674-5.197, p < 0.001); and the age (HR 1.047, 95% CI 1.006-1.090, p = 0.025) and pN+ at radical cystectomy histopathology (HR 4.150, 95% CI 1.917-8.981, p < 0.001) were independent predictors of recurrence-free survival. CONCLUSION: Neoadjuvant chemotherapy does not provide any survival advantage in variant histology; therefore, considering the disadvantages, such as delaying radical cystectomy, which can lead to inadvertent disease progression and chemotherapy-related toxicities, cautious should be exercised when administering neoadjuvant chemotherapy. CI - (c) 2025 The Japanese Urological Association. FAU - Akpinar, Cagri AU - Akpinar C AUID- ORCID: 0000-0002-0288-8272 AD - Department of Urology, School of Medicine, Ankara University, Ankara, Turkey. FAU - Suer, Evren AU - Suer E AUID- ORCID: 0000-0003-4093-5436 AD - Department of Urology, School of Medicine, Ankara University, Ankara, Turkey. FAU - Akdogan, Bulent AU - Akdogan B AD - Department of Urology, School of Medicine, Hacettepe University, Ankara, Turkey. FAU - Izol, Volkan AU - Izol V AD - Department of Urology, School of Medicine, Cukurova University, Adana, Turkey. FAU - Celik, Serdar AU - Celik S AUID- ORCID: 0000-0003-0939-9989 AD - University of Health Sciences Turkey, Izmir Bozyaka Training and Research Hospital, Clinic of Urology, Izmir, Turkey. FAU - Aslan, Guven AU - Aslan G AD - Department of Urology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey. FAU - Akgul, Haci Murat AU - Akgul HM AD - Department of Urology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey. FAU - Bolat, Deniz AU - Bolat D AD - Department of Urology, University of Health Sciences Turkey, Izmir Tepecik Training and Research Hospital, Clinic of Urology, Izmir, Turkey. FAU - Sozen, Sinan AU - Sozen S AD - Department of Urology, Faculty of Medicine, Gazi University, Ankara, Turkey. FAU - Deger, Mutlu AU - Deger M AUID- ORCID: 0000-0002-8357-5744 AD - Department of Urology, School of Medicine, Cukurova University, Adana, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, School of Medicine, Ankara University, Ankara, Turkey. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250121 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Chemotherapy, Adjuvant MH - *Cystectomy/methods MH - Disease-Free Survival MH - Kaplan-Meier Estimate MH - *Neoadjuvant Therapy/methods MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Retrospective Studies MH - Survival Rate MH - Turkey/epidemiology MH - Urinary Bladder/pathology/surgery MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy/diagnosis/surgery/drug therapy OTO - NOTNLM OT - bladder cancer OT - neoadjuvant therapy OT - radical cystectomy OT - variant histology EDAT- 2025/01/21 12:27 MHDA- 2025/04/25 06:28 CRDT- 2025/01/21 07:22 PHST- 2024/08/19 00:00 [received] PHST- 2025/01/08 00:00 [accepted] PHST- 2025/04/25 06:28 [medline] PHST- 2025/01/21 12:27 [pubmed] PHST- 2025/01/21 07:22 [entrez] AID - 10.1111/iju.15683 [doi] PST - ppublish SO - Int J Urol. 2025 May;32(5):508-515. doi: 10.1111/iju.15683. Epub 2025 Jan 21. PMID- 39828834 OWN - NLM STAT- MEDLINE DCOM- 20250119 LR - 20250522 IS - 0030-9982 (Print) IS - 0030-9982 (Linking) VI - 75 IP - 1 DP - 2025 Jan TI - Blue light cystoscopy- as an improvised diagnostic modality for bladder tumours. PG - 84-90 LID - 10.47391/JPMA.20055 [doi] AB - Bladder cancer remains a significant global health concern, being the 10th most common malignancy worldwide and the 6th most common neoplasia in males, with alarming annual incidence and mortality rates. The current narrative review was planned to delve into the multifaceted landscape of bladder cancer, exploring its epidemiology, risk factors and diagnostic modalities. While white light cystoscopy has long been considered the gold standard for bladder cancer diagnosis and surveillance, the emergence of blue light cystoscopy has ushered in a new era of early detection. Numerous studies have demonstrated BLC's superiority in reducing the risk of progression and recurrence of this lethal cancer. However, the widespread adoption of this technology remains elusive. Recent advancements in diagnostic procedures have revolutionised imaging modalities, with blue light cystoscopy and narrow-band imaging emerging as promising replacements for white light cystoscopy. Clinical trials have underscored the superior performance of blue light cystoscopy over white light cystoscopy, with reduced recurrence and progression rates. For non-muscle invasive bladder cancer, Bacillus Calmette-Guerin immunotherapy remains the gold standard adjuvant therapy, while cystectomy is considered for cases resistant to Bacillus Calmette-Guerin or with a high risk of progression. Transurethral resection of bladder tumour followed by intravesical chemotherapy is a key intervention for earlystage bladder cancer. Blue light cystoscopy is poised to overcome the limitations of white light cystoscopy by providing comprehensive visualisation of neoplastic boundaries, particularly benefiting late-detected squamous-type non-muscle invasive urothelial carcinomas associated with lower survival rates. The current findings highlighted the transformative potential of blue light cystoscopy and other emerging diagnostic techniques, offering a ray of hope in the battle against bladder cancer, while emphasising the need for wider adoption and integration into clinical practice. FAU - Mushtaq, Rabeea AU - Mushtaq R AD - Dow Medical College, Karachi, Pakistan. FAU - Samad, Saba AU - Samad S AD - Dow Medical College, Karachi, Pakistan. FAU - Raza, Areeba AU - Raza A AD - Dow Medical College, Karachi, Pakistan. FAU - Raiz, Aiman AU - Raiz A AD - Dow Medical College, Karachi, Pakistan. FAU - Naseem, Hamna AU - Naseem H AD - Dow Medical College, Karachi, Pakistan. FAU - Mushtaq, Naseha AU - Mushtaq N AD - Department of Physiology, Karachi University, Karachi, Pakistan. LA - eng PT - Journal Article PT - Review PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/therapy/diagnostic imaging/pathology/epidemiology MH - *Cystoscopy/methods MH - Narrow Band Imaging/methods MH - BCG Vaccine/therapeutic use MH - Cystectomy MH - Neoplasm Recurrence, Local MH - Early Detection of Cancer/methods MH - Blue Light OTO - NOTNLM OT - Bladder carcinoma, Blue light cystoscopy, White light cystoscopy, Urothelial carcinoma, Non-muscle invasive carcinoma, Narrow-band imaging.. EDAT- 2025/01/20 22:54 MHDA- 2025/01/20 22:55 CRDT- 2025/01/19 23:19 PHST- 2025/01/20 22:55 [medline] PHST- 2025/01/20 22:54 [pubmed] PHST- 2025/01/19 23:19 [entrez] AID - 10.47391/JPMA.20055 [doi] PST - ppublish SO - J Pak Med Assoc. 2025 Jan;75(1):84-90. doi: 10.47391/JPMA.20055. PMID- 39816235 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 13 IP - 12 DP - 2024 Dec 31 TI - Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer Registry vs. data from a detailed research database. PG - 2757-2770 LID - 10.21037/tau-24-454 [doi] AB - BACKGROUND: A previously published study at Norrland University Hospital, Umea, Sweden, found that in 29.5% of patients with urinary bladder cancer (UBC) who underwent cystectomy, incorrect cT-stage (clinical T-stage) was registered in the Swedish National Register of Urinary Bladder Cancer (SNRUBC). Tumor in bladder diverticulum (TIBD) and tumor-associated hydronephrosis (TAH) were common causes for misclassification. Our aim was to further investigate cT-staging, as well as pathoanatomical markers, in the SNRUBC, compared to detailed data from medical records in a larger, retrospective multicenter cohort. Our secondary objective was to describe the frequency of pathoanatomical markers in pathology reports (PAD) after transurethral resection of the bladder (TURb): variant histology (VH), concomitant carcinoma in situ (CIS), lymphovascular invasion (LVI) and perineural invasion (PNI). METHODS: Medical records of 630 patients planned for radical cystectomy in the years 2009-2022 in the Northern Healthcare Region, Region of Gavleborg and Region of Vastmanland were reviewed. Factors impacting risk of misclassification of cT-staging were identified through logistic regression. In TURb pathology reports, all comments on pathoanatomical markers were identified. For each pathoanatomical marker, respectively, comments were then registered as positive or negative. The absence of a comment on a marker was registered as "not commented". RESULTS: A total discrepancy rate of 36.5% was found between validated cT-staging and the SNRUBC, of which 13.3% were upstaged from /=T2. The results are presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Registrations with discrepancy were significantly associated with TIBD (OR: 10.28, 95% CI: 5.20-20.34), TAH (OR: 9.60, 95% CI: 6.12-15.10) and year of cystectomy 2009-2011 (OR: 3.38, 95% CI: 2.13-5.36). Incorrect CIS registration: 134 (35.8%); incorrect histology registration: 98 (25.6%). Total frequencies of recorded pathoanatomical markers in TURb-reports were for VH =23.8%, concomitant CIS =36.9%, LVI =30.4%, PNI =2.3%. CONCLUSIONS: The SNRUBC has a significant prevalence of misclassification of cT-staging with a large proportion due to TAH and TIBD. Misclassification of VH and CIS is also common. Improved guidelines could increase consistency. Total rates of recorded pathoanatomical markers in TURb-reports are low. CI - 2024 AME Publishing Company. All rights reserved. FAU - Wedholm, Albin AU - Wedholm A AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Wiberg, Erik AU - Wiberg E AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Styrke, Johan AU - Styrke J AUID- ORCID: 0000-0001-8455-2010 AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Liden, Oskar AU - Liden O AD - Department of Surgery and Urology, Hudiksvall County Hospital, Hudiksvall, Sweden. FAU - Alamdari, Farhood AU - Alamdari F AUID- ORCID: 0000-0003-3589-7789 AD - Department of Urology, Vastmanland County Hospital, Vasteras, Sweden. FAU - Svensson, Johan AU - Svensson J AUID- ORCID: 0000-0002-8601-0159 AD - Department of Statistics, Umea School of Business, Economics and Statistics (USBE), Umea University, Umea, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden. LA - eng PT - Journal Article DEP - 20241228 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC11732309 OTO - NOTNLM OT - Bladder cancer OT - diverticulum OT - hydronephrosis OT - national registry OT - tumor staging COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-454/coif). A.S. received grant No. Bas-ALF/VLL RV-848051 as funding concerning this project, from The Swedish Research Council funding for clinical research in medicine (ALF) in Vaesterbotten, VLL, Sweden. A.S. also received honorarium as better define for a trial from Bristol Myers Squibb, unrelated to this study. The other authors have no conflicts of interest to declare. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2024/12/31 CRDT- 2025/01/16 04:35 PHST- 2024/08/29 00:00 [received] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:35 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - tau-13-12-2757 [pii] AID - 10.21037/tau-24-454 [doi] PST - ppublish SO - Transl Androl Urol. 2024 Dec 31;13(12):2757-2770. doi: 10.21037/tau-24-454. Epub 2024 Dec 28. PMID- 39816229 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 13 IP - 12 DP - 2024 Dec 31 TI - An 11-gene glycosyltransferases-related model for the prognosis of patients with bladder urothelial carcinoma: development and validation based on TCGA and GEO datasets. PG - 2771-2786 LID - 10.21037/tau-2024-632 [doi] AB - BACKGROUND: Bladder urothelial carcinoma (BLCA) is a highly heterogeneous cancer with a wide range of prognoses, ranging from low-grade non-muscle-invasive bladder cancer (NMIBC), which has a good prognosis but a high recurrence rate, to high-grade muscle-invasive bladder cancer (MIBC), which has a poor prognosis. Glycosylation dysregulation plays a significant role in cancer development. Therefore, this study aimed to investigate the role of glycosyltransferases (GT)-related genes in the prognosis of BLCA and to develop a prognostic model based on these genes to predict overall survival (OS) and assess its clinical application. METHODS: The Cancer Genome Atlas (TCGA)-BLCA dataset, comprising 411 tumor and 19 normal samples. The validation set, GSE13507 from the Gene Expression Omnibus (GEO) database, included 165 primary bladder cancer samples with survival data. Differentially expressed GT-related genes (DEGRGs) in BLCA were identified in the training set. Predictive DEGRGs were used to construct risk score models by univariate Cox regression, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression. The predictive value of the models was assessed using Kaplan-Meier survival analysis and receiver operating characteristic (ROC) analysis in the training and validation sets. A nomogram was developed and its performance was evaluated with calibration curves. In addition, the relationship between the risk score and the tumor immune microenvironment was explored, and tumor immune dysfunction score (TIDE) and immune signature scores were used to predict the response to immunotherapy in BLCA patients. RESULTS: Thirty-three DEGRGs were identified in the comparison of BLCA patients with control samples. A risk score model was constructed based on 11 of these genes (GYS2, GALNTL6, GLT8D2, PYGB, B3GALNT2, GALNT15, ST6GALNAC3, ST8SIA6, CHPF, ALG9 and B3GALT2). The model performed well in predicting 3-, 5-, and 7-year overall survival (OS), with areas under the curve (AUC) of 0.65, 0.67, and 0.68, respectively. In addition, patients in the high-risk group had significantly lower survival than those in the low-risk group, and there were significant differences in immune status between the two groups. Based on age, tumor stage, T stage, and risk score, a Nomogram was constructed to predict the probability of OS, and the results of the calibration curves showed that the model had high predictive accuracy. Further analysis showed that the rejection score and TIDE were higher in the high-risk group, while the GT-related pathway was significantly upregulated in the high-risk group. CONCLUSIONS: The 11 GT-related genes identified were associated with OS in BLCA patients, suggesting that the model has potential predictive value. At the same time, further research is needed to explore its role in clinical practice. CI - 2024 AME Publishing Company. All rights reserved. FAU - Li, Weiping AU - Li W AD - Department of Urology, the First Hospital of Lanzhou University, Lanzhou, China. FAU - Zuo, Kangwei AU - Zuo K AD - Department of Urology, the First Hospital of Lanzhou University, Lanzhou, China. FAU - Zhao, Qi AU - Zhao Q AD - Department of Urology, the First Hospital of Lanzhou University, Lanzhou, China. FAU - Guo, Chenhao AU - Guo C AD - Institute of Urology, Lanzhou University Second Hospital, Lanzhou, China. FAU - Liu, Zirong AU - Liu Z AD - William Marsh Rice University, Houston, TX, USA. FAU - Liu, Cheng AU - Liu C AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Jing, Suoshi AU - Jing S AUID- ORCID: 0000-0002-7194-5293 AD - Department of Urology, the First Hospital of Lanzhou University, Lanzhou, China. LA - eng PT - Journal Article DEP - 20241228 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC11732298 OTO - NOTNLM OT - Bladder urothelial carcinoma (BLCA) OT - biomarkers OT - glycosyltransferases (GT) OT - immune microenvironment OT - prognosis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-632/coif). The authors have no conflicts of interest to declare. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2024/12/31 CRDT- 2025/01/16 04:35 PHST- 2024/11/06 00:00 [received] PHST- 2024/12/21 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:35 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - tau-13-12-2771 [pii] AID - 10.21037/tau-2024-632 [doi] PST - ppublish SO - Transl Androl Urol. 2024 Dec 31;13(12):2771-2786. doi: 10.21037/tau-2024-632. Epub 2024 Dec 28. PMID- 39816220 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250116 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 13 IP - 12 DP - 2024 Dec 31 TI - Clinicopathologic features and prognosis of incidental prostate cancer after radical cysto-prostatectomy: a comparative study between China and the West. PG - 2694-2704 LID - 10.21037/tau-24-441 [doi] AB - BACKGROUND: Bladder cancer (BCa) is one of the most common tumors of the urinary system, imposing a significant societal burden. BCa is categorized into muscle-invasive BCa (MIBC) and non-MIBC (NMIBC) types. Radical cystoprostatectomy (RCP) is the standard treatment for MIBC and refractory NMIBC, but it can lead to serious side effects. Incidental prostate cancer (IPCa) is frequently found in RCP specimens, with varying incidence rates across ethnic groups, ranging from 7.3% to 60%. The clinical significance is unclear, and disparities in incidence and tumor characteristics exist within the Chinese population. The impact of IPCa on survival is debated, highlighting the need for research on its incidence and pathology for tailored interventions. This study aimed to compare the clinicopathological characteristics and prognostic significance of IPCa in RCP specimens taken from Chinese and Western BCa populations. METHODS: Data from patients who underwent RCP in our hospital between 2008 and 2022 were collated and compared to data from the Surveillance, Epidemiology, and End Results (SEER) database between 2008 and 2019. Chi-squared and non-parametric testing were conducted with survival analysis to investigate differences between IPCa traits and their impact on prognosis. RESULTS: Twenty-four IPCa cases were detected in 300 patients undergoing RCP, with a median age of 73 [interquartile range (IQR), 67-77] years. The median prostate-specific antigen (PSA) value was 2.81 (IQR, 1.19-4.81) ng/mL. 66.6% (n=16) had Gleason score (GS) /=18 years who presented with hematuria and had suspected BC based on imaging findings. Patients with a history of intravesical chemotherapy, radiotherapy and immunotherapy were excluded. Urine samples were collected prior to the cystoscopy. Detection of urinary CYFRA21-1 was carried out using the enzyme-linked immunosorbent assay (ELISA) method. Of 154 patients included in the study, the diagnosis of BC was confirmed in 92 patients. Patients with BC had significantly higher urinary CYFRA21-1 levels compared to the non-bladder cancer group. The sensitivity, specificity, positive and negative predictive value, and positive likelihood ratio of the CYFRA21-1 were 80.4%, 43.5%, 67.9%, 60% and 1.425, respectively. The area under the curve (AUC) for CYFRA21-1 was 0.608, computed from a receiver operating curve (ROC) with a cut-off value of 13.3 ng/mL. In conclusion, urinary CYFRA21-1 levels have moderate diagnostic accuracy in determining BC among suspected individuals. Due to its high sensitivity, this biomarker could potentially be used alongside other screening tools for BC detection. CI - (c) 2024 The Author(s). FAU - Setianingsih, Yennie A AU - Setianingsih YA AD - Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Department of Urology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Djatisoesanto, Wahjoe AU - Djatisoesanto W AD - Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Department of Urology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Laksita, Tetuka B AU - Laksita TB AD - Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. AD - Department of Urology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. FAU - Aryati, Aryati AU - Aryati A AD - Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. LA - eng PT - Journal Article DEP - 20241024 PL - Indonesia TA - Narra J JT - Narra J JID - 9918625888906676 RN - 0 (Keratin-19) RN - 0 (antigen CYFRA21.1) RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/urine MH - *Keratin-19/urine MH - Female MH - Male MH - *Antigens, Neoplasm/urine MH - Middle Aged MH - Cross-Sectional Studies MH - Aged MH - *Biomarkers, Tumor/urine MH - Adult MH - Sensitivity and Specificity MH - Aged, 80 and over MH - Enzyme-Linked Immunosorbent Assay PMC - PMC11731656 OTO - NOTNLM OT - Bladder cancer OT - CYFRA21-1 OT - diagnostic accuracy OT - tumor marker OT - urinary biomarker COIS- All the authors declare that they have no known conflicts of interest. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2024/10/24 CRDT- 2025/01/16 04:34 PHST- 2024/07/09 00:00 [received] PHST- 2024/10/13 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:34 [entrez] PHST- 2024/10/24 00:00 [pmc-release] AID - NarraJ-4-e1142 [pii] AID - 10.52225/narra.v4i3.1142 [doi] PST - ppublish SO - Narra J. 2024 Dec;4(3):e1142. doi: 10.52225/narra.v4i3.1142. Epub 2024 Oct 24. PMID- 39811386 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250116 IS - 1643-8876 (Print) IS - 2299-0038 (Electronic) IS - 1643-8876 (Linking) VI - 23 IP - 4 DP - 2024 Dec TI - Mullerianosis of the urinary bladder in pre- and postmenopausal women: a literature review. PG - 216-224 LID - 10.5114/pm.2024.145955 [doi] AB - Mullerianosis of the urinary bladder is a rare pathological condition involving ectopic Mullerian-derived tissues within the bladder. Despite its benign nature, due to its ability to mimic malignant conditions such as bladder carcinoma, diagnosis might be challenging. In this review, data from 36 cases across 32 studies were analyzed, focusing on patient demographics, symptomatology, diagnostic imaging, and histopathological features. The average patient age was 42.4 years. Common symptoms included dysuria, hematuria, and pelvic pain. Diagnostic challenges arise from the nonspecific nature of symptoms and imaging findings, making histopathological confirmation necessary. Surgical treatment is mainly involved, with transurethral resection being the most common approach. In some cases, hormonal therapy is also explored. While the prognosis is generally favorable, recurrence is possible, emphasizing the need for long-term follow-up. The review underscores the importance of early diagnosis and individualized management strategies to improve patient outcomes. CI - Copyright (c) 2024 Termedia. FAU - Diamantidis, Dimitrios AU - Diamantidis D AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Tsakaldimis, Georgios AU - Tsakaldimis G AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Lailisidis, Stavros AU - Lailisidis S AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Deligeorgiou, Evangelia AU - Deligeorgiou E AD - Department of Pathology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Panagiotopoulos, Nikolaos AU - Panagiotopoulos N AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Kritsotaki, Nektraria AU - Kritsotaki N AD - Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Kafalis, Charalampos AU - Kafalis C AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Chousein, Chousein AU - Chousein C AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Giannakopoulos, Stilianos AU - Giannakopoulos S AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Kalaitzis, Christos AU - Kalaitzis C AD - Department of Urology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. LA - eng PT - Journal Article PT - Review DEP - 20241222 PL - Poland TA - Prz Menopauzalny JT - Przeglad menopauzalny = Menopause review JID - 101263235 PMC - PMC11726190 OTO - NOTNLM OT - Mullerianosis of the urinary bladder OT - endocervicosis OT - endometriosis OT - endosalpingiosis COIS- None. EDAT- 2025/01/15 06:20 MHDA- 2025/01/15 06:21 PMCR- 2024/12/01 CRDT- 2025/01/15 04:47 PHST- 2024/09/22 00:00 [received] PHST- 2024/11/30 00:00 [accepted] PHST- 2025/01/15 06:21 [medline] PHST- 2025/01/15 06:20 [pubmed] PHST- 2025/01/15 04:47 [entrez] PHST- 2024/12/01 00:00 [pmc-release] AID - 55357 [pii] AID - 10.5114/pm.2024.145955 [doi] PST - ppublish SO - Prz Menopauzalny. 2024 Dec;23(4):216-224. doi: 10.5114/pm.2024.145955. Epub 2024 Dec 22. PMID- 39808304 OWN - NLM STAT- MEDLINE DCOM- 20250501 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jan 14 TI - Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy. PG - 71 LID - 10.1007/s00345-024-05436-w [doi] AB - PURPOSES: This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guerin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra. METHODS: Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, >/= 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra. RESULTS: The median follow-up period was 57 months (interquartile range, 30-85 months). The exact T stage of the patients with UC of the prostatic urethra was carcinoma in situ (CIS) in 29 (27 in the prostatic urethral mucosa and two in the ductal spread), Ta in 7, Ta + CIS in 2, and T1 in 1. All 39 patients had previous or concurrent bladder cancer. Patients with UC of the prostatic urethra experienced significantly higher rates of intravesical recurrence, progression (MIBC or metastasis), and subsequent radical cystectomy than those without UC of the prostatic urethra. In the multivariate analysis, UC of the prostatic urethra was a significant risk factor for progression (hazard ratio 4.06, 95% confidence interval 1.86-8.86, p < 0.001). CONCLUSIONS: This study reported the largest number of clinical outcomes after BCG treatment in patients with UC of the prostatic urethra. Concomitant UC of the prostatic urethra is a strong predictor of subsequent progression; therefore, early timing of radical cystectomy should be discussed. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yamashita, Ryo AU - Yamashita R AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. r.yamashita@scchr.jp. FAU - Sugino, Takashi AU - Sugino T AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Notsu, Akifumi AU - Notsu A AD - Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Ito, Kana AU - Ito K AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. FAU - Sakura, Yuma AU - Sakura Y AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. FAU - Shinsaka, Hideo AU - Shinsaka H AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. FAU - Matsuzaki, Masato AU - Matsuzaki M AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. FAU - Niwakawa, Masashi AU - Niwakawa M AD - Division of Urology, Shizuoka Cancer Center, Shizuoka, 1007, Shimonagakubo, Suntougun, Nagaizumi, Shizuoka, 411-8777, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Saint Marianna University School of Medicine, Kawasaki, Japan. LA - eng PT - Journal Article DEP - 20250114 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - World J Urol. 2025 Mar 10;43(1):156. doi: 10.1007/s00345-025-05482-y. PMID: 40063282 MH - Humans MH - *BCG Vaccine/therapeutic use MH - Male MH - *Cystectomy MH - Aged MH - *Urethral Neoplasms/drug therapy/pathology/surgery MH - *Adjuvants, Immunologic/therapeutic use MH - *Carcinoma, Transitional Cell/drug therapy/surgery/pathology MH - Middle Aged MH - Treatment Outcome MH - Retrospective Studies MH - Urinary Bladder Neoplasms MH - Aged, 80 and over MH - Neoplasm Recurrence, Local/epidemiology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Metastasis OT - Prostatic urethra OT - Urothelial carcinoma COIS- Declarations. Conflict of interest: The authors declare no conflict of interests. Informed consent: The requirement for informed consent was waived owing to the retrospective nature of this study. The study information was placed on the hospital's homepage to provide the means to opt out. Approval of the research protocol by an institutional reviewer board: This single-center study was approved by the Institutional Review Board of Shizuoka Cancer Center (J2023-170-2023-1-3). Animal studies: Not applicable. EDAT- 2025/01/14 12:34 MHDA- 2025/01/14 12:35 CRDT- 2025/01/14 11:14 PHST- 2024/10/30 00:00 [received] PHST- 2024/12/31 00:00 [accepted] PHST- 2025/01/14 12:35 [medline] PHST- 2025/01/14 12:34 [pubmed] PHST- 2025/01/14 11:14 [entrez] AID - 10.1007/s00345-024-05436-w [pii] AID - 10.1007/s00345-024-05436-w [doi] PST - epublish SO - World J Urol. 2025 Jan 14;43(1):71. doi: 10.1007/s00345-024-05436-w. PMID- 39800632 OWN - NLM STAT- MEDLINE DCOM- 20250517 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 6 DP - 2025 Jun TI - Study of urine-based mRNA biomarkers for early detection of nonmuscle invasive bladder cancer (NMIBC). PG - 393.e9-393.e17 LID - S1078-1439(24)01050-0 [pii] LID - 10.1016/j.urolonc.2024.12.273 [doi] AB - BACKGROUND AND OBJECTIVE: Research into new noninvasive diagnostic tools for bladder cancer (BCa) with superior sensitivity and specificity to cystoscopy and cytology is promising. The current study evaluated a diagnostic panel of tumor progression-related mRNAs in urine samples of NMIBC patients and controls. METHODS: This study carefully selected 129 participants, including 67 NMIBC patients, 31 hematuria patients due to nonmalignant urological disorders, and 31 healthy individuals. Subsequently, ten significantly dysregulated mRNAs were identified in the urine specimens of these participants using RT-qPCR. KEY FINDINGS: Expression levels of CA9, CDK1, CD24, TERT, CEP55, TOP2A, IQGAP3, UBE2C, and CRH in urine samples from NMIBC patients were higher than those in healthy individuals. Notably, CD24, TOP2A, IQGAP3, UBE2C, and CRH mRNA levels in NMIBC patients were significantly higher than in the hematuria group. In diagnosing low-grade from healthy and hematuria groups, analysis of the 5-gene profile yielded a sensitivity of 98 % and a specificity of 100 % and 90 %, respectively. For diagnosing high-grade tumors from healthy and hematuria groups, sensitivity was 96 % and 100 %, and specificity was 100 % and 83 %, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: These results emphasize the potential application of urine mRNA profiling in the early diagnosis of NMIBC and provide new insights into the molecular mechanisms involved. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Abazari, Omid AU - Abazari O AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - Shahidi, Maryamsadat AU - Shahidi M AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - Dayati, Parisa AU - Dayati P AD - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Valizadeh, Sahar AU - Valizadeh S AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - Vahidi, Serajoddin AU - Vahidi S AD - Andrology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. FAU - Tafti, Mahmood Akhavan AU - Tafti MA AD - Department of Pathology, School of Medicine, Shahid Sadoughi University of Medical Sciences. Yazd, Iran. FAU - Zavarreza, Javad AU - Zavarreza J AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Electronic address: jzavar@ssu.ac.ir. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250111 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (RNA, Messenger) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/diagnosis/genetics/pathology MH - *RNA, Messenger/urine/genetics MH - Female MH - Male MH - *Biomarkers, Tumor/urine/genetics MH - Middle Aged MH - *Early Detection of Cancer/methods MH - Aged MH - Case-Control Studies MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Biomarkers OT - NMIBC OT - Urine OT - mRNA COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/13 00:20 MHDA- 2025/05/18 17:01 CRDT- 2025/01/12 22:02 PHST- 2024/10/08 00:00 [received] PHST- 2024/11/25 00:00 [revised] PHST- 2024/12/24 00:00 [accepted] PHST- 2025/05/18 17:01 [medline] PHST- 2025/01/13 00:20 [pubmed] PHST- 2025/01/12 22:02 [entrez] AID - S1078-1439(24)01050-0 [pii] AID - 10.1016/j.urolonc.2024.12.273 [doi] PST - ppublish SO - Urol Oncol. 2025 Jun;43(6):393.e9-393.e17. doi: 10.1016/j.urolonc.2024.12.273. Epub 2025 Jan 11. PMID- 39798618 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20251018 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 199 DP - 2025 May TI - A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological Outcomes. PG - 171-178 LID - S0090-4295(25)00006-8 [pii] LID - 10.1016/j.urology.2025.01.004 [doi] AB - This study evaluated the efficacy, recurrence rates, and safety of intravesical gemcitabine plus docetaxel compared to standard Bacillus Calmette-Guerin (BCG) therapy for treating naive non-muscle-invasive bladder cancer (NMIBC), with a focus on reducing recurrence and progression concerns associated with transurethral resection (TURBT). A systematic review and meta-analysis of three original studies were conducted, assessing recurrence rates and safety profiles. The meta-analysis revealed no heterogeneity in recurrence rates between the gemcitabine plus docetaxel and BCG groups, with an overall Odds Ratio for recurrence of 0.72 (95% CI: 0.36-1.47). Although the clinical recurrence rate was slightly lower in the gemcitabine plus docetaxel group, the difference was not statistically significant (Z = 0.89, P = 0.37). The gemcitabine plus docetaxel group experienced fewer severe side effects compared to the BCG group. Due to the limited number of studies available, further randomized trials are necessary to confirm the role of intravesical gemcitabine plus docetaxel in NMIBC management. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Tripathy, Rachana AU - Tripathy R AD - Department of Obstetrics & Gynaecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Lalit AU - Kumar L AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Electronic address: lalitkumarims@bhu.ac.in. FAU - Agarwal, Sakshi AU - Agarwal S AD - Department of Obstetrics & Gynaecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Thakur, Anuja AU - Thakur A AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Khairnar, Mahesh AU - Khairnar M AD - Faculty of Dental Science, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Trivedi, Sameer AU - Trivedi S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Sankhwar, Satya N AU - Sankhwar SN AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20250109 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Urology. 2025 May;199:179-180. doi: 10.1016/j.urology.2025.02.001. PMID: 39938601 CIN - Urology. 2025 May;199:181. doi: 10.1016/j.urology.2025.02.015. PMID: 39983790 CIN - Urology. 2025 Oct;204:356-357. doi: 10.1016/j.urology.2025.05.047. PMID: 40449667 CIN - Urology. 2025 Oct;204:358-359. doi: 10.1016/j.urology.2025.06.027. PMID: 40532978 MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Administration, Intravesical MH - *Docetaxel/administration & dosage MH - *BCG Vaccine/administration & dosage MH - Adjuvants, Immunologic/administration & dosage MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Neoplasm Recurrence, Local/epidemiology MH - *Antineoplastic Combined Chemotherapy Protocols/administration & dosage COIS- Declaration of Competing Interest The authors have no conflict of interest to declare. EDAT- 2025/01/12 15:21 MHDA- 2025/05/09 11:51 CRDT- 2025/01/11 19:25 PHST- 2024/11/01 00:00 [received] PHST- 2024/12/13 00:00 [revised] PHST- 2025/01/02 00:00 [accepted] PHST- 2025/05/09 11:51 [medline] PHST- 2025/01/12 15:21 [pubmed] PHST- 2025/01/11 19:25 [entrez] AID - S0090-4295(25)00006-8 [pii] AID - 10.1016/j.urology.2025.01.004 [doi] PST - ppublish SO - Urology. 2025 May;199:171-178. doi: 10.1016/j.urology.2025.01.004. Epub 2025 Jan 9. PMID- 39798182 OWN - NLM STAT- MEDLINE DCOM- 20250430 LR - 20250521 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 2 DP - 2025 Apr TI - Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer. PG - 102290 LID - S1558-7673(24)00260-X [pii] LID - 10.1016/j.clgc.2024.102290 [doi] AB - OBJECTIVE: To evaluate the oncological outcomes of selective bladder preservation therapy, comprising maximal TURBT plus neoadjuvant chemotherapy (NAC) followed by 2nd-TURBT. METHODS: From 2012 to 2022, 110 localized muscle-invasive bladder cancer patients who desired bladder preservation (BP) received maximal TURBT plus NAC followed by restaging (CT scan+ 1st-TURBT) and 2nd-TURBT. Sixty-one patients with pure urothelial carcinoma of the urinary bladder (PUCUB) who achieved noninvasive downstaging (NID) after NAC and had no residual tumor at 2nd-TURBT underwent conservative treatment (BP group). Overall survival (OS), cancer-specific survival (CSS), distant metastasis-free survival (DMFS), and cystectomy and distant metastasis-free survival (CDMFS) were estimated using the Kaplan-Meyer method. Propensity score matching was performed to compare the survival outcomes of patients in the BP group with those who underwent NAC + radical cystectomy (RC) and were diagnosed with ypT1 or less (RC group, n = 42). Multivariable Cox regression (MCR) models addressed survivals according to each treatment method. RESULTS: In the BP group, 5-year OS, CSS, DMFS, and CDMFS were 87.4%, 93.8%, 83.1%, and 76.8%, respectively. MCR models for survival showed no differences in OS (BP: hazard ratio [HR] 1.24, P = .83), CSS (BP: HR 1.15, P = .74), and DMFS (BP: HR 1.09, P = .91) between the matched cohort. CONCLUSIONS: BP therapy incorporating maximal TURBT plus NAC followed by 2nd-TURBT may be used as an alternative therapy to RC for selected muscle-invasive PUCUB patients. As this was a retrospective study, further randomized trials with longer follow-up are needed. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Onishi, Takehisa AU - Onishi T AD - Department of Urology, Ise Red Cross Hospital, Ise, Japan. Electronic address: iseredcrossuro@gmail.com. FAU - Shibahara, Takuji AU - Shibahara T AD - Department of Urology, Ise Red Cross Hospital, Ise, Japan. FAU - Sekito, Sho AU - Sekito S AD - Department of Urology, Ise Red Cross Hospital, Ise, Japan. FAU - Kato, Manabu AU - Kato M AD - Department of Urology, Aichi Cancer Center, Nagoya, Japan. FAU - Sugino, Yusuke AU - Sugino Y AD - Department of Urology, Mie University hospital, Tsu, Japan. FAU - Inoue, Takahiro AU - Inoue T AD - Department of Urology, Mie University hospital, Tsu, Japan. LA - eng PT - Journal Article DEP - 20241210 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality/surgery/drug therapy MH - Male MH - Female MH - *Cystectomy/methods MH - Aged MH - Middle Aged MH - Neoadjuvant Therapy/methods MH - Feasibility Studies MH - Retrospective Studies MH - *Organ Sparing Treatments/methods MH - Neoplasm Staging MH - Neoplasm Invasiveness MH - Treatment Outcome MH - *Carcinoma, Transitional Cell/therapy/pathology/mortality MH - Urinary Bladder/surgery/pathology MH - Chemotherapy, Adjuvant MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Transurethral Resection of Bladder OTO - NOTNLM OT - Conservative treatment OT - Maximal TURBT OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Re-staging COIS- Disclosure Authors have no potential conflict of interest. EDAT- 2025/01/12 15:21 MHDA- 2025/03/14 11:23 CRDT- 2025/01/11 18:00 PHST- 2024/09/19 00:00 [received] PHST- 2024/10/15 00:00 [revised] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/03/14 11:23 [medline] PHST- 2025/01/12 15:21 [pubmed] PHST- 2025/01/11 18:00 [entrez] AID - S1558-7673(24)00260-X [pii] AID - 10.1016/j.clgc.2024.102290 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Apr;23(2):102290. doi: 10.1016/j.clgc.2024.102290. Epub 2024 Dec 10. PMID- 39795587 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250113 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 1 DP - 2024 Dec 29 TI - CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer. LID - 10.3390/diagnostics15010059 [doi] LID - 59 AB - Background: Bladder cancer (BC) is one of the ten most common cancers worldwide, with a high recurrence rate and significant variation in clinical outcomes based on tumor grade and stage. This study aimed to investigate the gene expression profiles at different cancer stages to assess their potential prognostic value. Methods: RNA was extracted from paraffin-embedded BC tissues and the gene expression levels of CDC20 and CCNB1 were analyzed using qRT-PCR. A total of 54 BC patient samples were included in the analysis and categorized into low-grade (LG) (n = 23) and high-grade (HG) (n = 31) tumors, as well as stages pTa, pT1, and pT2. Results: CDC20 gene expression was significantly higher in the HG group (mean fold-change: 16.1) compared to the LG group (mean fold-change: 10.54), indicating a significant association with tumor grade (p = 0.039). However, no significant differences were observed in CDC20 expression across the cancer stages. For CCNB1, while gene expression was significantly elevated in higher-stage tumors (pT2 vs. pTa; p = 0.038), no significant association was found between CCNB1 expression and tumor grade. Survival analysis revealed that increased CCNB1 expression and advanced cancer stage were associated with poorer overall survival, whereas no significant impact of CDC20 expression or tumor grade on survival was observed. Correlation analysis indicated a positive relationship between CDC20 expression and tumor grade (r = 0.284, p = 0.038) and between CCNB1 expression and tumor stage (r = 0.301, p = 0.027). Conclusions: Our findings suggest that CDC20 overexpression is linked to higher tumor grades, while CCNB1 overexpression is associated with more advanced cancer stages in BC. These results underscore the potential utility of CDC20 and CCNB1 as biomarkers for tumor prognosis and as therapeutic targets. Further studies with larger cohorts are needed to validate these findings and better understand the molecular mechanisms driving BC progression. FAU - Sevim Nalkiran, Hatice AU - Sevim Nalkiran H AUID- ORCID: 0000-0002-1115-2005 AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. FAU - Biri, Ilknur AU - Biri I AUID- ORCID: 0009-0009-5040-2167 AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. FAU - Nalkiran, Ihsan AU - Nalkiran I AUID- ORCID: 0000-0002-7246-2592 AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. FAU - Uzun, Hakki AU - Uzun H AUID- ORCID: 0000-0002-5189-3166 AD - Department of Urology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. FAU - Durur, Sumeyye AU - Durur S AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. FAU - Bedir, Recep AU - Bedir R AD - Department of Medical Pathology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkiye. LA - eng PT - Journal Article DEP - 20241229 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11719780 OTO - NOTNLM OT - CDC20 OT - Cyclin B1 OT - bladder cancer OT - cancer stage OT - overall survival OT - tumor grade COIS- The authors declare no conflicts of interest. EDAT- 2025/01/11 14:01 MHDA- 2025/01/11 14:02 PMCR- 2024/12/29 CRDT- 2025/01/11 01:05 PHST- 2024/10/18 00:00 [received] PHST- 2024/12/05 00:00 [revised] PHST- 2024/12/27 00:00 [accepted] PHST- 2025/01/11 14:02 [medline] PHST- 2025/01/11 14:01 [pubmed] PHST- 2025/01/11 01:05 [entrez] PHST- 2024/12/29 00:00 [pmc-release] AID - diagnostics15010059 [pii] AID - diagnostics-15-00059 [pii] AID - 10.3390/diagnostics15010059 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Dec 29;15(1):59. doi: 10.3390/diagnostics15010059. PMID- 39777731 OWN - NLM STAT- MEDLINE DCOM- 20250408 LR - 20250408 IS - 2444-054X (Electronic) IS - 0009-7411 (Linking) VI - 93 IP - 2 DP - 2025 Jan 8 TI - Do the inflammatory markers have a prognostic role in an elderly patient population diagnosed with non-muscle invasive bladder cancer? PG - 202-210 LID - 10.24875/CIRU.23000278 [doi] AB - OBJECTIVE: To evaluate whether the systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and De-Ritis ratio (DRR) are determinants of progression-free survival (PFS), recurrence-free survival (RFS) and overall survival (OS) in patients aged >/= 70 years diagnosed with non-muscle invasive bladder cancer (NMIBC). METHOD: The study included 173 elderly patients diagnosed with NMIBC between January 2015 and March 2022. The clinical and pathological data of the patients were examined. Cox regression analysis was performed. RESULTS: The patient's mean age was 75.6 +/- 4.57 years. A statistically significant correlation was determined between higher mean NLR, PLR, and SII values and PFS (p = 0.04, p = 0.009, and p = 0.007, respectively) and OS (p = 0.001, p = 0.003, and p < 0.001, respectively). The multivariate analysis results showed that tumor size (>/= 3 cm) and PLR (> 144.6) were independent risk factors for PFS (HR: 2.09, p = 0.03; HR:3.2, p = 0.01, respectively), the presence of multiple tumors for RFS (HR: 1.73, p = 0.01), and comorbid diseases for OS (HR: 2.18, p = 0.006). CONCLUSION: Inflammatory parameters were found to have no independent effects on RFS and OS in patients of advanced age with NMIBC, and only PLR could be used to predict PFS. FAU - Demirci, Aykut AU - Demirci A AD - Department of Urology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. FAU - Uzel, Tuncel AU - Uzel T AD - Department of Urology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. FAU - Bolat, Abdullah AU - Bolat A AD - Department of Urology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. FAU - Basar, Halil AU - Basar H AD - Department of Urology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20250108 PL - Mexico TA - Cir Cir JT - Cirugia y cirujanos JID - 0372736 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/blood/mortality/immunology MH - Aged MH - Male MH - Female MH - Prognosis MH - Aged, 80 and over MH - Lymphocyte Count MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Neutrophils MH - Platelet Count MH - Progression-Free Survival MH - Inflammation/blood MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder Cancer. Systemic immune-inflammation index. The neutrophil-lymphocyte ratio. Platelet-lymphocyte ratio. De-Ritis ratio. EDAT- 2025/01/09 00:23 MHDA- 2025/04/09 10:13 CRDT- 2025/01/08 18:24 PHST- 2025/04/09 10:13 [medline] PHST- 2025/01/09 00:23 [pubmed] PHST- 2025/01/08 18:24 [entrez] AID - 10.24875/CIRU.23000278 [doi] PST - epublish SO - Cir Cir. 2025 Jan 8;93(2):202-210. doi: 10.24875/CIRU.23000278. PMID- 39774140 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20261006 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 49 IP - 2 DP - 2025 Feb 1 TI - A Proposal for Revised and Simplified Renal Pelvic Urothelial Carcinoma Staging Criteria: A Clinicopathologic Study of 141 Tumors. PG - 113-120 LID - 10.1097/PAS.0000000000002331 [doi] AB - Staging of renal pelvic urothelial carcinoma can be challenging due to anatomic variation at the renal pelvis compared with ureter and bladder and calls into question the prognostic accuracy of the current TNM staging. In this study, we determined staging and cancer-specific survival (CSS) in 141 patients undergoing nephroureterectomy for renal pelvic urothelial carcinoma (pTa=50, pT1=29, pT2=10, pT3=36, and pT4=16). Under current staging criteria, we found no significant difference in CSS between adjacent staging categories step-wise across pTa, pT1, pT2, and pT3 tumors. When pT3 tumors were subcategorized into renal medulla, peripelvic adipose, or renal cortex invasion with or without peripelvic adipose invasion, we found that cortical invasion was associated with significantly worse CSS compared with medulla or peripelvic adipose invasion only. We next revised staging criteria such that pT1 correlated with invasion of lamina or muscularis propria (n=37), T2 with invasion of medulla or peripelvic adipose only (n=26), and pT3 with cortical invasion (n=12). Under the new criteria, better separation of survival curves was achieved; however, pT1 and pT2 remained statistically insignificant. When further redefining pT3 as invasive of cortex only (n=12) and combining medulla with lamina and muscularis propria invasion as a lower stage (pT1, n=63), there was further improvement in the prognostic stratification. Therefore, our data show that consideration of revised and simplified T staging criteria at the renal pelvis is warranted, wherein invasion of any anatomic structure up to the cortex shows a similar prognosis (combined pT1 category) and invasion of cortex showing significantly worse prognosis (pT3). CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Machacek, Miranda E AU - Machacek ME AUID- ORCID: 0000-0003-1067-0561 AD - Department of Pathology, Massachusetts General Hospital. FAU - Wang, Hanzhang AU - Wang H AD - Department of Pathology, Massachusetts General Hospital. FAU - Devins, Kyle AU - Devins K AD - Department of Pathology, Massachusetts General Hospital. FAU - Sadow, Peter M AU - Sadow PM AD - Department of Pathology, Massachusetts General Hospital. FAU - Wu, Chin-Lee AU - Wu CL AD - Department of Pathology, Massachusetts General Hospital. FAU - Oliva, Esther AU - Oliva E AD - Department of Pathology, Massachusetts General Hospital. FAU - Saylor, Philip J AU - Saylor PJ AD - Department of Medicine, Massachusetts General Hospital Cancer, Boston, MA. FAU - Cornejo, Kristine M AU - Cornejo KM AD - Department of Pathology, Massachusetts General Hospital. LA - eng PT - Journal Article DEP - 20241114 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Humans MH - Female MH - *Neoplasm Staging/methods/standards MH - Male MH - *Kidney Neoplasms/pathology/mortality/surgery MH - Aged MH - Middle Aged MH - *Kidney Pelvis/pathology/surgery MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - *Urothelium/pathology/surgery MH - Adult MH - Predictive Value of Tests MH - *Carcinoma, Transitional Cell/mortality/pathology/surgery MH - Nephroureterectomy MH - Retrospective Studies MH - Prognosis COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2025/01/08 18:22 MHDA- 2025/01/15 06:21 CRDT- 2025/01/08 15:51 PHST- 2025/01/15 06:21 [medline] PHST- 2025/01/08 18:22 [pubmed] PHST- 2025/01/08 15:51 [entrez] AID - 00000478-990000000-00438 [pii] AID - 10.1097/PAS.0000000000002331 [doi] PST - ppublish SO - Am J Surg Pathol. 2025 Feb 1;49(2):113-120. doi: 10.1097/PAS.0000000000002331. Epub 2024 Nov 14. PMID- 39768623 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250108 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 24 DP - 2024 Dec 17 TI - Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data. LID - 10.3390/jcm13247701 [doi] LID - 7701 AB - Background: The majority of patients with bladder cancer suffer from tumour recurrence. Identifying prognostic factors for tumour recurrence is crucial for treatment and follow-up in affected patients. The study aimed to assess the impact of somatic mutations in bladder cancer on patient outcomes and tumour recurrence. Methods: The study group comprised 46 patients with urothelial bladder cancers referred for transurethral resection of the tumour. A molecular study on tumour-derived DNA was performed using next-generation sequencing. Somatic mutations were screened in 50 genes involved in carcinogenesis. Results: We identified 81 variants in 23 genes, including 54 pathogenic mutations, 18 likely pathogenic variants, and 9 variants of unknown significance. The most frequently mutated genes were FGFR3, PIK3CA, and TP53 in 52%, 35%, and 24% of tumours, respectively. The average tumour-free survival was significantly longer in cases with mutations in the PIK3CA gene (p = 0.02), and mutations in the PIK3CA gene were associated with a decreased risk of tumour recurrence (Hazard Ratio = 0.26; 95% CI: 0.11-0.62; p = 0.018). Conclusions: The PIK3CA gene was shown to be a predictive marker of a low risk of bladder tumour recurrence. Molecular screening of bladder cancers supported predictive biomarkers of tumour recurrence and showed that tumour-free survival is molecularly determined. FAU - Myszka, Aleksander AU - Myszka A AUID- ORCID: 0000-0002-2931-7920 AD - Institute of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland. FAU - Ciesla, Marek AU - Ciesla M AD - Institute of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland. FAU - Siekierzynska, Aleksandra AU - Siekierzynska A AUID- ORCID: 0000-0003-1261-3050 AD - Department of Biotechnology and Plant Physiology, University of Rzeszow, 35-601 Rzeszow, Poland. FAU - Sendera, Anna AU - Sendera A AD - Institute of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland. FAU - Constantinou, Constantina AU - Constantinou C AD - Medical School, University of Nicosia, Nicosia 2414, Cyprus. FAU - Karpinski, Pawel AU - Karpinski P AD - Department of Genetics, Wroclaw Medical University, 50-368 Wroclaw, Poland. FAU - Wysiadecki, Grzegorz AU - Wysiadecki G AUID- ORCID: 0000-0003-3631-2295 AD - Department of Normal and Clinical Anatomy, Medical University of Lodz, 90-752 Lodz, Poland. FAU - Balawender, Krzysztof AU - Balawender K AD - Institute of Medical Sciences, University of Rzeszow, 35-310 Rzeszow, Poland. LA - eng GR - 2022/Uniwersytet Rzeszowski/ PT - Journal Article DEP - 20241217 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11677048 OTO - NOTNLM OT - bladder cancer recurrence OT - disease-free survival OT - molecular biomarkers OT - somatic mutations COIS- The authors declare no conflicts of interest. EDAT- 2025/01/08 06:20 MHDA- 2025/01/08 06:21 PMCR- 2024/12/17 CRDT- 2025/01/08 01:19 PHST- 2024/11/07 00:00 [received] PHST- 2024/12/12 00:00 [revised] PHST- 2024/12/12 00:00 [accepted] PHST- 2025/01/08 06:21 [medline] PHST- 2025/01/08 06:20 [pubmed] PHST- 2025/01/08 01:19 [entrez] PHST- 2024/12/17 00:00 [pmc-release] AID - jcm13247701 [pii] AID - jcm-13-07701 [pii] AID - 10.3390/jcm13247701 [doi] PST - epublish SO - J Clin Med. 2024 Dec 17;13(24):7701. doi: 10.3390/jcm13247701. PMID- 39767473 OWN - NLM STAT- MEDLINE DCOM- 20250108 LR - 20260728 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 21 IP - 12 DP - 2024 Dec 8 TI - The Potential for Lifestyle Intervention Among Patients Undergoing Transurethral Resection of Bladder Tumour Based on Patient Needs Including Smoking and Other Risky Lifestyle Factors: A Cross-Sectional Study. LID - 10.3390/ijerph21121633 [doi] LID - 1633 AB - Bladder cancer is the tenth most common cancer worldwide, with non-muscle invasive bladder cancer (NMIBC) accounting for 75% of cases. Transurethral resection of bladder tumours (TURBT) is the standard treatment, but it is associated with significant risks of complications and recurrence. Risky lifestyle factors, including smoking, malnutrition, obesity, risky alcohol use, and physical inactivity (collectively termed SNAP factors), may worsen surgical outcomes and increase cancer recurrence. Prehabilitation programmes targeting these modifiable risk factors could improve patient outcomes. This cross-sectional study assessed 100 TURBT patients at a Danish university hospital to determine the prevalence of SNAP factors and the potential for lifestyle interventions. Data were collected via structured interviews, and intervention scenarios were projected based on efficacy rates of 5-100%. In total, 58% of patients had at least one risky SNAP factor, with smoking (29%) being the most prevalent, followed by physical inactivity (19%) and risky alcohol use (18%). Obesity (7%) and malnutrition (8%) were less common. Seventeen percent had multiple SNAP factors. No significant demographic indicators were associated with the presence of SNAP factors. TURBT patients with NMIBC show a high prevalence of risky lifestyle factors, including smoking and obesity, with over half affected. Systematic screening and targeted interventions could significantly improve patient outcomes and long-term health. FAU - Lydom, Line Noes AU - Lydom LN AUID- ORCID: 0000-0001-9431-9984 AD - WHO-CC/Clinical Health Promotion Centre, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 2000 Frederiksberg, Denmark. FAU - Lauridsen, Susanne Vahr AU - Lauridsen SV AUID- ORCID: 0000-0001-6045-4723 AD - WHO-CC/Clinical Health Promotion Centre, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 2000 Frederiksberg, Denmark. AD - Centre for Perioperative Optimization, Department of Surgery, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark. FAU - Joensen, Ulla Nordstrom AU - Joensen UN AUID- ORCID: 0000-0001-5400-4531 AD - Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark. AD - Department of Urology, Copenhagen University Hospital Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark. FAU - Tonnesen, Hanne AU - Tonnesen H AUID- ORCID: 0000-0002-7161-3416 AD - WHO-CC/Clinical Health Promotion Centre, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 2000 Frederiksberg, Denmark. LA - eng GR - R223-A13094/Danish Cancer Society/ GR - 2021-0304/Sygeforsikringen Danmark/ GR - OFIL-24-074/Oak Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241208 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/epidemiology MH - Cross-Sectional Studies MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Smoking/epidemiology MH - Denmark/epidemiology MH - Risk Factors MH - Life Style MH - Aged, 80 and over MH - Alcohol Drinking/epidemiology MH - Adult MH - Transurethral Resection of Bladder PMC - PMC11675626 OTO - NOTNLM OT - NMIBC OT - prehabilitation OT - smoking cessation OT - surgery OT - transurethral resection of bladder tumours COIS- The authors declare that they have no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2025/01/08 06:20 MHDA- 2025/01/08 06:21 PMCR- 2024/12/08 CRDT- 2025/01/08 01:13 PHST- 2024/10/14 00:00 [received] PHST- 2024/12/03 00:00 [revised] PHST- 2024/12/04 00:00 [accepted] PHST- 2025/01/08 06:21 [medline] PHST- 2025/01/08 06:20 [pubmed] PHST- 2025/01/08 01:13 [entrez] PHST- 2024/12/08 00:00 [pmc-release] AID - ijerph21121633 [pii] AID - ijerph-21-01633 [pii] AID - 10.3390/ijerph21121633 [doi] PST - epublish SO - Int J Environ Res Public Health. 2024 Dec 8;21(12):1633. doi: 10.3390/ijerph21121633. PMID- 39758247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250107 IS - 2732-7787 (Electronic) IS - 2732-7787 (Linking) VI - 5 IP - 1 DP - 2025 Jan-Feb TI - Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. PG - 122-126 LID - 10.21873/cdp.10420 [doi] AB - BACKGROUND/AIM: This study examined the treatment outcomes of radical cystectomy (RC) for micropapillary subtype (MPS) bladder cancer treated at our hospital. PATIENTS AND METHODS: Histopathological findings of RC specimens collected from 2003 to 2020 were evaluated. Recurrence-free survival (RFS) and overall survival (OS) after RC, as well as the efficacy of chemotherapy in cases of recurrence, were retrospectively assessed. RESULTS: Of 202 patients who underwent RC, seven (3.4%) had MPS bladder cancer. All seven patients underwent immediate RC without neoadjuvant chemotherapy. The median patient age was 58 years (range=52-71 years), and all patients were male. After RC, median RFS was 14 months (range=6-115 months), and median OS was 31 months (range=18-115 months). The clinical tumor stage was cT1 or lower in two patients (28.5%), cT2 in two patients (28.5%), and cT3 or higher in three patients (42.8%). No preoperative lymph node metastasis was observed. The pathological tumor stage was pT1 or lower in one patient (14.2%), pT2 in one patient (14.2%), and pT3 or higher in five patients (71.4%). The pathological lymph node stage was observed in five patients (71.4%). Although six of seven patients (85.7%) received adjuvant chemotherapy, all patients experienced relapse. The objective response rates of primary and secondary chemotherapy at relapse were both 33%. One patient received immune checkpoint inhibitor therapy and maintained stable disease for 12 months. CONCLUSION: The recurrence rate after RC for MPS bladder cancer was high, and prognosis was poor. CI - (c)2025 The Author(s). Published by the International Institute of Anticancer Research. FAU - Jojima, Kazumasa AU - Jojima K AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Minato, Akinori AU - Minato A AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Noguchi, Hirotsugu AU - Noguchi H AD - Department of Pathology, Field of Oncology, Graduate School of Medical and Dental Science, Kagoshima University, Kagoshima, Japan. FAU - Tsuda, Yojiro AU - Tsuda Y AD - Department of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. AD - Department of Urology, Kurate Hospital, Kurate, Japan. LA - eng PT - Journal Article DEP - 20250103 PL - Greece TA - Cancer Diagn Progn JT - Cancer diagnosis & prognosis JID - 9918316186306676 PMC - PMC11696342 OTO - NOTNLM OT - Bladder cancer OT - chemotherapy OT - cystectomy OT - immune checkpoint inhibitor OT - micropapillary OT - programmed cell death protein 1 OT - subtype OT - urothelial carcinoma COIS- The Authors declare that they have no competing interests in relation to this study. EDAT- 2025/01/06 10:08 MHDA- 2025/01/06 10:09 PMCR- 2025/01/03 CRDT- 2025/01/06 05:17 PHST- 2024/10/10 00:00 [received] PHST- 2024/10/23 00:00 [revised] PHST- 2024/10/24 00:00 [accepted] PHST- 2025/01/06 10:09 [medline] PHST- 2025/01/06 10:08 [pubmed] PHST- 2025/01/06 05:17 [entrez] PHST- 2025/01/03 00:00 [pmc-release] AID - 10.21873/cdp.10420 [doi] PST - epublish SO - Cancer Diagn Progn. 2025 Jan 3;5(1):122-126. doi: 10.21873/cdp.10420. eCollection 2025 Jan-Feb. PMID- 39757038 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 7 DP - 2025 Jul TI - Development of point-of-care tests for urinary bladder cancer - an historic review and view to future prospectives. PG - 401-411 LID - S1078-1439(24)01043-3 [pii] LID - 10.1016/j.urolonc.2024.12.263 [doi] AB - Urine is an attractive biospecimen for noninvasive tests to facilitate bladder tumor diagnostics. Three different point-of-care (POC) tests based on lateral flow immunoassays (LFAs) are currently commercially available: UBC(R) Rapid Test, BTA stat(R), and NMP22(TM) BladderChek. The present review discusses these different tests based on their performance, clinical utility and the nature of the respective analytes. The level of sensitivities of UBC Rapid Test(R) and BTA stat(R) for detection of high-grade nonmuscle invasive bladder cancer using urine is in the order of 80%. Estimations of performance are highly dependent on patient selection criteria. UBC(R) Rapid Test shows a sensitivity of approximately 85% in patients presenting with macrohematuria which is the most common initial clinical symptom. Estimations of specificity are complicated by differences in how control groups are selected in different studies and are therefore more difficult to compare between published reports. Different POC tests differ with regard to the source of the analytes that are measured. The BTA Stat(R) test is based on detection of plasma proteins (Factor H/Factor H-related proteins), potentially leading to a lack of specificity during conditions of renal dysfunction. A large number of analytes to be used for urine-based bladder cancer tests have been described in the literature, including cytokines and proteases implicated in tumor invasion. These proteins, although biologically relevant, are often present at very low levels in urine that may be unsuitable for development of LFAs. Release of abundant intracellular structural proteins from cells such as cytokeratins (UBC(R) Rapid Test) and nuclear matrix proteins (NMP22(TM)) may therefore be advantageous. We conclude that available data support the use of urine-based POC tests as adjuncts during the clinical work up of suspected bladder cancer. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Ecke, Thorsten H AU - Ecke TH AD - Department of Urology, Helios Hospital, Bad Saarow, Germany; Department of Urology, Charite - Universitatsmedizin Berlin, Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany. Electronic address: thorsten.ecke@helios-gesundheit.de. FAU - Styrke, Johan AU - Styrke J AD - Department of Diagnostics and Intervention, Urology and Andrology, Umea University, Umea, Sweden. FAU - Jagarlamudi, Kiran AU - Jagarlamudi K AD - Department of Anatomy, Physiology, and Biochemistry, Faculty of Veterinary Medicine and Animal Sciences, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden. FAU - Linder, Stig AU - Linder S AD - Department of Biomedical and Clinical Sciences, Linkoping University, Linkoping, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. LA - eng PT - Journal Article PT - Review DEP - 20250104 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/urine MH - *Point-of-Care Testing/trends MH - *Point-of-Care Systems MH - Biomarkers, Tumor/urine MH - Immunoassay/methods OTO - NOTNLM OT - Bladder cancer OT - Recurrence OT - Urine-based tumour markers COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stig Linder reports a relationship with AroCell AB that includes: consulting or advisory. Kiran Jagarlamudi reports a relationship with AroCell AB that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/06 10:07 MHDA- 2025/05/31 00:37 CRDT- 2025/01/05 21:53 PHST- 2024/10/09 00:00 [received] PHST- 2024/12/07 00:00 [revised] PHST- 2024/12/15 00:00 [accepted] PHST- 2025/05/31 00:37 [medline] PHST- 2025/01/06 10:07 [pubmed] PHST- 2025/01/05 21:53 [entrez] AID - S1078-1439(24)01043-3 [pii] AID - 10.1016/j.urolonc.2024.12.263 [doi] PST - ppublish SO - Urol Oncol. 2025 Jul;43(7):401-411. doi: 10.1016/j.urolonc.2024.12.263. Epub 2025 Jan 4. PMID- 39754342 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250520 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 92 IP - 2 DP - 2025 May TI - Neutrophils to lymphocytes ratio as a predictor of BCG response in non-muscle invasive bladder cancer. PG - 237-242 LID - 10.1177/03915603241308974 [doi] AB - AIM: To evaluate the role of preoperative neutrophils to lymphocytes ratio (NLR) as a predictor for the response to BCG in patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS: Nighty six patients with NMIBC were prospectively included in our study. Our study population was classified into two groups, based on pre-operative (NLR) either ⩽ or > 3. After receiving BCG, patients were followed up for 3 years to evaluate the correlation between BCG failure and (NLR). RESULTS: Nighty two patients were evaluated at the end of our study. The NLR > 3 group of patients showed a higher age and T stage compared to the NLR ⩽ 3 group with a significant difference. BCG failure was reported to be higher in the NLR > 3 group with a failure rate of 66.7% compared to 28.3% in the other group (p-value < 0.001). Time to failure in NLR > 3 group compared to NLR ⩽ 3 group was 10.44 +/- 4.3 and 15 +/- 3.9 months respectively with a (p-value = 0.002). Univariate and multivariate logistic regression revealed that the most significant predictors of BCG failure were NLR > 3, Initial T stage, and age respectively. CONCLUSION: BCG response is highly affected by the NLR, with a higher failure rate with NLR > 3. FAU - Higazy, Ahmed AU - Higazy A AD - Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Elsawy, Amr AU - Elsawy A AD - Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Lofty, Ahmed AU - Lofty A AD - Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Abdallah, Hany M AU - Abdallah HM AD - Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Radwan, Ahmed AU - Radwan A AUID- ORCID: 0000-0002-9679-4241 AD - Faculty of Medicine, Ain Shams University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20250103 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/blood MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - *Neutrophils MH - Aged MH - Neoplasm Invasiveness MH - Prospective Studies MH - Middle Aged MH - Predictive Value of Tests MH - *Lymphocytes MH - *Adjuvants, Immunologic/therapeutic use MH - Lymphocyte Count MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Neutrophil-lymphocyte ratio OT - immunotherapy OT - non-muscle invasive bladder cancer OT - superficial bladder tumor OT - urothelial tumor COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/01/04 20:04 MHDA- 2025/04/02 12:35 CRDT- 2025/01/04 01:12 PHST- 2025/04/02 12:35 [medline] PHST- 2025/01/04 20:04 [pubmed] PHST- 2025/01/04 01:12 [entrez] AID - 10.1177/03915603241308974 [doi] PST - ppublish SO - Urologia. 2025 May;92(2):237-242. doi: 10.1177/03915603241308974. Epub 2025 Jan 3. PMID- 39752014 OWN - NLM STAT- MEDLINE DCOM- 20250103 LR - 20260109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2025 Jan 3 TI - PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. PG - 57 LID - 10.1007/s00345-024-05392-5 [doi] LID - 57 AB - PURPOSE: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guerin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1). Here, we hypothesized that PD-L1 protein expression could serve as a biomarker for BCG-failure. METHODS: HR-NMIBC patients who received >/= 5 BCG instillations were included. Tissue microarrays were constructed from BCG-naive tumors and recurrences and stained with the PD-L1 (SP142) antibody. PD-L1 status was defined as >/= 5% tumor-infiltrating immune cells with membrane staining in the tumor area. Clinicopathological associations with PD-L1 positive tumors were investigated, and time-to-event analyses were performed comparing PD-L1 positive vs. negative tumors. RESULTS: 432 BCG-naive tumors and 160 recurrences were included, and 91% of patients received adequate BCG. In BCG-naive tumors, PD-L1 was expressed in 7% of patients and PD-L1 expression was associated with stage T1 versus Ta disease (p = 0.015). PD-L1 expression was not associated with treatment failure after adequate BCG (p = 0.782) nor with progression-free survival (p = 0.732). Testing cut-offs of >/= 1% and >/= 10% PD-L1 positivity did not alter results. High PD-L1 expression was more frequent in tumor recurrences (14%) as compared to BCG-naive tumors (p = 0.012). CONCLUSION: PD-L1 expression in HR-NMIBC is not a biomarker of response to BCG. However, PD-L1 is higher in a subset of tumors that failed BCG treatment. More research is needed to determine the role of PD-L1 in tumors where BCG treatment failed. CI - (c) 2025. The Author(s). FAU - de Jong, Florus C AU - de Jong FC AUID- ORCID: 0000-0001-6853-5982 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands. FAU - Kvikstad, Vebjorn AU - Kvikstad V AD - Department of Pathology, Helse Stavanger HF, Stavanger, Norway. FAU - Hoedemaeker, Robert F AU - Hoedemaeker RF AD - Pathan BV, Department of Pathology, Rotterdam, The Netherlands. FAU - van der Made, Angelique C J AU - van der Made ACJ AD - Department of Pathology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - van der Bosch, Thierry P AU - van der Bosch TP AD - Pathan BV, Department of Pathology, Rotterdam, The Netherlands. FAU - van Casteren, Niels J AU - van Casteren NJ AD - Department of Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. FAU - van Kessel, Kim E M AU - van Kessel KEM AD - Department of Urology, Amphia, Breda, The Netherlands. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands. t.zuiverloon@erasmusmc.nl. LA - eng GR - MRACE2017/Erasmus Universitair Medisch Centrum Rotterdam/ PT - Journal Article DEP - 20250103 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (CD274 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/drug therapy MH - *B7-H1 Antigen/metabolism/biosynthesis MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - Aged MH - *Biomarkers, Tumor/metabolism MH - *Neoplasm Invasiveness MH - Middle Aged MH - Adjuvants, Immunologic/therapeutic use MH - Retrospective Studies MH - Risk Assessment MH - Administration, Intravesical MH - Neoplasm Recurrence, Local MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11698758 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Immunotherapy OT - PD-L1 OT - Prognosis OT - Progression OT - Recurrence COIS- Declarations. Conflict of interest: All other authors declare no conflicts of interest, including specific (non-)financial interests and relationships or employment relevant to the subject matter. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Erasmus University Medical Center (MEC-2018-1097) on April 9th, 2018. Informed consent: Written informed consent was obtained from all subjects involved in the study to publish this paper if patients were alive. Patient consent was waived if patients were deceased. No patients can be identified in this publication. EDAT- 2025/01/03 12:21 MHDA- 2025/01/03 18:20 PMCR- 2025/01/03 CRDT- 2025/01/03 11:21 PHST- 2024/01/29 00:00 [received] PHST- 2024/11/19 00:00 [accepted] PHST- 2025/01/03 18:20 [medline] PHST- 2025/01/03 12:21 [pubmed] PHST- 2025/01/03 11:21 [entrez] PHST- 2025/01/03 00:00 [pmc-release] AID - 10.1007/s00345-024-05392-5 [pii] AID - 5392 [pii] AID - 10.1007/s00345-024-05392-5 [doi] PST - epublish SO - World J Urol. 2025 Jan 3;43(1):57. doi: 10.1007/s00345-024-05392-5. PMID- 39747744 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250304 IS - 1869-4101 (Print) IS - 1869-4101 (Electronic) IS - 1869-4101 (Linking) VI - 16 IP - 1 DP - 2025 Jan 2 TI - Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer. PG - 7 LID - 10.1186/s13244-024-01884-5 [doi] LID - 7 AB - Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting. The Vesical Imaging Reporting and Data System (VI-RADS), a multiparametric MRI (mpMRI)-based consensus reporting platform, allows for standardized preoperative muscle invasion assessment in BCa with proven diagnostic accuracy. However, post-treatment assessment using VI-RADS is challenging because of anatomical changes, especially in the interpretation of the muscle layer. MRI techniques that provide tumor tissue physiological information, including diffusion-weighted (DW)- and dynamic contrast-enhanced (DCE)-MRI, combined with derived quantitative imaging biomarkers (QIBs), may potentially overcome the limitations of BCa evaluation when predominantly focusing on anatomic changes at MRI, particularly in the therapy response setting. Delta-radiomics, which encompasses the assessment of changes (Delta) in image features extracted from mpMRI data, has the potential to monitor treatment response. In comparison to the current Response Evaluation Criteria in Solid Tumors (RECIST), QIBs and mpMRI-based radiomics, in combination with artificial intelligence (AI)-based image analysis, may potentially allow for earlier identification of therapy-induced tumor changes. This review provides an update on the potential of QIBs and mpMRI-based radiomics and discusses the future applications of AI in BCa management, particularly in assessing treatment response. CRITICAL RELEVANCE STATEMENT: Incorporating mpMRI-based quantitative imaging biomarkers, radiomics, and artificial intelligence into bladder cancer management has the potential to enhance treatment response assessment and prognosis prediction. KEY POINTS: Quantitative imaging biomarkers (QIBs) from mpMRI and radiomics can outperform RECIST for bladder cancer treatments. AI improves mpMRI segmentation and enhances radiomics feature extraction effectively. Predictive models integrate imaging biomarkers and clinical data using AI tools. Multicenter studies with strict criteria validate radiomics and QIBs clinically. Consistent mpMRI and AI applications need reliable validation in clinical practice. CI - (c) 2024. The Author(s). FAU - Arita, Yuki AU - Arita Y AUID- ORCID: 0000-0002-5285-0352 AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. yukiarita1113@gmail.com. FAU - Kwee, Thomas C AU - Kwee TC AD - Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands. FAU - Akin, Oguz AU - Akin O AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Shigeta, Keisuke AU - Shigeta K AD - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. AD - Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. FAU - Paudyal, Ramesh AU - Paudyal R AD - Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Roest, Christian AU - Roest C AD - Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands. FAU - Ueda, Ryo AU - Ueda R AD - Office of Radiation Technology, Keio University Hospital, Shinjuku-ku, Tokyo, Japan. FAU - Lema-Dopico, Alfonso AU - Lema-Dopico A AD - Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Nalavenkata, Sunny AU - Nalavenkata S AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Ruby, Lisa AU - Ruby L AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Nissan, Noam AU - Nissan N AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Edo, Hiromi AU - Edo H AD - Department of Radiology, National Defense Medical College, Tokorozawa, Saitama, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Shukla-Dave, Amita AU - Shukla-Dave A AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. AD - Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Schwartz, Lawrence H AU - Schwartz LH AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250102 PL - Germany TA - Insights Imaging JT - Insights into imaging JID - 101532453 PMC - PMC11695553 OTO - NOTNLM OT - Artificial intelligence OT - Biomarker OT - Multiparametric magnetic resonance imaging OT - Treatment response OT - Urinary bladder neoplasm COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: Y.A. is one of the scientific editorial board members of the ESR journal (European Radiology), but he was not involved in the manuscript handling process. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. EDAT- 2025/01/03 06:21 MHDA- 2025/01/03 06:22 PMCR- 2025/01/02 CRDT- 2025/01/03 00:14 PHST- 2024/08/14 00:00 [received] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/01/03 06:22 [medline] PHST- 2025/01/03 06:21 [pubmed] PHST- 2025/01/03 00:14 [entrez] PHST- 2025/01/02 00:00 [pmc-release] AID - 10.1186/s13244-024-01884-5 [pii] AID - 1884 [pii] AID - 10.1186/s13244-024-01884-5 [doi] PST - epublish SO - Insights Imaging. 2025 Jan 2;16(1):7. doi: 10.1186/s13244-024-01884-5. PMID- 41725977 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260223 LR - 20260813 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 78 IP - 4 DP - 2025 TI - Regulatory T cells in non-muscle invasive bladder cancer: Immune modulators, prognostic markers, and therapeutic targets. PG - 462-469 LID - 10.5173/ceju.2025.0036 [doi] AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) is characterized by a high recurrence rate and variable response to intravesical Bacillus Calmette-Guerin (BCG) therapy. Regulatory T cells (Tregs), a specialized subset of CD4+ T lymphocytes expressing FOXP3, play a crucial role in shaping the tumor immune microenvironment by suppressing anti-tumor immune responses. Their presence in NMIBC has been associated with both immune evasion and, paradoxically, potential protective effects under specific conditions.This review examines the role of Tregs in NMIBC, focusing on their impact on the tumor microenvironment, prognosis, and therapeutic potential. MATERIAL AND METHODS: A literature review was conducted using PubMed to analyze studies on Tregs in NMIBC, including their immunosuppressive mechanisms and therapeutic targeting strategies. RESULTS: Tregs suppress anti-tumor immunity through cytokine secretion (interleukin-10, tumor growth factor beta), metabolic adaptations, and inhibition of CD8+ T cells. High FOXP3+ Treg levels are associated with increased recurrence and progression, particularly post-BCG. PD-L1+ Tregs contribute to BCG resistance, making them a potential target for immune checkpoint inhibitors and combination therapies. CONCLUSIONS: Tregs are key modulators of NMIBC progression and treatment response. Targeting their suppressive functions may enhance immunotherapy outcomes and improve patient prognosis. CI - Copyright by Polish Urological Association. FAU - Diamantidis, Dimitrios AU - Diamantidis D AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Tsakaldimis, Georgios AU - Tsakaldimis G AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. AD - Endoscopy Unit, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Giannakopoulos, Stilianos AU - Giannakopoulos S AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. AD - Endoscopy Unit, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Giatromanolaki, Alexandra AU - Giatromanolaki A AD - Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Deligeorgiou, Evangelia AU - Deligeorgiou E AD - Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Lailisidis, Stavros AU - Lailisidis S AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Kalaitzis, Christos AU - Kalaitzis C AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. LA - eng PT - Journal Article PT - Review DEP - 20251008 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC12924066 OTO - NOTNLM OT - BCG therapy OT - FOXP3 OT - immune suppression OT - immunotherapy OT - non-muscle invasive bladder cancer OT - regulatory T cells COIS- The authors declare no conflict of interest. EDAT- 2025/01/01 00:00 MHDA- 2025/01/01 00:01 PMCR- 2025/01/01 CRDT- 2026/02/23 06:18 PHST- 2025/02/15 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2025/01/01 00:01 [medline] PHST- 2025/01/01 00:00 [pubmed] PHST- 2026/02/23 06:18 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - CEJU-78-04-0036 [pii] AID - 10.5173/ceju.2025.0036 [doi] PST - ppublish SO - Cent European J Urol. 2025;78(4):462-469. doi: 10.5173/ceju.2025.0036. Epub 2025 Oct 8. PMID- 41725964 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260223 LR - 20260813 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 78 IP - 4 DP - 2025 TI - Development of a predictive risk score for 1-year intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. PG - 453-461 LID - 10.5173/ceju.2025.0191 [doi] AB - INTRODUCTION: The study aims to develop and internally validate a novel risk stratification model specifically designed to predict 1-year intravesical recurrence (IVR) following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), integrating readily available clinicopathologic parameters. MATERIAL AND METHODS: We retrospectively analyzed 87 patients who underwent RNU for UTUC between 2012 and 2024. Patients were stratified according to IVR status at 12 months postoperatively. Univariate and LASSO logistic regression analyses were conducted to identify independent predictors. A simplified risk score was derived from regression coefficients. Model performance was assessed using area under the ROC curve (AUC), calibration plots, and bootstrap validation. Clinical utility was evaluated with decision curve analysis (DCA). RESULTS: One-year IVR occurred in 34 patients (39.1%). Seven independent predictors were identified: tumor multifocality, ureteral tumor location, history of non-muscle-invasive bladder cancer, chronic kidney disease, preoperative ureteroscopy, intravesical bladder cuff excision, and positive surgical margins. The final model showed excellent discriminative performance (AUC = 0.854) and good calibration. Patients were stratified into low (0-2 points), intermediate (3-5), and high-risk (6-9) groups, with IVR rates of 11.1%, 53.7%, and 80.0%, respectively (p for trend <0.001). DCA demonstrated a favorable net benefit across a wide range of thresholds. CONCLUSIONS: We present a novel, internally validated scoring system that integrates routine clinicopathologic parameters to predict early IVR following RNU for UTUC. This tool may support urologists in implementing risk-adapted cystoscopic surveillance protocols and identifying candidates for early intravesical therapy. External validation is warranted prior to clinical implementation. CI - Copyright by Polish Urological Association. FAU - Kayar, Ridvan AU - Kayar R AD - Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Kayar, Kemal AU - Kayar K AD - Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Artuk, Ilker AU - Artuk I AD - Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Demir, Samet AU - Demir S AD - Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Erdogan, Emre AU - Erdogan E AD - Department of Urology, Medical Park Goztepe Hospital Complex, Bahcesehir University, Istanbul, Turkey. FAU - Tokuc, Emre AU - Tokuc E AD - Department of Urology, Medical Park Goztepe Hospital Complex, Bahcesehir University, Istanbul, Turkey. FAU - Ozturk, Metin AU - Ozturk M AD - Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20251126 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC12924064 OTO - NOTNLM OT - intravesical recurrence OT - radical nephroureterectomy OT - risk stratification OT - upper tract urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2025/01/01 00:00 MHDA- 2025/01/01 00:01 PMCR- 2025/01/01 CRDT- 2026/02/23 06:18 PHST- 2025/08/22 00:00 [received] PHST- 2025/10/06 00:00 [accepted] PHST- 2025/01/01 00:01 [medline] PHST- 2025/01/01 00:00 [pubmed] PHST- 2026/02/23 06:18 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - CEJU-78-04-0191 [pii] AID - 10.5173/ceju.2025.0191 [doi] PST - ppublish SO - Cent European J Urol. 2025;78(4):453-461. doi: 10.5173/ceju.2025.0191. Epub 2025 Nov 26. PMID- 39739061 OWN - NLM STAT- MEDLINE DCOM- 20241231 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2024 Dec 30 TI - Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer. PG - 52 LID - 10.1007/s00345-024-05417-z [doi] AB - OBJECTIVE: The intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) prognostic group is heterogeneous. Growing evidence supports the role of active surveillance (AS) for patients with low-risk NMIBC, however, no clear data exists considering IR-NMIBC. The aim of the study was to assess the risk of recurrence of patients eligible for AS based on the International Bladder Cancer Group (IBCG) stratification. METHODS: We retrospectively evaluated 174 LG IR-NMIBC patients who underwent transurethral resection of bladder tumor (index TURBT) from 2012 to 2023 at a tertiary referral center and fulfilled the inclusion criteria for enrollment in AS protocols at the index TURBT (/= 3 risk factors. The 3-year HG-RFS was > 90% for patients with 0 and 1-2 risk factors, compared to 76% (95% CI 58-99%) for those with >/= 3 risk factors. At MVA, the presence of >/= 3 risk factors was associated with a higher risk of recurrence [hazard ratio: 4.74, 95% CI 1.75-12.8, p = 0.002]. CONCLUSION: Among patients with LG IR-NMIBC eligible for AS, those with more than 2 IBCG risk factors may not be suitable candidates due to a higher risk of developing HG recurrence. Randomized controlled trials with standardized AS protocols are necessary to validate these findings and optimize patient selection for AS in LG IR-NMIBC. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Zaurito, Paolo AU - Zaurito P AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. scilipoti.pietro@hsr.it. AD - Vita-Salute San Raffaele University, Milan, Italy. scilipoti.pietro@hsr.it. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Re, Chiara AU - Re C AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Quarta, Leonardo AU - Quarta L AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Burgio, Giusy AU - Burgio G AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. FAU - Pellegrino, Francesco AU - Pellegrino F AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy. LA - eng PT - Journal Article DEP - 20241230 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM CIN - World J Urol. 2025 Feb 10;43(1):113. doi: 10.1007/s00345-025-05475-x. PMID: 39928159 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - Risk Assessment MH - *Watchful Waiting MH - *Neoplasm Grading MH - *Neoplasm Recurrence, Local/epidemiology MH - Patient Selection MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Active surveillance OT - Intermediate risk OT - International bladder cancer group OT - Low-grade OT - Non-muscle invasive bladder cancer COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/01/01 12:42 MHDA- 2025/01/01 12:43 CRDT- 2024/12/31 13:11 PHST- 2024/08/12 00:00 [received] PHST- 2024/12/16 00:00 [accepted] PHST- 2025/01/01 12:43 [medline] PHST- 2025/01/01 12:42 [pubmed] PHST- 2024/12/31 13:11 [entrez] AID - 10.1007/s00345-024-05417-z [pii] AID - 10.1007/s00345-024-05417-z [doi] PST - epublish SO - World J Urol. 2024 Dec 30;43(1):52. doi: 10.1007/s00345-024-05417-z. PMID- 39737155 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2296-861X (Print) IS - 2296-861X (Electronic) IS - 2296-861X (Linking) VI - 11 DP - 2024 TI - Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder cancer: a retrospective study. PG - 1472104 LID - 10.3389/fnut.2024.1472104 [doi] LID - 1472104 AB - BACKGROUND: Bladder carcinoma is a type of urological tumor with high risks of recurrence and progression. The triglyceride-glucose (TyG) index has demonstrated significant promise as a prognostic marker for metabolic health in different types of cancer. Further research is needed to explore the relationships among non-muscle-invasive bladder cancer (NMIBC), the TyG index, and its prognostic importance. Purpose of this preliminary research is to assess the predictive significance of the TyG index for recurrence and progression risk in NMIBC patients. METHODS: Data from patients admitted between October 2018 and July 2021 were reviewed, and there are 198 patients in total were included. The experimental data were supplied by medical records. In addition, patient prognoses were followed up via telephone. Furthermore, patients were separated into two groups: the high and low TyG groups, using X-tile software. Apart from recurrence-free survival (RFS), progression-free survival (PFS) was the main outcome. According to the TyG index, nomograms were also established. RESULTS: The cohort consisted of 93 patients in the high TyG group and 105 patients in the low TyG group. The TyG index was a key prognostic factor for postoperative RFS (HR = 2.726, 95% CI = 1.474-5.041, p = 0.001) and PFS (HR = 2.846, 95% CI = 1.359-5.957, p = 0.006) among patients with NMIBC. The log-rank test revealed a notable disparity between the low and high TyG groups regarding RFS (p = 0.0025) and PFS (p = 0.0110). Moreover, it was strongly connected to well-known NMIBC risk factors. Because the TyG index exhibited good predictive value, the nomogram models were formulated. CONCLUSION: The TyG index serves as an isolated predictor of both RFS and PFS among patients with NMIBC, revealing new insights into disease treatment mechanisms. Indeed, the TyG index serves as a credible indicator of risk classification while facilitating early intervention among patients with NMIBC. CI - Copyright (c) 2024 Zhang, Shao, Ding, Xia, Wang, Jiang, Wang and Wang. FAU - Zhang, Yan AU - Zhang Y AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Shao, Xianfeng AU - Shao X AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Ding, Li AU - Ding L AD - Department of Urology, Shanghai Tenth People's Hospital, Shanghai, China. FAU - Xia, Wentao AU - Xia W AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Kun AU - Wang K AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Jiang, Shan AU - Jiang S AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Jiahao AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. LA - eng PT - Journal Article DEP - 20241216 PL - Switzerland TA - Front Nutr JT - Frontiers in nutrition JID - 101642264 PMC - PMC11682997 OTO - NOTNLM OT - NMIBC OT - TyG index OT - bladder cancer OT - insulin resistance OT - nomogram OT - prognosis OT - tumor recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/12/31 11:04 MHDA- 2024/12/31 11:05 PMCR- 2024/01/01 CRDT- 2024/12/31 04:04 PHST- 2024/07/28 00:00 [received] PHST- 2024/12/03 00:00 [accepted] PHST- 2024/12/31 11:05 [medline] PHST- 2024/12/31 11:04 [pubmed] PHST- 2024/12/31 04:04 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fnut.2024.1472104 [doi] PST - epublish SO - Front Nutr. 2024 Dec 16;11:1472104. doi: 10.3389/fnut.2024.1472104. eCollection 2024. PMID- 39732133 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250520 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 1 DP - 2025 Feb TI - Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis. PG - 102286 LID - S1558-7673(24)00256-8 [pii] LID - 10.1016/j.clgc.2024.102286 [doi] AB - OBJECTIVE: To assess the association of being overweight or obese with Nonmuscle invasive bladder cancer (NMIBC) recurrence, stage progression, and grade progression. METHODS: Patients with NMIBC were included and categorized into 3 groups based on their body mass index (BMI): normal weight, overweight, and obese. Recurrence was defined as any histologically proven bladder cancer on subsequent transurethral resection of bladder tumor (TURBT). Progression was defined as upgrading from low to high grade, upstaging to pT1 from pTa, or to muscle-invasion from pT1 disease. RESULTS: A total of 457 patients were analyzed, 135 (29.5%) had normal weight, 192 (42.6%) were overweight, and 130 (28.4%) were obese, with a median BMI of 27.1 (24.4-30.7) Kg/m2. The study found no significant difference in the time to recurrence, stage progression, and grade progression within the BMI categories (P < .05). Additionally, no increased risk was observed in BMI categories (Obesity recurrence HR: 1.067, CI 95%: 0.783-1.453; Obesity stage progression HR: 1.315, 95% CI: 0.635-2.724; Obesity grade progression HR: 0.586, 95% CI: 0.195-1.760). CONCLUSIONS: In our cohort, body weight category showed no association with NMIBC recurrence, stage progression, or grade progression. These findings highlight the need to identify other potential risk factors that could improve NMIBC risk stratification. Further studies are warranted to validate our results and explore additional predictors of NMIBC outcomes. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Thomas, Jamie AU - Thomas J AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL; Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL. FAU - Jain, Aakangsha AU - Jain A AD - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL. FAU - Hirpara, Ram AU - Hirpara R AD - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL. FAU - Blachman-Braun, Ruben AU - Blachman-Braun R AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology, University of Iowa Health Care, Iowa City, IA. FAU - Soodana-Prakash, Nachiketh AU - Soodana-Prakash N AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Velasquez, Maria C AU - Velasquez MC AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Ajami, Tarek AU - Ajami T AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Nahar, Bruno AU - Nahar B AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Kava, Bruce AU - Kava B AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Punnen, Sanoj AU - Punnen S AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Parekh, Dipen J AU - Parekh DJ AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Ritch, Chad R AU - Ritch CR AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. Electronic address: critch@miami.edu. LA - eng PT - Journal Article DEP - 20241207 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Male MH - Female MH - Aged MH - *Body Mass Index MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Disease Progression MH - *Obesity/complications/epidemiology MH - Prognosis MH - Middle Aged MH - Retrospective Studies MH - Neoplasm Staging MH - *Overweight/complications/epidemiology MH - Risk Factors MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Neoplasm Grading OTO - NOTNLM OT - BMI OT - Grade progression OT - Recurrence OT - Risk category groups OT - Stage progression COIS- Disclosure All authors have no conflict of interests to disclose. EDAT- 2024/12/29 00:20 MHDA- 2025/01/24 00:25 CRDT- 2024/12/28 18:56 PHST- 2023/07/06 00:00 [received] PHST- 2024/11/27 00:00 [revised] PHST- 2024/12/01 00:00 [accepted] PHST- 2025/01/24 00:25 [medline] PHST- 2024/12/29 00:20 [pubmed] PHST- 2024/12/28 18:56 [entrez] AID - S1558-7673(24)00256-8 [pii] AID - 10.1016/j.clgc.2024.102286 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Feb;23(1):102286. doi: 10.1016/j.clgc.2024.102286. Epub 2024 Dec 7. PMID- 39729958 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250519 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 266 DP - 2025 Feb TI - Allelic variants in xenobiotic metabolism genes predict susceptibility and worse prognosis of urothelial bladder cancer. PG - 155767 LID - S0344-0338(24)00678-2 [pii] LID - 10.1016/j.prp.2024.155767 [doi] AB - Biomarkers that identify tumors with better/worse prognosis can help reduce treatment costs and contribute to patient survival. In urothelial bladder cancer (UBC), accurate prediction of recurrence and progression is essential to inform therapeutic management. Herein, we explore the role of genetic variants of xenobiotic metabolic pathways in UBC susceptibility and prognosis. In total, 295 participants with UBC and 295 controls were genotyped using TaqMan(R) probes. CYP1A1 (rs1048943), CYP3A4 (rs4646437), CYP3A5 (rs4646450), UGT2B7 (rs7438135), and UGT2B15 (rs3100) allele frequencies were compared between UBC patients and controls and were analyzed concerning tumor grade, invasion, and recurrence. CYP3A4 (AA) increased susceptibility to UBC 3-fold when interacting with CYP3A5 (AA+AA). The susceptibility was higher in CYP3A4 (AA) males (OR=3.189) and individuals exposed to pesticides (OR=5.492). When interacting with hypertension, the allele C of CYP1A1 also increased UBC susceptibility by 2-fold. The UGT2B15 mutant allele was associated with high-grade tumors (OR=2.196) and recurrences (OR=2.561), as well as tumor grade when associated with mutated alleles of CYP3A4 (OR=6.171) and CYP3A5 (OR=3.492). Genes-encoding proteins were further analyzed using the STRING program, demonstrating that the proteins had known interactions in databases and were co-expressed. This study is a pioneer in evaluating these variants in a Latin American population from Brazil and confirms occupational pesticide exposure as a risk factor for UBC, mainly in genetically susceptible individuals. Furthermore, these variants may have additional clinical value for predicting susceptibility and prognostic stratification in patients with exposure-related cancers such as UBC. CI - Copyright (c) 2024 Elsevier GmbH. All rights reserved. FAU - da Silva, Isabely Mayara AU - da Silva IM AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. FAU - Maraslis, Flora Troina AU - Maraslis FT AD - Department of Biosciences, Institute for Health and Society, Federal University of Sao Paulo (UNIFESP), Santos 11060-001, Brazil. FAU - Kawasaki, Julia Ayumi Ikeda AU - Kawasaki JAI AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. FAU - Aida, Natieli Kazue AU - Aida NK AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. FAU - Barcelos, Gustavo Rafael Mazzaron AU - Barcelos GRM AD - Department of Biosciences, Institute for Health and Society, Federal University of Sao Paulo (UNIFESP), Santos 11060-001, Brazil. FAU - Koike, Alexsandro AU - Koike A AD - Londrina Cancer Hospital, Londrina 86015-520, Brazil. FAU - Fuganti, Paulo Emilio AU - Fuganti PE AD - Londrina Cancer Hospital, Londrina 86015-520, Brazil. FAU - Colus, Ilce Mara de Syllos AU - Colus IMS AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. FAU - Guembarovski, Roberta Losi AU - Guembarovski RL AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. FAU - Serpeloni, Juliana Mara AU - Serpeloni JM AD - Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil. Electronic address: julianaserpeloni@uel.br. LA - eng PT - Journal Article DEP - 20241220 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - EC 2.4.1.17 (Glucuronosyltransferase) RN - EC 1.14.14.1 (Cytochrome P-450 CYP3A) RN - EC 1.14.14.55 (CYP3A4 protein, human) RN - EC 1.14.14.1 (Cytochrome P-450 CYP1A1) RN - 0 (Xenobiotics) RN - EC 2.4.1.17 (UDP-glucuronosyltransferase 2B15, human) RN - EC 1.14.14.1 (CYP1A1 protein, human) RN - EC 1.14.14.1 (CYP3A5 protein, human) RN - EC 2.4.1.- (UGT2B7 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Male MH - Female MH - *Genetic Predisposition to Disease/genetics MH - Middle Aged MH - Aged MH - Prognosis MH - Glucuronosyltransferase/genetics MH - Cytochrome P-450 CYP3A/genetics MH - Cytochrome P-450 CYP1A1/genetics MH - Xenobiotics/metabolism MH - Polymorphism, Single Nucleotide MH - Alleles MH - Gene Frequency MH - Biomarkers, Tumor/genetics OTO - NOTNLM OT - Bladder cancer OT - Detoxification pathway OT - MIBC OT - NMIBC OT - SNV COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/28 11:41 MHDA- 2025/02/14 00:24 CRDT- 2024/12/27 18:09 PHST- 2024/10/02 00:00 [received] PHST- 2024/12/04 00:00 [revised] PHST- 2024/12/11 00:00 [accepted] PHST- 2025/02/14 00:24 [medline] PHST- 2024/12/28 11:41 [pubmed] PHST- 2024/12/27 18:09 [entrez] AID - S0344-0338(24)00678-2 [pii] AID - 10.1016/j.prp.2024.155767 [doi] PST - ppublish SO - Pathol Res Pract. 2025 Feb;266:155767. doi: 10.1016/j.prp.2024.155767. Epub 2024 Dec 20. PMID- 39724414 OWN - NLM STAT- MEDLINE DCOM- 20241226 LR - 20261008 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 43 IP - 1 DP - 2024 Dec 26 TI - Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series. PG - 47 LID - 10.1007/s00345-024-05410-6 [doi] AB - PURPOSE: This study aimed to comprehensively evaluate the prognostic value of T1 histo-anatomic substaging (T1a/T1b) for high grade (HG) non-muscle invasive bladder cancer (NMIBC) over a large single-centre cohort. MATERIALS AND METHODS: Patients with primary HG T1 NMIBC were identified from our Institutional database, between 2011 and 2022. Data from diagnosis to repeated transurethral resection of bladder tumour (RE-TURBT), bacillus Calmette-Guerin (BCG) treatment and follow-up were collected. Patients were stratified based on histo-anatomic landmark into T1a (invasion above the Muscularis Mucosa-MM) and T1b (into/beyond MM). Kaplan-Meier curves and multivariate Cox regression analyses were used to assess the impact of histo-anatomic substaging on recurrence-free survival (RFS), cancer-specific survival (CSS), and progression-free survival (PFS). RESULTS: Substaging was feasible in 88% of cases. The median (IQR) follow-up was 40 (17-72) months. T1b patients had larger initial tumours (> 3 cm: 43.2% vs. 26.1%, p < 0.001), while upstaging to muscle-invasive bladder cancer (MIBC) at RE-TURBT was more frequent in T1b than in T1a (5.9% vs. 1.5%, p = 0.02). T1b patients without BCG induction had worse RFS and PFS (all p /=3 cm (p = 0.012) were more likely to receive immediate RC. CONCLUSION: Immediate and delayed eRC show comparable survival outcomes. The present study emphasizes the need for accurate risk stratification of patients with NMIBC to identify the most advantageous therapy for individual patients. CI - (c) 2024 S. Karger AG, Basel. FAU - Yang, Yushan AU - Yang Y AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Holbach, Sonja AU - Holbach S AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Haas, Maximilian AU - Haas M AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Engelmann, Simon Udo AU - Engelmann SU AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Gossler, Christopher AU - Gossler C AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, University of Regensburg, Caritas St. Josef Hospital Regensburg, Regensburg, Germany. LA - eng PT - Comparative Study PT - Journal Article DEP - 20241223 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - Treatment Outcome MH - Middle Aged MH - Time Factors MH - Retrospective Studies MH - Neoplasm Invasiveness MH - *Time-to-Treatment OTO - NOTNLM OT - High risk non-muscle-invasive bladder cancer OT - Radical cystectomy OT - TCC OT - Urothelial carcinoma EDAT- 2024/12/24 00:25 MHDA- 2025/08/06 00:27 CRDT- 2024/12/23 18:25 PHST- 2024/08/11 00:00 [received] PHST- 2024/12/16 00:00 [accepted] PHST- 2025/08/06 00:27 [medline] PHST- 2024/12/24 00:25 [pubmed] PHST- 2024/12/23 18:25 [entrez] AID - 000543235 [pii] AID - 10.1159/000543235 [doi] PST - ppublish SO - Urol Int. 2025;109(4):315-322. doi: 10.1159/000543235. Epub 2024 Dec 23. PMID- 39709558 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250519 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 55 IP - 4 DP - 2025 Apr 6 TI - Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer. PG - 414-420 LID - 10.1093/jjco/hyae183 [doi] AB - OBJECTIVE: This study aimed to assess the oncological outcomes of the subtype of urothelial carcinoma (SUC), including divergent differentiation and histologic subtype, in comparison with those of pure urothelial carcinoma (PUC) in nonmuscle-invasive bladder cancer. METHODS: We retrospectively evaluated patients who were initially treated with transurethral resection of the bladder tumor (TURBT) between March 2005 and August 2020 at a single institution. Patients with PUC and SUC were compared in terms of recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). RESULTS: Out of 853 enrolled patients, 783 (91.8%) and 70 (8.2%) had PUC and SUC, respectively. SUC presence was significantly associated with old age, tumor size (>/=3 cm), higher pT1 rate, high grade, concomitant carcinoma in situ, and lymphovascular invasion. RFS rates after TURBT did not significantly differ between the PUC and SUC groups. With a median follow-up period of 66 months (interquartile range, 38-103 months), the rates and median time of progression to muscle invasion were 6.9% and 22.5 months in the PUC group, and 22.9% and 10.0 months in the SUC group. Moreover, the incidence of progression to metastasis was 4.6% and 15.7% in the PUC and SUC groups, respectively. The 5-year PFS rates (64.5% and 81.9%, P < .001) and 5-year OS rates (71.7% and 86.2%, P = .009) were lower in the SUC group than in the PUC group. On multivariate analysis, SUC presence independently predicted progression to muscle invasion and metastasis. CONCLUSION: At initial TURBT diagnosis, we must pay more attention to higher progression risk of SUC than that of PUC in nonmuscle-invasive bladder cancer. CI - (c) The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Minato, Akinori AU - Minato A AUID- ORCID: 0000-0001-6303-1128 AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Yoshii, Moena AU - Yoshii M AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Watanabe, Shuki AU - Watanabe S AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. AD - Department of Urology, Kitakyushu City Yahata Hospital, Kitakyushu, Japan. FAU - Moriya, Ryosuke AU - Moriya R AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. AD - Department of Urology, Kyushu Rosai Hospital, Moji Medical Center, Kitakyushu, Japan. FAU - Kashiwagi, Eiji AU - Kashiwagi E AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. AD - Department of Urology, Kurate Hospital, Kurate, Japan. LA - eng GR - JP23K15773/JSPS KAKENHI/ PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Middle Aged MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality OTO - NOTNLM OT - divergent differentiation OT - histologic subtype OT - histologic variant OT - nonmuscle-invasive bladder cancer OT - urothelial carcinoma EDAT- 2024/12/22 12:19 MHDA- 2025/04/07 13:17 CRDT- 2024/12/22 10:12 PHST- 2024/09/23 00:00 [received] PHST- 2024/12/11 00:00 [accepted] PHST- 2025/04/07 13:17 [medline] PHST- 2024/12/22 12:19 [pubmed] PHST- 2024/12/22 10:12 [entrez] AID - 7930335 [pii] AID - 10.1093/jjco/hyae183 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2025 Apr 6;55(4):414-420. doi: 10.1093/jjco/hyae183. PMID- 39701156 OWN - NLM STAT- MEDLINE DCOM- 20241219 LR - 20260811 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 21 IP - 1 DP - 2025 Dec TI - State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. PG - 2440165 LID - 10.1080/21645515.2024.2440165 [doi] LID - 2440165 AB - In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC. FAU - Tassinari, Elisa AU - Tassinari E AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. FAU - Danielli, Linda AU - Danielli L AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. FAU - Marchetti, Andrea AU - Marchetti A AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. FAU - Rosellini, Matteo AU - Rosellini M AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. FAU - Ricci, Costantino AU - Ricci C AD - Pathology Unit, DIAP-Dipartimento InterAziendale di Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, Italy. FAU - Piazza, Pietro AU - Piazza P AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. AD - Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Mottaran, Angelo AU - Mottaran A AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. AD - Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. AD - Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Santoni, Matteo AU - Santoni M AD - Oncology Unit, Macerata Hospital, Macerata, Italy. FAU - Mollica, Veronica AU - Mollica V AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Massari, Francesco AU - Massari F AUID- ORCID: 0000-0001-6476-6871 AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241219 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (Immune Checkpoint Inhibitors) RN - 31YO63LBSN (Nivolumab) SB - IM MH - Humans MH - Chemotherapy, Adjuvant/methods MH - *Immune Checkpoint Inhibitors/therapeutic use MH - *Immunotherapy/methods MH - Nivolumab/therapeutic use MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/immunology/therapy PMC - PMC11730629 OAB - This review discusses the latest advancements in post-surgery immune treatments given to prevent recurrences from urothelial cancer. Urothelial cancer is the most frequent type of tumor that affects the bladder and the upper parts of the urinary tract. Immunotherapy is a treatment that helps the body's immune system to fight cancer cells more effectively. Unlike other treatments - such as chemotherapy - that directly kills tumor cells, immunotherapy boosts the natural defenses of the body to attack the cancer. Our article provides a summary of the current state of adjuvant immunotherapy, with the most recent progress and the ongoing clinical trials based on immune checkpoint inhibitors (ICIs). These agents help the immune defenses to recognize and attack cancer cells by blocking specific proteins that prevent the immune system from working properly. Additionally, the review analyzes the innovative drugs that are being developed for earlier stages of the disease, especially for non-muscle-invasive bladder cancer (NMIBC), a type of tumor that has not spread into the muscle layer of the bladder wall. Furthermore, our work also examines potential biological indicators, known as biomarkers that can help clinicians to identify which patients are most likely to benefit from specific treatments, making therapies more effective and personalized. Finally, the article looks at how ongoing research and recent approval of new treatments could lead to significant changes in clinical practice, potentially setting up new standards for treating patients with early-stage urothelial cancer. OABL- eng OTO - NOTNLM OT - Urothelial cancer OT - adjuvant therapy OT - biomarkers OT - bladder cancer OT - immunotherapy OT - muscle-invasive bladder cancer OT - non-muscle invasive bladder cancer COIS- No potential conflict of interest was reported by the author(s). EDAT- 2024/12/20 00:23 MHDA- 2024/12/20 00:24 PMCR- 2024/12/19 CRDT- 2024/12/19 19:13 PHST- 2024/12/20 00:24 [medline] PHST- 2024/12/20 00:23 [pubmed] PHST- 2024/12/19 19:13 [entrez] PHST- 2024/12/19 00:00 [pmc-release] AID - 2440165 [pii] AID - 10.1080/21645515.2024.2440165 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2025 Dec;21(1):2440165. doi: 10.1080/21645515.2024.2440165. Epub 2024 Dec 19. PMID- 39698899 OWN - NLM STAT- MEDLINE DCOM- 20241219 LR - 20250104 IS - 2162-402X (Electronic) IS - 2162-4011 (Print) IS - 2162-4011 (Linking) VI - 14 IP - 1 DP - 2025 Dec TI - Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer. PG - 2438291 LID - 10.1080/2162402X.2024.2438291 [doi] LID - 2438291 AB - High-risk non-muscle-invasive bladder cancer (NMIBC) presents high recurrence and progression rates. Despite the use of Bacillus Calmette-Guerin gold-standard immunotherapy and the recent irruption of anti-PD-1/PD-L1 drugs, we are missing a comprehensive understanding of the tumor microenvironment (TME) that may help us find biomarkers associated to treatment outcome. Here, we prospectively analyzed TME composition and PD-L1 expression of tumor and non-tumoral tissue biopsies from 73 NMIBC patients and used scRNA-seq, transcriptomic cohorts and tissue micro-array to validate the prognostic value of cell types of interest. Compared to non-tumoral tissue, NMIBC presented microvascular alterations, increased cancer-associated fibroblast (CAF) and myofibroblast (myoCAF) presence, and varied immune cell distribution, such as increased macrophage infiltration. Heterogeneous PD-L1 expression was observed across subsets, with macrophages showing the highest expression levels, but cancer cells as the primary potential anti-PD-L1 binding targets. Unbiased analysis revealed that myoCAF and M2-like macrophages are specifically enriched in high-grade NMIBC tumors. The topological distribution of these two cell types changed as NMIBC progresses, as shown by immunofluorescence. Only myoCAFs were associated with higher rates of progression and recurrence in three independent cohorts (888 total patients), reaching prediction values comparable to transcriptomic classes, which we further validated using tissue micro-array. Our study provides a roadmap to establish the landscape of the NMIBC TME, highlighting myoCAFs as potential prognostic markers. FAU - Canizo, Carmen G AU - Canizo CG AD - Urology Department, University Hospital '12 de Octubre', Madrid, Spain. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Urology Department, University Hospital '12 de Octubre', Madrid, Spain. FAU - Perez Escavy, Mercedes AU - Perez Escavy M AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Lodewijk, Iris AU - Lodewijk I AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Suarez-Cabrera, Cristian AU - Suarez-Cabrera C AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Morales, Lucia AU - Morales L AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Nunes, Sandra P AU - Nunes SP AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network) Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal. FAU - Munera-Maravilla, Ester AU - Munera-Maravilla E AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Rubio, Carolina AU - Rubio C AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Sanchez, Rebeca AU - Sanchez R AD - Cell Technology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Enfermedades Raras (CIBERER), Madrid, Spain. FAU - Rodriguez-Izquierdo, Marta AU - Rodriguez-Izquierdo M AD - Urology Department, University Hospital '12 de Octubre', Madrid, Spain. FAU - Martinez de Villarreal, Jaime AU - Martinez de Villarreal J AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain. FAU - Real, Francisco X AU - Real FX AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Epithelial Carcinogenesis Group, Spanish National Cancer Centre-CNIO, Madrid, Spain. AD - Departament de Medicina i Ciencies de la Vida, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Castellano, Daniel AU - Castellano D AD - Oncology Department, University Hospital '12 de Octubre', Madrid, Spain. FAU - Martin-Arriscado, Cristina AU - Martin-Arriscado C AD - Scientific Support Unit, Research Institute I+12, University Hospital 12 de Octubre, Madrid, Spain. FAU - Lora Pablos, David AU - Lora Pablos D AD - Scientific Support Unit, Research Institute I+12, University Hospital 12 de Octubre, Madrid, Spain. FAU - Rodriguez Antolin, Alfredo AU - Rodriguez Antolin A AD - Urology Department, University Hospital '12 de Octubre', Madrid, Spain. FAU - Duenas, Marta AU - Duenas M AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Paramio, Jesus M AU - Paramio JM AUID- ORCID: 0000-0001-7520-3177 AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. FAU - Martinez, Victor G AU - Martinez VG AUID- ORCID: 0000-0002-5515-0626 AD - Molecular and Translational Oncology Division, Biomedical Innovation Unit, CIEMAT, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. AD - Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain. LA - eng PT - Journal Article DEP - 20241219 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/immunology/genetics MH - *Tumor Microenvironment/immunology MH - *B7-H1 Antigen/metabolism/genetics MH - *Myofibroblasts/metabolism/pathology MH - Male MH - Prognosis MH - Female MH - Aged MH - *Biomarkers, Tumor/metabolism/genetics MH - Middle Aged MH - Cancer-Associated Fibroblasts/metabolism/pathology MH - Prospective Studies MH - Aged, 80 and over MH - Macrophages/metabolism/immunology/pathology PMC - PMC11660370 OTO - NOTNLM OT - Bladder cancer OT - Myofibroblasts OT - PD-L1 OT - cancer-associated fibroblasts OT - tumor microenvironment COIS- F.G.R. conflicts of interest: Research support/PI for Combat Medical; Employee for SERMAS (Servicio Madrileno de Salud); Consultant for Janssen, Pfizer, Merck, Roche; Speakers bureau for Combat Medical, Janssen, Nucleix, Pfizer, Merck, Astellas Oncology, BMS, AstraZeneca; Travel for Janssen, Nucleix, Pfizer, Recordati, Ipsen, Combat Medical; Scientific advisory board for AstraZeneca, BMS, Combat Medical, Janssen, Nucleix, Pfizer, Taris; Manuscript support for Pfizer, Janssen, Combat Medical. D.C. conflicts of interest: Consulting or Advisory Role: Janssen Oncology, Roche/Genentech, Astellas Pharma, AstraZeneca, Pfizer, Novartis, Ipsen, Bristol-Myers Squibb, MSD Oncology, Bayer, Lilly, Sanofi, Pierre Fabre, Boehringer Ingelheim; Research Funding: Janssen Oncology; Travel, Accommodations, Expenses: Pfizer, Roche, Bristol-Myers Squibb, AstraZeneca. EDAT- 2024/12/19 12:21 MHDA- 2024/12/19 12:22 PMCR- 2024/12/19 CRDT- 2024/12/19 07:03 PHST- 2024/12/19 12:22 [medline] PHST- 2024/12/19 12:21 [pubmed] PHST- 2024/12/19 07:03 [entrez] PHST- 2024/12/19 00:00 [pmc-release] AID - 2438291 [pii] AID - 10.1080/2162402X.2024.2438291 [doi] PST - ppublish SO - Oncoimmunology. 2025 Dec;14(1):2438291. doi: 10.1080/2162402X.2024.2438291. Epub 2024 Dec 19. PMID- 39697728 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 13 IP - 11 DP - 2024 Nov 30 TI - Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer. PG - 6489-6502 LID - 10.21037/tcr-24-180 [doi] AB - Bladder cancer is a commonly diagnosed cancer, especially in men, and 70% of new diagnoses are considered non-muscle invasive bladder cancer (NMIBC). Bladder cancer is prone to high rates of recurrence, and this risk is greatest in high risk NMIBC. Intravesical bacillus Calmette-Guerin (BCG) is standard of care for reducing rates of recurrence for high risk NMIBC. Despite its favorable efficacy a significant proportion of patients do not have durable prolonged response to BCG and some patients progress to muscle invasive bladder cancer worsening prognosis. Predictive tools are needed in clinical practice to identify patients who are not likely to respond to BCG and need alternative treatments. The European Organization for Research and Treatment of Cancer (EORTC) and Club Urologico Espanol de Tratamiento Oncologico (CUETO) have proposed outcome prediction tables for NMIBC patients, providing risk stratification and recurrence and progression probability scores. While valuable in clinical practice, these tables have limitations and overestimate recurrence and progression for high risk NMIBC. Several efforts have attempted to refine our ability to better understand which patients derive the greatest benefit from BCG. T1 pathologic substaging, tumor budding, and artificial intelligence techniques studying pathologic features of the tumor and the microenvironment have been applied to high risk NMIBC as a means of identifying patients less likely to respond to BCG. Molecular markers, genomic alterations and transcriptomic signatures are promising and hold the potential to aid in forecasting tumor progression and response to therapy. However, their application is still in its initial phases and necessitates additional validation through further studies. This review describes both clinical and molecular risk factors that could prove beneficial in anticipating the response to BCG, with a particular focus on high-risk T1 bladder cancers. CI - 2024 AME Publishing Company. All rights reserved. FAU - Soltani-Tehrani, Amir M AU - Soltani-Tehrani AM AD - Department of Urology, Ohio State University Wexner Medical Centre/The James Cancer Hospital, Columbus, OH, USA. FAU - Kumar, Aman AU - Kumar A AD - Department of Urology, Ohio State University Wexner Medical Centre/The James Cancer Hospital, Columbus, OH, USA. FAU - Pohar, Kamal S AU - Pohar KS AD - Department of Urology, Ohio State University Wexner Medical Centre/The James Cancer Hospital, Columbus, OH, USA. LA - eng PT - Journal Article PT - Review DEP - 20240730 PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC11651738 OTO - NOTNLM OT - Bladder cancer OT - bacillus Calmette-Guerin (BCG) OT - molecular markers OT - non-muscle invasive bladder cancer (NMIBC) OT - urine cytokine COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-180/coif). The authors have no conflicts of interest to declare. EDAT- 2024/12/19 06:23 MHDA- 2024/12/19 06:24 PMCR- 2024/11/30 CRDT- 2024/12/19 05:12 PHST- 2024/01/26 00:00 [received] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/12/19 06:24 [medline] PHST- 2024/12/19 06:23 [pubmed] PHST- 2024/12/19 05:12 [entrez] PHST- 2024/11/30 00:00 [pmc-release] AID - tcr-13-11-6489 [pii] AID - 10.21037/tcr-24-180 [doi] PST - ppublish SO - Transl Cancer Res. 2024 Nov 30;13(11):6489-6502. doi: 10.21037/tcr-24-180. Epub 2024 Jul 30. PMID- 39697701 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 13 IP - 11 DP - 2024 Nov 30 TI - Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review. PG - 6413-6429 LID - 10.21037/tcr-24-726 [doi] AB - BACKGROUND AND OBJECTIVE: A standard of care for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Given recent improvements in NAC and the morbidity associated with RC, bladder-sparing therapy has been investigated as a promising treatment for patients with MIBC who experience a complete clinical response (CCR) to systemic therapy. However, clinical staging is unreliable, making it challenging to determine ideal candidates for bladder-sparing therapy. Our primary objective is to review the efficacy of NAC, strategies for determining a CCR as a surrogate for a complete pathologic response, and the emerging role of imaging, tumor genomics, and biomarkers in selecting candidates for bladder-sparing therapy. METHODS: We surveyed the literature for studies investigating the outcomes of current treatment modalities for MIBC and methods for determining a CCR following systemic therapy as well as the impact this has on pathologic staging. Studies employing imaging, tumor biomarkers, and genomics were included. KEY CONTENT AND FINDINGS: Clinical staging with cystoscopy or transurethral resection shows significant discordance with final pathology, with high rates of understaging. Multiparametric magnetic resonance imaging (mpMRI) has shown strong utility in determining the presence of MIBC, but it has yet to reliably identify CCR. Meanwhile, somatic DNA damage repair mutations and biomarkers such as circulating and urinary tumor DNA are strong predictors of recurrence, showing promise in predicting and monitoring a CCR to systemic therapy. Multiple ongoing trials are currently assessing the use of biomarkers and genomic analyses in determining eligibility for bladder-sparing therapy. CONCLUSIONS: While no one method has reliably demonstrated the ability to detect a true CCR, a multimodal approach involving imaging, biomarkers, and genomic analyses holds promise. We eagerly await the results of clinical trials investigating these tools, which may allow for the safe recommendation of bladder-sparing therapy. CI - 2024 AME Publishing Company. All rights reserved. FAU - Patel, Mann AU - Patel M AUID- ORCID: 0009-0002-0193-6102 AD - Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Moore, Kyle AU - Moore K AD - Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Lichtbroun, Benjamin L AU - Lichtbroun BL AD - Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Stephenson, Ryan D AU - Stephenson RD AD - Division of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Mayer, Tina AU - Mayer T AD - Division of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Saraiya, Biren AU - Saraiya B AD - Division of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Golombos, David AU - Golombos D AD - Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Jang, Thomas AU - Jang T AD - Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Section of Urologic Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA. LA - eng PT - Journal Article PT - Review DEP - 20241111 PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC11651806 OTO - NOTNLM OT - Muscle-invasive bladder cancer (MIBC) OT - bladder-sparing therapy OT - complete clinical response (CCR) OT - neoadjuvant chemotherapy (NAC) OT - tumor biomarker COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-726/coif). V.T.P. receives consulting and speakers' bureaus fees from Veracyte. The other authors have no conflicts of interest to declare. EDAT- 2024/12/19 06:22 MHDA- 2024/12/19 06:23 PMCR- 2024/11/30 CRDT- 2024/12/19 05:12 PHST- 2024/05/05 00:00 [received] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/12/19 06:23 [medline] PHST- 2024/12/19 06:22 [pubmed] PHST- 2024/12/19 05:12 [entrez] PHST- 2024/11/30 00:00 [pmc-release] AID - tcr-13-11-6413 [pii] AID - 10.21037/tcr-24-726 [doi] PST - ppublish SO - Transl Cancer Res. 2024 Nov 30;13(11):6413-6429. doi: 10.21037/tcr-24-726. Epub 2024 Nov 11. PMID- 39694798 OWN - NLM STAT- MEDLINE DCOM- 20250322 LR - 20250605 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 2 DP - 2025 Apr TI - Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guerin in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer. PG - 469-476 LID - S2588-9311(24)00288-8 [pii] LID - 10.1016/j.euo.2024.12.005 [doi] AB - BACKGROUND AND OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guerin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for NMIBC. This study aims to compare oncologic outcomes between sequential intravesical gem/doce versus additional BCG in patients with BCG-unresponsive NMIBC. METHODS: Data were collected from ten academic institutions on patients with BCG-unresponsive NMIBC based on the Food and Drug Administration guidelines. Information on high-grade recurrence-free (HGRFS), progression-free (PFS), cystectomy-free (CFS), metastasis-free (MFS), cancer-specific (CSS), and overall (OS) survival was collected. The Kaplan-Meier method and Cox proportional hazard ratios (HRs) were used to determine differences in oncologic outcomes between the Gem/Doce and BCG groups. KEY FINDINGS AND LIMITATIONS: Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: The findings from this study suggest that intravesical gem/doce is associated with lower rates of progression than additional BCG in patients with BCG-unresponsive NMIBC who decline or are ineligible for cystectomy. PATIENT SUMMARY: In this report, we looked at outcomes between patients with noninvasive bladder cancer who were treated with additional bacillus Calmette-Guerin (BCG) or gemcitabine-docetaxel combination after not responding to primary BCG therapy. We found that intravesical gemcitabine-docetaxel was associated with fewer progression events than additional salvage BCG therapy. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Taylor, Jacob AU - Taylor J AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Annapureddy, Drupad AU - Annapureddy D AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Khene, Zine-Eddine AU - Khene ZE AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Howard, Jeffrey AU - Howard J AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Tan, Wei Shen AU - Tan WS AD - UT MD Anderson Cancer Center, Houston, TX, USA. FAU - McElree, Ian M AU - McElree IM AD - University of Iowa, Iowa City, IA, USA. FAU - Facundo, Davaro AU - Facundo D AD - Moffit Cancer Center, Tampa, FL, USA. FAU - Yim, Kendrick AU - Yim K AD - Brigham and Women's Hospital, Boston, MA, USA. FAU - Harrington, Stephen AU - Harrington S AD - Penn State University, Hershey, PA, USA. FAU - Dyer, Elizabeth AU - Dyer E AD - Penn State University, Hershey, PA, USA. FAU - Black, Anna J AU - Black AJ AD - University of British Columbia, Vancouver, BC, Canada. FAU - Kanabur, Pratik AU - Kanabur P AD - Baylor College of Medicine, Houston, TX, USA. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - CHU-Institut Universitaire du Cancer-Oncopole, Toulouse, France. FAU - Lerner, Seth AU - Lerner S AD - Baylor College of Medicine, Houston, TX, USA. FAU - Black, Peter C AU - Black PC AD - University of British Columbia, Vancouver, BC, Canada. FAU - Raman, Jay D AU - Raman JD AD - Penn State University, Hershey, PA, USA. FAU - Preston, Mark AU - Preston M AD - Brigham and Women's Hospital, Boston, MA, USA. FAU - Steinberg, Gary AU - Steinberg G AD - Rush University, Chicago, IL, USA. FAU - Huang, William AU - Huang W AD - New York University Langone Health, New York, NY, USA. FAU - Li, Roger AU - Li R AD - Moffit Cancer Center, Tampa, FL, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - University of Iowa, Iowa City, IA, USA. FAU - Woldu, Solomon L AU - Woldu SL AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Lotan, Yair AU - Lotan Y AD - University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: yair.lotan@utsouthwestern.edu. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - University of Iowa, Iowa City, IA, USA. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20241217 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Docetaxel/administration & dosage MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Male MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage MH - Treatment Outcome MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic MH - Retrospective Studies MH - Aged, 80 and over MH - Cystectomy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder-sparing therapy OT - Docetaxel OT - Gemcitabine OT - Intravesical therapy OT - Urinary bladder neoplasms EDAT- 2024/12/19 00:20 MHDA- 2025/03/23 16:51 CRDT- 2024/12/18 21:57 PHST- 2024/08/15 00:00 [received] PHST- 2024/11/25 00:00 [revised] PHST- 2024/12/05 00:00 [accepted] PHST- 2025/03/23 16:51 [medline] PHST- 2024/12/19 00:20 [pubmed] PHST- 2024/12/18 21:57 [entrez] AID - S2588-9311(24)00288-8 [pii] AID - 10.1016/j.euo.2024.12.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Apr;8(2):469-476. doi: 10.1016/j.euo.2024.12.005. Epub 2024 Dec 17. PMID- 39689991 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20250519 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 1 DP - 2025 Feb TI - Association Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin Immunotherapy. PG - 164-170 LID - S2588-9311(24)00284-0 [pii] LID - 10.1016/j.euo.2024.12.002 [doi] AB - BACKGROUND AND OBJECTIVE: There is a lack of data on the impact of hypoglycemia agents, especially metformin, on prognosis for non-muscle-invasive bladder cancer (NMIBC). Our aim was to investigate the association between hypoglycemia agents, especially metformin, and long-term survival outcomes for patients with NMIBC treated with bacillus Calmette-Guerin. METHODS: All patients with NMIBC treated with intravesical BCG therapy from 2001 to 2020 were identified in a territory-wide database in Hong Kong. Patients were stratified into two groups according to whether or not they were taking a hypoglycemia agent at BCG treatment initiation. We analyzed data for overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust for potential confounding factors and estimate hazard ratio (HRs) and 95% confidence intervals (CIs). Subgroup analyses were conducted to assess the specific influence of metformin on survival outcomes. KEY FINDINGS AND LIMITATIONS: Of 2602 patients with NMIBC treated with intravesical BCG, 19.5% (n = 507) were taking a hypoglycemia agent at BCG initiation (treatment group) and 80.5% (n = 2095) were not (control group). At median follow-up of 11 yr, Kaplan-Meier analysis revealed a significant difference in OS between the groups (p < 0.01), but not in CSS (p = 0.36), RFS (p = 0.19), or PFS (p = 0.05). Subgroup analysis comparing outcomes for patients taking metformin, patients taking a hypoglycemia agent other than metformin, and control subjects revealed significant differences in OS (p < 0.01) and RFS (p = 0.02), but not in CSS (p = 0.59) or PFS (p = 0.08). Multivariable Cox regression analysis identified metformin-based treatment for hypoglycemia as an independent risk factor for RFS (HR 1.22, 95% CI 1.02-1.46), whereas hypoglycemia agents other than metformin were not significantly associated with RFS (HR 0.71, 95% CI 0.47-1.06). CONCLUSIONS AND CLINICAL IMPLICATIONS: Metformin-based hypoglycemia treatment was an independent risk factor for RFS in BCG-treated NMIBC. Hypoglycemia treatment with an agent other than metformin was not related to long-term survival outcomes. PATIENT SUMMARY: We investigated the relationship between treatment for high blood sugar and long-term survival for patients with intermediate-risk or high-risk non-muscle-invasive bladder cancer. The patients had received BCG (bacillus Calmette-Guerin) treatment in Hong Kong for their bladder cancer over the past two decades. Our results show that metformin, but not other drugs used to treat high blood sugar, was associated with poorer survival free from bladder cancer recurrence for these patients. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chen, Xuan AU - Chen X AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Wu, Hongwei AU - Wu H AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ko, Ivan Ching-Ho AU - Ko IC AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Nicoletti, Rossella AU - Nicoletti R AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: ngcf@surgery.cuhk.edu.hk. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Urology, Medical University of Vienna, Austria, Vienna. Electronic address: jeremyteoh@surgery.cuhk.edu.hk. LA - eng PT - Journal Article DEP - 20241216 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Hypoglycemic Agents) RN - 9100L32L2N (Metformin) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/mortality/pathology MH - Male MH - Female MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Aged MH - Middle Aged MH - *Hypoglycemic Agents/therapeutic use MH - *Metformin/therapeutic use MH - Administration, Intravesical MH - *Immunotherapy/methods MH - *Hypoglycemia/chemically induced/drug therapy MH - Retrospective Studies MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Survival Rate MH - Treatment Outcome MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Cancer-specific survival OT - Hypoglycemia agents OT - Metformin OT - Non-muscle-invasive bladder cancer OT - Overall survival OT - Progression-free survival OT - Recurrence-free survival EDAT- 2024/12/18 00:23 MHDA- 2025/02/13 00:21 CRDT- 2024/12/17 21:54 PHST- 2024/07/16 00:00 [received] PHST- 2024/11/25 00:00 [revised] PHST- 2024/12/02 00:00 [accepted] PHST- 2025/02/13 00:21 [medline] PHST- 2024/12/18 00:23 [pubmed] PHST- 2024/12/17 21:54 [entrez] AID - S2588-9311(24)00284-0 [pii] AID - 10.1016/j.euo.2024.12.002 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Feb;8(1):164-170. doi: 10.1016/j.euo.2024.12.002. Epub 2024 Dec 16. PMID- 39685620 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 23 DP - 2024 Nov 26 TI - Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis. LID - 10.3390/jcm13237159 [doi] LID - 7159 AB - Bladder cancer (BC) currently ranks as the 9th most common cancer worldwide. It is characterised by very high rates of recurrence and metastasis. Most cases of BC are of urothelial origin, and due to its ability to penetrate muscle tissue, BC is divided into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). The current diagnosis of BC is still based primarily on invasive cystoscopy, which is an expensive and invasive method that carries a risk of various complications. Urine sediment cytology is often used as a complementary test, the biggest drawback of which is its very low sensitivity concerning the detection of BC at early stages, which is crucial for prompt implementation of appropriate treatment. Therefore, there is a great need to develop innovative diagnostic techniques that would enable early detection and accurate prognosis of BC. Great potential in this regard is shown by epigenetic changes, which are often possible to observe long before the onset of clinical symptoms of the disease. In addition, these changes can be detected in readily available biological material, such as urine or blood, indicating the possibility of constructing non-invasive diagnostic tests. Over the past few years, many studies have emerged using epigenetic alterations as novel diagnostic and prognostic biomarkers of BC. This review provides an update on promising diagnostic biomarkers for the detection and prognosis of BC based on epigenetic changes such as DNA methylation and expression levels of selected non-coding RNAs (ncRNAs), taking into account the latest literature data. FAU - Jaszek, Natalia AU - Jaszek N AD - Department of Laboratory Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland. FAU - Bogdanowicz, Alicja AU - Bogdanowicz A AD - Department of Laboratory Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland. FAU - Siwiec, Jan AU - Siwiec J AD - Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland. FAU - Starownik, Radoslaw AU - Starownik R AD - Department of Urology and Urological Oncology, Medical University of Lublin, 20-090 Lublin, Poland. FAU - Kwasniewski, Wojciech AU - Kwasniewski W AUID- ORCID: 0000-0002-7522-1401 AD - Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-081 Lublin, Poland. FAU - Mlak, Radoslaw AU - Mlak R AUID- ORCID: 0000-0001-7399-8340 AD - Department of Laboratory Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland. LA - eng PT - Journal Article PT - Review DEP - 20241126 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11642161 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - early detection OT - epigenetics OT - prognosis COIS- The authors declare no conflicts of interest. EDAT- 2024/12/17 11:49 MHDA- 2024/12/17 11:50 PMCR- 2024/11/26 CRDT- 2024/12/17 01:20 PHST- 2024/10/22 00:00 [received] PHST- 2024/11/20 00:00 [revised] PHST- 2024/11/24 00:00 [accepted] PHST- 2024/12/17 11:50 [medline] PHST- 2024/12/17 11:49 [pubmed] PHST- 2024/12/17 01:20 [entrez] PHST- 2024/11/26 00:00 [pmc-release] AID - jcm13237159 [pii] AID - jcm-13-07159 [pii] AID - 10.3390/jcm13237159 [doi] PST - epublish SO - J Clin Med. 2024 Nov 26;13(23):7159. doi: 10.3390/jcm13237159. PMID- 39682286 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 23 DP - 2024 Dec 7 TI - Sex Disparities in Bladder Cancer Diagnosis and Treatment. LID - 10.3390/cancers16234100 [doi] LID - 4100 AB - Gender differences in prevalence, tumor invasiveness, response to treatment, and clinical outcomes exist in different types of cancer. The aim of this article is to summarize the sex disparities in bladder cancer diagnosis and treatment and try to suggest areas for improvement. Although men are at a higher risk of developing bladder tumors, women tend to be diagnosed with more advanced stages at diagnosis and are more likely to present with upfront muscle-invasive disease. Non-urothelial histological subtypes are more frequently reported in women. Regarding non-muscle-invasive bladder cancer (NMIBC), several studies have shown that women have a higher risk of disease recurrence after treatment with Bacillus Calmette-Guerin, due to different immunogenicities. In localized muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy and cystectomy are less likely to be performed on women and sexual-sparing procedures with neobladder diversion are rarely offered. Finally, women appear to have a poorer prognosis than men, potentially due to the sex-associated intrinsic features of hosts and tumors that may drive differential therapeutic responses, particularly to immune-based therapies. Women are also more likely to develop severe adverse events related to systemic therapies and are underrepresented in randomized studies, leading to a gap between the real world and trials. In conclusion, studies investigating the role of sex and gender are urgently needed to improve the management of urothelial carcinoma. FAU - Pignot, Geraldine AU - Pignot G AUID- ORCID: 0000-0001-5282-9134 AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009 Marseille, France. FAU - Barthelemy, Philippe AU - Barthelemy P AD - Medical Oncology Unit, ICANS, Hopitaux Universitaires de Strasbourg, 67200 Strasbourg, France. FAU - Borchiellini, Delphine AU - Borchiellini D AD - Medical Oncology Unit, Centre Antoine Lacassagne, Universite Cote d'Azur, 06000 Nice, France. LA - eng PT - Journal Article PT - Review DEP - 20241207 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11640134 OTO - NOTNLM OT - bladder cancer OT - immunotherapy OT - prognosis OT - sex differences OT - treatment COIS- On behalf of all authors, the corresponding author states that there is no conflict of interest. EDAT- 2024/12/17 11:48 MHDA- 2024/12/17 11:49 PMCR- 2024/12/07 CRDT- 2024/12/17 01:01 PHST- 2024/11/01 00:00 [received] PHST- 2024/11/28 00:00 [revised] PHST- 2024/12/06 00:00 [accepted] PHST- 2024/12/17 11:49 [medline] PHST- 2024/12/17 11:48 [pubmed] PHST- 2024/12/17 01:01 [entrez] PHST- 2024/12/07 00:00 [pmc-release] AID - cancers16234100 [pii] AID - cancers-16-04100 [pii] AID - 10.3390/cancers16234100 [doi] PST - epublish SO - Cancers (Basel). 2024 Dec 7;16(23):4100. doi: 10.3390/cancers16234100. PMID- 39678572 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 1943-8141 (Print) IS - 1943-8141 (Electronic) IS - 1943-8141 (Linking) VI - 16 IP - 11 DP - 2024 TI - Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence. PG - 6914-6924 LID - 10.62347/UVFF9164 [doi] AB - OBJECTIVE: To investigate the effectiveness of combining transurethral resection of bladder tumor (TURBT) with Bacille Calmette-Guerin (BCG) intravesical instillation in treating high-risk non-muscle invasive bladder cancer (HRNMIBC). METHODS: We retrospectively reviewed the clinical data from 118 HRNMIBC patients treated at Tongren Hospital between March 2020 and June 2022. The patients were categorized into two groups based on their treatment regimen: the control group (n=60) which received regular pirarubicin intravesical instillation, and the observation group (n=58) which received additional BCG intravesical instillation alongside pirarubicin. All patients underwent TURBT. Postoperative follow-up included monitoring recurrence and adverse reactions. Quality of life was assessed for both groups before and after treatment. Peripheral blood T lymphocyte subsets and immunoglobulin levels were measured pre- and post-instillation. Patients were further classified into recurrence and non-recurrence groups to analyze factors influencing HRNMIBC recurrence. RESULTS: The observation group exhibited a recurrence rate of 22.41% (13/58), notably lower than the 41.66% (25/60) in the control group (P<0.05). Both groups showed improved postoperative scores in somatic, emotional, social, cognitive, and role functions compared to preoperative scores, with the observation group demonstrating significantly higher scores across all domains (all P<0.05). Post-instillation, CD4+, CD4+/CD8+, Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA) levels were elevated in both groups relative to pre-instillation levels, whereas CD8+ levels were reduced. The observation group showed significantly higher levels of CD4+, CD4+/CD8+, IgM, IgG, and IgA, and lower levels of CD8+ compared to the control group following instillation (all P<0.05). Univariate analysis revealed that tumor number, stage, grade, and primary tumor status were all significantly associated with HRNMIBC recurrence (all P<0.05). Multivariate logistic regression further identified tumor number, stage, grade, and primary status as independent predictors of HRNMIBC recurrence (all P<0.05). CONCLUSION: The combination of TURBT with pirarubicin and BCG intravesical instillation significantly lowers the recurrence rate in HRNMIBC patients and enhances both quality of life and immune function recovery. Independent factors affecting HRNMIBC recurrence include tumor number, stage, grade, and primary tumor status. CI - AJTR Copyright (c) 2024. FAU - Xu, An AU - Xu A AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. FAU - Liu, Min AU - Liu M AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. FAU - Han, Chengtao AU - Han C AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. FAU - Wang, Zhou AU - Wang Z AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. FAU - Jia, Boshen AU - Jia B AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. FAU - Zhao, Shutian AU - Zhao S AD - Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200050, China. LA - eng PT - Journal Article DEP - 20241115 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC11645617 OTO - NOTNLM OT - Bacille Calmette-Guerin vaccine OT - High-risk non-muscle invasive bladder cancer OT - efficacy OT - influencing factor OT - relapse OT - transurethral resection of bladder tumor COIS- None. EDAT- 2024/12/16 17:25 MHDA- 2024/12/16 17:26 PMCR- 2024/11/15 CRDT- 2024/12/16 07:09 PHST- 2024/08/04 00:00 [received] PHST- 2024/10/30 00:00 [accepted] PHST- 2024/12/16 17:26 [medline] PHST- 2024/12/16 17:25 [pubmed] PHST- 2024/12/16 07:09 [entrez] PHST- 2024/11/15 00:00 [pmc-release] AID - 10.62347/UVFF9164 [doi] PST - epublish SO - Am J Transl Res. 2024 Nov 15;16(11):6914-6924. doi: 10.62347/UVFF9164. eCollection 2024. PMID- 39677281 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 17 DP - 2024 TI - Predictive Value of the Platelet-Lymphocyte Ratio for Intravesical Recurrence After Radical Nephroureterectomy: A Retrospective Study. PG - 10819-10833 LID - 10.2147/JIR.S483242 [doi] AB - OBJECTIVE: The aim of this study was to evaluate the impact of preoperative platelet lymphocyte ratio (PLR) on the prognosis of patients after radical nephrectomy (RNU). METHODS: We retrospectively analyzed clinical data from 226 patients without a history of bladder cancer who underwent RNU at Beijing Chaoyang Hospital, Capital Medical University between January 2009 and December 2020. Patients were stratified into two groups (A low PLR group (n = 174) and a high PLR group (PLR >/= 169.4) based on an optimal PLR threshold (PLR=169.4). The predictive accuracy of inflammatory biomarkers was assessed using receiver operating characteristic curves. Univariate and multivariate Cox proportional risk analyses were used to estimate the effect of PLR on intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), and overall survival (OS). The effect of PLR on IVRFS, RFS and OS was further examined using Kaplan-Meier survival curve analysis. RESULTS: The study cohort comprised 226 individuals with a mean age of 67.2 +/- 9.8, 113 (50%) males and 113 (50%) females, 68 (30.1%) low-grade tumors and 158 (69.9%) high-grade tumors. In this study, 81 patients (36.7%) relapsed and 73 patients (32.3%) died. The area under the curve for PLR prediction of IVRFS was 0.603, superior to other inflammatory biomarkers. Multivariate analysis showed that PLR > 169.4 independently increased the risk of IVR after RNU, resulting in lower IVRFS [2.028 (1.014-4.057), P = 0.046], RFS [1.900 (1.168-3.090), P = 0.010], and OS [1.866 (1.099-3.167), P = 0.021]. In addition, survival analysis showed lower IVRFS [8.815 (62.722-97.278), P = 0.007], RFS [12.084 (44.315-91.685), P = 0.003] and OS RFS [10.165 (62.077-101.923), P = 0.005] in the low PLR group. CONCLUSION: Elevated preoperative PLR is strongly associated with prognosis in patients with upper urothelial carcinoma (UTUC) after RNU without a history of bladder cancer. CI - (c) 2024 Zhao et al. FAU - Zhao, Yu AU - Zhao Y AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Ma, Yina AU - Ma Y AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Zhang, Wenhui AU - Zhang W AUID- ORCID: 0000-0002-5769-4942 AD - Department of Hepatobiliary Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Jiao, Binbin AU - Jiao B AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Chen, Yuanhao AU - Chen Y AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Li, Gao AU - Li G AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Zhang, Xin AU - Zhang X AD - Department of Urology Surgery, Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20241211 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 PMC - PMC11646459 OTO - NOTNLM OT - intravesical recurrence OT - platelet-lymphocyte ratio OT - radical nephroureterectomy OT - upper urinary tract uroepithelial carcinoma COIS- The authors declare no competing interests in this work. EDAT- 2024/12/16 17:25 MHDA- 2024/12/16 17:26 PMCR- 2024/12/11 CRDT- 2024/12/16 06:27 PHST- 2024/06/18 00:00 [received] PHST- 2024/11/27 00:00 [accepted] PHST- 2024/12/16 17:26 [medline] PHST- 2024/12/16 17:25 [pubmed] PHST- 2024/12/16 06:27 [entrez] PHST- 2024/12/11 00:00 [pmc-release] AID - 483242 [pii] AID - 10.2147/JIR.S483242 [doi] PST - epublish SO - J Inflamm Res. 2024 Dec 11;17:10819-10833. doi: 10.2147/JIR.S483242. eCollection 2024. PMID- 39672689 OWN - NLM STAT- MEDLINE DCOM- 20250301 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 3 DP - 2025 Mar TI - Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy. PG - 189.e1-189.e8 LID - S1078-1439(24)00748-8 [pii] LID - 10.1016/j.urolonc.2024.11.015 [doi] AB - INTRODUCTION: The nonmuscle invasive bladder cancer treated with BCG instillations in patients who smoke could potentially lead to poorer oncological results in the light of the new EAU risk groups classification for NMIBC that did not include BCG treated patients or smoking status. PATIENT AND METHODS: Outcomes from 1313 patients with nonmuscle invasive bladder cancer treated with TURBT, re-TURBT and BCG instillations at 13 academic hospital centers, since 2002, has been included in this retrospective study. The study variables, including cumulative smoking exposure have been analyzed. A multivariable Cox proportional hazard model was used to assess associations between smoking variables and disease progression and repeated in the EAU high risk and very high-risk group. The statistical significance threshold was set at 0.05, and the statistical analysis was performed using Stata/SE version 17 (StataCorp, College Station, TX, USA). RESULTS: Cox regression analysis revealed in 1313 patients diagnosed with T1G3 NMIBC that patients with a history of heavy and long-term smoking faced a more than twofold increased risk of disease progression compared to nonsmoker patients (HR 2.35; 95% CI: 1.7-3.2; P < 0.01) and a significantly poorer PFS for patients with a history of heavy long-term smoke exposure (P < 0.01). Patients with heavy long-term smoking exposure according to the EAU21 high-risk group had a PFS comparable to very high-risk patients and high-risk patients with heavy long-term smoking exposure showed a higher risk of progression when compared to the high-risk group (HR 1.4; 95% CI: 1.3-1.6; P < 0.01). CONCLUSIONS: This study adds valuable information on the relationship between smoking and the progression of NMIBC and BCG therapy. The findings emphasize the need for healthcare providers to consider a patient's smoking history when managing NMIBC and express the need for individualized smoking cessation counseling and individualized treatment approach. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. FAU - Claps, Francesco AU - Claps F AD - Urology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56127 Pisa, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. FAU - Aveta, Achille AU - Aveta A AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - Pandolfo, Savio AU - Pandolfo S AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, 10043 Orbassano, Turin, Italy. FAU - Fiori, Cristian AU - Fiori C AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, 10043 Orbassano, Turin, Italy. FAU - Barone, Biagio AU - Barone B AD - Division of Urology, Department of Surgical Sciences, AORN Sant'Anna e San Sebastiano, 81100 Caserta, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - Ditonno, Pasquale AU - Ditonno P AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Lasorsa, Francesco AU - Lasorsa F AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Falagario, Ugo AU - Falagario U AD - Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Giudice, Francesco Del AU - Giudice FD AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, 16126 Genoa, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, 16126 Genoa, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Unit of Urology, Department of Surgery, Tor Vergata University, Rome, Italy; Department of Urology, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy, 00165 Rome, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Todea-Moga, Ciprian AU - Todea-Moga C AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, 540142 Targu Mures, Romania. FAU - Minervini, Andrea AU - Minervini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Musi, Gennaro AU - Musi G AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Fallara, Giuseppe AU - Fallara G AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Bianchi, Roberto AU - Bianchi R AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Tozzi, Marco AU - Tozzi M AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy. FAU - Janello, Letizia M I AU - Janello LMI AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Russo, Giorgio I AU - Russo GI AD - Department of Surgery, Urology Section, University of Catania, 95124 Catania, Italy. FAU - Schips, Luigi AU - Schips L AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy. FAU - Perdona, Sisto AU - Perdona S AD - G. Pascale IRCCS Foundation, 80131 Naples, Italy. FAU - Tataru, Octavian S AU - Tataru OS AD - I.O.S.U.D., George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, 540142 Targu Mures, Romania. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Rush University Medical Center, Chicago, IL 60612, USA. FAU - Catellani, Michele AU - Catellani M AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy. FAU - Sighinolfi, Chiara AU - Sighinolfi C AD - U.O.C. Clinica Urologica, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Universita Cattolica del Sacro Cuore, Milam, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Stasi, Savino M Di AU - Stasi SMD AD - Department of Experimental Medicine and Surgery, Tor Vegata University, 00133 Rome, Italy. FAU - Rocco, Bernardo AU - Rocco B AD - U.O.C. Clinica Urologica, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Universita Cattolica del Sacro Cuore, Milam, Italy. Electronic address: bernardomariacesare.rocco@unicatt.it. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, Milan 20142, Italy. Electronic address: matteo.ferro@ieo.it. LA - eng PT - Journal Article DEP - 20241212 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *BCG Vaccine/therapeutic use MH - Disease Progression MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Smoking/adverse effects MH - Middle Aged MH - *Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Risk Factors OTO - NOTNLM OT - BCG OT - Nonmuscle invasive bladder cancer OT - Progression OT - Smoking COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/14 00:24 MHDA- 2025/03/03 00:54 CRDT- 2024/12/13 21:57 PHST- 2024/03/05 00:00 [received] PHST- 2024/11/04 00:00 [revised] PHST- 2024/11/11 00:00 [accepted] PHST- 2025/03/03 00:54 [medline] PHST- 2024/12/14 00:24 [pubmed] PHST- 2024/12/13 21:57 [entrez] AID - S1078-1439(24)00748-8 [pii] AID - 10.1016/j.urolonc.2024.11.015 [doi] PST - ppublish SO - Urol Oncol. 2025 Mar;43(3):189.e1-189.e8. doi: 10.1016/j.urolonc.2024.11.015. Epub 2024 Dec 12. PMID- 39672342 OWN - NLM STAT- MEDLINE DCOM- 20250312 LR - 20250724 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 197 DP - 2025 Mar TI - Effect of Bacillus Calmette-Guerin Instillation Timing on Oncological Survivals After Transurethral Resection of Bladder Tumor. PG - 126-132 LID - S0090-4295(24)01133-6 [pii] LID - 10.1016/j.urology.2024.12.003 [doi] AB - OBJECTIVE: To investigate whether the timing of bacillus Calmette-Guerin instillation (TTBCG), which plays a key role in treating non-muscle invasive bladder cancer (NMIBC), after transurethral resection of bladder tumor (TURBT) affects oncologic outcomes. METHODS: Patient data obtained from the Urologic Cancer Database-Bladder (UroCaD-B) of Turkish Uro-oncology Association (TUOA) were evaluated. Data from 292 patients from 12 centers with primary T1HG treated with TURBT and maintenance BCG between 2003 and 2023 were retrospectively analyzed. The population was subdivided according to TTBCG, while recurrence-free survival (RFS) and progression-free survival (PFS) were estimated by log-rank tests and univariable and multivariable regression analyses. RESULTS: A total of 292 patients were followed, and 86% (n=251) of those included in the study were male. The median duration of TTBCG was 38.5 days (19-73). The median follow-up period was 38.4 months (21.5-72.1 months). During follow-up, recurrence was detected in 55 (18.5%) patients and progression was detected in 22 (7.5%) patients. In univariate Cox regression analysis, long TTBCG (>27.5 days) was found to have a statistically significant effect on the risk of short RFS and PFS (P=.05). BCG-related side effects were not associated with TTBCG (P=.313). Kaplan-Meier analysis showed that there was a significant difference in RFS and PFS between the TTBCG groups (P=.04, P=.011, respectively). CONCLUSION: In this retrospective non-randomized study, we showed the negative effects of BCG delay on progression and recurrence in T1HG patients. Therefore, we think that BCG should be instilled within 4 weeks after surgery. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Cetin, Taha AU - Cetin T AD - Izmir University of Economics Medical Point Hospital Urology Dept., Izmir, Turkey. Electronic address: tahacetin88@gmail.com. FAU - Bolat, Deniz AU - Bolat D AD - Health Science University Izmir City Hospital Urology Dept, Izmir, Turkey. FAU - Akgul, Murat AU - Akgul M AD - Health Science University Umraniye Research and Training Hospital Urology Dept., Istanbul, Turkey. FAU - Yazici, Sertac AU - Yazici S AD - Hacettepe University Faculty of Medicine Urology Dept. Ankara, Turkey. FAU - Aslan, Guven AU - Aslan G AD - Dokuz Eylul University Faculty of Medicine Urology Dept., Izmir, Turkey. FAU - Akan, Serkan AU - Akan S AD - Health Science University Fatih Sultan Mehmet Research and Training Hospital Urology Dept., Istanbul, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Ankara University Faculty of Medicine Urology Dept., Ankara, Turkey. FAU - Muezzinoglu, Talha AU - Muezzinoglu T AD - Celal Bayar University Faculty of Medicine Urology Dept., Manisa, Turkey. FAU - Bayazit, Yildirim AU - Bayazit Y AD - Cukurova University Faculty of Medicine Urology Dept., Adana, Turkey. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20241211 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/surgery/therapy/pathology/drug therapy MH - *BCG Vaccine/administration & dosage MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - *Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Middle Aged MH - *Cystectomy/methods MH - Time Factors MH - Neoplasm Recurrence, Local/epidemiology MH - Progression-Free Survival MH - Survival Rate MH - Transurethral Resection of Bladder COIS- Declaration of Competing Interest The authors have no conflict of interest to declare. EDAT- 2024/12/14 00:25 MHDA- 2025/03/13 00:33 CRDT- 2024/12/13 19:27 PHST- 2024/10/06 00:00 [received] PHST- 2024/11/19 00:00 [revised] PHST- 2024/12/02 00:00 [accepted] PHST- 2025/03/13 00:33 [medline] PHST- 2024/12/14 00:25 [pubmed] PHST- 2024/12/13 19:27 [entrez] AID - S0090-4295(24)01133-6 [pii] AID - 10.1016/j.urology.2024.12.003 [doi] PST - ppublish SO - Urology. 2025 Mar;197:126-132. doi: 10.1016/j.urology.2024.12.003. Epub 2024 Dec 11. PMID- 39668728 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1366-5804 (Electronic) IS - 1354-750X (Linking) VI - 30 IP - 1 DP - 2025 Feb TI - CD105-microvessel density analysis and its clinical value in urothelial carcinoma of bladder patients. PG - 23-36 LID - 10.1080/1354750X.2024.2435876 [doi] AB - BACKGROUND: Endoglin/CD105-microvessel density (CD105-MVD) is identified as one of the most potential methods for semi-quantification of angiogenesis in human cancer tissues. Present study aimed to examine the diagnosticand prognostic value of CD105-MVD in two clinically distinct subtypes of urothelial carcinoma of bladder (UCB) namely non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients. METHODS: Message expression of endoglin was analysed by real-time quantitative polymerase chain reaction (RT-qPCR) and MVD measurement was done by immunohistochemical staining in 90 UCB [NMIBC: 60; MIBC: 30] patients. SEM studies were carried out to examine tumor vasculature and extent of neoangiogenesis in NMIBC and MIBC patients. RESULTS: Elevated message expression of CD105 showed statistical significance with tumor stage, grade, smoking/tobacco chewing history in NMIBC andage in MIBC cohort. Higher values of CD105-MVD showed statistical relevance with tumor stage, grade, size, smoking/tobacco chewing history in NMIBC cohort. Kaplan Meier test identified high CD105-MVD as strong predictor of poor RFS in NMIBC patients. CONCLUSIONS: Association of CD105 expression and MVD with the clinicohistopathological features as well as poor survival outcomes potentially identify it as a preferred marker of clinical significance in a given cohort of UCB patients.Clinical significanceStrong association of CD105 at message level with the demographics of UCB patients identifies it as a marker of diagnosis in a given cohort of patients.Survival analysis examined CD105-MVD as an independent strong predictor of poor recurrence free survival in NMIBC patients.Present study provides clear evidence of increased vascular density, vascular sprouts proliferation and new blood vessel formation with disease aggressiveness indicating CD105 as a preferred marker of neoangiogenesis in the given cohort of patients.The study describes CD105-MVD as a biomarker of diagnosis and prognosis with the sensitivity of 91.67% and 93.33% in a given cohort of NMIBC and MIBC patients. FAU - Siddhartha, Rohit AU - Siddhartha R AUID- ORCID: 0000-0002-2106-9694 AD - Department of Biochemistry, University of Lucknow, Lucknow, India. FAU - Singhai, Atin AU - Singhai A AUID- ORCID: 0000-0001-8018-0723 AD - Department of Pathology, King George's Medical University, Lucknow, India. FAU - Goel, Apul AU - Goel A AUID- ORCID: 0000-0002-5813-3012 AD - Department of Urology, King George's Medical University, Lucknow, India. FAU - Garg, Minal AU - Garg M AUID- ORCID: 0000-0002-4069-8138 AD - Department of Biochemistry, University of Lucknow, Lucknow, India. LA - eng PT - Journal Article DEP - 20241213 PL - England TA - Biomarkers JT - Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals JID - 9606000 RN - 0 (Endoglin) RN - 0 (ENG protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/blood supply/genetics/diagnosis/mortality/metabolism MH - *Endoglin/genetics/metabolism MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Biomarkers, Tumor/genetics/metabolism MH - *Microvascular Density MH - Prognosis MH - *Neovascularization, Pathologic/pathology MH - Kaplan-Meier Estimate MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/genetics OTO - NOTNLM OT - CD105 OT - NMIBC and MIBC OT - clinical significance OT - microvessel density OT - tumor vasculature EDAT- 2024/12/13 11:32 MHDA- 2025/02/24 06:20 CRDT- 2024/12/13 03:43 PHST- 2025/02/24 06:20 [medline] PHST- 2024/12/13 11:32 [pubmed] PHST- 2024/12/13 03:43 [entrez] AID - 10.1080/1354750X.2024.2435876 [doi] PST - ppublish SO - Biomarkers. 2025 Feb;30(1):23-36. doi: 10.1080/1354750X.2024.2435876. Epub 2024 Dec 13. PMID- 39668105 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 4 DP - 2025 Apr TI - FOXP3/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion. PG - 268.e9-268.e26 LID - S1078-1439(24)00750-6 [pii] LID - 10.1016/j.urolonc.2024.11.017 [doi] AB - OBJECTIVE: Bladder carcinoma (BC) is a common type of cancer. Approximately 20% of BC patients have non-muscle invasive bladder cancer (NMIBC). Despite adequate BCG treatment, recurrence occurs in approximately 40% of the patients. There is no adequate prognostic marker for recurrence in a group of patients. Forkhead box P3 (FOXP3) is a regulatory T cell marker that sometimes exhibits anti-tumoral effects and can be used as a tumor marker. T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune checkpoint inhibitor of T cells. Tertiary lymphoid structures (TLS) increase malignancy and inflammation in non-lymphoid organs. Therefore, we aimed to evaluate the prognostic value of FOXP3, TIM-3, and TLS in patients with NMIBC. METHODS: Patients with pathologically confirmed NMIBC were included in this study. Stromal and intraepithelial cells were evaluated separately using immunohistochemistry, and FOXP3, TIM-3, TLS, FOXP3/TLS, and TIM-3/TLS were calculated and noted. The cutoff value was determined using ROC analysis. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using univariate and multivariate Cox proportional hazard analyses. RESULTS: The study included ninety-six patients. FOXP3/TLS high group had a better RFS than FOXP3/TLS low group (P = 0.001; HR, 0.079; 95% CI, 0.019-0.337). This was also significant in the multivariate analysis (P = 0.018; HR, 0.125; 95% CI, 0.022-0.705). In the group receiving BCG, FOXP3/TLS, FOXP3-TLS, TIM-3-TLS and TIM-3/TLS elevation were lower in patients with relapse than in patients without relapse and were statistically significant. Combined TIM-3 and FOXP3 elevation was found to be good prognostic regardless of whether it was found in intraepithelial, stromal or TLS. CONCLUSION: FOXP3/TLS elevation is a good prognostic and predictive marker in all non-muscle invasive bladder cancer cases and in the subgroup receiving BCG. Elevation of FOXP3-TLS, TIM-3-TLS, and TIM-3/TLS is associated with longer RFS in patients receiving BCG. Combined TIM-3 and FOXP3 elevation is indicative of a low recurrence rate in NMIBC. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Balcik, Onur Yazdan AU - Balcik OY AD - Alanya Alaaddin Keykubat University Medical Oncolog, Antalya, Turkey. Electronic address: yazdanbalcik@hotmail.com. FAU - Yilmaz, Fatih AU - Yilmaz F AD - Mardin Training and Research Hospital, Pathology Laboratory, Mardin, Turkey. Electronic address: faatiihyiilmaaz@yahoo.com.tr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241212 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Forkhead Transcription Factors) RN - 0 (FOXP3 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Hepatitis A Virus Cellular Receptor 2) RN - 0 (HAVCR2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/mortality MH - *Forkhead Transcription Factors/metabolism MH - Female MH - Male MH - Prognosis MH - Aged MH - Middle Aged MH - *Biomarkers, Tumor/metabolism MH - Hepatitis A Virus Cellular Receptor 2/metabolism MH - Neoplasm Invasiveness MH - Aged, 80 and over OTO - NOTNLM OT - FOXP3 OT - RFS OT - TIM-3 OT - TLS OT - Treg COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Onur Yazdan Balcik reports financial support was provided by Interdisciplinary Oncology Society (IDOD). Onur Yazdan Balcik reports a relationship with Interdisciplinary Oncology Society (IDOD) that includes: funding grants. There is no conflict of interest between the authors or between the authors and others. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/13 00:22 MHDA- 2025/03/13 00:33 CRDT- 2024/12/12 22:19 PHST- 2024/08/27 00:00 [received] PHST- 2024/11/04 00:00 [revised] PHST- 2024/11/12 00:00 [accepted] PHST- 2025/03/13 00:33 [medline] PHST- 2024/12/13 00:22 [pubmed] PHST- 2024/12/12 22:19 [entrez] AID - S1078-1439(24)00750-6 [pii] AID - 10.1016/j.urolonc.2024.11.017 [doi] PST - ppublish SO - Urol Oncol. 2025 Apr;43(4):268.e9-268.e26. doi: 10.1016/j.urolonc.2024.11.017. Epub 2024 Dec 12. PMID- 39659789 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241212 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Asystematic review and meta-analysis of clinical prognostic factors linked to extravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. PG - 1475044 LID - 10.3389/fonc.2024.1475044 [doi] LID - 1475044 AB - OBJECTIVE: Numerous studies have investigated predictors of intravesical recurrence following radical nephrectomy (RNU) in patients with upper urinary tract uroepithelial carcinoma (UTUC). In contrast, extravesical recurrence (EUR) has received less focus. Consequently, this study aims to evaluate the significant predictors of EUR after RNU through a systematic review of the literature and a meta-analysis. METHODOLOGY: We conducted a computerized bibliographic search across PubMed, Embase, and Cochrane databases to identify reports that include detailed results from multivariate analyses of predictors of EUR. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) criteria, we selected thirteen retrospective studies, each with a sample size exceeding 100 cases. Using Review Manager 5.4 software, we performed cumulative analyses of available HR and their corresponding 95% confidence intervals to evaluate potential predictors of EUR. RESULTS: Our findings indicate that patient-specific predictors include preoperative Ki-67 with a HR of 3.61 (P = 0.003), neutrophil-to-lymphocyte ratio with an HR of 2.20 (P = 0.0005), and glomerular filtration rate with an HR of 3.35 (P = 0.0009). Tumor-specific predictors identified were tumor stage with an HR of 4.67 (P < 0.00001), lymphovascular invasion with an HR of 2.37 (P = 0.004), and lymph node status with an HR of 2.68 (P < 0.0001). Regarding treatment-specific predictors, positive surgical margins were associated with an HR of 3.97 (P = 0.0005), and adjuvant chemotherapy was associated with an HR of 1.65 (P = 0.03). DISCUSSION: Our study identified three significant predictors across patient, tumor, and treatment dimensions for extravesical recurrence following radical nephroureterectomy in patients with upper urinary tract uroepithelial carcinoma. We hypothesize that history of bladder cancer, platelet-to-lymphocyte ratio, and urinary cytology could also be strong predictors of post- RNU extravesical recurrence in patients with upper UTUC, assuming adequate sample size and controlled heterogeneity. This research aims to provide urological clinicians with enhanced guidance for postoperative decision-making. CI - Copyright (c) 2024 Zhang, Jiang, Chen, Zhao, Wang, Liu, Ding and Shan. FAU - Zhang, Guanlan AU - Zhang G AD - Urology Department, Henan Provincial People's Hospital, Zhengzhou, China. AD - Department of Medicine, Graduate School, Henan University, Kaifeng, China. FAU - Jiang, Zhaoqiang AU - Jiang Z AD - Urology Department, Henan Provincial People's Hospital, Zhengzhou, China. FAU - Chen, Jiawei AU - Chen J AD - Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. FAU - Zhao, Ying AU - Zhao Y AD - Urology Department, China-Japan Friendship Hospital, Beijing, China. FAU - Wang, Jianan AU - Wang J AD - Urology Department, Henan Provincial People's Hospital, Zhengzhou, China. FAU - Liu, Jinxing AU - Liu J AD - Urology Department, Henan Provincial People's Hospital, Zhengzhou, China. FAU - Ding, Zhenshan AU - Ding Z AD - Urology Department, China-Japan Friendship Hospital, Beijing, China. FAU - Shan, Lei AU - Shan L AD - Urology Department, Henan Provincial People's Hospital, Zhengzhou, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20241126 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11628382 OTO - NOTNLM OT - extravesical recurrence OT - meta-analysis OT - predictor OT - ureter OT - urinary tract OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/12/11 11:28 MHDA- 2024/12/11 11:29 PMCR- 2024/01/01 CRDT- 2024/12/11 04:33 PHST- 2024/08/02 00:00 [received] PHST- 2024/10/29 00:00 [accepted] PHST- 2024/12/11 11:29 [medline] PHST- 2024/12/11 11:28 [pubmed] PHST- 2024/12/11 04:33 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1475044 [doi] PST - epublish SO - Front Oncol. 2024 Nov 26;14:1475044. doi: 10.3389/fonc.2024.1475044. eCollection 2024. PMID- 39638259 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250430 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 35 IP - 3 DP - 2025 Apr TI - High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care. PG - 102838 LID - S2950-3930(24)00306-1 [pii] LID - 10.1016/j.fjurol.2024.102838 [doi] AB - INTRODUCTION: High-grade non-muscle invasive bladder cancer (HG-NMIBC) exposes to a high risk of recurrence and progression. Standard of care includes repeated trans-urethral resection of bladder tumor (reTURBT) and bacillus Calmette-Guerin (BCG) therapy. Not following Standard of care (SOC) may be associated with a worse prognosis. We aimed to compare prognosis outcomes of patients with primary HG-NMIBC according to the respect of the SOC or not. MATERIALS AND METHODS: We conducted an eleven-year retrospective observational study including all patients undergoing initial bladder resection for de novo HG-NMIBC at our institution. Exclusion criteria were prior urothelial carcinoma histology, low grade NMIBC or >/=T2 staging. Four groups were formed according to the treatment received. RESULTS: Among 164 patients, 44.5% received standard of care, 18.3% received only BCG-therapy, 16.5% benefited only from reTURBT and 20.7% did not receive treatment. Upstaging to T2 tumor was found in 6% of reTURBT specimens. Presence of residual tumor (RT) on re-TURBT (P<10(-4)) and having benefited from SOC (P=0.016) impacted recurrence-free survival. Progression-free survival was impacted by presence of RT (P=0.001) but not by SOC (P=0.284). CONCLUSION: Performing standard of care on patients with HG-NMIBC is associated with a lower risk of recurrence. We believe SOC should be provided for all HG-NMIBC patients, especially those with poor prognostic factors such as T1 tumor, or multiplicity or largeness of the bladder tumor. CI - Copyright (c) 2024 Elsevier Masson SAS. All rights reserved. FAU - Palkowski, Thomas AU - Palkowski T AD - Department of Urology, Andrology and Renal Transplantation, University Hospital of Besancon, 25000 Besancon, France; University of Franche-Comte, 25000 Besancon, France. FAU - Bibeau, Frederic AU - Bibeau F AD - University of Franche-Comte, 25000 Besancon, France; Department of Pathology, University Hospital of Besancon, 25000 Besancon, France. FAU - Thiery-Vuillemin, Antoine AU - Thiery-Vuillemin A AD - University of Franche-Comte, 25000 Besancon, France; Department of Medical Oncology, University Hospital of Besancon, 25000 Besancon, France; INSERM UMR 1098, 25000 Besancon, France. FAU - Kleinclauss, Francois AU - Kleinclauss F AD - Department of Urology, Andrology and Renal Transplantation, University Hospital of Besancon, 25000 Besancon, France; University of Franche-Comte, 25000 Besancon, France; Nanomedicine Lab, Imagery and Therapeutics, EA 4662, France. FAU - Frontczak, Alexandre AU - Frontczak A AD - Department of Urology, Andrology and Renal Transplantation, University Hospital of Besancon, 25000 Besancon, France; University of Franche-Comte, 25000 Besancon, France; Nanomedicine Lab, Imagery and Therapeutics, EA 4662, France. Electronic address: a.frontczak@chu-besancon.fr. LA - eng PT - Journal Article PT - Observational Study DEP - 20241203 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality/surgery MH - Retrospective Studies MH - Male MH - Female MH - *Standard of Care MH - Aged MH - *BCG Vaccine/therapeutic use MH - Middle Aged MH - Neoplasm Invasiveness MH - *Cystectomy/methods MH - Neoplasm Recurrence, Local MH - Prognosis MH - Treatment Outcome MH - Aged, 80 and over MH - Adjuvants, Immunologic/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Residual tumor OT - Transurethral resection of bladder tumor OT - Urothelial carcinoma EDAT- 2024/12/06 05:31 MHDA- 2025/04/24 06:27 CRDT- 2024/12/05 19:19 PHST- 2024/07/17 00:00 [received] PHST- 2024/10/23 00:00 [revised] PHST- 2024/11/28 00:00 [accepted] PHST- 2025/04/24 06:27 [medline] PHST- 2024/12/06 05:31 [pubmed] PHST- 2024/12/05 19:19 [entrez] AID - S2950-3930(24)00306-1 [pii] AID - 10.1016/j.fjurol.2024.102838 [doi] PST - ppublish SO - Fr J Urol. 2025 Apr;35(3):102838. doi: 10.1016/j.fjurol.2024.102838. Epub 2024 Dec 3. PMID- 39631746 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20250517 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 135 IP - 5 DP - 2025 May TI - The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study. PG - 766-774 LID - 10.1111/bju.16611 [doi] AB - OBJECTIVE: To evaluate whether surgical margin status, alongside existing postoperative risk indicators, improves the identification of bladder cancer patients who may benefit from adjuvant therapy following radical cystectomy (RC). METHODS: In this nationwide cohort study, patients aged >/=18 years diagnosed with muscle-invasive bladder cancer (MIBC) without nodal or distant metastasis (cT2-4aN0/xM0) between November 2017 and December 2020 who underwent RC were selected from the Netherlands Cancer Registry. Detailed information on surgical margin status was obtained through linkage with the Dutch central pathology database, Palga. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method. Multivariable Cox regression analysis was performed to assess the independent prognostic effect of positive surgical margins (carcinoma in situ (CIS) only or invasive carcinoma) on PFS and OS. RESULTS: We identified 1445 MIBC patients treated by RC (53% open, 47% robot-assisted), of whom 135 (9.3%) had positive surgical margins (10.7% in the open and 7.7% in the robot-assisted cohort). In the entire cohort, OS was 79% and 60% at 12 and 48 months after RC, respectively. PFS was 70% and 61% at 12 and 24 months, respectively. Multivariable Cox regression showed worse PFS (hazard ratio (HR) 2.13, 95% confidence interval (CI) 1.67-2.72) and OS (HR 2.02, 95% CI 1.58-2.58) in patients with surgical margins with invasive carcinoma vs patients with negative margins. Patients with only CIS in the margins also appeared to have worse PFS (HR 1.60, 95% CI 1.00-2.58) but these results were not statistically significant. No difference was found for OS (HR 1.30, 95% CI 0.80-2.12). CONCLUSION: Positive margins should be considered a 'high risk feature', as they result in increased risk of disease progression and impaired survival outcomes. These findings support further investigation of the potential efficacy of adjuvant therapy (i.e., radiotherapy and systemic therapy) among patients with positive surgical margins. CI - (c) 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Bosveld, Jikke AU - Bosveld J AUID- ORCID: 0009-0004-4409-4341 AD - Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands. AD - Department of Research, The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Nguyen, Tri Q AU - Nguyen TQ AD - Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Mehra, Niven AU - Mehra N AD - Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Department IQ Health, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department of Research, The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. AD - Department IQ Health, Radboud University Medical Center, Nijmegen, the Netherlands. CN - ProBCI Study Group FAU - Meijer, Richard P AU - Meijer RP AD - Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Richters, Anke AU - Richters A AUID- ORCID: 0000-0002-1580-1543 AD - Department of Research, The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. AD - Department IQ Health, Radboud University Medical Center, Nijmegen, the Netherlands. LA - eng GR - AstraZeneca/ GR - Astellas Pharma/ GR - KWF Kankerbestrijding/ GR - Gilead Sciences/ GR - Merck/ PT - Journal Article DEP - 20241204 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Margins of Excision MH - Male MH - Female MH - Aged MH - Middle Aged MH - Netherlands/epidemiology MH - Aged, 80 and over MH - Adult MH - Treatment Outcome MH - Cohort Studies PMC - PMC11975155 OTO - NOTNLM OT - adjuvant therapy OT - muscle-invasive bladder cancer OT - overall survival OT - radical cystectomy OT - surgical margins EDAT- 2024/12/05 05:31 MHDA- 2025/04/07 18:24 PMCR- 2025/04/07 CRDT- 2024/12/04 19:33 PHST- 2025/04/07 18:24 [medline] PHST- 2024/12/05 05:31 [pubmed] PHST- 2024/12/04 19:33 [entrez] PHST- 2025/04/07 00:00 [pmc-release] AID - BJU16611 [pii] AID - 10.1111/bju.16611 [doi] PST - ppublish SO - BJU Int. 2025 May;135(5):766-774. doi: 10.1111/bju.16611. Epub 2024 Dec 4. PMID- 39627202 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20250515 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 15 IP - 1 DP - 2024 Dec 3 TI - Loss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis. PG - 10378 LID - 10.1038/s41467-024-54246-6 [doi] LID - 10378 AB - Advances in bladder cancer (BCa) treatment have been hampered by the lack of predictive biomarkers and targeted therapies. Here, we demonstrate that loss of the tumor suppressor NUMB promotes aggressive bladder tumorigenesis and worsens disease outcomes. Retrospective cohort studies show that NUMB-loss correlates with poor prognosis in post-cystectomy muscle-invasive BCa patients and increased risk of muscle invasion progression in non-muscle invasive BCa patients. In mouse models, targeted Numb ablation induces spontaneous tumorigenesis and sensitizes the urothelium to carcinogenic insults, accelerating tumor onset and progression. Integrative transcriptomic and functional analyses in mouse and human BCa models reveal that upregulation of YAP transcriptional activity via a RHOA/ROCK-dependent pathway is a hallmark of NUMB-deficient BCa. Pharmacological or genetic inhibition of this molecular pathway selectively inhibits proliferation and invasion of NUMB-deficient BCa cells in 3D-Matrigel organoids. Thus, NUMB-loss could serve as a biomarker for identifying high-risk patients who may benefit from targeted anti-RHOA/ROCK/YAP therapies. CI - (c) 2024. The Author(s). FAU - Tucci, F A AU - Tucci FA AUID- ORCID: 0000-0001-6247-5392 AD - European Institute of Oncology IRCCS, Milan, Italy. AD - School of Pathology, University of Milan, Milan, Italy. FAU - Pennisi, R AU - Pennisi R AUID- ORCID: 0000-0001-6542-7898 AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology, University of Turin, Turin, Italy. FAU - Rigiracciolo, D C AU - Rigiracciolo DC AD - European Institute of Oncology IRCCS, Milan, Italy. AD - IRCCS Scientific Institute San Raffaele, Milan, Italy. FAU - Filippone, M G AU - Filippone MG AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Bonfanti, R AU - Bonfanti R AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Romeo, F AU - Romeo F AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Freddi, S AU - Freddi S AUID- ORCID: 0000-0003-4263-3060 AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Guerrera, E AU - Guerrera E AUID- ORCID: 0009-0004-7492-1563 AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Soriani, C AU - Soriani C AUID- ORCID: 0000-0003-4363-6597 AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Rodighiero, S AU - Rodighiero S AUID- ORCID: 0000-0003-4236-7823 AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Gunby, R H AU - Gunby RH AUID- ORCID: 0000-0002-4359-3884 AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Jodice, G AU - Jodice G AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Sanguedolce, F AU - Sanguedolce F AD - Department of Pathology, University of Foggia, Foggia, Italy. FAU - Renne, G AU - Renne G AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Fusco, N AU - Fusco N AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Di Fiore, P P AU - Di Fiore PP AUID- ORCID: 0000-0002-2252-0950 AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Pruneri, G AU - Pruneri G AD - School of Pathology, University of Milan, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Bertalot, G AU - Bertalot G AD - Department of Anatomy and Pathological Histology, APSS, Trento, Italy. AD - Centre for Medical Sciences-CISMed, University of Trento, Trento, Italy. FAU - Musi, G AU - Musi G AD - European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Vago, G AU - Vago G AD - School of Pathology, University of Milan, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Tosoni, D AU - Tosoni D AUID- ORCID: 0000-0003-4443-1059 AD - European Institute of Oncology IRCCS, Milan, Italy. daniela.tosoni@ieo.it. FAU - Pece, S AU - Pece S AUID- ORCID: 0000-0003-1764-3929 AD - European Institute of Oncology IRCCS, Milan, Italy. salvatore.pece@ieo.it. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. salvatore.pece@ieo.it. LA - eng SI - GEO/GSE256272 GR - IG 23049/Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)/ GR - IG 23060/Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)/ GR - MIUR-PRIN2017/Ministero dell'Istruzione, dell'Universita e della Ricerca (Ministry of Education, University and Research)/ GR - MIUR/PRIN2020/Ministero dell'Istruzione, dell'Universita e della Ricerca (Ministry of Education, University and Research)/ GR - 5x1000 funds/Ministero della Salute (Ministry of Health, Italy)/ GR - Ricerca Corrente/Ministero della Salute (Ministry of Health, Italy)/ GR - RF-2016-02361540/Ministero della Salute (Ministry of Health, Italy)/ GR - RF-2021-12373957/Ministero della Salute (Ministry of Health, Italy)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241203 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - EC 3.6.5.2 (rhoA GTP-Binding Protein) RN - EC 2.7.11.1 (rho-Associated Kinases) RN - 0 (Nerve Tissue Proteins) RN - 0 (NUMB protein, human) RN - 0 (Transcription Factors) RN - 0 (Membrane Proteins) RN - 0 (Numb protein, mouse) RN - 0 (Adaptor Proteins, Signal Transducing) RN - 124671-05-2 (RHOA protein, human) RN - 0 (YAP-Signaling Proteins) RN - 0 (Cell Cycle Proteins) SB - IM MH - *Urinary Bladder Neoplasms/genetics/pathology/metabolism MH - Animals MH - Humans MH - *rhoA GTP-Binding Protein/metabolism/genetics MH - *rho-Associated Kinases/metabolism/genetics MH - *Signal Transduction MH - *Nerve Tissue Proteins/metabolism/genetics MH - Mice MH - *Transcription Factors/metabolism/genetics MH - *Membrane Proteins/metabolism/genetics MH - Cell Line, Tumor MH - Female MH - Male MH - Adaptor Proteins, Signal Transducing/metabolism/genetics MH - YAP-Signaling Proteins/metabolism MH - Cell Proliferation MH - Gene Expression Regulation, Neoplastic MH - Prognosis MH - Cell Cycle Proteins/metabolism/genetics MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Carcinogenesis/genetics/pathology MH - Mice, Knockout PMC - PMC11615365 COIS- Competing interests: G. Renne, G. Vago, D. Tosoni and S. Pece are co-inventors of a patent (EP24191940.6) related to this work, pending to the European Institute of Oncology and University of Milan. All the other authors declare no competing interests. EDAT- 2024/12/04 00:23 MHDA- 2024/12/04 00:24 PMCR- 2024/12/03 CRDT- 2024/12/03 23:16 PHST- 2024/02/09 00:00 [received] PHST- 2024/11/05 00:00 [accepted] PHST- 2024/12/04 00:24 [medline] PHST- 2024/12/04 00:23 [pubmed] PHST- 2024/12/03 23:16 [entrez] PHST- 2024/12/03 00:00 [pmc-release] AID - 10.1038/s41467-024-54246-6 [pii] AID - 54246 [pii] AID - 10.1038/s41467-024-54246-6 [doi] PST - epublish SO - Nat Commun. 2024 Dec 3;15(1):10378. doi: 10.1038/s41467-024-54246-6. PMID- 39626834 OWN - NLM STAT- MEDLINE DCOM- 20250313 LR - 20250724 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 197 DP - 2025 Mar TI - Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology. PG - 119-125 LID - S0090-4295(24)01113-0 [pii] LID - 10.1016/j.urology.2024.11.056 [doi] AB - OBJECTIVE: To compare all available rapid tests on a large cohort of recurrent bladder cancer during follow-up in this multicentre-study is the first study. BTA stat, NMP22 BladderChek, UBC Rapid Test CancerCheck UBC rapid VISUAL, and uromonitor are urinary-based rapid tests for bladder cancer detection. METHODS: In total, 187 urine samples were analyzed from patients with suspected recurrent non-muscle invasive urothelial bladder cancer on cystoscopy during follow-up in a real-world assessment. All suspicious lesions were resected with 110 samples showing recurrent urothelial cancer. Urine samples were analyzed by the BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology. Sensitivities and specificities were calculated by contingency analyses. RESULTS: All investigated urinary markers could detect a higher percentage of pathological results in urine of bladder cancer patients compared to urine of tumor free patients. The calculated diagnostic sensitivities for BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology were 60.0%, 10.0%, 58.0%, 32.0%, 54.5%, and 41.5% for non-muscle invasive low-grade, and 64.0%, 40.0%, 77.8%, 50.0%, 56.0%, and 65.5% for non-muscle invasive high-grade bladder cancer. The specificity was 51.3%, 94.8%, 66.2%, 89.5%, 94.9%, and 66.2%, respectively. CONCLUSION: During follow-up sensitivities and specificities of most urinary markers are higher compared to cytology for the detection of recurrent bladder cancer. BTA stat, UBC Rapid Test, and uromonitor appear useful in this setting. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Ecke, Thorsten H AU - Ecke TH AD - Department of Urology, Helios Hospital, Bad Saarow, Germany; Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: thorsten.ecke@helios-gesundheit.de. FAU - Meisl, Christina J AU - Meisl CJ AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Schlomm, Thorsten AU - Schlomm T AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Rabien, Anja AU - Rabien A AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Labonte, Flora AU - Labonte F AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Rong, Dezhi AU - Rong D AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. FAU - Hofbauer, Sebastian AU - Hofbauer S AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Friedersdorff, Frank AU - Friedersdorff F AD - Department of Urology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Urology, Evangelisches Krankenhaus Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Sommerfeldt, Lilli AU - Sommerfeldt L AD - Department of Urology, Evangelisches Krankenhaus Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Gagel, Nella AU - Gagel N AD - Department of Urology, Evangelisches Krankenhaus Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Gossl, Andreas AU - Gossl A AD - Rheinland Klinikum Neuss, Department of Urology, Neuss, Germany. FAU - Barski, Dimitri AU - Barski D AD - Rheinland Klinikum Neuss, Department of Urology, Neuss, Germany. FAU - Otto, Thomas AU - Otto T AD - Rheinland Klinikum Neuss, Department of Urology, Neuss, Germany; University Hospital Essen, Essen, Germany. FAU - Grunewald, Camilla M AU - Grunewald CM AD - Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany. FAU - Niegisch, Gunter AU - Niegisch G AD - Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany. FAU - Hennig, Martin J P AU - Hennig MJP AD - Department of Urology, University Hospital Lubeck, Lubeck, Germany. FAU - Kramer, Mario W AU - Kramer MW AD - Department of Urology, Stadtisches Klinikum Luneburg, Luneburg, Germany. FAU - Koch, Stefan AU - Koch S AD - Institute of Pathology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany. FAU - Roggisch, Jenny AU - Roggisch J AD - Institute of Pathology, Helios Hospital, Bad Saarow, Germany. FAU - Weiss, Sarah AU - Weiss S AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. FAU - Waldner, Michael AU - Waldner M AD - Department of Urology, St. Elisabeth Hospital, Cologne, Germany. FAU - Graff, Johannes AU - Graff J AD - Department of Urology, St. Elisabeth Hospital, Cologne, Germany. FAU - Veltrup, Elke AU - Veltrup E AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Linden, Friederike AU - Linden F AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Hake, Roland AU - Hake R AD - Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany. FAU - Eidt, Sebastian AU - Eidt S AD - Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20241201 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/diagnosis MH - *Cystoscopy MH - *Biomarkers, Tumor/urine MH - Male MH - *Neoplasm Recurrence, Local/urine/pathology/diagnosis MH - Female MH - Aged MH - Middle Aged MH - Follow-Up Studies MH - Neoplasm Invasiveness MH - Sensitivity and Specificity MH - *Carcinoma, Transitional Cell/urine/pathology MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms COIS- Declaration of Competing Interest The authors have no conflict of interest to declare. EDAT- 2024/12/04 00:23 MHDA- 2025/03/13 06:27 CRDT- 2024/12/03 19:28 PHST- 2024/10/03 00:00 [received] PHST- 2024/10/29 00:00 [revised] PHST- 2024/11/26 00:00 [accepted] PHST- 2025/03/13 06:27 [medline] PHST- 2024/12/04 00:23 [pubmed] PHST- 2024/12/03 19:28 [entrez] AID - S0090-4295(24)01113-0 [pii] AID - 10.1016/j.urology.2024.11.056 [doi] PST - ppublish SO - Urology. 2025 Mar;197:119-125. doi: 10.1016/j.urology.2024.11.056. Epub 2024 Dec 1. PMID- 39625636 OWN - NLM STAT- MEDLINE DCOM- 20250618 LR - 20260824 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 77 IP - 3 DP - 2025 Jun TI - Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guerin response among bladder cancer patients: a novel machine-learning approach. PG - 338-346 LID - 10.23736/S2724-6051.24.05876-2 [doi] AB - BACKGROUND: Approximately 70% of bladder cancer is diagnosed as non-muscle invasive (NMIBC) and inflammation is known to impact the oncological outcomes. Adjuvant intravesical BCG in intermediate/high risk can lower recurrence and progression. The efficacy of intravesical BCG can be impacted by smoking effects on systemic inflammation. METHODS: Our retrospective, multicenter study with data from 1.313 NMIBC patients aimed to assess the impact of smoking and the systemic inflammatory status on BCG response in T1G3 bladder cancer, using a machine-learning CART based algorithm. RESULTS: In a median of 50-month follow-up (IQR 41-75), 344 patients experienced progression to muscle invasive or metastatic disease and 65 died due to bladder cancer. A CART algorithm has been employed to stratify patients in three prognostic clusters using smoking status, LMR (lymphocytes to monocytes ratio), NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio) as variables. Cox regression models revealed a 1.5-fold (HR 1.66, 95%, CI 1.20-2.29, P=0.002) and three-fold (HR 2.99, 95% CI 2.08-4.30, P<0.001) risk of progression, in intermediate and high risk NMIBC respectively, compared to the low-risk group. The model's concordance index was 0.66. CONCLUSIONS: Our study provides an insight into the influence of smoking on inflammatory markers and BCG response in NMIBC patients. Our machine-learning approach provides clinicians a valuable tool for risk stratification, treatment, and decision-making. Future research in larger prospective cohorts is required for validating these findings. FAU - Ferro, Matteo AU - Ferro M AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy - matteo.ferro@unimi.it. FAU - Tataru, Octavian S AU - Tataru OS AD - I.O.S.U.D., George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Fallara, Giuseppe AU - Fallara G AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Fiori, Cristian AU - Fiori C AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. FAU - Manfredi, Matteo AU - Manfredi M AD - Division of Urology, Department of Oncology, School of Medicine, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. FAU - Claps, Francesco AU - Claps F AD - Urology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - IRCCS Department of Urology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. FAU - Buffi, Nicolo M AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - IRCCS Department of Urology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. FAU - Aveta, Achille AU - Aveta A AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Pandolfo, Savio D AU - Pandolfo SD AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Barone, Biagio AU - Barone B AD - Division of Urology, Department of Surgical Sciences, AORN Sant'Anna e San Sebastiano, Caserta, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Ditonno, Pasquale AU - Ditonno P AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Lasorsa, Francesco AU - Lasorsa F AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Busetto, Gian M AU - Busetto GM AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Falagario, Ugo G AU - Falagario UG AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, La Sapienza University, Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Urology, La Sapienza University, Rome, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Genoa, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Genoa, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Department of Urology, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, Verona, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, Verona, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Gherasim, Raul AU - Gherasim R AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Todea-Moga, Ciprian AU - Todea-Moga C AD - Department of Urology, George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Musi, Gennaro AU - Musi G AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Mistretta, Francesco A AU - Mistretta FA AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Bianchi, Roberto AU - Bianchi R AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Tozzi, Marco AU - Tozzi M AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Turin, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Turin, Turin, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio, University of Chieti, Chieti, Italy. FAU - Janello, Letizia M AU - Janello LM AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University Federico II, Naples, Italy. FAU - Russo, Giorgio I AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Schips, Luigi AU - Schips L AD - Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio, University of Chieti, Chieti, Italy. FAU - Perdona, Sisto AU - Perdona S AD - G. Pascale IRCCS Foundation, Naples, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Rush University Medical Center, Chicago, IL, USA. FAU - Catellani, Michele AU - Catellani M AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Sighinolfi, Chiara AU - Sighinolfi C AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - DI Stasi, Savino M AU - DI Stasi SM AD - Division of Urology, Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. FAU - Rocco, Bernardo AU - Rocco B AD - Unit of Urology, Department of Medicine and Translational Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Unit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20241203 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/blood/mortality MH - *Machine Learning MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Retrospective Studies MH - Female MH - Male MH - Middle Aged MH - *Smoking/adverse effects MH - Aged MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - *Inflammation/blood MH - Neutrophils MH - Disease Progression MH - Administration, Intravesical EDAT- 2024/12/03 12:26 MHDA- 2025/06/18 06:25 CRDT- 2024/12/03 11:12 PHST- 2025/06/18 06:25 [medline] PHST- 2024/12/03 12:26 [pubmed] PHST- 2024/12/03 11:12 [entrez] AID - S2724-6051.24.05876-2 [pii] AID - 10.23736/S2724-6051.24.05876-2 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2025 Jun;77(3):338-346. doi: 10.23736/S2724-6051.24.05876-2. Epub 2024 Dec 3. PMID- 39608442 OWN - NLM STAT- MEDLINE DCOM- 20241208 LR - 20241208 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 610 DP - 2025 Feb 1 TI - Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. PG - 217339 LID - S0304-3835(24)00734-1 [pii] LID - 10.1016/j.canlet.2024.217339 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) often recurs and can progress to MIBC due to resistance to treatments like intravesical chemotherapy or Bacillus Calmette-Guerin (BCG). Therefore, we established the Gemcitabine-Resistant Cells (GRCs) to study the molecular evolution under external pressure. A 63-gene Chemoresistance-Motility (CrM) signature was created to identify stage-specific traits of GRCs. This signature was tested on 1846 samples using log-rank tests and Cox regression to evaluate clinical utility. Early and intermediate resistance stages showed increased cell motility and metastatic potential. FAK, PI3K-AKT, and TGFbeta pathways were activated first, followed by MAPK signaling. Single-cell analysis and experiments utilizing the CrM signature confirmed interaction with cancer-associated fibroblasts (CAFs). The high-CrM groups mainly included NMIBC patients with poor prognosis (progression-free survival analysis by log-rank test based on UROMOL cohort, p < 0.001), T1-high grade, high European Association of Urology (EAU) risk score, and also included MIBC patients with a history of metastases. Additionally, relative ineffectiveness was observed for BCG (the chi-square test based on BRS cohort, p = 0.02) and immune checkpoint inhibitors (ICIs) in patients with high-CrM. In addition, we identified five drugs that can be used with gemcitabine in these patients, including doxorubicin, docetaxel, paclitaxel, napabucacin, and valrubicin, and verified their efficacy. This study provides insights into NMIBC progression to MIBC via molecular evolution. The CrM signature can assess NMIBC prognosis and BCG treatment response, suggesting alternative treatments. Furthermore, these results need to be prospectively validated. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Jeong, Mi-So AU - Jeong MS AD - Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 46033, South Korea. FAU - Baek, Seung-Woo AU - Baek SW AD - Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, South Korea. FAU - Yang, Gi-Eun AU - Yang GE AD - Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Department of Health Sciences, The Graduated of Dong-A University, Busan, 49315, South Korea. FAU - Mun, Jeong-Yeon AU - Mun JY AD - Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA. FAU - Kim, Jeong Ah AU - Kim JA AD - Center for Scientific Instrumentation, Korea Basic Science Institute, Chungbuk, 28119, South Korea. FAU - Kim, Tae-Nam AU - Kim TN AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Biomedical Research Institute and Pusan National University Hospital, Busan, 49241, South Korea. FAU - Nam, Jong-Kil AU - Nam JK AD - Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Yangsan, 50612, South Korea. FAU - Choi, Yung-Hyun AU - Choi YH AD - Department of Biochemistry, College of Oriental Medicine, Anti-Aging Research Center, Dong-eui University, Busan, 47227, South Korea. FAU - Lee, Ju-Seog AU - Lee JS AD - Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA. FAU - Chu, In-Sun AU - Chu IS AD - Bioneer Corporation, Daejeon, 34013, South Korea. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Department of Health Sciences, The Graduated of Dong-A University, Busan, 49315, South Korea. Electronic address: shleem@dau.ac.kr. LA - eng PT - Journal Article DEP - 20241126 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology/mortality MH - *Drug Resistance, Neoplasm/genetics MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/pharmacology/therapeutic use MH - Cell Movement/drug effects MH - Male MH - Female MH - Cancer-Associated Fibroblasts/metabolism/drug effects/pathology MH - BCG Vaccine/therapeutic use MH - Prognosis MH - Aged MH - Cell Line, Tumor MH - Middle Aged MH - Neoplasm Invasiveness MH - Gene Expression Regulation, Neoplastic MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Alternative chemotherapy OT - Cancer-associated fibroblast OT - Chemoresistance-motility signature OT - Immunotherapy OT - Non-muscle-invasive bladder cancer OT - Stepwise molecular evolution COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/29 05:20 MHDA- 2024/12/09 00:22 CRDT- 2024/11/28 19:30 PHST- 2024/06/04 00:00 [received] PHST- 2024/11/18 00:00 [revised] PHST- 2024/11/19 00:00 [accepted] PHST- 2024/12/09 00:22 [medline] PHST- 2024/11/29 05:20 [pubmed] PHST- 2024/11/28 19:30 [entrez] AID - S0304-3835(24)00734-1 [pii] AID - 10.1016/j.canlet.2024.217339 [doi] PST - ppublish SO - Cancer Lett. 2025 Feb 1;610:217339. doi: 10.1016/j.canlet.2024.217339. Epub 2024 Nov 26. PMID- 39606239 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260911 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies. PG - 1418131 LID - 10.3389/fimmu.2024.1418131 [doi] LID - 1418131 AB - Bladder cancer (BC) is the ninth most common and "expensive" cancer in the world. Despite the availability of various treatment modalities such as chemotherapy, immunotherapy and surgery, the overall survival rate of patients with advanced bladder cancer remains low. As one of the most abundant infiltrating immune cells in bladder cancer, tumor-associated macrophages (TAMs) play an important role in the development of BC and in the standard regimen of intravesical BCG therapy. Targeting TAMs have achieved excellent results in clinical trials for a variety of other cancers, but few studies have been conducted for bladder cancer. Further exploration is still needed to develop TAM-related therapeutic strategies for BC treatment, which are expected to improve the therapeutic efficacy and life quality of patients. This review summarizes the relationship between TAMs in bladder cancer and disease staging, evolution, patient prognosis, and treatment outcome. Several potential TAM targets in BC are also pointed, which may help to inhibit tumor-promoting TAMs and provide new therapeutic approaches for advanced BC. CI - Copyright (c) 2024 Ma, Sun, Guo and Yang. FAU - Ma, Yuanchun AU - Ma Y AD - Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. FAU - Sun, Ying AU - Sun Y AD - Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. AD - Department of Urology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing University Advanced Institute of Life Sciences (NAILS), Nanjing, China. FAU - Guo, Hongqian AU - Guo H AD - Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. FAU - Yang, Rong AU - Yang R AD - Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241113 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/therapy/pathology MH - *Tumor-Associated Macrophages/immunology/metabolism MH - Animals MH - Tumor Microenvironment/immunology MH - Molecular Targeted Therapy MH - Immunotherapy/methods MH - Prognosis MH - Neoplasm Staging PMC - PMC11599180 OTO - NOTNLM OT - bladder cancer OT - macrophage polarization OT - macrophage targeted therapy OT - tumor immune microenvironment OT - tumor-associated macrophage COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/11/28 06:37 MHDA- 2024/11/28 06:38 PMCR- 2024/01/01 CRDT- 2024/11/28 05:03 PHST- 2024/04/16 00:00 [received] PHST- 2024/10/25 00:00 [accepted] PHST- 2024/11/28 06:38 [medline] PHST- 2024/11/28 06:37 [pubmed] PHST- 2024/11/28 05:03 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1418131 [doi] PST - epublish SO - Front Immunol. 2024 Nov 13;15:1418131. doi: 10.3389/fimmu.2024.1418131. eCollection 2024. PMID- 39602003 OWN - NLM STAT- MEDLINE DCOM- 20250718 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 57 IP - 4 DP - 2025 Apr TI - Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer. PG - 1143-1149 LID - 10.1007/s11255-024-04297-x [doi] AB - PURPOSE: To predict oncological outcomes and select appropriate treatments for non-muscle-invasive bladder cancer (NMIBC), pre-treatment predictors such as neutrophil-to-lymphocyte ratio (NLR) are being used. This study aims to evaluate whether NLR is an independent predictor of disease and disease recurrence in NMIBC patients. METHODS: In this prospective clinical study, from March 2018 to March 2023, preoperative NLR values were monitored in 99 patients newly diagnosed with NMIBC, who were initially treated with trans-urethral resection of bladder tumor (TURBT) and adjuvant intravesical therapy. To evaluate the best NLR cutoff points to predict recurrence, the ROC (receiver operating characteristic) curve and the Youden index were used. The monitoring period was 24 months. RESULTS: With the cutoff value of NLR = 1.73, there is a statistically significant correlation (p = 0.008) between the NLR value and the increased risk of recurrence. Univariate and multivariate Cox regression analyses show the significant prognostic impact of NLR on the recurrence of the disease. CONCLUSION: The value of NLR > 1.73 is a significant preoperative predictor in risk assessment and will help with proper selection of treatment in the high- and intermediate-risk groups of patients. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Ivanic, Davor AU - Ivanic D AUID- ORCID: 0009-0007-8112-234X AD - Clinic for Urology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Dug, Haris AU - Dug H AUID- ORCID: 0009-0005-4290-5849 AD - Clinic for Urology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Jagodic, Samed AU - Jagodic S AUID- ORCID: 0009-0004-7980-9562 AD - Clinic for Urology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Delibegovic, Samir AU - Delibegovic S AUID- ORCID: 0000-0003-0525-3288 AD - Clinic for Surgery, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. delibegovic.samir@gmail.com. AD - Faculty of Medicine, University of Tuzla, Univerzitetska 1, 75000, Tuzla, Bosnia and Herzegovina. delibegovic.samir@gmail.com. LA - eng PT - Clinical Study PT - Journal Article DEP - 20241127 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Prospective Studies MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - Lymphocyte Count MH - *Urinary Bladder Neoplasms/immunology MH - *Neoplasm Recurrence, Local/immunology MH - Carcinoma, Transitional Cell/immunology MH - Predictive Value of Tests MH - Preoperative Period OTO - NOTNLM OT - Disease recurrence OT - Invasive bladder cancer OT - Lymphocyte ratio OT - Neutrophil OT - Non-muscle OT - Pre-treatment predictors OT - To COIS- Declarations. Conflict of interests: The authors declare no competing interests. The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethical Committee of University Clinic Center Tuzla (30.10.2018. No: 02-09/2-56/18). Consent to participate: Informed consent was obtained from all the individual participants included in the study. EDAT- 2024/11/27 12:34 MHDA- 2025/03/12 18:17 CRDT- 2024/11/27 11:20 PHST- 2024/10/05 00:00 [received] PHST- 2024/11/15 00:00 [accepted] PHST- 2025/03/12 18:17 [medline] PHST- 2024/11/27 12:34 [pubmed] PHST- 2024/11/27 11:20 [entrez] AID - 10.1007/s11255-024-04297-x [pii] AID - 10.1007/s11255-024-04297-x [doi] PST - ppublish SO - Int Urol Nephrol. 2025 Apr;57(4):1143-1149. doi: 10.1007/s11255-024-04297-x. Epub 2024 Nov 27. PMID- 39594156 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 22 DP - 2024 Nov 7 TI - Multi-Centre Study of Progression Factors and Intravesical Recurrence in Patients with Urothelial Carcinoma of the Upper Urinary Tract. LID - 10.3390/diagnostics14222491 [doi] LID - 2491 AB - BACKGROUND/OBJECTIVES: A retrospective analysis was conducted to identify factors associated with disease progression and intravesical recurrence (IVR) in a multi-centre cohort of patients with upper urinary tract urothelial carcinoma (UTUC) treated surgically between 2015 and 2021. METHODS: Progression-free survival (PFS) and IVR-free survival were evaluated using a Kaplan-Meier survival curve and a Log-Rank test. Prognostic factors for progression and IVR were analysed using Cox logistic regression analysis. RESULTS: A total of 170 patients were analysed. Up to 32.9% developed progression within 65.64 +/- 3.44 months. Multivariate analysis showed that pT (HR 2.9, 95%CI 1.54-5.48, p = 0.01), margin status (HR 2.89, 95%CI 2.88-57.68, p = 0.01), and lymphovascular involvement (HR 7.97, 95% CI 1.43-44.42, p = 0.02) were independent risk factors for PFS. Up to 25.9% of patients presented with IVR at a mean time of 68.33 +/- 3.59 months. A previous diagnosis of bladder cancer (BC) (HR 3.73, 95% CI 1.24-11.22, p = 0.02) and the non-invasive appearance of the tumour on computed tomography were significant risk factors for IVR (HR 0.23, 95% CI 0.05-0.95, p = 0.03). CONCLUSIONS: pT stage, margin involvement, and lymphovascular involvement were independent risk factors for UTUC progression. The main risk factor for presenting with IVR after UTUC was a previous diagnosis of BC. FAU - Garcia-Morales, Lucia AU - Garcia-Morales L AUID- ORCID: 0000-0002-5241-9351 AD - Urology Department, Reina Sofia University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC/UCO), Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. FAU - Contreras-Matos, Francisco Javier AU - Contreras-Matos FJ AD - Department of Urology, Virgen de las Nieves University Hospital, Biosanitary Research Institute of Granada (IBS), 18071 Granada, Spain. FAU - Blanca-Pedregosa, Ana AU - Blanca-Pedregosa A AUID- ORCID: 0000-0002-4360-4352 AD - Urology Department, Reina Sofia University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC/UCO), Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. FAU - Mellado-Castillero, Alejandro AU - Mellado-Castillero A AD - Institute of Urological Surgery, 29007 Malaga, Spain. FAU - Campos-Hernandez, Juan Pablo AU - Campos-Hernandez JP AD - Urology Department, Reina Sofia University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC/UCO), Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. FAU - Lara, Maria Fernanda AU - Lara MF AUID- ORCID: 0000-0001-6335-2183 AD - Faculty of Medicine, University of Malaga (UMA), IBIMA, BIONAND, 29010 Malaga, Spain. FAU - Puche-Sanz, Ignacio AU - Puche-Sanz I AUID- ORCID: 0000-0003-4121-0162 AD - Department of Urology, Virgen de las Nieves University Hospital, Biosanitary Research Institute of Granada (IBS), 18071 Granada, Spain. FAU - Gomez-Gomez, Enrique AU - Gomez-Gomez E AUID- ORCID: 0000-0002-8753-3306 AD - Urology Department, Reina Sofia University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC/UCO), Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. LA - eng GR - EMERGIA20_00285/Scientific research and innovation of the Ministry of Economic Transformation, Industry, Knowledge and Universities of the Government of Andalucia/ PT - Journal Article DEP - 20241107 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11593072 OTO - NOTNLM OT - disease progression OT - intravesical recurrence OT - risk factors OT - urothelial carcinoma COIS- The authors declare no conflicts of interest in relation to the execution of this project, entitled "Multi-Centre Study of Progression Factors and Intravesical Recurrence in Patients with Urothelial Carcinoma of the Upper Urinary Tract". EDAT- 2024/11/27 06:19 MHDA- 2024/11/27 06:20 PMCR- 2024/11/07 CRDT- 2024/11/27 01:10 PHST- 2024/09/25 00:00 [received] PHST- 2024/11/03 00:00 [revised] PHST- 2024/11/05 00:00 [accepted] PHST- 2024/11/27 06:20 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 01:10 [entrez] PHST- 2024/11/07 00:00 [pmc-release] AID - diagnostics14222491 [pii] AID - diagnostics-14-02491 [pii] AID - 10.3390/diagnostics14222491 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Nov 7;14(22):2491. doi: 10.3390/diagnostics14222491. PMID- 39592360 OWN - NLM STAT- MEDLINE DCOM- 20250517 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 6 DP - 2025 Jun TI - The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer. PG - 390.e13-390.e22 LID - S1078-1439(24)00692-6 [pii] LID - 10.1016/j.urolonc.2024.10.012 [doi] AB - BACKGROUND: The European Association of Urology (EAU) recommends early radical cystectomy (RC) for very-high-risk (VHR) nonmuscle invasive bladder cancer (NMIBC), in part due to suboptimal efficacy from BCG in this setting. Effective bladder-sparing alternatives are needed. We compared the oncological outcomes of Gemcitabine/Docetaxel (Gem/Doce) to BCG therapy in patients with VHR NMIBC. METHODS: Retrospective analysis of oncological outcomes in 129 treatment naive VHR NMIBC patients receiving intravesical Gem/Doce (n = 65) was compared to BCG (n = 64) using Cox regression. RESULTS: Recurrence-free survival (RFS) at 12- and 24-months was 63% and 54% for BCG compared to 79% and 73% for Gem/Doce. Progression-free survival (PFS) at 24-months for BCG was 88% compared to 97% for Gem/Doce. Gem/Doce showed a decreased risk of tumor recurrence compared to BCG (hazard ratio, 0.55; 95% confidence interval, 0.30-0.99; P = 0.05). Moreover, patients in the Gem/Doce group were less prone to discontinue therapy (3.1% vs. 14.1%; P = 0.03). CONCLUSIONS: Gem/Doce provides a level of efficacy in terms of RFS and PFS at least as good as BCG for treatment naive VHR NMIBC. Prospective validation is needed. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa, Iowa City, Iowa, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Jersey, USA. FAU - McElree, Ian M AU - McElree IM AD - Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, Iowa, USA. Electronic address: michael-odonnell@uiowa.edu. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241125 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - Docetaxel/administration & dosage MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Europe MH - Adjuvants, Immunologic MH - Urology MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Docetaxel OT - EAU OT - Gemcitabine OT - Non-muscle invasive bladder cancer OT - Survival OT - Very High-risk COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/27 00:20 MHDA- 2025/05/18 17:01 CRDT- 2024/11/26 22:00 PHST- 2024/08/18 00:00 [received] PHST- 2024/09/28 00:00 [revised] PHST- 2024/10/14 00:00 [accepted] PHST- 2025/05/18 17:01 [medline] PHST- 2024/11/27 00:20 [pubmed] PHST- 2024/11/26 22:00 [entrez] AID - S1078-1439(24)00692-6 [pii] AID - 10.1016/j.urolonc.2024.10.012 [doi] PST - ppublish SO - Urol Oncol. 2025 Jun;43(6):390.e13-390.e22. doi: 10.1016/j.urolonc.2024.10.012. Epub 2024 Nov 25. PMID- 39589523 OWN - NLM STAT- MEDLINE DCOM- 20241126 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Nov 26 TI - Squamous cell carcinoma of the upper urinary tract: clinical characteristics, treatment patterns, and survival outcomes in the National Cancer Database. PG - 647 LID - 10.1007/s00345-024-05362-x [doi] AB - PURPOSE: We sought to investigate the disease characteristics, treatment patterns, and survival outcomes of upper urinary tract squamous cell carcinoma (UT-SCC) using the National Cancer Database (NCDB). METHODS: The NCDB was queried for UT-SCC patients from 2004 to 2020. Patients with upper tract urothelial carcinoma (UTUC) were also identified for comparison with UT-SCC. Baseline characteristics were compared between UT-SCC and UTUC patients. Kaplan-Meier analysis assessed stage-based differences in median overall survival (mOS) between 1:4 propensity-matched cohorts of UT-SCC and UTUC patients. Predictors of mortality were assessed via multivariate cox regression. RESULTS: 644 cases of UT-SCC and 55,994 cases of UTUC were identified. Compared to UTUC, UT-SCC patients were more likely to have a higher TNM stage, lymphovascular invasion, and positive surgical margins. UT-SCC demonstrated a comparable mOS to UTUC for non-metastatic T1-T2 disease (74.84 vs. 106.38 months, p = 0.353) and metastatic disease (5.62 vs. 7.16 months, p = 0.058). However, UT-SCC carried a poorer prognosis for carcinoma in situ (45.14 vs. 69.32 months, p = 0.032) and non-metastatic T3-T4 disease (13.63 vs. 31.93 months, p < 0.001). Moreover, we found increasing T stage, metastatic disease, and positive surgical margins to be significant predictors of UT-SCC mortality. Lastly, we found that surgery does not confer a survival benefit over other management strategies for metastatic UT-SCC. CONCLUSIONS: UT-SCC is a rare, aggressive malignancy that typically presents with a more advanced stage than UTUC. Surgical margin status may represent one of the most salient predictors of UT-SCC mortality. Further studies are needed to best define treatment strategy for this uncommon malignancy. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Connors, Christopher AU - Connors C AUID- ORCID: 0000-0003-3143-8745 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. christopher.connors@icahn.mssm.edu. FAU - Omidele, Olamide AU - Omidele O AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Tomer, Nir AU - Tomer N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Levy, Micah AU - Levy M AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Badani, Ketan AU - Badani K AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng PT - Journal Article DEP - 20241126 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - *Databases, Factual MH - *Ureteral Neoplasms/mortality/therapy/pathology MH - *Carcinoma, Squamous Cell/mortality/therapy/pathology MH - Survival Rate MH - United States/epidemiology MH - Middle Aged MH - *Kidney Neoplasms/mortality/therapy/pathology MH - Retrospective Studies MH - Neoplasm Staging MH - Carcinoma, Transitional Cell/mortality/therapy/pathology MH - Aged, 80 and over OTO - NOTNLM OT - Renal pelvis OT - Squamous cell carcinoma OT - Survival analysis OT - Upper tract urothelial cell carcinoma OT - Ureter COIS- Declarations. Ethical approval: Our study was deemed exempt from review from our institutional review board as it is a retrospective study using de-identified data from a national database. Competing interests: The authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/11/26 12:30 MHDA- 2024/11/26 12:31 CRDT- 2024/11/26 11:15 PHST- 2024/05/15 00:00 [received] PHST- 2024/11/04 00:00 [accepted] PHST- 2024/11/26 12:31 [medline] PHST- 2024/11/26 12:30 [pubmed] PHST- 2024/11/26 11:15 [entrez] AID - 10.1007/s00345-024-05362-x [pii] AID - 10.1007/s00345-024-05362-x [doi] PST - epublish SO - World J Urol. 2024 Nov 26;42(1):647. doi: 10.1007/s00345-024-05362-x. PMID- 39586489 OWN - NLM STAT- MEDLINE DCOM- 20241208 LR - 20250630 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 609 DP - 2025 Jan 28 TI - Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer. PG - 217352 LID - S0304-3835(24)00747-X [pii] LID - 10.1016/j.canlet.2024.217352 [doi] AB - Urinary Bladder Cancer (UBC) ranks among the most prevalent cancers worldwide, has a high recurrence rate and unpredictable treatment responses. Thus, biomarkers are urgently needed. Extracellular vesicles (EVs) are released from both cancer- and immune cells and provide a snapshot of the originating cell. They are abundant in urine and are therefore candidate biomarkers for UBC. Isolated urinary EVs from 39 UBC patients were compared with EVs from healthy controls, prostate cancer patients and whole urine. Samples were from bladder urine at time of both transurethral resection of the bladder tumour (TURB) and cystectomy, as well as urine taken from the ureter at cystectomy. EVs were isolated by tangential flow filtration and differential ultracentrifugation and their protein composition was detected by Proximity Extension Assay (PEA; Olink, immuno-oncology panel). In UBC patients, the proteomic signature of bladder urine EVs differed from ureter urine EVs from the same individuals, and from bladder urine derived EVs of both healthy and prostate cancer controls. Pairwise comparison was performed with matched whole urine revealing proteins solely detected in isolated vesicles. Additionally, a distinct signature was identified in bladder urine EVs correlating with muscle invasiveness, and a trained classifier could predict UBC with 92 % accuracy. Some differentially expressed proteins, HO-1 and MMP7, were analysed by bead-based flow cytometry, where HO-1 was detected on the EV surface. Taken together, these results strengthen the rationale of using EVs as non-invasive biomarkers and prognostic tools for UBC. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Steiner, Loic AU - Steiner L AD - Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. FAU - Eldh, Maria AU - Eldh M AD - Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. FAU - Offens, Annemarijn AU - Offens A AD - Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. FAU - Veerman, Rosanne E AU - Veerman RE AD - Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. FAU - Johansson, Markus AU - Johansson M AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden; Department of Surgery, Urology Section, Sundsvall-Harnosand Hospital, Sundsvall, Sweden. FAU - Hemdan, Tammer AU - Hemdan T AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Netterling, Hans AU - Netterling H AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Huge, Ylva AU - Huge Y AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Abdul-Sattar Aljabery, Firas AU - Abdul-Sattar Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Alamdari, Farhood AU - Alamdari F AD - Department of Urology, Vastmanland Hospital, Vasteras, Sweden. FAU - Liden, Oskar AU - Liden O AD - Department of Surgery and Urology, Hudiksvall Hospital, Hudiksvall, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Diagnostics and Intervention, Umea University, Umea, Sweden; Department of Biomedical and Clinical Sciences, Division of Urology, Linkoping University, 581 85, Linkoping, Sweden. FAU - Gabrielsson, Susanne AU - Gabrielsson S AD - Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. Electronic address: Susanne.Gabrielsson@ki.se. LA - eng PT - Journal Article DEP - 20241123 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 RN - 0 (Biomarkers, Tumor) RN - EC 3.4.24.23 (Matrix Metalloproteinase 7) RN - EC 3.4.24.23 (MMP7 protein, human) SB - IM EIN - Cancer Lett. 2025 Apr 28;616:217592. doi: 10.1016/j.canlet.2025.217592. PMID: 40050200 EIN - Cancer Lett. 2025 Oct 10;630:217876. doi: 10.1016/j.canlet.2025.217876. PMID: 40588429 MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/surgery MH - *Extracellular Vesicles/metabolism MH - Male MH - *Biomarkers, Tumor/urine/metabolism MH - *Neoplasm Invasiveness MH - Aged MH - Middle Aged MH - *Proteomics/methods MH - Female MH - Case-Control Studies MH - Prostatic Neoplasms/urine/pathology/surgery/metabolism MH - Matrix Metalloproteinase 7/urine/metabolism MH - Cystectomy MH - Aged, 80 and over OTO - NOTNLM OT - Biomarkers OT - Exosomes OT - Extracellular vesicles OT - Neoadjuvant chemotherapy OT - Urinary bladder cancer COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Susanne Gabrielsson has a patent on B cell derived exosomes in immune therapy and is part of the Scientific Advisory Board of Anjarium Biosciences. The other authors don't have any additional competing interests. EDAT- 2024/11/26 00:16 MHDA- 2024/12/09 00:22 CRDT- 2024/11/25 19:15 PHST- 2024/09/30 00:00 [received] PHST- 2024/11/22 00:00 [revised] PHST- 2024/11/22 00:00 [accepted] PHST- 2024/12/09 00:22 [medline] PHST- 2024/11/26 00:16 [pubmed] PHST- 2024/11/25 19:15 [entrez] AID - S0304-3835(24)00747-X [pii] AID - 10.1016/j.canlet.2024.217352 [doi] PST - ppublish SO - Cancer Lett. 2025 Jan 28;609:217352. doi: 10.1016/j.canlet.2024.217352. Epub 2024 Nov 23. PMID- 39581669 OWN - NLM STAT- MEDLINE DCOM- 20241124 LR - 20241125 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 12 DP - 2024 Nov TI - French AFU Cancer Committee Guidelines - Update 2024-2026: Upper urinary tract urothelial cancer (UTUC). PG - 102722 LID - S2950-3930(24)00179-7 [pii] LID - 10.1016/j.fjurol.2024.102722 [doi] AB - INTRODUCTION: The purpose of this study was to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC). METHODS: A systematic Medline search for epidemiology, risk factors, diagnosis, prognosis, treatment options and follow-up of UTUC was performed between 2022 and 2024 to evaluate available references and their levels of evidence. RESULTS: UTUC is a rare malignancy with specific risk factors, including exposure to aristolochic acid and Lynch syndrome. Its diagnosis is based on the use of computed tomography urography and ureterorenoscopy with biopsies. A prognostic classification has been proposed to discriminate low- and high-risk lesions mainly on the basis of tumour grade (low/high) and imaging aspects (non-invasive/invasive). Tumour size (<2/>/=2cm), focality (uni-/multifocal), and hydronephrosis (absent/present) are more relative risk factors. The standard of care for low-risk patients is currently conservative treatment involving ureterorenoscopy laser ablation, whereas radical nephroureterectomy (RNU) is advised for those with high-risk disease. Adjuvant treatments after RNU include intravesical instillation of chemotherapy to decrease the risk of bladder recurrence and delivery of platinum-based chemotherapy in pT2-T4 and/or pN+ patients. First-line treatment for metastatic UTUC is based on the combination of enfortumab vedotin plus pembrolizumab. For unfit patients, platinum-based chemotherapy plus nivolumab followed by maintenance nivolumab or platinum-based chemotherapy followed by maintenance avelumab in those with at least stable disease can be proposed. The surveillance regimen and schedule depend on the disease stage. CONCLUSION: These updated guidelines will contribute to improving the management of patients diagnosed with UTUC. CI - Copyright (c) 2024. Published by Elsevier Masson SAS. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. Electronic address: roumiguie.m@chu-toulouse.fr. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, 75013 Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Hopital Saint-Louis AP-HP, Universite Paris Cite, Paris, France. FAU - Prost, Doriane AU - Prost D AD - Urology Department, Paris Saint Joseph Hospital, Sorbonne University, Paris, France. FAU - Allory, Y AU - Allory Y AD - Department of Pathology, Institut Curie, Universite Paris Saclay, Saint-Cloud, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Urology Department, Hopital Bichat-Claude Bernard AP-HP, Universite Paris Cite, Paris, France. FAU - Leon, Priscilla AU - Leon P AD - Urology Department, Clinique Pasteur, Royan, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. FAU - Pradere, Benjamin AU - Pradere B AD - UROSUD Urology Department, Clinique Croix Du Sud, 31130 Quint-Fonsegrives, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000 Lille, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Urology Department, Hopital Foch, Universite Paris Saclay, Suresnes, France. FAU - Thibault, Constance AU - Thibault C AD - Medical Oncology Department, Hopital europeen Georges-Pompidou AP-HP centre, Universite Paris Cite, Paris, France. FAU - Audenet, Francois AU - Audenet F AD - Department of Urology, Hopital Europeen Georges-Pompidou AP-HP Centre, Universite Paris Cite, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, 75013 Paris, France. LA - eng PT - Journal Article PT - Practice Guideline PT - Review PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/therapy/pathology/diagnosis MH - *Ureteral Neoplasms/therapy/diagnosis/pathology MH - Kidney Neoplasms/therapy/pathology/diagnosis MH - Urologic Neoplasms/therapy/diagnosis/pathology OTO - NOTNLM OT - Cancer OT - Kidney OT - Renal pelvis OT - Survival OT - Ureter OT - Ureteroscopy OT - Urinary cytology OT - Urothelial carcinoma EDAT- 2024/11/25 01:26 MHDA- 2024/11/25 01:27 CRDT- 2024/11/24 20:58 PHST- 2024/08/12 00:00 [received] PHST- 2024/08/27 00:00 [accepted] PHST- 2024/11/25 01:27 [medline] PHST- 2024/11/25 01:26 [pubmed] PHST- 2024/11/24 20:58 [entrez] AID - S2950-3930(24)00179-7 [pii] AID - 10.1016/j.fjurol.2024.102722 [doi] PST - ppublish SO - Fr J Urol. 2024 Nov;34(12):102722. doi: 10.1016/j.fjurol.2024.102722. PMID- 39581667 OWN - NLM STAT- MEDLINE DCOM- 20241124 LR - 20250711 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 12 DP - 2024 Nov TI - French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC). PG - 102742 LID - S2950-3930(24)00199-2 [pii] LID - 10.1016/j.fjurol.2024.102742 [doi] AB - OBJECTIVE: To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC). METHODS: A systematic review (Medline) of the literature from 20222024 was performed, taking into account the elements of diagnosis, treatment options and monitoring of NMIBC and evaluating references with their level of evidence. RESULTS: The diagnosis of NMIBC (Ta, T1, or CIS) is made after complete and deep tumour resection. The use of bladder photodynamic diagnosis and the indication for a second TURBT (4 to 6weeks later) help to improve the initial diagnosis. The risk of recurrence and/or tumour progression is assessed via the EORTC score. By stratifying patients into low-, intermediate- and high-risk groups, adjuvant treatment can be proposed, including endovesical instillations of chemotherapy (immediate postoperative regimen), BCG (induction and maintenance regimen), or even the indication of cystectomy for unresponsive patients. CONCLUSION: Updating the CCAFU's recommendations should help improve patient management, as well as the diagnosis and treatment of NMIBC. CI - Copyright (c) 2024. Published by Elsevier Masson SAS. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. Electronic address: roumiguie.m@chu-toulouse.fr. FAU - Leon, Priscilla AU - Leon P AD - Urology Department, Clinique Pasteur, Royan, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Urology Department, Hopital Bichat-Claude-Bernard, AP-HP, Universite Paris Cite, Paris, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Institut Curie, Universite Paris Saclay, Saint-Cloud, France. FAU - Audenet, Francois AU - Audenet F AD - Department of Urology, Hopital europeen Georges-Pompidou, AP-HP Centre, Universite Paris Cite, Paris, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU de Lille, Universite de Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-U1277, Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), 59000 Lille, France. FAU - Prost, Doriane AU - Prost D AD - Urology Department, Paris Saint-Joseph Hospital, Sorbonne University, Paris, France. FAU - Thibault, Constance AU - Thibault C AD - Medical Oncology Department, Hopital europeen Georges-Pompidou, AP-HP Centre, Universite Paris Cite, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Hopital Saint-Louis, AP-HP, Universite Paris Cite, Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, 75013 Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - UROSUD Urology Department, Clinique Croix Du Sud, 31130 Quint-Fonsegrives, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Hopital Pitie-Salpetriere, 75013 Paris, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Urology Department, Hopital Foch, Universite Paris Saclay, Suresnes, France. LA - eng PT - Journal Article PT - Practice Guideline PT - Systematic Review PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Humans MH - *Neoplasm Invasiveness MH - Cystectomy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder tumours OT - Cancer OT - Cystectomy OT - Survival OT - Urinary cytology EDAT- 2024/11/25 01:26 MHDA- 2024/11/25 01:27 CRDT- 2024/11/24 20:58 PHST- 2024/08/12 00:00 [received] PHST- 2024/09/06 00:00 [revised] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/11/25 01:27 [medline] PHST- 2024/11/25 01:26 [pubmed] PHST- 2024/11/24 20:58 [entrez] AID - S2950-3930(24)00199-2 [pii] AID - 10.1016/j.fjurol.2024.102742 [doi] PST - ppublish SO - Fr J Urol. 2024 Nov;34(12):102742. doi: 10.1016/j.fjurol.2024.102742. PMID- 39578213 OWN - NLM STAT- MEDLINE DCOM- 20251011 LR - 20251208 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 11 IP - 2 DP - 2025 Mar TI - Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. PG - 374-385 LID - S2405-4569(24)00244-X [pii] LID - 10.1016/j.euf.2024.11.003 [doi] AB - BACKGROUND AND OBJECTIVE: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). It is highly invasive and associated with perioperative risks, while bladder-preserving trimodality therapy (TMT) offers a less invasive alternative with preferable quality of life for selected patients. We aimed to compare oncological outcomes of TMT and RC in MIBC patients, and evaluate TMT-specific outcomes. METHODS: In December 2023, PubMed, Scopus, and Web of Science were searched for studies on MIBC patients treated with TMT. Pairwise meta-analyses were conducted to compare overall survival (OS) and cancer-specific survival (CSS) between MIBC patients treated with TMT and RC, utilizing hazard ratios (HRs). We included only matched cohort studies to minimize selection bias. TMT-specific outcomes, such as response, recurrence, and toxicity rates, were pooled separately. KEY FINDINGS AND LIMITATIONS: Eighty-seven studies (n = 28 218) were identified. No significant differences in OS (HR: 1.05; 95% confidence interval [CI]: 0.78-1.40) and CSS (HR: 1.05; 95% CI: 0.69-1.58) were found for TMT compared with RC. In patients treated with TMT, the complete response was achieved in 74.4% (95% CI: 69.1-79.1), the estimated rate of intravesical recurrence was 23.1% (95% CI: 19.0-27.7), and the rate of grade >/=3 acute toxicity was 11.4% (95% CI: 4.0-28.4). CONCLUSIONS AND CLINICAL IMPLICATIONS: The oncological outcomes of TMT were comparable with those of RC, with an acceptable toxicity profile. TMT appears as a safe and effective treatment for appropriately selected MIBC patients who want to preserve their bladder. However, evidence from high-volume controlled trials is needed. PATIENT SUMMARY: Well-selected patients with nonmetastatic muscle-invasive bladder cancer can be treated with "trimodality therapy" to preserve the bladder. So far, the reported outcomes are comparable with those of radical surgery, and we found no signs of excess toxicity. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miszczyk, Marcin AU - Miszczyk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran. FAU - Fazekas, Tamas AU - Fazekas T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Tsuboi, Ichiro AU - Tsuboi I AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan. FAU - Mancon, Stefano AU - Mancon S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Klemm, Jakob AU - Klemm J AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Schulz, Robert AU - Schulz R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Cadenar, Anna AU - Cadenar A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Unit of Oncologic Minimally Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, the University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20241121 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - *Cystectomy/methods MH - Neoplasm Invasiveness MH - Cohort Studies MH - Combined Modality Therapy OTO - NOTNLM OT - Chemoradiation OT - Meta-analysis OT - Muscle-invasive bladder cancer OT - Preservation therapy OT - Radical cystectomy OT - Trimodality therapy EDAT- 2024/11/23 11:12 MHDA- 2025/10/12 00:34 CRDT- 2024/11/22 21:57 PHST- 2024/07/12 00:00 [received] PHST- 2024/09/20 00:00 [revised] PHST- 2024/11/11 00:00 [accepted] PHST- 2025/10/12 00:34 [medline] PHST- 2024/11/23 11:12 [pubmed] PHST- 2024/11/22 21:57 [entrez] AID - S2405-4569(24)00244-X [pii] AID - 10.1016/j.euf.2024.11.003 [doi] PST - ppublish SO - Eur Urol Focus. 2025 Mar;11(2):374-385. doi: 10.1016/j.euf.2024.11.003. Epub 2024 Nov 21. PMID- 39578137 OWN - NLM STAT- MEDLINE DCOM- 20241202 LR - 20241218 IS - 1769-6658 (Electronic) IS - 1278-3218 (Linking) VI - 28 IP - 8 DP - 2024 Dec TI - Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. PG - 657-666 LID - S1278-3218(24)00169-0 [pii] LID - 10.1016/j.canrad.2024.05.005 [doi] AB - PURPOSE: Trimodal therapy, an organ-sparing alternative, may be proposed for selected patients with muscle-invasive bladder cancer instead of radical cystectomy. In this multicentre retrospective study, we aimed to assess the oncological outcomes of patients who had trimodal therapy for a muscle-invasive bladder cancer. MATERIALS AND METHODS: Seventy-three patients from four centres treated who had trimodal therapy (maximal transurethral resection of bladder tumour and concomitant chemoradiotherapy) for localized muscle-invasive bladder cancer were included. Patients meeting the optimal trimodal therapy eligibility criteria as per the European Association of Urology guidelines were identified. Overall survival, recurrence-free survival and cancer-specific survival were assessed using the Kaplan-Meier method. The cumulative incidence of recurrence was estimated using the Kalbfleisch-Prentice method. RESULTS: Median overall survival was 27.0 months (95 % confidence interval [CI]: 20.3-58.3 months), 5-years overall-, cancer-specific- and recurrence-free survival rates were 37.5% (95 % CI: 25.5-49.5 %), 60 % (95 % CI: 48.3-72.0 %), and 17.9 % (95 % CI: 9.3-28.8 %), respectively. There was no significant difference in 5-year overall survival and recurrence-free survival between the trimodal therapy-eligible and non-eligible patients (hazard ratio [HR]: 1.38, P=0.30 and HR: 0.96, P=0.90, respectively). The univariate analysis did not reveal any significant prognostic factors associated with recurrence-free or overall survival. CONCLUSION: Trimodal therapy offers encouraging specific survival, the prognosis remains poor. Our study highlights the low number and high frailty of patients to whom trimodal therapy is offered in clinical practice. CI - Copyright (c) 2024 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. FAU - Brassart, Carolinne AU - Brassart C AD - Academic Department of Radiation Oncology, centre Oscar-Lambret, 3, rue Frederic-Combemale, 59000 Lille, France. FAU - Coutte, Alexandre AU - Coutte A AD - Academic Department of Radiation Oncology, CHU d'Amiens, 1, rue du Professeur-Christian-Cabrol, 80000 Amiens, France. FAU - Wallet, Jennifer AU - Wallet J AD - Methodology and Biostatistics unit, centre Oscar-Lambret, Lille, France. FAU - Meyer, Emmanuel AU - Meyer E AD - Department of Radiation Oncology, centre Francois-Baclesse, 3, avenue du General-Harris, 14000, Caen, France. FAU - Benyoucef, Ahmed AU - Benyoucef A AD - Academic Department of Radiation Oncology, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France. FAU - Mnif, Hajer AU - Mnif H AD - Academic Department of Radiation Oncology, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France. FAU - Kowalski, Vincent AU - Kowalski V AD - Academic Department of Radiation Oncology, CHU d'Amiens, 1, rue du Professeur-Christian-Cabrol, 80000 Amiens, France. FAU - Barthoulot, Mael AU - Barthoulot M AD - Methodology and Biostatistics unit, centre Oscar-Lambret, Lille, France. FAU - Pasquier, David AU - Pasquier D AD - Academic Department of Radiation Oncology, centre Oscar-Lambret, 3, rue Frederic-Combemale, 59000 Lille, France; Centre de recherche en informatique, signal et automatique de Lille, Cristal UMR 9189, universite de Lille, Lille, France. Electronic address: d-pasquier@o-lambret.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20241121 PL - France TA - Cancer Radiother JT - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique JID - 9711272 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - France MH - Chemoradiotherapy MH - Cystectomy MH - Neoplasm Recurrence, Local MH - Aged, 80 and over MH - Combined Modality Therapy MH - Treatment Outcome MH - Organ Sparing Treatments MH - Kaplan-Meier Estimate MH - Disease-Free Survival OTO - NOTNLM OT - Bladder-preservation therapy OT - Muscle-invasive bladder cancer OT - Preservation vesicale OT - Radiation therapy OT - Radiotherapie OT - Traitement tri modal OT - Trimodal therapy OT - Tumeur de vessie infiltrant le muscle EDAT- 2024/11/23 11:12 MHDA- 2024/12/03 00:23 CRDT- 2024/11/22 21:54 PHST- 2024/03/26 00:00 [received] PHST- 2024/05/14 00:00 [revised] PHST- 2024/05/15 00:00 [accepted] PHST- 2024/12/03 00:23 [medline] PHST- 2024/11/23 11:12 [pubmed] PHST- 2024/11/22 21:54 [entrez] AID - S1278-3218(24)00169-0 [pii] AID - 10.1016/j.canrad.2024.05.005 [doi] PST - ppublish SO - Cancer Radiother. 2024 Dec;28(8):657-666. doi: 10.1016/j.canrad.2024.05.005. Epub 2024 Nov 21. PMID- 39577123 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250517 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 23 IP - 1 DP - 2025 Feb TI - Differential Analysis of Surgical Treatment Modalities in T2N0M0 Bladder Cancer Patients: A Novel Propensity Score-Based Cohort Study. PG - 102257 LID - S1558-7673(24)00227-1 [pii] LID - 10.1016/j.clgc.2024.102257 [doi] AB - OBJECTIVE: This study explored prognostic differences between radical cystectomy (RC), tri-modality treatment (TURBt combined with radiotherapy and chemotherapy, TMT), electrocautery (EC) and partial cystectomy (PC) for T2N0M0 MIBC. MATERIALS AND METHODS: Using SEER data (2004-2015, 2018-2020), we identified T2N0M0 MIBC patients treated with RC, TMT, EC, or PC. Propensity score matching (PSM, 1:1, caliper=0.1) minimized confounding. Kaplan-Meier analysis and Cox regression identified independent prognostic factors, stratified by tumor size and age. RESULT: This study included 6526 patients with T2N0M0 MIBC. Among them, 348(5.33%) underwent PC, 309(4.73%)underwent EC, 1833(28.09%)received TMT, and 4036(61.84%) RC. After 1:1 propensity score matching, RC showed improved CSS (HR=0.67, 95%CI 0.47-0.95 , and PC also benefited (HR=0.97, 95%CI 0.69-1.36) compared to EC. While TMT showed a worse end (HR=1.41, 95%Cl 1.03-1.92) compared to EC. Cox analysis was used to stratify tumor size and age for subgroup analysis. Results for tumor size subgroups were aligned with PSM findings. In the age-stratified subgroups, patients aged <67 years, both RC (HR=0.54, P=0.107) and TMT(HR=0.91, P=0.785) showed better prognoses compared to EC treatment, while PC treatment showed worse prognoses compared to EC treatment (HR=1.23, P=0.542).; for 68-77 years, RC(0.64, P=0.1436) and PC(HR=0.46, P=0.0283)had advantages, and PC is more recommended. For >78 years, RC had superior CSS over EC and PC, whereas TMT had the poorest prognosis. CONCLUSION: In clinical T2N0M0 MIBC, overall, RC outperformed focal-tumor therapy and PC, irrespective of tumor size. However, considering age, we recommend PC treatment for patients aged 68-77 and EC for those aged >78 years. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Yang, Yu-Xuan AU - Yang YX AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Ye, Gui-Chen AU - Ye GC AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xiang, Jia-Cheng AU - Xiang JC AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Luo, Kuang-Di AU - Luo KD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: sgwangtjm@163.com. FAU - Xia, Qi-Dong AU - Xia QD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: qidongxia_md@163.com. LA - eng PT - Journal Article DEP - 20241102 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Female MH - Male MH - Propensity Score MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality/surgery MH - Aged MH - *Cystectomy/methods/statistics & numerical data MH - Middle Aged MH - Prognosis MH - SEER Program MH - Neoplasm Staging MH - Retrospective Studies MH - Kaplan-Meier Estimate MH - Electrocoagulation/methods MH - Treatment Outcome MH - Combined Modality Therapy OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - Partial cystectomy OT - Prognosis OT - Radical cystectomy OT - SEER database EDAT- 2024/11/23 11:12 MHDA- 2025/01/24 00:26 CRDT- 2024/11/22 18:06 PHST- 2024/07/17 00:00 [received] PHST- 2024/10/24 00:00 [revised] PHST- 2024/10/26 00:00 [accepted] PHST- 2025/01/24 00:26 [medline] PHST- 2024/11/23 11:12 [pubmed] PHST- 2024/11/22 18:06 [entrez] AID - S1558-7673(24)00227-1 [pii] AID - 10.1016/j.clgc.2024.102257 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2025 Feb;23(1):102257. doi: 10.1016/j.clgc.2024.102257. Epub 2024 Nov 2. PMID- 39567720 OWN - NLM STAT- MEDLINE DCOM- 20241120 LR - 20241125 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Nov 20 TI - Nomogram for predicting all-cause mortality and cancer-specific mortality after TURBT for non-muscle-invasive bladder cancer. PG - 28759 LID - 10.1038/s41598-024-80333-1 [doi] LID - 28759 AB - The main purpose of this study was to construct two nomograms to predict all-cause mortality (ACM) and cause-specific mortality (CSM) in non-muscle-invasive bladder cancer (NMIBC) patients after transurethral resection of bladder tumors (TURBTs). We selected NMIBC patients who underwent TURBT between 2004 and 2017 from the Surveillance, Epidemiology, and End Results database. The patients were randomly divided into a training set and a validation set at a ratio of 7:3. The independent influencing factors of ACM and CSM in the training set were determined by univariate and multivariate Cox regression analyses. We then integrated those independent influencing factors to construct nomograms. These prediction nomograms were further verified in the validation set. The C-index, calibration curve, receiver operating characteristic (ROC) curve and decision curve analysis (DCA) curve were used to evaluate the identification, calibration, predictive ability and clinical effectiveness of the nomograms. A total of 28,086 cases were ultimately included in this study, which were divided into a training set (19,661 individuals) and a validation set (8425 individuals). Nine variables, including age at diagnosis, race, marital status, tumor grade, T stage, tumor size, number of tumors, and primary site, were obtained via multivariate Cox regression of the training set and used to construct two nomograms prediction model. The C-index values for the ACM nomogram were 0.743 and 0.741 for the training and validation sets, respectively. Moreover, the corresponding values of the C-index for the CSM nomogram were 0.785 and 0.786, respectively. The ROC curves, calibration curves, and DCA curves showed good predictive performance. The nomograms can assist clinicians in identifying high-risk populations and devising more individualized treatment strategies for NMIBC patients. CI - (c) 2024. The Author(s). FAU - Luo, Yao AU - Luo Y AD - Xuzhou Clinical College, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China. FAU - Wei, Sujing AU - Wei S AD - Xuzhou Clinical College, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China. FAU - Yang, Jing AU - Yang J AD - Xuzhou Clinical College, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China. 1977241811@qq.com. FAU - Tan, Zaixiang AU - Tan Z AD - School of Management, Xuzhou Medical University, Xuzhou, 221004, Jiangsu Province, China. tanzaixiang@126.com. AD - Modern Hospital Management Research Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu province, China. tanzaixiang@126.com. AD - Research Center for Health Policy and Health Management, Xuzhou Medical University, Xuzhou, 221004, Jiangsu province, China. tanzaixiang@126.com. LA - eng GR - KC22157/Xuzhou Science and Technology Program/ PT - Journal Article DEP - 20241120 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/pathology/surgery MH - *Nomograms MH - Male MH - Female MH - Aged MH - Middle Aged MH - ROC Curve MH - SEER Program MH - Aged, 80 and over MH - Adult MH - Neoplasm Invasiveness MH - Proportional Hazards Models MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11579018 OTO - NOTNLM OT - All-cause mortality OT - Cause-specific mortality OT - Nomogram OT - Nonmuscle invasive bladder cancer OT - SEER OT - TURBT COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2024/11/21 00:22 MHDA- 2024/11/21 00:23 PMCR- 2024/11/20 CRDT- 2024/11/20 23:45 PHST- 2024/05/10 00:00 [received] PHST- 2024/11/18 00:00 [accepted] PHST- 2024/11/21 00:23 [medline] PHST- 2024/11/21 00:22 [pubmed] PHST- 2024/11/20 23:45 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - 10.1038/s41598-024-80333-1 [pii] AID - 80333 [pii] AID - 10.1038/s41598-024-80333-1 [doi] PST - epublish SO - Sci Rep. 2024 Nov 20;14(1):28759. doi: 10.1038/s41598-024-80333-1. PMID- 39561374 OWN - NLM STAT- MEDLINE DCOM- 20250207 LR - 20260318 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 213 IP - 3 DP - 2025 Mar TI - Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer. PG - 304-312 LID - 10.1097/JU.0000000000004335 [doi] AB - PURPOSE: Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in nonmuscle-invasive bladder cancer (NMIBC) follow-up are needed. Uromonitor is a urine biomarker test detecting bladder cancer recurrence through the screening of TERT, FGFR3, and KRAS hotspot mutations. The aim of this study was to assess Uromonitor performance by comparing it with the current SOC methods. MATERIALS AND METHODS: Four hundred thirty-nine patients with 528 NMIBC surveillances were enrolled in this study. All patients underwent SOC methods and provided a urine sample for Uromonitor analysis before undergoing cystoscopy. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for recurrence and compared with the gold standard cystoscopy plus transurethral resection of bladder tumor histopathology. RESULTS: Uromonitor displayed a sensitivity of 87% (95% CI, 74-95), with only 6 of 47 recurrences failing to be detected; specificity of 99% (98-100); PPV of 93% (82-98); and an NPV of 99% (97-99). Cystoscopy showed a total of 22 false positives (32%) not confirmed by transurethral resection of bladder tumor, whereas Uromonitor presented only 3 positive tests where no lesions were found. Overall recurrence rate was 8.9% (n = 47) among 528 total screenings. Sensitivity, specificity, PPV, and NPV values for Uromonitor remained high across all NMIBC grades and stages. CONCLUSIONS: Uromonitor represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor's performance, thus validating its usefulness in clinical practice. FAU - Ramos, Pedro AU - Ramos P AUID- ORCID: 0000-0003-2172-7439 AD - Departamento de Urologia, Centro Hospitalar e Universitario Sao Joao, Porto, Portugal. AD - Instituto de Investigacao em Ciencias da Vida e Saude-ICVS/3bs Laboratorio Associado, Escola de Medicina, Universidade do Minho, Braga, Portugal. FAU - Bras, Joao P AU - Bras JP AUID- ORCID: 0000-0003-1867-0486 AD - Instituto de Investigacao e Inovacao em Saude (i3S), Universidade do Porto, Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular, Universidade do Porto (Ipatimup), Porto, Portugal. FAU - Dias, Carolina AU - Dias C AD - Instituto de Investigacao e Inovacao em Saude (i3S), Universidade do Porto, Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular, Universidade do Porto (Ipatimup), Porto, Portugal. FAU - Bessa-Goncalves, Mafalda AU - Bessa-Goncalves M AD - Instituto de Investigacao e Inovacao em Saude (i3S), Universidade do Porto, Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular, Universidade do Porto (Ipatimup), Porto, Portugal. FAU - Botelho, Francisco AU - Botelho F AD - Departamento de Urologia, Centro Hospitalar e Universitario Sao Joao, Porto, Portugal. AD - Instituto de Investigacao em Ciencias da Vida e Saude-ICVS/3bs Laboratorio Associado, Escola de Medicina, Universidade do Minho, Braga, Portugal. FAU - Silva, Joao AU - Silva J AD - Departamento de Urologia, Centro Hospitalar e Universitario Sao Joao, Porto, Portugal. AD - Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. FAU - Silva, Carlos AU - Silva C AD - Departamento de Urologia, Centro Hospitalar e Universitario Sao Joao, Porto, Portugal. AD - Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. FAU - Pacheco-Figueiredo, Luis AU - Pacheco-Figueiredo L AD - Departamento de Urologia, Centro Hospitalar e Universitario Sao Joao, Porto, Portugal. AD - Instituto de Investigacao em Ciencias da Vida e Saude-ICVS/3bs Laboratorio Associado, Escola de Medicina, Universidade do Minho, Braga, Portugal. LA - eng PT - Journal Article PT - Validation Study DEP - 20241119 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - EC 2.7.7.49 (Telomerase) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - 0 (KRAS protein, human) SB - IM CIN - J Urol. 2025 Mar;213(3):311-312. doi: 10.1097/JU.0000000000004347. PMID: 39635897 MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology/diagnosis/genetics MH - Male MH - Female MH - *Biomarkers, Tumor/urine MH - Aged MH - Middle Aged MH - *Neoplasm Recurrence, Local/urine/diagnosis MH - Cystoscopy MH - Proto-Oncogene Proteins p21(ras)/genetics MH - Telomerase/genetics MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Sensitivity and Specificity MH - Predictive Value of Tests MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Mutation OTO - NOTNLM OT - NMIBC OT - cystoscopy OT - follow-up OT - molecular diagnostics OT - urinary biomarkers EDAT- 2024/11/19 22:19 MHDA- 2025/02/07 12:25 CRDT- 2024/11/19 17:03 PHST- 2025/02/07 12:25 [medline] PHST- 2024/11/19 22:19 [pubmed] PHST- 2024/11/19 17:03 [entrez] AID - 10.1097/JU.0000000000004335 [doi] PST - ppublish SO - J Urol. 2025 Mar;213(3):304-312. doi: 10.1097/JU.0000000000004335. Epub 2024 Nov 19. PMID- 39555422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241119 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 40 IP - 4 DP - 2024 Oct-Dec TI - Performance and Clinical Implications of VI-RADS in detecting muscle invasion in bladder tumors: A prospective observational study. PG - 243-249 LID - 10.4103/iju.iju_462_23 [doi] AB - INTRODUCTION: Bladder cancer staging is pivotal for guiding therapeutic decisions. In this study, the primary objective was to assess the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI), The study aimed to classify bladder tumors as either nonmuscle-invasive bladder cancers or muscle-invasive bladder cancers (MIBC) using the Vesical Imaging Reporting and Data System (VI-RADS) scoring. A secondary objective of the study focused on the accuracy of biparametric magnetic resonance imaging (bpMRI) in comparison to mpMRI. METHODS: Thirty-three patients with bladder tumors were enrolled and underwent both mpMRI and bpMRI scoring assessments. VI-RADS scores were assigned and subsequently compared with histopathological findings posttransurethral resection of bladder tumor., Statistical measures included sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for VI-RADS scores at cutoff thresholds of >/=4 and 5. RESULTS: MpMRI at a VI-RADS cutoff of >/=4 yielded an 83.33% sensitivity and 100% specificity, with a diagnostic accuracy of 90.91%. At a cutoff of 5, sensitivity was 100%, specificity was 77.27%, and diagnostic accuracy was 84.85%. bpMRI at a cutoff of >/=4 showed an 80% sensitivity and 100% specificity, with diagnostic accuracy matching mpMRI at 90.91%. CONCLUSIONS: This prospective analysis demonstrates that VI-RADS scoring with mpMRI provides reliable diagnostic accuracy for bladder cancer staging. mpMRI exhibits high sensitivity and specificity at a cutoff of >/= 4, making it a robust tool for MIBC detection. bpMRI is an effective alternative in select patients. The study validates the use of VI-RADS scoring in clinical practice for effective treatment planning. CI - Copyright: (c) 2024 Indian Journal of Urology. FAU - Reddy, Bommireddy V AU - Reddy BV AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Gali, Kasi Viswanath AU - Gali KV AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Chawla, Arun AU - Chawla A AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Singh, Anshuman AU - Singh A AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Bhaskara, Sunil Pillai AU - Bhaskara SP AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Hegde, Padmaraj AU - Hegde P AD - Department of Urology and Renal Transplant, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. LA - eng PT - Journal Article DEP - 20241001 PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC11567586 COIS- There are no conflicts of interest. EDAT- 2024/11/18 16:20 MHDA- 2024/11/18 16:21 PMCR- 2024/10/01 CRDT- 2024/11/18 06:38 PHST- 2023/12/04 00:00 [received] PHST- 2024/06/22 00:00 [revised] PHST- 2024/06/22 00:00 [accepted] PHST- 2024/11/18 16:21 [medline] PHST- 2024/11/18 16:20 [pubmed] PHST- 2024/11/18 06:38 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - IJU-40-243 [pii] AID - 10.4103/iju.iju_462_23 [doi] PST - ppublish SO - Indian J Urol. 2024 Oct-Dec;40(4):243-249. doi: 10.4103/iju.iju_462_23. Epub 2024 Oct 1. PMID- 39552639 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241119 IS - 1758-8340 (Print) IS - 1758-8359 (Electronic) IS - 1758-8340 (Linking) VI - 16 DP - 2024 TI - Role of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review. PG - 17588359241298470 LID - 10.1177/17588359241298470 [doi] LID - 17588359241298470 AB - BACKGROUND: Repeat transurethral resection of bladder tumour (reTURB) is a conventional treatment for non-muscle-invasive bladder cancer (NMIBC) to enhance prognosis. However, the necessity of reTURB in NMIBC remains controversial owing to upstaging of treatments and new evidence. OBJECTIVES: We performed an umbrella review to determine the need for reTURB in patients with NMIBC. DESIGN: We extracted data from meta-analyses that were screened out after a systematic search of PubMed, Embase, the Web of Science and the Cochrane Database of Systematic Reviews. METHODS: Risk of Bias in Systematic Reviews and the Grading of Recommendations, Assessment, Development and Evaluation tools were used to assess the quality of each included meta-analysis and outcomes. RESULTS: Our study included seven meta-analyses. Two studies assessed the efficiency of reTURB in patients who underwent en bloc resection of bladder tumours (ERBT). Patients who underwent ERBT reported low residual tumour and upstaging rates of 5.9% and 0.3%, respectively. Conversely, patients who underwent conventional transurethral resection for bladder cancer (cTURB) had high residual tumour rates. Patients who underwent cTURB and reTURB had significantly improved 1-year recurrence-free survival (RFS) compared to those who underwent initial cTURB alone. In terms of progression-free survival (PFS), a meta-analysis reported that patients who underwent cTURB and reTURB had significantly improved PFS compared with those who underwent initial cTURB alone. In the subgroup analyses of ERBT, reTURB did not affect the RFS and PFS of patients who received ERBT. Currently, only a limited number of randomised clinical trials have evaluated reTURB, and various factors have influenced its efficacy. CONCLUSION: There was significant variation in survival outcomes among patients undergoing reTURB. The necessity and efficacy of reTURB depend on numerous factors, such as surgical approach, equipment and medication usage. Patients eligible for ERBT may constitute a group that does not require reTURB. Further clinical trials are required to validate these findings. REGISTRATION: This umbrella review was registered with the International Prospective Register of Systematic Reviews (CRD42023439078). CI - (c) The Author(s), 2024. FAU - Yu, Qing-Xin AU - Yu QX AUID- ORCID: 0000-0002-4925-4568 AD - Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ning 685 East Section of Huancheng North Road, Ningbo City, Zhejiang Province 315211, China. AD - Department of Pathology, Ningbo Medical Centre Lihuili Hospital, Ningbo City, Zhejiang Province, 315040, China. FAU - Wu, Rui-Cheng AU - Wu RC AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Tuo, Zhou-Ting AU - Tuo ZT AD - Department of Urological Surgery, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing, China. FAU - Zhu, Wei-Zhen AU - Zhu WZ AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Wang, Jie AU - Wang J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Ye, Xing AU - Ye X AD - Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Yoo, Koo Han AU - Yoo KH AD - Department of Urology, Kyung Hee University, Seoul, Republic of Korea. FAU - Wei, Wu-Ran AU - Wei WR AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Feng, De-Chao AU - Feng DC AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province 610041, China. AD - Division of Surgery & Interventional Science, University College London, London, UK. FAU - Li, Deng-Xiong AU - Li DX AUID- ORCID: 0009-0009-8071-7434 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province, 610041, China. LA - eng PT - Journal Article DEP - 20241116 PL - England TA - Ther Adv Med Oncol JT - Therapeutic advances in medical oncology JID - 101510808 PMC - PMC11569495 OTO - NOTNLM OT - bladder cancer OT - en-bloc resection of bladder tumour OT - repeat transurethral resection of bladder tumour OT - umbrella review COIS- The authors declare that there is no conflict of interest. EDAT- 2024/11/18 06:22 MHDA- 2024/11/18 06:23 PMCR- 2024/11/16 CRDT- 2024/11/18 05:54 PHST- 2024/04/29 00:00 [received] PHST- 2024/10/18 00:00 [accepted] PHST- 2024/11/18 06:23 [medline] PHST- 2024/11/18 06:22 [pubmed] PHST- 2024/11/18 05:54 [entrez] PHST- 2024/11/16 00:00 [pmc-release] AID - 10.1177_17588359241298470 [pii] AID - 10.1177/17588359241298470 [doi] PST - epublish SO - Ther Adv Med Oncol. 2024 Nov 16;16:17588359241298470. doi: 10.1177/17588359241298470. eCollection 2024. PMID- 39549749 OWN - NLM STAT- MEDLINE DCOM- 20250201 LR - 20261018 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 154 DP - 2024 Dec TI - Validation of Keratin 17 as a tissue biomarker in the diagnosis of upper tract urothelial carcinoma. PG - 105682 LID - S0046-8177(24)00191-6 [pii] LID - 10.1016/j.humpath.2024.105682 [doi] AB - Upper tract urothelial carcinoma (UTUC) has a relatively low incidence but presents significant surveillance and treatment challenges. Therefore, novel biomarkers for the accurate detection of upper tract urothelial tumors are urgently needed. We evaluated the expression of Keratin 17 (KRT17), an oncoprotein implicated in the cell cycle progression of multiple human cancers and previously studied in bladder urothelial carcinoma, by immunohistochemistry in 139 UTUC cases, including noninvasive, invasive papillary urothelial carcinoma and urothelial carcinoma in situ. KRT17 expression pattern (basal/negative vs. nonbasal) and H-score were evaluated. The expression pattern was significantly different in normal (NL) compared to malignant urothelium. Nonbasal KRT17 expression was significantly higher in pTa (p < 0.001) and invasive (pTinv) (p = 0.0023) urothelial carcinoma compared to NL, and in pTinv compared to pTa (p = 0.0391). Sensitivity and specificity for distinguishing benign from malignant tumors were 85% and 82, respectively, with an area under the curve of 0.83 (p < 0.001). The KRT17 H-score was significantly higher in pTa and pTinv compared to NL (p < 0.001 and p = 0.0035, respectively). Sensitivity and specificity for distinguishing benign from malignant carcinoma were 91% and 69%, respectively, with an AUC of 0.81 (p = 0.0010). KRT17 was not associated with tumor site, grade, or stage. In summary, K17 is a sensitive and specific marker of neoplastic upper tract urothelium, and its potential use in routine diagnostics should be explored in larger studies. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Smelser, Woodson AU - Smelser W AD - Division of Urology, Washington University in St. Louis, MO, USA. FAU - Kim, Nam AU - Kim N AD - KDx Diagnostics Inc, Campbell, CA, USA. FAU - Jahanfard, Sholeh AU - Jahanfard S AD - KDx Diagnostics Inc, Campbell, CA, USA. FAU - Sarno, Mark AU - Sarno M AD - Vision Clinical Research, LLC, San Marcos, CA, USA. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Giannico, Giovanna A AU - Giannico GA AD - Department of Pathology, University of California Irvine Medical Center, 101 The City Dr. South, Orange, 92868, CA, USA. Electronic address: ggiannico@iuhealth.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20241115 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Keratin-17) RN - 0 (Biomarkers, Tumor) RN - 0 (KRT17 protein, human) SB - IM MH - Humans MH - *Keratin-17/analysis MH - *Biomarkers, Tumor/analysis MH - Male MH - Female MH - Aged MH - Middle Aged MH - Immunohistochemistry MH - *Urothelium/pathology/chemistry MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell/pathology/diagnosis/chemistry MH - Adult MH - Predictive Value of Tests MH - *Urologic Neoplasms/pathology/diagnosis MH - *Ureteral Neoplasms/pathology/diagnosis OTO - NOTNLM OT - Immunohistochemistry OT - Keratin 17 OT - UTUC OT - Upper tract urothelial carcinoma OT - Urothelial carcinoma COIS- Declaration of competing interest N.K. and S.J. are employees of KDx Diagnostics Inc. M.S. is Chief Executive Officer at Vision Clinical Research, LLC. The remaining authors declare that they have no conflict of interest. EDAT- 2024/11/17 04:19 MHDA- 2025/02/02 05:11 CRDT- 2024/11/16 19:22 PHST- 2024/08/08 00:00 [received] PHST- 2024/11/04 00:00 [revised] PHST- 2024/11/11 00:00 [accepted] PHST- 2025/02/02 05:11 [medline] PHST- 2024/11/17 04:19 [pubmed] PHST- 2024/11/16 19:22 [entrez] AID - S0046-8177(24)00191-6 [pii] AID - 10.1016/j.humpath.2024.105682 [doi] PST - ppublish SO - Hum Pathol. 2024 Dec;154:105682. doi: 10.1016/j.humpath.2024.105682. Epub 2024 Nov 15. PMID- 39540204 OWN - NLM STAT- MEDLINE DCOM- 20241114 LR - 20261001 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 13 IP - 22 DP - 2024 Nov TI - A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients. PG - e70349 LID - 10.1002/cam4.70349 [doi] LID - e70349 AB - BACKGROUND: Despite the high recurrence rate of non-muscle-invasive bladder cancer (NMIBC), there are limitations in accurately predicting recurrence after transurethral resection of bladder tumor (TURBT) based on clinicopathological factors alone. However, prediction of recurrence using biomolecular characteristics of bladder tumors has not been applied to clinical practice. The objective of this study was to establish a new gene expression scoring system for identifying patients at high risk of recurrence. METHODS: NMIBC and normal bladder samples were subjected to microarray analysis to obtain gene expression profiles. We identified 6 genes that were specifically upregulated in bladder cancer and also in recurrent cases. All patients were randomly grouped into a discovery cohort (n = 59) and a validation cohort (n = 30). Gene expression score (GES) was defined as the mean Z-score of the 6 genes specific for recurrent bladder cancer. RESULTS: The intravesical recurrence rate of the high GES group (n = 38) was higher than the low GES group (n = 21). GES was significantly associated with recurrence-free survival in the validation cohort as well. In prognostic analysis, the European Organization for Research and Treatment of Cancer (EORTC) risk classification was not related to recurrence after TURBT in either univariate or multivariate analysis. On the other hand, the GES we developed was an independent factor for recurrence in NMIBC. CONCLUSIONS: A novel gene expression scoring system was shown to predict recurrence in NMIBC patients after TURBT and might be helpful in clinical decision-making for NMIBC patients. CI - (c) 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. FAU - Kayama, Emina AU - Kayama E AUID- ORCID: 0009-0004-6647-1945 AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Uemura, Motohide AU - Uemura M AUID- ORCID: 0000-0001-7263-7965 AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. AD - Department of Urology, Iwase General Hospital, Fukushima, Japan. FAU - Onagi, Akifumi AU - Onagi A AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Meguro, Satoru AU - Meguro S AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Ogawa, Soichiro AU - Ogawa S AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Yaginuma, Kei AU - Yaginuma K AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Matsuoka, Kanako AU - Matsuoka K AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Hoshi, Seiji AU - Hoshi S AUID- ORCID: 0000-0003-1545-1827 AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Koguchi, Tomoyuki AU - Koguchi T AUID- ORCID: 0009-0001-9045-9426 AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Hata, Junya AU - Hata J AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Sato, Yuichi AU - Sato Y AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Akaihata, Hidenori AU - Akaihata H AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. FAU - Honma, Reiko AU - Honma R AD - Nippon Gene Co. Ltd., Tokyo, Japan. FAU - Watanabe, Shinya AU - Watanabe S AD - Translational Research Center, Fukushima Medical University, Fukushima, Japan. FAU - Kojima, Yoshiyuki AU - Kojima Y AD - Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. LA - eng PT - Journal Article PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology/mortality/surgery MH - Male MH - Female MH - *Neoplasm Recurrence, Local/genetics/pathology MH - Aged MH - Middle Aged MH - Prognosis MH - *Gene Expression Profiling/methods MH - Biomarkers, Tumor/genetics MH - Gene Expression Regulation, Neoplastic MH - Neoplasm Invasiveness MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11561421 OTO - NOTNLM OT - gene expression OT - microarray analysis OT - non-muscle-invasive bladder cancer OT - prognostic biomarker OT - recurrence risk COIS- The authors declare no conflicts of interest. EDAT- 2024/11/14 17:37 MHDA- 2024/11/14 18:31 PMCR- 2024/11/14 CRDT- 2024/11/14 04:30 PHST- 2024/10/05 00:00 [revised] PHST- 2024/04/15 00:00 [received] PHST- 2024/10/07 00:00 [accepted] PHST- 2024/11/14 18:31 [medline] PHST- 2024/11/14 17:37 [pubmed] PHST- 2024/11/14 04:30 [entrez] PHST- 2024/11/14 00:00 [pmc-release] AID - CAM470349 [pii] AID - 10.1002/cam4.70349 [doi] PST - ppublish SO - Cancer Med. 2024 Nov;13(22):e70349. doi: 10.1002/cam4.70349. PMID- 39533991 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 11 IP - 4 DP - 2024 Oct TI - Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer. PG - 625-632 LID - 10.1016/j.ajur.2023.04.007 [doi] AB - OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) remains a common challenge in uro-oncology with conflicting reports on recurrence risk. This study aimed to elucidate the recurrence rate of NMIBC in the Cancer Clinic of Shahid Beheshti Hospital in Iran and to investigate related parameters affecting recurrence risk. METHODS: The data of 143 patients with NMIBC, who underwent treatment between January 2017 and January 2020 and were followed up from the initial transurethral resection of bladder tumor until November 30, 2020 in our institution, were retrospectively assessed. The Cox regression analysis and Kaplan-Meier plot of recurrence-free survival were used to determine independent contributing factors for tumor recurrence. RESULTS: Among patients with NMIBC, 83.9% were male, and 16.1% were female, with a mean age of 64.4 (standard deviation [SD] 12.9) years. During the follow-up, 71 (49.7%) patients showed tumor recurrence, with a mean recurrence time of 11.5 (SD 6.9) months. In the Chi-square test or Fisher's exact test, the age (>/=65 years) (p=0.037), obesity (body mass index >/=30 kg/m(2)) (p=0.004), no diabetes mellitus (p=0.005), smoking (current or former smoker) (p=0.001), immediate perfusion therapy (p=0.035), number of tumors (>3) (p<0.001), and tumor stage (Ta, T1, and Tis) (p=0.001) had independent significant effects on the recurrence of NMIBC. The multivariate Cox regression analysis indicated that preoperative obesity (hazards ratio [HR] 7.90; 95% confidential interval [CI] 4.01-15.55; p<0.001), current or former smoking (HR 1.85; 95% CI 1.07-3.20; p=0.027), and a high-grade tumor (HR 4.03; 95% CI 1.59-10.25; p=0.003) were significant predictors of tumor recurrence. The Kaplan-Meier plot of recurrence-free survival showed that obesity (log-rank p<0.001), current or former smoking (log-rank p=0.001), and a high-grade tumor (log-rank p=0.006) were associated with a shorter time interval until the first tumor recurrence. CONCLUSION: The study found a high recurrence rate of NMIBC in Iran from January 2017 to January 2020, with the obesity, smoking history, and the high-grade tumor as contributing factors. CI - (c) 2024 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. FAU - Ahmadi, Niloufar AU - Ahmadi N AD - Department of Urology, School of Medicine, Babol University of Medical Sciences, Babol, Iran. FAU - Shafee, Hamid AU - Shafee H AD - Department of Urology, School of Medicine, Babol University of Medical Sciences, Babol, Iran. FAU - Moudi, Emaduddin AU - Moudi E AD - Department of Surgery, Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. LA - eng PT - Journal Article DEP - 20240223 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC11551389 OTO - NOTNLM OT - Bladder cancer OT - Non-muscle-invasive OT - Prediction OT - Recurrence EDAT- 2024/11/14 03:59 MHDA- 2024/11/14 04:00 PMCR- 2024/02/23 CRDT- 2024/11/13 04:14 PHST- 2023/01/30 00:00 [received] PHST- 2023/04/26 00:00 [accepted] PHST- 2024/11/14 04:00 [medline] PHST- 2024/11/14 03:59 [pubmed] PHST- 2024/11/13 04:14 [entrez] PHST- 2024/02/23 00:00 [pmc-release] AID - S2214-3882(24)00018-3 [pii] AID - 10.1016/j.ajur.2023.04.007 [doi] PST - ppublish SO - Asian J Urol. 2024 Oct;11(4):625-632. doi: 10.1016/j.ajur.2023.04.007. Epub 2024 Feb 23. PMID- 39535158 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260708 IS - 1744-8352 (Electronic) IS - 1473-7159 (Linking) VI - 24 IP - 10 DP - 2024 Oct TI - Biomarkers of treatment response in bladder cancer. PG - 957-969 LID - 10.1080/14737159.2024.2428747 [doi] AB - INTRODUCTION: There have been many recent advancements in the treatment of bladder cancer including the approval of novel intravesical agents for non-muscle-invasive disease and systemic-targeted therapeutics for muscle-invasive and advanced disease. However, treatment strategies for bladder cancer are still largely based on clinicopathologic characteristics. AREAS COVERED: Based on primary literature sourced from PubMed, Embase, and Cochrane Library, we review the current status of molecular markers and biomarker panels with respective to their value in predicting response to standard chemotherapeutics and novel agents in non-muscle-invasive, muscle-invasive, and advanced bladder cancer. EXPERT OPINION: Several biomarkers based on molecular characterization of tumors and quantification of circulating tumor DNA have been associated with response or resistance to standard chemotherapeutics. More recent investigations have reported on predictive biomarkers for novel therapeutics in bladder cancer, although large-scale validation is still needed. Given the increasing therapeutic options for this disease, employment of such predictive biomarkers may help guide treatment selection and sequencing. FAU - Heard, John R AU - Heard JR AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Ahdoot, Michael AU - Ahdoot M AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Theodorescu, Dan AU - Theodorescu D AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Mitra, Anirban P AU - Mitra AP AUID- ORCID: 0000-0002-6549-5943 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20241113 PL - England TA - Expert Rev Mol Diagn JT - Expert review of molecular diagnostics JID - 101120777 RN - 0 (Biomarkers, Tumor) RN - 0 (Antineoplastic Agents) RN - 0 (Circulating Tumor DNA) SB - IM MH - *Urinary Bladder Neoplasms/therapy/diagnosis/genetics/drug therapy/metabolism MH - Humans MH - *Biomarkers, Tumor MH - Antineoplastic Agents/therapeutic use MH - Treatment Outcome MH - Circulating Tumor DNA/blood MH - Drug Resistance, Neoplasm OTO - NOTNLM OT - Antibody-drug conjugates OT - biomarkers OT - chemotherapy OT - gene therapy OT - genomic profiling OT - immune checkpoint inhibitors OT - therapeutic response OT - urothelial carcinoma EDAT- 2024/11/13 13:56 MHDA- 2024/11/28 06:35 CRDT- 2024/11/13 08:23 PHST- 2024/11/28 06:35 [medline] PHST- 2024/11/13 13:56 [pubmed] PHST- 2024/11/13 08:23 [entrez] AID - 10.1080/14737159.2024.2428747 [doi] PST - ppublish SO - Expert Rev Mol Diagn. 2024 Oct;24(10):957-969. doi: 10.1080/14737159.2024.2428747. Epub 2024 Nov 13. PMID- 39532830 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 15 IP - 1 DP - 2024 Nov 13 TI - Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy. PG - 649 LID - 10.1007/s12672-024-01548-2 [doi] LID - 649 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is renowned for its high recurrence, invasiveness, and poor prognosis. Consequently, developing new biomarkers for risk assessment and investigating innovative therapeutic targets postoperative in NMIBC patients are crucial to aid in treatment planning. APPROACHES: Differential gene expression analysis was performed using multiple Gene Expression Omnibus (GEO) datasets to identify differentially expressed genes (DEGs) between NMIBC and normal tissue, as well as between NMIBC and muscle-invasive bladder cancer (MIBC). Functional enrichment analysis was conducted based on the DEGs identified. Subsequently, prognosis-related genes were selected using Kaplan-Meier (KM) analysis and Cox regression analysis. The Boruta algorithm was utilized to further screen for core DEGs related to postoperative progression in NMIBC based on the aforementioned prognosis-related genes. Single-cell and clinical correlation studies were performed to verify their expression across various stages of bladder cancer. To investigate the link between core genes and the immune microenvironment, single-sample gene set enrichment analysis (ssGSEA) was utilized, and Receiver Operating Characteristic (ROC) and KM analyses were performed to confirm predictive power for immune therapy outcomes. Machine learning (ML) models were constructed using the DepMap dataset to predict the efficacy of core gene inhibitors in treating bladder cancers. The prognostic performance of the core genes was evaluated using ROC curve analysis. An online prediction tool was developed based on the core genes to provide prognostic predictions. Finally, RT-qPCR, CCK-8, and Transwell assays were used to verify the pro-tumor effects of the GINS2 in bladder cancer. RESULTS: A total of 70 DEGs were identified, among which 11 prognostic genes were obtained through KM analysis, and an additional 8 prognostic genes were obtained through COX analysis. The Boruta algorithm selected AURKB, GINS2, and UHRF1 as the three core DEGs. Single-cell and clinical variable correlation analyses indicated that the core genes promoted the progression of bladder cancer. The analysis of immune infiltration revealed a strong positive association between the core genes and both activated CD4 T cells and Type 2 helper T cells. Two random forest (RF) models were constructed to effectively predict the treatment effect of bladder cancer after targeted inhibition of AURKB and GINS2. In addition, an online nomogram tool was developed to effectively predict the risk of postoperative progression in NMIBC patients undergoing TURBT. Finally, RT-qPCR, CCK8, and Transwell assays showed that GINS2 promoted the growth and progression of bladder cancer. CONCLUSION: AURKB, GINS2, and UHRF1 have the potential to enhance postoperative management of NMIBC patients undergoing transurethral resection of bladder tumor (TURBT) and can predict immunotherapy response, establishing them as promising therapeutic targets. CI - (c) 2024. The Author(s). FAU - Xiao, Zhiliang AU - Xiao Z AD - Department of Urology, The Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi, China. FAU - Liu, Xin AU - Liu X AD - Department of Urology, The Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi, China. FAU - Wang, Yuan AU - Wang Y AD - Guangzhou Medical University, Guangzhou, 511436, China. FAU - Jiang, Sicong AU - Jiang S AD - Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi, China. 18270200970@163.com. FAU - Feng, Yan AU - Feng Y AD - Department of Urology, The Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi, China. 549507501@qq.com. LA - eng PT - Journal Article DEP - 20241113 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC11557814 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Machine learning OT - Single-cell RNA sequencing COIS- Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. EDAT- 2024/11/13 13:53 MHDA- 2024/11/13 13:54 PMCR- 2024/11/13 CRDT- 2024/11/12 23:25 PHST- 2024/08/11 00:00 [received] PHST- 2024/11/06 00:00 [accepted] PHST- 2024/11/13 13:54 [medline] PHST- 2024/11/13 13:53 [pubmed] PHST- 2024/11/12 23:25 [entrez] PHST- 2024/11/13 00:00 [pmc-release] AID - 10.1007/s12672-024-01548-2 [pii] AID - 1548 [pii] AID - 10.1007/s12672-024-01548-2 [doi] PST - epublish SO - Discov Oncol. 2024 Nov 13;15(1):649. doi: 10.1007/s12672-024-01548-2. PMID- 39529480 OWN - NLM STAT- MEDLINE DCOM- 20250205 LR - 20260710 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 35 IP - 2 DP - 2025 Mar 1 TI - The role of MRI in muscle-invasive bladder cancer: an update from the last two years. PG - 165-170 LID - 10.1097/MOU.0000000000001249 [doi] AB - PURPOSE OF REVIEW: Muscle invasive bladder cancer (MIBC) is aggressive and requires radical cystectomy and neoadjuvant therapy, yet over 40% of patients face recurrence. The loss of the bladder also significantly reduces quality of life. Accurate staging, crucial for treatment decisions, is typically done through transurethral resection (TURBT), but inconsistencies in pathology affect diagnosis in 25% of cases. MRI is the most precise imaging method for evaluating local tumor invasiveness. This review discusses recent advances in MRI for staging MIBC and predicting responses to neoadjuvant therapy. RECENT FINDINGS: Vesical imaging - reporting and data system (VI-RADS) accuracy may improve if combined with ADC maps and tumor contact length, while a bi-parametric MRI approach without contrast could reduce side effects without losing diagnostic precision, though evidence is mixed. VI-RADS shows promise in predicting neoadjuvant therapy responses, and the new nacVI-RADS score is in development. Non-Gaussian diffusion-weighted imaging techniques and machine learning could enhance accuracy but need more integration with mpMRI. VI-RADS may assist in evaluating responses in bladder-sparing regimens. Urodrill, an MRI-guided biopsy, aims to replace diagnostic TURBT but needs more accuracy data. SUMMARY: MRI in MIBC is evolving, offering potential for accurate local staging and reduced side effects by avoiding TURBT. Predicting neoadjuvant treatment response could guide personalized treatment and bladder preservation. Larger trials are needed to validate these findings. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Pastorino, Giovanni Luigi AU - Pastorino GL AD - Vita-Salute San Raffaele University, Milan. FAU - Mercinelli, Chiara AU - Mercinelli C AD - Vita-Salute San Raffaele University, Milan. AD - Medical Oncology Unit 2, Santa Chiara Hospital, Azienda Ospedaliero-Universitaria Pisana, Pisa. FAU - Necchi, Andrea AU - Necchi A AD - Vita-Salute San Raffaele University, Milan. AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241111 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/diagnostic imaging MH - Neoplasm Invasiveness/diagnostic imaging MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - *Magnetic Resonance Imaging/methods MH - Cystectomy MH - *Urinary Bladder/pathology/diagnostic imaging/surgery MH - Neoplasm Recurrence, Local/prevention & control/pathology MH - Predictive Value of Tests EDAT- 2024/11/13 13:54 MHDA- 2025/02/05 06:21 CRDT- 2024/11/12 02:53 PHST- 2025/02/05 06:21 [medline] PHST- 2024/11/13 13:54 [pubmed] PHST- 2024/11/12 02:53 [entrez] AID - 00042307-990000000-00207 [pii] AID - 10.1097/MOU.0000000000001249 [doi] PST - ppublish SO - Curr Opin Urol. 2025 Mar 1;35(2):165-170. doi: 10.1097/MOU.0000000000001249. Epub 2024 Nov 11. PMID- 39529478 OWN - NLM STAT- MEDLINE DCOM- 20241204 LR - 20260710 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 35 IP - 1 DP - 2025 Jan 1 TI - Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma. PG - 75-82 LID - 10.1097/MOU.0000000000001247 [doi] AB - PURPOSE OF REVIEW: The purpose of this review is to summarize the most recent evidence on surgical management, strategies to reduce tumor recurrence, and surveillance regimens in patients diagnosed with upper tract urothelial carcinoma (UTUC) and elected for radical treatment. RECENT FINDINGS: Minimally invasive surgery is gaining momentum in the surgical management of UTUC. Chemoprophylaxis is still the gold standard to reduce intravesical recurrence after radical nephroureterectomy (RNU). Novel surveillance strategies have been proposed to adapt follow-up regimens to patients' characteristics. SUMMARY: Minimally invasive surgery has been associated with comparable oncological outcomes to the open approach while improving postoperative morbidity. In these cases, bladder cuff excision (BCE) is mostly performed by an extravesical approach, that demonstrates a noninferiority compared to the intravesical one in terms of oncological outcomes. Although lymphadenectomy is recommended in patients with high-risk tumors, its benefits are still unclear. Currently, there is a lack of recent prospective trials on chemoprophylaxis to reduce intravesical recurrence post RNU, making single-dose postoperative chemotherapy instillation the standard treatment. Although novel risk stratification models were released by international urological guidelines, their validity is mainly nonevidence-based. Risk-adapted follow-up strategies incorporating cystoscopy and cross-sectional imaging accounting for individual patient factors should be implemented. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Basile, Giuseppe AU - Basile G AD - Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Bandini, Marco AU - Bandini M AD - Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida, USA. FAU - Poch, Michael A AU - Poch MA AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida, USA. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida, USA. LA - eng PT - Journal Article PT - Review DEP - 20241111 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Carcinoma, Transitional Cell/surgery/pathology/prevention & control/diagnosis MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology MH - *Ureteral Neoplasms/surgery/pathology/diagnosis MH - Kidney Neoplasms/surgery/pathology/prevention & control MH - Chemoprevention/methods MH - Treatment Outcome MH - Chemotherapy, Adjuvant/methods EDAT- 2024/11/13 13:56 MHDA- 2024/12/04 06:22 CRDT- 2024/11/12 02:53 PHST- 2024/12/04 06:22 [medline] PHST- 2024/11/13 13:56 [pubmed] PHST- 2024/11/12 02:53 [entrez] AID - 00042307-990000000-00208 [pii] AID - 10.1097/MOU.0000000000001247 [doi] PST - ppublish SO - Curr Opin Urol. 2025 Jan 1;35(1):75-82. doi: 10.1097/MOU.0000000000001247. Epub 2024 Nov 11. PMID- 39518145 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 21 DP - 2024 Nov 1 TI - The Role of Bladder-Washing Cytology as an Adjunctive Method to Cystoscopy During Follow-Up for Low-Grade TaT1 Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers16213708 [doi] LID - 3708 AB - BACKGROUND AND OBJECTIVE: The role of urine cytology during follow-up for low-grade (LG) non-muscle-invasive bladder cancer (NMIBC) is not well established, although cytology has low sensitivity in detecting LG recurrences. Our study aims to evaluate the impact of urine cytology as a complementary method to cystoscopy during follow-up for LG NMIBC. METHODS: Patients diagnosed with primary LG TaT1 bladder cancer (BC) between 2010 and 2020 were included. Patients were stratified according to the EAU NMIBC scoring model. Urine cytology was performed during follow-up cystoscopy. The outcomes of the study were BC recurrence and upgrading to high-grade (HG). Cytology utility was established by assessing whether its result led to management change. RESULTS: We included 337 patients with LG TaT1 BC. EAU risk group distribution was low in 262 (77.7%), intermediate in 57 (16.9%), and high-risk in 18 (5.3%) cases. With a median follow-up of 5 years, 166 (49.3%) patients experienced recurrence. Cystoscopy was positive in 154 (92.8%) and suspicious in 12 (7.2%) cases. Urine cytology was positive in 33 (19.9%) cases but only changed management in 3 (0.89%), all with suspicious cystoscopy. Positive cytology at first recurrence was associated with higher risk of upgrading during follow-up (HR 2.781, p = 0.006) and lower upgrading-free survival (p = 0.001). CONCLUSIONS: The role of urine cytology to detect first recurrences during follow-up for primary LG TaT1 NMIBC might be limited to patients with non-conclusive lesions in the cystoscopy. A positive cytology at first recurrence is associated with a higher risk of upgrading to HG BC during follow-up. FAU - Carbonell, Enric AU - Carbonell E AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Mercader, Claudia AU - Mercader C AUID- ORCID: 0000-0002-5710-958X AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Alfambra, Hector AU - Alfambra H AUID- ORCID: 0009-0001-8144-7714 AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Narvaez, Paulette AU - Narvaez P AUID- ORCID: 0009-0004-6901-4432 AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Villalba, Eric AU - Villalba E AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Pages, Rita AU - Pages R AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Asiain, Ignacio AU - Asiain I AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Costa, Meritxell AU - Costa M AUID- ORCID: 0009-0008-5422-4057 AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Franco, Agustin AU - Franco A AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Ribal, Maria Jose AU - Ribal MJ AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. FAU - Vilaseca, Antoni AU - Vilaseca A AUID- ORCID: 0000-0003-0160-620X AD - Department of Urology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. LA - eng PT - Journal Article DEP - 20241101 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11545547 OTO - NOTNLM OT - cystoscopy OT - follow-up OT - non-muscle-invasive bladder cancer OT - urine cytology OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2024/11/13 14:01 MHDA- 2024/11/13 14:02 PMCR- 2024/11/01 CRDT- 2024/11/09 01:06 PHST- 2024/09/18 00:00 [received] PHST- 2024/10/25 00:00 [revised] PHST- 2024/10/30 00:00 [accepted] PHST- 2024/11/13 14:02 [medline] PHST- 2024/11/13 14:01 [pubmed] PHST- 2024/11/09 01:06 [entrez] PHST- 2024/11/01 00:00 [pmc-release] AID - cancers16213708 [pii] AID - cancers-16-03708 [pii] AID - 10.3390/cancers16213708 [doi] PST - epublish SO - Cancers (Basel). 2024 Nov 1;16(21):3708. doi: 10.3390/cancers16213708. PMID- 39518090 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 21 DP - 2024 Oct 29 TI - Cohort Profile: VZNKUL-NMIBC Quality Indicators Program: A Flemish Prospective Cohort to Evaluate the Quality Indicators in the Treatment of Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers16213653 [doi] LID - 3653 AB - Purpose: Bladder cancer (BC) is a heterogeneous disease with varying outcomes, influenced by disease heterogeneity and variability in treatment and follow-up. Risk groups have been established for non-muscle-invasive BC (NMIBC) to standardize therapy, and several quality control indicators (QCIs) monitor adherence to these risk group-based guidelines. However, controversial results had been obtained regarding the oncological benefits of these QCIs until recent high-quality studies from large registries showed their usefulness. To improve adherence to the European Association of Urology (EAU) Guidelines and benchmark current care in Flemish hospitals within Vlaams Ziekenhuisnetwerk-KU Leuven (VZNKUL), a QCI program for NMIBC was initiated in 2013. This study aims to describe the demographic, clinical, and treatment data of patients enrolled in this program. Participants: The VZNKUL-NMIBC Quality Indicators Program Registry is a prospective cohort including patients treated and followed up with at seven academic and non-academic Flemish hospitals since June 2013. Data collection includes patient characteristics, tumor data, treatment, and oncological outcomes. Findings to date: From June 2013 to December 2020, 4744 transurethral resections of bladder tumors (TURBTs) from 2237 unique patients were analyzed. Most patients (80%) were men with a median age of 73. The median time from diagnosis to TURBT was 19 days. A single tumor was detected in 37% of TURBTs. Tumors larger than 3 cm were found in 20.8% of cases. In 46% of TURBTs, a reTURBT was scheduled according to guidelines. The complication rates were 7.5% and 2.4% for bladder perforation and bleeding, respectively. Postoperative single intravesical instillation of chemotherapy (SIVIC) was administered to 56.9% of 1533 indicated patients with a median time to administration of 4.7 h. Among the cohort, 60.4% had NMIBC, and 9.3% had muscle-invasive BC. Of 972 high-risk patients, 60.7% received adequate BCG induction, while 39.4% received adequate maintenance. After BCG induction +/- maintenance, 39.7% were tumor-free, with 17.7% recurrence and 4% progression to muscle-invasive BC. BCG treatment was terminated early for 17% of patients due to intolerance. Early cystectomy was performed for 2.4% of the BCG-naive patients, and 27.7% of patients with BCG failure underwent a BCG rechallenge. For intermediate-risk patients, 2.1% received adequate BCG, and 23% received intravesical chemotherapy. The median follow-up was 57 months. Five-year recurrence-free, progression-free, cancer-free, overall, and cancer-specific survival rates were 53%, 91.6%, 89%, 70.6%, and 95.6%, respectively, for the NMIBC patients. Of 400 non-metastatic MIBC patients, 217 (54.3%) underwent radical cystectomy (RC), of whom 46% received neoadjuvant chemotherapy, while 18 (4.5%) refused RC, and 74 (18.5%) were considered unfit for the surgery. Future plans: The VZNKUL-NMIBC Quality Indicators Program Registry will continue collecting data to evaluate QCIs and monitor treatment quality, enabling hospitals to benchmark their performance and improve patient care. Additionally, the registry's real-world data can support research and international collaboration. Trial registration: The study was registered on ClinicalTrials.gov (NCT04167332). FAU - Akand, Murat AU - Akand M AUID- ORCID: 0000-0001-8840-5771 AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. FAU - Veys, Ralf AU - Veys R AD - Department of Urology, AZ Groeninge, 8500 Kortrijk, Belgium. FAU - Ost, Dieter AU - Ost D AD - Department of Urology, AZ Sint Blasius, 9200 Dendermonde, Belgium. FAU - Vander Eeckt, Kathy AU - Vander Eeckt K AD - Department of Urology, AZ Sint Blasius, 9200 Dendermonde, Belgium. FAU - Baekelandt, Frederic AU - Baekelandt F AD - Department of Urology, AZ Sint-Lucas Brugge, 8310 Brugge, Belgium. FAU - Van Reusel, Raf AU - Van Reusel R AD - Department of Urology, AZ Turnhout, 2300 Turnhout, Belgium. FAU - Mattelaer, Pieter AU - Mattelaer P AD - Department of Urology, AZ Oostende Damiaan, 8400 Oostende, Belgium. FAU - Baekelandt, Loic AU - Baekelandt L AUID- ORCID: 0000-0002-8962-9395 AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. FAU - Van Cleynenbreugel, Ben AU - Van Cleynenbreugel B AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AUID- ORCID: 0000-0003-3195-9890 AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AUID- ORCID: 0000-0002-4617-3666 AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. LA - eng SI - ClinicalTrials.gov/NCT04167332 PT - Journal Article DEP - 20241029 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11545168 OTO - NOTNLM OT - bladder cancer OT - non-muscle-invasive OT - progression OT - prospective OT - quality indicator OT - recurrence OT - registry OT - survival OT - treatment COIS- The authors declare no conflict of interest. EDAT- 2024/11/13 13:53 MHDA- 2024/11/13 13:54 PMCR- 2024/10/29 CRDT- 2024/11/09 01:06 PHST- 2024/09/18 00:00 [received] PHST- 2024/10/14 00:00 [revised] PHST- 2024/10/22 00:00 [accepted] PHST- 2024/11/13 13:54 [medline] PHST- 2024/11/13 13:53 [pubmed] PHST- 2024/11/09 01:06 [entrez] PHST- 2024/10/29 00:00 [pmc-release] AID - cancers16213653 [pii] AID - cancers-16-03653 [pii] AID - 10.3390/cancers16213653 [doi] PST - epublish SO - Cancers (Basel). 2024 Oct 29;16(21):3653. doi: 10.3390/cancers16213653. PMID- 39518066 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 21 DP - 2024 Oct 27 TI - A Systematic Review of the Use of Surgical Checklists in Transurethral Resection of Bladder Tumour. LID - 10.3390/cancers16213626 [doi] LID - 3626 AB - CONTEXT: Surgical checklists have previously been shown to improve surgical quality and patient outcomes. However, their use in transurethral resection of bladder tumour (TURBT), one of the most commonly performed urological procedures, has yet to be explored in depth. OBJECTIVE: To evaluate the effect of surgical checklist implementation in TURBT on documentation quality, specimen quality, and oncological outcomes according to the existing literature. We then hope to develop an optimised TURBT checklist by identifying the most pertinent parameters for inclusion. EVIDENCE ACQUISITION: A literature search using PubMed was performed to identify literature pertaining to the use of surgical checklists in the context of TURBT. A systematic review was then performed on the 41 identified studies, of which six were included in the final analysis. EVIDENCE SYNTHESIS: We explored three primary outcomes that arose from the literature, namely: (1) comprehensiveness of documentation; (2) resection quality; and (3) recurrence rates and recurrence-free survival (RFS). We found agreement in the literature that surgical checklist implementation does lead to an overall improvement in documentation. The effect of surgical checklists on resection quality and recurrence rates, however, was mixed in the literature, with some studies showing statistically significant improvements and others showing no significant change. CONCLUSIONS: There are multiple benefits to surgical checklist implementation in TURBT procedures. We propose an optimised 14-item surgical checklist that should be implemented in every TURBT report to ensure sufficient information documentation for risk stratification and post-operative management. FAU - Botros, Abram AU - Botros A AUID- ORCID: 0009-0008-1980-1023 AD - Faculty of Medicine, Nursing and Health Sciences, Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia. AD - Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia. FAU - Rival, Paul M AU - Rival PM AUID- ORCID: 0000-0002-4859-9150 AD - Faculty of Medicine, Nursing and Health Sciences, Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia. AD - Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia. FAU - Davis, Ian D AU - Davis ID AUID- ORCID: 0000-0002-9066-8244 AD - Faculty of Medicine, Nursing and Health Sciences, Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia. AD - Department of Oncology, Eastern Health, Box Hill, VIC 3128, Australia. FAU - Sengupta, Shomik AU - Sengupta S AUID- ORCID: 0000-0003-3357-1216 AD - Faculty of Medicine, Nursing and Health Sciences, Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia. AD - Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia. LA - eng PT - Journal Article PT - Review DEP - 20241027 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11545027 OTO - NOTNLM OT - bladder cancer OT - checklist OT - systematic review OT - transurethral resection of bladder tumour COIS- I.D.D. and S.S. are unpaid Board Directors of the ANZUP cancer trials group. I.D.D. has been a member or chair of advisory boards for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Merck/Pfizer, MSD, Pio Therapeutics, Roche, and Xennials. All honoraria are invoiced by and paid directly to ANZUP Cancer Trials Group. I.D.D. is supported in part by an Australian NHMRC Investigator Grant (2016274). S.S. has been an adviser/speaker for Mundipharma, Ipsen, Abbvie and MSD (with honoraria donated directly into departmental research funds) and a paid adviser/speaker for Bristol Myers Squibb and Janssen. EDAT- 2024/11/13 13:47 MHDA- 2024/11/13 13:48 PMCR- 2024/10/27 CRDT- 2024/11/09 01:06 PHST- 2024/09/08 00:00 [received] PHST- 2024/10/18 00:00 [revised] PHST- 2024/10/22 00:00 [accepted] PHST- 2024/11/13 13:48 [medline] PHST- 2024/11/13 13:47 [pubmed] PHST- 2024/11/09 01:06 [entrez] PHST- 2024/10/27 00:00 [pmc-release] AID - cancers16213626 [pii] AID - cancers-16-03626 [pii] AID - 10.3390/cancers16213626 [doi] PST - epublish SO - Cancers (Basel). 2024 Oct 27;16(21):3626. doi: 10.3390/cancers16213626. PMID- 39513886 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20250127 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 13 IP - 21 DP - 2024 Oct 27 TI - Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target. LID - 10.3390/cells13211779 [doi] LID - 1779 AB - Bladder cancer remains a prevalent and challenging malignancy. Myeloid-derived suppressor cells (MDSCs) have emerged as key contributors to the immunosuppressive tumor microenvironment, facilitating tumor progression, immune evasion, and resistance to therapies. This review explores the role of MDSC in bladder cancer, highlighting their involvement in immune regulation; tumor progression; and resistance to therapies such as bacillus Calmette-Guerin (BCG) therapy, chemotherapy, and immune checkpoint inhibitors (ICIs). We also discuss their potential as biomarkers and therapeutic targets, with current evidence suggesting that targeting MDSCs, either alone or in combination with existing treatments such as BCG and ICIs, may enhance anti-tumor immunity and improve clinical outcomes. However,, challenges remain, particularly regarding the identification and therapeutic modulation of MDSC subpopulations. Further research is warranted to fully elucidate their role in bladder cancer and to optimize MDSC-targeted therapies. FAU - Klein, Clement AU - Klein C AUID- ORCID: 0000-0003-1839-5875 AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Urology, University Hospital of Bordeaux, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Mebroukine, Samy AU - Mebroukine S AUID- ORCID: 0000-0002-1331-3212 AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Urology, University Hospital of Bordeaux, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Madery, Mathilde AU - Madery M AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Moisand, Alexandra AU - Moisand A AUID- ORCID: 0009-0002-6608-6866 AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Boyer, Thomas AU - Boyer T AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Larmonier, Nicolas AU - Larmonier N AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Robert, Gregoire AU - Robert G AUID- ORCID: 0000-0001-5249-8689 AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Urology, University Hospital of Bordeaux, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. FAU - Domblides, Charlotte AU - Domblides C AUID- ORCID: 0000-0002-9455-0657 AD - CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Leo Saignat, 33000 Bordeaux, France. AD - Department of Biological and Medical Sciences, University of Bordeaux, 33000 Bordeaux, France. AD - Department of Medical Oncology, University Hospital of Bordeaux, 33000 Bordeaux, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241027 PL - Switzerland TA - Cells JT - Cells JID - 101600052 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/pathology/drug therapy MH - *Myeloid-Derived Suppressor Cells/immunology/pathology MH - *Tumor Microenvironment/immunology MH - Animals MH - Immunotherapy/methods PMC - PMC11544784 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - immune inhibition OT - immunotherapy OT - myeloid-derived suppressor cells OT - tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2024/11/13 13:52 MHDA- 2024/11/14 03:55 PMCR- 2024/10/27 CRDT- 2024/11/08 09:43 PHST- 2024/10/03 00:00 [received] PHST- 2024/10/21 00:00 [revised] PHST- 2024/10/25 00:00 [accepted] PHST- 2024/11/14 03:55 [medline] PHST- 2024/11/13 13:52 [pubmed] PHST- 2024/11/08 09:43 [entrez] PHST- 2024/10/27 00:00 [pmc-release] AID - cells13211779 [pii] AID - cells-13-01779 [pii] AID - 10.3390/cells13211779 [doi] PST - epublish SO - Cells. 2024 Oct 27;13(21):1779. doi: 10.3390/cells13211779. PMID- 39509334 OWN - NLM STAT- MEDLINE DCOM- 20241220 LR - 20260627 IS - 2379-3708 (Electronic) IS - 2379-3708 (Linking) VI - 9 IP - 24 DP - 2024 Dec 20 TI - Targeting ketone body metabolism in mitigating gemcitabine resistance. LID - 10.1172/jci.insight.177840 [doi] LID - e177840 AB - Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance. Here, we report a gemcitabine resistance mechanism that promotes cancer reprogramming via the metabolic enzyme OXCT1. This mitochondrial enzyme, responsible for the rate-limiting step in beta-hydroxybutyrate (betaHB) catabolism, was elevated in muscle invasive disease and in patients with chemoresistant BCa. Resistant orthotopic tumors presented an OXCT1-dependent rise in mitochondrial oxygen consumption rate, ATP, and nucleotide biosynthesis. In resistant BCa, knocking out OXCT1 restored gemcitabine sensitivity, and administering the nonmetabolizable betaHB enantiomer (S-betaHB) only partially restored gemcitabine sensitivity. Suggesting an extrametabolic role for OXCT1, multi-omics analysis of gemcitabine sensitive and resistant cells revealed an OXCT1-dependent signature with the transcriptional repressor OVOL1 as a master regulator of epithelial differentiation. The elevation of OVOL1 target genes was associated with its cytoplasmic translocation and poor prognosis in a cohort of patients with BCa who have been treated with chemotherapy. The KO of OXCT1 restored OVOL1 transcriptional repressive activity by its nuclear translocation. Orthotopic mouse models of BCa supported OXCT1 as a mediator of gemcitabine sensitivity through ketone metabolism and regulating cancer stem cell differentiation. FAU - Rohena-Rivera, Krizia AU - Rohena-Rivera K AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. FAU - You, Sungyong AU - You S AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. AD - Department of Urology and. AD - Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Kim, Minhyung AU - Kim M AD - Department of Urology and. FAU - Billet, Sandrine AU - Billet S AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. FAU - Ten Hoeve, Johanna AU - Ten Hoeve J AD - UCLA Metabolomics Center, Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, California, USA. FAU - Gonzales, Gabrielle AU - Gonzales G AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. FAU - Huang, Chengqun AU - Huang C AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Heard, Ashley AU - Heard A AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. FAU - Chan, Keith Syson AU - Chan KS AD - Department of Urology and Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA. FAU - Bhowmick, Neil A AU - Bhowmick NA AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. AD - Samuel Oschin Cancer Center, Los Angeles, California, USA. AD - Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA. LA - eng SI - GEO/GSE280095 GR - I01 BX001040/BX/BLRD VA/United States GR - P01 CA233452/CA/NCI NIH HHS/United States GR - R01 CA255609/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20241220 PL - United States TA - JCI Insight JT - JCI insight JID - 101676073 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Ketone Bodies) RN - TZP1275679 (3-Hydroxybutyric Acid) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/pharmacology/therapeutic use MH - Humans MH - *Drug Resistance, Neoplasm/genetics MH - Animals MH - Mice MH - *Ketone Bodies/metabolism MH - *Urinary Bladder Neoplasms/drug therapy/metabolism/pathology/genetics MH - Cell Line, Tumor MH - 3-Hydroxybutyric Acid/metabolism/pharmacology MH - Female MH - Mitochondria/metabolism/drug effects MH - Antimetabolites, Antineoplastic/pharmacology/therapeutic use MH - Male PMC - PMC11665555 OTO - NOTNLM OT - Cancer OT - Drug therapy OT - Oncology OT - Urology COIS- Conflict of interest: The authors have declared that no conflict of interest exists. EDAT- 2024/11/13 14:00 MHDA- 2024/12/20 12:21 PMCR- 2024/12/20 CRDT- 2024/11/07 13:03 PHST- 2023/12/05 00:00 [received] PHST- 2024/10/30 00:00 [accepted] PHST- 2024/12/20 12:21 [medline] PHST- 2024/11/13 14:00 [pubmed] PHST- 2024/11/07 13:03 [entrez] PHST- 2024/12/20 00:00 [pmc-release] AID - 177840 [pii] AID - 10.1172/jci.insight.177840 [doi] PST - epublish SO - JCI Insight. 2024 Dec 20;9(24):e177840. doi: 10.1172/jci.insight.177840. PMID- 39507536 OWN - NLM STAT- MEDLINE DCOM- 20241107 LR - 20261020 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guerin immunotherapy: a systematic review and meta-analysis. PG - 1464635 LID - 10.3389/fimmu.2024.1464635 [doi] LID - 1464635 AB - BACKGROUND: The predictive accuracy of the preoperative neutrophil-to-lymphocyte ratio (NLR) on the prognosis of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmette-Guerin immunotherapy (BCG) after transurethral resection of the bladder tumor (TURBT) remains unknown. Therefore, the current study performed a systematic review and meta-analysis to examine the relationship between preoperative NLR and the prognosis of patients with NMIBC with intravesical BCG immunotherapy. METHODS: For this systematic review and meta-analysis, articles were retrieved from PubMed, Cochrane Library, Web of Science, and Embase databases from their inception to 14 May 2024. The role of NLR in predicting recurrence and progression in NMIBC was determined using pooled hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Seven articles were included in this meta-analysis, involving 4,187 patients. An elevated NLR was significantly associated with recurrence (HR = 2.67, 95% CI = 1.34-5.32, P < 0.001) and progression (HR = 1.72, 95% CI = 1.13-2.60, P = 0.004) in patients with NMIBC with intravesical BCG immunotherapy. CONCLUSION: This meta-analysis demonstrated that elevated preoperative NLR levels were significantly associated with recurrence and disease progression in patients with NMIBC who underwent intravesical BCG immunotherapy after TURBT. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2024-7-0058/, identifier 202470058. CI - Copyright (c) 2024 Huang, Lin, Mao, Hua and Guan. FAU - Huang, Jiaguo AU - Huang J AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China. FAU - Lin, Li AU - Lin L AD - Department of Science and Education, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China. FAU - Mao, Dikai AU - Mao D AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China. FAU - Hua, Runmiao AU - Hua R AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China. FAU - Guan, Feifei AU - Guan F AD - Physical Examination Center, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20241023 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - *Urinary Bladder Neoplasms/therapy/immunology/blood MH - Humans MH - *Neutrophils/immunology MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Administration, Intravesical MH - Prognosis MH - *Lymphocytes/immunology MH - Immunotherapy/methods MH - Neoplasm Recurrence, Local MH - Adjuvants, Immunologic/administration & dosage/therapeutic use MH - Disease Progression MH - Lymphocyte Count MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11538002 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - meta-analysis OT - neutrophil-tolymphocyte ratio OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - systematic review COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/11/12 04:45 MHDA- 2024/11/12 04:46 PMCR- 2024/01/01 CRDT- 2024/11/07 04:35 PHST- 2024/07/16 00:00 [received] PHST- 2024/10/03 00:00 [accepted] PHST- 2024/11/12 04:46 [medline] PHST- 2024/11/12 04:45 [pubmed] PHST- 2024/11/07 04:35 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1464635 [doi] PST - epublish SO - Front Immunol. 2024 Oct 23;15:1464635. doi: 10.3389/fimmu.2024.1464635. eCollection 2024. PMID- 39503747 OWN - NLM STAT- MEDLINE DCOM- 20241106 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Nov 6 TI - The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer. PG - 630 LID - 10.1007/s00345-024-05342-1 [doi] AB - PURPOSE: There is lack of evidence regarding the indication for re-transurethral resection of bladder tumor (reTURBT) for Ta high grade (HG) non-muscle invasive bladder cancer (NMIBC). This study aims to evaluate the oncological outcomes of patients with TaHG NMIBC to determine the benefit from performing reTURBT. METHODS: We relied on a multicenter cohort of 317 TaHG NMIBC from 12 centers who underwent TURBT and a subsequent complete Bacillus Calmette-Guerin induction from 2009 to 2021. Kaplan Meier analyses estimated recurrence free survival (RFS) and progression free survival (PFS) according to reTURBT. Sub-analyses evaluated PFS in patients with multiple risk factors indicating necessity for reTURBT according to international guidelines (multifocality, size > 3 cm, recurrent cancer, carcinoma in situ, lymph vascular invasion, histological variant, incomplete and absence of muscle layer at index TURBT). Multivariable cox-regression analysis predicted recurrence and progression. RESULTS: Of the 317 patients, 123 (39%) underwent reTURBT, while 194 (61%) did not. Residual disease was detected in 46% of cases, with a 3.2% upstaging rate. Median follow-up was 30 months. The 3-year RFS was higher in patients who underwent reTURBT (79% vs. 58%, p < 0.001), but no significant difference was observed in PFS. ReTURBT reduced the risk of recurrence [multivariable hazard ratio: 0.45, 95% Confidence interval (CI) 0.29-0.71]. Among patients who did not undergo reTURBT, those with >/= 2 risk factors had lower 3-year PFS (73% vs. 92%, p < 0.001) than those with 0-1 risk factor, whereas no difference in 3-year PFS was observed in patients who underwent reTURBT regardless of the number of risk factors (85% vs. 87%, p = 0.8). CONCLUSION: ReTURBT demonstrated efficacy in reducing recurrence among patients with TaHG NMIBC, yet its impact on progression remained uncertain. Our study underscores the importance of adhering to current international guidelines, particularly for patients with multiple risk factors indicating necessity for reTURBT. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. moschini.marco@hsr.it. FAU - de Angelis, Mario AU - de Angelis M AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Tremolada, Giovanni AU - Tremolada G AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Zaurito, Paolo AU - Zaurito P AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Viti, Alessandro AU - Viti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Santangelo, Alfonso AU - Santangelo A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Necchi, Andrea AU - Necchi A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Laukthina, Ekaterina AU - Laukthina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Sapienza University, Umberto I Polyclinic Hospital, Rome, Italy. FAU - Mertens, Laura AU - Mertens L AD - Department of Urology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Puigvert Foundation, Autonomous University of Barcelona, Barcelona, Spain. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Turin, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Carando, Roberto AU - Carando R AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - Sant'Anna Clinic, Swiss Medical Group, Sorengo, Switzerland. AD - Belegarzt fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. CN - European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20241106 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Cystectomy/methods MH - *Neoplasm Invasiveness MH - Retrospective Studies MH - Neoplasm Grading MH - Urethra MH - Neoplasm Recurrence, Local/epidemiology MH - Reoperation MH - Treatment Outcome MH - Transurethral Resection of Bladder OTO - NOTNLM OT - Non muscle invasive bladder cancer OT - Progression OT - Re-transurethral resection of bladder tumor OT - Recurrence OT - Ta high grade EDAT- 2024/11/06 12:27 MHDA- 2024/11/06 12:28 CRDT- 2024/11/06 11:03 PHST- 2024/06/04 00:00 [received] PHST- 2024/10/22 00:00 [accepted] PHST- 2024/11/06 12:28 [medline] PHST- 2024/11/06 12:27 [pubmed] PHST- 2024/11/06 11:03 [entrez] AID - 10.1007/s00345-024-05342-1 [pii] AID - 10.1007/s00345-024-05342-1 [doi] PST - epublish SO - World J Urol. 2024 Nov 6;42(1):630. doi: 10.1007/s00345-024-05342-1. PMID- 39499231 OWN - NLM STAT- MEDLINE DCOM- 20250214 LR - 20260729 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 156 IP - 8 DP - 2025 Apr 15 TI - Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer. PG - 1529-1540 LID - 10.1002/ijc.35250 [doi] AB - Studies on the relationship of cigarette smoking with the risks of recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are inconsistent and prospective data are scarce. Therefore, we aimed to assess the association of smoking behavior with risks of NMIBC recurrence and progression. We used data of the prospective multi-center cohort study UroLife, including 1495 patients with NMIBC who reported information on smoking at 6 weeks post-diagnosis (baseline; reflecting present and pre-diagnosis). This included smoking status (also based on reporting 3 months post-diagnosis), intensity, duration, pack years, and time since smoking cessation, if applicable. Hazard ratios and 95% confidence intervals (CIs) for risks of first recurrence, multiple recurrences, and progression were computed using multivariable proportional hazards regression models. During a total median follow-up period of 4.6 years, 517 patients developed >/=1 recurrence and 163 had progression. Higher versus lowest categories of smoking intensities and pack years up to baseline were significantly associated with a higher risk of first recurrence. No significant linear associations were found, except for smoking intensity among BCG-treated patients (per 10 cigarettes/day increase: HR 1.23, 95%CI 1.02, 1.48). No associations for smoking status, duration, and time since cessation were observed. Analyses of multiple recurrence risk showed comparable results. Regarding progression risk, no consistent associations were found. In conclusion, heavier smoking was associated with higher recurrence risk, particularly among BCG-treated patients. This may be attributable to persistent damage through its carcinogenic compounds. Given the mixed results across different exposures, the effect of smoking behavior on NMIBC prognosis remains unclear. CI - (c) 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Kiebach, Joann AU - Kiebach J AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Beeren, Ivy AU - Beeren I AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng GR - IIG_2022_017/Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme/ GR - 2017-2/11179/Dutch Cancer Society/ GR - KUN 2013-5926/Alpe d'HuZes/Dutch Cancer Society/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20241105 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/epidemiology/etiology MH - Female MH - Male MH - *Neoplasm Recurrence, Local/epidemiology/pathology/etiology MH - Disease Progression MH - Aged MH - Middle Aged MH - Prospective Studies MH - *Smoking/adverse effects MH - Risk Factors MH - BCG Vaccine/therapeutic use MH - Neoplasm Invasiveness MH - Follow-Up Studies MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11826114 OTO - NOTNLM OT - cancer survivors OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - smoking COIS- The authors report no conflict of interest. EDAT- 2024/11/05 19:20 MHDA- 2025/02/14 06:21 PMCR- 2025/02/14 CRDT- 2024/11/05 10:43 PHST- 2024/10/07 00:00 [revised] PHST- 2024/06/07 00:00 [received] PHST- 2024/10/14 00:00 [accepted] PHST- 2025/02/14 06:21 [medline] PHST- 2024/11/05 19:20 [pubmed] PHST- 2024/11/05 10:43 [entrez] PHST- 2025/02/14 00:00 [pmc-release] AID - IJC35250 [pii] AID - 10.1002/ijc.35250 [doi] PST - ppublish SO - Int J Cancer. 2025 Apr 15;156(8):1529-1540. doi: 10.1002/ijc.35250. Epub 2024 Nov 5. PMID- 39497708 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241106 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies. PG - 1424293 LID - 10.3389/fonc.2024.1424293 [doi] LID - 1424293 AB - Bladder cancer (BC) is the most common malignancy of the urinary tract. About 75% of all BC patients present with non-muscle-invasive BC (NMIBC), of which up to 70% will recur, and 15% will progress in stage and grade. As the recurrence and progression rates of NMIBC are strongly associated with some clinical and pathological factors, several risk stratification models have been developed to individually predict the short- and long-term risks of disease recurrence and progression. The NMIBC patients are stratified into four risk groups as low-, intermediate-, high-risk, and very high-risk by the European Association of Urology (EAU). Significant heterogeneity in terms of oncological outcomes and prognosis has been observed among NMIBC patients within the same EAU risk group, which has been partly attributed to the intrinsic heterogeneity of BC at the molecular level. Currently, we have a poor understanding of how to distinguish intermediate- and (very-)high-risk NMIBC with poor outcomes from those with a more benign disease course and lack predictive/prognostic tools that can specifically stratify them according to their pathologic and molecular properties. There is an unmet need for developing a more accurate scoring system that considers the treatment they receive after TURBT to enable their better stratification for further follow-up regimens and treatment selection, based also on a better response prediction to the treatment. Based on these facts, by employing a multi-layered -omics (namely, genomics, epigenetics, transcriptomics, proteomics, lipidomics, metabolomics) and immunohistopathology approach, we hypothesize to decipher molecular heterogeneity of intermediate- and (very-)high-risk NMIBC and to better stratify the patients with this disease. A combination of different -omics will provide a more detailed and multi-dimensional characterization of the tumor and represent the broad spectrum of NMIBC phenotypes, which will help to decipher the molecular heterogeneity of intermediate- and (very-)high-risk NMIBC. We think that this combinatorial multi-omics approach has the potential to improve the prediction of recurrence and progression with higher precision and to develop a molecular feature-based algorithm for stratifying the patients properly and guiding their therapeutic interventions in a personalized manner. CI - Copyright (c) 2024 Akand, Jatsenko, Muilwijk, Gevaert, Joniau and Van der Aa. FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Jatsenko, Tatjana AU - Jatsenko T AD - Laboratory for Cytogenetics and Genome Research, KU Leuven, Leuven, Belgium. AD - Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Gevaert, Thomas AU - Gevaert T AD - Department of Pathology, AZ Klina, Brasschaat, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. LA - eng PT - Journal Article DEP - 20241021 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11532112 OTO - NOTNLM OT - -omics OT - bladder cancer OT - epigenetics OT - genomics OT - non-muscle-invasive OT - progression OT - recurrence OT - transcriptomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/11/05 10:54 MHDA- 2024/11/05 10:55 PMCR- 2024/01/01 CRDT- 2024/11/05 04:24 PHST- 2024/04/27 00:00 [received] PHST- 2024/09/13 00:00 [accepted] PHST- 2024/11/05 10:55 [medline] PHST- 2024/11/05 10:54 [pubmed] PHST- 2024/11/05 04:24 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1424293 [doi] PST - epublish SO - Front Oncol. 2024 Oct 21;14:1424293. doi: 10.3389/fonc.2024.1424293. eCollection 2024. PMID- 39496057 OWN - NLM STAT- MEDLINE DCOM- 20241104 LR - 20250503 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 103 IP - 44 DP - 2024 Nov 1 TI - Comparison of prognosis after transurethral resection of bladder tumor between solitary and multiple bladder cancers. PG - e40314 LID - 10.1097/MD.0000000000040314 [doi] LID - e40314 AB - This study investigates the difference in overall survival rates after transurethral resection of bladder tumor between solitary and multiple bladder cancers, aiming to provide guidance for clinical practitioners. A retrospective analysis was conducted on 133 patients with bladder cancer who underwent transurethral resection of bladder tumor from April 2017 to October 2023, of which 112 patients had complete clinical and follow-up data. Clinical and follow-up data were collected, and the overall survival rates after surgery were compared between solitary and multiple bladder cancers. In this study, the recurrence rate after transurethral resection of bladder tumor was 23.21% (26/112), and the overall survival rate was 80.36% (90/112). The overall survival rate after transurethral resection of bladder tumor was 92.11% (35/38) in the solitary bladder cancer group and 74.32% (55/74) in the multiple bladder cancer group, with a statistically significant difference between the 2 groups (P = .025). The proportion of high-grade pathology was 7.89% (3/38) in the solitary bladder cancer group and 25.68% (19/74) in the multiple bladder cancer group after transurethral resection of bladder tumor, with a statistically significant difference between the 2 groups (P = .025). The mean tumor diameter after transurethral resection of bladder tumor was 2.76 +/- 1.66 cm in the solitary bladder cancer group and 4.04 +/- 3.17 cm in the multiple bladder cancer group, with a statistically significant difference between the 2 groups (P = .023). Univariate and multivariate regression analyses revealed that the number of bladder tumors is a risk factor for overall survival after bladder cancer surgery (P = .004). Multiple bladder cancers have a higher pathological grade, larger tumor diameter, and poorer prognosis after transurethral resection of bladder tumor compared to solitary bladder cancers. The number of bladder tumors is an independent risk factor for overall survival after bladder cancer surgery. CI - Copyright (c) 2024 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Diao, Mingxin AU - Diao M AD - Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China. FAU - Li, Yue AU - Li Y AD - Department of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Gao, Zihui AU - Gao Z AD - Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China. FAU - Wang, Chunji AU - Wang C AD - Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China. FAU - Gu, Yaming AU - Gu Y AUID- ORCID: 0009-0001-5900-4191 AD - Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - Prognosis MH - *Cystectomy/methods MH - Neoplasm Recurrence, Local/epidemiology MH - Survival Rate MH - Aged, 80 and over MH - Adult MH - Transurethral Resection of Bladder PMC - PMC11537651 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2024/11/04 22:24 MHDA- 2024/11/04 22:25 PMCR- 2024/11/01 CRDT- 2024/11/04 15:33 PHST- 2024/11/04 22:25 [medline] PHST- 2024/11/04 22:24 [pubmed] PHST- 2024/11/04 15:33 [entrez] PHST- 2024/11/01 00:00 [pmc-release] AID - 00005792-202411010-00090 [pii] AID - MD-D-24-03946 [pii] AID - 10.1097/MD.0000000000040314 [doi] PST - ppublish SO - Medicine (Baltimore). 2024 Nov 1;103(44):e40314. doi: 10.1097/MD.0000000000040314. PMID- 39495364 OWN - NLM STAT- MEDLINE DCOM- 20241221 LR - 20241221 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 32 IP - 1 DP - 2025 Jan TI - Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients. PG - 609-618 LID - 10.1245/s10434-024-16424-0 [doi] AB - BACKGROUND: Bladder cancer (BCa) diagnosis relies on distinguishing muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC) forms. Transurethral resection of the bladder tumor (TURBT) is a standard procedure for initial staging and treatment. The Vesical Imaging-Reporting and Data System (VI-RADS) enhances diagnostic accuracy for muscle invasiveness through advanced imaging techniques, potentially reducing reliance on repeat TURBT and improving patient management. OBJECTIVE: We aimed to evaluate the role of VI-RADS in predicting muscle invasiveness in BCa and its potential to predict adverse pathology in high-risk NMIBC to avoid unnecessary repeat TURBT procedures. METHODS: In this prospective study, we included 62 patients over the age of 18 years who underwent TURBT. In a secondary phase, patients selected for restaging TURBT (re-TURBT) were included, but those with T2 tumors or low-risk NMIBC were excluded. Multiparametric magnetic resonance imaging (MRI) examinations were scored by a radiologist using the VI-RADS 5 method, while a pathologist analyzed TURBT and re-TURBT samples for accurate staging. Statistical analysis evaluated the role of VI-RADS in BCa staging. RESULTS: The VI-RADS score was the only predictive factor for muscle invasion in multivariate analysis. Setting the VI-RADS score at >3 resulted in the highest sensitivity, specificity, and diagnostic accuracy, with values of 67.0%, 89.0%, and 78%, respectively. The receiver operating characteristic area under the curve score for VI-RADS for muscle invasion was 85% for stage Ta, 61% for stage T1, and 88% for stage T2, which shows the utility of VI-RADS in the predictiveness of MIBC/NMIBC. CONCLUSION: VI-RADS is effective in stratifying BCa patients by predicting muscle invasiveness and identifying NMIBC cases that may not need repeat TURBT. CI - (c) 2024. Society of Surgical Oncology. FAU - Kural, Sukhad AU - Kural S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Pathak, Abhay Kumar AU - Pathak AK AD - DST-CIMS, Institute of Science, Banaras Hindu University, Varanasi, India. FAU - Singh, Shweta AU - Singh S AD - Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi, India. FAU - Jain, Garima AU - Jain G AD - Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi, India. FAU - Yadav, Mahima AU - Yadav M AD - Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Agarwal, Sakshi AU - Agarwal S AD - Department of Obstetrics and Gynaecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Ishan AU - Kumar I AD - Department of Radio-Diagnosis and Imaging, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Gupta, Manjari AU - Gupta M AD - DST-CIMS, Institute of Science, Banaras Hindu University, Varanasi, India. FAU - Singh, Yashasvi AU - Singh Y AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Kumar, Ujwal AU - Kumar U AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Trivedi, Sameer AU - Trivedi S AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Sankhwar, S N AU - Sankhwar SN AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. FAU - Das, Parimal AU - Das P AD - Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi, India. FAU - Kumar, Lalit AU - Kumar L AD - Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. lalitkumarims@bhu.ac.in. LA - eng GR - IoE Sch-6031-B-21966/Banaras Hindu University/ PT - Journal Article DEP - 20241104 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/diagnostic imaging MH - Prospective Studies MH - Female MH - Male MH - *Neoplasm Invasiveness MH - Aged MH - Middle Aged MH - *Neoplasm Staging MH - Cystectomy/methods MH - Follow-Up Studies MH - Multiparametric Magnetic Resonance Imaging/methods MH - Prognosis MH - Aged, 80 and over MH - ROC Curve MH - Adult MH - Magnetic Resonance Imaging/methods MH - Reoperation OTO - NOTNLM OT - Bladder cancer OT - Multiparametric magnetic resonance imaging OT - NMIBC OT - TURBT OT - VI-RADS COIS- Disclosure: The authors have no conflicts of interest to declare. Informed consent: All participants in this study provided informed consent prior to their involvement in the research. EDAT- 2024/11/04 12:23 MHDA- 2024/12/21 16:44 CRDT- 2024/11/04 11:16 PHST- 2024/08/19 00:00 [received] PHST- 2024/10/12 00:00 [accepted] PHST- 2024/12/21 16:44 [medline] PHST- 2024/11/04 12:23 [pubmed] PHST- 2024/11/04 11:16 [entrez] AID - 10.1245/s10434-024-16424-0 [pii] AID - 10.1245/s10434-024-16424-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2025 Jan;32(1):609-618. doi: 10.1245/s10434-024-16424-0. Epub 2024 Nov 4. PMID- 39493819 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241105 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 10 IP - 3 DP - 2024 TI - A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer. PG - 233-242 LID - 10.3233/BLC-240017 [doi] AB - BACKGROUND: High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for surveillance of HR-NMIBC patients with high sensitivity and anticipatory value. OBJECTIVE: We aimed to validate the performance of the assay in an unselected prospectively collected cohort of HR-NMIBC patients under surveillance. METHODS: We included patients from five centers and collected urine sample pairs (evening and morning urines) prior to cystoscopy. Mutation status (FGFR3/TERT) and methylation status (OTX1) was analyzed on DNA from voided urine specimens. A test was considered positive if>/=1 alteration was detected in at least one urine sample. The primary endpoint was tumor recurrence. Sensitivity and specificity were determined. A generalized mixed effects model was used to adjust for within-patient correlation. Cox proportional hazard analyses with time-dependent covariates assessed the anticipatory effect of the urine assay. RESULTS: In total, 204 patients and 736 sample pairs were collected. Sixty-three recurrences were diagnosed for which we had concomitant assay results. On cross-sectional analyses, the assay detected 75% (95% CI 62.1% -84.7%) of recurrences, with a specificity of 70% (95% CI 66.4% -73.5%). Furthermore, mixed effects model analyses revealed OTX1 (p = 0.005) and TERT (p = 0.004) as significant predictors for disease recurrence. Median follow-up was 25.3 months (IQR 18.6-30.7). Twenty-nine tumors were diagnosed without concomitant urine samples, which included recurrences detected after urine collection ended. Longitudinal analyses showed that a positive urine assay predicted a recurrence over time (HR 3.5, p < 0.001). Furthermore, a recurrence during the study period was also a predictor for developing future recurrences (HR 2.1, p < 0.001). CONCLUSIONS: This study validates the performance of a previously developed urine assay in an unselected cohort of HR-NMIBC patients under surveillance. With a robust sensitivity/specificity and a strong anticipatory effect, this assay proves a useful adjunct ready for evaluation in a future randomized controlled trial. CI - (c) 2024 - The authors. Published by IOS Press. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - de Jong, Florus C AU - de Jong FC AD - Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands. FAU - van der Made, Angelique C J AU - van der Made ACJ AD - Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - van Casteren, Niels J AU - van Casteren NJ AD - Department of Urology, Franciscus Hospital, Rotterdam, The Netherlands. FAU - Roshani, Hossain AU - Roshani H AD - Department of Urology, Haga Teaching Hospital, The Hague, The Netherlands. FAU - Oomens, Eric H G M AU - Oomens EHGM AD - Department of Urology, Amphia Hospital, Breda, The Netherlands. FAU - Pelger, Rob C M AU - Pelger RCM AD - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Steyerberg, Ewout W AU - Steyerberg EW AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands. FAU - Bangma, Chris H AU - Bangma CH AD - Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20241023 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11530022 OTO - NOTNLM OT - Keywords (MeSH): Bladder cancer OT - methylation OT - mutation OT - prospective OT - urinary biomarkers COIS- TZ and EZ are Editorial Board members of this journal, but were not involved in the peer-review process nor had access to any information regarding its peer-review. TZ declares Grant/Research support from: Genecentric/Janssen, InnoSign and Merk AG (all paid to Erasmus MC). EZ declares a License agreement with MDxHealth / Vesica and a patent for OTX1 and ONECUT2 methylation issued in EU and Canada, and a pending patent in the USA. JB declares consultantcy / speaker's fee (all paid to Erasmus MC) from: Janssen, BMS, AstraZeneca, Merck AG/Pfizer, MSD, Bayer, Ismar Healtcare. Research collaborations with: Merck AG, MSD, Janssen, VitroScan and Merk Serono. Member of the Scientific Congress Committee European Association of Urology. JJ, FJ, AM, NC, HR, EO, RP, EW and CB declare no conflicts of interest related to this topic nor to the contents of this manuscript. EDAT- 2024/11/04 06:23 MHDA- 2024/11/04 06:24 PMCR- 2024/10/23 CRDT- 2024/11/04 05:10 PHST- 2024/03/11 00:00 [received] PHST- 2024/08/20 00:00 [accepted] PHST- 2024/11/04 06:24 [medline] PHST- 2024/11/04 06:23 [pubmed] PHST- 2024/11/04 05:10 [entrez] PHST- 2024/10/23 00:00 [pmc-release] AID - BLC240017 [pii] AID - 10.3233/BLC-240017 [doi] PST - epublish SO - Bladder Cancer. 2024 Oct 23;10(3):233-242. doi: 10.3233/BLC-240017. eCollection 2024. PMID- 39488989 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20241128 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 264 DP - 2024 Dec TI - BCL-2 and gamma-H2AX immunostaining profile in urothelial bladder cancer prognosis. PG - 155680 LID - S0344-0338(24)00591-0 [pii] LID - 10.1016/j.prp.2024.155680 [doi] AB - Urothelial bladder carcinoma (UBC) is a malignant neoplasm of the urinary tract that is highly prevalent worldwide and has a high rate of tumor recurrence. It is known that the BCL2 apoptosis regulator (BCL-2) gene encodes a mitochondrial protein that regulates programmed death cells by apoptosis. In contrast, the H2A.X histone variant (H2AX) gene encodes a histone responsible for regulating and signaling genomic instability processes. The present study aimed to analyze the immunostaining profiles of BCL-2 and gamma-H2AX proteins in tissue samples (n=80) from UBC patients (muscle-invasive MI; and non-muscle invasive NMI) using indirect immunohistochemistry and to correlate the results with prognostic and clinical parameters. BCL-2 protein expression was cytoplasmic and absent in half of the samples, including the MI and NMI groups. Strong nuclear expression was observed for gamma-H2AX, predominant in the MI samples. The immunostaining profile of both proteins was not associated with tumor recurrence or invasion, and no significant associations were found in relation to prognosis (tumor grade, pathological staging). No significant correlation was found between protein profiles in malignant tissue. All in all, BCL-2 and gamma-H2AX did not prove to be candidate markers for UBC clinical management in the present sample, despite their expression in malignant bladder tissue. CI - Copyright (c) 2024 Elsevier GmbH. All rights reserved. FAU - Kawasaki, Julia Ayumi Ikeda AU - Kawasaki JAI AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. FAU - Pinheiro, Lais Capelasso Lucas AU - Pinheiro LCL AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. FAU - da Silva, Isabely Mayara AU - da Silva IM AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. FAU - Miqueloto, Carlos Alberto AU - Miqueloto CA AD - Laboratory of Extracellular Matrix, Department of General Biology, Londrina State University, Londrina, PR, Brazil. FAU - de Oliveira, Karen Brajao AU - de Oliveira KB AD - Laboratory of Molecular Genetic and Immunology, Department of Pathologic Science, Londrina State University, Londrina, PR, Brazil. FAU - Ribeiro, Diego Luis AU - Ribeiro DL AD - Laboratory of DNA Repair, Department of Microbiology, Institute of Biomedical Sciences, Sao Paulo University, Sao Paulo, SP, Brazil. FAU - Guembarovski, Alda Fiorina Maria Losi AU - Guembarovski AFML AD - Micropar - Laboratory of Pathological Anatomy and Cytology, Londrina, PR, Brazil. FAU - Terziotti, Fernando AU - Terziotti F AD - Cancer Hospital of Londrina - HCL, Londrina, PR, Brazil. FAU - Martinez-Lopez, Wilner AU - Martinez-Lopez W AD - Genetics Department and Biodosimetry Service, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay. FAU - Serpeloni, Juliana Mara AU - Serpeloni JM AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. FAU - Guembarovski, Roberta Losi AU - Guembarovski RL AD - Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. Electronic address: robertalosi@uel.br. LA - eng PT - Journal Article DEP - 20241026 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Histones) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Biomarkers, Tumor) RN - 0 (H2AX protein, human) RN - 0 (BCL2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism MH - *Histones/metabolism MH - *Proto-Oncogene Proteins c-bcl-2/metabolism/analysis MH - Male MH - Female MH - Prognosis MH - Middle Aged MH - *Biomarkers, Tumor/analysis/metabolism MH - Aged MH - *Immunohistochemistry MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/metabolism MH - Adult OTO - NOTNLM OT - apoptosis OT - genomic instability OT - muscle invasion OT - protein expression OT - tumor recurrence COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/04 00:31 MHDA- 2024/11/29 05:20 CRDT- 2024/11/03 18:05 PHST- 2024/07/31 00:00 [received] PHST- 2024/10/22 00:00 [revised] PHST- 2024/10/25 00:00 [accepted] PHST- 2024/11/29 05:20 [medline] PHST- 2024/11/04 00:31 [pubmed] PHST- 2024/11/03 18:05 [entrez] AID - S0344-0338(24)00591-0 [pii] AID - 10.1016/j.prp.2024.155680 [doi] PST - ppublish SO - Pathol Res Pract. 2024 Dec;264:155680. doi: 10.1016/j.prp.2024.155680. Epub 2024 Oct 26. PMID- 39483518 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241102 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 70 DP - 2024 Dec TI - Prototol for the Prospective Sample Collection for Cancer of Bladder (ProCaB) Trial by the Cancer of the Bladder Leuven (CaBLe) Consortium. PG - 21-27 LID - 10.1016/j.euros.2024.09.006 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease categorized as low, intermediate, high, or very high risk, for which recurrence and progression rates and thus management strategies differ. Current molecular subclassification of bladder cancer (BC) is mainly based on data for muscle-invasive disease, with very few data for NMIBC. A more accurate classification system is needed for better stratification of NMIBC using multiomics and immunohistopathological molecular data alongside clinical data collected in a prospective cohort. ProCaB (Prospective Sample Collection for Cancer of Bladder) is a single-center non-interventional, prospective study recruiting all eligible patients diagnosed with BC in a tertiary center in the Flanders region of Belgium. Clinical data have been collected in a prospective registry since August 2013. Biosamples (blood, urine, and BC tissue) are collected from each patient at diagnosis and are stored at -80 degrees C at BioBank UZ Leuven after appropriate processing according to the protocol. Multiomics (genomics, epigenetics, transcriptomics, proteomics, lipidomics, metabolomics) and immunohistopathology analyses will be performed on appropriate samples. The target is to enroll 300 patients over a 5-yr period, and all patients will be followed for 5 yr. The objective is to create a biobank of samples from patients diagnosed with BC for use in multiomics and immunohistopathological analyses. Results from these analyses, together with long-term clinical data, can be used for comprehensive multilayered molecular characterization of disease recurrence and progression in intermediate- and (very) high-risk NMIBC, identification of multibiomarker panels for better stratification, and identification of a patient subgroup that does not respond to bacillus Calmette-Guerin treatment. This trial is registered on ClinicalTrials.gov as NCT04167332. CI - (c) 2024 The Author(s). FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Van Cleynenbreugel, Ben AU - Van Cleynenbreugel B AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Gevaert, Thomas AU - Gevaert T AD - Department of Pathology, AZ Klina, Brasschaat, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Laboratory of Experimental Urology, Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. LA - eng SI - ClinicalTrials.gov/NCT04167332 PT - Journal Article DEP - 20241015 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC11525467 OTO - NOTNLM OT - Biobank OT - Biomarker OT - Bladder cancer OT - Collection OT - Non-muscle-invasive OT - Omics OT - Progression OT - Prospective registry OT - Protocol OT - Recurrence EDAT- 2024/11/04 07:23 MHDA- 2024/11/04 07:24 PMCR- 2024/10/15 CRDT- 2024/11/01 05:00 PHST- 2024/09/06 00:00 [accepted] PHST- 2024/11/04 07:24 [medline] PHST- 2024/11/04 07:23 [pubmed] PHST- 2024/11/01 05:00 [entrez] PHST- 2024/10/15 00:00 [pmc-release] AID - S2666-1683(24)00921-2 [pii] AID - 10.1016/j.euros.2024.09.006 [doi] PST - epublish SO - Eur Urol Open Sci. 2024 Oct 15;70:21-27. doi: 10.1016/j.euros.2024.09.006. eCollection 2024 Dec. PMID- 39488630 OWN - NLM STAT- MEDLINE DCOM- 20241103 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Nov 2 TI - Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer. PG - 619 LID - 10.1007/s00345-024-05329-y [doi] AB - PURPOSE: To compare the oncological outcomes between standard radical cystectomy (SRC) and organ-sparing cystectomy (OSC) in male patients diagnosed with bladder cancer. METHODS: Patients with stage Ta-T3 bladder cancer who underwent OSC or SRC were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The association between preoperative factors and the implementation of OSC was analyzed using logistic regression. Propensity score matching (PSM) was employed to balance baseline characteristics between the two groups. Patients' overall survival (OS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Subgroup analyses based on the T stage were also conducted. RESULTS: A total of 7264 patients were included, with 96.8% (7033 patients) receiving SRC and 3.2% (231 patients) receiving OSC. Patients with higher T stages and high-grade tumors were less likely to undergo OSC. After PSM, OSC was associated with significantly worse OS and CSS than SRC. Subgroup analysis revealed that OSC did not lead to worse OS and CSS in non-muscle invasive bladder cancer and T2 stage patients, but it resulted in significantly worse outcomes in T3 stage patients. CONCLUSION: Our study indicates that OSC is associated with poorer oncological outcomes compared to SRC, particularly in patients with advanced-stage tumors. These findings suggest the need for stringent selection criteria for OSC in bladder cancer patients. Given the negative impact on prognosis, stage T3 should potentially be considered a contraindication for OSC. Further evidence is required to confirm these assertions. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Han, Zeyu AU - Han Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 88 South Keyuan Road, Chengdu, 610041, China. FAU - Tang, Yaxiong AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 88 South Keyuan Road, Chengdu, 610041, China. FAU - Yi, Xianyanling AU - Yi X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 88 South Keyuan Road, Chengdu, 610041, China. FAU - Li, Jin AU - Li J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 88 South Keyuan Road, Chengdu, 610041, China. FAU - Ai, Jianzhong AU - Ai J AUID- ORCID: 0000-0003-0617-9286 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 88 South Keyuan Road, Chengdu, 610041, China. jianzhong.ai@scu.edu.cn. LA - eng GR - 2023YFC3403200/National Key R&D Program of China/ GR - 82070784/National Natural Science Foundation of China/ GR - 81702536/National Natural Science Foundation of China/ GR - 2022JDRC0040/Science and Technology Department of Sichuan Province/ PT - Comparative Study PT - Journal Article DEP - 20241102 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Male MH - *Cystectomy/methods MH - *Organ Sparing Treatments MH - Aged MH - Middle Aged MH - Treatment Outcome MH - *Neoplasm Staging MH - Retrospective Studies MH - Survival Rate MH - Propensity Score MH - SEER Program OTO - NOTNLM OT - Bladder cancer OT - Oncological outcomes OT - Organ-sparing cystectomy OT - Radical cystectomy OT - SEER database EDAT- 2024/11/03 06:21 MHDA- 2024/11/03 06:22 CRDT- 2024/11/03 00:25 PHST- 2024/05/26 00:00 [received] PHST- 2024/10/14 00:00 [accepted] PHST- 2024/11/03 06:22 [medline] PHST- 2024/11/03 06:21 [pubmed] PHST- 2024/11/03 00:25 [entrez] AID - 10.1007/s00345-024-05329-y [pii] AID - 10.1007/s00345-024-05329-y [doi] PST - epublish SO - World J Urol. 2024 Nov 2;42(1):619. doi: 10.1007/s00345-024-05329-y. PMID- 39485082 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20260924 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 135 IP - 4 DP - 2025 Apr TI - A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. PG - 648-656 LID - 10.1111/bju.16572 [doi] AB - OBJECTIVE: To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non-coding RNA (lncRNA)-based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer. PATIENTS AND METHODS: Transcriptome-wide expression profiling using Decipher Bladder was performed on transurethral resection of bladder tumour samples from a cohort of patients with high-grade, clinically organ-confined (cTa-T2N0M0) urothelial carcinoma (UC) who subsequently underwent RC without any neoadjuvant therapy (n = 226). The lncRNA-based luminal favourable status was determined using a previously developed GC. The primary endpoint was overall survival (OS) after RC. Secondary endpoints included cancer-specific mortality and upstaging at RC. RESULTS: In the study, 134 patients were clinical non-muscle-invasive bladder cancer (cTa/Tis/T1) and 92 patients were cT2. We identified 60 patients with luminal favourable subtype, all of which showed robust gene expression patterns associated with less aggressive bladder cancer biology. On multivariate analysis, patients with the luminal favourable subtype (vs without) were significantly associated with lower odds of upstaging to pathological (p)T3+ disease (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.12-0.82; P = 0.02), any upstaging (OR 0.41, 95% CI 0.20-0.83; P = 0.01), and any upstaging and/or pN+ (OR 0.50, 95% CI 0.25-1.00; P = 0.05). Luminal favourable bladder cancer was significantly associated with better OS (hazard ratio 0.33, 95% CI 0.15-0.74; P = 0.007). CONCLUSIONS: This study validates the performance of the GC for identifying UCs with a luminal favourable subtype, harbouring less aggressive tumour biology. CI - (c) 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Proudfoot, James A AU - Proudfoot JA AD - Veracyte Inc., San Francisco, CA, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. FAU - Svatek, Robert S AU - Svatek RS AD - University of Texas Health San Antonio, San Antonio, TX, USA. FAU - Narayan, Vikram AU - Narayan V AD - Emory University School of Medicine, Atlanta, GA, USA. FAU - Gibb, Ewan A AU - Gibb EA AD - Veracyte Inc., San Francisco, CA, USA. FAU - Davicioni, Elai AU - Davicioni E AD - Veracyte Inc., San Francisco, CA, USA. FAU - Joshi, Shreyas AU - Joshi S AD - Emory University School of Medicine, Atlanta, GA, USA. FAU - Dahmen, Aaron AU - Dahmen A AD - Moffitt Cancer Center, Tampa, FL, USA. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Moffitt Cancer Center, Tampa, FL, USA. FAU - Inman, Brant A AU - Inman BA AUID- ORCID: 0000-0002-6060-4485 AD - Western University, London, Ontario, Canada. FAU - Shah, Paras AU - Shah P AD - Mayo Clinic, Rochester, MN, USA. FAU - Chaplin, Iftach AU - Chaplin I AD - University of Texas Southwestern, Dallas, TX, USA. FAU - Wright, Jonathan AU - Wright J AD - University of Washington, Seattle, WA, USA. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - University of Texas Southwestern, Dallas, TX, USA. LA - eng GR - Wilson Foundation/ PT - Journal Article DEP - 20241101 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (RNA, Long Noncoding) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/genetics/mortality/pathology MH - *Cystectomy/methods MH - Male MH - Female MH - Aged MH - Middle Aged MH - *RNA, Long Noncoding/genetics MH - Gene Expression Profiling MH - Prognosis MH - *Carcinoma, Transitional Cell/genetics/surgery/pathology/mortality MH - Treatment Outcome MH - Aged, 80 and over PMC - PMC11913596 OTO - NOTNLM OT - bladder cancer OT - gene expression profiling OT - luminal favourable OT - molecular subtyping OT - radical cystectomy EDAT- 2024/11/01 12:25 MHDA- 2025/03/18 00:26 PMCR- 2025/03/18 CRDT- 2024/11/01 09:33 PHST- 2025/03/18 00:26 [medline] PHST- 2024/11/01 12:25 [pubmed] PHST- 2024/11/01 09:33 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - BJU16572 [pii] AID - 10.1111/bju.16572 [doi] PST - ppublish SO - BJU Int. 2025 Apr;135(4):648-656. doi: 10.1111/bju.16572. Epub 2024 Nov 1. PMID- 39483069 OWN - NLM STAT- MEDLINE DCOM- 20241204 LR - 20260710 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 35 IP - 1 DP - 2025 Jan 1 TI - Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance. PG - 68-74 LID - 10.1097/MOU.0000000000001240 [doi] AB - PURPOSE OF REVIEW: In recent years, intraluminal therapies have become a valid alternative for low grade upper tract urothelial carcinoma (UTUC) patients, as overall survival and cancer-specific survival rates were shown to be comparable to those achieved with radical nephroureterectomy for selected cases. Nonetheless, endoscopic treatment has its limitations. As technology progresses and the demand for endoscopic treatments increases, intraluminal chemotherapy and immunotherapy instillations within the upper tract have increasingly become the subject areas of research. RECENT FINDINGS: The main intraluminal therapies and relevant instillation approaches are reviewed in this study, including recent publications and their main outcomes. The recurrence rates demonstrated in the literature strengthen the notion that patients with UTUC following current intraluminal treatments have a better prognosis than in the past. Updated relevant guidelines regarding surveillance among this population are also reviewed and summarized. SUMMARY: The treatment of upper tract urothelial carcinoma is clinically challenging. Developments in recent years show promising results in this field and ongoing research with new developments is emerging. Further studies are required to better understand the contribution of intraluminal therapies to the management of this disease. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lasmanovich, Rinat AU - Lasmanovich R AD - Department of Urology, Sheba Medical Center, Ramat Gan. AD - School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Shvero, Asaf AU - Shvero A AD - Department of Urology, Sheba Medical Center, Ramat Gan. AD - School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Kleinmann, Nir AU - Kleinmann N AD - Department of Urology, Sheba Medical Center, Ramat Gan. AD - School of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article PT - Review DEP - 20241029 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/therapy/pathology/diagnosis MH - Chemotherapy, Adjuvant/methods MH - Ureteral Neoplasms/therapy/pathology/diagnosis MH - Conservative Treatment/methods MH - Neoplasm Recurrence, Local/prevention & control/epidemiology MH - Kidney Neoplasms/therapy/pathology MH - Ureteroscopy/methods MH - Immunotherapy/methods MH - Treatment Outcome MH - Watchful Waiting MH - Administration, Intravesical EDAT- 2024/11/01 06:22 MHDA- 2024/12/04 06:22 CRDT- 2024/11/01 04:43 PHST- 2024/12/04 06:22 [medline] PHST- 2024/11/01 06:22 [pubmed] PHST- 2024/11/01 04:43 [entrez] AID - 00042307-990000000-00204 [pii] AID - 10.1097/MOU.0000000000001240 [doi] PST - ppublish SO - Curr Opin Urol. 2025 Jan 1;35(1):68-74. doi: 10.1097/MOU.0000000000001240. Epub 2024 Oct 29. PMID- 39474781 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20250131 IS - 1440-1711 (Electronic) IS - 0818-9641 (Linking) VI - 102 IP - 10 DP - 2024 Nov TI - Altered immunophenotypic expression in the peripheral bladder cancer immune landscape. PG - 949-962 LID - 10.1111/imcb.12829 [doi] AB - Treatments targeting the immune system only benefit a subset of patients with bladder cancer (BC). Biomarkers predictive of BC progression and response to specific therapeutic interventions are required. We evaluated whether peripheral blood immune subsets and expression of clinically relevant immune checkpoint markers are associated with clinicopathologic features of BC. Peripheral blood mononuclear cells isolated from blood collected from 23 patients with BC and 9 age-matched unaffected-by-cancer control donors were assessed using a 21-parameter flow cytometry panel composed of markers of T, B, natural killer and myeloid populations and immune checkpoint markers. Patients with BC had significantly lower numbers of circulating CD19(+) B cells and elevated circulating CD4(+)CD8(+) T cells compared with the control cohort. Immune checkpoint markers programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) were elevated in the total peripheral immune cell population in patients with BC. Within the BC cohort, PD-1 expression in T and myeloid cells was elevated in muscle-invasive compared with non-muscle-invasive disease. In addition, elevated T, B and myeloid PD-1 cell surface expression was significantly associated with tumor stage, suggesting that measures of peripheral immune cell exhaustion may be a predictor of tumor progression in BC. Finally, positive correlations between expression levels of the various immune checkpoints both overall and within key peripheral blood immune subsets collected from patients with BC were observed, highlighting likely coregulation of peripheral immune checkpoint expression. The peripheral blood immunophenotype in patients with BC is altered compared with cancer-free individuals. Understanding this dysregulated immune profile will contribute to the identification of diagnostic and prognostic indicators to guide effective immune-targeted, personalized treatments. CI - (c) 2024 the Australian and New Zealand Society for Immunology, Inc. FAU - Mackenzie, Nathan J AU - Mackenzie NJ AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. FAU - Zimmermann, Kate AU - Zimmermann K AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Centre for Immunology and Infection Control, Queensland University of Technology (QUT), Brisbane, QLD, Australia. AD - Centre for Microbiome Research, Queensland University of Technology (QUT), Brisbane, QLD, Australia. FAU - Nicholls, Clarissa AU - Nicholls C AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. FAU - Perera, Mahasha Pj AU - Perera MP AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. AD - Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Ngoo, Alexander AU - Ngoo A AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. AD - Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia. AD - Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia. FAU - Jeffery, Penny L AU - Jeffery PL AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. FAU - Vela, Ian AU - Vela I AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. AD - Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Kenna, Tony J AU - Kenna TJ AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Centre for Immunology and Infection Control, Queensland University of Technology (QUT), Brisbane, QLD, Australia. AD - Centre for Microbiome Research, Queensland University of Technology (QUT), Brisbane, QLD, Australia. FAU - Williams, Elizabeth D AU - Williams ED AUID- ORCID: 0000-0002-3364-6655 AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. AD - Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), Brisbane, QLD, Australia. FAU - Thomas, Patrick B AU - Thomas PB AUID- ORCID: 0000-0002-3649-7923 AD - Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. AD - Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia. AD - Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia. AD - Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia. LA - eng GR - PA Research Foundation/ GR - Australian Government/ GR - Queensland University of Technology/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241030 PL - United States TA - Immunol Cell Biol JT - Immunology and cell biology JID - 8706300 RN - 0 (Biomarkers, Tumor) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/immunology/pathology MH - Male MH - Female MH - *Immunophenotyping MH - Aged MH - Middle Aged MH - Biomarkers, Tumor/metabolism/blood MH - Programmed Cell Death 1 Receptor/metabolism MH - Aged, 80 and over MH - Leukocytes, Mononuclear/immunology/metabolism MH - Tumor Microenvironment/immunology OTO - NOTNLM OT - Bladder cancer OT - flow cytometry OT - immunology OT - peripheral blood OT - precision medicine EDAT- 2024/10/30 06:21 MHDA- 2024/11/13 13:59 CRDT- 2024/10/30 05:53 PHST- 2024/09/24 00:00 [revised] PHST- 2024/05/31 00:00 [received] PHST- 2024/10/01 00:00 [accepted] PHST- 2024/11/13 13:59 [medline] PHST- 2024/10/30 06:21 [pubmed] PHST- 2024/10/30 05:53 [entrez] AID - 10.1111/imcb.12829 [doi] PST - ppublish SO - Immunol Cell Biol. 2024 Nov;102(10):949-962. doi: 10.1111/imcb.12829. Epub 2024 Oct 30. PMID- 39471563 OWN - NLM STAT- MEDLINE DCOM- 20241201 LR - 20260919 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 9 IP - 11 DP - 2024 Nov TI - Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. PG - 103964 LID - S2059-7029(24)01734-4 [pii] LID - 10.1016/j.esmoop.2024.103964 [doi] LID - 103964 AB - BACKGROUND: The purpose of this study was to analyze survival outcomes and pathologic response of patients with cT1N0 small-cell neuroendocrine carcinoma (SCNEC) of the bladder treated with neoadjuvant chemotherapy (neoCTX). MATERIALS AND METHODS: All cases of bladder SCNEC treated at our institution from January 1996 to July 2023 were identified. cT1N0 was defined as transurethral resection pathology showing lamina propria invasion with present and uninvolved muscularis propria. Pathologic downstaging and recurrences were evaluated. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Cox regression and Kaplan-Meier method. RESULTS: A total of 30 patients with cT1N0 bladder SCNEC were included. Median follow-up was 88 months [95% confidence interval (CI) 44-131 months]. NeoCTX was given to 21 (70%) patients with a median of 4 cycles (range 1-6 cycles). A total of 27 (90%) patients received definitive local therapy. In cT1 bladder SCNEC, neoCTX was associated with decreased odds of pathologic upstaging [odds ratio = 0.07 (95% CI 0.01-0.45), P = 0.004], decreased odds of relapse [odds ratio = 0.12 (95% CI 0.02-0.65), P = 0.01], improved DFS [hazard ratio (HR) 0.30, 95% CI 0.09-0.96, P = 0.04], and improved OS (HR 0.32, 95% CI 0.10-1.02, P = 0.05). Compared with cT2N0 treated with neoCTX, cT1N0 treated with neoCTX had improved median DFS (HR 0.44, 95% CI 0.19-1.03, P = 0.05) and improved median OS (HR 0.52, 95% CI 0.22-1.24, P = 0.14). CONCLUSIONS: NeoCTX had suggestive benefit in patients with cT1 bladder SCNEC with decreased odds of pathologic upstaging, metastatic relapse, and improved survival. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Myers, A A AU - Myers AA AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Fang, A M AU - Fang AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Moussa, M J AU - Moussa MJ AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Hwang, H AU - Hwang H AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Wilson, N R AU - Wilson NR AD - Department of Oncology, University of Michigan, Ann Arbor, USA. FAU - Campbell, M T AU - Campbell MT AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Msaouel, P AU - Msaouel P AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Lee, B H AU - Lee BH AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Guo, C C AU - Guo CC AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Zhang, M AU - Zhang M AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Zhao, J AU - Zhao J AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Siefker-Radtke, A O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Kamat, A M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: AKamat@mdanderson.org. FAU - Alhalabi, O AU - Alhalabi O AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: OAlhalabi@mdanderson.org. LA - eng GR - T32 CA009357/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20241030 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 SB - IM MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/pathology/drug therapy/therapy/mortality MH - Middle Aged MH - *Carcinoma, Neuroendocrine/pathology/drug therapy/mortality MH - Aged MH - Retrospective Studies MH - Neoadjuvant Therapy/methods MH - Adult MH - Neoplasm Staging MH - Carcinoma, Small Cell/pathology/mortality/drug therapy/therapy MH - Disease-Free Survival MH - Aged, 80 and over MH - Neoplasm Recurrence, Local PMC - PMC11550343 OTO - NOTNLM OT - bladder cancer OT - neoadjuvant chemotherapy OT - small cell carcinoma of the bladder EDAT- 2024/10/30 04:20 MHDA- 2024/12/02 05:29 PMCR- 2024/10/30 CRDT- 2024/10/29 19:04 PHST- 2024/06/08 00:00 [received] PHST- 2024/09/22 00:00 [revised] PHST- 2024/09/23 00:00 [accepted] PHST- 2024/12/02 05:29 [medline] PHST- 2024/10/30 04:20 [pubmed] PHST- 2024/10/29 19:04 [entrez] PHST- 2024/10/30 00:00 [pmc-release] AID - S2059-7029(24)01734-4 [pii] AID - 103964 [pii] AID - 10.1016/j.esmoop.2024.103964 [doi] PST - ppublish SO - ESMO Open. 2024 Nov;9(11):103964. doi: 10.1016/j.esmoop.2024.103964. Epub 2024 Oct 30. PMID- 39470318 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260318 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 213 IP - 3 DP - 2025 Mar TI - Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder Cancer. PG - 295-303 LID - 10.1097/JU.0000000000004305 [doi] AB - PURPOSE: Patients with Ta low-grade (LG) nonmuscle-invasive bladder cancer (NMIBC) rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined. MATERIALS AND METHODS: This retrospective study included 521 patients diagnosed with primary TaLG NMIBC (n = 491) or papillary urothelial neoplasm of low malignant potential (n = 30) from 1989 to 2019 at an academic center. Patient data were acquired using patient records chart review and a bladder cancer informatics registry at the center. Risk of recurrence and progression in stage to muscle invasion, metastases, and death due to bladder cancer (BC) were analyzed. RNAseq assessed the transcriptomic profiles of 4 TaLG NMIBCs that metastasized. Interobserver variability in pathological grading (WHO 2004/2022 and 1973, n = 80) was blindly assessed by 3 expert pathologists. RESULTS: The median follow-up was 9.6 (95% CI: 8.6-10.2) years. Among 521 patients (73% men, median age 67.0 years), 350 recurred, 57 progressed in stage, 20 developed metastases, and 15 died of BC (median 9.6 years after diagnosis). Cancer-specific survival probabilities were 0.99, 0.98, and 0.96 at 5, 10, and 15 years, respectively. Fifty patients who were recurrence free for the first 5 years developed late recurrences and 2 of them died of BC. Metastatic TaLG NMIBC had more adverse transcriptomic findings in keeping with higher-grade tumors despite being phenotypically similar to indolent tumors. Grading concordance for the 2004/2022 system and WHO 1973 was 0.78 (95% CI: 0.65-0.90) and 0.41 (95% CI: 0.32-0.50), respectively. CONCLUSIONS: This study with long-term data challenges the assumption that primary TaLG NMIBC nearly never progresses to lethal disease if followed long enough. However, the risk of BC-related mortality is extremely low in patients who are recurrence free for the first 5 years. Minimizing variability in pathological grading remains an unmet need. FAU - Villegas, Eunice AU - Villegas E AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. FAU - Lajkosz, Katherine AU - Lajkosz K AD - Department of Biostatistics, University Health Network, Toronto, Ontario, Canada. FAU - Din, Shayan AU - Din S AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. FAU - Kuk, Cynthia AU - Kuk C AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Chan, Amy AU - Chan A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Kwong, Jethro C C AU - Kwong JCC AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Vitug, Christian AU - Vitug C AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. FAU - Gao, Bruce AU - Gao B AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Hemminki, Otto AU - Hemminki O AD - Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Kot, Dhiral AU - Kot D AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Misurka, Jimmy AU - Misurka J AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Black, Peter C AU - Black PC AD - Division of Urology, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Jewett, Michael AU - Jewett M AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Soloway, Mark S AU - Soloway MS AD - Division of Urology, Memorial Physician Group, Memorial Healthcare System, Aventura, Florida. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, General Hospital Vienna, Vienna, Austria. FAU - Sweet, Joan AU - Sweet J AD - Department of Pathology, University Health Network, Toronto, Ontario, Canada. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Fleshner, Neil E AU - Fleshner NE AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Wrana, Jeffrey AU - Wrana J AD - The Centre for Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Department of Pathology, University Health Network, Toronto, Ontario, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada. AD - Divisions of Urology and Surgical Oncology, Department of Surgery, University Health Network, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20241029 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/diagnosis MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Grading MH - Middle Aged MH - *Cystoscopy/statistics & numerical data MH - Neoplasm Invasiveness MH - Follow-Up Studies MH - Time Factors MH - Neoplasm Metastasis MH - Disease Progression MH - Risk Assessment MH - Aged, 80 and over OTO - NOTNLM OT - bladder cancer OT - low grade OT - non-muscle invasive EDAT- 2024/10/29 16:14 MHDA- 2025/02/07 12:26 CRDT- 2024/10/29 09:22 PHST- 2025/02/07 12:26 [medline] PHST- 2024/10/29 16:14 [pubmed] PHST- 2024/10/29 09:22 [entrez] AID - 10.1097/JU.0000000000004305 [doi] PST - ppublish SO - J Urol. 2025 Mar;213(3):295-303. doi: 10.1097/JU.0000000000004305. Epub 2024 Oct 29. PMID- 39462182 OWN - NLM STAT- MEDLINE DCOM- 20250221 LR - 20250522 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 135 IP - 3 DP - 2025 Mar TI - An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial. PG - 446-455 LID - 10.1111/bju.16543 [doi] AB - OBJECTIVES: To determine the safety and oncological advantages of en bloc resection of bladder tumour (ERBT) vs conventional transurethral resection of bladder tumour (cTURBT) in terms of resection quality, staging quality, and safety. PATIENTS AND METHODS: We conducted a single-blinded randomised controlled trial at seven European hospitals with the following inclusion criteria: first diagnosis of non-muscle-invasive bladder cancer, no singular carcinoma in situ, and tumour size >4.3 mm. Patients were randomised intraoperatively in a 1:1 ratio to either the ERBT or cTURBT group. Outcome analysis was performed using the chi-square test, t-test, and multivariate regression analysis. RESULTS: A total of 97 patients were randomised into the study (cTURBT = 40, ERBT = 57). A switch to cTURBT was necessary in two patients (3.5%) and 11.5% of the screened patients were preoperatively excluded for ERBT. There was no difference in the specimen presence of detrusor muscle with 73.7% in cTURBT and 67.3% in ERBT specimens (P = 0.69). There were no significant differences in mean operative time (ERBT 27.6 vs cTURBT 25.4 min, P = 0.450) or mean resection time (ERBT 16.3 vs cTURBT 15.5 min, P = 0.732). Overall the complication rate did not differ significantly (ERBT 18.2% vs cTURBT 7.5%, P = 0.142). Bladder perforations occurred significantly more often in the ERBT group (ERBT seven vs cTURBT none, P = 0.020). R0 status was reported more often after ERBT, whilst a second resection was significantly less frequent after ERBT (P = 0.018). Recurrence rates were comparable for both techniques after 6 months of follow-up. CONCLUSION: The feasibility of ERBT is higher than previously reported. Whereas other perioperative and safety parameters are comparable to cTURBT, bladder perforations occurred significantly more often in the ERBT group and raised safety concerns. This is why this trial was terminated. CI - (c) 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Struck, Julian Peter AU - Struck JP AD - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Department of Urology, Brandenburg Medical School Theodor Fontane (MHB), Brandenburg an der Havel, Germany. FAU - Moharam, Nadim AU - Moharam N AUID- ORCID: 0000-0001-5464-0626 AD - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Department of Urology and Urologic Surgery, University Medical Centre Mannheim, Mannheim, Germany. FAU - Leitenberger, Armin AU - Leitenberger A AD - Department of Urology, Wolfsburg Hospital, Wolfsburg, Germany. FAU - Weber, Jorg AU - Weber J AD - Department of Urology, Wolfsburg Hospital, Wolfsburg, Germany. FAU - Lusuardi, Lukas AU - Lusuardi L AD - Department of Urology and Andrology, Salzburg University Hospital, Salzburg, Austria. FAU - Oswald, David AU - Oswald D AD - Department of Urology and Andrology, Salzburg University Hospital, Salzburg, Austria. FAU - Rassweiler, Jens J AU - Rassweiler JJ AD - Department of Urology and Pediatric Urology, SLK-Klinikum, Heilbronn, Germany. FAU - Fiedler, Marcel AU - Fiedler M AD - Department of Urology and Pediatric Urology, SLK-Klinikum, Heilbronn, Germany. FAU - Hornak, Jakub AU - Hornak J AD - Department of Urology of the 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Motol University Hospital, Prague, Czech Republic. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology of the 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Motol University Hospital, Prague, Czech Republic. FAU - Micali, Salvatore AU - Micali S AD - Department of Urology, Ospedale Civile S. Agostino Estense, Modena, Italy. FAU - Zaraca, Carlo AU - Zaraca C AD - Department of Urology, Ospedale Civile S. Agostino Estense, Modena, Italy. FAU - Spreu, Thomas AU - Spreu T AD - Department of Urology, Protest and Hospital Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Friedersdorff, Frank AU - Friedersdorff F AD - Department of Urology, Protest and Hospital Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Borgmann, Hendrik AU - Borgmann H AD - Department of Urology, Brandenburg Medical School Theodor Fontane (MHB), Brandenburg an der Havel, Germany. FAU - Merseburger, Axel S AU - Merseburger AS AD - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Kramer, Mario W AU - Kramer MW AD - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20241027 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - *Cystectomy/methods/adverse effects MH - Middle Aged MH - Single-Blind Method MH - Aged, 80 and over MH - Treatment Outcome MH - Transurethral Resection of Bladder PMC - PMC11842884 OTO - NOTNLM OT - EBRUC II OT - bladder cancer OT - en bloc resection OT - non-muscle-invasive bladder cancer OT - transurethral resection of bladder tumour EDAT- 2024/10/27 17:13 MHDA- 2025/02/21 06:22 PMCR- 2025/02/21 CRDT- 2024/10/27 04:43 PHST- 2025/02/21 06:22 [medline] PHST- 2024/10/27 17:13 [pubmed] PHST- 2024/10/27 04:43 [entrez] PHST- 2025/02/21 00:00 [pmc-release] AID - BJU16543 [pii] AID - 10.1111/bju.16543 [doi] PST - ppublish SO - BJU Int. 2025 Mar;135(3):446-455. doi: 10.1111/bju.16543. Epub 2024 Oct 27. PMID- 39457670 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241029 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 10 DP - 2024 Oct 16 TI - Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients. LID - 10.3390/biomedicines12102359 [doi] LID - 2359 AB - Non-muscle-invasive bladder cancer (NMIBC) prognosis varies significantly due to the biological and clinical heterogeneity. High-risk stage T1-G3, comprising 15-20% of NMIBCs, involves the lamina propria and is associated with higher rates of recurrence, progression, and cancer-specific mortality. In the present study, we have evaluated the enumeration of tumour-derived extracellular vesicles (tdEVs) and circulating tumour cells (CTCs) in high-risk NMIBC patients and their correlation with survival outcomes such as time to progression (TTP), and cancer-specific survival (CSS). Eighty-three high-risk T1-G3 NMIBC patients treated between September 2010 and January 2013 were included. Blood samples were collected before a transurethral resection of the bladder (TURB) and analysed using the CellSearch((R)) system. The presence of at least one CTC was associated with a shorter TTP and CSS. Extending follow-up to 120 months and incorporating automated tdEV evaluation using ACCEPT software demonstrated that tdEV count may additionally stratify patient risk. Combining tdEVs and CTCs improves risk stratification for NMIBC progression, suggesting that tdEVs could be valuable biomarkers for prognosis and disease monitoring. Further research is needed to confirm these findings and establish the clinical significance of tdEVs in early-stage cancers. FAU - Magri, Valentina AU - Magri V AUID- ORCID: 0000-0001-7312-2904 AD - Department of Pathology, Oncology and Radiology, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00161 Rome, Italy. FAU - Marino, Luca AU - Marino L AUID- ORCID: 0000-0001-7380-6222 AD - Department of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00184 Rome, Italy. AD - Emergency Medicine Unit, Department of Emergency-Acceptance, Critical Areas and Trauma, Policlinico "Umberto I", 00183 Rome, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - De Meo, Michela AU - De Meo M AUID- ORCID: 0000-0002-3024-2233 AD - Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. FAU - Siringo, Marco AU - Siringo M AUID- ORCID: 0000-0002-0489-1790 AD - Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy. FAU - Gandini, Orietta AU - Gandini O AUID- ORCID: 0000-0002-7867-1010 AD - Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. FAU - Santini, Daniele AU - Santini D AD - Department of Medical-Surgical Sciences and Biotechnologies, "Sapienza" University, 04100 Latina, Italy. FAU - Nicolazzo, Chiara AU - Nicolazzo C AUID- ORCID: 0000-0002-2551-8979 AD - Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. FAU - Gazzaniga, Paola AU - Gazzaniga P AUID- ORCID: 0000-0002-2325-2273 AD - Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy. LA - eng GR - NA/A.R.Ger.on onlus/ GR - NA/F.O RO. onlus/ PT - Journal Article DEP - 20241016 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11505137 OTO - NOTNLM OT - ACCEPT OT - Cellsearch(R) system OT - circulating tumour cell OT - extracellular vesicle OT - non-muscle invasive bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2024/10/26 19:24 MHDA- 2024/10/26 19:25 PMCR- 2024/10/16 CRDT- 2024/10/26 01:10 PHST- 2024/09/11 00:00 [received] PHST- 2024/10/04 00:00 [revised] PHST- 2024/10/11 00:00 [accepted] PHST- 2024/10/26 19:25 [medline] PHST- 2024/10/26 19:24 [pubmed] PHST- 2024/10/26 01:10 [entrez] PHST- 2024/10/16 00:00 [pmc-release] AID - biomedicines12102359 [pii] AID - biomedicines-12-02359 [pii] AID - 10.3390/biomedicines12102359 [doi] PST - epublish SO - Biomedicines. 2024 Oct 16;12(10):2359. doi: 10.3390/biomedicines12102359. PMID- 39456941 OWN - NLM STAT- MEDLINE DCOM- 20241026 LR - 20241028 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 20 DP - 2024 Oct 17 TI - Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment. LID - 10.3390/ijms252011157 [doi] LID - 11157 AB - Recent studies have identified a urinary microbiome, dispelling the myth of urine sterility. Intravesical bacillus Calmette-Guerin (BCG) therapy is the preferred treatment for intermediate to high-risk non-muscle-invasive bladder cancer (BCa), although resistance occurs in 30-50% of cases. Progression to muscle-invasive cancer necessitates radical cystectomy. Our research uses 16S rRNA gene sequencing to investigate how the urinary microbiome influences BCa and its response to BCG therapy. Urine samples were collected via urethral catheterization from patients with benign conditions and non-muscle-invasive BCa, all of whom underwent BCG therapy. We utilized 16S rRNA gene sequencing to analyze the bacterial profiles and metabolic pathways in these samples. These pathways were validated using a real metabolite dataset, and we developed predictive models for malignancy and BCG response. In this study, 87 patients participated, including 29 with benign diseases and 58 with BCa. We noted distinct bacterial compositions between benign and malignant samples, indicating the potential role of the toluene degradation pathway in mitigating BCa development. Responders to BCG had differing microbial compositions and higher quinolone synthesis than non-responders, with two Bifidobacterium species being prevalent among responders, associated with prolonged recurrence-free survival. Additionally, we developed highly accurate predictive models for malignancy and BCG response. Our study delved into the mechanisms behind malignancy and BCG responses by focusing on the urinary microbiome and metabolic pathways. We pinpointed specific beneficial microbes and developed clinical models to predict malignancy and BCG therapy outcomes. These models can track recurrence and facilitate early predictions of treatment responses. FAU - Min, Kyungchan AU - Min K AUID- ORCID: 0000-0001-5238-6265 AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Zheng, Chuang-Ming AU - Zheng CM AUID- ORCID: 0000-0003-1925-0571 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. FAU - Kim, Sujeong AU - Kim S AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Kim, Hyun AU - Kim H AUID- ORCID: 0000-0001-5026-1178 AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Lee, Minji AU - Lee M AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Piao, Xuan-Mei AU - Piao XM AUID- ORCID: 0000-0001-6847-7743 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. FAU - Kim, Yunjae AU - Kim Y AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Joo, Yanghyun AU - Joo Y AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Cho, Beomki AU - Cho B AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. FAU - Moon, Seongmin AU - Moon S AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. AD - Department of Convergence of Medical Science, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Park, Hansoo AU - Park H AD - Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. AD - Genome and Company, Seongnam 13486, Republic of Korea. FAU - Yun, Seok Joong AU - Yun SJ AUID- ORCID: 0000-0001-7737-4746 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. LA - eng GR - RS-2023-00245919, 2020R1I1A3062508, 2021R1I1A1A01050891, 2021RIS-001, 5199990614277/Ministry of Education/ GR - Grant of the MD-PhD/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI),/Korea Health Industry Development Institute/Republic of Korea PT - Journal Article DEP - 20241017 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BCG Vaccine) RN - 0 (RNA, Ribosomal, 16S) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/microbiology/drug therapy MH - *Microbiota MH - *BCG Vaccine/therapeutic use MH - Male MH - Female MH - *RNA, Ribosomal, 16S/genetics MH - Aged MH - Middle Aged MH - Bacteria/genetics/classification PMC - PMC11508893 OTO - NOTNLM OT - 16S rRNA gene sequencing OT - Bifidobacterium OT - Bladder cancer OT - Intravesical BCG treatment OT - Quinolone OT - Urinary microbiome COIS- Author Hansoo Park was employed by Genome and Company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/10/26 19:22 MHDA- 2024/10/26 19:23 PMCR- 2024/10/17 CRDT- 2024/10/26 01:06 PHST- 2024/08/21 00:00 [received] PHST- 2024/10/07 00:00 [revised] PHST- 2024/10/12 00:00 [accepted] PHST- 2024/10/26 19:23 [medline] PHST- 2024/10/26 19:22 [pubmed] PHST- 2024/10/26 01:06 [entrez] PHST- 2024/10/17 00:00 [pmc-release] AID - ijms252011157 [pii] AID - ijms-25-11157 [pii] AID - 10.3390/ijms252011157 [doi] PST - epublish SO - Int J Mol Sci. 2024 Oct 17;25(20):11157. doi: 10.3390/ijms252011157. PMID- 39455346 OWN - NLM STAT- MEDLINE DCOM- 20250210 LR - 20260513 IS - 1878-4046 (Electronic) IS - 1076-6332 (Linking) VI - 32 IP - 2 DP - 2025 Feb TI - Coupling Habitat Radiomic Analysis with the Diversification of the Tumor ecosystem: Illuminating New Strategy in the Assessment of Postoperative Recurrence of Non-Muscle Invasive Bladder Cancer. PG - 821-833 LID - S1076-6332(24)00685-8 [pii] LID - 10.1016/j.acra.2024.09.036 [doi] AB - RATIONALE AND OBJECTIVES: Non-muscle-invasive bladder cancer (NMIBC) is highly recurrent, with each recurrence potentially progressing to muscle-invasive cancer, affecting patient prognosis. Intratumoral heterogeneity plays a crucial role in NMIBC recurrence. This study investigated a novel habitat-based radiomic analysis for stratifying NMIBC recurrence risk. MATERIALS AND METHODS: A retrospective collection of 382 NMIBC patients between 2015 and 2021 from two medical institutions was carried out. Patients' CT images were collected across three phases, with tumor sites delineated within the bladder. Intratumoral habitats were identified using K-means clustering on 19 texture features of the tumor sites, followed by the extraction of 107 radiomic features per habitat with PyRadiomics. These features were integrated into machine learning algorithms to develop a habitat-based model (HBM) for predicting two-year recurrence of NMIBC patients. The clinical and multiphase radiomic models were also constructed for comparison, with the Delong test comparing their diagnostic efficiency. The impact of HMB on patients' recurrence-free survival and the correlation between HBM and tumor-stroma ratio were further analyzed. RESULTS: Three distinct habitats were identified within NMIBC. The HBM showed an AUC of 0.932 (95% CI: 0.906 - 0.958) in the training cohort and 0.782 (95% CI: 0.674 - 0.890) in the validation cohort for predicting two-year recurrence. With comparison between different models, The HBM is demonstrated to possess superior diagnostic efficacy to the clinical model (p < 0.001) in the training cohort. However, no significant difference was noted between the multiphase and clinical models (p = 0.130) in the training cohort. The HBM score effectively distinguished the recurrence-free survival of NIMBC patients and demonstrated a significant correlation with the tumor-stroma ratio. CONCLUSIONS: Habitat-based radiomics, coupled with machine learning, efficiently predicts NMIBC recurrence. Further research on habitat-based radiomics offers potential improvement in clinical management of NMIBC. CI - Copyright (c) 2025 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved. FAU - Li, Hong AU - Li H AD - Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China (H.L., Y.T.). FAU - Sui, Yiqun AU - Sui Y AD - Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China (Y.S.). FAU - Tao, Yongli AU - Tao Y AD - Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China (H.L., Y.T.). FAU - Cao, Jin AU - Cao J AD - Department of Pathology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China (J.C., X.J.). FAU - Jiang, Xiang AU - Jiang X AD - Department of Pathology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China (J.C., X.J.). FAU - Wang, Bo AU - Wang B AD - Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China (B.W., Y.D.). FAU - Du, Yiheng AU - Du Y AD - Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China (B.W., Y.D.). Electronic address: pnan1989@alumni.sjtu.edu.cn. LA - eng PT - Journal Article DEP - 20241024 PL - United States TA - Acad Radiol JT - Academic radiology JID - 9440159 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - *Neoplasm Recurrence, Local/diagnostic imaging/pathology MH - Female MH - Male MH - Retrospective Studies MH - Middle Aged MH - Aged MH - *Tomography, X-Ray Computed/methods MH - Neoplasm Invasiveness MH - Machine Learning MH - *Tumor Microenvironment MH - Non-Muscle Invasive Bladder Neoplasms MH - Radiomics OTO - NOTNLM OT - Bladder cancer OT - Habitat OT - Intratumoral Heterogeneity OT - Machine Learning OT - Radiomics COIS- Declaration of Competing Interest The authors declare no conflict of interest in this manuscript and approve the final version of the submitted manuscript. EDAT- 2024/10/26 19:24 MHDA- 2025/02/11 00:18 CRDT- 2024/10/25 21:59 PHST- 2024/07/09 00:00 [received] PHST- 2024/09/16 00:00 [revised] PHST- 2024/09/16 00:00 [accepted] PHST- 2025/02/11 00:18 [medline] PHST- 2024/10/26 19:24 [pubmed] PHST- 2024/10/25 21:59 [entrez] AID - S1076-6332(24)00685-8 [pii] AID - 10.1016/j.acra.2024.09.036 [doi] PST - ppublish SO - Acad Radiol. 2025 Feb;32(2):821-833. doi: 10.1016/j.acra.2024.09.036. Epub 2024 Oct 24. PMID- 39455338 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260626 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 6 DP - 2024 Dec TI - Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study. PG - 102214 LID - S1558-7673(24)00184-8 [pii] LID - 10.1016/j.clgc.2024.102214 [doi] AB - PURPOSE: The PURE-01 clinical trial reported the use of neoadjuvant treatment with pembrolizumab prior to radical cystectomy (RC) in patients with muscle-invasive bladder. Specific molecular subtypes and immune signatures were reported to be associated with a favorable survival. However, reports on the detailed tumor biology of patients relapsing after neoadjuvant pembrolizumab are lacking. MATERIALS AND METHODS: Microarray data from transurethral resection of the bladder tumor (TURBT; n = 102) and matched RC (N = 25) tissue from patients in PURE-01 who experience a disease relapse were analyzed, with gene expression signatures and molecular subtypes. The Kaplan-Meier method was used to estimate differences in patient outcomes. Immune-signatures were split by median for survival analysis. All significance testing used a two-sided t-test at a threshold of P < .05. RESULTS: The study cohort consisted of 102 patients, of whom N = 19 (19%) experienced relapse. Molecular subtyping revealed that neuroendocrine-like tumors had the worst outcomes, while tumors classified as Claudin-low did show only one recurrence event. Differential gene expression analysis identified genes associated with relapse, including KRT20, H19, and immune-associated genes such as CXCL9 and CXCL11. CONCLUSION: This study provides a detailed characterization of patients who relapsed after neoadjuvant pembrolizumab and RC and identifies distinct gene expression patterns associated with relapse. These findings may have implications for predicting patient response and guiding treatment decisions in the neoadjuvant setting. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Reike, Moritz J AU - Reike MJ AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Germany. FAU - Raggi, Daniele AU - Raggi D AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Mercinelli, Chiara AU - Mercinelli C AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Cigliola, Antonio AU - Cigliola A AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Tateo, Valentina AU - Tateo V AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Patane, Damiano Alfio AU - Patane DA AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Crupi, Emanuele AU - Crupi E AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - de Padua, Tiago Costa AU - de Padua TC AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Gibb, Ewan A AU - Gibb EA AD - Decipher Urologic Cancers, Veracyte Inc, Vancouver, Canada. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: necchi.andrea@hsr.it. LA - eng SI - ClinicalTrials.gov/NCT02736266 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240920 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/surgery/genetics/pathology MH - *Neoadjuvant Therapy/methods MH - *Cystectomy MH - *Antibodies, Monoclonal, Humanized/therapeutic use MH - Male MH - Female MH - *Neoplasm Recurrence, Local/genetics/drug therapy MH - Aged MH - Middle Aged MH - Gene Expression Regulation, Neoplastic MH - Antineoplastic Agents, Immunological/therapeutic use MH - Gene Expression Profiling MH - Prognosis MH - Biomarkers, Tumor/genetics/metabolism OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Immunotherapy OT - Neoadjuvant OT - Relapse COIS- Disclosure Moritz Johannes Reike certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending) are the following: Peter C. Black has acted as a consultant or speaker for Janssen, Merck, Roche, BMS, Urogen, EMD Serono, Bayer, Astellas, AbbVie, AstraZeneca, Ferring, Sanofi, Pfizer, Protara, Porkarium, Stimit and Verity, and shares a patent with Veracyte Inc Ewan A Gibb is an employee of Veracyte Inc Andrea Necchi reports grants and personal fees from Merck and AstraZeneca, and personal fees from Roche, Janssen, BMS, Astellas, Bayer, Incyte, and Seattle Genetics during the conduct of the study; and grants and personal fees from Merck, AstraZeneca, and BMS, and personal fees from Astellas, Bayer, Incyte, Janssen, Roche, and Seattle Genetics outside the submitted work. No disclosures were reported by the other authors. EDAT- 2024/10/26 19:26 MHDA- 2024/11/29 05:20 CRDT- 2024/10/25 21:59 PHST- 2024/03/29 00:00 [received] PHST- 2024/08/22 00:00 [revised] PHST- 2024/08/24 00:00 [accepted] PHST- 2024/11/29 05:20 [medline] PHST- 2024/10/26 19:26 [pubmed] PHST- 2024/10/25 21:59 [entrez] AID - S1558-7673(24)00184-8 [pii] AID - 10.1016/j.clgc.2024.102214 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Dec;22(6):102214. doi: 10.1016/j.clgc.2024.102214. Epub 2024 Sep 20. PMID- 39443252 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 4 DP - 2025 Apr TI - Long-term oncologic outcomes and complications of robot-assisted radical cystectomy for the treatment of urothelial carcinoma of the bladder. PG - 267.e19-267.e27 LID - S1078-1439(24)00687-2 [pii] LID - 10.1016/j.urolonc.2024.10.009 [doi] AB - INTRODUCTION: To report the long-term outcomes of robot-assisted radical cystectomy (RARC) for the treatment of muscle invasive and high-risk non-muscle invasive bladder cancer. METHODS: We reviewed a single tertiary center database of RARC from 2004 to 2020. Concomitant extended pelvic lymph node dissection and extracorporeal urinary diversion were performed. Cox regression analysis and the Kaplan-Meier method were used to identify factors associated with and report time-to-event estimations of recurrence-free survival and overall survival. Clavien-Dindo complications were identified, categorized, and substratified by time from surgery within 90-days and between 90-days and >5-years postoperatively. RESULTS: A total of 510 patients with median follow-up of 57.1 months (IQR 21.8-103.6) were included. Continent diversion was performed in 259 (51%) patients. Of the 340 (67%) >/=cT2 patients, 153 (45%) received cisplatin-based neoadjuvant chemotherapy. Recurrence was identified in 157 (31%) patients, and 118 (23%) died from bladder cancer. The overall complication rate was 52% with 267 (41%) major grade >/= III events. Infectious (25%) and genitourinary (22%) complications were the most common irrespective of the time interval beyond 90-days. The risk of recurrence or death were increased by extravesical disease (HR 1.91 and 1.97, respectively) and lymph node positivity (HR 4.58 and 2.42, respectively) in multivariable analysis (all, P < 0.001). The estimated 5-, and 10-year recurrence-free and overall survival rates were 69% and 64% and 61% and 44%, respectively. CONCLUSIONS: RARC is a durable treatment that optimizes the probability of cure for patients requiring extirpation for bladder cancer. Targeting the modifiable complications of radical surgery may further improve the risk/benefit ratio of RARC. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Lama, Daniel J AU - Lama DJ AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: dlama@coh.org. FAU - Okunowo, Oluwatimilehin AU - Okunowo O AD - Department of Computational and Quantitative Medicine, Division of Biostatistics, Beckman Research Institute of City of Hope, Duarte, CA. FAU - Yamzon, Jonathan AU - Yamzon J AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Zhumkhawala, Ali-Asghar AU - Zhumkhawala AA AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Wilson, Timothy G AU - Wilson TG AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Urologic Oncology, Providence St. John's Cancer Institute, Santa Monica, CA. FAU - Lau, Clayton S AU - Lau CS AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Yuh, Bertram E AU - Yuh BE AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. FAU - Chan, Kevin G AU - Chan KG AD - Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA. LA - eng PT - Journal Article DEP - 20241022 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Cystectomy/methods/adverse effects MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Female MH - *Robotic Surgical Procedures/methods/adverse effects MH - Aged MH - Middle Aged MH - *Postoperative Complications/epidemiology/etiology MH - *Carcinoma, Transitional Cell/surgery/pathology/mortality MH - Treatment Outcome MH - Retrospective Studies OTO - NOTNLM OT - Complication OT - Long-term OT - Muscle invasive bladder cancer OT - Radical cystectomy OT - Robotic surgical procedures COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/10/24 00:22 MHDA- 2025/03/13 00:32 CRDT- 2024/10/23 21:58 PHST- 2024/05/07 00:00 [received] PHST- 2024/09/27 00:00 [revised] PHST- 2024/10/05 00:00 [accepted] PHST- 2025/03/13 00:32 [medline] PHST- 2024/10/24 00:22 [pubmed] PHST- 2024/10/23 21:58 [entrez] AID - S1078-1439(24)00687-2 [pii] AID - 10.1016/j.urolonc.2024.10.009 [doi] PST - ppublish SO - Urol Oncol. 2025 Apr;43(4):267.e19-267.e27. doi: 10.1016/j.urolonc.2024.10.009. Epub 2024 Oct 22. PMID- 39426738 OWN - NLM STAT- MEDLINE DCOM- 20241206 LR - 20250723 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 194 DP - 2024 Dec TI - VI-RADS-based Algorithm for Bladder Cancer Management Randomized Retrospective Study. PG - 225-230 LID - S0090-4295(24)00867-7 [pii] LID - 10.1016/j.urology.2024.10.002 [doi] AB - OBJECTIVE: To evaluate if VI-RADS can distinguish between nonmuscle-invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and high-risk nonmuscle-invasive bladder cancers (HR-NMIBCs). It is unclear if the Vesical Imaging-Reporting and Data System (VI-RADS) can replace repeated transurethral resection of bladder tumor (Re-TURBT) as in the new VI-RADS-based algorithm. METHODS: Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of the VI-RADS score were calculated for mpMRI performance in patients undergoing TURBT and HR-NMIBC patients for only Re-TURBT. RESULTS: Of 283 cases, when VI-RADS >/=3 lesions were considered muscle-invasive, its sensitivity was 95.7% and specificity was 92.5%. PPV and NPV were 86.6% and 97.7%, respectively. The area under the curve (AUC) was 0.942 (P <.001). Of 89 patients undergoing post-Re-TURBT, 41 (46%) were tumor-free, 47 (50.5%) showed permanent HR-NMIBC, and 3 (2.2%) were upgraded to MIBC. Per the new VI-RADS-based approach, 73 (41%) of the 178 HR-NMIBCs with VI-RADS /=4, 6 (6) with HR-NMIBCs (8%) would not undergo Re-TURBT. When incomplete resections were excluded, 35 (60.3%) of the patients had complete resection, 23 (39.7%) had residual disease, and complete resection would not have been performed in these patients, and 2 (100%) still had residual disease. CONCLUSION: The new VI-RADS-based algorithm helped VI-RADS >/=4 patients by switching to radical treatment. Since the residual disease is high in cases with VI-RADS /=1 mm) disease, dividing the patients into Focal and Extended groups. RESULTS: The study included 114 patients, with a median (Interquartile Range (IQR)) age of 78 (71-87) and a Charlson Comorbidity Index (CCI) of 6 (5-7). The median follow-up was 33 (20-53) months. Of these, 56 patients (49.0%) were classified as having focal invasive, while 58 (51.0%) had Extended invasion. Demographic and pathological characteristics were evenly distributed between the two groups without significant differences (p > 0.05). However, Extended disease was more prevalent at initial diagnosis (Odds Ratio (OR) 5.44, p = 0.003). Multivariate analysis identified a first diagnosis of BC, pathological Grade 3 (G3), presence of Carcinoma in situ (CIS) and residual tumour at second resection as independent predictors of Extended pT1. Recurrence rates, progression rates and cancer-specific mortality were 41.2%, 5.3% and 1.8%, respectively. There were no statistically significant differences between the Focal and Extended groups in 3-year recurrence-free (58.9% vs 63.8%, p = 0.654), progression-free (92.9% vs 96.5%, p = 0.270) and cancer-specific survival (100% vs 98.3%, p = 0.425) rates. CONCLUSIONS: In this retrospective, single-centre study, substaging by depth of invasion did not predict recurrence, progression or cancer-specific mortality in patients with pT1 NMIBC. The initial diagnosis of pT1 BC, presence of G3, CIS and residual tumour at the second resection were identified as independent predictors of Extended pT1. CI - (c) 2024 The Author(s). FAU - Lorusso, Vito AU - Lorusso V AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. FAU - Palmisano, Franco AU - Palmisano F AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. FAU - Piccinelli, Mattia Luca AU - Piccinelli ML AD - Department of Urology, IEO European Institute of Oncology, IRCCS, 20141 Milan, Italy. FAU - Rossi, Roberta Simona AU - Rossi RS AD - Pathology Unit, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy. FAU - Lucignani, Gianpaolo AU - Lucignani G AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. FAU - Incarbone, Giacomo Piero AU - Incarbone GP AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. FAU - Granata, Antonio Maria AU - Granata AM AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. FAU - Saredi, Giovanni AU - Saredi G AD - Department of Urology, ASST-Valle Olona, Ospedale di Busto Arsizio, 21052 Busto Arsizio, Italy. FAU - Bozzini, Giorgio AU - Bozzini G AD - Department of Urology, ASST-Lariana, Ospedale Sant'Anna, 22042 San Fermo della Battaglia, Italy. FAU - Gregori, Andrea AU - Gregori A AD - Department of Urology, ASST Fatebenefratelli-Sacco Hospitals, 20157 Milan, Italy. AD - University of Milan, 20122 Milan, Italy. LA - eng PT - Journal Article PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Retrospective Studies MH - Male MH - Aged MH - Female MH - *Neoplasm Recurrence, Local MH - *Disease Progression MH - *Neoplasm Invasiveness MH - Aged, 80 and over MH - *Neoplasm Staging MH - Neoplasm Grading MH - Prognosis MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - bladder cancer OT - non-muscle invasive OT - recurrence OT - risk factors OT - tumor staging COIS- The authors declare no conflict of interest. EDAT- 2024/10/10 06:23 MHDA- 2024/10/10 06:24 CRDT- 2024/10/10 01:52 PHST- 2024/10/10 06:24 [medline] PHST- 2024/10/10 06:23 [pubmed] PHST- 2024/10/10 01:52 [entrez] AID - 1727661857752-1977397988 [pii] AID - 10.56434/j.arch.esp.urol.20247708.119 [doi] PST - ppublish SO - Arch Esp Urol. 2024 Sep;77(8):843-849. doi: 10.56434/j.arch.esp.urol.20247708.119. PMID- 39383345 OWN - NLM STAT- MEDLINE DCOM- 20250109 LR - 20260919 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 213 IP - 2 DP - 2025 Feb TI - Predicting Response to Intravesical Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. PG - 192-204 LID - 10.1097/JU.0000000000004278 [doi] AB - PURPOSE: There are few markers to identify those likely to recur or progress after treatment with intravesical bacillus Calmette-Guerin (BCG). We developed and validated artificial intelligence (AI)-based histologic assays that extract interpretable features from transurethral resection of bladder tumor digitized pathology images to predict risk of recurrence, progression, development of BCG-unresponsive disease, and cystectomy. MATERIALS AND METHODS: Pre-BCG resection-derived whole-slide images and clinical data were obtained for high-risk nonmuscle-invasive bladder cancer cases treated with BCG from 12 centers and were analyzed through a segmentation and feature extraction pipeline. Features associated with clinical outcomes were defined and tested on independent development and validation cohorts. Cases were classified into high or low risk for recurrence, progression, BCG-unresponsive disease, and cystectomy. RESULTS: Nine hundred forty-four cases (development: 303, validation: 641, median follow-up: 36 months) representative of the intended use population were included (high-grade Ta: 34.1%, high-grade T1: 54.8%; carcinoma in situ only: 11.1%, any carcinoma in situ: 31.4%). In the validation cohort, "high recurrence risk" cases had inferior high-grade recurrence-free survival vs "low recurrence risk" cases (HR, 2.08, P < .0001). "High progression risk" patients had poorer progression-free survival (HR, 3.87, P < .001) and higher risk of cystectomy (HR, 3.35, P < .001) than "low progression risk" patients. Cases harboring the BCG-unresponsive disease signature had a shorter time to development of BCG-unresponsive disease than cases without the signature (HR, 2.31, P < .0001). AI assays provided predictive information beyond clinicopathologic factors. CONCLUSIONS: We developed and validated AI-based histologic assays that identify high-risk nonmuscle-invasive bladder cancer cases at higher risk of recurrence, progression, BCG-unresponsive disease, and cystectomy, potentially aiding clinical decision making. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Krishna, Viswesh AU - Krishna V AD - Valar Labs, Palo Alto, California. FAU - Abuzeid, Waleed M AU - Abuzeid WM AUID- ORCID: 0000-0003-2489-0514 AD - Valar Labs, Palo Alto, California. FAU - Launer, Bryn AU - Launer B AD - Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Krishna, Vrishab AU - Krishna V AD - Valar Labs, Palo Alto, California. FAU - Shingi, Siddhant AU - Shingi S AD - Valar Labs, Palo Alto, California. FAU - Gordetsky, Jennifer B AU - Gordetsky JB AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Gerald, Thomas AU - Gerald T AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Woldu, Solomon AU - Woldu S AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Shkolyar, Eugene AU - Shkolyar E AD - Department of Urology, Stanford Medicine, Palo Alto, California. FAU - Hayne, Dickon AU - Hayne D AD - Department of Urology, University of Western Australia, Perth, Australia. FAU - Redfern, Andrew AU - Redfern A AD - Department of Medical Oncology, University of Western Australia, Perth, Australia. FAU - Spalding, Lisa AU - Spalding L AD - Department of Urology, University of Western Australia, Perth, Australia. FAU - Stewart, Courtney AU - Stewart C AD - Department of Urology, University of Texas Medical Branch, Galveston, Texas. FAU - Eyzaguirre, Eduardo AU - Eyzaguirre E AD - Department of Pathology, University of Texas Medical Branch, Galveston, Texas. FAU - Imtiaz, Shamsunnahar AU - Imtiaz S AD - Department of Urology, Emory University School of Medicine, Atlanta, Georgia. FAU - Narayan, Vikram M AU - Narayan VM AD - Department of Urology, Emory University School of Medicine, Atlanta, Georgia. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City, Iowa. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, Iowa. FAU - Li, Roger AU - Li R AD - Department of Urology, Moffitt Cancer Center, Tampa, Florida. FAU - Baekelandt, Loic AU - Baekelandt L AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Zuiverloon, Tahlita AU - Zuiverloon T AD - Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Fernandez, Mario I AU - Fernandez MI AD - Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Schultz, Marcela AU - Schultz M AD - Department of Pathology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, Kentucky. FAU - Allison, Derek AU - Allison D AD - Department of Pathology, University of Kentucky College of Medicine, Lexington, Kentucky. FAU - Taylor, John A AU - Taylor JA AD - Department of Urology, University of Kansas Medical Center, Kansas City, Kansas. FAU - Hamza, Ameer AU - Hamza A AD - Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas. FAU - Kamat, Ashish AU - Kamat A AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Nimgaonkar, Vivek AU - Nimgaonkar V AD - Valar Labs, Palo Alto, California. FAU - Sonawane, Snehal AU - Sonawane S AD - Valar Labs, Palo Alto, California. FAU - Miller, Daniel L AU - Miller DL AD - Valar Labs, Palo Alto, California. FAU - Watson, Drew AU - Watson D AD - Valar Labs, Palo Alto, California. FAU - Vrabac, Damir AU - Vrabac D AD - Valar Labs, Palo Alto, California. FAU - Joshi, Anirudh AU - Joshi A AD - Valar Labs, Palo Alto, California. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, Stanford Medicine, Palo Alto, California. FAU - Williams, Stephen B AU - Williams SB AD - Department of Urology, University of Texas Medical Branch, Galveston, Texas. LA - eng GR - P30 CA177558/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20241009 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - J Urol. 2025 Feb;213(2):204. doi: 10.1097/JU.0000000000004290. PMID: 39435758 MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Humans MH - *BCG Vaccine/administration & dosage/therapeutic use MH - *Artificial Intelligence MH - Male MH - Female MH - Administration, Intravesical MH - Aged MH - *Adjuvants, Immunologic/administration & dosage MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Invasiveness MH - Disease Progression MH - Risk Assessment/methods MH - Cystectomy/methods MH - Treatment Outcome PMC - PMC12674634 MID - NIHMS2110677 OTO - NOTNLM OT - artificial intelligence OT - bladder cancer OT - progression OT - recurrence EDAT- 2024/10/09 18:51 MHDA- 2025/01/09 16:58 PMCR- 2025/12/17 CRDT- 2024/10/09 15:03 PHST- 2025/01/09 16:58 [medline] PHST- 2024/10/09 18:51 [pubmed] PHST- 2024/10/09 15:03 [entrez] PHST- 2025/12/17 00:00 [pmc-release] AID - JU-24-446 [pii] AID - 10.1097/JU.0000000000004278 [doi] PST - ppublish SO - J Urol. 2025 Feb;213(2):192-204. doi: 10.1097/JU.0000000000004278. Epub 2024 Oct 9. PMID- 39380003 OWN - NLM STAT- MEDLINE DCOM- 20241009 LR - 20260718 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 22 IP - 1 DP - 2024 Oct 8 TI - Dynamic landscape of m6A modifications and related post-transcriptional events in muscle-invasive bladder cancer. PG - 912 LID - 10.1186/s12967-024-05701-x [doi] LID - 912 AB - BACKGROUND: Muscle-invasive bladder carcinoma (MIBC) is a serious and more advanced stage of bladder carcinoma. N6-Methyladenosine (m6A) is a dynamic and reversible modifications that primarily affects RNA stability and alternative splicing. The dysregulation of m6A in MIBC can be potential target for clinical interventions, but there have been limited studies on m6A modifications in MIBC and their associations with post-transcriptional regulatory processes. METHODS: Paired tumor and adjacent-normal tissues were obtained from three patients with MIBC following radical cystectomy. The additional paired tissues for validation were obtained from patients underwent transurethral resection. Utilizing Nanopore direct-RNA sequencing, we characterized the m6A RNA methylation landscape in MIBC, with a focus on identifying post-transcriptional events potentially affected by changes in m6A sites. This included an examination of differential transcript usage, polyadenylation signal sites, and variations in poly(A) tail length, providing insights into the broader impact of m6A alterations on RNA processing in MIBC. RESULTS: The prognostic-related m6A genes and m6A-risk model constructed by machine learning enables the stratification of high and low-risk patients with precision. A novel m6A modification site in the 3' untranslated region (3'UTR) of IGLL5 gene were identified, characterized by a lower m6A methylation ratio, elongated poly(A) tails, and a notable bias in transcript usage. Furthermore, we discovered two particular transcripts, VWA1-203 and CEBPB-201. VWA1-203 displayed diminished m6A methylation levels, a truncated 3'UTR, and an elongated poly(A) tail, whereas CEBPB-201 showed opposite trends, highlighting the complex interplay between m6A modifications and RNA processing. Source code was provided on GitHub ( https://github.com/lelelililele/Nanopore-m6A-analysis ). CONCLUSIONS: The state-of-the-art Nanopore direct-RNA sequencing and machine learning techniques enables comprehensive identification of m6A modification and provided insights into the potential post-transcriptional regulation mechanisms on the development and progression in MIBC. CI - (c) 2024. The Author(s). FAU - Zhang, Lili AU - Zhang L AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Chen, Ziwei AU - Chen Z AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Sun, Gaoyuan AU - Sun G AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Chang AU - Li C AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Xu, Wenrui AU - Xu W AD - Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China. FAU - Zhu, Hui AU - Zhu H AD - Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing, China. FAU - Zhang, Zaifeng AU - Zhang Z AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Tang, Yongbin AU - Tang Y AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Yayu AU - Li Y AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - University of Chinese Academy of Sciences Medical School, Beijing, China. FAU - Li, Yifei AU - Li Y AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Xu, Siyuan AU - Xu S AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Hexin AU - Li H AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Chen, Meng AU - Chen M AD - National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Xiao, Fei AU - Xiao F AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. xiaofei3965@bjhmoh.cn. AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. xiaofei3965@bjhmoh.cn. FAU - Zhang, Yaqun AU - Zhang Y AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. zhangyaqun@yeah.net. FAU - Zhang, Wei AU - Zhang W AUID- ORCID: 0000-0003-1515-964X AD - Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. zwigyl@hotmail.com. LA - eng GR - mnzl202009/Bethune Charitable Foundation/ GR - BJ-2022-144/National High Level Hospital Clinical Research Funding/ GR - BJ-2022-174/National High Level Hospital Clinical Research Funding/ GR - BJ-2023-198/National High Level Hospital Clinical Research Funding/ GR - BJ-2024-153/National High Level Hospital Clinical Research Funding/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241008 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - K72T3FS567 (Adenosine) RN - CLE6G00625 (N-methyladenosine) RN - 0 (RNA, Messenger) RN - 0 (3' Untranslated Regions) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - *Adenosine/analogs & derivatives/metabolism MH - *Neoplasm Invasiveness MH - RNA Processing, Post-Transcriptional/genetics MH - Methylation MH - Male MH - Gene Expression Regulation, Neoplastic MH - RNA, Messenger/genetics/metabolism MH - Machine Learning MH - Muscles/pathology/metabolism MH - Female MH - Middle Aged MH - Prognosis MH - Aged MH - 3' Untranslated Regions/genetics PMC - PMC11460118 OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - Nanopore sequencing OT - Transcriptional events OT - m6A modification COIS- The authors declare that they have no competing interests. EDAT- 2024/10/09 00:23 MHDA- 2024/10/09 10:18 PMCR- 2024/10/08 CRDT- 2024/10/08 23:54 PHST- 2024/08/05 00:00 [received] PHST- 2024/09/23 00:00 [accepted] PHST- 2024/10/09 10:18 [medline] PHST- 2024/10/09 00:23 [pubmed] PHST- 2024/10/08 23:54 [entrez] PHST- 2024/10/08 00:00 [pmc-release] AID - 10.1186/s12967-024-05701-x [pii] AID - 5701 [pii] AID - 10.1186/s12967-024-05701-x [doi] PST - epublish SO - J Transl Med. 2024 Oct 8;22(1):912. doi: 10.1186/s12967-024-05701-x. PMID- 39379837 OWN - NLM STAT- MEDLINE DCOM- 20241009 LR - 20241011 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 24 IP - 1 DP - 2024 Oct 8 TI - Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study. PG - 1239 LID - 10.1186/s12885-024-13022-x [doi] LID - 1239 AB - PURPOSE: The advantages of en bloc resection of bladder tumors (ERBT) over transurethral resection of bladder tumors (TURBT) in terms of patient prognosis are not yet clear, and there are some technical limitations. We aimed to compare the tumor recurrence in non-muscle invasive bladder cancer (NMIBC) patients with tumor diameter >/= 3 cm undergoing either TURBT or thulium laser ERBT. METHODS: The patients included were those diagnosed with NMIBC based on pathological confirmation and underwent TURBT or modified thulium laser ERBT in the Department of Urology at Tongji Hospital from 2019 to 2024. The patients' medical records were meticulously collected and postoperative follow-up was diligently conducted by trained personnel. Recurrence-free survival curves were generated utilizing the Kaplan-Meier method, and group comparisons were performed using the log-rank trend test. To minimize biases, we employed stratified survival analysis, alongside univariate and multivariate Cox regression analysis. RESULTS: This study included a total of 396 patients with NMIBC, with 214 undergoing TURBT and 182 undergoing ERBT. For all patients, there was no significant difference (P = 0.180) in RFS between the TURBT and ERBT groups. For patients with tumor diameter >/= 3 cm, stratified analysis revealed that the RFS of the ERBT group was significantly better than that of the TURBT group (P = 0.033). However, in patients with tumor diameter < 3 cm, there was no significant difference (P = 0.150) between the two groups. Univariate (HR: 0.52, 95% CI 0.28-0.96, P = 0.036) and multivariate (HR: 0.49, 95% CI 0.25-0.93, P = 0.031) Cox analyses revealed that ERBT was an independent protective factor for recurrence in NMIBC patients with tumor diameter >/=3cm. CONCLUSION: This study found that thulium laser ERBT may offer advantages in managing NMIBC patients with tumor diameters >/= 3 cm. This could potentially drive the clinical application of thulium laser ERBT. TRIAL REGISTRATION: Protocol was registered at Chinese Clinical Trial Register (ChiCTR) with number ChiCTR2000035407 on 12 August 2020. CI - (c) 2024. The Author(s). FAU - Yao, Zhipeng AU - Yao Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Li, Yang AU - Li Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Ding, Yuhong AU - Ding Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Hou, Yaxin AU - Hou Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Hu, Junyi AU - Hu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Liu, Zhenghao AU - Liu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Shi, Pengjie AU - Shi P AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Hu, Henglong AU - Hu H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Li, Fan AU - Li F AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Hu, Jia AU - Hu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Song, Wen AU - Song W AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Song, Xiaodong AU - Song X AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. FAU - Chen, Ke AU - Chen K AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. shenke@hust.edu.cn. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. shenke@hust.edu.cn. FAU - Liu, Lilong AU - Liu L AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. ddluis1204@163.com. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. ddluis1204@163.com. FAU - Liu, Zheng AU - Liu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. lz2013tj@163.com. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. lz2013tj@163.com. LA - eng GR - 82303623/the National Natural Science Foundation of China/ GR - GZB20230243/the National Sponsored Postdoctoral Research Program of China/ GR - 2023M731199/the China Postdoctoral Science Foundation/ GR - 331048/the Postdoctoral Innovation Research Position of Hubei Province, China/ GR - ZRMS2020002466/the Natural Science Foundation of Hubei Province/ PT - Comparative Study PT - Journal Article DEP - 20241008 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 8RKC5ATI4P (Thulium) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Female MH - *Neoplasm Recurrence, Local MH - Aged MH - Middle Aged MH - *Thulium/therapeutic use MH - Cystectomy/methods MH - Non-Randomized Controlled Trials as Topic MH - Laser Therapy/methods MH - Prognosis MH - Lasers, Solid-State/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11460129 OTO - NOTNLM OT - ERBT OT - Large-volume tumor OT - NMIBC OT - TURBT OT - Thulium laser COIS- The authors declare no competing interests. EDAT- 2024/10/09 00:23 MHDA- 2024/10/09 07:33 PMCR- 2024/10/08 CRDT- 2024/10/08 23:46 PHST- 2024/04/03 00:00 [received] PHST- 2024/10/03 00:00 [accepted] PHST- 2024/10/09 07:33 [medline] PHST- 2024/10/09 00:23 [pubmed] PHST- 2024/10/08 23:46 [entrez] PHST- 2024/10/08 00:00 [pmc-release] AID - 10.1186/s12885-024-13022-x [pii] AID - 13022 [pii] AID - 10.1186/s12885-024-13022-x [doi] PST - epublish SO - BMC Cancer. 2024 Oct 8;24(1):1239. doi: 10.1186/s12885-024-13022-x. PMID- 39368942 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 4 DP - 2025 Apr TI - Quantification of micropapillary component on transurethral resection is associated with likelihood of occult lymph node metastasis at radical cystectomy. PG - 266.e1-266.e7 LID - S1078-1439(24)00646-X [pii] LID - 10.1016/j.urolonc.2024.09.005 [doi] AB - INTRODUCTION/BACKGROUND: Micropapillary variant urothelial carcinoma (MPUC) is associated with increased risk of treatment failure with intravesical therapy likely due to the increased risk of occult lymph node (LN) metastasis at radical cystectomy (RC). To date, limited data exists as to whether percent MPUC present within transurethral resection (TUR) samples impacts LN positivity at RC. Our objective is to evaluate the association of percentage MP variant on TUR on incidence of lymph node metastasis and survival outcomes. METHODS: A total of 67 patients with MPUC on TUR were identified from a prospectively maintained database of patients undergoing RC at our institution between 2007 and 2022. TUR samples were rereviewed by an expert GU pathologist with over ten years of experience. Presence and percent MP component, LVI, CIS, grade, and clinical stage were evaluated. Pathologic outcomes were collected from subsequent RC specimens, and recurrence free (RFS) and overall survival (OS) were estimated via the Kaplan-Meier method. Associations between percent MP and lymph node metastasis, RFS, and OS were assessed with univariate and multivariable logistic regression and Cox survival analyses as appropriate. RESULTS: Thirty four of 67 (51%) patients underwent RC for cT1 disease, the remainder harbored >/=cT2 disease. 19 of 33 (58%) patients with >/=cT2 disease received neoadjuvant chemotherapy (NAC). Mean percent MPUC was 35% in cT1 patients and 28% in cT2 patients (P = 0.25). On univariate analysis, both MPUC >/= 30% (Odds Ratio (OR) 3.38, P = 0.02) and clinical >/=T2 (OR 2.88, P = 0.04) were significant predictors of nodal metastasis at RC. On multivariable analysis, MPUC% (OR 1.02, P = 0.036) or MPUC% >/= 30% (OR 4.01, P = 0.013) and clinical T stage >/=2 (OR 3.73, P = 0.018) were significant predictors of pathologic node positive disease. The lowest rate of LN metastasis was found in patients with cT1 disease and MPUC <30% (3/16, 18.7%), versus the highest in >/=cT2 disease and MP >/= 30% (12/16, 75%). CONCLUSIONS: Percent MPUC component on TUR is associated with increased risk of occult lymph node metastasis at RC. Routine pathologic evaluation of percent MP component has the potential to help select patients with MPUC that might be reasonable candidates for intravesical therapy. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Wood, Andrew M AU - Wood AM AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: wooda10@ccf.org. FAU - Benidir, Tarik AU - Benidir T AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Campbell, Rebecca AU - Campbell R AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Li, Jianbo AU - Li J AD - Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Lone, Zaeem AU - Lone Z AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Haywood, Samuel AU - Haywood S AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Eltemamy, Mohamed AU - Eltemamy M AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Weight, Christopher J AU - Weight CJ AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Haber, Georges-Pascal AU - Haber GP AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Almassi, Nima AU - Almassi N AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Alaghehbandan, Reza AU - Alaghehbandan R AD - Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio. LA - eng PT - Journal Article DEP - 20241005 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Cystectomy/methods MH - Male MH - Female MH - Lymphatic Metastasis MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Lymph Nodes/pathology MH - Aged, 80 and over MH - Retrospective Studies OTO - NOTNLM OT - Bladder Cancer OT - Micropapillary Variant OT - Pathologic quantification OT - Urothelial carcinoma OT - Variant Histology COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/10/06 13:43 MHDA- 2025/03/13 06:27 CRDT- 2024/10/05 21:56 PHST- 2024/04/29 00:00 [received] PHST- 2024/07/29 00:00 [revised] PHST- 2024/09/05 00:00 [accepted] PHST- 2025/03/13 06:27 [medline] PHST- 2024/10/06 13:43 [pubmed] PHST- 2024/10/05 21:56 [entrez] AID - S1078-1439(24)00646-X [pii] AID - 10.1016/j.urolonc.2024.09.005 [doi] PST - ppublish SO - Urol Oncol. 2025 Apr;43(4):266.e1-266.e7. doi: 10.1016/j.urolonc.2024.09.005. Epub 2024 Oct 5. PMID- 39366885 OWN - NLM STAT- MEDLINE DCOM- 20251011 LR - 20251011 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 11 IP - 2 DP - 2025 Mar TI - Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder. PG - 251-257 LID - S2405-4569(24)00180-9 [pii] LID - 10.1016/j.euf.2024.09.013 [doi] AB - BACKGROUND AND OBJECTIVE: Trimodal therapy (TMT) provided significant survival advantage relative to external beam radiation therapy (EBRT) alone in prospective trials. However, the magnitude of survival benefit has not been validated in population-based studies. The objective of this study is to determine whether TMT is associated with lower cancer-specific mortality (CSM) rates relative to EBRT. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4aN0M0 urothelial carcinoma of urinary bladder (UCUB) treated with either TMT or EBRT. Cumulative incidence plots and multivariable competing risk regression (CRR) models addressed CSM after additional adjustment for other-cause mortality and standard covariates. The same methodology was repeated according to stage and age categories. KEY FINDINGS AND LIMITATIONS: Of 4471 patients, 3391 (76%) underwent TMT versus 1080 (24%) EBRT. TMT rates increased over time in the overall cohort (estimated annual percent change [EAPC]: 1.8%, p < 0.001) as well as in organ-confined (OC) stage (EAPC: 1.7%, p < 0.001), but not in non-organ-confined (NOC) stage (p = 0.051). In the overall cohort, 5-yr CSM rates were 43.6% in TMT versus 52.7% in EBRT. In multivariable CRR models, TMT was an independent predictor of lower CSM (hazard ratio [HR]: 0.76, p < 0.001). In OC patients, 5-yr CSM rates were 42.0% in TMT versus 51.9% in EBRT (p < 0.001). In multivariable CRR models, TMT was an independent predictor of lower CSM (HR: 0.74, p < 0.001). Conversely, in NOC patients, TMT did not achieve independent predictor status (p = 0.3). CONCLUSIONS AND CLINICAL IMPLICATIONS: In this population-based study, relative to EBRT, TMT is associated with lower CSM in OC stage, but not in NOC UCUB patients. PATIENT SUMMARY: In this report, we investigated the survival benefit of administering systemic chemotherapy in addition to radiotherapy in patients who are candidates for bladder-sparing strategies. We found that the combination of systemic chemotherapy and radiotherapy leads to improved cancer-specific survival compared with radiotherapy alone in patients with organ-confined urothelial carcinoma. We conclude that among patients who are candidates for bladder-sparing strategies, following transurethral resection, the combination of radiotherapy and chemotherapy (namely, trimodal therapy) should always be offered in those with organ-confined urothelial carcinoma. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - de Angelis, Mario AU - de Angelis M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: deangelis.mario@hsr.it. FAU - Siech, Carolin AU - Siech C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Di Bello, Francesco AU - Di Bello F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Rodriguez Penaranda, Natali AU - Rodriguez Penaranda N AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Longo, Nicola AU - Longo N AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Puliatti, Stefano AU - Puliatti S AD - Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Stabile, Armando AU - Stabile A AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Comparative Study PT - Journal Article DEP - 20241004 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/therapy/pathology MH - Male MH - Female MH - Aged MH - *Carcinoma, Transitional Cell/mortality/therapy/pathology MH - Middle Aged MH - Survival Rate MH - Combined Modality Therapy MH - SEER Program OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific mortality OT - Muscle-invasive bladder cancer OT - Non-organ confined OT - Organ confined OT - Radiotherapy OT - Trimodal therapy OT - Urothelial carcinoma EDAT- 2024/10/06 07:18 MHDA- 2025/10/12 00:33 CRDT- 2024/10/04 21:56 PHST- 2024/06/29 00:00 [received] PHST- 2024/08/12 00:00 [revised] PHST- 2024/09/17 00:00 [accepted] PHST- 2025/10/12 00:33 [medline] PHST- 2024/10/06 07:18 [pubmed] PHST- 2024/10/04 21:56 [entrez] AID - S2405-4569(24)00180-9 [pii] AID - 10.1016/j.euf.2024.09.013 [doi] PST - ppublish SO - Eur Urol Focus. 2025 Mar;11(2):251-257. doi: 10.1016/j.euf.2024.09.013. Epub 2024 Oct 4. PMID- 39353825 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260307 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 87 IP - 2 DP - 2025 Feb TI - FGFR Inhibition in Urothelial Carcinoma. PG - 110-122 LID - S0302-2838(24)02605-8 [pii] LID - 10.1016/j.eururo.2024.09.012 [doi] AB - BACKGROUND AND OBJECTIVE: The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of bladder cancer, and the challenges that remain. METHODS: Original articles relevant to FGFR inhibitors in urothelial cancer between 1995 and 2024 were systematically identified in the PubMed and MEDLINE databases using the search terms "FGFR" and "bladder cancer". An international expert panel with extensive experience in FGFR inhibitor treatment was convened to synthesize a collaborative narrative review. KEY FINDINGS AND LIMITATIONS: Somatic FGFR3 alterations are found in up to 70% of low-grade non-muscle-invasive bladder cancers; these activate downstream signaling cascades and culminate in cellular proliferation. Beyond a link to lower-grade/lower-stage tumors, there is little consistency regarding whether these alterations confer prognostic risks for cancer recurrence or progression. FGFR3-altered tumors have been linked to a non-inflamed tumor microenvironment, but paradoxically do not seem to impact the response to systemic immunotherapy. Several pan-FGFR inhibitors have been investigated in mUC. With the introduction of novel intravesical drug delivery systems, FGFR inhibitors are poised to transform the therapeutic landscape for early-stage UC. CONCLUSIONS AND CLINICAL IMPLICATIONS: With deepening understanding of the biology of bladder cancer, novel diagnostics, and improved drug delivery methods, we posit that FGFR inhibition will lead the way in advancing precision treatment of bladder cancer. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: roger.li@moffitt.org. FAU - Linscott, Joshua AU - Linscott J AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Catto, James W F AU - Catto JWF AD - Department of Urology, University of Sheffield, Sheffield, UK. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, Keck School of Medicine of USC, Los Angeles, CA, USA. FAU - Faltas, Bishoy M AU - Faltas BM AD - Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology and Biochemistry, Northwestern University, Chicago, IL, USA. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Ross, Jeffrey S AU - Ross JS AD - Department of Pathology, State University of New York Upstate Medical University, Syracuse, NY, USA; Office of the CEO, Foundation Medicine, Boston, MA, USA. FAU - van der Heijden, Michiel S AU - van der Heijden MS AD - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Loriot, Yohann AU - Loriot Y AD - Departement de Medecine Oncologique, Institut Gustave Roussy, Universite Paris-Saclay, Villejuif, France. LA - eng GR - I01 BX005599/BX/BLRD VA/United States GR - R01 CA298333/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20240930 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - 890E37NHMV (erdafitinib) RN - 0 (Receptors, Fibroblast Growth Factor) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Antineoplastic Agents) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - *Carcinoma, Transitional Cell/drug therapy/genetics/pathology MH - *Receptor, Fibroblast Growth Factor, Type 3/antagonists & inhibitors/genetics MH - *Receptors, Fibroblast Growth Factor/antagonists & inhibitors MH - *Protein Kinase Inhibitors/therapeutic use MH - *Antineoplastic Agents/therapeutic use MH - Pyrazoles MH - Quinoxalines OTO - NOTNLM OT - FGFR inhibitor OT - Immunotherapy OT - Precision oncology OT - Urothelial cancer EDAT- 2024/10/03 03:38 MHDA- 2025/01/26 02:10 CRDT- 2024/10/01 21:54 PHST- 2024/03/30 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/09/09 00:00 [accepted] PHST- 2025/01/26 02:10 [medline] PHST- 2024/10/03 03:38 [pubmed] PHST- 2024/10/01 21:54 [entrez] AID - S0302-2838(24)02605-8 [pii] AID - 10.1016/j.eururo.2024.09.012 [doi] PST - ppublish SO - Eur Urol. 2025 Feb;87(2):110-122. doi: 10.1016/j.eururo.2024.09.012. Epub 2024 Sep 30. PMID- 39351147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241003 IS - 2296-634X (Print) IS - 2296-634X (Electronic) IS - 2296-634X (Linking) VI - 12 DP - 2024 TI - Integrating oxidative-stress biomarkers into a precision oncology risk-stratification model for bladder cancer prognosis and therapy. PG - 1453448 LID - 10.3389/fcell.2024.1453448 [doi] LID - 1453448 AB - INTRODUCTION: Bladder cancer is a common malignant tumor with significant heterogeneity, making personalized risk stratification crucial for optimizing treatment and prognosis. This study aimed to develop a prognostic model based on oxidative stress-related genes to guide risk assessment in bladder cancer. METHODS: Differentially expressed oxidative stress-related genes were identified using the GEO database. Functional enrichment and survival analyses were performed on these genes. A risk-scoring model was built and tested for prognostic value and therapeutic response prediction. Expression of key genes was validated by qRT-PCR in samples from two muscle-invasive and two non-muscle-invasive bladder cancer patients. RESULTS: Several oxidative stress-related genes were identified as significantly associated with survival. The risk-scoring model stratified patients into high- and low-risk groups, accurately predicting prognosis and therapeutic responses. qRT-PCR confirmed the differential expression of key genes in patient samples. DISCUSSION: The study provides a concise risk stratification model based on oxidative stress-related genes, offering a practical tool for improving personalized treatment in bladder cancer. Further validation is required for broader clinical application. CI - Copyright (c) 2024 Huang, Zhou, Luo, Liu, Zheng and Wang. FAU - Huang, Jianxu AU - Huang J AD - Shantou University Medical College, Shantou University, Shantou, China. AD - Department of Experiment & Research, South China Hospital, Medical School, Shenzhen University, Shenzhen, China. FAU - Zhou, Dewang AU - Zhou D AD - Department of Experiment & Research, South China Hospital, Medical School, Shenzhen University, Shenzhen, China. AD - Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China. FAU - Luo, Weihan AU - Luo W AD - Shantou University Medical College, Shantou University, Shantou, China. FAU - Liu, Yujun AU - Liu Y AD - Medical School, Anhui University of Science and Technology, Huainan, China. FAU - Zheng, Haoxiang AU - Zheng H AD - Department of Experiment & Research, South China Hospital, Medical School, Shenzhen University, Shenzhen, China. FAU - Wang, Yongqiang AU - Wang Y AD - Department of Experiment & Research, South China Hospital, Medical School, Shenzhen University, Shenzhen, China. LA - eng PT - Journal Article DEP - 20240916 PL - Switzerland TA - Front Cell Dev Biol JT - Frontiers in cell and developmental biology JID - 101630250 PMC - PMC11439827 OTO - NOTNLM OT - bladder cancer OT - oxidative stress OT - prognostic model OT - risk stratification OT - treatment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/10/01 06:55 MHDA- 2024/10/01 06:56 PMCR- 2024/01/01 CRDT- 2024/10/01 04:20 PHST- 2024/06/23 00:00 [received] PHST- 2024/08/28 00:00 [accepted] PHST- 2024/10/01 06:56 [medline] PHST- 2024/10/01 06:55 [pubmed] PHST- 2024/10/01 04:20 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 1453448 [pii] AID - 10.3389/fcell.2024.1453448 [doi] PST - epublish SO - Front Cell Dev Biol. 2024 Sep 16;12:1453448. doi: 10.3389/fcell.2024.1453448. eCollection 2024. PMID- 39342596 OWN - NLM STAT- MEDLINE DCOM- 20240929 LR - 20250107 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 25 IP - 9 DP - 2024 Sep 1 TI - Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study. PG - 3173-3177 LID - 91309 [pii] LID - 10.31557/APJCP.2024.25.9.3173 [doi] AB - Backgroundsː The objective of this study was to assess the efficacy of gemcitabine as a treatment option for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) who had previously experienced failure with Bacillus Calmette-Guerin (BCG) therapy in the last year. METHODS: We prospectively enrolled 28 patients with recurrent NMIBC after previous intravesical treatment in the last year who declined or were unsuitable for cystectomy between 2021 and 2023. Gemcitabine at 2,000 mg/100 mL was instilled weekly for 6 weeks. Patients were assessed for response after 8 weeks, with subsequent evaluations scheduled every three months to one year. RESULTS: The findings demonstrated that out of the 28 patients, 20 (71.4%) exhibited a complete response to intravesical gemcitabine treatment, and 8 (28.6%) had no complete response. The average age of the participants was 60.25 years. The study identified significant differences in treatment response based on age but without significant differences based on gender. Furthermore, there was no noteworthy association between tumor stage and grade and treatment response. Moreover, among patients with low-grade tumors, 66.7% achieved a complete response, while 72.7% reached a complete response among those with high-grade tumors. Of the patients who reached a complete response, 28.6% experienced no recurrence during one year of follow-up, and 42.9% developed recurrent disease within one year of treatment initiation. Ten months following treatment, a patient developed muscle-invasive bladder cancer and went on to cystectomy. CONCLUSION: In conclusion, the results suggest that intravesical gemcitabine could represent a feasible choice for NMIBC patients unresponsive to BCG therapy and ineligible for or unwilling to undergo cystectomy. FAU - Mirzaee, Elahe AU - Mirzaee E AD - Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Novin, Kambiz AU - Novin K AD - Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Fadavi, Pedram AU - Fadavi P AUID- ORCID: 0000-0001-7491-2561 AD - Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Soltani, Sepideh AU - Soltani S AUID- ORCID: 0009-0000-7334-0370 AD - Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Kafash Nayeri, Reza AU - Kafash Nayeri R AD - Department of Urology and Urological Oncology, Iran University of Medical Sciences, Tehran, Iran. FAU - Amanollahi, Alireza AU - Amanollahi A AD - Trauma and injury Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Arefpour, Amir Mohammad AU - Arefpour AM AD - Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.. LA - eng PT - Journal Article DEP - 20240901 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - Male MH - Female MH - Middle Aged MH - Prospective Studies MH - Administration, Intravesical MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Aged MH - *Antimetabolites, Antineoplastic/therapeutic use/administration & dosage MH - Neoplasm Recurrence, Local/drug therapy/pathology MH - Follow-Up Studies MH - Treatment Failure MH - Adjuvants, Immunologic/administration & dosage MH - Neoplasm Invasiveness MH - Prognosis MH - Adult MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11700316 OTO - NOTNLM OT - BCG OT - Cystectomy OT - Gemcitabine OT - NMIBC COIS- The authors report no conflicts of interest. EDAT- 2024/09/29 18:59 MHDA- 2024/09/29 19:00 PMCR- 2024/03/01 CRDT- 2024/09/29 12:13 PHST- 2024/04/18 00:00 [received] PHST- 2024/09/29 19:00 [medline] PHST- 2024/09/29 18:59 [pubmed] PHST- 2024/09/29 12:13 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - 91309 [pii] AID - 10.31557/APJCP.2024.25.9.3173 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3173-3177. doi: 10.31557/APJCP.2024.25.9.3173. PMID- 39342212 OWN - NLM STAT- MEDLINE DCOM- 20240929 LR - 20241001 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 24 IP - 1 DP - 2024 Sep 28 TI - Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value. PG - 210 LID - 10.1186/s12894-024-01592-8 [doi] LID - 210 AB - BACKGROUND: Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. METHODS: Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. RESULTS: The mean serum fibronectin level in the patient group was 76.794 +/- 66.998ng/ml. Simultaneously, it was 50.486 +/- 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 +/- 86.1 ng/ml, while it was 44.7 +/- 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. CONCLUSIONS: The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited. CI - (c) 2024. The Author(s). FAU - Nebioglu, Ali AU - Nebioglu A AUID- ORCID: 0000-0001-6325-1534 AD - Department of Urology, Mersin City Training and Research Hospital, Korukent Mah. 96015 St. Mersin Integrated Health Campus, Toroslar, Mersin, 33240, Turkey. alinebioglu90@gmail.com. FAU - Tanriverdi, Rojda AU - Tanriverdi R AUID- ORCID: 0000-0002-7004-790X AD - Department of Medical Biochemistry, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Basaranoglu, Mert AU - Basaranoglu M AUID- ORCID: 0000-0002-9873-4920 AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Saylam, Baris AU - Saylam B AUID- ORCID: 0000-0003-3256-8752 AD - Department of Urology, Mersin City Training and Research Hospital, Korukent Mah. 96015 St. Mersin Integrated Health Campus, Toroslar, Mersin, 33240, Turkey. FAU - Ulusoy, Ercument AU - Ulusoy E AUID- ORCID: 0000-0002-9385-128X AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Bozlu, Murat AU - Bozlu M AUID- ORCID: 0000-0002-8624-0149 AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Akbay, Erdem AU - Akbay E AUID- ORCID: 0000-0001-7669-414X AD - Department of Urology, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Tamer, Lulufer AU - Tamer L AUID- ORCID: 0000-0002-0997-0260 AD - Department of Medical Biochemistry, Mersin University Faculty of Medicine, Mersin, Turkey. FAU - Erdogan, Semra AU - Erdogan S AUID- ORCID: 0000-0003-2935-0760 AD - Department of Biostatistics and Medical Informatics, Mersin University Faculty of Medicine, Mersin, Turkey. LA - eng GR - BAP 2022-1-TP3-4563./Mersin University Scientific Research Projects Unit/ PT - Journal Article DEP - 20240928 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Fibronectins) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/drug therapy/genetics MH - *Fibronectins/blood MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - Administration, Intravesical MH - Middle Aged MH - Aged MH - Prognosis MH - *Neoplasm Invasiveness MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Polymorphism, Genetic MH - Prospective Studies MH - Neoplasm Recurrence, Local/blood MH - Biomarkers, Tumor/blood MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11438143 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Fibronectin OT - Gene Polymorphism COIS- The authors declare no competing interests. EDAT- 2024/09/29 00:43 MHDA- 2024/09/29 10:18 PMCR- 2024/09/28 CRDT- 2024/09/28 23:39 PHST- 2024/06/13 00:00 [received] PHST- 2024/09/12 00:00 [accepted] PHST- 2024/09/29 10:18 [medline] PHST- 2024/09/29 00:43 [pubmed] PHST- 2024/09/28 23:39 [entrez] PHST- 2024/09/28 00:00 [pmc-release] AID - 10.1186/s12894-024-01592-8 [pii] AID - 1592 [pii] AID - 10.1186/s12894-024-01592-8 [doi] PST - epublish SO - BMC Urol. 2024 Sep 28;24(1):210. doi: 10.1186/s12894-024-01592-8. PMID- 39341566 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20260417 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 48 IP - 10 DP - 2024 Dec TI - Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. PG - 718-731 LID - S2173-5786(24)00109-4 [pii] LID - 10.1016/j.acuroe.2024.09.005 [doi] AB - Patients with non-muscle-invasive bladder cancer (NMIBC) in the intermediate and high-risk groups must receive adjuvant treatment with intravesical Bacillus Calmette-Guerin (BCG) following transurethral resection (TUR), as it reduces the risk of recurrence and presumably the risk of progression as well. Optimization of BCG efficacy is achieved by administering maintenance therapy. However, since many immunological aspects of the mechanism of action of BCG in the bladder remain unknown, the implementation of the optimal dose, number of instillations, strains and adequate maintenance regimen over the last decades has been heterogeneous. Additionally, this has hindered the interpretation of efficacy in terms of oncologic outcomes. This, together with the shortages of BCG in recent years, have forced scientific societies to adapt their clinical practice guidelines and modify their protocols of adjuvant treatment with BCG. This includes changes to strains, doses, and maintenance during this period of time. This consensus document evaluates the current status of adjuvant BCG treatment and the implications of BCG supply availability in the treatment of patients with NMIBC. It also addresses the implementation of novel therapies that will improve cancer prognosis and the quality of life of patients with NMIBC in the future. CI - Copyright (c) 2024 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Rodriguez Faba, O AU - Rodriguez Faba O AD - Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: orodriguez@fundacio-puigvert.es. FAU - Fernandez Gomez, J M AU - Fernandez Gomez JM AD - Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain. FAU - Guerrero-Ramos, F AU - Guerrero-Ramos F AD - Hospital Universitario 12 de Octubre, Madrid, ROC Clinic y Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Alvarez-Maestro, M AU - Alvarez-Maestro M AD - Hospital Universitario La Paz - IdiPAZ, Madrid, Spain. FAU - Ledo Cepero, M J AU - Ledo Cepero MJ AD - Hospital Universitario Puerta del Mar, Cadiz, Spain. FAU - Unda Urzaiz, M AU - Unda Urzaiz M AD - Laboratorio Mixto de Investigacion Traslacional en Cancer de Prostata, CICbioGUNE-Basurto, IIS Biobizkaia, Spain. FAU - Martinez-Pineiro, L AU - Martinez-Pineiro L AD - Hospital Universitario La Paz - IdiPAZ, Madrid, Spain. FAU - Cozar Olmo, J M AU - Cozar Olmo JM AD - Servicio de Urologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Redorta, J Palou AU - Redorta JP AD - Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Alvarez-Ossorio, J L AU - Alvarez-Ossorio JL AD - Hospital Universitario Puerta del del Mar, Cadiz, Spain. LA - eng LA - spa PT - Consensus Statement PT - Journal Article DEP - 20240926 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/therapy/drug therapy/pathology OTO - NOTNLM OT - BCG OT - BCG shortage OT - BCG supply standardization OT - Desabastecimiento BCG OT - Non-muscle-invasive bladder cancer OT - Normalizacion BCG OT - Tumor vesical no-musculo invasor EDAT- 2024/09/29 00:43 MHDA- 2024/12/04 00:23 CRDT- 2024/09/28 19:21 PHST- 2024/05/30 00:00 [received] PHST- 2024/06/19 00:00 [revised] PHST- 2024/06/20 00:00 [accepted] PHST- 2024/12/04 00:23 [medline] PHST- 2024/09/29 00:43 [pubmed] PHST- 2024/09/28 19:21 [entrez] AID - S2173-5786(24)00109-4 [pii] AID - 10.1016/j.acuroe.2024.09.005 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2024 Dec;48(10):718-731. doi: 10.1016/j.acuroe.2024.09.005. Epub 2024 Sep 26. PMID- 39336970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 18 DP - 2024 Sep 15 TI - The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/jcm13185483 [doi] LID - 5483 AB - Background: Glutathione, along with its related enzymes, constitutes a key antioxidant defense mechanism against oxidative stress and cancer formation in the body. Among urological malignancies, bladder cancer ranks second following prostate cancer. Oxidative stress has significant involvement in the development and prognosis of bladder cancer. This investigation aimed to examine the impact of glutathione on prognosis in patients with non-muscle-invasive bladder cancer. Methods: This study included 98 patients with high grade non-muscle-invasive bladder cancer who had undergone intravesical Bacillus Calmette-Guerin therapy and 30 healthy controls with no history of uroepithelial carcinoma of the bladder. The patients with bladder cancer were evaluated in three subgroups. Group 1 consisted of 41 patients who did not experience recurrence during follow-up, Group 2 included 28 patients who had recurrent tumors, and Group 3 consisted of 29 patients who progressed to muscle-invasive stages. Blood samples were collected from all participants. Blood levels of reduced, oxidized, and total glutathione were measured spectrophotometrically. Results: Reduced glutathione levels significantly differed among the groups (p < 0.001), attributed to the control group exhibiting higher reduced glutathione levels compared with Groups 1, 2, and 3 (p < 0.001). There were no significant differences in reduced glutathione levels between Groups 1 and 2, Groups 1 and 3, or Groups 2 and 3 (p > 0.05). Total glutathione levels varied significantly among the groups (p < 0.001), with the control group having higher levels than Groups 1, 2, and 3 (p < 0.001). No significant differences were detected between any of the paired patient groups in terms of total glutathione levels (p > 0.05). Regarding oxidized glutathione levels, the difference was statistically significant (p < 0.001), with the control group showing lower levels than the remaining three groups (p < 0.001). Paired comparisons revealed no significant differences in oxidized glutathione levels (p > 0.05). Conclusions: This study revealed that glutathione had an effect on the emergence of bladder cancer but did not affect its prognosis. Nevertheless, we recommend that future studies with larger bladder cancer patient cohorts should be conducted to comprehensively determine the impact of glutathione on the prognosis of this cancer. FAU - Gok, Gamze AU - Gok G AUID- ORCID: 0000-0002-2804-5548 AD - Department of Biochemistry, Ankara Bilkent City Hospital, Ankara 06800, Turkey. FAU - Kucuk, Tarik AU - Kucuk T AUID- ORCID: 0000-0001-7886-5694 AD - Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara 06110, Turkey. AD - Department of Urology, Etlik City Hospital, Ankara 06010, Turkey. FAU - Cimen, Sertac AU - Cimen S AD - Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara 06110, Turkey. AD - Department of Urology, Etlik City Hospital, Ankara 06010, Turkey. FAU - Gok, Alper AU - Gok A AD - Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara 06110, Turkey. AD - Department of Urology, Etlik City Hospital, Ankara 06010, Turkey. FAU - Goktug, Goksel AU - Goktug G AD - Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara 06110, Turkey. AD - Department of Urology, Etlik City Hospital, Ankara 06010, Turkey. FAU - Erel, Ozcan AU - Erel O AUID- ORCID: 0000-0002-2996-3236 AD - Department of Biochemistry, Ankara Bilkent City Hospital, Ankara 06800, Turkey. FAU - Imamoglu, Muhammet Abdurrahim AU - Imamoglu MA AD - Department of Urology, Diskapi Yildirim Beyazit Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara 06110, Turkey. AD - Department of Urology, Etlik City Hospital, Ankara 06010, Turkey. LA - eng PT - Journal Article DEP - 20240915 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11432633 OTO - NOTNLM OT - bladder cancer OT - glutathione OT - oxidants/antioxidants OT - oxidative stress COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:43 MHDA- 2024/09/28 22:44 PMCR- 2024/09/15 CRDT- 2024/09/28 01:14 PHST- 2024/07/22 00:00 [received] PHST- 2024/09/07 00:00 [revised] PHST- 2024/09/14 00:00 [accepted] PHST- 2024/09/28 22:44 [medline] PHST- 2024/09/28 22:43 [pubmed] PHST- 2024/09/28 01:14 [entrez] PHST- 2024/09/15 00:00 [pmc-release] AID - jcm13185483 [pii] AID - jcm-13-05483 [pii] AID - 10.3390/jcm13185483 [doi] PST - epublish SO - J Clin Med. 2024 Sep 15;13(18):5483. doi: 10.3390/jcm13185483. PMID- 39331198 OWN - NLM STAT- MEDLINE DCOM- 20240927 LR - 20250103 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Sep 27 TI - Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. PG - 547 LID - 10.1007/s00345-024-05218-4 [doi] LID - 547 AB - OBJECTIVE: To investigate the impact of ageing on survival outcomes in Bacillus Calmette-Guerin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment. METHOD: Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment. RESULTS: Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group. CONCLUSIONS: Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment. CI - (c) 2024. The Author(s). FAU - Liu, Kang AU - Liu K AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Nicoletti, Rossella AU - Nicoletti R AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Zhao, Hongda AU - Zhao H AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Chen, Xuan AU - Chen X AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Wu, Hongwei AU - Wu H AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Leung, Chi-Ho AU - Leung CH AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, 10024, Turin, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands. AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Wroclawski, Marcelo Langer AU - Wroclawski ML AD - Department of Urology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil. AD - Department of Urology, Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil. AD - Department of Urology, Faculdade de Medicina Do ABC, Santo Andre, Brazil. FAU - Castellani, Daniele AU - Castellani D AD - Urology Unit, Azienda Ospedaliero-Universitaria Delle Marche, Universita Politecnica Delle Marche, Ancona, Italy. FAU - Gauhar, Vineet AU - Gauhar V AD - Department of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore. FAU - Rivas, Juan Gomez AU - Rivas JG AD - Department of Urology, Clinico San Carlos University Hospital, Madrid, Spain. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Division of Urology, Rabin Medical Center, Petah Tikva, Israel. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta Della Salute E Della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - 2nd Faculty of Medicine, Hospital Motol, Department of Urology, Charles University, Prague, Czech Republic. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. AD - Research Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Ng, Chi-Fai AU - Ng CF AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. ngcf@surgery.cuhk.edu.hk. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S. H. Ho Urology Centre, Faculty of Medicine, Department of Surgery, The Chinese University of Hong Kong, 4/F LCW Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. jeremyteoh@surgery.cuhk.edu.hk. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. jeremyteoh@surgery.cuhk.edu.hk. AD - Urothelial Cancer Working Group, European Association of Urology-Young Academic Urologists (EAU-YAU), Amsterdam, Netherlands. jeremyteoh@surgery.cuhk.edu.hk. LA - eng GR - 8601521/UGC Research Matching Fund/ GR - 14117421/General Research Fund and Early Career Scheme/ PT - Journal Article DEP - 20240927 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/therapy/mortality MH - *BCG Vaccine/therapeutic use MH - Male MH - Aged MH - Female MH - Middle Aged MH - *Neoplasm Invasiveness MH - Age Factors MH - Treatment Outcome MH - Retrospective Studies MH - *Adjuvants, Immunologic/therapeutic use MH - Survival Rate MH - Aged, 80 and over MH - Administration, Intravesical MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11436433 OTO - NOTNLM OT - Age OT - Cancer OT - Free survival OT - Invasive bladder cancer OT - Muscle OT - Non OT - Overall survival OT - Progression OT - Recurrence OT - Specific survival COIS- All authors declare they have no conflicts of interest to disclose. EDAT- 2024/09/27 12:43 MHDA- 2024/09/27 12:44 PMCR- 2024/09/27 CRDT- 2024/09/27 11:17 PHST- 2024/06/27 00:00 [received] PHST- 2024/08/12 00:00 [accepted] PHST- 2024/09/27 12:44 [medline] PHST- 2024/09/27 12:43 [pubmed] PHST- 2024/09/27 11:17 [entrez] PHST- 2024/09/27 00:00 [pmc-release] AID - 10.1007/s00345-024-05218-4 [pii] AID - 5218 [pii] AID - 10.1007/s00345-024-05218-4 [doi] PST - epublish SO - World J Urol. 2024 Sep 27;42(1):547. doi: 10.1007/s00345-024-05218-4. PMID- 39327188 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250515 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 8 IP - 2 DP - 2025 Apr TI - Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer - a contemporary cohort. PG - 249-252 LID - S2588-9311(24)00216-5 [pii] LID - 10.1016/j.euo.2024.09.006 [doi] AB - Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) receive bacillus Calmette-Guerin (BCG) instillations to reduce the risk of progression. For patients with very high-risk NMIBC, immediate radical cystectomy may be considered, as patients who experience disease progression despite BCG treatment have a worse prognosis. However, guideline-recommended stratification for the risk of progression is based on data from patients who were not exposed to BCG. We evaluated the risk of progression in a contemporary cohort of patients with primary high-grade/grade 3 (HG/G3) T1 NMIBC (n = 1268) who received at least one BCG instillation and underwent at least one cystoscopic evaluation. The primary endpoint was the 1-yr risk of progression for all patients and for the subgroup that received adequate BCG, defined as at least five induction instillations and at least two instillations provided as a second BCG course within 6 mo. Progression was defined as detrusor muscle invasion or lymph node or distant metastasis. The 1-yr risk of progression was 6.5% (95% confidence interval [CI] 5.2-8.0) for patients with primary HG/G3 T1 NMIBC who started BCG treatment, and 4.6% (95% CI 3.3-6.4) 1 yr after the first instillation of the second BCG course for patients who received adequate BCG (n = 746). In conclusion, the contemporary risk of progression for patients with HG/G3 T1 NMIBC who receive BCG appears to be low, especially for patients who receive adequate BCG treatment. PATIENT SUMMARY: Our study shows that for patients with a high-grade bladder tumor who received in-bladder BCG (bacillus Calmette-Guerin), the risk of disease progression was 6.5% at 1 yr after their first BCG instillation. For patients who continued with BCG maintenance treatments, the risk of progression was 4.6% after the first BCG maintenance instillation. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Pijpers, Olga M AU - Pijpers OM AD - Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - van Hoogstraten, Lisa M C AU - van Hoogstraten LMC AD - Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Remmers, Sebastiaan AU - Remmers S AD - Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Beijert, Irene J AU - Beijert IJ AD - Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. FAU - Alfred Witjes, J AU - Alfred Witjes J AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: j.boormans@erasmusmc.nl. LA - eng PT - Journal Article DEP - 20240925 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Disease Progression MH - Male MH - Female MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Aged MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Grading MH - Administration, Intravesical MH - Cohort Studies MH - Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Aged, 80 and over MH - Risk Factors MH - Cystectomy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Progression OT - Urothelial cancer EDAT- 2024/09/27 00:42 MHDA- 2025/03/23 16:51 CRDT- 2024/09/26 21:54 PHST- 2024/07/22 00:00 [received] PHST- 2024/08/30 00:00 [revised] PHST- 2024/09/11 00:00 [accepted] PHST- 2025/03/23 16:51 [medline] PHST- 2024/09/27 00:42 [pubmed] PHST- 2024/09/26 21:54 [entrez] AID - S2588-9311(24)00216-5 [pii] AID - 10.1016/j.euo.2024.09.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2025 Apr;8(2):249-252. doi: 10.1016/j.euo.2024.09.006. Epub 2024 Sep 25. PMID- 39324506 OWN - NLM STAT- MEDLINE DCOM- 20250120 LR - 20250604 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 135 IP - 2 DP - 2025 Feb TI - Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. PG - 329-338 LID - 10.1111/bju.16516 [doi] AB - OBJECTIVE: To report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guerin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible. METHODS: We detail consecutive participants screened for the BRAVO randomised controlled trial comparing RC with BCG (International Standard Randomised Controlled Trial Number [ISRCTN]12509361). Patients were prospectively registered and case-note review used for outcomes. The primary outcome was overall survival. Secondary outcomes included recurrence, progression, metastasis, and bladder cancer-specific survival. RESULTS AND LIMITATIONS: A total of 193 patients were screened, including 106 (54.9%) who received BCG, 43 (22.3%) primary RC, 37 (19.2%) 'other' treatment and seven (3.6%) hyperthermic intravesical mitomycin C. All-cause death occurred in 55 (28.5%) patients at median (interquartile range [IQR]) of 29.0 (19.5-42.0) months. In multivariable analysis, overall mortality was more common in older patients (hazard ratio [HR] 2.63, 95% confidence interval [CI] 1.35-5.13; Cox P = 0.004 for age >70 years), those recruited from district hospitals (HR 0.53, 95% CI 0.3-0.95; P = 0.032) and those who did not undergo RC as their first treatment (HR 2.16, 95% CI 1.17-3.99; P = 0.014). In all, 17 (8.8%) patients died from bladder cancer (BC) at median (IQR) of 22.5 (19-36.25) months. In multivariable analysis, BC-specific mortality was more common in older patients (HR 4.87, 95% CI 1.1-21.6; P = 0.037) and those with Tis/T1 disease (HR 2.26, 95% CI 1.23-4.16; P = 0.008) but did not vary with initial treatment. CONCLUSIONS: Patients with HRNMIBC are at high-risk of mortality. Those choosing RC as their initial treatment have lower risks of mortality than others, although this may reflect fitness and selection. CI - (c) 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Conroy, Samantha AU - Conroy S AUID- ORCID: 0000-0001-7167-4908 AD - Division of Clinical Medicine, University of Sheffield, Sheffield, UK. AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Jubber, Ibrahim AU - Jubber I AD - Division of Clinical Medicine, University of Sheffield, Sheffield, UK. AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Noon, Aidan P AU - Noon AP AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Rosario, Derek J AU - Rosario DJ AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Griffin, Jon AU - Griffin J AUID- ORCID: 0000-0003-3969-7637 AD - Division of Clinical Medicine, University of Sheffield, Sheffield, UK. AD - Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Morgan, Susan AU - Morgan S AD - Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Hubbard, Rachel AU - Hubbard R AD - Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Kennish, Steve AU - Kennish S AD - Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Mitchell, Stephen AU - Mitchell S AD - Department of Urology, Wycombe Hospital, Buckinghamshire Healthcare NHS Trust, High Wycombe, UK. FAU - Venugopal, Suresh AU - Venugopal S AD - Department of Urology, The Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK. FAU - Linton, Kate AU - Linton K AD - Department of Urology, Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, UK. FAU - Rajasundaram, Ramanan AU - Rajasundaram R AD - Department of Urology, Doncaster Royal Infirmary, Doncaster, UK. FAU - Hussain, Syed A AU - Hussain SA AD - Division of Clinical Medicine, University of Sheffield, Sheffield, UK. AD - Department of Oncology, Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Catto, James W F AU - Catto JWF AUID- ORCID: 0000-0003-2787-8828 AD - Division of Clinical Medicine, University of Sheffield, Sheffield, UK. AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20240926 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/therapy/pathology MH - Female MH - Male MH - Aged MH - *Cystectomy/methods MH - *BCG Vaccine/therapeutic use MH - Middle Aged MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Adjuvants, Immunologic/therapeutic use MH - Prospective Studies MH - Aged, 80 and over MH - Mitomycin/therapeutic use/administration & dosage MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11745995 OTO - NOTNLM OT - BCG OT - High-risk non-muscle-invasive bladder cancer OT - RCT OT - bladder cancer OT - feasibility study OT - radical cystectomy OT - real-world data OT - surgical trial EDAT- 2024/09/26 12:42 MHDA- 2025/01/21 09:01 PMCR- 2025/01/21 CRDT- 2024/09/26 06:53 PHST- 2025/01/21 09:01 [medline] PHST- 2024/09/26 12:42 [pubmed] PHST- 2024/09/26 06:53 [entrez] PHST- 2025/01/21 00:00 [pmc-release] AID - BJU16516 [pii] AID - 10.1111/bju.16516 [doi] PST - ppublish SO - BJU Int. 2025 Feb;135(2):329-338. doi: 10.1111/bju.16516. Epub 2024 Sep 26. PMID- 39318722 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240926 IS - 2214-7500 (Electronic) IS - 2214-7500 (Linking) VI - 13 DP - 2024 Dec TI - An overview of immune checkpoint inhibitor toxicities in bladder cancer. PG - 101732 LID - 10.1016/j.toxrep.2024.101732 [doi] LID - 101732 AB - Bladder cancer is the tenth most prevalent malignancy worldwide, with a significant mortality burden. Urothelial carcinoma (UC) is the most common histological subtype, and treatment options are guided by whether the disease is muscle-invasive (MIBC) or non-muscle-invasive (NMIBC), with subsequent risk group stratification. The growing popularity of immune checkpoint inhibitors (ICIs) to treat MIBC and NMIBC as either monotherapy or combined with intravesical agents, may radically change the treatment paradigm of UC. Current treatments for NMBIC includes intravesical chemotherapy after trans-urethral resection of the bladder tumour, intravesical bacillus Calmette-Guerin (BCG) or radical cystectomy. Cisplatin-based chemotherapy is widely regarded as the first-line treatment for metastatic UC due to its beneficial response and survival rates when compared to alternative therapies. However, up to 70 % of metastatic UC patients are ineligible, and the prognosis of these patients remains poor, with a median survival of 13-16 months. For NMIBC and MIBC, ICIs provide a promising alternative for cisplatin-ineligible patients. In UC, ICIs including atezolizumab, nivolumab, avelumab, and pembrolizumab are Food and Drug Administration (FDA)-approved for monotherapy, and have demonstrated promising results, particularly in those who cannot receive cisplatin-based chemotherapy, and as a second-line treatment option for recurrent UC following platinum-based chemotherapy. It is important to consider that some patients may experience adverse events (AEs) with limited clinical benefit. Infusion-related reactions and immune-mediated AEs (imAEs) such as colitis, endocrinopathies, hepatitis, pneumonitis, interstitial lung disease, renal dysfunction, nephritis, cutaneous and neurological toxicities must be monitored for. Currently, there is no clear consensus on the role of a 'two-year stopping rule' in reducing the risk of imAEs, with further research on the optimal treatment duration of ICIs required. With increased ICI use, vigilance regarding their side effects is imperative. This review aims to provide an updated overview of ICI toxicities in bladder cancer, to assist clinicians in their therapeutic decision-making, with consideration of patient characteristics and the clinical context. CI - (c) 2024 The Authors. FAU - Mavadia, Avenie AU - Mavadia A AD - GKT School of Medicine, King's College London, London SE1 9RT, UK. FAU - Choi, Sunyoung AU - Choi S AD - Hampshire Hospitals NHS Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK. FAU - Ismail, Ayden AU - Ismail A AD - GKT School of Medicine, King's College London, London SE1 9RT, UK. FAU - Ghose, Aruni AU - Ghose A AD - Department of Medical Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Heath NHS Trust, London EC1A 7BE, UK. AD - Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire Trust, London HA6 2RN, UK. AD - Health Systems and Treatment Optimisation Network, European Cancer Organisation, Brussels 1040, Belgium. AD - Immuno-Oncology Clinical Network, Liverpool, UK. AD - Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK. FAU - Tan, Joecelyn Kirani AU - Tan JK AD - School of Medicine, University of St. Andrews, North Haugh, Fife, Scotland KY16 9TF, UK. AD - St Andrews Oncology Society, St Mary's Place, Scotland KY16 9UZ, UK. FAU - Papadopoulos, Vasileios AU - Papadopoulos V AD - Kent and Canterbury Hospital, Ethelbert Road, Canterbury CT1 3NG, UK. FAU - Sanchez, Elisabet AU - Sanchez E AD - Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK. FAU - Boussios, Stergios AU - Boussios S AD - Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK. AD - Faculty of Medicine, Health, and Social Care, Canterbury Christ Church University, Canterbury CT2 7PB, UK. AD - King's College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, London SE1 9RT, UK. AD - Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, UK. AD - AELIA Organization, 9th Km Thessaloniki - Thermi, Thessaloniki 57001, Greece. LA - eng PT - Journal Article PT - Review DEP - 20240911 PL - Ireland TA - Toxicol Rep JT - Toxicology reports JID - 101630272 PMC - PMC11420502 OTO - NOTNLM OT - Bladder Cancer OT - CTLA-4 OT - Immune Checkpoint Inhibitor OT - PD-1 OT - PD-L1 OT - Toxicity COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/09/25 10:18 MHDA- 2024/09/25 10:19 PMCR- 2024/09/11 CRDT- 2024/09/25 04:19 PHST- 2024/04/17 00:00 [received] PHST- 2024/07/04 00:00 [revised] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/09/25 10:19 [medline] PHST- 2024/09/25 10:18 [pubmed] PHST- 2024/09/25 04:19 [entrez] PHST- 2024/09/11 00:00 [pmc-release] AID - S2214-7500(24)00115-X [pii] AID - 101732 [pii] AID - 10.1016/j.toxrep.2024.101732 [doi] PST - epublish SO - Toxicol Rep. 2024 Sep 11;13:101732. doi: 10.1016/j.toxrep.2024.101732. eCollection 2024 Dec. PMID- 39311994 OWN - NLM STAT- MEDLINE DCOM- 20250927 LR - 20250927 IS - 1573-4927 (Electronic) IS - 0006-2928 (Linking) VI - 63 IP - 5 DP - 2025 Oct TI - Matrix Metalloproteinases -2 and -9, Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and CD105- Micro-Vessel Density are Predictive Markers of Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer Subtypes. PG - 4057-4112 LID - 10.1007/s10528-024-10921-3 [doi] AB - Matrix metalloproteinases (MMPs) are involved in extracellular matrix (ECM) remodeling during embryogenesis, wound healing and tumor development. Aberrant expressions and activation of MMP-2 and MMP-9 are examined as one of the major attributes acquired by tumor neoangiogenic markers including vascular endothelial growth factor (VEGF), basic growth factor (bFGF) and CD105-microvessel density (CD105-MVD) during bladder tumorigenesis. The present study examined the levels of MMP-2, MMP-9, VEGF, bFGF and CD105 to elucidate the relationship among them and associated clinical features in the given cohort of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients. Real time-quantitative PCR was done to examine the gene expressions of MMP-2, MMP-9, VEGF, bFGF and CD105 in 70 NMIBC and 40 MIBC patients. Western blotting and immunohistochemical staining were done to check their immunolevels followed by statistical analyses of their expressions with patients' demographic variables. Scanning electron microscopic (SEM) studies were done in representative non-muscle and muscle invasive tumor specimens to elucidate the tumor vasculature and extent of neoangiogenesis. The study reported an increase in gene expression and immunolevels of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD with tumor stage and tumor grade. Statistical studies examined the relevant associations of their expressions with tumor stage, tumor grade, tumor size, tumor type, and tobacco chewing/smoking history of patients. SEM studies revealed marked differences in the vascular architecture and their spatial distribution indicated by increase in vascular density, vascular sprout proliferation and new blood vessel formation with tumor stage and tumor grade. The discriminatory ability of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD in the diagnosis of NMIBC and MIBC was confirmed by ROC curve analysis which revealed the high sensitivity and low specificity of these markers in a given cohort of patients. Observed positive correlations of angiogenic markers with MMP-2 and MMP-9 in the given cohorts of NMIBC and MIBC patients explain their possible effects on bladder tumorigenesis via vascular angiogenesis. Cox regression (univariate and multivariate) and Kaplan-Meier along with log-rank survival analysis examined the strong expressions of these markers as the predictive indicators of poor survival probability (OS, RFS, PFS, and CSS) in 52 NMIBC and 36 MIBC patients. Significant associations of expressions of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD with clinical variables emphasized their significance in diagnosis of NMIBC and MIBC patients. Survival analysis identified these markers as the independent prognosticators of poor survival of NMIBC and MIBC patients. Nevertheless, multi-center analysis is required to validate their importance in the clinical management of NMIBC and MIBC patients. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Siddhartha, Rohit AU - Siddhartha R AUID- ORCID: 0000-0002-2106-9694 AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. FAU - Goel, Apul AU - Goel A AUID- ORCID: 0000-0002-5813-3012 AD - Department of Urology, King George Medical University, Lucknow, 226003, India. FAU - Singhai, Atin AU - Singhai A AUID- ORCID: 0000-0001-8018-0723 AD - Department of Pathology, King George Medical University, Lucknow, 226003, India. FAU - Garg, Minal AU - Garg M AUID- ORCID: 0000-0002-4069-8138 AD - Department of Biochemistry, & Director, Institute of Advanced Molecular Genetics and Infectious Diseases, OCAS, University of Lucknow, Lucknow, 226007, India. garg_minal@lkouniv.ac.in. LA - eng GR - 5/3/8/24/2020-ITR/Indian Council of Medical Research (ICMR), Govt. of India/ PT - Journal Article DEP - 20240923 PL - United States TA - Biochem Genet JT - Biochemical genetics JID - 0126611 RN - 0 (Endoglin) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (Biomarkers, Tumor) RN - 0 (ENG protein, human) RN - 0 (VEGFA protein, human) RN - EC 3.4.24.35 (MMP9 protein, human) RN - EC 3.4.24.24 (MMP2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/genetics/blood supply MH - Male MH - Endoglin/metabolism MH - Female MH - *Matrix Metalloproteinase 9/genetics/metabolism MH - *Fibroblast Growth Factor 2/metabolism/genetics MH - *Matrix Metalloproteinase 2/genetics/metabolism MH - *Vascular Endothelial Growth Factor A/metabolism/genetics MH - Middle Aged MH - *Biomarkers, Tumor/metabolism/genetics MH - Aged MH - Neoplasm Invasiveness MH - Neovascularization, Pathologic/metabolism/pathology MH - Microvascular Density MH - Adult MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Angiogenesis OT - Basic fibroblast growth factor OT - Matrix metalloproteinases OT - Microvessel density OT - NMIBC and MIBC patients OT - Vascular endothelial growth factor COIS- Declarations. Competing interest: The authors declare no competing interests. Ethical Approval: Studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Ethical clearance was obtained from the institutional bioethical cell (Institutional Ethical Committee Ref no.115thECM IIA/P3) at KGMU, Lucknow. Consent to Participate: Analysis used anonymous data that were obtained after each patient agreed to participate in the study. A written informed consent was taken from each patient or their immediate family member. EDAT- 2024/09/23 12:49 MHDA- 2025/09/27 12:33 CRDT- 2024/09/23 11:16 PHST- 2024/06/02 00:00 [received] PHST- 2024/09/15 00:00 [accepted] PHST- 2025/09/27 12:33 [medline] PHST- 2024/09/23 12:49 [pubmed] PHST- 2024/09/23 11:16 [entrez] AID - 10.1007/s10528-024-10921-3 [pii] AID - 10.1007/s10528-024-10921-3 [doi] PST - ppublish SO - Biochem Genet. 2025 Oct;63(5):4057-4112. doi: 10.1007/s10528-024-10921-3. Epub 2024 Sep 23. PMID- 39308592 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240924 IS - 2330-1910 (Print) IS - 2330-1910 (Electronic) IS - 2330-1910 (Linking) VI - 12 IP - 4 DP - 2024 TI - Identification of ECM and EMT relevant genes involved in the progression of bladder cancer through bioinformatics analysis. PG - 183-193 LID - 10.62347/XNTC7030 [doi] AB - BACKGROUND: Bladder cancer (BC) is very common among cancers of urinary system. It was usually categorized into two types: non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). NMIBC and MIBC groupings are heterogeneous and have different characteristics. OBJECTIVES: The study was aimed to find some hub genes and related signal pathways which might be engaged in the progression of BC and to investigate the relationship with clinical stages and its prognostic significance. METHODS: GSE37317 datasets were acquired from Gene Expression Omnibus (GEO) database. GEO2R on-line tool was selected to screen the differentially expressed genes (DEGs) of the two different types of BC. Then, Gene Ontology (GO) enrichment and KOBAS-Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of these DEGs were conducted. A protein-protein interaction (PPI) network was employed to help us screen hub genes and find significant modules. Finally, we made analysis of gene expression and survival curve by GEPIA and Kaplan-Meier plotter database. RESULTS: 224 DEGs were screened in total, with 110 showing increased expression and 114 demonstrating decreased expression. GO and KEGG pathway enrichment analysis showed that DEGs were mostly involved in collagen fibril organization, extracellular matrix (ECM) structural constituent, bHLH transcription factor binding, AGE-RAGE signaling pathway and TGF-beta signaling pathway. Only 3 hub genes (DCN, JUN, THBS1) displayed significantly higher expression compared to those in the healthy controls. These hub genes were also strongly related to clinical stages as well as overall survival (OS) of BC patients. CONCLUSIONS: Taken together, most of hub genes involved in the progression of BC were related to ECM and EMT. In addition, 3 hub genes (DCN, JUN, THBS1) were strongly related with clinical stages and OS of BC patients. This study can enhance our comprehension of the progression of NMIBC and identify novel potential targets for MIBC. CI - AJCEU Copyright (c) 2024. FAU - Cao, Kai AU - Cao K AD - Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing 210008, Jiangsu, China. FAU - Shi, Honglei AU - Shi H AD - Department of Urology, Wujin Hospital Affiliated with Jiangsu University Changzhou 213164, Jiangsu, China. AD - Department of Urology, The Wujin Clinical College of Xuzhou Medical University Changzhou 213164, Jiangsu, China. FAU - Wu, Bin AU - Wu B AD - Department of Urology, Wujin Hospital Affiliated with Jiangsu University Changzhou 213164, Jiangsu, China. AD - Department of Urology, The Wujin Clinical College of Xuzhou Medical University Changzhou 213164, Jiangsu, China. FAU - Lv, Zhong AU - Lv Z AD - Department of Urology, Wujin Hospital Affiliated with Jiangsu University Changzhou 213164, Jiangsu, China. AD - Department of Urology, The Wujin Clinical College of Xuzhou Medical University Changzhou 213164, Jiangsu, China. FAU - Yang, Rong AU - Yang R AD - Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing 210008, Jiangsu, China. LA - eng PT - Journal Article DEP - 20240825 PL - United States TA - Am J Clin Exp Urol JT - American journal of clinical and experimental urology JID - 101634566 PMC - PMC11411181 OTO - NOTNLM OT - Muscle invasive bladder cancer OT - bioinformatics analysis OT - clinical stages OT - differentially expressed genes OT - non-muscle invasive bladder cancer COIS- None. EDAT- 2024/09/23 11:43 MHDA- 2024/09/23 11:44 PMCR- 2024/08/25 CRDT- 2024/09/23 05:35 PHST- 2024/06/04 00:00 [received] PHST- 2024/08/16 00:00 [accepted] PHST- 2024/09/23 11:44 [medline] PHST- 2024/09/23 11:43 [pubmed] PHST- 2024/09/23 05:35 [entrez] PHST- 2024/08/25 00:00 [pmc-release] AID - 10.62347/XNTC7030 [doi] PST - epublish SO - Am J Clin Exp Urol. 2024 Aug 25;12(4):183-193. doi: 10.62347/XNTC7030. eCollection 2024. PMID- 39306526 OWN - NLM STAT- MEDLINE DCOM- 20250616 LR - 20250616 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 11 IP - 1 DP - 2025 Jan TI - Comparative Effectiveness of Bacillus Calmette-Guerin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naive Intermediate-risk Non-muscle-invasive Bladder Cancer. PG - 142-149 LID - S2405-4569(24)00173-1 [pii] LID - 10.1016/j.euf.2024.09.006 [doi] AB - BACKGROUND AND OBJECTIVE: Sequential intravesical gemcitabine/docetaxel (Gem/Doce) has emerged as a potential alternative to bacillus Calmette-Guerin (BCG) for the treatment of non-muscle-invasive bladder cancer (NMIBC). Our aim was to determine the comparative effectiveness of BCG and Gem/Doce for patients with intermediate-risk (IR) NMIBC, composed mainly of high-grade (HG) Ta disease. METHODS: Patients with IR-NMIBC who received either BCG or Gem/Doce during 2013-2023 were included. Maintenance BCG (as per the Southwest Oncology Group protocol) and monthly Gem/Doce maintenance for 1 yr were offered to patients with no evidence of recurrence after induction. Routine surveillance with cystoscopy was performed according to the American Urological Association guidelines. The Kaplan-Meier method was used to assess high-grade and any-grade recurrence-free survival (RFS). Cox regression analysis was performed to find predictors of recurrence. KEY FINDINGS AND LIMITATIONS: Of 483 patients, 127 had IR-NMIBC; 66 patients received BCG and 61 received Gem/Doce. Median age was 69 yr (interquartile range [IQR] 61-76) for the BCG group and 72 yr (IQR 62-76) for the Gem/Doce group. Median follow-up was 53.1 mo (IQR 25.3-71.2) for the BCG group and 20.2 mo (IQR 8.28-33.1) for the Gem/Doce group. The 2-yr high-grade RFS rates for primary high-grade tumors for BCG versus Gem/Doce groups were 81% versus 61%, with corresponding any-grade RFS rates of 60% versus 41%. Induction with Gem/Doce predicted any-grade recurrence (hazard ratio [HR] 1.87, 95% confidence interval [CI] 1.1-3.2) and high-grade recurrence for primary high-grade tumors (HR 3.4 95% CI 1.27-9.13), while receipt of maintenance therapy decreased the risk of any-grade recurrence (HR 0.4, 95% CI 0.22-0.72). This study is limited by its retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: For patients with IR-NMIBC, BCG was associated with superior any-grade RFS and high-grade RFS for primary high-grade tumors. Maintenance therapy was associated with better RFS when receiving Gem/Doce. Standardization and longer maintenance therapy protocols should be considered for Gem/Doce treatment. PATIENT SUMMARY: We compared outcomes for patients who received two different in-bladder treatments for intermediate-risk bladder cancer. Bacillus Calmette-Guerin (BCG) led to better outcomes than gemcitabine + docetaxel (Gem/Doce). Monthly maintenance therapy improved recurrence-free survival for patients who received Gem/Doce. We conclude that maintenance therapy is essential for patients receiving Gem/Doce to avoid bladder cancer recurrence after treatment. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Ben-David, Reuben AU - Ben-David R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Lidagoster, Sarah AU - Lidagoster S AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Almoflihi, Mohammed AU - Almoflihi M AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Tillu, Neeraja AU - Tillu N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Eraky, Ahmed AU - Eraky A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Alerasool, Parissa AU - Alerasool P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Waigankar, Nikhil AU - Waigankar N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: john.sfakianos@mountsinai.org. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240920 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Gemcitabine MH - *BCG Vaccine/administration & dosage MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Female MH - Male MH - Aged MH - Administration, Intravesical MH - *Docetaxel/administration & dosage MH - Middle Aged MH - Adjuvants, Immunologic/administration & dosage MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Treatment Outcome MH - *Antineoplastic Combined Chemotherapy Protocols/administration & dosage MH - Neoplasm Recurrence, Local MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Docetaxel OT - Gemcitabine OT - Intravesical drug administration OT - Non-muscle-invasive bladder neoplasms OT - Urinary bladder neoplasms EDAT- 2024/09/22 04:20 MHDA- 2025/06/16 11:11 CRDT- 2024/09/21 21:59 PHST- 2024/07/09 00:00 [received] PHST- 2024/08/24 00:00 [revised] PHST- 2024/09/11 00:00 [accepted] PHST- 2025/06/16 11:11 [medline] PHST- 2024/09/22 04:20 [pubmed] PHST- 2024/09/21 21:59 [entrez] AID - S2405-4569(24)00173-1 [pii] AID - 10.1016/j.euf.2024.09.006 [doi] PST - ppublish SO - Eur Urol Focus. 2025 Jan;11(1):142-149. doi: 10.1016/j.euf.2024.09.006. Epub 2024 Sep 20. PMID- 39301124 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240921 IS - 2049-9469 (Electronic) IS - 2049-9450 (Print) IS - 2049-9450 (Linking) VI - 21 IP - 5 DP - 2024 Nov TI - Impact of variant histology in the prognosis of non‑muscle invasive bladder cancer with low‑tumor burden: A propensity score‑matched analysis with conventional urothelial carcinoma. PG - 80 LID - 10.3892/mco.2024.2778 [doi] LID - 80 AB - Bladder cancer (BCa) with variant histology (VH) is associated with an increased risk of recurrence and progression, as well as worse survival. However, the available literature does not provide the prognostic value of VH based on its tumor burden in non-muscle invasive BCa (NMIBC). The purpose of the present study was to investigate the prognosis of VH in NMIBC with low-tumor volume compared with conventional urothelial carcinoma (UC) with a similar tumor burden. The present single-center study analyzed patients diagnosed with NMIBC and retrospectively characterized them based on their VH status. Propensity scores for VH status were calculated to match patients with VH with those with conventional UC (1:3). The VH group was further divided into two subgroups based on pathological aggressiveness: Aggressive and highly aggressive variants. Oncological outcomes were compared among the three groups. Among the 494 patients with NMIBC, 60 (12.1%) had VH. Patients with VH had a higher tumor stage and grade and more multiple tumors (all P<0.05). In the matched cohort, >80% had tumors <3 cm, and >65% had solitary tumors. During a median follow-up of 42.5 months (range, 4.0-122.0 months), 35.1% (85/240) experienced recurrence and 5.4% (13/240) progressed to muscle-invasive disease. Prognosis did not differ between patients with aggressive or highly aggressive variants and those with conventional UC, including 5-year recurrence-free and pathologic progression-free survival (log-rank, P=0.510 and 0.257, respectively). Intravesical Bacillus Galmette-Guerin was the only factor associated with reduced recurrence (P<0.001). In conclusion, NMIBC with low-tumor burden and VH have similar oncologic outcomes to conventional UC with a similar tumor burden, indicating that bladder-sparing methods currently used for high-risk conventional NMIBC may be effective for managing low-tumor burden NMIBC with VH. CI - Copyright: (c) 2024 Lee et al. FAU - Lee, Hyun Seok AU - Lee HS AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Min, Kweon Sik AU - Min KS AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Seo, Won Ik AU - Seo WI AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Sou, Sung Jun AU - Sou SJ AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Chung, Jae Il AU - Chung JI AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Jung, Soo Jin AU - Jung SJ AD - Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. FAU - Lee, Chan Ho AU - Lee CH AD - Department of Urology, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea. LA - eng PT - Journal Article DEP - 20240905 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC11411584 OTO - NOTNLM OT - non-muscle invasive bladder neoplasms OT - prognosis OT - progression-free survival OT - propensity score COIS- The authors declare that they have no competing interests. EDAT- 2024/09/21 13:19 MHDA- 2024/09/21 13:20 PMCR- 2024/09/05 CRDT- 2024/09/20 03:57 PHST- 2024/06/01 00:00 [received] PHST- 2024/08/08 00:00 [accepted] PHST- 2024/09/21 13:20 [medline] PHST- 2024/09/21 13:19 [pubmed] PHST- 2024/09/20 03:57 [entrez] PHST- 2024/09/05 00:00 [pmc-release] AID - MCO-21-5-02778 [pii] AID - 10.3892/mco.2024.2778 [doi] PST - epublish SO - Mol Clin Oncol. 2024 Sep 5;21(5):80. doi: 10.3892/mco.2024.2778. eCollection 2024 Nov. PMID- 39297968 OWN - NLM STAT- MEDLINE DCOM- 20240919 LR - 20250103 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Sep 19 TI - Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review. PG - 527 LID - 10.1007/s00345-024-05196-7 [doi] LID - 527 AB - PURPOSE: Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols. METHODS: A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted. RESULTS: Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14-52%; 3-16% were muscle-invasive while 11-36% were non-muscle invasive. Nodal recurrence occurred at 13-16% and distant metastases at 15-35%. After 5 and 10 years of follow-up, around 60-85% and 45-75% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (> c/pT2), presence of extensive/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar. CONCLUSION: Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation. CI - (c) 2024. The Author(s). FAU - Kaufmann, Ernest AU - Kaufmann E AD - Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. FAU - Aeppli, Stefanie AU - Aeppli S AD - Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. FAU - Arnold, Winfried AU - Arnold W AD - Department of Radiation-Oncology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Balermpas, Panagiotis AU - Balermpas P AD - Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland. FAU - Beyer, Jorg AU - Beyer J AD - Department of Oncology, Inselspital Bern, Berne, Switzerland. FAU - Bieri, Uwe AU - Bieri U AD - Department of Urology, Kantonsspital Baden, Baden, Switzerland. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Cathomas, Richard AU - Cathomas R AD - Department of Oncology, Kantonsspital Chur, Chur, Switzerland. FAU - de Bari, Berardino AU - de Bari B AD - Department of Radiation-Oncology, Reseau Hospitalier Neuchatelois, Neuchatel, Switzerland. FAU - Dressler, Marco AU - Dressler M AD - Zentrum Fur Onkologie Luzern, Lucerne, Switzerland. FAU - Engeler, Daniel S AU - Engeler DS AD - Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland. FAU - Erdmann, Andreas AU - Erdmann A AD - Department of Oncology, Kantonsspital Baden, Baden, Switzerland. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, EOC Ente Ospedaliero Cantonale, Lugano, Switzerland. FAU - Gomez, Silvia AU - Gomez S AD - Department of Radiation-Oncology, Kantonsspital Aarau, Aarau, Switzerland. FAU - Guckenberger, Matthias AU - Guckenberger M AD - Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland. FAU - Herrmann, Thomas R W AU - Herrmann TRW AUID- ORCID: 0000-0003-4493-1301 AD - Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Frauenfeld, Switzerland. AD - Division of Urology, Department of Surgical Sciences, Stellenbosch University, Western Cape, South Africa. AD - Hannover Medical School, Hannover, Germany. FAU - Hermanns, Thomas AU - Hermanns T AD - Zentrum fur Urologie Zurich, Zurich, Switzerland. FAU - Ilaria, Lucca AU - Ilaria L AD - Department of Urology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. FAU - John, Hubert AU - John H AD - Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Kessler, Thomas M AU - Kessler TM AD - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland. FAU - Klein, Jan AU - Klein J AD - Department of Urology, Kantonsspital Munsterlingen, Musterlingen, Switzerland. AD - Department of Urology, Medical School, Ulm, Germany. FAU - Laouiti, Mohamed AU - Laouiti M AD - Department of Radiation-Oncology, Hopital Riviera Chablais, Rennaz, Switzerland. FAU - Lauffer, David AU - Lauffer D AD - Department of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. FAU - Muntener, Michael AU - Muntener M AD - Department of Urology, Stadtspital Triemli, Zurich, Switzerland. FAU - Nguyen, Daniel AU - Nguyen D AD - Department of Urology, Reseau Hospitalier Neuchatelois, Neuchatel, Switzerland. FAU - Niederberger, Philipp AU - Niederberger P AD - Department of Oncology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Papachristofilou, Alexandros AU - Papachristofilou A AD - Department of Radiation-Oncology, University Hospital Basel, Basel, Switzerland. FAU - Prause, Lukas AU - Prause L AD - Department of Urology, Kantonsspital Aarau, Aarau, Switzerland. FAU - Reinhardt, Karsten AU - Reinhardt K AD - Department of Urology, St. Clara Hospital Basel, Basel, Switzerland. FAU - Salati, Emanuela AU - Salati E AD - Department of Oncology, Hopital Riviera Chablais, Rennaz, Switzerland. FAU - Sebe, Philippe AU - Sebe P AD - Department of Urology, University Hospital Geneva, Geneva, Switzerland. FAU - Shelan, Mohamed AU - Shelan M AD - Department of Radiation-Oncology, Inselspital Bern, Berne, Switzerland. FAU - Strebel, Rato AU - Strebel R AD - Department of Urology, Kantonsspital Chur, Chur, Switzerland. FAU - Templeton, Arnoud J AU - Templeton AJ AD - Department of Oncology, St. Claraspital Basel and Faculty of Medicine, University Basel, Basel, Switzerland. FAU - Vogl, Ursula AU - Vogl U AD - Department of Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland. FAU - Wettstein, Marian S AU - Wettstein MS AD - Department of Uro-Oncology, University of Toronto, Toronto, Canada. FAU - Zihler, Deborah AU - Zihler D AD - Department of Oncology, Kantonsspital Aarau, Aarau, Switzerland. FAU - Zilli, Thomas AU - Zilli T AD - Department of Radiation-Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland. FAU - Zwahlen, Daniel AU - Zwahlen D AD - Department of Radiation-Oncology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Roth, Beat AU - Roth B AD - Department of Urology, Inselspital Bern, Berne, Switzerland. FAU - Fankhauser, Christian AU - Fankhauser C AUID- ORCID: 0000-0002-4073-5488 AD - Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. cdfankhauser@gmail.com. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240919 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - *Neoplasm Invasiveness MH - Combined Modality Therapy MH - Neoplasm Recurrence, Local MH - Follow-Up Studies MH - Cystectomy/methods PMC - PMC11413066 OTO - NOTNLM OT - Bladder preservation OT - Follow-up OT - Functional outcomes OT - Oncological outcomes OT - Trimodal treatment OT - Trimodality COIS- The authors declare no competing interests. EDAT- 2024/09/21 13:19 MHDA- 2024/09/21 13:20 PMCR- 2024/09/19 CRDT- 2024/09/19 11:13 PHST- 2024/05/08 00:00 [received] PHST- 2024/07/19 00:00 [accepted] PHST- 2024/09/21 13:20 [medline] PHST- 2024/09/21 13:19 [pubmed] PHST- 2024/09/19 11:13 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 10.1007/s00345-024-05196-7 [pii] AID - 5196 [pii] AID - 10.1007/s00345-024-05196-7 [doi] PST - epublish SO - World J Urol. 2024 Sep 19;42(1):527. doi: 10.1007/s00345-024-05196-7. PMID- 39300124 OWN - NLM STAT- MEDLINE DCOM- 20240919 LR - 20250616 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 15 IP - 1 DP - 2024 Sep 19 TI - Full-course NIR-II imaging-navigated fractionated photodynamic therapy of bladder tumours with X-ray-activated nanotransducers. PG - 8240 LID - 10.1038/s41467-024-52607-9 [doi] LID - 8240 AB - The poor 5-year survival rate for bladder cancers is associated with the lack of efficient diagnostic and treatment techniques. Despite cystoscopy-assisted photomedicine and external radiation being promising modalities to supplement or replace surgery, they remain invasive or fail to provide real-time navigation. Here, we report non-invasive fractionated photodynamic therapy of bladder cancer with full-course real-time near-infrared-II imaging based on engineered X-ray-activated nanotransducers that contain lanthanide-doped nanoscintillators with concurrent emissions in visible and the second near-infrared regions and conjugated photosensitizers. Following intravesical instillation in mice with carcinogen-induced autochthonous bladder tumours, tumour-homing peptide-labelled nanotransducers realize enhanced tumour regression, robust recurrence inhibition, improved survival rates, and restored immune homeostasis under X-ray irradiation with accompanied near-infrared-II imaging. On-demand fractionated photodynamic therapy with customized doses is further achieved based on quantifiable near-infrared-II imaging signal-to-background ratios. Our study presents a promising non-invasive strategy to confront the current bladder cancer dilemma from diagnosis to treatment and prognosis. CI - (c) 2024. The Author(s). FAU - He, Liangrui AU - He L AUID- ORCID: 0000-0002-6323-0095 AD - State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, PR China. FAU - Wang, Liyang AU - Wang L AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China. FAU - Yu, Xujiang AU - Yu X AUID- ORCID: 0000-0002-8916-0742 AD - State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, PR China. yuxuj1017@sjtu.edu.cn. FAU - Tang, Yizhang AU - Tang Y AD - State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, PR China. FAU - Jiang, Zhao AU - Jiang Z AD - State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, PR China. FAU - Yang, Guoliang AU - Yang G AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China. ygl0511@126.com. FAU - Liu, Zhuang AU - Liu Z AUID- ORCID: 0000-0002-1629-1039 AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, PR China. zliu@suda.edu.cn. FAU - Li, Wanwan AU - Li W AUID- ORCID: 0000-0003-3809-0737 AD - State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, PR China. wwli@sjtu.edu.cn. LA - eng GR - 82372089,82272823,82273288/National Natural Science Foundation of China (National Science Foundation of China)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240919 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - 0 (Photosensitizing Agents) SB - IM MH - Animals MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy/pathology MH - *Photochemotherapy/methods MH - Mice MH - *Photosensitizing Agents/therapeutic use MH - X-Rays MH - Cell Line, Tumor MH - Female MH - Humans MH - Infrared Rays PMC - PMC11413067 COIS- The authors declare no competing interests. EDAT- 2024/09/20 01:06 MHDA- 2024/09/20 01:07 PMCR- 2024/09/19 CRDT- 2024/09/19 23:29 PHST- 2024/01/15 00:00 [received] PHST- 2024/09/12 00:00 [accepted] PHST- 2024/09/20 01:07 [medline] PHST- 2024/09/20 01:06 [pubmed] PHST- 2024/09/19 23:29 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 10.1038/s41467-024-52607-9 [pii] AID - 52607 [pii] AID - 10.1038/s41467-024-52607-9 [doi] PST - epublish SO - Nat Commun. 2024 Sep 19;15(1):8240. doi: 10.1038/s41467-024-52607-9. PMID- 39299443 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20260625 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 36 IP - 1 DP - 2025 Jan TI - Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. PG - 89-98 LID - S0923-7534(24)04016-X [pii] LID - 10.1016/j.annonc.2024.09.008 [doi] AB - BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard treatment for muscle-invasive bladder cancer (MIBC), yet 40% of patients progress, emphasizing the need for biomarkers predictive for response or chemoresistance. Gene expression-based subtypes may serve as biomarkers, though which subtypes will respond, notably when it comes to the basal subtype, remains contentious. PATIENTS AND METHODS: This post hoc study analyzed 300 NAC-treated patients enrolled in the GETUG/AFU VESPER trial, with transurethral diagnostic formalin-fixed paraffin-embedded tissue which underwent pathological review before being sequenced. 'Mixed' subtype was defined for tumors displaying at least two different Consensus molecular subtypes in separate regions. We evaluated the association between molecular subtypes and outcome after NAC. Tumors with remaining tissue at cystectomy (n = 83) were compared with pre-treatment tumors. RESULTS: Cases were classified basal/squamous (Ba/Sq) (n = 84), luminal unstable (n = 57), stroma-rich (n = 53), mixed (n = 48), luminal papillary (n = 39), luminal non-specific (n = 18), and neuroendocrine-like (n = 1), with 30/48 mixed cases including a Ba/Sq component. Compared with other molecular subtypes in a multivariate Cox model, Ba/Sq (pure or mixed) patients had an increased hazard ratio (HR) of progression-free survival [HR 2.0, 95% confidence interval (CI) 1.36-3.0]. Mixed tumors were associated with decreased metabolic activity that could account for chemoresistance. Ba/Sq and mixed non-responders mostly maintained their subtype at cystectomy and have fewer myeloid dendritic cells after NAC. Tumors classified luminal papillary at transurethral resection of the urinary bladder tumor exhibited an increase in T CD4+ and macrophage signatures after NAC. Other subtypes did not show significant immune changes after NAC. Our study design relied on detailed pathological review, which precluded evaluating the mixed subtype in published datasets. Furthermore, the sample size for post-NAC analyses constrained the statistical power of these findings. CONCLUSIONS: Our findings underscore the importance of recognizing intra-tumor heterogeneity in MIBC and its role in chemoresistance associated with Ba/Sq subtype, and provide valuable insights that could help future treatment development and improve patient outcomes. CI - Copyright (c) 2024 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. FAU - Groeneveld, C S AU - Groeneveld CS AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris; Centre de Recherche des Cordeliers, Universite Paris-Cite, UMRS1138, Paris. FAU - Pfister, C AU - Pfister C AD - Universite de Rouen Normandie, Inserm, CIC Inserm 1404, Onco-Urology, Rouen; Department of Urology, Hopital Universitaire Charles Nicolle, Rouen. FAU - Culine, S AU - Culine S AD - Department of Medical Oncology, Universite de Paris Cite, AP-HP, Hopital Saint-Louis, Paris. FAU - Harter, V AU - Harter V AD - Centre Francois Baclesse, North-West Canceropole Data Center, Caen. FAU - Krucker, C AU - Krucker C AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris. FAU - Fontugne, J AU - Fontugne J AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris; Department of Pathology, Universite Paris-Saclay, UVSQ, Institut Curie, Saint-Cloud, France. FAU - Dixon, V AU - Dixon V AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris. FAU - Sirab, N AU - Sirab N AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris. FAU - Bernard-Pierrot, I AU - Bernard-Pierrot I AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris. FAU - de Reynies, A AU - de Reynies A AD - Centre de Recherche des Cordeliers, Universite Paris-Cite, UMRS1138, Paris. FAU - Radvanyi, F AU - Radvanyi F AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris. FAU - Allory, Y AU - Allory Y AD - Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisee Ligue Contre le Cancer, Paris; Department of Pathology, Universite Paris-Saclay, UVSQ, Institut Curie, Saint-Cloud, France. Electronic address: yves.allory@curie.fr. CN - VESPER trial investigators LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20240917 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Biomarkers, Tumor/genetics/metabolism MH - *Chemotherapy, Adjuvant/methods MH - Cystectomy MH - *Neoadjuvant Therapy/methods MH - Prognosis MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery/genetics/mortality MH - *Carcinoma, Squamous Cell/drug therapy MH - *Basal Cell Carcinoma/drug therapy/pathology MH - Treatment Outcome OTO - NOTNLM OT - basal subtype OT - bladder cancer OT - intra-tumor heterogeneity OT - molecular subtype OT - neoadjuvant chemotherapy OT - prognosis FIR - Pignot, G IR - Pignot G FIR - Fendler, J P IR - Fendler JP FIR - Guy, L IR - Guy L FIR - Verhoest, G IR - Verhoest G FIR - Mottet, N IR - Mottet N FIR - Doerfler, A IR - Doerfler A FIR - Abadie-Lacourtoisie, S IR - Abadie-Lacourtoisie S FIR - Azzouzi, A IR - Azzouzi A FIR - Mongiat, P IR - Mongiat P FIR - Geoffrois, L IR - Geoffrois L FIR - Eschwege, P IR - Eschwege P FIR - Di Fiore, F IR - Di Fiore F FIR - Roubaud, G IR - Roubaud G FIR - Hoepffner, J L IR - Hoepffner JL FIR - Barthelemy, P IR - Barthelemy P FIR - Lang, H IR - Lang H FIR - Voog, E IR - Voog E FIR - Mandron, E IR - Mandron E FIR - Tourani, J M IR - Tourani JM FIR - Serrrate, C IR - Serrrate C FIR - Colau, A IR - Colau A FIR - Saldana, C IR - Saldana C FIR - de La Taille, A IR - de La Taille A FIR - Nguyen, T IR - Nguyen T FIR - Kleinclauss, F IR - Kleinclauss F FIR - Loriot, Y IR - Loriot Y FIR - Irani, J IR - Irani J FIR - Eymard, J C IR - Eymard JC FIR - Larre, S IR - Larre S FIR - Huillard, O IR - Huillard O FIR - Zerbib, M IR - Zerbib M FIR - Rolland, F IR - Rolland F FIR - Rigaud, J IR - Rigaud J FIR - Houede, N IR - Houede N FIR - Droupy, S IR - Droupy S FIR - Malouf, G IR - Malouf G FIR - Roupret, M IR - Roupret M FIR - Vieillot, S IR - Vieillot S FIR - Letang, N IR - Letang N FIR - Lharidon, T IR - Lharidon T FIR - Gaschignard, N IR - Gaschignard N FIR - Hilgers, W IR - Hilgers W FIR - Davin, J L IR - Davin JL EDAT- 2024/09/20 11:25 MHDA- 2025/01/07 00:21 CRDT- 2024/09/19 19:26 PHST- 2024/02/06 00:00 [received] PHST- 2024/07/19 00:00 [revised] PHST- 2024/09/10 00:00 [accepted] PHST- 2025/01/07 00:21 [medline] PHST- 2024/09/20 11:25 [pubmed] PHST- 2024/09/19 19:26 [entrez] AID - S0923-7534(24)04016-X [pii] AID - 10.1016/j.annonc.2024.09.008 [doi] PST - ppublish SO - Ann Oncol. 2025 Jan;36(1):89-98. doi: 10.1016/j.annonc.2024.09.008. Epub 2024 Sep 17. PMID- 39284988 OWN - NLM STAT- MEDLINE DCOM- 20241109 LR - 20250403 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 31 IP - 13 DP - 2024 Dec TI - Developing a Novel Prognostic Model Based on Muscle-Invasive Bladder Cancer Types: A Multicenter Retrospective Cohort Study of Patients Who Received Radical Cystectomy and Chemotherapy. PG - 8967-8977 LID - 10.1245/s10434-024-16226-4 [doi] AB - BACKGROUND: To develop a prognostic model to manage patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC) and chemotherapy. PATIENTS AND METHODS: Clinicopathologic characteristics and survival data were collated from a North American database to develop a model. Genomic and clinicopathologic data were also obtained from European and Asian databases to externally validate the model. Patients were classified as either "primary" or "progressive" MIBC according to non-muscle invasive stage history. Optimized cancer-specific survival (CSS) models, based on MIBC types, were constructed using Cox's proportional hazard regression. Differences of biological function and tumor immunity, between two risk-based groups stratified according to the prognostic model, were estimated. RESULTS: There were 2631 participants in the American cohort, 291 in the European cohort and 142 in the Asian cohort. Under Cox's regression analysis, tumor stage, lymph node stage, age, ethnicity, and MIBC types were independent CSS predictors (all p < 0.05). The constructed nomogram, which integrated these variables, improved the predictive power. This model had good discrimination and calibration. Patients were categorized into high- or low-risk groups according to the total points calculated. Kaplan-Meier curves revealed that patients in the high-risk group had poorer survival (p < 0.001). This was confirmed with two external validation cohorts (both with p < 0.001). Higher stromal scores and increased M0 and M2 macrophage numbers were observed in samples from the high-risk group, whereas regulatory T cells had lower infiltration in these populations (all with p < 0.05). CONCLUSIONS: This MIBC type-based nomogram provides accurate CSS predictions, which could help improve patient management and clinical decision-making. CI - (c) 2024. Society of Surgical Oncology. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. FAU - Hu, Haopu AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Song, Yuxuan AU - Song Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Seery, Samuel AU - Seery S AD - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK. FAU - Ni, Runfeng AU - Ni R AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Wang, Huanrui AU - Wang H AD - Department of Urology, Peking University People's Hospital, Beijing, China. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. FAU - Zhang, Guan AU - Zhang G AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. gzhang2016@sina.com. FAU - Hu, Hao AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. huhao@bjmu.edu.cn. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. huhao@bjmu.edu.cn. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, China. xutao@pkuph.edu.cn. AD - The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. xutao@pkuph.edu.cn. LA - eng GR - Grant BMU2023YFJHPY009/Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation and the Fundamental Research Funds for the Central Universities/ GR - EBS number 2127000305/Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation and the Fundamental Research Funds for the Central Universities/ GR - RDJP2022-69/Peking University People's Hospital Research And Development Funds/ PT - Journal Article PT - Multicenter Study DEP - 20240916 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/drug therapy/mortality MH - *Cystectomy MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Survival Rate MH - Middle Aged MH - *Neoplasm Invasiveness MH - Prognosis MH - *Nomograms MH - Follow-Up Studies MH - *Neoplasm Staging MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Combined Modality Therapy MH - Carcinoma, Transitional Cell/pathology/surgery/mortality/drug therapy OTO - NOTNLM OT - Primary muscle-invasive bladder cancer OT - Prognoses OT - Prognostic model OT - Progressive muscle-invasive bladder cancer OT - Radical cystectomy EDAT- 2024/09/17 10:47 MHDA- 2024/11/13 13:57 CRDT- 2024/09/16 23:24 PHST- 2024/06/03 00:00 [received] PHST- 2024/09/01 00:00 [accepted] PHST- 2024/11/13 13:57 [medline] PHST- 2024/09/17 10:47 [pubmed] PHST- 2024/09/16 23:24 [entrez] AID - 10.1245/s10434-024-16226-4 [pii] AID - 10.1245/s10434-024-16226-4 [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Dec;31(13):8967-8977. doi: 10.1245/s10434-024-16226-4. Epub 2024 Sep 16. PMID- 39277526 OWN - NLM STAT- MEDLINE DCOM- 20241129 LR - 20250318 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 43 IP - 1 DP - 2025 Jan TI - The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis. PG - 66.e9-66.e17 LID - S1078-1439(24)00576-3 [pii] LID - 10.1016/j.urolonc.2024.08.006 [doi] AB - BACKGROUND AND OBJECTIVE: Neoadjuvant therapy followed by radical cystectomy with lymphadenectomy remains the gold standard of treatment in patients with muscle-invasive bladder cancer. Pathologically positive lymph node (pN+) disease is known to convey a poor prognosis. Tumor-informed circulating tumor DNA (ctDNA) has emerged as a possible novel prognostic biomarker in the field. We seek to assess recurrence-free survival (RFS) for patients undergoing robotic-assisted radical cystectomy (RARC) with extended pelvic lymphadenectomy (ePLND) and to assess whether ctDNA status can be a prognostic marker for RFS outcomes in patients with pN+ disease. METHODS: Patients who underwent RARC + ePLND during 2015 to 2023 were included. A sub-group analysis (n = 109) of patients who had prospectively collected serial-longitudinal tumor-informed ctDNA analyses during 2021-2023 was performed. Survival analysis and Cox-regression models were conducted. RESULTS: Included were 458 patients with a median age of 69 (IQR 63-76), and a median follow-up time of 20 months (IQR 10-37). RFS for pN0 (n = 353) and pN+ (n = 105) at 12, 24 and 36 months were 87% vs. 54%, 80% vs. 39%, and 74% vs. 35%, respectively (log-rank, P < 0.0001). On Cox multivariate analysis >/=pT3 disease (Hazzard ratio [HR] = 3.36 [2.18-5.18], P < 0.001), pN+ disease (HR = 2.39 [1.55-3.7], P < 0.001), and recipients of neoadjuvant treatment (HR = 1.61 [1.11-2.34], P = 0.013) were predictive of disease relapse. Patients with pN+ disease and undetectable precystectomy or postcystectomy ctDNA status had similar RFS to patients with pN0 with undetectable ctDNA. On Cox-regression multivariate sub-group analysis, detectable precystectomy ctDNA status (HR = 3.89 [1.32-11.4], P = 0.014), detectable ctDNA status in the minimal residual disease window ([MRD], HR = 2.89 [1.12-7.47], P = 0.028), and having >/=pT3 with pN+ disease (HR = 4.2 [1.43-12.3], P = 0.009) were predictive of disease relapse. CONCLUSIONS: Patients with pN+ .after RARC had worse oncological outcomes than patients with pN0 disease. Undetectable ctDNA status was informative of RFS regardless of nodal status at both the precystectomy and the MRD window. Patients with undetectable ctDNA status and pN+ disease may benefit from treatment de-escalation. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Ben-David, Reuben AU - Ben-David R AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. Electronic address: reuben.bendavid@mountsinai.org. FAU - Lidagoster, Sarah AU - Lidagoster S AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Geduldig, Jack AU - Geduldig J AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Kolanukuduru, Kaushik P AU - Kolanukuduru KP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Elkun, Yuval AU - Elkun Y AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Tillu, Neeraja AU - Tillu N AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Cumarasamy, Shivaram AU - Cumarasamy S AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Rich, Jordan M AU - Rich JM AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Almoflihi, Mohammed AU - Almoflihi M AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. LA - eng PT - Journal Article DEP - 20240914 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Circulating Tumor DNA) SB - IM MH - Humans MH - *Cystectomy/methods MH - Male MH - Aged MH - Female MH - *Urinary Bladder Neoplasms/surgery/blood/pathology/genetics MH - Middle Aged MH - Prognosis MH - *Circulating Tumor DNA/blood/genetics MH - *Robotic Surgical Procedures/methods MH - Lymphatic Metastasis MH - Lymph Node Excision/methods OTO - NOTNLM OT - Circulating tumor DNA OT - Nonmuscle invasive bladder neoplasms OT - Tumor biomarkers OT - Urinary bladder neoplasms COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/09/15 14:09 MHDA- 2024/11/30 11:16 CRDT- 2024/09/14 22:00 PHST- 2024/06/03 00:00 [received] PHST- 2024/07/30 00:00 [revised] PHST- 2024/08/12 00:00 [accepted] PHST- 2024/11/30 11:16 [medline] PHST- 2024/09/15 14:09 [pubmed] PHST- 2024/09/14 22:00 [entrez] AID - S1078-1439(24)00576-3 [pii] AID - 10.1016/j.urolonc.2024.08.006 [doi] PST - ppublish SO - Urol Oncol. 2025 Jan;43(1):66.e9-66.e17. doi: 10.1016/j.urolonc.2024.08.006. Epub 2024 Sep 14. PMID- 39269616 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 15 IP - 1 DP - 2024 Sep 13 TI - Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression. PG - 440 LID - 10.1007/s12672-024-01324-2 [doi] LID - 440 AB - Emerging evidence indicates that androgen receptor (AR) signaling plays a critical role in the pathogenesis of male-dominant urothelial cancer and its outgrowth. Meanwhile, latrophilins (LPHNs), a group of the G-protein-coupled receptors to which a spider venom latrotoxin (LTX) is known to bind, remain largely uncharacterized in neoplastic diseases. The present study aimed to determine the functional role of LPHN3 (encoded by the ADGRL3 gene), in association with AR signaling, in the progression of bladder cancer. In AR-positive bladder cancer lines, dihydrotestosterone considerably increased the expression levels of ADGRL3 and LPHN3, while chromatin immunoprecipitation assay revealed the binding of AR to the promoter region of ADGRL3. Treatment with LPHN3 ligands (e.g. alpha-LTX, FLRT3) resulted in the induction of ADGRL3 expression, as well as cell viability, in bladder cancer lines. By contrast, LPHN3 knockdown via shRNA virus infection significantly reduced the viability and migration of these cells. Immunohistochemistry in transurethral resection specimens further showed a strong correlation between LPHN3 and AR expression. Moreover, LPHN3 positivity in muscle-invasive bladder tumors, as an independent prognosticator, was associated with a significantly higher risk of disease progression and disease-specific mortality following radical cystectomy. These findings suggest that LPHN3 functions as a downstream effector of AR and promotes the growth of bladder cancer. CI - (c) 2024. The Author(s). FAU - Goto, Takuro AU - Goto T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. FAU - Teramoto, Yuki AU - Teramoto Y AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. FAU - Nagata, Yujiro AU - Nagata Y AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hiroshi_miyamoto@urmc.rochester.edu. LA - eng PT - Journal Article DEP - 20240913 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC11399515 OTO - NOTNLM OT - ADGRL3 OT - Androgen receptor OT - Bladder cancer OT - FLRT3 OT - LPHN3 OT - Latrotoxin COIS- The authors declare no competing interests. EDAT- 2024/09/13 14:45 MHDA- 2024/09/13 14:46 PMCR- 2024/09/13 CRDT- 2024/09/13 11:13 PHST- 2024/06/17 00:00 [received] PHST- 2024/09/06 00:00 [accepted] PHST- 2024/09/13 14:46 [medline] PHST- 2024/09/13 14:45 [pubmed] PHST- 2024/09/13 11:13 [entrez] PHST- 2024/09/13 00:00 [pmc-release] AID - 10.1007/s12672-024-01324-2 [pii] AID - 1324 [pii] AID - 10.1007/s12672-024-01324-2 [doi] PST - epublish SO - Discov Oncol. 2024 Sep 13;15(1):440. doi: 10.1007/s12672-024-01324-2. PMID- 39266874 OWN - NLM STAT- MEDLINE DCOM- 20250415 LR - 20261010 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 27 IP - 4 DP - 2025 Apr TI - Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer. PG - 1695-1711 LID - 10.1007/s12094-024-03694-z [doi] AB - BACKGROUND: It is well established that smoking is the most significant risk factor for bladder cancer, yet the impact of smoking on the recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) remains a contentious issue. OBJECTIVE: To review all relevant literature published to date, providing a comprehensive assessment of the effects of smoking on the recurrence and progression of NMIBC, thereby offering a basis for smoking cessation management in NMIBC patients. METHODS: A search was conducted for all relevant literature published up to April 2024 in PubMed, Web of Science, and Embase databases. The existing literature results and deficiencies were analyzed, and the gaps in understanding between different studies were highlighted, with recommendations for future research. RESULTS: A total of 24 studies were included in this work. Among them, 14 studies suggested that smoking promotes the recurrence and progression of NMIBC, while another 10 studies concluded that smoking has no effect on the recurrence and progression of NMIBC patients. CONCLUSIONS: Our research indicates that smoking increases the risk of recurrence and progression in NMIBC patients, and quitting smoking can improve health-related quality of life. High-quality, large-sample prospective cohort studies (or randomized controlled studies) are still needed in the future. CI - (c) 2024. The Author(s), under exclusive licence to Federacion de Sociedades Espanolas de Oncologia (FESEO). FAU - Chen, Chaohu AU - Chen C AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Fan, Guangrui AU - Fan G AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Li, Pan AU - Li P AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Yang, Enguang AU - Yang E AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Jing, Suoshi AU - Jing S AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Shi, Yibo AU - Shi Y AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Gong, Yuwen AU - Gong Y AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Zhang, Luyang AU - Zhang L AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. FAU - Wang, Zhiping AU - Wang Z AUID- ORCID: 0000-0002-8140-591X AD - Institute of Urology, Lanzhou University Second Hospital, Chengguan District, No.82 Linxia Road, Lanzhou, 730030, People's Republic of China. wangzplzu@163.com. AD - Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, People's Republic of China. wangzplzu@163.com. LA - eng GR - 82060459/the National Natural Science Foundation of China/ PT - Journal Article PT - Review DEP - 20240912 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/etiology MH - *Neoplasm Recurrence, Local/epidemiology/etiology/pathology MH - Disease Progression MH - *Smoking/adverse effects MH - Neoplasm Invasiveness MH - Smoking Cessation MH - Risk Factors MH - Quality of Life MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - NMIBC OT - Progression OT - Recurrence OT - Smoking COIS- Declarations. Conflicts of interest: No conflicts of interest have been disclosed by the authors. Ethical approval: Ethical approval does not apply because this work is not research involving humans and/or animals. Informed consent: Not applicable. EDAT- 2024/09/13 00:46 MHDA- 2025/04/15 12:30 CRDT- 2024/09/12 23:37 PHST- 2024/08/08 00:00 [received] PHST- 2024/08/21 00:00 [accepted] PHST- 2025/04/15 12:30 [medline] PHST- 2024/09/13 00:46 [pubmed] PHST- 2024/09/12 23:37 [entrez] AID - 10.1007/s12094-024-03694-z [pii] AID - 10.1007/s12094-024-03694-z [doi] PST - ppublish SO - Clin Transl Oncol. 2025 Apr;27(4):1695-1711. doi: 10.1007/s12094-024-03694-z. Epub 2024 Sep 12. PMID- 39265259 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260626 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 6 DP - 2024 Dec TI - Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy. PG - 102211 LID - S1558-7673(24)00181-2 [pii] LID - 10.1016/j.clgc.2024.102211 [doi] AB - BACKGROUND: Prior research has demonstrated a discrepancy between pathologic and clinical staging in individuals with muscle-invasive bladder cancer (MIBC) following neoadjuvant chemotherapy (NAC). These findings were the major reasons for the under-usage of the bladder preservation strategy. Hence, we aim to explore the reliable markers in identifying pathological complete response (ypCR) status in MIBC patients who achieved clinical complete response (cCR) after NAC. METHODS: Between January 2016 and April 2023, 161 consecutive MIBC patients treated with NAC and achieved cCR were enrolled in the study. Patient clinicopathologic information was documented. Multivariate binary logistic regression was used for determining adjusted odds ratios (OR) and 95% confidence intervals (CI). It considered statistically significant when a P < .05. RESULTS: Of the 161 MIBC patients with cCR after NAC, 64.0% (103/161) achieved ypCR after RC. The independent factors for ypCR status were the origin of MIBC (secondary vs. Primary) with odds ratios (OR) of 0.433 (P = .027), the pathological type (pure vs. mixed) with OR of 3.556 (P = .003), concurrent carcinoma in situ (yes vs. no) with OR of 0.360 (P = .016), and lymphovascular invasion (yes vs. no) with OR of 0.271 (P = .007). CONCLUSION: This study demonstrated that primary MIBC, pure UC pathological type, absence of concurrent CIS, and LVI were significant predictors of ypCR in MIBC patients who achieved cCR after NAC and before surgery. These findings may contribute to the decision-making process of bladder preservation strategy in selected patients. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Piao, Chengri AU - Piao C AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. FAU - Liu, Dongmei AU - Liu D AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. FAU - Liu, Zhen AU - Liu Z AD - Department of Urology, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: liuzhenplp@163.com. FAU - Shan, Liping AU - Shan L AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: shanliping81@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240823 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Male MH - *Neoadjuvant Therapy MH - Female MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - Treatment Outcome MH - Retrospective Studies MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Neoplasm Staging MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Aged, 80 and over OTO - NOTNLM OT - Clinical complete response OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Pathological complete response OT - Radical cystectomy COIS- Disclosures Liping Shan, and Zhen Liu certifies that all conflicts of interest are none. EDAT- 2024/09/13 00:46 MHDA- 2024/11/29 05:21 CRDT- 2024/09/12 18:03 PHST- 2024/03/22 00:00 [received] PHST- 2024/08/18 00:00 [revised] PHST- 2024/08/19 00:00 [accepted] PHST- 2024/11/29 05:21 [medline] PHST- 2024/09/13 00:46 [pubmed] PHST- 2024/09/12 18:03 [entrez] AID - S1558-7673(24)00181-2 [pii] AID - 10.1016/j.clgc.2024.102211 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Dec;22(6):102211. doi: 10.1016/j.clgc.2024.102211. Epub 2024 Aug 23. PMID- 39265258 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260626 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 6 DP - 2024 Dec TI - Characteristics of Abdominal Fat Based on CT Measurements to Predict Early Recurrence After Initial Surgery of NMIBC in Stage Ta/T1. PG - 102199 LID - S1558-7673(24)00169-1 [pii] LID - 10.1016/j.clgc.2024.102199 [doi] AB - INTRODUCTION: This study aimed to assess the predictive value of abdominal fat characteristics measured by computed tomography (CT) in identifying early recurrence within one year post-initial transurethral resection of bladder tumor (TURBT) in patients with nonmuscle-invasive bladder cancer (NMIBC). A predictive model integrating fat features and clinical factors was developed to guide individualized treatment. MATERIALS AND METHODS: A retrospective analysis of 203 NMIBC patients from two medical centers was conducted. Abdominal CT images were analyzed using 3D Slicer software. Spearman correlation, logistic regression, and the Lasso algorithm were employed for data analysis. Predictive efficacy was assessed using the area under the curve (AUC) of receiver operating characteristic (ROC) and decision curve analysis (DCA). Calibration was evaluated using the Hosmer-Lemeshow test. RESULTS: Significant differences in abdominal fat characteristics were found between the recurrence and nonrecurrence groups. All fat features positively correlated with body mass index (BMI), with bilateral perirenal fat thickness (PrFT) showing superior predictive performance. Multivariate logistic regression identified independent predictors of early recurrence, including tumor number, early perfusion chemotherapy, left and right PrFT, and visceral fat area (VFA) at umbilical and renal hilum levels. The Lasso-based model achieved an AUC of 0.904, outperforming existing models. CONCLUSION: Abdominal fat characteristics, especially bilateral PrFT, strongly correlate with early recurrence in NMIBC. The Lasso-based model, integrating fat and clinical factors, offers superior predictive efficacy and could improve individualized treatment strategies. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Yu, Nengfeng AU - Yu N AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Xu, Congcong AU - Xu C AD - Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Jiang, Yiwei AU - Jiang Y AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Liu, Dekai AU - Liu D AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Lin, Lianghao AU - Lin L AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Zheng, Gangfu AU - Zheng G AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Du, Jiaqi AU - Du J AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Yang, Kefan AU - Yang K AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Zhong, Qifeng AU - Zhong Q AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China. FAU - Chen, Yicheng AU - Chen Y AD - Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: chenyicheng@zju.edu.cn. FAU - Zheng, Yichun AU - Zheng Y AD - Department of Urology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China; Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: 2101090@zju.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240811 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/diagnostic imaging/surgery MH - *Urinary Bladder Neoplasms/surgery/diagnostic imaging/pathology MH - Aged MH - Middle Aged MH - *Tomography, X-Ray Computed/methods MH - *Abdominal Fat/diagnostic imaging/surgery/pathology MH - Neoplasm Staging MH - ROC Curve MH - Predictive Value of Tests MH - Body Mass Index MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Abdominal fat OT - Computed tomography OT - Early recurrence after initial surgery OT - Nonmuscle invasive bladder cancer OT - Prediction model COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/09/13 00:46 MHDA- 2024/11/29 05:20 CRDT- 2024/09/12 18:03 PHST- 2024/05/27 00:00 [received] PHST- 2024/07/29 00:00 [revised] PHST- 2024/08/07 00:00 [accepted] PHST- 2024/11/29 05:20 [medline] PHST- 2024/09/13 00:46 [pubmed] PHST- 2024/09/12 18:03 [entrez] AID - S1558-7673(24)00169-1 [pii] AID - 10.1016/j.clgc.2024.102199 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Dec;22(6):102199. doi: 10.1016/j.clgc.2024.102199. Epub 2024 Aug 11. PMID- 39261258 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260626 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 6 DP - 2024 Dec TI - Clinical, Prognosis, and Treatment Effect Features Analysis of Metachronous and Synchronous UTUC and BUC. PG - 102192 LID - S1558-7673(24)00162-9 [pii] LID - 10.1016/j.clgc.2024.102192 [doi] AB - OBJECTIVE: To provide a comprehensive understanding of the clinical features of patients with synchronous and metachronous upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) and inform surgical and postoperative adjuvant treatment planning. PATIENTS AND METHOD: A total of 292 consecutive patients with synchronous and metachronous UTUC-BUC were retrospectively enrolled and were categorized into three groups: (1) UTUC metachronous BUC (N = 185, UTUC-mBUC), (2) BUC-metachronous UTUC (N = 43, BUC-mUTUC), (3) synchronous UTUC-BUC (N = 64, sUTUC-BUC). We compared pathological characteristics and survival data among groups with Wilcoxon's rank sum tests, Pearson's chi-squared, and the Kaplan-Meier method. RESULTS: In the sUTUC-BUC group, a higher proportion of patients exhibited UTUC tumors with grade G3 (56%, P = .001) and stage T4 (6%, P < .001) than group UTUC-mBUC (G3 = 16%, T4 = 0%). The proportion of patients with variant histology subtype in group sUTUC-BUC was higher than that of metachronous UTUC-BUC, involving squamous (P = .003), adenoid (P = .012), and sarcomatoid (P < .001) differentiation. It was also observed that the maximum diameter of the UTUC tumor of group sUTUC-BUC (median = 3.5) was significantly larger than group UTUC-mBUC (median = 2.5, P = .002) and group BUC-mUTUC (median = 2.2, P < .001). Notably, sUTUC-BUC has an increased risk of cancer-specific death compared with UTUC-mBUC (P < .001) and BUC-mUTUC (P < .001). On multivariable Cox regression, synchronous UTUC-BUC was an independent predictor of both RFS (P < .001; vs. UTUC-mBUC: HR 0.555, P = .004; vs. BUC-mUTUC: HR 0.279, P < .001) and CSS (P < .001, HR 29.737). Moreover, sUTUC-BUC showed a better response to intravesical therapy and chemotherapy with higher cancer-specific survival (P < .001) and recurrence-free survival (P = .034). CONCLUSIONS: The prognosis and pathological characteristics among different metachronous and synchronous UTUC and BUC were diverse. The synchronous UTUC-BUC group showed variant histology subtype, high-grade tumors, advanced tumors, multifocal UTUC, worse cancer-specific survival, but better response to intravesical therapy and chemotherapy. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Zuo, Wei AU - Zuo W AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhang, Jilong AU - Zhang J AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xu, Liqing AU - Xu L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xu, Chunru AU - Xu C AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Tang, Qi AU - Tang Q AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: drtangq@163.com. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: pineneedle@sina.com. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: zhoulqmail@sina.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240812 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy MH - Aged MH - Retrospective Studies MH - Middle Aged MH - Prognosis MH - *Neoplasms, Multiple Primary/pathology/mortality/therapy/surgery MH - Neoplasms, Second Primary/pathology/mortality MH - Treatment Outcome MH - Carcinoma, Transitional Cell/pathology/mortality/therapy/surgery/drug therapy MH - Survival Analysis MH - Aged, 80 and over OTO - NOTNLM OT - BUC OT - Metachronous OT - Metastasis OT - Prognosis OT - Synchronous OT - UTUC COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2024/09/12 00:42 MHDA- 2024/11/29 05:20 CRDT- 2024/09/11 22:00 PHST- 2024/06/20 00:00 [received] PHST- 2024/08/05 00:00 [revised] PHST- 2024/08/06 00:00 [accepted] PHST- 2024/11/29 05:20 [medline] PHST- 2024/09/12 00:42 [pubmed] PHST- 2024/09/11 22:00 [entrez] AID - S1558-7673(24)00162-9 [pii] AID - 10.1016/j.clgc.2024.102192 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Dec;22(6):102192. doi: 10.1016/j.clgc.2024.102192. Epub 2024 Aug 12. PMID- 39260096 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20260626 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 6 DP - 2024 Dec TI - Oncological and Survival Outcomes of Pelvic Lymph Node Dissection in Patients with Nonmuscle Invasive Bladder Cancer Undergoing Radical Cystectomy Using the National Cancer Database. PG - 102197 LID - S1558-7673(24)00167-8 [pii] LID - 10.1016/j.clgc.2024.102197 [doi] AB - OBJECTIVE: To evaluate the role of pelvic lymph node dissection (PLND) in patients diagnosed with high-risk nonmuscle-invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC) using a national cohort of NMIBC patients. METHODS: A cohort of patients diagnosed with NMIBC cancer with urothelial carcinoma from the National Cancer Database (NCDB) between 2004 and 2019 was utilized. The cohort consists of patients who have not received BCG and underwent upfront radical cystectomy or pelvic exenteration. Kaplan-Meier analysis was utilized to assess overall survival (OS) outcomes. Cox regression was also utilized to identify independent predictors of OS. RESULTS: The cohort of 9399 patients was stratified by clinical T stage and then subdivided by pathological outcome. For patients with cTa, a majority received a lymph node dissection 97.74% (941/1019), amongst the entire cohort, a minority had node positive disease 3.3% (34/1019). For cTis, most patients received a lymph node dissection 94.08% (482/507), and a minority had node positive disease 5.1% (26/507). For cT1, most patients had a lymph node dissection 95.62% (6,060/6,337), and a 13.1% (832/6337) of patients had a positive lymph node. Amongst patients with cT1 disease who underwent PLND, KMA demonstrated better OS compared to patients who did not undergo PLND (P < .001). CONCLUSION: The data suggests an OS benefit in patients with later stage (cT1) NMIBC. Thus, our findings support the existing clinical guidelines of pelvic lymph node dissection in patients with high-risk nonmuscle invasive bladder cancer. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Moldovan, Matthew AU - Moldovan M AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Nam, Percival AU - Nam P AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Satpathy, Yasoda AU - Satpathy Y AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Wang, Luke AU - Wang L AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Salmasi, Amirali AU - Salmasi A AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Stewart, Tyler F AU - Stewart TF AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Derweesh, Ithaar AU - Derweesh I AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. FAU - Javier-DesLoges, Juan AU - Javier-DesLoges J AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. Electronic address: Jjavierdesloges@health.ucsd.edu. LA - eng PT - Journal Article DEP - 20240813 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Lymph Node Excision MH - Female MH - Male MH - Aged MH - *Databases, Factual MH - Middle Aged MH - Pelvis/surgery MH - Carcinoma, Transitional Cell/surgery/mortality/pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Lymph Nodes/pathology/surgery MH - Lymphatic Metastasis MH - United States/epidemiology MH - Neoplasm Invasiveness MH - Survival Rate MH - Treatment Outcome OTO - NOTNLM OT - National cancer database OT - Nonmuscle-invasive bladder cancer OT - Pelvic lymph node dissection OT - Radical cystectomy OT - Urothelial carcinoma COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2024/09/11 20:42 MHDA- 2024/11/29 05:20 CRDT- 2024/09/11 18:04 PHST- 2023/10/26 00:00 [received] PHST- 2024/07/14 00:00 [revised] PHST- 2024/08/07 00:00 [accepted] PHST- 2024/11/29 05:20 [medline] PHST- 2024/09/11 20:42 [pubmed] PHST- 2024/09/11 18:04 [entrez] AID - S1558-7673(24)00167-8 [pii] AID - 10.1016/j.clgc.2024.102197 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Dec;22(6):102197. doi: 10.1016/j.clgc.2024.102197. Epub 2024 Aug 13. PMID- 39257199 OWN - NLM STAT- MEDLINE DCOM- 20241210 LR - 20241210 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 135 IP - 1 DP - 2025 Jan TI - The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer. PG - 88-94 LID - 10.1111/bju.16493 [doi] AB - OBJECTIVE: To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guerin (BCG) immunotherapy. PATIENTS AND METHODS: A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression. RESULTS: A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013). CONCLUSIONS: Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG. CI - (c) 2024 BJU International. FAU - Liu, Kang AU - Liu K AUID- ORCID: 0000-0001-7929-6534 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Nicoletti, Rossella AU - Nicoletti R AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Zhao, Hongda AU - Zhao H AUID- ORCID: 0000-0003-2414-1484 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chen, Xuan AU - Chen X AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AUID- ORCID: 0000-0002-1499-8372 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Rivas, Juan Gomez AU - Rivas JG AUID- ORCID: 0000-0002-0556-3035 AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Campi, Riccardo AU - Campi R AUID- ORCID: 0000-0001-5237-0888 AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy. AD - European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands. FAU - Mir, Maria Carmen AU - Mir MC AUID- ORCID: 0000-0002-1391-1378 AD - Department of Urology, Hospital Universitario La Ribera, Valencia, Spain. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Marienkrankenhaus Hamburg gGmbH, Hamburg, Germany. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, GRC 5 Predictive Onco-Urology, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - European Association of Urology - Young Academic Urologists Urothelial Carcinoma Working Group, Arnhem, Netherlands. LA - eng GR - 8601521/University Grants Committee (UGC) Research Matching Fund/ GR - 14117421/General Research Fund/Early Career Scheme of the Research Grants Council, Hong Kong/ PT - Journal Article DEP - 20240910 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/mortality MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - *BCG Vaccine/therapeutic use MH - Aged MH - Middle Aged MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - cancer-specific survival OT - non-muscle-invasive bladder cancer OT - overall survival OT - progression-free survival OT - recurrence-free survival OT - statins EDAT- 2024/09/11 07:43 MHDA- 2024/12/10 06:23 CRDT- 2024/09/11 02:43 PHST- 2024/12/10 06:23 [medline] PHST- 2024/09/11 07:43 [pubmed] PHST- 2024/09/11 02:43 [entrez] AID - 10.1111/bju.16493 [doi] PST - ppublish SO - BJU Int. 2025 Jan;135(1):88-94. doi: 10.1111/bju.16493. Epub 2024 Sep 10. PMID- 39256148 OWN - NLM STAT- MEDLINE DCOM- 20241118 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 12 DP - 2024 Dec TI - The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association. PG - 452.e1-452.e13 LID - S1078-1439(24)00570-2 [pii] LID - 10.1016/j.urolonc.2024.07.017 [doi] AB - INTRODUCTION: Bladder cancer disproportionately affects men and often presents as nonmuscle-invasive bladder cancer (NMIBC). Despite initial treatments, the recurrence and progression of NMIBC are linked to autophagy. This study investigates the expression of autophagy genes (mTOR, ULK1, Beclin1, and LC3) in low and high-grade NMIBC, providing insights into potential prognostic markers and therapeutic targets. MATERIAL AND METHODS: A total of 115 tissue samples (n = 85 NMIBC (pTa, pT1, and CIS) and n = 30 control from BPH patients) were collected. The expression level of autophagy genes (mTOR, ULK1, Beclin1, and LC3) and their proteins were assessed in low and high-grade NMIBC, along with control tissue samples using quantitative real-time polymerase chain reaction and western blotting. Association with clinicopathological characteristics and autophagy gene expression was analyzed by multivariate and univariate survival analysis using SPSS. RESULT: In high-grade NMIBC, ULK1, P = 0.0150, Beclin1, P = 0.0041, and LC3, P = 0.0014, were substantially downregulated, whereas mTOR, P = 0.0006, was significantly upregulated. The KM plots show significant survival outcomes with autophagy genes. The clinicopathological characters, high grade (P = 0.019), tumor stage (CIS P = 0.039, pT1 P = 0.018, P = 0.045), male (P = 0.010), lymphovascular invasion (P = 0.028) and autophagy genes (ULK1 P = 0.002, beclin1 (P = 0.010, P = 0.022) were associated as risk factors for survival outcome in NMIBC patients. CONCLUSION: The upregulated mTOR, downregulated ULK1, and beclin1 expression is linked to a high-grade, CIS and pT1 stage, resulting in poor recurrence-free survival and progression-free survival and highlights the prognostic significance of autophagy gene in nonmuscle-invasive bladder cancer. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Kumar, Anil AU - Kumar A AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Singh, Mukul Kumar AU - Singh MK AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Singh, Vishwajeet AU - Singh V AD - Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. Electronic address: drvishwajeet68@gmail.com. FAU - Shrivastava, Ashutosh AU - Shrivastava A AD - Center For Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India. FAU - Sahu, Dinesh Kumar AU - Sahu DK AD - Central Research Facility, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India. FAU - Bisht, Dakshina AU - Bisht D AD - Department Microbiology, Santosh Deemed to Be University, Ghaziabad, Uttar Pradesh, India. FAU - Singh, Shubhendu AU - Singh S AD - Department Microbiology, Santosh Deemed to Be University, Ghaziabad, Uttar Pradesh, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240910 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - EC 2.7.11.1 (Autophagy-Related Protein-1 Homolog) RN - EC 2.7.11.1 (ULK1 protein, human) RN - 0 (Intracellular Signaling Peptides and Proteins) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics/mortality/metabolism MH - *Autophagy/genetics MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Neoplasm Grading MH - Survival Analysis MH - Neoplasm Invasiveness MH - Autophagy-Related Protein-1 Homolog/metabolism/genetics MH - Prognosis MH - Intracellular Signaling Peptides and Proteins OTO - NOTNLM OT - Autophagy OT - NMIBC OT - Prognostic OT - Survival outcome OT - low and high grade COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/09/11 00:43 MHDA- 2024/11/19 00:22 CRDT- 2024/09/10 21:59 PHST- 2024/03/21 00:00 [received] PHST- 2024/07/16 00:00 [revised] PHST- 2024/07/28 00:00 [accepted] PHST- 2024/11/19 00:22 [medline] PHST- 2024/09/11 00:43 [pubmed] PHST- 2024/09/10 21:59 [entrez] AID - S1078-1439(24)00570-2 [pii] AID - 10.1016/j.urolonc.2024.07.017 [doi] PST - ppublish SO - Urol Oncol. 2024 Dec;42(12):452.e1-452.e13. doi: 10.1016/j.urolonc.2024.07.017. Epub 2024 Sep 10. PMID- 39249915 OWN - NLM STAT- MEDLINE DCOM- 20240909 LR - 20260711 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 65 IP - 5 DP - 2024 Sep TI - Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea. PG - 435-441 LID - 10.4111/icu.20240047 [doi] AB - PURPOSE: In high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guerin (BCG) is the standard adjuvant therapy post-transurethral resection of bladder tumor (TURBT). Intravesical gemcitabine, used as an alternative or second-line therapy amid BCG shortages, lacks outcome studies in the Korean population. MATERIALS AND METHODS: Patients who received weekly intravesical gemcitabine for 6 weeks after TURBT from 2019 to 2022 were retrospectively investigated. Based on the American Urological Association risk classification, patients with high- or very high-risk NMIBC who refused cystectomy were included. Maintenance treatment was performed depending on their risk. Recurrence was defined as histologic confirmation on subsequent cystoscopic biopsies or TURBT. Disease free survival (DFS) was evaluated by the Kaplan-Meier method. RESULTS: The study included 60 patients, comprising 45 high-risk (group 1) patients with a median age of 76 years and 15 very high-risk (group 2) patients with a median age of 68 years. Among them, 28 patients had previously received intravesical BCG. Over a median follow-up of 22 months, recurrence occurred in 31 patients in group 1 and 11 in group 2. The DFS rates of the high-risk group and the very high-risk group were 57.8% versus 40% at 1 year, 20.7% versus 21.3% at 2 years and 20.7% versus 21.3% at 3 years, respectively (p=0.831). Tis stage (p=0.042) and prostatic urethra invasion (p=0.028) were significant predictors of DFS. Cancer-specific mortality rates were 2.2% in group 1 and 6.7% in group 2 (p=0.441). CONCLUSIONS: Similar DFS outcome between high-risk and very high-risk patients were observed based on short-term results in Korea. This finding is crucial for clinical practice; however, studies analyzing more patients and long-term outcomes are needed. CI - (c) The Korean Urological Association. FAU - Kim, Gang Kyu AU - Kim GK AUID- ORCID: 0009-0000-3954-3975 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Jo, Young Heun AU - Jo YH AUID- ORCID: 0000-0002-5604-9781 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Lee, Jongsoo AU - Lee J AUID- ORCID: 0000-0002-9984-1138 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Han, Hyun Ho AU - Han HH AUID- ORCID: 0000-0002-6268-0860 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Ham, Won Sik AU - Ham WS AUID- ORCID: 0000-0003-2246-8838 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Jang, Won Sik AU - Jang WS AUID- ORCID: 0000-0002-9082-0381 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Heo, Ji Eun AU - Heo JE AUID- ORCID: 0000-0002-4184-8468 AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. HEOJI87@yuhs.ac. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy/mortality/surgery MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Male MH - Administration, Intravesical MH - Aged MH - Female MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Middle Aged MH - *Neoplasm Invasiveness MH - *Antimetabolites, Antineoplastic/administration & dosage MH - Treatment Outcome MH - Time Factors MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11390271 OTO - NOTNLM OT - Bladder cancer OT - Gemcitabine OT - Intravesical instillation COIS- The authors have nothing to disclose. EDAT- 2024/09/09 12:42 MHDA- 2024/09/09 12:43 PMCR- 2024/09/01 CRDT- 2024/09/09 11:35 PHST- 2024/02/02 00:00 [received] PHST- 2024/04/23 00:00 [revised] PHST- 2024/07/01 00:00 [accepted] PHST- 2024/09/09 12:43 [medline] PHST- 2024/09/09 12:42 [pubmed] PHST- 2024/09/09 11:35 [entrez] PHST- 2024/09/01 00:00 [pmc-release] AID - 65.435 [pii] AID - 10.4111/icu.20240047 [doi] PST - ppublish SO - Investig Clin Urol. 2024 Sep;65(5):435-441. doi: 10.4111/icu.20240047. PMID- 39246267 OWN - NLM STAT- MEDLINE DCOM- 20240909 LR - 20260923 IS - 2046-4924 (Electronic) IS - 1366-5278 (Print) IS - 1366-5278 (Linking) VI - 28 IP - 42 DP - 2024 Aug TI - Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. PG - 1-65 LID - 10.3310/DEHT5407 [doi] AB - BACKGROUND: Transurethral resection of bladder tumour has been the mainstay of bladder cancer staging for > 60 years. Staging inaccuracies are commonplace, leading to delayed treatment of muscle-invasive bladder cancer. Multiparametric magnetic resonance imaging offers rapid, accurate and non-invasive staging of muscle-invasive bladder cancer, potentially reducing delays to radical treatment. OBJECTIVES: To assess the feasibility and efficacy of the introducing multiparametric magnetic resonance imaging ahead of transurethral resection of bladder tumour in the staging of suspected muscle-invasive bladder cancer. DESIGN: Open-label, multistage randomised controlled study in three parts: feasibility, intermediate and final clinical stages. The COVID pandemic prevented completion of the final stage. SETTING: Fifteen UK hospitals. PARTICIPANTS: Newly diagnosed bladder cancer patients of age >/= 18 years. INTERVENTIONS: Participants were randomised to Pathway 1 or 2 following visual assessment of the suspicion of non-muscle-invasive bladder cancer or muscle-invasive bladder cancer at the time of outpatient cystoscopy, based upon a 5-point Likert scale: Likert 1-2 tumours considered probable non-muscle-invasive bladder cancer; Likert 3-5 possible muscle-invasive bladder cancer. In Pathway 1, all participants underwent transurethral resection of bladder tumour. In Pathway 2, probable non-muscle-invasive bladder cancer participants underwent transurethral resection of bladder tumour, and possible muscle-invasive bladder cancer participants underwent initial multiparametric magnetic resonance imaging. Subsequent therapy was determined by the treating team and could include transurethral resection of bladder tumour. MAIN OUTCOME MEASURES: Feasibility stage: proportion with possible muscle-invasive bladder cancer randomised to Pathway 2 which correctly followed the protocol. Intermediate stage: time to correct treatment for muscle-invasive bladder cancer. RESULTS: Between 31 May 2018 and 31 December 2021, of 638 patients approached, 143 participants were randomised; 52.1% were deemed as possible muscle-invasive bladder cancer and 47.9% probable non-muscle-invasive bladder cancer. Feasibility stage: 36/39 [92% (95% confidence interval 79 to 98%)] muscle-invasive bladder cancer participants followed the correct treatment by pathway. Intermediate stage: median time to correct treatment was 98 (95% confidence interval 72 to 125) days for Pathway 1 versus 53 (95% confidence interval 20 to 89) days for Pathway 2 [hazard ratio 2.9 (95% confidence interval 1.0 to 8.1)], p = 0.040. Median time to correct treatment for all participants was 37 days for Pathway 1 and 25 days for Pathway 2 [hazard ratio 1.4 (95% confidence interval 0.9 to 2.0)]. LIMITATIONS: For participants who underwent chemotherapy, radiotherapy or palliation for multiparametric magnetic resonance imaging-diagnosed stage T2 or higher disease, it was impossible to conclusively know whether these were correct treatments due to the absence of histopathologically confirmed muscle invasion, this being confirmed radiologically in these cases. All patients had histological confirmation of their cancers. Due to the COVID-19 pandemic, we were unable to realise the final stage. CONCLUSION: The multiparametric magnetic resonance imaging-directed pathway led to a substantial 45-day reduction in time to correct treatment for muscle-invasive bladder cancer, without detriment to non-muscle-invasive bladder cancer participants. Consideration should be given to the incorporation of multiparametric magnetic resonance imaging ahead of transurethral resection of bladder tumour into the standard pathway for all patients with suspected muscle-invasive bladder cancer. The improved decision-making accelerated time to treatment, even though many patients subsequently needed transurethral resection of bladder tumour. A proportion of patients can avoid transurethral resection of bladder tumour completely, reducing costs and morbidity, given the much lower cost of magnetic resonance imaging and biopsy compared to transurethral resection of bladder tumour. FUTURE WORK: Further work to cross-correlate with the recently developed Vesical Imaging-Reporting and Data System will improve accuracy and aid dissemination. Longer follow-up to examine the effect of the pathway on outcomes is also required. Incorporation of liquid deoxyribonucleic acid-based biomarkers may further improve the quality of decision-making and should also be investigated further. STUDY REGISTRATION: This study is registered as ISRCTN 35296862. FUNDING: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR135775) and is published in full in Health Technology Assessment; Vol. 28, No. 42. See the NIHR Funding and Awards website for further award information. FAU - James, Nicholas AU - James N AUID- ORCID: 0000-0002-7314-8204 AD - Institute of Cancer Research, London, UK. FAU - Pirrie, Sarah AU - Pirrie S AUID- ORCID: 0000-0002-2894-2230 AD - Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Liu, Wenyu AU - Liu W AUID- ORCID: 0000-0002-6682-2053 AD - Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Catto, James AU - Catto J AUID- ORCID: 0000-0003-2787-8828 AD - Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Jefferson, Kieran AU - Jefferson K AUID- ORCID: 0000-0002-0029-8359 AD - Department of Urology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. FAU - Patel, Prashant AU - Patel P AUID- ORCID: 0000-0002-2882-5990 AD - Institute of Cancer and Genomic Sciences, University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Hughes, Ana AU - Hughes A AUID- ORCID: 0000-0001-7274-9422 AD - Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Pope, Ann AU - Pope A AUID- ORCID: 0000-0001-7458-3294 AD - Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Nanton, Veronica AU - Nanton V AUID- ORCID: 0000-0002-9553-822X AD - Medical School, University of Warwick, Warwick, UK. FAU - Mintz, Harriet P AU - Mintz HP AUID- ORCID: 0000-0003-1583-6268 AD - Cancer Research Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Medical School, University of Birmingham, Birmingham, UK. FAU - Knight, Allen AU - Knight A AUID- ORCID: 0000-0001-8123-9547 AD - Patient and Public Involvement Representatives, Gallagher, Bradford Knight, Basingstoke, UK. FAU - Gallagher, Jean AU - Gallagher J AUID- ORCID: 0009-0007-6308-2292 AD - Patient and Public Involvement Representatives, Gallagher, Bradford Knight, Basingstoke, UK. FAU - Bryan, Richard T AU - Bryan RT AUID- ORCID: 0000-0003-2853-4293 AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - Health Technol Assess JT - Health technology assessment (Winchester, England) JID - 9706284 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/diagnostic imaging MH - Male MH - Female MH - Aged MH - *Neoplasm Staging MH - Middle Aged MH - United Kingdom MH - COVID-19 MH - Multiparametric Magnetic Resonance Imaging MH - Cystoscopy/methods MH - Feasibility Studies MH - Neoplasm Invasiveness MH - Critical Pathways MH - Technology Assessment, Biomedical MH - Aged, 80 and over PMC - PMC11403381 OAB - The BladderPath trial explored how to accelerate diagnosis and avoid unnecessary surgery for patients with bladder cancer which had grown into the muscle wall of the bladder, referred to as muscle-invasive bladder cancer. Following initial outpatient diagnosis, bladder cancer patients currently undergo inpatient or day-case surgical tumour removal using a telescope (transurethral resection of bladder tumour). This surgery is fundamental to the treatment of early bladder cancer (non-muscle-invasive). However, for muscle-invasive disease, the main role of transurethral resection of bladder tumour is to confirm that the tumour has grown into the bladder muscle, and this is often inaccurate; the actual correct treatment for muscle-invasive bladder cancer patients should include chemotherapy, radiotherapy and/or bladder removal. For these patients, having transurethral resection of bladder tumour may delay this correct treatment and impact survival. Additionally, for patients determined to need palliative care due to advanced disease, the transurethral resection of bladder tumour may represent over-treatment. A magnetic resonance imaging scan with contrast agent (called multiparametric magnetic resonance imaging) gives a clearer picture of the bladder than normal scans, allowing distinction between invasive and non-invasive tumours. The BladderPath trial investigated adding multiparametric magnetic resonance imaging for patients with suspected muscle-invasive bladder cancer and the effect on treatment times. Subsequent therapy could include transurethral resection of bladder tumour if clinically determined as necessary by the treating team. Trial participants were randomly allocated either to the standard pathway (Pathway 1: all underwent transurethral resection of bladder tumour) or to a new pathway (Pathway 2). In Pathway 2, urologists conducting the initial outpatient diagnostic bladder inspections used a scale to assess whether tumours appeared to be either probably non-muscle-invasive or possibly muscle-invasive. Participants whose tumours appeared possibly muscle-invasive had initial multiparametric magnetic resonance imaging as their next investigation instead of transurethral resection of bladder tumour. We then compared the duration of time from initial diagnosis to receiving the correct treatment for participants in each pathway. Of the 143 participants, 75 (52.1%) were diagnosed as possibly muscle invasive. In Pathway 1, the duration for half of the participants in the group to have received their correct treatment for muscle-invasive bladder cancer was 98 days, which reduced to 53 days in Pathway 2. Furthermore, the duration for half of all the participants in the two groups to have received their correct treatment was 37 days for Pathway 1 and 31 days for Pathway 2. In summary, use of initial multiparametric magnetic resonance imaging in suspected muscle-invasive bladder cancer participants substantially reduced the time to correct treatment (surgery, radiotherapy, chemotherapy or instigation of palliative care) and avoided unnecessary surgery. There was no negative impact on participants with non-invasive disease. Adopting multiparametric magnetic resonance imaging into the pathway ahead of transurethral resection of bladder tumour for patients with suspected muscle-invasive bladder cancer is recommended. OABL- eng OTO - NOTNLM OT - BLADDER CANCER OT - CLINICAL PATHWAY OT - CLINICAL TRIAL OT - MAGNETIC RESONANCE IMAGING OT - MRI OT - STAGING OT - TRANSURETHRAL RESECTION OT - TURBT EDAT- 2024/09/09 06:41 MHDA- 2024/09/09 06:42 PMCR- 2024/09/16 CRDT- 2024/09/09 04:43 PHST- 2024/09/09 06:42 [medline] PHST- 2024/09/09 06:41 [pubmed] PHST- 2024/09/09 04:43 [entrez] PHST- 2024/09/16 00:00 [pmc-release] AID - 10.3310/DEHT5407 [doi] PST - ppublish SO - Health Technol Assess. 2024 Aug;28(42):1-65. doi: 10.3310/DEHT5407. PMID- 39229422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 8 DP - 2024 Aug TI - Clinicohistopathological Correlation and Prognostic Significance of Molecular Biomarkers in Urinary Bladder Neoplasms: A Comprehensive Analysis. PG - e66088 LID - 10.7759/cureus.66088 [doi] LID - e66088 AB - BACKGROUND: Urinary bladder neoplasms constitute a heterogeneous group of tumors with diverse clinical behaviors and outcomes. Understanding the correlation between clinicopathological characteristics and the prognostic significance of molecular biomarkers in bladder cancer is vital for personalized treatment strategies and improved patient outcomes. OBJECTIVE: This prospective observational study aimed to comprehensively investigate the clinicopathological correlations and prognostic significance of molecular biomarkers in urinary bladder neoplasms. METHODS: A cohort of 174 patients diagnosed with urinary bladder neoplasm participated in this study. Clinicopathological data, including demographic information, medical history, imaging findings, and histopathological reports, were collected from the patient records. Tissue samples obtained from transurethral resection or biopsy were subjected to molecular biomarker analysis using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and molecular profiling techniques. Longitudinal follow-up assessments were conducted to monitor disease progression, recurrence, and overall survival. RESULT: Out of 174 patients diagnosed with bladder neoplasms, the mean age of the patients was 62.4 years (+/-8.7), indicating that the study cohort primarily comprised elderly individuals. The majority of patients were male (126, 72.4%), reflecting the higher prevalence of bladder cancer among men compared to women. Preliminary analysis revealed significant associations between clinicopathological parameters, molecular biomarker expression profiles, and clinical outcomes in patients with urinary bladder neoplasms. Elevated expression levels of specific biomarkers such as tumor protein p53 (p53), Ki-67, and estimated glomerular filtration rate (EGFR) were observed in advanced tumor stages (p < 0.001) and higher histological grades (p < 0.05), indicating their potential prognostic significance. Furthermore, genetic alterations detected using molecular profiling techniques, including chromosomal gains and losses, were significantly correlated with aggressive disease phenotypes and increased recurrence risk (p < 0.01). Longitudinal follow-up data demonstrated that patients with elevated biomarker expression levels or genetic alterations had poorer treatment responses and shorter overall survival durations than those with lower biomarker expression levels. CONCLUSION: This study highlights the importance of integrating clinicopathological parameters and molecular biomarker data for the risk stratification, treatment selection, and prognostic assessment of urinary bladder neoplasms. CI - Copyright (c) 2024, Mane et al. FAU - Mane, Avinash AU - Mane A AD - Department of Pathology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND. FAU - Patil, Nanda J AU - Patil NJ AD - Department of Pathology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND. FAU - Hulwan, Atul B AU - Hulwan AB AD - Department of Pathology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND. FAU - Koley, Avishek AU - Koley A AD - Department of General Surgery, Sarojini Naidu Medical College, Agra, IND. LA - eng PT - Journal Article DEP - 20240803 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11368705 OTO - NOTNLM OT - bladder cancer OT - molecular biomarkers OT - neoplasms OT - prognostic significance OT - urinary bladder COIS- Human subjects: Consent was obtained or waived by all participants in this study. Krishna Vishwa Vidyapeeth issued approval IEC/839/2022-23. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/09/04 06:42 MHDA- 2024/09/04 06:43 PMCR- 2024/08/03 CRDT- 2024/09/04 04:39 PHST- 2024/06/06 00:00 [received] PHST- 2024/07/31 00:00 [accepted] PHST- 2024/09/04 06:43 [medline] PHST- 2024/09/04 06:42 [pubmed] PHST- 2024/09/04 04:39 [entrez] PHST- 2024/08/03 00:00 [pmc-release] AID - 10.7759/cureus.66088 [doi] PST - epublish SO - Cureus. 2024 Aug 3;16(8):e66088. doi: 10.7759/cureus.66088. eCollection 2024 Aug. PMID- 39228216 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20260703 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 34 IP - 6 DP - 2024 Nov 1 TI - Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker. PG - 464-470 LID - 10.1097/MOU.0000000000001221 [doi] AB - PURPOSE OF REVIEW: Tumor-informed circulating tumor DNA (ctDNA) is an emerging biomarker in urothelial carcinoma. Recent clinical trials have investigated the integration of ctDNA into clinical decision-making in patients with muscle-invasive bladder cancer, their findings suggest that ctDNA may potentially revolutionize the way we stratify patients to different treatment modalities. RECENT FINDINGS: ctDNA informed from TURBT specimens was found to be prognostic of disease outcomes among patients with localized nonmetastatic bladder cancer. Detectable precystectomy ctDNA status was associated with worse survival outcomes. Additionally, ctDNA status was predictive of adverse disease on radical cystectomy, including the likelihood of disease upstaging, lymph node involvement, and having a locally advanced disease (>/=pT3a). In the postcystectomy minimal residual disease (MRD) period, ctDNA status may refine patient selection to adjuvant therapy, and if validated by ongoing clinical trials, patients with undetectable postcystectomy ctDNA status may forgo adjuvant treatment, regardless of pathological stage. On the contrary, patients with pre or postcystectomy detectable ctDNA status may benefit from treatment intensification. SUMMARY: The integration of ctDNA in clinical decision-making has the potential to revolutionize the way we manage urothelial carcinoma by refining patient selection to different treatment modalities. This approach could ultimately lead to personalization of oncological care, with the potential to reduce both treatment-related and financial toxicity. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Ben-David, Reuben AU - Ben-David R AD - Department of Urology, Icahn School of Medicine at The Mount Sinai Hospital, New York, New York, USA. FAU - Mehrazin, Reza AU - Mehrazin R FAU - Attalla, Kyrollis AU - Attalla K FAU - Wiklund, Peter AU - Wiklund P FAU - Sfakianos, John P AU - Sfakianos JP LA - eng PT - Journal Article PT - Review DEP - 20240903 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Circulating Tumor DNA/blood/genetics MH - *Urinary Bladder Neoplasms/blood/genetics/pathology/surgery/therapy/diagnosis MH - *Biomarkers, Tumor/blood/genetics MH - *Carcinoma, Transitional Cell/blood/genetics/surgery/diagnosis/pathology/therapy MH - Cystectomy/methods MH - Prognosis MH - Clinical Decision-Making/methods MH - Neoplasm, Residual MH - Neoplasm Staging EDAT- 2024/09/04 06:41 MHDA- 2024/11/13 13:54 CRDT- 2024/09/04 03:03 PHST- 2024/11/13 13:54 [medline] PHST- 2024/09/04 06:41 [pubmed] PHST- 2024/09/04 03:03 [entrez] AID - 00042307-202411000-00012 [pii] AID - 10.1097/MOU.0000000000001221 [doi] PST - ppublish SO - Curr Opin Urol. 2024 Nov 1;34(6):464-470. doi: 10.1097/MOU.0000000000001221. Epub 2024 Sep 3. PMID- 39222123 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250428 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 486 IP - 4 DP - 2025 Apr TI - A single-center retrospective comparison of pT1 substaging methods in bladder cancer. PG - 817-826 LID - 10.1007/s00428-024-03907-4 [doi] AB - Substaging of T1 urothelial cancer is associated with tumor progression and its reporting is recommended by international guidelines. However, it has not been integrated in risk stratification tools and there is no agreement on the best method to use for its reporting. We aimed to investigate the applicability, interobserver variability, and prognostic value of histological landmark based and micrometric (aggregate linear length of invasive carcinoma (ALLICA), microscopic vs. extensive system, Rete Oncologica Lombarda (ROL) system) substaging methods. A total of 79 patients with the primary diagnosis of T1 urothelial cancer treated with conventional transurethral resection and adjuvant BCG therapy between 2000 and 2020 at the Medical University of Vienna were included. The anatomical and metrical substaging systems were evaluated using agreement rate, Cohen's kappa, Kendall's tau, and Spearman rank correlation. Prognostic value for high-grade recurrence or T2 progression was evaluated in uni- and multivariable analysis. Applicability and reproducibility were good to moderate and varied between substaging methods. Obstacles are mainly due to fragmentation of samples. Anatomical substaging was associated with progression in univariable and multivariable analysis. In our cohort, we could only identify anatomical landmark-based substaging to be prognostic for T2 progression. A major obstacle for proper pathological assessment is fragmentation of samples due to operational procedure. Avoiding such fragmentation might improve reproducibility and significance of pathological T1 substaging of urothelial cancer. CI - (c) 2024. The Author(s). FAU - Klager, Johannes AU - Klager J AUID- ORCID: 0000-0001-5761-0713 AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. Johannes.klaeger@meduniwien.ac.at. FAU - Koeller, Maximilian C AU - Koeller MC AUID- ORCID: 0000-0001-9699-3390 AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Oszwald, Andre AU - Oszwald A AUID- ORCID: 0000-0002-8298-6381 AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Wasinger, Gabriel AU - Wasinger G AUID- ORCID: 0000-0002-0323-7180 AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Comperat, Eva AU - Comperat E AUID- ORCID: 0000-0001-8488-543X AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240902 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Neoplasm Staging/methods MH - Aged, 80 and over MH - Disease Progression MH - Reproducibility of Results MH - Prognosis MH - Observer Variation MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/pathology/therapy PMC - PMC12018629 OTO - NOTNLM OT - Anatomical substaging OT - Interobserver variability OT - Metrical substaging OT - Staging urothelial carcinoma OT - T1 urothelial cancer OT - T1 urothelial cancer substaging OT - Urothelial carcinoma COIS- Declarations. Ethics approval: The submitted work was approved by the local ethics committee. Competing interests: The authors declare no competing interests. EDAT- 2024/09/02 12:42 MHDA- 2025/04/23 12:27 PMCR- 2024/09/02 CRDT- 2024/09/02 11:04 PHST- 2024/05/27 00:00 [received] PHST- 2024/08/20 00:00 [accepted] PHST- 2024/07/26 00:00 [revised] PHST- 2025/04/23 12:27 [medline] PHST- 2024/09/02 12:42 [pubmed] PHST- 2024/09/02 11:04 [entrez] PHST- 2024/09/02 00:00 [pmc-release] AID - 10.1007/s00428-024-03907-4 [pii] AID - 3907 [pii] AID - 10.1007/s00428-024-03907-4 [doi] PST - ppublish SO - Virchows Arch. 2025 Apr;486(4):817-826. doi: 10.1007/s00428-024-03907-4. Epub 2024 Sep 2. PMID- 39219882 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240903 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 7 DP - 2024 Jul TI - Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer. PG - e65816 LID - 10.7759/cureus.65816 [doi] LID - e65816 AB - Introduction Bladder cancer is a significant health issue with an increased recurrence and progression rate, requiring invasive follow-up, which shows a poor prognosis. In addition, the prognostic role of mutant fibroblast growth factor receptor 3 (FGFR3) and tumor protein P53 (TP53) is controversial; therefore, we investigated the methylation status and their altered gene expression in low- and high-grade non-muscle-invasive bladder cancer (NMIBC) subjects. Materials and methods This case-control study was conducted between 2020 and 2023, in which n = 115 tumor tissues (NMIBC n = 85) and (controls n = 30) were examined for FGFR3 and FGFR promoter methylation and expression using methylation-specific PCR (MSP) and real-time PCR. The multivariate regression analysis and Kaplan-Meier (KM) plots were used to establish the association of FGFR3 and TP53 with clinicopathological features and survival outcomes of NMIBC patients. Results High-grade NMIBC tumors showed substantial methylation patterns, with TP53 hypomethylated (p = 0.034) and FGFR3 hypermethylated (p = 0.046), as well as significant mRNA expression of Tp53 and FGFR3 (p = 0.001). The multivariate analysis shows FGFR3 and Tp53 were associated with recurrence-free survival with sensitivity (p = 0.045 (78%); 0.034 (70.7%)) and progression-free survival (p = 0.022(61.5%); 0.038 (69.2%)). Conclusion The findings of this investigation indicate that FGFR3 hypermethylation and TP53 hypomethylation are independent prognostic indicators that aid in the evaluation of disease outcomes in high-grade NMIBC tumors. CI - Copyright (c) 2024, Kumar et al. FAU - Kumar, Anil AU - Kumar A AD - Urology, King George's Medical University, Lucknow, IND. FAU - Singh, Vivek K AU - Singh VK AD - Urology, King George's Medical University, Lucknow, IND. FAU - Singh, Vishwajeet AU - Singh V AD - Urology, King George's Medical University, Lucknow, IND. FAU - Singh, Mukul K AU - Singh MK AD - Urology, King George's Medical University, Lucknow, IND. FAU - Shrivastava, Ashutosh AU - Shrivastava A AD - Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, IND. FAU - Sahu, Dinesh K AU - Sahu DK AD - Central Research Facility/Molecular Biology, Post Graduate Institute of Child Health, Noida, IND. LA - eng PT - Journal Article DEP - 20240731 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11362872 OTO - NOTNLM OT - bladder cancer OT - high grade OT - low grade OT - methylation OT - recurrence COIS- Human subjects: Consent was obtained or waived by all participants in this study. King George's Medical University issued approval 120 ECM I B-Ph.d. / P-1. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/09/02 08:45 MHDA- 2024/09/02 08:46 PMCR- 2024/07/31 CRDT- 2024/09/02 05:09 PHST- 2024/07/30 00:00 [accepted] PHST- 2024/09/02 08:46 [medline] PHST- 2024/09/02 08:45 [pubmed] PHST- 2024/09/02 05:09 [entrez] PHST- 2024/07/31 00:00 [pmc-release] AID - 10.7759/cureus.65816 [doi] PST - epublish SO - Cureus. 2024 Jul 31;16(7):e65816. doi: 10.7759/cureus.65816. eCollection 2024 Jul. PMID- 39209674 OWN - NLM STAT- MEDLINE DCOM- 20241113 LR - 20241114 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 86 IP - 5 DP - 2024 Nov TI - The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer. PG - 391-399 LID - S0302-2838(24)02528-4 [pii] LID - 10.1016/j.eururo.2024.08.013 [doi] AB - Grade is an important determinant of progression in non-muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1: hazard ratio [HR] = 1.92; cohort 2: HR = 2.51, and cohort 3: HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Beijert, Irene J AU - Beijert IJ AD - Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. Electronic address: i.j.beijert@amsterdamumc.nl. FAU - Hagberg, Oskar AU - Hagberg O AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Northern Registry Centre, Department of Diagnostics and Intervention, Umea University, Umea, Sweden. FAU - Johnston, Allan AU - Johnston A AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. FAU - Trail, Matthew AU - Trail M AD - Department of Urology, Ninewells Hospital, Dundee, UK. FAU - Hamid, Sami AU - Hamid S AD - Department of Urology, Ninewells Hospital, Dundee, UK. FAU - Dreyer, Barend A AU - Dreyer BA AD - Department of Urology, Victoria Hospital, Kirkcaldy, UK. FAU - Padovani, Luisa AU - Padovani L AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Garau, Roberta AU - Garau R AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Hasan, Rami AU - Hasan R AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; Department of Urology, University Hospital Ayr, Ayr, UK. FAU - Ahmad, Imran AU - Ahmad I AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; School of Cancer Sciences, University of Glasgow, Glasgow, UK. FAU - Hendry, David AU - Hendry D AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Burger, Maximilian AU - Burger M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Pitie Salpetriere Hospital, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; University of Edinburgh, Edinburgh, UK. Electronic address: Param.Mariappan@nhs.scot. FAU - Liedberg, Fredrik AU - Liedberg F AD - Institution of Translational Medicine, Lund University, Malmo, Sweden; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Skane University Hospital, Malmo, Sweden. Electronic address: fredrik.liedberg@med.lu.se. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: b.v.rhijn@nki.nl. CN - BladderBaSe-Consortium CN - Scot BC Quality OPS Collaborative CN - Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973 CN - WHO2004/2016 Classification Systems for Grade LA - eng PT - Journal Article DEP - 20240829 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/classification MH - *Neoplasm Grading MH - Male MH - Female MH - Aged MH - *Disease Progression MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Prognosis MH - Time Factors MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder OT - Cancer OT - Grading OT - Hybrid grade OT - World Health Organization 1973 OT - World Health Organization 1999 OT - World Health Organization 2004 OT - World Health Organization 2016 EDAT- 2024/08/31 09:46 MHDA- 2024/11/14 03:54 CRDT- 2024/08/29 21:58 PHST- 2024/04/18 00:00 [received] PHST- 2024/07/10 00:00 [revised] PHST- 2024/08/03 00:00 [accepted] PHST- 2024/11/14 03:54 [medline] PHST- 2024/08/31 09:46 [pubmed] PHST- 2024/08/29 21:58 [entrez] AID - S0302-2838(24)02528-4 [pii] AID - 10.1016/j.eururo.2024.08.013 [doi] PST - ppublish SO - Eur Urol. 2024 Nov;86(5):391-399. doi: 10.1016/j.eururo.2024.08.013. Epub 2024 Aug 29. PMID- 39187984 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20260715 IS - 1940-6215 (Electronic) IS - 1940-6207 (Print) IS - 1940-6215 (Linking) VI - 18 IP - 1 DP - 2025 Jan 6 TI - Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. PG - 31-39 LID - 10.1158/1940-6207.CAPR-24-0194 [doi] AB - We performed a clinical trial in patients with non-muscle-invasive (NMI) urothelial cancer randomized (2:1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally once weekly x 3 doses prior to scheduled surgery) to assess for a difference in EGFR phosphorylation in tumor-adjacent normal urothelium <24 hours post-study dose and tolerance of weekly erlotinib therapy. Thirty-seven volunteers (6 female/31 male; mean age 70; 35 White/2 non-White) with confirmed or suspected NMI urothelial cancer were enrolled into either erlotinib (n = 24; 900 mg-13, 600 mg-11) or placebo (n = 13). IHC assessment of phosphorylated and total EGFR in tumor-adjacent normal urothelium (20 erlotinib and 9 placebo subjects) or tumor (21 erlotinib and 11 placebo subjects) at study end showed no significant difference between those receiving erlotinib or placebo. This was also true for other assessed tissue biomarkers (phosphorylated ERK, ERK, E-cadherin, p53, and Ki67). Adverse events were more common, in a dose-related fashion, in participants receiving erlotinib, e.g., 38% experienced grade 1 with rare grade 2 diarrhea and skin toxicity versus 8% in placebo. Clinically insignificant but statistically significant (P = 0.001) elevations in serum total bilirubin and creatinine were observed in participants receiving erlotinib. Serum erlotinib and metabolite concentrations (OSI-420) confirmed compliance in all subjects receiving erlotinib and did not significantly differ between the 600 and 900 mg doses. Despite compelling preclinical and clinical data for targeted EGFR inhibition in bladder cancer prevention, these data do not support the use of weekly erlotinib therapy to prevent progression of NMI bladder cancer. Prevention Relevance: We evaluated the potential of erlotinib in preventing cancer by performing a randomized, double-blind, placebo-controlled trial of weekly erlotinib therapy in participants undergoing surgical removal of suspected noninvasive bladder neoplasia. Weekly erlotinib therapy was tolerated with common grade 1 to 2 toxicities but without evidence of beneficial effect upon urothelial tissue. See related Spotlight, p. 7. CI - (c)2024 American Association for Cancer Research. FAU - Downs, Tracy M AU - Downs TM AUID- ORCID: 0009-0006-4646-4064 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Bailey, Howard H AU - Bailey HH AUID- ORCID: 0000-0002-9149-3378 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Lozar, Taja AU - Lozar T AUID- ORCID: 0000-0003-2893-5580 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Schmitz, Natalie S AU - Schmitz NS AUID- ORCID: 0000-0002-4229-919X AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - Analytical Instrumentation Center, School of Pharmacy, University of Wisconsin, Madison, Wisconsin. FAU - Green, Heather AU - Green H AUID- ORCID: 0009-0008-5039-1368 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Scarlett, Cameron O AU - Scarlett CO AUID- ORCID: 0009-0004-5902-4637 AD - Analytical Instrumentation Center, School of Pharmacy, University of Wisconsin, Madison, Wisconsin. FAU - Havighurst, Thomas C AU - Havighurst TC AUID- ORCID: 0000-0002-9270-3189 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin. FAU - Twaroski, Kyleigh AU - Twaroski K AUID- ORCID: 0000-0002-3343-1515 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - DeShong, Katina AU - DeShong K AUID- ORCID: 0009-0002-1970-4262 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Wollmer, Barbara AU - Wollmer B AUID- ORCID: 0000-0002-5286-8990 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AUID- ORCID: 0000-0002-0870-4366 AD - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland. FAU - Saltzstein, Daniel R AU - Saltzstein DR AUID- ORCID: 0009-0005-7628-1931 AD - Urology San Antonio Research, San Antonio, Texas. FAU - Shore, Neal AU - Shore N AUID- ORCID: 0000-0001-5767-0548 AD - Carolina Urologic Research Center, Myrtle Beach, South Carolina. FAU - Kim, KyungMann AU - Kim K AUID- ORCID: 0000-0002-6726-003X AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin. FAU - Huang, Wei AU - Huang W AUID- ORCID: 0000-0003-0813-4188 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Ricke, William A AU - Ricke WA AUID- ORCID: 0000-0002-9807-2090 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Barroilhet, Lisa AU - Barroilhet L AUID- ORCID: 0000-0001-9315-2414 AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - House, Margaret AU - House M AUID- ORCID: 0000-0001-6887-1046 AD - Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland. FAU - Parnes, Howard L AU - Parnes HL AUID- ORCID: 0000-0003-3401-0007 AD - Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland. FAU - Messing, Edward AU - Messing E AUID- ORCID: 0000-0002-0985-7065 AD - University of Rochester, Rochester, New York. LA - eng SI - ClinicalTrials.gov/NCT02169284 GR - P30 CAO14520/National Cancer Institute (NCI)/ GR - M01 RR003186/RR/NCRR NIH HHS/United States GR - N01 CN05014/National Cancer Institute (NCI)/ GR - P30 CA014520/CA/NCI NIH HHS/United States GR - UG1 CA242635/CA/NCI NIH HHS/United States GR - UG1CA242635/National Cancer Institute (NCI)/ GR - M01 RR03186/National Institutes of Health (NIH)/ GR - U54 DK104310/DK/NIDDK NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PL - United States TA - Cancer Prev Res (Phila) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - DA87705X9K (Erlotinib Hydrochloride) RN - EC 2.7.10.1 (ErbB Receptors) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.1 (EGFR protein, human) SB - IM CIN - Cancer Prev Res (Phila). 2025 Jan 6;18(1):7-9. doi: 10.1158/1940-6207.CAPR-24-0491. PMID: 39757805 MH - Humans MH - *Erlotinib Hydrochloride/administration & dosage MH - *Urinary Bladder Neoplasms/surgery/prevention & control/pathology MH - Female MH - Male MH - Aged MH - Middle Aged MH - *ErbB Receptors/antagonists & inhibitors MH - Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use MH - Double-Blind Method MH - Aged, 80 and over MH - Phosphorylation/drug effects MH - Chemoprevention/methods PMC - PMC11703677 MID - NIHMS2020710 COIS- Statement of conflicts of interests: The authors declare no potential conflicts of interest. EDAT- 2024/08/27 09:49 MHDA- 2025/01/07 04:51 PMCR- 2025/07/06 CRDT- 2024/08/27 00:52 PHST- 2024/04/26 00:00 [received] PHST- 2024/07/12 00:00 [revised] PHST- 2024/08/23 00:00 [accepted] PHST- 2025/01/07 04:51 [medline] PHST- 2024/08/27 09:49 [pubmed] PHST- 2024/08/27 00:52 [entrez] PHST- 2025/07/06 00:00 [pmc-release] AID - 747402 [pii] AID - 10.1158/1940-6207.CAPR-24-0194 [doi] PST - ppublish SO - Cancer Prev Res (Phila). 2025 Jan 6;18(1):31-39. doi: 10.1158/1940-6207.CAPR-24-0194. PMID- 39186114 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 2730-6011 (Electronic) IS - 2730-6011 (Linking) VI - 15 IP - 1 DP - 2024 Aug 26 TI - Establish TIIC signature score based the machine learning fusion in bladder cancer. PG - 368 LID - 10.1007/s12672-024-01187-7 [doi] LID - 368 AB - BACKGROUND: Bladder cancer is a prevalent malignant tumor with high heterogeneity. Current treatments, such as transurethral resection of bladder tumor (TURBT) and intravesical Bacillus Calmette-Guerin (BCG) therapy, still have limitations, with approximately 30% of non-muscle-invasive bladder cancer (NMIBC) progressing to muscle-invasive bladder cancer (MIBC), and a substantial number of MIBC patients experiencing recurrence after surgery. Immunotherapy has shown potential benefits, but accurate prediction of its prognostic effects remains challenging. METHODS: We analyzed bladder cancer RNA-seq data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and used various machine learning algorithms to screen for feature RNAs related to tumor-infiltrating immune cells (TIICs) from single-cell data. Based on these RNAs, we established a TIIC signature score and evaluated its relationship with overall survival (OS) and immunotherapy response in bladder cancer patients. RESULTS: The study identified 171 TIIC-RNAs and selected 11 TIIC-RNAs with prognostic value through survival analysis. The TIIC signature score established using a machine learning fusion method was significantly associated with OS and showed good predictive performance in different datasets. Additionally, the signature score was negatively correlated with immunotherapy response, with patients with low TIIC feature scores showing better survival outcomes after immunotherapy. Further biological functional analysis revealed a close association between the TIIC signature score and immune regulation processes, cellular metabolism, and genetic variations. CONCLUSION: This study successfully constructed and validated an RNA signature scoring system based on tumor-infiltrating immune cell (TIIC) features, which can effectively predict OS and the effectiveness of immunotherapy in bladder cancer patients. CI - (c) 2024. The Author(s). FAU - Zeng, Xiangju AU - Zeng X AD - Department of Outpatient, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. FAU - Lu, Zhijie AU - Lu Z AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. FAU - Dai, Caixia AU - Dai C AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. FAU - Su, Hao AU - Su H AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. FAU - Liu, Ziqi AU - Liu Z AD - Department of Acupuncture and Moxibustion, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China. FAU - Cheng, Shunhua AU - Cheng S AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. csh2394@csu.edu.cn. LA - eng PT - Journal Article DEP - 20240826 PL - United States TA - Discov Oncol JT - Discover oncology JID - 101775142 PMC - PMC11347539 OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - Prognostic prediction OT - TIIC signature score OT - Tumor microenvironment COIS- The authors declare no competing interests. EDAT- 2024/08/26 13:45 MHDA- 2024/08/26 13:46 PMCR- 2024/08/26 CRDT- 2024/08/26 11:04 PHST- 2024/05/26 00:00 [received] PHST- 2024/07/23 00:00 [accepted] PHST- 2024/08/26 13:46 [medline] PHST- 2024/08/26 13:45 [pubmed] PHST- 2024/08/26 11:04 [entrez] PHST- 2024/08/26 00:00 [pmc-release] AID - 10.1007/s12672-024-01187-7 [pii] AID - 1187 [pii] AID - 10.1007/s12672-024-01187-7 [doi] PST - epublish SO - Discov Oncol. 2024 Aug 26;15(1):368. doi: 10.1007/s12672-024-01187-7. PMID- 39184817 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240827 IS - 2251-9637 (Print) IS - 2251-9645 (Electronic) IS - 2251-9637 (Linking) VI - 13 IP - 2 DP - 2024 TI - An Intricate Relationship Between miR-155-5p Expression and Oxidative Stress in Bladder Cancer Patients Treated with Calmette-Guerin Immunotherapy. PG - 186-197 LID - 10.22088/IJMCM.BUMS.13.2.186 [doi] AB - Treatment failure after intravesical instillation of Bacillus Calmette-Guerin immunotherapy (BCG) for non-muscle-invasive bladder cancer (BCa) occurs frequently. The exact effects of BCG on cellular redox status and gene expression remain unclear. We assessed oxidative stress biomarkers and changes in miR-155-5p expression in response to BCG. Twenty-seven patients with BCa were recruited for measuring tissue and serum malondialdehyde (MDA) and total antioxidant capacity (TAC) levels, and tissue expression of miR-155-5p at two-time points: pre and 6 weeks post BCG. Recurrence of BCa was observed after 20 months. R statistical software was used for paired comparisons of biomarkers, as well as the correlation between variables. Significant increases in TAC were observed after BCG (P= <0.001). Tissue MDA levels were significantly reduced (P= 0.003). miR-155-5p was slightly overexpressed after BCG (median fold change=1.3, P=0.25). At the 20-month follow-up, it was observed that improved MDA and TAC changes were significant only in patients without recurrence of BCa. In patients with recurrence, the pre-treatment expression ratio of miR-155-p5 was positively correlated with TAC (R=0.63, P= 0.032) and negatively correlated with MDA (R=-0.72, P=0.037). In patients with recurrence of BCa pre-treatment miR-155-5p showed negative correlation with its expression changes after BCG (R=-0.78, P=0.004). Conclusions: Treatment with BCG has some beneficial effects on the oxidative stress status, which is probably modulated by miR-155-5p. A well-controlled oxidative balance may enhance overall survival of BCa. Considering its high recurrence rate, our pilot experiment can open a window toward better management of patients with BCa. CI - (c) The Author(s). FAU - Darzi, Mohammad Mehdi AU - Darzi MM AD - Student Research Committee, Babol University of Medical Sciences, Babol, Iran. AD - Department of Urology, Hashemi Nejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran. FAU - Neamati, Nahid AU - Neamati N AD - Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. AD - Pasteur Institute of Iran, Tehran, Iran. FAU - Sadeghi, Farzin AU - Sadeghi F AD - Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. FAU - Bijani, Ali AU - Bijani A AD - Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. FAU - Moudi, Emadoddin AU - Moudi E AD - Clinical Research Development Center, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iran. AD - Department of Urology, School of Medicine, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iran. LA - eng PT - Journal Article PL - Iran TA - Int J Mol Cell Med JT - International journal of molecular and cellular medicine JID - 101598104 PMC - PMC11344563 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - malondialdehyde OT - miR-155-5p OT - total antioxidant capacity EDAT- 2024/08/26 12:38 MHDA- 2024/08/26 12:39 PMCR- 2024/01/01 CRDT- 2024/08/26 05:08 PHST- 2024/06/26 00:00 [received] PHST- 2024/07/17 00:00 [accepted] PHST- 2024/08/26 12:39 [medline] PHST- 2024/08/26 12:38 [pubmed] PHST- 2024/08/26 05:08 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.22088/IJMCM.BUMS.13.2.186 [doi] PST - ppublish SO - Int J Mol Cell Med. 2024;13(2):186-197. doi: 10.22088/IJMCM.BUMS.13.2.186. PMID- 39184050 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240827 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review. PG - 1441883 LID - 10.3389/fonc.2024.1441883 [doi] LID - 1441883 AB - Bladder cancer (BC) is the second most common type of cancer of the urinary system. Approximately 75% of the cases are non-muscle invasive bladder cancer (NMIBC), which has a high recurrence and progression rate. Current diagnosis and surveillance methods present challenges, including risks to the patients. For this reason, urinary biomarkers have been proposed as alternatives to the methods. The goal of this mini-review is to describe urinary mRNA-based biomarkers available in current literature for NMIBC tumors, using the PubMed database. The search included the following keywords: "biomarkers" AND "bladder cancer" AND "urine" and "RNA" and "non-muscle". The search yielded 11 original researchers utilizing mRNA-based urinary biomarkers. Although there is a wide variety of biomarkers described, the cohorts of the studies were not exclusively NMIBC, which is the subtype of BC that would mostly benefit from the introduction of a good follow-up biomarker, highlighting the need for randomized interventional trials for NMIBC. CI - Copyright (c) 2024 Coelho, Wosniaki, Marin, Fabris, Borges dos Reis, Aoki and Zanette. FAU - Coelho, Karoline Brito Caetano Andrade AU - Coelho KBCA AD - Uro-Oncology Laboratory, Surgery and Anatomy Department, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. FAU - Wosniaki, Denise Kusma AU - Wosniaki DK AD - Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Parana, Brazil. FAU - Marin, Anelis Maria AU - Marin AM AD - Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Parana, Brazil. FAU - Fabris, Laura AU - Fabris L AD - Department of Applied Science and Technology, Politecnico di Torino, Torino, Italy. FAU - Borges Dos Reis, Rodolfo AU - Borges Dos Reis R AD - Uro-Oncology Laboratory, Surgery and Anatomy Department, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. FAU - Aoki, Mateus Nobrega AU - Aoki MN AD - Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Parana, Brazil. FAU - Zanette, Dalila Luciola AU - Zanette DL AD - Uro-Oncology Laboratory, Surgery and Anatomy Department, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. AD - Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Parana, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20240809 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11341357 OTO - NOTNLM OT - aggressiveness OT - mRNA-based OT - muscle-invasive bladder cancer (MIBC) OT - non-muscle invasive bladder cancer (NMIBC) OT - surveillance OT - urinary biomarkers COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2024/08/26 12:39 MHDA- 2024/08/26 12:40 PMCR- 2024/01/01 CRDT- 2024/08/26 04:58 PHST- 2024/05/31 00:00 [received] PHST- 2024/07/16 00:00 [accepted] PHST- 2024/08/26 12:40 [medline] PHST- 2024/08/26 12:39 [pubmed] PHST- 2024/08/26 04:58 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1441883 [doi] PST - epublish SO - Front Oncol. 2024 Aug 9;14:1441883. doi: 10.3389/fonc.2024.1441883. eCollection 2024. PMID- 39182466 OWN - NLM STAT- MEDLINE DCOM- 20241116 LR - 20241116 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 73 DP - 2024 Dec TI - The association between variant histology and prognostic, histomorphological and clinical aspects of bladder urothelial carcinoma. PG - 152373 LID - S1092-9134(24)00110-2 [pii] LID - 10.1016/j.anndiagpath.2024.152373 [doi] AB - This study underscores the imperative consideration of histological subtypes and divergent differentiation in accurately estimating bladder urothelial carcinoma prognosis and guiding treatment decisions. A comparative analysis was conducted, examining clinical, histological, and prognostic factors between conventional urothelial carcinoma and urothelial carcinoma with variant histology in a clinical sample. A retrospective analysis of slides and other clinicopathologic data was conducted these cases, with an emphasis on key diagnostic elements. We examined 829 cases of urothelial carcinoma of the bladder, comprising of 744 transurethral resection (TUR) and 85 radical cystectomy (RS) specimens, an analysis that showed that 80.5 % (667 cases) were conventional urothelial carcinoma (CUC) and that 19.5 % (162 cases) exhibited variant histology (hereafter "urothelial carcinoma with subtype histology" [UCSH]). TNM classifications for the RS cases were as follows: 2 cases were stage group 0a, 11 stage group 1, 16 stage group 2, 45 stage group 3a, 2 stage group 3b, 1 stage group 4a, and 8 stage group 4b. Only 2 of the RS cases were found to be non-invasive. Among 744 TUR specimens, 387 were found to have a non-invasive tumor whereas 357 had invasive tumors. The most prevalent subtype in the UCSH group was urothelial carcinoma with squamous differentiation, accounting for 54.3 % (88 cases). Notably, 8.02 % (13 cases) exhibited more than one histological subtype. Papillary configuration, histological grade, lamina propria, muscularis mucosa and serosa invasion, lymphovascular invasion, presence of urothelial carcinoma in situ, and overall survival significantly differed between the UCSH and CUC groups (p < 0.05). However, mean age, gender, tumor size, lymphocytic response, disease-free survival, and survival status did not differ significantly (p > 0.05). Among the UCSH group, lower levels of papillary configuration, higher histological grade, higher degree of lamina propria, muscularis mucosa and serosa invasion, and the presence of carcinoma in situ corresponded to higher percentage of histological subtype morphology (p < 0.05). No significant difference in survival status was observed between the groups with and without subtype histology (p = 0.083). This study found that clinical and histopathological prognostic factors associated with a more aggressive disease were linked to the presence and percentage of histological subtypes. Recognizing histological subtype is crucial for treatment decisions and prognosis prediction in urothelial carcinoma cases with these subtypes. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Akbas, Pelin AU - Akbas P AD - Pathology, Gaziosmanpasa Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. Electronic address: drakbaspelin@gmail.com. FAU - Bektas, Sibel AU - Bektas S AD - Pathology, Gaziosmanpasa Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Yazici, Gokhan AU - Yazici G AD - Urology, Arnavutkoy State Hospital, Republic of Turkey Ministry of Health, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20240822 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Male MH - Female MH - Prognosis MH - Aged MH - Retrospective Studies MH - Middle Aged MH - *Carcinoma, Transitional Cell/pathology/mortality MH - *Cystectomy/methods MH - Aged, 80 and over MH - Neoplasm Staging/methods MH - Urothelium/pathology MH - Adult MH - Urinary Bladder/pathology OTO - NOTNLM OT - Bladder OT - Histological subtypes OT - Radical cystectomy OT - Transurethral resection OT - Urothelial carcinoma COIS- Declaration of competing interest None. EDAT- 2024/08/26 12:39 MHDA- 2024/11/17 00:30 CRDT- 2024/08/25 18:08 PHST- 2024/06/01 00:00 [received] PHST- 2024/08/12 00:00 [revised] PHST- 2024/08/19 00:00 [accepted] PHST- 2024/11/17 00:30 [medline] PHST- 2024/08/26 12:39 [pubmed] PHST- 2024/08/25 18:08 [entrez] AID - S1092-9134(24)00110-2 [pii] AID - 10.1016/j.anndiagpath.2024.152373 [doi] PST - ppublish SO - Ann Diagn Pathol. 2024 Dec;73:152373. doi: 10.1016/j.anndiagpath.2024.152373. Epub 2024 Aug 22. PMID- 39182105 OWN - NLM STAT- MEDLINE DCOM- 20240824 LR - 20240829 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 22 IP - 1 DP - 2024 Aug 24 TI - Pelvic organ-preserving radical cystectomy versus standard radical cystectomy in female patients diagnosed with bladder cancer. PG - 218 LID - 10.1186/s12957-024-03502-6 [doi] LID - 218 AB - BACKGROUND: Pelvic organ-preserving radical cystectomy (POPRC) has been reported to result in a better postoperative quality of life in female with bladder cancer compared to standard radical cystectomy (SRC). However, its oncological outcomes remain a concern. PATIENTS AND METHODS: Female patients with bladder cancer who underwent POPRC or SRC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was used to identify predictors of POPRC usage. To avoid the potential impact of baseline differences between groups on survival, a 1:2 propensity score matching (PSM) was implemented. After that, Kaplan-Meier curves and Log-rank tests were used to determine the significance of overall survival (OS) differences between patients in the SRC group and POPRC group. Finally, subgroup analysis based on predetermined indicators was performed. RESULTS: A total of 2193 patients were included with a median follow-up of 53 months, of whom 233 (10.6%) received POPRC and 1960 (89.4%) received SRC. No definitive predictors of POPRC were identified. Before PSM, POPRC resulted in comparable OS to SRC (HR = 1.09, p = 0.309), while after PSM, POPRC was associated with significantly worse OS (HR = 1.23, p = 0.038). In subgroup analyses, POPRC led to non-inferior OS (HR = 1.18, 95%CI 0.71-1.95, p = 0.531) in patients with non-muscle invasive bladder cancer (NMIBC) and T2 patients (HR = 1.07, p = 0.669), but significantly worse OS in T3 patients (HR = 1.41, p = 0.02). CONCLUSION: Currently, patients undergoing POPRC have not undergone strict screening, and candidates for POPRC should have more stringent criteria in the future to achieve satisfactory oncological outcomes. However, flaws in the study make more evidence needed to support our findings. CI - (c) 2024. The Author(s). FAU - Wang, Chuanlin AU - Wang C AD - Department of Urology, Chongqing University Fuling Hospital, No.2 Gaosuntang Road, Fuling District, Chongqing, 408000, China. FAU - Zhang, Xin AU - Zhang X AD - Department of Urology, Chongqing University Fuling Hospital, No.2 Gaosuntang Road, Fuling District, Chongqing, 408000, China. zxwl15123300513@163.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240824 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Cystectomy/methods MH - Aged MH - Middle Aged MH - Follow-Up Studies MH - Survival Rate MH - *SEER Program/statistics & numerical data MH - Prognosis MH - Organ Sparing Treatments/methods/statistics & numerical data MH - Quality of Life MH - Retrospective Studies MH - Propensity Score MH - Pelvis/surgery/pathology MH - Neoplasm Staging PMC - PMC11344460 OTO - NOTNLM OT - Bladder cancer OT - Pelvic organ-preserving radical cystectomy OT - Radical cystectomy OT - SEER database COIS- The authors declare no competing interests. EDAT- 2024/08/26 12:39 MHDA- 2024/08/26 12:40 PMCR- 2024/08/24 CRDT- 2024/08/24 23:30 PHST- 2024/03/09 00:00 [received] PHST- 2024/08/13 00:00 [accepted] PHST- 2024/08/26 12:40 [medline] PHST- 2024/08/26 12:39 [pubmed] PHST- 2024/08/24 23:30 [entrez] PHST- 2024/08/24 00:00 [pmc-release] AID - 10.1186/s12957-024-03502-6 [pii] AID - 3502 [pii] AID - 10.1186/s12957-024-03502-6 [doi] PST - epublish SO - World J Surg Oncol. 2024 Aug 24;22(1):218. doi: 10.1186/s12957-024-03502-6. PMID- 39169215 OWN - NLM STAT- MEDLINE DCOM- 20240821 LR - 20240826 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Aug 21 TI - Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer. PG - 19352 LID - 10.1038/s41598-024-70379-6 [doi] LID - 19352 AB - This study aims to evaluate the prognostic utility of Activity-dependent neuroprotective protein (ADNP) expression in Circulating Tumor Cells (CTCs) inpatients with Non-muscle-invasive Bladder Cancer (NMIBC) undergoing Transurethral Resection of Bladder Tumor (TURBT). A prospective cohort of 74 bladder cancer patients and 22 non-cancer controls were enrolled. The expression of ADNP mRNA was detected by immunomagnetic beads-droplet digital PCR. The ADNP mRNA expression was evaluated in patients with high-risk NMIBC and those with indeterminate invasion depth post 2nd TURBT. Primary cultured bladder cancer cells and PBMCs from healthy donors were immunofluorescence stained. Our findings suggest that baseline ADNP mRNA level in CTCs shows potential as a prognostic marker for NMIBC with a sensitivity of 83.33% and a specificity of 73.58%. In comparison to baseline, ADNP mRNA expression increased post 2nd TURBT in 5 patients, where 2 experienced recurrence. Meanwhile, among the 12 patients with decreased levels, only one patient relapsed. A considerable limitation of this study entails the small sample size. The Immuno-magnetic beads-ddPCR technique provided a viable method for ADNP mRNA detection in CTCs from bladder cancer patients. The preoperative ADNP mRNA level in CTCs was identified as a prognostic indicator for NMIBC. Longitudinal monitoring of ADNP mRNA in CTCs of bladder cancer patients shows promise in evaluating treatment responses and predicting prognosis. CI - (c) 2024. The Author(s). FAU - Wen, Yuheng AU - Wen Y AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Ming, Zhihao AU - Ming Z AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Li, Hong AU - Li H AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Zhu, Shuai AU - Zhu S AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Cao, Jian AU - Cao J AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Ye, Mingji AU - Ye M AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - Gan, Tian AU - Gan T AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. FAU - She, Xiangqun AU - She X AD - The Second People's Hospital of Huaihua, Huaihua, Hunan, China. FAU - Zeng, Yong AU - Zeng Y AD - Clinical Translational Research Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. 47537511@qq.com. FAU - Xie, Yu AU - Xie Y AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China. xieyu420@sina.com. LA - eng GR - NCC201818A55/National Cancer Center Clinical Research in "Climbing" Foundation of China/ GR - 2021JJ70030/Natural Science Foundation Health Union Foundation of Hunan Province, China/ PT - Journal Article DEP - 20240821 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (Nerve Tissue Proteins) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Biomarkers, Tumor/genetics/blood MH - Neoplasm Invasiveness MH - *Neoplastic Cells, Circulating/metabolism/pathology MH - Nerve Tissue Proteins/genetics/metabolism MH - *Non-Muscle Invasive Bladder Neoplasms/blood/diagnosis/genetics/pathology MH - Prognosis MH - Prospective Studies MH - RNA, Messenger/genetics/metabolism PMC - PMC11339371 OTO - NOTNLM OT - ADNP OT - Longitudinal monitoring OT - Non-muscle invasive bladder cancer (NMIBC) OT - Prognosis OT - ddPCR COIS- The authors declare no competing interests. EDAT- 2024/08/22 00:42 MHDA- 2024/08/22 00:43 PMCR- 2024/08/21 CRDT- 2024/08/21 23:39 PHST- 2024/03/03 00:00 [received] PHST- 2024/08/16 00:00 [accepted] PHST- 2024/08/22 00:43 [medline] PHST- 2024/08/22 00:42 [pubmed] PHST- 2024/08/21 23:39 [entrez] PHST- 2024/08/21 00:00 [pmc-release] AID - 10.1038/s41598-024-70379-6 [pii] AID - 70379 [pii] AID - 10.1038/s41598-024-70379-6 [doi] PST - epublish SO - Sci Rep. 2024 Aug 21;14(1):19352. doi: 10.1038/s41598-024-70379-6. PMID- 39168785 OWN - NLM STAT- MEDLINE DCOM- 20241118 LR - 20250605 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 12 DP - 2024 Dec TI - Clinical performance of Bladder EpiCheck versus voided urine cytology for detecting recurrence of nonmuscle invasive bladder cancer: Systematic review and meta-analysis. PG - 449.e21-449.e28 LID - S1078-1439(24)00548-9 [pii] LID - 10.1016/j.urolonc.2024.07.009 [doi] AB - BACKGROUND: Nonmuscle invasive bladder cancer (NMIBC) has a favorable prognosis but has high propensity for recurrence. Recent development in one of the urinary biomarker tests, Bladder EpiCheck, offers a noninvasive and accurate method to detect NMIBC recurrence. In this study, we aimed to compare the diagnostic performance of Bladder EpiCheck with urine cytology to detect NMIBC recurrence. METHODS: We performed a systematic review search through PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus from inception to July 2023. Diagnostic accuracy was defined by sensitivity, negative predictive value (NPV), specificity, and positive predictive value (PPV). RESULTS: A total of 6 studies involving 1588 patients were included. Bladder EpiCheck has a sensitivity and specificity of 0.81 (95% CI: 0.63-0.91; I(2): 43%) and 0.87 (95% CI: 0.83-0.91; I(2): 20%), respectively. On the other hand, urine cytology has a sensitivity and specificity of 0.63 (95% CI: 0.29-0.87; I(2): 61%) and 0.97 (95% CI: 0.78-1.00; I(2): 79%), respectively. EpiCheck has a higher NPV (0.94 (95% CI: 0.87-0.97) vs. 0.84 (95% CI: 0.80-0.87) though a lower PPV (0.62 (95% CI: 0.45-0.76) vs. 0.87 (95% CI: 0.56-0.97) than urine cytology. In our subgroup analysis, the sensitivity of Bladder EpiCheck for detecting high-grade tumors improved to 0.90 (95% CI: 0.83-0.94) while that for urine cytology improved to 0.72 (95% CI: 0.50-0.87). CONCLUSION: Bladder EpiCheck has a high sensitivity and NPV for detecting recurrence among patients with NMIBC. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Chiang, Cho-Han AU - Chiang CH AD - Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Chang, Yu-Cheng AU - Chang YC AD - Department of Medicine, Danbury Hospital, Danbury, Connecticut. FAU - Peng, Chun-Yu AU - Peng CY AD - Department of Medicine, Danbury Hospital, Danbury, Connecticut. FAU - Wang, Shih-Syuan AU - Wang SS AD - Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York City, New York. FAU - Jaroenlapnopparat, Aunchalee AU - Jaroenlapnopparat A AD - Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Wang, Jeff Chun Hao AU - Wang JCH AD - Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan. FAU - Jou, Chen Liang AU - Jou CL AD - Department of Medical Education, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Tang, Pui-Un AU - Tang PU AD - Department of Pediatrics, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Hsia, Yuan Ping AU - Hsia YP AD - Department of Family Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan. Electronic address: ustwhealth.datascience.group@gmail.com. FAU - Chiang, Cho-Hsien AU - Chiang CH AD - Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei, Taiwan; London School of Hygiene and Tropical Medicine, London, UK. FAU - Chiang, Cho-Hung AU - Chiang CH AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20240821 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/urine/diagnosis/pathology MH - Urinalysis/methods MH - Urine/cytology MH - *Non-Muscle Invasive Bladder Neoplasms/diagnosis/pathology/urine MH - Liquid Biopsy/instrumentation/methods OTO - NOTNLM OT - Bladder EpiCheck OT - Bladder cancer OT - Surveillance OT - Urine cytology COIS- Declaration of competing interest No financial or personal conflicts of interest to declare. EDAT- 2024/08/22 00:42 MHDA- 2024/11/19 00:22 CRDT- 2024/08/21 21:59 PHST- 2023/08/17 00:00 [received] PHST- 2024/06/24 00:00 [revised] PHST- 2024/07/07 00:00 [accepted] PHST- 2024/11/19 00:22 [medline] PHST- 2024/08/22 00:42 [pubmed] PHST- 2024/08/21 21:59 [entrez] AID - S1078-1439(24)00548-9 [pii] AID - 10.1016/j.urolonc.2024.07.009 [doi] PST - ppublish SO - Urol Oncol. 2024 Dec;42(12):449.e21-449.e28. doi: 10.1016/j.urolonc.2024.07.009. Epub 2024 Aug 21. PMID- 39168722 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20260502 IS - 1878-4046 (Electronic) IS - 1076-6332 (Linking) VI - 32 IP - 1 DP - 2025 Jan TI - Multi-DECT Image-based Intratumoral and Peritumoral Radiomics for Preoperative Prediction of Muscle Invasion in Bladder Cancer. PG - 287-297 LID - S1076-6332(24)00573-7 [pii] LID - 10.1016/j.acra.2024.08.010 [doi] AB - OBJECTIVES: To assess the predictive value of intratumoral and peritumoral radiomics based on Dual-energy CT urography (DECTU) multi-images for preoperatively predicting the muscle invasion status of bladder cancer (BCa). MATERIAL AND METHODS: This retrospective analysis involved 202 BCa patients who underwent DECTU. DECTU-derived quantitative parameters were identified as risk factors through stepwise regression analysis to construct a DECT model. The radiomic features from the intratumoral and 3 mm outward peritumoral regions were extracted from the 120 kVp-like, 40 keV, 100 keV, and iodine-based material-decomposition (IMD) images in the venous-phase and were screened using Mann-Whitney U test, Spearman correlation analysis, and LASSO. Radiomics models were developed using the Multilayer Perceptron for the intratumoral, peritumoral and intra- and peritumoral (IntraPeri) regions. Subsequently, a nomogram was created by integrating the multi-image IntraPeri radiomics and DECT model. Model performance was evaluated using area-under-the-curve (AUC), accuracy, sensitivity, and specificity. RESULTS: Normalized iodine concentration (NIC) was identified as an independent predictor for the DECT model. The IntraPeri model demonstrated superior performance compared to the intratumoral and peritumoral models both in 40 keV (0.830 vs. 0.766 vs. 0.763) and IMD images (0.881 vs. 0.840 vs. 0.821) in the test cohort. In the test cohort, the nomogram exhibited the best predictability (AUC=0.886, accuracy=0.836, sensitivity=0.737, and specificity=0.881), outperformed the DECT model (AUC=0.763, accuracy=0.754, sensitivity=0.632, and specificity=0.810) in predicting muscle invasion status of BCa with a statistically significant difference (p < 0.05). CONCLUSION: The nomogram, incorporating IntraPeri radiomics and NIC, serves as a valuable and non-invasive tool for preoperatively assessing the muscle invasion status of BCa. CI - Copyright (c) 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved. FAU - Hu, Mengting AU - Hu M AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (M.H., J.Z., Q.C., W.W., Y.L. ). Electronic address: tttop_0819@163.com. FAU - Zhang, Jingyi AU - Zhang J AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (M.H., J.Z., Q.C., W.W., Y.L. ). Electronic address: jingyizhang0330@163.com. FAU - Cheng, Qiye AU - Cheng Q AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (M.H., J.Z., Q.C., W.W., Y.L. ). Electronic address: cqy13469258368@163.com. FAU - Wei, Wei AU - Wei W AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (M.H., J.Z., Q.C., W.W., Y.L. ). Electronic address: weiweidy1988@163.com. FAU - Liu, Yijun AU - Liu Y AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (M.H., J.Z., Q.C., W.W., Y.L. ). Electronic address: yijunliu1965@126.com. FAU - Li, Jianying AU - Li J AD - CT Research, GE Healthcare, Dalian, China (J.L.). Electronic address: Jianying.Li@med.ge.com. FAU - Liu, Lei AU - Liu L AD - Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China (L.L.). Electronic address: liuleidmu1989@163.com. LA - eng PT - Journal Article DEP - 20240821 PL - United States TA - Acad Radiol JT - Academic radiology JID - 9440159 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Male MH - Female MH - Retrospective Studies MH - Neoplasm Invasiveness/diagnostic imaging MH - Aged MH - Middle Aged MH - *Tomography, X-Ray Computed/methods MH - *Urography/methods MH - Sensitivity and Specificity MH - Predictive Value of Tests MH - Aged, 80 and over MH - Nomograms MH - Preoperative Care MH - Adult MH - *Radiography, Dual-Energy Scanned Projection/methods MH - Radiomics OTO - NOTNLM OT - Artificial Intelligence OT - Non-Muscle Invasive Bladder Neoplasms OT - Radiomics OT - Tomography OT - X-Ray Computed COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/08/22 00:42 MHDA- 2025/01/20 22:52 CRDT- 2024/08/21 21:57 PHST- 2024/06/06 00:00 [received] PHST- 2024/07/28 00:00 [revised] PHST- 2024/08/06 00:00 [accepted] PHST- 2025/01/20 22:52 [medline] PHST- 2024/08/22 00:42 [pubmed] PHST- 2024/08/21 21:57 [entrez] AID - S1076-6332(24)00573-7 [pii] AID - 10.1016/j.acra.2024.08.010 [doi] PST - ppublish SO - Acad Radiol. 2025 Jan;32(1):287-297. doi: 10.1016/j.acra.2024.08.010. Epub 2024 Aug 21. PMID- 39167019 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250514 IS - 1522-2586 (Electronic) IS - 1053-1807 (Linking) VI - 61 IP - 3 DP - 2025 Mar TI - Multiparametric MRI-Based Deep Learning Radiomics Model for Assessing 5-Year Recurrence Risk in Non-Muscle Invasive Bladder Cancer. PG - 1442-1456 LID - 10.1002/jmri.29574 [doi] AB - BACKGROUND: Accurately assessing 5-year recurrence rates is crucial for managing non-muscle-invasive bladder carcinoma (NMIBC). However, the European Organization for Research and Treatment of Cancer (EORTC) model exhibits poor performance. PURPOSE: To investigate whether integrating multiparametric MRI (mp-MRI) with clinical factors improves NMIBC 5-year recurrence risk assessment. STUDY TYPE: Retrospective. POPULATION: One hundred ninety-one patients (median age, 65 years; age range, 54-73 years; 27 females) underwent mp-MRI between 2011 and 2017, and received >/=5-year follow-ups. They were divided into a training cohort (N = 115) and validation/testing cohorts (N = 38 in each). Recurrence rates were 23.5% (27/115) in the training cohort and 23.7% (9/38) in both validation and testing cohorts. FIELD STRENGTH/SEQUENCE: 3-T, fast spin echo T2-weighted imaging (T2WI), single-shot echo planar diffusion-weighted imaging (DWI), and volumetric spoiled gradient echo dynamic contrast-enhanced (DCE) sequences. ASSESSMENT: Radiomics and deep learning (DL) features were extracted from the combined region of interest (cROI) including intratumoral and peritumoral areas on mp-MRI. Four models were developed, including clinical, cROI-based radiomics, DL, and clinical-radiomics-DL (CRDL) models. STATISTICAL TESTS: Student's t-tests, DeLong's tests with Bonferroni correction, receiver operating characteristics with the area under the curves (AUCs), Cox proportional hazard analyses, Kaplan-Meier plots, SHapley Additive ExPlanations (SHAP) values, and Akaike information criterion for clinical usefulness. A P-value <0.05 was considered statistically significant. RESULTS: The cROI-based CRDL model showed superior performance (AUC 0.909; 95% CI: 0.792-0.985) compared to other models in the testing cohort for assessing 5-year recurrence in NMIBC. It achieved the highest Harrell's concordance index (0.804; 95% CI: 0.749-0.859) for estimating recurrence-free survival. SHAP analysis further highlighted the substantial role (22%) of the radiomics features in NMIBC recurrence assessment. DATA CONCLUSION: Integrating cROI-based radiomics and DL features from preoperative mp-MRI with clinical factors could improve 5-year recurrence risk assessment in NMIBC. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 3. CI - (c) 2024 International Society for Magnetic Resonance in Medicine. FAU - Huang, Haolin AU - Huang H AUID- ORCID: 0000-0002-2742-5055 AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, China. AD - School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China. FAU - Huang, Yiping AU - Huang Y AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Kaggie, Joshua D AU - Kaggie JD AD - Department of Radiology, University of Cambridge, Cambridge, UK. FAU - Cai, Qian AU - Cai Q AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Yang, Peng AU - Yang P AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wei, Jie AU - Wei J AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wang, Lijuan AU - Wang L AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, China. AD - School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - Guo, Yan AU - Guo Y AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Lu, Hongbing AU - Lu H AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wang, Huanjun AU - Wang H AUID- ORCID: 0000-0001-9089-7736 AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. AD - Department of Radiology, University of Cambridge, Cambridge, UK. FAU - Xu, Xiaopan AU - Xu X AUID- ORCID: 0000-0003-3707-1104 AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, China. LA - eng GR - 2021YFC12001/National Key Research and Development Program of China/ GR - 2021YFC1200100/National Key Research and Development Program of China/ GR - NIHR203312/NIHR Cambridge Biomedical Research Council/ GR - 82071989/National Natural Science Foundation of China/ GR - 82372035/National Natural Science Foundation of China/ GR - 2024RCYGXXP/Sword Action Talent Program/ GR - 2024XijingPIXXP/Xijing Innovation Research Institute-Joint Innovation Fund/ GR - 2021A1515012243/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20240821 PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Female MH - Male MH - *Deep Learning MH - Middle Aged MH - Aged MH - *Multiparametric Magnetic Resonance Imaging/methods MH - *Neoplasm Recurrence, Local/diagnostic imaging MH - Retrospective Studies MH - Risk Assessment MH - *Magnetic Resonance Imaging MH - Neoplasm Invasiveness MH - Reproducibility of Results MH - Urinary Bladder/diagnostic imaging MH - Risk Factors MH - Non-Muscle Invasive Bladder Neoplasms MH - Radiomics OTO - NOTNLM OT - deep learning OT - multiparametric MRI OT - non-muscle-invasive bladder cancer OT - radiomics OT - recurrence risk assessment EDAT- 2024/08/21 17:42 MHDA- 2025/02/07 12:25 CRDT- 2024/08/21 10:03 PHST- 2024/08/03 00:00 [revised] PHST- 2024/03/15 00:00 [received] PHST- 2024/08/06 00:00 [accepted] PHST- 2025/02/07 12:25 [medline] PHST- 2024/08/21 17:42 [pubmed] PHST- 2024/08/21 10:03 [entrez] AID - 10.1002/jmri.29574 [doi] PST - ppublish SO - J Magn Reson Imaging. 2025 Mar;61(3):1442-1456. doi: 10.1002/jmri.29574. Epub 2024 Aug 21. PMID- 39161208 OWN - NLM STAT- MEDLINE DCOM- 20241017 LR - 20260923 IS - 2523-3548 (Electronic) IS - 2523-3548 (Linking) VI - 44 IP - 10 DP - 2024 Oct TI - FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. PG - 1189-1208 LID - 10.1002/cac2.12602 [doi] AB - In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non-muscle-invasive and muscle-invasive forms of the disease. FGFR3 mutations in up to half of BLCAs play a well-established role in tumorigenesis, shaping distinct tumor initiation patterns and impacting the tumor microenvironment (TME). Emphasizing the importance of considering epithelial-mesenchymal transition profile and TME status, we revisit their relevance in predicting responses to immune checkpoint inhibitors in FGFR3-mutated BLCAs. This writing highlights the initially promising yet transient efficacy of the FGFR inhibitor Erdafitinib on FGFR3-mutated BLCA, stressing the pressing need to unravel resistance mechanisms and identify co-targets for future combinatorial studies. A thorough analysis of recent preclinical and clinical evidence reveals resistance mechanisms, including secondary mutations, epigenetic alterations in pathway effectors, phenotypic heterogeneity, and population-specific variations within FGFR3 mutational status. Lastly, we discuss the potential of combinatorial treatments and concepts like synthetic lethality for discovering more effective targeted therapies against FGFR3-mutated BLCA. CI - (c) 2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center. FAU - Noeraparast, Maxim AU - Noeraparast M AUID- ORCID: 0000-0002-3216-5630 AD - Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany. FAU - Krajina, Katarina AU - Krajina K AD - Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Niedersuss-Beke, Dora AU - Niedersuss-Beke D AD - Department of Hematology and Oncology, Clinics Ottakring, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Grunwald, Viktor AU - Grunwald V AD - Interdisciplinary Genitourinary Oncology, Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Hufelandstrasse 55, Essen, Germany. FAU - Ahyai, Sascha AU - Ahyai S AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Pichler, Martin AU - Pichler M AD - Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany. LA - eng PT - Journal Article PT - Review DEP - 20240819 PL - United States TA - Cancer Commun (Lond) JT - Cancer communications (London, England) JID - 101723675 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - 890E37NHMV (erdafitinib) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/drug therapy MH - *Receptor, Fibroblast Growth Factor, Type 3/genetics/antagonists & inhibitors MH - *Drug Resistance, Neoplasm/genetics MH - *Mutation MH - Molecular Targeted Therapy/methods MH - Tumor Microenvironment/genetics/drug effects MH - Epithelial-Mesenchymal Transition/genetics/drug effects MH - Pyrazoles MH - Quinoxalines PMC - PMC11483561 OTO - NOTNLM OT - Bladder Cancer OT - Erdafitinib OT - FGFR inhibition OT - FGFR3 mutations OT - Resistance to Erdafitinib OT - Tumor Microenvironment COIS- The authors declare no conflict of interest. EDAT- 2024/08/20 06:42 MHDA- 2024/10/17 16:23 PMCR- 2024/08/19 CRDT- 2024/08/20 02:52 PHST- 2024/07/24 00:00 [revised] PHST- 2024/04/07 00:00 [received] PHST- 2024/08/06 00:00 [accepted] PHST- 2024/10/17 16:23 [medline] PHST- 2024/08/20 06:42 [pubmed] PHST- 2024/08/20 02:52 [entrez] PHST- 2024/08/19 00:00 [pmc-release] AID - CAC212602 [pii] AID - 10.1002/cac2.12602 [doi] PST - ppublish SO - Cancer Commun (Lond). 2024 Oct;44(10):1189-1208. doi: 10.1002/cac2.12602. Epub 2024 Aug 19. PMID- 39159955 OWN - NLM STAT- MEDLINE DCOM- 20240819 LR - 20240822 IS - 1526-2359 (Electronic) IS - 1073-2748 (Print) IS - 1073-2748 (Linking) VI - 31 DP - 2024 Jan-Dec TI - Treatment Options for Signet Ring Cell Carcinoma of the Urinary Bladder: A Population-Based Study. PG - 10732748241278485 LID - 10.1177/10732748241278485 [doi] LID - 10732748241278485 AB - OBJECTIVES: Signet ring cell carcinoma (SRCC) of the urinary bladder is a rare and highly aggressive form of bladder cancer, with no widely agreed-upon treatment strategy. The aim of this study was to identify important factors influencing patient prognosis and to assess how various treatment approaches affect survival outcomes. METHODS: A retrospective study was conducted using data from the Surveillance, Epidemiology, and End Results (SEER) Program, including patients with bladder primary SRCC who were presented between 2000 and 2017. Univariate and multivariate Cox regression models were used to examine the impact of various factors on cancer-specific survival (CSS) and overall survival (OS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were applied to homogenize both groups. The impact of different treatment regimens on patient CSS and OS was analyzed using the Kaplan-Meier method. RESULTS: A total of 33 cases of non-muscular invasive SRCC and 210 cases of muscular invasive SRCC were included in this study. Multivariate analysis identified race, TNM stage, and surgical method as independent variables influencing both OS and CSS. In non-muscle invasive bladder SRCC patients, radical cystectomy showed no CSS benefit compared to transurethral resection of bladder tumors (P = 0.304). For muscle invasive SRCC, patients who underwent partial cystectomy had better OS and CSS compared to those who underwent radical cystectomy (P = 0.019, P = 0.024). However, after conducting a PSM analysis, the differences between the two surgical outcomes were not statistically significant (P = 0.504, P = 0.335). Lymphadenectomy, chemotherapy, and radiation did not show any benefit to the prognosis of patients. CONCLUSION: This study identified race, TNM stage, and surgical approach as significant independent predictors for SRCC outcomes. Simple radical cystectomy and partial cystectomy proved to be effective treatments for SRCC. The optimal treatment option still needs to be supported by a number of prospective research trials. FAU - Xie, Yingwei AU - Xie Y AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Zhang, Yishan AU - Zhang Y AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Du, Zhen AU - Du Z AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Liu, Dan AU - Liu D AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Yan, Wei AU - Yan W AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Liu, Yuexin AU - Liu Y AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 FAU - Ping, Hao AU - Ping H AUID- ORCID: 0000-0003-2912-0965 AD - Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. RINGGOLD: 12517 LA - eng PT - Journal Article PL - United States TA - Cancer Control JT - Cancer control : journal of the Moffitt Cancer Center JID - 9438457 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/mortality/surgery MH - Female MH - Male MH - *Carcinoma, Signet Ring Cell/pathology/therapy/mortality/surgery MH - Retrospective Studies MH - Middle Aged MH - *SEER Program MH - Aged MH - *Cystectomy/methods MH - Prognosis MH - Neoplasm Staging MH - Propensity Score MH - Kaplan-Meier Estimate MH - Adult PMC - PMC11334141 OTO - NOTNLM OT - bladder cancer OT - radical cystectomy OT - signet ring cell carcinoma COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/08/20 00:42 MHDA- 2024/08/20 00:43 PMCR- 2024/08/19 CRDT- 2024/08/19 20:33 PHST- 2024/08/20 00:43 [medline] PHST- 2024/08/20 00:42 [pubmed] PHST- 2024/08/19 20:33 [entrez] PHST- 2024/08/19 00:00 [pmc-release] AID - 10.1177_10732748241278485 [pii] AID - 10.1177/10732748241278485 [doi] PST - ppublish SO - Cancer Control. 2024 Jan-Dec;31:10732748241278485. doi: 10.1177/10732748241278485. PMID- 39157168 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260922 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 5 IP - 8 DP - 2024 Aug TI - Optimal Management for Primary High Grade Ta Bladder Cancer: Role of re-staging TURBT and Intravesical Adjuvant Therapy. PG - 799-805 LID - 10.1002/bco2.363 [doi] AB - OBJECTIVE: This study aims to investigate the impact of risk group classification, restaging transurethral resection (re-TURBT), and adjuvant treatment intensity on recurrence and progression risks in high-grade Ta tumours in patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data from a comprehensive bladder cancer database were utilized for this study. Patients with primary high-grade Ta tumours were included. Risk groups were classified according to AUA/SUO criteria. Tumour characteristics and patient demographics were analysed using descriptive statistics. Cox proportional hazard regression models were used to assess the effect of re-TURBT and other clinical/treatment-related predictors on recurrence- and progression-free survivals. The survivals by selected predictors were estimated using Kaplan-Meier method, and groups were compared by the log-rank test. RESULTS: Among 218 patients with high-grade Ta bladder cancer, those who underwent re-TURBT had significantly better 5-year recurrence-free survival (71.1% vs. 26.8%, p = 0.0009) and progression-free survival (98.6% vs. 73%, p = 0.0018) compared with those with initial TURBT alone. Full BCG treatment (induction and maintenance) showed lower recurrence risk, especially in high-risk patients. However, residual disease at re-TURBT did not significantly affect recurrence risk. CONCLUSIONS: This study highlights the significance of risk group classification, the role of re-TURBT, and the intensity of adjuvant treatment in the management of high-grade Ta tumours. A risk-adapted model is crucial to reduce the burden of unnecessary intravesical treatment and endoscopic procedures. CI - (c) 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Ajami, Tarek AU - Ajami T AUID- ORCID: 0000-0002-3505-8232 AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Han, Sunwoo AU - Han S AD - Biostatistics and Bioinformatics Shared Resource Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami FL United States. FAU - Blachman-Braun, Ruben AU - Blachman-Braun R AUID- ORCID: 0000-0001-9700-0805 AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology University of Iowa Hospitals and Clinics Iowa City IA United States. FAU - Avda, Yuval AU - Avda Y AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Nahar, Bruno AU - Nahar B AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Punnen, Sanoj AU - Punnen S AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Parekh, Dipen J AU - Parekh DJ AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. FAU - Reis, Isildinha M AU - Reis IM AD - Biostatistics and Bioinformatics Shared Resource Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami FL United States. AD - Department of Public Health Sciences University of Miami Miller School of Medicine Miami FL United States. FAU - Ritch, Chad R AU - Ritch CR AUID- ORCID: 0000-0003-4211-3372 AD - Desai Sethi Urology Institute University of Miami Miller School of Medicine Miami FL United States. LA - eng PT - Journal Article DEP - 20240417 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 EIN - BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. PMID: 39744071 PMC - PMC11327485 OTO - NOTNLM OT - non-muscle invasive bladder cancer OT - progression-free survival OT - recurrence-free survival OT - restaging transurethral resection of bladder tumour COIS- The authors declare no conflicts of interest. EDAT- 2024/08/19 06:42 MHDA- 2024/08/19 06:43 PMCR- 2024/04/17 CRDT- 2024/08/19 05:19 PHST- 2023/12/26 00:00 [received] PHST- 2024/02/19 00:00 [revised] PHST- 2024/03/13 00:00 [accepted] PHST- 2024/08/19 06:43 [medline] PHST- 2024/08/19 06:42 [pubmed] PHST- 2024/08/19 05:19 [entrez] PHST- 2024/04/17 00:00 [pmc-release] AID - BCO2363 [pii] AID - 10.1002/bco2.363 [doi] PST - epublish SO - BJUI Compass. 2024 Apr 17;5(8):799-805. doi: 10.1002/bco2.363. eCollection 2024 Aug. PMID- 39155194 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20260121 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 86 IP - 6 DP - 2024 Dec TI - European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. PG - 531-549 LID - S0302-2838(24)02514-4 [pii] LID - 10.1016/j.eururo.2024.07.027 [doi] AB - BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. METHODS: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice. CI - Copyright (c) 2024 European Association of Urology. All rights reserved. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. Electronic address: paolo.gontero@unito.it. FAU - Birtle, Alison AU - Birtle A AD - Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Liedberg, Fredrik AU - Liedberg F AD - Institute of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, The University of Edinburgh, Edinburgh, UK. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, APHP, Saint Louis Hospital, Universite de Paris, Paris, France. FAU - Mostafid, Hugh A AU - Mostafid HA AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Rai, Bhavan P AU - Rai BP AD - Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Seisen, Thomas AU - Seisen T AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Wood, Robert AU - Wood R AD - EAU Guidelines Office, Arnhem, The Netherlands. FAU - Xylinas, Evanguelos N AU - Xylinas EN AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20240817 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - *Neoplasm Invasiveness MH - *Carcinoma in Situ/therapy/pathology MH - Urology/standards MH - Europe MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bacillus Calmette-Guerin unresponsive OT - Bladder cancer OT - Classification OT - Cystoscopy OT - Diagnosis OT - Follow-up OT - Guidelines OT - Intravesical chemotherapy OT - Prognosis OT - Radical cystectomy OT - Transurethral resection OT - Urothelial carcinoma EDAT- 2024/08/19 00:41 MHDA- 2024/12/13 00:23 CRDT- 2024/08/18 21:55 PHST- 2024/07/11 00:00 [received] PHST- 2024/07/29 00:00 [accepted] PHST- 2024/12/13 00:23 [medline] PHST- 2024/08/19 00:41 [pubmed] PHST- 2024/08/18 21:55 [entrez] AID - S0302-2838(24)02514-4 [pii] AID - 10.1016/j.eururo.2024.07.027 [doi] PST - ppublish SO - Eur Urol. 2024 Dec;86(6):531-549. doi: 10.1016/j.eururo.2024.07.027. Epub 2024 Aug 17. PMID- 39147803 OWN - NLM STAT- MEDLINE DCOM- 20240815 LR - 20240819 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Aug 15 TI - Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image. PG - 18931 LID - 10.1038/s41598-024-66870-9 [doi] LID - 18931 AB - We aimed to build a deep learning-based pathomics model to predict the early recurrence of non-muscle-infiltrating bladder cancer (NMIBC) in this work. A total of 147 patients from Xuzhou Central Hospital were enrolled as the training cohort, and 63 patients from Suqian Affiliated Hospital of Xuzhou Medical University were enrolled as the test cohort. Based on two consecutive phases of patch level prediction and WSI-level predictione, we built a pathomics model, with the initial model developed in the training cohort and subjected to transfer learning, and then the test cohort was validated for generalization. The features extracted from the visualization model were used for model interpretation. After migration learning, the area under the receiver operating characteristic curve for the deep learning-based pathomics model in the test cohort was 0.860 (95% CI 0.752-0.969), with good agreement between the migration training cohort and the test cohort in predicting recurrence, and the predicted values matched well with the observed values, with p values of 0.667766 and 0.140233 for the Hosmer-Lemeshow test, respectively. The good clinical application was observed using a decision curve analysis method. We developed a deep learning-based pathomics model showed promising performance in predicting recurrence within one year in NMIBC patients. Including 10 state prediction NMIBC recurrence group pathology features be visualized, which may be used to facilitate personalized management of NMIBC patients to avoid ineffective or unnecessary treatment for the benefit of patients. CI - (c) 2024. The Author(s). FAU - Wang, Guang-Yue AU - Wang GY AD - Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China. AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. FAU - Zhu, Jing-Fei AU - Zhu JF AD - School of Mathematics and Statistics and Jiangsu Key Laboratory of Education Big Data Science and Engineering, Jiangsu Normal University, No.101, Shanghai Road, Tangshan New District, Xuzhou, Jiangsu, China. FAU - Wang, Qi-Chao AU - Wang QC AD - Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China. FAU - Qin, Jia-Xin AU - Qin JX AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Wang, Xin-Lei AU - Wang XL AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Liu, Xing AU - Liu X AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Liu, Xin-Yu AU - Liu XY AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Chen, Jun-Zhi AU - Chen JZ AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Zhu, Jie-Fei AU - Zhu JF AD - Department of Pathology, Xuzhou Central Hospital, Xuzhou, China. FAU - Zhuo, Shi-Chao AU - Zhuo SC AD - Department of Pathology, Xuzhou Central Hospital, Xuzhou, China. FAU - Wu, Di AU - Wu D AD - Department of Pathology, Xuzhou Central Hospital, Xuzhou, China. FAU - Li, Na AU - Li N AD - The First Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Chao, Liu AU - Chao L AD - School of Life Sciences, Jiangsu Normal University, Xuzhou, China. AD - Department of Urology, The Suqian Affiliated Hospital of Xuzhou Medical University, Suqian, China. FAU - Meng, Fan-Lai AU - Meng FL AD - Department of Pathology, The Suqian Affiliated Hospital of Xuzhou Medical University, Suqian, China. FAU - Lu, Hao AU - Lu H AD - Department of Urology, Heilongjiang Provincial Hospital, Harbin, China. FAU - Shi, Zhen-Duo AU - Shi ZD AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. AD - School of Life Sciences, Jiangsu Normal University, Xuzhou, China. AD - Department of Urology, Heilongjiang Provincial Hospital, Harbin, China. FAU - Jia, Zhi-Gang AU - Jia ZG AD - School of Mathematics and Statistics and Jiangsu Key Laboratory of Education Big Data Science and Engineering, Jiangsu Normal University, No.101, Shanghai Road, Tangshan New District, Xuzhou, Jiangsu, China. zhgjia@jsnu.edu.cn. FAU - Han, Cong-Hui AU - Han CH AD - Department of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. hanconghuidoctor@vip.qq.com. AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China. hanconghuidoctor@vip.qq.com. AD - School of Life Sciences, Jiangsu Normal University, Xuzhou, China. hanconghuidoctor@vip.qq.com. AD - Department of Urology, Heilongjiang Provincial Hospital, Harbin, China. hanconghuidoctor@vip.qq.com. LA - eng GR - XWKYHT20220092/Xuzhou City health Commission general project/ GR - KC23233/2023 Xuzhou City to promote science and technology innovation special fund key projects/ GR - KC23231/2023 Xuzhou City to promote science and technology innovation special fund key projects/ GR - BE2020758/the Jiangsu Province Key Research and Development Program/ GR - BE2019637/the Jiangsu Province Key Research and Development Program/ GR - KC19075/the Key Projects of Xuzhou Science and Technology Plan/ GR - XWRCHT20220055/the Xuzhou Medical Key Talents Project/ GR - 12271467/the National Natural Science Foundation of China/ GR - Xuzhou Health Education Research [2017] No.22/the Xuzhou Medical Outstanding Talents/ GR - 2018TD004/the Xuzhou Clinical Medicine Expert Team Project/ PT - Journal Article DEP - 20240815 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Deep Learning MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - *Non-Muscle Invasive Bladder Neoplasms/pathology MH - ROC Curve MH - Risk Assessment/methods PMC - PMC11327297 COIS- The authors declare no competing interests. EDAT- 2024/08/16 01:43 MHDA- 2024/08/16 01:44 PMCR- 2024/08/15 CRDT- 2024/08/15 23:18 PHST- 2023/12/11 00:00 [received] PHST- 2024/07/04 00:00 [accepted] PHST- 2024/08/16 01:44 [medline] PHST- 2024/08/16 01:43 [pubmed] PHST- 2024/08/15 23:18 [entrez] PHST- 2024/08/15 00:00 [pmc-release] AID - 10.1038/s41598-024-66870-9 [pii] AID - 66870 [pii] AID - 10.1038/s41598-024-66870-9 [doi] PST - epublish SO - Sci Rep. 2024 Aug 15;14(1):18931. doi: 10.1038/s41598-024-66870-9. PMID- 39147209 OWN - NLM STAT- MEDLINE DCOM- 20241214 LR - 20260714 IS - 1879-355X (Electronic) IS - 0360-3016 (Print) IS - 0360-3016 (Linking) VI - 121 IP - 1 DP - 2025 Jan 1 TI - Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial. PG - 153-161 LID - S0360-3016(24)03230-9 [pii] LID - 10.1016/j.ijrobp.2024.08.007 [doi] AB - PURPOSE: For bladder-sparing treatment of muscle-invasive bladder cancer, 5-fluorouracil/cisplatin with twice-daily radiation (FCT) or gemcitabine plus daily radiation (GD) are effective chemoradiation (CRT) regimens. This trial evaluated these regimens and demonstrated efficacy with either regimen at 3 years. With further follow-up, longer-term results are reported here. METHODS AND MATERIALS: Patients with cT2 to cT4a muscle-invasive bladder cancer were randomized to FCT or GD. Patients had a transurethral resection and induction CRT to 40 Gy. Patients with a complete response received consolidation CRT to 64 Gy. Others had cystectomy. Adjuvant gemcitabine/cisplatin chemotherapy was administered. The primary endpoint was freedom from distant metastasis (FDM). This updated analysis reports 7-year data. Toxicity and efficacy endpoints, including bladder-intact distant metastasis-free survival (BI-DMFS) were also assessed. RESULTS: From December 2008 to April 2014, 70 patients were enrolled; 66 were eligible for analysis, 33 per arm. Median follow-up was 9.1 years for eligible living patients. At 7 years, FDM was 65% and 73% for FCT and GD, respectively. Bladder-intact distant metastasis-free survival was 58% (95% CI, 41-76) and 68% (95% CI, 51-84), respectively. The post hoc hazard ratio of 0.75 (95% CI, 0.37-1.55) showed no difference between treatments (P = .44). Overall survival at 7 years was 48% and 59%. There were 4 and 5 cystectomies performed for FCT and GD, respectively. In the FCT arm, there were 5 (16%), 1 (3%), and 0 grade 3, 4, and 5 late toxicities reported, respectively. In the GD arm, there were 7 (23%), 0, and 0 grade 3, 4, and 5 late toxicities reported, respectively. CONCLUSIONS: Both regimens maintained high FDM rates at 7 years. Cystectomy rates were low and overall survival rates were high on both arms. Late toxicity rates were low. Either gemcitabine and daily radiation or a cisplatin-based regimen are effective bladder-sparing therapies. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Coen, John J AU - Coen JJ AD - Roger Williams Radiation Oncology, Providence, Rhode Island. Electronic address: jcoen1@me.com. FAU - Rodgers, Joseph P AU - Rodgers JP AD - NRG Oncology Statistics and Data Management Center - American College of Radiology, Philadelphia, Pennsylvania. FAU - Saylor, Philip J AU - Saylor PJ AD - Massachusetts General Hospital, Boston, Massachusetts. FAU - Lee, Cheryl T AU - Lee CT AD - Ohio State University Comprehensive Center, Columbus, Ohio. FAU - Wu, Chin-Lee AU - Wu CL AD - Massachusetts General Hospital, Boston, Massachusetts. FAU - Parker, William AU - Parker W AD - McGill University Health Centre, Montreal, Quebec, Canada. FAU - Lautenschlaeger, Tim AU - Lautenschlaeger T AD - Indiana University, Indianapolis, Indiana. FAU - Zietman, Anthony L AU - Zietman AL AD - Massachusetts General Hospital, Boston, Massachusetts. FAU - Efstathiou, Jason AU - Efstathiou J AD - Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Jani, Ashesh B AU - Jani AB AD - Emory University, Atlanta, Georgia. FAU - Kucuk, Omer AU - Kucuk O AD - Emory University, Atlanta, Georgia. FAU - Souhami, Luis AU - Souhami L AD - McGill University Health Centre, Montreal, Quebec, Canada. FAU - Pugh, Stephanie L AU - Pugh SL AD - NRG Oncology Statistics and Data Management Center - American College of Radiology, Philadelphia, Pennsylvania. FAU - Sandler, Howard M AU - Sandler HM AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Shipley, William U AU - Shipley WU AD - Massachusetts General Hospital, Boston, Massachusetts. LA - eng GR - U10 CA180822/CA/NCI NIH HHS/United States GR - U10 CA180868/CA/NCI NIH HHS/United States GR - UG1 CA189867/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20240813 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/mortality/drug therapy MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - *Cisplatin/administration & dosage MH - Aged MH - Male MH - Middle Aged MH - *Fluorouracil/administration & dosage MH - Female MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Organ Sparing Treatments/methods MH - *Chemoradiotherapy/methods MH - *Neoplasm Invasiveness MH - Cystectomy/methods MH - Urinary Bladder/radiation effects/pathology MH - Aged, 80 and over MH - Adult MH - Time Factors PMC - PMC12090354 MID - NIHMS2061493 COIS- Drs Coen, Jani, Kucuk, Lautenschlaeger, Pugh, Saylor, Shipley and Mr. Rodgers have nothing to disclose. Dr Efstathiou declares in the last 36 months consulting fees from Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Genentech, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from IBA and Elekta, participation on a data safety monitoring board or advisory board at Merck, Roivant Pharma, Myovant, Sciences, Janssen, Bayer Healthcare, Progenics Pharmaceuticals, Pfizer, Gilead, Lantheus, Blue Earth Diagnostics and Angiodynamics and leadership or fiduciary role in other board, society, committee or advocacy group as unpaid board member at Massachusetts Prostate Cancer, Coalition (MPCC); American College of Radiation Oncology (ACRO); Radiation Oncology Institute (ROI). Dr Lee declares in the last 36 months grants or contracts from any entity in the form of payments made to me as an active WebMD podcast host, and consulting fees (expired) from Merck. Dr Parker declares in the last 36 months support for attending meetings and/or travel from employer, McGill University Health Centre. Dr Sandler declares in the last 36 months consulting fees as a member of a clinical trial steering committee at Janssen, support for attending meetings and/or travel to XIV International Uro-Oncology Conference from Nonpharma travel to cancer congress in Brazil and leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid at ASTRO as a member of the board of directors. Dr Souhami declares in the last 36 months payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from Varian Medical Systems and support for attending meetings and/or travel from Varian Medical Systems. Dr Wu declares in the last 36 months consulting fees from OrigiMed Co. Ltd, payment for expert testimony for Conrad Trosch & Kemmy, P.A. and stock in GoPath Diagnostics, LLC. Dr Zeitman declares in the last 36 months leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as Editor-in-Chief of International Journal of Radiation Oncology, Biology, Physics from 2011 through 2021. EDAT- 2024/08/16 01:19 MHDA- 2024/12/15 00:41 PMCR- 2025/05/20 CRDT- 2024/08/15 19:22 PHST- 2024/01/26 00:00 [received] PHST- 2024/07/15 00:00 [revised] PHST- 2024/08/02 00:00 [accepted] PHST- 2024/12/15 00:41 [medline] PHST- 2024/08/16 01:19 [pubmed] PHST- 2024/08/15 19:22 [entrez] PHST- 2025/05/20 00:00 [pmc-release] AID - S0360-3016(24)03230-9 [pii] AID - 10.1016/j.ijrobp.2024.08.007 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):153-161. doi: 10.1016/j.ijrobp.2024.08.007. Epub 2024 Aug 13. PMID- 39144899 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240816 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 7 DP - 2024 Jul TI - Exploring the Histopathological Landscape of Urinary Bladder Diseases: A Tertiary Care Center Study. PG - e64557 LID - 10.7759/cureus.64557 [doi] LID - e64557 AB - Introduction Urinary bladder lesions encompass a wide spectrum, from benign inflammatory conditions to malignant neoplasms, presenting diagnostic and therapeutic challenges. Urothelial carcinoma predominates among bladder malignancies, exhibiting diverse clinical presentations and prognoses. Objective This study aimed to delineate the histopathological spectrum of urinary bladder lesions and correlate demographic profiles, clinical features, and cystoscopic findings with various bladder lesions. Methods This prospective descriptive observational study spanned 24 months at a tertiary care center, involving 65 cases of urinary bladder biopsies, including transurethral resection of bladder tumors, cystoscopic biopsies, and cystectomy specimens. The histopathological examination followed the WHO 2022 classification of urinary bladder tumors and the American Joint Committee on Cancer eighth edition staging. Clinical data, including age, gender, cystoscopic findings, and presenting symptoms, were correlated with histopathological diagnoses to explore the spectrum of bladder lesions. Results Neoplastic lesions predominated, constituting 92.3% of cases, with urothelial carcinoma comprising 83.33% of these cases. Among neoplastic lesions, invasive high-grade urothelial carcinoma (36.7%) and non-invasive low-grade papillary urothelial neoplasm (20.0%) were the most frequently observed subtypes. Non-neoplastic lesions accounted for 7.7%, including various forms of cystitis. Hematuria was the predominant presenting symptom (81.5%), while cystoscopic examinations revealed that most lesions were situated in the lateral bladder wall. High-grade urothelial carcinomas were mostly associated with muscularis propria invasion. Conclusion This study underscores the critical role of histopathological examination in diagnosing and managing urinary bladder diseases and distinguishing between non-neoplastic and neoplastic lesions. Urothelial carcinoma, prevalent among older age groups, often demonstrated muscle invasion indicative of high-grade tumors. Including the muscle layer in cystoscopic biopsies is crucial for an accurate diagnosis. Conversely, though less common, non-neoplastic conditions encompass various forms of cystitis. These findings highlight the importance of precise diagnostic tools such as cystoscopy and histopathological examination for the early detection and management of bladder neoplasms. Histopathological assessment offers essential prognostic guidance, aids in precise staging and grading, and directs tailored treatment strategies. CI - Copyright (c) 2024, Kundlia et al. FAU - Kundlia, Aakriti AU - Kundlia A AD - Pathology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, Pune, IND. FAU - Dharwadkar, Arpana AU - Dharwadkar A AD - Pathology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, Pune, IND. FAU - Gore, Charusheela AU - Gore C AD - Pathology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, Pune, IND. FAU - Viswanathan, Vidya AU - Viswanathan V AD - Pathology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, Pune, IND. FAU - Ingale, Yaminy AU - Ingale Y AD - Pathology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, Pune, IND. LA - eng PT - Journal Article DEP - 20240715 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11323198 OTO - NOTNLM OT - biopsy OT - bladder carcinoma OT - cystitis OT - cystoscopy OT - histopathology OT - neoplastic OT - non-neoplastic OT - tumours OT - urinary bladder OT - urothelial carcinoma COIS- Human subjects: Consent was obtained or waived by all participants in this study. Dr. D.Y. Patil Medical College, Hospital and Research Centre Institutional Ethics Sub-committee issued approval IESC/PGS/2022/187. The synopsis was approved by Dr. D. Y. Patil Medical College, Hospital and Research Centre Institutional Ethics Sub-committee, Pune, in its meeting held on September 28, 2022. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/08/15 06:42 MHDA- 2024/08/15 06:43 PMCR- 2024/07/15 CRDT- 2024/08/15 04:54 PHST- 2024/07/15 00:00 [accepted] PHST- 2024/08/15 06:43 [medline] PHST- 2024/08/15 06:42 [pubmed] PHST- 2024/08/15 04:54 [entrez] PHST- 2024/07/15 00:00 [pmc-release] AID - 10.7759/cureus.64557 [doi] PST - epublish SO - Cureus. 2024 Jul 15;16(7):e64557. doi: 10.7759/cureus.64557. eCollection 2024 Jul. PMID- 39139561 OWN - NLM STAT- MEDLINE DCOM- 20240814 LR - 20261016 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - The clinical significance and anti-tumor role of PRKG1 in bladder cancer. PG - 1442555 LID - 10.3389/fimmu.2024.1442555 [doi] LID - 1442555 AB - INTRODUCTION: cGMP-dependent protein kinase 1 (PRKG1) has shown to be associated with some tumorigenesis, while the role of PRKG1 in bladder cancer is unclear. METHODS: To investigate the biological and clinical significance of PRKG1 in bladder cancer, we detected the expression of PRKG1 and explored the function of PRKG1 in bladder cancer cells. The PRKG1 transcripts data was downloaded from The Cancer Genome Atlas (TCGA) database, and immunohistochemistry staining was conducted on formalin-fixed paraffin-embedded (FFPE) sample tissues. Relationship between clinical characteristics of patients and expression of PRKG1 was analyzed in FFPE samples, TCGA database, and GSE19423 dataset. PRKG1 was over-expressed, and cell proliferation, migration, invasion, apoptosis, and spheroidizing ability were then detected. Chemosensitivity to cisplatin was detected with cell viability, and half-maximal drug inhibitory concentration (IC50) was calculated. In addition, the relation between PRKG1 expression and the infiltration level of tumor immune cells in tumor microenvironment were analyzed. RESULTS: The results showed expression of PRKG1 was lower in bladder cancer, compared with normal tissues both at protein and transcript levels. Lower PRKG1 expression was related to higher tumor grade, T stage, and muscle invasion, also predicted worse overall survival and recurrence free survival in patients treated with Bacillus Calmette-Guerin (BCG) intravesical immunotherapy. Analysis of tumor immune cells infiltration showed lower PRKG1 was associated with non-inflamed tumor microenvironment. CONCLUSION: The present study firstly identified the anti-tumor role and tumor immune regulatory role of PRKG1, also found loss of PRKG1 could be used as a prognosis factor. The present study provided a potential biomarker and therapy target to bladder cancer. CI - Copyright (c) 2024 Jin, Chen, Sun, Dai, Yao, Yuan, Liu and Xue. FAU - Jin, Lu AU - Jin L AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Chen, Ting AU - Chen T AD - Department of Pathology, Children's Hospital of Soochow University, Suzhou, China. FAU - Sun, Huan AU - Sun H AD - Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Dai, Guangcheng AU - Dai G AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Yao, Qiu AU - Yao Q AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Yuan, Feng AU - Yuan F AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Liu, Xiaolong AU - Liu X AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. FAU - Xue, Boxin AU - Xue B AD - Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240730 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EC 2.7.11.12 (Cyclic GMP-Dependent Protein Kinase Type I) RN - 0 (Biomarkers, Tumor) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - *Urinary Bladder Neoplasms/immunology/genetics/pathology/mortality MH - Humans MH - Female MH - Male MH - *Tumor Microenvironment/immunology MH - Middle Aged MH - Cell Line, Tumor MH - *Cyclic GMP-Dependent Protein Kinase Type I/genetics/metabolism MH - Biomarkers, Tumor/genetics MH - Prognosis MH - Cell Proliferation MH - Aged MH - Apoptosis MH - Gene Expression Regulation, Neoplastic MH - Cisplatin/therapeutic use/pharmacology MH - Cell Movement MH - Clinical Relevance PMC - PMC11319154 OTO - NOTNLM OT - BCG OT - PRKG1 OT - bladder cancer OT - immunotherapy OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/08/14 06:42 MHDA- 2024/08/14 06:43 PMCR- 2024/01/01 CRDT- 2024/08/14 04:19 PHST- 2024/06/02 00:00 [received] PHST- 2024/07/09 00:00 [accepted] PHST- 2024/08/14 06:43 [medline] PHST- 2024/08/14 06:42 [pubmed] PHST- 2024/08/14 04:19 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1442555 [doi] PST - epublish SO - Front Immunol. 2024 Jul 30;15:1442555. doi: 10.3389/fimmu.2024.1442555. eCollection 2024. PMID- 39133324 OWN - NLM STAT- MEDLINE DCOM- 20240812 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Aug 12 TI - Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer. PG - 480 LID - 10.1007/s00345-024-05192-x [doi] AB - PURPOSE: To assess prognostic significance of residual tumor at repeat transurethral resection (reTUR) in contemporary non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: Patients were identified retrospectively from eight referral centers in France, Italy and Spain. The cohort included consecutive patients with high or very-high risk NMIBC who underwent reTUR and subsequent adjuvant BCG therapy. RESULTS: A total of 440 high-risk NMIBC patients were screened, 29 (6%) were upstaged >/= T2 at reTUR and 411 were analyzed (T1 stage: n = 275, 67%). Residual tumor was found in 191 cases (46%). In patients with T1 tumor on initial TURBT, persistent T1 tumor was found in 18% of reTUR (n = 49/275). In patients with high-grade Ta tumor on initial TURBT, T1 tumor was found in 6% of reTUR (n = 9/136). In multivariable logistic regression analysis, we found no statistical association between the use of photodynamic diagnosis (PDD, p = 0.4) or type of resection (conventional vs. en bloc, p = 0.6) and the risk of residual tumor. The estimated 5-yr recurrence and progression-free survival were 56% and 94%, respectively. Residual tumor was significantly associated with a higher risk of recurrence (p < 0.001) but not progression (p = 0.11). Only residual T1 tumor was associated with a higher risk of progression (p < 0.001) with an estimated 5-yr progression-free survival rate of 76%. CONCLUSIONS: ReTUR should remain a standard for T1 tumors, irrespective of the use of en bloc resection or PDD and could be safely omitted in high-grade Ta tumors. Persistent T1 tumor at reTUR should not exclude these patients from conservative management, and further studies are needed to explore the benefit of a third resection in this subgroup. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Guigui, Alexandre AU - Guigui A AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Basile, Giuseppe AU - Basile G AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Zattoni, Fabio AU - Zattoni F AD - Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Verri, Paolo AU - Verri P AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Aumatell, Julia AU - Aumatell J AD - Urology Department, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos, Mostoles, Madrid, Spain. FAU - Gondran-Tellier, Bastien AU - Gondran-Tellier B AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Lechevallier, Eric AU - Lechevallier E AD - Department of Urology, La Conception Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Bastide, Cyrille AU - Bastide C AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Uleri, Alessandro AU - Uleri A AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Sica, Michele AU - Sica M AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Long-Depaquit, Thibaut AU - Long-Depaquit T AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. FAU - Dinoi, Giuseppe AU - Dinoi G AD - Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. FAU - Moro, Fabrizio Dal AU - Moro FD AD - Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. FAU - Akiki, Akram AU - Akiki A AD - Department of Urology, Aubagne Hospital, Aubagne, France. FAU - Toledano, Harry AU - Toledano H AD - Department of Urology, Martigues Hospital, Martigues, France. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Medical University of Silesia, Zabrze, Poland. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Amparore, Daniele AU - Amparore D AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Baboudjian, Michael AU - Baboudjian M AUID- ORCID: 0000-0001-6935-3873 AD - Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. Michael.BABOUDJIAN@outlook.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240812 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Neoplasm, Residual MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - Prognosis MH - *Cystectomy/methods MH - *Neoplasm Invasiveness MH - *Neoplasm Staging MH - Middle Aged MH - Urethra MH - Risk Assessment MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Nmibc OT - Prognostic OT - Residual tumor OT - Restaging EDAT- 2024/08/12 12:41 MHDA- 2024/08/12 12:42 CRDT- 2024/08/12 11:16 PHST- 2024/01/16 00:00 [received] PHST- 2024/07/20 00:00 [accepted] PHST- 2024/08/12 12:42 [medline] PHST- 2024/08/12 12:41 [pubmed] PHST- 2024/08/12 11:16 [entrez] AID - 10.1007/s00345-024-05192-x [pii] AID - 10.1007/s00345-024-05192-x [doi] PST - epublish SO - World J Urol. 2024 Aug 12;42(1):480. doi: 10.1007/s00345-024-05192-x. PMID- 39133312 OWN - NLM STAT- MEDLINE DCOM- 20240812 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Aug 12 TI - Impact of diabetes mellitus on oncologic outcomes in patients receiving robot-assisted radical cystectomy for bladder cancer. PG - 479 LID - 10.1007/s00345-024-05178-9 [doi] AB - PURPOSE: Aim of this study is to investigate the association between DM and oncological outcomes among patients with muscle-invasive (MI) or high-risk non-muscle invasive (NMI) bladder cancer (BC) who underwent robot-assisted radical cystectomy with intracorporeal urinary diversion (RARC). METHODS: An IRB approved multi-institutional BC database was queried, including patients underwent RARC between January 2013 and June 2023. Patients were divided into two groups according to DM status. Baseline, clinical, perioperative, pathologic data were compared. Chi-square and Student t tests were performed to compare categorical and continuous variables, respectively. Kaplan-Meier method and Cox regression analyses were performed to assess the association between DM and oncologic outcomes. RESULTS: Out of 547 consecutive patients, 97 (17.7%) had DM. The two cohorts showed similar preoperative features, except for ASA score (p = 0.01) and Hypertension rates (p < 0.001). No differences were detected for perioperative complications, pT stage, pN stages and surgical margins status (all p > 0.12). DM patients displayed significantly lower 5-yr disease-free survival (DFS) (44.6% vs. 63.3%, p = 0.007), 5-yr cancer-specific survival (CSS) (45.1% vs. 70.1%, p = 0.001) and 5-yr Overall survival (OS) (39.9% vs. 63.8%, p = 0.001). At Multivariable Cox-regression analyses DM status was identified as independent predictor of worse cancer-specific survival (CSS) (HR 2.1; p = 0.001) and overall survival (OS) (HR 2.05; p < 0.001). CONCLUSION: Among BC patients who underwent RARC, DM patients showed worse oncologic outcomes than the non-DM patients, with DM status playing an independent negative predicting role in CSS and OS. Future prospective studies are awaited, stimulating basic and translational research to identify possible mechanisms of interaction between DM and BC. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Chiacchio, Giuseppe AU - Chiacchio G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. gipeppo1@gmail.com. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Anceschi, Umberto AU - Anceschi U AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Bove, Alfredo Maria AU - Bove AM AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Brassetti, Aldo AU - Brassetti A AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - D'Annunzio, Simone AU - D'Annunzio S AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Ferriero, Mariaconsiglia AU - Ferriero M AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Misuraca, Leonardo AU - Misuraca L AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Proietti, Flavia AU - Proietti F AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Flammia, Rocco Simone AU - Flammia RS AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Guaglianone, Salvatore AU - Guaglianone S AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Lombardo, Riccardo AU - Lombardo R AD - Department of Urology, "Sapienza" University of Rome-Ospedale Sant'Andrea, Rome, Italy. FAU - Anselmi, Marianna AU - Anselmi M AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Zampa, Ashanti AU - Zampa A AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Nunzio, CosimoDe AU - Nunzio C AD - Department of Urology, "Sapienza" University of Rome-Ospedale Sant'Andrea, Rome, Italy. FAU - Pastore, Antonio Luigi AU - Pastore AL AD - Department of Urology, "Sapienza" University of Rome -ICOT Latina Polo Pontino, Latina, Italy. FAU - Galosi, Andrea Benedetto AU - Galosi AB AD - Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Universita Politecnica delle Marche, Ancona, Italy. FAU - Leonardo, Costantino AU - Leonardo C AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240812 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - *Robotic Surgical Procedures MH - Male MH - Female MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Treatment Outcome MH - Diabetes Mellitus/epidemiology OTO - NOTNLM OT - Bladder cancer OT - Diabetes mellitus OT - Oncologic outcomes OT - Radical cystectomy OT - Robotic EDAT- 2024/08/12 12:42 MHDA- 2024/08/12 12:43 CRDT- 2024/08/12 11:15 PHST- 2024/06/25 00:00 [received] PHST- 2024/07/15 00:00 [accepted] PHST- 2024/08/12 12:43 [medline] PHST- 2024/08/12 12:42 [pubmed] PHST- 2024/08/12 11:15 [entrez] AID - 10.1007/s00345-024-05178-9 [pii] AID - 10.1007/s00345-024-05178-9 [doi] PST - epublish SO - World J Urol. 2024 Aug 12;42(1):479. doi: 10.1007/s00345-024-05178-9. PMID- 39123411 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240812 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 15 DP - 2024 Jul 28 TI - Impact of Pre-Operative Ureteroscopy on Bladder Recurrence Following Nephroureterectomy for UTUC. LID - 10.3390/cancers16152683 [doi] LID - 2683 AB - (1) Introduction: Diagnostic ureteroscopy (URS) is an important component in the workup of upper tract urothelial carcinoma (UTUC). Whether URS was associated with increased recurrence in the bladder was not fully concluded. The current study aimed to evaluate the implication of URS on the incidences of intravesical recurrence following radical nephroureterectomy (RNU) in non-metastatic UTUC patients without prior history of bladder cancer via multi-institutional data. (2) Patients and Methods: Data were obtained from the Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract (CROES-UTUC) registry, a prospective, multicentre database. Patients with non-metastatic UTUC treated with RNU were divided into two groups: those undergoing upfront RNU and those having diagnostic URS prior to RNU. Intravesical recurrence-free survival (IVRS) was the primary endpoint, evaluated through Kaplan-Meier analysis and multivariate Cox regression. Cases with adequate follow-up data were included. (3) Results: The analysis included 269 patients. Of these, 137 (50.9%) received upfront RNU and 132 (49.1%) received pre-RNU URS. The URS group exhibited an inferior 24-month IVRS compared to the upfront RNU group (HR = 1.705, 95% CI = 1.082-2.688; p = 0.020). Multivariate analysis confirmed URS as the only significant predictor of IVR (p = 0.019). Ureteric access sheath usage, flexible ureteroscopy, ureteric biopsy, retrograde contrast studies, and the duration of URS did not significantly affect IVRS. (4) Conclusions: Diagnostic URS prior to RNU was found to be associated with an increased risk of IVR in patients with UTUC. The risk was not significantly influenced by auxiliary procedures during URS. Physicians were advised to meticulously evaluate the necessity of diagnostic URS. FAU - Wong, Chris Ho-Ming AU - Wong CH AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ko, Ivan Ching-Ho AU - Ko IC AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Leung, David Ka-Wai AU - Leung DK AUID- ORCID: 0000-0002-2078-7934 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Liu, Kang AU - Liu K AUID- ORCID: 0000-0001-7929-6534 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AUID- ORCID: 0000-0003-0705-7643 AD - Department of Urology, Hospital Universitario La Paz, 28046 Madrid, Spain. FAU - Pes, Maria Del Pilar Laguna AU - Pes MDPL AD - Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul 34083, Turkiye. FAU - de la Rosette, Jean AU - de la Rosette J AUID- ORCID: 0000-0002-6308-1763 AD - Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul 34083, Turkiye. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China. LA - eng PT - Journal Article DEP - 20240728 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11311632 OTO - NOTNLM OT - bladder recurrence OT - nephroureterectomy OT - survival outcomes OT - upper tract urothelial carcinoma OT - ureteroscopy COIS- The authors do not have any conflicts of interest to declare. EDAT- 2024/08/10 15:47 MHDA- 2024/08/10 15:48 PMCR- 2024/07/28 CRDT- 2024/08/10 01:01 PHST- 2024/06/20 00:00 [received] PHST- 2024/07/25 00:00 [revised] PHST- 2024/07/26 00:00 [accepted] PHST- 2024/08/10 15:48 [medline] PHST- 2024/08/10 15:47 [pubmed] PHST- 2024/08/10 01:01 [entrez] PHST- 2024/07/28 00:00 [pmc-release] AID - cancers16152683 [pii] AID - cancers-16-02683 [pii] AID - 10.3390/cancers16152683 [doi] PST - epublish SO - Cancers (Basel). 2024 Jul 28;16(15):2683. doi: 10.3390/cancers16152683. PMID- 39115589 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20250131 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Aug 8 TI - Do we need a re-TUR after en bloc resection of T1 stage bladder cancer? PG - 475 LID - 10.1007/s00345-024-05175-y [doi] LID - 475 AB - BACKGROUND: A second look trans-urethral resection of the bladder (re-TUR) is recommended after the diagnosis of T1 high grade (T1HG) bladder cancer. Few studies have evaluated the results of re-TUR after a first en bloc resection (EBR) and none of them have specifically reported the pathological results on the field of previous T1 disease. OBJECTIVE: To report the rate of upstaging and the rate of residual disease (RD) on the field of T1HG lesions resected with EBR. MATERIALS AND METHODS: Between 01/2014 and 06/2022, patients from 2 centers who had a re-TUR after an EBR for T1HG urothelial carcinoma were retrospectively included. Primary endpoint was the rate of RD including the rate of upstaging to T2 disease on the scar of the primary resection. Secondary endpoints were the rate of any residual disease outside the field. RESULTS: Seventy-five patients were included. No muscle invasive bladder cancer lesions were found after re-TUR. Among the 16 patients who had a RD, 4 were on the resection scar. All of these lesions were papillary and high grade. RD outside the field of the first EBR was observed in 12 patients. CONCLUSION: After EBR of T1HG disease, none of our patients had an upstaging to MIBC. However, the rate of RD either on and outside the field of the EBR remains quite significant. We suggested that predictive factors of residual papillary disease (number of tumors at the initial TUR and concomitant CIS) might be suitable to select patient who will benefit of the re-TUR. CI - (c) 2024. The Author(s). FAU - Levy, Stephan AU - Levy S AUID- ORCID: 0009-0002-8383-0108 AD - Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse Oncopole, 1 Av Jean Poulhes, 31059, Toulouse, France. FAU - Pericart, Sarah AU - Pericart S AD - Department of Pathology, CHU-Institut Universitaire du Cancer de Toulouse, Toulouse, France. FAU - Bajeot, Anne Sophie AU - Bajeot AS AD - Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse Oncopole, 1 Av Jean Poulhes, 31059, Toulouse, France. FAU - Fakhfakh, Sami AU - Fakhfakh S AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France. FAU - Lesourd, Marine AU - Lesourd M AD - Department of Urology, Clinique La Croix du Sud, Quint Fonsegrives, France. FAU - Soulie, Michel AU - Soulie M AD - Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse Oncopole, 1 Av Jean Poulhes, 31059, Toulouse, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse Oncopole, 1 Av Jean Poulhes, 31059, Toulouse, France. roumiguie_mathieu@yahoo.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240808 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Cystectomy/methods MH - Neoplasm Staging MH - *Neoplasm, Residual MH - Reoperation MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery/pathology PMC - PMC11310258 OTO - NOTNLM OT - Bladder tumor OT - En bloc resection OT - High-grade T1 OT - Oncology OT - Second look OT - Trans-urethral bladder resection OT - Urology COIS- SL has nothing to declare. GP has nothing to declare. MR has nothing to declare. EDAT- 2024/08/08 12:42 MHDA- 2024/08/08 12:43 PMCR- 2024/08/08 CRDT- 2024/08/08 11:04 PHST- 2024/03/26 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/08/08 12:43 [medline] PHST- 2024/08/08 12:42 [pubmed] PHST- 2024/08/08 11:04 [entrez] PHST- 2024/08/08 00:00 [pmc-release] AID - 10.1007/s00345-024-05175-y [pii] AID - 5175 [pii] AID - 10.1007/s00345-024-05175-y [doi] PST - epublish SO - World J Urol. 2024 Aug 8;42(1):475. doi: 10.1007/s00345-024-05175-y. PMID- 39101895 OWN - NLM STAT- MEDLINE DCOM- 20240916 LR - 20241101 IS - 1553-3514 (Electronic) IS - 1553-3506 (Linking) VI - 31 IP - 5 DP - 2024 Oct TI - Laparoscopic Versus Open Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Propensity-Score Matched Studies. PG - 520-529 LID - 10.1177/15533506241273378 [doi] AB - BACKGROUND: The effectiveness of laparoscopic nephroureterectomy (LNU) vs open nephroureterectomy (ONU) for upper tract urothelial carcinoma (UTUC) is unclear. METHODS: We conducted a meta-analysis of studies based on propensity score-matched cohorts to compare the surgical and oncological outcomes of LNU and ONU in UTUC patients. A literature search was conducted on PubMed, Embase, and Cochrane Library until July 12, 2023. The Newcastle-Ottawa Scale was utilized to assess the quality of eligible studies. Measurements of surgical and oncological outcomes were extracted and pooled including mean difference (MD), risk ratio (RR), hazard ratios (HR), and 95% confidence intervals (CI). RESULTS: Five high-quality retrospective studies were included, totaling 6422 patients; 2080 (32.4%) underwent LNU, and 4342 (67.6%) underwent ONU. With respect to surgical outcomes, patients in the LNU group experienced less estimated blood loss and had shorter hospital stay than those in the ONU group, but there was no significant difference in complication rates and operation time. In regard to oncological outcomes, there were no significant differences between the LNU and ONU groups in 3-year overall survival (OS) and cancer-specific survival (CSS). However, 3-year intravesical recurrence free survival (IVRFS) was worse in the LNU group compared to the ONU group. CONCLUSION: LNU was associated with less estimated blood loss and shorter hospital stays than ONU, but there were no differences in OS and CSS between the surgical modalities. Nonetheless, LNU might result in poorer IVRFS than ONU. FAU - Deng, Shidong AU - Deng S AUID- ORCID: 0009-0001-6874-2225 AD - Department of Urology, Hengyang Medical School, University of South China, Hengyang, China. RINGGOLD: 574417 FAU - Liu, Lingzhi AU - Liu L AD - Department of Urology, Hengyang Medical School, University of South China, Hengyang, China. RINGGOLD: 574417 FAU - Wang, Yurou AU - Wang Y AD - Department of Urology, Hengyang Medical School, University of South China, Hengyang, China. RINGGOLD: 574417 FAU - Zhou, Chuan AU - Zhou C AD - Department of Urology, Hengyang Medical School, University of South China, Hengyang, China. RINGGOLD: 574417 FAU - Zhang, Huihui AU - Zhang H AD - Department of Urology, Hengyang Medical School, University of South China, Hengyang, China. RINGGOLD: 574417 AD - Institute of Hospital Administration, University of South China, Hengyang, China. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20240805 PL - United States TA - Surg Innov JT - Surgical innovation JID - 101233809 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - *Laparoscopy/methods/statistics & numerical data MH - *Propensity Score MH - Carcinoma, Transitional Cell/surgery/mortality MH - Ureteral Neoplasms/surgery/mortality MH - Urologic Neoplasms/surgery/mortality MH - Kidney Neoplasms/surgery/mortality MH - Male OTO - NOTNLM OT - laparoscopy OT - meta-analysis OT - nephroureterectomy OT - propensity score matching OT - urothelial carcinoma COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/08/05 12:42 MHDA- 2024/09/17 10:42 CRDT- 2024/08/05 10:43 PHST- 2024/09/17 10:42 [medline] PHST- 2024/08/05 12:42 [pubmed] PHST- 2024/08/05 10:43 [entrez] AID - 10.1177/15533506241273378 [doi] PST - ppublish SO - Surg Innov. 2024 Oct;31(5):520-529. doi: 10.1177/15533506241273378. Epub 2024 Aug 5. PMID- 39100608 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240806 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 40 IP - 3 DP - 2024 Jul-Sep TI - The prognostic role of preoperative neutrophil-to-lymphocyte ratio in upper tract urothelial carcinoma. PG - 191-196 LID - 10.4103/iju.iju_22_24 [doi] AB - INTRODUCTION: The blood-based inflammatory marker, neutrophil-to-lymphocyte ratio (NLR), is a reliable prognostic biomarker for several cancers. Although the literature supports the correlation between preoperative NLR, clinicopathological characteristics, and oncological outcomes in upper tract urothelial carcinoma (UTUC), the cutoff of NLR is still debated. This study aimed to determine the prognostic value of NLR in patients with UTUC. METHODS: This was a retrospective analysis of prospectively collected data from July 2012 to December 2022 evaluating patients with UTUC who underwent radical nephroureterectomy (RNU). NLR was calculated using the neutrophil and lymphocyte counts obtained a day before the surgery and the cutoff value was set as 2.5. Kaplan-Meier and Cox's proportional hazards regression were used to analyze the association between NLR and the oncological outcomes. RESULTS: The study included 91 patients (78 males, 13 females) in the final analysis with a median follow-up of 49 months (8-130). The mean age of the patients with NLR <2.5 and NLR >/=2.5 was 56.88 years and 56.35 years, respectively, and the pathological stage was pT1 in 48%, pT2 in 20.88%, pT3 in 27.47%, and pT4 in 3.30% of the patients. Multivariable Cox regression analysis showed that the preoperative NLR >/=2.5 was significantly associated (Hz = 7.17) with higher T stage, lymphovascular invasion, necrosis, nodal involvement, adjuvant chemotherapy, and worse overall survival (OS) (Hz = 9.87). The Kaplan-Meier analysis revealed an improved OS in patients with NLR <2.5, but a statistically significant difference in the recurrence-free survival was not found. CONCLUSIONS: Preoperative NLR is an easily available, inexpensive, and important prognostic biomarker of survival in patients with UTUC and has a potential role in risk stratification by predicting adverse clinicopathological characteristics. CI - Copyright: (c) 2024 Indian Journal of Urology. FAU - Ghorai, Rudra Prasad AU - Ghorai RP AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Nayak, Brusabhanu AU - Nayak B AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Goel, Ritesh AU - Goel R AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Gupta, Prashant AU - Gupta P AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Raj, Rahul AU - Raj R AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Kaushal, Seema AU - Kaushal S AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Nayyar, Rishi AU - Nayyar R AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Kumar, Rajeev AU - Kumar R AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Seth, Amlesh AU - Seth A AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. LA - eng PT - Journal Article DEP - 20240701 PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC11296577 COIS- There are no conflicts of interest. EDAT- 2024/08/05 06:43 MHDA- 2024/08/05 06:44 PMCR- 2024/07/01 CRDT- 2024/08/05 05:07 PHST- 2024/01/11 00:00 [received] PHST- 2024/05/07 00:00 [revised] PHST- 2024/05/23 00:00 [accepted] PHST- 2024/08/05 06:44 [medline] PHST- 2024/08/05 06:43 [pubmed] PHST- 2024/08/05 05:07 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - IJU-40-191 [pii] AID - 10.4103/iju.iju_22_24 [doi] PST - ppublish SO - Indian J Urol. 2024 Jul-Sep;40(3):191-196. doi: 10.4103/iju.iju_22_24. Epub 2024 Jul 1. PMID- 39095581 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20261010 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 22 IP - 2 DP - 2025 Feb TI - Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. PG - 75-91 LID - 10.1038/s41585-024-00914-7 [doi] AB - The global incidence of bladder cancer is more than half a million diagnoses each year. Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC), which accounts for ~75% of diagnoses, and muscle-invasive bladder cancer (MIBC). Up to 45% of patients with NMIBC develop disease progression to MIBC, which is associated with a poor outcome, highlighting a clinical need to identify these patients. Current risk stratification has a prognostic value, but relies solely on clinicopathological parameters that might not fully capture the complexity of disease progression. Molecular research has led to identification of multiple crucial players involved in NMIBC progression. Identified biomarkers of progression are related to cell cycle, MAPK pathways, apoptosis, tumour microenvironment, chromatin stability and DNA-damage response. However, none of these biomarkers has been prospectively validated. Reported gene signatures of progression do not improve NMIBC risk stratification. Molecular subtypes of NMIBC have improved our understanding of NMIBC progression, but these subtypes are currently unsuitable for clinical implementation owing to a lack of prospective validation, limited predictive value as a result of intratumour subtype heterogeneity, technical challenges, costs and turnaround time. Future steps include the development of consensus molecular NMIBC subtypes that might improve conventional clinicopathological risk stratification. Prospective implementation studies of biomarkers and the design of biomarker-guided clinical trials are required for the integration of molecular biomarkers into clinical practice. CI - (c) 2024. Springer Nature Limited. FAU - Olislagers, Mitchell AU - Olislagers M AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - de Jong, Florus C AU - de Jong FC AUID- ORCID: 0000-0001-6853-5982 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Rutten, Vera C AU - Rutten VC AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Boormans, Joost L AU - Boormans JL AUID- ORCID: 0000-0002-5127-0436 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Mahmoudi, Tokameh AU - Mahmoudi T AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. AD - Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AUID- ORCID: 0000-0002-4002-9006 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. t.zuiverloon@erasmusmc.nl. LA - eng SI - ClinicalTrials.gov//NCT03892642, NCT05943106 ,NCT04452591 , NCT03837821 , NCT04887831 ,NCT03528694 , PT - Journal Article PT - Review DEP - 20240802 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Biomarkers, Tumor/genetics/metabolism MH - Disease Progression MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms MH - Prognosis MH - Risk Assessment MH - *Urinary Bladder Neoplasms/genetics/pathology/diagnosis/metabolism COIS- Competing interests: T.M. has a research collaboration with HUB Organoids, Gilead and Viiv. J.L.B. receives consultancy fees (all paid to Erasmus MC) from Janssen, BMS, AstraZeneca, Merck AG/Pfizer, MSD and Bayer. He also has research collaborations with Merck AG/Pfizer, MSD, Janssen, and VitroScan and has done book writing for Astellas. T.C.M.Z. has research collaborations with Vitroscan, HUB Organoids and Valar Labs. The other authors declare no competing interests. EDAT- 2024/08/03 10:42 MHDA- 2025/02/06 06:20 CRDT- 2024/08/02 23:28 PHST- 2024/06/21 00:00 [accepted] PHST- 2025/02/06 06:20 [medline] PHST- 2024/08/03 10:42 [pubmed] PHST- 2024/08/02 23:28 [entrez] AID - 10.1038/s41585-024-00914-7 [pii] AID - 10.1038/s41585-024-00914-7 [doi] PST - ppublish SO - Nat Rev Urol. 2025 Feb;22(2):75-91. doi: 10.1038/s41585-024-00914-7. Epub 2024 Aug 2. PMID- 39089974 OWN - NLM STAT- MEDLINE DCOM- 20241118 LR - 20250605 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 12 DP - 2024 Dec TI - Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method? PG - 450.e13-450.e22 LID - S1078-1439(24)00509-X [pii] LID - 10.1016/j.urolonc.2024.06.010 [doi] AB - OBJECTIVE: This study aims to reveal the importance of tertiary lymphoid structures (TLS) in transurethral resection of bladder tumor (TURBT) materials with a practical and applicable method in which the effect of a certain threshold value on survival and treatment response can be implicated. METHODS: TURBT materials that had not previously received any treatment (chemotherapy, radiotherapy, or immunotherapy) and were diagnosed for the first time at Mardin Training and Research Hospital between 2014 and 2022 were included in the study. The maximum TLS per 4x magnification field (field diameter: 4.5 mm) was recorded. Grouping and statistical analysis of the TLS number were performed using threshold values of ">/=1", ">/=2", and ">/=3". RESULTS: TLSs were more frequently found in high-grade tumors (P = 0.008) and showed a strong association with stage progression (P < 0.001). It was also significantly associated with many adverse histopathological parameters. Conversely, high TLS (>/=1, >/=2, and >/=3) appeared to be associated with fewer recurrences (P = 0.032, P = 0.001, and P = 0.018, respectively), and cases with higher TLS showed longer recurrence-free survival (P = 0.089, P = 0.023, P = 0.037, respectively). TLS>/=3 was found to be an independent parameter that was associated with favorable RFS (P = 0.019, HR = 0.401), and multifocality was found to be an independent risk factor for RFS (P = 0.023, HR = 2.302). CONCLUSION: This study is the first to demonstrate the relationship between the presence and specific thresholds of TLS in TURBT materials with prognostic parameters. Including this information in the routine pathological examination of TURBT materials will allow a more accurate approach to treatment and follow-up, especially in patients with non-muscle invasive bladder cancer (NMIBC). CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Yilmaz, Fatih AU - Yilmaz F AD - Pathology Laboratory, Mardin Training and Research Hospital, Mardin, Turkey. Electronic address: faatiihyiilmaaz@yahoo.com.tr. FAU - Sagir, Suleyman AU - Sagir S AD - Department of Urology, Mardin Artuklu University, Mardin, Turkey. Electronic address: dr.sagiroglu414@gmail.com. LA - eng PT - Journal Article DEP - 20240801 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Prognosis MH - Female MH - Male MH - *Tertiary Lymphoid Structures/pathology MH - Aged MH - Middle Aged MH - Predictive Value of Tests MH - Retrospective Studies MH - Aged, 80 and over MH - Cystectomy/methods OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Recurrence OT - TURBT OT - Tertiary lymphoid structure COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/08/02 00:46 MHDA- 2024/11/19 00:22 CRDT- 2024/08/01 22:01 PHST- 2024/02/24 00:00 [received] PHST- 2024/05/22 00:00 [revised] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/11/19 00:22 [medline] PHST- 2024/08/02 00:46 [pubmed] PHST- 2024/08/01 22:01 [entrez] AID - S1078-1439(24)00509-X [pii] AID - 10.1016/j.urolonc.2024.06.010 [doi] PST - ppublish SO - Urol Oncol. 2024 Dec;42(12):450.e13-450.e22. doi: 10.1016/j.urolonc.2024.06.010. Epub 2024 Aug 1. PMID- 39085366 OWN - NLM STAT- MEDLINE DCOM- 20240731 LR - 20240807 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Jul 31 TI - Development and validation of competing risk nomograms for predicting cancer‑specific mortality in non-metastatic patients with non‑muscle invasive urothelial bladder cancer. PG - 17641 LID - 10.1038/s41598-024-68474-9 [doi] LID - 17641 AB - We aimed to assess the cumulative incidences of cancer-specific mortality (CSM) in non-metastatic patients with non‑muscle invasive urothelial bladder cancer (NMIUBC) and establish competing risk nomograms to predict CSM. Patient data was sourced from the Surveillance, Epidemiology, and End Results database, as well as the electronic medical record system in our institution to form the external validation cohort. Sub-distribution proportional hazards model was utilized to determine independent risk factors influencing CSM in non-metastatic NMIUBC patients. Competitive risk nomograms were constructed to predict 3-year, 5-year, and 8-year cancer-specific survival (CSS) in all patients group, TURBT group and cystectomy group, respectively. The discrimination and accuracy of the model were validated through the concordance index (C-index), the area under the receiver operating characteristic curve (AUC), and calibration curves. Decision curve analysis (DCA) and a risk stratification system was employed to evaluate the clinical utility of the model. Race, age, marital status, surgery in other sites, tumor size, histological type, histological grade, T stage and N stage were identified as independent risk factors to predict CSS in all patients group. The C-index for 3-year CSS was 0.771, 0.770 and 0.846 in the training, testing and external validation sets, respectively. The ROC curves showed well discrimination and the calibration plots were well fitted and consistent. Moreover, DCA demonstrated well clinical effectiveness. Altogether, the competing risk nomogram displayed excellent discrimination and accuracy for predicting CSS in non-metastatic NMIUBC patients, which can be applied in clinical practice to help tailor treatment plans and make clinical decisions. CI - (c) 2024. The Author(s). FAU - Li, Shan AU - Li S AD - Department of Urology, Children's Hospital of Chongqing Medical University, Zhongshan 2nd Road, No.136, Yuzhong District, Chongqing, 400014, China. AD - Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, China. AD - China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. FAU - Wang, Jinkui AU - Wang J AD - Department of Urology, Children's Hospital of Chongqing Medical University, Zhongshan 2nd Road, No.136, Yuzhong District, Chongqing, 400014, China. AD - Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, China. AD - China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. FAU - Zhang, Zhaoxia AU - Zhang Z AD - Department of Urology, Children's Hospital of Chongqing Medical University, Zhongshan 2nd Road, No.136, Yuzhong District, Chongqing, 400014, China. AD - Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, China. AD - China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. FAU - Wu, Yuzhou AU - Wu Y AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China. FAU - Liu, Zhenyu AU - Liu Z AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China. FAU - Yin, Zhikang AU - Yin Z AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, China. yinzhikang2005@sina.com. FAU - Liu, Junhong AU - Liu J AD - Department of Urology, Children's Hospital of Chongqing Medical University, Zhongshan 2nd Road, No.136, Yuzhong District, Chongqing, 400014, China. knifeuro@163.com. AD - Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, 400014, China. knifeuro@163.com. AD - China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. knifeuro@163.com. LA - eng GR - No. cstc2019jscx-msxmX0142/Chongqing Municipal Science and Technology Bureau/ GR - No. cstc2019jscx-msxmX0142/Chongqing Municipal Science and Technology Bureau/ GR - No. cstc2019jscx-msxmX0142/Chongqing Municipal Science and Technology Bureau/ GR - No. cstc2019jscx-msxmX0142/Chongqing Municipal Science and Technology Bureau/ PT - Journal Article PT - Validation Study DEP - 20240731 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - *Nomograms MH - Male MH - Female MH - Aged MH - Middle Aged MH - Risk Factors MH - Risk Assessment/methods MH - ROC Curve MH - Cystectomy MH - SEER Program MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Carcinoma, Transitional Cell/mortality/pathology MH - Prognosis PMC - PMC11291689 OTO - NOTNLM OT - Bladder cancer OT - Competing risk model OT - Cumulative incidence curves OT - Nomogram OT - SEER COIS- The authors declare no competing interests. EDAT- 2024/08/01 00:42 MHDA- 2024/08/01 00:43 PMCR- 2024/07/31 CRDT- 2024/07/31 23:26 PHST- 2023/12/30 00:00 [received] PHST- 2024/07/24 00:00 [accepted] PHST- 2024/08/01 00:43 [medline] PHST- 2024/08/01 00:42 [pubmed] PHST- 2024/07/31 23:26 [entrez] PHST- 2024/07/31 00:00 [pmc-release] AID - 10.1038/s41598-024-68474-9 [pii] AID - 68474 [pii] AID - 10.1038/s41598-024-68474-9 [doi] PST - epublish SO - Sci Rep. 2024 Jul 31;14(1):17641. doi: 10.1038/s41598-024-68474-9. PMID- 39082304 OWN - NLM STAT- MEDLINE DCOM- 20241210 LR - 20250722 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 135 IP - 1 DP - 2025 Jan TI - Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel. PG - 125-132 LID - 10.1111/bju.16486 [doi] AB - OBJECTIVES: To investigate the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the prediction of response to sequential intravesical therapy, gemcitabine and docetaxel (Gem/Doce), given to patients with bacille Calmette-Guerin (BCG)- naive high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A retrospective analysis was conducted on 115 patients who received intravesical Gem/Doce for high-risk NMIBC between January 2011 and December 2021. Data were computed as the median (interquartile range [IQR]) or mean (standard deviation [sd]). Cox regression analysis was performed to determine if neutrophilia, NLR, platelet counts, and PLR before instillation therapy were predictive of recurrence-free survival (RFS) and overall survival (OS). Predictive performance was estimated using Uno's C-statistic. RESULTS: The median (IQR) follow-up for the overall cohort was 23 (13-36) months. The mean (sd) values for NLR, PLR and platelet counts were 3.4 (2.3), 142.2 (85.5), and 225.2 (75.1) x 10(9)/L, respectively. NLR was associated with RFS, with a hazard ratio of 1.32 (95% confidence interval CI 1.19-1.46). Concordance analysis showed that NLR had a good ability to predict RFS (C-index: 0.7, P < 0.01). The PLR and platelet count were not associated with RFS and did not predict recurrence. In terms of OS, none of these cellular inflammatory markers showed any prediction value. CONCLUSION: Pre-treatment NLR provides some predictive accuracy for RFS in high-risk BCG-naive patients receiving Gem/Doce. Further prospective trials are needed to validate this finding. CI - (c) 2024 BJU International. FAU - Chakra, Mohamad Abou AU - Chakra MA AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. FAU - Lassila, Riitta AU - Lassila R AUID- ORCID: 0000-0002-1911-3094 AD - Unit of Coagulation Disorders, Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland. AD - Research Program Unit in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. FAU - El Beayni, Nancy AU - El Beayni N AUID- ORCID: 0000-0002-5127-5069 AD - Unit of Coagulation Disorders, Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland. AD - Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AUID- ORCID: 0000-0001-7202-6427 AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. LA - eng GR - P30 CA086862/CA/NCI NIH HHS/United States GR - John and Carol Walter Family Foundation/ PT - Journal Article DEP - 20240731 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/blood/mortality MH - *Gemcitabine MH - Male MH - Female MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - Retrospective Studies MH - *Neutrophils MH - *Docetaxel/administration & dosage MH - Aged MH - Administration, Intravesical MH - Middle Aged MH - Prognosis MH - *Lymphocytes MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Lymphocyte Count MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - docetaxel OT - gemcitabine OT - inflammatory markers OT - non-muscle-invasive bladder cancer OT - survival EDAT- 2024/07/31 12:44 MHDA- 2024/12/10 06:23 CRDT- 2024/07/31 06:22 PHST- 2024/12/10 06:23 [medline] PHST- 2024/07/31 12:44 [pubmed] PHST- 2024/07/31 06:22 [entrez] AID - 10.1111/bju.16486 [doi] PST - ppublish SO - BJU Int. 2025 Jan;135(1):125-132. doi: 10.1111/bju.16486. Epub 2024 Jul 31. PMID- 39075659 OWN - NLM STAT- MEDLINE DCOM- 20241007 LR - 20260301 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 85 IP - 5 DP - 2024 Nov TI - Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature. PG - 748-759 LID - 10.1111/his.15287 [doi] AB - AIMS: Urothelial carcinoma (UC) demonstrates significant molecular and histologic heterogeneity. The WHO 2022 classification has hinted at adding molecular signatures to the morphologic diagnosis. As morphology and associated molecular repertoire may potentially translate to choices of and response to therapy and relapse rate, broader acceptability of recognizing these key features among uropathologists is needed. This prompted an international survey to ascertain the practice patterns in classical/subtype UC among uropathologists across the globe. METHODS AND RESULTS: A survey instrument was shared among 98 uropathologists using SurveyMonkey software. Anonymized respondent data were analysed. The response rate was 85%. A majority were in concordance with the profiles of luminal (93%) and basal (82%) types. Opinion on the FGFR3 testing platform was variable. While 95% concurred that TERT promoter mutation is the key driver in UC, 72% had the opinion that APOBEC mutagenesis is the main signature in muscle invasive bladder cancer (MIBC). Uropathologists have divergent opinions on MIBC and ERCC2 mutations. Among the participants, 94% would quantify aggressive micropapillary and sarcomatoid histology, while 88% would reevaluate another transurethral resection of the bladder tumour specimen in nonmuscle invasive tumour with micropapillary, small cell, or sarcomatoid histology. A leading number agreed to specific molecular signatures of micropapillary (93%), plasmacytoid (97%), and small cell (86%) subtypes. Ninety-six percent of participants agreed that a small-cell component portends a more aggressive course and should be treated with neoadjuvant chemotherapy and 63% would perform HER2/neu testing only on oncologist's request in advanced tumours. Ninety percent agreed that microsatellite instability testing, although not a standard protocol, should be considered in young patients with upper tract UC. Eighty-six percent agreed that UC with high tumour mutational burden would be a better candidate for immunotherapy. CONCLUSION: In the era of precision medicine, enhanced understanding of molecular heterogeneity of UC will contribute to better therapeutic options, novel biomarker discovery, innovative management protocols, and outcomes. Our survey provides a broad perspective of pathologists' perceptions and experience regarding incorporation of histomolecular approaches to "personalize" therapy. Due to variable clinical adoption, there is a need for additional data using uniform study criteria. This will drive generation of best practice guidelines in this area for widespread and consistent clinical utility. CI - (c) 2024 John Wiley & Sons Ltd. FAU - Lobo, Anandi AU - Lobo A AUID- ORCID: 0000-0002-3051-8009 AD - Department of Pathology, Kapoor Centre of Urology and Pathology, Raipur, India. FAU - Collins, Katrina AU - Collins K AUID- ORCID: 0000-0002-9603-6731 AD - Department of Pathology, Indiana University Health, Indiana, USA. FAU - Kaushal, Seema AU - Kaushal S AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Acosta, Andres M AU - Acosta AM AUID- ORCID: 0000-0001-8817-6331 AD - Department of Pathology, Indiana University Health, Indiana, USA. FAU - Akgul, Mahmut AU - Akgul M AD - Department of Pathology, Albany Medical Center, Albany, USA. FAU - Adhya, Amit K AU - Adhya AK AD - Department of Pathology, All India Institute of Medical Sciences, Bhubaneswar, India. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AD - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA. FAU - Al-Obaidy, Khaleel I AU - Al-Obaidy KI AUID- ORCID: 0000-0001-9890-8751 AD - Department of Pathology, Henry Ford Health System, Detroit, USA. FAU - Amin, Ali AU - Amin A AD - Department of Pathology, Alpert Medical School of Brown University, Providence, USA. FAU - Amin, Mahul B AU - Amin MB AD - Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, USA. FAU - Aron, Manju AU - Aron M AD - Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, USA. FAU - Balzer, Bonnie L AU - Balzer BL AD - Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, USA. FAU - Biswal, Rupanita AU - Biswal R AD - Department of Pathology, Bagchi Sri Shankara Cancer Hospital, Bhubaneswar, India. FAU - Mohanty, Subashish AU - Mohanty S AD - Department of Pathology, SUM Ultimate Medicare Hospital, Bhubaneswar, India. FAU - Browning, Lisa AU - Browning L AD - Department of Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Chakrabarti, Indranil AU - Chakrabarti I AD - Department of Pathology, All India Institute of Medical Sciences, Kalyani, India. FAU - Cima, Luca AU - Cima L AD - Department of Pathology, Santa Chiara Hospital of Trento, Trento, Italy. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Department of Pathology, Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy. FAU - Desai, Sangeeta AU - Desai S AUID- ORCID: 0000-0002-3588-9888 AD - Department of Pathology, Tata Memorial Hospital, Mumbai, India. FAU - Dhillon, Jasreman AU - Dhillon J AD - Department of Pathology, Moffitt Cancer Center, Tampa, USA. FAU - Deshwal, Akansha AU - Deshwal A AD - Department of Pathology, ESI Hospital, New Delhi, India. FAU - Diego, Guillermo G AU - Diego GG AD - Department of Pathology, University Gregorio Maranon Hospital, Madrid, Spain. FAU - Diwaker, Preeti AU - Diwaker P AD - Department of Pathology, University College of Medical Sciences, New Delhi, India. FAU - Galea, Laurence A AU - Galea LA AUID- ORCID: 0000-0001-7968-1846 AD - Department of Pathology, Melbourne Pathology, Melbourne, Australia. FAU - Magi-Galluzzi, Cristina AU - Magi-Galluzzi C AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, USA. FAU - Giannico, Giovanna A AU - Giannico GA AUID- ORCID: 0000-0002-0326-3207 AD - Department of Pathology, University of California - Irvine, Irvine, USA. FAU - Gupta, Nilesh S AU - Gupta NS AD - Department of Pathology, Henry Ford Health System, Detroit, USA. FAU - Haider, Aiman AU - Haider A AD - Department of Pathology, University College London Hospitals NHS Foundation Trust, London, UK. FAU - Hirsch, Michelle S AU - Hirsch MS AUID- ORCID: 0000-0002-8767-8564 AD - Department of Pathology, Brigham and Women's Hospital, Boston, USA. FAU - Iczkowski, Kenneth A AU - Iczkowski KA AD - Department of Pathology, University of California - Davis, Davis, USA. FAU - Arora, Samriti AU - Arora S AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Jain, Ekta AU - Jain E AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Jain, Deepika AU - Jain D AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Jha, Shilpy AU - Jha S AD - Department of Pathology, Advanced Medical and Research Institute, Bhubaneswar, India. FAU - Kandukuri, Shivani AU - Kandukuri S AD - Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, USA. FAU - Kao, Chia-Sui AU - Kao CS AD - Department of Pathology, Cleveland Clinic, Cleveland, USA. FAU - Kryvenko, Oleksandr N AU - Kryvenko ON AUID- ORCID: 0000-0001-5731-1748 AD - Department of Pathology, University of Miami Miller School of Medicine, Miami, USA. FAU - Kumar, Ramani M AU - Kumar RM AD - Department of Pathology, Dane Diagnostics, Palakkad, India. FAU - Kumari, Niraj AU - Kumari N AD - Department of Pathology, All India Institute of Medical Sciences, Raebareli, India. FAU - Kunju, Lakshmi P AU - Kunju LP AD - Department of Pathology, University of Michigan, Ann Arbor, USA. FAU - Kuthi, Levente AU - Kuthi L AD - Department of Pathology, Albert Szent-Gyorgyi Medical School, University of Szeged, Szeged, Hungary. FAU - Lobo, Joao AU - Lobo J AD - Department of Pathology, Portuguese Oncology Institute - Porto, Porto, Portugal. FAU - Lopez, Jose I AU - Lopez JI AD - Department of Pathology, Cruces University Hospital, Barakaldo, Spain. FAU - Luthringer, Daniel J AU - Luthringer DJ AD - Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, USA. FAU - Maclean, Fiona AU - Maclean F AD - Department of Pathology, Douglass Hanly Moir Pathology, Sydney, Australia. FAU - Manini, Claudia AU - Manini C AD - Department of Pathology, University of Turin, Turin, Italy. FAU - Mannan, Rahul AU - Mannan R AD - Department of Pathology, University of Michigan, Ann Arbor, USA. FAU - Martos, Maria G AU - Martos MG AD - Department of Pathology, University Gregorio Maranon Hospital, Madrid, Spain. FAU - Mehra, Rohit AU - Mehra R AUID- ORCID: 0000-0002-6955-8884 AD - Department of Pathology, University of Michigan, Ann Arbor, USA. FAU - Menon, Santosh AU - Menon S AUID- ORCID: 0000-0002-4140-0671 AD - Department of Pathology, Tata Memorial Hospital, Mumbai, India. FAU - Mishra, Pritinanda AU - Mishra P AD - Department of Pathology, All India Institute of Medical Sciences, Bhubaneswar, India. FAU - Moch, Holger AU - Moch H AD - Department of Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Montironi, Rodolfo AU - Montironi R AD - Department of Pathology, Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy. FAU - Baisakh, Manas R AU - Baisakh MR AD - Department of Pathology, Prolife Diagnostics, Bhubaneswar, India. FAU - Netto, George J AU - Netto GJ AD - Department of Pathology, University of Pennsylvania, Philadelphia, USA. FAU - Nigam, Lovelesh K AU - Nigam LK AD - Department of Pathology, Institute of Kidney Diseases and Research Center, Ahmedabad, India. FAU - Osunkoya, Adeboye O AU - Osunkoya AO AUID- ORCID: 0000-0001-5712-8134 AD - Department of Pathology, Emory University School of Medicine, Atlanta, USA. FAU - Pagliuca, Francesca AU - Pagliuca F AD - Department of Pathology, Universita degliStudidella Campania Luigi Vanvitelli, Caserta, Italy. FAU - Paner, Gladell P AU - Paner GP AD - Department of Pathology, University of Chicago, Chicago, USA. FAU - Panizo, Angel AU - Panizo A AD - Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Spain. FAU - Parwani, Anil V AU - Parwani AV AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, USA. FAU - Picken, Maria M AU - Picken MM AD - Department of Pathology, Loyola University Medical Center, Hines, USA. FAU - Prendeville, Susan AU - Prendeville S AD - Department of Pathology, University Health Network, University of Toronto, Toronto, Canada. FAU - Przybycin, Christopher G AU - Przybycin CG AUID- ORCID: 0000-0001-9426-7272 AD - Department of Pathology, Cleveland Clinic, Cleveland, USA. FAU - Purkait, Suvendu AU - Purkait S AD - Department of Pathology, All India Institute of Medical Sciences, Bhubaneswar, India. FAU - Queipo, Francisco J AU - Queipo FJ AUID- ORCID: 0000-0002-4173-6300 AD - Department of Pathology, Hospital Universitario de A Coruna, A Coruna, Spain. FAU - Rao, B Vishal AU - Rao BV AUID- ORCID: 0000-0001-7109-548X AD - Department of Pathology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Rao, Priya AU - Rao P AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Reuter, Victor E AU - Reuter VE AD - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA. FAU - Sancheti, Sankalp AU - Sancheti S AD - Department of Pathology, Homi Bhabha Cancer Hospital, Punjab, India. FAU - Sangoi, Ankur R AU - Sangoi AR AD - Department of Pathology, Stanford University, Stanford, USA. FAU - Sardana, Rohan AU - Sardana R AD - Department of Pathology, Sardana Laboratories, Jalandhar, India. FAU - Satturwar, Swati AU - Satturwar S AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, USA. FAU - Shah, Rajal B AU - Shah RB AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA. FAU - Sharma, Shivani AU - Sharma S AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Dixit, Mallika AU - Dixit M AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Verma, Monica AU - Verma M AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. FAU - Sirohi, Deepika AU - Sirohi D AD - Department of Pathology, University of California, San Francisco, USA. FAU - Smith, Steven C AU - Smith SC AUID- ORCID: 0000-0003-0982-4607 AD - Department of Pathology, Virginia Commonwealth University School of Medicine, Richmond, USA. FAU - Soni, Shailesh AU - Soni S AD - Department of Pathology, Muljibhai Patel Urological Hospital, Nadiad, India. FAU - Sundaram, Sandhya AU - Sundaram S AD - Department of Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India. FAU - Swain, Meenakshi AU - Swain M AD - Department of Pathology, Apollo Hospitals, Hyderabad, India. FAU - Tretiakova, Maria AU - Tretiakova M AUID- ORCID: 0000-0002-0819-9638 AD - Department of Pathology, University of Washington, Seattle, USA. FAU - Trpkov, Kiril AU - Trpkov K AUID- ORCID: 0000-0003-3142-8846 AD - Department of Pathology, University of Calgary, Calgary, Canada. FAU - MunizUnamunzaga, Gorka AU - MunizUnamunzaga G AD - Department of Pathology, Hospital San Jorge, San Juan, Spain. FAU - Zhou, Ming AU - Zhou M AD - Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts, USA. FAU - Williamson, Sean R AU - Williamson SR AUID- ORCID: 0000-0002-3898-1460 AD - Department of Pathology, Cleveland Clinic, Cleveland, USA. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AUID- ORCID: 0000-0003-3161-8164 AD - Department of Pathology, Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, Cordoba, Spain. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology, Alpert Medical School of Brown University, Providence, USA. FAU - Mohanty, Sambit K AU - Mohanty SK AUID- ORCID: 0000-0001-5094-2424 AD - Department of Pathology, CORE Diagnostics, Gurgaon, India. AD - Department of Pathology, Advanced Medical and Research Institute, Bhubaneswar, India. LA - eng PT - Journal Article PT - Review DEP - 20240729 PL - England TA - Histopathology JT - Histopathology JID - 7704136 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/genetics MH - *Carcinoma, Transitional Cell/pathology/genetics MH - *Pathologists MH - Surveys and Questionnaires MH - Mutation MH - Biomarkers, Tumor/genetics MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Telomerase/genetics MH - Genetic Heterogeneity EDAT- 2024/07/30 06:42 MHDA- 2024/10/07 16:22 CRDT- 2024/07/30 00:13 PHST- 2024/07/08 00:00 [revised] PHST- 2024/02/22 00:00 [received] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/10/07 16:22 [medline] PHST- 2024/07/30 06:42 [pubmed] PHST- 2024/07/30 00:13 [entrez] AID - 10.1111/his.15287 [doi] PST - ppublish SO - Histopathology. 2024 Nov;85(5):748-759. doi: 10.1111/his.15287. Epub 2024 Jul 29. PMID- 39075503 OWN - NLM STAT- MEDLINE DCOM- 20240730 LR - 20240801 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 24 IP - 1 DP - 2024 Jul 29 TI - Preoperative analysis of factors associated with prolonged pneumoretroperitoneum time during retroperitoneal laparoscopic nephroureterectomy for upper tract urothelial carcinoma. PG - 155 LID - 10.1186/s12894-024-01538-0 [doi] LID - 155 AB - BACKGROUND: Prolonged laparoscopic nephroureterectomy (LNU) for upper tract urothelial cancer (UTUC) can increase the frequency of intravesical recurrence after surgery. Therefore, it is important for urological surgeons to have knowledge on preoperative risk factors for prolonged LNU. However, few studies have investigated the risk factors for prolonged LNU. We hypothesized that the quantity of perirenal fat affects the pneumoretroperitoneum time (PRT) of retroperitoneal LNU (rLNU). This study aimed to investigate the preoperative risk factors for prolonged PRT during rLNU. METHODS: We reviewed the data of 115 patients who underwent rLNU for UTUC between 2013 and 2021. The perirenal fat thickness (PFT) observed on preoperative computed tomography (CT) images was used to evaluate the perinephric fat quantity. Preoperative risk factors for PRT during rLNU were analyzed using logistic regression models. The cutoff value for PRT was determined based on the median time.The cutoff values for fat-related factors influencing PRT were defined according to receiver operating characteristic curve analysis. RESULTS: The median PRT for rLNU was 182 min (interquartile range, 155-230 min). The cutoff values of posterior, lateral, and anterior PFTs were 15 mm, 24 mm, and 6 mm, respectively. Multivariate analysis revealed that a posterior PFT >/= 15 mm (odds ratio [OR], 2.72; 95% confidence interval, 1.04-7.08; p = 0.0410) was an independent risk factor for prolonged PRT. CONCLUSIONS: Thick posterior PFT is a preoperative risk factor for prolonged PRT during rLNU. For patients with UTUC and thick posterior PFT, surgeons should develop optimal surgical strategies, including the selecting an expert surgeon as a primary surgeon and the selecting transperitoneal approach to surgery or open surgery. CI - (c) 2024. The Author(s). FAU - Yanagi, Masato AU - Yanagi M AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. area-i@nms.ac.jp. FAU - Kiriyama, Tomonari AU - Kiriyama T AD - Department of Radiology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Akatsuka, Jun AU - Akatsuka J AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Endo, Yuki AU - Endo Y AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Takeda, Hayato AU - Takeda H AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Hamasaki, Tsutomu AU - Hamasaki T AD - Department of Urology, Nippon Medical School Musashikosugi Hospital, 1-396, Kosugimachi, Nakahara-Ku, Kawasaki-City, Kanagawa, 211-8533, Japan. FAU - Nishimura, Taiji AU - Nishimura T AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Kondo, Yukihiro AU - Kondo Y AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. LA - eng PT - Journal Article DEP - 20240729 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Male MH - *Laparoscopy/methods MH - Female MH - Aged MH - Retroperitoneal Space MH - *Kidney Neoplasms/surgery MH - Middle Aged MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/surgery MH - *Ureteral Neoplasms/surgery MH - Risk Factors MH - Time Factors MH - Operative Time MH - Preoperative Period PMC - PMC11285617 OTO - NOTNLM OT - Body mass index OT - Perirenal fat stranding OT - Perirenal fat thickness OT - Pneumoretroperitoneum time OT - Retroperitoneoscopic nephroureterectomy OT - Upper tract urothelial carcinoma COIS- The authors declare no competing interests. EDAT- 2024/07/30 00:42 MHDA- 2024/07/30 06:42 PMCR- 2024/07/29 CRDT- 2024/07/29 23:50 PHST- 2024/03/12 00:00 [received] PHST- 2024/07/09 00:00 [accepted] PHST- 2024/07/30 06:42 [medline] PHST- 2024/07/30 00:42 [pubmed] PHST- 2024/07/29 23:50 [entrez] PHST- 2024/07/29 00:00 [pmc-release] AID - 10.1186/s12894-024-01538-0 [pii] AID - 1538 [pii] AID - 10.1186/s12894-024-01538-0 [doi] PST - epublish SO - BMC Urol. 2024 Jul 29;24(1):155. doi: 10.1186/s12894-024-01538-0. PMID- 39071456 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240730 IS - 2218-4333 (Print) IS - 2218-4333 (Electronic) IS - 2218-4333 (Linking) VI - 15 IP - 7 DP - 2024 Jul 24 TI - Histologic subtypes of non-muscle invasive bladder cancer. PG - 835-839 LID - 10.5306/wjco.v15.i7.835 [doi] AB - The majority of bladder cancers (BCs) are non-muscle invasive BCs (NMIBCs) and show the morphology of a conventional urothelial carcinoma (UC). Aberrant morphology is rare but can be observed. The classification and characterization of histologic subtypes (HS) in UC in BC have mainly been described in muscle invasive bladder cancer (MIBC). However, the currently used classification is applied for invasive urothelial neoplasm and therefore, also valid for a subset of NMIBC. The standard transurethral diagnostic work-up misses the presence of HS in NMIBC in a considerable percentage of patients and the real prevalence is not known. HS in NMIBC are associated with an aggressive phenotype. Consequently, clinical guidelines categorize HS of NMIBC as "(very) high-risk" tumors and recommend offering radical cystectomy to these patients. Alternative strategies for bladder preservation can only be offered to highly selected patients and ideally within clinical trials. Novel treatment strategies and biomarkers have been established MIBC and NMIBC but have not been comprehensively investigated in the context of HS in NMIBC. Further evaluation prior to implementation into clinical practice is needed. CI - (c)The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Giudici, Nicola AU - Giudici N AD - Department of Urology, Spitalzentrum Biel, Biel 2501, Switzerland. nicolagiudici@gmail.com. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, Spitalzentrum Biel, Biel 2501, Switzerland. AD - Department of BioMedical Research, University of Bern, Bern 3010, Switzerland. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Clin Oncol JT - World journal of clinical oncology JID - 101549149 PMC - PMC11271725 OTO - NOTNLM OT - Histologic subtypes OT - Histologic variants OT - Muscle invasive bladder cancer OT - Non-muscle invasive bladder cancer OT - Urothelial carcinoma COIS- Conflict-of-interest statement: The authors have no conflicts of interest to declare. EDAT- 2024/07/29 06:42 MHDA- 2024/07/29 06:43 PMCR- 2024/07/24 CRDT- 2024/07/29 05:46 PHST- 2024/03/28 00:00 [received] PHST- 2024/05/21 00:00 [revised] PHST- 2024/05/30 00:00 [accepted] PHST- 2024/07/29 06:43 [medline] PHST- 2024/07/29 06:42 [pubmed] PHST- 2024/07/29 05:46 [entrez] PHST- 2024/07/24 00:00 [pmc-release] AID - 10.5306/wjco.v15.i7.835 [doi] PST - ppublish SO - World J Clin Oncol. 2024 Jul 24;15(7):835-839. doi: 10.5306/wjco.v15.i7.835. PMID- 39064112 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 14 DP - 2024 Jul 12 TI - The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study. LID - 10.3390/jcm13144072 [doi] LID - 4072 AB - Background: Programmed death-ligand 1 (PD-L1) expression has been recognized as a potential biomarker for various cancers, yet its diagnostic and prognostic significance in urothelial bladder cancer (BCa) requires further investigation. Methods: In this prospective single-center study, we aimed to assess the feasibility and diagnostic adequacy of PD-L1 expression analysis using cytoinclusion in BCa patients. We enrolled consecutive patients undergoing endoscopic transurethral resection of bladder tumor (TURBT), repeat TURBT, or robot-assisted radical cystectomy. Urinary and tissue specimens were collected from these patients for cytoinclusion and histopathological analysis to evaluate PD-L1 expression. Results: Out of 29 patients, PD-L1 expression was detected from cytoinclusion in 42.8% (3 out of 7), 10% (1 out of 10), and 66.8% (8 out of 12) of patients with negative/papilloma, low-grade, and high-grade tumors, respectively. Conversely, histopathological analysis identified PD-L1 expression in 57.2% (4 out of 7), 30% (3 out of 10), and 83.3% (10 out of 12) of patients with negative/papilloma, low-grade, and high-grade tumors, respectively. The diagnostic concordance between cytoinclusion and histopathology was 85.7%, 80%, and 83.3% in patients with negative/papilloma, low-grade, and high-grade tumors, respectively. Conclusions: Our study underscores the promise of cytoinclusion as a minimally invasive method for quantifying urinary PD-L1 percentages. This approach could serve as both a potential prognostic and diagnostic indicator, easily obtainable from urine samples. Standardizing this technique could facilitate its widespread use as a valuable tool. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AUID- ORCID: 0000-0002-0564-7415 AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Montagner, Isabella Monia AU - Montagner IM AD - Anatomy and Pathological Histology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy. FAU - Tormen, Debora AU - Tormen D AD - Anatomy and Pathological Histology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy. FAU - Crestani, Alessandro AU - Crestani A AD - Department of Urology, Ospedale Santa Maria Della Misericordia di Udine, 33100 Udine, Italy. FAU - Amodeo, Antonio AU - Amodeo A AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Corsi, Paolo AU - Corsi P AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - De Marchi, Davide AU - De Marchi D AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Miglioranza, Eugenio AU - Miglioranza E AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Lista, Giuliana AU - Lista G AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Simonetti, Francesca AU - Simonetti F AUID- ORCID: 0009-0006-8387-8290 AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology, University of Foggia, 71122 Foggia, Italy. FAU - Maggi, Martina AU - Maggi M AUID- ORCID: 0000-0003-4672-850X AD - Department of Urology, Sapienza University, 00185 Rome, Italy. FAU - Marino, Filippo AU - Marino F AUID- ORCID: 0000-0002-2908-6907 AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, University of Sacre Heart, 00168 Rome, Italy. FAU - Scapinello, Antonio AU - Scapinello A AD - Anatomy and Pathological Histology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Veneto Institute of Oncology (IOV)-IRCCS, Headquarter of Castelfranco Veneto, 35128 Padua, Italy. LA - eng PT - Journal Article DEP - 20240712 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11277725 OTO - NOTNLM OT - PD-L1 OT - cytoinclusion technique OT - urinary biomarkers OT - urothelial bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:44 MHDA- 2024/07/27 10:45 PMCR- 2024/07/12 CRDT- 2024/07/27 01:19 PHST- 2024/05/16 00:00 [received] PHST- 2024/06/29 00:00 [revised] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/07/27 10:45 [medline] PHST- 2024/07/27 10:44 [pubmed] PHST- 2024/07/27 01:19 [entrez] PHST- 2024/07/12 00:00 [pmc-release] AID - jcm13144072 [pii] AID - jcm-13-04072 [pii] AID - 10.3390/jcm13144072 [doi] PST - epublish SO - J Clin Med. 2024 Jul 12;13(14):4072. doi: 10.3390/jcm13144072. PMID- 39062114 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 7 DP - 2024 Jul 11 TI - Can We Go beyond Pathology? The Prognostic Role of Risk Scoring Tools for Cancer-Specific Survival of Patients with Bladder Cancer Undergoing Radical Cystectomy. LID - 10.3390/biomedicines12071541 [doi] LID - 1541 AB - Radical cystectomy (RC) remains a mainstay surgical treatment for non-metastatic muscle-invasive and BCG-unresponsive bladder cancer. Various perioperative scoring tools assess comorbidity burden, complication risks, and cancer-specific mortality (CSM) risk. We investigated the prognostic value of these scores in patients who underwent RC between 2015 and 2021. Cox proportional hazards were used in survival analyses. Risk models' accuracy was assessed with the concordance index (C-index) and area under the curve. Among 215 included RC patients, 63 (29.3%) died, including 53 (24.7%) cancer-specific deaths, with a median follow-up of 39 months. The AJCC system, COBRA score, and Charlson comorbidity index (CCI) predicted CSM with low accuracy (C-index: 0.66, 0.65; 0.59, respectively). Multivariable Cox regression identified the AJCC system and CCI > 5 as significant CSM predictors. Additional factors included the extent of lymph node dissection, histology, smoking, presence of concomitant CIS, and neutrophil-to-lymphocyte ratio, and model accuracy was high (C-index: 0.80). The internal validation of the model with bootstrap samples revealed its slight optimism of 0.06. In conclusion, the accuracy of the AJCC staging system in the prediction of CSM is low and can be improved with the inclusion of other pathological data, CCI, smoking history and inflammatory indices. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Wolanski, Rafal AU - Wolanski R AUID- ORCID: 0009-0003-6590-0288 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Milow, Jerzy AU - Milow J AUID- ORCID: 0009-0008-7880-6801 AD - 2nd Clinic of Urology, Medical University of Lodz, 93-513 Lodz, Poland. FAU - Piekarczyk, Hanna AU - Piekarczyk H AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Lipinski, Piotr AU - Lipinski P AD - 2nd Clinic of Urology, Medical University of Lodz, 93-513 Lodz, Poland. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Niemczyk, Grzegorz AU - Niemczyk G AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Kurzyna, Pawel AU - Kurzyna P AUID- ORCID: 0000-0001-6651-888X AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Wrobel, Andrzej AU - Wrobel A AUID- ORCID: 0000-0002-5772-0573 AD - Second Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland. FAU - Rozanski, Waldemar AU - Rozanski W AD - 2nd Clinic of Urology, Medical University of Lodz, 93-513 Lodz, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AUID- ORCID: 0000-0001-7340-280X AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20240711 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11275140 OTO - NOTNLM OT - AJCC system OT - Charlson comorbidity index OT - bladder cancer OT - cancer-specific survival OT - comorbidities OT - radical cystectomy COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:45 MHDA- 2024/07/27 10:46 PMCR- 2024/07/11 CRDT- 2024/07/27 01:07 PHST- 2024/04/18 00:00 [received] PHST- 2024/07/09 00:00 [revised] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/07/27 10:46 [medline] PHST- 2024/07/27 10:45 [pubmed] PHST- 2024/07/27 01:07 [entrez] PHST- 2024/07/11 00:00 [pmc-release] AID - biomedicines12071541 [pii] AID - biomedicines-12-01541 [pii] AID - 10.3390/biomedicines12071541 [doi] PST - epublish SO - Biomedicines. 2024 Jul 11;12(7):1541. doi: 10.3390/biomedicines12071541. PMID- 39061999 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 7 DP - 2024 Jun 27 TI - The Role of Semaphorin 6D (Sema6D) in Non-Muscle-Invasive Bladder Cancer-A Preliminary Study on Human Plasma and Urine. LID - 10.3390/biomedicines12071426 [doi] LID - 1426 AB - The incidence of bladder cancer worldwide in the last three decades has been increasing in both men and women. So far, there is no established non-invasive bladder cancer biomarker in daily clinical practice. Semaphorin 6D (sema6D) is a transmembrane protein that belongs to the class VI semaphorins. The aim of this study was to evaluate for the first time the potential role of sema6D in bladder cancer. The study group consisted of 40 patients with non-muscle-invasive bladder cancer (NMIBC) and the control group of 20 patients without malignancies. There was a statistically significantly higher urinary sema6D concentration in patients than controls (p < 0.05) but no significant difference in plasma 6D. There were no statistically significant differences in urinary or plasma concentration of sema6D between low- or high-grade cancer and according to the tumor stage in TNM classification. There was a statistically significant negative correlation between plasma sema6D and age of patients (R = -0.6; p = 0.019). Plasma sema6D does not seem to be useful in the clinical practice at this point. However, the urinary sema6D concentration could potentially serve as a marker of NMIBC used for diagnostic purposes, monitoring, and early relapse detection or the assessment of the treatment efficacy. Urinary sema6D is probably not associated with the grading or staging of NMIBC, so it cannot be used for the prediction of disease prognosis. FAU - Purpurowicz, Piotr AU - Purpurowicz P AD - Department of Urology and Urological Oncology, Municipal Hospital in Olsztyn, 10-045 Olsztyn, Poland. FAU - Kaminski, Tomasz W AU - Kaminski TW AUID- ORCID: 0000-0002-8688-4171 AD - Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA. AD - Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI 53226, USA. FAU - Kordan, Wladyslaw AU - Kordan W AD - Department of Animal Biochemistry and Biotechnology, Faculty of Animal Bioengineering, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland. FAU - Korzekwa, Anna J AU - Korzekwa AJ AUID- ORCID: 0000-0002-1044-9288 AD - Research Group of Biodiversity Protection, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn, 10-748 Olsztyn, Poland. FAU - Purpurowicz, Zbigniew AU - Purpurowicz Z AD - Department of Urology and Urological Oncology, Municipal Hospital in Olsztyn, 10-045 Olsztyn, Poland. FAU - Jablonowski, Zbigniew AU - Jablonowski Z AD - 1st Department of Urology, Medical University of Lodz, 90-549 Lodz, Poland. LA - eng GR - 11.610.003-110/Faculty Research Fund of the University of Warmia and Mazury University in Olsztyn/ PT - Journal Article DEP - 20240627 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11274001 OTO - NOTNLM OT - bladder cancer OT - sema6D OT - semaphorin 6D OT - urology COIS- The authors declare no conflicts of interests. EDAT- 2024/07/27 10:45 MHDA- 2024/07/27 10:46 PMCR- 2024/06/27 CRDT- 2024/07/27 01:06 PHST- 2024/06/01 00:00 [received] PHST- 2024/06/20 00:00 [revised] PHST- 2024/06/24 00:00 [accepted] PHST- 2024/07/27 10:46 [medline] PHST- 2024/07/27 10:45 [pubmed] PHST- 2024/07/27 01:06 [entrez] PHST- 2024/06/27 00:00 [pmc-release] AID - biomedicines12071426 [pii] AID - biomedicines-12-01426 [pii] AID - 10.3390/biomedicines12071426 [doi] PST - epublish SO - Biomedicines. 2024 Jun 27;12(7):1426. doi: 10.3390/biomedicines12071426. PMID- 39060208 OWN - NLM STAT- MEDLINE DCOM- 20241118 LR - 20250605 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 12 DP - 2024 Dec TI - Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center. PG - 451.e1-451.e10 LID - S1078-1439(24)00538-6 [pii] LID - 10.1016/j.urolonc.2024.06.026 [doi] AB - BACKGROUND: Induction followed by 1 year maintenance instillation of intravesical Bacillus Calmette-Guerin (BCG) is the standard treatment for intermediate-risk (IR) nonmuscle invasive bladder cancer (NMIBC) patients. Few data exist on the efficacy of Mitomycin C (MMC) instillation in this setting. METHODS: We retrospectively analyzed 226 IR-NMIBC patients classified by the International Bladder Cancer Group (IBCG) and 250 IR-NMIBC intravescical treatment-naive patients classified by the European Association of Urology (EAU). All patients received either a full induction course of BCG or 40 mg/40 ml MMC from 2012 to 2022. Optimal treatment was defined as 1-year maintenance for BCG and 11 monthly maintenance instillations for MMC. Kaplan-Meier analysis estimated recurrence-free survival (RFS) before and after inverse probability of treatment-weighting (IPTW) and progression-free survival (PFS). Multivariable Cox regression was used to evaluate difference in recurrence after adjustment for clinically relevant variables before and after IPTW. RESULTS: Optimal BCG and MMC courses were administered to 21% of IR-IBCG and 23% of IR-EAU patients. At 4-years, patients treated with optimal MMC and BCG treatment had similar RFS and PFS in both EAU and IBCG groups. Patients receiving nonoptimal BCG compared to optimal MMC exhibited lower 4-year RFS after IPTW (82% vs. 68% in EAU and 82% vs. 65% in IBCG). At 4-year optimal MMC had greater PFS non optimal BCG. Optimal MMC treatment predicted recurrence in EAU (adjusted and weighted HR 0.33, 95% CI, 0.11-0.98) and IBCG (adjusted and weighted HR 0.29, 95% CI, 0.08-0.97) groups compared to nonoptimal BCG. CONCLUSIONS: Optimal 40 mg/40 ml MMC treatment was as effective as optimal BCG in IR-IBCG and IR-EAU NMIBC patients, reducing both recurrence and progression compared to nonoptimal BCG. MMC could be a valid first line alternative to BCG for both IR-EAU and IR-IBCG intravescical treatment-naive patients, during BCG shortages. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Re, Chiara AU - Re C AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Bertini, Alessandro AU - Bertini A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Cannoletta, Donato AU - Cannoletta D AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Burgio, Giusy AU - Burgio G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Luciano, Roberta AU - Luciano R AD - Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: moschini.marco@hsr.it. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240726 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Mitomycin/therapeutic use/administration & dosage MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Male MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/therapeutic use/administration & dosage MH - Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Treatment Outcome OTO - NOTNLM OT - BCG instillations OT - Bladder Cancer OT - Intermediate Risk OT - Mitomycin C instillation OT - Non Muscle-Invasive Bladder Cancer OT - Progression Free Survival OT - Recurrence Free Survival COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/07/27 10:42 MHDA- 2024/11/19 00:21 CRDT- 2024/07/26 21:55 PHST- 2024/03/12 00:00 [received] PHST- 2024/06/13 00:00 [revised] PHST- 2024/06/30 00:00 [accepted] PHST- 2024/11/19 00:21 [medline] PHST- 2024/07/27 10:42 [pubmed] PHST- 2024/07/26 21:55 [entrez] AID - S1078-1439(24)00538-6 [pii] AID - 10.1016/j.urolonc.2024.06.026 [doi] PST - ppublish SO - Urol Oncol. 2024 Dec;42(12):451.e1-451.e10. doi: 10.1016/j.urolonc.2024.06.026. Epub 2024 Jul 26. PMID- 39059766 OWN - NLM STAT- MEDLINE DCOM- 20240911 LR - 20240911 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 9 DP - 2024 Sep TI - Prospective evaluation of surgical margins in non-muscle invasive bladder cancer following primary transurethral resection. PG - 102705 LID - S2950-3930(24)00162-1 [pii] LID - 10.1016/j.fjurol.2024.102705 [doi] AB - PURPOSE: Non-muscle invasive bladder cancers (NMIBC) constitute approximately 75% of bladder cancer cases. Primary transurethral resection (TUR) plays a pivotal role in both diagnosis and treatment. However, despite initial resection, tumors are often missed, leaving behind microscopic residual tumors. This study aims to prospectively investigate the surgical margins of tumors, which may serve as a potential source of residual tumors. MATERIALS AND METHODS: Seventy patients diagnosed with NMIBC who underwent primary TUR were enrolled in this study. Following initial resection, samples were collected from the normal-appearing mucosa extending 1cm beyond the surgical margins. Lesions were categorized as 'healthy margins' for benign lesions, 'tumoral margins' for urothelial cancer, and 'dysplastic margins' for urothelial dysplasia. Clinical and pathological features of these groups were compared, and risk factors for detecting transitional cell carcinoma (TCC) in the normal-looking mucosa were analyzed. RESULTS: The tumoral margins group showed a significantly higher rate of T1 stage tumors compared to the healthy margins group, and a significantly higher rate of high-grade (HG) tumors compared to the dysplastic margins group. Moreover, the tumoral margins group had a significantly higher proportion of high-risk patients (85.7%) compared to the other groups, while the healthy margins group had a significantly higher proportion of low-risk patients (35.3%) compared to the tumoral margins group (0.0%). Additionally, the tumoral margins group demonstrated a significantly higher rate of carcinoma in situ (CIS) compared to the healthy margins group (35.7% vs. 5.9%). Detection of urothelial cancer at the margins was associated with T1 stage, HG stage, and the presence of CIS based on univariate analyses. CONCLUSION: To minimize residual tumors and prevent recurrence in patients undergoing primary TUR, we advocate for the resection of macroscopically visible tumors with nearly 2cm of intact bladder tissue, thereby enhancing the quality of TUR. LEVEL OF EVIDENCE: This study provides Level II evidence, based on its design as a prospective observational study. The findings are derived from well-designed cohort analyses, providing significant associations and insights into the factors affecting surgical margins in NMIBC patients. CI - Copyright (c) 2024 Elsevier Masson SAS. All rights reserved. FAU - Ozsoy, Cagatay AU - Ozsoy C AD - Adnan Menderes University Medical Faculty, Department of Urology, Aydin, Turkey. Electronic address: cagatayozsoy89@gmail.com. FAU - Demir, Yigit AU - Demir Y AD - Antalya Training and Research Hospital, Department of Urology, Antalya, Turkey. FAU - Yilmaz, Kayhan AU - Yilmaz K AD - Antalya Training and Research Hospital, Department of Urology, Antalya, Turkey. FAU - Olcucu, Mahmut Taha AU - Olcucu MT AD - Antalya Training and Research Hospital, Department of Urology, Antalya, Turkey. FAU - Kilic, Sahin AU - Kilic S AD - Antalya Training and Research Hospital, Department of Urology, Antalya, Turkey. FAU - Ates, Mutlu AU - Ates M AD - Antalya Training and Research Hospital, Department of Urology, Antalya, Turkey. LA - eng PT - Journal Article DEP - 20240724 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Margins of Excision MH - Male MH - Female MH - Prospective Studies MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - *Neoplasm, Residual/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Cystectomy/methods MH - Aged, 80 and over MH - Neoplasm Staging MH - Urethra/pathology/surgery MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder OT - Cancer OT - Margin OT - Surgical EDAT- 2024/07/27 10:42 MHDA- 2024/09/12 00:42 CRDT- 2024/07/26 19:24 PHST- 2024/03/10 00:00 [received] PHST- 2024/07/17 00:00 [revised] PHST- 2024/07/18 00:00 [accepted] PHST- 2024/09/12 00:42 [medline] PHST- 2024/07/27 10:42 [pubmed] PHST- 2024/07/26 19:24 [entrez] AID - S2950-3930(24)00162-1 [pii] AID - 10.1016/j.fjurol.2024.102705 [doi] PST - ppublish SO - Fr J Urol. 2024 Sep;34(9):102705. doi: 10.1016/j.fjurol.2024.102705. Epub 2024 Jul 24. PMID- 39059758 OWN - NLM STAT- MEDLINE DCOM- 20241019 LR - 20241019 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 49 DP - 2024 Oct TI - Identification of risk factors associated with oral 5-aminolevulinic acid induced adverse events in photodynamic diagnosis-transurethral resection of bladder tumor. PG - 104291 LID - S1572-1000(24)00328-4 [pii] LID - 10.1016/j.pdpdt.2024.104291 [doi] AB - BACKGROUND: Oral 5-aminolevulinic acid for transurethral resection of bladder tumor reduces bladder cancer recurrence compared with standard white-light transurethral resection of bladder tumor. However, data regarding risks of adverse events with this drug are unclear. The aim of the present study was to identify risk factors associated with oral 5-aminolevulinic acid induced adverse events in photodynamic diagnosis-transurethral resection of bladder tumor. METHODS: We studied 104 cases of 5-aminolevulinic acid-photodynamic diagnosis-transurethral resection of bladder tumor from October 2021 to April 2023, administering 20 mg/kg 5-aminolevulinic acid orally at least 2 h pre-surgery. Four major adverse events associated with 5-aminolevulinic acid were selected to identify risk factors for their occurrence, including perioperative hypotension, nausea and/or vomiting, photosensitivity, and liver dysfunction. Univariate and multivariate analyses were conducted to identify the risk factors of those adverse events. RESULTS: Perioperative hypotension (11.5 %), nausea and/or vomiting (37.5 %) photosensitivity (31.7 %), and liver dysfunction (51.9 %) were observed. Multivariate analyses revealed that spinal anesthesia was associated with hypotension (p = 0.02), whereas advanced age (p < 0.01) and higher body mass index (p < 0.01) were associated with nausea and/or vomiting. Also, male sex (p < 0.01) and longer operative time (p = 0.01) were associated with photosensitivity, and renin-angiotensin system inhibitors use was associated with postoperative liver dysfunction (p < 0.01). CONCLUSIONS: For elderly male obese patients taking renin-angiotensin system inhibitors, particular attention is needed during the perioperative period of photodynamic diagnosis-transurethral resection of bladder tumor under spinal anesthesia due to the higher risk of onset of the adverse events involved in oral administration of 5-aminolevulinic acid. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Okabe, Yu AU - Okabe Y AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Fukuhara, Yuichiro AU - Fukuhara Y AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Matsuoka, Wataru AU - Matsuoka W AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Nakamura, Nobuyuki AU - Nakamura N AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Matsuzaki, Hiroshi AU - Matsuzaki H AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Miyazaki, Takeshi AU - Miyazaki T AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Gunge, Naotaka AU - Gunge N AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Tominaga, Kosuke AU - Tominaga K AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Tsubouchi, Kazuna AU - Tsubouchi K AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Tachibana, Masahiro AU - Tachibana M AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Nakagawa, Chizuru AU - Nakagawa C AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Yamazaki, Fumihiro AU - Yamazaki F AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. FAU - Haga, Nobuhiro AU - Haga N AD - Department of Urology, Fukuoka University Faculty of Medicine, Fukuoka, Japan. Electronic address: nhaga@fukuoka-u.ac.jp. LA - eng PT - Journal Article DEP - 20240724 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) SB - IM MH - Humans MH - *Aminolevulinic Acid/adverse effects/administration & dosage MH - Male MH - *Photosensitizing Agents/therapeutic use/administration & dosage MH - Female MH - Risk Factors MH - *Urinary Bladder Neoplasms/surgery MH - Aged MH - Middle Aged MH - Administration, Oral MH - Hypotension/etiology/chemically induced MH - Photochemotherapy/methods/adverse effects MH - Aged, 80 and over MH - Retrospective Studies MH - Transurethral Resection of Bladder OTO - NOTNLM OT - 5-Aminolevulinic acid OT - Adverse events OT - Photodynamic diagnosis OT - Risk factors OT - Transurethral resection of bladder tumor EDAT- 2024/07/27 10:42 MHDA- 2024/10/20 04:18 CRDT- 2024/07/26 19:23 PHST- 2024/05/17 00:00 [received] PHST- 2024/07/04 00:00 [revised] PHST- 2024/07/22 00:00 [accepted] PHST- 2024/10/20 04:18 [medline] PHST- 2024/07/27 10:42 [pubmed] PHST- 2024/07/26 19:23 [entrez] AID - S1572-1000(24)00328-4 [pii] AID - 10.1016/j.pdpdt.2024.104291 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2024 Oct;49:104291. doi: 10.1016/j.pdpdt.2024.104291. Epub 2024 Jul 24. PMID- 39044944 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240725 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 66 DP - 2024 Aug TI - Fibroblast Activation Protein-alpha and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression. PG - 67-74 LID - 10.1016/j.euros.2024.06.011 [doi] AB - BACKGROUND AND OBJECTIVE: The tumor microenvironment (TME) in non-muscle-invasive bladder cancer (NMIBC) plays an important role in the anticancer response. We aimed to identify the prognostic biomarkers in the TME of patients with NMIBC for progression to >/=T2. METHODS: From our institutional database, 40 patients with T1 high-risk NMIBC who progressed were pair matched for Club Urologico Espanol de Tratamiento Oncologico (CUETO) progression variables with 80 patients who never progressed despite longer follow-up. Progression was defined as >/=T2 or extravesical disease. Patients were treated at least with bacillus Calmette-Guerin (BCG) induction (five or more of six doses). Immunohistochemical (IHC) markers for the TME were used on tissue at first T1 diagnosis: CD8-PanCK, GZMB-CD8-FOXP3, CD163, PD-L1 SP142/SP263, fibroblast activation protein-alpha (FAP), and CK5-GATA3. Full tissue slides were annotated digitally. Relative marker area (IHC-positive area/total area) or density (IHC-positive cells per area; n/mm(2)) was calculated, differentiating between regions of interest (ROIs; T1, Ta, and carcinoma in situ) and between compartments (stromal, epithelial, and combined). Differences in IHC variables were assessed using the t test, for continuous variables using analysis of variance and comparisons of more than two groups using Tukey's test. Conditional logistic regression for progression at 5-yr follow-up was performed with clusters based on pair matching. KEY FINDINGS AND LIMITATIONS: Only FAP expression (increase per 50%) in T1 (odds ratio [OR]: 1.33; 95% confidence interval [CI]: 1.04-1.70) and all ROIs combined (OR: 1.62; 95% CI: 1.14-2.29) correlated significantly with progression. None of the other clinicopathological/IHC variables correlated with progression. CONCLUSIONS AND CLINICAL IMPLICATIONS: FAP is a potential prognostic biomarker for progression in high-risk NMIBC. FAP is a marker for cancer-associated fibroblasts and is linked to immunosuppression and neoangiogenesis, which makes future investigation clinically relevant. PATIENT SUMMARY: We found that progression of high-risk non-muscle-invasive bladder cancer to muscle-invasive disease is less in patients with lower fibroblast activation protein-alpha (FAP) expression, which is a marker for cancer-associated fibroblasts. CI - (c) 2024 The Authors. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Baekelandt, Loic AU - Baekelandt L AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Daelemans, Sofie AU - Daelemans S AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. AD - Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium. FAU - Marien, Koen AU - Marien K AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Waumans, Yannick AU - Waumans Y AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - van Dam, Pieter-Jan AU - van Dam PJ AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Kockx, Mark AU - Kockx M AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Van den Broeck, Thomas AU - Van den Broeck T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van Cleynenbreugel, Ben AU - Van Cleynenbreugel B AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Gevaert, Thomas AU - Gevaert T AD - Organ Systems, KU Leuven, Leuven, Belgium. AD - Department of Pathology, AZ Klina, Brasschaat, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. LA - eng PT - Journal Article DEP - 20240701 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC11263494 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Biomarker OT - Carcinoma in situ OT - Fibroblast activation protein-alpha OT - Non-muscle-invasive bladder cancer OT - Prognosis OT - Progression OT - Progression-free survival EDAT- 2024/07/24 06:42 MHDA- 2024/07/24 06:43 PMCR- 2024/07/01 CRDT- 2024/07/24 04:16 PHST- 2024/06/19 00:00 [accepted] PHST- 2024/07/24 06:43 [medline] PHST- 2024/07/24 06:42 [pubmed] PHST- 2024/07/24 04:16 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - S2666-1683(24)00488-9 [pii] AID - 10.1016/j.euros.2024.06.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2024 Jul 1;66:67-74. doi: 10.1016/j.euros.2024.06.011. eCollection 2024 Aug. PMID- 39040623 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250831 IS - 2699-9404 (Electronic) IS - 2699-9404 (Linking) VI - 11 IP - 3 DP - 2024 Sep TI - ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate. PG - 233-240 LID - 10.1055/s-0044-1788614 [doi] AB - Background Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. Aim To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. Materials and Methods In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. Results No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 ( p < 0.001), A1 ( p < 0.001), and B ( p = 0.013), and a lower proportion of metastatic disease in A2 (0%, p = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, p < 0.001), A1 (70.1%, p = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, p < 0.001), O2 (100%, p = 0.045), and recurrent tumors in patients with O1 (70.2%, p < 0.001) and A1 (74.2%, p = 0.007) alleles. Conclusion We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ). FAU - Milas, Ivan AU - Milas I AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Kastelan, Zeljko AU - Kastelan Z AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. AD - Department of Medical Sciences, Croatian Academy of Sciences and Art, Zagreb, Croatia. FAU - Petrik, Joszef AU - Petrik J AD - Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia. FAU - Bingulac-Popovic, Jasna AU - Bingulac-Popovic J AD - Medical Department, Croatian Institute of Transfusion Medicine, Zagreb, Croatia. FAU - Cikic, Bojan AU - Cikic B AD - Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Sribar, Andrej AU - Sribar A AD - Clinical Department of Anesthesiology and Intensive Care Medicine, Dubrava University Hospital , Zagreb, Croatia. FAU - Jukic, Irena AU - Jukic I AD - Medical Department, Croatian Institute of Transfusion Medicine, Zagreb, Croatia. AD - Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Coratia. LA - eng PT - Journal Article DEP - 20240722 PL - Netherlands TA - Glob Med Genet JT - Global medical genetics JID - 101769583 PMC - PMC11262885 OTO - NOTNLM OT - ABO allele OT - ABO blood groups OT - ABO genotype OT - ABO phenotype OT - case-control study OT - urinary bladder cancer COIS- Conflict of Interest None declared. EDAT- 2024/07/23 06:42 MHDA- 2024/07/23 06:43 PMCR- 2024/07/01 CRDT- 2024/07/23 04:21 PHST- 2024/07/23 06:43 [medline] PHST- 2024/07/23 06:42 [pubmed] PHST- 2024/07/23 04:21 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - S2699-9404(24)00038-9 [pii] AID - GMG-D-24-00047 [pii] AID - 10.1055/s-0044-1788614 [doi] PST - epublish SO - Glob Med Genet. 2024 Jul 22;11(3):233-240. doi: 10.1055/s-0044-1788614. eCollection 2024 Sep. PMID- 39038654 OWN - NLM STAT- MEDLINE DCOM- 20241123 LR - 20241123 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 13 DP - 2024 Dec TI - Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC. PG - 102699 LID - S2950-3930(24)00156-6 [pii] LID - 10.1016/j.fjurol.2024.102699 [doi] AB - INTRODUCTION: Intermediate-risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC) is associated with a high rate of tumor recurrence. To improve patient outcomes, it is recommended to use adjuvant intravesical therapy, by mitomycin C (MMC) or Bacillus Calmette Guerin (BCG). Gemcitabine (GMC) is a known molecule used in urothelial cancer. We aimed to study the efficacy and safety profile of a gemcitabine solution, compared to mitomycin C, in the treatment of IR NMIBC. MATERIAL: In this retrospective study, patients with IR NMIBC treated between 2016 and 2020 were selected from two participating centers using either gemcitabine (center A) as the intravesical chemotherapy regimen or mitomycin C (center B). The primary endpoint was recurrence rate and secondary end points were treatment interruption and its causes. RESULTS: In our cohort of 102 IR NMIBC patients, 49 patients received GMC and 53 MMC with a median follow-up of 30 months. Overall recurrence rate was 42.1% with 22.4% in the GMC group and 60.3% in the MMC group (P<0.01). This difference was also found in the multifactorial analysis. Course interruption was observed in 14.7% of all patients, primarily attributed to adverse events (46.6%), without difference between groups. CONCLUSION: Adjuvant intravesical gemcitabine in patients with IR NMIBC seems to be an interesting option associated with a lower tumor recurrence rate and a favorable tolerance profile when compared to MMC. Larger scale prospective randomized trials are needed to validate our findings. LEVEL OF EVIDENCE: III. CI - Copyright (c) 2024 Elsevier Masson SAS. All rights reserved. FAU - Abou Chaaya, Carla AU - Abou Chaaya C AD - Service d'urologie et chirurgie de la transplantation, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France; Service d'urologie, hospices civils de Lyon, hopital Lyon Sud, Lyon, France; Universite Claude-Bernard-Lyon 1, Lyon, France. Electronic address: carla.abou-chaaya@chu-lyon.fr. FAU - Ourfali, Said AU - Ourfali S AD - Service d'urologie, hospices civils de Lyon, hopital Lyon Sud, Lyon, France. FAU - Marchand, Chloe AU - Marchand C AD - Plateforme FRIPHARM(R), service de pharmacie, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France. FAU - Merienne, Camille AU - Merienne C AD - Plateforme FRIPHARM(R), service de pharmacie, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France. FAU - Ruffion, Alain AU - Ruffion A AD - Service d'urologie, hospices civils de Lyon, hopital Lyon Sud, Lyon, France; Universite Claude-Bernard-Lyon 1, Lyon, France. FAU - Brouzes, Hugo AU - Brouzes H AD - Service d'urologie et chirurgie de la transplantation, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France; Service d'urologie, hospices civils de Lyon, hopital Lyon Sud, Lyon, France; Universite Claude-Bernard-Lyon 1, Lyon, France. FAU - Abid, Nadia AU - Abid N AD - Service d'urologie et chirurgie de la transplantation, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France. FAU - Pirot, Fabrice AU - Pirot F AD - Plateforme FRIPHARM(R), service de pharmacie, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France; Universite Claude-Bernard-Lyon 1, Lyon, France. FAU - Colombel, Marc AU - Colombel M AD - Service d'urologie et chirurgie de la transplantation, hospices civils de Lyon, hopital Edouard-Herriot, Lyon, France; Universite Claude-Bernard-Lyon 1, Lyon, France. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20240720 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 50SG953SK6 (Mitomycin) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use/adverse effects MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Mitomycin/therapeutic use/adverse effects/administration & dosage MH - Administration, Intravesical MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Antimetabolites, Antineoplastic/administration & dosage/adverse effects/therapeutic use MH - Treatment Outcome MH - Antibiotics, Antineoplastic/therapeutic use/adverse effects/administration & dosage MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/drug therapy MH - Risk Assessment MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Arret de traitement OT - Gemcitabine OT - Intermediate risk NMIBC OT - Mitomycin OT - Mitomycine OT - Recurrence OT - Recidive OT - Treatment interruption OT - Tumeur de vessie de risque intermediaire EDAT- 2024/07/23 00:42 MHDA- 2024/11/24 00:44 CRDT- 2024/07/22 19:23 PHST- 2024/03/22 00:00 [received] PHST- 2024/07/07 00:00 [revised] PHST- 2024/07/17 00:00 [accepted] PHST- 2024/11/24 00:44 [medline] PHST- 2024/07/23 00:42 [pubmed] PHST- 2024/07/22 19:23 [entrez] AID - S2950-3930(24)00156-6 [pii] AID - 10.1016/j.fjurol.2024.102699 [doi] PST - ppublish SO - Fr J Urol. 2024 Dec;34(13):102699. doi: 10.1016/j.fjurol.2024.102699. Epub 2024 Jul 20. PMID- 39037600 OWN - NLM STAT- MEDLINE DCOM- 20240722 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Jul 22 TI - Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer. PG - 428 LID - 10.1007/s00345-024-05148-1 [doi] AB - The aim of this study was to investigate the prognostic role of blood-based nutritional biomarkers, including red blood cell (RBC count), hemoglobin (Hb), total protein (TP), albumin, the serum albumin to globulin ratio (AGR) and the prognostic nutritional index (PNI) in patients who underwent intravesical treatment for non-muscle invasive bladder cancer (NMIBC). A total of 501 NMIBC patients who received intravesical Bacillus Calmette-Guerin (BCG) treatment following transurethral resection of bladder tumor (TURBT) were included. The optimal cutoff values for these nutrition-based indicators were determined using receiver operating characteristic curve analysis. We observed a significantly higher recurrence-free survival (RFS) rate in patients with elevated levels of RBC count, Hb, TP, and albumin. Cox univariate and multivariate Cox regression analyses demonstrated that serum albumin (P = 0.002, HR = 0.51, 95%CI: 0.33-0.78), RBC count (P = 0.002, HR = 0.50, 95%CI: 0.32-0.77), TP (P = 0.028, HR = 0.62, 95%CI: 0.41-0.95), Hb (P = 0.004, HR = 0.53, 95%CI: 0.33-0.84), AGR (P = 0.003, HR = 0.46, 95%CI: 0.27-0.76) and PNI (P = 0.019, HR = 0.56, 95%CI: 0.35-0.91) were significant independent factors predicting RFS. These cost-effective and convenient blood-based nutritional biomarkers have the potential to serve as valuable prognostic indicators for predicting recurrence in NMIBC patients undergoing BCG-immunotherapy. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ye, Junjiang AU - Ye J AUID- ORCID: 0009-0000-3020-5996 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Tang, Cai AU - Tang C AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Wu, Ruicheng AU - Wu R AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Tang, Yin AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Yin, Hesheng AU - Yin H AD - West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. FAU - Bai, Yunjin AU - Bai Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. hanping@scu.edu.cn. LA - eng GR - 21PJ041/Health and Family Planning Commission of Sichuan Province/ PT - Journal Article DEP - 20240722 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Serum Albumin) RN - 0 (Hemoglobins) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/pathology/drug therapy/therapy/surgery MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - Aged MH - Prognosis MH - Middle Aged MH - Administration, Intravesical MH - *Adjuvants, Immunologic/therapeutic use/administration & dosage MH - *Nutrition Assessment MH - *Neoplasm Invasiveness MH - Retrospective Studies MH - Serum Albumin/analysis MH - Hemoglobins/analysis/metabolism MH - Biomarkers/blood MH - Preoperative Period MH - Erythrocyte Count MH - Nutritional Status MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Albumin OT - Hemoglobin OT - Malnutrition OT - Non-muscle-invasive bladder cancer OT - Red blood cell count OT - The prognostic nutritional index OT - The serum albumin to globulin ratio OT - Total protein EDAT- 2024/07/22 12:43 MHDA- 2024/07/22 12:44 CRDT- 2024/07/22 11:13 PHST- 2024/03/15 00:00 [received] PHST- 2024/06/23 00:00 [accepted] PHST- 2024/07/22 12:44 [medline] PHST- 2024/07/22 12:43 [pubmed] PHST- 2024/07/22 11:13 [entrez] AID - 10.1007/s00345-024-05148-1 [pii] AID - 10.1007/s00345-024-05148-1 [doi] PST - epublish SO - World J Urol. 2024 Jul 22;42(1):428. doi: 10.1007/s00345-024-05148-1. PMID- 39029806 OWN - NLM STAT- MEDLINE DCOM- 20241109 LR - 20250710 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 193 DP - 2024 Nov TI - Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time. PG - 166-172 LID - S0090-4295(24)00572-7 [pii] LID - 10.1016/j.urology.2024.07.017 [doi] AB - OBJECTIVE: To investigate the cadence of recurrence in patients with low grade intermediate-risk non-muscle invasive bladder cancer (LG IR-NMIBC) based on clinical determinants. We aim to describe patterns in rates of recurrence to better inform surveillance regimens for this chronic, burdensome, and costly disease. METHODS: Using baseline and follow-up data from participants in the West Midlands' (United Kingdom, UK) Bladder Cancer Prognosis Programme (BCPP), we assessed overall recurrence rate and recurrence-free intervals throughout the follow-up period for IR-NMIBC participants. Recurrence-free intervals were calculated using the Kaplan-Meier method. RESULTS: We identified 379 patients with G1/G2 pTa tumors classified as intermediate risk. Median age was 70 and 284/379 (75%) were male. The median follow-up time was 4.2 years (95% CI: 3.9-4.8). After 5 years of follow-up, 53% of patients had at least one recurrence. One-year recurrence-free survival (RFS) was 75% and 4-year RFS was 50%. The median time to or between 1st, 2nd, 3rd, 4th, and 5th sequential recurrences was 49, 19, 12, 14, and 10 months, respectively. CONCLUSION: Over half of patients with IR-NMIBC are destined to recur. Our data suggest that a subset of patients experience acceleration of recurrence over time and that this acceleration may serve as a potential kinetic biomarker for these individuals that could inform surveillance intervals and future treatment strategies. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Sankin, Alex AU - Sankin A AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address: asankin@montefiore.org. FAU - Dave, Priya AU - Dave P AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. FAU - Cherrill, Louise-Rae AU - Cherrill LR AD - Cancer Research United Kingdom Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, England, UK. FAU - Boucher, Rebecca H AU - Boucher RH AD - Cancer Research United Kingdom Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, England, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Maastricht University, Schools of NUTRIM and CAPHRI, Department of Epidemiology, Maastricht, the Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer Research, London, UK. FAU - Agalliu, Ilir AU - Agalliu I AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, England, UK. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240718 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2024 Nov;193:173. doi: 10.1016/j.urology.2024.07.058. PMID: 39127158 MH - Humans MH - Male MH - Aged MH - Female MH - *Urinary Bladder Neoplasms/pathology/mortality MH - *Neoplasm Recurrence, Local/epidemiology MH - *Carcinoma, Transitional Cell/pathology/mortality MH - Neoplasm Grading MH - Time Factors MH - Middle Aged MH - Follow-Up Studies MH - United Kingdom/epidemiology COIS- Declaration of Competing Interest Dr. Alexander Sankin is a paid consultant to Ambu Inc; Nicholas D. James has contributed to advisory boards for Merck USA and Pierre Fabre; Richard Bryan is a paid consultant to Cystotech ApS (Denmark), an unpaid charity trustee for Action Bladder Cancer UK, and has research funded by grants from Cancer Research UK and Janssen. The remaining authors declare that they have no conflict of interest. EDAT- 2024/07/20 10:44 MHDA- 2024/11/13 13:52 CRDT- 2024/07/19 19:33 PHST- 2024/01/31 00:00 [received] PHST- 2024/06/04 00:00 [revised] PHST- 2024/07/09 00:00 [accepted] PHST- 2024/11/13 13:52 [medline] PHST- 2024/07/20 10:44 [pubmed] PHST- 2024/07/19 19:33 [entrez] AID - S0090-4295(24)00572-7 [pii] AID - 10.1016/j.urology.2024.07.017 [doi] PST - ppublish SO - Urology. 2024 Nov;193:166-172. doi: 10.1016/j.urology.2024.07.017. Epub 2024 Jul 18. PMID- 39028359 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250428 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 486 IP - 4 DP - 2025 Apr TI - Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer. PG - 769-779 LID - 10.1007/s00428-024-03875-9 [doi] AB - Carcinoma in situ (CIS) of the bladder is a known parameter regarding the prognosis and recurrence tendency of urothelial carcinomas. Nevertheless, there is little evidence whether the amount of CIS or other precursor lesions, as well as the quantified tumor mass of muscle-invasive urothelial carcinoma, has an influence on the survival or recurrence rate of affected patients. From 80 patients with muscle invasive urothelial bladder cancer and radical cystectomy, 23 samples each were obtained as part of a whole organ mapping in a single institution study, in which the precursor lesions and tumor area were digitally measured and further correlated to pathological standard parameters, patient survival, molecular luminal and basal subtypes, and immune infiltration. Significant correlations were found between tumor mass and surface lining CIS amount for pT-stage, lymphovascular invasion, and perineural infiltration. Furthermore, an increased tumor mass as well as an increased amount of CIS combined with an increased tumor mass showed a significantly reduced survival rate in multivariable analysis (HR = 2.75; P = 0.019 vs. HR = 3.54; P = 0.002) as well as a significantly increased recurrence. No correlations could be found with molecular subtypes and immune infiltration. The exact measurement of the tumor mass with and without the CIS surface area, whether manually or, more specifically, digitally, could be incorporated into routine diagnostics and implemented as an independent predictor for patient post-surgical outcomes. It can therefore serve as an additional predictor for risk stratification and, if necessary, intensified follow-up care or therapy. CI - (c) 2024. The Author(s). FAU - Lange, Fabienne AU - Lange F AUID- ORCID: 0000-0003-2707-7676 AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. Fabienne.lange@uk-erlangen.de. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Fabienne.lange@uk-erlangen.de. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. Fabienne.lange@uk-erlangen.de. FAU - Geppert, Carol I AU - Geppert CI AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. FAU - Bahlinger, Veronika AU - Bahlinger V AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. AD - Institute of Pathology, University Hospital Tubingen, Tubingen, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, Krankenhausstrasse. 8-10, Erlangen, 91054, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Bavarian Cancer Research Center (Bayrisches Zentrum Fur Krebsforschung, BZKF), Erlangen, Germany. LA - eng PT - Journal Article DEP - 20240719 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma in Situ/pathology/mortality MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Prognosis MH - Cystectomy MH - Adult MH - Urothelium/pathology MH - Neoplasm Staging PMC - PMC12018511 OTO - NOTNLM OT - Muscle invasive bladder cancer OT - Prognosis OT - Radical cystectomy OT - Survival OT - Urothelial carcinoma OT - Urothelial carcinoma in situ COIS- Declarations. Conflict of interest: FL reports no conflict of interest. CG reports speaker's honoraria from Sysmex. VB reports speaker's honoraria from MSD and Biocartis and reports research funding from Gilead. SB reports no conflict of interest. RS reports no conflict of interest. DS reports no conflict of interest. HT reports speaker honoraria from Qiagen. SW reports no conflict of interest. BW reports speaker's honoraria from Astellas, Janssen-Cilag, and MSD. AH reports honoraria for lectures for Eisai, Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, and 3DHistotech; advisory role for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, and 3DHistotech; and research funding from AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche, STRATIFYER, and Owkin. ME reports speaker's honoraria from Eisai, Roche, Astellas, MSD, AstraZeneca, Janssen-Cilag, Cepheid, and Diaceutics; reports research funding from STRATIFYER, AstraZeneca, Janssen-Cilag, Gilead Sciences, Cepheid, and Owkin; reports advisory honoraria from AstraZeneca, Janssen-Cilag, GenomicHealth, Cepheid, and Diaceutics; and reports a part time employment as scientific advisor for Diaceutics. EDAT- 2024/07/19 12:42 MHDA- 2025/04/23 12:28 PMCR- 2024/07/19 CRDT- 2024/07/19 11:04 PHST- 2024/04/07 00:00 [received] PHST- 2024/07/09 00:00 [accepted] PHST- 2024/06/10 00:00 [revised] PHST- 2025/04/23 12:28 [medline] PHST- 2024/07/19 12:42 [pubmed] PHST- 2024/07/19 11:04 [entrez] PHST- 2024/07/19 00:00 [pmc-release] AID - 10.1007/s00428-024-03875-9 [pii] AID - 3875 [pii] AID - 10.1007/s00428-024-03875-9 [doi] PST - ppublish SO - Virchows Arch. 2025 Apr;486(4):769-779. doi: 10.1007/s00428-024-03875-9. Epub 2024 Jul 19. PMID- 39027774 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240720 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - Predicting the Lymphovascular Invasion in Carcinoma Bladder at Transurethral Resection. PG - e62595 LID - 10.7759/cureus.62595 [doi] LID - e62595 AB - INTRODUCTION: Bladder cancer is among the most common malignant neoplasms in the world. Transurethral resection of bladder tumor (TURBT) is considered the standard procedure for diagnosis, staging, and risk classification of bladder tumors. Lymphovascular invasion (LVI) is considered a poor prognostic factor. Its assessment of TURBT is very important for risk stratification and decision-making for further treatment. The purpose of our clinical study is to attempt to predict/assess the correlation between LVI and various preoperative (age, gender, history of smoking, hematuria, urine cytology, and hydronephrosis/hydroureteronephrosis), intraoperative (tumor number, size, and appearance - sessile/ pedunculated) and histopathological (tumor histology, grading, and muscle invasion) factors. METHODOLOGY: In this prospective study, 75 patients with bladder tumors underwent TURBT (standard monopolar TURBT with 1.5% glycine as irrigation solution) in the Department of Urology at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati between October 2021 and March 2023. Histopathological examination (HPE) reports were looked for the presence or absence of LVI. Accordingly, patients were divided into two groups, i.e., those with LVI and those without LVI. Various preoperative and intraoperative variables were analyzed for each subject in both groups. Statistically significant variables occurring in those patients with LVI compared to those without LVI were considered predictors of LVI in bladder tumors. Results: Sixteen patients out of 75 (21.33%) had LVI on their histopathology examination. The mean age was 68.19 years in the group with LVI and 64.14 years in the group without LVI. A total of 60 men (80%) and 15 women (20%) were included in our study. Thirteen men (21.7%) and three women (20%) were found to have LVI. We observed a significant association between the appearance of the tumor and LVI. Fifty-four subjects in our study had sessile tumors. Fifteen out of them (27.8%) had LVI, while only one out of 21 patients (4.8%) with pedunculated tumors had LVI (p-value=0.028). 30% of subjects who had high-grade tumors on HPE also had LVI. On the contrary, only one of 25 patients (4%) with low-grade tumors had LVI (p-value=0.010). Our study also showed a significant association between muscle invasion and LVI. Thirty-four (45.3%) and 41 (54.7%) patients had muscle-invasive and non-muscle-invasive tumors, respectively. While 12 (35.3%) patients with muscle-invasive tumors had LVI, only four (9.8%) patients with non-muscle-invasive tumors showed LVI (p-value=0.007). CONCLUSION: We observed that LVI of bladder tumors at first TURBT is significantly associated with tumor grade, tumor appearance, and depth of invasion of the tumor. Though statistically not significant, we further observed that LVI was more commonly found in smokers, patients with hematuria, and larger tumor sizes. We conclude that these factors can be used as reliable predictors of LVI of bladder tumors at their first TURBT. CI - Copyright (c) 2024, Nallabothula et al. FAU - Nallabothula, Anil Kumar AU - Nallabothula AK AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Mudunuri, Harsha Vardhana Varma AU - Mudunuri HVV AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Nalumaru, Anirudh Suseel AU - Nalumaru AS AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Kodamanchile, Viswanth AU - Kodamanchile V AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Varanasi, Sai Bhashya Vamsi Krishna AU - Varanasi SBVK AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Yadlapalli, Naveen Kumar AU - Yadlapalli NK AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. FAU - Earla, Dinesh AU - Earla D AD - Department of Urology, Sri Venkateswara Institute of Medical Sciences, Tirupati, IND. LA - eng PT - Journal Article DEP - 20240618 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11256733 OTO - NOTNLM OT - bladder cancer OT - hematuria OT - high-grade urothelial carcinoma OT - histopathology examination OT - lymphovascular invasion OT - turbt COIS- Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of Sri Venkateswara Institute of Medical Sciences issued approval 1218. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/19 06:42 MHDA- 2024/07/19 06:43 PMCR- 2024/06/18 CRDT- 2024/07/19 04:51 PHST- 2024/06/16 00:00 [accepted] PHST- 2024/07/19 06:43 [medline] PHST- 2024/07/19 06:42 [pubmed] PHST- 2024/07/19 04:51 [entrez] PHST- 2024/06/18 00:00 [pmc-release] AID - 10.7759/cureus.62595 [doi] PST - epublish SO - Cureus. 2024 Jun 18;16(6):e62595. doi: 10.7759/cureus.62595. eCollection 2024 Jun. PMID- 39022656 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 5 IP - 7 DP - 2024 Jul TI - Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review. PG - 651-661 LID - 10.1002/bco2.365 [doi] AB - INTRODUCTION: Bladder cancer (BCa) is characterised by high prevalence, multifocality, and frequent recurrence, imposing significant clinical and economic burdens. Accurate staging, particularly distinguishing non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC) disease, is crucial for guiding treatment decisions. This narrative review explores the potential implications of incorporating multiparametric magnetic resonance imaging (mpMRI) and the Vesical Imaging Reporting Data System (VI-RADS) into BCa staging, focusing on repeat transurethral resection of bladder tumour (re-TURBT). METHODS: A comprehensive search of PubMed, EMBASE, and MEDLINE databases identified studies published from 2018 to 2023 discussing mpMRI or VI-RADS in the context of re-TURBT for BCa staging. Studies meeting inclusion criteria underwent qualitative analysis. RESULTS: Six recent studies met inclusion criteria. VI-RADS scoring, accurately predicted muscle invasion, aiding in NMIBC/MIBC differentiation. VI-RADS scores of >/=3 indicated MIBC with high sensitivity and specificity. VI-RADS potentially identified patients benefiting from re-TURBT and those for whom it could be safely omitted. DISCUSSION: mpMRI and VI-RADS offer promising prospects for BCa staging, potentially correlating more closely with re-TURBT and radical cystectomy histopathology than initial TURBT. However, validation and careful evaluation of clinical integration are needed. Future research should refine patient selection and optimise mpMRI's role in BCa management. CONCLUSION: VI-RADS scoring could revolutionise BCa staging, especially regarding re-TURBT. There is potential that VI-RADS correlates more with the histopathology of re-TURBT and radical cystectomy than initial TURBT. While promising, ongoing research is essential to validate utility, refine selection criteria, and address economic considerations. Integration of VI-RADS into BCa staging holds potential benefits for patients and health care systems. CI - (c) 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Klempfner, Hugo AU - Klempfner H AUID- ORCID: 0009-0008-0782-2863 AD - Department of Medicine, Melbourne Health and Northern Health The University of Melbourne Victoria Melbourne Australia. FAU - Anderson, Paul AU - Anderson P AD - Department of Urology Royal Melbourne Hospital Melbourne Australia. LA - eng PT - Journal Article PT - Review DEP - 20240424 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 EIN - BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. PMID: 39744071 PMC - PMC11250143 OTO - NOTNLM OT - VI-RADS OT - bladder cancer OT - multiparametric MRI OT - narrative review OT - re-TURBT COIS- The authors declare no conflicts of interest. EDAT- 2024/07/18 06:42 MHDA- 2024/07/18 06:43 PMCR- 2024/04/24 CRDT- 2024/07/18 04:52 PHST- 2024/02/15 00:00 [received] PHST- 2024/03/25 00:00 [accepted] PHST- 2024/07/18 06:43 [medline] PHST- 2024/07/18 06:42 [pubmed] PHST- 2024/07/18 04:52 [entrez] PHST- 2024/04/24 00:00 [pmc-release] AID - BCO2365 [pii] AID - 10.1002/bco2.365 [doi] PST - epublish SO - BJUI Compass. 2024 Apr 24;5(7):651-661. doi: 10.1002/bco2.365. eCollection 2024 Jul. PMID- 39004700 OWN - NLM STAT- MEDLINE DCOM- 20240714 LR - 20240717 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 24 IP - 1 DP - 2024 Jul 14 TI - Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia. PG - 839 LID - 10.1186/s12885-024-12632-9 [doi] LID - 839 AB - BACKGROUND: A few studies regarding the epidemiology and risk factors of Non-muscle Invasive Bladder Cancer (NMIBC) are reported from Sub-Saharan African countries (SSA), including Somalia, and the African literature is scant on the management of NMIBC. The present study aims to evaluate the clinical-histopathological characteristics and factors associated with the survival rate of patients with NMIBC. METHOD: This six-year cohort study included 196 patients with NMIBC. It reviewed the clinical and histopathological characteristics and factors predicting cancer-specific survival for these patients. RESULTS: The mean patient age was 59.01 +/- 11.50 years, with a male-to-female ratio of 2.8:1. Urothelial carcinoma (UC) constituted the most common pathological type, accounting for 90.8%; Ta LG and T1HG were the most common histopathological tumour stage and grade (n = 90, 45.9%, vs. n = 56, 28.6%), respectively. The mean tumour size was 4.72 +/- 2.81 cm. The cancer-specific mortality(CSM) was 13.3%. Age [2.252(2.310-2.943], p < 0.001], Gender [1.031(0.981-1.1.242),p < 0.001], tumour stage and grade [4.902(3.607-5.614),p < 0.001], tumour location [1.135(0.806-1.172),p < 0.001], number [0.510(0.410-0.920),p = 0.03], tumour size [1.523(0.936-1.541),p < 0.001], use of intravesical chemotherapy or BCG [2.810(1.972-4.381),p < 0.001], preoperative hydronephrosis grade [1.517(1.172-2.154),p < 0.001], and follow-up compliance [3.376(2.633-5.018),p < 0.001] were all associated with CSM. The 5-year overall survival was 57.1%, and cardiovascular diseases were the leading cause of mortality (n = 34), followed by diabetes (n = 28). CONCLUSION: Our study findings revealed that UC constituted the most common pathological subtype, though less than forty per cent of our patients receive intravesical adjuvant therapies, which are crucial to minimizing disease morbidity and mortality. Initiatives improving uro-oncological care, including subspecialty training in oncology and essential cancer therapies, better access to urology services, and cancer screening programs, are much needed for optimal management plans and care in the country. CI - (c) 2024. The Author(s). FAU - Mohamed, Abdikarim Hussein AU - Mohamed AH AD - Mogadishu Somalia Turkish Training and Research Hospital, Mogadishu, Somalia. abdikarimgabeyre@gmail.com. AD - University of Somalia, Mogadishu, Somalia. abdikarimgabeyre@gmail.com. FAU - Mohamed, Khaled Ali AU - Mohamed KA AD - Mogadishu Somalia Turkish Training and Research Hospital, Mogadishu, Somalia. FAU - Kayacan, Ertan AU - Kayacan E AD - Mogadishu Somalia Turkish Training and Research Hospital, Mogadishu, Somalia. FAU - Nur, Yassin AU - Nur Y AD - University of Somalia, Mogadishu, Somalia. FAU - Nur-Amin, Mohamed Abdikarim AU - Nur-Amin MA AD - University of Somalia, Mogadishu, Somalia. LA - eng PT - Journal Article DEP - 20240714 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy MH - Male MH - Female MH - Middle Aged MH - *Tertiary Care Centers/statistics & numerical data MH - Aged MH - Somalia/epidemiology MH - Survival Rate MH - Risk Factors MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Neoplasm Staging MH - Prognosis MH - Adult MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11246571 OTO - NOTNLM OT - Intravesical chemotherapy OT - Mortality OT - Non-muscle invasive bladder cancer OT - Sub-saharan African countries COIS- The authors declare no competing interests. EDAT- 2024/07/15 00:41 MHDA- 2024/07/15 00:42 PMCR- 2024/07/14 CRDT- 2024/07/14 23:13 PHST- 2024/02/19 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/07/15 00:42 [medline] PHST- 2024/07/15 00:41 [pubmed] PHST- 2024/07/14 23:13 [entrez] PHST- 2024/07/14 00:00 [pmc-release] AID - 10.1186/s12885-024-12632-9 [pii] AID - 12632 [pii] AID - 10.1186/s12885-024-12632-9 [doi] PST - epublish SO - BMC Cancer. 2024 Jul 14;24(1):839. doi: 10.1186/s12885-024-12632-9. PMID- 39003377 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20240815 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 31 IP - 9 DP - 2024 Sep TI - Preoperative Prediction of Muscle Invasiveness in Bladder Cancer: The Role of 3D Volumetric Radiomics Using Diffusion-Weighted MRI, the VI-RADS Score, or a Combination of Both. PG - 5845-5850 LID - 10.1245/s10434-024-15760-5 [doi] AB - BACKGROUND: Bladder cancer treatment decisions hinge on detecting muscle invasion. The 2018 "Vesical Imaging Reporting and Data System" (VI-RADS) standardizes multiparametric MRI (mp-MRI) use. Radiomics, an analysis framework, provides more insightful information than conventional methods. PURPOSE: To determine how well MIBC (Muscle Invasive Bladder Cancer) and NMIBC (Non-Muscle Invasive Bladder Cancer) can be distinguished using mp-MRI radiomics features. METHODS: We conducted a study with 73 bladder cancer patients diagnosed pathologically, who underwent preoperative mp-MRI from January 2020 to July 2022. Utilizing 3D Slicer (version 4.8.1) and Pyradiomics, we manually extracted radiomic features from apparent diffusion coefficient (ADC) maps created from diffusion-weighted imaging. The LASSO approach identified optimal features, and we addressed sample imbalance using SMOTE. We developed a classification model using textural features alone or combined with VI-RADS, employing a random forest classifier with 10-fold cross-validation. Diagnostic performance was assessed using the area under the ROC curve analysis. RESULTS: Among 73 patients (63 men, 10 women; median age: 63 years), 41 had muscle-invasive and 32 had superficial bladder cancer. Muscle invasion was observed in 25 of 41 patients with VI-RADS 4 and 5 scores and 12 of 32 patients with VI-RADS 1, 2, and 3 scores (accuracy: 77.5%, sensitivity: 67.7%, specificity: 88.8%). The combined VI-RADS score and radiomics model (AUC = 0.92 +/- 0.12) outperformed the single radiomics model using ADC MRI (AUC = 0.83 +/- 0.22 with 10-fold cross-validation) in this dataset. CONCLUSION: Before undergoing surgery, bladder cancer invasion in muscle might potentially be predicted using a radiomics signature based on mp-MRI. CI - (c) 2024. Society of Surgical Oncology. FAU - Sam Ozdemir, Merve AU - Sam Ozdemir M AD - Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. mervesam@msn.com. FAU - Azamat, Sena AU - Azamat S AD - Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Ozdemir, Harun AU - Ozdemir H AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Keskin, Emin Taha AU - Keskin ET AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Savun, Metin AU - Savun M AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Simsek, Abdulmuttalip AU - Simsek A AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. FAU - Yardimci, Aytul Hande AU - Yardimci AH AD - Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20240713 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Diffusion Magnetic Resonance Imaging/methods MH - Follow-Up Studies MH - Imaging, Three-Dimensional/methods MH - Multiparametric Magnetic Resonance Imaging/methods MH - *Neoplasm Invasiveness MH - Preoperative Care MH - Prognosis MH - *Radiomics MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Multiparametric MRI OT - Muscle invasion OT - Radiomics OT - Vesical imaging reporting and data system EDAT- 2024/07/14 02:43 MHDA- 2024/08/08 06:42 CRDT- 2024/07/13 23:25 PHST- 2024/04/12 00:00 [received] PHST- 2024/06/24 00:00 [accepted] PHST- 2024/08/08 06:42 [medline] PHST- 2024/07/14 02:43 [pubmed] PHST- 2024/07/13 23:25 [entrez] AID - 10.1245/s10434-024-15760-5 [pii] AID - 10.1245/s10434-024-15760-5 [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Sep;31(9):5845-5850. doi: 10.1245/s10434-024-15760-5. Epub 2024 Jul 13. PMID- 39001362 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240715 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 13 DP - 2024 Jun 22 TI - Photodynamic Diagnosis and Therapy in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers16132299 [doi] LID - 2299 AB - Bladder cancer (BC) possesses distinct molecular profiles that influence progression depending on its biological nature and delivered treatment intensity. Muscle-invasive BC (MIBC) and non-MIBC (NMIBC) demonstrate great intrinsic heterogeneity regarding different prognoses, survival, progression, and treatment outcomes. Transurethral resection of bladder tumor (TURBT) is the standard of care in treating NMIBC and serves both diagnostic and therapeutic purposes despite the prevalent recurrence and progression among many patients. In particular, flat urothelial carcinoma in situ and urothelial carcinoma with lamina propria invasion are the major precursors of MIBC. A new-generation photosensitizer, 5-Aminolevulinic acid (5-ALA), demonstrates high tumor specificity by illuminating the tumor lesion with a specific wavelength of light to produce fluorescence and has been studied for photodynamic diagnosis to detect precise tumor areas by TURBT. Additionally, it has been applied for treatment by producing its cytotoxic reactive oxygen species, as well as screening for urological carcinomas by excreting porphyrin in the blood and urine. Moreover, 5-ALA may contribute to screening before and after TURBT in NMIBC. Here, we summarize the updated evidence and ongoing research on photodynamic technology for NMIBC, providing insight into the potential for improving patient outcomes. FAU - Kurabayashi, Atsushi AU - Kurabayashi A AUID- ORCID: 0000-0001-7202-9820 AD - Department of Pathology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. FAU - Fukuhara, Hideo AU - Fukuhara H AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. FAU - Furihata, Kaoru AU - Furihata K AD - Department of Pathology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. FAU - Iwashita, Waka AU - Iwashita W AD - Department of Pathology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. FAU - Furihata, Mutsuo AU - Furihata M AD - Department of Pathology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nankoku 783-8505, Kochi, Japan. LA - eng PT - Journal Article PT - Review DEP - 20240622 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11240600 OTO - NOTNLM OT - 5-Aminolevulinic acid OT - non-muscle-invasive bladder cancer OT - photodynamic diagnosis OT - photodynamic therapy OT - transurethral resection of bladder tumor COIS- The authors declare no conflicts of interest. EDAT- 2024/07/13 07:43 MHDA- 2024/07/13 07:44 PMCR- 2024/06/22 CRDT- 2024/07/13 01:21 PHST- 2024/04/19 00:00 [received] PHST- 2024/06/17 00:00 [revised] PHST- 2024/06/19 00:00 [accepted] PHST- 2024/07/13 07:44 [medline] PHST- 2024/07/13 07:43 [pubmed] PHST- 2024/07/13 01:21 [entrez] PHST- 2024/06/22 00:00 [pmc-release] AID - cancers16132299 [pii] AID - cancers-16-02299 [pii] AID - 10.3390/cancers16132299 [doi] PST - epublish SO - Cancers (Basel). 2024 Jun 22;16(13):2299. doi: 10.3390/cancers16132299. PMID- 38994240 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 9 IP - 4 DP - 2023 TI - Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. PG - 327-334 LID - 10.3233/BLC-230047 [doi] AB - BACKGROUND: Adjuvant bacillus Calmette-Guerin (BCG) is recommended for high-risk (HR) non-muscle invasive bladder cancer (NMIBC), but BCG shortages have led to exploration of reduced-dose regimens and shortened maintenance durations out of necessity, with limited data on treatment efficacy in Latin America. OBJECTIVE: Oncological outcomes of HR-NMIBC patients treated with reduced (RD,1/4th dose) vs full dose (FD) BCG instillations of Danish Strain 1331 BCG. METHODS: We performed a retrospective study of HR-NMIBC patients treated with BCG between 2003 and 2022 at our center in Santiago Chile. We stratified patients according to either RD (1/4th dose) or FD BCG. Univariate and multivariable Cox regression models were used to predict recurrence. Kaplan-Meier method was used to calculate survival estimates. RESULTS: Of a total of 200 patients, 116 (58%) had RD and 84 (42%) FD BCG. Median follow-up was 57 months (IQR: 29-100). Patients who received FD BCG had a lower risk of recurrence (HR: 0.41, 95% CI 0.22-0.74) and high-grade (HG)-recurrence (HR: 0.30, 95% CI 0.15-0.61; p = 0.001). More patients in the RD vs FD group progressed to MIBC (10/84 vs 2/116; p = 0.18). Additionally, patients were less likely to stop BCG treatment in the RD group compared to the FD group due to toxicity (5% vs 11%, p = 0.14). CONCLUSIONS: A 1/4th dose of Danish Strain 1331 BCG treatment was associated with worse recurrence free rate and HG-recurrence rate in our cohort. Patients with RD had lower discontinuation treatment rates due to a reduced toxicity profile. These findings would suggest that RD BCG would compromise oncological outcomes in HR-NMIBC patients. CI - (c) 2023 - The authors. Published by IOS Press. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Flores, Marta AU - Flores M AD - Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Schultz, Marcela AU - Schultz M AD - Department of Pathology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Pinochet, Rodrigo AU - Pinochet R AD - Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Bustamante, Alberto AU - Bustamante A AD - Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Fernandez, Mario I AU - Fernandez MI AD - Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. LA - eng PT - Journal Article DEP - 20231213 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11165921 OTO - NOTNLM OT - BCG. non-muscle-invasive bladder cancer OT - Bacillus Calmette-Guerin OT - reduced dose COIS- Valentina Grajales has no conflict of interest to report. Roberto Contieri has no conflict of interest to report. Wei Shen Tan was a consultant to Combat Medical. Marta Flores has no conflict of interest to report. Marcela Schultz has no conflict of interest to report. Rodrigo Pinochet has no conflict of interest to report. Alberto Bustamante has no conflict of interest to report. Ashish M. Kamat is an Editorial Board Member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. Ashish M. Kamat is a consultant or advisory board member for Abbott Molecular, Arquer Diagnostics, ArTara Therapeutics, Asieris Pharmaceuticals, AstraZeneca, BioClin Therapeutics, Bristol Myers Squibb, Cepheid, Cold Genesys, Eisai, Engene, Ferring Pharmaceuticals, FerGene, Imagine Pharma, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara Therapeutics, Roviant Sciences, Seattle Genetics, Sessen Bio, Theralase Technologies, TMC Innovation, and US Biotest; has received grants and/or research support from Adolor Corporation, Bristol Myers Squibb, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH, Specialized Programs of Research Excellence (SPORE), and AIBCCR; and holds the patent for Cytokine Predictors of Response to Intravesical Therapy (CyPRIT) jointly with UT MD Anderson Cancer Center. Mario I. Fernandez is an Editorial Board Member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. Mario I. Fernandez is a consultant or advisory board member for Grunenthal. EDAT- 2024/07/12 06:42 MHDA- 2024/07/12 06:43 PMCR- 2023/12/13 CRDT- 2024/07/12 04:48 PHST- 2023/07/09 00:00 [received] PHST- 2023/10/20 00:00 [accepted] PHST- 2024/07/12 06:43 [medline] PHST- 2024/07/12 06:42 [pubmed] PHST- 2024/07/12 04:48 [entrez] PHST- 2023/12/13 00:00 [pmc-release] AID - BLC230047 [pii] AID - 10.3233/BLC-230047 [doi] PST - epublish SO - Bladder Cancer. 2023 Dec 13;9(4):327-334. doi: 10.3233/BLC-230047. eCollection 2023. PMID- 38993532 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 10 IP - 1 DP - 2024 TI - Effect of Bacille Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer After Prostate Radiotherapy. PG - 35-45 LID - 10.3233/BLC-230073 [doi] AB - BACKGROUND: Little is known about the impact of prior prostate radiation therapy (RT) on the Bacille Calmette-Guerin (BCG) immunotherapy response in patients with non-muscle invasive bladder cancer (NMIBC). OBJECTIVE: We hypothesized that the damaging radiation effects on the bladder could negatively influence BCG efficacy. METHODS: Men with a history of high-risk NMIBC were identified within the Surveillance, Epidemiology, and End Results-Medicare database. All patients completed adequate BCG defined as at least 5 plus 2 treatments completed within 12 months. Patients were stratified into 2 groups: with prior RT for prostate cancer and without prior RT before the diagnosis of NMIBC. The primary endpoint was a 5-year composite for progression defined as disease progression requiring systemic chemotherapy, checkpoint inhibitors, radical or partial cystectomy, or cancer-specific death. RESULTS: We identified 3,466 patients with NMIBC, including 145 with prior RT for prostate cancer. Five-year progression occurred in 471 patients (13.6%). Patients with prior RT were older than patients without prior RT (77.0 vs 75.0 years; P < .001). The distribution of T stage was significantly different at diagnosis between the RT and non-RT groups (RT: Ta, 44.8%; Tis, 18.6%; T1, 36.6%; without RT: Ta, 40.9%; Tis, 10.8%; T1, 48.3%; P = .002). No difference in the risk of total progression was observed between patients with and without prior RT (P = .67). Similarly, no difference was observed after multivariable adjustment (hazard ratio, 0.99; 95% CI, 0.61-1.58; P = .95). CONCLUSION: For patients with NMIBC who undergo adequate BCG treatment, prior RT for prostate cancer was not associated with worse 5-year progression-free survival. CI - (c) 2024 - The authors. Published by IOS Press. FAU - Durant, Adri M AU - Durant AM AD - Department of Urology, Mayo Clinic, Phoenix, AZ, USA. FAU - Lee, Yeonsoo S AU - Lee YS AD - Mayo Clinic Alix School of Medicine - Florida campus, Mayo Clinic College of Medicine and Science, Jacksonville, FL, USA. FAU - Mi, Lanyu AU - Mi L AD - Division of Clinical Trials and Biostatistics, Mayo Clinic, Scottsdale, AZ, USA. FAU - Faraj, Kassem AU - Faraj K AD - Department of Urology, University of Michigan, Ann Arbor, MI, USA. FAU - Lyon, Timothy D AU - Lyon TD AD - Department of Urology, Mayo Clinic, Jacksonville, FL, USA. FAU - Singh, Parminder AU - Singh P AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA. FAU - Tyson Ii, Mark D AU - Tyson Ii MD AD - Department of Urology, Mayo Clinic, Phoenix, AZ, USA. LA - eng PT - Journal Article DEP - 20240312 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181702 OTO - NOTNLM OT - Bacille Calmette-Guerin OT - bladder cancer OT - outcomes OT - prostate cancer OT - radiation therapy COIS- Adri M. Durant, Yeonsoo S. Lee, Lanyu Mi, Kassem Faraj, Timothy D. Lyon, Parminder Singh and Mark D. Tyson II have no known conflicts of interest. EDAT- 2024/07/12 06:41 MHDA- 2024/07/12 06:42 PMCR- 2024/03/12 CRDT- 2024/07/12 04:39 PHST- 2023/09/12 00:00 [received] PHST- 2023/12/20 00:00 [accepted] PHST- 2024/07/12 06:42 [medline] PHST- 2024/07/12 06:41 [pubmed] PHST- 2024/07/12 04:39 [entrez] PHST- 2024/03/12 00:00 [pmc-release] AID - BLC230073 [pii] AID - 10.3233/BLC-230073 [doi] PST - epublish SO - Bladder Cancer. 2024 Mar 12;10(1):35-45. doi: 10.3233/BLC-230073. eCollection 2024. PMID- 38993297 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 9 IP - 2 DP - 2023 TI - Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy. PG - 175-186 LID - 10.3233/BLC-230028 [doi] AB - BACKGROUND: The mode of action of Bacillus Calmette-Guerin (BCG) in the treatment of patients with non-muscle invasive bladder cancer (NMIBC) is incompletely understood, but recent studies support an association between BCG-induced trained immunity in circulating monocytes and disease-free survival. OBJECTIVE: We compared epigenetic profiles in monocytes from NMIBC patients with early disease recurrence with those from recurrence-free patients. METHODS: We conducted chromatin immunoprecipitation and DNA sequencing (ChIP-seq) on monocytes from seven patients treated with BCG (four with early recurrences and three recurrence-free after one year) to determine genome-wide distribution and abundance of histone 3 lysine 4 trimethylation (H3K4me3) prior to and after five weeks of induction therapy. RESULTS: Genome-wide H3K4me3 profiles before or after BCG induction distinguished patients with early recurrences from those remaining recurrence-free. Furthermore, H3K4me3 levels at genes involved in specific pathways were increased in the recurrence-free group. Independent quantification showed increased H3K4me3 levels in elements of the Wnt and AMPK signaling pathways in the recurrence-free group before BCG initiation, while elements of the MAPK showed increased levels after five weeks of induction in the same group. Validation of these genes on an independent cohort of four additional patients that remained recurrence-free after one year and three with early recurrences revealed consistent increases in H3K4me3 levels associated with MAPK pathway genes after five weeks of BCG treatment in the recurrence-free group. CONCLUSIONS: Recurrence-free survival following BCG immunotherapy for NMIBC is associated with the accumulation of H3K4me3 at specific gene loci, and could lead to identification of prognostic biomarkers. CI - (c) 2023 - The authors. Published by IOS Press. FAU - Pare, Jean-Franccois AU - Pare JF AUID- ORCID: 0000-0001-5621-9472 AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Tabasinezhad, Maryam AU - Tabasinezhad M AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Grossman, Arielle AU - Grossman A AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Atallah, Aline AU - Atallah A AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Hindmarch, Charles C T AU - Hindmarch CCT AUID- ORCID: 0000-0002-6036-1292 AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Medicine, Queen's University, Kingston, ON, Canada. FAU - Tyryshkin, Kathrin AU - Tyryshkin K AUID- ORCID: 0000-0002-7726-6654 AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. AD - School of Computing, Queen's University, Kingston, ON, Canada. FAU - Siemens, D Robert AU - Siemens DR AUID- ORCID: 0000-0002-3203-6468 AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Urology, Queen's University, Kingston, ON, Canada. FAU - Graham, Charles H AU - Graham CH AUID- ORCID: 0000-0002-7014-8639 AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Urology, Queen's University, Kingston, ON, Canada. LA - eng PT - Journal Article DEP - 20230627 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181793 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - epigenetics OT - histone methylation OT - immunotherapy OT - recurrence COIS- JFP, MT, AG, AA, CCTH, KT, DRS and CG have no conflict of interest to report. EDAT- 2024/07/12 06:42 MHDA- 2024/07/12 06:43 PMCR- 2023/06/27 CRDT- 2024/07/12 04:36 PHST- 2023/03/30 00:00 [received] PHST- 2023/06/14 00:00 [accepted] PHST- 2024/07/12 06:43 [medline] PHST- 2024/07/12 06:42 [pubmed] PHST- 2024/07/12 04:36 [entrez] PHST- 2023/06/27 00:00 [pmc-release] AID - BLC230028 [pii] AID - 10.3233/BLC-230028 [doi] PST - epublish SO - Bladder Cancer. 2023 Jun 27;9(2):175-186. doi: 10.3233/BLC-230028. eCollection 2023. PMID- 38983467 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 13 IP - 6 DP - 2024 Jun 30 TI - The current role of pentafecta in the reporting of radical cystectomy outcomes: a scoping review. PG - 1037-1048 LID - 10.21037/tau-23-593 [doi] AB - BACKGROUND: Pentafecta has recently been validated for reporting radical cystectomy (RC) outcomes in open, laparoscopic and robotic series. We aim in this review to explore the current role of pentafecta in the reporting of RC outcomes. METHODS: A comprehensive literature search was performed in the PubMed database to identify relevant articles. The pentafecta achievement (PA) was defined originally as negative soft tissue surgical margin (NSTSM), lymph node (LN) dissection (LND) with removal of >/=16 LNs, absence of 90-days grade >/=3 Clavien-Dindo (CD) complications, a time interval of less than 3 months between the last transurethral resection of bladder tumor (TURBT) with evidence of muscle invasive bladder cancer (MIBC) and RC, and absence of local pelvic recurrence within 1 year. The definition was later modified and the last two criteria were replaced by absence of urinary diversion (UD) related complications and any clinical recurrence at one year. RESULTS: Twelve studies with 4,946 patients were enrolled in the present review. All the studies were retrospective except one recently published randomized study comparing open and robotic-assisted RC. Pentafecta was totally achieved in 34% and main causes of missing pentafecta were the number of resected LNs and 90-days major complications. Type of UD, increasing age, advanced tumor stage, and decreasing surgical experience were the factors most commonly associated with a lower likelihood of PA. A positive correlation was seen between PA and long-term oncological outcome and quality of life. The main limitations in the present studies are their retrospective nature, relatively small sample size, and short median follow-up, most of which was less than 3 years. CONCLUSIONS: The new pentafecta definition provides a comprehensive tool for reporting RC outcomes by including measures of postoperative morbidity, functional outcomes and local cancer control. Pentafecta include standards that could be useful for improving surgical quality, surgical education and comparing different techniques. However, pentafecta is not yet suitable for perioperative risk stratification and patient counseling. CI - 2024 Translational Andrology and Urology. All rights reserved. FAU - Mahmoud, Osama AU - Mahmoud O AD - Department of Urology, University Hospital Essen, Essen, Germany. AD - Department of Urology, Qena faculty of Medicine, South Valley University, Qena, Egypt. FAU - Al-Nader, Mulham AU - Al-Nader M AD - Department of Urology, University Hospital Essen, Essen, Germany. FAU - Pullen, Lukas AU - Pullen L AD - Department of Urology, University Hospital Essen, Essen, Germany. FAU - Tschirdewahn, Stephan AU - Tschirdewahn S AD - Department of Urology, University Hospital Essen, Essen, Germany. FAU - Hadaschik, Boris A AU - Hadaschik BA AD - Department of Urology, University Hospital Essen, Essen, Germany. LA - eng PT - Journal Article PT - Scoping Review DEP - 20240620 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC11228677 OTO - NOTNLM OT - Bladder cancer OT - pentafecta OT - radical cystectomy (RC) OT - trifecta OT - urinary diversion (UD) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-593/coif). S.T. has received research funding from Ipsen, personal fees from Eisai, personal fees from Bayer, personal fees from Janssen, personal fees from Novartis, personal fees from Bristol-Myers-Squibb, personal fees from BrachySolutions, outside this submitted work. B.A.H. reports serving on advisory boards for Janssen, Bayer, ABX, Lightpoint, Amgen, MSD, Pfizer, Novartis; being an invited speaker for Astellas, Janssen R&D; receiving institutional royalties from Uromed; receiving institutional funding from AAA/Novartis, Bristol Myers Squibb, MS, and German Research Foundation; holding an advisory role for German Cancer Aid; and holding a leadership role/speaker for DKG AUO, outside this submitted work. The other authors have no conflicts of interest to declare. EDAT- 2024/07/10 06:42 MHDA- 2024/07/10 06:43 PMCR- 2024/06/30 CRDT- 2024/07/10 04:38 PHST- 2023/11/19 00:00 [received] PHST- 2024/03/10 00:00 [accepted] PHST- 2024/07/10 06:43 [medline] PHST- 2024/07/10 06:42 [pubmed] PHST- 2024/07/10 04:38 [entrez] PHST- 2024/06/30 00:00 [pmc-release] AID - tau-13-06-1037 [pii] AID - 10.21037/tau-23-593 [doi] PST - ppublish SO - Transl Androl Urol. 2024 Jun 30;13(6):1037-1048. doi: 10.21037/tau-23-593. Epub 2024 Jun 20. PMID- 38982920 OWN - NLM STAT- MEDLINE DCOM- 20250926 LR - 20260127 IS - 1875-533X (Electronic) IS - 0929-8673 (Linking) VI - 32 IP - 27 DP - 2025 TI - Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis: In-silico and Clinical Studies. PG - 5843-5860 LID - 10.2174/0109298673302140240627053904 [doi] AB - BACKGROUND: Most patients with non-muscle invasive bladder cancer (NMIBC) have a high direction for recurrence and disease progression, which remains a significant unresolved challenge in bladder cancer patients. Therefore, a constant search is necessary for identifying appropriate and reliable biomarkers for early diagnosis of NMIBC. The current study has aimed to search for valuable diagnostic biomarkers in the tissue and urine specimens of NMIBC patients. METHODS: The changes of twelve candidate mRNAs in a screening phase (40 tissue samples of NMIBC patients and their corresponding 40 urine specimens) and a subsequent independent validation phase (40 urine specimens) were estimated using real-time polymerase chain reaction (RT-qPCR). The receiver operating characteristic (ROC) analysis was executed to determine the potential diagnostic values of mRNAs. RESULTS: The mRNA levels of seven candidate genes were markedly higher in tissue specimens relative to their neighboring tissues. Among them, four mRNAs, including ERBB2, CCND1, MKI67, and MAGEA6, were differentially expressed in urine samples of NMIBC patients relative to control subjects. Further, the expression of these four mRNAs was validated in the validation step. Combining these biomarkers showed better diagnostic performance than single biomarkers in the urine sample for non-invasive NMIBC detection. The combination of these mRNAs and cytology enhanced the sensitivity of cytology from 37% to 87%. CONCLUSION: Our findings suggested that a four-mRNA panel may be promising in the non-invasive diagnosis of NMIBC, which deserves further investigation. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Abazari, Omid AU - Abazari O AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - Dayati, Parisa AU - Dayati P AD - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Shahidi, Maryamsadat AU - Shahidi M AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - ZavarReza, Javad AU - ZavarReza J AD - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. FAU - Rahmanian, Mehdi AU - Rahmanian M AD - Breast Cancer Research Center, Biomaterials and Tissue Engineering Department, Motamed Cancer Institute, ACECR, Tehran, Iran. FAU - Naghib, Seyed Morteza AU - Naghib SM AD - Nanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology, Tehran, Iran. LA - eng PT - Journal Article PL - United Arab Emirates TA - Curr Med Chem JT - Current medicinal chemistry JID - 9440157 RN - 0 (RNA, Messenger) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 136601-57-5 (Cyclin D1) RN - 0 (Antigens, Neoplasm) RN - 0 (Ki-67 Antigen) RN - 0 (Neoplasm Proteins) RN - 0 (MKI67 protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - 0 (CCND1 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/genetics/urine MH - *RNA, Messenger/genetics/urine MH - *Biomarkers, Tumor/genetics/urine MH - Male MH - Female MH - Middle Aged MH - Aged MH - Erb-b2 Receptor Tyrosine Kinases/genetics MH - Cyclin D1/genetics MH - ROC Curve MH - Computer Simulation MH - Antigens, Neoplasm/genetics MH - Ki-67 Antigen/genetics MH - Neoplasm Proteins/genetics OTO - NOTNLM OT - Bladder cancer OT - cytology OT - diagnosis. OT - gene expression OT - non-invasive OT - urine EDAT- 2024/07/10 06:41 MHDA- 2025/09/26 12:32 CRDT- 2024/07/10 04:03 PHST- 2024/02/21 00:00 [received] PHST- 2024/04/08 00:00 [revised] PHST- 2024/04/24 00:00 [accepted] PHST- 2025/09/26 12:32 [medline] PHST- 2024/07/10 06:41 [pubmed] PHST- 2024/07/10 04:03 [entrez] AID - CMC-EPUB-141528 [pii] AID - 10.2174/0109298673302140240627053904 [doi] PST - ppublish SO - Curr Med Chem. 2025;32(27):5843-5860. doi: 10.2174/0109298673302140240627053904. PMID- 38982775 OWN - NLM STAT- MEDLINE DCOM- 20240710 LR - 20240710 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 77 IP - 5 DP - 2024 Jun TI - Factors Influencing Bladder Perforation during Transurethral Resection of Bladder Cancer: A Comprehensive Analysis. PG - 471-478 LID - 10.56434/j.arch.esp.urol.20247705.66 [doi] AB - BACKGROUND: Bladder perforation (BP) is one of the important complications during transurethral resection of bladder tumour (TURBT). Additionally, multiple factors can contribute to BP. Here, we investigated the rates of BP, specifically in variant histology of bladder cancer (BC), and examined the clinical follow-up of relevant patients. METHODS: Of the 797 patients who underwent TURBT between 2015 and 2023, they were divided into two groups according to BP during the operation. Group 1 (n = 744) consisted of patients without BP, whereas Group 2 (n = 53) consisted of patients with BP. Demographic, operative, postoperative and follow-up data were investigated and analysed. Groups were examined in terms of causes of BP. Significance was set at p < 0.05. RESULTS: A significantly higher rate of BP was found in patients operated with bipolar energy (p = 0.027) than in their counterparts. In multivariable analysis, the presence of the obturator reflex during TURBT was significantly associated with an increased risk of BP (p < 0.001). We observed a statistically significant increase in the rate of BP in patients with a history of previous intravesical Bacillus Calmette-Guerin (BCG) therapy (p = 0.023). Variant histology was reported in 32 patients (4%). However, we could not find any statistically significant relationship between the development of BP and the variant histology of BC (p = 0.641). CONCLUSIONS: Multiple factors can affect BP during TURBT. Understanding the factors associated with BP is crucial for improving patient safety and outcomes. According to the results of the present study, the energy source, the presence of obturator reflex during TURBT and intravesical BCG therapy may increase BP. Nevertheless, the presence of variant histology was not significantly associated with BP. CI - (c) 2024 The Author(s). FAU - Yorulmaz, Enis Mert AU - Yorulmaz EM AD - Department of Urology, Izmir Katip Celebi University, 35360 Izmir, Turkey. FAU - Kose, Osman AU - Kose O AD - Department of Urology, Izmir Katip Celebi University, 35360 Izmir, Turkey. FAU - Ozcan, Serkan AU - Ozcan S AD - Department of Urology, Izmir Katip Celebi University, 35360 Izmir, Turkey. FAU - Gorgel, Sacit Nuri AU - Gorgel SN AD - Department of Urology, Izmir Katip Celebi University, 35360 Izmir, Turkey. FAU - Akin, Yigit AU - Akin Y AD - Department of Urology, Izmir Katip Celebi University, 35360 Izmir, Turkey. LA - eng PT - Journal Article PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - Male MH - Female MH - Aged MH - *Cystectomy/adverse effects MH - *Intraoperative Complications/etiology/epidemiology MH - *Urinary Bladder/injuries MH - Middle Aged MH - Retrospective Studies MH - Urethra/injuries MH - Aged, 80 and over MH - Risk Factors MH - Transurethral Resection of Bladder OTO - NOTNLM OT - TURBT OT - bipolar energy OT - bladder perforation OT - obturator reflex OT - variant histology COIS- The authors declare no conflict of interest. EDAT- 2024/07/10 06:42 MHDA- 2024/07/10 06:43 CRDT- 2024/07/10 02:53 PHST- 2024/07/10 06:43 [medline] PHST- 2024/07/10 06:42 [pubmed] PHST- 2024/07/10 02:53 [entrez] AID - 1720059358564-1228665564 [pii] AID - 10.56434/j.arch.esp.urol.20247705.66 [doi] PST - ppublish SO - Arch Esp Urol. 2024 Jun;77(5):471-478. doi: 10.56434/j.arch.esp.urol.20247705.66. PMID- 38982774 OWN - NLM STAT- MEDLINE DCOM- 20240710 LR - 20240712 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 77 IP - 5 DP - 2024 Jun TI - Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review. PG - 463-470 LID - 10.56434/j.arch.esp.urol.20247705.65 [doi] AB - BACKGROUND: Bladder cancer is highly prevalent even though its incidence is considerably lower in patients younger than 40 years, thus raising the issue of the influence of age at diagnosis on the natural history of this disease. This study aimed to evaluate the characteristics and progression of young patients with urothelial bladder carcinoma with at least 10 years of follow-up and to compare the results with those of previously reported studies. MATERIAL AND METHODS: A retrospective study between 1990 and 2007 was conducted. The medical records and tissue samples of patients with urothelial bladder tumours were reviewed, and patients with a first diagnosis of urothelial carcinoma of the bladder at age 40 years or younger were selected. Their clinical and pathological data and disease-free survival were analysed. RESULTS: This study included 43 patients, with a median follow-up of 152 months (interquartile range (IQR): 96-222) and a mean age at diagnosis of 34 years (SD: 4.6). Thirty-five patients (81.4%) had non-muscle invasive tumours at diagnosis, and 53.5%, 27.9% and 18.6% had tumour grades of G1, G2 and G3, respectively. Fifteen patients (34.9%) experienced recurrence, and eight (18.6%) progressed. At 24 and 60 months, the recurrence-free survival rates were 84.8% (95% confidence interval (CI): 69.2%-92.9%) and 68.9% (95% CI: 51.7%-81%), respectively, and the progression-free survival rates were 94.9% (95% CI: 81%-98.7%) and 92.2% (95% CI: 77.8%-97.4%), respectively. CONCLUSIONS: Bladder cancer is an uncommon disease in young patients. In most cases, it consists of non-muscle-invasive tumours, with a low rate of recurrence and progression. The prognosis is based on the tumour's characteristics and not on the patient's age. CI - (c) 2024 The Author(s). FAU - Perez Gonzalez, Sonia AU - Perez Gonzalez S AD - Department of Urology, Infanta Leonor University Hospital, 28031 Madrid, Spain. FAU - Heredia-Soto, Victoria AU - Heredia-Soto V AD - Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain. AD - Center for Biomedical Research in the Cancer Network (CIBERONC), Carlos III Health Institute, 28029 Madrid, Spain. FAU - Giron de Francisco, Manuel AU - Giron de Francisco M AD - Department of Urology, La Paz University Hospital, 28046 Madrid, Spain. FAU - Perez-Fernandez, Elia AU - Perez-Fernandez E AD - Research Unit, Alcorcon Foundation University Hospital, 28922 Madrid, Spain. FAU - Casans-Frances, Ruben AU - Casans-Frances R AD - Department of Anesthesia and Pain Medicine, Infanta Elena University Hospital, 28342 Madrid, Spain. FAU - Del Rosario Rodriguez, Virginia AU - Del Rosario Rodriguez V AD - Department of Urology, Infanta Leonor University Hospital, 28031 Madrid, Spain. FAU - Mendiola Sabio, Marta AU - Mendiola Sabio M AD - Center for Biomedical Research in the Cancer Network (CIBERONC), Carlos III Health Institute, 28029 Madrid, Spain. AD - Molecular Pathology and Therapeutic Targets Group, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain. FAU - Gonzalez-Peramato, Pilar AU - Gonzalez-Peramato P AD - Department of Pathology, La Paz University Hospital, 28046 Madrid, Spain. AD - Department of Pathological Anatomy, Autonomous University of Madrid, 28049 Madrid, Spain. AD - Cellular Engineering Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain. LA - eng PT - Journal Article PT - Review PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality MH - Retrospective Studies MH - Adult MH - Male MH - *Disease Progression MH - Female MH - *Carcinoma, Transitional Cell/pathology/mortality OTO - NOTNLM OT - bladder OT - urothelial carcinoma OT - young COIS- The authors declare no conflict of interest. EDAT- 2024/07/10 06:41 MHDA- 2024/07/10 06:42 CRDT- 2024/07/10 02:53 PHST- 2024/07/10 06:42 [medline] PHST- 2024/07/10 06:41 [pubmed] PHST- 2024/07/10 02:53 [entrez] AID - 1720059354043-761219225 [pii] AID - 10.56434/j.arch.esp.urol.20247705.65 [doi] PST - ppublish SO - Arch Esp Urol. 2024 Jun;77(5):463-470. doi: 10.56434/j.arch.esp.urol.20247705.65. PMID- 38973234 OWN - NLM STAT- MEDLINE DCOM- 20240829 LR - 20250104 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 76 IP - 9 DP - 2024 TI - A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. PG - 861-869 LID - 10.1080/01635581.2024.2374046 [doi] AB - The study aimed to examine the impact of diabetes mellitus type 2 (DMII) on the oncological outcomes of non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) using comprehensive real-world data. We performed an analysis of data on NMIBC patients treated with BCG from the United States (US) National Phase II BCG/Interferon (IFN) trial database (125 centers) and pooled databases from three tertiary care institutions: France (FR), Lebanon (LB) (2000-2021), and the US (University of Iowa) (2011-2021). There were 867 patients from the Phase II trial, 1232 from the FR/LB cohort, and 233 from the US (Iowa) cohort (n = 2332). DM II was reported in 13% of the Phase II trial cohort, 14.4% of the FR/LB cohort, and 33.5% of the US (Iowa) cohort. The median follow-up was 24 months in the Phase II trial cohort, 25 months in the FR/LB cohort, and 48 months in the US (Iowa) cohort. In multivariable Cox regression analyses, DMII was not significantly associated with recurrence or progression of the tumor in any of the cohorts included in this study. DMII may not be a clinical prognostic factor for NMIBC patients treated with BCG. Prospective evaluation is needed. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA. FAU - Moussa, Mohamad AU - Moussa M AD - Department of Urology, Lebanese University, Al Zahraa Hospital, Beirut, Lebanon. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240707 PL - United States TA - Nutr Cancer JT - Nutrition and cancer JID - 7905040 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Male MH - Aged MH - Prognosis MH - Middle Aged MH - *Diabetes Mellitus, Type 2/drug therapy/complications MH - United States MH - Aged, 80 and over MH - Lebanon MH - France MH - Non-Muscle Invasive Bladder Neoplasms EDAT- 2024/07/08 06:42 MHDA- 2024/08/31 09:46 CRDT- 2024/07/08 02:53 PHST- 2024/08/31 09:46 [medline] PHST- 2024/07/08 06:42 [pubmed] PHST- 2024/07/08 02:53 [entrez] AID - 10.1080/01635581.2024.2374046 [doi] PST - ppublish SO - Nutr Cancer. 2024;76(9):861-869. doi: 10.1080/01635581.2024.2374046. Epub 2024 Jul 7. PMID- 38969304 OWN - NLM STAT- MEDLINE DCOM- 20240911 LR - 20240911 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 9 DP - 2024 Sep TI - Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France. PG - 102675 LID - S2950-3930(24)00132-3 [pii] LID - 10.1016/j.fjurol.2024.102675 [doi] AB - OBJECTIVE: Information on bladder cancer (BC) according to the risk scoring for recurrence or progression in a general population is scarce despite its clinical relevance. The objective was to describe the characteristics of incident BC in a general population, with a focus on the initial management of high-risk non-muscle invasive BC (HR-NMIBC). MATERIALS: BC incident in 2011-2012 recorded in a population-based cancer registry were studied. Data was extracted from medical files. NMIBC were classified according to potential risk for recurrence/progression. Individual and tumor characteristics of incident BC were described. Incidence, initial management and survival (12/31/2021) of HR-NMIBC were assessed. RESULTS: Among 538 BC cases, 380 were NMIBC [119 low (22.1%), 163 intermediate (30.3%), 98 high (18.2%) risk] and 147 (27.3%) were MIBC. HR-NMIBC diagnostic and therapeutic management [imaging, re-TUR, multidisciplinary team meetings (MDT) assessment, specific treatment] revealed discrepancies with guidelines recommendations. Seventy-two out of 98 cases were assessed in an MDT with a median time from diagnosis of 18days [first quartile: 12-third quartile: 32]. Globally, treatment agreed with MDT decisions. Intravesical instillation was the most common treatment (n=56) but 27 HR-NMIBC did not receive specific treatment after TUR. Five and 10years overall survival was 52% [42-63] and 41% [31-51], respectively. Five years net survival was 63% [47-75]. CONCLUSIONS: Despite National cancer plans aiming to improve care giving and despite the severity of HR-NMIBC, guideline-recommended patterns of care were underused in this region. This may deserve attention to identify obstacles to guideline adoption to try to improve BC patient care and survival. CI - Copyright (c) 2024 Elsevier Masson SAS. All rights reserved. FAU - Saint, Fabien AU - Saint F AD - Universite de Lille, CHU de Lille, Department of Urology, 59000 Lille, France; EPROAD Laboratory EA 4669, Picardie Jules-Verne University, Lille, France. FAU - Pasquier, David AU - Pasquier D AD - Academic Department of Radiation Oncology, Centre Oscar-Lambret, Lille, France; Universite de Lille, CRIStAL UMR 9189, Lille, France. FAU - Villers, Arnauld AU - Villers A AD - Universite de Lille, CHU de Lille, Department of Urology, 59000 Lille, France. FAU - Massa, Jordan AU - Massa J AD - Universite de Lille, CHU de Lille, Department of Urology, 59000 Lille, France. FAU - Colin, Pierre AU - Colin P AD - Service d'Urologie, Hopital Prive La Louviere, 59800 Lille, France. FAU - Vankemmel, Olivier AU - Vankemmel O AD - Hopital Prive le Bois, Lille, France. FAU - Leroy, Xavier AU - Leroy X AD - Universite de Lille, CHU de Lille, Department of Pathology, 59000 Lille, France. FAU - Bonnal, Jean-Louis AU - Bonnal JL AD - Service d'Urologie, Groupement des Hopitaux de l'Institut Catholique de Lille, Universite Nord de France, Lille, France. FAU - Plouvier, Sandrine D AU - Plouvier SD AD - General Cancer Registry of Lille area, C2RC, Lille, France. Electronic address: splouvier@registrecancers59.fr. LA - eng PT - Journal Article DEP - 20240703 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/mortality/pathology/epidemiology MH - Male MH - Female MH - Aged MH - France/epidemiology MH - Incidence MH - Middle Aged MH - *Neoplasm Invasiveness MH - Aged, 80 and over MH - Registries/statistics & numerical data MH - Risk Assessment MH - Survival Rate MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Retrospective Studies MH - Disease Progression MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder neoplasms OT - Epidemiology OT - Haut risque OT - High-risk OT - Management OT - Therapeutics OT - Traitement OT - Tumeurs de vessie OT - Epidemiologie EDAT- 2024/07/06 10:43 MHDA- 2024/09/12 00:42 CRDT- 2024/07/05 19:32 PHST- 2023/08/18 00:00 [received] PHST- 2024/05/25 00:00 [revised] PHST- 2024/06/26 00:00 [accepted] PHST- 2024/09/12 00:42 [medline] PHST- 2024/07/06 10:43 [pubmed] PHST- 2024/07/05 19:32 [entrez] AID - S2950-3930(24)00132-3 [pii] AID - 10.1016/j.fjurol.2024.102675 [doi] PST - ppublish SO - Fr J Urol. 2024 Sep;34(9):102675. doi: 10.1016/j.fjurol.2024.102675. Epub 2024 Jul 3. PMID- 38966038 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240706 IS - 2950-3299 (Print) IS - 2950-3299 (Electronic) IS - 2950-3299 (Linking) VI - 32 IP - 2 DP - 2024 Jun 20 TI - CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients. PG - 200818 LID - 10.1016/j.omton.2024.200818 [doi] LID - 200818 AB - Bladder cancer (BlCa) is an extensively heterogeneous disease that leads to great variability in tumor evolution scenarios and lifelong patient surveillance, emphasizing the need for modern, minimally invasive precision medicine. Here, we explored the clinical significance of copy number alterations (CNAs) in BlCa. CNA profiling was performed in 15 patient-derived xenografts (PDXs) and validated in The Cancer Genome Atlas BlCa (TCGA-BLCA; n = 408) and Lindgren et al. (n = 143) cohorts. CDKN2A copy number loss was identified as the most frequent CNA in bladder tumors, associated with reduced CDKN2A expression, tumors of a papillary phenotype, and prolonged PDX survival. The study's screening cohort consisted of 243 BlCa patients, and CDKN2A copy number was assessed in genomic DNA and cell-free DNA (cfDNA) from 217 tumors and 189 pre-treatment serum samples, respectively. CDKN2A copy number loss was correlated with superior disease-free and progression-free survival of non-muscle-invasive BlCa (NMIBC) patients. Moreover, a higher CDKN2A index (CDKN2A/LEP ratio) in pre-treatment cfDNA was associated with advanced tumor stage and grade and short-term NMIBC progression to invasive disease, while multivariate models fitted for CDKN2A index in pre-treatment cfDNA offered superior risk stratification of T1/high-grade and EORTC high-risk patients, enhancing prediction of treatment outcome. CDKN2A copy number status could serve as a minimally invasive tool to improve risk stratification and support personalized prognosis in BlCa. CI - (c) 2024 The Author(s). FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Pilala, Katerina-Marina AU - Pilala KM AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Panoutsopoulou, Konstantina AU - Panoutsopoulou K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Kotronopoulos, Georgios AU - Kotronopoulos G AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Kanaki, Zoi AU - Kanaki Z AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Loules, Gedeon AU - Loules G AD - CeMIA SA, Larissa, Greece. FAU - Zamanakou, Maria AU - Zamanakou M AD - CeMIA SA, Larissa, Greece. FAU - Linardoutsos, Dimitrios AU - Linardoutsos D AD - First Department of Propaedeutic Surgery, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Sideris, Diamantis C AU - Sideris DC AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Klinakis, Apostolos AU - Klinakis A AD - Biomedical Research Foundation Academy of Athens, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. AD - Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. LA - eng PT - Journal Article DEP - 20240524 PL - United States TA - Mol Ther Oncol JT - Molecular therapy. Oncology JID - 9918752083706676 PMC - PMC11223115 OTO - NOTNLM OT - CNV OT - DNA-seq OT - MT: Regular Issue OT - PDX mouse model OT - cfDNA OT - copy number variation OT - ctDNA OT - liquid biopsy OT - p14ARF OT - p16INK4A OT - prognosis COIS- The authors declare no competing interests. EDAT- 2024/07/05 06:42 MHDA- 2024/07/05 06:43 PMCR- 2024/05/24 CRDT- 2024/07/05 04:03 PHST- 2023/10/09 00:00 [received] PHST- 2024/03/20 00:00 [revised] PHST- 2024/05/22 00:00 [accepted] PHST- 2024/07/05 06:43 [medline] PHST- 2024/07/05 06:42 [pubmed] PHST- 2024/07/05 04:03 [entrez] PHST- 2024/05/24 00:00 [pmc-release] AID - S2950-3299(24)00060-2 [pii] AID - 200818 [pii] AID - 10.1016/j.omton.2024.200818 [doi] PST - epublish SO - Mol Ther Oncol. 2024 May 24;32(2):200818. doi: 10.1016/j.omton.2024.200818. eCollection 2024 Jun 20. PMID- 38965292 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20240726 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Jul 4 TI - Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients. PG - 15390 LID - 10.1038/s41598-024-65972-8 [doi] LID - 15390 AB - Non-muscle invasive bladder cancers (NMIBC) pTa-pT1 are depicted by a high risk of recurrence and/or progression with an unpredictable clinical evolution. Our aim was to identify, from the original resection specimen, tumors that will progress to better manage patients. We previously showed that A-FABP (Adipocyte- Fatty Acid Binding Protein) loss predicted NMIBC progression. Here we determined by immunohistochemistry the prognostic value of E-FABP (Epidermal-Fatty Acid Binding Protein) expression in 210 tumors (80 pTa, 75 pT1, 55 pT2-T4). Thus, E-FABP low expression was correlated with a high grade/stage, the presence of metastatic lymph nodes, and visceral metastases (p < 0.001). Unlike A-FABP in NMIBC, E-FABP low expression was not associated with RFS or PFS in Kaplan-Meier analysis. But patients of the overall cohort with a high E-FABP expression had a longer mOS (53.8 months vs. 29.3 months, p = 0.029). The immunohistochemical analysis on the same NMIBC tissue sections revealed that when A-FABP is absent, a high E-FABP expression is detected. E-FABP could compensate A-FABP loss. Interestingly, patients, whose original tumor presents both low E-FABP and negative A-FABP, had the worse survival, those maintaining the expression of both markers had better survival. To conclude, the combined evaluation of A- and E-FABP expression allowed to stratify patients with urothelial carcinoma for optimizing treatment and follow-up. CI - (c) 2024. The Author(s). FAU - Saizonou, Ines AU - Saizonou I AD - CHU Besancon, Service Anatomie et Cytologie Pathologiques, 25000, Besancon, France. FAU - Lascombe, Isabelle AU - Lascombe I AD - Universite Franche-Comte, SINERGIES - LabEx LipSTIC ANR-11-LABX-0021, 25030, Besancon, France. FAU - Monnien, Franck AU - Monnien F AD - CHU Besancon, Service Anatomie et Cytologie Pathologiques, 25000, Besancon, France. FAU - Bedgedjian, Isabelle AU - Bedgedjian I AD - CHU Besancon, Service Anatomie et Cytologie Pathologiques, 25000, Besancon, France. FAU - Kleinclauss, Francois AU - Kleinclauss F AD - CHU Besancon, Service Urologie, Andrologie et Transplantation Renale, 25000, Besancon, France. FAU - Algros, Marie-Paule AU - Algros MP AD - CHU Besancon, Service Anatomie et Cytologie Pathologiques, 25000, Besancon, France. FAU - Fauconnet, Sylvie AU - Fauconnet S AD - Universite Franche-Comte, SINERGIES - LabEx LipSTIC ANR-11-LABX-0021, 25030, Besancon, France. sylvie.fauconnet@univ-fcomte.fr. AD - CHU Besancon, Service Urologie, Andrologie et Transplantation Renale, 25000, Besancon, France. sylvie.fauconnet@univ-fcomte.fr. AD - CHU Besancon, Centre Investigation Clinique, Inserm CIC 1431, 25000, Besancon, France. sylvie.fauconnet@univ-fcomte.fr. LA - eng PT - Journal Article DEP - 20240704 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (Fatty Acid-Binding Proteins) RN - 0 (FABP4 protein, human) RN - 0 (FABP5 protein, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Biomarkers, Tumor/metabolism MH - *Fatty Acid-Binding Proteins/metabolism/genetics MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology/metabolism/mortality/genetics PMC - PMC11224272 COIS- The authors declare no competing interests. EDAT- 2024/07/05 00:42 MHDA- 2024/07/05 00:43 PMCR- 2024/07/04 CRDT- 2024/07/04 23:30 PHST- 2023/03/13 00:00 [received] PHST- 2024/06/25 00:00 [accepted] PHST- 2024/07/05 00:43 [medline] PHST- 2024/07/05 00:42 [pubmed] PHST- 2024/07/04 23:30 [entrez] PHST- 2024/07/04 00:00 [pmc-release] AID - 10.1038/s41598-024-65972-8 [pii] AID - 65972 [pii] AID - 10.1038/s41598-024-65972-8 [doi] PST - epublish SO - Sci Rep. 2024 Jul 4;14(1):15390. doi: 10.1038/s41598-024-65972-8. PMID- 38957323 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240704 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Comparative efficacy of Bacillus Calmette-Guerin instillation and radical cystectomy treatments for high-risk non-muscle-invasive urothelial cancer classified as high-grade T1 in initial and repeat transurethral resection of bladder tumor. PG - 1394451 LID - 10.3389/fonc.2024.1394451 [doi] LID - 1394451 AB - OBJECTIVE: To compare the differential therapeutic effects of Bacillus Calmette-Guerin (BCG) instillation and radical cystectomy (RC) for high-risk non-muscle-invasive urothelial cancer (NMIBC) classified as high-grade T1 in initial and repeat transurethral resection of bladder tumors (TURBT) and to construct a prediction model. METHODS: We retrospectively analyzed the clinical data of patients with malignant bladder tumors treated at the First Affiliated Hospital of Soochow University from January 2016 to December 2017 and compared the differences in 1-year, 2-year, 3-year, 5-year, and comprehensive overall survival (OS) and progression-free survival (PFS) between BCG instillation treatment and RC treatment. Survival curves were drawn to show differences in OS and PFS between the two groups. Concurrently, univariate and multivariate COX analyses were performed to identify risk factors affecting OS and PFS, and a nomogram was created. RESULTS: In total, 146 patients were included in the study, of whom 97 and 49 were in the BCG and RC groups, respectively. No statistical differences were observed in the 1- and 2-year OS and PFS between the two groups, whereas significant statistical differences were found in the 3-year, 5-year, and comprehensive OS and PFS. Survival curves also confirmed the statistical differences in OS and PFS between the BCG and RC groups. Multivariate COX analysis revealed that the treatment method, concomitant satellite lesions, and albumin-to-alkaline phosphatase ratio (AAPR) were independent risk factors affecting OS and PFS. The nomogram that was further plotted showed good predictive ability for OS and PFS. CONCLUSION: For patients who exhibit high-level T1 pathology after both initial and repeat TURBT, especially those with low AAPR, and concomitant satellite lesions, choosing RC as a treatment method offers a better prognosis. CI - Copyright (c) 2024 Zhen, Hao, Yanhang, Yuxin, Jun and Zhiyu. FAU - Zhen, Song AU - Zhen S AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. AD - Department of Urology, Taixing People's Hospital, Taizhou, China. FAU - Hao, Chen AU - Hao C AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Yanhang, Yu AU - Yanhang Y AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Yuxin, Lin AU - Yuxin L AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Jun, Ouyang AU - Jun O AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Zhiyu, Zhang AU - Zhiyu Z AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. LA - eng PT - Journal Article DEP - 20240618 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11217478 OTO - NOTNLM OT - Bacillus Calmette-Guerin instillation OT - high-risk non-muscle-invasive urothelial cancer OT - overall survival OT - progression-free survival OT - radical cystectomy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/07/03 06:42 MHDA- 2024/07/03 06:43 PMCR- 2024/01/01 CRDT- 2024/07/03 04:06 PHST- 2024/03/01 00:00 [received] PHST- 2024/05/31 00:00 [accepted] PHST- 2024/07/03 06:43 [medline] PHST- 2024/07/03 06:42 [pubmed] PHST- 2024/07/03 04:06 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1394451 [doi] PST - epublish SO - Front Oncol. 2024 Jun 18;14:1394451. doi: 10.3389/fonc.2024.1394451. eCollection 2024. PMID- 38949559 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20251023 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 77 IP - 4 DP - 2025 Aug TI - The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach. PG - 518-527 LID - 10.23736/S2724-6051.24.05747-1 [doi] AB - BACKGROUND: The risk of recurrence for non-muscle invasive bladder cancer (NMIBC) is high, and the current methods of predicting it rely on clinical and histopathological markers. Personalized risk assessment can be improved by including new prognostic biomarkers. Our research explores the potential of urinary metabolomics to predict cancer recurrence in NMIBC patients within three years. METHODS: Fifty NMIBC patients were included in the study. Urine samples were collected at diagnosis and before TUR-BT. After three years, patients were classified as relapsed or non-relapsed. An NMR-based metabolomics approach was used to measure the concentration of 44 metabolites in the urine of these patients at the time of their diagnosis. This method provides a comprehensive view of many urinary compounds potentially valuable for discriminating relapsing from non-relapsing patients. The measured metabolic profiles were analyzed through multivariate analysis, probability ROC curves, and Mann-Whitney tests. RESULTS: Seven metabolites were involved in NMIBC recurrence prediction. We interpret their alteration as the consequence of three main events: gut dysbiosis, systemic inflammation, and immune inhibition. Since these compounds have already been proposed for BC diagnosis, what distinguishes their role as prognostic or diagnostic is the grade of their alteration. Limitations: small sample size; further research to confirm urinary compounds' correlation with physiological processes. CONCLUSIONS: This study exploits urinary metabolic profiles to predict NMIBC recurrence. Specific metabolites are found to be significantly related to cancer relapse. The study highlights the grade of inflammation, immune suppression, and gut dysbiosis in predicting cancer recurrence. FAU - Petrella, Greta AU - Petrella G AD - Department of Chemical Science and Technology, Tor Vergata University of Rome, Rome, Italy - petrella@scienze.uniroma2.it. FAU - Ciufolini, Giorgia AU - Ciufolini G AD - Department of Chemical Science and Technology, Tor Vergata University of Rome, Rome, Italy. FAU - Lentini, Sara AU - Lentini S AD - Department of Chemical Science and Technology, Tor Vergata University of Rome, Rome, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Pieri, Massimo AU - Pieri M AD - Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy. AD - Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Unit of Urology, Department of Surgical Sciences, Tor Vergata University of Rome, Rome, Italy. FAU - Vago, Riccardo AU - Vago R AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Cicero, Daniel Oscar AU - Cicero DO AD - Department of Chemical Science and Technology, Tor Vergata University of Rome, Rome, Italy. LA - eng PT - Journal Article DEP - 20240701 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 SB - IM CIN - Minerva Urol Nephrol. 2025 Oct;77(5):721-723. doi: 10.23736/S2724-6051.25.06712-6. PMID: 41128043 MH - Humans MH - Middle Aged MH - Aged MH - *Neoplasm Recurrence, Local/etiology/immunology/microbiology/urine MH - *Urinary Bladder Neoplasms/complications/immunology/microbiology/urine MH - *Metabolomics/methods MH - ROC Curve MH - Statistics, Nonparametric MH - Risk Assessment MH - Prognosis MH - Gastrointestinal Microbiome MH - *Dysbiosis/complications/urine MH - *Inflammation/complications/urine MH - Predictive Value of Tests EDAT- 2024/07/01 12:42 MHDA- 2025/09/02 14:42 CRDT- 2024/07/01 09:56 PHST- 2025/09/02 14:42 [medline] PHST- 2024/07/01 12:42 [pubmed] PHST- 2024/07/01 09:56 [entrez] AID - S2724-6051.24.05747-1 [pii] AID - 10.23736/S2724-6051.24.05747-1 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2025 Aug;77(4):518-527. doi: 10.23736/S2724-6051.24.05747-1. Epub 2024 Jul 1. PMID- 38947615 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240702 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 5 DP - 2024 May TI - Association Between Residual Urine Volume and Recurrence Among Patients at High Risk of Non-Muscle-Invasive Bladder Carcinoma With Versus Without Bacillus Calmette-Guerin Treatment. PG - e61345 LID - 10.7759/cureus.61345 [doi] LID - e61345 AB - Non-muscle-invasive bladder carcinoma often occurs in older adults, who often also have urinary dysfunction. The residual urine volume is an important indicator of urinary dysfunction. However, the impact of the residual urine volume on intravesical recurrence remains unclear. In the present study, we analyzed the data of 372 patients at high or very high risk of cancer progression according to the Japanese Urological Association classification who had undergone transurethral resection of a bladder tumor. In univariate analysis, postoperative absence of intravesical Bacillus Calmette-Guerin (BCG) induction was an independent risk factor for intravesical recurrence (hazard ratio 1.94, absence versus presence, p = 0.0019). The incidence of intravesical recurrence did not significantly differ between the mild, intermediate, and severe residual urine groups in the total cohort. Among the BCG-treated cohort, the three groups showed similar trends. Among the non-BCG-treated cohort, although the patients with more than 100 ml of residual urine tended to have more intravesical recurrence than patients with a smaller residual urine volume, this difference did not reach statistical significance. BCG treatment is recommended for patients at high risk of bladder carcinoma. Patients with a large residual urine volume without BCG treatment may be at high risk of intravesical recurrence. CI - Copyright (c) 2024, Murakami et al. FAU - Murakami, Yuki AU - Murakami Y AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Tsukamoto, Ryo AU - Tsukamoto R AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Sato, Hiroaki AU - Sato H AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Ando, Keisuke AU - Ando K AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Kanesaka, Manato AU - Kanesaka M AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Yamada, Yasutaka AU - Yamada Y AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Imamura, Yusuke AU - Imamura Y AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Sakamoto, Shinichi AU - Sakamoto S AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Urology, Chiba University Graduate School of Medicine, Chiba, JPN. LA - eng PT - Journal Article DEP - 20240530 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11214650 OTO - NOTNLM OT - bacillus calmette-guerin (bcg) OT - intravesical recurrence OT - non-muscle-invasive bladder cancer OT - residual urine OT - risk factor COIS- Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board, Chiba University issued approval 2554. Informed consent was obtained by the opt-out method. The need for patient consent was waived because this study was a retrospective review of medical practice covered by health insurance. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This research was supported by Grants-in-Aid for Scientific Research (grant number 22K09494 to TS). Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/01 06:42 MHDA- 2024/07/01 06:43 PMCR- 2024/05/30 CRDT- 2024/07/01 05:45 PHST- 2024/05/29 00:00 [accepted] PHST- 2024/07/01 06:43 [medline] PHST- 2024/07/01 06:42 [pubmed] PHST- 2024/07/01 05:45 [entrez] PHST- 2024/05/30 00:00 [pmc-release] AID - 10.7759/cureus.61345 [doi] PST - epublish SO - Cureus. 2024 May 30;16(5):e61345. doi: 10.7759/cureus.61345. eCollection 2024 May. PMID- 38937340 OWN - NLM STAT- MEDLINE DCOM- 20241029 LR - 20250312 IS - 2366-0058 (Electronic) VI - 49 IP - 11 DP - 2024 Nov TI - Impact of virtual monochromatic images of different low-energy levels in dual-energy CT on radiomics models for predicting muscle invasion in bladder cancer. PG - 3883-3892 LID - 10.1007/s00261-024-04459-6 [doi] AB - OBJECTIVE: The purpose of this study was to investigate the impact of different low-energy virtual monochromatic images (VMIs) in dual-energy CT on the performance of radiomics models for predicting muscle invasive status in bladder cancer (BCa). MATERIALS AND METHODS: A total of 127 patients with pathologically proven muscle-invasive BCa (n = 49) and non-muscle-invasive BCa (n = 78) were randomly allocated into the training and test cohorts at a ratio of 7:3. Feature extraction was performed on the venous phase images reconstructed at 40, 50, 60 and 70-keV (single-energy analysis) or in combination (multi-energy analysis). Recursive feature elimination (RFE) and the least absolute shrinkage and selection operator (LASSO) were employed to select the most relevant features associated with BCa. Models were built using a support vector machine (SVM) classifier. Diagnostic performance was assessed through receiver operating characteristic curves, evaluating sensitivity, specificity, accuracy, precision, and the area-under-the curve (AUC) values. RESULTS: In the test cohort, the multi-energy model achieved the best diagnostic performance with AUC, sensitivity, specificity, accuracy, and precision of 0.917, 0.800, 0.833, 0.821, and 0.750, respectively. Conversely, the single-energy model exhibited lower AUC and sensitivity in predicting the muscle invasion status. CONCLUSIONS: By combining information from VMIs of various energies, the multi-energy model displays superior performance in preoperatively predicting the muscle invasion status of bladder cancer. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Hu, Mengting AU - Hu M AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Wei, Wei AU - Wei W AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Zhang, Jingyi AU - Zhang J AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Wang, Shigeng AU - Wang S AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Tong, Xiaoyu AU - Tong X AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Fan, Yong AU - Fan Y AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Cheng, Qiye AU - Cheng Q AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Liu, Yijun AU - Liu Y AD - Department of Radiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Li, Jianying AU - Li J AD - CT Research, GE Healthcare, Dalian, China. FAU - Liu, Lei AU - Liu L AUID- ORCID: 0009-0003-9112-5158 AD - Department of Urology, First Affiliated Hospital of Dalian Medical University, Xigang District, Lianhe Road, No.193, Dalian, China. liuleidmu1989@163.com. LA - eng PT - Journal Article DEP - 20240627 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Humans MH - Male MH - Female MH - *Tomography, X-Ray Computed/methods MH - *Neoplasm Invasiveness MH - Aged MH - Middle Aged MH - *Radiography, Dual-Energy Scanned Projection/methods MH - *Radiographic Image Interpretation, Computer-Assisted/methods MH - Sensitivity and Specificity MH - Retrospective Studies MH - Aged, 80 and over MH - Radiomics OTO - NOTNLM OT - Dual-energy CT OT - Muscles OT - Radiomics OT - Urinary bladder neoplasms EDAT- 2024/06/28 00:42 MHDA- 2024/10/29 06:23 CRDT- 2024/06/27 23:15 PHST- 2024/04/15 00:00 [received] PHST- 2024/06/15 00:00 [accepted] PHST- 2024/06/11 00:00 [revised] PHST- 2024/10/29 06:23 [medline] PHST- 2024/06/28 00:42 [pubmed] PHST- 2024/06/27 23:15 [entrez] AID - 10.1007/s00261-024-04459-6 [pii] AID - 10.1007/s00261-024-04459-6 [doi] PST - ppublish SO - Abdom Radiol (NY). 2024 Nov;49(11):3883-3892. doi: 10.1007/s00261-024-04459-6. Epub 2024 Jun 27. PMID- 38930060 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 12 DP - 2024 Jun 17 TI - Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study. LID - 10.3390/jcm13123531 [doi] LID - 3531 AB - Background: Photodynamic diagnosis (PDD) during transurethral resection of bladder tumor (TURBT) is guideline recommended, as it improves bladder cancer detection rates. However, the extent to which PDD is implemented in everyday clinical practice has not been thoroughly assessed. We aimed to evaluate the current trends and major perioperative outcomes of TURBT with PDD. Methods: The present study evaluated the GeRmAn Nationwide inpatient Data (GRAND) from 2010 (the year when PDD started to be coded separately in Germany) to 2021, which were made available from the Research Data Center of the German Bureau of Statistics. We undertook numerous patient-level and multivariable logistic regression analyses. Results: Overall, 972,208 TURBTs [228,207 (23%) with PDD and 744,001 (77%) with white light] were performed. Patients offered PDD during TURBT were younger (p < 0.001), presented fewer comorbidities (p < 0.001) and were discharged earlier from hospital (p < 0.001). PDD was associated with additional costs of about EUR 500 compared to white-light TURBT (p < 0.001). The yearly TURBT cases remained relatively stable from 2010 to 2021, whereas utilization of PDD underwent a 2-fold increase. After adjusting for major risk factors in the multivariate regression analysis, PDD was related to lower rates of transfusion (1.4% vs. 5.6%, OR: 0.29, 95% CI: 0.28 to 0.31, p < 0.001), intensive care unit admission (0.7% vs. 1.4%, OR: 0.56, 95% CI: 0.53 to 0.59, p < 0.001) and 30-day in-hospital mortality (0.1% vs. 0.7%, OR: 0.24, 95% CI: 0.22 to 0.27, p < 0.001) compared to white-light TURBT. On the contrary, PDD was related to clinically insignificant higher rates of bladder perforation (0.6% versus 0.5%, OR: 1.3, 95% CI: 1.2 to 1.4, p < 0.001), and reoperation (2.6% versus 2.3%, OR: 1.2, 95% CI: 1.1 to 1.2, p < 0.001). Conclusions: The utilization of PDD with TURBT is steadily increasing. Nevertheless, the road toward the establishment of PDD as the standard of care for TURBT is still long, despite of the advantages of PDD. FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AUID- ORCID: 0000-0002-7707-8426 AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Tzelves, Lazaros AU - Tzelves L AUID- ORCID: 0000-0003-4619-9783 AD - 2nd Department of Urology, Sismanoglio General Hospital of Athens, 15126 Athens, Greece. FAU - Somani, Bhaskar K AU - Somani BK AUID- ORCID: 0000-0002-6248-6478 AD - Department of Urology, University of Hospital Southampton NHS Trust, Southampton SO16 6YD, UK. FAU - Juliebo-Jones, Patrick AU - Juliebo-Jones P AD - Department of Urology, Haukeland University Hospital, 5009 Bergen, Norway. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Medical University Innsbruck, 6020 Innsbruck, Austria. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Medical University Innsbruck, 6020 Innsbruck, Austria. FAU - Volz, Yannic AU - Volz Y AUID- ORCID: 0000-0002-5468-9398 AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Ebner, Benedikt AU - Ebner B AUID- ORCID: 0000-0003-2126-7305 AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AUID- ORCID: 0000-0002-9971-4411 AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Semmler, Marie AU - Semmler M AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Surgical Sciences, University of Turin, Citta della Salute e della Scienza, 10126 Turin, Italy. FAU - Stief, Christian G AU - Stief CG AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. FAU - Schulz, Gerald B AU - Schulz GB AUID- ORCID: 0000-0002-0340-0304 AD - Department of Urology, University Hospital, Ludwig Maximilian University Munich, 81377 Munich, Germany. LA - eng PT - Journal Article DEP - 20240617 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11204857 OTO - NOTNLM OT - bladder cancer OT - cohort study OT - perioperative outcomes OT - photodynamic diagnosis OT - transurethral resection of bladder tumors COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:43 MHDA- 2024/06/27 06:44 PMCR- 2024/06/17 CRDT- 2024/06/27 01:16 PHST- 2024/05/10 00:00 [received] PHST- 2024/05/30 00:00 [revised] PHST- 2024/06/13 00:00 [accepted] PHST- 2024/06/27 06:44 [medline] PHST- 2024/06/27 06:43 [pubmed] PHST- 2024/06/27 01:16 [entrez] PHST- 2024/06/17 00:00 [pmc-release] AID - jcm13123531 [pii] AID - jcm-13-03531 [pii] AID - 10.3390/jcm13123531 [doi] PST - epublish SO - J Clin Med. 2024 Jun 17;13(12):3531. doi: 10.3390/jcm13123531. PMID- 38928456 OWN - NLM STAT- MEDLINE DCOM- 20240627 LR - 20240717 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 12 DP - 2024 Jun 19 TI - Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. LID - 10.3390/ijms25126750 [doi] LID - 6750 AB - The management of advanced bladder carcinoma involves a multidisciplinary approach, but the prognosis remains poor for many patients. The immune system plays a crucial role in this disease, influencing both tumor development and response to treatment, and exploiting the immune system against the tumor can be a valuable strategy to destroy neoplastic cells. This is the biological principle underlying Bacillus Calmette-Guerin (BCG) use and, more recently, immune checkpoint inhibitors (ICIs), like PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) inhibitors. In fact, one of the best studied immune checkpoints is represented by the PD-1/PD-L1 axis, which is a well-known immune escape system adopted by neoplastic bladder cells. PD-L1 expression has been associated with a higher pathologic stage and has shown prognostic value in bladder carcinoma. Interestingly, high-grade bladder cancers tend to express higher levels of PD-1 and PD-L1, suggesting a potential role of such an axis in mediating disease progression. Immunotherapy with PD-1 and PD-L1 inhibitors has therefore emerged as a valuable treatment option and has shown efficacy in advanced bladder cancer patients, with high PD-L1 expression levels associated with better treatment responses. Our review aims to provide a comprehensive overview of the role of PD-L1 in advanced bladder cancer, focusing on its implications for treatment decisions and the prediction of treatment response. Overall, our work aims to contribute to the understanding of PD-L1 as a predictive biomarker and highlight its role in shaping therapeutic approaches for advanced bladder cancer. FAU - Germana, Emanuela AU - Germana E AUID- ORCID: 0009-0008-1905-8700 AD - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy. FAU - Pepe, Ludovica AU - Pepe L AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Pizzimenti, Cristina AU - Pizzimenti C AUID- ORCID: 0000-0002-4387-7174 AD - Pathology Unit, Papardo Hospital, 98158 Messina, Italy. FAU - Ballato, Mariagiovanna AU - Ballato M AUID- ORCID: 0009-0003-5638-0508 AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Pierconti, Francesco AU - Pierconti F AD - Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy. FAU - Tuccari, Giovanni AU - Tuccari G AUID- ORCID: 0000-0002-1561-4246 AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Ieni, Antonio AU - Ieni A AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Giuffre, Giuseppe AU - Giuffre G AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Fadda, Guido AU - Fadda G AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Fiorentino, Vincenzo AU - Fiorentino V AUID- ORCID: 0000-0002-1132-1761 AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. FAU - Martini, Maurizio AU - Martini M AUID- ORCID: 0000-0002-6260-6310 AD - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240619 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/metabolism/pathology/genetics MH - *B7-H1 Antigen/metabolism/genetics MH - Prognosis MH - Biomarkers, Tumor/metabolism MH - Immunohistochemistry MH - Immune Checkpoint Inhibitors/therapeutic use/pharmacology MH - Immunotherapy/methods MH - Programmed Cell Death 1 Receptor/metabolism/antagonists & inhibitors PMC - PMC11203574 OTO - NOTNLM OT - PD-1/PD-L1 axis OT - bladder carcinoma OT - immune system OT - immunotherapy COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:43 MHDA- 2024/06/27 06:44 PMCR- 2024/06/19 CRDT- 2024/06/27 01:07 PHST- 2024/05/12 00:00 [received] PHST- 2024/06/17 00:00 [revised] PHST- 2024/06/18 00:00 [accepted] PHST- 2024/06/27 06:44 [medline] PHST- 2024/06/27 06:43 [pubmed] PHST- 2024/06/27 01:07 [entrez] PHST- 2024/06/19 00:00 [pmc-release] AID - ijms25126750 [pii] AID - ijms-25-06750 [pii] AID - 10.3390/ijms25126750 [doi] PST - epublish SO - Int J Mol Sci. 2024 Jun 19;25(12):6750. doi: 10.3390/ijms25126750. PMID- 38927966 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 12 DP - 2024 Jun 18 TI - Identification of Alcohol Use Prior to Major Cancer Surgery: Timeline Follow Back Interview Compared to Four Other Markers. LID - 10.3390/cancers16122261 [doi] LID - 2261 AB - BACKGROUND: The postoperative complication rate is 30-64% among patients undergoing muscle-invasive and recurrent high-risk non-muscle-invasive bladder cancer surgery. Preoperative risky alcohol use increases the risk. The aim was to evaluate the accuracy of markers for identifying preoperative risky alcohol. METHODS: Diagnostic test sub-study of a randomized controlled trial (STOP-OP trial), based on a cohort of 94 patients scheduled for major bladder cancer surgery. Identification of risky alcohol use using Timeline Follow Back interviews (TLFB) were compared to the AUDIT-C questionnaire and three biomarkers: carbohydrate-deficient transferrin in plasma (P-CDT), phosphatidyl-ethanol in blood (B-PEth), and ethyl glucuronide in urine (U-EtG). RESULTS: The correlation between TLFB and AUDIT-C was strong (rho = 0.75), while it was moderate between TLFB and the biomarkers (rho = 0.55-0.65). Overall, sensitivity ranged from 56 to 82% and specificity from 38 to 100%. B-PEth showed the lowest sensitivity at 56%, but the highest specificity of 100%. All tests had high positive predictive values (79-100%), but low negative predictive values (42-55%). CONCLUSIONS: Despite high positive predictive values, negative predictive values were weak compared to TLFB. For now, TLFB interviews seem preferable for preoperative identification of risky alcohol use. FAU - Nicklasson, Johanna AU - Nicklasson J AUID- ORCID: 0009-0009-1651-3752 AD - Department of Health Sciences, Faculty of Medicine, Lund University, 22100 Lund, Sweden. FAU - Sjodell, Moa AU - Sjodell M AD - Department of Health Sciences, Faculty of Medicine, Lund University, 22100 Lund, Sweden. FAU - Tonnesen, Hanne AU - Tonnesen H AUID- ORCID: 0000-0002-7161-3416 AD - Department of Health Sciences, Faculty of Medicine, Lund University, 22100 Lund, Sweden. AD - WHO Collaborating Centre for Evidence-Based Clinical Health Promotion, The Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, 2000 Copenhagen, Denmark. FAU - Lauridsen, Susanne Vahr AU - Lauridsen SV AUID- ORCID: 0000-0001-6045-4723 AD - WHO Collaborating Centre for Evidence-Based Clinical Health Promotion, The Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, 2000 Copenhagen, Denmark. AD - Department of Surgery, Herlev-Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark. FAU - Rasmussen, Mette AU - Rasmussen M AUID- ORCID: 0000-0003-2847-1544 AD - National Institute of Public Health, University of Southern Denmark, 1455 Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20240618 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11202089 OTO - NOTNLM OT - AUDIT-C OT - CDT OT - EtG OT - PEth OT - Timeline Follow Back OT - alcohol drinking OT - biomarkers OT - cancer surgery OT - diagnostic OT - test performance COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/06/18 CRDT- 2024/06/27 01:05 PHST- 2024/05/17 00:00 [received] PHST- 2024/06/07 00:00 [revised] PHST- 2024/06/14 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:05 [entrez] PHST- 2024/06/18 00:00 [pmc-release] AID - cancers16122261 [pii] AID - cancers-16-02261 [pii] AID - 10.3390/cancers16122261 [doi] PST - epublish SO - Cancers (Basel). 2024 Jun 18;16(12):2261. doi: 10.3390/cancers16122261. PMID- 38914229 OWN - NLM STAT- MEDLINE DCOM- 20241109 LR - 20250710 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 193 DP - 2024 Nov TI - Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience. PG - 136-142 LID - S0090-4295(24)00481-3 [pii] LID - 10.1016/j.urology.2024.06.035 [doi] AB - OBJECTIVE: To describe the management and outcomes of patients with Ta predominantly low-grade urothelial carcinoma with focal high-grade features (FHG) (<5%), compared to those with Ta low grade (LG) and Ta high grade (HG). METHODS: Retrospective review of all patients who underwent transurethral resection of bladder tumor between 2005 and 2023. Patients with Ta disease were identified and categorized into LG, FHG, and HG. Kaplan Meier method was used to depict high-grade recurrence, T-stage progression, and radical cystectomy-free survival. RESULTS: Four hundred forty-nine patients with Ta disease were identified (LG 48%, FHG 12%, and HG 40%). Patients with FHG (32%) had a second-look transurethral resection of bladder tumor more frequently compared to LG (7%) and HG (29%) (P <.01). They received intravesical therapy more frequently compared to LG (36% vs 20%) but lower than HG (55%) (P <.01). They received radical cystectomy less frequently (7% compared to 20% for HG and 11% for LG, P = .01). HG recurrence-free survival at 1, 3, and 5years was HG (68%, 52%, and 43%), FHG (74%, 53%, and 49%), and LG (87%, 79%, and 73%) (log-rank P <.01). T progression-free survival at 1, 3, and 5years was HG (84%, 77%, and 70%), FHG (92%, 82%, and 82%), and LG (94%, 89%, and 85%) (log-rank P = .02). Cystectomy-free survival at 1, 3, and 5years was HG (92%, 84%, and 80%), FHG (96%, 94%, and 94%), and LG (99%, 95%, and 92%) (log-rank P <.01). CONCLUSION: Patients with Ta FHG seem to behave more like Ta HG disease in terms of high-grade recurrences, but they are less likely to experience T-stage progression and convert to cystectomy. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Abou Heidar, Nassib AU - Abou Heidar N AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Mahmood, Abdul Wasay AU - Mahmood AW AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Khan, Mohammad AU - Khan M AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Harrington, Grace AU - Harrington G AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Ahmad, Ali AU - Ahmad A AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Abdelhaq, Dawod AU - Abdelhaq D AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Colan, Nicholas AU - Colan N AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Whitt, Jor'Dan AU - Whitt J AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Sullivan, Daniel AU - Sullivan D AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Howlader, Muhsinah AU - Howlader M AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Plecas, Zachary AU - Plecas Z AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Ahmed, Zaineb AU - Ahmed Z AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Jing, Zhe AU - Jing Z AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Li, Qiang AU - Li Q AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Guru, Khurshid A AU - Guru KA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Hussein, Ahmed A AU - Hussein AA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ahmed.aly@roswellpark.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240622 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2024 Nov;193:143-144. doi: 10.1016/j.urology.2024.07.019. PMID: 39032795 CIN - Urology. 2024 Nov;193:145-146. doi: 10.1016/j.urology.2024.08.046. PMID: 39208946 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - *Carcinoma, Transitional Cell/pathology/surgery/mortality MH - Middle Aged MH - *Neoplasm Grading MH - Prognosis MH - *Cystectomy/methods MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - Disease Progression MH - Aged, 80 and over COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/25 00:43 MHDA- 2024/11/13 13:50 CRDT- 2024/06/24 19:23 PHST- 2024/02/12 00:00 [received] PHST- 2024/05/21 00:00 [revised] PHST- 2024/06/13 00:00 [accepted] PHST- 2024/11/13 13:50 [medline] PHST- 2024/06/25 00:43 [pubmed] PHST- 2024/06/24 19:23 [entrez] AID - S0090-4295(24)00481-3 [pii] AID - 10.1016/j.urology.2024.06.035 [doi] PST - ppublish SO - Urology. 2024 Nov;193:136-142. doi: 10.1016/j.urology.2024.06.035. Epub 2024 Jun 22. PMID- 38906794 OWN - NLM STAT- MEDLINE DCOM- 20241206 LR - 20260106 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 6 DP - 2024 Dec TI - Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration. PG - 1497-1503 LID - S2588-9311(24)00151-2 [pii] LID - 10.1016/j.euo.2024.06.004 [doi] AB - BACKGROUND AND OBJECTIVE: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms of disease recurrence and progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide a clinical validation of the IBCG scoring system and substratification model for IR NMIBC. METHODS: This was an international multicenter retrospective study. Patients diagnosed with IR NMIBC between 2012 and 2022 and treated with transurethral resection of the bladder and adjuvant intravesical chemotherapy were included. According to the presence or absence of risk factors, patients with IR NMIBC were further categorized in IR-low (no risk factors), IR-intermediate (1-2 risk factors), and IR-high (>/=3 risk factors) groups. The 1-yr and 3-yr rates for recurrence-free survival (RFS) and progression-free survival (PFS) were evaluated for each subgroup. Cox regression analyses were used to compare oncological outcomes between the groups. KEY FINDINGS AND LIMITATIONS: Of the 677 patients with IR NMIBC included in the study, 231 (34%), 364 (54%), and 82 (12%) were categorized in the IR-low, IR-intermediate, and IR-high groups, respectively. There were significant differences in RFS and PFS rates between these groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: We provide the first clinical validation of the IBCG scoring system and model for substratification of IR NMIBC. PATIENT SUMMARY: Our study demonstrates that patients with intermediate-risk non-muscle-invasive bladder cancer can be correctly classified into three distinct subgroups according to their risk of both disease recurrence and progression. Our results support use of this scoring system in clinical practice. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. Electronic address: francesco.soria@unito.it. FAU - Rosazza, Matteo AU - Rosazza M AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Livoti, Simone AU - Livoti S AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - De Angelis, Mario AU - De Angelis M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Hospital, Rozzano, Italy. FAU - Mancon, Stefano AU - Mancon S AD - Department of Urology, Humanitas Clinical and Research Hospital, Rozzano, Italy. FAU - Carrion, Diego M AU - Carrion DM AD - Department of Urology, Torrejon University Hospital, Madrid, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Dutto, Daniele AU - Dutto D AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Colucci, Fulvia AU - Colucci F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Casale, Giulia AU - Casale G AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Fertitta, Giorgia AU - Fertitta G AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Albisinni, Simone AU - Albisinni S AD - Unit of Urology, Department of Surgical Sciences, Tor Vergata University Hospital, Tor Vergata University of Rome, Rome, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, UROSUD, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Teoh, Jeremy Y C AU - Teoh JYC AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. LA - eng PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20240620 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - Risk Assessment/methods MH - Neoplasm Invasiveness MH - Risk Factors MH - Urology/standards MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Intermediate risk OT - International Bladder Cancer Group OT - Model OT - Non-muscle-invasive bladder cancer OT - Substratification EDAT- 2024/06/22 05:43 MHDA- 2024/12/07 14:45 CRDT- 2024/06/21 22:00 PHST- 2024/04/19 00:00 [received] PHST- 2024/05/20 00:00 [revised] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/12/07 14:45 [medline] PHST- 2024/06/22 05:43 [pubmed] PHST- 2024/06/21 22:00 [entrez] AID - S2588-9311(24)00151-2 [pii] AID - 10.1016/j.euo.2024.06.004 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Dec;7(6):1497-1503. doi: 10.1016/j.euo.2024.06.004. Epub 2024 Jun 20. PMID- 38902138 OWN - NLM STAT- MEDLINE DCOM- 20241206 LR - 20260106 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 6 DP - 2024 Dec TI - The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PG - 1293-1302 LID - S2588-9311(24)00152-4 [pii] LID - 10.1016/j.euo.2024.06.005 [doi] AB - BACKGROUND AND OBJECTIVE: Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was to assess the effectiveness of adjuvant MMC and compare different MMC regimens in preventing recurrence. METHODS: We performed a comprehensive search in PubMed, Scopus, and Web of Science in November 2023 for studies investigating recurrence-free survival (RFS) among patients with IR-NMIBC who received adjuvant MMC. Prospective trials with different MMC regimens or other intravesical drugs as comparators were considered eligible. KEY FINDINGS AND LIMITATIONS: Overall, 14 studies were eligible for systematic review and 11 for meta-analysis of RFS. Estimates of 1-yr, 2-yr, and 5-yr RFS rates were 84% (95% confidence interval [CI] 79-89%), 75% (95% CI 68-82%), and 51% (95% CI 40-63%) for patients treated with MMC induction plus maintenance, and 88% (95% CI 83-94%), 78% (95% CI 67-89%), and 66% (95% CI 57-75%) for patients treated with bacillus Calmette-Guerin (BCG) maintenance, respectively. Estimates of 2-yr RFS rates for MMC maintenance regimens were 76% (95% CI 69-84%) for 40 mg MMC (2 studies) and 66% (95% CI 60-72%) for 30 mg MMC (4 studies). Among the studies included, BCG maintenance provided comparable 2-yr RFS to 40 mg MMC with maintenance (78% vs 76%). RFS did not differ by MMC maintenance duration (>1 yr vs 1 yr vs <1 yr). CONCLUSIONS AND CLINICAL IMPLICATIONS: MMC induction and maintenance regimens seem to provide short-term RFS rates equivalent to those for BCG maintenance in IR-NMIBC. For adjuvant induction and maintenance, 40 mg of MMC appears to be more effective in preventing recurrence than 30 mg. We did not observe an RFS benefit for longer maintenance regimens. PATIENT SUMMARY: For patients with intermediate-risk non-muscle-invasive bladder cancer, bladder treatments with a solution of a drug called mitomycin C (MMC) seem to be as effective as BCG (bacillus Calmette-Guerin) in preventing recurrence after tumor removal. Further trials are needed for stronger evidence on the best MMC dose and treatment time. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Scilipoti, Pietro AU - Scilipoti P AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - de Angelis, Mario AU - de Angelis M AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Instituto Ramon y Cajal de Investigacion Sanitaria, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, University of Tor Vergata, Rome, Italy. FAU - Mertens, Laura AU - Mertens L AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Necchi, Andrea AU - Necchi A AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC no. 5, Predictive Onco-Urology, Hopital Pitie-Salpetriere, AP-HP, Sorbonne Universite, Paris, France. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: moschini.marco@hsr.it. CN - European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20240619 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 50SG953SK6 (Mitomycin) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Mitomycin/therapeutic use/administration & dosage MH - *Antibiotics, Antineoplastic/therapeutic use/administration & dosage MH - Administration, Intravesical MH - *Neoplasm Invasiveness MH - Risk Assessment MH - Neoplasm Recurrence, Local/prevention & control MH - Chemotherapy, Adjuvant/methods MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Intermediate risk OT - Intravesical chemotherapy OT - Mitomycin C OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence EDAT- 2024/06/21 00:42 MHDA- 2024/12/07 14:45 CRDT- 2024/06/20 21:57 PHST- 2024/04/29 00:00 [received] PHST- 2024/05/23 00:00 [revised] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/12/07 14:45 [medline] PHST- 2024/06/21 00:42 [pubmed] PHST- 2024/06/20 21:57 [entrez] AID - S2588-9311(24)00152-4 [pii] AID - 10.1016/j.euo.2024.06.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Dec;7(6):1293-1302. doi: 10.1016/j.euo.2024.06.005. Epub 2024 Jun 19. PMID- 38901718 OWN - NLM STAT- MEDLINE DCOM- 20240819 LR - 20240819 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 48 DP - 2024 Aug TI - Comparison of PDD-TURBT alone versus white light TURBT plus intravesical BCG therapy: A propensity-score matching study. PG - 104254 LID - S1572-1000(24)00291-6 [pii] LID - 10.1016/j.pdpdt.2024.104254 [doi] AB - BACKGROUND: Although photodynamic-diagnosed transurethral resection of bladder cancer (PDD-TURBT) and Bacillus Calmette-Guerin (BCG) intravesical instillation are the two representative therapies for non-muscle invasive bladder cancer (NMIBC), no studies directly compare their efficacy. We evaluated the outcome of PDD-TURBT alone compared with white light TURBT with intravesical BCG therapy and analyzed the efficacy of both therapies depending on the characteristics of the tumors. METHODS: We retrospectively analyzed intermediate- and high-risk NMIBC patients treated with PDD-TURBT alone (the PDD group) or white light TURBT with BCG therapy (the white light group) using propensity score matched analysis. RESULTS: In the propensity score matched cohort, the 1-, 2-, and 3-year recurrence-free survival rates for the PDD group were 77.6 %, 64.1 %, and 48.1 %, respectively, compared to 84.6 %, 75.1 %, and 75.1 % for the white light group (p = 0.44, 0.27, 0.17, respectively). The difference in recurrence rates between the two groups tended to become more pronounced over time, although there was no significant difference. In the univariate and multivariate analysis, recurrence, multiplicity, and tumor grade were the significant prognostic factors of recurrence in the PDD group (p = 0.010, 0.047, 0.048, respectively). Long-term RFS was similar in the PDD and white light groups when the population was limited to the primary and single tumors, suggesting that PDD-TURBT alone may be sufficient in this spectrum of patients. CONCLUSIONS: PDD-TURBT alone is insufficient to control the long-term recurrence of bladder cancer but can be effective in selected cases such as primary and single tumors. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Miyakawa, Jimpei AU - Miyakawa J AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan; Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Yamada, Yuta AU - Yamada Y AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. Electronic address: yyamada2029@gmail.com. FAU - Hakozaki, Yuji AU - Hakozaki Y AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Makino, Katsuhiro AU - Makino K AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Kamei, Jun AU - Kamei J AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Akiyama, Yoshiyuki AU - Akiyama Y AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Yamada, Daisuke AU - Yamada D AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, Graduate School of Medicine, the University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240618 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 0 (BCG Vaccine) RN - 0 (Photosensitizing Agents) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/therapy MH - Male MH - *Propensity Score MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Female MH - Retrospective Studies MH - Administration, Intravesical MH - Aged MH - Middle Aged MH - Photochemotherapy/methods MH - Neoplasm Recurrence, Local MH - Photosensitizing Agents/therapeutic use MH - Combined Modality Therapy MH - Aged, 80 and over MH - Adjuvants, Immunologic/therapeutic use/administration & dosage OTO - NOTNLM OT - 5-aminolevulinic acid OT - BCG OT - Photodynamic diagnosis OT - Propensity score matching EDAT- 2024/06/21 00:42 MHDA- 2024/08/20 00:42 CRDT- 2024/06/20 19:28 PHST- 2024/03/10 00:00 [received] PHST- 2024/06/03 00:00 [revised] PHST- 2024/06/17 00:00 [accepted] PHST- 2024/08/20 00:42 [medline] PHST- 2024/06/21 00:42 [pubmed] PHST- 2024/06/20 19:28 [entrez] AID - S1572-1000(24)00291-6 [pii] AID - 10.1016/j.pdpdt.2024.104254 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2024 Aug;48:104254. doi: 10.1016/j.pdpdt.2024.104254. Epub 2024 Jun 18. PMID- 38896113 OWN - NLM STAT- MEDLINE DCOM- 20240619 LR - 20240619 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 59 DP - 2024 Jun 19 TI - Violation of onco-surgical principles is associated with survival outcomes in upper tract urothelial carcinomas after radical nephroureterectomy. PG - 131-136 LID - 10.2340/sju.v59.25973 [doi] AB - OBJECTIVE: Disease recurrence, particularly intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), is common. We investigated whether violations of onco-surgical principles before or during RNU, collectively referred to as surgical violation (SV), were associated with survival outcomes. Material and methods: Data from a consecutive series of patients who underwent RNU for UTUC 2001-2012 at Skane University Hospital Lund/Malmo were collected. Preoperative insertion of a nephrostomy tube, opening the urinary tract during surgery or refraining from excising the distal ureter were considered as SVs. Survival outcomes in patients with and without SV (IVR-free [IVRFS], disease-specific [DSS] and overall survival [OS]) were assessed using multivariate Cox regression analyses (adjusted for tumour stage group, prior or concomitant bladder cancer, comorbidity and preoperative urinary cytology). RESULTS: Of 150 patients, 47 (31%) were subjected to at least one SV. Overall, SV was not associated with IVRFS (HR 0.81, 95% CI 0.4-1.6) but with worse DSS (HR 1.9, 95% CI 1.03-3.7) and OS (HR 1.9, 95% CI 1.2-3) in multivariable analysis. Additional analyses with a broader definition of SV including also preoperative instrumentation of the upper urinary tract (ureteroscopy and/or double J stenting) showed similar outcomes for DSS (HR 2.1, 95% CI 1.1-4.3). CONCLUSION: Worse survival outcomes, despite no difference in IVR, for patients that were subjected to the violation of sound onco-surgical principles before or during RNU for UTUC strengthen the notion that adhering to such principles is a cornerstone in upper tract urothelial cancer surgery. FAU - Patras, Ioannis AU - Patras I AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. ioannis.patras@med.lu.se. FAU - Abrahamsson, Johan AU - Abrahamsson J AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Gerdtsson, Axel AU - Gerdtsson A AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Nyberg, Martin AU - Nyberg M AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Saemundsson, Ymir AU - Saemundsson Y AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Stahl, Elin AU - Stahl E AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Sorenby, Anne AU - Sorenby A AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Warnolf, Asa AU - Warnolf A AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Bobjer, Johannes AU - Bobjer J AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology Skane University Hospital, Malmo, and Institution of Translational Medicine, Lund University, Malmo, Sweden. LA - eng PT - Journal Article DEP - 20240619 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - *Nephroureterectomy/methods MH - Female MH - Male MH - Aged MH - *Ureteral Neoplasms/surgery/mortality/pathology MH - *Carcinoma, Transitional Cell/surgery/mortality/pathology MH - *Kidney Neoplasms/surgery/mortality/pathology MH - Middle Aged MH - Survival Rate MH - Retrospective Studies MH - Neoplasm Recurrence, Local/epidemiology MH - Aged, 80 and over MH - Ureter/surgery EDAT- 2024/06/19 12:43 MHDA- 2024/06/19 12:44 CRDT- 2024/06/19 10:43 PHST- 2023/11/13 00:00 [received] PHST- 2024/05/27 00:00 [accepted] PHST- 2024/06/19 12:44 [medline] PHST- 2024/06/19 12:43 [pubmed] PHST- 2024/06/19 10:43 [entrez] AID - 10.2340/sju.v59.25973 [doi] PST - epublish SO - Scand J Urol. 2024 Jun 19;59:131-136. doi: 10.2340/sju.v59.25973. PMID- 38886756 OWN - NLM STAT- MEDLINE DCOM- 20240618 LR - 20250718 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 43 IP - 1 DP - 2024 Jun 18 TI - Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment. PG - 170 LID - 10.1186/s13046-024-03088-7 [doi] LID - 170 AB - BACKGROUND: Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-muscle invasive bladder cancer. Despite their ability to induce an enhanced immune reaction within the lesion, the intracellular survival signaling of cancer cells has not been thoroughly addressed. METHODS: An analysis of the prognostic data revealed a high probability of therapeutic efficacy with simultaneous inhibition of mTOR and STAT3. Considering the challenges of limited pharmaco-accessibility to the bladder due to its pathophysiological structure and the partially undruggable nature of target molecules, we designed a dual siRNA system targeting both mRNAs. Subsequently, this dual siRNA system was encoded into the adenovirus 5/3 (Ad 5/3) to enhance in vivo delivery efficiency. RESULTS: Gene-targeting efficacy was assessed using cells isolated from xenografted tumors using a single-cell analysis system. Our strategy demonstrated a balanced downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo. This approach reduced tumor growth in bladder cancer xenograft and orthotopic animal experiments. In addition, increased infiltration of CD8(+) T cells was observed in a humanized mouse model. We provided helpful and safe tissue distribution data for intravesical therapy of siRNAs coding adenoviruses. CONCLUSIONS: The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with "undruggability." Hence, we propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses. CI - (c) 2024. The Author(s). FAU - Lee, Dae Hoon AU - Lee DH AD - Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. FAU - Yoo, Jung Ki AU - Yoo JK AD - Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. FAU - Um, Ki Hwan AU - Um KH AD - Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. AD - Department of Regulatory Science, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. FAU - Ha, Wootae AU - Ha W AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. FAU - Lee, Soo Min AU - Lee SM AD - Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. AD - Department of Regulatory Science, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. FAU - Park, Junseong AU - Park J AD - Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea. FAU - Kye, Min Jeong AU - Kye MJ AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. FAU - Suh, Jungyo AU - Suh J AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea. FAU - Choi, Jin Woo AU - Choi JW AD - Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. jinwoo.ch@khu.ac.kr. AD - Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. jinwoo.ch@khu.ac.kr. AD - R&D Center of Curigin Ltd., Curigin, Seoul, 04778, Republic of Korea. jinwoo.ch@khu.ac.kr. AD - Department of Regulatory Science, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. jinwoo.ch@khu.ac.kr. LA - eng PT - Journal Article DEP - 20240618 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 RN - 0 (STAT3 Transcription Factor) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (STAT3 protein, human) RN - EC 2.7.1.1 (MTOR protein, human) SB - IM EIN - J Exp Clin Cancer Res. 2025 Jul 17;44(1):210. doi: 10.1186/s13046-025-03469-6. PMID: 40676701 MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics/therapy MH - Humans MH - *STAT3 Transcription Factor/metabolism MH - Animals MH - Mice MH - *TOR Serine-Threonine Kinases/metabolism/antagonists & inhibitors MH - Administration, Intravesical MH - Female MH - Cell Line, Tumor MH - Xenograft Model Antitumor Assays PMC - PMC11184849 OTO - NOTNLM OT - Bladder cancer OT - Cancer therapy OT - STAT3 OT - mTOR OT - siRNA COIS- D.H.L., J.K.Y., K.H.U., W.H., and M.J.K. have partially received the research grant from Curigin. Ltd. S.M.L., J.P., J.S., and J.W.C. declare no competing interests associated with this manuscript. EDAT- 2024/06/18 00:43 MHDA- 2024/06/18 06:41 PMCR- 2024/06/18 CRDT- 2024/06/17 23:46 PHST- 2024/03/05 00:00 [received] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/06/18 06:41 [medline] PHST- 2024/06/18 00:43 [pubmed] PHST- 2024/06/17 23:46 [entrez] PHST- 2024/06/18 00:00 [pmc-release] AID - 10.1186/s13046-024-03088-7 [pii] AID - 3088 [pii] AID - 10.1186/s13046-024-03088-7 [doi] PST - epublish SO - J Exp Clin Cancer Res. 2024 Jun 18;43(1):170. doi: 10.1186/s13046-024-03088-7. PMID- 38886638 OWN - NLM STAT- MEDLINE DCOM- 20240617 LR - 20240620 IS - 1471-2342 (Electronic) IS - 1471-2342 (Linking) VI - 24 IP - 1 DP - 2024 Jun 17 TI - Compressed sensing 3D T2WI radiomics model: improving diagnostic performance in muscle invasion of bladder cancer. PG - 148 LID - 10.1186/s12880-024-01318-0 [doi] LID - 148 AB - BACKGROUND: Preoperative discrimination between non-muscle-invasive bladder cancer (NMIBC) and the muscle invasive bladder cancer (MIBC) is a determinant of management. The purpose of this research is to employ radiomics to evaluate the diagnostic value in determining muscle invasiveness of compressed sensing (CS) accelerated 3D T2-weighted-SPACE sequence with high resolution and short acquisition time. METHODS: This prospective study involved 108 participants who underwent preoperative 3D-CS-T2-weighted-SPACE, 3D-T2-weighted-SPACE and T2-weighted sequences. The cohort was divided into training and validation cohorts in a 7:3 ratio. In the training cohort, a Rad-score was constructed based on radiomic features selected by intraclass correlation coefficients, pearson correlation coefficient and least absolute shrinkage and selection operator . Multivariate logistic regression was used to develop a nomogram combined radiomics and clinical indices. In the validation cohort, the performances of the models were evaluated by ROC, calibration, and decision curves. RESULTS: In the validation cohort, the area under ROC curve of 3D-CS-T2-weighted-SPACE, 3D-T2-weighted-SPACE and T2-weighted models were 0.87(95% confidence interval (CI):0.73-1.00), 0.79(95%CI:0.63-0.96) and 0.77(95%CI:0.60-0.93), respectively. The differences in signal-to-noise ratio and contrast-to-noise ratio between 3D-CS-T2-weighted-SPACE and 3D-T2-weighted-SPACE sequences were not statistically significant(p > 0.05). While the clinical model composed of three clinical indices was 0.74(95%CI:0.55-0.94) and the radiomics-clinical nomogram model was 0.88(95%CI:0.75-1.00). The calibration curves confirmed high goodness of fit, and the decision curve also showed that the radiomics model and combined nomogram model yielded higher net benefits than the clinical model. CONCLUSION: The radiomics model based on compressed sensing 3D T2WI sequence, which was acquired within a shorter acquisition time, showed superior diagnostic efficacy in muscle invasion of bladder cancer. Additionally, the nomogram model could enhance the diagnostic performance. CI - (c) 2024. The Author(s). FAU - Li, Shuo AU - Li S AD - Department of Radiology, The First Hospital of Shanxi Medical University, No.85 Jiefang South Road, Taiyuan, 030001, Shanxi Province, P.R. China. FAU - Fan, Zhichang AU - Fan Z AD - Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, Shanxi, P.R. China. FAU - Guo, Junting AU - Guo J AD - Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, Shanxi, P.R. China. FAU - Li, Ding AU - Li D AD - Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, Shanxi, P.R. China. FAU - Chen, Zeke AU - Chen Z AD - Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, Shanxi, P.R. China. FAU - Zhang, Xiaoyue AU - Zhang X AD - Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, Shanxi, P.R. China. FAU - Wang, Yongfang AU - Wang Y AD - Department of Radiology, The First Hospital of Shanxi Medical University, No.85 Jiefang South Road, Taiyuan, 030001, Shanxi Province, P.R. China. FAU - Li, Yan AU - Li Y AD - Department of Radiology, The First Hospital of Shanxi Medical University, No.85 Jiefang South Road, Taiyuan, 030001, Shanxi Province, P.R. China. FAU - Yang, Guoqiang AU - Yang G AD - Department of Radiology, The First Hospital of Shanxi Medical University, No.85 Jiefang South Road, Taiyuan, 030001, Shanxi Province, P.R. China. FAU - Wang, Xiaochun AU - Wang X AD - Department of Radiology, The First Hospital of Shanxi Medical University, No.85 Jiefang South Road, Taiyuan, 030001, Shanxi Province, P.R. China. 2010xiaochun@163.com. LA - eng GR - 81971592/National Natural Science Foundation of China/ GR - 2023XM011/Four "Batches" Innovation Project of Invigorating Medical through Science and Technology of Shanxi Province/ GR - z-2014-07-2301/China International Medical Foundation of China/ PT - Journal Article DEP - 20240617 PL - England TA - BMC Med Imaging JT - BMC medical imaging JID - 100968553 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Male MH - Female MH - Middle Aged MH - *Neoplasm Invasiveness/diagnostic imaging MH - Prospective Studies MH - *Imaging, Three-Dimensional/methods MH - Aged MH - Magnetic Resonance Imaging/methods MH - ROC Curve MH - Nomograms MH - Radiomics PMC - PMC11181529 OTO - NOTNLM OT - Bladder cancer OT - Compressed sensing OT - Magnetic resonance imaging OT - Muscle invasion OT - Radiomics COIS- The authors declare no competing interests. EDAT- 2024/06/18 00:43 MHDA- 2024/06/18 00:44 PMCR- 2024/06/17 CRDT- 2024/06/17 23:39 PHST- 2024/02/20 00:00 [received] PHST- 2024/06/03 00:00 [accepted] PHST- 2024/06/18 00:44 [medline] PHST- 2024/06/18 00:43 [pubmed] PHST- 2024/06/17 23:39 [entrez] PHST- 2024/06/17 00:00 [pmc-release] AID - 10.1186/s12880-024-01318-0 [pii] AID - 1318 [pii] AID - 10.1186/s12880-024-01318-0 [doi] PST - epublish SO - BMC Med Imaging. 2024 Jun 17;24(1):148. doi: 10.1186/s12880-024-01318-0. PMID- 38879411 OWN - NLM STAT- MEDLINE DCOM- 20240905 LR - 20250605 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 11 DP - 2024 Nov TI - CTLA4 genetic variants associated with urothelial bladder cancer susceptibility. PG - 374.e1-374.e10 LID - S1078-1439(24)00490-3 [pii] LID - 10.1016/j.urolonc.2024.05.017 [doi] AB - PURPOSE: The study evaluated the relationship between the CTLA4 rs231775 (+49A>G) and rs231779 (+1822C>T) variants and susceptibility, stage, prognosis and response to treatment of the urothelial bladder cancer (UBC). METHODS: A total of 140 patients with UBC and 145 controls were enrolled. The patients were stratified as non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MICB), metastasis, recurrence, low/moderate/high/very high risk. Demographic, anthropometric, epidemiological, and clinical data were obtained from all individuals using a structured questionnaire. The CTLA4 variants were determined using real-time polymerase chain reaction (qPCR) and the genotypes were tested in the allelic, codominant, dominant, recessive, and overdominant genetic models. RESULTS: The UBC patients were older and mostly smokers (P < 0.001), with greater waist circumference, systolic, and diastolic arterial pressure (P = 0.005, P = 0.006, and P < 0.001, respectively) than controls. A protective effect for the UBC was observed among the patients carrying the heterozygote genotypes of the CTLA4 rs231775 [odds ratio (OR = 0.40; 95% confidence interval (CI): 0.160.98, P = 0.045) and rs231779 (OR = 0.35; 95% CI: 0.14-0.87, P = 0.024). R(2) Nagelkerke analysis demonstrated that a model with age and smoking added to the CTLA4 rs231775 SNVs explained 77.0% of the susceptibility to UBC and a model with age and smoking added to the CLTA4 rs231779 explained 77.2% of the susceptibility to UBC. CONCLUSION: The CTLA4 rs231775 AG and rs231779 CT heterozygous genotypes in the overdominant model together with age and smoking may be useful as potential biomarkers for the UBC susceptibility. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Koike, Alexsandro AU - Koike A AD - Department of Clinical Surgery, Health Sciences Center, State University of Londrina, Londrina, Parana, Brazil; Postgraduate Program of Clinical and Laboratory Physiopathology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Cancer Hospital of Londrina, Londrina, Parana, Brazil. FAU - Colado Simao, Andrea Name AU - Colado Simao AN AD - Postgraduate Program of Clinical and Laboratory Physiopathology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Ahrens, Tainah Mendes AU - Ahrens TM AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Cardoso, Kaue de Morais AU - Cardoso KM AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Espinosa, Beatriz Rabello AU - Espinosa BR AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Gualberto, Roberson Henrique Gobanhi AU - Gualberto RHG AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Santos, Daniel Felipe Piva AU - Santos DFP AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Trigo, Guilherme Lerner AU - Trigo GL AD - Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. FAU - Reiche, Edna Maria Vissoci AU - Reiche EMV AD - Postgraduate Program of Clinical and Laboratory Physiopathology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil.; Pontifical Catholic University of Parana, School of Medicine, Campus Londrina, Londrina, Parana, Brazil. Electronic address: reiche@sercomtel.com.br. FAU - Lozovoy, Marcell Alysson Batisti AU - Lozovoy MAB AD - Postgraduate Program of Clinical and Laboratory Physiopathology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Parana, Brazil.; Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Parana, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240615 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (CTLA-4 Antigen) RN - 0 (CTLA4 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - *CTLA-4 Antigen/genetics MH - Female MH - Male MH - *Genetic Predisposition to Disease MH - Middle Aged MH - Aged MH - Case-Control Studies MH - Polymorphism, Single Nucleotide MH - Prognosis MH - Genotype OTO - NOTNLM OT - Bladder cancer OT - CTLA4 OT - Overdominant OT - Single nucleotide variant OT - Urothelial bladder cancer COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/16 11:58 MHDA- 2024/09/06 01:02 CRDT- 2024/06/15 21:58 PHST- 2024/04/02 00:00 [received] PHST- 2024/05/14 00:00 [revised] PHST- 2024/05/19 00:00 [accepted] PHST- 2024/09/06 01:02 [medline] PHST- 2024/06/16 11:58 [pubmed] PHST- 2024/06/15 21:58 [entrez] AID - S1078-1439(24)00490-3 [pii] AID - 10.1016/j.urolonc.2024.05.017 [doi] PST - ppublish SO - Urol Oncol. 2024 Nov;42(11):374.e1-374.e10. doi: 10.1016/j.urolonc.2024.05.017. Epub 2024 Jun 15. PMID- 38861054 OWN - NLM STAT- MEDLINE DCOM- 20240629 LR - 20240819 IS - 1744-7682 (Electronic) IS - 1471-2598 (Linking) VI - 24 IP - 6 DP - 2024 Jun TI - An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer. PG - 415-423 LID - 10.1080/14712598.2024.2365802 [doi] AB - INTRODUCTION: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) represent a significant therapeutic challenge in the treatment of bladder cancer. Nadofaragene firadenovec, represents a breakthrough in this area, offering a novel approach for the treatment of BCG-unresponsive NMIBC. AREAS COVERED: This overview explores the historical development of nadofaragene firadenovec, assessing its efficacy and safety, and discusses future NMIBC therapy directions. EXPERT OPINION: Patients with high grade NMIBC who are BCG unresponsive will have a growing number of treatment alternatives to bladder removal. Nadofaragene firadenovec offers good short-term efficacy but lacks significant durability for most patients. Its strengths include ease of administration and low risk of adverse events. This will need to balance with risk of progression and cost. Furthermore, the likely approval of other agents will require consideration of which therapy to use and for which patient. The need for biomarkers to tailor treatment choices to individual patient needs is becoming more critical. The treatment field is rapidly advancing, with several Phase 3 single-arm trials underway, indicating a potential broader range of treatment options for NMIBC. Further research will be necessary to determine the optimal choice for patients. FAU - Khene, Zine-Eddine AU - Khene ZE AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20240613 PL - England TA - Expert Opin Biol Ther JT - Expert opinion on biological therapy JID - 101125414 RN - 0 (BCG Vaccine) RN - 0 (Cancer Vaccines) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Cancer Vaccines/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder sparing treatment OT - carcinoma in situ OT - gene therapy OT - interferon-2b OT - non-muscle invasive bladder cancer EDAT- 2024/06/11 12:44 MHDA- 2024/06/29 15:42 CRDT- 2024/06/11 11:06 PHST- 2024/06/29 15:42 [medline] PHST- 2024/06/11 12:44 [pubmed] PHST- 2024/06/11 11:06 [entrez] AID - 10.1080/14712598.2024.2365802 [doi] PST - ppublish SO - Expert Opin Biol Ther. 2024 Jun;24(6):415-423. doi: 10.1080/14712598.2024.2365802. Epub 2024 Jun 13. PMID- 38859794 OWN - NLM STAT- MEDLINE DCOM- 20240917 LR - 20240917 IS - 1724-6008 (Electronic) IS - 0393-6155 (Linking) VI - 39 IP - 3 DP - 2024 Sep TI - The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer. PG - 255-264 LID - 10.1177/03936155241261719 [doi] AB - BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is the most prevalent type of bladder cancer, typically associated with a favorable prognosis and a risk of recurrence during the follow-up period. Inflammatory markers have been used to predict prognosis in various cancer types. The aim of this study was to explore the prognostic value of the readily accessible inflammatory markers, platelet-to-lymphocyte ratio (PLR) and interleukin-6 (IL-6), in NMIBC. METHODS: The study comprised a retrospective analysis of clinical data collected from NMIBC patients diagnosed between October 2018 and October 2020. PLR was calculated using the routine preoperative blood test results, and preoperative IL-6 levels were recorded. Receiver operating characteristic (ROC) curves were generated for PLR and IL-6 level and the optimal cut-off values were determined using Youden's index. Survival curves were generated to evaluate the association between PLR and IL-6, and recurrence-free survival (RFS), and univariate and multivariate analysis were performed using the Cox proportional hazards regression model. A nomogram and calibration curve were generated to assess the clinical significance of the model. RESULTS: The ROC curves demonstrated that PLR and IL-6 levels were significantly associated with tumor pathology grade, with area under the curve (AUC) values of 0.833 (95% CI 0.757, 0.910) for PLR and 0.724 (95% CI 0.622, 0.825) for IL-6 levels. PLR and IL-6 levels were also positively associated with tumor recurrence, with AUC values of 0.647 (95% CI 0.538, 0.756) and 0.846 (95% CI 0.769, 0.924), respectively. The survival curves indicated that patients with high PLR and high IL-6 levels had shorter RFS than those with low PLR and low IL-6 level (P < 0.01). Univariate Cox proportional hazards regression analysis showed that age, tumor size, tumor number, pathological grade, PLR and IL-6 were potential risk factors for NMIBC recurrence. Multivariate analysis further revealed that tumor number, smoking, PLR, and IL-6 were independent risk factors for NMIBC recurrence (P < 0.05). CONCLUSIONS: Preoperative peripheral blood inflammatory markers (PLR and IL-6) are useful predictors of RFS in NMIBC patients at the time of initial diagnosis. High PLR and high IL-6 were identified as independent risk factors for tumor recurrence and could serve as potential biological markers for prediction of NMIBC recurrence. FAU - Wang, Xiangyu AU - Wang X AUID- ORCID: 0009-0005-5805-8875 AD - Department of Urology Surgery, Nanjing Drum-Tower Hospital Group Suqian Hospital, The Affiiated Suqian Hospital of Xuzhou Medical University, Suqian, China. RINGGOLD: 658990 FAU - Zhang, Shaoqi AU - Zhang S AD - Department of Urology Surgery, Nanjing Drum-Tower Hospital Group Suqian Hospital, The Affiiated Suqian Hospital of Xuzhou Medical University, Suqian, China. RINGGOLD: 658990 FAU - Sun, Yongming AU - Sun Y AD - Department of Urology Surgery, Nanjing Drum-Tower Hospital Group Suqian Hospital, The Affiiated Suqian Hospital of Xuzhou Medical University, Suqian, China. RINGGOLD: 658990 FAU - Cai, Longjun AU - Cai L AD - Department of Urology Surgery, Nanjing Drum-Tower Hospital Group Suqian Hospital, The Affiiated Suqian Hospital of Xuzhou Medical University, Suqian, China. RINGGOLD: 658990 FAU - Zhang, Jianjun AU - Zhang J AD - Department of Urology Surgery, Nanjing Drum-Tower Hospital Group Suqian Hospital, The Affiiated Suqian Hospital of Xuzhou Medical University, Suqian, China. RINGGOLD: 658990 LA - eng PT - Journal Article DEP - 20240611 PL - United States TA - Int J Biol Markers JT - The International journal of biological markers JID - 8712411 RN - 0 (Interleukin-6) RN - 0 (Biomarkers, Tumor) RN - 0 (IL6 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/blood/pathology MH - *Interleukin-6/blood MH - Male MH - Female MH - Prognosis MH - Aged MH - Retrospective Studies MH - Middle Aged MH - *Blood Platelets/pathology/metabolism MH - *Lymphocytes/pathology MH - Biomarkers, Tumor/blood MH - ROC Curve MH - Platelet Count MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - interleukin-6 OT - platelet-to-lymphocyte ratio OT - preoperative inflammatory markers OT - prognosis COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/06/11 06:42 MHDA- 2024/09/17 10:45 CRDT- 2024/06/11 03:52 PHST- 2024/09/17 10:45 [medline] PHST- 2024/06/11 06:42 [pubmed] PHST- 2024/06/11 03:52 [entrez] AID - 10.1177/03936155241261719 [doi] PST - ppublish SO - Int J Biol Markers. 2024 Sep;39(3):255-264. doi: 10.1177/03936155241261719. Epub 2024 Jun 11. PMID- 38852435 OWN - NLM STAT- MEDLINE DCOM- 20240617 LR - 20260629 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 4 DP - 2024 Aug TI - Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy. PG - 102119 LID - S1558-7673(24)00090-9 [pii] LID - 10.1016/j.clgc.2024.102119 [doi] AB - INTRODUCTION: Trimodal therapy (TMT) is guideline-recommended for the management of organ confined urothelial carcinoma of urinary bladder (UCUB). However, temporal trends in TMT use and cancer-specific mortality free-survival (CSM-FS) between historical TMT versus contemporary TMT have not been assessed. We addressed this knowledge gap. MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified nonmetastatic UCUB patients with cT2-T4aN0-N2 treated with TMT, defined as the combination of transurethral resection of bladder tumor, chemotherapy and radiotherapy. Temporal trends described TMT use over time. Subsequently, patients were divided between historical (2004-2012) versus contemporary (2013-2020) cohorts. Survival analyses consisting of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM-FS. Separate analyses addressed patients with organ confined (OC: cT2N0M0) versus nonorgan confined (NOC: cT3-4a and/or cN1-2) clinical stages. RESULTS: Of 4,097 assessable UCUB TMT patients, 1744 (43%) were treated in the historical period (2004-2012) versus 2353 (58%) in the contemporary period (2013-2020). TMT use increased over time in OC patients (EAPC:+3.4%, P < .001), as well as in NOC (EAPC:+2.7%, P < .001). In OC stage, median CSM-FS was 55.3% in historical versus 49.0% in contemporary patients (HR:0.75, P < .001). Similarly, in NOC stage, 5-year median CSM-FS was 43.0% in historical versus 32.8% in contemporary patients (HR:0.78, P = .01). CONCLUSION: TMT rates have increased over time in both OC and NOC patients. Contemporary TMT patients benefit of better cancer-specific survival. Interestingly, this benefit applies equally to OC and NOC TMT-treated patients. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - de Angelis, Mario AU - de Angelis M AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Division of Experimental Oncology/Departmen of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: deangelis.mario@hsr.it. FAU - Scheipner, Lukas AU - Scheipner L AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Medical University of Graz, Graz, Austria. FAU - Siech, Carolin AU - Siech C AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Jannello, Letizia Maria Ippolita AU - Jannello LMI AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Baudo, Andrea AU - Baudo A AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Bello, Francesco Di AU - Bello FD AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, University Hospital, Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Vitucci, Kira AU - Vitucci K AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Longo, Nicola AU - Longo N AD - Department of Urology, University Hospital, Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Ahyai, Sascha AU - Ahyai S AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Carmignani, Luca AU - Carmignani L AD - Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Division of Experimental Oncology/Departmen of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Departmen of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Departmen of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Departmen of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20240510 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/therapy/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - *SEER Program MH - *Carcinoma, Transitional Cell/mortality/therapy/pathology MH - Neoplasm Staging MH - Combined Modality Therapy MH - Cystectomy MH - Aged, 80 and over MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Kaplan-Meier Estimate OTO - NOTNLM OT - Bladder cancer OT - Multimodal treatment OT - Muscle-invasive bladder cancer OT - Organ confined OT - Survival EDAT- 2024/06/10 00:42 MHDA- 2024/06/18 04:22 CRDT- 2024/06/09 18:10 PHST- 2024/01/22 00:00 [received] PHST- 2024/04/08 00:00 [revised] PHST- 2024/05/06 00:00 [accepted] PHST- 2024/06/18 04:22 [medline] PHST- 2024/06/10 00:42 [pubmed] PHST- 2024/06/09 18:10 [entrez] AID - S1558-7673(24)00090-9 [pii] AID - 10.1016/j.clgc.2024.102119 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Aug;22(4):102119. doi: 10.1016/j.clgc.2024.102119. Epub 2024 May 10. PMID- 38848543 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20260318 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 212 IP - 3 DP - 2024 Sep TI - The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer. PG - 420-430 LID - 10.1097/JU.0000000000004070 [doi] AB - PURPOSE: Nonmuscle-invasive bladder cancer (NMIBC) has high recurrence rates and is often treated with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG). Their efficacy relies on phase 2 enzyme metabolism and immune response activation, respectively. Dietary isothiocyanates, phytochemicals in cruciferous vegetables, are phase 2 enzyme inducers and immunomodulators, and may impact treatment outcomes. We investigated the modifying effects of cruciferous vegetable and isothiocyanate intake on recurrence risk following MMC or BCG treatment. MATERIALS AND METHODS: Self-reported cruciferous vegetable intake, estimated isothiocyanate intake, and urinary isothiocyanate metabolites were collected from 1158 patients with incident NMIBC in the prospective Be-Well Study. Hazard ratios (HRs) and 95% CIs were calculated from Cox proportional hazards regression models for risk of first recurrences, and random effects Cox shared frailty models for multiple recurrences. RESULTS: Over median follow-up of 23 months, 343 (30%) recurrences occurred. Receipt of MMC and BCG was associated with decreased risks of first recurrence (MMC: HR = 0.58; 95% CI: 0.46-0.73; BCG: HR = 0.66; 95% CI: 0.49-0.88) and multiple recurrences (MMC: HR = 0.55; 95% CI: 0.44-0.68; BCG: HR = 0.72; 95% CI: 0.55-0.95). Patients receiving BCG and having high intake (>2.4 servings/mo), but not low intake, of raw cruciferous vegetables had reduced risk of recurrence (HR: 0.56; 95% CI: 0.36-0.86; P for interaction = .02) and multiple recurrences (HR: 0.51; 95% CI: 0.34-0.77; P for interaction < .001). The inverse association between MMC receipt and recurrence risk was not modified. CONCLUSIONS: For NMIBC patients who receive induction BCG, increasing consumption of raw cruciferous vegetables could be a promising strategy to attenuate recurrence risk. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Wang, Zinian AU - Wang Z AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Haque, Reina AU - Haque R AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. AD - Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California. FAU - Pratt, Rachel AU - Pratt R AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Goniewicz, Maciej AU - Goniewicz M AD - Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, Downey, California. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente South San Francisco Medical Center, Oakland, California. FAU - Quesenberry, Charles P Jr AU - Quesenberry CP Jr AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Zhang, Yuesheng AU - Zhang Y AD - Department of Pharmacology and Toxicology, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia. FAU - Ambrosone, Christine B AU - Ambrosone CB AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, California. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R01 CA172855/CA/NCI NIH HHS/United States GR - R01 CA257480/CA/NCI NIH HHS/United States GR - U01 CA280991/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20240607 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Isothiocyanates) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - J Urol. 2024 Sep;212(3):429-430. doi: 10.1097/JU.0000000000004086. PMID: 38865686 CIN - J Urol. 2024 Sep;212(3):430. doi: 10.1097/JU.0000000000004108. PMID: 38901040 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - *Mitomycin/therapeutic use MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - *Isothiocyanates/therapeutic use/pharmacology MH - Prospective Studies MH - Aged MH - Middle Aged MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology MH - Treatment Outcome MH - Antibiotics, Antineoplastic/therapeutic use MH - Adjuvants, Immunologic/therapeutic use MH - Diet MH - Neoplasm Invasiveness MH - Follow-Up Studies PMC - PMC11309891 MID - NIHMS1996520 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - cruciferous vegetable OT - isothiocyanate OT - nonmuscle invasive bladder cancer OT - recurrence COIS- Conflicts of Interest None EDAT- 2024/06/07 18:42 MHDA- 2024/08/08 12:43 PMCR- 2025/09/01 CRDT- 2024/06/07 16:33 PHST- 2024/08/08 12:43 [medline] PHST- 2024/06/07 18:42 [pubmed] PHST- 2024/06/07 16:33 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 10.1097/JU.0000000000004070 [doi] PST - ppublish SO - J Urol. 2024 Sep;212(3):420-430. doi: 10.1097/JU.0000000000004070. Epub 2024 Jun 7. PMID- 38846969 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression. PG - 1325157 LID - 10.3389/fonc.2024.1325157 [doi] LID - 1325157 AB - INTRODUCTION: Urothelial Bladder Cancer (BC) is the ninth most common cancer worldwide. It is classified into Non Muscle Invasive (NMIBC) and Muscle Invasive Bladder Cancer (MIBC), which are characterized by frequent recurrences and progression rate, respectively. The diagnosis and monitoring are obtained through invasive methods as cystoscopy and post-surgery biopsies. Thus, a panel of biomarkers able to discriminate BC based on grading or staging represents a significant step forward in the patients' workup. In this perspective, long non-coding RNAs (lncRNAs) are emerged as reliable candidates as potential biomarker given their specific and regulated expression. In the present work we propose two lncRNAs, the Small Ubiquitin Modifier 1 pseudogene 3 (SUMO1P3), a poorly characterized pseudogene, and the Urothelial Carcinoma Associated 1 (UCA1) as candidates to monitor the BC progression. METHODS: This study was a retrospective trial enrolling NMIBC and MIBC patients undergoing surgical intervention: the expression of the lncRNA SUMO1P3 and UCA1 was evaluated in urine from 113 subjects (cases and controls). The receiver operating characteristic curve analysis was used to evaluate the performance of single or combined biomarkers in discriminating cases from controls. RESULTS: SUMO1P3 and UCA1 expression in urine was able to significantly discriminate low grade NMIBC, healthy control and benign prostatic hyperplasia subjects versus high grade NMIBC and MIBC patients. We also demonstrated that miR-320a, which binds SUMO1P3, was reduced in high grade NMIBC and MIBC patients and the SUMO1P3/miR-320a ratio was used to differentiate cases versus controls, showing a statistically significant power. Finally, we provided an automated method of RNA extraction coupled to ddPCR analysis in a perspective of clinical application. DISCUSSION: We have shown that the lncRNA SUMO1P3 is increased in urine from patients with high grade NMIBC and MIBC and that it is likely to be good candidate to predict bladder cancer progression if used alone or in combination with UCA1 or with miRNA320a. CI - Copyright (c) 2024 Galbiati, Bettiga, Colciago, Senti, Trevisani, Villa, Marzinotto, Ghidini, Passalacqua, Montorsi, Salonia and Vago. FAU - Galbiati, Silvia AU - Galbiati S AD - Complications of Diabetes Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Bettiga, Arianna AU - Bettiga A AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Colciago, Giorgia AU - Colciago G AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Senti, Chiara AU - Senti C AD - Oncology Unit, ASST of Cremona, Hospital of Cremona, Cremona, Italy. FAU - Trevisani, Francesco AU - Trevisani F AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Villa, Giulia AU - Villa G AD - Center for Nursing Research and Innovation, Vita-Salute San Raffaele University, Milan, Italy. FAU - Marzinotto, Ilaria AU - Marzinotto I AD - Beta Cell Biology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Ghidini, Michele AU - Ghidini M AD - Oncology Unit, ASST of Cremona, Hospital of Cremona, Cremona, Italy. FAU - Passalacqua, Rodolfo AU - Passalacqua R AD - Oncology Unit, ASST of Cremona, Hospital of Cremona, Cremona, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Faculty of Medicine and Surgery, Universita Vita-Salute San Raffaele, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Faculty of Medicine and Surgery, Universita Vita-Salute San Raffaele, Milan, Italy. FAU - Vago, Riccardo AU - Vago R AD - Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Faculty of Medicine and Surgery, Universita Vita-Salute San Raffaele, Milan, Italy. LA - eng PT - Journal Article DEP - 20240523 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11153750 OTO - NOTNLM OT - SUMO1P3 OT - bladder cancer progression OT - liquid biopsy OT - long non-coding RNA OT - urinary biomarker COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/06/07 06:42 MHDA- 2024/06/07 06:43 PMCR- 2024/01/01 CRDT- 2024/06/07 04:51 PHST- 2023/10/20 00:00 [received] PHST- 2024/05/06 00:00 [accepted] PHST- 2024/06/07 06:43 [medline] PHST- 2024/06/07 06:42 [pubmed] PHST- 2024/06/07 04:51 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1325157 [doi] PST - epublish SO - Front Oncol. 2024 May 23;14:1325157. doi: 10.3389/fonc.2024.1325157. eCollection 2024. PMID- 38846356 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240609 IS - 2689-968X (Electronic) IS - 2689-968X (Linking) VI - 6 IP - 1 DP - 2024 TI - The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers. PG - 1-13 LID - 10.33696/cancerimmunol.6.078 [doi] AB - INTRODUCTION & OBJECTIVE: The role of the microbiome in the development and treatment of genitourinary malignancies is just starting to be appreciated. Accumulating evidence suggests that the microbiome can modulate immunotherapy through signaling in the highly dynamic tumor microenvironment. Nevertheless, much is still unknown about the immuno-oncology-microbiome axis, especially in urologic oncology. The objective of this review is to synthesize our current understanding of the microbiome's role in modulating and predicting immunotherapy response to genitourinary malignancies. METHODS: A literature search for peer-reviewed publications about the microbiome and immunotherapy response in bladder, kidney, and prostate cancer was conducted. All research available in PubMed, Google Scholar, clinicaltrials.gov, and bioRxiv up to September 2023 was analyzed. RESULTS: Significant differences in urinary microbiota composition have been found in patients with genitourinary cancers compared to healthy controls. Lactic acid-producing bacteria, such as Bifidobacterium and Lactobacillus genera, may have value in augmenting BCG responsiveness to bladder cancer. BCG may also be a dynamic regulator of PD-L1. Thus, the combination of BCG and immune checkpoint inhibitors may be an effective strategy for bladder cancer management. In advanced renal cell carcinoma, studies show that recent antibiotic administration negatively impacts survival outcomes in patients undergoing immunotherapy, while administration of CBM588, a live bacterial product, is associated with improved progression-free survival. Specific bacterial taxa, such as Streptococcus salivarius, have been linked with response to pembrolizumab in metastatic castrate-resistant prostate cancer. Fecal microbiota transplant has been shown to overcome resistance and reduce toxicity to immunotherapy; it is currently being investigated for both kidney and prostate cancers. CONCLUSIONS: Although the exact mechanism is unclear, several studies identify a symbiotic relationship between microbiota-centered interventions and immunotherapy efficacy. It is possible to improve immunotherapy responsiveness in genitourinary malignancies using the microbiome, but further research with more standardized methodology is warranted. FAU - Pfail, John AU - Pfail J AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Drobner, Jake AU - Drobner J AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Doppalapudi, Krishna AU - Doppalapudi K AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Saraiya, Biren AU - Saraiya B AD - Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. FAU - Packiam, Vignesh AU - Packiam V AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - J Cancer Immunol (Wilmington) JT - Journal of cancer immunology JID - 101766319 PMC - PMC11156155 MID - NIHMS1989125 OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - Kidney cancer OT - Microbiome OT - Prostate cancer OT - Tumor microenvironment OT - Urologic oncology COIS- Conflict of Interests The authors declare that they have no conflicts of interest. EDAT- 2024/06/07 06:42 MHDA- 2024/06/07 06:43 PMCR- 2024/06/06 CRDT- 2024/06/07 04:43 PHST- 2024/06/07 06:43 [medline] PHST- 2024/06/07 06:42 [pubmed] PHST- 2024/06/07 04:43 [entrez] PHST- 2024/06/06 00:00 [pmc-release] AID - 10.33696/cancerimmunol.6.078 [doi] PST - ppublish SO - J Cancer Immunol (Wilmington). 2024;6(1):1-13. doi: 10.33696/cancerimmunol.6.078. PMID- 38846211 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 5 DP - 2024 May TI - A Clinicopathologic Study of Urinary Bladder Lesions Amongst North Indian Population: An Experience From a Tertiary Care Centre. PG - e59792 LID - 10.7759/cureus.59792 [doi] LID - e59792 AB - BACKGROUND: Urinary bladder cancer (UBC) is amongst the most common urological malignancies. AIM: To study different types of urinary bladder lesions in the north Indian population and to correlate various clinical and pathological findings. MATERIALS AND METHODS: The present prospective study was conducted on 100 cases undergoing transurethral resection of bladder tumor (TURBT) and/or radical cystectomy over a period of 2.5 years followed by histopathological examination. Liquid-based cytology for malignant cells in urine was also performed. Immunohistochemistry was employed for tumor typing wherever needed. RESULTS: A total of 100 cases were studied. Male to female ratio was 15.7:1 and most of the patients were in the sixth decade (40%). Painless hematuria was the commonest clinical presentation (60%) and smoking was the commonest risk factor (80%). The most common lesion was infiltrating urothelial carcinoma seen in 72 cases followed by papillary urothelial neoplasm of low malignant potential (PUNLMP) seen in eight cases. Grade and depth of invasion were assessed and correlated. Several variants of infiltrating urothelial carcinoma such as squamous differentiation, glandular differentiation, microcystic, clear cell, nested, and micropapillary were also identified. Clinical, cystoscopic and histopathological findings were correlated in all the cases. CONCLUSION: Infiltrating urothelial carcinoma high grade was the most common bladder lesion identified and muscle invasion was more common with higher-grade lesions. A decade-younger age group was found to be more affected in the present series. Urine cytology for malignant cells is useful for early diagnosis of cancer. Immunohistochemistry is an important ancillary adjunct. CI - Copyright (c) 2024, Agarwal et al. FAU - Agarwal, Savita AU - Agarwal S AD - Pathology, Uttar Pradesh University of Medical Sciences, Saifai, IND. FAU - Pandey, Pinki AU - Pandey P AD - Pathology, Uttar Pradesh University of Medical Sciences, Saifai, IND. FAU - Ralli, Megha AU - Ralli M AD - Pathology, Post Graduate Institute of Child Health, New Delhi, IND. FAU - Agarwal, Roopak AU - Agarwal R AD - Pathology, Uttar Pradesh University of Medical Sciences, Saifai, IND. FAU - Yadav, Alka AU - Yadav A AD - Pathology, Uttar Pradesh University of Medical Sciences, Saifai, IND. FAU - Dwivedi, Neetu AU - Dwivedi N AD - Pathology, Uttar Pradesh University of Medical Sciences, Saifai, IND. LA - eng PT - Journal Article DEP - 20240507 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11154845 OTO - NOTNLM OT - hematuria OT - infiltrating urothelial carcinoma OT - radical cystectomy OT - smoking OT - turbt OT - urinary bladder COIS- The authors have declared that no competing interests exist. EDAT- 2024/06/07 06:42 MHDA- 2024/06/07 06:43 PMCR- 2024/05/07 CRDT- 2024/06/07 04:41 PHST- 2024/05/07 00:00 [accepted] PHST- 2024/06/07 06:43 [medline] PHST- 2024/06/07 06:42 [pubmed] PHST- 2024/06/07 04:41 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - 10.7759/cureus.59792 [doi] PST - epublish SO - Cureus. 2024 May 7;16(5):e59792. doi: 10.7759/cureus.59792. eCollection 2024 May. PMID- 38838438 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260922 IS - 1936-5233 (Print) IS - 1936-5233 (Electronic) IS - 1936-5233 (Linking) VI - 46 DP - 2024 Aug TI - Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer. PG - 102003 LID - S1936-5233(24)00130-X [pii] LID - 10.1016/j.tranon.2024.102003 [doi] LID - 102003 AB - METHODS: One-hundred-six patients diagnosed with non-muscle invasive bladder cancer and treated with intravesical BCG were included and divided into two groups, BCG-responsive (n = 47) and -unresponsive (n = 59). Immunohistochemistry was used to evaluate PD-L1 expression and MSI was assessed by a commercial multiplex PCR kit. The mRNA expression profile of 15 immune checkpoints was performed using the nCounter technology. For in silico validation, two distinct cohorts sourced from the Gene Expression Omnibus (GEO) database were used. RESULTS: Among the 106 patients, only one (<1 %) exhibited MSI instability. PD-L1 expression was present in 9.4 % of cases, and no association was found with BCG-responsive status. We found low gene expression of canonic actionable immune checkpoints PDCD1 (PD-1), CD274 (PD-L1), and CTLA4, while high expression was observed for CD276 (B7-H3), CD47, TNFRSF14, IDO1 and PVR (CD155) genes. High IDO1 expression levels was associated with worst overall survival. The PDCD1, CTLA4 and TNFRSF14 expression levels were associated with BCG responsiveness, whereas TIGIT and CD276 were associated with unresponsiveness. Finally, CD276 was validated in silico cohorts. CONCLUSION: In NMIBC, MSI is rare and PD-L1 expression is present in a small subset of cases. Expression levels of PDCD1, CTLA4, TNFRSF14, TIGIT and CD276 could constitute predictive biomarkers of BCG responsiveness. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Zucca, Luis Eduardo Rosa AU - Zucca LER AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Instituto do Cancer Brasil, Taubate, Brazil. FAU - Laus, Ana Carolina AU - Laus AC AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. FAU - Sorroche, Bruna Pereira AU - Sorroche BP AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. FAU - Paro, Eduarda AU - Paro E AD - Barretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, Brazil. FAU - Sussuchi, Luciane AU - Sussuchi L AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. FAU - Marques, Rui Ferreira AU - Marques RF AD - Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal. FAU - Teixeira, Gustavo Ramos AU - Teixeira GR AD - Pathology Department, Barretos Cancer Hospital, Barretos, Brazil. FAU - Berardinelli, Gustavo Noriz AU - Berardinelli GN AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. FAU - Arantes, Lidia Maria Rebolho Batista AU - Arantes LMRB AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. FAU - Reis, Rui Manuel AU - Reis RM AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal; 3ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal. FAU - Carcano, Flavio Mavignier AU - Carcano FM AD - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil. Electronic address: flavio.carcano@medicos.oncoclinicas.com. LA - eng PT - Journal Article DEP - 20240604 PL - United States TA - Transl Oncol JT - Translational oncology JID - 101472619 PMC - PMC11214516 OTO - NOTNLM OT - BCG vaccine (2) OT - Gene expression profiling(3) OT - Immunity active(4) OT - Urinary bladder neoplasms(1) COIS- Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/06/06 01:14 MHDA- 2024/06/06 01:15 PMCR- 2024/06/04 CRDT- 2024/06/05 18:02 PHST- 2023/12/22 00:00 [received] PHST- 2024/04/05 00:00 [revised] PHST- 2024/05/19 00:00 [accepted] PHST- 2024/06/06 01:15 [medline] PHST- 2024/06/06 01:14 [pubmed] PHST- 2024/06/05 18:02 [entrez] PHST- 2024/06/04 00:00 [pmc-release] AID - S1936-5233(24)00130-X [pii] AID - 102003 [pii] AID - 10.1016/j.tranon.2024.102003 [doi] PST - ppublish SO - Transl Oncol. 2024 Aug;46:102003. doi: 10.1016/j.tranon.2024.102003. Epub 2024 Jun 4. PMID- 38813272 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240531 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 4 DP - 2024 Apr TI - The Role of Thrombocyte/Lymphocyte Ratio and Aspartate Transaminase/Alanine Transaminase (De Ritis) Ratio in Prediction of Recurrence and Progression in Non-muscle Invasive Bladder Cancer. PG - e59299 LID - 10.7759/cureus.59299 [doi] LID - e59299 AB - AIM: The purpose of the study was to determine the predictive value of platelet-to-lymphocyte ratio (PLR) and Aspartate transaminase (AST)/alanine transaminase (ALT) ratio (De Ritis ratio) for recurrence and progression in non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 231 patients who underwent transurethral tumor resection between 2016 and 2022 were retrospectively analyzed. Preoperative test results, including AST, ALT, platelet, and lymphocyte counts, were used to calculate the PLR and De Ritis ratio. Univariate and multivariate analyses were performed to identify the predictive factors associated with recurrence and progression. RESULTS: Based on the ROC curve, 1.19 and 1.21 were identified as the optimal cut-off values of the De Ritis ratio for recurrence and progression, respectively. Furthermore, PLR cut-off values for recurrence and progression were 114 and 118, respectively. There is a significant difference in recurrence-free survival (RFS) and progression-free survival (PFS) between the groups of patients with high and low De Ritis ratios (p = 0.028 and p = 0.021, respectively). In multivariate analysis, De Ritis ratio >/= 1.19 and European Organization for Research and Treatment of Cancer (EORTC) high recurrence risk were determined to be significant predictors of tumor recurrence. Multivariate analysis also determined that T1 pathological stage, high tumor grade, European Organization for Research and Treatment of Cancer (EORTC) high progression risk, and De Ritis ratio >/= 1.21 were risk factors for tumor progression. CONCLUSION: In our study, the preoperative De Ritis ratio represented an independent predictive factor for recurrence and progression in non-muscle invasive bladder cancer. The use of this biomarker in combination with other diagnostic/predictive tools might help urologists improve the clinical decision-making process in the future. CI - Copyright (c) 2024, Avci et al. FAU - Avci, Mustafa Asim AU - Avci MA AD - Urology, Republic of Turkey Ministry of Health, Bayburt State Hospital, Bayburt, TUR. FAU - Arslan, Burak AU - Arslan B AD - Urology, University of Health Sciences Gaziosmanpasa Training and Research Hospital, Istanbul, TUR. FAU - Arslan, Oyku AU - Arslan O AD - Department of Hematology, Basaksehir Cam and Sakura City Hospital, Istanbul, TUR. FAU - Ozdemir, Enver AU - Ozdemir E AD - Urology, University of Health Sciences Gaziosmanpasa Training and Research Hospital, Istanbul, TUR. LA - eng PT - Journal Article DEP - 20240429 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11135962 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - de ritis ratio OT - nmibc OT - progression OT - recurrence COIS- The authors have declared that no competing interests exist. EDAT- 2024/05/30 06:35 MHDA- 2024/05/30 06:36 PMCR- 2024/04/29 CRDT- 2024/05/30 04:01 PHST- 2024/04/27 00:00 [accepted] PHST- 2024/05/30 06:36 [medline] PHST- 2024/05/30 06:35 [pubmed] PHST- 2024/05/30 04:01 [entrez] PHST- 2024/04/29 00:00 [pmc-release] AID - 10.7759/cureus.59299 [doi] PST - epublish SO - Cureus. 2024 Apr 29;16(4):e59299. doi: 10.7759/cureus.59299. eCollection 2024 Apr. PMID- 38812783 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240917 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. PG - 1341655 LID - 10.3389/fonc.2024.1341655 [doi] LID - 1341655 AB - INTRODUCTION: Bladder preservation with concurrent chemoradiotherapy after maximum transurethral resection of bladder tumor is an alternative to radical cystectomy in select patients with muscle invasive bladder cancer (MIBC). Concurrent administration of radio-sensitizing chemotherapy and radiation therapy (RT) has been shown to have superior disease control compared with RT alone and can often be administered with modest added toxicity. We sought to describe national patterns of chemotherapy use. METHODS: The linked surveillance, epidemiology, and end results (SEER)-Medicare database was used to identify patients with cT2-4, N0/X, M0/X BC who received radiation between 2004 and 2018. Data on demographics, clinicopathologic factors, therapy and outcomes were extracted. Concurrent utilization of chemotherapy with RT was also identified (CRT). Multivariate logistic regression (MVA) models were used to explore factors associated with receipt of chemotherapy and overall survival (OS). RESULTS: 2190 patients met inclusion criteria. Of these, 850 (38.8%) received no chemotherapy. Among those receiving chemotherapy, the most frequent regimens were single agent carboplatin, cisplatin, or gemcitabine. Factors that were independently associated with decreased likelihood of chemotherapy use were increasing age (OR 0.93, CI 0.92 - 0.95), Hispanic race (compared with White, OR 0.62, CI 0.39 - 0.99), cT3 or T4 (compared with cT2, OR 0.70, CI 0.55 - 0.90), and lower National Cancer Institute comorbidity index (OR 0.60, CI 0.51 - 0.70) (p < 0.05). Variables independently associated with increased likelihood of receipt of chemotherapy were married status (OR 1.28, CI 1.06 - 1.54), higher socioeconomic status (OR 1.31, CI 1.06 - 1.64), and later year of diagnosis (OR 1.09, CI 1.06 - 1.12). Receipt of concurrent chemotherapy with RT was associated with superior OS compared with RT alone. CONCLUSION: Over a third of patients >/65 years old receiving curative-intent RT for MIBC do not receive concurrent chemotherapy. Considering the improvement in oncologic outcomes with CRT over RT alone and more options, such as low dose gemcitabine which can be administered with modest toxicity, efforts are needed to identify barriers to utilization and increase the use of radio-sensitizing chemotherapy. CI - Copyright (c) 2024 Ghali, Holt, Koehne, Chen, Weg, Liao, Zeng, Grivas, Hawley, Hsieh, Montgomery and Wright. FAU - Ghali, Fady AU - Ghali F AD - Department of Urology, Yale School of Medicine, New Haven, CT, United States. FAU - Holt, Sarah K AU - Holt SK AD - Department of Urology, University of Washington School of Medicine, Seattle, WA, United States. FAU - Koehne, Elizabeth L AU - Koehne EL AD - Department of Urology, University of Washington School of Medicine, Seattle, WA, United States. FAU - Chen, Jonathan J AU - Chen JJ AD - Division of Radiation Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. FAU - Weg, Emily S AU - Weg ES AD - Division of Radiation Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. FAU - Liao, Jay J AU - Liao JJ AD - Division of Radiation Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. FAU - Zeng, Jing AU - Zeng J AD - Division of Radiation Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. FAU - Grivas, Petros AU - Grivas P AD - Division of Hematology Oncology, Department of Medicine, University of Washington School of medicine, Seattle, WA, United States. AD - Fred Hutchinson Cancer Center, Seattle, WA, United States. FAU - Hawley, Jessica E AU - Hawley JE AD - Division of Hematology Oncology, Department of Medicine, University of Washington School of medicine, Seattle, WA, United States. AD - Fred Hutchinson Cancer Center, Seattle, WA, United States. FAU - Hsieh, Andrew C AU - Hsieh AC AD - Division of Hematology Oncology, Department of Medicine, University of Washington School of medicine, Seattle, WA, United States. AD - Fred Hutchinson Cancer Center, Seattle, WA, United States. FAU - Montgomery, Robert Bruce AU - Montgomery RB AD - Division of Hematology Oncology, Department of Medicine, University of Washington School of medicine, Seattle, WA, United States. AD - Fred Hutchinson Cancer Center, Seattle, WA, United States. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology, University of Washington School of Medicine, Seattle, WA, United States. AD - Fred Hutchinson Cancer Center, Seattle, WA, United States. LA - eng GR - R01 CA276308/CA/NCI NIH HHS/United States GR - R37 CA230617/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20240515 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11133586 OTO - NOTNLM OT - bladder cancer OT - chemotherapy OT - organ-preservation OT - radiation OT - trimodal therapy COIS- Author FG: Consulting - Immunity Bio. Author PG: Consultancy to 4D Pharma, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, PureTech, QED Therapeutics, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen Pharma. Research funding to institution last 2 years: ALX Oncology, Acrivon Therapeutics, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GSK, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, QED Therapeutics. J.Wright: Clinical Trial suport over past 3 years-Merck, BMS, Janssen, Seagen, Nucleix, Pacific Edge. Royalties-UpToDate. Consulting -ImmunityBio, Pacific Edge, The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/05/30 06:35 MHDA- 2024/05/30 06:36 PMCR- 2024/01/01 CRDT- 2024/05/30 03:49 PHST- 2023/11/20 00:00 [received] PHST- 2024/04/08 00:00 [accepted] PHST- 2024/05/30 06:36 [medline] PHST- 2024/05/30 06:35 [pubmed] PHST- 2024/05/30 03:49 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1341655 [doi] PST - epublish SO - Front Oncol. 2024 May 15;14:1341655. doi: 10.3389/fonc.2024.1341655. eCollection 2024. PMID- 38812516 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20260526 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3beta inhibitor enhances antitumor immune response against bladder cancer. PG - 1360436 LID - 10.3389/fimmu.2024.1360436 [doi] LID - 1360436 AB - Bladder cancer is a common type of cancer around the world, and the majority of patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC). Although low-risk NMIBC has a good prognosis, the disease recurrence rate and development of treatment-refractory disease remain high in intermediate- to high-risk NMIBC patients. To address these challenges for the treatment of NMIBC, a novel combination therapy composed of an oncolytic adenovirus (oAd) co-expressing interleukin (IL)-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and relaxin (RLX; HY-oAd) and a clinical-stage glycogen synthase kinase (GSK)-3beta inhibitor (9-ING-41; elraglusib) was investigated in the present report. Our findings demonstrate that HY-oAd and 9-ING-41 combination therapy (HY-oAd+9-ING-41) exerted superior inhibition of tumor growth compared with respective monotherapy in a syngeneic NMIBC tumor model. HY-oAd+9-ING-41 induced high-level tumor extracellular matrix (ECM) degradation and a more potent antitumor immune response than the respective monotherapy. In detail, HY-oAd+9-ING-41 induced superior accumulation of intratumoral T cells, prevention of immune cell exhaustion, and induction of tumor-specific adaptive immune response compared to either monotherapy. Collectively, these results demonstrate that the combination of HY-oAd and 9-ING-41 may be a promising approach to elicit a potent antitumor immune response against bladder cancer. CI - Copyright (c) 2024 Yoon, Jiao, Hong, Kim and Yun. FAU - Yoon, A-Rum AU - Yoon AR AD - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea. AD - Institute of Nano Science and Technology (INST), Hanyang University, Seoul, Republic of Korea. AD - Hanyang Institute of Bioscience and Biotechnology (HY-IBB), Hanyang University, Seoul, Republic of Korea. FAU - Jiao, Ao AU - Jiao A AD - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea. FAU - Hong, JinWoo AU - Hong J AD - GeneMedicine Co., Ltd., Seoul, Republic of Korea. FAU - Kim, Bomi AU - Kim B AD - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea. FAU - Yun, Chae-Ok AU - Yun CO AD - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea. AD - Institute of Nano Science and Technology (INST), Hanyang University, Seoul, Republic of Korea. AD - Hanyang Institute of Bioscience and Biotechnology (HY-IBB), Hanyang University, Seoul, Republic of Korea. AD - GeneMedicine Co., Ltd., Seoul, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240515 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta) SB - IM MH - *Urinary Bladder Neoplasms/therapy/immunology MH - *Tumor Microenvironment/immunology/drug effects MH - Animals MH - *Adenoviridae/genetics MH - *Oncolytic Virotherapy/methods MH - *Oncolytic Viruses/immunology MH - Mice MH - Humans MH - *Glycogen Synthase Kinase 3 beta/antagonists & inhibitors MH - Cell Line, Tumor MH - Combined Modality Therapy MH - Female PMC - PMC11133599 OTO - NOTNLM OT - GSK-3beta inhibitor OT - adenovirus OT - antitumor immune response OT - bladder cancer OT - oncolytic virus COIS- Author JH is an employee of the company GeneMedicine Co., Ltd. C-OY is the CEO of GeneMedicine, Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/05/30 06:35 MHDA- 2024/05/30 06:36 PMCR- 2024/01/01 CRDT- 2024/05/30 03:44 PHST- 2023/12/23 00:00 [received] PHST- 2024/04/29 00:00 [accepted] PHST- 2024/05/30 06:36 [medline] PHST- 2024/05/30 06:35 [pubmed] PHST- 2024/05/30 03:44 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1360436 [doi] PST - epublish SO - Front Immunol. 2024 May 15;15:1360436. doi: 10.3389/fimmu.2024.1360436. eCollection 2024. PMID- 38807901 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240530 IS - 1687-6369 (Print) IS - 1687-6377 (Electronic) IS - 1687-6369 (Linking) VI - 2024 DP - 2024 TI - Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer. PG - 5894288 LID - 10.1155/2024/5894288 [doi] LID - 5894288 AB - BACKGROUND: Although routine surveillance imaging to examine upper urinary tract urothelial cancer recurrence during follow-up of nonmuscle invasive bladder cancer is recommended, its necessity remains invalidated. A single-institute long-term follow-up cohort study to evaluate the clinical impact of routine surveillance imaging and identify risk factors for upper urinary tract urothelial cancer recurrence after nonmuscle invasive bladder cancer treatment was conducted. METHODS AND MATERIALS: A retrospective chart review of 864 patients with primary nonmuscle invasive bladder cancer who underwent initial transurethral resection of bladder tumor between 1980 and 2020 was conducted. The opportunities to diagnose its recurrence were examined. Moreover, oncological outcomes included upper urinary tract urothelial cancer recurrence-free survival and overall survival. RESULTS: Of 864 patients, 19 (2.2%) experienced upper urinary tract urothelial cancer recurrence. Among 19 patients, recurrence was detected through routine imaging in 12 (63.2%), cystoscopy in 2 (10.5%), urine cytology in 2 (10.5%), and presence of gross hematuria in 1 (5.3%). All patients had high- or highest-risk NMIBC at diagnosis of primary nonmuscle invasive bladder cancer. On multivariate Fine-Gray proportional regression analyses, a tumor size of >/=30 mm and carcinoma in situ were independently associated with short upper urinary tract urothelial cancer recurrence-free survival (P=0.040 and 0.0089, respectively). CONCLUSION: Most patients experiencing upper urinary tract urothelial cancer recurrence were diagnosed by routine surveillance imaging, suggesting its clinical importance, especially for patients with nonmuscle invasive bladder cancer accompanied by a tumor size of >/=30 mm and carcinoma in situ. CI - Copyright (c) 2024 Nobutaka Nishimura et al. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. LA - eng PT - Journal Article DEP - 20240521 PL - United States TA - Adv Urol JT - Advances in urology JID - 101476240 PMC - PMC11132829 COIS- The authors declare that they have no conflicts of interest. EDAT- 2024/05/29 06:42 MHDA- 2024/05/29 06:43 PMCR- 2024/05/21 CRDT- 2024/05/29 03:39 PHST- 2024/02/05 00:00 [received] PHST- 2024/04/18 00:00 [revised] PHST- 2024/04/26 00:00 [accepted] PHST- 2024/05/29 06:43 [medline] PHST- 2024/05/29 06:42 [pubmed] PHST- 2024/05/29 03:39 [entrez] PHST- 2024/05/21 00:00 [pmc-release] AID - 10.1155/2024/5894288 [doi] PST - epublish SO - Adv Urol. 2024 May 21;2024:5894288. doi: 10.1155/2024/5894288. eCollection 2024. PMID- 38807772 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240530 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 14 DP - 2024 TI - Neoadjuvant chemotherapy prior to radical cystectomy for non-muscle invasive bladder cancer: national trends and pathologic outcomes. PG - 1392062 LID - 10.3389/fonc.2024.1392062 [doi] LID - 1392062 AB - BACKGROUND: There is a sparsity of literature on treatment outcomes for patients with non-muscle invasive bladder cancer (NMIBC) who received neoadjuvant chemotherapy (NAC). We aim to analyze the outcomes associated with the use of NAC prior to radical cystectomy for NMIBC utilizing the National Cancer Database. MATERIALS/METHODS: The National Cancer Database bladder dataset was evaluated for patients with NMIBC and known pT staging undergoing RC from 2006-2016. The primary outcome was the utilization of NAC. The secondary outcomes were pathologic down staging to pT0, positive surgical margins, 30-day readmission, and overall survival. RESULTS: The proportion of patients receiving NAC prior to radical cystectomy for NMIBC increased from 8.6% in 2006 to 14.8% in 2016. Those who received NAC had significantly higher tumor stages (cT1 vs cTa/is) with 85.7% of patients receiving NAC presenting with cT1 as opposed to only 82% in those not receiving NAC (p < 0.001). Similarly, there were significantly more patients who were cN+ in the NAC group as compared to those who did not receive NAC (5.5% vs. 1.1%, p < 0.001). For patients who received NAC, the rate of downstaging to pT0 was 12.7% as compared to only 3.3% in patients who did not receive NAC (p < 0.001). There was no significant difference comparing the rates of positive margins or 30-day readmissions between groups. On multivariable logistic regression for pathologic downstaging, NAC was significant (OR 4.1, p < 0.05). There was no significant difference in overall survival between patients treated with or without NAC. CONCLUSION: NAC prior to RC in patients with NMIBC has increased in recent years and correlates with tumor downstaging. Further research is requisite to identify patients who obtain the greatest benefit of NAC in the NMIBC setting. CI - Copyright (c) 2024 Davis, Orf, Ballon-Landa and Hamilton. FAU - Davis, Kailey AU - Davis K AD - Division of Urology, Department of Surgery, Saint Louis University, St. Louis, MO, United States. FAU - Orf, Jeffrey AU - Orf J AD - Division of Urology, Department of Surgery, Saint Louis University, St. Louis, MO, United States. FAU - Ballon-Landa, Eric AU - Ballon-Landa E AD - Division of Urology, Department of Surgery, Saint Louis University, St. Louis, MO, United States. FAU - Hamilton, Zachary AU - Hamilton Z AD - Division of Urology, Department of Surgery, Saint Louis University, St. Louis, MO, United States. LA - eng PT - Journal Article DEP - 20240513 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC11131100 OTO - NOTNLM OT - Non-muscle invasive bladder cancer (NMIBC) OT - clinical practice patterns OT - complications OT - neoadjuvant chemotherapy OT - radical cystectomy (RC) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/05/29 06:42 MHDA- 2024/05/29 06:43 PMCR- 2024/01/01 CRDT- 2024/05/29 03:37 PHST- 2024/02/26 00:00 [received] PHST- 2024/04/25 00:00 [accepted] PHST- 2024/05/29 06:43 [medline] PHST- 2024/05/29 06:42 [pubmed] PHST- 2024/05/29 03:37 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2024.1392062 [doi] PST - epublish SO - Front Oncol. 2024 May 13;14:1392062. doi: 10.3389/fonc.2024.1392062. eCollection 2024. PMID- 38802293 OWN - NLM STAT- MEDLINE DCOM- 20240621 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 9 DP - 2024 Sep TI - Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma. PG - 289.e7-289.e12 LID - S1078-1439(24)00465-4 [pii] LID - 10.1016/j.urolonc.2024.05.007 [doi] AB - PURPOSE: To evaluate the efficacy of intravesical (IVe) Bacillus Calmette-Guerin (BCG) to treat non-muscle invasive bladder cancer (NMIBC) recurrences in patients who have previously undergone nephroureterectomy for upper tract urothelial carcinoma (UTUC). METHODS: We performed a single institution retrospective review of patients who underwent nephroureterectomy for UTUC from 2009 to 2021. Patients who subsequently developed NMIBC treated with transurethral resection followed by IVe BCG were included in the study group. A control cohort was formed by retrospective review of patents with primary NMIBC treated with BCG during the same period. Patients in the control cohort were matched by stage of bladder cancer at a 2:1 ratio of control to study subjects. Demographic data, pathology of bladder tumors prior to and following BCG, use of maintenance BCG (mBCG), time to recurrence, time to progression, progression to cystectomy, and progression to metastatic disease were collected on all patients. Descriptive statistics were utilized to compare the 2 groups. The primary outcome was progression to muscle invasive disease. Secondary outcomes included intravesical recurrence free survival, disease free survival, and progression to metastatic disease. Univariable and multivariable logistic regression analysis was performed to elucidate independent variables associated with bladder tumor recurrence. Multivariable Cox regression analysis was used to assess the impact of prior UTUC on time to bladder tumor recurrence. RESULTS: One-hundred and ninety-one patients underwent nephroureterectomy at our institution from 2009 to 2021 for UTUC. Twenty-five patients were identified to have subsequently developed NMIBC recurrences treated with inductions BCG. The control group was comprised of 50 patients with primary NMIBC matched by stage of bladder cancer for which BCG was indicated in the study group. Median (interquartile range [IQR]) follow-up was significantly longer in the control group relative to the study group (64.8 [50.1-85.6] vs 25 months [17-35]; P = 0.001). There were no significant differences in demographics between the study and control groups. The rate of progression to muscle invasive disease was 17% vs 0% in the study group and control group respectively (P = 0.0521). History of UTUC was associated with increased risk of intravesical bladder tumor recurrence post BCG on multivariable analysis (HR 2.5; P = 0.017) and Kaplan Meier survival analysis (P = 0.039). The mean time to bladder tumor recurrence after treatment with BCG was significantly worse in the study group at (7.9 vs. 23.9 months; P = 0.0322). Similarly, the rate of progression to metastatic disease was worse in the study group (24% vs 2%; P = 0.0047). Overall disease-free survival was also noted to be significantly worse on Kaplan Meier survival analysis in the study group (P = 0.0074). No statistically significant differences in the stage grade of bladder tumor recurrence, grade of bladder tumor recurrence, or rate of progression to cystectomy were identified. CONCLUSIONS: Our study suggests reduced efficacy of BCG for NMIBC in patients with a history of UTUC. Patients in this population should be counseled accordingly. Research into alternative treatments for bladder tumor recurrence and more aggressive prophylactic regimens after nephroureterectomy for prevention of bladder tumor recurrence in this population is encouraged. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Massari, Michael AU - Massari M AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. Electronic address: michael.massari@urology.ufl.edu. FAU - O'Malley, Padraic AU - O'Malley P AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. FAU - Benidir, Tarik AU - Benidir T AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. FAU - Su, Li-Ming AU - Su LM AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. FAU - Gao, Hanzhi AU - Gao H AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. FAU - Crispen, Paul L AU - Crispen PL AD - Department of Urology, University of Florida, 1600 SW Archer Road, Room N203, PO Box 100247, Gainesville, FL 32610. LA - eng PT - Journal Article DEP - 20240526 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/surgery/pathology/drug therapy MH - Kidney Neoplasms/surgery/pathology/drug therapy MH - *Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/prevention & control MH - *Nephroureterectomy/methods MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology/surgery MH - Retrospective Studies MH - Treatment Outcome MH - *Ureteral Neoplasms/surgery/pathology/drug therapy OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Bladder tumor recurrence OT - Nephroureterectomy OT - Upper tract OT - Urothelial carcinoma COIS- Declaration of competing interest None of the authors have a conflict of interest with the submitted research. There were no funding sources for the research submitted. All listed authors have contributed significantly to the published research and reviewed the above manuscript. There was no use of artificial intelligence software in the writing or editing of the submitted research. EDAT- 2024/05/28 00:43 MHDA- 2024/06/22 05:43 CRDT- 2024/05/27 21:51 PHST- 2023/10/30 00:00 [received] PHST- 2024/04/17 00:00 [revised] PHST- 2024/05/10 00:00 [accepted] PHST- 2024/06/22 05:43 [medline] PHST- 2024/05/28 00:43 [pubmed] PHST- 2024/05/27 21:51 [entrez] AID - S1078-1439(24)00465-4 [pii] AID - 10.1016/j.urolonc.2024.05.007 [doi] PST - ppublish SO - Urol Oncol. 2024 Sep;42(9):289.e7-289.e12. doi: 10.1016/j.urolonc.2024.05.007. Epub 2024 May 26. PMID- 38788195 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20250108 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 110 IP - 9 DP - 2024 Sep 1 TI - The prognostic impact of tumor location in nonmuscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing Chinese multicenter and SEER registries. PG - 5641-5651 LID - 10.1097/JS9.0000000000001675 [doi] AB - OBJECTIVE: Most bladder cancers are nonmuscle invasive bladder cancer (NMIBC), and transurethral resection of bladder tumors (TURBT) is the standard treatment. However, postoperative recurrence remains a significant challenge, and the influence of bladder tumor location on prognosis is still unclear. This study aims to investigate how tumor location affects the prognosis of NMIBC patients undergoing TURBT and to identify the optimal surgical approach. METHODS: A multicenter study was conducted, which included Chinese NMIBC data from 15 hospitals (1996-2019) and data from 17 registries of the Surveillance, Epidemiology, and End Results database (SEER) (2000-2020). Patients initially diagnosed with NMIBC and undergoing TURBT or partial cystectomy were analyzed, with cases lost to follow-up or with missing data excluded. The study investigated the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) among patients with different tumor locations. Kaplan-Meier, Cox regression, and propensity score matching methods were employed to explore the association between tumor location and prognosis. Stratified populations were analyzed to minimize bias. RESULTS: This study included 118 477 NMIBC patients and highlighted tumor location as a crucial factor impacting post-TURBT prognosis. Both anterior wall and dome tumors independently predicted adverse outcomes in two cohorts. For anterior wall tumors, the Chinese cohort showed hazard ratios (HR) for OS of 4.35 ( P <0.0001); RFS of 2.21 ( P <0.0001); SEER cohort OS HR of 1.10 ( P =0.0001); DSS HR of 1.13 ( P =0.0183). Dome tumors displayed similar trends [Chinese NMIBC cohort OS HR of 7.91 ( P <0.0001); RFS HR of 2.12 ( P <0.0001); SEER OS HR of 1.05 ( P =0.0087); DSS HR of 1.14 ( P =0.0006)]. Partial cystectomy significantly improved the survival of dome tumor patients compared to standard TURBT treatment ( P <0.01). CONCLUSION: This study reveals the significant impact of tumor location in NMIBC patients on the outcomes of TURBT treatment, with tumors in the anterior wall and bladder dome showing poor post-TURBT prognosis. Compared to TURBT treatment, partial cystectomy improves the prognosis for bladder dome tumors. This study provides guidance for personalized treatment and prognosis management for NMIBC patients. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Liu, Lilong AU - Liu L AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Li, Kaiwen AU - Li K AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, Guangdong. FAU - Wang, Shao-Gang AU - Wang SG AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Wang, Jianli AU - Wang J AD - Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei. FAU - Yao, Zhipeng AU - Yao Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Xie, Yu AU - Xie Y AD - Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine of Central South University, Hunan Cancer Hospital, Changsha, Hunan. FAU - Ji, Zhigang AU - Ji Z AD - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. FAU - Chen, Zhiwen AU - Chen Z AD - Department of Urology, The First Affiliated Hospital of the Third Military Medical University, Chongqing. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin. FAU - Chen, Haige AU - Chen H AD - Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai. FAU - Hu, Junyi AU - Hu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Hou, Yaxin AU - Hou Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Liu, Zhenghao AU - Liu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Li, Yang AU - Li Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Ding, Yuhong AU - Ding Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Kuang, Yingchun AU - Kuang Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Xun, Yang AU - Xun Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Hu, Jia AU - Hu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Zhang, Jiaqiao AU - Zhang J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Li, Heng AU - Li H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Chong, Tie AU - Chong T AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi. FAU - Bi, Jianbin AU - Bi J AD - Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning. FAU - Wang, Zhiping AU - Wang Z AD - Clinical Center of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Lanzhou City, Gansu. FAU - Wang, Yinhuai AU - Wang Y AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan. FAU - Chen, Zhaohui AU - Chen Z AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei. FAU - Li, Lei AU - Li L AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, Guangdong. FAU - Liu, Zheng AU - Liu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. FAU - Chen, Ke AU - Chen K AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. CN - Chinese Bladder Cancer Consortium LA - eng SI - ClinicalTrials.gov/NCT06245759 PT - Journal Article PT - Multicenter Study DEP - 20240901 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Cystectomy MH - Prognosis MH - *SEER Program MH - China/epidemiology MH - Cohort Studies MH - Registries MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology/epidemiology MH - Propensity Score MH - East Asian People PMC - PMC11392199 COIS- The authors have no potential conflicts of interest to disclose. EDAT- 2024/05/24 18:43 MHDA- 2024/09/14 10:47 PMCR- 2024/09/12 CRDT- 2024/05/24 16:43 PHST- 2024/02/15 00:00 [received] PHST- 2024/05/10 00:00 [accepted] PHST- 2024/09/14 10:47 [medline] PHST- 2024/05/24 18:43 [pubmed] PHST- 2024/05/24 16:43 [entrez] PHST- 2024/09/12 00:00 [pmc-release] AID - 01279778-202409000-00033 [pii] AID - IJS-D-24-00569 [pii] AID - 10.1097/JS9.0000000000001675 [doi] PST - epublish SO - Int J Surg. 2024 Sep 1;110(9):5641-5651. doi: 10.1097/JS9.0000000000001675. PMID- 38775530 OWN - NLM STAT- MEDLINE DCOM- 20240522 LR - 20260203 IS - 1806-9282 (Electronic) IS - 0104-4230 (Print) IS - 0104-4230 (Linking) VI - 70 IP - 5 DP - 2024 TI - Increased risk of bladder cancer recurrence due to bacillus Calmette-Guerin shortage in Brazil. PG - e20231116 LID - S0104-42302024000500605 [pii] LID - 10.1590/1806-9282.20231116 [doi] LID - e20231116 AB - OBJECTIVE: Our study aimed to evaluate the impact of bacillus Calmette-Guerin shortage on recurrence and progression in patients with non-muscle invasive bladder cancer in a Brazilian cohort. METHODS: We retrospectively reviewed the clinicopathological data of 409 patients who had their first transurethral resection of the bladder tumor for intermediate or high-risk non-muscle invasive bladder cancer between June 2014 and May 2021 in a tertiary public hospital in Brazil. Patients included had non-muscle-invasive urothelial carcinoma of the bladder resected completely for the first time, regardless of bacillus Calmette-Guerin use. Low-risk disease patients were excluded from the analysis. Demographic, clinicopathological, and bacillus Calmette-Guerin use data were collected from our database. Recurrence and progression data were obtained from patient records or through telephone interviews. Recurrence-free survival and progression-free survival were calculated from the date of transurethral resection of the bladder tumor until the events of recurrence, progression, last office visit, or phone interview. RESULTS: Within a median follow-up period of 26.7 months, 168 (41.1%) patients experienced a recurrence in a median time of 27 months (95%CI 16.1-38). Bacillus Calmette-Guerin was administered to 57 (13.9%) individuals after transurethral resection of the bladder tumor. Patients with >/=3 lesions (p<0.001), those with lesions >3 cm (p=0.02), and those without bacillus Calmette-Guerin treatment (p<0.001) had shorter recurrence-free survival. According to a Cox multivariate regression model, bacillus Calmette-Guerin use was independently associated with a reduced recurrence rate, with an HR of 0.43 (95%CI 0.25-0.72). Out of the patients studied, 26 (6.4%) experienced progression. T1 stage (p<0.001) and high-grade (p<0.001) were associated with shorter progression-free survival. Bacillus Calmette-Guerin did not influence bladder cancer progression. In the Cox multivariate analysis, high-risk disease was independently associated with progression (p<0.001). CONCLUSION: Our study confirms that non-muscle invasive bladder cancer exhibits a high recurrence rate. The use of adjuvant bacillus Calmette-Guerin in intermediate and high-risk patients significantly reduces this rate. Furthermore, the bacillus Calmette-Guerin shortage could have negatively impacted these patients. FAU - Murta, Claudio Bovolenta AU - Murta CB AUID- ORCID: 0000-0001-7813-7128 AD - Instituto do Cancer do Estado de Sao Paulo, Department of Urology - Sao Paulo (SP), Brazil. AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. FAU - Hayek, Kayann Kaled Reda El AU - Hayek KKRE AUID- ORCID: 0000-0002-3262-4550 AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. FAU - Dias, Bruno Cesar AU - Dias BC AUID- ORCID: 0009-0000-6680-2119 AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. FAU - Yorioka, Marco Aurelio Watanabe AU - Yorioka MAW AUID- ORCID: 0000-0001-7899-5827 AD - Instituto do Cancer do Estado de Sao Paulo, Department of Urology - Sao Paulo (SP), Brazil. AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. FAU - Cassao, Valter DellAcqua AU - Cassao VD AUID- ORCID: 0000-0003-4994-9164 AD - Instituto do Cancer do Estado de Sao Paulo, Department of Urology - Sao Paulo (SP), Brazil. AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. FAU - Claro, Joaquim Francisco de Almeida AU - Claro JFA AUID- ORCID: 0000-0002-6307-7342 AD - Hospital Brigadeiro, Men's Health Centre, Division of Urology - Sao Paulo (SP), Brazil. LA - eng PT - Journal Article DEP - 20240517 PL - Brazil TA - Rev Assoc Med Bras (1992) JT - Revista da Associacao Medica Brasileira (1992) JID - 9308586 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Male MH - *BCG Vaccine/therapeutic use MH - Female MH - Retrospective Studies MH - *Neoplasm Recurrence, Local MH - Brazil/epidemiology MH - Aged MH - Middle Aged MH - Risk Factors MH - Adjuvants, Immunologic/therapeutic use MH - Disease Progression MH - Administration, Intravesical MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/surgery PMC - PMC11101183 COIS- Conflicts of interest: the authors declare there is no conflicts of interest. EDAT- 2024/05/22 12:43 MHDA- 2024/05/22 12:44 PMCR- 2024/05/17 CRDT- 2024/05/22 09:13 PHST- 2023/12/17 00:00 [received] PHST- 2024/01/19 00:00 [accepted] PHST- 2024/05/22 12:44 [medline] PHST- 2024/05/22 12:43 [pubmed] PHST- 2024/05/22 09:13 [entrez] PHST- 2024/05/17 00:00 [pmc-release] AID - S0104-42302024000500605 [pii] AID - 10.1590/1806-9282.20231116 [doi] PST - epublish SO - Rev Assoc Med Bras (1992). 2024 May 17;70(5):e20231116. doi: 10.1590/1806-9282.20231116. eCollection 2024. PMID- 38774951 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 2 DP - 2024 Aug TI - Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment? PG - 195-197 LID - 10.1111/bju.16406 [doi] FAU - Finocchiaro, Alessio AU - Finocchiaro A AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AUID- ORCID: 0000-0002-8456-6495 AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Science, Humanitas University, Milan, Italy. AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, IRCCS - Humanitas Research Hospital, Milan, Italy. LA - eng PT - Journal Article DEP - 20240522 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology MH - *Neoplasm Recurrence, Local MH - Risk Assessment MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Cystectomy/methods MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - active surveillance OT - cost-effectiveness OT - high-grade recurrence OT - in-office fulguration OT - low-grade pTa OT - non-muscle-invasive bladder cancer OT - upgrade rate EDAT- 2024/05/22 06:42 MHDA- 2024/07/18 00:42 CRDT- 2024/05/22 03:55 PHST- 2024/07/18 00:42 [medline] PHST- 2024/05/22 06:42 [pubmed] PHST- 2024/05/22 03:55 [entrez] AID - 10.1111/bju.16406 [doi] PST - ppublish SO - BJU Int. 2024 Aug;134(2):195-197. doi: 10.1111/bju.16406. Epub 2024 May 22. PMID- 38757774 OWN - NLM STAT- MEDLINE DCOM- 20240725 LR - 20240725 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 76 IP - 4 DP - 2024 Aug TI - The impact of purified protein derivative prior to intravesical bacillus Calmette-Guerin for the treatment of patients with non-muscle invasive bladder cancer. PG - 474-483 LID - 10.23736/S2724-6051.23.05515-5 [doi] AB - BACKGROUND: The aim of this study is to investigate the impact of the intradermal injection of purified protein derivative (PPD) and PPD skin test reactions on the oncological outcomes of patients with non-muscle invasive bladder cancer (NMIBC) treated by trans-urethral resection of bladder tumor (TURBT) and adjuvant intravesical BCG. METHODS: The study included 100 consecutive patients with NMIBC prospectively given intradermal PPD 1-2 weeks before starting BCG therapy. Another 100 patients with NMIBC not given intradermal PPD before starting BCG were chosen as a historical control. The control group was chosen to be matching with the study group regarding baseline characteristics. The study group was divided into 2 subgroups with positive and negative reaction to PPD skin test. Oncological outcomes, immunological markers (TNF-alpha and IL-6) changes and BCG side effects were evaluated. RESULTS: There were no significant differences between patients who received PPD or not regarding the 2-year recurrence free survival (RFS) rates and progression-free survival (PFS) rates and immunological markers changes. The 2-year RFS and PFS rates were significantly higher in patients with positive reactions. Post-induction values of immunological markers increased in all patients with a significant increase in patients with positive reactions. BCG side effects were significantly higher in patients with positive reactions. CONCLUSIONS: The intradermal injection of PPD before intravesical BCG has no impact on oncological outcomes of patients with NMIBC treated with TURBT and intravesical BCG. However, the PPD skin test reactions before BCG therapy can predict the oncological outcomes, BCG side effects and the immunological outcomes of patients. FAU - Zawky, Mohamed AU - Zawky M AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt - mohamedzawky@yahoo.com. FAU - Elsayed, Asmaa AU - Elsayed A AD - Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. AD - Genetics Research Unit, Faculty of Medicine, Delta University for Science ad Technology, Gamasa, Egypt. FAU - Awadallah, Amira AU - Awadallah A AD - Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abdelhalim, Ahmed AU - Abdelhalim A AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. AD - Department of Urology, West Virginia University, Morgantown, WV, USA. FAU - Abolenein, Hassan AU - Abolenein H AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. AD - Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed AU - Shokeir A AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. AD - Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20240517 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Tuberculin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/immunology/pathology MH - *BCG Vaccine/therapeutic use/administration & dosage/immunology MH - Male MH - Female MH - Administration, Intravesical MH - Aged MH - Middle Aged MH - Prospective Studies MH - Adjuvants, Immunologic/administration & dosage/therapeutic use/pharmacology/adverse effects MH - Neoplasm Invasiveness MH - Tuberculin/immunology/administration & dosage MH - Injections, Intradermal MH - Treatment Outcome MH - Non-Muscle Invasive Bladder Neoplasms EDAT- 2024/05/17 12:44 MHDA- 2024/07/26 12:42 CRDT- 2024/05/17 08:15 PHST- 2024/07/26 12:42 [medline] PHST- 2024/05/17 12:44 [pubmed] PHST- 2024/05/17 08:15 [entrez] AID - S2724-6051.23.05515-5 [pii] AID - 10.23736/S2724-6051.23.05515-5 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2024 Aug;76(4):474-483. doi: 10.23736/S2724-6051.23.05515-5. Epub 2024 May 17. PMID- 38754471 OWN - NLM STAT- MEDLINE DCOM- 20240516 LR - 20260127 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 22 IP - 4 DP - 2024 May TI - NCCN Guidelines(R) Insights: Bladder Cancer, Version 3.2024. PG - 216-225 LID - 10.6004/jnccn.2024.0024 [doi] AB - Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non-muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guerin (BCG)-unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease. FAU - Flaig, Thomas W AU - Flaig TW AD - 1University of Colorado Cancer Center. FAU - Spiess, Philippe E AU - Spiess PE AD - 2Moffitt Cancer Center. FAU - Abern, Michael AU - Abern M AD - 3Duke Cancer Institute. FAU - Agarwal, Neeraj AU - Agarwal N AD - 4Huntsman Cancer Institute at the University of Utah. FAU - Bangs, Rick AU - Bangs R AD - 5Patient Advocate. FAU - Buyyounouski, Mark K AU - Buyyounouski MK AD - 6Stanford Cancer Institute. FAU - Chan, Kevin AU - Chan K AD - 7City of Hope National Medical Center. FAU - Chang, Sam S AU - Chang SS AD - 8Vanderbilt-Ingram Cancer Center. FAU - Chang, Paul AU - Chang P AD - 9The UChicago Medicine Comprehensive Cancer Center. FAU - Friedlander, Terence AU - Friedlander T AD - 10UCSF Helen Diller Family Comprehensive Cancer Center. FAU - Greenberg, Richard E AU - Greenberg RE AD - 11Fox Chase Cancer Center. FAU - Guru, Khurshid A AU - Guru KA AD - 12Roswell Park Comprehensive Cancer Center. FAU - Herr, Harry W AU - Herr HW AD - 13Memorial Sloan Kettering Cancer Center. FAU - Hoffman-Censits, Jean AU - Hoffman-Censits J AD - 14The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. FAU - Kaimakliotis, Hristos AU - Kaimakliotis H AD - 15Indiana University Melvin and Bren Simon Comprehensive Cancer Center. FAU - Kishan, Amar U AU - Kishan AU AD - 16UCLA Jonsson Comprehensive Cancer Center. FAU - Kundu, Shilajit AU - Kundu S AD - 17Robert H. Lurie Comprehensive Cancer Center of Northwestern University. FAU - Lele, Subodh M AU - Lele SM AD - 18Fred & Pamela Buffett Cancer Center. FAU - Mamtani, Ronac AU - Mamtani R AD - 19Abramson Cancer Center at the University of Pennsylvania. FAU - Mian, Omar Y AU - Mian OY AD - 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute. FAU - Michalski, Jeff AU - Michalski J AD - 21Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. FAU - Montgomery, Jeffrey S AU - Montgomery JS AD - 22University of Michigan Rogel Cancer Center. FAU - Parikh, Mamta AU - Parikh M AD - 23UC Davis Comprehensive Cancer Center. FAU - Patterson, Anthony AU - Patterson A AD - 24St. Jude Children's Research Hospital/The University of Tennessee Health Science Center. FAU - Peyton, Charles AU - Peyton C AD - 25O'Neal Comprehensive Cancer Center at UAB. FAU - Plimack, Elizabeth R AU - Plimack ER AD - 11Fox Chase Cancer Center. FAU - Preston, Mark A AU - Preston MA AD - 26Dana-Farber/Brigham and Women's Cancer Center. FAU - Richards, Kyle AU - Richards K AD - 27University of Wisconsin Carbone Cancer Center. FAU - Sexton, Wade J AU - Sexton WJ AD - 2Moffitt Cancer Center. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - 28The University of Texas MD Anderson Cancer Center. FAU - Stewart, Tyler AU - Stewart T AD - 29UC San Diego Moores Cancer Center. FAU - Sundi, Debasish AU - Sundi D AD - 30The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. FAU - Tollefson, Matthew AU - Tollefson M AD - 31Mayo Clinic Comprehensive Cancer Center. FAU - Tward, Jonathan AU - Tward J AD - 4Huntsman Cancer Institute at the University of Utah. FAU - Wright, Jonathan L AU - Wright JL AD - 32Fred Hutchinson Cancer Center. FAU - Cassara, Carly J AU - Cassara CJ AD - 33National Comprehensive Cancer Network. FAU - Gurski, Lisa A AU - Gurski LA AD - 33National Comprehensive Cancer Network. LA - eng PT - Journal Article PT - Practice Guideline PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/diagnosis/pathology MH - Male MH - Neoplasm Staging MH - BCG Vaccine/therapeutic use EDAT- 2024/05/17 00:43 MHDA- 2024/05/17 00:44 CRDT- 2024/05/16 19:05 PHST- 2024/05/17 00:44 [medline] PHST- 2024/05/17 00:43 [pubmed] PHST- 2024/05/16 19:05 [entrez] AID - 10.6004/jnccn.2024.0024 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024. PMID- 38736621 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240515 IS - 2330-1910 (Print) IS - 2330-1910 (Electronic) IS - 2330-1910 (Linking) VI - 12 IP - 2 DP - 2024 TI - The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer. PG - 88-99 LID - 10.62347/MEQO6014 [doi] AB - Sex-determining region Y-box 2 (SOX2) is a transcription factor with a central role in embryologic development. SOX2 is also an oncogene in several cancer types. Prior work by our group has shown SOX2 activity associates with cell cycle dysregulation in early-stage bladder cancer. The present study was thus undertaken to broadly investigate SOX2 in bladder cancer, with emphasis on associations with tumor stage, clinical outcomes, and tumorigenicity. Gene expression was quantified by immunohistochemistry in an established tissue microarray (n=303 cystectomy specimens, all stages) and whole tissue sections of noninvasive papillary urothelial carcinoma (n=25). Gene expression by RNA sequencing was evaluated in non-muscle invasive and muscle-invasive cohorts from publicly available repositories. By immunohistochemistry, SOX2 was expressed in 40% of whole tissue sections of noninvasive papillary carcinoma, which correlated with SOX2 expression by RNA sequencing (r=0.6, P=0.001, Spearman correlation). Expression tended to be focal (median H-score =6). SOX2 was expressed in only 9% of TMA cases, consistent with focal expression. SOX2 expression was substantially higher in muscle-invasive compared with noninvasive papillary urothelial carcinoma by RNA sequencing (P<0.001, Wilcoxon rank sum test). SOX2 expression associated with stage progression in lamina-propria invasive cancers (hazard ratio =2, P=0.05, Cox model, binary, RNA sequencing) but not noninvasive papillary cancers (P=0.5, Cox model, binary, RNA sequencing). SOX2 expression did not associate with overall survival in muscle-invasive carcinoma. Activity of SOX2 in bladder cancer was tested in vivo using murine allografts created with MB49 cells that express human SOX2 (MB49-SOX). MB49-SOX allografts expressed this protein focally by immunohistochemistry, much like human tumors. Compared with controls, MB49 allografts demonstrated larger tumor size (P=0.03, Wilcoxon rank sum test) and higher tumor burden in mesenteric metastases (P=0.009, Wilcoxon rank sum test). Though SOX2 expression is focal within tumors, it may drive tumorigenesis, increase growth rate, and promote aggressive features of bladder cancer, particularly stage progression of early-stage disease. CI - AJCEU Copyright (c) 2024. FAU - Griffin, Rachel L AU - Griffin RL AD - Department of Comparative Medicine, Penn State College of Medicine Hershey, PA, USA. FAU - Shuman, Lauren AU - Shuman L AD - Department of Urology, Penn State College of Medicine Hershey, PA, USA. FAU - Yamashita, Hironobu AU - Yamashita H AD - Department of Urology, Penn State College of Medicine Hershey, PA, USA. FAU - Wu, Qingqing AU - Wu Q AD - Department of Pathology, Penn State College of Medicine Hershey, PA, USA. FAU - Chen, Guoli AU - Chen G AD - Department of Pathology, Penn State College of Medicine Hershey, PA, USA. FAU - Brown, Ryan M AU - Brown RM AD - Department of Pathology, University of Illinois at Chicago Chicago, IL, USA. FAU - Vander Griend, Don AU - Vander Griend D AD - Department of Pathology, University of Illinois at Chicago Chicago, IL, USA. FAU - DeGraff, David J AU - DeGraff DJ AD - Department of Urology, Penn State College of Medicine Hershey, PA, USA. AD - Department of Pathology, Penn State College of Medicine Hershey, PA, USA. FAU - Warrick, Joshua I AU - Warrick JI AD - Department of Urology, Penn State College of Medicine Hershey, PA, USA. AD - Department of Pathology, Penn State College of Medicine Hershey, PA, USA. LA - eng GR - R21 CA259102/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20240415 PL - United States TA - Am J Clin Exp Urol JT - American journal of clinical and experimental urology JID - 101634566 PMC - PMC11087210 OTO - NOTNLM OT - Bladder cancer OT - SOX2 OT - non-muscle invasive OT - sex-determining region Y-box 2 OT - urothelial carcinoma COIS- None. EDAT- 2024/05/13 06:42 MHDA- 2024/05/13 06:43 PMCR- 2024/04/15 CRDT- 2024/05/13 03:58 PHST- 2023/10/25 00:00 [received] PHST- 2024/04/11 00:00 [accepted] PHST- 2024/05/13 06:43 [medline] PHST- 2024/05/13 06:42 [pubmed] PHST- 2024/05/13 03:58 [entrez] PHST- 2024/04/15 00:00 [pmc-release] AID - 10.62347/MEQO6014 [doi] PST - epublish SO - Am J Clin Exp Urol. 2024 Apr 15;12(2):88-99. doi: 10.62347/MEQO6014. eCollection 2024. PMID- 38735433 OWN - NLM STAT- MEDLINE DCOM- 20241003 LR - 20260209 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 48 IP - 8 DP - 2024 Oct TI - Use of Bladder Epicheck(R) in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review. PG - 555-564 LID - S2173-5786(24)00064-7 [pii] LID - 10.1016/j.acuroe.2024.05.004 [doi] AB - INTRODUCTION: In recent years, different urinary markers such as the Bladder Epicheck(R) have been developed in an attempt to reduce the number of cystoscopies in the follow-up of non-muscle invasive bladder cancer (NMIBC). AIM: To provide a systematic review of Bladder Epicheck(R) and its current clinical utility in the follow-up and detection of recurrence of NMIBC. MATERIAL AND METHODS: Systematic review based on a literature search of PubMed, Web of Science and Scopus databases until October 2023, according to PRISMA and Quadas-2 criteria. Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of the marker were calculated. Diagnostic performance was evaluated by the area under the curve (AUC). RESULTS: Fifteen studies were analyzed (n = 3761) including 86.7% prospective studies. Of the patient series, 53.2% had received previous intravesical instillations. The mean Se of the biomarker in the detection of recurrence varied according to tumor grade (87.9%-high grade/HG vs. 44.9%-low grade/LG, respectively). Their weighted mean Se and Sp were 71.6% and 84.5%, respectively. The mean recurrence rate was 29.1%. The weighted mean PPV and NPV were 56.4% and 92.8% (97.7% non-LG), respectively. The mean AUC was 85.63%. CONCLUSION: Bladder Epicheck(R) is a useful urinary marker in the follow-up of NMIBC, with significantly high Se and NPV in the detection of recurrences, especially in cases of HG disease. Its use can reduce the number of cystoscopies required in the follow-up of NMIBC, improving the quality of life of patients and potentially increasing health economic savings. CI - Copyright (c) 2024 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Cano Velasco, J AU - Cano Velasco J AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. Electronic address: jorge.cano@salud.madrid.org. FAU - Artero Fullana, S AU - Artero Fullana S AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Polanco Pujol, L AU - Polanco Pujol L AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Lafuente Puentedura, A AU - Lafuente Puentedura A AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Subiela, J D AU - Subiela JD AD - Servicio de Urologia, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Aragon Chamizo, J AU - Aragon Chamizo J AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Moralejo Garate, M AU - Moralejo Garate M AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Hernandez Fernandez, C AU - Hernandez Fernandez C AD - Servicio de Urologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Systematic Review DEP - 20240510 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Biomarkers, Tumor) SB - IM MH - *Urinary Bladder Neoplasms/pathology/urine/diagnosis MH - Humans MH - *Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local MH - Follow-Up Studies MH - Biomarkers, Tumor/urine MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Biomarcador urinario OT - Bladder Epicheck(R) OT - Bladder cancer OT - Cistoscopia OT - Cystoscopy OT - Cancer de vejiga OT - Follow-up OT - Seguimiento OT - Urinary biomarker EDAT- 2024/05/13 00:42 MHDA- 2024/10/04 00:42 CRDT- 2024/05/12 19:24 PHST- 2023/12/16 00:00 [received] PHST- 2024/02/19 00:00 [accepted] PHST- 2024/10/04 00:42 [medline] PHST- 2024/05/13 00:42 [pubmed] PHST- 2024/05/12 19:24 [entrez] AID - S2173-5786(24)00064-7 [pii] AID - 10.1016/j.acuroe.2024.05.004 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2024 Oct;48(8):555-564. doi: 10.1016/j.acuroe.2024.05.004. Epub 2024 May 10. PMID- 38734774 OWN - NLM STAT- MEDLINE DCOM- 20240511 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 May 11 TI - Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols. PG - 315 LID - 10.1007/s00345-024-04992-5 [doi] AB - INTRODUCTION: The combination of sequential intravesical gemcitabine and docetaxel (Gem/Doce) chemotherapy has been considered a feasible option for BCG (Bacillus Calmette-Guerin) treatment in non-muscle invasive bladder cancer (NMIBC), gaining popularity during BCG shortage period. We seek to determine the efficacy of the treatment by comparing Gem/Doce induction alone vs induction with maintenance, and to evaluate the treatment outcomes of two different dosage protocols. METHODS: A bi-center retrospective analysis of consecutive patients treated with Gem/Doce for NMIBC between 2018 and 2023 was performed. Baseline characteristics, risk group stratification (AUA 2020 guidelines), pathological, and surveillance reports were collected. Kaplan-Meier survival analysis was performed to detect Recurrence-free survival (RFS). RESULTS: Overall, 83 patients (68 males, 15 females) with a median age of 73 (IQR 66-79), and a median follow-up time of 18 months (IQR 9-25), were included. Forty-one had an intermediate-risk disease (49%) and 42 had a high-risk disease (51%). Thirty-seven patients (45%) had a recurrence; 19 (23%) had a high-grade recurrence. RFS of Gem/Doce induction-only vs induction + maintenance was at 6 months 88% vs 100%, at 12 months 71% vs 97%, at 18 months 57% vs 91%, and at 24 months 31% vs 87%, respectively (log-rank, p < 0.0001). Patients who received 2 g Gemcitabine with Docetaxel had better RFS for all-grade recurrences (log-rank, p = 0.017). However, no difference was found for high-grade recurrences. CONCLUSION: Gem/Doce induction with maintenance resulted in significantly better RFS than induction-only. Combining 2 g gemcitabine with docetaxel resulted in better RFS for all-grade but not for high-grade recurrences. Further prospective trials are necessary to validate our results. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ben-David, Reuben AU - Ben-David R AUID- ORCID: 0000-0001-7946-7145 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. reuben.bendavid@mountsinai.org. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. reuben.bendavid@mountsinai.org. FAU - Tillu, Neeraja AU - Tillu N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. FAU - Alerasool, Parissa AU - Alerasool P AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. AD - School of Medicine, New York Medical College, Valhalla, NY, USA. FAU - Bieber, Christine AU - Bieber C AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. FAU - Ranti, Daniel AU - Ranti D AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. FAU - Tolani, Serena AU - Tolani S AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. FAU - Eisenhauer, Justin AU - Eisenhauer J AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. FAU - Chung, Rainjade AU - Chung R AD - Department of Urology, Columbia University Irving Medical Center, New York, NY, USA. FAU - Lavallee, Etienne AU - Lavallee E AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. FAU - Waingankar, Nikhil AU - Waingankar N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Columbia University Irving Medical Center, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, The Milton and Carroll Petrie, New York, NY, USA. AD - Department of Urology, Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, 1425 Madison Avenue, New York, NY, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240511 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Administration, Intravesical MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - *Docetaxel/administration & dosage MH - Dose-Response Relationship, Drug MH - *Gemcitabine MH - Induction Chemotherapy/methods MH - Maintenance Chemotherapy/methods MH - *Neoplasm Invasiveness MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy MH - Retrospective Studies MH - Risk Assessment MH - Treatment Outcome OTO - NOTNLM OT - Intravesical drug administration OT - Non-muscle invasive bladder neoplasms OT - Urinary bladder neoplasms EDAT- 2024/05/12 00:44 MHDA- 2024/05/12 00:45 CRDT- 2024/05/11 23:27 PHST- 2023/10/25 00:00 [received] PHST- 2024/04/11 00:00 [accepted] PHST- 2024/05/12 00:45 [medline] PHST- 2024/05/12 00:44 [pubmed] PHST- 2024/05/11 23:27 [entrez] AID - 10.1007/s00345-024-04992-5 [pii] AID - 10.1007/s00345-024-04992-5 [doi] PST - epublish SO - World J Urol. 2024 May 11;42(1):315. doi: 10.1007/s00345-024-04992-5. PMID- 38732167 OWN - NLM STAT- MEDLINE DCOM- 20240511 LR - 20260923 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 9 DP - 2024 May 1 TI - Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration. LID - 10.3390/ijms25094945 [doi] LID - 4945 AB - Bladder cancer (BC) presents a significant global health burden, characterized by high recurrence rates post-initial treatment. Gender differences in BC prevalence and response to therapy emphasize the importance of personalized treatment strategies. While Bacillus Calmette-Guerin (BCG) remains a cornerstone of BC therapy, resistance poses a challenge, necessitating alternative strategies. Immune checkpoint inhibitors (ICIs) have shown promise, yet systemic toxicity raises concern. Intravesical administration of ICIs offers a potential solution, with recent studies demonstrating the feasibility and efficacy of intravesical pembrolizumab. Although systemic toxicity remains a concern, its localized administration may mitigate adverse events. Additionally, liposomal delivery of ICIs exhibits promises in enhancing drug penetration and reducing toxicity. Novel imaging modalities compatible with Vesical Imaging-Reporting and Data System (VI-RADS) and capable of predicting high-grade bladder cancer can aid the pre-operative shared decision making of patient and surgeon. Future research should focus on refining treatment approaches, optimizing dosing regimens, and leveraging advanced imaging techniques to improve patient outcomes. In conclusion, intravesical immunotherapy presents a promising avenue for BC treatment, offering enhanced therapeutic effectiveness while minimizing systemic toxicity. Continued research efforts are essential to validate these findings and optimize intravesical immunotherapy's role in BC management, ultimately improving patient outcomes. FAU - Tyagi, Pradeep AU - Tyagi P AUID- ORCID: 0000-0001-6586-4545 AD - Departments of Urology, University of Pittsburgh, Pittsburgh, PA 15260, USA. FAU - Hafron, Jason AU - Hafron J AD - Michigan Institute of Urology, Troy, MI 48084, USA. FAU - Kaufman, Jonathan AU - Kaufman J AD - Lipella Pharmaceuticals, Inc., Pittsburgh, PA 15208, USA. FAU - Chancellor, Michael AU - Chancellor M AUID- ORCID: 0000-0001-9480-8972 AD - Lipella Pharmaceuticals, Inc., Pittsburgh, PA 15208, USA. LA - eng GR - R21 CA263243/CA/NCI NIH HHS/United States GR - R41 DK108397/DK/NIDDK NIH HHS/United States GR - R42 DK108397/DK/NIDDK NIH HHS/United States GR - R44 DK108397/DK/NIDDK NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Review DEP - 20240501 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy MH - *Immune Checkpoint Inhibitors/therapeutic use/administration & dosage/adverse effects MH - Administration, Intravesical MH - Immunotherapy/methods MH - Treatment Outcome PMC - PMC11084450 OTO - NOTNLM OT - MRI OT - PD1 OT - bladder cancer OT - checkpoint inhibitor OT - drug delivery OT - liposome COIS- P.T. and J.H. are consultants to Lipella, J.K. and M.C. are employees of Lipella Pharmaceuticals, Inc. EDAT- 2024/05/11 19:44 MHDA- 2024/05/11 19:45 PMCR- 2024/05/01 CRDT- 2024/05/11 01:10 PHST- 2024/03/19 00:00 [received] PHST- 2024/04/26 00:00 [revised] PHST- 2024/04/30 00:00 [accepted] PHST- 2024/05/11 19:45 [medline] PHST- 2024/05/11 19:44 [pubmed] PHST- 2024/05/11 01:10 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - ijms25094945 [pii] AID - ijms-25-04945 [pii] AID - 10.3390/ijms25094945 [doi] PST - epublish SO - Int J Mol Sci. 2024 May 1;25(9):4945. doi: 10.3390/ijms25094945. PMID- 38731992 OWN - NLM STAT- MEDLINE DCOM- 20240511 LR - 20240513 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 9 DP - 2024 Apr 27 TI - Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy. LID - 10.3390/ijms25094776 [doi] LID - 4776 AB - Non-muscle-invasive papillary urothelial carcinoma (NMIPUC) of the urinary bladder is the most common type of bladder cancer. Intravesical Bacille Calmette-Guerin (BCG) immunotherapy is applied in patients with a high risk of recurrence and progression of NMIPUC to muscle-invasive disease. However, the tumor relapses in about 30% of patients despite the treatment, raising the need for better risk stratification. We explored the potential of spatial distributions of immune cell subtypes (CD20, CD11c, CD163, ICOS, and CD8) within the tumor microenvironment to predict NMIPUC recurrence following BCG immunotherapy. Based on analyses of digital whole-slide images, we assessed the densities of the immune cells in the epithelial-stromal interface zone compartments and their distribution, represented by an epithelial-stromal interface density ratio (IDR). While the densities of any cell type did not predict recurrence, a higher IDR of CD11c (HR: 0.0012, p-value = 0.0002), CD8 (HR: 0.0379, p-value = 0.005), and ICOS (HR: 0.0768, p-value = 0.0388) was associated with longer recurrence-free survival (RFS) based on the univariate Cox regression. The history of positive repeated TUR (re-TUR) (HR: 4.93, p-value = 0.0001) and T1 tumor stage (HR: 2.04, p-value = 0.0159) were associated with shorter RFS, while G3 tumor grade according to the 1973 WHO classification showed borderline significance (HR: 1.83, p-value = 0.0522). In a multivariate analysis, the two models with a concordance index exceeding 0.7 included the CD11c IDR in combination with either a history of positive re-TUR or tumor stage. We conclude that the CD11c IDR is the most informative predictor of NMIPUC recurrence after BCG immunotherapy. Our findings highlight the importance of assessment of the spatial distribution of immune cells in the tumor microenvironment. FAU - Drachneris, Julius AU - Drachneris J AUID- ORCID: 0000-0003-4818-8316 AD - Department of Pathology and Forensic Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Morkunas, Mindaugas AU - Morkunas M AUID- ORCID: 0000-0002-1360-6533 AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. FAU - Fabijonavicius, Mantas AU - Fabijonavicius M AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Cekauskas, Albertas AU - Cekauskas A AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Jankevicius, Feliksas AU - Jankevicius F AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Laurinavicius, Arvydas AU - Laurinavicius A AUID- ORCID: 0000-0001-9232-1730 AD - Department of Pathology and Forensic Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. LA - eng GR - S-MIP-21-31/Lietuvos Mokslo Taryba/ PT - Journal Article DEP - 20240427 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Tumor Microenvironment/immunology MH - *Urinary Bladder Neoplasms/immunology/pathology/therapy MH - Male MH - *BCG Vaccine/therapeutic use MH - *Neoplasm Recurrence, Local/immunology MH - Female MH - *Immunotherapy/methods MH - Aged MH - Middle Aged MH - *Macrophages/immunology/metabolism MH - Carcinoma, Papillary/pathology/immunology/therapy MH - Lymphocyte Subsets/immunology/metabolism MH - Prognosis MH - Aged, 80 and over PMC - PMC11084693 OTO - NOTNLM OT - digital image analysis OT - non-muscle-invasive bladder cancer OT - tumor microenvironment OT - tumor-associated macrophages OT - tumor-infiltrating lymphocytes COIS- The authors declare no conflicts of interest. EDAT- 2024/05/11 19:44 MHDA- 2024/05/11 19:45 PMCR- 2024/04/27 CRDT- 2024/05/11 01:09 PHST- 2024/03/27 00:00 [received] PHST- 2024/04/21 00:00 [revised] PHST- 2024/04/24 00:00 [accepted] PHST- 2024/05/11 19:45 [medline] PHST- 2024/05/11 19:44 [pubmed] PHST- 2024/05/11 01:09 [entrez] PHST- 2024/04/27 00:00 [pmc-release] AID - ijms25094776 [pii] AID - ijms-25-04776 [pii] AID - 10.3390/ijms25094776 [doi] PST - epublish SO - Int J Mol Sci. 2024 Apr 27;25(9):4776. doi: 10.3390/ijms25094776. PMID- 38730636 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240513 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 9 DP - 2024 Apr 26 TI - Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers16091684 [doi] LID - 1684 AB - The currently available EORTC, CUETO and EAU2021 risk stratifications were originally developed to predict recurrence and progression in non-muscle-invasive bladder cancer (NMIBC). However, they have not been validated to differentiate between high-grade (HG) and low-grade (LG) recurrence-free survival (RFS), which are distinct events with specific implications. We aimed to evaluate the accuracy of available risk models and identify additional risk factors for HG RFS and PFS among NMIBC patients treated with Bacillus Calmette-Guerin (BCG). We retrospectively included 171 patients who underwent transurethral resection of the bladder tumor (TURBT), of whom 73 patients (42.7%) experienced recurrence and 29 (17%) developed progression. Initially, there were 21 low-grade and 52 high-grade recurrences. EORTC2006, EORTC2016 and CUETO recurrence scoring systems lacked accuracy in the prediction of HG RFS (C-index 0.63/0.55/0.59, respectively). EAU2021 risk stratification, EORTC2006, EORTC2016, and CUETO progression scoring systems demonstrated low to moderate accuracy (C-index 0.59/0.68/0.65/0.65) in the prediction of PFS. In the multivariable analysis, T1HG at repeat TURBT (HR = 3.17 p < 0.01), tumor multiplicity (HR = 2.07 p < 0.05), previous history of HG NMIBC (HR = 2.37 p = 0.06) and EORTC2006 progression risk score (HR = 1.1 p < 0.01) were independent predictors for HG RFS. To conclude, available risk models lack accuracy in predicting HG RFS and PFS in -NMIBC patients treated with BCG. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland. FAU - Garbas, Karolina AU - Garbas K AUID- ORCID: 0000-0002-2671-3610 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland. FAU - Pustula, Patryk AU - Pustula P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AUID- ORCID: 0000-0001-7340-280X AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20240426 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11083007 OTO - NOTNLM OT - BCG OT - EORTC OT - high-grade recurrence OT - non-muscle-invasive bladder cancer OT - progression OT - risk model COIS- The authors declare no conflicts of interest. EDAT- 2024/05/11 19:44 MHDA- 2024/05/11 19:45 PMCR- 2024/04/26 CRDT- 2024/05/11 01:02 PHST- 2024/04/04 00:00 [received] PHST- 2024/04/20 00:00 [revised] PHST- 2024/04/22 00:00 [accepted] PHST- 2024/05/11 19:45 [medline] PHST- 2024/05/11 19:44 [pubmed] PHST- 2024/05/11 01:02 [entrez] PHST- 2024/04/26 00:00 [pmc-release] AID - cancers16091684 [pii] AID - cancers-16-01684 [pii] AID - 10.3390/cancers16091684 [doi] PST - epublish SO - Cancers (Basel). 2024 Apr 26;16(9):1684. doi: 10.3390/cancers16091684. PMID- 38725894 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240511 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 40 IP - 2 DP - 2024 Apr-Jun TI - Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting. PG - 127-132 LID - 10.4103/iju.iju_324_23 [doi] AB - INTRODUCTION: The prognostic significance of steroid receptors in bladder cancer remains controversial. This study was designed to determine the expression status of androgen receptor (AR), estrogen receptors (ERalpha and Erbeta), and its potential role in predicting survival in patients with nonmuscle invasive bladder cancer (NMIBC). METHODS: Sixty patients of NMIBC were screened and 57 (41 males and 16 females) were included in our study. The tissue microarray slides were evaluated by pathologists blinded to the clinical information. Association of distribution of steroid receptors with stage, grade, progression, and recurrence was seen. RESULTS: The mean age of the population was 60.9 +/- 9.3 years. Pathologically, majority of the patients were Ta (Ta: T1 stage 61.4% vs. 38.6%). Nine (15.8%) of the tumors stained positive for AR while one (1.8%) tumor stained positive for ERalpha and 36 (63.2%) tumors stained for ERbeta. A higher proportion of male NMIBC stained positive for AR (19.5% vs. 6.2%, P = 0.420) while ERbeta positivity was higher in females (58.5% vs. and 75%,P = 0.247). AR-negative tumors showed higher recurrence (20/48%-42%) as compared to AR-positive tumors (2/9%-22%). ERbeta-positive tumors showed higher recurrence (15/36%-42% vs. 7/21%-33%, P = 0.179). Progression-free survival (PFS) was found to be significantly lower for ERbeta-negative group (log-rank test P = 0.035). CONCLUSION: AR and ERbeta positivity is found in NMIBC patients while ERalpha shows minimal staining in NMIBC patients. Although it did not reach a statistical significance, a higher proportion of AR-negative and ERbeta-positive tumors recurred as compared to AR-positive and ERbeta-negative patients. PFS was significantly lower in ERbeta-negative group. Further exploratory studies on larger sample sizes are required to validate these findings in NMIBC patients. CI - Copyright: (c) 2024 Indian Journal of Urology. FAU - Sharma, Aditya Prakash AU - Sharma AP AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Singh, Puranjay Pratap AU - Singh PP AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Chauhan, Rohit AU - Chauhan R AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Panda, Ipsita AU - Panda I AD - Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Devana, Sudheer Kumar AU - Devana SK AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Bora, Girdhar S AU - Bora GS AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Mavuduru, Ravimohan Suryanarayan AU - Mavuduru RS AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Kakkar, Nandita AU - Kakkar N AD - Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Kumar, Santosh AU - Kumar S AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Mete, Uttam AU - Mete U AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. LA - eng PT - Journal Article DEP - 20240401 PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC11078449 COIS- There are no conflicts of interest. EDAT- 2024/05/10 06:42 MHDA- 2024/05/10 06:43 PMCR- 2024/04/01 CRDT- 2024/05/10 03:51 PHST- 2023/08/22 00:00 [received] PHST- 2024/02/26 00:00 [revised] PHST- 2024/03/03 00:00 [accepted] PHST- 2024/05/10 06:43 [medline] PHST- 2024/05/10 06:42 [pubmed] PHST- 2024/05/10 03:51 [entrez] PHST- 2024/04/01 00:00 [pmc-release] AID - IJU-40-127 [pii] AID - 10.4103/iju.iju_324_23 [doi] PST - ppublish SO - Indian J Urol. 2024 Apr-Jun;40(2):127-132. doi: 10.4103/iju.iju_324_23. Epub 2024 Apr 1. PMID- 38720532 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20260701 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 18 IP - 11 DP - 2024 Nov TI - Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. PG - 2684-2695 LID - 10.1002/1878-0261.13639 [doi] AB - Cystoscopy is the gold standard for surveillance of non-muscle invasive bladder cancer (NMIBC), but the procedure is invasive and has suboptimal accuracy. The aim of this study was to investigate the potential of analyzing urine samples for the presence of urine tumor DNA (utDNA) to replace cystoscopy for surveillance of bladder cancer recurrence. In this longitudinal, prospective, and observational study, 47 patients were followed for recurrence for 2 years, involving analysis of utDNA using the BladMetrix DNA methylation biomarker test at each cystoscopy. In total, utDNA was detected in 21/23 recurrences (91% sensitivity), including 5/5 T1, T2, and carcinoma in situ (CIS) tumors (100%) and 10/12 Ta tumors (83%), with < 1% false-negative test results. Importantly, utDNA analysis showed the potential to reduce the number of cystoscopies by 55%, benefitting 79% of the patients. Eleven of 23 recurrences (48%) were detected earlier with utDNA than with cystoscopy, and distinct patterns of residual utDNA post-surgery indicated minimal residual disease (MRD) or field effect in 6% and 15% of the patients, respectively. In conclusion, utDNA analysis shows high sensitivity to detect tumor recurrence, potential to reduce the number of cystoscopies, and promise to guide patient-specific surveillance regimens. CI - (c) 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Vedeld, Hege Marie AU - Vedeld HM AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. FAU - Pharo, Heidi AU - Pharo H AUID- ORCID: 0000-0002-7865-7091 AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. FAU - Sorbo, Anne Klara AU - Sorbo AK AD - Department of Urology, Oslo University Hospital, Norway. FAU - Brandt-Winge, Sara AU - Brandt-Winge S AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. FAU - Five, May-Britt AU - Five MB AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. FAU - Jeanmougin, Marine AU - Jeanmougin M AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. FAU - Guldberg, Per AU - Guldberg P AUID- ORCID: 0000-0002-4424-4803 AD - Danish Cancer Society Research Center, Copenhagen, Denmark. AD - Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark. FAU - Wahlqvist, Rolf AU - Wahlqvist R AD - Department of Urology, Oslo University Hospital, Norway. FAU - Lind, Guro Elisabeth AU - Lind GE AUID- ORCID: 0000-0003-4643-9345 AD - Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. AD - Department of Biosciences, The Faculty of Mathematics and Natural Sciences, University of Oslo, Norway. LA - eng GR - 2018203/KLINBEFORSK/ GR - 300741/H10/Norges Forskningsrad/ GR - 2019074/Helse Sor-Ost RHF/ PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240508 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 RN - 0 (DNA, Neoplasm) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/genetics/diagnosis/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - Longitudinal Studies MH - *Neoplasm Recurrence, Local/genetics/urine MH - *DNA, Neoplasm/urine/genetics MH - Aged, 80 and over MH - Prospective Studies MH - Biomarkers, Tumor/urine/genetics MH - DNA Methylation/genetics MH - Cystoscopy PMC - PMC11547231 OTO - NOTNLM OT - BladMetrix OT - DNA methylation OT - biomarker OT - field effect OT - minimal residual disease OT - recurrence COIS- GEL is named on a patent (WO/2012/052844) proposing VIM as a biomarker forthe detection of bladder cancer, granted in US (US9797016) and EP (2630261). GEL, RW, and HP are named on a pending PCT patent application (WO/2020/099938) covering the biomarkers used in this study. GEL, MJ, and HP are named on two pending US national applications (US/2019/0221286 and WO/2019/106149) covering the 4Plex control and PoDCall algorithm used in the present study for normalization of DNA methylation ddPCR results. The remaining authors have nothing to disclose. EDAT- 2024/05/09 06:42 MHDA- 2024/11/13 13:57 PMCR- 2024/05/08 CRDT- 2024/05/09 02:23 PHST- 2024/02/20 00:00 [revised] PHST- 2023/09/06 00:00 [received] PHST- 2024/03/14 00:00 [accepted] PHST- 2024/11/13 13:57 [medline] PHST- 2024/05/09 06:42 [pubmed] PHST- 2024/05/09 02:23 [entrez] PHST- 2024/05/08 00:00 [pmc-release] AID - MOL213639 [pii] AID - 10.1002/1878-0261.13639 [doi] PST - ppublish SO - Mol Oncol. 2024 Nov;18(11):2684-2695. doi: 10.1002/1878-0261.13639. Epub 2024 May 8. PMID- 38714518 OWN - NLM STAT- MEDLINE DCOM- 20240507 LR - 20260710 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 65 IP - 3 DP - 2024 May TI - Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence. PG - 279-285 LID - 10.4111/icu.20230284 [doi] AB - PURPOSE: To investigate the relationship between urine cytology results after overnight continuous saline irrigation (OCSI) following transurethral resection of bladder tumor (TURBT) and bladder tumor recurrence in non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A retrospective study was conducted on patients diagnosed with NMIBC between 2016 and 2020 after undergoing TURBT at our hospital. All patients received OCSI following TURBT and had urine cytology test at postoperative 1 day. Urine cytology was classified into three groups: Negative, low-grade urothelial neoplasm (LGUN)+atypical urothelial cells (AUC), and suspicious for high-grade urothelial carcinoma (SHGUC)+high-grade urothelial carcinoma (HGUC). Recurrence-free survival (RFS) in each group was compared using the Kaplan-Meier method. Univariable and multivariable Cox regression analyses were performed to evaluate independent prognostic factors. RESULTS: A total of 172 patients were included in this study. Based on urine cytology group (after OCSI), RFS did not reach the median value in the Negative group. In the LGUN+AUC group, the median RFS was 615.00 days. In the SHGUC+HGUC group, the median RFS was 377.00 days. In survival analysis, the Negative group had a longer RFS than the SHGUC+HGUC group (p=0.013). However, Cox regression analysis showed that SHGUC+HGUC was not an independent prognostic factor for recurrence. CONCLUSIONS: Urine cytology results after OCSI following TURBT in NMIBC were associated with bladder tumor recurrence. Specifically, SHGUC or HGUC in urine cytology after OCSI showed earlier recurrence than negative cases. However, further research is needed to accurately determine whether it is an independent prognostic factor. CI - (c) The Korean Urological Association. FAU - Kim, Dae Hyun AU - Kim DH AUID- ORCID: 0009-0006-7062-9666 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Choi, Min Sung AU - Choi MS AUID- ORCID: 0009-0003-7605-1824 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Choi, Jae Hwi AU - Choi JH AUID- ORCID: 0000-0002-9305-2015 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Lee, Chunwoo AU - Lee C AUID- ORCID: 0000-0002-5846-7039 AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea. FAU - Jeh, Seong Uk AU - Jeh SU AUID- ORCID: 0000-0002-0206-0555 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Kam, Sung Chul AU - Kam SC AUID- ORCID: 0000-0001-5403-3623 AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea. FAU - Hwa, Jeong Seok AU - Hwa JS AUID- ORCID: 0000-0003-3821-5237 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Hyun, Jae Seog AU - Hyun JS AUID- ORCID: 0000-0002-8820-4117 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Choi, See Min AU - Choi SM AUID- ORCID: 0000-0002-6599-2640 AD - Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. choi9854@hanmail.net. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Saline Solution) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cystectomy/methods MH - *Neoplasm Recurrence, Local/urine MH - Retrospective Studies MH - *Saline Solution/administration & dosage MH - *Therapeutic Irrigation MH - Time Factors MH - Transurethral Resection of Bladder MH - Urethra/pathology MH - Urinalysis MH - *Urinary Bladder Neoplasms/pathology/urine/surgery MH - *Urine/cytology PMC - PMC11076798 OTO - NOTNLM OT - Bladder tumor OT - Cytology OT - Saline solution OT - Therapeutic irrigation OT - Urine COIS- The authors have nothing to disclose. EDAT- 2024/05/08 02:06 MHDA- 2024/05/08 02:07 PMCR- 2024/05/01 CRDT- 2024/05/07 22:43 PHST- 2023/08/28 00:00 [received] PHST- 2023/10/26 00:00 [revised] PHST- 2024/01/22 00:00 [accepted] PHST- 2024/05/08 02:07 [medline] PHST- 2024/05/08 02:06 [pubmed] PHST- 2024/05/07 22:43 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - 65.279 [pii] AID - 10.4111/icu.20230284 [doi] PST - ppublish SO - Investig Clin Urol. 2024 May;65(3):279-285. doi: 10.4111/icu.20230284. PMID- 38714515 OWN - NLM STAT- MEDLINE DCOM- 20240507 LR - 20260710 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 65 IP - 3 DP - 2024 May TI - Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guerin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study. PG - 248-255 LID - 10.4111/icu.20230313 [doi] AB - PURPOSE: This study investigated the efficacy of intravesical gemcitabine as an alternative to bacillus Calmette-Guerin (BCG) therapy. MATERIALS AND METHODS: Data were retrospectively collected across seven institutions from February 1999 to May 2023. Inclusion criteria included patients with intermediate- or high-risk non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumors (TURBT) and received at least four sessions of intravesical gemcitabine or BCG induction therapy. Patient characteristics, complete remission (CR), occurrence, and progression rates were compared. RESULTS: In total, 149 patients were included in this study (gemcitabine, 63; BCG, 86). No differences were apparent between the two groups in baseline characteristics, except for the follow-up period (gemcitabine, 9.2+/-5.9 months vs. BCG, 43.9+/-41.4 months, p<0.001). There were no consistent significant differences observed between the two groups in the 3-month (gemcitabine, 98.4% vs. BCG, 95.3%; p=0.848), 6-month (94.9% vs. 90.0%, respectively; p=0.793) and 1-year CR rates (84.2% vs. 83.3%, respectively; p=0.950). Also, there was no significant statistical difference in progression-free survival between the two groups (p=0.953). The occurrence rates of adverse events were similar between the groups (22.2% vs. 22.1%; p=0.989); however, the rate of Clavien-Dindo grade 2 or higher was significantly higher in the BCG group (1.6% vs. 16.3%, respectively; p<0.001). CONCLUSIONS: Intravesical gemcitabine demonstrated efficacy comparable to BCG therapy for the first year in patients with intermediate- and high-risk NMIBC. However, long-term follow-up studies are warranted. CI - (c) The Korean Urological Association. FAU - Choi, Joongwon AU - Choi J AUID- ORCID: 0000-0001-5978-8179 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Kim, Kyung Hwan AU - Kim KH AUID- ORCID: 0000-0001-7162-6527 AD - Department of Urology, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea. FAU - Kim, Hyung Suk AU - Kim HS AUID- ORCID: 0000-0002-3661-275X AD - Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea. FAU - Yoon, Hyun Sik AU - Yoon HS AUID- ORCID: 0000-0002-0328-4999 AD - Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea. FAU - Kim, Jung Hoon AU - Kim JH AUID- ORCID: 0000-0002-0947-876X AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Kim, Jin Wook AU - Kim JW AUID- ORCID: 0000-0003-4157-9365 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Lee, Yong Seong AU - Lee YS AUID- ORCID: 0000-0003-0611-4554 AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea. FAU - Choi, Se Young AU - Choi SY AUID- ORCID: 0000-0002-4615-0966 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Chang, In Ho AU - Chang IH AUID- ORCID: 0000-0003-0240-1310 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Ko, Young Hwii AU - Ko YH AUID- ORCID: 0000-0002-9150-4292 AD - Department of Urology, Yeungnam University College of Medicine, Daegu, Korea. FAU - Song, Wan AU - Song W AUID- ORCID: 0000-0003-0971-1805 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AUID- ORCID: 0000-0002-5399-2184 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Nam, Jong Kil AU - Nam JK AUID- ORCID: 0000-0002-3424-2417 AD - Department of Urology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan, Korea. tuff-kil@hanmail.net. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 0 (BCG Vaccine) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery/therapy MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage MH - Retrospective Studies MH - *BCG Vaccine/administration & dosage/therapeutic use MH - Male MH - Female MH - Administration, Intravesical MH - Aged MH - *Neoplasm Recurrence, Local MH - *Antimetabolites, Antineoplastic/administration & dosage MH - Middle Aged MH - *Adjuvants, Immunologic/administration & dosage MH - Cystectomy/methods MH - Risk Assessment MH - Urethra PMC - PMC11076792 OTO - NOTNLM OT - Bladder neoplasms OT - Gemcitabine OT - Mycobacterium bovis COIS- The authors have nothing to disclose. EDAT- 2024/05/08 02:05 MHDA- 2024/05/08 02:06 PMCR- 2024/05/01 CRDT- 2024/05/07 22:43 PHST- 2023/09/13 00:00 [received] PHST- 2024/01/03 00:00 [revised] PHST- 2024/03/04 00:00 [accepted] PHST- 2024/05/08 02:06 [medline] PHST- 2024/05/08 02:05 [pubmed] PHST- 2024/05/07 22:43 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - 65.248 [pii] AID - 10.4111/icu.20230313 [doi] PST - ppublish SO - Investig Clin Urol. 2024 May;65(3):248-255. doi: 10.4111/icu.20230313. PMID- 38700051 OWN - NLM STAT- MEDLINE DCOM- 20240801 LR - 20260702 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 31 IP - 8 DP - 2024 Aug TI - A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review. PG - 846-851 LID - 10.1111/iju.15480 [doi] AB - To preserve the bladder without compromising survival, further treatments need to be optimized to prevent the recurrence and progression of non-muscle invasive bladder cancer. In clinical practice, transurethral resection of bladder tumors is essential for bladder cancer management. The primary goal of surgery is to achieve accurate pathological evaluation and complete resection of bladder cancer; high resection quality is required for the procedure. A representative surrogate indicator of the resection quality is the presence of the detrusor muscle in the resection specimen. Therefore, complete visual resection of bladder cancer with a muscle layer is crucial for decreasing the recurrence and progression rates of non-muscle-invasive bladder cancer. However, this procedure is complex and requires sufficient experience and knowledge to be performed thoroughly, safely, and efficiently. Surgical checklists represent an approach to filling the knowledge and experience gaps and improving the quality and safety of surgery. By checking items during transurethral resection, it is expected that the recording of risk factors related to recurrence and progression will improve, the rate of visually complete resection with muscles will increase, and the rate of intravesical recurrence will decrease. The simplicity of checklists is an additional benefit. In recent years, surgical checklists have received increasing attention in order to achieve high-quality resections and reduce disparities between surgeons and institutions. This literature review outlines the evolving treatment strategies for patients with non-muscle-invasive bladder cancer, focusing on surgical checklists for the transurethral resection of bladder tumors. CI - (c) 2024 The Japanese Urological Association. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AUID- ORCID: 0000-0001-9266-782X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. LA - eng PT - Journal Article PT - Review DEP - 20240503 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Humans MH - *Checklist MH - *Cystectomy/methods/standards MH - *Neoplasm Recurrence, Local/prevention & control/epidemiology MH - Urinary Bladder/surgery/pathology MH - Treatment Outcome MH - Disease Progression OTO - NOTNLM OT - detrusor muscle OT - literature review OT - non-muscle invasive bladder cancer OT - surgical checklist OT - transurethral resection of bladder tumor EDAT- 2024/05/03 12:52 MHDA- 2024/08/01 12:42 CRDT- 2024/05/03 06:43 PHST- 2024/03/01 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/08/01 12:42 [medline] PHST- 2024/05/03 12:52 [pubmed] PHST- 2024/05/03 06:43 [entrez] AID - 10.1111/iju.15480 [doi] PST - ppublish SO - Int J Urol. 2024 Aug;31(8):846-851. doi: 10.1111/iju.15480. Epub 2024 May 3. PMID- 38697874 OWN - NLM STAT- MEDLINE DCOM- 20240725 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 10 DP - 2024 Oct TI - Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status. PG - 333.e1-333.e13 LID - S1078-1439(24)00438-1 [pii] LID - 10.1016/j.urolonc.2024.04.020 [doi] AB - OBJECTIVE: To compare survival and pathologic outcomes in patients with progressive muscle-invasive bladder cancer (pgMIBC) and de novo muscle-invasive bladder cancer (dnMIBC) after radical cystectomy (RC), with a focus on the role of neoadjuvant chemotherapy (NAC). METHODS: A comprehensive literature search was conducted on PubMed and EMBASE databases to identify studies comparing pgMIBC to dnMIBC. Survival outcomes, including cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS), and pathologic outcomes (rates of pT2. CONCLUSIONS: The clinical outcome of mixed-grade carcinomas was similar to what has been reported for low-grade carcinomas. Based on our results, and prior congruent studies of mixed-grade lesions, these lesions may be regarded as a distinct sub-category with a better prognosis than high-grade tumors. FAU - Chambers, Meagan AU - Chambers M AUID- ORCID: 0000-0002-8741-0509 AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 FAU - Andre, Alexa T AU - Andre AT AD - University of Washington Medical School, Seattle, WA, USA. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 AD - Fred Hutchinson Cancer Research Center, Seattle, WA, USA. FAU - Vakar-Lopez, Funda AU - Vakar-Lopez F AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 FAU - Tretiakova, Maria AU - Tretiakova M AUID- ORCID: 0000-0002-0819-9638 AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 FAU - Reder, Nicholas P AU - Reder NP AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 AD - Department of Mechanical Engineering, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 FAU - Haffner, Michael C AU - Haffner MC AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 AD - Fred Hutchinson Cancer Research Center, Seattle, WA, USA. FAU - True, Lawrence D AU - True LD AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. RINGGOLD: 7284 LA - eng PT - Journal Article DEP - 20240430 PL - United States TA - Int J Surg Pathol JT - International journal of surgical pathology JID - 9314927 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/therapy/diagnosis MH - Male MH - Female MH - Middle Aged MH - Aged MH - Neoplasm Grading MH - *Carcinoma, Papillary/pathology/mortality/therapy MH - Aged, 80 and over MH - Prognosis MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Urinary Bladder/pathology/surgery MH - Adult MH - Retrospective Studies MH - Neoplasm Invasiveness MH - Follow-Up Studies OTO - NOTNLM OT - neoplasm grading OT - papillary carcinoma OT - survival OT - transitional cell carcinoma OT - urothelial carcinoma COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/05/01 06:56 MHDA- 2025/01/27 12:23 CRDT- 2024/05/01 01:24 PHST- 2025/01/27 12:23 [medline] PHST- 2024/05/01 06:56 [pubmed] PHST- 2024/05/01 01:24 [entrez] AID - 10.1177/10668969241246492 [doi] PST - ppublish SO - Int J Surg Pathol. 2025 Feb;33(1):19-25. doi: 10.1177/10668969241246492. Epub 2024 Apr 30. PMID- 38687165 OWN - NLM STAT- MEDLINE DCOM- 20240801 LR - 20260702 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 31 IP - 8 DP - 2024 Aug TI - Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer. PG - 876-885 LID - 10.1111/iju.15474 [doi] AB - OBJECTIVES: The aim of this study was to compare clinical outcomes between patients receiving second TUR after initial white-light transurethral resection of bladder tumor (WL-TURBT) and initial photodynamic diagnosis (PDD)-assisted TURBT. METHODS: A total of 1007 patients were divided into four groups based on the treatment pattern: WL-TURBT with second TUR (161 patients, WL-second group) or without second TUR (540 patients, WL-alone group) and PDD-TURBT with second TUR (112 patients, PDD-second group) or without second TUR (194 patients, PDD-alone group). Oncologic outcomes (bladder cancer recurrence, progression, urothelial cancer-specific mortality) and rates of residual tumor and risk stratification of non-muscle-invasive bladder cancer (NMIBC) after second TUR were evaluated. RESULTS: After propensity score-matching 121 patients were included each in the WL-alone and WL-second groups, and 63 patients each in the PDD-alone and PDD-second groups. In the WL group, the second TUR was significantly associated with improved progression-free (p = 0.012) and urothelial cancer-specific free survival (p = 0.011), but not with recurrence-free survival (p = 0.93). Patients initially treated with PDD-TURBT, and with a tumor diameter <30 mm and multifocality had a relatively high benefit from second TUR. The rates of residual tumor and risk stratification of NMIBC did not significantly differ between WL-TURBT and PDD-TURBT groups. CONCLUSIONS: Our findings suggested that a second TUR could be omitted after an initial PDD-TURBT in selected patients with high-risk NMIBC. CI - (c) 2024 The Japanese Urological Association. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Nakahama, Tomonori AU - Nakahama T AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Nishimoto, Koshiro AU - Nishimoto K AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AUID- ORCID: 0000-0002-8159-9793 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. AD - Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Fukuhara, Hideo AU - Fukuhara H AUID- ORCID: 0000-0002-9079-0995 AD - Department of Urology, Kochi Medical School, Nankoku, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nankoku, Japan. FAU - Kobayashi, Keita AU - Kobayashi K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. AD - Department of Urology, JA Yamaguchi Kouseiren Nagato General Hospital, Nagato, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan. AD - Division of Fostering Required Medical Human Resources, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan. FAU - Hirao, Yoshihiko AU - Hirao Y AD - Department of Urology, Osaka Gyoumeikan Hospital, Konohana-ku, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Japan. LA - eng GR - 16K20159/Japan Society for the Promotion of Science/ GR - 26861290/Japan Society for the Promotion of Science/ GR - 23K08720/Japan Society for the Promotion of Science/ PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240430 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cystectomy/methods MH - Disease Progression MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Neoplasm, Residual MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/pathology/surgery MH - Progression-Free Survival MH - Propensity Score MH - Reoperation/statistics & numerical data MH - Retrospective Studies MH - Urinary Bladder/pathology/surgery OTO - NOTNLM OT - aminolevulinic acid OT - disease progression OT - local OT - neoplasm recurrence OT - photodynamic diagnosis OT - urinary bladder neoplasms EDAT- 2024/04/30 13:42 MHDA- 2024/08/01 12:42 CRDT- 2024/04/30 09:42 PHST- 2024/01/03 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/08/01 12:42 [medline] PHST- 2024/04/30 13:42 [pubmed] PHST- 2024/04/30 09:42 [entrez] AID - 10.1111/iju.15474 [doi] PST - ppublish SO - Int J Urol. 2024 Aug;31(8):876-885. doi: 10.1111/iju.15474. Epub 2024 Apr 30. PMID- 38687138 OWN - NLM STAT- MEDLINE DCOM- 20240801 LR - 20260702 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 31 IP - 8 DP - 2024 Aug TI - Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid. PG - 891-898 LID - 10.1111/iju.15477 [doi] AB - OBJECTIVE: Intraoperative hypotension remains a serious adverse event of photodynamic diagnosis-assisted transurethral resection of bladder tumor with oral administration of 5-aminolevulinic acid. We conducted a re-analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of the bladder tumor with oral 5-aminolevulinic acid to ascertain its safety. METHODS: A total of 407 cases who underwent transurethral resection of bladder tumors in our institution were reviewed (274 cases for the PDD group with photodynamic diagnosis and 133 for the white light (WL) group without). A classification of hypotension severity was devised to identify risk factors for clinically troublesome hypotension. The distribution of hypotension severity in each of the PDD and WL groups was compared. Additionally, the patient background and perioperative data by hypotension severity were compared only in the PDD group. RESULTS: More patients with moderate and severe hypotension were noted in the PDD group. The renal function was lower with increasing hypotension severity in the PDD group. More patients on general anesthesia were included in the mild and moderate hypotension group, whereas more patients on spinal anesthesia were included in the severe hypotension group. Furthermore, the frequency of side effects other than hypotension tended to increase with hypotension severity. CONCLUSIONS: Renal function impairment and the other adverse effects of 5-aminolevulinic acid may be risk factors for severe hypotension. Mild or moderate hypotension may be caused by general anesthesia and severe hypotension may be caused by spinal anesthesia. To elucidate specific risk factors, further case-control studies are warranted. CI - (c) 2024 The Japanese Urological Association. FAU - Nohara, Takahiro AU - Nohara T AUID- ORCID: 0000-0001-9792-2068 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Takimoto, Atsuya AU - Takimoto A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Shinzawa, Rei AU - Shinzawa R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Kurauchi, Daimon AU - Kurauchi D AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Toriumi, Ren AU - Toriumi R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Nakagawa, Ryunosuke AU - Nakagawa R AUID- ORCID: 0000-0002-2503-8908 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Aoyama, Shuhei AU - Aoyama S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Kamijima, Taiki AU - Kamijima T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Kano, Hiroshi AU - Kano H AUID- ORCID: 0000-0002-3543-1236 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Naito, Renato AU - Naito R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Kadomoto, Suguru AU - Kadomoto S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Iwamoto, Hiroaki AU - Iwamoto H AUID- ORCID: 0000-0003-3599-2217 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Yaegashi, Hiroshi AU - Yaegashi H AUID- ORCID: 0000-0003-3188-8834 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Kawaguchi, Shohei AU - Kawaguchi S AUID- ORCID: 0000-0001-6847-9861 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Shigehara, Kazuyoshi AU - Shigehara K AUID- ORCID: 0000-0002-2118-9135 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Izumi, Kouji AU - Izumi K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, Kanazawa, Ishikawa, Japan. LA - eng PT - Journal Article DEP - 20240430 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Aminolevulinic Acid/administration & dosage/adverse effects MH - Cystectomy/adverse effects MH - *Hypotension/etiology/diagnosis MH - Intraoperative Complications/etiology/diagnosis MH - *Photosensitizing Agents/administration & dosage/adverse effects MH - Retrospective Studies MH - Risk Factors MH - Severity of Illness Index MH - *Transurethral Resection of Bladder/adverse effects MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - 5-aminolevulinic acid OT - hypotension OT - spinal anesthesia OT - transurethral resection of bladder tumor EDAT- 2024/04/30 13:43 MHDA- 2024/08/01 12:42 CRDT- 2024/04/30 09:23 PHST- 2023/12/02 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/08/01 12:42 [medline] PHST- 2024/04/30 13:43 [pubmed] PHST- 2024/04/30 09:23 [entrez] AID - 10.1111/iju.15477 [doi] PST - ppublish SO - Int J Urol. 2024 Aug;31(8):891-898. doi: 10.1111/iju.15477. Epub 2024 Apr 30. PMID- 38684494 OWN - NLM STAT- MEDLINE DCOM- 20240429 LR - 20240501 IS - 2239-253X (Electronic) IS - 0003-469X (Linking) VI - 95 IP - 2 DP - 2024 TI - Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer. PG - 246-252 LID - 10.62713/aic.3335 [doi] AB - BACKGROUND: Bladder cancer is the most common malignancy of the urinary system, and the search for new and reliable biomarkers has important clinical significance for the personalized treatment of bladder cancer. This study aims to explore the correlation between nuclear proliferation antigen (Ki-67) or Profilin-1 (PFN1) levels, clinicopathological characteristics, and postoperative prognosis in patients with bladder cancer. METHODS: Patients with bladder cancer who underwent transurethral resection of bladder cancer tumor in The Fourth Affiliated Hospital of Soochow University, hospital from January 2019 to January 2021 were selected as the study group (n = 60), and patients with benign lesions of bladder cancer during the same period were selected as the control group (n = 60). The expression of Ki-67 and PFN1 in tumor and bladder tissues of the two groups was analyzed. Ki-67 recorded the patient's pathological parameters and calculated the patient's postoperative prognosis. The correlation between Ki-67 and PFN1 expression levels, pathological parameters, and postoperative prognosis was analyzed. RESULTS: The positive expression rates of Ki-67 and PFN1 in the study group were 63.33% and 73.33%, respectively, which were significantly higher than the positive expression rates in the control group (chi2 = 14.803, 17.757, p < 0.001). The positive expression rates of Ki-67 and PFN1 were related to histological grade, clinical stage, infiltration, and lymph node metastasis, and the differences were statistically significant (p < 0.05). Bladder cancer patients with non muscle-invasive bladder cancer (NMIBC), high-grade histological grade, Ta~T1 clinical stage, invasive, and lymph node metastasis have a higher Ki-67 positive expression rate than bladder cancer patients with muscle-invasive bladder cancer (MIBC), low-grade histological grade, T2~T4, non-invasive, and no lymph node metastasis. The high expression level of Ki-67 has little relationship with gender, age, tumor diameter, and vascular invasion (p > 0.05). The survival time and three-year survival rate of the Ki-67 positive expression group were significantly lower than those of the Ki-67 negative expression group (p < 0.05). The survival time and three-year survival rate of the PFN1 positive expression group were significantly lower than those of the PFN1 negative expression group (p < 0.05). CONCLUSION: The positive expression rates of Ki-67 and PFN1 in bladder tumor tissue are significantly higher than those in bladder tissue, and pathological pattern, histological grade, clinical stage, infiltration, and lymph node metastasis are related to the positive expression rates of Ki-67 and PFN1, and different genders, ages, tumors diameter and vascular invasion are not related to the positive expression rates of Ki-67 and PFN1. The survival time and three-year survival rates of bladder cancer patients with Ki-67 positive and PFN1 positive expression are shorter. FAU - Li, Jianwen AU - Li J AD - Department of Urology, The Fourth Affiliated Hospital of Soochow University, 215100 Suzhou, Jiangsu, China. LA - eng PT - Journal Article PL - Italy TA - Ann Ital Chir JT - Annali italiani di chirurgia JID - 0372343 RN - 0 (Ki-67 Antigen) RN - 0 (Profilins) RN - 0 (PFN1 protein, human) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology/mortality/metabolism/chemistry MH - *Ki-67 Antigen/analysis MH - *Profilins/analysis MH - Male MH - Female MH - Prognosis MH - Middle Aged MH - Aged MH - Biomarkers, Tumor/analysis/metabolism MH - Neoplasm Staging EDAT- 2024/04/30 00:42 MHDA- 2024/04/30 00:43 CRDT- 2024/04/29 23:03 PHST- 2024/04/30 00:43 [medline] PHST- 2024/04/30 00:42 [pubmed] PHST- 2024/04/29 23:03 [entrez] AID - 10.62713/aic.3335 [doi] PST - ppublish SO - Ann Ital Chir. 2024;95(2):246-252. doi: 10.62713/aic.3335. PMID- 38680592 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240430 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 11 IP - 2 DP - 2024 Apr TI - Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades. PG - 242-252 LID - 10.1016/j.ajur.2022.08.003 [doi] AB - OBJECTIVE: The role of ureteroscopy in the diagnosis of upper tract urothelial carcinoma is yet to be fully determined. We aimed to provide an up to date evaluation of its role and the emerging technologies in the field. METHODS: A literature search of the last two decades (from 24th May, 2001 to 24th May, 2021) was carried out identifying 147 papers for potential inclusion within this narrative review. RESULTS: Diagnostic ureteroscopy is undeniably useful in its ability to visualise and biopsy indeterminate lesions, and to risk stratify malignant lesions that may be suitable for kidney sparing surgery. However, an increased risk of intravesical recurrence following nephroureterectomy when a prior diagnostic ureteroscopy has been performed, inadequate sampling at biopsy, complications from the procedure, and difficult ureteric access are all potential drawbacks. Furthermore, whilst generally an accurate diagnostic procedure, it risks missing carcinoma in-situ lesions. Despite this, evidence shows that routine use of ureteroscopy changes the management of patients in a large proportion of cases, preventing unnecessary surgery or facilitating kidney sparing surgery. The overall rate of complications is low, and improved biopsy techniques and the use of tissue biomarkers for improved staging and grading are encouraging. The risks of delays to definitive management and post-ureteroscopy intravesical recurrence do not seem to affect survival, and trials are in progress to determine whether intravesical therapy can mitigate the latter. Further promising techniques are being investigated to improve shortcomings, particularly in relation to improved diagnosis of carcinoma in situ and preoperative staging. CONCLUSION: Ureteroscopy has a role in the diagnosis of upper tract malignancy, though whether it should be used routinely is yet to be determined. CI - (c) 2024 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. FAU - Gravestock, Paul AU - Gravestock P AD - Urology Department, Freeman Hospital, Newcastle Upon Tyne, UK. FAU - Cullum, Daniel AU - Cullum D AD - Urology Department, Freeman Hospital, Newcastle Upon Tyne, UK. FAU - Somani, Bhaskar AU - Somani B AD - Department of Urology, University Hospital Southampton, Southampton, UK. FAU - Veeratterapillay, Rajan AU - Veeratterapillay R AD - Urology Department, Freeman Hospital, Newcastle Upon Tyne, UK. LA - eng PT - Journal Article PT - Review DEP - 20220923 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC11053284 OTO - NOTNLM OT - Biopsy OT - Carcinoma OT - Carcinoma in situ OT - Transitional cell OT - Ureteral neoplasms OT - Ureteroscopy OT - Urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2024/04/29 06:44 MHDA- 2024/04/29 06:45 PMCR- 2022/09/23 CRDT- 2024/04/29 04:01 PHST- 2022/04/07 00:00 [received] PHST- 2022/08/13 00:00 [accepted] PHST- 2024/04/29 06:45 [medline] PHST- 2024/04/29 06:44 [pubmed] PHST- 2024/04/29 04:01 [entrez] PHST- 2022/09/23 00:00 [pmc-release] AID - S2214-3882(22)00105-9 [pii] AID - 10.1016/j.ajur.2022.08.003 [doi] PST - ppublish SO - Asian J Urol. 2024 Apr;11(2):242-252. doi: 10.1016/j.ajur.2022.08.003. Epub 2022 Sep 23. PMID- 38680113 OWN - NLM STAT- MEDLINE DCOM- 20240826 LR - 20250708 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 134 IP - 3 DP - 2024 Sep TI - Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system. PG - 473-483 LID - 10.1111/bju.16380 [doi] AB - OBJECTIVE: To describe patient characteristics and pathological stage at bladder cancer (BCa) diagnosis in a diverse population within a national, equal-access healthcare system. METHODS: This retrospective cohort study identified 15 966 men diagnosed with BCa in the Veterans Affairs (VA) healthcare system from 2000 to 2020. The primary outcome was pathological stage at diagnosis, determined by index transurethral resection of bladder tumour. Logistic regression was used to assess the relationship between race and stage. Competing risk models tested the association between race and BCa-specific mortality with cumulative incidence estimates. RESULTS: Of 15 966 BCa patients, 12 868 (81%), 1726 (11%), 493 (3%) and 879 (6%) were White, Black, Hispanic and Other race, respectively. Black patients had significantly higher muscle-invasive bladder cancer (MIBC) rates than White patients (35% vs 32%; P = 0.009). In multivariable analysis, the odds of presenting with MIBC did not differ significantly between Black and White patients (odds ratio [OR] 1.10, 95% confidence interval [CI] 0.98-1.22) or between Hispanic patients (OR 0.82, 95% CI 0.67-1.01) and White patients. Compared to White patients, Black patients had a similar risk of BCa-specific mortality (hazard ratio [HR] 0.89, 95% CI 0.75-1.06), whereas Hispanic patients had a lower risk (HR 0.56, 95% CI 0.38-0.82). CONCLUSIONS: Black patients presented with the highest rates of de novo MIBC. However, in a large, equal-access healthcare system, this did not result in a difference in BCa-specific mortality. In contrast, Hispanic patients had lower risks of MIBC and BCa-specific mortality. CI - (c) 2024 BJU International. FAU - Bree, Kelly K AU - Bree KK AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Janes, Jessica L AU - Janes JL AD - Division of Urology, Durham Veterans Affairs Health Care System, Durham, NC, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Srinivasan, Aditya AU - Srinivasan A AD - Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA. FAU - De Hoedt, Amanda M AU - De Hoedt AM AUID- ORCID: 0000-0002-3899-7702 AD - Division of Urology, Durham Veterans Affairs Health Care System, Durham, NC, USA. FAU - Das, Sanjay AU - Das S AD - Division of Urology, Durham Veterans Affairs Health Care System, Durham, NC, USA. AD - Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA. AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Freedland, Stephen J AU - Freedland SJ AUID- ORCID: 0000-0002-8104-6419 AD - Division of Urology, Durham Veterans Affairs Health Care System, Durham, NC, USA. AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Williams, Stephen B AU - Williams SB AUID- ORCID: 0000-0002-2683-2185 AD - Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA. LA - eng GR - T32 CA251072/CA/NCI NIH HHS/United States GR - U.S. Department of Defense/ GR - PCORT/ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240429 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Aged, 80 and over MH - Humans MH - Male MH - Middle Aged MH - Healthcare Disparities/ethnology/statistics & numerical data MH - Hispanic or Latino MH - *Neoplasm Staging MH - Retrospective Studies MH - United States/epidemiology MH - United States Department of Veterans Affairs MH - *Urinary Bladder Neoplasms/diagnosis/ethnology/mortality MH - Black or African American MH - White PMC - PMC12232451 MID - NIHMS2094141 OTO - NOTNLM OT - bladder cancer OT - disparities OT - equal access OT - muscle-invasive bladder cancer OT - race COIS- Disclosure of Interests Dr. Williams is a consultant for Photocure, Janseen, Merck, Valar Labs; BJUI section editor. EDAT- 2024/04/29 06:44 MHDA- 2024/08/27 09:49 PMCR- 2025/07/07 CRDT- 2024/04/29 03:43 PHST- 2024/08/27 09:49 [medline] PHST- 2024/04/29 06:44 [pubmed] PHST- 2024/04/29 03:43 [entrez] PHST- 2025/07/07 00:00 [pmc-release] AID - 10.1111/bju.16380 [doi] PST - ppublish SO - BJU Int. 2024 Sep;134(3):473-483. doi: 10.1111/bju.16380. Epub 2024 Apr 29. PMID- 38677753 OWN - NLM STAT- MEDLINE DCOM- 20240427 LR - 20260127 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 44 IP - 5 DP - 2024 May TI - Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer. PG - 1837-1844 LID - 10.21873/anticanres.16985 [doi] AB - BACKGROUND/AIM: Although there are curative treatment options for non-muscle-invasive bladder cancer, the recurrence of this tumor is high. Therefore, novel targeted therapies are needed for the complete removal of bladder cancer cells in stages of localized disease, in order to avoid local recurrence, to spare bladder cancer patients from stressful and expensive treatment procedures and to increase their quality of life and life expectancy. This study tested a new approach for the photoimmunotherapy (PIT) of bladder cancer. MATERIALS AND METHODS: We generated a cysteine modified recombinant version of the antibody cetuximab targeting the epidermal growth factor receptor (EGFR) on the surface of bladder cancer cells. Then, we coupled the novel photoactivatable phthalocyanine dye WB692-CB1 via a maleimide linker to the free cysteines of the antibody. PIT was performed by incubating bladder cancer cells with the antibody dye conjugate followed by irradiation with visible red light. RESULTS: The conjugate was able to induce specific cytotoxicity in EGFR-positive bladder cancer cells in a light dose-dependent manner. Enhanced cytotoxicity in RT112 bladder cancer cells was evoked by addition of a second antibody dye conjugate targeting HER2 or by repeated cycles of PIT. CONCLUSION: Our new antibody dye conjugate targeting EGFR-expressing bladder cancer cells is a promising candidate for the future PIT of bladder cancer patients. CI - Copyright (c) 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Huber, Fabian AU - Huber F AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Wolf, Isis AU - Wolf I AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. AD - Faculty of Biology, University of Freiburg, Freiburg, Germany. FAU - Storz, Jonas AU - Storz J AD - Institute for Organic Chemistry, University of Freiburg, Freiburg, Germany. FAU - Schultze-Seemann, Susanne AU - Schultze-Seemann S AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Lauw, Susan AU - Lauw S AD - Core Facility Signalling Factory & Robotics, University of Freiburg, Freiburg, Germany. AD - BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany. FAU - Klemenz, Lukas AU - Klemenz L AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Miernik, Arkadiusz AU - Miernik A AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Gratzke, Christian AU - Gratzke C AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Bruckner, Reinhard AU - Bruckner R AD - Institute for Organic Chemistry, University of Freiburg, Freiburg, Germany. FAU - Wolf, Philipp AU - Wolf P AD - Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany; philipp.wolf@uniklinik-freiburg.de. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Immunoconjugates) RN - PQX0D8J21J (Cetuximab) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM EIN - Anticancer Res. 2024 Jun;44(6):2763. doi: 10.21873/anticanres.17086. PMID: 38821629 MH - Humans MH - *Urinary Bladder Neoplasms/therapy/drug therapy/pathology MH - *ErbB Receptors/immunology/antagonists & inhibitors MH - *Erb-b2 Receptor Tyrosine Kinases/immunology/metabolism/antagonists & inhibitors MH - *Immunotherapy/methods MH - *Immunoconjugates/pharmacology/therapeutic use MH - Cell Line, Tumor MH - Cetuximab/pharmacology/therapeutic use/chemistry MH - Phototherapy/methods OTO - NOTNLM OT - Bladder cancer OT - HER2 antigen OT - cetuximab OT - epidermal growth factor receptor OT - photoimmunotherapy OT - trastuzumab EDAT- 2024/04/28 07:25 MHDA- 2024/04/28 07:26 CRDT- 2024/04/27 20:43 PHST- 2024/03/14 00:00 [received] PHST- 2024/03/27 00:00 [revised] PHST- 2024/03/28 00:00 [accepted] PHST- 2024/04/28 07:26 [medline] PHST- 2024/04/28 07:25 [pubmed] PHST- 2024/04/27 20:43 [entrez] AID - 44/5/1837 [pii] AID - 10.21873/anticanres.16985 [doi] PST - ppublish SO - Anticancer Res. 2024 May;44(5):1837-1844. doi: 10.21873/anticanres.16985. PMID- 38675715 OWN - NLM STAT- MEDLINE DCOM- 20240427 LR - 20260922 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 29 IP - 8 DP - 2024 Apr 22 TI - Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. LID - 10.3390/molecules29081896 [doi] LID - 1896 AB - Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease which is associated with a 10-15% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder cancer (MIBC) is associated with about 50% 5 year survival when treated by radical cystectomy or trimodality therapy; stage IV disease is associated with 10-15% 5 year survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and/or chemoradiation, although patients with relapsed or refractory disease have a poor prognosis. However, the rapid success of immuno-oncology in various hematologic and solid malignancies offers new targets with tremendous therapeutic potential in UC. Historically, there were no predictive biomarkers to guide the clinical management and treatment of UC, and biomarker development was an unmet need. However, recent and ongoing clinical trials have identified several promising tumor biomarkers that have the potential to serve as predictive or prognostic tools in UC. This review provides a comprehensive summary of emerging biomarkers and molecular tumor targets including programmed death ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor (FGFR), DNA damage response and repair (DDR) mutations, poly (ADP-ribose) polymerase (PARP) expression and circulating tumor DNA (ctDNA), as well as their clinical utility in UC. We also evaluate recent advancements in precision oncology in UC, while illustrating limiting factors and challenges related to the clinical application of these biomarkers in clinical practice. FAU - Eturi, Aditya AU - Eturi A AUID- ORCID: 0009-0005-4702-2017 AD - Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. FAU - Bhasin, Amman AU - Bhasin A AD - Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA. FAU - Zarrabi, Kevin K AU - Zarrabi KK AUID- ORCID: 0000-0002-9351-2317 AD - Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. FAU - Tester, William J AU - Tester WJ AUID- ORCID: 0000-0002-5766-0195 AD - Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. LA - eng PT - Journal Article PT - Review DEP - 20240422 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Antigens, Neoplasm/metabolism MH - *Biomarkers, Tumor MH - Carcinoma, Transitional Cell/therapy/metabolism/drug therapy/pathology MH - *Molecular Targeted Therapy MH - Prognosis MH - *Urinary Bladder Neoplasms/therapy/metabolism/drug therapy MH - *Urologic Neoplasms/therapy PMC - PMC11054340 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - ctDNA OT - targeted therapies OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2024/04/27 09:52 MHDA- 2024/04/27 09:53 PMCR- 2024/04/22 CRDT- 2024/04/27 01:24 PHST- 2024/02/27 00:00 [received] PHST- 2024/04/01 00:00 [revised] PHST- 2024/04/19 00:00 [accepted] PHST- 2024/04/27 09:53 [medline] PHST- 2024/04/27 09:52 [pubmed] PHST- 2024/04/27 01:24 [entrez] PHST- 2024/04/22 00:00 [pmc-release] AID - molecules29081896 [pii] AID - molecules-29-01896 [pii] AID - 10.3390/molecules29081896 [doi] PST - epublish SO - Molecules. 2024 Apr 22;29(8):1896. doi: 10.3390/molecules29081896. PMID- 38673455 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240429 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 8 DP - 2024 Apr 10 TI - Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues. LID - 10.3390/jcm13082182 [doi] LID - 2182 AB - Bladder cancer (BC) is one of the most prevalent cancers worldwide. Non-muscle invasive bladder cancer (NMIBC), comprising the majority of initial BC presentations, requires accurate risk stratification for optimal management. This review explores the evolving role of programmed cell death ligand 1 (PD-L1) as a prognostic biomarker in NMIBC, with a particular focus on its implications in the context of Bacillus Calmette-Guerin (BCG) immunotherapy. The literature suggests a potential association between elevated PD-L1 status and adverse outcomes, resistance to BCG treatment, and disease progression. However, conflicting findings and methodological issues highlight the heterogeneity of PD-L1 assessment in NMIBC, probably due to the complex biological mechanisms that regulate the interaction between PD-L1 and the tumor microenvironment. The identification of PD-L1 as a prognostic biomarker provides ground for tailored therapeutic interventions, including immune checkpoint inhibitors (ICIs). Nevertheless, challenges such as intratumoral heterogeneity and technical issues underscore the need for standardized protocols and larger, homogeneous trials. This review contributes to the ongoing debate on the personalized management of NMIBC patients, focusing on the advances and perspectives of incorporating PD-L1 as a biomarker in this setting. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Zanelli, Magda AU - Zanelli M AUID- ORCID: 0000-0002-8733-9933 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Palicelli, Andrea AU - Palicelli A AUID- ORCID: 0000-0003-2299-5160 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Zizzo, Maurizio AU - Zizzo M AUID- ORCID: 0000-0001-9841-7856 AD - Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Angelo AU - Cormio A AUID- ORCID: 0000-0002-6897-7040 AD - Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universita Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. AD - Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240410 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11050441 OTO - NOTNLM OT - NMIBC OT - PD-L1 OT - biomarker OT - bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2024/04/27 09:52 MHDA- 2024/04/27 09:53 PMCR- 2024/04/10 CRDT- 2024/04/27 01:11 PHST- 2024/02/22 00:00 [received] PHST- 2024/03/17 00:00 [revised] PHST- 2024/03/30 00:00 [accepted] PHST- 2024/04/27 09:53 [medline] PHST- 2024/04/27 09:52 [pubmed] PHST- 2024/04/27 01:11 [entrez] PHST- 2024/04/10 00:00 [pmc-release] AID - jcm13082182 [pii] AID - jcm-13-02182 [pii] AID - 10.3390/jcm13082182 [doi] PST - epublish SO - J Clin Med. 2024 Apr 10;13(8):2182. doi: 10.3390/jcm13082182. PMID- 38672670 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240429 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 8 DP - 2024 Apr 20 TI - tRNA-Derived Fragments as Biomarkers in Bladder Cancer. LID - 10.3390/cancers16081588 [doi] LID - 1588 AB - Bladder cancer (BC) diagnosis is reliant on cystoscopy, an invasive procedure associated with urinary tract infections. This has sparked interest in identifying noninvasive biomarkers in body fluids such as blood and urine. A source of biomarkers in these biofluids are extracellular vesicles (EVs), nanosized vesicles that contain a wide array of molecular cargo, including small noncoding RNA such as transfer RNA-derived fragments (tRF) and microRNA. Here, we performed small-RNA next-generation sequencing from EVs from urine and serum, as well as from serum supernatant. RNA was extracted from 15 non-cancer patients (NCPs) with benign findings in cystoscopy and 41 patients with non-muscle invasive BC. Urine and serum were collected before transurethral resection of bladder tumors (TUR-b) and at routine post-surgery check-ups. We compared levels of tRFs in pre-surgery samples to samples from NCPs and post-surgery check-ups. To further verify our findings, samples from 10 patients with stage T1 disease were resequenced. When comparing tRF expression in urine EVs between T1 stage BC patients and NCPs, 14 differentially expressed tRFs (DEtRFs) were identified. In serum supernatant, six DEtRFs were identified among stage T1 patients when comparing pre-surgery to post-surgery samples and four DEtRFs were found when comparing pre-surgery samples to NCPs. By performing a blast search, we found that sequences of DEtRFs aligned with genomic sequences pertaining to processes relevant to cancer development, such as enhancers, regulatory elements and CpG islands. Our findings display a number of tRFs that may hold potential as biomarkers for the diagnosis and recurrence-free survival of BC. FAU - Stromme, Olaf AU - Stromme O AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. FAU - Heck, Kathleen A AU - Heck KA AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. FAU - Brede, Gaute AU - Brede G AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. FAU - Lindholm, Havard T AU - Lindholm HT AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. AD - Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada. FAU - Otterlei, Marit AU - Otterlei M AUID- ORCID: 0000-0002-5232-1186 AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. FAU - Arum, Carl-Jorgen AU - Arum CJ AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway. AD - Department of Urology, St. Olav's University Hospital, 7030 Trondheim, Norway. LA - eng GR - 2017/22110/Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (SO)/ GR - 2019/38882/The Joint Research Committee between St. Olav's Hospital and the Faculty of Medicine and Health Sciences, NTNU (FFU)/ GR - 2016/43/16/Kreftfondet (Cancer Research Fund), St. Olav's Hospital/ PT - Journal Article DEP - 20240420 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11049458 OTO - NOTNLM OT - EV OT - biomarker OT - bladder cancer OT - exosomes OT - tRF OT - tRNA OT - tRNA-derived fragment COIS- The authors claim no conflicts of interest. EDAT- 2024/04/27 09:54 MHDA- 2024/04/27 09:55 PMCR- 2024/04/20 CRDT- 2024/04/27 01:06 PHST- 2024/03/29 00:00 [received] PHST- 2024/04/16 00:00 [revised] PHST- 2024/04/18 00:00 [accepted] PHST- 2024/04/27 09:55 [medline] PHST- 2024/04/27 09:54 [pubmed] PHST- 2024/04/27 01:06 [entrez] PHST- 2024/04/20 00:00 [pmc-release] AID - cancers16081588 [pii] AID - cancers-16-01588 [pii] AID - 10.3390/cancers16081588 [doi] PST - epublish SO - Cancers (Basel). 2024 Apr 20;16(8):1588. doi: 10.3390/cancers16081588. PMID- 38668066 OWN - NLM STAT- MEDLINE DCOM- 20240426 LR - 20240524 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 31 IP - 4 DP - 2024 Apr 12 TI - Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review. PG - 2201-2220 LID - 10.3390/curroncol31040163 [doi] AB - Bladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health system associated with therapy. In this clinical scenario, strategies such as active surveillance have emerged that propose to manage low-risk BC with follow-up; however, due to the low evidence available, this is a strategy that is underutilized by clinicians. On the other hand, in the era of biomarkers, it is increasingly known how to use them as a tool in BC. Therefore, the aim of this review is to provide to clinical practitioners the evidence available to date on AS and the potential role of biomarkers in this therapeutic strategy in patients with low-grade/risk NMIBC. This is the first review linking use of biomarkers and active surveillance, including 29 articles. FAU - Parrao, Diego AU - Parrao D AUID- ORCID: 0000-0003-0411-0672 AD - School of Medicine, University of O'Higgins, Rancagua 282000, Chile. FAU - Lizana, Nemecio AU - Lizana N AUID- ORCID: 0000-0002-3824-4129 AD - School of Medicine, University of O'Higgins, Rancagua 282000, Chile. FAU - Saavedra, Catalina AU - Saavedra C AD - School of Medicine, University of O'Higgins, Rancagua 282000, Chile. FAU - Larranaga, Matias AU - Larranaga M AUID- ORCID: 0009-0006-2146-5677 AD - Department of Urology, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile. FAU - Lindsay, Carolina B AU - Lindsay CB AD - Research Department, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile. FAU - San Francisco, Ignacio F AU - San Francisco IF AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Bravo, Juan Cristobal AU - Bravo JC AUID- ORCID: 0000-0001-8581-7658 AD - Department of Urology, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240412 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Biomarkers, Tumor MH - *Non-Muscle Invasive Bladder Neoplasms/diagnosis MH - Watchful Waiting/methods PMC - PMC11048875 OTO - NOTNLM OT - NMIBC OT - TURBT OT - active surveillance OT - biomarkers OT - bladder cancer OT - cystoscopy COIS- The authors declare no conflicts of interest. EDAT- 2024/04/26 13:22 MHDA- 2024/04/26 13:23 PMCR- 2024/04/12 CRDT- 2024/04/26 09:28 PHST- 2024/03/15 00:00 [received] PHST- 2024/04/05 00:00 [revised] PHST- 2024/04/11 00:00 [accepted] PHST- 2024/04/26 13:23 [medline] PHST- 2024/04/26 13:22 [pubmed] PHST- 2024/04/26 09:28 [entrez] PHST- 2024/04/12 00:00 [pmc-release] AID - curroncol31040163 [pii] AID - curroncol-31-00163 [pii] AID - 10.3390/curroncol31040163 [doi] PST - epublish SO - Curr Oncol. 2024 Apr 12;31(4):2201-2220. doi: 10.3390/curroncol31040163. PMID- 38667314 OWN - NLM STAT- MEDLINE DCOM- 20240426 LR - 20260922 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 13 IP - 8 DP - 2024 Apr 18 TI - Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guerin Immunotherapy of Bladder Cancer. LID - 10.3390/cells13080699 [doi] LID - 699 AB - The clinical management of bladder cancer continues to present significant challenges. Bacillus Calmette-Guerin (BCG) immunotherapy remains the gold standard of treatment for non-muscle invasive bladder cancer (NMIBC), but many patients develop recurrence and progression to muscle-invasive disease (MIBC), which is resistant to BCG. This review focuses on the immune mechanisms mobilized by BCG in bladder cancer tumor microenvironments (TME), mechanisms of BCG resistance, the dual role of the BCG-triggered NFkB/TNFalpha/PGE2 axis in the regulation of anti-tumor and tumor-promoting aspects of inflammation, and emerging strategies to modulate their balance. A better understanding of BCG resistance will help develop new treatments and predictive biomarkers, paving the way for improved clinical outcomes in bladder cancer patients. FAU - Ibrahim, Omar M AU - Ibrahim OM AUID- ORCID: 0000-0002-9903-6657 AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. FAU - Kalinski, Pawel AU - Kalinski P AUID- ORCID: 0000-0001-7025-3562 AD - Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. LA - eng GR - P01CA132714/CA/NCI NIH HHS/United States GR - P50 CA159981/CA/NCI NIH HHS/United States GR - P01CA234212/CA/NCI NIH HHS/United States GR - P01 CA234212/CA/NCI NIH HHS/United States GR - P01 CA132714/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240418 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (BCG Vaccine) SB - IM MH - *Urinary Bladder Neoplasms/immunology/therapy/drug therapy/pathology MH - Humans MH - *Tumor Microenvironment/immunology MH - *BCG Vaccine/therapeutic use/immunology MH - *Immunotherapy/methods MH - Animals PMC - PMC11049012 OTO - NOTNLM OT - BCG OT - Toll-like-receptors OT - bladder cancer OT - chemokines OT - cytokines OT - immunotherapy OT - inflammation OT - lymphocytes OT - macrophages OT - tumor microenvironment OT - urothelial cancer COIS- PK received past research funding from IKENA, which develops selective EP4 blockers. EDAT- 2024/04/26 13:21 MHDA- 2024/04/26 13:22 PMCR- 2024/04/18 CRDT- 2024/04/26 09:16 PHST- 2024/02/16 00:00 [received] PHST- 2024/04/13 00:00 [revised] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/04/26 13:22 [medline] PHST- 2024/04/26 13:21 [pubmed] PHST- 2024/04/26 09:16 [entrez] PHST- 2024/04/18 00:00 [pmc-release] AID - cells13080699 [pii] AID - cells-13-00699 [pii] AID - 10.3390/cells13080699 [doi] PST - epublish SO - Cells. 2024 Apr 18;13(8):699. doi: 10.3390/cells13080699. PMID- 38659423 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240426 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 27 IP - 6 DP - 2024 Jun TI - Perfusion drugs for non‑muscle invasive bladder cancer (Review). PG - 267 LID - 10.3892/ol.2024.14400 [doi] LID - 267 AB - The high recurrence rate and poor prognosis of non-muscle invasive bladder cancer (BC) are challenges that need to be urgently addressed. Transurethral cystectomy for bladder tumors is often combined with bladder perfusion therapy, which can effectively reduce the recurrence and progression rates of BC. The present review integrated and analyzed currently available bladder perfusion drugs, mainly including chemotherapeutic agents, immunotherapeutic agents and other adjuvant perfusion drugs. Bacillus Calmette-Guerin (BCG) perfusion was the pioneering immunotherapy for early BC and still ranks high in the selection of perfusion drugs. However, BCG infusion has a high toxicity profile and has been shown to be ineffective in some patients. Due to the limitations of BCG, new bladder perfusion drugs are constantly being developed. Immunotherapeutic agents have opened a whole new chapter in the selection of therapeutic agents for bladder perfusion. The present review explored the mechanism of action, clinical dosage and adverse effects of a variety of bladder perfusion drugs currently in common use, described combined perfusion and compared the effects of certain drugs on BC. CI - Copyright: (c) 2024 Qian et al. FAU - Qian, Jingyuan AU - Qian J AD - Department of Nursing, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Zhang, Qiuchen AU - Zhang Q AD - Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Cao, Yang AU - Cao Y AD - Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Chu, Xi AU - Chu X AD - Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Gao, Yiyang AU - Gao Y AD - Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Xu, Haifei AU - Xu H AD - Department of Urology, Nantong Tumor Hospital, Nantong, Jiangsu 226006, P.R. China. FAU - Cai, Hongzhou AU - Cai H AD - Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. FAU - Wu, Jiajia AU - Wu J AD - Department of Nursing, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China. LA - eng PT - Journal Article PT - Review DEP - 20240415 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC11040539 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - chemotherapy OT - interferon OT - perfusion therapy COIS- The authors declare that they have no competing interests. EDAT- 2024/04/25 06:49 MHDA- 2024/04/25 06:50 PMCR- 2024/04/15 CRDT- 2024/04/25 03:45 PHST- 2024/02/16 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/04/25 06:50 [medline] PHST- 2024/04/25 06:49 [pubmed] PHST- 2024/04/25 03:45 [entrez] PHST- 2024/04/15 00:00 [pmc-release] AID - OL-27-6-14400 [pii] AID - 10.3892/ol.2024.14400 [doi] PST - epublish SO - Oncol Lett. 2024 Apr 15;27(6):267. doi: 10.3892/ol.2024.14400. eCollection 2024 Jun. PMID- 38658172 OWN - NLM STAT- MEDLINE DCOM- 20240924 LR - 20250711 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 4 DP - 2024 Oct TI - Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis. PG - 526-533 LID - 10.1111/bju.16364 [doi] AB - OBJECTIVE: To compare the value of flexible blue-light cystoscopy (BLC) vs flexible white-light cystoscopy (WLC) in the surveillance setting of non-muscle-invasive bladder cancer (NMIBC). METHODS: All major databases were searched for articles published before May 2023 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome was the accuracy of flexible BLC vs WLC in detecting bladder cancer recurrence among suspicious bladder lesions. RESULTS: A total of 10 articles, comprising 1634 patients, were deemed eligible for the quantitative synthesis. In the meta-analysis focusing on the detection of disease recurrence, there was no difference between flexible BLC and WLC (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.82-1.41)]; the risk difference (RD) showed 1% of flexible BLC, corresponding to a number needed to treat (NNT) of 100. In the subgroup meta-analysis of detection of carcinoma in situ (CIS) only, there was again no significant difference between flexible BLC and WLC (OR 1.19, 95% CI 0.82-1.69), BLC was associated with a RD of 2% (NNT = 50). The positive predictive values for flexible BLC and WLC in detecting all types of recurrence were 72% and 66%, respectively, and for CIS they were 39% and 29%, respectively. CONCLUSION: Surveillance of NMIBC with flexible BLC could detect more suspicious lesions and consequently more tumour recurrences compared to flexible WLC, with a increase in the rate of false positives leading to overtreatment. A total of 100 and 50 flexible BLC procedures would need to be performed to find on additional tumor and CIS recurences, respectively. A risk-stratified strategy for patient selection could be considered when using flexible BLC for the surveillance of NMIBC patients. CI - (c) 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AUID- ORCID: 0000-0002-3819-9911 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Ghoreifi, Alireza AU - Ghoreifi A AUID- ORCID: 0000-0002-7368-7240 AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kawada, Tatsushi AU - Kawada T AUID- ORCID: 0000-0002-8369-9712 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Ahyai, Sascha AU - Ahyai S AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Merseburger, Axel S AU - Merseburger AS AD - Department of Urology, Campus Lubeck, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - The National Center for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan. FAU - Abern, Michael AU - Abern M AD - Department of Urology, Duke University, Durham, NC, USA. FAU - Djaladat, Hooman AU - Djaladat H AUID- ORCID: 0000-0002-1984-3556 AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AUID- ORCID: 0000-0001-6224-9598 AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20240424 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - *Urinary Bladder Neoplasms/pathology/diagnosis MH - Humans MH - *Cystoscopy/methods MH - Neoplasm Recurrence, Local MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - CIS OT - bladder cancer OT - blue-light cystoscopy OT - carcinoma in situ OT - flexible cystoscopy OT - recurrence EDAT- 2024/04/25 00:54 MHDA- 2024/09/24 22:18 CRDT- 2024/04/24 21:23 PHST- 2024/09/24 22:18 [medline] PHST- 2024/04/25 00:54 [pubmed] PHST- 2024/04/24 21:23 [entrez] AID - 10.1111/bju.16364 [doi] PST - ppublish SO - BJU Int. 2024 Oct;134(4):526-533. doi: 10.1111/bju.16364. Epub 2024 Apr 24. PMID- 38645508 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250401 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 11 DP - 2024 TI - A retrospective study of paraganglioma of the urinary bladder and literature review. PG - 1348737 LID - 10.3389/fsurg.2024.1348737 [doi] LID - 1348737 AB - OBJECTIVE: To review and summarize the characteristics and therapy of paraganglioma of the urinary bladder (PUB). METHOD: Patients who underwent the operation in Peking Union Medical College Hospital between January 2012 and December 2021 were reviewed for this retrospective study. RESULTS: A total of 29 patients, comprising 9 (31%) men and 20 (69%) women, were included. The main manifestations were hypertension, palpitation, and micturition syncope. Eight patients had an increased 24-h urinary catecholamine, and seven of them had increased norepinephrine. Normetanephrine in seven patients was increased. Six of 18 metaiodobenzylguanidine and 8 of 22 octreotide scans were positive. In total, 15 cases underwent laparoscopic partial cystectomy and 14 underwent transurethral resection of bladder tumor. In all patients, the immunohistochemical index of Melan-A, AE1/AE3, and alpha-inhibin were negative, and chromogranin A, S-100, and succinate dehydrogenase were positive. The Ki-67 of 28/29 cases was under 5%, and 1 case with a Ki-67 of 20% was diagnosed with malignant PUB. A total of 27 patients had a regular follow-up, 2 patients were lost during the follow-up, 3 patients had a recurrence, and 1 of these patients died within 1 year of surgery. The symptoms all disappeared or were relieved after the surgery. CONCLUSION: The transurethral surgery approach fits PUB tumors with a size <3 cm or that protrudes into the bladder and can significantly reduce the postoperative hospital stay. Early detection and treatment are effective, and regular review is necessary after the surgery. CI - (c) 2024 Zhao, Zhang, Wang, Wen, Wang, Ji, Zhang and Li. FAU - Zhao, Yi AU - Zhao Y AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Zhijun AU - Zhang Z AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, ShiJun AU - Wang S AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wen, Jin AU - Wen J AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Dong AU - Wang D AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Ji, ZhiGang AU - Ji Z AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, YuShi AU - Zhang Y AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, HanZhong AU - Li H AD - Institution of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article DEP - 20240405 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 EIN - Front Surg. 2025 Mar 04;12:1556161. doi: 10.3389/fsurg.2025.1556161. PMID: 40104408 PMC - PMC11026576 OTO - NOTNLM OT - cystectomy OT - diagnosis OT - paraganglioma of the urinary bladder OT - prognosis OT - transurethral resection of bladder tumor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/04/22 06:44 MHDA- 2024/04/22 06:45 PMCR- 2024/04/05 CRDT- 2024/04/22 04:04 PHST- 2023/12/03 00:00 [received] PHST- 2024/03/20 00:00 [accepted] PHST- 2024/04/22 06:44 [pubmed] PHST- 2024/04/22 06:45 [medline] PHST- 2024/04/22 04:04 [entrez] PHST- 2024/04/05 00:00 [pmc-release] AID - 10.3389/fsurg.2024.1348737 [doi] PST - epublish SO - Front Surg. 2024 Apr 5;11:1348737. doi: 10.3389/fsurg.2024.1348737. eCollection 2024. PMID- 38641323 OWN - NLM STAT- MEDLINE DCOM- 20240621 LR - 20260823 IS - 1530-0285 (Electronic) IS - 0893-3952 (Linking) VI - 37 IP - 6 DP - 2024 Jun TI - Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma. PG - 100495 LID - S0893-3952(24)00075-9 [pii] LID - 10.1016/j.modpat.2024.100495 [doi] AB - Homozygous deletion of the chromosomal region 9p21.3 is common in urothelial carcinoma (UC) and leads to loss of several genes, including CDKN2A and MTAP, resulting in loss of MTAP protein expression. Here, we aimed to explore the diagnostic potential of MTAP immunohistochemistry (IHC) as a surrogate marker for homozygous 9p21.3 deletion (9p21 homozygous deletion [HD]) in UC. MTAP status was determined by IHC on 27 UC tissue specimens with known 9p21.3 status as defined by fluorescence in situ hybridization in matched cytological specimens, by IHC and fluorescence in situ hybridization on a tissue microarray (TMA) containing 359 UC at different stages, and by IHC on 729 consecutive UC from routine practice. Moreover, we analyzed a longitudinal series of matched specimens from 38 patients with MTAP-negative recurrent UC. MTAP loss by IHC was found in all 17 patients with 9p21 HD and in 2/8 cases without 9p21 HD. In the TMA, MTAP loss was more common in metastases (53%) than in muscle-invasive (33%) and non-muscle-invasive UC (29%) (P = .03). In the consecutive series, 164/729 (22%) cases showed loss of MTAP expression. In 41 of these 164 cases (25%), loss of MTAP expression was heterogenous. We also discovered loss of MTAP expression in flat urothelium adjacent to MTAP-negative low-grade UC, suggesting true flat low-grade neoplasia that could not be diagnosed by morphology alone. Longitudinal analysis of recurrences showed persistent negative MTAP status over time in 37/38 (97%) patients. MTAP IHC can serve as a surrogate marker for 9p21 HD in UC and as a diagnostic tool to differentiate reactive urothelium from urothelial neoplasia. It also provides a unique opportunity to study clinicopathological associations and the heterogeneity of 9p21 HD across the whole spectrum of UC manifestations. CI - Copyright (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. FAU - Vlajnic, Tatjana AU - Vlajnic T AD - Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: Tatjana.Vlajnic@usb.ch. FAU - Chijioke, Obinna AU - Chijioke O AD - Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Roma, Luca AU - Roma L AD - Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Savic Prince, Spasenija AU - Savic Prince S AD - Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Zellweger, Tobias AU - Zellweger T AD - Division of Urology, St. Clara Hospital, Basel, Switzerland. FAU - Rentsch, Cyrill A AU - Rentsch CA AD - Department of Urology, University Hospital Basel, Basel, Switzerland. FAU - Bubendorf, Lukas AU - Bubendorf L AD - Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. LA - eng PT - Journal Article DEP - 20240417 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Biomarkers, Tumor) RN - EC 2.4.2.28 (5'-methylthioadenosine phosphorylase) RN - EC 2.4.2.1 (Purine-Nucleoside Phosphorylase) SB - IM MH - Humans MH - *Immunohistochemistry MH - *Biomarkers, Tumor/analysis/genetics MH - *Chromosomes, Human, Pair 9/genetics MH - Female MH - Male MH - Middle Aged MH - Aged MH - *Purine-Nucleoside Phosphorylase/analysis/genetics MH - *In Situ Hybridization, Fluorescence MH - *Urinary Bladder Neoplasms/genetics/pathology/metabolism MH - Chromosome Deletion MH - Carcinoma, Transitional Cell/genetics/pathology/metabolism MH - Adult MH - Tissue Array Analysis MH - Aged, 80 and over MH - Homozygote OTO - NOTNLM OT - 9p21 deletion OT - MTAP OT - MTAP immunohistochemistry OT - urothelial carcinoma EDAT- 2024/04/20 00:43 MHDA- 2024/06/22 05:43 CRDT- 2024/04/19 19:33 PHST- 2023/08/13 00:00 [received] PHST- 2024/02/13 00:00 [revised] PHST- 2024/04/10 00:00 [accepted] PHST- 2024/06/22 05:43 [medline] PHST- 2024/04/20 00:43 [pubmed] PHST- 2024/04/19 19:33 [entrez] AID - S0893-3952(24)00075-9 [pii] AID - 10.1016/j.modpat.2024.100495 [doi] PST - ppublish SO - Mod Pathol. 2024 Jun;37(6):100495. doi: 10.1016/j.modpat.2024.100495. Epub 2024 Apr 17. PMID- 38637674 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240426 IS - 2398-6352 (Electronic) IS - 2398-6352 (Linking) VI - 7 IP - 1 DP - 2024 Apr 18 TI - Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI. PG - 98 LID - 10.1038/s41746-024-01088-7 [doi] LID - 98 AB - Accurate prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) is essential to inform management and eligibility for clinical trials. Despite substantial interest in developing artificial intelligence (AI) applications in NMIBC, their clinical readiness remains unclear. This systematic review aimed to critically appraise AI studies predicting NMIBC outcomes, and to identify common methodological and reporting pitfalls. MEDLINE, EMBASE, Web of Science, and Scopus were searched from inception to February 5th, 2024 for AI studies predicting NMIBC recurrence or progression. APPRAISE-AI was used to assess methodological and reporting quality of these studies. Performance between AI and non-AI approaches included within these studies were compared. A total of 15 studies (five on recurrence, four on progression, and six on both) were included. All studies were retrospective, with a median follow-up of 71 months (IQR 32-93) and median cohort size of 125 (IQR 93-309). Most studies were low quality, with only one classified as high quality. While AI models generally outperformed non-AI approaches with respect to accuracy, c-index, sensitivity, and specificity, this margin of benefit varied with study quality (median absolute performance difference was 10 for low, 22 for moderate, and 4 for high quality studies). Common pitfalls included dataset limitations, heterogeneous outcome definitions, methodological flaws, suboptimal model evaluation, and reproducibility issues. Recommendations to address these challenges are proposed. These findings emphasise the need for collaborative efforts between urological and AI communities paired with rigorous methodologies to develop higher quality models, enabling AI to reach its potential in enhancing NMIBC care. CI - (c) 2024. The Author(s). FAU - Kwong, Jethro C C AU - Kwong JCC AUID- ORCID: 0000-0003-4728-1025 AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada. FAU - Wu, Jeremy AU - Wu J AD - Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Malik, Shamir AU - Malik S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Khondker, Adree AU - Khondker A AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Gupta, Naveen AU - Gupta N AD - Georgetown University School of Medicine, Georgetown University, Washington, DC, USA. AD - Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. FAU - Bodnariuc, Nicole AU - Bodnariuc N AD - Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Narayana, Krishnateja AU - Narayana K AD - Western University, London, ON, Canada. FAU - Malik, Mikail AU - Malik M AD - Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. FAU - Johnson, Alistair E W AU - Johnson AEW AD - Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada. AD - Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada. AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AUID- ORCID: 0000-0002-6929-6124 AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. girish.kulkarni@uhn.ca. AD - Temerty Centre for AI Research and Education in Medicine, University of Toronto, Toronto, ON, Canada. girish.kulkarni@uhn.ca. AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. girish.kulkarni@uhn.ca. LA - eng PT - Journal Article PT - Review DEP - 20240418 PL - England TA - NPJ Digit Med JT - NPJ digital medicine JID - 101731738 PMC - PMC11026453 COIS- A.R.Z. reports participation on a data safety monitoring board or advisory board for Janssen, Verity Pharmaceuticals, Ferring, mIR Scientific, Tolmar, and Theralase; and consulting fees from Janssen, Verity Pharmaceuticals, Ferring, mIR Scientific, Tolmar, and Theralase. G.S.K. reports advisory, consultant, or trial work with Merck, BMS, EMD Serono, Pfizer, Janssen, Ferring, Theralase, Verity, TerSera, Knight Therapeutics, PhotoCure, Astra Zeneca. All other authors declare no competing interests. EDAT- 2024/04/19 00:44 MHDA- 2024/04/19 00:45 PMCR- 2024/04/18 CRDT- 2024/04/18 23:37 PHST- 2023/11/02 00:00 [received] PHST- 2024/03/29 00:00 [accepted] PHST- 2024/04/19 00:45 [medline] PHST- 2024/04/19 00:44 [pubmed] PHST- 2024/04/18 23:37 [entrez] PHST- 2024/04/18 00:00 [pmc-release] AID - 10.1038/s41746-024-01088-7 [pii] AID - 1088 [pii] AID - 10.1038/s41746-024-01088-7 [doi] PST - epublish SO - NPJ Digit Med. 2024 Apr 18;7(1):98. doi: 10.1038/s41746-024-01088-7. PMID- 38633828 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240425 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 5 IP - 4 DP - 2024 Apr TI - Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer. PG - 473-479 LID - 10.1002/bco2.304 [doi] AB - OBJECTIVES: We aim to assess the clinical value of (18)F-fluorodeoxyglucose positron ((18)F-FDG-PET) scan in detecting nodal and distant metastasis compared with computed tomography (CT) scan in patients with urothelial carcinoma or bladder cancer, aiming to improve staging accuracy and thereby better prognosticate and determine therapy. METHODS: A retrospective review of 75 patients with invasive bladder cancer (>/=T1) who were staged with both CT and (18)F-FDG-PET within an 8-week interval was performed for the period between 2015 and 2020. Seventy-two per cent (54/75) had formal pelvic lymph node (LN) dissection or biopsy of lesions suspicious for metastases. FDG-PET definitions for positive sites were assessed depending on SUV Max (nodes with SUVmax >4 at any size, SUV > 2 for lymph nodes >8 mm, or any SUV if the lymph node was >10 mm on axial images). For CT scanning, enlarged LN by RECIST 1.1 criteria (>10 mm) as well as qualitative findings suggesting metastasis were considered positive. The analysis was based on the comparison of CT and (18)F-FDG-PET findings to histopathology results from LN dissection or biopsies. RESULTS: Sensitivity, specificity, positive predictive values (PPV) and negative predictive value (NPV) of CT versus FDG-PET for detecting metastasis, in patients who underwent pelvic LN dissection or biopsy of lesions suspicious of metastases, were 46.6% (95% CI: 21%-70%) versus 60% (95% CI: 32%-84%), 100% (95% CI: 91%-100%) versus 83.78% (95% CI: 69%-94%), 100% (95% CI: 63%-100%) versus 60% (95% CI: 32%-84%), and 82.2% (95% CI: 68%-92%) versus 83.78% (95% CI: 69%-94%), respectively. 7/75 (9.3%) patients avoided cystectomy due to (18)F-FDG-PET features of metastases that were not detected by CT. CONCLUSION: FDG-PET may be more sensitive than CT for metastases in the staging of bladder cancer, which resulted in significant avoidance of aggressive local management in cases with occult metastasis. CI - (c) 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Al-Zubaidi, Mohammed AU - Al-Zubaidi M AUID- ORCID: 0000-0001-9375-7229 AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. AD - UWA Medical School University of Western Australia Crawley Australia. FAU - Ong, Katherine AU - Ong K AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. FAU - Viswambaram, Pravin AU - Viswambaram P AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. AD - UWA Medical School University of Western Australia Crawley Australia. FAU - Bangash, Haider AU - Bangash H AUID- ORCID: 0000-0003-4037-240X AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. FAU - Boardman, Glenn AU - Boardman G AD - Research Support and Development Unit Fiona Stanley Hospital Murdoch Australia. FAU - McCombie, Steve P AU - McCombie SP AUID- ORCID: 0000-0002-3920-994X AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. AD - UWA Medical School University of Western Australia Crawley Australia. FAU - Oey, Oliver AU - Oey O AD - UWA Medical School University of Western Australia Crawley Australia. FAU - Swarbrick, Nicole AU - Swarbrick N AD - Pathwest Fiona Stanley Hospital Murdoch Australia. FAU - Redfern, Andrew AU - Redfern A AD - Department of Medical Oncology Fiona Stanley Hospital Murdoch Australia. FAU - Ong, Jeremy AU - Ong J AD - Department of Nuclear Medicine Fiona Stanley Hospital Murdoch Australia. FAU - Gauci, Richard AU - Gauci R AD - Department of Nuclear Medicine Fiona Stanley Hospital Murdoch Australia. FAU - Low, Ronny AU - Low R AD - Department of Radiology Fiona Stanley Hospital Murdoch Australia. FAU - Hayne, Dickon AU - Hayne D AD - Department of Urology Fiona Stanley Hospital Murdoch Australia. AD - UWA Medical School University of Western Australia Crawley Australia. LA - eng PT - Journal Article DEP - 20240220 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC11019246 OTO - NOTNLM OT - CT scan OT - FDG-PET OT - bladder cancer OT - metastasis OT - neoadjuvant chemotherapy OT - radical cystectomy OT - urothelial carcinoma COIS- None. EDAT- 2024/04/18 06:43 MHDA- 2024/04/18 06:44 PMCR- 2024/02/20 CRDT- 2024/04/18 04:12 PHST- 2023/04/17 00:00 [received] PHST- 2023/09/15 00:00 [revised] PHST- 2023/09/26 00:00 [accepted] PHST- 2024/04/18 06:44 [medline] PHST- 2024/04/18 06:43 [pubmed] PHST- 2024/04/18 04:12 [entrez] PHST- 2024/02/20 00:00 [pmc-release] AID - BCO2304 [pii] AID - 10.1002/bco2.304 [doi] PST - epublish SO - BJUI Compass. 2024 Feb 20;5(4):473-479. doi: 10.1002/bco2.304. eCollection 2024 Apr. PMID- 38631711 OWN - NLM STAT- MEDLINE DCOM- 20240419 LR - 20250811 IS - 2051-1426 (Electronic) IS - 2051-1426 (Linking) VI - 12 IP - 4 DP - 2024 Apr 16 TI - Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. LID - 10.1136/jitc-2023-008571 [doi] LID - e008571 AB - Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Yet, only half of the early responders will continue to be disease-free by 12 months, and resistance mechanisms are poorly defined. We performed spatial profiling of BCG-unresponsive tumors from patients responsive or resistant to intravenous pembrolizumab treatment, analyzing samples both before initiating and 3 months post-intravenous pembrolizumab treatment. We analyzed 119 regions of interest, which included 59 pairs of epithelial and adjacent stromal segments across five patients: two responders and three non-responders. We demonstrate that BCG unresponsive tumors with an inflamed PanCK+ tumor area and an infiltrated stromal segment respond better to intravenous pembrolizumab. Furthermore, using segment-specific gene signatures generated from a cohort of BCG unresponsive NMIBC treated with intravesical BCG+pembrolizumab, we find that non-inflamed, immune-cold tumors that do not respond to intravenous pembrolizumab exhibit a favorable outcome to the combined application of BCG and pembrolizumab. For the first time, we have identified molecular features of tumors associated with response and resistance to intravenous pembrolizumab in BCG unresponsive NMIBCs. Further research with more patients and alternative checkpoint inhibitors is essential to validate our findings. We anticipate that using a transcriptomics signature like the one described here can help identify tumors with a higher possibility of responding to intravenous pembrolizumab. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Meghani, Khyati AU - Meghani K AD - Departments of Urology, and Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Frydenlund, Noah AU - Frydenlund N AD - Departments of Urology, and Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Yu, Yanni AU - Yu Y AD - Departments of Urology, and Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Choy, Bonnie AU - Choy B AD - Department of Pathology, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Meeks, Joshua J AU - Meeks JJ AUID- ORCID: 0000-0002-5444-5510 AD - Departments of Urology, and Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, Illinois, USA joshua.meeks@northwestern.edu. AD - Jesse Brown VA Medical Center, Chicago, Illinois, USA. LA - eng GR - I01 BX003692/BX/BLRD VA/United States GR - I01 BX005599/BX/BLRD VA/United States GR - P30 CA060553/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240416 PL - England TA - J Immunother Cancer JT - Journal for immunotherapy of cancer JID - 101620585 RN - DPT0O3T46P (pembrolizumab) RN - 0 (BCG Vaccine) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM UOF - medRxiv. 2023 Nov 29:2023.11.28.23299093. doi: 10.1101/2023.11.28.23299093. PMID: 38077072 MH - Humans MH - BCG Vaccine MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Antibodies, Monoclonal, Humanized PMC - PMC11029500 OTO - NOTNLM OT - Biomarker OT - Bladder Cancer OT - Genitourinary Cancer OT - Immune Checkpoint Inhibitor COIS- Competing interests: NF: Research Funding from the AUA FoundationJM advisory board/consulting: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring; Research Funding: VHA, NIH, DoD, Compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday; Clinical Trials: SWOG, Genentech, Merck, AstraZeneca. EDAT- 2024/04/18 00:45 MHDA- 2024/04/19 06:43 PMCR- 2024/04/16 CRDT- 2024/04/17 20:43 PHST- 2024/04/04 00:00 [accepted] PHST- 2024/04/19 06:43 [medline] PHST- 2024/04/18 00:45 [pubmed] PHST- 2024/04/17 20:43 [entrez] PHST- 2024/04/16 00:00 [pmc-release] AID - jitc-2023-008571 [pii] AID - 10.1136/jitc-2023-008571 [doi] PST - epublish SO - J Immunother Cancer. 2024 Apr 16;12(4):e008571. doi: 10.1136/jitc-2023-008571. PMID- 38627025 OWN - NLM STAT- MEDLINE DCOM- 20240924 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 4 DP - 2024 Oct TI - Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer. PG - 644-651 LID - 10.1111/bju.16371 [doi] AB - OBJECTIVE: To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients. PATIENTS AND METHODS: In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low- or high-risk NMIBC were excluded from the analysis. Associations between adjuvant therapy administration with recurrence-free survival (RFS) and progression-free survival (PFS) rates were assessed in Cox regression models. RESULTS: A total of 2206 patients with intermediate-risk NMIBC were included in the analysis. Among them, 1427 patients underwent adjuvant therapy, such as bacille Calmette-Guerin (n = 168), or chemotherapeutic agents, such as mitomycin C or epirubicin (n = 1259), in different regimens up to 1 year. The median (interquartile range) follow-up was 73.3 (38.4-106.9) months. The RFS at 1 and 5 years in patients treated with adjuvant therapy and those without were 72.6% vs 69.5% and 50.8% vs 41.3%, respectively. Adjuvant therapy was associated with better RFS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.70-0.89, P < 0.001), but not with PFS (P = 0.09). In the subgroup of patients aged 70 years, tumour multiplicity, recurrent tumour and tumour size >/=3 cm (n = 1878), adjuvant intravesical therapy was associated with improved RFS (HR 0.78, 95% CI 0.68-0.88, P < 0.001). CONCLUSION: In our study, patients with intermediate-risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate. CI - (c) 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. FAU - Trinh, Quoc-Dien AU - Trinh QD AUID- ORCID: 0000-0003-3857-9276 AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Chlosta, Piotr AU - Chlosta P AD - Department of Urology, Jagiellonian University, Cracow, Poland. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Klemm, Jakob AU - Klemm J AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bekku, Kensuke AU - Bekku K AUID- ORCID: 0000-0003-0002-1592 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AUID- ORCID: 0000-0002-3324-762X AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Semmelweis University, Budapest, Hungary. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. AD - Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240416 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) RN - 3Z8479ZZ5X (Epirubicin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy/drug therapy/mortality MH - Male MH - Female MH - Aged MH - Retrospective Studies MH - Administration, Intravesical MH - Middle Aged MH - Chemotherapy, Adjuvant MH - BCG Vaccine/therapeutic use/administration & dosage MH - Neoplasm Invasiveness MH - Mitomycin/administration & dosage/therapeutic use MH - Cystectomy/methods MH - Epirubicin/administration & dosage MH - Disease-Free Survival MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - NMIBC OT - adjuvant OT - chemotherapy OT - intravesical EDAT- 2024/04/17 00:43 MHDA- 2024/09/24 18:51 CRDT- 2024/04/16 21:13 PHST- 2024/09/24 18:51 [medline] PHST- 2024/04/17 00:43 [pubmed] PHST- 2024/04/16 21:13 [entrez] AID - 10.1111/bju.16371 [doi] PST - ppublish SO - BJU Int. 2024 Oct;134(4):644-651. doi: 10.1111/bju.16371. Epub 2024 Apr 16. PMID- 38624056 OWN - NLM STAT- MEDLINE DCOM- 20240417 LR - 20250730 IS - 0006-9248 (Print) IS - 0006-9248 (Linking) VI - 125 IP - 5 DP - 2024 TI - Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence. PG - 311-317 LID - 10.4149/BLL_2024_46 [doi] AB - OBJECTIVES: In this study, we analyzed pTa bladder cancer (BC) for molecular markers BCL2, TP53, FOXA1, and GATA3 in relation to cancer recurrence. METHODS: We analyzed samples of 79 patients with the pTa stage of BC using a real-time polymerase chain reaction (real-time PCR) between September 2018 and September 2020. The expression levels of BCL2, TP53, FOXA1, and GATA3 were compared with homologous non-tumor bladder tissue. RESULTS: Expression of FOXA1, GATA3, and TP53 was significantly higher (p<0.01) in NMIBC samples compared to homologous non-tumor tissue. The expression of TP53 and FOXA1 in pTa was significantly lower (p<0.01) in the high-grade (HG) tumor when compared to the low-grade (LG) tumor. In contrast, the relative quantification (RQ) of GATA3 was significantly higher (p<0.01) in HG pTa. Patients with recurrence (pTa=33) had significantly higher expression of TP53, and GATA3 (p<0.01), and the gene of FOXA1 (p<0.01) had a significantly lower expression when compared to pTa tumors without recurrence. The expression of Bcl-2 was not statistically significant. CONCLUSION: Our results, indicate, that comparing expression levels of these genes in cancer and cancer-free tissue could provide valuable data, as patients with pTa BC recurrence within up to 54 months of follow-up had a significantly higher RQ of TP53, GATA3, and FOXA1 when compared to pTa BC patients without recurrence (Tab. 2, Fig. 8, Ref. 54). Text in PDF www.elis.sk Keywords: bladder cancer, gene expression, recurrence, GATA3, FOXA1, TP53, BCL2. FAU - Varchulova Novakova, Zuzana AU - Varchulova Novakova Z FAU - Harsanyi, Stefan AU - Harsanyi S FAU - Bevizova, Katarina AU - Bevizova K FAU - Kuniakova, Marcela AU - Kuniakova M FAU - Schwarzova, Lucia AU - Schwarzova L FAU - Trebaticky, Branislav AU - Trebaticky B FAU - Danisovic, Lubos AU - Danisovic L FAU - Ziaran, Stanislav AU - Ziaran S LA - eng PT - Journal Article PL - Germany TA - Bratisl Lek Listy JT - Bratislavske lekarske listy JID - 0065324 RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Biomarkers, Tumor) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (GATA3 protein, human) RN - 0 (GATA3 Transcription Factor) RN - 0 (FOXA1 protein, human) RN - 0 (Hepatocyte Nuclear Factor 3-alpha) RN - 0 (BCL2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder/chemistry/metabolism/pathology MH - *Urinary Bladder Neoplasms/genetics MH - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism MH - Biomarkers, Tumor/analysis MH - Tumor Suppressor Protein p53/genetics MH - GATA3 Transcription Factor/genetics/metabolism MH - Hepatocyte Nuclear Factor 3-alpha/genetics/metabolism EDAT- 2024/04/16 12:44 MHDA- 2024/04/17 06:42 CRDT- 2024/04/16 07:43 PHST- 2024/04/17 06:42 [medline] PHST- 2024/04/16 12:44 [pubmed] PHST- 2024/04/16 07:43 [entrez] AID - 10.4149/BLL_2024_46 [doi] PST - ppublish SO - Bratisl Lek Listy. 2024;125(5):311-317. doi: 10.4149/BLL_2024_46. PMID- 38619611 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20250224 IS - 2366-0058 (Electronic) VI - 49 IP - 6 DP - 2024 Jun TI - Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics. PG - 1975-1986 LID - 10.1007/s00261-024-04265-0 [doi] AB - OBJECTIVE: To investigate multiphase computed tomography (CT) radiomics-based combined with clinical factors to predict overall survival (OS) in patients with bladder urothelial carcinoma (BLCA) who underwent transurethral resection of bladder tumor (TURBT). METHODS: Data were retrospectively collected from 114 patients with primary BLCA from February 2016 to February 2018. The regions of interest (ROIs) of the plain, arterial, and venous phase images were manually segmented. The Cox regression algorithm was used to establish 3 basic models for the plain phase (PP), arterial phase (AP), and venous phase (VP) and 2 combination models (AP + VP and PP + AP + VP). The highest-performing radiomics model was selected to calculate the radiomics score (Rad-score), and independent risk factors affecting patients' OS were analyzed using Cox regression. The Rad-score and clinical risk factors were combined to construct a joint model and draw a visualized nomogram. RESULTS: The combined model of PP + AP + VP showed the best performance with the Akaike Information Criterion (AIC) and Consistency Index (C-index) in the test group of 130.48 and 0.779, respectively. A combined model constructed with two independent risk factors (age and Ki-67 expression status) in combination with the Rad-score outperformed the radiomics model alone; AIC and C-index in the test group were 115.74 and 0.840, respectively. The calibration curves showed good agreement between the predicted probabilities of the joint model and the actual (p < 0.05). The decision curve showed that the joint model had good clinical application value within a large range of threshold probabilities. CONCLUSION: This new model can be used to predict the OS of patients with BLCA who underwent TURBT. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Xue, Jing AU - Xue J AD - Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China. FAU - Zhuang, Zijian AU - Zhuang Z AD - Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China. FAU - Peng, Lin AU - Peng L AD - School of Medicine, Jiangsu University, Zhenjiang, 212001, Jiangsu, China. FAU - Chen, Xingchi AU - Chen X AD - School of Medicine, Jiangsu University, Zhenjiang, 212001, Jiangsu, China. FAU - Zhu, Haitao AU - Zhu H AD - Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China. FAU - Wang, Dongqing AU - Wang D AD - Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China. wangdongqing71@163.com. FAU - Zhang, Lirong AU - Zhang L AD - Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China. tianchen861@ujs.edu.cn. LA - eng GR - K2019024/Key project of Jiangsu Provincial Health Commission/ GR - BK20191223/Natural Science Foundation of Jiangsu Province/ GR - YLJ202111/Scientific research project of Jinshan Talent Training Program for high-level leading Talents/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240415 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 RN - 0 (Contrast Media) SB - IM MH - Humans MH - Male MH - Female MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Prognosis MH - *Tomography, X-Ray Computed/methods MH - Predictive Value of Tests MH - Aged, 80 and over MH - Nomograms MH - Carcinoma, Transitional Cell/diagnostic imaging/pathology MH - Adult MH - Contrast Media MH - Cystectomy/methods MH - Risk Factors MH - Radiomics OTO - NOTNLM OT - Bladder urothelial carcinoma OT - Multiphase CT OT - Overall survival OT - Radiomics EDAT- 2024/04/15 12:45 MHDA- 2024/06/28 12:41 CRDT- 2024/04/15 11:16 PHST- 2023/10/25 00:00 [received] PHST- 2024/02/21 00:00 [accepted] PHST- 2024/02/19 00:00 [revised] PHST- 2024/06/28 12:41 [medline] PHST- 2024/04/15 12:45 [pubmed] PHST- 2024/04/15 11:16 [entrez] AID - 10.1007/s00261-024-04265-0 [pii] AID - 10.1007/s00261-024-04265-0 [doi] PST - ppublish SO - Abdom Radiol (NY). 2024 Jun;49(6):1975-1986. doi: 10.1007/s00261-024-04265-0. Epub 2024 Apr 15. PMID- 38612609 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20240415 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 7 DP - 2024 Mar 28 TI - A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guerin and Immune Checkpoint Inhibitors. LID - 10.3390/ijms25073800 [doi] LID - 3800 AB - Approximately 75% of bladder cancer cases originate as non-muscle-invasive bladder cancer (NMIBC). Despite initial diagnosis, NMIBC commonly recurs, with up to 45% advancing to muscle-invasive bladder cancer (MIBC) and metastatic disease. Treatment for high-risk NMIBC typically includes procedures like transurethral resection and, depending on recurrence risk, intravesical chemotherapy or immunotherapy such as Bacillus Calmette-Guerin (BCG). However, persistent shortages of BCG necessitate alternative first-line treatments. We aim to use a multi-gene signature in high-risk NMIBC patients to determine whether patients may benefit from immune checkpoint inhibitors (ICIs) as an alternative to BCG and to evaluate their clinical utility. The multi-gene signature obtained from the three independent NMIBC cohorts was applied to stratify the UROMOL2016 cohort (n = 476) using consensus clustering. Each subtype was distinguished by biological pathway analysis. Validation analysis using a machine learning algorithm was performed in six independent cohorts including the BRS (n = 283) cohort treated with BCG and the IMvigor210 (n = 298) clinical trials treated with PD-L1 inhibitors. Based on consensus cluster analysis, NMIBC patients in the UROMOL2016 cohort were classified into three classes exhibiting distinguished characteristics, including DNA damage repair (DDR). Survival analysis showed that the NMIBC-DDR class had the highest rates of disease progression (progression-free survival, p = 0.002 by log-rank test) in the UROMOL cohort and benefited from BCG and ICIs (respectively, p = 0.02 and p = 0.03 by log-rank test). This study suggests that the multi-gene signature may have a role in identifying high-risk NMIBC patients and improving the responsiveness of ICIs. Additionally, we propose immunotherapy as a new first-line treatment for patients with high-risk NMIBC because of the shortage of BCG supply. It is important to help more patients prioritize cancer immunotherapy. FAU - Baek, Seung-Woo AU - Baek SW AUID- ORCID: 0000-0003-4664-4162 AD - Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea. AD - Department of Health Sciences, The Graduate School of Dong-A University, Busan 49315, Republic of Korea. LA - eng GR - 2022R1A2C1012173, 2022R1A6A3A01087141, 2023R1A2C1002940/National Research Foundation of Korea/ PT - Journal Article DEP - 20240328 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Immune Checkpoint Inhibitors/therapeutic use MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Immunotherapy MH - *Urinary Bladder Neoplasms/genetics/therapy MH - *Mycobacterium bovis/genetics PMC - PMC11012101 OTO - NOTNLM OT - BCG shortage OT - high-risk non-muscle-invasive bladder cancer OT - immunotherapy OT - molecular subtype OT - prognosis OT - the multi-gene signature COIS- The authors declare no conflicts of interest. EDAT- 2024/04/13 10:43 MHDA- 2024/04/15 06:42 PMCR- 2024/03/28 CRDT- 2024/04/13 01:14 PHST- 2024/03/05 00:00 [received] PHST- 2024/03/25 00:00 [revised] PHST- 2024/03/26 00:00 [accepted] PHST- 2024/04/15 06:42 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:14 [entrez] PHST- 2024/03/28 00:00 [pmc-release] AID - ijms25073800 [pii] AID - ijms-25-03800 [pii] AID - 10.3390/ijms25073800 [doi] PST - epublish SO - Int J Mol Sci. 2024 Mar 28;25(7):3800. doi: 10.3390/ijms25073800. PMID- 38611077 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240425 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 7 DP - 2024 Apr 2 TI - Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy. LID - 10.3390/cancers16071398 [doi] LID - 1398 AB - To evaluate hyperthermic intravesical chemotherapy (HIVEC) using conductive heating and epirubicin in an optimized setting as an alternative to radical cystectomy in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who have failed bacillus Calmette-Guerin (BCG) therapy. We retrospectively analyzed our prospectively recorded database of patients who underwent HIVEC between 11/2017 and 11/2022 at two Swiss University Centers. Cox regression analysis was used for univariate/multivariate analysis, and the Kaplan-Meier method for survival analysis. Of the 39 patients with NMIBC recurrence after failed BCG therapy, 25 (64%) did not recur within the bladder after a median follow-up of 28 months. The 12- and 24-month intravesical RFS were 94.8% and 80%, respectively. Extravesical recurrence developed in 14/39 (36%) of patients. Only 7/39 (18%) patients had to undergo radical cystectomy. Seven patients (18%) progressed to metastatic disease, with five of these (71%) having previously developed extravesical disease. No adverse events > grade 2 occurred during HIVEC. Device-assisted HIVEC using epirubicin in an optimized setting achieved excellent RFS rates in this recurrent NMIBC population at highest risk for recurrence after previously failed intravesical BCG therapy. Extravesical disease during or after HIVEC, however, was frequent and associated with metastatic disease and consecutively poor outcomes. FAU - Blanc, Julien AU - Blanc J AUID- ORCID: 0000-0001-7537-2763 AD - Department of Urology, University Hospital of Lausanne, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Ruggiero, Jonathan AU - Ruggiero J AD - Department of Urology, University Hospital of Lausanne, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Lucca, Ilaria AU - Lucca I AD - Department of Urology, University Hospital of Lausanne, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Arnold, Nicolas AU - Arnold N AD - Department of Urology, University Hospital of Bern, University of Bern, 3010 Bern, Switzerland. FAU - Kiss, Bernhard AU - Kiss B AD - Department of Urology, University Hospital of Bern, University of Bern, 3010 Bern, Switzerland. FAU - Roth, Beat AU - Roth B AD - Department of Urology, University Hospital of Lausanne, University of Lausanne, 1011 Lausanne, Switzerland. AD - Department of Urology, University Hospital of Bern, University of Bern, 3010 Bern, Switzerland. LA - eng PT - Journal Article DEP - 20240402 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11011040 OTO - NOTNLM OT - bladder cancer OT - complications OT - cystectomy OT - gastrointestinal recovery OT - lymph node dissection OT - postoperative pain COIS- The authors declare no conflicts of interest. EDAT- 2024/04/13 10:43 MHDA- 2024/04/13 10:44 PMCR- 2024/04/02 CRDT- 2024/04/13 01:05 PHST- 2024/02/21 00:00 [received] PHST- 2024/03/19 00:00 [revised] PHST- 2024/03/25 00:00 [accepted] PHST- 2024/04/13 10:44 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:05 [entrez] PHST- 2024/04/02 00:00 [pmc-release] AID - cancers16071398 [pii] AID - cancers-16-01398 [pii] AID - 10.3390/cancers16071398 [doi] PST - epublish SO - Cancers (Basel). 2024 Apr 2;16(7):1398. doi: 10.3390/cancers16071398. PMID- 38611034 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240415 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 7 DP - 2024 Mar 29 TI - PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guerin (BCG) Therapy. LID - 10.3390/cancers16071356 [doi] LID - 1356 AB - In the expanding landscape of immune checkpoint inhibitors (CPI) in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC), the role of programmed death ligand 1 (PD-L1) as prognostic and predictive is increasingly significant. However, data evaluating its variability and susceptibility to Bacillus Calmette-Guerin (BCG) therapy in HR NMIBC patients is scarce. This retrospective study analyzed 126 HR NMIBC tissue samples from 63 patients (38x BCG-treated, 25x BCG-naive) at two time points to assess PD-L1 expression using the 'combined positivity score' (CPS) with the 22C3 DAKO antibody method and correlated it with clinicopathological parameters. A CPS > 10 defined PD-L1 positivity. The impact of initial PD-L1 status and its change over time on time-to-recurrence, progression-free survival, and overall survival (TTR, PFS, OS) was analyzed using Kaplan-Meier and Cox proportional hazard models. BCG treatment significantly increased PD-L1 expression (5.31 vs. 0.22, p = 0.0423), with PD-L1 positive cases rising post-treatment in the BCG group and remaining unchanged in BCG-naive patients. Multivariate analysis including T-stage, CIS, grading, tumor size, multifocality, age, and sex revealed a significant correlation between PD-L1 status change to positivity and improved TTR (p = 0.03). Our findings demonstrate a potential modulation of the PD-L1 status by an intravesical BCG therapy. However, its prognostic value appears limited. FAU - Maas, Moritz AU - Maas M AUID- ORCID: 0000-0001-7127-2466 AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. FAU - Hilsendecker, Andreas AU - Hilsendecker A AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Pertoll, Alexandra AU - Pertoll A AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Stuhler, Viktoria AU - Stuhler V AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Walz, Simon AU - Walz S AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Rausch, Steffen AU - Rausch S AUID- ORCID: 0000-0002-6398-8701 AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Tsaur, Igor AU - Tsaur I AUID- ORCID: 0000-0001-5107-3523 AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Hennenlotter, Jorg AU - Hennenlotter J AUID- ORCID: 0000-0003-3827-6996 AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Aufderklamm, Stefan AU - Aufderklamm S AD - Department of Urology, University Hospital Tubingen, Eberhard Karls University, 72076 Tuebingen, Germany. AD - Department of Urology, General Hospital of Bregenz, 6900 Bregenz, Austria. LA - eng PT - Journal Article DEP - 20240329 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11011000 OTO - NOTNLM OT - BCG OT - biomarker OT - bladder cancer OT - immunotherapy OT - non-muscle-invasive bladder cancer COIS- S.R. received consultant/speaker honoraria from Advanced Accelerator Applications Germany GmbH, Janssen-Cilag AG, MdxHealth, Astellas Pharma, Pfizer Oncology, Desitin Pharma, Bayer Oncology, Merck Healtcare Germany GmbH, BMS Pharma, Eisai Pharma, MSD, Amgen Pharma and is member of the advisory board of Ambu A/S, Merck Healtcare Germany GmbH, Pfizer Oncology, Bayer Oncology and BMS Pharma, Eisai Pharma. I.T. received speaker honoraria of Bayer, Sanofi, Astellas, Janssen and Intuitive, is member of the advisory board of Janssen-Cilag AG, Sanofi, MSD, Pfizer and Apogepha and received travel funding of Bayer, Astellas, Janssen, Pfizer, Merck and Apogepha. A.S: Consultancies and Speaker's Bureau: Ipsen, Roche, Janssen, BMS, Alere, Stebabiotech, Synergo, Ferring, Astellas, Amgen, Sanofi Aventis, CureVac and study participation or research grants with institutional funding: Johnson & Johnson, Roche, Cepheid, Amgen, Bayer, CureVac, GemeDx biotechnologies GmbH, Novartis, Karl Storz, immatics biotechnologies GmbH. M.M., A.H., A.P., V.S., S.W., J.H. and S.A. have no conflicts of interest to declare. EDAT- 2024/04/13 10:43 MHDA- 2024/04/13 10:44 PMCR- 2024/03/29 CRDT- 2024/04/13 01:05 PHST- 2024/02/13 00:00 [received] PHST- 2024/03/25 00:00 [revised] PHST- 2024/03/27 00:00 [accepted] PHST- 2024/04/13 10:44 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:05 [entrez] PHST- 2024/03/29 00:00 [pmc-release] AID - cancers16071356 [pii] AID - cancers-16-01356 [pii] AID - 10.3390/cancers16071356 [doi] PST - epublish SO - Cancers (Basel). 2024 Mar 29;16(7):1356. doi: 10.3390/cancers16071356. PMID- 38610970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240425 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 7 DP - 2024 Mar 27 TI - Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis. LID - 10.3390/cancers16071292 [doi] LID - 1292 AB - BACKGROUND: Trimodal therapy is considered the most validated bladder-sparing treatment in patients with organ-confined urothelial carcinoma of the urinary bladder (T2N0M0). However, scarce evidence exists regarding cancer-specific mortality (CSM) differences between trimodal therapy and other non-extirpative multimodal treatment options such as radiotherapy alone after transurethral resection (TURBT + RT) or chemotherapy alone after transurethral resection (TURBT + CT). METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified T2N0M0 patients treated with either trimodal therapy, TURBT + CT, or TURBT + RT. Temporal trends described trimodal therapy vs. TUBRT + CT vs. TURBT + RT use over time. Survival analyses consisting of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM according to each treatment modality. RESULTS: 3729 (40%) patients underwent TMT vs. 4030 (43%) TURBT + CT vs. 1599 (17%) TURBT + RT. Over time, trimodal therapy use (Estimating annual percent change, EAPC: +1.2%, p = 0.01) and TURBT + CT use increased (EAPC: +1.5%, p = 0.01). In MCR models, relative to trimodal therapy, TURBT + CT exhibited 1-14-fold higher CSM and TURBT + RT 1.68-fold higher CSM. In a subgroup analysis, TURBT + RT was associated with 1.42-fold higher CSM than TURBT + CT (p < 0.001). CONCLUSIONS: Strict trimodal therapy that includes both CT and RT after TURBT offers the best cancer control. When strict trimodal therapy cannot be delivered, cancer-specific survival outcomes appear to be superior with TURBT + chemotherapy compared to TURBT + RT. FAU - de Angelis, Mario AU - de Angelis M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. AD - Division of Experimental Oncology, Unit of Urology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Baudo, Andrea AU - Baudo A AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. AD - Department of Urology, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Siech, Carolin AU - Siech C AUID- ORCID: 0000-0002-5460-4171 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. AD - Department of Urology, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany. FAU - Jannello, Letizia Maria Ippolita AU - Jannello LMI AUID- ORCID: 0000-0002-0612-0519 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy. FAU - Di Bello, Francesco AU - Di Bello F AUID- ORCID: 0000-0002-8585-3701 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. FAU - Longo, Nicola AU - Longo N AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany. FAU - Saad, Fred AU - Saad F AUID- ORCID: 0000-0003-2986-5617 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. AD - Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan. FAU - Carmignani, Luca AU - Carmignani L AD - Department of Urology, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Division of Experimental Oncology, Unit of Urology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Unit of Urology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology, Unit of Urology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology, Unit of Urology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 3E4, Canada. LA - eng PT - Journal Article DEP - 20240327 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11010909 OTO - NOTNLM OT - MIBC OT - TMT OT - bladder cancer OT - cancer-specific mortality OT - chemotherapy OT - non-surgical management OT - radiotherapy OT - trimodal therapy OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2024/04/13 10:43 MHDA- 2024/04/13 10:44 PMCR- 2024/03/27 CRDT- 2024/04/13 01:05 PHST- 2024/03/02 00:00 [received] PHST- 2024/03/25 00:00 [revised] PHST- 2024/03/25 00:00 [accepted] PHST- 2024/04/13 10:44 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:05 [entrez] PHST- 2024/03/27 00:00 [pmc-release] AID - cancers16071292 [pii] AID - cancers-16-01292 [pii] AID - 10.3390/cancers16071292 [doi] PST - epublish SO - Cancers (Basel). 2024 Mar 27;16(7):1292. doi: 10.3390/cancers16071292. PMID- 38610824 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240425 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 7 DP - 2024 Apr 2 TI - Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma. LID - 10.3390/jcm13072057 [doi] LID - 2057 AB - Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by recurrence rates of over 50% in both muscle-invasive and non-muscle-invasive bladder cancer. As such, the American Urological Association (AUA) recommends that patients undergo close surveillance during and after treatment. This surveillance is in the form of cystoscopy or imaging tests, which can be invasive and costly tests. Considering this, there have been recent pushes to find complements to bladder cancer surveillance. Cell-free DNA (CfDNA), or DNA released from dying cells, and circulating tumor DNA (ctDNA), or mutated DNA released from tumor cells, can be analyzed to detect and characterize the molecular characteristics of tumors. Research has shown promising results for ctDNA use in the BC care realm. A PubMed literature review was performed finding studies discussing cfDNA and ctDNA in BC detection, prognostication, and monitoring for recurrence. Keywords used included bladder cancer, cell-free DNA, circulating tumor DNA, urothelial carcinoma, and liquid biopsy. Studies show that ctDNA can serve as prognostic indicators of both early- and late-stage BC, aid in risk stratification prior to major surgery, assist in detection of disease progression and metastatic relapse, and can assess patients who may respond to immunotherapy. The benefit of ctDNA is not confined to BC, as studies have also suggested its promise as a biomarker for neoadjuvant chemotherapy in upper-tract UC. However, there are some limitations to ctDNA that require improvements in ctDNA-specific detection methods and BC-specific mutations before widespread utilization can be achieved. Further prospective, randomized trials are needed to elucidate the true potential ctDNA has in advancements in BC care. FAU - Bhalla, Sophia AU - Bhalla S AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA. FAU - Passarelli, Rachel AU - Passarelli R AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA. FAU - Biswas, Antara AU - Biswas A AD - Center for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, 195 Albany St., New Brunswick, NJ 08901, USA. FAU - De, Subhajyoti AU - De S AD - Center for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, 195 Albany St., New Brunswick, NJ 08901, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AUID- ORCID: 0000-0001-8901-0210 AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States GR - R01 GM129066/GM/NIGMS NIH HHS/United States GR - R35 GM149224/GM/NIGMS NIH HHS/United States GR - P30CA072720/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20240402 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11012937 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - cell-free DNA OT - circulating tumor DNA OT - urothelial carcinoma COIS- The authors declare no conflicts of interest. EDAT- 2024/04/13 10:43 MHDA- 2024/04/13 10:44 PMCR- 2024/04/02 CRDT- 2024/04/13 01:04 PHST- 2023/12/22 00:00 [received] PHST- 2024/03/20 00:00 [revised] PHST- 2024/03/28 00:00 [accepted] PHST- 2024/04/13 10:44 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:04 [entrez] PHST- 2024/04/02 00:00 [pmc-release] AID - jcm13072057 [pii] AID - jcm-13-02057 [pii] AID - 10.3390/jcm13072057 [doi] PST - epublish SO - J Clin Med. 2024 Apr 2;13(7):2057. doi: 10.3390/jcm13072057. PMID- 38609747 OWN - NLM STAT- MEDLINE DCOM- 20240516 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 7 DP - 2024 Jul TI - Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guerin for the treatment of upper tract carcinoma in situ. PG - 221.e9-221.e16 LID - S1078-1439(24)00397-1 [pii] LID - 10.1016/j.urolonc.2024.03.012 [doi] AB - INTRODUCTION: Nephroureterectomy is commonly performed for high-grade (HG) upper tract (UT) urothelial carcinoma (UC). However, some patients may benefit from a de-escalation of surgical management, particularly for noninvasive disease and carcinoma in situ (CIS). Bacillus Calmette-Guerin (BCG) is currently the only guideline-recommended endoluminal treatment option. Gemcitabine/Docetaxel (Gem/Doce) has shown promising efficacy as a treatment for noninvasive HG UTUC, though a comparison to BCG is lacking. We report the outcomes of patients treated with endoluminal Gem/Doce vs. BCG for UT-CIS. METHODS: A single-institutional retrospective review of patients treated with Gem/Doce vs. BCG for UT-CIS was performed. Treatment was instilled via nephrostomy or retrograde ureteral catheter. In both treatment groups, induction consisted of 6 weekly instillations. Maintenance was initiated if disease-free and consisted of 6 monthly instillations in the Gem/Doce group and a reduced dose (one-tenth) 3-week course at 3 months in the BCG group. Recurrence was defined as biopsy-proven disease or HG cytology. RESULTS: The final cohort included 53 patients with 65 upper tract units; 31 received BCG and 34 received Gem/Doce. Median follow-up was 88 and 29 months in the BCG and Gem/Doce groups, respectively. Presenting pathology included biopsy-proven CIS and HG cytology in 9.7% and 90% of the BCG group, and 8.8% and 91% of the Gem/Doce group, respectively. The 2-year estimates for recurrence-free and nephroureterectomy-free survival were 61% and 89% for the BCG group and 54% and 100% for the Gem/Doce group, respectively. Upon multivariable analysis, instillation via percutaneous nephrostomy tube was associated with an increased risk of recurrence (HR 3.89, 95% CI 1.59-9.53). The development of any symptom was not statistically different between treatment groups (P = 0.12). There were 2 treatment-related deaths that occurred, 1 within each treatment group. CONCLUSION: Endoluminal Gem/Doce and BCG have similar oncological outcomes and major adverse event rates in the treatment of UT-CIS. Further prospective evaluation is warranted. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - McElree, Ian M AU - McElree IM AD - Carver College of Medicine, University of Iowa, Iowa City, IA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - Hougen, Helen Y AU - Hougen HY AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City, IA. Electronic address: Ryan-steinberg@uiowa.edu. LA - eng GR - P30 CA086862/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240411 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Gemcitabine MH - *Deoxycytidine/analogs & derivatives/administration & dosage/therapeutic use MH - *Docetaxel/administration & dosage/therapeutic use MH - Male MH - Female MH - Retrospective Studies MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Aged MH - *Carcinoma in Situ/drug therapy/pathology MH - Middle Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Aged, 80 and over MH - Administration, Intravesical MH - Treatment Outcome OTO - NOTNLM OT - BCG OT - Docetaxel OT - Gemcitabine OT - Urinary bladder neoplasms COIS- Declaration of competing interest MO is a consultant for Abbott, Fidia, Merck, Photocure, Theralase, Urogen, Vaxiion. There are no conflicts of interest regarding the contents of this article from any of the authors. IM, HH, RLS, SM, and VP have no disclosures to make. EDAT- 2024/04/13 10:42 MHDA- 2024/05/17 00:43 CRDT- 2024/04/12 23:33 PHST- 2024/01/24 00:00 [received] PHST- 2024/02/27 00:00 [revised] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/05/17 00:43 [medline] PHST- 2024/04/13 10:42 [pubmed] PHST- 2024/04/12 23:33 [entrez] AID - S1078-1439(24)00397-1 [pii] AID - 10.1016/j.urolonc.2024.03.012 [doi] PST - ppublish SO - Urol Oncol. 2024 Jul;42(7):221.e9-221.e16. doi: 10.1016/j.urolonc.2024.03.012. Epub 2024 Apr 11. PMID- 38602577 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20240510 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 31 IP - 6 DP - 2024 Jun TI - ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study. PG - 3910-3911 LID - 10.1245/s10434-024-15248-2 [doi] FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. slusarczyk.aleksander@gmail.com. LA - eng PT - Journal Article DEP - 20240411 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Prospective Studies MH - *Microbiota MH - Cystectomy MH - Observational Studies as Topic MH - Prognosis MH - Neoplasm Invasiveness PMC - PMC11076312 COIS- No conflict of interest to declare. EDAT- 2024/04/11 12:43 MHDA- 2024/05/08 06:45 PMCR- 2024/04/11 CRDT- 2024/04/11 11:16 PHST- 2024/03/07 00:00 [received] PHST- 2024/03/07 00:00 [accepted] PHST- 2024/05/08 06:45 [medline] PHST- 2024/04/11 12:43 [pubmed] PHST- 2024/04/11 11:16 [entrez] PHST- 2024/04/11 00:00 [pmc-release] AID - 10.1245/s10434-024-15248-2 [pii] AID - 15248 [pii] AID - 10.1245/s10434-024-15248-2 [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Jun;31(6):3910-3911. doi: 10.1245/s10434-024-15248-2. Epub 2024 Apr 11. PMID- 38600583 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20240429 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 43 IP - 1 DP - 2024 Apr 10 TI - A paclitaxel-hyaluronan conjugate (ONCOFID-P-B) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment. PG - 109 LID - 10.1186/s13046-024-03028-5 [doi] LID - 109 AB - BACKGROUND: The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B in patients with bacillus Calmette-Guerin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response. METHODS: The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed in biopsies from the 20 patients enrolled in the NCT04798703 phase I study collected before starting ONCOFID-P-B therapy (baseline), and after the intensive and the maintenance phases. Clinical data were correlated with cell densities, cell distribution and cell interactions. Associations between immune populations or HA receptors expression and outcome were analyzed using univariate Cox regression and log-rank analysis. RESULTS: In baseline biopsies, patients achieving CR after the intensive phase had a lower density of intra-tumoral CD8+ cytotoxic T lymphocytes (CTL), but also fewer interactions between CTL and macrophages or T-regulatory cells, as compared to non-responders (NR). NR expressed higher levels of the HA receptors CD44v6, ICAM-1 and RHAMM. The intra-tumoral macrophage density was positively correlated with the expression of the pro-metastatic and aggressive variant CD44v6, and the combined score of intra-tumoral macrophage density and CD44v6 expression had an AUC of 0.85 (95% CI 0.68-1.00) for patient response prediction. CONCLUSIONS: The clinical response to ONCOFID-P-B in bladder CIS likely relies on several components of the TME, and the combined evaluation of intra-tumoral macrophages density and CD44v6 expression is a potentially new predictive biomarker for patient response. Overall, our data allow to advance a potential rationale for combinatorial treatments targeting the immune infiltrate such as immune checkpoint inhibitors, to make bladder CIS more responsive to ONCOFID-P-B treatment. CI - (c) 2024. The Author(s). FAU - Tosi, Anna AU - Tosi A AD - Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy. anna.tosi@iov.veneto.it. FAU - Parisatto, Beatrice AU - Parisatto B AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, 35128, Padova, Italy. FAU - Gaffo, Enrico AU - Gaffo E AD - Department of Molecular Medicine, University of Padova, Padova, Italy. FAU - Bortoluzzi, Stefania AU - Bortoluzzi S AD - Department of Molecular Medicine, University of Padova, Padova, Italy. FAU - Rosato, Antonio AU - Rosato A AUID- ORCID: 0000-0002-5263-8386 AD - Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy. antonio.rosato@unipd.it. AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, 35128, Padova, Italy. antonio.rosato@unipd.it. LA - eng GR - Specific grant to AR/Fidia Farmaceutici/ PT - Clinical Trial, Phase I PT - Journal Article DEP - 20240410 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 RN - 0 (ONCOFID-P) RN - 9004-61-9 (Hyaluronic Acid) RN - 0 (BCG Vaccine) RN - P88XT4IS4D (Paclitaxel) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Urinary Bladder/pathology MH - Hyaluronic Acid/therapeutic use/*analogs & derivatives MH - BCG Vaccine/therapeutic use MH - Tumor Microenvironment MH - Paclitaxel/therapeutic use/*analogs & derivatives MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma in Situ/drug therapy/pathology MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/drug therapy PMC - PMC11005197 OTO - NOTNLM OT - Bladder cancer OT - CD44 OT - CD44v6 OT - Hyaluronic acid OT - Macrophages OT - Predictive biomarkers COIS- This study was supported by a specific grant from Fidia Farmaceutici SpA to AR. EDAT- 2024/04/11 00:42 MHDA- 2024/04/12 06:44 PMCR- 2024/04/10 CRDT- 2024/04/10 23:46 PHST- 2023/12/12 00:00 [received] PHST- 2024/03/26 00:00 [accepted] PHST- 2024/04/12 06:44 [medline] PHST- 2024/04/11 00:42 [pubmed] PHST- 2024/04/10 23:46 [entrez] PHST- 2024/04/10 00:00 [pmc-release] AID - 10.1186/s13046-024-03028-5 [pii] AID - 3028 [pii] AID - 10.1186/s13046-024-03028-5 [doi] PST - epublish SO - J Exp Clin Cancer Res. 2024 Apr 10;43(1):109. doi: 10.1186/s13046-024-03028-5. PMID- 38600160 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20240425 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Apr 10 TI - Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer. PG - 8440 LID - 10.1038/s41598-024-58809-x [doi] LID - 8440 AB - Various guidelines recommend the first follow-up cystoscopy at 3 months; however, no data exist on the optimal timing for initial follow-up cystoscopy. We tried to provide evidence on the timing of the first cystoscopy after the initial transurethral resection of bladder tumor (TUR-BT) for patients with non-muscle invasive bladder cancer (NMIBC) using big data. This was a retrospective National Health Insurance Service database analysis. The following outcomes were considered: recurrence, progression, cancer-specific mortality, and all-cause mortality. Exposure was the time-to-treatment initiation (TTI), a continuous variable representing the time to the first cystoscopy from the first TUR-BT within 1 year. Additionally, we categorized TTI (TTIc) into five levels: < 2, 2-4, 4-6, 6-8, and 8-12 months. A landmark time of 1 year after the initial TUR-BT was described to address immortal-time bias. We identified the optimal time for the first cystoscopy using Cox regression models with and without restricted cubic splines (RCS) for TTI and TTIc, respectively. Among 26,660 patients, 16,880 (63.3%) underwent cystoscopy within 2-4 months. A U-shaped trend of the lowest risks at TTI was observed in the 2-4 months group for progression, cancer-specific mortality, and all-cause mortality. TTI within 0-2 months had a higher risk of progression (aHR 1.36; 95% confidence intervals [CI] 1.15-1.60; p < 0.001) and cancer-specific mortality (aHR 1.29; 95% CI 1.05-1.58; p = 0.010). Similarly, TTI within 8-12 months had a higher risk of progression (aHR 2.09; 95% CI 1.67-2.63; p < 0.001) and cancer-specific mortality (aHR 1.96; 95% CI 1.48-2.60; p < 0.001). Based on the RCS models, the risks of progression, cancer-specific mortality, and all-cause mortality were lowest at TTI of 4 months. The timing of the first cystoscopy follow-up was associated with oncologic prognosis. In our model, undergoing cystoscopy at 4 months has shown the best outcomes in clinical course. Therefore, patients who do not receive cystoscopy at approximately 4 months for any reason need more careful follow-up to predict a poor clinical course. CI - (c) 2024. The Author(s). FAU - Kim, Jeong-Soo AU - Kim JS AD - Department of Applied Statistics, Chung-Ang University, Seoul, South Korea. FAU - Lee, Jooyoung AU - Lee J AD - Department of Applied Statistics, Chung-Ang University, Seoul, South Korea. FAU - Nguyen, Tuan Thanh AU - Nguyen TT AD - Department of Urology, Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. FAU - Choi, Se Young AU - Choi SY AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, South Korea. urosyc@cau.ac.kr. LA - eng GR - NRF-2022R1A2C2008207/This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT)/ GR - NRF-2023R1A2C1003830/This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT)/ PT - Journal Article DEP - 20240410 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Follow-Up Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Cystoscopy MH - Disease Progression MH - Neoplasm Recurrence, Local MH - Neoplasm Invasiveness PMC - PMC11006935 OTO - NOTNLM OT - Cystoscopy OT - Follow-up OT - Non-muscle invasive bladder cancer OT - Restricted cubic spline function OT - Time to treatment initiation COIS- The authors declare no competing interests. EDAT- 2024/04/11 00:42 MHDA- 2024/04/12 06:44 PMCR- 2024/04/10 CRDT- 2024/04/10 23:20 PHST- 2024/01/16 00:00 [received] PHST- 2024/04/03 00:00 [accepted] PHST- 2024/04/12 06:44 [medline] PHST- 2024/04/11 00:42 [pubmed] PHST- 2024/04/10 23:20 [entrez] PHST- 2024/04/10 00:00 [pmc-release] AID - 10.1038/s41598-024-58809-x [pii] AID - 58809 [pii] AID - 10.1038/s41598-024-58809-x [doi] PST - epublish SO - Sci Rep. 2024 Apr 10;14(1):8440. doi: 10.1038/s41598-024-58809-x. PMID- 38590954 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240410 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 13 IP - 3 DP - 2024 Mar 31 TI - Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective study. PG - 414-422 LID - 10.21037/tau-23-561 [doi] AB - BACKGROUND: An earlier systematic review and meta-analysis found that patients with a certain histological variant of upper tract urothelial carcinoma (UTUC) exhibited more advanced disease and poorer survival than those with pure UTUC. A difference in the clinicopathological UTUC characteristics of Caucasian and Japanese patients has been reported, but few studies have investigated the clinical impact of the variant histology in Japanese UTUC patients. METHODS: We retrospectively enrolled 824 Japanese patients with pTa-4N0-1M0 UTUCs who underwent radical nephroureterectomy without neoadjuvant chemotherapy. Subsequently, we explored the effects of the variant histology on disease aggressiveness and the oncological outcomes. We used Cox's proportional hazards models to identify significant predictors of oncological outcomes, specifically intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). RESULTS: Of the 824 UTUC patients, 32 (3.9%) exhibited a variant histology that correlated significantly with a higher pathological T stage and lymphovascular invasion (LVI). Univariate analysis revealed that the variant histology was an independent risk factor for suboptimal RFS, CSS, and OS. However, significance was lost on multivariate analyses. CONCLUSIONS: The variant histology does not add to the prognostic information imparted by the pathological findings after radical nephroureterectomy, particularly in Japanese UTUC patients. CI - 2024 Translational Andrology and Urology. All rights reserved. FAU - Uchida, Naoki AU - Uchida N AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AUID- ORCID: 0000-0002-2599-8183 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Suhara, Yushi AU - Suhara Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Goto, Yuma AU - Goto Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yoshihara, Kentaro AU - Yoshihara K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Sadakane, Ibuki AU - Sadakane I AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yata, Yuji AU - Yata Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kurawaki, Shiro AU - Kurawaki S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miyajima, Keiichiro AU - Miyajima K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Ishikawa, Mimu AU - Ishikawa M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Kazuhiro AU - Takahashi K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Kashiwa Hospital, Chiba, Japan. FAU - Imai, Yu AU - Imai Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sakanaka, Keigo AU - Sakanaka K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Nakazono, Minoru AU - Nakazono M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hisakane, Akira AU - Hisakane A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kurauchi, Takashi AU - Kurauchi T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kayano, Sotaro AU - Kayano S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Onuma, Hajime AU - Onuma H AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Aikawa, Koichi AU - Aikawa K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tashiro, Kojiro AU - Tashiro K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Kashiwa Hospital, Chiba, Japan. FAU - Furuta, Akira AU - Furuta A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20240306 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC10999016 OTO - NOTNLM OT - Japanese patients OT - Upper tract urothelial carcinoma (UTUC) OT - oncological outcomes OT - variant histology COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-561/coif). The authors have no conflicts of interest to declare. EDAT- 2024/04/09 06:45 MHDA- 2024/04/09 06:46 PMCR- 2024/03/31 CRDT- 2024/04/09 03:56 PHST- 2023/11/04 00:00 [received] PHST- 2024/01/18 00:00 [accepted] PHST- 2024/04/09 06:46 [medline] PHST- 2024/04/09 06:45 [pubmed] PHST- 2024/04/09 03:56 [entrez] PHST- 2024/03/31 00:00 [pmc-release] AID - tau-13-03-414 [pii] AID - 10.21037/tau-23-561 [doi] PST - ppublish SO - Transl Androl Urol. 2024 Mar 31;13(3):414-422. doi: 10.21037/tau-23-561. Epub 2024 Mar 6. PMID- 38581346 OWN - NLM STAT- MEDLINE DCOM- 20240426 LR - 20260618 IS - 1613-4133 (Electronic) IS - 1613-4125 (Print) IS - 1613-4125 (Linking) VI - 68 IP - 8 DP - 2024 Apr TI - Modifying Effects of Genetic Variations on the Association Between Dietary Isothiocyanate Exposure and Non-muscle Invasive Bladder Cancer Prognosis in the Be-Well Study. PG - e2400087 LID - 10.1002/mnfr.202400087 [doi] AB - SCOPE: Dietary isothiocyanate (ITC) exposure from cruciferous vegetable (CV) intake may improve non-muscle invasive bladder cancer (NMIBC) prognosis. This study aims to investigate whether genetic variations in key ITC-metabolizing/functioning genes modify the associations between dietary ITC exposure and NMIBC prognosis outcomes. METHODS AND RESULTS: In the Bladder Cancer Epidemiology, Wellness, and Lifestyle Study (Be-Well Study), a prospective cohort of 1472 incident NMIBC patients, dietary ITC exposure is assessed by self-reported CV intake and measured in plasma ITC-albumin adducts. Using Cox proportional hazards regression models, stratified by single nucleotide polymorphisms (SNPs) in nine key ITC-metabolizing/functioning genes, it is calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence and progression. The rs15561 in N-acetyltransferase 1 (NAT1) is alter the association between CV intake and progression risk. Multiple SNPs in nuclear factor E2-related factor 2 (NRF2) and nuclear factor kappa B (NFkappaB) are modify the associations between plasma ITC-albumin adduct level and progression risk (p(int) < 0.05). No significant association is observed with recurrence risk. Overall, >80% study participants are present with at least one protective genotype per gene, showing an average 65% reduction in progression risk with high dietary ITC exposure. CONCLUSION: Despite that genetic variations in ITC-metabolizing/functioning genes may modify the effect of dietary ITCs on NMIBC prognosis, dietary recommendation of CV consumption may help improve NMIBC survivorship. CI - (c) 2024 Wiley-VCH GmbH. FAU - Wang, Zinian AU - Wang Z AUID- ORCID: 0000-0002-3088-6995 AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Haque, Reina AU - Haque R AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. AD - Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. FAU - Singh, Prashant K AU - Singh PK AD - Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. FAU - Goniewicz, Maciej AU - Goniewicz M AD - Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. FAU - Pratt, Rachel AU - Pratt R AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, Downey, CA, USA. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA. FAU - Quesenberry, Charles P AU - Quesenberry CP AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Zhang, Yuesheng AU - Zhang Y AD - Department of Pharmacology and Toxicology, and Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA. FAU - Ambrosone, Christine B AU - Ambrosone CB AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. FAU - Tang, Li AU - Tang L AUID- ORCID: 0000-0002-6776-1846 AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R01 CA257480/CA/NCI NIH HHS/United States GR - R01CA172855/CA/NCI NIH HHS/United States GR - R01CA257480/CA/NCI NIH HHS/United States GR - R01 CA172855/CA/NCI NIH HHS/United States GR - U01 CA280991/CA/NCI NIH HHS/United States GR - P30CA016056/CA/NCI NIH HHS/United States GR - U01CA280991/CA/NCI NIH HHS/United States GR - 3R01CA172855-04S1/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20240406 PL - Germany TA - Mol Nutr Food Res JT - Molecular nutrition & food research JID - 101231818 RN - 0 (Isothiocyanates) RN - 0 (NF-E2-Related Factor 2) RN - EC 2.3.1.5 (Arylamine N-Acetyltransferase) RN - 0 (NFE2L2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Male MH - Female MH - *Isothiocyanates/pharmacology/administration & dosage MH - *Polymorphism, Single Nucleotide MH - Middle Aged MH - Prognosis MH - Aged MH - Prospective Studies MH - *Diet MH - NF-E2-Related Factor 2/genetics/metabolism MH - Arylamine N-Acetyltransferase/genetics MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11272391 MID - NIHMS2007966 OTO - NOTNLM OT - cruciferous vegetables OT - isothiocyanate OT - non-muscle invasive bladder cancer OT - progression OT - recurrence OT - single nucleotide polymorphisms COIS- Conflict of Interest The authors declare no conflict of interest. EDAT- 2024/04/06 17:45 MHDA- 2024/04/26 06:55 PMCR- 2025/04/06 CRDT- 2024/04/06 08:03 PHST- 2024/03/10 00:00 [revised] PHST- 2024/02/02 00:00 [received] PHST- 2024/04/26 06:55 [medline] PHST- 2024/04/06 17:45 [pubmed] PHST- 2024/04/06 08:03 [entrez] PHST- 2025/04/06 00:00 [pmc-release] AID - 10.1002/mnfr.202400087 [doi] PST - ppublish SO - Mol Nutr Food Res. 2024 Apr;68(8):e2400087. doi: 10.1002/mnfr.202400087. Epub 2024 Apr 6. PMID- 38579191 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20260617 IS - 2473-4284 (Electronic) IS - 2473-4284 (Linking) VI - 8 DP - 2024 Apr TI - MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome. PG - e2300414 LID - 10.1200/PO.23.00414 [doi] AB - PURPOSE: The lack of personalized management of bladder cancer (BlCa) results in patients' lifelong post-treatment monitoring with invasive interventions, underlying the urgent need for tailored and minimally invasive health care services. On the basis of our previous findings on miR-143/145 cluster methylation in bladder tumors, we evaluated its clinical significance in pretreatment cell-free DNA (cfDNA) of patients with BlCa. MATERIALS AND METHODS: Methylation analysis was performed in our screening cohort (120 patients with BlCa; 20 age-matched healthy donors) by bisulfite-based pyrosequencing. Tumor recurrence/progression for patients with non-muscle-invasive bladder cancer, and progression and mortality for patients with muscle-invasive bladder cancer (MIBC) were used as clinical end point events in survival analysis. Bootstrap analysis was applied for internal validation of Cox regression models and decision curve analysis for assessment of clinical benefit on disease prognosis. RESULTS: Decreased methylation of MIR145 core promoter in pretreatment cfDNA was associated with short-term disease progression (multivariate Cox: hazard ratio [HR], 2.027 [95% CI, 1.157 to 3.551]; P = .010) and poor overall survival (multivariate Cox: HR, 2.098 [95% CI, 1.154 to 3.817]; P = .009) of patients with MIBC after radical cystectomy (RC). Multivariate models incorporating MIR145 promoter methylation in cfDNA with tumor stage clearly ameliorated patients' risk stratification, highlighting superior clinical benefit in MIBC prognostication. CONCLUSION: Reduced pretreatment cfDNA methylation of MIR145 core promoter was markedly correlated with increased risk for short-term progression and worse survival of patients with MIBC after RC and adjuvant therapy, supporting modern personalized and minimally invasive prognosis. Methylation profiling of MIR145 core promoter in pretreatment cfDNA could serve as a minimally invasive and independent predictor of MIBC treatment outcome and emerge as a promising marker for blood-based test in BlCa. FAU - Pilala, Katerina-Marina AU - Pilala KM AUID- ORCID: 0000-0002-0187-6907 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kotronopoulos, Georgios AU - Kotronopoulos G AUID- ORCID: 0000-0002-8157-1029 AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AUID- ORCID: 0000-0002-2759-0237 AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Giagkos, Georgios-Christos AU - Giagkos GC AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Vassilacopoulou, Dido AU - Vassilacopoulou D AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AUID- ORCID: 0000-0002-2135-9886 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. AD - Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - JCO Precis Oncol JT - JCO precision oncology JID - 101705370 RN - 0 (Cell-Free Nucleic Acids) RN - 0 (MicroRNAs) RN - 0 (MIRN145 microRNA, human) SB - IM MH - Humans MH - *Cell-Free Nucleic Acids/genetics/therapeutic use MH - Liquid Biopsy MH - Methylation MH - *MicroRNAs/genetics/therapeutic use MH - Muscles/pathology MH - Neoplasm Recurrence, Local/pathology MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy MH - DNA Methylation/genetics EDAT- 2024/04/05 18:42 MHDA- 2024/04/08 06:43 CRDT- 2024/04/05 16:03 PHST- 2024/04/08 06:43 [medline] PHST- 2024/04/05 18:42 [pubmed] PHST- 2024/04/05 16:03 [entrez] AID - 10.1200/PO.23.00414 [doi] PST - ppublish SO - JCO Precis Oncol. 2024 Apr;8:e2300414. doi: 10.1200/PO.23.00414. PMID- 38575067 OWN - NLM STAT- MEDLINE DCOM- 20240603 LR - 20260209 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 48 IP - 5 DP - 2024 Jun TI - Is trimodal therapy the current standard for muscle-invasive bladder cancer? PG - 345-355 LID - S2173-5786(24)00028-3 [pii] LID - 10.1016/j.acuroe.2024.04.001 [doi] AB - OBJECTIVE: The aim of this review is to summarize the current evidence and future perspectives of bladder-sparing treatment for MIBC. METHODS: A non-systematic literature search in Medline/Pubmed was performed in October 2023 with the following keywords "bladder cancer", "bladder-sparing", "trimodal therapy", "chemoradiation", "biomarkers", "immunotherapy", "neoadjuvant chemotherapy", "radiotherapy". RESULTS: Urology guidelines recommend radical cystectomy as the standard curative treatment for muscle-invasive urothelial bladder cancer, reserving radiotherapy for patients who are unfit or who want to preserve their bladder. Given the morbidity and mortality of cystectomy and its impact on quality of life and bladder function, modern oncologic therapies are increasingly oriented toward organ preservation and maximizing functional outcomes while maintaining treatment efficacy. Trimodal therapy, which incorporates maximal transurethral resection followed by radiotherapy with concurrent radiosensitizing chemotherapy, is an effective regimen for bladder function preservation in well-selected patients. Despite the absence of comparative data from randomized trials, the two approaches seem to provide comparable oncologic outcomes. Studies are evaluating the expansion of eligibility criteria for trimodal therapy, the optimization of radiotherapy and immunotherapy delivery to further improve outcomes, and the validation of biomarkers to guide bladder preservation. CONCLUSIONS: Trimodal therapy has shown acceptable outcomes for bladder preservation; therefore, it provides a valid treatment option in well-selected patients. CI - Copyright (c) 2024 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Lopez Valcarcel, M AU - Lopez Valcarcel M AD - Servicio de Oncologia Radioterapica, Hospital Universitario Puerta de Hierro, Madrid, Spain, Miembro del GUARD Consortium. Electronic address: mlvalcarcel@madrid.salud.es. FAU - Barrado Los Arcos, M AU - Barrado Los Arcos M AD - Servicio de Oncologia Radioterapica, Hospital Universitario de Navarra, Instituto de Investigacion Navarra (IdiSNA), Pamplona, Navarra, Spain. FAU - Ferri Molina, M AU - Ferri Molina M AD - Servicio de Oncologia Radioterapica, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Universidad de Cantabria, Spain. FAU - Cienfuegos Belmonte, I AU - Cienfuegos Belmonte I AD - Servicio de Urologia, Hospital Virgen del Puerto, Plasencia, Caceres, Extremadura, Spain. FAU - Duque Santana, V AU - Duque Santana V AD - Servicio de Oncologia Radioterapica, Hospital Universitario Quironsalud y Hospital Universitario La Luz, Universidad Europea de Madrid, Spain. FAU - Gajate Borau, P AU - Gajate Borau P AD - Servicio de Oncologia Medica, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain. FAU - Fernandez Ibiza, J AU - Fernandez Ibiza J AD - Servicio de Oncologia Radioterapica, GenesisCare Clinica Corachan, Barcelona, Spain. FAU - Alvarez Maestro, M AU - Alvarez Maestro M AD - Servicio de Urologia, Hospital Universitario La Paz, Madrid, Spain. FAU - Sargos, P AU - Sargos P AD - Servicio de Oncologia Radioterapica, Institut Bergonie, Burdeos, France. FAU - Lopez Campos, F AU - Lopez Campos F AD - Servicio de Oncologia Radioterapica, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Counago, F AU - Counago F AD - Servicio de Oncologia Radioterapica, GenesisCare Madrid, Hospital Universitario San Francisco de Asis y Hospital Universitario La Milagrosa, Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Review DEP - 20240402 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Humans MH - *Neoplasm Invasiveness MH - Combined Modality Therapy MH - Organ Sparing Treatments MH - Cystectomy/methods OTO - NOTNLM OT - Bladder sparing OT - Chemotherapy OT - Preservacion de vejiga OT - Quimioterapia OT - Radioterapia OT - Radiotherapy OT - Terapia trimodal OT - Trimodal therapy EDAT- 2024/04/05 00:43 MHDA- 2024/06/04 00:45 CRDT- 2024/04/04 19:24 PHST- 2023/11/20 00:00 [received] PHST- 2023/12/29 00:00 [revised] PHST- 2024/01/02 00:00 [accepted] PHST- 2024/06/04 00:45 [medline] PHST- 2024/04/05 00:43 [pubmed] PHST- 2024/04/04 19:24 [entrez] AID - S2173-5786(24)00028-3 [pii] AID - 10.1016/j.acuroe.2024.04.001 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2024 Jun;48(5):345-355. doi: 10.1016/j.acuroe.2024.04.001. Epub 2024 Apr 2. PMID- 38573204 OWN - NLM STAT- MEDLINE DCOM- 20240405 LR - 20250730 IS - 1531-703X (Electronic) IS - 1040-8746 (Linking) VI - 36 IP - 3 DP - 2024 May 1 TI - Organ preservation in muscle-invasive urothelial bladder cancer. PG - 155-163 LID - 10.1097/CCO.0000000000001038 [doi] AB - PURPOSE OF REVIEW: The most common definitive treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy. However, removing the bladder and surrounding organs poses risks of morbidity that can reduce quality of life, and raises the risk of death. Treatment strategies that preserve the organs can manage the local tumor and mitigate the risk of distant metastasis. Recent data have demonstrated promising outcomes in several bladder-preservation strategies. RECENT FINDINGS: Bladder preservation with trimodality therapy (TMT), combining maximal transurethral resection of the bladder tumor, chemotherapy, and radiotherapy (RT), was often reserved for nonsurgical candidates for radical cystectomy. Recent meta-analyses show that outcomes of TMT and radical cystectomy are similar. More recent bladder-preservation approaches include combining targeted RT (MRI) and immune checkpoint inhibitors (ICIs), ICIs and chemotherapy, and selecting patients based on genomic biomarkers and clinical response to systemic therapies. These are all promising strategies that may circumvent the need for radical cystectomy. SUMMARY: MIBC is an aggressive disease with a high rate of systemic progression. Current management includes neoadjuvant cisplatin-based chemotherapy and radical cystectomy with lymph node dissection. Novel alternative strategies, including TMT approaches, combinations with RT, chemotherapy, and/or ICIs, and genomic biomarkers, are in development to further advance bladder-preservation options for patients with MIBC. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Niglio, Scot A AU - Niglio SA AD - Department of Hematology and Medical Oncology, Perlmutter Cancer at NYU Langone Health, New York, New York. FAU - Purswani, Juhi M AU - Purswani JM AD - Department of Radiation Oncology at NYU Langone Health, New York, New York. FAU - Schiff, Peter B AU - Schiff PB AD - Department of Radiation Oncology at NYU Langone Health, New York, New York. FAU - Lischalk, Jonathan W AU - Lischalk JW AD - Department of Radiation Oncology at NYU Langone Health, New York, New York. FAU - Huang, William C AU - Huang WC AD - Department of Urology, NYU-Langone Health, New York, New York. FAU - Murray, Katie S AU - Murray KS AD - Department of Urology, NYU-Langone Health, New York, New York. FAU - Apolo, Andrea B AU - Apolo AB AD - Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. LA - eng PT - Journal Article PT - Review DEP - 20240308 PL - United States TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Organ Preservation MH - Quality of Life MH - *Urinary Bladder Neoplasms/drug therapy MH - Biomarkers MH - Muscles EDAT- 2024/04/04 12:44 MHDA- 2024/04/05 06:44 CRDT- 2024/04/04 10:32 PHST- 2024/04/05 06:44 [medline] PHST- 2024/04/04 12:44 [pubmed] PHST- 2024/04/04 10:32 [entrez] AID - 00001622-202405000-00007 [pii] AID - 10.1097/CCO.0000000000001038 [doi] PST - ppublish SO - Curr Opin Oncol. 2024 May 1;36(3):155-163. doi: 10.1097/CCO.0000000000001038. Epub 2024 Mar 8. PMID- 38570378 OWN - NLM STAT- MEDLINE DCOM- 20240613 LR - 20240710 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 31 IP - 7 DP - 2024 Jul TI - Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study. PG - 4773-4786 LID - 10.1245/s10434-024-15198-9 [doi] AB - BACKGROUND: This study aimed to characterize the urinary and tumor microbiomes in patients with non-muscle-invasive bladder cancer (NMIBC) before and after transurethral resection of the bladder tumor (TURBT). METHODS: This single-center prospective study included 26 samples from 11 patients with low-grade Ta papillary NMIBC. Urine samples were collected at the index TURBT and at a 1-year follow-up cystoscopy. The metagenomic analysis of bacterial and archaeal populations was performed based on the highly variable V3-V4 region of the 16S rRNA gene. RESULTS: Phylogenetic alpha diversity of the bladder microbiome detected in urine was found to be lower at the 1-year follow-up cystoscopy compared to the time of the index TURBT (p < 0.01). Actinomyces, Candidatus cloacimonas, Sphingobacterium, Sellimonas, Fusobacterium, and Roseobacter were more differentially enriched taxa in urine at the follow-up cystoscopy than at the index TURBT. Beta diversity of urine microbiome significantly changed over time (p < 0.05). Phylogenetic alpha diversity of the microbiome was greater in tumor tissues than in paired urine samples (p<0.01). Sphingomonas, Acinetobacter, Candidatus, and Kocuria were more differentially overrepresented in tumor tissues than in urine. The enrichment of the abundance of Corynebacterium and Anaerococcus species in urine collected at TURBT was observed in patients who experienced recurrence within the follow-up period. CONCLUSIONS: In patients with low-grade NMIBC, the urine microbiome undergoes changes over time after removal of the tumor. The microbiome detected in tumor tissues is more phylogenetically diverse than in paired urine samples collected at TURBT. The interplay between bladder microbiome, tumor microbiome, and their alterations requires further studies to elucidate their predictive value and perhaps therapeutic implications. CI - (c) 2024. Society of Surgical Oncology. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. slusarczyk.aleksander@gmail.com. FAU - Ismail, Hamza AU - Ismail H AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Piecha, Tomasz AU - Piecha T AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. LA - eng GR - M/MB/07/22/Warszawski Uniwersytet Medyczny/ PT - Journal Article PT - Observational Study DEP - 20240403 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (RNA, Ribosomal, 16S) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/microbiology/surgery/pathology/urine MH - Prospective Studies MH - Male MH - Female MH - *Microbiota MH - Aged MH - Middle Aged MH - Follow-Up Studies MH - Prognosis MH - Cystectomy MH - Neoplasm Invasiveness MH - RNA, Ribosomal, 16S/genetics/analysis MH - Bacteria/isolation & purification/genetics/classification MH - Phylogeny MH - Non-Muscle Invasive Bladder Neoplasms EDAT- 2024/04/04 00:43 MHDA- 2024/06/13 06:44 CRDT- 2024/04/03 23:15 PHST- 2024/01/12 00:00 [received] PHST- 2024/03/04 00:00 [accepted] PHST- 2024/06/13 06:44 [medline] PHST- 2024/04/04 00:43 [pubmed] PHST- 2024/04/03 23:15 [entrez] AID - 10.1245/s10434-024-15198-9 [pii] AID - 10.1245/s10434-024-15198-9 [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Jul;31(7):4773-4786. doi: 10.1245/s10434-024-15198-9. Epub 2024 Apr 3. PMID- 38567601 OWN - NLM STAT- MEDLINE DCOM- 20240404 LR - 20260815 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 28 IP - 6 DP - 2024 Mar TI - Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence. PG - 2387-2395 LID - 35745 [pii] LID - 10.26355/eurrev_202403_35745 [doi] AB - OBJECTIVE: Upper tract urothelial carcinoma (UTUC) is a relatively rare but aggressive type of urologic cancer that includes renal pelvic tumors and ureteral tumors with a poor prognosis. Full-length nephroureterectomy plus sleeve bladder resection is the standard treatment for the disease, but patients are prone to recurrence of bladder tumors after surgery. Intravesical infusion therapy is the main means to prevent the recurrence and progression of bladder cancer. Epirubicin and gemcitabine are widely used in clinical practice as first-line or salvage therapy for intravesical chemotherapy; however, the efficacy of these agents is rarely discussed. The purpose of this study was to investigate the effects of epirubicin and gemcitabine on the occurrence of bladder cancer after radical nephroureterectomy for UTUC and to analyze the risk factors affecting the recurrence of postoperative bladder cancer. PATIENTS AND METHODS: A total of 215 patients with diagnosed UTUC and treated in our hospital from June 2019 to August 2021 were retrospectively selected as the research subjects, and they were divided into an observation group (120 cases) and a control group (95 cases) according to different treatment methods. The patients in the control group were treated with epirubicin, while those in the observation group received gemcitabine. All patients were followed up by telephone or outpatient examination for 12 months to record the occurrence of adverse reactions. The occurrence of bladder cancer was recorded at 3 months, 6 months, and 12 months after the surgery. According to the occurrence of bladder cancer after surgery, the patients were divided into a bladder cancer group (63 cases) and a non-bladder cancer group (152 cases). Multivariate Logistic regression analysis was used to analyze the risk factors of bladder cancer after surgery. RESULTS: The total incidence of adverse reactions in the control group was 49.47%, which was higher than that in the observation group with 15.00% (p<0.01). The incidence of bladder tumors in the observation group and the control group was 0.00% and 2.11% at 3 months, 5.00% and 8.42% at 6 months, 13.33% and 15.79% at 12 months, without significant difference (p>0.05). After 12 months of perfusion, the levels of acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) in the two groups were significantly lower than those before perfusion (p<0.05). In the observation group, the levels of these three factors were slightly decreased compared with those in the control group, without a significant difference (p>0.05). Between the bladder cancer and non-bladder cancer groups, there were significant differences in tumor location, number of lesions, tumor stage, preoperative ureteral examination, and preoperative history of bladder cancer (p<0.05). The above indexes were all risk factors for postoperative bladder cancer (p<0.05). CONCLUSIONS: Epirubicin and gemcitabine reduced the occurrence of bladder cancer and effectively inhibited tumor angiogenesis after radical nephroureterectomy for UTUC. The tumor location, number of lesions, tumor stage, preoperative ureteral examination, and preoperative history of bladder cancer were risk factors for postoperative bladder cancer. FAU - Jiang, S-C AU - Jiang SC AD - Department of Urinary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China. NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, China. hekaihk@21cn.com. FAU - Liao, Y-G AU - Liao YG FAU - Luo, J AU - Luo J FAU - Hu, D AU - Hu D FAU - Wang, Y-D AU - Wang YD FAU - He, K AU - He K LA - eng PT - Journal Article PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 3Z8479ZZ5X (Epirubicin) RN - 0 (Gemcitabine) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Humans MH - Nephroureterectomy MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology MH - *Carcinoma, Transitional Cell/drug therapy/surgery MH - Retrospective Studies MH - Epirubicin/therapeutic use MH - Gemcitabine MH - Vascular Endothelial Growth Factor A MH - Risk Factors MH - Neoplasm Recurrence, Local/pathology MH - Nephrectomy EDAT- 2024/04/03 06:45 MHDA- 2024/04/04 06:45 CRDT- 2024/04/03 05:43 PHST- 2024/04/04 06:45 [medline] PHST- 2024/04/03 06:45 [pubmed] PHST- 2024/04/03 05:43 [entrez] AID - 35745 [pii] AID - 10.26355/eurrev_202403_35745 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2024 Mar;28(6):2387-2395. doi: 10.26355/eurrev_202403_35745. PMID- 38561917 OWN - NLM STAT- MEDLINE DCOM- 20240624 LR - 20240624 IS - 1532-4230 (Electronic) IS - 1532-1819 (Linking) VI - 45 IP - 3 DP - 2024 May 3 TI - Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer. PG - 261-270 LID - 10.1080/15321819.2024.2335154 [doi] AB - Non muscle invasive bladder cancer (NMIBC) has unpredictable outcomes with a variable risk of recurrence and progression. Many clinic-pathological prognostic factors have been identified but remain insufficient, raising the need to investigate new biomarkers. The aim of our study was to assess the prognostic value of the immunohistochemical (IHC) markers E-Cadherin and B-Catenin in NMIBC. All cases of NMIBC were collected between 2008 and 2013. IHC analysis was performed using E-Cadherin and B-Catenin. Reduced or loss of E-Cadherin expression was assessed as abnormal. Only cases with B-Catenin intense membranous staining were considered normal. A correlation was found between abnormal E-Cadherin expression and stage (p = 0.001), grade (p = 0.0000000), recurrence (p = 0.0000000), progression (p = 0.01), recurrence-free survival (p = 0.00000001), and progression-free survival (p = 0.01). A statistically significant association was found between B-Catenin and stage (p = 0. 05), grade (p = 0.02), and recurrence (p = 0.02). The abnormal expression of these markers could help to identify a high-risk subgroup of NMIBC that might benefit from either more accurate follow-up or more aggressive treatment. FAU - Ben Rejeb, Sarra AU - Ben Rejeb S AUID- ORCID: 0000-0001-9150-3444 AD - Pathology Department, Security Forces Hospital, Marsa, Tunisia. FAU - Kouki, Nadia AU - Kouki N AD - Pathology Department, Security Forces Hospital, Marsa, Tunisia. FAU - Ben Ghachem, Dorra AU - Ben Ghachem D AD - Pathology Department, Security Forces Hospital, Marsa, Tunisia. FAU - Khouni, Hassen AU - Khouni H AD - Urology Department, Security Forces Hospital, Marsa, Tunisia. FAU - Bellil, Khadija AU - Bellil K AD - Pathology Department, Security Forces Hospital, Marsa, Tunisia. LA - eng PT - Journal Article DEP - 20240401 PL - England TA - J Immunoassay Immunochem JT - Journal of immunoassay & immunochemistry JID - 100963688 RN - 0 (Cadherins) RN - 0 (beta Catenin) RN - 0 (Biomarkers, Tumor) RN - 0 (Antigens, CD) RN - 0 (CTNNB1 protein, human) RN - 0 (CDH1 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/diagnosis MH - *Cadherins/metabolism/analysis MH - Male MH - Female MH - *beta Catenin/metabolism/analysis MH - Middle Aged MH - Aged MH - Prognosis MH - Biomarkers, Tumor/metabolism/analysis MH - Aged, 80 and over MH - Neoplasm Invasiveness MH - Adult MH - Antigens, CD/metabolism/analysis MH - Immunohistochemistry MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - B-Catenin OT - Bladder OT - Cancer OT - E-Cadherin OT - Non-muscle invasive EDAT- 2024/04/02 06:46 MHDA- 2024/06/24 12:42 CRDT- 2024/04/02 01:03 PHST- 2024/06/24 12:42 [medline] PHST- 2024/04/02 06:46 [pubmed] PHST- 2024/04/02 01:03 [entrez] AID - 10.1080/15321819.2024.2335154 [doi] PST - ppublish SO - J Immunoassay Immunochem. 2024 May 3;45(3):261-270. doi: 10.1080/15321819.2024.2335154. Epub 2024 Apr 1. PMID- 38553264 OWN - NLM STAT- MEDLINE DCOM- 20240426 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 6 DP - 2024 Jun TI - Evaluation of URO17(R) to improve non-invasive detection of bladder cancer. PG - 176.e21-176.e28 LID - S1078-1439(24)00345-4 [pii] LID - 10.1016/j.urolonc.2024.02.012 [doi] AB - BACKGROUND: The gold standard for detecting bladder cancer is cystoscopy with biopsy or transurethral resection confirming histologic diagnosis. URO17(R) employs a chromogenically labeled monoclonal antibody to keratin 17 (k17), an intermediate filament cytoskeleton molecule associated with bladder, pancreatic, and cervical cancers. Preliminary studies evaluating k17 demonstrated a high sensitivity and specificity for the detection of bladder cancer, supporting the need for further study. OBJECTIVE: To evaluate the sensitivity and specificity of URO17. METHODS: This is a cross-sectional study of participants undergoing urologic procedures between July 6, 2018 and July 17, 2019 at a single institution. Patients undergoing cystectomy, endoscopic bladder and/or upper tract procedure for probable urothelial carcinoma comprised cases; patients undergoing urologic procedures for other reasons comprised the control group (i.e. prostatectomy, nephrectomy, etc.). Voided urine samples were at the time of procedure; a minority of participants underwent multiple resections in the study period, thus, as many as three urine samples were taken from any given participant. Samples were distributed for blinded testing with URO17. Sensitivity and specificity were calculated. RESULTS: In 152 participants and 167 samples, URO17 demonstrated an overall sensitivity of 90% and 92% and a specificity of 88% and 87%, respectively. In 76 participants and 91 samples from patients with suspected urothelial carcinoma, the sensitivity was 90% and 92%, and the specificity was 50% and 54%, respectively. No controls demonstrated a positive URO17 result, and URO17 superseded urine cytology detection of low-grade and high-grade Ta. False positive results were associated with inflamed tissue or urothelial atypia on histology; the large majority had a history of intravesical therapy. CONCLUSION: Limitations include cross-sectional design and convenience sampling. URO17 may improve sensitivity of urine cytology in the detection of urothelial cancer, though further study is required to refine the application of this biomarker in clinical practice. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California, San Francisco, CA. Electronic address: Sima.Porten@ucsf.edu. FAU - Wang, Elizabeth Y AU - Wang EY AD - Department of Surgery, The Mount Sinai Hospital, New York, NY. FAU - Vohra, Poonam AU - Vohra P AD - Department of Anatomic Pathology, University of California, San Francisco, CA. FAU - Carroll, Peter R AU - Carroll PR AD - Department of Urology, University of California, San Francisco, CA. FAU - Jahanfard, Sholeh AU - Jahanfard S AD - KDx Diagnostics Inc, San Jose, CA. FAU - Kim, Nam W AU - Kim NW AD - KDx Diagnostics Inc, San Jose, CA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240328 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/urine/diagnosis/pathology MH - Male MH - Cross-Sectional Studies MH - Female MH - Aged MH - Middle Aged MH - Sensitivity and Specificity MH - Biomarkers, Tumor/urine/analysis MH - Aged, 80 and over OTO - NOTNLM OT - Bladder cancer OT - Cytology OT - Urinary biomarkers COIS- Declaration of competing interest SJ is co-founder, President, and COO of KDx diagnostics; NK is co-founder and CEO of KDx diagnostics. EDAT- 2024/03/30 11:46 MHDA- 2024/04/27 09:48 CRDT- 2024/03/29 22:58 PHST- 2023/03/09 00:00 [received] PHST- 2024/02/05 00:00 [revised] PHST- 2024/02/27 00:00 [accepted] PHST- 2024/04/27 09:48 [medline] PHST- 2024/03/30 11:46 [pubmed] PHST- 2024/03/29 22:58 [entrez] AID - S1078-1439(24)00345-4 [pii] AID - 10.1016/j.urolonc.2024.02.012 [doi] PST - ppublish SO - Urol Oncol. 2024 Jun;42(6):176.e21-176.e28. doi: 10.1016/j.urolonc.2024.02.012. Epub 2024 Mar 28. PMID- 38542446 OWN - NLM STAT- MEDLINE DCOM- 20240329 LR - 20260127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 6 DP - 2024 Mar 20 TI - Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients. LID - 10.3390/ijms25063473 [doi] LID - 3473 AB - Urinary bladder cancer (BC) represents a major health issue, and identifying novel biomarkers for early disease detection and outcome prediction is paramount. It has already been established that the immune system plays a role in tumour initiation and progression in which the inflammatory marker pentraxin 3 (PTX3) might be involved, presenting a variety of functions in different cancers. The aim of this study was to investigate whether plasma levels of PTX3 could be used as a biomarker for patients with BC. Plasma levels of PTX3 were determined in 118 BC patients and 50 controls by ELISA. Patients with BC had significantly higher PTX3 levels compared to controls. The value as a diagnostic biomarker is probably limited, however, since no significant difference in PTX3 levels was seen between patients with non-muscle-invasive BC and controls; they were seen only between patients with muscle-invasive disease and controls. However, the potential value of PTX3 as a prognostic biomarker was indicated by significantly higher PTX3 levels in patients who developed metastatic disease during follow-up compared to patients who did not develop metastatic disease. The conclusions from this study are that plasma levels of PTX3 have limited value as a diagnostic biomarker, although they have potential as a prognostic biomarker for patients with BC. FAU - Vikerfors, Anders AU - Vikerfors A AUID- ORCID: 0009-0003-5439-4850 AD - Department of Urology, Faculty of Medicine and Health, Orebro University, 703 62 Orebro, Sweden. FAU - Davidsson, Sabina AU - Davidsson S AUID- ORCID: 0000-0002-2850-6009 AD - Department of Urology, Faculty of Medicine and Health, Orebro University, 703 62 Orebro, Sweden. FAU - Carlsson, Jessica AU - Carlsson J AUID- ORCID: 0000-0001-8457-7592 AD - Department of Urology, Faculty of Medicine and Health, Orebro University, 703 62 Orebro, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, Faculty of Medicine and Health, Orebro University, 703 62 Orebro, Sweden. LA - eng GR - AV2018/Lions Cancer research fund in Uppsala/ GR - OLL-779321/Region Orebro County research committee/ GR - OLL-811611/Region Orebro County research committee/ GR - OLL-869141/Region Orebro County research committee/ PT - Journal Article DEP - 20240320 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 9007-41-4 (C-Reactive Protein) RN - 0 (Biomarkers) RN - 0 (Serum Amyloid P-Component) RN - 0 (Pentraxins) SB - IM MH - Humans MH - Prognosis MH - *C-Reactive Protein/analysis MH - Biomarkers MH - *Urinary Bladder Neoplasms/diagnosis MH - *Serum Amyloid P-Component MH - Pentraxins PMC - PMC10970929 OTO - NOTNLM OT - PTX3 OT - diagnostic OT - plasma biomarker OT - prognostic OT - urinary bladder cancer COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2024/03/28 06:46 MHDA- 2024/03/29 06:46 PMCR- 2024/03/20 CRDT- 2024/03/28 01:19 PHST- 2024/02/26 00:00 [received] PHST- 2024/03/12 00:00 [revised] PHST- 2024/03/15 00:00 [accepted] PHST- 2024/03/29 06:46 [medline] PHST- 2024/03/28 06:46 [pubmed] PHST- 2024/03/28 01:19 [entrez] PHST- 2024/03/20 00:00 [pmc-release] AID - ijms25063473 [pii] AID - ijms-25-03473 [pii] AID - 10.3390/ijms25063473 [doi] PST - epublish SO - Int J Mol Sci. 2024 Mar 20;25(6):3473. doi: 10.3390/ijms25063473. PMID- 38534771 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240329 IS - 1467-3045 (Electronic) IS - 1467-3037 (Print) IS - 1467-3037 (Linking) VI - 46 IP - 3 DP - 2024 Mar 14 TI - Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes-Preliminary Report. PG - 2456-2467 LID - 10.3390/cimb46030155 [doi] AB - There is an ongoing need for biomarkers that could reliably predict the outcome of BC and that could guide the management of this disease. In this setting, we aimed to explore the prognostic value of the transcription factor P63 in patients with muscle-invasive bladder cancer (MIBC) having undergone radical cystectomy. The correlation between P63 expression and clinicopathological features (tumor stage, nodes involvement, patterns of muscularis propria invasion, papillary architecture, anaplasia, concomitant carcinoma in situ, lymphovascular invasion, perineural invasion, necrosis) and molecular subtyping (basal and luminal type tumors) was tested in 65 radical cystectomy specimens and matched with cancer-specific survival (CSS) and overall survival (OS). P63-negative tumors displayed significantly higher rates of pattern 2 of muscularis propria invasion (50% vs. 14%, p = 0.002) and variant histology (45% vs. 19%, p = 0.022) compared to P63-positive ones. According to the combined expression of CK5/6 and CK20 (Algorithm #1), P63-positive and P63-negative tumors were mostly basal-like and double-negative, respectively (p = 0.004). Using Algorithm #2, based on the combined expression of CK5/6 and GATA3, the vast majority of tumors were luminal overall and in each group (p = 0.003). There was no significant difference in CSS and OS between P63-positive and P63-negative tumors, but the former featured a trend towards longer OS. Though associated with pathological features harboring negative prognostic potential, P63 status as such failed to predict CSS and OS. That said, it may contribute to better molecular subtyping of MIBC. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Zanelli, Magda AU - Zanelli M AUID- ORCID: 0000-0002-8733-9933 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Palicelli, Andrea AU - Palicelli A AUID- ORCID: 0000-0003-2299-5160 AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Zizzo, Maurizio AU - Zizzo M AUID- ORCID: 0000-0001-9841-7856 AD - Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy. FAU - Ascani, Stefano AU - Ascani S AD - Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy. FAU - Tortorella, Simona AU - Tortorella S AD - Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Angelo AU - Cormio A AUID- ORCID: 0000-0002-6897-7040 AD - Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universita Politecnica Delle Marche, 60126 Ancona, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy. AD - Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy. LA - eng PT - Journal Article DEP - 20240314 PL - Switzerland TA - Curr Issues Mol Biol JT - Current issues in molecular biology JID - 100931761 PMC - PMC10968749 OTO - NOTNLM OT - P63 OT - molecular subtyping OT - muscle-invasive bladder cancer OT - prognosis OT - radical cystectomy COIS- The authors declare no conflicts of interest. EDAT- 2024/03/27 12:46 MHDA- 2024/03/27 12:47 PMCR- 2024/03/14 CRDT- 2024/03/27 09:26 PHST- 2024/02/09 00:00 [received] PHST- 2024/03/07 00:00 [revised] PHST- 2024/03/11 00:00 [accepted] PHST- 2024/03/27 12:47 [medline] PHST- 2024/03/27 12:46 [pubmed] PHST- 2024/03/27 09:26 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - cimb46030155 [pii] AID - cimb-46-00155 [pii] AID - 10.3390/cimb46030155 [doi] PST - epublish SO - Curr Issues Mol Biol. 2024 Mar 14;46(3):2456-2467. doi: 10.3390/cimb46030155. PMID- 38533164 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240328 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 2 DP - 2024 Feb TI - The Effect of Lymphovascular Invasion on Short-Term Tumor Recurrence and Progression in Stage T1 Bladder Cancer. PG - e54844 LID - 10.7759/cureus.54844 [doi] LID - e54844 AB - Introduction Lymphovascular invasion (LVI) is the most important stage for tumor spread and metastasis. The role of LVI in transurethral resection is not yet clear. In this study, the progression and recurrences of patients who underwent transurethral resection bladder tumor (TUR-BT) and T1 high-grade tumor and concomitant LVI were detected in pathology results and were evaluated. Methods Our study included 58 patients, who underwent TUR-BT with the suspicion of bladder cancer and were pathologically diagnosed with T1 stage bladder cancer and who did not undergo radical surgery, in the Urology Clinic of Afyonkarahisar Health Sciences University, Turkey. The patient's age, gender, tumor size, tumor grade, presence of LVI, second resection, recurrence, and progression rates at three months and one year were compared. Results LVI was detected in the pathology specimens of nine (15.5%) of the 58 patients who were included in the study. When the one-year progression was evaluated, progression to T2 tumor was detected in six (66.7%) patients in the group with LVI and five (10.2%) patients in the group without LVI, and the progression was significantly higher in the group with LVI (p=0.001). In logistic regression analysis, the only significant predictor for one-year progression was the presence of LVI (p=0.001). Conclusion According to the results of our study, the presence of LVI in the pathology specimens of patients with T1 high grade significantly increases the progression. Suggesting radical cystectomy and neoadjuvant chemotherapy to patients with LVI in the early period seems to be a more accurate approach, considering the course of the disease. CI - Copyright (c) 2024, Gercek et al. FAU - Gercek, Osman AU - Gercek O AD - Urology, Afyonkarahisar Health Sciences University, Afyonkarahisar, TUR. FAU - Senkol, Melih AU - Senkol M AD - Urology, Afyonkarahisar Health Sciences University, Afyonkarahisar, TUR. FAU - Yazar, Veli Mert AU - Yazar VM AD - Urology, Afyonkarahisar Health Sciences University, Afyonkarahisar, TUR. FAU - Topal, Kutay AU - Topal K AD - Urology, Afyonkarahisar State Hospital, Afyonkarahisar, TUR. LA - eng PT - Journal Article DEP - 20240224 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10964124 OTO - NOTNLM OT - bladder cancer OT - disease progression OT - lymphatic metastasis OT - malignant tumor resection OT - recurrence COIS- The authors have declared that no competing interests exist. EDAT- 2024/03/27 06:43 MHDA- 2024/03/27 06:44 PMCR- 2024/02/24 CRDT- 2024/03/27 03:51 PHST- 2024/02/24 00:00 [accepted] PHST- 2024/03/27 06:44 [medline] PHST- 2024/03/27 06:43 [pubmed] PHST- 2024/03/27 03:51 [entrez] PHST- 2024/02/24 00:00 [pmc-release] AID - 10.7759/cureus.54844 [doi] PST - epublish SO - Cureus. 2024 Feb 24;16(2):e54844. doi: 10.7759/cureus.54844. eCollection 2024 Feb. PMID- 38530585 OWN - NLM STAT- MEDLINE DCOM- 20240723 LR - 20260923 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 56 IP - 8 DP - 2024 Aug TI - Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer. PG - 2577-2587 LID - 10.1007/s11255-024-03971-4 [doi] AB - PURPOSE: T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. METHODS: Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan-Meier curves were used for data analysis. RESULTS: Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. CONCLUSION: This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer. CI - (c) 2024. The Author(s). FAU - Silva Medeiros, Mariana AU - Silva Medeiros M AUID- ORCID: 0009-0006-6152-4555 AD - Department of Urology, Central Lisbon University Hospital Centre, Lisbon, Portugal. mmariana.medeiros92@gmail.com. FAU - Botelho de Carvalho, Luis Andre AU - Botelho de Carvalho LA AD - Department of Chemistry, Faculty of Science and Technology, Caparica, Portugal. FAU - Alves, Marta AU - Alves M AD - Epidemiology and Statistics Unit, Research Centre, Central Lisbon University Hospital Centre, Lisbon, Portugal. FAU - Papoila, Ana AU - Papoila A AD - Epidemiology and Statistics Unit, Research Centre, Central Lisbon University Hospital Centre, Lisbon, Portugal. FAU - Baptista Carreira Dos Santos, Hugo Miguel AU - Baptista Carreira Dos Santos HM AD - Department of Chemistry, Faculty of Science and Technology, Caparica, Portugal. FAU - Capelo-Martinez, Jose-Luis AU - Capelo-Martinez JL AD - Department of Chemistry, Faculty of Science and Technology, Caparica, Portugal. FAU - Viegas de Campos Pinheiro, Luis Manuel AU - Viegas de Campos Pinheiro LM AD - Department of Urology, Central Lisbon University Hospital Centre, Lisbon, Portugal. LA - eng PT - Journal Article DEP - 20240326 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Biomarkers, Tumor) RN - EC 1.11.1.7 (Peroxidase) RN - 0 (intrinsic factor-cobalamin receptor) RN - 0 (Receptors, Cell Surface) SB - IM CIN - Int Urol Nephrol. 2024 Sep;56(9):2963-2964. doi: 10.1007/s11255-024-04035-3. PMID: 38564080 MH - Humans MH - *Urinary Bladder Neoplasms/urine/pathology MH - Male MH - Female MH - *Biomarkers, Tumor/urine MH - Prognosis MH - Aged MH - *Neoplasm Staging MH - Middle Aged MH - *Peroxidase MH - *Neoplasm Grading MH - Receptors, Cell Surface PMC - PMC11266244 OTO - NOTNLM OT - CUBN/MPO OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Urinary proteome EDAT- 2024/03/26 18:44 MHDA- 2024/07/24 00:42 PMCR- 2024/03/26 CRDT- 2024/03/26 12:23 PHST- 2023/09/12 00:00 [received] PHST- 2024/02/03 00:00 [accepted] PHST- 2024/07/24 00:42 [medline] PHST- 2024/03/26 18:44 [pubmed] PHST- 2024/03/26 12:23 [entrez] PHST- 2024/03/26 00:00 [pmc-release] AID - 10.1007/s11255-024-03971-4 [pii] AID - 3971 [pii] AID - 10.1007/s11255-024-03971-4 [doi] PST - ppublish SO - Int Urol Nephrol. 2024 Aug;56(8):2577-2587. doi: 10.1007/s11255-024-03971-4. Epub 2024 Mar 26. PMID- 38528549 OWN - NLM STAT- MEDLINE DCOM- 20240327 LR - 20240328 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 24 IP - 1 DP - 2024 Mar 25 TI - Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters. PG - 67 LID - 10.1186/s12894-024-01437-4 [doi] LID - 67 AB - PURPOSE: A prevalent condition with a high probability of recurrence, non-muscle invasive bladder cancer (NMIBC) necessitates lifetime surveillance. In patients with pathologically confirmed NMIBC, our goal was to create a unique nomogram to predict recurrence after transurethral resection of bladder tumor (TURBT). METHODS: Our institution's 91 NMIBC patients with complete follow-up data between January 2017 and February 2021 were included in the retrospective analysis. The nomogram predicting the 0.5, 1, 2 and 3-year likelihood of recurrence was created using multivariate Cox proportional hazard models to find the significant determinants of recurrence. Using the concordance index (C-index), calibration curves, receiver operating characteristic (ROC) curves, and decision curve analyses (DCA), we internally validated the nomogram. RESULTS: The significant factors related to NMIBC recurrence were age, blood platelet count, especially for the urine leukocyte count and mucus filament. The constructed nomogram performed well in the customized prediction of NMIBC recurrence at 6th, 12th, 24th and 36th month, of which the C-index was 0.724. The calibration curve and the ROC curve both validated the prediction accuracy. On DCA, the nomogram presented good net benefit gains across a wide range of threshold probabilities. Furthermore, the Nomogram-related risk score was used to divide the patient population into two groups with significant recurrence disparities. CONCLUSION: For the prediction of NMIBC recurrence, our unique nomogram demonstrated a respectable degree of discriminative capacity, sufficient calibration, and considerable net benefit gain. There will be a need for additional internal and external validation. CI - (c) 2024. The Author(s). FAU - He, Yi AU - He Y AD - Department of Urology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Pan, Chenxi AU - Pan C AD - Department of Urology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Zhang, Yue AU - Zhang Y AD - Department of Urology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Lv, Meihong AU - Lv M AD - Department of Anesthesiology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. lvmeihongmz@163.com. AD - The First Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Xigang District, Dalian, 116011, China. lvmeihongmz@163.com. FAU - Yang, Bo AU - Yang B AD - Department of Urology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. yangbo20160101@163.com. AD - The First Affiliated Hospital of Dalian Medical University, 222, Zhongshan Road, Xigang District, Dalian, 116011, China. yangbo20160101@163.com. AD - The Second Affiliated Hospital of Dalian Medical University, 467, Zhongshan Road, Shahekou District, Dalian, 116044, China. yangbo20160101@163.com. LA - eng GR - dy2yynpy202220/the cultivating scientific research project of the Second Hospital of Dalian Medical University/ GR - LJKZ0858/the Basic scientific research project of Liaoning Provincial Education Department/ GR - 2022LCYJZD02/"1+X" program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University/ PT - Journal Article DEP - 20240325 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Nomograms MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Risk Factors PMC - PMC10964628 OTO - NOTNLM OT - Nomogram OT - Primary non-muscle-invasive bladder cancer OT - Recurrence COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/26 06:45 MHDA- 2024/03/27 06:44 PMCR- 2024/03/25 CRDT- 2024/03/26 01:19 PHST- 2023/06/12 00:00 [received] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/03/27 06:44 [medline] PHST- 2024/03/26 06:45 [pubmed] PHST- 2024/03/26 01:19 [entrez] PHST- 2024/03/25 00:00 [pmc-release] AID - 10.1186/s12894-024-01437-4 [pii] AID - 1437 [pii] AID - 10.1186/s12894-024-01437-4 [doi] PST - epublish SO - BMC Urol. 2024 Mar 25;24(1):67. doi: 10.1186/s12894-024-01437-4. PMID- 38525411 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240326 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment. PG - 1240378 LID - 10.3389/fonc.2023.1240378 [doi] LID - 1240378 AB - Intravesical Bacillus Calmettes-Guerin (BCG) instillations is the gold standard adjuvant treatment for high and very high-risk non-muscle-invasive bladder cancer (NMIBC). Antibiotics may be required to treat asymptomatic bacteriuria before instillations or to prevent side effects. By modifying the bladder microbiota and through its bactericidal action, it could modify the efficacy of BCG. This study evaluates the impact of antibiotics received during BCG-induction treatment on the oncological outcomes for high and very high risk NMIBC. We retrospectively included all patients who received a full induction regimen of BCG therapy between January 2017 and June 2022. Clinical and tumor characteristics as well as tolerability were collected. Recurrence-free survival (RFS) and progression-free survival (PFS) were compared according to the prescription of antibiotics, its type and duration. A total of 126 patients were included, 86.5% of the tumors were high risk and 13.5% very high risk. The median follow-up was 31 months (7-60). 36% of the patients received antibiotics during BCG-induction treatment (among which 44% received fluoroquinolones). 21.4% of patients had tumor recurrence. There was no difference in RFS (p=0.902) or PFS (p=0.88) according to the duration or the type of antibiotics received. The use of a prolonged antibiotic treatment (> 7 days) significantly increased the duration of the BCG-induction treatment from 35 to 41,5 days (p=0,049) and the median number of delayed treatments by 1,5 [0-4]. Neither the use of antibiotics nor their duration modified the risk of recurrence or the intensity of side effects in multivariate analysis. Antibiotics received during BCG-induction immunotherapy did not influence oncological short-term outcomes or intensity of side effects. CI - Copyright (c) 2024 Aubert, Culty, Zidane, Bigot and Lebdai. FAU - Aubert, Cecile AU - Aubert C AD - Urology Department, University Hospital of Angers, Angers, France. FAU - Culty, Thibaut AU - Culty T AD - Urology Department, University Hospital of Angers, Angers, France. FAU - Zidane, Merzouka AU - Zidane M AD - Pathology Department, University Hospital of Angers, Angers, France. FAU - Bigot, Pierre AU - Bigot P AD - Urology Department, University Hospital of Angers, Angers, France. FAU - Lebdai, Souhil AU - Lebdai S AD - Urology Department, University Hospital of Angers, Angers, France. LA - eng PT - Journal Article DEP - 20240308 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10957779 OTO - NOTNLM OT - Bacillus Calmettes et Guerin OT - antibiotics OT - bladder OT - cancer OT - fluoroquinolones COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/03/25 06:43 MHDA- 2024/03/25 06:44 PMCR- 2023/01/01 CRDT- 2024/03/25 04:42 PHST- 2023/06/19 00:00 [received] PHST- 2023/12/29 00:00 [accepted] PHST- 2024/03/25 06:44 [medline] PHST- 2024/03/25 06:43 [pubmed] PHST- 2024/03/25 04:42 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1240378 [doi] PST - epublish SO - Front Oncol. 2024 Mar 8;13:1240378. doi: 10.3389/fonc.2023.1240378. eCollection 2023. PMID- 38524652 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240326 IS - 2192-3183 (Electronic) IS - 2192-3183 (Linking) VI - 13 IP - 2 DP - 2024 Apr TI - Primary signet-ring cell carcinoma of the bladder treated with laparoscopic radical cystectomy: a case report. PG - 129-133 LID - 10.1007/s13691-023-00648-0 [doi] AB - Primary bladder adenocarcinomas comprise 0.5-2% of all epithelial bladder neoplasms. Of these, primary signet-ring cell carcinoma of the bladder is particularly rare, accounting for 0.24% of all bladder malignancies. This tumor is frequently diagnosed at an advanced stage and has a poor prognosis. No standard treatment has yet been established. We here report a patient in whom laparoscopic cystectomy following neoadjuvant chemotherapy was effective. Our patient was a 69-year-old man who had had microscopic hematuria, undergone transurethral resection of a mass in the bladder, and been diagnosed pathologically with a primary signet-ring cell carcinoma of the bladder. No metastases were detected on computed tomography. The patient was treated with a combination of paclitaxel, cisplatin, and gemcitabine prior to undergoing laparoscopic cystectomy. The histopathological diagnosis on this operative specimen was dysplasia and no metastases were detected in the dissected lymph nodes. Complete remission has now been maintained for 9 years. CI - (c) The Author(s) 2024. FAU - Mukae, Yuta AU - Mukae Y AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Ohba, Kojiro AU - Ohba K AUID- ORCID: 0000-0003-2841-1998 AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Araki, Kyohei AU - Araki K AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Nakamura, Yuichiro AU - Nakamura Y AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Nakanishi, Hiromi AU - Nakanishi H AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Yasuda, Takuji AU - Yasuda T AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Mitsunari, Kensuke AU - Mitsunari K AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Mochizuki, Yasushi AU - Mochizuki Y AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 FAU - Irie, Junji AU - Irie J AD - Department of Pathology, Nagasaki Harbor Medical Center, Shinchi-Machi 6-39, Nagasaki, Japan. FAU - Imamura, Ryoichi AU - Imamura R AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, Japan. ROR: https://ror.org/05kd3f793. GRID: grid.411873.8. ISNI: 0000 0004 0616 1585 LA - eng PT - Journal Article DEP - 20240206 PL - Singapore TA - Int Cancer Conf J JT - International cancer conference journal JID - 101734231 PMC - PMC10957812 OTO - NOTNLM OT - Laparoscopic cystectomy OT - Neoadjuvant chemotherapy OT - Paclitaxel OT - Signet-ring cell carcinoma OT - Urinary bladder COIS- Conflict of interestThe authors declare that they have no conflict of interest. EDAT- 2024/03/25 06:43 MHDA- 2024/03/25 06:44 PMCR- 2024/02/06 CRDT- 2024/03/25 04:28 PHST- 2023/11/01 00:00 [received] PHST- 2023/12/14 00:00 [accepted] PHST- 2024/03/25 06:44 [medline] PHST- 2024/03/25 06:43 [pubmed] PHST- 2024/03/25 04:28 [entrez] PHST- 2024/02/06 00:00 [pmc-release] AID - 648 [pii] AID - 10.1007/s13691-023-00648-0 [doi] PST - epublish SO - Int Cancer Conf J. 2024 Feb 6;13(2):129-133. doi: 10.1007/s13691-023-00648-0. eCollection 2024 Apr. PMID- 38524643 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250125 IS - 2192-3183 (Electronic) IS - 2192-3183 (Linking) VI - 13 IP - 2 DP - 2024 Apr TI - Multidisciplinary treatment for small cell carcinoma of the bladder: a case report. PG - 103-107 LID - 10.1007/s13691-023-00644-4 [doi] AB - Small cell carcinoma (SCC) of the urinary bladder is a rare and highly aggressive subtype of bladder cancer. Most cases are diagnosed at advanced stages, and its therapeutic strategy remains unestablished. Here, we report a case of bladder SCC in which multidisciplinary treatment has resulted in relatively long-term survival. A 68-year-old man presented with gross hematuria. A cystoscopy revealed an invasive bladder tumor. A transurethral resection of bladder tumor (TURBT) was performed, and the pathological diagnosis was SCC. After systemic chemotherapy using etoposide and carboplatin and subsequent TURBT, a radical cystectomy and ileal conduit were performed. Three months postoperatively, the patient had a recurrence in the para-aortic lymph node. Systemic combination chemotherapy with carboplatin plus irinotecan (CBDCA + CPT-11) was administered, followed by amrubicin and an immune checkpoint inhibitor. In addition to this treatment, radiation therapy for the metastatic region led to the reduction of pain and shrinkage of the metastatic lesion. The patient survived for 2 years after the initial diagnosis. Our report indicates that multidisciplinary treatment can be effective for SCC of the bladder, and a therapeutic strategy including the identification of novel biomarkers should be established. CI - (c) The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Mita, Yoshie AU - Mita Y AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 AD - Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan. ROR: https://ror.org/03tgsfw79. GRID: grid.31432.37. ISNI: 0000 0001 1092 3077 FAU - Teishima, Jun AU - Teishima J AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 AD - Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan. ROR: https://ror.org/03tgsfw79. GRID: grid.31432.37. ISNI: 0000 0001 1092 3077 FAU - Yao, Akihisa AU - Yao A AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 FAU - Uematsu, Riku AU - Uematsu R AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 FAU - Yoshii, Takahiko AU - Yoshii T AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 FAU - Hara, Takuto AU - Hara T AD - Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan. ROR: https://ror.org/03tgsfw79. GRID: grid.31432.37. ISNI: 0000 0001 1092 3077 FAU - Fujisawa, Masato AU - Fujisawa M AD - Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan. ROR: https://ror.org/03tgsfw79. GRID: grid.31432.37. ISNI: 0000 0001 1092 3077 FAU - Nakamura, Ichiro AU - Nakamura I AD - Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan. ROR: https://ror.org/0466c1b11. GRID: grid.415419.c. ISNI: 0000 0004 7870 0146 LA - eng PT - Journal Article DEP - 20240124 PL - Singapore TA - Int Cancer Conf J JT - International cancer conference journal JID - 101734231 PMC - PMC10957848 OTO - NOTNLM OT - Bladder cancer OT - Multidisciplinary treatment OT - Small cell carcinoma COIS- Conflict of interestThe authors declare that they have no conflict of interest. EDAT- 2024/03/25 06:42 MHDA- 2024/03/25 06:43 PMCR- 2025/01/24 CRDT- 2024/03/25 04:28 PHST- 2023/10/08 00:00 [received] PHST- 2023/11/27 00:00 [accepted] PHST- 2024/03/25 06:43 [medline] PHST- 2024/03/25 06:42 [pubmed] PHST- 2024/03/25 04:28 [entrez] PHST- 2025/01/24 00:00 [pmc-release] AID - 644 [pii] AID - 10.1007/s13691-023-00644-4 [doi] PST - epublish SO - Int Cancer Conf J. 2024 Jan 24;13(2):103-107. doi: 10.1007/s13691-023-00644-4. eCollection 2024 Apr. PMID- 38522634 OWN - NLM STAT- MEDLINE DCOM- 20240622 LR - 20250320 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 188 DP - 2024 Jun TI - Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index. PG - 104-110 LID - S0090-4295(24)00201-2 [pii] LID - 10.1016/j.urology.2024.03.026 [doi] AB - OBJECTIVE: To evaluate the mFI-5 as a predictor of postoperative outcomes following transurethral resection of bladder tumor (TURBT). METHODS: The National Surgical Quality Improvement Program database was queried for TURBT cases from 2015-2019. mFI-5 scores were calculated by assigning a point to chronic obstructive pulmonary disease, congestive heart failure, dependent functional status, hypertension, and diabetes. Patients were stratified by mFI-5 scores. Demographics and 30-day outcomes including Clavien-Dindo (CD) complications, mortality, and increased healthcare resource utilization (HCRU) were compared. HCRU outcomes included prolonged length of stay, unplanned readmission, and discharge to continued care. Multivariate regression assessed the predictive value of mFI-5 scores on outcomes. RESULTS: 40,278 TURBT cases were identified (mFI-5 =0: 12,400, mFI-5 =1: 17,328, mFI-5 =2: 9225, mFI-5 >/=3: 1416). Patients with higher mFI-5 scores were more likely to be older, male, White, and have larger tumors, all P < .05. Increasing mFI-5 scores resulted in increased frequency of all adverse outcomes, all P < .001. On multivariate analysis, mFI-5 >/= 3 classification was a predictor of CD I/II (OR=1.280), CD IV (OR=2.539), mortality (OR=2.202), HCRU (OR=2.094), prolonged length of stay (OR=2.136), discharge to continued care (OR=3.401), and unplanned readmission (OR=1.705), all P < .05. A mFI-5 >/= 3 demonstrated a sensitivity ranging from 6.0%-13.5% and a specificity ranging from 96.6%-97.0% for all outcomes. CONCLUSION: The mFI-5 is an easily ascertainable preoperative risk assessment tool that is a predictor of adverse clinical and HCRU outcomes following TURBT. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Connors, Christopher AU - Connors C AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: christopher.connors@icahn.mssm.edu. FAU - Wang, Daniel AU - Wang D AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Levy, Micah AU - Levy M AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Ravivarapu, Krishna T AU - Ravivarapu KT AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Chin, Chih Peng AU - Chin CP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Arroyave, Juan Sebastian AU - Arroyave JS AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Omidele, Olamide AU - Omidele O AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Larenas, Francisca AU - Larenas F AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Palese, Michael AU - Palese M AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. LA - eng PT - Journal Article DEP - 20240324 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/mortality/pathology MH - Male MH - Female MH - Aged MH - *Frailty/complications MH - *Postoperative Complications/epidemiology/etiology MH - Middle Aged MH - *Cystectomy/methods MH - Retrospective Studies MH - Treatment Outcome MH - Risk Assessment/methods MH - Aged, 80 and over MH - Length of Stay/statistics & numerical data MH - Patient Readmission/statistics & numerical data MH - Transurethral Resection of Bladder COIS- Declaration of Competing Interest The authors have no conflict of interest to declare. EDAT- 2024/03/25 00:42 MHDA- 2024/06/23 00:42 CRDT- 2024/03/24 20:27 PHST- 2023/10/19 00:00 [received] PHST- 2024/01/15 00:00 [revised] PHST- 2024/03/14 00:00 [accepted] PHST- 2024/06/23 00:42 [medline] PHST- 2024/03/25 00:42 [pubmed] PHST- 2024/03/24 20:27 [entrez] AID - S0090-4295(24)00201-2 [pii] AID - 10.1016/j.urology.2024.03.026 [doi] PST - ppublish SO - Urology. 2024 Jun;188:104-110. doi: 10.1016/j.urology.2024.03.026. Epub 2024 Mar 24. PMID- 38521660 OWN - NLM STAT- MEDLINE DCOM- 20240926 LR - 20240926 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 5 DP - 2024 Oct TI - Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy. PG - 1105-1112 LID - S2588-9311(24)00055-5 [pii] LID - 10.1016/j.euo.2024.03.002 [doi] AB - BACKGROUND AND OBJECTIVE: Decision-making on the use of neoadjuvant and adjuvant treatment for patients with bladder cancer undergoing radical cystectomy (RC) currently depends on assessment of clinical and pathological features, which lack sensitivity. Circulating tumor DNA (ctDNA) has emerged as a possible novel prognostic biomarker in the field. Our aim was to assess whether ctDNA status before RC is predictive of pathological and oncological outcomes. We also evaluated the dynamic changes in ctDNA status after RC in relation to recurrence-free survival (RFS). METHODS: We analyzed data for patients who underwent RC during 2021-2023 for whom prospective tumor-informed ctDNA analyses were conducted before and after RC. RFS was evaluated using the Kaplan-Meier method. Predictors for disease recurrence were assessed using Cox proportional-hazards models. Pathological outcomes associated with detectable ctDNA before RC were assessed in univariable and multivariable regression analyses. KEY FINDINGS AND LIMITATIONS: We included 112 patients in the analysis. Median follow-up was 8 mo (interquartile range 4-13). ctDNA was detected before RC in 59 patients (53%) and was associated with poor RFS (log-rank p < 0.0001). Detectable ctDNA before RC was associated with poor outcomes regardless of clinical stage (/=cT2) and receipt of neoadjuvant therapy. Multivariable analyses revealed that detectable ctDNA before RC was associated with a higher risk of nodal disease (odds ratio 5.4, 95% confidence interval [CI] 1.9-18.2; p = 0.003) and locally advanced disease (odds ratio 3.6, 95% CI 1.5-9; p = 0.005). Cox regression analyses showed that detectable ctDNA before RC (hazard ratio 4.5, 95% CI 1-19; p = 0.04) and detectable ctDNA at the minimal residual disease window (hazard ratio 9.9, 95% CI 2.6-37; p < 0.001) were predictive of disease recurrence. CONCLUSIONS AND CLINICAL IMPLICATIONS: Detectable ctDNA before definitive therapy with RC is predictive of nodal involvement, locally advanced disease, and disease recurrence in patients with bladder cancer. ctDNA status holds promise for improving clinical staging and augmenting current decision-making tools. PATIENT SUMMARY: We found that for patients with bladder cancer undergoing radical cystectomy, a test to show the presence of tumor DNA in blood before surgery was able to predict the risk of disease relapse and adverse pathology. Use of this assay could help in decision-making by clinicians and patients for optimal personalized treatment of this disease. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Ben-David, Reuben AU - Ben-David R AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: reuben.bendavid@mountsinai.org. FAU - Tillu, Neeraja AU - Tillu N AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Cumarasamy, Shivaram AU - Cumarasamy S AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Alerasool, Parissa AU - Alerasool P AD - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Rich, Jordan M AU - Rich JM AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kaufmann, Basil AU - Kaufmann B AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Elkun, Yuval AU - Elkun Y AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Attalla, Kyrollis AU - Attalla K AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Wiklund, Peter AU - Wiklund P AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Urology Department, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng PT - Journal Article DEP - 20240322 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Circulating Tumor DNA) SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/blood/pathology/genetics MH - Male MH - Female MH - *Circulating Tumor DNA/blood MH - Aged MH - Prognosis MH - *Neoplasm Staging MH - Middle Aged MH - Prospective Studies OTO - NOTNLM OT - Circulating tumor DNA OT - Non-muscle-invasive bladder neoplasms OT - Tumor biomarkers OT - Urinary bladder neoplasms EDAT- 2024/03/24 00:42 MHDA- 2024/09/27 00:42 CRDT- 2024/03/23 23:22 PHST- 2024/01/08 00:00 [received] PHST- 2024/02/14 00:00 [revised] PHST- 2024/03/01 00:00 [accepted] PHST- 2024/09/27 00:42 [medline] PHST- 2024/03/24 00:42 [pubmed] PHST- 2024/03/23 23:22 [entrez] AID - S2588-9311(24)00055-5 [pii] AID - 10.1016/j.euo.2024.03.002 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Oct;7(5):1105-1112. doi: 10.1016/j.euo.2024.03.002. Epub 2024 Mar 22. PMID- 38519296 OWN - NLM STAT- MEDLINE DCOM- 20240606 LR - 20260630 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 3 DP - 2024 Jun TI - A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non-Muscle-Invasive Bladder Cancer. PG - 102061 LID - S1558-7673(24)00034-X [pii] LID - 10.1016/j.clgc.2024.02.012 [doi] AB - BACKGROUND: There is an urgent need to identify a robust predictor for BCG response in patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy. METHODS: After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening. Then, we developed the BCGI using a Lasso regression model and subsequently evaluated its performance in both the train and internal test datasets through Kaplan-Meier survival curves and Cox regression analysis. Then, we also evaluated the prognostic value of BCGI alongside the EAU2021 model. RESULTS: The training dataset and internal test dataset contained 295 and 196 patients, respectively. Referring to the Lasso results, BCGI consisted of hemoglobin, albumin, and platelet count, which could significantly predict the recurrence of NMIBC patients who accepted BCG in train (P = .012) and test (P = .004) datasets. The BCGI also exhibited statistically prognostic value in no smoking history, World Health Organization high grade, and T1 subgroups, both in train and test datasets. In multivariable analysis, BCGI exhibited independent prognostic value in train (P = .012) and test (P = .012) datasets. Finally, we constructed a nomogram that consisted of smoking history, T stage, World Health Organization grade, tumor size, and BCGI. Then, BCGI demonstrated significant independent prognostic value in NMIBC patients treated with BCG, a result not observed with the EAU2021 score or classification. CONCLUSION: Based on the results, we reasonably suggest that BCGI may be a useful predictor for NMIBC patients who accepted BCG. Furthermore, we have demonstrated the efficacy of constructing a prognostic index using clinical factors and a Lasso regression model, a versatile approach applicable to various medical conditions. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Li, Dengxiong AU - Li D AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wu, Ruicheng AU - Wu R AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Jie AU - Wang J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Ye, Junjiang AU - Ye J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Yu, Qingxin AU - Yu Q AD - Ningbo Diagnostic Pathology Center, Ningbo City, Zhejiang Province, China. FAU - Feng, Dechao AU - Feng D AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: fdcfenix@stu.scu.edu.cn. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: hanping@scu.edu.cn. LA - eng PT - Journal Article DEP - 20240229 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/drug therapy MH - Male MH - Female MH - Prognosis MH - Aged MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Middle Aged MH - Inflammation MH - Retrospective Studies MH - Kaplan-Meier Estimate MH - Preoperative Period MH - Neoplasm Recurrence, Local MH - Treatment Outcome MH - Platelet Count MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Inflammation OT - Lasso model OT - NMIBC OT - Nutrition COIS- Disclosure The authors have no conflicts of interest to declare. EDAT- 2024/03/23 05:42 MHDA- 2024/06/07 00:43 CRDT- 2024/03/22 23:02 PHST- 2023/12/10 00:00 [received] PHST- 2024/02/21 00:00 [revised] PHST- 2024/02/24 00:00 [accepted] PHST- 2024/06/07 00:43 [medline] PHST- 2024/03/23 05:42 [pubmed] PHST- 2024/03/22 23:02 [entrez] AID - S1558-7673(24)00034-X [pii] AID - 10.1016/j.clgc.2024.02.012 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Jun;22(3):102061. doi: 10.1016/j.clgc.2024.02.012. Epub 2024 Feb 29. PMID- 38515791 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241106 IS - 2468-0540 (Electronic) IS - 2468-0540 (Linking) VI - 9 IP - 2 DP - 2024 Jun TI - Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism. PG - 560-582 LID - 10.1016/j.ncrna.2024.01.009 [doi] AB - Bladder cancer (BC) is a highly frequent neoplasm in correlation with significant rate of morbidity, mortality, and cost. The onset of BC is predominantly triggered by environmental and/or occupational exposures to carcinogens, such as tobacco. There are two distinct pathways by which BC can be developed, including non-muscle-invasive papillary tumors (NMIBC) and non-papillary (or solid) muscle-invasive tumors (MIBC). The Cancer Genome Atlas project has further recognized key genetic drivers of MIBC along with its subtypes with particular properties and therapeutic responses; nonetheless, NMIBC is the predominant BC presentation among the suffering individuals. Radical cystoprostatectomy, radiotherapy, and chemotherapy have been verified to be the common therapeutic interventions in metastatic tumors, among which chemotherapeutics are more conventionally utilized. Although multiple chemo drugs have been broadly administered for BC treatment, cisplatin is reportedly the most effective chemo drug against the corresponding malignancy. Notwithstanding, tumor recurrence is usually occurred following the consumption of cisplatin regimens, particularly due to the progression of chemo-resistant trait. In this framework, non-coding RNAs (ncRNAs), as abundant RNA transcripts arise from the human genome, are introduced to serve as crucial contributors to tumor expansion and cisplatin chemo-resistance in bladder neoplasm. In the current review, we first investigated the best-known ncRNAs, i.e. microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), correlated with cisplatin chemo-resistance in BC cells and tissues. We noticed that these ncRNAs could mediate the BC-related cisplatin-resistant phenotype through diverse cellular processes and signaling mechanisms, reviewed here. Eventually, diagnostic and prognostic potential of ncRNAs, as well as their therapeutic capabilities were highlighted in regard to BC management. CI - (c) 2024 The Authors. FAU - Hashem, Mehrdad AU - Hashem M AD - Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Mohandesi Khosroshahi, Elaheh AU - Mohandesi Khosroshahi E AD - Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Aliahmady, Melika AU - Aliahmady M AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Ghanei, Morvarid AU - Ghanei M AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Soofi Rezaie, Yasamin AU - Soofi Rezaie Y AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Alsadat Jafari, Yasamin AU - Alsadat Jafari Y AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. FAU - Rezaei, Fatemeh AU - Rezaei F AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. FAU - Khodaparast Eskadehi, Ramtin AU - Khodaparast Eskadehi R AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. FAU - Kia Kojoori, Kimia AU - Kia Kojoori K AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. FAU - Jamshidian, Faranak AU - Jamshidian F AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran. FAU - Nabavi, Noushin AU - Nabavi N AD - Department of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, V6H3Z6, Vancouver, BC, Canada. FAU - Rashidi, Mohsen AU - Rashidi M AD - The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran. AD - Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. FAU - Hasani Sadi, Farzaneh AU - Hasani Sadi F AD - General Practitioner, Kerman University of Medical Sciences, Kerman, 7616913555, Iran. FAU - Taheriazam, Afshin AU - Taheriazam A AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Department of Orthopedics, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Entezari, Maliheh AU - Entezari M AD - Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. AD - Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20240122 PL - Netherlands TA - Noncoding RNA Res JT - Non-coding RNA research JID - 101688191 PMC - PMC10955558 OTO - NOTNLM OT - Cisplatin OT - Drug resistance OT - Non-coding RNAs OT - Signal transduction OT - Urinary bladder neoplasms COIS- The authors declare that they have no competing interests. EDAT- 2024/03/22 06:44 MHDA- 2024/03/22 06:45 PMCR- 2024/01/22 CRDT- 2024/03/22 04:00 PHST- 2023/11/09 00:00 [received] PHST- 2024/01/12 00:00 [revised] PHST- 2024/01/14 00:00 [accepted] PHST- 2024/03/22 06:45 [medline] PHST- 2024/03/22 06:44 [pubmed] PHST- 2024/03/22 04:00 [entrez] PHST- 2024/01/22 00:00 [pmc-release] AID - S2468-0540(24)00009-X [pii] AID - 10.1016/j.ncrna.2024.01.009 [doi] PST - epublish SO - Noncoding RNA Res. 2024 Jan 22;9(2):560-582. doi: 10.1016/j.ncrna.2024.01.009. eCollection 2024 Jun. PMID- 38514751 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20240325 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Mar 21 TI - Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients. PG - 6801 LID - 10.1038/s41598-024-55251-x [doi] LID - 6801 AB - We designed this multi-center prospective study with the following objectives: (1) the cross-sectional validation of extracellular vesicles (EV) mRNA markers to detect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (2) the longitudinal validation of EV mRNA markers to monitor non-muscle invasive bladder cancer (NMIBC) recurrence after TURBT. EV mRNA markers evaluated in this study were KRT17, GPRC5A, and SLC2A1 in addition to two additional markers from literatures, MDK and CXCR2, and measured by quantitative RT-PCR with normalization by a reference gene (ALDOB). Diagnostic performances of EV mRNA markers were compared to conventional markers. Regarding the first objective, we confirmed that EV mRNA biomarkers in urine were higher in UBC patients, particularly those with higher stage/grade tumors, than in those without UBC (n = 278 in total) and the diagnostic performance of EV mRNA MDK and KRT17 outperformed conventional biomarkers with AUC 0.760 and 0.730, respectively. Concerning the second objective, we prospectively analyzed the time courses of EV mRNA markers while NMIBC patients (n = 189) (median follow-up 19 months). The expression of EV mRNA KRT17 was significantly high in patients with recurrence, while it gradually decreased over time in those without recurrence (p < 0.01). CI - (c) 2024. The Author(s). FAU - Murakami, Taku AU - Murakami T AD - Research & Development, Showa Denko Materials (America), Inc., Irvine, CA, USA. FAU - Minami, Keita AU - Minami K AD - Departments of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan. FAU - Harabayashi, Toru AU - Harabayashi T AD - Department of Urology, Hokkaido Cancer Center, Sapporo, Japan. FAU - Maruyama, Satoru AU - Maruyama S AD - Department of Urology, Hokkaido Cancer Center, Sapporo, Japan. FAU - Takada, Norikata AU - Takada N AD - Department of Urology, Hokkaido Cancer Center, Sapporo, Japan. FAU - Kashiwagi, Akira AU - Kashiwagi A AD - Department of Urology, Teine Keijinkai Hospital, Sapporo, Japan. FAU - Miyata, Haruka AU - Miyata H AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Sato, Yasuyuki AU - Sato Y AD - Department of Urology, Sapporo Keiyukai Hospital, Sapporo, Japan. FAU - Matsumoto, Ryuji AU - Matsumoto R AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Kikuchi, Hiroshi AU - Kikuchi H AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Ito, Yoichi M AU - Ito YM AD - Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan. FAU - Murai, Sachiyo AU - Murai S AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. FAU - Harada, Hiroshi AU - Harada H AD - Departments of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AD - Department of Urology, Hokkaido University Hospital, N15 W7 Kita-ku, Sapporo, 060-8638, Japan. taka0573@med.hokudai.ac.jp. LA - eng GR - 22K09439/Japan Society for the Promotion of Science/ PT - Journal Article PT - Multicenter Study DEP - 20240321 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers) RN - 0 (GPRC5A protein, human) RN - 0 (Receptors, G-Protein-Coupled) SB - IM MH - Humans MH - Prospective Studies MH - Cross-Sectional Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/genetics/pathology MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell MH - Biomarkers MH - Neoplasm Invasiveness MH - Receptors, G-Protein-Coupled PMC - PMC10957914 OTO - NOTNLM OT - Biomarker OT - Cancer recurrence OT - Exosome OT - Extracellular vesicles OT - Non-muscle invasive bladder cancer OT - mRNA COIS- The authors of this manuscript have the following conflicts of interest to disclose. TM is an employee of Showa Denko Materials America, formerly known as Hitachi Chemical Co. America. The present study was funded by the Japan Society for the Promotion of Science (KAKENHI, Grant Number 22K09439) and Showa Denko Materials America. Parts of this study were presented in American Urological Association annual meetings in 2019 and 2020. Parts of this study were presented in American Urological Association annual meetings in 2019 and 2020. EDAT- 2024/03/22 06:45 MHDA- 2024/03/25 06:42 PMCR- 2024/03/21 CRDT- 2024/03/22 00:35 PHST- 2023/10/22 00:00 [received] PHST- 2024/02/21 00:00 [accepted] PHST- 2024/03/25 06:42 [medline] PHST- 2024/03/22 06:45 [pubmed] PHST- 2024/03/22 00:35 [entrez] PHST- 2024/03/21 00:00 [pmc-release] AID - 10.1038/s41598-024-55251-x [pii] AID - 55251 [pii] AID - 10.1038/s41598-024-55251-x [doi] PST - epublish SO - Sci Rep. 2024 Mar 21;14(1):6801. doi: 10.1038/s41598-024-55251-x. PMID- 38512511 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Mar 21 TI - Treatment patterns and prognosis in patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis. PG - 185 LID - 10.1007/s00345-024-04834-4 [doi] AB - PURPOSE: The International Bladder Cancer Group designated the subgroup that is resistant to Bacillus Calmette-Guerin (BCG) but does not meet the criteria for BCG-unresponsive NMIBC as "BCG-exposed high-risk NMIBC" to guide optimal trial design. We aimed to investigate the treatment patterns and prognoses of patients with BCG-exposed NMIBC. METHODS: We conducted a retrospective chart review of 3283 patients who received intravesical BCG therapy for NMIBC at 14 participating institutions between January 2000 and December 2019. Patients meeting the criteria for BCG-exposed and BCG-unresponsive NMIBC, as defined by the Food and Drug Administration and International Bladder Cancer Group, were selected. To compare treatment patterns and outcomes, high-risk recurrence occurring more than 24 months after the last dose of BCG was defined as "BCG-treated NMIBC." In addition, we compared prognoses between BCG rechallenge and early cystectomy in patients with BCG-exposed NMIBC. RESULTS: Of 3283 patients, 108 (3.3%), 150 (4.6%), and 391 (11.9%) were classified as having BCG-exposed, unresponsive, and treated NMIBC, respectively. BCG-exposed NMIBC demonstrated intermediate survival curves for intravesical recurrence-free and progression-free survival, falling between those of BCG-unresponsive and treated NMIBC. Among patients with BCG-exposed NMIBC, 48 (44.4%) received BCG rechallenge, which was the most commonly performed treatment, and 19 (17.6%) underwent early cystectomy. No significant differences were observed between BCG rechallenge and early cystectomy in patients with BCG-exposed NMIBC. CONCLUSIONS: The newly proposed definition of BCG-exposed NMIBC may serve as a valuable disease subgroup for distinguishing significant gray areas, except in cases of BCG-unresponsive NMIBC. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Tomida, Ryotaro AU - Tomida R AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemoto-Machi Kou, Matsuyama, Ehime, 791-0280, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Zaifucho, Hirosaki, 036-8562, Japan. FAU - Okajima, Eijiro AU - Okajima E AD - Department of Urology, Nara Prefecture General Medical Center, 897-5, Shichijo-Nishi Machi 2 Chome, Nara, 630-8581, Japan. FAU - Yajima, Shugo AU - Yajima S AD - Division of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - Division of Urology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. FAU - Terada, Naoki AU - Terada N AD - Department of Urology, Miyazaki University, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center Hospital, Kanokoden, Chikusa-Ku, Nagoya, 464-8681, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. LA - eng PT - Journal Article DEP - 20240321 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - Adjuvants, Immunologic/therapeutic use MH - Prognosis MH - *Urinary Bladder Neoplasms/drug therapy MH - Data Analysis MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/drug therapy OTO - NOTNLM OT - Adequate BCG therapy OT - BCG-exposed NMIBC OT - BCG-unresponsive NMIBC OT - Delayed relapse after adequate BCG OT - Delayed relapse after inadequate BCG EDAT- 2024/03/21 18:45 MHDA- 2024/03/25 06:42 CRDT- 2024/03/21 12:16 PHST- 2023/10/03 00:00 [received] PHST- 2024/01/16 00:00 [accepted] PHST- 2024/03/25 06:42 [medline] PHST- 2024/03/21 18:45 [pubmed] PHST- 2024/03/21 12:16 [entrez] AID - 10.1007/s00345-024-04834-4 [pii] AID - 10.1007/s00345-024-04834-4 [doi] PST - epublish SO - World J Urol. 2024 Mar 21;42(1):185. doi: 10.1007/s00345-024-04834-4. PMID- 38507101 OWN - NLM STAT- MEDLINE DCOM- 20240322 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Mar 20 TI - Multiparametric Magnetic Resonance Imaging in the follow-up of non-muscle-invasive bladder tumors after intravesical instillations: a promising tool. PG - 178 LID - 10.1007/s00345-024-04868-8 [doi] AB - PURPOSE: The standard follow-up for non-muscle-invasive bladder cancer is based on cystoscopy. Unfortunately, post-instillation inflammatory changes can make the interpretation of this exam difficult, with lower specificity. This study aimed to evaluate the interest of bladder MRI in the follow-up of patients following intravesical instillation. METHODS: Data from patients who underwent cystoscopy and bladder MRI in a post-intravesical instillation setting between February 2020 and March 2023 were retrospectively collected. Primary endpoint was to evaluate and compare the diagnostic performance of cystoscopy and bladder MRI in the overall cohort (n = 67) using the pathologic results of TURB as a reference. The secondary endpoint was to analyze the diagnostic accuracy of cystoscopy and bladder MRI according to the appearance of the lesion on cystoscopy [flat (n = 40) or papillary (n = 27)]. RESULTS: The diagnostic performance of bladder MRI was better than that of cystoscopy, with a specificity of 47% (vs. 6%, p < 0.001), a negative predictive value of 88% (vs. 40%, p = 0.03), and a positive predictive value of 66% (vs. 51%, p < 0.001), whereas the sensitivity did not significantly differ between the two exams. In patients with doubtful cystoscopy and negative MRI findings, inflammatory changes were found on TURB in most cases (17/19). The superiority in MRI bladder performance prevailed for "flat lesions", while no significant difference was found for "papillary lesions". CONCLUSIONS: In cases of doubtful cystoscopy after intravesical instillations, MRI appears to be relevant with good performance in differentiating post-therapeutic inflammatory changes from recurrent tumor lesions and could potentially allow avoiding unnecessary TURB. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Klein, Clement AU - Klein C AUID- ORCID: 0000-0003-1839-5875 AD - Urology Department, CHU Bordeaux, 33000, Bordeaux, France. clement.klein@chu-bordeaux.fr. FAU - Brunelle, Serge AU - Brunelle S AD - Radiology Department, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Illy, Mathias AU - Illy M AD - Radiology Department, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - De Luca, Valeria AU - De Luca V AD - Radiology Department, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Doisy, Laure AU - Doisy L AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Lannes, Francois AU - Lannes F AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Sypre, Davidson AU - Sypre D AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Branger, Nicolas AU - Branger N AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Maubon, Thomas AU - Maubon T AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Rybikowski, Stanislas AU - Rybikowski S AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Guerin, Mathilde AU - Guerin M AD - Medical Oncology Department, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Gravis, Gwenaelle AU - Gravis G AD - Medical Oncology Department, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Walz, Jochen AU - Walz J AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. LA - eng PT - Journal Article DEP - 20240320 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Administration, Intravesical MH - Follow-Up Studies MH - *Multiparametric Magnetic Resonance Imaging MH - Retrospective Studies MH - Neoplasm Recurrence, Local/diagnostic imaging/drug therapy MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy MH - Cystoscopy/methods OTO - NOTNLM OT - Bladder cancer OT - Intravesical instillation OT - Magnetic Imaging Resonance OT - Non-muscle-invasive bladder cancer OT - Urothelial carcinoma EDAT- 2024/03/20 18:46 MHDA- 2024/03/22 06:44 CRDT- 2024/03/20 12:16 PHST- 2023/10/06 00:00 [received] PHST- 2024/02/08 00:00 [accepted] PHST- 2024/03/22 06:44 [medline] PHST- 2024/03/20 18:46 [pubmed] PHST- 2024/03/20 12:16 [entrez] AID - 10.1007/s00345-024-04868-8 [pii] AID - 10.1007/s00345-024-04868-8 [doi] PST - epublish SO - World J Urol. 2024 Mar 20;42(1):178. doi: 10.1007/s00345-024-04868-8. PMID- 38502214 OWN - NLM STAT- MEDLINE DCOM- 20240521 LR - 20240624 IS - 2366-0058 (Electronic) VI - 49 IP - 5 DP - 2024 May TI - Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis. PG - 1593-1602 LID - 10.1007/s00261-024-04245-4 [doi] AB - PURPOSE: To assess VIRADS performance and inter-reader agreement for detecting muscle-invasive bladder cancer (MIBC) following transurethral resection of bladder tumor (TURBT). METHODS: An IRB-approved, HIPAA-compliant, retrospective study from 2016 to 2020 included patients with bladder urothelial carcinoma who underwent MRI after TURBT, and cystectomy within 3 months without post-MRI treatments. Three radiologists blinded to pathology results independently reviewed MR images and assigned a VI-RADS score. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of VI-RADS were assessed for diagnosing MIBC using VI-RADS scores >/= 3 and >/= 4. Inter-reader agreement was assessed using Gwet's agreement coefficient (AC) and percent agreement. RESULTS: The cohort consisted of 70 patients (mean age, 68 years +/- 11 [SD]; range 39-85; 58 men) and included 32/70 (46%) with MIBC at cystectomy. ROC analysis revealed an AUC ranging from 0.67 to 0.77 and no pairwise statistical difference between readers (p-values, 0.06, 0.08, 0.97). Percent sensitivity, specificity, PPV, NPV and accuracy for diagnosing MIBC for the three readers ranged from 81.3-93.8, 36.8-55.3, 55.6-60.5, 77.3-87.5, and 62.9-67.1 respectively for VI-RADS score >/= 3, and 78.1-81.3, 47.4-68.4, 55.6-67.6, 72.0-78.8 and 61.4-72.9 respectively for VI-RADS score >/= 4. Gwet's AC was 0.63 [95% confidence interval (CI): 0.49,0.78] for VI-RADS score >/= 3 with 79% agreement [95% CI 72,87] and 0.54 [95%CI 0.38,0.70] for VI-RADS score >/= 4 with 76% agreement [95% CI 69,84]. VIRADS performance was not statistically different among 31/70 (44%) patients who received treatments prior to MRI (p >/= 0.16). CONCLUSION: VI-RADS had moderate sensitivity and accuracy but low specificity for detection of MIBC following TURBT, with moderate inter-reader agreement. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Chai, Jessie L AU - Chai JL AUID- ORCID: 0000-0001-9936-6042 AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. jlchai@bwh.harvard.edu. FAU - Roller, Lauren A AU - Roller LA AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. FAU - Liu, Xiaoyang AU - Liu X AD - Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. FAU - Lan, Zhou AU - Lan Z AUID- ORCID: 0000-0001-5881-2827 AD - Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. FAU - Mossanen, Matthew AU - Mossanen M AD - Department of Urology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. FAU - Silverman, Stuart G AU - Silverman SG AUID- ORCID: 0000-0001-9461-8028 AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. FAU - Shinagare, Atul B AU - Shinagare AB AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. LA - eng PT - Journal Article DEP - 20240319 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery/pathology MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - Middle Aged MH - *Magnetic Resonance Imaging/methods MH - Aged, 80 and over MH - *Neoplasm Invasiveness MH - *Sensitivity and Specificity MH - Adult MH - *Cystectomy/methods MH - Predictive Value of Tests MH - Radiology Information Systems OTO - NOTNLM OT - Bladder cancer OT - MRI OT - Muscle-invasive bladder cancer (MIBC) OT - Transurethral resection of bladder tumor (TURBT) OT - Urothelial carcinoma OT - Vesical Imaging-Reporting and Data System (VI-RADS) EDAT- 2024/03/19 18:42 MHDA- 2024/05/21 12:45 CRDT- 2024/03/19 12:04 PHST- 2023/10/25 00:00 [received] PHST- 2024/02/07 00:00 [accepted] PHST- 2024/02/05 00:00 [revised] PHST- 2024/05/21 12:45 [medline] PHST- 2024/03/19 18:42 [pubmed] PHST- 2024/03/19 12:04 [entrez] AID - 10.1007/s00261-024-04245-4 [pii] AID - 10.1007/s00261-024-04245-4 [doi] PST - ppublish SO - Abdom Radiol (NY). 2024 May;49(5):1593-1602. doi: 10.1007/s00261-024-04245-4. Epub 2024 Mar 19. PMID- 38502027 OWN - NLM STAT- MEDLINE DCOM- 20240405 LR - 20260127 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 96 IP - 1 DP - 2024 Mar 19 TI - Office-based management of Non-Muscle Invasive Bladder Cancer (NMIBC): A position paper on current state of the art and future perspectives. PG - 12404 LID - 10.4081/aiua.2024.12404 [doi] AB - To the Editor, Bladder cancer is one of the most common cancers in humans, representing the 7th and 17th type of neoplasm in both genders. Its incidence and mortality are quite heterogeneous in different countries and are due to different risk factors, quality and prevalence of healthcare and the possibility of early diagnosis and treatment of the tumor and its potential recurrences [...]. FAU - Leonardi, Rosario AU - Leonardi R AD - Casa di Cura Musumeci GECAS, Gravina di Catania; Urologi Ospedalita Gestione Privata (UrOP). leonardi.r@tiscali.it. FAU - Ambrosini, Francesca AU - Ambrosini F AD - IRCCS Policlinico San Martino, Genova. f.ambrosini1@gmail.com. FAU - Cafarelli, Angelo AU - Cafarelli A AD - Urology Unit, Villa Igea, Ancona; Urologi Ospedalita Gestione Privata (UrOP). info@angelocafarelli.it. FAU - Calarco, Alessandro AU - Calarco A AD - Villa Pia Hospital, Rome; Urologi Ospedalita Gestione Privata (UrOP). info@alessandrocalarco.com. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Vita e Salute San Raffaele University, Milan; Urologi Ospedalita Gestione Privata (UrOP). colombo.renzo@hsr.it. FAU - Tuzzolo, Domenico AU - Tuzzolo D AD - Urologi Ospedalita Gestione Privata (UrOP). info@casadelsole.it. FAU - De Marco, Ferdinando AU - De Marco F AD - I.N.I. Grottaferrata, Rome; Urologi Ospedalita Gestione Privata (UrOP). info@clinicavillamargherita.it. FAU - Ferrari, Giovanni AU - Ferrari G AD - Hesperia Hospital, Modena; Urologi Ospedalita Gestione Privata (UrOP). visite@giovanniferrariurologo.it. FAU - Ludovico, Giuseppe AU - Ludovico G AD - Ospedale Miulli, Acquaviva delle Fonti, Bari; Urologi Ospedalita Gestione Privata (UrOP). g.ludovico@miulli.it. FAU - Pecoraro, Stefano AU - Pecoraro S AD - NEUROMED, Avellino; Urologi Ospedalita Gestione Privata (UrOP). cup@diagnosticamedica.org. FAU - De Cobelli, Ottavio AU - De Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan; Urologi Ospedalita Gestione Privata (UrOP). Ottavio.DeCobelli@unimi.it. FAU - Terrone, Carlo AU - Terrone C AD - Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova. carlo.terrone@hsanmartino.it. FAU - Mantica, Guglielmo AU - Mantica G AD - Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova. guglielmo.mantica@gmail.com. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20240319 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Humans MH - Male MH - Female MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Staging MH - Neoplasm Invasiveness/pathology MH - *Urinary Bladder Neoplasms/diagnosis/therapy/pathology MH - Risk Factors MH - Neoplasm Recurrence, Local/therapy/epidemiology EDAT- 2024/03/19 12:42 MHDA- 2024/04/05 06:45 CRDT- 2024/03/19 10:33 PHST- 2024/02/20 00:00 [received] PHST- 2024/02/24 00:00 [accepted] PHST- 2024/04/05 06:45 [medline] PHST- 2024/03/19 12:42 [pubmed] PHST- 2024/03/19 10:33 [entrez] AID - 10.4081/aiua.2024.12404 [doi] PST - epublish SO - Arch Ital Urol Androl. 2024 Mar 19;96(1):12404. doi: 10.4081/aiua.2024.12404. PMID- 38497799 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20251104 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 43 IP - 14 DP - 2025 Sep TI - Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder cancer. PG - 7465-7474 LID - 10.1080/07391102.2024.2329799 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) is considered one of the most costly malignancies, requiring significant surgical and therapeutic measures. However, progression and non-responsiveness to immunotherapy are common outcomes of treatment. In this study, we conducted comparative transcriptomic analysis of non-responders from two distinct populations (Asian and American) and identified six common genes associated with disease prognosis. Among these genes, MDM-2 is a major oncogenic protein linked to seven different types of cancers, as it is involved in the degradation of the tumor suppressor protein p53. To address this, we explored novel therapeutic drugs to block the binding of p53 and MDM-2 using a targeted molecular docking approach. High-throughput screening of 2500 drugs from the FDA-approved drug database led to the identification of three drug compounds: Mol-126, Mol-679, and Mol-768. Subsequently, we evaluated the structural stability and binding of these drugs for the targeted inhibition of the MDM-2 active site (hydrophobic cleft) using molecular dynamics simulations. Analysis of five trajectories, including RMSD, RMSF, hydrogen bond, radius of gyration, coulomb short-range electrostatic spectra, and free binding energy, confirmed that Mol-126 exhibited the highest structural stability compared to the reference drug (Alrizomadlin). Notably, Mol-126 is a derivative of 3-phenoxypropionic acid, which shows promise for the development of alternative therapeutic treatments for non-responsive bladder cancer patients. FAU - Wu, Hongjian AU - Wu H AD - Department of Urology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China. FAU - Jin, Hui AU - Jin H AD - Intensive Care Unit, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China. FAU - Cai, Yongjian AU - Cai Y AD - Department of Urology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China. LA - eng PT - Journal Article DEP - 20240318 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.3.2.27 (MDM2 protein, human) RN - 0 (Antineoplastic Agents) SB - IM MH - *Urinary Bladder Neoplasms/drug therapy/pathology/genetics/metabolism MH - Humans MH - *Proto-Oncogene Proteins c-mdm2/chemistry/antagonists & inhibitors/metabolism/genetics MH - Molecular Docking Simulation MH - Molecular Dynamics Simulation MH - Tumor Suppressor Protein p53/metabolism/chemistry MH - Protein Binding MH - *Antineoplastic Agents/chemistry/pharmacology/therapeutic use MH - Hydrogen Bonding MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - MDM-2 OT - Non-invasive bladder cancer OT - p-53 activation EDAT- 2024/03/18 12:46 MHDA- 2025/11/04 12:27 CRDT- 2024/03/18 11:09 PHST- 2025/11/04 12:27 [medline] PHST- 2024/03/18 12:46 [pubmed] PHST- 2024/03/18 11:09 [entrez] AID - 10.1080/07391102.2024.2329799 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2025 Sep;43(14):7465-7474. doi: 10.1080/07391102.2024.2329799. Epub 2024 Mar 18. PMID- 38496823 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241102 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 62 DP - 2024 Apr TI - Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer. PG - 99-106 LID - 10.1016/j.euros.2024.02.010 [doi] AB - BACKGROUND AND OBJECTIVE: To assess the effectiveness of a urine-based proenkephalin (PENK) methylation test using linear target enrichment-quantitative methylation-specific polymerase chain reaction (mePENK test) for detection of non-muscle-invasive bladder cancer (NMIBC) recurrence compared to cytology and the NMP22 test. METHODS: We first conducted a retrospective case-control study involving 54 patients with primary BC and 29 healthy individuals. We then prospectively enrolled 186 patients (January to December 2022) undergoing cystoscopy surveillance after transurethral resection of bladder tumor, of whom 59 had recurrent tumors. We analyzed voided urine samples for PENK methylation levels in urinary DNA. Cystoscopy with histology was used as the reference standard for assessing the diagnostic accuracy of the mePENK test in detecting BC recurrence. We calculated the sensitivity and specificity using receiver operating characteristic curve analysis. Survival differences were determined using the Kaplan-Meier method and Cox proportional-hazards model. A p < 0.05 was considered statistically significant. KEY FINDINGS AND LIMITATIONS: In the case-control study, the PENK test had sensitivity of 83.3% and specificity of 100%. For NMIBC patients undergoing cystoscopy surveillance, the sensitivity was 76.3% (95% confidence interval [CI] 63.4-86.4%) and the specificity was 85% (95% CI 77.6-90.7%), outperforming cytology (sensitivity: 28.8%, 95% CI 17.8-42.1%; p < 0.001; specificity: 97.6%, 95% CI 93.2-99.5%) and the NMP22 test (sensitivity: 54.2%, 95% CI 40.7-67.2%; p = 0.016; specificity 81.9%, 95% CI 74.1-88.2%). In the high-risk group, the mePENK test had sensitivity of 89.7% (95% CI 75.8-97.1%) and a negative predictive value of 96.9%. For the group with low/intermediate risk, the sensitivity was 41.7%. In the group with negative cystoscopy, recurrence-free survival was shorter for patients with positive than for those with negative mePENK results (245 vs 503 d), with a hazard ratio of 9.4 (p < 0.001). The main study limitation is the small sample size. CONCLUSIONS AND CLINICAL IMPLICATIONS: The mePENK test showed good performance for detection of NMIBC recurrence and has potential for use for prognosis and prediction. PATIENT SUMMARY: We found that a test used to analyze urine samples showed good performance in detecting recurrence of NMIBC. This noninvasive mePENK test may help in personalized follow-up care for patients with NMIBC. CI - (c) 2024 The Authors. FAU - Han, Hyunho AU - Han H AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Oh, Tae Jeong AU - Oh TJ AD - Genomictree, Inc., Daejeon, Republic of Korea. FAU - Heo, Ji Eun AU - Heo JE AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Lee, Jongsoo AU - Lee J AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Jang, Won Sik AU - Jang WS AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Lee, Seung Hwan AU - Lee SH AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Ham, Won Sik AU - Ham WS AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Hwang, Jaehee AU - Hwang J AD - Genomictree, Inc., Daejeon, Republic of Korea. FAU - An, Sungwhan AU - An S AD - Genomictree, Inc., Daejeon, Republic of Korea. FAU - Choi, Young-Deuk AU - Choi YD AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20240307 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC10940910 OTO - NOTNLM OT - Bladder cancer OT - Molecular biomarker OT - PENK methylation OT - Surveillance OT - Urine-derived DNA EDAT- 2024/03/18 06:42 MHDA- 2024/03/18 06:43 PMCR- 2024/03/07 CRDT- 2024/03/18 04:43 PHST- 2024/02/20 00:00 [accepted] PHST- 2024/03/18 06:43 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 04:43 [entrez] PHST- 2024/03/07 00:00 [pmc-release] AID - S2666-1683(24)00267-2 [pii] AID - 10.1016/j.euros.2024.02.010 [doi] PST - epublish SO - Eur Urol Open Sci. 2024 Mar 7;62:99-106. doi: 10.1016/j.euros.2024.02.010. eCollection 2024 Apr. PMID- 38495492 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241101 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 15 IP - 8 DP - 2024 TI - Uncovering Microbial Composition of the Tissue Microenvironment in Bladder Cancer using RNA Sequencing Data. PG - 2431-2441 LID - 10.7150/jca.93055 [doi] AB - Purpose: Bladder cancer (BC) is one of the top 10 common tumors in the world. It has been reported that microbiota can colonize tissues and play important roles in tumorigenesis and progression. However, the current understanding of microorganisms in the BC tissue microenvironment remains unclear. Methods: In this study, we integrated the RNA-seq data of 479 BC tissue samples from seven datasets combined with a range of bioinformatics tools to explore the landscape of microbiome in the BC tissue microenvironment. Results: The pan-microbiome was estimated to surpass 1,400 genera. A total of seven core microbiota (Bacillus, Corynebacterium, Cutibacterium, Escherichia, Halomonas, Pasteurella, and Streptomyces) were identified. Among them, Bacillus was widely distributed in all datasets with a high relative abundance (10.11% of all samples on average). Moreover, some biological factors, including tissue source and tumor grade, were found significant effects on the microbial composition of the bladder tissue. Pseudomonas, Porphyrobacter, and Acinetobacter were enriched in tumor tissues, while Mycolicibacterium and Streptomyces were enriched in patients who showed durable response to BCG therapy. In addition, we established microbial co-occurrence networks and found that the BCG therapy may attenuate the microbiological interactions. Conclusions: This study clearly provided a microbial landscape of the BC tissue microenvironment, which was important for exploring the interactions between microorganisms and BC tissues. The identified specific taxa might be potential biomarkers for BC. CI - (c) The author(s). FAU - Yao, Ruiqian AU - Yao R AD - School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China. AD - Department of Medical Genetics, Naval Medical University, Xiang-Yin Road, 800, Shanghai 200433, China. FAU - Ai, Bin AU - Ai B AD - Department of Precision Medicine, Translational Medicine Research Center, Naval Medical University, Xiang-Yin Road, 800, Shanghai 200433, China. AD - Shanghai Key Laboratory of Cell Engineering, Shanghai, China. FAU - Wang, Zeyi AU - Wang Z AD - Department of Urology, Huadong Hospital, Fudan University, Shanghai, China. FAU - Shen, Bing AU - Shen B AD - Department of Urology, Shanghai General Hospital Affiliated to Nanjing Medical University, Shanghai, 200080, China. AD - Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China. FAU - Xue, Geng AU - Xue G AD - Department of Medical Genetics, Naval Medical University, Xiang-Yin Road, 800, Shanghai 200433, China. FAU - Yu, Dong AU - Yu D AD - Department of Precision Medicine, Translational Medicine Research Center, Naval Medical University, Xiang-Yin Road, 800, Shanghai 200433, China. AD - Shanghai Key Laboratory of Cell Engineering, Shanghai, China. LA - eng PT - Journal Article DEP - 20240304 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC10937280 OTO - NOTNLM OT - Biological factors OT - Bladder cancer OT - Cancer microbiome OT - Co-occurrence network analysis COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2024/03/18 06:43 MHDA- 2024/03/18 06:44 PMCR- 2024/01/01 CRDT- 2024/03/18 04:21 PHST- 2023/12/08 00:00 [received] PHST- 2024/01/27 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/03/18 06:43 [pubmed] PHST- 2024/03/18 04:21 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - jcav15p2431 [pii] AID - 10.7150/jca.93055 [doi] PST - epublish SO - J Cancer. 2024 Mar 4;15(8):2431-2441. doi: 10.7150/jca.93055. eCollection 2024. PMID- 38494989 OWN - NLM STAT- MEDLINE DCOM- 20240924 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 4 DP - 2024 Oct TI - Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer. PG - 602-607 LID - 10.1111/bju.16333 [doi] AB - OBJECTIVE: To address cancer-specific mortality free-survival (CSM-FS) differences in patients with urothelial carcinoma of the urinary bladder (UCUB) vs non-UCUB who underwent trimodal therapy (TMT), according to organ confined (OC: T2N0M0) vs non-organ confined (NOC: T3-4NanyM0 or TanyN1-3M0) clinical stages. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4N0-N3M0 bladder cancer treated with TMT, defined as the combination of transurethral resection of bladder tumour, chemotherapy, and radiotherapy. Temporal trends described TMT use over time. Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM in UCUB vs non-UCUB according to OC vs NOC stages. RESULTS: Of 5130 assessable TMT-treated patients, 425 (8%) harboured non-UCUB vs 4705 (92%) who had UCUB. The TMT rates increased for patients with OC UCUB from 92.4% to 96.8% (estimated annual percentage change of 0.4%, P < 0.001), but not in the NOC stages (P = 0.3). In the OC stage, the median CSM-FS was 36 months in patients with non-UCUB vs 60 months in those with UCUB, respectively (P = 0.01). Conversely, in the NOC stage, the median CSM-FS was 23 months both in UCUB and non-UCUB (P = 0.9). In the MCR models addressing OC stage, non-UCUB histology independently predicted higher CSM (hazard ratio 1.45, P = 0.004), but not in the NOC stage (P = 0.9). CONCLUSION: In OC UCUB, TMT rates have increased over time in a guideline-consistent fashion. Patients with OC non-UCUB treated with TMT showed a CSM disadvantage relative to OC UCUB. In the NOC stage, use of TMT resulted in dismal CSM, regardless of UCUB vs non-UCUB histology. CI - (c) 2024 BJU International. FAU - de Angelis, Mario AU - de Angelis M AUID- ORCID: 0009-0008-0494-7839 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Division of Experimental Oncology/Unit of Urology, URI, Milan, Italy. AD - IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Baudo, Andrea AU - Baudo A AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Siech, Carolin AU - Siech C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Jannello, Letizia Maria Ippolita AU - Jannello LMI AUID- ORCID: 0000-0002-0612-0519 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Di Bello, Francesco AU - Di Bello F AUID- ORCID: 0000-0002-8585-3701 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Goyal, Jordan A AU - Goyal JA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Longo, Nicola AU - Longo N AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Goethe University Frankfurt am Main, Frankfurt am Main, Germany. FAU - Saad, Fred AU - Saad F AUID- ORCID: 0000-0003-2986-5617 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Carmignani, Luca AU - Carmignani L AD - Department of Urology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Division of Experimental Oncology/Unit of Urology, URI, Milan, Italy. AD - IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, URI, Milan, Italy. AD - IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Division of Experimental Oncology/Unit of Urology, URI, Milan, Italy. AD - IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, Milan, Italy. AD - IRCCS Ospedale San Raffaele, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240318 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/mortality/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/therapy/mortality/pathology MH - Combined Modality Therapy MH - Neoplasm Staging MH - SEER Program MH - Survival Rate MH - Aged, 80 and over MH - Cystectomy OTO - NOTNLM OT - bladder cancer OT - cancer-specific mortality OT - non-organ confined OT - non-urothelial carcinoma OT - organ confined OT - trimodal therapy (TMT) OT - urothelial carcinoma EDAT- 2024/03/18 06:42 MHDA- 2024/09/24 22:18 CRDT- 2024/03/18 03:53 PHST- 2024/09/24 22:18 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 03:53 [entrez] AID - 10.1111/bju.16333 [doi] PST - ppublish SO - BJU Int. 2024 Oct;134(4):602-607. doi: 10.1111/bju.16333. Epub 2024 Mar 18. PMID- 38493314 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20240819 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 21 IP - 3 DP - 2024 May 6 TI - Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients. PG - 169-174 LID - 10.22037/uj.v20i.7854 [doi] AB - PURPOSE: To evaluate the performance of the European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) risk scoring models in non-muscle-invasive bladder cancer (NMIBC) patients defined as high risk according to European Association of Urology guidelines and managed based on current recommendations. MATERIAL AND METHODS: Data from 187 high-risk NMIBC patients treated at a tertiary center between July 2010 and November 2021 were analyzed retrospectively. One- and five-year recurrence- and progression-free survival were assessed for each patient using the EORTC and CUETO risk scores. The patients were divided into four risk groups according to their risk scores as low, medium-low, medium-high and high risk, as indicated in the models. Discriminative ability was evaluated with the Harrell's concordance index (c-index). RESULTS: Both risk scoring models overestimated the risk of recurrence and progression at one and five years. Only the prediction of recurrence at five years in the high risk group according to the CUETO model was compatible with our cohort. CUETO (c-indices for recurrence and progression were 0.802 and 0.834, respectively) exhibited better discrimination than EORTC (0.722 for recurrence and 0.752 for progression) in the prediction of disease recurrence and progression. CONCLUSION: The CUETO model was superior to the EORTC model in predicting recurrence and progression and stratifying patients with different prognoses in our high-risk NMIBC patient population treated according to current guideline recommendations. However, both models overestimated the probability of disease recurrence and progression. Only the probability of recurrence at five years in the high-risk group of the CUETO model was compatible with our cohort. FAU - Pazir, Yasar AU - Pazir Y AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. ypazir@hotmail.com. FAU - Esmeray, Abdullah AU - Esmeray A AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. esmerayabdullah@gmail.com. FAU - Gelmis, Mucahit AU - Gelmis M AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. mucahitgelmis@gmail.com. FAU - Caglar, Ufuk AU - Caglar U AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. ufukcglr@gmail.com. FAU - Ozgor, Faruk AU - Ozgor F AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. md.farukozgor@yahoo.com. FAU - Sarilar, Omer AU - Sarilar O AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. omer.sarilar@gmail.com. FAU - Akbulut, Fatih AU - Akbulut F AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. drfakbulut@hotmail.com. LA - eng PT - Journal Article DEP - 20240506 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Disease Progression MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/therapy MH - Prognosis MH - Retrospective Studies MH - Risk Assessment EDAT- 2024/03/17 06:42 MHDA- 2024/05/08 06:45 CRDT- 2024/03/17 03:53 PHST- 2024/05/08 06:45 [medline] PHST- 2024/03/17 06:42 [pubmed] PHST- 2024/03/17 03:53 [entrez] AID - 7854 [pii] AID - 10.22037/uj.v20i.7854 [doi] PST - epublish SO - Urol J. 2024 May 6;21(3):169-174. doi: 10.22037/uj.v20i.7854. PMID- 38480078 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 5 DP - 2024 May TI - Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases. PG - 162.e11-162.e23 LID - S1078-1439(24)00337-5 [pii] LID - 10.1016/j.urolonc.2024.02.007 [doi] AB - BACKGROUND: Recent studies have highlighted the overall survival (OS) benefit of cytoreductive radical cystectomy (CRC) in metastatic bladder cancer (mBCa). Cytoreductive surgery has been established in other urologic cancers. However, the efficacy of CRC and optimal criteria for patient selection in mBCa is unclear. This study investigated the oncologic efficacy of CRC, particularly emphasizing the location and number of metastasis sites as a predictor of survival and treatment response. METHODS: A retrospective analysis of cT2-4N0-3M1 mBCa patients treated with multiagent chemotherapy between 2004 and 2019 was conducted using the National Cancer Database. Patients were classified by additional treatment with CRC or conservative local treatment (CLT), consisting of transurethral resection of bladder tumor, radiation, or no local treatment and propensity score (PS) matched. Kaplan-Meier analysis and multivariate Cox Proportional Hazards model assessed the effect of CRC or CLT on OS within the matched cohort and in four subgroups (1) patients with only distant lymph node (LN) metastasis vs. any organ metastasis, (2) patients with single metastasis vs. multiple metastases. Sensitivity analysis estimated the influence of unmeasured confounders on CRC OS benefit. RESULTS: Propensity matching yielded 247 and 251 patients treated with CRC and CLT, respectively. Median OS in patients who received CRC was greater than that of patients treated with CLT (20.4 months vs. 12.0 months, P < 0.001). CRC was associated with reduced mortality risk in patients with only distant LN metastases (HR = 0.545, P = 0.039), any organ metastasis (HR = 0.421, P < 0.001), and single visceral metastasis (HR = 0.483, P = 0.002). However, CRC did not significantly improve OS in patients with multiple metastases (HR = 0.501, P = 0.064). CONCLUSION: These findings demonstrate an OS benefit of CRC with multiagent chemotherapy and pinpoint multiple visceral metastases as a potential contraindication for CRC. Although limited by the influence of unmeasured confounders, these findings may inform future prospective investigations into CRC. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Xu, Vincent E AU - Xu VE AD - Department of Urology, George Washington University School of Medicine, Washington, DC. Electronic address: xuve@gwu.edu. FAU - Antar, Ryan M AU - Antar RM AD - Department of Urology, George Washington University School of Medicine, Washington, DC. FAU - Bertozzi, Luca AU - Bertozzi L AD - Department of Urology, George Washington University School of Medicine, Washington, DC. FAU - Drouaud, Arthur AU - Drouaud A AD - Department of Urology, George Washington University School of Medicine, Washington, DC. FAU - Azari, Sarah AU - Azari S AD - Department of Urology, George Washington University School of Medicine, Washington, DC. FAU - Lee, Sean M AU - Lee SM AD - Office of Clinical Research, George Washington University School of Medicine, Washington, DC. FAU - Whalen, Michael J AU - Whalen MJ AD - Department of Urology, George Washington University School of Medicine, Washington, DC. LA - eng PT - Journal Article DEP - 20240312 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 37870-87-4 (3-methoxybutylcyanoacrylate) RN - 0 (Cyanoacrylates) SB - IM MH - Humans MH - Cytoreduction Surgical Procedures MH - Cystectomy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Lymphatic Metastasis MH - Treatment Outcome MH - *Cyanoacrylates OTO - NOTNLM OT - Cytoreductive cystectomy OT - Local treatment OT - Metastasis OT - Metastatic bladder cancer OT - National Cancer Database OT - Radical cystectomy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/14 00:43 MHDA- 2024/04/15 06:42 CRDT- 2024/03/13 23:00 PHST- 2023/10/30 00:00 [received] PHST- 2024/02/06 00:00 [revised] PHST- 2024/02/19 00:00 [accepted] PHST- 2024/04/15 06:42 [medline] PHST- 2024/03/14 00:43 [pubmed] PHST- 2024/03/13 23:00 [entrez] AID - S1078-1439(24)00337-5 [pii] AID - 10.1016/j.urolonc.2024.02.007 [doi] PST - ppublish SO - Urol Oncol. 2024 May;42(5):162.e11-162.e23. doi: 10.1016/j.urolonc.2024.02.007. Epub 2024 Mar 12. PMID- 38477374 OWN - NLM STAT- MEDLINE DCOM- 20240608 LR - 20240608 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 85 IP - 1 DP - 2024 Jul TI - Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection. PG - 92-103 LID - 10.1111/his.15177 [doi] AB - AIMS: We aimed to assess the oncological impact of micrometric extent of invasion in patients with pT1 bladder cancer (BCa) who underwent en-bloc resection for bladder tumour (ERBT). METHODS AND RESULTS: We retrospectively analysed the records and specimens of 106 pT1 high-grade BCa patients who underwent ERBT. The extent of invasion, such as depth from basal membrane, number of invasive foci, maximum width of invasive focus, muscularis mucosae invasion and infiltration pattern (pattern A: solid sheet-like, nodular or nested growth, pattern B: trabecular, small cluster or single-cell pattern) were evaluated by a single genitourinary pathologist. The end-points were recurrence-free (RFS) and progression-free survival (PFS). Within a median follow-up of 23 months, overall, 36 patients experienced recurrence and 13 patients experienced disease progression. The 2-year PFS differed significantly depending on depth from basal membrane (< 1.3 mm: 94.8% versus >== 1.3 mm: 65.2%, P = 0.005), maximum width of invasive focus (< 4 mm: 91.7% versus >== 4 mm: 62.3%, P < 0.001), muscularis mucosae (MM) invasion (above MM = 96.1% versus into or beyond MM = 64.8%, P = 0.002) and infiltration pattern (pattern A: 100% versus pattern B: 83.3%, P = 0.037). In a multivariable analysis, MM invasion [hazard ratio (HR) = 4.54, 95% confidence interval (CI) = 1.25-16.5] and maximum width of invasive focus >== 4 mm (HR = 4.79, 95% CI = 1.25-16.5) were independent prognostic factors of progression. CONCLUSIONS: En-bloc resection facilitates the evaluation of pathologic variables that might be useful in predicting disease recurrence and progression. In particular, not only the MM invasion but also the maximum width of invasion focus, reflecting the invasive volume, appear to be reliable prognosticators for disease progression. CI - (c) 2024 The Authors. Histopathology published by John Wiley & Sons Ltd. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan. FAU - Okada, Yohei AU - Okada Y AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shimoda, Masayuki AU - Shimoda M AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20240313 PL - England TA - Histopathology JT - Histopathology JID - 7704136 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Prognosis MH - Aged, 80 and over MH - Neoplasm Recurrence, Local/pathology MH - Cystectomy/methods MH - Adult MH - Neoplasm Staging MH - Neoplasm Invasiveness MH - Disease Progression MH - Disease-Free Survival OTO - NOTNLM OT - bladder cancer OT - en-bloc TUR OT - invasion OT - pT1 OT - pathological diagnosis OT - progression EDAT- 2024/03/13 12:45 MHDA- 2024/06/08 10:45 CRDT- 2024/03/13 08:05 PHST- 2024/02/19 00:00 [revised] PHST- 2023/11/05 00:00 [received] PHST- 2024/02/29 00:00 [accepted] PHST- 2024/06/08 10:45 [medline] PHST- 2024/03/13 12:45 [pubmed] PHST- 2024/03/13 08:05 [entrez] AID - 10.1111/his.15177 [doi] PST - ppublish SO - Histopathology. 2024 Jul;85(1):92-103. doi: 10.1111/his.15177. Epub 2024 Mar 13. PMID- 38473256 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240315 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 5 DP - 2024 Feb 23 TI - Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. LID - 10.3390/cancers16050894 [doi] LID - 894 AB - This study aimed to evaluate the outcomes and identify the predictive factors of a bladder-preservation approach incorporating maximal transurethral resection of bladder tumor (TURBT) coupled with either pembrolizumab or chemotherapy for patients diagnosed with muscle-invasive bladder cancer (MIBC) who opted against definitive local therapy. We conducted a retrospective analysis on 53 MIBC (cT2-T3N0M0) patients who initially planned for neoadjuvant pembrolizumab or chemotherapy after maximal TURBT but later declined radical cystectomy and radiotherapy. Post-therapy clinical restaging and conservative bladder-preservation measures were employed. Clinical complete remission was defined as negative findings on cystoscopy with biopsy confirming the absence of malignancy if performed, negative urine cytology, and unremarkable cross-sectional imaging (either CT scan or MRI) following neoadjuvant therapy. Twenty-three patients received pembrolizumab, while thirty received chemotherapy. Our findings revealed that twenty-three (43.4%) patients achieved clinical complete response after neoadjuvant therapy. The complete remission rate was marginally higher in pembrolizumab group in comparison to chemotherapy group (52.1% vs. 36.7%, p = 0.26). After a median follow-up of 37.6 months, patients in the pembrolizumab group demonstrated a longer PFS (median, not reached vs. 20.2 months, p = 0.078) and OS (median, not reached vs. 26.8 months, p = 0.027) relative to those in chemotherapy group. Those achieving clinical complete remission post-neoadjuvant therapy also exhibited prolonged PFS (median, not reached vs. 10.2 months, p < 0.001) and OS (median, not reached vs. 24.4 months, p = 0.004). In the multivariate analysis, clinical complete remission subsequent to neoadjuvant therapy was independently associated with superior PFS and OS. In conclusion, bladder preservation emerges as a viable therapeutic strategy for a carefully selected cohort of MIBC patients without definitive local therapy, especially those achieving clinical complete remission following neoadjuvant treatment. For patients unfit for chemotherapy, pembrolizumab offers a promising alternative treatment option. FAU - Chang, Pei-Hung AU - Chang PH AUID- ORCID: 0000-0002-5006-0277 AD - Division of Hematology Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan. AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan. FAU - Chen, Hung-Yi AU - Chen HY AD - Division of Urology, Department of Surgery, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan. FAU - Chang, Yueh-Shih AU - Chang YS AUID- ORCID: 0000-0001-5182-7911 AD - Division of Hematology Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan. AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. FAU - Su, Po-Jung AU - Su PJ AD - Division of Hematology Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan. FAU - Huang, Wen-Kuan AU - Huang WK AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan. AD - Division of Hematology Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan. FAU - Lin, Cheng-Feng AU - Lin CF AD - Division of Urology, Department of Surgery, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan. FAU - Hsieh, Jason Chia-Hsun AU - Hsieh JC AD - Division of Hematology Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan. AD - Division of Hematology Oncology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei 236017, Taiwan. FAU - Wu, Chun-Te AU - Wu CT AUID- ORCID: 0000-0002-2748-4493 AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan. AD - Division of Urology, Department of Surgery, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan. AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan. LA - eng PT - Journal Article DEP - 20240223 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10930778 OTO - NOTNLM OT - bladder preservation OT - clinical complete remission OT - muscle-invasive bladder cancer OT - neoadjuvant chemotherapy OT - pembrolizumab COIS- The authors declare no conflicts of interest. EDAT- 2024/03/13 06:46 MHDA- 2024/03/13 06:47 PMCR- 2024/02/23 CRDT- 2024/03/13 01:19 PHST- 2023/10/23 00:00 [received] PHST- 2024/01/27 00:00 [revised] PHST- 2024/02/19 00:00 [accepted] PHST- 2024/03/13 06:47 [medline] PHST- 2024/03/13 06:46 [pubmed] PHST- 2024/03/13 01:19 [entrez] PHST- 2024/02/23 00:00 [pmc-release] AID - cancers16050894 [pii] AID - cancers-16-00894 [pii] AID - 10.3390/cancers16050894 [doi] PST - epublish SO - Cancers (Basel). 2024 Feb 23;16(5):894. doi: 10.3390/cancers16050894. PMID- 38430858 OWN - NLM STAT- MEDLINE DCOM- 20240606 LR - 20260629 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 3 DP - 2024 Jun TI - Recurrent Bacteriuria as a Prognosis Marker in the Adjuvant Treatment of Non-Muscle Invasive Bladder Cancer. PG - 102048 LID - S1558-7673(24)00021-1 [pii] LID - 10.1016/j.clgc.2024.01.020 [doi] AB - PURPOSE: Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer (NMIBC). The main aim of this study was to examine the effect of recurrent bacteriuria (RB) on the prognosis of NMIBC in women receiving intravesical therapy. MATERIALS AND METHODS: We designed a prospective observational study from 2012 to 2019. We included women with bladder cancer treated with transurethral resection of the bladder (TURB) and adjuvant intravesical treatment. Significant bacteriuria was defined as a presence in urine cultures at or above 100,000 colony-forming units per millilitre. The recurrent bacteriuria group included patients with significant bacteriuria in at least two determinations in 6 months or in 3 or more determinations in a year. The institutional board approved the study. RESULTS: One hundred thirty-six patients diagnosed with NMIBC participate in the study, of whom 100 met the inclusion criteria. During follow-up, 48 were categorized in the RB group and 52 formed the non-bacteriuria group (NB). RB GROUP HAD A BETTER OUTCOME: Eight patients (16.67%) experiencing a recurrence of the same grade, with no progression to a higher-grade tumor or muscle-invasive tumor. In the NB group, 18 (34.6%) patients presented a recurrence (P = .001) and 22 (42.3%) progressed to a higher-grade tumor or muscular invasion (P = .001). The presence of RB was identified as a predictor of good response in multivariate regression with a relative risk of 0.13 (P = .018) CONCLUSIONS: Female patients with RB had a better response to adjuvant treatment for NMIBC. The RB group showed lower rates of tumor recurrences and progression. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Szczesniewski, Juliusz J AU - Szczesniewski JJ AD - Department of Surgery, Faculty of Medicine, University of Salamanca, Salamanca, Spain; Department of Urology, University Hospital of Getafe, Madrid, Spain. Electronic address: juliusz.szcz@gmail.com. FAU - Marquez-Sanchez, Magaly T AU - Marquez-Sanchez MT AD - Department of Surgery, Faculty of Medicine, University of Salamanca, Salamanca, Spain; Instituto de Investigacion Biomedica de Salamanca (IBSAL), Faculty of Medicine, University of Salamanca, Salamanca, Spain. FAU - Padilla-Fernandez, Barbara AU - Padilla-Fernandez B AD - Department of Urology, Canarias University Hospital, Tenerife, La Laguna, Spain. FAU - Llanes-Gonzalez, Luis AU - Llanes-Gonzalez L AD - Department of Urology, University Hospital of Getafe, Madrid, Spain; University of Francisco de Vitoria, Carretera Pozuelo a Majadahonda, Madrid, Spain. FAU - Lorenzo-Gomez, Maria F AU - Lorenzo-Gomez MF AD - Department of Surgery, Faculty of Medicine, University of Salamanca, Salamanca, Spain; Department of Urology, Salamanca University Hospital, Salamanca, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20240201 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology/therapy MH - Female MH - Aged MH - *Bacteriuria/drug therapy MH - Prospective Studies MH - Prognosis MH - Middle Aged MH - *Neoplasm Recurrence, Local MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Chemotherapy, Adjuvant/methods MH - Treatment Outcome MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Asymptomatic bacteriuria OT - Intravesical instillation OT - Progression OT - Recurrence OT - Urinary tract infection COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2024/03/03 17:42 MHDA- 2024/06/07 00:43 CRDT- 2024/03/02 18:14 PHST- 2023/08/22 00:00 [received] PHST- 2024/01/28 00:00 [revised] PHST- 2024/01/29 00:00 [accepted] PHST- 2024/06/07 00:43 [medline] PHST- 2024/03/03 17:42 [pubmed] PHST- 2024/03/02 18:14 [entrez] AID - S1558-7673(24)00021-1 [pii] AID - 10.1016/j.clgc.2024.01.020 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Jun;22(3):102048. doi: 10.1016/j.clgc.2024.01.020. Epub 2024 Feb 1. PMID- 38423631 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240304 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 44 IP - 3 DP - 2024 Mar TI - Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer. PG - 1299-1307 LID - 10.21873/anticanres.16925 [doi] AB - BACKGROUND/AIM: This study aimed to compare the clinical efficacy of two different Bacillus Calmette-Guerin (BCG) strains, TICE strain (OncoTICE) and Connaught strain (ImmuCyst), as a first line intravesical instillation therapy in patients with T1 high grade bladder cancer. PATIENTS AND METHODS: Patients with newly diagnosed T1 high-grade bladder cancer who underwent transurethral resection of bladder tumor (TURBT) followed by intravesical instillation therapy were enrolled. The effects of BCG strain on recurrence, progression, and side effects were analyzed using Kaplan-Meier and Cox proportional hazards models. RESULTS: Among 147 patients, 53 patients received Connaught strain and 94 patients received TICE strain. The completion rate of induction instillation was 92.45% in the Connaught group and 91.49% in the TICE group (p=1.00). The three-year recurrence-free survival rate was 71.7% in the Connaught group and 63.83% in the TICE group (p=0.33), whereas the three-year progression-free survival rate was 96.23% in the Connaught group and 89.36% in the TICE group (p=0.21). On Cox regression test, carcinoma in situ and >/=eight lesions were significant predictors for recurrence. No significant difference was observed in recurrence and progression between the two BCG regimens. The complication rates according to the Cleveland Clinic grading system showed no significant difference between the two groups (p=0.13). CONCLUSION: Both the Connaught and TICE strains of BCG demonstrated comparable three-year recurrence-free survival rates and three-year progression-free survival rates for T1 high grade bladder cancer, as well as comparable adverse events. Due to the global BCG shortage, further strain comparisons are essential for clinical validation. CI - Copyright (c) 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Yu, Ssu-Hung AU - Yu SH AD - School of Medicine (Bachelor Program), Tzu-Chi University, Hualian, Taiwan, R.O.C. FAU - Wang, Ci-Yu AU - Wang CY AD - Department of Economics, National Taiwan University, Taipei, Taiwan, R.O.C. FAU - Wang, Shian-Shiang AU - Wang SS AD - Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. AD - Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C. FAU - Li, Jian-Ri AU - Li JR AD - Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. AD - Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, R.O.C. FAU - Hung, Sheng-Chun AU - Hung SC AD - Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; weshong1118@gmail.com. AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. AD - Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, R.O.C. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - recurrence EDAT- 2024/03/01 01:22 MHDA- 2024/03/04 06:50 CRDT- 2024/02/29 20:53 PHST- 2023/10/01 00:00 [received] PHST- 2023/11/07 00:00 [revised] PHST- 2023/11/09 00:00 [accepted] PHST- 2024/03/04 06:50 [medline] PHST- 2024/03/01 01:22 [pubmed] PHST- 2024/02/29 20:53 [entrez] AID - 44/3/1299 [pii] AID - 10.21873/anticanres.16925 [doi] PST - ppublish SO - Anticancer Res. 2024 Mar;44(3):1299-1307. doi: 10.21873/anticanres.16925. PMID- 38421912 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240820 IS - 1527-1323 (Electronic) IS - 0271-5333 (Linking) VI - 44 IP - 3 DP - 2024 Mar TI - Practical Guide to VI-RADS: MRI Protocols, Lesion Characterization, and Pitfalls. PG - e230149 LID - 10.1148/rg.230149 [doi] AB - Urothelial carcinoma is the most common type of bladder cancer (BC), accounting for approximately 90% of all cases. Evaluating the depth of tumor invasion in the bladder wall (tumor staging) is essential for determining the treatment and prognosis in patients with BC. Neoadjuvant therapy followed by radical cystectomy is the most common treatment of localized muscle-invasive BC (MIBC). Therefore, it is vital to differentiate non-MIBC from MIBC. Transurethral resection of bladder tumor (TURBT) is the reference standard to determine the extent of tumor invasion into the bladder wall through tissue sampling. However, this diagnostic and therapeutic method may not adequately sample the muscularis propria, leading to a higher risk of residual disease, early recurrence, and tumor understaging in approximately 50% of patients during the initial TURBT. Multiparametric MRI can overcome some of the limitations of TURBT when evaluating BC, particularly regarding tumor staging. In this context, the Vesical Imaging Reporting and Data System (VI-RADS) classification was developed to establish standards for bladder multiparametric MRI and interpretation. It uses a 5-point scale to assess the likelihood of detrusor muscle invasion. T2-weighted MR images are particularly useful as an initial guide, especially for categories 1-3, while the presence of muscular invasion is determined with diffusion-weighted and dynamic contrast-enhanced sequences. Diffusion-weighted imaging takes precedence as the dominant method when optimal image quality is achieved. The presence of a stalk or a thickened inner layer and no evidence of interruption of the signal intensity of the muscular layer are central for predicting a low likelihood of muscle invasion. ((c))RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material. See the invited commentary by Hoegger in this issue. FAU - Favero Prietto Dos Santos, Jonatas AU - Favero Prietto Dos Santos J AUID- ORCID: 0000-0002-2896-5707 AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Ghezzi, Caroline Lorenzoni Almeida AU - Ghezzi CLA AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Pedrollo, Ivan Morzoletto AU - Pedrollo IM AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Cruz, Italo Ribeiro AU - Cruz IR AUID- ORCID: 0009-0008-0220-9680 AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Orozco, Oscar Fernando Ghattas AU - Orozco OFG AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Zapparoli, Mauricio AU - Zapparoli M AUID- ORCID: 0000-0002-3787-3273 AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Schuch, Alice AU - Schuch A AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). FAU - Muglia, Valdair Francisco AU - Muglia VF AD - From the Department of Radiology, Division of Body Imaging, Hospital Moinhos de Vento, 910 Ramiro Barcelos St, Porto Alegre, RS 90035-000, Brazil, and Program in Pneumology Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (J.F.P.d.S.); Department of Radiology, Division of Abdominal Imaging, Hospital Moinhos de Vento, Porto Alegre, Brazil (C.L.A.G., I.M.P., A.S.); Department of Radiology, Division of Abdominal Imaging, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (C.L.A.G., I.M.P); Department of Radiology, Division of Abdominal Imaging, Hospital da Restauracao, Recife, Brazil, Centro de Diagnostico Boris Berenstein, Recife, Brazil, and Department of Radiology, Division of Abdominal Imaging, Hospital Santa Joana, Recife, Brazil (I.R.C.); Division of Abdominal Imaging, Diagnostico Avancado por Imagem (DAPI), Curitiba, Brazil, and Department of Internal Medicine, Division of Abdominal Imaging, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (O.F.G.O., M.Z.); and Department of Radiology, Oncology and Hematology, Division of Abdominal Imaging, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil (V.F.M.). LA - eng PT - Journal Article PL - United States TA - Radiographics JT - Radiographics : a review publication of the Radiological Society of North America, Inc JID - 8302501 SB - IM MH - Humans MH - Urinary Bladder/diagnostic imaging MH - *Urinary Bladder Neoplasms/diagnostic imaging MH - *Carcinoma, Transitional Cell/diagnostic imaging/pathology/surgery MH - Magnetic Resonance Imaging/methods MH - Diffusion Magnetic Resonance Imaging/methods EDAT- 2024/02/29 18:42 MHDA- 2024/03/04 06:44 CRDT- 2024/02/29 13:03 PHST- 2024/03/04 06:44 [medline] PHST- 2024/02/29 18:42 [pubmed] PHST- 2024/02/29 13:03 [entrez] AID - 10.1148/rg.230149 [doi] PST - ppublish SO - Radiographics. 2024 Mar;44(3):e230149. doi: 10.1148/rg.230149. PMID- 38419309 OWN - NLM STAT- MEDLINE DCOM- 20240301 LR - 20240301 IS - 0386-300X (Print) IS - 0386-300X (Linking) VI - 78 IP - 1 DP - 2024 Feb TI - Prostate Biopsy May Not Be Indicated Early after Bacillus Calmette Guerin Treatment. PG - 9-13 LID - 10.18926/AMO/66665 [doi] AB - Bacillus Calmette-Guerin (BCG) treatment for non-muscle-invasive bladder cancer frequently causes an intraprostatic BCG granuloma. We investigated the optimal timing for a prostate biopsy after BCG treatment by retrospectively analyzing the cases of 22 patients with non-muscle-invasive bladder cancer who underwent a prostate biopsy after BCG treatment at our institute (2013-2017). Biopsies were indicated for a rising prostate-specific antigen (PSA) level, positive digital rectal examination findings, or the appearance of de novo low apparent diffusion coefficient lesions on MRI. The control group was comprised of 28 age- and PSA-matched patients. The relationships among the cancer detection rate and the patients' PSA levels and MRI findings were analyzed. Prostate cancer was detected by biopsy in only 13.9% (3/22) of the patients in the BCG group but in 78.5% (22/28) of the control patients (p=0.0001). The three patients in the BCG group in whom prostate cancer was detected had all undergone the biopsy > 1 year after their BCG treatment. The remaining biopsies were performed within 1 year after BCG treatment and resulted in no diagnoses of prostate cancer. We suggest that performing a prostate biopsy early after BCG treatment is not informative or useful. FAU - Akagi, Naoki AU - Akagi N AD - Department of Urology, Hyogo Medical University. FAU - Kanematsu, Akihiro AU - Kanematsu A AD - Department of Urology, Hyogo Medical University. FAU - Shigesaka, Koji AU - Shigesaka K AD - Department of Urology, Hyogo Medical University. FAU - Shimatani, Kimihiro AU - Shimatani K AD - Department of Urology, Hyogo Medical University. FAU - Yamamoto, Shingo AU - Yamamoto S AD - Department of Urology, Hyogo Medical University. LA - eng PT - Journal Article PL - Japan TA - Acta Med Okayama JT - Acta medica Okayama JID - 0417611 RN - 0 (BCG Vaccine) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Male MH - Humans MH - BCG Vaccine/therapeutic use MH - Prostate/pathology MH - Prostate-Specific Antigen MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy MH - Biopsy MH - *Prostatic Neoplasms/drug therapy/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - bacillus Calmette-Guerin OT - bladder cancer OT - prostate biopsy OT - prostate cancer OT - prostate granuloma COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2024/02/29 06:43 MHDA- 2024/03/01 06:44 CRDT- 2024/02/29 01:23 PHST- 2024/03/01 06:44 [medline] PHST- 2024/02/29 06:43 [pubmed] PHST- 2024/02/29 01:23 [entrez] AID - 10.18926/AMO/66665 [doi] PST - ppublish SO - Acta Med Okayama. 2024 Feb;78(1):9-13. doi: 10.18926/AMO/66665. PMID- 38417288 OWN - NLM STAT- MEDLINE DCOM- 20240327 LR - 20240327 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 173 DP - 2024 Apr TI - Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer. PG - 116312 LID - S0753-3322(24)00193-8 [pii] LID - 10.1016/j.biopha.2024.116312 [doi] AB - Bladder cancer (BC) is a common malignant tumor of urinary system, which can be divided into muscle-invasive BC (MIBC) and nonmuscle-invasive BC (NMIBC). The number of BC patients has been gradually increasing currently. At present, bladder tumours are diagnosed and followed-up using a combination of cystoscopic examination, cytology and histology. However, the detection of early grade tumors, which is much easier to treat effectively than advanced stage disease, is still insufficient. It frequently recurs and can progress when not expeditiously diagnosed and monitored following initial therapy for NMIBC. Treatment strategies are totally different for different stage diseases. Therefore, it is of great practical significance to study new biomarkers for diagnosis and prognosis. In this review, we summarize the current state of biomarker development in BC diagnosis and prognosis prediction. We retrospectively analyse eight diagnostic biomarkers and eight prognostic biomarkers, in which CK, P53, PPARgamma, PTEN and ncRNA are emphasized for discussion. Eight molecular subtype systems are also identified. Clinical translation of biomarkers for diagnosis, prognosis, monitoring and treatment will hopefully improve outcomes for patients. These potential biomarkers provide an opportunity to diagnose tumors earlier and with greater accuracy, and help identify those patients most at risk of disease recurrence. CI - Copyright (c) 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Fan, Junping AU - Fan J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Chen, Bo AU - Chen B AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Luo, Qiuping AU - Luo Q AD - Out-patient Department, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Jinze AU - Li J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Huang, Yin AU - Huang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Zhu, Mengli AU - Zhu M AD - Research Core Facility, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Zeyu AU - Chen Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Li, Jin AU - Li J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; West China School of Medicine, Sichuan University, Chengdu, China. FAU - Wang, Jia AU - Wang J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Liangren AU - Liu L AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: weiqiang933@126.com. FAU - Cao, Dehong AU - Cao D AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: hxcaodehong@163.com. LA - eng PT - Journal Article PT - Review DEP - 20240227 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Biomarkers, Tumor/genetics MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Molecular biomarkers OT - Molecular subtyping OT - Prognosis COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/29 00:43 MHDA- 2024/03/27 06:43 CRDT- 2024/02/28 18:06 PHST- 2023/12/18 00:00 [received] PHST- 2024/02/07 00:00 [revised] PHST- 2024/02/17 00:00 [accepted] PHST- 2024/03/27 06:43 [medline] PHST- 2024/02/29 00:43 [pubmed] PHST- 2024/02/28 18:06 [entrez] AID - S0753-3322(24)00193-8 [pii] AID - 10.1016/j.biopha.2024.116312 [doi] PST - ppublish SO - Biomed Pharmacother. 2024 Apr;173:116312. doi: 10.1016/j.biopha.2024.116312. Epub 2024 Feb 27. PMID- 38415551 OWN - NLM STAT- MEDLINE DCOM- 20240229 LR - 20240510 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 25 IP - 2 DP - 2024 Feb 1 TI - Immunohistochemical Expression of Claudin-1 and Claudin-4 in Urothelial Carcinoma of the Urinary Bladder. PG - 637-646 LID - 91023 [pii] LID - 10.31557/APJCP.2024.25.2.637 [doi] AB - BACKGROUND: In Egypt, bladder cancer occupies the second rankamong reported cancers in men. Claudins are tight junctions that have a critical role in tumor pathogenesis, invasion, progression, and metastasis and currentlyare a focus of interest for targeting therapies. OBJECTIVES: We aimed to evaluatethe immunohistochemical expression of Claudin-1 and Claudin-4 in urinary bladder urothelial carcinoma and investigate the relationshipbetweenthe expressed Claudins with differentclinicopathological parameters. METHODS: Claudin-1 and Claudin-4 immunohistochemical expression was studied in 62 cases of urinary bladder urothelial carcinomas. The cases were classified into two categories; low and high Claudin-1 and Claudin-4 expression. RESULTS: High Claudin-1 expression was detected in67.7% of the studied urothelial carcinomas while 32.3% showed low expression. Claudin-1 expression was reduced significantly with high tumor grade, non-papillary tumors, muscle invasion, schistosomal infestation, and perineural invasion (p-value < 0.05). Claudin-4 high expression was detected in 82.3% of our cases while low expression was detected in 17.7%. Claudin-4 reduced expression was significantly associated with non-papillary tumors, muscle invasion, advanced T stages, and associated lympho-vascular emboli (P-value < 0.05). CONCLUSION: According to the results ofthe present study, the reduced expressions of Claudin-1 and Claudin-4 provide clues concerning the progression of urothelial carcinoma. Consequently, it is thought that Claudin-1 and Claudin-4 could help to differentiatelow-grade from high-grade and muscle-invasive from non-muscle-invasive urothelial carcinomas. In addition, it can be introduced as a possible therapeutic target. FAU - Elsayed, Aya Magdy AU - Elsayed AM AUID- ORCID: 0000-0002-4111-5491 AD - Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. FAU - Mahmoud, Eman Ibrahim AU - Mahmoud EI AD - Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. FAU - Salem, Mostafa Mohamed AU - Salem MM AD - Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. FAU - Khairy, Rasha Ahmed AU - Khairy RA AUID- ORCID: 0000-0002-9373-354X AD - Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20240201 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Claudin-4) RN - 0 (Claudin-1) RN - 0 (Claudins) RN - 0 (Biomarkers, Tumor) SB - IM MH - Male MH - Humans MH - *Carcinoma, Transitional Cell/metabolism MH - *Urinary Bladder Neoplasms/pathology MH - Claudin-4 MH - Claudin-1 MH - Urinary Bladder/metabolism MH - Claudins MH - Biomarkers, Tumor/metabolism PMC - PMC11077106 OTO - NOTNLM OT - Claudin-1 OT - Urothelial carcinoma OT - claudin-4 OT - immunohistochemistry OT - urinary bladder COIS- The authors declare there is no conflict of interest EDAT- 2024/02/28 12:42 MHDA- 2024/02/29 06:42 PMCR- 2024/03/01 CRDT- 2024/02/28 07:20 PHST- 2023/10/15 00:00 [received] PHST- 2024/02/29 06:42 [medline] PHST- 2024/02/28 12:42 [pubmed] PHST- 2024/02/28 07:20 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - 91023 [pii] AID - 10.31557/APJCP.2024.25.2.637 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2024 Feb 1;25(2):637-646. doi: 10.31557/APJCP.2024.25.2.637. PMID- 38409965 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 2 DP - 2024 Aug TI - A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer. PG - 249-257 LID - 10.1111/bju.16298 [doi] AB - OBJECTIVE: To develop a prognostically relevant scoring system for stage pT1 non-muscle-invasive bladder cancer (NMIBC) incorporating tumour budding, growth pattern and invasion pattern because the World Health Organisation grading system shows limited prognostic value in such patients. PATIENTS AND METHODS: The tissue specimens and clinical data of 113 patients with stage pT1 NMIBC who underwent transurethral resection of bladder tumour were retrospectively investigated. Tumour budding, and growth and invasion patterns were evaluated and categorised into two grade groups (GGs). GGs and other clinical and histopathological variables were investigated regarding recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using univariable and multivariable Cox regression analyses. RESULTS: The integration of two tumour budding groups, two growth patterns, and two invasion patterns yielded an unfavourable GG (n = 28; 24.7%) that had a high impact on oncological outcomes. The unfavourable GG was identified as an independent RFS and OS predictor (P = 0.004 and P = 0.046, respectively) and linked to worse PFS (P = 0.001) and CSS (P = 0.001), irrespective of the European Association of Urology risk group. The unfavourable GG was associated with higher rates of BCG-unresponsive tumours (P = 0.006). Study limitations include the retrospective, single-centre design, diverse therapies and small cohort. CONCLUSIONS: We present a morphology-based grading system for stage pT1 NMIBC that correlates with disease aggressiveness and oncological patient outcomes. It therefore identifies a highest risk group of stage pT1 NMIBC patients, who should be followed up more intensively or receive immediate radical cystectomy. The grading incorporates objective variables assessable on haematoxylin and eosin slides and immunohistochemistry, enabling an easy-to-use low-cost approach that is applicable in daily routine. Further studies are needed to validate and confirm these results. CI - (c) 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Haas, Maximilian AU - Haas M AUID- ORCID: 0000-0003-3132-0130 AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Engelmann, Simon U AU - Engelmann SU AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Gossler, Christopher AU - Gossler C AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Pickl, Christoph AU - Pickl C AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Kalble, Sebastian AU - Kalble S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Yang, Yushan AU - Yang Y AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Valerie AU - Hartmann V AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AUID- ORCID: 0000-0003-0674-4150 AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20240226 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/surgery MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Neoplasm Grading MH - *Neoplasm Staging MH - Middle Aged MH - Prognosis MH - *Neoplasm Invasiveness MH - Cystectomy/methods MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - EMT OT - NMIBC OT - bladder cancer OT - grade group OT - tumour budding EDAT- 2024/02/27 06:45 MHDA- 2024/07/18 00:42 CRDT- 2024/02/27 02:43 PHST- 2024/07/18 00:42 [medline] PHST- 2024/02/27 06:45 [pubmed] PHST- 2024/02/27 02:43 [entrez] AID - 10.1111/bju.16298 [doi] PST - ppublish SO - BJU Int. 2024 Aug;134(2):249-257. doi: 10.1111/bju.16298. Epub 2024 Feb 26. PMID- 38409928 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 133 IP - 6 DP - 2024 Jun TI - Lessons from a population-based bladder cancer registry: exploring why survival is not improving. PG - 699-708 LID - 10.1111/bju.16286 [doi] AB - OBJECTIVE: To explore the causes of the decrease in bladder cancer survival that has occurred over the past four decades. METHODS: We extracted data from the South Australian Cancer Registry. Data from the period 1 January 1977 to 31 December 2020 were extracted to explore changes in incidence and survival among a total of 8356 patients diagnosed with >/=pT1 disease. Invasive bladder cancer was defined as >/=pT1 in this study. RESULTS: Invasive bladder cancer age-standardized incidence decreased from 7.20 cases per 100 000 people in 1977 to 5.85 cases per 100 000 in 2020. The mean age at diagnosis increased from 68 years to 76 years. The crude incidence for patients aged 80 years and over increased by 3.3% per year (95% confidence interval [CI] 2.1 to 4.6). Overall survival decreased over the study period (hazard ratio [HR] 1.22 [95% CI 1.09 to 1.35]), however, survival increased after adjusting for age at diagnosis (HR 0.80 [95% CI 0.76 to 0.94]). Despite a decrease in non-bladder cancer-specific deaths in older people, there was no change in the bladder cancer-specific death rate in older people (HR 0.94 [95% CI 0.70 to 1.26]). Male sex was associated with higher survival (HR 0.87 [95% CI 0.83 to 0.92]), whereas socioeconomic advantage was not. CONCLUSIONS: Invasive bladder cancer survival has decreased over the past 40 years, with the age structure of the population being a significant contributing factor. PATIENT SUMMARY: We looked at why bladder cancer survival is decreasing using a large cancer registry with information from 1977 to 2020. We found that people are now more likely to be diagnosed at an older age. Older people often live for a shorter time with bladder cancer compared to younger people. Bladder cancer survival has decreased because there are more older people with the disease than previously. CI - (c) 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Tempo, Jake A AU - Tempo JA AUID- ORCID: 0000-0002-7404-2356 AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. AD - Urology Unit, Austin Health, Melbourne, VIC, Australia. FAU - Sii, Samuel AU - Sii S AD - Urology Unit, Sunshine Coast University Hospital, Sunshine Coast, QLD, Australia. FAU - Ischia, Joseph AU - Ischia J AD - Urology Unit, Austin Health, Melbourne, VIC, Australia. FAU - Bolton, Damien M AU - Bolton DM AD - Urology Unit, Austin Health, Melbourne, VIC, Australia. FAU - D'Onise, Katina AU - D'Onise K AD - Prevention and Population Health, Wellbeing SA, Adelaide, SA, Australia. FAU - Meng, Rosie AU - Meng R AD - Prevention and Population Health, Wellbeing SA, Adelaide, SA, Australia. FAU - Watson, David I AU - Watson DI AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - O'Callaghan, Michael AU - O'Callaghan M AUID- ORCID: 0000-0001-5038-5859 AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. AD - Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia. AD - Urology Unit, Flinders Medical Centre, Bedford Park, SA, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240226 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/pathology MH - Male MH - *Registries MH - Female MH - Aged MH - Aged, 80 and over MH - Incidence MH - Survival Rate MH - Middle Aged MH - South Australia/epidemiology MH - Adult OTO - NOTNLM OT - bladder cancer OT - elderly OT - older people OT - survival OT - urology EDAT- 2024/02/27 06:45 MHDA- 2024/05/10 06:42 CRDT- 2024/02/27 02:35 PHST- 2024/05/10 06:42 [medline] PHST- 2024/02/27 06:45 [pubmed] PHST- 2024/02/27 02:35 [entrez] AID - 10.1111/bju.16286 [doi] PST - ppublish SO - BJU Int. 2024 Jun;133(6):699-708. doi: 10.1111/bju.16286. Epub 2024 Feb 26. PMID- 38408431 OWN - NLM STAT- MEDLINE DCOM- 20240320 LR - 20250227 IS - 1540-1413 (Electronic) IS - 1540-1405 (Print) IS - 1540-1405 (Linking) VI - 22 IP - 2 DP - 2024 Feb 26 TI - Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer. LID - e237086 [pii] LID - 10.6004/jnccn.2023.7086 [doi] AB - BACKGROUND: As one of the 10 most common cancers in the United States, bladder cancer is the most expensive cancer to treat. Most bladder cancers (70%-80%) are diagnosed at early stages as non-muscle-invasive bladder cancer (NMIBC), which can be removed. However, 50% to 80% of NMIBC recurs within 5 years, and 15% to 30% progresses with poor survival. Besides life-long surveillance, current treatment is limited. Preclinical and epidemiologic evidence suggest that dietary isothiocyanates (ITCs) in cruciferous vegetables (Cruciferae) could be a noninvasive and cost-effective strategy to improve NMIBC prognosis. Yet, a Cruciferae intervention that increases ITC exposure in NMIBC survivors has not been tested. Thus, the primary aim of this study was to test the effect of a Cruciferae intervention on urinary ITC levels and Cruciferae intake in NMIBC survivors. PATIENTS AND METHODS: We conducted a 2-arm, double-blinded, randomized controlled trial to test the efficacy of a Cruciferae intervention against a general fruit and vegetable intervention (control) for NMIBC survivors. Both 6-month interventions consisted of mailed educational materials, a live call with staff to review the materials, and 11 interactive voice response calls. We anticipated that our Cruciferae intervention (Power to Redefine Your Health [POW-R Health]) would increase Cruciferae intake to 1 cup/day (secondary outcome), thus raising urinary ITC levels to 10 microM (primary outcome) from baseline to 6-month follow-up. RESULTS: We randomized 49 patients with NMIBC diagnosed in 2018 through 2019, and retained 42 patients at 6-month follow-up. The treatment group reported 0.94 cups (95% CI, 0.24-1.65; P=.010) higher Cruciferae intake (treatment, 1.37 +/- 1.19 cups vs control, 0.56 +/- 0.72 cups) and increased urinary ITC levels by 11.1 mumol/g creatinine (treatment, 26.2 +/- 20.9 vs control, 7.8 +/- 11.5; P=.027) at 6-month follow-up compared with the control group. CONCLUSIONS: Our dietary intervention is the first to significantly increase Cruciferae intake and urinary ITC levels in NMIBC survivors, demonstrating an increase in ITC to levels that significantly decrease risk of disease-specific survival. A future randomized controlled trial testing POW-R Health on bladder cancer recurrence and progression is warranted. If proven to improve bladder cancer outcomes, our intervention has the potential to be a noninvasive, cost-effective, easily accessible way for NBMIC survivors to improve their bladder cancer prognosis. FAU - Yeary, Karen H Kim AU - Yeary KHK AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Yu, Han AU - Yu H AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Kuliszewski, Margaret Gates AU - Kuliszewski MG AD - New York State Cancer Registry, Albany, NY. FAU - Li, Qiang AU - Li Q AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - McCann, Susan E AU - McCann SE AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Pratt, Rachel AU - Pratt R AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Saad-Harfouche, Frances G AU - Saad-Harfouche FG AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Wang, Zinian AU - Wang Z AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Clark, Nikia AU - Clark N AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Wang, Chong AU - Wang C AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - DiCarlo, Elizabeth AU - DiCarlo E AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Tang, Li AU - Tang L AD - Roswell Park Comprehensive Cancer Center, Buffalo, NY. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R21 CA253910/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240226 PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/therapy MH - Prognosis MH - Survivors MH - Neoplasm Recurrence, Local/epidemiology/prevention & control PMC - PMC11325219 MID - NIHMS2013944 EDAT- 2024/02/27 00:42 MHDA- 2024/03/20 06:45 PMCR- 2025/02/26 CRDT- 2024/02/26 18:04 PHST- 2023/04/12 00:00 [received] PHST- 2023/09/12 00:00 [accepted] PHST- 2024/03/20 06:45 [medline] PHST- 2024/02/27 00:42 [pubmed] PHST- 2024/02/26 18:04 [entrez] PHST- 2025/02/26 00:00 [pmc-release] AID - e237086 [pii] AID - 10.6004/jnccn.2023.7086 [doi] PST - epublish SO - J Natl Compr Canc Netw. 2024 Feb 26;22(2):e237086. doi: 10.6004/jnccn.2023.7086. PMID- 38403529 OWN - NLM STAT- MEDLINE DCOM- 20240602 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 8 DP - 2024 Aug TI - Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer. PG - 229-235 LID - S1078-1439(24)00041-3 [pii] LID - 10.1016/j.urolonc.2024.01.025 [doi] AB - A plethora of urine markers for the management of patients with bladder cancer has been developed and studied in the past. However, the clinical impact of urine testing on patient management remains obscure. The goal of this manuscript is to identify scenarios for the potential use of molecular urine markers in the follow-up of patients with high-risk non-muscle-invasive BC (NMIBC) and estimate potential risks and benefits. Information on the course of disease of patients with high-risk NMIBC and performance data of a point-of-care test (UBC rapid), an MCM-5 directed ELISA (ADXBLADDER), and 2 additional novel assays targeting alterations of mRNA expression and DNA methylation (Xpert bladder cancer monitor, Epicheck) were retrieved from high-quality trials and/or meta-analyses. In addition, the sensitivity of white light cystoscopy (WLC) and the impact of a urine marker result on the performance of WLC were estimated based on fluorescence cystoscopy data and information from the CeFub trial. This information was applied to different scenarios in patient follow-up and sensitivity, estimated number of cystoscopies, and the numbers needed to diagnose were calculated. The sensitivity of guideline-based regular follow-up (SOC) at 1 year was calculated at 96%. For different marker-supported strategies sensitivities ranging from 77% to 97.9% were estimated. Calculations suggest that several strategies are effective for the SOC. While for the SOC 24.6 WLCs were required to diagnose 1 tumor recurrence (NND), this NND dropped below 5 in some marker-supported strategies. Based on the results of this simulation, a marker-supported follow-up of patients with HR NMIBC is safe and offers the option to significantly reduce the number of WLCs. Further research focusing on prospective randomized trials is needed to finally find a way to implement urine markers into clinical decision-making. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Benderska-Soder, Natalya AU - Benderska-Soder N AD - Urologie 24, St. Theresienkrankenhaus, Nurnberg, Germany. FAU - Ecke, Thorsten AU - Ecke T AD - Department of Urology, Helios Klinikum, Bad Saarow, Germany; Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany. FAU - Kleinlein, Lisa AU - Kleinlein L AD - Urologie 24, St. Theresienkrankenhaus, Nurnberg, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marienhospital Herne, Ruhr-University Bochum, Germany. FAU - Bismarck, Ekkehardt AU - Bismarck E AD - Urologie 24, St. Theresienkrankenhaus, Nurnberg, Germany. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, University of Regensburg, Caritas-Hospital St. Josef, Regensburg, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls-University of Tubingen, Tubingen, Germany. FAU - Witjes, Johannes Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Studienpraxis Urologie, Nurtingen, Germany. FAU - Hakenberg, Oliver W AU - Hakenberg OW AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - Grimm, Marc Oliver AU - Grimm MO AD - Department of Urology, University of Jena, Jena, Germany. FAU - Goebell, Peter J AU - Goebell PJ AD - Department of Urology, Friedrich-Alexander University, Erlangen, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Caritas-Hospital St. Josef, Regensburg, Germany. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology and Clinical Medicine, University of Aarhus, Aarhus, Denmark. FAU - Schmitz-Drager, Bernd J AU - Schmitz-Drager BJ AD - Urologie 24, St. Theresienkrankenhaus, Nurnberg, Germany; Studienpraxis Urologie, Nurtingen, Germany. Electronic address: bernd_sd@yahoo.de. LA - eng PT - Journal Article PT - Review DEP - 20240224 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - *Urinary Bladder Neoplasms/urine/pathology MH - Humans MH - *Biomarkers, Tumor/urine MH - Follow-Up Studies MH - Neoplasm Invasiveness MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Disease management OT - Follow-up OT - High grade OT - Surveillance OT - Urinary tumor markers COIS- Declaration of competing interest Thorsten Ecke is trialist for Concile GmbH, Germany. Florian Roghmann is trialist for Cepheid, CA, USA. Bas W.G. van. Rhijn is consultant for QED Therapeutics, CA, USA and Incyte International Biosciences, DE, USA. Arnulf Stenzl is trialist and consultant for Arquer Ltd, UK, Cepheid, CA, USA and Nucleix Inc., Israel. J. Alfred Witjes is trialist and consultant for Arquer Ltd, UK, Cepheid, CA, USA and Nucleix Inc., Israel. Peter J. Goebell is trialist for Cepheid, CA, USA. Jorgen Bjerggaard Jensen is trialist and consultant for Cepheid, CA, USA and Nucleix Inc., Israel. Bernd J. Schmitz-Drager is trialist and consultant for Arquer Ltd, UK, Cepheid, CA, USA, Concile GmbH, Germany and Nucleix Inc., Israel. Remaining authors have no conflict of interest to disclose. EDAT- 2024/02/26 00:42 MHDA- 2024/06/03 00:42 CRDT- 2024/02/25 21:54 PHST- 2023/11/26 00:00 [received] PHST- 2024/01/05 00:00 [revised] PHST- 2024/01/25 00:00 [accepted] PHST- 2024/06/03 00:42 [medline] PHST- 2024/02/26 00:42 [pubmed] PHST- 2024/02/25 21:54 [entrez] AID - S1078-1439(24)00041-3 [pii] AID - 10.1016/j.urolonc.2024.01.025 [doi] PST - ppublish SO - Urol Oncol. 2024 Aug;42(8):229-235. doi: 10.1016/j.urolonc.2024.01.025. Epub 2024 Feb 24. PMID- 38401816 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20240530 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 46 DP - 2024 Apr TI - Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor? PG - 104023 LID - S1572-1000(24)00062-0 [pii] LID - 10.1016/j.pdpdt.2024.104023 [doi] AB - BACKGROUND: Photodynamic diagnosis-assisted transurethral resection of bladder tumor (PDD-TURBT) for nonmuscle-invasive bladder cancer is superior to conventional white-light TURBT for cancer detection. However, when performing PDD-TURBT, cystoscopy findings vary depending on the quality of the endoscopic equipment. In this study, we compared the effects of different types of endoscopic equipment on postoperative outcomes. METHODS: Patients who underwent their first PDD-TURBT at our clinic were selected. Patients on whom PDD-TURBT was performed using endoscopic equipment A were sorted into Group A, and patients on whom PDD-TURBT was performed using equipment S were sorted into Group S. The characteristics, recurrence-free survival (RFS), and recurrence frequency of these patients were retrospectively investigated and compared. The prognostic factors for RFS were also analyzed. RESULTS: A total of 49 patients were included in Group A and 46 in Group S. In Group S, a higher detection rate (8.2% vs. 30.4 %, p < 0.01) of carcinoma in situ (CIS) was noted. RFS tended to be better in Group S (HR 0.63, p = 0.15). The frequency of recurrence also tended to be lower in Group S (4.92 vs. 3.66 per 10,000 person-days, p = 0.08). Furthermore, CIS (HR 0.30, p = 0.04) and Bacillus Calmette-Guerin therapy (HR: 0.26, p = 0.01) were significant favorable prognostic factors for RFS. CONCLUSION: The quality of the endoscopic equipment may influence postoperative recurrence after PDD-TURBT. Higher-quality endoscopic instruments have superior CIS detection capabilities, which can lead to improvements in postoperative outcomes with the appropriate selection of postoperative adjuvant therapy. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Nakagawa, Ryunosuke AU - Nakagawa R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Nohara, Takahiro AU - Nohara T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Electronic address: t_nohara704@yahoo.co.jp. FAU - Kano, Hiroshi AU - Kano H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Makino, Tomoyuki AU - Makino T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Naito, Renato AU - Naito R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Iwamoto, Hiroaki AU - Iwamoto H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Yaegashi, Hiroshi AU - Yaegashi H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Kawaguchi, Shohei AU - Kawaguchi S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Shigehara, Kazuyoshi AU - Shigehara K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Izumi, Kouji AU - Izumi K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. LA - eng PT - Journal Article DEP - 20240222 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 0 (Photosensitizing Agents) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - *Neoplasm Recurrence, Local MH - Retrospective Studies MH - Middle Aged MH - *Cystoscopy/methods MH - Photosensitizing Agents/therapeutic use MH - Aged, 80 and over MH - Transurethral Resection of Bladder OTO - NOTNLM OT - Endoscopic equipment OT - Nonmuscle-invasive bladder cancer OT - Photodiagnosis OT - Photodynamic diagnosis-assisted transurethral resection of bladder tumor COIS- Declaration of competing interest All authors declare that there are no potential conflicts of interest relevant to this article. EDAT- 2024/02/25 00:42 MHDA- 2024/05/31 00:42 CRDT- 2024/02/24 19:18 PHST- 2023/12/15 00:00 [received] PHST- 2024/02/13 00:00 [revised] PHST- 2024/02/21 00:00 [accepted] PHST- 2024/05/31 00:42 [medline] PHST- 2024/02/25 00:42 [pubmed] PHST- 2024/02/24 19:18 [entrez] AID - S1572-1000(24)00062-0 [pii] AID - 10.1016/j.pdpdt.2024.104023 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2024 Apr;46:104023. doi: 10.1016/j.pdpdt.2024.104023. Epub 2024 Feb 22. PMID- 38398151 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 4 DP - 2024 Feb 12 TI - Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up. LID - 10.3390/cancers16040758 [doi] LID - 758 AB - We performed a urine cytology analysis of a pharmacologically induced diuresis for the diagnosis of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, an initial cohort of 77 consecutive patients with primary upper tract urothelial carcinoma treated via radical surgery was enrolled. To evaluate pharmacologically forced diuresis cytology as a follow-up procedure, a second cohort of 1250 patients who underwent a radical cystectomy for bladder cancer was selected. In the first cohort, the sensitivity of cytology of pharmacologically forced diuresis in patients with invasive, high-grade, low-grade, and concomitant carcinoma in situ was 8%, 9%, 0%, and 14%, respectively. In the second cohort, cytology of pharmacologically forced diuresis was positive in 30/689 (4.3%) patients, in whom upper urinary tract recurrence was present in 21/30 (70%) of cases, and urethral recurrence was present in 8/30 (26%) of cases. As a follow-up tool, cytology of pharmacologically forced diuresis showed a sensitivity, specificity, and positive and negative predictive values of 60%, 99%, 70%, and 98%, respectively. Overall, as a diagnostic tool, the sensitivity of cytology of pharmacologically forced diuresis is slightly better in patients with invasive upper tract urothelial carcinoma and concomitant carcinoma in situ. As a follow-up method, positive cytology of pharmacologically forced diuresis is strongly related to cancer recurrence and can reveal urethral recurrence. Cytology of pharmacologically forced diuresis might be useful in cases with contraindications for imaging or when achieving endoscopic access to the upper urinary tract is difficult. FAU - Giudici, Nicola AU - Giudici N AUID- ORCID: 0009-0005-9844-1799 AD - Department of Urology, Hospital Center Biel, Vogelsang 84, 2501 Biel, Switzerland. FAU - Blarer, Jennifer AU - Blarer J AD - Department of Urology, Hospital Center Biel, Vogelsang 84, 2501 Biel, Switzerland. FAU - Sathianathen, Niranjan AU - Sathianathen N AUID- ORCID: 0000-0002-3710-014X AD - Department of Urology, The University of Melbourne, Royal Melbourne Hospital, Parkville, VIC 3052, Australia. FAU - Burkhard, Fiona C AU - Burkhard FC AD - Department of Urology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Wuethrich, Patrick Y AU - Wuethrich PY AUID- ORCID: 0000-0003-3704-6785 AD - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Thalmann, George N AU - Thalmann GN AUID- ORCID: 0000-0002-1908-3286 AD - Department of Urology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Seiler, Roland AU - Seiler R AUID- ORCID: 0000-0002-3529-2088 AD - Department of Urology, Hospital Center Biel, Vogelsang 84, 2501 Biel, Switzerland. AD - Department for BioMedical Research, Translational Organoid Resource Core, University of Bern, 3010 Bern, Switzerland. FAU - Furrer, Marc A AU - Furrer MA AD - Department of Urology, The University of Melbourne, Royal Melbourne Hospital, Parkville, VIC 3052, Australia. AD - Department of Urology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. AD - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. AD - Department of Urology, Solothurner Spitaler AG, Kantonsspital Olten, 4600 Olten, Switzerland. AD - Department of Urology, Solothurner Spitaler AG, Burgerspital Solothurn, 4500 Solothurn, Switzerland. LA - eng PT - Journal Article DEP - 20240212 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10886451 OTO - NOTNLM OT - diagnostic value for diagnosis and follow-up OT - pharmacologically forced diuresis OT - upper tract urothelial carcinoma OT - urine cytology COIS- The authors declare no conflicts of interest. EDAT- 2024/02/24 11:45 MHDA- 2024/02/24 11:46 PMCR- 2024/02/12 CRDT- 2024/02/24 01:11 PHST- 2024/01/08 00:00 [received] PHST- 2024/02/02 00:00 [revised] PHST- 2024/02/08 00:00 [accepted] PHST- 2024/02/24 11:46 [medline] PHST- 2024/02/24 11:45 [pubmed] PHST- 2024/02/24 01:11 [entrez] PHST- 2024/02/12 00:00 [pmc-release] AID - cancers16040758 [pii] AID - cancers-16-00758 [pii] AID - 10.3390/cancers16040758 [doi] PST - epublish SO - Cancers (Basel). 2024 Feb 12;16(4):758. doi: 10.3390/cancers16040758. PMID- 38397962 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 2 DP - 2024 Feb 3 TI - Prediction of Non-Muscle Invasive Papillary Urothelial Carcinoma Relapse from Hematoxylin-Eosin Images Using Deep Multiple Instance Learning in Patients Treated with Bacille Calmette-Guerin Immunotherapy. LID - 10.3390/biomedicines12020360 [doi] LID - 360 AB - The limited reproducibility of the grading of non-muscle invasive papillary urothelial carcinoma (NMIPUC) necessitates the search for more robust image-based predictive factors. In a cohort of 157 NMIPUC patients treated with Bacille Calmette-Guerin (BCG) immunotherapy, we explored the multiple instance learning (MIL)-based classification approach for the prediction of 2-year and 5-year relapse-free survival and the multiple instance survival learning (MISL) framework for survival regression. We used features extracted from image patches sampled from whole slide images of hematoxylin-eosin-stained transurethral resection (TUR) NPMIPUC specimens and tested several patch sampling and feature extraction network variations to optimize the model performance. We selected the model showing the best patient survival stratification for further testing in the context of clinical and pathological variables. MISL with the multiresolution patch sampling technique achieved the best patient risk stratification (concordance index = 0.574, p = 0.010), followed by a 2-year MIL classification. The best-selected model revealed an independent prognostic value in the context of other clinical and pathologic variables (tumor stage, grade, and presence of tumor on the repeated TUR) with statistically significant patient risk stratification. Our findings suggest that MISL-based predictions can improve NMIPUC patient risk stratification, while validation studies are needed to test the generalizability of our models. FAU - Drachneris, Julius AU - Drachneris J AUID- ORCID: 0000-0003-4818-8316 AD - Department of Pathology and Forensic Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Morkunas, Mindaugas AU - Morkunas M AUID- ORCID: 0000-0002-1360-6533 AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. FAU - Fabijonavicius, Mantas AU - Fabijonavicius M AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Cekauskas, Albertas AU - Cekauskas A AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Jankevicius, Feliksas AU - Jankevicius F AD - Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 08406 Vilnius, Lithuania. AD - Center of Urology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Laurinavicius, Arvydas AU - Laurinavicius A AUID- ORCID: 0000-0001-9232-1730 AD - Department of Pathology and Forensic Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. LA - eng GR - S-MIP-21-31/Lietuvos Mokslo Taryba/ PT - Journal Article DEP - 20240203 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC10886666 OTO - NOTNLM OT - bladder cancer OT - cancer prognosis OT - deep learning OT - digital image analysis OT - feature extraction OT - survival prediction COIS- The authors declare no conflicts of interest. EDAT- 2024/02/24 11:45 MHDA- 2024/02/24 11:46 PMCR- 2024/02/03 CRDT- 2024/02/24 01:10 PHST- 2023/12/28 00:00 [received] PHST- 2024/01/29 00:00 [revised] PHST- 2024/02/01 00:00 [accepted] PHST- 2024/02/24 11:46 [medline] PHST- 2024/02/24 11:45 [pubmed] PHST- 2024/02/24 01:10 [entrez] PHST- 2024/02/03 00:00 [pmc-release] AID - biomedicines12020360 [pii] AID - biomedicines-12-00360 [pii] AID - 10.3390/biomedicines12020360 [doi] PST - epublish SO - Biomedicines. 2024 Feb 3;12(2):360. doi: 10.3390/biomedicines12020360. PMID- 38393775 OWN - NLM STAT- MEDLINE DCOM- 20240425 LR - 20250730 IS - 1744-7666 (Electronic) IS - 1465-6566 (Linking) VI - 25 IP - 3 DP - 2024 Feb TI - Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG). PG - 315-324 LID - 10.1080/14656566.2024.2323609 [doi] AB - BACKGROUND: To evaluate the impact of having first-degree relatives (FDR) with bladder cancer (BC) among non-muscle invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette - Guerin (BCG) on their oncological outcomes. METHODS: The National Phase II BCG/Interferon (IFN) trial database from 125 sites in the U.S.A. (1999-2001) and multi-institutional databases from France (FR) and Lebanon (LB) (2000-2021) were queried for NMIBC patients treated with BCG. Cox regression models were used to evaluate the effect of BC family history on tumor recurrence and progression in their relatives. RESULTS: There were 867 patients in the U.S.A. cohort and 1232 patients in the FR/LB cohort. Almost 8% of patients in both cohorts had FDR with BC. Patients in the FR/LB cohort were more likely to have carcinoma in situ tumors (CIS) (41% vs. 24%, p < 0.01). Having FDR with BC was not significantly associated with tumor recurrence or progression in the U.S.A. cohort. Conversely, on multivariable analysis FDR history was significantly associated with a 2.10 times increased risk of recurrence (p < 0.01) and a 3.01 times increased risk of progression (p < 0.01) in the FR/LB cohort. CONCLUSION: A family history of BC could have an important impact on the response to BCG. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA. FAU - Moussa, Mohamad AU - Moussa M AD - Department of Urology, Lebanese University, Beirut, Lebanon. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA. LA - eng PT - Journal Article DEP - 20240228 PL - England TA - Expert Opin Pharmacother JT - Expert opinion on pharmacotherapy JID - 100897346 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - *Urinary Bladder Neoplasms/pathology/drug therapy/genetics/therapy MH - Humans MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Male MH - Female MH - Aged MH - Middle Aged MH - Prognosis MH - *Neoplasm Recurrence, Local/pathology MH - *Disease Progression MH - Cohort Studies MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - BCG OT - family history OT - intravesical OT - non-muscle invasive bladder cancer OT - oncological outcome EDAT- 2024/02/23 12:43 MHDA- 2024/04/25 12:50 CRDT- 2024/02/23 11:54 PHST- 2024/04/25 12:50 [medline] PHST- 2024/02/23 12:43 [pubmed] PHST- 2024/02/23 11:54 [entrez] AID - 10.1080/14656566.2024.2323609 [doi] PST - ppublish SO - Expert Opin Pharmacother. 2024 Feb;25(3):315-324. doi: 10.1080/14656566.2024.2323609. Epub 2024 Feb 28. PMID- 38386788 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20260512 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 50 IP - 2 DP - 2024 Mar-Apr TI - Identify risk factors for perioperative outcomes in Intracorporeal Urinary Diversion and Extracorporeal Urinary Diversion with Robotic Cystectomy. PG - 178-191 LID - 10.1590/S1677-5538.IBJU.2023.0477 [doi] AB - INTRODUCTION: The increasing adoption of robotic-assisted cystectomy with intracorporeal urinary diversion (ICUD), despite its complexity, prompts a detailed comparison with extracorporeal urinary diversion (ECUD). Our study at a single institution investigates perioperative outcomes and identifies risk factors impacting the success of these surgical approaches. METHODS: In this retrospective analysis, 174 patients who underwent robotic-assisted cystectomy at the University of Louisville from June 2016 to August 2021 were reviewed. The cohort was divided into two groups based on the urinary diversion method: 30 patients underwent ECUD and 144 underwent ICUD. Data on demographics, complication rates, length of hospital stay, and readmission rates were meticulously collected and analyzed. RESULTS: Operative times were comparable between the ICUD and ECUD groups. However, the ICUD group had a significantly lower intraoperative transfusion rate (0.5 vs. 1.0, p=0.02) and shorter hospital stay (7.8 vs. 12.3 days, p<0.001). Factors such as male sex, smoking history, diabetes mellitus, intravesical therapy, higher ASA, and ACCI scores were associated with increased Clavien-Dindo Grade 3 or higher complications. Age over 70 was the sole factor linked to a higher 90-day readmission rate, with no specific characteristics influencing the 30-day rate. CONCLUSION: Robotic cystectomy with ICUD results in shorter hospitalizations and lower intraoperative transfusion rates compared to ECUD, without differences in operative time, high-grade postoperative complications, or readmission rates. These findings can inform clinical decision-making, highlighting ICUD as a potentially more favorable option in appropriate settings. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Fu, Hangcheng AU - Fu H AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. FAU - Davis, Laura AU - Davis L AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. AD - Case Western Urology Institute, University Hospital Cleveland Medical Center, Cleveland OH, United States. FAU - Ramakrishnan, Venkat AU - Ramakrishnan V AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. AD - Division of Urology, Brigham and Women's Hospital, Boston. MA, USA. FAU - Barefoot, Thomas AU - Barefoot T AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. FAU - Sholtes, Colleen AU - Sholtes C AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. AD - Department of Urology, Urology & Pelvic Health Center, Cleveland Clinic Akron General, OH, United States. FAU - Liang, Lifan AU - Liang L AD - Department of Medicine, University of Louisville School of Medicine, Louisville, KY, United States. FAU - Said, Mohammed AU - Said M AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. FAU - Messer, Jamie AU - Messer J AD - Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Humans MH - Male MH - Cystectomy/adverse effects MH - Retrospective Studies MH - *Robotic Surgical Procedures/adverse effects MH - *Urinary Diversion/adverse effects MH - Risk Factors PMC - PMC10953604 OTO - NOTNLM OT - Urinary Diversion OT - Robotic Surgical Procedures OT - Urinary Bladder Neoplasms COIS- None declared. EDAT- 2024/02/22 18:42 MHDA- 2024/02/26 06:43 PMCR- 2024/03/18 CRDT- 2024/02/22 14:27 PHST- 2023/10/30 00:00 [received] PHST- 2024/01/17 00:00 [accepted] PHST- 2024/02/26 06:43 [medline] PHST- 2024/02/22 18:42 [pubmed] PHST- 2024/02/22 14:27 [entrez] PHST- 2024/03/18 00:00 [pmc-release] AID - IBJU20230477 [pii] AID - S1677-5538.IBJU.2023.0477 [pii] AID - 10.1590/S1677-5538.IBJU.2023.0477 [doi] PST - ppublish SO - Int Braz J Urol. 2024 Mar-Apr;50(2):178-191. doi: 10.1590/S1677-5538.IBJU.2023.0477. PMID- 38376603 OWN - NLM STAT- MEDLINE DCOM- 20240221 LR - 20261010 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 41 IP - 3 DP - 2024 Feb 20 TI - Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target. PG - 74 LID - 10.1007/s12032-024-02299-4 [doi] AB - Urothelial Carcinoma of Bladder is complex disease with high mortality and recurrence rates. Current standard regimes have exhibited anti-tumor activity but still, a proportion of patients are non-responsive or in-eligible to receive such treatments. Immune checkpoints have emerged as potential class of therapeutics to be tested in UCB patients. Clinical trials targeting PD-1/PD-L1 axis have been tested in UCB but still a proportion of patients are non-responsive to it which stresses upon identifying new targets. New immune checkpoint B7-H4 has been shown to negatively regulate T cell activity in cancer and is a poor prognostic factor in various solid tumors. In this study we assessed the novel immune checkpoint B7-H4 status in UCB patients. We observed elevated expression of B7-H4 and PD-L1 on CD8+ T cells in circulation of UCB patients. Relative mRNA expression and immunohistochemistry displayed upregulation in bladder tumor tissue. Increased expression of B7-H4 along with PD-L1 in periphery and tumor of UCB patients highlights involvement of B7-H4 in disease progression. Combinatorial blocking of B7-H4 and PD-L1 enhanced IFN-gamma and granzyme B in CD8+ T cells functional T cell immune response in UCB patients. Also, B7-H4 was significantly associated with clinico-pathological parameters. Our findings highlight B7-H4 as potential therapeutic target for treatment of UCB patients in future after further validation. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Raja, David AU - Raja D AD - Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Singh, Aishwarya AU - Singh A AD - Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Kurra, Santosh AU - Kurra S AD - Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Nayak, Brusabhanu AU - Nayak B AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Kaushal, Seema AU - Kaushal S AD - Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Sharma, Alpana AU - Sharma A AD - Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Singh, Prabhjot AU - Singh P AUID- ORCID: 0000-0001-7633-9973 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. drprabhjotsingh@aiims.edu. LA - eng GR - E8-734/A-734/2019/RS/Intramural Grant All India Institute of Medical Sciences New Delhi/ PT - Journal Article DEP - 20240220 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (B7-H1 Antigen) RN - 0 (Immune Checkpoint Proteins) SB - IM MH - Humans MH - B7-H1 Antigen/genetics MH - *Carcinoma, Transitional Cell/drug therapy MH - Clinical Relevance MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/drug therapy MH - *Immune Checkpoint Proteins OTO - NOTNLM OT - B7-H4 OT - Immune checkpoints OT - Immunotherapy OT - Muscle invasive/and Non-muscle invasive bladder cancer OT - PD-L1 OT - Urothelial carcinoma of bladder EDAT- 2024/02/20 12:51 MHDA- 2024/02/21 11:22 CRDT- 2024/02/20 11:08 PHST- 2023/09/03 00:00 [received] PHST- 2023/12/29 00:00 [accepted] PHST- 2024/02/21 11:22 [medline] PHST- 2024/02/20 12:51 [pubmed] PHST- 2024/02/20 11:08 [entrez] AID - 10.1007/s12032-024-02299-4 [pii] AID - 10.1007/s12032-024-02299-4 [doi] PST - epublish SO - Med Oncol. 2024 Feb 20;41(3):74. doi: 10.1007/s12032-024-02299-4. PMID- 38375346 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240221 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 60 DP - 2024 Feb TI - The Value of Negative Urinary Dipstick Tests for Haematuria in Patients Undergoing Surveillance for Low-grade Ta Urothelial Cancer: A Two-stage Prospective Clinical Study in 524 Patients. PG - 24-31 LID - 10.1016/j.euros.2023.12.006 [doi] AB - BACKGROUND AND OBJECTIVE: The risk of first recurrence beyond 5 yr for patients with low-grade (LG) Ta non-muscle-invasive bladder cancer (NMIBC) is low enough to consider discontinuing cystoscopic surveillance at that point. However, a positive urinary dipstick test for haematuria (UDH) during and beyond the period of cystoscopic surveillance can disrupt plans to cease surveillance because the association between UDH positivity and recurrence in LG Ta NMIBC is unknown. In a two-stage study, we evaluated this association and explored the role of UDH negativity in predicting the absence of recurrence. METHODS: Because of previously demonstrated changes in recurrence patterns over time, two prospective cohorts were assessed: an "exploratory" cohort (January 2007-March 2008) and a "validation" cohort (November 2017-August 2018). UDH was performed before flexible cystoscopy. Patient, operative, and surveillance data have been recorded prospectively using standard pro forma sheets since 1978 in our institution. Only patients with primary LG Ta pTa NMIBC were included for analysis. KEY FINDINGS AND LIMITATIONS: We assessed 231 patients in the exploratory group and 293 in the validation group. The proportion of smokers (67% vs 70%; p = 0.5) and mean follow-up (72.2 vs 79.9 mo; p = 0.2) were similar between the groups. The recurrence rate was higher in the exploratory group (19% vs 11%; p = 0.009), as was the UDH positivity rate (37% vs 11%; p < 0.001). The specificity and negative predictive value were 64% and 83% in the exploratory group, and 90% and 90%, respectively, in the validation group. These values increased further for the subgroup with solitary primary tumours the subgroup without recurrence for 3 yr. CONCLUSIONS AND CLINICAL IMPLICATIONS: UDH negativity has a high probability of being associated with the absence of recurrence in small LG Ta NMIBC and could be an inexpensive adjunct during surveillance. Ongoing validation, which started in 2019, is being performed in a now-nationalised Scottish protocol in which UDH replaces cystoscopy in years 2 and 4 for patients in the low-risk group. PATIENT SUMMARY: We investigated the accuracy of a dipstick test for blood in the urine for patients undergoing surveillance for low-grade noninvasive bladder cancer. We found that a negative dipstick test result was highly associated with the absence of tumour recurrence, particularly for patients with the lowest risk. These findings have been introduced into a national protocol designed to reduce the frequency of telescopic inspection of the bladder during surveillance to reduce the burden for patients. CI - (c) 2023 The Author(s). FAU - Shah, Chandrarajan Premal AU - Shah CP AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. AD - The University of Edinburgh, Edinburgh, UK. FAU - Lord-McKenzie, Tanya AU - Lord-McKenzie T AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Makris, Antonios AU - Makris A AD - Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Trail, Matthew AU - Trail M AD - Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Gray, Jennifer AU - Gray J AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Smith, Gordon AU - Smith G AD - Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK. AD - The University of Edinburgh, Edinburgh, UK. LA - eng PT - Journal Article DEP - 20240109 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC10874875 OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Efficiency OT - Haematuria OT - Low-grade cancer OT - Noninvasive cancer OT - Non-muscle-invasive bladder cancer OT - Surveillance OT - Ta cancer OT - Urinary dipstick EDAT- 2024/02/20 11:50 MHDA- 2024/02/20 11:51 PMCR- 2024/01/09 CRDT- 2024/02/20 03:43 PHST- 2023/12/22 00:00 [accepted] PHST- 2024/02/20 11:51 [medline] PHST- 2024/02/20 11:50 [pubmed] PHST- 2024/02/20 03:43 [entrez] PHST- 2024/01/09 00:00 [pmc-release] AID - S2666-1683(23)02538-7 [pii] AID - 10.1016/j.euros.2023.12.006 [doi] PST - epublish SO - Eur Urol Open Sci. 2024 Jan 9;60:24-31. doi: 10.1016/j.euros.2023.12.006. eCollection 2024 Feb. PMID- 38374699 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20260923 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 56 IP - 3 DP - 2024 Jul TI - Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. PG - 893-897 LID - 10.4143/crt.2024.015 [doi] AB - PURPOSE: Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT. MATERIALS AND METHODS: The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT. RESULTS: Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976). CONCLUSION: The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC. FAU - Cho, Sung Wook AU - Cho SW AD - Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lim, Sung Hee AU - Lim SH AD - Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kwon, Ghee Young AU - Kwon GY AD - Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Chan Kyo AU - Kim CK AD - Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Park, Won AU - Park W AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Pyo, Hongryull AU - Pyo H AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Chung, Jae Hoon AU - Chung JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Song, Wan AU - Song W AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Park, Se Hoon AU - Park SH AD - Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng GR - TPP 10-008/HX/HSRD VA/United States PT - Clinical Trial, Phase II PT - Journal Article DEP - 20240215 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - Q20Q21Q62J (Cisplatin) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/mortality/pathology/drug therapy MH - Male MH - *Cisplatin/therapeutic use/administration & dosage MH - Female MH - *Neoadjuvant Therapy/methods MH - Aged MH - Middle Aged MH - *Chemoradiotherapy/methods MH - Prospective Studies MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Organ Sparing Treatments/methods MH - Treatment Outcome MH - Neoplasm Invasiveness MH - Adult MH - Carcinoma, Transitional Cell/therapy/pathology/mortality/drug therapy MH - Deoxycytidine/analogs & derivatives/therapeutic use/administration & dosage MH - Aged, 80 and over MH - Gemcitabine PMC - PMC11261190 OTO - NOTNLM OT - Muscle-invasive OT - Neoadjuvant chemoradiotherapy OT - Urinary bladder neoplasms COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2024/02/20 11:50 MHDA- 2024/07/17 06:43 PMCR- 2024/07/01 CRDT- 2024/02/20 02:39 PHST- 2024/01/04 00:00 [received] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/07/17 06:43 [medline] PHST- 2024/02/20 11:50 [pubmed] PHST- 2024/02/20 02:39 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - crt.2024.015 [pii] AID - crt-2024-015 [pii] AID - 10.4143/crt.2024.015 [doi] PST - ppublish SO - Cancer Res Treat. 2024 Jul;56(3):893-897. doi: 10.4143/crt.2024.015. Epub 2024 Feb 15. PMID- 38374533 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20250602 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 133 IP - 6 DP - 2024 Jun TI - Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. PG - 733-741 LID - 10.1111/bju.16293 [doi] AB - OBJECTIVE: To evaluate the prognostic value of T1 substaging in patients treated with bacillus Calmette-Guerin (BCG) or immediate radical cystectomy (iRC). MATERIALS AND METHODS: We performed an institutional review board-approved retrospective study analysing non-muscle-invasive bladder cancer (NMIBC) patients with pT1 disease treated with either BCG or iRC between 2000 and 2020. Lamina propria (LP) invasion characteristics were extracted from the pathology report. The Kaplan-Meier method was used to calculate overall survival (OS), cancer-specific survival (CSS) and metastasis-free survival (MFS). Multivariable Cox models were used to determine the association between progression-free survival (PFS) and characteristics in the BCG cohort. A logistic regression model explored the relationship between T1 substaging and upstaging to >pT2 at iRC. RESULTS: A total of 411 T1 high-grade patients were identified. LP invasion characteristics were as follows: not specified: 115 (28%); focal/superficial (F/S): 147 (35.8%); and extensive/multifocal (E/M): 149 (36.2%). Overall, 303 patients (73.7%) received BCG, and 108 patients (26.3%) underwent iRC. The median (interquartile range) follow-up was 53 (32-96) months. Patients with E/M LP invasion were significantly more likely to undergo iRC (34% vs. 19%; P = 0.003). Patients with E/M LP invasion showed poorer MFS and CSS compared to those with F/S LP invasion when treated with BCG but not when treated with iRC. Among BCG-treated patients, progression occurred in 41 patients and E/M LP invasion was independently associated with progression after BCG (hazard ratio 5.3, 95% confidence interval [CI] 2.2-13.1; P < 0.001). T1 substaging was not associated with upstaging at RC (odds ratio 3.15, 95% CI 0.82-12.12; P = 0.095). CONCLUSIONS: Extensive/multifocal LP invasion was associated with poor PFS, MFS and CSS in patients treated with BCG. T1 substaging provides valuable prognostic information and should be reported in pathology reports. CI - (c) 2024 BJU International. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Bree, Kelly AU - Bree K AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Myers, Amanda AU - Myers A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Nogueras-Gonzalez, Graciela AU - Nogueras-Gonzalez G AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Guo, Charles AU - Guo C AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240219 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Adjuvants, Immunologic/therapeutic use MH - *BCG Vaccine/therapeutic use MH - *Cystectomy MH - *Mucous Membrane/pathology MH - Neoplasm Grading MH - *Neoplasm Invasiveness MH - Neoplasm Staging MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/surgery MH - Prognosis MH - Retrospective Studies PMC - PMC12118599 MID - NIHMS2084382 OTO - NOTNLM OT - T1 substaging OT - bacillus Calmette-Guerin OT - non-muscle-invasive bladder cancer OT - progression OT - radical cystectomy EDAT- 2024/02/20 11:51 MHDA- 2024/05/10 06:42 PMCR- 2025/06/01 CRDT- 2024/02/20 00:18 PHST- 2024/05/10 06:42 [medline] PHST- 2024/02/20 11:51 [pubmed] PHST- 2024/02/20 00:18 [entrez] PHST- 2025/06/01 00:00 [pmc-release] AID - 10.1111/bju.16293 [doi] PST - ppublish SO - BJU Int. 2024 Jun;133(6):733-741. doi: 10.1111/bju.16293. Epub 2024 Feb 19. PMID- 38372785 OWN - NLM STAT- MEDLINE DCOM- 20240220 LR - 20260127 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 150 IP - 2 DP - 2024 Feb 19 TI - Current look at the most promising proteomic and glycomic biomarkers of bladder cancer. PG - 96 LID - 10.1007/s00432-024-05623-7 [doi] LID - 96 AB - BACKGROUND: Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential. METHODS: We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%. FINDINGS: Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC. CI - (c) 2024. The Author(s). FAU - Harsanyi, Stefan AU - Harsanyi S AD - Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. stefan.harsanyi@fmed.uniba.sk. FAU - Kianickova, Kristina AU - Kianickova K AD - Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia. FAU - Katrlik, Jaroslav AU - Katrlik J AD - Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia. FAU - Danisovic, Lubos AU - Danisovic L AD - Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. FAU - Ziaran, Stanislav AU - Ziaran S AD - Department of Urology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. LA - eng GR - 313021BUZ3/Operational Programme Integrated Infrastructure/ PT - Journal Article PT - Review DEP - 20240219 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers) RN - 0 (Nuclear Proteins) RN - 0 (Biomarkers, Tumor) RN - 0 (BLCA-4 protein, human) RN - 0 (Neoplasm Proteins) SB - IM MH - Humans MH - *Glycomics MH - Proteomics MH - *Urinary Bladder Neoplasms/diagnosis MH - Biomarkers MH - Phenotype MH - Nuclear Proteins MH - Biomarkers, Tumor MH - Neoplasm Proteins PMC - PMC10876723 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Diagnostics OT - Glycoprotein OT - Protein COIS- The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article. EDAT- 2024/02/19 12:42 MHDA- 2024/02/20 11:57 PMCR- 2024/02/19 CRDT- 2024/02/19 11:06 PHST- 2023/08/09 00:00 [received] PHST- 2024/01/12 00:00 [accepted] PHST- 2024/02/20 11:57 [medline] PHST- 2024/02/19 12:42 [pubmed] PHST- 2024/02/19 11:06 [entrez] PHST- 2024/02/19 00:00 [pmc-release] AID - 10.1007/s00432-024-05623-7 [pii] AID - 5623 [pii] AID - 10.1007/s00432-024-05623-7 [doi] PST - epublish SO - J Cancer Res Clin Oncol. 2024 Feb 19;150(2):96. doi: 10.1007/s00432-024-05623-7. PMID- 38371197 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241027 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 5 IP - 2 DP - 2024 Mar TI - Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines. PG - 269-280 LID - 10.1002/bco2.305 [doi] AB - OBJECTIVE: The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the European Organization for Research and Treatment of Cancer, Club Urologico Espanol de Tratamiento Oncologico, and Japanese Nishinihon Uro-oncology Extensive Collaboration Group. PATIENTS AND METHODS: This retrospective multi-institutional database study included two cohorts-3024 patients receiving intravesical bacillus Calmette-Guerin (BCG) treatment (BCG cohort) and 789 patients not receiving BCG treatment (non-BCG cohort). The Kaplan-Meier estimate and log-rank test were used to visualize and compare oncological survival outcomes after transurethral surgery among the risk groups. Harrell's concordance index (C-index) was used to evaluate the predictive ability of the models. RESULTS: We observed a risk shift from the 2019 EAU risk grouping to the 2021 EAU risk grouping in a substantial number of patients. For progression, the C-index of the 2021 EAU model was significantly higher than that of the 2019 EAU model in both the BCG (0.617 vs. 0.572; P = 0.011) and non-BCG (0.718 vs. 0.560; P < 0.001) cohorts. According to the 2021 EAU model, 731 (24%) and 130 (16%) patients in the BCG and non-BCG cohorts, respectively, were considered to have a very high risk. Survival analysis showed no significant differences among the five very high-risk subgroups in both cohorts. A major limitation was potential selection bias owing to the retrospective nature of this study. CONCLUSIONS: The updated 2021 EAU model showed better stratification than the three existing risk models, especially for progression, in both cohorts, determining the most appropriate postoperative treatment and identifying patients requiring intensified surveillance or early cystectomy. CI - (c) 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine University of Toyama Toyama Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Nakahama, Tomonori AU - Nakahama T AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology Nara Medical University Kashihara Nara Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan. AD - Department of Urology JA Yamaguchi Kouseiren Nagato General Hospital Nagato Japan. FAU - Yonemori, Masaya AU - Yonemori M AD - Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan. FAU - Enokida, Hideki AU - Enokida H AD - Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine Kagawa University Takamatsu Kagawa Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology Aichi Cancer Center Nagoya Aichi Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology National Cancer Center Hospital Tokyo Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine University of Toyama Toyama Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology Nara Medical University Kashihara Nara Japan. CN - Nishinihon Uro-oncology Extensive Collaboration group and the Japanese Urological Oncology Group LA - eng PT - Journal Article DEP - 20231103 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC10869660 OTO - NOTNLM OT - prediction OT - prognosis OT - progression OT - recurrence OT - risk OT - urinary bladder neoplasms COIS- The authors disclose no potential conflict of interest. EDAT- 2024/02/19 06:42 MHDA- 2024/02/19 06:43 PMCR- 2023/11/03 CRDT- 2024/02/19 04:21 PHST- 2023/07/22 00:00 [received] PHST- 2023/09/23 00:00 [revised] PHST- 2023/09/26 00:00 [accepted] PHST- 2024/02/19 06:43 [medline] PHST- 2024/02/19 06:42 [pubmed] PHST- 2024/02/19 04:21 [entrez] PHST- 2023/11/03 00:00 [pmc-release] AID - BCO2305 [pii] AID - 10.1002/bco2.305 [doi] PST - epublish SO - BJUI Compass. 2023 Nov 3;5(2):269-280. doi: 10.1002/bco2.305. eCollection 2024 Mar. PMID- 38368856 OWN - NLM STAT- MEDLINE DCOM- 20240604 LR - 20240604 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 108 IP - 3 DP - 2024 TI - Systemic Inflammatory Index: A Promising Non-Invasive Marker for the Prediction of Response to Neoadjuvant Chemotherapy prior to Cystectomy. PG - 226-233 LID - 10.1159/000537894 [doi] AB - INTRODUCTION: The main challenge to the optimal use of neoadjuvant chemotherapy (NAC) is the difficulty in selecting patients who may or may not benefit from NAC. Our aim in this study was to investigate whether the Systemic Inflammatory Index (SII) predicts response to chemotherapy in patients who receive NAC prior to cystectomy. METHODS: We retrospectively analysed the data of patients who underwent NAC followed by cystectomy at our institution between January 2010 and September 2015 and whose 5-year follow-up was completed. All patients who underwent diagnostic biopsy with complete transurethral resection of bladder tumour at our hospital and whose pathology result was muscle-invasive transitional cell carcinoma were included in the study. At least 3 courses of gemcitabine/cisplatin NAC were given to all patients. A pathological response was defined as a reduction in cystectomy to a lower pathological stage after NAC. RESULTS: The SII was 320.8 +/- 51 in the responders and 388.28 +/- 50 in the non-responders. SII optimal cut-off of 350 was determined. The sensitivity and specificity of SII in predicting response were found to be 80% and 83%, respectively. Low SII (<350) was found to be a significant predictor of response compared with the other factors on multivariate analysis. The mean overall survival time was 55.4 months in patients with a low SII value and 40.3 months in the high SII group. CONCLUSION: SII, together with known clinicopathological factors and newer genetic and molecular markers, can be used to select patients for NAC. CI - (c) 2024 S. Karger AG, Basel. FAU - Ozcan, Levent AU - Ozcan L AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. FAU - Polat, Emre Can AU - Polat EC AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. FAU - Baran, Caner AU - Baran C AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. FAU - Boylu, Ahmet AU - Boylu A AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. FAU - Erkoc, Mustafa AU - Erkoc M AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. FAU - Otunctemur, Alper AU - Otunctemur A AD - University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Urology, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20240217 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Gemcitabine) RN - Q20Q21Q62J (Cisplatin) RN - 0W860991D6 (Deoxycytidine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology MH - *Cystectomy/methods MH - *Neoadjuvant Therapy MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - Middle Aged MH - *Carcinoma, Transitional Cell/drug therapy/surgery/pathology/therapy MH - Treatment Outcome MH - Inflammation MH - Chemotherapy, Adjuvant MH - Predictive Value of Tests MH - Gemcitabine MH - Cisplatin/therapeutic use/administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Deoxycytidine/analogs & derivatives/therapeutic use/administration & dosage OTO - NOTNLM OT - Cystectomy OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Systemic Inflammatory Index EDAT- 2024/02/19 00:42 MHDA- 2024/06/05 02:20 CRDT- 2024/02/18 18:25 PHST- 2024/01/07 00:00 [received] PHST- 2024/02/08 00:00 [accepted] PHST- 2024/06/05 02:20 [medline] PHST- 2024/02/19 00:42 [pubmed] PHST- 2024/02/18 18:25 [entrez] AID - 000537894 [pii] AID - 10.1159/000537894 [doi] PST - ppublish SO - Urol Int. 2024;108(3):226-233. doi: 10.1159/000537894. Epub 2024 Feb 17. PMID- 38355375 OWN - NLM STAT- MEDLINE DCOM- 20241206 LR - 20241219 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 6 DP - 2024 Dec TI - Unlocking the Potential of Adequate Bacillus Calmette-Guerin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics. PG - 1367-1375 LID - S2588-9311(24)00043-9 [pii] LID - 10.1016/j.euo.2024.01.017 [doi] AB - BACKGROUND: The European Association of Urology (EAU) recommends discussing upfront radical cystectomy for all patients with very high risk (VHR) non-muscle-invasive bladder carcinoma (NMIBC), but the role of bacillus Calmette-Guerin (BCG) treatment remains controversial. OBJECTIVE: To analyze oncological outcomes in VHR NMIBC patients (EAU risk groups) treated with adequate BCG. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional retrospective study involving patients with VHR NMIBC who received adequate BCG therapy from 2007 to 2020 was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A survival analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), and the cumulative incidence of cancer-specific mortality (CSM) after accounting for other causes of mortality as competing risk events and of the overall mortality (OM). Conditional survival probabilities for 0-4 yr without events were computed. Cox regression assessed the predictors of oncological outcomes. RESULTS AND LIMITATION: A total of 640 patients, with a median 47 (32-67) mo follow-up for event-free individuals, were analyzed. High-grade RFS and PFS at 5 yr were 53% (49-57%) and 78% (74-82%), respectively. The cumulative incidence of CSM and OM at 5 yr was 13% (10-16%) and 16% (13-19%), respectively. Conditional RFS, PFS, overall survival, and cancer-specific survival at 4 yr were 91%, 96%, 87%, and 94%, respectively. Cox regression identified tumor grade (hazard ratio [HR]: 1.54; 1.1-2) and size (HR: 1.3; 1.1-1.7) as RFS predictors. Tumor multiplicity predicted RFS (HR: 1.6; 1.3-2), PFS (HR: 2; 1.2-3.3), and CSM (HR: 2; 1.2-3.2), while age predicted OM (HR: 1.48; 1.1-2). CONCLUSIONS: Patients with VHR NMIBC who receive adequate BCG therapy have a more favorable prognosis than predicted by EAU risk groups, especially among those with a sustained response, in whom continuing maintenance therapy emerges as a viable alternative to radical cystectomy. PATIENT SUMMARY: Our research shows that a sustained response to bacillus Calmette-Guerin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. Electronic address: jdsubiela@gmail.com. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Gonzalez-Padilla, Daniel A AU - Gonzalez-Padilla DA AD - Department of Urology, Clinica Universidad de Navarra, Madrid, Spain. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Taborda, Javier AU - Taborda J AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Mostoles, Madrid, Spain. FAU - Sanchez Encinas, Miguel AU - Sanchez Encinas M AD - Servicio de Urologia, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Mostoles, Madrid, Spain. FAU - Basile, Giuseppe AU - Basile G AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Cano-Velasco, Jorge AU - Cano-Velasco J AD - Department of Urology, Hospital Universitario Gregorio Maranon, Madrid, Spain. FAU - Lopez Perez, Enrique AU - Lopez Perez E AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Del Olmo Duran, Pedro AU - Del Olmo Duran P AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Institute of Health Sciences, Opole University, Opole, Poland; University Clinical Hospital in Opole, Opole, Poland. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Yuen-Chun Teoh, Jeremy AU - Yuen-Chun Teoh J AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region. FAU - Serna Cespedes, Alejandra AU - Serna Cespedes A AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Pichler, Renate AU - Pichler R AD - Medical University of Innsbruck, Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Innsbruck, Austria. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences Molinette Hospital University of Torino School of Medicine, Torino, Italy. FAU - Ploussard, Guillaume AU - Ploussard G AD - Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain; ROC Clinic, Madrid, Spain; Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Rodriguez-Faba, Oscar AU - Rodriguez-Faba O AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Dominguez-Escrig, Jose Luis AU - Dominguez-Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Gomez Dos Santos, Victoria AU - Gomez Dos Santos V AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Jimenez Cidre, Miguel Angel AU - Jimenez Cidre MA AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Burgos Revilla, Francisco Javier AU - Burgos Revilla FJ AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. CN - European Association of Urology-Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240213 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/mortality/therapy/pathology MH - *BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - Middle Aged MH - *Neoplasm Invasiveness MH - Treatment Outcome MH - Immunotherapy/methods MH - Risk Assessment MH - Adjuvants, Immunologic/therapeutic use MH - Aged, 80 and over MH - Administration, Intravesical OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder carcinoma OT - Very high risk EDAT- 2024/02/15 00:42 MHDA- 2024/12/07 14:47 CRDT- 2024/02/14 21:55 PHST- 2023/10/25 00:00 [received] PHST- 2023/12/09 00:00 [revised] PHST- 2024/01/29 00:00 [accepted] PHST- 2024/12/07 14:47 [medline] PHST- 2024/02/15 00:42 [pubmed] PHST- 2024/02/14 21:55 [entrez] AID - S2588-9311(24)00043-9 [pii] AID - 10.1016/j.euo.2024.01.017 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Dec;7(6):1367-1375. doi: 10.1016/j.euo.2024.01.017. Epub 2024 Feb 13. PMID- 38347103 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240216 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Feb 12 TI - Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma. PG - 3497 LID - 10.1038/s41598-024-54232-4 [doi] LID - 3497 AB - We compared the progression patterns after radical nephroureterectomy (RNU) and elective distal ureterectomy (DU) in patients with urothelial carcinoma of the distal ureter. Between Jan 2011 and Dec 2020, 127 patients who underwent RNU and 46 who underwent elective DU for distal ureteral cancer were enrolled in this study. The patterns of progression and upper tract recurrence were compared between the two groups. Progression was defined as a local recurrence and/or distant metastasis after surgery. Upper tract recurrence and subsequent treatment in patients with DU were analyzed. Progression occurred in 35 (27.6%) and 10 (21.7%) patients in the RNU and DU groups, respectively. The progression pattern was not significantly different (p = 0.441), and the most common progression site was the lymph nodes in both groups. Multivariate logistic regression analysis revealed that pT2 stage, concomitant lymphovascular invasion, and nodal stage were significant predictors of disease progression. Upper tract recurrence was observed in nine (19.6%) patients with DU, and six (66.7%) patients had a prior history of bladder tumor. All patients with upper tract recurrence after DU were managed with salvage RNU. Elective DU with or without salvage treatment was not a risk factor for disease progression (p = 0.736), overall survival (p = 0.457), cancer-specific survival (p = 0.169), or intravesical recurrence-free survival (p = 0.921). In terms of progression patterns and oncological outcomes, there was no difference between patients who underwent RNU and elective DU with/without salvage treatment. Elective DU should be considered as a therapeutic option for distal ureter tumor. CI - (c) 2024. The Author(s). FAU - Lee, Chung Un AU - Lee CU AD - Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Gyeonggi-do, Republic of Korea. FAU - Lee, Jong Hoon AU - Lee JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Lee, Hye Won AU - Lee HW AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Chung, Jae Hoon AU - Chung JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Song, Wan AU - Song W AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. hyunhwan.sung@samsung.com. LA - eng PT - Journal Article DEP - 20240212 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Ureter/surgery/pathology MH - *Ureteral Neoplasms MH - Nephroureterectomy MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/surgery MH - Nephrectomy MH - *Kidney Neoplasms/pathology MH - Disease Progression MH - Retrospective Studies MH - Neoplasm Recurrence, Local/surgery PMC - PMC10861547 OTO - NOTNLM OT - Distal ureter OT - Distal ureterectomy OT - Progression OT - Radical nephroureterectomy OT - Therapeutic outcome OT - Urothelial carcinoma COIS- The authors declare no competing interests. EDAT- 2024/02/13 00:42 MHDA- 2024/02/13 12:47 PMCR- 2024/02/12 CRDT- 2024/02/12 23:24 PHST- 2023/12/25 00:00 [received] PHST- 2024/02/10 00:00 [accepted] PHST- 2024/02/13 12:47 [medline] PHST- 2024/02/13 00:42 [pubmed] PHST- 2024/02/12 23:24 [entrez] PHST- 2024/02/12 00:00 [pmc-release] AID - 10.1038/s41598-024-54232-4 [pii] AID - 54232 [pii] AID - 10.1038/s41598-024-54232-4 [doi] PST - epublish SO - Sci Rep. 2024 Feb 12;14(1):3497. doi: 10.1038/s41598-024-54232-4. PMID- 38344879 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20250304 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 134 IP - 2 DP - 2024 Aug TI - Prognostic impact of histological discordance between transurethral resection and radical cystectomy. PG - 207-218 LID - 10.1111/bju.16296 [doi] AB - OBJECTIVE: To analyse the impact of histological discordance of subtypes (subtypes or divergent differentiation [DD]) in specimens from transurethral resection (TUR) and radical cystectomy (RC) on the outcome of the patients with bladder cancer receiving RC. PATIENTS AND METHODS: We analysed data for 2570 patients from a Japanese nationwide cohort with bladder cancer treated with RC between January 2013 and December 2019 at 36 institutions. The non-urinary tract recurrence-free survival (NUTR-FS) and overall survival (OS) stratified by TUR or RC specimen histology were determined. We also elucidated the predictive factors for OS in patients with subtype/DD bladder cancer. RESULTS: At median follow-up of 36.9 months, 835 (32.4%) patients had NUTR, and 691 (26.9%) died. No statistically significant disparities in OS or NUTR-FS were observed when TUR specimens were classified as pure-urothelial carcinoma (UC), subtypes, DD, or non-UC. Among 2449 patients diagnosed with pure-UC or subtype/DD in their TUR specimens, there was discordance between the pathological diagnosis in TUR and RC specimens. Histological subtypes in RC specimens had a significant prognostic impact. When we focused on 345 patients with subtype/DD in TUR specimens, a multivariate Cox regression analysis identified pre-RC neutrophil-lymphocyte ratio and pathological stage as independent prognostic factors for OS (P = 0.016 and P = 0.001, respectively). The presence of sarcomatoid subtype in TUR specimens and lymphovascular invasion in RC specimens had a marginal effect (P = 0.069 and P = 0.056, respectively). CONCLUSION: This study demonstrated that the presence of subtype/DD in RC specimens but not in TUR specimens indicated a poor prognosis. In patients with subtype/DD in TUR specimens, pre-RC neutrophil-lymphocyte ratio and pathological stage were independent prognostic factors for OS. CI - (c) 2024 BJU International. FAU - Matsuda, Ayumu AU - Matsuda A AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. AD - Department of Urology, The Jikei University School of Medicine, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AUID- ORCID: 0000-0003-1044-912X AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. AD - Department of Urology, The Jikei University School of Medicine, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. FAU - Fujii, Yoichi AU - Fujii Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Japan. FAU - Kato, Minoru AU - Kato M AUID- ORCID: 0000-0002-4171-6027 AD - Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Urabe, Fumihiko AU - Urabe F AUID- ORCID: 0000-0002-2599-8183 AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. AD - Department of Urology, Jikei University Hospital, Tokyo, Japan. FAU - Kashima, Soki AU - Kashima S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Naito, Hirohito AU - Naito H AD - Department of Urology, Kurashiki Central Hospital, Okayama, Japan. FAU - Murakami, Yoji AU - Murakami Y AD - Department of Urology, Graduate School of Life Science, Kumamoto University, Kumamoto, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Daizumoto, Kei AU - Daizumoto K AD - Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Hayashi, Takuji AU - Hayashi T AD - Department of Urology, Osaka International Cancer Institute, Osaka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Sugino, Yusuke AU - Sugino Y AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin General Hospital, Fukuoka, Japan. FAU - Yamaguchi, Noriya AU - Yamaguchi N AD - Department of Urology, Tottori University Faculty of Medicine, Tottori, Japan. FAU - Iio, Hiroyuki AU - Iio H AD - Department of Urology, Hyogo College of Medicine, Hyogo, Japan. FAU - Yasue, Keiji AU - Yasue K AD - Department of Urology, Jikei University Katsushika Medical Center, Tokyo, Japan. FAU - Abe, Takashige AU - Abe T AUID- ORCID: 0000-0002-5468-7632 AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. FAU - Nakanishi, Shotaro AU - Nakanishi S AD - Department of Urology, Graduate School of Medicine, University of Ryukyus, Okinawa, Japan. FAU - Matsumura, Masafumi AU - Matsumura M AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan. FAU - Fujii, Masato AU - Fujii M AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Nishihara, Kiyoaki AU - Nishihara K AD - Department of Urology, Kurume University School of Medicine, Fukuoka, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology Graduate School of Medicine Yamaguchi University, Yamaguchi, Japan. FAU - Tatarano, Shuichi AU - Tatarano S AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Wada, Koichiro AU - Wada K AD - Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan. FAU - Sekito, Sho AU - Sekito S AD - Department of Urology, Aichi Cancer Center Hospital, Aichi, Japan. FAU - Maruyama, Ryo AU - Maruyama R AD - Department of Urology, Niigata University Graduate School of Medicine, Niigata, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AUID- ORCID: 0000-0002-2953-7085 AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. CN - Japanese Urological Oncology Group LA - eng PT - Journal Article DEP - 20240212 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Cystectomy/methods MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality MH - Male MH - Female MH - Prognosis MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Carcinoma, Transitional Cell/pathology/surgery/mortality MH - Japan/epidemiology OTO - NOTNLM OT - Bladder cancer OT - discordance OT - divergent differentiation OT - neutrophil-lymphocyte ratio OT - radical cystectomy OT - sarcomatoid OT - subtype OT - transurethral resection OT - urothelial carcinoma OT - variant histology EDAT- 2024/02/12 15:42 MHDA- 2024/07/18 00:42 CRDT- 2024/02/12 05:33 PHST- 2024/07/18 00:42 [medline] PHST- 2024/02/12 15:42 [pubmed] PHST- 2024/02/12 05:33 [entrez] AID - 10.1111/bju.16296 [doi] PST - ppublish SO - BJU Int. 2024 Aug;134(2):207-218. doi: 10.1111/bju.16296. Epub 2024 Feb 12. PMID- 38339010 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 3 DP - 2024 Jan 31 TI - The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer. LID - 10.3390/ijms25031732 [doi] LID - 1732 AB - Bladder cancer (BC) constitutes one of the most diagnosed types of cancer worldwide. Advancements in and new methodologies for DNA sequencing, leading to high-throughput microbiota testing, have pinpointed discrepancies in urinary microbial fingerprints between healthy individuals and patients with BC. Although several studies suggest an involvement of microbiota dysbiosis in the pathogenesis, progression, and therapeutic response to bladder cancer, an established direct causal relationship remains to be elucidated due to the lack of standardized methodologies associated with such studies. This review compiles an overview of the microbiota of the human urinary tract in healthy and diseased individuals and discusses the evidence to date on microbiome involvement and potential mechanisms by which the microbiota may contribute to the development of BC. We also explore the potential profiling of urinary microbiota as a biomarker for risk stratification, as well as the prediction of the response to intravesical therapies and immunotherapy in BC patients. Further investigation into the urinary microbiome of BC patients is imperative to unravel the complexities of the role played by host-microbe interactions in shaping wellness or disease and yield valuable insights into and strategies for the prevention and personalized treatment of BC. FAU - Kustrimovic, Natasa AU - Kustrimovic N AUID- ORCID: 0000-0002-5524-5238 AD - Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Universita del Piemonte Orientale, 28100 Novara, Italy. FAU - Bilato, Giorgia AU - Bilato G AD - Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy. FAU - Mortara, Lorenzo AU - Mortara L AUID- ORCID: 0000-0002-4757-7101 AD - Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy. FAU - Baci, Denisa AU - Baci D AD - Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy. AD - Molecular Cardiology Laboratory, IRCCS-Policlinico San Donato, 20097 Milan, Italy. LA - eng GR - GR-019-12370076/Ministero della Salute/ GR - FAR2021 and FAR2022/University of Insubria/ PT - Journal Article PT - Review DEP - 20240131 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Urinary Tract/pathology MH - *Microbiota/genetics MH - Host Microbial Interactions MH - Immunotherapy PMC - PMC10855347 OTO - NOTNLM OT - bladder cancer OT - genitourinary microbiome OT - inflammation COIS- The authors declare no conflicts of interest. EDAT- 2024/02/10 10:46 MHDA- 2024/02/11 07:43 PMCR- 2024/01/31 CRDT- 2024/02/10 01:12 PHST- 2023/12/19 00:00 [received] PHST- 2024/01/24 00:00 [revised] PHST- 2024/01/28 00:00 [accepted] PHST- 2024/02/11 07:43 [medline] PHST- 2024/02/10 10:46 [pubmed] PHST- 2024/02/10 01:12 [entrez] PHST- 2024/01/31 00:00 [pmc-release] AID - ijms25031732 [pii] AID - ijms-25-01732 [pii] AID - 10.3390/ijms25031732 [doi] PST - epublish SO - Int J Mol Sci. 2024 Jan 31;25(3):1732. doi: 10.3390/ijms25031732. PMID- 38338835 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 3 DP - 2024 Jan 26 TI - Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement. LID - 10.3390/ijms25031557 [doi] LID - 1557 AB - Bladder cancer is the tenth most common cancer and is a significant burden on health care services worldwide, as it is one of the most costly cancers to treat per patient. This expense is due to the extensive treatment and follow-ups that occur with costly and invasive procedures. Improvement in both treatment options and the quality of life these interventions offer has not progressed at the rates of other cancers, and new alternatives are desperately needed to ease the burden. A more modern approach needs to be taken, with urinary biomarkers being a positive step in making treatments more patient-friendly, but there is still a long way to go to make these widely available and of a comparable standard to the current treatment options. New targets to hit the major signalling pathways that are upregulated in bladder cancer, such as the PI3K/AkT/mTOR pathway, are urgently needed, with only one drug approved so far, Erdafitinib. Immune checkpoint inhibitors also hold promise, with both PD-1 and CDLA-4 antibody therapies approved for use. They effectively block ligand/receptor binding to block the immune checkpoint used by tumour cells. Other avenues must be explored, including drug repurposing and novel biomarkers, which have revolutionised this area in other cancers. FAU - Gill, Emily AU - Gill E AUID- ORCID: 0009-0004-9073-7897 AD - Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB, UK. FAU - Perks, Claire M AU - Perks CM AUID- ORCID: 0000-0003-1562-891X AD - Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB, UK. LA - eng PT - Journal Article PT - Review DEP - 20240126 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Quality of Life MH - Phosphatidylinositol 3-Kinases MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Biomarkers MH - Neoplasm Invasiveness/pathology PMC - PMC10855537 OTO - NOTNLM OT - biomarkers OT - bladder cancer treatment OT - muscle-invasive bladder cancer OT - non-muscle-invasive bladder cancer OT - radial cystectomy OT - transurethral resection of the bladder tumour COIS- The authors declare no conflicts of interest. EDAT- 2024/02/10 10:46 MHDA- 2024/02/11 16:42 PMCR- 2024/01/26 CRDT- 2024/02/10 01:11 PHST- 2023/12/03 00:00 [received] PHST- 2024/01/18 00:00 [revised] PHST- 2024/01/24 00:00 [accepted] PHST- 2024/02/11 16:42 [medline] PHST- 2024/02/10 10:46 [pubmed] PHST- 2024/02/10 01:11 [entrez] PHST- 2024/01/26 00:00 [pmc-release] AID - ijms25031557 [pii] AID - ijms-25-01557 [pii] AID - 10.3390/ijms25031557 [doi] PST - epublish SO - Int J Mol Sci. 2024 Jan 26;25(3):1557. doi: 10.3390/ijms25031557. PMID- 38336681 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 24 IP - 1 DP - 2024 Feb 9 TI - The role of URO17(R) in diagnosis and follow up of bladder cancer patients. PG - 34 LID - 10.1186/s12894-024-01426-7 [doi] LID - 34 AB - OBJECTIVE: to evaluate the role of urinary URO17(R) biomarker in the detection of urothelial tumors in haematuria patients and the detection of recurrence in non-muscle invasive bladder urothelial tumors. MATERIALS AND METHODS: Our study was formed of two cohorts of patients, group I represents patients presenting with haematuria (n = 98), while group II represents patients with known non-muscle invasive bladder cancers on their scheduled follow up cystoscopic investigation (n = 51). For both groups, patients were asked to provide urine samples before cystoscopy, either primary as part of the haematuria investigation or as a scheduled follow-up. Urine samples were sent anonymously for standard urine cytology and URO17(R) biomarker immunostaining. Results were compared to cystoscopic findings using Chi-square analysis and Fisher's exact test (P < 0.05). RESULTS: Group I was formed of 98 patients, with an average age of 60 years. URO17(R) showed 100% sensitivity and 96.15% specificity with a negative predictive value (NPV) of 100 and a positive predictive value (PPV) of 95.83. The results showed statistical significance with P value < 0.001. Group II was formed of 51 patients, with an average age of 75 years. URO17(R) was shown to have a sensitivity of 85.71% and NPV of 95.45. Eleven patients of group II were on scheduled BacillusCalmette-Guerin (BCG) and another 5 received Mitomycin C (MMC). The overall results of both groups combined (n = 149) showed statistical significance between flexible cystoscopy results and the results of urinary URO17(R) and urine cytology. CONCLUSION: URO17(R) has a potential to be a reliable test for diagnosis and follow up of urothelial cancer patients and a screening tool adjunct to flexible cystoscopy. TRIAL REGISTRATION: Not applicable as the current study is not a clinical trial, as per according to the National Institutes of Health, "studies that involve a comparison of methods and that do not evaluate the effect of the interventions on the participant do not meet the NIH clinical trial definition." CI - (c) 2024. Crown. FAU - Ibrahim, Mohamed AU - Ibrahim M AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. mohamed.ibrahim34@nhs.net. FAU - Rabinowitz, Joshua AU - Rabinowitz J AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Hilbert, Rebecca AU - Hilbert R AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Ghose, Aruni AU - Ghose A AD - Mount Vernon Hospital, Northwood, UK. FAU - Agarwal, Samita AU - Agarwal S AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Swamy, Rajiv AU - Swamy R AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Bulut, Ismail AU - Bulut I AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Guttierrez, Mirian AU - Guttierrez M AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. FAU - Buali, Ebtisam AU - Buali E AD - King Hamad University Hospital, Al Sayh, Bahrain. FAU - Nassar, Ekram AU - Nassar E AD - King Hamad University Hospital, Al Sayh, Bahrain. FAU - Jhavar, Parag AU - Jhavar P AD - King Hamad University Hospital, Al Sayh, Bahrain. FAU - Al-Hashimi, Fatima AU - Al-Hashimi F AD - King Hamad University Hospital, Al Sayh, Bahrain. FAU - Vasdev, Nikhil AU - Vasdev N AD - Department of Urology, Lister Hospital, East & North Hertfordshire NHS Trust, Coreys Mill Lane, Stevenage, Hertfordshire, UK. AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. LA - eng PT - Journal Article DEP - 20240209 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers) SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Follow-Up Studies MH - *Hematuria/diagnosis/etiology MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - Cystoscopy MH - Biomarkers MH - Neoplasm Recurrence, Local/diagnosis/pathology PMC - PMC10858619 OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive tumor OT - URO17(R) OT - Urothelial cancer OT - cancer follow-up COIS- The authors declare no competing interests. EDAT- 2024/02/10 13:18 MHDA- 2024/02/10 22:55 PMCR- 2024/02/09 CRDT- 2024/02/09 23:35 PHST- 2023/10/16 00:00 [received] PHST- 2024/02/01 00:00 [accepted] PHST- 2024/02/10 22:55 [medline] PHST- 2024/02/10 13:18 [pubmed] PHST- 2024/02/09 23:35 [entrez] PHST- 2024/02/09 00:00 [pmc-release] AID - 10.1186/s12894-024-01426-7 [pii] AID - 1426 [pii] AID - 10.1186/s12894-024-01426-7 [doi] PST - epublish SO - BMC Urol. 2024 Feb 9;24(1):34. doi: 10.1186/s12894-024-01426-7. PMID- 38329573 OWN - NLM STAT- MEDLINE DCOM- 20240620 LR - 20241001 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 56 IP - 7 DP - 2024 Jul TI - Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study. PG - 2243-2250 LID - 10.1007/s11255-023-03924-3 [doi] AB - AIM: Intravesical thermochemotherapy, also known as HIVEC (Hyperthermic Intra-VEsical Chemotherapy), represents an alternative adjuvant topical treatment for non-muscle-invasive urothelial bladder cancer (NMIBC). High-risk (HR) and very HR tumors carry a substantial risk of recurrence and progression. In this study, we present our own results using HIVEC as an alternative to unavailable Bacillus Calmette-Guerin (BCG) vaccine in the treatment of such groups of patients. METHODS: During the period of November 2014-June 2022, a total of 47 patients with HR and very HR NMIBC underwent treatment with HIVEC after transurethral resection. They were given an induction of 6 instillations with/without a maintenance. The aim was to evaluate the time to recurrence, event-free survival (recurrence or progression), as measured by Kaplan-Meier analysis, the effect of maintenance treatment and other factors on survival (log-rank test and multivariable Cox regression analysis), and complications. RESULTS: The median follow-up for patients who did not experience an event was 32 months. The median time to HR (high grade and/or T1 tumor) recurrence in those who recurred was 15 months. The survival rate without HR recurrence at 12, 24, and 48 months was 84, 70, and 59%, respectively. Progression was detected in 10.6% of patients, which translated to 89% of patients living without progression after 24 months. Maintenance treatment (defined as more than six instillations) and presence of CIS significantly correlated with risk of HR recurrence (Hazard ratio 0.34 and 3.12, respectively). One female patient underwent salvage cystectomy due to contractory bladder, and 19.1% of patients experienced transient lower urinary tract symptoms. CONCLUSION: Based on our experience, HIVEC represents an adequate and safe alternative treatment for HR and very HR NMIBC in situations where BCG is not available or radical cystectomy is not an option for the patient. However, high-quality data from prospective randomized studies are still lacking, and thus, thermochemotherapy should still be regarded as an experimental treatment modality. CI - (c) 2024. The Author(s). FAU - Brisuda, Antonin AU - Brisuda A AUID- ORCID: 0000-0001-5103-1358 AD - 2nd Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague 5, Czech Republic. antonin.brisuda@fnmotol.cz. FAU - Hornak, Jakub AU - Hornak J AD - 2nd Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague 5, Czech Republic. FAU - Zemlickova, Barbora AU - Zemlickova B AD - 2nd Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague 5, Czech Republic. FAU - Hacek, Jaromir AU - Hacek J AD - 2nd Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague 5, Czech Republic. FAU - Babjuk, Marek AU - Babjuk M AD - 2nd Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague 5, Czech Republic. LA - eng PT - Journal Article DEP - 20240208 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/therapy/pathology/drug therapy MH - Female MH - Male MH - Aged MH - Administration, Intravesical MH - *Hyperthermia, Induced MH - *Neoplasm Invasiveness MH - Middle Aged MH - Carcinoma, Transitional Cell/therapy/pathology/drug therapy MH - Risk Assessment MH - Aged, 80 and over MH - Retrospective Studies MH - Treatment Outcome PMC - PMC11190016 OTO - NOTNLM OT - Adjuvant instillations OT - Intravesical thermochemotherapy OT - Non-muscle-invasive bladder cancer OT - Urothelial carcinoma COIS- The authors declare having no conflict of interest regarding this work. EDAT- 2024/02/08 12:43 MHDA- 2024/06/20 12:43 PMCR- 2024/02/08 CRDT- 2024/02/08 11:11 PHST- 2023/09/14 00:00 [received] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/06/20 12:43 [medline] PHST- 2024/02/08 12:43 [pubmed] PHST- 2024/02/08 11:11 [entrez] PHST- 2024/02/08 00:00 [pmc-release] AID - 10.1007/s11255-023-03924-3 [pii] AID - 3924 [pii] AID - 10.1007/s11255-023-03924-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2024 Jul;56(7):2243-2250. doi: 10.1007/s11255-023-03924-3. Epub 2024 Feb 8. PMID- 38304824 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240203 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 2 DP - 2024 Jan 30 TI - Development and validation of a CT-based deep learning radiomics nomogram to predict muscle invasion in bladder cancer. PG - e24878 LID - 10.1016/j.heliyon.2024.e24878 [doi] LID - e24878 AB - OBJECTIVE: This study aimed to develop a nomogram combining CT-based handcrafted radiomics and deep learning (DL) features to preoperatively predict muscle invasion in bladder cancer (BCa) with multi-center validation. METHODS: In this retrospective study, 323 patients underwent radical cystectomy with pathologically confirmed BCa were enrolled and randomly divided into the training cohort (n = 226) and internal validation cohort (n = 97). And fifty-two patients from another independent medical center were enrolled as an independent external validation cohort. Handcrafted radiomics and DL features were constructed from preoperative nephrographic phase CT images. Least absolute shrinkage and selection operator (LASSO) regression was used to identify the most discriminative features in train cohort. Multivariate logistic regression was used to develop the predictive model and a deep learning radiomics nomogram (DLRN) was constructed. The predictive performance of models was evaluated by area under the curves (AUC) in the three cohorts. The calibration and clinical usefulness of DLRN were estimated by calibration curve and decision curve analysis. RESULTS: The nomogram that incorporated radiomics signature and DL signature demonstrated satisfactory predictive performance for differentiating non-muscle invasive bladder cancer (NMIBC) from muscle invasive bladder cancer (MIBC), with an AUC of 0.884 (95 % CI: 0.813-0.953) in internal validation cohort and 0.862 (95 % CI: 0.756-0.968) in external validation cohort, respectively. Decision curve analysis confirmed the clinical usefulness of the nomogram. CONCLUSIONS: A CT-based deep learning radiomics nomogram exhibited a promising performance for preoperative prediction of muscle invasion in bladder cancer, and may be helpful in the clinical decision-making process. CI - (c) 2024 The Authors. FAU - Wei, Zongjie AU - Wei Z AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Huayun AU - Liu H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xv, Yingjie AU - Xv Y AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liao, Fangtong AU - Liao F AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - He, Quanhao AU - He Q AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xie, Yongpeng AU - Xie Y AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Lv, Fajin AU - Lv F AD - Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Jiang, Qing AU - Jiang Q AD - Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xiao, Mingzhao AU - Xiao M AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20240117 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC10831750 OTO - NOTNLM OT - Bladder cancer OT - Computed tomography OT - Deep learning OT - Nomogram OT - Radiomics COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/02 06:42 MHDA- 2024/02/02 06:43 PMCR- 2024/01/17 CRDT- 2024/02/02 04:13 PHST- 2023/12/21 00:00 [received] PHST- 2024/01/16 00:00 [revised] PHST- 2024/01/16 00:00 [accepted] PHST- 2024/02/02 06:43 [medline] PHST- 2024/02/02 06:42 [pubmed] PHST- 2024/02/02 04:13 [entrez] PHST- 2024/01/17 00:00 [pmc-release] AID - S2405-8440(24)00909-5 [pii] AID - e24878 [pii] AID - 10.1016/j.heliyon.2024.e24878 [doi] PST - epublish SO - Heliyon. 2024 Jan 17;10(2):e24878. doi: 10.1016/j.heliyon.2024.e24878. eCollection 2024 Jan 30. PMID- 38302322 OWN - NLM STAT- MEDLINE DCOM- 20240926 LR - 20240926 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 5 DP - 2024 Oct TI - Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? PG - 1069-1079 LID - S2588-9311(24)00036-1 [pii] LID - 10.1016/j.euo.2024.01.011 [doi] AB - BACKGROUND: Age disparity in patients with non-muscle-invasive bladder cancer (NMIBC) exists. Whether this is due to differences in adequate cancer care or tumour biology is unclear. OBJECTIVE: To investigate age disparities in NMIBC using the Surveillance, Epidemiology, and End Results (SEER)-Medicare and UROMOL datasets. DESIGN, SETTING, AND PARTICIPANTS: The SEER-Medicare data were used to identify patients with clinical stage Ta, Tis, and T1 NMIBC between 2005 and 2017 (n = 32 225). Using the UROMOL cohort (n = 834), age disparities across transcriptomic, genomic, and spatial proteomic domains were assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For the SEER-Medicare data, multivariable competing-risk regression was used to examine the association between age and recurrence, progression, and bladder cancer-specific mortality (BCSM). For the UROMOL cohort, multivariable general linear model and multinomial logistic regression were performed to evaluate the association between age and tumour biology. RESULTS AND LIMITATIONS: An analysis of the SEER-Medicare cohort revealed 5-yr recurrence rates of 55.2%, 57.4%, and 58.9%; 5-yr progression rates of 25.6%, 29.2%, and 36.9%; and 5-yr BCSM rates of 3.9%, 5.8%, and 11.8% in patients aged 66-70, 71-80, and >/=81 yr, respectively. After multivariable adjustment, age >/=81 yr was associated with a higher risk of recurrence (hazard ratio [HR] 1.07, 95% confidence interval [CI] 1.03-1.12; p = 0.001), progression (HR 1.32, p < 0.001), and BCSM (HR 2.58, p < 0.001). UROMOL2021 transcriptomic class 2a was most frequently observed in patients with advanced age (34.0% in >/=76 yr vs 21.6% in /=76 yr (4.9% vs 24.2%; p = 0.001). Limitations include the definitions used for recurrence and progression, which may lead to under- or overestimation of true rates. CONCLUSIONS: Among SEER-Medicare patients with NMIBC, advanced age is associated with inferior oncological outcomes. These results reflect age-related molecular biological differences observed across transcriptomic and genomic domains, providing further evidence that innate tumour biology contributes to observed disparities in NMIBC outcomes. PATIENT SUMMARY: Older patients with non-muscle-invasive bladder cancer have worse oncological outcomes than younger patients. Some of this age disparity may be due to differences in tumour biology. CI - Copyright (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Lobo, Niyati AU - Lobo N AD - Department of Urology, Royal Free London NHS Trust, London, UK; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Duan, Zhigang AU - Duan Z AD - Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Sood, Akshay AU - Sood A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lindskrog, Sia V AU - Lindskrog SV AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Zhao, Hui AU - Zhao H AD - Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Giordano, Sharon H AU - Giordano SH AD - Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Urology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article DEP - 20240201 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/mortality/epidemiology MH - Aged MH - Female MH - Male MH - Aged, 80 and over MH - Age Factors MH - Neoplasm Invasiveness MH - SEER Program MH - United States/epidemiology MH - Medicare/statistics & numerical data MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Age OT - Disparity OT - Non-muscle-invasive bladder cancer OT - Tumour biology OT - UROMOL EDAT- 2024/02/02 00:42 MHDA- 2024/09/27 00:42 CRDT- 2024/02/01 22:00 PHST- 2023/10/28 00:00 [received] PHST- 2023/12/04 00:00 [revised] PHST- 2024/01/05 00:00 [accepted] PHST- 2024/09/27 00:42 [medline] PHST- 2024/02/02 00:42 [pubmed] PHST- 2024/02/01 22:00 [entrez] AID - S2588-9311(24)00036-1 [pii] AID - 10.1016/j.euo.2024.01.011 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Oct;7(5):1069-1079. doi: 10.1016/j.euo.2024.01.011. Epub 2024 Feb 1. PMID- 38302296 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 3 DP - 2024 Mar TI - Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. PG - 69.e17-69.e25 LID - S1078-1439(24)00003-6 [pii] LID - 10.1016/j.urolonc.2024.01.001 [doi] AB - BACKGROUND: In patients affected by high-risk nonmuscle invasive bladder cancer (HR-NMIBC) progression to muscle invasive status is considered as the main indicator of local treatment failure. We aimed to investigate the effect of progression and time to progression on overall survival (OS) and to investigate their validity as surrogate endpoints. METHODS: A total of 1,510 patients from 18 different institutions treated for T1 high grade NMIBC, followed by a secondary transurethral resection and BCG intravesical instillation. We relied on random survival forest (RSF) to rank covariates based on OS prediction. Cox's regression models were used to quantify the effect of covariates on mortality. RESULTS: During a median follow-up of 49.0 months, 485 (32.1%) patients progressed to MIBC, while 163 (10.8%) patients died. The median time to progression was 82 (95%CI: 78.0-93.0) months. In RSF time-to-progression and age were the most predictive covariates of OS. The survival tree defined 5 groups of risk. In multivariable Cox's regression models accounting for progression status as time-dependent covariate, shorter time to progression (as continuous covariate) was associated with longer OS (HR: 9.0, 95%CI: 3.0-6.7; P < 0.001). Virtually same results after time to progression stratification (time to progression >/=10.5 months as reference). CONCLUSION: Time to progression is the main predictor of OS in patients with high risk NMIBC treated with BCG and might be considered a coprimary endpoint. In addition, models including time to progression could be considered for patients' stratification in clinical practice and at the time of clinical trials design. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Porreca, Annamaria AU - Porreca A AD - Biostatistics Laboratory, Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti, Chieti, Italy. FAU - Di Nicola, Marta AU - Di Nicola M AD - Biostatistics Laboratory, Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti, Chieti, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Dorin, Vartolomei Mihai AU - Dorin VM AD - Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology from Targu Mures, Targu Mures, Romania. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University Federico II, Napoli, Italy. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Buonerba, Carlo AU - Buonerba C AD - CRTR Rare Tumors Reference Center, AOU Federico II, Napoli, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, University of Verona, Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Verona, Italy. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, University of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, La Sapienza University of Rome, Rome, Italy. FAU - Ferretti, Simone AU - Ferretti S AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, "G. d'Annunzio" University of Chieti, Chieti, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Prete, Paola Del AU - Prete PD AD - Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Department of Robotic Urologic Surgery, Abano Terme Hospital, Abano Terme, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Amparore, Daniele AU - Amparore D AD - Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Division of Urology, Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Rush University Medical Center, Chicago, IL. FAU - Piccinelli, Mattia AU - Piccinelli M AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Brescia, Antonio AU - Brescia A AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Tataru, Sabin Octavian AU - Tataru SO AD - I.O.S.U.D., George Emil Palade University of Medicine, Pharmacy, Sciences and Technology from Targu Mures, Targu Mures, Romania. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. FAU - Giudice, Arturo Lo AU - Giudice AL AD - Department of Urology, University of Catania, Catania, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Schips, Luigi AU - Schips L AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, "G. d'Annunzio" University of Chieti, Chieti, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, "G. d'Annunzio" University of Chieti, Chieti, Italy. Electronic address: mic.marchioni@gmail.com. LA - eng PT - Journal Article DEP - 20240201 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/surgery MH - Treatment Failure MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use MH - Retrospective Studies OTO - NOTNLM OT - Bacillus of Calmette-Guerin OT - High risk nonmuscle invasive bladder cancer OT - Overall survival OT - Progression-free survival OT - Surrogate endpoint COIS- Declaration of competing interest Each of the authors certify that the manuscript represents original and valid work that has not been previously published and is not currently under consideration by any other journal. Additionally, all the authors: have given final approval of the submitted manuscript approved the contents of this paper and have participated sufficiently in the work to take public responsibility for all content. None of the contributing authors have any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. No funding or other financial support was received. EDAT- 2024/02/02 00:42 MHDA- 2024/03/11 06:43 CRDT- 2024/02/01 21:59 PHST- 2023/06/10 00:00 [received] PHST- 2023/11/13 00:00 [revised] PHST- 2024/01/01 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2024/02/02 00:42 [pubmed] PHST- 2024/02/01 21:59 [entrez] AID - S1078-1439(24)00003-6 [pii] AID - 10.1016/j.urolonc.2024.01.001 [doi] PST - ppublish SO - Urol Oncol. 2024 Mar;42(3):69.e17-69.e25. doi: 10.1016/j.urolonc.2024.01.001. Epub 2024 Feb 1. PMID- 38296735 OWN - NLM STAT- MEDLINE DCOM- 20241206 LR - 20241206 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 6 DP - 2024 Dec TI - Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer. PG - 1327-1337 LID - S2588-9311(24)00037-3 [pii] LID - 10.1016/j.euo.2024.01.012 [doi] AB - BACKGROUND: Noncompliance with evidence-based interventions and guidelines contributes to significant and variable recurrence and progression in patients with non-muscle-invasive bladder cancer (NMIBC). The implementation of a quality performance indicator (QPI) programme in Scotland's National Health Service (NHS) aimed to improve cancer outcomes and reduce nationwide variance. OBJECTIVE: To evaluate the effect of hospitals achieving benchmarks for two specific QPIs on time to recurrence and progression in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: QPIs for bladder cancer (BC) were enforced nationally in April 2014. NHS health boards collected prospective data on all new BC patients. Prospectively recorded surveillance data were pooled from 12 collaborating centres. INTERVENTION: QPIs of interest were (1) hospitals achieving detrusor muscle (DM) sampling target at initial transurethral resection of bladder tumour (TURBT) and (2) use of single instillation of mitomycin C after TURBT (SI-MMC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary and secondary endpoints were time to recurrence and progression, respectively. Kaplan-Meier and Cox multivariable regression analyses were performed. KEY FINDINGS AND LIMITATIONS: Between April 1, 2014 and March 31, 2017, we diagnosed 3899 patients with new BC, of which 2688 were NMIBC . With a median follow up of 60.3 mo, hospitals achieving the DM sampling target had a 5.4% lower recurrence rate at 5 yr than hospitals not achieving this target (442/1136 [38.9%] vs 677/1528 [44.3%], 95% confidence interval [CI] = 1.6-9.2, p = 0.005). SI-MMC was associated with a 20.4% lower recurrence rate (634/1791 [35.4%] vs 469/840 [55.8%], 95% CI = 16.4-24.5, p < 0.001). On Cox multivariable regression, meeting the DM target and SI-MMC were associated with significant improvement in recurrence (hazard ratio [HR] 0.81, 95% CI = 0.73-0.91, p = 0.0002 and HR 0.66, 95% CI = 0.59-0.74, p < 0.004, respectively) as well as progression-free survival (HR 0.62, 95% CI = 0.45-0.84, p = 0.002 and HR 0.65, 95% CI = 0.49-0.87, p = 0.004, respectively). We did not have a national multicentre pre-QPI control. CONCLUSIONS: Within a national QPI programme, meeting targets for sampling DM and SI-MMC in the real world were independently associated with delays to recurrence and progression in NMIBC patients. PATIENT SUMMARY: Following the first 3 yr of implementing a novel quality performance indicator programme in Scotland, we evaluated compliance and outcomes in non-muscle-invasive bladder cancer. In 2688 patients followed up for 5 yr, we found that achieving targets for sampling detrusor muscle and the single instillation of mitomycin C during and after transurethral resection of bladder tumour, respectively, were associated with delays in cancer recurrence and progression. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; The University of Edinburgh, Edinburgh, UK. Electronic address: param.mariappan@nhslothian.scot.nhs.uk. FAU - Johnston, Allan AU - Johnston A AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. FAU - Trail, Matthew AU - Trail M AD - Department of Urology, Ninewells Hospital, Dundee, UK. FAU - Hamid, Sami AU - Hamid S AD - Department of Urology, Ninewells Hospital, Dundee, UK. FAU - Hollins, Graham AU - Hollins G AD - Department of Urology, University Hospital Ayr, Ayr, UK. FAU - Dreyer, Barend A AU - Dreyer BA AD - Department of Urology, Victoria Hospital, Kirkcaldy, UK. FAU - Ramsey, Sara AU - Ramsey S AD - Department of Urology, Raigmore Hospital, Inverness, UK. FAU - Padovani, Luisa AU - Padovani L AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Garau, Roberta AU - Garau R AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Enriquez, Julia Guerrero AU - Enriquez JG AD - Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK. FAU - Boden, Alasdair AU - Boden A AD - Department of Urology, University Hospital Monklands, Airdrie, UK. FAU - Maresca, Gianluca AU - Maresca G AD - Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Simpson, Helen AU - Simpson H AD - Department of Urology, Victoria Hospital, Kirkcaldy, UK. FAU - Hasan, Rami AU - Hasan R AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; Department of Urology, University Hospital Ayr, Ayr, UK. FAU - Sharpe, Claire AU - Sharpe C AD - Department of Urology, Dumfries & Galloway Royal Infirmary, Dumfries, UK. FAU - Thomas, Benjamin G AU - Thomas BG AD - Department of Urology, Borders General Hospital, Melrose, UK; Department of Urology, Western General Hospital, Edinburgh, UK. FAU - Chaudhry, Altaf H AU - Chaudhry AH AD - Department of Urology, Dumfries & Galloway Royal Infirmary, Dumfries, UK. FAU - Khan, Rehan S AU - Khan RS AD - Department of Urology, University Hospital Monklands, Airdrie, UK. FAU - Bhatt, Jaimin R AU - Bhatt JR AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. FAU - Ahmad, Imran AU - Ahmad I AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; School of Cancer Sciences, University of Glasgow, Glasgow, UK. FAU - Nandwani, Ghulam M AU - Nandwani GM AD - Department of Urology, Ninewells Hospital, Dundee, UK. FAU - Dimitropoulos, Konstantinos AU - Dimitropoulos K AD - Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Makaroff, Lydia AU - Makaroff L AD - Fight Bladder Cancer, Oxfordshire, UK; World Bladder Cancer Patient Coalition, Brussels, Belgium. FAU - Shaw, Johnstone AU - Shaw J AD - Fight Bladder Cancer, Scotland, UK. FAU - Graham, Catriona AU - Graham C AD - Edinburgh Clinical Research Facility, The University of Edinburgh, Edinburgh, UK. FAU - Hendry, David AU - Hendry D AD - Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. CN - Scot BC Quality OPS Clinical Collaborative LA - eng PT - Journal Article DEP - 20240130 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/therapy MH - *Disease Progression MH - *Neoplasm Recurrence, Local/epidemiology MH - Male MH - *Benchmarking MH - Female MH - Aged MH - *Quality Indicators, Health Care MH - Middle Aged MH - Neoplasm Invasiveness MH - Scotland MH - Prospective Studies MH - Aged, 80 and over MH - Mitomycin/therapeutic use MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Evidence-based medicine OT - Guidelines OT - Non-muscle-invasive bladder cancer OT - Progression OT - Quality indicators OT - Quality performance indicator, Quality control OT - Recurrence OT - Transurethral resection of bladder tumour EDAT- 2024/02/01 00:42 MHDA- 2024/12/07 14:47 CRDT- 2024/01/31 22:00 PHST- 2023/10/22 00:00 [received] PHST- 2023/12/04 00:00 [revised] PHST- 2024/01/04 00:00 [accepted] PHST- 2024/12/07 14:47 [medline] PHST- 2024/02/01 00:42 [pubmed] PHST- 2024/01/31 22:00 [entrez] AID - S2588-9311(24)00037-3 [pii] AID - 10.1016/j.euo.2024.01.012 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Dec;7(6):1327-1337. doi: 10.1016/j.euo.2024.01.012. Epub 2024 Jan 30. PMID- 38277354 OWN - NLM STAT- MEDLINE DCOM- 20240129 LR - 20260603 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 1 DP - 2024 TI - Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas. PG - e0297141 LID - 10.1371/journal.pone.0297141 [doi] LID - e0297141 AB - Non-muscle invasive papillary urothelial carcinoma is a prevalent disease with a high recurrence tendency. Good prognostic and reproducible biomarkers for tumor recurrence and disease progression are lacking. Currently, WHO grade and tumor stage are essential in risk stratification and treatment decision-making. Here we present the prognostic value of proliferation markers (Ki67, mitotic activity index (MAI) and PPH3) together with p53, CD25 and CK20 immunohistochemistry (IHC). In this population-based retrospective study, 349 primary non-muscle invasive bladder cancers (NMIBC) were available. MAI and PPH3 were calculated manually according to highly standardized previously described methods, Ki-67 by the semi-automated QPRODIT quantification system, p53 and CD25 by the fully automated digital image analysis program Visipharm(R) and CK20 with the help of the semi-quantitative immunoreactive score (IRS). Survival analyses with log rank test, as well as univariate and multivariate Cox regression analyses were performed for all investigated variables. Age and multifocality were the only significant variables for tumor recurrence. All investigated variables, except gender, were significantly associated with stage progression. In multivariate analysis, MAI was the only prognostic variable for stage progression (p<0.001). CI - Copyright: (c) 2024 Kvikstad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Kvikstad, Vebjorn AU - Kvikstad V AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. FAU - Lillesand, Melinda AU - Lillesand M AUID- ORCID: 0000-0001-8898-1330 AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. FAU - Gudlaugsson, Einar AU - Gudlaugsson E AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Mangrud, Ok Malfrid AU - Mangrud OM AD - Cancer Registry of Norway, Oslo, Norway. FAU - Rewcastle, Emma AU - Rewcastle E AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. FAU - Skaland, Ivar AU - Skaland I AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Baak, Jan P A AU - Baak JPA AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Dr. Med. Jan Baak AS, Tananger, Norway. FAU - Janssen, Emiel A M AU - Janssen EAM AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. LA - eng PT - Journal Article DEP - 20240126 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Tumor Suppressor Protein p53 MH - Immunohistochemistry MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Biomarkers, Tumor MH - Ki-67 Antigen/metabolism MH - Prognosis MH - *Carcinoma in Situ/pathology MH - Cell Proliferation PMC - PMC10817121 COIS- The authors have declared that no competing interests exist. EDAT- 2024/01/26 18:42 MHDA- 2024/01/29 06:43 PMCR- 2024/01/26 CRDT- 2024/01/26 13:33 PHST- 2023/05/12 00:00 [received] PHST- 2023/12/28 00:00 [accepted] PHST- 2024/01/29 06:43 [medline] PHST- 2024/01/26 18:42 [pubmed] PHST- 2024/01/26 13:33 [entrez] PHST- 2024/01/26 00:00 [pmc-release] AID - PONE-D-23-12362 [pii] AID - 10.1371/journal.pone.0297141 [doi] PST - epublish SO - PLoS One. 2024 Jan 26;19(1):e0297141. doi: 10.1371/journal.pone.0297141. eCollection 2024. PMID- 38271926 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20240724 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 56 IP - 3 DP - 2024 Jul TI - Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma. PG - 877-884 LID - 10.4143/crt.2023.1219 [doi] AB - PURPOSE: We aimed to assess the effectiveness of early single intravesical administration of epirubicin in preventing intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. MATERIALS AND METHODS: Patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy between November 2018 and May 2022 were retrospectively reviewed. Intravesical epirubicin was administered within 48 hours if no evidence of leakage was observed. Epirubicin (50 mg) in 50 mL normal saline solution was introduced into the bladder via a catheter and maintained for 60 minutes. The severity of adverse events was graded using the Clavien-Dindo classification. We compared intravesical recurrence rate between the two groups. Multivariate analyses were performed to identify the independent predictors of bladder recurrence following radical nephroureterectomy. RESULTS: Epirubicin (n=55) and control (n=116) groups were included in the analysis. No grade 1 or higher bladder symptoms have been reported. A statistically significant difference in the intravesical recurrence rate was observed between the two groups (11.8% at 1 year in the epirubicin group vs. 28.4% at 1 year in the control group; log-rank p=0.039). In multivariate analysis, epirubicin instillation (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.20 to 0.93; p=0.033) and adjuvant chemotherapy (HR, 0.29; 95% CI, 0.13 to 0.65; p=0.003) were independently predictive of a reduced incidence of bladder recurrence. CONCLUSION: This retrospective review revealed that a single immediate intravesical instillation of epirubicin is safe and can reduce the incidence of intravesical recurrence after radical nephroureterectomy. However, further prospective trials are required to confirm these findings. FAU - Lee, Jong Hoon AU - Lee JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Chung Un AU - Lee CU AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Chung, Jae Hoon AU - Chung JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Song, Wan AU - Song W AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng GR - CDA 10-016/HX/HSRD VA/United States PT - Journal Article DEP - 20240117 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - 3Z8479ZZ5X (Epirubicin) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - *Epirubicin/administration & dosage/therapeutic use MH - Administration, Intravesical MH - Female MH - *Nephroureterectomy/methods MH - Male MH - Aged MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Neoplasm Recurrence, Local/prevention & control MH - Retrospective Studies MH - *Antibiotics, Antineoplastic/administration & dosage/therapeutic use MH - Middle Aged MH - Carcinoma, Transitional Cell/surgery/pathology MH - Aged, 80 and over MH - Ureteral Neoplasms/surgery/pathology/drug therapy PMC - PMC11261194 OTO - NOTNLM OT - Intravesical administration OT - Local neoplasm recurrence OT - Nephroureterectomy OT - Urologic neoplasms OT - Urothelium COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2024/01/26 00:43 MHDA- 2024/07/17 06:43 PMCR- 2024/07/01 CRDT- 2024/01/25 18:09 PHST- 2023/11/14 00:00 [received] PHST- 2024/01/16 00:00 [accepted] PHST- 2024/07/17 06:43 [medline] PHST- 2024/01/26 00:43 [pubmed] PHST- 2024/01/25 18:09 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - crt.2023.1219 [pii] AID - crt-2023-1219 [pii] AID - 10.4143/crt.2023.1219 [doi] PST - ppublish SO - Cancer Res Treat. 2024 Jul;56(3):877-884. doi: 10.4143/crt.2023.1219. Epub 2024 Jan 17. PMID- 38267301 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240907 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 3 DP - 2024 Mar TI - Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy. PG - 69.e11-69.e16 LID - S1078-1439(23)00487-8 [pii] LID - 10.1016/j.urolonc.2023.12.008 [doi] AB - INTRODUCTION: Variant histology (VH) of urothelial carcinoma is uncommon and frequently presents at the muscle-invasive stage. VH is considering a significant risk factor for progression among patients with nonmuscle invasive bladder cancer (NMIBC). While there is some debate, expert opinion is generally that upfront radical cystectomy (RC) should be consider for these patients. Limited data exists to support this position. In this study, we sought to examine the rate of upstaging and overall survival for patients with VH NMIBC against patients with pure urothelial NMIBC who underwent RC, to help clarify the optimal treatment strategy for these patients. METHODS: The institutional REDCap database was utilized to identify all patients with T1 and Ta bladder cancer that underwent RC over the study period (2004-2022). Matched-pair analysis was performed between patients with VH and pure urothelial NMIBC; 42 pairs were matched on prior intravesical therapy, presence of muscularis propria on transurethral resection of bladder tumor (TURBT), any carcinoma in situ presence on prior TURBTs, and final tumor staging on TURBT. The primary outcomes of interest were pathologic tumor upstaging rate at RC and overall survival. Secondary outcomes of interest included association of demographic or pretreatment variables with upstaging, and upstaging rates for specific variant histologies. RESULTS: Patients with VH NMIBC undergoing RC were upstaged at a significantly higher rate than a matched cohort of patients with pure urothelial NMIBC (73.8% vs. 52.4%, P = 0.0244) and among those upstaged, had significantly higher rates of pT3 to pT4 (54.7% vs. 23.8%, P = 0.0088). Rate of node positivity at RC for VH NMIBC was also higher compared to pure urothelial NMIBC (40.5% vs. 21.4%, P = 0.0389). Among histologic variants, patients with plasmacytoid and sarcomatoid subtypes demonstrated the highest rates of upstaging; differences were not statistically significant. The overall median survival was 28.4 months for patients with VH after RC compared to 155.1 months for patients with pure urothelial NMIBC (P = 0.009). CONCLUSION: Patients with VH NMIBC undergoing RC are at significantly higher risk of upstaging at RC when compared to patients with pure urothelial NMIBC and have worse overall survival. While this study supports the concept of an aggressive treatment approach for patients with VH NMIBC, improvements in understanding of the disease are necessary to improve outcomes. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - McFadden, J AU - McFadden J AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: jmcfadden2@iuhealth.org. FAU - Tachibana, I AU - Tachibana I AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Adra, N AU - Adra N AD - Department of Medicine, Division of Hematology/Oncology, Indiana University Hospital, Indianapolis, IN. FAU - Collins, K AU - Collins K AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, IN. FAU - Cary, C AU - Cary C AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Koch, M AU - Koch M AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Kaimakliotis, H AU - Kaimakliotis H AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Masterson, T A AU - Masterson TA AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Rice, K R AU - Rice KR AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. LA - eng PT - Journal Article DEP - 20240123 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Nat Rev Urol. 2024 Sep;21(9):519-520. doi: 10.1038/s41585-024-00886-8. PMID: 38649437 MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Cystectomy MH - *Non-Muscle Invasive Bladder Neoplasms MH - Urinary Bladder/pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - Nonmuscle invasive bladder cancer OT - Urothelial carcinoma OT - Variant histology COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/25 00:42 MHDA- 2024/03/11 06:44 CRDT- 2024/01/24 21:54 PHST- 2023/06/28 00:00 [received] PHST- 2023/11/12 00:00 [revised] PHST- 2023/12/11 00:00 [accepted] PHST- 2024/03/11 06:44 [medline] PHST- 2024/01/25 00:42 [pubmed] PHST- 2024/01/24 21:54 [entrez] AID - S1078-1439(23)00487-8 [pii] AID - 10.1016/j.urolonc.2023.12.008 [doi] PST - ppublish SO - Urol Oncol. 2024 Mar;42(3):69.e11-69.e16. doi: 10.1016/j.urolonc.2023.12.008. Epub 2024 Jan 23. PMID- 38267300 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 5 DP - 2024 May TI - Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm? PG - 161.e1-161.e8 LID - S1078-1439(24)00010-3 [pii] LID - 10.1016/j.urolonc.2024.01.009 [doi] AB - INTRODUCTION: Bladder cancer (BC) is an increasingly frequent malignancy worldwide. Several variant histologies (VH) have been described in BC with a distinct clinical behavior. OBJECTIVES: This study aims to assess the prognostic impact of VH in BC, comparing its outcomes to pure urothelial carcinoma PUC in both non-muscle invasive (NMIBC) and muscle-invasive (MIBC) settings. METHODS: We included patients with primary BC, comparing those with VH with those with PUC, with an age and sex-matched proportion of 1:3, considering stage at diagnosis, recurrence-free, progression-free, and overall survival (OS). A total of 616 patients were included in the study, (460 UC and 151 VH). RESULTS: After first TURBT, MIBC was present in 99 (64.1%) of patients with VH, and 95 (20.6%) with UC (p<0.001). Concerning NMIBC, we observed higher rates of progression to MIBC amid patients with VH (p=0.009). Nodal involvement (p=0.020) and metastatic disease (p<0.001) were significantly higher within the VH group. A higher OS was observed among patients with NMIBC of PUC (p<0.001). There were no statistically significant differences of metastasis-free survival and OS between VH and UC groups within the MIBC setting. CONCLUSION: We confirmed that VH presents a more aggressive clinical course compared to PUC. An earlier radical treatment within the NMIBC setting could increase the oncological outcomes of the VH patients. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Ramos, Pedros AU - Ramos P AD - School of Medicine, University of Minho, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; Department of Urology, Centro Hosspitalar Sao Joao, Porto, Portugal. Electronic address: pedror1mb@gmail.com. FAU - Mateus, Andre AU - Mateus A AD - School of Medicine, University of Minho, Braga, Portugal. FAU - Manso, Margarida AU - Manso M AD - Department of Urology, Centro Hosspitalar Sao Joao, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Botelho, Francisco AU - Botelho F AD - School of Medicine, University of Minho, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; Department of Urology, Centro Hosspitalar Sao Joao, Porto, Portugal. FAU - Silva, Andre AU - Silva A AD - Faculty of Medicine, University of Porto, Porto, Portugal; Department of Urology, Trofa Saude Private Hospitals, Portugal. FAU - Silva, Joao AU - Silva J AD - Department of Urology, Centro Hosspitalar Sao Joao, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Silva, Carlos AU - Silva C AD - Department of Urology, Centro Hosspitalar Sao Joao, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Pacheco-Figueiredo, Luis AU - Pacheco-Figueiredo L AD - School of Medicine, University of Minho, Braga, Portugal; Department of Urology, Trofa Saude Private Hospitals, Portugal. LA - eng PT - Journal Article DEP - 20240123 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Nat Rev Urol. 2024 Sep;21(9):519-520. doi: 10.1038/s41585-024-00886-8. PMID: 38649437 MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - *Carcinoma, Transitional Cell/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - Cystectomy MH - Retrospective Studies OTO - NOTNLM OT - Cystectomy OT - Risk stratification OT - Urinary bladder neoplasms OT - Variant histology COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/25 00:42 MHDA- 2024/04/15 06:44 CRDT- 2024/01/24 21:54 PHST- 2023/10/15 00:00 [received] PHST- 2023/12/22 00:00 [revised] PHST- 2024/01/07 00:00 [accepted] PHST- 2024/04/15 06:44 [medline] PHST- 2024/01/25 00:42 [pubmed] PHST- 2024/01/24 21:54 [entrez] AID - S1078-1439(24)00010-3 [pii] AID - 10.1016/j.urolonc.2024.01.009 [doi] PST - ppublish SO - Urol Oncol. 2024 May;42(5):161.e1-161.e8. doi: 10.1016/j.urolonc.2024.01.009. Epub 2024 Jan 23. PMID- 38264853 OWN - NLM STAT- MEDLINE DCOM- 20240327 LR - 20260306 IS - 1744-7666 (Electronic) IS - 1465-6566 (Linking) VI - 25 IP - 2 DP - 2024 Feb TI - Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? PG - 203-214 LID - 10.1080/14656566.2024.2310073 [doi] AB - INTRODUCTION: The combination of intravesical gemcitabine (Gem) with docetaxel (Doce) or with mitomycin C (MMC) has been used in the primary setting as an alternative to Bacillus Calmette-Guerin (BCG) to treat high-risk (HR) and intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC), as well in the rescue setting for patients in whom BCG has failed. AREA COVERED: Efficacy and safety of Gem/Doce and Gem/MMC to treat NMIBC in BCG-naive and failure settings. EXPERT OPINION: In the BCG-naive setting, Gem/Doce was the primary alternative combination therapy reported, with a weighted mean of 12- and 24-month recurrence-free survival (RFS) of 79% and 77% for HR disease and 84% and 76% for IR disease, respectively. In the HR BCG-failure setting, the weighted mean of 12- and 24-month RFS was 60% and 42% for Gem/Doce and 63% and 40% for Gem/MMC. While patients without BCG exposure and papillary disease only benefit the most from Gem/Doce, there is also reasonable efficacy in BCG refractory disease and CIS. Combination therapy is well tolerated, with grade III toxicity reported in less than 1% of patients. Unlike single-agent chemotherapy, intravesical Gem/Doce is considered effective and safe regardless of risk-stratification. FAU - Abou Chakra, Mohamad AU - Abou Chakra M AD - Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Jersey, NJ, USA. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin Hospital, Paris, France. FAU - McElree, Ian M AU - McElree IM AD - Carver College of Medicine, University of Iowa, Iowa City, IA, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA. LA - eng GR - P30 CA086862/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20240130 PL - England TA - Expert Opin Pharmacother JT - Expert opinion on pharmacotherapy JID - 100897346 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Docetaxel/therapeutic use MH - Gemcitabine MH - Mitomycin/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - BCG failure OT - BCG naive OT - Non-muscle invasive OT - bladder cancer OT - docetaxel OT - gemcitabine OT - intravesical OT - mitomycin C EDAT- 2024/01/24 06:43 MHDA- 2024/03/27 06:43 CRDT- 2024/01/24 04:33 PHST- 2024/03/27 06:43 [medline] PHST- 2024/01/24 06:43 [pubmed] PHST- 2024/01/24 04:33 [entrez] AID - 10.1080/14656566.2024.2310073 [doi] PST - ppublish SO - Expert Opin Pharmacother. 2024 Feb;25(2):203-214. doi: 10.1080/14656566.2024.2310073. Epub 2024 Jan 30. PMID- 38263921 OWN - NLM STAT- MEDLINE DCOM- 20240125 LR - 20240914 IS - 2724-7031 (Electronic) IS - 0041-4131 (Print) IS - 0041-4131 (Linking) VI - 101 IP - 3 DP - 2023 Mar 5 TI - Predictive factors of bladder tumor recurrence after radical treatment of upper urinary tract cancer. PG - 356-361 AB - INTRODUCTION: The main problem after Radical Nephroureterectomy (RNU) for localized non-metastatic upper urinary tract urothelial cancer (NM-UUT-UC) is bladder recurrence. AIM: To identify factors of bladder recurrence of localized NM-UUT-UC after radical treatment. METHODS: It is an analytical and observational study that was conducted in the department of urology of La Rabta Hospital in Tunis. We collected the data of patients diagnosed with localized NM-UUT-UC who had RNU between 2005 and 2019. RESULTS: The mean age of the 73 eligible patients was 68 years (+/-11). The sex ratio was 5/2. Macroscopic hematuria was the revealing clinical sign in 66% of patients, while low back pain was the most frequent sign in 88% of patients. The most frequent tumor stage was pT1 in 20 patients while 32% of them had a pT2-T3 stage. Bladder recurrence was reported in 22% of patients with a median time of nine months [4-27] and extremes of three and 69 months. Factors of bladder recurrence in the univariate analysis were smoking, tumor localization in the ureter and the extravesical excision of the intramural ureter and bladder cuff. On multivariate analysis, the only independent predictor of bladder tumor recurrence was ureteral location (OR=3.65; CI95%=[1.02-13.1] ; p=0.047). CONCLUSION: Tumor localization in the ureter was an independent predictor of bladder recurrence after radical treatment for localized NM-UUT-UC. FAU - Ouanes, Yassine AU - Ouanes Y AD - Department of Urology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. FAU - Chaker, Kays AU - Chaker K AD - Department of Urology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. FAU - Yaich, Slaheddine AU - Yaich S AD - Department of Urology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. FAU - Foued, Daly AU - Foued D AD - Department of Cardiology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. FAU - Marrak, Mahdi AU - Marrak M AD - Department of Urology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. FAU - Nouira, Yassine AU - Nouira Y AD - Department of Urology, La Rabta Hospital. Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia. LA - eng PT - Journal Article PT - Observational Study DEP - 20230305 PL - Tunisia TA - Tunis Med JT - La Tunisie medicale JID - 0413766 SB - IM MH - Humans MH - Aged MH - Urinary Bladder MH - Neoplasm Recurrence, Local MH - *Urologic Neoplasms MH - *Urinary Bladder Neoplasms MH - *Kidney Neoplasms PMC - PMC11389700 OAB - INTRODUCTION: The main problem after Radical Nephroureterectomy (RNU) for localized non-metastatic upper urinary tract urothelial cancer (NM-UUT-UC) is bladder recurrence. AIM : To identify factors of bladder recurrence of localized NM-UUT-UC after radical treatment. METHODS : It is an analytical and observational study that was conducted in the department of urology of La Rabta Hospital in Tunis. We collected the data of patients diagnosed with localized NM-UUT-UC who had RNU between 2005 and 2019. RESULTS : The mean age of the 73 eligible patients was 68 years (+/-11). The sex ratio was 5/2. Macroscopic hematuria was the revealing clinical sign in 66% of patients, while low back pain was the most frequent sign in 88% of patients. The most frequent tumor stage was pT1 in 20 patients while 32% of them had a pT2-T3 stage. Bladder recurrence was reported in 22% of patients with a median time of nine months [4-27] and extremes of three and 69 months. Factors of bladder recurrence in the univariate analysis were smoking, tumor localization in the ureter and the extravesical excision of the intramural ureter and bladder cuff. On multivariate analysis, the only independent predictor of bladder tumor recurrence was ureteral location (OR=3.65; CI95%=[1.02-13.1] ; p=0.047). CONCLUSION : Tumor localization in the ureter was an independent predictor of bladder recurrence after radical treatment for localized NM-UUT-UC. OABL- eng EDAT- 2024/01/24 06:42 MHDA- 2024/01/25 06:43 PMCR- 2023/03/05 CRDT- 2024/01/24 03:35 PHST- 2023/06/02 00:00 [received] PHST- 2023/06/11 00:00 [accepted] PHST- 2024/01/25 06:43 [medline] PHST- 2024/01/24 06:42 [pubmed] PHST- 2024/01/24 03:35 [entrez] PHST- 2023/03/05 00:00 [pmc-release] PST - epublish SO - Tunis Med. 2023 Mar 5;101(3):356-361. PMID- 38260237 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241023 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 9 IP - 1 DP - 2024 Jan TI - Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection. PG - 101302 LID - 10.1016/j.adro.2023.101302 [doi] LID - 101302 AB - PURPOSE: The aim of this study was to determine whether escalating the local radiation dose can improve the outcome of residual bladder cancer after transurethral resection of bladder tumor without increasing treatment-related toxicity. METHODS AND MATERIALS: The treatment plans and medical records of patients with bladder cancer treated with curative-intent radiation therapy between 2008 and 2020 were reviewed. Those who had residual tumors in the computed tomography simulation images were included. A cumulative radiation dose higher than 6600 cGy was defined as dose escalation. The effect of dose escalation on 3-year locoregional control, progression-free survival, and overall survival was evaluated. RESULTS: A total of 149 patients with residual tumors were identified. The median follow-up period was 27.5 months. Among them, 51 patients received an escalated radiation dose, and 98 received a standard dose in the residual tumor area. Patients in the dose-escalation group had higher 3-year locoregional control (65.6% vs 27.8%; P < .001) and progression-free survival (42.6% vs 18.2%; P < .001) than the standard-dose group. Overall survival also showed a trend favoring the dose-escalation group (54.9% vs 36.2%; P = .059). In the multivariate analyses, the differences between the dose-escalation and standard-dose groups were significant in terms of locoregional control (hazard ratio, 0.32; CI, 0.18-0.59; P = <.001) and progression-free survival (hazard ratio, 0.51; CI, 0.32-0.82; P = .005). There was no statistical difference in acute and chronic treatment-related toxicities between the 2 groups. CONCLUSIONS: The outcome of residual bladder cancer after transurethral resection of bladder tumor could be improved by dose-escalated radiation therapy. CI - (c) 2023 The Authors. FAU - Chang, Yu-Chen AU - Chang YC AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. FAU - Wu, Yao-Yu AU - Wu YY AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. FAU - Tsan, Din-Li AU - Tsan DL AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. AD - Department of Radiation Oncology, Chang Gung Memorial Hospital, Keelung, Taiwan. FAU - Yap, Wing-Keen AU - Yap WK AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. FAU - Fan, Kan-Hsin AU - Fan KH AD - Department of Radiation Oncology, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan. FAU - Chang, Joseph Tung-Chieh AU - Chang JT AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. FAU - Shen, Eric Yi-Liang AU - Shen EY AD - Department of Radiation Oncology and Proton Therapy Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan City, Taiwan. AD - Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom. AD - Clinical Metabolomics Core Lab, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20240112 PL - United States TA - Adv Radiat Oncol JT - Advances in radiation oncology JID - 101677247 PMC - PMC10801638 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/23 12:42 MHDA- 2024/01/23 12:43 PMCR- 2024/01/12 CRDT- 2024/01/23 10:35 PHST- 2022/11/28 00:00 [received] PHST- 2023/03/26 00:00 [accepted] PHST- 2024/01/23 12:43 [medline] PHST- 2024/01/23 12:42 [pubmed] PHST- 2024/01/23 10:35 [entrez] PHST- 2024/01/12 00:00 [pmc-release] AID - S2452-1094(23)00130-6 [pii] AID - 101302 [pii] AID - 10.1016/j.adro.2023.101302 [doi] PST - epublish SO - Adv Radiat Oncol. 2024 Jan 12;9(1):101302. doi: 10.1016/j.adro.2023.101302. eCollection 2024 Jan. PMID- 38247255 OWN - NLM STAT- MEDLINE DCOM- 20250421 LR - 20260918 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 43 IP - 5 DP - 2025 Mar TI - Novel integrated Omics based computational approach for drug repurposing for non-muscle invasive bladder cancer (NMIBC). PG - 2560-2570 LID - 10.1080/07391102.2024.2302343 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) refers to a subtype of bladder carcinoma where cancer is localized in the inner lining of bladder. NMIBC consider as one of most costly malignancy and requires significant surgical and therapeutic measure. However, recurrence and progression of tumor is common in treated patients. Here we presented an integrated OMICs approach for the identification and inhibition of NMIBC specific genes. We utilized a case study where three group of patients were compared: 1) Relapsed tumors 2) recurrent tumors and 3) tumor in progression. Common transcriptome signature between patients facing recurrence and progression allowed us to identify three NMIBC specific genes FLT-1, WHSC-1 and CD34. We further utilized novel approach of Co-expressed gene-set enrichment analysis (COGENA) on the differentially expressed genes of this case study. Three drugs (paroxetine, adiphenine and H-89) with role of receptors inhibition were identified and predicted as repurposed drugs for the inhibition NMIBC specific genes. We further tested this hypothesis by performing molecular docking and simulation analysis between cancer specific proteins and drugs. FLT-1 have shown significant stable interaction with both drugs paroxetine and adiphenine whereas WHSC-1 have shown compact interaction with adiphenine and H-89. In the light of these evidence, we suggest that adiphenine could be repositioned as alternate targeted medicine for the treatment of NMIBC. In the future, this study will help for strengthening the strategies development at the molecular level for the control of carcinomas at early as well as detection of active and binding site, receptor-ligand interaction and also make drug repurposing for the early treatment of the carcinomas. FAU - Liu, Tiantian AU - Liu T AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. FAU - Ul-Haq, Waqar- AU - Ul-Haq W AD - Evolutionary Biology Lab, CABB, University of Agriculture Faisalabad, Pakistan. FAU - Tang, Qing AU - Tang Q AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. FAU - Li, Wei AU - Li W AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. FAU - Wang, Zhixia AU - Wang Z AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. FAU - Shan, Qiujie AU - Shan Q AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. FAU - Serfraz, Saad AU - Serfraz S AD - Evolutionary Biology Lab, CABB, University of Agriculture Faisalabad, Pakistan. FAU - Shakir, Yasmeen AU - Shakir Y AD - Department of Biochemistry, Hazara University, Mansehra, Khyber Pakhtunkhua, Pakistan. FAU - Ullah Kakar, Mohib AU - Ullah Kakar M AD - Faculty of Marine Sciences, Lasbela University of Agriculture, Water and Marine Sciences, Uthal, Balochistan, Pakistan. FAU - Sun, Lizhu AU - Sun L AD - The Department of Oncology, Affiliated with Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240121 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology/metabolism MH - *Drug Repositioning/methods MH - Molecular Docking Simulation MH - Gene Expression Regulation, Neoplastic/drug effects MH - Transcriptome MH - *Antineoplastic Agents/chemistry/pharmacology/therapeutic use MH - *Computational Biology/methods MH - Gene Expression Profiling MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - COGENA OT - Drug repurposing OT - adiphenine OT - bladder cancer OT - paroxetine OT - urothelial carcinoma EDAT- 2024/01/22 06:42 MHDA- 2025/02/13 12:27 CRDT- 2024/01/22 02:13 PHST- 2025/02/13 12:27 [medline] PHST- 2024/01/22 06:42 [pubmed] PHST- 2024/01/22 02:13 [entrez] AID - 10.1080/07391102.2024.2302343 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2025 Mar;43(5):2560-2570. doi: 10.1080/07391102.2024.2302343. Epub 2024 Jan 21. PMID- 38238965 OWN - NLM STAT- MEDLINE DCOM- 20240417 LR - 20250825 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 133 Suppl 4 DP - 2024 Apr TI - Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation. PG - 44-52 LID - 10.1111/bju.16226 [doi] AB - OBJECTIVE: To evaluate near-infrared (NIR) spectroscopy in differentiating between benign and malignant bladder pathologies ex vivo immediately after resection, including the grade and stage of malignancy. PATIENTS AND METHODS: A total of 355 spectra were measured on 71 bladder specimens from patients undergoing transurethral resection of bladder tumour (TURBT) between April and August 2022. Scan time was 5 s, undertaken using a portable NIR spectrometer within 10 min from excision. Specimens were then sent for routine histopathological correlation. Machine learning models were applied to the spectral dataset to construct diagnostic algorithms; these were then tested for their ability to predict the histological diagnosis of each sample using its NIR spectrum. RESULTS: A two-group algorithm comparing low- vs high-grade urothelial cancer demonstrated 97% sensitivity, 99% specificity, and the area under the receiver operating characteristic curve (AUC) was 0.997. A three-group algorithm predicting stages Ta vs T1 vs T2 achieved 97% sensitivity, 92% specificity, and the AUC was 0.996. CONCLUSIONS: This first study evaluating the diagnostic potential of NIR spectroscopy in urothelial cancer shows that it can be accurately used to assess tissue in an ex vivo setting immediately after TURBT. This offers point-of-care assessment of bladder pathology, with potential to influence the extent of resection, reducing both the need for re-resection where invasive disease may be suspected, and also the potential for complications where extent of diagnostic resection can be limited. Further studies utilising fibre-optic probes offer the potential for in vivo assessment. CI - (c) 2023 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Yim, Arthur AU - Yim A AD - Department of Urology, Austin Health, Heidelberg, Victoria, Australia. AD - Young Urology Researchers Organisation (YURO), Melbourne, Victoria, Australia. FAU - Alberto, Matthew AU - Alberto M AD - Department of Urology, Austin Health, Heidelberg, Victoria, Australia. FAU - Sharma, Varun AU - Sharma V AD - Department of Cardiac Surgery, Austin Health, Heidelberg, Victoria, Australia. AD - Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. AD - Spectromix Lab, Melbourne, Victoria, Australia. FAU - Green, Alexander AU - Green A AD - Centre for Biospectroscopy, Monash University, Clayton, Victoria, Australia. FAU - Mclean, Aaron AU - Mclean A AD - Centre for Biospectroscopy, Monash University, Clayton, Victoria, Australia. FAU - du Plessis, Justin AU - du Plessis J AD - Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia. FAU - Wong, Lih-Ming AU - Wong LM AD - Department of Urology, Austin Health, Heidelberg, Victoria, Australia. FAU - Wood, Bayden AU - Wood B AD - Spectromix Lab, Melbourne, Victoria, Australia. AD - Centre for Biospectroscopy, Monash University, Clayton, Victoria, Australia. FAU - Ischia, Joseph AU - Ischia J AD - Department of Urology, Austin Health, Heidelberg, Victoria, Australia. FAU - Raman, Jaishankar AU - Raman J AD - Department of Cardiac Surgery, Austin Health, Heidelberg, Victoria, Australia. AD - Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. AD - Spectromix Lab, Melbourne, Victoria, Australia. FAU - Bolton, Damien AU - Bolton D AD - Department of Urology, Austin Health, Heidelberg, Victoria, Australia. LA - eng PT - Journal Article DEP - 20240118 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - Urinary Bladder/pathology MH - Spectroscopy, Near-Infrared MH - *Urinary Bladder Neoplasms/diagnosis/surgery/pathology MH - *Carcinoma, Transitional Cell/diagnosis/surgery MH - Cystectomy/methods OTO - NOTNLM OT - bladder cancer OT - diagnosis OT - machine learning OT - near-infrared OT - point-of-care OT - spectroscopy OT - urothelial cell carcinoma COIS- All authors declare that they have no conflicts of interest. Dr Jaishankar Raman is a founder of the Spectromix Lab, a non-commercial organisation. EDAT- 2024/01/19 06:42 MHDA- 2024/04/17 06:42 CRDT- 2024/01/19 00:33 PHST- 2024/04/17 06:42 [medline] PHST- 2024/01/19 06:42 [pubmed] PHST- 2024/01/19 00:33 [entrez] AID - 10.1111/bju.16226 [doi] PST - ppublish SO - BJU Int. 2024 Apr;133 Suppl 4:44-52. doi: 10.1111/bju.16226. Epub 2024 Jan 18. PMID- 38228414 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240410 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 2 DP - 2024 Apr TI - Bladder-Preserving Trimodality Therapy With Capecitabine. PG - 476-482.e1 LID - S1558-7673(24)00003-X [pii] LID - 10.1016/j.clgc.2024.01.002 [doi] AB - INTRODUCTION: Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy with maximal transurethral resection of bladder tumor (TURBT) and chemoradiotherapy with cisplatin or mitomycin C. Given the benefit of chemotherapy in bladder-preserving therapy, less-intense concurrent chemotherapy regimens are needed. This study reports on efficacy and toxicity for patients treated with trimodality therapy using single-agent concurrent capecitabine. MATERIALS AND METHODS: Patients deemed ineligible for radical cystectomy or standard chemoradiotherapy by a multidisciplinary tumor board and patients who refused cystectomy were included. Following TURBT, patients received twice-daily capecitabine (goal dose 825 mg/m(2)) concurrent with radiotherapy to the bladder +/- pelvis depending on nodal staging and patient risk factors. Toxicity was evaluated prospectively in weekly on-treatment visits and follow-up visits by the treating physicians. Descriptive statistics are provided. Overall, progression-free, cancer-specific, distant metastasis-free, and bladder recurrence-free survival were estimated using the Kaplan-Meier method. RESULTS: Twenty-seven consecutive patients met criteria for inclusion from 2013 to 2023. The median age was 79 with 9 patients staged cT3-4a and 7 staged cN1-3. The rate of complete response in the bladder and pelvis was 93%. Overall, progression-free, cancer-specific, distant metastasis-free, and bladder recurrence-free survival at 2 years were estimated as 81%, 65%, 91%, 75%, and 92%, respectively. There were 2 bladder recurrences, both noninvasive. There were 7 grade 3 acute hematologic or metabolic events but no other grade 3+ toxicities. CONCLUSION: Maximal TURBT followed by radiotherapy with concurrent capecitabine offers a high rate of bladder control and low rates of acute and late toxicity. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Lynch, Connor AU - Lynch C AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. FAU - Sweis, Randy F AU - Sweis RF AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - Modi, Parth AU - Modi P AD - Department of Urology, University of Chicago, Chicago, IL. FAU - Agarwal, Piyush K AU - Agarwal PK AD - Department of Urology, University of Chicago, Chicago, IL. FAU - Szmulewitz, Russell Z AU - Szmulewitz RZ AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - Stadler, Walter M AU - Stadler WM AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - O'Donnell, Peter H AU - O'Donnell PH AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - Liauw, Stanley L AU - Liauw SL AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. FAU - Pitroda, Sean P AU - Pitroda SP AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. Electronic address: spitroda@uchicago.edu. LA - eng PT - Journal Article DEP - 20240109 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 6804DJ8Z9U (Capecitabine) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - Aged MH - Capecitabine/adverse effects MH - Combined Modality Therapy MH - *Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Cisplatin/therapeutic use MH - Cystectomy MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder cancer OT - Chemoradiation therapy OT - Radiation therapy COIS- Disclosure Walter M. Stadler: consultant for Astra-Zeneca, Merck, Pfizer, Treadwell Therapeutics, Caremark/CVS, EMA Wellness, Fortress Biotech; speaker's bureau for Dava Oncology, Global Academy for Medical Education, OncLive, PeerView, Research to Practice, Vindico; Grant/research support to the institution from Abbvie, Amgen, Astra-Zeneca, Astellas (Medivation), Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Calithera, Clovis, Corvus, Eisai, Exilixis, Genentech (Roche), Johnson & Johnson (Janssen), Merck, Novartis, Pfizer, Seattle Genetics, X4Pharmaceuticals, Xencor; stockholder in Fortress Biotech Peter H. O'Donnell: reports past research funding from the Translational Breast Cancer Research Consortium to perform pharmacogenomic studies related to capecitabine. The other authors does not have conflicts of interest to disclose. EDAT- 2024/01/17 00:42 MHDA- 2024/03/11 06:44 CRDT- 2024/01/16 21:55 PHST- 2023/12/03 00:00 [received] PHST- 2024/01/02 00:00 [revised] PHST- 2024/01/02 00:00 [accepted] PHST- 2024/03/11 06:44 [medline] PHST- 2024/01/17 00:42 [pubmed] PHST- 2024/01/16 21:55 [entrez] AID - S1558-7673(24)00003-X [pii] AID - 10.1016/j.clgc.2024.01.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Apr;22(2):476-482.e1. doi: 10.1016/j.clgc.2024.01.002. Epub 2024 Jan 9. PMID- 38228116 OWN - NLM STAT- MEDLINE DCOM- 20240404 LR - 20240404 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 108 IP - 2 DP - 2024 TI - Hemangioma of the Urinary Bladder: A Brief Narrative Review of Their Diagnosis, Histology, and Treatment Options. PG - 83-88 LID - 10.1159/000536057 [doi] AB - BACKGROUND: Hemangioma of the urinary bladder is a rare benign tumor. Although benign, their presenting symptoms are alarming for both patients and doctors, and their rarity makes them challenging to correctly diagnosis and treat. This review paper summarizes current knowledge about hemangioma of the urinary bladder, treatment options, and follow-up modalities. SUMMARY: After the kidney, the bladder is the second most common location of hemangiomas in the urinary tract. There is painless gross hematuria on clinical presentation once the lesion has eroded the urothelium. Magnetic resonance imaging (MRI) has been reported to be valuable in diagnosing soft-tissue hemangiomas. Cystoscopic findings of a sessile, blue, multilocular mass suggest hemangioma. Most tumors are solitary, smaller than 3 cm, and have smooth or irregular surfaces. Histologically, lesions comprise numerous proliferative capillaries with thin-walled, dilated, blood-filled vessels lined with flattened endothelium. The treatment of patients with hemangioma has been controversial. It depends on the tumor size and the degree of penetration. The prognosis of these tumors is excellent. KEY MESSAGES: Despite the widespread use of MRI, CT, and endoscopy in evaluating hematuria, hemangioma remains one of the rarest bladder tumors. Moreover, only a histological examination can confirm the diagnosis. Transurethral resection, fulguration, and YAG laser ablation are standard treatments for small tumors. In terms of follow-up, cystoscopy after 6 months of treatment helps assess recurrence. In addition, MRI is a practical, noninvasive technique for follow-up of small hemangiomas. CI - (c) 2024 S. Karger AG, Basel. FAU - Garaz, Radion AU - Garaz R AD - Department of Urology, University Hospital of Tubingen, Tubingen, Germany. FAU - Stuhler, Viktoria AU - Stuhler V AD - Department of Urology, University Hospital of Tubingen, Tubingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital of Tubingen, Tubingen, Germany. FAU - Rottscholl, Robert AU - Rottscholl R AD - Department of Pathology, University Hospital Tubingen, Tubingen, Germany. FAU - Amend, Bastian AU - Amend B AD - Department of Urology, University Hospital of Tubingen, Tubingen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20240116 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - Urinary Bladder/pathology MH - Hematuria/etiology/pathology MH - *Hemangioma/diagnosis/therapy/pathology MH - *Urinary Bladder Neoplasms/diagnosis/therapy/pathology MH - Cystoscopy OTO - NOTNLM OT - Bladder hemangiomas OT - Cystoscopy OT - Electrocoagulation OT - Magnetic resonance imaging EDAT- 2024/01/17 00:42 MHDA- 2024/04/04 06:44 CRDT- 2024/01/16 18:27 PHST- 2023/09/19 00:00 [received] PHST- 2023/12/28 00:00 [accepted] PHST- 2024/04/04 06:44 [medline] PHST- 2024/01/17 00:42 [pubmed] PHST- 2024/01/16 18:27 [entrez] AID - 000536057 [pii] AID - 10.1159/000536057 [doi] PST - ppublish SO - Urol Int. 2024;108(2):83-88. doi: 10.1159/000536057. Epub 2024 Jan 16. PMID- 38226931 OWN - NLM STAT- MEDLINE DCOM- 20240223 LR - 20240417 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 11 IP - 2 DP - 2024 Mar TI - Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin‒Unresponsive Nonmuscle-Invasive Bladder Cancer. PG - 367-375 LID - 10.1097/UPJ.0000000000000517 [doi] AB - INTRODUCTION: In the phase 2/3 study QUILT-3.032 (NCT03022825), the ability of the IL-15RalphaFc superagonist N-803 (nogapendekin alfa inbakicept) plus bacillus Calmette-Guerin (BCG) to elicit durable complete responses in patients with BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) was demonstrated. As a secondary end point, patient-reported outcomes (PROs) were assessed. METHODS: Both cohort A patients with carcinoma in situ with or without Ta/T1 disease and cohort B patients with high-grade Ta/T1 papillary disease who received N-803 plus BCG therapy completed the EORTC (European Organization for Research and Treatment of Cancer) Core 30 and Quality of Life NMIBC-Specific 24 questionnaires at baseline and months 6, 12, 18, and 24 on study. Scores were analyzed using descriptive statistics, and multivariable analyses were performed to identify baseline variables associated with PROs. RESULTS: On study, mean physical function (PF) and global health (GH) scores remained relatively stable from baseline for cohorts A (n = 86) and B (n = 78). At month 6, cohort A patients with a complete response reported higher PF scores than those without (P = .0659); at month 12, > 3 as compared with 4) and continuously coded CCI. RESULTS: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6-79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06-1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00-1.10, p = 0.04). CONCLUSIONS: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols. FAU - Scheipner, Lukas AU - Scheipner L AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Zurl, Hanna AU - Zurl H AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Altziebler, Julia V AU - Altziebler JV AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Pichler, Georg P AU - Pichler GP AUID- ORCID: 0000-0003-4906-3187 AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Schopfer-Schwab, Stephanie AU - Schopfer-Schwab S AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Jasarevic, Samra AU - Jasarevic S AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Gaisl, Michael AU - Gaisl M AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Pohl, Klara C AU - Pohl KC AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Pemberger, Karl AU - Pemberger K AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Andlar, Stefan AU - Andlar S AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Hutterer, Georg C AU - Hutterer GC AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Bele, Uros AU - Bele U AUID- ORCID: 0000-0002-8029-1586 AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Leitsmann, Conrad AU - Leitsmann C AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Leitsmann, Marianne AU - Leitsmann M AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. AD - Institute for Applied Quality Improvement and Research in Health Care, 37073 Goettingen, Germany. FAU - Augustin, Herbert AU - Augustin H AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Ahyai, Sascha AU - Ahyai S AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. FAU - Mischinger, Johannes AU - Mischinger J AUID- ORCID: 0000-0003-3593-0622 AD - Department of Urology, Medical University of Graz, 8010 Graz, Austria. LA - eng PT - Journal Article DEP - 20231208 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10742244 OTO - NOTNLM OT - CCI OT - Charlson comorbidity index OT - NMIBC OT - predictor OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2023/12/23 12:42 MHDA- 2023/12/23 12:43 PMCR- 2023/12/08 CRDT- 2023/12/23 01:03 PHST- 2023/11/04 00:00 [received] PHST- 2023/11/19 00:00 [revised] PHST- 2023/12/04 00:00 [accepted] PHST- 2023/12/23 12:43 [medline] PHST- 2023/12/23 12:42 [pubmed] PHST- 2023/12/23 01:03 [entrez] PHST- 2023/12/08 00:00 [pmc-release] AID - cancers15245770 [pii] AID - cancers-15-05770 [pii] AID - 10.3390/cancers15245770 [doi] PST - epublish SO - Cancers (Basel). 2023 Dec 8;15(24):5770. doi: 10.3390/cancers15245770. PMID- 38135946 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231225 IS - 2306-5354 (Print) IS - 2306-5354 (Electronic) IS - 2306-5354 (Linking) VI - 10 IP - 12 DP - 2023 Nov 25 TI - Radiomics Prediction of Muscle Invasion in Bladder Cancer Using Semi-Automatic Lesion Segmentation of MRI Compared with Manual Segmentation. LID - 10.3390/bioengineering10121355 [doi] LID - 1355 AB - Conventional radiomics analysis requires the manual segmentation of lesions, which is time-consuming and subjective. This study aimed to assess the feasibility of predicting muscle invasion in bladder cancer (BCa) with radiomics using a semi-automatic lesion segmentation method on T2-weighted images. Cases of non-muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) were pathologically identified in a training cohort and in internal and external validation cohorts. For bladder tumor segmentation, a deep learning-based semi-automatic model was constructed, while manual segmentation was performed by a radiologist. Semi-automatic and manual segmentation results were respectively used in radiomics analyses to distinguish NMIBC from MIBC. An equivalence test was used to compare the models' performance. The mean Dice similarity coefficients of the semi-automatic segmentation method were 0.836 and 0.801 in the internal and external validation cohorts, respectively. The area under the receiver operating characteristic curve (AUC) were 1.00 (0.991) and 0.892 (0.894) for the semi-automated model (manual) on the internal and external validation cohort, respectively (both p < 0.05). The average total processing time for semi-automatic segmentation was significantly shorter than that for manual segmentation (35 s vs. 92 s, p < 0.001). The BCa radiomics model based on semi-automatic segmentation method had a similar diagnostic performance as that of manual segmentation, while being less time-consuming and requiring fewer manual interventions. FAU - Ye, Yaojiang AU - Ye Y AD - Department of Radiology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. FAU - Luo, Zixin AU - Luo Z AD - Medical AI Lab, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. FAU - Qiu, Zhengxuan AU - Qiu Z AD - Medical AI Lab, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. FAU - Cao, Kangyang AU - Cao K AD - Medical AI Lab, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. FAU - Huang, Bingsheng AU - Huang B AD - Medical AI Lab, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. FAU - Deng, Lei AU - Deng L AD - Department of Radiology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. FAU - Zhang, Weijing AU - Zhang W AD - Imaging Department, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. FAU - Liu, Guoqing AU - Liu G AD - College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China. FAU - Zou, Yujian AU - Zou Y AD - Department of Radiology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. FAU - Zhang, Jian AU - Zhang J AD - Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. AD - Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen 518060, China. FAU - Li, Jianpeng AU - Li J AD - Department of Radiology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. LA - eng GR - 20211800905212/Dongguan Science and Technology of Social Development Program/ GR - 2020A1515010571/Guangdong Basic and Applied Basic Research Foundation/ GR - 2022SHIBS0003/Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions/ GR - JSGG20210713091539014/Shenzhen Science and Technology Innovation Commission Key Technical Project/ PT - Journal Article DEP - 20231125 PL - Switzerland TA - Bioengineering (Basel) JT - Bioengineering (Basel, Switzerland) JID - 101676056 PMC - PMC10740947 OTO - NOTNLM OT - magnetic resonance imaging OT - muscles OT - radiomics OT - semi-automatic segmentation OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2023/12/23 12:44 MHDA- 2023/12/23 12:45 PMCR- 2023/11/25 CRDT- 2023/12/23 01:01 PHST- 2023/09/22 00:00 [received] PHST- 2023/11/10 00:00 [revised] PHST- 2023/11/23 00:00 [accepted] PHST- 2023/12/23 12:45 [medline] PHST- 2023/12/23 12:44 [pubmed] PHST- 2023/12/23 01:01 [entrez] PHST- 2023/11/25 00:00 [pmc-release] AID - bioengineering10121355 [pii] AID - bioengineering-10-01355 [pii] AID - 10.3390/bioengineering10121355 [doi] PST - epublish SO - Bioengineering (Basel). 2023 Nov 25;10(12):1355. doi: 10.3390/bioengineering10121355. PMID- 38129811 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20241018 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 23 IP - 1 DP - 2023 Dec 21 TI - Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis. PG - 212 LID - 10.1186/s12894-023-01387-3 [doi] LID - 212 AB - BACKGROUND: Radical nephroureterectomy (RNU) is the primary treatment strategy for upper tract urothelial carcinoma (UTUC). However, the intravesical recurrence occurs in 20-50% of all patients. The specific effect of subsequent bladder cancer (SBCa) on survival remains unclear. Therefore, we investigated the effect of SBCa following RNU in patients with UTUC. METHODS: PubMed, EMBASE, and Cochrane Library were exhaustively searched for studies comparing oncological outcomes between SBCa and without SBCa. Standard cumulative analyses using hazard ratios (HR) with 95% confidence intervals (CI) were performed using Review Manager (version 5.3). RESULTS: Five studies involving 2057 patients were selected according to the predefined eligibility criteria. Meta-analysis of cancer-specific survival (CSS) and overall survival (OS) revealed no significant differences between the SBCa and non-SBCa groups. However, subgroup analysis of pT0-3N0M0 patients suggested that people with SBCa had worse CSS (HR = 5.13, 95%CI 2.39-10.98, p < 0.0001) and OS (HR = 4.00, 95%CI 2.19-7.31, p < 0.00001). CONCLUSIONS: SBCa appears to be associated with worse OS in patients with early stage UTUC. However, caution must be taken before recommendations are made because this interpretation is based on very few clinical studies and a small sample size. Research sharing more detailed surgical site descriptions, as well as enhanced outcome data collection and improved reporting, is required to further investigate these nuances. CI - (c) 2023. The Author(s). FAU - Hu, Haopu AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Wang, Mingrui AU - Wang M AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Tang, Xinwei AU - Tang X AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Lai, Chin-Hui AU - Lai CH AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Xu, Kexin AU - Xu K AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Hu, Hao AU - Hu H AD - Department of Urology, Peking University People's Hospital, Beijing, China. huhao@bjmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20231221 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - Nephroureterectomy MH - *Carcinoma, Transitional Cell/pathology MH - Retrospective Studies MH - *Ureteral Neoplasms/pathology PMC - PMC10734187 OTO - NOTNLM OT - Cancer- specific survival OT - Overall survival OT - Subsequent bladder cancer OT - Upper urinary tract urothelial carcinoma COIS- The authors declare no competing interests. EDAT- 2023/12/22 06:42 MHDA- 2023/12/25 06:42 PMCR- 2023/12/21 CRDT- 2023/12/22 00:20 PHST- 2023/06/17 00:00 [received] PHST- 2023/12/05 00:00 [accepted] PHST- 2023/12/25 06:42 [medline] PHST- 2023/12/22 06:42 [pubmed] PHST- 2023/12/22 00:20 [entrez] PHST- 2023/12/21 00:00 [pmc-release] AID - 10.1186/s12894-023-01387-3 [pii] AID - 1387 [pii] AID - 10.1186/s12894-023-01387-3 [doi] PST - epublish SO - BMC Urol. 2023 Dec 21;23(1):212. doi: 10.1186/s12894-023-01387-3. PMID- 38128940 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20240124 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 12 DP - 2023 Dec 20 TI - Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. PG - e075942 LID - 10.1136/bmjopen-2023-075942 [doi] LID - e075942 AB - PURPOSE: Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting. PARTICIPANTS: COBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up. FINDINGS TO DATE: We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage 10%) belong to the group with a lower risk of recurrence. The cancer in this group also frequently recurs after 12 months (p = 0.0005). CONCLUSIONS: The evaluation of CD4(+) and CD20(+) cells in the tumor microenvironment, in addition to PD-L1 on tumor cells, facilitates the determination of a group of patients with a low risk of recurrence. FAU - Semeniuk-Wojtas, Aleksandra AU - Semeniuk-Wojtas A AUID- ORCID: 0000-0001-9421-6694 AD - Oncology Department, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Modzelewska, Magdalena AU - Modzelewska M AD - Pathomorphology Department, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Poddebniak-Strama, Karolina AU - Poddebniak-Strama K AD - Oncology Department, 4 Military Clinical Hospital with a Polyclinic, 53-114 Wroclaw, Poland. FAU - Kolaczynska, Sylwia AU - Kolaczynska S AD - Oncology Department, 4 Military Clinical Hospital with a Polyclinic, 53-114 Wroclaw, Poland. FAU - Lubas, Arkadiusz AU - Lubas A AUID- ORCID: 0000-0002-3248-4615 AD - Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland. FAU - Gornicka, Barbara AU - Gornicka B AD - Pathomorphology Department, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Jakiela, Anna AU - Jakiela A AD - Oncology Department, 4 Military Clinical Hospital with a Polyclinic, 53-114 Wroclaw, Poland. FAU - Stec, Rafal AU - Stec R AD - Oncology Department, Medical University of Warsaw, 02-091 Warsaw, Poland. LA - eng GR - #68288599/Phizer PolskaSp z o.o./ PT - Journal Article DEP - 20231122 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10705362 OTO - NOTNLM OT - CD20 OT - CD4 OT - NMIBC OT - PD-L1 OT - bladder cancer OT - immune cells OT - tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2023/12/09 10:42 MHDA- 2023/12/09 10:43 PMCR- 2023/11/22 CRDT- 2023/12/09 01:03 PHST- 2023/10/23 00:00 [received] PHST- 2023/11/13 00:00 [revised] PHST- 2023/11/15 00:00 [accepted] PHST- 2023/12/09 10:43 [medline] PHST- 2023/12/09 10:42 [pubmed] PHST- 2023/12/09 01:03 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - cancers15235529 [pii] AID - cancers-15-05529 [pii] AID - 10.3390/cancers15235529 [doi] PST - epublish SO - Cancers (Basel). 2023 Nov 22;15(23):5529. doi: 10.3390/cancers15235529. PMID- 38065872 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240214 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 102 IP - 49 DP - 2023 Dec 8 TI - Incidence of intraoperative hypotension in older patients undergoing total intravenous anesthesia by remimazolam versus propofol: A randomized controlled trial. PG - e36440 LID - 10.1097/MD.0000000000036440 [doi] LID - e36440 AB - BACKGROUND: An increase in the frequency of surgeries among older individuals is observed in some countries. Hypotension is common and exaggerated in older patients and can lead to increased morbidity and mortality. Total intravenous anesthesia is commonly administered with propofol, while remimazolam has been suggested as an alternative to propofol because of advantages such as a more stable hemodynamic profile and less respiratory suppression. We conducted a single-blind, parallel-group randomized controlled trial to compare the incidence of intraoperative hypotension between patients administered with remimazolam and propofol. METHODS: A total of 132 patients, aged between 65 to 80 years and undergoing laparoscopic cholecystectomy or transurethral resection of bladder tumors were randomly assigned to the propofol or remimazolam group with a permuted block system while being blinded to the hypnotic agent. Remifentanil was administered via target-controlled infusion in both groups, with an initial effect-site concentration of 3.0 ng/mL and titration range of 1.5 to 4.0 ng/mL intraoperatively. The primary outcome of this study was the overall incidence of hypotension during general anesthesia. RESULTS: Patients in the propofol group experienced higher intraoperative hypotension than those in the remimazolam group (59.7% vs 33.3%, P = .006). Multivariate logistic regression analysis showed that remimazolam administration was associated with reduced hypotension (adjusted odds ratio, 0.34; 95% CI, 0.16-0.73). Secondary outcomes such as recovery time, delirium, and postoperative nausea and vomiting were comparable in both groups. CONCLUSION: Total intravenous anesthesia with remimazolam was associated with less intraoperative hypotension than propofol in older patients, with a comparable recovery profile. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Jeon, Yeong-Gwan AU - Jeon YG AUID- ORCID: 0000-0003-0486-0908 AD - Department of Anesthesiology and Pain Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea. FAU - Kim, Sujin AU - Kim S AUID- ORCID: 0000-0001-9220-4614 AD - Department of Anesthesiology and Pain Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea. FAU - Park, Ji-Hyoung AU - Park JH AUID- ORCID: 0000-0003-1320-411 AD - Department of Anesthesiology and Pain Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea. FAU - Lee, Jonghoon AU - Lee J AD - Department of Anesthesiology and Pain Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea. FAU - Song, Sang A AU - Song SA AD - Department of Anesthesiology and Pain Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea. FAU - Lim, Hyun Kyo AU - Lim HK AUID- ORCID: 0000-0003-4812-1728 AD - Department of Anesthesiology and Pain Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea. FAU - Song, Seung Woo AU - Song SW AUID- ORCID: 0000-0002-1030-5348 AD - Department of Anesthesiology and Pain Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - YI7VU623SF (Propofol) RN - 7V4A8U16MB (remimazolam) RN - 12794-10-4 (Benzodiazepines) SB - IM MH - Humans MH - Aged MH - Aged, 80 and over MH - *Propofol/adverse effects MH - Incidence MH - Anesthesia, Intravenous/adverse effects MH - Single-Blind Method MH - Anesthesia, General MH - Benzodiazepines/adverse effects MH - *Hypotension/chemically induced/epidemiology PMC - PMC10713151 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/12/09 05:42 MHDA- 2023/12/17 13:19 PMCR- 2023/12/08 CRDT- 2023/12/08 22:33 PHST- 2023/12/17 13:19 [medline] PHST- 2023/12/09 05:42 [pubmed] PHST- 2023/12/08 22:33 [entrez] PHST- 2023/12/08 00:00 [pmc-release] AID - 00005792-202312080-00030 [pii] AID - 10.1097/MD.0000000000036440 [doi] PST - ppublish SO - Medicine (Baltimore). 2023 Dec 8;102(49):e36440. doi: 10.1097/MD.0000000000036440. PMID- 38057353 OWN - NLM STAT- MEDLINE DCOM- 20231211 LR - 20231222 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Dec 6 TI - Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy. PG - 21502 LID - 10.1038/s41598-023-48840-9 [doi] LID - 21502 AB - Vesical Imaging Reporting and Data System (VI-RADS) shows good potential in determining muscle-invasive bladder cancer (MIBC) patients. However, whether VI-RADS could predict the prognosis of radical cystectomy (RC) patients has not been reported. Our purpose is to determine whether VI-RADS contributed to predict oncologic outcomes. In this retrospective study, we analysed the information of bladder cancer patients who admitted to our centre from June 2012 to June 2022. All patients who underwent multiparametric magnetic resonance imaging (mpMRI) and underwent RC were included. VI-RADS scoring was performed by two radiologists blinded to the clinical data. Patients' clinical features, pathology data, and imaging information were recorded. Kaplan-Meier method was used to estimate patients' overall survival (OS) and progression-free survival (PFS). Log-rank test was used to assess statistical differences. COX regression analysis was used to estimate risk factors. Ultimately, we included 219 patients, with 188 males and 31 females. The median age was 66 (IQR = 61-74.5) years. The VI-RADS scores were as follows: VI-RADS 1, 4 (1.8%); VI-RADS 2, 68 (31.1%); VI-RADS 3, 40 (18.3%); VI-RADS 4, 69 (31.5%); and VI-RADS 5, 38 (17.4%). Patients with VI-RADS >/= 3 had poorer OS and PFS than those with VI-RADS < 3. The AUC of VI-RADS predicting 3-year OS was 0.804, with sensitivity of 0.824 and negative predictive value of 0.942. Multivariate COX analysis showed that VI-RADS >/= 3 was risk factors for OS (HR = 3.517, P = 0.003) and PFS (HR = 4.175, P < 0.001). In the MIBC subgroup, patients with VI-RADS >/= 4 had poorer OS and PFS. In the non-muscle invasive bladder cancer (NMIBC) subgroup, the prognosis of patients with VI-RADS >/= 3 remained poorer. VI-RADS scores could effectively predict the survival of patients after RC. CI - (c) 2023. The Author(s). FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. AD - Wuxi Medical Center, Nanjing Medical University, Wuxi, China. FAU - Sun, Huanyou AU - Sun H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Li, Kai AU - Li K AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yu, Ruixi AU - Yu R AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. yangxiao2915@163.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. doctorlvqiang@njmu.edu.cn. LA - eng GR - JSPH-MC-2021-15/Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project/ GR - JSPH-MA-2022-5/Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project/ GR - 82072832, 82273152/the National Natural Science Foundation of China/ PT - Journal Article DEP - 20231206 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Male MH - Female MH - Humans MH - Aged MH - *Urinary Bladder/diagnostic imaging/surgery/pathology MH - Cystectomy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery/pathology MH - Prognosis MH - Magnetic Resonance Imaging/methods PMC - PMC10700510 COIS- The authors declare no competing interests. EDAT- 2023/12/07 00:42 MHDA- 2023/12/11 12:42 PMCR- 2023/12/06 CRDT- 2023/12/06 23:24 PHST- 2023/07/08 00:00 [received] PHST- 2023/11/30 00:00 [accepted] PHST- 2023/12/11 12:42 [medline] PHST- 2023/12/07 00:42 [pubmed] PHST- 2023/12/06 23:24 [entrez] PHST- 2023/12/06 00:00 [pmc-release] AID - 10.1038/s41598-023-48840-9 [pii] AID - 48840 [pii] AID - 10.1038/s41598-023-48840-9 [doi] PST - epublish SO - Sci Rep. 2023 Dec 6;13(1):21502. doi: 10.1038/s41598-023-48840-9. PMID- 38055616 OWN - NLM STAT- MEDLINE DCOM- 20240603 LR - 20241207 IS - 1476-6256 (Electronic) IS - 0002-9262 (Print) IS - 0002-9262 (Linking) VI - 193 IP - 6 DP - 2024 Jun 3 TI - Environmental and occupational exposures and prognosis in patients with non-muscle-invasive bladder cancer in the Be-Well Study. PG - 863-873 LID - 10.1093/aje/kwad236 [doi] AB - Bladder cancer is primarily diagnosed as non-muscle-invasive bladder cancer (NMIBC), with high recurrence and progression rates. Environmental and occupational exposures to carcinogens are well-known risk factors for developing bladder cancer, yet their effects on prognosis remain unknown. In the Be-Well Study, a population-based prospective cohort study of 1472 Kaiser Permanente patients newly diagnosed with NMIBC in California from 2015 to 2019, we examined history of environmental and occupational exposures in relation to tumor stage and grade at initial diagnosis by multivariable logistic regression, and subsequent recurrence and progression by Cox proportional hazards regression. Exposure to environmental and occupational carcinogens was significantly associated with increased risk of progression (hazard ratio (HR) = 1.79; 95% CI, 1.04-3.09), specifically with increased progression to muscle-invasive disease (HR = 2.28; 95% CI, 1.16-4.50). Exposures to asbestos and arsenic were associated with increased odds of advanced stage at diagnosis (asbestos: odds ratio (OR) = 1.43 [95% CI, 1.11-1.84]; arsenic: OR = 1.27 [95% CI, 1.01-1.63]), and formaldehyde exposure was associated with increased risk of recurrence (HR = 1.38; 95% CI, 1.12-1.69). Our findings suggest that considering a patient's history of these exposures may benefit current risk stratification systems in better tailoring clinical care and improving prognosis among patients with NMIBC. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Wang, Zinian AU - Wang Z AUID- ORCID: 0000-0002-3088-6995 FAU - Kwan, Marilyn L AU - Kwan ML FAU - Haque, Reina AU - Haque R FAU - Pratt, Rachel AU - Pratt R FAU - Lee, Valerie S AU - Lee VS FAU - Roh, Janise M AU - Roh JM FAU - Ergas, Isaac J AU - Ergas IJ FAU - Cannavale, Kimberly L AU - Cannavale KL FAU - Loo, Ronald K AU - Loo RK FAU - Aaronson, David S AU - Aaronson DS FAU - Quesenberry, Charles P AU - Quesenberry CP FAU - Ambrosone, Christine B AU - Ambrosone CB FAU - Kushi, Lawrence H AU - Kushi LH FAU - Tang, Li AU - Tang L LA - eng GR - R01 CA172855/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Am J Epidemiol JT - American journal of epidemiology JID - 7910653 RN - 1332-21-4 (Asbestos) RN - N712M78A8G (Arsenic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/epidemiology/pathology MH - *Occupational Exposure/adverse effects/statistics & numerical data MH - Male MH - Female MH - Aged MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - *Environmental Exposure/adverse effects MH - Risk Factors MH - California/epidemiology MH - Disease Progression MH - Neoplasm Recurrence, Local/epidemiology MH - Proportional Hazards Models MH - Asbestos/adverse effects MH - Neoplasm Staging MH - Arsenic/adverse effects/toxicity MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms PMC - PMC11466861 OTO - NOTNLM OT - environmental exposure OT - grade OT - non-muscle-invasive bladder cancer OT - occupational exposure OT - progression OT - recurrence OT - stage COIS- The authors report no conflicts of interest. EDAT- 2023/12/06 18:42 MHDA- 2024/06/03 12:43 PMCR- 2024/12/05 CRDT- 2023/12/06 12:53 PHST- 2023/02/14 00:00 [received] PHST- 2023/11/16 00:00 [revised] PHST- 2023/12/01 00:00 [accepted] PHST- 2024/06/03 12:43 [medline] PHST- 2023/12/06 18:42 [pubmed] PHST- 2023/12/06 12:53 [entrez] PHST- 2024/12/05 00:00 [pmc-release] AID - 7459181 [pii] AID - kwad236 [pii] AID - 10.1093/aje/kwad236 [doi] PST - ppublish SO - Am J Epidemiol. 2024 Jun 3;193(6):863-873. doi: 10.1093/aje/kwad236. PMID- 38054524 OWN - NLM STAT- MEDLINE DCOM- 20231207 LR - 20260127 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 58 DP - 2023 Dec 6 TI - Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy. PG - 120-125 LID - 10.2340/sju.v58.10160 [doi] AB - OBJECTIVES: To compare the recurrence of non-muscle invasive bladder carcinoma (NMIBC) after transurethral resection employing cystoscopy with hexaminolevulinate-based photodynamic diagnosis (PDD) or with standard white light. PATIENTS AND METHODS: We included patients with newly suspected NMIBC in this retrospective cohort study and compared those undergoing transurethral resection by white light cystoscopy (WLC) (2008-2010) and PDD (2010-2012). All patients were treated following established criteria for good quality resection. The primary outcome was the difference in the recurrence rate after 60 months' follow-up, but we also stratified recurrence by risk groups, as set by the European Organization for Research and Treatment of Cancer. The mean recurrence-free survival was compared between the cohorts. Odds ratios or hazard ratios are reported with their 95% confidence intervals. RESULTS: The WLC and PDD cohorts comprised 124 and 91 subjects, respectively. There were no significant differences in recurrence rates between the cohorts at 6 months (recurrence rate 9/123; 7.3%), 12 months (17/118; 14.4%) or 60 months (39/102; 38.2%), with odds ratios of 1.23 (CI 0.48-3.25), 1.32 (CI 0.67-2.62) and 1.12 (CI 0.70-1.79), in favour of WLC, respectively. Further analysis showed no significant effect of PDD on either recurrence by risk group or on mean recurrence-free survival (hazard ratio, 1.12 [CI 0.70-1.79]). CONCLUSION: We found no relevant differences in the recurrence of NMIBC after the introduction of PDD with hexaminolevulinate compared to standard WLC when used for transurethral resection in our single institution. FAU - Hoogeveen, Fjs AU - Hoogeveen F AD - Department of urology, Isala hospital, Zwolle, The Netherlands. sebastiaanhoogeveen@gmail.com. FAU - Blanker, M H AU - Blanker MH AD - Department of general practice and elderly care medicine, University Medical Center Groningen, Groningen, The Netherlands . FAU - Cauberg, Ecc AU - Cauberg E AD - Department of urology, Isala hospital, Zwolle, The Netherlands. FAU - Steffens, M G AU - Steffens MG AD - Department of urology, Isala hospital, Zwolle, The Netherlands. LA - eng PT - Journal Article DEP - 20231206 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Humans MH - Cystoscopy MH - Urinary Bladder/surgery MH - Retrospective Studies MH - Aminolevulinic Acid/analogs & derivatives MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma/pathology MH - Neoplasm Recurrence, Local/epidemiology/pathology EDAT- 2023/12/06 12:42 MHDA- 2023/12/07 12:42 CRDT- 2023/12/06 08:14 PHST- 2023/02/22 00:00 [received] PHST- 2023/10/13 00:00 [accepted] PHST- 2023/12/07 12:42 [medline] PHST- 2023/12/06 12:42 [pubmed] PHST- 2023/12/06 08:14 [entrez] AID - 10.2340/sju.v58.10160 [doi] PST - epublish SO - Scand J Urol. 2023 Dec 6;58:120-125. doi: 10.2340/sju.v58.10160. PMID- 38044211 OWN - NLM STAT- MEDLINE DCOM- 20240621 LR - 20240621 IS - 0929-6646 (Print) IS - 0929-6646 (Linking) VI - 123 IP - 7 DP - 2024 Jul TI - Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area. PG - 758-763 LID - S0929-6646(23)00477-1 [pii] LID - 10.1016/j.jfma.2023.11.011 [doi] AB - OBJECTIVE: This study aimed to assess the impact of preoperative chronic kidney disease (CKD) on the oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) who underwent standard radical nephroureterectomy (RNU). METHODS: A total of 1172 UTUC patients who received RNU at a single center in Taiwan between February 2005 and August 2019 were included. The patients were categorized into two groups based on their preoperative CKD stage: CKD stage 3 (361 patients). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. The study investigated the oncological outcomes, including intravesical recurrence, non-urothelial recurrence, and cancer-specific mortality, stratified by preoperative CKD status. RESULTS: The main findings indicated that UTUC patients with CKD stage >3 in Taiwan exhibited a higher proportion of females (p < 0.001), a greater history of concurrent bladder cancer (p = 0.003), more multifocal tumor behavior (p < 0.001), a higher incidence of carcinoma in situ (p = 0.008), increased rates of intravesical recurrence (p < 0.001), a lower prevalence of smoking history (p = 0.003), lower utilization of adjuvant chemotherapy (p < 0.001), reduced occurrence of non-urothelial recurrence (p < 0.001), and lower cancer-specific mortality (p = 0.006) compared to patients with CKD stage 3 and CKD stage 3 group exhibited lower rates of intravesical recurrence (p = 0.0014), higher rates of non-urothelial recurrence (p < 0.0001), and increased cancer-specific mortality (p = 0.0091) compared to the CKD stage 3 exhibit distinct characteristics compared to the general population with urothelial carcinoma. They are associated with a non-smoking status, a higher proportion of females, and less aggressive pathological features. Additionally, CKD stage >3 can serve as a clinical indicator for intravesical and non-urothelial recurrence. Further investigation into molecular aspects and treatment modifications for these patients is warranted. CI - Copyright (c) 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. FAU - Lee, I-Wen AU - Lee IW AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wang, Hung-Jen AU - Wang HJ AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Liu, Hui-Ying AU - Liu HY AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chang, Yin-Lun AU - Chang YL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wu, Yen-Tin AU - Wu YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yen Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cheng, Yuan Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Kang, Chih Hsiung AU - Kang CH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chuang, Yao Chi AU - Chuang YC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Luo, Hao-Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan. Electronic address: alesy1980@gmail.com. LA - eng PT - Journal Article DEP - 20231202 PL - Singapore TA - J Formos Med Assoc JT - Journal of the Formosan Medical Association = Taiwan yi zhi JID - 9214933 SB - IM MH - Humans MH - Female MH - Male MH - Taiwan/epidemiology MH - Aged MH - *Renal Insufficiency, Chronic/complications/epidemiology/mortality MH - Middle Aged MH - Prevalence MH - *Nephroureterectomy MH - *Neoplasm Recurrence, Local/epidemiology MH - *Glomerular Filtration Rate MH - Retrospective Studies MH - Carcinoma, Transitional Cell/mortality/surgery MH - Risk Factors MH - Aged, 80 and over MH - Urinary Bladder Neoplasms/mortality/surgery/pathology MH - Ureteral Neoplasms/mortality/surgery/complications MH - Urologic Neoplasms/surgery/mortality MH - Proportional Hazards Models COIS- Declaration of competing interest The authors declare no conflicts of interest. EDAT- 2023/12/04 00:42 MHDA- 2024/06/22 05:43 CRDT- 2023/12/03 22:00 PHST- 2023/05/23 00:00 [received] PHST- 2023/11/14 00:00 [revised] PHST- 2023/11/21 00:00 [accepted] PHST- 2024/06/22 05:43 [medline] PHST- 2023/12/04 00:42 [pubmed] PHST- 2023/12/03 22:00 [entrez] AID - S0929-6646(23)00477-1 [pii] AID - 10.1016/j.jfma.2023.11.011 [doi] PST - ppublish SO - J Formos Med Assoc. 2024 Jul;123(7):758-763. doi: 10.1016/j.jfma.2023.11.011. Epub 2023 Dec 2. PMID- 38037752 OWN - NLM STAT- MEDLINE DCOM- 20240101 LR - 20260922 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 24 DP - 2023 Dec TI - Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. PG - 21944-21968 LID - 10.1002/cam4.6768 [doi] AB - BACKGROUND: High-risk non-muscle-invasive bladder cancer (HR-NMIBC) presents a challenge to many physicians due to its ability to resist Bacillus Calmette-Guerin (BCG) intravesical therapy and the substantial rate of progression into muscle-invasive bladder cancer (MIBC). Patients who are BCG-unresponsive have worse prognosis and thus require further management including radical cystectomy (RC), which significantly impacts quality of life. Moreover, the ongoing worldwide shortage of BCG warrants the need for policies that prioritize drug use and utilize alternative treatment strategies. Hence, there is a significant unmet need for bladder preserving therapy in this subset of patients. METHODS: To address this issue, we searched the relevant literature in PUBMED for articles published from 2019 through May of 2023 using appropriate keywords. All clinical trials of patients with HR-NMIBC treated with immune-related agents were retrieved from clinicaltrials.gov. FINDINGS AND FUTURE PERSPECTIVES: Exploratory treatments for BCG-Unresponsive HR-NMIBC included immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators targeting TLR, EpCaM, FGFR, MetAP2, and IDO1. Some combination therapies have been found to work synergistically and are preferred therapeutically over monotherapy. Three drugs-pembrolizumab, valrubicin, and most recently, nadofaragene firadenovec-vncg-have been FDA approved for the treatment of BCG-unresponsive NMIBC in patients who are ineligible for or decline RC. However, all explored treatment options tend to postpone RC rather than provide long-term disease control. Additional combination strategies need to be studied to enhance the effects of immunotherapy. Despite the challenges faced in finding effective therapies, many potential treatments are currently under investigation. Addressing the landscape of biomarkers, mechanisms of progression, BCG resistance, and trial design challenges in HR-NMIBC is essential for the discovery of new targets and the development of effective treatments. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Hannouneh, Zein Alabdin AU - Hannouneh ZA AUID- ORCID: 0000-0002-4516-9526 AD - Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syrian Arab Republic. AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. FAU - Hijazi, Amjad AU - Hijazi A AUID- ORCID: 0009-0007-7054-6155 AD - Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syrian Arab Republic. AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. FAU - Alsaleem, Alaa Aldeen AU - Alsaleem AA AUID- ORCID: 0009-0001-6585-0255 AD - Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syrian Arab Republic. AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. FAU - Hami, Siwan AU - Hami S AUID- ORCID: 0009-0002-1220-7722 AD - Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syrian Arab Republic. AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. FAU - Kheyrbek, Nina AU - Kheyrbek N AUID- ORCID: 0000-0002-3435-6385 AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. AD - Faculty of Medicine, Tishreen University, Lattakia, Syrian Arab Republic. FAU - Tanous, Fadi AU - Tanous F AUID- ORCID: 0009-0002-2749-7363 AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. AD - Faculty of Medicine, Al-Baath University, Homs, Syrian Arab Republic. FAU - Khaddour, Karam AU - Khaddour K AUID- ORCID: 0000-0001-6697-3516 AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. FAU - Abbas, Abdulfattah AU - Abbas A AD - Professor of Nephrology, Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syrian Arab Republic. FAU - Alshehabi, Zuheir AU - Alshehabi Z AUID- ORCID: 0000-0002-6519-7954 AD - Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic. AD - Department of Pathology, Tishreen University Hospital, Lattakia, Syrian Arab Republic. LA - eng PT - Journal Article PT - Review DEP - 20231201 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Quality of Life MH - *Urinary Bladder Neoplasms/drug therapy MH - Immunotherapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local PMC - PMC10757155 OTO - NOTNLM OT - Bacillus Calmette-Guerin-unresponsive OT - gene therapy OT - immune checkpoint inhibitors OT - immunotherapy OT - non-muscle-invasive bladder cancer OT - oncolytic viral therapy OT - targeted therapy COIS- The authors declare no conflict of interest. EDAT- 2023/12/01 06:43 MHDA- 2024/01/02 11:43 PMCR- 2023/12/01 CRDT- 2023/12/01 04:33 PHST- 2023/11/10 00:00 [revised] PHST- 2023/09/23 00:00 [received] PHST- 2023/11/17 00:00 [accepted] PHST- 2024/01/02 11:43 [medline] PHST- 2023/12/01 06:43 [pubmed] PHST- 2023/12/01 04:33 [entrez] PHST- 2023/12/01 00:00 [pmc-release] AID - CAM46768 [pii] AID - 10.1002/cam4.6768 [doi] PST - ppublish SO - Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1. PMID- 38030469 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 1 DP - 2024 Jan TI - The bladder microbiota is not significantly altered by intravesical BCG therapy. PG - 22.e13-22.e21 LID - S1078-1439(23)00355-1 [pii] LID - 10.1016/j.urolonc.2023.11.003 [doi] AB - INTRODUCTION: Bladder microbiota dysbiosis has been associated with several urological disorders. However, dysbiosis markers in bladder cancer have not been identified and little is known about the effect of Bacillus Calmette-Guerin (BCG) intravesical therapy on the bladder microbiota. In this study, we compared the bladder microbiota of patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy to nononcological controls. We also longitudinally analyzed the impact of BCG therapy on the bladder microbiota of NMIBC patients and addressed whether bladder microbiota is associated with BCG efficacy. METHODS: We collected catheterized urine samples from males with intermediate/high-risk NMIBC (cancer group, n = 32) or benign prostatic hyperplasia (control group, n = 41). The cancer group also provided urine samples during and after BCG induction. We used 16S rRNA gene sequencing to characterize the bladder microbiota. Bladder microbiota parameters, such as diversity and taxonomic composition, were compared between groups and associated with clinicopathological data and BCG efficacy. RESULTS: We observed no significant differences between the bladder microbiota of NMIBC patients and controls. BCG intravesical instillations did not significantly alter the bladder microbiota of NMIBC patients, and BCG was rarely detected in the bladder during and after BCG therapy. Microbiota diversity and overall composition before BCG induction did not influence disease persistence at 3 months. However, higher abundance of Lactobacillus, Streptococcus, and Cutibacterium in the pre-BCG bladder microbiota was associated with BCG effectiveness. CONCLUSION: We were unable to identify markers of bladder microbiota dysbiosis among male NMIBC patients. Moreover, we demonstrated for the first time using longitudinally collected samples that BCG cannot persist in the bladder microbiota nor significantly alter its diversity and composition. The associations found between bladder microbes and BCG efficacy highlight the potential of microbial-based therapeutic and risk-stratification strategies in the intermediate/high-risk NMIBC setting. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Heidrich, Vitor AU - Heidrich V AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil; Departamento de Bioquimica, Instituto de Quimica, Universidade de Sao Paulo, Sao Paulo, Brazil. FAU - Mariotti, Antonio C H AU - Mariotti ACH AD - Instituto de Ensino e Pesquisa, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Inoue, Lilian T AU - Inoue LT AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Coser, Elisangela M AU - Coser EM AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Dos Santos, Ernande X AU - Dos Santos EX AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Dos Santos, Hugo D B AU - Dos Santos HDB AD - Instituto de Ensino e Pesquisa, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Asprino, Paula F AU - Asprino PF AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Bettoni, Fabiana AU - Bettoni F AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Costa, Guilherme A P AU - Costa GAP AD - Hospital Amaral Carvalho, Jau, Brazil. FAU - Bastos, Diogo A AU - Bastos DA AD - Centro de Oncologia, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Jardim, Denis L AU - Jardim DL AD - Centro de Oncologia, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Arap, Marco A AU - Arap MA AD - Departamento de Urologia, Hospital Sirio-Libanes, Sao Paulo, Brazil. FAU - Camargo, Anamaria A AU - Camargo AA AD - Centro de Oncologia Molecular, Hospital Sirio-Libanes, Sao Paulo, Brazil. Electronic address: anamaria.acamargo@hsl.org.br. LA - eng PT - Journal Article DEP - 20231128 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (RNA, Ribosomal, 16S) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Male MH - Urinary Bladder/pathology MH - BCG Vaccine/therapeutic use MH - Dysbiosis/drug therapy MH - *Non-Muscle Invasive Bladder Neoplasms MH - RNA, Ribosomal, 16S/genetics MH - Adjuvants, Immunologic/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Administration, Intravesical MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - BCG response OT - Biomarkers OT - Bladder cancer OT - Urinary microbiota COIS- Declaration of Competing Interest The authors declare that they have no competing interests. EDAT- 2023/11/30 00:42 MHDA- 2023/12/25 06:43 CRDT- 2023/11/29 22:03 PHST- 2023/06/13 00:00 [received] PHST- 2023/10/02 00:00 [revised] PHST- 2023/11/05 00:00 [accepted] PHST- 2023/12/25 06:43 [medline] PHST- 2023/11/30 00:42 [pubmed] PHST- 2023/11/29 22:03 [entrez] AID - S1078-1439(23)00355-1 [pii] AID - 10.1016/j.urolonc.2023.11.003 [doi] PST - ppublish SO - Urol Oncol. 2024 Jan;42(1):22.e13-22.e21. doi: 10.1016/j.urolonc.2023.11.003. Epub 2023 Nov 28. PMID- 38023187 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231201 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - High systemic immune-inflammation index predicts poor prognosis and response to intravesical BCG treatment in patients with urothelial carcinoma: a systematic review and meta-analysis. PG - 1229349 LID - 10.3389/fonc.2023.1229349 [doi] LID - 1229349 AB - BACKGROUND: The systemic immune-inflammation index (SII) has emerged as a promising marker predicting the prognosis of some cancers, while its role in urothelial carcinoma (UC) remains uncertain, especially in upper urinary tract urothelial carcinoma (UTUC). This meta-analysis aimed to investigate the association of SII with the prognosis of UC and the response to intravesical Bacillus Calmette-Guerin (BCG) therapy of non-muscle invasive bladder cancer (NMIBC). METHODS: A systematic search in PubMed, Embase, Web of Science, and the Cochrane Library was performed to identify relevant studies. The extracted hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the association between SII and overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) of patients with UC. Additionally, we pooled odds ratios (ORs) and 95% CIs to assess the relationship between SII and BCG response in patients with NMIBC. Subgroup and sensitivity analyses were performed to explore potential sources of heterogeneity. RESULTS: Twenty studies comprising a total of 12,645 patients were eligible. This meta-analysis revealed that high SII levels independently increased the risk of OS (HR 1.55, 95%CI 1.25-1.92), CSS (HR 1.82, 95%CI 1.36-2.45), and RFS (HR 1.26, 95% CI 1.18-1.35) in patients with UC, including those with upper tract urothelial carcinoma. Additionally, elevated SII levels could predict a lower response to intravesical BCG treatment (OR 0.18, 95%CI 0.07-0.45) and higher disease recurrence (HR 1.61, 95%CI 1.31-1.98) in patients with NMIBC. Furthermore, elevated SII levels were positively associated with advanced age, lymphovascular invasion, hydronephrosis, and high tumor grade and stage (pT >/= 3). CONCLUSIONS: Elevated preoperative SII levels are associated with poor survival outcomes in patients with UC, as well as worse response to BCG treatment in patients with NMIBC. Therefore, SII can serve not only as an independent prognostic predictor of patients with UC but also as a guide for BCG therapy in NMIBC. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023409077, identifier CRD42023409077. CI - Copyright (c) 2023 Liu, Zhang, Wang, Wang and Yang. FAU - Liu, Wen AU - Liu W AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Yixuan AU - Zhang Y AD - School of Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Wang, Miaomiao AU - Wang M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Miao AU - Wang M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Yang, Qingya AU - Yang Q AD - Department of Urology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20231101 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10646434 OTO - NOTNLM OT - Bacillus Calmette Guerin OT - meta-analysis OT - prognosis OT - systemic immune-inflammation index OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/11/29 18:42 MHDA- 2023/11/29 18:43 PMCR- 2023/01/01 CRDT- 2023/11/29 15:41 PHST- 2023/06/05 00:00 [received] PHST- 2023/10/20 00:00 [accepted] PHST- 2023/11/29 18:43 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 15:41 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1229349 [doi] PST - epublish SO - Front Oncol. 2023 Nov 1;13:1229349. doi: 10.3389/fonc.2023.1229349. eCollection 2023. PMID- 37996278 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20240717 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 4 DP - 2024 Aug TI - Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort. PG - 829-837 LID - S2588-9311(23)00252-3 [pii] LID - 10.1016/j.euo.2023.11.007 [doi] AB - BACKGROUND: The health-related quality of life (HRQoL) of patients with non-muscle-invasive bladder cancer (NMIBC) may be impaired due to the chronic and burdensome disease course, but longitudinal data are limited. OBJECTIVE: To evaluate HRQoL outcomes during the first 4 yr after NMIBC diagnosis, and to compare HRQoL across patient characteristics and with a normative population. DESIGN, SETTING, AND PARTICIPANTS: Patients with NMIBC (n = 1019) were included from the multicentre prospective cohort UroLife. Data were collected at 6 wk (baseline), and 3, 15, and 51 mo after diagnosis. Longitudinal reference data were obtained from an age- and sex-matched normative population (n = 490). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer- and NMIBC-specific HRQoL outcomes (range 0-100) were evaluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires, respectively. Linear mixed modelling was used to analyse within-group changes and between-group differences. RESULTS AND LIMITATIONS: The majority of HRQoL outcomes remained stable over time. Observed changes were only of small clinical relevance. Improvements were noted in insomnia, social functioning, and three NMIBC-specific symptoms, while minor deteriorations in appetite and diarrhoea lasted until 51 mo. HRQoL in some domains was worse for high-grade NMIBC, high European Association of Urology (EAU) risk group, initial Bacillus Calmette-Guerin (BCG) treatment, being female, and being younger (<65 yr); yet differences were few, small, and temporary. No differences were observed across recurrence status. Compared with a normative population, clinically relevant worse scores were observed for six of 15 outcomes, which mostly recovered at 51 mo, except for minor symptoms of appetite loss and diarrhoea. CONCLUSIONS: No remarkable changes in HRQoL were observed during the first 4 yr after NMIBC diagnosis. Grade, EAU risk group, initial treatment, recurrence, sex, and age did not importantly affect HRQoL. HRQoL was largely comparable with that of the general population, especially after 4 yr. PATIENT SUMMARY: Quality of life is not largely affected during the first 4 yr after non-muscle-invasive bladder cancer diagnosis. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Beeren, Ivy AU - Beeren I AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Klerks, Nena E AU - Klerks NE AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K AU - Aben KK AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Alina.Vrieling@radboudumc.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20231122 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Quality of Life MH - *Urinary Bladder Neoplasms/psychology/pathology/diagnosis/therapy MH - Female MH - Male MH - Prospective Studies MH - Aged MH - Middle Aged MH - Time Factors MH - Neoplasm Invasiveness MH - Cohort Studies MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Health-related quality of life OT - Non-muscle-invasive bladder cancer OT - Patient-reported outcomes EDAT- 2023/11/24 00:42 MHDA- 2024/07/18 00:42 CRDT- 2023/11/23 21:59 PHST- 2023/07/12 00:00 [received] PHST- 2023/10/18 00:00 [revised] PHST- 2023/11/10 00:00 [accepted] PHST- 2024/07/18 00:42 [medline] PHST- 2023/11/24 00:42 [pubmed] PHST- 2023/11/23 21:59 [entrez] AID - S2588-9311(23)00252-3 [pii] AID - 10.1016/j.euo.2023.11.007 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Aug;7(4):829-837. doi: 10.1016/j.euo.2023.11.007. Epub 2023 Nov 22. PMID- 37993346 OWN - NLM STAT- MEDLINE DCOM- 20241127 LR - 20241203 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 10 IP - 4 DP - 2024 Jul TI - Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? PG - 564-566 LID - S2405-4569(23)00249-3 [pii] LID - 10.1016/j.euf.2023.11.007 [doi] AB - Adjuvant bacillus Calmette-Guerin (BCG) instillations represent a cornerstone in the treatment of non-muscle-invasive bladder cancer. Instillation schedule and dose modifications have been evaluated in efforts to reduce the incidence of adverse events (AEs), but none so far has the same treatment efficacy as the full-dose recommended schedule. It has been shown that prophylactic quinolone use in conjunction with BCG instillations reduces AE incidence and improves timely completion of instillation regimens and patient survival. However, the European Medicines Agency imposed restrictions on the use of quinolones in 2019 because of side effects. Nevertheless, rational use of quinolone prophylaxis could be considered for selected individuals treated with BCG without risk factors for quinolone-associated side effects in conjunction with patient information about side-effect symptoms. PATIENT SUMMARY: Bladder instillations of BCG (bacillus Calmette-Guerin) are used in the treatment of non-muscle-invasive bladder cancer. Antibiotics from the quinolone class can reduce the adverse effects of BCG and help patients in completing the treatment course; however, these antibiotics have their own side effects. Our mini review suggests that the antibiotics could be used in selective cases if patients are given adequate information on these side effects and their symptoms. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden; Institute of Translational Medicine, Lund University, Malmo, Sweden. Electronic address: fredrik.liedberg@med.lu.se. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris Cite, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231122 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) RN - 0 (Quinolones) RN - 0 (Adjuvants, Immunologic) RN - 0 (Anti-Bacterial Agents) SB - IM MH - *Urinary Bladder Neoplasms/drug therapy MH - Humans MH - *BCG Vaccine/administration & dosage/therapeutic use/adverse effects MH - *Quinolones/therapeutic use/administration & dosage MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use/administration & dosage/adverse effects MH - Antibiotic Prophylaxis/methods MH - Anti-Bacterial Agents/therapeutic use/administration & dosage EDAT- 2023/11/23 00:41 MHDA- 2024/11/28 00:24 CRDT- 2023/11/22 22:01 PHST- 2023/09/02 00:00 [received] PHST- 2023/10/31 00:00 [revised] PHST- 2023/11/10 00:00 [accepted] PHST- 2024/11/28 00:24 [medline] PHST- 2023/11/23 00:41 [pubmed] PHST- 2023/11/22 22:01 [entrez] AID - S2405-4569(23)00249-3 [pii] AID - 10.1016/j.euf.2023.11.007 [doi] PST - ppublish SO - Eur Urol Focus. 2024 Jul;10(4):564-566. doi: 10.1016/j.euf.2023.11.007. Epub 2023 Nov 22. PMID- 37989709 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240409 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 2 DP - 2024 Apr TI - Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy. PG - 201-209.e7 LID - S1558-7673(23)00234-3 [pii] LID - 10.1016/j.clgc.2023.10.014 [doi] AB - PURPOSE: The survival benefit of neoadjuvant chemotherapy (NAC) before definitive radical cystectomy (RC) varied among patients, suggesting proper selection of patients for NAC to maximize the survival benefit. This study aimed to investigate the role of lymphovascular invasion (LVI) in transurethral resection (TUR) specimens in selecting patients with MIBC for NAC. METHODS: Two retrospective cohorts of patients with cT2-4aN0 MIBC who underwent RC from 2004 to 2015 provided by Lund University were included. Inverse probability weighting was applied to make the NAC-treated (NAC) and untreated (non-NAC) cohorts comparable. Survival benefits were estimated with Kaplan-Meier curves and Cox proportional hazards models. The primary endpoint was cancer-specific survival (CSS). LVI in TUR specimens and molecular taxonomies (BASE47, UNC, and LundTax) were examined, and bulk RNA-seq datasets were explored for LVI-relevant signatures. RESULTS: A total of 341 patients with cT2-4aN0 MIBC were included. The NAC cohort included 125 patients, whereas the non-NAC cohort included 216 patients. The 3-year CSS benefit of NAC was 7.1%. For patients with positive LVI in TUR specimens, the 3-year CSS benefit of NAC was 26.2% (48.1% vs. 74.3%), with a risk reduction of 56% (HR = 0.44, P = .03). A sensitivity analysis confirmed a significant interaction between LVI and NAC. This study failed to identify the molecular subtypes that maximized the survival benefit of NAC. Exploration of LVI-relevant signatures remains inconclusive. CONCLUSIONS: LVI in TUR specimens could help identify patients with MIBC who would derive maximal survival benefit from NAC. Further prospective validation is necessary. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Wang, Ziwei AU - Wang Z AD - Department of Urology, Changhai Hospital, Shanghai, China. FAU - He, Wei AU - He W AD - Department of Clinical Medicine, Naval Medical University, Shanghai, China. FAU - Ying, Yidie AU - Ying Y AD - Department of Urology, Changhai Hospital, Shanghai, China. FAU - Wang, Maoyu AU - Wang M AD - Department of Urology, Changhai Hospital, Shanghai, China. FAU - Chen, Qing AU - Chen Q AD - Department of Urology, Changhai Hospital, Shanghai, China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Changhai Hospital, Shanghai, China. Electronic address: 13761178177@163.com. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Changhai Hospital, Shanghai, China. Electronic address: zengshuxiong@126.com. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Changhai Hospital, Shanghai, China. Electronic address: chuanliang_xu@126.com. LA - eng PT - Journal Article DEP - 20231102 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 49DFR088MY (Platinum) SB - IM MH - Humans MH - Retrospective Studies MH - *Platinum/therapeutic use MH - Neoadjuvant Therapy MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Cystectomy MH - Muscles MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bioinformatics OT - Biomarkers OT - Inverse probability treatment weighting OT - Molecular Subtype OT - Survival analysis EDAT- 2023/11/22 00:42 MHDA- 2024/03/11 06:44 CRDT- 2023/11/21 22:02 PHST- 2023/07/14 00:00 [received] PHST- 2023/10/23 00:00 [revised] PHST- 2023/10/29 00:00 [accepted] PHST- 2024/03/11 06:44 [medline] PHST- 2023/11/22 00:42 [pubmed] PHST- 2023/11/21 22:02 [entrez] AID - S1558-7673(23)00234-3 [pii] AID - 10.1016/j.clgc.2023.10.014 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Apr;22(2):201-209.e7. doi: 10.1016/j.clgc.2023.10.014. Epub 2023 Nov 2. PMID- 37980689 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 56 IP - 4 DP - 2024 Apr TI - Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis? PG - 1323-1333 LID - 10.1007/s11255-023-03867-9 [doi] AB - PURPOSE: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, restaging-TURB is required if the first resection was macroscopically complete but contained no detrusor muscle (DM) and second-TURB is advised for all completely resected T1-tumors with DM in the resection specimen. This study assessed the long-term outcomes after repeat-, second-, and restaging-TURB in T1-NMIBC patients. METHODS: Individual patient data with tumor characteristics of 1660 primary T1-patients (muscle-invasion at re-TURB omitted) diagnosed from 1990 to 2018 in 17 hospitals were analyzed. Time to recurrence, progression, death due to bladder cancer (BC), and all causes (OS) were visualized with cumulative incidence functions and analyzed by log-rank tests and multivariable Cox-regression models stratified by institution. RESULTS: Median follow-up was 45.3 (IQR 22.7-81.1) months. There were no differences in time to recurrence, progression, or OS between patients undergoing restaging (135 patients), second (644 patients), or repeat-TURB (84 patients), nor between patients who did or who did not undergo second or restaging-TURB. However, patients who underwent repeat-TURB had a shorter time to BC death compared to those who had second- or restaging-TURB (multivariable HR 3.58, P = 0.004). CONCLUSION: Prognosis did not significantly differ between patients who underwent restaging- or second-TURB. However, a worse prognosis in terms of death due to bladder cancer was found in patients who underwent repeat-TURB compared to second-TURB and restaging-TURB, highlighting the importance of separately evaluating different indications for re-TURB. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Beijert, Irene J AU - Beijert IJ AUID- ORCID: 0000-0002-0510-2300 AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. AD - Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. AD - Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Plass, Karin AU - Plass K AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Subiela Henriquez, Jose D AU - Subiela Henriquez JD AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Soria, Francesco AU - Soria F AD - Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bauerova, Lenka AU - Bauerova L AD - Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Pesl, Michael AU - Pesl M AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bruins, H Maxim AU - Bruins HM AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Urology, Zuyderland Medical Center, Sittard/Heerlen, The Netherlands. FAU - Runneboom, Willemien AU - Runneboom W AD - Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Calatrava, Ana AU - Calatrava A AD - Pathology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Urology, Medical University of Graz, Graz, Austria. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Ashabere, David AU - Ashabere D AD - Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Huebner, Nicolai AU - Huebner N AD - Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cotte, Juliette AU - Cotte J AD - Urology, Pitie Salpetriere Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France. FAU - Contieri, Roberto AU - Contieri R AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Claps, Francesco AU - Claps F AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Liedberg, Fredrik AU - Liedberg F AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Lunelli, Luca AU - Lunelli L AD - Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - El Sheikh, Soha AU - El Sheikh S AD - Pathology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Volanis, Dimitrios AU - Volanis D AD - Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Cote, Jean-Francois AU - Cote JF AD - Pathology, Pierre et Marie Curie Medical School, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Pitie Salpetriere Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France. FAU - Haitel, Andrea AU - Haitel A AD - Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. AD - Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Hacek, Jaromir AU - Hacek J AD - Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Burger, Maximilian AU - Burger M AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Evert, Matthias AU - Evert M AD - Pathology, University of Regensburg, Regensburg, Germany. FAU - Hulsbergen-van de Kaa, Christina A AU - Hulsbergen-van de Kaa CA AD - Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Molinaro, Luca AU - Molinaro L AD - Pathology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. FAU - Llorente, Carlos AU - Llorente C AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - N'Dow, James AU - N'Dow J AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. AD - Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.v.rhijn@nki.nl. AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. b.v.rhijn@nki.nl. AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. b.v.rhijn@nki.nl. AD - Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. b.v.rhijn@nki.nl. LA - eng PT - Journal Article DEP - 20231119 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Prognosis MH - Urologic Surgical Procedures MH - Urinary Bladder/surgery/pathology MH - Cystectomy MH - Neoplasm Staging OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Prognosis OT - Re-TURB OT - Repeat TURB OT - Restaging TURB OT - Second TURB EDAT- 2023/11/19 18:41 MHDA- 2024/03/11 06:41 CRDT- 2023/11/19 15:19 PHST- 2023/10/12 00:00 [received] PHST- 2023/10/23 00:00 [accepted] PHST- 2024/03/11 06:41 [medline] PHST- 2023/11/19 18:41 [pubmed] PHST- 2023/11/19 15:19 [entrez] AID - 10.1007/s11255-023-03867-9 [pii] AID - 10.1007/s11255-023-03867-9 [doi] PST - ppublish SO - Int Urol Nephrol. 2024 Apr;56(4):1323-1333. doi: 10.1007/s11255-023-03867-9. Epub 2023 Nov 19. PMID- 37980528 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20240228 IS - 1476-4598 (Electronic) IS - 1476-4598 (Linking) VI - 22 IP - 1 DP - 2023 Nov 18 TI - The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer. PG - 185 LID - 10.1186/s12943-023-01897-6 [doi] LID - 185 AB - BACKGROUND: Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA). METHODS: A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months. RESULTS: FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more prevalent in aFGFR3, whereas the Ba/Sq subtype exhibited similarity between intact FGFR3 (iFGFR3) and aFGFR3 cases. We revealed that basal markers were significantly increased in MIBC/aFGFR3 compared to MIBC/iFGFR3. Transcriptome analysis highlighted TIM3 as the most upregulated immune-related gene in iFGFR3, with differential immune cell compositions observed between iFGFR3 and aFGFR3. Using EcoTyper, TME heterogeneity was discerned even within aFGFR cases, suggesting potential variations in the response to checkpoint inhibitors (CPIs). Among 72 patients treated with CPIs, the objective response rate (ORR) was comparable between iFGFR3 and aFGFR3 (20% vs 31%; p = 0.467). Strikingly, a significantly higher ORR was noted in LumP/aFGFR3 compared to LumP/iFGFR3 (50% vs 5%; p = 0.022). This trend was validated using data from the IMvigor210 trial. Additionally, several immune-related genes, including IDO1, CCL24, IL1RL1, LGALS4, and NCAM (CD56) were upregulated in LumP/iFGFR3 compared to LumP/aFGFR3 cases. CONCLUSIONS: Differential pathways influenced by aFGFR3 were observed between NMIBC and MIBC, highlighting the upregulation of both luminal and basal markers in MIBC/aFGFR3. Heterogeneous TME was identified within MIBC/aFGFR3, leading to differential outcomes for CPIs. Specifically, a favorable ORR in LumP/aFGFR3 and a poor ORR in LumP/iFGFR3 were observed. We propose TIM3 as a potential target for iFGFR3 (ORR: 20%) and several immune checkpoint genes, including IDO1 and CCL24, for LumP/iFGFR3 (ORR: 5%), indicating promising avenues for precision immunotherapy for BLCA. CI - (c) 2023. The Author(s). FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. kazumasa.komura@ompu.ac.jp. AD - Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. kazumasa.komura@ompu.ac.jp. FAU - Hirosuna, Kensuke AU - Hirosuna K AD - Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. AD - Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho Kitaku, Okayama City, Okayama, 700-8558, Japan. FAU - Tokushige, Satoshi AU - Tokushige S AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Tsujino, Takuya AU - Tsujino T AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Nishimura, Kazuki AU - Nishimura K AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. FAU - Ishida, Mitsuaki AU - Ishida M AD - Department of Pathology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Hayashi, Takuo AU - Hayashi T AD - Department of Human Pathology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. FAU - Ura, Ayako AU - Ura A AD - Department of Human Pathology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. FAU - Ohno, Takaya AU - Ohno T AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Yamazaki, Shogo AU - Yamazaki S AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Nakamori, Keita AU - Nakamori K AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Kinoshita, Shoko AU - Kinoshita S AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Maenosono, Ryoichi AU - Maenosono R AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. AD - Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. FAU - Ajiro, Masahiko AU - Ajiro M AD - Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. FAU - Yoshikawa, Yuki AU - Yoshikawa Y AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Takai, Tomoaki AU - Takai T AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Tsutsumi, Takeshi AU - Tsutsumi T AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Taniguchi, Kohei AU - Taniguchi K AD - Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Tanaka, Tomohito AU - Tanaka T AD - Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Takahara, Kiyoshi AU - Takahara K AD - Department of Urology, Fujita-Health University School of Medicine, Toyoake City, 1-98 Dengakugakubo, KutsukakeAichi, 470-1192, Japan. FAU - Konuma, Tsuyoshi AU - Konuma T AD - Graduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-Cho, Tsurumiku-Ku, Yokohama, Kanagawa, 230-0045, Japan. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Hirose, Yoshinobu AU - Hirose Y AD - Department of Pathology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Ono, Fumihito AU - Ono F AD - Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. FAU - Shiraishi, Yuichi AU - Shiraishi Y AD - Division of Genome Analysis Platform Development, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. FAU - Yoshimi, Akihide AU - Yoshimi A AD - Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. ayoshimi@ncc.go.jp. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, 569-8686, Japan. LA - eng GR - 21H03070/Japan Society for the Promotion of Science/ GR - 21H04828/Japan Society for the Promotion of Science/ GR - JP22jm0210085, JP22am0401007, and JP22ym0126804 (21-A-22)/Japan Agency for Medical Research and Development/ GR - 2020-A-2 and 2023-S-6/National Cancer Center Research and Development Funds/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231118 PL - England TA - Mol Cancer JT - Molecular cancer JID - 101147698 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - 0 (Hepatitis A Virus Cellular Receptor 2) RN - EC 2.7.10.1 (FGFR3 protein, human) SB - IM MH - Humans MH - Prognosis MH - *Immune Checkpoint Inhibitors/pharmacology/therapeutic use MH - Biomarkers, Tumor/genetics MH - Retrospective Studies MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Tumor Microenvironment MH - Hepatitis A Virus Cellular Receptor 2 MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology PMC - PMC10657138 OTO - NOTNLM OT - Bladder cancer OT - Fibroblast growth factor receptor OT - Fusion OT - Immune checkpoint inhibitor OT - Molecular subtypes OT - Mutation OT - Tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2023/11/19 09:42 MHDA- 2023/11/27 12:43 PMCR- 2023/11/18 CRDT- 2023/11/19 03:33 PHST- 2023/08/31 00:00 [received] PHST- 2023/11/06 00:00 [accepted] PHST- 2023/11/27 12:43 [medline] PHST- 2023/11/19 09:42 [pubmed] PHST- 2023/11/19 03:33 [entrez] PHST- 2023/11/18 00:00 [pmc-release] AID - 10.1186/s12943-023-01897-6 [pii] AID - 1897 [pii] AID - 10.1186/s12943-023-01897-6 [doi] PST - epublish SO - Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. PMID- 37980231 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 1 DP - 2024 Jan TI - Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection. PG - 102548 LID - S1166-7087(23)00238-5 [pii] LID - 10.1016/j.purol.2023.10.002 [doi] AB - PURPOSE: Performing restaging transurethral bladder resection (reTURB) for high-risk non-muscle invasive bladder cancer (NMIBC) reduces the risk of recurrence and tumour understaging. Management of residual high-grade papillary Ta or T1 after reTURB has changed this last 10years in international recommendations. This study aimed to compare the recurrence free survival according to the different management procedures performed. MATERIALS AND METHODS: Patients who underwent reTURB for initial high-risk NMIBC between 2011 and 2020 were included. Patients with residual high-grade papillary Ta or T1 tumour after reTURB were divided into two groups: BCG instillations upfront versus BCG following a third-look resection (3TURB). Patient and tumour characteristics, BCG instillations, recurrence-free survival were retrospectively analysed. RESULTS: A total of 162 high-risk patients were included. Sixty-one (37.7%) had residual high-grade papillary Ta or T1 at reTURB: 35 (21.6%) had BCG instillations upfront, 18 (11.2%) had a 3TURB and 8 (5%) had other management. The mean follow-up was 34.2weeks+/-20.2. Recurrence-free survival was significantly better in patients who underwent BCG instillations upfront (P<0.0043). Recurrence after BCG therapy following reTURB was significantly lower in patients with no residual NMIBC at 6 (92.5% vs. 72.4%, P<0.004) and 12months (85% vs. 67.3%, P<0.03). CONCLUSIONS: The efficacy of intravesical BCG is compromised in case of residual tumour following TURB. The role of a 3TURB following a positive reTURB is not yet determined. This study has confirmed that residual tumor following reTURB is a negative predictive factor but could not demonstrate the value of a 3TURB compared to upfront BCG. CI - Copyright (c) 2023 Elsevier Masson SAS. All rights reserved. FAU - Arnaud, Q AU - Arnaud Q AD - Department of Urology, University Hospital of Bicetre, Paris Sud-Saclay University, Le Kremlin-Bicetre, France. Electronic address: quentinarnaud8@gmail.com. FAU - Sebe, P AU - Sebe P AD - Department of Urology, Hospital Group Diaconesses Croix Saint-Simon, Paris, France. FAU - Colau, A AU - Colau A AD - Department of Urology, Hospital Group Diaconesses Croix Saint-Simon, Paris, France. FAU - Mouton, M AU - Mouton M AD - Department of Urology, Hospital Group Diaconesses Croix Saint-Simon, Paris, France. FAU - Desgrandchamps, F AU - Desgrandchamps F AD - Department of Urology, Saint-Louis Hospital, University of Paris, Paris, France. FAU - Masson-Lecomte, A AU - Masson-Lecomte A AD - Department of Urology, Saint-Louis Hospital, University of Paris, Paris, France. FAU - Bessede, T AU - Bessede T AD - Department of Urology, University Hospital of Bicetre, Paris Sud-Saclay University, Le Kremlin-Bicetre, France. FAU - Irani, J AU - Irani J AD - Department of Urology, University Hospital of Bicetre, Paris Sud-Saclay University, Le Kremlin-Bicetre, France. FAU - Dominique, I AU - Dominique I AD - Department of Urology, Hospital Group Diaconesses Croix Saint-Simon, Paris, France. LA - eng PT - Journal Article DEP - 20231118 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Staging MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - BCG instillations OT - High-risk OT - Non-muscle invasive bladder cancer OT - Restaging transurethral bladder resection EDAT- 2023/11/19 09:42 MHDA- 2024/02/12 15:42 CRDT- 2023/11/18 22:00 PHST- 2023/04/23 00:00 [received] PHST- 2023/08/04 00:00 [revised] PHST- 2023/10/09 00:00 [accepted] PHST- 2024/02/12 15:42 [medline] PHST- 2023/11/19 09:42 [pubmed] PHST- 2023/11/18 22:00 [entrez] AID - S1166-7087(23)00238-5 [pii] AID - 10.1016/j.purol.2023.10.002 [doi] PST - ppublish SO - Fr J Urol. 2024 Jan;34(1):102548. doi: 10.1016/j.purol.2023.10.002. Epub 2023 Nov 18. PMID- 37975369 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20251211 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 27 IP - 21 DP - 2023 Nov TI - Young population bladder neoplasms. PG - 10454-10461 LID - 34320 [pii] LID - 10.26355/eurrev_202311_34320 [doi] AB - OBJECTIVE: Bladder urothelial carcinoma is a rare condition that primarily affects the elderly and is rare in people under 40 years of age. There is no definitive information about the prognosis and clinical behavior of bladder cancer in young individuals. In our study, we aimed to investigate the prognosis and clinicopathological features of bladder tumors in patients under 40. PATIENTS AND METHODS: A retrospective analysis was performed on patients diagnosed with urothelial neoplasia who underwent bladder surgery between January 2008 and December 2020. The patient's medical records in our cancer database were collected. The study included stage, grade, multifocality, smoking habits, recurrence, and survival. The cases were divided into two groups: those under 40 (Group 1) and those over 40 (Group 2). The clinical and pathological features of young and old patients were compared. RESULTS: 17 patients (14 men and 3 women) under 40 were identified. The age ranged between 19 and 40, and the average was 30.6. One infiltrating urothelial carcinoma (pT1), twelve papillary urothelial carcinomas (pTa), two papillary urothelial neoplasias with low malignant potential, and two urothelial papillomas were all identified by pathology. Dysuria was the primary symptom that initially manifested. Recurrence occurred in two of 12 patients with low-grade papillary urothelial carcinoma in the young patient group. In a similar group of patients over 40, recurrence was detected in 7 out of 10 patients. Patients with urothelial carcinoma under the age of 40 have been noted to have single, small tumors, unlike older patients. No tumor progression was detected in young patients. All young patients are still alive and have not experienced any recurrences. In the group of older patients, tumor progression was observed in 11 patients (16.4%). CONCLUSIONS: Patients under 40 typically have low-grade and low-stage bladder urothelial cancer. Because urothelial tumors in young people frequently have a good prognosis and seldom recur, transurethral excision is the preferred treatment method for bladder tumors. FAU - Civi Cetin, K AU - Civi Cetin K AD - Department of Pathology, Eskisehir City Hospital, Eskisehir, Turkey. kismet.civicetin@sbu.edu.tr. FAU - Oner, S AU - Oner S FAU - Erdogan, B AU - Erdogan B FAU - Simsek, G AU - Simsek G FAU - Sezer, M AU - Sezer M LA - eng PT - Journal Article PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 SB - IM MH - Male MH - Humans MH - Female MH - Adolescent MH - Aged MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell MH - Retrospective Studies MH - Prognosis MH - Neoplasm Recurrence, Local/pathology EDAT- 2023/11/17 15:32 MHDA- 2023/11/20 06:55 CRDT- 2023/11/17 06:33 PHST- 2023/11/20 06:55 [medline] PHST- 2023/11/17 15:32 [pubmed] PHST- 2023/11/17 06:33 [entrez] AID - 34320 [pii] AID - 10.26355/eurrev_202311_34320 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2023 Nov;27(21):10454-10461. doi: 10.26355/eurrev_202311_34320. PMID- 37974430 OWN - NLM STAT- MEDLINE DCOM- 20240208 LR - 20240210 IS - 1465-3621 (Electronic) IS - 0368-2811 (Print) IS - 0368-2811 (Linking) VI - 54 IP - 2 DP - 2024 Feb 7 TI - The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin therapy. PG - 192-200 LID - 10.1093/jjco/hyad155 [doi] AB - OBJECTIVE: Several guidelines recommended that second transurethral resection should be performed in patients with diagnosis of high-risk non-muscle-invasive bladder cancer. However, therapeutic benefits of second transurethral resection before bacillus Calmette-Guerin intravesical instillation were conflicting amongst previous studies. We investigated the prognostic impact of second transurethral resection before bacillus Calmette-Guerin instillation in high-risk non-muscle-invasive bladder cancer patients. METHODS: This retrospective study included 3104 non-muscle-invasive bladder cancer patients who received bacillus Calmette-Guerin instillations between 2000 and 2019 at 31 collaborative institutions. Univariate and multivariate Cox proportional hazards models were used to assess the risk factors of intravesical recurrence, disease progression, cancer-specific mortality and overall mortality. RESULTS: In the entire population, patients undergoing second transurethral resection (33%, 1026/3104) had a lower risk of intravesical recurrence on univariate analysis (hazard ratio 0.85, 95% confidence interval 0.73-0.98, P = 0.027), although it did not remain significant on multivariate analysis (hazard ratio 0.90, 95% confidence interval 0.76-1.07, P = 0.24). Subgroup analysis revealed that, in pT1 patients (n = 1487), second transurethral resection was significantly correlated with a lower risk of intravesical recurrence on multivariate analysis (hazard ratio 0.80, 95% confidence interval 0.64-1.00, P = 0.048), but lower risks of disease progression (hazard ratio 0.75, 95% confidence interval 0.56-1.00, P = 0.049), cancer-specific mortality (hazard ratio 0.54, 95% confidence interval 0.35-0.85, P = 0.007) and overall mortality (hazard ratio 0.73, 95% confidence interval 0.55-0.97, P = 0.027) on univariate analysis. CONCLUSIONS: Second transurethral resection confers accurate pathological staging and could be used to safely select good candidates for intravesical bacillus Calmette-Guerin instillation. We further confirm that second transurethral resection could confer an oncological benefit in pT1 bladder cancer patients treated by bacillus Calmette-Guerin instillation, and so strongly recommend second transurethral resection in this patient population. CI - (c) The Author(s) 2023. Published by Oxford University Press. FAU - Kikuchi, Hiroshi AU - Kikuchi H AUID- ORCID: 0000-0003-4999-8994 AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Abe, Takashige AU - Abe T AUID- ORCID: 0000-0002-5468-7632 AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyata, Haruka AU - Miyata H AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Matsumoto, Ryuji AU - Matsumoto R AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tomida, Ryotaro AU - Tomida R AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AUID- ORCID: 0000-0002-5899-1738 AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AUID- ORCID: 0000-0002-8159-9793 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Sato, Takuma AU - Sato T AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Departments of Urology, Kagawa University Faculty of Medicine, Takamatsu, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kojima, Takahiro AU - Kojima T AUID- ORCID: 0000-0003-4150-9631 AD - Department of Urology, Aichi Cancer Center, Nagoya City, Aichi, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Administration, Intravesical MH - Disease Progression MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - Adjuvants, Immunologic/therapeutic use PMC - PMC10849170 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - non-muscle invasive bladder cancer OT - second transurethral resection COIS- None declared. EDAT- 2023/11/17 15:28 MHDA- 2024/02/08 06:42 PMCR- 2023/11/16 CRDT- 2023/11/17 03:42 PHST- 2023/09/14 00:00 [received] PHST- 2023/10/24 00:00 [accepted] PHST- 2024/02/08 06:42 [medline] PHST- 2023/11/17 15:28 [pubmed] PHST- 2023/11/17 03:42 [entrez] PHST- 2023/11/16 00:00 [pmc-release] AID - 7424469 [pii] AID - hyad155 [pii] AID - 10.1093/jjco/hyad155 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2024 Feb 7;54(2):192-200. doi: 10.1093/jjco/hyad155. PMID- 37968169 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 12 DP - 2023 Dec TI - Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition. PG - 461-475 LID - S1078-1439(23)00342-3 [pii] LID - 10.1016/j.urolonc.2023.10.004 [doi] AB - Transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guerin (BCG) is the standard of care in high-risk, non-muscle-invasive bladder cancer (NMIBC). Although many patients respond, recurrence and progression are common. In addition, patients may be unable to receive induction + maintenance due to intolerance or supply issues. Therefore, alternative treatment options are urgently required. Programmed cell death (ligand) 1 (PD-[L]1) inhibitors show clinical benefit in phase 1/2 trials in BCG-unresponsive NMIBC patients. This review presents the status of PD-(L)1 inhibition in high-risk NMIBC and discusses future directions. PubMed and Google scholar were searched for articles relating to NMIBC immunotherapy and ClinicalTrials.gov for planned and ongoing clinical trials. Preclinical and early clinical studies show that BCG upregulates PD-L1 expression in bladder cancer cells and, when combined with a PD-(L)1 inhibitor, a potent antitumor response is activated. Based on this mechanism, several PD-(L)1 inhibitors are in phase 3 trials in BCG-naive, high-risk NMIBC in combination with BCG. Whereas PD-(L)1 inhibitors are well characterized in patients with advanced malignancies, the impact of immune-related adverse events (irAE) on the benefit/risk ratio in NMIBC should be determined. Alternative routes to intravenous administration, like subcutaneous and intravesical administration, may facilitate adherence and access. The outcomes of combination of PD-(L)1 inhibitors and BCG in NMIBC are highly anticipated. There will be a need to address treatment resources, optimal management of irAEs and education and training related to use of this therapy in clinical practice. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Bedke, Jens AU - Bedke J AD - Department of Urology and Transplantation Surgery, Kilinikum Stuttgart, Stuttgart, Germany. Electronic address: bedke@live.com. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Szabados, Bernadett AU - Szabados B AD - University College London Hospital, London, UK; Bart's Cancer Institute, Queen Mary University of London, London, UK. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Shariat, Shahrokh Francois AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Network, Medical University of Vienna, Vienna, Austria. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Hopital Bichat - Claude-Bernard, Universite de Paris Cite, Paris, France. FAU - Brinkmann, Julia AU - Brinkmann J AD - Pfizer Pharma GmbH, Berlin, Germany. FAU - Blake-Haskins, John A AU - Blake-Haskins JA AD - Pfizer Inc., San Diego, CA. FAU - Cesari, Rossano AU - Cesari R AD - Pfizer Inc., Milan, Italy. FAU - Redorta, Joan Palou AU - Redorta JP AD - Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20231114 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Adjuvants, Immunologic/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - BCG Vaccine/pharmacology/therapeutic use MH - *Urinary Bladder Neoplasms/pathology MH - Risk Assessment MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy OTO - NOTNLM OT - BCG OT - High risk OT - Immune checkpoint inhibitors OT - PD-(L)1 inhibition OT - non-muscle-invasive bladder cancer COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/11/16 00:42 MHDA- 2023/12/17 09:45 CRDT- 2023/11/15 21:57 PHST- 2023/04/18 00:00 [received] PHST- 2023/09/27 00:00 [revised] PHST- 2023/10/16 00:00 [accepted] PHST- 2023/12/17 09:45 [medline] PHST- 2023/11/16 00:42 [pubmed] PHST- 2023/11/15 21:57 [entrez] AID - S1078-1439(23)00342-3 [pii] AID - 10.1016/j.urolonc.2023.10.004 [doi] PST - ppublish SO - Urol Oncol. 2023 Dec;41(12):461-475. doi: 10.1016/j.urolonc.2023.10.004. Epub 2023 Nov 14. PMID- 37962848 OWN - NLM STAT- MEDLINE DCOM- 20241009 LR - 20260705 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 42 IP - 17 DP - 2024 Oct TI - Identification of potential phytochemical for the inhibition of non-muscle invasive bladder cancer (NMIBC). PG - 8772-8780 LID - 10.1080/07391102.2023.2280914 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) is one of the most common type of bladder cancer. Here, we have utilized an integrated transcriptomic-computational approach to identify alternate treatments to the NMIBC. In this study, we have performed the comprehensive comparative analysis between three groups of 36 patients with non-relapsed (NR), recurrence and progressive symptoms. Differentially expressed genes involved in the pathways associated with the NMIBC were identified. In silico protein-protein interaction (PPI) network was performed to create the network of the hub genes associated with NMIBC. Further, we compared NR individuals with two cohorts of patients with recurrent and progressive symptoms that lead to the identification of three major biomarkers CD34, FLT1 and WHSC1 genes. Concurrently, PPI also suggests that they are significant hub genes responsible for disease recurrence and progression. Furthermore, targeted genes WHSC-1 and FLT-1 were subjected to virtual screening for identification phytochemical inhibitors. Docking and molecular dynamics simulations concluded that the phytochemicals anonymously named 'UNK' and '6-hydroxycyanidin' are suitable for the inhibition of the proteins causing the NMIBC. In the future, this study will help for strengthening the strategies development at the molecular level for the control of carcinomas at early as well as detection of active and binding site, receptor-ligand interaction and also make drug designing for the early treatment of the carcinomas.Communicated by Ramaswamy H. Sarma. FAU - Liu, Tiantian AU - Liu T AD - The Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, China. FAU - Tang, Qing AU - Tang Q AD - The Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, China. FAU - Shan, Qiujie AU - Shan Q AD - The Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, China. FAU - Wang, Zhixia AU - Wang Z AD - The Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, China. FAU - Shakir, Yasmeen AU - Shakir Y AD - Department of Biochemistry, Hazara University, Mansehra, KPK, Pakistan. FAU - Waqar-Ul-Haq AU - Waqar-Ul-Haq AD - Evolutionary Biology Lab, CABB, University of Agriculture Faisalabad, Faisalabad, Pakistan. FAU - Serfraz, Saad AU - Serfraz S AD - Evolutionary Biology Lab, CABB, University of Agriculture Faisalabad, Faisalabad, Pakistan. FAU - Sun, Lizhu AU - Sun L AD - The Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, China. LA - eng PT - Journal Article DEP - 20231114 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - 0 (Phytochemicals) RN - 0 (Biomarkers, Tumor) SB - IM MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - Humans MH - *Molecular Docking Simulation MH - *Phytochemicals/pharmacology/chemistry MH - *Molecular Dynamics Simulation MH - *Protein Interaction Maps/drug effects MH - Gene Expression Regulation, Neoplastic/drug effects MH - Biomarkers, Tumor/genetics/metabolism MH - Gene Expression Profiling MH - Neoplasm Invasiveness MH - Transcriptome MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Cancer OT - bladder cancer OT - drug discovery OT - phytochemicals OT - transcriptomics EDAT- 2023/11/14 12:43 MHDA- 2024/10/09 12:25 CRDT- 2023/11/14 11:15 PHST- 2024/10/09 12:25 [medline] PHST- 2023/11/14 12:43 [pubmed] PHST- 2023/11/14 11:15 [entrez] AID - 10.1080/07391102.2023.2280914 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2024 Oct;42(17):8772-8780. doi: 10.1080/07391102.2023.2280914. Epub 2023 Nov 14. PMID- 37962240 OWN - NLM STAT- MEDLINE DCOM- 20231219 LR - 20260921 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 23 DP - 2023 Dec TI - Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette-Guerin perfusion. PG - 21279-21286 LID - 10.1002/cam4.6707 [doi] AB - OBJECTIVE: There is no consensus regarding the best interval time between transurethral resection of a bladder tumor and Bacillus Calmette-Guerin (BCG) perfusion. This study was to explore whether the interval time has an impact on the prognosis and adverse effects. METHODS: We retrospectively reviewed the clinical data of patients who received BCG intravesical perfusion at Sun Yat-sen University Cancer Center (SYSUCC) from September 2015 to October 2021. Recurrence-free survival (RFS) and progression-free survival were the primary endpoints. Cox regression was used to explore independent predictors. The association between interval time and adverse effect grade was detected by logistic regression. Propensity score matching (PSM) was performed. RESULTS: A total of 403 patients were enrolled, the median interval time was 24 days (6-163 days), and the follow-up was 28 months (7-82 months). Eighty-eight (20.9%) patients relapsed, and 40 patients (10.0%) suffered progression. The multivariate Cox regression analysis confirmed that interval time was an independent predictor of RFS (p = 0.017). Notably, when the interval time was less than or equal to 26 days, there was a trend toward better RFS, PSM resulted in 65 matched pairs in each group, and Kaplan-Meier analysis showed that there was a significant difference in RFS between groups (p = 0.009). The logistic regression analysis showed that there was no correlation between interval time and adverse effects and their grades (p > 0.05). CONCLUSIONS: We considered that the first BCG perfusion could be performed within 2-4 weeks after surgery. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Cai, Tao-Nong AU - Cai TN AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Lu, Jiang-Li AU - Lu JL AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Chen, Zhi AU - Chen Z AD - Department of Hepatobiliary Surgery II, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liu, Zhen-Hua AU - Liu ZH AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Liu, Zhuo-Wei AU - Liu ZW AUID- ORCID: 0000-0002-8159-3033 AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Yao, Kai AU - Yao K AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Qin, Zi-Ke AU - Qin ZK AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. FAU - Ye, Yun-Lin AU - Ye YL AUID- ORCID: 0000-0001-5424-7066 AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. LA - eng GR - 2022A1515111119/Basic and Applied Basic Research Foundation of Guangdong Province/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231114 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *BCG Vaccine/adverse effects MH - Retrospective Studies MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Perfusion MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology PMC - PMC10726810 OTO - NOTNLM OT - BCG instillation OT - TURBT OT - adverse reaction OT - bladder cancer OT - interval time COIS- The author declares that there is no conflict of interest. EDAT- 2023/11/14 12:42 MHDA- 2023/12/19 06:42 PMCR- 2023/11/14 CRDT- 2023/11/14 07:56 PHST- 2023/09/20 00:00 [revised] PHST- 2023/07/03 00:00 [received] PHST- 2023/10/26 00:00 [accepted] PHST- 2023/12/19 06:42 [medline] PHST- 2023/11/14 12:42 [pubmed] PHST- 2023/11/14 07:56 [entrez] PHST- 2023/11/14 00:00 [pmc-release] AID - CAM46707 [pii] AID - 10.1002/cam4.6707 [doi] PST - ppublish SO - Cancer Med. 2023 Dec;12(23):21279-21286. doi: 10.1002/cam4.6707. Epub 2023 Nov 14. PMID- 37960856 OWN - NLM STAT- MEDLINE DCOM- 20240403 LR - 20240410 IS - 2045-6441 (Electronic) IS - 0036-9330 (Linking) VI - 69 IP - 1 DP - 2024 Feb TI - HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins. PG - 3-9 LID - 10.1177/00369330231213935 [doi] AB - BACKGROUND: Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guerin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood. AIMS: This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins. METHOD: Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups. RESULTS & CONCLUSION: This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins. FAU - Krishnan, Jamie AU - Krishnan J AUID- ORCID: 0000-0001-7324-3386 AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. FAU - Symington, Andrew AU - Symington A AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. FAU - Kernohan, Neil AU - Kernohan N AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. FAU - Bray, Suan AU - Bray S AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. FAU - Robertson, Allison AU - Robertson A AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. FAU - Nabi, Ghulam AU - Nabi G AD - Urology, Ninewells Hospital and Medical School, Dundee, UK. LA - eng PT - Journal Article DEP - 20231113 PL - Scotland TA - Scott Med J JT - Scottish medical journal JID - 2983335R RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Humans MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine/therapeutic use MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - BCG OT - HMG co-reductase OT - Urinary bladder OT - cancer OT - cholesterol COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/14 06:43 MHDA- 2024/04/03 06:44 CRDT- 2023/11/14 03:39 PHST- 2024/04/03 06:44 [medline] PHST- 2023/11/14 06:43 [pubmed] PHST- 2023/11/14 03:39 [entrez] AID - 10.1177/00369330231213935 [doi] PST - ppublish SO - Scott Med J. 2024 Feb;69(1):3-9. doi: 10.1177/00369330231213935. Epub 2023 Nov 13. PMID- 37958973 OWN - NLM STAT- MEDLINE DCOM- 20231117 LR - 20260127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 21 DP - 2023 Nov 5 TI - Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer. LID - 10.3390/ijms242115990 [doi] LID - 15990 AB - Bladder cancer is a common cancer with well-established therapeutic strategies. However, recurrence occurs in 50% of patients with non-muscle-invasive bladder cancer, and 20% of patients progress to muscle-invasive bladder cancer. The 5-year survival rate for muscle-invasive bladder cancer patients is disappointingly low, ranging from 36% to 48%. A molecular marker of interest is chitinase 3-like-1 (CHI3L1), which is elevated in various cancers, including bladder cancer. In addition to its role in cancer cells, CHI3L1 also has regulatory abilities in immune cells. Neutrophil infiltration has been shown to positively correlate with overall survival, progression-free survival, and relapse-free survival in bladder cancer patients. However, the relationship between CHI3L1 and neutrophils remain poorly understood. Therefore, this study investigated the relationship between CHI3L1 level and protumor neutrophil infiltration in bladder cancer. We analyzed the GSE128959 dataset and the data of a bladder cancer cohort undergoing chemotherapy. We observed higher expression of CHI3L1 in bladder cancer patients with invasive or chemotherapy-resistance. Our results revealed a positive correlation between CHI3L1 expression and protumor neutrophil infiltration. Elevated CHI3L1 expression was associated with genes which were related to the recruitment and infiltration of neutrophils. Consequently, CHI3L1 may serve as a novel evaluation factor for the degree of neutrophil infiltration in advanced bladder cancer in those scheduled for chemotherapy. FAU - Xiao, Ling-Yi AU - Xiao LY AUID- ORCID: 0000-0002-3412-7515 AD - Department of Laboratory Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung 404327, Taiwan. FAU - Su, Yu-Li AU - Su YL AD - Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung 83301, Taiwan. AD - Genomic & Proteomic Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan. FAU - Huang, Shih-Yu AU - Huang SY AUID- ORCID: 0000-0002-9444-2285 AD - Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung 83301, Taiwan. FAU - Chen, Yi-Hua AU - Chen YH AUID- ORCID: 0000-0002-4390-1090 AD - Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung 83301, Taiwan. FAU - Hsueh, Po-Ren AU - Hsueh PR AD - Department of Laboratory Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung 404327, Taiwan. AD - Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan. AD - Ph.D. Program for Aging, School of Medicine, China Medical University, Taichung 404327, Taiwan. LA - eng PT - Journal Article DEP - 20231105 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers) RN - EC 3.2.1.14 (Chitinases) RN - 0 (CHI3L1 protein, human) RN - 0 (Chitinase-3-Like Protein 1) SB - IM MH - Humans MH - Biomarkers MH - *Chitinases MH - Neoplasm Recurrence, Local/pathology MH - Neutrophil Infiltration MH - Tumor Microenvironment/genetics MH - *Urinary Bladder Neoplasms/genetics MH - Chitinase-3-Like Protein 1 PMC - PMC10648396 OTO - NOTNLM OT - CHI3L1 OT - bladder cancer OT - neutrophil COIS- The authors declare no conflict of interest. EDAT- 2023/11/14 06:43 MHDA- 2023/11/15 06:43 PMCR- 2023/11/05 CRDT- 2023/11/14 02:11 PHST- 2023/09/25 00:00 [received] PHST- 2023/11/02 00:00 [revised] PHST- 2023/11/03 00:00 [accepted] PHST- 2023/11/15 06:43 [medline] PHST- 2023/11/14 06:43 [pubmed] PHST- 2023/11/14 02:11 [entrez] PHST- 2023/11/05 00:00 [pmc-release] AID - ijms242115990 [pii] AID - ijms-24-15990 [pii] AID - 10.3390/ijms242115990 [doi] PST - epublish SO - Int J Mol Sci. 2023 Nov 5;24(21):15990. doi: 10.3390/ijms242115990. PMID- 37953186 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20250104 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 42 IP - 1 DP - 2024 Jan TI - Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer. PG - 21.e9-21.e20 LID - S1078-1439(23)00324-1 [pii] LID - 10.1016/j.urolonc.2023.09.009 [doi] AB - INTRODUCTION: Pelvic lymphadenectomy (PLND) alongside radical cystectomy (RC), provides crucial diagnostic and therapeutic value in patients with bladder cancer. With the advent of neoadjuvant chemotherapy and prospective data supporting standard PLND, controversy remains regarding the optimal PLND extent and patient selection. Nearly 40% of patients may not receive adequate PLND, even though 25% of patients have positive lymph nodes (LN) at time of RC. We hypothesized that PLND still remains an important facet of bladder cancer treatment. To clarify the prognostic importance of nodal yield, we performed a retrospective investigation of a heterogenous population (pTanyNx/0M0) of patients undergoing RC. METHODS: From the Surveillance, Epidemiology, and End Results (SEER) program, we identified pTanyNx/0M0 bladder cancer patients undergoing RC from 2004 to 2015. Kaplan Meier curves and Cox proportional hazards models assessed cancer-specific survival. Patients were analyzed with PLND performed as the primary covariate. Survival analysis then stratified patients undergoing PLND by LN yield, both as a continuous and categorial variable (30), and T stage. RESULTS: The final cohort included pTanyNx/0M0 patients with urothelial bladder cancer (n = 12,096); median follow up was 39 (IQR: 17-77) months. PLND was performed in 81.45% of patients with a median LN yield of 14 (IQR: 7-23). Most commonly, patients had T2 disease (44.68%). After controlling for age and T stage, patients receiving PLND had improved CSS (HR = 0.56, [95% CI: 0.51-0.62]) compared to those that did not receive PLND. When grouping patients by LN yield, survival improved in a "dose dependent" manner (>30 LN: HR = 0.76, [95% CI: 0.66-0.87]). We noted similar results when stratifying patients into non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC). CONCLUSIONS: In a large contemporary series of pTanyNx/0M0 bladder cancer patients, we found a significant oncologic benefit to PLND. Higher LN yield correlated to improved CSS in non-muscle-invasive and muscle-invasive disease. Our data support the possibility of occult micrometastasis even in non-muscle-invasive disease. Additionally, in light of recent advances in adjuvant immunotherapy, our results emphasize the importance of adequate nodal yield for accurate staging and optimal treatment. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Sodagum, Lohit AU - Sodagum L AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Passarelli, Rachel AU - Passarelli R AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Pfail, John AU - Pfail J AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Patel, Hiren V AU - Patel HV AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Chua, Kevin AU - Chua K AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Doppalapudi, Sai Krishnaraya AU - Doppalapudi SK AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Golombos, David AU - Golombos D AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Elsamra, Sammy E AU - Elsamra SE AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Singer, Eric A AU - Singer EA AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Jang, Thomas L AU - Jang TL AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. FAU - Srivastava, Arnav AU - Srivastava A AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. Electronic address: arnav.srivastava13@gmail.com. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20231110 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Retrospective Studies MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Lymph Node Excision/methods MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy/methods MH - Lymph Nodes/surgery/pathology PMC - PMC10842630 MID - NIHMS1934334 OTO - NOTNLM OT - Bladder cancer OT - Lymph node dissection OT - Urothelial cancer COIS- Declaration of Competing Interest The authors declare no conflicts of interests in preparing this article. EDAT- 2023/11/13 00:42 MHDA- 2023/12/25 06:42 PMCR- 2025/01/01 CRDT- 2023/11/12 21:56 PHST- 2023/04/07 00:00 [received] PHST- 2023/08/28 00:00 [revised] PHST- 2023/09/19 00:00 [accepted] PHST- 2023/12/25 06:42 [medline] PHST- 2023/11/13 00:42 [pubmed] PHST- 2023/11/12 21:56 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S1078-1439(23)00324-1 [pii] AID - 10.1016/j.urolonc.2023.09.009 [doi] PST - ppublish SO - Urol Oncol. 2024 Jan;42(1):21.e9-21.e20. doi: 10.1016/j.urolonc.2023.09.009. Epub 2023 Nov 10. PMID- 37950252 OWN - NLM STAT- MEDLINE DCOM- 20231113 LR - 20231113 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 23 IP - 1 DP - 2023 Nov 10 TI - Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer. PG - 182 LID - 10.1186/s12894-023-01342-2 [doi] LID - 182 AB - PURPOSE: To investigate prognostic values of prostatic urethra involvement (PUI) and construct a prognostic model that estimates the probability of cancer-specific survival for T1 bladder cancer patients. METHOD AND MATERIALS: We investigated the national Surveillance, Epidemiology, and End Results (SEER) database (2004-2015) to get patients diagnosed with T1 bladder cancer. An external validation cohort was obtained from the First Affiliated Hospital of Nanchang University. The Kaplan-Meier method with the log-rank test was applied to assess cancer-specific survival (CSS) and overall survival (OS). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were performed. All patients were randomly divided into the development cohort and validation group at the ratio of 7:3. The performance of the model was internally validated by calibration curves and the concordance index (C-index). RESULTS: The PUI group had a lower survival rate of both CSS and overall survival OS before and after PSM when compared to non-involved patients (All P < 0.05). Multivariate analysis revealed a poor prognosis in the PUI group for cancer-specific mortality (CSM) and all-cause mortality (ACM) analyses before and after PSM (All P < 0.05). Seven variables, including age, surgery, radiotherapy, tumour size, PUI, and marital status, were incorporated in the final nomogram. The C-index in the development cohort was 0.715 (0.711-0.719), while it was 0.672 (0.667-0.677) in the validation group. Calibration plots for 3- and 5-year cancer-specific survival showed good concordance in the development and validation cohorts. CONCLUSIONS: PUI was an independent risk factor of ACM and CSM in T1 bladder cancer patients. In addition, a highly discriminative and precise nomogram that predicted the individualized probability of cancer-specific survival for patients with T1 bladder cancer was constructed. CI - (c) 2023. The Author(s). FAU - Wan, Hao AU - Wan H AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Zhan, Xiangpeng AU - Zhan X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Li, Xuwen AU - Li X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Deng, Xinxi AU - Deng X AD - Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Liu, Yang AU - Liu Y AD - Department of Urology, Jiu Jiang NO.1 People's Hospital, Jiujiang, Jiangxi Province, China. FAU - Deng, Jun AU - Deng J AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Fu, Bin AU - Fu B AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Li, Yu AU - Li Y AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. 290062469@163.com. LA - eng GR - 20202BAB216026/Provincial Natural Youth Fund Project/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20231110 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Prognosis MH - *Nomograms MH - Urethra MH - Databases, Factual MH - *Neoplasms PMC - PMC10638768 OTO - NOTNLM OT - Nomogram OT - Prognosis OT - Prostatic urethra involved OT - SEER OT - T1 bladder cancer COIS- The authors declare no competing interests. EDAT- 2023/11/11 11:46 MHDA- 2023/11/13 06:42 PMCR- 2023/11/10 CRDT- 2023/11/11 00:02 PHST- 2023/02/22 00:00 [received] PHST- 2023/10/16 00:00 [accepted] PHST- 2023/11/13 06:42 [medline] PHST- 2023/11/11 11:46 [pubmed] PHST- 2023/11/11 00:02 [entrez] PHST- 2023/11/10 00:00 [pmc-release] AID - 10.1186/s12894-023-01342-2 [pii] AID - 1342 [pii] AID - 10.1186/s12894-023-01342-2 [doi] PST - epublish SO - BMC Urol. 2023 Nov 10;23(1):182. doi: 10.1186/s12894-023-01342-2. PMID- 37944501 OWN - NLM STAT- MEDLINE DCOM- 20240216 LR - 20240216 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 108 IP - 1 DP - 2024 TI - Upstaging after Transurethral Resection of the Bladder for Non-Muscle-Invasive Cancer of the Bladder: Who Is at Highest Risk? PG - 42-48 LID - 10.1159/000535024 [doi] AB - INTRODUCTION: Transurethral resection of the bladder (TUR-BT) is the standard initial treatment and diagnosis of bladder cancer (BC). Of note, upstaging into muscle-invasive disease (MIBC) during re-resection occurs in a significant proportion of patients. This study aimed to define risk factors at initial TUR-BT for upstaging. METHODS: TUR-BT between 2009 and 2021 were retrospectively screened (n = 3,237). We included patients with visible tumors that received their primary and re-TUR-BT at our institution. Upstaging was defined as pathological tumor stage progression into MIBC at re-TUR-BT. Clinicopathological variables were analyzed for the impact on upstaging. RESULTS: Two hundred and sixty-six patients/532 TUR-BTs were included in the final analysis. Upstaging occurred in 7.9% (21/266) patients. Patients with upstaging presented with stroma-invasive and papillary non-muscle-invasive BC at primary resection in 85.7% (18/21) and 14.3% (3/21), respectively. Detrusor muscle at primary TUR-BT was significantly less present in patients with upstaging (4.1 vs. 95.9%; p < 0.001). After multivariate analysis, solid tumor configuration (HR: 4.17; 95% CI: 1.23-14.15; p = 0.022) and missing detrusor muscle at initial TUR-BT (HR: 3.58; 95% CI: 1.05-12.24; p = 0.043) were significant risk factors for upstaging into MIBC. CONCLUSIONS: The current study defined two major risk factors for upstaging: missing detrusor muscle and solid tumor configuration. We propose that a second resection should be performed earlier if these risk factors apply. CI - (c) 2023 S. Karger AG, Basel. FAU - Volz, Yannic AU - Volz Y AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Trappmann, Rabea AU - Trappmann R AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Ebner, Benedikt AU - Ebner B AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Enzinger, Benazir AU - Enzinger B AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Hermans, Julian AU - Hermans J AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Stief, Christian AU - Stief C AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. FAU - Schulz, Gerald B AU - Schulz GB AD - Department of Urology, University Hospital, LMU Munich, Munich, Germany. LA - eng PT - Journal Article DEP - 20231109 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Urinary Bladder/surgery/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Urologic Surgical Procedures MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery MH - *Transurethral Resection of Bladder OTO - NOTNLM OT - Carcinoma OT - Muscle-invasive disease OT - Pathology OT - Quality control OT - Surgical procedure OT - Transitional cell OT - Upstaging OT - Urinary bladder neoplasms EDAT- 2023/11/10 00:44 MHDA- 2024/02/06 06:42 CRDT- 2023/11/09 18:26 PHST- 2023/05/13 00:00 [received] PHST- 2023/10/25 00:00 [accepted] PHST- 2024/02/06 06:42 [medline] PHST- 2023/11/10 00:44 [pubmed] PHST- 2023/11/09 18:26 [entrez] AID - 000535024 [pii] AID - 10.1159/000535024 [doi] PST - ppublish SO - Urol Int. 2024;108(1):42-48. doi: 10.1159/000535024. Epub 2023 Nov 9. PMID- 37931278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241026 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 18 IP - 2 DP - 2024 Feb TI - Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation. PG - 17-24 LID - 10.5489/cuaj.8386 [doi] AB - INTRODUCTION: Elective pelvic nodal irradiation for patients with muscle-invasive bladder cancer (MIBC) undergoing trimodal therapy (TMT ) is controversial. In patients with node-negative (N0) MIBC, the benefit of elective whole-pelvis concurrent chemoradiation (WP-CCR) compared to bladder-only (BO )-CCR has not been demonstrated. Using real-world data from the National Cancer Database (NCDB ), we sought to compare the overall survival (OS ) between BO-CCR and WP-CCR for MIBC. METHODS: Using the 2020 NCDB Participant User File, we identified cases of MIBC diagnosed between 2017 and 2019. We selected patients with clinical T2-T4aN0M0 disease receiving CCR as first-line treatment. CCR was defined as transurethral resection of bladder tumor followed by >/=40 Gy radiation to the bladder with concurrent single- or multiple-agent chemotherapy. Based on elective nodal irradiation status, patients were stratified as having received BO-CCR vs. WP-CCR. OS analysis was performed using summary three-month conditional landmark, inverse probability treatment weighting (IPTW)-adjusted Kaplan-Meier estimates, and Cox regression. RESULTS: A total of 604 patients receiving CCR for MIBC were identified: 367 (60.8%) BO-CCR and 237 (39.2%) WP-CCR. Before IPTW, the groups were imbalanced in terms of baseline characteristics. The median followup of the weighted population was 42.3 months (interquartile range 18.1-49.1 months). In IPTW-adjusted Cox proportional hazards regression analysis, WP-CCR was associated with a significant OS benefit compared to BO-CCR (adjusted hazard ratio 0.72, 95% confidence interval 0.54-0.96, p=0.026). CONCLUSIONS: In the setting of CCR for N0 MIBC, this retrospective NCDB analysis revealed that WP-CCR was associated with a benefit in OS compared to BO-CCR. FAU - Riveros, Carlos AU - Riveros C AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Ranganathan, Sanjana AU - Ranganathan S AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Haque, Waqar AU - Haque W AD - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, United States. FAU - Huang, Emily AU - Huang E AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Xu, Jiaqiong AU - Xu J AD - Center for Health Data Science and Analytics, Houston Methodist Hospital, Houston, TX, United States. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, University of Toronto, Toronto, ON, Canada. FAU - Geng, Michael AU - Geng M AD - School of Engineering Medicine, Texas A&M University, Houston, TX, United States. FAU - Anis, Maryam AU - Anis M AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Muhammad, Taliah AU - Muhammad T AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Chan, Keith Syson AU - Chan KS AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. AD - Center for TME Spatial Profiling in GU Oncology, Houston Methodist Research Institute, Houston, TX, United States. FAU - Farach, Andrew AU - Farach A AD - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, United States. FAU - Teh, Bin S AU - Teh BS AD - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, United States. FAU - Miles, Brian J AU - Miles BJ AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. FAU - Klaassen, Zachary AU - Klaassen Z AD - Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Sonpavde, Guru P AU - Sonpavde GP AD - Genitourinary Oncology Program, AdventHealth Cancer Institute, Orlando, FL, United States. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Division of Urology, Mount Sinai Hospital, Toronto, ON, Canada. AD - Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, University of Toronto, Toronto, ON, Canada. FAU - Satkunasivam, Raj AU - Satkunasivam R AD - Department of Urology, Houston Methodist Hospital, Houston, TX, United States. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC10841558 COIS- COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work. EDAT- 2023/11/06 18:41 MHDA- 2023/11/06 18:42 PMCR- 2024/02/01 CRDT- 2023/11/06 17:13 PHST- 2023/11/06 18:42 [medline] PHST- 2023/11/06 18:41 [pubmed] PHST- 2023/11/06 17:13 [entrez] PHST- 2024/02/01 00:00 [pmc-release] AID - cuaj.8386 [pii] AID - cuaj-2-17 [pii] AID - 10.5489/cuaj.8386 [doi] PST - ppublish SO - Can Urol Assoc J. 2024 Feb;18(2):17-24. doi: 10.5489/cuaj.8386. PMID- 37923633 OWN - NLM STAT- MEDLINE DCOM- 20241127 LR - 20260824 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 10 IP - 4 DP - 2024 Jul TI - Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. PG - 648-653 LID - S2405-4569(23)00236-5 [pii] LID - 10.1016/j.euf.2023.10.019 [doi] AB - BACKGROUND: High-level evidence supporting the role of repeat transurethral resection (reTUR) in non-muscle-invasive bladder cancer (NMIBC) is lacking. A randomized controlled trial (RCT) assessing whether immediate reTUR has an impact on patient prognosis is essential. However, since such a RCT will require enrollment of a high number of patients, a preliminary feasibility study is appropriate. OBJECTIVE: To assess the feasibility of an RCT investigating the impact of immediate reTUR + adjuvant bacillus Calmette-Guerin (BCG) versus upfront induction BCG after initial TUR in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Eligible patients were randomly assigned to receive either reTUR + adjuvant BCG or upfront induction BCG after TUR. Patients with macroscopically completely resected high-grade T1 NMIBC, with or without concomitant carcinoma in situ, and with detrusor muscle (DM) present in the initial TUR specimen were considered eligible for inclusion. Exclusion criteria included lymphovascular invasion (LVI), histological subtypes, hydronephrosis, concomitant upper tract urothelial carcinoma (UTUC), or urothelial carcinoma within the prostatic urethra. The aim was to enroll 30 patients in this feasibility study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The patient recruitment rate was the primary outcome. Oncological outcomes (recurrence-free and progression-free survival) were secondary endpoints. RESULTS AND LIMITATIONS: Overall, 30 patients (15 per arm) were randomized over a period of 14 mo (August 2020-October 2021). Two eligible patients refused the randomization, resulting in a patient compliance rate of 93.3% for the study protocol. We excluded 49 ineligible patients before randomization because of histological subtypes (n = 16, 33%), LVI (n = 9, 18%), DM absence in the TUR specimen (n = 12, 24%), metastatic disease (n = 5, 10%), concomitant UTUC (n = 3, 6%), or hydronephrosis (n = 4, 8%). At reTUR, persistent disease was found in four patients (29%) and upstaging to muscle-invasive disease in one (7%). Over median follow-up of 17 mo, disease recurrence was detected in three patients (23%) in the reTUR arm and six patients (40%) in the upfront BCG arm. Progression to muscle-invasive disease was observed in one patient treated with upfront BCG. CONCLUSIONS: The feasibility of conducting an RCT comparing upfront BCG versus reTUR + BCG in high-grade T1 NMIBC has been demonstrated. Our results underline the need to screen a large number of patients owing to characteristics meeting the exclusion criteria in a high percentage of cases. PATIENT SUMMARY: We found that a clinical trial of the role of a repeat surgical procedure to remove bladder tumors through the urethra would be feasible among patients with high-grade non-muscle-invasive bladder cancer. These preliminary results may help in refining the role of this repeat procedure for patients in this category. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. Electronic address: francesco.soria@unito.it. FAU - Rosazza, Matteo AU - Rosazza M AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Livoti, Simone AU - Livoti S AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Dutto, Daniele AU - Dutto D AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Colucci, Fulvia AU - Colucci F AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20231103 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Eur Urol Focus. 2024 Mar;10(2):246. doi: 10.1016/j.euf.2023.12.007. PMID: 38272719 CIN - Eur Urol Focus. 2024 Mar;10(2):247. doi: 10.1016/j.euf.2024.01.004. PMID: 38278711 MH - *Urinary Bladder Neoplasms/surgery/pathology/drug therapy MH - Humans MH - *Feasibility Studies MH - *BCG Vaccine/therapeutic use/administration & dosage MH - *Neoplasm Invasiveness MH - *Adjuvants, Immunologic/therapeutic use MH - Cystectomy/methods MH - Male MH - Aged MH - Reoperation MH - Female MH - Urethra MH - Middle Aged MH - Combined Modality Therapy MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - High-grade T1 non-muscle-invasive bladder cancer OT - Randomized controlled trial OT - Repeat transurethral resection EDAT- 2023/11/06 01:19 MHDA- 2024/11/28 00:24 CRDT- 2023/11/03 22:55 PHST- 2023/09/02 00:00 [received] PHST- 2023/10/10 00:00 [revised] PHST- 2023/10/21 00:00 [accepted] PHST- 2024/11/28 00:24 [medline] PHST- 2023/11/06 01:19 [pubmed] PHST- 2023/11/03 22:55 [entrez] AID - S2405-4569(23)00236-5 [pii] AID - 10.1016/j.euf.2023.10.019 [doi] PST - ppublish SO - Eur Urol Focus. 2024 Jul;10(4):648-653. doi: 10.1016/j.euf.2023.10.019. Epub 2023 Nov 3. PMID- 37925655 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240529 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 31 IP - 2 DP - 2024 Feb TI - Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma. PG - 1393-1401 LID - 10.1245/s10434-023-14514-z [doi] AB - OBJECTIVE: We aimed to develop and validate a preoperative nomogram that predicts low-grade, non-muscle invasive upper urinary tract urothelial carcinoma (LG-NMI UTUC), thereby aiding in the accurate selection of endoscopic management (EM) candidates. METHODS: This was a retrospective study that included 454 patients who underwent radical surgery (Cohort 1 and Cohort 2), and 26 patients who received EM (Cohort 3). Utilizing a multivariate logistic regression model, a nomogram predicting LG-NMI UTUC was developed based on data from Cohort 1. The nomogram's accuracy was compared with conventional European Association of Urology (EAU) and National Comprehensive Cancer Network (NCCN) models. External validation was performed using Cohort 2 data, and the nomogram's prognostic value was evaluated via disease progression metrics in Cohort 3. RESULTS: In Cohort 1, multivariate analyses highlighted the absence of invasive disease on imaging (odds ratio [OR] 7.04; p = 0.011), absence of hydronephrosis (OR 2.06; p = 0.027), papillary architecture (OR 24.9; p < 0.001), and lack of high-grade urine cytology (OR 0.22; p < 0.001) as independent predictive factors for LG-NMI disease. The nomogram outperformed the two conventional models in predictive accuracy (0.869 vs. 0.759-0.821) and exhibited a higher net benefit in decision curve analysis. The model's clinical efficacy was corroborated in Cohort 2. Moreover, the nomogram stratified disease progression-free survival rates in Cohort 3. CONCLUSION: Our nomogram ( https://kmur.shinyapps.io/UTUC_URS/ ) accurately predicts LG-NMI UTUC, thereby identifying suitable candidates for EM. Additionally, the model serves as a useful tool for prognostic stratification in patients undergoing EM. CI - (c) 2023. Society of Surgical Oncology. FAU - Nakamoto, Takahiro AU - Nakamoto T AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. AD - Department of Pathology, Kansai Medical University Hospital, Osaka, Japan. FAU - Yoshida, Takashi AU - Yoshida T AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. yoshidtk@takii.kmu.ac.jp. AD - Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan. yoshidtk@takii.kmu.ac.jp. AD - Faculty of Engineering, Tottori University Graduate School of Engineering, Tottori, Japan. yoshidtk@takii.kmu.ac.jp. FAU - Katayama, Satoshi AU - Katayama S AD - Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - Ohe, Chisato AU - Ohe C AD - Department of Pathology, Kansai Medical University Hospital, Osaka, Japan. AD - Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan. FAU - Kawaura, Takayuki AU - Kawaura T AD - Department of Mathematics, Kansai Medical University, Osaka, Japan. FAU - Horii, Satoshi AU - Horii S AD - Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - Ikeda, Junichi AU - Ikeda J AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. FAU - Kono, Yumiko AU - Kono Y AD - Department of Radiology, Kansai Medical University, Osaka, Japan. FAU - Murota, Takashi AU - Murota T AD - Department of Urology and Andrology, General Medical Center, Kansai Medical University, Osaka, Japan. FAU - Kitawaki, Tomoki AU - Kitawaki T AD - Department of Mathematics, Kansai Medical University, Osaka, Japan. FAU - Araki, Motoo AU - Araki M AD - Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - Kinoshita, Hidefumi AU - Kinoshita H AD - Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. LA - eng PT - Journal Article DEP - 20231105 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2024 Feb;31(2):1412-1413. doi: 10.1245/s10434-023-14604-y. PMID: 37957505 EIN - Ann Surg Oncol. 2024 Feb;31(2):1422. doi: 10.1245/s10434-023-14635-5. PMID: 37991583 MH - Humans MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Nomograms MH - Retrospective Studies MH - *Urinary Bladder Neoplasms MH - *Ureteral Neoplasms MH - *Kidney Neoplasms MH - Decision Making MH - *Urinary Tract/pathology EDAT- 2023/11/05 18:42 MHDA- 2024/01/05 06:42 CRDT- 2023/11/05 15:04 PHST- 2023/06/26 00:00 [received] PHST- 2023/10/12 00:00 [accepted] PHST- 2024/01/05 06:42 [medline] PHST- 2023/11/05 18:42 [pubmed] PHST- 2023/11/05 15:04 [entrez] AID - 10.1245/s10434-023-14514-z [pii] AID - 10.1245/s10434-023-14514-z [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Feb;31(2):1393-1401. doi: 10.1245/s10434-023-14514-z. Epub 2023 Nov 5. PMID- 37916931 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20250824 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 110 IP - 2 DP - 2024 Feb 1 TI - HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study. PG - 847-858 LID - 10.1097/JS9.0000000000000859 [doi] AB - INTRODUCTION: Human epidermal growth factor receptor type 2 (HER2) overexpression is a prognostic factor and a therapeutic target for breast cancer; however, anti-HER2 therapies are ineffective in patients with bladder cancer. The authors investigated the effect of HER2 overexpression (HER2 + ) on the prognosis of muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: This retrospective cohort study included patients who underwent initial transurethral resection of bladder tumors between 2005 and 2013 and were registered in the Korea National Health Insurance Database, which provides data on overall survival (OS). Sixty-one patients with clinically nonmetastatic de novo MIBC were included in this study. As a subgroup, 33 patients who underwent immediate radical cystectomy (RC) were analyzed. Univariate and multivariate Cox proportional hazards models were used to identify prognostic factors for survival. A multivariable binary logistic regression model was used to identify the favorable T stage. RESULTS: Among the 61 patients with d-MIBC, 14 were HER2 + and 47 HER2 - . Age less than 70 years [hazard ratio (HR): 0.312, CI: 0.16-0.59, P <0.001] and HER2 + status (HR: 0.40, CI: 0.19-0.85, P =0.02) were favorable prognostic factors for OS after adjusting for clinical variables. In the RC subgroup, HER2 + status was a significant predictive factor for the pT2 stage (HR): 36.8, CI: 4.83-797.41, P <0.01). Age less than 70 years (HR: 0.15, CI: 0.05-0.42, P <0.001) and HER2 + status (HR: 0.11, CI: 0.02-0.54, P =0.01) were favorable prognostic factors for OS after adjusting for RC pathological variables. CONCLUSIONS: HER2 + status could be a marker for an indolent subset of MIBC and could predict favorable survival regardless of RC status. Moreover, HER2 + status not only consistently predicted a favorable T stage after RC, but also predicted better survival than pathological outcomes. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Kim, So Won AU - Kim SW AD - Department of Pharmacology. AD - Bio-Medical Institute of Technology, University of Ulsan, Seoul. FAU - Yu, Hoon AU - Yu H AD - Bio-Medical Institute of Technology, University of Ulsan, Seoul. AD - Department of Nephrology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. FAU - Kim, Younjuong AU - Kim Y AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine. FAU - Nam, Kyeng Hyun AU - Nam KH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine. FAU - Chae, Han Kyu AU - Chae HK AD - Department of Urology. FAU - Nam, Wook AU - Nam W AD - Department of Urology. FAU - Eom, Dae-Woon AU - Eom DW AD - Department of Pathology. FAU - Park, Jong Yeon AU - Park JY AD - Department of Urology. FAU - Kim, Sung Jin AU - Kim SJ AD - Bio-Medical Institute of Technology, University of Ulsan, Seoul. AD - Department of Urology. LA - eng PT - Journal Article DEP - 20240201 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - Aged MH - *Cystectomy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Muscles/pathology MH - Neoplasm Invasiveness PMC - PMC10871625 COIS- All authors have no conflicts of interest. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. EDAT- 2023/11/02 12:43 MHDA- 2024/02/19 06:43 PMCR- 2024/02/16 CRDT- 2023/11/02 10:03 PHST- 2023/07/27 00:00 [received] PHST- 2023/10/10 00:00 [accepted] PHST- 2024/02/19 06:43 [medline] PHST- 2023/11/02 12:43 [pubmed] PHST- 2023/11/02 10:03 [entrez] PHST- 2024/02/16 00:00 [pmc-release] AID - 01279778-202402000-00024 [pii] AID - IJS-D-23-01589 [pii] AID - 10.1097/JS9.0000000000000859 [doi] PST - epublish SO - Int J Surg. 2024 Feb 1;110(2):847-858. doi: 10.1097/JS9.0000000000000859. PMID- 37915689 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231103 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 85 IP - 11 DP - 2023 Nov TI - Intravesical mitomycin C efficacy in acidic and alkaline urinary pH: impact on recurrence-free survival rate after TURBT. PG - 5323-5327 LID - 10.1097/MS9.0000000000001350 [doi] AB - BACKGROUND: Urinary bladder tumor recurrence following transurethral resection of bladder tumor (TURBT) is a common issue. This study aims to determine how urine alkalinization affects bladder tumor recurrence after surgery. MATERIALS AND METHODS: Sixty patients receiving mitomycin C (MMC) therapy after TURBT were divided into two groups based on mean pH values. Twenty-six patients were in group A, whose urine pH was below 5.5. However, there were 34 patients in group B, and their urine pH was higher than 5.5. Both groups of patients were given intravesical MMC once weekly for 6 weeks following TURBT. A cystoscopy was performed as a follow-up at 3, 6, and 12 months. Urine pH and the recurrence-free survival rate were compared using Kaplan-Meier survival analysis and the COX proportional hazard model. RESULTS: The mean time to tumor recurrence in group A (intravesical MMC in acidic urine) and group B (intravesical MMC in alkaline urine) was 12.48 versus 16.84 months, respectively. Alkaline urine pH was identified as an independent predictor of preventing the recurrence of superficial bladder tumors by univariate COX regression analysis. Age, sex, and mean tumor size did not affect the likelihood of tumor recurrence. However, smoking had an association with increased tumor recurrence. CONCLUSION: Tumor recurrence post-TURBT is delayed in patients with alkaline urine pH. Smoking is an independent risk factor for bladder tumors. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Naeem, Muhammad Tayyab AU - Naeem MT AD - Shaikh Zayed Hospital, Lahore. FAU - Usman, Ahmed Hassan AU - Usman AH AD - University Hospitals of Birmingham, Birmingham, UK. FAU - Ali, Sarmad AU - Ali S AD - Al-Shifa Hospital, Hospital Road, Mandi Bahuddin. FAU - Raza, Hassan AU - Raza H AD - Gujranwala Teaching Hospital, Gujranwala, Pakistan. FAU - Shah, Ali Nawaz AU - Shah AN AD - Pak Oilfields Limited Hospital, Khaur, Attock. FAU - Mahmmoud Fadelallah Eljack, Mohammed AU - Mahmmoud Fadelallah Eljack M AD - Faculty of Medicine and Health Sciences, University of Bakht Alruda, Ad Duwaym, Sudan. LA - eng PT - Journal Article DEP - 20231002 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC10617880 OTO - NOTNLM OT - TURBT OT - carcinoma OT - medicine OT - mitomycin C OT - tumor recurrence COIS- The authors declared no potential conflicts of interest. EDAT- 2023/11/02 06:42 MHDA- 2023/11/02 06:43 PMCR- 2023/10/02 CRDT- 2023/11/02 04:04 PHST- 2023/05/27 00:00 [received] PHST- 2023/09/17 00:00 [accepted] PHST- 2023/11/02 06:43 [medline] PHST- 2023/11/02 06:42 [pubmed] PHST- 2023/11/02 04:04 [entrez] PHST- 2023/10/02 00:00 [pmc-release] AID - AMSU-D-23-01170 [pii] AID - 10.1097/MS9.0000000000001350 [doi] PST - epublish SO - Ann Med Surg (Lond). 2023 Oct 2;85(11):5323-5327. doi: 10.1097/MS9.0000000000001350. eCollection 2023 Nov. PMID- 37910382 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 56 IP - 3 DP - 2024 Mar TI - Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer. PG - 827-837 LID - 10.1007/s11255-023-03851-3 [doi] AB - PURPOSE: There is significant lack on evidence regarding the effect of non-adherence to a recommended protocol in follow-up of high-risk non-muscle-invasive bladder cancer (NMIBC), or the impact of delaying detection of recurrent lesion. Here, we aimed to investigate the optimal frequency of follow-up cystoscopy of high-risk NMIBC with respect to oncological safety in the Japanese real-world clinical practice. METHODS: This retrospective single-center study included 206 patients with primary high-risk NMIBC. The intensity (%) of follow-up cystoscopy was calculated based on actual visits for cystoscopy and guideline-recommended frequency in the first 24-month follow-up period. Inverse probability of treatment weighting analyses was used to reduce the risk of bias between groups. We performed a restricted cubic spline analysis with knots at intensity of follow-up cystoscopy 75% intensity groups. A restricted cubic spline analysis suggested no significant effect of the intensity of follow-up on progression risk, and hazard ratios of patients of < 100% intensity were equivalent to those of patients of 100% intensity. CONCLUSION: Our finding suggested decreased intensity of follow-up cystoscopy did not affect oncological outcomes in patients with high-risk NMIBC. Further prospective trials directly aimed at investigating optimized follow-up schedules for NMIBC are mandatory before substantial changes to existing clinical guidelines. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Nishioka, Yuichi AU - Nishioka Y AD - Department of Public Health, Health Management, and Policy, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan. FAU - Oda, Yuki AU - Oda Y AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Tomizawa, Mitsuru AU - Tomizawa M AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Ohnishi, Kenta AU - Ohnishi K AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, Japan. FAU - Imamura, Tomoaki AU - Imamura T AD - Department of Public Health, Health Management, and Policy, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. LA - eng PT - Journal Article DEP - 20231101 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - Cystoscopy/methods MH - *Non-Muscle Invasive Bladder Neoplasms MH - Follow-Up Studies MH - Retrospective Studies MH - Disease Progression MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Follow-up OT - Surveillance EDAT- 2023/11/01 18:44 MHDA- 2024/02/12 05:13 CRDT- 2023/11/01 12:12 PHST- 2023/09/13 00:00 [received] PHST- 2023/10/09 00:00 [accepted] PHST- 2024/02/12 05:13 [medline] PHST- 2023/11/01 18:44 [pubmed] PHST- 2023/11/01 12:12 [entrez] AID - 10.1007/s11255-023-03851-3 [pii] AID - 10.1007/s11255-023-03851-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2024 Mar;56(3):827-837. doi: 10.1007/s11255-023-03851-3. Epub 2023 Nov 1. PMID- 37909427 OWN - NLM STAT- MEDLINE DCOM- 20240328 LR - 20240328 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 91 IP - 1 DP - 2024 Feb TI - Prognostic significance of preoperative pyuria & neutrophil to lymphocyte ratio in patients with non-muscle-invasive bladder cancer: A prospective cohort study. PG - 69-75 LID - 10.1177/03915603231203780 [doi] AB - BACKGROUND: The most prevalent cancer of the urinary system and the fourth most frequent cancer in men is bladder cancer. Up to 45% of non-muscle-invasive bladder cancers (NMIBC), may develop into muscle-invasive disease within 5 years after initial diagnosis, depending on the risk profile. The neutrophil to lymphocyte ratio (NLR), which is an emerging marker of host inflammation and can be easily calculated from routine complete blood counts (CBCs) with differentials, has shown to be an independent prognostic factor for a variety of solid malignancies, including urinary tract cancer. Pyuria is a well-documented prognostic factor in urinary tract carcinomas, according to several research. The relationship between preoperative pyuria and recurrence in patients with NMIBC is unclear, even though some studies found that pyuria was a strong predictor of poor prognosis in patients with NMIBC. Our study's objective was to compare the prognostic effect of pre-treatment pyuria and NLR on the likelihood of progression and recurrence in individuals with primary NMIBC. MATERIALS AND METHODOLOGY: Data obtained from 100 bladder cancer patients who underwent transurethral resection of bladder tumor (TURBT) from June 2021 to January 2023 were evaluated prospectively. INCLUSION CRITERIA: Age more than 18 years, having tumor size less than 3 x 3 cm, single tumor, no H/O TURBT. EXCLUSION CRITERIA: Age less than 18 years, size more than 3 x 3 cm, multiple tumors, H/O TURBT. RESULTS: We demonstrated in the current study that, compared to NLR, preoperative pyuria was more substantially linked with intravesical recurrence, higher T stage and disease progression following TURBT for NMIBC. FAU - Singh, Rahul AU - Singh R AUID- ORCID: 0000-0002-3534-2532 AD - Department of Urology, SMS Medical College, Jaipur, Rajasthan, India. FAU - Sharma, Govind AU - Sharma G AD - Department of Urology, SMS Medical College, Jaipur, Rajasthan, India. FAU - Priyadarshi, Shivam AU - Priyadarshi S AD - SMS Medical College, Jaipur, Rajasthan, India. FAU - Fauzdar, Gaurav AU - Fauzdar G AUID- ORCID: 0000-0001-5024-8336 AD - Department of Urology, SMS Medical College, Jaipur, Rajasthan, India. LA - eng PT - Journal Article DEP - 20231101 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Male MH - Humans MH - Adolescent MH - Prognosis MH - Neutrophils/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - Prospective Studies MH - *Pyuria/pathology MH - *Urinary Bladder Neoplasms/surgery MH - Lymphocytes/pathology MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - NMIBC OT - Pyuria OT - TURBT OT - carcinoma in situ OT - neutrophil to lymphocyte ratio COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/01 12:42 MHDA- 2024/03/28 06:45 CRDT- 2023/11/01 07:33 PHST- 2024/03/28 06:45 [medline] PHST- 2023/11/01 12:42 [pubmed] PHST- 2023/11/01 07:33 [entrez] AID - 10.1177/03915603231203780 [doi] PST - ppublish SO - Urologia. 2024 Feb;91(1):69-75. doi: 10.1177/03915603231203780. Epub 2023 Nov 1. PMID- 37907551 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231108 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Oct 31 TI - Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics. PG - 18754 LID - 10.1038/s41598-023-45581-7 [doi] LID - 18754 AB - Cancer is one of the most widespread diseases around the world with millions of new patients each year. Bladder cancer is one of the most prevalent types of cancer affecting all individuals alike with no obvious "prototypical patient". The current standard treatment for BC follows a routine weekly Bacillus Calmette-Guerin (BCG) immunotherapy-based therapy protocol which is applied to all patients alike. The clinical outcomes associated with BCG treatment vary significantly among patients due to the biological and clinical complexity of the interaction between the immune system, treatments, and cancer cells. In this study, we take advantage of the patient's socio-demographics to offer a personalized mathematical model that describes the clinical dynamics associated with BCG-based treatment. To this end, we adopt a well-established BCG treatment model and integrate a machine learning component to temporally adjust and reconfigure key parameters within the model thus promoting its personalization. Using real clinical data, we show that our personalized model favorably compares with the original one in predicting the number of cancer cells at the end of the treatment, with [Formula: see text] improvement, on average. CI - (c) 2023. The Author(s). FAU - Savchenko, Elizaveta AU - Savchenko E AD - Department of Mathematics, Ariel University, Ariel, Israel. FAU - Rosenfeld, Ariel AU - Rosenfeld A AD - Department of Information Science, Bar Ilan University, Ramat-Gan, Israel. FAU - Bunimovich-Mendrazitsky, Svetlana AU - Bunimovich-Mendrazitsky S AD - Department of Mathematics, Ariel University, Ariel, Israel. svetlanabu@ariel.ac.il. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231031 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy MH - Immunotherapy/methods MH - Models, Theoretical MH - Administration, Intravesical MH - Demography MH - Neoplasm Recurrence, Local/drug therapy PMC - PMC10618543 COIS- The authors declare no competing interests. EDAT- 2023/11/01 06:43 MHDA- 2023/11/02 12:46 PMCR- 2023/10/31 CRDT- 2023/11/01 00:30 PHST- 2023/07/25 00:00 [received] PHST- 2023/10/21 00:00 [accepted] PHST- 2023/11/02 12:46 [medline] PHST- 2023/11/01 06:43 [pubmed] PHST- 2023/11/01 00:30 [entrez] PHST- 2023/10/31 00:00 [pmc-release] AID - 10.1038/s41598-023-45581-7 [pii] AID - 45581 [pii] AID - 10.1038/s41598-023-45581-7 [doi] PST - epublish SO - Sci Rep. 2023 Oct 31;13(1):18754. doi: 10.1038/s41598-023-45581-7. PMID- 37905506 OWN - NLM STAT- MEDLINE DCOM- 20240328 LR - 20240328 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 91 IP - 1 DP - 2024 Feb TI - Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer. PG - 61-68 LID - 10.1177/03915603231206603 [doi] AB - OBJECTIVES: We aimed to compare the efficacy and adverse events of Bacillus Calmette-Guerin (BCG) versus Mitomycin C (MMC) in high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients. METHODS: This randomized controlled study was conducted over 24 months in four hospitals in Egypt. A sample of 90 patients was randomly assigned to either treatment group, with procedures including baseline examinations, a single postoperative instillation of chemotherapy, a 6-week induction cycle of the assigned drug, and regular follow-up cystoscopies and upper urinary tract imaging. Treatment results and side effects were monitored, with data analyzed via Statistical Package for Social Sciences (SPSS). RESULTS: No significant differences were observed in mean age or tumor characteristics (p > 0.05). However, adverse reactions were significantly higher in the BCG group, including cystitis (40% vs. 17.78%, p = 0.020), hematuria (24.44% vs. 4.44%, p = 0.007), overall local reactions (75.56% vs. 26.67%, p < 0.001), fever (13.33% vs. 2.22%, p = 0.049), and fatigue (17.78% vs. 2.22%, p = 0.014). The MMC group had a slightly higher recurrence rate (28.89% vs. 17.78%, hazard ratio 1.89, 95% CI: 0.78-4.55, p = 0.15) with a shorter median time to recurrence (six vs. 12 months). Progression rates were similar (8.89% MMC vs. 4.44% BCG, p = 0.398). CONCLUSION: Although BCG and MMC have comparable efficacy in managing high-risk NMIBC, BCG demonstrated a higher rate of adverse reactions. Decision-making should consider this balance, patient preferences, and health status. Further research is needed for the validation and exploration of these findings. FAU - Zaza, Mohamed Mahmoud Abdelfatah AU - Zaza MMA AD - Department of Urology, Faculty of Medicine, Helwan University, Cairo, Egypt. FAU - Salem, Tarek Abd El-Mageed AU - Salem TAE AD - Department of Urology, Faculty of Medicine, Helwan University, Cairo, Egypt. FAU - El-Sadat, Ahmed Mohamed AU - El-Sadat AM AUID- ORCID: 0009-0005-5398-5450 AD - Urology Department, Air Force Hospital, Military Medical Academy, Cairo, Egypt. FAU - Hassan Ali, Mohammed AU - Hassan Ali M AD - Department of Urology, Faculty of Medicine, Helwan University, Cairo, Egypt. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20231031 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Mitomycin/adverse effects MH - BCG Vaccine MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Treatment Outcome MH - Administration, Intravesical MH - Neoplasm Recurrence, Local MH - Adjuvants, Immunologic MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Mitomycin C OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/10/31 12:41 MHDA- 2024/03/28 06:44 CRDT- 2023/10/31 07:11 PHST- 2024/03/28 06:44 [medline] PHST- 2023/10/31 12:41 [pubmed] PHST- 2023/10/31 07:11 [entrez] AID - 10.1177/03915603231206603 [doi] PST - ppublish SO - Urologia. 2024 Feb;91(1):61-68. doi: 10.1177/03915603231206603. Epub 2023 Oct 31. PMID- 37894293 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 20 DP - 2023 Oct 10 TI - Oncological Efficacy of Robotic Nephroureterectomy vs. Open and Laparoscopic Nephroureterectomy for Suspected Non-Metastatic UTUC-A Systematic Review and Meta-Analysis. LID - 10.3390/cancers15204926 [doi] LID - 4926 AB - INTRODUCTION AND AIMS: The optimal approach for nephroureterectomy in patients with suspected UTUC remains a point of debate. In this review, we compare the oncological outcomes of robotic nephroureterectomy (RNU) with open (ONU) or laparoscopic nephroureterectomy (LNU). METHODS: All randomized trials and observational studies comparing RNU with ONU and/or LNU for suspected non-metastatic UTUC are included in this review. The systematic review was performed in accordance with the Cochrane Guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The primary outcome measures were overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IV-RFS). The secondary outcome measures were the lymph node dissection (LND) rates, positive margin rates, and the proportion of patients receiving bladder intravesical chemotherapy. RESULTS: We identified 8172 references through our electronic searches and 8 studies through manual searching. A total of 15 studies met the inclusion criteria. The total number of patients in the review was 18,964. RNU had superior OS compared to LNU (HR: 0.81 (95% CI: 0.71, 0.93), p-0.002 (very low certainty)). RNU and ONU had similar OS (HR: 0.83 (95% CI: 0.52, 1.34), p-0.44 (very low certainty)). One study reported an independent association of RNU as a worse predictor of IV-RFS when compared to ONU (HR-1.73 (95% CI: 1.22, 2.45)). The LND rates were higher in the RNU cohort when compared to the LNU cohort (RR 1.24 (95% CI: 1.03, 1.51), p-0.03 (low certainty)). The positive margin rate was lower in the RNU cohort when compared to the ONU cohort (RR 0.29 (95% CI: 0.08, 0.86), p-0.03 (low certainty)). CONCLUSION: RNU offers comparable oncological efficacy to ONU, except for intravesical recurrence-free survival (IV-RFS). RNU has fewer positive surgical margin rates compared to ONU in well-balanced studies. RNU appears to outperform LNU for certain oncological parameters, such as OS and the proportion of patients who receive lymph node dissections. The quality of evidence comparing surgical techniques for UTUC has remained poor in the last decade. FAU - Rajan, Karthik AU - Rajan K AD - Department of Urology, Freeman Hospital, Newcastle NE7 7PJ, UK. FAU - Khalifa, Ahmad AU - Khalifa A AUID- ORCID: 0000-0003-1376-5697 AD - Department of Urology, Freeman Hospital, Newcastle NE7 7PJ, UK. FAU - Geraghty, Robert AU - Geraghty R AD - Department of Urology, Freeman Hospital, Newcastle NE7 7PJ, UK. FAU - Parmar, Kalpesh AU - Parmar K AD - Department of Urology, Freeman Hospital, Newcastle NE7 7PJ, UK. FAU - KandaSwamy, Gokul AU - KandaSwamy G AD - Department of Urology, Morriston Hospital, Swansea SA6 6NL, UK. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AUID- ORCID: 0000-0002-0556-3035 AD - Department of Urology, Hospital Clinico San Carlos, 28040 Madrid, Spain. FAU - Somani, Bhaskar AU - Somani B AUID- ORCID: 0000-0002-6248-6478 AD - Department of Urology, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Rai, Bhavan Prasad AU - Rai BP AD - Department of Urology, Freeman Hospital, Newcastle NE7 7PJ, UK. LA - eng PT - Journal Article PT - Review DEP - 20231010 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10605607 OTO - NOTNLM OT - laparoscopic nephroureterectomy OT - minimally invasive techniques OT - neoplasms of ureter OT - open nephroureterectomy OT - radical nephroureterectomy OT - robotic nephroureterectomy OT - robotic surgery OT - upper tract urothelial carcinoma COIS- The authors do not have any conflict of interest to declare. EDAT- 2023/10/28 11:46 MHDA- 2023/10/28 11:47 PMCR- 2023/10/10 CRDT- 2023/10/28 01:14 PHST- 2023/09/01 00:00 [received] PHST- 2023/09/28 00:00 [revised] PHST- 2023/10/02 00:00 [accepted] PHST- 2023/10/28 11:47 [medline] PHST- 2023/10/28 11:46 [pubmed] PHST- 2023/10/28 01:14 [entrez] PHST- 2023/10/10 00:00 [pmc-release] AID - cancers15204926 [pii] AID - cancers-15-04926 [pii] AID - 10.3390/cancers15204926 [doi] PST - epublish SO - Cancers (Basel). 2023 Oct 10;15(20):4926. doi: 10.3390/cancers15204926. PMID- 37892022 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 20 DP - 2023 Oct 13 TI - Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence. LID - 10.3390/diagnostics13203201 [doi] LID - 3201 AB - Next-generation sequencing (NGS) is widely used in muscle-invasive bladder cancer but has limited use in non-muscle-invasive bladder cancer (NMIBC) due to significant heterogeneity and high cancer-specific survival. Therefore, we evaluated the genomic information of NMIBC and identified molecular alterations associated with tumour recurrence. A total of 43 patients with NMIBC who underwent transurethral resection of the bladder were enrolled. We performed NGS using an Oncomine panel of tumour specimens and blood samples corresponding to each specimen. The somatic mutation results were analysed by pairwise comparison and logistic regression according to the recurrence of bladder tumours within 1 year. The median incidence of genetic variations in 43 tumour samples was 56 variations per sample, and a high tumour mutation burden (TMB) was associated with tumour recurrence (median variation 33 vs. 64, p = 0.023). The most mutated gene was adipose tissue macrophages (ATM) (79%), followed by neurofibromatosis-1 (NF1) (79%), and neurogenic locus notch homolog protein 1 (NOTCH1) (79%). In multivariable analysis, mutation of epidermal growth factor receptor (EGFR) (odds ratio [OR], 9.95; 95% confidence interval [CI], 1.40-70.96; p = 0.022) and telomerase reverse transcriptase (TERT) (OR, 7.92; 95% CI, 1.22-51.51; p = 0.030) were significant factors associated with the recurrence of bladder tumour within 1 year. Our results revealed that high TMB, EGFR mutation, and TERT mutation had a significant association with tumour recurrence in NMIBC. In addition, somatic mutations in EGFR and TERT could be useful prognostic biomarkers in NMIBC. FAU - Yu, Seong Hyeon AU - Yu SH AUID- ORCID: 0000-0002-1761-2025 AD - Department of Urology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju 61469, Republic of Korea. FAU - Kim, Sung Sun AU - Kim SS AUID- ORCID: 0000-0002-8569-2178 AD - Department of Pathology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju 61469, Republic of Korea. FAU - Lee, Hyungki AU - Lee H AD - MediCloud Corporation, Hwasun 58128, Republic of Korea. FAU - Kim, Shinseung AU - Kim S AD - MediCloud Corporation, Hwasun 58128, Republic of Korea. FAU - Kang, Taek Won AU - Kang TW AD - Department of Urology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju 61469, Republic of Korea. LA - eng GR - BCRI 21006/Chonnam National University Hospital Institute for Biomedical Science/ PT - Journal Article DEP - 20231013 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10606398 OTO - NOTNLM OT - biomarkers OT - genetic testing OT - next-generation sequencing OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2023/10/28 11:44 MHDA- 2023/10/28 11:45 PMCR- 2023/10/13 CRDT- 2023/10/28 01:01 PHST- 2023/08/23 00:00 [received] PHST- 2023/09/29 00:00 [revised] PHST- 2023/10/11 00:00 [accepted] PHST- 2023/10/28 11:45 [medline] PHST- 2023/10/28 11:44 [pubmed] PHST- 2023/10/28 01:01 [entrez] PHST- 2023/10/13 00:00 [pmc-release] AID - diagnostics13203201 [pii] AID - diagnostics-13-03201 [pii] AID - 10.3390/diagnostics13203201 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Oct 13;13(20):3201. doi: 10.3390/diagnostics13203201. PMID- 37884699 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240529 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 31 IP - 2 DP - 2024 Feb TI - Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer. PG - 1384-1392 LID - 10.1245/s10434-023-14449-5 [doi] AB - PURPOSE: We aimed to evaluate whether maximal transurethral resection (TUR) affects the oncological outcome of partial cystectomy (PC) performed in patients with muscle-invasive bladder cancer (MIBC), although radical cystectomy (RC) and trimodal therapy (TMT) are regarded as standard treatments for MIBC. METHODS: In this retrospective study, we evaluated the data of 98 patients who underwent PC due to MIBC between January 2006 and December 2018. Of the 98 patients, 71 underwent maximal TUR. We evaluated the recurrence-free survival (PFS), pelvic recurrence-free survival (pPFS), cancer-specific survival (CSS), and overall survival (OS) using the Kaplan-Meier method according to the maximal TUR status. Variables associated with survival were analyzed using Cox regression analyses. RESULTS: The 5-year PFS (42.5% vs. 20.3%, p = 0.008), pPFS (50.7% vs. 24.1%, p = 0.003), and CSS (74.0% vs. 51.0%, p = 0.016) were also higher in patients who underwent maximal TUR. The multivariable Cox regression analysis showed that maximal TUR was associated with PFS (hazard ratio [HR] = 0.500, p = 0.029), pPFS (HR = 0.353, p = 0.004), and CSS (HR = 0.416, p = 0.027). However, maximal TUR did not affect the OS (HR = 0.618, p = 0.132). CONCLUSION: PC resulted in acceptable oncological outcomes in patients with MIBC, while maximal TUR played an important role in improving the oncological outcomes. PC after maximal TUR can be suggested as a treatment option for MIBC patients who are unable to undergo RC and TMT. CI - (c) 2023. Society of Surgical Oncology. FAU - Ham, Won Sik AU - Ham WS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Park, Jee Soo AU - Park JS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Jang, Won Sik AU - Jang WS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Kim, Jongchan AU - Kim J AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. lumpakcef@yuhs.ac. AD - Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Yongin-si, Gyeonggi-do, Korea. lumpakcef@yuhs.ac. LA - eng GR - 6-2021-0106/Yonsei University College of Medicine/ GR - 2019R1A2C1002863/National Research Foundation of Korea/ GR - 2022R1A2C2003831/National Research Foundation of Korea/ GR - HI17C1095/Korea Health Industry Development Institute/Republic of Korea PT - Journal Article DEP - 20231026 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - *Cystectomy MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/therapy MH - Muscles MH - Treatment Outcome MH - Neoplasm Invasiveness EDAT- 2023/10/27 00:42 MHDA- 2024/01/05 06:42 CRDT- 2023/10/26 23:38 PHST- 2023/05/12 00:00 [received] PHST- 2023/10/02 00:00 [accepted] PHST- 2024/01/05 06:42 [medline] PHST- 2023/10/27 00:42 [pubmed] PHST- 2023/10/26 23:38 [entrez] AID - 10.1245/s10434-023-14449-5 [pii] AID - 10.1245/s10434-023-14449-5 [doi] PST - ppublish SO - Ann Surg Oncol. 2024 Feb;31(2):1384-1392. doi: 10.1245/s10434-023-14449-5. Epub 2023 Oct 26. PMID- 37884563 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20251203 IS - 2056-676X (Electronic) IS - 2056-676X (Linking) VI - 9 IP - 1 DP - 2023 Oct 26 TI - Bladder cancer. PG - 58 LID - 10.1038/s41572-023-00468-9 [doi] AB - Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease. Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification. Subtyping of both forms of bladder cancer is likely to change considerably with the advent of single-cell analysis methods. Early detection signifies a better disease prognosis; thus, minimally invasive diagnostic options are needed to improve patient outcomes. Urine-based tests are available for disease diagnosis and surveillance, and analysis of blood-based cell-free DNA is a promising tool for the detection of minimal residual disease and metastatic relapse. Transurethral resection is the cornerstone treatment for non-muscle-invasive bladder cancer and intravesical therapy can further improve oncological outcomes. For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the standard of care with evidence supporting trimodality therapy. Immune-checkpoint inhibitors have demonstrated benefit in non-muscle-invasive, muscle-invasive and metastatic bladder cancer. Effective management requires a multidisciplinary approach that considers patient characteristics and molecular disease characteristics. CI - (c) 2023. Springer Nature Limited. FAU - Dyrskjot, Lars AU - Dyrskjot L AUID- ORCID: 0000-0001-7061-9851 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Hansel, Donna E AU - Hansel DE AD - Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Efstathiou, Jason A AU - Efstathiou JA AUID- ORCID: 0000-0003-0996-0350 AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. FAU - Knowles, Margaret A AU - Knowles MA AUID- ORCID: 0000-0002-9363-8657 AD - Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, UK. FAU - Galsky, Matthew D AU - Galsky MD AUID- ORCID: 0000-0001-7655-9378 AD - Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Teoh, Jeremy AU - Teoh J AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Theodorescu, Dan AU - Theodorescu D AUID- ORCID: 0000-0002-8708-8206 AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. dan.theodorescu@cshs.org. AD - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. dan.theodorescu@cshs.org. AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. dan.theodorescu@cshs.org. LA - eng GR - R01 CA075115/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20231026 PL - England TA - Nat Rev Dis Primers JT - Nature reviews. Disease primers JID - 101672103 SB - IM MH - Humans MH - Female MH - Male MH - Treatment Outcome MH - *Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy MH - Urinary Bladder/surgery MH - Prognosis PMC - PMC11218610 MID - NIHMS1966010 COIS- Competing interests L.D. has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure and Ferring, has an advisory/consulting role at Ferring, MSD and UroGen, has received speaker honoraria from AstraZeneca, Pfizer and Roche, and is a board member for BioXpedia. D.E.H. is an advisory board member for AstraZeneca. M.D.G. receives or has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech. M.D.G. is or was a consultant for Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie, Analogue Devices and Veracyte. J.A.E. is or was a consultant/advisory board member and receives or has received honoraria from Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Lantheus, IBA, Astellas, Pfizer, Merck, Roivant Pharma, Myovant Sciences, Janssen, Bayer Healthcare, Progenics Pharmaceuticals, Genentech, Gilead, Angiodynamics and UptoDate. The other authors declare no competing interests. EDAT- 2023/10/27 00:42 MHDA- 2023/10/30 06:46 PMCR- 2024/07/02 CRDT- 2023/10/26 23:23 PHST- 2023/09/20 00:00 [accepted] PHST- 2023/10/30 06:46 [medline] PHST- 2023/10/27 00:42 [pubmed] PHST- 2023/10/26 23:23 [entrez] PHST- 2024/07/02 00:00 [pmc-release] AID - 10.1038/s41572-023-00468-9 [pii] AID - 10.1038/s41572-023-00468-9 [doi] PST - epublish SO - Nat Rev Dis Primers. 2023 Oct 26;9(1):58. doi: 10.1038/s41572-023-00468-9. PMID- 37884420 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20260127 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 4 DP - 2024 Aug TI - Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer. PG - 760-769 LID - S2588-9311(23)00219-5 [pii] LID - 10.1016/j.euo.2023.10.003 [doi] AB - BACKGROUND: Guidelines recommend intravesical instillation of bacillus Calmette-Guerin (BCG) as the first-choice treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). However, there is no therapeutic biomarker for predicting BCG efficacy, especially in high-risk cases with high failure rates. HER2 expression is considered a prognostic factor for bladder cancer. OBJECTIVE: To elucidate the predictive value and significance of HER2 expression in patients with BCG-exposed NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 454 patients with NMIBC were included. All patients started BCG intravesical instillation (1.2 x 10(8) CFU, strain D2PB302) 2-6 wk after transurethral resection of bladder tumor and received 19 treatments over a period of 1 yr. HER2 immunohistochemistry (IHC) results available for 314 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcomes investigated were recurrence-free survival (RFS) and progression-free survival (PFS). Outcome relationships were explored using multivariable Cox regression and log-rank analysis. RESULTS AND LIMITATIONS: In the IHC population, 35.7% of patients had HER2 overexpression (IHC score 2/3+). This group had a poor 5-yr RFS rate of 16.5%, in comparison to 68.0% in the group with low HER2 expression (p < 0.001). Patients with high-risk NMIBC and HER2 overexpression had the highest risk of BCG treatment failure, with 5-yr RFS and PFS rates of 19.0% and 58.2%, respectively. Conversely, HER2-negative (IHC score 0) patients with high-risk NMIBC experienced a long-term BCG benefit, with 5-yr RFS and PFS rates of 80.8% and 92.1%, respectively. Limitations include the retrospective study design and the limited details regarding BCG use. CONCLUSIONS: HER2 was an independent predictor of poor BCG efficacy in NMIBC. Patients with high-risk NMIBC and HER2 overexpression had the highest risk of disease recurrence and progression after exposure to BCG. Anti-HER2 targeted therapies could be considered for these patients. PATIENT SUMMARY: Measurement of blood levels of the protein HER2 can be used to predict outcomes after BCG (bacillus Calmette-Guerin) bladder therapy for patients with intermediate- or high-risk non-muscle-invasive bladder cancer. Measurement results for HER2 may help in guiding personalized treatment for these patients. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Tan, Xingliang AU - Tan X AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Liu, Zhicheng AU - Liu Z AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Cai, Taonong AU - Cai T AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Wang, Yanjun AU - Wang Y AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Wu, Zhiming AU - Wu Z AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Qin, Zike AU - Qin Z AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Li, Zhiyong AU - Li Z AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Liu, Zhenhua AU - Liu Z AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. FAU - Yuan, Gangjun AU - Yuan G AD - Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Chongqing, China; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China. Electronic address: yuangj@cqu.edu.cn. FAU - Zhou, Qianghua AU - Zhou Q AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: zhouqh28@mail.sysu.edu.cn. FAU - Yao, Kai AU - Yao K AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: yaokai@sysucc.org.cn. LA - eng PT - Journal Article DEP - 20231024 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Adjuvants, Immunologic) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/metabolism/drug therapy/therapy MH - *BCG Vaccine/therapeutic use MH - *Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Female MH - Male MH - Aged MH - Prognosis MH - Middle Aged MH - Retrospective Studies MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic/therapeutic use MH - Aged, 80 and over MH - Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - HER2 OT - Intravesical instillation OT - Non-muscle-invasive bladder cancer OT - Recurrence EDAT- 2023/10/27 00:42 MHDA- 2024/07/18 00:42 CRDT- 2023/10/26 21:54 PHST- 2023/08/04 00:00 [received] PHST- 2023/09/07 00:00 [revised] PHST- 2023/10/06 00:00 [accepted] PHST- 2024/07/18 00:42 [medline] PHST- 2023/10/27 00:42 [pubmed] PHST- 2023/10/26 21:54 [entrez] AID - S2588-9311(23)00219-5 [pii] AID - 10.1016/j.euo.2023.10.003 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Aug;7(4):760-769. doi: 10.1016/j.euo.2023.10.003. Epub 2023 Oct 24. PMID- 37880772 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20231122 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 21 IP - 1 DP - 2023 Oct 26 TI - Prognostic value of the systemic immune-inflammation index in patients with upper tract urothelial carcinoma after radical nephroureterectomy. PG - 337 LID - 10.1186/s12957-023-03225-0 [doi] LID - 337 AB - BACKGROUND: To investigate the prognostic significance of the systemic immune-inflammation index (SII) for patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) and develop nomogram models for predicting overall survival (OS), intravesical recurrence (IVR), and extra-urothelial recurrence (EUR). METHODS: We retrospectively studied the clinical and pathological features of 195 patients who underwent RNU for UTUC. All patients were randomly divided into a training cohort (99 cases) and a validation cohort (96 cases). The training cohort was used to develop nomogram models, and the models were validated by the validation cohort. The least absolute shrinkage and selection operator (LASSO) regression and Cox regression were performed to identify independent predictors. The concordance index (C-index), receiver operator characteristics (ROC) analysis, and calibration plot were used to evaluate the reliability of the models. The clinical utility compared with the pathological T stage was assessed using the net reclassification index (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). RESULTS: SII was an independent risk factor in predicting OS and EUR. The C-index values of the nomogram predicting OS, IVR, and EUR were 0.675, 0.702, and 0.756 in the training cohort and 0.715, 0.756, and 0.713 in the validation cohort. A high level of SII was correlated with the invasion of the mucosa, muscle layer of the ureter, nerves, vessels, and fat tissues. CONCLUSION: We developed nomogram models to predict the OS, IVR, and EUR of UTUC patients. The efficacy of these models was substantiated through internal validation, demonstrating favorable discrimination, calibration, and clinical utility. A high level of SII was associated with both worse OS and shorter EUR-free survival. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Luo, Zhenkai AU - Luo Z AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, No. 17 Nanli, Panjiayuan, Chaoyang District, Beijing, 100730, China. AD - Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Nanli, Panjiayuan, Chaoyang District, Beijing, 100021, China. FAU - Yan, Yangxuanyu AU - Yan Y AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Jiao, Binbin AU - Jiao B AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. FAU - Huang, Tao AU - Huang T AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No.300. Guangzhou Road, Nanjing, 210029, China. FAU - Liu, Yuhao AU - Liu Y AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Chen, Haijie AU - Chen H AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Guan, Yunfan AU - Guan Y AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Ding, Zhenshan AU - Ding Z AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. dzsfighting@126.com. FAU - Zhang, Guan AU - Zhang G AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. gzhang2016@sina.com. LA - eng PT - Journal Article DEP - 20231026 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/surgery MH - Inflammation MH - Nephrectomy MH - Nephroureterectomy MH - Prognosis MH - Reproducibility of Results MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery PMC - PMC10601258 OTO - NOTNLM OT - Extraurothelial recurrence OT - Radical nephroureterectomy OT - Risk factor OT - Systemic immune-inflammation index OT - Upper tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2023/10/26 06:42 MHDA- 2023/10/27 06:42 PMCR- 2023/10/26 CRDT- 2023/10/26 00:06 PHST- 2023/06/16 00:00 [received] PHST- 2023/10/14 00:00 [accepted] PHST- 2023/10/27 06:42 [medline] PHST- 2023/10/26 06:42 [pubmed] PHST- 2023/10/26 00:06 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - 10.1186/s12957-023-03225-0 [pii] AID - 3225 [pii] AID - 10.1186/s12957-023-03225-0 [doi] PST - epublish SO - World J Surg Oncol. 2023 Oct 26;21(1):337. doi: 10.1186/s12957-023-03225-0. PMID- 37874923 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20260430 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 29 IP - 2 DP - 2024 Feb 2 TI - Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder. PG - e248-e258 LID - 10.1093/oncolo/oyad283 [doi] AB - OBJECTIVE: To evaluate the presence and subtypes of tertiary lymphatic structures (TLSs) in urothelial carcinoma of the bladder (UCB) and to analyze their associated clinicopathological characteristics and prognostic significance. METHODS: The study enrolled 580 patients with surgically treated UCB, including 313 non-muscle invasive bladder cancer (NMIBC) and 267 muscle-invasive bladder cancer (MIBC). The presence and subtypes of TLSs were identified by immunohistochemistry (CD20, CD3, Bcl-6, and CD21). TLSs were classified into non-GC (nGC) TLS and GC TLS subtypes based on germinal center (GC) formation. Disease-free survival (DFS) was used as an endpoint outcome to evaluate the prognostic significance of TLS and its subtypes in UCB. RESULTS: TLSs were more common in MIBC than in NMIBC (67.8% vs 48.2%, P < .001), and the tumor-infiltrating lymphocyte (TIL) mean density was significantly higher in MIBC than in NMIBC (24.0% vs 17.5%, P < .001). Moreover, a positive correlation was found between TLS presence and GC structure formation and TIL infiltration in UCB. Endpoint events occurred in 191 patients. Compared to patients with endpoint events, patients without disease progression exhibited higher TIL density and more TLSs (P < .05). Kaplan-Meier curves showed that TLS was associated with better DFS in NMIBC (P = .041) and MIBC (P = .049). However, the Cox multivariate analysis did not demonstrate the prognostic significance of TLS. CONCLUSIONS: TLS is heterogeneous in UCB, and that TLS and GC structures are related to TIL density and prognostic events. However, TLS as a prognostic indicator remains unclear, warranting further investigation. CI - (c) The Author(s) 2023. Published by Oxford University Press. FAU - Ma, Guofeng AU - Ma G AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Jia, Huiqing AU - Jia H AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Zhang, Guofang AU - Zhang G AD - Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Liang, Ye AU - Liang Y AD - Key Laboratory, Department of Urology and Andrology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Dong, Xianning AU - Dong X AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Fu, Guangming AU - Fu G AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Wang, Xinsheng AU - Wang X AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. FAU - Niu, Haitao AU - Niu H AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China. LA - eng GR - 82071750/National Natural Science Foundation of China/ GR - tsqn20161077/Taishan Scholar Program of Shandong Province/ GR - 2022-2-002-YY/Shinan District Science and Technology Program of Qingdao/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Oncologist JT - The oncologist JID - 9607837 SB - IM MH - Humans MH - Prognosis MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Urinary Bladder/surgery/pathology MH - *Tertiary Lymphoid Structures/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - Lymphocytes, Tumor-Infiltrating/pathology PMC - PMC10836299 OTO - NOTNLM OT - MIBC OT - NMIBC OT - prognosis OT - tertiary lymphatic structures OT - tumor-infiltrating lymphocytes OT - urothelial carcinoma of the bladder COIS- The authors indicated no financial relationships. EDAT- 2023/10/24 18:42 MHDA- 2024/02/05 06:43 PMCR- 2023/10/24 CRDT- 2023/10/24 15:23 PHST- 2023/07/16 00:00 [received] PHST- 2023/09/27 00:00 [accepted] PHST- 2024/02/05 06:43 [medline] PHST- 2023/10/24 18:42 [pubmed] PHST- 2023/10/24 15:23 [entrez] PHST- 2023/10/24 00:00 [pmc-release] AID - 7329110 [pii] AID - oyad283 [pii] AID - 10.1093/oncolo/oyad283 [doi] PST - ppublish SO - Oncologist. 2024 Feb 2;29(2):e248-e258. doi: 10.1093/oncolo/oyad283. PMID- 37872516 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20231123 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Oct 23 TI - The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer. PG - 1018 LID - 10.1186/s12885-023-11523-9 [doi] LID - 1018 AB - OBJECTIVE: Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one year after transurethral resection of bladder tumor(TURBT), there is no consensus on the optimal duration of chemotherapy. Hence, we explored the optimal duration of maintenance intravesical chemotherapy in patients with intermediate-risk NMIBC. SUBJECTS AND METHODS: This was a real-world single-center retrospective cohort study. In total 158 patients with pathologically confirmed intermediate-risk NMIBC were included, who were divided into 4 subgroups based on the number of instillations given. We used Cox regression analysis and survival analysis chart to explore the 3-yr recurrence outcomes of tumor.The optimal duration was determined by receive operating characteristic curve (ROC). RESULTS: The median follow-up was 5.2 years. Compared with instillation for 1-2 months, the Hazard Ratios(HR) values of instillation for less than 1 month, maintenance instillation for 3-6 months and > 6 months were 3.57、1.57 and 0.22(95% CI 1.27-12.41;0.26-9.28;0.07-0.80, P = 0.03;0.62;0.02, respectively). We found a significant improvement in 3-yr relapse-free survival in intermediate-risk NMIBC patients who maintained intravesical instillation chemotherapy for longer than 6 months, and the best benefit was achieved with 10.5 months of maintenance chemotherapy by ROC. CONCLUSIONS: In our scheme, the optimal duration of intravesical instillation with pirrubicin is 10.5 months. This new understanding provides valuable experience for the precise medical treatment model of intermediate-risk NMIBC. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Chen, Jian-Xin AU - Chen JX AD - Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. AD - Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Huang, Wen-Ting AU - Huang WT AD - Department of Nursing, Guangxi Health Science College, Nanning, Guangxi, 530021, China. FAU - Zhang, Qing-Yun AU - Zhang QY AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Deng, Cheng-En AU - Deng CE AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Wei, Jue-Ling AU - Wei JL AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Xie, Yuan-Liang AU - Xie YL AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Lin, Rui AU - Lin R AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Feng, Guan-Zheng AU - Feng GZ AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Yang, Guang-Lin AU - Yang GL AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Long, Jun AU - Long J AD - Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. FAU - Lu, Hao-Yuan AU - Lu HY AD - Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. 443640708@qq.com. FAU - Mo, Zeng-Nan AU - Mo ZN AD - Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. mozengnan@gxmu.edu.cn. AD - Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, China. mozengnan@gxmu.edu.cn. LA - eng GR - S2019048/Development, Promotion and Application of Feasible Medical Health Technologies of Guangxi/ GR - 2021GXNSFAA196071/Guangxi Natural Science Fundation/ GR - 2021AB13014/Guangxi Key Research and Development Program/ GR - AA18118016/Major Project of Guangxi Innovation Driven/ GR - 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33/Guangxi key Laboratory for Genomic and Personalized Medicine/ PT - Journal Article DEP - 20231023 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Administration, Intravesical MH - Maintenance Chemotherapy MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/drug therapy/pathology MH - *Urinary Bladder Neoplasms/pathology MH - BCG Vaccine/therapeutic use MH - Neoplasm Invasiveness PMC - PMC10591423 OTO - NOTNLM OT - Intravesical chemotherapy OT - Non-muscle-invasive Bladder cancer OT - Pirrubicin OT - Tumor recurrence COIS- The authors declare no competing interests. EDAT- 2023/10/24 00:41 MHDA- 2023/10/30 06:46 PMCR- 2023/10/23 CRDT- 2023/10/23 23:47 PHST- 2023/03/18 00:00 [received] PHST- 2023/10/13 00:00 [accepted] PHST- 2023/10/30 06:46 [medline] PHST- 2023/10/24 00:41 [pubmed] PHST- 2023/10/23 23:47 [entrez] PHST- 2023/10/23 00:00 [pmc-release] AID - 10.1186/s12885-023-11523-9 [pii] AID - 11523 [pii] AID - 10.1186/s12885-023-11523-9 [doi] PST - epublish SO - BMC Cancer. 2023 Oct 23;23(1):1018. doi: 10.1186/s12885-023-11523-9. PMID- 37871701 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20260625 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 35 IP - 1 DP - 2024 Jan TI - Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. PG - 98-106 LID - S0923-7534(23)04015-2 [pii] LID - 10.1016/j.annonc.2023.09.3116 [doi] AB - BACKGROUND: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guerin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment. PATIENTS AND METHODS: Patients aged >/=18 years with recurrent, BCG-treated, papillary-only high-risk NMIBC (high-grade Ta/T1) and select FGFR alterations refusing or ineligible for radical cystectomy were randomized to 6 mg daily oral erdafitinib or investigator's choice of intravesical chemotherapy (mitomycin C or gemcitabine). The primary endpoint was recurrence-free survival (RFS). The key secondary endpoint was safety. RESULTS: Study enrollment was discontinued due to slow accrual. Seventy-three patients were randomized 2 : 1 to erdafitinib (n = 49) and chemotherapy (n = 24). Median follow-up for RFS was 13.4 months for both groups. Median RFS was not reached for erdafitinib [95% confidence interval (CI) 16.9 months-not estimable] and was 11.6 months (95% CI 6.4-20.1 months) for chemotherapy, with an estimated hazard ratio of 0.28 (95% CI 0.1-0.6; nominal P value = 0.0008). In this population, safety results were generally consistent with known profiles for erdafitinib and chemotherapy. CONCLUSIONS: Erdafitinib prolonged RFS compared with intravesical chemotherapy in patients with papillary-only, high-risk NMIBC harboring FGFR alterations who had disease recurrence after BCG therapy and refused or were ineligible for radical cystectomy. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Catto, J W F AU - Catto JWF AD - Department of Oncology and Metabolism, University of Sheffield, Sheffield; Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk. FAU - Tran, B AU - Tran B AD - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. FAU - Roupret, M AU - Roupret M AD - Department of Urology, GRC 5 Predictive Onco-Uro, Hopital Pitie-Salpetriere, Sorbonne University, Paris, France. FAU - Gschwend, J E AU - Gschwend JE AD - Department of Urology, School of Medicine and Health, Technical University of Munich, Munich, Germany. FAU - Loriot, Y AU - Loriot Y AD - Department of Cancer Medicine, INSERM U981, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Nishiyama, H AU - Nishiyama H AD - Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Redorta, J P AU - Redorta JP AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Daneshmand, S AU - Daneshmand S AD - Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA. FAU - Hussain, S A AU - Hussain SA AD - Department of Oncology and Metabolism, University of Sheffield, Sheffield; Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. FAU - Cutuli, H J AU - Cutuli HJ AD - Uro-oncology and Research Unit, Sirio Libanes Hospital, Buenos Aires, Argentina. FAU - Procopio, G AU - Procopio G AD - Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy. FAU - Guadalupi, V AU - Guadalupi V AD - Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy. FAU - Vasdev, N AU - Vasdev N AD - Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. FAU - Naini, V AU - Naini V AD - Janssen Research & Development, San Diego. FAU - Crow, L AU - Crow L AD - Janssen Research & Development, Spring House. FAU - Triantos, S AU - Triantos S AD - Janssen Research & Development, Spring House. FAU - Baig, M AU - Baig M AD - Janssen Research & Development, Spring House. FAU - Steinberg, G AU - Steinberg G AD - Department of Urology, Rush University Medical Center, Chicago, USA. CN - THOR-2 Cohort 1 Investigators LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20231021 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - 890E37NHMV (erdafitinib) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) SB - IM MH - Humans MH - Adolescent MH - Adult MH - BCG Vaccine/adverse effects MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms MH - Neoplasm Invasiveness MH - *Pyrazoles MH - *Quinoxalines OTO - NOTNLM OT - FGFR OT - erdafitinib OT - intravesical chemotherapy OT - non-muscle-invasive bladder cancer OT - recurrence-free survival OT - safety FIR - Bengio, Ruben IR - Bengio R FIR - Cutuli, Hernan IR - Cutuli H FIR - Salinas, Jorge IR - Salinas J FIR - Ameye, Filip IR - Ameye F FIR - Joniau, Steven IR - Joniau S FIR - Rodrigues da Rosa, Diogo IR - Rodrigues da Rosa D FIR - Martins da Trindade, Karine IR - Martins da Trindade K FIR - Luz, Murilo Almeida IR - Luz MA FIR - Bavaresco, Mario Henrique IR - Bavaresco MH FIR - de Paula, Adriano IR - de Paula A FIR - Santiag, Jose IR - Santiag J FIR - Wang, Shaogang IR - Wang S FIR - Ye, Dingwei IR - Ye D FIR - Boegemann, Martin IR - Boegemann M FIR - Roghmann, Florian IR - Roghmann F FIR - Heidrich, Albert IR - Heidrich A FIR - Hellmis, Eva IR - Hellmis E FIR - Faba, Oscar Rodriguez IR - Faba OR FIR - Dominguez, Jose Luis IR - Dominguez JL FIR - Mathieu, Romain IR - Mathieu R FIR - Colombel, Marc IR - Colombel M FIR - Bladou, Franck IR - Bladou F FIR - Artignan, Xavier IR - Artignan X FIR - Vasdev, Nikhil IR - Vasdev N FIR - Shimpi, Rajendra IR - Shimpi R FIR - Guadalupi, Valentina IR - Guadalupi V FIR - Tambaro, Rosa IR - Tambaro R FIR - Sirotova, Zuzana IR - Sirotova Z FIR - Spada, Massimiliano IR - Spada M FIR - Necchi, Andrea IR - Necchi A FIR - Nakatsu, Hiroomi IR - Nakatsu H FIR - Kikuchi, Eiji IR - Kikuchi E FIR - Shimizu, Nobuaki IR - Shimizu N FIR - Kanao, Kent IR - Kanao K FIR - Sumitomo, Makoto IR - Sumitomo M FIR - Naito, Yushi IR - Naito Y FIR - Ham, Won Sik IR - Ham WS FIR - Jung, Seung-Il IR - Jung SI FIR - Ha, Hongkoo IR - Ha H FIR - Joo, Kwan Joong IR - Joo KJ FIR - Ku, Ja Hyeon IR - Ku JH FIR - Seo, Ho Kyung IR - Seo HK FIR - Yun, Seokjoong IR - Yun S FIR - Kolodziej, Anna IR - Kolodziej A FIR - Lawinski, Janusz IR - Lawinski J FIR - Morris, David IR - Morris D FIR - Daneshmand, Siamak IR - Daneshmand S FIR - Mian, Badar IR - Mian B FIR - Lee, Eugene IR - Lee E EDAT- 2023/10/24 00:41 MHDA- 2024/01/15 12:42 CRDT- 2023/10/23 19:27 PHST- 2023/09/19 00:00 [received] PHST- 2023/09/29 00:00 [accepted] PHST- 2024/01/15 12:42 [medline] PHST- 2023/10/24 00:41 [pubmed] PHST- 2023/10/23 19:27 [entrez] AID - S0923-7534(23)04015-2 [pii] AID - 10.1016/j.annonc.2023.09.3116 [doi] PST - ppublish SO - Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. PMID- 37867055 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 42 IP - 2 DP - 2024 Feb TI - Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC. PG - 30.e9-30.e16 LID - S1078-1439(23)00331-9 [pii] LID - 10.1016/j.urolonc.2023.09.018 [doi] AB - PURPOSE: To develop a novel combination therapy for high-risk nonmuscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT), namely, intra-arterial chemotherapy (IAC) plus BCG immunotherapy, and to compare the feasibility and safety of the 2 therapies. MATERIALS AND METHODS: A retrospective study was conducted on the data of 119 patients who were diagnosed with high-risk NMIBC and underwent TURBT in the past 5 years. Those who did not complete the treatment were excluded, and the remaining 98 patients were divided into 2 groups: both groups received intravesical BCG immunotherapy, while the BCG+IAC group received 4 courses of extra intra-arterial chemotherapy. Clinical and follow-up data were processed using statistical software. RESULTS: The recurrence rate was 22.2% in the BCG+IAC group and 35.8% in the BCG group, whereas the progression rates were 8.9% and 24.5%, respectively. In the Kaplan-Meier plot, a statistically significant difference was observed with respect to recurrence-free survival (p = 0.025), as well as the progression-free survival of the two groups was similar (p = 0.019). A total of 22.2% of the patients with adverse effects of IAC and 79.6% of patients suffered from adverse reactions to BCG immunotherapy, and most of the adverse effects were mild and tolerable. Univariate and multivariate analysis indicated that multifocal and treatment were independent risk factors for recurrence, while the history of recurrence and treatment were independent risk factors for progression. CONCLUSION: IAC could be a promising auxiliary treatment for BCG immunotherapy in decreasing the recurrence and progression rate of high-risk NMIBC with little additional toxicity. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Luo, Shuhang AU - Luo S AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China; Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R.China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P.R.China. FAU - Wu, Yukun AU - Wu Y AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Yang, Rui AU - Yang R AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Huang, Gaowei AU - Huang G AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Lei, Jiahao AU - Lei J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Liu, Jinwen AU - Liu J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Lin, Shengjie AU - Lin S AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Chen, Lingwu AU - Chen L AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. FAU - Chen, Junxing AU - Chen J AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. Electronic address: chenjunx@mail.sysu.edu.cn. FAU - Huang, Bin AU - Huang B AD - Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. Electronic address: huangb48@mail.sysu.edu.cn. LA - eng PT - Journal Article DEP - 20231020 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Chemotherapy, Adjuvant OTO - NOTNLM OT - BCG OT - Combination therapy OT - High-risk non-muscle-invasive bladder cancer OT - Intra-arterial chemotherapy OT - Retrospective study COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/10/23 00:44 MHDA- 2024/02/11 07:43 CRDT- 2023/10/22 22:02 PHST- 2023/05/30 00:00 [received] PHST- 2023/09/20 00:00 [revised] PHST- 2023/09/26 00:00 [accepted] PHST- 2024/02/11 07:43 [medline] PHST- 2023/10/23 00:44 [pubmed] PHST- 2023/10/22 22:02 [entrez] AID - S1078-1439(23)00331-9 [pii] AID - 10.1016/j.urolonc.2023.09.018 [doi] PST - ppublish SO - Urol Oncol. 2024 Feb;42(2):30.e9-30.e16. doi: 10.1016/j.urolonc.2023.09.018. Epub 2023 Oct 20. PMID- 37859896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231021 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Can Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder Cancer Has Invaded Muscles? PG - e45488 LID - 10.7759/cureus.45488 [doi] LID - e45488 AB - OBJECTIVES: The presence of muscle invasion is an important factor in establishing a treatment strategy for bladder cancer (BCa). The aim of this study is to reveal the diagnostic performance of radiomic shape features in predicting muscle-invasive BCa. METHODS: In this study, 60 patients with histologically proven BCa who underwent a preoperative MRI were retrospectively recruited. The whole tumor volume was segmented on apparent diffusion coefficient (ADC) maps and T2W images. Afterward, the shape features of the volume of interest were extracted using PyRadiomics. Machine learning classification was performed using statistically different shape features in MATLAB((R)) (The MathWorks, Inc., Natick, Massachusetts, United States). RESULTS: The findings revealed that 27 bladder cancer patients had muscle invasion, while 33 had superficial bladder cancer (53 men and seven women; mean age: 62+/-14). Surface area, volume, and relevant features were significantly greater in the invasive group than in the non-invasive group based on the ADC maps (P<0.05). Superficial bladder cancer had a more spherical form compared to invasive bladder cancer (P=0.05) with both imaging modalities. Flatness and elongation did not differ significantly between groups with either modality (P>0.05). Logistic regression had the highest accuracy of 83.3% (sensitivity 82.8%, specificity 84%) in assessing invasion based on the shape features of ADC maps, while K-nearest neighbors had the highest accuracy of 78.2% (sensitivity 79.1%, specificity 69.4%) in assessing invasion based on T2W images. CONCLUSIONS: Shape features can be helpful in predicting muscle invasion in bladder cancer using machine learning methods. CI - Copyright (c) 2023, Ozdemir et al. FAU - Ozdemir, Harun AU - Ozdemir H AD - Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, TUR. FAU - Azamat, Sena AU - Azamat S AD - Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, TUR. FAU - Sam Ozdemir, Merve AU - Sam Ozdemir M AD - Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, TUR. LA - eng PT - Journal Article DEP - 20230918 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10584356 OTO - NOTNLM OT - bladder cancer OT - cancer staging OT - muscle invazion OT - shape feature OT - urogenital neoplasms COIS- The authors have declared that no competing interests exist. EDAT- 2023/10/20 06:42 MHDA- 2023/10/20 06:43 PMCR- 2023/09/18 CRDT- 2023/10/20 04:21 PHST- 2023/09/18 00:00 [accepted] PHST- 2023/10/20 06:43 [medline] PHST- 2023/10/20 06:42 [pubmed] PHST- 2023/10/20 04:21 [entrez] PHST- 2023/09/18 00:00 [pmc-release] AID - 10.7759/cureus.45488 [doi] PST - epublish SO - Cureus. 2023 Sep 18;15(9):e45488. doi: 10.7759/cureus.45488. eCollection 2023 Sep. PMID- 37852817 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20250104 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 42 IP - 1 DP - 2024 Jan TI - Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions. PG - 21.e21-21.e28 LID - S1078-1439(23)00323-X [pii] LID - 10.1016/j.urolonc.2023.09.010 [doi] AB - INTRODUCTION: Bacillus Calmette-Guerin (BCG) is the most effective therapy available to treat high-risk nonmuscle invasive bladder cancer (NMIBC) patients. However, for patients with immunomodulating conditions BCG is a relative contraindication due to efficacy and safety concerns. To our knowledge, no population-level study evaluating the efficacy and safety profile of BCG for immunomodulated patients exists. METHODS: NMIBC patients aged 66 years or older were identified in the Surveillance, Epidemiology, and End Results (SEER) - Medicare database from 1975-2013. All patients completed adequate BCG (at least 5 plus 2 treatments completed within 12 months of diagnosis). Two groups were defined: an immunomodulated population identified by immunomodulating conditions such as solid-organ transplantation, HIV, and autoimmune conditions, and an immunocompetent group. The primary endpoint was 5-year progression-free survival defined as progression to systemic chemotherapy, checkpoint inhibitors, radical or partial cystectomy, metastasis, or cancer-specific death. A safety analysis was performed as a secondary outcome. RESULTS: In a total of 4,277 patients with NMIBC who completed adequate BCG, 606 (14.2%) were immunomodulated. The immunomodulated group was older at diagnosis (P < 0.001), more likely to be female (P < 0.001), more likely to live in a metropolitan area (P < 0.001), and had higher Charlson comorbidity scores (P < 0.001). There were no differences in progression to chemotherapy (P = 0.17), checkpoint inhibitors (P > 0.99), radical cystectomy (P = 0.40), partial cystectomy (P = 0.93), metastasis (P = 0.19), cancer-specific death (P = 0.18) or 5-year total bladder cancer progression (P = 0.30) between the groups. For the safety analysis, rates of disseminated BCG were similar between immunomodulated and immunocompetent patients (0.7% vs. <1.8%, P = 0.51). On multivariable analysis 5-year total bladder cancer progression (HR 1.07 [CI 0.88-1.30]) was similar between the groups. CONCLUSION: Rates of bladder cancer progression and disseminated BCG complications 5-years after BCG therapy were similar regardless of immunomodulation status. These findings suggest that BCG intravesical therapy can be offered to immunomodulated patients with high-risk NMIBC although theoretical infectious complication risks remain. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Durant, Adri M AU - Durant AM AD - Department of Urology, Mayo Clinic Arizona, Phoenix, AZ. Electronic address: durant.adri@mayo.edu. FAU - Choudry, Mouneeb M AU - Choudry MM AD - Department of Urology, Mayo Clinic Arizona, Phoenix, AZ. FAU - Madura, Grace AU - Madura G AD - Mayo Clinic College of Medicine and Science, Scottsdale, AZ. FAU - Mi, Lanyu AU - Mi L AD - Department of Quantitative Health Sciences, Mayo Clinic Arizona, Scottsdale, AZ. FAU - Faraj, Kassem S AU - Faraj KS AD - Department of Urology, University of Michigan, Ann Arbor, MI. FAU - Tyson, Mark D AU - Tyson MD AD - Department of Urology, Mayo Clinic Arizona, Phoenix, AZ. LA - eng GR - N01 CA015083/CA/NCI NIH HHS/United States GR - P30 CA015083/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20231016 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - United States MH - Humans MH - Aged MH - Female MH - Male MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - Medicare MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - Administration, Intravesical PMC - PMC10842448 MID - NIHMS1940132 OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - Outcomes studies COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/10/19 00:43 MHDA- 2023/12/25 06:42 PMCR- 2025/01/01 CRDT- 2023/10/18 21:59 PHST- 2023/05/02 00:00 [received] PHST- 2023/08/18 00:00 [revised] PHST- 2023/09/19 00:00 [accepted] PHST- 2023/12/25 06:42 [medline] PHST- 2023/10/19 00:43 [pubmed] PHST- 2023/10/18 21:59 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S1078-1439(23)00323-X [pii] AID - 10.1016/j.urolonc.2023.09.010 [doi] PST - ppublish SO - Urol Oncol. 2024 Jan;42(1):21.e21-21.e28. doi: 10.1016/j.urolonc.2023.09.010. Epub 2023 Oct 16. PMID- 37848639 OWN - NLM STAT- MEDLINE DCOM- 20240117 LR - 20240606 IS - 2366-0058 (Electronic) VI - 49 IP - 1 DP - 2024 Jan TI - Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer. PG - 163-172 LID - 10.1007/s00261-023-04069-8 [doi] AB - PURPOSE: To investigate computed tomography (CT)-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer (NMIBC). METHODS: This retrospective study evaluated 147 consecutive patients who underwent contrast-enhanced CT and surgery for bladder cancer. Using corticomedullary-to-portal venous phase images, two independent readers analyzed bladder muscle invasion, tumor stalk, and tumor size, respectively. Three-point scale (i.e., from 0 to 2) was applied for assessing the suspicion degree of muscle invasion or tumor stalk. A multivariate prediction model using the CT parameters for achieving high positive predictive value (PPV) for NMIBC was investigated. The PPVs from raw data or 1000 bootstrap resampling and inter-reader agreement using Gwet's AC1 were analyzed, respectively. RESULTS: Proportion of patients with NMIBC was 81.0% (119/147). The CT criteria of the prediction model were as follows: (a) muscle invasion score < 2; (b) tumor stalk score > 0; and (c) tumor size < 3 cm. From the raw data, PPV of the model for NMIBC was 92.7% (51/55; 95% confidence interval [CI] 82.4-98.0) in reader 1 and 93.3% (42/45; 95% CI 81.7-98.6) in reader 2. From the bootstrap data, PPV was 92.8% (95% CI 85.2-98.3) in reader 1 and 93.4% (95% CI 84.9-99.9) in reader 2. The model's AC1 was 0.753 (95% CI 0.647-0.859). CONCLUSION: The current CT-derived prediction model demonstrated high PPV for identifying patients with NMIBC. Depending on CT findings, approximately 30% of patients with bladder cancer may have a low need for additional MRI for interpreting vesical imaging-reporting and data system. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kang, Kyung A AU - Kang KA AD - Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. FAU - Kim, Min Je AU - Kim MJ AD - Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. FAU - Kwon, Ghee Young AU - Kwon GY AD - Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kim, Chan Kyo AU - Kim CK AD - Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. FAU - Park, Sung Yoon AU - Park SY AUID- ORCID: 0000-0003-0996-7595 AD - Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. yoonio78@gmail.com. LA - eng PT - Journal Article DEP - 20231017 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Magnetic Resonance Imaging/methods MH - Tomography, X-Ray Computed/methods MH - Probability OTO - NOTNLM OT - Bladder OT - Cancer OT - Computed tomography OT - Magnetic resonance imaging EDAT- 2023/10/18 00:42 MHDA- 2024/01/17 06:42 CRDT- 2023/10/17 23:40 PHST- 2023/05/12 00:00 [received] PHST- 2023/09/19 00:00 [accepted] PHST- 2023/09/18 00:00 [revised] PHST- 2024/01/17 06:42 [medline] PHST- 2023/10/18 00:42 [pubmed] PHST- 2023/10/17 23:40 [entrez] AID - 10.1007/s00261-023-04069-8 [pii] AID - 10.1007/s00261-023-04069-8 [doi] PST - ppublish SO - Abdom Radiol (NY). 2024 Jan;49(1):163-172. doi: 10.1007/s00261-023-04069-8. Epub 2023 Oct 17. PMID- 37847504 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20260518 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 6 IP - 10 DP - 2023 Oct 2 TI - Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial. PG - e2337494 LID - 10.1001/jamanetworkopen.2023.37494 [doi] LID - e2337494 AB - IMPORTANCE: Selenium and vitamin E have been identified as promising agents for the chemoprevention of recurrence and progression of non-muscle-invasive bladder cancer. OBJECTIVE: To determine whether selenium and/or vitamin E may prevent disease recurrence in patients with newly diagnosed NMIBC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective, double-blinded, placebo-controlled, 2 x 2 factorial randomized clinical trial included patients with newly diagnosed NMIBC recruited from 10 secondary or tertiary care hospitals in the UK. A total of 755 patients were screened for inclusion; 484 did not meet the inclusion criteria, and 1 declined to participate. A total of 270 patients were randomly assigned to 4 groups (selenium plus placebo, vitamin E plus placebo, selenium plus vitamin E, and placebo plus placebo) in a double-blind fashion between July 17, 2007, and October 10, 2011. Eligibility included initial diagnosis of NMIBC (stages Ta, T1, or Tis); randomization within 12 months of first transurethral resection was required. INTERVENTIONS: Oral selenium (200 mug/d of high-selenium yeast) and matched vitamin E placebo, vitamin E (200 IU/d of d-alfa-tocopherol) and matched selenium placebo, selenium and vitamin E, or placebo and placebo. MAIN OUTCOME AND MEASURES: Recurrence-free interval (RFI) on an intention-to-treat basis (analyses completed on November 28, 2022). RESULTS: The study randomized 270 patients (mean [SD] age, 68.9 [10.4] years; median [IQR] age, 69 [63-77] years; 202 male [75%]), with 65 receiving selenium and vitamin E placebo, 71 receiving vitamin E and selenium placebo, 69 receiving selenium and vitamin E, and 65 receiving both placebos. Median overall follow-up was 5.5 years (IQR, 5.1-6.1 years); 228 patients (84%) were followed up for more than 5 years. Median treatment duration was 1.5 years (IQR, 0.9-2.5 years). The study was halted because of slow accrual. For selenium (n = 134) vs no selenium (n = 136), there was no difference in RFI (hazard ratio, 0.92; 95% CI, 0.65-1.31; P = .65). For vitamin E (n = 140) vs no vitamin E (n = 130), there was a statistically significant detriment to RFI (hazard ratio, 1.46; 95% CI, 1.02-2.09; P = .04). No significant differences were observed for progression-free interval or overall survival time with either supplement. Results were unchanged after Cox proportional hazards regression modeling to adjust for known prognostic factors. In total, 1957 adverse events were reported; 85 were serious adverse events, and all were considered unrelated to trial treatment. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of selenium and vitamin E, selenium supplementation did not reduce the risk of recurrence in patients with NMIBC, but vitamin E supplementation was associated with an increased risk of recurrence. Neither selenium nor vitamin E influenced progression or overall survival. Vitamin E supplementation may be harmful to patients with NMIBC, and elucidation of the underlying biology is required. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN13889738. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Pirrie, Sarah J AU - Pirrie SJ AD - Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, United Kingdom. FAU - Abbotts, Ben AU - Abbotts B AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Maycock, Shanna AU - Maycock S AD - Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, United Kingdom. FAU - During, Vinnie AU - During V AD - Department of Urology, The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom. FAU - Lewis, Carolyn AU - Lewis C AD - MAC Clinical Research, Lancashire, United Kingdom. FAU - Grant, Margaret AU - Grant M AD - Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, United Kingdom. FAU - Bird, Deborah AU - Bird D AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Devall, Adam J AU - Devall AJ AD - Institute of Metabolism and Systems Research, University of Birmingham, United Kingdom. FAU - Wallace, D Michael A AU - Wallace DMA AD - Department of Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - James, Nicholas D AU - James ND AD - Prostate and Bladder Cancer Research Team, The Institute of Cancer Research, London, United Kingdom. FAU - Billingham, Lucinda J AU - Billingham LJ AD - Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, United Kingdom. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Epidemiology, Maastricht University, Maastricht, the Netherlands. AD - MPB holding, Heerlen, the Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, United Kingdom. CN - SELENIB Investigators LA - eng SI - ISRCTN/ISRCTN13889738 GR - 25354/CRUK_/Cancer Research UK/United Kingdom GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom GR - C22436/A25354/CRUK_/Cancer Research UK/United Kingdom GR - C1343/A5738/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20231002 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 1406-18-4 (Vitamin E) RN - H6241UJ22B (Selenium) SB - IM CIN - Nat Rev Urol. 2024 Aug;21(8):458-459. doi: 10.1038/s41585-024-00859-x. PMID: 38317014 MH - Humans MH - Male MH - Aged MH - Vitamin E/therapeutic use MH - *Selenium/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Prospective Studies MH - Neoplasm Recurrence, Local/prevention & control/drug therapy MH - *Urinary Bladder Neoplasms/prevention & control/drug therapy PMC - PMC10582794 COIS- Conflict of Interest Disclosures: Dr Bryan reported receiving grants from Cancer Research UK and nonfinancial support from Pharma Nord during the conduct of the study, receiving personal fees from Cystotech ApS outside the submitted work, and serving as an unpaid charity trustee for Action Bladder Cancer UK. Dr Pirrie reported receiving grants from Cancer Research UK during the conduct of the study. Dr Billingham reported receiving grants from Cancer Research UK during the conduct of the study. No other disclosures were reported. FIR - Choudry, Gun IR - Choudry G FIR - Khwaja, Sikander IR - Khwaja S FIR - Desai, Ken IR - Desai K FIR - Jefferson, Kieran P IR - Jefferson KP FIR - Emtage, Lawrence A IR - Emtage LA FIR - Chakravarti, Aniruddha IR - Chakravarti A FIR - Foster, Michael C IR - Foster MC FIR - Sarmar, B Dev IR - Sarmar BD FIR - Luscombe, Christopher J IR - Luscombe CJ FIR - Wallace, D Michael A IR - Wallace DMA FIR - James, Nicholas J IR - James NJ FIR - Cooke, Peter W IR - Cooke PW FIR - Kadow, Krzysztof IR - Kadow K FIR - Parkin, John IR - Parkin J FIR - Makar, Adel IR - Makar A EDAT- 2023/10/17 12:42 MHDA- 2023/10/23 01:18 PMCR- 2023/10/17 CRDT- 2023/10/17 11:32 PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/17 12:42 [pubmed] PHST- 2023/10/17 11:32 [entrez] PHST- 2023/10/17 00:00 [pmc-release] AID - 2810773 [pii] AID - zoi231096 [pii] AID - 10.1001/jamanetworkopen.2023.37494 [doi] PST - epublish SO - JAMA Netw Open. 2023 Oct 2;6(10):e2337494. doi: 10.1001/jamanetworkopen.2023.37494. PMID- 37847325 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 56 IP - 3 DP - 2024 Mar TI - Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer. PG - 935-940 LID - 10.1007/s11255-023-03829-1 [doi] AB - OBJECTIVE: This study is planned based on the hypothesis that if bladder cancer is detected early, the disease would be less advanced and the possibility of treatment will increase, at least the recurrence-free survival will be longer. Regarding this hypothesis, it is aimed to investigate the effect of delayed diagnosis primarily on the disease factors. MATERIALS AND METHODS: The study included 169 patients, who underwent TUR-BT with the suspicion of bladder cancer in the urology clinic of Afyonkarahisar Faculty of Medicine between April 2018 and April 2023. Demographic and clinical data of the patients were recorded and compared. RESULTS: It was observed that the delay in diagnosis was significantly longer in patients with tumors larger than 3 cm compared to patients with tumors smaller than 3 cm (p < 0.001). In the correlation analysis between tumor size, duration of diagnosis delay, age, T stage, and tumor grade, a low level of positive correlation was observed between tumor size and duration of diagnosis delay, and it was statistically significant (r = 0.215, p = 0.005). CONCLUSION: In our study, it was shown that the tumor size increases as the duration of diagnosis delay increases and this increase causes an increase of 0.088 mm in the pathological size of the tumor in the 1-day delay period. Considering that tumor size changes the risk group of the disease in bladder tumors, and relatedly the follow-up and treatment process changes, we believe that these data will be valuable in the management of bladder cancer. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Gercek, O AU - Gercek O AUID- ORCID: 0000-0002-8710-7171 AD - Department of Urology, Afyonkarahisar Health Sciences University, 03100, Afyonkarahisar, Turkey. osmangercek1989@hotmail.com. FAU - Ulusoy, K AU - Ulusoy K AUID- ORCID: 0009-0007-4714-8028 AD - Department of Urology, Afyonkarahisar Health Sciences University, 03100, Afyonkarahisar, Turkey. FAU - Yazar, V M AU - Yazar VM AUID- ORCID: 0000-0001-7885-1401 AD - Department of Urology, Afyonkarahisar Health Sciences University, 03100, Afyonkarahisar, Turkey. FAU - Topal, K AU - Topal K AUID- ORCID: 0000-0001-7501-7251 AD - Department of Urology, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey. LA - eng PT - Journal Article DEP - 20231017 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - *Delayed Diagnosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Risk Factors MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Malignancy OT - TNM staging EDAT- 2023/10/17 12:43 MHDA- 2024/02/12 05:11 CRDT- 2023/10/17 11:09 PHST- 2023/09/11 00:00 [received] PHST- 2023/09/29 00:00 [accepted] PHST- 2024/02/12 05:11 [medline] PHST- 2023/10/17 12:43 [pubmed] PHST- 2023/10/17 11:09 [entrez] AID - 10.1007/s11255-023-03829-1 [pii] AID - 10.1007/s11255-023-03829-1 [doi] PST - ppublish SO - Int Urol Nephrol. 2024 Mar;56(3):935-940. doi: 10.1007/s11255-023-03829-1. Epub 2023 Oct 17. PMID- 37835857 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 19 DP - 2023 Oct 2 TI - Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette-Guerin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/diagnostics13193114 [doi] LID - 3114 AB - We investigated the prognosis of BCG induction-only treatment and non-complete response (CR) at the first 3-month evaluation and examined factors associated with CR. In total, 209 patients with moderate- and high-risk NMIBC who received BCG induction-only treatment between 2008 and 2020 were retrospectively analyzed. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed based on the initial NMIBC stage. PFS and associated factors of non-CR compared to CR were also assessed. Initial T1 high-grade (HG) (n = 93) had poorer RFS and PFS after BCG induction-only treatment than Ta low-grade (LG) (p = 0.029, p = 0.002). Non-CR (n = 37) had a different neutrophil-to-lymphocyte ratio (NLR) (2.81 +/- 1.02 vs. 1.97 +/- 0.92) and T staging from CR (p < 0.001, p = 0.008). T1HG recurrence was associated with a worse PFS compared to non-T1HG (13.7 months vs. 101.7 months, p < 0.001). There was no difference in PFS between T1HG and T1LG. T1 and NLR were predictors of response at 3 months in multivariable analysis (p = 0.004, p = 0.029). NLR was also found to be an associated factor with RFS and PFS of bladder cancer (p < 0.001, p < 0.001). BCG induction-only treatment was effective for high-risk TaLG but not for T1HG. T1HG recurrence at 3 months after BCG induction has a poor prognosis for bladder cancer. Preoperative NLR and T1 were predictors of non-CR, and NLR was also associated with the long-term prognosis of bladder cancer. FAU - Lee, Junghoon AU - Lee J AUID- ORCID: 0000-0002-8330-0329 AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. FAU - Yoo, Sangjun AU - Yoo S AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. FAU - Choo, Min Soo AU - Choo MS AUID- ORCID: 0000-0002-7852-5822 AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. FAU - Cho, Min Chul AU - Cho MC AUID- ORCID: 0000-0001-7288-1706 AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. FAU - Son, Hwancheol AU - Son H AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. AD - Institute for Peace and Unification Studies, Seoul National University, Seoul 08826, Republic of Korea. FAU - Jeong, Hyeon AU - Jeong H AD - Department of Urology, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Republic of Korea. LA - eng PT - Journal Article DEP - 20231002 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10572862 OTO - NOTNLM OT - BCG failure OT - BCG induction OT - neutrophil-to-lymphocytes ratio OT - non-complete response OT - non-muscle-invasive bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2023/10/14 10:45 MHDA- 2023/10/14 10:46 PMCR- 2023/10/02 CRDT- 2023/10/14 01:14 PHST- 2023/07/27 00:00 [received] PHST- 2023/09/14 00:00 [revised] PHST- 2023/09/25 00:00 [accepted] PHST- 2023/10/14 10:46 [medline] PHST- 2023/10/14 10:45 [pubmed] PHST- 2023/10/14 01:14 [entrez] PHST- 2023/10/02 00:00 [pmc-release] AID - diagnostics13193114 [pii] AID - diagnostics-13-03114 [pii] AID - 10.3390/diagnostics13193114 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Oct 2;13(19):3114. doi: 10.3390/diagnostics13193114. PMID- 37833193 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20240111 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 6 DP - 2023 Dec TI - Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. PG - 611-620 LID - S2588-9311(23)00198-0 [pii] LID - 10.1016/j.euo.2023.09.004 [doi] AB - BACKGROUND: Neoadjuvant chemotherapy (neoCTX) has been recommended as the optimal strategy in surgically resectable neuroendocrine carcinoma (NEC) of the urinary tract (NEC-URO). OBJECTIVE: To determine the systemic therapy regimen and timing, which are most active against NEC-URO. DESIGN, SETTING, AND PARTICIPANTS: We used our institutional historical clinical and pathological database to study 203 patients (cT2, 74%; cT3/4a, 22%; and cTx, 4%) with surgically resectable NEC-URO between November 1985 and May 2020. A total of 141 patients received neoCTX and 62 underwent initial radical surgery, 24 of whom received adjuvant CTX (adjCTX). INTERVENTION: Neoadjuvant CTX with etoposide/cisplatin (EP), an alternating doublet of ifosfamide/doxorubicin (IA) and EP, dose-dense methotrexate/vinblastine/doxorubicin/cisplatin (MVAC), gemcitabine/cisplatin (GC), or others. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS), downstaging rate, and pathological complete response using a multivariable model adjusting for tumor- and patient-related factors. RESULTS AND LIMITATIONS: Downstaging rate was significantly improved with neoCTX versus initial surgery (49.6% vs 14.5%, p < 0.0001), stage cT2N0 versus cT3/4N0 (44% vs 25%, p = 0.01), or presence of carcinoma in situ (47% vs 28%, p = 0.01). Downstaging was greatest with IA/EP (65%) versus EP (39%), MVAC/GC (27%), or others (36%, p = 0.04). After adjusting for age and Eastern Cooperative Oncology Group performance status, IA/EP was still associated with improved downstaging (odds ratio = 3.7 [1.3-10.2], p = 0.01). At a median follow-up of 59.7 mo, 5-yr OS rates for neoCTX followed by surgery, surgery alone, and surgery followed by adjCTX were 57%, 22%, and 30%, respectively. An NEC regimen (IA/EP or EP) versus a urothelial regimen (MVAC/GC or others) was associated with improved survival (145.4 vs 42.5 mo, hazard ratio = 0.49, 95% confidence interval: 0.25-0.94). CONCLUSIONS: Neoadjuvant CTX remains the standard-of-care treatment for NEC-URO with an advantage for NEC regimens over traditional urothelial regimens. IA/EP improves pathological downstaging at the time of surgery compared with EP, but is reserved for younger and higher function patients. PATIENT SUMMARY: In this report, we looked at the outcomes from invasive neuroendocrine carcinoma of the urinary tract in a large US population. We found that the outcomes varied with treatment strategy. We conclude that the best outcomes are seen in patients treated with chemotherapy prior to surgery and regimens tailored to histology and tolerance. CI - Copyright (c) 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Alhalabi, Omar AU - Alhalabi O AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: oalhalabi@mdanderson.org. FAU - Wilson, Nathaniel AU - Wilson N AD - Department of Internal Medicine, University of Texas Houston, McGovern Medical School, Houston, TX, USA. FAU - Xiao, Lianchun AU - Xiao L AD - Department of Statistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lin, Yiyun AU - Lin Y AD - Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Khandelwal, Jaanki AU - Khandelwal J AD - Department of Internal Medicine, University of Texas Houston, McGovern Medical School, Houston, TX, USA. FAU - Moussa, Mohammad Jad AU - Moussa MJ AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Msaouel, Pavlos AU - Msaouel P AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Gao, Jianjun AU - Gao J AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Pilie, Patrick AU - Pilie P AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Shah, Amishi Y AU - Shah AY AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Goswami, Sangeeta AU - Goswami S AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matin, Surena AU - Matin S AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kovitz, Craig AU - Kovitz C AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Holla, Vijaykumar AU - Holla V AD - Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles AU - Guo C AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Czerniak, Bogdan AU - Czerniak B AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Logothetis, Christopher AU - Logothetis C AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Corn, Paul G AU - Corn PG AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Campbell, Matthew T AU - Campbell MT AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hansel, Donna E AU - Hansel DE AD - Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tannir, Nizar M AU - Tannir NM AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: asiefker@mdanderson.org. LA - eng PT - Journal Article DEP - 20231011 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Cisplatin/therapeutic use MH - Gemcitabine MH - Deoxycytidine/therapeutic use MH - *Urinary Tract/pathology MH - *Carcinoma, Neuroendocrine/drug therapy/surgery OTO - NOTNLM OT - Cisplatin OT - Etoposide OT - Ifosfamide OT - Large cell carcinoma OT - Neuroendocrine OT - Neuroendocrine carcinoma OT - Small cell carcinoma OT - Systemic therapy OT - Urothelial cancer EDAT- 2023/10/14 10:43 MHDA- 2023/12/04 12:42 CRDT- 2023/10/13 22:00 PHST- 2023/03/20 00:00 [received] PHST- 2023/09/04 00:00 [revised] PHST- 2023/09/14 00:00 [accepted] PHST- 2023/12/04 12:42 [medline] PHST- 2023/10/14 10:43 [pubmed] PHST- 2023/10/13 22:00 [entrez] AID - S2588-9311(23)00198-0 [pii] AID - 10.1016/j.euo.2023.09.004 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Dec;6(6):611-620. doi: 10.1016/j.euo.2023.09.004. Epub 2023 Oct 11. PMID- 37829946 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231031 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Role of GATA3 in Early-Stage Urothelial Bladder Carcinoma Local Recurrence. PG - e44998 LID - 10.7759/cureus.44998 [doi] LID - e44998 AB - Background One of the most characteristic features of non-invasive urothelial carcinoma (UC) is its high recurrence rate. Guanine-adenine-thymine-adenine nucleotide sequence-binding protein 3 (GATA3), as a transcription factor, correlates with urothelial differentiation and has been reported with poor prognosis in high-grade UC and recurrence in breast malignancies. As such, we set out to study the specifics of GATA3 in non-invasive UC, emphasizing on prediction for recurrence. Methods The cohort comprised 163 patients, with a follow-up period of five years, including 109 pTa cases and 54 pT1 cases. Immunohistochemical expression of GATA3 was assessed using a histo score (H-score). Kaplan-Meier test was conducted for the time to recurrence, according to the level of expression of GATA3 and the indicators studied. Receiver operating characteristic (ROC) curve analysis was done to determine the role of accuracy and specificity of predictability of the indicators. Results Recurrence within the follow-up period was noted in 41.72% of cases. No recurrence relationship was established for age and gender. GATA3 expression showed a varying H-score. Using ROC curve analysis, a cut-off value of 155 divided UC expression levels into low and high, with a sensitivity of 72.7% and specificity of 78.7% (area under the curve=0.800, 95% confidence interval: 0.696-0.904, p<0.001), further showing an association between high levels of nuclear expression and risk of local recurrence (p<0.0001). Conclusion Herein we have described the sensitivity of high GATA3 expression in non-invasive UC of the urinary bladder and its relation to local recurrence, independent of gender, age, tumor differentiation, and stage. CI - Copyright (c) 2023, Popov et al. FAU - Popov, Hristo AU - Popov H AD - General and Clinical Pathology, Forensic Medicine and Deontology, Medical University of Varna, Varna, BGR. FAU - Ghenev, Peter AU - Ghenev P AD - General and Clinical Pathology, Forensic Medicine and Deontology, Medical University of Varna, Varna, BGR. FAU - Stoyanov, George S AU - Stoyanov GS AD - Pathology, Complex Oncology Center, Shumen, BGR. LA - eng PT - Journal Article DEP - 20230910 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10565122 OTO - NOTNLM OT - early stage carcinoma OT - gata3 OT - reccurence OT - urinary bladder OT - urothelial carcinoma COIS- The study was funded via the Medical University of Varna Scientific Fund, grant number 15019. The authors would like to disclose that one of the authors (George Stoyanov, MD, Ph.D.) was a member of the editorial approval board of the journal (Cureus Journal of Medical Science) at the time of the manuscript submission. The authors affirm that this in no way, shape, or form resulted in manipulating the reviewer selection process, reviews, or the initial or final editorial decision. At the time of the study conceptualization, data analysis, and manuscript drafting, all authors were contracted to St. Marina University Hospital, Varna, and Medical University, Varna. EDAT- 2023/10/13 06:45 MHDA- 2023/10/13 06:46 PMCR- 2023/09/10 CRDT- 2023/10/13 04:13 PHST- 2023/09/09 00:00 [accepted] PHST- 2023/10/13 06:46 [medline] PHST- 2023/10/13 06:45 [pubmed] PHST- 2023/10/13 04:13 [entrez] PHST- 2023/09/10 00:00 [pmc-release] AID - 10.7759/cureus.44998 [doi] PST - epublish SO - Cureus. 2023 Sep 10;15(9):e44998. doi: 10.7759/cureus.44998. eCollection 2023 Sep. PMID- 37828777 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20260918 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 31 IP - 2 DP - 2024 Feb TI - Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study. PG - 125-132 LID - 10.1111/iju.15321 [doi] AB - OBJECTIVE: The population with pathological T3 (pT3) upper tract urothelial carcinoma (UTUC) is heterogeneous, thereby making prognostication challenging. We assessed the clinical ramifications of subclassifying pT3 UTUC after nephroureterectomy. METHODS: We conducted a retrospective analysis including 308 patients who underwent nephroureterectomy for pT3N0-1M0 UTUC. pT3 was subclassified into pT3a and pT3b based on invasion of the peripelvic and/or periureteral fat. Cox's proportional hazard models were utilized to determine the significant prognosticators of oncological outcomes, encompassing intravesical recurrence-free survival, recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival. RESULTS: Multivariate analysis elucidated that pT3b status, pathological N1 status, and lymphovascular invasion status were independent risk factors for an unfavorable RFS and CSS. Although the RFS and CSS of patients with pT3b UTUC were superior to those in patients with pT4 UTUC, no significant disparities were detected between patients with pT3a and pT2. CONCLUSION: Our findings demonstrate that pT3 UTUC with peripelvic/periureteral fat invasion is independently associated with metastasis and cancer-specific death after nephroureterectomy. These findings provide patients and physicians with invaluable insight into the risk for disease progression in pT3 UTUC patients. CI - (c) 2023 The Japanese Urological Association. FAU - Suhara, Yushi AU - Suhara Y AUID- ORCID: 0000-0002-3239-2016 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AUID- ORCID: 0000-0002-2599-8183 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yoshihara, Kentaro AU - Yoshihara K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Kurawaki, Shiro AU - Kurawaki S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AUID- ORCID: 0000-0003-1044-912X AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Imai, Yu AU - Imai Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sakanaka, Keigo AU - Sakanaka K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hisakane, Akira AU - Hisakane A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kurauchi, Takashi AU - Kurauchi T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kayano, Sotaro AU - Kayano S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Onuma, Hajime AU - Onuma H AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Shoji AU - Kimura S AUID- ORCID: 0000-0001-7194-5982 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tashiro, Kojiro AU - Tashiro K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AUID- ORCID: 0000-0001-6164-4684 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. CN - JIKEI YAYOI Collaborative Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20231012 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2024 Feb;31(2):133. doi: 10.1111/iju.15343. PMID: 37997623 MH - Humans MH - Prognosis MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms MH - Retrospective Studies MH - Nephroureterectomy/methods MH - *Urologic Neoplasms/pathology OTO - NOTNLM OT - pathological T3 OT - subclassification of pT3 OT - upper tract urothelial carcinoma EDAT- 2023/10/13 06:45 MHDA- 2024/02/05 06:43 CRDT- 2023/10/13 02:58 PHST- 2023/07/18 00:00 [received] PHST- 2023/09/26 00:00 [accepted] PHST- 2024/02/05 06:43 [medline] PHST- 2023/10/13 06:45 [pubmed] PHST- 2023/10/13 02:58 [entrez] AID - 10.1111/iju.15321 [doi] PST - ppublish SO - Int J Urol. 2024 Feb;31(2):125-132. doi: 10.1111/iju.15321. Epub 2023 Oct 12. PMID- 37827948 OWN - NLM STAT- MEDLINE DCOM- 20240517 LR - 20260918 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 7 IP - 3 DP - 2024 Jun TI - A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guerin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. PG - 438-446 LID - S2588-9311(23)00206-7 [pii] LID - 10.1016/j.euo.2023.09.014 [doi] AB - BACKGROUND: Current European Association of Urology (EAU) guidelines support adjuvant intravesical Bacillus Calmette-Guerin (BCG) treatment after Transurethral Resection of Bladder Tumor (TURB) for intermediate- or high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients, aiming to reduce the risk of tumor recurrence. The quality of data, however, does not allow definitive conclusions on whether different strains and dosages of BCG have different efficacies on long-term survival outcomes. OBJECTIVE: To evaluate the long-term survival outcomes of different strains and dosages of BCG in patients with NMIBC. DESIGN, SETTING, AND PARTICIPANTS: All NMIBC patients treated with intravesical BCG therapy from 2001 to 2020 were identified using a territory-wide database in Hong Kong. INTERVENTION: BCG strains and dosages (Connaught strain 81 mg, Connaught strain 27 mg, Tokyo strain 80 mg, and Danish strain 30 mg) were retrieved from medical records. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. A multivariable Cox regression analysis was used to adjust potential confounding factors, and to estimate Hazard Ratio (HR) and 95% confidence interval (CI) of different BCG strains. A further subgroup analysis on adequate versus inadequate BCG treatment was performed. RESULTS AND LIMITATIONS: A total of 2602 NMIBC patients treated with intravesical BCG were identified. Among them, 1291 (49.6%) received Connaught strain 81 mg, 199 (7.6%) received Connaught strain 27 mg, 1014 (39.0%) received Tokyo strain, and 98 (3.8%) received Danish strain. The median follow-up was 11.0 years. No statistically significant differences in OS, CSS, RFS, and PFS were detected among the different groups. At the multivariable analysis, the Connaught strain 27 mg group was inferior to the Connaught strain 81 mg group in terms of OS (HR: 1.26, 95% CI: 1.05-1.51), CSS (HR: 1.69, 95% CI: 1.08-2.66), and PFS (HR: 1.86, 95% CI: 1.20-2.88). Adequate BCG treatment was associated with improved OS (HR: 0.82, 95% CI: 0.73-0.92), CSS (HR: 0.64, 95% CI: 0.47-0.86), RFS (HR: 0.80, 95% CI: 0.70-0.92), and PFS (HR: 0.52, 95% CI: 0.39-0.68). Among patients treated with adequate BCG, at the multivariable analysis the Connaught strain 27 mg group showed worse results than the Connaught strain 81 mg group in terms of CSS (HR: 1.93, 95% CI: 1.07-3.51). Compared with the Connaught strain 81 mg group, both Tokyo and Danish strains had similar survival outcomes in the whole cohort and the adequate BCG treatment subgroup. CONCLUSIONS: Our findings suggest that adequate BCG remains the most important factor in optimizing survival outcomes in patients with intermediate- and high-risk NMIBC. No significant differences in survival outcomes were observed between full-dose Connaught, Tokyo, and Danish strains. Reduced-dose Connaught strain was associated with the worst survival outcomes. PATIENT SUMMARY: We evaluated the efficacy of different strains and dosages of bacillus Calmette-Guerin (BCG) in patients with intermediate- or high-risk non-muscle-invasive bladder cancer in the past two decades in Hong Kong. We conclude no significant differences in long-term survival outcomes in terms of full-dose Connaught, Tokyo, and Danish strains, while reduced-dose Connaught strain was inferior to the full-dose group. Adequate BCG treatment benefits long-term survival. CI - Copyright (c) 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chen, Xuan AU - Chen X AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Nicoletti, Rossella AU - Nicoletti R AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy. FAU - Vasdev, Nikhil AU - Vasdev N AD - Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Soria, Francesco AU - Soria F AD - AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Rabin Medical Center, Petah Tikva, Israel and Medical University of Vienna, Austria. FAU - Shariat, Shahrokh AU - Shariat S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. FAU - Kamat, Ashish AU - Kamat A AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - Giannarini, Gianluca AU - Giannarini G AD - Unit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: jeremyteoh@surgery.cuhk.edu.hk. CN - European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231011 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Adjuvants, Immunologic/therapeutic use/administration & dosage MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use/administration & dosage MH - Hong Kong/epidemiology MH - Neoplasm Invasiveness MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/therapy MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/mortality/therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Cancer-specific survival OT - Non-muscle-invasive bladder cancer OT - Overall survival OT - Progression-free survival OT - Recurrence-free survival EDAT- 2023/10/13 00:43 MHDA- 2024/05/18 04:22 CRDT- 2023/10/12 22:01 PHST- 2023/08/02 00:00 [received] PHST- 2023/08/30 00:00 [revised] PHST- 2023/09/01 00:00 [accepted] PHST- 2024/05/18 04:22 [medline] PHST- 2023/10/13 00:43 [pubmed] PHST- 2023/10/12 22:01 [entrez] AID - S2588-9311(23)00206-7 [pii] AID - 10.1016/j.euo.2023.09.014 [doi] PST - ppublish SO - Eur Urol Oncol. 2024 Jun;7(3):438-446. doi: 10.1016/j.euo.2023.09.014. Epub 2023 Oct 11. PMID- 37800879 OWN - NLM STAT- MEDLINE DCOM- 20240104 LR - 20260701 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 31 IP - 1 DP - 2024 Jan TI - Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories. PG - 64-71 LID - 10.1111/iju.15309 [doi] AB - OBJECTIVES: Multiple clinical practice guidelines, conflicting evidence, and physician perceptions result in variations in risk stratification among patients with non-muscle-invasive bladder cancer (NMIBC). This study aims to describe the extent of this variation and its impact on management approaches in the Asia-Pacific region. METHODS: We conducted a cross-sectional survey involving 32 urologists and seven medical oncologists with >/=8 years of experience managing early-stage bladder cancer patients across Australia, Hong Kong, Japan, South Korea, Singapore, and Taiwan. The physicians completed an anonymous questionnaire that assessed their risk stratification and respective management approaches, based on 19 NMIBC characteristics. For each NMIBC characteristic, they were required to select one risk group, and their most preferred management approach. RESULTS: Our results demonstrated a higher consensus on risk classification versus management approaches. More than 50% of the respondents agreed on the risk classification of all NMIBC characteristics, but 42% or fewer chose the same treatment option as their preferred choice for all but two characteristics-existence of variant histology (55%) and persistent high-grade T1 disease on repeat resection (52%). Across territories, there was the greatest variation in preferred treatment options (i.e., no treatment, intravesical chemotherapy, or Bacillus Calmette-Guerin [BCG] treatment) for intermediate-risk patients and the highest consensus on the treatment of very high-risk patients, namely radical cystectomy. CONCLUSIONS: Our study revealed considerable variation in risk stratification and management of NMIBC in the region. It is critical to develop practical algorithms to facilitate the recognition of NMIBC and standardize the treatment of NMIBC patients. CI - (c) 2023 Merck Sharp & Dohme LLC, and The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-5874-9167 AD - Seoul National University, Seoul, South Korea. FAU - Lee, Lui Shiong AU - Lee LS AUID- ORCID: 0000-0002-8208-0635 AD - Seng Kang General Hospital, Singapore, Singapore. FAU - Lin, Tzu-Ping AU - Lin TP AD - Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Kikuchi, Eiji AU - Kikuchi E AUID- ORCID: 0000-0002-1624-6676 AD - St Marianna University School of Medicine, Kawasaki, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - University of Toyama, Toyama, Japan. FAU - Ng, Chi-Fai AU - Ng CF AUID- ORCID: 0000-0002-1723-9646 AD - The Chinese University of Hong Kong, Hong Kong, Hong Kong. FAU - Ng, Junice Yi Siu AU - Ng JYS AD - IQVIA Asia-Pacific, Singapore, Singapore. FAU - Poon, Darren Ming-Chun AU - Poon DM AD - Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong. FAU - Kanesvaran, Ravindran AU - Kanesvaran R AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Seo, Ho Kyung AU - Seo HK AD - National Cancer Center, Goyang, South Korea. FAU - Spiteri, Carmel AU - Spiteri C AD - MSD, Macquarie Park, New South Wales, Australia. FAU - Tan, Ee Min AU - Tan EM AUID- ORCID: 0000-0003-1418-8529 AD - IQVIA Asia-Pacific, Singapore, Singapore. FAU - Tran, Ben AU - Tran B AD - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. FAU - Tsai, Yuh-Shyan AU - Tsai YS AD - National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - University of Tsukuba, Tsukuba, Japan. LA - eng GR - MSD International GmBH (Singapore)/ PT - Journal Article DEP - 20231006 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Int J Urol. 2024 Jan;31(1):71-72. doi: 10.1111/iju.15340. PMID: 37967160 MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Cross-Sectional Studies MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy MH - Administration, Intravesical MH - Urologists MH - Surveys and Questionnaires MH - Risk Assessment MH - Hong Kong MH - BCG Vaccine/therapeutic use MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic MH - Neoplasm Recurrence, Local/drug therapy PMC - PMC11524120 OTO - NOTNLM OT - NMIBC OT - clinical practice OT - physician OT - survey OT - treatment guidelines COIS- LLS received research funding from Janssen, honoraria from AstraZeneca, MSD, Bayer, Astellas and Janssen; played an advisory role for AstraZeneca, MSD, Bayer, Astellas and Janssen. LTP received honoraria from Astellas, MSD, Ferring pharmaceuticals, Janssen, Bayer and AstraZeneca; received Docetaxel/Cabazitaxel compounds from Sanofi. KE received consulting fees and honoraria from MSD. KH received consulting fees from Kissei and Takeda; received honoraria from Astellas, AstraZeneca, MSD, Sanofi, Takeda, Bayer, Bristol Myers Squibb, Merck Biopharma and Janssen; played an advisory role for Janssen, Astellas, MSD and Pfizer. NCF received consulting fees from Cornerstone Medical and Agilis; received honoraria from Boston Scientific, Janssen, Olympus, Bayer and Ipsen; played an advisory role for Newlife Medical Limited, Jiangsu Hengrui Medicine and Nonagen. He also received equipment materials/drugs from Olympus and Janssen. KR received consulting fees from MSD, AstraZeneca, Bristol-Myers Squibb, Eisai, Astellas, Johnson & Johnson and Pfizer; received honoraria from MSD, AstraZeneca, Bristol-Myers Squibb, Astellas, Pfizer and Johnson & Johnson. TB received research fundings Bristol-Myers Squibb, MSD, Ipsen, Astellas Pharma, Janssen-Cilag, Amgen, Pfizer, Genentech, AstraZeneca and Bayer. He received honoraria from Astellas Pharma, MSD, Janssen-Cilag, Sanofi, Tolmar, Amgen, Bristol-Myers Squibb, Pfizer, Janssen and Bayer; received travel grants from Amgen and Astellas Pharma; played an advisory role for Amgen, Astellas Pharma, Bayer, Sanofi, Tolmar, Janssen-Cilag, Bristol-Meyers Squibb, Ipsen, MSD Oncology, IQVIA, Novartis, Pfizer/EMD Serono, AstraZeneca and Roche Molecular Diagnostic. NH received research grants from Chugai Pharmaceutical and Ono Pharmaceutical; received honoraria from MSD, Astellas, Bristol Myers Squibb, Pfizer/Merck Biopharma and Nihonkayaku; played an advisory role for AstraZeneca, MSD, Astellas, Chugai Pharmaceutical, Ono Pharmaceutical and Janssen. NJYS and TEM were full-time employees of IQVIA, that was commissioned to carry out this study. SC was a full-time employee of MSD. KJH, PDMC, SHK, TYS received honoraria from MSD and have no other conflicts of interest to declare. This work was supported by funding from MSD International GmBH (Singapore). The funding source had no role in the analysis of this study. EDAT- 2023/10/06 12:45 MHDA- 2024/01/04 11:44 PMCR- 2024/10/30 CRDT- 2023/10/06 08:43 PHST- 2023/03/31 00:00 [received] PHST- 2023/09/13 00:00 [accepted] PHST- 2024/01/04 11:44 [medline] PHST- 2023/10/06 12:45 [pubmed] PHST- 2023/10/06 08:43 [entrez] PHST- 2024/10/30 00:00 [pmc-release] AID - IJU15309 [pii] AID - 10.1111/iju.15309 [doi] PST - ppublish SO - Int J Urol. 2024 Jan;31(1):64-71. doi: 10.1111/iju.15309. Epub 2023 Oct 6. PMID- 37800635 OWN - NLM STAT- MEDLINE DCOM- 20231117 LR - 20231122 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 20 DP - 2023 Oct TI - Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer. PG - 20459-20469 LID - 10.1002/cam4.6620 [doi] AB - BACKGROUND: Obesity may be associated with increased risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC), but evidence is limited and inconsistent. We examined the associations of body mass index (BMI), waist circumference, and waist-to-hip ratio (WHR) with risk of recurrence and progression among patients with NMIBC. METHODS: This prospective study included 1029 patients diagnosed with primary NMIBC between 2014 and 2017. Patients reported weight 2 years before diagnosis at baseline, and weight, waist and hip circumference at 3 months postdiagnosis. Associations were quantified using Cox proportional hazard analyses, adjusted for clinical and lifestyle characteristics. RESULTS: More than half of patients were overweight (49%) or obese (19%) after diagnosis. During a median follow-up time of 3.6 years, 371 patients developed >/=1 recurrence and 53 experienced progression. No associations with recurrence were observed for BMI (HR(per 5 kg/m2) 0.94; 95% CI 0.82, 1.07), waist circumference (HR(per 10 cm) 0.95; 95% CI 0.86, 1.05), or WHR (HR(per 0.1 unit) 0.90; 95% CI 0.76, 1.06). In contrast, higher BMI was associated with a 40% increased risk of progression, with only the 2-year prediagnosis association reaching statistical significance (HR(per 5 kg/m2) 1.42; 95% CI 1.09, 1.84). No associations for pre-to-postdiagnosis weight change were found. CONCLUSION: General and abdominal obesity were not associated with recurrence risk among patients with NMIBC, but might be associated with increased risk of progression. Studies with sufficient sample size to stratify by tumor stage and treatment are needed to better understand whether and how obesity could influence prognosis. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - van Zutphen, Moniek AU - van Zutphen M AUID- ORCID: 0000-0002-2368-0606 AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Beeren, Ivy AU - Beeren I AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231006 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Humans MH - Body Mass Index MH - Waist Circumference MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Obesity/complications/epidemiology MH - *Urinary Bladder Neoplasms/etiology/complications MH - Risk Factors PMC - PMC10652337 OTO - NOTNLM OT - abdominal OT - non-muscle invasive bladder cancer OT - obesity OT - progression OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2023/10/06 12:43 MHDA- 2023/11/17 15:26 PMCR- 2023/10/06 CRDT- 2023/10/06 07:24 PHST- 2023/08/25 00:00 [revised] PHST- 2023/04/21 00:00 [received] PHST- 2023/09/23 00:00 [accepted] PHST- 2023/11/17 15:26 [medline] PHST- 2023/10/06 12:43 [pubmed] PHST- 2023/10/06 07:24 [entrez] PHST- 2023/10/06 00:00 [pmc-release] AID - CAM46620 [pii] AID - 10.1002/cam4.6620 [doi] PST - ppublish SO - Cancer Med. 2023 Oct;12(20):20459-20469. doi: 10.1002/cam4.6620. Epub 2023 Oct 6. PMID- 37795933 OWN - NLM STAT- MEDLINE DCOM- 20240104 LR - 20260701 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 31 IP - 1 DP - 2024 Jan TI - Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific. PG - 32-38 LID - 10.1111/iju.15298 [doi] AB - OBJECTIVES: Examine the understanding of terminologies and management patterns of bacillus Calmette-Guerin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) in six territories in Asia-Pacific. METHODS: This study involved two phases: (1) a survey with 32 urologists and 7 medical oncologists (MOs) and (2) a factorial experiment and in-depth interviews with 23 urologists and 2 MOs. All clinicians had >/=8 years' experience managing NMIBC patients in Australia, Hong Kong, Japan, South Korea, Singapore, and Taiwan. Data from Phase 1 were summarized using descriptive statistics; content and thematic analyses applied in Phase 2. RESULTS: In phase 1, 35% of clinicians defined BCG-unresponsive as BCG-refractory, -relapse and -resistant, 6% defined it as BCG-refractory and -relapse; 22% classified BCG-failure as BCG-refractory, -relapse, -resistant, and when muscle-invasive bladder cancer is detected. If eligible and willing, 50% (interquartile range [IQR], 50%-80%) of BCG-unresponsive patients would undergo radical cystectomy (RC), and 50% (IQR 20%-50%) of RC-eligible patients would receive bladder-sparing treatment or surveillance. In phase 2, we found that 32%, 88%, and 48% of clinicians, respectively, used "BCG-unresponsive," "BCG-refractory," and "BCG-relapse" in clinical practice but with no consistent interpretation of the terms. Compared with EAU definitions, 8%-60% of clinicians appropriately classified 9 tumor types that are persistent or recurrent after adequate BCG. Fifty percent of clinicians mentioned a lack of bladder-preserving treatment that outperforms RC in quality of life as a reason to retreat BCG-unresponsive patients with BCG. CONCLUSIONS: Our study revealed varied understanding and application of BCG-unresponsive terminologies in practice. There is a need for a uniform and simple definition of BCG-unresponsive disease in Asia-Pacific. CI - (c) 2023 Merck Sharp & Dohme, LLC and The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Kikuchi, Eiji AU - Kikuchi E AUID- ORCID: 0000-0002-1624-6676 AD - Department of Urology, St. Marianna University School of Medicine, Kawasaki, Japan. FAU - Ng, Chi-Fai AU - Ng CF AUID- ORCID: 0000-0002-1723-9646 AD - Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, University of Toyama, Toyoma, Japan. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University, Seoul, South Korea. FAU - Lee, Lui Shiong AU - Lee LS AUID- ORCID: 0000-0002-8208-0635 AD - Department of Urology, Seng Kang General Hospital, Singapore, Singapore. FAU - Lin, Tzu-Ping AU - Lin TP AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Ng, Junice Yi Siu AU - Ng JYS AD - Health Economics and Outcomes Research, IQVIA Asia-Pacific, Singapore, Singapore. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba, Tsukuba, Japan. FAU - Poon, Darren Ming-Chun AU - Poon DM AD - Comprehensive Oncology Center, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong. FAU - Kanesvaran, Ravindran AU - Kanesvaran R AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, National Cancer Center, Goyang-si, South Korea. FAU - Spiteri, Carmel AU - Spiteri C AD - Market Access Asia Pacific, MSD Macquarie Park, NSW, Macquarie Park, Australia. FAU - Tan, Ee Min AU - Tan EM AUID- ORCID: 0000-0003-1418-8529 AD - Health Economics and Outcomes Research, IQVIA Asia-Pacific, Singapore, Singapore. FAU - Tsai, Yuh-Shyan AU - Tsai YS AD - Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Tran, Ben AU - Tran B AD - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. LA - eng GR - MSD International GmbH (Singapore)/ PT - Journal Article DEP - 20231005 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - Quality of Life MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Invasiveness MH - Recurrence MH - Hong Kong MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/prevention & control/drug therapy PMC - PMC11524088 OTO - NOTNLM OT - BCG vaccine OT - neoplasm recurrence OT - patient care management OT - practice guidelines as topic OT - urinary bladder neoplasms COIS- LLS received research funding from Janssen, honoraria from AstraZeneca, MSD, Bayer, Astellas, and Janssen; played an advisory role for AstraZeneca, MSD, Bayer, Astellas, and Janssen. KE received consulting fees and honoraria from MSD. LTP received honoraria from Astellas, MSD, Ferring pharmaceuticals, Janssen, Bayer, and AstraZeneca; received Docetaxel/Cabazitaxel compounds from Sanofi. KH received consulting fees from Kissei and Takeda; received honoraria from Astellas, AstraZeneca, MSD, Sanofi, Takeda, Bayer, Bristol Myers Squibb, Merck Biopharma, and Janssen; played an advisory role for Janssen, Astellas, MSD, and Pfizer. NCF received consulting fees from Cornerstone Medical and Agilis; received honoraria from Boston Scientific, Janssen, Olympus, Bayer, and Ipsen; played an advisory role for Newlife Medical Limited, Jiangsu Hengrui Medicine and Nonagen. He also received equipment materials/drugs from Olympus and Janssen. KR received consulting fees from MSD, AstraZeneca, Bristol-Myers Squibb, Eisai, Astellas, Johnson & Johnson, and Pfizer; received honoraria from MSD, AstraZeneca, Bristol-Myers Squibb, Astellas, Pfizer, and Johnson & Johnson. TB received research fundings Bristol-Myers Squibb, MSD, Ipsen, Astellas Pharma, Janssen-Cilag, Amgen, Pfizer, Genentech, AstraZeneca, and Bayer. He received honoraria from Astellas Pharma, MSD, Janssen-Cilag, Sanofi, Tolmar, Amgen, Bristol-Myers Squibb, Pfizer, Janssen, and Bayer; received travel grants from Amgen and Astellas Pharma; played an advisory role for Amgen, Astellas Pharma, Bayer, Sanofi, Tolmar, Janssen-Cilag, Bristol-Meyers Squibb, Ipsen, MSD Oncology, IQVIA, Novartis, Pfizer/EMD Serono, AstraZeneca, and Roche Molecular Diagnostic. NH received research grants from Astellas, MSD, Bayer, Ono Pharmaceutical and Takeda Pharmaceutical; received honoraria from MSD, Chugai Pharmaceutical and Astellas. NJYS and TEM are full-time employees of IQVIA, that was commissioned to carry out this study. SC was a full-time employees of MSD. KJH, PDMC, SHK, and TYS received honoraria from MSD and have no other conflicts of interest to declare. This work was supported by funding from MSD International GmbH (Singapore). The funding source had no role in the analysis of this study. EDAT- 2023/10/05 12:43 MHDA- 2024/01/04 11:45 PMCR- 2024/10/30 CRDT- 2023/10/05 08:32 PHST- 2023/04/17 00:00 [received] PHST- 2023/09/06 00:00 [accepted] PHST- 2024/01/04 11:45 [medline] PHST- 2023/10/05 12:43 [pubmed] PHST- 2023/10/05 08:32 [entrez] PHST- 2024/10/30 00:00 [pmc-release] AID - IJU15298 [pii] AID - 10.1111/iju.15298 [doi] PST - ppublish SO - Int J Urol. 2024 Jan;31(1):32-38. doi: 10.1111/iju.15298. Epub 2023 Oct 5. PMID- 37787829 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20261010 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 31 IP - 10 DP - 2023 Oct 3 TI - Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy. PG - 607 LID - 10.1007/s00520-023-08087-6 [doi] AB - PURPOSE: To evaluate the significance of local radiation therapy (LRT) for prevention of local symptoms (LSs) caused by muscle-invasive bladder cancer (MIBC). METHODS: We retrospectively reviewed the clinical records of 133 patients from 13 hospitals. MIBC patients with or without metastases who were treated with LRT alone from January 2015 through December 2020 were enrolled. Exclusion criteria were urinary diversion (UD) prior to LRT, non-MIBC, or lack of clinical information. LSs were defined as hematuria requiring invasive treatment or transfusion, UD after LRT, bladder tamponade, and opioid use for bladder pain. RESULTS: One hundred fourteen patients were finally enrolled in the study. During the median follow-up period of 13.5 months, 30 patients (26.3%) had LSs. Risk factors of LSs in multivariate analysis were a prior history of non-MIBC (NMIBC) (hazard ratio [HR] 2.99; 95% confidence interval [CI], 1.36 to 6.56; P < 0.01), radiation dose of less than 50 Gray (Gy) (HR 3.99; 95% CI, 1.80 to 8.82; P < 0.01), and tumor stage 3 or more (HR 2.43; 95% CI, 1.14 to 5.21; P = 0.02). Risk factors of overall survival (OS) in multivariate analysis were being female (HR 3.32; 95% CI, 1.68 to 6.58; P < 0.01), an age-adjusted Charlson Comorbidity index of 6 or more (HR 2.19; 95% CI, 1.18 to 4.10; P = 0.01), distant metastases (HR 3.20; 95% CI, 1.39 to 6.58; P < 0.01), and tumor size of 40 mm or more (HR 2.38; 95% CI, 1.34 to 4.52; P < 0.01). Toxicity (all grades) occurred in 40.4% of the patients, 4.8% with grade 3 or more and 95.2% with lower grades. CONCLUSIONS: We determined the risk factors for LSs in MIBC patients treated with LRT alone. An escalated-dose of 50 Gy or more may contribute to prevention of LSs caused by MIBC. Thus, dose-escalated LRT for MIBC patients who can expect favorable survival may be a good option to avoid future annoying LSs. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Okada, Manabu AU - Okada M AD - Department of Urology, Obihiro Kyokai Hospital, Obihiro, Japan. FAU - Shindo, Tetsuya AU - Shindo T AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. shindo1013@yahoo.co.jp. FAU - Fujino, Keiko AU - Fujino K AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. FAU - Maeda, Toshihiro AU - Maeda T AD - Department of Urology, Oji General Hospital, Tomakomai, Japan. FAU - Ito, Naoki AU - Ito N AD - Department of Urology, NTT East Medical Center Sapporo, Sapporo, Japan. FAU - Takahashi, Atsushi AU - Takahashi A AD - Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Hotta, Hiroshi AU - Hotta H AD - Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan. FAU - Kunishima, Yasuharu AU - Kunishima Y AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan. FAU - Matsukawa, Masanori AU - Matsukawa M AD - Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan. FAU - Takayanagi, Akio AU - Takayanagi A AD - Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan. FAU - Wanifuchi, Atsushi AU - Wanifuchi A AD - Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan. FAU - Nofuji, Seisuke AU - Nofuji S AD - Department of Urology, Hokkaido Medical Center, Sapporo, Japan. FAU - Kato, Ryuichi AU - Kato R AD - Department of Urology, Muroran City General Hospital, Muroran, Japan. FAU - Fukuta, Fumimasa AU - Fukuta F AD - Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan. FAU - Hashimoto, Kohei AU - Hashimoto K AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. FAU - Kobayashi, Ko AU - Kobayashi K AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. FAU - Tanaka, Toshiaki AU - Tanaka T AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, S1W16, Chuo-Ku, Sapporo, 060-8543, Japan. LA - eng PT - Journal Article DEP - 20231003 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Humans MH - Female MH - Male MH - Retrospective Studies MH - *Clinical Relevance MH - Cystectomy MH - *Urinary Bladder Neoplasms/pathology MH - Muscles/pathology MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - Local symptoms OT - Muscle-invasive bladder cancer OT - Palliative OT - Prevention OT - Radiation therapy EDAT- 2023/10/03 12:45 MHDA- 2023/10/23 01:18 CRDT- 2023/10/03 11:06 PHST- 2023/05/15 00:00 [received] PHST- 2023/09/27 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/03 12:45 [pubmed] PHST- 2023/10/03 11:06 [entrez] AID - 10.1007/s00520-023-08087-6 [pii] AID - 10.1007/s00520-023-08087-6 [doi] PST - epublish SO - Support Care Cancer. 2023 Oct 3;31(10):607. doi: 10.1007/s00520-023-08087-6. PMID- 37784106 OWN - NLM STAT- MEDLINE DCOM- 20231004 LR - 20231119 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 21 IP - 1 DP - 2023 Oct 2 TI - Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study. PG - 685 LID - 10.1186/s12967-023-04528-2 [doi] LID - 685 AB - BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is known for its elevated recurrence rate, necessitating an enhancement in the current risk stratification for recurrence. The urine-based fluorescence in situ hybridization (FISH) assay has emerged as a noninvasive auxiliary tool for detecting bladder cancer. The aim of this study was to explore the potential relationship between the preoperative FISH assay and recurrence, and to develop a FISH-clinical nomogram for predicting the recurrence-free survival (RFS) in NMIBC patients. METHODS: In total, 332 eligible patients were enrolled from two hospitals. The SYSMH cohort was randomly assigned to the training set (n = 168) and the validation set I (n = 72) at a ratio of 7:3, while the SYSUTH cohort was allocated to the validation set II (n = 92). The correlation between the preoperative FISH assay and recurrence was determined through the Cox regression analysis. The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was used for model construction. The performance of the model was assessed by its discrimination, calibration, and clinical usefulness. RESULTS: We uncovered that chromosome 7 aneuploidy, p16 locus loss, number of the positive FISH sites, and the FISH test result were significantly associated with tumor recurrence. Then, a FISH-clinical nomogram incorporating the FISH test result, T stage, associated CIS, tumor grade, and tumor status was developed. It showed favorable calibration and discrimination with a C-index of 0.683 (95%CI, 0.611-0.756) in the training set, which was confirmed in the validation set I and validation set II with C-indexes of 0.665 (95%CI, 0.565-0.765) and 0.778 (95%CI, 0.665-0.891), respectively. Decision curve analysis revealed the clinical usefulness of the nomogram. Moreover, our proposed nomogram significantly outperformed the guideline-recommended EORTC and CUETO scoring models. CONCLUSION: Our study confirmed the prognostic value of the preoperative FISH assay and proposed a FISH-clinical nomogram to predict RFS in NMIBC patients. Our nomogram can serve as a more precise tool for recurrence risk stratification, which may optimize disease management in bladder cancer and improve patient prognosis. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Zheng, Junjiong AU - Zheng J AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Lu, Sihong AU - Lu S AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Huang, Yi AU - Huang Y AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Chen, Xu AU - Chen X AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Zhang, Jie AU - Zhang J AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Yao, Yuhui AU - Yao Y AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Cai, Jinhua AU - Cai J AD - Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. FAU - Wu, Jieying AU - Wu J AD - Department of Urology, the Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Guangzhou, People's Republic of China. wujying@mail.sysu.edu.cn. FAU - Kong, Jianqiu AU - Kong J AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. kongjq5@mail.sysu.edu.cn. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Provincial Clinical Research Center for Urological Diseases, 107 Yan Jiang West Road, Guangzhou, People's Republic of China. lintx@mail.sysu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231002 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/genetics/pathology MH - In Situ Hybridization, Fluorescence MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/genetics/surgery/pathology MH - Prognosis MH - Retrospective Studies PMC - PMC10546664 OTO - NOTNLM OT - Fluorescence in situ hybridization OT - Nomogram OT - Non-muscle invasive bladder cancer OT - Recurrence COIS- The authors declare that they have no competing interests. EDAT- 2023/10/03 00:42 MHDA- 2023/10/04 06:43 PMCR- 2023/10/02 CRDT- 2023/10/02 23:48 PHST- 2023/04/21 00:00 [received] PHST- 2023/09/15 00:00 [accepted] PHST- 2023/08/22 00:00 [revised] PHST- 2023/10/04 06:43 [medline] PHST- 2023/10/03 00:42 [pubmed] PHST- 2023/10/02 23:48 [entrez] PHST- 2023/10/02 00:00 [pmc-release] AID - 10.1186/s12967-023-04528-2 [pii] AID - 4528 [pii] AID - 10.1186/s12967-023-04528-2 [doi] PST - epublish SO - J Transl Med. 2023 Oct 2;21(1):685. doi: 10.1186/s12967-023-04528-2. PMID- 37781991 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231103 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 23 IP - 11 DP - 2023 Jul-Dec TI - 2023 ASCO Genitourinary Cancers Symposium: a focus on urothelial carcinoma. PG - 1123-1126 LID - 10.1080/14737140.2023.2265570 [doi] AB - In this article, we describe the main acquisitions of urothelial carcinoma (UC) management reported at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. A major development of this year was characterized by the confirmation of a disease-free survival advantage of adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma after radical resection at longer follow-up. In the metastatic setting, the updated analysis of the IMvigor130 study confirmed the failure of the strategy of adding immunotherapy (i.e. atezolizumab) to first-line chemotherapy; analogously atezolizumab monotherapy did not improve overall survival compared to chemotherapy in untreated metastatic urothelial carcinoma (mUC). Furthermore, interesting data were presented concerning future treatment options. In particular, immunotherapy (IO) with pembrolizumab showed promising activity in patients with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guerin (KEYNOTE-057). The antibody-drug conjugate sacituzumab govitecan demonstrated a relevant activity in platinum (PT)-ineligible mUC patients progressed after prior IO. Certainly, the lack of predictive biomarkers of response to a specific therapy highlights the urgent need for comprehensive characterization of UC for a personalized therapeutic approach that will improve patient outcomes. FAU - Cigliola, Antonio AU - Cigliola A AD - Medical Oncology Unit, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Beccia, Viria AU - Beccia V AD - Medical Oncology Unit, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Anghelone, Annunziato AU - Anghelone A AD - Medical Oncology Unit, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Panebianco, Martina AU - Panebianco M AD - Medical Oncology Unit, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Ciccarese, Chiara AU - Ciccarese C AD - Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. FAU - Iacovelli, Roberto AU - Iacovelli R AD - Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. LA - eng PT - Journal Article DEP - 20231027 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 31YO63LBSN (Nivolumab) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Nivolumab/therapeutic use MH - Adjuvants, Immunologic MH - Progression-Free Survival OTO - NOTNLM OT - ASCO GU 2023 OT - HR-MIUC OT - HR-NMIBC OT - KEYNOTE-057 OT - Urothelial carcinoma OT - adjuvant nivolumab EDAT- 2023/10/02 12:42 MHDA- 2023/10/02 12:43 CRDT- 2023/10/02 07:23 PHST- 2023/10/02 12:43 [medline] PHST- 2023/10/02 12:42 [pubmed] PHST- 2023/10/02 07:23 [entrez] AID - 10.1080/14737140.2023.2265570 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1123-1126. doi: 10.1080/14737140.2023.2265570. Epub 2023 Oct 27. PMID- 37769147 OWN - NLM STAT- MEDLINE DCOM- 20260310 LR - 20260310 IS - 1944-8252 (Electronic) IS - 1944-8244 (Linking) VI - 15 IP - 40 DP - 2023 Oct 11 TI - Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer. PG - 46668-46680 LID - 10.1021/acsami.3c09564 [doi] AB - Bladder cancer is one of the most common malignancies in the urinary system, with high risk of recurrence and progression. However, the difficulty in detecting small tumor lesions and the lack of selectivity of intravesical treatment seriously affect the prognosis of patients with bladder cancer. In the present work, a nanoparticle-based delivery system with tumor targeting, high biocompatibility, simple preparation, and the ability to synergize imaging and therapy was fabricated. Specifically, this nanosystem consisted of the core of doxorubicin (DOX)-loaded polydopamine nanoparticles (PDD NPs) and the shell of hyaluronic acid (HA)-conjugated IR780 (HA-IR780). The HA-IR780-covered PDD NPs (HR-PDD NPs) demonstrated tumor targeting and visualization both in vitro and in vivo with properties of promoted cancer cell endocytosis and lysosomal escape, efficiently delivering drugs to the target site and exerting a killing effect on tumor cells. Encouragingly, intravesical instillation of HR-PDD NPs improved drug retention in the bladder and promoted its accumulation in tumor tissue, resulting in better tumor proliferation inhibition and apoptosis in an orthotopic bladder cancer model in rats. This study provides a promising strategy for the diagnosis and therapy of bladder cancer. FAU - Qiu, Heping AU - Qiu H AUID- ORCID: 0000-0003-0652-6858 AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Wang, Jianwu AU - Wang J AUID- ORCID: 0000-0001-9298-6724 AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Zhi, Yi AU - Zhi Y AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Yan, Benhuang AU - Yan B AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Huang, Yuandi AU - Huang Y AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Li, Jinjin AU - Li J AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Shen, Chongxing AU - Shen C AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Dai, Linyong AU - Dai L AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Fang, Qiang AU - Fang Q AUID- ORCID: 0009-0004-0892-1960 AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. FAU - Shi, Chunmeng AU - Shi C AUID- ORCID: 0000-0002-8264-738X AD - Institute of Rocket Force Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University (Third Military Medical University), Chongqing 400038, China. FAU - Li, Weibing AU - Li W AUID- ORCID: 0000-0001-6431-8251 AD - Department of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China. LA - eng PT - Journal Article DEP - 20230928 PL - United States TA - ACS Appl Mater Interfaces JT - ACS applied materials & interfaces JID - 101504991 RN - 0 (polydopamine) RN - 9004-61-9 (Hyaluronic Acid) RN - 0 (Indoles) RN - 0 (Polymers) RN - 80168379AG (Doxorubicin) RN - 0 (Fluorescent Dyes) SB - IM MH - *Urinary Bladder Neoplasms/drug therapy/diagnostic imaging/pathology MH - *Hyaluronic Acid/chemistry MH - *Indoles/chemistry/pharmacology MH - *Polymers/chemistry/pharmacology MH - Animals MH - Humans MH - *Doxorubicin/chemistry/pharmacology/therapeutic use MH - *Nanoparticles/chemistry MH - Mice MH - *Fluorescent Dyes/chemistry/pharmacology MH - Cell Line, Tumor MH - Nanomedicine MH - Female MH - Optical Imaging MH - Apoptosis/drug effects OTO - NOTNLM OT - bladder cancer OT - imaging OT - intravesical chemotherapy OT - polydopamine OT - targeting EDAT- 2023/09/29 00:42 MHDA- 2026/03/10 18:36 CRDT- 2023/09/28 18:47 PHST- 2026/03/10 18:36 [medline] PHST- 2023/09/29 00:42 [pubmed] PHST- 2023/09/28 18:47 [entrez] AID - 10.1021/acsami.3c09564 [doi] PST - ppublish SO - ACS Appl Mater Interfaces. 2023 Oct 11;15(40):46668-46680. doi: 10.1021/acsami.3c09564. Epub 2023 Sep 28. PMID- 37758560 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240409 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 2 DP - 2024 Apr TI - Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study. PG - 38-46.e1 LID - S1558-7673(23)00186-6 [pii] LID - 10.1016/j.clgc.2023.08.003 [doi] AB - OBJECTIVES: To predict response of patients with muscle invasive bladder cancer (MIBC) to neoadjuvant chemotherapy (NAC) through analysis of molecular profile assessed clinically (radiologically and by pathological examination of transurethral resection biopsy [TURBT] specimens) and definitively with histopathological examination after radical cystectomy (RC). METHODS: In a prospective study, tumor biopsies were obtained from patients with urothelial MIBC (T2-4a N0-2 M0) during TURBT. Patients were eligible for RC received 4 cycles of cisplatin-based NAC. DNA repair genes (BRACA1, ERCC1) & CTR gene m-RNA expression levels were assessed in resected tissue. The response to chemotherapy was assessed clinically (radiologically & TURBT) following NAC. Response was re-assessed for 64 patients who underwent RC and predictors of cancer-free survival (CFS) were calculated. Receiver operating characteristic (ROC) curve was used to delineate cutoff value copes with the best sensitivity and specificity for prediction of response to NAC. RESULTS: The study included 104 patients, 42 (40.4%) responded well to NAC clinically. Out of 64 patients who underwent RC, 26 (40.6%) showed good response to NAC. CFS at 18 months for patients who underwent RC was 60%. Statistical analysis showed that molecular profile was an independent predictor of good response to NAC both clinically and pathologically and also predicted better CFS. CONCLUSION: Molecular profile could play a decisive role in early detection of patients with MIBC who will get benefit from preoperative NAC. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Elkarta, Ahmed AU - Elkarta A AD - Urology department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Awadalla, Amira AU - Awadalla A AD - Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Hefnawy, Ahmed AU - El-Hefnawy A AD - Urology department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Mosbah, Ahmed AU - Mosbah A AD - Urology department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abolenein, Hassan AU - Abolenein H AD - Urology department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt; Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed AU - Shokeir A AD - Urology department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt; Center of Excellence of Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. Electronic address: ahmed.shokeir@hotmail.com. LA - eng PT - Journal Article DEP - 20230810 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - *Cisplatin/therapeutic use MH - Prospective Studies MH - Neoadjuvant Therapy MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - Cystectomy MH - Muscles/metabolism/pathology MH - Neoplasm Invasiveness MH - Retrospective Studies OTO - NOTNLM OT - Cisplatin OT - Genetics OT - Neoadjuvant chemotherapy OT - Radical cystectomy EDAT- 2023/09/28 00:42 MHDA- 2024/03/11 06:42 CRDT- 2023/09/27 21:54 PHST- 2023/02/02 00:00 [received] PHST- 2023/07/09 00:00 [revised] PHST- 2023/08/07 00:00 [accepted] PHST- 2024/03/11 06:42 [medline] PHST- 2023/09/28 00:42 [pubmed] PHST- 2023/09/27 21:54 [entrez] AID - S1558-7673(23)00186-6 [pii] AID - 10.1016/j.clgc.2023.08.003 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Apr;22(2):38-46.e1. doi: 10.1016/j.clgc.2023.08.003. Epub 2023 Aug 10. PMID- 37753732 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20260803 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 18 IP - 2 DP - 2024 Feb TI - Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy. PG - 291-304 LID - 10.1002/1878-0261.13530 [doi] AB - Intravesical therapy (IVT) is the standard of care to decrease risk of recurrence and progression for high-grade nonmuscle-invasive bladder cancer. However, post-IVT recurrence remains common and the ability to risk-stratify patients before or after IVT is limited. In this prospectively designed and accrued cohort study, we examine the utility of urinary comprehensive genomic profiling (uCGP) for predicting recurrence risk following transurethral resection of bladder tumor (TURBT) and evaluating longitudinal IVT response. Urine was collected before and after IVT instillation and uCGP testing was done using the UroAmp platform. Baseline uCGP following TURBT identified patients with high (61%) and low (39%) recurrence risk. At 24 months, recurrence-free survival (RFS) was 100% for low-risk and 45% for high-risk patients with a hazard ratio (HR) of 9.3. Longitudinal uCGP classified patients as minimal residual disease (MRD) Negative, IVT Responder, or IVT Refractory with 24-month RFS of 100%, 50%, and 32%, respectively. Compared with MRD Negative patients, IVT Refractory patients had a HR of 10.5. Collectively, uCGP enables noninvasive risk assessment of patients following TURBT and induction IVT. uCGP could inform surveillance cystoscopy schedules and identify high-risk patients in need of additional therapy. CI - (c) 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Rac, Goran AU - Rac G AUID- ORCID: 0000-0003-4694-1634 AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. FAU - Patel, Hiten D AU - Patel HD AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. AD - Department of Urology, Fienberg School of Medicine, Northwestern University, Evanston, IL, USA. FAU - James, Christopher AU - James C AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. FAU - Desai, Shalin AU - Desai S AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. FAU - Caruso, Vincent M AU - Caruso VM AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Fischer, Daniel S AU - Fischer DS AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Lentz, Peter S AU - Lentz PS AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Ward, Ceressa T AU - Ward CT AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Mazzarella, Brian C AU - Mazzarella BC AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Phillips, Kevin G AU - Phillips KG AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Doshi, Chirag AU - Doshi C AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. FAU - Bicocca, Vincent T AU - Bicocca VT AUID- ORCID: 0000-0002-5702-4586 AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Levin, Trevor G AU - Levin TG AD - Convergent Genomics, Inc., South San Francisco, CA, USA. FAU - Wolfe, Alan J AU - Wolfe AJ AUID- ORCID: 0000-0003-4532-0545 AD - Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA. FAU - Gupta, Gopal N AU - Gupta GN AUID- ORCID: 0000-0002-8502-708X AD - Department of Urology, Loyola University Medical Center, Maywood, IL, USA. AD - Department of Radiology, Loyola University Medical Center, Maywood, IL, USA. AD - Department of Surgery, Loyola University Medical Center, Maywood, IL, USA. LA - eng SI - BioProject/PRJNA973097 GR - R44 CA200174/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20231005 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Cohort Studies MH - Administration, Intravesical MH - Genomics MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies PMC - PMC10850796 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - genomics OT - intravesical instillation OT - personalized medicine OT - risk assessment COIS- VMC, DSF, PSL, CTW, BCM, KGP, VTB, and TGL report being employees and shareholders of Convergent Genomics. AJW discloses membership on the advisory boards of Urobiome Therapeutics and Pathnostics and funding from Pathnostics, VB Tech, the Craig H. Neilsen Foundation, and NIH. All other authors have no disclosures. EDAT- 2023/09/27 06:42 MHDA- 2024/02/09 00:42 PMCR- 2023/10/05 CRDT- 2023/09/27 05:52 PHST- 2023/08/24 00:00 [revised] PHST- 2023/05/18 00:00 [received] PHST- 2023/09/25 00:00 [accepted] PHST- 2024/02/09 00:42 [medline] PHST- 2023/09/27 06:42 [pubmed] PHST- 2023/09/27 05:52 [entrez] PHST- 2023/10/05 00:00 [pmc-release] AID - MOL213530 [pii] AID - 10.1002/1878-0261.13530 [doi] PST - ppublish SO - Mol Oncol. 2024 Feb;18(2):291-304. doi: 10.1002/1878-0261.13530. Epub 2023 Oct 5. PMID- 37745737 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230926 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer. PG - e45672 LID - 10.7759/cureus.45672 [doi] LID - e45672 AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) is a frequently diagnosed neoplasm, which is typically managed with transurethral resection of bladder tumor (TURBT) eventually followed by intravesical therapies. Bacillus Calmette-Guerin (BCG) is used as first-line adjuvant treatment in high- (HR) and intermediate-risk (IR) NMIBC, although, in the latter, mitomycin C (MMC) may also be used. Multiple limitations to the use of BCG encouraged the search for therapeutic alternatives. In this context, hyperthermic intravesical chemotherapy with MMC (HIVEC-MMC) emerged as a promising therapy in the adjuvant setting for NMIBC. The aim of our study was to evaluate the tolerability, compliance, and survival outcomes of HIVEC-MMC in patients with IR- and HR-NMIBC. MATERIAL AND METHODS: This was a single-center retrospective analysis of IR- and HR- NMIBC patients who received HIVEC-MMC after TURBT between August 2018 and August 2022. Levels of risk stratification were defined using the European Association of Urology (EAU) criteria. The protocol consisted of four weekly HIVEC-MMC instillations (induction) followed by six monthly instillations (maintenance). The primary outcomes were to evaluate the tolerability and compliance with the HIVEC-MMC protocol and secondary outcomes were disease-free survival (DFS) and overall survival (OS). For the purpose of statistical analysis, methods of descriptive statistics, survival analysis (Kaplan-Meier estimation), and multivariate analysis (Cox regression, and binary logistic regression) were used. RESULTS: Fifty-seven patients were enrolled with a median age of 67.9 (34.4-83.5) years old. In this cohort, 40 patients (70.2%) had primary tumors. At the time of referral for HIVEC-MMC, the majority of the patients had IR-NMIBC (n= 33, 57.9%). A total of 41 patients (71.9%) completed the HIVEC-MMC protocol. Disease recurrence and adverse events (AEs) were the most common reasons to stop the protocol. After a median follow-up of 31 months (95% CI, 5.0-54.0), 32 patients (61.4%) were disease-free, 22 (38.6%) experienced recurrent disease and six patients (10.5%) died, although only one death was directly attributable to bladder cancer. The median DFS was 42 months (95% CI, 28.0-56.0). Completion of the HIVEC-MMC maintenance phase protocol stood as a predictive factor for DFS (44 months, 95% CI 29.1-58.9 vs. 14 months, 95% CI 0.0-29.6, p < 0.001; HR 4.48, 95% CI 1.65-12.15). The median OS was not reached; the 24- and 48-month OS were 92.6% and 82.7%, respectively. EAU risk group, ECOG-PS, and completion of HIVEC protocol were found to be significant predictive factors of OS but lost their significance on multivariate analysis. However, if we exclude those who experienced recurrence during the maintenance phase protocol, treatment completion had a significant positive impact on OS (HR: 42.8, 95% CI 1.75-1045.072, p= 0.021). CONCLUSIONS: Our study suggests that HIVEC is a secure and well-tolerated treatment with promising efficacy data, making this therapeutic approach a feasible option in IR- and HR-NMIBC patients, mainly in those who cannot tolerate or have contraindications to BCG therapy, but also as an alternative during BCG shortages. CI - Copyright (c) 2023, Magalhaes et al. FAU - Magalhaes, Joana C AU - Magalhaes JC AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. FAU - Sousa, Maria AU - Sousa M AD - Medical Oncology, Centro Hospitalar Universitario do Porto, Porto, PRT. FAU - Basto, Raquel AU - Basto R AD - Medical Oncology, Centro Hospitalar Vila Nova de Gaia/Espinho, Gaia, PRT. FAU - Fraga, Teresa AU - Fraga T AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. FAU - Gomes, Ines AU - Gomes I AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. FAU - Fernandes, Catarina AU - Fernandes C AD - Medical Oncology, Centro Hospitalar Universitario de Sao Joao, Porto, PRT. FAU - Mariano, Monica AU - Mariano M AD - Medical Oncology, Centro Hospitalar e Universitario de Coimbra, Coimbra, PRT. FAU - Paulo, Judy AU - Paulo J AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. FAU - Madeira, Pedro AU - Madeira P AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. FAU - Sousa, Gabriela AU - Sousa G AD - Medical Oncology, Instituto Portugues de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, PRT. LA - eng PT - Journal Article DEP - 20230921 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10512434 OTO - NOTNLM OT - adjuvant intravesical chemotherapy OT - bacillus calmette-guerin OT - hyperthermic intravesical chemotherapy OT - mitomycin c OT - non-muscle invasive bladder cancer COIS- The authors have declared that no competing interests exist. EDAT- 2023/09/25 06:43 MHDA- 2023/09/25 06:44 PMCR- 2023/09/21 CRDT- 2023/09/25 05:06 PHST- 2023/09/20 00:00 [accepted] PHST- 2023/09/25 06:44 [medline] PHST- 2023/09/25 06:43 [pubmed] PHST- 2023/09/25 05:06 [entrez] PHST- 2023/09/21 00:00 [pmc-release] AID - 10.7759/cureus.45672 [doi] PST - epublish SO - Cureus. 2023 Sep 21;15(9):e45672. doi: 10.7759/cureus.45672. eCollection 2023 Sep. PMID- 37738002 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20250824 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 110 IP - 1 DP - 2024 Jan 1 TI - Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study. PG - 270-279 LID - 10.1097/JS9.0000000000000790 [doi] AB - OBJECTIVE: To assess prognostic differences between primary and progressive muscle-invasive bladder cancer (MIBC) following radical cystectomy. MATERIAL AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to abstract MIBC data following radical cystectomy from 2000 to 2019. Patients were classified as either 'Primary' MIBC (defined as the presentation of muscle-invasive disease at initial diagnosis) or 'Progressive' MIBC (defined as a non-muscle invasive disease that later progressed to MIBC). Baseline characteristics for the two groups were balanced using a propensity score overlap weight (PSOW) technique. Survival differences between the two groups were analyzed using Kaplan-Meier's plots and log-rank tests. Cox's proportional hazard regression was used to assess risk factors associated with overall survival (OS) and cancer-specific survival (CSS). RESULTS: Six thousand six hundred thirty-two MIBC patients were identified in the SEER database. Among them, 83.3% ( n =5658) were considered primary MIBC patients, and 16.7% ( n =974) were categorized as progressive MIBC patients. Distribution of baseline covariates, including age, sex, race, T stage, N stage, tumour grade, marital status, and chemotherapy, were well-balanced after PSOWs were applied. After stable PSOW adjustments, Kaplan-Meier survival analysis showed that the CSS for progressive MIBC [hazard ratio (HR)=1.25, 95% confidence interval (CI): 1.12-1.38, P <0.001) was poorer than the primary MIBC group. However, the difference in OS (HR=1.08, 95% CI: 0.99-1.18) was not significant ( P =0.073). Multivariate analysis also suggested that patients with progressive MIBC have significantly poorer CSS (HR=1.24, 95% CI: 1.19-1.38, P <0.001) but not OS (HR=1.08, 95% CI: 0.99-1.18, P =0.089). CONCLUSION: CSS for progressive MIBC patients appears worse than for those with primary MIBC. This highlights the need to direct more resources for this patient population and particularly for high-risk cases of non-MIBC, where timely radical surgery will improve patients prognoses. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences. AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences. AD - Beijing Hospital Continence Center, Beijing, China. FAU - Lai, Chin-Hui AU - Lai CH AD - Department of Urology, Peking University People's Hospital. FAU - Seery, Samuel AU - Seery S AD - Faculty of Health and Medicine, Division of Health Research, Lancaster University, Lancaster, LA1 4YW, UK. FAU - Hu, Haopu AU - Hu H AD - Department of Urology, Peking University People's Hospital. FAU - Wang, Mingrui AU - Wang M AD - Department of Urology, Peking University People's Hospital. FAU - Hu, Hao AU - Hu H AD - Department of Urology, Peking University People's Hospital. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240101 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - Prognosis MH - *Cystectomy/methods MH - Propensity Score MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Cohort Studies MH - Muscles/pathology MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies PMC - PMC10793809 COIS- The authors declare that they have no conflict of interest. EDAT- 2023/09/22 12:42 MHDA- 2024/02/07 06:43 PMCR- 2024/01/17 CRDT- 2023/09/22 11:13 PHST- 2023/08/01 00:00 [received] PHST- 2023/09/10 00:00 [accepted] PHST- 2024/02/07 06:43 [medline] PHST- 2023/09/22 12:42 [pubmed] PHST- 2023/09/22 11:13 [entrez] PHST- 2024/01/17 00:00 [pmc-release] AID - 01279778-202401000-00029 [pii] AID - IJS-D-23-01623 [pii] AID - 10.1097/JS9.0000000000000790 [doi] PST - epublish SO - Int J Surg. 2024 Jan 1;110(1):270-279. doi: 10.1097/JS9.0000000000000790. PMID- 37730609 OWN - NLM STAT- MEDLINE DCOM- 20230922 LR - 20231121 IS - 1748-717X (Electronic) IS - 1748-717X (Linking) VI - 18 IP - 1 DP - 2023 Sep 20 TI - Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer. PG - 154 LID - 10.1186/s13014-023-02338-w [doi] LID - 154 AB - PURPOSE/OBJECTIVE: Definitive radiotherapy (RT) is an alternative to radical cystectomy for select patients with muscle invasive bladder cancer (MIBC); however, there is limited data on dose-painted RT approaches. We report the clinical and dosimetric outcomes of a cohort of MIBC patients treated with dose-painted RT. MATERIAL/METHODS: This was a single institution retrospective study of cT2-4N0M0 MIBC patients treated with external beam radiotherapy (EBRT) to the bladder, and sequential or concomitant boost to the tumor bed. The target delineation was guided by either intravesical injection of Lipiodol or through fusion of the pre-treatment imaging. The majority were treated with daily image-guidance. Kaplan-Meier was used to characterize overall survival (OS) and progression-free survival (PFS). Cumulative incidence function (CIF) was used to estimate local (intravesical) recurrence (LR), regional recurrence (RR) and distant metastasis (DM). Univariable and multivariable cause-specific hazard model was used to assess factors associated with LR and OS. RESULTS: 117 patients were analyzed. The median age was 73 years (range 43, 95). The median EQD2 to the boost volume was 66 Gy (range 52.1, 70). Lipiodol injection was used in 64 patients (55%), all treated with IMRT/VMAT. 95 (81%) received concurrent chemotherapy, of whom, 44 (38%) received neoadjuvant chemotherapy. The median follow-up was 37 months (IQR 16.2, 83.3). At 5-year, OS and PFS were 79% (95% CI 70.5-89.2) and 46% (95% CI 36.5-57.5). Forty-five patients had bladder relapse, of which 30 patients (67%) were at site of the tumor bed. Nine patients underwent salvage-cystectomy. Late high-grade (G3-G4) genitourinary and gastrointestinal toxicity were 3% and 1%. CONCLUSION: Partial boost RT in MIBC is associated with good local disease control and high rates of cystectomy free survival. We observed a pattern of predominantly LR in the tumor bed, supporting the use of a dose-painted approach/de-escalation strategy to the uninvolved bladder. Prospective trials are required to compare oncological and toxicity outcomes between dose-painted and homogeneous bladder RT techniques. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Navarro-Domenech, Inmaculada AU - Navarro-Domenech I AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Arulanantham, Shinthujah AU - Arulanantham S AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Liu, Zhihui Amy AU - Liu ZA AD - Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada. zhihuiamy.liu@uhn.ca. FAU - Tjong, Michael AU - Tjong M AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Kong, Vickie AU - Kong V AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Malkov, Victor AU - Malkov V AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Tadic, Tony AU - Tadic T AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Fleshner, Neil AU - Fleshner N AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Kulkarni, Girish AU - Kulkarni G AD - Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - Catton, Charles AU - Catton C AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Berlin, Alejandro AU - Berlin A AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Sridhar, Srikala AU - Sridhar S AD - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - Jiang, Di Maria AU - Jiang DM AD - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - Chung, Peter AU - Chung P AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. FAU - Raman, Srinivas AU - Raman S AD - Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. Srinivas.Raman@rmp.uhn.ca. LA - eng PT - Journal Article DEP - 20230920 PL - England TA - Radiat Oncol JT - Radiation oncology (London, England) JID - 101265111 RN - 8008-53-5 (Ethiodized Oil) SB - IM MH - Humans MH - *Ethiodized Oil MH - Prospective Studies MH - Retrospective Studies MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/radiotherapy MH - Muscles PMC - PMC10512471 OTO - NOTNLM OT - Bladder cancer OT - Dose-painted OT - Lipiodol OT - Radiotherapy OT - Tri-modal therapy COIS- None. The authors declare no competing interests. EDAT- 2023/09/21 00:42 MHDA- 2023/09/22 06:42 PMCR- 2023/09/20 CRDT- 2023/09/20 23:37 PHST- 2023/06/27 00:00 [received] PHST- 2023/08/24 00:00 [accepted] PHST- 2023/09/22 06:42 [medline] PHST- 2023/09/21 00:42 [pubmed] PHST- 2023/09/20 23:37 [entrez] PHST- 2023/09/20 00:00 [pmc-release] AID - 10.1186/s13014-023-02338-w [pii] AID - 2338 [pii] AID - 10.1186/s13014-023-02338-w [doi] PST - epublish SO - Radiat Oncol. 2023 Sep 20;18(1):154. doi: 10.1186/s13014-023-02338-w. PMID- 37730166 OWN - NLM STAT- MEDLINE DCOM- 20231222 LR - 20240423 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 182 DP - 2023 Dec TI - Impact of Agent Orange Exposure on Non-muscle Invasive Bladder Cancer Outcomes. PG - 175-180 LID - S0090-4295(23)00794-X [pii] LID - 10.1016/j.urology.2023.08.037 [doi] AB - OBJECTIVE: To explore the effect of Agent Orange (AO) exposure on bladder cancer (BCa) outcomes in patients receiving Bacillus Calmette-Guerin (BCG) for non-muscle invasive BCa (NMIBC). METHODS: We retrospectively examined the association between AO exposure in patients with NMIBC in national veterans affairs databases who were being treated with BCG. Patients were diagnosed with NMIBC from 2000 to 2010 with follow-up through 2018. Clinical, pathological, and demographic variables were compared by AO exposure. Associations of AO exposure with recurrence, progression, and cancer-specific survival were performed using Cox proportional hazard models after inverse propensity score weighting and competing risks adjustments. We also assessed the association of AO exposure on grade and stage via multivariable logistic regression models. RESULTS: A total of 7651 patients were identified of which 753 (9.8%) were exposed to AO. The median follow-up time was 130 months. The AO-exposed patients were younger (age 61 vs 71 years, P <.001), but had similar Charlson comorbidity scores and stage/grade distribution as the non-AO exposed patients. AO exposure was not associated with higher grade or stage. In our Cox multivariable analyses, AO exposure was not associated with worse recurrence (hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.72-1.10, P = .29), progression (HR 1.08, 95% CI 0.86-1.36, P = .51), or cancer-specific survival (HR 1.31, 95% CI 0.92-1.87, P = .13). CONCLUSION: AO exposure was not associated with worse oncologic outcomes in patients receiving BCG for NMIBC. While this is reassuring, additional research is needed in other patient populations and disease states to determine if the effect is consistent. CI - Published by Elsevier Inc. FAU - Penn, Taylor AU - Penn T AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI. FAU - Borza, Tudor AU - Borza T AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI. FAU - Liou, Jinn-Ing AU - Liou JI AD - The University of Wisconsin-Madison, Department of Medicine, Madison, WI. FAU - Jason Abel, E AU - Jason Abel E AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI. FAU - Shapiro, Daniel D AU - Shapiro DD AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI; William S. Middleton Memorial Veterans Hospital, Division of Urology, Madison, WI. FAU - Jarrard, David F AU - Jarrard DF AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI. FAU - Ricke, William A AU - Ricke WA AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI. FAU - Richards, Kyle A AU - Richards KA AD - The University of Wisconsin-Madison, Department of Urology, Madison, WI; William S. Middleton Memorial Veterans Hospital, Division of Urology, Madison, WI. Electronic address: kyle.richards@va.gov. LA - eng PT - Journal Article DEP - 20230918 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 39277-47-9 (Agent Orange) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Middle Aged MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *Agent Orange/therapeutic use MH - BCG Vaccine/adverse effects MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/drug therapy MH - *Non-Muscle Invasive Bladder Neoplasms/complications/therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/complications/therapy MH - Aged COIS- Declaration of Competing Interest The authors have nothing to disclose. EDAT- 2023/09/21 00:42 MHDA- 2023/12/11 12:42 CRDT- 2023/09/20 19:17 PHST- 2023/07/18 00:00 [received] PHST- 2023/08/28 00:00 [revised] PHST- 2023/08/30 00:00 [accepted] PHST- 2023/12/11 12:42 [medline] PHST- 2023/09/21 00:42 [pubmed] PHST- 2023/09/20 19:17 [entrez] AID - S0090-4295(23)00794-X [pii] AID - 10.1016/j.urology.2023.08.037 [doi] PST - ppublish SO - Urology. 2023 Dec;182:175-180. doi: 10.1016/j.urology.2023.08.037. Epub 2023 Sep 18. PMID- 37728495 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20240125 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 75 IP - 5 DP - 2023 Oct TI - Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guerin immunotherapy. PG - 591-599 LID - 10.23736/S2724-6051.23.05418-6 [doi] AB - BACKGROUND: The existence and prognosis of T1LG (T1 low-grade) bladder cancer is controversial. Also, because of data paucity, it remains unclear what is the clinical history of bacillus Calmette-Guerin (BCG) treated T1LG tumors and if it differs from other NMIBC (non-muscle-invasive bladder cancer) representatives. The aim of this study was to analyse recurrence-free survival (RFS) and progression-free survival (PFS) in patients with T1LG bladder cancers treated with BCG immunotherapy. METHODS: A multi-institutional and retrospective study of 2510 patients with Ta/T1 NMIBC with or without carcinoma in situ (CIS) treated with BCG (205 T1LG patients) was performed. Kaplan-Meier estimates and log-rank test for RFS and PFS to compare the survival between TaLG, TaHG, T1LG, and T1HG NMIBC were used. Also, T1LG tumors were categorized into EAU2021 risk groups and PFS analysis was performed, and Cox multivariate model for both RFS and PFS were constructed. RESULTS: The median follow-up was 52 months. For the T1LG cohort, the estimated RFS and PFS rates at 5-year were 59.3% and 89.2%, respectively. While there were no differences in RFS between NMIBC subpopulations, a slightly better PFS was found in T1LG NMIBC compared to T1HG (5-year PFS; T1LG vs. T1HG: 82% vs. 89%; P<0.001). A heterogeneous classification of patients with T1LG NMIBC was observed when EAU 2021 prognostic model was applied, finding a statistically significant worse PFS in patients classified as high-risk T1LG (5-year PFS; 81.8%) compared to those in intermediate (5-year PFS; 93,4%), and low-risk T1LG tumors (5-year PFS; 98,1%). CONCLUSIONS: The RFS of T1LG was comparable to other NMIBC subpopulations. The PFS of T1LG tumors was significantly better than of T1HG NMIBC. The EAU2021 scoring model heterogeneously categorized the risk of progression in T1LG tumors and the high-risk T1LG had the worst PFS. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland - wk@softstar.pl. FAU - Subiela, Jose D AU - Subiela JD AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Saint-Louis Hospital, APHP, Paris Cite University, Paris, France. FAU - Bebane, Sonia AU - Bebane S AD - Department of Urology, Saint-Louis Hospital, APHP, Paris Cite University, Paris, France. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, Polytechnic University of Marche, Ospedali Riuniti, Ancona, Italy. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Department of Urology, Pitie-Salpetriere Hospital, APHP, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere Hospital, APHP, Sorbonne University, Paris, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Gutierrez Hidalgo, Beatriz AU - Gutierrez Hidalgo B AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin School of Medicine, Turin, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, Erasme Hospital, University Clinics of Brussels, Free University of Brussels, Brussels, Belgium. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Puigvert Foundation, Autonomous University of Barcelona, Barcelona, Spain. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Marcq, Gautier AU - Marcq G AD - Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Halon, Agnieszka AU - Halon A AD - Division of Clinical Pathology, Department of Clinical and Experimental Pathology, Wroclaw Medical University, Wroclaw, Poland. FAU - Carrion, Diego M AU - Carrion DM AD - Department of Urology, Torrejon University Hospital, Madrid, Spain. FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Palou, Juan AU - Palou J AD - Department of Urology, Puigvert Foundation, Autonomous University of Barcelona, Barcelona, Spain. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Burgos Revilla, Javier AU - Burgos Revilla J AD - Department of Urology, Ramon y Cajal University Hospital, IRYCIS, University of Alcala, Madrid, Spain. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. CN - European Association of Urology EAU-Young Academic Urologists YAU Urothelial Cancer Working Party LA - eng PT - Journal Article PT - Multicenter Study PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (BCG Vaccine) SB - IM CIN - Minerva Urol Nephrol. 2023 Dec;75(6):773-775. doi: 10.23736/S2724-6051.23.05636-7. PMID: 38126290 MH - Humans MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell MH - Immunotherapy MH - *Mycobacterium bovis MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2023/09/20 12:51 MHDA- 2023/09/21 06:43 CRDT- 2023/09/20 09:58 PHST- 2023/09/21 06:43 [medline] PHST- 2023/09/20 12:51 [pubmed] PHST- 2023/09/20 09:58 [entrez] AID - S2724-6051.23.05418-6 [pii] AID - 10.23736/S2724-6051.23.05418-6 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2023 Oct;75(5):591-599. doi: 10.23736/S2724-6051.23.05418-6. PMID- 37727442 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230921 IS - 2162-2531 (Print) IS - 2162-2531 (Electronic) IS - 2162-2531 (Linking) VI - 33 DP - 2023 Sep 12 TI - Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model. PG - 960-982 LID - 10.1016/j.omtn.2023.06.009 [doi] AB - A progressive subclass of early-stage non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progress into invasive carcinoma, thus decreasing the overall survival rate of NMIBC. However, therapeutic development for progressive NMIBC has been challenging due to the lack of molecularly validated in vivo models and agents targeting its genetic vulnerability. We herein molecularly characterized an interventional model of progressive NMIBC and revealed the principal functions and therapeutic potential of microRNA-145 (miR-145) in early bladder tumorigenesis. N-butyl-N-(4-hydroxybutyl)nitrosamine-induced premalignant lesions (BiPLs) in rats exhibited downregulated expression of miR-145 as well as highly similar mutation/expression profiles to those of the human progressive NMIBC subclass with the worst prognosis. The expression patterns of miR-145 inversely correlated with those of BC-related oncogenes in BiPLs. We also demonstrated that miR-145 dominantly regulated interferon pathways and c-Myc expression, which play a crucial role in the pathogenesis of progressive NMIBC. Furthermore, we demonstrated that miR-145 replacement with a novel miR-145-based intravesical agent (miR-145S1) significantly inhibited the progression of BiPLs in vivo. These results provide insights into the essential role of miR-145 as the earliest-acting oncogenic driver of bladder tumorigenesis as well as a validated interventional model and novel miR-145-based nucleic acid therapeutic agent for progressive NMIBC. CI - (c) 2023 The Author(s). FAU - Heishima, Kazuki AU - Heishima K AD - The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan. AD - Institute for Advanced Study (GUiAS), Gifu University, Gifu, Gifu, Japan. AD - Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Gifu, Japan. FAU - Sugito, Nobuhiko AU - Sugito N AD - The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan. FAU - Abe, Chikara AU - Abe C AD - Department of Physiology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan. FAU - Hirata, Akihiro AU - Hirata A AD - Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Gifu, Japan. AD - Laboratory of Veterinary Pathology, Joint Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Gifu, Japan. FAU - Sakai, Hiroki AU - Sakai H AD - Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Gifu, Japan. AD - Laboratory of Veterinary Pathology, Joint Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Gifu, Japan. FAU - Akao, Yukihiro AU - Akao Y AD - The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan. LA - eng PT - Journal Article DEP - 20230703 PL - United States TA - Mol Ther Nucleic Acids JT - Molecular therapy. Nucleic acids JID - 101581621 PMC - PMC10505924 OTO - NOTNLM OT - MT: Non-coding RNAs OT - NMIBC OT - early bladder cancer OT - early bladder cancer rat model OT - intravesical therapy OT - microRNA OT - microRNA-145 OT - non-muscle-invasive bladder cancer COIS- Y.A. is the author of a patent for miR-145 assessed in this study. Y.A. has received grant support and LNP suspensions from Daiichi Sankyo Co., Ltd. EDAT- 2023/09/20 06:42 MHDA- 2023/09/20 06:43 PMCR- 2023/07/03 CRDT- 2023/09/20 03:50 PHST- 2022/11/21 00:00 [received] PHST- 2023/06/09 00:00 [accepted] PHST- 2023/09/20 06:43 [medline] PHST- 2023/09/20 06:42 [pubmed] PHST- 2023/09/20 03:50 [entrez] PHST- 2023/07/03 00:00 [pmc-release] AID - S2162-2531(23)00159-2 [pii] AID - 10.1016/j.omtn.2023.06.009 [doi] PST - epublish SO - Mol Ther Nucleic Acids. 2023 Jul 3;33:960-982. doi: 10.1016/j.omtn.2023.06.009. eCollection 2023 Sep 12. PMID- 37726806 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20231120 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 21 IP - 1 DP - 2023 Sep 19 TI - A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients. PG - 357 LID - 10.1186/s12916-023-03065-5 [doi] LID - 357 AB - BACKGROUND: Currently, the clinical strategy for diagnosis of non-muscle invasive bladder cancer (NMIBC) such as cystoscopy and cytology are invasive and/or with limited accuracy. OncoUrine, a urinary assay for mutation and methylation biomarkers, have showed a high accuracy in the detection of upper tract urinary carcinoma (UTUC) patients with hematuria. The aim of this study is to evaluate the performance of OncoUrine in diagnosis of NMIBC patients. METHODS: In this multicenter prospective study, a total of 203 patients were enrolled, including 60 patients present with hematuria and 143 NMIBC patients under recurrence surveillance. Urine samples were collected before cystoscopy to undergo OncoUrine test. OncoUrine performance was calculated compared to clinical standard methods in hematuria cohort and recurrence surveillance cohort, respectively. Furthermore, NMIBC patients were followed up with a median time of 20.5 months (range 0.03 to 24.03 months) to assess the predictive value of OncoUrine during recurrence monitoring. RESULTS: For bladder cancer diagnosis, OncoUrine tested 47 samples and achieved a sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 80% (95% CI 44.2-96.5)/91.9% (95% CI 77.0-97.9)/72.7% (95% CI 39.3-92.7)/94.4% (95% CI 80.0-99.0) (kappa value 69.4%, 95% CI 44.4-94.3), indicating 72.3% of unnecessary cystoscopy. For recurrence diagnosis, OncoUrine tested 93 samples, and the sensitivity/specificity/PPV/NPV was 100% (95% CI 59.8-100.0)/68.2% (95% CI 57.1-77.7)/22.9% (95% CI 11.0-40.6)/100% (95% CI 92.3-100.0) (kappa value 27.0%, 95% CI 11.1-42.8), indicating 62.4% of spared cystoscopy. What is more, OncoUrine correctly predicted 80% (20/25) of final recurrence with 12/25 (48%) patients who were OncoUrine positive, but cystoscopy negative was followed with recurrence during follow-up. The test result of OncoUrine was also found significantly correlated with recurrence free survival (RFS) of NMIBC patients (median 34.4-month vs unreached; HR 6.0, 95% CI 2.7-13.5, P < 0.0001). CONCLUSIONS: OncoUrine showed potential value to reduce the frequency of unnecessary cystoscopy and the healthcare cost of bladder cancer patients. Patients with positive test results represented a population who were at high risk of recurrence and thus should be subject to frequent surveillance to ensure timely detection of any potential recurrence. This study has been registered in ClinicalTrials.gov with the number NCT04994197 posted on August 2021. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Huang, Hai AU - Huang H AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Liu, Ao AU - Liu A AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Liang, Yiming AU - Liang Y AD - Hangzhou Jichenjunchuang Medical Laboratory, Co., Ltd., Hangzhou, 310000, China. FAU - Xin, Yaqun AU - Xin Y AD - Hangzhou Jichenjunchuang Medical Laboratory, Co., Ltd., Hangzhou, 310000, China. FAU - Liu, Jiacheng AU - Liu J AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Hao, Yining AU - Hao Y AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Huang, Da AU - Huang D AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Chen, Lu AU - Chen L AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Li, Wei AU - Li W AD - Hangzhou Jichenjunchuang Medical Laboratory, Co., Ltd., Hangzhou, 310000, China. FAU - Jiang, Guangliang AU - Jiang G AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. FAU - Huang, Yuhua AU - Huang Y AD - Department of Urology, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China. FAU - Xu, Yaoting AU - Xu Y AD - Department of Urologic Surgery, Shanghai Fourth People;S Hospital Affiliated to Tongji University, No.1279, Sanmen Road, Shanghai, 200081, China. FAU - Zhang, Jie AU - Zhang J AD - Hangzhou Jichenjunchuang Medical Laboratory, Co., Ltd., Hangzhou, 310000, China. FAU - Ma, Tonghui AU - Ma T AD - Hangzhou Jichenjunchuang Medical Laboratory, Co., Ltd., Hangzhou, 310000, China. math11@mails.jlu.edu.cn. AD - Department of Translational Medicine, Genecn-Biotech. Co., Ltd., Hangzhou, 310000, China. math11@mails.jlu.edu.cn. FAU - Xu, Danfeng AU - Xu D AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. xdf12036@rjh.com.cn. FAU - Gao, Yi AU - Gao Y AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Road No.2, Shanghai, 200025, China. gy12065@rjh.com.cn. LA - eng SI - ClinicalTrials.gov/NCT04994197 PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20230919 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (Biomarkers) SB - IM MH - Humans MH - Hematuria MH - Methylation MH - *Non-Muscle Invasive Bladder Neoplasms MH - Prospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/genetics MH - Mutation MH - Biomarkers PMC - PMC10510256 OTO - NOTNLM OT - Cystoscopy OT - Diagnosis OT - Methylation OT - Mutation OT - Non-muscle invasive bladder cancer OT - Recurrence surveillance COIS- The authors declare that they have no competing interests. EDAT- 2023/09/20 00:43 MHDA- 2023/09/21 06:42 PMCR- 2023/09/19 CRDT- 2023/09/19 23:52 PHST- 2023/03/29 00:00 [received] PHST- 2023/09/04 00:00 [accepted] PHST- 2023/09/21 06:42 [medline] PHST- 2023/09/20 00:43 [pubmed] PHST- 2023/09/19 23:52 [entrez] PHST- 2023/09/19 00:00 [pmc-release] AID - 10.1186/s12916-023-03065-5 [pii] AID - 3065 [pii] AID - 10.1186/s12916-023-03065-5 [doi] PST - epublish SO - BMC Med. 2023 Sep 19;21(1):357. doi: 10.1186/s12916-023-03065-5. PMID- 37723173 OWN - NLM STAT- MEDLINE DCOM- 20230920 LR - 20260518 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Sep 18 TI - Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). PG - 15437 LID - 10.1038/s41598-023-42088-z [doi] LID - 15437 AB - To determine whether Xpert bladder cancer monitor, a noninvasive PCR-based biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better than clinical assessment. Patients scheduled for TURB were prospectively screened. After initial TURB, patients were assigned to 2nd TURB or follow-up cystoscopy at 3 months (FU) by clinicians' discretion. Central urine cytology and Xpert monitor tests were performed prior to the 1st TURB and 2nd TURB or FU, respectively. Statistical analysis to compare clinical assessment and Xpert monitor comprised sensitivity (SENS), specificity (SPEC), NPV and PPV. Of 756 screened patients, 171 were included (114 with 2nd TURB, 57 with FU). Residual tumors were detected in 34 patients who underwent 2nd TURB, and recurrent tumors were detected in 2 patients with FU. SENS and SPEC of Xpert monitor were 83.3% and 53.0%, respectively, PPV was 32.6% and NPV was 92.1%. Clinical risk assessment outperformed Xpert monitor. In patients with pTa disease at initial TURB, Xpert monitor revealed a NPV of 96%. Xpert monitor was not superior than clinical assessment in predicting the need for 2nd TURB. It might be an option to omit 2nd TURB for selected patients with pTa disease. CI - (c) 2023. Springer Nature Limited. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. johannes.breyer@ukr.de. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Wezel, Felix AU - Wezel F AD - Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Brehmer, Mirco AU - Brehmer M AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - Stratifyer Molecular Pathology GmbH, Cologne, Germany. AD - Institute of Pathology, St. Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Jarczyk, Jonas AU - Jarczyk J AD - Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Bahlinger, Veronika AU - Bahlinger V AD - Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Goldschmidt, Franziska AU - Goldschmidt F AD - Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Fechner, Guido AU - Fechner G AD - Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Chen, Jack AU - Chen J AD - Biostatistics, Cepheid Inc., Sunnyvale, CA, USA. FAU - Paxinos, Ellen AU - Paxinos E AD - Medical and Scientific Affairs, Cepheid Inc., Sunnyvale, CA, USA. FAU - Bates, Michael AU - Bates M AD - Medical and Scientific Affairs, Cepheid Inc., Sunnyvale, CA, USA. FAU - Haas, Maximilian AU - Haas M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Zengerling, Friedemann AU - Zengerling F AD - Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. FAU - Kriegmair, Maximilian C AU - Kriegmair MC AD - Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. AD - BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. CN - BRIDGE Consortium e.V. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230918 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis MH - Urinary Bladder MH - Cystoscopy MH - Neoplasm, Residual MH - Polymerase Chain Reaction PMC - PMC10507065 COIS- Johannes Breyer declares an advisory role for Pfizer; personal fees and travel costs from Apogepha, Ipsen, Janssen, Pfizer, and Photocure; research support from Cepheid and Janssen; and speakers honoraria from Ipsen, Pfizer, BMS, AstraZeneca, Merck, and Roche. Markus Eckstein declares advisory roles for Janssen, AstraZeneca, MSD, Cepheid, Diaceutics and GenomicHealth; personal fees and travel costs from Janssen, AstraZeneca, MSD, Cepheid, Diaceutics, GenomicHealth; research support from Janssen, AstraZeneca, Cepeheid and STRATIFYER; speakers honoraria from Janssen, AstraZeneca, MSD, Diaceutics, Roche, Astellas; part time employment at Diaceutics. Danijel Sikic declares no conflict of interest. Felix Wezel Advisory roles for Bayer, AstraZeneca; speaker honoraria and travel expenses from Medac; travel costs from Pfizer. Florian Roghmann declares speaker honoraria and travel expenses from Janssen, Roche, Merck, MSD, Pfizer, AstraZeneca, QED; advisory roles for Janssen, Roche, Merck, QED; research funding from Janssen. Mirco Brehmer declares no conflict of interest Ralph M. Wirtz is founder and employee of STRATIFYER Molecular Pathology GmbH. Jonas Jarczyk declares speakers honoraria form Medac GmbH. Philipp Erben declares research support from Janssen, Cepheid, and STRATIFYER. Veronika Bahlinger declares personal fees from MSD; research support from Gilead, speakers honoraria from MSD. Franziska Goldschmidt declares no conflict of interest Guido Fechner declares no conflict of interest Jack Chen is an employee of Cepheid. Ellen Paxinos is an employee of Cepheid. Michael Bates is an employee of Cepheid. Maximilian Haas declares speakers honoraria from Pfizer and Merck. Friedemann Zengerling declares honoraria from Astellas, Bayer Health, Bristol-Myers Squibb, Ipsen, Novartis, Roche, Sanofi/Aventis, Pfizer, Merck Healthcare; consulting fees from Apogepha, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, Novartis, Roche, Sanofi/Aventis, Pfizer, Merck Healthcare, MSD; travel support from Bayer Health, Ipsen, Janssen-Cilag, Pfizer Christian Bolenz declares honoraria from AstraZeneca GmbH, Janssen-Cilag GmbH, Medac GmbH, Takeda Pharma GmbH, and Roche Pharma AG; and research support from AstraZeneca GmbH and ERBE Elektromedizin GmbH. Maximilian Burger declares honoraria from Bayer, BMS, Janssen, Medac, MSD, and Pfizer; consulting honoraria from Photocure. Arndt Hartmann declares honoraria from Agilent, AstraZeneca, BMS, CEA, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Phaon, QIAGEN, and Roche; consulting fees from Abbvie, Agilent, AstraZeneca, BMS, Cepheid, Diaceutics, Illumina, Ipsen, Janssen, Lilly, Nanostring, Phaon, and QIAGEN; travel support from Agilent, AstraZeneca, BMS, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Phaon, QIAGEN, and Roche; participation on data safety monitoring board or advisory board for Agilent, AstraZeneca, BMS, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Phaon, QIAGEN, and Roche; and has a leadership role as president of the German IAP. Maximilian Kriegmair declares an advisory role for BMS, Esai, Cepheid and Photocure; Speakers honoraria from, BMS, Pfizer, Merck, Astellas and Medac. FIR - Breyer, Johannes IR - Breyer J FIR - Eckstein, Markus IR - Eckstein M FIR - Sikic, Danijel IR - Sikic D FIR - Wezel, Felix IR - Wezel F FIR - Roghmann, Florian IR - Roghmann F FIR - Wirtz, Ralph M IR - Wirtz RM FIR - Jarczyk, Jonas IR - Jarczyk J FIR - Erben, Philipp IR - Erben P FIR - Bahlinger, Veronika IR - Bahlinger V FIR - Goldschmidt, Franziska IR - Goldschmidt F FIR - Fechner, Guido IR - Fechner G FIR - Haas, Maximilian IR - Haas M FIR - Zengerling, Friedemann IR - Zengerling F FIR - Bolenz, Christian IR - Bolenz C FIR - Burger, Maximilian IR - Burger M FIR - Hartmann, Arndt IR - Hartmann A FIR - Kriegmair, Maximilian C IR - Kriegmair MC EDAT- 2023/09/19 00:43 MHDA- 2023/09/20 06:42 PMCR- 2023/09/18 CRDT- 2023/09/18 23:20 PHST- 2022/12/20 00:00 [received] PHST- 2023/09/05 00:00 [accepted] PHST- 2023/09/20 06:42 [medline] PHST- 2023/09/19 00:43 [pubmed] PHST- 2023/09/18 23:20 [entrez] PHST- 2023/09/18 00:00 [pmc-release] AID - 10.1038/s41598-023-42088-z [pii] AID - 42088 [pii] AID - 10.1038/s41598-023-42088-z [doi] PST - epublish SO - Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. PMID- 37721600 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20231221 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 41 IP - 12 DP - 2023 Dec TI - Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC. PG - 3421-3427 LID - 10.1007/s00345-023-04583-w [doi] AB - PURPOSE: The prognosis of upper urinary tract urothelial carcinoma (UTUC) is associated with tumour grade (G) and stage. Despite preoperative risk stratification and radical treatment, recurrence and progression are common. Thus, prognostic and monitoring biomarkers are needed. This feasibility study aimed to investigate if targeted analyses on circulating tumour DNA (ctDNA) in plasma could identify tumour-specific gene variants, and thus have potential for further evaluation as a biomarker in UTUC. METHODS: Nine UTUC patients with genetically characterised tumours were included in this prospective pilot study. Two tumour-specific variants were chosen for targeted analyses with multiplex droplet digital PCR on cell-free DNA (cfDNA) from plasma at diagnosis or from recurrence. RESULTS: Of six patients with diagnostic plasma samples, ctDNA was detected in four with G2 or G3 tumours and tumours > 300m(2) in size. Three of these patients progressed in their disease and the fourth had the largest G3 tumour at sampling. In contrast, the two patients with undetectable ctDNA in diagnostic plasma had a G1 tumour and G3 carcinoma in situ (CIS), respectively. The patient with G3 CIS had detectable ctDNA later during follow-up and progressed thereafter with aggressive intravesical recurrence and CT-scan-verified CIS progression in the upper urinary tract. In three patients with small recurrent G1 or G2 tumours, none had detectable ctDNA in plasma and all were progression free. CONCLUSION: Our early findings demonstrate that ctDNA in plasma can be detected by targeted analysis in patients with UTUC. However, further studies are needed to determine its role as a potential biomarker. CI - (c) 2023. The Author(s). FAU - Mu, Ninni AU - Mu N AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. AD - Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. FAU - Jylha, Cecilia AU - Jylha C AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. AD - Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. FAU - Axelsson, Tomas AU - Axelsson T AD - Division of Urology, Danderyd Hospital, Stockholm, Sweden. FAU - Syden, Filip AU - Syden F AD - Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. FAU - Brehmer, Marianne AU - Brehmer M AD - Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. AD - Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden. FAU - Tham, Emma AU - Tham E AUID- ORCID: 0000-0001-6079-164X AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. emma.tham@ki.se. AD - Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. emma.tham@ki.se. LA - eng GR - FoUI-961732/Region Stockholm/ GR - FoUI-973659/Region Stockholm/ GR - 2022-PHJ537/Japanese Swedish Research Foundation/ GR - 2021-XET421/Japanese Swedish Research Foundation/ GR - TJ2021-0125/Barncancerfonden/ GR - 22 2451 Fk/Cancerfonden/ PT - Journal Article DEP - 20230918 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/diagnosis/genetics/surgery MH - *Circulating Tumor DNA MH - Pilot Projects MH - Prospective Studies MH - Prognosis MH - Biomarkers MH - Biomarkers, Tumor/genetics MH - Neoplasm Recurrence, Local/pathology PMC - PMC10693512 OTO - NOTNLM OT - Cell-free DNA OT - Circulating tumour DNA OT - Prognosis OT - Targeted biomarker OT - Upper urinary tract urothelial carcinoma OT - ddPCR COIS- The authors have no conflict of interest. EDAT- 2023/09/18 12:42 MHDA- 2023/12/04 12:43 PMCR- 2023/09/18 CRDT- 2023/09/18 11:05 PHST- 2023/04/01 00:00 [received] PHST- 2023/08/15 00:00 [accepted] PHST- 2023/12/04 12:43 [medline] PHST- 2023/09/18 12:42 [pubmed] PHST- 2023/09/18 11:05 [entrez] PHST- 2023/09/18 00:00 [pmc-release] AID - 10.1007/s00345-023-04583-w [pii] AID - 4583 [pii] AID - 10.1007/s00345-023-04583-w [doi] PST - ppublish SO - World J Urol. 2023 Dec;41(12):3421-3427. doi: 10.1007/s00345-023-04583-w. Epub 2023 Sep 18. PMID- 37719020 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230919 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - The effect of different timing of blood transfusion on oncological outcomes of patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis. PG - 1223592 LID - 10.3389/fonc.2023.1223592 [doi] LID - 1223592 AB - HIGHLIGHTS: This meta-analysis and systematic review aim to analyze the association between BT and oncological outcomes of patients undergoing RC for bladder cancer, and tries to find out whether the timing of blood transfusion could also have an effect on this relationship. A total of 20 retrospective studies from online databases and other sources are identified and enrolled in this study. The results show that BT administration during RC operation or perioperative period is significantly associated with worse oncological outcomes including ACM, CSM and DR. BACKGROUND: Bladder cancer is one of the most common urological malignancies. Radical cystectomy (RC) remains the main treatment for localized muscle-invasive bladder cancer (MIBC) or high-grade non-muscle-invasive bladder cancer (NMIBC). In the process of RC, the administration of blood transfusion (BT) is sometimes needed, however, it may cause transfusion-related complications or lead to worse oncological outcomes. This meta-analysis and systematic review aims to give a comprehensive insight into the association between BT and oncological outcomes of patients undergoing RC, and tries to find out whether the timing of blood transfusion could also have an impact on this association. METHODS: This systematic review and meta-analysis were carried out according to the PRISMA 2020 reporting guideline. We have searched four bibliographic databases including PubMed (Medline), EMBASE, Cochrane Library, and Web of Science with no language limitation. Studies investigating the association between BT and oncological outcomes of patients undergoing RC are identified and included in this research from inception through March 20, 2023. This research calculates the pooled hazard ratios (pHR) and 95% confidence intervals (95% CI) of all-cause mortality (ACM), cancer-specific mortality (CSM) and disease recurrence (DR) using Random Effects models or Fixed Effects models. Subgroup analyses stratified by parameters such as timing of transfusion are also conducted. This meta-analysis was registered with PROSPERO, CRD42022381656. RESULTS: A total of 20 retrospective studies from online databases and other sources are identified and enrolled in this study. Results show that blood transfusion significantly increased the risks for ACM (HR = 1.33, 95% CI: 1.23-1.44), CSM (HR = 1.25, 95% CI: 1.15 - 1.35) and DR (HR = 1.26, 95% CI: 1.15 - 1.38). However, when stratified by the timing of BT, we find that only intraoperative and perioperative transfusion significantly increased in risks for worse prognosis, while postoperative transfusion raised none of the risks of ACM (HR = 1.26, 95% CI: 0.92-1.73), CSM (HR = 1.08, 95% CI: 0.93-1.26) nor DR (HR = 1.08, 95% CI: 0.90-1.29) significantly. CONCLUSION: BT administration during RC operation or perioperative period is significantly associated with worse oncological outcomes including ACM, CSM and DR. Clinicians should consider carefully when deciding to administrate BT to patients undergoing RC and carry out according to current guidelines. CI - Copyright (c) 2023 Ma, An, Sun, Xu, Liu, Xu, Zhong, Zeng, He, Xia and Wang. FAU - Ma, Si-Yang AU - Ma SY AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - An, Ye AU - An Y AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Jian-Xuan AU - Sun JX AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Meng-Yao AU - Xu MY AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Chen-Qian AU - Liu CQ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Jin-Zhou AU - Xu JZ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhong, Xing-Yu AU - Zhong XY AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zeng, Na AU - Zeng N AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - He, Hao-Dong AU - He HD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230830 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10499617 OTO - NOTNLM OT - bladder cancer OT - blood transfusion OT - meta-analysis OT - oncological OT - radical cystectomy OT - systematic review COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/18 06:42 MHDA- 2023/09/18 06:43 PMCR- 2023/01/01 CRDT- 2023/09/18 04:14 PHST- 2023/05/16 00:00 [received] PHST- 2023/08/16 00:00 [accepted] PHST- 2023/09/18 06:43 [medline] PHST- 2023/09/18 06:42 [pubmed] PHST- 2023/09/18 04:14 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1223592 [doi] PST - epublish SO - Front Oncol. 2023 Aug 30;13:1223592. doi: 10.3389/fonc.2023.1223592. eCollection 2023. PMID- 37718188 OWN - NLM STAT- MEDLINE DCOM- 20231219 LR - 20240805 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 85 IP - 1 DP - 2024 Jan TI - Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer. PG - 82-92 LID - S0302-2838(23)03014-2 [pii] LID - 10.1016/j.eururo.2023.07.014 [doi] AB - BACKGROUND: Field cancerization is characterized by areas of normal tissue affected by mutated clones. Bladder field cancerization may explain the development and recurrence of bladder cancer and may be associated with treatment outcomes. OBJECTIVE: To investigate the predictive and prognostic roles of field cancerization in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guerin (BCG). DESIGN, SETTING, AND PARTICIPANTS: We conducted comprehensive genomic and proteomic analyses for 751 bladder biopsies and 234 urine samples from 136 patients with NMIBC. The samples were collected at multiple time points during the disease course. Field cancerization in normal-appearing bladder biopsies was measured using deep-targeted sequencing and error correction models. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Endpoints included the rates of recurrence and progression. Cox regression and Wilcoxon rank-sum and Fisher's exact tests were used. RESULTS AND LIMITATIONS: A high level of field cancerization was associated with high tumor mutational burden (p = 0.007), high tumor neoantigen load (p = 0.029), and high tumor-associated CD8 T-cell exhaustion (p = 0.017). In addition, high field cancerization was associated with worse short-term outcomes (p = 0.029). Nonsynonymous mutations in bladder cancer-associated genes such as KDM6A, ARID1A, and TP53 were identified as early disease drivers already found in normal-appearing bladder biopsies. Urinary tumor DNA (utDNA) levels reflected the bladder tumor burden and originated from tumors and field cancerization. High levels of utDNA after BCG were associated with worse clinical outcomes (p = 0.027) and with disease progression (p = 0.003). High field cancerization resulted in high urinary levels of proteins associated with angiogenesis and proliferation. Limitations include variation in the number of biopsies and time points analyzed. CONCLUSIONS: Field cancerization levels are associated with tumor development, immune responses, and clinical outcomes. utDNA measurements can be used to monitor disease status and treatment response. PATIENT SUMMARY: Molecular changes in the tissue lining the bladder result in tumor recurrence. Urinary measurements may be used to monitor bladder cancer status and treatment responses. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Strandgaard, Trine AU - Strandgaard T AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Nordentoft, Iver AU - Nordentoft I AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. FAU - Birkenkamp-Demtroder, Karin AU - Birkenkamp-Demtroder K AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Salminen, Liina AU - Salminen L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Rasmussen, Julie AU - Rasmussen J AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Andreasen, Tine Ginnerup AU - Andreasen TG AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lindskrog, Sia Viborg AU - Lindskrog SV AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Christensen, Emil AU - Christensen E AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lamy, Philippe AU - Lamy P AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. FAU - Knudsen, Michael AU - Knudsen M AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. FAU - Steiniche, Torben AU - Steiniche T AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Pathology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: lars@clin.au.dk. LA - eng PT - Journal Article DEP - 20230916 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Transl Androl Urol. 2024 Jul 31;13(7):1319-1323. doi: 10.21037/tau-24-8. PMID: 39100848 MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Proteomics MH - T-Cell Exhaustion MH - Disease-Free Survival MH - Disease Progression MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/therapy/drug therapy MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Administration, Intravesical OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Biomarkers OT - Bladder cancer OT - Field cancerization OT - Field effect OT - Urinary tumor DNA EDAT- 2023/09/18 00:41 MHDA- 2023/12/19 06:42 CRDT- 2023/09/17 21:55 PHST- 2023/03/28 00:00 [received] PHST- 2023/06/23 00:00 [revised] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/12/19 06:42 [medline] PHST- 2023/09/18 00:41 [pubmed] PHST- 2023/09/17 21:55 [entrez] AID - S0302-2838(23)03014-2 [pii] AID - 10.1016/j.eururo.2023.07.014 [doi] PST - ppublish SO - Eur Urol. 2024 Jan;85(1):82-92. doi: 10.1016/j.eururo.2023.07.014. Epub 2023 Sep 16. PMID- 37714725 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250508 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 12 DP - 2023 Dec TI - Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. PG - 484.e7-484.e15 LID - S1078-1439(23)00263-6 [pii] LID - 10.1016/j.urolonc.2023.08.004 [doi] AB - PURPOSE: Detrusor muscle (DM) in the resected specimen of patients with pT1 bladder cancer (BCa) is a quality-of-care criteria. We aimed to assess whether obtaining adequate DM is dependent on surgeon's experience, whether is a surrogate for resection quality, and whether the degree of DM thickness is related to postoperative outcomes in en bloc resection for bladder tumors (ERBT). MATERIALS AND METHODS: We retrospectively analyzed the records of 106 pT1 high-grade BCa patients who underwent ERBT at several institutions. All specimens were reviewed by a single pathologist who assessed the presence or absence of DM and its thickness measured by a micrometer, when present. Early recurrence, defined as pathologically confirmed BCa on repeat resection or tumor recurrence at the first follow-up cystoscopy (within 3 months), was the endpoint reflective of the resection quality. RESULTS: Of 106 patients, DM was detected in 99 (93%), and the median DM thickness was 1.8 mm. Large tumor size (>30 mm) was associated with adequate DM sampling (>1.8mm) (odds ratio [OR]: 6.10, 95% confidence intervals [CIs]: 2.08-17.9, P = 0.001), while surgeon's experience was not. DM presence and DM thickness were both not associated with early recurrence, while positive surgical margin was an independent prognosticator for early recurrence (OR: 3.38, 95% CI: 1.12-10.2, P = 0.031). Excessive DM sampling (>2.1 mm) was associated with prolonged urethral catheterization (OR: 28.8, 95% CI: 3.36-248, P = 0.002). CONCLUSIONS: In ERBT, surgeon's experience seems irrelevant to obtain DM. Resection quality relies on surgical margin status, not the degree of DM. Obtaining excessive DM incurs adverse events/unnecessary medical care. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: t.yanagisawa.jikei@gmail.com. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan. FAU - Okada, Yohei AU - Okada Y AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shimoda, Masayuki AU - Shimoda M AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20230914 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Urol Oncol. 2024 May;42(5):155. doi: 10.1016/j.urolonc.2024.01.017. PMID: 38326213 MH - Humans MH - Retrospective Studies MH - *Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Cystectomy MH - Muscles/pathology OTO - NOTNLM OT - Detrusor muscle OT - En bloc resection OT - Muscularis propria OT - Non-muscle-invasive bladder cancer OT - T1 OT - TURBT COIS- Declaration of Competing Interest Takahiro Kimura is a paid consultant/advisor of Astellas, Bayer, Janssen and Sanofi. Shahrokh F. Shariat received as follows: Honoraria: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, Takeda Consulting or Advisory Role: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Takeda Speakers Bureau: Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, Takeda. Shin Egawa is a paid consultant/advisor of Takeda, Astellas, AstraZeneca, Sanofi, Janssen, and Pfizer. The other authors declare no conflicts of interest associated with this manuscript. EDAT- 2023/09/16 05:42 MHDA- 2023/12/17 09:43 CRDT- 2023/09/15 21:53 PHST- 2023/04/18 00:00 [received] PHST- 2023/06/28 00:00 [revised] PHST- 2023/08/04 00:00 [accepted] PHST- 2023/12/17 09:43 [medline] PHST- 2023/09/16 05:42 [pubmed] PHST- 2023/09/15 21:53 [entrez] AID - S1078-1439(23)00263-6 [pii] AID - 10.1016/j.urolonc.2023.08.004 [doi] PST - ppublish SO - Urol Oncol. 2023 Dec;41(12):484.e7-484.e15. doi: 10.1016/j.urolonc.2023.08.004. Epub 2023 Sep 14. PMID- 37705979 OWN - NLM STAT- MEDLINE DCOM- 20230915 LR - 20230916 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. PG - 1260498 LID - 10.3389/fimmu.2023.1260498 [doi] LID - 1260498 AB - Bladder cancer is a prevalent malignancy with limited therapeutic options, particularly for patients who are unresponsive to Bacillus Calmette-Guerin (BCG). The approval of interferon-alpha (IFNalpha) gene therapy with nadofaragene firadenovec (Adstiladrin((R))), the first gene therapy for genitourinary malignancies, has provided a promising alternative. This article reviews the research and milestones that led to the development and approval of nadofaragene firadenovec. Bladder cancer is well-suited for gene therapy due to direct access to the bladder and the availability of urine and tissue samples for monitoring. Early challenges included effective gene transfer across the urothelium, which was overcome initially by modulating the expression of coxsackie/adenovirus receptor (CAR) and, ultimately, by disrupting the urothelial barrier with Syn3. Nadofaragene firadenovec is a modified adenoviral vector carrying the IFNalpha gene. Clinical trials have shown promising results, with high response rates and manageable adverse events. Ongoing research focuses on improving patient selection, identifying biomarkers for response prediction, exploring alternative vectors for enhanced transfection efficiency, and developing combination strategies targeting resistance mechanisms. The approval of nadofaragene firadenovec marks a significant milestone in the field of gene therapy for bladder cancer, and future developments hold promise for further enhancing its efficacy and impact. CI - Copyright (c) 2023 Martini, Tholomier, Mokkapati and Dinney. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Tholomier, Come AU - Tholomier C AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Mokkapati, Sharada AU - Mokkapati S AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. LA - eng PT - Journal Article PT - Review DEP - 20230829 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antineoplastic Agents) RN - 0 (Interferon-alpha) SB - IM MH - Humans MH - *Antineoplastic Agents MH - Interferon-alpha/genetics/therapeutic use MH - *Urinary Bladder Neoplasms/genetics/therapy MH - Immunotherapy MH - Genetic Therapy PMC - PMC10495564 OTO - NOTNLM OT - BCG unresponsive bladder cancer OT - bladder cancer OT - gene therapy OT - immunogene therapy OT - novel medications COIS- AM owns shares of Oltre Medical Consulting, LLC, Toulouse, FRrance. CD receives Cancer Center Support Grant funding from the National Institutes for Health/National Cancer Institute award number P30CA016672 at MD Anderson Cancer Center, has received grants and personal fees from FKD Therapies, and is a creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to nadofaragene firadenovec. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/14 06:42 MHDA- 2023/09/15 06:43 PMCR- 2023/01/01 CRDT- 2023/09/14 04:11 PHST- 2023/07/17 00:00 [received] PHST- 2023/08/01 00:00 [accepted] PHST- 2023/09/15 06:43 [medline] PHST- 2023/09/14 06:42 [pubmed] PHST- 2023/09/14 04:11 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1260498 [doi] PST - epublish SO - Front Immunol. 2023 Aug 29;14:1260498. doi: 10.3389/fimmu.2023.1260498. eCollection 2023. PMID- 37704624 OWN - NLM STAT- MEDLINE DCOM- 20230915 LR - 20231119 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 14 IP - 1 DP - 2023 Sep 13 TI - Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ. PG - 5670 LID - 10.1038/s41467-023-41139-3 [doi] LID - 5670 AB - The progression of urothelial bladder cancer (UC) is a complicated multi-step process. We perform a comprehensive multi-omics analysis of 448 samples from 190 UC patients, covering the whole spectrum of disease stages and grades. Proteogenomic integration analysis indicates the mutations of HRAS regulated mTOR signaling to form urothelial papilloma rather than papillary urothelial cancer (PUC). DNA damage is a key signaling pathway in the progression of carcinoma in situ (CIS) and related to APOBEC signature. Glucolipid metabolism increase and lower immune cell infiltration are associated with PUC compared to CIS. Proteomic analysis distinguishes the origins of invasive tumors (PUC-derived and CIS-derived), related to distinct clinical prognosis and molecular features. Additionally, loss of RBPMS, associated with CIS-derived tumors, is validated to increase the activity of AP-1 and promote metastasis. This study reveals the characteristics of two distinct branches (PUC and CIS) of UC progression and may eventually benefit clinical practice. CI - (c) 2023. Springer Nature Limited. FAU - Yao, Zhenmei AU - Yao Z AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Xu, Ning AU - Xu N AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Shang, Guoguo AU - Shang G AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Wang, Haixing AU - Wang H AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Tao, Hui AU - Tao H AD - Department of Cardiothoracic Surgery, Second Hospital of Anhui Medical University, and Cardiovascular Research Center, Anhui Medical University, Hefei, 230601, China. FAU - Wang, Yunzhi AU - Wang Y AUID- ORCID: 0000-0002-1086-8896 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Qin, Zhaoyu AU - Qin Z AUID- ORCID: 0000-0003-4437-0268 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Tan, Subei AU - Tan S AUID- ORCID: 0000-0001-9869-6074 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Feng, Jinwen AU - Feng J AUID- ORCID: 0000-0003-1683-4280 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Zhu, Jiajun AU - Zhu J AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Ma, Fahan AU - Ma F AUID- ORCID: 0000-0002-3474-1179 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Tian, Sha AU - Tian S AUID- ORCID: 0000-0003-4407-8873 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Zhang, Qiao AU - Zhang Q AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. FAU - Qu, Yuanyuan AU - Qu Y AD - Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Genitourinary Cancer Institute, Shanghai, 200032, China. FAU - Hou, Jun AU - Hou J AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. Hou.Jun@zs-hospital.sh.cn. FAU - Guo, Jianming AU - Guo J AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. guo.jianmin@zs-hospital.sh.cn. FAU - Zhao, Jianyuan AU - Zhao J AUID- ORCID: 0000-0001-9861-0330 AD - Institute for Developmental and Regenerative Cardiovascular Medicine, MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. zhaojy@fudan.edu.cn. AD - School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China. zhaojy@fudan.edu.cn. FAU - Hou, Yingyong AU - Hou Y AUID- ORCID: 0000-0001-9156-2305 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. hou.yingyong@zs-hospital.sh.cn. FAU - Ding, Chen AU - Ding C AUID- ORCID: 0000-0001-8673-3464 AD - State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200433, China. chend@fudan.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230913 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 SB - IM MH - Humans MH - *Proteogenomics MH - Proteomics MH - *Urinary Bladder Neoplasms/genetics MH - *Carcinoma, Transitional Cell MH - *Carcinoma in Situ MH - *Carcinoma, Papillary/genetics PMC - PMC10499981 COIS- The authors declare no competing interests. EDAT- 2023/09/14 00:42 MHDA- 2023/09/15 06:43 PMCR- 2023/09/13 CRDT- 2023/09/13 23:17 PHST- 2023/03/17 00:00 [received] PHST- 2023/08/23 00:00 [accepted] PHST- 2023/09/15 06:43 [medline] PHST- 2023/09/14 00:42 [pubmed] PHST- 2023/09/13 23:17 [entrez] PHST- 2023/09/13 00:00 [pmc-release] AID - 10.1038/s41467-023-41139-3 [pii] AID - 41139 [pii] AID - 10.1038/s41467-023-41139-3 [doi] PST - epublish SO - Nat Commun. 2023 Sep 13;14(1):5670. doi: 10.1038/s41467-023-41139-3. PMID- 37704483 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20240410 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 21 IP - 6 DP - 2023 Dec TI - Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder? PG - 653-659.e1 LID - S1558-7673(23)00181-7 [pii] LID - 10.1016/j.clgc.2023.07.011 [doi] AB - BACKGROUND: Non-muscle invasive bladder cancer (non-MIBC) that is high-grade and confined to the lamina propria (HGT1) often has an aggressive clinical course. Currently, there is limited data on the comparative effectiveness of RT vs. CRT for HGT1 non-MIBC. We hypothesized that CRT would be associated with improved overall survival (OS) vs. RT in HGT1 bladder cancer. METHODS: Patients diagnosed with HGT1 non-MIBC, and treated with transurethral resection of bladder tumor followed by either treatment with RT alone or CRT, were identified in the National Cancer Database. Inverse probability of treatment weighting (IPTW) was employed and weight-adjusted multivariable analysis (MVA) using Cox regression modeling was used to compare overall survival (OS) hazard ratios. OS was the primary endpoint, and was estimated using the Kaplan-Meier method and log-rank tests. RESULTS: A total of 259 patients with HGT1 UC were treated with: (i) RT alone (n = 123) or (ii) CRT (n = 136). Propensity-weighted MVA showed that combined modality treatment with CRT was associated with improved OS relative to radiation alone (Hazard Ratio [HR]: 0.62, 95% Confidence Interval (95% CI): 0.44-0.88, P = .007). Four-year OS for the CRT vs. RT alone was 36% and 19%, respectively (log-rank P <.008). CONCLUSION: For patients with HGT1 bladder cancer, concurrent CRT was associated with improved OS compared with radiation alone in a retrospective cohort. These results are hypothesis-generating. The NRG is currently developing a phase II randomized clinical trial comparing CRT to other novel, bladder preservation strategies. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Andruska, Neal AU - Andruska N AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. FAU - Waters, Michael R AU - Waters MR AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. FAU - Fischer-Valuck, Benjamin W AU - Fischer-Valuck BW AD - Department of Radiation Oncology, Springfield Clinic, Springfield, IL. FAU - Smith, Zachary L AU - Smith ZL AD - Division of Urology, Washington University School of Medicine, St Louis, MO. FAU - Kim, Eric H AU - Kim EH AD - Division of Urology, Washington University School of Medicine, St Louis, MO. FAU - Reimers, Melissa AU - Reimers M AD - Division of Medical Oncology, Washington University School of Medicine, St Louis, MO. FAU - Brenneman, Randall AU - Brenneman R AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. FAU - Gay, Hiram A AU - Gay HA AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. FAU - Patel, Sagar A AU - Patel SA AD - Department of Radiation Oncology, Emory University, Atlanta, GA. FAU - Michalski, Jeff M AU - Michalski JM AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. FAU - Delacroix, Scott E AU - Delacroix SE AD - Department of Urology, Louisiana State University School of Medicine, New Orleans, LA. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Harvard University School of Medicine, Boston, MA. FAU - Baumann, Brian C AU - Baumann BC AD - Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO; Department of Radiation Oncology, Springfield Clinic, Springfield, IL. Electronic address: bbaumann@springfieldclinic.com. LA - eng GR - P30 CA091842/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20230802 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/therapy MH - Urinary Bladder/surgery/pathology MH - Chemoradiotherapy/methods MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Bladder cancer OT - Bladder preservation OT - Inverse probability of treatment weighting OT - National Cancer Database OT - Non-muscle invasive bladder cancer COIS- Declaration of interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BCB declares consulting work for Varian Medical Systems and Boston Scientific, outside of the scope of thesubmitted work. The others have no conflicts of interest that are relevant to the submitted work. EDAT- 2023/09/14 00:42 MHDA- 2023/11/27 12:42 CRDT- 2023/09/13 21:53 PHST- 2023/03/07 00:00 [received] PHST- 2023/07/25 00:00 [revised] PHST- 2023/07/26 00:00 [accepted] PHST- 2023/11/27 12:42 [medline] PHST- 2023/09/14 00:42 [pubmed] PHST- 2023/09/13 21:53 [entrez] AID - S1558-7673(23)00181-7 [pii] AID - 10.1016/j.clgc.2023.07.011 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2023 Dec;21(6):653-659.e1. doi: 10.1016/j.clgc.2023.07.011. Epub 2023 Aug 2. PMID- 37701172 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230915 IS - 1733-134X (Print) IS - 1899-0967 (Electronic) IS - 1733-134X (Linking) VI - 88 DP - 2023 TI - Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer. PG - e356-e364 LID - 10.5114/pjr.2023.130807 [doi] AB - PURPOSE: The purpose of the present study was to assess the diagnostic accuracy of the Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle infiltration of bladder cancer (BC) on a pre-operative multiparametric magnetic resonance imaging (mpMRI). METHODS: The prospective study enrolled patients with bladder lesions detected on a preliminary ultrasonography or cystoscopy. The patients underwent mpMRI on a 3T MRI scanner followed by surgery within 2 weeks. The tumours were assigned a VI-RADS score by 2 experienced abdominal radiologists. The VI-RADS score was compared with postoperative histopathological findings to confirm detrusor muscle infiltration. The diagnostic performance of VI-RADS for predicting muscle invasion was assessed by calculating sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy. RESULTS: A total of 60 patients were included in the study with a male: female ratio of 4.4 : 1. Transurethral resection of bladder tumour (TURBT) was performed in 47 (78.4%) and radical cystectomy in 13 (21.6%) patients. 19 (31.7%) had non-muscle invasive invasive BC (NMIBCa) and 41 (68.3%) had muscle invasive BC (MIBCa) on histopathology. There was a significant association between VI-RADS score and its components with muscle invasion (p < 0.05). A VI-RADS score of >/= 3 had a sensitivity of 97.56% (95% CI: 0.87-0.99%), specificity of 73.68% (95% CI: 0.49-0.91), positive predictive value of 88.9% (95% CI: 0.79-0.94), negative predictive value of 93.33% (95% CI: 0.66-0.99), and diagnostic accuracy of 90% (95% CI: 0.80-0.96) for prediction of muscle invasion. CONCLUSION: VI-RADS scoring system pre-operatively predicts the likelihood of muscle invasion in BC with a satisfactory diagnostic performance, and it should be incorporated in the diagnostic work-up of BC patients. CI - (c) Pol J Radiol 2023. FAU - Islam, Naseer Ul AU - Islam NU AD - Government Medical College, Srinagar, Jammu and Kashmir, India. FAU - Jehangir, Majid AU - Jehangir M AD - Government Medical College, Srinagar, Jammu and Kashmir, India. FAU - Parry, Arshed Hussain AU - Parry AH AD - Government Medical College, Srinagar, Jammu and Kashmir, India. FAU - Nazir, Syed Sajjad AU - Nazir SS AD - Government Medical College, Srinagar, Jammu and Kashmir, India. FAU - Bilal, Sheikh AU - Bilal S AD - Government Medical College, Srinagar, Jammu and Kashmir, India. LA - eng PT - Journal Article DEP - 20230811 PL - Poland TA - Pol J Radiol JT - Polish journal of radiology JID - 101175532 PMC - PMC10493860 OTO - NOTNLM OT - Vesical Imaging-Reporting and Data System (VI-RADS) OT - bladder cancer OT - multiparametric magnetic resonance imaging (mpMRI) OT - muscle invasion OT - prediction COIS- The authors report no conflict of interest. EDAT- 2023/09/13 06:41 MHDA- 2023/09/13 06:42 PMCR- 2023/01/01 CRDT- 2023/09/13 04:02 PHST- 2023/04/21 00:00 [received] PHST- 2023/06/30 00:00 [accepted] PHST- 2023/09/13 06:42 [medline] PHST- 2023/09/13 06:41 [pubmed] PHST- 2023/09/13 04:02 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 51316 [pii] AID - 10.5114/pjr.2023.130807 [doi] PST - epublish SO - Pol J Radiol. 2023 Aug 11;88:e356-e364. doi: 10.5114/pjr.2023.130807. eCollection 2023. PMID- 37691944 OWN - NLM STAT- MEDLINE DCOM- 20230912 LR - 20230915 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer. PG - 1187286 LID - 10.3389/fimmu.2023.1187286 [doi] LID - 1187286 AB - BACKGROUND: Bladder cancer (BCa) is a malignant tumor that usually forms cancer cells in the inner lining of the bladder. Hundreds of thousands of people worldwide have BCa diagnosed each year. The purpose of this study was to construct a prognostic model by differential expression of genes between muscular and non-muscular invasive BCa, and to investigate the prognosis of BCa patients. METHODS: The data of BCa patients was sourced from the GEO and TCGA database. Single-cell sequencing data was obtained from three patients in the GSE135337 database, and microarray data for verification was obtained from GSE32894. Univariate, Lasso and multivariate cox regression analyses were performed to construct the prognostic model. The prognostic features, immune features and drug sensitivity of the model were further evaluated. Single-cell data and microarray data were used to validate the differential expression of model genes between muscle-invasive and non-muscle-invasive BCa. The invasion and migration of BCa cells were evaluated using the transwell assay and wound-healing assay. The cell proliferation capacity was simultaneously evaluated using Colony formation experiments. The protein expression of the specific gene was detected by western blot analysis. RESULTS: We identified 183 differentially expressed muscle-invasive-related differential genes (MIRDGs), among which four were selected to establish a prognostic model. Based on our signature, patients in different groups displayed varying levels of immune infiltration and immunotherapy profiles. Single-cell sequencing data and microarray data confirmed that four invasion-related genes were expressed at higher levels in muscle-invasive BCa. Given the critical role of S100A9 in the progression of BCa, we performed further analysis. The results showed that protein expression of S100A9 was high in muscle-invasive BCa, and S100A9 knockdown could inhibit the proliferation, migration and invasion of BCa. CONCLUSION: These findings demonstrated that the prognostic model for BCa patients was reasonably accurate and valid, and it may prove to be of considerable value for the treatment and prognosis of BCa patients in the future. S100A9 may become a better prognostic marker and potential therapeutic target to further guide clinical treatment decisions. CI - Copyright (c) 2023 Wang, Zhang, Jiang, Xu, Chen, Li, Wang, Le and Zhang. FAU - Wang, Weizhuo AU - Wang W AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China. FAU - Zhang, Xi AU - Zhang X AD - Department of Urology, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Jiang, Silin AU - Jiang S AD - Department of Urology, Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Xu, Peng AU - Xu P AD - Department of Urology, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Chen, Kang AU - Chen K AD - Department of Urology, North China University of Science and Technology, Tangshan, China. FAU - Li, Kai AU - Li K AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China. FAU - Wang, Fei AU - Wang F AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China. FAU - Le, Xiang AU - Le X AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China. FAU - Zhang, Ke AU - Zhang K AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230824 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Calgranulin B) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Muscles MH - *Urinary Bladder Neoplasms/genetics MH - Prognosis MH - Urinary Bladder MH - Calgranulin B PMC - PMC10483405 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - immune microenvironment OT - muscle-invasive OT - prognostic signature COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/11 06:42 MHDA- 2023/09/12 06:41 PMCR- 2023/01/01 CRDT- 2023/09/11 04:30 PHST- 2023/03/15 00:00 [received] PHST- 2023/07/26 00:00 [accepted] PHST- 2023/09/12 06:41 [medline] PHST- 2023/09/11 06:42 [pubmed] PHST- 2023/09/11 04:30 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1187286 [doi] PST - epublish SO - Front Immunol. 2023 Aug 24;14:1187286. doi: 10.3389/fimmu.2023.1187286. eCollection 2023. PMID- 37690934 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 12 DP - 2023 Dec TI - The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment. PG - 486.e1-486.e13 LID - S1078-1439(23)00283-1 [pii] LID - 10.1016/j.urolonc.2023.08.012 [doi] AB - INTRODUCTION: Nonmuscle invasive bladder cancers (NMIBC) are common tumors diagnosed in older individuals and men (median age: 69 years). Immunotherapy is a treatment option in cases resistant to Bacillus-Calmette-Guerin (BCG) therapy. We aimed to evaluate the prognostic role of programmed-cell-death ligand (PD-L)-1 (PD-L1), PD-L2, and signal transducer and activator of transcription 3 (STAT3) expressions, which are closely related to immune mechanisms, in the response to BCG treatment of NMIBC. METHODS: The data of patients at the Ta and T1 stages of the cancer without muscularis propria invasion, who were treated with intravesical BCG therapy between 2017 and 2022 were retrospectively analyzed. Immunohistochemical staining for PD-L1, PD-L2, and STAT3 was performed on transurethral resection materials. RESULTS: The mean age of 59 patients was 66.5 +/-7.7 and 83.9% were male. The percentage of patients with complete response to BCG treatment was 66.1% and that of BCG refractory patients was 33.9%. Demographic and clinical data did not differ significantly according to BCG treatment response (P> 0.05). The proportion of patients with tumor-infiltrating lymphocytes (TILs) >/=20% were 9.7% among those with Ta-stage tumors and 46.4% among those with T1-stage tumors (P = 0.0014). The percentages of tumor cell scoring (TCS), immune cell scoring (ICS), combined scoring (CS), and expression levels of PD-L1, PD-L2, and H-score of STAT3 did not differ significantly according to tumor stage and treatment response (P > 0.05). However, the median ICS and CS for PD-L1 and median H-score for STAT3 were significantly higher among patients in T1 stage compared to those in Ta stage (P = 0.0487, 0.0462, 0.0112, respectively). Among BCG refractory patients, median STAT3 of patients in T1 stage was significantly higher than those at stage Ta (P = 0.0356) and the rate of TILs was >/=20% in only 3 patients in T1 stage (P = 0.031). Among all patients, significant positive correlation was found between TCS for PD-L1 and H-score for STAT3 (P = 0.0302); and between ICS for PD-L1 and TCS for PD-L2 (P = 0.0053) and TILs ratio (P < 0.0001). Among BCG-refractory cases, pretreatment and post-treatment TCS for PD-L2 and H-scores for STAT3 were significantly correlated (P = 0.0361 and 0.0021, respectively). CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Civriz, Aziz Hakki AU - Civriz AH AD - Department of Pathology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Teke, Kerem AU - Teke K AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Akdas, Enes Malik AU - Akdas EM AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Dillioglugil, Ozdal AU - Dillioglugil O AD - Department of Urology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Vural, Cigdem AU - Vural C AD - Department of Pathology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. FAU - Yaprak Bayrak, Busra AU - Yaprak Bayrak B AD - Department of Pathology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. Electronic address: busra.yaprakbayrak@kocaeli.edu.tr. LA - eng PT - Journal Article DEP - 20230909 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (B7-H1 Antigen) RN - 0 (STAT3 Transcription Factor) RN - 0 (BCG Vaccine) RN - 0 (STAT3 protein, human) SB - IM MH - Humans MH - Male MH - Aged MH - Middle Aged MH - Female MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Prognosis MH - Retrospective Studies MH - B7-H1 Antigen/metabolism MH - STAT3 Transcription Factor/metabolism/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - BCG Vaccine/therapeutic use OTO - NOTNLM OT - BCG OT - PD-L1 OT - PD-L2 OT - STAT3 OT - Urothelial Carcinoma COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/11 00:42 MHDA- 2023/12/17 09:42 CRDT- 2023/09/10 22:01 PHST- 2023/06/06 00:00 [received] PHST- 2023/08/10 00:00 [revised] PHST- 2023/08/17 00:00 [accepted] PHST- 2023/12/17 09:42 [medline] PHST- 2023/09/11 00:42 [pubmed] PHST- 2023/09/10 22:01 [entrez] AID - S1078-1439(23)00283-1 [pii] AID - 10.1016/j.urolonc.2023.08.012 [doi] PST - ppublish SO - Urol Oncol. 2023 Dec;41(12):486.e1-486.e13. doi: 10.1016/j.urolonc.2023.08.012. Epub 2023 Sep 9. PMID- 37690933 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 11 DP - 2023 Nov TI - Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. PG - 458.e1-458.e7 LID - S1078-1439(23)00229-6 [pii] LID - 10.1016/j.urolonc.2023.06.018 [doi] AB - PURPOSE: Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk nonmuscle invasive bladder cancer (NMIBC), but half of patients develop disease recurrence. Intravesical regimens for BCG unresponsive NMIBC are limited. We report the safety, efficacy, and differential response of sequential gemcitabine/docetaxel (gem/doce) depending on BCG failure classification. METHODS: Multi-institutional retrospective analysis of patients treated with induction intravesical gem/doce (>/=5/6 instillations) for recurrent high-risk NMIBC after BCG therapy from May 2018 to December 2021. Maintenance therapy was provided to those without high-grade (HG) recurrence on surveillance cystoscopy. Kaplan-Meier curves and Cox regression analyses were utilized to assess survival and risk factors for disease recurrence. RESULTS: Our cohort included 102 patients with BCG-unresponsive NMIBC. Median age was 72 years and median follow-up was 18 months. Six-, 12-, and 24-month high-grade recurrence-free survival was 78%, 65%, and 49%, respectively. Twenty patients underwent radical cystectomy (median 15.5 months from induction). Six patients progressed to muscle invasive disease. Fifty-seven percent of patients experienced mild/moderate adverse effects (AE), but only 6.9% experienced a delay in treatment schedule. Most common AE were urinary frequency/urgency (41%) and dysuria (21%). Patients with BCG refractory disease were more likely to develop HG recurrence when compared to patients with BCG relapsing disease (HR 2.14; 95% CI 1.02-4.49). CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Yim, Kendrick AU - Yim K AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Melnick, Kevin AU - Melnick K AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Mott, Sarah L AU - Mott SL AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Carvalho, Filipe L F AU - Carvalho FLF AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Zafar, Affan AU - Zafar A AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Clinton, Timothy N AU - Clinton TN AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Mossanen, Matthew AU - Mossanen M AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Steele, Graeme S AU - Steele GS AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - Hirsch, Michelle AU - Hirsch M AD - Department of Pathology, Brigham and Women's Hospital, Boston MA. FAU - Rizzo, Natalie AU - Rizzo N AD - Department of Pathology, Brigham and Women's Hospital, Boston MA. FAU - Wu, Chin-Lee AU - Wu CL AD - Department of Pathology, Massachusetts General Hospital, Boston, MA. FAU - Mouw, Kent W AU - Mouw KW AD - Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA. FAU - Wszolek, Matthew AU - Wszolek M AD - Department of Urology, Massachusetts General Hospital, Boston, MA. FAU - Salari, Keyan AU - Salari K AD - Department of Urology, Massachusetts General Hospital, Boston, MA. FAU - Feldman, Adam AU - Feldman A AD - Department of Urology, Massachusetts General Hospital, Boston, MA. FAU - Kibel, Adam S AU - Kibel AS AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Preston, Mark A AU - Preston MA AD - Division of Urology, Brigham and Women's Hospital, Boston, MA. Electronic address: MPreston@bwh.harvard.edu. LA - eng PT - Journal Article DEP - 20230909 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Gemcitabine) RN - 15H5577CQD (Docetaxel) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Aged MH - Gemcitabine MH - Docetaxel/therapeutic use MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Intravesical therapy OT - Nonmuscle invasive bladder cancer OT - Outcomes COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/11 00:42 MHDA- 2023/12/05 12:42 CRDT- 2023/09/10 22:01 PHST- 2023/03/29 00:00 [received] PHST- 2023/06/06 00:00 [revised] PHST- 2023/06/26 00:00 [accepted] PHST- 2023/12/05 12:42 [medline] PHST- 2023/09/11 00:42 [pubmed] PHST- 2023/09/10 22:01 [entrez] AID - S1078-1439(23)00229-6 [pii] AID - 10.1016/j.urolonc.2023.06.018 [doi] PST - ppublish SO - Urol Oncol. 2023 Nov;41(11):458.e1-458.e7. doi: 10.1016/j.urolonc.2023.06.018. Epub 2023 Sep 9. PMID- 37682528 OWN - NLM STAT- MEDLINE DCOM- 20231115 LR - 20260127 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 29 IP - 22 DP - 2023 Nov 14 TI - Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. PG - 4586-4595 LID - 10.1158/1078-0432.CCR-23-1283 [doi] AB - PURPOSE: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered urothelial carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment genomic evolution. EXPERIMENTAL DESIGN: Prospectively collected clinical data were integrated with institutional genomic data to define the landscape of FGFR2/3-altered urothelial carcinoma. To identify mechanisms of erdafitinib resistance, a subset of patients underwent prospective cell-free (cf) DNA assessment. RESULTS: FGFR3 alterations predictive of erdafitinib sensitivity were identified in 39% (199/504) of patients with non-muscle invasive, 14% (75/526) with muscle-invasive, 43% (81/187) with localized upper tract, and 26% (59/228) with metastatic specimens. One patient had a potentially sensitizing FGFR2 fusion. Among 27 FGFR3-altered cases with a primary tumor and metachronous metastasis, 7 paired specimens (26%) displayed discordant FGFR3 status. Erdafitinib achieved a response rate of 40% but median progression-free and overall survival of only 2.8 and 6.6 months, respectively (n = 32). Dose reductions (38%, 12/32) and interruptions (50%, 16/32) were common. Putative resistance mutations detected in cfDNA involved TP53 (n = 5), AKT1 (n = 1), and second-site FGFR3 mutations (n = 2). CONCLUSIONS: FGFR3 mutations are common in urothelial carcinoma, whereas FGFR2 alterations are rare. Discordance of FGFR3 mutational status between primary and metastatic tumors occurs frequently and raises concern over sequencing archival primary tumors to guide patient selection for erdafitinib therapy. Erdafitinib responses were typically brief and dosing was limited by toxicity. FGFR3, AKT1, and TP53 mutations detected in cfDNA represent putative mechanisms of acquired erdafitinib resistance. CI - (c)2023 American Association for Cancer Research. FAU - Guercio, Brendan J AU - Guercio BJ AUID- ORCID: 0000-0001-6296-2473 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. FAU - Sarfaty, Michal AU - Sarfaty M AUID- ORCID: 0000-0002-9603-3207 AD - Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Teo, Min Yuen AU - Teo MY AUID- ORCID: 0000-0003-2511-6731 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Ratna, Neha AU - Ratna N AUID- ORCID: 0009-0005-3040-6874 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Duzgol, Cihan AU - Duzgol C AUID- ORCID: 0000-0002-0310-576X AD - Commonwealth Radiology Associates, Andover, Massachusetts. FAU - Funt, Samuel A AU - Funt SA AUID- ORCID: 0000-0002-7235-6319 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Lee, Chung-Han AU - Lee CH AUID- ORCID: 0000-0001-5511-0635 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Aggen, David H AU - Aggen DH AUID- ORCID: 0000-0003-3963-5751 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Regazzi, Ashley M AU - Regazzi AM AUID- ORCID: 0000-0002-6019-1852 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Chen, Ziyu AU - Chen Z AUID- ORCID: 0000-0002-1198-1516 AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Lattanzi, Michael AU - Lattanzi M AUID- ORCID: 0000-0002-6500-4753 AD - Texas Oncology, Austin, Texas. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AUID- ORCID: 0000-0002-2938-6627 AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Brannon, A Rose AU - Brannon AR AUID- ORCID: 0000-0003-4610-0149 AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Shah, Ronak AU - Shah R AUID- ORCID: 0000-0001-9042-6213 AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Chu, Carissa AU - Chu C AUID- ORCID: 0000-0003-3065-389X AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Lenis, Andrew T AU - Lenis AT AUID- ORCID: 0000-0001-9413-7793 AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. FAU - Pietzak, Eugene AU - Pietzak E AUID- ORCID: 0000-0002-5121-5701 AD - Weill Cornell Medical College, New York, New York. AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Bochner, Bernard H AU - Bochner BH AUID- ORCID: 0000-0003-0846-0848 AD - Weill Cornell Medical College, New York, New York. AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Berger, Michael F AU - Berger MF AUID- ORCID: 0000-0003-3882-5000 AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Solit, David B AU - Solit DB AUID- ORCID: 0000-0002-6614-802X AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AUID- ORCID: 0000-0003-2637-4249 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Bajorin, Dean F AU - Bajorin DF AUID- ORCID: 0000-0003-4001-7088 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. FAU - Iyer, Gopa AU - Iyer G AUID- ORCID: 0000-0002-5093-6099 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Weill Cornell Medical College, New York, New York. LA - eng GR - N/A/Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO)/ GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - P50-CA221745/National Cancer Institute (NCI)/ GR - P01-CA221757/National Cancer Institute (NCI)/ GR - N/A/Cycle for Survival/ GR - T32 CA082088/CA/NCI NIH HHS/United States GR - P30-CA008748/National Cancer Institute (NCI)/ GR - P01 CA221757/CA/NCI NIH HHS/United States GR - T32-CA009207/National Cancer Institute (NCI)/ GR - T32 CA009207/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - 0 (Cell-Free Nucleic Acids) RN - 890E37NHMV (erdafitinib) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) RN - EC 2.7.10.1 (FGFR3 protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - *Carcinoma, Transitional Cell/drug therapy/genetics/pathology MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Treatment Outcome MH - Genomics MH - *Cell-Free Nucleic Acids MH - Pyrazoles MH - Quinoxalines PMC - PMC11233068 MID - NIHMS1931569 COIS- Conflicts of Interest: B. Guercio reports honoraria from Medscape; institutional research funding from Oncocyte and Genentech; as well as expenses from Seagen/Astellas, EMD Serono, Natera, Gilead, Aveo Oncology, and Exelixis. M. Sarfaty reports honoraria from Pfizer, Bristol Myers Squibb/Pfizer, Janssen, Astellas Pharma, Astellas Pharma, MSD Oncology, MSD Oncology; consulting or advisory role with Astellas Pharma and MSD Oncology; as well as institutional research funding from AstraZeneca. M.Y. Teo reports consulting/advisory role for Janssen Oncology and institutional research funding from Bristol-Myers Squibb, Clovis Oncology, and Pharmacyclics. S.A. Funt reports employment with ByHeart; stock and other ownership interests in Kite, a Gilead company, UroGen pharma, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, Vida Ventures, IconOVir Bio, and Doximity, 76Bio; consulting or advisory roles with Merck, Immunai, and BioNTech; institutional research funding from Genentech/Roche, AstraZeneca, Decibel Therapeutics; as well as travel, accommodations, or expenses from Bristol Myers Squibb, and AstraZeneca/MedImmune. C.H. Lee reports honoraria from Intellisphere, Research to Practice, and American Institute of Continuing Medical Education; consulting or advisory role for Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Merck, and Pfizer; as well as institutional research funding from Bristol Myers Squibb, Calithera Biosciences, Eisai, Eli Lilly, Exelixis, Merck, and Pfizer. D.H. Aggen reports research funds from Seattle Genetics and Astellas. M. Lattanzi reports consulting with Janssen, Aveo, Merck, Aadi; and speaking fees from Seagen, Janssen, Astrazeneca, EMD Serono. H.A. Al-Ahmadie has provided consultation to AstraZeneca, Janssen Biotech, Bristol-Myers-Squibb, and Paige.ai. E. Pietzak reports honoraria from UpToDate; consulting or advisory roles with Merck, Chugai Pharma, QED Therapeutics, Janssen, and Urogen pharma; as well as research funding from Janssen. B.H. Bochner reports consulting or advisory role for Olympus. M.F. Berger reports a patent pending on "Systems and Methods for Detecting Cancer Via cfDNA Screening;" research funding from Grail; consulting fees from Eli Lilly and PetDx. L.D.E.: and is an employee of and shareholder in Puma Biotechnology, Inc. D.B. Solit has served as a consultant for/received honorarium from Pfizer, Loxo/Lilly Oncology, Vividion Therapeutics, Scorpion Therapeutics, Fore Therapeutics, FOG Pharma, Rain Therapeutics, and BridgeBio. J.E. Rosenberg has served as a consultant for Astellas, Seagen, Merck, Roche, Genentech, AstraZeneca, Janssen Biotech, Gilead, Pfizer, EMD-Serono, Mirati, Boehringer Ingelheim, Pharmacyclis, GSK, Infinity, Tyra BioSciences, Bayer, and QED Therapeutics and received honoraria from EMD-Serono. D.F. Bajorin reports honoraria from Bristol Myers Squibb/Medarex; consulting or advisory roles with Merck, Bristol Myers Squibb Foundation; as well as institutional research funding from Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Astellas Pharma, and Seattle Genetics/Astellas. G. Iyer reports consulting or advisory roles with Bayer, Janssen, Mirati Therapeutics, Basilea, Flare Therapeutics, and Loxo/Lilly; speakers' bureau activities with Gilead Sciences and Lynx Group; as well as institutional research funding from Mirati Therapeutics, Novartis, Debiopharm Group, Bayer, Janssen, and Seattle Genetics. N. Ratna, C. Duzgol, A.M. Regazzi, Z. Chen, A.R. Brannon, R. Shah, C. Chu, A.T. Lenis declare no potential conflicts of interest. EDAT- 2023/09/08 12:43 MHDA- 2023/11/15 06:42 PMCR- 2024/07/09 CRDT- 2023/09/08 11:17 PHST- 2023/05/04 00:00 [received] PHST- 2023/07/02 00:00 [revised] PHST- 2023/09/06 00:00 [accepted] PHST- 2023/11/15 06:42 [medline] PHST- 2023/09/08 12:43 [pubmed] PHST- 2023/09/08 11:17 [entrez] PHST- 2024/07/09 00:00 [pmc-release] AID - 728984 [pii] AID - 10.1158/1078-0432.CCR-23-1283 [doi] PST - ppublish SO - Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. PMID- 37671794 OWN - NLM STAT- MEDLINE DCOM- 20240425 LR - 20260501 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 148 IP - 5 DP - 2024 May 1 TI - pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens. PG - 573-580 LID - 10.5858/arpa.2023-0044-OA [doi] AB - CONTEXT: The pathologic diagnosis of pT1 substage in conventional transurethral resection of bladder tumor specimens is inaccurate and has low interobserver reproducibility owing to fragmentation and cauterization of the specimens. En bloc resection of bladder tumor is a novel surgical procedure that improves diagnostic feasibility and accuracy in the pathologic diagnosis of bladder cancer, including depth and extent of invasion. OBJECTIVE: To examine the prognostic value of multiple pT1 subclassification methods, using only en bloc resection specimens. DESIGN: We examined 106 patients with T1 bladder cancer who underwent en bloc resection. The pT1 substages were assigned by 3 different subclassification methods by using the muscularis mucosae or stalk of the papillary lesion as diagnostic landmarks or millimetric depth of invasion. Intergroup differences in progression-free survival and recurrence-free survival rates were analyzed. The prognostic values of clinicopathologic factors for progression/recurrence were analyzed by using multivariate analysis. RESULTS: The pT1 substage was evaluable in all cases. Tumors with invasion into/beyond the muscularis mucosae and those beyond the stalk of the papillary lesion were associated with worse progression-free survival (P = .002 and P = .01, respectively). Notably, no patient with invasion confined to the stalk had disease progression during the 23-month median follow-up period. Only the pT1 subclassification method using the muscularis mucosae was an independent prognosticator of progression in multivariate analysis (P = .03). CONCLUSIONS: Precise pathologic subclassification of invasion using en bloc resection specimens may enable accurate prognosis and assessment in patients with bladder cancer with suspicious shallow invasion. CI - (c) 2024 College of American Pathologists. FAU - Sato, Shun AU - Sato S AD - From the Department of Pathology, Jikei University School of Medicine, Tokyo, Japan(Sato, Shimoda, Takahashi). FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Miki, Jun AU - Miki J AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Hayashida, Yasushi AU - Hayashida Y AD - the Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan (Hayashida). FAU - Okada, Yohei AU - Okada Y AD - the Department of Urology, Saitama Medical Center, Saitama, Japan (Okada). FAU - Iwatani, Kosuke AU - Iwatani K AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Matsukawa, Akihiro AU - Matsukawa A AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Kimura, Takahiro AU - Kimura T AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Egawa, Shin AU - Egawa S AD - From the Department of Urology, , Jikei University School of Medicine, Tokyo, Japan(Yanagisawa, Miki, Iwatani, Matsukawa, Kimura, Egawa). FAU - Shimoda, Masayuki AU - Shimoda M AD - From the Department of Pathology, Jikei University School of Medicine, Tokyo, Japan(Sato, Shimoda, Takahashi). FAU - Takahashi, Hiroyuki AU - Takahashi H AD - From the Department of Pathology, Jikei University School of Medicine, Tokyo, Japan(Sato, Shimoda, Takahashi). LA - eng PT - Journal Article PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/mortality/classification MH - Male MH - Female MH - Aged MH - Middle Aged MH - Progression-Free Survival MH - Aged, 80 and over MH - Prognosis MH - Neoplasm Staging/methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Cystectomy/methods MH - Carcinoma, Transitional Cell/pathology/surgery/mortality/classification MH - Adult MH - Urinary Bladder/pathology/surgery COIS- The authors have no relevant financial interest in the products or companies described in this article. EDAT- 2023/09/06 12:42 MHDA- 2024/04/25 18:56 CRDT- 2023/09/06 08:02 PHST- 2023/06/07 00:00 [accepted] PHST- 2024/04/25 18:56 [medline] PHST- 2023/09/06 12:42 [pubmed] PHST- 2023/09/06 08:02 [entrez] AID - 495590 [pii] AID - 10.5858/arpa.2023-0044-OA [doi] PST - ppublish SO - Arch Pathol Lab Med. 2024 May 1;148(5):573-580. doi: 10.5858/arpa.2023-0044-OA. PMID- 37668795 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 149 IP - 17 DP - 2023 Nov TI - Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder. PG - 15795-15804 LID - 10.1007/s00432-023-05348-z [doi] AB - INTRODUCTION: The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERalpha and ERbeta) in patients with bladder cancer and their correlation with clinicopathologic features. MATERIALS AND METHODS: In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied. RESULTS: A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC). CONCLUSION: Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Shrivastava, Nikita AU - Shrivastava N AUID- ORCID: 0000-0002-0334-0890 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Jena, Rahul AU - Jena R AUID- ORCID: 0000-0003-0952-7514 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Choudhary, Gautam Ram AU - Choudhary GR AUID- ORCID: 0000-0003-0533-6227 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. gautamoshu@gmail.com. FAU - Bhargava, Priyank AU - Bhargava P AUID- ORCID: 0000-0003-1579-6681 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Vishwajeet, Vikarn AU - Vishwajeet V AD - Department of Pathology, All India Institute of Medical Sciences, Jodhpur, India. FAU - Elhence, Poonam AU - Elhence P AD - Department of Pathology, All India Institute of Medical Sciences, Jodhpur, India. FAU - Singh, Mahendra AU - Singh M AUID- ORCID: 0000-0001-8769-8269 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Bhirud, Deepak Prakash AU - Bhirud DP AUID- ORCID: 0000-0003-3908-4275 AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Sandhu, Arjun Singh AU - Sandhu AS AD - Department of Urology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. LA - eng PT - Journal Article DEP - 20230905 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Receptors, Estrogen) RN - 0 (Receptors, Androgen) RN - 0 (Androgens) RN - 0 (Estrogen Receptor alpha) RN - 0 (Estrogen Receptor beta) RN - 0 (Estrogens) SB - IM MH - Humans MH - Receptors, Estrogen/metabolism MH - Receptors, Androgen/metabolism MH - Androgens/metabolism MH - Urinary Bladder MH - Estrogen Receptor alpha/metabolism MH - Estrogen Receptor beta/metabolism MH - Retrospective Studies MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Estrogens PMC - PMC11796757 OTO - NOTNLM OT - Androgen receptor OT - Estrogen receptor alpha OT - Estrogen receptor beta OT - Urinary bladder cancer COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/09/05 12:42 MHDA- 2023/11/02 12:47 PMCR- 2023/09/05 CRDT- 2023/09/05 11:14 PHST- 2023/07/14 00:00 [received] PHST- 2023/08/25 00:00 [accepted] PHST- 2023/11/02 12:47 [medline] PHST- 2023/09/05 12:42 [pubmed] PHST- 2023/09/05 11:14 [entrez] PHST- 2023/09/05 00:00 [pmc-release] AID - 10.1007/s00432-023-05348-z [pii] AID - 5348 [pii] AID - 10.1007/s00432-023-05348-z [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 Nov;149(17):15795-15804. doi: 10.1007/s00432-023-05348-z. Epub 2023 Sep 5. PMID- 37663619 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230905 IS - 2452-199X (Electronic) IS - 2452-199X (Linking) VI - 31 DP - 2024 Jan TI - Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer. PG - 315-332 LID - 10.1016/j.bioactmat.2023.08.013 [doi] AB - Surgical resection remains the prefer option for bladder cancer treatment. However, the effectiveness of surgery is usually limited for the high recurrence rate and poor prognosis. Consequently, intravesical chemotherapy synergize with immunotherapy in situ is an attractive way to improve therapeutic effect. Herein, a combined strategy based on thermo-sensitive PLEL hydrogel drug delivery system was developed. GEM loaded PLEL hydrogel was intravesical instilled to kill tumor cells directly, then PLEL hydrogel incorporated with CpG was injected into both groins subcutaneously to promote immune responses synergize with GEM. The results demonstrated that drug loaded PLEL hydrogel had a sol-gel phase transition behavior in response to physiological temperature and presented sustained drug release, and the PLEL-assisted combination therapy could have better tumor suppression effect and stronger immunostimulating effect in vivo. Hence, this combined treatment with PLEL hydrogel system has great potential and suggests a clinically-relevant and valuable option for bladder cancer. CI - (c) 2023 The Authors. FAU - Liu, J AU - Liu J AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Yang, T Y AU - Yang TY AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Dai, L Q AU - Dai LQ AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Shi, K AU - Shi K AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Hao, Y AU - Hao Y AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Chu, B Y AU - Chu BY AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Hu, D R AU - Hu DR AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Bei, Z W AU - Bei ZW AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Yuan, L P AU - Yuan LP AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Pan, M AU - Pan M AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Qian, Z Y AU - Qian ZY AD - Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. LA - eng PT - Journal Article DEP - 20230822 PL - China TA - Bioact Mater JT - Bioactive materials JID - 101685294 PMC - PMC10468327 OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - Intravesical chemotherapy OT - Localized drug delivery OT - Thermo-responsive hydrogel COIS- The authors declare that they have no competing interests in this paper. EDAT- 2023/09/04 06:42 MHDA- 2023/09/04 06:43 PMCR- 2023/08/22 CRDT- 2023/09/04 05:03 PHST- 2023/06/21 00:00 [received] PHST- 2023/08/12 00:00 [revised] PHST- 2023/08/12 00:00 [accepted] PHST- 2023/09/04 06:43 [medline] PHST- 2023/09/04 06:42 [pubmed] PHST- 2023/09/04 05:03 [entrez] PHST- 2023/08/22 00:00 [pmc-release] AID - S2452-199X(23)00252-9 [pii] AID - 10.1016/j.bioactmat.2023.08.013 [doi] PST - epublish SO - Bioact Mater. 2023 Aug 22;31:315-332. doi: 10.1016/j.bioactmat.2023.08.013. eCollection 2024 Jan. PMID- 37661872 OWN - NLM STAT- MEDLINE DCOM- 20231121 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 38 IP - 3 DP - 2023 TI - Prediction for recurrent non-muscle invasive bladder cancer. PG - 275-285 LID - 10.3233/CBM-220373 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) has a high recurrence rate, which places a significant burden on both patients and the healthcare system. Hence, it holds significant importance to predict the recurrence risk following treatment for individuals diagnosed with non-muscle invasive bladder cancer (NMIBC). As new generation technologies continue to emerge, an increasing number of recurrence risk prediction tools are being developed and discovered. This article provides an overview of the primary recurrence risk prediction tools currently available, including the liquid biopsy, tissue biopsy, and risk prediction tables. Each of these tools is described in detail and illustrated with relevant examples. Furthermore, we conduct an analysis of the advantages and disadvantages of these tools. This article aims to enhance the reader's understanding of the current progress in recurrence prediction tools and encourage their practical utilization in the fields of precision medicine and public health. FAU - Li, Keqiang AU - Li K AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. AD - Academy of Medical Sciences, Zhengzhou University, Henan, China. FAU - Raveendran, Aravind AU - Raveendran A AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. FAU - Xie, Guoqing AU - Xie G AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. AD - Academy of Medical Sciences, Zhengzhou University, Henan, China. FAU - Zhang, Yu AU - Zhang Y AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. AD - Academy of Medical Sciences, Zhengzhou University, Henan, China. FAU - Wu, Haofan AU - Wu H AD - Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Huang, Zhenlin AU - Huang Z AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. FAU - Jia, Zhankui AU - Jia Z AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. FAU - Yang, Jinjian AU - Yang J AD - Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Biopsy MH - Liquid Biopsy MH - Precision Medicine MH - *Urinary Bladder Neoplasms/diagnosis/therapy PMC - PMC12412867 OTO - NOTNLM OT - Bladder cancer OT - NMIBC OT - biopsy OT - prediction OT - recurrence EDAT- 2023/09/04 06:43 MHDA- 2023/11/21 06:42 PMCR- 2023/11/20 CRDT- 2023/09/04 04:14 PHST- 2023/11/21 06:42 [medline] PHST- 2023/09/04 06:43 [pubmed] PHST- 2023/09/04 04:14 [entrez] PHST- 2023/11/20 00:00 [pmc-release] AID - CBM220373 [pii] AID - 10.3233/CBM-220373 [doi] PST - ppublish SO - Cancer Biomark. 2023;38(3):275-285. doi: 10.3233/CBM-220373. PMID- 37661507 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240409 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 22 IP - 2 DP - 2024 Apr TI - Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. PG - 27-37 LID - S1558-7673(23)00184-2 [pii] LID - 10.1016/j.clgc.2023.08.001 [doi] AB - INTRODUCTION: Upper tract urothelial carcinoma is rare but has a poor prognosis. Prognostic factors have been extensively studied in order to provide the best possible management for patients. We have aimed to investigate commonly available factors predictive of recurrence and survival in this patient population at high risk of death and recurrence, with an emphasis on the effects of age (using a cutoff of 70 years) on survival outcomes. PATIENTS AND METHODS: From 1387 patients with clinically nonmetastatic upper tract urothelial carcinoma treated with radical nephroureterectomy at 21 academic hospital centers between 2005 and 2021, 776 patients were eligible and included in the study. Univariable and multivariable Cox regression models were built to evaluate the independent prognosticators for intravesical and extravesical recurrence, overall survival, and cancer-specific survival according to age groups. A P value of <.05 was considered statistically significant. RESULTS: We did not find an association between groups aged <70 and >70 years old and preoperatively clinical or histopathological characteristics. Kaplan-Meier analysis was found no statistical significance between the 2 age groups in terms of intravesical or extravesical recurrence (P = .09 and P = .57). Overall survival (P = .0001) and cancer-specific survival (P = .0001) have been found to be statistically significantly associated with age as independent predictors (confounding factors: gender, tumor size, tumor side, clinical T stage, localization, preoperative hydronephrosis, tumor localization, type of surgery, multifocality of the tumor, pathological grade, lymphovascular invasion, concomitant CIS, lymph node status, necrosis, or history of previous bladder cancer). CONCLUSION: This research confirms that patients aged 70 and above who undergo radical nephroureterectomy may have worse outcomes compared to younger patients, older patients needing an improved care and management of UTUC to improve their outcomes in the setting of an increase in this aged population group. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ferro, Matteo AU - Ferro M AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Chiujdea, Sever AU - Chiujdea S AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Urology, Medical University of Vienna, Wien, Austria; The Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Urology, Medical University of Vienna, Wien, Austria; The Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Bove, Pierluigi AU - Bove P AD - San Carlo di Nancy Hospital, Rome, Italy; Department of Experimental Medicine, Tor vergata Oncoscience Research Centre of Excellence, TOR, University of Rome Tor Vergata, Rome, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Oncological Urology, Veneto Institute of Oncology (IOV), IRCCS, Padua, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. FAU - Foschi, Nazario AU - Foschi N AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Racioppi, Marco AU - Racioppi M AD - Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Department of Urology, Rush University Medical Center, Chicago, IL. FAU - Chiancone, Francesco AU - Chiancone F AD - Department of Urology, A.O.R.N. A. Cardarelli, Naples, Italy. FAU - Longo, Nicola AU - Longo N AD - Urology Unit, Department of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Barone, Biagio AU - Barone B AD - Urology Unit, Department of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Urology Unit, Department of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Piccinelli, Mattia Luca AU - Piccinelli ML AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy. FAU - Tataru, Octavian Sabin AU - Tataru OS AD - The Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania; Department of Simulation Applied in Medicine, George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology from Targu Mures, Targu Mures, Romania. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy. FAU - Liguori, Giovanni AU - Liguori G AD - Urology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical Integrated Sciences (DISC), Urology Section, University of Genova, Genova, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. FAU - Greco, Francesco AU - Greco F AD - Department of Urology, IRCCS Humanitas Gavazzeni, Bergamo, Italy. FAU - Schips, Luigi AU - Schips L AD - Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio, University of Chieti, Chieti, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio, University of Chieti, Chieti, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Urology, Andrology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy. FAU - Dutto, Daniele AU - Dutto D AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Colucci, Fulvia AU - Colucci F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Surgery, Urology Section, University of Catania, Catania, Italy. FAU - Giudice, Arturo Lo AU - Giudice AL AD - Department of Surgery, Urology Section, University of Catania, Catania, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Boeri, Luca AU - Boeri L AD - Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Rosazza, Matteo AU - Rosazza M AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Livoti, Simone AU - Livoti S AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. LA - eng PT - Journal Article DEP - 20230811 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Aged MH - *Urinary Bladder Neoplasms/surgery MH - *Carcinoma, Transitional Cell/surgery MH - Nephroureterectomy MH - *Ureter/surgery MH - Kaplan-Meier Estimate MH - Retrospective Studies MH - Prognosis MH - *Ureteral Neoplasms/surgery MH - Neoplasm Recurrence, Local/surgery OTO - NOTNLM OT - Cancer-specific survival OT - Elderly patients OT - Multicenter study OT - Overall survival OT - Upper urothelial carcinoma EDAT- 2023/09/04 06:43 MHDA- 2024/03/11 06:43 CRDT- 2023/09/04 00:59 PHST- 2023/03/23 00:00 [received] PHST- 2023/07/26 00:00 [revised] PHST- 2023/08/04 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2023/09/04 06:43 [pubmed] PHST- 2023/09/04 00:59 [entrez] AID - S1558-7673(23)00184-2 [pii] AID - 10.1016/j.clgc.2023.08.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2024 Apr;22(2):27-37. doi: 10.1016/j.clgc.2023.08.001. Epub 2023 Aug 11. PMID- 37652824 OWN - NLM STAT- MEDLINE DCOM- 20231106 LR - 20231106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 10 DP - 2023 Oct TI - Preoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis. PG - 433.e1-433.e7 LID - S1078-1439(23)00226-0 [pii] LID - 10.1016/j.urolonc.2023.06.012 [doi] AB - PURPOSE: Urothelial carcinomas (UCs) are often characterized by frequent recurrences after surgery, making UC one of the costliest cancers. Chromosomal instability (CIN) has been proven to be a hallmark of UCs and is related to the prognosis of many cancer types. In this study, we evaluated CIN of urine sediments as a prognostic indicator for UCs. METHODS: Patients with UC were prospectively recruited. Preoperative urine samples were collected for whole genome sequencing and urine cytology tests. Patients underwent standard-of-care treatment and were followed up until disease relapse or study ended. Concordance and accuracy of CIN alone or in combination with cytology in predicting disease relapse were assessed. The value of CIN combined with European Organization for Research and Treatment of Cancer (EORTC) model were also analyzed. RESULTS: A total of 137 patients with UCs were included in this study. Median follow-up was 44.2 months and 41.61% patients suffered from cancer relapse. Patients with CIN-high indicated higher relapse rate, and this distinction was significant for patients underwent transurethral resection of bladder tumor (57.89% vs. 34.29%, P = 0.016). Combination of cytology and CIN result could further classified patients into subgroups with distinct relapse risks. Meanwhile, the combination of CIN and EORTC model significantly improved the prediction accuracy compared with EORTC alone (Harrel's C-index: 0.71 vs. 0.65). CONCLUSION: CIN level of preoperative urine exfoliated cells had robust prognostic value for bladder cancer patients underwent TURBT. The prognostic model by combining CIN and EORTC may help in stratifying patients to optimize follow-up regimen. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ying, Yidie AU - Ying Y AD - Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China. FAU - Xing, Naidong AU - Xing N AD - Department of Urology, Qilu Hospital of Shandong University, Ji'nan, Shandong, P. R. China. FAU - Qian, Ziliang AU - Qian Z AD - Suzhou Hongyuan Biotech Inc., Biobay, Suzhou, P. R. China. FAU - Wang, Baiyun AU - Wang B AD - Suzhou Hongyuan Biotech Inc., Biobay, Suzhou, P. R. China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China. Electronic address: zengshuxiong@126.com. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China. Electronic address: chuanliang_xu@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230829 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/genetics/surgery/pathology MH - Chromosomal Instability MH - Prognosis MH - *Carcinoma, Transitional Cell/genetics/surgery MH - Recurrence MH - Urine OTO - NOTNLM OT - Bladder cancer OT - Chromosomal instability OT - Prognostic factor OT - Whole genome sequencing COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/01 00:42 MHDA- 2023/11/06 06:42 CRDT- 2023/08/31 22:00 PHST- 2023/04/18 00:00 [received] PHST- 2023/06/01 00:00 [revised] PHST- 2023/06/24 00:00 [accepted] PHST- 2023/11/06 06:42 [medline] PHST- 2023/09/01 00:42 [pubmed] PHST- 2023/08/31 22:00 [entrez] AID - S1078-1439(23)00226-0 [pii] AID - 10.1016/j.urolonc.2023.06.012 [doi] PST - ppublish SO - Urol Oncol. 2023 Oct;41(10):433.e1-433.e7. doi: 10.1016/j.urolonc.2023.06.012. Epub 2023 Aug 29. PMID- 37647883 OWN - NLM STAT- MEDLINE DCOM- 20240404 LR - 20240406 IS - 1423-0232 (Electronic) IS - 0030-2414 (Print) IS - 0030-2414 (Linking) VI - 102 IP - 4 DP - 2024 TI - Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes. PG - 337-342 LID - 10.1159/000533410 [doi] AB - INTRODUCTION: The aim was to investigate the risk factors for recurrence after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to provide a basis for clinical prevention of recurrence of NMIBC. METHODS: From January 2012 to December 2020, 592 patients with NMIBC who underwent TURBT attending the Second Affiliated Hospital of Xi'an Jiaotong University were retrospectively included in this study. Patients were divided into relapse and relapse-free groups according to whether relapse occurred within 2 years. Ultimately, 72 patients were included in the relapse group and 350 patients were included in the relapse-free group. Observation indicators included age, sex, smoking, underlying disease (hypertension, diabetes, coronary heart disease), two or more lesions, tumor size, hematuria, pathology grading (low, medium, high), staging (Ta, T1), muscular invasion in initial pathology, tumor base (sessile, pedunculated), use of intravesical drug (pirarubicin, bacillus Calmette-Guerin [BCG], mitomycin, hydroxycamptothecin, gemcitabine). RESULTS: In this study, the 2-year recurrence rate of NMIBC patients after TURBT was 17.06%. There were significant differences in comparison of pirarubicin, BCG, and mitomycin treatment between the two groups (p < 0.05). To avoid missing risk factors for recurrence, factors with p < 0.1 were analyzed. The results of univariate logistic regression analysis showed that NMIBC patients with BCG treatment (OR = 5.088, 95% CI = 1.444-17.73, p = 0.012), high pathology grading (OR = 0.415, 95% CI = 0.197-0.880, p = 0.023), T1 stage (OR = 2.097, 95% CI = 0.996-4.618, p = 0.059), mitomycin treatment (OR = 5.029, 95% CI = 1.149-21.77, p = 0.031), and pirarubicin treatment (OR = 1.794, 95% CI = 1.079-3.030, p = 0.024) had significantly higher risk of recurrence within 2 years after TURBT. The results of multivariate logistic regression analysis showed that NMIBC patients with high pathology grading (OR = 0.4030, 95% CI = 0.1702-0.8426, p = 0.0241), pirarubicin treatment (OR = 1.961, 95% CI = 1.159-3.348, p = 0.0125), and BCG treatment (OR = 6.201, 95% CI = 1.275-29.73, p = 0.0190) had significantly higher risk of recurrence within 2 years after TURBT. CONCLUSION: Our study highlights the importance of postoperative surveillance and individualized treatment for patients with NMIBC. Our findings show that high pathology grading, pirarubicin treatment, and BCG treatment are independent risk factors for recurrence after TURBT in patients with NMIBC. However, caution is warranted when interpreting our findings due to the small sample size and the need for further research to confirm the negative impact of mitomycin and BCG on recurrence rates. CI - (c) 2023 S. Karger AG, Basel. FAU - Li, Hecheng AU - Li H AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Li AU - Wang L AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Li, Hongliang AU - Li H AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Li, Zhaolun AU - Li Z AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Xue, Li AU - Xue L AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Zhenlong AU - Wang Z AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Fu, Delai AU - Fu D AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Chen, Qi AU - Chen Q AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Luo, Qidong AU - Luo Q AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Chong, Tie AU - Chong T AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Ziming AU - Wang Z AD - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Journal Article DEP - 20230830 PL - Switzerland TA - Oncology JT - Oncology JID - 0135054 RN - D58G680W0G (pirarubicin) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) RN - 80168379AG (Doxorubicin) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Follow-Up Studies MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - Transurethral Resection of Bladder MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology MH - Mitomycin/therapeutic use MH - Risk Factors MH - Recurrence MH - Neoplasm Invasiveness MH - Doxorubicin/*analogs & derivatives PMC - PMC10994582 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Recurrence OT - Risk factors OT - Transurethral resection of bladder tumor COIS- The authors declare that they have no competing interests. EDAT- 2023/08/31 00:41 MHDA- 2024/04/04 06:44 PMCR- 2023/08/30 CRDT- 2023/08/30 18:24 PHST- 2023/05/10 00:00 [received] PHST- 2023/07/29 00:00 [accepted] PHST- 2024/04/04 06:44 [medline] PHST- 2023/08/31 00:41 [pubmed] PHST- 2023/08/30 18:24 [entrez] PHST- 2023/08/30 00:00 [pmc-release] AID - 000533410 [pii] AID - 533410 [pii] AID - 10.1159/000533410 [doi] PST - ppublish SO - Oncology. 2024;102(4):337-342. doi: 10.1159/000533410. Epub 2023 Aug 30. PMID- 37640572 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 11 DP - 2023 Nov TI - Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy. PG - 456.e13-456.e20 LID - S1078-1439(23)00264-8 [pii] LID - 10.1016/j.urolonc.2023.08.003 [doi] AB - OBJECTIVES: To characterize the treatments received by muscle-invasive bladder cancer (MIBC) patients, analyze their use according to sociodemographic, clinical, pathologic, and facility variables, and identify possibilities for improvement in care, with the understanding that patients with MIBC face a potentially lethal disease, yet often do not receive guideline-concordant potentially curative therapies. MATERIALS AND METHODS: Using the National Cancer Data Base (NCDB), we analyzed 102,119 patients with MIBC diagnosed from 2009 to 2018. Treatments included cystectomy, radiation, chemotherapy (CT), or observation. Treatments including cystectomy or radiotherapy (RT) >/=50 Gy were considered aggressive therapy (AT). A multivariable generalized estimating equation model was used to assess the impact of the independent variables with receiving AT, using SAS version 9.4. RESULTS: The median age was 73 years, with 72.9% male, 84.3% White, and 7.1% Black. Stage distribution was 59.4% stage II, 23.0% stage III, and 17.6% stage IV. Overall, 55.2% of patients received AT, while 41.1% did not, with 26.6% receiving observation alone after transurethral resection of bladder tumor. 45.4% received cystectomy, 9.8% received RT, and 12.8% received CT as primary treatment. Notably, over 30% of patients ages 50 to 70 did not receive aggressive therapy. On multivariate analysis, factors associated with nonreceipt of AT included age >70 (OR < 0.79, P < 0.0001), Black race (OR 0.70, P < 0.0001), underinsured status (OR 0.62, P < 0.0001), high comorbidity (OR 0.74, P < 0.0001), and treatment at low volume (OR 0.72 P < 0.0001) or nonacademic cancer program (OR 0.54, P < 0.0001). Long-term trends included increases in utilization of perioperative CT (17.5% in 2009 to 46.7% in 2018, P < 0.001), and chemoradiation (5.4% in 2009 to 8.8% in 2018, P < 0.001). Using Cox regression analysis to control for confounding variables, receipt of aggressive therapy was associated with improved overall survival. CONCLUSIONS: Over a third of patients did not receive AT for MIBC, with many of these patients seemingly eligible by age and comorbidity status. Prospective studies are needed to determine why these patients do not receive AT. A better understanding of patient vs. access to care vs. provider factors will help to focus efforts to improve care for MIBC patients. CI - Published by Elsevier Inc. FAU - Moon, Sol AU - Moon S AD - Department of Urology, University of Alabama Birmingham, Birmingham, AL. FAU - Pandya, Vishruti AU - Pandya V AD - Department of Medicine, Division of Preventive Medicine, University of Alabama Birmingham, Birmingham, AL. FAU - McDonald, Andrew AU - McDonald A AD - Department of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL; Institute for Cancer Outcomes and Survivorship, University of Alabama Birmingham, Birmingham, AL. FAU - Basu, Arnab AU - Basu A AD - Department of Medicine, Division of Hematology-Oncology, University of Alabama Birmingham, Birmingham, AL. FAU - Bae, Sejong AU - Bae S AD - Department of Medicine, Division of Preventive Medicine, University of Alabama Birmingham, Birmingham, AL; O'Neal Comprehensive Cancer Center, Birmingham, AL. FAU - Ferguson, James E 3rd AU - Ferguson JE 3rd AD - Department of Urology, University of Alabama Birmingham, Birmingham, AL; Birmingham Veterans Affairs Medical Center, Birmingham, AL; O'Neal Comprehensive Cancer Center, Birmingham, AL. Electronic address: jferguson@uabmc.edu. LA - eng PT - Journal Article DEP - 20230826 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - Neoplasm Staging MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Cystectomy MH - Muscles/pathology OTO - NOTNLM OT - Bladder cancer OT - Cystectomy, Disparities COIS- Declaration of Competing Interest None. EDAT- 2023/08/29 00:42 MHDA- 2023/12/05 12:41 CRDT- 2023/08/28 21:56 PHST- 2023/02/14 00:00 [received] PHST- 2023/06/20 00:00 [revised] PHST- 2023/08/04 00:00 [accepted] PHST- 2023/12/05 12:41 [medline] PHST- 2023/08/29 00:42 [pubmed] PHST- 2023/08/28 21:56 [entrez] AID - S1078-1439(23)00264-8 [pii] AID - 10.1016/j.urolonc.2023.08.003 [doi] PST - ppublish SO - Urol Oncol. 2023 Nov;41(11):456.e13-456.e20. doi: 10.1016/j.urolonc.2023.08.003. Epub 2023 Aug 26. PMID- 37637042 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230829 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor. PG - 1180888 LID - 10.3389/fonc.2023.1180888 [doi] LID - 1180888 AB - INTRODUCTION: Body status, categorized as sarcopenia or obesity and assessed using body mass index and body composition, affects the outcome of bladder cancer patients. However, studies comparing disease progression, recurrence, or overall survival in patients with non-muscle-invasive bladder cancer (NMIBC) with different body compositions are lacking. Therefore, we conducted a retrospective study to identify the impact of body composition, sarcopenia, and obesity on the oncological prognosis of patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) with Bacillus Calmette-Guerin (BCG) intravesical instillation (IVI). METHODS: Patients with NMIBC who had undergone TURBT with adjuvant IVI with BCG from March 2005 to April 2021 were included. Body composition parameters were evaluated using computed tomography images of the third lumbar vertebrae and further categorized by sarcopenia and obesity. Oncological outcomes including recurrence-free survival (RFS), progression-free survival, and overall survival (OS) after treatment were analyzed. RESULTS: A total of 269 patients were enrolled. Subcutaneous adipose tissue (SAT) density was a significant predictor of RFS, whereas psoas muscle density was a significant predictor of OS in the multivariate analysis. Patients with sarcopenia but without obesity tolerated significantly fewer BCG IVIs than patients without sarcopenia or obesity. Patients with sarcopenia had poorer RFS and OS than those without sarcopenia. In contrast, patients with obesity had better OS than those without obesity. DISCUSSION: Body composition parameters, including SAT density and psoas muscle density, emerged as significant predictors of OS and RFS, respectively. Hence, our findings indicate that body composition is a helpful measurement to assess the oncological outcomes of patients with NMIBC. CI - Copyright (c) 2023 Huang, Lin, Chuang, Chuang, Pang, Wu, Chang, Yu, Lin, Kan, Chu, Hung, Hsieh and Shao. FAU - Huang, Liang-Kang AU - Huang LK AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Lin, Yu-Ching AU - Lin YC AD - Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan. FAU - Chuang, Hai-Hua AU - Chuang HH AD - Department of Family Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chuang, Cheng-Keng AU - Chuang CK AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Pang, See-Tong AU - Pang ST AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Wu, Chun-Te AU - Wu CT AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chang, Ying-Hsu AU - Chang YH AD - Department of Urology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei, Taiwan. FAU - Yu, Kai-Jie AU - Yu KJ AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Lin, Po-Hung AU - Lin PH AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Kan, Hung-Cheng AU - Kan HC AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chu, Yuan-Cheng AU - Chu YC AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hung, Wei-Kang AU - Hung WK AD - College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Hsieh, Ming-Li AU - Hsieh ML AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Shao, I-Hung AU - Shao IH AD - Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20230810 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10448957 OTO - NOTNLM OT - bladder cancer OT - body composition OT - intravesical instillation OT - non-muscle-invasive bladder cancer OT - obesity OT - sarcopenia OT - transurethral resection COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/08/28 06:43 MHDA- 2023/08/28 06:44 PMCR- 2023/01/01 CRDT- 2023/08/28 04:43 PHST- 2023/03/06 00:00 [received] PHST- 2023/07/07 00:00 [accepted] PHST- 2023/08/28 06:44 [medline] PHST- 2023/08/28 06:43 [pubmed] PHST- 2023/08/28 04:43 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1180888 [doi] PST - epublish SO - Front Oncol. 2023 Aug 10;13:1180888. doi: 10.3389/fonc.2023.1180888. eCollection 2023. PMID- 37636200 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240923 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 4 IP - 5 DP - 2023 Sep TI - Comparing different pneumoperitoneum (12 vs. 15 mmHg) pressures with cytokine analysis to evaluate clinical outcomes in patients undergoing robotic-assisted laparoscopic radical cystectomy and intracorporeal robotic urinary diversion. PG - 575-583 LID - 10.1002/bco2.240 [doi] AB - BACKGROUND: Robotic cystectomy is the mainstay surgical intervention for treatment-refractory nonmuscle-invasive and muscle-invasive bladder cancer. However, paralytic ileus may complicate the postoperative recovery and may be a consequence of an inflammatory response associated with transient gut ischaemia. We have therefore investigated clinical, operative and inflammatory biomarker associations between paralytic ileus in the context of robotic cystectomy and intracorporeal ileal conduit urinary diversion. METHODS: Prospective consective patients referred for robotic cystectomy were consented and included in the study, while patients >75 years old and converted to open procedure were excluded. The pneumoperitoneum pressure (PP) for carbon dioxide insufflation required to perform the procedure efficiently and safely was recorded (12 or 15 mmHg). We also recorded the postoperative days patients passed flatus and stools, whether they developed ileus, as well as other standard clinical and demographic data. The expression of select proinflammatory and anti-inflammatory cytokines was determined by multiplex analysis using a cytometric bead array with changes in profiles correlated with the pressures applied and with the existence of an ileus. RESULTS: Twenty-seven patients were recruited, but only 20 were used in the study with 10 patients in each PP group. Seven patients were excluded all of whom had an extracorporeal ileal conduit formation. There were differences in the 40-min shorter operative time and 1 day shorter length of stay, as well as passing flatus 1 day and stools 1.5 days earlier in the 12 mmHg compared with the 15 mmHg group. More patients had ileus in the 15 mmHg group vs 12 mmHg group (30% vs. 10.0%). These were not statistically significant. Similarly, there were no statistical differences in the expression of proinflammatory cytokines at the two different pressures or between patient groups, but there were outliers, with the median indicating nonsymmetrical distribution. By comparison, anti-inflammatory cytokines showed some significant differences between groups, with IL-6 and IL-10 showing elevated levels postsurgery. No statistical difference was observed between pressures or the existence of an ileus, but the maximum levels of IL-6 and IL-10 detected in some patients reflect a pressure difference. CONCLUSIONS: The initial findings of this novel scientific study indicated a higher risk of paralytic ileus postrobotic cystectomy and robotic intracorporeal urinary diversion when a higher pressure of 15 mmHg is used compared with 12 mmHg. Although further studies are required to establish the linkage between cytokine profile expression, pressure and ileus, our initial data reinforces the advantages of lower pressure robotic cystectomy and intracorporeal urinary diversion in patient outcomes. CI - (c) 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Vasdev, Nikhil AU - Vasdev N AUID- ORCID: 0000-0002-3966-5734 AD - Department of Urology, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. AD - School of Life and Medical Sciences University of Hertfordshire Hatfield UK. FAU - Martin, Naomi AU - Martin N AD - Faulty of Health and Life Sciences De Montfort University Leicester UK. AD - Department of Respiratory Sciences University of Leicester Leicester UK. FAU - Hackney, Amon B AU - Hackney AB AD - Department of Respiratory Sciences University of Leicester Leicester UK. FAU - Piedad, John AU - Piedad J AD - Department of Urology, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Hampson, Alexander AU - Hampson A AUID- ORCID: 0000-0003-3517-2534 AD - Department of Urology, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Shan, Gowrie-Mohan AU - Shan GM AD - Department of Anaesthetics, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Prasad, Venkat AU - Prasad V AD - Department of Anaesthetics, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Chilvers, Michael AU - Chilvers M AD - Department of Anaesthetics, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Ebon, Martin AU - Ebon M AD - Department of Research, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Smith, Philip AU - Smith P AD - Department of Research, Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK. FAU - Tegan, Gary AU - Tegan G AD - Research and Development CONMED Corporation Largo Florida USA. FAU - Decaestecker, Karel AU - Decaestecker K AUID- ORCID: 0000-0003-0767-940X AD - Department of Urology Maria Middelares General Hospital Ghent Belgium. AD - Department of Urology Ghent University Hospital Ghent Belgium. FAU - Baydoun, Anwar AU - Baydoun A AUID- ORCID: 0000-0002-9701-2985 AD - Department of Respiratory Sciences University of Leicester Leicester UK. LA - eng PT - Journal Article DEP - 20230411 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC10447212 OTO - NOTNLM OT - cytokines OT - patient outcomes OT - robotic surgery OT - robotic urinary diversion COIS- The authors declare no conflicts of interest. EDAT- 2023/08/28 06:42 MHDA- 2023/08/28 06:43 PMCR- 2023/04/11 CRDT- 2023/08/28 04:32 PHST- 2022/11/24 00:00 [received] PHST- 2023/03/05 00:00 [revised] PHST- 2023/03/17 00:00 [accepted] PHST- 2023/08/28 06:43 [medline] PHST- 2023/08/28 06:42 [pubmed] PHST- 2023/08/28 04:32 [entrez] PHST- 2023/04/11 00:00 [pmc-release] AID - BCO2240 [pii] AID - 10.1002/bco2.240 [doi] PST - epublish SO - BJUI Compass. 2023 Apr 11;4(5):575-583. doi: 10.1002/bco2.240. eCollection 2023 Sep. PMID- 37632533 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20261010 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 483 IP - 5 DP - 2023 Nov TI - Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma. PG - 621-634 LID - 10.1007/s00428-023-03625-3 [doi] AB - The World Health Organization/International Society of Urological Pathology (2022 WHO/ISUP) classification categorizes noninvasive carcinomas based on the highest grade observed in a pathology sample. According to this classification, a lesion is classified as mixed-grade (MG) if the highest-grade component comprises less than 5% high-grade (HG) carcinoma [14]. This study included 160 cases of low-grade papillary urothelial carcinoma (LGUC) and 160 cases of HG papillary urothelial carcinoma (HGUC), selected randomly. In addition, 160 consecutive and unselected cases of MG papillary urothelial carcinoma (MGUC) were obtained from all bladder transurethral resection specimens diagnosed with papillary urothelial carcinoma between January 2007 and January 2021. The results of the multivariate analysis showed that histologic grade, invasion of the lamina propria, and the presence of carcinoma in situ at presentation were independent prognostic parameters regarding recurrence-free survival (p = 0.002; hazard ratio (HR) = 1.44, 95% confidence interval (CI) = 1.059-1.956, p = 0.02; and HR = 1.76, 95% CI = 1.159-2.684, p = 0.008, respectively). Histologic grade was the only independent prognostic parameter of disease-specific survival (DSS) (p < 0.001). Comparisons between non-muscle invasive (NMI) MGUC and NMI LGUC, as well as between NMI MGUC and NMI HGUC, revealed statistically significant differences in terms of DSS (HR = 0.07, 95% CI = 0.024-0.252, p < 0.001 and HR = 1.59, 95% CI = 1.023-2.460, p = 0.039, respectively). Our study findings demonstrate statistically significant differences regarding DSS between NMI MGUC and NMI HGUC, as well as between NMI MGUC and NMI LGUC. Therefore, we suggested that considering the presence of less than 5% MGUC as a separate category may be appropriate. However, it is important to validate our results in larger cohorts with longer follow-up periods to establish the clinical significance of MGUC and provide guidance for patient management. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kir, Gozde AU - Kir G AD - Pathology Department, Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Dr.Erkin Caddesi, Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Patoloji Laboratuari, 34720, Kadikoy, Istanbul, Turkey. gozkir@yahoo.com. FAU - Cecikoglu, Gozde Ecem AU - Cecikoglu GE AD - Pathology Department, Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Fahrettin Kerim Gokay Caddesi, 34722, Kadikoy, Istanbul, Turkey. FAU - Topal, Cumhur Selcuk AU - Topal CS AD - Pathology Department, Umraniye Training and Research Hospital, Elmalikent Mahallesi, Adem Yavuz Cad. No:1, 34764, Umraniye, Istanbul, Turkey. FAU - Sorkun, Muhammet Huseyin AU - Sorkun MH AD - Istanbul Medeniyet University, Dumlupinar D100 No: 98, 34720, Kadikoy, Istanbul, Turkey. FAU - Culpan, Meftun AU - Culpan M AD - Urology Department, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, Fahrettin Kerim Gokay Caddesi, Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi Patoloji Laboratuvari, 34722, Kadikoy, Istanbul, Turkey. FAU - Suceken, Ferhat Yakup AU - Suceken FY AD - Urology Department, Umraniye Training and Research Hospital, Elmalikent Mahallesi, Adem Yavuz Cad. No:1, 34764, Umraniye, Istanbul, Turkey. FAU - Karaca, Hakan AU - Karaca H AD - Urology Department, Umraniye Training and Research Hospital, Elmalikent Mahallesi, Adem Yavuz Cad. No:1, 34764, Umraniye, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Urology Department, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, Fahrettin Kerim Gokay Caddesi, Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi Patoloji Laboratuvari, 34722, Kadikoy, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20230826 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - *Carcinoma, Papillary/pathology MH - Cystectomy MH - *Carcinoma in Situ/surgery OTO - NOTNLM OT - High-grade OT - Low-grade OT - Mixed-grade OT - Survival OT - Urothelial carcinoma EDAT- 2023/08/27 05:42 MHDA- 2023/11/27 12:42 CRDT- 2023/08/26 11:03 PHST- 2023/03/26 00:00 [received] PHST- 2023/08/09 00:00 [accepted] PHST- 2023/07/18 00:00 [revised] PHST- 2023/11/27 12:42 [medline] PHST- 2023/08/27 05:42 [pubmed] PHST- 2023/08/26 11:03 [entrez] AID - 10.1007/s00428-023-03625-3 [pii] AID - 10.1007/s00428-023-03625-3 [doi] PST - ppublish SO - Virchows Arch. 2023 Nov;483(5):621-634. doi: 10.1007/s00428-023-03625-3. Epub 2023 Aug 26. PMID- 37627895 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230828 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 16 DP - 2023 Aug 9 TI - Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression. LID - 10.3390/diagnostics13162636 [doi] LID - 2636 AB - Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder cancer patients. The protein expression of HOXA13 and HOXB13 in formalin-fixed paraffin-embedded (FFPE) bladder cancer tissues was determined by immunohistochemistry (IHC) analysis. The association between HOXA13/HOXB13 protein expression and demographic/clinicopathological characteristics of the bladder cancer patients was determined by chi-square analysis. Approximately 63.6% of the bladder cancer tissues harbored high HOXA13 expression. High HOXA13 expression was significantly associated with non-muscle invasive bladder cancer, lower tumor grade, higher number of lymph node metastases, and recurrence risk. In contrast, low HOXB13 expression (including those with negative expression) was observed in 71.6% of the bladder cancer tissues analyzed. Low HOXB13 expression was significantly associated with muscle-invasive bladder cancer, higher tumor stage, tumor grade, and metastatic risk. Both HOXA13 and HOXB13 protein expression were found to be associated with bladder tumorigenesis. The putative oncogenic and tumor suppressive roles of HOXA13 and HOXB13, respectively, suggest their potential utility as biomarkers in bladder cancer. FAU - Chin, Fee-Wai AU - Chin FW AUID- ORCID: 0000-0002-4073-5461 AD - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia. FAU - Hussin, Huzlinda AU - Hussin H AUID- ORCID: 0000-0002-5136-4352 AD - Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia. FAU - Chau, De-Ming AU - Chau DM AD - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia. FAU - Ong, Teng-Aik AU - Ong TA AD - Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia. FAU - Yunus, Rosna AU - Yunus R AD - Department of Pathology, Hospital Kuala Lumpur, Kuala Lumpur 50586, Malaysia. FAU - Abdul Razack, Azad Hassan AU - Abdul Razack AH AD - Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia. FAU - Yusoff, Khatijah AU - Yusoff K AD - Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia. AD - Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Kajang 43000, Selangor, Malaysia. FAU - Chan, Soon-Choy AU - Chan SC AUID- ORCID: 0000-0001-6089-0111 AD - Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Kajang 43000, Selangor, Malaysia. AD - School of Liberal Arts, Science and Technology, Perdana University, Kuala Lumpur 50490, Malaysia. FAU - Veerakumarasivam, Abhi AU - Veerakumarasivam A AD - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia. AD - Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Kajang 43000, Selangor, Malaysia. AD - School of Medical and Life Sciences, Sunway University, Bandar Sunway 47500, Selangor, Malaysia. LA - eng GR - FRGS/2/2014/SKK01/PERDANA/03/01/Ministry of Higher Education/ GR - FP0514B0021-2 (DSTIN)/Ministry of Energy, Science, Technology, Environmental and Climate Change, Malaysia/ GR - UM.C/625/1/HIR/130/Ministry of Higher Education/ PT - Journal Article DEP - 20230809 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10453033 OTO - NOTNLM OT - HOXA13 OT - HOXB13 OT - biomarker OT - bladder cancer OT - immunohistochemistry COIS- The authors declare no conflict of interest. EDAT- 2023/08/26 10:41 MHDA- 2023/08/26 10:42 PMCR- 2023/08/09 CRDT- 2023/08/26 01:09 PHST- 2023/05/30 00:00 [received] PHST- 2023/07/02 00:00 [revised] PHST- 2023/07/08 00:00 [accepted] PHST- 2023/08/26 10:42 [medline] PHST- 2023/08/26 10:41 [pubmed] PHST- 2023/08/26 01:09 [entrez] PHST- 2023/08/09 00:00 [pmc-release] AID - diagnostics13162636 [pii] AID - diagnostics-13-02636 [pii] AID - 10.3390/diagnostics13162636 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Aug 9;13(16):2636. doi: 10.3390/diagnostics13162636. PMID- 37608369 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231121 IS - 1749-8546 (Print) IS - 1749-8546 (Electronic) IS - 1749-8546 (Linking) VI - 18 IP - 1 DP - 2023 Aug 22 TI - Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3beta/beta-catenin signaling pathways: a network pharmacology-directed experimental investigation. PG - 104 LID - 10.1186/s13020-023-00818-5 [doi] LID - 104 AB - PURPOSE: The combination of Xiaozheng decoction with postoperative intravesical instillation has been shown to improve the prognosis of bladder cancer patients and prevent recurrence. However, the mechanisms underlying the efficacy of this herbal formula remain largely unclear. This research aims to identify the important components of Xiaozheng decoction and explore their anti-bladder cancer effect and mechanism using network pharmacology-based experiments. METHODS: The chemical ingredients of each herb in the Xiaozheng decoction were collected from the Traditional Chinese Medicine (TCM) database. Network pharmacology was employed to predict the target proteins and pathways of action. Disease databases were utilized to identify target genes associated with bladder cancer. A Protein-Protein Interaction (PPI) network was constructed to illustrate the interaction with intersected target proteins. Key targets were identified using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis. A compound-target-pathway network was established after molecular docking predictions. In vitro experiments with bladder cancer cell lines were conducted using core chemical components confirmed by ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS) to verify the conclusions of network pharmacology. RESULTS: 45 active compounds were extracted, and their relationships with Traditional Chinese Medicines (TCMs) and protein targets were presented, comprising 7 herbs, 45 active compounds, and 557 protein targets. The intersection between potential TCM target genes and bladder cancer-related genes yielded 322 genes. GO and KEGG analyses indicated that these targets may be involved in numerous cancer-related pathways. Molecular docking results showed that candidate compounds except mandenol could form stable conformations with the receptor. In vitro experiments on three bladder cancer cell lines demonstrated that quercetin and two other impressive new compounds, bisdemethoxycurcumin (BDMC) and kumatakenin, significantly promoted cancer cell apoptosis through the B-cell lymphoma 2/Bcl-2-associated X (Bcl-2/BAX) pathway and inhibited proliferation and migration through the glycogen synthase kinase 3 beta (GSK3beta)/beta-catenin pathway. CONCLUSION: By employing network pharmacology and conducting in vitro experiments, the mechanism of Xiaozheng decoction's effect against bladder cancer was tentatively elucidated, and its main active ingredients and targets were identified, providing a scientific basis for future research. CI - (c) 2023. International Society for Chinese Medicine and BioMed Central Ltd. FAU - Zhuang, Jingming AU - Zhuang J AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Mo, Jiahang AU - Mo J AD - Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. FAU - Huang, Zhengnan AU - Huang Z AD - Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. FAU - Yan, Yilin AU - Yan Y AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Zeyi AU - Wang Z AD - Department of Urology, Shanghai General Hospital Affiliated to Nanjing Medical University, Shanghai, China. FAU - Cao, Xiangqian AU - Cao X AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yang, Chenkai AU - Yang C AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Shen, Bing AU - Shen B AUID- ORCID: 0000-0002-0952-2257 AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. urodrshenbing@shsmu.edu.cn. FAU - Zhang, Fang AU - Zhang F AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. medego@shsmu.edu.cn. LA - eng GR - 82072821/National Natural Science Foundation of China/ GR - 92059112/National Natural Science Foundation of China/ GR - 20SJKJGG250/Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation/ PT - Journal Article DEP - 20230822 PL - England TA - Chin Med JT - Chinese medicine JID - 101265109 PMC - PMC10464372 OTO - NOTNLM OT - Apoptosis OT - Bladder cancer OT - GSK3beta/beta-catenin OT - Network pharmacology OT - Xiaozheng decoction COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests. EDAT- 2023/08/23 06:42 MHDA- 2023/08/23 06:43 PMCR- 2023/08/22 CRDT- 2023/08/23 00:30 PHST- 2023/05/07 00:00 [received] PHST- 2023/08/12 00:00 [accepted] PHST- 2023/08/23 06:43 [medline] PHST- 2023/08/23 06:42 [pubmed] PHST- 2023/08/23 00:30 [entrez] PHST- 2023/08/22 00:00 [pmc-release] AID - 10.1186/s13020-023-00818-5 [pii] AID - 818 [pii] AID - 10.1186/s13020-023-00818-5 [doi] PST - epublish SO - Chin Med. 2023 Aug 22;18(1):104. doi: 10.1186/s13020-023-00818-5. PMID- 37578604 OWN - NLM STAT- MEDLINE DCOM- 20231012 LR - 20231113 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 30 IP - 12 DP - 2023 Nov TI - Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis. PG - 7892-7902 LID - 10.1245/s10434-023-14051-9 [doi] AB - BACKGROUND AND PURPOSE: Non-muscle-invasive bladder cancer (NMIBC) constitutes a heterogeneous group of tumors with different prognoses. This population-based study aimed to report real-world cancer-specific survival (CSS) of NMIBC and create a prognostic nomogram based on the identified risk factors. METHODS: The Surveillance, Epidemiology, and End Results database was searched for patients diagnosed with NMIBC from 2004 to 2015, who underwent transurethral resection of the bladder tumor. The dataset was divided into development and validation cohorts. Factors associated with CSS were identified using Cox proportional hazards and used to develop a prognostic nomogram. RESULTS: In total, 98,238 patients with NMIBC were included. At the median follow-up of 124 months (IQR 81-157 months), cancer-specific mortality (CSM) was highest for T1HG (19.52%), followed by Tis (15.56%), similar for T1LG and TaHG (10.88% and 9.23%, respectively), and lowest for TaLG (3.76%). Multivariable Cox regression for CSS prediction was utilized to develop a nomogram including the following risk factors: tumor T category and grade, age, tumor size and location, histology type, primary character, race, income, and marital status. In the validation cohort, the model was characterized by an AUC of 0.824 and C-index that reached 0.795. CONCLUSIONS: To conclude, NMIBC is associated with a significant risk of long-term CSM especially, but not only, in patients with T1HG. Rarely diagnosed TaHG and T1LG tumors should be regarded as high-risk due to approximately 10% CSM. T category, grading, and age remain the most powerful determinants of CSS in NMIBC, but sociodemographic factors might also influence its prognosis. CI - (c) 2023. The Author(s). FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological, and Functional Urology, Medical University of Warsaw, Warsaw, Poland. slusarczyk.aleksander@gmail.com. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological, and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological, and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Borkowski, Tomasz AU - Borkowski T AD - Department of General, Oncological, and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological, and Functional Urology, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20230814 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2023 Dec;30(13):8791-8792. doi: 10.1245/s10434-023-14355-w. PMID: 37777686 MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Nomograms MH - Risk Factors PMC - PMC10562346 OTO - NOTNLM OT - Age OT - Cancer-specific survival OT - Nomogram OT - Non-muscle-invasive bladder cancer OT - Stage COIS- The authors declare no conflict of interest. EDAT- 2023/08/14 12:42 MHDA- 2023/10/12 06:43 PMCR- 2023/08/14 CRDT- 2023/08/14 11:26 PHST- 2023/04/21 00:00 [received] PHST- 2023/07/06 00:00 [accepted] PHST- 2023/10/12 06:43 [medline] PHST- 2023/08/14 12:42 [pubmed] PHST- 2023/08/14 11:26 [entrez] PHST- 2023/08/14 00:00 [pmc-release] AID - 10.1245/s10434-023-14051-9 [pii] AID - 14051 [pii] AID - 10.1245/s10434-023-14051-9 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Nov;30(12):7892-7902. doi: 10.1245/s10434-023-14051-9. Epub 2023 Aug 14. PMID- 37569864 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20230814 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 15 DP - 2023 Aug 6 TI - Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. LID - 10.3390/ijms241512489 [doi] LID - 12489 AB - Bladder cancer and upper urothelial tract carcinoma are common diseases with a high risk of recurrence, thus necessitating follow-up after initial treatment. The management of non-muscle invasive bladder carcinoma (NMIBC) after transurethral resection involves surveillance, intravesical therapy, and cytology with cystoscopy. Urinary cytology, cystoscopy, and radiological evaluation of the upper urinary tract are recommended during follow-up in the international urological guidelines. Cystoscopy is the standard examination for the first assessment and follow-up of NMIBC, and urine cytology is a widely used urinary test with high sensitivity for high-grade urothelial carcinoma (HGUC) and carcinoma in situ (CIS). In recent years, various urinary assays, including DNA methylation markers, have been used to detect bladder tumors. Among these, the Bladder EpiCheck test is one of the most widely used and is based on analysis of the methylation profile of urothelial cells to detect bladder neoplasms. This review assesses the importance of methylation analysis and the Bladder EpiCheck test as urinary biomarkers for diagnosing urothelial carcinomas in patients in follow-up for NMIBC, helping cytology and cystoscopy in doubtful cases. A combined approach of cytology and methylation analysis is suggested not only to diagnose HGUC, but also to predict clinical and histological recurrences. FAU - Fiorentino, Vincenzo AU - Fiorentino V AUID- ORCID: 0000-0002-1132-1761 AD - Department of Human Pathology of the Adult and Developmental Age "G. Barresi", University of Messina, 98125 Messina, Italy. FAU - Pizzimenti, Cristina AU - Pizzimenti C AUID- ORCID: 0000-0002-4387-7174 AD - PhD Programme in Translational Molecular Medicine and Surgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy. FAU - Franchina, Mariausilia AU - Franchina M AD - Department of Human Pathology of the Adult and Developmental Age "G. Barresi", University of Messina, 98125 Messina, Italy. FAU - Rossi, Esther Diana AU - Rossi ED AD - Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy. FAU - Tralongo, Pietro AU - Tralongo P AD - Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy. FAU - Carlino, Angela AU - Carlino A AD - Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy. FAU - Larocca, Luigi Maria AU - Larocca LM AD - Department of Medicine and Surgery, Saint Camillus International University of Health and Medical Sciences (UniCamillus), 00131 Rome, Italy. FAU - Martini, Maurizio AU - Martini M AUID- ORCID: 0000-0002-6260-6310 AD - Department of Human Pathology of the Adult and Developmental Age "G. Barresi", University of Messina, 98125 Messina, Italy. FAU - Fadda, Guido AU - Fadda G AD - Department of Human Pathology of the Adult and Developmental Age "G. Barresi", University of Messina, 98125 Messina, Italy. FAU - Pierconti, Francesco AU - Pierconti F AD - Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230806 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/diagnosis/pathology MH - Urinary Bladder/pathology MH - Cystoscopy MH - Epithelial Cells/pathology MH - Urine PMC - PMC10420163 OTO - NOTNLM OT - bladder carcinoma OT - methylation OT - tumoral recurrence OT - urinary biomarkers COIS- The authors declare no conflict of interest. EDAT- 2023/08/12 10:46 MHDA- 2023/08/14 06:42 PMCR- 2023/08/06 CRDT- 2023/08/12 01:12 PHST- 2023/07/05 00:00 [received] PHST- 2023/08/01 00:00 [revised] PHST- 2023/08/04 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2023/08/12 10:46 [pubmed] PHST- 2023/08/12 01:12 [entrez] PHST- 2023/08/06 00:00 [pmc-release] AID - ijms241512489 [pii] AID - ijms-24-12489 [pii] AID - 10.3390/ijms241512489 [doi] PST - epublish SO - Int J Mol Sci. 2023 Aug 6;24(15):12489. doi: 10.3390/ijms241512489. PMID- 37566017 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20230815 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 12 IP - 15 DP - 2023 Jul 26 TI - Intratumoral PD1(+)CD38(+)Tim3(+) CD8(+) T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer. LID - 10.3390/cells12151939 [doi] LID - 1939 AB - Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is a standard of care therapy for non-muscle invasive bladder cancer (NMIBC), which accounts for about 75% of newly diagnosed urothelial cancer. However, given the frequent recurrence and progression, identification of a pre-treatment biomarker capable of predicting responsiveness to BCG in NMIBC is of utmost importance. Herein, using multiparametric flow cytometry, we characterized CD8(+) T cells from peripheral blood and tumor tissues collected from 27 pre-BCG patients bearing NMIBC to obtain immune correlates of bladder cancer prognosis and responsiveness to BCG therapy. We observed that intratumoral CD8(+) T cell subsets were highly heterogenous in terms of their differentiation state and exist at different proportions in tumor tissues. Remarkably, among the different CD8(+) T cell subsets present in the tumor tissues, the frequency of the terminally exhausted-like CD8(+) T cell subset, marked as PD1(+)CD38(+)Tim3(+) CD8(+) T cells, was inversely correlated with a favorable outcome for patients and a responsiveness to BCG therapy. Moreover, we also noted that the intratumoral abundance of the progenitor exhausted-like PD1(+)CD8(+) T cell subset in pre-BCG NMIBC tumor tissues was indicative of better recurrence-free survival after BCG. Collectively, our study led to the identification of biomarkers that can predict the therapeutic responsiveness of BCG in NMIBC. FAU - Basak, Debashree AU - Basak D AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. AD - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. FAU - Mondal, Soumya AU - Mondal S AUID- ORCID: 0000-0002-5023-7773 AD - Department of Urology, IPGME&R and SSKM Hospital, Kolkata 700020, India. FAU - Srivastava, Swadeep Kumar AU - Srivastava SK AD - Department of Urology, IPGME&R and SSKM Hospital, Kolkata 700020, India. FAU - Sarkar, Deborpita AU - Sarkar D AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. FAU - Sarkar, Ishita AU - Sarkar I AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. AD - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. FAU - Basu, Sukanya AU - Basu S AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. FAU - Bhoumik, Arpita AU - Bhoumik A AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. FAU - Chowdhury, Snehanshu AU - Chowdhury S AUID- ORCID: 0000-0002-7114-4656 AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. AD - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. FAU - Pal, Dilip Kumar AU - Pal DK AD - Department of Urology, IPGME&R and SSKM Hospital, Kolkata 700020, India. FAU - Chatterjee, Shilpak AU - Chatterjee S AUID- ORCID: 0000-0002-8428-6434 AD - Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India. AD - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230726 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (BCG Vaccine) RN - 0 (Hepatitis A Virus Cellular Receptor 2) SB - IM MH - Humans MH - *BCG Vaccine/therapeutic use MH - CD8-Positive T-Lymphocytes/pathology MH - Hepatitis A Virus Cellular Receptor 2 MH - Immunotherapy MH - *Non-Muscle Invasive Bladder Neoplasms/drug therapy/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC10416886 OTO - NOTNLM OT - BCG immunotherapy OT - CD8+ T cells OT - biomarker OT - non-muscle invasive bladder cancer OT - prognosis COIS- The authors declare no conflict of interest. EDAT- 2023/08/11 12:42 MHDA- 2023/08/14 06:42 PMCR- 2023/07/26 CRDT- 2023/08/11 10:43 PHST- 2023/03/10 00:00 [received] PHST- 2023/05/09 00:00 [revised] PHST- 2023/06/06 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2023/08/11 12:42 [pubmed] PHST- 2023/08/11 10:43 [entrez] PHST- 2023/07/26 00:00 [pmc-release] AID - cells12151939 [pii] AID - cells-12-01939 [pii] AID - 10.3390/cells12151939 [doi] PST - epublish SO - Cells. 2023 Jul 26;12(15):1939. doi: 10.3390/cells12151939. PMID- 37548555 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20260316 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 210 IP - 4 DP - 2023 Oct TI - Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). PG - 619-629 LID - 10.1097/JU.0000000000003645 [doi] AB - PURPOSE: Low-grade intermediate-risk nonmuscle-invasive bladder cancer is a chronic illness commonly treated by repetitive transurethral resection of bladder tumor. We compared the efficacy and safety of intravesical chemoablation with UGN-102 (a reverse thermal gel containing mitomycin), with or without subsequent transurethral resection of bladder tumor, to transurethral resection of bladder tumor alone in patients with low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: This prospective, randomized, phase 3 trial recruited patients with new or recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer to receive initial treatment with either UGN-102 once weekly for 6 weeks or transurethral resection of bladder tumor. Patients were followed quarterly by endoscopy, cytology, and for-cause biopsy. The primary end point was disease-free survival. All patients were followed for adverse events. RESULTS: Trial enrollment was halted by the sponsor to pursue an alternative development strategy after 282 of a planned 632 patients were randomized to UGN-102 +/- subsequent transurethral resection of bladder tumor (n=142) or transurethral resection of bladder tumor monotherapy (n=140), rendering the trial underpowered to perform hypothesis testing. Patients were predominantly male and >/=65 years of age. Tumor-free complete response 3 months after initial treatment was achieved by 92 patients (65%) who received UGN-102 and 89 patients (64%) treated by transurethral resection of bladder tumor. The estimated probability of disease-free survival 15 months after randomization was 72% for UGN-102 +/- transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (hazard ratio 0.45). The most common adverse events (incidence >/=10%) in the UGN-102 group were dysuria, micturition urgency, nocturia, and pollakiuria. CONCLUSIONS: Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation. FAU - Prasad, Sandip M AU - Prasad SM AD - Morristown Medical Center/Atlantic Health System and Garden State Urology, Morristown, New Jersey. FAU - Huang, William C AU - Huang WC AD - NYU Langone Urology Associates, New York, New York. FAU - Shore, Neal D AU - Shore ND AD - Carolina Urologic Research Center, Myrtle Beach, South Carolina. FAU - Hu, Brian AU - Hu B AD - The Department of Urology, Loma Linda University, Loma Linda, California. FAU - Bjurlin, Marc AU - Bjurlin M AD - The Department of Urology, University of North Carolina, Chapel Hill, North Carolina. FAU - Brown, Gordon AU - Brown G AD - New Jersey Urology, Cherry Hill, New Jersey. FAU - Genov, Pencho AU - Genov P AD - Department of Urology, University Multiprofile Hospital for Active Treatment "Kanev," Ruse, Bulgaria. FAU - Shishkov, Dimitar AU - Shishkov D AD - Department of Urology, University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria. FAU - Khuskivadze, Alexandre AU - Khuskivadze A AD - Urology Department, LTD Gidmedi, Tbilisi, Georgia. FAU - Ganev, Tosho AU - Ganev T AD - Urology Clinic, Multiprofile Hospital for Active Treatment "Sveta Anna," Varna, Bulgaria. FAU - Marchev, Dobri AU - Marchev D AD - Department of Urology Multiprofile Hospital for Active Treatment-Shumen, Shumen, Bulgaria. FAU - Orlov, Igor AU - Orlov I AD - Department of Urology, St Luka Clinical Hospital, Saint Petersburg, Russia. FAU - Kopyltsov, Evgeny AU - Kopyltsov E AD - Department of Urology and Oncology, Clinical Oncology Center, Omsk, Russia. FAU - Zubarev, Vadim AU - Zubarev V AD - Department of Urology, Medical and Sanitary Unit 70 of Passazhiravtotrans, Saint Petersburg, Russia. FAU - Nosov, Alexander AU - Nosov A AD - Oncourology Department, NN Petrov National Medical Research Center of Oncology, Leningrad, Russia. FAU - Komlev, Dmitrii AU - Komlev D AD - Medical Center for Diagnostics and Prevention Plus, Yaroslavl, Russia. FAU - Burger, Brent AU - Burger B AD - UroGen Pharma, Princeton, New Jersey. FAU - Raju, Sunil AU - Raju S AD - UroGen Pharma, Princeton, New Jersey. FAU - Meads, Andrew AU - Meads A AD - UroGen Pharma, Princeton, New Jersey. FAU - Schoenberg, Mark AU - Schoenberg M AD - UroGen Pharma, Princeton, New Jersey. AD - The Department of Urology, The Albert Einstein College of Medicine & The Montefiore Medical Center, Bronx, New York. LA - eng SI - ClinicalTrials.gov/NCT04688931 PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20230807 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 50SG953SK6 (Mitomycin) SB - IM CIN - J Urol. 2024 Mar;211(3):482-483. doi: 10.1097/JU.0000000000003815. PMID: 38329052 CIN - Transl Androl Urol. 2024 Apr 30;13(4):639-642. doi: 10.21037/tau-23-563. PMID: 38721284 CIN - Transl Androl Urol. 2024 Apr 30;13(4):647-649. doi: 10.21037/tau-23-569. PMID: 38721287 MH - Humans MH - Male MH - Female MH - Prospective Studies MH - *Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Urologic Surgical Procedures MH - Mitomycin/therapeutic use MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology PMC - PMC12721658 OTO - NOTNLM OT - ablation techniques OT - clinical trial OT - mitomycin OT - non-muscle invasive bladder neoplasms OT - phase III COIS- Conflict of Interest: GB: Astellas, Speakers Bureau, Consultancy; Janssen: Speakers Bureau, Consultancy; Bayer: Speakers Bureau, Consultancy, Ad Boards; Pfizer: Consultancy, Ad Boards, Lecture Bureau. EDAT- 2023/08/07 13:09 MHDA- 2023/09/11 06:42 PMCR- 2025/12/22 CRDT- 2023/08/07 09:54 PHST- 2023/09/11 06:42 [medline] PHST- 2023/08/07 13:09 [pubmed] PHST- 2023/08/07 09:54 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - JU-23-1115 [pii] AID - 10.1097/JU.0000000000003645 [doi] PST - ppublish SO - J Urol. 2023 Oct;210(4):619-629. doi: 10.1097/JU.0000000000003645. Epub 2023 Aug 7. PMID- 37543821 OWN - NLM STAT- MEDLINE DCOM- 20230807 LR - 20250503 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 102 IP - 31 DP - 2023 Aug 4 TI - Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade non-muscle-invasive bladder cancer who underwent radical cystectomy. PG - e34501 LID - 10.1097/MD.0000000000034501 [doi] LID - e34501 AB - Patients with non-muscle-invasive bladder cancer (NMIBC) who are at high and very high risk of disease progression are recommended for radical cystectomy (RC). However, the impact of neoadjuvant chemotherapy (NAC) on survival outcomes in NMIBC patients undergoing RC remains unclear. Patients diagnosed with T1 high-grade NMIBC who underwent RC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) was assessed using the Kaplan-Meier technique, and multivariable Cox regression analysis was conducted to determine the independent factors of OS. A total of 1268 T1 high-grade NMIBC patients who underwent RC between 2004 and 2015 were included in the study. NAC was administered to 76 (6.0%) patients. At a median follow-up of 75 months, there was no significant difference in the OS between the NAC and non-NAC groups (HR = 0.89, 95% CI 0.61-1.30, P = .539). However, in the multivariate Cox regression model, NAC demonstrated a more pronounced improvement in OS approaching statistical significance (HR = 0.7, 95% CI 0.47-1.05, P = .088). Subgroup analysis revealed a survival benefit of NAC in patients with lymph node metastasis. In summary, the results of this study suggest that NAC has the potential to confer a survival advantage in patients diagnosed with T1 high-grade NMIBC who undergo RC, but additional studies are needed. Nonetheless, the survival benefits of NAC in patients with lymph node involvement are apparent. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Huang, Long AU - Huang L AD - Department of Urology, Chengdu, China. FAU - Jia, Kang AU - Jia K FAU - Yao, Kai AU - Yao K FAU - Liu, Dongliang AU - Liu D FAU - Xu, Yan AU - Xu Y FAU - Liu, Quanda AU - Liu Q AUID- ORCID: 0009-0009-6809-7324 LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Cystectomy/methods MH - Neoadjuvant Therapy/methods MH - *Non-Muscle Invasive Bladder Neoplasms MH - Disease-Free Survival MH - Kaplan-Meier Estimate MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Retrospective Studies PMC - PMC10402986 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2023/08/06 07:41 MHDA- 2023/08/07 06:42 PMCR- 2023/08/04 CRDT- 2023/08/06 01:53 PHST- 2023/08/07 06:42 [medline] PHST- 2023/08/06 07:41 [pubmed] PHST- 2023/08/06 01:53 [entrez] PHST- 2023/08/04 00:00 [pmc-release] AID - 00005792-202308040-00064 [pii] AID - 10.1097/MD.0000000000034501 [doi] PST - ppublish SO - Medicine (Baltimore). 2023 Aug 4;102(31):e34501. doi: 10.1097/MD.0000000000034501. PMID- 37543464 OWN - NLM STAT- MEDLINE DCOM- 20240910 LR - 20260821 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 5 DP - 2023 Oct TI - En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. PG - 508-515 LID - S2588-9311(23)00154-2 [pii] LID - 10.1016/j.euo.2023.07.010 [doi] AB - BACKGROUND: En bloc transurethral resection of the bladder (eTURB) might improve the surgical management of non-muscle-invasive bladder cancer (NMIBC) in comparison to conventional TURB (cTURB). OBJECTIVE: To evaluate whether eTURB is superior to cTURB in resection of NMIBC and specimen retrieval. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, multicenter trial in patients with up to three cTa-T1 NMIBC tumors of 1-3 cm in size, who were enrolled from January 2019 to January 2022. INTERVENTION: Participants were randomized 1:1 to undergo eTURB (n = 192) or cTURB (n = 192). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the prevalence of detrusor muscle (DM) in the specimen retrieved. Secondary endpoints included bladder perforation, persistent disease at second-look TURB, positive lateral resection margin, positive deep resection margin, operation time, perforation rate, obturator reflex, conversion from eTURB to cTURB, recurrence-free survival, and disease recurrence at 3 mo. RESULTS AND LIMITATIONS: A total of 384 patients were randomized to undergo eTURB or cTURB. A total of 452 tumors were resected and analyzed for the primary outcome. eTURB was superior to cTURB in retrieval of DM (80.7% vs 71.1%; mixed-model p = 0.01). Bladder perforation (5.6% vs 12%; difference -6.4%; 95% confidence interval [CI] -12.2% to -0.6%) and obturator reflex (8.4% vs 16%; difference -7.6%; 95% CI -14.3% to -0.9%) were less frequent in the eTURB arm than in the cTURB arm. Operation time did not differ between the two techniques (26 min, interquartile range [IQR] 20-38 for eTURB vs 25 min, IQR 17-35 for cTURB; difference 1 min, 95% CI -25.9 to 4.99). Second-look TURB was performed in 24 patients in the eTURB arm and 34 in the cTURB arm, with no difference in the rate of residual papillary disease (pTa/pT1: 56% vs 55.9%; difference 0.1%, 95% CI -25.5% to 25.7%). At median follow-up of 13 mo (IQR 7-20), 18.4% of the patients in the eTURB arm and 16.7% in the cTURB arm had experienced bladder cancer recurrence (Cox hazard ratio 0.87, 95% CI 0.49-1.52; p = 0.6). CONCLUSIONS: In patients with clinical NMIBC with up to three tumors of 1-3 cm in size, tumor removal via eTURB resulted in a higher rate of DM in the pathologic specimen in comparison to cTURB. Moreover, eTURB was associated with lower frequency of obturator reflex and bladder perforation than cTURB was. While improving on the quality indicators for NMIBC, the long-term differential oncologic benefits of eTURB remain uncertain. PATIENT SUMMARY: We compared two techniques for removal of bladder tumors and found that tumor removal in a single piece, called en bloc resection, provides a better-quality specimen for pathology analysis and fewer complications in comparison to the conventional method. This trial is registered at ClinicalTrials.gov as NCT03718754. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: dd.dandrea@gmail.com. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza, Torino School of Medicine, Turin, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Kotov, Sergey AU - Kotov S AD - Department of Urology and Andrology, Pirogov Russian National Research Medical University, Moscow, Russia. FAU - Regnier, Sophie AU - Regnier S AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite Paris Cite, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite Paris Cite, Paris, France. FAU - Lusuardi, Lukas AU - Lusuardi L AD - Department of Urology and Andrology, Paracelsius Medical University, Salzburg, Austria. FAU - Heidenreich, Axel AU - Heidenreich A AD - Department of Urology, Uro-oncology, Robot-Assisted and Specialized Surgery, University of Cologne, Cologne, Germany. FAU - Cai, Chao AU - Cai C AD - Department of Urology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. FAU - Frego, Nicola AU - Frego N AD - Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy. FAU - Taraktin, Mark AU - Taraktin M AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Ryabov, Maxim AU - Ryabov M AD - Department of Urology, MEDSI, Moscow, Russia. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza, Torino School of Medicine, Turin, Italy. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. CN - eBLOC Study Team LA - eng SI - ClinicalTrials.gov/NCT03718754 PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20230804 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM CIN - Eur Urol Oncol. 2024 Jun;7(3):636. doi: 10.1016/j.euo.2023.10.020. PMID: 37951819 MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Male MH - Female MH - Aged MH - Middle Aged MH - Prospective Studies MH - *Cystectomy/methods MH - Treatment Outcome OTO - NOTNLM OT - Bladder cancer OT - En bloc resection OT - Non-muscle-invasive bladder cancer OT - Randomized trial OT - Transurethral resection of the bladder EDAT- 2023/08/06 05:42 MHDA- 2024/09/10 12:46 CRDT- 2023/08/05 21:54 PHST- 2023/05/24 00:00 [received] PHST- 2023/06/24 00:00 [revised] PHST- 2023/07/19 00:00 [accepted] PHST- 2024/09/10 12:46 [medline] PHST- 2023/08/06 05:42 [pubmed] PHST- 2023/08/05 21:54 [entrez] AID - S2588-9311(23)00154-2 [pii] AID - 10.1016/j.euo.2023.07.010 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Oct;6(5):508-515. doi: 10.1016/j.euo.2023.07.010. Epub 2023 Aug 4. PMID- 37540255 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250718 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 149 IP - 15 DP - 2023 Nov TI - Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study. PG - 13905-13913 LID - 10.1007/s00432-023-05206-y [doi] AB - PURPOSE: This study compared the efficacy and safety of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for high-risk nonmuscle invasive bladder cancer (HRNMIBC) patients after transurethral resection of the bladder tumor (TURBT) surgery. METHODS: A retrospective analysis was performed on 349 HRNMIBC cases admitted to TangDu hospital between January 2014 and June 2019. After TURBT, 262 patients received intravesical chemotherapy alone, whereas 87 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. The recurrence rate and progression rate were assessed by Chi-square test, the prognostic factors for tumor recurrence were predicted by univariable and multivariable Cox hazards analyses, recurrence-free survival (RFS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method. RESULTS: In this study, the recurrence rate was 24.7% (19/77) in the intravenous chemotherapy combined group and 41.6% (102/245) in the intravesical chemotherapy group, while the progression rate was 6.5% (5/77) and 14.3% (35/245) in the two groups respectively. The two groups differed significantly in recurrence rate (p = 0.007) while the progression rate did not show a significant difference (p = 0.071). Multivariable analyses revealed that additional intravenous chemotherapy treatment was an independent prognostic factor for tumor recurrence in the cohort (hazard ratio [HR], 0.495, 95% confidence interval [CI], 0.275-0.892, p = 0.019). Kaplan-Meier curves showed significant differences in RFS and PFS between the two groups, with a log-rank P value of p < 0.005 and p = 0.045, respectively. Grade 3/4 toxicity was reported in 2 of 77 patients in the intravenous chemotherapy combined group, including nausea/vomiting 1.3% (1/77) and hypoleukemia 1.3% (1/77). CONCLUSION: Intravenous chemotherapy of gemcitabine and cisplatin combined with intravesical chemotherapy after TURBT can effectively reduce the postoperative recurrence rate, most toxicities were minor and reversible, and it may be considered as a new choice for HRNMIBC patients. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Chen, Jianbai AU - Chen J AD - Air Force Medical University, Xi'an, China. FAU - Zhang, Zhiming AU - Zhang Z AD - Department of Urology, TangDu Hospital, Air Force Medical University, Xi'an, China. FAU - Nie, Zhiyong AU - Nie Z AD - Department of Urology, TangDu Hospital, Air Force Medical University, Xi'an, China. FAU - Qiu, Jianxin AU - Qiu J AD - Department of Urology, TangDu Hospital, Air Force Medical University, Xi'an, China. qjianxin@21cn.com. LA - eng PT - Journal Article DEP - 20230804 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 SB - IM PMC - PMC11798301 OTO - NOTNLM OT - High risk nonmuscle invasive bladder cancer OT - Intravenous chemotherapy OT - Progression OT - Recurrence OT - Risk factors COIS- The authors have no relevant financial or nonfinancial interests to disclose. EDAT- 2023/08/04 13:10 MHDA- 2023/08/04 13:11 PMCR- 2023/08/04 CRDT- 2023/08/04 11:04 PHST- 2023/06/20 00:00 [received] PHST- 2023/07/25 00:00 [accepted] PHST- 2023/08/04 13:11 [medline] PHST- 2023/08/04 13:10 [pubmed] PHST- 2023/08/04 11:04 [entrez] PHST- 2023/08/04 00:00 [pmc-release] AID - 10.1007/s00432-023-05206-y [pii] AID - 5206 [pii] AID - 10.1007/s00432-023-05206-y [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 Nov;149(15):13905-13913. doi: 10.1007/s00432-023-05206-y. Epub 2023 Aug 4. PMID- 37540248 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20231221 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 41 IP - 12 DP - 2023 Dec TI - Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today? PG - 3395-3403 LID - 10.1007/s00345-023-04530-9 [doi] AB - PURPOSE: To summarise the current knowledge regarding diagnostics, prognostication and follow-up in upper tract urothelial carcinoma (UTUC). METHODS: A scoping review combined with expert opinion was applied to provide an overview of the current research field. Based on the published literature and the experts' own experience and opinions, consensus was reached through presentations and discussions at the meeting Consultation on UTUC II in Stockholm 2022. RESULTS: The strongest prognostic factors in UTUC are tumour grade and stage. They are correlated, and grade is used for indirect staging. The diagnostic examinations should include multiphase computed tomography urography (CTU) with corticomedullary phase, and urethrocystoscopy with cytology. If there is no clear diagnosis for clinical decision-making, ureterorenoscopy (URS) with focal cytology and biopsies should be performed. Both WHO classification systems (1973/1999 and 2004/2016) should be used. Novel biomarker tests are not yet widespread nor recommended for the detection of UTUC. Long-term, regular follow-up, including URS in patients who have had organ-sparing treatment, is important to check for tumour recurrences, intravesical recurrences, metastases and progression of the tumour. CONCLUSION: Proper diagnostics with correct grading of UTUC are necessary for appropriate treatment decisions. The diagnostics should include CTU with corticomedullary phase, urine or bladder cytology, URS with focal barbotage cytology, and biopsies when needed for proper diagnosis and risk stratification. Regular, long-term follow-ups are fundamental, due to the high rate of recurrence and risk of progression. CI - (c) 2023. The Author(s). FAU - Syden, Filip AU - Syden F AD - Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Bultitude, Matthew AU - Bultitude M AD - Guy's and St. Thomas' NHS Foundation Trust, Urology Centre/Stone Unit, Guy's and St. Thomas' Hospital, London, UK. FAU - Keeley, Francis Xavier Jr AU - Keeley FX Jr AD - Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Paris, France. FAU - Thomas, Kay AU - Thomas K AD - Guy's and St. Thomas' NHS Foundation Trust, Urology Centre/Stone Unit, Guy's and St. Thomas' Hospital, London, UK. FAU - Axelsson, Tomas Andri AU - Axelsson TA AD - Department of Surgery and Urology, Danderyd Hospital, Stockholm, Sweden. FAU - Jaremko, Georg AU - Jaremko G AD - Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden. FAU - Jung, Helene AU - Jung H AD - Department of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark. FAU - Malm, Camilla AU - Malm C AUID- ORCID: 0000-0003-1564-0011 AD - Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. FAU - Proietti, Silvia AU - Proietti S AD - Urology Department, San Raffaele Hospital, Milan, Italy. FAU - Osther, Palle Jorn Sloth AU - Osther PJS AD - Department of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark. FAU - Brehmer, Marianne AU - Brehmer M AUID- ORCID: 0000-0001-9232-363X AD - Department of Urology, Stockholm South General Hospital, Stockholm, Sweden. marianne.brehmer@ki.se. AD - Department of Clinical Sciences Karolinska Institute, Stockholm, Sweden. marianne.brehmer@ki.se. LA - eng PT - Journal Article PT - Review DEP - 20230804 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/diagnosis MH - *Kidney Neoplasms/pathology MH - Follow-Up Studies MH - *Ureteral Neoplasms/pathology MH - Neoplasm Recurrence, Local/diagnosis PMC - PMC10693525 OTO - NOTNLM OT - Biopsy OT - Computed tomography urography OT - Cytology OT - Diagnostics OT - Follow-up OT - Prognostication OT - UTUC OT - Upper tract urothelial carcinoma OT - Ureterorenoscopy COIS- Filip Syden: no conflict of interest; Joyce Baard: consultation for Coloplast, BSC, Urogen, and Olympus; Matthew Bultitude: no conflict of interest; Francis Xavier Keeley, Jr: no conflict of interest; Morgan Roupret: Advisory Board for Ferring, Roche, BMS, Janssen, Ipsen, and Bayer; Kay Thomas: no conflict of interest; Tomas Andri Axelsson: no conflict of interest; Georg Jaremko: no conflict of interest; Helene Jung: consultation for Boston Scientific and AMBU A/S; Camilla Malm: no conflict of interest; Silvia Proietti: no conflict of interest; Palle Jorn Sloth Osther: no conflict of interest; Marianne Brehmer: consultation for Boston Scientific. EDAT- 2023/08/04 13:10 MHDA- 2023/12/04 12:43 PMCR- 2023/08/04 CRDT- 2023/08/04 11:04 PHST- 2023/03/31 00:00 [received] PHST- 2023/07/07 00:00 [accepted] PHST- 2023/12/04 12:43 [medline] PHST- 2023/08/04 13:10 [pubmed] PHST- 2023/08/04 11:04 [entrez] PHST- 2023/08/04 00:00 [pmc-release] AID - 10.1007/s00345-023-04530-9 [pii] AID - 4530 [pii] AID - 10.1007/s00345-023-04530-9 [doi] PST - ppublish SO - World J Urol. 2023 Dec;41(12):3395-3403. doi: 10.1007/s00345-023-04530-9. Epub 2023 Aug 4. PMID- 37538149 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230805 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 10 IP - 3 DP - 2023 Jul TI - The natural course of bacillus Calmette-Guerin induced bladder lesions: A long-term follow-up study and systematic review. PG - 356-363 LID - 10.1016/j.ajur.2022.12.006 [doi] AB - OBJECTIVE: Bacillus Calmette-Guerin (BCG) instillation is the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. Nevertheless, its toxicity often causes bladder complications. On follow-up cystoscopy, post-BCG bladder lesions can be pathologically benign, urothelial carcinoma recurrence, or other types of bladder malignancy. Only a small number of case reports have been published on post-BCG bladder lesions. Their clinical features, natural course, and management remain unknown. METHODS: We retrospectively studied cystoscopic videos and medical records of BCG-treated bladder cancer patients at our center. During a long-term follow-up, we took biopsies on tumor-like lesions and described their changes. In addition, we summarized previous studies on post-BCG bladder lesions by systematic literature searching and review. RESULTS: We described a series of three cases with post-BCG bladder lesions mimicking tumor recurrence from a total of 38 cases with follow-up data for more than 5 years. Those lesions could last, grow, or disappear spontaneously, and remain pathological benign for years. In systematic review, we identified and analyzed a total of 15 cases with post-BCG bladder lesions with detailed clinical information. Eleven of the 15 were benign and have a good prognosis with nephrogenic adenoma being the most common pathological type. CONCLUSION: Based on previous studies and our experience, benign lesions after BCG instillation cannot distinguish with cancer recurrence by cystoscopy alone, even under narrow band imaging mode. Nonetheless, given most of them have a good prognosis, random biopsy or transurethral resection might be spared in the patients with long-term negative biopsy and urine cytology. CI - (c) 2023 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. FAU - Ma, Chong AU - Ma C AD - Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Dai, Lihe AU - Dai L AD - Department of Urology, The 943 Hospital of Joint Logistics Support Force of Chinese PLA, Gansu, China. FAU - Han, Huan AU - Han H AD - Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Song, Ruixiang AU - Song R AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Xu, Jinshan AU - Xu J AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Ai, Xing AU - Ai X AD - Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. LA - eng PT - Journal Article DEP - 20230414 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC10394293 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Cystoscopy OT - Follow-up OT - Side effects COIS- The authors declare no conflict of interest. EDAT- 2023/08/04 06:43 MHDA- 2023/08/04 06:44 PMCR- 2023/04/14 CRDT- 2023/08/04 03:56 PHST- 2022/10/15 00:00 [received] PHST- 2022/11/18 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/08/04 06:44 [medline] PHST- 2023/08/04 06:43 [pubmed] PHST- 2023/08/04 03:56 [entrez] PHST- 2023/04/14 00:00 [pmc-release] AID - S2214-3882(23)00037-1 [pii] AID - 10.1016/j.ajur.2022.12.006 [doi] PST - ppublish SO - Asian J Urol. 2023 Jul;10(3):356-363. doi: 10.1016/j.ajur.2022.12.006. Epub 2023 Apr 14. PMID- 37535836 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260316 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 210 IP - 5 DP - 2023 Nov TI - International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. PG - 763-770 LID - 10.1097/JU.0000000000003639 [doi] AB - PURPOSE: We sought to determine if the International Bladder Cancer Group IR-NMIBC (Intermediate-risk Nonmuscle-invasive Bladder Cancer) scoring system can predict the requirement of delayed transurethral resection of bladder tumor in low-grade nonmuscle-invasive bladder cancer managed by active surveillance. MATERIALS AND METHODS: We prospectively studied recurrent low-grade Ta/T1 nonmuscle-invasive bladder cancer patients managed with active surveillance with the following characteristics: low-grade papillary nonmuscle-invasive bladder cancer, /=3 risk factors (59% vs 24%). Multivariable Cox regression suggested that the International Bladder Cancer Group IR-NMIBC scoring system was associated with subsequent transurethral resection of bladder tumor (1-2 risk factors [HR: 1.66, 95% CI: 0.96-2.90, P = .072], >/=3 risk factors [HR: 3.21, 95% CI: 1.70-6.09, P < .001]) after adjusting for age, T stage, and sex. CONCLUSIONS: The International Bladder Cancer Group IR-NMIBC scoring system can predict the risk of subsequent transurethral resection of bladder tumor in patients with low-grade nonmuscle-invasive bladder cancer on active surveillance. FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Soloway, Mark AU - Soloway M AD - Division of Urology, Memorial Cancer Institute, Memorial Hospital, Hollywood, Florida. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. LA - eng PT - Journal Article DEP - 20230803 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2023 Nov;210(5):769-770. doi: 10.1097/JU.0000000000003639.01. PMID: 37622524 MH - Humans MH - *Urinary Bladder Neoplasms/pathology/surgery/therapy MH - Male MH - Female MH - *Watchful Waiting MH - Aged MH - Neoplasm Invasiveness MH - Prospective Studies MH - Risk Assessment MH - Middle Aged MH - Neoplasm Staging MH - Aged, 80 and over MH - Prognosis MH - Neoplasm Grading OTO - NOTNLM OT - non-muscle invasive bladder neoplasms OT - risk, prognosis OT - watchful waiting EDAT- 2023/08/03 19:14 MHDA- 2026/03/11 19:00 CRDT- 2023/08/03 15:02 PHST- 2026/03/11 19:00 [medline] PHST- 2023/08/03 19:14 [pubmed] PHST- 2023/08/03 15:02 [entrez] AID - 10.1097/JU.0000000000003639 [doi] PST - ppublish SO - J Urol. 2023 Nov;210(5):763-770. doi: 10.1097/JU.0000000000003639. Epub 2023 Aug 3. PMID- 37531827 OWN - NLM STAT- MEDLINE DCOM- 20230922 LR - 20260127 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 123 DP - 2023 Oct TI - A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad(R) immunotherapy associated with platelet-rich plasma. PG - 110723 LID - S1567-5769(23)01048-2 [pii] LID - 10.1016/j.intimp.2023.110723 [doi] AB - Patients with non-muscle invasive bladder cancer (NMIBC) that are unresponsive to Bacillus Calmette-Guerin (BCG) have historically had limited treatment options. A new perspective is represented by OncoTherad(R) (MRB-CFI-1) immunotherapy, a nanostructured inorganic phosphate complex associated with glycosidic protein, developed by the University of Campinas in Brazil. Previous studies have shown that Platelet-Rich Plasma (PRP) also acts on immune activation and exerts antitumor effects. This study characterized the effects of the OncoTherad(R) associated with PRP in the treatment of NMIBC chemically induced in mice. When treated intravesically with PRP only, mice showed 28.6% of tumor progression inhibition rate; with OncoTherad(R) 85.7%; and with OncoTherad(R)+PRP 71.4%. Intravesical treatments led to distinct activation of Toll-like Receptors (TLRs) 2 and 4-mediated innate immune system in the interleukins (canonical) and interferons (non-canonical) signaling pathways. OncoTherad(R) isolated or associated with PRP upregulated TLR4 and its downstream cascade mediators as well as increased interleukins 6 (IL-6) and 1beta (IL-1beta), and interferon-gamma (IFN-gamma). In this way, the NMIBC microenvironment was modulated to a cytotoxic profile correlated with the IL-1beta increase by stimulating immune pathways for IFN-gamma production and consequent cytotoxic T lymphocytes (as CD8+ T-cells) activation and regulatory T-cells (Tregs) reduction. In addition, PRP did not trigger carcinogenic effects through the biomarkers evaluated. Considering the possibility of personalizing the treatment with the PRP use as well as the antitumor properties of OncoTherad(R), we highlight this association as a potential new therapeutic strategy for NMIBC, mainly in cases of relapse and/or resistance to BCG. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Ribeiro de Souza, Bianca AU - Ribeiro de Souza B AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: bianca.ribeiro@ubc.ca. FAU - Brum Reis, Ianny AU - Brum Reis I AD - Department of Diagnosis and Surgery, School of Dentistry - Sao Paulo State University (UNESP), Araraquara, Sao Paulo, Brazil. Electronic address: ib.reis@unesp.br. FAU - Cardoso de Arruda Camargo, Gabriela AU - Cardoso de Arruda Camargo G AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: g172612@dac.unicamp.br. FAU - Oliveira, Gabriela AU - Oliveira G AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: gabrielaufscar@gmail.com. FAU - Cristina Dias, Queila AU - Cristina Dias Q AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: qcdias@unicamp.br. FAU - Duran, Nelson AU - Duran N AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil; Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), Santo Andre, Sao Paulo, Brazil. Electronic address: nduran@unicamp.br. FAU - Jose Favaro, Wagner AU - Jose Favaro W AD - Department of Structural and Functional Biology, Institute of Biology - University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic address: favarowj@unicamp.br. LA - eng PT - Journal Article DEP - 20230731 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (BCG Vaccine) RN - 0 (Phosphates) RN - 0 (Adjuvants, Immunologic) RN - 0 (MRB-CFI-1) RN - 0 (Glycoproteins) SB - IM MH - Humans MH - Mice MH - Animals MH - BCG Vaccine MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy MH - Phosphates/therapeutic use MH - Immunotherapy MH - *Platelet-Rich Plasma MH - Adjuvants, Immunologic/therapeutic use MH - Tumor Microenvironment MH - Glycoproteins MH - Nanostructures OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - OncoTherad OT - PRP OT - Toll-Like receptors COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/08/03 01:06 MHDA- 2023/09/22 06:42 CRDT- 2023/08/02 18:07 PHST- 2023/05/28 00:00 [received] PHST- 2023/07/25 00:00 [revised] PHST- 2023/07/26 00:00 [accepted] PHST- 2023/09/22 06:42 [medline] PHST- 2023/08/03 01:06 [pubmed] PHST- 2023/08/02 18:07 [entrez] AID - S1567-5769(23)01048-2 [pii] AID - 10.1016/j.intimp.2023.110723 [doi] PST - ppublish SO - Int Immunopharmacol. 2023 Oct;123:110723. doi: 10.1016/j.intimp.2023.110723. Epub 2023 Jul 31. PMID- 37530330 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231102 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 66 IP - 3 DP - 2023 Jul-Sep TI - The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer. PG - 502-510 LID - 10.4103/ijpm.ijpm_1236_21 [doi] AB - CONTEXT: Despite the follow-up protocols developed in non-muscle-invasive bladder cancer patients, progression and recurrence could not be prevented. AIMS: We aimed to investigate whether proteins such as OCT-4, CD47, p53, Ki-67, and Survivin, which increase in bladder cancer cells, can be used as prognostic markers for patients with non-muscle-invasive bladder cancer. SETTINGS AND DESIGN: The study included a total of 89 patients with newly diagnosed non-muscle-invasive bladder cancer between January 2015 and December 2020. MATERIALS AND METHODS: Levels of OCT-4, CD47, p53, KI-67, and Survivin proteins in cancer cells were determined with a semi-quantitative immunohistochemical experiment. Pathological data and survival rates were compared according to the staining rates. STATISTICAL ANALYSIS USED: Data obtained in the study were analyzed statistically with SPSS 22.0 (SPSS, Chicago, IL, USA). RESULTS: The mean age of the patients was 64.25 +/- 9.91 years, and the median follow-up period was 55 months. Recurrence rate was determined to be 36% (n = 32), and the rate of progression at 40.4% (n = 36). The staining rates were stronger for each marker in the progression group and advanced-stage tumors (p < 0.001). The findings of the multivariate analysis carried out as part of the study showed that older age and higher tumor stage were independent risk factors for recurrence-free survival (HR = 1.048 and 7.074, respectively; P = 0.02). Also, higher tumor stages, diameters, and grades were associated with reduced progression-free survival (HR = 0.105, 0.395, 0.225, respectively; P < 0.05). CONCLUSIONS: Although immunohistochemical staining rates are promising, it is more appropriate to use tumor characteristics when assessing survival rate in patients with non-muscle-invasive bladder cancer. FAU - Demirci, Aykut AU - Demirci A AD - Department of Urology, Aksaray University Training and Research Hospital, Aksaray, Turkey. FAU - Ordu, Melike AU - Ordu M AD - Department of Medical Pathology, Aksaray University Training and Research Hospital, Aksaray, Turkey. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Survivin) RN - 0 (CD47 Antigen) RN - 0 (Ki-67 Antigen) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Prognosis MH - Survivin/metabolism MH - CD47 Antigen/metabolism MH - Ki-67 Antigen/metabolism MH - Tumor Suppressor Protein p53 MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/diagnosis MH - Neoplasm Recurrence, Local/pathology MH - Disease Progression MH - Biomarkers, Tumor OTO - NOTNLM OT - Bladder cancer OT - CD47 OT - KI-67 OT - OCT-4 OT - Survivin OT - p53 COIS- None EDAT- 2023/08/02 13:08 MHDA- 2023/08/02 13:09 CRDT- 2023/08/02 07:48 PHST- 2023/08/02 13:09 [medline] PHST- 2023/08/02 13:08 [pubmed] PHST- 2023/08/02 07:48 [entrez] AID - IndianJPatholMicrobiol_2023_66_3_502_345854 [pii] AID - 10.4103/ijpm.ijpm_1236_21 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2023 Jul-Sep;66(3):502-510. doi: 10.4103/ijpm.ijpm_1236_21. PMID- 37525073 OWN - NLM STAT- MEDLINE DCOM- 20230829 LR - 20230831 IS - 1573-4978 (Electronic) IS - 0301-4851 (Print) IS - 0301-4851 (Linking) VI - 50 IP - 9 DP - 2023 Sep TI - Molecular classification of urothelial bladder carcinoma. PG - 7867-7877 LID - 10.1007/s11033-023-08689-7 [doi] AB - Urothelial bladder carcinoma (UC) ranks among the top ten most commonly diagnosed cancers worldwide on an annual basis. The standardized classification system for urothelial bladder tumors is the Tumor, Node, Metastasis classification, which reflects differences between non-muscle-invasive bladder carcinoma (NMIBC) and muscle-invasive bladder carcinoma (MIBC) and it depends on the extent to which tumor has infiltrated the bladder wall and other tissues and organs. NMIBC and MIBC exhibit great intrinsic heterogeneity regarding different prognoses, survival, progression, and treatment outcomes. In recent years, studies based on mRNA expression profiling revealed the existence of biologically relevant molecular subtypes of UC, which show variant molecular features that can provide more precise stratification of UC patients. Here, we present a complex classification of UC based on mRNA expression studies and molecular subtypes of NMIBC and MIBC in detail with regard to different mRNA expression profiles, mutational signatures, and infiltration by non-tumor cells. The possible impact of molecular subtyping on treatment decisions and patients' outcomes is outlined, too. CI - (c) 2023. The Author(s). FAU - Schwarzova, Lucia AU - Schwarzova L AD - Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. FAU - Varchulova Novakova, Zuzana AU - Varchulova Novakova Z AD - Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. FAU - Danisovic, Lubos AU - Danisovic L AUID- ORCID: 0000-0002-5074-9621 AD - Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. lubos.danisovic@fmed.uniba.sk. FAU - Ziaran, Stanislav AU - Ziaran S AUID- ORCID: 0000-0002-5487-0875 AD - Department of Urology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. LA - eng GR - 313021BUZ3/Operational Program Integrated Infrastructure/ GR - UK/41/2023/Comenius University/ PT - Journal Article PT - Review DEP - 20230731 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 SB - IM MH - Humans MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/diagnosis MH - *Carcinoma, Transitional Cell MH - Mutation/genetics MH - Neoplasm Invasiveness/genetics PMC - PMC10460735 OTO - NOTNLM OT - Expression OT - MIBC OT - Molecular subtypes of bladder tumors OT - NMIBC OT - Urothelial bladder carcinoma COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/08/01 01:08 MHDA- 2023/08/29 12:43 PMCR- 2023/07/31 CRDT- 2023/07/31 23:34 PHST- 2023/05/02 00:00 [received] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/08/29 12:43 [medline] PHST- 2023/08/01 01:08 [pubmed] PHST- 2023/07/31 23:34 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - 10.1007/s11033-023-08689-7 [pii] AID - 8689 [pii] AID - 10.1007/s11033-023-08689-7 [doi] PST - ppublish SO - Mol Biol Rep. 2023 Sep;50(9):7867-7877. doi: 10.1007/s11033-023-08689-7. Epub 2023 Jul 31. PMID- 37524576 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20240411 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 11 DP - 2023 Nov TI - Assessing utilities for muscle-invasive bladder cancer-related health states. PG - 456.e7-456.e12 LID - S1078-1439(23)00239-9 [pii] LID - 10.1016/j.urolonc.2023.07.005 [doi] AB - OBJECTIVES: How patients value functional outcomes against oncologic outcomes during decision-making for muscular-invasive bladder cancer (MIBC) remains unclear. We sought to quantify individuals' preferences on a scale of 0 to 1, where 1 represents perfect health and 0 represents death. METHODS: Descriptions of 6 hypothetical health states were developed. These included: Neoadjuvant chemotherapy followed by radical cystectomy with ileal conduit (IC) or with neobladder reconstruction (NB), Transurethral resection and chemotherapy/radiation (CRT), CRT requiring salvage cystectomy (SC), Recurrent/metastatic bladder cancer after local therapy (RMBC), and Metastatic bladder cancer (MBC). Descriptions consisted of diagnosis, treatments, adverse effects, follow-up protocol, and prognosis and were reviewed for accuracy by expert panel. Included individuals were asked to evaluate states using the visual analog scale (VAS) and standard gamble (SG) methods. RESULTS: Fifty-four individuals were included for analysis. No score differences were observed between IC, NB, and CRT on VAS or SG. On VAS, SC (value = 0.429) was rated as significantly worse (P < 0.001) than NB (value = 0.582) and CRT (value = 0.565). However, this was not the case using the SG method. Both RMBC (VAS value = 0.178, SG value = 0.631) and MBC (VAS value = 0.169, SG value = 0.327) rated as significantly worse (P < 0.001) than the other states using both VAS and SG. CONCLUSIONS: Within this sample of the general population, preferences for local treatments including IC, NB, and CRT were not found to be significantly different. These values can be used to calculate quality-adjusted life expectancy in future cost-effectiveness analyses. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Chaballout, Basil H AU - Chaballout BH AD - Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC. FAU - Chang, Eric M AU - Chang EM AD - Interstate Radiation Oncology Center, Kaiser Permanente Northwest, Portland, Oregon. FAU - Parikh, Neil R AU - Parikh NR AD - Department of Radiation Oncology, UCLA, Los Angeles, CA. FAU - Min, Yugang AU - Min Y AD - Department of Radiation Oncology, UCLA, Los Angeles, CA. FAU - Raldow, Ann C AU - Raldow AC AD - Department of Radiation Oncology, UCLA, Los Angeles, CA. Electronic address: ARaldow@mednet.ucla.edu. LA - eng PT - Journal Article DEP - 20230730 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/surgery MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Cystectomy/methods MH - Muscles/pathology OTO - NOTNLM OT - Bladder cancer OT - Health states OT - Health utilities OT - Muscle-invasive OT - Radiotherapy COIS- Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/08/01 01:08 MHDA- 2023/12/05 12:42 CRDT- 2023/07/31 21:52 PHST- 2023/01/17 00:00 [received] PHST- 2023/06/12 00:00 [revised] PHST- 2023/07/10 00:00 [accepted] PHST- 2023/12/05 12:42 [medline] PHST- 2023/08/01 01:08 [pubmed] PHST- 2023/07/31 21:52 [entrez] AID - S1078-1439(23)00239-9 [pii] AID - 10.1016/j.urolonc.2023.07.005 [doi] PST - ppublish SO - Urol Oncol. 2023 Nov;41(11):456.e7-456.e12. doi: 10.1016/j.urolonc.2023.07.005. Epub 2023 Jul 30. PMID- 37522629 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231115 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 30 IP - 11 DP - 2023 Nov TI - Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease. PG - 944-957 LID - 10.1111/iju.15263 [doi] AB - In the management of non-muscle invasive bladder cancer (NMIBC), disease progression and long-term control are determined by the intensity of delivered treatment and surveillance and the cancer cells' biological nature. This requires risk stratification-based postoperative management, such as intravesical instillation of chemotherapy drugs, Bacillus Calmette-Guerin (BCG), and radical cystectomy. Advancements in mechanical engineering, molecular biology, and surgical skills have evolved the clinical management of NMIBC. In this review, we describe the updated evidence and perspectives regarding the following aspects: (1) advancements in surgical concepts, techniques, and devices for transurethral resection of the bladder tumor; (2) advancements in risk stratification tools for NMIBC; and (3) advancements in treatment strategies for BCG-treated NMIBC. Repeat transurethral resection, en-bloc transurethral resection, and enhanced tumor visualization, including photodynamic diagnosis and narrow-band imaging, help reduce residual cancer cells, provide accurate diagnosis and staging, and sensitive detection, which are the first essential steps for cancer cure. Risk stratification should always be updated and improved because the treatment strategy changes over time. The BCG-treated disease concept has recently diversified to include BCG failure, resistance, refractory, unresponsiveness, exposure, and intolerance. A BCG-unresponsive disease is an extremely aggressive subset unlikely to respond to a rechallenge with BCG. Numerous ongoing clinical trials aim to develop a future bladder-sparing approach for very high-risk BCG-naive NMIBC and BCG-unresponsive NMIBC. The key to improving the quality of patient care lies in the continuous efforts to overcome the clinical limitations of bedside management. CI - (c) 2023 The Japanese Urological Association. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Nara, Japan. LA - eng PT - Journal Article PT - Review DEP - 20230731 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Int J Urol. 2023 Nov;30(11):957-958. doi: 10.1111/iju.15286. PMID: 37608457 MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/surgery/drug therapy MH - Administration, Intravesical MH - Risk Assessment/methods MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - risk stratification OT - transurethral resection OT - tumor visualization OT - urinary bladder neoplasms EDAT- 2023/07/31 13:08 MHDA- 2023/11/02 12:45 CRDT- 2023/07/31 08:33 PHST- 2023/05/05 00:00 [received] PHST- 2023/07/13 00:00 [accepted] PHST- 2023/11/02 12:45 [medline] PHST- 2023/07/31 13:08 [pubmed] PHST- 2023/07/31 08:33 [entrez] AID - 10.1111/iju.15263 [doi] PST - ppublish SO - Int J Urol. 2023 Nov;30(11):944-957. doi: 10.1111/iju.15263. Epub 2023 Jul 31. PMID- 37521452 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230911 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 21 IP - 3 DP - 2023 TI - Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients? PG - 142-149 LID - 10.1080/2090598X.2023.2190687 [doi] AB - BACKGROUND: We lack tools to predict treatment and survival outcomes in patients receiving additional BCG therapy as a bladder-preserving therapy in high grade/T1, Tis NMIBC patients who showed persistent/recurrent tumors at three-month follow-up. OBJECTIVES: To assess the predictors of additional BCG response in patients who experienced persistent/recurrent tumors at three-month follow-up after BCG induction. PATIENTS AND METHODS: We retrospectively analyzed database for NMIBC. Between 2000 and 2019, 231 patients with high-grade T1/Tis NMIBC showed persistent/recurrent tumors at 3-month after BCG-induction, refused or were unfit to radical cystectomy (RC) and were offered additional intravesical BCG as bladder-preserving treatment. Predictors of the outcome after additional BCG were studied using univariate and multivariate logistic regression analysis. Kaplan Meier curve was utilized to estimate the recurrence-free survival (RFS) and progression-free survival (PFS). COX regression analysis was performed to identify independent predictors or RFS and PFS. RESULTS: During a median (range) of 148 (24-224) months, poor response to additional BCG (tumor recurrence and/or progression) was noted in 112 (48.5%) patients. On multivariate logistic regression analysis, 3-month tumor features (persistent T stage, persistent grade and persistent/new CIS) significantly predicted poor response to additional BCG (OR: 3.4, 95%CI: 1.3-10.8, p = 0.021, OR: 2.1, 95%CI: 1.1-4.1, p = 0.02 and OR: 16.6, 95%CI: 4.5-109, p=<0.001, respectively). The mean RFS was 26 (9-152) months with identified 3-month tumor features (persistent T stage and persistent/new CIS) as independent predictors of RFS (HR = 11.5, 95%CI = 2.7-48.3, p = 0.001 and HR = 2.5, 95%CI = 1.5-4.1, p=<0.001, respectively) on multivariate COX regression analysis. In addition, 3-month tumor features (persistent/new CIS, non-papillary shape and bladder neck involvement) were identified to significantly predict PFS (HR = 6.2, 95%CI = 3.4-11.5, p=<0.001 and HR = 2.3, 95%CI = 1.3-4.3 p = 0.001 and HR = 2.1, 95%CI = 1.2-3.8, p=<0.005, respectively). CONCLUSIONS: Three-month tumor features could be utilized as a tool to predict treatment outcomes and survival benefits when additional intravesical BCG is utilized as a bladder-preserving treatment in patients with recurrent/persistent tumors at three-month follow-up. CI - (c) 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Elsawy, Amr A AU - Elsawy AA AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Laymon, Mahmoud AU - Laymon M AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Mansour, Islam AU - Mansour I AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Elghareeb, Ahmed AU - Elghareeb A AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Harraz, Ahmed AU - Harraz A AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20230321 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC10373613 OTO - NOTNLM OT - BCG refractory OT - Bladder cancer OT - progression OT - recurrence OT - three-month cystoscopy COIS- No potential conflict of interest was reported by the authors. EDAT- 2023/07/31 06:43 MHDA- 2023/07/31 06:44 PMCR- 2023/03/21 CRDT- 2023/07/31 05:08 PHST- 2023/07/31 06:44 [medline] PHST- 2023/07/31 06:43 [pubmed] PHST- 2023/07/31 05:08 [entrez] PHST- 2023/03/21 00:00 [pmc-release] AID - 2190687 [pii] AID - 10.1080/2090598X.2023.2190687 [doi] PST - epublish SO - Arab J Urol. 2023 Mar 21;21(3):142-149. doi: 10.1080/2090598X.2023.2190687. eCollection 2023. PMID- 37509344 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230731 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 14 DP - 2023 Jul 19 TI - Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted? LID - 10.3390/cancers15143683 [doi] LID - 3683 AB - XBM was prospectively assessed in spontaneous urine collected just before flexible cystoscopy and washing cytology carried out within the first 2 years follow-up of 337 patients with NMIBC. Recurrences were pathologically confirmed in 49 patients (14.5%), 22 of them being high-risk (6.5%). The XBM sensitivity for detecting any type of recurrence was 69.4% and 63.6% in the cases of high-risk NMIBC. Negative predictive value (NPV) for XBM was 93% for all recurrences and 96.2% for high-risk recurrences. XBM could have avoided 213 invasive controls but missed the detection of 15 recurrences (30.6%)-8 of them of high-risk (36.4%). XBM false positive elevations were detected in 90 patients (26.7%), whereas 10 patients with the invasive method had a false positive result (3%), p <0.001. However, early detection of recurrences during the first year's follow-up after an XBM false positive result was observed in 18 patients (20%). On the other hand, 19 recurrences were detected during this period among the rest of the patients (7.7%)-p = 0.003, and odds ratio (OR) 3.0 (95% CI 1.5-6.0). Regarding one-year follow-up recurrences, 10% were high-risk recurrences in the XBM false positive group and 3.2% in the rest of the patients-p = 0.021, and OR 3.3 (95% CI 1.2-8.9). Additionally, 11.3% of the patients without false positive results developed a recurrence, p = 0.897, for any recurrence, being 10% and 5.2%, respectively, and high-risk and low-risk recurrences, p = 0.506. After searching for the best XBM cutoff for detecting the 38 high-risk initial recurrences and the early high-risk recurrences after a one-year follow-up, a linear discriminant analysis (LDA) of 0.13 could have avoided 11.3% of cystoscopies and bladder wash cytologies, as this cutoff missed only 1 high-risk recurrence (2.6%). More extensive and well-designed studies will confirm if XBM can improve the surveillance of NMIBC. FAU - Lozano, Fernando AU - Lozano F AUID- ORCID: 0000-0001-9513-0614 AD - Department of Urology, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, 08035 Barcelona, Spain. FAU - Raventos, Carles X AU - Raventos CX AD - Department of Urology, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, 08035 Barcelona, Spain. FAU - Carrion, Albert AU - Carrion A AUID- ORCID: 0000-0002-4639-1532 AD - Department of Urology, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, 08035 Barcelona, Spain. FAU - Dinares, Carme AU - Dinares C AD - Pathology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. FAU - Hernandez, Javier AU - Hernandez J AUID- ORCID: 0000-0003-1526-3201 AD - Pathology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. FAU - Trilla, Enrique AU - Trilla E AD - Department of Urology, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, 08035 Barcelona, Spain. FAU - Morote, Juan AU - Morote J AD - Department of Urology, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, 08035 Barcelona, Spain. LA - eng PT - Journal Article DEP - 20230719 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10378094 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - surveillance COIS- The authors of this article do not declare any conflict of interest. Cepheid had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/07/29 11:51 MHDA- 2023/07/29 11:52 PMCR- 2023/07/19 CRDT- 2023/07/29 01:11 PHST- 2023/05/19 00:00 [received] PHST- 2023/06/28 00:00 [revised] PHST- 2023/07/15 00:00 [accepted] PHST- 2023/07/29 11:52 [medline] PHST- 2023/07/29 11:51 [pubmed] PHST- 2023/07/29 01:11 [entrez] PHST- 2023/07/19 00:00 [pmc-release] AID - cancers15143683 [pii] AID - cancers-15-03683 [pii] AID - 10.3390/cancers15143683 [doi] PST - epublish SO - Cancers (Basel). 2023 Jul 19;15(14):3683. doi: 10.3390/cancers15143683. PMID- 37504348 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20250626 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 7 DP - 2023 Jul 12 TI - The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 6648-6665 LID - 10.3390/curroncol30070488 [doi] AB - BACKGROUND: Statins are widely used due to their ability to lower plasma cholesterol and offer protection from the effects of atherosclerosis. However, their role in urology and specifically bladder cancer remains unclear. We aimed to systematically address this issue in the literature and determine any possible effects of statin therapy on bladder cancer. METHODS: We searched MEDLINE (PubMed) and Cochrane Library databases for records up to 26 March 2023, for studies evaluating the effects of statins on urinary bladder cancer (UBC). We included all randomized controlled trials (RCTs), cohorts, and case-control studies that were conducted on the adult population. PROSPERO registration number: CRD42023407795. RESULTS: Database searches returned 2251 reports, and after thorough investigation and assessment for eligibility, 32 reports were included in the analysis. Of them, 4 were RCTs, 6 were case-control studies, and 22 were cohort studies. Our qualitative analysis demonstrated no association between statin administration and UBC local control, recurrence, survival, or mortality, or between statin administration and bacille Calmette-Guerin (BCG) immunotherapy effectiveness. A meta-analysis of 10 trials revealed a non-significant reduction of 11% in UBC risk among users compared with non-users in RCTs (RR: 0.89, 95% CI 0.68-1.16, p = 0.37) and a non-significant increase of 32% of UBC risk among statin users compared with non-users in the analysis of the cohort studies (RR: 1.32, 95% CI 0.76-2.30, p = 0.33). CONCLUSIONS: Our results provide strong evidence to support the neutral effect of statins on UBC local control, recurrence, survival, and mortality, and on BCG immunotherapy. Our meta-analysis revealed a non-significant effect on UBC risk among statin users when compared with non-users, indicating no statin effect on UBC incidence and overall prognosis. FAU - Symvoulidis, Panagiotis AU - Symvoulidis P AUID- ORCID: 0009-0000-6883-7323 AD - School of Medicine, European University Cyprus, Nicosia 2404, Cyprus. FAU - Tsioutis, Constantinos AU - Tsioutis C AUID- ORCID: 0000-0002-7865-8529 AD - School of Medicine, European University Cyprus, Nicosia 2404, Cyprus. FAU - Zamboglou, Constantinos AU - Zamboglou C AD - School of Medicine, European University Cyprus, Nicosia 2404, Cyprus. AD - Department of Radiation Oncology, Medical Center University of Freiburg, 79106 Freiburg, Germany. AD - Department of Internal Medicine, German Oncology Center, Limassol 4108, Cyprus. FAU - Agouridis, Aris P AU - Agouridis AP AUID- ORCID: 0000-0002-9749-5075 AD - School of Medicine, European University Cyprus, Nicosia 2404, Cyprus. AD - Department of Internal Medicine, German Oncology Center, Limassol 4108, Cyprus. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230712 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (BCG Vaccine) SB - IM MH - Adult MH - Humans MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - BCG Vaccine MH - Incidence MH - Prognosis MH - *Urinary Bladder Neoplasms/drug therapy/epidemiology PMC - PMC10378493 OTO - NOTNLM OT - HMG-CoA reductase inhibitors OT - meta-analysis OT - statins OT - systematic review OT - urinary bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2023/07/28 13:11 MHDA- 2023/07/31 11:42 PMCR- 2023/07/12 CRDT- 2023/07/28 08:35 PHST- 2023/05/23 00:00 [received] PHST- 2023/06/28 00:00 [revised] PHST- 2023/07/10 00:00 [accepted] PHST- 2023/07/31 11:42 [medline] PHST- 2023/07/28 13:11 [pubmed] PHST- 2023/07/28 08:35 [entrez] PHST- 2023/07/12 00:00 [pmc-release] AID - curroncol30070488 [pii] AID - curroncol-30-00488 [pii] AID - 10.3390/curroncol30070488 [doi] PST - epublish SO - Curr Oncol. 2023 Jul 12;30(7):6648-6665. doi: 10.3390/curroncol30070488. PMID- 37503461 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230729 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 6 DP - 2023 Jun TI - The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. PG - e40962 LID - 10.7759/cureus.40962 [doi] LID - e40962 AB - Non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy, and bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment in intermediate and high-risk groups. However, BCG failure occurs in a significant proportion of patients, emphasizing the need for effective alternative treatment modalities to address this burden. These treatments include immunotherapy, enhanced drug delivery, targeted therapy, device-assisted chemotherapy, vaccine therapy, and gene therapy, which show varying degrees of safety and efficacy. The objective of this review is to summarize the current evidence and ongoing research on these emerging therapies, offering insight into their potential for improving patient outcomes and quality of life. Although radical cystectomy remains the standard of care for high-risk NMIBC patients unresponsive to BCG, novel treatment modalities hold promise for the future management of this challenging patient population. CI - Copyright (c) 2023, Kodera et al. FAU - Kodera, Ahmed AU - Kodera A AD - Urology, Worcestershire Acute Hopsitals NHS Trust, Worcester, GBR. FAU - Mohammed, Mahmoud AU - Mohammed M AD - Urology, Worcestershire Acute Hospitals NHS Trust, Worcester, GBR. AD - Surgical Oncology, South Egypt Cancer Institute, Assiut, EGY. FAU - Lim, Paul AU - Lim P AD - Urology, Worcestershire Acute Hospitals NHS Trust, Worcestershire, GBR. FAU - Abdalla, Omer AU - Abdalla O AD - Urology, Wirral University Hospital, Liverpool, GBR. FAU - Elhadi, Mohammed AU - Elhadi M AD - Urology, Dudley Group NHS Hospital, Bromsrgrove, GBR. LA - eng PT - Journal Article PT - Review DEP - 20230626 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10369196 OTO - NOTNLM OT - bcg failure OT - bcg refractory OT - bladder sparing OT - management OT - non- muscle invasive bladder cancer OT - non-muscle invasive bladder cancer COIS- The authors have declared that no competing interests exist. EDAT- 2023/07/28 06:43 MHDA- 2023/07/28 06:44 PMCR- 2023/06/26 CRDT- 2023/07/28 04:31 PHST- 2023/06/26 00:00 [accepted] PHST- 2023/07/28 06:44 [medline] PHST- 2023/07/28 06:43 [pubmed] PHST- 2023/07/28 04:31 [entrez] PHST- 2023/06/26 00:00 [pmc-release] AID - 10.7759/cureus.40962 [doi] PST - epublish SO - Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. eCollection 2023 Jun. PMID- 37501157 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230729 IS - 1542-6416 (Print) IS - 1559-0275 (Electronic) IS - 1542-6416 (Linking) VI - 20 IP - 1 DP - 2023 Jul 27 TI - Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity. PG - 28 LID - 10.1186/s12014-023-09419-8 [doi] LID - 28 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate and muscle-invasive bladder cancer (MIBC) has unfavorable outcomes in urothelial bladder cancer (UBC) patients. Complex UBC-related protein biomarkers for outcome prediction may provide a more efficient management approach with an improved clinical outcome. The aim of this study is to recognize tumor-associated proteins, which are differentially expressed in different stages of UBC patients compared non-cancerous tissues. METHODS: The proteome of tissue samples of 42 UBC patients (NMIBC n = 25 and MIBC n = 17) was subjected to two-dimensional electrophoresis (2-DE) combined with Liquid chromatography-mass spectrometry (LC-MS) system to identify differentially expressed proteins. The intensity of protein spots was quantified and compared with Prodigy SameSpots software. Functional, pathway, and interaction analyses of identified proteins were performed using geneontology (GO), PANTHER, Reactome, Gene MANIA, and STRING databases. RESULTS: Twelve proteins identified by LC-MS showed differential expression (over 1.5-fold, p < 0.05) by LC-MS, including 9 up-regulated in NMIBC and 3 up-regulated in MIBC patients. Proteins involved in the detoxification of reactive oxygen species and cellular responses to oxidative stress showed the most significant changes in UBC patients. Additionally, the most potential functions related to these detected proteins were associated with peroxidase, oxidoreductase, and antioxidant activity. CONCLUSION: We identified several alterations in protein expression involved in canonical pathways which were correlated with the clinical outcomes suggested might be useful as promising biomarkers for early detection, monitoring, and prognosis of UBC. CI - (c) 2023. The Author(s). FAU - Tabaei, Samira AU - Tabaei S AD - Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Haghshenas, Mohammad Reza AU - Haghshenas MR AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ariafar, Ali AU - Ariafar A AD - Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Gilany, Kambiz AU - Gilany K AD - Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. FAU - Stensballe, Allan AU - Stensballe A AD - Department of Health Science and Technology, Aalborg University, Gistrup, 9260, Denmark. AD - Clinical Cancer Research Center, Aalborg University hospital, Gistrup, 9260, Denmark. FAU - Farjadian, Shirin AU - Farjadian S AD - Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ghaderi, Abbas AU - Ghaderi A AUID- ORCID: 0000-0003-0849-3375 AD - Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Ghaderia@sums.ac.ir. AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Ghaderia@sums.ac.ir. LA - eng GR - 5072-00007B/Danish National Mass Spectrometry Platform for Functional Proteomics/ GR - 23083/Shiraz University of Medical Sciences/ GR - ICR-100-503/Shiraz Institute for Cancer research/ PT - Journal Article DEP - 20230727 PL - England TA - Clin Proteomics JT - Clinical proteomics JID - 101184586 PMC - PMC10373361 OTO - NOTNLM OT - Biomarker OT - Cellular responses OT - Proteomics OT - Urothelial bladder cancer COIS- The authors declare no competing interests. EDAT- 2023/07/28 01:08 MHDA- 2023/07/28 01:09 PMCR- 2023/07/27 CRDT- 2023/07/27 23:44 PHST- 2023/02/12 00:00 [received] PHST- 2023/07/10 00:00 [accepted] PHST- 2023/07/28 01:09 [medline] PHST- 2023/07/28 01:08 [pubmed] PHST- 2023/07/27 23:44 [entrez] PHST- 2023/07/27 00:00 [pmc-release] AID - 10.1186/s12014-023-09419-8 [pii] AID - 9419 [pii] AID - 10.1186/s12014-023-09419-8 [doi] PST - epublish SO - Clin Proteomics. 2023 Jul 27;20(1):28. doi: 10.1186/s12014-023-09419-8. PMID- 37500129 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230731 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 8 DP - 2023 Aug TI - Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study. PG - 3615-3621 LID - 10.21873/anticanres.16541 [doi] AB - BACKGROUND/AIM: Photodynamic diagnosis (PDD)-assisted transurethral resection of a bladder tumor (PDD-TURBT) in a patient receiving 5-aminolevulinic acid improved the detection of micro- and flat lesions of the bladder. This study used real-world data in Japan to examine the diagnostic accuracy of PDD-assisted targeted biopsies and white-light (WL) random biopsies and reevaluated the necessity of random biopsies. PATIENTS AND METHODS: A total of 133 patients diagnosed with bladder cancer who underwent TURBT from April 2020 to March 2022 were included in the study. Biopsy specimens obtained from 407 flat lesions or normal-like lesions, excluding biopsies from elevated lesions and TUR specimens, were used to analyze diagnostic accuracy in PDD and WL findings. RESULTS: The respective sensitivities, specificities, and negative predictive values of PDD vs. WL findings were 81.4% vs. 54.0% (p=0.0039), 70.4% vs. 81.4% (p=0.0012), and 96.4% vs. 90.6% (p=0.0144), indicating that PDD was useful for a diagnosis of exclusion. Combining the PDD and WL findings improved the detection of malignant flat lesions. Ten (PDD-positive and WL-negative) specimens from 9 patients were diagnosed as malignant. The results of PDD-assisted targeted biopsy provided an accurate assessment of the risk classification for recurrence and progression of non-muscle invasive bladder cancer (NMIBC) as defined by the Japanese Urological Association (JUA) guidelines. CONCLUSION: For NMIBC treatment, a more accurate diagnosis is important for postoperative treatment decisions. PDD-assisted targeted biopsy may be necessary and sufficient for diagnosis of flat lesions in patients with bladder cancer for treatment decision making based on JUA risk classification. CI - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Arai, Takayuki AU - Arai T AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan tomo1ata2@yahoo.co.jp. FAU - Oka, Ryuji AU - Oka R AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Tsukamoto, Ryo AU - Tsukamoto R AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Sato, Hiroaki AU - Sato H AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Goto, Yusuke AU - Goto Y AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Imamura, Yusuke AU - Imamura Y AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Sakamoto, Shinichi AU - Sakamoto S AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (Photosensitizing Agents) SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - East Asian People MH - Aminolevulinic Acid MH - *Urinary Bladder Neoplasms/pathology MH - Biopsy MH - Photosensitizing Agents OTO - NOTNLM OT - Bladder cancer OT - NMIBC OT - PDD-TURBT OT - PDD-assisted targeted biopsy OT - photodynamic diagnosis OT - transurethral resection of bladder tumor EDAT- 2023/07/28 01:08 MHDA- 2023/07/31 06:43 CRDT- 2023/07/27 20:43 PHST- 2023/05/18 00:00 [received] PHST- 2023/06/12 00:00 [revised] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/07/28 01:08 [pubmed] PHST- 2023/07/27 20:43 [entrez] AID - 43/8/3615 [pii] AID - 10.21873/anticanres.16541 [doi] PST - ppublish SO - Anticancer Res. 2023 Aug;43(8):3615-3621. doi: 10.21873/anticanres.16541. PMID- 37497994 OWN - NLM STAT- MEDLINE DCOM- 20230912 LR - 20230912 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 107 IP - 8 DP - 2023 TI - The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours. PG - 792-800 LID - 10.1159/000531443 [doi] AB - INTRODUCTION: Urine cytology (UC) is a recommended tool for the diagnosis of urothelial malignancies. Thus far, no specific recommendations regarding the role of washing cytology (WC) have been included in the guidelines. The goal of our study was to analyse the relationship between the histology of transurethrally (transurethral resection of the bladder [TURBT]) resected bladder tumours (BCa) and intraoperative UC or WC findings. MATERIALS AND METHODS: Five hundred consecutive primary TURBT cases conducted between November 2010 and 2015 at our department of the University Hospital Luebeck were retrospectively analysed. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of UC and WC were evaluated to detect BCa. Multivariate logistic regression models were fit to further examine associations between patient- and tumour-related factors and a bladder UC or WC positive for BCa. RESULTS: UC was performed in 297 patients, WC in 294 patients, and both in 261 patients. Sensitivity was 50.7% in UC, 58.1% in WC, and 62.1% for both tests combined. Specificity was 97.8% for UC, 98.0% for WC, and 96.4% for the combined tests. PPV was 98.0% for UC, 98.1% for WC, and 97.2% for combined tests. NPV was 47.8% for UC, 54.5% for WC, and 55.9% for the combined tests. The multivariate analyses revealed no association between positive UC or WC results and subsequent radical cystectomy (UC OR 1.35, 95% CI: 0.3-5.7; WC OR 2.0, 95% CI: 0.4-11.4). Neither UC nor WC was significantly correlated with local recurrence. CONCLUSIONS: Cytologic testing is an important diagnostic tool in BCa detection, showing acceptable sensitivity of around 60% and excellent specificity of over 90%. UC and WC present similar sensitivity. Our results advocate, however, against cytologic testing during primary TURBT, especially with regard to the lack of value in assessing the risk of recurrence. The clinical benefit of taking both types of samples at once is minimal. Furthermore, intraoperative WC collection does not reliably predict subsequent cystectomies. CI - (c) 2023 S. Karger AG, Basel. FAU - Struck, Julian P AU - Struck JP AD - Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg a.d. Havel, Germany. AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. FAU - Ozimek, Tomasz AU - Ozimek T AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. AD - Department of Urology, Vivantes Klinikum am Urban, Berlin, Germany. FAU - Schnoor, Maike AU - Schnoor M AD - Department of Social Medicine and Epidemiology and Department of Cancer Epidemiology, University of Luebeck, Luebeck, Germany. FAU - Offermann, Anne AU - Offermann A AD - Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. AD - Institute of Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany. FAU - Guenther, Marlis AU - Guenther M AD - Institute for Pathology, Medical School Brandenburg, Brandenburg a.d. Havel, Germany. FAU - Roesch, Marie C AU - Roesch MC AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. FAU - Wiessmeye, Judith R AU - Wiessmeye JR AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. FAU - Katalinic, Alexander AU - Katalinic A AD - Department of Social Medicine and Epidemiology and Department of Cancer Epidemiology, University of Luebeck, Luebeck, Germany. FAU - Perner, Sven AU - Perner S AD - Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. AD - Institute of Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany. FAU - Borgmann, Hendrik AU - Borgmann H AD - Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg a.d. Havel, Germany. FAU - Merseburger, Axel S AU - Merseburger AS AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. FAU - Kramer, Mario W AU - Kramer MW AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. LA - eng PT - Journal Article DEP - 20230727 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - Retrospective Studies MH - *Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/diagnosis/surgery/pathology MH - Predictive Value of Tests MH - Cystectomy MH - Urine MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - Bladder cancer OT - Cytology OT - Diagnostic test OT - Sensitivity OT - Transurethral resection of the bladder OT - Urothelial carcinoma EDAT- 2023/07/27 13:10 MHDA- 2023/09/12 06:41 CRDT- 2023/07/27 08:33 PHST- 2023/01/22 00:00 [received] PHST- 2023/05/31 00:00 [accepted] PHST- 2023/09/12 06:41 [medline] PHST- 2023/07/27 13:10 [pubmed] PHST- 2023/07/27 08:33 [entrez] AID - 000531443 [pii] AID - 10.1159/000531443 [doi] PST - ppublish SO - Urol Int. 2023;107(8):792-800. doi: 10.1159/000531443. Epub 2023 Jul 27. PMID- 37495458 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20260612 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 10 IP - 1 DP - 2024 Jan TI - Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era. PG - 41-56 LID - S2405-4569(23)00173-6 [pii] LID - 10.1016/j.euf.2023.07.002 [doi] AB - CONTEXT: Repeat transurethral resection (reTUR) is a guideline-recommended treatment strategy in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with transurethral resection of bladder tumor (TURBT); however, the impact of recent procedural/technological developments on reTUR outcomes has not been assessed yet. OBJECTIVE: To assess the outcomes of reTUR for NMIBC in the contemporary era, focusing on whether temporal differences and technical advancement, specifically, photodynamic diagnosis and en bloc resection of bladder tumor (ERBT), affect the outcomes. EVIDENCE ACQUISITION: Multiple databases were queried in February 2023 for studies investigating reTUR outcomes, such as residual tumor and/or upstaging rates, its predictive factors, and oncologic outcomes, including recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall (OS) survival. We synthesized comparative outcomes adjusting for the effect of possible confounders. EVIDENCE SYNTHESIS: Overall, 81 studies were eligible for the meta-analysis. In T1 patients initially treated with conventional TURBT (cTURBT) in the 2010s, the pooled rates of any residual tumors and upstaging on reTUR were 31.4% (95% confidence interval [CI]: 26.0-37.2%) and 2.8% (95% CI: 2.0-3.8%), respectively. Despite a potential publication bias, these rates were significantly lower than those in patients treated in the 1990-2000s (both p < 0.001). ERBT and visual enhancement-guided cTURBT significantly improved any residual tumor rates on reTUR compared with cTURBT based on both matched-cohort and multivariable analyses. Among studies adjusting for the effect of possible confounders, patients who underwent reTUR had better RFS (hazard ratio [HR]: 0.78, 95% CI: 0.62-0.97) and OS (HR: 0.86, 95% CI: 0.81-0.93) than those who did not, while it did not lead to superior PFS (HR: 0.74, 95% CI: 0.47-1.15) and CSS (HR: 0.94, 95% CI: 0.86-1.03). CONCLUSIONS: reTUR is currently recommended for high-risk NMIBC based on the persistent high rates of residual tumors after primary resection. Improvement of resection quality based on checklist applications and recent technical/procedural advancements hold the promise to omit reTUR. PATIENT SUMMARY: Recent endoscopic/procedural developments improve the outcomes of repeat resection for high-risk non-muscle-invasive bladder cancer. Further investigations are urgently needed to clarify the potential impact of the use of these techniques on the need for repeat transurethral resection in the contemporary era. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bekku, Kensuke AU - Bekku K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Chlosta, Marcin AU - Chlosta M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20230724 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 MH - Humans MH - *Cystectomy/methods MH - *Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm, Residual MH - *Non-Muscle Invasive Bladder Neoplasms/pathology/surgery MH - *Reoperation MH - Treatment Outcome MH - *Urethra/surgery OTO - NOTNLM OT - En bloc resection OT - Non-muscle-invasive bladder cancer OT - Photodynamic diagnosis OT - Repeat transurethral resection OT - Transurethral resection of bladder tumor EDAT- 2023/07/27 01:09 MHDA- 2024/03/12 06:43 CRDT- 2023/07/26 21:57 PHST- 2023/05/06 00:00 [received] PHST- 2023/06/04 00:00 [revised] PHST- 2023/07/13 00:00 [accepted] PHST- 2024/03/12 06:43 [medline] PHST- 2023/07/27 01:09 [pubmed] PHST- 2023/07/26 21:57 [entrez] AID - S2405-4569(23)00173-6 [pii] AID - 10.1016/j.euf.2023.07.002 [doi] PST - ppublish SO - Eur Urol Focus. 2024 Jan;10(1):41-56. doi: 10.1016/j.euf.2023.07.002. Epub 2023 Jul 24. PMID- 37489422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240922 IS - 2039-7275 (Print) IS - 2039-7283 (Electronic) IS - 2039-7275 (Linking) VI - 13 IP - 4 DP - 2023 Jul 9 TI - Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. PG - 806-819 LID - 10.3390/clinpract13040073 [doi] AB - INTRODUCTION: The identification of bladder detrusor muscle invasion in urothelial cancer is essential for prognosis and management. We studied the clinical, histological, and immunohistochemical expression of p16, p53, and Ki-67 in urothelial detrusor muscle-invasive bladder cancer (MIBC) and urothelial non-detrusor muscle-invasive bladder cancer (NMIBC) in Egyptian patients. METHODS: Sixty-two bladder urothelial cancer cases obtained through TURBT were included and divided into two groups: (MIBC, stage T2) and NMIBC (T1). Tissue blocks were recut and re-examined microscopically; then, the immunostaining of p16, p53, and Ki-67 was performed to compare both groups and evaluate the 13% cut-off for Ki-67, 20% for p53, and p16 intensity in various conditions aided by telepathology technology. RESULTS AND CONCLUSION: Hematuria was the main clinical first presentation, with no significant difference between either group. The mean age was 61.6 years, with male predominance (52 males and 10 females). The absence of papillary histological pattern was associated with a higher stage, including detrusor muscle invasion (p = 0.000). The overall average percent of p53 immunostaining was 12.9%, revealing no significant difference between MIBC and NMIBC when a cut-off of 20% was implicated. The Ki-67 expression was correlated with higher grade and muscle invasion; however, no association was found with the other two markers' expression. The negative immunostaining of p16 was associated with low grade and NMIBC in the case of the preservation of the papillary pattern. We recommend further studies on the cut-off of widely used markers and more immunohistochemical and genetic studies on the p16(INK4A), taking into consideration the histological pattern of conventional carcinomas. FAU - Hasan, Abdulkarim AU - Hasan A AUID- ORCID: 0000-0003-0391-306X AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Mohammed, Yasien AU - Mohammed Y AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Basiony, Mostafa AU - Basiony M AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Hanbazazh, Mehenaz AU - Hanbazazh M AD - Pathology Department, Faculty of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia. FAU - Samman, Abdulhadi AU - Samman A AD - Pathology Department, Faculty of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia. FAU - Abdelaleem, Mohamed Fayek AU - Abdelaleem MF AD - Preventive Medicine, Ministry of Health, Cairo 11516, Egypt. AD - Medixia Global LLC, Sharjah 32223, United Arab Emirates. FAU - Nasr, Mohamed AU - Nasr M AD - Histology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Abozeid, Hesham AU - Abozeid H AD - Urology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Mohamed, Hassan Ismail AU - Mohamed HI AD - Urology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Faisal, Mahmoud AU - Faisal M AD - Urology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. AD - Urology Department, King Abdullah Medical City, Makkah 24246, Saudi Arabia. FAU - Mohamed, Eslam AU - Mohamed E AD - Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt. FAU - Ashmawy, Diaa AU - Ashmawy D AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt. FAU - Tharwat, Mohamed AU - Tharwat M AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Assiut 71524, Egypt. FAU - Morsi, Deaa Fekri AU - Morsi DF AD - Pathology Department, Faculty of Medicine, Helwan University, Helwan 11795, Egypt. FAU - Farag, Abeer Said AU - Farag AS AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt. FAU - Ahmed, Eman Mohamed AU - Ahmed EM AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt. FAU - Aly, Noha M AU - Aly NM AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt. FAU - Abdel-Hamied, Hala E AU - Abdel-Hamied HE AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt. FAU - Salama, Doaa E A AU - Salama DEA AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt. AD - Pathology Department, School of Medicine, Badr University in Cairo (BUC), Cairo 11829, Egypt. FAU - Mandour, Essam AU - Mandour E AD - Pathology Department, School of Medicine, Badr University in Cairo (BUC), Cairo 11829, Egypt. LA - eng PT - Journal Article DEP - 20230709 PL - Switzerland TA - Clin Pract JT - Clinics and practice JID - 101563282 PMC - PMC10366752 OTO - NOTNLM OT - Ki-67 antigen OT - TP53 protein OT - TURBT OT - muscle-invasive bladder cancer OT - p16(INK4A) OT - telehealth OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2023/07/25 06:42 MHDA- 2023/07/25 06:43 PMCR- 2023/07/09 CRDT- 2023/07/25 04:44 PHST- 2023/06/10 00:00 [received] PHST- 2023/07/02 00:00 [revised] PHST- 2023/07/05 00:00 [accepted] PHST- 2023/07/25 06:43 [medline] PHST- 2023/07/25 06:42 [pubmed] PHST- 2023/07/25 04:44 [entrez] PHST- 2023/07/09 00:00 [pmc-release] AID - clinpract13040073 [pii] AID - clinpract-13-00073 [pii] AID - 10.3390/clinpract13040073 [doi] PST - epublish SO - Clin Pract. 2023 Jul 9;13(4):806-819. doi: 10.3390/clinpract13040073. PMID- 37487846 OWN - NLM STAT- MEDLINE DCOM- 20231106 LR - 20260813 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 41 IP - 10 DP - 2023 Oct TI - Evaluation of sarcopenia in patients receiving intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer. PG - 431.e15-431.e20 LID - S1078-1439(23)00198-9 [pii] LID - 10.1016/j.urolonc.2023.05.021 [doi] AB - BACKGROUND: Sarcopenia is associated with adverse outcomes for patients with muscle invasive bladder cancer (MIBC), but less is known about its impact in the setting of non-muscle invasive bladder cancer (NMIBC). Sarcopenia, skeletal muscle density, and adipose tissue area have been studied as markers of malnutrition and can be determined radiographically. The purpose of this study is to characterize the prevalence of sarcopenia in patients with NMIBC receiving intravesical Bacillus Calmette-Guerin (BCG). METHODS: Following institutional review board approval, patients with NMIBC having received intravesical BCG were identified using institutional pharmacy records. Patients having undergone computed tomography (CT) of the abdomen and pelvis within 90 days of treatment were included in the analysis. Using sliceOmatic 5.0 software, skeletal muscle area (cm(2)) was measured at the L3 level to calculate skeletal muscle index (SMI), a marker of sarcopenia. Subcutaneous, visceral, and intramuscular adipose tissue areas in addition to skeletal muscle density were also measured. Frailty was evaluated as a secondary aim using the 5-Item Modified Frailty Index (mFI-5). Using predefined cutoffs, the prevalence of sarcopenia was determined. Descriptive statistics were used to characterize frailty and secondary body composition characteristics. Statistical analysis was performed to evaluate the impact of sarcopenia on recurrence rate and progression. RESULTS: A total of 308 patients having received BCG between 2015 and 2020 were identified, of which 90 met criteria for analysis. Nearly all (94%) patients completed at least 5 out of 6 BCG induction instillations. Median body mass index (kg/m(2)) was 27.64 (IQR 24.9, 30.5) for females and 27.7 (IQR 24.9, 30.66) for males. Median SMI (cm(2)/m(2)) was 49.44 (IQR 39.39, 55.17) for females and 49.58 (IQR 40.25, 55.58) for males. A majority (61%) of patients were found to be sarcopenic. High-risk frailty was identified 36% of patients. There was no association between sarcopenia and recurrence rate or progression. CONCLUSIONS: Sarcopenia and frailty are highly prevalent amongst patients with NMIBC. A diagnosis of NMIBC represents a window of opportunity to identify and intervene on modifiable risk factors such as sarcopenia and frailty, which are associated with adverse outcomes in more advanced disease states. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Alam, Syed M AU - Alam SM AD - Department of Urology, University of Kansas Health System, Kansas City, KS. FAU - Larson, Matthew AU - Larson M AD - Department of Urology, University of Kansas Health System, Kansas City, KS. FAU - Srinivasan, Pugazhendhi AU - Srinivasan P AD - Department of Dietetics and Nutrition, University of Kansas, Kansas City, KS. FAU - Genz, Nick AU - Genz N AD - Department of Urology, University of Kansas Health System, Kansas City, KS. FAU - Fleer, Ryan AU - Fleer R AD - Department of Pharmacy Practice, University of Kansas Health System, Kansas City, KS. FAU - Sardiu, Mihaela AU - Sardiu M AD - Department of Biostatistics, University of Kansas, Kansas City, KS. FAU - Thompson, Jeffrey AU - Thompson J AD - Department of Biostatistics, University of Kansas, Kansas City, KS. FAU - Lee, Eugene AU - Lee E AD - Department of Urology, University of Kansas Health System, Kansas City, KS. FAU - Hamilton-Reeves, Jill AU - Hamilton-Reeves J AD - Department of Urology, University of Kansas Health System, Kansas City, KS; Department of Dietetics and Nutrition, University of Kansas, Kansas City, KS; Department of Medicine, Division of Medical Oncology, University of Kansas, Kansas City, KS. FAU - Wulff-Burchfield, Elizabeth AU - Wulff-Burchfield E AD - Department of Medicine, Division of Medical Oncology, University of Kansas, Kansas City, KS. Electronic address: ewulffburchfield@kumc.edu. LA - eng GR - P30 CA168524/CA/NCI NIH HHS/United States GR - R37 CA218118/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230722 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Male MH - Female MH - Humans MH - BCG Vaccine/adverse effects MH - *Sarcopenia/epidemiology/etiology MH - *Frailty/epidemiology MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/complications/drug therapy MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local PMC - PMC13036759 MID - NIHMS2153934 OTO - NOTNLM OT - Body composition OT - Local OT - Malnutrition OT - Neoplasm recurrence OT - Sarcopenia OT - Urinary bladder neoplasms COIS- Declaration of Competing Interest The author has no competing interests to disclose, financial or otherwise. EDAT- 2023/07/25 01:09 MHDA- 2023/11/06 06:42 PMCR- 2026/03/31 CRDT- 2023/07/24 21:59 PHST- 2023/02/11 00:00 [received] PHST- 2023/05/17 00:00 [revised] PHST- 2023/05/30 00:00 [accepted] PHST- 2023/11/06 06:42 [medline] PHST- 2023/07/25 01:09 [pubmed] PHST- 2023/07/24 21:59 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - S1078-1439(23)00198-9 [pii] AID - 10.1016/j.urolonc.2023.05.021 [doi] PST - ppublish SO - Urol Oncol. 2023 Oct;41(10):431.e15-431.e20. doi: 10.1016/j.urolonc.2023.05.021. Epub 2023 Jul 22. PMID- 37482868 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20230725 IS - 0030-9982 (Print) IS - 0030-9982 (Linking) VI - 73(Suppl 4) IP - 4 DP - 2023 Apr TI - Comparison of holmium laser, bipolar and conventional monopolar transurethral resection of bladder tumour in primary non-muscle invasive bladder cancer. PG - S251-S256 LID - 10.47391/JPMA.EGY-S4-50 [doi] AB - OBJECTIVES: To compare the efficiency and safety profile of conventional monopolar, bipolar plasmakinetic and holmium laser techniques for transurethral resection of bladder tumour. METHOD: The prospective comparative study was conducted from July 2019 to May 2021 after approval from the ethicsreview committee of Kafrelsheikh University, Egypt, and comprised patients of either gender with primary non muscle invasive bladder cancer who qualified for transurethral resection of bladder tumour. The patients were stratified into low-risk group A, intermediate risk group B and high-risk group C in accordance with the guidelines of the European Association of Urology. Comprehensive cystoscopy and panendoscopy were done in all cases. Once panendoscopy was done, tumour resection was performed with monopolar resectoscope in group A, plasmakinetic resectoscope in group B and holmium laser in group C). Data was collected at preoperative, peroperative, postoperative and follow-up stages. Data was analysed using SPSS 21. RESULTS: Of the 84 patients, 67(79.76%) were males and 17(20.23%) were females. There were 27(32.14%) patients in group A; 21(77.8%) males and 6(22.2%) females withy mean age 60.63+/-11.76 years. Group B had 32(38%) patients; 26(81.2%) males and 6(18.8%) females with mean age 65.34+/-7.55 years. Group C had 25(29.76%) patients; 20(80%) males and 5(20%) females with mean age 59.48+/-12.6 years. The mean follow-up period was 12.97+/-2.70 months in group A, 12.81+/-2.75 monthsin group B and 13.48+/-3.3 monthsin group C. Visualised complete resection was done in 23(85.8%) group A patients, 29(90.6%) group B patients and 24(96%) group C patients(p=0.018). Visualised complete resection, tumour multiplicity, tumour size, catheter duration, and hospital stay were significant predictors (p<0.05). Survival analysis showed 26(96.3%), 30(93.75%) and 25(100%) cases in groups A, B and C, respectively. CONCLUSIONS: Bipolar plasmakinetic and holmium laser techniques were found to be more effective and safer than the conventional monopolar technique for transurethral resection of bladder tumour in patients with primary non-muscle invasive bladder cancer. FAU - Elmekawy, Salah AU - Elmekawy S AD - Department of Urology, Kafrelsheikh University,Egypt. FAU - Taha, Diaa Eldin AU - Taha DE AD - Department of Urology, Kafrelsheikh University,Egypt. FAU - Nabeeh, Hosam Eldeen AU - Nabeeh HE AD - Department of Urology, Kafrelsheikh University,Egypt. FAU - Ibrahim, Ali AU - Ibrahim A AD - Department of Urology, Kafrelsheikh University,Egypt. FAU - Zeid, Ahmed Elsayed AU - Zeid AE AD - Department of Urology, Kafrelsheikh University,Egypt. FAU - Abdelbaky, Tarek AU - Abdelbaky T AD - Department of Urology, Kafrelsheikh University,Egypt. LA - eng PT - Journal Article PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 SB - IM MH - Male MH - Female MH - Humans MH - Middle Aged MH - Aged MH - *Lasers, Solid-State/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Prospective Studies MH - *Prostatic Hyperplasia/surgery MH - Transurethral Resection of Bladder MH - *Transurethral Resection of Prostate MH - *Urinary Bladder Neoplasms/surgery/pathology OTO - NOTNLM OT - Bladder neoplasms, Lasers, Prognosis, Urology, Catheters. EDAT- 2023/07/24 06:42 MHDA- 2023/07/25 06:43 CRDT- 2023/07/24 03:32 PHST- 2023/07/25 06:43 [medline] PHST- 2023/07/24 06:42 [pubmed] PHST- 2023/07/24 03:32 [entrez] AID - 10.47391/JPMA.EGY-S4-50 [doi] PST - ppublish SO - J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S251-S256. doi: 10.47391/JPMA.EGY-S4-50. PMID- 37482843 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20230725 IS - 0030-9982 (Print) IS - 0030-9982 (Linking) VI - 73(Suppl 4) IP - 4 DP - 2023 Apr TI - The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder Carcinoma Patients. PG - S118-S123 LID - 10.47391/JPMA.EGY-S4-25 [doi] AB - OBJECTIVES: To evaluate programmed death-ligand 1 immunohistochemical expression in the available variants of urinary bladder carcinoma, and to correlate its expression with the available clinicopathological features. METHOD: The retrospective study was conducted at the Faculty of Medicine, Kafrelsheikh University, Egypt, from February 2020 to April 2021, and comprised formalin-fixed and paraffin-embedded specimens of urinary bladder carcinoma belonging to patients who had no history of radiotherapy or chemotherapy. Immunohistochemicalstaining of all cases was done using anti-programmed death-ligand 1 antibody. Data was analysed using SPSS 20. RESULTS: Of the 70 specimens, 58(82.86%) had been obtained through transurethral resection of bladder tumours and 12(17.14%) through radical cystectomy. Also, 53(75.7%) specimens belonged to males and 27(24.3%) to females. The age of the cases ranged 34-83 years, and 59(84.3%) were aged >/=45 years. There were 27(38.6%) noninvasive bladder tumours and 43(61.4%) were infiltrating bladder carcinomas. Positive programmed death-ligand 1 expression was detected in 42(60%) cases. Age, gender and histopathological type were not significantly associated with the expression of programmed death-ligand 1. CONCLUSIONS: Programmed death-ligand 1 could be considered a predictive marker for aggressive bladder carcinoma and its immunohistochemical expression may aid in identifying selective patients for targeted immunotherapy. FAU - Ahmed Nor, Eman Mohamed AU - Ahmed Nor EM AD - Department of Pathology, Kafrelsheikh University,Egypt. FAU - Saied, Eman Mohamed AU - Saied EM AD - Department of Pathology, Kafrelsheikh University,Egypt. FAU - Alshenawy, Hanan Alsaeid AU - Alshenawy HA AD - Department of Pathology,Tanta University,Egypt. FAU - Shams Eldeen, Aliaa Atef AU - Shams Eldeen AA AD - Department of Pathology,Tanta University,Egypt. LA - eng PT - Journal Article PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 RN - 0 (CD274 protein, human) RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) SB - IM MH - Male MH - Female MH - Humans MH - Urinary Bladder/pathology MH - B7-H1 Antigen/analysis/metabolism MH - Egypt/epidemiology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma/pathology MH - Biomarkers, Tumor/metabolism OTO - NOTNLM OT - Carcinoma, Cell, Urinary bladder, Neoplasms, Antigen, Receptor, Immunotherapy, Muscles. EDAT- 2023/07/24 06:42 MHDA- 2023/07/25 06:43 CRDT- 2023/07/24 03:32 PHST- 2023/07/25 06:43 [medline] PHST- 2023/07/24 06:42 [pubmed] PHST- 2023/07/24 03:32 [entrez] AID - 10.47391/JPMA.EGY-S4-25 [doi] PST - ppublish SO - J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S118-S123. doi: 10.47391/JPMA.EGY-S4-25. PMID- 37482566 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230726 IS - 2510-3636 (Electronic) IS - 2510-3636 (Linking) VI - 7 IP - 1 DP - 2023 Jul 24 TI - FDG-PET/CT for lymph node staging prior to radical cystectomy. PG - 13 LID - 10.1186/s41824-023-00170-9 [doi] LID - 13 AB - BACKGROUND: (18)F-Fluorodeoxyglucose positron emission combined with computed tomography (FDG-PET/CT) has been proposed to improve preoperative staging in patients with bladder cancer subjected to radical cystectomy (RC). OBJECTIVE: Our aim was to assess the accuracy of FDG-PET/CT for lymph node staging ascertained at the multidisciplinary tumour board compared to lymph node status in the surgical lymphadenectomy specimen obtained at RC, and to explore potential factors associated with false-positive FDG-PET/CT results. DESIGN, SETTING AND PARTICIPANTS: Consecutive patients with bladder cancer undergoing RC with extended lymph node dissection between 2011 and 2019 without preoperative chemotherapy in a tertial referral cystectomy unit were included in the study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Sensitivity, specificity, positive and negative predictive values and likelihood ratios were calculated. Potential factors investigated for association with false-positive FDG-PET/CT were; bacteriuria within four weeks prior to FDG-PET/CT, Bacillus Calmette-Guerin (BCG) treatment within 12 months prior to FDG-PET/CT and transurethral resection of bladder tumour (TURB) within four weeks prior to FDG-PET/CT. RESULTS: Among 157 patients included for analysis, 44 (28%) were clinically node positive according to FDG-PET/CT. The sensitivity and specificity for detection of lymph node metastasis were 50% and 84%, respectively, and the corresponding positive predictive and negative predictive values were 61% and 76%. Positive and negative likelihood ratios were 3.0 and 0.6, respectively. No association was found between bacteriuria, previous BCG treatment or TURB within 28 days and false-positive FDG-PET/CT results. CONCLUSIONS: Preoperative FDG-PET/CT prior to RC had a clinically meaningful high specificity (84%) but lower sensitivity (50%) for detection of lymph node metastases compared to lymph node status in an extended pelvic lymphadenectomy template. We could not identify any factors associated with false-positive FDG-PET/CT outcomes. CI - (c) 2023. The Author(s). FAU - Pihl, Vilhelm AU - Pihl V AUID- ORCID: 0000-0002-5791-1193 AD - Department of Urology, Skane University Hospital, Jan Waldenstroms Gata 7, 205 02, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Markus, Maria AU - Markus M AD - Clinical Physiology and Nuclear Medicine, Skane University Hospital, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Abrahamsson, Johan AU - Abrahamsson J AD - Department of Urology, Skane University Hospital, Jan Waldenstroms Gata 7, 205 02, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Blackberg, Mats AU - Blackberg M AD - Department of Urology, Helsingborg County Hospital, Helsingborg, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Kollberg, Petter AU - Kollberg P AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Simoulis, Athanasios AU - Simoulis A AD - Department of Pathology, Skane University Hospital, Malmo, Sweden. FAU - Tragardh, Elin AU - Tragardh E AD - Clinical Physiology and Nuclear Medicine, Skane University Hospital, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Jan Waldenstroms Gata 7, 205 02, Malmo, Sweden. fredrik.liedberg@med.lu.se. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. fredrik.liedberg@med.lu.se. LA - eng GR - 2020/0709/Cancerfonden/ PT - Journal Article DEP - 20230724 PL - England TA - Eur J Hybrid Imaging JT - European journal of hybrid imaging JID - 101724113 PMC - PMC10363520 OTO - NOTNLM OT - Bladder cancer OT - FDG-PET/CT OT - Lymph node metastasis OT - Radical cystectomy OT - Sensitivity OT - Specificity OT - Staging COIS- The authors declare that they have no competing interests. EDAT- 2023/07/24 00:41 MHDA- 2023/07/24 00:42 PMCR- 2023/07/24 CRDT- 2023/07/23 23:06 PHST- 2023/04/16 00:00 [received] PHST- 2023/06/21 00:00 [accepted] PHST- 2023/07/24 00:42 [medline] PHST- 2023/07/24 00:41 [pubmed] PHST- 2023/07/23 23:06 [entrez] PHST- 2023/07/24 00:00 [pmc-release] AID - 10.1186/s41824-023-00170-9 [pii] AID - 170 [pii] AID - 10.1186/s41824-023-00170-9 [doi] PST - epublish SO - Eur J Hybrid Imaging. 2023 Jul 24;7(1):13. doi: 10.1186/s41824-023-00170-9. PMID- 37477495 OWN - NLM STAT- MEDLINE DCOM- 20231006 LR - 20250530 IS - 1940-6215 (Electronic) IS - 1940-6207 (Print) IS - 1940-6215 (Linking) VI - 16 IP - 10 DP - 2023 Oct 2 TI - Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection. PG - 561-570 LID - 10.1158/1940-6207.CAPR-23-0112 [doi] AB - FGFR3 and PIK3CA are among the most frequently mutated genes in bladder tumors. We hypothesized that recurrent mutations in these genes might be caused by common carcinogenic exposures such as smoking and other factors. We analyzed 2,816 bladder tumors with available data on FGFR3 and/or PIK3CA mutations, focusing on the most recurrent mutations detected in >/=10% of tumors. Compared to tumors with other FGFR3/PIK3CA mutations, FGFR3-Y375C was more common in tumors from smokers than never-smokers (P = 0.009), while several APOBEC-type driver mutations were enriched in never-smokers: FGFR3-S249C (P = 0.013) and PIK3CA-E542K/PIK3CA-E545K (P = 0.009). To explore possible causes of these APOBEC-type mutations, we analyzed RNA sequencing (RNA-seq) data from 798 bladder tumors and detected several viruses, with BK polyomavirus (BKPyV) being the most common. We then performed IHC staining for polyomavirus (PyV) Large T-antigen (LTAg) in an independent set of 211 bladder tumors. Overall, by RNA-seq or IHC-LTAg, we detected PyV in 26 out of 1,010 bladder tumors with significantly higher detection (P = 4.4 x 10-5), 25 of 554 (4.5%) in non-muscle-invasive bladder cancers (NMIBC) versus 1 of 456 (0.2%) of muscle-invasive bladder cancers (MIBC). In the NMIBC subset, the FGFR3/PIK3CA APOBEC-type driver mutations were detected in 94.7% (18/19) of PyV-positive versus 68.3% (259/379) of PyV-negative tumors (P = 0.011). BKPyV tumor positivity in the NMIBC subset with FGFR3- or PIK3CA-mutated tumors was also associated with a higher risk of progression to MIBC (P = 0.019). In conclusion, our results support smoking and BKPyV infection as risk factors contributing to bladder tumorigenesis in the general patient population through distinct molecular mechanisms. PREVENTION RELEVANCE: Tobacco smoking likely causes one of the most common mutations in bladder tumors (FGFR3-Y375C), while viral infections might contribute to three others (FGFR3-S249C, PIK3CA-E542K, and PIK3CA-E545K). Understanding the causes of these mutations may lead to new prevention and treatment strategies, such as viral screening and vaccination. CI - (c)2023 American Association for Cancer Research. FAU - Rao, Nina AU - Rao N AUID- ORCID: 0000-0002-0718-2148 AD - Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. AD - Department of Biology, Johns Hopkins University, Baltimore, Maryland. FAU - Starrett, Gabriel J AU - Starrett GJ AUID- ORCID: 0000-0001-5871-5306 AD - Laboratory of Cellular Oncology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. FAU - Piaskowski, Mary L AU - Piaskowski ML AUID- ORCID: 0000-0001-8453-6416 AD - Laboratory of Cellular Oncology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. FAU - Butler, Kelly E AU - Butler KE AUID- ORCID: 0000-0001-6873-325X AD - Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Golubeva, Yelena AU - Golubeva Y AUID- ORCID: 0000-0002-4576-6320 AD - Molecular Digital Pathology Laboratory, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Yan, Wusheng AU - Yan W AUID- ORCID: 0000-0002-4722-1156 AD - Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Lawrence, Scott M AU - Lawrence SM AUID- ORCID: 0000-0002-5297-7978 AD - Molecular Digital Pathology Laboratory, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Dean, Michael AU - Dean M AUID- ORCID: 0000-0003-2234-0631 AD - Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Garcia-Closas, Montserrat AU - Garcia-Closas M AUID- ORCID: 0000-0003-1033-2650 AD - Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Baris, Dalsu AU - Baris D AUID- ORCID: 0009-0001-6520-9249 AD - Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Johnson, Alison AU - Johnson A AUID- ORCID: 0000-0002-1113-1191 AD - Vermont Department of Health, Burlington, Vermont. FAU - Schwenn, Molly AU - Schwenn M AUID- ORCID: 0000-0002-9395-4887 AD - Maine Cancer Registry, Augusta, Maine. FAU - Malats, Nuria AU - Malats N AUID- ORCID: 0000-0003-2538-3784 AD - CNIO, Madrid, Spain. AD - CIBERONC, Madrid, Spain. FAU - Real, Francisco X AU - Real FX AUID- ORCID: 0000-0001-9501-498X AD - CNIO, Madrid, Spain. AD - CIBERONC, Madrid, Spain. AD - Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Kogevinas, Manolis AU - Kogevinas M AUID- ORCID: 0000-0002-9605-0461 AD - Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. FAU - Rothman, Nathaniel AU - Rothman N AUID- ORCID: 0000-0001-6924-0895 AD - Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Silverman, Debra T AU - Silverman DT AUID- ORCID: 0000-0001-8894-0301 AD - Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Dyrskjot, Lars AU - Dyrskjot L AUID- ORCID: 0000-0001-7061-9851 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Buck, Christopher B AU - Buck CB AUID- ORCID: 0000-0003-3165-8094 AD - Laboratory of Cellular Oncology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. FAU - Koutros, Stella AU - Koutros S AUID- ORCID: 0000-0001-5294-5485 AD - Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. FAU - Prokunina-Olsson, Ludmila AU - Prokunina-Olsson L AUID- ORCID: 0000-0002-9622-2091 AD - Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. LA - eng GR - R21 CA266660/CA/NCI NIH HHS/United States GR - ZIA CP010201/ImNIH/Intramural NIH HHS/United States GR - Z01 CP010125/ImNIH/Intramural NIH HHS/United States GR - ZIA CP010125/ImNIH/Intramural NIH HHS/United States GR - R01 CA256188/CA/NCI NIH HHS/United States GR - Z99 CA999999/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PL - United States TA - Cancer Prev Res (Phila) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Mutation MH - Urinary Bladder/pathology MH - Class I Phosphatidylinositol 3-Kinases/genetics MH - *Virus Diseases PMC - PMC10592262 MID - NIHMS1920861 COIS- CBB is an inventor on patents issued to NCI and receives licensing royalties for BKPyV vaccine technologies. LD has sponsored research agreements with C2i Genomics, Photocure, Natera, AstraZeneca and Ferring, has advisory/consulting roles at Ferring, UroGEN, and has received speaker/video honoraria from Roche, Pfizer and Astellas. Other authors have no conflicts of interest to report in relation to this work. EDAT- 2023/07/21 13:14 MHDA- 2023/10/06 06:42 PMCR- 2024/04/02 CRDT- 2023/07/21 09:14 PHST- 2023/03/30 00:00 [received] PHST- 2023/06/16 00:00 [revised] PHST- 2023/07/18 00:00 [accepted] PHST- 2023/10/06 06:42 [medline] PHST- 2023/07/21 13:14 [pubmed] PHST- 2023/07/21 09:14 [entrez] PHST- 2024/04/02 00:00 [pmc-release] AID - 727879 [pii] AID - 10.1158/1940-6207.CAPR-23-0112 [doi] PST - ppublish SO - Cancer Prev Res (Phila). 2023 Oct 2;16(10):561-570. doi: 10.1158/1940-6207.CAPR-23-0112. PMID- 37476386 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230722 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation. PG - 1133161 LID - 10.3389/fonc.2023.1133161 [doi] LID - 1133161 AB - BACKGROUND: The high recurrence rate of non-muscle-invasive bladder cancer (NMIBC) after tumor resection brings huge physical and financial burdens for patients. Several predictive models that predict the recurrence of patients with NMIBC have drawbacks in clinical practice. With the rapid development of therapeutic methods, more factors should be taken into consideration when constructing predictive model. METHODS: We retrospectively enrolled 90 patients who were diagnosed as intermediate- or high-risk NMIBC and received a Thulium laser resection of bladder tumor (TmLRBT) or transurethral resection of bladder tumor (TURBT) followed by BCG instillation. Univariate Cox regression analysis and multivariate Cox regression analysis were performed to screen out the independent prognostic factors of recurrence free survival (RFS). A nomogram and risk index were constructed using these prognostic factors. RESULTS: In this study, 22 patients suffered recurrence; 37 patients (41%) received TmLRBT, and over 90% patients completed intravesical BCG instillation for one year. The univariate Cox regression showed that surgery (TURBT vs TmLRBT), previous bladder tumor, tumor number, pathological stage, post-operative catheterization and number of BCG therapy were associated with RFS. The multivariate Cox regression revealed that surgery (TURBT vs TmLRBT) (HR = 3.16, 95%CI [1.02 - 9.83]); previous bladder tumor (HR = 4.03, 95%CI [1.41 - 11.54]); number of BCG therapy (HR = 0.89, 95%CI [0.84 - 0.95]) were independent prognostic factors. A nomogram was constructed and exhibited excellent capability in predicting the RFS with an AUC of 0.789, 0.848, 0.806 at 6-, 12- and 24-months respectively and a c-index of 0.822. Also, the calibration curve and decision curve analysis were performed to verify the predictive efficacy. The risk index was derived from the nomogram and also exhibited favorable capability in predicting the progression free survival (PFS) of patients. CONCLUSIONS: Patients who received TmLRBT, without previous bladder tumor history and had more intravesical BCG instillations are likely to have better RFS. The nomogram and the risk index which were constructed to predict the RFS and PFS of patients may help urologists to make clinical decisions and aid in precision medicine. CI - Copyright (c) 2023 Sun, An, Xu, Liu, Xu, Xia and Wang. FAU - Sun, Jian-Xuan AU - Sun JX AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - An, Ye AU - An Y AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Meng-Yao AU - Xu MY AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Chen-Qian AU - Liu CQ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Jin-Zhou AU - Xu JZ AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20230705 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10354449 OTO - NOTNLM OT - BCG immunotherapy OT - en-bloc resection of bladder tumor OT - non-muscle invasive bladder cancer OT - thulium laser OT - transurethral resection of bladder tumor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YZ declared a shared affiliation with the authors to the handling editor at the time of review. EDAT- 2023/07/21 06:43 MHDA- 2023/07/21 06:44 PMCR- 2023/01/01 CRDT- 2023/07/21 04:04 PHST- 2022/12/28 00:00 [received] PHST- 2023/06/14 00:00 [accepted] PHST- 2023/07/21 06:44 [medline] PHST- 2023/07/21 06:43 [pubmed] PHST- 2023/07/21 04:04 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1133161 [doi] PST - epublish SO - Front Oncol. 2023 Jul 5;13:1133161. doi: 10.3389/fonc.2023.1133161. eCollection 2023. PMID- 37470584 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231102 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 19 IP - 3 DP - 2023 Apr-Jun TI - Unusual histomorphological spectrum of urinary bladder cancers and their treatment modalities revisited: Our experience with series of five cases. PG - 617-623 LID - 10.4103/jcrt.jcrt_134_21 [doi] AB - BACKGROUND: Urinary bladder cancer is the eighth-most frequent carcinoma in men, commonly occurs in elderly male. Major risk factors are smoking, chronic cystitis, urinary stones. The most common histologic variant of bladder cancer is urothelial carcinoma (UC), but certain variants are unusual yet aggressive for which there is no consensus guideline of therapy. Those entities include neuroendocrine tumors both primary and metastatic, squamous cell carcinoma, and sarcomatoid carcinoma. Neuroendocrine tumors comprise carcinoid, small-cell carcinoma, and large-cell carcinoma. AIM: The present study is undertaken to highlight certain biological features of these unusual aggressive histological forms of bladder carcinoma and their recent treatment modality to prevent recurrence, metastasis, upgrading of tumor stage, and enable surprisingly complete remission. METHODS: This piece of hospital-based perspective study was done from June 2018 to May 2020. Both transurethral resection of bladder tumor and cystectomy surgical samples of the symptomatic patients were collected from the urology department of our institute along with demographic data. Then processed, stained in both routine H and E stain and immunohistochemical stains (Immunohistochemistry [IHC]) like PanCK, NSE, synaptophysin, chromogranin, etc. RESULTS: Total number of bladder cancer encountered was 42 cases; of these five rare variants were observed, i.e., one case each of primary and secondary small cell neuroendocrine carcinoma, one large cell carcinoma, one squamous cell carcinoma (SCC), and one case of sarcomatoid carcinoma. Histomorphology with IHC conferred the diagnosis then multimodality therapy (neoadjuvant/radiotherapy/surgery) was installed and followed up. CONCLUSION: The unconventional forms of UC can be easily diagnosed by histomorphology and can have better survival with the help of the recent multimodal treatment approach. FAU - Mohanty, Pranita AU - Mohanty P AD - Department of Pathology, IMS and SUM Hospital, Bhubaneswar, Odisha, India. FAU - Mohapatra, Ajit S AU - Mohapatra AS AD - Department of Pathology, IMS and SUM Hospital, Bhubaneswar, Odisha, India. FAU - Sabat, Debabrat AU - Sabat D AD - Department of Urology, IMS and SUM Hospital, Bhubaneswar, Odisha, India. FAU - Nayak, Jhasaketan AU - Nayak J AD - Department of Hemato-oncology, AIIMS, Bhubaneswar, Odisha, India. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 SB - IM MH - Humans MH - Male MH - Aged MH - *Carcinoma, Transitional Cell/surgery MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Small Cell/diagnosis/therapy MH - *Neuroendocrine Tumors/surgery MH - *Carcinoma, Squamous Cell/pathology MH - Cystectomy OTO - NOTNLM OT - Bladder cancer OT - cystectomy OT - large cell neuroendocrine carcinoma OT - neoadjuvant OT - neuroendocrine carcinoma OT - small cell carcinoma COIS- None EDAT- 2023/07/20 13:06 MHDA- 2023/07/20 13:07 CRDT- 2023/07/20 09:29 PHST- 2023/07/20 13:07 [medline] PHST- 2023/07/20 13:06 [pubmed] PHST- 2023/07/20 09:29 [entrez] AID - JCanResTher_2023_19_3_617_355653 [pii] AID - 10.4103/jcrt.jcrt_134_21 [doi] PST - ppublish SO - J Cancer Res Ther. 2023 Apr-Jun;19(3):617-623. doi: 10.4103/jcrt.jcrt_134_21. PMID- 37470132 OWN - NLM STAT- MEDLINE DCOM- 20231129 LR - 20240105 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 132 IP - 6 DP - 2023 Dec TI - Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial. PG - 671-677 LID - 10.1111/bju.16134 [doi] AB - OBJECTIVES: To compare University of Southern California (USC) Institute of Urology pentafecta and trifecta achievement comparing open radical cystectomy (ORC) vs robot-assisted RC (RARC) with totally intracorporeal urinary diversion (iUD) from a randomised controlled trial (RCT). PATIENTS AND METHODS: Patients were eligible for randomisation if they had a diagnostic transurethral resection of bladder tumour with clinical T stage (cT)2-4, cN0, cM0, or recurrent high-grade non-muscle-invasive bladder cancer and no anaesthesia contraindications to robotic surgery. Patients were enrolled with a covariate adaptive randomisation process based on the following variables: body mass index, American Society of Anesthesiologists score, preoperative haemoglobin, planned UD, neoadjuvant chemotherapy, and cT stage. USC pentafecta was defined as the combination at 1 year after surgery of: negative soft tissue surgical margins, >/=16 lymph node (LN) yield, absence of major (Clavien-Dindo Grade >/=III) complications at 90 days, absence of UD-related long-term sequalae, and absence of clinical recurrence. Trifecta was defined as the coexistence of daytime urinary continence, absence of major complications and recurrence-free status, all assessed at 1 year. Continuous and categorical variables were compared using Student's t-test and chi-square test, respectively. Univariable logistic regression analysis was performed to assess the role of USC pentafecta and trifecta achievement on health-related quality of life (HRQoL). RESULTS: There was no statistically significant difference in USC pentafecta and trifecta achievement between groups. Among secondary outcomes, univariable logistic regression analysis was performed and both 1-year USC pentafecta and trifecta achievement were predictors of 2-year unmodified global HRQoL. CONCLUSIONS: This study supports equivalence of RARC-iUD and ORC with regard to surgical quality as described by the USC pentafecta and trifecta. We described a significant impact of USC pentafecta and trifecta achievement on global health status/HRQoL, providing a strict correlation between objective evaluation of surgical outcomes and self-reported HRQoL. CI - (c) 2023 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Mastroianni, Riccardo AU - Mastroianni R AUID- ORCID: 0000-0003-3708-2209 AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AUID- ORCID: 0000-0003-4480-9090 AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Ferriero, Mariaconsiglia AU - Ferriero M AUID- ORCID: 0000-0001-5188-8001 AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Anceschi, Umberto AU - Anceschi U AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Bove, Alfredo Maria AU - Bove AM AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Brassetti, Aldo AU - Brassetti A AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Misuraca, Leonardo AU - Misuraca L AUID- ORCID: 0000-0002-6521-6289 AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - D'Annunzio, Simone AU - D'Annunzio S AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Guaglianone, Salvatore AU - Guaglianone S AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AUID- ORCID: 0000-0002-4868-9025 AD - Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. LA - eng GR - Ministero della Salute/ PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20230804 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - Cystectomy MH - Treatment Outcome MH - *Robotics MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Urinary Diversion MH - *Robotic Surgical Procedures/adverse effects MH - Margins of Excision MH - Postoperative Complications/surgery OTO - NOTNLM OT - bladder cancer OT - open radical cystectomy OT - randomised controlled trial OT - robot-assisted radical cystectomy OT - robotic surgery EDAT- 2023/07/20 06:42 MHDA- 2023/11/29 06:42 CRDT- 2023/07/20 04:33 PHST- 2023/11/29 06:42 [medline] PHST- 2023/07/20 06:42 [pubmed] PHST- 2023/07/20 04:33 [entrez] AID - 10.1111/bju.16134 [doi] PST - ppublish SO - BJU Int. 2023 Dec;132(6):671-677. doi: 10.1111/bju.16134. Epub 2023 Aug 4. PMID- 37468392 OWN - NLM STAT- MEDLINE DCOM- 20231024 LR - 20260611 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 5 DP - 2023 Oct TI - Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. PG - 531-534 LID - S2588-9311(23)00143-8 [pii] LID - 10.1016/j.euo.2023.06.011 [doi] AB - Adjuvant treatment with either chemotherapy or bacillus Calmette-Guerin (BCG) is recommended for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC). In this multi-institutional retrospective review, we evaluated oncological outcomes for 182 patients with IR-NMIBC treated with BCG (n = 100) or intravesical sequential gemcitabine and docetaxel (Gem/Doce; n = 82). Median follow-up was 48.6 mo (interquartile range 24.9-70.9). No patient had a previous diagnosis of high-grade disease. Recurrence rates were similar in the two treatment groups (hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.65-1.73; p = 0.8). Results were consistent after adjusting for International Bladder Cancer Group (IBCG) risk subgroups, use of single-instillation postoperative chemotherapy, use of blue light cystoscopy, and receipt of maintenance therapy (HR 0.88, 95% CI 0.47-1.64; p = 0.7). Similarly, there was no difference in the rate of stage/grade progression between the treatment groups (HR 0.66, 95% CI 0.21-2.12; p = 0.5). Rates of progression to muscle-invasive disease/metastasis (2.2%) and cancer-specific mortality (1.7%) were low in the cohort. Our results support the use of Gem/Doce as an alternative to BCG in patients with IR-NMIBC. PATIENT SUMMARY: We compared cancer control outcomes for two different treatments for intermediate-risk non-muscle-invasive bladder cancer. Our results show that a chemotherapy combination of docetaxel and gemcitabine is as effective as the BCG (bacillus Calmette-Guerin) treatment traditionally used for this type of bladder cancer. CI - Copyright (c) 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - McElree, Ian M AU - McElree IM AD - Carver College of Medicine, University of Iowa, Iowa City, IA, USA. FAU - Davaro, Facundo AU - Davaro F AD - Department of Urology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Bree, Kelly AU - Bree K AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Li, Roger AU - Li R AD - Department of Urology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City, IA, USA. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20230718 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) SB - IM CIN - Eur Urol Oncol. 2024 Feb;7(1):163. doi: 10.1016/j.euo.2023.08.007. PMID: 37679244 MH - Humans MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Docetaxel/therapeutic use MH - Gemcitabine MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Retrospective Studies EDAT- 2023/07/20 01:07 MHDA- 2023/10/23 00:44 CRDT- 2023/07/19 22:00 PHST- 2023/05/23 00:00 [received] PHST- 2023/06/19 00:00 [revised] PHST- 2023/06/29 00:00 [accepted] PHST- 2023/10/23 00:44 [medline] PHST- 2023/07/20 01:07 [pubmed] PHST- 2023/07/19 22:00 [entrez] AID - S2588-9311(23)00143-8 [pii] AID - 10.1016/j.euo.2023.06.011 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Oct;6(5):531-534. doi: 10.1016/j.euo.2023.06.011. Epub 2023 Jul 18. PMID- 37456236 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231004 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model. PG - 1189086 LID - 10.3389/fonc.2023.1189086 [doi] LID - 1189086 AB - PURPOSE: Patients with non-muscle invasive bladder cancer (NMIBC) have a high possibility of recurrence after surgery. We aimed to assess the factors associated with tumor recurrence and to construct a nomogram model that can contribute to personalized treatment plans of each patient. METHODS: 496 patients with primary bladder cancer (BC) from 2 centers were retrospectively analyzed. Preoperative neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and traditional clinical parameters were collected, then using univariate and multivariate Cox regression analysis to find out the independent risk factors associated with tumor recurrence among them, and then these independent factors were incorporated into the nomogram model. The internal calibration curves and the external calibration curves were used to verify their usefulness. RESULTS: In the training cohort, 150 patients (43.1%) experienced recurrence. After Cox regression analysis, the independent risk factors affecting recurrence-free survival (RFS) were tumor grade, immediate postoperative instillation therapy (IPPIT), NLR, and SII. These factors were used to construct a model to predict RFS 1, 2, 3, and 5 years of NMIBC patients after surgery. And then, we found that the constructed model outperforms the conventional model in terms of accuracy and predictability, the results were verified by statistical tests. CONCLUSION: Preoperative inflammatory response markers have a predictive value for postoperative recurrence in patients with NMIBC. The constructed nomogram model can be helpful in guiding personalized clinical evaluation and subsequent treatment. CI - Copyright (c) 2023 Yi, Pi, Liu, Xiong, Liu, Fu, Wang and Zhao. FAU - Yi, Xinping AU - Yi X AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. FAU - Pi, Jiangchuan AU - Pi J AD - Department of Urology, Chengdu Second People's Hospital, Chengdu, China. FAU - Liu, Chuan AU - Liu C AD - Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xiong, Yongjiang AU - Xiong Y AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Jiaji AU - Liu J AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. FAU - Fu, Wenyu AU - Fu W AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. FAU - Wang, Lanxi AU - Wang L AD - Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhao, Tao AU - Zhao T AD - Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20230629 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10339648 OTO - NOTNLM OT - Kaplan-Meier survival OT - inflammatory factors OT - intravesical instillation OT - prognostic risk factors OT - tumor recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/17 06:42 MHDA- 2023/07/17 06:43 PMCR- 2023/01/01 CRDT- 2023/07/17 04:22 PHST- 2023/03/18 00:00 [received] PHST- 2023/06/12 00:00 [accepted] PHST- 2023/07/17 06:43 [medline] PHST- 2023/07/17 06:42 [pubmed] PHST- 2023/07/17 04:22 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1189086 [doi] PST - epublish SO - Front Oncol. 2023 Jun 29;13:1189086. doi: 10.3389/fonc.2023.1189086. eCollection 2023. PMID- 37454489 OWN - NLM STAT- MEDLINE DCOM- 20230816 LR - 20230816 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 248 DP - 2023 Aug TI - miRNAs orchestration of gallbladder cancer - Particular emphasis on diagnosis, progression and drug resistance. PG - 154684 LID - S0344-0338(23)00384-9 [pii] LID - 10.1016/j.prp.2023.154684 [doi] AB - Gallbladder cancer (GBC) is characterized by a highly invasive nature and a poor prognosis, with adenocarcinoma being the main histological subtype. According to statistical data, patients diagnosed with advanced GBC have a survival rate of less than 5% for 5 years. Despite the novel therapeutic techniques, the unsatisfactory results could be related to the underlying biology of tumor cells and resistance to chemotherapy. Early diagnosis is more important than clinical therapy as it assists in determining the pathological stage of cancer and facilitates the selection of appropriate medication. Hence, it is very important to understand the precise pathogenesis of GBC and to discover potential novel biomarkers for early diagnosis of GBC. Non-coding RNAs, such as microRNAs, long non-coding RNAs, and circular RNAs, have been found to influence the transcriptional regulation of target genes associated with cancer, either directly or indirectly. microRNAs are a group of small, non-coding, single-stranded RNAs that are expressed endogenously. miRNAs play significant roles in various fundamental cellular processes. Therefore, miRNAs have the potential to serve as valuable biomarkers and therapeutic targets for GBC. CI - Copyright (c) 2023 Elsevier GmbH. All rights reserved. FAU - Shahin, Reem K AU - Shahin RK AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Elkady, Mohamed A AU - Elkady MA AD - Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11231 Cairo, Egypt. FAU - Abulsoud, Ahmed I AU - Abulsoud AI AD - Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11231 Cairo, Egypt; Biochemistry Department, Faculty of Pharmacy, Heliopolis University, Cairo 11785, Egypt. FAU - Abdelmaksoud, Nourhan M AU - Abdelmaksoud NM AD - Biochemistry Department, Faculty of Pharmacy, Heliopolis University, Cairo 11785, Egypt. FAU - Abdel Mageed, Sherif S AU - Abdel Mageed SS AD - Department of Pharmacology & Toxicology, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - El-Dakroury, Walaa A AU - El-Dakroury WA AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Zewail, Moataz B AU - Zewail MB AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Elazazy, Mahmoud AU - Elazazy M AD - Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. FAU - Sobhy, Mohamed H AU - Sobhy MH AD - Nanomedicine Research Labs, Center for Materials Science, Zewail City of Science and Technology, 6th of October City, Giza, Egypt. FAU - Nomier, Yousra AU - Nomier Y AD - Pharmacology Department, Pharmacy College, Jazan University, Saudi Arabia. FAU - Elazazy, Ola AU - Elazazy O AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Elballal, Mohammed S AU - Elballal MS AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Mohammed, Osama A AU - Mohammed OA AD - Department of Clinical Pharmacology, Faculty of Medicine, Bisha University, Bisha 61922, Saudi Arabia; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt. FAU - Midan, Heba M AU - Midan HM AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. FAU - Elrebehy, Mahmoud A AU - Elrebehy MA AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. Electronic address: mahmoud.elrebeihy@buc.edu.eg. FAU - Ziada, Bassant O AU - Ziada BO AD - Research Department, Utopia Pharmaceuticals, Nasr City, 11765 Cairo, Egypt. FAU - Doghish, Ahmed S AU - Doghish AS AD - Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt; Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11231 Cairo, Egypt. Electronic address: ahmed_doghish@azhar.edu.eg. LA - eng PT - Journal Article PT - Review DEP - 20230713 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (MicroRNAs) SB - IM MH - Humans MH - *MicroRNAs/genetics MH - *Gallbladder Neoplasms/diagnosis/genetics/pathology MH - Gene Expression Regulation, Neoplastic/genetics MH - *Carcinoma in Situ MH - Drug Resistance MH - Prognosis OTO - NOTNLM OT - Diagnosis OT - Drug resistance OT - GBC OT - Gall bladder cancer OT - MiRNA OT - Prognosis COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.. EDAT- 2023/07/17 00:42 MHDA- 2023/08/16 06:42 CRDT- 2023/07/16 18:03 PHST- 2023/06/26 00:00 [received] PHST- 2023/07/07 00:00 [revised] PHST- 2023/07/10 00:00 [accepted] PHST- 2023/08/16 06:42 [medline] PHST- 2023/07/17 00:42 [pubmed] PHST- 2023/07/16 18:03 [entrez] AID - S0344-0338(23)00384-9 [pii] AID - 10.1016/j.prp.2023.154684 [doi] PST - ppublish SO - Pathol Res Pract. 2023 Aug;248:154684. doi: 10.1016/j.prp.2023.154684. Epub 2023 Jul 13. PMID- 37446024 OWN - NLM STAT- MEDLINE DCOM- 20230717 LR - 20250626 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 13 DP - 2023 Jun 29 TI - Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. LID - 10.3390/ijms241310846 [doi] LID - 10846 AB - MicroRNAs (miRNAs) are emerging as biomarkers for the detection and prognosis of cancers due to their inherent stability and resilience. To summarize the evidence regarding the role of urinary miRNAs (umiRNAs) in the detection, prognosis, and therapy of genitourinary cancers, we performed a systematic review of the most important scientific databases using the following keywords: (urinary miRNA) AND (prostate cancer); (urinary miRNA) AND (bladder cancer); (urinary miRNA) AND (renal cancer); (urinary miRNA) AND (testicular cancer); (urinary miRNA) AND (urothelial cancer). Of all, 1364 articles were screened. Only original studies in the English language on human specimens were considered for inclusion in our systematic review. Thus, a convenient sample of 60 original articles was identified. UmiRNAs are up- or downregulated in prostate cancer and may serve as potential non-invasive molecular biomarkers. Several umiRNAs have been identified as diagnostic biomarkers of urothelial carcinoma and bladder cancer (BC), allowing us to discriminate malignant from nonmalignant forms of hematuria. UmiRNAs could serve as therapeutic targets or recurrence markers of non-muscle-invasive BC and could predict the aggressivity and prognosis of muscle-invasive BC. In renal cell carcinoma, miRNAs have been identified as predictors of tumor detection, aggressiveness, and progression to metastasis. UmiRNAs could play an important role in the diagnosis, prognosis, and therapy of urological cancers. FAU - Aveta, Achille AU - Aveta A AUID- ORCID: 0000-0001-8470-1995 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", 80138 Naples, Italy. AD - Department of Urology, Institut Paoli-Calmettes Cancer Centre, 13055 Marseille, France. FAU - Cilio, Simone AU - Cilio S AUID- ORCID: 0000-0002-8431-9830 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", 80138 Naples, Italy. AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy. FAU - Spena, Gianluca AU - Spena G AUID- ORCID: 0000-0002-6714-9315 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", 80138 Naples, Italy. FAU - Napolitano, Luigi AU - Napolitano L AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", 80138 Naples, Italy. FAU - Manfredi, Celeste AU - Manfredi C AUID- ORCID: 0000-0002-9706-8516 AD - Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Franco, Antonio AU - Franco A AD - Department of Urology, Sant'Andrea Hospital, "La Sapienza" University, 00189 Rome, Italy. FAU - Crocerossa, Fabio AU - Crocerossa F AUID- ORCID: 0000-0002-5114-2952 AD - Department of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Cerrato, Clara AU - Cerrato C AD - Urology Unit, University Hospital Southampton NHS Trust, Southampton SO16 6YD, UK. FAU - Ferro, Matteo AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Division of Urology, European Institute of Oncology, 20122 Milan, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Urology, University Sapienza, 00185 Rome, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081 Fisciano, Italy. FAU - Lasorsa, Francesco AU - Lasorsa F AUID- ORCID: 0000-0001-8884-0757 AD - Urology, Andrology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", 70124 Bari, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy. FAU - Nair, Rajesh AU - Nair R AUID- ORCID: 0000-0003-1760-9608 AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK. FAU - Walz, Jochen AU - Walz J AD - Department of Urology, Institut Paoli-Calmettes Cancer Centre, 13055 Marseille, France. FAU - Lucarelli, Giuseppe AU - Lucarelli G AUID- ORCID: 0000-0001-7807-1229 AD - Urology, Andrology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", 70124 Bari, Italy. FAU - Pandolfo, Savio Domenico AU - Pandolfo SD AUID- ORCID: 0000-0001-9621-3059 AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", 80138 Naples, Italy. AD - Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081 Fisciano, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230629 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Male MH - Humans MH - *MicroRNAs/genetics MH - *Testicular Neoplasms MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy MH - *Carcinoma, Transitional Cell MH - *Urologic Neoplasms/diagnosis/genetics MH - *Kidney Neoplasms/genetics MH - *Carcinoma, Renal Cell/genetics MH - *Prostatic Neoplasms/genetics MH - Biomarkers, Tumor/genetics PMC - PMC10341705 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - microRNAs OT - prostate cancer OT - renal cancer OT - upper tract urothelial carcinoma OT - urological cancers COIS- The authors declare no conflict of interest. EDAT- 2023/07/14 13:07 MHDA- 2023/07/17 06:42 PMCR- 2023/06/29 CRDT- 2023/07/14 01:14 PHST- 2023/05/25 00:00 [received] PHST- 2023/06/26 00:00 [revised] PHST- 2023/06/27 00:00 [accepted] PHST- 2023/07/17 06:42 [medline] PHST- 2023/07/14 13:07 [pubmed] PHST- 2023/07/14 01:14 [entrez] PHST- 2023/06/29 00:00 [pmc-release] AID - ijms241310846 [pii] AID - ijms-24-10846 [pii] AID - 10.3390/ijms241310846 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jun 29;24(13):10846. doi: 10.3390/ijms241310846. PMID- 37442722 OWN - NLM STAT- MEDLINE DCOM- 20240312 LR - 20260824 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 10 IP - 1 DP - 2024 Jan TI - Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary? PG - 189-196 LID - S2405-4569(23)00153-0 [pii] LID - 10.1016/j.euf.2023.06.012 [doi] AB - BACKGROUND: While low-risk non-muscle-invasive bladder cancer (LR-NMIBC) has a low propensity to progress, the risk of recurrence remains high (50% within 4 yr). Guidelines recommend cystoscopic surveillance after resection, but the necessary duration of follow-up is debated. OBJECTIVE: To determine the risk of recurrence beyond 5 yr after diagnosis in patients with LR-NMIBC, and to identify risk factors of recurrence. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter retrospective observational study, patients who received their first transurethral bladder tumor resection before 2016 for LR-NMIBC were included. Low risk was defined as a primary, solitary, low grade, Ta bladder tumor measuring <3 cm. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was determination of the recurrence rates at 1, 2, and 5 yr. The secondary endpoints included overall recurrence-free survival (RFS) and high-risk RFS. A univariate analysis and multivariable logistic regression were performed to assess the risk factors for recurrence over the study period. RESULTS AND LIMITATIONS: The median age of the 577 patients was 70.9 yr, and 126 (21.8%) patients were female. The median follow-up was 69.6 (interquartile range: 58.4) mo, and recurrence was observed in 236 (40.9%) patients. The 1-, 2-, and 5-yr RFS rates were 81.6% (95% confidence interval 78.4-84.9), 72.4% (68.7-76.3), and 59.2% (55-63.8), respectively. Recurrence after 5 yr was observed in 13.1% (28/213). High-risk recurrence, defined as the first recurrence of a high-grade and/or >/=T1 tumor, occurred in 6.2% (36/579) overall and 2.8% (6/213) after 5 yr. The lack of a single postoperative dose of chemotherapy and tumor size >2 cm were prognostic factors of recurrence. CONCLUSIONS: The risk of recurrence in patients with LR-NMIBC decreases progressively after the 1st year and remains low beyond 5 yr. Discontinuation of endoscopic surveillance after 5 yr in patients with LR-NMIBC can be discussed. Treatment with postoperative chemotherapy and tumor size <2 cm may be relevant variables to identify patients who will benefit from cystoscopic follow-up as short as 12 mo. PATIENT SUMMARY: In this study, we observed that 13% of patients who did not have a recurrence during the first 5 yr following the diagnosis of low-risk non-muscle-invasive bladder cancer will recur after this time point. Discontinuation of cystoscopic surveillance can be discussed after 5 yr in these patients. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Ma, Joshua AU - Ma J AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse, Toulouse, France. Electronic address: roumiguie_mathieu@yahoo.fr. FAU - Hayashi, Tetsutaro AU - Hayashi T AD - Department of Urology, Hiroshima University, Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Kohada, Yuki AU - Kohada Y AD - Department of Urology, Hiroshima University, Graduate School of Biomedical Sciences, Hiroshima, Japan; Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, Sinai Health System, Toronto, ON, Canada; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada. FAU - Levy, Stephan AU - Levy S AD - Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse, Toulouse, France. FAU - Matsumoto, Takashi AU - Matsumoto T AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Sano, Takeshi AU - Sano T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20230711 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - Female MH - Male MH - *Non-Muscle Invasive Bladder Neoplasms MH - Disease Progression MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - Risk Factors OTO - NOTNLM OT - Cystoscopy OT - Long-term follow-up OT - Low grade OT - Urinary bladder neoplasm EDAT- 2023/07/14 13:06 MHDA- 2024/03/12 06:43 CRDT- 2023/07/13 22:00 PHST- 2023/01/31 00:00 [received] PHST- 2023/06/02 00:00 [revised] PHST- 2023/06/27 00:00 [accepted] PHST- 2024/03/12 06:43 [medline] PHST- 2023/07/14 13:06 [pubmed] PHST- 2023/07/13 22:00 [entrez] AID - S2405-4569(23)00153-0 [pii] AID - 10.1016/j.euf.2023.06.012 [doi] PST - ppublish SO - Eur Urol Focus. 2024 Jan;10(1):189-196. doi: 10.1016/j.euf.2023.06.012. Epub 2023 Jul 11. PMID- 37442564 OWN - NLM STAT- MEDLINE DCOM- 20231220 LR - 20250104 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 133 IP - 1 DP - 2024 Jan TI - Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin. PG - 63-70 LID - 10.1111/bju.16127 [doi] AB - OBJECTIVE: To evaluate the impact of age on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette-Guerin (BCG). PATIENTS AND METHODS: We performed an Institutional Review Board-approved retrospective study analysing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020. Adequate BCG was defined as per United States Food and Drug Administration (FDA) guidelines as being receipt of at least five of six induction BCG instillations with a minimum of two additional doses (of planned maintenance or of re-induction) of BCG instillations within a span of 6 months. The study's primary outcome was to determine if age >70 years was associated with progression to MIBC cancer or distant metastasis. The cumulative incidence method and the competing-risk regression analyses were used to investigate the association of advanced age (>70 years) with progression, high-grade (HG) recurrence and cancer-specific mortality (CSM). RESULTS: Overall, data from 632 patients were analysed: 355 patients (56.2%) were aged 70 years. Age >70 years did not adversely affect either cumulative incidence of progression or HG recurrence (P = 0.067 and P = 0.644, respectively). On competing-risk regression analyses, age >70 years did not emerge as an independent predictor of progression or HG recurrence (sub-standardised hazard ratio [SHR] 1.57, 95% confidence interval [CI] 0.87-2.81, P = 0.134; and SHR 1.05, 95% CI 0.77-1.44, P = 0.749). Not unexpectedly, patients in the older group did have higher overall mortality (P < 0.001) but not CSM (P = 0.057). CONCLUSION: Age >70 years was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. BCG should not be withheld from older patients seeking for bladder sparing options. CI - (c) 2023 BJU International. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. AD - Humanitas University, Milan, Italy. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Sood, Akshay AU - Sood A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick AU - Hensley P AD - Department of Urology, University of Kentucky, Lexington, KY, USA. FAU - Bree, Kelly AU - Bree K AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Lobo, Niyati AU - Lobo N AUID- ORCID: 0000-0002-6505-8399 AD - Department of Urology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom of Great Britain and Northern Ireland. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230802 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/pathology MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/pathology PMC - PMC10787034 MID - NIHMS1918072 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - age OT - competing risk analysis OT - non-muscle-invasive bladder cancer OT - oncological outcomes OT - progression EDAT- 2023/07/14 13:06 MHDA- 2023/12/20 06:42 PMCR- 2025/01/01 CRDT- 2023/07/13 20:33 PHST- 2023/12/20 06:42 [medline] PHST- 2023/07/14 13:06 [pubmed] PHST- 2023/07/13 20:33 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.1111/bju.16127 [doi] PST - ppublish SO - BJU Int. 2024 Jan;133(1):63-70. doi: 10.1111/bju.16127. Epub 2023 Aug 2. PMID- 37441349 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 53 DP - 2023 Jul TI - Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. PG - 16-22 LID - 10.1016/j.euros.2023.04.013 [doi] AB - BACKGROUND: Data for bladder-sparing treatment (BST) in bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) patients report short-term outcomes limited to 1-2 yr. OBJECTIVE: To assess long-term survival outcomes of BCG-unresponsive NMIBC patients treated with BST. DESIGN SETTING AND PARTICIPANTS: BCG-unresponsive NMIBC patients diagnosed between January 2000 and September 2021 from an institutional NMIBC registry were evaluated. INTERVENTION: Long-term survival outcomes for patients receiving BST, early radical cystectomy (RC), and delayed RC were compared. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoints were overall survival (OS) and cancer-specific survival (CSS). RESULTS AND LIMITATIONS: In total, 114 patients with a median follow-up of 71.2 mo (interquartile range: 32.6-132.2) were analyzed. There were no significant differences in OS (hazard ratio [HR]: 1.40, 95% confidence interval [CI]: 0.68-2.89, p = 0.4) or CSS (HR: 0.88, 95% CI: 0.22-3.55, p = 0.9) between patients undergoing early RC (n = 38) and BST (n = 76). At 60 mo, BST patients had a high-grade recurrence-free rate, muscle-invasive disease/metastasis progression-free rate, and avoidance of RC rate of 37%, 83%, and 58%, respectively. Current smoker status (HR: 4.44, 95% CI: 1.41-13.97, p = 0.011) was the only variable predictive of high-grade recurrence following a multivariable analysis. The median time to RC from BCG-unresponsive date was 2.1 and 11.7 mo for those undergoing early RC and delayed RC (after BST), respectively. Patients treated with early RC had a higher incidence of cT1 disease (53% vs 36%, p = 0.049) and lymphovascular invasion (LVI; 11% vs 0%, p = 0.011) compared to patients treated with BST. Survival outcomes were similar between groups: 10-yr OS-58% versus 50% (HR: 1.40, 95% CI: 0.68-2.89, p = 0.4), and 10-yr CSS-81% versus 85% (HR: 0.88, 95% CI: 0.22-3.55, p = 0.9). CONCLUSIONS: An analysis of long-term survival of BCG-unresponsive NMIBC patients receiving BST suggests that it may be safe in patients without LVI and/or variant histology and nonsmokers. Survival outcomes for patients treated with BST may not be inferior to those receiving early RC. PATIENT SUMMARY: Bladder-sparing treatment can be offered to appropriately selected patients who have bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer. Long-term outcomes may not be inferior to those for patients who opt for early radical cystectomy. CI - (c) 2023 The Author(s). FAU - Tan, Wei Shen AU - Tan WS AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grajales, Valentina AU - Grajales V AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick AU - Hensley P AD - Department of Urology, University of Kentucky, Lexington, KY, USA. FAU - Bree, Kelly AU - Bree K AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Msaouel, Pavlos AU - Msaouel P AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Genitourinary Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article DEP - 20230513 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC10334230 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Intravesical OT - Non-muscle-invasive bladder cancer OT - Radical cystectomy OT - Survival EDAT- 2023/07/13 19:14 MHDA- 2023/07/13 19:15 PMCR- 2023/05/13 CRDT- 2023/07/13 15:25 PHST- 2023/04/20 00:00 [accepted] PHST- 2023/07/13 19:15 [medline] PHST- 2023/07/13 19:14 [pubmed] PHST- 2023/07/13 15:25 [entrez] PHST- 2023/05/13 00:00 [pmc-release] AID - S2666-1683(23)00213-6 [pii] AID - 10.1016/j.euros.2023.04.013 [doi] PST - epublish SO - Eur Urol Open Sci. 2023 May 13;53:16-22. doi: 10.1016/j.euros.2023.04.013. eCollection 2023 Jul. PMID- 37417560 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20250923 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 64 IP - 4 DP - 2023 Jul TI - Pyuria as an independent predictor of intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial carcinoma. PG - 353-362 LID - 10.4111/icu.20230066 [doi] AB - PURPOSE: About one-third of patients who undergo radical nephroureterectomy (RNUx) for upper tract urothelial carcinoma (UTUC) experience intravesical recurrence (IVR). This study investigated whether pyuria is a feasible predictor of IVR after RNUx in patients with UTUC. MATERIALS AND METHODS: Seven hundred forty-three patients with UTUC who underwent RNUx at a single institute were analyzed in this study. The participants were divided into two groups: those without pyuria (non-pyuria) and those with pyuria. Kaplan-Meier survival analysis was performed, and p-values were assessed using the log-rank test. Cox regression analyses were performed to identify the independent predictors of survival. RESULTS: The pyuria group had a shorter IVR-free survival period (p=0.009). The five-year IVR-free survival rate was 60.0% in the non-pyuria group vs. 49.7% in the pyuria group according to the Kaplan-Meier survival analysis. After the multivariate Cox regression analysis, pyuria (hazard ratio [HR]=1.368; p=0.041), a concurrent bladder tumor (HR=1.757; p=0.005), preoperative ureteroscopy (HR=1.476; p=0.013), laparoscopic surgery (HR=0.682; p=0.048), tumor multiplicity (HR=1.855; p=0.007), and a larger tumor (HR=1.041; p=0.050) were predictors of risk for IVR. There was no association between pyuria and recurrence-free survival (p=0.057) or cancer-specific survival (p=0.519) in the Kaplan-Meier survival analysis. CONCLUSIONS: This study concluded that pyuria was an independent predictor of IVR in patients with UTUC after RNUx. CI - (c) The Korean Urological Association. FAU - Lee, Jooho AU - Lee J AUID- ORCID: 0000-0001-7989-2045 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Si Hyun AU - Kim SH AUID- ORCID: 0000-0002-5984-9485 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AUID- ORCID: 0000-0002-8076-3643 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Han, Jang Hee AU - Han JH AUID- ORCID: 0000-0003-4942-4632 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AUID- ORCID: 0000-0002-5874-9167 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AUID- ORCID: 0000-0002-2200-5019 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AUID- ORCID: 0000-0002-1987-2111 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. kuuro70@snu.ac.kr. LA - eng PT - Journal Article PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Humans MH - Nephroureterectomy MH - *Urinary Bladder Neoplasms/complications/surgery MH - *Carcinoma, Transitional Cell/complications/surgery/pathology MH - Retrospective Studies MH - Ureteroscopy/adverse effects MH - *Pyuria/etiology PMC - PMC10330412 OTO - NOTNLM OT - Carcinoma OT - Pyuria OT - Transitional cell carcinoma OT - Urinary bladder COIS- The authors have nothing to disclose. EDAT- 2023/07/07 13:05 MHDA- 2023/07/10 06:42 PMCR- 2023/07/01 CRDT- 2023/07/07 07:53 PHST- 2023/02/27 00:00 [received] PHST- 2023/04/07 00:00 [revised] PHST- 2023/04/12 00:00 [accepted] PHST- 2023/07/10 06:42 [medline] PHST- 2023/07/07 13:05 [pubmed] PHST- 2023/07/07 07:53 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - 64.353 [pii] AID - 10.4111/icu.20230066 [doi] PST - ppublish SO - Investig Clin Urol. 2023 Jul;64(4):353-362. doi: 10.4111/icu.20230066. PMID- 37415632 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 26 IP - 2 DP - 2023 Aug TI - Combined use of a 980‑nm diode laser and preoperative intravesical instillation of pirarubicin for the prevention of short‑term recurrence of non‑muscle invasive bladder cancer: A pilot study. PG - 322 LID - 10.3892/ol.2023.13908 [doi] LID - 322 AB - At present, transurethral resection of bladder tumors (TURBT) is the main surgical method for treating non-muscle invasive bladder cancer (NMIBC), but its postoperative recurrence needs to be prevented. The aim of the present study was to investigate the efficacy of a 980-nm diode laser combined with preoperative intravesical instillation of pirarubicin (THP) for the prevention of NMIBC recurrence. The data of 120 patients with NMIBC who underwent transurethral resection between May 2021 and July 2022 were retrospectively collected, and these patients were followed up. The patients were divided into four groups based on the surgical method used and preoperative intravesical instillation of THP as follows: i) 980-nm diode laser with THP (LaT); ii) 980-nm diode laser alone (La); iii) TURBT with THP (TUT); and iv) TURBT alone (TU). Clinicopathological variables, postoperative complications and short-term outcomes among the aforementioned groups were analyzed. The blood loss volume and the incidence of perforation and delayed bleeding were significantly lower in the LaT and La groups compared with those in the TUT and TU groups. The days of bladder irrigation, catheter extubation and postoperative hospitalization were significantly shorter in the LaT and La groups compared with the TUT and TU groups. The detection rate of suspicious lesions was significantly higher in the THP irrigation groups (LaT and TUT) compared with that in the saline irrigation groups (La and TU). Tumor diameter and number, 980-nm laser and THP irrigation were shown to be independent risk factors in the Cox regression analysis. In addition, the recurrence-free survival (RFS) rate of the LaT group was significantly higher than that of the other three groups. In conclusion, a 980-nm diode laser can effectively reduce intraoperative blood loss and the incidence of perforation, and accelerate postoperative recovery. Preoperative intravesical instillation of THP is conducive to identifying suspicious lesions. The combination of a 980-nm laser with preoperative THP intravesical instillation can significantly prolong RFS time. CI - Copyright: (c) Tang et al. FAU - Tang, Zhen AU - Tang Z AD - Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China. FAU - Peng, Jiao AU - Peng J AD - Department of Medical Imaging, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China. FAU - Wu, Shangxin AU - Wu S AD - Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China. FAU - Zhao, Fenfen AU - Zhao F AD - Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China. FAU - Wu, Mingui AU - Wu M AD - Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China. LA - eng PT - Journal Article DEP - 20230613 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC10320430 OTO - NOTNLM OT - 980-nm diode laser OT - NMIBC OT - THP COIS- The authors declare that they have no competing interests. EDAT- 2023/07/07 06:42 MHDA- 2023/07/07 06:43 PMCR- 2023/06/13 CRDT- 2023/07/07 03:55 PHST- 2023/02/18 00:00 [received] PHST- 2023/05/31 00:00 [accepted] PHST- 2023/07/07 06:43 [medline] PHST- 2023/07/07 06:42 [pubmed] PHST- 2023/07/07 03:55 [entrez] PHST- 2023/06/13 00:00 [pmc-release] AID - OL-26-2-13908 [pii] AID - 10.3892/ol.2023.13908 [doi] PST - epublish SO - Oncol Lett. 2023 Jun 13;26(2):322. doi: 10.3892/ol.2023.13908. eCollection 2023 Aug. PMID- 37410236 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20231117 IS - 1940-6029 (Electronic) IS - 1064-3745 (Linking) VI - 2684 DP - 2023 TI - Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer. PG - 199-212 LID - 10.1007/978-1-0716-3291-8_12 [doi] AB - BACKGROUND: Although a plethora of urine markers for diagnosis and follow-up of patients with bladder cancer (BC) has been developed and studied, the clinical impact of urine testing on patient management remains unclear. The goal of this manuscript is to identify scenarios for a potential use of modern point-of-care (POC) urine marker assays in the follow-up of patients with high-risk non-muscle-invasive BC (NMIBC) and estimate potential risks and benefits. METHODS: To permit comparison between different assays, the results of 5 different POC assays studied in a recent prospective multicenter study including 127 patients with suspicious cystoscopy undergoing TURB were used for this simulation. For the current standard of care (SOC), a "marker-enforced" procedure, and a combined strategy sensitivity (Se), estimated number of cystoscopies, and the numbers needed to diagnose (NND) over a 1-year follow-up period were calculated. RESULTS: For regular cystoscopy (SOC), a Se of 91.7% and a NND of 42.2 repetitive office cystoscopies (WLCs) for 1 recurrent tumor at 1 year were calculated. For the "marker-enforced" strategy, marker sensitivities between 94.7% and 97.1% were observed. The "combined" strategy yielded for markers with a Se exceeding 50% an overall Se at 1 year similar or superior to the current SOC. Savings regarding the number of cystoscopies in the "marker-enforced" strategy vs. the SOC were small, while, depending on the marker, up to 45% of all cystoscopies may be saved using the "combined" strategy. CONCLUSIONS: Based on the results of this simulation, a marker-supported follow-up of patients with high-risk (HR) NMIBC is safe and offers options to significantly reduce the number of cystoscopies without compromising the Se. Further research focusing on prospective randomized trials is needed to finally find a way to include marker results into clinical decision-making. CI - (c) 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Ecke, Thorsten H AU - Ecke TH AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. thorsten.ecke@helios-gesundheit.de. AD - Department of Urology, Universitatsmedizin Berlin Charite, Berlin, Germany. thorsten.ecke@helios-gesundheit.de. AD - German Study Group of Bladder Cancer (DFBK e.V.), Munich, Germany. thorsten.ecke@helios-gesundheit.de. FAU - Benderska-Soder, Natalya AU - Benderska-Soder N AD - Urologie 24, Nurnberg, Germany. FAU - Bismarck, Ekkehardt AU - Bismarck E AD - Urologie 24, Nurnberg, Germany. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Urology, University of Regensburg, Caritas-Hospital St. Josef, Regensburg, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Studienpraxis Urologie, Nurtingen, Germany. AD - Medical Faculty, University of Tubingen, Tubingen, Germany. FAU - Schmitz-Drager, Bernd J AU - Schmitz-Drager BJ AD - Urologie 24, Nurnberg, Germany. AD - Department of Urology, Friedrich-Alexander University, Erlangen, Germany. LA - eng PT - Journal Article PT - Multicenter Study PL - United States TA - Methods Mol Biol JT - Methods in molecular biology (Clifton, N.J.) JID - 9214969 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Follow-Up Studies MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Point-of-Care Systems MH - Biomarkers, Tumor MH - *Urinary Bladder Neoplasms/diagnosis/pathology OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Disease management OT - Follow-up OT - Surveillance OT - Urinary tumor markers EDAT- 2023/07/06 13:14 MHDA- 2023/07/10 06:42 CRDT- 2023/07/06 11:11 PHST- 2023/07/10 06:42 [medline] PHST- 2023/07/06 13:14 [pubmed] PHST- 2023/07/06 11:11 [entrez] AID - 10.1007/978-1-0716-3291-8_12 [doi] PST - ppublish SO - Methods Mol Biol. 2023;2684:199-212. doi: 10.1007/978-1-0716-3291-8_12. PMID- 37410232 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20260127 IS - 1940-6029 (Electronic) IS - 1064-3745 (Linking) VI - 2684 DP - 2023 TI - Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry. PG - 145-151 LID - 10.1007/978-1-0716-3291-8_8 [doi] AB - Bladder cancer is the fifth most common cancer in the United States. Most bladder cancers are early-stage lesions confined to the mucosa or submucosa and are therefore classified as non-muscle-invasive bladder cancer (NMIBC). A minority of tumors are diagnosed after they have invaded the underlying detrusor muscle and are classified as muscle-invasive bladder cancer (MIBC). Mutational inactivation of the STAG2 tumor suppressor gene is common in bladder cancer, and we and others have recently demonstrated that STAG2 mutation status can be used as an independent prognostic biomarker to predict whether NMIBC will recur and/or progress to MIBC. Here we describe an immunohistochemistry-based assay for identifying the STAG2 mutational status of bladder tumors. CI - (c) 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Park, Youngrok AU - Park Y AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Lelo, Alana AU - Lelo A AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Harris, Brent AU - Harris B AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Berry, Deborah L AU - Berry DL AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Chaldekas, Krysta AU - Chaldekas K AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Kim, Jung-Sik AU - Kim JS AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. FAU - Waldman, Todd AU - Waldman T AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA. waldmant@georgetown.edu. LA - eng GR - R01 CA169345/CA/NCI NIH HHS/United States GR - R01 CA267872/CA/NCI NIH HHS/United States GR - P30 CA051008/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Methods Mol Biol JT - Methods in molecular biology (Clifton, N.J.) JID - 9214969 RN - 0 (Antigens, Nuclear) RN - 0 (Cell Cycle Proteins) RN - 0 (STAG2 protein, human) RN - 0 (Cohesins) SB - IM MH - Humans MH - Immunohistochemistry MH - *Antigens, Nuclear/genetics MH - Cell Cycle Proteins MH - Neoplasm Recurrence, Local/genetics MH - *Urinary Bladder Neoplasms/diagnosis/genetics/pathology MH - Neoplasm Invasiveness MH - Cohesins OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Cohesin OT - Immunohistochemistry OT - STAG2 EDAT- 2023/07/06 13:14 MHDA- 2023/07/10 06:42 CRDT- 2023/07/06 11:11 PHST- 2023/07/10 06:42 [medline] PHST- 2023/07/06 13:14 [pubmed] PHST- 2023/07/06 11:11 [entrez] AID - 10.1007/978-1-0716-3291-8_8 [doi] PST - ppublish SO - Methods Mol Biol. 2023;2684:145-151. doi: 10.1007/978-1-0716-3291-8_8. PMID- 37396698 OWN - NLM STAT- MEDLINE DCOM- 20230705 LR - 20230705 IS - 1937-8688 (Electronic) VI - 44 DP - 2023 TI - Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study. PG - 145 LID - 10.11604/pamj.2023.44.145.38621 [doi] LID - 145 AB - INTRODUCTION: neutrophil/lymphocyte ratio (NLR), as a biomarker of the systemic inflammatory response, has been studied for diverse tumors. Our study aims to determine whether the NLR can be reliably used as a tool to predict disease course in patients diagnosed with primary non-muscle invasive bladder tumors (NMIBC). METHODS: a retrospective study between 2009 to 2014 was conducted on 300 patients newly diagnosed with NMIBC at our institution. The cut-off value of NLR was set at 2.5. Survival curves were compared using the log-rank test. The association between recurrence, progression, and NLR was assessed univariate, and the prognostic significance of high NLR was assessed using multivariate analysis. RESULTS: one hundred and seventy-five patients had an NLR <2.5 and 125 patients had an NLR >/= 2.5. The survival rate with recurrence at 5 years was higher in the group with an NLR >2.5 (p<0.001, 35 vs 18 months), similarly, the survival rate with progression at 5 years was higher in the group with an NLR > 2.5 (p=0.001, 36 vs. 27 months). The failure rate of immunotherapy using BCG was higher when the NLR was over 2.5. In a multivariate analysis, the factors associated with recurrence were NLR>2.5 (HR=2.03, 95% CI=1.32-3.11, p=0.001), pathologic stage pT1 (HR=2.42, 95% CI=1.52-3.85, p=0.001), high-grade (HR=1.76, 95% CI=1.52-3.92, p=0.01), concomitant CIS lesions (HR=2.31, 95% CI=1.36-3.92, p=0.001), presence of lymphovascular emboli (HR=5.77, 95% CI=1.77-18.78, p=0.004), and BCG immunotherapy failure (HR=5.29, 95% CI=2.88-9.70, p=0.001). With regard to progression, in a multivariate study, the significant factors were NLR>2.5(HR=2.91, 95% CI=1.17-7.23, p=0.01), BCG immunotherapy failure (HR=5.68, 95% CI=3.16-10.22, p=0.001), and the presence of lymphovascular emboli (HR=5.01, 95% CI=1.50-16.05, p=0.001). CONCLUSION: preoperative NLR value could predict recurrence, progression, and failure of BCG immunotherapy in NMIBC patients. CI - Copyright: Idriss Ziani et al. FAU - Ziani, Idriss AU - Ziani I AD - Department of Urological Surgery "A", Ibn Sina University Hospital of Rabat, Rabat, Morocco. AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. FAU - Ibrahimi, Ahmed AU - Ibrahimi A AD - Department of Urological Surgery "A", Ibn Sina University Hospital of Rabat, Rabat, Morocco. AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. FAU - Zaoui, Youssef AU - Zaoui Y AD - Department of Urological Surgery "A", Ibn Sina University Hospital of Rabat, Rabat, Morocco. AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. FAU - El Sayegh, Hachem AU - El Sayegh H AD - Department of Urological Surgery "A", Ibn Sina University Hospital of Rabat, Rabat, Morocco. AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. FAU - Abouqal, Redouane AU - Abouqal R AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. AD - Acute Medical Unit, Ibn Sina University Hospital, Faculty of Medicine and Pharmacy, Rabat, Morocco. AD - Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University in Rabat, Rabat, Morocco. FAU - Nouini, Yassine AU - Nouini Y AD - Department of Urological Surgery "A", Ibn Sina University Hospital of Rabat, Rabat, Morocco. AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. FAU - Bouziane, Amal AU - Bouziane A AD - Faculty of Medicine of Rabat, Mohammed V University in Rabat, Rabat, Morocco. AD - Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University in Rabat, Rabat, Morocco. AD - Department of Periodontology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco. LA - eng PT - Journal Article DEP - 20230327 PL - Uganda TA - Pan Afr Med J JT - The Pan African medical journal JID - 101517926 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Neutrophils MH - Retrospective Studies MH - BCG Vaccine MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Lymphocytes/pathology MH - Prognosis MH - Neoplasm Recurrence, Local/pathology MH - Disease Progression PMC - PMC10311227 OTO - NOTNLM OT - BCG failure OT - Non-muscle invasive bladder cancer OT - biomarker OT - immunotherapy OT - neutrophil/lymphocyte ratio COIS- The authors declare no competing interests. EDAT- 2023/07/03 13:06 MHDA- 2023/07/05 06:42 PMCR- 2023/03/27 CRDT- 2023/07/03 11:24 PHST- 2022/12/25 00:00 [received] PHST- 2023/03/10 00:00 [accepted] PHST- 2023/07/05 06:42 [medline] PHST- 2023/07/03 13:06 [pubmed] PHST- 2023/07/03 11:24 [entrez] PHST- 2023/03/27 00:00 [pmc-release] AID - PAMJ-44-145 [pii] AID - 10.11604/pamj.2023.44.145.38621 [doi] PST - epublish SO - Pan Afr Med J. 2023 Mar 27;44:145. doi: 10.11604/pamj.2023.44.145.38621. eCollection 2023. PMID- 37395155 OWN - NLM STAT- MEDLINE DCOM- 20230922 LR - 20230922 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 132 IP - 4 DP - 2023 Oct TI - Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series. PG - 428-434 LID - 10.1111/bju.16098 [doi] AB - OBJECTIVES: To evaluate the oncological and perioperative outcomes from a large, single-centre, robot-assisted radical cystectomy (RARC) cohort performed with intracorporeal urinary diversion (ICUD). PATIENTS AND METHODS: Patients who underwent RARC because of bladder cancer or recurrent carcinoma in situ from June 2009 until August 2020 at Herlev and Gentofte Hospital were prospectively and consecutively included. Kaplan-Meier survival analysis was used to estimate recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). A Cox proportional hazards model was used to identify individual predictors of outcomes. Multiple logistic regression analysis was used to identify predictors of high-grade complications (Clavien-Dindo Grade >/=III). RESULTS: A total of 542 patients were included. The median (interquartile range) follow-up was 5.3 (2.73-8.06) years. In all, 78 patients (14%) were converted to open surgery; 15 (3%) during cystectomy and 63 patients (12%) were converted from ICUD to extracorporeal urinary diversion. The 5-year RFS, CSS and OS rates were 63% (95% confidence interval [CI] 59%-68%), 75% (95% CI 72%-80%) and 67% (95% CI 63%-72%), respectively. Pathological non-organ-confined disease (tumour stage >T2 or positive lymph nodes) predicted poorer RFS, CSS and OS. Reconstruction with a neobladder (20% of cases) compared to an ileal conduit was the only predictor of high-grade complications (odds ratio 2.54, 95% CI 1.46-4.43; P < 0.001). CONCLUSION: A RARC with ICUD is feasible as a standard surgical procedure for bladder cancer with only a few patients converted to open surgery. In our hands reconstruction with a neobladder was a strong predictor for high-grade complications. CI - (c) 2023 BJU International. FAU - Vrang, Marie-Louise AU - Vrang ML AUID- ORCID: 0000-0002-5489-851X AD - Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark. FAU - Ostergren, Peter Busch AU - Ostergren PB AUID- ORCID: 0000-0003-4762-039X AD - Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark. FAU - Fode, Mikkel Mejlgaard AU - Fode MM AUID- ORCID: 0000-0002-8963-4581 AD - Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark. FAU - Vangedal, Michael AU - Vangedal M AUID- ORCID: 0009-0002-6740-6040 AD - Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark. FAU - Lam, Gitte Wrist AU - Lam GW AUID- ORCID: 0000-0003-0399-0575 AD - Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20230703 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - Cystectomy/methods MH - *Robotics MH - Treatment Outcome MH - Lymph Node Excision/adverse effects MH - Retrospective Studies MH - *Urinary Diversion/adverse effects MH - *Urinary Bladder Neoplasms/pathology MH - Denmark MH - *Robotic Surgical Procedures/methods MH - Postoperative Complications/etiology OTO - NOTNLM OT - bladder cancer OT - high-grade complications OT - intracorporeal diversion OT - robot-assisted radical cystectomy OT - survival EDAT- 2023/07/03 06:41 MHDA- 2023/09/22 06:42 CRDT- 2023/07/03 05:29 PHST- 2023/09/22 06:42 [medline] PHST- 2023/07/03 06:41 [pubmed] PHST- 2023/07/03 05:29 [entrez] AID - 10.1111/bju.16098 [doi] PST - ppublish SO - BJU Int. 2023 Oct;132(4):428-434. doi: 10.1111/bju.16098. Epub 2023 Jul 3. PMID- 37391708 OWN - NLM STAT- MEDLINE DCOM- 20230703 LR - 20250530 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jun 30 TI - Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer. PG - 605 LID - 10.1186/s12885-023-11100-0 [doi] LID - 605 AB - BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interventions whilst indicating aggressive measures when required. METHODS: In this study, immuno-oncology focused, multiplexed proximity extension assays were utilised to analyse plasma (n = 90) and urine (n = 40) samples from 90 newly-diagnosed and treatment-naive bladder cancer patients. Public single-cell RNA-sequencing and microarray data from patient tumour tissues and murine OH-BBN-induced urothelial carcinomas were also explored to further corroborate the proteomic findings. RESULTS: Plasma from muscle-invasive, urothelial bladder cancer patients displayed higher levels of MMP7 (p = 0.028) and CCL23 (p = 0.03) compared to NMIBC patients, whereas urine displayed higher levels of CD27 (p = 0.044) and CD40 (p = 0.04) in the NMIBC group by two-sided Wilcoxon rank-sum tests. Random forest survival and multivariable regression analyses identified increased MMP12 plasma levels as an independent marker (p < 0.001) associated with shorter overall survival (HR = 1.8, p < 0.001, 95% CI:1.3-2.5); this finding was validated in an independent patient OLINK cohort, but could not be established using a transcriptomic microarray dataset. Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12. CONCLUSIONS: The measurable levels of tumour-localised, immune-cell-derived MMP12 in blood suggest MMP12 as an important biomarker that could complement histopathology-based risk stratification. As MMP12 stems from infiltrating immune cells rather than the tumor cells themselves, analyses performed on tissue biopsy material risk a biased selection of biomarkers produced by the tumour, while ignoring the surrounding microenvironment. CI - (c) 2023. The Author(s). FAU - Kerzeli, Iliana K AU - Kerzeli IK AD - Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Kostakis, Alexandros AU - Kostakis A AD - Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Turker, Polat AU - Turker P AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Hemdan, Tammer AU - Hemdan T AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Mezheyeuski, Artur AU - Mezheyeuski A AD - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. AD - Vall d'Hebron Institute of Oncology, Barcelona, Spain. FAU - Ward, Douglas G AU - Ward DG AD - Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Lord, Martin AU - Lord M AD - Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Mangsbo, Sara M AU - Mangsbo SM AD - Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. sara.mangsbo@farmaci.uu.se. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article DEP - 20230630 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - EC 3.4.24.65 (Matrix Metalloproteinase 12) RN - EC 3.4.24.65 (MMP12 protein, human) SB - IM MH - Humans MH - Animals MH - Mice MH - Matrix Metalloproteinase 12/genetics MH - Proteomics MH - Quality of Life MH - *Urinary Bladder Neoplasms MH - *Carcinoma, Transitional Cell MH - Macrophages MH - Prognosis MH - Tumor Microenvironment PMC - PMC10311740 OTO - NOTNLM OT - Biomarkers OT - Macrophages OT - Matrix metalloproteinase 12 (MMP12) OT - Proteomics OT - Proximity Extension Assay (PEA) OT - Single-cell transcriptomics OT - Urothelial bladder cancer COIS- The authors declare no competing interests. EDAT- 2023/07/01 11:41 MHDA- 2023/07/03 06:41 PMCR- 2023/06/30 CRDT- 2023/06/30 23:35 PHST- 2022/11/14 00:00 [received] PHST- 2023/06/21 00:00 [accepted] PHST- 2023/07/03 06:41 [medline] PHST- 2023/07/01 11:41 [pubmed] PHST- 2023/06/30 23:35 [entrez] PHST- 2023/06/30 00:00 [pmc-release] AID - 10.1186/s12885-023-11100-0 [pii] AID - 11100 [pii] AID - 10.1186/s12885-023-11100-0 [doi] PST - epublish SO - BMC Cancer. 2023 Jun 30;23(1):605. doi: 10.1186/s12885-023-11100-0. PMID- 37382156 OWN - NLM STAT- MEDLINE DCOM- 20231221 LR - 20261006 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 48 IP - 1 DP - 2024 Jan 1 TI - International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. PG - e11-e23 LID - 10.1097/PAS.0000000000002077 [doi] AB - The 2022 International Society of Urological Pathology (ISUP) Consensus Conference on Urinary Bladder Cancer Working Group 2 was tasked to provide evidence-based proposals on the applications of grading in noninvasive urothelial carcinoma with mixed grades, invasive urothelial carcinoma including subtypes (variants) and divergent differentiations, and in pure non-urothelial carcinomas. Studies suggested that predominantly low-grade noninvasive papillary urothelial carcinoma with focal high-grade component has intermediate outcome between low- and high-grade tumors. However, no consensus was reached on how to define a focal high-grade component. By 2004 WHO grading, the vast majority of lamina propria-invasive (T1) urothelial carcinomas are high-grade, and the rare invasive low-grade tumors show only limited superficial invasion. While by 1973 WHO grading, the vast majority of T1 urothelial carcinomas are G2 and G3 and show significant differences in outcome based on tumor grade. No consensus was reached if T1 tumors should be graded either by the 2004 WHO system or by the 1973 WHO system. Because of the concern for underdiagnosis and underreporting with potential undertreatment, participants unanimously recommended that the presence of urothelial carcinoma subtypes and divergent differentiations should be reported. There was consensus that the extent of these subtypes and divergent differentiations should also be documented in biopsy, transurethral resection, and cystectomy specimens. Any distinct subtype and divergent differentiation should be diagnosed without a threshold cutoff, and each type should be enumerated in tumors with combined morphologies. The participants agreed that all subtypes and divergent differentiations should be considered high-grade according to the 2004 WHO grading system. However, participants strongly acknowledged that subtypes and divergent differentiations should not be considered as a homogenous group in terms of behavior. Thus, future studies should focus on individual subtypes and divergent differentiations rather than lumping these different entities into a single clinicopathological group. Likewise, clinical recommendations should pay attention to the potential heterogeneity of subtypes and divergent differentiations in terms of behavior and response to therapy. There was consensus that invasive pure squamous cell carcinoma and pure adenocarcinoma of the bladder should be graded according to the degree of differentiation. In conclusion, this summary of the International Society of Urological Pathology Working Group 2 proceedings addresses some of the issues on grading beyond its traditional application, including for papillary urothelial carcinomas with mixed grades and with invasive components. Reporting of subtypes and divergent differentiation is also addressed in detail, acknowledging their role in risk stratification. This report could serve as a guide for best practices and may advise future research and proposals on the prognostication of these tumors. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Paner, Gladell P AU - Paner GP AD - Departments of Pathology and Surgery (Urology), University of Chicago, Chicago, IL. FAU - Kamat, Ashish AU - Kamat A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Netto, George J AU - Netto GJ AD - Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL. FAU - Samaratunga, Hemamali AU - Samaratunga H AD - Aquesta Uropathology, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia. FAU - Varma, Murali AU - Varma M AD - Department of Cellular Pathology, University Hospital of Wales, Cardiff, Wales, UK. FAU - Bubendorf, Lukas AU - Bubendorf L AD - Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School; Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, RI. CN - Members of the ISUP Bladder Tumor Consensus Panel LA - eng PT - Consensus Statement PT - Journal Article DEP - 20230629 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/therapy/pathology MH - Urinary Bladder/pathology MH - *Carcinoma, Squamous Cell/pathology MH - *Carcinoma in Situ/pathology MH - Neoplasm Grading COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. FIR - Adeniran, Adebowale IR - Adeniran A FIR - Al-Ahimadie, Hikmat IR - Al-Ahimadie H FIR - Algaba, Fernando IR - Algaba F FIR - Bhattarai, Yves Allory Selina IR - Bhattarai YAS FIR - Black, Peter IR - Black P FIR - Berman, David IR - Berman D FIR - Bertz, Simone IR - Bertz S FIR - Bubendorf, Lukas IR - Bubendorf L FIR - Carlsen, Birgitte IR - Carlsen B FIR - Carvalho, Rita IR - Carvalho R FIR - Cheng, Liang IR - Cheng L FIR - Chijioke, Obinna IR - Chijioke O FIR - Cho, Yong Mee IR - Cho YM FIR - Comperat, Eva IR - Comperat E FIR - di Cunha, Isabela IR - di Cunha I FIR - Dagher, Julien IR - Dagher J FIR - de Cunha, Isabella IR - de Cunha I FIR - Delahunt, Brett IR - Delahunt B FIR - Downes, Michelle IR - Downes M FIR - Flaig, Thomas IR - Flaig T FIR - Fleischmann, Achim IR - Fleischmann A FIR - Florescu, Cosmin IR - Florescu C FIR - Fontugne, Jacqueline IR - Fontugne J FIR - Genitsch, Vera IR - Genitsch V FIR - Gloersen, Guro Horni IR - Gloersen GH FIR - von Gunten, Michael IR - von Gunten M FIR - Grobholz, Rainer IR - Grobholz R FIR - Hansel, Donna IR - Hansel D FIR - Hartmann, Arndt IR - Hartmann A FIR - Hernandez, Loren Herrera IR - Hernandez LH FIR - Hogland, Mattias IR - Hogland M FIR - Huang, Jiaoti IR - Huang J FIR - Jensen, Brad IR - Jensen B FIR - Iczkowski, Kenneth IR - Iczkowski K FIR - Jimenez, Rafael IR - Jimenez R FIR - Jovanovic, Bojana IR - Jovanovic B FIR - Kamat, Ashish IR - Kamat A FIR - Koellermann, Jens IR - Koellermann J FIR - Levin, Trevor IR - Levin T FIR - Liedberg, Fredrik IR - Liedberg F FIR - Lopez-Beltran, Antonio IR - Lopez-Beltran A FIR - Loya, Anand C IR - Loya AC FIR - Lyngra, Marianne IR - Lyngra M FIR - McHale, Teresa IR - McHale T FIR - Mokeddem, Khadidja IR - Mokeddem K FIR - Netto, George IR - Netto G FIR - Nourieh, Maya IR - Nourieh M FIR - O'Rourke, Declan IR - O'Rourke D FIR - Ostahi, Irina-Alexandra IR - Ostahi IA FIR - Paner, Gladell IR - Paner G FIR - Picken, Maria M IR - Picken MM FIR - Pineda, Flavia Guzman IR - Pineda FG FIR - Raspollini, Camelia Radulescu Maria IR - Raspollini CRM FIR - Reis, Henning IR - Reis H FIR - Ruoyu, Shi IR - Ruoyu S FIR - Samaratunga, Hemamali IR - Samaratunga H FIR - Semba, Remi IR - Semba R FIR - Shah, Nigam IR - Shah N FIR - Shen, Steven IR - Shen S FIR - Smith, Steven IR - Smith S FIR - Smith, Tovia IR - Smith T FIR - Srigley, John IR - Srigley J FIR - Suzigan, Sueli IR - Suzigan S FIR - Swarbrick, Nicole IR - Swarbrick N FIR - Szalay, Ildiko IR - Szalay I FIR - Talleraas, Inger IR - Talleraas I FIR - Tille, Jean-Christophe IR - Tille JC FIR - Toma, Marieta IR - Toma M FIR - Trias, Isabel IR - Trias I FIR - Tsuzuki, Toyonori IR - Tsuzuki T FIR - van der Kwast, Theodorus IR - van der Kwast T FIR - van Rhijn, Bas IR - van Rhijn B FIR - Varma, Murali IR - Varma M FIR - Verbeke, Sofie IR - Verbeke S FIR - Verma, Sangeeta IR - Verma S FIR - Vlajnic, Tatjana IR - Vlajnic T FIR - Vlatkovic, Ljiljana IR - Vlatkovic L FIR - Warren, Anne IR - Warren A FIR - Warrick, Joshua IR - Warrick J FIR - Williamson, Sean IR - Williamson S FIR - Wobker, Sara IR - Wobker S FIR - Woods, Clifton IR - Woods C FIR - Yang, Chen IR - Yang C FIR - Yoon, Ghilsuk IR - Yoon G EDAT- 2023/06/29 13:42 MHDA- 2023/12/21 06:43 CRDT- 2023/06/29 06:37 PHST- 2023/12/21 06:43 [medline] PHST- 2023/06/29 13:42 [pubmed] PHST- 2023/06/29 06:37 [entrez] AID - 00000478-202401000-00003 [pii] AID - 10.1097/PAS.0000000000002077 [doi] PST - ppublish SO - Am J Surg Pathol. 2024 Jan 1;48(1):e11-e23. doi: 10.1097/PAS.0000000000002077. Epub 2023 Jun 29. PMID- 37380971 OWN - NLM STAT- MEDLINE DCOM- 20230630 LR - 20260127 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jun 28 TI - Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma. PG - 599 LID - 10.1186/s12885-023-11090-z [doi] LID - 599 AB - BACKGROUND: Dihydropyrimidinase-like 3 (DPYSL3) is a cytosolic phosphoprotein expressed in the nervous system and is crucial for neurogenesis. A previous study showed that increased DPYSL3 expression promotes tumour aggressiveness in pancreatic ductal adenocarcinoma, gastric cancer, and colon cancer. However, the role of DPYSL3 in affecting the biological behaviour of urothelial carcinoma (UC) is not yet understood. METHODS: A UC transcriptomic dataset from the Gene Expression Omnibus and the Urothelial Bladder Cancer (BLCA) dataset from The Cancer Genome Atlas were used for the in silico study. We collected 340 upper urinary tract urothelial carcinoma (UTUC) and 295 urinary bladder urothelial carcinoma (UBUC) samples for the immunohistochemical study. Fresh tumour tissue from 50 patients was used to examine the DPYSL3 mRNA level. In addition, urothelial cell lines with and without DPYSL3 knockdown were used for the functional study. RESULTS: The in silico study revealed that DPYSL3 correlated with advanced tumour stage and metastasis development while functioning primarily in the nucleobase-containing compound metabolic process (GO:0006139). DPYSL3 mRNA expression is significantly upregulated in advanced UC. Furthermore, overexpression of the DPYSL3 protein is significantly associated with the aggressive behaviour of UTUC and UBUC. DPYSL3 expression independently predicts disease-specific survival (DSS) and metastatic-free survival (MFS) in patients with UC. In non-muscle-invasive UBUC, DPYSL3 expression predicts local recurrence-free survival. UC cell lines with DPYSL3 knockdown exhibited decreased proliferation, migration, invasion, and human umbilical vein endothelial cells (HUVECs) tube formation but increased apoptosis and G1 arrest. Gene ontology enrichment analysis revealed that the enriched processes related to DPYSL3 overexpression in UC were tissue morphogenesis, cell mesenchyme migration, smooth muscle regulation, metabolic processes, and RNA processing. In vivo study revealed DPYSL3 knockdown in UC tumours significantly suppressed the growth of tumours and decreased MYC and GLUT1 protein expression. CONCLUSIONS: DPYSL3 promotes the aggressiveness of UC cells by changing their biological behaviours and is likely associated with cytoskeletal and metabolic process modifications. Furthermore, DPYSL3 protein overexpression in UC was associated with aggressive clinicopathological characteristics and independently predicted poor clinical outcomes. Therefore, DPYSL3 can be used as a novel therapeutic target for UC. CI - (c) 2023. The Author(s). FAU - Liang, Peir-In AU - Liang PI AD - Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan. FAU - Lai, Hong-Yue AU - Lai HY AD - Department of Medical Research, Chi Mei Medical Center, Tainan, 710402, Taiwan. FAU - Chan, Ti-Chun AU - Chan TC AD - Department of Medical Research, Chi Mei Medical Center, Tainan, 710402, Taiwan. AD - National Institute of Cancer Research, National Health Research Institutes, Tainan, 704016, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan. AD - Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan. AD - Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, 90054, Taiwan. FAU - Hsing, Chung-Hsi AU - Hsing CH AD - Department of Medical Research, Chi Mei Medical Center, Tainan, 710402, Taiwan. AD - Department of Anesthesiology, Chi Mei Medical Center, Tainan, 710402, Taiwan. FAU - Huang, Steven K AU - Huang SK AD - Department of Surgery, Division of Urology, Chi Mei Medical Center, Tainan, 710402, Taiwan. AD - Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan, 711301, Taiwan. FAU - Hsieh, Kun-Lin AU - Hsieh KL AD - Department of Surgery, Division of Urology, Chi Mei Medical Center, Tainan, 710402, Taiwan. FAU - Tseng, Wen-Hsin AU - Tseng WH AD - Department of Surgery, Division of Urology, Chi Mei Medical Center, Tainan, 710402, Taiwan. FAU - Chen, Tzu-Ju AU - Chen TJ AD - Department of Clinical Pathology, Chi Mei Medical Center, Tainan, 710402, Taiwan. AD - Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan, 71703, Taiwan. FAU - Li, Wan-Shan AU - Li WS AD - Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan, 71703, Taiwan. AD - Department of Pathology, Chi Mei Medical Center, Tainan, 710402, Taiwan. FAU - Chen, Huan-Da AU - Chen HD AD - Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 807378, Taiwan. FAU - Kuo, Yu-Hsuan AU - Kuo YH AD - Department of Internal Medicine, Division of Hematology and Oncology, Chi-Mei Medical Center, Tainan, 710402, Taiwan. a10901@mail.chimei.org.tw. AD - College of Pharmacy and Science, Chia Nan University, Tainan, 71710, Taiwan. a10901@mail.chimei.org.tw. FAU - Li, Chien-Feng AU - Li CF AD - Department of Medical Research, Chi Mei Medical Center, Tainan, 710402, Taiwan. angelo.p@yahoo.com.tw. AD - National Institute of Cancer Research, National Health Research Institutes, Tainan, 704016, Taiwan. angelo.p@yahoo.com.tw. LA - eng GR - KMUH107-7M39/Kaohsiung Medical University Hospital, Kaohsiung, Taiwan/ GR - MOST108-2320-B-037-027/Ministry of Science and Technology, Taiwan/ PT - Journal Article DEP - 20230628 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Muscle Proteins) RN - EC 3.5.2.2 (dihydropyrimidinase) RN - EC 3.5.- (Amidohydrolases) RN - 0 (DPYSL3 protein, human) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell MH - *Urinary Bladder Neoplasms/genetics MH - Up-Regulation MH - Endothelial Cells MH - *Pancreatic Neoplasms MH - Prognosis MH - Muscle Proteins/genetics MH - Amidohydrolases PMC - PMC10304234 OTO - NOTNLM OT - Cellular Myelocytomatosis (C-Myc) OT - Cytoskeleton modification OT - Dihydropyrimidinase-like 3 (DPYSL3) OT - Glucose transporter 1 (GLUT1) OT - Mammalian target of rapamycin (mTOR) OT - Metabolic process reprogramming OT - Ribosomal protein S6 (RPS6) OT - Upper urinary tracts urothelial carcinoma (UTUC) OT - Urinary bladder urothelial carcinoma (UBUC) COIS- The authors declare no competing interests. EDAT- 2023/06/29 01:08 MHDA- 2023/06/30 06:42 PMCR- 2023/06/28 CRDT- 2023/06/28 23:35 PHST- 2022/06/16 00:00 [received] PHST- 2023/06/20 00:00 [accepted] PHST- 2023/06/30 06:42 [medline] PHST- 2023/06/29 01:08 [pubmed] PHST- 2023/06/28 23:35 [entrez] PHST- 2023/06/28 00:00 [pmc-release] AID - 10.1186/s12885-023-11090-z [pii] AID - 11090 [pii] AID - 10.1186/s12885-023-11090-z [doi] PST - epublish SO - BMC Cancer. 2023 Jun 28;23(1):599. doi: 10.1186/s12885-023-11090-z. PMID- 37373873 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 13 IP - 6 DP - 2023 May 24 TI - Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer. LID - 10.3390/jpm13060885 [doi] LID - 885 AB - OBJECTIVE: CD47 is an antiphagocytic molecule that plays a critical role in immune surveillance. A variety of malignancies have been shown to evade the immune system by increasing the expression of CD47 on the cell surface. As a result, anti-CD47 therapy is under clinical investigation for a subset of these tumors. Interestingly, CD47 overexpression is associated with negative clinical outcomes in lung and gastric cancers; however, the expression and functional significance of CD47 in bladder cancer is not fully understood. MATERIALS AND METHODS: We retrospectively studied patients with muscle invasion bladder cancer (MIBC) who underwent a transurethral resection of bladder tumor (TURBT) and subsequently underwent radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC). CD47 expression was examined by IHC in both TURBT and matched RC specimens. The difference in CD47 expression levels between TURBT and RC was also compared. The association of CD47 levels (TURBT) with clinicopathological parameters and survival outcomes was evaluated by Pearson's chi-squared tests and the Kaplan-Meier method, respectively. RESULTS: A total of 87 MIBC patients were included. The median age was 66 (39-84) years. Most patients were Caucasian (95%), male (79%), and aged >60 (63%) and most often (75%) underwent NAC prior to RC. Of those who received NAC, 35.6% were responders and 64.4% were non-responders. The final reported stages as per AJCC for all patients were as follows: stage 0 (32%), stage 1 (1%), stage 2 (20%), stage 3 (43%), and stage 4a (5%). A total of 60% of patients were alive; of those, 30% had disease recurrence and 40% died from bladder cancer at a median follow-up of 3.1 (0.2-14.2) years. CD47 levels were detectable in 38 (44%) TURBT samples. There was no association between CD47 levels and clinicopathological parameters such as age, gender, race, NAC, final stage, disease recurrence, and overall survival (OS). Patients aged >60 (p = 0.006), non-responders (p = 0.002), and at stage >/= 3 (p < 0.001) were associated with worse OS by a univariate analysis and stage >/= 3 remained significant even after a multivariate analysis. In patients managed with NAC, there were decreased CD47 levels in RC specimens compared to the TURBT specimens, but this did not reach statistical significance. CONCLUSION: CD47 expression was not a predictive nor prognostic marker for MIBC patients. However, expression of CD47 was detected in nearly half of MIBCs, and future studies are needed to explore the potential role of anti-CD47 therapy in these patients. Furthermore, there was a slight positive trend in decreased CD47 levels (from TURBT to RC) in patients receiving NAC. As a result, more research is needed to understand how NAC may modify immune surveillance mechanisms in MIBC. FAU - Myint, Zin W AU - Myint ZW AUID- ORCID: 0000-0002-3479-4203 AD - Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA. AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. FAU - Chahine, Zena AU - Chahine Z AD - Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA. AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. FAU - Jayswal, Rani AU - Jayswal R AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. FAU - Bachert, Emily AU - Bachert E AUID- ORCID: 0000-0003-2596-2604 AD - Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA. FAU - McDonald, Robert J AU - McDonald RJ AD - Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA. FAU - Strup, Stephen E AU - Strup SE AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. AD - Department of Urology, University of Kentucky, Lexington, KY 40536, USA. FAU - James, Andrew C AU - James AC AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. AD - Department of Urology, University of Kentucky, Lexington, KY 40536, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. AD - Department of Urology, University of Kentucky, Lexington, KY 40536, USA. FAU - Allison, Derek B AU - Allison DB AUID- ORCID: 0000-0002-5119-2474 AD - Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. AD - Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA. AD - Department of Urology, University of Kentucky, Lexington, KY 40536, USA. LA - eng GR - P30 CA177558/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20230524 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC10301952 OTO - NOTNLM OT - CD47 expression OT - biomarker OT - muscle invasive bladder cancer OT - neoadjuvant therapy COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/05/24 CRDT- 2023/06/28 01:23 PHST- 2023/05/11 00:00 [received] PHST- 2023/05/20 00:00 [revised] PHST- 2023/05/22 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:23 [entrez] PHST- 2023/05/24 00:00 [pmc-release] AID - jpm13060885 [pii] AID - jpm-13-00885 [pii] AID - 10.3390/jpm13060885 [doi] PST - epublish SO - J Pers Med. 2023 May 24;13(6):885. doi: 10.3390/jpm13060885. PMID- 37371512 OWN - NLM STAT- MEDLINE DCOM- 20230629 LR - 20230701 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 13 IP - 6 DP - 2023 Jun 1 TI - Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients. LID - 10.3390/biom13060932 [doi] LID - 932 AB - Urinary extracellular vesicles (EVs) are an attractive source of bladder cancer biomarkers. Here, a protein biomarker discovery study was performed on the protein content of small urinary EVs (sEVs) to identify possible biomarkers for the primary diagnosis and recurrence of non-muscle-invasive bladder cancer (NMIBC). The sEVs were isolated by ultrafiltration (UF) in combination with size-exclusion chromatography (SEC). The first part of the study compared healthy individuals with NMIBC patients with a primary diagnosis. The second part compared tumor-free patients with patients with a recurrent NMIBC diagnosis. The separated sEVs were in the size range of 40 to 200 nm. Based on manually curated high quality mass spectrometry (MS) data, the statistical analysis revealed 69 proteins that were differentially expressed in these sEV fractions of patients with a first bladder cancer tumor vs. an age- and gender-matched healthy control group. When the discriminating power between healthy individuals and first diagnosis patients is taken into account, the biomarkers with the most potential are MASP2, C3, A2M, CHMP2A and NHE-RF1. Additionally, two proteins (HBB and HBA1) were differentially expressed between bladder cancer patients with a recurrent diagnosis vs. tumor-free samples of bladder cancer patients, but their biological relevance is very limited. FAU - Jordaens, Stephanie AU - Jordaens S AUID- ORCID: 0000-0001-6730-367X AD - Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, 2610 Wilrijk, Belgium. FAU - Oeyen, Eline AU - Oeyen E AD - Health Unit, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium. AD - Centre for Proteomics (CfP), University of Antwerp, 2020 Antwerp, Belgium. FAU - Willems, Hanny AU - Willems H AD - Health Unit, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium. FAU - Ameye, Filip AU - Ameye F AD - Department of Urology, AZ Maria Middelares, 9000 Ghent, Belgium. FAU - De Wachter, Stefan AU - De Wachter S AD - Department of Urology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium. FAU - Pauwels, Patrick AU - Pauwels P AD - Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, 2610 Wilrijk, Belgium. AD - Laboratory of Pathological Anatomy, Antwerp University Hospital (UZA), 2650 Edegem, Belgium. FAU - Mertens, Inge AU - Mertens I AUID- ORCID: 0000-0002-4888-3485 AD - Health Unit, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium. AD - Centre for Proteomics (CfP), University of Antwerp, 2020 Antwerp, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230601 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Ultrafiltration MH - *Urinary Bladder Neoplasms/diagnosis MH - Urinary Bladder/metabolism MH - Biomarkers, Tumor/metabolism MH - Chromatography, Gel PMC - PMC10296596 OTO - NOTNLM OT - biomarker OT - extracellular vesicles OT - liquid biopsy OT - non-muscle-invasive bladder cancer (NMIBC) OT - oncology OT - proteomics OT - urine COIS- The authors report no conflicts of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/29 06:43 PMCR- 2023/06/01 CRDT- 2023/06/28 01:07 PHST- 2023/04/20 00:00 [received] PHST- 2023/05/26 00:00 [revised] PHST- 2023/05/30 00:00 [accepted] PHST- 2023/06/29 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:07 [entrez] PHST- 2023/06/01 00:00 [pmc-release] AID - biom13060932 [pii] AID - biomolecules-13-00932 [pii] AID - 10.3390/biom13060932 [doi] PST - epublish SO - Biomolecules. 2023 Jun 1;13(6):932. doi: 10.3390/biom13060932. PMID- 37370698 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20251230 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 12 DP - 2023 Jun 7 TI - The Potent Anti-Tumor Effects of Rhodiola Drinking Are Associated with the Inhibition of the mTOR Pathway and Modification of Tumor Metabolism in the UPII-Mutant Ha-Ras Model. LID - 10.3390/cancers15123086 [doi] LID - 3086 AB - Background: SHR-5 has been used as an "adaptogen" for enhancing physical and mental performance and for fighting stress in the healthy population. The purpose of this study is to determine the chemopreventive efficacy of SHR-5 for superficial bladder cancer and to investigate the underlying mechanisms of action. Methods: UPII-mutant Ha-ras bladder-cancer-transgenic mice, that developed low-grade and noninvasive papillary transitional urothelial cell carcinoma, were fed with 1.25 and 6.25 mg/mL SHR-5 in drinking water for 6 months. The survival of the mice, obstructive uropathy, tumor burden and morphology, and proliferation were evaluated by pathological, molecular, metabolic, and statistical analyses. Results: Approximately 95% or more of the male UPII-mutant Ha-ras mice that drank SHR-5 daily survived over 6 months of age, while only 33.3% of those mice that drank normal water survived over 6 months of age (p < 0.0001); SHR-5 drinking exposure also reduced tumor-bearing bladder weight and urinary tract obstruction and inhibited mTOR signaling in neoplastic tissues. Global metabolic analysis revealed that SHR-5 resulted in increased phenolic metabolites and decreased CoA, a critical metabolic cofactor for lipid metabolism. Conclusions: Our findings highlight the potential of SHR-5 as an anti-aging agent for bladder cancer prevention through reshaping tumor metabolism via the inhibition of the mTOR signaling. Global metabolomics profiling provides a unique and efficient tool for studying the mechanisms of complex herb extracts' action. FAU - Liu, Zhongbo AU - Liu Z AUID- ORCID: 0000-0003-0075-1261 AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Yokoyama, Noriko N AU - Yokoyama NN AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Song, Liankun AU - Song L AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Xie, Jun AU - Xie J AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Sadeghi, Zhina AU - Sadeghi Z AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Wu, Yi Xi AU - Wu YX AUID- ORCID: 0000-0001-7833-1481 AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Yee, Sarah AU - Yee S AD - Department of Urology, University of California, Irvine, CA 92868, USA. FAU - Wu, Xue-Ru AU - Wu XR AD - Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA. FAU - Wang, Beverly AU - Wang B AD - Department of Pathology and Laboratory Medicine, University of California, Irvine, CA 92868, USA. FAU - Uchio, Edward AU - Uchio E AD - Department of Urology, University of California, Irvine, CA 92868, USA. AD - Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92868, USA. FAU - Zi, Xiaolin AU - Zi X AD - Department of Urology, University of California, Irvine, CA 92868, USA. AD - Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92868, USA. AD - Veterans Affairs Long Beach Healthcare System, Long Beach, CA 90822, USA. LA - eng GR - I01 BX005597/BX/BLRD VA/United States GR - R21 CA152804/CA/NCI NIH HHS/United States GR - R21CA152804/GF/NIH HHS/United States PT - Journal Article DEP - 20230607 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 EIN - Cancers (Basel). 2025 Dec 11;17(24):3954. doi: 10.3390/cancers17243954. PMID: 41463287 PMC - PMC10296277 OTO - NOTNLM OT - bladder cancer chemoprevention OT - mTOR OT - metabolism OT - rhodiola COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/06/07 CRDT- 2023/06/28 01:02 PHST- 2023/05/03 00:00 [received] PHST- 2023/06/05 00:00 [revised] PHST- 2023/06/06 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:02 [entrez] PHST- 2023/06/07 00:00 [pmc-release] AID - cancers15123086 [pii] AID - cancers-15-03086 [pii] AID - 10.3390/cancers15123086 [doi] PST - epublish SO - Cancers (Basel). 2023 Jun 7;15(12):3086. doi: 10.3390/cancers15123086. PMID- 37365053 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20240410 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 21 IP - 6 DP - 2023 Dec TI - Impairment in Activities of Daily Living Assessed by the Barthel Index Predicts Adverse Oncological Outcomes After Radical Cystectomy for Bladder Cancer. PG - e495-e501.e2 LID - S1558-7673(23)00141-6 [pii] LID - 10.1016/j.clgc.2023.06.002 [doi] AB - INTRODUCTION: We tested the association between functional impairment in activities of daily living (ADL) assessed through the Barthel Index (BI), and oncological outcomes following radical cystectomy (RC) for bladder cancer (BCa). PATIENTS AND METHODS: We retrospectively analyzed data of 262 clinically nonmetastatic BCa patients, who underwent RC between 2015 and 2022, with available follow-up. According to preoperative BI, patients were divided in 2 groups: BI T was the most common base substitution. Single nucleotide polymorphism (SNP) and deletion (DEL) were the common variant types in our cohort. The top 10 mutant genes were ROS1 (37%), PIK3CA (35%), FGFR3 (34%), BRAF (34%), ERBB2 (32%), ALK (27%), RET (27%), NTRK1 (24%), MET (23%), and EGFR (18%). FGFR3 mutations were detected more frequently in non-muscle-invasive bladder cancer (stages 0a, I) patients than in muscle-invasive bladder cancer (stage II, III, and IV) patients. The top 3 altered types of FGFR3 were p.Ser249Cys, p.Tyr375Cys, and p.Arg248Cys. CONCLUSIONS: This study examined the mutated types and frequency of FGFR3 and the prognosis of Chinese BC patients with FGFR mutations. We hope that our findings will enable clinical individualization strategies for BC patients to be optimized. CI - 2023 Translational Andrology and Urology. All rights reserved. FAU - Hao, Lanxiang AU - Hao L AD - Department of Pathology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China. FAU - Fang, Jiang AU - Fang J AD - Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. AD - The School of Clinical Medicine, Fujian Medical University, Fuzhou, China. FAU - Xu, Ran AU - Xu R AD - Department of Urology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China. FAU - Liu, Shuo AU - Liu S AD - Department of Urology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China. FAU - Luo, Guangcheng AU - Luo G AD - The School of Clinical Medicine, Fujian Medical University, Fuzhou, China. AD - Department of Urology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China. FAU - Wang, Xinjun AU - Wang X AD - The School of Clinical Medicine, Fujian Medical University, Fuzhou, China. AD - Department of Urology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China. LA - eng PT - Journal Article DEP - 20230524 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC10251100 OTO - NOTNLM OT - Bladder cancer (BC) OT - fibroblast growth factor receptor 3 (FGFR3) OT - mutation types OT - next-generation sequencing (NGS) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-247/coif). All authors report the technical support from Shanghai Tongshu Biotechnology Co., Ltd. The authors have no other conflicts of interest to declare. EDAT- 2023/06/12 06:42 MHDA- 2023/06/12 06:43 PMCR- 2023/05/31 CRDT- 2023/06/12 04:26 PHST- 2023/03/22 00:00 [received] PHST- 2023/05/18 00:00 [accepted] PHST- 2023/06/12 06:43 [medline] PHST- 2023/06/12 06:42 [pubmed] PHST- 2023/06/12 04:26 [entrez] PHST- 2023/05/31 00:00 [pmc-release] AID - tau-12-05-761 [pii] AID - 10.21037/tau-23-247 [doi] PST - ppublish SO - Transl Androl Urol. 2023 May 31;12(5):761-769. doi: 10.21037/tau-23-247. Epub 2023 May 24. PMID- 37304240 OWN - NLM STAT- MEDLINE DCOM- 20230613 LR - 20230613 IS - 1555-3906 (Electronic) IS - 0965-0407 (Print) IS - 0965-0407 (Linking) VI - 31 IP - 2 DP - 2023 TI - A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guerin in patients with non-muscle invasive bladder carcinoma: A retrospective study. PG - 207-220 LID - 10.32604/or.2023.028163 [doi] AB - Intravesical Bacillus Calmette Guerin (BCG) is the gold standard therapy for intermediate/high-risk non-muscle invasive bladder cancer (NMIBC). However, the response rate is ~60%, and 50% of non-responders will progress to muscle-invasive disease. BCG induces massive local infiltration of inflammatory cells (Th1) and ultimately cytotoxic tumor elimination. We searched for predictive biomarker of BCG response by analyzing tumor-infiltrating lymphocyte (TIL) polarization in the tumor microenvironment (TME) in pre-treatment biopsies. Pre-treatment biopsies from patients with NMIBC who received adequate intravesical instillation of BCG (n = 32) were evaluated retrospectively by immunohistochemistry. TME polarization was assessed by quantifying the T-Bet+ (Th1) and GATA-3+ (Th2) lymphocyte ratio (G/T), and the density and degranulation of EPX+ eosinophils. In addition, PD-1/PD-L1 staining was quantified. The results correlated with BCG response. In most non-responders, Th1/Th2 markers were compared in pre-and post-BCG biopsies. ORR was 65.6% in the study population. BCG responders had a higher G/T ratio and a greater number of degranulated EPX+ cells. Variables combined into a Th2-score showed a significant association with higher scores in responders (p = 0.027). A Th2-score cut-off value >48.1 allowed discrimination of responders with 91% sensitivity but lower specificity. Relapse-free survival was significantly associated with the Th2-score (p = 0.007). In post-BCG biopsies from recurring patients, TILs increased Th2-polarization, probably reflecting BCG failure to induce a pro-inflammatory status and, thus, a lack of response. PD-L1/PD-1 expression was not associated with the response to BCG. Our results support the hypothesis that a pre-existing Th2-polarized TME predicts a better response to BCG, assuming a reversion to Th1 polarization and antitumor activity. CI - (c) 2023 Villoldo et al. FAU - Villoldo, Gustavo Martin AU - Villoldo GM AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Pombo, Maria Teresa AU - Pombo MT AD - Immunohistochemistry Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Aris, Mariana AU - Aris M AD - Centro de Investigaciones Oncologicas, Fundacion Cancer FUCA, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Chemi, Joaquin AU - Chemi J AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Mando, Pablo AU - Mando P AD - Centro de Investigaciones Oncologicas, Fundacion Cancer FUCA, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Nagaraju, Supriya AU - Nagaraju S AD - Urology Department, MD Anderson Cancer Center, Houston, TX, 77030, USA. FAU - Camean, Juan AU - Camean J AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Burioni, Adrian AU - Burioni A AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Egea, Deborah AU - Egea D AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Amat, Mora AU - Amat M AD - Pathology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Mellado, Jose Leon AU - Mellado JL AD - Centro de Investigaciones Oncologicas, Fundacion Cancer FUCA, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Mordoh, Jose AU - Mordoh J AD - Centro de Investigaciones Oncologicas, Fundacion Cancer FUCA, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Villaronga, Alberto AU - Villaronga A AD - Urology Department, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, 1426, Argentina. FAU - Barrio, Maria Marcela AU - Barrio MM AD - Centro de Investigaciones Oncologicas, Fundacion Cancer FUCA, Ciudad Autonoma de Buenos Aires, 1426, Argentina. LA - eng PT - Journal Article DEP - 20230410 PL - United States TA - Oncol Res JT - Oncology research JID - 9208097 RN - 0 (BCG Vaccine) RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - B7-H1 Antigen MH - Programmed Cell Death 1 Receptor MH - Tumor Microenvironment MH - Urinary Bladder MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/drug therapy MH - Biomarkers MH - *Carcinoma PMC - PMC10208021 OTO - NOTNLM OT - BCG predictive biomarkers OT - Lymphocyte polarization OT - Non-muscle invasive bladder cancer COIS- The authors declare that they have no conflicts of interest to report regarding the present study. EDAT- 2023/06/12 06:42 MHDA- 2023/06/13 06:42 PMCR- 2023/04/10 CRDT- 2023/06/12 04:06 PHST- 2022/12/08 00:00 [received] PHST- 2023/02/15 00:00 [accepted] PHST- 2023/06/13 06:42 [medline] PHST- 2023/06/12 06:42 [pubmed] PHST- 2023/06/12 04:06 [entrez] PHST- 2023/04/10 00:00 [pmc-release] AID - 28163 [pii] AID - 10.32604/or.2023.028163 [doi] PST - epublish SO - Oncol Res. 2023 Apr 10;31(2):207-220. doi: 10.32604/or.2023.028163. eCollection 2023. PMID- 37298214 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20260127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 11 DP - 2023 May 25 TI - Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform. LID - 10.3390/ijms24119258 [doi] LID - 9258 AB - Cellular and molecular immune components play a crucial role in the development and perpetuation of human malignancies, shaping anti-tumor responses. A novel immune regulator is interleukin-37 (IL-37), already shown to be involved in the inflammation associated with the pathophysiology of many human disorders, including cancer. The interplay between tumor and immune cells is of great importance, especially for highly immunogenic tumors such as bladder urothelial carcinoma (BLCA). This study aimed to investigate the potential of IL-37 and its receptor SIGIRR (single immunoglobulin IL-1-related receptor) to serve as prognostic and/or diagnostic markers in patients with BLCA. To this end, a series of bioinformatics tools processing -omics datasets and specifically designed qPCR assays on human BLCA tumors and cancer cell lines were utilized. Bioinformatics analysis revealed that IL-37 levels correlate with BLCA tumor development and are higher in patients with longer overall survival. Furthermore, mutations on SIGIRR are associated with enhanced infiltration of the tumor by regulatory T cells and dendritic cells. Based on the qPCR validation experiments, BLCA epithelial cells express the IL-37c and IL-37e isoforms, while the latter is the predominant variant detected in tumor biopsies, also associated with higher grade and the non-muscle-invasive type. This is the first time, to the best of our knowledge, that IL-37 and SIGIRR levels have been assessed in BLCA tumor lesions, and associations with pathological and survival parameters are described, while a transcript variant-specific signature is indicated to have a diagnostic potential. These data strongly indicate the need for further investigation of the involvement of this cytokine and interconnected molecules in the pathophysiology of the disease and its prospective as a therapeutic target and biomarker for BLCA. FAU - Papasavva, Maria AU - Papasavva M AD - Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus. FAU - Amvrosiou, Styliana AU - Amvrosiou S AD - Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus. FAU - Pilala, Katerina-Marina AU - Pilala KM AUID- ORCID: 0000-0002-0187-6907 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Soureas, Konstantinos AU - Soureas K AUID- ORCID: 0000-0002-4644-5625 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. AD - Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, 11527 Athens, Greece. FAU - Christodoulou, Panayiota AU - Christodoulou P AD - Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus. AD - School of Medicine, European University Cyprus, Nicosia 2404, Cyprus. FAU - Ji, Yuan AU - Ji Y AD - School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Xu, Damo AU - Xu D AD - State Key Laboratory of Respiratory Disease for Allergy Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, School of Medicine, Shenzhen University, Shenzhen 518055, China. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AUID- ORCID: 0000-0002-2135-9886 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. AD - Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, 11527 Athens, Greece. FAU - Christodoulou, Maria-Ioanna AU - Christodoulou MI AUID- ORCID: 0000-0003-1659-4993 AD - Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus. AD - School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK. LA - eng PT - Journal Article DEP - 20230525 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (IL37 protein, human) RN - 0 (Interleukin-1) RN - 0 (SIGIRR protein, human) RN - 0 (Receptors, Interleukin-1) SB - IM MH - Humans MH - Biopsy MH - *Carcinoma, Transitional Cell MH - Prospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnosis/genetics MH - Interleukin-1 MH - Receptors, Interleukin-1 PMC - PMC10253379 OTO - NOTNLM OT - advanced stage OT - biomarker OT - bladder cancer OT - interleukin (IL-)37 OT - survival COIS- The authors declare no conflict of interest. EDAT- 2023/06/10 15:14 MHDA- 2023/06/12 06:43 PMCR- 2023/05/25 CRDT- 2023/06/10 01:11 PHST- 2023/04/13 00:00 [received] PHST- 2023/05/15 00:00 [revised] PHST- 2023/05/17 00:00 [accepted] PHST- 2023/06/12 06:43 [medline] PHST- 2023/06/10 15:14 [pubmed] PHST- 2023/06/10 01:11 [entrez] PHST- 2023/05/25 00:00 [pmc-release] AID - ijms24119258 [pii] AID - ijms-24-09258 [pii] AID - 10.3390/ijms24119258 [doi] PST - epublish SO - Int J Mol Sci. 2023 May 25;24(11):9258. doi: 10.3390/ijms24119258. PMID- 37288590 OWN - NLM STAT- MEDLINE DCOM- 20230621 LR - 20230621 IS - 2042-650X (Electronic) IS - 2042-6496 (Linking) VI - 14 IP - 12 DP - 2023 Jun 19 TI - Comparative transcriptomic analysis and mechanistic characterization revealed the use of formononetin for bladder cancer treatment. PG - 5787-5804 LID - 10.1039/d2fo03962a [doi] AB - Bladder cancer is one of the most common cancers worldwide, with 213 000 deaths reported in 2020. Patients with a progression from non-muscle-invasive bladder cancer to muscle-invasive disease have poorer prognosis and survival rates. Therefore, there is an urgent need to identify novel drugs to prevent the recurrence and metastasis of bladder cancer. Formononetin is an active compound extracted from the herb Astragalus membranaceus that possesses anticancer properties. Few studies have demonstrated the anti-bladder cancer effects of formononetin; however, the detailed mechanism remains unknown. In this study, we used two bladder cancer cell lines, TM4 and 5637, to investigate the potential role of formononetin in bladder cancer treatment. Comparative transcriptomic analysis was conducted to delineate the molecular mechanisms underlying the anti-bladder cancer effects of formononetin. Our results showed that formononetin treatment inhibited the proliferation and colony-forming abilities of bladder cancer cells. Additionally, formononetin reduced the migration and invasion of bladder cancer cells. Transcriptomic analysis further highlighted the involvement of formononetin-mediated two clusters of genes involved in endothelial cell migration (FGFBP1, LCN2, and STC1) and angiogenesis (SERPINB2, STC1, TNFRSF11B, and THBS2). Taken together, our results suggest the potential use of formononetin to inhibit the recurrence and metastasis of bladder cancer through the regulation of different oncogenes. FAU - Zhou, Huanhuan AU - Zhou H AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, No.1 Zhiyuan Road, Lingui District, Guilin 541004, China. college_zhangxing@126.com. AD - Key Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guilin, China. FAU - Wang, Ping AU - Wang P AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, No.1 Zhiyuan Road, Lingui District, Guilin 541004, China. college_zhangxing@126.com. AD - Key Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guilin, China. FAU - Qin, Xian AU - Qin X AUID- ORCID: 0000-0002-2109-8823 AD - Department of Chemistry, City University of Hong Kong, Hong Kong SAR, China. FAU - Zhang, Xing AU - Zhang X AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, No.1 Zhiyuan Road, Lingui District, Guilin 541004, China. college_zhangxing@126.com. AD - Key Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guilin, China. FAU - Lai, Keng Po AU - Lai KP AUID- ORCID: 0000-0001-8237-6658 AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, No.1 Zhiyuan Road, Lingui District, Guilin 541004, China. college_zhangxing@126.com. AD - Key Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guilin, China. FAU - Chen, Jian AU - Chen J AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, No.1 Zhiyuan Road, Lingui District, Guilin 541004, China. college_zhangxing@126.com. AD - Key Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guilin, China. LA - eng PT - Journal Article DEP - 20230619 PL - England TA - Food Funct JT - Food & function JID - 101549033 RN - 295DQC67BJ (formononetin) RN - 0 (Isoflavones) SB - IM MH - Humans MH - Cell Proliferation MH - Transcriptome MH - *Urinary Bladder Neoplasms/drug therapy/genetics MH - *Isoflavones/pharmacology/therapeutic use MH - Cell Line, Tumor EDAT- 2023/06/08 06:42 MHDA- 2023/06/21 06:42 CRDT- 2023/06/08 05:35 PHST- 2023/06/21 06:42 [medline] PHST- 2023/06/08 06:42 [pubmed] PHST- 2023/06/08 05:35 [entrez] AID - 10.1039/d2fo03962a [doi] PST - epublish SO - Food Funct. 2023 Jun 19;14(12):5787-5804. doi: 10.1039/d2fo03962a. PMID- 37287055 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20230610 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 23 IP - 1 DP - 2023 Jun 7 TI - Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk? PG - 106 LID - 10.1186/s12894-023-01278-7 [doi] LID - 106 AB - INTRODUCTION: As a high-quality TUR-BT is important to ensure adequate treatment for bladder cancer patients, the aim of the current study is to investigate the impact of patient-related, surgical and tumor-specific parameters on detrusor muscle (DM) absence (primary objective) and to assess the impact of DM on the prognosis after a TUR-BT (secondary objective). PATIENTS AND METHODS: Transurethral resection of bladder tumors (TUR-BTs) between 2009 and 2021 were retrospectively screened (n = 3237). We included 2058 cases (1472 patients) for the primary and 472 patients for secondary objective. Clinicopathological variables including tumor size, localization, multifocality, configuration, operation time and skill-level of the urologist were assessed. We analyzed predictors for missing DM and prognostic factors for recurrence-free survival (RFS) for the complete cohort and subgroups. RESULTS: DM was present in 67.6% (n = 1371/2058). Surgery duration (continuous, minutes) was an independent predictor for absence of DM in the complete cohort (OR:0.98, r:0.012, 95%CI:0.98-0.99, p = 0.001). Other significant risk factors for missing DM were papillary tumors (OR:1.99, r:0.251, 95%CI:1.22-3.27, p = 0.006) in the complete cohort and bladder-roof and posterior-bladder-wall localization for re-resections. Absence of DM in high-grade BC correlated with reduced RFS (HR:1.96, 95%CI:1.0-3.79, p = 0.045). CONCLUSION: Sufficient time for a TUR-BT is mandatory to assure DM in the TUR-BT specimen. Also, cases with more difficult locations of bladder tumors should be performed with utmost surgical diligence and endourological training should incorporate how to perform such operations. Of note, DM correlates with improved oncological prognosis in high-grade BC. CI - (c) 2023. The Author(s). FAU - Volz, Yannic AU - Volz Y AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. yannic.volz@med.uni-muenchen.de. FAU - Trappmann, Rabea AU - Trappmann R AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Ebner, Benedikt AU - Ebner B AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Pfitzinger, Paulo AU - Pfitzinger P AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Bischoff, Robert AU - Bischoff R AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Schlenker, Boris AU - Schlenker B AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Stief, Christian AU - Stief C AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, Ludwig-Maximilian-University Hospital , Munich, Germany. gerald.schulz@med.uni-muenchen.de. LA - eng PT - Journal Article DEP - 20230607 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Urologic Surgical Procedures MH - Prognosis MH - Muscles/pathology MH - Neoplasm Recurrence, Local/pathology PMC - PMC10249185 OTO - NOTNLM OT - Carcinoma OT - Disease-free survival OT - Pathology OT - Quality control OT - Surgical OT - Transitional cell OT - Urinary bladder neoplasms COIS- The authors declare no competing interests. EDAT- 2023/06/08 01:08 MHDA- 2023/06/09 06:42 PMCR- 2023/06/07 CRDT- 2023/06/07 23:45 PHST- 2023/02/21 00:00 [received] PHST- 2023/05/25 00:00 [accepted] PHST- 2023/06/09 06:42 [medline] PHST- 2023/06/08 01:08 [pubmed] PHST- 2023/06/07 23:45 [entrez] PHST- 2023/06/07 00:00 [pmc-release] AID - 10.1186/s12894-023-01278-7 [pii] AID - 1278 [pii] AID - 10.1186/s12894-023-01278-7 [doi] PST - epublish SO - BMC Urol. 2023 Jun 7;23(1):106. doi: 10.1186/s12894-023-01278-7. PMID- 37284047 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230608 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 52 DP - 2023 Jun TI - International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. PG - 154-165 LID - 10.1016/j.euros.2023.03.019 [doi] AB - BACKGROUND: Grade of non-muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1-3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. OBJECTIVE: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. DESIGN SETTING AND PARTICIPANTS: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. RESULTS AND LIMITATIONS: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. CONCLUSIONS: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. PATIENT SUMMARY: Grading of non-muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the "old" World Health Organization (WHO) 1973 and the "new" WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative. CI - (c) 2023 The Author(s). FAU - Beijert, Irene J AU - Beijert IJ AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center and Legorreta Cancer Center at Brown University, Providence, RI, USA. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Plass, Karin AU - Plass K AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - Williamson, Sean R AU - Williamson SR AD - Department of Pathology, Cleveland Clinic, Cleveland, OH, USA. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. AD - Department of Urology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Berman, David M AU - Berman DM AD - Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada. AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, Friedrich-Alexander-University of Erlangen-Nurnberg, Erlangen, Germany. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Pitie Salpetriere Hospital, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain. AD - Anatomic Pathology, Champalimaud Clinical Center, Lisbon, Portugal. FAU - Samaratunga, Hemamali AU - Samaratunga H AD - Department of Pathology, Aquesta Uropathology and University of Queensland, Brisbane, Australia. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Varma, Murali AU - Varma M AD - Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK. FAU - Shen, Steven AU - Shen S AD - Department of Pathology Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. FAU - Burger, Maximilian AU - Burger M AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Palou, Joan AU - Palou J AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Pathology, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Downes, Michelle R AU - Downes MR AD - Division of Anatomic Pathology, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20230510 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC10240524 OTO - NOTNLM OT - Bladder OT - Cancer OT - European Association of Urology OT - Grading OT - International Society of Urological Pathology OT - Survey OT - WHO1973 OT - WHO2004 EDAT- 2023/06/07 13:10 MHDA- 2023/06/07 13:11 PMCR- 2023/05/10 CRDT- 2023/06/07 09:42 PHST- 2023/03/29 00:00 [accepted] PHST- 2023/06/07 13:11 [medline] PHST- 2023/06/07 13:10 [pubmed] PHST- 2023/06/07 09:42 [entrez] PHST- 2023/05/10 00:00 [pmc-release] AID - S2666-1683(23)00189-1 [pii] AID - 10.1016/j.euros.2023.03.019 [doi] PST - epublish SO - Eur Urol Open Sci. 2023 May 10;52:154-165. doi: 10.1016/j.euros.2023.03.019. eCollection 2023 Jun. PMID- 37283762 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20240919 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer. PG - 1162580 LID - 10.3389/fimmu.2023.1162580 [doi] LID - 1162580 AB - BACKGROUND: Recent developments in MIBC treatment suggest good efficacy of bladder sparing treatment combined with immune checkpoint inhibitor. However, there is no standard treatment mode. A retrospective analysis was conducted to reveal the efficacy and safety of PD-1 inhibitor in combination with radiotherapy or chemoradiotherapy. METHODS: We retrospectively analyzed 25 patients with MIBC T2-T3N0M0 disease who were unfit or unwilling to undergo RC. These patients underwent the maximum TURBT followed by PD-1 inhibitor (Tislelizumab or Toripalimab) in combination with radiotherapy or chemoradiotherapy (gemcitabine plus cisplatin) between April 2020 and May 2022. The primary outcome was clinical complete response (cCR) rate. The secondary outcomes were disease free survival (DFS) and overall survival (OS). RESULTS: Revised: Of 25 patients, 22 were T2 (88%), while 3 were T3 (12%). The median age is 65 years (51-80). Twenty-one patients had programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or more, and 4 patients had CPS<1 or unknown. Sixteen patients received chemoradiotherapy. Tislelizumab and Toripalimab were administered to 19 and 6 patients, respectively. The median number of cycles of immunotherapy was 8. Twenty-three patients (92%) achieved cCR. Following a median of 13 months of follow-up (range, 5-34 months), 1-year DFS and OS rate were 92% and 96%, respectively. In the univariate analysis, T stage significantly influenced OS and ORR, and efficacy evaluation significantly influenced OS, DFS, and ORR. The expression of PD-L1 and chemotherapy had no effect on prognosis. In the multivariate analysis, no independent prognostic factors were found. Grade 3 or 4 adverse events (AE) were reported in 35.7% patients. CONCLUSIONS: Bladder sparing therapy with PD-1 inhibitor in combination with radiotherapy or chemoradiotherapy is feasible, safe, and highly effective for patients who were unfit or unwilling to undergo RC. CI - Copyright (c) 2023 Xu, Zou, Zhang, Xu, Li, Feng, Zhao, Wang, Liu and Wang. FAU - Xu, Chao AU - Xu C AD - Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zou, Wen AU - Zou W AD - Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Xu, Ran AU - Xu R AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Li, Yuan AU - Li Y AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Feng, Yeqian AU - Feng Y AD - Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zhao, Runtian AU - Zhao R AD - Department of Oncology, Guilin Hospital of the Second Xiangya Hospital, Central South University, Guilin, China. FAU - Wang, Yinhuai AU - Wang Y AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Liu, Xianling AU - Liu X AD - Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Wang, Jingjing AU - Wang J AD - Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230522 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (B7-H1 Antigen) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Retrospective Studies MH - *Immune Checkpoint Inhibitors/adverse effects MH - *Urinary Bladder Neoplasms/drug therapy MH - Urinary Bladder MH - B7-H1 Antigen MH - Cisplatin/therapeutic use MH - Chemoradiotherapy MH - Muscles PMC - PMC10239884 OTO - NOTNLM OT - bladder cancer OT - bladder-sparing treatment OT - muscle-invasive bladder urothelial cancer OT - programmed cell death protein-1 inhibitors OT - radiotherapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/06/07 13:10 MHDA- 2023/06/09 06:41 PMCR- 2023/01/01 CRDT- 2023/06/07 09:37 PHST- 2023/02/09 00:00 [received] PHST- 2023/04/27 00:00 [accepted] PHST- 2023/06/09 06:41 [medline] PHST- 2023/06/07 13:10 [pubmed] PHST- 2023/06/07 09:37 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1162580 [doi] PST - epublish SO - Front Immunol. 2023 May 22;14:1162580. doi: 10.3389/fimmu.2023.1162580. eCollection 2023. PMID- 37280316 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20230810 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 55 IP - 9 DP - 2023 Sep TI - The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study. PG - 2205-2213 LID - 10.1007/s11255-023-03655-5 [doi] AB - PURPOSE: To identify the risk factors for 5-year cancer-specific (CSS) and overall survival (OS) and to compare the accuracy of logistic regression (LR) and artificial neural network (ANN) in the prediction of survival outcomes in T1 non-muscle-invasive bladder cancer. METHODS: This is a population-based analysis using the Surveillance, Epidemiology, and End Results database. Patients with T1 bladder cancer (BC) who underwent transurethral resection of the tumour (TURBT) between 2004 and 2015 were included in the analysis. The predictive abilities of LR and ANN were compared. RESULTS: Overall 32,060 patients with T1 BC were randomly assigned to training and validation cohorts in the proportion of 70:30. There were 5691 (17.75%) cancer-specific deaths and 18,485 (57.7%) all-cause deaths within a median of 116 months of follow-up (IQR 80-153). Multivariable analysis with LR revealed that age, race, tumour grade, histology variant, the primary character, location and size of the tumour, marital status, and annual income constitute independent risk factors for CSS. In the validation cohort, LR and ANN yielded 79.5% and 79.4% accuracy in 5-year CSS prediction respectively. The area under the ROC curve for CSS predictions reached 73.4% and 72.5% for LR and ANN respectively. CONCLUSIONS: Available risk factors might be useful to estimate the risk of CSS and OS and thus facilitate optimal treatment choice. The accuracy of survival prediction is still moderate. T1 BC with adverse features requires more aggressive treatment after initial TURBT. CI - (c) 2023. The Author(s). FAU - Slusarczyk, Aleksander AU - Slusarczyk A AUID- ORCID: 0000-0002-4344-0191 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. slusarczyk.aleksander@gmail.com. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Olszewska-Slusarczyk, Zofia AU - Olszewska-Slusarczyk Z AD - Faculty of Electronics and Information Technology, Warsaw University of Technology, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20230606 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - Logistic Models MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Cystectomy/methods MH - Neural Networks, Computer PMC - PMC10406653 OTO - NOTNLM OT - Artificial neural network OT - Deep learning OT - Non-muscle-invasive bladder cancer OT - Survival OT - T1 stage COIS- The authors declare no conflict of interest. EDAT- 2023/06/07 01:07 MHDA- 2023/08/09 06:43 PMCR- 2023/06/06 CRDT- 2023/06/06 23:22 PHST- 2023/03/26 00:00 [received] PHST- 2023/05/27 00:00 [accepted] PHST- 2023/08/09 06:43 [medline] PHST- 2023/06/07 01:07 [pubmed] PHST- 2023/06/06 23:22 [entrez] PHST- 2023/06/06 00:00 [pmc-release] AID - 10.1007/s11255-023-03655-5 [pii] AID - 3655 [pii] AID - 10.1007/s11255-023-03655-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2023 Sep;55(9):2205-2213. doi: 10.1007/s11255-023-03655-5. Epub 2023 Jun 6. PMID- 37278493 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231115 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 30 IP - 10 DP - 2023 Oct TI - Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort. PG - 853-858 LID - 10.1111/iju.15214 [doi] AB - INTRODUCTION: This study aimed to identify preoperative risk factors and create a risk classification for intravesical recurrence of upper urinary tract urothelial carcinoma only after laparoscopic radical nephroureterectomy in a multi-institutional cohort. METHODS: We retrospectively analyzed 283 patients who had undergone laparoscopic radical nephroureterectomy for nonmetastatic upper tract urothelial cancer between March 2002 and March 2020. The cumulative incidence of intravesical recurrence for 224 patients without previous or concomitant bladder cancer was examined using multivariate Fine-Gray competing risks proportional hazards models. A risk stratification model was created to predict subsequent patient outcomes based on the results. RESULTS: The median follow-up duration was 33.3 months, and 71 (31.7%) patients experienced intravesical recurrence. The estimated cumulative incidence of intravesical recurrence at one and 5 years was 23.5% and 36.4%, respectively. In multivariate analysis, the presence of ureter tumors and multiple tumors were shown to be independently significant predictive factors for intravesical recurrence. Based on the results, we classified patients into three risk groups. The cumulative incidence rates of intravesical recurrence within 5 years after surgery were 24.4%, 42.5%, and 66.7% in the low-, intermediate-, and high-risk groups, respectively. CONCLUSIONS: We identified risk factors and created a risk classification model for intravesical recurrence of upper urinary tract urothelial carcinoma only after laparoscopic radical nephroureterectomy. Based on this model, an individualized surveillance protocol or adjuvant therapy could be provided. CI - (c) 2023 The Japanese Urological Association. FAU - Somiya, Shinya AU - Somiya S AUID- ORCID: 0000-0002-4151-7984 AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Kobori, Go AU - Kobori G AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Ito, Katsuhiro AU - Ito K AUID- ORCID: 0000-0002-6322-9190 AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Nakagawa, Hiromichi AU - Nakagawa H AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Takahashi, Toshifumi AU - Takahashi T AUID- ORCID: 0000-0003-1979-8270 AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Koterazawa, Shigeki AU - Koterazawa S AUID- ORCID: 0000-0002-3211-1835 AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Takaoka, Naoto AU - Takaoka N AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Haitani, Takao AU - Haitani T AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Nagahama, Kanji AU - Nagahama K AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Ito, Masaaki AU - Ito M AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Megumi, Yuzuru AU - Megumi Y AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Higashi, Yoshihito AU - Higashi Y AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Moroi, Seiji AU - Moroi S AD - Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. FAU - Akao, Toshiya AU - Akao T AD - Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan. FAU - Yamada, Hitoshi AU - Yamada H AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. FAU - Kanno, Toru AU - Kanno T AUID- ORCID: 0000-0001-9445-4035 AD - Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230606 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2023 Oct;30(10):859. doi: 10.1111/iju.15238. PMID: 37395269 MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - *Carcinoma, Transitional Cell/epidemiology/surgery/pathology MH - Nephroureterectomy/methods MH - Retrospective Studies MH - *Ureteral Neoplasms/epidemiology/surgery/pathology MH - *Kidney Neoplasms/epidemiology/surgery/pathology MH - *Laparoscopy/adverse effects MH - Neoplasm Recurrence, Local/pathology MH - Nephrectomy/adverse effects/methods MH - *Ureter/surgery/pathology OTO - NOTNLM OT - intravesical recurrence OT - laparoscopic radial nephroureterectomy OT - risk classification OT - upper tract urothelial carcinoma EDAT- 2023/06/06 13:09 MHDA- 2023/10/23 00:42 CRDT- 2023/06/06 08:33 PHST- 2023/01/28 00:00 [received] PHST- 2023/05/22 00:00 [accepted] PHST- 2023/10/23 00:42 [medline] PHST- 2023/06/06 13:09 [pubmed] PHST- 2023/06/06 08:33 [entrez] AID - 10.1111/iju.15214 [doi] PST - ppublish SO - Int J Urol. 2023 Oct;30(10):853-858. doi: 10.1111/iju.15214. Epub 2023 Jun 6. PMID- 37276643 OWN - NLM STAT- MEDLINE DCOM- 20230622 LR - 20230622 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 164 DP - 2023 Aug TI - Fluoxetine inactivates STAT3/NF-kappaB signaling and promotes sensitivity to cisplatin in bladder cancer. PG - 114962 LID - S0753-3322(23)00752-7 [pii] LID - 10.1016/j.biopha.2023.114962 [doi] AB - Bladder cancer is known as one of the top ten most common cancer types worldwide and can be majorly divided into muscles invasive bladder cancer (MIBC) and non-muscles invasive type (NMIBC). However, the prognosis of BC remains poor under standard treatment including radical cystectomy or concurrent chemoradiotherapy. Numerous studies have reported that the prognosis of BC is associated with the activation of signal transducer and activator of transcription (STAT3) and nuclear factor kappa-B (NF-kappaB). Fluoxetine, a well-known anti-depressant, has been reported to against various type of cancers. However, it is unclear whether fluoxetine has the capacity to inhibit BC progression by targeting STAT3 and NF-kappaB-mediated signaling. Here, we used cell viability, apoptosis assay, wound healing assay, invasion/migration assay, Western blotting assay, immunofluorescence staining, as well as animal experiments, to elucidate the efficacy of fluoxetine on in vitro and in vivo BC models. We found that fluoxetine may induce cytotoxicity and intrinsic/extrinsic apoptosis in BC and enhance the potential of cisplatin. Fluoxetine promoted both caspase-dependent and caspase-independent apoptosis signaling by activating caspase-3, 8, 9, apoptosis-inducing factor (AIF), and EndG. Furthermore, fluoxetine suppressed invasion and migration ability and the expression of metastasis-associated genes. Fluoxetine was also found to inactivate the phosphorylation of STAT3 (Tyr705) and NF-kappaB (Ser536) and suppress the nuclear translocation of NF-kappaB. In MB49-bearing mice, fluoxetine effectively delayed the progression of BC without inducing general toxicity. In summary, the induction of apoptosis and the inhibition of invasion triggered by fluoxetine are associated with the inactivation of STAT3 and NF-kappaB. CI - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Yang, Che-Jui AU - Yang CJ AD - Department of Urology, Show Chwan Memorial Hospital, Changhua, Taiwan, ROC; Division of Urology, Department of Surgery, Chang Bing Show-Chwan Memorial Hospital, Changhua, Taiwan, ROC. FAU - Tan, Zhao-Lin AU - Tan ZL AD - Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC. FAU - Yang, Jr-Di AU - Yang JD AD - Division of Urology, Department of Surgery, National Yang-Ming Chiao Tung University Hospital, Yilan, Taiwan, ROC. FAU - Hsu, Fei-Ting AU - Hsu FT AD - Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC. FAU - Chiang, Chih-Hung AU - Chiang CH AD - Department of Urology, National Taiwan University Hospital, Taipei, Taiwan, ROC; Department of Urology, Taipei Veterans General Hospital, Yuan-Shan Branch, Yi-Lan, Taiwan, ROC; Department of Nursing, Cardinal Tien Junior College of Healthcare and Management, New Taipei City, Taiwan, ROC. Electronic address: guchiang@gmail.com. LA - eng PT - Journal Article DEP - 20230603 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (NF-kappa B) RN - Q20Q21Q62J (Cisplatin) RN - 01K63SUP8D (Fluoxetine) RN - EC 3.4.22.- (Caspases) RN - 0 (STAT3 Transcription Factor) SB - IM MH - Animals MH - Mice MH - *NF-kappa B/metabolism MH - Cisplatin/pharmacology/metabolism MH - Fluoxetine/pharmacology/therapeutic use MH - Cell Line, Tumor MH - *Urinary Bladder Neoplasms/drug therapy/metabolism MH - Apoptosis MH - Caspases/metabolism MH - STAT3 Transcription Factor/metabolism OTO - NOTNLM OT - Apoptosis OT - Fluoxetine OT - Muscles invasive bladder cancer OT - NF-kappaB OT - STAT3 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/06/05 19:10 MHDA- 2023/06/22 06:42 CRDT- 2023/06/05 18:00 PHST- 2023/03/25 00:00 [received] PHST- 2023/05/25 00:00 [revised] PHST- 2023/05/27 00:00 [accepted] PHST- 2023/06/22 06:42 [medline] PHST- 2023/06/05 19:10 [pubmed] PHST- 2023/06/05 18:00 [entrez] AID - S0753-3322(23)00752-7 [pii] AID - 10.1016/j.biopha.2023.114962 [doi] PST - ppublish SO - Biomed Pharmacother. 2023 Aug;164:114962. doi: 10.1016/j.biopha.2023.114962. Epub 2023 Jun 3. PMID- 37273148 OWN - NLM STAT- MEDLINE DCOM- 20240103 LR - 20261010 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 26 IP - 1 DP - 2024 Jan TI - Comparison of different prediction tools for the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a propensity-matched analysis. PG - 136-146 LID - 10.1007/s12094-023-03226-1 [doi] AB - OBJECTIVE: To compare the predictive performance of the current clinical prediction models for predicting intravesical recurrence (IVR) after radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC). METHODS: We retrospectively analysed upper tract urothelial carcinoma patients who underwent radical nephroureterectomy in our centre from January 2009 to December 2019. We used the propensity score matching (PSM) method to adjust the confounders between the IVR and non-IVR groups. Additionally, Xylinas' reduce model and full model, Zhang's model, and Ishioka's risk stratification model were used to retrospectively calculate predictions for each patient. Receiver operating characteristic (ROC) curves were generated, and the areas under the curves (AUCs) were compared to identify the method with the highest predictive value. RESULTS: We included 217 patients with a median follow-up of 41 months, of which 57 had IVR. After PSM analysis, 52 pairs of well-matched patients were included in the comparative study. No significant difference was found in clinical indicators besides hydronephrosis. The model comparison showed that the AUCs of the reduced Xylinas' model for 12 months, 24 months, and 36 months were 0.69, 0.73, and 0.74, respectively, and those of the full Xylinas' model were 0.72, 0.75, and 0.74, respectively. The AUC of Zhang's model for 12 months, 24 months, and 36 months was 0.63, 0.71, and 0.71, respectively, the performance of Ishioka's model is that the AUC of 12 months, 24 months and 36 months was 0.66, 0.71, and 0.74, respectively. CONCLUSION: The external verification results of the four models show that more comprehensive data and a larger sample size of patients are needed to strengthen the models' derivation and updating procedure, to better apply them to different populations. CI - (c) 2023. The Author(s), under exclusive licence to Federacion de Sociedades Espanolas de Oncologia (FESEO). FAU - Luo, Zhenkai AU - Luo Z AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, No. 17 Nanli, Panjiayuan, Chaoyang District, Beijing, 100730, China. AD - Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Nanli, Panjiayuan, Chaoyang District, Beijing, 100021, China. FAU - Jiao, Binbin AU - Jiao B AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. FAU - Zhao, Hang AU - Zhao H AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Huang, Tao AU - Huang T AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, China. FAU - Liu, Yuhao AU - Liu Y AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Chen, Haijie AU - Chen H AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Guan, Yunfan AU - Guan Y AD - Peking University China-Japan Friendship School of Clinical Medicine, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. FAU - Zhang, Guan AU - Zhang G AUID- ORCID: 0000-0002-5942-2481 AD - Department of Urology, China-Japan Friendship Hospital, Yinghuadong Road, Chaoyang District, Beijing, 100029, China. gzhang2016@sina.com. FAU - Jiang, Zhaoqiang AU - Jiang Z AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, 450003, China. jiangzhaoqiang@zzu.edu.cn. LA - eng PT - Journal Article DEP - 20230605 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Nephroureterectomy MH - Retrospective Studies MH - Nephrectomy MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - Clinical prediction model OT - External validation OT - Intravesical recurrence OT - Risk factor OT - Upper tract urothelial carcinoma EDAT- 2023/06/05 13:04 MHDA- 2024/01/03 09:41 CRDT- 2023/06/05 11:12 PHST- 2023/04/27 00:00 [received] PHST- 2023/05/22 00:00 [accepted] PHST- 2024/01/03 09:41 [medline] PHST- 2023/06/05 13:04 [pubmed] PHST- 2023/06/05 11:12 [entrez] AID - 10.1007/s12094-023-03226-1 [pii] AID - 10.1007/s12094-023-03226-1 [doi] PST - ppublish SO - Clin Transl Oncol. 2024 Jan;26(1):136-146. doi: 10.1007/s12094-023-03226-1. Epub 2023 Jun 5. PMID- 37272323 OWN - NLM STAT- MEDLINE DCOM- 20230606 LR - 20230612 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 47 IP - 5 DP - 2023 Jun TI - Evaluation of incidence, predictive factors and treatment considerations for asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin therapy. PG - 317-326 LID - S2173-5786(22)00102-0 [pii] LID - 10.1016/j.acuroe.2022.09.003 [doi] AB - INTRODUCTION AND OBJECTIVES: Although the complications of intravesical BCG treatment are well described, asymptomatic genitourinary granulomas after BCG therapy have rarely been reported and management strategy for these conditions remains controversial. The objective of this study is to evaluate the incidence rate of asymptomatic genitourinary granuloma formation mimicking bladder cancer recurrence after intravesical bacillus Calmette-Guerin (BCG) therapy and to identify the diagnostic and treatment strategies according to patient conditions. PATIENTS AND METHODS: A retrospective review was conducted on 162 patients who underwent intravesical BCG therapy. For patients who developed granulomas, we evaluated the time interval between BCG instillation and the development of granuloma, the presence of acid-fast bacteria on pathology specimens, culture/polymerase chain reaction results, management strategies for the lesions, and clinical outcomes. RESULTS: Asymptomatic genitourinary masses developed in 14 patients, of whom 5 underwent histological examinations and all were confirmed to have granulomatous inflammation. The affected organs included the kidney, bladder, prostate, and penis. While four of the five patients did not receive treatment for their granulomas, one patient was administered antituberculous medication to prevent worsening of the lesion during the perioperative period of the scheduled cystoprostatectomy. None of the patients experienced worsening or recurrence of granulomatous lesions. Patients who developed asymptomatic masses (n = 14) were significantly younger than those who did not (p = 0.0076) and multivariate analysis also showed that younger age was independently associated with the development of clinically suspicious lesions (p = 0.032); however, none of the parameters were associated with histologically confirmed granuloma formation. CONCLUSIONS: Genitourinary granulomas mimicking recurrence of carcinoma may develop in nearly 10% of patients after intravesical BCG therapy. Most patients can be managed without potentially toxic antituberculosis therapy. CI - Copyright (c) 2022 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Soda, T AU - Soda T AD - Department of Urology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. Electronic address: ts11885@gmail.com. FAU - Tashiro, Y AU - Tashiro Y AD - Department of Urology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. FAU - Koike, S AU - Koike S AD - Department of Urology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. FAU - Ikeuchi, R AU - Ikeuchi R AD - Department of Urology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. FAU - Okada, T AU - Okada T AD - Department of Urology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. LA - eng LA - spa PT - Journal Article DEP - 20221001 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (BCG Vaccine) SB - IM MH - Male MH - Humans MH - *BCG Vaccine/adverse effects MH - Incidence MH - Neoplasm Recurrence, Local/epidemiology MH - *Urinary Bladder Neoplasms/pathology MH - Granuloma/etiology/microbiology OTO - NOTNLM OT - Asintomatico OT - Asymptomatic OT - Bacillus Calmette-Guerin OT - Bacilo de Calmette-Guerin OT - Bladder cancer OT - Complicacion OT - Complication OT - Cancer de vejiga OT - Granuloma OT - Instilacion intravesical OT - Intravesical instillation EDAT- 2023/06/05 06:42 MHDA- 2023/06/06 06:42 CRDT- 2023/06/05 04:32 PHST- 2022/03/25 00:00 [received] PHST- 2022/08/08 00:00 [revised] PHST- 2022/08/10 00:00 [accepted] PHST- 2023/06/06 06:42 [medline] PHST- 2023/06/05 06:42 [pubmed] PHST- 2023/06/05 04:32 [entrez] AID - S2173-5786(22)00102-0 [pii] AID - 10.1016/j.acuroe.2022.09.003 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2023 Jun;47(5):317-326. doi: 10.1016/j.acuroe.2022.09.003. Epub 2022 Oct 1. PMID- 37270737 OWN - NLM STAT- MEDLINE DCOM- 20230818 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 7 DP - 2023 Jul TI - Impact of diagnostic ureteral catheterization on intravesical tumour recurrence following radical nephroureterectomy for upper tract urothelial carcinoma. PG - 1869-1875 LID - 10.1007/s00345-023-04446-4 [doi] AB - PURPOSE: To investigate whether even a minimally invasive diagnostic procedure for the upper tract such as ureteral catheterization (UCath) may substantially increase the risk of intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: The present, retrospective study enrolled 163 patients undergoing RNU for UTUC between 2010 and 2021 at two, tertiary care hospitals. The primary endpoint was the association between UCath and IVR-free survival (IVRFS). The secondary endpoints were the association of ureterorenoscopy (URS) and URS biopsy (URSBx) with IVRFS. Directed acyclic graph (DAG)-guided multivariable models were used to adjust for potential confounders. RESULTS: Of the 163 patients, 128 (79%), 88 (54%), and 67 (41%) received UCath, URS, and URSBx, respectively. URS was performed concurrently with UCath. During the follow-up period (median: 47 months), IVR developed in 62 patients (5-year IVRFS rate: 52%). A DAG included concurrent bladder cancer, tumour size, hydronephrosis, positive cytology, and multiple UTUCs as potential confounders of the association between UCath and IVR. Both DAG-guided and stepwise multivariable models revealed a significant association between UCath and IVR (hazard ratio: 17.8; P < 0.001). UCath was also associated with shorter IVRFS in a subset of 75 patients who had not received URS (P < 0.001). In contrast, URS and URSBx were not associated with IVR in patients who had received UCath and URS, respectively. CONCLUSION: Any diagnostic manipulations of the upper urinary tract, even a minimally invasive procedure like UCath, could confer a risk of post-RNU IVR in UTUC patients. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yonese, Ichiro AU - Yonese I AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, Japan. FAU - Ito, Masaya AU - Ito M AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, Japan. FAU - Waseda, Yuma AU - Waseda Y AD - Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan. FAU - Kobayashi, Shuichiro AU - Kobayashi S AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, Japan. FAU - Toide, Masahiro AU - Toide M AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, Japan. FAU - Takazawa, Ryoji AU - Takazawa R AD - Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan. FAU - Koga, Fumitaka AU - Koga F AUID- ORCID: 0000-0001-7888-0085 AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, Japan. fumitaka_koga@tmhp.jp. LA - eng PT - Journal Article DEP - 20230604 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - *Urinary Catheterization/adverse effects MH - Humans MH - *Nephroureterectomy MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - *Ureteral Neoplasms/diagnosis/epidemiology/surgery MH - *Carcinoma, Transitional Cell/diagnosis/epidemiology/surgery MH - Retrospective Studies MH - Male MH - Female OTO - NOTNLM OT - Intravesical tumour recurrence OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma OT - Ureteral catheterization OT - Ureterorenoscopy EDAT- 2023/06/04 13:12 MHDA- 2023/07/19 06:43 CRDT- 2023/06/04 11:04 PHST- 2023/01/09 00:00 [received] PHST- 2023/05/17 00:00 [accepted] PHST- 2023/07/19 06:43 [medline] PHST- 2023/06/04 13:12 [pubmed] PHST- 2023/06/04 11:04 [entrez] AID - 10.1007/s00345-023-04446-4 [pii] AID - 10.1007/s00345-023-04446-4 [doi] PST - ppublish SO - World J Urol. 2023 Jul;41(7):1869-1875. doi: 10.1007/s00345-023-04446-4. Epub 2023 Jun 4. PMID- 37267612 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20230908 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 49 IP - 4 DP - 2023 Jul-Aug TI - Effects of different combinations of radical nephroureterectomy and bladder cuff excision procedures for upper tract urothelial carcinoma on bladder recurrence. PG - 469-478 LID - 10.1590/S1677-5538.IBJU.2023.0031 [doi] AB - PURPOSE: To compare the effects of different combinations of radical nephroureterectomy (RNU) and bladder cuff excision (BCE) surgical procedures on intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: This retrospective observational study included 452 patients who underwent RNU with BCE for UTUC between January 2010 and December 2020. The patients were classified into three groups based on different combinations of RNU and BCE surgical procedures: open RNU with open BCE (group 1, n=104), minimally invasive (MIS) RNU with open BCE (group 2, n=196), and MIS RNU with intracorporeal BCE (group 3, n=152). Data on demographics, body mass index, history, preoperative renal function, perioperative status, tumor characteristics, histopathology, and recurrence conditions were collected. Multivariate Cox regression analyses were performed to determine the impact of the surgical procedures on IVR. P-values < 0.05 were considered statistically significant. RESULTS: After a median follow-up of 29.5 months, the IVR rate was 29.6% and the IVR-free survival rate was the lowest in group 2 (group 1 vs. group 2 vs. group 3: 69.0% vs. 55.1% vs. 67.5%; log-rank P=0.048). The overall survival rate was comparable among the three groups. Multivariate analysis revealed that group 2 had a significantly higher risk of IVR than group 1 (hazard ratio=1.949, 95% confidence interval=1.082-3.511, P=0.026), while groups 1 and 3 had similar risks. CONCLUSIONS: For patients with UTUC, MIS RNU with open BCE is associated with a higher risk of IVR than open RNU with open BCE and MIS RNU with intracorporeal BCE. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Huang, Eric Yi-Hsiu AU - Huang EY AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Tai, Meng-Che AU - Tai MC AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. AD - Division of Urology, Department of Surgery, Taipei Veterans General Hospital Taoyuan Branch, Taoyuan, Taiwan. FAU - Chung, Hsiao-Jen AU - Chung HJ AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Chang, Yen-Hwa AU - Chang YH AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Huang, William J AU - Huang WJ AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. LA - eng PT - Journal Article PT - Observational Study PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Nephroureterectomy/methods MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Urinary Bladder/surgery/pathology MH - Nephrectomy/methods MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - *Ureteral Neoplasms/surgery/pathology PMC - PMC10482446 OTO - NOTNLM OT - Recurrence OT - Urinary Bladder OT - Nephroureterectomy COIS- None declared. EDAT- 2023/06/02 19:13 MHDA- 2023/06/05 06:42 PMCR- 2023/05/20 CRDT- 2023/06/02 16:58 PHST- 2023/01/23 00:00 [received] PHST- 2023/05/02 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/06/02 19:13 [pubmed] PHST- 2023/06/02 16:58 [entrez] PHST- 2023/05/20 00:00 [pmc-release] AID - IBJU20230031 [pii] AID - S1677-5538.IBJU.2023.0031 [pii] AID - 10.1590/S1677-5538.IBJU.2023.0031 [doi] PST - ppublish SO - Int Braz J Urol. 2023 Jul-Aug;49(4):469-478. doi: 10.1590/S1677-5538.IBJU.2023.0031. PMID- 37263278 OWN - NLM STAT- MEDLINE DCOM- 20250206 LR - 20260730 IS - 1438-8820 (Electronic) IS - 0001-7868 (Linking) VI - 56 IP - 1 DP - 2025 Feb TI - Clinical and pathological risk factors for tumour recurrence and upstaging in second TURBT for patients with NMIBC: a systematic review and meta-analysis. PG - 30-40 LID - 10.1055/a-2063-3144 [doi] AB - ZIEL: Offenlegung signifikanter Risikofaktoren durch Identifizierung gepoolter Effektschatzungsstatistiken in einer systemischen Uberprufung und Metaanalyse klinischer und pathologischer Risikofaktoren, die ein Tumorrezidiv und ein Upstaging auf eine zweite TURBT bei Patienten mit hochgradigem NMIBC vorhersagen. MATERIAL-METHODE: Alle Datenquellen wurden umfassend bis Oktober 2022 untersucht. Die Daten wurden aus den relevanten Studien extrahiert und mit der Software RevMan analysiert. In einem inversen Varianzmodell mit zufalligen und festen Effekten werden Odds Ratio (OR)-Werte mit 95%-Konfidenzintervallen [95%-KI] angegeben. ERGEBNISSE: Der Review umfasste insgesamt 18 Studien und 4548 Patienten. Gemass den gepoolten Effektschatzern waren Carcinoma in situ (CIS), Tumorgrad, Multiplizitat und Chirurgenfaktoren signifikante Risikofaktoren. Die gepoolten Effektschatzungen fur das Tumorstadium und die Tumormorphologie waren sehr nahe an der Signifikanz. Fur CIS, Grad, Multiplizitat und Chirurgenfaktor, OR, IVR oder IVF [95%-KI] waren die p- und I2-Werte 1,8 [1,1, 3,0], 0,03, 75%; 2 [1,1, 3,4], 0,02, 53%; 1,3 [1,2, 1,6], <0,01, 40%; und 2 [1,4, 3], <0,01, 66%. SCHLUSSFOLGERUNGEN: Als Ergebnis der ersten TURBT; Eine zweite TURBT sollte in den 2-6 Wochen der postoperativen Phase fur Patienten mit hochgradigem, begleitendem CIS, multipler, solider Morphologie, DM(-) im pathologischen Praparat und NMIBC, das von Trainern/Juniorchirurgen operiert wird, geplant werden. CI - Thieme. All rights reserved. FAU - Guler, Yavuz AU - Guler Y AUID- ORCID: 0000-0001-7770-8013 AD - Department of Urology, TC Istanbul Rumeli University, Istanbul, Turkey. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review TT - Klinische und pathologische Risikofaktoren fur Tumorrezidive und Upstaging in der zweiten TURBT fur Patienten mit NMIBC: Eine systematische Uberprufung und Metaanalyse. DEP - 20230601 PL - Germany TA - Aktuelle Urol JT - Aktuelle Urologie JID - 0421406 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/pathology MH - Risk Factors MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Neoplasm Staging MH - Non-Muscle Invasive Bladder Neoplasms COIS- The authors declare that they have no conflict of interest. EDAT- 2023/06/02 01:07 MHDA- 2025/02/07 00:20 CRDT- 2023/06/01 18:52 PHST- 2025/02/07 00:20 [medline] PHST- 2023/06/02 01:07 [pubmed] PHST- 2023/06/01 18:52 [entrez] AID - 10.1055/a-2063-3144 [doi] PST - ppublish SO - Aktuelle Urol. 2025 Feb;56(1):30-40. doi: 10.1055/a-2063-3144. Epub 2023 Jun 1. PMID- 37259815 OWN - NLM STAT- MEDLINE DCOM- 20230616 LR - 20230616 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 95 IP - 2 DP - 2023 May 31 TI - History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer. PG - 11380 LID - 10.4081/aiua.2023.11380 [doi] AB - OBJECTIVE: To evaluate the utility of infantile BCG vaccination history in predicting stage and grade of tumours in non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively analyzed data from patients from a single center who were diagnosed with new NMIBC and underwent transurethral resection of bladder tumour (TURBT) between 2017 and 2022. We assessed BCG immunization status with various demographics and comorbidities, as well as tumour recurrence, progression, stage, and grade. RESULTS: A total of 188 patients met the inclusion criteria for our study. The mean age of patients at the time of diagnosis was significantly lower in those that had been immunized with BCG (71 +/- 9) than those who had not (77 +/- 10) (p < 0.0001). History of BCG immunization did not correlate with sex, history of diabetes mellitus (DM), prior history of intravesical BCG treatment, and tumour recurrence, progression, stage, and grade. CONCLUSIONS: History of infantile BCG vaccination did not correlate with the depth of invasion and/or the grade in patients with non-muscle invasive bladder cancer. Patients that received infantile BCG vaccination were significantly younger at the time of diagnosis of NMIBC. FAU - MacDonald, Anastasia AU - MacDonald A AD - Northern Ontario School of Medicine, Thunder Bay, ON. anamacdonald@nosm.ca. FAU - Mehrnoush, Vahid AU - Mehrnoush V AD - Northern Ontario School of Medicine, Thunder Bay, ON. vahidmehrnoush7@gmail.com. FAU - Ismail, Asmaa AU - Ismail A AD - Northern Ontario School of Medicine, Thunder Bay, ON. asmaaismail0782@gmail.com. FAU - Di Matteo, Livio AU - Di Matteo L AD - Department of Economics, Lakehead University, Thunder Bay, ON. ldimatte@lakeheadu.ca. FAU - Zakaria, Ahmed AU - Zakaria A AD - Northern Ontario School of Medicine, Thunder Bay, ON. aszakaria81@yahoo.com. FAU - Shabana, Waleed AU - Shabana W AD - Northern Ontario School of Medicine, Thunder Bay, ON. waleed.shabana@gmail.com. FAU - Shaban, Ashraf AU - Shaban A AD - Northern Ontario School of Medicine, Thunder Bay, ON. ashraf.shaban@tbh.net. FAU - Bassuony, Mohammed AU - Bassuony M AD - Northern Ontario School of Medicine, Thunder Bay, ON. mohammed.bassuony@tbh.net. FAU - Elmansy, Hazem AU - Elmansy H AD - Northern Ontario School of Medicine, Thunder Bay, ON. hazem.elmansy@tbh.net. FAU - Shahrour, Walid AU - Shahrour W AD - Northern Ontario School of Medicine, Thunder Bay, ON. walid.shahrour@tbh.net. FAU - Prowse, Owen AU - Prowse O AD - Northern Ontario School of Medicine, Thunder Bay, ON. owen.prowse@tbh.net. FAU - Kotb, Ahmed AU - Kotb A AD - Northern Ontario School of Medicine, Thunder Bay, ON. drahmedfali@gmail.com. LA - eng PT - Journal Article DEP - 20230531 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine MH - Retrospective Studies MH - Neoplasm Recurrence, Local MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic MH - *Urinary Bladder Neoplasms/pathology MH - Immunization MH - Neoplasm Invasiveness EDAT- 2023/06/01 06:42 MHDA- 2023/06/16 06:42 CRDT- 2023/06/01 04:40 PHST- 2023/04/11 00:00 [received] PHST- 2023/05/26 00:00 [accepted] PHST- 2023/06/16 06:42 [medline] PHST- 2023/06/01 06:42 [pubmed] PHST- 2023/06/01 04:40 [entrez] AID - 10.4081/aiua.2023.11380 [doi] PST - epublish SO - Arch Ital Urol Androl. 2023 May 31;95(2):11380. doi: 10.4081/aiua.2023.11380. PMID- 37258363 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20240212 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 84 IP - 5 DP - 2023 Nov TI - Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection. PG - 473-483 LID - S0302-2838(23)02816-6 [pii] LID - 10.1016/j.eururo.2023.05.011 [doi] AB - CONTEXT: Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized muscle-invasive UC (MIUC), upper tract UC, and non-muscle-invasive bladder cancer (NMIBC) disease state. OBJECTIVE: To assess the outcomes and toxicity of CPIs across the treatment landscape of UC and contextualize their application to current real-world treatment. EVIDENCE ACQUISITION: We queried PubMed, Web of Science, and EMBASE databases and conference abstracts to identify prospective trials examining CPIs in UC. The primary endpoints included overall survival, recurrence-free survival, and toxicity (when available). A secondary analysis included biomarker evaluation of response. EVIDENCE SYNTHESIS: We identified 21 trials, 12 phase 2 and nine phase 3 trials, in which a CPI was used for metastatic UC (seven), MIUC (nine), and NMIBC (five). For first-line (1L) metastatic UC, concurrent chemotherapy with CPIs failed to show superiority. Improved overall and progression-free survival for switch maintenance avelumab (after achieving stable disease or response with induction systemic chemotherapy) has established the current standard of care for 1L metastatic UC. A single-agent CPI is a consideration for patients unable to tolerate chemotherapy. CPIs in the perioperative setting are limited to only the adjuvant treatment with nivolumab after radical surgery for MIUC in patients at a higher risk of recurrence based on pathologic stage. Only pembrolizumab is approved by the Food and Drug Administration for carcinoma in situ unresponsive to bacillus Calmette-Guerin (BCG) in patients who are not fit for or who refuse radical cystectomy. Trials investigating CPIs in combination with multiple immune regulators, antibody drug conjugates, targeted therapies, antiangiogenic agents, chemotherapy, and radiotherapy are enrolling patients and may shape the future treatment of patients with UC. CONCLUSIONS: CPIs have an established role across multiple states of UC, with broadened applications likely to occur in the future. Several combinations are being evaluated, while the development of predictive biomarkers and their validation may help identify patients who are most likely to respond. PATIENT SUMMARY: Our findings highlight the broad activity of checkpoint inhibitors in urothelial carcinoma, noting the need for further investigation for the best application of combinations and patient selection to patient care. CI - Published by Elsevier B.V. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, IL, USA; Jesse Brown VAMC, Chicago, IL, USA. Electronic address: joshua.meeks@northwestern.edu. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Galsky, Matthew AU - Galsky M AD - Tisch Cancer Institute, New York, NY, USA. FAU - Grivas, Petros AU - Grivas P AD - Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. FAU - Hahn, Noah M AU - Hahn NM AD - Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Hussain, Syed A AU - Hussain SA AD - Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. FAU - Milowsky, Matthew I AU - Milowsky MI AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, NYU Langone, New York, NY, USA. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX, USA. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. LA - eng GR - I01 BX005599/BX/BLRD VA/United States GR - R01 CA235681/CA/NCI NIH HHS/United States GR - UM1 CA186691/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - I01 BX003692/BX/BLRD VA/United States GR - P50 CA221745/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review DEP - 20230529 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antibodies, Monoclonal) RN - 0 (Biomarkers) RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Prospective Studies MH - Antibodies, Monoclonal/therapeutic use MH - Biomarkers MH - BCG Vaccine/therapeutic use OTO - NOTNLM OT - Biomarkers OT - Immune signatures OT - Immunotherapy OT - Metastatic cancer OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive cancer EDAT- 2023/06/01 01:08 MHDA- 2023/10/23 12:43 CRDT- 2023/05/31 22:02 PHST- 2023/01/13 00:00 [received] PHST- 2023/04/22 00:00 [revised] PHST- 2023/05/13 00:00 [accepted] PHST- 2023/10/23 12:43 [medline] PHST- 2023/06/01 01:08 [pubmed] PHST- 2023/05/31 22:02 [entrez] AID - S0302-2838(23)02816-6 [pii] AID - 10.1016/j.eururo.2023.05.011 [doi] PST - ppublish SO - Eur Urol. 2023 Nov;84(5):473-483. doi: 10.1016/j.eururo.2023.05.011. Epub 2023 May 29. PMID- 37254927 OWN - NLM STAT- MEDLINE DCOM- 20230616 LR - 20230616 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 95 IP - 2 DP - 2023 May 30 TI - HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones. PG - 11313 LID - 10.4081/aiua.2023.11313 [doi] AB - BACKGROUND: Transurethral resection (TUR) followed by adjuvant therapy is still the treatment of choice of Non-Muscle-Invasive Bladder Urothelial Carcinoma (NMIBUC). However, recurrence is one of the most troublesome features of these lesions. Early second resection and adjuvant BCG therapy has been shown to improve the outcome. OBJECTIVE: To evaluate the prognostic value of C-erbB-2 (HER2/neu) expression status in Non-Muscle-Invasive Bladder Urothelial Carcinoma cases, before and after intravesical Bacillus Calmette Guerin (BCG immunotherapy). MATERIALS AND METHODS: HER2/neu expression was studied in 120 (Ta-T1) Non-Muscle-Invasive Urothelial Carcinoma cases. The expression was evaluated and compared to the expression after Bacillus Calmette Guerin (BCG) immunotherapy. RESULTS: HER2/neu expression in low and high grade of the Non- Muscle-Invasive Urothelial Carcinoma was (38%) and (83%) respectively. The difference of the expression rates by tumor grade was statistically significant. In recurring lesions post BCG therapy, C-erbB-2 expression was markedly decreased (31.6%) when compared to its expression before therapy (65%). CONCLUSIONS: The HER2/neu expression increased as the tumor grade rose. The reduction in expression following BCG treatment in Non-Invasive transitional cell carcinoma cases could reflect a reduction of the potential malignancy of the tumor. FAU - Ali, Mohamed Yousef AU - Ali MY AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo. mohamedyousef79@gmail.com. FAU - Aboelsaad, Ahmed Yousef AU - Aboelsaad AY AD - Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta. aboelsaadurology@hotmail.com. FAU - Abdel Gawad, Ahmed M AU - Abdel Gawad AM AD - Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta. aa.urology@domazhermedicine.edu.eg. FAU - Abouelgreed, Tamer A AU - Abouelgreed TA AD - Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. mohamedyousef79@gmail.com. FAU - El Gammal, Ahmed A AU - El Gammal AA AD - Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. aelgammal36@gmail.com. FAU - Ghoneimy, Osama M AU - Ghoneimy OM AD - Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. elgendyosama787@gmail.com. FAU - El-Dydamony, Eman M AU - El-Dydamony EM AD - Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. emanmohamed.8@azhar.edu.eg. FAU - Alrefaey, Ahmed A AU - Alrefaey AA AD - Urology Department, Faculty of Medicine, Al-Azhar University, Cairo. A7medrefa3y.ash@gmail.com. FAU - Mohamed, Eslam AU - Mohamed E AD - Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo. eslamoncology2016@gmail.com. FAU - Azzam, Sherif AU - Azzam S AD - Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo. azzams9689@gmail.com. FAU - Abdulmohaymen, Ayman AU - Abdulmohaymen A AD - Surgical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo. AAbdulmohaymen@azhar.edu.ed. FAU - Mohammed, Yasien AU - Mohammed Y AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo. Dr.yasien2@gmail.com. FAU - Abdelwahed, Mohammed S AU - Abdelwahed MS AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo; Pathology Department, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia. mohammedsaber75@hotmail.com. FAU - Elsayed, Ahmed Fawzi A AU - Elsayed AFA AD - Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta. mohamedyousef79@gmail.com. FAU - Fathi, Basem A AU - Fathi BA AD - Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. basemhara@gmail.com. FAU - Abd Alrahim, Nosaiba M AU - Abd Alrahim NM AD - Clinical pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. mohamedyousef79@gmail.com. FAU - Farag, Abeer S AU - Farag AS AD - Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo. mohamedyousef79@gmail.com. FAU - Mahmoud, Alaa R AU - Mahmoud AR AD - Urology Department, Faculty of Medicine, Al-Azhar University, Assiut. mohamedyousef79@gmail.com. FAU - Mohamed, Hasan Ismail AU - Mohamed HI AD - Urology Department, Faculty of Medicine, Al-Azhar University, Cairo. mohamedyousef79@gmail.com. FAU - Horsu, Seth AU - Horsu S AD - Histopathology Department, St. Vincent's University Hospital, Dublin. mohamedyousef79@gmail.com. FAU - Hasan, Abdulkarim AU - Hasan A AD - Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo. doctorabdulkarim7@gmail.com. LA - eng PT - Journal Article DEP - 20230530 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - BCG Vaccine/therapeutic use MH - Urinary Bladder/pathology MH - Administration, Intravesical MH - Neoplasm Recurrence, Local MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness EDAT- 2023/05/31 13:12 MHDA- 2023/06/16 06:42 CRDT- 2023/05/31 06:43 PHST- 2023/03/14 00:00 [received] PHST- 2023/04/01 00:00 [accepted] PHST- 2023/06/16 06:42 [medline] PHST- 2023/05/31 13:12 [pubmed] PHST- 2023/05/31 06:43 [entrez] AID - 10.4081/aiua.2023.11313 [doi] PST - epublish SO - Arch Ital Urol Androl. 2023 May 30;95(2):11313. doi: 10.4081/aiua.2023.11313. PMID- 37246824 OWN - NLM STAT- MEDLINE DCOM- 20231221 LR - 20261007 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 48 IP - 1 DP - 2024 Jan 1 TI - International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance. PG - e1-e10 LID - 10.1097/PAS.0000000000002059 [doi] AB - Grade is a key prognostic factor in determining progression in nonmuscle invasive papillary urothelial carcinomas. The 2 most common grading methods in use worldwide are the World Health Organization (WHO) 2004 and 1973 schemes. The International Society of Urological Pathology (ISUP) organized the 2022 consensus conference in Basel, Switzerland on current issues in bladder cancer and tasked working group 1 to make recommendations for future iterations of bladder cancer grading. For this purpose, the ISUP developed in collaboration with the European Association of Urology a 10-question survey for their memberships to understand the current use of grading schemes by pathologists and urologists and to ascertain the areas of potential improvements. An additional survey was circulated to the ISUP membership for their opinion on interobserver variability in grading, reporting of urine cytology, and challenges encountered in grade assignment. Comprehensive literature reviews were performed on bladder cancer grading prognosis and interobserver variability along with The Paris System for urine cytology. There are notable differences in practice patterns between North American and European pathologists in terms of used grading scheme and diagnosis of papillary urothelial neoplasm of low malignant potential. Areas of common ground include difficulty in grade assignment, a desire to improve grading criteria, and a move towards subclassifying high-grade urothelial carcinomas. The surveys and in-person voting demonstrated a strong preference to refine current grading into a 3-tier scheme with the division of WHO 2004 high grade into clinically relevant categories. More variable opinions were voiced regarding the use of papillary urothelial carcinoma with low malignant potential. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Downes, Michelle R AU - Downes MR AD - Precision Diagnostics & Therapeutics Program, Department of Anatomic Pathology, Sunnybrook Health Sciences Centre. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Shen, Steven AU - Shen S AD - Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi Prefecture, Japan. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Bubendorf, Lukas AU - Bubendorf L AD - Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Laboratory Medicine Program, Department of Anatomic Pathology, University Health Network, Toronto, ON, Canada. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, RI. CN - Members of the ISUP Bladder Tumor Consensus Panel LA - eng PT - Consensus Statement PT - Journal Article DEP - 20230529 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/diagnosis/pathology MH - *Urologic Neoplasms/pathology MH - Prognosis MH - *Urology MH - Neoplasm Grading COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2023/05/29 13:05 MHDA- 2023/12/21 06:43 CRDT- 2023/05/29 08:23 PHST- 2023/12/21 06:43 [medline] PHST- 2023/05/29 13:05 [pubmed] PHST- 2023/05/29 08:23 [entrez] AID - 00000478-202401000-00002 [pii] AID - 10.1097/PAS.0000000000002059 [doi] PST - ppublish SO - Am J Surg Pathol. 2024 Jan 1;48(1):e1-e10. doi: 10.1097/PAS.0000000000002059. Epub 2023 May 29. PMID- 37246134 OWN - NLM STAT- MEDLINE DCOM- 20230912 LR - 20230912 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 9 DP - 2023 Sep TI - Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database. PG - 390.e19-390.e26 LID - S1078-1439(23)00105-9 [pii] LID - 10.1016/j.urolonc.2023.03.014 [doi] AB - INTRODUCTION: Despite significant morbidity, radical cystectomy (RC) is standard of care for muscle invasive bladder cancer, certain high-risk nonmuscle invasive tumors and after failure of intravesical or trimodal therapy. Modern efforts have hastened the recovery after this surgery without impact on overall complication rates. Our primary aim was to examine changes in complication rates of RC over time. METHODS: The National Surgical Quality Improvement Program database included 11,351 RC from 2006 to 2018 for nondisseminated bladder cancer. Baseline characteristics and complication rates were studied across time periods: 2006 to 2011, 2012 to 2014, and 2015 to 2018. Thirty-day complications, readmissions, and mortality were identified. RESULTS: Overall complication rates decreased over time (56.5%, 57.4%, 50.6%, P < 0.01). Infectious complications were stable, including UTIs (10.1%, 8.8%, 8.3% respectively, P = 0.11) and sepsis (10.4%, 8.8%, 8.7% respectively, P = 0.20). On multivariable analysis, ASA>/=3 (OR 1.399, 95% CI 1.279-1.530) was associated with increased complications, while procedures in 2015 to 2018 (OR 0.825, 95% CI 0.722-0.942), laparoscopic/robotic approach (OR 0.555, 95%CI 0.494-0.622), and ileal conduit (OR 0.796, 95% CI 0.719-0.882) were associated with decreased complication rates. Other outcomes of interest included mean length of stay (LOS), which decreased over time (10.5, 9.8, 8.6 days, respectively, P < 0.01) and readmission (20.0%, 21.3%, 21.0%, respectively, P = 0.84) and mortality rates were stable (2.7%, 1.7%, 2.0%, respectively, P = 0.13). CONCLUSION: Decreased early complications and LOS after RC over time may reflect beneficial effects of recent advances in bladder cancer treatment such as enhanced recovery after surgery protocols and minimally invasive techniques. Further opportunities to improve long term outcomes, readmissions and infection rates are needed. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Chua, Kevin J AU - Chua KJ AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Patel, Hiren V AU - Patel HV AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Srivastava, Arnav AU - Srivastava A AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Doppalapudi, Sai Krishnaraya AU - Doppalapudi SK AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Lichtbroun, Benjamin AU - Lichtbroun B AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Patel, Nikhil AU - Patel N AD - Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Elsamra, Sammy E AU - Elsamra SE AD - Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Singer, Eric A AU - Singer EA AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Division of Urologic Oncology, The Ohio State Comprehensive Cancer Center, Columbus, OH. FAU - Jang, Thomas L AU - Jang TL AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. FAU - Ghodoussipour, Saum B AU - Ghodoussipour SB AD - Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Electronic address: sg1621@cinj.rutgers.edu. LA - eng GR - P30 CA072720/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230526 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Cystectomy/adverse effects/methods MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - *Urinary Diversion/adverse effects MH - Postoperative Complications/epidemiology/etiology/surgery MH - Length of Stay MH - Retrospective Studies OTO - NOTNLM OT - Bladder cancer OT - Cystectomy COIS- Declaration of Competing Interest The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors. EDAT- 2023/05/29 00:42 MHDA- 2023/09/12 06:41 CRDT- 2023/05/28 22:01 PHST- 2023/01/22 00:00 [received] PHST- 2023/03/19 00:00 [revised] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/09/12 06:41 [medline] PHST- 2023/05/29 00:42 [pubmed] PHST- 2023/05/28 22:01 [entrez] AID - S1078-1439(23)00105-9 [pii] AID - 10.1016/j.urolonc.2023.03.014 [doi] PST - ppublish SO - Urol Oncol. 2023 Sep;41(9):390.e19-390.e26. doi: 10.1016/j.urolonc.2023.03.014. Epub 2023 May 26. PMID- 37238229 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230530 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 10 DP - 2023 May 15 TI - Differential Expression of LncRNA in Bladder Cancer Development. LID - 10.3390/diagnostics13101745 [doi] LID - 1745 AB - Bladder cancer (BC) is the tenth most common cancer, with urothelial carcinoma representing about 90% of all BC, including neoplasms and carcinomas of different grades of malignancy. Urinary cytology has a significant role in BC screening and surveillance, although it has a low detection rate and high dependence on the pathologist's experience. The currently available biomarkers are not implemented into routine clinical practice due to high costs or low sensitivity. In recent years, the role of lncRNAs in BC has emerged, even though it is still poorly explored. We have previously shown that the lncRNAs Metallophosphoesterase Domain-Containing 2 Antisense RNA 1 (MPPED2-AS1), Rhabdomyosarcoma-2 Associated Transcript (RMST), Kelch-like protein 14 antisense (Klhl14AS) and Prader Willi/Angelman region RNA 5 (PAR5) are involved in the progression of different types of cancers. Here, we investigated the expression of these molecules in BC, first by interrogating the GEPIA database and observing a different distribution of expression levels between normal and cancer specimens. We then measured them in a cohort of neoplastic bladder lesions, either benign or malignant, from patients with suspicion of BC undergoing transurethral resection of bladder tumor (TURBT). The total RNA from biopsies was analyzed using qRT-PCR for the expression of the four lncRNA genes, showing differential expression of the investigated lncRNAs between normal tissue, benign lesions and cancers. In conclusion, the data reported here highlight the involvement of novel lncRNAs in BC development, whose altered expression could potentially affect the regulatory circuits in which these molecules are involved. Our study paves the way for testing lncRNA genes as markers for BC diagnosis and/or follow-up. FAU - Spirito, Lorenzo AU - Spirito L AD - Urology Unit, Department of Woman Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138 Naples, Italy. FAU - Maturi, Rufina AU - Maturi R AUID- ORCID: 0009-0006-0493-3651 AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. FAU - Credendino, Sara Carmela AU - Credendino SC AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. FAU - Manfredi, Celeste AU - Manfredi C AUID- ORCID: 0000-0002-9706-8516 AD - Urology Unit, Department of Woman Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138 Naples, Italy. FAU - Arcaniolo, Davide AU - Arcaniolo D AUID- ORCID: 0000-0002-5282-2335 AD - Urology Unit, Department of Woman Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138 Naples, Italy. FAU - De Martino, Marco AU - De Martino M AD - Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council (CNR), Via Pansini, 5, 80131 Naples, Italy. AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138 Napoli, Italy. FAU - Esposito, Francesco AU - Esposito F AD - Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council (CNR), Via Pansini, 5, 80131 Naples, Italy. FAU - Napolitano, Luigi AU - Napolitano L AUID- ORCID: 0000-0003-2036-0356 AD - Urology Unit, Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. FAU - Di Bello, Francesco AU - Di Bello F AUID- ORCID: 0000-0002-8585-3701 AD - Urology Unit, Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. FAU - Fusco, Alfredo AU - Fusco A AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. AD - Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council (CNR), Via Pansini, 5, 80131 Naples, Italy. FAU - Pallante, Pierlorenzo AU - Pallante P AUID- ORCID: 0000-0001-7319-684X AD - Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council (CNR), Via Pansini, 5, 80131 Naples, Italy. FAU - De Sio, Marco AU - De Sio M AD - Urology Unit, Department of Woman Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Via De Crecchio 7, 80138 Naples, Italy. FAU - De Vita, Gabriella AU - De Vita G AUID- ORCID: 0000-0002-7302-1174 AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. LA - eng PT - Journal Article DEP - 20230515 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10217243 OTO - NOTNLM OT - bladder cancer OT - gene expression OT - lncRNAs COIS- The authors declare no conflict of interest. EDAT- 2023/05/27 09:42 MHDA- 2023/05/27 09:43 PMCR- 2023/05/15 CRDT- 2023/05/27 01:04 PHST- 2023/04/19 00:00 [received] PHST- 2023/05/05 00:00 [revised] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/05/27 09:43 [medline] PHST- 2023/05/27 09:42 [pubmed] PHST- 2023/05/27 01:04 [entrez] PHST- 2023/05/15 00:00 [pmc-release] AID - diagnostics13101745 [pii] AID - diagnostics-13-01745 [pii] AID - 10.3390/diagnostics13101745 [doi] PST - epublish SO - Diagnostics (Basel). 2023 May 15;13(10):1745. doi: 10.3390/diagnostics13101745. PMID- 37228940 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230530 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 85 IP - 5 DP - 2023 May TI - Plasmacytoid bladder cancer: a rare case report. PG - 1885-1887 LID - 10.1097/MS9.0000000000000374 [doi] AB - Plasmacytoid carcinoma of the bladder is a rare histological variant of urothelial carcinoma associated with late presentation. This pattern of disease may portend an extremely poor prognosis and significant challenges for treatment with curative intent. CASE PRESENTATION: The authors report a case of a patient with locally advanced plasmacytoid urothelial carcinoma (PUC) of the bladder. A 71-year-old man with a history of chronic obstructive pulmonary disease presented with gross hematuria. The rectal examination revealed a fixed bladder base. A computed tomography scan showed a pedunculated lesion arising from the anterior and left lateral bladder wall and extended to the perivesical fat. The patient underwent transurethral resection of the tumor. The histologic examination revealed the presence of muscle-invasive PUC of the bladder. The decision of the multidisciplinary consultation meeting was to do palliative chemotherapy. Thus, the patient could not receive systemic chemotherapy and died 6 weeks after transurethral resection of the bladder tumor. CLINICAL DISCUSSION: A plasmacytoid variant of urothelial carcinoma is a rare subtype of urothelial carcinoma that has a poor prognosis with a high mortality rate. The disease is usually diagnosed at an advanced stage. Given the rarity of plasmacytoid bladder cancer, treatment guidelines are not clear; therefore, more aggressive treatment may be required. CONCLUSION: PUC of the bladder is characterized by high aggressiveness, an advanced stage at the time of diagnosis, and a poor prognosis. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Benabdallah, Wajdi AU - Benabdallah W AD - Urology Department. FAU - Ben Othmane, Mouna AU - Ben Othmane M AD - Urology Department. FAU - Ouahchi, Ines AU - Ouahchi I AUID- ORCID: 0000-0003-4116-1647 AD - Department of Cytogenetic and Reproductive Biology, Farhat Hached University Teaching Hospital, Sousse, Tunisia. FAU - Mestiri, Sarra AU - Mestiri S AD - Pathology Department, Sahloul Hospital. FAU - Belkacem, Oussama AU - Belkacem O AUID- ORCID: 0000-0003-0936-6044 AD - Pathology Department, Sahloul Hospital. FAU - Bouassida, Khaireddine AU - Bouassida K AD - Urology Department. FAU - Hmida, Wissem AU - Hmida W AD - Urology Department. FAU - Jaidane, Mehdi AU - Jaidane M AUID- ORCID: 0000-0001-7270-5753 AD - Urology Department. LA - eng PT - Journal Article DEP - 20230411 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC10205280 OTO - NOTNLM OT - bladder cancer OT - case report OT - plasmacytoid variant OT - urothelial carcinoma COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/05/25 19:12 MHDA- 2023/05/25 19:13 PMCR- 2023/04/11 CRDT- 2023/05/25 14:17 PHST- 2023/02/02 00:00 [received] PHST- 2023/02/25 00:00 [accepted] PHST- 2023/05/25 19:13 [medline] PHST- 2023/05/25 19:12 [pubmed] PHST- 2023/05/25 14:17 [entrez] PHST- 2023/04/11 00:00 [pmc-release] AID - 10.1097/MS9.0000000000000374 [doi] PST - epublish SO - Ann Med Surg (Lond). 2023 Apr 11;85(5):1885-1887. doi: 10.1097/MS9.0000000000000374. eCollection 2023 May. PMID- 37224225 OWN - NLM STAT- MEDLINE DCOM- 20230526 LR - 20240926 IS - 1946-6242 (Electronic) IS - 1946-6234 (Print) IS - 1946-6234 (Linking) VI - 15 IP - 697 DP - 2023 May 24 TI - Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin. PG - eabn4118 LID - 10.1126/scitranslmed.abn4118 [doi] AB - The recommended treatment for patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guerin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. If progression to advanced disease occurs, then patients must undergo a radical cystectomy with risks of substantial morbidity and poor clinical outcome. Identifying tumors unlikely to respond to BCG can translate into alternative treatments, such as early radical cystectomy, targeted therapies, or immunotherapies. Here, we conducted molecular profiling of 132 patients with BCG-naive HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1, 2 and BRS3). Patients with BRS3 tumors had a reduced recurrence-free and progression-free survival compared with BRS1/2. BRS3 tumors expressed high epithelial-to-mesenchymal transition and basal markers and had an immunosuppressive profile, which was confirmed with spatial proteomics. Tumors that recurred after BCG were enriched for BRS3. BRS stratification was validated in a second cohort of 151 BCG-naive patients with HR-NMIBC, and the molecular subtypes outperformed guideline-recommended risk stratification based on clinicopathological variables. For clinical application, we confirmed that a commercially approved assay was able to predict BRS3 tumors with an area under the curve of 0.87. These BCG response subtypes will allow for improved identification of patients with HR-NMIBC at the highest risk of progression and have the potential to be used to select more appropriate treatments for patients unlikely to respond to BCG. FAU - de Jong, Florus C AU - de Jong FC AUID- ORCID: 0000-0001-6853-5982 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. FAU - Laajala, Teemu D AU - Laajala TD AUID- ORCID: 0000-0002-7016-7354 AD - Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. AD - Department of Mathematics and Statistics, University of Turku, FI-20014 Turku, Finland. FAU - Hoedemaeker, Robert F AU - Hoedemaeker RF AD - Pathan, Pathological Laboratory, 3045 PM Rotterdam, Netherlands. FAU - Jordan, Kimberley R AU - Jordan KR AUID- ORCID: 0000-0001-8380-7157 AD - Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. FAU - van der Made, Angelique C J AU - van der Made ACJ AD - Department of Pathology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. FAU - Boeve, Egbert R AU - Boeve ER AD - Department of Urology, Franciscus Gasthuis & Vlietland, 3045 PM Rotterdam, Netherlands. FAU - van der Schoot, Deric K E AU - van der Schoot DKE AUID- ORCID: 0000-0001-6113-5150 AD - Department of Urology, Amphia, 4818 CK, Breda, Netherlands. FAU - Nieuwkamer, Bart AU - Nieuwkamer B AUID- ORCID: 0000-0003-3417-8344 AD - Department of Urology, Reinier de Graaf Gasthuis, 2625 AD Delft, Netherlands. FAU - Janssen, Emiel A M AU - Janssen EAM AUID- ORCID: 0000-0002-7760-5396 AD - Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. FAU - Mahmoudi, Tokameh AU - Mahmoudi T AUID- ORCID: 0000-0002-2060-9353 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. AD - Department of Pathology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. FAU - Boormans, Joost L AU - Boormans JL AUID- ORCID: 0000-0002-5127-0436 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. FAU - Theodorescu, Dan AU - Theodorescu D AUID- ORCID: 0000-0002-8708-8206 AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, CA 90048, USA. FAU - Costello, James C AU - Costello JC AUID- ORCID: 0000-0003-3158-9682 AD - Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AUID- ORCID: 0000-0003-0991-0812 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, Netherlands. LA - eng GR - P30 CA046934/CA/NCI NIH HHS/United States GR - R01 CA075115/CA/NCI NIH HHS/United States GR - R29 CA075115/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230524 PL - United States TA - Sci Transl Med JT - Science translational medicine JID - 101505086 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Eur Urol. 2023 Nov;84(5):447-448. doi: 10.1016/j.eururo.2023.06.017. PMID: 37400353 MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy MH - Adjuvants, Immunologic/pharmacology/therapeutic use MH - Biological Assay PMC - PMC10572776 MID - NIHMS1932685 COIS- Competing interests: JLB is paid consultant for BMS, Astellas, Janssen, Astra Zeneca, MSD, Merck and Pfizer; all paid to Erasmus MC and not relevant to this work. JCC is a co-founder of PrecisionProfile and OncoRx Insights. TZ is on the Merck Scientific Committee and Janssen Scientific committee. The other authors declare no competing interests. EDAT- 2023/05/24 19:13 MHDA- 2023/05/26 06:42 PMCR- 2023/11/24 CRDT- 2023/05/24 14:02 PHST- 2023/05/26 06:42 [medline] PHST- 2023/05/24 19:13 [pubmed] PHST- 2023/05/24 14:02 [entrez] PHST- 2023/11/24 00:00 [pmc-release] AID - 10.1126/scitranslmed.abn4118 [doi] PST - ppublish SO - Sci Transl Med. 2023 May 24;15(697):eabn4118. doi: 10.1126/scitranslmed.abn4118. Epub 2023 May 24. PMID- 37210247 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230802 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 8 DP - 2023 Aug TI - Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy. PG - 356.e11-356.e18 LID - S1078-1439(23)00137-0 [pii] LID - 10.1016/j.urolonc.2023.04.017 [doi] AB - PURPOSE: While radical cystectomy (RC) is the standard of care for muscle invasive bladder cancer (MIBC), partial cystectomy (PC) is an effective alternative in select patients. We sought to examine differences in survival for RC and PC in a hospital-based registry. MATERIAL AND METHODS: We identified patients diagnosed with cT2-4 bladder cancer who underwent RC or PC from 2003 to 2015 in the National Cancer Database (NCDB). Using inverse probability treatment weighting (IPTW) to control for known confounders, we compared the primary outcome of overall survival (OS) in patients who underwent RC vs. PC. Kaplan-Meier survival analysis, univariable and multivariable Cox proportional hazards modeling were used. We performed a secondary survival analysis for a subcohort of patients with cT2, cN0, tumor size 2 complications occurred. The duration of catheter indwelling was 3.6 +/- 1.8 days. The hospital stay was 6.0 +/- 2.3 days. The median follow-up was 80 months. A total of 17 patients had a recurrence during follow-up, and the recurrence-free survival (RFS) rate was 77.3%. In the multivariable analysis, the tumor risk group were independently associated with the recurrence of NMIBC (p = 0.026). CONCLUSIONS: After TURBT with a 2-micrometer continuous-wave laser, RFS was 77.3% at the median follow-up of 80 months. All complications were mild. Only tumor risk group was independently associated with the recurrence of NMIBC. CI - (c) 2023 Lu, Jiang, Yin, Guo, Zhu, Ma, Zhang, Yu, Xiao and Yang. FAU - Lu, Yongliang AU - Lu Y AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Jiang, Sinan AU - Jiang S AD - Department of Urology, The Fourth Medical Centre of PLA General Hospital, Beijing, China. FAU - Yin, Xiaotao AU - Yin X AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Guo, Jiaxiang AU - Guo J AD - Department of Urology, The Fourth Medical Centre of PLA General Hospital, Beijing, China. FAU - Zhu, Xiaoying AU - Zhu X AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Ma, Han AU - Ma H AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Zhang, Guohui AU - Zhang G AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Yu, Hualiang AU - Yu H AD - Department of Urology, The Fourth Medical Centre of PLA General Hospital, Beijing, China. FAU - Xiao, Yi AU - Xiao Y AD - Senior Department of Urology, The Third Medical Centre of PLA General Hospital, Beijing, China. FAU - Yang, Yong AU - Yang Y AD - Department of Urology, The Fourth Medical Centre of PLA General Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20230417 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC10149721 OTO - NOTNLM OT - 2um laser OT - bladder cancer OT - cystectomy OT - long-term effect OT - non-muscle invasive COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/04 06:41 MHDA- 2023/05/04 06:42 PMCR- 2023/04/17 CRDT- 2023/05/04 02:15 PHST- 2022/12/07 00:00 [received] PHST- 2023/02/27 00:00 [accepted] PHST- 2023/05/04 06:42 [medline] PHST- 2023/05/04 06:41 [pubmed] PHST- 2023/05/04 02:15 [entrez] PHST- 2023/04/17 00:00 [pmc-release] AID - 10.3389/fsurg.2023.1117997 [doi] PST - epublish SO - Front Surg. 2023 Apr 17;10:1117997. doi: 10.3389/fsurg.2023.1117997. eCollection 2023. PMID- 37138354 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230506 IS - 2050-7771 (Print) IS - 2050-7771 (Electronic) IS - 2050-7771 (Linking) VI - 11 IP - 1 DP - 2023 May 3 TI - Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression. PG - 47 LID - 10.1186/s40364-023-00488-3 [doi] LID - 47 AB - BACKGROUND: Urinary bladder cancer (UBC) is a common malignancy of the urinary tract; however, the mechanism underlying its high recurrence and responses to immunotherapy remains unclear, making clinical outcome predictions difficult. Epigenetic alterations, especially DNA methylation, play important roles in bladder cancer development and are increasingly being investigated as biomarkers for diagnostic or prognostic predictions. However, little is known about hydroxymethylation since previous studies based on bisulfite-sequencing approaches could not differentiate between 5mC and 5hmC signals, resulting in entangled methylation results. METHODS: Tissue samples of bladder cancer patients who underwent laparoscopic radical cystectomy (LRC), partial cystectomy (PC), or transurethral resection of bladder tumor (TURBT) were collected. We utilized a multi-omics approach to analyze both primary and recurrent bladder cancer samples. By integrating various techniques including RNA sequencing, oxidative reduced-representation bisulfite sequencing (oxRRBS), reduced-representation bisulfite sequencing (RRBS), and whole exome sequencing, a comprehensive analysis of the genome, transcriptome, methylome, and hydroxymethylome landscape of these cancers was possible. RESULTS: By whole exome sequencing, we identified driver mutations involved in the development of UBC, including those in FGFR3, KDMTA, and KDMT2C. However, few of these driver mutations were associated with the down-regulation of programmed death-ligand 1 (PD-L1) or recurrence in UBC. By integrating RRBS and oxRRBS data, we identified fatty acid oxidation-related genes significantly enriched in 5hmC-associated transcription alterations in recurrent bladder cancers. We also observed a series of 5mC hypo differentially methylated regions (DMRs) in the gene body of NFATC1, which is highly involved in T-cell immune responses in bladder cancer samples with high expression of PD-L1. Since 5mC and 5hmC alternations are globally anti-correlated, RRBS-seq-based markers that combine the 5mC and 5hmC signals, attenuate cancer-related signals, and therefore, are not optimal as clinical biomarkers. CONCLUSIONS: By multi-omics profiling of UBC samples, we showed that epigenetic alternations are more involved compared to genetic mutations in the PD-L1 regulation and recurrence of UBC. As proof of principle, we demonstrated that the combined measurement of 5mC and 5hmC levels by the bisulfite-based method compromises the prediction accuracy of epigenetic biomarkers. CI - (c) 2023. The Author(s). FAU - Shi, Zhen-Duo AU - Shi ZD AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. AD - School of Life Sciences, Jiangsu Normal University, Jiangsu, China. AD - Department of Urology, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Xiangfang District, Harbin City, Heilongjiang Province, China. FAU - Han, Xiao-Xiao AU - Han XX AD - Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China. FAU - Song, Zi-Jian AU - Song ZJ AD - Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Dong, Yang AU - Dong Y AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Pang, Kun AU - Pang K AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Wang, Xin-Lei AU - Wang XL AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Liu, Xin-Yu AU - Liu XY AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Lu, Hao AU - Lu H AD - Department of Urology, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Xiangfang District, Harbin City, Heilongjiang Province, China. FAU - Xu, Guang-Zhi AU - Xu GZ AD - Department of Urology, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Xiangfang District, Harbin City, Heilongjiang Province, China. FAU - Hao, Lin AU - Hao L AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Dong, Bing-Zheng AU - Dong BZ AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Liang, Qing AU - Liang Q AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. FAU - Wu, Xiao-Ke AU - Wu XK AD - Department of Reproductive Medicine, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Xiangfang DistrictHeilongjiang Province, Harbin City, China. xiaokewu2002@vip.sina.com. AD - Department of Gynaecology and Obstetrics, Heilongjiang Provincial Clinical Research Centre for Ovary Diseases, First Affiliated Hospital, Heilongjiang University of Chineses Medicine, 26 Heping Road, Xiangfang District, Harbin, Heilongjiang, China. xiaokewu2002@vip.sina.com. FAU - Han, Cong-Hui AU - Han CH AD - Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. hanchdoctor@st.btbu.edu.cn. AD - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. hanchdoctor@st.btbu.edu.cn. AD - School of Life Sciences, Jiangsu Normal University, Jiangsu, China. hanchdoctor@st.btbu.edu.cn. AD - Department of Urology, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Xiangfang District, Harbin City, Heilongjiang Province, China. hanchdoctor@st.btbu.edu.cn. LA - eng GR - 12271467，82204866, 82004110/National Natural Science Foundation of China/ PT - Journal Article DEP - 20230503 PL - England TA - Biomark Res JT - Biomarker research JID - 101607860 PMC - PMC10155358 COIS- The authors declare no competing interests. EDAT- 2023/05/04 00:42 MHDA- 2023/05/04 00:43 PMCR- 2023/05/03 CRDT- 2023/05/03 23:41 PHST- 2023/01/08 00:00 [received] PHST- 2023/04/18 00:00 [accepted] PHST- 2023/05/04 00:43 [medline] PHST- 2023/05/04 00:42 [pubmed] PHST- 2023/05/03 23:41 [entrez] PHST- 2023/05/03 00:00 [pmc-release] AID - 10.1186/s40364-023-00488-3 [pii] AID - 488 [pii] AID - 10.1186/s40364-023-00488-3 [doi] PST - epublish SO - Biomark Res. 2023 May 3;11(1):47. doi: 10.1186/s40364-023-00488-3. PMID- 37137745 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20250626 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 6 DP - 2023 Jun TI - The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis. PG - 261-273 LID - S1078-1439(23)00118-7 [pii] LID - 10.1016/j.urolonc.2023.04.003 [doi] AB - This study aimed to assess both efficacy and safety outcomes of lowering the dose of BCG compared to intravesical chemotherapies in non-muscle-invasive bladder cancer (NMIBC) patients using a systematic review, meta-analysis, and network meta-analysis approach. A comprehensive literature search was performed through Pubmed(R), Web of Science, and Scopus(R) in December 2022 to identify randomized controlled trials comparing the oncologic and/or safety outcomes of reduced dose intravesical BCG and/or intravesical chemotherapies according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement. The outcomes of interest were risk of recurrence, progression, treatment-related adverse events, and discontinuation. Overall, 24 studies were eligible for quantitative synthesis. Among 22 studies that adopted induction followed by maintenance intravesical therapy, with reference to the lower-dose BCG, epirubicin was associated with a significantly higher risk of recurrence (Odds ratio [OR]: 2.82, 95% CI: 1.54-5.15), but not other intravesical chemotherapies. There were no significant differences in risk of progression among the intravesical therapies. On the other hand, standard-dose BCG was associated with a higher risk of any AEs (OR: 1.91, 95% CI: 1.07-3.41) but other intravesical chemotherapies had a comparable risk of AEs compared to lower-dose BCG. The discontinuation rate did not significantly differ between lower-dose and standard-dose BCG (OR: 1.40, 95% CI: 0.81-2.43) as well as other intravesical. According to the surface under the cumulative ranking curve, gemcitabine, and standard-dose BCG were preferable to lower-dose BCG in terms of recurrence risk; gemcitabine was also preferable to lower-dose BCG in terms of risk of AEs. In patients with NMIBC, lowering the dose of BCG decreases the risks of AEs and discontinuation rate compared to standard-dose BCG, but there is no difference in these endpoints compared to other intravesical chemotherapies. Standard-dose of BCG is preferred for all intermediate and high-risk NMIBC patients based on oncologic efficacy; however, lower-dose BCG and intravesical chemotherapies, especially gemcitabine, could be considered a reasonable alternative to BCG in selected patients who suffer from significant AEs or in case standard-dose BCG is not available. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Bekku, Kensuke AU - Bekku K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - von Deimling, Markus AU - von Deimling M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Chlosta, Marcin AU - Chlosta M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jagiellonian University Medical College, Cracow, Poland. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic. FAU - Araki, Motoo AU - Araki M AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20230502 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (Gemcitabine) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy MH - Gemcitabine MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy OTO - NOTNLM OT - BCG OT - Instillation OT - Intravesical OT - Low dose OT - Non-muscle-invasive bladder cancer COIS- Declaration of Competing Interest None. EDAT- 2023/05/04 00:42 MHDA- 2023/06/09 06:41 CRDT- 2023/05/03 21:55 PHST- 2023/02/09 00:00 [received] PHST- 2023/04/01 00:00 [accepted] PHST- 2023/06/09 06:41 [medline] PHST- 2023/05/04 00:42 [pubmed] PHST- 2023/05/03 21:55 [entrez] AID - S1078-1439(23)00118-7 [pii] AID - 10.1016/j.urolonc.2023.04.003 [doi] PST - ppublish SO - Urol Oncol. 2023 Jun;41(6):261-273. doi: 10.1016/j.urolonc.2023.04.003. Epub 2023 May 2. PMID- 37134243 OWN - NLM STAT- MEDLINE DCOM- 20240131 LR - 20250908 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 148 IP - 2 DP - 2024 Feb 1 TI - Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features. PG - 223-229 LID - 10.5858/arpa.2022-0268-OA [doi] AB - CONTEXT.-: Noninvasive papillary urothelial carcinomas (PUCs) comprise most urinary bladder tumors. Distinction between low-grade (LG-PUC) and high-grade (HG-PUC) PUCs is pivotal for determining prognosis and subsequent treatment. OBJECTIVE.-: To investigate the histologic characteristics of tumors with borderline features between LG-PUC and HG-PUC, focusing on the risk of recurrence and progression. DESIGN.-: We reviewed the clinicopathologic parameters of noninvasive PUC. Tumors with borderline features were subcategorized as follows: tumors that look like LG-PUC but have occasional pleomorphic nuclei (1-BORD-NUP) or elevated mitotic count (2-BORD-MIT), and tumors with side-by-side distinct LG-PUC and less than 50% HG-PUC (3-BORD-MIXED). Recurrence-free, total progression-free, and specific invasion-free survival curves were derived from the Kaplan-Meier method, and Cox regression analysis was performed. RESULTS.-: A total of 138 patients with noninvasive PUC were included, with the following distribution: LG-PUC (n = 52; 38%), HG-PUC (n = 34; 25%), BORD-NUP (n = 21; 15%), BORD-MIT (n = 14; 10%), and BORD-MIXED (n = 17; 12%). Median (interquartile range) follow-up was 44.2 months (29.9-73.1 months). Invasion-free survival was different between the 5 groups (P = .004), and pairwise comparison showed that HG-PUC had a worse prognosis compared with LG-PUC (P /= pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in >/= pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients. CONCLUSION: Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC. FAU - Song, Sang Hun AU - Song SH AD - Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Lee, Jaewon AU - Lee J AD - Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Ko, Young Hwii AU - Ko YH AD - Department of Urology, Yeungnam University Hospital, Daegu, Korea. FAU - Kim, Jong Wook AU - Kim JW AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Jung, Seung Il AU - Jung SI AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Korea University School of Medicine, Seoul, Korea. FAU - Park, Jinsung AU - Park J AD - Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Urologic, National Cancer Center, Goyang, Korea. FAU - Kim, Hyung Joon AU - Kim HJ AD - Department of Urology, Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Tae-Hwan AU - Kim TH AD - Department of Urology, Kyungpook National University College of Medicine, Daegu, Korea. FAU - Choi, Se Young AU - Choi SY AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Nam, Jong Kil AU - Nam JK AD - Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea. FAU - Ku, Ja Yoon AU - Ku JY AD - Department of Urology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea. FAU - Joo, Kwan Joong AU - Joo KJ AD - Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jang, Won Sik AU - Jang WS AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Yoon, Young Eun AU - Yoon YE AD - Department of Urology, Hanyang University Hospital, Seoul, Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea. FAU - Hong, Sung-Hoo AU - Hong SH AD - Department of Urology, Seoul St. Mary's Hospital, Seoul, Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. LA - eng GR - 02-2021-0031/Seoul National University Bundang Hospital/ GR - 2020R1A2C1100011/National Research Foundation of Korea/ PT - Journal Article PT - Multicenter Study DEP - 20230417 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - Urachal cancer SB - IM MH - Humans MH - Middle Aged MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/surgery MH - Prognosis MH - Retrospective Studies PMC - PMC10582549 OTO - NOTNLM OT - Cystectomy OT - Neoplasm staging OT - Survival analysis OT - TNM classification OT - Urachal cancer OT - Urinary bladder neoplasms COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2023/04/21 00:41 MHDA- 2023/10/23 12:45 PMCR- 2023/10/01 CRDT- 2023/04/20 20:46 PHST- 2023/02/24 00:00 [received] PHST- 2023/04/15 00:00 [accepted] PHST- 2023/10/23 12:45 [medline] PHST- 2023/04/21 00:41 [pubmed] PHST- 2023/04/20 20:46 [entrez] PHST- 2023/10/01 00:00 [pmc-release] AID - crt.2023.417 [pii] AID - crt-2023-417 [pii] AID - 10.4143/crt.2023.417 [doi] PST - ppublish SO - Cancer Res Treat. 2023 Oct;55(4):1337-1345. doi: 10.4143/crt.2023.417. Epub 2023 Apr 17. PMID- 37080348 OWN - NLM STAT- MEDLINE DCOM- 20230703 LR - 20230703 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 42 DP - 2023 Jun TI - Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival. PG - 103574 LID - S1572-1000(23)00301-0 [pii] LID - 10.1016/j.pdpdt.2023.103574 [doi] AB - BACKGROUND: Intravesical Bacille Calmette-Guerin (BCG) therapy has been reported to be effective in preventing recurrence and progression in non-muscle invasive bladder cancer. Furthermore, photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) improves the accuracy of cancer diagnosis and contributes to lower recurrence rates. The purpose of this study is to investigate whether more tumor resection with PDD-TURBT rather than conventional TURBT before BCG therapy outweighs the benefit of BCG therapy alone. METHODS: Patients who underwent intravesical BCG therapy following TURBT in our institution from 2010 to 2021 were included. They were divided into the following two groups: those who received PDD-TURBT before BCG treatment (PDD + BCG group) and those who received conventional TURBT before BCG treatment (WL + BCG group). The 2-year recurrence-free survival (RFS) and progression-free survival (PFS) of the two groups were retrospectively analyzed and compared. RESULTS: The 2-year RFS was significantly improved in the PDD + BCG group (hazard ratio [HR]: 2.41, 95% confidence interval [CI]: 1.26-4.60; p = 0.025). No significant difference in 2-year PFS was noted between the two groups. Analysis of prognostic factors for RFS showed that PDD-TURBT w We think that this text does not adequately express the meaning that we want to deliver to the reader.as a significant prognostic factor in univariate analysis (HR: 0.41, 95% CI: 0.18-0.92; p = 0.03). CONCLUSION: BCG treatment following PDD-TURBT significantly improved RFS more than BCG therapy following WL-TURBT. More accurate tumor localization and more efficient tumor resection by PDD-TURBT may have a positive impact on subsequent BCG treatments even if the treatment is administered postoperatively. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Nakagawa, Ryunosuke AU - Nakagawa R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Nohara, Takahiro AU - Nohara T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Electronic address: t_nohara704@yahoo.co.jp. FAU - Naito, Renato AU - Naito R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Kadomoto, Suguru AU - Kadomoto S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Iwamoto, Hiroaki AU - Iwamoto H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Yaegashi, Hiroshi AU - Yaegashi H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Kawaguchi, Shohei AU - Kawaguchi S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Shigehara, Kazuyoshi AU - Shigehara K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Izumi, Kouji AU - Izumi K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Kadono, Yoshifumi AU - Kadono Y AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. LA - eng PT - Journal Article DEP - 20230418 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 0 (BCG Vaccine) RN - 0 (Photosensitizing Agents) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Transurethral Resection of Bladder MH - Photosensitizing Agents/therapeutic use MH - *Photochemotherapy/methods MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Neoplasm Recurrence, Local/prevention & control/pathology MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - 5-ALA OT - Bacille Calmette-Guerin therapy OT - Carcinoma in situ OT - Non-muscle invasive bladder cancer OT - Photodiagnosis OT - Photodynamic diagnosis-assisted transurethral resection of bladder tumor OT - TURP COIS- Declaration of Competing Interest All authors declare that there are no potential conflicts of interest relevant to this article. EDAT- 2023/04/21 00:41 MHDA- 2023/07/03 06:41 CRDT- 2023/04/20 19:25 PHST- 2023/02/06 00:00 [received] PHST- 2023/04/15 00:00 [revised] PHST- 2023/04/17 00:00 [accepted] PHST- 2023/07/03 06:41 [medline] PHST- 2023/04/21 00:41 [pubmed] PHST- 2023/04/20 19:25 [entrez] AID - S1572-1000(23)00301-0 [pii] AID - 10.1016/j.pdpdt.2023.103574 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2023 Jun;42:103574. doi: 10.1016/j.pdpdt.2023.103574. Epub 2023 Apr 18. PMID- 37067512 OWN - NLM STAT- MEDLINE DCOM- 20230602 LR - 20241113 IS - 1097-0339 (Electronic) IS - 1097-0339 (Linking) VI - 51 IP - 7 DP - 2023 Jul TI - Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCell technology: Potential as a simple cytology test. PG - E219-E223 LID - 10.1002/dc.25141 [doi] AB - Circulating tumor cells (CTC) are a recent technique which is a potentially important prognostic factor in many solid tumors. There are many techniques of detecting CTCs, but they usually implement costly techniques like EpCAM targeted detection, fluorescence-based diagnosis, or magnetic bead based positive or negative selection. The diagnostic utility of simple cytomorphological diagnosis after routine staining of CTCs have been rarely studied. We aimed to detect CTCs in 24 patients clinically suspected to have Urinary Bladder Cancer using a simple but efficient patented filtration technology (ScreenCell), followed by optical microscopic visualization after routine May-Grunwald-Giemsa (MGG) staining. The detected CTCs were then tested for association with the histologic type, lamina propria invasion, deep muscle invasion and the T-stage. Out of the 24 patients tested, one was found to have papilloma, nine had low grade urothelial carcinoma, 13 had high grade urothelial carcinoma and one had poorly differentiated adenocarcinoma. Of these, two LGUC, eight HGUC and one adenocarcinoma had detectable CTC. Presence of CTCs had a statistically significant association with Lamina propria invasion (P = .006) and T-stage (P = .02), and a trend toward significance for differentiating LGUC from HGUC (P = .10). These results suggest that cytomorphological detection of CTC is likely to be clinically useful in diagnosis and prognostication of urinary blader cancers. These findings need to be confirmed on studies with larger sample sizes. CI - (c) 2023 Wiley Periodicals LLC. FAU - Jahan, Meriyam AU - Jahan M AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, India. FAU - Mittal, Ankur AU - Mittal A AD - Department of Urology, All India Institute of Medical Sciences, Rishikesh, India. FAU - Rao, Shalinee AU - Rao S AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, India. FAU - Kishore, Sanjeev AU - Kishore S AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, India. FAU - Singh, Ashok AU - Singh A AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, India. FAU - Jadli, Mohit AU - Jadli M AD - Multidisciplinary Research Unit, All India Institute of Medical Sciences, Rishikesh, India. FAU - Paul, Pranoy AU - Paul P AUID- ORCID: 0000-0003-2625-0799 AD - Multidisciplinary Research Unit, All India Institute of Medical Sciences, Rishikesh, India. FAU - Iqbal, Asif AU - Iqbal A AD - Healthica Path Labs, New Delhi, India. FAU - Chowdhury, Nilotpal AU - Chowdhury N AUID- ORCID: 0000-0002-3178-2039 AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, India. AD - Multidisciplinary Research Unit, All India Institute of Medical Sciences, Rishikesh, India. LA - eng GR - AIIMS/IM/RC/196/2021/All India Institute of Medical Sciences, Rishikesh/ PT - Journal Article DEP - 20230417 PL - United States TA - Diagn Cytopathol JT - Diagnostic cytopathology JID - 8506895 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/pathology MH - *Carcinoma, Transitional Cell/pathology MH - *Neoplastic Cells, Circulating/pathology MH - *Adenocarcinoma MH - Cytodiagnosis OTO - NOTNLM OT - cancer OT - circulating tumor cells OT - cytology OT - non-muscle invasive bladder neoplasms OT - urinary bladder EDAT- 2023/04/18 06:00 MHDA- 2023/06/02 06:43 CRDT- 2023/04/17 10:43 PHST- 2023/04/02 00:00 [revised] PHST- 2023/01/18 00:00 [received] PHST- 2023/04/07 00:00 [accepted] PHST- 2023/06/02 06:43 [medline] PHST- 2023/04/18 06:00 [pubmed] PHST- 2023/04/17 10:43 [entrez] AID - 10.1002/dc.25141 [doi] PST - ppublish SO - Diagn Cytopathol. 2023 Jul;51(7):E219-E223. doi: 10.1002/dc.25141. Epub 2023 Apr 17. PMID- 37062074 OWN - NLM STAT- MEDLINE DCOM- 20230620 LR - 20230621 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 11 DP - 2023 Jun TI - Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors. PG - 12084-12094 LID - 10.1002/cam4.5895 [doi] AB - PURPOSE: To clarify the necessity and effect of a single intraoperative instillation of chemotherapy during radical cystectomy. METHODS: Patients who underwent radical cystectomy for bladder cancer between January 2013 and April 2019 were retrospectively evaluated and divided into a non-instillation group and an instillation group according to the intraoperative instillation of chemotherapy. Univariate and multivariate Cox regression was used to determine the clinical predictors of overall survival and disease-free survival. Kaplan-Meier analysis and log-rank tests were performed to analyze overall survival and disease-free survival. RESULTS: Of the 320 patients who were enrolled in the study, 113 underwent radical cystectomy with intraoperative instillation of chemotherapy. Univariate Cox analysis showed that intraoperative instillation was not a risk factor for overall survival or disease-free survival (HR: 1.04, 95% CI: 0.66-1.63, p = 0.864; HR: 1.11, 95% CI: 0.76-1.62, p = 0.602, respectively). As shown in the Kaplan-Meier analysis, no significant differences were noted in overall survival (p = 0.857) and disease-free survival (p = 0.600) between the two groups. A subgroup analysis demonstrated that intraoperative instillation was not associated with a statistically better overall survival and disease-free survival in the nonmuscle invasive (p = 0.852 and 0.836) and muscle-invasive (p = 0.929 and 0.805) patients. CONCLUSION: A single intraoperative instillation of chemotherapy during radical cystectomy was not related to better disease-free survival or overall survival. It is unnecessary to consider single instillation of chemotherapy as a regular procedure during radical cystectomy. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Yang, Jingtian AU - Yang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Li, Kaiwen AU - Li K AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Zhang, Yishan AU - Zhang Y AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Hu, Jintao AU - Hu J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Liu, Hao AU - Liu H AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Dong, Wen AU - Dong W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Huang, Hai AU - Huang H AUID- ORCID: 0000-0002-2013-073X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Lin, Tianxin AU - Lin T AUID- ORCID: 0000-0003-3180-8697 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - Huang, Jian AU - Huang J AUID- ORCID: 0000-0001-7315-4252 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. FAU - He, Wang AU - He W AUID- ORCID: 0000-0002-3765-3991 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. AD - Guangdong Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, P. R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230416 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Humans MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Urinary Bladder/surgery MH - Cystectomy/methods PMC - PMC10278504 OTO - NOTNLM OT - bladder cancer OT - disease-free survival OT - instillation of chemotherapy OT - intravesical chemotherapy OT - overall survival OT - radical cystectomy COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/04/17 06:00 MHDA- 2023/06/20 06:42 PMCR- 2023/04/16 CRDT- 2023/04/16 16:54 PHST- 2023/03/05 00:00 [revised] PHST- 2022/10/20 00:00 [received] PHST- 2023/03/22 00:00 [accepted] PHST- 2023/06/20 06:42 [medline] PHST- 2023/04/17 06:00 [pubmed] PHST- 2023/04/16 16:54 [entrez] PHST- 2023/04/16 00:00 [pmc-release] AID - CAM45895 [pii] AID - 10.1002/cam4.5895 [doi] PST - ppublish SO - Cancer Med. 2023 Jun;12(11):12084-12094. doi: 10.1002/cam4.5895. Epub 2023 Apr 16. PMID- 37061568 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Apr 15 TI - Telocytes and ezrin expression in normal-appearing tissues adjacent to urothelial bladder carcinoma as predictors of invasiveness and recurrence. PG - 6179 LID - 10.1038/s41598-023-33282-0 [doi] LID - 6179 AB - Recurrence and progression rates vary widely among different histological subtypes of bladder cancer (BC). Normal-appearing mucosa in non-muscle invasive bladder cancer and muscle-invasive bladder cancer in cystoscopy and histopathology is a factor in staging and treatment. Telocytes (TCs) are spindle-shaped cells that connect with other cell types allowing communication though cytoskeletal signaling. They are involved in tissue regeneration and pathogenesis of diseases and cancer. In this study, 12 normal-appearing tissues from urinary bladder with BC, both invasive and non-invasive were evaluated in patients who had either trans-urethral resection of bladder tumor or cystectomy. In each case, cystoscopy, intraoperative inspection, and histopathology all confirmed the absence of cancerous elements. Five patients with neurogenic bladder were used as a control group. Immunohistochemistry revealed that c-Kit + cells were intensively distributed in bladder layers from BC samples, while they were seldom detected in the control group. Ultrastructural examination of reprocessed tissue showed an intense distribution of TCs and telopodes in the submucosa and between smooth muscle cells in BC. Telopodes were numerous, arborizing, and intercommunicating. Whereas TCs and telopodes were scarce in the neurogenic bladder. Also, cancerous tissue had the highest expression level of ezrin protein, and this level gradually decreased as we moved away from the tumor. Our finding of TCs number in normal-appearing tissues in conjunction with ezrin expression may compete invasiveness and possibly a trail to reduce recurrence rates. CI - (c) 2023. The Author(s). FAU - Wishahi, Mohamed AU - Wishahi M AD - Department of Urology, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba, P.O. 30, Giza, 12411, Egypt. wishahi@gmx.net. FAU - Hassan, Sarah AU - Hassan S AD - Department of Electron Microscopy, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba, P.O. 30, Giza, 12411, Egypt. FAU - Hassan, Marwa AU - Hassan M AD - Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt. FAU - Badawy, Mohamed AU - Badawy M AD - Department of Urology, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba, P.O. 30, Giza, 12411, Egypt. FAU - Hafiz, Ehab AU - Hafiz E AD - Department of Electron Microscopy, Theodor Bilharz Research Institute, Kornaish El Nile, Warrak El-Hadar, Imbaba, P.O. 30, Giza, 12411, Egypt. dr_ehabosama@yahoo.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230415 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Ezrin) SB - IM MH - Humans MH - Urinary Bladder/pathology MH - *Urinary Bladder, Neurogenic/metabolism MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - *Telocytes/metabolism MH - Neoplasm Invasiveness/pathology MH - Ezrin PMC - PMC10105776 COIS- The authors declare no competing interests. EDAT- 2023/04/16 06:00 MHDA- 2023/04/18 06:41 PMCR- 2023/04/15 CRDT- 2023/04/15 23:17 PHST- 2022/10/16 00:00 [received] PHST- 2023/04/11 00:00 [accepted] PHST- 2023/04/18 06:41 [medline] PHST- 2023/04/15 23:17 [entrez] PHST- 2023/04/16 06:00 [pubmed] PHST- 2023/04/15 00:00 [pmc-release] AID - 10.1038/s41598-023-33282-0 [pii] AID - 33282 [pii] AID - 10.1038/s41598-023-33282-0 [doi] PST - epublish SO - Sci Rep. 2023 Apr 15;13(1):6179. doi: 10.1038/s41598-023-33282-0. PMID- 37059267 OWN - NLM STAT- MEDLINE DCOM- 20230724 LR - 20230724 IS - 1530-0307 (Electronic) IS - 0023-6837 (Linking) VI - 103 IP - 7 DP - 2023 Jul TI - Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma. PG - 100155 LID - S0023-6837(23)00098-3 [pii] LID - 10.1016/j.labinv.2023.100155 [doi] AB - In nonmuscle invasive bladder cancer, grade drives important treatment and management decisions. However, grading is complex and qualitative, and it has considerable interobserver and intraobserver variability. Previous literature showed that nuclear features quantitatively differ between bladder cancer grades, but these studies were limited in size and scope. In this study, we aimed to measure morphometric features relevant to grading criteria and build simplified classification models that objectively distinguish between the grades of noninvasive papillary urothelial carcinoma (NPUC). We analyzed 516 low-grade and 125 high-grade 1.0-mm diameter image samples from a cohort of 371 NPUC cases. All images underwent World Health Organization/International Society of Urological Pathology 2004 consensus pathologist grading at our institution that was subsequently validated by expert genitourinary pathologists from 2 additional institutions. Automated software segmented the tissue regions and measured the nuclear features of size, shape, and mitotic rate for millions of nuclei. Then, we analyzed differences between grades and constructed classification models, which had accuracies up to 88% and areas under the curve as high as 0.94. Variation in the nuclear area was the best univariate discriminator and was prioritized, along with the mitotic index, in the top-performing classifiers. Adding shape-related variables improved accuracy further. These findings indicate that nuclear morphometry and automated mitotic figure counts can be used to objectively differentiate between grades of NPUC. Future efforts will adapt the workflow to whole slides and tune grading thresholds to best reflect time to recurrence and progression. Defining these essential quantitative elements of grading has the potential to revolutionize pathologic assessment and provide a starting point from which to improve the prognostic utility of grade. CI - Copyright (c) 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. FAU - Slotman, Ava AU - Slotman A AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Xu, Minqi AU - Xu M AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Lindale, Katherine AU - Lindale K AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Hardy, Celine AU - Hardy C AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; Now with College of Medicine, Upstate Medical University, Syracuse, New York. FAU - Winkowski, Dan AU - Winkowski D AD - Visiopharm Corporation, Westminster, Colorado. FAU - Baird, Regan AU - Baird R AD - Visiopharm Corporation, Westminster, Colorado. FAU - Chen, Lina AU - Chen L AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; Now with Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. FAU - Lal, Priti AU - Lal P AD - Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada. FAU - Jackson, Chelsea L AU - Jackson CL AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; Now with CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada; Now with Department of Pathology, Rady Faculty of Health Science, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Gooding, Robert J AU - Gooding RJ AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario, Canada. FAU - Berman, David M AU - Berman DM AD - Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: bermand@queensu.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230413 PL - United States TA - Lab Invest JT - Laboratory investigation; a journal of technical methods and pathology JID - 0376617 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Artificial Intelligence MH - *Carcinoma, Papillary/pathology MH - Prognosis MH - Neoplasm Grading OTO - NOTNLM OT - artificial intelligence OT - digital pathology OT - grading OT - urothelial carcinoma EDAT- 2023/04/15 06:00 MHDA- 2023/07/24 06:42 CRDT- 2023/04/14 19:26 PHST- 2023/01/16 00:00 [received] PHST- 2023/03/20 00:00 [revised] PHST- 2023/04/01 00:00 [accepted] PHST- 2023/07/24 06:42 [medline] PHST- 2023/04/15 06:00 [pubmed] PHST- 2023/04/14 19:26 [entrez] AID - S0023-6837(23)00098-3 [pii] AID - 10.1016/j.labinv.2023.100155 [doi] PST - ppublish SO - Lab Invest. 2023 Jul;103(7):100155. doi: 10.1016/j.labinv.2023.100155. Epub 2023 Apr 13. PMID- 37058048 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20231002 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 102 IP - 15 DP - 2023 Apr 14 TI - The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis. PG - e33485 LID - 10.1097/MD.0000000000033485 [doi] LID - e33485 AB - Lymphovascular invasion (LVI) predicts poor survival in patients with pathologically localized or locally advanced upper urinary tract urothelial carcinoma (UT-UC). However, LVI is associated with high tumor grade, tumor necrosis, advanced tumor stage, tumor location, concomitant carcinoma in situ, lymph node metastasis, and sessile tumor architecture. These factors might interfere with the analysis of the impact of LVI on oncological prognosis. To address this, this study aimed to clarify the relationship between LVI and patient prognosis in UT-UC using propensity score weighting. Data were collected from 789 patients with UT-UC treated with radical nephroureterectomy without chemotherapy. We evaluated the significance of LVI in predicting metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) using propensity score weighting. All weighted baseline characteristics included in the propensity score model were balanced between the LVI (+) and LVI (-) groups. The MFS, CSS, and OS were all significantly poorer in the LVI (+) group. For patients without LVI, the 5-year MFS, CSS, and OS rates were 65.3%, 73.1%, and 67.3%, respectively, whereas the corresponding rates were 50.2%, 63.8 %, and 54.6%, respectively, for patients with LVI. (all P < .001). For patients without LVI, the 10-year MFS, CSS, and OS rates were 61.5%, 69.6%, and 59.2%, respectively, whereas those for patients with LVI were 44.5%, 57.0%, and 42.7%, respectively (all P < .001). LVI is an important pathological feature that predicts metastasis development and worse survival outcome after radical surgery in UT-UC patients. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Chang, Yin Lun AU - Chang YL AUID- ORCID: 0000-0002-1297-7922 AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yen Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wang, Hung Hen AU - Wang HH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chiang, Po Hui AU - Chiang PH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cheng, Yuan Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Kang, Chih Hsiung AU - Kang CH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chuang, Yao Chi AU - Chuang YC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lee, Wei Chin AU - Lee WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Yang, Wen Chou AU - Yang WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Liu, Hui Ying AU - Liu HY AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Su, Yu Li AU - Su YL AD - Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Huang, Chun Chieh AU - Huang CC AD - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Tse, Sung Min AU - Tse SM AD - Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Luo, Hao Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Prognosis MH - *Carcinoma, Transitional Cell/pathology MH - Propensity Score MH - Nephrectomy MH - *Urinary Bladder Neoplasms/surgery MH - *Ureteral Neoplasms/pathology MH - *Kidney Neoplasms/pathology MH - Kidney Pelvis/pathology MH - Retrospective Studies PMC - PMC10101277 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/04/15 06:00 MHDA- 2023/04/18 06:42 PMCR- 2023/04/14 CRDT- 2023/04/14 10:13 PHST- 2023/04/18 06:42 [medline] PHST- 2023/04/14 10:13 [entrez] PHST- 2023/04/15 06:00 [pubmed] PHST- 2023/04/14 00:00 [pmc-release] AID - 00005792-202304140-00038 [pii] AID - 10.1097/MD.0000000000033485 [doi] PST - ppublish SO - Medicine (Baltimore). 2023 Apr 14;102(15):e33485. doi: 10.1097/MD.0000000000033485. PMID- 37052619 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20230503 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 23 IP - 5 DP - 2023 May TI - Recent advances in the understanding of urothelial tumorigenesis. PG - 485-493 LID - 10.1080/14737140.2023.2203388 [doi] AB - INTRODUCTION: Patients with non-muscle-invasive bladder tumor suffer from disease recurrence following transurethral surgery even with intravesical pharmacotherapy, while muscle-invasive disease is often deadly. It is therefore critical to elucidate the underlying molecular mechanisms responsible for not only bladder tumor progression but also its tumorigenesis. Indeed, various molecules and/or signaling pathways have been suggested to contribute to the pathogenesis of bladder cancer. AREAS COVERED: We summarize the progress during the last few years on the initiation or development, but not progression, of urothelial cancer. The clinical implications of these available data, including prognostic significance and possible application for the prevention of the recurrence of non-muscle-invasive bladder tumors, are also discussed. EXPERT OPINION: Bladder cancer is a heterogeneous group of neoplasms. The establishment of personalized therapeutic options based on the molecular profile in each case should thus be considered. On that account, further accumulation of data on urothelial tumorigenesis is warranted to identify promising targets for the prevention of postoperative tumor recurrence or tumor development in otherwise high-risk patients. FAU - Yasui, Masato AU - Yasui M AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. FAU - Cui, Liam AU - Cui L AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. FAU - Miyamoto, Hiroshi AU - Miyamoto H AUID- ORCID: 0000-0001-7610-7769 AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. LA - eng PT - Journal Article DEP - 20230418 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 SB - IM MH - Humans MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/therapy/drug therapy MH - Prognosis MH - Carcinogenesis/genetics MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder cancer OT - progression OT - recurrence OT - targeted therapy OT - tumorigenesis OT - urothelial cancer EDAT- 2023/04/14 06:00 MHDA- 2023/04/28 06:41 CRDT- 2023/04/13 11:03 PHST- 2023/04/28 06:41 [medline] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/13 11:03 [entrez] AID - 10.1080/14737140.2023.2203388 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2023 May;23(5):485-493. doi: 10.1080/14737140.2023.2203388. Epub 2023 Apr 18. PMID- 37046810 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 7 DP - 2023 Apr 4 TI - Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype. LID - 10.3390/cancers15072149 [doi] LID - 2149 AB - This study evaluated a panel including the molecular taxonomy subtype and the expression of 27 genes as a diagnostic tool to stratify bladder cancer patients at risk of aggressive behavior, using a well-characterized series of non-muscle invasive bladder cancer (NMIBC) as well as muscle-invasive bladder cancer (MIBC). The study was conducted using the novel NanoString nCounter gene expression analysis. This technology allowed us to identify the molecular subtype and to analyze the gene expression of 27 bladder-cancer-related genes selected through a recent literature search. The differential gene expression was correlated with clinicopathological variables, such as the molecular subtypes (luminal, basal, null/double negative), histological subtype (conventional urothelial carcinoma, or carcinoma with variant histology), clinical subtype (NMIBC and MIBC), tumor stage category (Ta, T1, and T2-4), tumor grade, PD-L1 expression (high vs. low expression), and clinical risk categories (low, intermediate, high and very high). The multivariate analysis of the 19 genes significant for cancer-specific survival in our cohort study series identified TP53 (p = 0.0001), CCND1 (p = 0.0001), MKI67 (p < 0.0001), and molecular subtype (p = 0.005) as independent predictors. A scoring system based on the molecular subtype and the gene expression signature of TP53, CCND1, or MKI67 was used for risk assessment. A score ranging from 0 (best prognosis) to 7 (worst prognosis) was obtained and used to stratify our patients into two (low [score 0-2] vs. high [score 3-7], model A) or three (low [score 0-2] vs. intermediate [score 3-4] vs. high [score 5-7], model B) risk categories with different survival characteristics. Mean cancer-specific survival was longer (122 + 2.7 months) in low-risk than intermediate-risk (79.4 + 9.4 months) or high-risk (6.2 + 0.9 months) categories (p < 0.0001; model A); and was longer (122 + 2.7 months) in low-risk than high-risk (58 + 8.3 months) (p < 0.0001; model B). In conclusion, the molecular risk assessment model, as reported here, might be used better to select the appropriate management for patients with bladder cancer. FAU - Blanca, Ana AU - Blanca A AUID- ORCID: 0000-0002-4360-4352 AD - Department of Urology, Maimonides Biomedical Research Institute of Cordoba, University Hospital of Reina Sofia, UCO, 14004 Cordoba, Spain. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AUID- ORCID: 0000-0003-3161-8164 AD - Department of Morphological Sciences, University of Cordoba Medical School, 14004 Cordoba, Spain. FAU - Lopez-Porcheron, Kevin AU - Lopez-Porcheron K AD - Department of Morphological Sciences, University of Cordoba Medical School, 14004 Cordoba, Spain. FAU - Gomez-Gomez, Enrique AU - Gomez-Gomez E AD - Department of Urology, Maimonides Biomedical Research Institute of Cordoba, University Hospital of Reina Sofia, UCO, 14004 Cordoba, Spain. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Department of Medical Area (DAME), Institute of Pathological Anatomy, University of Udine, 33100 Udine, Italy. FAU - Bile-Silva, Andreia AU - Bile-Silva A AD - Urology Department, Egas Moniz Hospital, Centro Hospitalar de Lisboa Occidental, 1349-019 Lisbon, Portugal. FAU - Gogna, Rajan AU - Gogna R AD - Department of Human & Molecular Genetics, VCU Institute of Molecular Medicine (VIMM), VCU Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA. AD - BRIC-Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark. AD - Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal. FAU - Montironi, Rodolfo AU - Montironi R AUID- ORCID: 0000-0003-3938-610X AD - Molecular Medicine and Cell Therapy Foundation, Polytechnic University of Marche, 60121 Ancona, Italy. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center, and the Legorreta Cancer Center at Brown University, Providence, RI 02903, USA. LA - eng GR - PI17/01981/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20230404 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10093178 OTO - NOTNLM OT - CCND1 OT - MKI67 OT - NanoString OT - TP53 OT - bladder cancer OT - gene expression OT - molecular subtypes OT - prognosis OT - risk categories COIS- The authors declare no conflict of interest. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/04/04 CRDT- 2023/04/13 01:08 PHST- 2023/02/24 00:00 [received] PHST- 2023/03/31 00:00 [revised] PHST- 2023/04/02 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:08 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/04 00:00 [pmc-release] AID - cancers15072149 [pii] AID - cancers-15-02149 [pii] AID - 10.3390/cancers15072149 [doi] PST - epublish SO - Cancers (Basel). 2023 Apr 4;15(7):2149. doi: 10.3390/cancers15072149. PMID- 37046663 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 7 DP - 2023 Mar 28 TI - Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG. LID - 10.3390/cancers15072002 [doi] LID - 2002 AB - Upper urinary tract urothelial carcinoma (UTUC) after intravesical bacillus Calmette-Guerin (BCG) therapy is rare, and its incidence, clinical impact, and risk factors are not fully understood. To elucidate the clinical implications of UTUC after intravesical BCG therapy, this retrospective cohort study used data collected between January 2000 and December 2019. A total of 3226 patients diagnosed with non-muscle-invasive bladder cancer (NMIBC) and treated with intravesical BCG therapy were enrolled (JUOG-UC 1901). UTUC impact was evaluated by comparing intravesical recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) rates. The predictors of UTUC after BCG treatment were assessed. Of these patients, 2873 with a medical history that checked UTUC were analyzed. UTUC was detected in 175 patients (6.1%) during the follow-up period. Patients with UTUC had worse survival rates than those without UTUC. Multivariate analyses revealed that tumor multiplicity (odds ratio [OR], 1.681; 95% confidence interval [CI], 1.005-2.812; p = 0.048), Connaught strain (OR, 2.211; 95% CI, 1.380-3.543; p = 0.001), and intravesical recurrence (OR, 5.097; 95% CI, 3.225-8.056; p < 0.001) were associated with UTUC after BCG therapy. In conclusion, patients with subsequent UTUC had worse RFS, CSS, and OS than those without UTUC. Multiple bladder tumors, treatment for Connaught strain, and intravesical recurrence after BCG therapy may be predictive factors for subsequent UTUC diagnosis. FAU - Numakura, Kazuyuki AU - Numakura K AUID- ORCID: 0000-0002-5899-1738 AD - Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Kobayashi, Mizuki AU - Kobayashi M AD - Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. FAU - Muto, Yumina AU - Muto Y AD - Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. FAU - Sekine, Yuya AU - Sekine Y AD - Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Shiga, Masanori AU - Shiga M AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8576, Japan. FAU - Morizane, Shuichi AU - Morizane S AD - Division of Urology, Faculty of Medicine, Tottori University, Tottori 683-8504, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8563, Japan. FAU - Matsumura, Yoshiaki AU - Matsumura Y AD - Department of Urology, Nara Prefecture General Medical Center, Nara 630-8054, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo 060-8648, Japan. FAU - Yamada, Takeshi AU - Yamada T AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Sagamihara 252-0373, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AUID- ORCID: 0000-0002-6791-905X AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Departments of Urology, Kagawa University Faculty of Medicine, Takamatsu 761-0793, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center, Nagoya 464-8681, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8576, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara 634-8521, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. LA - eng GR - 17K11121 and 20K09553/Grants-in-Aid for Scientific Research, Japan/ PT - Journal Article DEP - 20230328 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10092972 OTO - NOTNLM OT - BCG OT - intravesical recurrence OT - multiple bladder tumors OT - non-muscle-invasive bladder cancer OT - upper urinary tract cancer COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/03/28 CRDT- 2023/04/13 01:07 PHST- 2023/02/16 00:00 [received] PHST- 2023/03/11 00:00 [revised] PHST- 2023/03/17 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:07 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/03/28 00:00 [pmc-release] AID - cancers15072002 [pii] AID - cancers-15-02002 [pii] AID - 10.3390/cancers15072002 [doi] PST - epublish SO - Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. PMID- 37046598 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 7 DP - 2023 Mar 23 TI - Efficacy of Different Bacillus of Calmette-Guerin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. LID - 10.3390/cancers15071937 [doi] LID - 1937 AB - BACKGROUND: In an era of Bacillus of Calmette-Guerin (BCG) shortages, the comparative efficacy from different adjuvant intravesical BCG strains in non-muscle invasive bladder cancer (NMIBC) has not been clearly elucidated. We aim to compare, through a systematic review and meta-analysis, the cumulative BC recurrence rates and the best efficacy profile of worldwide available BCG strains over the last forty years. METHODS: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from 1982 up to 2022. A meta-analysis of pooled BC recurrence rates was stratified for studies with 3-y recurrence-free survival (RFS) endpoints and the strain of BCG. Sensitivity analysis, sub-group analysis, and meta-regression were implemented to investigate the contribution of moderators to heterogeneity. A random-effect network meta-analysis was performed to compare BCG strains on a multi-treatment level. RESULTS: In total, n = 62 series with n = 15,412 patients in n = 100 study arms and n = 10 different BCG strains were reviewed. BCG Tokyo 172 exhibited the lowest pooled BC recurrence rate among studies with 3-y RFS outcomes. Sub-group and meta-regression analyses highlighted the influence of NMIBC risk-group classification and previous intravesical treated categories. Out of the n = 11 studies with n = 7 BCG strains included in the network, BCG RIVM, Tice, and Tokyo 172 presented with the best-predicted probability for efficacy, yet no single strain was significantly superior to another in preventing BC recurrence risk. CONCLUSION: We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA. FAU - Asero, Vincenzo AU - Asero V AUID- ORCID: 0000-0001-5293-9253 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Bologna, Eugenio AU - Bologna E AUID- ORCID: 0000-0002-1140-0590 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Scornajenghi, Carlo Maria AU - Scornajenghi CM AUID- ORCID: 0000-0001-7600-7434 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Carino, Dalila AU - Carino D AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Dolci, Virginia AU - Dolci V AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Viscuso, Pietro AU - Viscuso P AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Salciccia, Stefano AU - Salciccia S AUID- ORCID: 0000-0003-4873-3257 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AUID- ORCID: 0000-0002-7899-8056 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1030 Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1030 Vienna, Austria. AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint-Fonsegrives, France. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, 20132 Milan, Italy. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, 50134 Florence, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, 00133 Rome, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AUID- ORCID: 0000-0002-5933-3753 AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1030 Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Department of Urology, Fundacio Puigvert, 16444 Barcelona, Spain. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands. FAU - Marcq, Gautier AU - Marcq G AUID- ORCID: 0000-0002-1806-1448 AD - Urology Department, Claude Huriez Hospital, CHU Lille, 59000 Lille, France. AD - Cancer Heterogeneity Plasticity and Resistance to Therapies, UMR9020-U1277-CANTHER, Institut Pasteur de LilleCHU Lille, Inserm, CNRS University of Lille, 59000 Lille, France. FAU - Cimadamore, Alessia AU - Cimadamore A AUID- ORCID: 0000-0001-5981-3514 AD - Department of Medical Area (DAME), Institute of Pathological Anatomy, University of Udine, 33100 Udine, Italy. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, 6004 Luzern, Switzerland. FAU - Soria, Francesco AU - Soria F AD - Urology Division, Department of Surgical Sciences, University of Studies of Torino, 10124 Turin, Italy. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. FAU - Tully, Karl Heinrich AU - Tully KH AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, 44780 Herne, Germany. FAU - Pichler, Renate AU - Pichler R AUID- ORCID: 0000-0001-5286-9048 AD - Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, 6020 Innsbruck, Austria. FAU - Ferro, Matteo AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Division of Urology, European Institute of Oncology, IRCCS, 20141 Milan, Italy. FAU - Tataru, Octavian Sabin AU - Tataru OS AUID- ORCID: 0000-0001-7057-7815 AD - Department of Simulation Applied in Medicine, The Institution Organizing University Doctoral Studies (I.O.S.U.D.), George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology, 540142 Targu Mures, Romania. FAU - Autorino, Riccardo AU - Autorino R AUID- ORCID: 0000-0001-7045-7725 AD - Department of Urology, Rush University Medical Center, Chicago, IL 60612, USA. FAU - Crivellaro, Simone AU - Crivellaro S AD - Health Sciences System, Department of Urology, University of Illinois Hospital e Camp, Chicago, IL 60612, USA. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Reproductive Sciences and Odontostomatology, Urology Unit, Department of Neurosciences, University of Naples "Federico II", 80138 Naples, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Basran, Satvir AU - Basran S AUID- ORCID: 0000-0003-4744-2853 AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA. FAU - Eisenberg, Michael L AU - Eisenberg ML AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA. FAU - Chung, Benjamin Inbeh AU - Chung BI AD - Department of Urology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00185 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230323 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10093360 OTO - NOTNLM OT - BCG immunotherapy OT - BCG strain OT - bladder cancer OT - network meta-analysis OT - non-muscle invasive bladder cancer OT - recurrence rate COIS- Authors have no conflict of interest to disclose. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/03/23 CRDT- 2023/04/13 01:07 PHST- 2023/01/14 00:00 [received] PHST- 2023/03/19 00:00 [revised] PHST- 2023/03/20 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:07 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/03/23 00:00 [pmc-release] AID - cancers15071937 [pii] AID - cancers-15-01937 [pii] AID - 10.3390/cancers15071937 [doi] PST - epublish SO - Cancers (Basel). 2023 Mar 23;15(7):1937. doi: 10.3390/cancers15071937. PMID- 37045982 OWN - NLM STAT- MEDLINE DCOM- 20230811 LR - 20261010 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 33 IP - 9 DP - 2023 Sep TI - Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer. PG - 6245-6255 LID - 10.1007/s00330-023-09627-8 [doi] AB - OBJECTIVES: To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients. METHODS: We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores /=2 recurrences compared with having one (OR: 0.34; 95% CI: 0.16, 0.68). Higher plasma concentrations of ITC-albumin adducts were associated with a reduced risk of progression, including progression to muscle-invasive disease (for benzyl ITC, HR: 0.40; 95% CI: 0.17, 0.93; for phenethyl ITC, HR: 0.40; 95% CI: 0.19, 0.86). CONCLUSIONS: Our findings indicate the possible beneficial role of dietary ITCs in NMIBC prognosis. Given the compelling preclinical evidence, increasing dietary ITC exposure with CV intake could be a promising strategy to attenuate recurrence and progression risks in patients with NMIBC. CI - Copyright (c) 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved. FAU - Wang, Zinian AU - Wang Z AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Haque, Reina AU - Haque R AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States. FAU - Goniewicz, Maciej AU - Goniewicz M AD - Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. FAU - Pratt, Rachel AU - Pratt R AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, Downey, CA, United States. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA, United States. FAU - Quesenberry, Charles P AU - Quesenberry CP AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Zhang, Yuesheng AU - Zhang Y AD - Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. FAU - Ambrosone, Christine B AU - Ambrosone CB AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. Electronic address: li.tang@roswellpark.org. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R01 CA172855/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230411 PL - United States TA - Am J Clin Nutr JT - The American journal of clinical nutrition JID - 0376027 RN - 3129-90-6 (isothiocyanic acid) RN - 0 (Isothiocyanates) RN - 0 (Albumins) SB - IM MH - Humans MH - Vegetables MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Brassicaceae MH - Isothiocyanates/pharmacology MH - *Urinary Bladder Neoplasms/prevention & control MH - Albumins MH - Neoplasm Recurrence, Local PMC - PMC10447500 OTO - NOTNLM OT - biomarker OT - cruciferous vegetable OT - isothiocyanate OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence EDAT- 2023/04/13 06:00 MHDA- 2023/06/05 06:42 PMCR- 2024/04/11 CRDT- 2023/04/12 19:23 PHST- 2022/08/26 00:00 [received] PHST- 2023/04/03 00:00 [revised] PHST- 2023/04/07 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/04/13 06:00 [pubmed] PHST- 2023/04/12 19:23 [entrez] PHST- 2024/04/11 00:00 [pmc-release] AID - S0002-9165(23)46835-9 [pii] AID - 10.1016/j.ajcnut.2023.04.006 [doi] PST - ppublish SO - Am J Clin Nutr. 2023 Jun;117(6):1110-1120. doi: 10.1016/j.ajcnut.2023.04.006. Epub 2023 Apr 11. PMID- 37035140 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230411 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Correlation between the timing of diagnostic ureteroscopy for upper tract urothelial cancer and intravesical recurrence after radical nephroureterectomy. PG - 1122877 LID - 10.3389/fonc.2023.1122877 [doi] LID - 1122877 AB - OBJECTIVE: We aimed to evaluate the effect of the timing of diagnostic ureteroscopy (URS) on intravesical recurrence (IVR) following radical nephroureterectomy (RNU). PATIENTS AND METHODS: The clinical data of 220 patients with upper tract urothelial carcinoma (UTUC) treated with RNU at our center from June 2010 to December 2020 were retrospectively analyzed. According to the timing of the URS, all patients were divided into three groups: the no URS group, the 1-session group (diagnostic URS immediately followed by RNU), and the 2-session group (RNU after diagnostic URS). Additionally, we analyzed IVR-free survival (IVRFS) using the Kaplan-Meier and Cox proportional regression methods. RESULTS: The median follow-up period of these 220 patents was 41 (range: 2-143) months. Among them, 58 patients developed IVR following RNU. Kaplan-Meier curve displayed a significantly higher IVR rate in both treatment groups than in the no-URS group (p=0.025). In the subgroup of patients with renal pelvis cancer, the incidence of IVR was significantly higher in both treatment groups than in the group without URS (p=0.006). In univariate Cox proportional regression analysis, the two treatment groups were risk factors for IVR compared to the no-URS group [p=0.027, hazard ratio (HR): 1.93, 95% confidence interval (CI): 1.08-3.46]. The two-stage group (p=0.032, HR: 1.98, 95% CI: 1.08-3.65), positive urine pathology (p<0.001, HR: 8.12, 95% CI: 3.63-18.15), adjuvant chemotherapy (p<0.001, HR: 0.20, 95% CI: 0.10-0.38), and positive margin (p<0.0001, HR: 7.50, 95% CI: 2.44-23.08) were all identified as independent predictors in the multivariate. CONCLUSION: This study revealed that delayed RNU following diagnostic URS may increase the risk of postoperative IVR in patients with UTUC, preoperatively positive uropathology, and positive surgical margin were risk factors for IVR after RNU, while early postoperative chemotherapy may effectively prevent IVR. Delay of RUN after URS could increase the risk of IVR. CI - Copyright (c) 2023 Luo, Jiao, Su, Zhao, Yan, Pan, Ren, Zhang and Ding. FAU - Luo, Zhenkai AU - Luo Z AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. AD - Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Jiao, Binbin AU - Jiao B AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. FAU - Su, Caixia AU - Su C AD - School of Public Health, Peking University, Beijing, China. FAU - Zhao, Hang AU - Zhao H AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. AD - China-Japan Friendship School Clinical Medicine, Peking University, Beijing, China. FAU - Yan, Yangxuanyu AU - Yan Y AD - China-Japan Friendship School Clinical Medicine, Peking University, Beijing, China. FAU - Pan, Yijin AU - Pan Y AD - China-Japan Friendship School Clinical Medicine, Peking University, Beijing, China. FAU - Ren, Jian AU - Ren J AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Zhang, Guan AU - Zhang G AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Ding, Zhenshan AU - Ding Z AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20230322 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10073531 OTO - NOTNLM OT - diagnosis ureteroscopy OT - intravesical recurrence OT - nephroureterectomy OT - the timing of ureteroscopy OT - upper tract urothelial cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/04/11 06:00 MHDA- 2023/04/11 06:01 PMCR- 2023/01/01 CRDT- 2023/04/10 04:17 PHST- 2022/12/20 00:00 [received] PHST- 2023/03/13 00:00 [accepted] PHST- 2023/04/11 06:01 [medline] PHST- 2023/04/10 04:17 [entrez] PHST- 2023/04/11 06:00 [pubmed] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1122877 [doi] PST - epublish SO - Front Oncol. 2023 Mar 22;13:1122877. doi: 10.3389/fonc.2023.1122877. eCollection 2023. PMID- 37025476 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230411 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 4 IP - 3 DP - 2023 May TI - Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes. PG - 305-313 LID - 10.1002/bco2.215 [doi] AB - OBJECTIVES: The objective of this work is to evaluate the additional oncological benefit of photodynamic diagnosis (PDD) using blue-light cystoscopy in transurethral resection (TURBT) for primary non-muscle-invasive bladder cancer (NMIBC) based on the International Bladder Cancer Group (IBCG)-defined progression and the subsequent pathological pathways. PATIENTS AND METHODS: We reviewed 1578 consecutive primary NMIBC patients undergoing white-light TURBT (WL-TURBT) or PDD-TURBT during 2006-2020. One-to-one propensity score-matching was performed using multivariable logistic regression to obtain balanced groups. IBCG-defined progression of NMIBC included stage-up and grade-up as well as conventional definitions such as the development of muscle-invasive BC or metastatic disease. Nine oncological endpoints were evaluated. Sankey diagrams were generated to visualize follow-up pathological pathways after the initial TURBT. RESULTS: Comparison of event-free survival between the matched groups revealed that PDD use decreased the bladder cancer recurrence risk and IBCG-defined progression risk, whereas no significant difference was noted in conventionally defined progression. This was attributable to a reduced risk of stage-up, from Ta to T1, and grade-up. Sankey diagrams of the matched groups showed that patients with primary Ta low-grade tumour and first-recurrence Ta low-grade tumour did not have bladder recurrence or progression, while some of those in the WL-TURBT group developed recurrence after treatment. CONCLUSIONS: The multiple survival analysis demonstrated that the risk of IBCG-defined progression was significantly decreased by PDD use in NMIBC patients. Sankey diagrams revealed possible differences in pathological pathways after the initial TURBT between the two groups, demonstrating that repeated recurrence could be prevented by PDD use. CI - (c) 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Nakahama, Tomonori AU - Nakahama T AD - Department of Urology Nara Medical University Kashihara Nara Japan. FAU - Nishimoto, Koshiro AU - Nishimoto K AD - Department of Uro-Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan. FAU - Oyama, Masafumi AU - Oyama M AUID- ORCID: 0000-0002-4887-5522 AD - Department of Uro-Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology Hamamatsu University School of Medicine Hamamatsu Shizuoka Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology Hamamatsu University School of Medicine Hamamatsu Shizuoka Japan. FAU - Fukuhara, Hideo AU - Fukuhara H AUID- ORCID: 0000-0001-9692-0239 AD - Department of Urology Kochi Medical School Nankoku Kochi Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology Kochi Medical School Nankoku Kochi Japan. FAU - Kobayashi, Keita AU - Kobayashi K AD - Department of Urology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology Nara Medical University Kashihara Nara Japan. FAU - Hirao, Yoshihiko AU - Hirao Y AD - Department of Urology Osaka Gyoumeikan Hospital Konohana-ku Osaka Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology Nara Medical University Kashihara Nara Japan. LA - eng PT - Journal Article DEP - 20230113 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC10071077 OTO - NOTNLM OT - aminolevulinic acid OT - disease progression OT - local OT - neoplasm recurrence OT - optical imaging OT - photodynamic diagnosis OT - urinary bladder neoplasms COIS- The authors disclose no potential conflicts of interest. EDAT- 2023/04/08 06:00 MHDA- 2023/04/08 06:01 PMCR- 2023/01/13 CRDT- 2023/04/07 02:30 PHST- 2022/11/08 00:00 [received] PHST- 2022/12/07 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/04/08 06:01 [medline] PHST- 2023/04/07 02:30 [entrez] PHST- 2023/04/08 06:00 [pubmed] PHST- 2023/01/13 00:00 [pmc-release] AID - BCO2215 [pii] AID - 10.1002/bco2.215 [doi] PST - epublish SO - BJUI Compass. 2023 Jan 13;4(3):305-313. doi: 10.1002/bco2.215. eCollection 2023 May. PMID- 37024557 OWN - NLM STAT- MEDLINE DCOM- 20230518 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 5 DP - 2023 May TI - External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. PG - 1317-1321 LID - 10.1007/s00345-023-04380-5 [doi] AB - PURPOSE: To investigate the risk of bladder cancer (BCa) in patients treated with brachytherapy for prostate cancer (PCa). METHODS: We retrospectively analyzed 583 patients with PCa who underwent brachytherapy with or without external beam radiotherapy (EBRT). We analyzed the disease-free survival (DFS) of BCa in patients with PCa who underwent brachytherapy with or without EBRT. We performed multivariate Cox regression analyses of DFS using age, EBRT, and Brinkman index (BI) score (number of cigarettes smoked per day x number of years smoking) >/= 200 as variables for BCa after brachytherapy. RESULTS: Fourteen patients (2.4%) developed BCa after brachytherapy with or without EBRT. The percentage of high-grade urothelial carcinoma (UC) was 63.6%. A total of 85.7% of patients had non-muscle invasive BCa, and 14.3% of patients had muscle invasive BCa. DFS was longer in brachytherapy monotherapy than in combination therapy (brachytherapy + EBRT). Multivariate Cox regression analysis showed that a BI score >/= 200 (Hazard Ratio (HR 8.61; 95% Confidence Interval (CI) 1.12-65.98) and EBRT combination (HR 3.29; 95% CI 1.03-10.52) were significantly associated with BCa development in patients with PCa treated with brachytherapy. Furthermore, patients with BI score >/= 200 and EBRT combination had a significantly higher risk of BCa compared with patients with BI score < 200 (HR Log-rank test P = 0.010). CONCLUSION: Most cases of BCa after brachytherapy with or without EBRT are high grade and invasive. We hypothesized that the EBRT combination might be a risk factor for BCa in patients with PCa who underwent brachytherapy. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Minami, Takafumi AU - Minami T AUID- ORCID: 0000-0002-6934-3760 AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. minami@med.kindai.ac.jp. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Hashimoto, Mamoru AU - Hashimoto M AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Nishimoto, Mitsuhisa AU - Nishimoto M AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Adomi, Shogo AU - Adomi S AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Banno, Eri AU - Banno E AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Nozawa, Masahiro AU - Nozawa M AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Nose, Kazuhiro AU - Nose K AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Yoshimura, Kazuhiro AU - Yoshimura K AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. FAU - Inada, Masahiro AU - Inada M AD - Department of Radiation Oncology, Kindai University, Faculty of Medicine, Osakasayama, Osaka, Japan. FAU - Yokokawa, Masaki AU - Yokokawa M AD - Department of Radiation Oncology, Kindai University, Faculty of Medicine, Osakasayama, Osaka, Japan. FAU - Nakamatsu, Kiyoshi AU - Nakamatsu K AD - Department of Radiation Oncology, Kindai University, Faculty of Medicine, Osakasayama, Osaka, Japan. FAU - Uemura, Hirotsugu AU - Uemura H AD - Department of Urology, Kindai University, Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan. LA - eng PT - Journal Article DEP - 20230406 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Male MH - Humans MH - *Brachytherapy/adverse effects MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/etiology MH - *Urinary Bladder Neoplasms/epidemiology/etiology/radiotherapy MH - *Prostatic Neoplasms/pathology MH - Risk Factors OTO - NOTNLM OT - Bladder cancer OT - Brachytherapy OT - External beam radiotherapy combination OT - Prostate cancer OT - Smoking EDAT- 2023/04/07 06:00 MHDA- 2023/05/18 06:42 CRDT- 2023/04/06 23:19 PHST- 2022/11/15 00:00 [received] PHST- 2023/03/17 00:00 [accepted] PHST- 2023/05/18 06:42 [medline] PHST- 2023/04/07 06:00 [pubmed] PHST- 2023/04/06 23:19 [entrez] AID - 10.1007/s00345-023-04380-5 [pii] AID - 10.1007/s00345-023-04380-5 [doi] PST - ppublish SO - World J Urol. 2023 May;41(5):1317-1321. doi: 10.1007/s00345-023-04380-5. Epub 2023 Apr 6. PMID- 37016361 OWN - NLM STAT- MEDLINE DCOM- 20230406 LR - 20230408 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 21 IP - 1 DP - 2023 Apr 5 TI - Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging. PG - 133 LID - 10.1186/s12916-023-02813-x [doi] LID - 133 AB - BACKGROUND: Bladder cancer (BC) is among the most common cancers diagnosed in men in the USA. The current gold standards for the diagnosis of BC are invasive or lack the sensitivity to correctly identify the disease. METHODS: An aptamer-based screen analyzed the expression of 1317 proteins in BC compared to urology clinic controls. The top hits were subjected to systems biology analyses. Next, 30 urine proteins were ELISA-validated in an independent cohort of 68 subjects. Three of these proteins were next validated in an independent BC cohort of differing ethnicity. RESULTS: Systems biology analysis implicated molecular functions related to the extracellular matrix, collagen, integrin, heparin, and transmembrane tyrosine kinase signaling in BC susceptibility, with HNF4A and NFKB1 emerging as key molecular regulators. STEM analysis of the dysregulated pathways implicated a functional role for the immune system, complement, and interleukins in BC disease progression. Of 21 urine proteins that discriminated BC from urology clinic controls (UC), urine D-dimer displayed the highest accuracy (0.96) and sensitivity of 97%. Furthermore, 8 urine proteins significantly discriminated MIBC from NMIBC (AUC = 0.75-0.99), with IL-8 and IgA being the best performers. Urine IgA and fibronectin exhibited the highest specificity of 80% at fixed sensitivity for identifying advanced BC. CONCLUSIONS: Given the high sensitivity (97%) of urine D-dimer for BC, it may have a role in the initial diagnosis or detection of cancer recurrence. On the other hand, urine IL-8 and IgA may have the potential in identifying disease progression during patient follow-up. The use of these biomarkers for initial triage could have a significant impact as the current cystoscopy-based diagnostic and surveillance approach is costly and invasive when compared to a simple urine test. CI - (c) 2023. The Author(s). FAU - Vanarsa, Kamala AU - Vanarsa K AD - Department Biomedical Engineering, University of Houston, 3517 Cullen Blvd., Room 2027, Houston, TX, 77204-5060, USA. FAU - Castillo, Jessica AU - Castillo J AD - Department Biomedical Engineering, University of Houston, 3517 Cullen Blvd., Room 2027, Houston, TX, 77204-5060, USA. FAU - Wang, Long AU - Wang L AD - Department of Urology, Third Xiangya Hospital of Central South University, Changsha, China. FAU - Lee, Kyung Hyun AU - Lee KH AD - Center for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Pedroza, Claudia AU - Pedroza C AD - Center for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Mohan, Chandra AU - Mohan C AD - Department Biomedical Engineering, University of Houston, 3517 Cullen Blvd., Room 2027, Houston, TX, 77204-5060, USA. cmohan@central.uh.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230405 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (Interleukin-8) RN - 0 (Biomarkers, Tumor) RN - 0 (Immunoglobulin A) SB - IM MH - Male MH - Humans MH - *Proteomics MH - Interleukin-8 MH - Biomarkers, Tumor/urine MH - Neoplasm Recurrence, Local/diagnosis MH - *Urinary Bladder Neoplasms/diagnosis MH - Disease Progression MH - Immunoglobulin A PMC - PMC10074794 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Diagnostic biomarkers OT - Protein biomarkers OT - Proteomics OT - Surveillance biomarkers COIS- The authors declare that they have no competing interests. EDAT- 2023/04/05 06:00 MHDA- 2023/04/06 10:16 PMCR- 2023/04/05 CRDT- 2023/04/04 23:47 PHST- 2022/08/15 00:00 [received] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/04/06 10:16 [medline] PHST- 2023/04/04 23:47 [entrez] PHST- 2023/04/05 06:00 [pubmed] PHST- 2023/04/05 00:00 [pmc-release] AID - 10.1186/s12916-023-02813-x [pii] AID - 2813 [pii] AID - 10.1186/s12916-023-02813-x [doi] PST - epublish SO - BMC Med. 2023 Apr 5;21(1):133. doi: 10.1186/s12916-023-02813-x. PMID- 37014771 OWN - NLM STAT- MEDLINE DCOM- 20230601 LR - 20230813 IS - 2542-5641 (Electronic) IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 136 IP - 9 DP - 2023 May 5 TI - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: a propensity score-matched study. PG - 1067-1073 LID - 10.1097/CM9.0000000000002512 [doi] AB - BACKGROUND: Studies have classified muscle-invasive bladder cancer (MIBC) into primary (initially muscle-invasive, PMIBC) and secondary subtypes (initially non-muscle-invasive but progresses, SMIBC), for which controversial survival outcomes were demonstrated. This study aimed to compare the survival outcomes between PMIBC and SMIBC patients in China. METHODS: Patients diagnosed with PMIBC or SMIBC at West China Hospital from January 2009 to June 2019 were retrospectively included. Kruskal-Wallis and Fisher tests were employed to compare clinicopathological characteristics. Kaplan-Meier curves and Cox competing proportional risk model were used to compare survival outcomes. Propensity score matching (PSM) was employed to reduce the bias and subgroup analysis was used to confirm the outcomes. RESULTS: A total of 405 MIBC patients were enrolled, including 286 PMIBC and 119 SMIBC, with a mean follow-up of 27.54 and 53.30 months, respectively. The SMIBC group had a higher proportion of older patients (17.65% [21/119] vs. 9.09% [26/286]), chronic disease (32.77% [39/119] vs . 22.38% [64/286]), and neoadjuvant chemotherapy (19.33% [23/119] vs . 8.04% [23/286]). Before matching, SMIBC had a lower risk of overall mortality (OM) (hazard ratios [HR] 0.60, 95% confidence interval [CI] 0.41-0.85, P = 0.005) and cancer-specific mortality (CSM) (HR 0.64, 95% CI 0.44-0.94, P = 0.022) after the initial diagnosis. However, higher risks of OM (HR 1.47, 95% CI 1.02-2.10, P = 0.038) and CSM (HR 1.58, 95% CI 1.09-2.29, P = 0.016) were observed for SMIBC once it became muscle-invasive. After PSM, the baseline characteristics of 146 patients (73 for each group) were well matched, and SMIBC was confirmed to have an increased CSM risk (HR 1.83, 95% CI 1.09-3.06, P = 0.021) than PMIBC after muscle invasion. CONCLUSIONS: Compared with PMIBC, SMIBC had worse survival outcomes once it became muscle-invasive. Specific attention should be paid to non-muscle-invasive bladder cancer with a high progression risk. CI - Copyright (c) 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. FAU - Lok, Waichan AU - Lok W AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Zhang, Jiapeng AU - Zhang J AD - West China Medical School, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Zheng, Xiaonan AU - Zheng X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. AD - Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Lin, Tianhai AU - Lin T AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Xu, Hang AU - Xu H AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Tan, Ping AU - Tan P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. LA - eng PT - Journal Article DEP - 20230505 PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 SB - IM MH - Humans MH - Retrospective Studies MH - Propensity Score MH - *Cystectomy MH - *Urinary Bladder Neoplasms/pathology MH - Neoadjuvant Therapy PMC - PMC10228478 COIS- None. EDAT- 2023/04/05 06:00 MHDA- 2023/06/01 06:42 PMCR- 2023/05/05 CRDT- 2023/04/04 12:43 PHST- 2023/06/01 06:42 [medline] PHST- 2023/04/05 06:00 [pubmed] PHST- 2023/04/04 12:43 [entrez] PHST- 2023/05/05 00:00 [pmc-release] AID - 00029330-202305050-00008 [pii] AID - CMJ-2022-575 [pii] AID - 10.1097/CM9.0000000000002512 [doi] PST - epublish SO - Chin Med J (Engl). 2023 May 5;136(9):1067-1073. doi: 10.1097/CM9.0000000000002512. PMID- 37006208 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231031 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 15 IP - 1 DP - 2023 Jan-Mar TI - The study of miRNA-200c expression and epithelial-to-mesenchymal transition-related transcription factors in the primary bladder urothelial carcinoma. PG - 35-42 LID - 10.4103/ua.ua_72_22 [doi] AB - BACKGROUND: Epithelial-mesenchymal transition (EMT) plays an important role in bladder carcinoma (BC) invasiveness and metastasis. Studies have shown that muscle-invasive BC (MIBC) and non-MIBC (NMIBC) are different at the molecular level owing to different EMT-related programming. Recent studies suggest that dysregulation of specific miRNAs is linked to EMT in BC. With this background, we aimed to study the immunoexpression of EMT-markers and its correlation with miRNA-200c expression in a series of MIBCs and NMIBCs. MATERIALS AND METHODS: Quantitative real-time-polymerase chain reaction for the quantification of miR-200c expression was performed on 50 cases of urinary BC obtained from transurethral resection of bladder tumor (TURBT), cystectomy specimens, and ten peritumoral bladder tissue. Immunohistochemistry for ZEB1, ZEB2, TWIST, E-cadherin, and beta-catenin was performed on tumor and peritumoral bladder tissue. RESULTS: Thirty-five TURBT and 15 cystectomy specimens were assessed. Among MIBC, loss of expression of E-cadherin (72.3%), beta-catenin (66.7%), and ZEB1, ZEB2, and TWIST2 immunoreactivity was noted in 53.3%, 86.7%, and 73.3% of cases, respectively. Among NMIBC, loss of expression of E-cadherin (22.5%), beta-catenin (17.1%) and ZEB1, ZEB2, and TWIST immunoreactivity was noted in 11.5%, 51.4%, and 91.4% of cases, respectively. Upregulation of miRNA-200c was noted in cases with retained E-cadherin and negative TWIST expression. Downregulation of miRNA-200c expression was noted in all the cases showing loss of E-cadherin, beta-catenin, and in cases immunoreactive for ZEB1, ZEB2, and TWIST in MIBC. Downregulation of miRNA-200c expression was also noted in cases of MIBC with retained beta-catenin and those immunonegative for ZEB1 and ZEB2. A similar trend was noted in NMIBC. Median miRNA-200c expression was low in both high-grade and low-grade NMIBC compared to peritumoral bladder tissue and was not statistically significant. CONCLUSION: This study for the first time explores the relation of miR200C with E-cadherin, b-catenin, and its direct transcriptional regulators, namely Zeb1, Zeb2, and Twist in the same cohort of BC. We observed that miRNA-200c is downregulated in both MIBC and NMIBC. We identified novel expression of TWIST in cases of BC showing downregulation of miR200Cs suggesting that it is one of the protein targets of altered miRNA-200c expression contributing to EMT and can serve as a promising diagnostic marker and therapeutic target. Loss of E-cadherin and ZEB1 immunoexpression in high-grade NMIBC suggests an aggressive clinical behavior. However, ZEB2 heterogeneous expression in BC limits its diagnostic and prognostic utility. CI - Copyright: (c) 2022 Urology Annals. FAU - Narwal, Anubhav AU - Narwal A AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Kumari, Kalpana AU - Kumari K AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Kaushal, Seema AU - Kaushal S AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Seth, Amlesh AU - Seth A AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Nayak, Brusabhanu AU - Nayak B AD - Department of Urology, All India Institute of Medical Sciences, New Delhi, India. FAU - Rustagi, Yashika AU - Rustagi Y AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. FAU - Dinda, Amit Kumar AU - Dinda AK AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. LA - eng PT - Journal Article DEP - 20221108 PL - India TA - Urol Ann JT - Urology annals JID - 101510823 PMC - PMC10062515 OTO - NOTNLM OT - Bladder carcinoma OT - TWIST OT - ZEB1 OT - ZEB2 OT - miRNA-200c COIS- There are no conflicts of interest. EDAT- 2023/04/04 06:00 MHDA- 2023/04/04 06:01 PMCR- 2023/01/01 CRDT- 2023/04/03 03:44 PHST- 2022/05/02 00:00 [received] PHST- 2022/08/17 00:00 [accepted] PHST- 2023/04/04 06:01 [medline] PHST- 2023/04/03 03:44 [entrez] PHST- 2023/04/04 06:00 [pubmed] PHST- 2023/01/01 00:00 [pmc-release] AID - UA-15-35 [pii] AID - 10.4103/ua.ua_72_22 [doi] PST - ppublish SO - Urol Ann. 2023 Jan-Mar;15(1):35-42. doi: 10.4103/ua.ua_72_22. Epub 2022 Nov 8. PMID- 37005214 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20240111 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 6 DP - 2023 Dec TI - Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers. PG - 597-603 LID - S2588-9311(23)00068-8 [pii] LID - 10.1016/j.euo.2023.03.004 [doi] AB - BACKGROUND: Radiation therapy (RT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: To analyze predictors of complete response (CR) and survival after RT for MIBC. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective study of 864 patients with nonmetastatic MIBC who underwent curative-intent RT from 2002 to 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Regression models were used to explore prognostic factors associated with CR, cancer-specific survival (CSS), and overall survival (OS). RESULTS AND LIMITATIONS: The median patient age was 77 yr and median follow-up was 34 mo. Disease stage was cT2 in 675 patients (78%) and cN0 in 766 (89%). Neoadjuvant chemotherapy (NAC) was given to 147 patients (17%) and concurrent chemotherapy to 542 (63%). A CR was experienced by 592 patients (78%). cT3-4 stage (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.29-0.63; p < 0.001) and hydronephrosis (OR 0.50, 95% CI 034-0.74; p = 0.001) were significantly associated with lower CR. The 5-yr survival rates were 63% for CSS and 49% for OS. Higher cT stage (HR 1.93, 95% CI 1.46-2.56; p < 0.001), carcinoma in situ (HR 2.10, 95% CI 1.25-3.53; p = 0.005), hydronephrosis (HR 2.36, 95% CI 1.79-3.10; p < 0.001), NAC use (HR 0.66, 95% CI 0.46-0.95; p = 0.025), and whole-pelvis RT (HR 0.66, 95% CI 0.51-0.86; p = 0.002) were independently associated with CSS; advanced age (HR 1.03, 95% CI 1.01-1.05; p = 0.001), worse performance status (HR 1.73, 95% CI 1.34-2.22; p < 0.001), hydronephrosis (HR 1.50, 95% CI 1.17-1.91; p = 0.001), NAC use (HR 0.69, 95% CI 0.49-0.97; p = 0.033), whole-pelvis RT (HR 0.64, 95% CI 0.51-0.80; p < 0.001), and being surgically unfit (HR 1.42, 95% CI 1.12-1.80; p = 0.004) were associated with OS. The study is limited by the heterogeneity of different treatment protocols. CONCLUSIONS: RT for MIBC yields a CR in most patients who elect for curative-intent bladder preservation. The benefit of NAC and whole-pelvis RT require prospective trial validation. PATIENT SUMMARY: We investigated outcomes for patients with muscle-invasive bladder cancer treated with curative-intent radiation therapy as an alternative to surgical removal of the bladder. The benefit of chemotherapy before radiotherapy and whole-pelvis radiation (bladder plus the pelvis lymph nodes) needs further study. CI - Copyright (c) 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kool, Ronald AU - Kool R AD - Division of Urology, McGill University Health Center, Montreal, Canada; Department of Abdominal Surgery, Erasto Gaertner Cancer Center, Curitiba, Brazil. FAU - Marcq, Gautier AU - Marcq G AD - Division of Urology, McGill University Health Center, Montreal, Canada; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France; Cancer Heterogeneity Plasticity and Resistance to Therapies, CNRS, Inserm, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France. FAU - Breau, Rodney H AU - Breau RH AD - Ottawa Hospital Research Institute, Division of Urology, University of Ottawa, Ottawa, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Shayegan, Bobby AU - Shayegan B AD - Division of Urology, McMaster University, Hamilton, Canada. FAU - Kim, Michael AU - Kim M AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada. FAU - Busca, Ionut AU - Busca I AD - Ottawa Hospital Research Institute, Division of Urology, University of Ottawa, Ottawa, Canada. FAU - Abdi, Hamidreza AU - Abdi H AD - Ottawa Hospital Research Institute, Division of Urology, University of Ottawa, Ottawa, Canada. FAU - Dawidek, Mark T AU - Dawidek MT AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Uy, Michael AU - Uy M AD - Division of Urology, McMaster University, Hamilton, Canada. FAU - Fervaha, Gagan AU - Fervaha G AD - Department of Urology, Queen's University, Kingston, Canada. FAU - Cury, Fabio L AU - Cury FL AD - Division of Urology, McGill University Health Center, Montreal, Canada; Department of Radiation Oncology, McGill University Health Center, Montreal, Canada. FAU - Alimohamed, Nimira S AU - Alimohamed NS AD - Division of Medical Oncology, University of Calgary, Calgary, Canada. FAU - Izawa, Jonathan I AU - Izawa JI AD - Division of Urology, Western University, London, Canada. FAU - Jeldres, Claudio AU - Jeldres C AD - Division of Urology, University of Sherbrooke, Sherbrooke, Canada. FAU - Rendon, Ricardo AU - Rendon R AD - Division of Urology, Dalhousie University, Halifax, Canada. FAU - Siemens, D Robert AU - Siemens DR AD - Department of Urology, Queen's University, Kingston, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University Health Center, Montreal, Canada. Electronic address: wassim.kassouf.med@ssss.gouv.qc.ca. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230331 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - Retrospective Studies MH - Prospective Studies MH - Disease-Free Survival MH - *Urinary Bladder Neoplasms/radiotherapy/drug therapy MH - *Hydronephrosis MH - Muscles/pathology OTO - NOTNLM OT - Bladder cancer OT - Radiotherapy OT - Urinary tract neoplasm EDAT- 2023/04/03 06:00 MHDA- 2023/12/04 12:42 CRDT- 2023/04/02 22:05 PHST- 2022/08/22 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/16 00:00 [accepted] PHST- 2023/12/04 12:42 [medline] PHST- 2023/04/03 06:00 [pubmed] PHST- 2023/04/02 22:05 [entrez] AID - S2588-9311(23)00068-8 [pii] AID - 10.1016/j.euo.2023.03.004 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Dec;6(6):597-603. doi: 10.1016/j.euo.2023.03.004. Epub 2023 Mar 31. PMID- 38994485 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 9 IP - 1 DP - 2023 TI - Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model. PG - 87-96 LID - 10.3233/BLC-220027 [doi] AB - BACKGROUND: Bladder cancer is the most expensive cancer to treat on a per-patient basis. Blue light cystoscopy with hexaminolevulinate (BLC) has demonstrated improved diagnostic accuracy compared with white light cystoscopy (WLC) in non-muscle invasive bladder cancer (NMIBC). With higher upfront costs, questions remain about long-term BLC cost outcomes. OBJECTIVE: This study seeks to investigate the 5-year cost comparison of BLC and WLC from the Medicare payer perspective. METHODS: A representative 5-year NMIBC management model was constructed and Medicare reimbursement values were overlaid. The primary outcome was mean year-over-year cumulative cost discounted to present value at a 3% annual percentage rate. The secondary outcome was the rate of clinical events. RESULTS: Patients in the BLC cohort experienced fewer recurrences. On a cumulative present value cost basis, BLC was more expensive per patient in years 1, 2, and 3 than WLC, however, in years 4 and 5, BLC was economically favorable. Year 5 BLC mean cumulative cost savings was $1,172 per patient. Overall, 31.6% of all patients in the BLC group generated cumulative cost savings compared to WLC at year 1 compared with 50.9% at the end of year 5. CONCLUSIONS: Despite a higher initial annual cost, a slight cumulative economic advantage of BLC is realized after surveillance year 3. Additionally, a greater proportion of patients who received BLC achieved cost savings at the end of year 5. As novel technology emerges, economic models can help health care systems predict associated costs and quality improvements. CI - (c) 2023 - The authors. Published by IOS Press. FAU - Creswell, Michael L AU - Creswell ML AD - Georgetown University School of Medicine, Washington, DC, USA. AD - Georgetown University McDonough School of Business, Washington, DC, USA. FAU - Sholklapper, Tamir N AU - Sholklapper TN AD - Georgetown University School of Medicine, Washington, DC, USA. FAU - Markel, Michael J AU - Markel MJ AD - Georgetown University School of Medicine, Washington, DC, USA. FAU - Mason, James B AU - Mason JB AD - Department of Urology, MedStar Georgetown University Hospital, Washington, DC, USA. FAU - Pianka, Mark A AU - Pianka MA AD - Georgetown University School of Medicine, Washington, DC, USA. FAU - Dall, Christopher P AU - Dall CP AD - Department of Urology, MedStar Georgetown University Hospital, Washington, DC, USA. FAU - Ulu, Canan AU - Ulu C AD - Georgetown University McDonough School of Business, Washington, DC, USA. FAU - Stamatakis, Lambros AU - Stamatakis L AD - Department of Urology, MedStar Georgetown University Hospital, Washington, DC, USA. AD - Department of Urology, MedStar Washington Hospital Center, Washington, DC, USA. LA - eng PT - Journal Article DEP - 20230331 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181828 OTO - NOTNLM OT - medicare OT - Urinary bladder neoplasms OT - aminolevulinic acid OT - economic evaluation COIS- Michael L. Creswell has no conflict of interest to report. Tamir N. Sholklapper has no conflict of interest to report. Michael J. Markel has no conflict of interest to report. James B. Mason has no conflict of interest to report. Mark A. Pianka has no conflict of interest to report. Christopher P. Dall has no conflict of interest to report. Canan Ulu has no conflict of interest to report. Lambros Stamatakis has no conflict of interest to report. EDAT- 2023/03/31 00:00 MHDA- 2023/03/31 00:01 PMCR- 2023/03/31 CRDT- 2024/07/12 04:51 PHST- 2022/04/11 00:00 [received] PHST- 2023/02/28 00:00 [accepted] PHST- 2023/03/31 00:01 [medline] PHST- 2023/03/31 00:00 [pubmed] PHST- 2024/07/12 04:51 [entrez] PHST- 2023/03/31 00:00 [pmc-release] AID - BLC220027 [pii] AID - 10.3233/BLC-220027 [doi] PST - epublish SO - Bladder Cancer. 2023 Mar 31;9(1):87-96. doi: 10.3233/BLC-220027. eCollection 2023. PMID- 38994482 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 9 IP - 1 DP - 2023 TI - An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer. PG - 59-71 LID - 10.3233/BLC-220076 [doi] AB - BACKGROUND: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied thoroughly in relation to risk of recurrence or progression in NMIBC. OBJECTIVE: To identify germline DNA variants in bladder carcinogenesis-related genes associated with recurrence or progression in NMIBC. METHODS: We analysed associations between single-nucleotide polymorphisms (SNPs) and NMIBC recurrence and progression using data from the Nijmegen Bladder Cancer Study (NBCS, 1,443 patients). We included 5,053 SNPs within 46 genes known to have mutation, overexpression or amplification in bladder cancer. We included all recurrences in the statistical analysis and performed both single variant analysis and gene-based analysis. SNPs and genes that showed significant or suggestive association (false discovery rate P value < 20%) were followed-up in independent cohorts for replication analysis, through eQTL analysis and tests for association of tumour expression levels with NMIBC recurrence and progression. RESULTS: Single variant analysis showed no statistically significant associations with recurrence or progression. In gene-based analysis, the aggregate effect of the 25 SNPs in the Cyclin D1 gene (CCND1) was statistically significantly associated with NMIBC recurrence (P(unadj) = 0.001, P(FDR) = 0.046), but not with progression (P(unadj) = 0.17, P(FDR) = 0.54). Validation analysis in independent cohorts did not confirm the association of CCND1 with NMIBC recurrence. CONCLUSIONS: We could not identify reproducible associations between common germline variants in bladder carcinogenesis-related genes and NMIBC recurrence or progression. CI - (c) 2023 - The authors. Published by IOS Press. FAU - Hof, Jasper P AU - Hof JP AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Verhaegh, Gerald W AU - Verhaegh GW AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Mengual, Lourdes AU - Mengual L AD - Department and Laboratory of Urology, Universitat de Barcelona, Barcelona, Spain. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer & Genomic Sciences, Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. FAU - Fleshner, Neil E AU - Fleshner NE AD - Department of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Galesloot, Tessel E AU - Galesloot TE AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20230331 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181778 OTO - NOTNLM OT - Bladder cancer OT - candidate gene analysis OT - genetic association study OT - progression OT - recurrence COIS- Jasper P. Hof J. Hof has no conflict of interest to report. Sita H. Vermeulen S. Vermeulen has no conflict of interest to report. Antoine G. van der Heijden Consultant: MSD, Astellas, MerckPfizer, MML Honoraria: MerckPfizer, Astellas Gerald W. Verhaegh G. Verhaegh has no conflict of interest to report. Lars Dyrskjot Grants: C2i genomics, Natera, Photocure, Ferring Consultant: Ferring Honoraria: Roche L. Dyrskjot is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. James W.F. Catto Grants: Roche Consultant or advisory board: Astra Zeneca, BMS, Gilead, QED Therapeutics, Roche, Ferring, Steba biotech, UroGen, Janssen, Photocure Honoraria: BMS, Astra Zeneca, Roche Board member: Fight Bladder Cancer UK J. Catto is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. Lourdes Mengual Honoraria: Fundacion Investigacion Urologia (AEU) Receipt of material or service: Nucleix Richard T. Bryan Funding: Cancer Research UK Grants: Urogen Pharma, QED Therapeutics, Janssen Royalties: Nonacus Limited Board member: The Lichfield Science and Engineering Society Trustee: Action Bladder Cancer UK Neil E. Fleshner Grants: Janssen, Astellas, Bayer, Sanofi, Nucleix, Progenix, SpectraCure AB, Bavarian Nordic Consultant: Amgen, Janssen, Astellas, Bayer, Sanofi, Abbvie, Ferring Board member: Verity Pharmaceuticals, POINT Biopharma Stock: POINT Biopharma, Verity Pharamceuticals Lambertus A.L.M. Kiemeney L.A.L.M. Kiemeney is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer-review. Tessel E. Galesloot Tessel E. Galesloot has no conflict of interest to report. EDAT- 2023/03/31 00:00 MHDA- 2023/03/31 00:01 PMCR- 2023/03/31 CRDT- 2024/07/12 04:51 PHST- 2022/09/05 00:00 [received] PHST- 2023/02/22 00:00 [accepted] PHST- 2023/03/31 00:01 [medline] PHST- 2023/03/31 00:00 [pubmed] PHST- 2024/07/12 04:51 [entrez] PHST- 2023/03/31 00:00 [pmc-release] AID - BLC220076 [pii] AID - 10.3233/BLC-220076 [doi] PST - epublish SO - Bladder Cancer. 2023 Mar 31;9(1):59-71. doi: 10.3233/BLC-220076. eCollection 2023. PMID- 38994480 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 9 IP - 1 DP - 2023 TI - Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy? PG - 41-48 LID - 10.3233/BLC-220066 [doi] AB - BACKGROUND: One of the best predictors of positive outcomes in bladder cancer (BC) is pT0 following radical cystectomy (RC). Discordance between clinical and pathologic staging affects decision-making in patients with clinical absence of disease (cT0). OBJECTIVES: We sought to determine whether a restaging transurethral resection of bladder tumor (re-TURBT) improves clinical staging accuracy relative to pathologic stage RC in patients treated with neoadjuvant chemotherapy (NAC) versus those who did not receive NAC. METHODS: We queried our prospectively maintained IRB approved institutional database to identify 129 patients who underwent RC from 2013 to 2019 with a re-TURBT prior to RC. 53 patients were treated with NAC between their initial and re-TURBT and 76 patients were not treated with NAC. RESULTS: The overall upstaging rate from re-TURBT to RC was 34.9%. There was no significant difference in the upstaging rate between the NAC and no-NAC groups - 31.0% vs. 37.0%, respectively. In patients who were cT0 on re-TURBT, the NAC group did not show a significantly greater rate of pathologic clinical CR (pT0) than the no NAC group - 38.5% vs. 37.5%, respectively. Re-TURBT with staging < rT2 as a predictor for absence of MIBC on pathologic staging (2700 urothelial bladder carcinomas in a tissue microarray format by immunohistochemistry. Cytoplasmic and membranous CK20 staining was seen in 1319 (51.8%) cancers. The fraction of CK20 positive and especially strongly positive cases increased from pTaG2 low grade (44.5% strongly positive) and pTaG2 high grade (57.7%) to pTaG3 high grade (62.3%; p = 0.0006) but was lower in muscle-invasive (pT2-4) carcinomas (51.1% in all pTa vs. 29.6% in pT2-4; p < 0.0001). Within pT2-4 carcinomas, CK20 positivity was linked to nodal metastasis and lymphatic vessel invasion (p < 0.0001 each) and to venous invasion (p = 0.0177). CK20 staining was unrelated to overall patient survival if all 605 pT2-4 carcinomas were jointly analyzed but subgroup analyses revealed a significant association of CK20 positivity with favorable prognosis in 129 pT4 carcinomas (p = 0.0005). CK20 positivity was strongly linked to the expression of GATA3 (p < 0.0001), another feature of luminal bladder cancer. The combined analysis of both parameters showed best prognosis for luminal A (CK20+/GATA3+, CK20+/GATA3-) and worst outcome for luminal B (CK20-/GATA3+) and basal/squamous (CK20-/GATA3-) in pT4 urothelial carcinomas (p = 0.0005). In summary, the results of our study demonstrate a complex role of CK20 expression in urothelial neoplasms including neoexpression in pTa tumors, a subsequent loss of CK20 expression in a subset of tumors progressing to muscle-invasion, and a stage dependent prognostic role in muscle-invasive cancers. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Bruch, Paul Giacomo AU - Bruch PG AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Plage, Henning AU - Plage H AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Hofbauer, Sebastian AU - Hofbauer S AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Kornienko, Kira AU - Kornienko K AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Weinberger, Sarah AU - Weinberger S AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Rossner, Florian AU - Rossner F AD - Institute of Pathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Schallenberg, Simon AU - Schallenberg S AD - Institute of Pathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Kluth, Martina AU - Kluth M AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Lennartz, Maximilian AU - Lennartz M AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Blessin, Niclas C AU - Blessin NC AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Marx, Andreas H AU - Marx AH AD - Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany. FAU - Samtleben, Henrik AU - Samtleben H AD - Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Slojewski, Marcin AU - Slojewski M AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Kaczmarek, Krystian AU - Kaczmarek K AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Ecke, Thorsten AU - Ecke T AD - Department of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany. FAU - Hallmann, Steffen AU - Hallmann S AD - Department of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany. FAU - Koch, Stefan AU - Koch S AD - Department of Pathology, Helios Hospital Bad Saarow, Bad Saarow, Germany. FAU - Adamini, Nico AU - Adamini N AD - Department of Urology, Albertinen Hospital, Hamburg, Germany. FAU - Minner, Sarah AU - Minner S AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Simon, Ronald AU - Simon R AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: R.Simon@uke.de. FAU - Sauter, Guido AU - Sauter G AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Zecha, Henrik AU - Zecha H AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany; Department of Urology, Albertinen Hospital, Hamburg, Germany. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Schlomm, Thorsten AU - Schlomm T AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Horst, David AU - Horst D AD - Institute of Pathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. FAU - Elezkurtaj, Sefer AU - Elezkurtaj S AD - Institute of Pathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin and Berlin Institute of Health, Berlin, Germany. LA - eng PT - Journal Article DEP - 20230414 PL - Netherlands TA - Exp Mol Pathol JT - Experimental and molecular pathology JID - 0370711 RN - 0 (Keratin-20) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/metabolism MH - *Urinary Bladder Neoplasms/metabolism MH - Keratin-20/metabolism MH - Urinary Bladder/metabolism MH - Biomarkers, Tumor/metabolism MH - Urothelium/chemistry/metabolism/pathology OTO - NOTNLM OT - CK20 OT - Cytokeratin 20 OT - Immunohistochemistry OT - Tissue micro array OT - Urothelial carcinoma of the bladder COIS- Declaration of Competing Interest The rabbit recombinant CK20 antibody, MSVA-620R was purchased from MS Validated Antibodies GmbH (owned by a family member of GS). EDAT- 2023/03/31 06:00 MHDA- 2023/06/09 06:42 CRDT- 2023/03/30 19:27 PHST- 2022/12/28 00:00 [received] PHST- 2023/03/01 00:00 [revised] PHST- 2023/03/25 00:00 [accepted] PHST- 2023/06/09 06:42 [medline] PHST- 2023/03/31 06:00 [pubmed] PHST- 2023/03/30 19:27 [entrez] AID - S0014-4800(23)00011-4 [pii] AID - 10.1016/j.yexmp.2023.104860 [doi] PST - ppublish SO - Exp Mol Pathol. 2023 Jun;131:104860. doi: 10.1016/j.yexmp.2023.104860. Epub 2023 Apr 14. PMID- 36991375 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230403 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 23 IP - 1 DP - 2023 Mar 29 TI - Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma. PG - 49 LID - 10.1186/s12894-023-01206-9 [doi] LID - 49 AB - BACKGROUND: The evidence of prognostic factors and individualized surveillance strategies for upper tract urothelial carcinoma are still weak. OBJECTIVES: To evaluate whether the history of previous malignancy (HPM) affects the oncological outcomes of upper tract urothelial carcinoma (UTUC). METHODS: The CROES-UTUC registry is an international, observational, multicenter cohort study on patients diagnosed with UTUC. Patient and disease characteristics from 2380 patients with UTUC were collected. The primary outcome of this study was recurrence-free survival. Kaplan-Meier and multivariate Cox regression analyses were performed by stratifying patients according to their HPM. RESULTS: A total of 996 patients were included in this study. With a median recurrence-free survival time of 7.2 months and a median follow-up time of 9.2 months, 19.5% of patients had disease recurrence. The recurrence-free survival rate in the HPM group was 75.7%, which was significantly lower than non-HPM group (82.7%, P = 0.012). Kaplan-Meier analyses also showed that HPM could increase the risk of upper tract recurrence (P = 0.048). Furthermore, patients with a history of non-urothelial cancers had a higher risk of intravesical recurrence (P = 0.003), and patients with a history of urothelial cancers had a higher risk of upper tract recurrence (P = 0.015). Upon multivariate Cox regression analysis, the history of non-urothelial cancer was a risk factor for intravesical recurrence (P = 0.004), and the history of urothelial cancer was a risk factor for upper tract recurrence (P = 0.006). CONCLUSION: Both previous non-urothelial and urothelial malignancy could increase the risk of tumor recurrence. But different cancer types may increase different sites' risk of tumor recurrence for patients with UTUC. According to present study, more personalized follow-up plans and active treatment strategies should be considered for UTUC patients. CI - (c) 2023. The Author(s). FAU - Zhao, Hongda AU - Zhao H AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Liu, Kang AU - Liu K AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Giannakopoulos, Stilianos AU - Giannakopoulos S AD - Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Yuruk, Emrah AU - Yuruk E AD - Department of Urology, The Ministry of Health, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, Turkey. FAU - De Naeyer, Geert AU - De Naeyer G AD - Department of Urology, Onze-Lieve-Vrouw Clinic, Aalst, Belgium. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Ng, Chi-Fai AU - Ng CF AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Laguna, Pilar AU - Laguna P AD - Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Turkey. FAU - De La Rosette, Jean AU - De La Rosette J AD - Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Turkey. FAU - Yuen-Chun Teoh, Jeremy AU - Yuen-Chun Teoh J AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk. AD - Department of Surgery, Prince of Wales Hospital, 4/F LCW Clinical Sciences Building, Shatin, New Territories, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20230329 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - Cohort Studies MH - Neoplasm Recurrence, Local/pathology MH - Nephrectomy MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery PMC - PMC10061966 OTO - NOTNLM OT - Intravesical recurrence OT - Outcome assessment OT - Previous malignancy OT - UTUC OT - Urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2023/03/30 06:00 MHDA- 2023/03/31 06:41 PMCR- 2023/03/29 CRDT- 2023/03/29 23:46 PHST- 2022/11/09 00:00 [received] PHST- 2023/03/07 00:00 [accepted] PHST- 2023/03/31 06:41 [medline] PHST- 2023/03/29 23:46 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 00:00 [pmc-release] AID - 10.1186/s12894-023-01206-9 [pii] AID - 1206 [pii] AID - 10.1186/s12894-023-01206-9 [doi] PST - epublish SO - BMC Urol. 2023 Mar 29;23(1):49. doi: 10.1186/s12894-023-01206-9. PMID- 36990941 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20240930 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 41 IP - 6 DP - 2023 Jun TI - The effect of treatment on work productivity in patients with bladder cancer. PG - 293.e15-293.e21 LID - S1078-1439(23)00056-X [pii] LID - 10.1016/j.urolonc.2023.01.020 [doi] AB - OBJECTIVE: To describe the impact of bladder-preserving treatment vs. cystectomy on work productivity and activity impairment (WPAI) among patients with bladder cancer. METHODS: Using cross-sectional survey data, we constructed 2-part models involving both logistic and linear prediction to describe the relationship between WPAI and treatment modality among patients with non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). RESULTS: A total of 848 patients were included in the analysis. Patients with NMIBC who had cystectomy were more likely to experience activity impairment compared with those receiving bladder-preserving treatment (OR: 4.25, 95% CI: 2.28-7.93). Among patients with MIBC, cystectomy was protective against increasing presenteeism (e;beta: 0.41, 95% CI: 0.23-0.71) and productivity loss (e;beta: 0.44, 95% CI: 0.21-0.88); however, the opposite effect was seen for absenteeism treatment (e;beta: 4.82, 95% CI: 1.72-13.49). CONCLUSION: Cystectomy increased the odds of experiencing activity impairment for patients with NMIBC. However, for patients with MIBC, cystectomy appears to be protective for presenteeism and productivity loss. Further work is needed in order to better understand these important relationships and improve both patient counseling and shared decision-making. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ahlschlager, Lauren AU - Ahlschlager L AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - McCabe, Sean AU - McCabe S AD - Indiana School of Medicine, Indianapolis, IN. FAU - Deal, Allison M AU - Deal AM AD - Indiana School of Medicine, Indianapolis, IN. FAU - Guo, Amy AU - Guo A AD - Fergene, Boston, MA. FAU - Gessner, Kathryn H AU - Gessner KH AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Lipman, Robert AU - Lipman R AD - Bladder Cancer Advocacy Network, Bethesda, MD. FAU - Chisolm, Stephanie AU - Chisolm S AD - Bladder Cancer Advocacy Network, Bethesda, MD. FAU - Gore, John L AU - Gore JL AD - Department of Urology, University of Washington, Seattle, WA. FAU - Smith, Angela B AU - Smith AB AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Indiana School of Medicine, Indianapolis, IN. Electronic address: angela_smith@med.unc.edu. LA - eng GR - T32 CA244125/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230327 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Urinary Bladder Neoplasms/surgery MH - Cystectomy MH - Neoplasm Invasiveness PMC - PMC10330641 MID - NIHMS1899776 OTO - NOTNLM OT - Bladder cancer OT - Bladder-sparing treatment OT - Cystectomy OT - Patient-reported outcomes OT - Urinary bladder neoplasms OT - Work productivity COIS- Conflicts of interest Angela B. Smith receives funding from AHRQ, PCORI, BCAN, and Genentech. EDAT- 2023/03/30 06:00 MHDA- 2023/06/09 06:42 PMCR- 2023/07/10 CRDT- 2023/03/29 22:08 PHST- 2022/06/07 00:00 [received] PHST- 2023/01/24 00:00 [revised] PHST- 2023/01/30 00:00 [accepted] PHST- 2023/06/09 06:42 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 22:08 [entrez] PHST- 2023/07/10 00:00 [pmc-release] AID - S1078-1439(23)00056-X [pii] AID - 10.1016/j.urolonc.2023.01.020 [doi] PST - ppublish SO - Urol Oncol. 2023 Jun;41(6):293.e15-293.e21. doi: 10.1016/j.urolonc.2023.01.020. Epub 2023 Mar 27. PMID- 36983967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230331 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 13 IP - 3 DP - 2023 Mar 17 TI - The Urinary Microbiome and Bladder Cancer. LID - 10.3390/life13030812 [doi] LID - 812 AB - Bladder cancer is the 10th most common cancer worldwide. Approximately 75% of patients with bladder cancer will present with non-muscle invasive disease. Patients are usually treated with transurethral resection of bladder tumor (TURBT), in addition to adjuvant intravesical therapy (chemotherapy or anti-cancer immunotherapy with Bacillus Calmette Guerin- BCG) for those at intermediate-risk and high-risk of recurrence and progression. For many years, urine has been thought to be "sterile"; however, advanced microbiological and molecular techniques, including 16S ribosomal RNA (16S rRNA) sequencing, have negated that previous paradigm and confirmed the presence of a urinary microbiome. The urinary microbiome has been associated with several urological diseases, including interstitial cystitis, urgency urinary incontinence, neurogenic bladder dysfunction, and others. More recently, many reports are emerging about the role of the urinary microbiome in urothelial carcinogenesis, including gender disparity in bladder cancer and responses to treatments. The urinary microbiome may serve as a biomarker that can help with risk stratification as well as prediction of the response to intravesical therapies. However, the microbiome literature has been hampered by the lack of a unified standardized methodology for sample collection, type, preservation, processing, as well as bioinformatics analysis. Herein we describe and critique the literature on the association between urinary microbiome and bladder cancer and highlight some of the future directions. FAU - Heidar, Nassib Abou AU - Heidar NA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. FAU - Bhat, Tariq A AU - Bhat TA AUID- ORCID: 0000-0003-0738-8776 AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. FAU - Shabir, Usma AU - Shabir U AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. FAU - Hussein, Ahmed A AU - Hussein AA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. AD - Department of Urology, Cairo University, Giza 12613, Egypt. LA - eng PT - Journal Article PT - Review DEP - 20230317 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC10053959 OTO - NOTNLM OT - BCG therapy OT - TURBT OT - bladder cancer OT - cystectomy OT - microbiome COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/17 CRDT- 2023/03/29 01:46 PHST- 2023/02/16 00:00 [received] PHST- 2023/03/09 00:00 [revised] PHST- 2023/03/11 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:46 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/17 00:00 [pmc-release] AID - life13030812 [pii] AID - life-13-00812 [pii] AID - 10.3390/life13030812 [doi] PST - epublish SO - Life (Basel). 2023 Mar 17;13(3):812. doi: 10.3390/life13030812. PMID- 36980524 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230331 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 6 DP - 2023 Mar 7 TI - Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data. LID - 10.3390/cancers15061638 [doi] LID - 1638 AB - Some researchers have found that preoperative pyuria is a risk factor for recurrence after transurethral resection of high-risk non-muscle invasive bladder cancer. However, to our knowledge, none have clarified the risks associated with pyuria according to bacille Calmette-Guerin (BCG) treatment status. We retrospectively selected patients with high-risk non-muscle invasive bladder cancer according to Japanese Urological Association guidelines. Pyuria was defined as >/=10 white blood cells per high-powered field. We analyzed recurrence-free rates (RFS) in 424 patients who had and had not undergone BCG treatment. The median duration of follow-up was 45.2 months. According to multivariate analysis, postoperative intravesical BCG induction and preoperative pyuria were independent risk factors for intravesical recurrence in the whole study cohort. We found no significant risk factors for recurrence in the BCG-treated group (n = 179). In the non-BCG-treated group (n = 245), patients with pyuria were much more frequently female and more often had T1 disease than patients without pyuria. According to univariate and multivariate analysis, preoperative pyuria is an independent risk factor for intravesical recurrence. There was no significant difference in the severity of pyuria between the BCG and non-BCG-treated groups. Aggressive BCG treatment may need to be considered in patients with high-risk NMIBC and pyuria. FAU - Tsukamoto, Ryo AU - Tsukamoto R AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Hattori, Yoshinori AU - Hattori Y AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Sato, Hiroaki AU - Sato H AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Arai, Takayuki AU - Arai T AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Goto, Yusuke AU - Goto Y AUID- ORCID: 0000-0001-7720-9740 AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Imamura, Yusuke AU - Imamura Y AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Sakamoto, Shinichi AU - Sakamoto S AUID- ORCID: 0000-0002-7508-7521 AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AUID- ORCID: 0000-0002-8637-4163 AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. LA - eng GR - 22K09494/Kaken Pharmaceutical (Japan)/ PT - Journal Article DEP - 20230307 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10046501 OTO - NOTNLM OT - BCG OT - intravesical recurrence OT - non-muscle invasive bladder cancer OT - pyuria OT - risk factor COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; collection of data, analyses, or interpretation of data; the writing of the manuscript; or the decision to publish the results. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/07 CRDT- 2023/03/29 01:25 PHST- 2023/02/23 00:00 [received] PHST- 2023/03/05 00:00 [revised] PHST- 2023/03/06 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:25 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/07 00:00 [pmc-release] AID - cancers15061638 [pii] AID - cancers-15-01638 [pii] AID - 10.3390/cancers15061638 [doi] PST - epublish SO - Cancers (Basel). 2023 Mar 7;15(6):1638. doi: 10.3390/cancers15061638. PMID- 36976368 OWN - NLM STAT- MEDLINE DCOM- 20230330 LR - 20261010 IS - 1573-689X (Electronic) IS - 0148-5598 (Linking) VI - 47 IP - 1 DP - 2023 Mar 28 TI - Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study. PG - 41 LID - 10.1007/s10916-023-01929-0 [doi] AB - OBJECTIVE: To investigate how well the Sysmex automated urine-analyzer's atypical-cell parameter can predict oncological outcomes when compared to cytology and pathology data in the follow-up of NMIBC patients. MATERIAL AND METHODS: We prospectively collected clinical data from 273 patients who underwent cystoscopic examination due to benign and malign reasons in our center between June 2020 and March 2021. Patients were divided into 2 groups. (Group-1: Patients with no previous diagnosis of bladder cancer(BC), Group-2: Patients with previously diagnosed NMIBC). The a typical-cell parameter was determined by studying the urine sample given by the patient for urinalysis. The atypical-cell parameter's sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were assessed. RESULTS: A total of 76(41.1%) patients underwent diagnostic procedures (Group-1) and remaining 109(58.9%) patients were NMIBC patients (Group-2) who subjected to control cystoscopy on follow-up. BC was detected in 70 patients, 28 of whom were newly diagnosed (Group-1). Remaining 42 patients had recurrence during their follow-up (Group-2). Atypical cell values of 70 patients with BC were determined to be statistically significantly higher than those without malignancy. In Group-2, median atypical-cell values for those with no malignancy, those with low-grade BC reccurrence, and those with high-grade BC recurrence were 0.00(IQR:0.00-0.80), 0.25(IQR:0.10℃1.10) and 1.20(IQR:0.70-2.15), respectively (p<0.001). For a cut-off of 0.1 atypical cells/microL, sensitivity and specificity were measured as 83.33% and 53.73%, respectivel (AUC:0.727;p-value<0.001). CONCLUSION: Atypical-cell parameter of the Sysmex-UF-5000 automated urine-analyzer is a newly introduced research parameter. The results of this study are promising. Based on our results, we presume that the atypical-cell parameter may be used in surveillance of the NMIBC patients. Multi-center studies with larger patient populations are required to prove its efficacy. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Karaburun, Murat Can AU - Karaburun MC AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Ozkaya, Mehmet Fatih AU - Ozkaya MF AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. drfatihozkaya@gmail.com. FAU - Erguder, Berrin Imge AU - Erguder BI AD - Department of Biochemistry, Ankara University School of Medicine, Ankara, Turkey. FAU - Suer, Evren AU - Suer E AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20230328 PL - United States TA - J Med Syst JT - Journal of medical systems JID - 7806056 SB - IM MH - Humans MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/diagnosis/pathology/urine MH - Sensitivity and Specificity MH - Predictive Value of Tests OTO - NOTNLM OT - Atypical cell OT - Biomarker OT - Bladder cancer OT - NMIBC OT - Urine cytology EDAT- 2023/03/29 06:00 MHDA- 2023/03/30 06:11 CRDT- 2023/03/28 11:16 PHST- 2022/07/07 00:00 [received] PHST- 2023/02/27 00:00 [accepted] PHST- 2023/03/30 06:11 [medline] PHST- 2023/03/28 11:16 [entrez] PHST- 2023/03/29 06:00 [pubmed] AID - 10.1007/s10916-023-01929-0 [pii] AID - 10.1007/s10916-023-01929-0 [doi] PST - epublish SO - J Med Syst. 2023 Mar 28;47(1):41. doi: 10.1007/s10916-023-01929-0. PMID- 36974830 OWN - NLM STAT- MEDLINE DCOM- 20230329 LR - 20230329 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 4 DP - 2023 Apr TI - Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. PG - 1725-1730 LID - 10.21873/anticanres.16325 [doi] AB - BACKGROUND/AIM: There are few reports confirming the relationship between the therapeutic effects of adjuvant systemic chemotherapy and intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. We aimed to evaluate the benefits of adjuvant systemic chemotherapy on intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 133 patients with pathological T stage >/=3 upper urinary tract urothelial carcinoma or lymph node metastasis who underwent radical nephroureterectomy between January 2010 and September 2020 at our hospital and other satellite hospitals. In total, 60 patients received adjuvant systemic chemotherapy, and 73 did not. The Student's t-test and chi-square (chi(2)) test were used to compare between-group differences. The log-rank test was utilized to compare differences in intravesical recurrence between patients with or without adjuvant systemic chemotherapy. Cox proportional hazards regression analysis was performed to identify the predictive factors of intravesical recurrence. RESULTS: The median follow-up period was 25 months. Forty (30.1%) patients presented with intravesical recurrence. The 1-year intravesical recurrence-free survival rates of patients with and without adjuvant systemic chemotherapy were 86.0% and 70.2%, respectively (p=0.046). Multivariate analysis showed that adjuvant systemic chemotherapy was significantly associated with a lower risk of intravesical recurrence (p=0.032). CONCLUSION: Patients with pathological T stage >/=3 upper urinary tract urothelial carcinoma or lymph node metastasis can have a satisfactory intravesical recurrence-free survival rate with adjuvant systemic chemotherapy. CI - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Yamaguchi, Noriya AU - Yamaguchi N AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Morizane, Shuichi AU - Morizane S AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan; morizane@tottori-u.ac.jp. FAU - Yumioka, Tetsuya AU - Yumioka T AD - Department of Urology, Matsue Red Cross Hospital, Matsue, Japan. FAU - Shimizu, Ryutaro AU - Shimizu R AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Teraoka, Shogo AU - Teraoka S AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Iwamoto, Hideto AU - Iwamoto H AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Hikita, Katsuya AU - Hikita K AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Honda, Masashi AU - Honda M AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Takenaka, Atsushi AU - Takenaka A AD - Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - Nephroureterectomy MH - *Urinary Bladder Neoplasms/pathology MH - Retrospective Studies MH - Lymphatic Metastasis MH - *Kidney Neoplasms/surgery MH - *Ureteral Neoplasms/drug therapy/surgery MH - Kidney Pelvis/pathology MH - Chemotherapy, Adjuvant MH - Neoplasm Recurrence, Local/drug therapy MH - Nephrectomy OTO - NOTNLM OT - Adjuvant systemic chemotherapy OT - intravesical recurrence OT - radical nephroureterectomy OT - upper urinary tract urothelial carcinoma EDAT- 2023/03/29 06:00 MHDA- 2023/03/29 06:05 CRDT- 2023/03/28 05:33 PHST- 2023/01/30 00:00 [received] PHST- 2023/02/11 00:00 [revised] PHST- 2023/02/13 00:00 [accepted] PHST- 2023/03/29 06:05 [medline] PHST- 2023/03/28 05:33 [entrez] PHST- 2023/03/29 06:00 [pubmed] AID - 43/4/1725 [pii] AID - 10.21873/anticanres.16325 [doi] PST - ppublish SO - Anticancer Res. 2023 Apr;43(4):1725-1730. doi: 10.21873/anticanres.16325. PMID- 36971825 OWN - NLM STAT- MEDLINE DCOM- 20230518 LR - 20230524 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 41 IP - 5 DP - 2023 May TI - Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle? PG - 1329-1335 LID - 10.1007/s00345-023-04372-5 [doi] AB - PURPOSE: Radical cystectomy (RC) is the standard treatment for high-risk non muscle-invasive bladder cancer (NMIBC) failing first BCG treatment. A second BCG course is an option for those patients who refuse RC or are not eligible for it, but its success rate is quite low. Aim of the present study was to determine whether the addition of intravesical electromotive drug administration of mytomicin-C (EMDA-MMC) improved the efficacy of second BCG course. METHODS: Patients with high-risk NMIBC having failed first BCG treatment and having refused RC were offered a second BCG induction course either alone (group A) or combined with EMDA-MMC (group B). Recurrence-free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS) were tested. RESULTS: Of the 80 evaluable patients, 44 were in group A and 36 in group B; median follow-up was 38 months. RFS was significantly worse in group A whereas there was no difference in PFS and CSS between the two groups. Stratifying by disease stage, Ta patients receiving combined treatment had statistically better RFS and PFS survival than those receiving BCG only; this difference did not apply to T1 patients. Multivariable analysis confirmed that combined treatment was a significant predictor of recurrence and was close to predict progression. No tested variable was predictive of recurrence or progression in T1 tumours. Among those who underwent RC, CSS was 61.5% in those who had progression and 100% in those who remained with NMIBC. CONCLUSION: Combined treatment improved RFS and PFS only in patients with Ta disease. CI - (c) 2023. The Author(s). FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. gianmaria.busetto@unifg.it. FAU - Finati, Marco AU - Finati M AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Chirico, Marco AU - Chirico M AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Cinelli, Francesco AU - Cinelli F AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - D'Altilia, Nicola AU - D'Altilia N AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Falagario, Ugo G AU - Falagario UG AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University of Foggia, Policlinico Riuniti, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Department of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Urology, University of Naples Federico II, Naples, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AD - Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy. FAU - Calo', Beppe AU - Calo' B AD - Bonomo Teaching Hospital, Andria, BAT, Italy. FAU - Mancini, Vito AU - Mancini V AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Bettocchi, Carlo AU - Bettocchi C AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology, University of Foggia, Policlinico Riuniti, Via Luigi Pinto, 1, 71122, Foggia, Italy. AD - Bonomo Teaching Hospital, Andria, BAT, Italy. LA - eng PT - Journal Article DEP - 20230327 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 50SG953SK6 (Mitomycin) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Mitomycin/therapeutic use MH - BCG Vaccine/therapeutic use MH - Conservative Treatment MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Combined Modality Therapy MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/drug therapy PMC - PMC10188396 OTO - NOTNLM OT - Adjuvant therapy OT - Bladder cancer OT - EMDA OT - High-risk OT - Instillation COIS- Authors have no potential conflict of interest to disclose. EDAT- 2023/03/28 06:00 MHDA- 2023/05/18 06:42 PMCR- 2023/03/27 CRDT- 2023/03/27 11:14 PHST- 2023/01/16 00:00 [received] PHST- 2023/03/10 00:00 [accepted] PHST- 2023/05/18 06:42 [medline] PHST- 2023/03/28 06:00 [pubmed] PHST- 2023/03/27 11:14 [entrez] PHST- 2023/03/27 00:00 [pmc-release] AID - 10.1007/s00345-023-04372-5 [pii] AID - 4372 [pii] AID - 10.1007/s00345-023-04372-5 [doi] PST - ppublish SO - World J Urol. 2023 May;41(5):1329-1335. doi: 10.1007/s00345-023-04372-5. Epub 2023 Mar 27. PMID- 36965102 OWN - NLM STAT- MEDLINE DCOM- 20230607 LR - 20250801 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 10 DP - 2023 May TI - Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer. PG - 11305-11314 LID - 10.1002/cam4.5840 [doi] AB - BACKGROUND: To assess urinary symptoms and urine cytology as screening tools for cystoscopic detection of local recurrence after bladder-preserving trimodality treatment (TMT). METHODS: Patients with muscle-invasive bladder cancer receiving definitive TMT follow-up three monthly for 2 years, six monthly for the next 3 years and then yearly, with a clinical review, urine cytology and cystoscopy at each visit (triple assessment, TA). Grade 2+ cystitis/haematuria absent/present was scored 0/1, and urine cytology reported negative/suspicious or positive was scored 0/1, respectively. The performance of these two parameters for predicting local recurrence in cystoscopic biopsy was tested. Other hypothetical surveillance schedules included cystoscopy on alternate visits (COAV), or suspected recurrence (COSR), six-monthly COSR and six-monthly TA. RESULTS: A total of 630 follow-up visits in 112 patients with 19 recurrences (7 muscle invasive, 12 non-muscle invasive) at a median follow-up of 19 months were analysed. The sensitivity and specificity of clinical symptoms were 47.4% and 92%, and for urine cytology 58% and 85%, respectively. The combination of clinical symptoms and cytology (COSR) was 95% sensitive and 78% specific for local recurrence but 100% sensitive for muscle-invasive recurrence. Both COAV and COSV schedules showed a high area under the curve (AUC) for detecting local recurrence (COAV = 0.84, COSR = 0.83), muscle-invasive recurrence (AUC = 0.848 each) and non-muscle-invasive recurrence (COAV = 0.82, COSR = 0.81); reducing the need for TAs by 64% and 67% respectively, and overall cost by 18% and 33%, respectively. CONCLUSION: Cystoscopy at suspected recurrence during follow-up is safe and the most cost-effective for detecting muscle-invasive local recurrences, while cystoscopy at alternate visits may be more optimal for detecting any local recurrence. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Krishnatry, Rahul AU - Krishnatry R AUID- ORCID: 0000-0003-4511-7782 AD - Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Maitre, Priyamvada AU - Maitre P AD - Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Kumar, Anuj AU - Kumar A AD - Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Telkhade, Tejshri AU - Telkhade T AD - Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Bakshi, Ganesh AU - Bakshi G AD - Department of Surgical Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Prakash, Gagan AU - Prakash G AD - Department of Surgical Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Pal, Mahendra AU - Pal M AD - Department of Surgical Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Joshi, Amit AU - Joshi A AD - Department of Medical Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Menon, Santosh AU - Menon S AD - Department of Pathology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. FAU - Murthy, Vedang AU - Murthy V AD - Department of Radiation Oncology, Tata Memorial Centre and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India. LA - eng PT - Journal Article DEP - 20230325 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - *Cystoscopy/economics MH - Cost of Illness MH - *Urinary Bladder Neoplasms/diagnosis/therapy MH - *Neoplasm Recurrence, Local/diagnosis/pathology MH - Organ Sparing Treatments MH - Cystoscopes MH - *Chemoradiotherapy MH - Humans MH - Male MH - Middle Aged MH - Aged MH - Costs and Cost Analysis MH - Female MH - Treatment Outcome PMC - PMC10242324 OTO - NOTNLM OT - cost reduction OT - cystoscopy OT - muscle-invasive bladder cancer OT - surveillance OT - trimodality therapy COIS- The authors have no conflict of interest to declare. EDAT- 2023/03/26 06:00 MHDA- 2023/06/07 06:42 PMCR- 2023/03/25 CRDT- 2023/03/25 16:05 PHST- 2023/02/28 00:00 [revised] PHST- 2023/01/19 00:00 [received] PHST- 2023/03/12 00:00 [accepted] PHST- 2023/06/07 06:42 [medline] PHST- 2023/03/26 06:00 [pubmed] PHST- 2023/03/25 16:05 [entrez] PHST- 2023/03/25 00:00 [pmc-release] AID - CAM45840 [pii] AID - 10.1002/cam4.5840 [doi] PST - ppublish SO - Cancer Med. 2023 May;12(10):11305-11314. doi: 10.1002/cam4.5840. Epub 2023 Mar 25. PMID- 36961272 OWN - NLM STAT- MEDLINE DCOM- 20230816 LR - 20240603 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 132 IP - 3 DP - 2023 Sep TI - Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model. PG - 298-306 LID - 10.1111/bju.16012 [doi] AB - OBJECTIVES: To test if intravesical instillation of both an anti-programmed cell death protein 1 (PD-1) inhibitor and an oncolytic reovirus would demonstrate a greater effect than either treatment alone, as non-muscle-invasive bladder cancer that is refractory to intravesical bacillus Calmette-Guerin can be treated by systemic anti-PD-1 immunotherapy and we previously demonstrated improved overall survival (OS) with six once-weekly instillations of intravesical anti-PD-1 in a murine model. MATERIALS AND METHODS: Using an orthotopic syngeneic C3H murine model of MBT2 urothelial bladder cancer, groups of 10 mice were compared between no treatment, intravesical anti-PD-1, intravesical oncolytic reovirus, or intravesical reovirus + anti-PD-1. A single intravesical treatment session was given. The primary outcome was OS, and the secondary outcomes included long-term immunity and tumour-immune profile. RESULTS: With a median follow-up of 9 months, all mice that received no treatment died with a median survival of 41 days, while the comparison median OS was not reached for reovirus (hazard ratio [HR] 14.4, 95% confidence interval [CI] 3.9-32.6; P < 0.001), anti-PD-1 (HR 28.4, 95% CI 7.0-115.9; P < 0.001), and reovirus + anti-PD-1 (HR 28.4, 95% CI 7.0-115.9; P < 0.001). Monotherapy with anti-PD-1 or reovirus demonstrated no significant differences in survival (P = 0.067). Mass cytometry showed that reovirus + anti-PD-1 treatment enriched monocytes and decreased myeloid-derived suppressor cells, generating an immuno-responsive tumour microenvironment. Depletion of CD8(+) T cells eliminated the survival advantage provided by the intravesical treatment. CONCLUSIONS: Treatment of murine orthotopic bladder tumours with a single instillation of intravesical reovirus, anti-PD-1 antibody, or the combination confers superior survival compared to controls. Tumour-immune microenvironment differences indicated myeloid-derived suppressor cells and CD8(+) T cells mediate the treatment response. CI - (c) 2023 BJU International. FAU - Smelser, Woodson W AU - Smelser WW AD - Department of Surgery, Division of Urology, Washington University in St. Louis, St. Louis, MI, USA. AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Wang, Jian AU - Wang J AD - Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Ogden, Kristen M AU - Ogden KM AD - Department of Pediatrics, Nashville, TN, USA. AD - Department of Pathology, Microbiology, and Immunology, Nashville, TN, USA. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Kirschner, Austin N AU - Kirschner AN AUID- ORCID: 0000-0003-3807-6900 AD - Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. LA - eng GR - K12 CA090625/CA/NCI NIH HHS/United States GR - R01 AI155646/AI/NIAID NIH HHS/United States GR - T32 CA106183/CA/NCI NIH HHS/United States GR - 5T32CA106183-18/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230404 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) SB - IM MH - Mice MH - Animals MH - *Oncolytic Virotherapy MH - Disease Models, Animal MH - CD8-Positive T-Lymphocytes/pathology MH - *Non-Muscle Invasive Bladder Neoplasms MH - Mice, Inbred C3H MH - *Urinary Bladder Neoplasms/pathology MH - Immunotherapy MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Tumor Microenvironment PMC - PMC10518025 MID - NIHMS1901700 OTO - NOTNLM OT - Intravesical therapy OT - Oncolytic therapy OT - genitourinary cancer/bladder cancer OT - immunotherapy OT - organism/animal model of cancer COIS- Disclosure of Interests The other authors declare no potential conflicts of interest. EDAT- 2023/03/25 06:00 MHDA- 2023/08/16 06:43 PMCR- 2024/06/01 CRDT- 2023/03/24 09:33 PHST- 2023/08/16 06:43 [medline] PHST- 2023/03/25 06:00 [pubmed] PHST- 2023/03/24 09:33 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - 10.1111/bju.16012 [doi] PST - ppublish SO - BJU Int. 2023 Sep;132(3):298-306. doi: 10.1111/bju.16012. Epub 2023 Apr 4. PMID- 36949824 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230324 IS - 2050-3121 (Print) IS - 2050-3121 (Electronic) IS - 2050-3121 (Linking) VI - 11 DP - 2023 TI - A systematic review on the available treatment modalities for Bacillus Calmette-Guerin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy. PG - 20503121231160408 LID - 10.1177/20503121231160408 [doi] LID - 20503121231160408 AB - INTRODUCTION: Globally, urothelial bladder carcinoma is a disease which carries a poor prognosis. There are various treatment modalities for urothelial bladder carcinoma with intravesical Bacillus Calmette-Guerin immunotherapy being the most efficacious intravesical therapy and the treatment of choice for patients with carcinoma in situ. A number of chemotherapeutic drugs are also available for the management of Ta/T1 tumors such as mitomycin C and epirubicin. However, relapse and progression is quite common. The optimal management of patients with Bacillus Calmette-Guerin-unresponsive disease remains to be a challenge. The purpose of this study was to conduct a systematic review on the treatment modalities available for the management of Bacillus Calmette-Guerin-unresponsive carcinoma in situ and urothelial bladder carcinoma in patients who are ineligible or decline radical cystectomy. METHODS: Two authors independently searched three databases on the treatment modalities available for the management of Bacillus Calmette-Guerin-unresponsive carcinoma in situ and Bacillus Calmette-Guerin-unresponsive urothelial bladder carcinoma. RESULTS: The systematic search resulted in 15 studies. We recommend the use of intravesical CG0070 adenovirus or hyperthermic intravesical chemotherapy mitomycin C in patients with carcinoma in situ only disease. In patients with carcinoma in situ +/- Ta/T1 disease, we recommend the use of intravesical radiofrequency-induced chemohyperthermia or electromotive drug administration of mitomycin C. In patients who have Ta/T1 disease, we recommend the use of either hyperthermic intravesical chemotherapy epirubicin or electromotive drug administration mitomycin C followed by chemohyperthermia mitomycin C. If any of these second line therapies fail, an alternative regimen would be a combination of gemcitabine, cabazitaxel, and cisplatin. CONCLUSION: This recommendation is subject to the available resources and clinical expertise available in different hospitals. More studies using study designs such as randomized controlled trials comparing multiple drugs with larger sample sizes and regular follow-up intervals should be performed to accurately assess the different medications and aid in designing guidelines to guide the management of Bacillus Calmette-Guerin-unresponsive non-muscle invasive intravesical bladder cancer. CI - (c) The Author(s) 2023. FAU - Syed, Saad AU - Syed S AUID- ORCID: 0000-0002-2193-4385 AD - Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE. FAU - Rahman, Mansoor AU - Rahman M AD - Lady Reading Hospital, Peshawar, Pakistan. FAU - Israr, Aisha AU - Israr A AD - Khyber Girls Medical College, Peshawar, Pakistan. FAU - Anwar, Masroor AU - Anwar M AD - Khyber Teaching Hospital, Peshawar, Pakistan. FAU - Khatroth, Sumalatha AU - Khatroth S AD - Mallareddy Medical College for Women, Hyderabad, Telangana, India. FAU - Safi, Danish AU - Safi D AUID- ORCID: 0000-0003-1257-7934 AD - West Virginia University, Morgantown, West Virginia, USA. FAU - Kamran, Amir AU - Kamran A AD - Charleston Area Medical Center, Charleston, West Virginia, USA. LA - eng PT - Journal Article PT - Review DEP - 20230316 PL - England TA - SAGE Open Med JT - SAGE open medicine JID - 101624744 PMC - PMC10026116 OTO - NOTNLM OT - BCG-refractory OT - BCG-unresponsive OT - Urothelial bladder carcinoma OT - carcinoma in-situ OT - non-muscle invasive bladder carcinoma OT - radical cystectomy COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/03/24 06:00 MHDA- 2023/03/24 06:01 PMCR- 2023/03/16 CRDT- 2023/03/23 02:15 PHST- 2022/10/20 00:00 [received] PHST- 2023/02/10 00:00 [accepted] PHST- 2023/03/23 02:15 [entrez] PHST- 2023/03/24 06:00 [pubmed] PHST- 2023/03/24 06:01 [medline] PHST- 2023/03/16 00:00 [pmc-release] AID - 10.1177_20503121231160408 [pii] AID - 10.1177/20503121231160408 [doi] PST - epublish SO - SAGE Open Med. 2023 Mar 16;11:20503121231160408. doi: 10.1177/20503121231160408. eCollection 2023. PMID- 36946716 OWN - NLM STAT- MEDLINE DCOM- 20230525 LR - 20230525 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 75 IP - 3 DP - 2023 Jun TI - Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review. PG - 278-288 LID - 10.23736/S2724-6051.23.05091-7 [doi] AB - INTRODUCTION: The identification of variant histology (VH) has been recognized as a critical element in the diagnostic pathway of bladder cancer (BCa), both for prognostic and therapeutic implications. However, the current evidence on the oncological outcomes of patients harboring VH BCa mostly derives from studies including muscle-invasive disease. Consequently, the correct management of patients with non-muscle invasive bladder cancer (NMIBC) and VH is limited and conflicting, and the optimal therapeutic approach remains therefore controversial. EVIDENCE ACQUISITION: In this review, we aimed at reporting the current evidence on NMIBC with VH. EVIDENCE SYNTHESIS: Despite a constant increase in VH reporting at transurethral resection of bladder tumor (TURBT) specimens as compared to previous decades, we found that the incidence of VH is still sparse among studies. Furthermore, the agreement between TURBT and radical cystectomy (RC) specimens in VH identification is another matter of debate. Currently, most of the included studies report a poor overall concordance, especially for the micropapillary variant. Finally, while squamous and micropapillary variants are those associated with the worst survival outcomes, immediate RC is mostly considered for micropapillary tumors. Conversely, the survival benefit of immediate RC as compared to bladder-sparing approaches (i.e., BCG immunotherapy) for the other types of VH BCa is still an open question owing to the paucity of data available. CONCLUSIONS: Thus, in these patients, BCG treatment could be proposed considering the need for more intensive oncological surveillance. FAU - Basile, Giuseppe AU - Basile G AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - de Angelis, Mario AU - de Angelis M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Leni, Riccardo AU - Leni R AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Re, Chiara AU - Re C AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Longoni, Mattia AU - Longoni M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, Florence, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, School of Medicine, Citta della Salute e della Scienza, Turin, Italy. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal Infant and Urologic Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, University Clinics of Brussels, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium. AD - Department of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium. AD - Unit of Urology, Department of Surgical Sciences, Tor Vergata University Hospital, Tor Vergata University, Rome, Italy. FAU - Gallioli, Andrea AU - Gallioli A AD - Department of Urology, Puigvert Foundation, Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Puigvert Foundation, Barcelona, Spain. FAU - Esperto, Francesco AU - Esperto F AD - Department of Urology, Campus Bio-Medico University Hospital, Rome, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy - marco.moschini87@gmail.com. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - Sant'Anna Clinic, Swiss Medical Group, Sorengo, Switzerland. CN - European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Systematic Review DEP - 20230322 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/surgery MH - Urinary Bladder/surgery MH - Prognosis EDAT- 2023/03/23 06:00 MHDA- 2023/05/25 06:42 CRDT- 2023/03/22 10:00 PHST- 2023/05/25 06:42 [medline] PHST- 2023/03/23 06:00 [pubmed] PHST- 2023/03/22 10:00 [entrez] AID - S2724-6051.23.05091-7 [pii] AID - 10.23736/S2724-6051.23.05091-7 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2023 Jun;75(3):278-288. doi: 10.23736/S2724-6051.23.05091-7. Epub 2023 Mar 22. PMID- 36945968 OWN - NLM STAT- MEDLINE DCOM- 20230323 LR - 20230802 IS - 1303-6165 (Electronic) IS - 1300-0144 (Print) IS - 1300-0144 (Linking) VI - 52 IP - 6 DP - 2022 Dec TI - Role of PD-1/PD-L1-mediated tumour immune escape mechanism and microsatellite instability in the BCG failure of high-grade urothelial carcinomas. PG - 1802-1813 LID - 10.55730/1300-0144.5526 [doi] AB - BACKGROUND: Intravesical BCG treatment fails inexplicably in 30%-45% of patients for high-grade nonmuscle-invasive bladder cancer (NMIBC). We aimed to investigate the role of PD-1/PD-L1 interaction on BCG failure of high-grade NMIBC and to identify biomarkers for predicting BCG responsive cases. METHODS: Thirty BCG responsive and 29 nonresponsive NMIBCs were included in the study. Expressions of PDL1(SP-263), MSH2, MSH6, PMS2, and MLH1 were evaluated on pre- and post-BCG transurethral resection (TUR-B) specimens by immunohistochemistry. PD-L1(SP-263) expression was categorised as negative/low, high. DNA mismatch repair protein (MMR) expressions were classified as "reduced" if 30% of nuclei stained. Microsatellite instability (MSI) testing was performed by PCR using five mononucleotide markers. RESULTS: Reduced DNA MMR protein expression was found to be significantly higher in the pretreatment biopsies of BCG-responsive group than the BCG nonresponsive tumour group (p = 0.022). PD-L1 expression did not show any significant difference between the pre- and posttreatment TUR-B specimens of the BCG nonresponsive tumour group or between the pretreatment TUR-B specimens of BCG nonresponsive and the BCG responsive groups (p = 0.508, p = 0.708, respectively). DISCUSSION: Immune escape of tumour cells by PD-1/PD-L1 interaction does not seem to have any role in BCG failure of NMIBCs. Reduced MMR expression may help to determine cases that will respond well to BCG therapy. A better antitumour activity of BCG in NMIBCs with reduced MMR expression may be related to the ongoing accumulation of cancer neoantigens in correlation with increased tumour mutation load as a result of DNA repair defects. FAU - Salman, Fadime Gul AU - Salman FG AD - Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Kankaya, Duygu AU - Kankaya D AD - Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Ozakinci, Hilal AU - Ozakinci H AD - Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Sahin, Yasemin AU - Sahin Y AD - Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Kubilay, Eralp AU - Kubilay E AD - Department of Urology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Suer, Evren AU - Suer E AD - Department of Urology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Hayme, Serhat AU - Hayme S AD - Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, Faculty of Medicine, Ankara University, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20221221 PL - Turkey TA - Turk J Med Sci JT - Turkish journal of medical sciences JID - 9441758 RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (BCG Vaccine) RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics MH - Microsatellite Instability MH - Programmed Cell Death 1 Receptor/genetics MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/genetics/pathology MH - B7-H1 Antigen MH - Tumor Escape MH - Biomarkers, Tumor/metabolism PMC - PMC10390201 OTO - NOTNLM OT - BCG therapy OT - Nonmuscle-invasive bladder carcinoma OT - PD-L1 OT - immunotherapy OT - microsatellite instability OT - mismatch repair EDAT- 2023/03/23 06:00 MHDA- 2023/03/24 06:00 PMCR- 2022/10/09 CRDT- 2023/03/22 03:44 PHST- 2022/02/23 00:00 [received] PHST- 2022/10/09 00:00 [accepted] PHST- 2023/03/22 03:44 [entrez] PHST- 2023/03/23 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2022/10/09 00:00 [pmc-release] AID - turkjmedsci-52-6-1802 [pii] AID - 10.55730/1300-0144.5526 [doi] PST - ppublish SO - Turk J Med Sci. 2022 Dec;52(6):1802-1813. doi: 10.55730/1300-0144.5526. Epub 2022 Dec 21. PMID- 36941190 OWN - NLM STAT- MEDLINE DCOM- 20230519 LR - 20230625 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 5 DP - 2023 May TI - Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer. PG - 256.e9-256.e15 LID - S1078-1439(23)00047-9 [pii] LID - 10.1016/j.urolonc.2023.01.016 [doi] AB - BACKGROUND: Data on Ta low-grade (LG) non-muscle invasive bladder cancer (NMIBC) have shown that follow-up cystoscopies are normal in 82% and 67% of patients with single and multiple tumors, respectively. OBJECTIVE: To develop a predictive model associated with recurrence-free survival (RFS) at 6, 12, 18 and 24 months in TaLG cases that consider the patients' risk aversion. MATERIALS AND METHODS: Data from a prospectively maintained database of 202 newly diagnosed TaLG NMIBC patients treated at Scandinavian institutions were used for the analysis. To identify risk groups associated with recurrence, we performed a classification tree analysis. Association between risk groups and RFS was evaluated by Kaplan Meier analysis. A Cox proportional hazard model selected significant risk factors associated with RFS using the variables defining the risk groups. The reported C index for the Cox model was 0.7. The model was internally validated and calibrated using 1000 bootstrapped samples. A nomogram to estimate RFS at 6, 12, 18, and 24 months was generated. The performance of our model was compared to EUA/AUA stratification using a decision curve analysis (DCA). RESULTS: The tree classification found that tumor number, tumor size and age were the most relevant variables associated with recurrence. The patients with the worst RFS were those with multifocal or single, >/= 4cm tumors. All the relevant variables identified by the classification tree were significantly associated with RFS in the Cox proportional hazard model. DCA analysis showed that our model outperformed EUA/AUA stratification and the treat all/none approaches. CONCLUSION: We developed a predictive model to identify TaLG patients that benefit from less frequent follow-up cystoscopy schedule based on the estimated RFS and personal recurrence risk aversion. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Daza, Jorge AU - Daza J AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Urology, Roswell Park Cancer Institute, Buffalo, NY. FAU - Grauer, Ralph AU - Grauer R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Chen, Sophie AU - Chen S AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Lavallee, Etienne AU - Lavallee E AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Razdan, Shirin AU - Razdan S AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Dey, Linda AU - Dey L AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Steineck, Gunnar AU - Steineck G AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Renstrom-Koskela, Lotta AU - Renstrom-Koskela L AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Li, Qiang AU - Li Q AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY. FAU - Hussein, Ahmed A AU - Hussein AA AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Waingankar, Nikhil AU - Waingankar N AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Guru, Khurshid AU - Guru K AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.sfakianos@mountsinai.org. LA - eng PT - Journal Article DEP - 20230321 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Nomograms MH - Risk Factors MH - Kaplan-Meier Estimate MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies OTO - NOTNLM OT - Bladder cancer OT - Low grade OT - Non-muscle invasive OT - Outcomes OT - Predictive model COIS- Conflict of Interest None declared. EDAT- 2023/03/21 06:00 MHDA- 2023/05/19 06:42 CRDT- 2023/03/20 23:01 PHST- 2022/07/12 00:00 [received] PHST- 2023/01/04 00:00 [revised] PHST- 2023/01/27 00:00 [accepted] PHST- 2023/05/19 06:42 [medline] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/20 23:01 [entrez] AID - S1078-1439(23)00047-9 [pii] AID - 10.1016/j.urolonc.2023.01.016 [doi] PST - ppublish SO - Urol Oncol. 2023 May;41(5):256.e9-256.e15. doi: 10.1016/j.urolonc.2023.01.016. Epub 2023 Mar 21. PMID- 36939965 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20230524 IS - 1573-4978 (Electronic) IS - 0301-4851 (Print) IS - 0301-4851 (Linking) VI - 50 IP - 5 DP - 2023 May TI - Urinary BLACAT1 as a non-invasive biomarker for bladder cancer. PG - 4339-4345 LID - 10.1007/s11033-023-08370-z [doi] AB - BACKGROUND: Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), which retains a feature of rapid progress and metastasis. In addition, only a limited number of biomarkers are available for diagnosing BC compared to other cancers. Hence, finding sensitive and specific biomarkers for predicting the diagnosis and prognosis of patients with BC is critically needed. Therefore, this study aimed to determine the expression and clinical significance of urinary lncRNA BLACAT1 as a non-invasively diagnostic and prognostic biomarker to detect and differentiate BCs stages. METHODS AND RESULTS: The expression levels of urinary BLACAT1 were detected by qRT-PCR assay in seventy (70) BC patients with different TNM grades (T0-T3) and twelve (12) healthy subjects as control. BLACAT1 was downregulated in superficial stages (T0 = 0.09 +/- 0.02 and T1 = 0.5 +/- 0.1) compared to healthy control. Furthermore, in the invasive stages, its levels started to elevate in the T2 stage (1.2 +/- 0. 2), and higher levels were detected in the T3 stage with a mean value of (5.2 +/- 0.6). This elevation was positively correlated with disease progression. Therefore, BLACAT1 can differentiate between metastatic and non-metastatic stages of BCs. Furthermore, its predictive values are not like to be influenced by schistosomal infection. CONCLUSIONS: Upregulation of BLACAT1 in invasive stages predicted an unfavorable prognosis for patients with BCs, as it contributes to the migration and metastasis of BCs. Therefore, we can conclude that urinary BLACAT1 may be considered a non-invasive promising metastatic biomarker for BCs. CI - (c) 2023. The Author(s). FAU - El Sharkawi, Fathia Z AU - El Sharkawi FZ AUID- ORCID: 0000-0002-5745-8296 AD - Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, P.O. Box 11795, Cairo, Egypt. FAU - El Sabah, Mahmoud AU - El Sabah M AD - Department of Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Cairo, Egypt. FAU - Atya, Hanaa B AU - Atya HB AUID- ORCID: 0000-0001-8593-9137 AD - Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, P.O. Box 11795, Cairo, Egypt. hanaa.atya@pharm.helwan.edu.eg. FAU - Khaled, Hussein M AU - Khaled HM AUID- ORCID: 0000-0003-1118-7467 AD - National Cancer Institute, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20230320 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) RN - 0 (long noncoding RNA BLACAT1, human) SB - IM MH - Humans MH - Biomarkers, Tumor/genetics MH - Disease Progression MH - Gene Expression Regulation, Neoplastic MH - *RNA, Long Noncoding/genetics MH - *Urinary Bladder Neoplasms/diagnosis/genetics PMC - PMC10147806 OTO - NOTNLM OT - BLACAT1 OT - Bladder cancer OT - LncRNA OT - Metastatic marker COIS- The authors declare that they have no financial or non-financial competing interests that are directly or indirectly related to this work. EDAT- 2023/03/21 06:00 MHDA- 2023/05/01 06:42 PMCR- 2023/03/20 CRDT- 2023/03/20 12:22 PHST- 2022/10/14 00:00 [received] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/20 12:22 [entrez] PHST- 2023/03/20 00:00 [pmc-release] AID - 10.1007/s11033-023-08370-z [pii] AID - 8370 [pii] AID - 10.1007/s11033-023-08370-z [doi] PST - ppublish SO - Mol Biol Rep. 2023 May;50(5):4339-4345. doi: 10.1007/s11033-023-08370-z. Epub 2023 Mar 20. PMID- 36933241 OWN - NLM STAT- MEDLINE DCOM- 20230512 LR - 20230512 IS - 1078-6791 (Print) IS - 1078-6791 (Linking) VI - 29 IP - 4 DP - 2023 May TI - Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. PG - 6-17 LID - AT7382 [pii] AB - CONTEXT: Bladder cancer is the fourth-most-common cancer in males in the U.S., who develop about 90% of the high-grade, carcinoma in situ (CIS) of non-muscle involved disease (NMIBC). Smoking and occupational carcinogens are well-known causes. For females without known risk factors, bladder cancer can be regarded as a sentinel environmental cancer. It's also one of the costliest to treat due to its high rate of recurrence. No treatment innovations have occurred in nearly two decades; intravesical instillation of Bacillus Calmette-Guerin (BCG), an agent in short supply globally, or Mitomycin-C (MIT-C) is effective in about 60% of cases. Cases refractory to BCG and MIT-C often undergo cystectomy, a procedure with numerous impacts on life styles and potential complications. The recent completion of a small Phase I trial of mistletoe in cancer patients that have exhausted known treatments at Johns Hopkins provides corroboration of its safety, with 25 % showing no disease progression. OBJECTIVE: The study examined the benefits of pharmacologic ascorbate (PA) and mistletoe for a nonsmoking female patient with an environmental history of NMIBC refractory to BCG, in a non-smoking female with exposures in childhood and early adult life to several known carcinogens, including ultrafine particulate air pollution, benzene, toluene, and other organic solvents, aromatic amines and engine exhausts, and possibly arsenic in water. DESIGN: The research team performed an integrative oncology case study on pharmacologic ascorbate (PA) and mistletoe, both agents shown to activate NK cells, enhance growth and maturation of T-cells, and induce dose-dependent pro-apoptotic cell death, suggesting shared and potentially synergistic mechanisms. SETTING: The study began at the University of Ottawa Medical Center in Canada with treatment continuing over six years at St. Johns Hospital Center in Jackson, Wyoming, and George Washington University Medical Center for Integrative Medicine, with surgical, cytological, and pathological evaluations at University of California San Francisco Medical Center. PARTICIPANT: The patient in the case study was a 76-year-old, well-nourished, athletic, nonsmoking female with high-grade CIS of the bladder. Her cancer was considered to be a sentinel environmental cancer. INTERVENTION: Intravenous pharmacologic ascorbate (PA) and subcutaneous mistletoe (three times weekly) and intravenous and intravesical mistletoe (once weekly) were employed for an 8-week induction treatment, using a dose-escalation protocol as detailed below. Maintenance therapy was carried out with the same protocol for three weeks every three months for two years. RESULTS: The patient has experienced a cancer-free outcome following 78 months of treatments that incorporated intravesical, intravenous, and subcutaneous mistletoe; intravenous PA; a program of selected nutraceuticals; exercise; and other supplementary treatments. CONCLUSIONS: This study is the first reported instance of combined treatments to achieve complete remission for high-grade NMIBC refractory to BCG and MIT-C, using intravesical, subcutaneous, and intravenous mistletoe and intravenous PA. It includes pharmacological information on possible mechanisms. In light of the global shortage of BCG, the high proportion of cases refractory to BCG and MIT-C, the unproven use of costly off-label pharmaceuticals, such as gemcitabine, and the relative cost-effectiveness of mistletoe and PA, clinicians should give serious consideration to employing these combined functional medicine treatments for BCG- and MIT-C-refractory NMIBC. Further research is needed with additional patients that can advance our understanding, including standardization of methods for systematically evaluating combined therapies-blinded and non-blinded, nomenclature regarding mistletoe preparation, doses, concentrations, regimes of administration, lengths of treatment, targeted cancer types, and other aspects. FAU - Davis, Devra AU - Davis D FAU - Seely, Dugald AU - Seely D FAU - Morash, Christopher AU - Morash C FAU - Armstrong, Jennifer AU - Armstrong J FAU - Meng, Maxwell AU - Meng M FAU - Lowe, Phillip AU - Lowe P FAU - Kogan, Mikhail AU - Kogan M LA - eng PT - Journal Article PL - United States TA - Altern Ther Health Med JT - Alternative therapies in health and medicine JID - 9502013 RN - 0 (BCG Vaccine) RN - 0 (Antineoplastic Agents) RN - 50SG953SK6 (Mitomycin) RN - 0 (Carcinogens) SB - IM MH - Humans MH - Male MH - Adult MH - Female MH - Aged MH - BCG Vaccine/therapeutic use MH - *Mistletoe MH - Urinary Bladder/pathology MH - *Antineoplastic Agents/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Mitomycin/adverse effects MH - *Carcinoma in Situ/drug therapy/pathology MH - Carcinogens MH - Neoplasm Recurrence, Local/chemically induced/drug therapy EDAT- 2023/03/19 06:00 MHDA- 2023/05/12 07:06 CRDT- 2023/03/18 15:52 PHST- 2023/05/12 07:06 [medline] PHST- 2023/03/19 06:00 [pubmed] PHST- 2023/03/18 15:52 [entrez] AID - AT7382 [pii] PST - ppublish SO - Altern Ther Health Med. 2023 May;29(4):6-17. PMID- 36928373 OWN - NLM STAT- MEDLINE DCOM- 20230615 LR - 20241231 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 72 IP - 7 DP - 2023 Jul TI - Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. PG - 1971-1989 LID - 10.1007/s00262-023-03376-9 [doi] AB - Bladder cancer (BC) can be divided into two subgroups depending on invasion of the muscular layer: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Its aggressiveness is associated, inter alia, with genetic aberrations like losses of 1p, 6q, 9p, 9q and 13q; gain of 5p; or alterations in the p53 and p16 pathways. Moreover, there are reported metabolic disturbances connected with poor diagnosis-for example, enhanced aerobic glycolysis, gluconeogenesis or haem catabolism.Currently, the primary way of treatment method is transurethral resection of the bladder tumour (TURBT) with adjuvant Bacillus Calmette-Guerin (BCG) therapy for NMIBC or radical cystectomy for MIBC combined with chemotherapy or immunotherapy. However, intravesical BCG immunotherapy and immune checkpoint inhibitors are not efficient in every case, so appropriate biomarkers are needed in order to select the proper treatment options. It seems that the success of immunotherapy depends mainly on the tumour microenvironment (TME), which reflects the molecular disturbances in the tumour. TME consists of specific conditions like hypoxia or local acidosis and different populations of immune cells including tumour-infiltrating lymphocytes, natural killer cells, neutrophils and B lymphocytes, which are responsible for shaping the response against tumour neoantigens and crucial pathways like the PD-L1/PD-1 axis.In this review, we summarise holistically the impact of the immune system, genetic alterations and metabolic changes that are key factors in immunotherapy success. These findings should enable better understanding of the TME complexity in case of NMIBC and causes of failures of current therapies. CI - (c) 2023. The Author(s). FAU - Semeniuk-Wojtas, Aleksandra AU - Semeniuk-Wojtas A AD - Oncology Department, Medical University of Warsaw, Warsaw, Poland. asemeniukwojtas@gmail.com. FAU - Poddebniak-Strama, Karolina AU - Poddebniak-Strama K AD - Oncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland. FAU - Modzelewska, Magdalena AU - Modzelewska M AD - Pathomorphology Department, Medical University of Warsaw, Warsaw, Poland. FAU - Baryla, Maksymilian AU - Baryla M AD - Oncology Department, Medical University of Warsaw, Warsaw, Poland. FAU - Dziag-Dudek, Ewelina AU - Dziag-Dudek E AD - Oncology Department, Medical University of Warsaw, Warsaw, Poland. FAU - Syrylo, Tomasz AU - Syrylo T AD - Department of General, Active and Oncological Urology, Military Institute of Medicine, Warsaw, Poland. FAU - Gornicka, Barbara AU - Gornicka B AD - Pathomorphology Department, Medical University of Warsaw, Warsaw, Poland. FAU - Jakiela, Anna AU - Jakiela A AD - Oncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland. FAU - Stec, Rafal AU - Stec R AD - Oncology Department, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20230316 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/pathology MH - Immunotherapy MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Adjuvants, Immunologic PMC - PMC10264486 OTO - NOTNLM OT - Bladder cancer OT - Cancer phenotype OT - Immunotheraphy OT - Microenvironment OT - NMIBC COIS- The authors did not receive support from any organization for the submitted work. The authors have no competing interests to declare that are relevant to the content of this article. EDAT- 2023/03/18 06:00 MHDA- 2023/06/15 06:42 PMCR- 2023/03/16 CRDT- 2023/03/17 09:06 PHST- 2022/06/23 00:00 [received] PHST- 2023/01/09 00:00 [accepted] PHST- 2023/06/15 06:42 [medline] PHST- 2023/03/18 06:00 [pubmed] PHST- 2023/03/17 09:06 [entrez] PHST- 2023/03/16 00:00 [pmc-release] AID - 10.1007/s00262-023-03376-9 [pii] AID - 3376 [pii] AID - 10.1007/s00262-023-03376-9 [doi] PST - ppublish SO - Cancer Immunol Immunother. 2023 Jul;72(7):1971-1989. doi: 10.1007/s00262-023-03376-9. Epub 2023 Mar 16. PMID- 36924379 OWN - NLM STAT- MEDLINE DCOM- 20230323 LR - 20230502 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 95 IP - 1 DP - 2023 Mar 15 TI - Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study. PG - 11026 LID - 10.4081/aiua.2023.11026 [doi] AB - INTRODUCTION: The presence of blood in the urine should be promptly investigated to rule out urological malignancies, bladder cancer being the most frequent. Given its frequency among general population and the lack of unlimited health resources in an era of cost-effectiveness, it is important to prioritize patients with higher risk of malignancy. OBJECTIVES: To identify predictive factors of bladder cancer among patients presenting with hematuria. PATIENTS AND METHODS: We retrospectively reviewed 296 cases referred to our department for hematuria. We evaluated different demographic, clinical and ultrasound features to uncover possible associations with diagnosis of bladder cancer in those patients, to estimate the individual risk of being diagnosed with bladder cancer during the investigation of hematuria. RESULTS: A total of 296 patients were studied for hematuria between January 1, 2017 and December 31, 2019, 23.6% of those having ultimately bladder cancer confirmed after transurethral resection. Older age, male gender (OR 2.727, p = 0.069), a history of smoking (OR 3.84, p < 0.05), recurrent hematuria (OR 3.396, p < 0.05) and positive ultrasound exam for bladder cancer (OR 30.423, p < 0.05) were identified as predictors of bladder cancer in patients with hematuria. CONCLUSIONS: This study suggests that it is possible to reliably estimate the risk of bladder cancer in patients with hematuria, using clinical and imaging data to help defining who should be investigated first and in whom the investigation could be postponed. FAU - Jarimba, Roberto AU - Jarimba R AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra; Faculty of Medicine, University of Coimbra. rjarimba@gmail.com. FAU - Quaresma, Vasco AU - Quaresma V AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra. vpdquaresma@gmail.com. FAU - Pedroso Lima, Joao AU - Pedroso Lima J AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra; Faculty of Medicine, University of Coimbra. Joaopedrosolima@gmail.com. FAU - Eliseu, Miguel AU - Eliseu M AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra; Faculty of Medicine, University of Coimbra. mgl.nobre@gmail.com. FAU - Tavares da Silva, Edgar AU - Tavares da Silva E AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra; Faculty of Medicine, University of Coimbra. edsilva.elv@gmail.com. FAU - Moreira, Pedro AU - Moreira P AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra. pedronetomoreira@gmail.com. FAU - Figueiredo, Arnaldo AU - Figueiredo A AD - Urology and Renal Transplantation Department, Centro Hospitalar e Universitario de Coimbra, Coimbra; Faculty of Medicine, University of Coimbra. ajcfigueiredo@gmail.com. LA - eng PT - Journal Article DEP - 20230315 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Humans MH - Male MH - Retrospective Studies MH - *Hematuria/epidemiology/etiology MH - *Urinary Bladder Neoplasms/complications/diagnosis/epidemiology MH - Urologic Surgical Procedures MH - Smoking EDAT- 2023/03/17 06:00 MHDA- 2023/03/24 06:00 CRDT- 2023/03/16 06:33 PHST- 2022/11/20 00:00 [received] PHST- 2022/11/22 00:00 [accepted] PHST- 2023/03/17 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2023/03/16 06:33 [entrez] AID - 10.4081/aiua.2023.11026 [doi] PST - epublish SO - Arch Ital Urol Androl. 2023 Mar 15;95(1):11026. doi: 10.4081/aiua.2023.11026. PMID- 36924368 OWN - NLM STAT- MEDLINE DCOM- 20230323 LR - 20230502 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 95 IP - 1 DP - 2023 Feb 22 TI - TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting. PG - 11171 LID - 10.4081/aiua.2023.11171 [doi] AB - To the Editor, Bladder cancer (BCa) is the second most common cancer in urological clinical practice, after prostate adenocarcinoma. Usually occurs in patients between 60 and 70 years old, three times more frequently in men than women. About 75% of bladder cancer are pTa or pT1, even more frequently considering a population younger than 40 years old. Early detection is of paramount importance since allows to find tumors when they are still superficial and therefore with a better prognosis. FAU - Leonardi, Rosario AU - Leonardi R AD - Musumeci GECAS Clinic, Gravina di Catania (CT). leonardi.r@tiscali.it. FAU - Vecco, Francesco AU - Vecco F AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova. francesco.vecco@gmail.com. FAU - Iacona, Gabriele AU - Iacona G AD - Musumeci GECAS Clinic, Gravina di Catania (CT). gabryiac@yahoo.it. FAU - Calarco, Alessandro AU - Calarco A AD - Department of Urology, "Cristo Re" Hospital, Rome. alecalarco@gmail.com. FAU - Mantica, Guglielmo AU - Mantica G AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova. guglielmo.mantica@gmail.com. LA - eng PT - Journal Article DEP - 20230222 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Male MH - Humans MH - Middle Aged MH - Aged MH - Adult MH - Outpatients MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - Prognosis MH - *Prostatic Neoplasms MH - Neoplasm Recurrence, Local/surgery EDAT- 2023/03/17 06:00 MHDA- 2023/03/24 06:00 CRDT- 2023/03/16 06:33 PHST- 2023/01/18 00:00 [received] PHST- 2023/01/21 00:00 [accepted] PHST- 2023/03/17 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2023/03/16 06:33 [entrez] AID - 10.4081/aiua.2023.11171 [doi] PST - epublish SO - Arch Ital Urol Androl. 2023 Feb 22;95(1):11171. doi: 10.4081/aiua.2023.11171. PMID- 36916547 OWN - NLM STAT- MEDLINE DCOM- 20230530 LR - 20230530 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 9 DP - 2023 May TI - Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67 correlation in bladder cancer in 3.0-T MRI. PG - 10462-10472 LID - 10.1002/cam4.5782 [doi] AB - OBJECTIVE: To investigate the value of 3.0T MRI multi-directional diffusion-weighted imaging (DWI) combined with T2WI morphological features and lesion distribution in preoperative prediction of muscle layer invasion of bladder cancer (BC) and the correlation with postoperative Ki-67. MATERIALS AND METHODS: This retrospective study enrolled patients with BC between 2019 and 2021. Patients with muscular invasive bladder cancer (MIBC) or non-muscular invasive BC (NMIBC) were also analyzed by preoperative 3.0T MRI aFostic efficacy. RESULTS: A total of 186 patients were enrolled. About 27 patients with MIBC (35 lesions in total) and 62 with NMIBC (99 lesions in total). We found the tumor with a larger size, a wide base, and a smaller apparent dispersion coefficient (ADC) value and normalized ADC(nADC) value, without a stalk, presenting a greater risk of muscle invasion. ADC value, nADC value, maximum diameter, and stalk were independently associated with muscle invasion. Lesions located at the bladder fundus or involvement of multiple sites were independently associated with muscle invasion compared to the bladder body. In combination with morphological features, the AUCs of ADC and nADC showed accuracies of 0.925 and 0.947-0.951, respectively. TADC and nTADC showed the best diagnostic efficacy in multiple respects. KI-67 LI was negatively correlated with ADC and nADC values. CONCLUSIONS: This is the first report in which we found Multi-directional DWI combined with T2WI in 3.0T MRI can be used to predict the muscle layer invasion of bladder cancer. ADC values reflect the muscular invasion of bladder cancer and show a moderate negative correlation with Ki-67. It is especially suitable for bladder cancer patients with renal insufficiency or tumor recurrence. CI - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Zhang, Wei AU - Zhang W AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Radiology, Fujian Provincial Hospital, Fuzhou, China. FAU - Zhang, Zhichao AU - Zhang Z AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Radiology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China. FAU - Xiao, Weixiong AU - Xiao W AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Radiology, Fujian Provincial Hospital, Fuzhou, China. FAU - Wang, Yiqian AU - Wang Y AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Radiology, Fujian Provincial Hospital, Fuzhou, China. FAU - Ye, Liefu AU - Ye L AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Urology, Fujian Provincial Hospital, Fuzhou, China. FAU - Wei, Yongbao AU - Wei Y AUID- ORCID: 0000-0003-3114-9214 AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Urology, Fujian Provincial Hospital, Fuzhou, China. FAU - Luo, Min AU - Luo M AD - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. AD - Department of Radiology, Fujian Provincial Hospital, Fuzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230314 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Ki-67 Antigen) SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - Ki-67 Antigen MH - Retrospective Studies MH - Neoplasm Recurrence, Local/diagnostic imaging MH - Magnetic Resonance Imaging MH - Diffusion Magnetic Resonance Imaging/methods MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Muscles/pathology PMC - PMC10225208 OTO - NOTNLM OT - bladder cancer OT - diffusion-weighted imaging OT - magnetic resonance imaging OT - neoplasm staging COIS- The author has no conflict of interest to declare. EDAT- 2023/03/15 06:00 MHDA- 2023/05/30 06:42 PMCR- 2023/03/14 CRDT- 2023/03/14 07:13 PHST- 2023/02/17 00:00 [revised] PHST- 2022/10/30 00:00 [received] PHST- 2023/02/25 00:00 [accepted] PHST- 2023/05/30 06:42 [medline] PHST- 2023/03/15 06:00 [pubmed] PHST- 2023/03/14 07:13 [entrez] PHST- 2023/03/14 00:00 [pmc-release] AID - CAM45782 [pii] AID - 10.1002/cam4.5782 [doi] PST - ppublish SO - Cancer Med. 2023 May;12(9):10462-10472. doi: 10.1002/cam4.5782. Epub 2023 Mar 14. PMID- 36915891 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230315 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 12 IP - 2 DP - 2023 Feb 28 TI - Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer. PG - 228-240 LID - 10.21037/tau-22-494 [doi] AB - BACKGROUND: Galectin-1 (Gal-1) and Galectin-3 (Gal-3) are carbohydrate binding proteins with a wide range of biological activity, including regulation of cellular adhesion, proliferation, and apoptosis in solid tumors. Prior small studies have reported that Gal-3 expression is associated with progression of disease in urothelial carcinoma (UC), from non-muscle invasive UC progression to muscle invasive UC. We assessed Gal-1 and Gal-3 protein expression H-score utilizing a tissue microarray (TMA) created from 301 cystectomy specimens. METHODS: Immunohistochemistry for Gal-1 and Gal-3 was performed on TMA generated from tumor blocks from chemotherapy naive cystectomy specimens. The variable of interest, H-score, was defined as the product of the percentage of cells staining positive (0-100) and intensity score (0-3) scored by a single pathologist. Survival end points were analyzed using Kaplan-Meier and Cox Proportional Hazards methods. Clinical data including Charlson Comorbidity Index (CCI), pathologic tumor (T) stage, tumor size, node stage, and surgical margins, were included in multivariable analysis. RESULTS: We found that Gal-1 and Gal-3 expression correlated with intratumoral T stage (median Gal-1 H-score was 0 across non-invasive tissue types and 200 in invasive, P<0.01 and median Gal-3 score was 270 across non-invasive tissue types and 70 in invasive, P<0.01). However, the highest intratumoral H-score per cystectomy core did not independently predict for recurrence-free survival (RFS) (Gal-1: HR =1.02, P=0.44, Gal-3: HR =1.01, P=0.65) or OS (Gal-1: HR =1.02, P=0.44, Gal-3: HR =1.01, P=0.72) in this cohort. Significant intratumoral heterogeneity was present for both Gal-1 and Gal-3, with an average difference between the highest and lowest H score was 95 for Gal-1 and 109 for Gal-3 for cystectomy specimens with more than one biopsy. CONCLUSIONS: Gal-1 and Gal-3 H-score per bladder did not independently predict for RFS or OS. Intra-tumoral Gal-1/Gal-3 heterogeneity complicates the use of Gal-1 and Gal-3 expression as a prognostic biomarker. Future studies should consider the evaluation of serum and urinary galectins as an approach to mitigate tumor heterogeneity. CI - 2023 Translational Andrology and Urology. All rights reserved. FAU - Zhu, Jason AU - Zhu J AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Livasy, Chad AU - Livasy C AD - Carolinas Pathology Group, Charlotte, NC, USA. FAU - Donahue, Erin E AU - Donahue EE AD - Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA. FAU - Symanowski, James T AU - Symanowski JT AD - Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA. FAU - Grigg, Claud M AU - Grigg CM AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Brown, Landon C AU - Brown LC AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Matulay, Justin T AU - Matulay JT AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Kearns, James T AU - Kearns JT AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Raghavan, Derek AU - Raghavan D AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Burgess, Earle F AU - Burgess EF AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Clark, Peter E AU - Clark PE AD - Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. LA - eng PT - Journal Article DEP - 20230207 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC10005997 OTO - NOTNLM OT - (Gal-3) urothelial carcinoma OT - Galectin-1 (Gal-1) OT - galectin-3 OT - tumor heterogeneity COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-494/coif). EFB reports honorarium fees from Exelixis and AstraZeneca, consulting relationship with Johnson and Johnson, and grants from Pfizer and Astellas, and owns stock in Exelixis, Becton Dickinson, Calithera Biosciences, Medtronic, Macrogenics, Arvinas, Autolus. The other authors have no conflicts of interest to declare. EDAT- 2023/03/15 06:00 MHDA- 2023/03/15 06:01 PMCR- 2023/02/28 CRDT- 2023/03/14 02:14 PHST- 2022/07/25 00:00 [received] PHST- 2022/12/15 00:00 [accepted] PHST- 2023/03/14 02:14 [entrez] PHST- 2023/03/15 06:00 [pubmed] PHST- 2023/03/15 06:01 [medline] PHST- 2023/02/28 00:00 [pmc-release] AID - tau-12-02-228 [pii] AID - 10.21037/tau-22-494 [doi] PST - ppublish SO - Transl Androl Urol. 2023 Feb 28;12(2):228-240. doi: 10.21037/tau-22-494. Epub 2023 Feb 7. PMID- 36915877 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230315 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 12 IP - 2 DP - 2023 Feb 28 TI - Accuracy of actual stage prediction using Vesical Imaging Reporting and Data System (VI-RADS) before radical cystectomy for urothelial carcinoma in SUPER-UC-Cx. PG - 168-175 LID - 10.21037/tau-22-704 [doi] AB - BACKGROUND: Previous studies using the Vesical Imaging Reporting and Data System (VI-RADS) to predict muscle-invasive bladder cancer (MIBC) had some limitations. Most studies were performed with transurethral resection of bladder tumor (TUR-BT) specimens with few samples. This study was conducted to address these shortcomings and confirm the accuracy of VI-RADS for bladder cancer. METHODS: This study used data from the Seoul National University Prospectively Enrolled Registry for Urothelial Cancer-Radical Cystectomy (SUPER-UC-Cx). Patients who underwent multiparametric magnetic resonance imaging (mp-MRI) before radical cystectomy (RC) were included in this study between March 2020 and March 2022. All images were reported by radiologists and reviewed by two urologists. The patient characteristics and clinical information were blinded during the review. The performance of qualitative and quantitative variables in predicting muscle layer invasion or perivesical fat infiltration was verified by receiver operating characteristic (ROC) curve analysis. RESULTS: Of 208 patients, 182 (87.5%) underwent mp-MRI before RC. Twenty-three patients with non-urothelial carcinoma, inappropriate MRI scans, and bladder filling were excluded. Cut-off for muscle invasion, VI-RADS score of 4 had the highest area under the curve (AUC) (sensitivity 0.84; specificity 0.93; accuracy 0.90; positive predictive value (PPV) 0.84; negative predictive value (NPV) 0.93, and AUC 0.88). Cut-off for perivesical fat invasion and VI-RADS score of 5 had the highest AUC (sensitivity, 0.78; specificity, 0.99; accuracy, 0.95; PPV, 0.96; NPV, 0.95; and AUC, 0.89). CONCLUSIONS: VI-RADS is a good predictor of bladder cancer staging before RC and is especially helpful in predicting muscle invasion and perivesical fat infiltration. CI - 2023 Translational Andrology and Urology. All rights reserved. FAU - Kim, Si Hyun AU - Kim SH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Han, Jang Hee AU - Han JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Seung-Hwan AU - Jeong SH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Sang Youn AU - Kim SY AD - Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Taek Min AU - Kim TM AD - Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Cho, Jeong Yeon AU - Cho JY AD - Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article DEP - 20230203 PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC10006012 OTO - NOTNLM OT - Vesical Imaging Reporting and Data System (VI-RADS) OT - bladder cancer OT - cancer staging OT - magnetic resonance imaging (MRI) OT - radical cystectomy (RC) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-704/coif). JHK serves as an unpaid editorial board member of Translational Andrology and Urology from January 2022 to December 2023. The other authors have no conflicts of interest to declare. EDAT- 2023/03/15 06:00 MHDA- 2023/03/15 06:01 PMCR- 2023/02/28 CRDT- 2023/03/14 02:14 PHST- 2022/10/26 00:00 [received] PHST- 2023/01/16 00:00 [accepted] PHST- 2023/03/14 02:14 [entrez] PHST- 2023/03/15 06:00 [pubmed] PHST- 2023/03/15 06:01 [medline] PHST- 2023/02/28 00:00 [pmc-release] AID - tau-12-02-168 [pii] AID - 10.21037/tau-22-704 [doi] PST - ppublish SO - Transl Androl Urol. 2023 Feb 28;12(2):168-175. doi: 10.21037/tau-22-704. Epub 2023 Feb 3. PMID- 36910609 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230314 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: A meta-analysis of observational studies. PG - 1097637 LID - 10.3389/fonc.2023.1097637 [doi] LID - 1097637 AB - BACKGROUND: This meta-analysis was conducted to compare cancer recurrence and survival rates in patients with bladder cancer receiving surgery under general anesthesia alone (i.e., GA group) or regional anesthesia (RA) with or without GA (i.e., RA +/- GA group). METHODS: Literature search on Cochrane library, EMBASE, Google scholar, and Medline databases was performed to identify all relevant studies from inception to April 30, 2022. The primary outcome was cancer recurrence rate, while the secondary outcomes included overall survival rate and cancer-specific survival rate. Subgroup analyses were performed based on study design [(Propensity-score matching (PSM) vs. no-PSM)] and type of surgery [transurethral resection of bladder tumor (TURBT) vs. radical cystectomy]. RESULTS: Ten retrospective studies with a total of 13,218 patients (RA +/- GA group n=4,884, GA group n=8,334) were included. There was no difference between RA +/- GA group and GA group in age, the proportion of males, severe comorbidities, the proportion of patients receiving chemotherapy, and the pathological findings (all p >0.05). Patients in the RA +/- GA group had significantly lower rate of bladder cancer recurrence [odds ratio (OR): 0.74, 95%CI: 0.61 to 0.9, p=0.003, I(2 =) 24%, six studies] compared to those in the GA group. Subgroup analyses based on study design revealed a consistent finding, while the beneficial effect of RA +/- GA on reducing cancer recurrence was only significant in patients receiving TURBT (p=0.02), but not in those undergoing radical cystectomy (p=0.16). There were no significant differences in overall survival rate and cancer-specific survival rate between RA +/- GA and GA groups. CONCLUSIONS: For patients receiving surgery for bladder cancer, the application of regional anesthesia with or without general anesthesia is associated with significant decrease in cancer recurrence, especially in patients undergoing TURBT for non-muscle invasive bladder cancer. Because of the limited number of studies included and potential confounding factors, our results should be interpreted carefully. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022328134. CI - Copyright (c) 2023 Illias, Yu, Wu, Cata, Tsai and Hung. FAU - Illias, Amina M AU - Illias AM AD - Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Yu, Kai-Jie AU - Yu KJ AD - Department of Urology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Wu, Shao-Chun AU - Wu SC AD - Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cata, Juan P AU - Cata JP AD - Department of Anesthesiology and Perioperative Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. FAU - Tsai, Yung-Fong AU - Tsai YF AD - Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hung, Kuo-Chuan AU - Hung KC AD - Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan. AD - School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230222 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9992181 OTO - NOTNLM OT - bladder cancer OT - cancer recurrence OT - general anesthesia OT - meta-analysis OT - regional anesthesia OT - survival rate COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/03/14 06:00 MHDA- 2023/03/14 06:01 PMCR- 2023/01/01 CRDT- 2023/03/13 04:15 PHST- 2022/11/14 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/03/13 04:15 [entrez] PHST- 2023/03/14 06:00 [pubmed] PHST- 2023/03/14 06:01 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1097637 [doi] PST - epublish SO - Front Oncol. 2023 Feb 22;13:1097637. doi: 10.3389/fonc.2023.1097637. eCollection 2023. PMID- 36906510 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20250626 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 3 DP - 2023 Jun TI - A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. PG - 251-262 LID - S2588-9311(23)00040-8 [pii] LID - 10.1016/j.euo.2023.02.008 [doi] AB - CONTEXT: Bladder-sparing strategies (BSSs) have been proposed for the treatment of muscle-invasive bladder cancer (MIBC) patients achieving clinical complete response (cCR) to initial systemic treatment to avoid toxicity related to radical cystectomy. OBJECTIVE: To systematically review the current literature evaluating oncological outcomes of BSSs in patients achieving cCR to initial systemic treatment for localized MIBC. EVIDENCE ACQUISITION: A computerized bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting oncological outcomes of MIBC patients undergoing either surveillance or radiation therapy after achieving cCR to initial systemic treatment. Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 23 noncomparative prospective or retrospective studies published between 1990 and 2021. The mean bladder and metastatic recurrence rates (range) as well as the mean bladder preservation rate (BPR; range) were calculated, and overall survival (OS) was extracted from included reports. EVIDENCE SYNTHESIS: Overall, 16 and seven studies evaluated surveillance (n = 610) and radiation therapy (n = 175) in MIBC patients achieving cCR to initial systemic treatment, respectively. With regard to surveillance, the median follow-up ranged from 10 to 120 mo, with a mean bladder recurrence rate of 43% (0-71%), including 65% of non-muscle-invasive bladder cancer (NMIBC) and 35% of MIBC recurrences. The mean BPR was 73% (49-100%). The mean metastatic recurrence rate was 9% (0-27%), while 5-yr OS rates ranged from 64% to 89%. With regard to radiation therapy, the median follow-up ranged from 12 to 60 mo, with a mean bladder recurrence rate of 15% (0-29%), including 24% of NMIBC, 43% of MIBC, and 33% of unspecified recurrences. The mean BPR was 74% (71-100%). The mean metastatic recurrence rate was 17% (0-22%), while the 4-yr OS rate was 79%. CONCLUSIONS: Our systematic review showed that only low-level evidence supports the effectiveness of BSSs in selected patients achieving cCR to initial systemic treatment for localized MIBC. These preliminary findings highlight the need for further prospective comparative research to demonstrate its efficacy. PATIENT SUMMARY: We reviewed studies evaluating bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Based on low-level evidence, we observed that selected patients could benefit from surveillance or radiation therapy in this setting, but prospective comparative research is requested to confirm their efficacy. CI - Copyright (c) 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Department of Urology, Pitie Salpetriere Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France; Division of Urology, Geneva University Hospitals, Geneva, Switzerland. FAU - Lenfant, Louis AU - Lenfant L AD - Department of Urology, Pitie Salpetriere Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France. FAU - Mir, Carmen AU - Mir C AD - Servicio de Urologia, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Giannarini, Gianluca AU - Giannarini G AD - Urology Unit, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Urology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain. FAU - Albersen, Maarten AU - Albersen M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie Salpetriere Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - Department of Urology, Pitie Salpetriere Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France. Electronic address: thomas.seisen@aphp.fr. CN - EAU Section of Oncological Urology (ESOU) Board LA - eng PT - Journal Article PT - Systematic Review DEP - 20230309 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/radiotherapy/pathology MH - Cystectomy MH - Recurrence OTO - NOTNLM OT - Bladder-sparing strategy OT - Clinical complete response OT - Localized muscle-invasive bladder cancer OT - Neoadjuvant OT - Systemic treatment EDAT- 2023/03/12 06:00 MHDA- 2023/06/19 13:08 CRDT- 2023/03/11 22:08 PHST- 2022/09/01 00:00 [received] PHST- 2022/12/14 00:00 [revised] PHST- 2023/02/08 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/11 22:08 [entrez] AID - S2588-9311(23)00040-8 [pii] AID - 10.1016/j.euo.2023.02.008 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Jun;6(3):251-262. doi: 10.1016/j.euo.2023.02.008. Epub 2023 Mar 9. PMID- 36900247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230313 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 5 DP - 2023 Feb 24 TI - Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure? LID - 10.3390/cancers15051455 [doi] LID - 1455 AB - CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (p = 0.52). Fifteen patients (12.9%) experienced progression to muscle-invasive bladder cancer with no significant difference between patients with and without CIS (2-year PFS rate = 71.8% vs. 88.8%, p = 0.32). In multivariate analysis, CIS was not a significant prognostic factor in terms of recurrence or progression. In conclusion, CIS may not be considered a contraindication to HIVEC, as there is no significant association between CIS and the risk of progression or recurrence after treatment. FAU - Anastay, Vassili AU - Anastay V AD - Department of Urology, La Conception Hospital, Aix-Marseille University, Assistance Publique des Hopitaux de Marseille (APHM), 13007 Marseille, France. FAU - Baboudjian, Michael AU - Baboudjian M AUID- ORCID: 0000-0001-6935-3873 AD - Department of Urology, La Conception Hospital, Aix-Marseille University, Assistance Publique des Hopitaux de Marseille (APHM), 13007 Marseille, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, University de Paris, APHP, Saint Louis Hospital, 75010 Paris, France. FAU - Lebacle, Cedric AU - Lebacle C AUID- ORCID: 0000-0002-8215-2918 AD - Department of Urology, Kremlin-Bicetre Academic Hospital, 94270 Bicetre, France. FAU - Chamouni, Alexandre AU - Chamouni A AD - Department of Urology, University de Paris, APHP, Saint Louis Hospital, 75010 Paris, France. FAU - Irani, Jacques AU - Irani J AUID- ORCID: 0000-0002-6321-9144 AD - Department of Urology, Kremlin-Bicetre Academic Hospital, 94270 Bicetre, France. FAU - Tillou, Xavier AU - Tillou X AD - Department of Urology, Centre Hospitalier Universitaire Caen, 14033 Caen, France. FAU - Waeckel, Thibaut AU - Waeckel T AD - Department of Urology, Centre Hospitalier Universitaire Caen, 14033 Caen, France. FAU - Monges, Arnaud AU - Monges A AD - Department of Urology, Polyclinique du Parc Rambot, Hopital Prive de Provence, 13080 Aix-en-Provence, France. FAU - Duperron, Celine AU - Duperron C AD - Department of Urology, University Hospital Francois Mitterrand, 21000 Dijon, France. FAU - Gravis, Gwenaelle AU - Gravis G AD - Department of Medical Oncology, Institut Paoli Calmettes Cancer Center, 13009 Marseille, France. FAU - Walz, Jochen AU - Walz J AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes Cancer Center, 13009 Marseille, France. FAU - Lechevallier, Eric AU - Lechevallier E AD - Department of Urology, La Conception Hospital, Aix-Marseille University, Assistance Publique des Hopitaux de Marseille (APHM), 13007 Marseille, France. FAU - Pignot, Geraldine AU - Pignot G AUID- ORCID: 0000-0001-5282-9134 AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes Cancer Center, 13009 Marseille, France. AD - Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232 Boulevard de Ste Marguerite, 13009 Marseille, France. LA - eng PT - Journal Article DEP - 20230224 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10001134 OTO - NOTNLM OT - BCG failure OT - CIS OT - HIVEC OT - NMIBC OT - bladder cancer OT - progression OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2023/03/12 06:00 MHDA- 2023/03/12 06:01 PMCR- 2023/02/24 CRDT- 2023/03/11 01:05 PHST- 2023/01/29 00:00 [received] PHST- 2023/02/22 00:00 [revised] PHST- 2023/02/23 00:00 [accepted] PHST- 2023/03/11 01:05 [entrez] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/12 06:01 [medline] PHST- 2023/02/24 00:00 [pmc-release] AID - cancers15051455 [pii] AID - cancers-15-01455 [pii] AID - 10.3390/cancers15051455 [doi] PST - epublish SO - Cancers (Basel). 2023 Feb 24;15(5):1455. doi: 10.3390/cancers15051455. PMID- 36900156 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230313 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 5 DP - 2023 Feb 21 TI - A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers15051364 [doi] LID - 1364 AB - BACKGROUND: Bladder carcinoma has elevated morbimortality due to its high recurrence and progression in localized disease. A better understanding of the role of the tumor microenvironment in carcinogenesis and response to treatment is needed. METHODS: Peripheral blood and samples of urothelial bladder cancer and adjacent healthy urothelial tissue were collected from 41 patients and stratified in low- and high-grade urothelial bladder cancer, excluding muscular infiltration or carcinoma in situ. Mononuclear cells were isolated and labeled for flow cytometry analysis with antibodies aimed at identifying specific subpopulations within T lymphocytes, myeloid cells and NK cells. RESULTS: In peripheral blood and tumor samples, we detected different percentages of CD4+ and CD8+ lymphocytes, monocyte and myeloid-derived suppressor cells, as well as differential expression of activation- and exhaustion-related markers. Conversely, only a significant increase in bladder total monocytes was found when comparing bladder and tumor samples. Interestingly, we identified specific markers differentially expressed in the peripheral blood of patients with different outcomes. CONCLUSION: The analysis of host immune response in patients with NMIBC may help to identify specific markers that allow optimizing therapy and patient follow-up. Further investigation is needed to establish a strong predictive model. FAU - Celada Luis, Guillermo AU - Celada Luis G AD - Department of Urology, Hospital Universitario de La Princesa, 28006 Madrid, Spain. FAU - Albers Acosta, Eduardo AU - Albers Acosta E AUID- ORCID: 0000-0002-0091-6209 AD - Department of Urology, Hospital Universitario de La Princesa, 28006 Madrid, Spain. FAU - de la Fuente, Hortensia AU - de la Fuente H AD - Department of Immunology, Hospital Universitario de la Princesa, 28006 Madrid, Spain. FAU - Velasco Balanza, Clara AU - Velasco Balanza C AD - Department of Urology, Hospital Universitario de La Princesa, 28006 Madrid, Spain. FAU - Arroyo Correas, Montserrat AU - Arroyo Correas M AD - Department of Immunology, Hospital Universitario de la Princesa, 28006 Madrid, Spain. FAU - Romero-Laorden, Nuria AU - Romero-Laorden N AD - Department of Medical Oncology, Hospital Universitario La Princesa, 28006 Madrid, Spain. FAU - Alfranca, Arantzazu AU - Alfranca A AD - Department of Immunology, Hospital Universitario de la Princesa, 28006 Madrid, Spain. FAU - Olivier Gomez, Carlos AU - Olivier Gomez C AD - Department of Urology, Hospital Universitario de La Princesa, 28006 Madrid, Spain. LA - eng GR - PI19/00549/Instituto de Salud Carlos III/ GR - PI22/01542/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20230221 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10000243 OTO - NOTNLM OT - T-cells OT - biomarkers OT - bladder cancer OT - immune response OT - immunotherapy OT - tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2023/03/12 06:00 MHDA- 2023/03/12 06:01 PMCR- 2023/02/21 CRDT- 2023/03/11 01:05 PHST- 2023/01/30 00:00 [received] PHST- 2023/02/17 00:00 [revised] PHST- 2023/02/18 00:00 [accepted] PHST- 2023/03/11 01:05 [entrez] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/12 06:01 [medline] PHST- 2023/02/21 00:00 [pmc-release] AID - cancers15051364 [pii] AID - cancers-15-01364 [pii] AID - 10.3390/cancers15051364 [doi] PST - epublish SO - Cancers (Basel). 2023 Feb 21;15(5):1364. doi: 10.3390/cancers15051364. PMID- 36900148 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230313 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 5 DP - 2023 Mar 6 TI - Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma. LID - 10.3390/diagnostics13051004 [doi] LID - 1004 AB - Upper tract urothelial carcinoma (UTUC) is a relatively rare, but highly malignant, disease with an estimated annual incidence of 2 cases per 100,000 people. The main surgical treatment modalities for UTUC are radical nephroureterectomy (RNU) with bladder cuff resection. After surgery, intravesical recurrence (IVR) can occur in up to 47% of patients, and 75% of them present with non-muscle invasive bladder cancer (NMIBC). However, there are few studies focused on the diagnosis and treatment of postoperatively recurrent bladder cancer for patients with previous UTUC history (UTUC-BC), and many of the influencing factors are still controversial. In this article, we performed a narrative review of the recent literature, mainly summarizing the factors influencing postoperative IVR in patients with UTUC and discussing the subsequent prevention, monitoring, and treatment tools for it. FAU - Hu, Xinfeng AU - Hu X AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Xue, Yufan AU - Xue Y AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Zhu, Guodong AU - Zhu G AUID- ORCID: 0000-0002-4514-5479 AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. LA - eng GR - No. 2020SF-119/The Research Funds on Social Development from the Department of Science and Technology of Shaanxi Province of China/ GR - No. xjj2018zyts34/The Fundamental Research Funds for the Central Universities of China/ PT - Journal Article PT - Review DEP - 20230306 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10000489 OTO - NOTNLM OT - intravesical recurrence OT - non-muscle invasive bladder cancer OT - risk factor OT - treatment OT - upper tract urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2023/03/12 06:00 MHDA- 2023/03/12 06:01 PMCR- 2023/03/06 CRDT- 2023/03/11 01:05 PHST- 2023/01/19 00:00 [received] PHST- 2023/02/08 00:00 [revised] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/03/11 01:05 [entrez] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/12 06:01 [medline] PHST- 2023/03/06 00:00 [pmc-release] AID - diagnostics13051004 [pii] AID - diagnostics-13-01004 [pii] AID - 10.3390/diagnostics13051004 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Mar 6;13(5):1004. doi: 10.3390/diagnostics13051004. PMID- 36897417 OWN - NLM STAT- MEDLINE DCOM- 20230515 LR - 20230515 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 6 DP - 2023 Jun TI - En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis. PG - 3820-3828 LID - 10.1245/s10434-023-13227-7 [doi] AB - BACKGROUND: We aimed to assess the clinical, oncological, and pathological impact of en bloc resection of bladder tumors (ERBT) compared with conventional transurethral resection of bladder tumors (cTURBT) for pT1 high-grade (HG) bladder cancer. PATIENTS AND METHODS: We retrospectively analyzed the record of 326 patients (cTURBT: n = 216, ERBT: n = 110) diagnosed with pT1 HG bladder cancer at multiple institutions. The cohorts were matched by one-to-one propensity scores based on patient and tumor demographics. Recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and perioperative and pathologic outcomes were compared. The prognosticators of RFS and PFS were analyzed using the Cox proportional hazard model. RESULTS: After matching, 202 patients (cTURBT: n = 101, ERBT: n = 101) were retained. There were no differences in perioperative outcomes between the two procedures. The 3-year RFS, PFS, and CSS were not different between the two procedures (p = 0.7, 1, and 0.7, respectively). Among patients who underwent repeat transurethral resection (reTUR), the rate of any residue on reTUR was significantly lower in the ERBT group (cTURBT: 36% versus ERBT: 15%, p = 0.029). Adequate sampling of muscularis propria (83% versus 93%, p = 0.029) and diagnostic rates of pT1a/b substaging (90% versus 100%, p < 0.001) were significantly better in ERBT specimen compared with cTURBT specimen. On multivariable analyses, pT1a/b substaging was a prognosticator of disease progression. CONCLUSIONS: In patients with pT1HG bladder cancer, ERBT had similar perioperative and mid-term oncologic outcomes compared with cTURBT. However, ERBT improves the quality of resection and specimen, yielding less residue on reTUR and yielding superior histopathologic information such as substaging. CI - (c) 2023. Society of Surgical Oncology. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan. FAU - Okada, Yohei AU - Okada Y AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Yorozu, Takashi AU - Yorozu T AD - Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sakanaka, Keigo AU - Sakanaka K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Urabe, Fumihiko AU - Urabe F AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shimoda, Masayuki AU - Shimoda M AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. junmiki.jikei@gmail.com. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20230310 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2023 Jun;30(6):3829-3830. doi: 10.1245/s10434-023-13291-z. PMID: 36907962 MH - Humans MH - Retrospective Studies MH - Propensity Score MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Cystectomy MH - Urologic Surgical Procedures/methods EDAT- 2023/03/11 06:00 MHDA- 2023/05/15 06:42 CRDT- 2023/03/10 11:17 PHST- 2022/10/04 00:00 [received] PHST- 2023/01/23 00:00 [accepted] PHST- 2023/05/15 06:42 [medline] PHST- 2023/03/11 06:00 [pubmed] PHST- 2023/03/10 11:17 [entrez] AID - 10.1245/s10434-023-13227-7 [pii] AID - 10.1245/s10434-023-13227-7 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Jun;30(6):3820-3828. doi: 10.1245/s10434-023-13227-7. Epub 2023 Mar 10. PMID- 36891448 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240302 IS - 0975-7651 (Print) IS - 0976-6952 (Electronic) IS - 0975-7651 (Linking) VI - 14 IP - 1 DP - 2023 Mar TI - Invasive Micropapillary Urothelial Carcinoma: an Uncommon and Underreported Variant in Cystectomy Specimens. PG - 222-227 LID - 10.1007/s13193-022-01692-7 [doi] AB - Conventional urothelial carcinoma is the most common histological type of urinary bladder carcinoma. The latest edition of the WHO classification of tumours of the urothelial tract lays special emphasis on the ability of urothelial tumours to exhibit divergent differentiation with multiple histologic variants and a diverse genomic landscape. The presence of a micropapillary component (MPC) in urothelial carcinoma is associated with high-grade disease and poor response to intravesical chemotherapy. The present study aims to enumerate the clinicohistological features of urothelial carcinomas with micropapillary differentiation. Slides from 144 radical cystectomy specimens received over 6 years were reviewed independently by two pathologists. A predominant histological pattern along with co-existing pathology was noted. Of these, five cases were pure micropapillary carcinomas, four had conventional urothelial carcinoma with a MPC, one had a microscopic tumour at the mucosal surface, and two cases showed micropapillary histology in the lymph node metastasis, following transurethral resection of bladder tumour and Bacillus Calmette-Guerin therapy. The tumours with pure micropapillary carcinoma presented with a higher pathological stage and poor overall survival. Organ and lymph node metastasis was noted in five and eight cases, respectively, of which six showed a micropapillary pattern in the lymph nodes. Micropapillary urothelial carcinoma is a rare and aggressive variant of urothelial carcinoma with unique histologic features. This variant is often missed and underreported in biopsy and surgical resection specimens. Since the presence of MPC confers a poorer prognosis, the identification and reporting of this entity are important. CI - (c) The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Prasad, Pallavi AU - Prasad P AUID- ORCID: 0000-0003-4270-8763 AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, New diagnostic block, Room no. 11First floor, C-block, Lucknow, 226014 India. GRID: grid.263138.d. ISNI: 0000 0000 9346 7267 FAU - Baranwal, Harshita AU - Baranwal H AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, New diagnostic block, Room no. 11First floor, C-block, Lucknow, 226014 India. GRID: grid.263138.d. ISNI: 0000 0000 9346 7267 FAU - Agrawal, Vinita AU - Agrawal V AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, New diagnostic block, Room no. 11First floor, C-block, Lucknow, 226014 India. GRID: grid.263138.d. ISNI: 0000 0000 9346 7267 LA - eng PT - Journal Article DEP - 20230202 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC9986161 OTO - NOTNLM OT - Cystectomy OT - Histopathology OT - Metastasis OT - Micropapillary carcinoma OT - Urinary bladder OT - Urothelial carcinoma COIS- Conflict of InterestThe authors declare no competing interests. EDAT- 2023/03/10 06:00 MHDA- 2023/03/10 06:01 PMCR- 2024/03/01 CRDT- 2023/03/09 02:14 PHST- 2022/05/16 00:00 [received] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/03/09 02:14 [entrez] PHST- 2023/03/10 06:00 [pubmed] PHST- 2023/03/10 06:01 [medline] PHST- 2024/03/01 00:00 [pmc-release] AID - 1692 [pii] AID - 10.1007/s13193-022-01692-7 [doi] PST - ppublish SO - Indian J Surg Oncol. 2023 Mar;14(1):222-227. doi: 10.1007/s13193-022-01692-7. Epub 2023 Feb 2. PMID- 36890105 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230807 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 4 DP - 2023 Aug TI - Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities. PG - 366-375 LID - S2588-9311(23)00043-3 [pii] LID - 10.1016/j.euo.2023.02.011 [doi] AB - CONTEXT: Bladder cancer (BLCA) is a highly prevalent tumour and a health problem worldwide, especially among men. Recent work has highlighted the relevance of the tumour microenvironment (TME) in cancer biology with translational implications. Cancer-associated fibroblasts (CAFs) are a prominent, heterogeneous population of cells in the TME. CAFs have been associated with tumour development, progression, and poor prognosis in several neoplasms. However, their role in BLCA has not yet been exploited deeply. OBJECTIVE: To review the role of CAFs in BLCA biology and provide an understanding of CAF origin, subtypes, markers, and phenotypic and functional characteristics to improve patient management. EVIDENCE ACQUISITION: A PubMed search was performed to review manuscripts published using the terms "cancer associated fibroblast" and "bladder cancer" or "urothelial cancer". All abstracts were reviewed, and the full content of all relevant manuscripts was analysed. In addition, selected manuscripts on CAFs in other tumours were considered. EVIDENCE SYNTHESIS: CAFs have been studied less extensively in BLCA than in other tumours. Thanks to new techniques, such as single-cell RNA-seq and spatial transcriptomics, it is now possible to accurately map and molecularly define the phenotype of fibroblasts in normal bladder and BLCA. Bulk transcriptomic analyses have revealed the existence of subtypes among both non-muscle-invasive and muscle-invasive BLCA; these subtypes display distinct features regarding their CAF content. We provide a higher-resolution map of the phenotypic diversity of CAFs in these tumour subtypes. Preclinical studies and recent promising clinical trials leverage on this knowledge through the combined targeting of CAFs or their effectors and the immune microenvironment. CONCLUSIONS: Current knowledge of BLCA CAFs and the TME is being increasingly applied to improve BLCA therapy. There is a need to acquire a deeper understanding of CAF biology in BLCA. PATIENT SUMMARY: Tumour cells are surrounded by nontumoural cells that contribute to the determination of the behaviour of cancers. Among them are cancer-associated fibroblasts. The "neighbourhoods" established through these cellular interactions can now be studied with much greater resolution. Understanding these features of tumours will contribute to the designing of more effective therapies, especially in relationship to bladder cancer immunotherapy. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Caramelo, Belen AU - Caramelo B AD - Instituto de Investigacion Marques de Valdecilla, IDIVAL, Santander, Spain; Hospital Sierrallana, Torrelavega, Spain. FAU - Zagorac, Sladjana AU - Zagorac S AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain. FAU - Corral, Sonia AU - Corral S AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain. FAU - Marques, Miriam AU - Marques M AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain; CIBERONC, Madrid, Spain. Electronic address: mmarques@cnio.es. FAU - Real, Francisco X AU - Real FX AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain; CIBERONC, Madrid, Spain; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: freal@cnio.es. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230306 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM CIN - Eur Urol Oncol. 2023 Aug;6(4):376-377. doi: 10.1016/j.euo.2023.05.005. PMID: 37268449 MH - Humans MH - Male MH - Urinary Bladder MH - *Cancer-Associated Fibroblasts MH - *Urinary Bladder Neoplasms/therapy MH - *Carcinoma, Transitional Cell MH - Biology MH - Tumor Microenvironment OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Fibroblasts OT - Immune checkpoint inhibitors OT - Immunotherapy OT - Molecular subtypes OT - Signatures OT - Single-cell RNA-seq OT - Tumour microenvironment OT - Urothelial carcinoma EDAT- 2023/03/09 06:00 MHDA- 2023/07/31 06:42 CRDT- 2023/03/08 22:09 PHST- 2022/08/11 00:00 [received] PHST- 2022/12/28 00:00 [revised] PHST- 2023/02/08 00:00 [accepted] PHST- 2023/07/31 06:42 [medline] PHST- 2023/03/09 06:00 [pubmed] PHST- 2023/03/08 22:09 [entrez] AID - S2588-9311(23)00043-3 [pii] AID - 10.1016/j.euo.2023.02.011 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Aug;6(4):366-375. doi: 10.1016/j.euo.2023.02.011. Epub 2023 Mar 6. PMID- 36882246 OWN - NLM STAT- MEDLINE DCOM- 20230309 LR - 20260109 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 3 DP - 2023 Mar 7 TI - EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial. PG - e071304 LID - 10.1136/bmjopen-2022-071304 [doi] LID - e071304 AB - INTRODUCTION: Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50-65% of patients undergoing RC experience perioperative complications. The risk, severity and impact of these complications is associated with a patient's preoperative cardiorespiratory fitness, nutritional and smoking status and presence of anxiety and depression. There is emerging evidence supporting multimodal prehabilitation as a strategy to reduce the risk of complications and improve functional recovery after major cancer surgery. However, for bladder cancer the evidence is still limited. The aim of this study is to investigate the superiority of a multimodal prehabilitation programme versus standard-of-care in terms of reducing perioperative complications in patients with bladder cancer undergoing RC. METHODS AND ANALYSIS: This multicentre, open label, prospective, randomised controlled trial, will include 154 patients with bladder cancer undergoing RC. Patients are recruited from eight hospitals in The Netherlands and will be randomly (1:1) allocated to the intervention group receiving a structured multimodal prehabilitation programme of approximately 3-6 weeks, or to the control group receiving standard-of-care. The primary outcome is the proportion of patients who develop one or more grade >/=2 complications (according to the Clavien-Dindo classification) within 90 days of surgery. Secondary outcomes include cardiorespiratory fitness, length of hospital stay, health-related quality of life, tumour tissue biomarkers of hypoxia, immune cell infiltration and cost-effectiveness. Data collection will take place at baseline, before surgery and 4 and 12 weeks after surgery. ETHICS AND DISSEMINATION: Ethical approval for this study was granted by the Medical Ethics Committee NedMec (Amsterdam, The Netherlands) under reference number 22-595/NL78792.031.22. Results of the study will be published in international peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05480735. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Akdemir, Emine AU - Akdemir E AUID- ORCID: 0000-0003-4220-5242 AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Center for Quality of Life, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Sweegers, Maike G AU - Sweegers MG AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Center for Quality of Life, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Rundqvist, Helene AU - Rundqvist H AD - Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. FAU - Meijer, Richard P AU - Meijer RP AD - Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Leliveld-Kors, Annemarie M AU - Leliveld-Kors AM AD - Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Rutten, Vera C AU - Rutten VC AUID- ORCID: 0000-0003-2452-5357 AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Koldewijn, Evert L AU - Koldewijn EL AD - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands. FAU - Bos, Siebe D AU - Bos SD AD - Department of Urology, Noordwest Hospital Group, Alkmaar, The Netherlands. FAU - Wijburg, Carl J AU - Wijburg CJ AD - Department of Urology, Rijnstate Hospital, Arnhem, The Netherlands. FAU - Marcelissen, Tom A T AU - Marcelissen TAT AD - Department of Urology, Maastricht University Medical Center+, Maastricht, The Netherlands. FAU - Bongers, Bart C AU - Bongers BC AD - Department of Nutrition and Movement Sciences, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. AD - Department of Surgery, Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. FAU - Retel, Valesca P AU - Retel VP AUID- ORCID: 0000-0002-5624-3234 AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. FAU - van Harten, Wim H AU - van Harten WH AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands. FAU - May, Anne M AU - May AM AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Groen, Wim G AU - Groen WG AD - Department of Medicine for Older People, Amsterdam University Medical Center Locatie VUmc, Amsterdam, The Netherlands. AD - Amsterdam Public Health, Aging & Later Life, Amsterdam, The Netherlands. FAU - Stuiver, Martijn M AU - Stuiver MM AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands m.stuiver@nki.nl. AD - Center of Expertise Urban Vitality, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands. LA - eng SI - ClinicalTrials.gov/NCT05480735 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230307 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Cystectomy MH - Preoperative Exercise MH - Prospective Studies MH - Quality of Life MH - *Urinary Bladder Neoplasms/surgery MH - Biomarkers, Tumor MH - Randomized Controlled Trials as Topic MH - Multicenter Studies as Topic MH - Equivalence Trials as Topic PMC - PMC10008243 OTO - NOTNLM OT - Nutritional support OT - REHABILITATION MEDICINE OT - SURGERY OT - Urological tumours COIS- Competing interests: CJW received a research grant from ZonMw and gives courses on robot-assisted radical cystectomy during conferences entitled with EAU. TATM received consulting fees as member of the advisory board prostate cancer of Janssen-Cilag B.V. BCB participates on a Data Safety Monitoring Board of an international prehabilitation study, is board member of Netherlands Society of Human Movement sciences, member of Exercise is Medicine of Vereniging voor Sportgeneeskunde and member of the Scientific Committee of Fit4Surgery. RPM received research grants from Janssen, Roche and Astellas, an educational grant from Merck, received consulting fees from Merck, MSD, Janssen, Bristol-Myers Squibb Company, received support for attending the 2022 Global Congress on Bladder Cancer, and is EAU Panel member of the Muscle Invasive Bladder Cancer Guideline. MMS is member of the Scientific Committee of Fit4Surgery and board member of Onconet. EDAT- 2023/03/08 06:00 MHDA- 2023/03/10 06:00 PMCR- 2023/03/07 CRDT- 2023/03/07 21:03 PHST- 2023/03/07 21:03 [entrez] PHST- 2023/03/08 06:00 [pubmed] PHST- 2023/03/10 06:00 [medline] PHST- 2023/03/07 00:00 [pmc-release] AID - bmjopen-2022-071304 [pii] AID - 10.1136/bmjopen-2022-071304 [doi] PST - epublish SO - BMJ Open. 2023 Mar 7;13(3):e071304. doi: 10.1136/bmjopen-2022-071304. PMID- 36870676 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20230401 IS - 1876-7737 (Electronic) IS - 1874-3919 (Linking) VI - 278 DP - 2023 Apr 30 TI - Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients. PG - 104865 LID - S1874-3919(23)00054-4 [pii] LID - 10.1016/j.jprot.2023.104865 [doi] AB - Bladder cancer (BCa) is a prevalent disease with a high risk of aggressive recurrence in T1-stage patients. Despite the efforts to anticipate recurrence, a reliable method has yet to be developed. In this work, we employed high-resolution mass spectrometry to compare the urinary proteome of T1-stage BCa patients with recurring versus non-recurring disease to uncover actionable clinical information predicting recurrence. All patients were diagnosed with T1-stage bladder cancer between the ages of 51 and 91, and urine samples were collected before medical intervention. Our results suggest that the urinary myeloperoxidase to cubilin ratio could be used as a new tool for predicting recurrence and that dysregulation of the inflammatory and immune systems may be a key driver of disease worsening. Furthermore, we identified neutrophil degranulation and neutrophil extracellular traps (NETs) as key pathways in the progression of T1-stage BCa. We propose that proteomics follow-up of the inflammatory and immune systems may be useful for monitoring the effectiveness of therapy. SIGNIFICANCE: This article describes how proteomics can be used to characterize tumor aggressiveness in patients with the same diagnosis of bladder cancer (BCa). LC-MS/MS in combination with label free quantification (LFQ) were used to explore potential protein and pathway level changes related to the aggressiveness of the disease in 13 and 17 recurring and non-recurring T1 stage BCa patients. We have shown that the MPO/CUBN protein ratio is a candidate for a urine prognosis tool in BCa. Furthermore, we identify dysregulation of inflammation process as a driver for BCa recurrence and progression. Moreover, we propose using proteomics to track the effectiveness of therapy in the inflammatory and immune systems. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Carvalho, Luis B AU - Carvalho LB AD - BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica 2829-516, Portugal; PROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica 2825-182, Portugal. FAU - Martinez, Jose Luis Capelo AU - Martinez JLC AD - BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica 2829-516, Portugal; PROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica 2825-182, Portugal. FAU - Lodeiro, Carlos AU - Lodeiro C AD - BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica 2829-516, Portugal; PROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica 2825-182, Portugal. FAU - Bento, Rafael AU - Bento R AD - BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica 2829-516, Portugal; PROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica 2825-182, Portugal. FAU - Dhir, Rajiv AU - Dhir R AD - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Morrissey, Jeremiah J AU - Morrissey JJ AD - Department of Anesthesiology, Division of Clinical and Translational Research, School of Medicine and Siteman Cancer Center, Washington University, St. Louis, MO, USA. FAU - Pinheiro, Luis Campos AU - Pinheiro LC AD - Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal.; NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal. FAU - Medeiros, Mariana AU - Medeiros M AD - Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal.; NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal. FAU - Santos, Hugo M AU - Santos HM AD - BIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica 2829-516, Portugal; PROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica 2825-182, Portugal; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: hmsantos@fct.unl.pt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230302 PL - Netherlands TA - J Proteomics JT - Journal of proteomics JID - 101475056 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Chromatography, Liquid MH - Follow-Up Studies MH - *Tandem Mass Spectrometry MH - *Urinary Bladder Neoplasms/diagnosis MH - Prognosis MH - Biomarkers, Tumor OTO - NOTNLM OT - Bladder cancer OT - Cubilin (CUBN) OT - Mass spectrometry OT - Neutrophil extracellular traps, myeloperoxidase (MPO) OT - Urine proteomics EDAT- 2023/03/05 06:00 MHDA- 2023/03/28 06:00 CRDT- 2023/03/04 19:33 PHST- 2022/11/30 00:00 [received] PHST- 2023/02/03 00:00 [revised] PHST- 2023/02/27 00:00 [accepted] PHST- 2023/03/05 06:00 [pubmed] PHST- 2023/03/28 06:00 [medline] PHST- 2023/03/04 19:33 [entrez] AID - S1874-3919(23)00054-4 [pii] AID - 10.1016/j.jprot.2023.104865 [doi] PST - ppublish SO - J Proteomics. 2023 Apr 30;278:104865. doi: 10.1016/j.jprot.2023.104865. Epub 2023 Mar 2. PMID- 36867328 OWN - NLM STAT- MEDLINE DCOM- 20230405 LR - 20231003 IS - 1865-8652 (Electronic) IS - 0741-238X (Linking) VI - 40 IP - 4 DP - 2023 Apr TI - Patient Blood Management in Transurethral Resection Surgery: Overview and Strategy Analysis from a French Tertiary Hospital. PG - 1830-1837 LID - 10.1007/s12325-023-02466-5 [doi] AB - INTRODUCTION: Since Patient blood management (PBM) suggests a bundle of measures aiming to reduce perioperative blood transfusion because preoperative anemia and blood transfusion are associated with poor postoperative outcomes. There is a lack of data on the effect of PBM in patients undergoing transurethral resection of prostate (TURP) or bladder tumor (TURBT). We aimed to assess the bleeding risk in TURP and TURBT procedures and the effect of preoperative anemia on postoperative morbimortality. METHODS: A single-center retrospective observational cohort study was conducted in a tertiary hospital in Marseille, France. All patients undergoing TURP or TURBT were included in 2020 and divided into two groups: preoperative anemia (n = 19) and no preoperative anemia (n = 59). We recorded demographic characteristics, preoperative hemoglobin concentration, iron deficiency markers, preoperative initiation of a treatment for anemia, perioperative bleeding, and postoperative outcomes up to 30 days including blood transfusion, hospital readmission, reintervention, infection, and mortality. RESULTS: Baseline characteristics were comparable between groups. No patient had iron deficiency markers and no prescription of iron was initiated before surgery. No major bleeding was reported during surgery. Postoperative anemia was found in 21 patients, including 16 (76%) in the preoperative anemia group and 5 (24%) in the non-preoperative anemia group. One patient of each group received a blood transfusion after surgery. No significant differences in 30-day outcomes were reported. CONCLUSION: Our study suggests that TURP and TURBT are not associated with a high-risk of postoperative bleeding. In such procedures, adherence PBM strategies do not seem beneficial. Since recent guidelines recommend restricting preoperative testing, our results may help to improve preoperative risk stratification. CI - (c) 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature. FAU - Pastene, Bruno AU - Pastene B AUID- ORCID: 0000-0002-6836-3903 AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. bruno.pastene@ap-hm.fr. AD - Centre for Cardiovascular and Nutrition Research (C2VN), INRA, Aix Marseille University, INSERM, Marseille, France. bruno.pastene@ap-hm.fr. AD - Service d'anesthesie et reanimation-Hopital Nord-Batiment Etoile 1er Etage, Chemin des Bourrely, 13015, Marseille, France. bruno.pastene@ap-hm.fr. FAU - Bernard, Raphael AU - Bernard R AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Colin, Manon AU - Colin M AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Zunino, Claire AU - Zunino C AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Chabert-Vaudran, Lenaick AU - Chabert-Vaudran L AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Bastide, Cyrille AU - Bastide C AD - Department of Urology, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Zieleskiewicz, Laurent AU - Zieleskiewicz L AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. AD - Centre for Cardiovascular and Nutrition Research (C2VN), INRA, Aix Marseille University, INSERM, Marseille, France. FAU - Leone, Marc AU - Leone M AD - Department of Anesthesiology and Intensive Care, Hopital Nord, Hopitaux Universitaires de Marseille, Marseille, France. AD - Centre for Cardiovascular and Nutrition Research (C2VN), INRA, Aix Marseille University, INSERM, Marseille, France. LA - eng PT - Journal Article PT - Observational Study DEP - 20230303 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 MH - Male MH - Humans MH - *Transurethral Resection of Prostate/adverse effects/methods MH - Retrospective Studies MH - Tertiary Care Centers MH - *Anemia MH - Blood Transfusion MH - *Iron Deficiencies MH - Treatment Outcome MH - *Prostatic Hyperplasia/complications OTO - NOTNLM OT - Anemia OT - Anesthesia OT - Enhanced recovery after surgery OT - Mini-invasive surgery OT - Patient blood management OT - Postoperative outcomes OT - Transurethral resection of bladder tumor OT - Transurethral resection of prostate OT - Urology EDAT- 2023/03/04 06:00 MHDA- 2023/04/05 06:42 CRDT- 2023/03/03 11:19 PHST- 2022/12/22 00:00 [received] PHST- 2023/02/14 00:00 [accepted] PHST- 2023/04/05 06:42 [medline] PHST- 2023/03/04 06:00 [pubmed] PHST- 2023/03/03 11:19 [entrez] AID - 10.1007/s12325-023-02466-5 [pii] AID - 10.1007/s12325-023-02466-5 [doi] PST - ppublish SO - Adv Ther. 2023 Apr;40(4):1830-1837. doi: 10.1007/s12325-023-02466-5. Epub 2023 Mar 3. PMID- 36856518 OWN - NLM STAT- MEDLINE DCOM- 20230303 LR - 20230308 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 55 IP - 1 DP - 2023 Dec TI - A serum miRNAs signature for early diagnosis of bladder cancer. PG - 736-745 LID - 10.1080/07853890.2023.2172206 [doi] AB - BACKGROUND: Bladder cancer accounts for the most common type of urologic malignancy and presents high recurrence rate after surgical resection and adjuvant intravesical therapy. We aim to search for an early diagnostic biomarker in serum for bladder cancer in this study. METHODS: The expression profiles of miRNAs in serum samples of 112 bladder cancer patients and 112 healthy controls were detected with real-time polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve and area under curve (AUC) analysis were performed to assess the diagnostic efficiency of miRNAs. Stepwise logic regression analysis was used to construct a diagnostic signature with highest sensitivity and specificity. Bioinformatics analysis was applied to explore the potential biological functions and mechanisms of candidate miRNAs. RESULTS: Five miRNAs including miR-451a, miR-381-3p, miR-223-3p, miR-142-5p and miR-27b-3p were found differentially expressed in serum samples of bladder patients and healthy subjects. The diagnostic signature was constructed with miR-27b-3p, miR-381-3p and miR-451a. AUC of the three-miRNA signature was 0.894 (0.837-0.936, p < 0.001). The sensitivity and specificity of this signature were 86.90% and 77.38%, respectively, indicating that this signature has a good ability to diagnose bladder cancer. CONCLUSION: The three-miRNA signature we constructed has favorable diagnostic capacity and may be a promising non-invasive biomarker in the early diagnosis of bladder cancer.KEY MESSAGESThere is still no clinical utilization of serum miRNAs in the early detection of bladder cancer.We screened and constructed a three-miRNA signature with the sensitivity of 86.90% and specificity of 77.38% which may be a promising non-invasive biomarker in the early diagnosis of bladder cancer. FAU - Yu, Zuhu AU - Yu Z AD - Department of Urology, University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen, China. FAU - Lu, Chong AU - Lu C AD - Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen, China. AD - The Fifth Clinical Medical College of Anhui Medical University, Hefei, China. FAU - Lai, Yongqing AU - Lai Y AD - Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 RN - 0 (MicroRNAs) RN - 0 (MIRN381 microRNA, human) SB - IM MH - Humans MH - *MicroRNAs MH - Early Detection of Cancer MH - *Urinary Bladder Neoplasms MH - Area Under Curve MH - Combined Modality Therapy PMC - PMC9980012 OTO - NOTNLM OT - Bladder cancer OT - diagnosis OT - miRNA OT - serum biomarker COIS- No potential conflict of interest was reported by the author(s). EDAT- 2023/03/02 06:00 MHDA- 2023/03/04 06:00 PMCR- 2023/03/01 CRDT- 2023/03/01 09:33 PHST- 2023/03/01 09:33 [entrez] PHST- 2023/03/02 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2023/03/01 00:00 [pmc-release] AID - 2172206 [pii] AID - 10.1080/07853890.2023.2172206 [doi] PST - ppublish SO - Ann Med. 2023 Dec;55(1):736-745. doi: 10.1080/07853890.2023.2172206. PMID- 36853609 OWN - NLM STAT- MEDLINE DCOM- 20230302 LR - 20231107 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 6 IP - 2 DP - 2023 Feb 1 TI - Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. PG - e230849 LID - 10.1001/jamanetworkopen.2023.0849 [doi] LID - e230849 AB - IMPORTANCE: Due to the ongoing bacillus Calmette-Guerin (BCG) shortage, sequential intravesical gemcitabine and docetaxel has been increasingly used as first-line therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). However, data directly comparing these 2 therapies are lacking. OBJECTIVE: To compare the outcomes of patients with high-risk NMIBC treated with gemcitabine and docetaxel vs BCG. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted from January 1, 2011, to December 31, 2021. The median (IQR) duration of follow-up was 23 (12-33) months for patients receiving gemcitabine and docetaxel and 49 (27-79) months for patients receiving BCG. All patients were treated at the University of Iowa tertiary care center. A total of 312 patients with high-risk treatment-naive NMIBC were included; 174 patients were treated with BCG therapy and 138 were treated with gemcitabine and docetaxel therapy. EXPOSURES: After undergoing complete transurethral resection of bladder tumor, patients received either sequential intravesical gemcitabine, 1 g, and docetaxel, 37.5 mg, or 1 vial of BCG. Induction treatments were administered once per week for 6 weeks. Maintenance regimens were initiated if the patient was disease free at the first follow-up visit. MAIN OUTCOMES AND MEASURES: The primary outcome was high-grade recurrence-free survival (RFS). Survival probabilities were estimated using the Kaplan-Meier method. Cox regression models were used to evaluate the association of covariates with outcomes. Adverse events were reported using the Common Terminology Criteria for Adverse Events, version 5. RESULTS: Among 312 patients, the median (IQR) age was 73 (66-79) years; 255 patients (81.7%) were male and 292 (93.6%) were White. Baseline clinicopathological characteristics such as sex, smoking status, and pretreatment tumor pathology were similar between treatment groups. High-grade RFS estimates were 76% (95% CI, 69%-82%) at 6 months, 71% (95% CI, 64%-78%) at 12 months, and 69% (95% CI, 62%-76%) at 24 months in the BCG group and 92% (95% CI, 86%-95%) at 6 months, 85% (95% CI, 78%-91%) at 12 months, and 81% (95% CI, 72%-87%) at 24 months in the gemcitabine and docetaxel group. Multivariable Cox regression analyses controlled for age, sex, treatment year, and presence of carcinoma in situ revealed that treatment with gemcitabine and docetaxel was associated with better high-grade RFS (hazard ratio, 0.57; 95% CI, 0.33-0.97; P = .04) and RFS (hazard ratio, 0.56; 95% CI, 0.34-0.92; P = .02) than treatment with BCG. Induction therapy for BCG was associated with greater treatment discontinuation than induction therapy for gemcitabine and docetaxel (9.2% vs 2.9%; P = .02). CONCLUSIONS AND RELEVANCE: In this cohort study, gemcitabine and docetaxel therapy was associated with less high-grade disease recurrence and treatment discontinuation than BCG therapy. These findings suggest that, while awaiting results from an ongoing randomized clinical trial during the current BCG shortage, use of gemcitabine and docetaxel can be considered for recommendation in updated practice guidelines. FAU - McElree, Ian M AU - McElree IM AD - Carver College of Medicine, University of Iowa, Iowa City. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City. LA - eng GR - P30 CA086862/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (BCG Vaccine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - *BCG Vaccine/therapeutic use MH - Docetaxel/therapeutic use MH - Gemcitabine MH - Cohort Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies PMC - PMC9975907 COIS- Conflict of Interest Disclosures: Dr O'Donnell reported receiving grants from the John and Carol Walter Family Foundation during the conduct of the study and personal fees from Fidia Pharma, Merck & Co, Sesen Bio, Theralase Technologies, and Urogen Pharma outside the submitted work. No other disclosures were reported. EDAT- 2023/03/01 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/02/28 CRDT- 2023/02/28 11:47 PHST- 2023/02/28 11:47 [entrez] PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/28 00:00 [pmc-release] AID - 2801788 [pii] AID - zoi230055 [pii] AID - 10.1001/jamanetworkopen.2023.0849 [doi] PST - epublish SO - JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849. PMID- 36847812 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 3 DP - 2023 Mar TI - Open vs robotic intracorporeal Padua ileal bladder: functional outcomes of a single-centre RCT. PG - 739-746 LID - 10.1007/s00345-023-04312-3 [doi] AB - PURPOSE: Functional outcomes of robot-assisted (RA) radical cystectomy (RC) with intracorporeal orthotopic neobladder (i-ON) have been poorly investigated. The study aimed to report functional outcomes of a prospective randomized controlled trial (RCT) comparing open RC (ORC) and RARC with i-ON. METHODS: Inclusion criteria were cT2-4/N0/M0, or BCG-failure high-grade urothelial carcinoma, candidate to RC with curative intent. A covariate adaptive randomization process was used, based on the following variables: BMI, ASA score, haemoglobin levels, cT-stage, neoadjuvant chemotherapy, urinary diversion. Day-time continence was defined as "totally dryness", nigh-time continence as pad wetness 50%), and no significant difference was found compared with the non-sarcomatoid group. Overall, a proportion of sarcomatoid components >50% was a predictor of CSS and RFS. Sarcomatoid components markedly increased the risk of death and recurrence in muscle-invasive BC, but not in non-muscle-invasive BC. A higher proportion of sarcomatoid components was significantly associated with poorer survival. CI - Copyright: (c) Liu et al. FAU - Liu, Shuai AU - Liu S AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China. FAU - Yao, Yu AU - Yao Y AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China. FAU - Wang, Zhan-Kun AU - Wang ZK AD - Department of Urology, Qingdao Eighth People's Hospital, Qingdao, Shandong 266121, P.R. China. FAU - Sun, Li-Jiang AU - Sun LJ AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China. FAU - Zhang, Gui-Ming AU - Zhang GM AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China. LA - eng PT - Journal Article DEP - 20230202 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC9932695 OTO - NOTNLM OT - bladder cancer OT - prognosis OT - recurrence OT - sarcomatoid carcinoma OT - survival COIS- The authors declare that they have no competing interests. EDAT- 2023/02/24 06:00 MHDA- 2023/02/24 06:01 PMCR- 2023/02/02 CRDT- 2023/02/23 09:30 PHST- 2022/11/02 00:00 [received] PHST- 2023/01/13 00:00 [accepted] PHST- 2023/02/23 09:30 [entrez] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/02/24 06:01 [medline] PHST- 2023/02/02 00:00 [pmc-release] AID - OL-25-3-13690 [pii] AID - 10.3892/ol.2023.13690 [doi] PST - epublish SO - Oncol Lett. 2023 Feb 2;25(3):103. doi: 10.3892/ol.2023.13690. eCollection 2023 Mar. PMID- 36816151 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240912 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 4 IP - 2 DP - 2023 Mar TI - Oncological and functional outcomes of organ-preserving cystectomy versus standard radical cystectomy: A systematic review and meta-analysis. PG - 135-155 LID - 10.1002/bco2.189 [doi] AB - INTRODUCTION: Radical cystectomy (RC) is historically considered the gold standard treatment for muscle invasive and high-risk non-muscle invasive bladder cancer. However, this technique leaves the majority of patients of both sexes with poor sexual and urinary function. Organ-sparing cystectomy (OSC) techniques are emerging as an alternative to the standard procedure to preserve these functions, without compromising the oncological outcomes. We present a systematic review and meta-analysis of the published literature. METHODS: MEDLINE, Embase and Web of Science were systematically searched for eligible studies on 6 April 2021. Primary outcomes studied were both oncological outcomes, specifically overall recurrence, and functional outcomes, specifically sexual function, and daytime and nighttime continence. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated. The PROSPERO registration reference number was CRD42018118897. RESULTS: From 13 894 identified abstracts, 19 studies (1886 male and 305 female patients) were eligible for inclusion in this review. These studies included patients who underwent either whole prostate, prostate capsule, seminal vesicle, nerve, uterus, ovary, vagina and fallopian tube sparing techniques. Four studies included only female patients.Thirteen studies reported oncological outcomes, and overall recurrence rate was similar between the two groups (five studies; OR 0.73; 95% CI 0.38-1.40, p = 0.34). Thirteen studies reported on male sexual function. In men, OSC had significantly greater odds of retaining potency (five studies; OR 9.05; 95% CI 5.07-16.16, p < 0.00001). Fourteen studies (13 on males and 1 female) reported urinary outcomes. In men, OSC demonstrated greater odds of daytime (seven studies; OR 2.61; 95% CI 1.74 to 3.92, p < 0.00001) and nighttime continence (seven studies; OR 2.62; 95% CI 1.76 to 3.89, p < 0.00001). CONCLUSION: In carefully selected patients, OSC allows the potential to provide better sexual and urinary function without compromising oncological outcomes. There remains, however, a paucity of OSC studies in females. Further studies are required to make recommendations based on robust clinical evidence. CI - (c) 2022 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Clay, Reece AU - Clay R AUID- ORCID: 0000-0002-4034-1868 AD - GKT School of Medical Education King's College London London UK. AD - William Harvey Hospital East Kent Hospital University Foundation Trust Kent UK. FAU - Shaunak, Raghav AU - Shaunak R AUID- ORCID: 0000-0001-9919-0649 AD - GKT School of Medical Education King's College London London UK. AD - St Peter's Hospital Ashford and St Peter's Hospital NHS Trust Chertsey UK. FAU - Raj, Siddarth AU - Raj S AUID- ORCID: 0000-0002-6341-6615 AD - GKT School of Medical Education King's College London London UK. AD - University Hospital University Hospitals Coventry and Warwickshire NHS Trust Coventry UK. FAU - Light, Alexander AU - Light A AUID- ORCID: 0000-0001-7246-3651 AD - Imperial College London London UK. AD - Department of Surgery and Cancer Imperial College Healthcare NHS Trust London UK. FAU - Malde, Sachin AU - Malde S AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. FAU - El-Hage, Oussama AU - El-Hage O AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. FAU - Dasgupta, Prokar AU - Dasgupta P AUID- ORCID: 0000-0001-8690-0445 AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. FAU - Khan, Muhammed Shamim AU - Khan MS AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. FAU - Nair, Rajesh AU - Nair R AUID- ORCID: 0000-0003-1760-9608 AD - The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust Guy's Hospital London UK. LA - eng PT - Journal Article PT - Review DEP - 20221003 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC9931545 OTO - NOTNLM OT - continence OT - cystectomy OT - functional OT - oncological OT - organ sparing OT - radical OT - review OT - sexual OT - urology COIS- All authors declare no conflicts of interest as per the ICMJE COI. EDAT- 2023/02/24 06:00 MHDA- 2023/02/24 06:01 PMCR- 2022/10/03 CRDT- 2023/02/23 09:18 PHST- 2022/05/26 00:00 [received] PHST- 2022/08/04 00:00 [revised] PHST- 2022/08/14 00:00 [accepted] PHST- 2023/02/23 09:18 [entrez] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/02/24 06:01 [medline] PHST- 2022/10/03 00:00 [pmc-release] AID - BCO2189 [pii] AID - 10.1002/bco2.189 [doi] PST - epublish SO - BJUI Compass. 2022 Oct 3;4(2):135-155. doi: 10.1002/bco2.189. eCollection 2023 Mar. PMID- 36812902 OWN - NLM STAT- MEDLINE DCOM- 20230608 LR - 20230608 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 107 IP - 6 DP - 2023 TI - Predicting Complexity in Transurethral Resection of Bladder Tumours: External Validation and Modification of the Bladder Complexity Score. PG - 583-590 LID - 10.1159/000528926 [doi] AB - INTRODUCTION: First external validation of the Bladder Complexity Score (BCS) for predicting complex transurethral resection of bladder tumours (TURBT). METHODS: For BCS calculation, TURBTs performed at our institution between January 2018 and December 2019 were reviewed for the presence of preoperative characteristics listed in the Bladder Complexity Checklist (BCC). Receiver operating characteristics (ROC) analysis was used for BCS validation. To establish a modified BCS (mBCS) with maximum area under the curve (AUC), multivariable logistic regression (MLR) analysis was performed with all BCC-characteristics for different definitions of complex TURBT. RESULTS: 723 TURBTs were included in statistical analyses. Cohort's mean BCS was 11.2 +/- 2.4 points (range: 5.5-22 points). In ROC analysis, BCS could not predict complex TURBT (AUC 0.573 [95% CI: 0.517-0.628]). MLR identified tumour size (OR 2.662, p < 0.001), and tumour number > 10 (OR 6.390, p = 0.032) as sole predictors for the modified endpoint of complex TURBT defined as a procedure meeting > 1 criterion: incomplete resection, surgery > 1 h, intraoperative complication, postoperative complications Clavien-Dindo >/= III. mBCS increased the prediction to an AUC of 0.770 (95% CI: 0.667-0.874). CONCLUSION: In this first external validation, BCS remained an insufficient predictor of complex TURBT. mBCS requires reduced parameters, is more predictive and easier to apply in clinical practice. CI - (c) 2023 S. Karger AG, Basel. FAU - Grune, Britta AU - Grune B AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Kowalewski, Karl-Friedrich AU - Kowalewski KF AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Weiss, Christel AU - Weiss C AD - Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Neuberger, Manuel AU - Neuberger M AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Nientiedt, Malin AU - Nientiedt M AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Wenk, Maren Juliane AU - Wenk MJ AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Hartung, Friedrich Otto AU - Hartung FO AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Kriegmair, Maximilian Christian AU - Kriegmair MC AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Waldbillig, Frank AU - Waldbillig F AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. LA - eng PT - Journal Article DEP - 20230222 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - Transurethral Resection of Bladder MH - Urologic Surgical Procedures MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology OTO - NOTNLM OT - Bladder cancer OT - Checklist OT - Complexity OT - Complications OT - Transurethral resection of bladder tumours EDAT- 2023/02/23 06:00 MHDA- 2023/06/08 06:42 CRDT- 2023/02/22 18:23 PHST- 2022/07/09 00:00 [received] PHST- 2022/12/22 00:00 [accepted] PHST- 2023/06/08 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 18:23 [entrez] AID - 000528926 [pii] AID - 10.1159/000528926 [doi] PST - ppublish SO - Urol Int. 2023;107(6):583-590. doi: 10.1159/000528926. Epub 2023 Feb 22. PMID- 36812689 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230523 IS - 1530-0285 (Electronic) IS - 0893-3952 (Linking) VI - 36 IP - 5 DP - 2023 May TI - Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets. PG - 100120 LID - S0893-3952(23)00025-X [pii] LID - 10.1016/j.modpat.2023.100120 [doi] AB - Flat urothelial lesions are controversial diagnostic and prognostic urologic entities whose importance relies mainly on their ability to progress to muscle-invasive tumors via urothelial carcinoma in situ (CIS). However, the carcinogenetic progression of preneoplastic flat urothelial lesions is not well established. Moreover, predictive biomarkers and therapeutic targets of the highly recurrent and aggressive urothelial CIS lesion are lacking. Using a targeted next-generation sequencing (NGS) panel of 17 genes directly involved in bladder cancer pathogenesis, we investigated alterations of genes and pathways with clinical and carcinogenic implications on 119 samples of flat urothelium, including normal urothelium (n = 7), reactive atypia (n = 10), atypia of unknown significance ( n = 34), dysplasia ( n = 23), and CIS (n = 45). The majority of the flat lesions were tumor-associated but grossly/microscopically or temporally separated from the main tumor. Mutations were compared across flat lesions and concerning the concomitant urothelial tumor. Associations between genomic mutations and recurrence after intravesical bacillus Calmette-Guerin treatment were estimated with Cox regression analysis. TERT promoter mutations were highly prevalent in intraurothelial lesions but not in the normal or reactive urothelium, suggesting that it is a critical driver mutation in urothelial tumorigenesis. We found that synchronous atypia of unknown significance-dysplasia-CIS lesions without concomitant papillary urothelial carcinomas had a similar genomic profile that differed from atypia of unknown significance-dysplasia lesions associated with papillary urothelial carcinomas, which harbored significantly more FGFR3, ARID1A, and PIK3CA mutations. KRAS G12C and ERBB2 S310F/Y mutations were exclusively detected in CIS and were associated with recurrence after bacillus Calmette-Guerin treatment (P = .0006 and P = .01, respectively). This targeted NGS study revealed critical mutations involved in the carcinogenetic progression of flat lesions with putative pathobiological pathways. Importantly, KRAS G12C and ERBB2 S310F/Y mutations were identified as potential prognostic and therapeutic biomarkers for urothelial carcinoma. CI - Copyright (c) 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. FAU - Musangile, Fidele Y AU - Musangile FY AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Matsuzaki, Ibu AU - Matsuzaki I AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Iwamoto, Ryuta AU - Iwamoto R AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Sagan, Kanako AU - Sagan K AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Nishikawa, Mizuki AU - Nishikawa M AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Mikasa, Yurina AU - Mikasa Y AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Takahashi, Yuichi AU - Takahashi Y AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Kojima, Fumiyoshi AU - Kojima F AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. FAU - Hara, Isao AU - Hara I AD - Department of Urology, Wakayama Medical University, Wakayama, Japan. FAU - Murata, Shin-Ichi AU - Murata SI AD - Department of Human Pathology, Wakayama Medical University, Wakayama, Japan. Electronic address: smurata@wakayama-med.ac.jp. LA - eng PT - Journal Article DEP - 20230202 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (BCG Vaccine) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Urothelium/pathology MH - BCG Vaccine/metabolism MH - Proto-Oncogene Proteins p21(ras)/genetics MH - Biomarkers/metabolism MH - Hyperplasia/pathology MH - High-Throughput Nucleotide Sequencing MH - *Carcinoma in Situ/pathology OTO - NOTNLM OT - CIS OT - Next-generation sequencing OT - atypical urothelium OT - dysplasia OT - flat urothelial lesion OT - urothelial carcinoma EDAT- 2023/02/23 06:00 MHDA- 2023/05/22 06:42 CRDT- 2023/02/22 18:04 PHST- 2022/10/04 00:00 [received] PHST- 2023/01/05 00:00 [revised] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/05/22 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 18:04 [entrez] AID - S0893-3952(23)00025-X [pii] AID - 10.1016/j.modpat.2023.100120 [doi] PST - ppublish SO - Mod Pathol. 2023 May;36(5):100120. doi: 10.1016/j.modpat.2023.100120. Epub 2023 Feb 2. PMID- 36811732 OWN - NLM STAT- MEDLINE DCOM- 20231109 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 11 DP - 2023 Nov TI - Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. PG - 3195-3203 LID - 10.1007/s00345-023-04332-z [doi] AB - PURPOSE: To evaluate hyperthermic intravesical chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with non-muscle invasive bladder cancer (NMIBC) who fail bacillus Calmette-Guerin (BCG) therapy. METHODS: This is a multicenter retrospective series from a national database (7 expert centers). Between January 2016 and October 2021, patients treated with HIVEC for NMIBC who failed BCG have been included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it. RESULTS: A total of 116 patients treated with HIVEC and with a follow-up > 6 months were included in this study and retrospectively analyzed. The median follow-up was 20.6 months. The 12 month-RFS (recurrence-free survival) rate was 62.9%. The bladder preservation rate was 87.1%. Fifteen patients (12.9%) progressed to muscle infiltration, three of them having a metastatic disease at the time of progression. Predictive factors of progression were T1 stage, high grade and very high-risk tumors according to the EORTC classification. CONCLUSION: Chemohyperthermia using HIVEC achieved an RFS rate of 62.9% at 1 year and enabled a bladder preservation rate of 87.1%. However, the risk of progression to muscle-invasive disease is not negligible, particularly for patients with very high-risk tumors. In these patients who fail BCG, cystectomy should remain the standard of care and HIVEC may be discussed cautiously for patients who are not eligible for surgery and well informed of the risk of progression. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Pignot, Geraldine AU - Pignot G AUID- ORCID: 0000-0001-5282-9134 AD - Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, 232 Boulevard de Ste Marguerite, 13009, Marseille, France. pignotg@ipc.unicancer.fr. FAU - Baboudjian, Michael AU - Baboudjian M AD - Department of Urology and Kidney Transplantation, Aix-Marseille University, APHM, Conception Academic Hospital, Marseille, France. FAU - Lebacle, Cedric AU - Lebacle C AD - Department of Urology, Kremlin-Bicetre Academic Hospital, Bicetre, France. FAU - Chamouni, Alexandre AU - Chamouni A AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. FAU - Lechevallier, Eric AU - Lechevallier E AD - Department of Urology and Kidney Transplantation, Aix-Marseille University, APHM, Conception Academic Hospital, Marseille, France. FAU - Irani, Jacques AU - Irani J AD - Department of Urology, Kremlin-Bicetre Academic Hospital, Bicetre, France. FAU - Tillou, Xavier AU - Tillou X AD - Department of Urology, Centre Hospitalier Universitaire Caen, Caen, France. FAU - Waeckel, Thibaut AU - Waeckel T AD - Department of Urology, Centre Hospitalier Universitaire Caen, Caen, France. FAU - Monges, Arnaud AU - Monges A AD - Department of Urology, Polyclinique du Parc Rambot, Hopital Prive de Provence, Aix-en-Provence, France. FAU - Doisy, Laure AU - Doisy L AD - Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, 232 Boulevard de Ste Marguerite, 13009, Marseille, France. FAU - Walz, Jochen AU - Walz J AD - Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, 232 Boulevard de Ste Marguerite, 13009, Marseille, France. FAU - Gravis, Gwenaelle AU - Gravis G AD - Department of Medical Oncology, Institut Paoli Calmettes Cancer Center, Marseille, France. FAU - Mourey, Eric AU - Mourey E AD - Department of Urology, University Hospital Francois Mitterrand, Dijon, France. FAU - Duperron, Celine AU - Duperron C AD - Department of Urology, University Hospital Francois Mitterrand, Dijon, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230222 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Disease-Free Survival MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - BCG-unresponsive OT - Bladder cancer OT - Chemohyperthermia OT - Cystectomy OT - Progression OT - Recurrence EDAT- 2023/02/23 06:00 MHDA- 2023/11/09 06:42 CRDT- 2023/02/22 15:56 PHST- 2023/01/04 00:00 [received] PHST- 2023/02/07 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 15:56 [entrez] AID - 10.1007/s00345-023-04332-z [pii] AID - 10.1007/s00345-023-04332-z [doi] PST - ppublish SO - World J Urol. 2023 Nov;41(11):3195-3203. doi: 10.1007/s00345-023-04332-z. Epub 2023 Feb 22. PMID- 36809748 OWN - NLM STAT- MEDLINE DCOM- 20230608 LR - 20230608 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 107 IP - 6 DP - 2023 TI - Predictive Role of the Systemic Immune Inflammation Index for Intravesical BCG Response in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer. PG - 617-623 LID - 10.1159/000528740 [doi] AB - INTRODUCTION: In this study, we aimed to explore using the predictive role of systemic immune inflammation index (SII) for responses of intravesical Bacillus Calmette-Guerin (BCG) therapy in patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). METHODS: From 9 centers, we reviewed the data of patients treated for intermediate- and high-risk NMIBC between 2011 and 2021. All patients enrolled in the study presented with T1 and/or high-grade tumors on initial TURB had undergone re-TURB within 4-6 weeks after initial TURB and had received at least a 6-week course of intravesical BCG induction. SII was calculated with the formula SII = (P x N)/L, where P, N, and L refer to peripheral platelet, neutrophil, and lymphocyte counts, respectively. In patients with intermediate- and high-risk NMIBC, the clinicopathological features and follow-up data were evaluated to compare SII with other systemic inflammation-based prognostic indices. These included the neutrophil-to-lymphocyte ratio (NLR), platelet-to-neutrophil ratio (PNR), and platelet-to-lymphocyte ratio (PLR). RESULTS: A total of 269 patients were enrolled in the study. Median follow-up time was 39 months. Disease recurrence and progression were observed in 71 (26.4%) and 19 (7.1%) patients, respectively. For groups with and without disease recurrence in terms of NLR, PLR, PNR, and SII calculated prior to intravesical BCG treatment, no statistically significant differences were observed (p = 0.470, p = 0.247, p = 0.495, and p = 0.243, respectively). Moreover, there were also no statistically significant differences between the groups with and without disease progression in terms of NLR, PLR, PNR, and SII (p = 0.504, p = 0.165, p = 0.410, and p = 0.242, respectively). SII did not show any statistically significant difference between early (<6 months) and late (>/=6 months) recurrence (p = 0.492) and progression groups (p = 0.216). CONCLUSION: For patients with intermediate- and high-risk NMIBC, serum SII levels do not present as an appropriate biomarker for the prediction of disease recurrence and progression following intravesical BCG therapy. A possible explanation for the failure of SII to predict BCG response may be found in the impact of Turkey's nationwide tuberculosis vaccination program. CI - (c) 2023 S. Karger AG, Basel. FAU - Bolat, Deniz AU - Bolat D AD - Department of Urology, Bozyaka Training and Research Hospital, Izmir Faculty of Medicine, University of Health Sciences, Izmir, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Akgul, Murat AU - Akgul M AD - Department of Urology, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey. FAU - Karabay, Emre AU - Karabay E AD - Department of Urology, Haydarpasa Training and Research Hospital, Istanbul, Turkey. FAU - Izol, Volkan AU - Izol V AD - Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey. FAU - Aslan, Guven AU - Aslan G AD - Department of Urology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey. FAU - Eskicorapci, Saadettin AU - Eskicorapci S AD - Department of Urology, Atakent Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey. FAU - Sahin, Hayrettin AU - Sahin H AD - Department of Urology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. FAU - Turkeri, Levent AU - Turkeri L AD - Department of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey. CN - Members of Bladder Cancer Study Group of Turkish Urooncology Association LA - eng PT - Journal Article PT - Review DEP - 20230221 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology MH - Administration, Intravesical MH - Inflammation MH - Neoplasm Invasiveness OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Inflammation OT - Intravesical BCG OT - Prognosis OT - Systemic immune inflammation index EDAT- 2023/02/23 06:00 MHDA- 2023/06/08 06:42 CRDT- 2023/02/22 14:08 PHST- 2022/10/13 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2023/06/08 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 14:08 [entrez] AID - 000528740 [pii] AID - 10.1159/000528740 [doi] PST - ppublish SO - Urol Int. 2023;107(6):617-623. doi: 10.1159/000528740. Epub 2023 Feb 21. PMID- 36805539 OWN - NLM STAT- MEDLINE DCOM- 20230223 LR - 20230226 IS - 2399-3642 (Electronic) IS - 2399-3642 (Linking) VI - 6 IP - 1 DP - 2023 Feb 20 TI - FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer. PG - 199 LID - 10.1038/s42003-023-04561-3 [doi] LID - 199 AB - Bladder cancer is mostly present in the form of urothelium carcinoma, causing over 150,000 deaths each year. Its histopathological classification as muscle invasive (MIBC) and non-muscle invasive (NMIBC) is the most prominent aspect, affecting the prognosis and progression of this disease. In this study, we defined the active regulatory landscape of MIBC and NMIBC cell lines using H3K27ac ChIP-seq and used an integrative approach to combine our findings with existing data. Our analysis revealed FRA1 and FLI1 as two critical transcription factors differentially regulating MIBC regulatory landscape. We show that FRA1 and FLI1 regulate the genes involved in epithelial cell migration and cell junction organization. Knock-down of FRA1 and FLI1 in MIBC revealed the downregulation of several EMT-related genes such as MAP4K4 and FLOT1. Further, ChIP-SICAP performed for FRA1 and FLI1 enabled us to infer chromatin binding partners of these transcription factors and link this information with their target genes. Finally, we show that knock-down of FRA1 and FLI1 result in significant reduction of invasion capacity of MIBC cells towards muscle microenvironment using IC-CHIP assays. Our results collectively highlight the role of these transcription factors in selection and design of targeted options for treatment of MIBC. CI - (c) 2023. The Author(s). FAU - Guneri-Sozeri, Perihan Yagmur AU - Guneri-Sozeri PY AUID- ORCID: 0000-0002-8221-2773 AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Ozden-Yilmaz, Gulden AU - Ozden-Yilmaz G AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. FAU - Kisim, Asli AU - Kisim A AUID- ORCID: 0000-0002-5245-1706 AD - Izmir Institute of Technology, Urla, 35430, Izmir, Turkey. FAU - Cakiroglu, Ece AU - Cakiroglu E AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Eray, Aleyna AU - Eray A AUID- ORCID: 0000-0001-6558-0649 AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Uzuner, Hamdiye AU - Uzuner H AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Karakulah, Gokhan AU - Karakulah G AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Pesen-Okvur, Devrim AU - Pesen-Okvur D AUID- ORCID: 0000-0001-8333-4193 AD - Izmir Institute of Technology, Urla, 35430, Izmir, Turkey. FAU - Senturk, Serif AU - Senturk S AUID- ORCID: 0000-0003-3963-2294 AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. AD - Dokuz Eylul University Izmir International Biomedicine and Genome Institute, Inciralti, 35340, Izmir, Turkey. FAU - Erkek-Ozhan, Serap AU - Erkek-Ozhan S AUID- ORCID: 0000-0003-4439-5203 AD - Izmir Biomedicine and Genome Center, Inciralti, 35340, Izmir, Turkey. serap.erkek@ibg.edu.tr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230220 PL - England TA - Commun Biol JT - Communications biology JID - 101719179 RN - EC 2.7.1.11 (MAP4K4 protein, human) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - 0 (Intracellular Signaling Peptides and Proteins) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics MH - Muscles MH - Cell Line MH - Cell Movement/genetics MH - Chromatin Immunoprecipitation MH - Tumor Microenvironment MH - Protein Serine-Threonine Kinases MH - Intracellular Signaling Peptides and Proteins PMC - PMC9941102 COIS- D.P.-O. is CTO of INITIO Cell Biyoteknoloji. The remaining authors declare no competing interests. EDAT- 2023/02/23 06:00 MHDA- 2023/02/25 06:00 PMCR- 2023/02/20 CRDT- 2023/02/22 09:41 PHST- 2021/12/13 00:00 [received] PHST- 2023/02/07 00:00 [accepted] PHST- 2023/02/22 09:41 [entrez] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/20 00:00 [pmc-release] AID - 10.1038/s42003-023-04561-3 [pii] AID - 4561 [pii] AID - 10.1038/s42003-023-04561-3 [doi] PST - epublish SO - Commun Biol. 2023 Feb 20;6(1):199. doi: 10.1038/s42003-023-04561-3. PMID- 36798814 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230218 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective. PG - 1042552 LID - 10.3389/fonc.2023.1042552 [doi] LID - 1042552 AB - According to the guidelines, transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains the standard strategy for the management of non-muscle invasive bladder cancer (NMIBC). However, even if patients receive standard strategy, the risk of postoperative recurrence and progression is high. From the clinical perspective, the standard strategy needs to be optimized and improved. Compared to conventional TURBT, the technique of en bloc resection of bladder tumor (ERBT) removes the tumor tissue in one piece, thus following the principles of cancer surgery. Meanwhile, the integrity and spatial orientation of tumor tissue is protected during the operation, which is helpful for pathologists to make accurate histopathological analysis. Then, urologists can make a postoperative individualized treatment plan based on the patient's clinical characteristics and histopathological results. To date, there is no strong evidence that NMIBC patients treated with ERBT achieve better oncological prognosis, which indicates that ERBT alone does not yet improve patient outcomes. With the development of enhanced imaging technology and proteogenomics technology, en bloc resection combined with these technologies will make it possible to achieve precise diagnosis and treatment of bladder cancer. In this review, the authors analyze the current existing shortcomings of en bloc resection and points out its future direction, in order to promote continuous optimization of the management strategy of bladder cancer. CI - Copyright (c) 2023 Yang, Wang, Li, Lu and Li. FAU - Yang, Yongjun AU - Yang Y AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China. FAU - Wang, Chen AU - Wang C AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China. FAU - Li, Zonglin AU - Li Z AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China. FAU - Li, Yuanwei AU - Li Y AD - Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China. LA - eng PT - Journal Article PT - Review DEP - 20230131 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9927396 OTO - NOTNLM OT - bladder cancer OT - en bloc resection OT - enhanced imaging OT - non-muscle invasive bladder cancer OT - precision medicine OT - proteogenomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/18 06:00 MHDA- 2023/02/18 06:01 PMCR- 2023/01/01 CRDT- 2023/02/17 02:16 PHST- 2022/09/12 00:00 [received] PHST- 2023/01/20 00:00 [accepted] PHST- 2023/02/17 02:16 [entrez] PHST- 2023/02/18 06:00 [pubmed] PHST- 2023/02/18 06:01 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1042552 [doi] PST - epublish SO - Front Oncol. 2023 Jan 31;13:1042552. doi: 10.3389/fonc.2023.1042552. eCollection 2023. PMID- 36795962 OWN - NLM STAT- MEDLINE DCOM- 20230410 LR - 20230421 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 209 IP - 5 DP - 2023 May TI - Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. PG - 882-889 LID - 10.1097/JU.0000000000003193 [doi] AB - PURPOSE: While the presence of residual disease at the time of radical cystectomy for bladder cancer is an established prognostic indicator, controversy remains regarding the importance of maximal transurethral resection prior to neoadjuvant chemotherapy. We characterized the influence of maximal transurethral resection on pathological and survival outcomes using a large, multi-institutional cohort. MATERIALS AND METHODS: We identified 785 patients from a multi-institutional cohort undergoing radical cystectomy for muscle-invasive bladder cancer after neoadjuvant chemotherapy. We employed bivariate comparisons and stratified multivariable models to quantify the effect of maximal transurethral resection on pathological findings at cystectomy and survival. RESULTS: Of 785 patients, 579 (74%) underwent maximal transurethral resection. Incomplete transurethral resection was more frequent in patients with more advanced clinical tumor (cT) and nodal (cN) stage (P < .001 and P < .01, respectively), with more advanced ypT stage at cystectomy and higher rates of positive surgical margins (P < .01 and P < .05, respectively). In multivariable models, maximal transurethral resection was associated with downstaging at cystectomy (adjusted odds ratio 1.6, 95% CI 1.1-2.5). In Cox proportional hazards analysis, maximal transurethral resection was not associated with overall survival (adjusted HR 0.8, 95% CI 0.6-1.1). CONCLUSIONS: In patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, maximal resection may improve pathological response at cystectomy. However, the ultimate effects on long-term survival and oncologic outcomes warrant further investigation. FAU - Kirk, Peter S AU - Kirk PS AD - Department of Urology, University of Washington, Seattle, Washington. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, Texas. FAU - Zargar, Homayoun AU - Zargar H AD - Department of Urology, Western Health, Melbourne, Australia. FAU - Fairey, Adrian S AU - Fairey AS AD - USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California. AD - University of Alberta, Edmonton, Alberta, Canada. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Mir, Maria C AU - Mir MC AD - Department of Urology, Fundacio Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - Department of Urology, University of Munster, Munster, Germany. FAU - Cookson, Michael S AU - Cookson MS AD - Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma. FAU - Jacobson, Niels-Erik AU - Jacobson NE AD - University of Alberta, Edmonton, Alberta, Canada. FAU - Montgomery, Jeffrey S AU - Montgomery JS AD - Department of Urology, University of Michigan Health System, Ann Arbor, Michigan. FAU - Vasdev, Nikhil AU - Vasdev N AD - Department of Urology, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, United Kingdom. AD - Department of Urology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. FAU - Yu, Evan Y AU - Yu EY AD - Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington. AD - Fred Hutchinson Cancer Center, Seattle, Washington. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, New York. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, Department of Surgery, McGill University Health Center, Montreal, Quebec, Canada. FAU - Dall'Era, Marc A AU - Dall'Era MA AD - Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, California. FAU - Sridhar, Srikala S AU - Sridhar SS AD - Princess Margaret Hospital, Toronto, Ontario, Canada. FAU - McGrath, Jonathan S AU - McGrath JS AD - Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom. FAU - Aning, Jonathan AU - Aning J AD - Department of Urology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. AD - Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, United Kingdom. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, University of Texas Southwestern, Dallas, Texas. AD - Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, New York. AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Thorpe, Andrew C AU - Thorpe AC AD - Department of Urology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. FAU - Morgan, Todd M AU - Morgan TM AD - Department of Urology, University of Michigan Health System, Ann Arbor, Michigan. FAU - Holzbeierlein, Jeff M AU - Holzbeierlein JM AD - Department of Urology, University of Kansas Medical Center, Kansas City, Kansas. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - North, Scott AU - North S AD - Division of Urology, Cross Cancer Institute, Edmonton, Alberta, Canada. FAU - Barocas, Daniel A AU - Barocas DA AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Grivas, Petros AU - Grivas P AD - Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington. AD - Fred Hutchinson Cancer Center, Seattle, Washington. FAU - Garcia, Jorge A AU - Garcia JA AD - Case Comprehensive Cancer Center, Cleveland, Ohio. FAU - Stephenson, Andrew J AU - Stephenson AJ AD - Department of Urology, Rush University, Chicago, Illinois. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, Stanford University, Palo Alto, California. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Mertens, Laura AU - Mertens L AD - Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Black, Peter AU - Black P AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology, University of Washington, Seattle, Washington. AD - Fred Hutchinson Cancer Center, Seattle, Washington. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20230216 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2023 May;209(5):888-889. doi: 10.1097/JU.0000000000003193.01. PMID: 36795961 MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - cystectomy OT - margins of excision OT - neoplasm staging OT - urinary bladder neoplasms EDAT- 2023/02/17 06:00 MHDA- 2023/04/10 10:16 CRDT- 2023/02/16 15:22 PHST- 2023/04/10 10:16 [medline] PHST- 2023/02/17 06:00 [pubmed] PHST- 2023/02/16 15:22 [entrez] AID - 10.1097/JU.0000000000003193 [doi] PST - ppublish SO - J Urol. 2023 May;209(5):882-889. doi: 10.1097/JU.0000000000003193. Epub 2023 Feb 16. PMID- 36793750 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230217 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 49 DP - 2023 Mar TI - Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies. PG - 60-66 LID - 10.1016/j.euros.2023.01.004 [doi] AB - CONTEXT: Bladder recurrences have been reported in 22-47% of patients after surgery for upper urinary tract urothelial carcinoma (UTUC). This collaborative review focuses on risk factors for and treatment strategies to reduce bladder recurrences after upper tract surgery for UTUC. OBJECTIVE: To review the current evidence on risk factors and treatment strategies for intravesical recurrence (IVR) after upper tract surgery for UTUC. EVIDENCE ACQUISITION: This collaborative review is based on a literature search of PubMed/Medline, Embase, Cochrane Library, and currently available guidelines on UTUC. Relevant papers on bladder recurrence (etiology, risk factors, and management) after upper tract surgery were selected. Special attention has been paid to (1) the genetic background of bladder recurrences, (2) bladder recurrences after ureterorenoscopy (URS) with or without a biopsy, and (3) postoperative or adjuvant intravesical instillations. The literature search was performed in September 2022. EVIDENCE SYNTHESIS: Recent evidence supports the hypothesis that bladder recurrences after upper tract surgery for UTUC are often clonally related. Clinicopathologic risk factors (patient, tumor, and treatment related) have been identified for bladder recurrences after UTUC diagnosis. Specifically, the use of diagnostic ureteroscopy before radical nephroureterectomy (RNU) is associated with an increased risk of bladder recurrences. Further, a recent retrospective study suggests that performing a biopsy during ureteroscopy may further worsen IVR (no URS: 15.0%; URS without biopsy: 18.4%; URS with biopsy: 21.9%). Meanwhile, a single postoperative instillation of intravesical chemotherapy has been shown to be associated with a reduced bladder recurrence risk after RNU compared with no instillation (hazard ratio 0.51, 95% confidence interval 0.32-0.82). Currently, there are no data on the value of a single postoperative intravesical instillation after ureteroscopy. CONCLUSIONS: Although based on limited retrospective data, performing URS seems to be associated with a higher risk of bladder recurrences. Future studies are warranted to assess the influence of other surgical factors as well as the role of URS biopsy or immediate postoperative intravesical chemotherapy after URS for UTUC. PATIENT SUMMARY: In this paper, we review recent findings on bladder recurrences after upper tract surgery for upper urinary tract urothelial carcinoma. CI - (c) 2023 The Author(s). FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Houston Thompson, R AU - Houston Thompson R AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, APHP, Saint-Louis Hospital, Universite Paris Cite, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20230128 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC9922921 OTO - NOTNLM OT - Bladder recurrence OT - Intravesical instillation OT - Nephroureterectomy OT - Upper tract OT - Ureterorenoscopy OT - Urothelial cancer EDAT- 2023/02/17 06:00 MHDA- 2023/02/17 06:01 PMCR- 2023/01/28 CRDT- 2023/02/16 02:20 PHST- 2023/01/10 00:00 [accepted] PHST- 2023/02/16 02:20 [entrez] PHST- 2023/02/17 06:00 [pubmed] PHST- 2023/02/17 06:01 [medline] PHST- 2023/01/28 00:00 [pmc-release] AID - S2666-1683(23)00005-8 [pii] AID - 10.1016/j.euros.2023.01.004 [doi] PST - epublish SO - Eur Urol Open Sci. 2023 Jan 28;49:60-66. doi: 10.1016/j.euros.2023.01.004. eCollection 2023 Mar. PMID- 36790518 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 4 DP - 2023 Apr TI - A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study. PG - 1077-1083 LID - 10.1007/s00345-023-04316-z [doi] AB - PURPOSE: To show the effect of a 6-month (4 times weekly followed by 5 times monthly) maintenance mitomycin C regimen on the prevention of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: A total of 119 patients undergoing a RNU between 2007 and 2021 in a single center hospital were retrospectively reviewed. A total of 66 patients were eligible for further analysis. 27 patients received no post-operative MMC (median follow-up: 110 months) and 39 patients received a 6-month (4 times weekly, 5 times monthly) maintenance regimen of MMC (median follow up: 48 months). The primary outcome was the 1-, 2- and 5-year bladder recurrence free survival (BRFS). RESULTS: There was a significant difference (p = 0.001) in BRFS between the two groups. The 1-, 2, and 5-year BRFS for the MMC- group was 67%, 63% and 43%, respectively. The 1-, 2- and 5-year BRFS for the MMC + group was 95%, 86% and 86%, respectively. Univariate analysis showed no other potential prognostic factors that had a significant effect on the BRFS. CONCLUSION: A 6-month maintenance schedule of MMC is effective at significantly reducing the risk of IVR after RNU for UTUC. We could not find any other significant prognostic factors to predict IVR. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - van Wijngaarden, Casper AU - van Wijngaarden C AUID- ORCID: 0000-0002-6884-2357 AD - Department of Urology, OLVG, Amsterdam, The Netherlands. casper_v_w@hotmail.com. FAU - Bus, Mieke Theodora Jenneke AU - Bus MTJ AD - Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Ruiter, Annebeth Evelien Cathelijn AU - Ruiter AEC AD - Department of Urology, OLVG, Amsterdam, The Netherlands. FAU - Lagerveld, Brunolf Walther AU - Lagerveld BW AD - Department of Urology, OLVG, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20230215 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Nephroureterectomy MH - Retrospective Studies MH - Mitomycin/therapeutic use MH - Neoplasm Recurrence, Local/epidemiology/prevention & control/pathology MH - *Ureteral Neoplasms/surgery/pathology OTO - NOTNLM OT - Intravesical chemotherapy OT - Intravesical recurrence OT - Mitomycin C OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2023/02/16 06:00 MHDA- 2023/05/08 06:41 CRDT- 2023/02/15 11:16 PHST- 2022/10/14 00:00 [received] PHST- 2023/01/22 00:00 [accepted] PHST- 2023/05/08 06:41 [medline] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/15 11:16 [entrez] AID - 10.1007/s00345-023-04316-z [pii] AID - 10.1007/s00345-023-04316-z [doi] PST - ppublish SO - World J Urol. 2023 Apr;41(4):1077-1083. doi: 10.1007/s00345-023-04316-z. Epub 2023 Feb 15. PMID- 36788781 OWN - NLM STAT- MEDLINE DCOM- 20230519 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 30 IP - 5 DP - 2023 May TI - Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study. PG - 473-481 LID - 10.1111/iju.15162 [doi] AB - OBJECTIVES: To validate the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer and provide a more accurate stratification model for a heterogeneous intermediate-risk group. METHODS: A total of 1610 patients, who underwent transurethral resection, diagnosed with non-muscle invasive bladder cancer in nine collaborating hospitals were retrospectively reviewed. They were classified into low-risk, intermediate-risk, high-risk, and highest-risk groups, and recurrence-free survival, progression-free survival, cancer-specific survival, and overall survival were compared among the groups. The intermediate-risk group was subdivided into two groups based on the multivariable Cox regression model of recurrence and progression risk factors, and a revised risk model was created. RESULTS: The progression-free survival, cancer-specific survival, and overall survival were well stratified, while the recurrence-free survival of the intermediate-risk group was the shortest among the four groups (p < 0.001). The independent risk factors for recurrence and progression-free survival in the intermediate-risk group were as follows: age >/= 70 years, sex, multiple tumors, tumor size >/=3 cm, and recurrent cases. The intermediate-risk group was subdivided into two groups: favorable intermediate-risk group and unfavorable intermediate-risk group. The revised risk model showed significant differences. CONCLUSION: We validated the Japanese Urological Association guidelines 2019 stratification model. The revised risk model provided a more accurate treatment selection for this disease subset. CI - (c) 2023 The Japanese Urological Association. FAU - Miyamoto, Tatsuki AU - Miyamoto T AUID- ORCID: 0000-0002-0065-881X AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakahama, Tomonori AU - Nakahama T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Onishi, Kenta AU - Onishi K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kouta AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Yonemori, Masaya AU - Yonemori M AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Enokida, Hideki AU - Enokida H AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Nakagawa, Masayuki AU - Nakagawa M AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AUID- ORCID: 0000-0003-0568-1258 AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AUID- ORCID: 0000-0002-8159-9793 AD - Department of Urology, Hamamatsu University of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Miyake, Hideaki AU - Miyake H AUID- ORCID: 0000-0002-9430-7518 AD - Department of Urology, Hamamatsu University of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, Nara, Japan. FAU - Baba, Satoshi AU - Baba S AD - Department of Pathology, Hamamatsu University of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Kinjyo, Mitsuru AU - Kinjyo M AD - Department of Pathology, Steel Memorial Yawata Hospital, Kitakyushu-shi, Fukuoka, Japan. FAU - Shimokama, Tatsuro AU - Shimokama T AD - Department of Pathology, Steel Memorial Yawata Hospital, Kitakyushu-shi, Fukuoka, Japan. FAU - Okumura, Koji AU - Okumura K AD - Department of Urology, Steel Memorial Yawata Hospital, Kitakyushu-shi, Fukuoka, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. CN - Nishinihon Uro-oncology Extensive Collaboration group LA - eng GR - 16K20159/JSPS KAKENHI/ GR - 26861290/JSPS KAKENHI/ GR - Fiscal Years 2015-2016 Nara Medical University Grant-in-Aid for Collaborative Research Projects/ PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20230214 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2023 May;30(5):481-482. doi: 10.1111/iju.15177. PMID: 36924311 MH - Aged MH - Humans MH - Disease Progression MH - East Asian People MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - *Non-Muscle Invasive Bladder Neoplasms MH - Retrospective Studies MH - Risk Assessment MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - European Association of Urology OT - Japanese Urological Association OT - intermediate risk OT - non-muscle invasive bladder cancer OT - risk stratification EDAT- 2023/02/16 06:00 MHDA- 2023/05/19 06:42 CRDT- 2023/02/15 02:03 PHST- 2021/12/11 00:00 [received] PHST- 2023/01/23 00:00 [accepted] PHST- 2023/05/19 06:42 [medline] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/15 02:03 [entrez] AID - 10.1111/iju.15162 [doi] PST - ppublish SO - Int J Urol. 2023 May;30(5):473-481. doi: 10.1111/iju.15162. Epub 2023 Feb 14. PMID- 36781128 OWN - NLM STAT- MEDLINE DCOM- 20230407 LR - 20230505 IS - 1938-3207 (Electronic) IS - 0002-9165 (Linking) VI - 117 IP - 4 DP - 2023 Apr TI - Adherence to lifestyle recommendations after non-muscle invasive bladder cancer diagnosis and risk of recurrence. PG - 681-690 LID - S0002-9165(23)04155-2 [pii] LID - 10.1016/j.ajcnut.2022.12.022 [doi] AB - BACKGROUND: Patients with non-muscle invasive bladder cancer (NMIBC) are at a high risk of tumor recurrence. It has not been previously investigated if adherence to cancer prevention recommendations lowers the risk of recurrence. OBJECTIVES: We examined whether the standardized lifestyle score measuring adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations was associated with the risk of recurrence and progression among patients with NMIBC. METHODS: The study population included patients diagnosed with primary NMIBC between 2014 and 2017 from the prospective cohort UroLife. Lifestyle was assessed at baseline (n = 979; reflecting the prediagnosis period) and 3-mo postdiagnosis (n = 885). The standardized 2018 WCRF/AICR score was constructed based on recommendations for body weight, physical activity, diet, and alcohol intake. We computed multivariable-adjusted HRs and 95% CIs using Cox proportional hazard regression models. RESULTS: During a median follow-up time of 3.7 y, 320 patients developed >/=1 recurrence(s) and 49 experienced progression. Patients in the highest compared with the lowest tertile of postdiagnosis WCRF/AICR scores had a lower risk of first bladder cancer recurrence (HR: 0.74; 95% CI: 0.56, 0.98). No associations were observed for multiple recurrences (HR: 0.90; 95% CI: 0.70, 1.15) or for the baseline score with either first (HR: 1.07; 95% CI: 0.82, 1.40) or multiple recurrences (HR: 1.04; 95% CI: 0.82, 1.31). Improving lifestyle after diagnosis (per 1-point increase) was not significantly associated with the risk of first or multiple recurrence(s) (HR: 0.87; 95% CI: 0.74, 1.02; HR: 0.93; 95% CI: 0.80, 1.08, respectively). No associations were observed for bladder cancer progression, but the power was limited. CONCLUSIONS: Better adherence to the WCRF/AICR cancer prevention recommendations 3 mo after NMIBC diagnosis, but not before diagnosis, is associated with a decreased risk of first bladder cancer recurrence. More studies evaluating postdiagnosis lifestyles are needed to provide solid support for lifestyle recommendations for cancer survivors. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - van Zutphen, Moniek AU - van Zutphen M AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Hof, Jasper P AU - Hof JP AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja Kh AU - Aben KK AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Kampman, Ellen AU - Kampman E AD - Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus Alm AU - Kiemeney LA AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Alina.Vrieling@radboudumc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230211 PL - United States TA - Am J Clin Nutr JT - The American journal of clinical nutrition JID - 0376027 SB - IM MH - Humans MH - United States MH - Prospective Studies MH - Cohort Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local MH - Life Style MH - *Urinary Bladder Neoplasms MH - Risk Factors OTO - NOTNLM OT - alcohol OT - body mass index OT - diet OT - lifestyle OT - non-muscle invasive bladder cancer OT - physical activity OT - recurrence EDAT- 2023/02/14 06:00 MHDA- 2023/04/07 06:41 CRDT- 2023/02/13 19:24 PHST- 2022/08/19 00:00 [received] PHST- 2022/11/30 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/04/07 06:41 [medline] PHST- 2023/02/14 06:00 [pubmed] PHST- 2023/02/13 19:24 [entrez] AID - S0002-9165(23)04155-2 [pii] AID - 10.1016/j.ajcnut.2022.12.022 [doi] PST - ppublish SO - Am J Clin Nutr. 2023 Apr;117(4):681-690. doi: 10.1016/j.ajcnut.2022.12.022. Epub 2023 Feb 11. PMID- 36777505 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230214 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 13 IP - 1 DP - 2023 TI - Clinical features of patients with MTAP-deleted bladder cancer. PG - 326-339 AB - Advanced urothelial carcinoma continues to have a dismal prognosis despite several new therapies in the last 5 years. FGFR2 and FGFR3 mutations and fusions, PD-L1 expression, tumor mutational burden, and microsatellite instability are established predictive biomarkers in advanced urothelial carcinoma. Novel biomarkers can optimize the sequencing of available treatments and improve outcomes. We describe herein the clinical and pathologic features of patients with an emerging subtype of bladder cancer characterized by deletion of the gene MTAP encoding the enzyme S-Methyl-5'-thioadenosine phosphatase, a potential biomarker of response to pemetrexed. We performed a retrospective analysis of 61 patients with advanced urothelial carcinoma for whom demographics, pathologic specimens, next generation sequencing, and clinical outcomes were available. We compared the frequency of histology variants, upper tract location, pathogenic gene variants, tumor response, progression free survival (PFS) and overall survival (OS) between patients with tumors harboring MTAP deletion (MTAP-del) and wild type tumors (MTAP-WT). A propensity score matching of 5 covariates (age, gender, presence of variant histology, prior surgery, and prior non-muscle invasive bladder cancer) was calculated to compensate for disparity when comparing survival in these subgroups. Non-supervised clustering analysis of differentially expressed genes between MTAP-del and MTAP-WT urothelial carcinomas was performed. MTAP-del occurred in 19 patients (31%). Tumors with MTAP-del were characterized by higher prevalence of squamous differentiation (47.4 vs 11.9%), bone metastases (52.6 vs 23.5%) and lower frequency of upper urinary tract location (5.2% vs 26.1%). Pathway gene set enrichment analysis showed that among the genes upregulated in the MTAP-del cohort, at least 5 were linked to keratinization (FOXN1, KRT33A/B, KRT84, RPTN) possibly contributing to the higher prevalence of squamous differentiation. Alterations in the PIK3 and MAPK pathways were more frequent when MTAP was deleted. There was a trend to inferior response to chemotherapy among MTAP-del tumors, but no difference in the response to immune checkpoint inhibitors or enfortumab. Median progression free survival after first line therapy (PFS1) was 5.5 months for patients with MTAP-WT and 4.5 months for patients with MTAP-del (HR = 1.30; 95% CI, 0.64-2.63; P = 0.471). There was no difference in the time from metastatic diagnosis to death (P = 0.6346). Median OS from diagnosis of localized or de novo metastatic disease was 16 months (range 1.5-60, IQR 8-26) for patients with MTAP-del and 24.5 months (range 3-156, IQR 16-48) for patients with MTAP-WT (P = 0.0218), suggesting that time to progression to metastatic disease is shorter in MTAP-del patients. Covariates did not impact significantly overall survival on propensity score matching. In conclusion, MTAP -del occurs in approximately 30% of patients with advanced urothelial carcinoma and defines a subgroup of patients with aggressive features, such as squamous differentiation, frequent bone metastases, poor response to chemotherapy, and shorter time to progression to metastatic disease. CI - AJCR Copyright (c) 2023. FAU - De Souza, Andre L AU - De Souza AL AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - Mega, Anthony E AU - Mega AE AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - Douglass, John AU - Douglass J AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - Olszewski, Adam J AU - Olszewski AJ AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - Gamsiz Uzun, Ece D AU - Gamsiz Uzun ED AD - Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center Providence, RI, United States. FAU - Uzun, Alper AU - Uzun A AD - Center for Computational Molecular Biology, Brown University Providence RI, United States. AD - Department of Pediatrics, The Warren Alpert Medical School, Brown University Providence, RI, United States. FAU - Chou, Charissa AU - Chou C AD - Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center Providence, RI, United States. FAU - Duan, Fenghai AU - Duan F AD - Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health Providence, RI, United States. FAU - Wang, Jinyu AU - Wang J AD - Data Science Initiative, Brown University Providence, RI, United States. FAU - Ali, Amin AU - Ali A AD - Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center Providence, RI, United States. FAU - Golijanin, Dragan J AU - Golijanin DJ AD - Urology Department, Minimally Invasive Urology Institute, The Miriam Hospital, The Warren Alpert Medical School of Brown University Providence, RI, United States. FAU - Holder, Sheldon L AU - Holder SL AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. AD - Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center Providence, RI, United States. FAU - Lagos, Galina G AU - Lagos GG AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - Safran, Howard AU - Safran H AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. FAU - El-Deiry, Wafik S AU - El-Deiry WS AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. AD - Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center Providence, RI, United States. FAU - Carneiro, Benedito A AU - Carneiro BA AD - Division of Hematology Oncology, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute Providence RI, United States. LA - eng PT - Journal Article DEP - 20230115 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC9906077 OTO - NOTNLM OT - MTAP OT - Urothelial carcinoma OT - chemotherapy OT - immunotherapy COIS- None. EDAT- 2023/02/14 06:00 MHDA- 2023/02/14 06:01 PMCR- 2023/01/15 CRDT- 2023/02/13 03:37 PHST- 2022/09/19 00:00 [received] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/02/13 03:37 [entrez] PHST- 2023/02/14 06:00 [pubmed] PHST- 2023/02/14 06:01 [medline] PHST- 2023/01/15 00:00 [pmc-release] PST - epublish SO - Am J Cancer Res. 2023 Jan 15;13(1):326-339. eCollection 2023. PMID- 36766850 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20230220 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 12 IP - 3 DP - 2023 Feb 3 TI - Novel Zebrafish Patient-Derived Tumor Xenograft Methodology for Evaluating Efficacy of Immune-Stimulating BCG Therapy in Urinary Bladder Cancer. LID - 10.3390/cells12030508 [doi] LID - 508 AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) immunotherapy is the standard-of-care adjuvant therapy for non-muscle-invasive bladder cancer in patients at considerable risk of disease recurrence. Although its exact mechanism of action is unknown, BCG significantly reduces this risk in responding patients but is mainly associated with toxic side-effects in those facing treatment resistance. Methods that allow the identification of BCG responders are, therefore, urgently needed. METHODS: Fluorescently labelled UM-UC-3 cells and dissociated patient tumor samples were used to establish zebrafish tumor xenograft (ZTX) models. Changes in the relative primary tumor size and cell dissemination to the tail were evaluated via fluorescence microscopy at three days post-implantation. The data were compared to the treatment outcomes of the corresponding patients. Toxicity was evaluated based on gross morphological evaluation of the treated zebrafish larvae. RESULTS: BCG-induced toxicity was avoided by removing the water-soluble fraction of the BCG formulation prior to use. BCG treatment via co-injection with the tumor cells resulted in significant and dose-dependent primary tumor size regression. Heat-inactivation of BCG decreased this effect, while intravenous BCG injections were ineffective. ZTX models were successfully established for six of six patients based on TUR-B biopsies. In two of these models, significant tumor regression was observed, which, in both cases, corresponded to the treatment response in the patients. CONCLUSIONS: The observed BCG-related anti-tumor effect indicates that ZTX models might predict the BCG response and thereby improve treatment planning. More experiments and clinical studies are needed, however, to elucidate the BCG mechanism and estimate the predictive value. FAU - Kowald, Saskia AU - Kowald S AUID- ORCID: 0000-0002-7652-4551 AD - Department of Health, Medicine and Care, Division of Diagnostics and Specialist Medicine, Linkoping University, SE-58185 Linkoping, Sweden. FAU - Huge, Ylva AU - Huge Y AD - Department of Biomedical and Clinical Sciences, Division of Urology, Linkoping University, SE-58185 Linkoping, Sweden. FAU - Tandiono, Decky AU - Tandiono D AD - BioReperia AB, SE-58213 Linkoping, Sweden. FAU - Ali, Zaheer AU - Ali Z AUID- ORCID: 0000-0002-6505-3096 AD - BioReperia AB, SE-58213 Linkoping, Sweden. FAU - Vazquez-Rodriguez, Gabriela AU - Vazquez-Rodriguez G AUID- ORCID: 0000-0001-9310-2433 AD - BioReperia AB, SE-58213 Linkoping, Sweden. FAU - Erkstam, Anna AU - Erkstam A AD - BioReperia AB, SE-58213 Linkoping, Sweden. FAU - Fahlgren, Anna AU - Fahlgren A AD - BioReperia AB, SE-58213 Linkoping, Sweden. AD - Department of Biomedical and Clinical Sciences, Division of Cell Biology, Linkoping University, SE-58185 Linkoping, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Biomedical and Clinical Sciences, Division of Urology, Linkoping University, SE-58185 Linkoping, Sweden. AD - Department of Surgery and Perioperative Sciences, Urology and Andrology, Umea University, SE-90187 Umea, Sweden. FAU - Cao, Yihai AU - Cao Y AD - Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, SE-17165 Stockholm, Sweden. FAU - Jensen, Lasse D AU - Jensen LD AUID- ORCID: 0000-0003-2338-357X AD - Department of Health, Medicine and Care, Division of Diagnostics and Specialist Medicine, Linkoping University, SE-58185 Linkoping, Sweden. AD - BioReperia AB, SE-58213 Linkoping, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230203 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (BCG Vaccine) SB - IM MH - Animals MH - Humans MH - *Zebrafish MH - BCG Vaccine/pharmacology/therapeutic use MH - Heterografts MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9914090 OTO - NOTNLM OT - BCG OT - PDX OT - cancer OT - immune-oncology OT - personalized medicine OT - xenograft OT - zebrafish COIS- D.T., Z.A., G.V.-R., A.E., A.F. and L.J. have been/are employees or shareholders in BioReperia AB, a company that is developing ZTX models for the diagnosis and prognosis of cancer patients. The other authors declare no conflict of interest related to this work. EDAT- 2023/02/12 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/02/03 CRDT- 2023/02/11 01:09 PHST- 2022/11/20 00:00 [received] PHST- 2023/01/28 00:00 [revised] PHST- 2023/01/31 00:00 [accepted] PHST- 2023/02/11 01:09 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/02/03 00:00 [pmc-release] AID - cells12030508 [pii] AID - cells-12-00508 [pii] AID - 10.3390/cells12030508 [doi] PST - epublish SO - Cells. 2023 Feb 3;12(3):508. doi: 10.3390/cells12030508. PMID- 36765894 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240912 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 3 DP - 2023 Feb 1 TI - Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients. LID - 10.3390/cancers15030934 [doi] LID - 934 AB - Patients with pT1 high-grade (HG) urothelial carcinoma (UC) and a very high risk of progression might benefit from immediate radical cystectomy (RC), but this option remains controversial. Validation of a standardized method to evaluate the extent of lamina propria (LP) invasion (with recognized prognostic value) in transurethral resection (TURBT) specimens is still needed. The Rete Oncologica Lombarda (ROL) system showed a high predictive value for progression after TURBT in recent retrospective studies. The ROL system was supposed to be validated on a large prospective series of primary urothelial carcinomas from a single institution. From 2016 to 2020, we adopted ROL for all patients with pT1 HG UC on TURBT. We employed a 1.0-mm threshold to stratify tumors in ROL1 and ROL2. A total of 222 pT1 HG UC were analyzed. The median age was 74 years, with a predominance of men (73.8%). ROL was feasible in all cases: 91 cases were ROL1 (41%), and 131 were ROL2 (59%). At a median follow-up of 26.9 months (IQR 13.8-40.6), we registered 81 recurrences and 40 progressions. ROL was a significant predictor of tumor progression in both univariable (HR 3.53; CI 95% 1.56-7.99; p < 0.01) and multivariable (HR 2.88; CI 95% 1.24-6.66; p = 0.01) Cox regression analyses. At Kaplan-Meier estimates, ROL showed a correlation with both PFS (p = 0.0012) and RFS (p = 0.0167). Our results confirmed the strong predictive value of ROL for progression in a large prospective series. We encourage the application of ROL for reporting the extent of LP invasion, substaging T1 HG UC, and improving risk tables for urological decision-making. FAU - Valeri, Marina AU - Valeri M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AUID- ORCID: 0000-0001-7011-0537 AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Iuzzolino, Martina AU - Iuzzolino M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Cieri, Miriam AU - Cieri M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Elefante, Grazia M AU - Elefante GM AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - De Carlo, Camilla AU - De Carlo C AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Bressan, Alessandra AU - Bressan A AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Saitta, Cesare AU - Saitta C AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Gobbo, Andrea AU - Gobbo A AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Avolio, Pier Paolo AU - Avolio PP AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Dacrema, Valerio AU - Dacrema V AD - Department of Pharmacy, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Taverna, Gianluigi AU - Taverna G AD - Department of Urology, Humanitas Mater Domini, Via Gerenzano 2, Castellanza, 21053 Varese, Italy. FAU - Terracciano, Luigi M AU - Terracciano LM AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AUID- ORCID: 0000-0002-6161-6138 AD - Department of Pathology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. LA - eng PT - Journal Article DEP - 20230201 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9913603 OTO - NOTNLM OT - BCG OT - ROL OT - TURBT OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - pT1 high-grade urothelial carcinoma OT - prospective validation OT - risk stratification OT - substaging OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/12 06:01 PMCR- 2023/02/01 CRDT- 2023/02/11 01:04 PHST- 2023/01/05 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/01/30 00:00 [accepted] PHST- 2023/02/11 01:04 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/12 06:01 [medline] PHST- 2023/02/01 00:00 [pmc-release] AID - cancers15030934 [pii] AID - cancers-15-00934 [pii] AID - 10.3390/cancers15030934 [doi] PST - epublish SO - Cancers (Basel). 2023 Feb 1;15(3):934. doi: 10.3390/cancers15030934. PMID- 36765767 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230213 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 3 DP - 2023 Jan 28 TI - Urinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway. LID - 10.3390/cancers15030809 [doi] LID - 809 AB - BACKGROUND: Increasing evidence points to the urinary microbiota as a possible key susceptibility factor for early-stage bladder cancer (BCa) progression. However, the interpretation of its underlying mechanism is often insufficient, given that various environmental conditions have affected the composition of urinary microbiota. Herein, we sought to rule out confounding factors and clarify how urinary Eubacterium sp. CAG:581 promoted non-muscle invasive bladder cancer (NMIBC) development. METHODS: Differentially abundant urinary microbiota of 51 NMIBC patients and 47 healthy controls (as Cohort 1) were first determined by metagenomics analysis. Then, we modeled the coculture of NMIBC organoids with candidate urinary Eubacterium sp. CAG:581 in anaerobic conditions and explored differentially expressed genes of these NMIBC tissues by RNA-Seq. Furthermore, we dissected the mechanisms involved into Eubacterium sp. CAG:581 by inducing extracellular matrix protein 1 (ECM1) and matrix metalloproteinase 9 (MMP9) upregulation. Finally, we used multivariate Cox modeling to investigate the clinical relevance of urinary Eubacterium sp. CAG:581 16S ribosomal RNA (16SrRNA) levels to the prognosis of 406 NMIBC patients (as Cohort 2). RESULTS: Eubacterium sp. CAG:581 infection accelerated the proliferation of NMIBC organoids (p < 0.01); ECM1 and MMP9 were the most upregulated genes induced by the increased colony forming units (CFU) gradient of Eubacterium sp. CAG:581 infection via phosphorylating ERK1/2 in NMIBC organoids of Cohort 1. Excluding the favorable impact of potential contributing factors, the ROC curve of Cohort 2 manifested its 3-year AUC value as 0.79 and the cut-off point of Eubacterium sp. CAG:581 16SrRNA as 10.3 (delta CT value). CONCLUSION: Our evidence suggests that urinary Eubacterium sp. CAG:581 promoted NMIBC progression through the ECM1/MMP9 pathway, which may serve as the promising noninvasive diagnostic biomarker for NMIBC. FAU - Zhang, Yuhang AU - Zhang Y AUID- ORCID: 0000-0001-9752-983X AD - Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China. AD - Department of Pharmacy, Peking University First Hospital, Beijing 100034, China. FAU - Wang, Wenyu AU - Wang W AD - Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100054, China. FAU - Zhou, Hang AU - Zhou H AD - Department of Urology Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing 100054, China. FAU - Cui, Yimin AU - Cui Y AUID- ORCID: 0000-0002-4186-1005 AD - Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China. AD - Department of Pharmacy, Peking University First Hospital, Beijing 100034, China. LA - eng GR - 82204515/National Natural Science Foundation of China/ GR - 2022RT04/National High Level Hospital Clinical Research Funding (Research Achievement Transformation Project of Peking University First Hospital)/ GR - 2022SF04/Research Seed Fund of Peking University First Hospital/ PT - Journal Article DEP - 20230128 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9913387 OTO - NOTNLM OT - Eubacterium sp. CAG:581 OT - extracellular matrix protein 1 (ECM1) OT - matrix metalloproteinase 9 (MMP9) OT - non-muscle invasive bladder cancer (NMIBC) OT - noninvasive urinary diagnostics COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/12 06:01 PMCR- 2023/01/28 CRDT- 2023/02/11 01:03 PHST- 2022/11/28 00:00 [received] PHST- 2023/01/11 00:00 [revised] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/02/11 01:03 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/12 06:01 [medline] PHST- 2023/01/28 00:00 [pmc-release] AID - cancers15030809 [pii] AID - cancers-15-00809 [pii] AID - 10.3390/cancers15030809 [doi] PST - epublish SO - Cancers (Basel). 2023 Jan 28;15(3):809. doi: 10.3390/cancers15030809. PMID- 36765629 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230213 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 3 DP - 2023 Jan 21 TI - Incidental Diagnosis of Urothelial Bladder Cancer: Associations with Overall Survival. LID - 10.3390/cancers15030668 [doi] LID - 668 AB - BACKGROUND: We investigated whether an incidental diagnosis (ID) of bladder cancer (BC) was associated with improved survival. METHODS: We retrospectively reviewed data of consecutive patients with no prior diagnosis of urothelial cancer who underwent a primary transurethral resection of bladder tumor (pTURBT) between January 2013 and February 2021 and were subsequently diagnosed with urothelial BC. The type of diagnosis (incidental or non-incidental) was identified. Overall, relative, recurrence-free, and progression-free survival rates (OS, RS, RFS, and PFS) after pTURBT were evaluated using the Kaplan-Meier curves and long-rank tests. A multivariable Cox regression model for the overall mortality was developed. RESULTS: A total of 435 patients were enrolled. The median follow-up was 2.7 years. ID cases were more likely to be low-grade (LG) and non-muscle-invasive. ID vs. non-ID was associated with a trend toward an improved 7-year OS (66% vs. 49%, p = 0.092) and a significantly improved 7-year OS, if incidental cases were limited to ultrasound-detected tumors (75% vs. 49%, p = 0.013). ID was associated with improved survival among muscle-invasive BC (MIBC) patients (3-year RS: 97% vs. 23%, p < 0.001), but not among other subgroups stratified according to disease stage or grade. In multivariable analysis, only age, MIBC, and high-grade (HG) cancer demonstrated an association with mortality. PFS and RFS among non-MIBC patients did not differ in regard to the type of diagnosis. CONCLUSIONS: Incidental diagnosis may contribute to an improved survival in BC patients, most probably in the mechanism of the relative downgrading of the disease, including the possible overdiagnosis of LG tumors. Nevertheless, in the subgroup analyses, we noted marked survival benefits in MIBC cases. Further prospective studies are warranted to gain a deeper understanding of the observed associations. FAU - Kamecki, Hubert AU - Kamecki H AUID- ORCID: 0000-0001-8387-1474 AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. AD - Second Department of Urology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland. FAU - Debowska, Malgorzata AU - Debowska M AD - Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. AD - Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland. FAU - Poleszczuk, Jan AU - Poleszczuk J AUID- ORCID: 0000-0001-8758-7200 AD - Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland. FAU - Demkow, Tomasz AU - Demkow T AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. FAU - Przewor, Artur AU - Przewor A AUID- ORCID: 0000-0002-2152-8950 AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. FAU - Nyk, Lukasz AU - Nyk L AD - Second Department of Urology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland. FAU - Sosnowski, Roman AU - Sosnowski R AUID- ORCID: 0000-0002-4894-4233 AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20230121 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9913049 OTO - NOTNLM OT - bladder cancer OT - incidental diagnosis OT - screening OT - survival COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/12 06:01 PMCR- 2023/01/21 CRDT- 2023/02/11 01:02 PHST- 2022/12/15 00:00 [received] PHST- 2023/01/07 00:00 [revised] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/02/11 01:02 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/12 06:01 [medline] PHST- 2023/01/21 00:00 [pmc-release] AID - cancers15030668 [pii] AID - cancers-15-00668 [pii] AID - 10.3390/cancers15030668 [doi] PST - epublish SO - Cancers (Basel). 2023 Jan 21;15(3):668. doi: 10.3390/cancers15030668. PMID- 36763567 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20230328 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 2 DP - 2023 TI - Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer. PG - e0275921 LID - 10.1371/journal.pone.0275921 [doi] LID - e0275921 AB - OBJECTIVES: The optimal frequency and duration of surveillance in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) remain unclear. The aim of the present study is to develop an optimal surveillance protocol based on the European Association of Urology (EAU) substratification in order to improve surveillance costs after transurethral resection of bladder tumor (TURBT) in patients with primary high-risk NMIBC. MATERIALS AND METHODS: We retrospectively evaluated 428 patients with primary high-risk NMIBC who underwent TURBT from November 1993 to April 2019. Patients were substratified into the highest-risk and high-risk without highest-risk groups based on the EAU guidelines. An optimized surveillance protocol that enhances cost-effectiveness was then developed using real incidences of recurrence after TURBT. A recurrence detection rate ([number of patients with recurrence / number of patients with surveillance] x 100) of >/= 1% during a certain period indicated that routine surveillance was necessary in this period. The 10-year total surveillance cost was compared between the EAU guidelines-based protocol and the optimized surveillance protocol developed herein. RESULTS: Among the 428 patients with primary high-risk NMIBC, 97 (23%) were substratified into the highest-risk group. Patients in the highest-risk group had a significantly shorter recurrence-free survival than those in the high-risk without highest-risk group. The optimized surveillance protocol promoted a 40% reduction ($394,990) in the 10-year total surveillance cost compared to the EAU guidelines-based surveillance protocol. CONCLUSION: The optimized surveillance protocol based on the EAU substratification could potentially reduce over investigation during follow-up and improve surveillance costs after TURBT in patients with primary high-risk NMIBC. CI - Copyright: (c) 2023 Fujita et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Okita, Kazutaka AU - Okita K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230210 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Urology MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Cystectomy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/surgery PMC - PMC9916549 COIS- The authors have declared that no competing interests exist. EDAT- 2023/02/11 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/02/10 CRDT- 2023/02/10 13:42 PHST- 2022/07/29 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2023/02/10 13:42 [entrez] PHST- 2023/02/11 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/02/10 00:00 [pmc-release] AID - PONE-D-22-21398 [pii] AID - 10.1371/journal.pone.0275921 [doi] PST - epublish SO - PLoS One. 2023 Feb 10;18(2):e0275921. doi: 10.1371/journal.pone.0275921. eCollection 2023. PMID- 36754206 OWN - NLM STAT- MEDLINE DCOM- 20230505 LR - 20230507 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 47 IP - 4 DP - 2023 May TI - BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours. PG - 250-258 LID - S2173-5786(23)00009-4 [pii] LID - 10.1016/j.acuroe.2023.01.005 [doi] AB - INTRODUCTION: During 2019 there was a worldwide shortage of BCG strains for intravesical instillation, limiting the availability of full dose schemes for maintenance courses. The main objective was to analyze the impact on tumoral relapse secondary to BCG shortage in our center. Secondary outcomes included recurrence and progression-free survival rates and tumoral relapse specific characteristics. METHODS: Retrospective cohort study including 158 subjects (64 treated during 2019 and 94 during 2017) with high-risk non-muscle invasive bladder cancer and treated with a combination of Transurethral bladder resection (TURB) followed by adjuvant intravesical instillation with BCG in a tertiary hospital in Spain. Basal characteristics of both groups were analyzed. Times to event of interest (relapse; including recurrence and/or progression) were estimated with Kaplan-Meier survival analysis. Disease-free survival rates were analyzed using a multivariable Cox regression model of proportional hazards. RESULTS: Median follow-up in the 2019 sample was 24 months and 50 months in the 2017 group with a median number of instillations of 8 and 12 respectively. Median time to relapse of 285 days (145-448) during 2019 and 382 days (215-567) in 2017 were observed (logRank p = 0.025). Further multivariable analysis revealed a proportional hazard ratio (HR) for disease-free survival rate of 1.87 (95% CI: 1.04-3.37 p = 0.036). No statistically significant differences in tumoral relapse characteristics were observed. CONCLUSION: BCG shortage and subsequent reduced-dose schemes used for intravesical instillation due to limited availability, increase early tumoral relapse rates. These findings are consistent with available evidence, showing the need for full-dose BCG courses. CI - Copyright (c) 2023. Published by Elsevier Espana, S.L.U. FAU - Perez-Aizpurua, X AU - Perez-Aizpurua X AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. Electronic address: xabier.perez@quironsalud.es. FAU - Monzo-Gardiner, J I AU - Monzo-Gardiner JI AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Maqueda-Arellano, J AU - Maqueda-Arellano J AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Buendia-Gonzalez, E AU - Buendia-Gonzalez E AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Cuello-Sanchez, L AU - Cuello-Sanchez L AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Tufet I Jaumot, J J AU - Tufet I Jaumot JJ AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Alonso-Roman, J AU - Alonso-Roman J AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Gomez-Jordana Manas, B AU - Gomez-Jordana Manas B AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Ruiz de Castroviejo Blanco, J AU - Ruiz de Castroviejo Blanco J AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Osorio Ospina, F AU - Osorio Ospina F AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Cabello Benavente, R AU - Cabello Benavente R AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. FAU - Gonzalez-Enguita, C AU - Gonzalez-Enguita C AD - Department of Urology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain. LA - eng LA - spa PT - Journal Article DEP - 20230206 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder MH - Administration, Intravesical MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology MH - Recurrence MH - BCG Vaccine/therapeutic use OTO - NOTNLM OT - BCG shortage OT - Bacilo de Calmette-Guerin OT - Calmette-Guerin bacillus OT - Cancer de vejiga no musculo invasivo OT - Escasez de BCG OT - Instilacion(es) intravesical(es) OT - Intravesical instillation(s) OT - Non-muscle invasive bladder cancer EDAT- 2023/02/09 06:00 MHDA- 2023/05/05 06:42 CRDT- 2023/02/08 19:25 PHST- 2022/11/02 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/05/05 06:42 [medline] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/08 19:25 [entrez] AID - S2173-5786(23)00009-4 [pii] AID - 10.1016/j.acuroe.2023.01.005 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2023 May;47(4):250-258. doi: 10.1016/j.acuroe.2023.01.005. Epub 2023 Feb 6. PMID- 36745012 OWN - NLM STAT- MEDLINE DCOM- 20230622 LR - 20230626 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 132 IP - 1 DP - 2023 Jul TI - Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. PG - 56-64 LID - 10.1111/bju.15983 [doi] AB - OBJECTIVE: To investigate the feasibility, efficacy, and safety of trimodal therapy (TMT) using a bifractionated split-course hypofractionated radiotherapy (RT) for non-metastatic muscle-invasive bladder cancer (MIBC) in elderly patients. PATIENTS AND METHODS: We retrospectively reviewed the characteristics and outcomes of patients aged >75 years with non-metastatic MIBC suitable or not for radical cystectomy (RC) and treated with transurethral resection of bladder tumour followed by concomitant radio-chemotherapy (platinum salt and 5-fluorouracil) at two institutions (Saint Louis Hospital, Paris, France and European Georges Pompidou Hospital, Paris, France) between 1990 and 2021. RT consisted of an adapted bifractionated split-course hypofractionated RT. Acute toxicities were reported according to Common Terminology Criteria for Adverse Events version 5.0 and late toxicities were reported according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer late radiation morbidity scoring schema. The primary end-point was overall survival (OS). Secondary end-points included other survivals outcomes and safety. RESULTS: A total of 122 patients were identified, with a median (range) follow-up of 51.1 (0.5-210.8) months. In all, 83.5% of patients completed radio-chemotherapy. The OS rate was 61.7% at 3 years and 51.2% at 5 years. In multivariate analysis, the completion of RT and concomitant chemotherapy were significantly associated with better OS and cancer-specific survival. For patients fit for RC, a complete histological response was achieved for 77 patients (91.7%) with radio-chemotherapy and the bladder conservation rate was 90.5%. Acute and late Grade >/=3 toxicities were <5%. CONCLUSION: Bifractionated split-course hypofractionated RT with concomitant chemotherapy regimen appears to be well-tolerated and effective. Trimodal treatment seems to be a curative option for elderly patients unfit for radical surgery compared with palliative care and may contribute to improved survival in these patients. CI - (c) 2023 BJU International. FAU - Mignot, Fabien AU - Mignot F AUID- ORCID: 0000-0001-7925-510X AD - Department of Radiation Oncology, Saint Louis Hospital, AP-HP, Paris, France. FAU - Fabiano, Emmanuelle AU - Fabiano E AD - Department of Radiation Oncology, European George Pompidou Hospital, AP-HP, Paris, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Paris, France. FAU - Alati, Aurelia AU - Alati A AD - Department of Radiation Oncology, European George Pompidou Hospital, AP-HP, Paris, France. FAU - Mejean, Arnaud AU - Mejean A AD - Department of Urology, European George Pompidou Hospital, AP-HP, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Saint Louis Hospital, AP-HP, Paris, France. FAU - Hermieu, Jean-Francois AU - Hermieu JF AD - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Paris, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - Department of Urology, Saint Louis Hospital, AP-HP, Paris, France. FAU - Hennequin, Christophe AU - Hennequin C AD - Department of Radiation Oncology, Saint Louis Hospital, AP-HP, Paris, France. FAU - Durdux, Catherine AU - Durdux C AD - Department of Radiation Oncology, European George Pompidou Hospital, AP-HP, Paris, France. FAU - Quero, Laurent AU - Quero L AD - Department of Radiation Oncology, Saint Louis Hospital, AP-HP, Paris, France. AD - INSERM U1160, Alloimmunity-Autoimmunity-Transplantation Research Unit, University of Paris, Paris, France. LA - eng PT - Journal Article DEP - 20230219 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - U3P01618RT (Fluorouracil) SB - IM MH - Aged MH - Humans MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/radiotherapy/drug therapy MH - Urinary Bladder/pathology MH - Cystectomy MH - Fluorouracil MH - Neoplasm Invasiveness MH - Treatment Outcome MH - Combined Modality Therapy OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - bladder cancer OT - elderly patient OT - hypofractionated radiotherapy EDAT- 2023/02/07 06:00 MHDA- 2023/06/22 06:41 CRDT- 2023/02/06 09:52 PHST- 2023/06/22 06:41 [medline] PHST- 2023/02/07 06:00 [pubmed] PHST- 2023/02/06 09:52 [entrez] AID - 10.1111/bju.15983 [doi] PST - ppublish SO - BJU Int. 2023 Jul;132(1):56-64. doi: 10.1111/bju.15983. Epub 2023 Feb 19. PMID- 36741702 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230207 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing. PG - 1105026 LID - 10.3389/fonc.2022.1105026 [doi] LID - 1105026 AB - Despite substantial advances in the treatment using immune checkpoint inhibitors (ICIs), the clinical expected therapeutic effect on bladder cancer has not been achieved, in which the tumor microenvironment (TME) occupies a notable position. In this research, 10X single-cell RNA-sequencing technology was conducted to analyze seven primary bladder tumor tissues (three non-muscle-invasive bladder cancer (NMIBC) and four muscle-invasive bladder cancer (MIBC)) and seven corresponding normal tissues adjacent to cancer; eight various cell types were identified in the bladder cancer (BC) TME, and a complete TME atlas in bladder cancer was made. Moreover, bladder cancer epithelial cells were further subdivided into 14 subgroups, indicating a high intra-tumoral heterogeneity. Additionally, the differences between NMIBC and MIBC were compared based on differential gene expression heatmap, copy number variation (CNV) distribution heatmap, Gene Ontology (GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) network mutual analysis, and the Kaplan-Meier survival prognosis analysis were used to identify six key genes associated with the prognosis of bladder cancer: VEGFA, ANXA1, HSP90B1, PSMA7, PRDX6, and PPP1CB. The dynamic change of the expression distribution of six genes on the pseudo-time axis was further verified by cell pseudo-time analysis. CI - Copyright (c) 2023 Chen, Chen, Song, Lv and Qi. FAU - Chen, Zhibin AU - Chen Z AD - Department of Urology and Andrology, Minimally Invasive Surgery Center, Guangdong Provincial KeyLaboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Chen, Dongmao AU - Chen D AD - Department of Urology and Andrology, Minimally Invasive Surgery Center, Guangdong Provincial KeyLaboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Song, Zhenfeng AU - Song Z AD - Department of Urology and Andrology, Minimally Invasive Surgery Center, Guangdong Provincial KeyLaboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Lv, Yifan AU - Lv Y AD - Department of Urology and Andrology, Minimally Invasive Surgery Center, Guangdong Provincial KeyLaboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Qi, Defeng AU - Qi D AD - Department of Urology and Andrology, Minimally Invasive Surgery Center, Guangdong Provincial KeyLaboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. LA - eng PT - Journal Article DEP - 20230119 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9893503 OTO - NOTNLM OT - MIBC (muscle-invasive bladder cancer) OT - NMIBC (non-muscle-invasive bladder cancer) OT - bladder cancer OT - prognosis gene OT - single-cell RNA-sequencing OT - tumor macroenvironment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/07 06:00 MHDA- 2023/02/07 06:01 PMCR- 2022/01/01 CRDT- 2023/02/06 03:34 PHST- 2022/11/22 00:00 [received] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/02/06 03:34 [entrez] PHST- 2023/02/07 06:00 [pubmed] PHST- 2023/02/07 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1105026 [doi] PST - epublish SO - Front Oncol. 2023 Jan 19;12:1105026. doi: 10.3389/fonc.2022.1105026. eCollection 2022. PMID- 36739339 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 3 DP - 2023 Mar TI - Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study. PG - 767-776 LID - 10.1007/s00345-023-04300-7 [doi] AB - PURPOSE: The prognosis of patients with pT3 upper tract urothelial carcinoma (UTUC) varies. The current study aimed to further classify patients with pT3 UTUC into different survival outcome groups based on tumor location and site of invasion. METHODS: This retrospective study included 323 patients with pT3 UTUC who underwent nephroureterectomy at 11 hospitals in Japan. Histological and clinical data were obtained via a chart review. Univariate and multivariate Cox proportional hazards analyses showed the effect of different variables on recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). RESULTS: The median age of the patients was 72 years. Patients with pT3 UTUCs were divided into two groups: those with renal parenchymal invasion only (pT3a, n = 95) and those with peripelvic or periureteral fat invasion (pT3b, n = 228). pT3b UTUC was significantly associated with hydronephrosis, low preoperative estimated glomerular filtration rate (eGFR), histological nodal metastasis, nuclear grade 3, lymphovascular invasion (LVI), carcinoma in situ, and positive surgical margin. Based on the univariate analyses, patients with pT3b UTUC had a significantly lower 5-year RFS (42.4% vs. 70.1%, p < 0.0001), 5-year CSS (54.3% vs. 80.0%, p = 0.0002), and 5-year OS (47.8% vs. 76.8%, p < 0.0001) than those with pT3a UTUC. According to the multivariate analyses, nodal metastasis, LVI, adjuvant chemotherapy, preoperative eGFR, nuclear grade (RFS only), surgical margin (RFS only), and Charlson comorbidity index (OS only), but not pT3b stage, were associated with survival. CONCLUSION: Compared with pT3a UTUC, pT3b UTUC was significantly associated with worse histological features, consequently resulting in unsatisfactory survival outcomes. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yamada, Yukio AU - Yamada Y AD - Department of Urology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan. AD - Department of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AUID- ORCID: 0000-0003-4041-7241 AD - Department of Urology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan. tohru-tky@umin.ac.jp. FAU - Miyakawa, Jimpei AU - Miyakawa J AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. AD - Department of Urology, Tokyo Teishin Hospital, Chiyoda, Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan. AD - Department of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan. AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. AD - Department of Urology, Tokyo Teishin Hospital, Chiyoda, Tokyo, Japan. FAU - Tabata, Mariko AU - Tabata M AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. AD - Department of Urology, Mitsui Memorial Hospital, Chiyoda, Tokyo, Japan. FAU - Kaneko, Tomoyuki AU - Kaneko T AD - Department of Urology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan. AD - Department of Urology, The Fraternity Memorial Hospital, Sumida, Tokyo, Japan. FAU - Ishikawa, Akira AU - Ishikawa A AD - Department of Urology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan. FAU - Miyazaki, Hideyo AU - Miyazaki H AD - Department of Urology, Center Hospital of the National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Kondo, Yasushi AU - Kondo Y AD - Department of Urology, Tokyo Metropolitan Bokutoh Hospital, Sumida, Tokyo, Japan. FAU - Matsumoto, Akihiko AU - Matsumoto A AD - Department of Urology, Yaizu City Hospital, Yaizu, Shizuoka, Japan. FAU - Naito, Akihiro AU - Naito A AD - Department of Urology, Japan Organization of Occupational Health and Safety Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan. FAU - Hikatsu, Masahiro AU - Hikatsu M AD - Department of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan. FAU - Fujii, Yoichi AU - Fujii Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Akiyama, Yoshiyuki AU - Akiyama Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Yamada, Yuta AU - Yamada Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Sato, Yusuke AU - Sato Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Nomiya, Akira AU - Nomiya A AD - Department of Urology, Japan Organization of Occupational Health and Safety Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan. FAU - Yamada, Daisuke AU - Yamada D AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. FAU - Murata, Taro AU - Murata T AD - Department of Urology, Tokyo Teishin Hospital, Chiyoda, Tokyo, Japan. FAU - Suzuki, Motofumi AU - Suzuki M AD - Department of Urology, Tokyo Metropolitan Bokutoh Hospital, Sumida, Tokyo, Japan. FAU - Enomoto, Yutaka AU - Enomoto Y AD - Department of Urology, Mitsui Memorial Hospital, Chiyoda, Tokyo, Japan. FAU - Nishimatsu, Hiroaki AU - Nishimatsu H AD - Department of Urology, The Fraternity Memorial Hospital, Sumida, Tokyo, Japan. FAU - Takeuchi, Takumi AU - Takeuchi T AD - Department of Urology, Japan Organization of Occupational Health and Safety Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan. FAU - Tanaka, Yoshinori AU - Tanaka Y AD - Department of Urology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230204 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Humans MH - Aged MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/surgery MH - Retrospective Studies MH - Prognosis MH - Nephroureterectomy/methods MH - *Urologic Neoplasms/pathology OTO - NOTNLM OT - Classification OT - Nephroureterectomy OT - Renal pelvis OT - Survival OT - Upper tract urothelial carcinoma OT - Urothelial carcinoma EDAT- 2023/02/05 06:00 MHDA- 2023/04/11 06:41 CRDT- 2023/02/04 23:41 PHST- 2022/09/12 00:00 [received] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/04/11 06:41 [medline] PHST- 2023/02/05 06:00 [pubmed] PHST- 2023/02/04 23:41 [entrez] AID - 10.1007/s00345-023-04300-7 [pii] AID - 10.1007/s00345-023-04300-7 [doi] PST - ppublish SO - World J Urol. 2023 Mar;41(3):767-776. doi: 10.1007/s00345-023-04300-7. Epub 2023 Feb 4. PMID- 36738246 OWN - NLM STAT- MEDLINE DCOM- 20230405 LR - 20230507 IS - 1530-8561 (Electronic) IS - 0009-9147 (Linking) VI - 69 IP - 4 DP - 2023 Apr 3 TI - Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome. PG - 399-410 LID - 10.1093/clinchem/hvac218 [doi] AB - BACKGROUND: Tumor heterogeneity and lack of personalized prognosis leads to bladder cancer (BlCa) patients' lifelong surveillance with invasive interventions, highlighting the need for modern minimally invasive tools for disease management. Herein, we have evaluated the clinical utility of preoperative serum cell-free DNA (cfDNA) in ameliorating patients' risk-stratification and prognosis. METHODS: cfDNA was purified from 190 preoperative BlCa patients and 26 healthy individuals' serum samples and quantified by 2 assays: an in-house quantitative real-time PCR (qPCR) assay using LEP as reference control and a direct fluorometric assay using Qubit HS dsDNA. Capillary electrophoresis was performed in 31 samples for cfDNA fragment profiling. Tumor relapse/progression and metastasis/death were used as clinical endpoints for non-muscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC), respectively. RESULTS: cfDNA profiling by capillary electrophoresis highlighted that total and fragment-related cfDNA levels were significantly increased in BlCa and associated with advance disease stages. Evaluation of cfDNA levels by both Qubit/qPCR displayed highly consistent results (rs = 0.960; P < 0.001). Higher cfDNA was correlated with MIBC and stronger risk for early metastasis (Qubit:hazard ratio [HR] = 3.016, P = 0.009; qPCR:HR = 2.918, P = 0.004) and poor survival (Qubit:HR = 1.898, P = 0.042; qPCR:HR = 1.888, P = 0.026) of MIBC patients. Multivariate cfDNA-fitted models led to superior risk stratification and net benefit for MIBC prognosis compared to disease established markers. CONCLUSIONS: Elevated preoperative cfDNA levels are strongly associated with higher risk for short-term metastasis and poor outcome of MIBC, supporting modern noninvasive disease prognosis and management. CI - (c) American Association for Clinical Chemistry 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kotronopoulos, Georgios AU - Kotronopoulos G AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AUID- ORCID: 0000-0002-2135-9886 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. AD - Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Clin Chem JT - Clinical chemistry JID - 9421549 RN - 0 (Cell-Free Nucleic Acids) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Cell-Free Nucleic Acids/genetics MH - Neoplasm Recurrence, Local/genetics MH - Prognosis MH - *Urinary Bladder Neoplasms/genetics/surgery MH - Treatment Outcome MH - Biomarkers, Tumor/genetics EDAT- 2023/02/05 06:00 MHDA- 2023/04/05 06:42 CRDT- 2023/02/04 07:12 PHST- 2022/07/15 00:00 [received] PHST- 2022/11/22 00:00 [accepted] PHST- 2023/04/05 06:42 [medline] PHST- 2023/02/05 06:00 [pubmed] PHST- 2023/02/04 07:12 [entrez] AID - 7026056 [pii] AID - 10.1093/clinchem/hvac218 [doi] PST - ppublish SO - Clin Chem. 2023 Apr 3;69(4):399-410. doi: 10.1093/clinchem/hvac218. PMID- 36737799 OWN - NLM STAT- MEDLINE DCOM- 20230209 LR - 20260127 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 18 IP - 1 DP - 2023 Feb 3 TI - Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. PG - 11 LID - 10.1186/s13000-023-01295-y [doi] LID - 11 AB - Muscle-invasive bladder cancers (MIBCs) is a group of molecularly heterogonous diseases that could be stratified into subtypes with distinct clinical courses and sensitivities to chemotherapy. Clinical application of molecular subtypes could help in prediction of neoadjuvant chemotherapy (NAC) responders. Immunohistochemical (IHC) markers such as GATA3, cytokeratin (CK) 5/6, and p53 are associated with these subtypes and are widely available. Human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) are mutated in multiple cancers including MIBC and are potential therapeutic targets. HER2/EGFR status of MIBC subtypes has not been investigated. Tissue microarrays (TMAs) were constructed from transurethral resection of the bladder tumor (TURB) specimens and stained with GATA3,CK5/6,p53 and HER2 in addition to Quantitative Reverse Transcription PCR for detection of EGFR gene. Of the total cases, 45% were luminal, 36.7% basal and 18.3% p53 wild subtype (p53-WT). Univariate analysis showed that overall survival (OS) and disease-free progression survival (DFS) were significantly longer for luminal subtype. In multivariate analysis, molecular subtype, HER2 status and LV invasion were independent prognostic factors for DFS and OS. Basal subtype showed a significantly better response to NAC. HER2 expression was significantly higher in luminal while EGFR expression was significantly higher in basal subtype. Kaplan-Meier survival curves revealed a significant longer OS and DFS for HER2 negative than positive cases. MIBC can be stratified using a simple IHC panel [GATA3,CK5/6,P53] into clinically relevant prognostic molecular subtypes. Basal tumors are aggressive and respond well to NAC while luminal have better OS. P53-WT tumors are chemoresistant and require further treatments. HER2 and EGFR are potential therapeutic targets for molecular subtypes of MIBC where luminal tumors are more likely to benefit from HER2 and basal from EGFR directed therapies. CI - (c) 2023. The Author(s). FAU - Helal, Duaa S AU - Helal DS AD - Pathology Department, Faculty of Medicine, Tanta University, Tanta, 31527, Egypt. Duaa.helal@med.tanta.edu.eg. FAU - Darwish, Sara A AU - Darwish SA AD - Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Awad, Radwa A AU - Awad RA AD - Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Ali, Dina A AU - Ali DA AD - Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - El-Guindy, Dina M AU - El-Guindy DM AD - Pathology Department, Faculty of Medicine, Tanta University, Tanta, 31527, Egypt. LA - eng PT - Journal Article DEP - 20230203 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Female MH - Humans MH - Biomarkers, Tumor/genetics/metabolism MH - ErbB Receptors/genetics/metabolism MH - Genes, erbB-1 MH - Muscles/metabolism/pathology MH - Neoadjuvant Therapy MH - Prognosis MH - Erb-b2 Receptor Tyrosine Kinases/genetics/metabolism MH - Tumor Suppressor Protein p53/genetics/metabolism MH - *Urinary Bladder Neoplasms/drug therapy/genetics/metabolism PMC - PMC9896690 OTO - NOTNLM OT - Basal OT - GATA3,CK5/6,p53,HER2,EGFR OT - Luminal OT - Molecular classification OT - Muscle invasive bladder cancer OT - Response to chemotherapy OT - Survival COIS- The authors declare no competing interests. EDAT- 2023/02/05 06:00 MHDA- 2023/02/08 06:00 PMCR- 2023/02/03 CRDT- 2023/02/04 00:07 PHST- 2022/08/20 00:00 [received] PHST- 2023/01/16 00:00 [accepted] PHST- 2023/02/04 00:07 [entrez] PHST- 2023/02/05 06:00 [pubmed] PHST- 2023/02/08 06:00 [medline] PHST- 2023/02/03 00:00 [pmc-release] AID - 10.1186/s13000-023-01295-y [pii] AID - 1295 [pii] AID - 10.1186/s13000-023-01295-y [doi] PST - epublish SO - Diagn Pathol. 2023 Feb 3;18(1):11. doi: 10.1186/s13000-023-01295-y. PMID- 36737511 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240918 IS - 2509-4254 (Electronic) IS - 2509-4262 (Print) IS - 2509-4262 (Linking) VI - 7 IP - 3 DP - 2023 May TI - Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC). PG - 469-477 LID - 10.1007/s41669-023-00392-4 [doi] AB - OBJECTIVES: The treatments for high-grade non-muscle invasive bladder cancer (NMIBC) vary between bladder preserving intravesical approaches and radical cystectomy. The impact of these treatments on health-related quality of life may vary widely. The purpose of this study was to elicit the general public's perspective on quality of life, measured as utility scores associated with treatment for Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC and disease progression, for supporting economic evaluation of newly developed treatments for NMIBC. MATERIALS AND METHODS: Part I involved the development and testing of health states describing NMIBC, which was informed by a rapid review, expert input and a patient advisor. Part II involved elicitation of societal utility values for the different health states. Time trade-off (TTO) interviews were conducted with members of the UK general public. Five health states described different NMIBC scenarios including disease recurrence and progression. Participants ranked each health state, followed by the TTO valuation exercise. Descriptors included NMIBC symptom severity, impact and treatment characteristics. RESULTS: In total, 202 members of the general public participated. The mean age was 46 (standard deviation [SD] 14.6) years. Sample mean (SD) EQ-5D-5L visual analogue scale (VAS) and index scores were 83.2 (12.3) and 0.89 (0.18), respectively. Mean utilities were 0.781 for No High-Grade Recurrence, 0.586 for High-Grade Recurrence, 0.572 for > 1-Year Post-cystectomy and 0.283 for metastatic disease. The First Year Post-cystectomy path health state had a mean utility of 0.288. Pairwise comparisons found statistically significant differences between utilities (p < 0.001), except between High-Grade Recurrence and > 1-Year Post-cystectomy (p = 0.524). There were significant differences in utility scores by age and employment status. CONCLUSION: This study provides utility scores for health states describing living with NMIBC, which is associated with a significant health-related quality-of-life burden. These values address an existing gap in available data and have the potential to be used in models evaluating the cost-effectiveness of both current and newly developed treatments for bladder cancer. CI - (c) 2023. The Author(s). FAU - Cooper, Owen Alan Edwards AU - Cooper OAE AD - Evidera by PPD, London, UK. FAU - Ghatnekar, Ola AU - Ghatnekar O AD - Ferring Pharmaceuticals A/S, Copenhagen, Denmark. FAU - Piglowska, Natalia AU - Piglowska N AD - Evidera by PPD, London, UK. FAU - Smith, Charlie A AU - Smith CA AD - Evidera by PPD, London, UK. FAU - Swinburn, Paul AU - Swinburn P AUID- ORCID: 0000-0002-3303-5934 AD - Evidera by PPD, London, UK. Paul.Swinburn@evidera.com. FAU - Catto, James W F AU - Catto JWF AD - Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. FAU - Niegisch, Gunter AU - Niegisch G AD - Medical Faculty and University Hospital Dusseldorf, Heinrich Heine University, Dusseldorf, Germany. FAU - Jakobsen, Jorn Skibsted AU - Jakobsen JS AD - Ferring Pharmaceuticals A/S, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20230203 PL - Switzerland TA - Pharmacoecon Open JT - PharmacoEconomics - open JID - 101700780 PMC - PMC9897878 COIS- Owen Alan Edwards Cooper, Natalia Piglowska, Charlie Smith and Paul Swinburn are employees of Evidera PPD, a CRO paid by Ferring Pharmaceuticals A/S to conduct this study. Ola Ghatnekar and Jorn Skibsted Jakobsen are employees of Ferring Pharmaceuticals A/S. James Catto received honoraria for membership of advisory boards for Ferring Pharmaceuticals A/S. Gunter Niegisch received consulting fees from Ferring Pharmaceuticals A/S. EDAT- 2023/02/04 06:00 MHDA- 2023/02/04 06:01 PMCR- 2023/02/03 CRDT- 2023/02/03 23:31 PHST- 2023/01/16 00:00 [accepted] PHST- 2023/02/04 06:01 [medline] PHST- 2023/02/04 06:00 [pubmed] PHST- 2023/02/03 23:31 [entrez] PHST- 2023/02/03 00:00 [pmc-release] AID - 10.1007/s41669-023-00392-4 [pii] AID - 392 [pii] AID - 10.1007/s41669-023-00392-4 [doi] PST - ppublish SO - Pharmacoecon Open. 2023 May;7(3):469-477. doi: 10.1007/s41669-023-00392-4. Epub 2023 Feb 3. PMID- 36730353 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20230406 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 2 DP - 2023 TI - Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: A population-based study. PG - e0281304 LID - 10.1371/journal.pone.0281304 [doi] LID - e0281304 AB - BACKGROUND: Intravesical recurrence (IVR) after surgery for upper tract urothelial carcinoma (UTUC) is a clinical problem. We investigated if preoperative invasive diagnostic modalities (IDM) such as antegrade/retrograde uretero-pyelography and/or selective urine cytology/barbotage, and URS with or without concomitant biopsy are associated with IVR after radical surgery for UTUC. Risk of death from urothelial cancer and all causes was investigated as secondary outcomes. METHODS: We investigated a population-based cohort of 1038 consecutive patients subjected to radical surgery for UTUC 2015-2019 in Sweden, using the Bladder Cancer Data Base Sweden (BladderBaSe 2.0), comprising all patients in the Swedish National Registry of Urinary Bladder Cancer. Risk estimates of IVR, death from urothelial cancer, and all causes was assessed using multivariable Cox regression models. RESULTS: The study included 536 cases with and 502 without preoperative IDM. IDM was associated with increased risk of IVR (HR 1.24, 95% CI 1.03-1.52) and risk of urothelial cancer death (HR 1.56, CI 1.12-2.18), compared to no IDM after a median follow-up of 1.3 yrs. Stratified analysis for tumor location showed that IDM was associated with risk of IVR in ureteric cancer (HR 1.66, 95% CI 1.21-2.28) but not in renal pelvic cancer (HR 1.07, 95% CI 0.81-1.41). Limitations included the observational setting and the lack of variables such as tumour grade, multifocality and preoperative hydronephrosis. CONCLUSIONS: Worse outcomes for patients subjected to preoperative IDM highlight the need for carefully considering diagnostic decisions for UTUC patients, specifically in tumours located in the ureter. CI - Copyright: (c) 2023 Liedberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Department of Public Health and Clinical Medicine, Northern Register Centre, Umea University, Umea, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AUID- ORCID: 0000-0003-4615-5238 AD - Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Department of Radiation Sciences, Umea University, Umea, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. AD - Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Karolinska University Hospital, Stockholm, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom. FAU - Bobjer, Johannes AU - Bobjer J AUID- ORCID: 0000-0001-8495-3498 AD - Department of Urology Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230202 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/surgery/complications MH - *Carcinoma, Transitional Cell/pathology MH - Nephrectomy/adverse effects MH - *Ureter/pathology MH - *Ureteral Neoplasms/diagnosis/surgery/pathology MH - Retrospective Studies MH - Neoplasm Recurrence, Local/surgery PMC - PMC9894449 COIS- The authors have declared that no competing interests exist. EDAT- 2023/02/03 06:00 MHDA- 2023/02/07 06:00 PMCR- 2023/02/02 CRDT- 2023/02/02 13:56 PHST- 2022/12/01 00:00 [received] PHST- 2023/01/20 00:00 [accepted] PHST- 2023/02/02 13:56 [entrez] PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] PHST- 2023/02/02 00:00 [pmc-release] AID - PONE-D-22-33016 [pii] AID - 10.1371/journal.pone.0281304 [doi] PST - epublish SO - PLoS One. 2023 Feb 2;18(2):e0281304. doi: 10.1371/journal.pone.0281304. eCollection 2023. PMID- 36727059 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240124 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis. PG - 1102392 LID - 10.3389/fonc.2022.1102392 [doi] LID - 1102392 AB - INTRODUCTION: Bladder cancer (BC) is a significant carcinoma of the urinary system that has a high incidence of morbidity and death owing to the challenges in accurately identifying people with early-stage BC and the lack of effective treatment options for those with advanced BC. Thus, there is a need to define new markers of prognosis and prediction. METHODS: In this study, we have performed a comprehensive proteomics experiment by label-free quantitative proteomics to compare the proteome changes in the serum of normal people and bladder cancer patients-the successful quantification of 2064 Quantifiable proteins in total. A quantitative analysis was conducted to determine the extent of changes in protein species' relative intensity and reproducibility. There were 43 upregulated proteins and 36 downregulated proteins discovered in non-muscle invasive bladder cancer and normal individuals. Sixty-four of these proteins were elevated, and 51 were downregulated in muscle-invasive and non-muscle-invasive bladder cancer, respectively. Functional roles of differentially expressed proteins were annotated using Gene Ontology (GO) and Clusters of Orthologous Groups of Proteins (COG). To analyze the functions and pathways enriched by differentially expressed proteins, GO enrichment analysis, protein domain analysis, and KEGG pathway analysis were performed. The proteome differences were examined and visualized using radar plots, heat maps, bubble plots, and Venn diagrams. RESULTS: As a result of combining the Venn diagram with protein-protein interactions (PPIs), Chloride intracellular channel 1 (CLIC1) was identified as the primary protein. Using the Gene Set Cancer Analysis (GSCA) website, the influence of CLIC1 on immune infiltration was analyzed. A negative correlation between CD8 naive and CLIC1 levels was found. For validation, immunohistochemical (IHC), qPCR, and western blotting (WB) were performed.Further, we found that CLIC1 was associated with a poor prognosis of bladder cancer in survival analysis. DISCUSSION: Our research screened CLIC1 as a tumor-promoting protein in bladder cancer for the first time using serum mass spectrometry. And CLIC1 associated with tumor stage, and immune infiltrate. The prognostic biomarker and therapeutic target CLIC1 may be new for bladder cancer patients. CI - Copyright (c) 2023 Wang, Huang, Lin, Ren, Fu and Mao. FAU - Wang, Weifeng AU - Wang W AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Huang, Guankai AU - Huang G AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Lin, Hansen AU - Lin H AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. AD - Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Ren, Lei AU - Ren L AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Fu, Liangmin AU - Fu L AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. AD - Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Mao, Xiaopeng AU - Mao X AD - Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. LA - eng PT - Journal Article DEP - 20230116 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 EIN - Front Oncol. 2024 Jan 09;13:1216134. doi: 10.3389/fonc.2023.1216134. PMID: 38264752 PMC - PMC9885092 OTO - NOTNLM OT - CLIC1 OT - biology-informed analysis OT - bladder cancer OT - prognosis OT - proteomics COIS- The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/03 06:00 MHDA- 2023/02/03 06:01 PMCR- 2022/01/01 CRDT- 2023/02/02 02:06 PHST- 2022/11/18 00:00 [received] PHST- 2022/12/22 00:00 [accepted] PHST- 2023/02/02 02:06 [entrez] PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/03 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1102392 [doi] PST - epublish SO - Front Oncol. 2023 Jan 16;12:1102392. doi: 10.3389/fonc.2022.1102392. eCollection 2022. PMID- 36725382 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20231117 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 7 DP - 2023 Jul TI - Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. PG - 325.e15-325.e23 LID - S1078-1439(22)00494-X [pii] LID - 10.1016/j.urolonc.2022.12.011 [doi] AB - BACKGROUND: Bladder-sparing chemoradiation therapy (CRT) is a definitive first-line treatment for muscle-invasive bladder cancer. The optimal radiotherapy target volume, either bladder-only (BO) or bladder plus pelvic lymph nodes (BPN), remains unclear. METHODS: We identified 2,104 patients in the National Cancer Database with cT2-4N0M0 urothelial cell carcinoma of the bladder treated with CRT following maximal transurethral resection of bladder tumor from 2004 to 2016. The exposure of interest was BO vs. BPN treatment volume. The primary outcome was overall survival (OS), compared between groups using Kaplan-Meier and multivariable Cox proportional hazards. Sensitivity analysis tested an interaction term for clinical T stage (T2 vs. T3-4) and radiation modality (3-dimensional conformal radiotherapy vs. intensity modulated radiotherapy or proton therapy). Annual use of BO vs. BPN from 2004 to 2016 was compared using Cochran-Armitage test. RESULTS: A total of 578 patients were treated with BO and 1,526 patients treated with BPN CRT. There was a significant increase in BPN use from 2004 to 2016 (66.9%-76.8%, P < 0.0001). With a median follow-up of 6.2 years, there was no survival difference between groups: 5- and 10-year OS 27.4% (95% CI 23.4%-31.4%) in the BO group vs. 31.9% (95% CI 29.3%-34.6%) in the BPN group, and 13.1% (95% CI 9.7%-17.1%) in the BO group vs. 13.2% (95% CI 10.6%-16.0%) in the BPN group, respectively (log-rank P = 0.10). On multivariable analysis, there was no significant association between BPN and OS (adjusted HR 0.90, 95% CI 0.81-1.02, P = 0.09). On sensitivity analysis, we found no differential effect by T stage or radiation modality. CONCLUSION: Use of pelvic lymph node radiation has risen in the US but may not impact long-term survival outcomes for patients with node-negative muscle-invasive bladder cancer (MIBC). Optimizing radiation treatment volumes for CRT for MIBC will be important to study under prospective trials, such as the SWOG/NRG 1806. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Patel, Sagar A AU - Patel SA AD - Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta GA. Electronic address: sagar.patel@emory.edu. FAU - Liu, Yuan AU - Liu Y AD - Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta GA. FAU - Solanki, Abhishek A AU - Solanki AA AD - Department of Radiation Oncology, Loyola University Medical Center, Chicago IL. FAU - Baumann, Brian C AU - Baumann BC AD - Department of Radiation Oncology, Washington University, St. Louis MO. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston MA. FAU - Jani, Ashesh B AU - Jani AB AD - Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta GA. FAU - Chang, Albert J AU - Chang AJ AD - Department of Radiation Oncology, University of California, Los Angeles CA. FAU - Fischer-Valuck, Benjamin AU - Fischer-Valuck B AD - Denver Radiation Oncology at Swedish, Englewood CO. FAU - Royce, Trevor J AU - Royce TJ AD - Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC. LA - eng GR - P30 CA138292/CA/NCI NIH HHS/United States GR - K12 CA237806/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230130 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Urinary Bladder/surgery/pathology MH - Prospective Studies MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/pathology MH - Lymph Nodes/pathology MH - Muscles/pathology OTO - NOTNLM OT - Bladder cancer OT - Pelvic nodes OT - Radiation, Fields COIS- Conflict of interest None. EDAT- 2023/02/02 06:00 MHDA- 2023/06/19 13:08 CRDT- 2023/02/01 21:59 PHST- 2022/11/08 00:00 [received] PHST- 2022/12/22 00:00 [revised] PHST- 2022/12/24 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/02/01 21:59 [entrez] AID - S1078-1439(22)00494-X [pii] AID - 10.1016/j.urolonc.2022.12.011 [doi] PST - ppublish SO - Urol Oncol. 2023 Jul;41(7):325.e15-325.e23. doi: 10.1016/j.urolonc.2022.12.011. Epub 2023 Jan 30. PMID- 36721688 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 10 IP - 1 DP - 2023 Jan TI - Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013. PG - 9-18 LID - 10.1016/j.ajur.2021.10.002 [doi] AB - OBJECTIVE: Guidelines for muscle-invasive bladder cancer (MIBC) recommend that patients receive neoadjuvant chemotherapy with radical cystectomy as treatment over radical cystectomy alone. Though trends and practice patterns of MIBC have been defined using the National Cancer Database, data using the Surveillance, Epidemiology, and End Results (SEER) program have been poorly described. METHODS: Using the SEER database, we collected data of MIBC according to the American Joint Commission on Cancer. We considered differences in patient demographics and tumor characteristics based on three treatment groups: chemotherapy (both adjuvant and neoadjuvant) with radical cystectomy, radical cystectomy, and chemoradiotherapy. Multinomial logistic regression was performed to compare likelihood ratios. Temporal trends were included for each treatment group. Kaplan-Meier curves were performed to compare cause-specific survival. A Cox proportional-hazards model was utilized to describe predictors of survival. RESULTS: Of 16 728 patients, 10 468 patients received radical cystectomy alone, 3236 received chemotherapy with radical cystectomy, and 3024 received chemoradiotherapy. Patients who received chemoradiotherapy over radical cystectomy were older and more likely to be African American; stage III patients tended to be divorced. Patients who received chemotherapy with radical cystectomy tended to be males; stage II patients were less likely to be Asian than Caucasian. Stage III patients were less likely to receive chemoradiotherapy as a treatment option than stage II. Chemotherapy with radical cystectomy and chemoradiotherapy are both underutilized treatment options, though increasingly utilized. Kaplan-Meier survival curves showed significant differences between stage II and III tumors at each interval. A Cox proportional-hazards model showed differences in gender, tumor stage, treatment modality, age, and marital status. CONCLUSION: Radical cystectomy alone is still the most commonly used treatment for muscle-invasive bladder cancer based on temporal trends. Significant disparities exist in those who receive radical cystectomy over chemoradiotherapy for treatment. CI - (c) 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. FAU - Chalfant, Victor AU - Chalfant V AD - Urology at CHI Health Creighton University Medical Center Omaha, NE, USA. FAU - Blute, Michael L Jr AU - Blute ML Jr AD - Urology at CHI Health Creighton University Medical Center Omaha, NE, USA. FAU - Silberstein, Peter AU - Silberstein P AD - Hematology Oncology at CHI Health Creighton University Medical Center Omaha, NE, USA. LA - eng PT - Journal Article DEP - 20211102 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC9875153 OTO - NOTNLM OT - Bladder-preservation therapy OT - Chemoradiotherapy OT - Epidemiology, and End Results Program OT - Kaplan-Meier survival curves OT - Muscle-invasive bladder cancer OT - Patient demographics OT - Practice trends OT - Surveillance OT - Transurethral resection of bladder tumor COIS- The authors declare no conflict of interest. EDAT- 2023/02/02 06:00 MHDA- 2023/02/02 06:01 PMCR- 2021/11/02 CRDT- 2023/02/01 01:49 PHST- 2020/09/06 00:00 [received] PHST- 2021/05/26 00:00 [revised] PHST- 2021/06/15 00:00 [accepted] PHST- 2023/02/01 01:49 [entrez] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/02/02 06:01 [medline] PHST- 2021/11/02 00:00 [pmc-release] AID - S2214-3882(21)00103-X [pii] AID - 10.1016/j.ajur.2021.10.002 [doi] PST - ppublish SO - Asian J Urol. 2023 Jan;10(1):9-18. doi: 10.1016/j.ajur.2021.10.002. Epub 2021 Nov 2. PMID- 36713575 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia. PG - 1101830 LID - 10.3389/fonc.2022.1101830 [doi] LID - 1101830 AB - INTRODUCTION: The inflammatory response plays a potential role in postoperative recurrence in patients with non-muscular invasive bladder cancer (NMIBC). We aimed to investigate whether platelet-to-lymphocyte ratio (PLR), mean platelet volume to lymphocyte ratio (MPVLR), and the systemic immune-inflammatory index (SII) have prognostic values in NMIBC treated with conventional intravesical chemotherapy or intravesical Chemohyperthermia (CHT) and the differences between them. MATERIALS AND METHODS: A retrospective cohort study was conducted on 222 patients with NMIBC treated with Intravesical Chemotherapy or Intravesical CHT between January 2016 and December 2020. Within a week before surgery, PLR, MPVLR, and SII were determined based on routine blood settling. The optimal cutoff value of each index was determined using the receiver operating characteristic curve, and various groups were categorized accordingly. The factors influencing the prognosis of NMIBC patients receiving various treatments were investigated using the Kaplan- Meier survival curve and the Cox regression model. RESULTS: 69 cases (46.3%) in the gemcitabine (GEM) group had tumor recurrence and 19 (12.8%) of them progressed to muscle-invasive bladder cancer (MIBC) or got metastasis, while 19 cases (26.0%) in the CHT group recurred and 2 (2.7%) progressed. Elevated PLR, MPVLR, and SII were associated with higher recurrence rates in the GEM group. Meanwhile, PLR and MPVLR were the independent risk factors. While in the CHT group, high PLR and SII were related to postoperative recurrence and none of them were independent risk factors. CONCLUSION: The preoperative clinical inflammatory indexes PLR, SII, and MPVLR have certain predictive value for the postoperative recurrence-free survival (RFS) in NMIBC patients treated with intravesical chemotherapy while PLR and SII can predict the prognosis of NMIBC patients treated with intravesical CHT, which indicates that intravesical CHT may stop tumor recurrence by influencing the effect of mean platelet volume on tumor growth through some unknown mechanisms. CI - Copyright (c) 2023 Wang, Jin, Ma and Dong. FAU - Wang, Chengbo AU - Wang C AD - The Department of Urology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu, China. FAU - Jin, Wenjun AU - Jin W AD - The Department of Urology, Wuwei Cancer Hospital of Gansu Province, Wuwei, Gansu, China. FAU - Ma, Xiaodong AU - Ma X AD - The Department of Urology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu, China. FAU - Dong, Zhilong AU - Dong Z AD - The Department of Urology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu, China. LA - eng PT - Journal Article DEP - 20230111 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9874935 OTO - NOTNLM OT - hyperthermia OT - intravesical chemotherapy OT - mean platelet volume to lymphocyte ratio OT - non-muscular invasive bladder cancer OT - platelet to lymphocyte ratio OT - recurrence OT - systemic immune inflammation index COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/31 06:00 MHDA- 2023/01/31 06:01 PMCR- 2022/01/01 CRDT- 2023/01/30 04:16 PHST- 2022/11/18 00:00 [received] PHST- 2022/12/22 00:00 [accepted] PHST- 2023/01/30 04:16 [entrez] PHST- 2023/01/31 06:00 [pubmed] PHST- 2023/01/31 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1101830 [doi] PST - epublish SO - Front Oncol. 2023 Jan 11;12:1101830. doi: 10.3389/fonc.2022.1101830. eCollection 2022. PMID- 36713366 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230202 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance. PG - 1071390 LID - 10.3389/fimmu.2022.1071390 [doi] LID - 1071390 AB - Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT), a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guerin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice. CI - Copyright (c) 2023 Liu, Li, Xia and Xu. FAU - Liu, Tiantian AU - Liu T AD - Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China. FAU - Li, Shihong AU - Li S AD - Department of Pathology, Maternal and Child Health Hospital of Liaocheng, Liaocheng, China. FAU - Xia, Chuanyou AU - Xia C AD - Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China. FAU - Xu, Dawei AU - Xu D AD - Department of Medicine, Bioclinicum and Center for Molecular Medicine (CMM), Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230112 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EC 2.7.7.49 (Telomerase) RN - EC 2.7.7.49 (TERT protein, human) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - *Carcinoma, Transitional Cell/genetics MH - *Telomerase/genetics/metabolism MH - Methylation MH - Clinical Relevance MH - Mutation PMC - PMC9877314 OTO - NOTNLM OT - BCG OT - TERT OT - immunotherapy OT - promoter methylation OT - promoter mutations OT - telomerase OT - urothelial carcinoma OT - urothelial cells COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/31 06:00 MHDA- 2023/02/01 06:00 PMCR- 2022/01/01 CRDT- 2023/01/30 04:15 PHST- 2022/10/16 00:00 [received] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/30 04:15 [entrez] PHST- 2023/01/31 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1071390 [doi] PST - epublish SO - Front Immunol. 2023 Jan 12;13:1071390. doi: 10.3389/fimmu.2022.1071390. eCollection 2022. PMID- 36713048 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 16 DP - 2023 TI - Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer. PG - 283-296 LID - 10.2147/JIR.S393511 [doi] AB - INTRODUCTION: Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) have been widely proposed to have predictive value for the patient prognosis of many malignancies, including bladder cancer. However, the predictive value of their combination in non-muscle-invasive bladder cancer (NMIBC) is unclear. METHODS: Cases of NMIBC patients who underwent transurethral resection of the bladder tumor were recruited from two tertiary public medical centers. A systemic inflammatory marker (SIM) score was calculated based on comprehensive consideration of NLR, PLR, and LMR. Recurrence-free survival (RFS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. The Log rank test was used to compare differences between the groups. Cox regression was used to screen risk factors affecting RFS and PFS. Nomogram models were established and validated, and patients were stratified based on the model scores. RESULTS: The study dataset was grouped according to a 7:3 randomization, with the training cohort consisting of 292 cases and the validation cohort consisting of 124 cases. Cox regression analysis showed that SIM score is an independent predictor of RFS and PFS in NMIBC patients. The novel models were established based on the SIM score and other statistically significant clinicopathological features. The area under the curve (AUC) for predicting 1-, 2-, and 3-year RFS was 0.667, 0.689, and 0.713, respectively. The AUC for predicting 1-, 2-, and 3-year PFS was 0.807, 0.775, and 0.862, respectively. Based on the risk stratification, patients at high risk of recurrence and progression could be accurately identified. The established models were applied to the patient evaluation of the validation cohort, which proved the great performance of the novel models. CONCLUSION: The novel models based on the SIM score and clinicopathological characteristics can accurately predict the survival prognosis of NMIBC patients, and the models can be used by clinicians for individualized patient assessment and to assist in clinical decision-making. CI - (c) 2023 Ding et al. FAU - Ding, Li AU - Ding L AUID- ORCID: 0000-0003-1561-0250 AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Deng, Xiaobin AU - Deng X AD - Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530000, People's Republic of China. FAU - Wang, Kun AU - Wang K AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Xia, Wentao AU - Xia W AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Zhang, Yang AU - Zhang Y AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Zhang, Yan AU - Zhang Y AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Shao, Xianfeng AU - Shao X AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People's Republic of China. LA - eng PT - Journal Article DEP - 20230121 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 PMC - PMC9875575 OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - nomogram OT - risk factor OT - systemic inflammatory markers OT - tumor recurrence COIS- The authors declare that they have no competing interests for this work. EDAT- 2023/01/31 06:00 MHDA- 2023/01/31 06:01 PMCR- 2023/01/21 CRDT- 2023/01/30 04:10 PHST- 2022/10/20 00:00 [received] PHST- 2022/12/24 00:00 [accepted] PHST- 2023/01/30 04:10 [entrez] PHST- 2023/01/31 06:00 [pubmed] PHST- 2023/01/31 06:01 [medline] PHST- 2023/01/21 00:00 [pmc-release] AID - 393511 [pii] AID - 10.2147/JIR.S393511 [doi] PST - epublish SO - J Inflamm Res. 2023 Jan 21;16:283-296. doi: 10.2147/JIR.S393511. eCollection 2023. PMID- 36704283 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 9 IP - 1 DP - 2023 Jan TI - Bladder cancer-associated microbiota: Recent advances and future perspectives. PG - e13012 LID - 10.1016/j.heliyon.2023.e13012 [doi] LID - e13012 AB - Recent evidence suggests that the human genitourinary microbiome plays a significant role in mediating the development and progression of urological tumors, including bladder cancer (BC). Clinicians widely recognize the role of Bacille Calmette Guerin (BCG), an attenuated Mycobacterium tuberculosis vaccine, in the management of intermediate- and high-risk NMIBC. However, compared to the large body of evidence on the gut microbiota and gastrointestinal tumors, limited information is available about the interaction between BC and the genitourinary microbiome. This is an expanding field that merits further investigation. Urologists will need to consider the potential impact of the microbiome in BC diagnosis, prevention of recurrence and progression, and treatment prospects in the future. This review highlights the approaches adopted for microbiome research and the findings and inadequacies of current research on BC. CI - (c) 2023 The Authors. Published by Elsevier Ltd. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Yang, Fuhan AU - Yang F AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Mao, Shiyu AU - Mao S AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Wang, Ruiliang AU - Wang R AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Chen, Haotian AU - Chen H AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Ran, Yuefei AU - Ran Y AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. AD - Shanghai Clinical College, Anhui Medical University, Hefei, China. FAU - Liu, Shenghua AU - Liu S AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Wu, Pengfei AU - Wu P AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Yan, Yang AU - Yan Y AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Li, Wei AU - Li W AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Zhang, Junfeng AU - Zhang J AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. LA - eng PT - Journal Article PT - Review DEP - 20230116 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC9871226 OTO - NOTNLM OT - Bladder cancer OT - Microbiota OT - Prognosis OT - Recurrence OT - Therapeutics COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/28 06:00 MHDA- 2023/01/28 06:01 PMCR- 2023/01/16 CRDT- 2023/01/27 02:22 PHST- 2022/10/31 00:00 [received] PHST- 2022/11/30 00:00 [revised] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/27 02:22 [entrez] PHST- 2023/01/28 06:00 [pubmed] PHST- 2023/01/28 06:01 [medline] PHST- 2023/01/16 00:00 [pmc-release] AID - S2405-8440(23)00219-0 [pii] AID - e13012 [pii] AID - 10.1016/j.heliyon.2023.e13012 [doi] PST - epublish SO - Heliyon. 2023 Jan 16;9(1):e13012. doi: 10.1016/j.heliyon.2023.e13012. eCollection 2023 Jan. PMID- 36693329 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230321 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 107 IP - 3 DP - 2023 TI - Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications. PG - 246-256 LID - 10.1159/000528579 [doi] AB - INTRODUCTION: RC represents a viable treatment option for certain NMIBC patients. However, studies investigating morbidity in the context of RC for NMIBC are scarce. The goal of the current study was to assess and compare morbidity after RC performed in patients with NMIBC and patients with MIBC and to identify risk factors for severe short-term complications. METHODS: Medical records of 521 patients who underwent RC for bladder cancer were retrospectively reviewed. Patients were divided into patients with NMIBC and patients with MIBC. The groups were compared and risk factors for severe complications were identified. RESULTS: RC for NMIBC was performed in 123 patients (23.6%). Histological upstaging was seen in 47 NMIBC patients (38.2%) and in 231 MIBC patients (58%, p < 0.001). OS was 29.8% and CSS was 15.5%. Both endpoints were higher for RC for MIBC (p < 0.001). More complications affecting the urinary diversion were seen with RC for NMIBC (p = 0.033) and more continent urinary diversions (p = 0.040) were performed in those patients. Obesity (p = 0.008), a higher ASA score (p = 0.004), and preoperative medical drug anticoagulation (p = 0.025) were risk factors for severe short-term morbidity after both, RC for NMIBC and for MIBC. CONCLUSION: Patients who underwent RC for NMIBC are exposed to a comparably high perioperative risk than patients with MIBC. RC seems to be a viable treatment option for certain NMIBC patients with a significant histological upstaging in both groups. In patients with obesity, a high ASA score, and with medical drug anticoagulation, the indication for surgery should be confirmed especially strict and possible treatment alternatives should be considered particularly thorough. CI - (c) 2023 The Author(s). Published by S. Karger AG, Basel. FAU - Haas, Maximilian AU - Haas M AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Knobloch, Charlotte AU - Knobloch C AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Pickl, Christoph AU - Pickl C AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Engelmann, Simon AU - Engelmann S AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. FAU - Holbach, Sonja AU - Holbach S AD - Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20230124 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - Cystectomy/adverse effects MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Risk Factors MH - Obesity/complications/surgery MH - Anticoagulants MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder carcinoma OT - Complications OT - Cystectomy OT - Morbidity OT - Non-muscle-invasive bladder cancer OT - Urothelial neoplasm EDAT- 2023/01/25 06:00 MHDA- 2023/03/22 06:00 CRDT- 2023/01/24 18:23 PHST- 2022/07/12 00:00 [received] PHST- 2022/11/22 00:00 [accepted] PHST- 2023/01/25 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] PHST- 2023/01/24 18:23 [entrez] AID - 000528579 [pii] AID - 10.1159/000528579 [doi] PST - ppublish SO - Urol Int. 2023;107(3):246-256. doi: 10.1159/000528579. Epub 2023 Jan 24. PMID- 36691055 OWN - NLM STAT- MEDLINE DCOM- 20230125 LR - 20231119 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 21 IP - 1 DP - 2023 Jan 23 TI - An artificial intelligence model for the pathological diagnosis of invasion depth and histologic grade in bladder cancer. PG - 42 LID - 10.1186/s12967-023-03888-z [doi] LID - 42 AB - BACKGROUND: Accurate pathological diagnosis of invasion depth and histologic grade is key for clinical management in patients with bladder cancer (BCa), but it is labour-intensive, experience-dependent and subject to interobserver variability. Here, we aimed to develop a pathological artificial intelligence diagnostic model (PAIDM) for BCa diagnosis. METHODS: A total of 854 whole slide images (WSIs) from 692 patients were included and divided into training and validation sets. The PAIDM was developed using the training set based on the deep learning algorithm ScanNet, and the performance was verified at the patch level in validation set 1 and at the WSI level in validation set 2. An independent validation cohort (validation set 3) was employed to compare the PAIDM and pathologists. Model performance was evaluated using the area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value and negative predictive value. RESULTS: The AUCs of the PAIDM were 0.878 (95% CI 0.875-0.881) at the patch level in validation set 1 and 0.870 (95% CI 0.805-0.923) at the WSI level in validation set 2. In comparing the PAIDM and pathologists, the PAIDM achieved an AUC of 0.847 (95% CI 0.779-0.905), which was non-inferior to the average diagnostic level of pathologists. There was high consistency between the model-predicted and manually annotated areas, improving the PAIDM's interpretability. CONCLUSIONS: We reported an artificial intelligence-based diagnostic model for BCa that performed well in identifying invasion depth and histologic grade. Importantly, the PAIDM performed admirably in patch-level recognition, with a promising application for transurethral resection specimens. CI - (c) 2023. The Author(s). FAU - Pan, Jiexin AU - Pan J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Hong, Guibin AU - Hong G AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Zeng, Hong AU - Zeng H AD - Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Liao, Chengxiao AU - Liao C AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. FAU - Li, Huarun AU - Li H AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. FAU - Yao, Yuhui AU - Yao Y AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. FAU - Gan, Qinghua AU - Gan Q AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. FAU - Wang, Yun AU - Wang Y AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. FAU - Wu, Shaoxu AU - Wu S AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. wushx29@mail.sysu.edu.cn. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. wushx29@mail.sysu.edu.cn. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, China. wushx29@mail.sysu.edu.cn. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. lintx@mail.sysu.edu.cn. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. lintx@mail.sysu.edu.cn. AD - Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou, Guangdong, China. lintx@mail.sysu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230123 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 SB - IM MH - Humans MH - *Artificial Intelligence MH - Algorithms MH - *Urinary Bladder Neoplasms MH - Predictive Value of Tests PMC - PMC9869632 OTO - NOTNLM OT - Artificial intelligence OT - Bladder cancer OT - Histologic grade OT - Muscle invasion OT - Pathological diagnosis COIS- The authors declare that they have no competing interests. EDAT- 2023/01/24 06:00 MHDA- 2023/01/26 06:00 PMCR- 2023/01/23 CRDT- 2023/01/23 23:39 PHST- 2022/08/20 00:00 [received] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/23 23:39 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/26 06:00 [medline] PHST- 2023/01/23 00:00 [pmc-release] AID - 10.1186/s12967-023-03888-z [pii] AID - 3888 [pii] AID - 10.1186/s12967-023-03888-z [doi] PST - epublish SO - J Transl Med. 2023 Jan 23;21(1):42. doi: 10.1186/s12967-023-03888-z. PMID- 36681259 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230403 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 41 DP - 2023 Mar TI - Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer. PG - 103294 LID - S1572-1000(23)00023-6 [pii] LID - 10.1016/j.pdpdt.2023.103294 [doi] AB - BACKGROUND: Patient selection for transurethral resection of the bladder tumor using photodynamic diagnosis (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA) hydrochloride for non-muscle-invasive bladder cancer (NMIBC) is still unclear as to the best balance of risks (adverse events including hypotension) and benefits (reduction of intravesical recurrence). METHODS: This single-center retrospective study between April 2013 and March 2022, compared the intravesical recurrence-free survival between patients who underwent PDD-TURBT and WL-TURBT using propensity score matching. RESULTS: A total of 222 patients who underwent PDD-TURBT and 177 patients who underwent WL-TURBT for NMIBC were included. Propensity score matching was used to compare intravesical recurrence-free survival in 119 NMIBC patients in the both treatment groups. The intravesical recurrence-free survival within 500 days was significantly higher in the PDD-TURBT group than in the WL-TURBT group (P = 0.039; hazard ratio [HR] 0.48 [0.23-0.98]). Subgroup analysis showed that PDD-TURBT contributed to the reduction of short-term intravesical recurrence in patients aged < 75 years (P = 0.02; HR 0.22 [0.06-0.79]) and primary disease (P = 0.038; HR 0.35 [0.13-0.94]). Hypotension with a systolic blood pressure of < 80 mmHg was observed in 79 patients (35.6%) during PDD-TURBT surgery. In particular, age >/=75 years and general anesthesia were independent prognostic factors for predicting intraoperative hypotension. CONCLUSIONS: PDD-TURBT reduced short-term intravesical recurrence in NMIBC, whereas a higher frequency of hypotension was found in patients aged >/= 75 years. These results suggest that the risks and benefits of PDD-TURBT are well balanced in younger patients (< 75 years) and those with primary disease. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Kobayashi, Keita AU - Kobayashi K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. Electronic address: kkoba@yamaguchi-u.ac.jp. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Oka, Shintaro AU - Oka S AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Nakamura, Kimihiko AU - Nakamura K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Misumi, Taku AU - Misumi T AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Hiroyoshi, Toshiya AU - Hiroyoshi T AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Ito, Hideaki AU - Ito H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Isoyama, Naohito AU - Isoyama N AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Hirata, Hiroshi AU - Hirata H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. FAU - Shiraishi, Koji AU - Shiraishi K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. LA - eng PT - Journal Article DEP - 20230118 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Humans MH - Photosensitizing Agents/adverse effects MH - Aminolevulinic Acid/adverse effects MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Photochemotherapy/methods MH - *Urinary Bladder Neoplasms/diagnosis MH - Cystectomy/methods MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - Risk Assessment OTO - NOTNLM OT - ALA OT - Bladder OT - Bladder cancer OT - Photodynamic Diagnosis OT - Transurethral resection COIS- Declaration of Competing Interest None. EDAT- 2023/01/22 06:00 MHDA- 2023/04/03 06:41 CRDT- 2023/01/21 19:26 PHST- 2022/11/22 00:00 [received] PHST- 2023/01/15 00:00 [revised] PHST- 2023/01/17 00:00 [accepted] PHST- 2023/04/03 06:41 [medline] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/21 19:26 [entrez] AID - S1572-1000(23)00023-6 [pii] AID - 10.1016/j.pdpdt.2023.103294 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2023 Mar;41:103294. doi: 10.1016/j.pdpdt.2023.103294. Epub 2023 Jan 18. PMID- 36680930 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20240628 IS - 1532-8198 (Electronic) IS - 1092-9134 (Print) IS - 1092-9134 (Linking) VI - 63 DP - 2023 Apr TI - Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma. PG - 152081 LID - S1092-9134(22)00183-6 [pii] LID - 10.1016/j.anndiagpath.2022.152081 [doi] AB - BACKGROUND: Recent studies have shown that the classification of high-grade urothelial carcinoma non-muscle invasive (HGBCNMI) based on molecular subtypes might be a valuable strategy to identify patients with a worse clinical prognosis. OBJECTIVE: Determine the effect of the luminal and basal molecular subtype determined by immunistochemical on prognosis in patients with HGBC in Mexican population. METHODS: Phenotypes were evaluated by immunohistochemical staining of luminal (GATA3, FOXA1) and basal (CK5/6, CK14) markers in paraffin-embedded tissue samples from 45 patients with a diagnosis of HGBCNMI treated at Instituto Nacional de Cancerologia-Mexico (INCan) between 2009 and 2019. The association with prognosis was evaluated using Kaplan-Meier curves and multivariable-adjusted Cox models. RESULTS: HGBCNMI patients showed mean age of 58.77 years (SD: +/-12.08 years). We identified expression of the luminal molecular subtype in 35 cases (77.78 %), and 10 cases (22.22 %) with "combined" expression of the molecular subtype (basal and luminal expression). The combined phenotype was statistically more frequent in metastatic cases (p-value = 0.028). In Kaplan-Meier curves, combined expression of luminal and basal molecular markers was associated with disease progression (p-value = 0.002, log-rank test). Cox regression models confirmed this association, which was not influenced by age (p-value = 0.007) or gender (p-value = 0.007). No association of phenotypes with overall survival (p-value = 0.860) or relapse (p-value = 0.5) was observed. CONCLUSION: The combined expression of immunohistochemical markers of the luminal and basal subtype might be considered as predictor for disease progression in patients with HGBCNMI in Mexican population. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Perez-Montiel, Delia AU - Perez-Montiel D AD - Departamento de Patologia, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Olivares-Mundo, Anny AU - Olivares-Mundo A AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Jimenez-Rios, Miguel A AU - Jimenez-Rios MA AD - Departamento de Urologia, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Morera, Carolina Silva AU - Morera CS AD - Departamento de Patologia, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Scavuzzo, Anna AU - Scavuzzo A AD - Departamento de Urologia, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Orozco-Mora, Alicia AU - Orozco-Mora A AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. FAU - Prada, Diddier AU - Prada D AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico; Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, 10032, USA. Electronic address: dpradao@incan.edu.mx. FAU - Cantu-de Leon, David AU - Cantu-de Leon D AD - Direccion de Investigacion, Instituto Nacional de Cancerologia, San Fernando 22, Colonia Seccion XVI, Tlalpan, Ciudad de Mexico 14050, Mexico. Electronic address: dcantude@gmail.com. LA - eng GR - R21 ES027087/ES/NIEHS NIH HHS/United States PT - Journal Article DEP - 20230117 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Biomarkers, Tumor/metabolism MH - Neoplasm Recurrence, Local MH - Prognosis MH - Disease Progression PMC - PMC11210443 MID - NIHMS2000660 OTO - NOTNLM OT - Immunohistochemistry OT - Survival Analysis OT - Urinary Bladder Neoplasm COIS- Declaration of competing interest The authors declare that they have no competing interest in any form. EDAT- 2023/01/22 06:00 MHDA- 2023/03/03 06:00 PMCR- 2024/06/27 CRDT- 2023/01/21 18:11 PHST- 2022/12/10 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/21 18:11 [entrez] PHST- 2024/06/27 00:00 [pmc-release] AID - S1092-9134(22)00183-6 [pii] AID - 10.1016/j.anndiagpath.2022.152081 [doi] PST - ppublish SO - Ann Diagn Pathol. 2023 Apr;63:152081. doi: 10.1016/j.anndiagpath.2022.152081. Epub 2023 Jan 17. PMID- 36674608 OWN - NLM STAT- MEDLINE DCOM- 20230127 LR - 20230127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 6 TI - Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. LID - 10.3390/ijms24021092 [doi] LID - 1092 AB - Bladder cancer (BC) is the most common neoplasm of the urinary tract, which originates in the epithelium that covers the inner surface of the bladder. The molecular BC profile has led to the development of different classifications of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). However, the genomic BC landscape profile of the Mexican population, including NMIBC and MIBC, is unknown. In this study, we aimed to identify somatic single nucleotide variants (SNVs) and copy number variations (CNVs) in Mexican patients with BC and their associations with clinical and pathological characteristics. We retrospectively evaluated 37 patients treated between 2012 and 2021 at the National Cancer Institute-Mexico (INCan). DNA samples were obtained from paraffin-embedded tumor tissues and exome sequenced. Strelka2 and Lancet packages were used to identify SNVs and insertions or deletions. FACETS was used to determine CNVs. We found a high frequency of mutations in TP53 and KMT2D, gains in 11q15.5 and 19p13.11-q12, and losses in 7q11.23. STAG2 mutations and 1q11.23 deletions were also associated with NMIBC and low histologic grade. FAU - Perez-Montiel, Maria D AU - Perez-Montiel MD AD - Departamento de Patologia, Instituto Nacional de Cancerologia (INCan), Mexico City 14080, Mexico. FAU - Cerrato-Izaguirre, Dennis AU - Cerrato-Izaguirre D AUID- ORCID: 0000-0002-6556-1998 AD - Departamento de Farmacologia, Centro de Investigacion y de Estudios Avanzados del I.P.N. (CINVESTAV), Avenida Instituto Politecnico Nacional No. 2508, Mexico City 07360, Mexico. AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Sanchez-Perez, Yesennia AU - Sanchez-Perez Y AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Diaz-Chavez, Jose AU - Diaz-Chavez J AUID- ORCID: 0000-0001-9583-3790 AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Cortes-Gonzalez, Carlo Cesar AU - Cortes-Gonzalez CC AUID- ORCID: 0000-0001-5516-6081 AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Rubio, Jairo A AU - Rubio JA AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Jimenez-Rios, Miguel A AU - Jimenez-Rios MA AD - Departamento de Urologia, Instituto Nacional de Cancerologia (INCan), Mexico City 14080, Mexico. FAU - Herrera, Luis A AU - Herrera LA AUID- ORCID: 0000-0003-3998-9306 AD - Direccion General, Instituto Nacional de Medicina Genomica, Mexico City 14610, Mexico. FAU - Scavuzzo, Anna AU - Scavuzzo A AD - Departamento de Urologia, Instituto Nacional de Cancerologia (INCan), Mexico City 14080, Mexico. FAU - Meneses-Garcia, Abelardo AU - Meneses-Garcia A AD - Direccion GENERAL, Instituto Nacional de Cancerologia (INCan), Mexico City 14080, Mexico. FAU - Hernandez-Martinez, Ricardo AU - Hernandez-Martinez R AUID- ORCID: 0000-0002-9376-8363 AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Vaca-Paniagua, Felipe AU - Vaca-Paniagua F AUID- ORCID: 0000-0002-2200-9706 AD - Laboratorio Nacional en Salud, Diagnostico Molecular y Efecto Ambiental en Enfermedades Cronico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla 54090, Mexico. FAU - Ramirez, Andrea AU - Ramirez A AD - Unidad de Apoyo Molecular a la Investigacion Clinica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Orozco, Alicia AU - Orozco A AD - Unidad de Apoyo Molecular a la Investigacion Clinica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. FAU - Cantu-de-Leon, David AU - Cantu-de-Leon D AD - Direccion de Investigacion, Instituto Nacional de Cancerologia (INCan), Mexico City 14080, Mexico. FAU - Prada, Diddier AU - Prada D AD - Subdireccion de Investigacion Basica, Instituto Nacional de Cancerologia (INCan), San Fernando No. 22, Tlalpan, Mexico City 14080, Mexico. AD - Department of Environmental Health Sciences, Mailman School of Public Health, New York, NY 10032, USA. LA - eng GR - FOSISS-2017-29041/Consejo Nacional de Ciencia y Tecnologia/ GR - FOSISS-2017-289503/Consejo Nacional de Ciencia y Tecnologia/ GR - R21ES027087/ES/NIEHS NIH HHS/United States PT - Journal Article DEP - 20230106 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (KMT2D protein, human) RN - 0 (DNA-Binding Proteins) RN - 0 (Neoplasm Proteins) SB - IM MH - Humans MH - *DNA Copy Number Variations MH - Mexico MH - Mutation MH - Neoplasm Invasiveness MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - *DNA-Binding Proteins/genetics MH - *Neoplasm Proteins/genetics PMC - PMC9866210 OTO - NOTNLM OT - Hispanics OT - Mexican population OT - bladder cancer OT - cancer genomics OT - muscle-invasive bladder cancer OT - mutations OT - non-muscle invasive bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 PMCR- 2023/01/06 CRDT- 2023/01/21 01:25 PHST- 2022/10/23 00:00 [received] PHST- 2022/11/27 00:00 [revised] PHST- 2022/12/03 00:00 [accepted] PHST- 2023/01/21 01:25 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/06 00:00 [pmc-release] AID - ijms24021092 [pii] AID - ijms-24-01092 [pii] AID - 10.3390/ijms24021092 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 6;24(2):1092. doi: 10.3390/ijms24021092. PMID- 36674480 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 4 TI - The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment. LID - 10.3390/ijms24020964 [doi] LID - 964 AB - Bladder cancer (BCa) is associated with significant morbidity, with development linked to environmental, lifestyle, and genetic causes. Recurrence presents a significant issue and is managed in the clinical setting with intravesical chemotherapy or immunotherapy. In order to address challenges such as a limited supply of BCG and identifying cases likely to recur, it would be advantageous to use molecular biomarkers to determine likelihood of recurrence and treatment response. Here, we review microRNAs (miRNAs) that have shown promise as predictors of BCa recurrence. MiRNAs are also discussed in the context of predicting resistance or susceptibility to BCa treatment. FAU - Das, Sanjna AU - Das S AD - Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA. FAU - Hayden, Joshua AU - Hayden J AD - Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA. FAU - Sullivan, Travis AU - Sullivan T AUID- ORCID: 0000-0002-3395-0294 AD - Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA. FAU - Rieger-Christ, Kimberly AU - Rieger-Christ K AD - Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA. LA - eng PT - Journal Article PT - Review DEP - 20230104 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (MicroRNAs) SB - IM MH - Humans MH - *MicroRNAs/genetics/therapeutic use MH - Neoplasm Recurrence, Local/genetics/drug therapy MH - *Urinary Bladder Neoplasms/therapy/drug therapy MH - Immunotherapy MH - Administration, Intravesical PMC - PMC9864802 OTO - NOTNLM OT - EMT OT - FGFR3 OT - HIPPO OT - Wnt OT - bladder cancer (BCa) OT - cell cycle OT - chemoresistance OT - fatty acid metabolism OT - miRNA OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 PMCR- 2023/01/04 CRDT- 2023/01/21 01:24 PHST- 2022/11/30 00:00 [received] PHST- 2022/12/22 00:00 [revised] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/21 01:24 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/04 00:00 [pmc-release] AID - ijms24020964 [pii] AID - ijms-24-00964 [pii] AID - 10.3390/ijms24020964 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 4;24(2):964. doi: 10.3390/ijms24020964. PMID- 36672328 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240720 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 2 DP - 2023 Jan 6 TI - Gene Screening for Prognosis of Non-Muscle-Invasive Bladder Carcinoma under Competing Risks Endpoints. LID - 10.3390/cancers15020379 [doi] LID - 379 AB - Background: Discovering clinically useful molecular markers for predicting the survival of patients diagnosed with non-muscle-invasive bladder cancer can provide insights into cancer dynamics and improve treatment outcomes. However, the presence of competing risks (CR) endpoints complicates the estimation and inferential framework. There is also a lack of statistical analysis tools and software for coping with the high-throughput nature of these data, in terms of marker screening and selection. Aims: To propose a gene screening procedure for proportional subdistribution hazards regression under a CR framework, and illustrate its application in using molecular profiling to predict survival for non-muscle invasive bladder carcinoma. Methods: Tumors from 300 patients diagnosed with bladder cancer were analyzed for genomic abnormalities while controlling for clinically important covariates. Genes with expression patterns that were associated with survival were identified through a screening procedure based on proportional subdistribution hazards regression. A molecular predictor of risk was constructed and examined for prediction accuracy. Results: A six-gene signature was found to be a significant predictor associated with survival of non-muscle-invasive bladder cancer, subject to competing risks after adjusting for age, gender, reevaluated WHO grade, stage and BCG/MMC treatment (p-value < 0.001). Conclusion: The proposed gene screening procedure can be used to discover molecular determinants of survival for non-muscle-invasive bladder cancer and in general facilitate high-throughput competing risks data analysis with easy implementation. FAU - Ke, Chenlu AU - Ke C AUID- ORCID: 0000-0003-1285-5164 AD - Department of Statistical Sciences and Operations Research, Virginia Commonwealth University, Richmond, VA 23284, USA. FAU - Bandyopadhyay, Dipankar AU - Bandyopadhyay D AUID- ORCID: 0000-0001-5421-1725 AD - Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23219, USA. FAU - Sarkar, Devanand AU - Sarkar D AUID- ORCID: 0000-0003-0973-2323 AD - Department of Human Genetics, Virginia Commonwealth University, Richmond, VA 23219, USA. LA - eng GR - R21 DE031879/DE/NIDCR NIH HHS/United States GR - R01 DE031134/DE/NIDCR NIH HHS/United States GR - P20 CA264067/CA/NCI NIH HHS/United States GR - P20CA252717; P20CA264067; R01DE031134; R21DE031879/NH/NIH HHS/United States GR - P20 CA252717/CA/NCI NIH HHS/United States GR - P30 CA016059/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20230106 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9856670 OTO - NOTNLM OT - bladder cancer OT - competing risk endpoints OT - gene screening OT - subdistribution hazards OT - survival analysis COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2023/01/22 06:00 MHDA- 2023/01/22 06:01 PMCR- 2023/01/06 CRDT- 2023/01/21 01:12 PHST- 2022/10/17 00:00 [received] PHST- 2022/12/25 00:00 [revised] PHST- 2022/12/27 00:00 [accepted] PHST- 2023/01/21 01:12 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/22 06:01 [medline] PHST- 2023/01/06 00:00 [pmc-release] AID - cancers15020379 [pii] AID - cancers-15-00379 [pii] AID - 10.3390/cancers15020379 [doi] PST - epublish SO - Cancers (Basel). 2023 Jan 6;15(2):379. doi: 10.3390/cancers15020379. PMID- 36671940 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20240911 IS - 2079-6374 (Electronic) IS - 2079-6374 (Linking) VI - 13 IP - 1 DP - 2023 Jan 6 TI - Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. LID - 10.3390/bios13010106 [doi] LID - 106 AB - Bladder cancer (BCa) is one of the most expensive and common malignancies in the urinary system due to its high progression and recurrence rate. Although there are various methods, including cystoscopy, biopsy, and cytology, that have become the standard diagnosis methods for BCa, their intrinsic invasive and inaccurate properties need to be overcome. The novel urine cancer biomarkers are assisted by nanomaterials-based biosensors, such as field-effect transistors (FETs) with high sensitivity and specificity, which may provide solutions to these problems. In addition, nanomaterials can be applied for the advancement of next-generation optical imaging techniques and the contrast agents of conventional techniques; for example, magnetic resonance imaging (MRI) for the diagnosis of BCa. Regarding BCa therapy, nanocarriers, including mucoadhesive nanoparticles and other polymeric nanoparticles, successfully overcome the disadvantages of conventional intravesical instillation and improve the efficacy and safety of intravesical chemotherapy for BCa. Aside from chemotherapy, nanomedicine-based novel therapies, including photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), and combination therapy, have afforded us new ways to provide BC therapy and hope, which can be translated into the clinic. In addition, nanomotors and the nanomaterials-based solid tumor disassociation strategy provide new ideas for future research. Here, the advances in BCa diagnosis and therapy mentioned above are reviewed in this paper. FAU - Song, Fan-Xin AU - Song FX AD - Department of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Xu, Xiaojian AU - Xu X AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China. FAU - Ding, Hengze AU - Ding H AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Yu, Le AU - Yu L AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Huang, Haochen AU - Huang H AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Hao, Jinting AU - Hao J AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Wu, Chenghao AU - Wu C AUID- ORCID: 0000-0002-3874-0069 AD - Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou 215123, China. AD - College of Nano Science & Technology (CNST), Soochow University, Suzhou 215123, China. FAU - Liang, Rui AU - Liang R AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China. FAU - Zhang, Shaohua AU - Zhang S AD - Department of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. AD - Department of Urology, The Affiliated South China Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. LA - eng GR - 82102171/National Natural Science Foundation of China/ GR - RCBS20200714114857172/Shenzhen Excellent Science and Technology Innovation Talents Training Project/ GR - 202110285027Z/the Undergraduate Training Program for Innovation and Entrepreneurship, Soochow University/ PT - Journal Article PT - Review DEP - 20230106 PL - Switzerland TA - Biosensors (Basel) JT - Biosensors JID - 101609191 SB - IM MH - Humans MH - Theranostic Nanomedicine/methods MH - *Urinary Bladder Neoplasms/diagnosis/therapy MH - *Nanostructures/therapeutic use MH - *Neoplasms/drug therapy MH - *Photochemotherapy MH - *Nanoparticles MH - Nanomedicine PMC - PMC9855444 OTO - NOTNLM OT - biosensors OT - bladder cancer OT - diagnosis OT - drug delivery systems OT - nanomedicine OT - therapy COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 PMCR- 2023/01/06 CRDT- 2023/01/21 01:09 PHST- 2022/10/19 00:00 [received] PHST- 2022/12/29 00:00 [revised] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/01/21 01:09 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/06 00:00 [pmc-release] AID - bios13010106 [pii] AID - biosensors-13-00106 [pii] AID - 10.3390/bios13010106 [doi] PST - epublish SO - Biosensors (Basel). 2023 Jan 6;13(1):106. doi: 10.3390/bios13010106. PMID- 36670543 OWN - NLM STAT- MEDLINE DCOM- 20230614 LR - 20260127 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 90 IP - 2 DP - 2023 May TI - Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance. PG - 248-260 LID - 10.1177/03915603221150965 [doi] AB - BACKGROUND: Bladder cancer (BC) has a particular importance in Egyptian patients due to aggressive behavior and absence of prognostic markers. OBJECTIVE: To evaluate the expression of gene and protein expression of HER2 and epidermal growth factor (EGFR) in Egyptian patients with BC and ultimately to investigate their clinical implication and prognostic significance. MATERIAL AND METHODS: The study was carried out on 46 patients with urothelial bladder BC. Tissue were obtained from transurethral resection (N = 22) and radical cystectomy (N = 24) specimens. The original hematoxylin and eosin slides were re-evaluated and the formalin fixed, paraffin-embedded (FFPE) tissues which had sufficient tumor tissue (>75%) and minimal or absent tumor necrosis were selected for immunohistochemistry (IHC) and RNA extraction. Furthermore, five control biopsies were obtained from patients with cystitis. Follow-up data were retrieved from the medical records which included the treatment regimen, disease recurrence and/or progression, and survival. RESULTS: EGFR and HER2 protein were overexpressed in 35% and 46% of patients respectively. EGFR was correlated with the tumor size, grade and pathological stage, with a similar trend for HER2. The recurrence rate was higher in patients with expression of any of the markers. Gene expression was significantly higher (10.6-folds) for EGFR and (21-folds) for HER2 in patients with BC in comparison to control patients. Survival analysis showed lower median disease-free survival in association with HER2 protein overexpression. CONCLUSIONS: Our data highlighted the prognostic significance of EGFR and HER in BC and proposed their possible use as predictive markers and potential therapeutic targets. FAU - Sami, Manal M AU - Sami MM AD - Department of Pathology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates. AD - Department of Pathology, Faculty of Medicine - Suez Canal University, Ismailia, Egypt. FAU - Sherief, Mahmoud H AU - Sherief MH AUID- ORCID: 0000-0002-5484-487X AD - Department of Urology, Faculty of Medicine - Suez Canal University, Ismailia, Egypt. FAU - El-Abaseri, Taghrid B AU - El-Abaseri TB AUID- ORCID: 0000-0002-1816-4009 AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine - Suez Canal University, Ismailia, Egypt. FAU - El-Sakka, Ahmed I AU - El-Sakka AI AD - Department of Urology, Faculty of Medicine - Suez Canal University, Ismailia, Egypt. FAU - El-Serafi, Ahmed T AU - El-Serafi AT AD - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine - Suez Canal University, Ismailia, Egypt. AD - Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. AD - Department of Biomedical and Clinical Sciences, Linkoping University, Linkoping, Sweden. LA - eng PT - Journal Article DEP - 20230120 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - Prognosis MH - Urinary Bladder/pathology MH - Egypt MH - Neoplasm Recurrence, Local MH - Erb-b2 Receptor Tyrosine Kinases/genetics/metabolism MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell MH - Biomarkers, Tumor OTO - NOTNLM OT - Bladder cancer OT - EGFR OT - HER1 OT - HER2 OT - bilharziasis OT - survival EDAT- 2023/01/22 06:00 MHDA- 2023/06/14 06:42 CRDT- 2023/01/21 00:32 PHST- 2023/06/14 06:42 [medline] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/21 00:32 [entrez] AID - 10.1177/03915603221150965 [doi] PST - ppublish SO - Urologia. 2023 May;90(2):248-260. doi: 10.1177/03915603221150965. Epub 2023 Jan 20. PMID- 36670042 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20230421 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 2 DP - 2023 Apr TI - Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. PG - 214-221 LID - S2588-9311(23)00004-4 [pii] LID - 10.1016/j.euo.2023.01.004 [doi] AB - BACKGROUND: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive. OBJECTIVE: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution. RESULTS AND LIMITATIONS: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is comparable to that of T1 G3 with CIS. Our results support the recent EAU NMIBC guideline changes for more refined risk stratification of Ta G3 tumors because many of these patients have better prognosis than previously thought. PATIENT SUMMARY: We used data from 17 centers in Europe and Canada to assess the prognosis for patients with stage Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC). Time to cancer progression for Ta G3 cancer differed from both Ta G2 and T1 G3 tumors. Our results support the recent change in the European Association of Urology guidelines for more refined risk stratification of Ta G3 NMIBC because many patients with this tumor have better prognosis than previously thought. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Beijert, Irene J AU - Beijert IJ AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Plass, Karin AU - Plass K AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Subiela Henriquez, Jose D AU - Subiela Henriquez JD AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Department of Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Bauerova, Lenka AU - Bauerova L AD - Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Pesl, Michael AU - Pesl M AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Bruins, H Maxim AU - Bruins HM AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Runneboom, Willemien AU - Runneboom W AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Calatrava, Ana AU - Calatrava A AD - Department of Pathology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Department of Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Ashabere, David AU - Ashabere D AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Huebner, Nicolai AU - Huebner N AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cotte, Juliette AU - Cotte J AD - Department of Urology, Pitie Salpetriere Hospital, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Claps, Francesco AU - Claps F AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Liedberg, Fredrik AU - Liedberg F AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Lunelli, Luca AU - Lunelli L AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - El Sheikh, Soha AU - El Sheikh S AD - Department of Pathology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Volanis, Dimitrios AU - Volanis D AD - Department of Urology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Cote, Jean-Francois AU - Cote JF AD - Department of Pathology, Pitie Salpetriere Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitie Salpetriere Hospital, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Hacek, Jaromir AU - Hacek J AD - Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Evert, Matthias AU - Evert M AD - Department of Pathology, University of Regensburg, Regensburg, Germany. FAU - Hulsbergen-van de Kaa, Christina A AU - Hulsbergen-van de Kaa CA AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department of Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia. FAU - Molinaro, Luca AU - Molinaro L AD - Department of Pathology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Llorente, Carlos AU - Llorente C AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Deaprtment of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - N'Dow, James AU - N'Dow J AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: b.v.rhijn@nki.nl. LA - eng PT - Journal Article DEP - 20230118 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM CIN - Eur Urol Oncol. 2023 Apr;6(2):222-223. doi: 10.1016/j.euo.2023.02.003. PMID: 36872141 MH - Humans MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/diagnosis/therapy/pathology MH - Prognosis MH - *Carcinoma/diagnosis/pathology MH - Urinary Bladder/pathology OTO - NOTNLM OT - Bladder OT - Cancer OT - Carcinomas OT - G3 OT - Grade OT - Non-muscle-invasive OT - Stage Ta OT - Urothelial OT - World Health Organization EDAT- 2023/01/21 06:00 MHDA- 2023/04/18 06:42 CRDT- 2023/01/20 22:04 PHST- 2022/08/23 00:00 [received] PHST- 2022/12/05 00:00 [revised] PHST- 2023/01/02 00:00 [accepted] PHST- 2023/04/18 06:42 [medline] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/20 22:04 [entrez] AID - S2588-9311(23)00004-4 [pii] AID - 10.1016/j.euo.2023.01.004 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Apr;6(2):214-221. doi: 10.1016/j.euo.2023.01.004. Epub 2023 Jan 18. PMID- 36658180 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20260518 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Jan 19 TI - Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection. PG - 1060 LID - 10.1038/s41598-023-27675-4 [doi] LID - 1060 AB - Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely unexplored. Massively-parallel sequencing of non-coding hotspots was applied to 884 urine cell pellet DNAs: 591 from haematuria clinic patients (165 BCs, 426 non-BCs) and 293 from non-muscle invasive BC surveillance patients (29 with recurrence). Urine samples from 142 non-BC haematuria clinic patients were used to optimise variant calling. Non-coding mutations are readily detectable in the urine of BC patients and undetectable, or present at much lower frequencies, in the absence of BC. The mutations can be used to detect incident BC with 66% sensitivity (95% CI 58-75) at 92% specificity (95% CI 88-95) and recurrent disease with 55% sensitivity (95% CI 36-74) at 85% specificity (95% CI 80-89%) using a 2% variant allele frequency threshold. In the NMIBC surveillance setting, the detection of non-coding mutations in urine in the absence of clinically detectable disease was associated with an increased relative risk of future recurrence (RR = 4.62 (95% CI 3.75-5.48)). As urinary biomarkers, non-coding hotspot mutations behave similarly to driver mutations in BC-associated genes and could be included in biomarker panels for BC detection. CI - (c) 2023. The Author(s). FAU - Baxter, L AU - Baxter L AD - Bioinformatics Research Technology Platform, University of Warwick, Coventry, UK. FAU - Gordon, N S AU - Gordon NS AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. FAU - Ott, S AU - Ott S AUID- ORCID: 0000-0002-5411-8114 AD - Bioinformatics Research Technology Platform, University of Warwick, Coventry, UK. AD - University of Warwick Medical School, University of Warwick, Coventry, UK. FAU - Wang, J AU - Wang J AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Patel, P AU - Patel P AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Goel, A AU - Goel A AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. FAU - Piechocki, K AU - Piechocki K AD - Nonacus Ltd, Birmingham Research Park, Birmingham, UK. FAU - Silcock, L AU - Silcock L AD - Nonacus Ltd, Birmingham Research Park, Birmingham, UK. FAU - Sale, C AU - Sale C AD - Nonacus Ltd, Birmingham Research Park, Birmingham, UK. FAU - Zeegers, M P AU - Zeegers MP AD - Department of Epidemiology, Care and Public Health Research Institute, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - James, N D AU - James ND AD - Institute of Cancer Research, London, UK. CN - BladderPath trial management group FAU - Bryan, R T AU - Bryan RT AUID- ORCID: 0000-0003-2853-4293 AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. FAU - Ward, D G AU - Ward DG AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. d.g.ward@bham.ac.uk. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom GR - MC_PC_18040/MRC_/Medical Research Council/United Kingdom GR - C16909/A23590/CRUK_/Cancer Research UK/United Kingdom GR - C1343/A5738/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230119 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (WDR74 protein, human) RN - 0 (RNA-Binding Proteins) SB - IM MH - Humans MH - *Hematuria MH - Biomarkers, Tumor/genetics/urine MH - *Urinary Bladder Neoplasms/diagnosis/genetics/urine MH - Urinary Bladder MH - Mutation MH - RNA-Binding Proteins/genetics PMC - PMC9852567 COIS- DGW and RTB are unpaid consultants to Nonacus Ltd (UK) regarding the development of liquid biopsy-based bladder cancer detection tests. The other authors declare no competing interests. FIR - Knight, A IR - Knight A FIR - Gallagher, J IR - Gallagher J FIR - Magwaro, S IR - Magwaro S FIR - Hughes, A IR - Hughes A FIR - Pope, A IR - Pope A FIR - Tunariu, N IR - Tunariu N FIR - Doyle, H IR - Doyle H FIR - Liu, W IR - Liu W FIR - Mintz, H IR - Mintz H FIR - Nanton, V IR - Nanton V FIR - James, K IR - James K FIR - Hafeez, S IR - Hafeez S FIR - Catto, J W F IR - Catto JWF FIR - Jefferson, K IR - Jefferson K FIR - Pirrie, S J IR - Pirrie SJ EDAT- 2023/01/20 06:00 MHDA- 2023/01/24 06:00 PMCR- 2023/01/19 CRDT- 2023/01/19 23:17 PHST- 2022/06/21 00:00 [received] PHST- 2023/01/05 00:00 [accepted] PHST- 2023/01/19 23:17 [entrez] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2023/01/19 00:00 [pmc-release] AID - 10.1038/s41598-023-27675-4 [pii] AID - 27675 [pii] AID - 10.1038/s41598-023-27675-4 [doi] PST - epublish SO - Sci Rep. 2023 Jan 19;13(1):1060. doi: 10.1038/s41598-023-27675-4. PMID- 36656398 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20261010 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 38 IP - 1 DP - 2023 Jan 19 TI - Retrospective analysis of 1470-/980-nm dual-wavelength laser en bloc resection versus transurethral resection of bladder tumor for primary non-muscle-invasive bladder cancer. PG - 44 LID - 10.1007/s10103-023-03708-2 [doi] AB - To compare the safety and efficacy of en bloc resection of non-muscle-invasive bladder cancer (NMIBC) using a 1470-/980-nm dual-wavelength laser (DwLRBT) compared to the gold standard, transurethral resection (TURBT). The study group included 251 patients with a confirmed diagnosis of NMIBC, 97 in the DwLRBT group and 154 in the TURBT group. Clinical characteristics, complications, and recurrence-free survival were compared between the two groups. There were no differences between the two groups with regard to age, sex, mean tumor size, mean tumor number, tumor location, risk, fever, and reoperation. Compared to TURBT, DwLRBT was associated with a shorter hospitalization time (mean+/-standard deviation: 5.81+/-1.48 days vs. 4.96+/-1.32, respectively, p=0.001), shorter catheterization time (4.98+/-1.47 vs. 4.20+/-1.48 days, respectively; p=0.035), and smaller volume of intraoperative bleeding (8.43+/-6.21 ml vs. 6.15+/-5.08, respectively; p=0.003). Recurrence-free survival (RFS) was better for DwLRBT than TURBT in the overall cohort (hazard ratio [HR], 0.4323; 95% confidence interval [CI], 0.2852-0.6554; p=0.0004) and for the following subgroups and tumor types: intermediate-risk (HR, 0.2654; 95%CI, 0.1020-0.6904; p=0.0245) and high-risk (HR, 0.4461; 95% CI, 0.2778-0.7162; p=0.0027) groups; and for pedunculate bladder tumors (HR, 0.4158; 95%CI, 0.2401-0.7202; p=0.0063), single bladder tumors (HR, 0.4136; 95%CI, 0.2376-0.7293; p=0.0072), and multiple bladder tumors (HR, 0.2727; 95%CI, 0.1408-0.5282; p=0.0014). DwLRBT is associated with better operative and postoperative outcomes, including, importantly, a longer RFS, compared to TURBT. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Zhang, Wenqiang AU - Zhang W AD - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. FAU - Zhou, Bin AU - Zhou B AD - Department of Pathology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. FAU - Deng, Jian AU - Deng J AD - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. FAU - Han, Gengyu AU - Han G AD - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. FAU - Ni, Wenjun AU - Ni W AD - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. niwj5@mail.sysu.edu.cn. FAU - Nie, Qiwei AU - Nie Q AUID- ORCID: 0000-0001-8103-746X AD - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University), Zhuhai, 519000, China. qwnie1@163.com. LA - eng GR - 2021A1515010697/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20230119 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 SB - IM MH - Humans MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Lasers MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness OTO - NOTNLM OT - 1470-/980-nm dual-wavelength laser OT - Non-muscle-invasive bladder OT - Recurrence-free survival OT - Transurethral resection of bladder tumor EDAT- 2023/01/20 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/19 11:18 PHST- 2022/06/03 00:00 [received] PHST- 2023/01/11 00:00 [accepted] PHST- 2023/01/19 11:18 [entrez] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] AID - 10.1007/s10103-023-03708-2 [pii] AID - 10.1007/s10103-023-03708-2 [doi] PST - epublish SO - Lasers Med Sci. 2023 Jan 19;38(1):44. doi: 10.1007/s10103-023-03708-2. PMID- 36647946 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 18 IP - 7 DP - 2022 Dec TI - Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis. PG - 1884-1893 LID - 10.4103/jcrt.jcrt_2187_21 [doi] AB - This meta-analysis investigated the efficacies of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) versus IVC alone in patients with non-muscle-invasive bladder cancer (NMIBC), and preoperative IAC versus preoperative intravenous chemotherapy (IV) in patients with bladder cancer. We also assessed the adverse reactions (ARs) of IAC. We searched the PubMed, Embase, Cochrane Library, and Web of Science databases for English articles published before April 2021. The qualities of cohort studies and randomized controlled trials were analyzed using the Newcastle-Ottawa Scale and Cochrane risk-of-bias tool, respectively. Effect outcomes were computed by random-effects and fixed-effects models. Statistical analyses were conducted using Stata 16.0 and RevMan v5.3.0. A total of seven articles were included. The analysis revealed that IAC plus IVC significantly prolonged recurrence-free survival (RFS) (hazard ratio [HR] = 0.55, 95% confidence interval [CI] = 0.40-0.76, I(2) = 0%) and progression-free survival (PFS) (HR = 0.59, 95% CI = 0.37-0.97, I(2) = 0%) compared with IVC alone in NMIBC patients after transurethral resection of bladder tumor (TURBT), but had no effect on overall survival (OS), tumor recurrence interval, or tumor-specific death rate. Preoperative IAC had no significant OS benefit compared with preoperative IV in bladder cancer patients. Regarding ARs, patients treated with IAC were significantly more likely to develop grade 1-2 ARs, including nausea/vomiting (odds ratio [OR] = 26.38, 95% CI = 1.88-370.79, I(2) = 78%), neutropenia (OR = 10.15, 95% CI = 3.01-34.24, I(2) = 0%), hypoleukemia (OR = 5.49, 95% CI = 1.38-21.82, I(2) = 26%), and increased alanine aminotransferase (OR = 12.28, 95% CI = 2.24-67.43, I(2) = 0%), but there was no significant difference between grade 1-2 ARs and grade 3-4 ARs in terms of increased creatinine in patients treated with IAC. Therefore, administration of IAC plus IVC after TURBT improved RFS and PFS compared with IAC alone in patients with NMIBC. IAC was associated with mild ARs and was well tolerated by most patients. FAU - Ji, Junjie AU - Ji J AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Yao, Yu AU - Yao Y AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Guan, Fengju AU - Guan F AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Sun, Lijiang AU - Sun L AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Zhang, Guiming AU - Zhang G AD - Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 SB - IM MH - Humans MH - *Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/pathology MH - Infusions, Intra-Arterial MH - Chemotherapy, Adjuvant OTO - NOTNLM OT - Adverse Reactions OT - bladder cancer OT - intra-arterial chemotherapy OT - meta-analysis OT - prognosis COIS- None EDAT- 2023/01/18 06:00 MHDA- 2023/01/19 06:00 CRDT- 2023/01/17 06:30 PHST- 2023/01/17 06:30 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] AID - JCanResTher_2022_18_7_1884_367468 [pii] AID - 10.4103/jcrt.jcrt_2187_21 [doi] PST - ppublish SO - J Cancer Res Ther. 2022 Dec;18(7):1884-1893. doi: 10.4103/jcrt.jcrt_2187_21. PMID- 36646178 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20230606 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 174 DP - 2023 Apr TI - Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. PG - 111-117 LID - S0090-4295(23)00029-8 [pii] LID - 10.1016/j.urology.2022.09.048 [doi] AB - OBJECTIVE: To evaluate a single institution experience of total intracorporeal bladder cuffing and distal ureterectomy (DUBC) in robotic radical nephrouretectomy (RNU) for upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: One hundred sixty-eight patients treated for UTUC with robotic RNU at our institution from May 2009 to October 2019 were retrospectively analyzed. Ninety-two patients underwent total intracorporeal DUBC after robotic dock repositioning, whereas 76 patients underwent open methods via Gibson incision. Perioperative outcomes including operation time, estimated blood loss (EBL), transfusion rates, use of painkillers, Visual analogue scale (VAS) pain scores, and complication rates were compared, as well as pathological and oncological outcomes. Uni- and multi-variate Cox regression models were performed for survival analysis. RESULTS: There were no significant differences in baseline patient characteristics between the 2 groups. Patients who underwent intracorporeal bladder cuffing had less EBL (169.8 +/- 150.4 vs 214.6 +/- 157.0, P = .091) and decreased pain at 1 week (VAS score 1.18 +/- 1.1 vs 2.2 +/- 1.1, P = .017). Pathological outcomes were not significantly different, and oncological outcomes including local and intravesical recurrence, cancer-specific and overall mortality were comparable to patients who received extracorporeal bladder cuffing. Intracorporeal bladder cuffing was not associated with increased risk of progression on univariate analysis (HR 0.600, 95% CI, 0.314-1.147; P = .122). CONCLUSION: Based on our experience, intracorporeal DUBC can be a safe and oncologically non-inferior alternative method to RNU, with benefits of decreased EBL and postoperative pain. Future prospective trials are necessary to further validate our results. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Song, Sang Hun AU - Song SH AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Jin Hyuck AU - Kim JH AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. FAU - Lee, Sangchul AU - Lee S AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. FAU - Hong, Sung Kyu AU - Hong SK AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Byun, Seok-Soo AU - Byun SS AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. Electronic address: urojin@snu.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230114 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2023 Apr;174:116-117. doi: 10.1016/j.urology.2022.09.051. PMID: 37030904 MH - Humans MH - Nephroureterectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Urinary Bladder/surgery/pathology MH - Retrospective Studies MH - *Robotic Surgical Procedures/adverse effects MH - Treatment Outcome MH - *Ureteral Neoplasms/pathology COIS- Conflict of Interest The authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/01/17 06:00 MHDA- 2023/04/11 06:41 CRDT- 2023/01/16 19:23 PHST- 2022/07/08 00:00 [received] PHST- 2022/09/12 00:00 [revised] PHST- 2022/09/18 00:00 [accepted] PHST- 2023/04/11 06:41 [medline] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/16 19:23 [entrez] AID - S0090-4295(23)00029-8 [pii] AID - 10.1016/j.urology.2022.09.048 [doi] PST - ppublish SO - Urology. 2023 Apr;174:111-117. doi: 10.1016/j.urology.2022.09.048. Epub 2023 Jan 14. PMID- 36646046 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230403 IS - 1423-0399 (Electronic) IS - 0042-1138 (Print) IS - 0042-1138 (Linking) VI - 107 IP - 3 DP - 2023 TI - Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guerin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study. PG - 230-238 LID - 10.1159/000527718 [doi] AB - INTRODUCTION: There are various doses, durations, and strains of bacillus Calmette-Guerin (BCG) intravesical instillation therapy, but optimal treatment has not yet been established. We retrospectively investigated the efficacy and safety of low-dose BCG therapy for non-muscle-invasive bladder cancer (NMIBC) and carcinoma in situ (CIS) in a multicenter study. METHODS: From 1991 to 2019, 323 patients who received BCG therapy to prevent recurrence of NMIBC were analyzed as group A. Similarly, 147 patients who received BCG therapy for the treatment of CIS were analyzed as group B. Patients received low- or full-dose Tokyo-172 strain or full-dose Connaught strain, and the three strains were compared. Survival curves were estimated by the Kaplan-Meier method, and independent risk factors for intravesical recurrence were examined by multivariate logistic regression. RESULTS: Recurrence-free survival (RFS) in group A was significantly better for the Connaught strain than the low-dose Tokyo-172 strain (p = 0.026), but not between the low- and full-dose Tokyo-172 strains (p = 0.443). RFS of group B, cancer-specific survival, and progression-free survival in both groups did not show statistically significant differences. Logistic analysis of group A showed that for intravesical recurrence, only pT1 was a significant risk factor, and there were no differences between the BCG strain and dose and no significant factors in group B. There were also no differences in the completion rate in both groups, but adverse events such as urinary frequency and feeling of residual urine were significantly lower with the low-dose Tokyo-172 strain. CONCLUSION: There was no difference in efficacy between the low- and full-dose Tokyo-172 strains, but to minimize adverse events, the low-dose Tokyo-172 strain may be worth considering. CI - (c) 2023 The Author(s). Published by S. Karger AG, Basel. FAU - Tachibana, Takashi AU - Tachibana T AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. AD - Department of Urology, Kitasato University Medical Center, Saitama, Japan. FAU - Ikeda, Masaomi AU - Ikeda M AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Shimura, Soichiro AU - Shimura S AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Amano, Noriyuki AU - Amano N AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Murakami, Yasukiyo AU - Murakami Y AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Yamada, Yasufumi AU - Yamada Y AD - Department of Urology, Sagamihara Kyodo Hospital, Kanagawa, Japan. FAU - Koguchi, Dai AU - Koguchi D AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. AD - Department of Urology, Yokosuka City Uwamachi Hospital, Kanagawa, Japan. FAU - Maeyama, Ryota AU - Maeyama R AD - Department of Urology, Higashiyamato Hospital, Tokyo, Japan. FAU - Kawamura, Mizuho AU - Kawamura M AD - Department of Urology, Sagamihara Hospital, Kanagawa, Japan. FAU - Sakata, Yusuke AU - Sakata Y AD - Department of Urology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan. FAU - Hagiwara, Masahiro AU - Hagiwara M AD - Department of Urology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20230116 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - Administration, Intravesical MH - *Non-Muscle Invasive Bladder Neoplasms MH - Tokyo MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma in Situ/drug therapy MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology PMC - PMC10064385 OTO - NOTNLM OT - Carcinoma in situ OT - Induction therapy OT - Low-dose bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Tokyo-172 strain COIS- The authors have no conflicts of interest to declare. EDAT- 2023/01/17 06:00 MHDA- 2023/03/22 06:00 PMCR- 2023/01/16 CRDT- 2023/01/16 18:22 PHST- 2022/06/26 00:00 [received] PHST- 2022/10/17 00:00 [accepted] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] PHST- 2023/01/16 18:22 [entrez] PHST- 2023/01/16 00:00 [pmc-release] AID - 000527718 [pii] AID - uin-0107-0230 [pii] AID - 10.1159/000527718 [doi] PST - ppublish SO - Urol Int. 2023;107(3):230-238. doi: 10.1159/000527718. Epub 2023 Jan 16. PMID- 36642638 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20241113 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 6 DP - 2023 Jun TI - Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion. PG - 296.e1-296.e8 LID - S1078-1439(22)00497-5 [pii] LID - 10.1016/j.urolonc.2022.12.012 [doi] AB - OBJECTIVE: To compare the performance of CellDetect, a new biomarker with urine cytology and UroVysiontechnology for bladder cancer detection. PATIENTS AND METHODS: We performed an IRB approved prospective, blinded single center study in patients on routine surveillance for nonmuscle invasive bladder cancer and those scheduled for transurethral resection of bladder tumor or radical cystectomy. Patients with bladder catheters, neobladder, ileal conduit, urinary stones, or those with upper tract carcinoma were excluded from the study. Voided urine sample was collected from the participants and each sample was divided into three equal aliquots (CellDetect, Urine cytology and Urovysion). Pathology of the operative specimen was considered the gold standard to which the three markers were compared. RESULTS: The study group included 93 patients with median age was 68 years (range: 34-92 years) with male to female ratio of 12:1. Pathologic evaluation revealed malignancy in 43 cases (46%) of whom 81% had previous history of urothelial bladder cancer. Among all studied markers CellDetect exhibited the best performance followed by urine cytology and U-FISH with diagnostic odds ratio of 4.33, 3.85, and 2.5 respectively. The overall sensitivity, specificity, negative predictive value, and positive predictive value for this test were 84%, 80%, 88%, and 74% respectively. The advantage of this new biomarker was observed both in high grade and low-grade cases. CONCLUSIONS: This study demonstrates the advantage of CellDetect as a urine-based assay to detect urothelial bladder cancer over urine cytology and U-FISH test. The high performance was maintained across all cancer grades and stages without compromising the assay specificity. Additional studies are required to test if it can be a noninvasive alternative to cystoscopy. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Shefer, Hila Kreizman AU - Shefer HK AD - Departments of Pathology, Haifa, Israel. FAU - Masarwe, Ismael AU - Masarwe I AD - Departments of Urology, Bnai Zion Medical Center, Haifa, Israel. FAU - Bejar, Jacob AU - Bejar J AD - Departments of Pathology, Haifa, Israel. FAU - Naamnih, Luna Hijazi AU - Naamnih LH AD - Departments of Pathology, Haifa, Israel. FAU - Gueta-Milshtein, Keren AU - Gueta-Milshtein K AD - Micromedic Technologies, Tel-Aviv, Israel. FAU - Shalata, Adel AU - Shalata A AD - The Simon Winter Institute for Human Genetics, Bnai Zion Medical Center, Haifa, Israel. FAU - Hadid, Yarin AU - Hadid Y AD - The Simon Winter Institute for Human Genetics, Bnai Zion Medical Center, Haifa, Israel. FAU - Nativ, Omri AU - Nativ O AD - Department of Urology, Rambam Medical Center, Haifa, Israel. Electronic address: _nativ@rambam.health.gov.il. FAU - Nativ, Ofer AU - Nativ O AD - Departments of Urology, Bnai Zion Medical Center, Haifa, Israel. LA - eng PT - Journal Article DEP - 20230114 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Male MH - Female MH - Humans MH - Prospective Studies MH - Sensitivity and Specificity MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - *Carcinoma, Transitional Cell/diagnosis/pathology MH - Urine MH - Cytodiagnosis OTO - NOTNLM OT - Detection OT - Malignant bladder neoplasm OT - Urinary biomarkers COIS- Conflict of Interest Hila Kreizman Shefer as well as all co-authors, except Keren Gueta-Milshtein, PhD, certify that they have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending). Keren Gueta-Milshtein, PhD, was an employee of Micromedic Technologies Ltd. during the conduction of the study. All the listed co-authors approve the submission of this manuscript, and the content of the manuscript has not been published, submitted for publication or is under consideration for publication with any other journal. EDAT- 2023/01/16 06:00 MHDA- 2023/06/09 06:42 CRDT- 2023/01/15 22:02 PHST- 2022/08/20 00:00 [received] PHST- 2022/11/28 00:00 [revised] PHST- 2022/12/26 00:00 [accepted] PHST- 2023/06/09 06:42 [medline] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/15 22:02 [entrez] AID - S1078-1439(22)00497-5 [pii] AID - 10.1016/j.urolonc.2022.12.012 [doi] PST - ppublish SO - Urol Oncol. 2023 Jun;41(6):296.e1-296.e8. doi: 10.1016/j.urolonc.2022.12.012. Epub 2023 Jan 14. PMID- 36621462 OWN - NLM STAT- MEDLINE DCOM- 20230328 LR - 20230411 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 21 IP - 2 DP - 2023 Apr TI - Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer. PG - 258-264 LID - S1558-7673(22)00262-2 [pii] LID - 10.1016/j.clgc.2022.12.004 [doi] AB - INTRODUCTION: The use of urine cytology in the surveillance of non-muscle invasive bladder cancer (NMIBC) is widely variable in clinical practice. We studied the impact of surveillance urine cytology on clinical decision making during NMIBC surveillance. METHODS: A retrospective chart review was conducted on patients surveilled for clinical NMIBC from 2013 to 2020 with at least one follow-up cytology result after diagnosis. Patients were classified into risk categories according to American Urological Association (AUA) NMIBC guidelines. Data were obtained regarding tumor recurrence pathology and the frequency and findings of surveillance cystoscopies and urine cytologies. Positive (suspicious, malignant) and negative (atypical or negative for malignant cells) cytology results were correlated with cystoscopy and pathology findings when obtained within 3 months of the cytology specimen to determine if cytology impacted plan of care. RESULTS: Two hundred fourteen patients with NMIBC were followed for a median of 34 months, with 1045 urine cytologies collectively obtained over the surveillance period. There were no positive urine cytologies among patients with low-risk NMIBC; therefore, cytology did not change management in this cohort. The potential for cytology to escalate management for patients of any risk group (ie, positive cytology in the absence of positive cystoscopy or pathology findings) occurred in 30 (2.9%) cases. However, clinical decision making was only altered in 4 cases (0.4% of all cytologies). CONCLUSIONS: Less than 1% of urine cytology specimens collected during NMIBC surveillance impacted clinical management, none of whom had low-risk disease. The use of urine cytology for surveillance of low-risk NMIBC should continue to be strongly discouraged, as it did not change management in any such cases. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Feiertag, Nathan AU - Feiertag N AD - Albert Einstein College of Medicine, Bronx, NY. FAU - Barry, Emily AU - Barry E AD - Albert Einstein College of Medicine, Bronx, NY. FAU - Abramson, Max AU - Abramson M AD - Albert Einstein College of Medicine, Bronx, NY. FAU - Park, Ju-Young AU - Park JY AD - Colby College, Waterville, ME. FAU - Kovac, Evan AU - Kovac E AD - Divsion of Urology, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ. FAU - Aboumohamed, Ahmed AU - Aboumohamed A AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. FAU - Watts, Kara AU - Watts K AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. FAU - Sankin, Alex AU - Sankin A AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. Electronic address: asankin@montefiore.org. LA - eng PT - Journal Article DEP - 20221223 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Humans MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/diagnosis/therapy/pathology MH - Cytodiagnosis MH - Cystoscopy/methods MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - Transurethral resection of bladder tumor OT - non muscle invasive bladder cancer OT - urine cytology OT - urothelial carcinoma COIS- Disclosure Alex Sankin, MD - Ambu Inc., advisory role. EDAT- 2023/01/10 06:00 MHDA- 2023/03/28 17:11 CRDT- 2023/01/09 04:54 PHST- 2022/09/20 00:00 [received] PHST- 2022/12/08 00:00 [revised] PHST- 2022/12/11 00:00 [accepted] PHST- 2023/03/28 17:11 [medline] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/09 04:54 [entrez] AID - S1558-7673(22)00262-2 [pii] AID - 10.1016/j.clgc.2022.12.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2023 Apr;21(2):258-264. doi: 10.1016/j.clgc.2022.12.004. Epub 2022 Dec 23. PMID- 36614970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 1 DP - 2022 Dec 26 TI - How to Perform Intravesical Chemotherapy after Second TURBT for Non-Muscle-Invasive Bladder Cancer: A Single-Center Experience. LID - 10.3390/jcm12010169 [doi] LID - 169 AB - PURPOSE: The objective of this study aimed to explore whether the original IVC regimen should be continued after the second TURBT or whether the IVC induction phase should be restarted from the beginning. METHODS: A retrospective analysis was performed on 137 patients who underwent a second TURBT at the Affiliated Hospital of Xuzhou Medical University between April 2014 and June 2022. Based on the pathological findings, patients were divided into two groups: group A patients, who did not have a residual tumor on pathological examination after the second TURBT; and group B patients, who had residual tumor. Recurrence was determined using cystoscopy and imaging every three months. The endpoint was recurrence-free survival. RESULT: In the entire cohort, there was a statistically significant difference in the RFS between patients in the two IVC regimens (p = 0.029). The RFS of patients in group B1 was significantly lower than that of patients in group B2 (p = 0.009). There was no significant difference in RFS between the subgroups A1 and A2 (p = 0.560). Multivariate Cox regression analysis confirmed that the IVC regimen after a second TURBT (p = 0.012) and T stage after a second TURBT (p = 0.005) were both independent predictors for patient RFS. CONCLUSION: If the pathological findings of the second TURBT specimen is benign, patients can continue their previous treatment regimen without restarting an IVC induction phase. Unnecessary IVC can be avoided in these patients. In contrast, for patients with residual tumors in the second TURBT specimen, the need to restart the IVC induction phase should be emphasized to improve patient prognosis. FAU - Li, Zhen AU - Li Z AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. AD - Graduate School, Xuzhou Medical University, Xuzhou 221000, China. FAU - Qi, Nienie AU - Qi N AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. FAU - Gao, Zhimin AU - Gao Z AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. AD - Graduate School, Xuzhou Medical University, Xuzhou 221000, China. FAU - Ding, Li AU - Ding L AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. AD - Graduate School, Xuzhou Medical University, Xuzhou 221000, China. FAU - Zhu, Jiawei AU - Zhu J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. AD - Graduate School, Xuzhou Medical University, Xuzhou 221000, China. FAU - Guo, Qingxiang AU - Guo Q AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. AD - Graduate School, Xuzhou Medical University, Xuzhou 221000, China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. FAU - Wen, Rumin AU - Wen R AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. FAU - Li, Hailong AU - Li H AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China. LA - eng GR - WSW-064/Six talent peaks project in Jiangsu Province/ GR - 19KJB310001/Project supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China/ GR - 2021K447C/Post-doctoral Research Funding Project in Jiangsu Province/ GR - XWRCHT20210027/Second Round of Xuzhou Medical Leading Talents Training Project/ GR - YB2020050/The Science and Technology Planning Project of Traditional Chinese Medicine of Jiangsu/ PT - Journal Article DEP - 20221226 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9820835 OTO - NOTNLM OT - chemotherapy OT - residual tumor OT - second-look TURBT OT - urinary bladder neoplasm COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/09 06:01 PMCR- 2022/12/26 CRDT- 2023/01/08 01:31 PHST- 2022/10/16 00:00 [received] PHST- 2022/12/05 00:00 [revised] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/08 01:31 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/09 06:01 [medline] PHST- 2022/12/26 00:00 [pmc-release] AID - jcm12010169 [pii] AID - jcm-12-00169 [pii] AID - 10.3390/jcm12010169 [doi] PST - epublish SO - J Clin Med. 2022 Dec 26;12(1):169. doi: 10.3390/jcm12010169. PMID- 36600418 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 12 DP - 2022 Dec 20 TI - Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. PG - e064898 LID - 10.1136/bmjopen-2022-064898 [doi] LID - e064898 AB - PURPOSE: We constructed Bladder Cancer Data Base Sweden (BladderBaSe) 2.0 to expand studies in BladderBaSe on incidence, treatment outcomes, side effects, survival and health economic aspects of men and women with cancer in the urinary bladder, upper tract urothelial carcinoma (UTUC) (renal pelvis and ureter) and urethral carcinoma. PARTICIPANTS: BladderBaSe 2.0 includes 53 298 patients with cancer in the urinary bladder, diagnosed from 1 January 1997 to 31 December 2019, and 961 patients with UTUC in the renal pelvis and 792 in the ureter, and 146 patients with urethral urothelial carcinoma, diagnosed from 1 January 2015 to 31 December 2019, and in total 275 816 participants in reference groups, free of cancer in the urinary tract, matched 1:5 on sex, age and county. FINDINGS TO DATE: To date, 18 published studies based on data from the BladderBaSe have investigated calendar time trends in survival; impact of gender, socioeconomic factors, tumour aggressiveness and hospital volume for radical cystectomy on prognosis; survival after radical cystectomy compared with radical radiotherapy; risk factors for complications and side effects after radical cystectomy such as thromboembolism, strictures of ureteroenterostomies and incisional hernia. FUTURE PLANS: The BladderBaSe initiators are currently investigating gender-dependent detection delays due to urinary tract infections; survival after non-muscle invasive bladder cancer with respect to the number of transurethral resections; short-term outcomes comparing open and robot-assisted radical cystectomy; studies on risk for intravesical recurrence after different diagnostic measures in UTUC, and suicide risk after bladder cancer diagnosis. The BladderBaSe project group is open for collaborations with national and international colleagues. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Haggstrom, Christel AU - Haggstrom C AUID- ORCID: 0000-0001-6808-4405 AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden christel.haggstrom@umu.se. AD - Northern Registry Centre, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Department of Translational Medicine, Lund University, Lund, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Department of Radiation Sciences, Umea University, Umea, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. AD - Department of Pelvic Cancer, Genitourinary Oncology and Urology unit, Karolinska University Hospital, Stockholm, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - School of Medical Sciences, Orebro University, Orebro, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Lund, Sweden. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Holmberg, Lars AU - Holmberg L AUID- ORCID: 0000-0003-4417-7396 AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221220 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Male MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/therapy/drug therapy MH - *Carcinoma, Transitional Cell/epidemiology/therapy MH - Sweden/epidemiology MH - Prognosis MH - Treatment Outcome MH - Cystectomy MH - Retrospective Studies PMC - PMC9772662 OTO - NOTNLM OT - Adult surgery OT - Adult urology OT - Radiation oncology OT - Urological tumours COIS- Competing interests: None declared. EDAT- 2023/01/06 06:00 MHDA- 2023/01/07 06:00 PMCR- 2022/12/20 CRDT- 2023/01/05 00:03 PHST- 2023/01/05 00:03 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/12/20 00:00 [pmc-release] AID - bmjopen-2022-064898 [pii] AID - 10.1136/bmjopen-2022-064898 [doi] PST - epublish SO - BMJ Open. 2022 Dec 20;12(12):e064898. doi: 10.1136/bmjopen-2022-064898. PMID- 36595982 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230120 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 52 DP - 2022 Dec 30 TI - A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin (BCG-CWS) for cervical cancer. PG - e32481 LID - 10.1097/MD.0000000000032481 [doi] LID - e32481 AB - Mycobacterium bovis Bacillus Calmette-Guerin (BCG) has the potential to promote adaptive immunity. We sought to examine the synergistic effect of BCG-CWS vaccination on cervical cancer patients undergoing standard treatments including surgery, chemotherapy, and/or radiation. We retrospectively analyzed 103 patients (13 cases administered with BCG-CWS vaccine and 90 controls without BCG-CWS) who underwent a standard treatment for cervical cancer from 2005 to 2021. The BCG-CWS group underwent repeated intradermal injections of the BCG-CWS vaccine before or immediately after the standard therapy start from 2011 to 2018. The vaccination was repeated weekly for 1 month, and then every 4 weeks thereafter. The effectiveness of the BCG-CWS vaccination on cervical cancer treatment was evaluated by determining the hazard ratios of overall survival between the BCG-CWS group and the control group with multivariate analysis using the Cox model. Hazard ratios between 2 groups were determined after adjustment by clinical parameters including surgery, chemotherapy, radiation, age, clinical stage, presence of human papillomavirus, and pathology. Long-term follow-up revealed a significantly better prognosis (hazard ratio: 0.2108, P = .008 by the Cox model) for patients with cervical cancer in the BCG-CWS group compared to patients in the control group. Among patients with advanced cancer worse than stage IB2, some completely cleared the disease, whereas the others showed long-term survival with recurrence. BCG-CWS therapy appears to be an effective immune adjuvant therapy for cervical cancer, although randomized control studies are needed to confirm this. We also need to clarify the underlying mechanisms slowing the progression of cervical cancer in those receiving this vaccination. This study sheds light on the potential of immunostimulatory drugs such as BCG-CWS and suggests the important role of immunity for cancer elimination in combination therapy. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Shibata, Takeo AU - Shibata T AD - Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. FAU - Takata, Emi AU - Takata E AD - Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. FAU - Sakamoto, Jinichi AU - Sakamoto J AD - Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. FAU - Shioya, Akihiro AU - Shioya A AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada, Japan. FAU - Yamada, Sohsuke AU - Yamada S AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada, Japan. FAU - Takakura, Masahiro AU - Takakura M AD - Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. FAU - Sasagawa, Toshiyuki AU - Sasagawa T AUID- ORCID: 0000-0002-8480-844 AD - Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Cell Wall Skeleton) RN - 0 (BCG Vaccine) SB - IM MH - Female MH - Humans MH - *Mycobacterium bovis MH - Cell Wall Skeleton/therapeutic use MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - *Uterine Cervical Neoplasms/drug therapy MH - Immunotherapy MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9803507 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 PMCR- 2022/12/30 CRDT- 2023/01/03 16:17 PHST- 2023/01/03 16:17 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - 00005792-202212300-00014 [pii] AID - 10.1097/MD.0000000000032481 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 30;101(52):e32481. doi: 10.1097/MD.0000000000032481. PMID- 36594099 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20240917 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 19 IP - 1 DP - 2023 TI - Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition. PG - 1-12 LID - 10.7150/ijbs.77181 [doi] AB - Bladder cancer (BlCa) is the ninth most common cancer worldwide, associated with significant morbidity and mortality. Thus, understand the biological mechanisms underlying tumour progression is of great clinical significance. Vimentin (VIM) is (over)expressed in several carcinomas, putatively in association with EMT. We have previously found that VIM promoter methylation accurately identified BlCa and VIM expression associated with unfavourable prognosis. Herein, we sought to investigate VIM expression regulation and its role in malignant transformation of BlCa. Analysis of tissue samples disclosed higher VIM transcript, protein, and methylation levels in BlCa compared with normal urothelium. VIM protein and transcript levels significantly increased from non-muscle invasive (NMIBC) to muscle-invasive (MIBC) cases and to BlCa metastases. Inverse correlation between epithelial CDH1 and VIM, and a positive correlation between mesenchymal CDH2 and VIM were also observed. In BlCa cell lines, exposure to demethylating agent increased VIM protein, with concomitant decrease in VIM methylation. Moreover, exposure to histone deacetylases pan-inhibitor increased the deposit of active post-translational marks (PTMs) across VIM promoter. In primary normal urothelium cells, lower levels of active PTMs with concomitant higher levels of repressive marks deposit were observed. Finally, VIM knockdown in UMUC3 cell line increased epithelial-like features and decreased migration and invasion in vitro, decreasing tumour size and angiogenesis in vivo. We demonstrated that VIM promoter is epigenetically regulated in normal and neoplastic urothelium, which determine a VIM switch associated with EMT and acquisition of invasive and metastatic properties. These findings might allow for development of new, epigenetic-based, therapeutic strategies for BlCa. CI - (c) The author(s). FAU - Monteiro-Reis, Sara AU - Monteiro-Reis S AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - INEGI-LAETA, Faculty of Engineering, University of Porto, Campus FEUP, Rua Dr. Roberto Frias 400, 4600-465, Porto, Portugal. FAU - Miranda-Goncalves, Vera AU - Miranda-Goncalves V AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal. FAU - Guimaraes-Teixeira, Catarina AU - Guimaraes-Teixeira C AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Martins-Lima, Claudia AU - Martins-Lima C AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Lobo, Joao AU - Lobo J AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto / Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Montezuma, Diana AU - Montezuma D AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Dias, Paula C AU - Dias PC AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto / Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Neyret-Kahn, Helene AU - Neyret-Kahn H AD - Institut Curie, UMR144, Centre de Recherche, 75005 Paris, France. FAU - Bernard-Pierrot, Isabelle AU - Bernard-Pierrot I AD - Institut Curie, UMR144, Centre de Recherche, 75005 Paris, France. FAU - Henrique, Rui AU - Henrique R AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto / Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Jeronimo, Carmen AU - Jeronimo C AD - Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230101 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 RN - 0 (Vimentin) SB - IM MH - Humans MH - Vimentin/genetics/metabolism MH - *Urinary Bladder Neoplasms/metabolism MH - Epigenesis, Genetic/genetics MH - Phenotype MH - Epithelial-Mesenchymal Transition/genetics MH - Gene Expression Regulation, Neoplastic/genetics PMC - PMC9760433 OTO - NOTNLM OT - Bladder Cancer OT - EMT. OT - Histones posttranslational modifications OT - Methylation OT - Vimentin COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/01/04 06:00 MHDA- 2023/01/05 06:00 PMCR- 2023/01/01 CRDT- 2023/01/03 02:00 PHST- 2022/07/16 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2023/01/03 02:00 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - ijbsv19p0001 [pii] AID - 10.7150/ijbs.77181 [doi] PST - epublish SO - Int J Biol Sci. 2023 Jan 1;19(1):1-12. doi: 10.7150/ijbs.77181. eCollection 2023. PMID- 36592175 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 41 IP - 2 DP - 2023 Feb TI - Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review. PG - 345-359 LID - 10.1007/s00345-022-04253-3 [doi] AB - BACKGROUND: Bladder cancer detection and follow-up is based on cystoscopy and/or cytology, but it remains imperfect and invasive. Current research focuses on diagnostic biomarkers that could improve bladder cancer detection and follow-up by discriminating patients at risk of aggressive cancer who need confirmatory TURBT (Transurethral Resection of Bladder Tumour) from patients at no risk of aggressive cancer who could be spared from useless explorations. OBJECTIVE: To perform a systematic review of data on the clinical validity and clinical utility of eleven urinary biomarkers (VisioCyt((R)), Xpert((R))Bladder, BTA stat((R)), BTA TRAK, NMP22 BC((R)), NMP22((R)) BladderChek((R)) Test, ImmunoCyt/uCyt1+, UroVysion Bladder Cancer Kit((R)), Cxbladder, ADXBLADDER, Urodiag((R))) for bladder cancer diagnosis and for non-muscle invasive bladder cancer (NMIBC) follow-up. METHODS: All available studies on the 11 biomarkers published between May 2010 and March 2021 and present in MEDLINE((R)) were reviewed. The main endpoints were clinical performance for bladder cancer detection, recurrence or progression during NMIBC monitoring, and additional value compared to cytology and/or cystoscopy. RESULTS: Most studies on urinary biomarkers had a prospective design and high level of evidence. However, their results should be interpreted with caution given the heterogeneity among studies. Most of the biomarkers under study displayed higher detection sensitivity compared with cytology, but lower specificity. Some biomarkers may have clinical utility for NMIBC surveillance in patients with negative or equivocal cystoscopy or negative or atypical urinary cytology findings, and also for recurrence prediction. CONCLUSION: Urinary biomarkers might have a complementary place in bladder cancer diagnosis and NMIBC surveillance. However, their clinical benefit remains to be confirmed. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Soorojebally, Yanish AU - Soorojebally Y AD - Department of Urology, Foch Hospital, Paris Saclay University, Suresnes, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Foch Hospital, Paris Saclay University, Suresnes, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, Toulouse Cedex, France. FAU - Lamy, Pierre-Jean AU - Lamy PJ AD - Biopathologie et Genetique des Cancers, Institut Medical d'Analyse Genomique, Imagenome, Inovie, Montpellier, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Institut Curie, Saint-Cloud, France. FAU - Descotes, Francoise AU - Descotes F AD - Biochemistry, Biology and Pathology Center South, Hospices Civils de Lyon (HCL), Universite Claude Bernard Lyon I, Pierre-Benite, France. FAU - Ferlicot, Sophie AU - Ferlicot S AD - Service d'Anatomie Pathologique, AP-HP,, Hopital de Bicetre, Le Kremlin Bicetre, France. FAU - Kassab-Chahmi, Diana AU - Kassab-Chahmi D AD - Association Francaise d'Urologie, Paris, France. FAU - Oudard, Stephane AU - Oudard S AD - Department of Medical Oncology, Hopital Europeen Georges Pompidou, AP-HP.Centre, Universite Paris Cite, Paris, France. FAU - Rebillard, Xavier AU - Rebillard X AD - Urology Department, Beausoleil Private Hospital, Montpellier, France. FAU - Roy, Catherine AU - Roy C AD - Department of Radiology B, Strasbourg University Hospital - New Civil Hospital, Strasbourg, France. FAU - Lebret, Thierry AU - Lebret T AD - Department of Urology, Foch Hospital, Paris Saclay University, Suresnes, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, F-75013, Paris, France. FAU - Audenet, Francois AU - Audenet F AUID- ORCID: 0000-0001-5722-2075 AD - Department of Urology, Hopital Europeen Georges Pompidou, AP-HP.Centre, Universite Paris Cite, Paris, France. francois.audenet@aphp.fr. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230102 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder/pathology MH - Biomarkers, Tumor/urine MH - *Urinary Bladder Neoplasms/pathology MH - Cystoscopy/methods MH - Cytodiagnosis MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Cystoscopy OT - Cytology OT - Diagnostic OT - Follow-up EDAT- 2023/01/03 06:00 MHDA- 2023/02/25 06:00 CRDT- 2023/01/02 11:12 PHST- 2022/11/17 00:00 [received] PHST- 2022/12/08 00:00 [accepted] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/01/02 11:12 [entrez] AID - 10.1007/s00345-022-04253-3 [pii] AID - 10.1007/s00345-022-04253-3 [doi] PST - ppublish SO - World J Urol. 2023 Feb;41(2):345-359. doi: 10.1007/s00345-022-04253-3. Epub 2023 Jan 2. PMID- 38384031 OWN - NLM STAT- MEDLINE DCOM- 20240223 LR - 20240223 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 19 IP - Suppl 2 DP - 2023 Jan 1 TI - Prognostic importance of PD-L1 expression in bladder cancer patients. PG - S633-S638 LID - 10.4103/jcrt.jcrt_1297_22 [doi] AB - BACKGROUND: PD-L1/PD-1 molecules are known as important mediators in immune-escape mechanisms of tumors. PD-L1 is highly expressed in various malignancies, including bladder cancer. However, the prognostic value of PD-L1 in bladder cancer patients remains controversial. AIM: To investigate the prognostic significance of PD-L1 expression in tumor tissues of bladder cancer patients. SUBJECTS AND METHODS: RNA was isolated from FFPE tumor tissues of 48 bladder cancer patients using the monophasic phenol and guanidine isothiocyanate method. Total RNA was converted to cDNA and gene expression levels were analyzed by qRT-PCR. The differential expression levels of the PD-L1 gene between tumor grade and cancer stage groups were analyzed by independent student's t-test and one-way ANOVA. RESULTS: Statistically significantly increased PD-L1 expression was observed in the high-grade tumor group (p < 0.05). No significant difference in PD-L1 expression was found among pTa, pT1, and pT2 groups. In addition, the difference in overall survival was not significantly different between groups. CONCLUSION: The results showed that high PD-L1 expression in bladder cancer was associated with tumor aggressiveness and grade. Despite the inability of the qRT-PCR to show the PD-L1 expression at different locations of tumor tissue, evaluation of PD-L1 mRNA expression by qRT-PCR, which is a highly sensitive and specific assay, appears to be a robust approach. Furthermore, these findings may contribute to a rationale for recommending anti-PD-L1 immunotherapy as an alternative to standard therapy for bladder cancer patients who are most likely to benefit from it. CI - Copyright (c) 2023 Copyright: (c) 2023 Journal of Cancer Research and Therapeutics. FAU - Durur, Sumeyye AU - Durur S AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. FAU - Uzun, Hakki AU - Uzun H AD - Department of Urology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. FAU - Bedir, Recep AU - Bedir R AD - Department of Medical Pathology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. FAU - Nalkiran, Ihsan AU - Nalkiran I AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. FAU - Nalkiran, Hatice Sevim AU - Nalkiran HS AD - Department of Medical Biology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. LA - eng PT - Journal Article DEP - 20230317 PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 RN - 0 (B7-H1 Antigen) RN - 63231-63-0 (RNA) SB - IM MH - Humans MH - Prognosis MH - *B7-H1 Antigen/metabolism MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Staging MH - RNA EDAT- 2023/01/01 00:00 MHDA- 2024/02/23 06:44 CRDT- 2024/02/22 01:00 PHST- 2022/06/22 00:00 [received] PHST- 2022/07/18 00:00 [accepted] PHST- 2024/02/23 06:44 [medline] PHST- 2023/01/01 00:00 [pubmed] PHST- 2024/02/22 01:00 [entrez] AID - 01363817-202319002-00027 [pii] AID - 10.4103/jcrt.jcrt_1297_22 [doi] PST - ppublish SO - J Cancer Res Ther. 2023 Jan 1;19(Suppl 2):S633-S638. doi: 10.4103/jcrt.jcrt_1297_22. Epub 2023 Mar 17. PMID- 38313102 OWN - NLM STAT- MEDLINE DCOM- 20240206 LR - 20240206 IS - 1986-5961 (Electronic) IS - 0350-199X (Print) IS - 0350-199X (Linking) VI - 77 IP - 6 DP - 2023 TI - Adjuvant Intravesical Chemotherapy Versus Immunotherapy for All Risk Groups of Patients With Non-muscle Invasive Bladder Cancer. PG - 460-464 LID - 10.5455/medarh.2023.77.460-464 [doi] AB - BACKGROUND: The treatment strategy for non-muscle invasive bladder cancer (NMIBC) has not changed significantly over the past 30 years. Chemotherapeutic agents (mitomycin-C, epirubicin, etc.) and BCG (Bacillus Calmette-Guerin) immunotherapy are used as adjuvant intravesical therapy. OBJECTIVE: To compare the difference between adjuvant chemotherapy and adjuvant immunotherapy in their efficacy of reducing the number of tumor recurrences. METHODS: In this prospective clinical study, which included 99 patients with NMIBC from March 2018.-March 2023., we publish the results for all risk groups of patients treated with intravesical chemotherapy Epirubicin or with BCG immunotherapy, after TURBT (Trans urethral resection of bladder tumor) within 1 year. Patients were stratified into 2 groups. The first group was treated with Epirubicin (1 dose within 24 hours of surgery, then 6 weekly instillations and 3 maintenance doses), and the second group was treated with BCG (2-3 weeks after TURBT 6 weekly instillations, and 3 maintenance doses). The monitoring period was 24 months. RESULTS: In patients treated with intravesical chemotherapy, recurrence occurred in 9 patients (17.64%), and in patients treated with BCG, recurrence occurred in 7 patients (14.58%). A similar incidence of disease recurrence was observed in both groups (p=0.787). CONCLUSION: The results of our study show a similar therapeutic response by risk groups of patients treated with chemotherapy and immunotherapy. Since BCG production will cease in the future, the task of urologists is to introduce intravesical chemotherapy into wider use and to modernize it as a safe and effective method of adjuvant treatment for non-muscle-invasive bladder cancer. CI - (c) 2023 Haris Djug, Sefik Hasukic, Samed Jagodic, Davor Ivanic. FAU - Djug, Haris AU - Djug H AD - Clinic for Urology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Hasukic, Sefik AU - Hasukic S AD - Department of Surgery, University Clinical Centre Tuzla, Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Jagodic, Samed AU - Jagodic S AD - Clinic for Urology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. FAU - Ivanic, Davor AU - Ivanic D AD - Clinic for Radiology and Nuclear medicine, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. LA - eng PT - Journal Article PL - Bosnia and Herzegovina TA - Med Arch JT - Medical archives (Sarajevo, Bosnia and Herzegovina) JID - 101635337 RN - 3Z8479ZZ5X (Epirubicin) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Epirubicin/therapeutic use MH - Prospective Studies MH - BCG Vaccine/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Adjuvants, Immunologic/therapeutic use MH - Chemotherapy, Adjuvant MH - Immunotherapy MH - Neoplasm Invasiveness/pathology PMC - PMC10834055 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle invasive bladder cancer OT - chemotherapy OT - epirubicin OT - immunotherapy COIS- None to declare EDAT- 2023/01/01 00:00 MHDA- 2024/02/06 06:42 PMCR- 2023/01/01 CRDT- 2024/02/05 04:32 PHST- 2023/10/06 00:00 [received] PHST- 2023/11/27 00:00 [accepted] PHST- 2024/02/06 06:42 [medline] PHST- 2023/01/01 00:00 [pubmed] PHST- 2024/02/05 04:32 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.5455/medarh.2023.77.460-464 [doi] PST - ppublish SO - Med Arch. 2023;77(6):460-464. doi: 10.5455/medarh.2023.77.460-464. PMID- 36586485 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230308 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 47 IP - 2 DP - 2023 Mar TI - Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis. PG - 92-98 LID - S2173-5786(22)00142-1 [pii] LID - 10.1016/j.acuroe.2022.12.003 [doi] AB - INTRODUCTION: We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. METHODS: A systematic literature search up to November 2021 was done and 6 studies included 389 subjects with non-muscle invasive bladder cancer at the start of the study; 197 of them were provided with intravesical-mitomycin and 192 with intravesical gemcitabine. The studies reported the relationships about the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) to assess the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer using the dichotomous method with a random or fixed-effect model. RESULTS: Intravesical mitomycin had significantly higher recurrence rates (OR, 2.41; 95% CI, 1.43-4.08, p=0.001) and chemical cystitis (OR, 4.39; 95% CI, 2.27-8.51, p<0.001) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. However, intravesical mitomycin had no significant difference in its effect on hematuria (OR, 1.71; 95% CI, 0.68-4.33, p=0.26), skin reaction (OR, 2.04; 95% CI, 0.59-7.07, p=0.26), and liver and kidney functions damage (OR, 1.96; 95% CI, 0.35-10.96, p=0.44) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. CONCLUSIONS: Intravesical mitomycin had significantly higher recurrence rates and chemical cystitis and no significant difference in its effect on hematuria, skin reaction, and liver and kidney functions damage compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. Further studies are required to validate these findings. CI - Copyright (c) 2022 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Cheng, W AU - Cheng W AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. FAU - Zhou, Y AU - Zhou Y AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. FAU - Chu, X AU - Chu X AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. FAU - Huang, S AU - Huang S AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. FAU - Zheng, X AU - Zheng X AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. Electronic address: zhenghao8678@outlook.com. FAU - Zheng, H AU - Zheng H AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China. LA - eng LA - spa PT - Journal Article PT - Meta-Analysis DEP - 20221228 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 50SG953SK6 (Mitomycin) RN - 0 (Gemcitabine) RN - 0W860991D6 (Deoxycytidine) SB - IM MH - Humans MH - Mitomycin MH - Gemcitabine MH - Hematuria MH - *Non-Muscle Invasive Bladder Neoplasms MH - Deoxycytidine/therapeutic use MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/drug therapy MH - *Cystitis OTO - NOTNLM OT - Chemical cystitis OT - Cistitis quimica OT - Cancer de vejiga sin invasion muscular OT - Gemcitabina intravesical OT - Hematuria OT - Intravesical gemcitabine OT - Intravesical mitomycin OT - Mitomicina intravesical OT - Non-muscle invasive bladder cancer OT - Recurrence rates OT - Tasas de recurrencia EDAT- 2023/01/01 06:00 MHDA- 2023/03/08 06:00 CRDT- 2022/12/31 19:13 PHST- 2021/12/14 00:00 [received] PHST- 2022/03/06 00:00 [accepted] PHST- 2023/01/01 06:00 [pubmed] PHST- 2023/03/08 06:00 [medline] PHST- 2022/12/31 19:13 [entrez] AID - S2173-5786(22)00142-1 [pii] AID - 10.1016/j.acuroe.2022.12.003 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2023 Mar;47(2):92-98. doi: 10.1016/j.acuroe.2022.12.003. Epub 2022 Dec 28. PMID- 36576469 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230103 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 94 IP - 4 DP - 2022 Dec 27 TI - AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomy. PG - 428-433 LID - 10.4081/aiua.2022.4.428 [doi] AB - OBJECTIVES: We investigated AB0 blood groups prevalence according to preoperative and pathological tumor characteristics, and their association with oncological outcomes, and renal function decline in a contemporary large cohort of bladder cancer (BCa) patients, who underwent radical cystectomy (RC) at a tertiary referral center. MATERIALS AND METHODS: We retrospectively evaluated data of patients with histologically confirmed and clinically non metastatic BCa, who underwent RC between 2014 and 2021 at our Institution. Kaplan-Meier (KM) plots and Cox regression (CR) models tested the relationship between AB0 blood groups and local recurrence-, metastasis-, cancer specific mortality-, and overall mortality-free survival. Logistic regression (LR) models tested the association between AB0 blood groups and renal function decline, defined as an estimated Glomerular Filtration Rate (eGFR) < 60 mL/min, at post-operative day 1, discharge and 6- months of follow-up. RESULTS: Of 301 included patients, 128 (42.5%) had group A, 126 (41.9%) had group 0, 28 (9.3%) had group B, and 19 (6.3%) had group AB. Patients with group 0 developed higher rates of muscle- invasive BCa (p = 0.028) with high-grade features (p = 0.005) at last bladder resection, and less frequently received preoperative immunotherapy with Bacillus of Calmette-Guerin (p = 0.044), than their non-0 counterparts. Additionally, these patients harbored more advanced pathologic tumor stage at RC (p = 0.024). KM plots showed no differences among all tested cancer control outcomes between AB0 blood groups (p > 0.05 in all cases). Patients with group AB presented the lowest median eGFR at each time point. In multivariable LR analyses addressing renal function decline, group AB was independently associated with eGFR< 60 mL/min at discharge (Odds Ratio: 4.28, p = 0.047). CONCLUSIONS: Among AB0 blood groups, patients with group 0 exhibited the most aggressive tumor profile. However, no differences were recorded in recurrence or survival rates. Group AB independently predicted renal function decline at discharge. FAU - Tafuri, Alessandro AU - Tafuri A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Department of Urology, "Vito Fazzi" Hospital, Lecce. aletaf@hotmail.it. FAU - Panunzio, Andrea AU - Panunzio A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. panunzioandrea@virgilio.it. FAU - Soldano, Antonio AU - Soldano A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. soldanoantonio@libero.it. FAU - Mazzucato, Giovanni AU - Mazzucato G AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. gio.mazzucato@gmail.com. FAU - Ornaghi, Paola Irene AU - Ornaghi PI AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. paolairene.ornaghi@gmail.com. FAU - Di Filippo, Giacomo AU - Di Filippo G AD - Department of General and Hepatobiliary Surgery, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona. giacomo.difilippo90@gmail.com. FAU - Gozzo, Alessandra AU - Gozzo A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. la.ale.gozzo@gmail.com. FAU - De Maria, Nicola AU - De Maria N AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. nicola.demaria02@gmail.com. FAU - Cianflone, Francesco AU - Cianflone F AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. fra1178@gmail.com. FAU - Shakir, Aliasger AU - Shakir A AD - USC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles. aliasgershakir@gmail.com. FAU - Tian, Zhe AU - Tian Z AD - Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. zhe.tian24@gmail.com. FAU - Brunelli, Matteo AU - Brunelli M AD - Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. matteo.brunelli@univr.it. FAU - Porcaro, Antonio Benito AU - Porcaro AB AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. drporcaro@yahoo.com. FAU - Pagliarulo, Vincenzo AU - Pagliarulo V AD - Department of Urology, "Vito Fazzi" Hospital, Lecce. enzopagliarulo@yahoo.com. FAU - Artibani, Walter AU - Artibani W AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. prof.artibani@gmail.com. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. pierrekarakiewicz@gmail.com. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. alessandro_antonelli@me.com. FAU - Cerruto, Maria Angela AU - Cerruto MA AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. mariaangela.cerruto@univr.it. LA - eng PT - Journal Article DEP - 20221227 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (Blood Group Antigens) SB - IM MH - Humans MH - Urinary Bladder/pathology MH - Cystectomy MH - Retrospective Studies MH - *Blood Group Antigens MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Recurrence, Local EDAT- 2022/12/29 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/12/28 10:33 PHST- 2022/09/21 00:00 [received] PHST- 2022/10/02 00:00 [accepted] PHST- 2022/12/28 10:33 [entrez] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] AID - 10.4081/aiua.2022.4.428 [doi] PST - epublish SO - Arch Ital Urol Androl. 2022 Dec 27;94(4):428-433. doi: 10.4081/aiua.2022.4.428. PMID- 36575910 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 30 IP - 4 DP - 2023 Apr TI - Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer. PG - 381-388 LID - 10.1111/iju.15136 [doi] AB - OBJECTIVES: Accurately predicting of progression is important for patients with non-muscle-invasive bladder cancer (NMIBC). We previously reported that bladder neck involvement (BNI) was significantly associated with progression of NMIBC. In this study, we evaluated the prognostic significance of the detailed BNI location in NMIBC patients. METHODS: We retrospectively reviewed 651 patients diagnosed with primary NMIBC at a single center between 2000 and 2018. Using the detailed BNI location, patients were divided into the following three groups: dorsal BNI (BNId; 4 to 8 o'clock position), ventral BNI (BNIv; 8 to 4 o'clock but not 4 to 8 o'clock position), and non-BNI group. Both time to progression to muscle-invasive disease and distant metastasis was compared among the three groups. A prognostic model was developed and its discriminative ability was evaluated. RESULTS: Dorsal bladder neck involvement and BNIv were observed in 43 (6.6%) and 36 (5.5%) patients, respectively. During a median follow-up of 61 months, 35 (5.4%) patients progressed. The cumulative incidence at 5 years was 12%, 0%, and 5.0% in BNId, BNIv, and non-BNI groups, respectively. On multivariate analysis, BNId was a significant and independent risk factor for progression, tumor stage pT1, and histologic grade G3. One point was assigned to each factor, and patients were classified into four well-stratified prognostic groups based on the total score. CONCLUSION: Dorsal bladder neck involvement was an independent and significant risk factor for progression in primary NMIBC. Our simple and practical prognostic model including BNId is easy to use and may help selecting the optimal treatment and its timing. CI - (c) 2022 The Japanese Urological Association. FAU - Nakamura, Yuki AU - Nakamura Y AUID- ORCID: 0000-0003-4931-2489 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fukushima, Hiroshi AU - Fukushima H AUID- ORCID: 0000-0001-7548-1580 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yoshitomi, Kasumi AU - Yoshitomi K AUID- ORCID: 0000-0003-1034-9874 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Soma, Takahiko AU - Soma T AUID- ORCID: 0000-0002-7086-8214 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Kobayashi, Masaki AU - Kobayashi M AUID- ORCID: 0000-0003-2738-9792 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fan, Bo AU - Fan B AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fujiwara, Motohiro AU - Fujiwara M AUID- ORCID: 0000-0001-9454-3345 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Ishikawa, Yudai AU - Ishikawa Y AUID- ORCID: 0000-0001-7118-5522 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fukuda, Shohei AU - Fukuda S AUID- ORCID: 0000-0003-2741-8338 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Waseda, Yuma AU - Waseda Y AUID- ORCID: 0000-0002-9319-1373 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Tanaka, Hajime AU - Tanaka H AUID- ORCID: 0000-0003-3632-2901 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AUID- ORCID: 0000-0003-2757-8083 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AUID- ORCID: 0000-0002-0245-8934 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AUID- ORCID: 0000-0002-6761-3229 AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20221227 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2023 Apr;30(4):388-389. doi: 10.1111/iju.15150. PMID: 36653186 CIN - Int J Urol. 2023 May;30(5):497. doi: 10.1111/iju.15200. PMID: 37161584 MH - Humans MH - Urinary Bladder/pathology MH - Retrospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - Follow-Up Studies MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Disease Progression MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local OTO - NOTNLM OT - bladder neck involvement OT - non-muscle-invasive bladder cancer OT - progression OT - risk substratification OT - transurethral resection EDAT- 2022/12/29 06:00 MHDA- 2023/04/04 06:42 CRDT- 2022/12/28 02:53 PHST- 2022/08/13 00:00 [received] PHST- 2022/12/15 00:00 [accepted] PHST- 2023/04/04 06:42 [medline] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/28 02:53 [entrez] AID - 10.1111/iju.15136 [doi] PST - ppublish SO - Int J Urol. 2023 Apr;30(4):381-388. doi: 10.1111/iju.15136. Epub 2022 Dec 27. PMID- 36574911 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20250808 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 173 DP - 2023 Mar TI - Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort. PG - 134-141 LID - S0090-4295(22)01071-8 [pii] LID - 10.1016/j.urology.2022.12.009 [doi] AB - OBJECTIVE: To describe the risk of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) and their impact on progression. Prognostic studies of IR-NMIBC have focused on initial recurrences, yet little is known about subsequent recurrences and their impact on progression. MATERIALS AND METHODS: IR-NMIBC patients from the Be-Well Study, a prospective cohort study of NMIBC patients diagnosed from 2015 to 2019 at Kaiser Permanente Northern California, were identified. The frequency of first, second, and third intravesical recurrences of urothelial carcinoma were characterized using conditional Kaplan-Meier analyses and random-effects shared-frailty models. The association of multiple recurrences with progression was examined. RESULTS: In 291 patients with IR-NMIBC (median follow-up 38 months), the 5-year risk of initial recurrence was 54.4%. After initial recurrence (n = 137), 60.1% of patients had a second recurrence by 2 years. After second recurrence (n = 70), 51.5% of patients had a third recurrence by 3 years. In multivariable analysis, female sex (Hazard Ratio 1.51, P< .01), increasing tumor size (HR 1.14, P< .01) and number of prior recurrences (HR 1.24, P< .01) were associated with multiple recurrences; whereas maintenance BCG (HR 0.66, P = .03) was associated with reduced recurrences. The 5-year risk of progression varied significantly (P< .01) by number of recurrences: 9.5%, 21.9%, and 37.9% for patients with 1, 2, and 3+ recurrences, respectively. CONCLUSIONS: Multiple recurrences are common in IR-NMIBC and are associated with progression. Female sex, larger tumors, number of prior recurrences, and lack of maintenance BCG were associated with multiple recurrences. Multiple recurrences may prove useful as a clinical trial endpoint for IR-NMIBC. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, University of California Los Angeles, Los Angeles, CA; Department of Urology, Mayo Clinic, Rochester, MN. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, University of California Los Angeles, Los Angeles, CA. FAU - Schoenberg, Mark AU - Schoenberg M AD - Department of Urology, The Albert Einstein College of Medicine, Bronx, NY. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA. FAU - Fero, Katherine AU - Fero K AD - Department of Urology, University of California Los Angeles, Los Angeles, CA. FAU - Lec, Patrick AU - Lec P AD - Department of Urology, University of California Los Angeles, Los Angeles, CA. FAU - Munneke, Julie R AU - Munneke JR AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA. FAU - Quesenberry, Charles P AU - Quesenberry CP AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Oakland, CA. Electronic address: Marilyn.L.Kwan@kp.org. LA - eng GR - R01 CA172855/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20221224 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - J Urol. 2023 Dec;210(6):928-930. doi: 10.1097/JU.0000000000003719. PMID: 37747154 MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Prospective Studies MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Disease Progression MH - Adjuvants, Immunologic/therapeutic use MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Invasiveness MH - Administration, Intravesical PMC - PMC12327494 MID - NIHMS2099206 EDAT- 2022/12/28 06:00 MHDA- 2023/03/28 06:00 PMCR- 2025/08/06 CRDT- 2022/12/27 19:13 PHST- 2022/07/29 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/28 06:00 [pubmed] PHST- 2023/03/28 06:00 [medline] PHST- 2022/12/27 19:13 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - S0090-4295(22)01071-8 [pii] AID - 10.1016/j.urology.2022.12.009 [doi] PST - ppublish SO - Urology. 2023 Mar;173:134-141. doi: 10.1016/j.urology.2022.12.009. Epub 2022 Dec 24. PMID- 36570433 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221227 IS - 2231-0770 (Print) IS - 2249-4464 (Electronic) IS - 2231-0770 (Linking) VI - 12 IP - 4 DP - 2022 Oct TI - Application of Vesical Imaging-Reporting and Data System in Evaluation of Urinary Bladder Cancer Using Multiparametric Magnetic Resonance Imaging: A Hospital-Based Cross-Sectional Study. PG - 162-168 LID - 10.1055/s-0042-1755334 [doi] AB - Background Multiparametric magnetic resonance imaging (mp-MRI) of urinary bladder (UB) is a novel imaging to predict detrusor muscle invasion in Bladder cancer (BC). The Vesical Imaging-Reporting and Data System (VI-RADS) was introduced in 2018 to standardize the reporting of BC with mp-MRI and to diagnose muscle invasion. This study was performed to evaluate the role of mp-MRI using VI-RADS to predict muscle invasive BC. Methods This prospective study was carried from June 2020 to May 2021 in a tertiary care institute. Thirty-six patients with untreated BC underwent mp-MRI followed by transuretheral resection of the tumor (TURBT). Mp-MRI findings were evaluated by two radiologists and BC was categorized according to VI-RADS scoring system. Resected tumors along with separate biopsy from the base were reported by two pathologists. Histopathological findings were compared with VI-RADS score and the performance of VI-RADS for determining detrusor muscle invasion was analyzed. Results VI-RADS scores of 4 and 5 were assigned to 9 (25%) and 15 (41.7%) cases, respectively, while 4 (13.3%) cases had VI-RADS score 3 on mp-MRI. VI-RADS 1 and 2 lesions were observed in six (16.7%) and two (5.5%) cases, respectively. On histopathology, 23 cases (63.9%) had muscle-invasive cancer and 13 cases (36.1%) had non-muscle-invasive cancer. The sensitivity and diagnostic accuracy of mp-MRI in predicting muscle invasive BC was 95.6 and 80.6%, respectively. Conclusion Mp-MRI has high sensitivity and diagnostic accuracy in predicting muscle invasive BC and should be advocated for evaluation of BC prior to surgery. CI - Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ). FAU - Gupta, Rahul AU - Gupta R AD - Department of Urology, Government Medical College, Jammu, Jammu and Kashmir, India. FAU - Mahajan, Manik AU - Mahajan M AD - Department of Radio-Diagnosis and Imaging, Government Medical College, Jammu, Jammu and Kashmir, India. FAU - Sharma, Poonam AU - Sharma P AUID- ORCID: 0000-0002-9058-6265 AD - Department of Pathology, All India Institute of Medical Sciences, Vijaypur, Jammu, Jammu and Kashmir, India. FAU - Bhardwaj, Subhash AU - Bhardwaj S AD - Department of Pathology, Government Medical College, Jammu, Jammu and Kashmir, India. FAU - Gupta, Vikrant AU - Gupta V AD - Department of Radiology, Government Medical College, Jammu, Jammu and Kashmir, India. FAU - Mahajan, Arti AU - Mahajan A AD - Department of Anaesthesia, Government Medical College, Jammu, Jammu and Kashmir, India. LA - eng PT - Journal Article DEP - 20220915 PL - Germany TA - Avicenna J Med JT - Avicenna journal of medicine JID - 101584155 PMC - PMC9771629 OTO - NOTNLM OT - bladder cancer OT - detrusor OT - magnetic resonance imaging OT - multiparametric OT - staging COIS- Conflict of Interest None declared. EDAT- 2022/12/27 06:00 MHDA- 2022/12/27 06:01 PMCR- 2022/09/01 CRDT- 2022/12/26 04:34 PHST- 2022/12/26 04:34 [entrez] PHST- 2022/12/27 06:00 [pubmed] PHST- 2022/12/27 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - 220014 [pii] AID - 10.1055/s-0042-1755334 [doi] PST - epublish SO - Avicenna J Med. 2022 Sep 15;12(4):162-168. doi: 10.1055/s-0042-1755334. eCollection 2022 Oct. PMID- 36566105 OWN - NLM STAT- MEDLINE DCOM- 20230519 LR - 20230625 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 5 DP - 2023 May TI - Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design. PG - 254.e9-254.e15 LID - S1078-1439(22)00431-8 [pii] LID - 10.1016/j.urolonc.2022.10.033 [doi] AB - INTRODUCTION: The path to approval of novel therapeutics for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) requires demonstration of efficacy in eradicating carcinoma in situ (CIS), as determined by cytology, white light cystoscopy and only sometimes mandatory re-biopsy. This paradigm is based on the premise that CIS, in contrast to papillary tumors, cannot be completely resected. We aimed to determine the accuracy of CIS by standard means and the rate at which CIS may be eradicated by transurethral bladder tumor resection (TURBT). METHODS: We performed a retrospective analysis of consecutive patients who underwent radical cystectomy (RC) for high risk NMIBC or muscle invasive bladder cancer (MIBC) between 2005 and 2019 in a tertiary academic center. The concordance in the presence of CIS in matched TURBT and RC samples was calculated. RESULTS: Complete pathologic information was available for 816 patients with urothelial carcinoma. CIS was detected at TURBT in 354 (43.4%) patients (64.0% NMIBC, 32.3% MIBC) and at RC in 436 (53.4%) patients (64.7% NMIBC, 47.4% MIBC). CIS was missed by TURBT in 199 (45.6%) of those cases (NMIBC 25.4%, MIBC 60.6%). CIS detected on TURBT was not found in the RC specimen in 33.1% (117/354) of cases. Lack of prospective bladder mapping and central pathology review are limitations. CONCLUSION: Our results suggest that TURBT is inaccurate in detecting CIS. The absence of CIS in the RC specimen after detection in the matched TURBT specimen suggests that CIS may be completely resected by TURBT in a proportion of patients. These factors need to be considered in the design of clinical trials in patients with NMIBC. The use of random biopsies or enhanced cystoscopy could improve the accuracy of CIS detection, but the former is associated with patient morbidity and randomization would alleviate concern about these variables impacting clinical trial outcomes. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; Department of Urology, Toulouse University Hospital, Toulouse, France. FAU - Wong, Amanda AU - Wong A AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Belanger, Eric AU - Belanger E AD - Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. FAU - Wang, Gang AU - Wang G AD - Department of Pathology, British Columbia Cancer Vancouver Centre, Vancouver, Canada. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: pblack@mail.ubc.ca. LA - eng PT - Journal Article DEP - 20221222 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Urinary Bladder/surgery/pathology MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Retrospective Studies MH - Neoplasm Staging MH - Clinical Trials as Topic MH - Cystectomy/methods MH - *Carcinoma in Situ/surgery/pathology MH - Neoplasm Invasiveness/pathology OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Clinical trials OT - Detection OT - Risk stratification EDAT- 2022/12/25 06:00 MHDA- 2023/05/19 06:41 CRDT- 2022/12/24 21:54 PHST- 2022/05/09 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/10/30 00:00 [accepted] PHST- 2023/05/19 06:41 [medline] PHST- 2022/12/25 06:00 [pubmed] PHST- 2022/12/24 21:54 [entrez] AID - S1078-1439(22)00431-8 [pii] AID - 10.1016/j.urolonc.2022.10.033 [doi] PST - ppublish SO - Urol Oncol. 2023 May;41(5):254.e9-254.e15. doi: 10.1016/j.urolonc.2022.10.033. Epub 2022 Dec 22. PMID- 36558023 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221227 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 27 IP - 24 DP - 2022 Dec 14 TI - Rapid Detection of Recurrent Non-Muscle Invasive Bladder Cancer in Urine Using ATR-FTIR Technology. LID - 10.3390/molecules27248890 [doi] LID - 8890 AB - Non-muscle Invasive Bladder Cancer (NMIBC) accounts for 80% of all bladder cancers. Although it is mostly low-grade tumors, its high recurrence rate necessitates three-times-monthly follow-ups and cystoscopy examinations to detect and prevent its progression. A rapid liquid biopsy-based assay is needed to improve detection and reduce complications from invasive cystoscopy. Here, we present a rapid spectroscopic method to detect the recurrence of NMIBC in urine. Urine samples from previously-diagnosed NMIBC patients (n = 62) were collected during their follow-up visits before cystoscopy examination. Cystoscopy results were recorded (41 cancer-free and 21 recurrence) and attenuated total refraction Fourier transform infrared (ATR-FTIR) spectra were acquired from urine samples using direct application. Spectral processing and normalization were optimized using parameter grid searching. We assessed their technical variability through multivariate analysis and principal component analysis (PCA). We assessed 35 machine learning models on a training set (70%), and the performance was evaluated on a held-out test set (30%). A Regularized Random Forests (RRF) model achieved a 0.92 area under the receiver operating characteristic (AUROC) with 86% sensitivity and 77% specificity. In conclusion, our spectroscopic liquid biopsy approach provides a promising technique for the early identification of NMIBC with a less invasive examination. FAU - El-Falouji, Abdullah I AU - El-Falouji AI AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Sabri, Dalia M AU - Sabri DM AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Lotfi, Naira M AU - Lotfi NM AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Medany, Doaa M AU - Medany DM AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Mohamed, Samar A AU - Mohamed SA AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Alaa-Eldin, Mai AU - Alaa-Eldin M AD - Institute of Biotechnology for Postgraduate Studies and Research (IBPR), Suez Canal University, Ismailia 41522, Egypt. FAU - Selim, Amr Mounir AU - Selim AM AD - Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt. FAU - El Leithy, Asmaa A AU - El Leithy AA AUID- ORCID: 0000-0002-8854-375X AD - College of Biotechnology, Misr University for Science and Technology, Giza 12562, Egypt. FAU - Kalil, Haitham AU - Kalil H AUID- ORCID: 0000-0002-5140-1504 AD - Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt. AD - Chemistry Department, Cleveland State University, Cleveland, OH 44115, USA. FAU - El-Tobgy, Ahmed AU - El-Tobgy A AD - Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt. FAU - Mohamed, Ahmed AU - Mohamed A AUID- ORCID: 0000-0001-6507-5300 AD - Division of Bioinformatics and Colonial Foundation Healthy Ageing Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia. LA - eng GR - 3/2020/Suez Canal University/ PT - Journal Article DEP - 20221214 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - EC 2.7.11.1 (ATR protein, human) RN - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins) SB - IM MH - Humans MH - Spectroscopy, Fourier Transform Infrared MH - Fourier Analysis MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/diagnosis/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Ataxia Telangiectasia Mutated Proteins PMC - PMC9785428 OTO - NOTNLM OT - FTIR OT - bladder cancer OT - liquid biopsy OT - machine learning COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 PMCR- 2022/12/14 CRDT- 2022/12/23 01:50 PHST- 2022/09/30 00:00 [received] PHST- 2022/11/17 00:00 [revised] PHST- 2022/12/09 00:00 [accepted] PHST- 2022/12/23 01:50 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/12/14 00:00 [pmc-release] AID - molecules27248890 [pii] AID - molecules-27-08890 [pii] AID - 10.3390/molecules27248890 [doi] PST - epublish SO - Molecules. 2022 Dec 14;27(24):8890. doi: 10.3390/molecules27248890. PMID- 36551596 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 24 DP - 2022 Dec 12 TI - Sex Remains Negative Prognostic Factor in Contemporary Cohort of High-Risk Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers14246110 [doi] LID - 6110 AB - Sex-specific differences in outcomes of patients diagnosed with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have been reported with controversial findings. This study aims to investigate sex-specific diversities in the treatment and oncologic outcomes of primary HR-NMIBC in a multicenter setting. A multicenter retrospective analysis of 519 patients (388 men and 131 women) treated with transurethral resection (TUR) for primary HR-NMIBC was performed. Univariable and multivariable Cox regression models were used to investigate the association of clinico-pathologic features and generate hazard ratios (HRs). Second-look TUR (reTUR) was performed in 406 (78%) patients. A total of 218 (42%) of patients were subjected to an induction course of intravesical BCG (Bacillus Calmette-Guerin) plus maintenance therapy. The median follow-up was 44 months. Among the entire cohort, 238 (46%) and 86 patients (17%) had recurred and progressed to muscle-invasive disease (MIBC), respectively. Female sex was associated with increased risk of disease recurrence in the entire cohort: HR = 1.94, 95% CI = 1.48-2.55, p < 0.001 and HR = 1.91, 95% CI = 1.39-2.60, p < 0.001 in univariate and multivariate analysis, respectively. In patients subjected to reTUR and treated additionally with BCG, female sex was associated with increased risk of disease recurrence in univariate analysis (HR 1.81, 95% CI 1.07-3.06, p = 0.03), but not in multivariate analysis (HR 1.99, 95% CI 0.98-4.02, p = 0.06). There was no difference between sexes with regard to disease progression. HR-NMIBC diagnosed in females is associated with higher risk of disease recurrence when compared to males. FAU - Bilski, Konrad AU - Bilski K AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland. FAU - Kozikowski, Mieszko AU - Kozikowski M AD - Polish Center of Advanced Urology, Department of Urology, St. Anne's Hospital EMC, 05-500 Piaseczno, Poland. AD - Department of Diagnostic Imaging-Quadia, 05-500 Piaseczno, Poland. FAU - Skrzypczyk, Michal A AU - Skrzypczyk MA AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland. FAU - Dobruch, Aleksandra AU - Dobruch A AUID- ORCID: 0000-0002-4381-9142 AD - Sapienza University of Rome, 00185 Rome, Italy. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, 1090 Vienna, Austria. FAU - Czech, Anna Katarzyna AU - Czech AK AD - Department of Urology, Jagiellonian University Medical College, 31-008 Cracow, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland. LA - eng GR - 2019/33/B/NZ5/02447/National Science Center/ PT - Journal Article DEP - 20221212 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9776018 OTO - NOTNLM OT - bladder cancer OT - gender OT - outcomes OT - sex OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/12 CRDT- 2022/12/23 01:11 PHST- 2022/11/14 00:00 [received] PHST- 2022/12/04 00:00 [revised] PHST- 2022/12/09 00:00 [accepted] PHST- 2022/12/23 01:11 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/12 00:00 [pmc-release] AID - cancers14246110 [pii] AID - cancers-14-06110 [pii] AID - 10.3390/cancers14246110 [doi] PST - epublish SO - Cancers (Basel). 2022 Dec 12;14(24):6110. doi: 10.3390/cancers14246110. PMID- 36549142 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20230227 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 63 DP - 2023 Apr TI - Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years). PG - 152079 LID - S1092-9134(22)00181-2 [pii] LID - 10.1016/j.anndiagpath.2022.152079 [doi] AB - PURPOSE: Our study aimed to determine the prognostic significance of minor high-grade components (HGC) in non-invasive papillary urothelial carcinomas compared with pure low-grade and high-grade tumors. MATERIAL AND METHODS: We retrospectively retrieved 273 in-house cases of non-invasive papillary urothelial carcinomas (pTa) from 2016 to 2018 for which follow up data was available in hospital archives. We stratified our data into four main groups (G). G1, pure low-grade (n = 164); G2, HGC 5 % to /=554 x 10(9)/l) accordingly. Multivariable Cox proportional hazard regression demonstrated that a high SII was an independent prognostic factor for worse OS (HR: 1.69 95% CI: 1.02-2.81, P = 0.0436) and RFS (HR: 1.88, 95% CI: 1.09-3.24, P = 0.0229) in NMIBC patients. A high SII was found to be an independent prognostic factor for worse RFS in patients with HBP (HR: 2.11, 95% CI: 1.34-3.30, P = 0.0012), with DM (HR: 3.76, 95% CI: 1.73-8.15, P = 0.0008), and without PNI (HR: 1.32, 95% CI: 1.04-1.69, P = 0.0238). CONCLUSIONS: The SII was a potential prognostic predictor for bladder cancer patients who underwent RC. Further prospective multicenter investigations are warranted. CI - Copyright (c) 2022 Zhang, Du, Zhong, Tan, Xu, Zhang, Jin, Li, Le, Xiong, Lin and Wei. FAU - Zhang, Shiyu AU - Zhang S AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Du, Jiajia AU - Du J AD - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Zhong, Xin AU - Zhong X AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Tan, Ping AU - Tan P AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. AD - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Xu, Hang AU - Xu H AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Zhang, Jiapeng AU - Zhang J AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Jin, Di AU - Jin D AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Li, Yifan AU - Li Y AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Le, Weizhen AU - Le W AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Xiong, Xingyu AU - Xiong X AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Lin, Tianhai AU - Lin T AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20221129 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Male MH - Humans MH - Female MH - Aged MH - *Cystectomy/adverse effects/methods MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Inflammation/pathology PMC - PMC9744948 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - prognosis OT - radical cystectomy (RC) OT - systemic immune-inflammation index (SII) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/17 06:00 MHDA- 2022/12/20 06:00 PMCR- 2022/01/01 CRDT- 2022/12/16 02:33 PHST- 2022/10/17 00:00 [received] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/12/16 02:33 [entrez] PHST- 2022/12/17 06:00 [pubmed] PHST- 2022/12/20 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1072433 [doi] PST - epublish SO - Front Immunol. 2022 Nov 29;13:1072433. doi: 10.3389/fimmu.2022.1072433. eCollection 2022. PMID- 36522359 OWN - NLM STAT- MEDLINE DCOM- 20221219 LR - 20240909 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Dec 15 TI - Noninvasive studies may have potential to replace cystoscopy in non-muscle invasive bladder cancer follow-up. PG - 21677 LID - 10.1038/s41598-022-23111-1 [doi] LID - 21677 AB - Bladder cancer has a high recurrence rate which requires frequent follow-up. Cystoscopy is currently the gold standard for follow-up which is invasive and undesirable procedure for patients. We aimed to investigate the feasibility of noninvasive studies for follow-up of non-muscle invasive bladder cancer. This retrospective study was done for non-muscle invasive bladder cancer patients with abnormal lesion at follow up cystoscopy, therefore those needed transurethral resection of bladder tumor (TUR-BT). Inclusion criteria was patients who had preoperative bladder magnetic resonance imaging (MRI) within 1 month to TUR-BT and urine cytology results. MRI, urine cytology, and surgical pathology results were analyzed for sensitivity, specificity, positive and negative predictive values, accuracy, diagnostic odds ratio, and number needed to misdiagnose for the diagnostic performance of non-invasive studies. From total of 2,258 TUR-BT cases, 1,532 cases of primary TUR-BT and 481 cases which bladder MRI were not done was excluded. Finally, 245 cases of TUR-BT were included. Combined urine cytology and bladder MRI showed 96% sensitivity, 43% specificity, 89% positive and 67% negative predictive values, 87% accuracy, 16.2 diagnostic odds ratio, and 7.4 number needed to misdiagnose values. Among nine false-negative cases, three (1.2%) were missed by the radiologist, two (0.8%) had an empty bladder during magnetic resonance imaging, and three (1.2%) had gross hematuria which needed cystoscopy despite of bladder MRI or urine cytology result. Only one case (0.4%) was missed based on symptoms and noninvasive tests. However, none of the false-negative cases showed rapid extensive progression requiring radical or partial cystectomy. The combination of bladder MRI and urine cytology was comparable to cystoscopy for the follow-up of recurred lesions in non-muscle invasive bladder cancer patients for sensitivity, but not for specificity. However, it may reduce the need for cystoscopy and allowing patients to have choices for follow up diagnostic methods. Also, additional imaging tests to evaluate kidney, ureter and peri-vesical lesions can be reduced. CI - (c) 2022. The Author(s). FAU - Lee, Jongsoo AU - Lee J AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. FAU - Heo, Ji Eun AU - Heo JE AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. FAU - Kang, Sung Ku AU - Kang SK AD - Department of Urology, National Health Insurance Service Ilsan hospital, Goyang, 10444, Korea. FAU - Lee, Kwang Suk AU - Lee KS AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. FAU - Han, Hyunho AU - Han H AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. FAU - Jang, Won Sik AU - Jang WS AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. FAU - Choi, Young Deuk AU - Choi YD AD - Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea. youngd74@yuhs.ac. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221215 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Cystoscopy/methods MH - Retrospective Studies MH - Follow-Up Studies MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Neoplasm Recurrence, Local/diagnostic imaging/pathology PMC - PMC9755302 COIS- The authors declare no competing interests. EDAT- 2022/12/16 06:00 MHDA- 2022/12/20 06:00 PMCR- 2022/12/15 CRDT- 2022/12/15 23:20 PHST- 2022/08/10 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/12/15 23:20 [entrez] PHST- 2022/12/16 06:00 [pubmed] PHST- 2022/12/20 06:00 [medline] PHST- 2022/12/15 00:00 [pmc-release] AID - 10.1038/s41598-022-23111-1 [pii] AID - 23111 [pii] AID - 10.1038/s41598-022-23111-1 [doi] PST - epublish SO - Sci Rep. 2022 Dec 15;12(1):21677. doi: 10.1038/s41598-022-23111-1. PMID- 36522279 OWN - NLM STAT- MEDLINE DCOM- 20230609 LR - 20230810 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 6 DP - 2023 Jun TI - Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients. PG - 295.e9-295.e17 LID - S1078-1439(22)00477-X [pii] LID - 10.1016/j.urolonc.2022.11.017 [doi] AB - BACKGROUND: Biodynamic signatures (temporal patterns of microscopic motion within a 3-dimensional tumor explant) offer phenomic biomarkers that are highly predictive for therapeutic response. OBJECTIVE: By utilizing motility contrast tomography, which provides a simple, fast assessment of motion patterns in living tissue, we evaluated the predictive accuracy of a biodynamic drug response classifier in muscle-invasive bladder cancer (MIBC) patients undergoing neoadjuvant chemotherapy (NAC). DESIGN, SETTING, AND PARTICIPANTS: One hundred five consecutive bladder cancer patients suspected of having MIBC were screened in a multi-institutional prospective observational study (NCT03739177) from July 2018 to June 2020, of whom, 30 completed NAC and radical cystectomy. INTERVENTION(S): Biodynamic signatures from treatment-naive fresh bladder tumor specimens obtained after transurethral resection were measured in living tumor fragments challenged by standard-of-care cytotoxins. Patients received gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin per institutional guidelines and were followed through radical cystectomy. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: A 4-level classifier was developed to predict pathologic complete response (pCR) vs. incomplete response utilizing a one-left-out cross-validation protocol to minimize over-fitting. Area under the curve evaluated predictive utility. RESULTS: Thirty percent (9 of 30) achieved pCR. Utilizing the 4-level classifier, biodynamically "favored" (scoring >/= 3) and "strongly favored" (scoring 4) regimens accurately predicted pCR at rates of 66.7% (4 of 6 patients) and 100% (4 of 4 patients), respectively. Biodynamically "favored" scores predicted pCR with 88% sensitivity and 95% negative predictive value, P < 0.0001. Only 5.0% (1 of 20 patients) achieved pCR from regimens scoring 1 or 2, indicating poor to no response from NAC. Area under the receiver operating curve was 96% (95% Confidence Interval: 79%-99%, P < 0.0001). Future direction involves validating this model prospectively. PRINCIPAL CONCLUSIONS: Biodynamic scoring accurately predicts response in MIBC patients receiving NAC and holds promise to substantially improve the scope of appropriate management intervention. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Laviana, Aaron A AU - Laviana AA AD - Department of Surgery and Perioperative Care, Dell Medical School at the University of Austin at Texas, Austin, TX. Electronic address: alaviana@gmail.com. FAU - Schiftan, Elizabeth G AU - Schiftan EG AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL. FAU - Mashni, Joseph W AU - Mashni JW AD - Department of Urology, Banner MD Anderson Cancer Center, Gilbert, AZ. FAU - Large, Michael C AU - Large MC AD - Urology of Indiana, Community Health Network, Indianapolis, IN. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University Medical Center, Indianapolis, IN. FAU - Nolte, David D AU - Nolte DD AD - Purdue University, West Lafayette, IN. FAU - Turek, John J AU - Turek JJ AD - Purdue University, West Lafayette, IN. FAU - An, Ran AU - An R AD - Animated Dynamics, Inc., Indianapolis, IN. FAU - Morgan, Travis A AU - Morgan TA AD - Animated Dynamics, Inc., Indianapolis, IN. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. LA - eng SI - ClinicalTrials.gov/NCT03739177 PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20221213 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - Q20Q21Q62J (Cisplatin) SB - IM CIN - J Urol. 2023 Sep;210(3):564-565. doi: 10.1097/JU.0000000000003577. PMID: 37334531 MH - Humans MH - *Cisplatin/therapeutic use MH - Neoadjuvant Therapy/adverse effects MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Cystectomy/methods MH - Muscles/pathology MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Invasiveness MH - Retrospective Studies OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Neoadjuvant chemotherapy OT - Targeted therapy COIS- Conflict of interest Certain authors (DN, JT, AN, TM) have an economic interest in Animated Dynamics, Inc. which holds an exclusive license from Purdue University to market biodynamic imaging technology. EDAT- 2022/12/16 06:00 MHDA- 2023/06/09 06:42 CRDT- 2022/12/15 22:07 PHST- 2022/08/16 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/22 00:00 [accepted] PHST- 2023/06/09 06:42 [medline] PHST- 2022/12/16 06:00 [pubmed] PHST- 2022/12/15 22:07 [entrez] AID - S1078-1439(22)00477-X [pii] AID - 10.1016/j.urolonc.2022.11.017 [doi] PST - ppublish SO - Urol Oncol. 2023 Jun;41(6):295.e9-295.e17. doi: 10.1016/j.urolonc.2022.11.017. Epub 2022 Dec 13. PMID- 36517190 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20250530 IS - 1532-9461 (Electronic) IS - 1053-4296 (Linking) VI - 33 IP - 1 DP - 2023 Jan TI - Pushing the Envelope: The Role of Radiation Therapy in Non-muscle-Invasive Bladder Cancer. PG - 21-25 LID - S1053-4296(22)00057-1 [pii] LID - 10.1016/j.semradonc.2022.10.003 [doi] AB - The standard of care for non-muscle-invasive bladder cancer (NMIBC) is transurethral resection followed by risk stratified use of intravesical immune- or chemotherapy and for multifocal, recurrent and high grade disease, radical cystectomy with high rates of cure. Bladder preservation analogous to the trimodality therapy approach in muscle-invasive bladder cancer (MIBC) has not been adequately explored but the available data suggests that NMIBC is a radioresponsive malignancy and that in a proportion of patients bladder preservation would be possible. Combination modality with chemotherapy, hypoxia sensitisation, hyperthermia and immunotherapy are all approaches which have been shown effective. Unfortunately the quality of the available data is poor. Although there are many putative prognostic biomarkers for progression in NMIBC none have emerged in clinical use and there are none predictive for response to non-surgical treatment. This would be an important component of future large scale studies to evaluate the precise role of radiotherapy within a multimodality schedule for bladder reservation in NMIBC. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Kombathula, Sri Harsha AU - Kombathula SH AD - Christie Hospital, Manchester. FAU - Hoskin, Peter AU - Hoskin P AD - Christie Hospital, Manchester; Division of Cancer Sciences, University of Manchester, Manchester; Mount Vernon Cancer Centre, Northwood. Electronic address: Hoskin@manchester.ac.uk. LA - eng GR - 28701/CRUK_/Cancer Research UK/United Kingdom GR - DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Semin Radiat Oncol JT - Seminars in radiation oncology JID - 9202882 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/radiotherapy MH - Cystectomy MH - Neoplasm Invasiveness COIS- Conflict of Interest The authors declare no conflict of interest. EDAT- 2022/12/15 06:00 MHDA- 2022/12/17 06:00 CRDT- 2022/12/14 21:06 PHST- 2022/12/14 21:06 [entrez] PHST- 2022/12/15 06:00 [pubmed] PHST- 2022/12/17 06:00 [medline] AID - S1053-4296(22)00057-1 [pii] AID - 10.1016/j.semradonc.2022.10.003 [doi] PST - ppublish SO - Semin Radiat Oncol. 2023 Jan;33(1):21-25. doi: 10.1016/j.semradonc.2022.10.003. PMID- 36514337 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221221 IS - 2001-0370 (Print) IS - 2001-0370 (Electronic) IS - 2001-0370 (Linking) VI - 21 DP - 2023 TI - Landscape of the intratumroal microenvironment in bladder cancer: Implications for prognosis and immunotherapy. PG - 74-85 LID - 10.1016/j.csbj.2022.11.052 [doi] AB - INTRODUCTION: This study aims to present the landscape of the intratumoral microenvironment and by which establish a classification system that can be used to predict the prognosis of bladder cancer patients and their response to anti-PD-L1 immunotherapy. METHODS: The expression profiles of 1554 bladder cancer cases were downloaded from seven public datasets. Single-sample gene set enrichment analysis (ssGSEA), univariate Cox regression analysis, and meta-analysis were employed to establish the bladder cancer immune prognostic index (BCIPI). Extensive analyses were executed to investigate the association between BCIPI and overall survival, tumor-infiltrated immunocytes, immunotherapeutic response, mutation load, etc. RESULTS: The results obtained from seven independent cohorts and meta-analyses suggested that the BCIPI is an effective classification system for estimating bladder cancer patients' overall survival. Patients in the BCIPI-High subgroup revealed different immunophenotypic outcomes from those in the BCIPI-Low subgroup regarding tumor-infiltrated immunocytes and mutated genes. Subsequent analysis suggested that patients in the BCIPI-High subgroup were more sensitive to anti-PD-L1 immunotherapy than those in the BCIPI-Low subgroup. CONCLUSIONS: The newly established BCIPI is a valuable tool for predicting overall survival outcomes and immunotherapeutic responses in patients with bladder cancer. CI - (c) 2022 The Author(s). FAU - Bian, Zichen AU - Bian Z AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. FAU - Chen, Jia AU - Chen J AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. FAU - Liu, Chang AU - Liu C AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. FAU - Ge, Qintao AU - Ge Q AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. FAU - Zhang, Meng AU - Zhang M AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. AD - Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, China. FAU - Meng, Jialin AU - Meng J AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. FAU - Liang, Chaozhao AU - Liang C AD - Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China. LA - eng PT - Journal Article DEP - 20221201 PL - United States TA - Comput Struct Biotechnol J JT - Computational and structural biotechnology journal JID - 101585369 PMC - PMC9730156 OTO - NOTNLM OT - AJCC, American Joint Committee on Cancer OT - Anti-PD-L1, Antitumor response to atezolizumab OT - BCG, Bacillus Calmette-Guerin OT - BCIPI, Bladder cancer immune prognostic index OT - Bladder cancer OT - CNVs, Copy number variations OT - FDA, Food and Drug Administration OT - FPKM, Fragments per kilobase per million OT - Genomic OT - ICI, Immune checkpoint inhibitor OT - IHC, Immunohistochemistry OT - Immunotherapy OT - MES, Mesenchymal transition OT - NES, Normalized enrichment score OT - Overall survival OT - RMA, Robust multiarray average OT - RMS, Restricted mean survival OT - TPM, Transcripts per kilobase million OT - ssGSEA, Single-sample GSEA COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/15 06:00 MHDA- 2022/12/15 06:01 PMCR- 2022/12/01 CRDT- 2022/12/14 01:54 PHST- 2022/09/09 00:00 [received] PHST- 2022/11/25 00:00 [revised] PHST- 2022/11/25 00:00 [accepted] PHST- 2022/12/14 01:54 [entrez] PHST- 2022/12/15 06:00 [pubmed] PHST- 2022/12/15 06:01 [medline] PHST- 2022/12/01 00:00 [pmc-release] AID - S2001-0370(22)00546-3 [pii] AID - 10.1016/j.csbj.2022.11.052 [doi] PST - epublish SO - Comput Struct Biotechnol J. 2022 Dec 1;21:74-85. doi: 10.1016/j.csbj.2022.11.052. eCollection 2023. PMID- 38994183 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 8 IP - 4 DP - 2022 TI - Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer. PG - 371-378 LID - 10.3233/BLC-220007 [doi] AB - BACKGROUND: T1 substaging is a predictive factor for non-muscle-invasive bladder cancer, and two types of T1 substaging systems (T1a/b/c and T1m/e) are currently in use. However, the predictive ability of both systems is poor, and there is debate over which system is better. OBJECTIVE: To confirm whether combination of two T1 substaging systems can improve the predictive ability of T1 substaging for tumor outcomes. METHODS: Patients with primary pT1 high-grade bladder cancer from three centers were included. All tumors were assessed with T1a/b/c and T1m/e substaging. A new variable named COMB was developed in which patients were stratified into T1a/b&T1m, T1a/b&T1e, T1c&T1m or T1c&T1e subgroups. A time-dependent receiver operating characteristic curve (ROC) analysis was used to test whether the accuracy of prediction could be improved with COMB. RESULTS: A total of 239 patients with primary pT1HG were analyzed. No tumor was T1c&T1m, and therefore, only three types of combinations were evaluated: T1a/b&T1m (62 patients), T1a/b&T1e (124 patients) and T1c&T1e (53 patients). Regardless of all patients or those treated with Re-TURBt and adequate BCG, patients with T1a/b&T1m have the best prognosis, and those with T1c&T1e have the poorest prognosis. The time-dependent ROC showed that, for both recurrence and progression, COMB had a higher AUC than T1a/b/c and T1m/e, regardless of population. CONCLUSIONS: Compared with either system alone, the combination of two T1 substaging systems improves the predictive ability of T1 substaging for tumor outcomes. CI - (c) 2022 - The authors. Published by IOS Press. FAU - Yang, Tao AU - Yang T AD - Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, P.R. China. FAU - Fan, Junjie AU - Fan J AD - Department of Urology, Baoji Central Hospital, Baoji, P.R. China. FAU - Pei, Xinqi AU - Pei X AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, P.R. China. FAU - Liang, Hua AU - Liang H AD - Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R.China. FAU - Fan, Jinhai AU - Fan J AUID- ORCID: 0000-0002-0153-1159 AD - Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. LA - eng PT - Journal Article DEP - 20221214 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181756 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Predictive ability OT - T1 substaging OT - Tumor outcomes COIS- Tao Yang, Junjie Fan, Xinqi Pei, Hua Liang and Jinhai Fan have no conflict of interest to report. EDAT- 2022/12/14 00:00 MHDA- 2022/12/14 00:01 PMCR- 2022/12/14 CRDT- 2024/07/12 04:47 PHST- 2022/01/19 00:00 [received] PHST- 2022/06/23 00:00 [accepted] PHST- 2022/12/14 00:01 [medline] PHST- 2022/12/14 00:00 [pubmed] PHST- 2024/07/12 04:47 [entrez] PHST- 2022/12/14 00:00 [pmc-release] AID - BLC220007 [pii] AID - 10.3233/BLC-220007 [doi] PST - epublish SO - Bladder Cancer. 2022 Dec 14;8(4):371-378. doi: 10.3233/BLC-220007. eCollection 2022. PMID- 38994181 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 8 IP - 4 DP - 2022 TI - Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models. PG - 339-357 LID - 10.3233/BLC-220055 [doi] AB - BACKGROUND: Several classifications have been reported to stratify non-muscle-invasive bladder cancer (NMIBC) in risk groups according to the probability of recurrence and progression. OBJECTIVE: To systematically review the current evidence regarding risk stratification of NMIBC. METHODS: The systematic review was performed in accordance with the PRISMA statement. Studies providing data on development and/or external validation cohorts of models and risk stratification tables for recurrence and/or progression for patients with NMIBC, reporting at least one discrimination measure (AUC or C-Index) were included. RESULTS: Twenty-five studies involving 22,737 patients were included. Six classifications were identified, three of them were predictive models (EORTC, CUETO, EAU 2021) and three were based on expert opinion (EAU 2020, AUA, NCCN). A high risk of bias was present in the majority of the studies. Certain heterogenicity was found among the studies regarding adjuvant therapy, postoperative instillation or second resection. The definition of oncological outcomes was not standardized in the included studies. CUETO and EORTC scoring systems are the most validated. In general, validations showed a poor discrimination capability to predict recurrence, slightly better for progression. The EAU 2021 model overestimates the risk of progression in patients treated with BCG. Carcinoma in situ is underrepresented in all the studies analyzed. CONCLUSIONS: The existing classifications show poor discrimination capability for recurrence and possibly helpful discrimination capability for progression in NMIBC patients. These results highlight the unmet need to develop novel accurate risk models for patients with NMIBC, which could be improved with the combination of clinicopathological and molecular information. CI - (c) 2022 - The authors. Published by IOS Press. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AD - ROC Clinic, Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. AD - Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Rodriguez-Faba, Oscar AU - Rodriguez-Faba O AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Manfredi, Celeste AU - Manfredi C AD - Unit of Urology, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Bozzini, Giorgio AU - Bozzini G AD - Department of Urology, ASST Lariana Ospedale Sant'Anna, Como, Italy. FAU - Romero-Otero, Javier AU - Romero-Otero J AD - ROC Clinic, Madrid, Spain. AD - Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain. FAU - Counago, Felipe AU - Counago F AD - Genesis Care Madrid, Madrid, Spain. AD - Hospital San Francisco de Asis, Madrid, Spain. AD - Hospital La Milagrosa, Madrid, Spain. LA - eng PT - Journal Article PT - Systematic Review DEP - 20221214 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181743 OTO - NOTNLM OT - Bladder cancer OT - calculator OT - progression OT - recurrence OT - risk stratification OT - scoring OT - survival OT - systematic review COIS- Felix Guerrero-Ramos declares the following conflicts of interest: Bristol-Myers Squibb, AstraZeneca, Janssen, Pfizer, Combat Medical (advisory/consultancy); Astellas, Janssen, Pfizer, AstraZeneca, Combat Medical, Palex, Rovi (speaker honoraria); Pfizer, Combat Medical, Cepheid, AstraZeneca, Bristol-Myers Squibb, Janssen, IDL Biotech, Astellas (clinical trials); Pfizer, Lacer, Ipsen, Janssen, Combat Medical, Rovi, Recordati (travel expenses). Felipe Counago-Lorenzo declares the following conflicts of interest: Janssen (sponsored research); Janssen, AstraZeneca (advisory/consultancy); Janssen, Roche, AstraZeneca, Astellas (speaker honoraria); AstraZeneca, Astellas, Janssen, Roche (travel expenses). Jose Daniel Subiela, Oscar Rodriguez-Faba, Julia Aumatell, Celeste Manfredi, Giorgio Bozzini and Javier Romero-Otero declare that they have no conflicts of interest. EDAT- 2022/12/14 00:00 MHDA- 2022/12/14 00:01 PMCR- 2022/12/14 CRDT- 2024/07/12 04:47 PHST- 2022/06/01 00:00 [received] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/12/14 00:01 [medline] PHST- 2022/12/14 00:00 [pubmed] PHST- 2024/07/12 04:47 [entrez] PHST- 2022/12/14 00:00 [pmc-release] AID - BLC220055 [pii] AID - 10.3233/BLC-220055 [doi] PST - epublish SO - Bladder Cancer. 2022 Dec 14;8(4):339-357. doi: 10.3233/BLC-220055. eCollection 2022. PMID- 36503724 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230529 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 21 IP - 3 DP - 2023 Jun TI - Systemic Immune-inflammation Index (SII) During Induction has Higher Predictive Value Than Preoperative SII in Non-muscle-invasive Bladder Cancer Patients Receiving Intravesical Bacillus Calmette -Guerin. PG - e145-e152 LID - S1558-7673(22)00247-6 [pii] LID - 10.1016/j.clgc.2022.11.013 [doi] AB - BACKGROUND: The prognostic value of the systemic immune-inflammation index during induction (ISII) remains unclear in non-muscle-invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guerin (BCG). We aimed to determine and compare the prognostic value of the ISII, preoperative systemic immune-inflammation index (PSII) and their dynamic changes (PISII). METHODS: This study respectively collected data from 362 NMIBC patients receiving BCG treatment in our institution. The prognostic values of PSII, ISII and PISII were analyzed by the Kaplan-Meier method and Cox proportional hazard regression models. The concordance index and receiver operating characteristic curve analysis were employed to compare the prognostic value of these 3 factors. RESULTS: Our study enrolled 197 patients. These patients included 170 male patients, and the mean age was 64.17 years. During the follow-up time, 85 patients experienced recurrence and 55 patients found progression. According to the results of Cox multivariable analysis, PSII (P = .001) and ISII (P < .001) could independently predict the recurrence of NMIBC patients receiving BCG. Meanwhile, PSII (P = .025) and ISII (P < .001) were also independent prognostic factors of progression. Compared with PSII, ISII was associated with better accuracy for NMIBC patients receiving BCG. CONCLUSION: This study first found that ISII could independently predict the prognosis of NMIBC patients receiving BCG. Furthermore, we also identified that ISII was associated with higher prognostic value than PSII and PISII, which might help to select an optimal treatment schedule for patients with NMIBC. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Deng-Xiong, Li AU - Deng-Xiong L AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Qing-Xin, Yu AU - Qing-Xin Y AD - Department of Pathology, Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang Province, China. FAU - De-Chao, Feng AU - De-Chao F AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Fa-Cai, Zhang AU - Fa-Cai Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Rui-Cheng, Wu AU - Rui-Cheng W AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Shi, Xu AU - Shi X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Electronic address: hanping@scu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221120 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Male MH - Middle Aged MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Inflammation MH - *Bacillus MH - Neoplasm Recurrence, Local MH - Neoplasm Invasiveness MH - Retrospective Studies OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Recurrence OT - SII OT - Systemic immune-inflammation index EDAT- 2022/12/13 06:00 MHDA- 2023/05/29 06:41 CRDT- 2022/12/12 09:35 PHST- 2022/05/06 00:00 [received] PHST- 2022/11/15 00:00 [revised] PHST- 2022/11/16 00:00 [accepted] PHST- 2023/05/29 06:41 [medline] PHST- 2022/12/13 06:00 [pubmed] PHST- 2022/12/12 09:35 [entrez] AID - S1558-7673(22)00247-6 [pii] AID - 10.1016/j.clgc.2022.11.013 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2023 Jun;21(3):e145-e152. doi: 10.1016/j.clgc.2022.11.013. Epub 2022 Nov 20. PMID- 36497249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 23 DP - 2022 Nov 23 TI - Does Bladder Cancer with Inchworm Sign Indicate Better Prognosis after TURBT? LID - 10.3390/cancers14235767 [doi] LID - 5767 AB - Background: Inchworm sign is considered to be a characteristic finding in non-muscle invasive bladder cancer (NMIBC). Nevertheless, pathologically diagnosed muscle invasive bladder cancers (MIBCs) are occasionally diagnosed from tissue obtained by transurethral resection of bladder tumor (TURBT) in patients with inchworm sign. Methods: We retrospectively investigated the factors related to muscle invasive status in bladder cancer associated with inchworm sign and the role of inchworm sign in tumor outcomes following TURBT. Results: Of the 109 patients with inchworm sign, 94 (86.2%) and 15 (13.8%) were NMIBC and MIBC, respectively. Non-papillary tumors (hazard ratio (HR): 9.55, 95% confidence interval (CI): 2.07-44.10; p < 0.01) and tumors located in the bladder neck (HR: 7.73, 95% CI: 1.83-32.76; p < 0.01) were significant predictors of MIBC in bladder cancer with inchworm sign. Furthermore, recurrence-free survival (RFS) and progression-free survival were compared between patients with NMIBC with and without inchworm sign; however, no significant differences were found. In patients with NMIBC with inchworm sign, positive urine cytology was a prognostic factor for RFS (HR: 1.90, 95% CI: 1.04-3.48; p = 0.04). Conclusions: In bladder cancer with inchworm sign, 86.2% were NMIBC. Even in the case of inchworm sign, the presence of a non-papillary tumor or a bladder neck tumor before TURBT should be noted because of the possibility of MIBC. In this study, the inchworm sign was not a prognostic factor in patients with NMIBC. FAU - Nakagawa, Ryunosuke AU - Nakagawa R AUID- ORCID: 0000-0002-2503-8908 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Izumi, Kouji AU - Izumi K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Naito, Renato AU - Naito R AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Kadomoto, Suguru AU - Kadomoto S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Iwamoto, Hiroaki AU - Iwamoto H AUID- ORCID: 0000-0003-3599-2217 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Yaegashi, Hiroshi AU - Yaegashi H AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Kawaguchi, Shohei AU - Kawaguchi S AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Nohara, Takahiro AU - Nohara T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Shigehara, Kazuyoshi AU - Shigehara K AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Yoshida, Kotaro AU - Yoshida K AUID- ORCID: 0000-0002-8398-0969 AD - Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Kadono, Yoshifumi AU - Kadono Y AUID- ORCID: 0000-0001-5780-4032 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AUID- ORCID: 0000-0002-5643-2182 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan. LA - eng PT - Journal Article DEP - 20221123 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9737124 OTO - NOTNLM OT - bladder neck OT - inchworm sign OT - muscle invasive bladder cancer OT - non-invasive muscle bladder cancer OT - non-papillary tumor COIS- The authors declare no conflict of interest. EDAT- 2022/12/12 06:00 MHDA- 2022/12/12 06:01 PMCR- 2022/11/23 CRDT- 2022/12/11 01:04 PHST- 2022/10/10 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/11/22 00:00 [accepted] PHST- 2022/12/11 01:04 [entrez] PHST- 2022/12/12 06:00 [pubmed] PHST- 2022/12/12 06:01 [medline] PHST- 2022/11/23 00:00 [pmc-release] AID - cancers14235767 [pii] AID - cancers-14-05767 [pii] AID - 10.3390/cancers14235767 [doi] PST - epublish SO - Cancers (Basel). 2022 Nov 23;14(23):5767. doi: 10.3390/cancers14235767. PMID- 36495164 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20230413 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 17 IP - 4 DP - 2023 Apr TI - Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer. PG - 564-581 LID - 10.1002/1878-0261.13360 [doi] AB - The incidence of bladder cancer and patient survival vary greatly among different populations, but the influence of the associated molecular features and evolutionary processes on its clinical treatment and prognostication remains unknown. Here, we analyze the genomic architectures of 505 bladder cancer patients from Asian/Black/White populations. We identify a previously unknown association between AHNAK mutations and activity of the APOBEC-a mutational signature, the activity of which varied substantially across populations. All significantly mutated genes but only half of arm-level somatic copy number alterations (SCNAs) are enriched with clonal events, indicating large-scale SCNAs as rich sources of bladder cancer clonal diversities. The prevalence of TP53 and ATM clonal mutations as well as the associated burden of SCNAs is significantly higher in Whites/Blacks than in Asians. We identify a trans-ancestry prognostic subtype of bladder cancer characterized by enrichment of non-muscle-invasive patients and muscle-invasive patients with good prognosis, increased CREBBP/FGFR3/HRAS/NFE2L2 mutations, decreased intra-tumor heterogeneity and genome instability, and an activated tumor microenvironment. CI - (c) 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Zhang, Baifeng AU - Zhang B AUID- ORCID: 0000-0003-1966-2285 AD - Departments of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, China. AD - Departments of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China. AD - Geneplus-Beijing, China. FAU - Jia, Peilin AU - Jia P AD - Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA. FAU - Wang, Jiayin AU - Wang J AD - Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi'an Jiaotong University, Shaanxi, China. FAU - Pei, Guangsheng AU - Pei G AD - Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA. FAU - Wang, Changxi AU - Wang C AD - Geneplus-Beijing, China. FAU - Pei, Shimei AU - Pei S AD - Geneplus-Beijing, China. FAU - Li, Xiangchun AU - Li X AUID- ORCID: 0000-0002-2230-2152 AD - Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, China. FAU - Zhao, Zhongming AU - Zhao Z AD - Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA. FAU - Yi, Xin AU - Yi X AD - Geneplus-Beijing, China. FAU - Guan, Xin-Yuan AU - Guan XY AD - Departments of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, China. AD - Departments of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China. FAU - Huang, Yi AU - Huang Y AD - Geneplus-Beijing, China. AD - Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi'an Jiaotong University, Shaanxi, China. AD - Luohu people's hospital, Shenzhen, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221229 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 SB - IM MH - Humans MH - Prognosis MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Mutation/genetics MH - Genomic Instability MH - Genomics MH - Tumor Microenvironment PMC - PMC10061287 OTO - NOTNLM OT - bladder cancer OT - genomic architectures OT - tumor heterogeneity OT - tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2022/12/11 06:00 MHDA- 2023/03/31 06:42 PMCR- 2022/12/29 CRDT- 2022/12/10 07:22 PHST- 2022/11/08 00:00 [revised] PHST- 2022/06/03 00:00 [received] PHST- 2022/12/09 00:00 [accepted] PHST- 2023/03/31 06:42 [medline] PHST- 2022/12/11 06:00 [pubmed] PHST- 2022/12/10 07:22 [entrez] PHST- 2022/12/29 00:00 [pmc-release] AID - MOL213360 [pii] AID - 10.1002/1878-0261.13360 [doi] PST - ppublish SO - Mol Oncol. 2023 Apr;17(4):564-581. doi: 10.1002/1878-0261.13360. Epub 2022 Dec 29. PMID- 36480752 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20221215 IS - 2444-054X (Electronic) IS - 0009-7411 (Linking) VI - 90 IP - S2 DP - 2022 TI - Effect of Re-TUR time on recurrence and progression in high-risk non-muscle-invasive bladder cancer. PG - 6-12 LID - 10.24875/CIRU.21000905 [doi] AB - OBJECTIVE: We aimed to investigate the significance of time to re-staging transurethral resection (re-TUR) on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer as a prospective randomized study. METHODS: The patients were randomly separated into three groups according to Re-TUR timing. In Groups 1, 2, and 3, the time interval between initial and re-TUR was 14-28 days, 29-42 days, and 43-56 days, respectively. Cox regression analysis was used to assess the effect of time from initial TUR to re-TUR on oncological outcomes. RESULTS: Twenty patients in Group 1 (14-28 days), 22 patients in Group 2 (29-42 days), and 29 patients in Group 3 (43-56 days) completed the study. Kaplan-Meier plots showed no differences in recurrence-free survival (RFS) and progression-free survival (PFS) rates between the three groups. Cox regression analysis demonstrated that only tumor number was found to be a prognostic factor on RFS rates. CONCLUSION: Our prospective study demonstrated that time laps from initial TUR to re-TUR did not significantly affect on RFS and PFS rates. CI - Copyright: (c) 2022 Permanyer. FAU - Demir, Demirhan O AU - Demir DO AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Doluoglu, Omer G AU - Doluoglu OG AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Yildiz, Ali K AU - Yildiz AK AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Kacan, Turgay AU - Kacan T AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Yazar, Veli M AU - Yazar VM AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Demirbas, Arif AU - Demirbas A AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. FAU - Ozgur, Berat C AU - Ozgur BC AD - Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey. LA - eng PT - Journal Article PT - Randomized Controlled Trial TT - Efecto del tiempo de Re-TUR en la recurrencia y progresion en cancer de vejiga no musculo invasivo de alto riesgo. PL - Mexico TA - Cir Cir JT - Cirugia y cirujanos JID - 0372736 SB - IM MH - Humans MH - Prospective Studies MH - *Non-Muscle Invasive Bladder Neoplasms OTO - NOTNLM OT - Alto grado OT - Cancer de vejiga no musculo invasivo OT - High grade OT - Non-muscle invasive bladder cancer OT - Oncological outcomes OT - Reestablecimiento de la reseccion transuretral OT - Restaging transurethral resection OT - Resultados oncologicos EDAT- 2022/12/09 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/12/08 15:53 PHST- 2022/12/08 15:53 [entrez] PHST- 2022/12/09 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] AID - j90/S2/6 [pii] AID - 10.24875/CIRU.21000905 [doi] PST - ppublish SO - Cir Cir. 2022;90(S2):6-12. doi: 10.24875/CIRU.21000905. PMID- 36479836 OWN - NLM STAT- MEDLINE DCOM- 20230405 LR - 20230409 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 6 DP - 2023 Mar TI - Preoperative systemic immune-inflammation index as a significant prognostic factor after TURBT in patients with non-muscle-invasive bladder cancer: A retrospective study based on propensity score matching analysis. PG - 7019-7028 LID - 10.1002/cam4.5501 [doi] AB - OBJECTIVE: To investigate the association of the preoperative systemic immune-inflammation index (SII) with recurrence-free survival (RFS) after transurethral resection of the bladder tumor (TURBT) of non-muscle-invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. METHODS: The clinicopathological characteristics and follow-up data of NMIBC patients were collected retrospectively from two tertiary medical centers. A 1:1 PSM analysis was carried out using the nearest-neighbor method (caliper size: 0.02). Cox regression analysis was used to identify the risk factors associated with RFS. RESULTS: A total of 416 NMIBC patients were included in this study. Before and after matching, patients with increased SII had worse RFS (p < 0.0001 and p = 0.027, respectively). Multivariate Cox analysis identified SII as an independent predictor of RFS before (HR [95% CI]: 1.789 [1.232, 2.599], p = 0.002) and after matching (HR [95% CI]: 1.646 [1.077, 2.515], p = 0.021). In the matched subgroup analysis, an elevated SII had a significant association with postoperative worse RFS in the T1 stage (p = 0.025), primary status (p = 0.049), high-grade (p = 0.0015), and multiple lesions (p = 0.043) subgroups. CONCLUSION: SII could accurately stratify the prognosis of NMIBC patients before and after PSM analysis. An elevated SII was significantly associated with worse RFS in NMIBC patients. CI - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Ding, Li AU - Ding L AUID- ORCID: 0000-0003-1561-0250 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. FAU - Wang, Xiangbu AU - Wang X AD - Department of Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. FAU - Deng, Xiaobin AU - Deng X AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China. FAU - Xia, Wentao AU - Xia W AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. FAU - Wang, Kun AU - Wang K AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. FAU - Yu, Xianlin AU - Yu X AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China. FAU - Huang, Yaotian AU - Huang Y AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221207 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Humans MH - Retrospective Studies MH - Prognosis MH - *Non-Muscle Invasive Bladder Neoplasms MH - Propensity Score MH - *Urinary Bladder Neoplasms/pathology MH - Inflammation PMC - PMC10067042 OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - prognosis OT - propensity score matching OT - systemic immune-inflammation index OT - tumor recurrence COIS- None of the authors have conflicts of interest to disclose. None of the authors have financial relationships relevant to this article to disclose. EDAT- 2022/12/09 06:00 MHDA- 2023/04/05 06:42 PMCR- 2022/12/07 CRDT- 2022/12/08 14:26 PHST- 2022/10/26 00:00 [revised] PHST- 2022/09/10 00:00 [received] PHST- 2022/11/19 00:00 [accepted] PHST- 2023/04/05 06:42 [medline] PHST- 2022/12/09 06:00 [pubmed] PHST- 2022/12/08 14:26 [entrez] PHST- 2022/12/07 00:00 [pmc-release] AID - CAM45501 [pii] AID - 10.1002/cam4.5501 [doi] PST - ppublish SO - Cancer Med. 2023 Mar;12(6):7019-7028. doi: 10.1002/cam4.5501. Epub 2022 Dec 7. PMID- 36479820 OWN - NLM STAT- MEDLINE DCOM- 20230524 LR - 20230531 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 131 IP - 6 DP - 2023 Jun TI - Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis. PG - 643-659 LID - 10.1111/bju.15944 [doi] AB - OBJECTIVE: To assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified. METHODS: Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC. RESULTS: Overall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48-1.74) and PFS (pooled HR 1.44, 95% CI 1.18-1.76) in NMIBC patients (including both Ta and T1). Tumour size (>/=3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69-2.30) and PFS (pooled HR 1.81, 95% CI 1.52-2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (>/=3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guerin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (>/=3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52-3.01) and PFS (pooled HR 2.17, 95% CI 1.42-3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25-2.72) and PFS (pooled HR 3.06, 95% CI 2.31-4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63-3.30). CONCLUSIONS: Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy. CI - (c) 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Quhal, Fahad AU - Quhal F AUID- ORCID: 0000-0002-8163-6953 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Kawada, Tatsushi AU - Kawada T AUID- ORCID: 0000-0002-8369-9712 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Mostafaei, Hadi AU - Mostafaei H AUID- ORCID: 0000-0001-5596-1771 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Motlagh, Reza Sari AU - Motlagh RS AUID- ORCID: 0000-0002-3819-9911 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rajwa, Pawel AU - Rajwa P AUID- ORCID: 0000-0003-4073-6584 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - von Deimling, Markus AU - von Deimling M AUID- ORCID: 0000-0002-9954-3413 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bianchi, Alberto AU - Bianchi A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. FAU - Pallauf, Maximilian AU - Pallauf M AUID- ORCID: 0000-0002-8496-4506 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria. FAU - Majdoub, Muhammad AU - Majdoub M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Hillel Yaffe Medical Center, Hadera, Israel. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AUID- ORCID: 0000-0002-6627-6179 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230113 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/pathology MH - Proportional Hazards Models MH - Cystoscopy MH - BCG Vaccine/therapeutic use MH - Administration, Intravesical MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness MH - Retrospective Studies OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - cystoscopy OT - gross appearance OT - multiplicity OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - size EDAT- 2022/12/09 06:00 MHDA- 2023/05/24 06:42 CRDT- 2022/12/08 14:25 PHST- 2023/05/24 06:42 [medline] PHST- 2022/12/09 06:00 [pubmed] PHST- 2022/12/08 14:25 [entrez] AID - 10.1111/bju.15944 [doi] PST - ppublish SO - BJU Int. 2023 Jun;131(6):643-659. doi: 10.1111/bju.15944. Epub 2023 Jan 13. PMID- 36477612 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230226 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 129 IP - 3 DP - 2023 Feb 1 TI - Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial. PG - 415-425 LID - 10.1002/cncr.34563 [doi] AB - BACKGROUND: Cryotherapy is a prevalent percutaneous ablative therapy for solid tumors. Here, we report a novel device using liquid nitrogen for endoscopic cryotherapy of bladder cancer. METHODS: In this multicenter, randomized, parallel controlled, Phase 2 trial, we compared endoscopic balloon cryoablation (EBCA) with a single instillation (SI) of pirarubicin after transurethral resection (TUR). Eligible participants were randomly assigned (1:1) to the TUR-EBCA or TUR-SI group. Repeat TUR or tissue biopsies were performed to evaluate residual tumor at 4 to 6 weeks after primary treatment. The primary end point was the local control rate. The secondary end points included the tumor upgrading/upstaging, catheter indwelling duration, and adverse events. RESULTS: In total, 205 patients received EBCA or SI after TUR between November 2017 and September 2020, of whom 163 completed all the required interventions. In the per-protocol set, the local control rate was 91.5% (75/82) in TUR-EBCA group compared with 76.5% (61/81) in TUR-SI group (risk difference, 15%; 95% CI, 0.03-0.27, p < .001), meeting the criteria for noninferiority. Similar results were found in the modified intention-to-treat analysis. Tumor upgrading/upstaging was found in five patients from the TUR-SI group. There was no significant difference in the catheter indwelling duration (5.1 vs. 5.2 days, p = .76) or serious adverse event rate (3.0% vs. 3.9%, p = .52). The median follow-up time of post hoc analysis was 31 (range, 15-50) months. Patients in the TUR-EBCA group had a better recurrence-free survival and progression-free survival. CONCLUSION: EBCA is a safe and effective adjuvant therapy with TUR for non-muscle-invasive bladder cancer. PLAIN LANGUAGE SUMMARY: This is the first randomized trial that evaluated endoscopic cryotherapy after transurethral resection (TUR) of bladder tumors. The efficacy and safety analysis shows endoscopic balloon cryoablation (EBCA) is a promising alternative. Results report that EBCA is not inferior to a single instillation of intravesical chemotherapy in eliminating residual bladder tumor. Further analysis with approximately 3 years' median follow-up suggested a better prognosis in patients who received EBCA after TUR. CI - (c) 2022 American Cancer Society. FAU - Xu, Chenyang AU - Xu C AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. FAU - Jiang, Shuai AU - Jiang S AD - Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Zou, Lujia AU - Zou L AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. FAU - Sheng, Lu AU - Sheng L AD - Department of Urology, Huadong Hospital Affiliated to Fudan University, Shanghai, China. FAU - Shi, Guowei AU - Shi G AD - Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China. FAU - Xu, Bin AU - Xu B AD - Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Wang, Zhong AU - Wang Z AD - Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Xu, Danfeng AU - Xu D AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Xie, Xin AU - Xie X AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Luo, Jianfeng AU - Luo J AD - Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China. FAU - Guo, Jianming AU - Guo J AUID- ORCID: 0000-0002-9300-8401 AD - Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Jiang, Haowen AU - Jiang H AUID- ORCID: 0000-0002-6608-0969 AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. LA - eng SI - ClinicalTrials.gov/NCT02760953 SI - ChiCTR/ChiCTR-INR-17013060 PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20221207 PL - United States TA - Cancer JT - Cancer JID - 0374236 SB - IM CIN - Cancer. 2023 Feb 1;129(3):333-334. doi: 10.1002/cncr.34560. PMID: 36477685 MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - *Cryosurgery MH - *Urinary Bladder Neoplasms/pathology MH - Urologic Surgical Procedures MH - Prognosis MH - Administration, Intravesical MH - Neoplasm Recurrence, Local/drug therapy OTO - NOTNLM OT - cryotherapy OT - endoscopy OT - intravesical administration OT - minimally invasive surgical procedures OT - urinary bladder neoplasms EDAT- 2022/12/09 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/12/08 12:00 PHST- 2022/08/20 00:00 [revised] PHST- 2022/06/20 00:00 [received] PHST- 2022/08/23 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/12/08 12:00 [entrez] AID - 10.1002/cncr.34563 [doi] PST - ppublish SO - Cancer. 2023 Feb 1;129(3):415-425. doi: 10.1002/cncr.34563. Epub 2022 Dec 7. PMID- 36465380 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221206 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Impact of SOX2 function and regulation on therapy resistance in bladder cancer. PG - 1020675 LID - 10.3389/fonc.2022.1020675 [doi] LID - 1020675 AB - Bladder cancer (BC) is a malignant disease with high rates of recurrence and mortality. It is mainly classified as non-muscle-invasive BC and muscle-invasive BC (MIBC). Often, MIBC is chemoresistant, which, according to cancer stem cells (CSCs) theory, is linked to the presence of bladder cancer stem cells (BCSCs). Sex-determining region Y- (SRY) Box transcription factor 2 (SOX2), which is a molecular marker of BCSCs, is aberrantly over-expressed in chemoresistant BC cell lines. It is one of the standalone prognostic factors for BC, and it has an inherently significant function in the emergence and progression of the disease. This review first summarizes the role of SRY-related high-mobility group protein Box (SOX) family genes in BC, focusing on the SOX2 and its significance in BC. Second, it discusses the mechanisms relevant to the regulation of SOX2. Finally, it summarizes the signaling pathways related to SOX2 in BC, suggests current issues to be addressed, and proposes potential directions for future research to provide new insights for the treatment of BC. CI - Copyright (c) 2022 Chen, Chen, Xu, Zhang, Zou and Wu. FAU - Chen, Guodong AU - Chen G AD - The First Clinical College, Gannan Medical University, Ganzhou, China. AD - Department of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. AD - Institute of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Chen, Yan AU - Chen Y AD - Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Xu, Ruiquan AU - Xu R AD - Department of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. AD - Institute of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Zhang, Guoxi AU - Zhang G AD - Department of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. AD - Institute of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Zou, Xiaofeng AU - Zou X AD - Department of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. AD - Institute of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Wu, Gengqing AU - Wu G AD - Department of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. AD - Institute of Urology, Affiliated Hospital of Gannan Medical University, Ganzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20221116 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9709205 OTO - NOTNLM OT - SOX2 OT - bladder cancer OT - bladder cancer stem cells OT - chemoresistant OT - non-coding RNAs COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/06 06:00 MHDA- 2022/12/06 06:01 PMCR- 2022/01/01 CRDT- 2022/12/05 03:41 PHST- 2022/08/16 00:00 [received] PHST- 2022/11/01 00:00 [accepted] PHST- 2022/12/05 03:41 [entrez] PHST- 2022/12/06 06:00 [pubmed] PHST- 2022/12/06 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1020675 [doi] PST - epublish SO - Front Oncol. 2022 Nov 16;12:1020675. doi: 10.3389/fonc.2022.1020675. eCollection 2022. PMID- 36458001 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20221205 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer. PG - 1070043 LID - 10.3389/fimmu.2022.1070043 [doi] LID - 1070043 AB - BACKGROUND: Transurethral resection of the bladder tumor with or without adjuvant intravesical instillation (IVI) has been the standard treatment for non-muscle-invasive bladder cancer (NMIBC), whereas a high percentage of patients still experience local tumor recurrence and disease progression after receiving the standard treatment modalities. Unfortunately, current relevant prediction models for determining the recurrent and progression risk of NMIBC patients are far from impeccable. METHODS: Clinicopathological characteristics and follow-up information were retrospectively collected from two tertiary medical centers between October 2018 and June 2021. The least absolute shrinkage and selection operator (LASSO) and Cox regression analysis were used to screen potential risk factors affecting recurrence-free survival (RFS) of patients. A nomogram model was established, and the patients were risk-stratified based on the model scores. Both internal and external validation were performed by sampling the model with 1,000 bootstrap resamples. RESULTS: The study included 299 patient data obtained from the Affiliated Hospital of Xuzhou Medical University and 117 patient data obtained from the First Affiliated Hospital of Guangxi Medical University. Univariate regression analysis suggested that urine red blood cell count and different tumor invasion locations might be potential predictors of RFS. LASSO-Cox regression confirmed that prior recurrence status, times of IVI, and systemic immune-inflammation index (SII) were independent factors for predicting RFS. The area under the curve for predicting 1-, 2-, and 3-year RFS was 0.835, 0.833, and 0.871, respectively. Based on the risk stratification, patients at high risk of recurrence and progression could be accurately identified. A user-friendly risk calculator based on the model is deposited at https://dl0710.shinyapps.io/nmibc_rfs/. CONCLUSION: Internal and external validation analyses showed that our model had excellent predictive discriminatory ability and stability. The risk calculator can be used for individualized assessment of survival risk in NMIBC patients and can assist in guiding clinical decision-making. CI - Copyright (c) 2022 Ding, Deng, Xia, Wang, Zhang, Zhang, Shao and Wang. FAU - Ding, Li AU - Ding L AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Deng, Xiaobin AU - Deng X AD - Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. FAU - Xia, Wentao AU - Xia W AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Kun AU - Wang K AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Zhang, Yang AU - Zhang Y AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Zhang, Yan AU - Zhang Y AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Shao, Xianfeng AU - Shao X AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. FAU - Wang, Junqi AU - Wang J AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221115 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - *Nomograms MH - *Urinary Bladder Neoplasms/surgery MH - Retrospective Studies MH - China MH - Postoperative Period PMC - PMC9706099 OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - nomogram OT - predictive indicator OT - risk calculator OT - risk factor OT - tumor recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/03 06:00 MHDA- 2022/12/06 06:00 PMCR- 2022/01/01 CRDT- 2022/12/02 02:33 PHST- 2022/10/14 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/12/02 02:33 [entrez] PHST- 2022/12/03 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1070043 [doi] PST - epublish SO - Front Immunol. 2022 Nov 15;13:1070043. doi: 10.3389/fimmu.2022.1070043. eCollection 2022. PMID- 36456144 OWN - NLM STAT- MEDLINE DCOM- 20221206 LR - 20221206 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 42 IP - 12 DP - 2022 Dec TI - Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer. PG - 5783-5794 LID - 10.21873/anticanres.16085 [doi] AB - BACKGROUND/AIM: Bladder cancer is the most common urinary tract cancer. Patients diagnosed with advanced T-stage/muscle-invasive bladder cancer through transurethral resection of bladder tumors (TURBT) are treated with total radical cystectomy; however, there is a high chance of recurrence. Nevertheless, markers for predicting this recurrence are not currently available. Here, we evaluated the chronological change of ephrin type-A receptor 2 (EPHA2) expression, a molecule known for its role in cell adhesion, to predict bladder cancer recurrence after cystectomy, using TURBT and cystectomy specimens. MATERIALS AND METHODS: An immunostaining evaluation method that combines whole-slide images and image analysis software was developed to quantify and evaluate stainability objectively. We assessed the correlation between EPHA2 expression and bladder cancer recurrence using this novel immunostaining method and chronological changes in target protein expression in TURBT and radical cystectomy samples. RESULTS: In TURBT specimens, the number of cases with a high N-terminal/C-terminal EPHA2 ratio in the group with recurrence was significantly higher than in the non-recurrent group (p=0.019). The number of cases with a high level of C-terminal EPHA2 positivity in the radical cystectomy specimen when compared to the TURBT specimen obtained from the same patient was significantly higher in the recurrent group than in the non-recurrent group (p=0.0034). CONCLUSION: EPHA2 appears to be a promising marker for bladder tumor recurrence after cystectomy and its evaluation may enable the selection of appropriate cases for adjuvant therapy among patients undergoing radical cystectomy. Further studies, including mass-scale analysis, are required to confirm these results. CI - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Koizumi, Mitsuyuki AU - Koizumi M AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Sato, Shinya AU - Sato S AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan; ssato53@gancen.asahi.yokohama.jp. AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. AD - Morphological Information Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan. FAU - Yoshihara, Mitsuyo AU - Yoshihara M AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - Morphological Information Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan. FAU - Nakamura, Yoshiyasu AU - Nakamura Y AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - Morphological Information Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan. FAU - Terao, Hideyuki AU - Terao H AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Okubo, Yoichiro AU - Okubo Y AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Washimi, Kota AU - Washimi K AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Yoshioka, Emi AU - Yoshioka E AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Yokose, Tomoyuki AU - Yokose T AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Kishida, Takeshi AU - Kishida T AD - Department of Urology, Kanagawa Cancer Center, Yokohama, Japan. FAU - Koshikawa, Naohiko AU - Koshikawa N AD - Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan. AD - Department of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan. FAU - Miyagi, Yohei AU - Miyagi Y AD - Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan. AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - EC 2.7.10.1 (Receptor, EphA2) RN - 0 (EPHA2 protein, human) SB - IM MH - Humans MH - Cystectomy MH - Neoplasm Recurrence, Local MH - *Receptor, EphA2 MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - EPHA2 OT - adipocytes OT - biomarker OT - cancer recurrence OT - machine learning EDAT- 2022/12/02 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/12/01 21:13 PHST- 2022/10/07 00:00 [received] PHST- 2022/10/14 00:00 [revised] PHST- 2022/10/24 00:00 [accepted] PHST- 2022/12/01 21:13 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] AID - 42/12/5783 [pii] AID - 10.21873/anticanres.16085 [doi] PST - ppublish SO - Anticancer Res. 2022 Dec;42(12):5783-5794. doi: 10.21873/anticanres.16085. PMID- 36450813 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20240908 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Nov 30 TI - Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS. PG - 20689 LID - 10.1038/s41598-022-19273-7 [doi] LID - 20689 AB - This study aimed to compare the diagnostic validity of biparametric magnetic resonance imaging (bpMRI) with that of multiparametric MRI (mpMRI) based on the Vesicle Imaging-Reporting and Data System (VI-RADS) in predicting muscle invasion by bladder cancer (BCa). We retrospectively examined 357 patients with an initial diagnosis of BCa who underwent preoperative MRI; 257 and 100 patients underwent mpMRI and bpMRI, respectively. Two urogenital radiologists evaluated all bpMRI and mpMRI scans using VI-RADS, and the diagnostic validity of VI-RADS for predicting muscle invasion by BCa was analyzed based on histopathology of the first and/or second transurethral resection of bladder tumors and radical cystectomy. Receiver operating characteristic (ROC) curves were plotted with the calculation of area under the curves (AUCs), and the level of significance was P < 0.05. Both groups showed optimal performance with a VI-RADS score >/= 3. BpMRI showed comparable diagnostic performance to mpMRI (reader 1: AUC, 0.903 [0.827-0.954] vs. 0.935 [0.884-0.968], p = 0.510; and reader 2: AUC, 0.901 [0.814-0.945] vs. 0.915 [0.874-0.946]; p = 0.655). The inter-reader agreement between both readers was excellent (Cohen's kappa value = 0.942 and 0.905 for bpMRI and mpMRI, respectively). This comparative study suggests that bpMRI has comparable diagnostic performance to mpMRI and may be an alternative option to predict muscle invasion by BCa. CI - (c) 2022. The Author(s). FAU - Noh, Tae Il AU - Noh TI AD - Department of Urology, Anam Hospital, Korea University College of Medicine, 73 Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Korea. FAU - Shim, Ji Sung AU - Shim JS AD - Department of Urology, Anam Hospital, Korea University College of Medicine, 73 Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Korea. FAU - Kang, Sung Gu AU - Kang SG AD - Department of Urology, Anam Hospital, Korea University College of Medicine, 73 Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Korea. FAU - Sung, Deuk Jae AU - Sung DJ AD - Department of Radiology, Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Cheon, Jun AU - Cheon J AD - Department of Urology, Anam Hospital, Korea University College of Medicine, 73 Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Korea. FAU - Sim, Ki Choon AU - Sim KC AD - Department of Radiology, Anam Hospital, Korea University College of Medicine, Seoul, Korea. ha2sky@hanmail.net. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Anam Hospital, Korea University College of Medicine, 73 Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Korea. mdksh@korea.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221130 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Multiparametric Magnetic Resonance Imaging MH - *Urinary Bladder Neoplasms/diagnostic imaging MH - Retrospective Studies MH - Cystectomy MH - Blister MH - Muscles/diagnostic imaging PMC - PMC9712519 COIS- The authors declare no competing interests. EDAT- 2022/12/01 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/30 CRDT- 2022/11/30 23:31 PHST- 2022/02/21 00:00 [received] PHST- 2022/08/26 00:00 [accepted] PHST- 2022/11/30 23:31 [entrez] PHST- 2022/12/01 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/30 00:00 [pmc-release] AID - 10.1038/s41598-022-19273-7 [pii] AID - 19273 [pii] AID - 10.1038/s41598-022-19273-7 [doi] PST - epublish SO - Sci Rep. 2022 Nov 30;12(1):20689. doi: 10.1038/s41598-022-19273-7. PMID- 36449779 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20230613 IS - 1806-9282 (Electronic) IS - 0104-4230 (Print) IS - 0104-4230 (Linking) VI - 68 IP - 11 DP - 2022 TI - The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer. PG - 1587-1592 LID - S0104-42302022001101587 [pii] LID - 10.1590/1806-9282.20220812 [doi] AB - OBJECTIVE: We aimed to investigate the impact of tumor necrosis in non-muscle invasive bladder cancer on patients' recurrence and progression rates and survival outcomes. METHODS: This study was conducted retrospectively in a single tertiary center in Turkey. Medical records of patients who underwent transurethral resection of the bladder tumor between January 2016 and January 2021 were reviewed. Patients with pTa and pT1 non-muscle invasive bladder cancer who had undergone complete resection were included in our study. All pathological specimens were reevaluated for the presence of tumor necrosis. RESULTS: A total of 287 patients (244 males and 43 females) were included in our study. Of them, 33 (11.5%) patients had tumor necrosis. The rates of multiple and large tumors (>3 cm) were higher in patients with tumor necrosis (p=0.002 and p<0.001, respectively). Tumor necrosis was associated with higher rates of pT1 diseases (p<0.001), high-grade tumors (p<0.001), and the presence of lymphovascular invasion (p=0.007). The mean recurrence-free survival of patients with tumor necrosis was 42.3 (4.6) months, and the recurrence-free survival of patients without tumor necrosis was 43.5 (1.8) months (p=0.720). The mean progression-free survival of patients with tumor necrosis was 43.1 (4.6) months, and the progression-free survival of patients without tumor necrosis was 58.4 (0.9) months. In log-rank analysis, there was a statistically significant difference between patients with and without tumor necrosis in terms of progression-free survival (p<0.001). CONCLUSION: In this study, we demonstrated that patients with non-muscle invasive bladder cancer and tumor necrosis in pathological specimens have shorter progression-free survival and more adverse pathological features. FAU - Culpan, Meftun AU - Culpan M AUID- ORCID: 0000-0001-8573-1192 AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology - Istanbul, Turkey. FAU - Iplikci, Ayberk AU - Iplikci A AUID- ORCID: 0000-0002-5822-7799 AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology - Istanbul, Turkey. FAU - Kir, Gozde AU - Kir G AUID- ORCID: 0000-0003-1933-9824 AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Pathology - Istanbul, Turkey. FAU - Cecikoglu, Gozde Ecem AU - Cecikoglu GE AUID- ORCID: 0000-0001-7839-7667 AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Pathology - Istanbul, Turkey. FAU - Atis, Gokhan AU - Atis G AUID- ORCID: 0000-0002-9065-6104 AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology - Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AUID- ORCID: 0000-0002-3386-971X AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Urology - Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20221128 PL - Brazil TA - Rev Assoc Med Bras (1992) JT - Revista da Associacao Medica Brasileira (1992) JID - 9308586 SB - IM CIN - Rev Assoc Med Bras (1992). 2023 May 29;69(6):e20230295. doi: 10.1590/1806-9282.20230295. PMID: 37255093 MH - Female MH - Male MH - Humans MH - Prognosis MH - *Urinary Bladder Neoplasms/surgery MH - Retrospective Studies MH - Medical Records MH - Necrosis PMC - PMC9720780 COIS- Conflicts of interest: the authors declare there is no conflicts of interest. EDAT- 2022/12/01 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/28 CRDT- 2022/11/30 14:43 PHST- 2022/07/21 00:00 [received] PHST- 2022/08/01 00:00 [accepted] PHST- 2022/11/30 14:43 [entrez] PHST- 2022/12/01 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/28 00:00 [pmc-release] AID - S0104-42302022001101587 [pii] AID - 1806-9282.20220812 [pii] AID - 10.1590/1806-9282.20220812 [doi] PST - epublish SO - Rev Assoc Med Bras (1992). 2022 Nov 28;68(11):1587-1592. doi: 10.1590/1806-9282.20220812. eCollection 2022. PMID- 36449286 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20240613 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 11 DP - 2022 Nov 1 TI - Smoking Behaviors and Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer in the Be-Well Study. PG - e2244430 LID - 10.1001/jamanetworkopen.2022.44430 [doi] LID - e2244430 AB - IMPORTANCE: Tobacco smoking is an established risk factor associated with bladder cancer, yet its impact on bladder cancer prognosis is unclear. OBJECTIVE: To examine associations of use of tobacco (cigarettes, pipes, and cigars), e-cigarettes, and marijuana with risk of recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) and to explore use of smoking cessation interventions. DESIGN, SETTING, AND PARTICIPANTS: The Be-Well Study is a prospective cohort study of patients with NMIBC diagnosed from 2015 to 2019 and followed-up for 26.4 months in the Kaiser Permanente Northern and Southern California integrated health care system. Eligibility criteria were age at least 21 years, first NMIBC diagnosis (stages Ta, Tis, or T1), alive, and not in hospice care. Exclusion criteria were previous diagnosis of bladder cancer or other cancer diagnoses within 1 year prior to or concurrent with NMIBC diagnosis. Data were analyzed from April 1 to October 4, 2022. EXPOSURES: Use of cigarettes, pipes, cigars, e-cigarettes, and marijuana was reported in the baseline interview. Use of smoking cessation interventions (counseling and medications) was derived from electronic health records. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) and 95% CIs of recurrence and progression of bladder cancer were estimated by multivariable Cox proportional hazards regression. RESULTS: A total of 1472 patients (mean [SD] age at diagnosis, 70.2 [10.8%] years; 1129 [76.7%] male patients) with NMIBC were enrolled at a mean (SD) of 2.3 (1.3) months after diagnosis, including 874 patients (59.4%) who were former smokers and 111 patients (7.5%) who were current cigarette smokers; 67 patients (13.7%) smoked pipes and/or cigars only, 65 patients (4.4%) used e-cigarettes, 363 patients (24.7%) used marijuana. Longer cigarette smoking duration and more pack-years were associated with higher risk of recurrence in a dose-dependent manner, with the highest risks for patients who had smoked for 40 or more years (HR, 2.36; 95% CI, 1.43-3.91) or 40 or more pack-years (HR, 1.97; 95% CI, 1.32-2.95). There was no association of having ever smoked, being a former or current cigarette smoker, and years since quit smoking with recurrence risk. No associations with pipes, cigars, e-cigarettes, or marijuana were found. Of 102 patients offered a smoking cessation intervention, 57 (53.8%) received an interventions after diagnosis, with female patients more likely than male patients to engage in such interventions (23 of 30 female patients [76.7%] vs 34 of 76 male patients [44.7%]; P = .003). CONCLUSIONS AND RELEVANCE: These findings suggest that longer duration and more pack-years of cigarette smoking were associated with higher risk of NMIBC recurrence. Cigarette smoking remains a critical exposure before and after diagnosis in survivors of NMIBC. FAU - Kwan, Marilyn L AU - Kwan ML AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Haque, Reina AU - Haque R AD - Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena. AD - Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California. FAU - Young-Wolff, Kelly C AU - Young-Wolff KC AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Wang, Zinian AU - Wang Z AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena. FAU - Ambrosone, Christine B AU - Ambrosone CB AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, Downey, California. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, California. FAU - Quesenberry, Charles P AU - Quesenberry CP AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, Oakland. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York. LA - eng GR - R01 CA172855/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20221101 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Hallucinogens) SB - IM CIN - J Urol. 2023 Oct;210(4):715-716. doi: 10.1097/JU.0000000000003630. PMID: 37527370 MH - Adult MH - Child MH - Female MH - Humans MH - Male MH - Young Adult MH - *Cannabis MH - *Electronic Nicotine Delivery Systems MH - *Hallucinogens MH - Prognosis MH - Prospective Studies MH - Smoking/epidemiology MH - *Urinary Bladder Neoplasms/epidemiology/etiology PMC - PMC9713602 COIS- Conflict of Interest Disclosures: Dr Kwan reported receiving grants from UroGen Pharma outside the submitted work. Dr Haque reported receiving grants from Pfizer and AstraZeneca outside the submitted work. Dr Young-Wolff reported receiving grants from National Institute on Drug Abuse outside the submitted work. Ms Lee reported receiving grants from UroGen Pharma outside the submitted work. Dr Quesenberry reported receiving grants from UroGen Pharma outside the submitted work. No other disclosures were reported. EDAT- 2022/12/01 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/30 CRDT- 2022/11/30 11:33 PHST- 2022/11/30 11:33 [entrez] PHST- 2022/12/01 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/30 00:00 [pmc-release] AID - 2799072 [pii] AID - zoi221254 [pii] AID - 10.1001/jamanetworkopen.2022.44430 [doi] PST - epublish SO - JAMA Netw Open. 2022 Nov 1;5(11):e2244430. doi: 10.1001/jamanetworkopen.2022.44430. PMID- 36448522 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230711 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 30 IP - 3 DP - 2023 Mar TI - C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guerin therapy: A Japan Urological Oncology Group study analysis. PG - 299-307 LID - 10.1111/iju.15106 [doi] AB - OBJECTIVE: To investigate the involvement of pretreatment C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) in the prognosis of patients who underwent intravesical bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC). METHODS: The clinicopathological data of 1709 patients with NMIBC who underwent initial intravesical BCG therapy after transurethral resection of bladder tumor were retrospectively analyzed to evaluate the outcome of intravesical BCG therapy in a multicenter study conducted by the Japan Urological Oncology Group. The prognoses of these patients were analyzed to determine whether the biomarkers (CRP and NLR) could predict the efficacy of intravesical BCG therapy. Patients were divided into two groups according to the pretreatment CRP and NLR, with cutoff values defined as CRP >/= 0.5 mg/dl and NLR >/= 2.5, based on several previous reports. RESULTS: In the univariable analysis, CRP >/= 0.5 mg/dl was significantly associated with intravesical recurrence, cancer-specific survival, and bladder cancer (BC) progression, while NLR >/= 2.5 was not significantly associated with patient prognosis. In the multivariable analysis, CRP >/= 0.5 mg/dl was significantly associated with intravesical recurrence and BC progression. The concordance index was used to examine the accuracy in predicting recurrence and progression events. While CRP was slightly, though not statistically significant, inferior to the European Association of Urology risk classification, the combination of them showed improved predictive accuracy. CONCLUSION: This study suggests that CRP can be a prognostic factor after intravesical BCG therapy and may provide useful data for determining treatment and follow-up strategies for patients with NMIBC. CI - (c) 2022 The Japanese Urological Association. FAU - Nishikawa, Ryoma AU - Nishikawa R AUID- ORCID: 0000-0001-6787-9601 AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Morizane, Shuichi AU - Morizane S AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. FAU - Shimizu, Ryutaro AU - Shimizu R AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. FAU - Teraoka, Shogo AU - Teraoka S AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. FAU - Honda, Masashi AU - Honda M AUID- ORCID: 0000-0002-0358-676X AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. FAU - Iida, Kota AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AUID- ORCID: 0000-0002-8902-7853 AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Chiba City, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, Jikei University School of Medicine, Tokyo, Minato-ku, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduates School of Medicine, Miyagi, Sendai, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin Hospital, Fukuoka City, Fukuoka, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center, Nagoya City, Aichi, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto City, Kyoto, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama City, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama City, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Takenaka, Atsushi AU - Takenaka A AD - Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Tottori, Yonago, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221130 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) RN - 9007-41-4 (C-Reactive Protein) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Prognosis MH - BCG Vaccine/therapeutic use MH - C-Reactive Protein MH - *Urology MH - Retrospective Studies MH - Japan MH - *Non-Muscle Invasive Bladder Neoplasms MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Adjuvants, Immunologic OTO - NOTNLM OT - C-reactive protein (CRP) OT - intravesical BCG therapy OT - neutrophil-to-lymphocyte ratio (NLR) OT - non-muscle invasive bladder cancer (NMIBC) OT - prognosis EDAT- 2022/12/01 06:00 MHDA- 2023/03/08 06:00 CRDT- 2022/11/30 05:43 PHST- 2022/02/04 00:00 [received] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/12/01 06:00 [pubmed] PHST- 2023/03/08 06:00 [medline] PHST- 2022/11/30 05:43 [entrez] AID - 10.1111/iju.15106 [doi] PST - ppublish SO - Int J Urol. 2023 Mar;30(3):299-307. doi: 10.1111/iju.15106. Epub 2022 Nov 30. PMID- 36441069 OWN - NLM STAT- MEDLINE DCOM- 20221130 LR - 20230228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 1 DP - 2023 Jan TI - Value of multiparametric magnetic resonance imaging for local staging of invasive urinary bladder tumours. PG - 49.e7-49.e12 LID - S1078-1439(22)00354-4 [pii] LID - 10.1016/j.urolonc.2022.09.026 [doi] AB - BACKGROUND: Initial tumour staging in bladder cancer mainly relies on the histo-pathological outcome of the transurethral bladder tumour resection (TURBT) and imaging by means of a CT-scan (CT-intravenous urography; CT-IVU). The reported risk of understaging varies from 24-50%. To further improve the the evaluation of depth of invasion of the bladder tumour the application of magnetic resonance imaging (MRI) may be useful. To substantiate the additional value of this imaging modality the present observational study was designed. STUDY DESIGN: This is a prospective observational study to analyse bladder tumour staging with multiparametric magnetic resonance imaging (mpMRI) in patients with a known bladder tumour, who are planned for radical cystectomy. STUDY POPULATION: Patients with an invasive bladder cancer who are planned for radical cystectomy. INTERVENTION: Patients were accrued during their visit to the outpatient department of urology. They underwent routine cystoscopy, laboratory tests (including serum Creatinin) and CT-IVU investigations and subsequently a mpMRI. MAIN STUDY PARAMETERS/ENDPOINTS: To demonstrate the value of mpMRI in the initial staging of bladder tumours using radiological bladder tumour stage (T-stage) based on mpMRI and pathological bladder tumour stage based on 'whole-mount' histo-pathology after radical cystectomy. RESULTS: Thirty-seven participants with known bladder tumours underwent mpMRI and subsequent cystectomy. After mpMRI 10 participants were diagnosed with non-muscle-invasive bladder cancer (NMIBC) and 27 participants with muscle-invasive bladder cancer (MIBC). In the 'whole-mount' pathology results 12 participants had NMIBC and 25 participants had MIBC. We found a sensitivity and specificity of 0.88 en 0.58 respectively, for the evaluation of MIBC. The positive and negative predictive value were 81% and 70% respectively. The diagnostic accuracy of mpMRI to differentiate between NMIBC and MIBC was 78%. CONCLUSIONS: We found a sensitivity of 88% and a specificity of 58% for mpMRI to discriminate NMIBC from MIBC. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Huele, Eline H AU - Huele EH AD - Department Oncological Urology, University Medical Center Utrecht, The Netherlands. FAU - Veenboer, Paul W AU - Veenboer PW AD - Department Oncological Urology, University Medical Center Utrecht, The Netherlands. FAU - Wessels, Frank J AU - Wessels FJ AD - Department Radiology, University Medical Center Utrecht, The Netherlands. FAU - Jonges, Trudy N AU - Jonges TN AD - Department Pathology, University Medical Center Utrecht, The Netherlands. FAU - Meijer, Richard P AU - Meijer RP AD - Department Oncological Urology, University Medical Center Utrecht, The Netherlands. Electronic address: rmeijer6@umcutrecht.nl. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20221029 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - *Multiparametric Magnetic Resonance Imaging MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery MH - Cystectomy MH - Urinary Bladder MH - Cystoscopy OTO - NOTNLM OT - Bladder cancer OT - Multiparametric MRI OT - Tumour staging OT - Whole-mount pathology EDAT- 2022/11/29 06:00 MHDA- 2022/12/01 06:00 CRDT- 2022/11/28 10:23 PHST- 2022/03/23 00:00 [received] PHST- 2022/09/21 00:00 [revised] PHST- 2022/09/23 00:00 [accepted] PHST- 2022/11/28 10:23 [entrez] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/12/01 06:00 [medline] AID - S1078-1439(22)00354-4 [pii] AID - 10.1016/j.urolonc.2022.09.026 [doi] PST - ppublish SO - Urol Oncol. 2023 Jan;41(1):49.e7-49.e12. doi: 10.1016/j.urolonc.2022.09.026. Epub 2022 Oct 29. PMID- 36439552 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240607 IS - 2673-9828 (Electronic) IS - 2673-9828 (Linking) VI - 2 DP - 2022 TI - Targeting Bladder Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell Proliferation by pHLIP-amanitin. LID - 868919 [pii] LID - 10.3389/fruro.2022.868919 [doi] AB - Acidity is a useful biomarker for the targeting of metabolically active-cells in tumors. pH Low Insertion Peptides (pHLIPs) sense the pH at the surfaces of tumor cells and can facilitate intracellular delivery of cell-permeable and cell-impermeable cargo molecules. In this study we have shown the targeting of malignant lesions in human bladders by fluorescent pHLIP agents, intracellular delivery of amanitin toxin by pHLIP for the inhibition of urothelial cancer cell proliferation, and enhanced potency of pHLIP-amanitin for cancer cells with 17p loss, a mutation frequently present in urothelial cancers. Twenty-eight ex-vivo bladder specimens, from patients undergoing robotic assisted laparoscopic radical cystectomy for bladder cancer, were treated via intravesical incubation for 15-60 minutes with pHLIP conjugated to indocyanine green (ICG) or IR-800 near infrared fluorescent (NIRF) dyes at concentrations of 4-8 muM. White light cystoscopy identified 47/58 (81%) and NIRF pHLIP cystoscopy identified 57/58 (98.3%) of malignant lesions of different subtypes and stages selected for histopathological processing. pHLIP NIRF imaging improved diagnosis by 17.3% (p < 0.05). All carcinoma-in-situ cases missed by white light cystoscopy were targeted by pHLIP agents and were diagnosed by NIRF imaging. We also investigated the interactions of pHLIP-amanitin with urothelial cancer cells of different grades. pHLIP-amanitin produced concentration- and pH-dependent inhibition of the proliferation of urothelial cancer cells treated for 2 hrs at concentrations up to 4 muM. A 3-4x enhanced cytotoxicity of pHLIP-amanitin was observed for cells with a 17p loss after 2 hrs of treatment at pH6. Potentially, pHLIP technology may improve the management of urothelial cancers, including imaging of malignant lesions using pHLIP-ICG for diagnosis and surgery, and the use of pHLIP-amanitin for treatment of superficial bladder cancers via intravesical instillation. FAU - Moshnikova, Anna AU - Moshnikova A AD - Physics Department, University of Rhode Island, Kingston, RI, USA. FAU - Golijanin, Borivoj AU - Golijanin B AD - Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA. AD - Division of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA. FAU - Amin, Ali AU - Amin A AD - Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI, USA. FAU - Doyle, Joshua AU - Doyle J AD - Physics Department, University of Rhode Island, Kingston, RI, USA. AD - Current address: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA. FAU - Kott, Ohad AU - Kott O AD - Division of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA. AD - Current address: Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - DuPont, Michael AU - DuPont M AD - Physics Department, University of Rhode Island, Kingston, RI, USA. FAU - Li, Yujing AU - Li Y AD - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Lu, Xiongbin AU - Lu X AD - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. AD - Melvin & Bren Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Engelman, Donald M AU - Engelman DM AD - Department of Molecular Biophysics and Biochemistry, Yale, New Haven, CT, USA. FAU - Andreev, Oleg A AU - Andreev OA AD - Physics Department, University of Rhode Island, Kingston, RI, USA. FAU - Reshetnyak, Yana K AU - Reshetnyak YK AD - Physics Department, University of Rhode Island, Kingston, RI, USA. FAU - Golijanin, Dragan AU - Golijanin D AD - Division of Urology, Department of Surgery, Brown University, The Miriam Hospital, Providence, RI, USA. LA - eng GR - P20 GM103430/GM/NIGMS NIH HHS/United States GR - R01 CA203737/CA/NCI NIH HHS/United States GR - R01 GM073857/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20220824 PL - Switzerland TA - Front Urol JT - Frontiers in urology JID - 9918503688806676 PMC - PMC9691284 MID - NIHMS1848049 OTO - NOTNLM OT - imaging OT - intravesical instillation OT - pH-dependent delivery OT - superficial bladder cancer OT - surgery OT - treatment OT - tumor acidity COIS- Conflict of Interest: D.M.E., O.A.A. and Y.K.R. are founders of pHLIP, Inc., and they have shares in the company. pHLIP, Inc did not provide funding for the research. X.L. has a U.S. patent (no. 10563204) on "Methods of treating cancer harboringhemizygous loss of TP53" licensed to Heidelberg Pharma AG. Other authors do not declare any competing interests. EDAT- 2022/11/29 06:00 MHDA- 2022/11/29 06:01 PMCR- 2022/11/24 CRDT- 2022/11/28 04:39 PHST- 2022/11/28 04:39 [entrez] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/29 06:01 [medline] PHST- 2022/11/24 00:00 [pmc-release] AID - 868919 [pii] AID - 10.3389/fruro.2022.868919 [doi] PST - ppublish SO - Front Urol. 2022;2:868919. doi: 10.3389/fruro.2022.868919. Epub 2022 Aug 24. PMID- 36430959 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20230308 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 22 DP - 2022 Nov 21 TI - Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups. LID - 10.3390/ijms232214481 [doi] LID - 14481 AB - To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment. FAU - Piao, Xuan-Mei AU - Piao XM AUID- ORCID: 0000-0001-6847-7743 AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. FAU - Kim, Seon-Kyu AU - Kim SK AUID- ORCID: 0000-0002-4176-5187 AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. FAU - Zheng, Chuang-Ming AU - Zheng CM AUID- ORCID: 0000-0003-1925-0571 AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AUID- ORCID: 0000-0002-8060-8926 AD - Urotech Institute, Cheongju 28120, Republic of Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food Science and Technology, Chung-Ang University, Ansung 456-756, Republic of Korea. FAU - Choi, Yung Hyun AU - Choi YH AUID- ORCID: 0000-0002-1454-3124 AD - Department of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan 614-052, Republic of Korea. FAU - Yun, Seok Joong AU - Yun SJ AUID- ORCID: 0000-0001-7737-4746 AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. LA - eng GR - 2021R1I1A1A01050891/National Research Foundation of Korea/ GR - 2020R1I1A3062508/National Research Foundation of Korea/ GR - 2020R1F1A1068488/National Research Foundation of Korea/ PT - Journal Article DEP - 20221121 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Neoplasm Recurrence, Local/genetics/pathology MH - Neoplasm Invasiveness MH - Disease Progression MH - Risk Factors PMC - PMC9696895 OTO - NOTNLM OT - molecular subtype OT - non-muscle invasive bladder cancer OT - progression OT - recurrence OT - risk score COIS- The authors declare no conflict of interest. EDAT- 2022/11/27 06:00 MHDA- 2022/11/30 06:00 PMCR- 2022/11/21 CRDT- 2022/11/26 01:20 PHST- 2022/10/25 00:00 [received] PHST- 2022/11/17 00:00 [revised] PHST- 2022/11/18 00:00 [accepted] PHST- 2022/11/26 01:20 [entrez] PHST- 2022/11/27 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/11/21 00:00 [pmc-release] AID - ijms232214481 [pii] AID - ijms-23-14481 [pii] AID - 10.3390/ijms232214481 [doi] PST - epublish SO - Int J Mol Sci. 2022 Nov 21;23(22):14481. doi: 10.3390/ijms232214481. PMID- 36428721 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221213 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 22 DP - 2022 Nov 16 TI - Intravesical Recurrence after Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma Is Associated with Flexible Diagnostic Ureteroscopy, but Not with Rigid Diagnostic Ureteroscopy. LID - 10.3390/cancers14225629 [doi] LID - 5629 AB - (1) Background: We assessed the impact of diagnostic ureteroscopy (URS) on intravesical recurrence (IVR) following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma according to the type of URS. (2) Methods: Data on 491 consecutive patients who underwent RNU at two institutions between 2016 and 2019 were retrospectively reviewed. The study population was classified according to the type of URS performed before RNU as follows: non-URS, rigid URS, and flexible URS. The study outcome was IVR occurring within 1 year of RNU. Univariable and multivariable Cox proportional hazards models were used to estimate the risk of IVR. (3) Results: Altogether, 396 patients were included for analysis. Rigid and flexible URS were performed in 178 (45%) and 111 (28%) patients, respectively, while 107 (27%) patients did not undergo URS. IVR was identified in 99 (25%) patients. Multivariable Cox regression analysis revealed that the flexible URS group was significantly associated with increased IVR, compared to the non-URS group (HR = 1.807, p = 0.0416). No significant difference in IVR was observed between the non-URS and rigid URS groups (HR = 1.301, p = 0.3388). (4) Conclusions: In patients with UTUC undergoing RNU, rigid URS may not increase the risk of IVR, whereas flexible URS appears to be associated with a higher risk of IVR. FAU - Ha, Jee Soo AU - Ha JS AUID- ORCID: 0000-0002-3923-4619 AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. FAU - Jeon, Jinhyung AU - Jeon J AUID- ORCID: 0000-0001-8663-1310 AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. FAU - Ko, Jong Cheol AU - Ko JC AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. FAU - Lee, Hye Sun AU - Lee HS AUID- ORCID: 0000-0001-6328-6948 AD - Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Yang, Juyeon AU - Yang J AUID- ORCID: 0000-0002-7621-5150 AD - Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Kim, Daeho AU - Kim D AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. FAU - Kim, June Seok AU - Kim JS AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. FAU - Ham, Won Sik AU - Ham WS AUID- ORCID: 0000-0003-2246-8838 AD - Department of Urology, Urological Science Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Choi, Young Deuk AU - Choi YD AUID- ORCID: 0000-0002-8545-5797 AD - Department of Urology, Urological Science Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Cho, Kang Su AU - Cho KS AUID- ORCID: 0000-0002-3500-8833 AD - Department of Urology, Prostate Cancer Center, Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea. AD - Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul 03722, Republic of Korea. LA - eng GR - 6-2020-0061/faculty research grant from Yonsei University College of Medicine/ PT - Journal Article DEP - 20221116 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9688462 OTO - NOTNLM OT - ureteral neoplasms OT - ureteroscopy OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2022/11/27 06:00 MHDA- 2022/11/27 06:01 PMCR- 2022/11/16 CRDT- 2022/11/26 01:05 PHST- 2022/10/11 00:00 [received] PHST- 2022/11/12 00:00 [revised] PHST- 2022/11/12 00:00 [accepted] PHST- 2022/11/26 01:05 [entrez] PHST- 2022/11/27 06:00 [pubmed] PHST- 2022/11/27 06:01 [medline] PHST- 2022/11/16 00:00 [pmc-release] AID - cancers14225629 [pii] AID - cancers-14-05629 [pii] AID - 10.3390/cancers14225629 [doi] PST - epublish SO - Cancers (Basel). 2022 Nov 16;14(22):5629. doi: 10.3390/cancers14225629. PMID- 36428168 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20230228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 2 DP - 2023 Feb TI - Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience. PG - 107.e9-107.e14 LID - S1078-1439(22)00347-7 [pii] LID - 10.1016/j.urolonc.2022.09.013 [doi] AB - OBJECTIVE: To examine the oncological outcomes and recurrence patterns in patients with no residual disease at the time of radical cystectomy (RC). METHODS: A retrospective review of our IRB-approved bladder cancer database identified patients who underwent RC between 2000 and 2019 and were found to have no residual disease (pT0N0), either following neoadjuvant chemotherapy (NAC) or transurethral resection (TURBT) alone. The primary outcome was recurrence-free survival (RFS). Regression models assessed factors influencing recurrence, and a detailed description of recurrence patterns was compiled. RESULTS: From a total of 2222 patients, 234 (10.5%) were included with a median age of 67 years. NAC was used in 89 (38%) patients and 145 (62%) cases were rendered pT0 following TURBT alone. At a median follow-up of 44 months, there were 16 (6.8%) recurrences, 10 (63%) of which occurred in the ypT0 group. None of the patients with clinical Ta/Tis disease had a recurrence after RC. The median time to recurrence was 9 months. Ninety-one percent (10/11) of recurrences in the ypT0 group were within 2 years of cystectomy, while half of the recurrences in the pT0 group occurred after 2 years. Patients with ypT0 had worse 2- and 5-year RFS compared to the pT0 group (85% and 84% vs. 99% and 95%, respectively; P = 0.003). Variant histology was noted in 49 (21%) patients; the recurrence rate was higher in this subgroup compared to those with pure urothelial carcinoma (12.2% vs. 5.4%, P = 0.02). Lung metastasis and involvement of distant organs, while rare, were noted at similar rates in both groups. CONCLUSION: Patients with pT0N0 pathology at the time of cystectomy should prudently undergo long-term surveillance as recurrence and metastasis can still develop up to 4 years after surgery. Patients achieving ypT0 after NAC exhibit worse prognosis and shorter times to recurrence, closer follow-up may be considered. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Douglawi, Antoin AU - Douglawi A AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Ghoreifi, Alireza AU - Ghoreifi A AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Lee, Ryan AU - Lee R AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Ladi-Seyedian, Seyedeh-Sanam AU - Ladi-Seyedian SS AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Alsyouf, Muhannad AU - Alsyouf M AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Ahmadi, Hamed AU - Ahmadi H AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Miranda, Gus AU - Miranda G AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Cai, Jie AU - Cai J AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Bhanvadia, Sumeet AU - Bhanvadia S AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Schuckman, Anne AU - Schuckman A AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA. Electronic address: daneshma@med.usc.edu. LA - eng PT - Journal Article DEP - 20221122 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Aged MH - Cystectomy MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/surgery MH - Urinary Bladder/pathology MH - Prognosis MH - Neoadjuvant Therapy MH - Neoplasm, Residual MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Bladder cancer OT - Complete pathologic response OT - Neoadjuvant chemotherapy OT - Recurrence EDAT- 2022/11/26 06:00 MHDA- 2023/02/15 06:00 CRDT- 2022/11/25 22:06 PHST- 2022/04/25 00:00 [received] PHST- 2022/09/04 00:00 [revised] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/11/26 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2022/11/25 22:06 [entrez] AID - S1078-1439(22)00347-7 [pii] AID - 10.1016/j.urolonc.2022.09.013 [doi] PST - ppublish SO - Urol Oncol. 2023 Feb;41(2):107.e9-107.e14. doi: 10.1016/j.urolonc.2022.09.013. Epub 2022 Nov 22. PMID- 36424085 OWN - NLM STAT- MEDLINE DCOM- 20221128 LR - 20221128 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 50 IP - 1 DP - 2023 Feb TI - The Association Between the Urinary Microbiome and Bladder Cancer. PG - 81-89 LID - S0094-0143(22)00072-6 [pii] LID - 10.1016/j.ucl.2022.09.012 [doi] AB - Many studies are currently investigating the association between the urinary microbiome and bladder cancer, focusing on differences between stages and with risk of recurrence and progression. However, many of these studies are limited by the small number of patients, presence of confounders and issues with sampling, DNA extraction, and analyses. Recently there has been a shift toward examining the microbiome of bladder tissues rather than urine samples; however, these studies remain a minority. Identification of the differences in microbiome composition between different stages of bladder cancer can provide biomarkers to identify the patients who are more likely to respond to intravesical treatment. Further, these differences in microbiome composition could provide novel therapeutic targets, whereby the modulation of specific bacterial taxa could selectively promote or inhibit response to intravesical therapy. CI - Published by Elsevier Inc. FAU - Hussein, Ahmed A AU - Hussein AA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Elm and Carlton Street, Buffalo, NY 14263, USA. Electronic address: Ahmed.Aly@RoswellPark.org. FAU - Smith, Gary AU - Smith G AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Elm and Carlton Street, Buffalo, NY 14263, USA. FAU - Guru, Khurshid A AU - Guru KA AD - Department of Urology, Roswell Park Comprehensive Cancer Center, Elm and Carlton Street, Buffalo, NY 14263, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy MH - Administration, Intravesical MH - *Microbiota/genetics MH - Urinary Bladder OTO - NOTNLM OT - Biofilms OT - Bladder cancer OT - Microbiome OT - Microbiota OT - Urinary EDAT- 2022/11/25 06:00 MHDA- 2022/11/29 06:00 CRDT- 2022/11/24 21:07 PHST- 2022/11/24 21:07 [entrez] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/29 06:00 [medline] AID - S0094-0143(22)00072-6 [pii] AID - 10.1016/j.ucl.2022.09.012 [doi] PST - ppublish SO - Urol Clin North Am. 2023 Feb;50(1):81-89. doi: 10.1016/j.ucl.2022.09.012. PMID- 36424083 OWN - NLM STAT- MEDLINE DCOM- 20221128 LR - 20221128 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 50 IP - 1 DP - 2023 Feb TI - Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer. PG - 53-67 LID - S0094-0143(22)00069-6 [pii] LID - 10.1016/j.ucl.2022.09.009 [doi] AB - Currently, evaluation for hematuria is driven by the AUA/SUFU guidelines, and urine markers are not recommended for routine evaluation. Bladder cancer is a disease characterized by a high recurrence rate that is impacted by stage and grade. The use of urine markers within the guidelines is recommended for very specific indications such as atypical cystoscopic findings or atypical cytologic findings. Routine use is also not recommended for patients undergoing surveillance. Many protein, DNA and RNA, and molecular biomarkers have been examined as an adjunct to cystoscopy and cytology in the diagnosis and surveillance of bladder cancer, and several FDA-approved tumor markers are now available. The role of biomarkers remains an important area of further study to enhance the diagnosis and surveillance of bladder cancer. Beyond this, tumor markers may also play an important role in risk stratification and prediction of treatment response, allowing for personalized care for patients with bladder cancer. This article reviews the urine biomarkers currently available in the diagnosis and surveillance of bladder cancer. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, 2001 Inwood Road, West Campus Building 3, Floor 4, Dallas, Texas 75390-9110, USA. Electronic address: Yair.Lotan@utsouthwestern.edu. FAU - Baky, Fady J AU - Baky FJ AD - Department of Urology, UT Southwestern Medical Center, 2001 Inwood Road, West Campus Building 3, Floor 4, Dallas, Texas 75390-9110, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/diagnosis/therapy MH - *Carcinoma, Transitional Cell/diagnosis MH - Cystoscopy MH - Biomarkers, Tumor/analysis OTO - NOTNLM OT - Bladder cancer OT - Detection OT - Hematuria OT - Surveillance OT - Urine markers EDAT- 2022/11/25 06:00 MHDA- 2022/11/29 06:00 CRDT- 2022/11/24 21:07 PHST- 2022/11/24 21:07 [entrez] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/29 06:00 [medline] AID - S0094-0143(22)00069-6 [pii] AID - 10.1016/j.ucl.2022.09.009 [doi] PST - ppublish SO - Urol Clin North Am. 2023 Feb;50(1):53-67. doi: 10.1016/j.ucl.2022.09.009. PMID- 36417048 OWN - NLM STAT- MEDLINE DCOM- 20230127 LR - 20230201 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 55 IP - 2 DP - 2023 Feb TI - The use of natural killer cell activity and PPD test in the prediction of results in intravesical BCG treatment of patients with nonmuscle-invasive bladder cancer. PG - 301-308 LID - 10.1007/s11255-022-03414-y [doi] AB - PURPOSE: To predict the efficacy of intravesical BCG therapy in patients with nonmuscle-invasive bladder tumors (NIBC) by using components of the cellular immune response such as the tuberculin skin test (PPD) and natural killer (NK) activity measurement. METHODS: Ninety-nine patients who were started on intravesical BCG therapy for NIBC were evaluated prospectively. Patients who were included in the intermediate, high, and very high-risk groups according to the EAU NMIBC Scoring System and who had never received intravesical BCG therapy previously were included. The clinical and demographic characteristics of the patients (age, gender, EAU NMBIC risk group, EORTC progression and recurrence scores, CUETO progression and recurrence scores, presence and types of comorbidity) were recorded. NK activity was measured and the PPD test was applied 3 days before the start of intravesical BCG therapy. The results of PPD were measured in millimeters 72 h after the test. RESULTS: PPD values measured before BCG treatment, as an independent variable, were found to be significantly lower in patients with recurrence. A significant correlation was detected between NK activity results obtained before BCG treatment and recurrence after treatment, when the cutoff was 200-500 pg/dl. There was no significant relationship between the time to recurrence and PPD and NKA measurements. CONCLUSION: We conclude that the results of PPD test and NK activity measurement performed before starting intravesical BCG therapy in NIBC may be a marker that can be used to predict the risk of recurrence under treatment. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Yazici, Gokhan AU - Yazici G AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Gokmen, Ersin AU - Gokmen E AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Kose, Mustafa Gokhan AU - Kose MG AUID- ORCID: 0000-0002-2491-0178 AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. vensyou@gmail.com. FAU - Cetin, Bugra AU - Cetin B AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Arslan, Burak AU - Arslan B AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Ozalevli, Mehmet AU - Ozalevli M AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Gov, Taha AU - Gov T AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Ozdemir, Enver AU - Ozdemir E AD - Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20221122 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (BCG Vaccine) RN - 0 (Tuberculin) SB - IM MH - Humans MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Killer Cells, Natural MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - *Tuberculin/therapeutic use MH - *Urinary Bladder Neoplasms/pathology/therapy OTO - NOTNLM OT - BCG complications OT - Intravesical BCG and PPD relationship OT - Intravesical BCG and natural killer cell activity relationship OT - Intravesical BCG efficacy OT - Intravesical BCG therapy OT - Nonmuscle-invasive bladder cancer EDAT- 2022/11/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/11/23 12:09 PHST- 2022/08/11 00:00 [received] PHST- 2022/11/11 00:00 [accepted] PHST- 2022/11/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/11/23 12:09 [entrez] AID - 10.1007/s11255-022-03414-y [pii] AID - 10.1007/s11255-022-03414-y [doi] PST - ppublish SO - Int Urol Nephrol. 2023 Feb;55(2):301-308. doi: 10.1007/s11255-022-03414-y. Epub 2022 Nov 22. PMID- 36416333 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221230 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 48 IP - 6 DP - 2022 Nov TI - Biopsy with Ureterorenoscopy Before Radical Nephroureterectomy is Associated with Increased Intravesical Recurrence in Urothelial Cancer Located in the Kidney. PG - 431-439 LID - 10.5152/tud.2022.22143 [doi] AB - OBJECTIVE: Diagnostic ureterorenoscopy is used to identify upper tract urothelial cancer before radical nephro ureterectomy, especially for uncertain lesions in imaging modalities or urine cytology. However, diagnostic ureterorenoscopy can potentially cause intravesical tumor spillage and can increase intravesical recurrence rates. We aimed to investigate the impact of diagnostic ureterorenoscopy before radical nephroureterectomy, with and without biopsy, on intravesical recurrence rates of patients with upper tract urothelial cancer. MATERIAL AND METHODS: Patients with localized upper tract urothelial cancer from 8 different tertiary referral centers, who underwent radical nephroureterectomy between 2001 and 2020, were included. Three groups were made: no URS (group 1); diagnostic ureterorenoscopy without biopsy (group 2); and diagnostic ure terorenoscopy with biopsy (group 3). Intravesical recurrence rates and survival outcomes were compared. Univariate and multivariate Cox regression analyses were performed to determine the factors that were asso ciated with intravesical recurrence-free survival. RESULTS: Twenty-two (20.8%), 10 (24.4%), and 23 (39%) patients experienced intravesical recurrence in groups 1, 2, and 3, respectively (P=.037) among 206 patients. The 2-year intravesical recurrence-free sur vival rate was 83.1%, 82.4%, and 69.2%, for groups 1, 2, and 3, respectively (P=.004). Cancer-specific survival and overall survival were comparable (P=.560 and P=.803, respectively). Diagnostic ureterore noscopy+biopsy (hazard ratio: 6.88, 95% CI: 2.41-19.65, P < .001) was the only independent predictor of intravesical recurrence in patients with upper tract urothelial cancer located in the kidney, according to tumor location. CONCLUSION: Diagnostic ureterorenoscopy+biopsy before radical nephroureterectomy significantly increased the rates of intravesical recurrence in tumors located in kidney. This result suggests tumor spillage with this type of biopsy, so further studies with different biopsy options or without biopsy can be designed. FAU - Culpan, Meftun AU - Culpan M AD - Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey. FAU - Cakici, Mehmet Caglar AU - Cakici MC AD - Department of Urology, Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey. FAU - Keser, Ferhat AU - Keser F AD - Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey. FAU - Yalcin, Mehmet Yigit AU - Yalcin MY AD - Department of Urology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Kargi, Taner AU - Kargi T AD - Department of Urology, University of Health Sciences, Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey. FAU - Kayar, Ridvan AU - Kayar R AD - Department of Urology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey. FAU - Abay, Erdal AU - Abay E AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tasciogulu City Hospital, Istanbul, Turkey. FAU - Ozenc, Gorkem AU - Ozenc G AD - Department of Urology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Istanbul, Turkey. FAU - Kumcu, Ali AU - Kumcu A AD - Department of Urology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey. FAU - Pehlivanoglu, Mehmet AU - Pehlivanoglu M AD - Department of Urology, University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital, Istanbul, Turkey. FAU - Turk, Semih AU - Turk S AD - Department of Urology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. FAU - Kisa, Erdem AU - Kisa E AD - Department of Urology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Sahin, Selcuk AU - Sahin S AD - Department of Urology, University of Health Sciences, Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey. FAU - Ozturk, Metin Ishak AU - Ozturk MI AD - Department of Urology, University of Health Sciences, Haydarpasa Training and Research Hospital, Istanbul, Turkey. FAU - Otunctemur, Alper AU - Otunctemur A AD - Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tasciogulu City Hospital, Istanbul, Turkey. FAU - Sobay, Resul AU - Sobay R AD - Department of Urology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey. FAU - Demirel, Huseyin Cihan AU - Demirel HC AD - Department of Urology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. FAU - Yilmaz, Omer AU - Yilmaz O AD - Department of Urology, University of Health Sciences, Sultan 2. Abdulhamid Han Training and Research Hospital, Istanbul, Turkey. FAU - Atis, Gokhan AU - Atis G AD - Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey. FAU - Imamoglu, Muhammet Abdurrahim AU - Imamoglu MA AD - Department of Urology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC9797743 EDAT- 2022/11/24 06:00 MHDA- 2022/11/24 06:01 PMCR- 2022/11/01 CRDT- 2022/11/23 06:53 PHST- 2022/11/23 06:53 [entrez] PHST- 2022/11/24 06:00 [pubmed] PHST- 2022/11/24 06:01 [medline] PHST- 2022/11/01 00:00 [pmc-release] AID - tju-48-6-431 [pii] AID - 10.5152/tud.2022.22143 [doi] PST - ppublish SO - Turk J Urol. 2022 Nov;48(6):431-439. doi: 10.5152/tud.2022.22143. PMID- 36408130 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221122 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction. PG - 1016542 LID - 10.3389/fonc.2022.1016542 [doi] LID - 1016542 AB - BACKGROUNDS: Approximately 75% of bladder cancer occurrences are of the non-muscle-invasive type. The estimated five-year survival rate is 26%-55%. Currently, there is no reliable biomarker available for early diagnosis and prognosis of bladder cancer. The present study aims to identify a biomarker using bioinformatic approaches to provide a new insight in clinical research for early diagnosis and prognosis of bladder cancer. METHODS: Clinical data and a transcriptome of bladder cancer were obtained from TCGA, GEO, GETx, and UCSC Xena. The differential expressed gene (DEG) analysis, weighted gene co-expression network analysis (WGCNA), and survival analysis using the Kaplan-Meier and Cox proportional-hazards models were used to identify the Microtubule-associated Proteins 1A (MAP1A). on overall survival (OS) and disease-free survival (DFS) was analyzed using GEPIA and GETx databases. The TIMER 2.0 database predicted the correlation between MAP1A and immunocytes and immune checkpoints. Target prediction of the regulated competing endogenous RNAs (ceRNAs) network of MAP1A was performed using starBase and TargetScan. Cystoscope v3.7.2 software was used to visualize the ceRNA coexpression network. The R programming language v4.0.2 was applied as an analytic tool. Gene expression of MAP1A verified by RT-qPCR. RESULTS: The low expression of MAP1A was verified in bladder cancer tissues and bladder cancer cell lines SW780 and 5637. P < 0.001 were obtained by Kaplan-Meier survival analysis and Cox proportional hazards model, with a hazard ratio (HR) of 1.4. Significant correlations between MAP1A and OS (P < 0.001, HR = 1.9) as well as DFS (P < 0.05, HR = 1.7) in bladder cancer were identified through gene expression profiling interactive analysis (GEPIA), indicating MAP1A may be a high-risk factor. Significant correlation in single copy-number variation of MAP1A gene with CD8(+) T cells, and myeloid dendritic cells (MDCs) (P < 0.05) was noted. MAP1A expression was shown to be significantly correlated with the amount of CD4(+) T cells and CD8(+) T cells, MDCs, macrophages, and neutrophils in a statistically significant positive manner (P < 0.001). However, the MAP1A expression demonstrated a strong negative connection with B cells (P < 0.001). Except for macrophage M1 genes IRF5 and PTGS2, MAP1A expression was significantly correlated with the gene levels in immunocytes such as CD4(+) T cells, CD8(+) T cells, B cells, dendritic cells (DCs), macrophages, and neutrophils (Cor > 0.2, P < 0.001), as well as immune checkpoint related genes including cytotoxic t-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) (P < 0.001). Finally, we predicted that the MAP1A-interacting miRNA was miR-34a-5p, and the MAP1A endogenous competing RNAs were LNC00667, circ_MAP1B, and circ_MYLK, respectively. These findings support the need for further studies on the mechanism underlying the pathogenesis of this disease. CONCLUSION: MAP1A is considered as a prospective biomarker for early diagnosis, therapeutic observation, and prognosis analysis in bladder cancer. CI - Copyright (c) 2022 Lyu, Qiang, Zhang, Xu, Cui and Ma. FAU - Lyu, Xiaoyue AU - Lyu X AD - College of Life Sciences, Northwest University, Xi'an, China. FAU - Qiang, Yujie AU - Qiang Y AD - College of Life Sciences, Northwest University, Xi'an, China. FAU - Zhang, Bo AU - Zhang B AD - Ankang Hospital of Traditional Chinese Medicine, Ankang, Shaanxi, China. FAU - Xu, Wei AU - Xu W AD - College of Life Sciences, Northwest University, Xi'an, China. FAU - Cui, Yali AU - Cui Y AD - College of Life Sciences, Northwest University, Xi'an, China. FAU - Ma, Le AU - Ma L AD - College of Life Sciences, Northwest University, Xi'an, China. LA - eng PT - Journal Article DEP - 20221102 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9667867 OTO - NOTNLM OT - MAP1A OT - bladder cancer OT - ceRNA network OT - diagnosis OT - immuno-infiltrating OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2022/01/01 CRDT- 2022/11/21 04:46 PHST- 2022/08/11 00:00 [received] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/11/21 04:46 [entrez] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1016542 [doi] PST - epublish SO - Front Oncol. 2022 Nov 2;12:1016542. doi: 10.3389/fonc.2022.1016542. eCollection 2022. PMID- 36404390 OWN - NLM STAT- MEDLINE DCOM- 20240124 LR - 20250801 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 149 IP - 6 DP - 2023 Jun TI - The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis. PG - 2673-2691 LID - 10.1007/s00432-022-04464-6 [doi] AB - OBJECTIVES: Although smoking is a well-recognized causative factor of urothelial bladder cancer and accounts for 50% of cases, less is known about the prognostic significance of smoking on non-muscle invasive bladder cancer (NMIBC) prognosis. This systematic review and meta-analysis aimed to evaluate the effect of smoking on the risk of NMIBC recurrence and progression. MATERIALS AND METHODS: We systematically searched Medline, Web of Science and Scopus databases for original articles published before October 2021 regarding the effect of smoking on NMIBC recurrence and progression. Information about smoking status and the number of events or odds ratio or hazard ratio for event-free survival must have been reported to include the study in the analysis. Quality In Prognosis Studies tool was utilized for the risk of bias assessment. RESULTS: We selected 64 eligible studies, including 28 617 patients with NMIBC with available data on smoking status. In a meta-analysis of 28 studies with 7885 patients, we found that smokers (current/former) were at higher risk for recurrence (OR = 1.68; 95% CI 1.34-2.09; P < 0.0001) compared to never smokers. Subgroup analysis of 2967 patients revealed that current smokers were at a 1.24 higher risk of recurrence (OR = 1.24; 95% CI 1.02-1.50; P = 0.03) compared to former smokers. A meta-analysis of the hazard ratio revealed that smokers are at higher risk of recurrence (HR = 1.31; 95%CI 1.15-1.48; P < 0.0001) and progression (HR = 1.18; 95%CI 1.08-1.29; P < 0.001) compared to never smokers. Detrimental prognostic effect of smoking on progression, but not for recurrence risk was also noted in the subgroup analysis of high-risk patients (HR = 1.30; 95%CI 1.09-1.55; P = 0.004) and BCG-treated ones (HR = 1.15; 95%CI 1.06-1.25; P < 0.001). CONCLUSION: In conclusion, patients with non-muscle invasive bladder cancer and a history of smoking have a worse prognosis regarding recurrence-free and progression-free survival compared to non-smokers. CI - (c) 2022. The Author(s). FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. aslusarczyk@wum.edu.pl. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. pzapala@wum.edu.pl. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20221121 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 SB - IM MH - *Smoking/adverse effects MH - *Neoplasm Recurrence, Local/mortality/pathology MH - *Non-Muscle Invasive Bladder Neoplasms/mortality/pathology MH - Humans MH - *Progression-Free Survival PMC - PMC10129946 OTO - NOTNLM OT - Current smoker OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence OT - Smoking COIS- The authors declare no conflict of interest. EDAT- 2022/11/21 06:00 MHDA- 2023/04/27 06:42 PMCR- 2022/11/21 CRDT- 2022/11/20 23:22 PHST- 2022/10/04 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2023/04/27 06:42 [medline] PHST- 2022/11/21 06:00 [pubmed] PHST- 2022/11/20 23:22 [entrez] PHST- 2022/11/21 00:00 [pmc-release] AID - 10.1007/s00432-022-04464-6 [pii] AID - 4464 [pii] AID - 10.1007/s00432-022-04464-6 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 Jun;149(6):2673-2691. doi: 10.1007/s00432-022-04464-6. Epub 2022 Nov 21. PMID- 36397760 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221119 IS - 1687-8450 (Print) IS - 1687-8469 (Electronic) IS - 1687-8450 (Linking) VI - 2022 DP - 2022 TI - Influence of Antibiotic Administration on the Urinary Bladder Cancer Early Recurrence Rate. PG - 9495920 LID - 10.1155/2022/9495920 [doi] LID - 9495920 AB - Bladder cancer tends to recur, making treatment one of the most expensive in oncology. The limited efficacy and high cost of adjuvant therapies in the treatment of bladder cancer prompt research on new drugs which could replace them. In vitro studies have established that antibiotics can have a cytostatic and cytotoxic effect on urinary bladder cancer cells. The objective of the study was to investigate the influence of antibiotics on the recurrence rate of bladder cancer. In a retrospective study, we analyzed a group of 199 patients with urinary bladder cancer from four urological centers. The study groups consisted of 40 patients who received ciprofloxacin and 83 patients who received beta-lactams as perioperative antimicrobial prophylaxis. The control group included 76 patients who did not get perioperative antimicrobial prophylaxis. The groups were analyzed for risk stratification, degree of malignancy, and size of the primary tumor. The average follow-up time was 24 months. The main focus of the study was to investigate the early recurrence rate of bladder cancer among studied groups, which could correlate with the effectiveness of currently used intravesical instillations. Additionally, cancer's early progression was examined. Regardless of the division used, the highest recurrence rate was found in the ciprofloxacin group. There were no statistical differences in the recurrence rate between patients who received beta-lactams and patients who did not receive any antibiotics. In addition, there were no differences due to the progression rate between the groups. Perioperative antibiotic administration does not influence the early recurrence rate in patients with nonmuscle invasive urothelial bladder cancer. CI - Copyright (c) 2022 Filip Kowalski et al. FAU - Kowalski, Filip AU - Kowalski F AUID- ORCID: 0000-0002-7981-8600 AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Drewa, Tomasz AU - Drewa T AUID- ORCID: 0000-0002-5529-4320 AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Adamowicz, Jan AU - Adamowicz J AUID- ORCID: 0000-0003-2479-7133 AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Wilamowski, Jacek AU - Wilamowski J AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Ostrowski, Adam AU - Ostrowski A AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Ostrowska, Magdalena AU - Ostrowska M AUID- ORCID: 0000-0003-3323-3516 AD - Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Kamecki, Krzysztof AU - Kamecki K AD - Department of Urology, F. Lukaszczyk Memorial Oncological Center, Bydgoszcz, Poland. FAU - Miklas, Marcin AU - Miklas M AD - Department of Urology, 10thMilitary Hospital, Bydgoszcz, Poland. FAU - Szlaga, Michal AU - Szlaga M AD - Department of Urology, M. Curie-Sklodowskiej Memorial Voivodeship Hospital, Zgierz, Poland. FAU - Mikolajczak, Witold AU - Mikolajczak W AD - Department of Urology, Nicolaus Copernicus Municipal Hospital, Torun, Poland. FAU - Pokrywczynska, Marta AU - Pokrywczynska M AUID- ORCID: 0000-0003-3259-087X AD - Chair of Urology and Andrology, Department of Regenerative Medicine, Cell and Tissue Bank, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. FAU - Juszczak, Kajetan AU - Juszczak K AD - Chair of Urology and Andrology, Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz Torun, Poland. AD - Department of Urology, L. Rydygier Memorial Specialist Hospital, Krakow, Poland. LA - eng PT - Journal Article DEP - 20221108 PL - Egypt TA - J Oncol JT - Journal of oncology JID - 101496537 PMC - PMC9666019 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/11/19 06:00 MHDA- 2022/11/19 06:01 PMCR- 2022/11/08 CRDT- 2022/11/18 02:04 PHST- 2021/12/06 00:00 [received] PHST- 2022/09/05 00:00 [revised] PHST- 2022/10/24 00:00 [accepted] PHST- 2022/11/18 02:04 [entrez] PHST- 2022/11/19 06:00 [pubmed] PHST- 2022/11/19 06:01 [medline] PHST- 2022/11/08 00:00 [pmc-release] AID - 10.1155/2022/9495920 [doi] PST - epublish SO - J Oncol. 2022 Nov 8;2022:9495920. doi: 10.1155/2022/9495920. eCollection 2022. PMID- 36388029 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221119 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 11 IP - 10 DP - 2022 Oct TI - Fluorescence in situ hybridization (FISH) to predict the efficacy of Bacillus Calmette-Guerin perfusion in bladder cancer. PG - 3448-3457 LID - 10.21037/tcr-22-1367 [doi] AB - BACKGROUND: Transurethral resection of bladder tumor (TURBT) combined with intravesical Bacillus Calmette-Guerin (BCG) perfusion is a widely accepted treatment for moderate or high risk non-muscular-invasive bladder cancer (BCa). Despite its effectiveness, the recurrence and progression rate of tumor are still high. We evaluated the predictive role of fluorescence in situ hybridization (FISH) for the response to BCG perfusion in BCa. METHODS: Patients with BCa who underwent BCG perfusion and FISH test in our hospital were selected. Logistic regression and Kaplan-Meier methods were used to evaluate the relationship between FISH results and tumor recurrence or progression. COX proportional hazards regression analysis was used to identify risk factors for recurrence or progression. SPSS (version 24.0, IBM Corporation, USA) was used for statistical analysis. RESULTS: Seventy-six patients were included in this study, with a median age of 63.0 (55.0-70.0) years, and a median follow-up time of 19.0 (7.5-29.0) months. Fifteen patients relapsed after BCG perfusion. Before TURBT, 39 patients were positive for FISH and 20 were negative. There was no significant difference in the recurrence rate of BCG after perfusion predicted by preoperative FISH positive (10.3% vs. 10%, P=0.675). No association was found between preoperative FISH and tumor recurrence (P=0.955) or disease progression (P=0.186). After BCG perfusion, 10 patients were FISH positive and 14 patients were FISH negative. There was significant difference in recurrence rate of BCa predicted by positive FISH (100% vs. 7.1%, P<0.001). FISH results were significantly associated with tumor recurrence (P<0.001) and disease progression (P=0.001). Kaplan-Meier and univariate COX proportional hazards regression analysis clarified that FISH positive after BCG perfusion, tumor-node-metastasis (TNM) stage, and multiple tumors were risk factors for tumor recurrence and progression (P<0.05). Tumor TNM stage and FISH positive after BCG perfusion were independent risk factors for recurrence. CONCLUSIONS: Positive FISH after BCG perfusion can well predict the risk of recurrence and progression of BCa, and recurrence within six months is more likely. After BCG perfusion, it is better to recommend close follow up in patients with positive FISH. CI - 2022 Translational Cancer Research. All rights reserved. FAU - Ke, Chunjin AU - Ke C AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. FAU - Liu, Zhenghao AU - Liu Z AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. FAU - Zhu, Junyu AU - Zhu J AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. FAU - Zeng, Xing AU - Zeng X AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. FAU - Hu, Zhiquan AU - Hu Z AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. FAU - Yang, Chunguang AU - Yang C AD - Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, China. LA - eng PT - Journal Article PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC9641077 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) perfusion OT - Fluorescence in situ hybridization (FISH) OT - bladder cancer (BCa) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1367/coif). The authors have no conflicts of interest to declare. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/10/01 CRDT- 2022/11/17 12:06 PHST- 2022/05/14 00:00 [received] PHST- 2022/08/25 00:00 [accepted] PHST- 2022/11/17 12:06 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/10/01 00:00 [pmc-release] AID - tcr-11-10-3448 [pii] AID - 10.21037/tcr-22-1367 [doi] PST - ppublish SO - Transl Cancer Res. 2022 Oct;11(10):3448-3457. doi: 10.21037/tcr-22-1367. PMID- 36388016 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221119 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 11 IP - 10 DP - 2022 Oct TI - Treatment decisions of bladder cancer in patients older than 85 years: a SEER-based analysis 2011-2015. PG - 3584-3592 LID - 10.21037/tcr-22-944 [doi] AB - BACKGROUND: To compare the survival outcomes of patients over 85 years of age with bladder cancer. METHODS: We used data collected from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier (KM) curves were generated for overall survival with 95% confidence intervals (CIs). Cox proportional hazard models were used to estimate the hazard ratios among cases in different groups. RESULTS: Of the 9,321 patients who met the inclusion criteria, 6,703 (71.9%) were men and 2,618 (28.1%) were women, with a mean (standard deviation) age of 88.68 (3.216) years. The median follow-up time of this cohort was 18 months. In the low-grade non-muscle-invasive bladder cancer (LG NMIBC) group, our analysis showed that no further treatment led to a better prognosis after the first transurethral bladder tumor resection (TURBT). In the high-grade NMIBC (HG NMIBC) cohort, major therapy was correlated with better OS in univariable and multivariable analyses [hazard ratio (HR) 0.450; 95% CI: 0.351-0.577]. Trimodal therapy gave a better prognosis in the muscle-invasive bladder cancer (MIBC) cohort (HR 1.395; 95% CI: 1.147-1.697). In addition, none of the county factors were risk factors for prognosis in multivariable analysis. CONCLUSIONS: Minor and major therapies do not have a better prognosis after TURBT in LG NMIBC. Major therapy has better oncological outcomes in LG NMIBC and MIBC than minor therapy. Trimodal therapy leads to longer OS in MIBC. In addition, none of the county factors were risk factors for prognosis. CI - 2022 Translational Cancer Research. All rights reserved. FAU - Zhu, Jun AU - Zhu J AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Ye, Xin AU - Ye X AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - He, Zhisong AU - He Z AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Jin, Jie AU - Jin J AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Yu, Wei AU - Yu W AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China. LA - eng PT - Journal Article PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC9641082 OTO - NOTNLM OT - Bladder cancer (BCa) OT - cystectomy OT - elderly OT - survival COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-944/coif). The authors have no conflicts of interest to declare. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/10/01 CRDT- 2022/11/17 12:06 PHST- 2022/04/05 00:00 [received] PHST- 2022/08/17 00:00 [accepted] PHST- 2022/11/17 12:06 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/10/01 00:00 [pmc-release] AID - tcr-11-10-3584 [pii] AID - 10.21037/tcr-22-944 [doi] PST - ppublish SO - Transl Cancer Res. 2022 Oct;11(10):3584-3592. doi: 10.21037/tcr-22-944. PMID- 36387926 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221119 IS - 1179-1349 (Print) IS - 1179-1349 (Electronic) IS - 1179-1349 (Linking) VI - 14 DP - 2022 TI - Positive Predictive Values of Procedure Codes on the Treatment of Non-Muscle Invasive Bladder Cancer in the Danish National Patient Registry. PG - 1317-1325 LID - 10.2147/CLEP.S376566 [doi] AB - PURPOSE: Globally non-muscle invasive bladder cancer (NMIBC) is a high-incidence disease. There is a large heterogeneity within NMIBC regarding recurrence- and progression risks, and large-scale studies of treatment patterns and prognoses in an everyday setting could result in NMIBC-subgroup treatment optimization, benefiting both patients and the economy. The Danish national registries provide such an opportunity if the registered procedure codes are valid. Therefore, the aim of the study was to validate the International Classification of Diseases, 10th Edition (ICD-10) codes of NMIBC treatment used in the Danish National Patient Registry (DNPR). PATIENTS AND METHODS: From the DNPR, we randomly selected 200 NMIBC treatment courses identified by the dates of the course and the codes of transurethral resection of the bladder ((TURB), n = 125), photodynamic diagnosis ((PDD), n = 25), bladder instillation with Bacillus Calmette vaccine ((BCG), n = 25), or bladder instillation with chemotherapy/Mitomycin C ((MMC), n = 25). We used medical record reviews as the reference standard and estimated positive predictive values (PPVs) of all procedure codes and negative predictive values (NPVs) of PDD- and the perioperative single-shot MMC codes. RESULTS: We identified the medical records in 150 (75%) of the 200 treatment courses (149 individual patients). The overall PPVs were TURB: 98.9% (95% confidence interval: 93.8; 100.0%), PDD: 95.8% (78.9; 99.9%), adjuvant BCG: 90.0% (68.3; 98.8%), perioperative single-shot MMC 1/5, and adjuvant MMC: 69.2% (38.6; 90.9%). The overall NPVs were PDD: 64.8% (54.4; 73.9%) and perioperative single-shot MMC: 97.7% (92.1; 99.4%). CONCLUSION: The ICD-10 NMIBC procedure codes recorded in the DNPR are generally valid with high PPVs. The NPV of the PPD code is acceptable. However, the code for perioperative single-shot MMC is uncertain with low PPV, but a high NPV. CI - (c) 2022 Blichert-Refsgaard et al. FAU - Blichert-Refsgaard, Linea AU - Blichert-Refsgaard L AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Norgaard, Mette AU - Norgaard M AUID- ORCID: 0000-0001-6110-5891 AD - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Bengtsen, Maria Bisgaard AU - Bengtsen MB AUID- ORCID: 0000-0002-4241-7213 AD - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. LA - eng PT - Journal Article DEP - 20221106 PL - New Zealand TA - Clin Epidemiol JT - Clinical epidemiology JID - 101531700 PMC - PMC9648184 OTO - NOTNLM OT - Danish National Patient Registry OT - non-muscle invasive bladder cancer OT - procedure codes OT - validation COIS- Professor Jorgen Bjerggaard Jensen reports grants from medac, Ferring, Photocure, Nucelix, non-financial support from Roche, Urotech, grants, non-financial support from Olympus, and personal fees from Pfizer, during the conduct of the study. The authors report no other conflicts of interest in this work. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/11/06 CRDT- 2022/11/17 12:04 PHST- 2022/06/02 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/11/17 12:04 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/11/06 00:00 [pmc-release] AID - 376566 [pii] AID - 10.2147/CLEP.S376566 [doi] PST - epublish SO - Clin Epidemiol. 2022 Nov 6;14:1317-1325. doi: 10.2147/CLEP.S376566. eCollection 2022. PMID- 36387197 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221118 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Survival and risk factors among upper tract urothelial carcinoma patients after radical nephroureterectomy in Northeast China. PG - 1012292 LID - 10.3389/fonc.2022.1012292 [doi] LID - 1012292 AB - OBJECTIVE: The study objective was to investigate the prognostic risk factors related to overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and metastasis-free survival (MFS) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Patients were then divided into different risk groups (based on their number of prognostic risk factors), and specific postoperative treatment plans were formulated for patients in different risk groups. METHODS: We retrospectively analyzed the data of 401 patients with UTUC who underwent RNU between 2010 and 2020. Univariate and multivariate Cox regression analyses were used to evaluate the associations of clinicopathological variables with prognosis among UTUC patients. Kaplan-Meier survival analysis of patients in different risk groups (based on their number of prognostic risk factors) was conducted. RESULTS: Multivariate Cox regression analysis showed that sex (being male), LVI, pT stage (>pT2), and lack of postoperative intravesical instillation were independent risk predictors of shorter OS, CSS, RFS, and MFS (all P<0.05). Laparoscopic RNU was also associated with shorter OS, CSS, and MFS, but not with shorter RFS (P=0.068). After risk stratification, the 5-year OS, CSS, RFS, and MFS in the high-risk group were 42.3%, 46.4%, 41%, and 46%, respectively. CONCLUSIONS: Sex (being male), LVI, pT stage (>pT2), and intravesical instillation were independent predictors of OS, CSS, RFS, and MFS for UTUC. All were risk factors, except for intravesical instillation, which was a protective factor. Additionally, laparoscopic RNU was an independent risk factor for OS, CSS, and MFS. Patients in the high-risk group may benefit greatly from adjuvant or neoadjuvant chemotherapy. CI - Copyright (c) 2022 Gao, Liu, Liu, Lin and Ding. FAU - Gao, Jianing AU - Gao J AD - Department of Urology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Liu, Jingya AU - Liu J AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Liu, Jianyu AU - Liu J AD - Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Lin, Shiyan AU - Lin S AD - Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Ding, Dexin AU - Ding D AD - Department of Urology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. LA - eng PT - Journal Article DEP - 20221025 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9648663 OTO - NOTNLM OT - metastasis OT - prognosis OT - radical nephroureterectomy (RNU) OT - recurrence OT - upper tract urothelial carcinoma (UTUC) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/01/01 CRDT- 2022/11/17 11:56 PHST- 2022/08/14 00:00 [received] PHST- 2022/10/10 00:00 [accepted] PHST- 2022/11/17 11:56 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1012292 [doi] PST - epublish SO - Front Oncol. 2022 Oct 25;12:1012292. doi: 10.3389/fonc.2022.1012292. eCollection 2022. PMID- 36387134 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221118 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatment. PG - 927410 LID - 10.3389/fonc.2022.927410 [doi] LID - 927410 AB - Intravesical bacillus Calmette-Guerin (BCG) instillation is recommended as an adjuvant therapy for intermediate-risk and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBt) with nearly 70% reoccurrence. In the present study, we investigated the dynamics of peripheral purified protein derivative (PPD)-specific immune responses along the treatment. Intravesical BCG instillation caused a significant increase in peripheral PPD-specific IFN-gamma release of NMIBC patients, when compared to those receiving chemo-drug instillation. Through a follow-up study, we detected rapid increase in PPD-specific IFN-gamma, IL-2, and IL-17A producing CD4(+) and CD8(+) T cells in the induction phase. Interestingly, the frequencies of PPD-specific IFN-gamma and IL-2 producing CD4(+) and CD8(+) T cells decreased dramatically after induction treatment and were restored after BCG re-instillation, whereas IL-17A-producing T cells remained at the maintenance phase. However, we only observed that the percentages of peripheral CD8(+) T cells were significantly higher in BCG responder patients than those in BCG refractory patients at the baseline with the potential of predicting the recurrence. A more dramatic increase in PPD-specific IFN-gamma and IL-2 producing CD4(+) and CD8(+) T cells after one and two dose BCG instillations was observed in refractory NMIBC patients. Therefore, regional BCG instillation induced transient peripheral PPD-specific T cell responses, which could be restored through repetitive BCG instillation. Higher proportions of peripheral CD8(+) T cells at baseline were associated with better responses to BCG instillation for the prevention of recurrence of bladder cancer. CI - Copyright (c) 2022 Duan, Xia, Xu, Chen, Ding, Wang, Sun, Yao, Zhang, Wu, Ji, Wang, Qian, Wang and Shen. FAU - Duan, Huangqi AU - Duan H AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Xia, Weimin AU - Xia W AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Xu, Ding AU - Xu D AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Chen, Yingying AU - Chen Y AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ding, Yu AU - Ding Y AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Wang, Chen AU - Wang C AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Sun, Ruiming AU - Sun R AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yao, Chengcheng AU - Yao C AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zhang, Shun AU - Zhang S AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Wu, Yu AU - Wu Y AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Ji, Ping AU - Ji P AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Shujun AU - Wang S AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Qian, Subo AU - Qian S AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Wang, Ying AU - Wang Y AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Shen, Haibo AU - Shen H AD - Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. LA - eng PT - Journal Article DEP - 20221027 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9646940 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - cytokine profiles OT - non-muscle invasive bladder cancer (NMIBC) OT - peripheral immune responses OT - predictor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/01/01 CRDT- 2022/11/17 11:55 PHST- 2022/04/24 00:00 [received] PHST- 2022/09/13 00:00 [accepted] PHST- 2022/11/17 11:55 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.927410 [doi] PST - epublish SO - Front Oncol. 2022 Oct 27;12:927410. doi: 10.3389/fonc.2022.927410. eCollection 2022. PMID- 36386555 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221118 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 14 DP - 2022 TI - Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation. PG - 3121-3130 LID - 10.2147/CMAR.S383627 [doi] AB - OBJECTIVE: Among intravesical instillation protocol in patients with non-muscle-invasive bladder cancer (NMIBC), chemotherapy agents have been widely used during the bacillus Calmette-Guerin (BCG) shortage era since the patient might under the risk of BCG discontinuation. This study evaluates the efficacy of incomplete BCG instillation compared with pure chemotherapy instillation protocol. MATERIALS AND METHODS: Patients newly diagnosed with intermediate- and high-risk NMIBC who received incomplete BCG intravesical instillation or chemotherapy instillation were retrospectively included. Patients were divided into three groups according to different intravesical instillation schedules: [BCG only], [BCG + Chemo], and [Chemo only]. Comparisons between these three groups were performed. Bladder recurrence-free survival (RFS) was analyzed as the primary endpoint. RESULTS: A total of 475 patients who received intravesical instillations were enrolled. Compared to the [Chemo only] group, the [BCG + Chemo] group had significantly better bladder RFS (p = 0.027). Multivariate analysis of recurrence revealed the [BCG + Chemo] regimen has a hazard ratio 0.381 (95% CI 0.154-0.941, p = 0.037). The total instillation number >12 was associated with better RFS (p = 0.001) compared with other instillation numbers. CONCLUSION: For NMIBC patients facing the risk of unexpected BCG instillation interruption, instead of starting instillation with chemotherapy agents, receiving BCG first till stoppage then shifting to chemotherapy agents is recommended. CI - (c) 2022 Lin et al. FAU - Lin, Po-Ting AU - Lin PT AUID- ORCID: 0000-0001-9196-2376 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. FAU - Hsieh, Ming-Li AU - Hsieh ML AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Su, Shih-Huan AU - Su SH AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. FAU - Chang, Ying-Hsu AU - Chang YH AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Department of Urology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei, Taiwan. FAU - Huang, Liang-Kang AU - Huang LK AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Chu, Yuan-Cheng AU - Chu YC AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Kan, Hung-Cheng AU - Kan HC AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Lin, Po-Hung AU - Lin PH AUID- ORCID: 0000-0001-8245-4302 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Yu, Kai-Jie AU - Yu KJ AUID- ORCID: 0000-0003-3656-8856 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Chuang, Cheng-Keng AU - Chuang CK AUID- ORCID: 0000-0001-6154-1220 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Wu, Chun-Te AU - Wu CT AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Keelung Branch, Keelung, Taiwan. FAU - Pang, See-Tong AU - Pang ST AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Shao, I-Hung AU - Shao IH AUID- ORCID: 0000-0002-4832-0113 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Cancer Genome Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20221104 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC9642073 OTO - NOTNLM OT - BCG OT - NMIBC OT - bladder cancer OT - bladder recurrence OT - intravesical chemotherapy OT - intravesical instillation COIS- The authors declare that they have no competing interests in this work. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/11/04 CRDT- 2022/11/17 11:45 PHST- 2022/07/25 00:00 [received] PHST- 2022/10/26 00:00 [accepted] PHST- 2022/11/17 11:45 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/11/04 00:00 [pmc-release] AID - 383627 [pii] AID - 10.2147/CMAR.S383627 [doi] PST - epublish SO - Cancer Manag Res. 2022 Nov 4;14:3121-3130. doi: 10.2147/CMAR.S383627. eCollection 2022. PMID- 36381599 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 2214-3882 (Print) IS - 2214-3890 (Electronic) IS - 2214-3882 (Linking) VI - 9 IP - 4 DP - 2022 Oct TI - Validation of Vesical Imaging Reporting and Data System score for the diagnosis of muscle-invasive bladder cancer: A prospective cross-sectional study. PG - 467-472 LID - 10.1016/j.ajur.2021.06.001 [doi] AB - OBJECTIVE: Vesical Imaging Reporting and Data System (VIRADS) score was developed to standardize the reporting and staging of bladder tumors on pre-operative multiparametric magnetic resonance imaging. It helps in avoiding unnecessary repeat transurethral resection of bladder tumor in high-risk non-muscle-invasive bladder cancer patients. This study was done to determine the validity of VIRADS score prospectively for the diagnosis of muscle-invasive bladder cancer. METHODS: This study was conducted from March 2019 to March 2020 at Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. Patients admitted with the provisional diagnosis of bladder tumor were included as participants. All these patients underwent a 3 Tesla mpMRI to obtain a VIRADS score before they underwent transurethral resection of bladder tumor and these data were analyzed to evaluate the correlation of pre-operative VIRADS score with muscle invasiveness of the tumor in final biopsy report. RESULTS: A cut-off of VIRADS >/=4 for prediction of detrusor muscle invasion yielded a sensitivity of 79.4%, specificity of 94.2%, positive predictive value of 90.0%, negative predictive value of 87.5%, and diagnostic accuracy of 86.4%. A cut off of VIRADS >/=3 for prediction of detrusor muscle invasion yielded a sensitivity of 91.2%, specificity of 78.8%, positive predictive value of 73.8%, negative predictive value of 93.2%, and accuracy of 83.7%. The receiver operating curve showed the area under the curve to be 0.922 (95% confidence interval: 0.862-0.983). CONCLUSION: VIRADS score appears to be an excellent and effective pre-operative radiological tool for the prediction of detrusor muscle invasion in bladder cancer. CI - (c) 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. FAU - Ghanshyam, Kumawat AU - Ghanshyam K AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Nachiket, Vyas AU - Nachiket V AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Govind, Sharma AU - Govind S AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Shivam, Priyadarshi AU - Shivam P AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Sahay, Gupta Bhagwan AU - Sahay GB AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Mohit, Singla AU - Mohit S AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Ashok, Kumar AU - Ashok K AD - Department of Urology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India. LA - eng PT - Journal Article DEP - 20210607 PL - Singapore TA - Asian J Urol JT - Asian journal of urology JID - 101699720 PMC - PMC9643153 OTO - NOTNLM OT - Bladder tumor OT - Detrusor invasion OT - Multiparametric magnetic resonance imaging OT - Vesical Imaging Reporting and Data System COIS- The authors declare no conflict of interest. EDAT- 2022/11/17 06:00 MHDA- 2022/11/17 06:01 PMCR- 2021/06/07 CRDT- 2022/11/16 02:55 PHST- 2020/05/23 00:00 [received] PHST- 2020/07/31 00:00 [revised] PHST- 2020/09/08 00:00 [accepted] PHST- 2022/11/16 02:55 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/17 06:01 [medline] PHST- 2021/06/07 00:00 [pmc-release] AID - S2214-3882(21)00052-7 [pii] AID - 10.1016/j.ajur.2021.06.001 [doi] PST - ppublish SO - Asian J Urol. 2022 Oct;9(4):467-472. doi: 10.1016/j.ajur.2021.06.001. Epub 2021 Jun 7. PMID- 36381153 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 75 IP - 3 DP - 2022 TI - Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer. PG - 240-247 LID - 10.5173/ceju.2022.0053 [doi] AB - INTRODUCTION: Non-urothelial variant histology (VH), non-muscle invasive bladder cancer (NMIBC) has received little attention in contemporary urologic literature. Specifically, the effect of female sex on stage at presentation, as well as on cancer-specific mortality (CSM) have not been previously examined in VH NMIBC. Our aim was to test the effect of female sex on stage at presentation and CSM in VH NMIBC. MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016), we identified patients aged >/=18 years, with histologically confirmed VH NMIBC. Logistic regression models addressed T1 stage at diagnosis after multivariable adjustments for tumor grade, age and race/ethnicity. Before Kaplan-Meier plots and Cox regression analyses, propensity score matched adjusting for histological variants, T-stage, tumor grade, age and race/ethnicity was performed. RESULTS: Overall, 2,205 VH NMIBC patients were identified. Of those, 28% (n = 607) were female. Females were older (77 vs 74 years, p <0.001) and more frequently harbored T1 stage (55 vs 45%, p <0.001). Female sex independently predicted T1 stage (odds ratio [OR] = 1.66, 95% Confidence Interval [CI] = 1.35-2.03, p <0.001). Female sex also exhibited higher CSM, after matching for all assessable variables, including stage (hazard ratio [HR] = 1.91, 95% CI = 1.45-2.54, p <0.001). CONCLUSIONS: In VH NMIBC, female sex is an indicator of higher rate of T1 stage and, fully independently of stage, female sex also results in higher CSM. CI - Copyright by Polish Urological Association. FAU - Flammia, Rocco Simone AU - Flammia RS AD - Department of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, Rome, Italy. AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Chierigo, Francesco AU - Chierigo F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Wurnschimmel, Christoph AU - Wurnschimmel C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Wenzel, Mike AU - Wenzel M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Horlemann, Benedikt AU - Horlemann B AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Tian, Zhen AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Borghesi, Marco AU - Borghesi M AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Leonardo, Costantino AU - Leonardo C AD - Department of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Tilki, Derya AU - Tilki D AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. AD - Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Weill Cornell Medical College, New York, New York, USA. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Anceschi, Umberto AU - Anceschi U AD - Department of Surgical Sciences, Sapienza Rome University, Rome, Italy. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Terrone, Carlo AU - Terrone C AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20220718 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC9628729 OTO - NOTNLM OT - Epidemiology OT - Surveillance OT - adenocarcinoma OT - and End Results OT - neuroendocrine carcinoma OT - non-muscle invasive bladder cancer OT - squamous cell carcinoma OT - variant histology COIS- The authors declare no conflicts of interest. EDAT- 2022/11/17 06:00 MHDA- 2022/11/17 06:01 PMCR- 2022/01/01 CRDT- 2022/11/16 02:48 PHST- 2022/03/05 00:00 [received] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/04 00:00 [accepted] PHST- 2022/11/16 02:48 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/17 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 0053 [pii] AID - 10.5173/ceju.2022.0053 [doi] PST - ppublish SO - Cent European J Urol. 2022;75(3):240-247. doi: 10.5173/ceju.2022.0053. Epub 2022 Jul 18. PMID- 36374405 OWN - NLM STAT- MEDLINE DCOM- 20230223 LR - 20230223 IS - 1699-3055 (Electronic) IS - 1699-048X (Print) IS - 1699-048X (Linking) VI - 25 IP - 3 DP - 2023 Mar TI - The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma. PG - 830-840 LID - 10.1007/s12094-022-02994-6 [doi] AB - PURPOSE: The mutation of p53 is considered a pivotal step in bladder cancer pathogenesis. Recently, distinct interactions between p53 and CDK9, a transcription regulator, have been described. In this work, we explored the prognostic role of p53 expression and evaluated its associations with CDK9 in urothelial carcinoma. MATERIALS AND METHODS: The research group consisted of 67 bladder cancer samples and 32 normal urothelial mucosa samples. All specimens were analyzed using ImageJ and the IHC profiler plugin. To validate the results, 406 cases from The Cancer Genome Atlas database were analyzed. RESULTS: P53 and CDK9 are overexpressed in urothelial cancer tissues when compared to normal urothelial tissues (p < 0.05). High p53 expression was observed in metastatic tumors and tumors with high CDK9 expression (p < 0,05). High p53 expression was predictive for shorter survival in patients with non-muscle-invasive bladder cancer (HR = 0.107 [0.012-0.96]; p = 0.046) but did not correlate with prognosis in the muscle-invasive group. In high CDK9 cancers, high p53 expression correlated with the occurrence of high-grade and muscle-invasive tumors (p < 0.05). CONCLUSION: High expression of p53 correlates with unfavorable clinical features of bladder cancer. CDK9 is associated with the expression of p53, possibly through interactions with p53 inhibitors. Since the blockade of CDK9 in other malignancies reactivates wild-p53 activity, confirming the crosstalk between p53 and CDK9 in bladder cancer may be another step to explain the mechanism of tumor progression in its early stages. CI - (c) 2022. The Author(s). FAU - Borowczak, Jedrzej AU - Borowczak J AUID- ORCID: 0000-0001-9873-3285 AD - Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, University Hospital No. 2 in Bydgoszcz, Ujejskiego 75, 85-168, Bydgoszcz, Poland. jedrzej.borowczak@gmail.com. FAU - Szczerbowski, Krzysztof AU - Szczerbowski K AD - Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, University Hospital No. 2 in Bydgoszcz, Ujejskiego 75, 85-168, Bydgoszcz, Poland. FAU - Maniewski, Mateusz AU - Maniewski M AD - Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, University Hospital No. 2 in Bydgoszcz, Ujejskiego 75, 85-168, Bydgoszcz, Poland. FAU - Zdrenka, Marek AU - Zdrenka M AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. FAU - Slupski, Piotr AU - Slupski P AD - Department of Urology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, Bydgoszcz, Poland. FAU - Andrusewicz, Hanna AU - Andrusewicz H AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. FAU - Lysik-Miskurka, Joanna AU - Lysik-Miskurka J AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. FAU - Rutkiewicz, Paula AU - Rutkiewicz P AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, Bydgoszcz, Poland. FAU - Bodnar, Magdalena AU - Bodnar M AD - Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, University Hospital No. 2 in Bydgoszcz, Ujejskiego 75, 85-168, Bydgoszcz, Poland. AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, Bydgoszcz, Poland. FAU - Szylberg, Lukasz AU - Szylberg L AD - Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, University Hospital No. 2 in Bydgoszcz, Ujejskiego 75, 85-168, Bydgoszcz, Poland. AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, Bydgoszcz, Poland. LA - eng PT - Journal Article DEP - 20221114 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.11.22 (CDK9 protein, human) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 9) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell MH - *Urinary Bladder Neoplasms/pathology MH - Prognosis MH - Tumor Suppressor Protein p53/metabolism MH - Biomarkers, Tumor/genetics/metabolism MH - Cyclin-Dependent Kinase 9/metabolism PMC - PMC9941229 OTO - NOTNLM OT - Bladder cancer OT - CDK9 OT - Expression OT - P53 OT - Prognosis COIS- The authors have no conflicts of interest to declare that are relevant to the content of this article. EDAT- 2022/11/15 06:00 MHDA- 2023/02/25 06:00 PMCR- 2022/11/14 CRDT- 2022/11/14 11:31 PHST- 2022/09/23 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2022/11/14 11:31 [entrez] PHST- 2022/11/14 00:00 [pmc-release] AID - 10.1007/s12094-022-02994-6 [pii] AID - 2994 [pii] AID - 10.1007/s12094-022-02994-6 [doi] PST - ppublish SO - Clin Transl Oncol. 2023 Mar;25(3):830-840. doi: 10.1007/s12094-022-02994-6. Epub 2022 Nov 14. PMID- 36367586 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 12 DP - 2022 Dec TI - Systematic review on oncologic outcomes on adjuvant endovesical treatment for non-muscle invasive bladder cancer in patients with solid organ transplant. PG - 2901-2910 LID - 10.1007/s00345-022-04188-9 [doi] AB - PURPOSE: Urothelial carcinoma has a higher incidence in renal transplanted patients according to several registries (relative risk x 3), and the global prognosis is inferior to the general population. The potential impact of immunosuppressive therapy on the feasibility, efficacy, and complications of endovesical treatment, especially Bacillus Calmette-Guerin, has a low level of evidence. We performed a systematic review that aimed to assess the morbidity and oncological outcomes of adjuvant endovesical treatment in solid organ transplanted patients. METHODS: Medline was searched up to December 2021 for all relevant publications reporting oncologic outcomes of endovesical treatment in solid organ transplanted patients with NMIBC. Data were synthesized in light of methodological and clinical heterogeneity. RESULTS: Twenty-three retrospective studies enrolling 238 patients were included: 206 (96%) kidney transplants, 5 (2%) liver transplants, and 2 (1%) heart transplants. Concerning staging: 25% were pTa, 62% were pT1, and 22% were CIS. 140/238 (59%) patients did not receive adjuvant treatment, 50/238 (21%) received mitomycin C, 4/238 (2%) received epirubicin, and 46/238 (19%) received BCG. Disease-free survival reached 35% with TURBT only vs. 47% with endovesical treatment (Chi-square test p = 0.08 OR 1.2 [0.98-1.53]). The complication rate of endovesical treatment was 12% and was all minor (Clavien-Dindo I). CONCLUSION: In solid organ transplanted patients under immunosuppressive treatment, both endovesical chemotherapy and BCG are safe, but the level of evidence concerning efficacy in comparison with the general population is low. According to these results, adjuvant treatment should be proposed for NMIC in transplanted patients as in the general population. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Simonet, Matthieu AU - Simonet M AD - Department of Urology and Renal Transplantation, Urology, University Hospital La Conception, Aix-Marseille University, Marseille, France. FAU - Dominguez Gutierrez, Ana AU - Dominguez Gutierrez A AD - Urology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Territo, Angelo AU - Territo A AD - Oncology and Renal Transplant Units, Puigvert's Foundation, Barcelona, Spain. FAU - Prudhomme, Thomas AU - Prudhomme T AD - Department of Urology, Rangueil University Hospital, Toulouse, France. FAU - Campi, Ricardo AU - Campi R AD - Department of Urology, Florence University Hospital, Florence, Italy. FAU - Andras, Iulia AU - Andras I AD - Department of Urology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Baboudjian, Michael AU - Baboudjian M AD - Department of Urology and Renal Transplantation, Urology, University Hospital La Conception, Aix-Marseille University, Marseille, France. FAU - Hevia, Vital AU - Hevia V AD - Urology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Boissier, Romain AU - Boissier R AUID- ORCID: 0000-0001-6428-0273 AD - Department of Urology and Renal Transplantation, Urology, University Hospital La Conception, Aix-Marseille University, Marseille, France. romain.boissier@ap-hm.fr. AD - Department of Urology and Kidney Transplantation, Aix-Marseille University, Conception Academic Hospital, APHM147 Boulevard Baille, 13005, Marseille, France. romain.boissier@ap-hm.fr. CN - Young Academic Urologist (YAU) E. A. U. Group of Renal Transplantation LA - eng PT - Journal Article PT - Systematic Review DEP - 20221111 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell MH - *Urinary Bladder Neoplasms/pathology MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - Administration, Intravesical MH - Adjuvants, Immunologic MH - *Organ Transplantation MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Chemotherapy OT - Mitomycin OT - Transplanted patients EDAT- 2022/11/12 06:00 MHDA- 2022/12/03 06:00 CRDT- 2022/11/11 11:14 PHST- 2022/04/10 00:00 [received] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/11 11:14 [entrez] AID - 10.1007/s00345-022-04188-9 [pii] AID - 10.1007/s00345-022-04188-9 [doi] PST - ppublish SO - World J Urol. 2022 Dec;40(12):2901-2910. doi: 10.1007/s00345-022-04188-9. Epub 2022 Nov 11. PMID- 36358870 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 21 DP - 2022 Nov 6 TI - Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee. LID - 10.3390/cancers14215452 [doi] LID - 5452 AB - Upper urinary tract urothelial carcinoma (UTUC) is an uncommon disease and its gold-standard treatment is radical nephroureterectomy (RNU). Distal ureterectomy (DU) might be an alternative for tumors of the distal ureter but its indications remain unclear. Here, we aimed to evaluate the oncological outcomes of DU for UTUC of the pelvic ureter. We performed a multicenter retrospective analysis of patients with UTUC who underwent DU. The primary endpoint was 5-year cancer-specific survival (CSS), followed by overall survival (OS), intravesical recurrence-free (IVR) and homolateral urinary tract recurrence-free (HUR) survivals as secondary endpoints. Univariate and multivariate Cox regressions were performed to assess factors associated with outcomes. 155 patients were included, 91% of which were high-risk. 5-year CSS was 84.4%, OS was 71.9%, IVR-free survival was 43.6% and HUR-free survival was 74.4%. Multifocality, high grade and tumor size were the most significant predictors of survival endpoints. Of note, neither hydronephrosis nor pre-operative diagnostic ureteroscopy/JJ stent were associated with any of the endpoints. Perioperative morbidity was minimal. In conclusion, DU stands as a possible alternative to RNU for UTUC of the pelvic ureter. Close monitoring is mandatory due to the high risk of recurrence in the remaining urinary tract. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, APHP, Hopital Saint Louis, 75010 Paris, France. AD - Inserm, CEA, HIPI, Universite Paris Cite, 75475 Paris, France. FAU - Vaillant, Victoire AU - Vaillant V AD - Department of Urology, APHP, Hopital Henri Mondor, Universite Paris-Est Creteil, 94000 Creteil, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, CHU de Toulouse, UPS, Universite de Toulouse, 31000 Toulouse, France. FAU - Levy, Stephan AU - Levy S AD - Department of Urology, CHU de Toulouse, UPS, Universite de Toulouse, 31000 Toulouse, France. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology-UROSUD, La Croix du Sud Hospital, 31130 Quint-Fonsegrives, France. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, APHP, Hopital Cochin, Universite Paris Cite, 75014 Paris, France. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, APHP, Hopital Cochin, Universite Paris Cite, 75014 Paris, France. FAU - De La Taille, Alexandre AU - De La Taille A AD - Department of Urology, APHP, Hopital Henri Mondor, Universite Paris-Est Creteil, 94000 Creteil, France. FAU - Lebacle, Cedric AU - Lebacle C AD - Department of Urology, APHP, Hopital Bicetre, Universite Paris Sud-Saclay, 94270 Le Kremlin-Bicetre, France. FAU - Panis, Adrien AU - Panis A AD - Department of Urology, APHP, Hopital Bicetre, Universite Paris Sud-Saclay, 94270 Le Kremlin-Bicetre, France. FAU - Traxer, Olivier AU - Traxer O AD - GRC 10 Lithiase Urinaire, Department of Urology, APHP, Tenon Hospital, Sorbonne University, 75020 Paris, France. FAU - Leon, Priscilla AU - Leon P AD - Department of Urology, clinique Pasteur, 17200 Royan, France. FAU - Hulin, Maud AU - Hulin M AD - Department of Urology, clinique Pasteur, 17200 Royan, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, APHP, Hopital Bichat Claude-Bernard, Universite Paris Cite, 75014 Paris, France. FAU - Audenet, Francois AU - Audenet F AUID- ORCID: 0000-0001-5722-2075 AD - Department of Urology, APHP, Hopital Europeen Georges Pompidou, Universite Paris Cite, 75014 Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - GRC 5 Predictive Onco-Urology, Department of Urology, APHP, Pitie Salpetriere Hospital, Sorbonne University, 75013 Paris, France. FAU - Loriot, Yohann AU - Loriot Y AD - Department of Cancer Medicine, INSERM U981, Gustave Roussy, Universite Paris-Saclay, 94805 Villejuif, France. FAU - Allory, Yves AU - Allory Y AUID- ORCID: 0000-0002-5526-077X AD - Department of Pathology, Curie Institute, University of Paris-Saclay-UVSQ, 92210 Saint-Cloud, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Urology, Department of Urology, APHP, Pitie Salpetriere Hospital, Sorbonne University, 75013 Paris, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Hopital Foch, University of Paris-Saclay-UVSQ, 92150 Suresnes, France. CN - French CCAFU Bladder Cancer Group LA - eng PT - Journal Article DEP - 20221106 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9656759 OTO - NOTNLM OT - cancer OT - cancer-specific survival OT - distal ureterectomy OT - high risk OT - intravesical recurrence-free survival OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/11/06 CRDT- 2022/11/11 01:07 PHST- 2022/09/27 00:00 [received] PHST- 2022/10/19 00:00 [revised] PHST- 2022/10/27 00:00 [accepted] PHST- 2022/11/11 01:07 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/11/06 00:00 [pmc-release] AID - cancers14215452 [pii] AID - cancers-14-05452 [pii] AID - 10.3390/cancers14215452 [doi] PST - epublish SO - Cancers (Basel). 2022 Nov 6;14(21):5452. doi: 10.3390/cancers14215452. PMID- 36358849 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240929 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 21 DP - 2022 Nov 4 TI - Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. LID - 10.3390/cancers14215431 [doi] LID - 5431 AB - This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is still <1 year and there is an urgent need for alternative therapies. The advent of next-generation sequencing has allowed widespread comprehensive molecular characterization of urothelial tumors and, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis such as FGFR inhibition, Nectin-4, Trop-2, and HER2 targeting. As these therapies are demonstrated to be effective in the second-line setting, they will be advanced in the treatment paradigm to localized and even non-muscle invasive disease. FAU - Katims, Andrew B AU - Katims AB AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Reisz, Peter A AU - Reisz PA AUID- ORCID: 0000-0002-1483-8133 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Nogueira, Lucas AU - Nogueira L AUID- ORCID: 0000-0002-3612-6524 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Truong, Hong AU - Truong H AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Lenis, Andrew T AU - Lenis AT AUID- ORCID: 0000-0001-9413-7793 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Kim, Kwanghee AU - Kim K AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Coleman, Jonathan A AU - Coleman JA AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - T32 CA082088/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20221104 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9655342 OTO - NOTNLM OT - antibody-drug conjugates OT - antineoplastic therapy OT - immunotherapy OT - metastatic urothelial carcinoma OT - molecular targeted therapy OT - monoclonal antibodies OT - next-generation sequencing OT - tumor biomarkers COIS- The authors declare no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/11/04 CRDT- 2022/11/11 01:07 PHST- 2022/10/19 00:00 [received] PHST- 2022/11/01 00:00 [revised] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/11 01:07 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/11/04 00:00 [pmc-release] AID - cancers14215431 [pii] AID - cancers-14-05431 [pii] AID - 10.3390/cancers14215431 [doi] PST - epublish SO - Cancers (Basel). 2022 Nov 4;14(21):5431. doi: 10.3390/cancers14215431. PMID- 36358715 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 21 DP - 2022 Oct 27 TI - The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy. LID - 10.3390/cancers14215295 [doi] LID - 5295 AB - Interferon gamma (IFNgamma) is central to the inflammatory immune response, such as that entrained by BCG immunotherapy for bladder cancer. However, immune-mediated tumour cell killing is subject to modulation by immunoinhibitory "checkpoint" receptors such as PD-L1. We investigated the effects of IFNgamma on barrier-forming in vitro-differentiated normal human urothelium using mRNA-sequencing, and showed canonical upregulation of MHC class I/II and de novo expression of the T cell tropic CXCL9-11 chemokines. Normal urothelium constitutively expressed immunoinhibitory B7 family member VSIR (VISTA), while CD274 (PD-L1) expression was induced/upregulated by IFNgamma. We generated a urothelial IFNgamma response gene signature. When applied to the unsupervised clustering of non-muscle-invasive bladder cancers, the IFNgamma-signature predicted longer recurrence-free survival. In muscle-invasive cancers, the IFNgamma-signature split the basal/squamous consensus subtype, with significantly worse overall survival when weak or absent. This study offers novel insights into strategies to enhance immunotherapy via the IFNgamma and VISTA/PD-L1 nexus. FAU - Baker, Simon C AU - Baker SC AUID- ORCID: 0000-0002-2755-6012 AD - Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK. FAU - Mason, Andrew S AU - Mason AS AUID- ORCID: 0000-0002-8222-3974 AD - Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK. FAU - Slip, Raphael G AU - Slip RG AUID- ORCID: 0000-0002-5218-2251 AD - Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK. FAU - Eriksson, Pontus AU - Eriksson P AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, 22184 Lund, Sweden. FAU - Sjodahl, Gottfrid AU - Sjodahl G AUID- ORCID: 0000-0002-7869-0473 AD - Department of Translational Medicine, Lund University, 20502 Malmo, Sweden. FAU - Trejdosiewicz, Ludwik K AU - Trejdosiewicz LK AD - Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK. FAU - Southgate, Jennifer AU - Southgate J AUID- ORCID: 0000-0002-0135-480X AD - Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK. LA - eng GR - NA/York Against Cancer/ PT - Journal Article DEP - 20221027 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9654607 OTO - NOTNLM OT - BCG OT - PD-L1 OT - VISTA OT - bladder cancer OT - immune checkpoint OT - immunotherapy OT - interferon gamma OT - urothelium COIS- The authors declare no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/10/27 CRDT- 2022/11/11 01:06 PHST- 2022/08/24 00:00 [received] PHST- 2022/10/04 00:00 [revised] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/11 01:06 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/10/27 00:00 [pmc-release] AID - cancers14215295 [pii] AID - cancers-14-05295 [pii] AID - 10.3390/cancers14215295 [doi] PST - epublish SO - Cancers (Basel). 2022 Oct 27;14(21):5295. doi: 10.3390/cancers14215295. PMID- 36353066 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221111 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 43 DP - 2022 Sep TI - Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. PG - 14-21 LID - 10.1016/j.euros.2022.06.009 [doi] AB - BACKGROUND: No biomarkers are recommended for patients undergoing radiation-based therapy (RT) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: We aim to evaluate the predictive role of programmed death-ligand 1 (PD-L1) expression on the oncological outcomes of patients treated with RT for MIBC. DESIGN SETTING AND PARTICIPANTS: A single-center retrospective analysis of tumor specimens collected through transurethral resection (TURBT) from 104 MIBC patients, implemented in a tissue microarray and stained with the SP263 PD-L1 clone (Ventana Medical Systems, Tucson, AZ, USA), was conducted. Two reviewers measured the PD-L1 H-score for tumor and immune cells. INTERVENTION: RT (maximal TURBT followed by radiation and concurrent chemotherapy when eligible). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic and Cox regression models were used to predict 3-mo complete response (CR) and overall survival (OS) after RT, respectively. RESULTS AND LIMITATIONS: A total of 88 (85%) patients had cT2 disease and 39 (37.5%) had high immune cell PD-L1 expression. A CR was achieved in 68 (65%) patients. On the multivariable analysis (MVA), a higher clinical stage (p = 0.02) and a low immune cell PD-L1 H-score (p = 0.02) were associated with a decreased CR after RT. The median time to death was 43 mo (95% confidence interval 20-66). On Cox MVA, a high immune cell PD-L1 H-score (p = 0.0017) was associated with better OS, independently of performance status (p = 0.0005) or tumor stage (p = 0.0013). A high tumor cell PD-L1 H-score was not an independent predictor of CR or OS. Limitations of the study include the retrospective design. CONCLUSIONS: MIBC patients with high PD-L1 expression on immune cells appear to have better oncological outcomes following RT. Our results may aid in patient stratification for future clinical trial design. PATIENT SUMMARY: In this report, we evaluated the role of programmed death-ligand 1 (PD-L1) expressed on tumor and immune cells in the tumor microenvironment for patients treated with a bladder-sparing regimen. We found that PD-L1 overexpression on immune cells is able to predict a better response to radiation-based therapy. CI - (c) 2022 The Author(s). FAU - Marcq, Gautier AU - Marcq G AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. AD - Urology department, Claude Huriez Hospital, CHU Lille, Lille, France. AD - CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France. FAU - Evaristo, Gertruda AU - Evaristo G AD - Division of Pathology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Kool, Ronald AU - Kool R AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Shinde-Jadhav, Surashri AU - Shinde-Jadhav S AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Skowronski, Rodrigo AU - Skowronski R AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Mansure, Jose Joao AU - Mansure JJ AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Souhami, Luis AU - Souhami L AD - Division of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Cury, Fabio AU - Cury F AD - Division of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Brimo, Fadi AU - Brimo F AD - Division of Pathology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20220713 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC9638761 OTO - NOTNLM OT - Bladder-sparing approach OT - Muscle-invasive bladder cancer OT - Programmed Death-Ligand 1 OT - Radiation-based therapy OT - Tumor microenvironment EDAT- 2022/11/11 06:00 MHDA- 2022/11/11 06:01 PMCR- 2022/07/13 CRDT- 2022/11/10 02:07 PHST- 2022/06/30 00:00 [accepted] PHST- 2022/11/10 02:07 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/11 06:01 [medline] PHST- 2022/07/13 00:00 [pmc-release] AID - S2666-1683(22)00725-X [pii] AID - 10.1016/j.euros.2022.06.009 [doi] PST - epublish SO - Eur Urol Open Sci. 2022 Jul 13;43:14-21. doi: 10.1016/j.euros.2022.06.009. eCollection 2022 Sep. PMID- 36352437 OWN - NLM STAT- MEDLINE DCOM- 20221111 LR - 20221116 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Nov 9 TI - Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study. PG - 175 LID - 10.1186/s12894-022-01112-6 [doi] LID - 175 AB - PURPOSE: This study aimed to evaluate the trend of adjuvant chemotherapy (AC) and neoadjuvant chemotherapy (NAC) in patients who underwent radical nephroureterectomy with bladder cuff excision (NUx) for upper tract urothelial carcinoma (UTUC) to compare the perioperative outcomes and overall survival (OS) between AC and NAC using nationwide population-based data. MATERIALS AND METHODS: We collected data on patients diagnosed with UTUC and treated with NUx between 2004 and 2016 using the National Health Insurance Service database, and evaluated the overall treatment trends. The AC and NAC groups were propensity score-matched. Cox proportional hazard and Kaplan-Meier analyses were used to assess survival. RESULTS: Of the 8,705 enrolled patients, 6,627 underwent NUx only, 94 underwent NAC, and 1,984 underwent AC. The rate of NUx without perioperative chemotherapy increased from 70.8 to 78.2% (R(2) = 0.632; p < 0.001). The rates of dialysis (p = 0.398), TUR-BT (p = 1.000), and radiotherapy (p = 0.497) after NUx were similar. In the Kaplan-Meier curve, the NAC and AC groups showed no significant difference (p = 0.480). In multivariate analysis, treatment with AC or NAC was not associated with OS (hazard ratio 0.83, 95% confidence interval 0.49-1.40, p = 0.477). CONCLUSION: The use of NUx without perioperative chemotherapy has tended to increase in South Korea. Dialysis, TUR-BT, and radiotherapy rates after NUx were similar between the NAC and AC groups. There was no significant difference in OS between the NAC and AC groups. Proper perioperative chemotherapy according to patient and tumor conditions should be determined by obtaining more evidence of UTUC. CI - (c) 2022. The Author(s). FAU - Tae, Jong Hyun AU - Tae JH AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. FAU - Ha, Moon Soo AU - Ha MS AD - Department of Urology, Hyundae General Hospital, Chung-Ang University College of Medicine, Gyeonggi-do, Republic of Korea. FAU - Chi, Byung Hoon AU - Chi BH AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. FAU - Chang, In Ho AU - Chang IH AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. FAU - Kim, Tae-Hyoung AU - Kim TH AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. FAU - Myung, Soon Chul AU - Myung SC AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. FAU - Nguyen, Tuan Thanh AU - Nguyen TT AD - Department of Urology, Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi, Minh City, Vietnam. FAU - Kim, Myoungsuk AU - Kim M AD - Data Science Team, Evidnet. Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea. FAU - Lee, Kyung-Eun AU - Lee KE AD - Data Science Team, Evidnet. Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea. FAU - Kim, Yuwon AU - Kim Y AD - Data Science Team, Evidnet. Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea. FAU - Woo, Hyun-Ki AU - Woo HK AD - Data Science Team, Evidnet. Co., Ltd, Seongnam, Gyeonggi-do, Republic of Korea. FAU - Kyoung, Dae-Sung AU - Kyoung DS AD - Data Science Team, Hanmi Pharm. Co., Ltd, Songpa-gu, Seoul, Republic of Korea. FAU - Kim, Hasung AU - Kim H AD - Data Science Team, Hanmi Pharm. Co., Ltd, Songpa-gu, Seoul, Republic of Korea. FAU - Choi, Se Young AU - Choi SY AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, 06973, Seoul, Republic of Korea. urosyc@cau.ac.kr. LA - eng GR - 2022R1A2C2008207/National Research Foundation of Korea/ PT - Journal Article DEP - 20221109 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Neoadjuvant Therapy MH - *Urinary Bladder Neoplasms/surgery MH - Cohort Studies MH - Chemotherapy, Adjuvant MH - Retrospective Studies PMC - PMC9644507 OTO - NOTNLM OT - Chemotherapy OT - Drug therapy OT - Population OT - Survival OT - Ureteral neoplasms COIS- The authors declare no conflicts of interest. EDAT- 2022/11/11 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/11/09 CRDT- 2022/11/10 00:08 PHST- 2022/04/21 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2022/11/10 00:08 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/11/09 00:00 [pmc-release] AID - 10.1186/s12894-022-01112-6 [pii] AID - 1112 [pii] AID - 10.1186/s12894-022-01112-6 [doi] PST - epublish SO - BMC Urol. 2022 Nov 9;22(1):175. doi: 10.1186/s12894-022-01112-6. PMID- 36352401 OWN - NLM STAT- MEDLINE DCOM- 20221111 LR - 20221116 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Nov 9 TI - CALN1 hypomethylation as a biomarker for high-risk bladder cancer. PG - 176 LID - 10.1186/s12894-022-01136-y [doi] LID - 176 AB - BACKGROUND: DNA methylation in cancer is considered a diagnostic and predictive biomarker. We investigated the usefulness of the methylation status of CALN1 as a biomarker for bladder cancer using methylation-sensitive restriction enzyme (MSRE)-quantitative polymerase chain reaction (qPCR). METHODS: Eighty-two bladder cancer fresh samples were collected via transurethral resection of bladder tumors. Genomic DNA was extracted from the samples, and MSRE-qPCR was performed to determine the CALN1 methylation percentage. Reverse transcription-qPCR was performed to assess the correlation between CALN1 methylation and mRNA expression. The association between CALN1 methylation percentage and clinicopathological variables of all cases and intravesical recurrence of non-muscle-invasive bladder cancer (non-MIBC) cases were analyzed. RESULTS: Of the 82 patients, nine had MIBC and 71 had non-MIBC who had not undergone total cystectomy. The median CALN1 methylation percentage was 79.5% (interquartile range: 51.1-92.6%). The CALN1 methylation percentage had a negative relationship with CALN1 mRNA expression (Spearman's rho = - 0.563 and P = 0.012). Hypomethylation of CALN1 was associated with advanced tumor stage (P = 0.0007) and histologically high grade (P = 0.018). Furthermore, multivariate analysis revealed that CALN1 hypomethylation was an independent risk factor for intravesical recurrence in non-MIBC patients (hazard ratio 3.83, 95% confidence interval; 1.14-13.0, P = 0.031). CONCLUSION: Our findings suggest that CALN1 methylation percentage could be a useful molecular biomarker for bladder cancer. CI - (c) 2022. The Author(s). FAU - Takagi, Kimiaki AU - Takagi K AUID- ORCID: 0000-0003-2774-925X AD - Department of Urology, Daiyukai Daiichi Hospital, 1-6-12 Hagoromo, Ichinomiya, Aichi, 491-0025, Japan. ktakagi@daiyukai.or.jp. FAU - Naruse, Azumi AU - Naruse A AD - Department of Research and Development, Daiyukai Research Institute for Medical Science, 25 Azaicho, Ichinomiya, Aichi, 491-0113, Japan. FAU - Akita, Kazutoshi AU - Akita K AD - Department of Urology, Daiyukai Daiichi Hospital, 1-6-12 Hagoromo, Ichinomiya, Aichi, 491-0025, Japan. FAU - Muramatsu-Maekawa, Yuka AU - Muramatsu-Maekawa Y AD - Department of Urology, Daiyukai Daiichi Hospital, 1-6-12 Hagoromo, Ichinomiya, Aichi, 491-0025, Japan. FAU - Kawase, Kota AU - Kawase K AD - Department of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1193, Japan. FAU - Koie, Takuya AU - Koie T AD - Department of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1193, Japan. FAU - Horie, Masanobu AU - Horie M AD - Department of Urology, Daiyukai Daiichi Hospital, 1-6-12 Hagoromo, Ichinomiya, Aichi, 491-0025, Japan. FAU - Kikuchi, Arizumi AU - Kikuchi A AD - Department of Research and Development, Daiyukai Research Institute for Medical Science, 25 Azaicho, Ichinomiya, Aichi, 491-0113, Japan. LA - eng PT - Journal Article DEP - 20221109 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - DNA Methylation MH - Cystectomy MH - Biomarkers MH - RNA, Messenger MH - Neoplasm Invasiveness/genetics MH - Neoplasm Recurrence, Local/surgery PMC - PMC9647952 OTO - NOTNLM OT - Bladder cancer OT - CALN1 OT - Methylation analysis OT - Methylation-sensitive restriction enzyme (MSRE) OT - Molecular diagnosis technique OT - Transurethral resection of bladder tumor (TURBT) COIS- The authors declare that they have no competing interests. EDAT- 2022/11/11 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/11/09 CRDT- 2022/11/10 00:06 PHST- 2022/02/11 00:00 [received] PHST- 2022/10/29 00:00 [accepted] PHST- 2022/11/10 00:06 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/11/09 00:00 [pmc-release] AID - 10.1186/s12894-022-01136-y [pii] AID - 1136 [pii] AID - 10.1186/s12894-022-01136-y [doi] PST - epublish SO - BMC Urol. 2022 Nov 9;22(1):176. doi: 10.1186/s12894-022-01136-y. PMID- 36349904 OWN - NLM STAT- MEDLINE DCOM- 20230130 LR - 20230415 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy. PG - 63-69 LID - 10.1111/iju.15061 [doi] AB - OBJECTIVES: Technical limitations of ureteroscopic (URS) biopsy has been considered responsible for substantial upgrading rate in upper tract urothelial carcinoma (UTUC). However, the impact of tumor specific factors for upgrading remain uninvestigated. METHODS: Patients who underwent URS biopsy were included between 2005 and 2020 at 13 institutions. We assessed the prognostic impact of upgrading (low-grade on URS biopsy) versus same grade (high-grade on URS biopsy) for high-grade UTUC tumors on radical nephroureterectomy (RNU) specimens. RESULTS: This study included 371 patients, of whom 112 (30%) and 259 (70%) were biopsy-based low- and high-grade tumors, respectively. Median follow-up was 27.3 months. Patients with high-grade biopsy were more likely to harbor unfavorable pathologic features, such as lymphovascular invasion (p < 0.001) and positive lymph nodes (LNs; p < 0.001). On multivariable analyses adjusting for the established risk factors, high-grade biopsy was significantly associated with worse overall (hazard ratio [HR] 1.74; 95% confidence interval [CI], 1.10-2.75; p = 0.018), cancer-specific (HR 1.94; 95% CI, 1.07-3.52; p = 0.03), and recurrence-free survival (HR 1.80; 95% CI, 1.13-2.87; p = 0.013). In subgroup analyses of patients with pT2-T4 and/or positive LN, its significant association retained. Furthermore, high-grade biopsy in clinically non-muscle invasive disease significantly predicted upstaging to final pathologically advanced disease (>/=pT2) compared to low-grade biopsy. CONCLUSIONS: High tumor grade on URS biopsy is associated with features of biologically and clinically aggressive UTUC tumors. URS low-grade UTUC that becomes upgraded to high-grade might carry a better prognosis than high-grade UTUC on URS. Tumor specific factors are likely to be responsible for upgrading to high-grade on RNU. CI - (c) 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Grossman, Nico C AU - Grossman NC AUID- ORCID: 0000-0001-8698-6461 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Potretzke, Aaron M AU - Potretzke AM AUID- ORCID: 0000-0003-4619-1773 AD - Department of Urology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Ghoreifi, Alireza AU - Ghoreifi A AUID- ORCID: 0000-0002-7368-7240 AD - Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. FAU - Daneshmand, Sia AU - Daneshmand S AD - Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. FAU - Djaladat, Hooman AU - Djaladat H AD - Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York City, New York, USA. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Khene, Zine-Eddine AU - Khene ZE AD - Department of Urology, Hospital Pontchaillou, CHU Rennes, Rennes, France. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Hayakawa, Nozomi AU - Hayakawa N AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Fontana, Matteo AU - Fontana M AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Antonelli, Alessandro AU - Antonelli A AD - Urology Unit AUOI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy. FAU - van Doeveren, Thomas AU - van Doeveren T AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands. FAU - Steinbach, Christina AU - Steinbach C AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada. FAU - Araki, Motoo AU - Araki M AUID- ORCID: 0000-0002-3172-2482 AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Comperat, Eva AU - Comperat E AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Nasu, Yasutomo AU - Nasu Y AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, Weill Cornell Medical College, New York City, New York, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article DEP - 20221109 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Humans MH - Nephroureterectomy MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/surgery MH - Prognosis MH - Ureteroscopy MH - *Ureteral Neoplasms/surgery/pathology MH - Biopsy MH - Retrospective Studies PMC - PMC10098861 OTO - NOTNLM OT - biopsy grade OT - intratumor heterogeneity OT - survival OT - upgrading OT - upper tract urothelial carcinoma COIS- None declared. EDAT- 2022/11/10 06:00 MHDA- 2023/01/31 06:00 PMCR- 2023/04/13 CRDT- 2022/11/09 06:12 PHST- 2022/05/28 00:00 [received] PHST- 2022/09/15 00:00 [accepted] PHST- 2022/11/10 06:00 [pubmed] PHST- 2023/01/31 06:00 [medline] PHST- 2022/11/09 06:12 [entrez] PHST- 2023/04/13 00:00 [pmc-release] AID - IJU15061 [pii] AID - 10.1111/iju.15061 [doi] PST - ppublish SO - Int J Urol. 2023 Jan;30(1):63-69. doi: 10.1111/iju.15061. Epub 2022 Nov 9. PMID- 36330353 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 1687-8450 (Print) IS - 1687-8469 (Electronic) IS - 1687-8450 (Linking) VI - 2022 DP - 2022 TI - Survival Outcome of Partial Cystectomy versus Transurethral Bladder Tumor Resection in T1 High-Grade Bladder Cancer Patients: A Propensity Score Matching Study. PG - 3016725 LID - 10.1155/2022/3016725 [doi] LID - 3016725 AB - PURPOSE: Partial cystectomy was investigated as a method of bladder preservation with better disease outcomes than transurethral bladder tumor resection in T1 high-grade bladder cancer patients. Method and materials. The national Surveillance, Epidemiology, and End Results database (SEER) (2004-2015) were used to obtain patients diagnosed with T1 high-grade bladder cancer, and finally, 25263 patients were enrolled in our study. The Kaplan-Meier method with the log-rank test was performed to analyze the outcome of overall survival (OS) and cancer-specific survival (CSS) between patients undergoing partial cystectomy (PC), transurethral resection of bladder tumor (TURBT), or radical cystectomy (RC). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were also utilized in the study. RESULTS: Ultimately, 24635 patients were undergoing TURBT, while 190 and 438 patients were, respectively, assigned to the PC and RC groups. Compared with patients with TURBT, a tendency of a higher proportion of higher older and male patients was observed in the PC group. When matching with RC patients, patients in the PC group were commonly older and had bigger tumor sizes and single tumors (All P < 0.05). After 1 : 1 PSM, 190 patients with TURBT and 160 patients receiving PC were selected. In survival analysis, the patients in the PC group had a higher survival probability of both OS and CSS before and after PSM compared with those in the TURBT group. Meanwhile, no significant differences were observed between the RC and PC groups in OS and CSS analysis. Moreover, multivariable Cox regression showed that PC was a protective factor for overall mortality (ACM) and cancer-specific mortality (CSM) compared with TURBT in T1 high-grade patients (All P < 0.05). CONCLUSION: Patients undergoing partial cystectomy were shown to have a better outcome compared with those with transurethral bladder tumor resection in T1 high-grade bladder cancer patients. Partial cystectomy could be the more worthwhile choice for bladder preservation in T1 high-grade bladder cancer patients. CI - Copyright (c) 2022 Zheng Ping et al. FAU - Ping, Zheng AU - Ping Z AD - Department of Urology, Shangrao Municipal Hospital, Shangrao, Jiangxi, China. FAU - Zhan, Xiangpeng AU - Zhan X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. FAU - Zheng, Yunwei AU - Zheng Y AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. FAU - Jiang, Ming AU - Jiang M AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. FAU - Li, Yu AU - Li Y AUID- ORCID: 0000-0002-9728-0170 AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. FAU - Fu, Bin AU - Fu B AUID- ORCID: 0000-0001-6686-7561 AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. LA - eng PT - Journal Article DEP - 20221025 PL - Egypt TA - J Oncol JT - Journal of oncology JID - 101496537 PMC - PMC9626196 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/11/05 06:00 MHDA- 2022/11/05 06:01 PMCR- 2022/10/25 CRDT- 2022/11/04 02:34 PHST- 2022/07/21 00:00 [received] PHST- 2022/09/21 00:00 [revised] PHST- 2022/10/10 00:00 [accepted] PHST- 2022/11/04 02:34 [entrez] PHST- 2022/11/05 06:00 [pubmed] PHST- 2022/11/05 06:01 [medline] PHST- 2022/10/25 00:00 [pmc-release] AID - 10.1155/2022/3016725 [doi] PST - epublish SO - J Oncol. 2022 Oct 25;2022:3016725. doi: 10.1155/2022/3016725. eCollection 2022. PMID- 36322407 OWN - NLM STAT- MEDLINE DCOM- 20221104 LR - 20240906 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 13 DP - 2022 Nov 2 TI - Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer. PG - 1188-1200 LID - 10.18632/oncotarget.28302 [doi] AB - INTRODUCTION: Identifying neoadjuvant chemotherapy (NAC) response in patients with muscle invasive bladder cancer (MIBC) has had limited success based on clinicopathological features and molecular subtyping. Identification of chemotherapy responsive cohorts would facilitate delivery to those most likely to benefit. OBJECTIVE: Develop a molecular signature that can identify MIBC NAC responders (R) and non-responders (NR) using a cohort of known NAC response phenotypes, and better understand differences in molecular pathways and subtype classifications between NAC R and NR. MATERIALS AND METHODS: Presented are the messenger RNA (mRNA) and microRNA (miRNA) differential expression profiles from initial transurethral resection of bladder tumor (TURBT) specimens of a discovery cohort of MIBC patients consisting of 7 known NAC R and 11 NR, and a validation cohort consisting of 3 R and 5 NR. Pathological response at time of cystectomy after NAC was used to classify initial TURBT specimens as R (pT0) versus NR (>/=pT2). RNA and miRNA from FFPE blocks were sequenced using RNAseq and qPCR, respectively. RESULTS: The discovery cohort had 2309 genes, while the validation cohort had 602 genes and 13 miRNA differentially expressed between R and NR. Gene set enrichment analysis identified mitochondrial gene expression, DNA replication initiation, DNA unwinding in the R discovery cohort and positive regulation of vascular associated smooth muscle cell proliferation in the NR discovery cohort. Canonical correlation (CC) analysis was applied to differentiate R versus NR. 3 CCs (CC13, CC16, and CC17) had an AUC >0.65 in the discovery and validation dataset. Gene ontology enrichment showed CC13 as nucleoside triphosphate metabolic process, CC16 as cell cycle and cellular response to DNA damage, CC17 as DNA packaging complex. All patients were classified using established molecular subtypes: Baylor, UNC, CIT, Lund, MD Anderson, TCGA, and Consensus Class. The MD Anderson p53-like subtype, CIT MC4 subtype and Consensus Class stroma rich subtype had the strongest correlation with a NR phenotype, while no subtype had a strong correlation with the R phenotype. CONCLUSIONS: Our results identify molecular signatures that can be used to differentiate MIBC NAC R versus NR, salient molecular pathway differences, and highlight the utility of molecular subtyping in relation to NAC response. FAU - Murphy, Neal AU - Murphy N AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA. AD - Northwell Health Cancer Institute, Lake Success, NY 11042, USA. FAU - Shih, Andrew J AU - Shih AJ AD - Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA. FAU - Shah, Paras AU - Shah P AD - Mayo Clinic, Rochester, MN 55902, USA. FAU - Yaskiv, Oksana AU - Yaskiv O AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA. AD - Northwell Health Department of Pathology, Greenvale, NY 11548, USA. FAU - Khalili, Houman AU - Khalili H AD - Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA. FAU - Liew, Anthony AU - Liew A AD - Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA. FAU - Lee, Annette T AU - Lee AT AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA. AD - Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA. AD - These authors contributed equally to this work and share last authorship. FAU - Zhu, Xin-Hua AU - Zhu XH AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA. AD - Northwell Health Cancer Institute, Lake Success, NY 11042, USA. AD - These authors contributed equally to this work and share last authorship. LA - eng PT - Journal Article DEP - 20221102 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology MH - Neoadjuvant Therapy MH - Biomarkers, Tumor/genetics/metabolism MH - Cystectomy MH - *MicroRNAs/genetics/therapeutic use MH - Muscles/pathology MH - Neoplasm Invasiveness MH - Retrospective Studies PMC - PMC9629806 OTO - NOTNLM OT - canonical correlation analysis OT - gene expression OT - molecular subtyping OT - muscle invasive bladder cancer OT - neoadjuvant chemotherapy COIS- CONFLICTS OF INTEREST The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest. EDAT- 2022/11/03 06:00 MHDA- 2022/11/05 06:00 PMCR- 2022/01/01 CRDT- 2022/11/02 12:33 PHST- 2022/11/02 12:33 [entrez] PHST- 2022/11/03 06:00 [pubmed] PHST- 2022/11/05 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 28302 [pii] AID - 10.18632/oncotarget.28302 [doi] PST - epublish SO - Oncotarget. 2022 Nov 2;13:1188-1200. doi: 10.18632/oncotarget.28302. PMID- 36322290 OWN - NLM STAT- MEDLINE DCOM- 20230719 LR - 20260127 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 149 IP - 8 DP - 2023 Jul TI - OncoTherad((R)) is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. PG - 5025-5036 LID - 10.1007/s00432-022-04449-5 [doi] AB - INTODUCTION: Bladder cancer is the second most common urinary tract cancer. Above 70% of the occurrence of bladder cancer is superficial (pTis, pTa, and pT1), non-muscle invasive tumor (NMIBC), and the incidence of invasive disease is occasional. Treatments for NMIBC consist of transurethral resection (TUR) and subsequently intravesical immunotherapy with Bacillus Calmette-Guerin (BCG), intending to prevent tumor progression and decrease recurrence. However, 20-30% of these tumors have progression, and 70% have a recurrence after exclusive TUR treatment. The immunomodulator of biological response, OncoTherad((R)), is an attractive potential to revolutionize cancer therapy. In our previous studies with mice, the results showed that treatment with OncoTherad((R)) reduced 100% of tumor progression in NMIBC through the activation of Toll-Like Receptors' non-canonical pathway. MATERIALS AND METHODS: In the present study, 36 female C57Bl/6J mice were divided into 6 groups (n = 6/group): Control, Cancer, Cancer + BCG, Cancer + OncoTherad((R)) (MRB-CFI-1), Cancer + P14-16 and Cancer + CFI-1. NMIBC was chemically induced and the treatments were followed for 6 weeks. A week after the last dose of treatment, animals were euthanized, the bladder was collected and routinely processed for immunohistochemical analyses of RANK, RANKL, FOXP3, and PD-1/PD-L1, such as PD-1/PD-L1 western blotting. CONCLUSION: The immunohistochemical results showed that OncoTherad((R)) reduced RANK and RANKL immunoreactivities compared to the cancer group, which indicates a good prognosis. Immunohistochemical and western blotting analyses confirmed that OncoTherad((R)) modulated PD-1/PD-L1 immune checkpoint. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Reis, Ianny Brum AU - Reis IB AD - Department of Diagnosis and Surgery, School of Dentistry at Araraquara, Sao Paulo State University (UNESP), Rua Humaita, 1680-Centro, Araraquara, SP, CEP 14801-903, Brazil. iannybrumreis@yahoo.com.br. FAU - Tibo, Luiz Henrique Soares AU - Tibo LHS AD - Institute of Biology, Universidade Estadual de Campinas/UNICAMP, Campinas, SP, Brazil. FAU - de Souza, Bianca Ribeiro AU - de Souza BR AD - Institute of Biology, Universidade Estadual de Campinas/UNICAMP, Campinas, SP, Brazil. FAU - Duran, Nelson AU - Duran N AD - Institute of Biology, Universidade Estadual de Campinas/UNICAMP, Campinas, SP, Brazil. AD - Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), Santo Andre, SP, Brazil. FAU - Favaro, Wagner Jose AU - Favaro WJ AD - Institute of Biology, Universidade Estadual de Campinas/UNICAMP, Campinas, SP, Brazil. LA - eng GR - 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/ GR - 2018/10052-1/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/ GR - 552120/2011-1/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/ PT - Journal Article DEP - 20221102 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) RN - 0 (MRB-CFI-1) RN - 0 (Glycoproteins) RN - 0 (Phosphates) SB - IM MH - Female MH - Animals MH - Mice MH - Programmed Cell Death 1 Receptor MH - B7-H1 Antigen MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Administration, Intravesical MH - *Urinary Bladder Neoplasms/pathology MH - Adjuvants, Immunologic/therapeutic use MH - Signal Transduction MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness MH - Glycoproteins MH - Phosphates MH - Nanostructures PMC - PMC11796628 OTO - NOTNLM OT - Cancer treatment OT - FOXP3 OT - Immune checkpoint OT - Immune system OT - RANKL COIS- The authors report the non-existence of any kind of conflict of interests. EDAT- 2022/11/03 06:00 MHDA- 2023/07/19 06:42 PMCR- 2022/11/02 CRDT- 2022/11/02 12:19 PHST- 2022/09/05 00:00 [received] PHST- 2022/10/20 00:00 [accepted] PHST- 2023/07/19 06:42 [medline] PHST- 2022/11/03 06:00 [pubmed] PHST- 2022/11/02 12:19 [entrez] PHST- 2022/11/02 00:00 [pmc-release] AID - 10.1007/s00432-022-04449-5 [pii] AID - 4449 [pii] AID - 10.1007/s00432-022-04449-5 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 Jul;149(8):5025-5036. doi: 10.1007/s00432-022-04449-5. Epub 2022 Nov 2. PMID- 36320325 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221104 IS - 2162-2531 (Print) IS - 2162-2531 (Electronic) IS - 2162-2531 (Linking) VI - 30 DP - 2022 Dec 13 TI - Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. PG - 311-322 LID - 10.1016/j.omtn.2022.10.001 [doi] AB - Owing to its highly heterogeneous molecular landscape, bladder cancer (BlCa) is still characterized by non-personalized treatment and lifelong surveillance. Motivated by our previous findings on miR-143/145 value in disease prognosis, we have studied the underlying epigenetic regulation of the miR-143/145 cluster in BlCa. Expression and DNA methylation of miR-143/145 cluster were analyzed in our screening (n = 162) and The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA; n = 412) cohorts. Survival analysis was performed using tumor relapse and progression as clinical endpoints for non-muscle-invasive bladder cancer (NMIBC; TaT1), while disease progression and patients' death were used for muscle-invasive bladder cancer (MIBC; T2-T4). TCGA-BLCA served as validation cohort. Bootstrap analysis was carried out for internal validation, while decision curve analysis was used to evaluate clinical benefit. TCGA-BLCA and screening cohorts highlighted MIR145 core promoter as the pivotal, epigenetic regulatory region on cluster's expression. Lower methylation of MIR145 core promoter was associated with aggressive disease phenotype, higher risk for NMIBC short-term progression, and poor MIBC survival. MIR145 methylation-fitted multivariate models with established disease markers clearly enhanced patients' risk stratification and prediction of treatment outcome. MIR145 core promoter methylation was identified as a potent epigenetic regulator of miR-143/145 cluster, supporting modern personalized risk stratification and management in BlCa. CI - (c) 2022 The Authors. FAU - Pilala, Katerina-Marina AU - Pilala KM AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Panoutsopoulou, Konstantina AU - Panoutsopoulou K AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Barbarigos, Petros AU - Barbarigos P AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Kotronopoulos, Georgios AU - Kotronopoulos G AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece. AD - Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, 11527 Athens, Greece. LA - eng PT - Journal Article DEP - 20221007 PL - United States TA - Mol Ther Nucleic Acids JT - Molecular therapy. Nucleic acids JID - 101581621 PMC - PMC9614648 OTO - NOTNLM OT - DNA methylation OT - MT: Non-coding RNAs OT - bladder tumors OT - epigenetics OT - miRNA OT - prognosis OT - pyrosequencing OT - tumor progression OT - urothelial bladder carcinoma COIS- The authors declare no potential conflicts of interest. EDAT- 2022/11/03 06:00 MHDA- 2022/11/03 06:01 PMCR- 2022/10/07 CRDT- 2022/11/02 02:05 PHST- 2022/06/16 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2022/11/02 02:05 [entrez] PHST- 2022/11/03 06:00 [pubmed] PHST- 2022/11/03 06:01 [medline] PHST- 2022/10/07 00:00 [pmc-release] AID - S2162-2531(22)00267-0 [pii] AID - 10.1016/j.omtn.2022.10.001 [doi] PST - epublish SO - Mol Ther Nucleic Acids. 2022 Oct 7;30:311-322. doi: 10.1016/j.omtn.2022.10.001. eCollection 2022 Dec 13. PMID- 36319557 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20230605 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 47 IP - 5 DP - 2023 Jun TI - En-bloc transurethral resection vs. conventional transurethral resection for primary non-muscle invasive bladder cancer: A meta-analysis. PG - 309-316 LID - S2173-5786(22)00087-7 [pii] LID - 10.1016/j.acuroe.2022.08.012 [doi] AB - INTRODUCTION: We performed a meta-analysis to evaluate the effect of en-bloc transurethral resection vs. conventional transurethral resection for primary non-muscle invasive bladder cancer. METHODS: A systematic literature search up to January 2022 was done and 28 studies included 3714 primary non-muscle invasive bladder cancer subjects at the start of the study; 1870 of them were en-bloc transurethral resection, and 1844 were conventional transurethral resection for primary non-muscle invasive bladder cancer. We calculated the odds-ratio (OR) and mean-difference (MD) with 95% confidence-intervals (CIs) to evaluate the effect of en-bloc transurethral resection compared with conventional transurethral resection for primary non-muscle invasive bladder cancer by the dichotomous or continuous methods with random or fixed-effects models. RESULTS: En-bloc transurethral resection had significantly lower twenty-four-month recurrence (OR: 0.63; 95%CI: 0.50-0.78; p < 0.001), catheterization-time (MD: -0.66; 95%CI: -1.02-[-0.29]; p < 0.001), length of hospital stay (MD: -0.95; 95%CI: -1.55-[-0.34]; p = 0.002), postoperative bladder irrigation duration (MD: -6.06; 95%CI: -9.45-[-2.67]; p < 0.001), obturator nerve reflex (OR: 0.08; 95%CI: 0.02-0.34; p = 0.03), and bladder perforation (OR: 0.14; 95%CI: 0.06-0.36: p < 0.001) and no significant difference in the 12-month-recurrence (OR: 0.79; 95%CI: 0.61-1.04; p = 0.09), the operation time (MD: 0.67; 95%CI: -1.92 to 3.25; p = 0.61), and urethral stricture (OR: 0.46; 95%CI: 0.14-1.47; p = 0.0.19) compared with conventional transurethral resection for primary non-muscle invasive bladder cancer subjects. CONCLUSIONS: En-bloc transurethral resection had a significantly lower twenty-four-month recurrence, catheterization time, length of hospital stay, postoperative bladder irrigation duration, obturator nerve reflex, bladder perforation, and no significant difference in the twelve-month recurrence, operation time, and urethral stricture compared with conventional transurethral resection for primary non-muscle invasive bladder cancer subjects. Further studies are required. CI - Copyright (c) 2022 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Di, Y AU - Di Y AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang, China. FAU - Li, H AU - Li H AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang, China. FAU - He, C AU - He C AD - Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang, China. FAU - Peng, H AU - Peng H AD - Department of Urology, The Fourth Hospital of Changsha, Hunan, China. Electronic address: penghongliang_sci@outlook.com. LA - eng LA - spa PT - Journal Article PT - Meta-Analysis DEP - 20220806 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Humans MH - *Urethral Stricture MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/surgery MH - Urologic Surgical Procedures/methods MH - Operative Time OTO - NOTNLM OT - Catheterization time OT - Conventional transurethral resection OT - Cancer vesical primario no musculo-infltrante OT - Duracion de la estancia hospitalaria OT - En-bloc transurethral resection OT - Length of hospital stay OT - Primary non-muscle invasive bladder cancer OT - Recurrence OT - Recurrencia OT - Reseccion transuretral convencional OT - Reseccion transuretral en bloque OT - Tiempo de sondaje EDAT- 2022/11/02 06:00 MHDA- 2023/06/05 06:42 CRDT- 2022/11/01 23:05 PHST- 2022/03/08 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/01 23:05 [entrez] AID - S2173-5786(22)00087-7 [pii] AID - 10.1016/j.acuroe.2022.08.012 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2023 Jun;47(5):309-316. doi: 10.1016/j.acuroe.2022.08.012. Epub 2022 Aug 6. PMID- 36319553 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20230228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 1 DP - 2023 Jan TI - 5alpha-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. PG - 50.e11-50.e17 LID - S1078-1439(22)00312-X [pii] LID - 10.1016/j.urolonc.2022.09.004 [doi] AB - PURPOSE: The ability of 5alpha-reductase inhibitors (5ARI) to reduce the risk of new onset bladder cancer (BC) has been studied with variable results. Our objective was to conduct a retrospective cohort population-based study to evaluate the association between 5ARI use, BC diagnosis, and BC mortality. PATIENTS AND METHODS: We used routinely collected health care data from Ontario, Canada. Men >/=66 years of age with a prescription for a 5ARI were matched to non-5ARI users. Matching was done using a propensity score of selected covariates to make 96 different covariates comparable. We measured 5 additional baseline variables which may have impacted the risk of future BC diagnosis: prior cystoscopy, urine cytology, urinalysis, gross hematuria episodes, and transurethral resection of a bladder lesion. Only the first period of continuous usage of 5ARIs was considered. The prespecified at-risk period for outcomes started 1 year after initiating therapy and ended at the last date of 5ARI exposure + 1 year. RESULTS: We identified 93,197 men who initiated 5ARI therapy (52% dutasteride, and 48% finasteride) between 2003 and 2013 and matched them 1:1 to men who did not start a 5ARI. The median at-risk period for the 5ARI group was 1.68 years (interquartile range 1.00, 4.27). With adjustment for the variables related to prior BC investigations there was no significant difference in BC diagnosis (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.82-1.32) during the period of 0 to <2 years of 5ARI use; however, after >/=2 years of 5ARI use, the risk of BC diagnosis was significantly lower among the 5ARI group (HR 0.82, 95% CI 0.79-0.94). In a similarly adjusted model, BC mortality was lower among 5ARI users, but no longer statistically significant (HR 0.82, 95% CI 0.65, 1.02). When stratified by type of 5ARI, finasteride significantly reduced the risk of BC diagnosis after >/=2 years of continuous use (HR 0.86, 95% CI 0.76, 0.96); however, dutasteride did not (HR 0.92, 95% CI 0.83, 1.03). CONCLUSIONS: In a large cohort of men, the use of a 5ARI was associated with a significantly decreased the risk of BC diagnosis after more than 2 years of continuous therapy. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Dekalo, Snir AU - Dekalo S AD - Division of Urology, Department of Surgery, Western University, London, Ontario, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: snirdekalo@gmail.com. FAU - McArthur, Eric AU - McArthur E AD - Institute for Clinical Evaluative Sciences, London, Ontario, Canada. FAU - Campbell, Jeffrey AU - Campbell J AD - Division of Urology, Department of Surgery, Western University, London, Ontario, Canada. FAU - Ordon, Michael AU - Ordon M AD - Institute for Clinical Evaluative Sciences, London, Ontario, Canada; Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Power, Nicholas AU - Power N AD - Division of Urology, Department of Surgery, Western University, London, Ontario, Canada. FAU - Welk, Blayne AU - Welk B AD - Division of Urology, Department of Surgery, Western University, London, Ontario, Canada; Institute for Clinical Evaluative Sciences, London, Ontario, Canada. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221029 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (5-alpha Reductase Inhibitors) RN - O0J6XJN02I (Dutasteride) RN - 57GNO57U7G (Finasteride) RN - EC 1.- (Oxidoreductases) SB - IM MH - Male MH - Humans MH - 5-alpha Reductase Inhibitors/therapeutic use MH - Dutasteride/therapeutic use MH - Finasteride/therapeutic use MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/epidemiology MH - Oxidoreductases MH - Ontario/epidemiology MH - *Prostatic Hyperplasia OTO - NOTNLM OT - 5ARI OT - Bladder cancer OT - Dutasteride OT - Finasteride COIS- Conflict of interest All authors report that there are no conflicts of interests. EDAT- 2022/11/02 06:00 MHDA- 2022/11/30 06:00 CRDT- 2022/11/01 23:05 PHST- 2022/04/27 00:00 [received] PHST- 2022/08/08 00:00 [revised] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/11/01 23:05 [entrez] AID - S1078-1439(22)00312-X [pii] AID - 10.1016/j.urolonc.2022.09.004 [doi] PST - ppublish SO - Urol Oncol. 2023 Jan;41(1):50.e11-50.e17. doi: 10.1016/j.urolonc.2022.09.004. Epub 2022 Oct 29. PMID- 36313211 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221102 IS - 2330-1910 (Print) IS - 2330-1910 (Electronic) IS - 2330-1910 (Linking) VI - 10 IP - 5 DP - 2022 TI - PD1.5 variant on PDCD1 gene, regulator of T lymphocyte activity, influences non-muscle-invasive bladder cancer risk. PG - 334-340 AB - BACKGROUND: Since failure in recognition of abnormal cells by the immune system has an important role in bladder cancer development and progression, this study aimed to evaluate whether PD1 (c.627+252C>T) and PD1.5 (c.804C>T) single-nucleotide variants (SNVs) in PDCD1 gene, enrolled in modulation of T lymphocyte activity, influence risk, clinicopathological aspects, and outcome of non-muscle-invasive bladder cancer (NMIBC) patients. MATERIAL AND METHODS: DNA genotyping by real-time polymerase chain reaction was offered to 160 non muscle invasive bladder cancer (NMIBC) patients and 250 controls. One hundred and twenty-seven patients treated with bladder transurethral resection and intravesical bacillus Calmette-Guerin were enrolled in survival analyses. RESULTS: Individuals with PD1.5 CC genotype had 2.3-fold increased risk of developing NMIBC. Similar genotype and haplotype frequencies were seen in patients stratified by clinicopathological aspects. Patients with T allele, CT or TT plus CT or TT genotype and TT haplotype of PD1 and PD1.5 SNVs had up to 4.0-times greater chances of presenting NMIBC relapse and death by any cause than the remaining patients, but analysis of NMIBC specific survival was not possible in study due to the small number of patients evolving to death during follow up. CONCLUSIONS: Our data presented for the first time, preliminary evidence that inherited abnormality in regulation of T lymphocyte activity alters NMIBC risk. CI - AJCEU Copyright (c) 2022. FAU - Gomez, Gabriela Vilas Boas AU - Gomez GVB AD - Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. FAU - Longhi, Larissa Nara Alegrini AU - Longhi LNA AD - Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. FAU - Saito, Helena Paes Almeida AU - Saito HPA AD - Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. FAU - Lourenco, Gustavo Jacob AU - Lourenco GJ AD - Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. FAU - Dos Reis, Rodolfo Borges AU - Dos Reis RB AD - Department of Surgery and Anatomy, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo Ribeirao Preto, Sao Paulo, Brazil. FAU - Tobias Machado, Marcos AU - Tobias Machado M AD - Department of Urooncology, Faculty of Medicine ABC Santo Andre, Sao Paulo, Brazil. FAU - Reis, Leonardo Oliveira AU - Reis LO AD - UroScience Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. AD - Life Sciences Center, Faculty of Medical Sciences, Pontifical Catholic University of Campinas Campinas, Sao Paulo, Brazil. FAU - Denardi, Fernandes AU - Denardi F AD - Department of Surgery, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. FAU - Lima, Carmen Silvia Passos AU - Lima CSP AD - Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. AD - Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas Campinas, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20221015 PL - United States TA - Am J Clin Exp Urol JT - American journal of clinical and experimental urology JID - 101634566 PMC - PMC9605939 OTO - NOTNLM OT - Bladder cancer OT - PDCD1 gene OT - prognosis OT - risk OT - single-nucleotide variant COIS- None. EDAT- 2022/11/01 06:00 MHDA- 2022/11/01 06:01 PMCR- 2022/10/15 CRDT- 2022/10/31 04:52 PHST- 2022/06/05 00:00 [received] PHST- 2022/08/21 00:00 [accepted] PHST- 2022/10/31 04:52 [entrez] PHST- 2022/11/01 06:00 [pubmed] PHST- 2022/11/01 06:01 [medline] PHST- 2022/10/15 00:00 [pmc-release] PST - epublish SO - Am J Clin Exp Urol. 2022 Oct 15;10(5):334-340. eCollection 2022. PMID- 36309406 OWN - NLM STAT- MEDLINE DCOM- 20221101 LR - 20221221 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 36 IP - 6 DP - 2022 Nov-Dec TI - Poor Prognosis With Intravesical Bacillus Calmette-Guerin History After Photodynamic Diagnosis-assisted Transurethral Resection Using 5-Aminolevulinic Acid. PG - 2952-2959 LID - 10.21873/invivo.13038 [doi] AB - BACKGROUND/AIM: Diagnostic efficacy and treatment outcome of orally administered 5 aminolevulinic acid (ALA) assessment for photodynamic diagnosis (PDD) in transurethral resection for non-muscle-invasive bladder cancer (NMIBC) in clinical practice. PATIENTS AND METHODS: A retrospective analysis was performed of 105 patients who underwent PDD transurethral resection using orally administered ALA and were pathologically diagnosed with Ta, T1, or Tis at the Ishikawa Prefectural Central Hospital from December 2018 to May 2022. RESULTS: Fluorescent light had a significantly higher sensitivity but a lower specificity in detecting carcinoma compared to white light (91.7% vs. 77.1%; p<0.05 and 43.0% vs. 85.2%; p<0.05, respectively), as well as in detecting carcinoma in situ lesions (80.4% vs. 28.6%; p<0.05 and 23.3% vs. 84.5%; p<0.05, respectively). The cumulative frequency of recurrence and progression 1 year after treatment were 26.3% and 12.3%, respectively. Multivariate analyses indicated that a Bacillus Calmette-Guerin (BCG) history instillation was an independent predictive factor for intravesical recurrence (hazard ratio=4.439; p=0.002) and disease progression (hazard ratio=8.534; p=0.005). The 1-year cumulative recurrence rates were 66.2% and 16.5%, respectively (p<0.001), and progression rates for patients with and without prior BCG intravesical instillation were 50.4% and 3.5%, respectively (p<0.001). CONCLUSION: Sufficient diagnostic accuracy and relatively good treatment outcome was shown in PDD-transurethral resection using ALA. However, prior BCG intravesical instillation for NMIBC patients was a poor prognostic factor of cancer recurrence and progression, and may be useful for clinicians in their postoperative follow-up. CI - Copyright (c) 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Makino, Tomoyuki AU - Makino T AD - Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; mackeeen511@gmail.com. FAU - Ofude, Mitsuo AU - Ofude M AD - Department of Urology, KKR Hokuriku Hospital, Kanazawa, Japan. FAU - Kawahara, Tetsuya AU - Kawahara T AD - Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. FAU - Hori, Tomohiro AU - Hori T AD - Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. FAU - Urata, Satoko AU - Urata S AD - Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. FAU - Miyagi, Tohru AU - Miyagi T AD - Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 RN - 88755TAZ87 (Aminolevulinic Acid) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Aminolevulinic Acid/therapeutic use MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/surgery MH - Treatment Outcome MH - Adjuvants, Immunologic/therapeutic use MH - Prognosis PMC - PMC9677785 OTO - NOTNLM OT - 5-aminolevulinic acid OT - Bacillus Calmette-Guerin OT - bladder cancer OT - fluorescence OT - photodynamic diagnosis OT - transurethral resection OT - urothelial carcinoma COIS- The Authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/30 06:00 MHDA- 2022/11/02 06:00 PMCR- 2022/11/03 CRDT- 2022/10/29 20:43 PHST- 2022/09/15 00:00 [received] PHST- 2022/09/28 00:00 [revised] PHST- 2022/09/29 00:00 [accepted] PHST- 2022/10/29 20:43 [entrez] PHST- 2022/10/30 06:00 [pubmed] PHST- 2022/11/02 06:00 [medline] PHST- 2022/11/03 00:00 [pmc-release] AID - 36/6/2952 [pii] AID - 10.21873/invivo.13038 [doi] PST - ppublish SO - In Vivo. 2022 Nov-Dec;36(6):2952-2959. doi: 10.21873/invivo.13038. PMID- 36308189 OWN - NLM STAT- MEDLINE DCOM- 20221101 LR - 20221101 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 65 IP - 4 DP - 2022 Oct-Dec TI - Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation. PG - 832-838 LID - 10.4103/ijpm.ijpm_95_21 [doi] AB - INTRODUCTION: Urothelial carcinoma poses a significant cause of morbidity and mortality. The recent classification of Tumors of Urinary System by World Health Organization fourth edition) has elucidated its molecular subtypes and its associated prognostic significance. METHODS: We used immunohistochemistry marker expression (CK5/6, CK20, CD44, EGFR) as a surrogate marker, to stratify 150 cases of high-grade urothelial carcinoma into the intrinsic molecular subtypes. A correlation was also done with immunohistochemical markers p53, p21, E-cadherin and Ki-67. RESULTS: On subtyping, 47.3% cases were basal, 42.7% luminal and 10% remained unclassified. We did not find GATA3 useful for molecular stratification in our study. Muscle invasion was seen in 59% of basal and 31% of luminal subtype (P = 0.016). Squamous differentiation was most commonly associated with basal subtype (P < 0.001). EGFR expression was seen in 62% of basal and 38% of luminal subtype (P = 0.014), and thus can be used as an additional marker for molecular stratification. Overexpression of p53 was seen in 64% cases of muscle invasive and 36% of non-muscle invasive high-grade carcinomas (P < 0.0001). An inverse relationship was observed between p53 and p21 immunoexpression (r = -0.494) (P < .0001). The overall survival at 1- and 2-year interval was more in the luminal subtype, suggesting an early mortality in basal group, (P = 0.827), and at 6 years both the groups had almost similar results. CONCLUSION: High-grade urothelial carcinoma is challenging in terms of therapeutic strategy. Increased understanding of underlying molecular basis helps identifying targetable treatment options, and newer biomarkers will enhance predictive and prognostic stratification. FAU - Gupta, Gurudutt AU - Gupta G AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Gupta, Rajee AU - Gupta R AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Pasricha, Sunil AU - Pasricha S AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Sharma, Anila AU - Sharma A AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Durga, Garima AU - Durga G AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Kamboj, Meenakshi AU - Kamboj M AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Tripathi, Rupal AU - Tripathi R AD - Department of Research, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. FAU - Mehta, Anurag AU - Mehta A AD - Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/genetics MH - Immunohistochemistry MH - *Urinary Bladder Neoplasms/diagnosis/genetics MH - Tumor Suppressor Protein p53/genetics MH - Biomarkers, Tumor/metabolism MH - *Carcinoma in Situ MH - ErbB Receptors/genetics OTO - NOTNLM OT - High-grade OT - immunohistochemistry OT - molecular stratification OT - urothelial carcinoma COIS- None EDAT- 2022/10/30 06:00 MHDA- 2022/11/02 06:00 CRDT- 2022/10/29 05:13 PHST- 2022/10/29 05:13 [entrez] PHST- 2022/10/30 06:00 [pubmed] PHST- 2022/11/02 06:00 [medline] AID - IndianJPatholMicrobiol_2022_65_4_832_346701 [pii] AID - 10.4103/ijpm.ijpm_95_21 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2022 Oct-Dec;65(4):832-838. doi: 10.4103/ijpm.ijpm_95_21. PMID- 36301957 OWN - NLM STAT- MEDLINE DCOM- 20221031 LR - 20221031 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 10 DP - 2022 TI - Quality improvement in managing patients with non-muscle-invasive bladder cancer by introducing a surgical checklist for transurethral resection of bladder tumor. PG - e0276816 LID - 10.1371/journal.pone.0276816 [doi] LID - e0276816 AB - BACKGROUND: The quality of transurethral resection of bladder tumor (TURBT) markedly varies among surgeons and may have a considerable impact on treatment outcomes. The importance of a surgical checklist for TURBT has been suggested in order to standardize the procedure and improve surgical and oncological outcomes. In the present study, we verified the usefulness of a checklist for managing patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: This retrospective study included 201 NMIBC patients diagnosed with Ta, T1, or Tis between October 2011 and February 2021. After September 2016, TURBT was performed with a checklist. We analyzed the intravesical recurrence-free survival (RFS) rate and the presence or absence of the detrusor muscle in resected specimens before and after the introduction of the checklist. Survival rates were compared using the Log-rank test. A multivariate analysis with Cox proportional hazards modeling was performed to verify risk factors for intravesical recurrence. RESULTS: Ninety-nine patients who underwent TURBT with the checklist (checklist group) were compared with 102 patients who underwent TURBT without the checklist (non-checklist group). When the analysis was narrowed down to 9 critical items, we observed a mean number of 9 documented items per operative report (98.0% completion) after implementation of the checklist. Two-year intravesical RFS rates in the checklist and non-checklist groups were 76.7 and 69.5%, respectively (p = 0.1059). The Cox proportional multivariate analysis showed that the rate of intravesical recurrence was slightly lower in the checklist group (hazard ratio 0.7376, 95% CI 0.4064-1.3388, P = 0.3170). CONCLUSION: The introduction of a checklist is recommended for the standardization of TURBT and increasing the quality of operative reporting, and it may also improve oncological outcomes. FAU - Kikuchi, Hiroshi AU - Kikuchi H AUID- ORCID: 0000-0003-4999-8994 AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. AD - Department of Urology, Teine Keijinkai Hospital, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AUID- ORCID: 0000-0003-4444-7958 AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Matsumoto, Ryuji AU - Matsumoto R AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Maruyama, Satoru AU - Maruyama S AUID- ORCID: 0000-0001-6547-0052 AD - Department of Urology, National Hospital Organisation Hokkaido Cancer Center, Sapporo, Japan. FAU - Murai, Sachiyo AU - Murai S AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article DEP - 20221027 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Retrospective Studies MH - Quality Improvement MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness/pathology MH - Cystectomy PMC - PMC9612454 COIS- The authors have declared that no competing interests exist. EDAT- 2022/10/28 06:00 MHDA- 2022/11/01 06:00 PMCR- 2022/10/27 CRDT- 2022/10/27 13:55 PHST- 2022/04/28 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/10/27 13:55 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/11/01 06:00 [medline] PHST- 2022/10/27 00:00 [pmc-release] AID - PONE-D-22-12479 [pii] AID - 10.1371/journal.pone.0276816 [doi] PST - epublish SO - PLoS One. 2022 Oct 27;17(10):e0276816. doi: 10.1371/journal.pone.0276816. eCollection 2022. PMID- 36300825 OWN - NLM STAT- MEDLINE DCOM- 20221104 LR - 20260120 IS - 2046-4924 (Electronic) IS - 1366-5278 (Print) IS - 1366-5278 (Linking) VI - 26 IP - 40 DP - 2022 Oct TI - Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. PG - 1-144 LID - 10.3310/PLPU1526 [doi] AB - BACKGROUND: Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule required after initial treatment has associated costs for patients and the NHS. In photodynamic diagnosis, before transurethral resection of bladder tumour, a photosensitiser that is preferentially absorbed by tumour cells is instilled intravesically. Transurethral resection of bladder tumour is then conducted under blue light, causing the photosensitiser to fluoresce. Photodynamic diagnosis-guided transurethral resection of bladder tumour offers better diagnostic accuracy than standard white-light-guided transurethral resection of bladder tumour, potentially reducing the chance of subsequent recurrence. OBJECTIVE: The objective was to assess the clinical effectiveness and cost-effectiveness of photodynamic diagnosis-guided transurethral resection of bladder tumour. DESIGN: This was a multicentre, pragmatic, open-label, parallel-group, non-masked, superiority randomised controlled trial. Allocation was by remote web-based service, using a 1 : 1 ratio and a minimisation algorithm balanced by centre and sex. SETTING: The setting was 22 NHS hospitals. PARTICIPANTS: Patients aged >/= 16 years with a suspected first diagnosis of high-risk non-muscle-invasive bladder cancer, no contraindications to photodynamic diagnosis and written informed consent were eligible. INTERVENTIONS: Photodynamic diagnosis-guided transurethral resection of bladder tumour and standard white-light cystoscopy transurethral resection of bladder tumour. MAIN OUTCOME MEASURES: The primary clinical outcome measure was the time to recurrence from the date of randomisation to the date of pathologically proven first recurrence (or intercurrent bladder cancer death). The primary health economic outcome was the incremental cost per quality-adjusted life-year gained at 3 years. RESULTS: We enrolled 538 participants from 22 UK hospitals between 11 November 2014 and 6 February 2018. Of these, 269 were allocated to photodynamic diagnosis and 269 were allocated to white light. A total of 112 participants were excluded from the analysis because of ineligibility (n = 5), lack of non-muscle-invasive bladder cancer diagnosis following transurethral resection of bladder tumour (n = 89) or early cystectomy (n = 18). In total, 209 photodynamic diagnosis and 217 white-light participants were included in the clinical end-point analysis population. All randomised participants were included in the cost-effectiveness analysis. Over a median follow-up period of 21 months for the photodynamic diagnosis group and 22 months for the white-light group, there were 86 recurrences (3-year recurrence-free survival rate 57.8%, 95% confidence interval 50.7% to 64.2%) in the photodynamic diagnosis group and 84 recurrences (3-year recurrence-free survival rate 61.6%, 95% confidence interval 54.7% to 67.8%) in the white-light group (hazard ratio 0.94, 95% confidence interval 0.69 to 1.28; p = 0.70). Adverse event frequency was low and similar in both groups [12 (5.7%) in the photodynamic diagnosis group vs. 12 (5.5%) in the white-light group]. At 3 years, the total cost was pound12,881 for photodynamic diagnosis-guided transurethral resection of bladder tumour and pound12,005 for white light. There was no evidence of differences in the use of health services or total cost at 3 years. At 3 years, the quality-adjusted life-years gain was 2.094 in the photodynamic diagnosis transurethral resection of bladder tumour group and 2.087 in the white light group. The probability that photodynamic diagnosis-guided transurethral resection of bladder tumour was cost-effective was never > 30% over the range of society's cost-effectiveness thresholds. LIMITATIONS: Fewer patients than anticipated were correctly diagnosed with intermediate- to high-risk non-muscle-invasive bladder cancer before transurethral resection of bladder tumour and the ratio of intermediate- to high-risk non-muscle-invasive bladder cancer was higher than expected, reducing the number of observed recurrences and the statistical power. CONCLUSIONS: Photodynamic diagnosis-guided transurethral resection of bladder tumour did not reduce recurrences, nor was it likely to be cost-effective compared with white light at 3 years. Photodynamic diagnosis-guided transurethral resection of bladder tumour is not supported in the management of primary intermediate- to high-risk non-muscle-invasive bladder cancer. FUTURE WORK: Further work should include the modelling of appropriate surveillance schedules and exploring predictive and prognostic biomarkers. TRIAL REGISTRATION: This trial is registered as ISRCTN84013636. FUNDING: This project was funded by the National Institute for Health and Care Research ( NIHR ) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 40. See the NIHR Journals Library website for further project information. FAU - Heer, Rakesh AU - Heer R AUID- ORCID: 0000-0003-1952-7462 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Lewis, Rebecca AU - Lewis R AUID- ORCID: 0000-0001-9222-5263 AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Duncan, Anne AU - Duncan A AUID- ORCID: 0000-0001-7644-006X AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Penegar, Steven AU - Penegar S AUID- ORCID: 0000-0002-3768-0236 AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Vadiveloo, Thenmalar AU - Vadiveloo T AUID- ORCID: 0000-0001-5531-6289 AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Clark, Emma AU - Clark E AUID- ORCID: 0000-0003-0065-1463 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Yu, Ge AU - Yu G AUID- ORCID: 0000-0002-0891-2501 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Mariappan, Paramananthan AU - Mariappan P AUID- ORCID: 0000-0001-8221-4640 AD - Department of Urology, Western General Hospital, NHS Lothian, Edinburgh, UK. FAU - Cresswell, Joanne AU - Cresswell J AUID- ORCID: 0000-0003-1699-0339 AD - Department of Urology, South Tees Hospitals NHS Trust, Middlesbrough, UK. FAU - McGrath, John AU - McGrath J AUID- ORCID: 0000-0001-9416-9912 AD - Department of Urology, Royal Devon and Exeter Hospital NHS Trust, Exeter, UK. FAU - N'Dow, James AU - N'Dow J AUID- ORCID: 0000-0001-5340-0081 AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. FAU - Nabi, Ghulam AU - Nabi G AUID- ORCID: 0000-0001-9406-5195 AD - School of Medicine, University of Dundee, Dundee, UK. FAU - Mostafid, Hugh AU - Mostafid H AUID- ORCID: 0000-0002-5095-2929 AD - Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, UK. FAU - Kelly, John AU - Kelly J AUID- ORCID: 0000-0002-7036-1923 AD - University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK. FAU - Ramsay, Craig AU - Ramsay C AUID- ORCID: 0000-0003-4043-7349 AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. FAU - Lazarowicz, Henry AU - Lazarowicz H AUID- ORCID: 0000-0003-0792-2983 AD - Department of Urology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK. FAU - Allan, Angela AU - Allan A AUID- ORCID: 0000-0001-7410-5778 AD - Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK. FAU - Breckons, Matthew AU - Breckons M AUID- ORCID: 0000-0003-3057-6767 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Campbell, Karen AU - Campbell K AUID- ORCID: 0000-0003-1215-8991 AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Campbell, Louise AU - Campbell L AUID- ORCID: 0000-0002-6440-6486 AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Feber, Andy AU - Feber A AUID- ORCID: 0000-0001-5282-0498 AD - University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK. FAU - McDonald, Alison AU - McDonald A AUID- ORCID: 0000-0002-0256-2889 AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Norrie, John AU - Norrie J AUID- ORCID: 0000-0001-9823-9252 AD - Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK. FAU - Orozco-Leal, Giovany AU - Orozco-Leal G AUID- ORCID: 0000-0002-7473-7318 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Rice, Stephen AU - Rice S AUID- ORCID: 0000-0002-6767-0813 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Tandogdu, Zafer AU - Tandogdu Z AUID- ORCID: 0000-0002-5309-3656 AD - University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK. FAU - Taylor, Ernest AU - Taylor E AD - Tyne and Wear, UK. FAU - Wilson, Laura AU - Wilson L AUID- ORCID: 0000-0002-7919-2230 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - Vale, Luke AU - Vale L AUID- ORCID: 0000-0001-8574-8429 AD - Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. FAU - MacLennan, Graeme AU - MacLennan G AUID- ORCID: 0000-0002-1039-5646 AD - Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK. FAU - Hall, Emma AU - Hall E AUID- ORCID: 0000-0001-5999-5020 AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. LA - eng SI - ISRCTN/ISRCTN84013636 GR - HSRU1/CSO_/Chief Scientist Office/United Kingdom PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Pragmatic Clinical Trial PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - Health Technol Assess JT - Health technology assessment (Winchester, England) JID - 9706284 RN - 0 (Biomarkers) SB - IM MH - Humans MH - Biomarkers MH - Cost-Benefit Analysis MH - Quality of Life MH - Quality-Adjusted Life Years MH - Technology Assessment, Biomedical MH - *Urinary Bladder Neoplasms/diagnosis/surgery MH - Light MH - Photochemotherapy PMC - PMC9639219 OAB - Around 7500 people are diagnosed with early-stage bladder cancer in the UK each year. Early bladder cancer is contained within the bladder and has not yet invaded the bladder's muscle wall or spread elsewhere in the body. The cancer will return (recur) in around half of people after initial treatment and they have to attend hospital for regular check-ups, with costs to both them and the NHS. The first step in treating early bladder cancer is surgery to remove the tumour. This surgery is normally performed under white light. Photodynamic diagnosis is a new technique in which a liquid is put into the patient's bladder before surgery and a blue light is used during the operation. This causes the bladder cancer to fluoresce so that it can be seen more easily by the surgeon. The Photodynamic versus white-light-guided resection of first diagnosis non-muscle-invasive bladder cancer ( PHOTO ) trial aimed to find out whether or not using photodynamic diagnosis at initial surgery would reduce how often the cancer recurred and whether or not this could reduce the cost of treating early bladder cancer. A total of 538 people with early bladder cancer who had a medium to high chance of their cancer returning after treatment were enrolled in the PHOTO trial. They were included in one of two treatment groups, at random: 269 had photodynamic surgery and 269 had standard white-light surgery. People in both groups were monitored regularly for any recurrences, with further treatment as appropriate. After 3 years, 4 out of 10 people in each group had a recurrence of their bladder cancer. We found no difference between the treatment groups in the number of people with recurrences. We found no evidence of a benefit to patients, and the total costs of photodynamic surgery were higher than those of standard white light. We therefore recommend that it is no longer used in the treatment of this group of patients. OABL- eng OTO - NOTNLM OT - BLADDER CANCER OT - NON-MUSCLE-INVASIVE BLADDER CANCER OT - PHASE III: TRANSURETHRAL RESECTION OT - PHOTODYNAMIC DETECTION OT - RANDOMISED TRIAL OT - SURGERY OT - TRANSURETHRAL RESECTION OF BLADDER TUMOUR OT - URINARY BLADDER NEOPLASMS EDAT- 2022/10/28 06:00 MHDA- 2022/10/29 06:00 PMCR- 2022/11/07 CRDT- 2022/10/27 08:03 PHST- 2022/10/27 08:03 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2022/11/07 00:00 [pmc-release] AID - 10.3310/PLPU1526 [doi] PST - ppublish SO - Health Technol Assess. 2022 Oct;26(40):1-144. doi: 10.3310/PLPU1526. PMID- 36300676 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20230612 IS - 1522-2586 (Electronic) IS - 1053-1807 (Linking) VI - 58 IP - 1 DP - 2023 Jul TI - Multi-Sequence and Multi-Regional MRI-Based Radiomics Nomogram for the Preoperative Assessment of Muscle Invasion in Bladder Cancer. PG - 258-269 LID - 10.1002/jmri.28498 [doi] AB - BACKGROUND: Whether bladder cancer (BCa) invades muscle is a determinant of management. However, the accuracy of preoperative diagnosis of muscle invasion is not satisfactory. PURPOSE: To investigate the value of multi-sequence and multi-regional magnetic resonance imaging (MRI)-based radiomics nomogram for assessing muscle invasion of BCa. STUDY TYPE: Retrospective. POPULATION: 342 BCa patients, divided into a training set (239 cases), a validation set (68 cases), and a test set (35 cases). FIELD STRENGTH/SEQUENCE: 3.0 T/T(2) -weighted image, diffusion-weighted imaging, and dynamic contrast-enhanced imaging. ASSESSMENT: Patients were divided into muscle-invasive (79 cases) and non-muscle-invasive (263 cases). Two radiologists delineated the whole tumor, tumor body, and muscle layer of BCa, respectively, and extracted radiomic features. STATISTICAL TESTS: Recursive feature elimination, Pearson correlation coefficient, logistic regression, least absolute shrinkage and selection operator (Lasso) regression analysis, and 5-fold cross-validation were used to screen features and build a radiomics model. The clinical data were collected to construct a clinical model and a radiomics-clinical nomogram. RESULTS: 23,688 features were extracted. After screening, the radiomics scoring model was constructed using nine radiomics features with area under curve (AUC) values of 0.933, 0.913, and 0.931 in the training, validation, and test sets, respectively. The clinical model was constructed using five clinical independent risk factors; the AUC values in the training, validation, and test set were 0.876, 0.859, and 0.824, respectively. After logistic regression analysis, the AUC values of the radiomics-clinical nomogram were made up of four clinical independent risk factors and radiomics scores were 0.955, 0.922, and 0.935 for the training, validation, and test sets, respectively. The DeLong test between clinical model and radiomics-clinical nomogram shows P < 0.001. CONCLUSION: Multi-sequence and multi-regional MRI-based radiomics models could effectively assess the state of BCa muscular invasion. The radiomics-clinical nomogram is superior to clinical model for assessing BCa muscular invasion. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY: Stage 2. CI - (c) 2022 International Society for Magnetic Resonance in Medicine. FAU - Zhang, Lu AU - Zhang L AUID- ORCID: 0000-0003-3769-4539 AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Li, Xiaoyang AU - Li X AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Yang, Li AU - Yang L AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Tang, Ying AU - Tang Y AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Guo, Junting AU - Guo J AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Li, Ding AU - Li D AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Li, Shuo AU - Li S AD - College of Medical Imaging, Shanxi Medical University, Taiyuan, China. FAU - Li, Yan AU - Li Y AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Wang, Le AU - Wang L AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Lei, Ying AU - Lei Y AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Qiao, Hong AU - Qiao H AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Yang, Guoqiang AU - Yang G AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Wang, Xiaochun AU - Wang X AUID- ORCID: 0000-0002-3216-5710 AD - Department of Radiology, The First Hospital of Shanxi Medical University, Taiyuan, China. LA - eng GR - 81971592/National Natural Science Foundation of China/ PT - Journal Article DEP - 20221027 PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 SB - IM MH - Humans MH - *Nomograms MH - Retrospective Studies MH - Magnetic Resonance Imaging/methods MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Diffusion Magnetic Resonance Imaging OTO - NOTNLM OT - bladder cancer OT - magnetic resonance imaging OT - muscle invasion OT - radiomics OT - tumor staging EDAT- 2022/10/28 06:00 MHDA- 2023/06/12 06:42 CRDT- 2022/10/27 07:04 PHST- 2022/10/10 00:00 [revised] PHST- 2022/08/01 00:00 [received] PHST- 2022/10/11 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/27 07:04 [entrez] AID - 10.1002/jmri.28498 [doi] PST - ppublish SO - J Magn Reson Imaging. 2023 Jul;58(1):258-269. doi: 10.1002/jmri.28498. Epub 2022 Oct 27. PMID- 36294528 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221030 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 20 DP - 2022 Oct 21 TI - Concomitant Endoscopic Surgery for Bladder Tumors and Prostatic Obstruction: Are We Safely Hitting Two Birds with One Stone? A Systematic Review and Meta-Analysis. LID - 10.3390/jcm11206208 [doi] LID - 6208 AB - BACKGROUND: Lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO) and bladder tumors may co-exist, especially among elderly patients. Transurethral resection of bladder tumors (TURBT) and endoscopic surgery for benign prostatic obstruction in the same setting are avoided by many surgeons due to concerns for tumor cell seeding and recurrences in the prostatic urethra. AIM: The aim of this study was assess the effect of concomitant TURBT and endoscopic BPO surgery on oncological safety and patient quality of life via systematic review and meta-analysis. METHODS: We searched the PubMed, Cochrane Library, EMBASE, Scopus, and Clinicaltrials.gov databases and sources of grey literature published before June 2021 for relevant studies. We performed a random-effects meta-analysis of odds ratios (ORs) or weighted mean differences (WMD) to compare concomitant TURBT and BPO surgery versus TURBT alone in terms of recurrence and progression rates. Accordingly, we undertook multiple subgroups and sensitivity analyses (PROSPERO: CRD42020173363). RESULTS: Three randomized and twelve retrospective observational studies with 2421 participants were included. Across studies with good methodological quality, no statistically significant differences were demonstrated regarding overall bladder tumors recurrence rates between concomitant endoscopic BPO surgery and TURBT versus TURBT alone (OR: 0.81, 95% CI: 0.60-1.09, I(2) = 42%). Similarly, no significant differences were observed in recurrences located at the bladder neck and/or prostatic urethra (OR: 1.06, 95% CI: 0.76-1.47, I(2) = 0%), time to first recurrence (WMD: -0.2 months, 95% Cl: -2.2-1.8, I(2) = 48%), and progression rate (OR: 1.05, 95% CI: 0.67-1.64, I(2) = 0%). Subgroup analyses based on tumor grade, number of tumors, and utilization of single-instillation chemotherapy post-TURBT did not detect any significant differences in overall bladder tumor recurrence. The level of evidence was estimated as low for all outcomes. Concomitant surgery improved lower urinary tract symptoms. CONCLUSION: Concomitant endoscopic BPO surgery and TURBT are oncologically safe and improve LUTS-related quality of life. FAU - Savvides, Eliophotos AU - Savvides E AUID- ORCID: 0000-0002-4719-9462 AD - 1st Department of Urology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, GR-55134 Thessaloniki, Greece. FAU - Pyrgidis, Nikolaos AU - Pyrgidis N AUID- ORCID: 0000-0002-7707-8426 AD - Department of Urology, 'Martha-Maria' Hospital Nuremberg, 90402 Nuremberg, Germany. FAU - Langas, Georgios AU - Langas G AUID- ORCID: 0000-0002-7684-1151 AD - 1st Department of Urology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, GR-55134 Thessaloniki, Greece. FAU - Symeonidis, Evangelos N AU - Symeonidis EN AUID- ORCID: 0000-0002-6360-0762 AD - 1st Department of Urology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, GR-55134 Thessaloniki, Greece. FAU - Dimitriadis, Georgios AU - Dimitriadis G AD - 1st Department of Urology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, GR-55134 Thessaloniki, Greece. FAU - Sountoulides, Petros AU - Sountoulides P AUID- ORCID: 0000-0003-2671-571X AD - 1st Department of Urology, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, GR-55134 Thessaloniki, Greece. LA - eng PT - Journal Article PT - Review DEP - 20221021 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9604964 OTO - NOTNLM OT - benign prostatic obstruction OT - bladder cancer OT - concomitant OT - recurrence OT - transurethral resection COIS- The authors declare no conflict of interest. EDAT- 2022/10/28 06:00 MHDA- 2022/10/28 06:01 PMCR- 2022/10/21 CRDT- 2022/10/27 01:31 PHST- 2022/09/15 00:00 [received] PHST- 2022/10/09 00:00 [revised] PHST- 2022/10/11 00:00 [accepted] PHST- 2022/10/27 01:31 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/28 06:01 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - jcm11206208 [pii] AID - jcm-11-06208 [pii] AID - 10.3390/jcm11206208 [doi] PST - epublish SO - J Clin Med. 2022 Oct 21;11(20):6208. doi: 10.3390/jcm11206208. PMID- 36291803 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 20 DP - 2022 Oct 14 TI - Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends. LID - 10.3390/cancers14205019 [doi] LID - 5019 AB - Bladder cancer (BC) is the 10th most common cancer globally and has a high mortality rate if not detected early and treated promptly. Non-muscle-invasive BC (NMIBC) is a subclassification of BC associated with high rates of recurrence and progression. Current tools for predicting recurrence and progression on NMIBC use scoring systems based on clinical and histopathological markers. These exclude other potentially useful biomarkers which could provide a more accurate personalized risk assessment. Future trends are likely to use artificial intelligence (AI) to enhance the prediction of recurrence in patients with NMIBC and decrease the use of standard clinical protocols such as cystoscopy and cytology. Here, we provide a comprehensive survey of the most recent studies from the last decade (N = 70 studies), focused on the prediction of patient outcomes in NMIBC, particularly recurrence, using biomarkers such as radiomics, histopathology, clinical, and genomics. The value of individual and combined biomarkers is discussed in detail with the goal of identifying future trends that will lead to the personalized management of NMIBC. FAU - Shalata, Aya T AU - Shalata AT AD - Biomedical Engineering Department, Faculty of Engineering, Mansoura University, Mansoura 35516, Egypt. FAU - Shehata, Mohamed AU - Shehata M AUID- ORCID: 0000-0001-6640-6183 AD - Bioengineering Department, University of Louisville, Louisville, KY 40292, USA. FAU - Van Bogaert, Eric AU - Van Bogaert E AD - Department of Radiology, University of Louisville, Louisville, KY 40202, USA. FAU - Ali, Khadiga M AU - Ali KM AUID- ORCID: 0000-0001-7556-7173 AD - Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. FAU - Alksas, Ahmed AU - Alksas A AUID- ORCID: 0000-0001-9409-931X AD - Bioengineering Department, University of Louisville, Louisville, KY 40292, USA. FAU - Mahmoud, Ali AU - Mahmoud A AUID- ORCID: 0000-0003-2557-9699 AD - Bioengineering Department, University of Louisville, Louisville, KY 40292, USA. FAU - El-Gendy, Eman M AU - El-Gendy EM AUID- ORCID: 0000-0001-7468-4087 AD - Computers and Control Systems Engineering Department, Faculty of Engineering, Mansoura University, Mansoura 35516, Egypt. FAU - Mohamed, Mohamed A AU - Mohamed MA AD - Electronics and Communication Engineering Department, Faculty of Engineering, Mansoura University, Mansoura 35516, Egypt. FAU - Giridharan, Guruprasad A AU - Giridharan GA AD - Bioengineering Department, University of Louisville, Louisville, KY 40292, USA. FAU - Contractor, Sohail AU - Contractor S AD - Department of Radiology, University of Louisville, Louisville, KY 40202, USA. FAU - El-Baz, Ayman AU - El-Baz A AUID- ORCID: 0000-0001-7264-1323 AD - Bioengineering Department, University of Louisville, Louisville, KY 40292, USA. LA - eng PT - Journal Article PT - Review DEP - 20221014 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9599984 OTO - NOTNLM OT - AI-based prediction systems OT - NMIBC OT - markers OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2022/10/28 06:00 MHDA- 2022/10/28 06:01 PMCR- 2022/10/14 CRDT- 2022/10/27 01:14 PHST- 2022/08/25 00:00 [received] PHST- 2022/10/01 00:00 [revised] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/10/27 01:14 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/28 06:01 [medline] PHST- 2022/10/14 00:00 [pmc-release] AID - cancers14205019 [pii] AID - cancers-14-05019 [pii] AID - 10.3390/cancers14205019 [doi] PST - epublish SO - Cancers (Basel). 2022 Oct 14;14(20):5019. doi: 10.3390/cancers14205019. PMID- 36282109 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1532-4192 (Electronic) IS - 0735-7907 (Linking) VI - 41 IP - 1 DP - 2023 Jan TI - Gender, Bladder Cancer Healthcare and Burden of COVID-19. PG - 58-69 LID - 10.1080/07357907.2022.2140351 [doi] AB - Bladder cancer as one of the main comorbid diseases might be more susceptible to develop COVID-19 infection with a higher mortality risk during the COVID-19 pandemic. The European Association of Urology (EAU) recommended a comprehensive panel for bladder cancer diagnosis and treatment during this global health problem. The urgent need for treatments of COVID-19 during the pandemic has persuaded researchers to evaluate the different medications, which may lead to drug shortages. Therefore, in this review paper, we have focused on the least recommendations of EAU about bladder cancer during of COVID-19 pandemic to provide a comprehensive panel for high-risk patients. FAU - Khansary, Shahede AU - Khansary S AD - Department of Gynecology, Faculty of Medicine, Hamadan university of Medical Sciences, Hamadan, Iran. FAU - Tavilani, Heidar AU - Tavilani H AD - Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Ghasemi, Hadi AU - Ghasemi H AUID- ORCID: 0000-0003-0662-3375 AD - Autophagy Research Center, Department of Biochemistry, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran. LA - eng PT - Journal Article PT - Review DEP - 20221102 PL - England TA - Cancer Invest JT - Cancer investigation JID - 8307154 SB - IM MH - Humans MH - *COVID-19 MH - Delivery of Health Care MH - Neoplasm Invasiveness MH - Pandemics MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - COVID-19 OT - SARS-CoV-2 OT - bladder cancer OT - risk factor EDAT- 2022/10/26 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/10/25 09:32 PHST- 2022/10/26 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/10/25 09:32 [entrez] AID - 10.1080/07357907.2022.2140351 [doi] PST - ppublish SO - Cancer Invest. 2023 Jan;41(1):58-69. doi: 10.1080/07357907.2022.2140351. Epub 2022 Nov 2. PMID- 36281169 OWN - NLM STAT- MEDLINE DCOM- 20221026 LR - 20221118 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 42 DP - 2022 Oct 21 TI - Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study. PG - e31175 LID - 10.1097/MD.0000000000031175 [doi] LID - e31175 AB - The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8% >70 years) in 7 tertiary Spanish hospitals; 82.2% had a noninvasive urothelial bladder cancer (NMIBC). Patients received mostly surgery plus adjuvant therapy (67.7%). BCG (32.8% patients) was the most frequently administered adjuvant therapy, followed by intravesical chemotherapy (17.8% patients) and radiotherapy (10.8%). The variability of administered treatments among hospitals was low. Patients with NMIBC were more likely to receive adjuvant therapy if they had a higher educational level, some comorbidities and a high-grade tumor. The number of fully active patients (ECOG 0) significantly decreased during the first year of follow-up from 58% to 36 % (OR: 2.41, 95%CI 1.82-3.20); at 12-month follow-up 10.8% patients had died from any cause. In conclusion, most of the patients had a NMIBC. Surgery alone or plus adjuvant therapy were the commonest curative options of bladder cancer. BCG therapy was the adjuvant therapy most frequently administered. Higher educational level, presence of comorbidities and a high-grade tumor were associated with adjuvant therapy. Patient performance status was worsening over time. Almost 1 of 10 patients died during the first year of follow-up. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Bonfill, Xavier AU - Bonfill X AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, Spain. AD - Public Health and Clinical Epidemiology Service Hospital de la Santa Creu I, Barcelona, Spain. AD - Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Martinez-Zapata, Maria Jose AU - Martinez-Zapata MJ AUID- ORCID: 0000-0002-5836-1138 AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, Spain. AD - Cochrane Ecuador. Centro de Investigacion en Salud Publica y Epidemiologia Clinica (CISPEC). Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnologica Equinoccial, Quito, Ecuador. FAU - Barrionuevo-Rosas, Leslie AU - Barrionuevo-Rosas L AD - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, Spain. FAU - Vernooij, Robin Wm AU - Vernooij RW AD - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, Spain. FAU - Sanchez, Maria Jose AU - Sanchez MJ AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Escuela Andaluza de Salud Publica, Instituto de Investigacion Biosanitaria de Granada, Barcelona, Spain. FAU - Morales-Suarez-Varela, Maria AU - Morales-Suarez-Varela M AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Valencia, Spain. FAU - De la Cruz, Javier AU - De la Cruz J AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Hospital 12 de Octubre, Madrid, Spain. FAU - Emparanza, Jose Ignacio AU - Emparanza JI AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Clinical Epidemiology Unit, Hospital Universitario Donostia, BioDonostia, San Sebastian, Spain. FAU - Ferrer, Montserrat AU - Ferrer M AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Health Services Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. FAU - Pijoan, Jose Ignacio AU - Pijoan JI AD - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain. AD - Clinical Epidemiology Unit, Hospital, Universitario Cruces. Biocruces, Barakaldo, Spain. FAU - Palou, Joan AU - Palou J AD - Fundacio Puigvert, Barcelona, Spain. FAU - Frances, Albert AU - Frances A AD - Urology Service. Hospital Ntra. Sra. Del Mar, Barcelona, Spain. FAU - Madrid, Eva AU - Madrid E AD - Cochrane Centre Universidad de Valparaiso, Chile. Interdisciplinary Centre for Health Studies CIESAL. Department of Public Health - School of Medicine - Universidad de Valparaiso - Chile. FAU - Coscia, Claudia AU - Coscia C AD - Unidad de Bioestadistica Clinica, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. FAU - Zamora, Javier AU - Zamora J AD - Unidad de Bioestadistica Clinica, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. AD - Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, UK. CN - EMPARO-CU study group LA - eng PT - Journal Article PT - Multicenter Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (BCG Vaccine) SB - IM MH - Male MH - Humans MH - Female MH - *Urinary Bladder Neoplasms/pathology MH - Prospective Studies MH - Spain/epidemiology MH - Cohort Studies MH - Aftercare MH - BCG Vaccine/therapeutic use MH - Administration, Intravesical MH - Neoplasm Recurrence, Local/drug therapy MH - Neoplasm Invasiveness PMC - PMC9592268 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2022/10/26 06:00 MHDA- 2022/10/27 06:00 PMCR- 2022/10/21 CRDT- 2022/10/25 01:15 PHST- 2022/10/25 01:15 [entrez] PHST- 2022/10/26 06:00 [pubmed] PHST- 2022/10/27 06:00 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - 00005792-202210210-00092 [pii] AID - 10.1097/MD.0000000000031175 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Oct 21;101(42):e31175. doi: 10.1097/MD.0000000000031175. PMID- 36277146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221025 IS - 1792-1015 (Electronic) IS - 1792-0981 (Print) IS - 1792-0981 (Linking) VI - 24 IP - 5 DP - 2022 Nov TI - Pre‑existing renal insufficiency synchronous with high preoperative neutrophil‑to‑lymphocyte ratio as a risk factor of intravesical recurrence in patients with pure upper tract urothelial carcinoma after radical nephroureterectomy. PG - 671 LID - 10.3892/etm.2022.11606 [doi] LID - 671 AB - The present study aimed to evaluate the influence of pre-treatment neutrophil-to-lymphocyte ratio (NLR) on bladder recurrence in patients with impaired renal function following radical nephrouretectomy (RNU) to treat pure upper tract urothelial carcinoma (UTUC). Retrospective data of 362 patients with pure UTUC who underwent RNU between 2008 and 2019 were analyzed. Kaplan-Meier analyses were performed to evaluate the association of preoperative NLR and estimation of the glomerular filtration rate (eGFR) with intravesical recurrence-free survival (IVRF). Furthermore, multivariate analyses were conducted to determine independent factors for predicting IVRF. In the retrospective cohort study of 362 patients, 103 patients (28%) had intravesical recurrence in a median follow-up of 50.1 months; among those, 85 (83%) developed bladder recurrence within two years after RNU. The Kaplan-Meier analysis indicated that patients exhibiting lower eGFR and higher NLR showed significantly poor IVRF rates (P=0.044). The simultaneous presence of eGFR <45 and NLR >3.8 was an independent factor for the shorter IVRF time in multivariate analysis with Cox's proportional hazards model. Most intravesical recurrences occurred within two years after RNU, particularly in pre-existing poor eGFR patients with preoperative high NLR. Moreover, pre-existing moderate to severe CKD synchronous with pre-operative NLR >3.8 was demonstrated as an independent factor for subsequent bladder recurrence in patients with pure UTUC following RNU. Therefore, such high-risk patients ought to be provided with close bladder monitoring during the follow-up. CI - Copyright: (c) Cheng et al. FAU - Cheng, Tsung-Han AU - Cheng TH AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. FAU - Hu, Che-Yuan AU - Hu CY AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. AD - Institute of Clinical Medicine, National Cheng Kung University, Tainan 70403, Taiwan, R.O.C. FAU - Wu, Kuan-Yu AU - Wu KY AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. FAU - Tai, Ta-Yao AU - Tai TY AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. FAU - Weng, Han-Yu AU - Weng HY AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. FAU - Yang, Wen-Horng AU - Yang WH AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. AD - Department of Urology, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan, R.O.C. FAU - Ou, Chien-Hui AU - Ou CH AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. AD - Department of Urology, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan, R.O.C. FAU - Jan, Hau-Chern AU - Jan HC AD - Department of Urology, National Cheng Kung University Hospital, Tainan 70403, Taiwan, R.O.C. AD - Division of Urology, Department of Surgery, National Cheng Kung University Hospital Dou-Liou Branch, Yunlin 64043, Taiwan, R.O.C. LA - eng PT - Journal Article DEP - 20220913 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC9500497 OTO - NOTNLM OT - bladder recurrence OT - glomerular filtration rate OT - intravesival recurrence OT - neutrophil-to-lymphocyte ratio OT - renal insufficiency OT - upper tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2022/10/25 06:00 MHDA- 2022/10/25 06:01 PMCR- 2022/09/13 CRDT- 2022/10/24 04:27 PHST- 2022/04/27 00:00 [received] PHST- 2022/08/02 00:00 [accepted] PHST- 2022/10/24 04:27 [entrez] PHST- 2022/10/25 06:00 [pubmed] PHST- 2022/10/25 06:01 [medline] PHST- 2022/09/13 00:00 [pmc-release] AID - ETM-24-5-11606 [pii] AID - 10.3892/etm.2022.11606 [doi] PST - epublish SO - Exp Ther Med. 2022 Sep 13;24(5):671. doi: 10.3892/etm.2022.11606. eCollection 2022 Nov. PMID- 36276104 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221025 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma. PG - 986006 LID - 10.3389/fonc.2022.986006 [doi] LID - 986006 AB - BACKGROUND: Bladder carcinoma is a common malignancy of the urinary system. The previous study showed that EPDR1 expression was significantly related to the carcinogenesis and progression of bladder carcinoma. METHODS: We retrospectively reviewed the records of 621 patients who were newly diagnosed with bladder carcinoma between January 2018 and August 2020 at The Affiliated Hospital of Zunyi Medical University. We conducted immunohistochemistry of EPDR1 in tumor tissues. Meanwhile, tumor budding evaluation was also carried out by 2 independent experienced pathologists. RESULTS: 80 patients were included in this study with a median age of 66 years (range; 42-88 years). 45% of the patients (36/80) were non-muscle-invasive bladder carcinoma patients, while 55% of muscle-invasive bladder carcinoma(44/80). The follow-up time was from 6 months to 36 months. We found that there were significant differences in expression of EPDR1 in the tumor pT stages(p<0.05), pM stages(p<0.05), and pN stages(p<0.05). Meanwhile, a higher expression of EPDR1 indicated a worse outcome for the patient(p<0.05). A tendency toward a worse status of the patient was accompanied by a high positive rate (p<0.001). Moreover, the IOD of EPDR1 had a positive relationship with TB (p<0.05). Furthermore, we found that EPDR1 and tumor budding could be crucial factors for affecting the prognosis of bladder carcinoma, even better than pTMN(Riskscore=(0.724)* pT_stage +(4.960) *EPDR1+(4.312)*TB). CONCLUSION: In conclusion, bladder cancer patients with higher expression levels of EPDR1 had worse survival outcomes. The combination of TB and EPDR1 levels could predict the prognosis for muscle-invasive bladder cancer patients. CI - Copyright (c) 2022 Yang, Xu, Zhu, Yuan, Zhang, Liu, Zhao and Liang. FAU - Yang, Yue AU - Yang Y AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. AD - Department of Urology, Affiliated Hospital and Clinical Medical College of Chengdu University, Chengdu, China. AD - Medical College of Soochow University, Suzhou, China. FAU - Xu, Hong AU - Xu H AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. FAU - Zhu, Han AU - Zhu H AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. FAU - Yuan, Dan AU - Yuan D AD - Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. FAU - Zhang, Hanchao AU - Zhang H AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. AD - Department of Urology, Affiliated Hospital and Clinical Medical College of Chengdu University, Chengdu, China. AD - Medical College of Soochow University, Suzhou, China. AD - Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. FAU - Liu, Zhengdao AU - Liu Z AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. AD - Medical College of Soochow University, Suzhou, China. FAU - Zhao, Faliang AU - Zhao F AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. AD - Medical College of Soochow University, Suzhou, China. FAU - Liang, Guobiao AU - Liang G AD - Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, China. AD - Medical College of Soochow University, Suzhou, China. LA - eng PT - Journal Article DEP - 20221007 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9585273 OTO - NOTNLM OT - EPDR1 OT - biomarker OT - bladder cancer OT - prognosis OT - tumor margin COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/25 06:00 MHDA- 2022/10/25 06:01 PMCR- 2022/01/01 CRDT- 2022/10/24 04:11 PHST- 2022/07/04 00:00 [received] PHST- 2022/09/13 00:00 [accepted] PHST- 2022/10/24 04:11 [entrez] PHST- 2022/10/25 06:00 [pubmed] PHST- 2022/10/25 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.986006 [doi] PST - epublish SO - Front Oncol. 2022 Oct 7;12:986006. doi: 10.3389/fonc.2022.986006. eCollection 2022. PMID- 36274226 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221123 IS - 1944-7930 (Electronic) IS - 1539-6509 (Linking) VI - 33 IP - 169 DP - 2022 Mar-Apr TI - Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status. PG - 85-92 AB - In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical BCG instillation. However, the BCG mechanism, usage, adverse events, and the definition of BCG failure are not yet fully understood or defined. In addition, despite BCG being generally efficacious, a number of bladder cancer patients are unresponsive to the BCG immunotherapy. In this review, we summarize the history and current status of BCG immunotherapy, and highlight recent developments in designing novel strategies for the treatment of BCG-unresponsive patients. FAU - Liu, Gang AU - Liu G AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. AD - Department of Urology, Ganyu District Hospital, Lianyungang, Jiangsu 222100, China. FAU - Li, Bingheng AU - Li B AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. FAU - Xu, Ziyang AU - Xu Z AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. FAU - Wang, Jie AU - Wang J AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. FAU - Ma, Sai AU - Ma S AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. FAU - Kan, Yi AU - Kan Y AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. FAU - Mao, Lijun AU - Mao L AD - Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. AD - Corresponding author. LA - eng PT - Journal Article PT - Review PL - United States TA - Discov Med JT - Discovery medicine JID - 101250006 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy MH - BCG Vaccine/therapeutic use MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Immunotherapy MH - Neoplasm Recurrence, Local EDAT- 2022/10/25 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/10/24 01:42 PHST- 2022/10/24 01:42 [entrez] PHST- 2022/10/25 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PST - ppublish SO - Discov Med. 2022 Mar-Apr;33(169):85-92. PMID- 36272946 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20221221 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 83 IP - 1 DP - 2023 Jan TI - Re: Management, Surveillance Patterns, and Costs Associated with Low-grade Papillary Stage Ta Non-muscle-invasive Bladder Cancer Among Older Adults, 2004-2013. PG - 92-93 LID - S0302-2838(22)02711-7 [pii] LID - 10.1016/j.eururo.2022.10.002 [doi] FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgery, Division of Urology, Mount Sinai Hospital and Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. Electronic address: alexandre.zlotta@sinaihealth.ca. LA - eng PT - Journal Article DEP - 20221019 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - Aged MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/epidemiology/therapy/pathology MH - Neoplasm Staging MH - Neoplasm Recurrence, Local EDAT- 2022/10/23 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/10/22 22:07 PHST- 2022/09/26 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2022/10/23 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/22 22:07 [entrez] AID - S0302-2838(22)02711-7 [pii] AID - 10.1016/j.eururo.2022.10.002 [doi] PST - ppublish SO - Eur Urol. 2023 Jan;83(1):92-93. doi: 10.1016/j.eururo.2022.10.002. Epub 2022 Oct 19. PMID- 36272276 OWN - NLM STAT- MEDLINE DCOM- 20221107 LR - 20260127 IS - 1873-264X (Electronic) IS - 0731-7085 (Linking) VI - 222 DP - 2023 Jan 5 TI - Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients. PG - 115103 LID - S0731-7085(22)00524-6 [pii] LID - 10.1016/j.jpba.2022.115103 [doi] AB - The urothelial basement membrane (UBM) contains type IV collagen, laminin-5, and fibronectin. Urothelial neoplasm can break through the UBM underlying the urothelium to invade the lamina propria. Conceptually, all bladder cancer staging over Ta (T1-T4) may demonstrate disturbances in the UBM structure, as well as alterations in the serum concentrations of the studied components. The aim of this study was to determine the blood serum concentration of collagen IV, laminin-5 and fibronectin in bladder cancer patients. Quantification of their concentrations and correlation with various clinicopathological parameters may be useful for making more accurate predictions and identifying high-risk patients. The study included 96 patients with bladder cancer confirmed by transurethral resection or cystectomy and 26 patients with diagnosed cystitis chronica or BPH (benign prostate hyperplasia). Collagen IV, laminin-5 and fibronectin were detected using Surface Plasmon Resonance Imaging biosensors. Significant differences in blood serum concentrations of the studied biomarkers were observed between the control group and bladder cancer patients, as well as between nonmuscle-invasive and muscle-invasive groups. ROC analysis gave satisfactory results for differentiation between the control group and bladder cancer group (AUC 0.92-0.99), with lower values only for collagen IV between nonmuscle-invasive and muscle-invasive patients (AUC 0.71), and a statistically insignificant difference for laminin-5. Laminin-5 concentration was more closely correlated to tumour grade, size and recurrence rate; fibronectin to tumour stage, size and morphology; and collagen IV to tumour stage, grade and recurrence rate. The relations between serum concentrations of the presented biomarkers of the urothelial basement membrane may be useful for bladder cancer detection and for determination of the tumour stage, hence simplifying the making of therapeutic decisions. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Guszcz, Tomasz AU - Guszcz T AD - Department of Urology, Hospital of Ministry of Interior and Administration in Bialystok, Fabryczna 27, 15-471 Bialystok, Poland. Electronic address: tomasz.guszcz@o2.pl. FAU - Sankiewicz, Anna AU - Sankiewicz A AD - Bioanalysis Laboratory, Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Poland. Electronic address: ania@uwb.edu.pl. FAU - Gorodkiewicz, Ewa AU - Gorodkiewicz E AD - Bioanalysis Laboratory, Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Poland. Electronic address: ewka@uwb.edu.pl. LA - eng PT - Journal Article DEP - 20221011 PL - England TA - J Pharm Biomed Anal JT - Journal of pharmaceutical and biomedical analysis JID - 8309336 RN - 0 (Collagen Type IV) RN - 0 (Fibronectins) RN - 0 (Biomarkers) RN - 0 (Kalinin) SB - IM MH - Male MH - Humans MH - *Urinary Bladder Neoplasms/surgery MH - Collagen Type IV MH - Fibronectins MH - Surface Plasmon Resonance MH - Serum MH - *Biosensing Techniques MH - Biomarkers MH - Kalinin OTO - NOTNLM OT - Antibody-antigen interaction OT - Biosensor SPRI OT - Collagen IV OT - Fibronectin OT - Laminin-5 OT - Transitional bladder cancer COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/23 06:00 MHDA- 2022/11/08 06:00 CRDT- 2022/10/22 18:25 PHST- 2022/07/07 00:00 [received] PHST- 2022/10/03 00:00 [revised] PHST- 2022/10/07 00:00 [accepted] PHST- 2022/10/23 06:00 [pubmed] PHST- 2022/11/08 06:00 [medline] PHST- 2022/10/22 18:25 [entrez] AID - S0731-7085(22)00524-6 [pii] AID - 10.1016/j.jpba.2022.115103 [doi] PST - ppublish SO - J Pharm Biomed Anal. 2023 Jan 5;222:115103. doi: 10.1016/j.jpba.2022.115103. Epub 2022 Oct 11. PMID- 36269742 OWN - NLM STAT- MEDLINE DCOM- 20221026 LR - 20250623 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 10 DP - 2022 TI - The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis. PG - e0276453 LID - 10.1371/journal.pone.0276453 [doi] LID - e0276453 AB - BACKGROUND: This review and meta-analysis aimed to systematically evaluate the clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C (MMC) in patients with nonmuscular invasive bladder cancer (NMIBC) after transurethral resection of bladder tumour (TURBT). METHODS: The Embase, PubMed, CNKI, CBM, WANGFANG, VIP, Cochrane Library, and Clinicaltrial.com databases were searched for articles published before April 2022. The experimental group was treated with intravesical instillation of MMC assisted by equipment, including radiofrequency-induced thermochemotherapy, conductive thermochemical therapy, electromotive drug administration, or locoregional hyperthermia. The control group was treated with simple MMC perfusion. The outcomes of interest in the meta-analysis were recurrence, progression, side-effects, gross haematuria, and bladder irritation. RESULTS: A total of 15 studies that enrolled 1,190 patients were included in the meta-analysis. Compared to that of the control group, device-assisted intravesical instillation of MMC significantly reduced both tumour recurrence (odds ratio [OR] = 0.32, 95% confidence interval [CI] [0.24, 0.42], P <0.00001) and progression (OR = 0.29, 95% CI [0.12, 0.67], P = 0.004). There were no significant differences between the two groups in terms of safety (OR = 1.21, 95% CI [0.66,2.21], P = 0.54), bladder irritation (OR = 1.06, 95% CI [0.72,1.55], P = 0.78), or gross haematuria (OR = 1.11, 95% CI [0.64,1.94], P = 0.72). CONCLUSIONS: Equipment-assisted intravesical instillation of MMC significantly reduced the recurrence and progression of patients with NMIBC who underwent TURBT and improved their quality of life. Given the significant heterogeneity in research quality and sample size among earlier studies, more prospective, multicentre, large sample randomized controlled trials are needed to supplement and verify this in the future. FAU - Zhou, Weijian AU - Zhou W AUID- ORCID: 0000-0003-4575-7114 AD - Department of Clinical Medicine, Weifang Medical University, Weifang, China. FAU - Liu, Jianping AU - Liu J AD - Department of Urology, The First People's Hospital, Yibin, China. FAU - Mao, Dongdong AU - Mao D AD - Department of Urology, Affiliated Hospital of Weifang Medical University, Weifang, China. FAU - Hu, Changying AU - Hu C AD - Department of Clinical Medicine, The Second Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital, Chengdu, China. FAU - Gao, Dianjun AU - Gao D AD - Department of Clinical Medicine, Weifang Medical University, Weifang, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20221021 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/administration & dosage MH - Hematuria/drug therapy MH - *Mitomycin/administration & dosage MH - Prospective Studies MH - Quality of Life MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery PMC - PMC9586381 COIS- The authors have declared that no competing interests exist. EDAT- 2022/10/22 06:00 MHDA- 2022/10/26 06:00 PMCR- 2022/10/21 CRDT- 2022/10/21 13:35 PHST- 2022/09/01 00:00 [received] PHST- 2022/10/07 00:00 [accepted] PHST- 2022/10/21 13:35 [entrez] PHST- 2022/10/22 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - PONE-D-22-24475 [pii] AID - 10.1371/journal.pone.0276453 [doi] PST - epublish SO - PLoS One. 2022 Oct 21;17(10):e0276453. doi: 10.1371/journal.pone.0276453. eCollection 2022. PMID- 36262084 OWN - NLM STAT- MEDLINE DCOM- 20230303 LR - 20230303 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 131 IP - 3 DP - 2023 Mar TI - DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. PG - 158-164 LID - 10.1002/cncy.22657 [doi] AB - BACKGROUND: Recently, it was reported that the Bladder EpiCheck test is likely to represent a valid tool in the diagnostic process of patients who have suspected bladder carcinoma, with some controversial management decisions because of the technical limitations of cytology. METHODS: Two hundred ninety patients with a diagnosis of nonmuscle-invasive bladder carcinoma who were admitted at the authors' department from March 2019 to December 2019 were treated and followed for 1 year. During follow-up, all patients were evaluated by voided urine cytology, white-light cystoscopy (according to European Association of Urology guidelines), and the Bladder EpiCheck test. RESULTS: The cytologic diagnoses of high-grade urothelial carcinoma (HGUC) and suspicious for HGUC were histologically confirmed in 5 of 20 patients (25%) who had quantitative Bladder EpiCheck scores (EpiScores) from 60 to 69, in 23 of 36 patients (64%) who had EpiScores from 70 to 79, and in 42 of 56 patients (75%) and 57 of 63 patients (90%) who had EpiScores between 80 and 89 and EpiScores >90, respectively. Of 48 patients who had a cytologic diagnosis of HGUC or suspicious for HGUC with EpiScores >/=60 and negative histology, 20 (42%) had a recurrence of HGUC, which was cytologically and histologically confirmed, at 6-12 months during follow-up. CONCLUSIONS: To the best of the authors' knowledge, this is the first study in which patients at high risk for HGUC were stratified using the Bladder EpiCheck EpiScore. The results validate this methylation analysis tool as a useful method for predicting recurrent HGUC during the follow-up of patients with nonmuscle-invasive bladder carcinoma. CI - (c) 2022 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society. FAU - Pierconti, Francesco AU - Pierconti F AUID- ORCID: 0000-0003-0951-4131 AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Rossi, Esther Diana AU - Rossi ED AUID- ORCID: 0000-0003-3819-4229 AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Cenci, Tonia AU - Cenci T AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Carlino, Angela AU - Carlino A AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Fiorentino, Vincenzo AU - Fiorentino V AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Totaro, Angelo AU - Totaro A AD - Institute of Urology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Sacco, Emilio AU - Sacco E AD - Institute of Urology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AD - Institute of Urology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Iacovelli, Roberto AU - Iacovelli R AD - Institute of Oncology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Larocca, Luigi Maria AU - Larocca LM AD - Institute of Pathology, Universita UniCamillus-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Bassi, Pier Francesco AU - Bassi PF AD - Institute of Urology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Martini, Maurizio AU - Martini M AD - Institute of Pathology, Universita Cattolica del S. Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. LA - eng PT - Journal Article DEP - 20221019 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Urinary Bladder/pathology MH - DNA Methylation MH - *Urinary Tract/pathology MH - Cytodiagnosis/methods MH - Urine MH - Urothelium/pathology OTO - NOTNLM OT - bladder carcinoma OT - high-grade urothelial carcinoma OT - methylation analysis OT - urinary cytology EDAT- 2022/10/21 06:00 MHDA- 2023/03/04 06:00 CRDT- 2022/10/20 02:02 PHST- 2022/08/10 00:00 [revised] PHST- 2022/06/09 00:00 [received] PHST- 2022/08/24 00:00 [accepted] PHST- 2022/10/21 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2022/10/20 02:02 [entrez] AID - 10.1002/cncy.22657 [doi] PST - ppublish SO - Cancer Cytopathol. 2023 Mar;131(3):158-164. doi: 10.1002/cncy.22657. Epub 2022 Oct 19. PMID- 36251366 OWN - NLM STAT- MEDLINE DCOM- 20230524 LR - 20240625 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 131 IP - 6 DP - 2023 Jun TI - Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators. PG - 712-719 LID - 10.1111/bju.15920 [doi] AB - OBJECTIVES: To address the association of perioperative surgical checklist across variable surgical expertise with transurethral resection of bladder tumour (TURBT) accuracy and oncological outcomes in non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We relied on our prospective collaborative database of patients treated with TURBT between 2012 and 2017. Surgical experience was stratified into three groups: resident vs young vs expert consultants. The association of surgical experience with detrusor muscle (DM) presence and adherence to the standardised peri-procedural nine-items TURBT checklist was evaluated with logistic regression models. A Cox regression model was used to investigate the association of surgical experience with recurrence-free survival (RFS). RESULTS: A total of 503 patients were available for analysis. TURBT was performed by expert consultants in 265 (52.7%) patients, by young consultants in 149 (29.6%) and by residents in 89 (17.7%). Residents were more likely to have DM in the TURBT specimen than expert consultants (odds ratio [OR] 1.75, 95% confidence interval [CI] 1.03-2.99, P = 0.04). Conversely, no differences in DM presence were seen between young vs expert consultants (OR 1.09, 95% CI 0.71-1.70, P = 0.69). The median checklist completion rate was higher for both residents and young consultants when compared to experts' counterparts (56% and 56% vs 44%, P = 0.009). When focusing on patients receiving a second-look TURBT, the persistent disease was associated with resident status (OR 4.24, 95% CI 1.14-17.70, P = 0.037) at initial TURBT. Surgical experience was not associated with 5-years RFS. CONCLUSION: Surgeon's experience in the case of adequate perioperative surgical checklist implementation was inversely associated with the presence of DM in the specimen but directly linked to higher probability of persistent disease at re-TURBT, although no 5-year RFS differences were noted. CI - (c) 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal Infant and Urologic Sciences, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy. AD - Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Berndl, Florian AU - Berndl F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Pallauf, Maximilian AU - Pallauf M AUID- ORCID: 0000-0002-8496-4506 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Flammia, Rocco Simone AU - Flammia RS AUID- ORCID: 0000-0002-3129-0544 AD - Department of Maternal Infant and Urologic Sciences, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy. FAU - Philipp, Dominik AU - Philipp D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Urology Department, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gallioli, Andrea AU - Gallioli A AUID- ORCID: 0000-0002-3316-5691 AD - Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Mertens, Laura S AU - Mertens LS AUID- ORCID: 0000-0003-3317-6427 AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Marcq, Gautier AU - Marcq G AD - Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France. AD - Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France. FAU - Cimadamore, Alessia AU - Cimadamore A AUID- ORCID: 0000-0001-5981-3514 AD - Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Gontero, Paolo AU - Gontero P AD - Urology Division, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Chung, Benjamin I AU - Chung BI AUID- ORCID: 0000-0001-9660-2732 AD - Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Urology Division, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. LA - eng PT - Journal Article DEP - 20221104 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - J Urol. 2024 Jan;211(1):185-186. doi: 10.1097/JU.0000000000003732. PMID: 37861111 MH - Humans MH - *Urology MH - Prospective Studies MH - Checklist MH - Quality Indicators, Health Care MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Cystectomy OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - resident OT - surgical experience OT - transurethral resection of bladder tumour EDAT- 2022/10/18 06:00 MHDA- 2023/05/24 06:42 CRDT- 2022/10/17 11:54 PHST- 2023/05/24 06:42 [medline] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/17 11:54 [entrez] AID - 10.1111/bju.15920 [doi] PST - ppublish SO - BJU Int. 2023 Jun;131(6):712-719. doi: 10.1111/bju.15920. Epub 2022 Nov 4. PMID- 36250944 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230810 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 209 IP - 1 DP - 2023 Jan TI - Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. PG - 140-149 LID - 10.1097/JU.0000000000003015 [doi] AB - PURPOSE: We sought to evaluate the impact of repeat transurethral resection of bladder tumor prior to radical cystectomy on oncologic outcomes in a contemporary cohort at a tertiary care center. MATERIALS AND METHODS: An Institutional Review Board approved review of 657 patients diagnosed with muscle-invasive bladder cancer who underwent radical cystectomy at our institution for clinical stage T2 urothelial carcinoma between 2005 and 2017 was performed. Patients with and without repeat transurethral resection of bladder tumor were matched 1-to-1 by propensity score. Matching was done by age, gender, receipt of neoadjuvant chemotherapy, preoperative hydronephrosis, variant histology, lymphovascular invasion, or carcinoma in situ on index transurethral resection of bladder tumor. RESULTS: A total of 548 patients with muscle-invasive bladder cancer were included after matching (2 groups of 274 patients). Kaplan-Meier estimates of recurrence-free and overall survival demonstrated no significant difference based upon performance of repeat transurethral resection of bladder tumor (P = 1.0 and P = .3, respectively). When outcomes were stratified by pathology of repeat transurethral resection of bladder tumor specimens, those with pT0 had superior recurrence-free and overall survival compared to those with residual muscle invasive disease (P < .001 and P = .001, respectively). Notably, more than 60% of patients who were pT0 on repeat transurethral resection of bladder tumor had residual disease at the time of radical cystectomy. CONCLUSIONS: Repeat transurethral resection of bladder tumor prior to radical cystectomy, irrespective of receipt of neoadjuvant chemotherapy, was not associated with improved survival outcomes in this propensity score matched muscle-invasive bladder cancer cohort. The absence of residual tumor on pathological evaluation of repeat transurethral resection of bladder tumor specimen was prognostic and was associated with improved survival outcomes. However, a large percentage of patients with pT0 disease on repeat transurethral resection of bladder tumor had residual disease on radical cystectomy pathology. FAU - Bree, Kelly K AU - Bree KK AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Kokorovic, Andrea AU - Kokorovic A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. AD - Department of Urology, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada. FAU - Westerman, Mary E AU - Westerman ME AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. AD - Department of Urology, Louisiana State University Health Science Center-New Orleans, New Orleans, Louisiana. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. AD - Department of Urology, University of Kentucky, Lexington, Kentucky. FAU - Brooks, Nathan A AU - Brooks NA AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. AD - Department of Urology, University of Pittsburgh Medical Center Central Pennsylvania, Harrisburg, Pennsylvania. FAU - Qiao, Wei AU - Qiao W AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Shen, Yu AU - Shen Y AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. LA - eng PT - Journal Article DEP - 20221011 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2023 Apr;209(4):678-679. doi: 10.1097/JU.0000000000003362. PMID: 36753683 CIN - J Urol. 2023 Jun;209(6):1107. doi: 10.1097/JU.0000000000003455. PMID: 37035866 CIN - J Urol. 2023 Sep;210(3):406-407. doi: 10.1097/JU.0000000000003613. PMID: 37409983 MH - Humans MH - Cystectomy MH - *Urinary Bladder Neoplasms/surgery MH - Prognosis MH - *Carcinoma, Transitional Cell/surgery MH - Muscles OTO - NOTNLM OT - cystectomy OT - neoadjuvant therapy OT - neoplasm invasiveness OT - restrospective studies OT - urinary bladder neoplasms EDAT- 2022/10/18 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/10/17 10:33 PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/17 10:33 [entrez] AID - 10.1097/JU.0000000000003015 [doi] PST - ppublish SO - J Urol. 2023 Jan;209(1):140-149. doi: 10.1097/JU.0000000000003015. Epub 2022 Oct 11. PMID- 36250938 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20251224 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 209 IP - 1 DP - 2023 Jan TI - Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. PG - 131-139 LID - 10.1097/JU.0000000000003002 [doi] AB - PURPOSE: Intravesical mitomycin-C is recommended immediately after transurethral resection of bladder tumor for nonmuscle-invasive bladder cancer. However, a lack of compliance occurs due to the associated complications. Here, we aimed to assess the efficacy and safety of intravesical mitomycin-C before transurethral resection of bladder tumor in patients with nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: This was a single-center, open-label, parallel-arm, randomized phase II clinical trial in patients with suspected nonmuscle-invasive bladder cancer before transurethral resection of bladder tumor. Participants were randomly assigned (1:1) to receive 2 doses of intravesical mitomycin-C (40 mg/20 mL) 1 day and 4 hours before transurethral resection of bladder tumor (n = 49) or no treatment (n = 50) with block randomization (size 2 and 4), stratified by bacillus Calmette-Guerin/intravesical mitomycin-C. The primary endpoint was recurrence-free survival and secondary endpoints were progression-free survival and adverse events in the per-protocol analysis. RESULTS: Seventy-one patients (33, intervention; 38, control) were well matched for baseline characteristics. Sixty-one had been followed without recurrence for at least 10.4 months; 3 and 8 patients showed recurrence in the intervention and control groups, respectively. The 1-year recurrence-free survival rate was 97% and 89% for the intervention and control groups, respectively. Neoadjuvant intravesical mitomycin-C resulted in a reduction (63%) in the relative recurrence risk (hazard ratio, 0.37; 80% 1-sided confidence interval, -infinity-0.65, P = .11). Disease progression occurred in 3 patients in the control group (P = .051) but not in the intervention group. Neoadjuvant intravesical mitomycin-C was well tolerated, and adverse events were local and of grade 1/2. CONCLUSIONS: Two doses of neoadjuvant intravesical mitomycin-C are safe and effective in reducing nonmuscle-invasive bladder cancer recurrence and progression after transurethral resection of bladder tumor. FAU - Lee, Hye Won AU - Lee HW AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Lee, Hyung Ho AU - Lee HH AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Park, Eun Young AU - Park EY AD - Biostatistics Collaboration Team, Research Core Center, National Cancer Center, Goyang, Korea. FAU - Park, Weon Seo AU - Park WS AD - Department of Pathology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Kim, Sung Han AU - Kim SH AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Joung, Jae Young AU - Joung JY AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Chung, Jinsoo AU - Chung J AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. AD - Division of tumor immunology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. AD - Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial DEP - 20221012 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 50SG953SK6 (Mitomycin) SB - IM CIN - J Urol. 2023 Jan;209(1):138. doi: 10.1097/JU.0000000000003002.01. PMID: 36317443 CIN - J Urol. 2023 Jan;209(1):138-139. doi: 10.1097/JU.0000000000003002.02. PMID: 36317444 CIN - J Urol. 2023 May;209(5):845-846. doi: 10.1097/JU.0000000000003407. PMID: 36893470 CIN - Eur Urol. 2023 Oct;84(4):439-440. doi: 10.1016/j.eururo.2023.03.010. PMID: 36967362 MH - Humans MH - *Mitomycin MH - Prospective Studies MH - Transurethral Resection of Bladder MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Treatment Outcome PMC - PMC12721670 OTO - NOTNLM OT - mitomycin OT - neoadjuvant therapy OT - urinary bladder neoplasms COIS- Conflict of Interest: The Authors have no conflicts of interest to disclose. EDAT- 2022/10/18 06:00 MHDA- 2022/12/15 06:00 PMCR- 2025/12/22 CRDT- 2022/10/17 10:33 PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/17 10:33 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - JU-22-508 [pii] AID - 10.1097/JU.0000000000003002 [doi] PST - ppublish SO - J Urol. 2023 Jan;209(1):131-139. doi: 10.1097/JU.0000000000003002. Epub 2022 Oct 12. PMID- 36248912 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20221020 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis. PG - 986911 LID - 10.3389/fimmu.2022.986911 [doi] LID - 986911 AB - BACKGROUND: Radical cystectomy and removal of pelvic lymph nodes (RC-PLND) is a recommended treatment for high-risk non-muscle-invasive and muscle-invasive non-metastatic bladder cancer (BC). However, 50% of patients relapse after RC-PLND. This study aimed to evaluate the effect of programmed cell death ligand-1 (PD-L1) on the prognosis of bladder urothelial carcinoma (BUC) after RC-PLND. METHODS: We present this meta-analysis according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Guidelines. The main outcomes were overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) of 3 and 5 years after RC-PLND. RESULTS: Overall, 11 studies and 1393 BUC cases were included in our meta-analysis. In tumor cells (TCs), the PD-L1 negative group had statistically significant advantage in 5-year OS (risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.74-0.97, P = 0.02), RFS (RR: 0.76, 95% CI: 0.58-0.99, P = 0.04), and CSS (RR: 0.73, 95% CI: 0.58-0.92, P = 0.009) compared with the PD-L1 positive group. But, no statistically significant difference in 5-year OS and RFS was observed between the PD-L1 negative and positive groups in tumor-infiltrating immune cells. CONCLUSIONS: Our study found that patients with BUC who tested positive for PD-L1 in TCs had a poor prognosis after RC-PLND. PD-1 or PD-L1 inhibitors could be used as a adjuvant medication for patients with BUC after RC-PLND who exhibit PD-L1 overexpression in TCs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022301424. CI - Copyright (c) 2022 Zhang, Song, Zhu, Liu and Wang. FAU - Zhang, Jindong AU - Zhang J AD - Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Song, Liangdong AU - Song L AD - Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhu, Huixuan AU - Zhu H AD - Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Liu, Qinyuan AU - Liu Q AD - Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Wang, Delin AU - Wang D AD - Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20220928 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (B7-H1 Antigen) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Ligands) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Apoptosis MH - B7-H1 Antigen/genetics/metabolism MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Humans MH - Immune Checkpoint Inhibitors MH - Ligands MH - Lymph Node Excision MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Programmed Cell Death 1 Receptor MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9554211 OTO - NOTNLM OT - bladder urothelial carcinoma OT - meta-analysis OT - prognostic value OT - programmed cell death ligand-1 OT - radical cystectomy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/18 06:00 MHDA- 2022/10/19 06:00 PMCR- 2022/01/01 CRDT- 2022/10/17 05:14 PHST- 2022/07/05 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/10/17 05:14 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.986911 [doi] PST - epublish SO - Front Immunol. 2022 Sep 28;13:986911. doi: 10.3389/fimmu.2022.986911. eCollection 2022. PMID- 36239855 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20261010 IS - 1573-4919 (Electronic) IS - 0300-8177 (Linking) VI - 478 IP - 6 DP - 2023 Jun TI - Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients. PG - 1169-1190 LID - 10.1007/s11010-022-04579-x [doi] AB - Mutation or overexpression renders pan-RAS (rat sarcoma) proteins insensitive to inactivation. Activated pan-RAS communicates signal from the cell surface receptor to activate RAS-MAPK/ERK (RAS-mitogen-activated protein kinases/extracellular signal regulated kinases) signaling and orchestrates epithelial-to-mesenchymal transition-activating transcription factors (EMT-ATFs) reprogramming to induce EMT. Owing to limited studies available in bladder cancer, the present study is taken up to examine the expressions of the EMT-associated markers in pan-RAS-pERK1/2 (pan-RAS-phosphoERK1/2)-positive well-characterized cohort of forty-two non-muscle invasive bladder cancer (NMIBC) and forty-five muscle invasive bladder cancer (MIBC) patients. Immunohistochemical staining was performed on paraffin embedded tissue sections to determine the immunolevels and cellular localization of marker proteins. Semi-quantitative expressions of pan-RAS, pERK1/2, and EMT markers (E-cadherin, Vimentin, N-cadherin, Snail, Slug Twist, and Zeb1) were statistically examined with clinicohistopathological profile of the patients using SPSS, version 20.0 software. The study documents the diagnostic relevance of immunohistochemical expressions of pan-RAS-pERK1/2/EMT-associated markers in order to stratify NMIBC and MIBC patients. Follow-up studies supported the role of altered EMT phenotype in pan-RAS-pERK1/2-activated positive tumors with disease aggressiveness. To the best of our knowledge, our study is the first concluding the impact of altered EMT phenotype via pan-RAS-pERK1/2 axis on the short survival outcome [short overall survival (OS) (p = 0.04), short progression-free survival (PFS) (p = 0.02) and short cancer-specific survival (CSS) (p = 0.03)] of muscle invasive bladder cancer patients. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Tripathi, Kiran AU - Tripathi K AUID- ORCID: 0000-0002-8693-4255 AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. FAU - Maurya, Niharika AU - Maurya N AUID- ORCID: 0000-0003-1433-3474 AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. FAU - Goel, Apul AU - Goel A AUID- ORCID: 0000-0002-5813-3012 AD - Department of Urology, King George's Medical University, Lucknow, 226003, India. FAU - Singhai, Atin AU - Singhai A AUID- ORCID: 0000-0001-8018-0723 AD - Department of Pathology, King George's Medical University, Lucknow, 226003, India. FAU - Garg, Minal AU - Garg M AUID- ORCID: 0000-0002-4069-8138 AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. minalakg@gmail.com. LA - eng GR - 47/2021/606/70-4-2021-4 (56)/2020/Research and Development, Department of Higher Education, UP State Govt./ PT - Journal Article DEP - 20221014 PL - Netherlands TA - Mol Cell Biochem JT - Molecular and cellular biochemistry JID - 0364456 RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - 0 (Cadherins) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/metabolism MH - Signal Transduction MH - Extracellular Signal-Regulated MAP Kinases/metabolism MH - Follow-Up Studies MH - Epithelial-Mesenchymal Transition/genetics MH - Cadherins/metabolism MH - Biomarkers, Tumor OTO - NOTNLM OT - Clinical significance OT - Epithelial-to-mesenchymal transition markers OT - Immunohistochemistry OT - Ras expression OT - Survival probabilities OT - Urothelial carcinoma of bladder OT - phospho-ERK1/2 EDAT- 2022/10/15 06:00 MHDA- 2023/05/08 10:17 CRDT- 2022/10/14 11:18 PHST- 2022/05/21 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2023/05/08 10:17 [medline] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/14 11:18 [entrez] AID - 10.1007/s11010-022-04579-x [pii] AID - 10.1007/s11010-022-04579-x [doi] PST - ppublish SO - Mol Cell Biochem. 2023 Jun;478(6):1169-1190. doi: 10.1007/s11010-022-04579-x. Epub 2022 Oct 14. PMID- 36230493 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 19 DP - 2022 Sep 21 TI - Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/cancers14194570 [doi] LID - 4570 AB - Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive disease (MIBC) significantly worsens life expectancy. Its risk can be assessed by clinicopathological factors according to international guidelines. However, additional molecular markers are needed to refine and improve the prediction. Therefore, in the present study, we aimed to predict the progression of NMIBCs to MIBC by assessing p53 expression, polysomy of chromosome 17 (Chr17) and HER2 status in the tissue specimens of the tumors of 90 NMIBC patients. Median follow-up was 77 months (range 2-158). Patients with Chr17 polysomy or HER2 gene amplification had a higher rate of disease progression (hazard ratio: 7.44; p < 0.001 and 4.04; p = 0.033, respectively; univariate Cox regression). Multivariable Cox regression models demonstrated that the addition of either Chr17 polysomy or HER2 gene amplification status to the European Association of Urology (EAU) progression risk score increases the c-index (from 0.741/EAU/ to 0.793 and 0.755, respectively), indicating that Chr17 polysomy/HER2 amplification status information improves the accuracy of the EAU risk table in predicting disease progression. HER2/Chr17 in situ hybridization can be used to select non-progressive cases not requiring strict follow-up, by reclassifying non-HER2-amplified, non-polysomic NMIBCs from the high- and very high-risk groups of EAU to the intermediate-risk group. FAU - Kocsmar, Ildiko AU - Kocsmar I AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. AD - Department of Urology, Semmelweis University, Ulloi Street 78b, H-1082 Budapest, Hungary. FAU - Kocsmar, Eva AU - Kocsmar E AUID- ORCID: 0000-0003-3061-1323 AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. FAU - Pajor, Gabor AU - Pajor G AD - Department of Pathology, Medical School and Clinical Center, University of Pecs, Szigeti Street 12, H-7624 Pecs, Hungary. FAU - Kulka, Janina AU - Kulka J AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. FAU - Szekely, Eszter AU - Szekely E AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. FAU - Kristiansen, Glen AU - Kristiansen G AD - Department of Pathology, University Hospital Bonn, Universitatsklinikum Bonn (AoR), Venusberg-Campus 1 Building 62, 53127 Bonn, Germany. FAU - Schilling, Oliver AU - Schilling O AUID- ORCID: 0000-0001-7678-7653 AD - Institute of Surgical Pathology, Medical Center, University of Freiburg, Breisacher Street 115A, 79106 Freiburg im Breisgau, Germany. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Ulloi Street 78b, H-1082 Budapest, Hungary. FAU - Kiss, Andras AU - Kiss A AUID- ORCID: 0000-0002-7453-3163 AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. FAU - Schaff, Zsuzsa AU - Schaff Z AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. FAU - Riesz, Peter AU - Riesz P AUID- ORCID: 0000-0001-5304-5841 AD - Department of Urology, Semmelweis University, Ulloi Street 78b, H-1082 Budapest, Hungary. FAU - Lotz, Gabor AU - Lotz G AUID- ORCID: 0000-0002-6921-8978 AD - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Ulloi Street 93, H-1091 Budapest, Hungary. LA - eng GR - K_18 128881/National Research, Development and Innovation Office (Hungary)/ GR - EFOP-3.6.3-VEKOP-16-2017-00009/Ministry of Human Capacities (Hungary)/ GR - start-up grant/Semmelweis University, Budapest, Hungary/ GR - UNKP-20-3-II-SE-36/New National Excellence Program/ GR - UNKP-21-4-I-SE-32/New National Excellence Program/ GR - 2020-4.1.1.-TKP2020/Ministry for Innovation and Technology (Hungary)/ PT - Journal Article DEP - 20220921 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9558547 OTO - NOTNLM OT - Chromosome 17 polysomy OT - HER2 amplification OT - fluorescence in situ hybridization OT - non-muscle-invasive bladder cancer OT - p53 expression OT - progression risk stratification COIS- The funders of the study had no role in the study design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors declare that they have no conflict of interest with respect to the research, authorship, and publication of this article, including specific financial interests and relationships or affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending). EDAT- 2022/10/15 06:00 MHDA- 2022/10/15 06:01 PMCR- 2022/09/21 CRDT- 2022/10/14 01:50 PHST- 2022/07/20 00:00 [received] PHST- 2022/09/02 00:00 [revised] PHST- 2022/09/16 00:00 [accepted] PHST- 2022/10/14 01:50 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/15 06:01 [medline] PHST- 2022/09/21 00:00 [pmc-release] AID - cancers14194570 [pii] AID - cancers-14-04570 [pii] AID - 10.3390/cancers14194570 [doi] PST - epublish SO - Cancers (Basel). 2022 Sep 21;14(19):4570. doi: 10.3390/cancers14194570. PMID- 36225922 OWN - NLM STAT- MEDLINE DCOM- 20221014 LR - 20221017 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer. PG - 1032907 LID - 10.3389/fimmu.2022.1032907 [doi] LID - 1032907 AB - BACKGROUND: To explore the prognostic significance of sarcopenia and systemic immune-inflammation index (SII) for response to intravesical Bacillus Calmette-Guerin (BCG) in patients with intermediate-, and high-risk non-muscle invasive bladder cancer (NMIBC). METHODS: We retrospectively analyzed 183 consecutive patients treated in Qilu hospital of Shandong University for a first diagnosis of intermediate and high risk NMIBC. Using computed tomography scans at the third lumbar vertebra level, we calculated skeletal muscle index (SMI). Sarcopenia was defined as SMI <43 cm(2)/m(2) for males with BMI < 25 kg/m(2), <53 cm(2)/m(2) for males with BMI >/= 25 kg/m(2), and <41 cm(2)/m(2) for females. The response to intravesical BCG immunotherapy and relapse-free survival (RFS) were analyzed. RESULTS: Compared with BCG responders, BCG non-responders were associated with sarcopenia (P < 0.001), carcinoma in situ (P < 0.001), T1 stage (P < 0.001), multiple tumor (P < 0.001), tumor diameter >=3cm (P < 0.001), and have a significant increase of neutrophil-to-lymphocyte ratio (NLR) (P < 0.001), platelet to lymphocyte ratio (PLR) (P = 0.004), SII (P < 0.001). The area under the ROC curve (AUC) of the BMI, NLR, PLR, and SII for response to intravesical BCG immunotherapy were 0.425, 0.693, 0.631, and 0.702 respectively. Logistic regression analysis demonstrated that sarcopenia and SII were predictors of response to intravesical BCG immunotherapy. The Kaplan-Meier survival analysis showed that the RFS of patients with BCG response, lower SII and no sarcopenia was significantly increased compared with that of patients with BCG non-response, higher SII and sarcopenia, respectively. Subgroup analysis demonstrated that the RFS of patients with high SII and sarcopenia was significantly decreased compared with those with low SII and no sarcopenia in Ta stage subgroup, T1 stage subgroup, non-Cis subgroup, multiple tumor subgroup, single tumor subgroup, tumor diameter>/=3cm subgroup and tumor diameter<3cm subgroup, respectively (P < 0.05). However, there was no significant difference in RFS for patients in CIS subgroup (P > 0.05). Multivariate Cox analysis shown that sarcopenia (p=0.005) and high SII (p = 0.003) were significantly associated with poor RFS. CONCLUSIONS: Both sarcopenia and high SII are useful predictors of response to intravesical BCG in intermediate- and high-risk NMIBC patients. Patients with intermediate- and high-risk NMIBC that had sarcopenia or high SII at diagnosis were associated with poor RFS, and the combination of sarcopenia and SII may be a better predictor of RFS. CI - Copyright (c) 2022 Liu, Chen, Gao, Liang, Sun, Shi, Zhang and Guo. FAU - Liu, Peng AU - Liu P AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Chen, Shouzhen AU - Chen S AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Gao, Xingzhe AU - Gao X AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Liang, Hao AU - Liang H AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Sun, Daqian AU - Sun D AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Shi, Benkang AU - Shi B AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Zhang, Qiujie AU - Zhang Q AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. FAU - Guo, Hu AU - Guo H AD - Department of Urology Surgery, Qilu Hospital of Shandong University, Jinan, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221007 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Immunotherapy MH - Inflammation MH - Male MH - *Mycobacterium bovis MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9549861 OTO - NOTNLM OT - BCG - Bacille Calmette-Guerin vaccine OT - NMIBC (non-muscle invasive bladder cancer) OT - SII OT - immunity OT - sarcopenia COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/14 06:00 MHDA- 2022/10/15 06:00 PMCR- 2022/01/01 CRDT- 2022/10/13 02:41 PHST- 2022/08/31 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2022/10/13 02:41 [entrez] PHST- 2022/10/14 06:00 [pubmed] PHST- 2022/10/15 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1032907 [doi] PST - epublish SO - Front Immunol. 2022 Oct 7;13:1032907. doi: 10.3389/fimmu.2022.1032907. eCollection 2022. PMID- 36216762 OWN - NLM STAT- MEDLINE DCOM- 20221109 LR - 20221212 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 46 IP - 9 DP - 2022 Nov TI - A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ. PG - 521-530 LID - S2173-5786(22)00088-9 [pii] LID - 10.1016/j.acuroe.2022.08.013 [doi] AB - BACKGROUND: Urothelial dysplasia and carcinoma in situ (CIS) are related to recurrence and progression of urothelial carcinoma. Differentiating CIS and dysplasia from reactive atypia is often difficult based only on histological features. The integration of histological findings with immunohistochemistry is used in routine practice to make a diagnosis of CIS and, for this purpose, the immunohistochemical markers CK20, CD44, Ki67 and p53 are used to supplement histology. In this work, we aimed to assess CK20, CD44, Ki67 and p53 as immunohistochemical markers in patients with CIS through a systematic review and meta-analysis. MATERIALS AND METHODS: A systematic review was performed by searching electronic databases for English-language studies published from January 2010 to April 2021. Studies were considered eligible if they evaluated the CK20, CD44, Ki67 and p53 expression in CIS. RESULTS: In total, 15 references were suitable for quantitative review. The overall rate of CK20, CD44, Ki67 and p53 expression in CIS was 43%, 31%, 44%, 38%, respectively. CONCLUSIONS: Our study supports the 2014 International Society of Urologic Pathology consensus that histological assessment remains the gold standard to diagnose urothelial CIS and suggests that a very close correlation between morphological, immunohistochemical and clinical data is essential to provide the best management for patients with bladder carcinoma. CI - Copyright (c) 2022. Published by Elsevier Espana, S.L.U. FAU - Straccia, P AU - Straccia P AD - Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. Electronic address: stracciapatrizia@libero.it. FAU - Fiorentino, V AU - Fiorentino V AD - Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. FAU - Martini, M AU - Martini M AD - Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Pierconti, F AU - Pierconti F AD - Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. LA - eng LA - spa PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220806 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (Keratin-20) RN - 0 (Ki-67 Antigen) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (KRT20 protein, human) SB - IM MH - Humans MH - Biomarkers, Tumor MH - *Carcinoma in Situ/diagnosis MH - *Carcinoma, Transitional Cell/pathology MH - Hyaluronan Receptors/metabolism MH - Keratin-20/analysis/metabolism MH - Ki-67 Antigen/metabolism MH - Tumor Suppressor Protein p53/analysis/metabolism MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/pathology MH - Urothelium/chemistry/metabolism/pathology OTO - NOTNLM OT - Bladder carcinoma OT - Carcinoma in situ OT - Carcinoma vesical OT - Displasia OT - Dysplasia OT - Immunomarkes OT - Inmunomarcadores EDAT- 2022/10/11 06:00 MHDA- 2022/11/09 06:00 CRDT- 2022/10/10 22:09 PHST- 2021/11/16 00:00 [received] PHST- 2021/12/18 00:00 [revised] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/10/10 22:09 [entrez] AID - S2173-5786(22)00088-9 [pii] AID - 10.1016/j.acuroe.2022.08.013 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2022 Nov;46(9):521-530. doi: 10.1016/j.acuroe.2022.08.013. Epub 2022 Aug 6. PMID- 36216663 OWN - NLM STAT- MEDLINE DCOM- 20221121 LR - 20230112 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 12 DP - 2022 Dec TI - Partial cystectomy: Review of a single center experience from 2004 to 2019. PG - 538.e1-538.e5 LID - S1078-1439(22)00311-8 [pii] LID - 10.1016/j.urolonc.2022.09.003 [doi] AB - PURPOSE: Partial cystectomy (PC) is a bladder sparing option to treat bladder cancer in a carefully selected group of patients. We sought to analyze outcomes of partial cystectomy (PC) in a contemporary cohort of patients at a single institution. MATERIAL AND METHODS: Records were reviewed for 43 patients with a primary urothelial carcinoma (UC) who had a partial cystectomy with curative intent at Columbia University Medical Center from 2004 to 2019. Endpoints of interest were noninvasive recurrence (defined as any recurrent nonmuscle invasive disease), advanced recurrence (defined as a muscle invasive recurrence or metastasis), and death. We used unadjusted Cox proportional hazards regressions and log rank tests to estimate the association between clinical characteristics and endpoints of interest. RESULTS: Among 43 patients with bladder cancer treated with partial cystectomy, median patient age was 73 years (interquartile range 67-77.5) and 86% were male. Twenty-three percent of patients received preoperative neoadjuvant chemotherapy (NAC) and 49% of patients were given perioperative intravesical chemotherapy at the time of PC. Pathologic stage was /=T2 for 20 (47%) patients. Pathology showed 14% of patients had lymph node involvement, and 9% had positive surgical margins. Mean follow-up was 51 months (range 1-176). Five-year overall survival was 78%. Of 43 patients, 23 patients (53%) had no recurrence, 9 patients (21%) experienced noninvasive intravesical recurrence, and 11 patients (26%) experienced advanced recurrences. Two patients (5%) required salvage radical cystectomy and 8 patients (19%) died of bladder cancer. On univariate analysis, lymphovascular invasion (hazard ratio [HR] 4.4, confidence interval [CI] 1.3-14.3), pathological stage (HR 5.9, CI 1.3-27.4), and NAC (HR 6.5, CI 1.9-22.7) were associated with advanced recurrence. Noninvasive recurrence was associated with not receiving perioperative intravesical chemotherapy (HR 0.7, CI 0.1-6.0). CONCLUSIONS: In well-selected patients, partial cystectomy offers adequate local control of bladder cancer. The risk of systemic progression is similar to reported case series of RC. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Chung, Rainjade AU - Chung R AD - Department of Urology, Columbia University Medical Center, New York, NY. FAU - Moran, George W AU - Moran GW AD - Department of Urology, Columbia University Medical Center, New York, NY. FAU - Wang, Connie AU - Wang C AD - Department of Urology, Columbia University Medical Center, New York, NY. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Medical Center, New York, NY. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Columbia University Medical Center, New York, NY. Electronic address: cba2125@cumc.columbia.edu. LA - eng PT - Journal Article DEP - 20221008 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - Cystectomy/adverse effects MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Bladder cancer OT - Intravesical therapy OT - Partial cystectomy OT - Recurrence OT - Survival EDAT- 2022/10/11 06:00 MHDA- 2022/11/22 06:00 CRDT- 2022/10/10 22:05 PHST- 2022/05/11 00:00 [received] PHST- 2022/07/30 00:00 [revised] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/11/22 06:00 [medline] PHST- 2022/10/10 22:05 [entrez] AID - S1078-1439(22)00311-8 [pii] AID - 10.1016/j.urolonc.2022.09.003 [doi] PST - ppublish SO - Urol Oncol. 2022 Dec;40(12):538.e1-538.e5. doi: 10.1016/j.urolonc.2022.09.003. Epub 2022 Oct 8. PMID- 36214475 OWN - NLM STAT- MEDLINE DCOM- 20230302 LR - 20260406 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 4 DP - 2023 Feb TI - Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer. PG - 4206-4217 LID - 10.1002/cam4.5284 [doi] AB - BACKGROUND: The Systemic Inflammatory Response Index (SIRI) is a novel prognostic biomarker based on peripheral blood counts of neutrophils, monocytes, and lymphocytes. Recent evidence suggests that it is associated with poor prognosis in various cancers. However, the predictive value of the SIRI in non-muscle-invasive bladder cancer (NMIBC) patients treated with intravesical Bacillus Calmette-Guerin (BCG) immunotherapy remains elusive. Therefore, this study aimed to evaluate the potential of SIRI as a prognostic factor in these patients. METHODS: A total of 540 patients with NMIBC who underwent BCG immunotherapy following transurethral resection of bladder tumor (TURBT) were enrolled in this study. Using receiver operating characteristic (ROC) curves and the Youden index, patients were divided into high and low SIRI groups based on the cutoff values. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of BCG non-response. Thereafter, propensity score matching (PSM) was used to eliminate bias due to confounding factors between the low and high SIRI groups. Finally, the Kaplan-Meier method was used to compare recurrence-free survival (RFS) and progression-free survival (PFS) between the two groups. RESULTS: Multivariable logistic regression analysis revealed that high SIRI (p = 0.001), high MLR (p = 0.015), and high tumor pathological T stage (p = 0.015) were significantly correlated with non-response to BCG therapy. In addition, both RFS and PFS were shorter in the high SIRI group than in the other group before and after PSM (both p < 0.05). Collectively, our results indicate that the combination of tumor pathological T staging and the SIRI can enhance the predictive power of BCG response. CONCLUSION: Pretreatment peripheral blood SIRI can be employed to predict the response to BCG immunotherapy and the prognosis of NMIBC patients. Taken together, the combination of T stage and SIRI demonstrated robust performance in predicting the response to BCG immunotherapy in NMIBC patients. CI - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Ye, Kun AU - Ye K AUID- ORCID: 0000-0002-5248-847X AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. FAU - Xiao, Ming AU - Xiao M AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. FAU - Li, Zitaiyu AU - Li Z AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. FAU - He, Kancheng AU - He K AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. FAU - Wang, Jinhua AU - Wang J AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. FAU - Zhu, Liang AU - Zhu L AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Xiong, Wei AU - Xiong W AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Zhong, Zhaohui AU - Zhong Z AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Tang, Yuxin AU - Tang Y AD - Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China. LA - eng PT - Journal Article DEP - 20221010 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Prognosis MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/drug therapy MH - Inflammation MH - Immunotherapy MH - Retrospective Studies PMC - PMC9972176 OTO - NOTNLM OT - BCG response OT - NMIBC OT - biomarkers OT - inflammation OT - systemic inflammatory response index EDAT- 2022/10/11 06:00 MHDA- 2023/03/03 06:00 PMCR- 2022/10/10 CRDT- 2022/10/10 08:03 PHST- 2022/08/26 00:00 [revised] PHST- 2022/07/04 00:00 [received] PHST- 2022/09/12 00:00 [accepted] PHST- 2022/10/11 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/10/10 08:03 [entrez] PHST- 2022/10/10 00:00 [pmc-release] AID - CAM45284 [pii] AID - 10.1002/cam4.5284 [doi] PST - ppublish SO - Cancer Med. 2023 Feb;12(4):4206-4217. doi: 10.1002/cam4.5284. Epub 2022 Oct 10. PMID- 36212478 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231106 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study. PG - 964672 LID - 10.3389/fonc.2022.964672 [doi] LID - 964672 AB - Tumour-infiltrating lymphocytes (TIL), known to be of prognostic value in various solid tumours, have been in the focus of research in the last years. TIL are often quantified via IMMUNOSCORE ((R)) (IS), a scoring system based on TIL cell densities. Recent studies were able to replicate these findings for muscle-invasive bladder cancer (MIBC), however data regarding non-muscle-invasive bladder cancer (NMIBC) are scarce. This study aimed to evaluate the value of a modified Immunoscore (mIS) as a predictive marker for NMIBC prognosis using tissue-micro-arrays (TMAs). We analysed two TMAs containing 316 samples from 158 patients with NMIBC, stained for CD3, CD8, CD45RO and FOXP3. Stained TIL were captured by digital pathology, cumulated, averaged, and reported as density (stained cells per mm(2)). The mIS was then constructed based on density of all four immune-cell types. Clinical, pathological and follow-up data were collected retrospectively. Univariable and multivariable cox regression analysis was performed to assess the potential value of mIS as a predictor for progression free survival (PFS) and recurrence-free-survival (RFS). Patients within "European Organisation for Research and Treatment of Cancer" (EORTC) risk groups were further substratified in high mIS and low mIS subgroups. Finally log-rank test was used to compare the different survival curves. The median age in our cohort was 68 years (Interquartile Range (IQR): 60 - 76), and 117 (74%) patients were male. A total of 26 patients (16.5%) were classified as EORTC low risk, 45 (28.5%) as intermediate risk and 87 (55.1%) as high risk. Patients in the EORTC high risk group with low mIS showed a shorter PFS in comparison to high mIS (HR 2.9, CI 0.79 - 11.0, p=0.082). In contrast, no predictive potential regarding PFS was observed in intermediate or low risk groups. Furthermore, mIS was not able to predict RFS in any EORTC risk group. mIS could be utilized to predict prognosis more accurately in high-risk patients with NMIBC by identifying those with higher or lower risk of progression. Therefore, mIS could be used to allocate these highrisk patients to more streamlined follow-up or more aggressive treatment strategies. CI - Copyright (c) 2022 Bieri, Enderlin, Buser, Wettstein, Eberli, Moch, Hermanns and Poyet. FAU - Bieri, Uwe AU - Bieri U AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Enderlin, Dominik AU - Enderlin D AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Buser, Lorenz AU - Buser L AD - Department of Pathology and Molecular Pathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Wettstein, Marian S AU - Wettstein MS AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Eberli, Daniel AU - Eberli D AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Moch, Holger AU - Moch H AD - Department of Pathology and Molecular Pathology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20220923 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9539272 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - digital pathology OT - immunoscore OT - prognosis OT - progression COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest. EDAT- 2022/10/11 06:00 MHDA- 2022/10/11 06:01 PMCR- 2022/01/01 CRDT- 2022/10/10 04:12 PHST- 2022/06/08 00:00 [received] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/10/10 04:12 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/11 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.964672 [doi] PST - epublish SO - Front Oncol. 2022 Sep 23;12:964672. doi: 10.3389/fonc.2022.964672. eCollection 2022. PMID- 36210217 OWN - NLM STAT- MEDLINE DCOM- 20221117 LR - 20230505 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 82 IP - 6 DP - 2022 Dec TI - Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guerin Failure in Patients with Non-muscle-invasive Bladder Cancer. PG - 646-656 LID - S0302-2838(22)02636-7 [pii] LID - 10.1016/j.eururo.2022.09.008 [doi] AB - BACKGROUND: The functional status of immune cells in the tumor microenvironment and tumor characteristics may explain bacillus Calmette-Guerin (BCG) failure in high-risk non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To characterize molecular correlates of post-BCG high-grade (HG) recurrence using multiomics analysis. DESIGN, SETTING, AND PARTICIPANTS: Patients with BCG-treated NMIBC (n = 156) were included in the study. Metachronous tumors were analyzed using RNA sequencing (n = 170) and whole-exome sequencing (n = 195). Urine samples were analyzed for immuno-oncology-related proteins (n = 190) and tumor-derived DNA (tdDNA; n = 187). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was post-BCG HG recurrence. Cox regression and Wilcoxon rank-sum, t, and Fisher's exact tests were used for analyses. RESULTS AND LIMITATIONS: BCG induced activation of the immune system regardless of clinical response; however, immunoinhibitory proteins were observed in the urine of patients with post-BCG HG recurrence (CD70, PD1, CD5). Post-BCG HG recurrence was associated with post-BCG T-cell exhaustion (p = 0.002). Pre-BCG tumors from patients with post-BCG T-cell exhaustion had high expression of genes related to cell division and immune function. A high predicted post-BCG exhaustion score for pre-BCG tumors was associated with worse post-BCG HG recurrence-free survival (HGRFS; p = 0.002). This was validated in independent cohorts. Pre-BCG class 2a and 2b tumors (UROMOL2021 scheme) were associated with worse post-BCG HGRFS (p = 0.015). Post-BCG exhaustion was observed in patients with high pre-BCG neoantigen load (p = 0.017) and MUC4 mutations (p = 0.002). Finally, the absence of post-BCG tdDNA clearance identified patients at high risk of recurrence (p = 0.018). The retrospective design and partial overlap for analyses are study limitations. CONCLUSIONS: Post-BCG HG recurrence may be caused by T-cell exhaustion. Tumor subtype and pre-BCG tumor characteristics may identify patients at high risk of post-BCG HG recurrence. Urinary measurements have potential for real-time assessment of treatment response. PATIENT SUMMARY: A dysfunctional immune response to bacillus Calmette-Guerin (BCG) therapy may explain high-grade recurrences of bladder cancer. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Strandgaard, Trine AU - Strandgaard T AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lindskrog, Sia Viborg AU - Lindskrog SV AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Nordentoft, Iver AU - Nordentoft I AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Christensen, Emil AU - Christensen E AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Birkenkamp-Demtroder, Karin AU - Birkenkamp-Demtroder K AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Andreasen, Tine Ginnerup AU - Andreasen TG AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lamy, Philippe AU - Lamy P AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Kjaer, Asbjorn AU - Kjaer A AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Ranti, Daniel AU - Ranti D AD - Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Wang, Yuanshuo Alice AU - Wang YA AD - Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Bieber, Christine AU - Bieber C AD - Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Rasmussen, Julie AU - Rasmussen J AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Steiniche, Torben AU - Steiniche T AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Birkbak, Nicolai AU - Birkbak N AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Sfakianos, John AU - Sfakianos J AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Horowitz, Amir AU - Horowitz A AD - Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: lars@clin.au.dk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221007 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (DNA, Neoplasm) SB - IM CIN - Nat Rev Urol. 2023 Apr;20(4):201-202. doi: 10.1038/s41585-022-00687-x. PMID: 36456853 MH - Humans MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/adverse effects MH - DNA, Neoplasm MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - T-Lymphocytes MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/therapy/drug therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Biomarkers OT - Bladder cancer OT - Response OT - T-cell dysfunction EDAT- 2022/10/10 06:00 MHDA- 2022/11/18 06:00 CRDT- 2022/10/09 22:03 PHST- 2022/03/31 00:00 [received] PHST- 2022/07/26 00:00 [revised] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/10/10 06:00 [pubmed] PHST- 2022/11/18 06:00 [medline] PHST- 2022/10/09 22:03 [entrez] AID - S0302-2838(22)02636-7 [pii] AID - 10.1016/j.eururo.2022.09.008 [doi] PST - ppublish SO - Eur Urol. 2022 Dec;82(6):646-656. doi: 10.1016/j.eururo.2022.09.008. Epub 2022 Oct 7. PMID- 36205740 OWN - NLM STAT- MEDLINE DCOM- 20221101 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - Bladder paraganglioma: basic characteristics and new perspectives on perioperative management. PG - 2807-2816 LID - 10.1007/s00345-022-04166-1 [doi] AB - PURPOSE: Paraganglioma and pheochromocytoma are rare neuroendocrine tumors with severe metabolic and cardiovascular complications. Bladder PGLs are rare, and their clinical management is not precise. Here, we discuss the basic characteristics and perioperative management of bladder PGLs. METHODS: We retrospectively reviewed 20 bladder PGL cases diagnosed at Sun Yat-sen University Cancer Center. Case notes were reviewed, clinical presentations, therapies, and outcomes were collected, and data analysis was performed. RESULTS: Ten male and ten female patients with a median age of 47.5 years (range 14-69 years) were included. Most patients (65%) had no symptoms, and PGL was detected incidentally during medical checkups. All patients were treated surgically; 4 (20%) underwent transurethral resection of bladder tumor (TURBT), and 16 (80%) underwent partial cystectomy. Strong intraoperative blood pressure fluctuations were observed in 13 patients (65%). Two patients who were treated preoperatively with alpha-receptor blockers also experienced severe intraoperative blood pressure fluctuations. Postoperative measurements of troponin I were available for 3 patients, and all were significantly elevated. All patients were diagnosed with bladder PGL on postoperative pathological examination. The median follow-up time was 51 months (range 2-147 months), and 2 patients were lost to follow-up at 1 and 3 months; 16 (88.9%) survived without recurrence, 2 patients (11.1%) experienced recurrence, and 1 patient died. CONCLUSION: Most bladder paragangliomas are easily mistaken for bladder urothelial carcinoma, and robust hemodynamic instability during surgery might be a challenge for urologists. Postoperative monitoring of troponin I, regardless of the presence of clinical symptoms, is recommended for patients with bladder PGL. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Cai, Taonong AU - Cai T AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Lu, Jiangli AU - Lu J AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Lin, Zhijun AU - Lin Z AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Luo, Mingrui AU - Luo M AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Liang, Haitao AU - Liang H AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. FAU - Qin, Zike AU - Qin Z AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. qinzk@sysucc.org.cn. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. qinzk@sysucc.org.cn. FAU - Ye, Yunlin AU - Ye Y AUID- ORCID: 0000-0003-1254-7700 AD - Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. yeyunl@sysucc.org.cn. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China. yeyunl@sysucc.org.cn. LA - eng PT - Journal Article DEP - 20221007 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Troponin I) SB - IM MH - Humans MH - Male MH - Female MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Aged MH - *Pheochromocytoma/pathology/surgery MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Urinary Bladder/pathology MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/pathology MH - Troponin I MH - *Paraganglioma/surgery/metabolism/pathology MH - *Adrenal Gland Neoplasms/surgery OTO - NOTNLM OT - Bladder OT - Clinical presentation OT - Myocardial injury OT - PGL OT - Perioperative OT - Prognosis EDAT- 2022/10/08 06:00 MHDA- 2022/11/02 06:00 CRDT- 2022/10/07 11:05 PHST- 2022/07/08 00:00 [received] PHST- 2022/09/24 00:00 [accepted] PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/11/02 06:00 [medline] PHST- 2022/10/07 11:05 [entrez] AID - 10.1007/s00345-022-04166-1 [pii] AID - 10.1007/s00345-022-04166-1 [doi] PST - ppublish SO - World J Urol. 2022 Nov;40(11):2807-2816. doi: 10.1007/s00345-022-04166-1. Epub 2022 Oct 7. PMID- 36204365 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221009 IS - 1661-7649 (Print) IS - 1661-7657 (Electronic) IS - 1661-7649 (Linking) VI - 16 IP - 3 DP - 2022 Sep TI - Complete transurethral resection of bladder tumor before radical cystectomy is not a risk factor for organ-confined bladder cancer: A case-control study. PG - 142-146 LID - 10.1097/CU9.0000000000000110 [doi] AB - OBJECTIVES: To investigate the role of complete transurethral resection of bladder tumor (TURBT) before radical cystectomy (RC) for organ-confined bladder cancer. MATERIALS AND METHODS: Data of patients who underwent RC in our center from January 2008 to December 2018 were retrospectively reviewed. Patients with >T2N0M0 disease and positive surgical margins and those who received neoadjuvant/adjuvant chemotherapy or radiotherapy were excluded. Complete TURBT was defined as no visible lesion under endoscopic examination after TURBT or in the bladder specimen after RC. Kaplan-Meier curves and log-rank tests assessed disease-free survival (DFS). Logistic and Cox regression analyses were performed to identify potential predictors. RESULTS: A total of 236 patients were included in this review, including 207 males, with a median age of 61 years. The median tumor size was 3 cm, and a total of 94 patients had identified pathological T2 stage disease. Complete TURBT was correlated with tumor size (p = 0.041), histological variants (p = 0.026), and down-staging (p < 0.001). Tumor size, grade, and histological variants were independent predictors of complete TURBT. During a median follow-up of 42.7 months, 30 patients developed disease recurrence. Age and histological variants were independent predictors of DFS (p = 0.022 and 0.032, respectively), whereas complete TURBT was not an independent predictor of DFS (p = 0.156). Down-staging was not associated with survival outcome. CONCLUSIONS: Complete TURBT was correlated with an increased rate of down-staging before RC. It was not associated with better oncologic outcomes for patients with organ-confined bladder cancer. CI - Copyright (c) 2022 The Authors. Published by Wolters Kluwer Health, Inc. FAU - Yuan, Xiaoxu AU - Yuan X AD - Department of Urology, Zhuhai People's Hospital, Zhuhai, China. FAU - Chen, Mingkun AU - Chen M AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Yang, Jing AU - Yang J AD - Department of Pathology, Zhuhai People's Hospital, Zhuhai, China. FAU - Ye, Yunlin AU - Ye Y AD - Department of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. LA - eng PT - Journal Article DEP - 20220827 PL - United States TA - Curr Urol JT - Current urology JID - 101471188 PMC - PMC9527917 OTO - NOTNLM OT - Bladder cancer OT - Complete transurethral resection of bladder tumor OT - Down-staging OT - Radical cystectomy EDAT- 2022/10/08 06:00 MHDA- 2022/10/08 06:01 PMCR- 2022/09/01 CRDT- 2022/10/07 02:52 PHST- 2021/12/19 00:00 [received] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/10/07 02:52 [entrez] PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/10/08 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - CURR-UROL_220003 [pii] AID - 10.1097/CU9.0000000000000110 [doi] PST - ppublish SO - Curr Urol. 2022 Sep;16(3):142-146. doi: 10.1097/CU9.0000000000000110. Epub 2022 Aug 27. PMID- 36204354 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221009 IS - 1661-7649 (Print) IS - 1661-7657 (Electronic) IS - 1661-7649 (Linking) VI - 16 IP - 3 DP - 2022 Sep TI - Clinical characteristics and treatment outcomes of patients with small cell carcinoma of the urinary bladder. PG - 136-141 LID - 10.1097/CU9.0000000000000125 [doi] AB - BACKGROUND: Small cell carcinoma of the urinary bladder (SCUB) is rare. The optimal treatment for SCUB remains unclear. To address the problem of appropriate treatment for each case, we assessed single-modality and surgery-based multimodality treatments in patients with SCUB. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 12 patients with SCUB between 1990 and 2013. All patients underwent transurethral resection of the bladder tumor and were diagnosed with SCUB. Their clinicopathological characteristics were assessed, and the outcomes were compared according to the treatment modality. RESULTS: The median (range) age at diagnosis was 66 years (range, 53-85 years). T1-4N0M0 was observed in 8 patients (66%), N1-3M0 in 2 (17%), and NanyM1 in 2 (17%). After transurethral resection of the bladder tumor, 6 patients (50%) underwent cystectomy alone, and 4 (33%) underwent cystectomy and presurgical or adjuvant chemotherapy with etoposide and cisplatin. During the median follow-up period of 20.7 months, 6 patients (50%) died of cancer, and 2 patients (17%) died of other causes. The median overall survival period was 1.9 years. The 5-year overall survival rate in patients who underwent cystectomy and chemotherapy was 75%, whereas that in those who underwent cystectomy alone and transurethral resection alone were 22% and 0%, respectively (p = 0.012). Recurrence-free survival was significantly correlated with cause-specific survival (r = 0.95; 95% confidence interval, 0.81-0.99; p < 0.001). CONCLUSIONS: Radical cystectomy with chemotherapy using the etoposide and cisplatin regimen improved the prognosis of patients with SCUB and TxNxM0. The time from initial progression to death due to cancer was very short, indicating that the initial treatment strategy is crucial. CI - Copyright (c) 2022 The Authors. Published by Wolters Kluwer Health, Inc. FAU - Muranaka, Takashi AU - Muranaka T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Hashimoto, Kohei AU - Hashimoto K AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Shindo, Tetsuya AU - Shindo T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Shibamori, Kosuke AU - Shibamori K AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kyoda, Yuki AU - Kyoda Y AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kobayashi, Ko AU - Kobayashi K AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Tanaka, Toshiaki AU - Tanaka T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article DEP - 20220827 PL - United States TA - Curr Urol JT - Current urology JID - 101471188 PMC - PMC9527920 OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Radical cystectomy OT - Small cell carcinoma OT - Treatment EDAT- 2022/10/08 06:00 MHDA- 2022/10/08 06:01 PMCR- 2022/09/01 CRDT- 2022/10/07 02:52 PHST- 2021/02/26 00:00 [received] PHST- 2022/01/28 00:00 [accepted] PHST- 2022/10/07 02:52 [entrez] PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/10/08 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - CURR-UROL_220022 [pii] AID - 10.1097/CU9.0000000000000125 [doi] PST - ppublish SO - Curr Urol. 2022 Sep;16(3):136-141. doi: 10.1097/CU9.0000000000000125. Epub 2022 Aug 27. PMID- 36203422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221009 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance. PG - 1019391 LID - 10.3389/fonc.2022.1019391 [doi] LID - 1019391 AB - Bladder cancer is one of the top ten most common cancers and top ten causes of cancer death globally. 5-year survival rates have decreased in Australia from 66% to 55% in the past three decades. The current gold standard for diagnosis is cystoscopy. However, cystoscopies are an invasive and health-resource intensive procedure which has sub-optimal sensitivity for flat lesions such as CIS (carcinoma in situ) and low specificity for differentiating inflammation from cancer - hence requiring biopsies under anesthesia. Frequent and life-long surveillance cystoscopy is required for most patients since there are high rates of progression and local recurrence in high-risk non-muscle invasive cancer (NMIBC) as well as poor outcomes associated with delayed detection of muscle-invasive bladder cancer (MIBC). There is an unmet need for a non-invasive test to provide better discrimination and risk-stratification of bladder cancer which could aid clinicians by improving patient selection for cystoscopy; enhanced risk stratification methods may guide the frequency of surveillance cystoscopies and inform treatment choices. Exosomes, which are nano-sized extracellular vesicles containing genetic material and proteins, have been shown to have functional roles in the development and progression of bladder cancer. Exosomes have also been demonstrated to be a robust source of potential biomarkers for bladder cancer diagnosis and prognosis and may also have roles as therapeutic agents. In this review, we summarize the latest evidence of biological roles of exosomes in bladder cancer and highlight their clinical significance in bladder cancer diagnosis, surveillance and treatment. CI - Copyright (c) 2022 Lee, Canagasingham, Bajaj, Shanmugasundaram, Hutton, Bucci, Graham, Thompson and Ni. FAU - Lee, Nicholas AU - Lee N AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. FAU - Canagasingham, Ashan AU - Canagasingham A AD - Department of Urology, St George Hospital, Kogarah, NSW, Australia. FAU - Bajaj, Mohit AU - Bajaj M AD - Department of Urology, St George Hospital, Kogarah, NSW, Australia. FAU - Shanmugasundaram, Ramesh AU - Shanmugasundaram R AD - Department of Urology, St George Hospital, Kogarah, NSW, Australia. FAU - Hutton, Anthony AU - Hutton A AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. AD - Department of Urology, St George Hospital, Kogarah, NSW, Australia. FAU - Bucci, Joseph AU - Bucci J AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. AD - Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia. FAU - Graham, Peter AU - Graham P AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. AD - Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia. FAU - Thompson, James AU - Thompson J AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. AD - Department of Urology, St George Hospital, Kogarah, NSW, Australia. FAU - Ni, Jie AU - Ni J AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, Australia. AD - Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia. LA - eng PT - Journal Article PT - Review DEP - 20220920 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9530625 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - diagnosis OT - exosome OT - liquid biopsy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/08 06:00 MHDA- 2022/10/08 06:01 PMCR- 2022/01/01 CRDT- 2022/10/07 02:34 PHST- 2022/08/15 00:00 [received] PHST- 2022/09/01 00:00 [accepted] PHST- 2022/10/07 02:34 [entrez] PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/10/08 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.1019391 [doi] PST - epublish SO - Front Oncol. 2022 Sep 20;12:1019391. doi: 10.3389/fonc.2022.1019391. eCollection 2022. PMID- 36197700 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230531 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 75 IP - 2 DP - 2023 Apr TI - Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. PG - 180-187 LID - 10.23736/S2724-6051.22.04953-9 [doi] AB - BACKGROUND: Recently, the European Association of Urology Guidelines Panel updated the prognostic factor risk groups model for non-muscle-invasive bladder cancer (NMIBC) with the introduction of a new group of patients at very high risk (VHR). Furthermore, three additional clinical risk factors (i.e., age>70 years, multiple papillary tumors; tumor diameter >3 cm) were proposed. However, the new scoring model was created by analyzing data from patients who did not receive BCG intravesical therapy. METHODS: This is a retrospective multicenter study analyzing data of 920 patients with HGT1 NMIBC that underwent ReTUR e following BCG intravesical therapy. Patients were stratified into risk groups according to the 2021 new EAU NMIBC prognostic factor risk groups model. This study aimed to identify variables related to disease progression in a large cohort of HGT1 NMIBC patients who underwent both Re-TURB and BCG intravesical immunotherapy. RESULTS: Median follow-up was 51 months (IQR 41-75), according to EAU NMIBC 2021 scoring model 179 (19.5%) patients were at VHR. Progression-free survival at 5 years was 68.2% and 59.9% for the whole sample and the VHR group, respectively. At multivariable regression model size >3 cm, multifocal tumor, concomitant CIS and LVI were identified as independently associated with disease progression. CONCLUSIONS: Although patients at VHR are more likely to experience disease progression during follow-up, the European Association of Urology (EAU) NMIBC 2021 scoring model appears to be suboptimal in patients who underwent ReTUR and intravesical BCG therapy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. FAU - Fiori, Cristian AU - Fiori C AD - Department of Urology, University of Turin, AOU San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. FAU - Barone, Biagio AU - Barone B AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Busetto, Gian M AU - Busetto GM AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Sapienza University, Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Urology, Sapienza University, Rome, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Genoa, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Unit of Urology, Department of Surgery, Tor Vergata University, Rome, Italy. AD - Department of Urology, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy. FAU - Bertolo, Riccardo AU - Bertolo R AD - Department of Urology, San Carlo di Nancy Hospital - GVM Care and Research, Rome, Italy. FAU - Papalia, Rocco AU - Papalia R AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. FAU - Mistretta, Francesco A AU - Mistretta FA AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, University of Turin, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, University of Turin, Turin, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, Chieti, Italy. FAU - LA Civita, Evelina AU - LA Civita E AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Russo, Giorgio I AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Schips, Luigi AU - Schips L AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, Chieti, Italy. FAU - Perdona, Sisto AU - Perdona S AD - G. Pascale IRCCS Foudation, Naples, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Tataru, Octavian S AU - Tataru OS AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, Targu Mures, Romania. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. AD - Department of Urology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, Targu Mures, Romania. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. FAU - DE Cobelli, Ottavio AU - DE Cobelli O AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. AD - Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy - matteo.ferro@ieo.it. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221005 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (BCG Vaccine) SB - IM CIN - Minerva Urol Nephrol. 2023 Jun;75(3):407-409. doi: 10.23736/S2724-6051.23.05337-5. PMID: 37221831 MH - Humans MH - Aged MH - BCG Vaccine/therapeutic use MH - *Urology MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Disease Progression EDAT- 2022/10/06 06:00 MHDA- 2023/04/03 06:42 CRDT- 2022/10/05 11:51 PHST- 2023/04/03 06:42 [medline] PHST- 2022/10/06 06:00 [pubmed] PHST- 2022/10/05 11:51 [entrez] AID - S2724-6051.22.04953-9 [pii] AID - 10.23736/S2724-6051.22.04953-9 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2023 Apr;75(2):180-187. doi: 10.23736/S2724-6051.22.04953-9. Epub 2022 Oct 5. PMID- 36189399 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221004 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 9 DP - 2022 TI - Can a reresection be avoided after initial en bloc resection for high-risk nonmuscle invasive bladder cancer? A systematic review and meta-analysis. PG - 849929 LID - 10.3389/fsurg.2022.849929 [doi] LID - 849929 AB - BACKGROUND: This study aims to evaluate the effectiveness of en bloc resection for patients with nonmuscle invasive bladder cancer (NMIBC) and explore whether a reresection can be avoided after initial en bloc resection. MATERIAL AND METHODS: We conducted research in PubMed, EMBASE, Cochrane Library, and Web of Science up to October 12, 2021, to identify studies on the second resection after initial en bloc resection of bladder tumor (ERBT). R software and the double arcsine method were used for data conversion and combined calculation of the incidence rate. RESULTS: A total of 8 studies involving 414 participants were included. The rate of detrusor muscle in the ERBT specimens was 100% (95%CI: 100%-100%), the rate of tumor residual in reresection specimens was 3.2% (95%CI: 1.4%-5.5%), and the rate of tumor upstaging was 0.3% (95%CI: 0%-1.5%). Two articles compared the prognostic data of the reresection and non-reresection groups after the initial ERBT. We found no significant difference in the 1-year recurrence-free survival (RFS) rate (OR = 1.44, 95%CI: 0.67-3.09, P = 0.35) between the two groups nor in the rate of tumor recurrence (OR = 0.72, 95%CI: 0.44-1.18, P = 0.2) or progression (OR = 0.98, 95%CI: 0.33-2.89, P = 0.97) at the final follow-up. CONCLUSIONS: ERBT can almost completely remove the detrusor muscle of the tumor bed with a very low postoperative tumor residue and upstaging rate. For high-risk NMIBC patients, an attempt to appropriately reduce the use of reresection after ERBT seems to be possible. CI - (c) 2022 Xu, Xu, Yin and Zang. FAU - Xu, Jiangnan AU - Xu J AD - Department of Urology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, Yancheng, China. AD - Department of Urology, The First People's Hospital of Yancheng, Yancheng, China. FAU - Xu, Zhenyu AU - Xu Z AD - Department of Urology, Kunshan Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China. FAU - Yin, HuMin AU - Yin H AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Zang, Jin AU - Zang J AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20220914 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC9515398 OTO - NOTNLM OT - en bloc resection OT - high-risk OT - nonmuscle-invasive bladder cancer OT - reresection OT - systematic review and meta-analysis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/04 06:00 MHDA- 2022/10/04 06:01 PMCR- 2022/09/14 CRDT- 2022/10/03 05:21 PHST- 2022/01/06 00:00 [received] PHST- 2022/08/25 00:00 [accepted] PHST- 2022/10/03 05:21 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/04 06:01 [medline] PHST- 2022/09/14 00:00 [pmc-release] AID - 10.3389/fsurg.2022.849929 [doi] PST - epublish SO - Front Surg. 2022 Sep 14;9:849929. doi: 10.3389/fsurg.2022.849929. eCollection 2022. PMID- 36189320 OWN - NLM STAT- MEDLINE DCOM- 20221004 LR - 20260824 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients. PG - 970931 LID - 10.3389/fimmu.2022.970931 [doi] LID - 970931 AB - High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Guerin (BCG). Although most bladder cancer patients respond well to BCG, there is no clinical parameter predictive of treatment response, and when treatment fails, the prognosis is very poor. Further, a high percentage of NMIBC patients treated with BCG suffer unwanted effects that force them to stop treatment. Thus, early identification of patients in which BCG treatment will fail is really important. Here, to identify early stage non-invasive biomarkers of non-responder patients and patients at risk of abandoning the treatment, we longitudinally analysed the phenotype of cells released into the urine of bladder cancer patients 3-7 days after BCG instillations. Mass cytometry (CyTOF) analyses revealed a large proportion of granulocytes and monocytes, mostly expressing activation markers. A novel population of CD15(+)CD66b(+)CD14(+)CD16(+) cells was highly abundant in several samples; expression of these markers was confirmed using flow cytometry and qPCR. A stronger inflammatory response was associated with increased cell numbers in the urine; this was not due to hematuria because the cell proportions were distinct from those in the blood. This pilot study represents the first CyTOF analysis of cells recruited to urine during BCG treatment, allowing identification of informative markers associated with treatment response for sub-selection of markers to confirm using conventional techniques. Further studies should jointly evaluate cells and soluble factors in urine in larger cohorts of patients to characterise the arms of the immune response activated in responders and to identify patients at risk of complications from BCG treatment. CI - Copyright (c) 2022 Castellano, Samba, Esteso, Simpson, Vendrame, Garcia-Cuesta, Lopez-Cobo, Alvarez-Maestro, Linares, Leibar, Ranganath, Reyburn, Martinez-Pineiro, Blish and Vales-Gomez. FAU - Castellano, Eva AU - Castellano E AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Samba, Celia AU - Samba C AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Esteso, Gloria AU - Esteso G AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Simpson, Laura AU - Simpson L AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. FAU - Vendrame, Elena AU - Vendrame E AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. FAU - Garcia-Cuesta, Eva M AU - Garcia-Cuesta EM AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Lopez-Cobo, Sheila AU - Lopez-Cobo S AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Urology Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Urology Unit, Infanta Sofia Hospital, Madrid, Spain. FAU - Linares, Ana AU - Linares A AD - Urology Unit, Infanta Sofia Hospital, Madrid, Spain. FAU - Leibar, Asier AU - Leibar A AD - Urology Unit, Infanta Sofia Hospital, Madrid, Spain. FAU - Ranganath, Thanmayi AU - Ranganath T AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. FAU - Reyburn, Hugh T AU - Reyburn HT AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Urology Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Urology Unit, Infanta Sofia Hospital, Madrid, Spain. FAU - Blish, Catherine AU - Blish C AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. AD - Chan Zuckerberg Biohub, San Francisco, CA, United States. FAU - Vales-Gomez, Mar AU - Vales-Gomez M AD - Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain. AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. LA - eng GR - DP2 AI112193/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220915 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Pilot Projects MH - Prognosis MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC9520259 OTO - NOTNLM OT - BCG - Bacille Calmette-Guerin vaccine OT - bladder cancer OT - granulocytes OT - immune response OT - leukocytes OT - mass cytometry (CyTOF) OT - urine cells COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/04 06:00 MHDA- 2022/10/05 06:00 PMCR- 2022/01/01 CRDT- 2022/10/03 05:19 PHST- 2022/06/16 00:00 [received] PHST- 2022/08/23 00:00 [accepted] PHST- 2022/10/03 05:19 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/05 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.970931 [doi] PST - epublish SO - Front Immunol. 2022 Sep 15;13:970931. doi: 10.3389/fimmu.2022.970931. eCollection 2022. PMID- 36187522 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230902 IS - 0975-7651 (Print) IS - 0976-6952 (Electronic) IS - 0975-7651 (Linking) VI - 13 IP - 3 DP - 2022 Sep TI - When to Avoid a Restaging Procedure for Non-muscle Invasive Bladder Cancer? Inferences from a Tertiary Care Center. PG - 604-611 LID - 10.1007/s13193-022-01516-8 [doi] AB - The increasing incidence of urinary bladder carcinoma is alarming. Approximately seventy percent of these patients are non-muscle invasive bladder cancer (NMIBC). Restage transurethral resection of bladder tumor (TURBT) is the current recommendation for any T1 and or high-grade non muscle invasive bladder cancers (NMIBC) to accurately stage the malignancy. The question whether a second surgery is always required as a restage procedure is still unanswered. The patient's concern about completeness, morbidity, and financial considerations of a major surgery cannot be overlooked. Moreover, it also puts a strain on the already overburdened healthcare system. To answer this question, whether it is oncologically sound to omit a second resection, the current study evaluated the outcomes of patients undergoing restage TURBT, and analyzed the preoperative factors predicting a change in the staging of this malignancy. The study design was a prospective observational including NMIBC patients from September 2018 to February 2020. A total of 72 patients underwent restage TURBT. Their demographic data, imaging and cystoscopic findings, and histopathological data were recorded. The objective was to study the clinico-pathological correlations and factors predicting recurrence and upstaging of tumor in NMIBC patients undergoing restage TURBT. A total of 101 patients were found eligible for restage TURBT. Eventually, 72 underwent restage TURBT. Twelve (16.7%) patient had recurrence at restage while 3(4.16%) were upstaged to T2. Presence of lower urinary tract symptoms (LUTS) was independently associated with the risk of recurrence of same stage compared to no recurrence (p-0.025, OR-8.793, 95% CI-1.316-98.773). Chemical exposure (p-0.042) was also significantly associated with the same. Presence of lymphadenopathy on CT was independently associated with the risk of upstaging compared to no recurrence (p-0.032, OR-18.25, 95% CI-1.292-257.85). The study concluded that in the presence of a well-performed and adequate initial TURBT, restage TURBT could be skipped for further management. However, in small subgroup of patients with lymphadenopathy on preoperative imaging having a higher risk of tumor recurrence and upstaging, and patients with a history of chemical exposure and previous lower urinary tract symptoms having a high risk of recurrence alone, restage TURBT should still be performed to accurately stage the disease. Further studies with large patient cohort are needed to confirm and reinforce the facts proposed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13193-022-01516-8. CI - (c) The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022. FAU - Bhirud, Deepak Prakash AU - Bhirud DP AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Mittal, Ankur AU - Mittal A AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Kumar, Sunil AU - Kumar S AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Narain, Tushar Aditya AU - Narain TA AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Kishore, Sanjeev AU - Kishore S AD - Department of Pathology, AiimsRishikesh, Uttarakhand India. FAU - Navriya, Shiv Charan AU - Navriya SC AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Ranjan, Satish Kumar AU - Ranjan SK AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. FAU - Panwar, Vikas Kumar AU - Panwar VK AD - Department of Urology, AiimsRishikesh, Uttarakhand India 249203. LA - eng PT - Journal Article DEP - 20220318 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC9515286 OTO - NOTNLM OT - Lower urinary tract symptoms (LUTS) OT - Non-muscle invasive bladder cancer (NMIBC) OT - Restage TURBT OT - Urothelial bladder cancer COIS- Conflict of InterestThe authors declare no competing interests. EDAT- 2022/10/04 06:00 MHDA- 2022/10/04 06:01 PMCR- 2023/09/01 CRDT- 2022/10/03 04:53 PHST- 2020/07/20 00:00 [received] PHST- 2022/01/31 00:00 [accepted] PHST- 2022/10/03 04:53 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/04 06:01 [medline] PHST- 2023/09/01 00:00 [pmc-release] AID - 1516 [pii] AID - 10.1007/s13193-022-01516-8 [doi] PST - ppublish SO - Indian J Surg Oncol. 2022 Sep;13(3):604-611. doi: 10.1007/s13193-022-01516-8. Epub 2022 Mar 18. PMID- 36183417 OWN - NLM STAT- MEDLINE DCOM- 20221201 LR - 20230125 IS - 1546-4156 (Electronic) IS - 0893-0341 (Linking) VI - 36 IP - 4 DP - 2022 Oct-Dec 01 TI - Intravesical BCG and Incidence of Alzheimer Disease in Patients With Bladder Cancer: Results From an Administrative Dataset. PG - 307-311 LID - 10.1097/WAD.0000000000000530 [doi] AB - INTRODUCTION: Alzheimer disease (AD) is a common neurodegenerative disease, and immunomodulation offers treatment opportunities. Preclinical data suggest that intravesical Bacillus Calmette-Guerin (BCG) treatment could delay AD development. We investigated this relationship in a population-based cancer database. SAMPLE AND METHODS: We queried the Surveillance, Epidemiology, and End Results-Medicare database for patients with high-risk nonmuscle-invasive bladder cancer (hrNMIBC). BCG dosage and subsequent Alzheimer diagnosis were collected through ICD-9/10 codes. Multivariable Cox regression was performed to assess the association between BCG therapy and subsequent Alzheimer diagnosis. RESULTS: We identified 26,584 hrNMIBC patients; 51% received BCG and 8.3% were diagnosed with Alzheimer. BCG exposure was significantly associated with lower Alzheimer occurrence (hazard ratio: 0.73, P <0.05), which was dose-dependent. Increasing age, female sex, Black race, and increasing comorbidity index were significantly associated with a greater risk of subsequent Alzheimer diagnosis. DISCUSSION: Treatment with intravesical BCG among patients with hrNMIBC was associated with a significantly lower risk for subsequent Alzheimer diagnosis, which seemed dose-dependent. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Makrakis, Dimitrios AU - Makrakis D AUID- ORCID: 0000-0003-3258-2984 AD - Division of Medical Oncology. FAU - Holt, Sarah K AU - Holt SK AD - Department of Urology. FAU - Bernick, Charles AU - Bernick C AD - Department of Neurology, University of Washington School of Medicine, Seattle, WA. FAU - Grivas, Petros AU - Grivas P AD - Division of Medical Oncology. FAU - Gore, John L AU - Gore JL AD - Department of Urology. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology. LA - eng PT - Journal Article DEP - 20220930 PL - United States TA - Alzheimer Dis Assoc Disord JT - Alzheimer disease and associated disorders JID - 8704771 RN - 0 (BCG Vaccine) SB - IM MH - United States/epidemiology MH - Humans MH - Female MH - Aged MH - *Urinary Bladder Neoplasms/epidemiology/drug therapy MH - *Alzheimer Disease/epidemiology MH - BCG Vaccine/therapeutic use MH - Incidence MH - *Neurodegenerative Diseases MH - Neoplasm Recurrence, Local/therapy MH - Neoplasm Invasiveness MH - Medicare COIS- C.B. has served as an advisor for Optina Diagnostics. P.G. (in the last 3 y) has provided consulting to AstraZeneca, Astellas Pharma, Bayer, Bristol Myers Squibb, Clovis Oncology, Dyania Health, Driver, EMD Serono, Exelixis, Foundation Medicine, Guardant Health, Genentech/Roche, Genzyme, GlaxoSmithKline, Heron Therapeutics, Immunomedics/Gilead, Infinity Pharmaceuticals, Janssen, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, 4D Pharma PLC, UroGen; his institution has received research funding from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics. J.L.G. has received research funding from FerGene Pharmaceuticals Inc. J.L.W. has received research funding from Alto Biosciences, Nucleix, Merck and Janssen, and he has served as a consultant to Sanofi Genzyme. He has also received royalties from up to date. The remaining authors declare no conflicts of interest. EDAT- 2022/10/03 06:00 MHDA- 2022/12/02 06:00 CRDT- 2022/10/02 17:58 PHST- 2021/11/08 00:00 [received] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/10/03 06:00 [pubmed] PHST- 2022/12/02 06:00 [medline] PHST- 2022/10/02 17:58 [entrez] AID - 00002093-202210000-00005 [pii] AID - 10.1097/WAD.0000000000000530 [doi] PST - ppublish SO - Alzheimer Dis Assoc Disord. 2022 Oct-Dec 01;36(4):307-311. doi: 10.1097/WAD.0000000000000530. Epub 2022 Sep 30. PMID- 36181128 OWN - NLM STAT- MEDLINE DCOM- 20221004 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 39 DP - 2022 Sep 30 TI - A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. PG - e30893 LID - 10.1097/MD.0000000000030893 [doi] LID - e30893 AB - BACKGROUND: Bladder cancer (BC) is the 10th most common malignancy worldwide, and some studies reported that ABO blood type or/and rhesus factor has been identified as a prognostic oncologic marker for patients with BC. We carried out a systematic review to assess the prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. METHODS: We searched databases through February 2022 for studies assessing blood group on outcomes in patients with bladder cancer. RESULTS: We included ten studies with 15,204 participants. We found that blood type A is relevant to non-muscle-invasive BC patients treated with transurethral resection of bladder tumor and blood type B patients have a lower incidence of disease recurrence and progression. Blood type O and non-O blood type have not been found to be related to disease recurrence. However, in multivariable analyses, blood type O and non-O blood type are associated with cancer-specific mortality (CSM). Other than that, blood type B doesn't have statistical significance for BC patients accepted radical cystectomy (RC). The same results showed in blood type AB non-muscle-invasive bladder cancer patients treated with RC. CONCLUSIONS: Our study confirmed that a particular association of blood type for prognosis of patients with BC, and ABO blood group antigen expression can be suitable biomarkers for BC. We also found that rhesus factor has no impact on prognosis of BC patients. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yang, Haiming AU - Yang H AD - Department of Interventional Therapy, Qinghai University, Xining, China. FAU - Yan, Jingxin AU - Yan J AUID- ORCID: 0000-0002-2734-6146 AD - Department of Interventional Therapy, Qinghai University, Xining, China. AD - Department of Postgraduate, Qinghai University, Xining, China. LA - eng PT - Journal Article PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (ABO Blood-Group System) SB - IM MH - ABO Blood-Group System MH - Cystectomy/methods MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9524977 COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/10/02 06:00 MHDA- 2022/10/05 06:00 PMCR- 2022/09/30 CRDT- 2022/10/01 01:02 PHST- 2022/10/01 01:02 [entrez] PHST- 2022/10/02 06:00 [pubmed] PHST- 2022/10/05 06:00 [medline] PHST- 2022/09/30 00:00 [pmc-release] AID - 00005792-202209300-00126 [pii] AID - 10.1097/MD.0000000000030893 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Sep 30;101(39):e30893. doi: 10.1097/MD.0000000000030893. PMID- 38319866 OWN - NLM STAT- MEDLINE DCOM- 20240208 LR - 20260612 IS - 2766-5526 (Electronic) IS - 2766-5526 (Linking) VI - 1 IP - 10 DP - 2022 Oct TI - A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer. PG - EVIDoa2200092 LID - 10.1056/EVIDoa2200092 [doi] AB - BACKGROUND: Recurrence of non-muscle-invasive bladder cancer (NMIBC) is common after transurethral resection of bladder tumor (TURBT). Photodynamic diagnosis (PDD) provides better diagnostic accuracy and more complete tumor resection and may reduce recurrence. However, there is limited evidence on the longer-term clinical effectiveness and cost-effectiveness of PDD-guided resection. METHODS: In this pragmatic, open-label, parallel-group randomized trial conducted in 22 U.K. National Health Service hospitals, we recruited participants with a suspected first diagnosis of NMIBC at intermediate or high risk for recurrence on the basis of routine visual assessment before being listed for TURBT. Participants were assigned (1:1) to PDD-guided TURBT or to standard white light (WL)-guided TURBT. The primary clinical outcome was time to recurrence at 3 years of follow-up, analyzed by modified intention to treat. RESULTS: A total of 538 participants were enrolled (269 in each group), and 112 participants without histologic confirmation of NMIBC or who had had cystectomy were excluded. After 44 months' median follow-up, 86 of 209 in the PDD group and 84 of 217 in the WL group had recurrences. The hazard ratio for recurrence was 0.94 (95% confidence interval [CI], 0.69 to 1.28; P=0.70). Three-year recurrence-free rates were 57.8% (95% CI, 50.7 to 64.2) and 61.6% (95% CI, 54.7 to 67.8) in the PDD and WL groups, respectively, with an absolute difference of -3.8 percentage points (95% CI, -13.37 to 5.59) favoring PDD. Adverse events occurred in less than 2% of participants, and rates were similar in both groups, as was health-related quality of life. PDD-guided TURBT was pound876 (95% CI, -766 to 2518; P=0.591) more costly than WL-guided TURBT over a 3-year follow-up, with no evidence of a difference in quality-adjusted life years (-0.007; 95% CI, -0.133 to 0.119; P=0.444). CONCLUSIONS: PDD-guided TURBT did not reduce recurrence rates, nor was it cost-effective compared with WL at 3 years. (Funded by the National Institute for Health and Care Research Health Technology Assessment program; ISRCTN number, ISRCTN84013636.) FAU - Heer, Rakesh AU - Heer R AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Lewis, Rebecca AU - Lewis R AD - The Institute of Cancer Research, London. FAU - Vadiveloo, Thenmalar AU - Vadiveloo T AD - Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, United Kingdom. FAU - Yu, Ge AU - Yu G AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh. FAU - Cresswell, Joanne AU - Cresswell J AD - South Tees Hospitals NHS Trust, Middlesbrough, United Kingdom. FAU - McGrath, John AU - McGrath J AD - Royal Devon and Exeter Hospital NHS Trust, Exeter, United Kingdom. FAU - Nabi, Ghulam AU - Nabi G AD - University of Dundee, Dundee, United Kingdom. FAU - Mostafid, Hugh AU - Mostafid H AD - Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom. FAU - Lazarowicz, Henry AU - Lazarowicz H AD - Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom. FAU - Kelly, John AU - Kelly J AD - University College London Hospitals NHS Foundation Trust, London. FAU - Duncan, Anne AU - Duncan A AD - Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, United Kingdom. FAU - Penegar, Steven AU - Penegar S AD - The Institute of Cancer Research, London. FAU - Breckons, Matt AU - Breckons M AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Wilson, Laura AU - Wilson L AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Clark, Emma AU - Clark E AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Feber, Andy AU - Feber A AD - University College London Hospitals NHS Foundation Trust, London. FAU - Orozco-Leal, Giovany AU - Orozco-Leal G AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Tandogdu, Zafer AU - Tandogdu Z AD - University College London Hospitals NHS Foundation Trust, London. FAU - Taylor, Ernest AU - Taylor E AD - PHOTO Trial patient representative, United Kingdom. FAU - N'Dow, James AU - N'Dow J AD - Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom. FAU - Norrie, John AU - Norrie J AD - Edinburgh Clinical Trials Unit, Edinburgh University, Edinburgh. FAU - Ramsay, Craig AU - Ramsay C AD - Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom. FAU - Rice, Stephen AU - Rice S AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Vale, Luke AU - Vale L AD - Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - MacLennan, Graeme AU - MacLennan G AD - Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, United Kingdom. FAU - Hall, Emma AU - Hall E AD - The Institute of Cancer Research, London. LA - eng PT - Journal Article PT - Pragmatic Clinical Trial PT - Randomized Controlled Trial DEP - 20220902 PL - United States TA - NEJM Evid JT - NEJM evidence JID - 9918317485806676 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM CIN - J Urol. 2023 Aug;210(2):379-381. doi: 10.1097/JU.0000000000003540. PMID: 37194390 CIN - Eur Urol. 2024 Feb;85(2):178-179. doi: 10.1016/j.eururo.2023.07.017. PMID: 37580211 MH - Humans MH - Photosensitizing Agents MH - Aminolevulinic Acid MH - *Non-Muscle Invasive Bladder Neoplasms MH - *Urinary Bladder Neoplasms/diagnosis MH - Urologic Surgical Procedures EDAT- 2022/10/01 00:00 MHDA- 2024/02/08 06:42 CRDT- 2024/02/06 13:04 PHST- 2024/02/08 06:42 [medline] PHST- 2022/10/01 00:00 [pubmed] PHST- 2024/02/06 13:04 [entrez] AID - 10.1056/EVIDoa2200092 [doi] PST - ppublish SO - NEJM Evid. 2022 Oct;1(10):EVIDoa2200092. doi: 10.1056/EVIDoa2200092. Epub 2022 Sep 2. PMID- 36180340 OWN - NLM STAT- MEDLINE DCOM- 20230328 LR - 20230411 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 21 IP - 2 DP - 2023 Apr TI - Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG. PG - e70-e77 LID - S1558-7673(22)00176-8 [pii] LID - 10.1016/j.clgc.2022.08.007 [doi] AB - INTRODUCTION: Predicting outcomes of patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) is critical. Here, we evaluate whether bladder tumor resection weight might serve as a prognostic factor for recurrence and progression of HR-NMIBC patients treated with Bacillus Calmette-Guerin (BCG). METHODS: In this retrospective, single-centre study in the UK, we analysed a consecutive cohort of HR-NMIBC patients who have received adequate intravesical BCG immunotherapy between 2009 and 2019. Univariable and multivariable Cox proportional hazards models were used to assess the association of resection weight and established predictors with recurrence and progression. RESULTS: A total of 187 HR-NMIBC patients were analysed. The median resection weight was 1.4g (range: 0.2-28.5g). Within a median follow-up of 41 months, 58 (31%) tumors recurred and 19 (10%) progressed. Fifty-four patients (29%) died from any cause and 16 (9%) died from bladder cancer. Both the risk of recurrence (P = .007) and progression (P = .019) increased with rising resection weight. On the multivariable analysis, a resection weight of >/= 2g and >/= 3g conferred a 4.35-fold and a 9.03-fold increased risk of bladder cancer recurrence (P < .001) and progression (P < .001), respectively. The addition of resection weight improved the C index of multivariable standard prognostic models to a clinically significant extent (+ 3.8% for recurrence, + 4.3% for progression). CONCLUSION: In our HR-NMIBC patient cohort treated with BCG, bladder tumor resection weight was associated with disease recurrence and progression. Its addition improves discrimination of standard prognostic factors. Measurement may therefore be considered for routine clinical practice. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Hald, Oliver C AU - Hald OC AD - Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK; Urology Centre, Guy's Hospital, Guys and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK. FAU - Phan, Yih Chyn AU - Phan YC AD - Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK; Department of Urology, Salisbury District Hospital, Salisbury NHS Foundation Trust, Salisbury, UK. FAU - Carter, Charles J M AU - Carter CJM AD - Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK; Department of Urology, Charite-Universitatsmedizin Berlin, Berlin, Germany. Electronic address: tobias.klatte@gmx.de. LA - eng PT - Journal Article DEP - 20220829 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Prognosis MH - *Urinary Bladder/surgery/pathology MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Neoplasm Invasiveness MH - Administration, Intravesical MH - Disease Progression OTO - NOTNLM OT - BCG OT - Non-muscle invasive bladder cancer OT - Prognosis OT - Progression OT - Recurrence OT - Weight EDAT- 2022/10/01 06:00 MHDA- 2023/03/28 17:04 CRDT- 2022/09/30 22:07 PHST- 2022/03/30 00:00 [received] PHST- 2022/08/18 00:00 [revised] PHST- 2022/08/21 00:00 [accepted] PHST- 2023/03/28 17:04 [medline] PHST- 2022/10/01 06:00 [pubmed] PHST- 2022/09/30 22:07 [entrez] AID - S1558-7673(22)00176-8 [pii] AID - 10.1016/j.clgc.2022.08.007 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2023 Apr;21(2):e70-e77. doi: 10.1016/j.clgc.2022.08.007. Epub 2022 Aug 29. PMID- 36163105 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20230406 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 9 IP - 2 DP - 2023 Mar TI - Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guerin: Implications for Risk-adapted Follow-up. PG - 325-332 LID - S2405-4569(22)00208-5 [pii] LID - 10.1016/j.euf.2022.09.007 [doi] AB - BACKGROUND: Limited data are available on patients with carcinoma in situ (CIS) of the bladder managed according to current clinical practice guidelines. OBJECTIVE: To assess the patterns of recurrence, progression to muscle-invasive bladder cancer (MIBC), and upper tract urothelial carcinoma (UTUC) in patients with CIS, and to compare the effectiveness of adequate versus inadequate bacillus Calmette-Guerin (BCG) immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of 386 patients with CIS of the bladder with or without associated pTa/pT1 disease treated with BCG between 2008 and 2015. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier estimations and an inverse probability of treatment weighting (IPTW)-Cox regression were performed to compare recurrence-free survival (RFS) and progression-free survival (PFS) and UTUC incidence over time for patients who received adequate versus inadequate BCG treatment. RESULTS AND LIMITATIONS: The median follow-up was 70.5 mo. At 5 and 10 yr, RFS was 82% and 52%, PFS was 93.6% and 75.8%, and UTUC incidence was 1.7% and 2.9%, respectively. Most recurrence (73.6%) and progression (69.1%) events occurred in the first 3 yr of follow-up, while 38.7% of UTUC incident events were recorded after 5 yr of follow-up. IPTW-Cox regression revealed that patients who received BCG treatment had a lower risk of recurrence (hazard ratio [HR] 0.21, 95% confidence interval [CI] 0.13-0.34), progression (HR 0.46, 95% CI 0.25-0.87), and UTUC incidence (HR 0.24, 95% CI 0.09-0.64). Limitations include the retrospective design and potential selection bias. CONCLUSIONS: Patients with CIS of the bladder show a high risk of recurrence, progression, and UTUC incidence. Most of these outcomes occur during the first 3 yr of follow-up, but a significant proportion of the events occur at long-term follow-up. Although receipt of adequate BCG treatment improves outcomes, intensive and long-term surveillance may be warranted. PATIENT SUMMARY: We investigated the long-term cancer control outcomes for patients with carcinoma in situ (CIS; cancerous cells that have not spread from where they first formed) of the bladder. Patients with CIS have a high risk of cancer recurrence and progression. Treatment with bacillus Calmette-Guerin (BCG) improves outcomes. CI - Copyright (c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. Electronic address: jdsubiela@gmail.com. FAU - Rodriguez Faba, Oscar AU - Rodriguez Faba O AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. FAU - Gonzalez-Padilla, Daniel Antonio AU - Gonzalez-Padilla DA AD - Department of Urology, Clinica Universidad de Navarra, Madrid, Spain. FAU - Rosales Bordes, Antonio AU - Rosales Bordes A AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. FAU - Huguet, Jorge AU - Huguet J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain; Department of Morphological Sciences, Barcelona, Spain. FAU - Lopez Curtis, David AU - Lopez Curtis D AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. FAU - Brasero Burgos, Jennifer AU - Brasero Burgos J AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. FAU - Sanchez Gonzalez, Alvaro AU - Sanchez Gonzalez A AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. FAU - Jimenez Cidre, Miguel Angel AU - Jimenez Cidre MA AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. FAU - Burgos Revilla, Francisco Javier AU - Burgos Revilla FJ AD - Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain. FAU - Breda, Alberto AU - Breda A AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Spain. LA - eng PT - Journal Article DEP - 20220924 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *Carcinoma, Transitional Cell/pathology MH - BCG Vaccine/therapeutic use MH - Urinary Bladder/pathology MH - Follow-Up Studies MH - Retrospective Studies MH - Disease Progression MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - *Carcinoma in Situ/drug therapy/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin immunotherapy OT - Carcinoma in situ OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence EDAT- 2022/09/27 06:00 MHDA- 2023/04/04 06:42 CRDT- 2022/09/26 23:40 PHST- 2022/07/26 00:00 [received] PHST- 2022/08/23 00:00 [revised] PHST- 2022/09/12 00:00 [accepted] PHST- 2023/04/04 06:42 [medline] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/26 23:40 [entrez] AID - S2405-4569(22)00208-5 [pii] AID - 10.1016/j.euf.2022.09.007 [doi] PST - ppublish SO - Eur Urol Focus. 2023 Mar;9(2):325-332. doi: 10.1016/j.euf.2022.09.007. Epub 2022 Sep 24. PMID- 36159866 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20220928 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Immune status for monitoring and treatment of bladder cancer. PG - 963877 LID - 10.3389/fimmu.2022.963877 [doi] LID - 963877 AB - The high recurrence rate of non-muscle invasive bladder cancer (BC) and poor prognosis of advanced BC are therapeutic challenges that need to be solved. Bacillus Calmette-Guerin (BCG) perfusion was the pioneer immunotherapy for early BC, and the discovery of immune checkpoint inhibitors has created a new chapter in the treatment of advanced BC. The benefit of immunotherapy is highly anticipated, but its effectiveness still needs to be improved. In this review, we collated and analysed the currently available information and explored the mechaisms by which the internal immune imbalance of BC leads to tumour progression. The relationship between immunity and progression and the prognosis of BC has been explored through tests using body fluids such as blood and urine. These analytical tests have attempted to identify specific immuyne cells and cytokines to predict treatment outcomes and recurrence. The diversity and proportion of immune and matrix cells in BC determine the heterogeneity and immune status of tumours. The role and classification of immune cells have also been redefined, e.g., CD4 cells having recognised cytotoxicity in BC. Type 2 immunity, including that mediated by M2 macrophages, Th2 cells, and interleukin (IL)-13, plays an important role in the recurrence and progression of BC. Pathological fibrosis, activated by type 2 immunity and cancer cells, enhances the rate of cancer progression and irreversibility. Elucidating the immune status of BC and clarifying the mechanisms of action of different cells in the tumour microenvironment is the research direction to be explored in the future. CI - Copyright (c) 2022 Pan, Li, Zhan, Chen, Sun, Liu, Wu, Li and Liu. FAU - Pan, Shen AU - Pan S AD - Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Li, Shijie AU - Li S AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Zhan, Yunhong AU - Zhan Y AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Chen, Xiaonan AU - Chen X AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Sun, Ming AU - Sun M AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Liu, Xuefeng AU - Liu X AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Wu, Bin AU - Wu B AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Li, Zhenhua AU - Li Z AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Liu, Bitian AU - Liu B AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220908 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Cytokines) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Interleukins) SB - IM MH - BCG Vaccine/therapeutic use MH - Cytokines/therapeutic use MH - Humans MH - Immune Checkpoint Inhibitors/therapeutic use MH - Interleukins/therapeutic use MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9492838 OTO - NOTNLM OT - BCG OT - bladder cancer OT - immune cells OT - immunotherapy OT - type 2 immunity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/27 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/01/01 CRDT- 2022/09/26 17:41 PHST- 2022/06/08 00:00 [received] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/09/26 17:41 [entrez] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.963877 [doi] PST - epublish SO - Front Immunol. 2022 Sep 8;13:963877. doi: 10.3389/fimmu.2022.963877. eCollection 2022. PMID- 36150105 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20260107 IS - 1728-7731 (Electronic) IS - 1726-4901 (Print) IS - 1726-4901 (Linking) VI - 85 IP - 9 DP - 2022 Sep 1 TI - The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-A real-world practice. PG - 928-934 LID - 10.1097/JCMA.0000000000000768 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) has been well recognized as the first-line intravesical therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). Oncotice, the Tice strain of BCG, serves as a viable alternative to the Connaught strain owing to the worldwide shortage of the latter. We retrospectively compared these two strains in terms of efficacy and adverse effects (AE) in patients who underwent at least one maintenance course after induction. METHODS: In this single-institution, retrospective study, patients diagnosed with NMIBC who were administered either Connaught or Tice intravesical therapy were enrolled. Recurrence was defined as the reappearance of urothelial carcinoma. Progression was defined as stage/grade advance, metastasis, or cancer-related death. The primary outcomes were recurrence-free survival (RFS) and progression-free survival (PFS), and the secondary outcome was AE. RESULTS: A total of 76 and 84 patients receiving Tice and Connaught, respectively were enrolled. The median follow-up periods for the Tice and Connaught groups were 32.0 months (range, 7-69 months) and 81.5 months (range, 9-154 months), respectively. Kaplan-Meier method showed no intergroup difference with regard to 3-year RFS and PFS. On Cox multivariate regression analysis, Tice was a significant predictor for inferior PFS (HR = 5.30; 95% CI, 1.11-25.29; p = 0.036). The AE incidence was 38.3% in the Connaught group and 25.0% in the Tice group (p = 0.079). CONCLUSION: Tice and Connaught were comparable in terms of RFS, PFS, and AE for patients with NMIBC accepting BCG induction and at least one maintenance course in our real-world practice. However, Tice was a predictor of inferior PFS on multivariate analysis. CI - Copyright (c) 2022, the Chinese Medical Association. FAU - Chen, Yu-Kuang AU - Chen YK AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. FAU - Huang, Eric Yi-Hsiu AU - Huang EY AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Chang, Yen-Hwa AU - Chang YH AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Kuo, Junne-Yih AU - Kuo JY AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Chung, Hsiao-Jen AU - Chung HJ AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Wu, Howard Hung-Hao AU - Wu HH AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Lin, Tzu-Ping AU - Lin TP AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Lin, Chih-Chieh AU - Lin CC AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Fan, Yu-Hua AU - Fan YH AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Huang, I-Shen AU - Huang IS AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Lin, Alex T L AU - Lin ATL AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Huang, William J AU - Huang WJ AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220923 PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 RN - 0 (BCG Vaccine) SB - IM MH - *BCG Vaccine/adverse effects MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC12755520 COIS- Conflicts of interest: Dr. William J. Huang, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. EDAT- 2022/09/24 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/23 CRDT- 2022/09/23 16:12 PHST- 2022/09/23 16:12 [entrez] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - 02118582-202209000-00009 [pii] AID - 10.1097/JCMA.0000000000000768 [doi] PST - ppublish SO - J Chin Med Assoc. 2022 Sep 1;85(9):928-934. doi: 10.1097/JCMA.0000000000000768. Epub 2022 Sep 23. PMID- 36149914 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221003 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 9 DP - 2022 TI - Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer. PG - e0274859 LID - 10.1371/journal.pone.0274859 [doi] LID - e0274859 AB - BACKGROUND: Previous research has associated repeated transurethral procedures after a diagnosis of non-muscle invasive bladder cancer (NMIBC) with increased risk of death of causes other than bladder cancer. AIM: We investigated the overall and disease-specific risk of death in patients with NMIBC compared to a background population sample. METHODS: We utilized the database BladderBaSe 2.0 containing tumor-specific, health-related and socio-demographic information for 38,547 patients with NMIBC not primarily treated with radical cystectomy and 192,733 individuals in a comparison cohort, matched on age, gender, and county of residence. The cohorts were compared using Kaplan-Meier curves and Hazard ratios (HR) from a Cox regression models. In the NMIBC cohort, we analyzed the association between number of transurethral procedures and death conditioned on surviving two or five years. RESULTS: Overall survival and survival from causes other than bladder cancer estimated with Kaplan-Meier curves was 9.3% (95% confidence interval (CI) (8.6%-10.0%)) and 1.4% (95% CI 0.7%-2.1%) lower respectively for the NMIBC cohort compared to the comparison cohort at ten years. In a Cox model adjusted for prognostic group, educational level and comorbidity, the HR was 1.03 (95% CI 1.01-1.05) for death from causes other than bladder cancer comparing the NMIBC cohort to the comparison cohort. Among the NMIBC patients, there was no discernible association between number of transurethral procedures and deaths of causes other than bladder cancer after adjustment. The number of procedures were, however, associated with risk of dying from bladder cancer HR 3.56 (95% CI 3.43-3.68) for four or more resections versus one within two years of follow-up. CONCLUSION: The results indicate that repeated diagnostic or therapeutic transurethral procedures under follow-up do not increase of risk dying from causes other than bladder cancer. The modestly raised risk for NMIBC patients dying from causes other than bladder cancer is likely explained by residual confounding. FAU - Holmberg, Lars AU - Holmberg L AUID- ORCID: 0000-0003-4417-7396 AD - Department of surgical Sciences, Uppsala, University, Uppsala, Sweden. AD - School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom. FAU - Hagberg, Oskar AU - Hagberg O AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of surgical Sciences, Uppsala, University, Uppsala, Sweden. AD - Department of Public Health and Clinical Medicine, Northern Register Centre, Umea University, Umea, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AUID- ORCID: 0000-0003-4615-5238 AD - Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Department of Radiation Sciences, Umea University, Umea, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. FAU - Enlund, Mats AU - Enlund M AD - Department of surgical Sciences, Uppsala, University, Uppsala, Sweden. AD - Region Vastmanland, Center for Clinical Research, Hospital of Vastmanland, Uppsala University, Vasteras, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of surgical Sciences, Uppsala, University, Uppsala, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220923 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Cystectomy/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder/surgery MH - *Urinary Bladder Neoplasms/diagnosis PMC - PMC9506622 COIS- The authors have declared that no competing interests exist. EDAT- 2022/09/24 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/23 CRDT- 2022/09/23 13:43 PHST- 2022/06/17 00:00 [received] PHST- 2022/09/07 00:00 [accepted] PHST- 2022/09/23 13:43 [entrez] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - PONE-D-22-17365 [pii] AID - 10.1371/journal.pone.0274859 [doi] PST - epublish SO - PLoS One. 2022 Sep 23;17(9):e0274859. doi: 10.1371/journal.pone.0274859. eCollection 2022. PMID- 36140796 OWN - NLM STAT- MEDLINE DCOM- 20220926 LR - 20230308 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 9 DP - 2022 Sep 10 TI - Identification of Epigenetic Interactions between miRNA and Gene Expression as Potential Prognostic Markers in Bladder Cancer. LID - 10.3390/genes13091629 [doi] LID - 1629 AB - Purpose: To identify the role of a set of microRNAs and their target genes and protein expression levels in the pathogenesis of bladder cancer with a muscular invasion (T2-T4) and non-muscular invasion (T1). Methods: In 157 patients, bladder specimen was examined for the expression of a set of miRNAs including let-7a-5p, miRNA-449a-5p, miRNA-145-3P, miRNA-124-3P, miRNA-138-5p, and miRNA-23a-5p and their targeted genes; beta-catenin, WNT7A, IRS2, FZD4, SOS1, HDAC1, HDAC2, HIF1alpha, and PTEN using the qRT-PCR technique. The prognostic effect of miRNAs and their targeted genes on cancer-specific survival (CSS) was evaluated in pT2-pT4 stages. Results: pT1 was found in 40 patients while pT2-4 was found in 117 patients. The expression of let-7a-5P, miR-124-3P, miR-449a-5P, and miR-138-5P significantly decreased in pT2-4 compared with pT1 (p < 0.001), in contrast, miR-23a-5P increased significantly in pT2-pT4 compared with pT1 (p < 0.001). Moreover, the expression of miR-145 did not show a significant change (p = 0.31). Higher expression levels of WNT7A, beta-catenin, IRS2, FZD4, and SOS1 genes were observed in pT2-pT4 compared with pT1, whereas HDAC1, HDAC2, HIF1alpha, and PTEN genes were downregulated in pT2-pT4 compared with pT1. Lower CSS was significantly associated with lower expression of let-7a-5P, miR-124-3P, miR-449a-5P, and miR-138-5P. Higher expression of beta-catenin, FZD4, IRS2, WNT7a, and SOS1 was significantly associated with worse CSS. In contrast, lower levels of HDAC1, HDAC2, HIF1alpha, and PTEN were associated with lower CSS. Conclusion: Our results support let-7a-5P, miR-124-3P, miR-138-5P, and their target genes can be developed as accurate biomarkers for prognosis in bladder cancer with a muscular invasion. FAU - Awadalla, Amira AU - Awadalla A AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Abol-Enein, Hassan AU - Abol-Enein H AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Hamam, Eman T AU - Hamam ET AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Ahmed, Asmaa E AU - Ahmed AE AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Khirallah, Salma M AU - Khirallah SM AUID- ORCID: 0000-0002-7631-6840 AD - Biochemistry Division, Chemistry Department, Faculty of Science, Port Said University, Port Said 42526, Egypt. FAU - El-Assmy, Ahmed AU - El-Assmy A AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Mostafa, Sally Abdallah AU - Mostafa SA AD - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. FAU - Babalghith, Ahmed O AU - Babalghith AO AUID- ORCID: 0000-0001-6650-9158 AD - Medical Genetics Department, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. FAU - Ali, Mohamed AU - Ali M AUID- ORCID: 0000-0003-4105-776X AD - Biochemistry Division, Chemistry Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt. FAU - Abdel-Rahim, Mona AU - Abdel-Rahim M AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Harraz, Ahmed M AU - Harraz AM AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220910 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (Biomarkers) RN - 0 (FZD4 protein, human) RN - 0 (Frizzled Receptors) RN - 0 (MIRN138 microRNA, human) RN - 0 (MIRN145 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (beta Catenin) SB - IM MH - Biomarkers MH - Epigenesis, Genetic/genetics MH - Frizzled Receptors/metabolism MH - Gene Expression MH - Humans MH - *MicroRNAs/genetics/metabolism MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology MH - beta Catenin/metabolism PMC - PMC9498328 OTO - NOTNLM OT - Wnt/beta-catenin OT - bladder cancer OT - mRNA OT - miRNAs OT - prognosis OT - protein expression COIS- The authors have no potential conflict of interest to declare. EDAT- 2022/09/24 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/10 CRDT- 2022/09/23 01:14 PHST- 2022/08/07 00:00 [received] PHST- 2022/09/03 00:00 [revised] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/09/23 01:14 [entrez] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/10 00:00 [pmc-release] AID - genes13091629 [pii] AID - genes-13-01629 [pii] AID - 10.3390/genes13091629 [doi] PST - epublish SO - Genes (Basel). 2022 Sep 10;13(9):1629. doi: 10.3390/genes13091629. PMID- 36134575 OWN - NLM STAT- MEDLINE DCOM- 20230425 LR - 20230531 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 131 IP - 5 DP - 2023 May TI - Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate. PG - 571-580 LID - 10.1111/bju.15898 [doi] AB - OBJECTIVES: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. PATIENTS AND METHODS: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). RESULTS: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade >/=III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P < 0.001). CONCLUSION: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa. CI - (c) 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AUID- ORCID: 0000-0003-1727-2283 AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Ploussard, Guillaume AU - Ploussard G AUID- ORCID: 0000-0002-6004-2152 AD - Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Turin, Italy. FAU - Roghmann, Florian AU - Roghmann F AUID- ORCID: 0000-0003-0299-489X AD - Department of Urology, Marien Hospital Herne, Herne, Germany. FAU - Muenker, Mara Anna AU - Muenker MA AD - Department of Urology, Marien Hospital Herne, Herne, Germany. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology, University Hospital of Toulouse Rangueil, Toulouse, France. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AUID- ORCID: 0000-0003-0705-7643 AD - Servicio de Urologia, Hospital Universitario La Paz, Madrid, Spain. FAU - Misrai, Vincent AU - Misrai V AUID- ORCID: 0000-0003-2029-0650 AD - Department of Urology, Clinique Pasteur, Toulouse, France. FAU - Antonelli, Alessandro AU - Antonelli A AUID- ORCID: 0000-0002-7455-8803 AD - Departement of Urology, University of Verona, Verona, Italy. FAU - Tafuri, Alessandro AU - Tafuri A AUID- ORCID: 0000-0003-1404-2925 AD - Departement of Urology, University of Verona, Verona, Italy. FAU - Simone, Giuseppe AU - Simone G AUID- ORCID: 0000-0002-4868-9025 AD - IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AUID- ORCID: 0000-0003-3708-2209 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Zhao, Hongda AU - Zhao H AUID- ORCID: 0000-0003-2414-1484 AD - Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Rahota, Razvan-George AU - Rahota RG AUID- ORCID: 0000-0003-2875-2936 AD - Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Service d'Urologie, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. FAU - Fajkovic, Harun AU - Fajkovic H AUID- ORCID: 0000-0001-9764-9962 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Enikeev, Dmitry AU - Enikeev D AUID- ORCID: 0000-0001-7169-2209 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Montorsi, Francesco AU - Montorsi F AUID- ORCID: 0000-0002-7267-4181 AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, Milan, Italy. AD - University Vita-Salute San Raffaele, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AUID- ORCID: 0000-0002-6627-6179 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France. CN - European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article DEP - 20221003 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - Aktuelle Urol. 2023 Jun;54(3):185. doi: 10.1055/a-2017-7108. PMID: 37224854 MH - Male MH - Humans MH - Prostate/surgery/pathology MH - *Transurethral Resection of Prostate/adverse effects/methods MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology MH - *Prostatic Hyperplasia/complications MH - *Urinary Bladder Neoplasms/pathology MH - Treatment Outcome OTO - NOTNLM OT - #BladderCancer OT - #UroBPH OT - #blcsm OT - #uroonc OT - BPH OT - TURB OT - TURP OT - bladder cancer OT - simultaneous EDAT- 2022/09/23 06:00 MHDA- 2023/04/25 06:42 CRDT- 2022/09/22 05:04 PHST- 2023/04/25 06:42 [medline] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/09/22 05:04 [entrez] AID - 10.1111/bju.15898 [doi] PST - ppublish SO - BJU Int. 2023 May;131(5):571-580. doi: 10.1111/bju.15898. Epub 2022 Oct 3. PMID- 36120543 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220920 IS - 2296-889X (Print) IS - 2296-889X (Electronic) IS - 2296-889X (Linking) VI - 9 DP - 2022 TI - Gasdermin D: A potential mediator and prognostic marker of bladder cancer. PG - 972087 LID - 10.3389/fmolb.2022.972087 [doi] LID - 972087 AB - Background: Bladder cancer is considered one of the commonest widespread cancers, its presentation ranges from non-muscle invasive form to being muscle-invasive. The gasdermin family of proteins consists of six proteins. Members of gasdermin family are involved in pyroptosis; which is considered as type of inflammatory apoptosis via participation of gasdermin D and inflammatory caspases. Purpose: The goal of this research was to look into the potential involvement of gasdermin D in pathogenesis of bladder cancer, In addition, to investigate its potential role as a prognostic marker of bladder cancer. Methods: Gasdermin D gene and protein expression was examined in fresh frozen 80 bladder cancer specimens (30 NMIBC, and 50 MIBC) and the matching 80 control tissue samples utilizing real-time polymerase chain reaction and western blotting. Furthermore, the immunoreactivity of gasdermin D protein was also detected by immunohistochemistry. Results: Gasdermin D gene and protein expression showed a highly significant difference between the control and the two bladder cancer groups (p < 0.001), as demonstrated by real-time PCR, western blotting and immunohistochemistry. Cox proportional hazards regression models showed that lower gasdermin D gene expression in cancer patients (2.18-fold), and lymph nodes' involvement were associated with an increased mortality. Conclusion: Gasdermin D is involved in the pathogenesis of bladder cancer and muscle invasion, in addition, tissue gasdermin D expression may be used as useful tool to predict local tumor recurrence. CI - Copyright (c) 2022 El-Gamal, Abdelrahim, El-Sherbiny, Enan and El-Nablaway. FAU - El-Gamal, Randa AU - El-Gamal R AD - Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt. AD - Medical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Abdelrahim, Mona AU - Abdelrahim M AD - Consultant of Pathology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Sherbiny, Mohamed AU - El-Sherbiny M AD - Department of Basic Medical Sciences, Anatomy Unit, College of Medicine, AlMaarefa University, Riyadh, Saudi Arabia. FAU - Enan, Eman T AU - Enan ET AD - Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - El-Nablaway, Mohammad AU - El-Nablaway M AD - Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt. AD - Medical Biochemistry Unit, Department of Basic Medical Sciences, College of Medicine, Almaarefa University, Riyad, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220901 PL - Switzerland TA - Front Mol Biosci JT - Frontiers in molecular biosciences JID - 101653173 PMC - PMC9474890 OTO - NOTNLM OT - bladder cancer OT - expression OT - gasdermin D OT - prognostic marker OT - tumor recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/20 06:00 MHDA- 2022/09/20 06:01 PMCR- 2022/01/01 CRDT- 2022/09/19 04:43 PHST- 2022/06/17 00:00 [received] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/09/19 04:43 [entrez] PHST- 2022/09/20 06:00 [pubmed] PHST- 2022/09/20 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 972087 [pii] AID - 10.3389/fmolb.2022.972087 [doi] PST - epublish SO - Front Mol Biosci. 2022 Sep 1;9:972087. doi: 10.3389/fmolb.2022.972087. eCollection 2022. PMID- 36117786 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220920 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 14 IP - 3 DP - 2022 Jul-Sep TI - Factors related to upstaging of clinical stage T2 organ-confined bladder cancer following radical cystectomy: A multicenter study. PG - 232-235 LID - 10.4103/UA.UA_186_20 [doi] AB - AIMS: This study aimed to detect possible risk factors related to upstaging of clinical stage T2 organ-confined (OC) to non-OC (nOC) bladder cancer (BC) following radical cystectomy (RC). SETTINGS AND DESIGN: This was a prospective multicenter study. SUBJECTS AND METHODS: This is a multicenter prospective study including 196 Egyptian BC patients undergoing RC from January 2017 to February 2019 at Cairo University, Fayoum University, and Menoufia University. Only patients with muscle invasive BC (T2) were included in the study. Patients' characteristics, preoperative clinical data (including Hydronephrosis), cystoscopy data, and biopsy pathological data were recorded. Preoperative clinical staging is compared to postoperative pathological staging, to determine upstaged cases. The occurrence of upstaging in correspondence to each preoperative factor is recorded and statistically analyzed. RESULTS: Among 196 BC patients of our study, upstaging from OC T2 to nOC occurred in 88 (44.9%) patients. Statistical analysis showed that the factors related to upstaging are older age (P Splicing Regulation/Alternative Splicing RNA in Disease and Development > RNA in Disease. CI - (c) 2022 The Authors. WIREs RNA published by Wiley Periodicals LLC. FAU - Montero-Hidalgo, Antonio J AU - Montero-Hidalgo AJ AUID- ORCID: 0000-0002-1948-7512 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. FAU - Perez-Gomez, Jesus M AU - Perez-Gomez JM AUID- ORCID: 0000-0003-1785-9797 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. FAU - Martinez-Fuentes, Antonio J AU - Martinez-Fuentes AJ AUID- ORCID: 0000-0003-0994-1037 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. FAU - Gomez-Gomez, Enrique AU - Gomez-Gomez E AUID- ORCID: 0000-0002-8753-3306 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - Urology Service, HURS/IMIBIC, Cordoba, 14004, Spain. FAU - Gahete, Manuel D AU - Gahete MD AUID- ORCID: 0000-0002-4578-2179 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. FAU - Jimenez-Vacas, Juan M AU - Jimenez-Vacas JM AUID- ORCID: 0000-0003-4391-3726 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. FAU - Luque, Raul M AU - Luque RM AUID- ORCID: 0000-0002-7585-1913 AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, 14004, Spain. AD - Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, 14004, Spain. AD - Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain. AD - CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, 14004, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220905 PL - United States TA - Wiley Interdiscip Rev RNA JT - Wiley interdisciplinary reviews. RNA JID - 101536955 RN - 0 (RNA, Circular) RN - 63231-63-0 (RNA) RN - 0 (Biomarkers) RN - 0 (PTBP1 protein, human) RN - 0 (Heterogeneous-Nuclear Ribonucleoproteins) RN - 139076-35-0 (Polypyrimidine Tract-Binding Protein) SB - IM MH - Humans MH - *Alternative Splicing/genetics MH - RNA, Circular/genetics/metabolism MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy MH - RNA/metabolism MH - Biomarkers/metabolism MH - Heterogeneous-Nuclear Ribonucleoproteins/metabolism MH - Polypyrimidine Tract-Binding Protein/genetics/metabolism OTO - NOTNLM OT - bladder cancer OT - circRNA OT - splicing OT - urothelial carcinoma EDAT- 2022/09/06 06:00 MHDA- 2023/05/15 06:42 CRDT- 2022/09/05 09:05 PHST- 2022/07/25 00:00 [revised] PHST- 2022/06/09 00:00 [received] PHST- 2022/08/05 00:00 [accepted] PHST- 2023/05/15 06:42 [medline] PHST- 2022/09/06 06:00 [pubmed] PHST- 2022/09/05 09:05 [entrez] AID - 10.1002/wrna.1760 [doi] PST - ppublish SO - Wiley Interdiscip Rev RNA. 2023 May-Jun;14(3):e1760. doi: 10.1002/wrna.1760. Epub 2022 Sep 5. PMID- 36059684 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220907 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Intravesical recurrence factors and outcome after radical nephroureterectomy for upper tract urothelial carcinoma: Multivariate analysis with propensity score matching. PG - 984014 LID - 10.3389/fonc.2022.984014 [doi] LID - 984014 AB - OBJECTIVE: The risk factors for intravesical recurrence (IVR) after radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC) remain inconsistent and unclear. Thus, the risk factors of IVR after RNU and the prognostic significance of the risk indicators were explored herein. METHODS: We retrospectively analyzed UTUC patients upon RNU in our center from January 2009 to December 2019. After propensity score matching, 139 patients were included in this study. Univariate and multivariate Cox proportional hazard regressions were used to estimate the hazard ratio and 95% confidence intervals. Overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS) were measured using the Kaplan-Meier curve with a log-rank test. A P-value < 0.05 was considered statistically significant. RESULTS: We included 139 patients with a median follow-up of 42 months, of which 48 patients had an intravesical recurrence. Multivariate Cox regression analysis showed cytological abnormalities in urine (HR=3.101, P=0.002), hydronephrosis (HR=1.852, P=0.042), adjuvant chemotherapy (HR=0.242, P<0.001), and previous history of bladder cancer (HR=5.51, P<0.001) were independent risk factors for IVR. As for clinical outcomes, OS and CSS suggested disadvantages in patients with IVR compared with patients without recurrence (P=0.042 for OS, P<0.0001 for CSS), OS of patients with abnormal urine cytology and OS and CSS of patients receiving adjuvant chemotherapy did not present clinical significance, and other risk factors all affected the clinical outcome. CONCLUSION: In this propensity-score matching study, cytological abnormality of urine, hydronephrosis, adjuvant chemotherapy and previous history of bladder cancer were shown to be independent risk factors for IVR. Moreover, risk factors also influence clinical outcomes, thereby rendering it necessary to adopt more active postoperative surveillance and treatment strategies for these patients, which may help improve treatment outcomes. CI - Copyright (c) 2022 Zhao, Jiao, Liu, Luo, Ding, Lai, Ren and Zhang. FAU - Zhao, Hang AU - Zhao H AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. AD - China-Japan Friendship School Clinical Medicine, Peking University, Beijing, China. FAU - Jiao, Binbin AU - Jiao B AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. FAU - Liu, Kunpeng AU - Liu K AD - Beijing Laboratory of Biomedical Materials, State Key Laboratory of Organic-Inorganic Composite Materials, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. FAU - Luo, Zhenkai AU - Luo Z AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. AD - Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Ding, Zhenshan AU - Ding Z AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Ren, Jian AU - Ren J AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Zhang, Guan AU - Zhang G AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. AD - China-Japan Friendship School Clinical Medicine, Peking University, Beijing, China. LA - eng PT - Journal Article DEP - 20220818 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9433701 OTO - NOTNLM OT - intravesical recurrence OT - oncological outcome OT - propensity score matching OT - risk factor OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors have fully disclosed their conflicts of interest in the manuscript and during the submission process. This manuscript has not been published and is not under consideration for publication elsewhere. EDAT- 2022/09/06 06:00 MHDA- 2022/09/06 06:01 PMCR- 2022/01/01 CRDT- 2022/09/05 03:41 PHST- 2022/07/01 00:00 [received] PHST- 2022/07/29 00:00 [accepted] PHST- 2022/09/05 03:41 [entrez] PHST- 2022/09/06 06:00 [pubmed] PHST- 2022/09/06 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.984014 [doi] PST - epublish SO - Front Oncol. 2022 Aug 18;12:984014. doi: 10.3389/fonc.2022.984014. eCollection 2022. PMID- 36059618 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220907 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - The role of radiomics with machine learning in the prediction of muscle-invasive bladder cancer: A mini review. PG - 990176 LID - 10.3389/fonc.2022.990176 [doi] LID - 990176 AB - Bladder cancer is a common malignant tumor in the urinary system. Depending on whether bladder cancer invades muscle tissue, it is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). It is crucial to accurately diagnose the muscle invasion of bladder cancer for its clinical management. Although imaging modalities such as CT and multiparametric MRI play an important role in this regard, radiomics has shown great potential with the development and innovation of precision medicine. It features outstanding advantages such as non-invasive and high efficiency, and takes on important significance in tumor assessment and laor liberation. In this article, we provide an overview of radiomics in the prediction of muscle-invasive bladder cancer and reflect on its future trends and challenges. CI - Copyright (c) 2022 Huang, Wang, Lan, Deng, Lei and Lin. FAU - Huang, Xiaodan AU - Huang X AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Wang, Xiangyu AU - Wang X AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Lan, Xinxin AU - Lan X AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Deng, Jinhuan AU - Deng J AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Lei, Yi AU - Lei Y AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Lin, Fan AU - Lin F AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China. LA - eng PT - Journal Article PT - Review DEP - 20220817 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9428259 OTO - NOTNLM OT - CT OT - MRI OT - bladder cancer OT - machine learning OT - muscle-invasive OT - radiomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/06 06:00 MHDA- 2022/09/06 06:01 PMCR- 2022/01/01 CRDT- 2022/09/05 03:40 PHST- 2022/07/09 00:00 [received] PHST- 2022/07/27 00:00 [accepted] PHST- 2022/09/05 03:40 [entrez] PHST- 2022/09/06 06:00 [pubmed] PHST- 2022/09/06 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.990176 [doi] PST - epublish SO - Front Oncol. 2022 Aug 17;12:990176. doi: 10.3389/fonc.2022.990176. eCollection 2022. PMID- 36055007 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20221129 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 61 DP - 2022 Dec TI - Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome. PG - 152030 LID - S1092-9134(22)00132-0 [pii] LID - 10.1016/j.anndiagpath.2022.152030 [doi] AB - BACKGROUND: Urothelial carcinoma of the urinary bladder is the most common malignancy of the urinary system. Patients with low grade papillary urothelial carcinoma (LGPUC) usually have a low risk for tumor recurrence and progression; yet a subset of patients develop recurrence or grade/stage progression to high-grade papillary urothelial carcinoma (HGPUC). The clinicopathological and molecular factors that contribute to this progression are yet to be determined. OBJECTIVES: In our study, we aimed to assess the incidence and clinicopathological factors associated with tumor recurrence/progression of LGPUC. METHODS: Using a pathological database of surgical specimens from patients who underwent bladder biopsies and/or transurethral resection of bladder tumors (TURBTs) between August 01, 2011, and July 31, 2021, at a large academic medical center, a single-center retrospective cohort analysis was performed, and medical charts of patients were reviewed. RESULTS: Of the total 258 patients included, 157 (60.9 %) had "no recurrence", 85 (32.9 %) had >/=1 "recurrence of LGPUC", and 16 (6.2 %) had "grade progression to HGPUC". The mean follow-up time was 31.5 +/- 32 months. Patients with "grade progression" and "recurrence of LGPUC" had larger mean tumor size on initial biopsy and multiple lesions on initial cystoscopy compared to those with "no recurrence." Interestingly, former smokers had 2.5- and 8.5-times higher risk of recurrence of LGPUC and grade progression, respectively. CONCLUSION: Since the majority of our patients did not develop recurrence, we question whether there is tendency to overclassify the papillomas as LGPUC based on the 2004 WHO/ISUP consensus grading classification. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Bahmad, Hisham F AU - Bahmad HF AD - Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. Electronic address: Hisham.Bahmad@msmc.com. FAU - Lopez, Olga AU - Lopez O AD - Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. FAU - Moreno, Juan Carlos Alvarez AU - Moreno JCA AD - Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. FAU - Lopez, Kalei AU - Lopez K AD - Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. FAU - Malik, Fayeza AU - Malik F AD - Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. FAU - Salami, Ali AU - Salami A AD - Department of Mathematics, Faculty of Sciences, Lebanese University, Nabatieh, Lebanon. FAU - Nieder, Alan M AU - Nieder AM AD - Division of Urology, Columbia University, Mount Sinai Medical Center, Miami Beach, FL 33140, USA; Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. FAU - Omarzai, Yumna AU - Omarzai Y AD - Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA; Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. FAU - Poppiti, Robert J AU - Poppiti RJ AD - Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA; Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA. LA - eng PT - Journal Article DEP - 20220828 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Urinary Bladder/pathology MH - Retrospective Studies MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Hyperplasia/pathology OTO - NOTNLM OT - Bladder OT - Low grade OT - Prognosis OT - Progression OT - Recurrence OT - Urothelial carcinoma COIS- Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/03 06:00 MHDA- 2022/11/30 06:00 CRDT- 2022/09/02 18:18 PHST- 2022/07/06 00:00 [received] PHST- 2022/08/20 00:00 [revised] PHST- 2022/08/21 00:00 [accepted] PHST- 2022/09/03 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/09/02 18:18 [entrez] AID - S1092-9134(22)00132-0 [pii] AID - 10.1016/j.anndiagpath.2022.152030 [doi] PST - ppublish SO - Ann Diagn Pathol. 2022 Dec;61:152030. doi: 10.1016/j.anndiagpath.2022.152030. Epub 2022 Aug 28. PMID- 36053728 OWN - NLM STAT- MEDLINE DCOM- 20230309 LR - 20230309 IS - 1943-7730 (Electronic) IS - 0007-5027 (Linking) VI - 54 IP - 2 DP - 2023 Mar 7 TI - Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing. PG - 142-152 LID - 10.1093/labmed/lmac083 [doi] AB - OBJECTIVE: Bladder cancer is one of the most common malignant tumors in urology in China. The analysis of gene mutation in bladder cancer and its relationship with clinical characteristics and prognosis will provide a basis for accurate treatment of bladder cancer. The aim of this study was to analyze the mutations and functional regions of bladder cancer-related genes based on high-throughput sequencing, and to explore the relationship between mutations and clinicopathological features, as well as its prognosis and clinical implication. METHODS: From April 2020 to October 2020, a total of 47 patients with bladder cancer in the Department of Urology, Affiliated Hospital of Chengde Medical College were studied. Gene sequencing was performed using Nextseq CN500 System, a high-throughput sequencing platform. The results of gene detection were described, and the relationship and clinical value of high frequency mutated genes with clinicopathological features and prognosis were systematically analyzed. RESULTS: A total of 29 mutation genes, 61 exons, and 95 mutation sites were identified in this study. The frequencies of TP53, FGFR3, PIK3CA, ERBB2, MUC4, and KRAS mutation are relatively high, accounting for 59.92 % of the total mutation frequency. The TP53 was significantly associated with muscle invasive bladder cancer, T2 stage, and progression-free survival, while FGFR3 was significantly associated with non-muscle invasive bladder cancer and T1 stage. CONCLUSION: High-throughput sequencing technology provides a successful approach for detecting bladder cancer gene mutations. The TP53, FGFR3, PIK3CA, ERBB2, MUC4, and KRAS genes have high mutation frequencies in bladder cancer patients. The TP53, FGFR3 and PIK3CA genes may play a predictive role in the prognosis of bladder cancer, which may hold certain guiding significance for in-depth study of the pathogenesis of bladder cancer and the development of targeted therapies. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Li, Xiaohang AU - Li X AUID- ORCID: 0000-0001-7439-2607 AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. FAU - Liu, Jie AU - Liu J AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. FAU - Li, An'an AU - Li A AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. FAU - Liu, Xin AU - Liu X AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. FAU - Miao, Yuesong AU - Miao Y AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. FAU - Wang, Zhiyong AU - Wang Z AD - Department of Urology, Affiliated Hospital of Chengde Medical University, Chengde, China. LA - eng PT - Journal Article PL - England TA - Lab Med JT - Laboratory medicine JID - 0250641 RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) SB - IM MH - Humans MH - *Proto-Oncogene Proteins p21(ras)/genetics MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis/genetics/pathology MH - Mutation/genetics MH - High-Throughput Nucleotide Sequencing MH - Class I Phosphatidylinositol 3-Kinases/genetics OTO - NOTNLM OT - bladder cancer OT - gene OT - high-throughput sequencing OT - mutation EDAT- 2022/09/03 06:00 MHDA- 2023/03/10 06:00 CRDT- 2022/09/02 12:13 PHST- 2022/09/03 06:00 [pubmed] PHST- 2023/03/10 06:00 [medline] PHST- 2022/09/02 12:13 [entrez] AID - 6687571 [pii] AID - 10.1093/labmed/lmac083 [doi] PST - ppublish SO - Lab Med. 2023 Mar 7;54(2):142-152. doi: 10.1093/labmed/lmac083. PMID- 36049631 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20231102 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 169 DP - 2022 Nov TI - An Evaluation of Peer-Rated Surgical Skill and its Relationship With Detrusor Muscle Sampling in Transurethral Resection of Bladder Tumor. PG - 134-140 LID - S0090-4295(22)00732-4 [pii] LID - 10.1016/j.urology.2022.07.057 [doi] AB - OBJECTIVE: To assess the reliability of peer-review of TURBT videos as a means to evaluate surgeon skill and its relationship to detrusor sampling. METHODS: Urologists from an academic health system submitted TURBT videos in 2019. Ten blinded peers evaluated each surgeon's performance using a 10-item scoring instrument to quantify surgeon skill. Normalized composite skill scores for each surgeon were calculated using peer ratings. For surgeons submitting videos, we retrospectively reviewed all TURBT pathology results (2018-2019) to assess surgeon-specific detrusor sampling. A hierarchical logistic regression model was fit to evaluate the association between skill and detrusor sampling, adjusting for patient and surgeon factors. RESULTS: Surgeon skill scores and detrusor sampling rates were determined for 13 surgeons performing 245 TURBTs. Skill scores varied from -6.0 to 5.1 [mean: 0; standard deviation (SD): 2.40]. Muscle was sampled in 72% of cases, varying considerably across surgeons (mean: 64.5%; SD: 30.7%). Among 8 surgeons performing >5 TURBTs during the study period, adjusted detrusor sampling rate was associated with sending separate deep specimens (odds ratio [OR]: 1.97; 95% confidence interval [CI]: 1.02-3.81, P = .045) but not skill (OR: 0.81; 95% CI: 0.57-1.17, P = .191). CONCLUSION: Surgeon skill was not associated with detrusor sampling, suggesting there may be other drivers of variability of detrusor sampling in TURBT. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Pham, Minh N AU - Pham MN AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Ko, Oliver S AU - Ko OS AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Huang, Reiping AU - Huang R AD - Surgical Outcomes and Quality Improvement Center, Feinberg School of Medicine, Chicago, IL. FAU - Vo, Amanda X AU - Vo AX AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Tsai, Kyle P AU - Tsai KP AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Lai, Jeremy D AU - Lai JD AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Hudnall, Matthew T AU - Hudnall MT AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Halpern, Joshua A AU - Halpern JA AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL; Surgical Outcomes and Quality Improvement Center, Feinberg School of Medicine, Chicago, IL. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Benson, Jonas AU - Benson J AD - Northwestern Medicine Central DuPage Hospital, Winfield, IL; Northwestern Medicine Delnor Hospital, Geneva, IL; UroPartners LLC, Winfield, IL. FAU - Soares, Ricardo AU - Soares R AD - Department of Urology, Northwestern Medicine Kishwaukee Hospital, DeKalb, IL. FAU - Kim, Ronald AU - Kim R AD - Northwestern Medicine Lake Forest Hospital, Lake Forest, IL; UroPartners LLC, Lake Forest, IL. FAU - Bilimoria, Karl Y AU - Bilimoria KY AD - Surgical Outcomes and Quality Improvement Center, Feinberg School of Medicine, Chicago, IL. FAU - Stulberg, Jonah J AU - Stulberg JJ AD - Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX. FAU - Auffenberg, Gregory B AU - Auffenberg GB AD - Urology of St. Louis, St. Louis, MO. Electronic address: gbanwu@gmail.com. LA - eng GR - UL1 TR001422/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220830 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2022 Nov;169:139-140. doi: 10.1016/j.urology.2022.07.058. PMID: 36371094 MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Retrospective Studies MH - Reproducibility of Results MH - Cystectomy/methods MH - Muscle, Smooth/pathology PMC - PMC10099284 MID - NIHMS1884411 EDAT- 2022/09/02 06:00 MHDA- 2022/11/16 06:00 PMCR- 2023/11/01 CRDT- 2022/09/01 19:25 PHST- 2022/03/06 00:00 [received] PHST- 2022/06/10 00:00 [revised] PHST- 2022/07/10 00:00 [accepted] PHST- 2022/09/02 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/09/01 19:25 [entrez] PHST- 2023/11/01 00:00 [pmc-release] AID - S0090-4295(22)00732-4 [pii] AID - 10.1016/j.urology.2022.07.057 [doi] PST - ppublish SO - Urology. 2022 Nov;169:134-140. doi: 10.1016/j.urology.2022.07.057. Epub 2022 Aug 30. PMID- 36043587 OWN - NLM STAT- MEDLINE DCOM- 20220901 LR - 20260127 IS - 0126-8635 (Print) IS - 0126-8635 (Linking) VI - 44 IP - 2 DP - 2022 Aug TI - The prognostic significance of HER2 expression in urothelial carcinoma. PG - 245-252 AB - INTRODUCTION: Urothelial carcinoma poses a great challenge in disease management due to the high recurrence rate and a greater likelihood of disease progression. HER2 (human epidermal growth factor receptor 2) is one of the proteins variably expressed in urothelial carcinoma, prompting its investigation as a potential predictive marker. The aim of this study was to assess the HER2 status in urothelial carcinoma, its correlation with tumour grade, tumour stage, recurrence and progression. MATERIALS AND METHODS: We retrospectively analysed 69 specimens of transurethral resection or cystectomy in patients with urothelial carcinoma. Immunohistochemistry for HER2 was performed and the expressions were correlated with tumour grade, tumour stage, presence of recurrence and tumour progression. Staining was evaluated according to the same criteria of breast cancer. Scores of 2+ and 3+ were considered positive. The data were analysed using the chi-square test with statistical significance set at P <0.05. RESULTS: Positive HER2 expression was found in 13 cases (18.8%). HER2 positivity was significantly associated with high-grade tumours (P=0.005). However, there is no significant association with tumour stage, recurrence or progression. CONCLUSION: HER2 is potentially a good immunohistochemical marker for identifying patients with higher-grade urothelial carcinoma and stratifying patients for future targeted therapy. FAU - Rosli, N AU - Rosli N AD - Universiti Kebangsaan Malaysia Medical Centre, Department of Pathology, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. FAU - Mahasin, M AU - Mahasin M AD - Universiti Kebangsaan Malaysia Medical Centre, Department of Pathology, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. FAU - Mohd Saleh, M F AU - Mohd Saleh MF AD - Universiti Kebangsaan Malaysia Medical Centre, Department of Pathology, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. FAU - Abd Shukor, N AU - Abd Shukor N AD - Universiti Kebangsaan Malaysia Medical Centre, Department of Pathology, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. nordashima@ppukm.ukm.edu.my. LA - eng PT - Journal Article PL - Malaysia TA - Malays J Pathol JT - The Malaysian journal of pathology JID - 8101177 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Prognosis MH - Erb-b2 Receptor Tyrosine Kinases MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology EDAT- 2022/09/01 06:00 MHDA- 2022/09/02 06:00 CRDT- 2022/08/31 07:22 PHST- 2022/08/31 07:22 [entrez] PHST- 2022/09/01 06:00 [pubmed] PHST- 2022/09/02 06:00 [medline] PST - ppublish SO - Malays J Pathol. 2022 Aug;44(2):245-252. PMID- 36043478 OWN - NLM STAT- MEDLINE DCOM- 20230302 LR - 20260406 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 4 DP - 2023 Feb TI - Dynamic alteration and prognostic significance of tumor-associated CD68(+) and CD68(+) PD-L1(-) macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. PG - 4981-4992 LID - 10.1002/cam4.5191 [doi] AB - BACKGROUND: The current study aimed to investigate the dynamic alteration and prognostic significance of tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and PD-L1 status of immune cells in muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy (NAC). METHODS: Multiplex immunofluorescence staining was performed to examine CD68(+) TAM, CD4(+) T cell, CD8(+) T cell, FOXP3(+) Treg cell, and PD-L1 expression in paired MIBC tissues (n = 54) before and after NAC. Patients were then divided into definite responders (DR), (0 lymph nodes examined) was performed in 1,092 patients (64.2%). The median number of lymph nodes examined was 8 (interquartile range, 0-20) in T1, 0 (interquartile range, 0-11) in Ta, and 0 (interquartile range, 0-14) in Tia patients. Compared with non-PLND, any level of PLND improved OS in T1 but not in Ta or Tis patients. Compared to limited (1-9 lymph nodes examined) and non-PLND, extensive PLND (lymph nodes examined >/=10) resulted in better OS only in T1 patients (all p < 0.001, adjusted significance level = 0.017). PLND was identified as a independent protective factor for OS. CONCLUSION: Based on the SEER database, we found that PLND during RC led to better OS and extensive PLND was associated with better OS in T1 but not in Ta or Tis patients. The implementation of PLND was insufficient both in population proportions and scope. CI - (c) 2022 Tang, Wu and Li. FAU - Tang, Yaxiong AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wu, Kan AU - Wu K AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Xiang AU - Li X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20220811 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC9403057 OTO - NOTNLM OT - non-muscle-invasive bladder cancer (NMIBC) OT - overall survival (OS) OT - pelvic lymph node dissection (PLND) OT - radical cystectomy (RC) OT - survival analyisis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/30 06:00 MHDA- 2022/08/30 06:01 PMCR- 2022/08/11 CRDT- 2022/08/29 05:07 PHST- 2022/06/04 00:00 [received] PHST- 2022/07/19 00:00 [accepted] PHST- 2022/08/29 05:07 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/30 06:01 [medline] PHST- 2022/08/11 00:00 [pmc-release] AID - 10.3389/fsurg.2022.961430 [doi] PST - epublish SO - Front Surg. 2022 Aug 11;9:961430. doi: 10.3389/fsurg.2022.961430. eCollection 2022. PMID- 36034368 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 9 DP - 2022 TI - Prognostic Value of Platelet-to-Lymphocyte Ratio in Non-Muscle Invasive Bladder Cancer Patients: Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor. PG - 907485 LID - 10.3389/fsurg.2022.907485 [doi] LID - 907485 AB - The objective of this study was to investigate the platelet-to-lymphocyte ratio (PLR) in patients who underwent intravesical treatment for non-muscle invasive bladder cancer (NMIBC). A total of 197 patients who underwent intravesical Bacillus Calmette-Guerin treatment after transurethral resection of bladder (TURB) were included. We divided the patients into different groups according to the treatment stage before and during induction treatment as Group 1 and Group 2, and set the change value of PLR as the Group 3. The cutoff values of PLR were determined through receiver operation characteristics curves analysis. we found a significant difference in recurrence-free survival (RFS) and progression-free survival (PFS) between patients with high serum PLR and those with low serum PLR in Group 1, as well as Group 2. Cox multivariate analysis revealed that tumor number >/=3, high grade, and history of carcinoma in situ (CIS) were significant factors predicting RFS and PFS. The PLR values before and during induction therapy could be used as predictors for the progression and recurrence of NMIBC patients receiving BCG immunotherapy. the PLR values after induction therapy have a stronger predictive power. CI - Copyright (c) 2022 Wu, Li, Zhang, Bai, Wang and Han. FAU - Wu, Ruicheng AU - Wu R AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Dengxiong AU - Li D AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Facai AU - Zhang F AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Bai, Yunjin AU - Bai Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Xiaoming AU - Wang X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20220523 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC9411071 OTO - NOTNLM OT - Bacillus Calmet-Guiren immunotherapy OT - bladder cancer OT - non-muscle invasive bladder cancer OT - platelet-tolymphocyte ratio OT - progression COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/30 06:00 MHDA- 2022/08/30 06:01 PMCR- 2022/05/23 CRDT- 2022/08/29 05:07 PHST- 2022/03/29 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2022/08/29 05:07 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/30 06:01 [medline] PHST- 2022/05/23 00:00 [pmc-release] AID - 10.3389/fsurg.2022.907485 [doi] PST - epublish SO - Front Surg. 2022 May 23;9:907485. doi: 10.3389/fsurg.2022.907485. eCollection 2022. PMID- 36032588 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2156-7085 (Print) IS - 2156-7085 (Electronic) IS - 2156-7085 (Linking) VI - 13 IP - 8 DP - 2022 Aug 1 TI - Prediction of the postoperative prognosis in patients with non-muscle-invasive bladder cancer based on preoperative serum surface-enhanced Raman spectroscopy. PG - 4204-4221 LID - 10.1364/BOE.465295 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is a common urinary tumor and has a high recurrence rate due to improper or inadequate conservative treatment. The early and accurate prediction of its recurrence can be helpful to implement timely and rational treatment. In this study, we explored a preoperative serum surface-enhanced Raman spectroscopy based prognostic protocol to predict the postoperative prognosis for NMIBC patients at the time even before treatment. The biochemical analysis results suggested that biomolecules related to DNA/RNA, protein substances, trehalose and collagen are expected to be potential prognostic markers, which further compared with several routine clinically used immunohistochemistry expressions with prognostic values. In addition, high prognostic accuracies of 87.01% and 89.47% were achieved by using the proposed prognostic models to predict the future postoperative recurrence and recurrent type, respectively. Therefore, we believe that the proposed method has great potential in the early and accurate prediction of postoperative prognosis in patients with NMIBC, which is with important clinical significance to guide the treatment and further improve the recurrence rate and survival time. CI - (c) 2022 Optica Publishing Group under the terms of the Optica Open Access Publishing Agreement. FAU - Zhu, Ruochen AU - Zhu R AD - College of Medicine and Biological Information Engineering, Northeastern University, Shenyang 110167, China. AD - Authors contributed equally. FAU - Jiang, Yuanjun AU - Jiang Y AD - Department of Urology, First Affiliated Hospital, China Medical University, Shenyang 110001, China. AD - Authors contributed equally. FAU - Zhou, Zheng AU - Zhou Z AD - School of Innovation and Entrepreneurship, Liaoning Institute of Science and Technology, Benxi 117004, China. FAU - Zhu, Shanshan AU - Zhu S AD - Research Institute for Medical and Biological Engineering, Ningbo University, Ningbo 315211, China. FAU - Zhang, Zhuoyu AU - Zhang Z AUID- ORCID: 0000-0001-6298-2589 AD - College of Medicine and Biological Information Engineering, Northeastern University, Shenyang 110167, China. FAU - Chen, Zhilin AU - Chen Z AD - College of Medicine and Biological Information Engineering, Northeastern University, Shenyang 110167, China. FAU - Chen, Shuo AU - Chen S AUID- ORCID: 0000-0003-3893-715X AD - College of Medicine and Biological Information Engineering, Northeastern University, Shenyang 110167, China. AD - Key Laboratory of Intelligent Computing in Medical Image, Ministry of Education, China. AD - chenshuo@bmie.neu.edu.cn. FAU - Zhang, Zhe AU - Zhang Z AD - Department of Urology, First Affiliated Hospital, China Medical University, Shenyang 110001, China. AD - zhezhangcmu@qq.com. LA - eng PT - Journal Article DEP - 20220711 PL - United States TA - Biomed Opt Express JT - Biomedical optics express JID - 101540630 PMC - PMC9408240 COIS- The authors declare no conflicts of interest. EDAT- 2022/08/30 06:00 MHDA- 2022/08/30 06:01 PMCR- 2022/08/01 CRDT- 2022/08/29 04:43 PHST- 2022/05/27 00:00 [received] PHST- 2022/06/29 00:00 [revised] PHST- 2022/06/30 00:00 [accepted] PHST- 2022/08/29 04:43 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/30 06:01 [medline] PHST- 2022/08/01 00:00 [pmc-release] AID - 465295 [pii] AID - 10.1364/BOE.465295 [doi] PST - epublish SO - Biomed Opt Express. 2022 Jul 11;13(8):4204-4221. doi: 10.1364/BOE.465295. eCollection 2022 Aug 1. PMID- 36013377 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240903 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 8 DP - 2022 Aug 6 TI - Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. LID - 10.3390/life12081198 [doi] LID - 1198 AB - Thromboembolic events (TEE) are high-risk complications in patients undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for urothelial muscle-invasive bladder cancer (MIBC). The purpose of the study was to investigate any differences in TEE-incidence, comparing peripherally inserted central catheter (PICC) versus a totally implanted port (PORT) as CVA (central venous access) during NAC. We identified 947 cystectomized MIBC-patients from four Swedish medical centers in 2009-2021. Inclusion criteria were cT2-T4aN0M0 and 375 patients were finally eligible and evaluated, divided into: NAC-administered (n = 283) resp. NAC-naive-NAC-eligible (n = 92), the latter as tentative control group. Data on TEEs and types of CVA were retrospectively collected and individually validated, from final transurethral resection of the bladder tumor (TUR-B) to 30 days post-RC. Adjusted logistic regression and log rank test were used for statistical analyses. Amongst NAC-administered, 83% (n = 235) received PICCs and 15% (n = 42) PORTs. Preoperative TEEs occurred in 38 PICC-patients (16.2%) and in one PORT-patient (2.4%), with 47 individual events registered. We found a significantly increased odds ratio of TEE in NAC-administered PICC-patients compared to in PORT-patients (OR: 8.140, p-value: 0.042, 95% CI 1.078-61.455). Our findings indicate a greater risk for pre-RC TEEs with PICCs than with PORTs, suggesting favoring the usage of PORTs for MIBC-NAC-patients. FAU - Rydell, Harriet AU - Rydell H AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 90187 Umea, Sweden. FAU - Huge, Ylva AU - Huge Y AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, 58183 Linkoping, Sweden. FAU - Eriksson, Victoria AU - Eriksson V AUID- ORCID: 0000-0001-7921-2425 AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 90187 Umea, Sweden. FAU - Johansson, Markus AU - Johansson M AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 90187 Umea, Sweden. FAU - Alamdari, Farhood AU - Alamdari F AD - Department of Urology, Vastmanland Hospital, 72189 Vasteras, Sweden. FAU - Svensson, Johan AU - Svensson J AUID- ORCID: 0000-0002-8601-0159 AD - Department of Statistics, Umea School of Business, Economics and Statistics (USBE), Umea University, 90187 Umea, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, 58183 Linkoping, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 90187 Umea, Sweden. AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, 58183 Linkoping, Sweden. LA - eng GR - Bas-ALF/VLL RV-848051/Swedish Research Council/ GR - CFF LP 13-2000/The Cancer Research Foundation in Norrland, Umea, Sweden/ PT - Journal Article DEP - 20220806 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9409854 OTO - NOTNLM OT - central venous catheters OT - complications OT - cystectomy OT - neoadjuvant therapy OT - thromboembolism OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2022/08/27 06:00 MHDA- 2022/08/27 06:01 PMCR- 2022/08/06 CRDT- 2022/08/26 01:29 PHST- 2022/07/08 00:00 [received] PHST- 2022/08/03 00:00 [revised] PHST- 2022/08/04 00:00 [accepted] PHST- 2022/08/26 01:29 [entrez] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/08/27 06:01 [medline] PHST- 2022/08/06 00:00 [pmc-release] AID - life12081198 [pii] AID - life-12-01198 [pii] AID - 10.3390/life12081198 [doi] PST - epublish SO - Life (Basel). 2022 Aug 6;12(8):1198. doi: 10.3390/life12081198. PMID- 36011373 OWN - NLM STAT- MEDLINE DCOM- 20220829 LR - 20251031 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 8 DP - 2022 Aug 17 TI - Identification of Long Non-Coding RNA MIR4435-2HG as a Prognostic Biomarker in Bladder Cancer. LID - 10.3390/genes13081462 [doi] LID - 1462 AB - The abnormal expression of long non-coding RNAs(lncRNAs) is closely related to the prognosis of patients. This finding may indicate a new target for the treatment of malignant tumors. Non-muscle invasive bladder cancer (NMIBC) is the most common subtype of bladder cancer, and BCG intravesical therapy is the first-line treatment for NMIBC, but about half of NMIBC patients relapse within two years after BCG treatment. Therefore, it is necessary to screen out lncRNAs related to the prognosis and treatment of BGC-resistant patients. Here, we performed differential expression analysis of lncRNAs in the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, and screened MIR4435-2HG as the only BCG-response-related lncRNA. Then, the prognosis value of MIR4435-2HG was validated in several publicly available cohorts, and confirmed its prognostic value in bladder cancer of different stages. In addition, we also analyzed its genetic alterations, clinical relevance, function enrichment, and association with other biomarkers. Further validation of the expression of MIR4435-2HG might be helpful to instruct NMIBC prognosis and treatment. FAU - Hu, Zhiquan AU - Hu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. FAU - Ma, Siquan AU - Ma S AUID- ORCID: 0000-0002-1877-689X AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. FAU - Sun, Yi AU - Sun Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. FAU - Long, Gongwei AU - Long G AUID- ORCID: 0000-0001-8008-2306 AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China. FAU - Chen, Ke AU - Chen K AUID- ORCID: 0000-0002-6914-6257 AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. AD - Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220817 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - 0 (MIR4435-2HG long non-coding RNA, human) RN - 0 (RNA, Long Noncoding) SB - IM MH - BCG Vaccine MH - Biomarkers MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Neoplasm Recurrence, Local/genetics MH - Prognosis MH - RNA, Long Noncoding/*genetics MH - *Urinary Bladder Neoplasms/genetics PMC - PMC9408477 OTO - NOTNLM OT - BCG OT - biomarkers OT - bladder cancer OT - lncRNA OT - prognosis COIS- The authors declare no conflict of interest. EDAT- 2022/08/27 06:00 MHDA- 2022/08/30 06:00 PMCR- 2022/08/17 CRDT- 2022/08/26 01:16 PHST- 2022/06/15 00:00 [received] PHST- 2022/08/05 00:00 [revised] PHST- 2022/08/08 00:00 [accepted] PHST- 2022/08/26 01:16 [entrez] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/08/30 06:00 [medline] PHST- 2022/08/17 00:00 [pmc-release] AID - genes13081462 [pii] AID - genes-13-01462 [pii] AID - 10.3390/genes13081462 [doi] PST - epublish SO - Genes (Basel). 2022 Aug 17;13(8):1462. doi: 10.3390/genes13081462. PMID- 36011016 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 16 DP - 2022 Aug 20 TI - Prognostic Impact of Post-Diagnosis Smoking Cessation among Bladder Cancer Patients: A Systematic Literature Review and Meta-Analysis. LID - 10.3390/cancers14164022 [doi] LID - 4022 AB - We reviewed the studies examining whether quitting smoking at or around diagnosis favourably affects the prognosis of bladder cancer (BC) patients, who are often active smokers at diagnosis. We found only nine eligible articles published until 31 January 2022, which encompassed around 5500 BC in total, the majority of which were nonmuscle invasive BC (only one paper included muscle-invasive BC). We used random effects meta-analysis to obtain a summary hazard ratio (SHR) and 95% confidence intervals (CI). The median proportion of smokers who quit at or around diagnosis was 29.8% (range 8.4-43.1%). For the overall, BC-specific, and progression-free survival, the studies were limited in number (n = 3) and provided conflicting results. At the same time, quitters did not appear to have a lower risk of recurrence than continued smokers (SHR 0.99, 95% CI 0.61-1.61). In conclusion, while the evidence is currently not sufficient to draw firm conclusions (especially for patients with muscle-invasive BC), physicians should not refrain from educating smoking BC patients about the benefits of smoking cessation and provide the necessary support. FAU - Caini, Saverio AU - Caini S AUID- ORCID: 0000-0002-2262-1102 AD - Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50139 Florence, Italy. FAU - Del Riccio, Marco AU - Del Riccio M AUID- ORCID: 0000-0002-2742-0297 AD - Postgraduate School in Hygiene and Preventive Medicine, University of Florence, 50134 Florence, Italy. FAU - Vettori, Virginia AU - Vettori V AUID- ORCID: 0000-0002-6699-8905 AD - Department of Health Sciences, University of Florence, 50134 Florence, Italy. FAU - Francolini, Giulio AU - Francolini G AD - Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy. FAU - D'Ecclesiis, Oriana AU - D'Ecclesiis O AD - Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy. FAU - Cai, Tommaso AU - Cai T AUID- ORCID: 0000-0002-7234-3526 AD - Department of Urology, Santa Chiara Regional Hospital, 38123 Trento, Italy. FAU - Gaeta, Aurora AU - Gaeta A AD - Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy. FAU - Bonaccorsi, Guglielmo AU - Bonaccorsi G AUID- ORCID: 0000-0002-5171-4308 AD - Department of Health Sciences, University of Florence, 50134 Florence, Italy. FAU - Zanna, Ines AU - Zanna I AD - Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50139 Florence, Italy. FAU - Palli, Domenico AU - Palli D AUID- ORCID: 0000-0002-5558-2437 AD - Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50139 Florence, Italy. FAU - Gandini, Sara AU - Gandini S AUID- ORCID: 0000-0002-1348-4548 AD - Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220820 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9406768 OTO - NOTNLM OT - bladder cancer OT - meta-analysis OT - smoking cessation OT - survival OT - systematic review COIS- The authors declare no conflict of interest. EDAT- 2022/08/27 06:00 MHDA- 2022/08/27 06:01 PMCR- 2022/08/20 CRDT- 2022/08/26 01:14 PHST- 2022/07/03 00:00 [received] PHST- 2022/08/18 00:00 [revised] PHST- 2022/08/18 00:00 [accepted] PHST- 2022/08/26 01:14 [entrez] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/08/27 06:01 [medline] PHST- 2022/08/20 00:00 [pmc-release] AID - cancers14164022 [pii] AID - cancers-14-04022 [pii] AID - 10.3390/cancers14164022 [doi] PST - epublish SO - Cancers (Basel). 2022 Aug 20;14(16):4022. doi: 10.3390/cancers14164022. PMID- 36010354 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 12 IP - 8 DP - 2022 Aug 19 TI - The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. LID - 10.3390/diagnostics12082005 [doi] LID - 2005 AB - BACKGROUND: Fluorescence in situ hybridization (FISH) has become a popular biomarker for subsequent monitoring the recurrence of non-muscle invasive bladder cancer (NMIBC), several studies have investigated the ability of FISH to detect recurrence in the surveillance of NMIBC. However, the results were inconsistent. METHODS: We conducted a systematic literature search extensively on authenticated databases including PubMed/Medline, Embase, Web of Science, Ovid, and Cochrane Library. Meta-analysis was performed to find out the sensitivity and specificity of FISH in predicting recurrence of NMIBC. RESULTS: 15 studies were ultimately included in this meta-analysis, a total of 2941 FISH evaluations from 2385 NMIBC patients were available. The pooled sensitivity of FISH was 68% (95% CI: 0.58-0.76), and the pooled specificity was 64% (95% CI: 0.53-0.74). Subgroup analyses were performed in 7 studies without Bacillus Calmette-Guerin (BCG) treatment, the pooled sensitivity was 82% (95% CI: 0.68-0.90), and the pooled specificity was 63% (95% CI: 0.37-0.82). And in 9 studies using "UroVysion standard" to define positive FISH results showed a pooled sensitivity of 60% (95% CI: 0.50-0.70) and specificity of 70% (95% CI: 0.61-0.78). CONCLUSIONS: The findings of this study indicate that FISH has a satisfactory sensitivity (68%) and specificity (64%) and could be a potential biomarker in the surveillance of NMIBC. Moreover, BCG treatment and different FISH methods may have an impact on the sensitivity and specificity, these factors should be taken into account when making clinical strategy. FAU - Zheng, Weitao AU - Zheng W AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Lin, Tianhai AU - Lin T AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Chen, Zeyu AU - Chen Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Cao, Dehong AU - Cao D AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Bao, Yige AU - Bao Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Yang, Lu AU - Yang L AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37, Guoxue Road, Chengdu 610041, China. LA - eng PT - Journal Article PT - Review DEP - 20220819 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC9407231 OTO - NOTNLM OT - fluorescence in situ hybridization OT - meta-analysis OT - non-muscle invasive bladder cancer OT - surveillance COIS- All authors declare that no competing interest associated with the manuscript needs to disclose. EDAT- 2022/08/27 06:00 MHDA- 2022/08/27 06:01 PMCR- 2022/08/19 CRDT- 2022/08/26 01:10 PHST- 2022/07/27 00:00 [received] PHST- 2022/08/11 00:00 [revised] PHST- 2022/08/16 00:00 [accepted] PHST- 2022/08/26 01:10 [entrez] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/08/27 06:01 [medline] PHST- 2022/08/19 00:00 [pmc-release] AID - diagnostics12082005 [pii] AID - diagnostics-12-02005 [pii] AID - 10.3390/diagnostics12082005 [doi] PST - epublish SO - Diagnostics (Basel). 2022 Aug 19;12(8):2005. doi: 10.3390/diagnostics12082005. PMID- 36008697 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 54 IP - 12 DP - 2022 Dec TI - The prognostic role of pre-cystectomy thrombocytosis in invasive bladder cancer. PG - 3153-3161 LID - 10.1007/s11255-022-03346-7 [doi] AB - PURPOSE: We aim to evaluate the impact of preoperative thrombocytosis on oncological outcomes in patients with bladder cancer (BC) who undergo radical cystectomy (RC). METHODS: Retrospective data collection of 1092 patients managed by RC for BC from 2 tertiary-care centers was performed. Elevated platelet count (PLT) was defined as > 450 x 10(9)/L. Univariable and multivariable logistic regression analyses were used to investigate the impact of thrombocytosis on oncological outcomes. These outcomes were also compared using Kaplan-Meier survival analysis. RESULTS: The median follow-up was 50 months (32-64 months). Thrombocytosis was detected in 18.6% of the patients. The 3-year cancer-specific survival (CSS) for patients with normal PLT count was 92% which was higher than those with elevated PLT count (55%, P < 0.001). Similar results were found for the 6-year CSS with 82% for the no thrombocytosis group and 27% for the thrombocytosis group. Thrombocytosis was still significantly associated with poor prognosis for overall survival and recurrence-free survival (P < 0.001). In the multivariate analysis, CSS was significantly lower in patients with thrombocytosis (HR = 1.71, 95% CI = 1.22-2.39, P = 0.002). Patients with elevated PLT counts were also significantly more likely to receive adjuvant chemotherapy, to have a T stage > pT2b (P = 0.024), to have a positive lymph node, to have variant histology and positive resection margins, and to have concomitant carcinoma in situ (CIS) on final pathology (all P < 0.001). CONCLUSIONS: Preoperative thrombocytosis was valuable for predicting the oncological outcomes of patients undergoing RC for BC. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Chakra, Mohamad Abou AU - Chakra MA AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. mohamedabouchakra@hotmail.com. AD - Department of Urology, Lebanese University, Beirut, Lebanon. mohamedabouchakra@hotmail.com. FAU - Azoulai, David AU - Azoulai D AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. FAU - Moussa, Mohamad AU - Moussa M AD - Surgery and Urology Department, Lebanese University, Beirut, Lebanon. FAU - Ismail, Khadija AU - Ismail K AD - Epidemiology and Statistic Department, Lebanese University, Beirut, Lebanon. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. FAU - Delongchamps, Nicolas Barry AU - Delongchamps NB AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. FAU - Saighi, Djillali AU - Saighi D AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. FAU - Bailly, Hugo AU - Bailly H AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. FAU - Duquesne, Igor AU - Duquesne I AD - Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75013, Paris, France. LA - eng PT - Journal Article DEP - 20220825 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Humans MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/complications/surgery MH - Prognosis MH - Retrospective Studies MH - *Thrombocytosis/complications/surgery MH - *Carcinoma, Transitional Cell/surgery OTO - NOTNLM OT - Bladder cancer OT - Oncological outcomes OT - Preoperative OT - Radical cystectomy OT - Thrombocytosis EDAT- 2022/08/26 06:00 MHDA- 2022/10/29 06:00 CRDT- 2022/08/25 23:37 PHST- 2022/05/11 00:00 [received] PHST- 2022/08/19 00:00 [accepted] PHST- 2022/08/26 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2022/08/25 23:37 [entrez] AID - 10.1007/s11255-022-03346-7 [pii] AID - 10.1007/s11255-022-03346-7 [doi] PST - ppublish SO - Int Urol Nephrol. 2022 Dec;54(12):3153-3161. doi: 10.1007/s11255-022-03346-7. Epub 2022 Aug 25. PMID- 36008193 OWN - NLM STAT- MEDLINE DCOM- 20221116 LR - 20260127 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 82 IP - 6 DP - 2022 Dec TI - First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin. PG - 602-610 LID - S0302-2838(22)02553-2 [pii] LID - 10.1016/j.eururo.2022.08.004 [doi] AB - BACKGROUND: Intravenous immune checkpoint inhibition is an effective anticancer strategy for bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) but may be associated with greater systemic toxicity compared with localized therapies. OBJECTIVE: We assessed the safety and antitumor activity of intravesical pembrolizumab combined with BCG. DESIGN, SETTING, AND PARTICIPANTS: A 3 + 3 phase 1 trial of pembrolizumab + BCG was conducted in patients with BCG-unresponsive NMIBC (NCT02808143). INTERVENTION: Pembrolizumab was given intravesically (1-5 mg/kg for 2 h) beginning 2 weeks prior to BCG induction until recurrence. Urine profiling during treatment and spatial transcriptomic profiling of pre- and post-treatment tumors were conducted to identify biomarkers that correlated with response. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Safety and tolerability of immune checkpoint inhibition were assessed, and Kaplan-Meier survival analysis was performed. RESULTS AND LIMITATIONS: Nine patients completed therapy. Median follow-up was 35 months for five patients still alive at the end of the trial. The trial was closed due to the COVID-19 pandemic. Grade 1-2 urinary symptoms were common. The maximum tolerated dose was not reached; however, one dose-limiting toxicity was reported (grade 2 diarrhea) in the only patient who reached 52 weeks without recurrence. One death occurred from myasthenia gravis that was deemed potentially related to treatment. The 6-mo and 1-yr recurrence-free rates were 67% (95% confidence interval [CI]: 42-100%) and 22% (95% CI: 6.5-75%), respectively. Pembrolizumab was detected in the urine and not in blood. CD4(+) T cells were significantly increased in the urine after treatment, and a transcriptomic analysis identified decreased expression of T-cell exhaustion markers in late recurrences. CONCLUSIONS: We demonstrate that intravesical pembrolizumab is safe, feasible, and capable of eliciting strong immune responses in a clinical setting and should be investigated further. PATIENT SUMMARY: Direct application of pembrolizumab to the bladder is a promising alternative for non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin and should be investigated further. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Meghani, Khyati AU - Meghani K AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Cooley, Lauren Folgosa AU - Cooley LF AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Choy, Bonnie AU - Choy B AD - Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Kocherginsky, Masha AU - Kocherginsky M AD - Division of Biostatistics, Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Swaminathan, Suchitra AU - Swaminathan S AD - Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Munir, Sabah S AU - Munir SS AD - Division of Biostatistics, Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, UT Health San Antonio, San Antonio, TX, USA. FAU - Kuzel, Timothy AU - Kuzel T AD - Division of Hematology and Oncology, Department of Medicine, Rush Medical College, Chicago, IL, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: joshua.meeks@northwestern.edu. LA - eng SI - ClinicalTrials.gov/NCT02808143 GR - I01 BX003692/BX/BLRD VA/United States GR - I01 BX005599/BX/BLRD VA/United States GR - P30 CA060553/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220823 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Adjuvants, Immunologic) RN - DPT0O3T46P (pembrolizumab) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM CIN - Eur Urol. 2022 Dec;82(6):611-612. doi: 10.1016/j.eururo.2022.08.032. PMID: 36153248 CIN - Nat Rev Urol. 2022 Dec;19(12):694. doi: 10.1038/s41585-022-00674-2. PMID: 36316466 CIN - Eur Urol. 2023 Feb;83(2):e54-e55. doi: 10.1016/j.eururo.2022.10.025. PMID: 36404205 CIN - J Urol. 2023 Jun;209(6):1228-1229. doi: 10.1097/JU.0000000000003411. PMID: 36950936 MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Administration, Intravesical MH - BCG Vaccine/adverse effects MH - Immune Checkpoint Inhibitors MH - Pandemics MH - Neoplasm Recurrence, Local/pathology MH - *COVID-19 MH - Neoplasm Invasiveness/pathology MH - Adjuvants, Immunologic MH - Antibodies, Monoclonal, Humanized PMC - PMC9669228 MID - NIHMS1838520 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Clinical trial OT - Digital spatial profiling OT - Intravesical pembrolizumab EDAT- 2022/08/26 06:00 MHDA- 2022/11/18 06:00 PMCR- 2022/12/01 CRDT- 2022/08/25 22:04 PHST- 2022/04/02 00:00 [received] PHST- 2022/07/15 00:00 [revised] PHST- 2022/08/03 00:00 [accepted] PHST- 2022/08/26 06:00 [pubmed] PHST- 2022/11/18 06:00 [medline] PHST- 2022/08/25 22:04 [entrez] PHST- 2022/12/01 00:00 [pmc-release] AID - S0302-2838(22)02553-2 [pii] AID - 10.1016/j.eururo.2022.08.004 [doi] PST - ppublish SO - Eur Urol. 2022 Dec;82(6):602-610. doi: 10.1016/j.eururo.2022.08.004. Epub 2022 Aug 23. PMID- 36005168 OWN - NLM STAT- MEDLINE DCOM- 20220826 LR - 20250728 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 8 DP - 2022 Jul 31 TI - Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. PG - 5442-5456 LID - 10.3390/curroncol29080430 [doi] AB - OBJECTIVES: The molecular landscape of non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer based on molecular characteristics is essential but poorly understood. In this pilot study we aimed to identify a multi-omics signature that can distinguish MIBC from NMIBC. Such a signature can assist in finding potential mechanistic biomarkers and druggable targets. METHODS: Patients diagnosed with NMIBC (n = 15) and MIBC (n = 11) were recruited at a tertiary-care hospital in Nanjing from 1 April 2021, and 31 July 2021. Blood, urine and stool samples per participant were collected, in which the serum metabolome, urine metabolome, gut microbiome, and serum extracellular vesicles (EV) proteome were quantified. The differences of the global profiles and individual omics measure between NMIBC vs. MIBC were assessed by permutational multivariate analysis and the Mann-Whitney test, respectively. Logistic regression analysis was used to assess the association of each identified analyte with NMIBC vs. MIBC, and the Spearman correlation was used to investigate the correlations between identified analytes, where both were adjusted for age, sex and smoking status. RESULTS: Among 3168 multi-omics measures that passed the quality control, 159 were identified to be differentiated in NMIBC vs. MIBC. Of these, 46 analytes were associated with bladder cancer progression. In addition, the global profiles showed significantly different urine metabolome (p = 0.029), gut microbiome (p = 0.036), and serum EV (extracellular vesicles) proteome (p = 0.039) but not serum metabolome (p = 0.059). We also observed 17 (35%) analytes that had been developed as drug targets. Multiple interactions were obtained between the identified analytes, whereas for the majority (61%), the number of interactions was at 11-20. Moreover, unconjugated bilirubin (p = 0.009) and white blood cell count (p = 0.006) were also shown to be different in NMIBC and MIBC, and associated with 11 identified omics analytes. CONCLUSIONS: The pilot study has shown promising to monitor the progression of bladder cancer by integrating multi-omics data and deserves further investigations. FAU - Yu, Evan Yi-Wen AU - Yu EY AUID- ORCID: 0000-0001-7825-5087 AD - Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. AD - Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, 6229 ER Maastricht, The Netherlands. FAU - Zhang, Hao AU - Zhang H AUID- ORCID: 0000-0001-9744-1707 AD - State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing 210096, China. AD - Nanjing EVLiXiR Biotechnology Co., Ltd., Nanjing 210032, China. FAU - Fu, Yuanqing AU - Fu Y AD - Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China. AD - Westlake Intelligent Biomarker Discovery Laboratory, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China. AD - Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China. FAU - Chen, Ya-Ting AU - Chen YT AD - Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Tang, Qiu-Yi AU - Tang QY AD - Medical School of Southeast University, Nanjing 210009, China. FAU - Liu, Yu-Xiang AU - Liu YX AD - Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Zhang, Yan-Xi AU - Zhang YX AUID- ORCID: 0000-0003-0929-3383 AD - Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Wang, Shi-Zhi AU - Wang SZ AD - Key Laboratory of Environmental Medicine Engineering, School of Public Health, Southeast University, Ministry of Education, Nanjing 210009, China. FAU - Wesselius, Anke AU - Wesselius A AUID- ORCID: 0000-0003-4474-9665 AD - Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, 6229 ER Maastricht, The Netherlands. AD - School of Nutrition and Translational Research in Metabolism, Maastricht University, 6229 ER Maastricht, The Netherlands. FAU - Li, Wen-Chao AU - Li WC AD - Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, China. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, 6229 ER Maastricht, The Netherlands. AD - School of Nutrition and Translational Research in Metabolism, Maastricht University, 6229 ER Maastricht, The Netherlands. FAU - Xu, Bin AU - Xu B AD - Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220731 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Proteome) SB - IM MH - Humans MH - Pilot Projects MH - Prognosis MH - Proteome MH - *Urinary Bladder Neoplasms/genetics PMC - PMC9406560 OTO - NOTNLM OT - bladder cancer OT - molecular epidemiology OT - multi-omics OT - progression of disease COIS- All the authors declare that they have no conflict of interest. EDAT- 2022/08/26 06:00 MHDA- 2022/08/27 06:00 PMCR- 2022/07/31 CRDT- 2022/08/25 07:33 PHST- 2022/07/01 00:00 [received] PHST- 2022/07/23 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/08/25 07:33 [entrez] PHST- 2022/08/26 06:00 [pubmed] PHST- 2022/08/27 06:00 [medline] PHST- 2022/07/31 00:00 [pmc-release] AID - curroncol29080430 [pii] AID - curroncol-29-00430 [pii] AID - 10.3390/curroncol29080430 [doi] PST - epublish SO - Curr Oncol. 2022 Jul 31;29(8):5442-5456. doi: 10.3390/curroncol29080430. PMID- 36002184 OWN - NLM STAT- MEDLINE DCOM- 20220826 LR - 20250728 IS - 2051-1426 (Electronic) IS - 2051-1426 (Linking) VI - 10 IP - 8 DP - 2022 Aug TI - Vdelta2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. LID - 10.1136/jitc-2022-004880 [doi] LID - e004880 AB - Background Bladder cancer is an important public health concern due to its prevalence, high risk of recurrence and associated cost of management. Although BCG instillation for urothelial cancer treatment is the gold-standard treatment for this indication, repeated BCG treatments are associated with significant toxicity and failure, underlining the necessity for alternative or complementary immunotherapy and overall for better understanding of T-cell responses generated within bladder mucosa. Tumor-infiltrating lymphocytes (TIL) have long been recognized as a crucial component of the tumor microenvironment for the control of tumor. Among TIL, unconventional gammadelta T cells sparked interest due to their potent antitumor functions. Although preclinical mouse xenograft models demonstrated the relevance of using gammadelta T cells as a novel therapy for bladder cancer (BCa), the contribution of gammadelta T cells in BCa patients' pathology remains unaddressed.Methods Therefore, we first determined the proportion of intratumor gammadelta T cells in muscle-invasive patients with BCa by deconvoluting data from The Cancer Genome Atlas (TCGA) and the frequency of blood Vdelta1, Vdelta2, and total gammadelta T cells, by flow cytometry, from 80 patients with BCa (40 non-muscle and 40 muscle-invasive patients with BCa), as well as from 20 age-matched non-tumor patients. Then we investigated in vitro which treatment may promote BCa tumor cell recognition by gammadelta T cells.Results We observed a decrease of gammadelta T-cell abundance in the tumor compared with corresponding normal adjacent tissue, suggesting that the tumor microenvironment may alter gammadelta T cells. Yet, high intratumor gammadelta T-cell proportions were significantly associated with better patient survival outcomes, potentially due to Vdelta2 T cells. In the blood of patients with BCa, we observed a lower frequency of total gammadelta, Vdelta1, and Vdelta2 T cells compared with non-tumor patients, similarly to the TCGA analysis. In addition, a favorable clinical outcome is associated with a high frequency of circulating gammadelta T cells, which might be mainly attributed to the Vdelta2 T-cell subset. Furthermore, in vitro assays revealed that either BCG, Zoledronate, or anti-BTN3 agonistic antibody treatment of bladder tumor cells induced Vdelta2 T-cell cytolytic (CD107a(+)) and cytokine-production (IFN-gamma and TNF-alpha). Strikingly, combining BCG and Zoledronate treatments significantly elicited the most quantitative and qualitative response by increasing the frequency and the polyfunctionality of bladder tumor-reactive Vdelta2 T cells.Conclusions Overall, our results suggest that (1) Vdelta2 T cells might play a prominent role in bladder tumor control and (2) non-muscle invasive patients with BCa undergoing BCG therapy may benefit from Zoledronate administration by boosting Vdelta2 T cells' antitumor activity. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. FAU - Nguyen, Sylvain AU - Nguyen S AUID- ORCID: 0000-0002-6508-1337 AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Chevalier, Mathieu F AU - Chevalier MF AUID- ORCID: 0000-0002-5601-2217 AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. AD - INSERM U976, HIPI Unit (Human Immunology, Pathophysiology and Immunotherapy), Hopital Saint-Louis, Paris, France. FAU - Benmerzoug, Sulayman AU - Benmerzoug S AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Cesson, Valerie AU - Cesson V AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Schneider, Anna K AU - Schneider AK AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Rodrigues-Dias, Sonia-Cristina AU - Rodrigues-Dias SC AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Dartiguenave, Florence AU - Dartiguenave F AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Lucca, Ilaria AU - Lucca I AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Jichlinski, Patrice AU - Jichlinski P AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Roth, Beat AU - Roth B AUID- ORCID: 0000-0002-7369-650X AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Nardelli-Haefliger, Denise AU - Nardelli-Haefliger D AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Derre, Laurent AU - Derre L AUID- ORCID: 0000-0002-3403-161X AD - Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Laurent.Derre@chuv.ch. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Immunother Cancer JT - Journal for immunotherapy of cancer JID - 101620585 RN - 0 (BCG Vaccine) RN - 0 (Receptors, Antigen, T-Cell, gamma-delta) RN - 6XC1PAD3KF (Zoledronic Acid) SB - IM MH - Animals MH - BCG Vaccine/therapeutic use MH - Humans MH - Mice MH - *Receptors, Antigen, T-Cell, gamma-delta MH - T-Lymphocyte Subsets MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/drug therapy MH - Zoledronic Acid/pharmacology/therapeutic use PMC - PMC9413168 OTO - NOTNLM OT - Immunity OT - Immunotherapy OT - Urinary Bladder Neoplasms COIS- Competing interests: None declared. EDAT- 2022/08/25 06:00 MHDA- 2022/08/27 06:00 PMCR- 2022/08/24 CRDT- 2022/08/24 21:02 PHST- 2022/08/02 00:00 [accepted] PHST- 2022/08/24 21:02 [entrez] PHST- 2022/08/25 06:00 [pubmed] PHST- 2022/08/27 06:00 [medline] PHST- 2022/08/24 00:00 [pmc-release] AID - jitc-2022-004880 [pii] AID - 10.1136/jitc-2022-004880 [doi] PST - ppublish SO - J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. PMID- 35999119 OWN - NLM STAT- MEDLINE DCOM- 20230515 LR - 20230517 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 83 IP - 6 DP - 2023 Jun TI - Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. PG - 497-504 LID - S0302-2838(22)02552-0 [pii] LID - 10.1016/j.eururo.2022.08.003 [doi] AB - BACKGROUND: Adjuvant intravesical chemotherapy following tumour resection is recommended for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To assess the efficacy and safety of adjuvant intravesical chemohyperthermia (CHT) for intermediate-risk NMIBC. DESIGN, SETTING, AND PARTICIPANTS: HIVEC-II is an open-label, phase 2 randomised controlled trial of CHT versus chemotherapy alone in patients with intermediate-risk NMIBC recruited at 15 centres between May 2014 and December 2017 (ISRCTN 23639415). Randomisation was stratified by treating hospital. INTERVENTIONS: Patients were randomly assigned (1:1) to adjuvant CHT with mitomycin C at 43 degrees C or to room-temperature mitomycin C (control). Both treatment arms received six weekly instillations of 40 mg of mitomycin C lasting for 60 min. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was 24-mo disease-free survival as determined via cystoscopy and urinary cytology. Analysis was by intention to treat. RESULTS: A total of 259 patients (131 CHT vs 128 control) were randomised. At 24 mo, 42 patients (32%) in the CHT group and 49 (38%) in the control group had experienced recurrence. Disease-free survival at 24 mo was 61% (95% confidence interval [CI] 51-69%) in the CHT arm and 60% (95% CI 50-68%) in the control arm (hazard ratio [HR] 0.92, 95% CI 0.62-1.37; log-rank p = 0.8). Progression-free survival was higher in the control arm (HR 3.44, 95% CI 1.09-10.82; log-rank p = 0.02) on intention-to-treat analysis but was not significantly higher on per-protocol analysis (HR 2.87, 95% CI 0.83-9.98; log-rank p = 0.06). Overall survival was similar (HR 2.55, 95% CI 0.77-8.40; log-rank p = 0.09). Patients undergoing CHT were less likely to complete their treatment (n =75, 59% vs n = 111, 89%). Adverse events were reported by 164 patients (87 CHT vs 77 control). Major (grade III) adverse events were rare (13 CHT vs 7 control). CONCLUSIONS: CHT cannot be recommended over chemotherapy alone for intermediate-risk NMIBC. Adverse events following CHT were of low grade and short-lived, although patients were less likely to complete their treatment. PATIENT SUMMARY: The HIVEC-II trial investigated the role of heated chemotherapy instillations in the bladder for treatment of intermediate-risk non-muscle-invasive bladder cancer. We found no cancer control benefit from heated chemotherapy instillations over room-temperature chemotherapy. Adverse events following heated chemotherapy were low grade and short-lived, although these patients were less likely to complete their treatment. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Tan, Wei Shen AU - Tan WS AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital, London, UK. Electronic address: wei.tan@ucl.ac.uk. FAU - Prendergast, Aaron AU - Prendergast A AD - Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. FAU - Ackerman, Charlotte AU - Ackerman C AD - Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. FAU - Yogeswaran, Yathushan AU - Yogeswaran Y AD - Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. FAU - Cresswell, Joanne AU - Cresswell J AD - Department of Urology, The James Cook University Hospital, Middlesbrough, UK. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Department of Urology, Edinburgh Bladder Cancer Surgery, Western General Hospital, Edinburgh, UK. FAU - Phull, Jaspal AU - Phull J AD - Department of Urology, Royal United Hospital, Bath, UK. FAU - Hunter-Campbell, Paul AU - Hunter-Campbell P AD - Department of Urology, University Hospital Plymouth, Plymouth, UK. FAU - Lazarowicz, Henry AU - Lazarowicz H AD - Department of Urology, The Royal Liverpool University Hospital, Liverpool, UK. FAU - Mishra, Vibhash AU - Mishra V AD - Department of Urology, Royal Free Hospital, London, UK. FAU - Rane, Abhay AU - Rane A AD - Department of Urology, East Surry Hospital, Redhill, UK. FAU - Davies, Melissa AU - Davies M AD - Department of Urology, Salisbury District Hospital, Salisbury, UK. FAU - Warburton, Hazel AU - Warburton H AD - Department of Urology, University Hospital of South Manchester, Manchester, UK. FAU - Cooke, Peter AU - Cooke P AD - Department of Urology, New Cross Hospital, Wolverhampton, UK. FAU - Mostafid, Hugh AU - Mostafid H AD - Department of Urology, The Royal Surrey County Hospital, Guildford, UK. FAU - Wilby, Daniel AU - Wilby D AD - Department of Urology, Queen Alexandra Hospital, Portsmouth, UK. FAU - Mills, Robert AU - Mills R AD - Department of Urology, Norfolk and Norwich University Hospital, Norwich, UK. FAU - Issa, Rami AU - Issa R AD - Department of Urology, St George's Hospital, London, UK. FAU - Kelly, John D AU - Kelly JD AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital, London, UK. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220820 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 50SG953SK6 (Mitomycin) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - Eur Urol. 2023 Feb;83(2):e56-e57. doi: 10.1016/j.eururo.2022.09.035. PMID: 36372625 CIN - Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. PMID: 36404203 CIN - Eur Urol. 2023 Feb;83(2):e48-e49. doi: 10.1016/j.eururo.2022.11.006. PMID: 36456403 CIN - Eur Urol. 2023 Jun;83(6):505-507. doi: 10.1016/j.eururo.2023.03.004. PMID: 36967360 MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Mitomycin MH - Antibiotics, Antineoplastic MH - Administration, Intravesical MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - Chemotherapy, Adjuvant OTO - NOTNLM OT - Control OT - Device-assisted therapy OT - Hyperthermia OT - Intravesical chemotherapy OT - Mitomycin C OT - Non-muscle-invasive bladder cancer OT - Randomised control trial EDAT- 2022/08/24 06:00 MHDA- 2023/05/15 06:42 CRDT- 2022/08/23 22:04 PHST- 2022/04/13 00:00 [received] PHST- 2022/07/25 00:00 [revised] PHST- 2022/08/03 00:00 [accepted] PHST- 2023/05/15 06:42 [medline] PHST- 2022/08/24 06:00 [pubmed] PHST- 2022/08/23 22:04 [entrez] AID - S0302-2838(22)02552-0 [pii] AID - 10.1016/j.eururo.2022.08.003 [doi] PST - ppublish SO - Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20. PMID- 35997477 OWN - NLM STAT- MEDLINE DCOM- 20221012 LR - 20230720 IS - 1305-3612 (Electronic) IS - 1305-3825 (Print) IS - 1305-3825 (Linking) VI - 28 IP - 5 DP - 2022 Sep TI - Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results. PG - 396-402 LID - 10.5152/dir.2022.201108 [doi] AB - PURPOSE We aimed to investigate the accuracy of Vesical Imaging - Reporting and Data System (VI-RADS) in the detection of muscle-invasive bladder cancer (MIBC) and to determine which factors affect the results of this scoring system. METHODS A prospective data analysis of 80 patients who were detected to have bladder tumor was performed between March 2019 and October 2020. VI-RADS scoring was used to determine the probability of muscle invasion. The scores were compared with pathological results to evaluate the accuracy of the VI-RADS scoring system. Interobserver agreement was assessed by VI-RADS scoring of 20 randomly chosen patients by a different experienced radiologist. RESULTS Using the VI-RADS scoring system, the sensitivity, specificity, positive predictive value, and negative predictive value of multiparametric magnetic resonance imaging (mpMRI) were 87.5%, 87.5%, 63.6%, and 96.6%, respectively. The interobserver agreement expressed as the interclass correlation coefficient (ICC) was 0.72 (95% CI: 0.44-0.84, P < .001). In addition, the flat appearance of the tumor was an important factor affecting the accuracy of the VI-RADS score (odds ratio: 5.3 [95% CI: 1.1-27.0] and relative risk: 1.87 [95% CI: 1.24-2.82]). CONCLUSION The mpMRI, used in conjunction with VI-RADS, has proven to be an effective imaging method for detecting muscle invasion in cases of bladder cancer. VI-RADS scoring system can distinguish whether there is a muscle-invasive and non-muscle invasive bladder cancer with acceptable accuracy. In addition, the flat appearance of the tumor is an important entity that can affect the accuracy of the VI-RADS scoring system. FAU - Oguz, Ural AU - Oguz U AD - Department of Urology, Giresun University School of Medicine, Giresun, Turkey. FAU - Bekci, Tumay AU - Bekci T AD - Department of Radiology, Giresun University School of Medicine, Giresun, Turkey. FAU - Ogreden, Ercan AU - Ogreden E AD - Department of Urology, Giresun University School of Medicine, Giresun, Turkey. FAU - Aslan, Serdar AU - Aslan S AD - Department of Radiology, Giresun University School of Medicine, Giresun, Turkey. FAU - Duman, Aslihan AU - Duman A AD - Department of Pathology, Giresun University School of Medicine, Giresun, Turkey. FAU - Demirelli, Erhan AU - Demirelli E AD - Department of Urology, Giresun University School of Medicine, Giresun, Turkey. FAU - Sengul, Demet AU - Sengul D AD - Department of Pathology, Giresun University School of Medicine, Giresun, Turkey. FAU - Tok, Dogan Sabri AU - Tok DS AD - Department of Urology, Giresun University School of Medicine, Giresun, Turkey. FAU - Ciftci, Osman Cagatay AU - Ciftci OC AD - Department of Urology, Giresun University School of Medicine, Giresun, Turkey. FAU - Tosun, Alptekin AU - Tosun A AD - Department of Radiology, Giresun University School of Medicine, Giresun, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Diagn Interv Radiol JT - Diagnostic and interventional radiology (Ankara, Turkey) JID - 101241152 SB - IM CIN - Diagn Interv Radiol. 2023 Mar 29;29(2):412-413. doi: 10.4274/dir.2022.221568. PMID: 36987930 MH - Data Systems MH - Humans MH - Magnetic Resonance Imaging/methods MH - *Multiparametric Magnetic Resonance Imaging MH - Predictive Value of Tests MH - Prospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology PMC - PMC9682553 EDAT- 2022/08/24 06:00 MHDA- 2022/10/13 06:00 PMCR- 2022/09/01 CRDT- 2022/08/23 08:52 PHST- 2022/08/24 06:00 [pubmed] PHST- 2022/10/13 06:00 [medline] PHST- 2022/08/23 08:52 [entrez] PHST- 2022/09/01 00:00 [pmc-release] AID - dir-28-5-396 [pii] AID - 10.5152/dir.2022.201108 [doi] PST - ppublish SO - Diagn Interv Radiol. 2022 Sep;28(5):396-402. doi: 10.5152/dir.2022.201108. PMID- 35992775 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220823 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Non-muscle invasive bladder cancer biomarkers beyond morphology. PG - 947446 LID - 10.3389/fonc.2022.947446 [doi] LID - 947446 AB - Non-muscle invasive bladder cancer (NMIBC) still represents a challenge in decision-making and clinical management since prognostic and predictive biomarkers of response to treatment are still under investigation. In addition to the risk factors defined by EORTC guidelines, histological features have also been considered key variables able to impact on recurrence and progression in bladder cancer. Conversely, the role of genomic rearrangements or expression of specific proteins at tissue level need further assessment in NMIBC. As with muscle-invasive cancer, NMIBC is a heterogeneous disease, characterized by genomic instability, varying rates of mutation and a wide range of protein tissue expression. In this Review, we summarized the recent evidence on prognostic and predictive tissue biomarkers in NMIBC, beyond morphological parameters, outlining how they could affect tumor biology and consequently its behavior during clinical care. Our aim was to facilitate clinical evaluation of promising biomarkers that may be employed to better stratify patients. We described the most common molecular events and immunohistochemical protein expressions linked to recurrence and progression. Moreover, we discussed the link between available treatments and molecular drivers that could be predictive of clinical response. In conclusion, we foster further investigations with particular focus on immunohistochemical evaluation of tissue biomarkers, a promising and cost-effective tool for daily practice. CI - Copyright (c) 2022 De Carlo, Valeri, Corbitt, Cieri and Colombo. FAU - De Carlo, Camilla AU - De Carlo C AD - Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Valeri, Marina AU - Valeri M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Corbitt, Devin Nicole AU - Corbitt DN AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Cieri, Miriam AU - Cieri M AD - Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220803 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9382689 OTO - NOTNLM OT - BCG response OT - biomarker OT - bladder cancer OT - molecular subtypes OT - non-muscle invasive bladder cancer OT - predictive OT - prognostic COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/23 06:00 MHDA- 2022/08/23 06:01 PMCR- 2022/01/01 CRDT- 2022/08/22 04:33 PHST- 2022/05/18 00:00 [received] PHST- 2022/07/11 00:00 [accepted] PHST- 2022/08/22 04:33 [entrez] PHST- 2022/08/23 06:00 [pubmed] PHST- 2022/08/23 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.947446 [doi] PST - epublish SO - Front Oncol. 2022 Aug 3;12:947446. doi: 10.3389/fonc.2022.947446. eCollection 2022. PMID- 35986963 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221025 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 237 DP - 2022 Sep TI - Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression. PG - 154072 LID - S0344-0338(22)00316-8 [pii] LID - 10.1016/j.prp.2022.154072 [doi] AB - There is limited evidence regarding the tumor expression of nectins and their clinical implications in muscle invasive bladder cancer. Herein, we evaluated expression of Nectins 1-4 in 64 patients with muscle invasive bladder cancer who underwent radical cystectomy using a histochemical scoring method (H-score; immunohistochemical staining intensity multiplied by the percentage of positive-staining cells). The cutoff values were defined based on the median H-scores. Of the 64 patients, 45 (70%) had residual tumors in radical cystectomy specimens, while 13 (20%) had lymph node metastasis. The median (interquartile range) H-scores of Nectin-1, - 2, - 3, and - 4 expression were 0 (0-10), 80 (30-180), 5 (0-30), and 100 (33-160), respectively. The Nectin-4 H-score of the neuroendocrine variant was significantly lower than that of pure urothelial carcinoma (P = 0.015). Post-neoadjuvant chemotherapy pathological response (/=pT2N0 disease at final pathology, was assessed using multivariable logistic regression. Recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS) were compared between upfront and delayed eRC groups using inverse probability of treatment weighting (IPTW)-adjusted Cox model. Results: Overall, 184 patients received either upfront (n = 87; 47%) or delayed (n = 97; 53%) eRC. No difference was observed in perioperative outcomes between the two treatment groups (all p > 0.05). Pathological upstaging occurred in 55 (30%) patients and upfront eRC was an independent predictor (HR = 2.65; 95% CI = (1.23-5.67); p = 0.012). In the IPTW-adjusted Cox analysis, there was no significant difference between upfront and delayed eRC in terms of RFS (HR = 1.31; 95% CI = (0.72-2.39); p = 0.38), CSS (HR = 1.09; 95% CI = (0.51-2.34); p = 0.82) and OS (HR = 1.19; 95% CI = (0.62-2.78); p = 0.60). Conclusion: our results suggest similar perioperative outcomes between upfront and delayed eRC, with an increased risk of upstaging after upfront eRC that did impact survival, as compared to delayed eRC. FAU - Diamant, Elliott AU - Diamant E AD - Sorbonne Universite, Department of Urology, GRC n degrees 5 Predictive Onco-Urology, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology, CHU-Institut Universitaire du Cancer-Oncopole, 31000 Toulouse, France. FAU - Ingels, Alexandre AU - Ingels A AD - Department of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Creteil, France. FAU - Parra, Jerome AU - Parra J AD - Sorbonne Universite, Department of Urology, GRC n degrees 5 Predictive Onco-Urology, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France. FAU - Vordos, Dimitri AU - Vordos D AD - Department of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Creteil, France. FAU - Bajeot, Anne-Sophie AU - Bajeot AS AD - Department of Urology, CHU-Institut Universitaire du Cancer-Oncopole, 31000 Toulouse, France. FAU - Chartier-Kastler, Emmanuel AU - Chartier-Kastler E AUID- ORCID: 0000-0003-4241-8125 AD - Sorbonne Universite, Department of Urology, GRC n degrees 5 Predictive Onco-Urology, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France. FAU - Soulie, Michel AU - Soulie M AD - Department of Urology, CHU-Institut Universitaire du Cancer-Oncopole, 31000 Toulouse, France. FAU - de la Taille, Alexandre AU - de la Taille A AD - Department of Urology, University Hospital Henri Mondor, APHP, UPEC, 94000 Creteil, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, Department of Urology, GRC n degrees 5 Predictive Onco-Urology, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne Universite, Department of Urology, GRC n degrees 5 Predictive Onco-Urology, AP-HP, Pitie-Salpetriere Hospital, 75013 Paris, France. LA - eng PT - Journal Article DEP - 20220804 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 EIN - Cancers (Basel). 2022 Dec 05;14(23):6001. doi: 10.3390/cancers14236001. PMID: 36497499 PMC - PMC9367342 OTO - NOTNLM OT - complication OT - cystectomy OT - non-muscle invasive bladder cancer OT - survival analysis OT - upstaging OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2022/08/13 06:00 MHDA- 2022/08/13 06:01 PMCR- 2022/08/04 CRDT- 2022/08/12 01:05 PHST- 2022/07/07 00:00 [received] PHST- 2022/07/24 00:00 [revised] PHST- 2022/08/01 00:00 [accepted] PHST- 2022/08/12 01:05 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/13 06:01 [medline] PHST- 2022/08/04 00:00 [pmc-release] AID - cancers14153797 [pii] AID - cancers-14-03797 [pii] AID - 10.3390/cancers14153797 [doi] PST - epublish SO - Cancers (Basel). 2022 Aug 4;14(15):3797. doi: 10.3390/cancers14153797. PMID- 35951254 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 54 IP - 12 DP - 2022 Dec TI - Routine urethroscopic surveillance is of limited value after radical cystectomy: a single centre retrospective cohort analysis. PG - 3139-3144 LID - 10.1007/s11255-022-03312-3 [doi] AB - PURPOSE: The incidence of urethral recurrence (UR) following radical cystectomy (RC) for transitional cell carcinoma (TCC) of the bladder varies between 1.5 and 6%. There is debate over the timing of urethrectomy for patients undergoing RC. We evaluated the requirement for a formal surveillance programme for UR in patients after RC. METHODS: We retrospectively reviewed the outcomes of patients who underwent RC between 2006 and 2019. Females, non-TCC cases and patients with neo-bladder diversions were excluded. Histological prostatic urethral involvement at the time of RC was deemed high risk for UR. Carcinoma in-situ, multifocal tumours and bladder neck involvement were deemed intermediate risk and the absence of the above features was considered low risk. RESULTS: 417 patients underwent RC, 300 cases remained after exclusion criteria were applied. 42 patients were high-risk for UR, 102 patients were intermediate risk and 156 were low risk. Of the 300, 24 urethrectomy cases were recorded. Six cases of UR occurred. Of these, 5 presented with symptoms and only 1 case was detected by surveillance. Only 1 low-risk patient developed UR, 7 years post RC. Using our risk stratification, UR rates for high, intermediate and low-risk cohorts were 25%, 10.5% and 0.8%, respectively. CONCLUSIONS: In our cohort, routine surveillance for all patients with annual urethroscopy was of limited value in detecting UR post RC. Staged Urethrectomy for high and intermediate-risk patients, and patient counselling in self-identification of recurrence symptoms for low-risk patients will improve the early detection of UR. CI - (c) 2022. Crown. FAU - Devlin, Conor M AU - Devlin CM AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. FAU - Molokwu, Chidi N AU - Molokwu CN AUID- ORCID: 0000-0002-6028-4389 AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. chidi.molokwu@nhs.net. FAU - Wood, Benjamin AU - Wood B AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. FAU - Yuen, Keith K AU - Yuen KK AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. FAU - Singh, Rajindra AU - Singh R AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. FAU - Chahal, Rohit AU - Chahal R AD - Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, UK. LA - eng PT - Journal Article DEP - 20220811 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Female MH - Humans MH - Cystectomy MH - Retrospective Studies MH - Urinary Bladder/surgery/pathology MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Neoplasm Recurrence, Local/pathology MH - *Carcinoma, Transitional Cell/surgery/pathology MH - Cohort Studies MH - *Urethral Neoplasms/diagnosis/surgery/pathology OTO - NOTNLM OT - Urethral cancer OT - Urethral recurrence OT - Urethrectomy OT - Urethroscopy OT - Urothelial cell carcinoma EDAT- 2022/08/12 06:00 MHDA- 2022/10/29 06:00 CRDT- 2022/08/11 11:26 PHST- 2021/06/16 00:00 [received] PHST- 2022/07/19 00:00 [accepted] PHST- 2022/08/12 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2022/08/11 11:26 [entrez] AID - 10.1007/s11255-022-03312-3 [pii] AID - 10.1007/s11255-022-03312-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2022 Dec;54(12):3139-3144. doi: 10.1007/s11255-022-03312-3. Epub 2022 Aug 11. PMID- 35945922 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220811 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 14 DP - 2022 TI - Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC. PG - 2291-2297 LID - 10.2147/CMAR.S371974 [doi] AB - PURPOSE: This study aimed to assess the relationship between the preoperative reactive oxygen species and free ferrous protoporphyrin (ROS and FH) combined test and the risk of recurrence in a pathologically confirmed non-muscular invasive bladder cancer (NMIBC) patients. PATIENTS AND METHODS: The retrospective study included 218 patients, newly diagnosed with NMIBC between January 2019 and February 2022. According to the results of FH and ROS combined test of voided urine, all patients were classified as FH(-)/ROS(-), FH(+)/ROS(-), or FH(+) /ROS(+). We reviewed demographic information, pathological results, and the FH and ROS combined test status. The clinicopathological characteristics were evaluated, and the survival rates of each group were compared. Finally, we also analyzed the association between preoperative free ferrous protoporphyrin and reactive oxygen species status and the tumor stage and grade. RESULTS: This study included 218 NMIBC patients with a median age of 68 years (interquartile range [IQR] 60-76 years). The number and proportion of patients in FH(-)/ROS(-), FH(+)/ROS(-) and FH(+) /ROS(+) were 95(43.6%), 79(36.2%) and 44(20.2%), respectively. And the pathological stages for those with FH(+) and ROS(+), FH(+) and ROS(-), FH(-) and ROS(-) at diagnosis were 0.5% Tis, 6.4% Ta, 13.3% T1; 2.3% Tis, 20.6% Ta, 13.3% T1; 5.5% Tis, 28.9% Ta, 9.2% T1, respectively. After adjusting for clinical factors, including tumor grade, tumor stage and FH/ROS status were independent risk factors for RFS In the multivariate Cox regression analysis. Through logistics regression analysis, FH(+)/ROS(+) were found to be corelated with high grade and more high stage (T1). Kaplan-Meier analysis showed that 1-year RFS of FH(+)/ROS(+), FH(+)/ROS(-) and FH(-)/ROS(-) were 46.0%, 87.8% and 93.4%, respectively (P=0.000). CONCLUSION: In newly diagnosed NMIBC patients, the status of FH(+)/ROS(+) has an association with a higher risk in recurrence. Furthermore, FH(+)/ROS(+) at diagnosis was correlated with high grade and higher stage (T1). Hence, the FH/ROS combined test can help specify treatment options for patients diagnosed with NMIBC. CI - (c) 2022 Li et al. FAU - Li, Shuaishuai AU - Li S AUID- ORCID: 0000-0002-6774-9839 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. FAU - Chen, Zeyu AU - Chen Z AUID- ORCID: 0000-0003-1120-6859 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. FAU - Chen, Rui AU - Chen R AUID- ORCID: 0000-0001-5040-5899 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. FAU - Xue, Ning AU - Xue N AUID- ORCID: 0000-0002-1599-6432 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. FAU - Shen, Xihao AU - Shen X AD - The First Clinical Medical College of Nanjing Medical University, NanJing, People's Republic of China. FAU - Zhu, Haitao AU - Zhu H AUID- ORCID: 0000-0003-4035-9096 AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. FAU - Peng, Yunpeng AU - Peng Y AD - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20220803 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC9357380 OTO - NOTNLM OT - free ferrous protoporphyrin OT - grade OT - non-muscular invasive bladder cancer OT - reactive oxygen species OT - recurrence-free survival OT - stage COIS- The authors declare no conflict of interest. EDAT- 2022/08/11 06:00 MHDA- 2022/08/11 06:01 PMCR- 2022/08/03 CRDT- 2022/08/10 01:44 PHST- 2022/05/02 00:00 [received] PHST- 2022/07/22 00:00 [accepted] PHST- 2022/08/10 01:44 [entrez] PHST- 2022/08/11 06:00 [pubmed] PHST- 2022/08/11 06:01 [medline] PHST- 2022/08/03 00:00 [pmc-release] AID - 371974 [pii] AID - 10.2147/CMAR.S371974 [doi] PST - epublish SO - Cancer Manag Res. 2022 Aug 3;14:2291-2297. doi: 10.2147/CMAR.S371974. eCollection 2022. PMID- 35945111 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221201 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - Clinical and histopathological features of bladder cancer following radiotherapy for prostate cancer: A comparative study. PG - 492.e1-492.e6 LID - S1078-1439(22)00240-X [pii] LID - 10.1016/j.urolonc.2022.06.021 [doi] AB - INTRODUCTION: Low certainty exists on how bladder cancer (BCa) after pelvic radiotherapy (RT) differs from BCa in radiation-naive patients from a histopathological and clinical perspective. This study aims to compare histopathological features of bladder tumors between patients with previous RT for prostate cancer (PCa) and radiation-naive patients using single-institutional data and to estimate relapse-free survival (eRFS) and cystectomy-free survival (eCFS) in both groups. MATERIALS AND METHODS: Comparative study in adult men diagnosed with BCa in Hospital Italiano de Buenos Aires, Argentina, between January 2015 and December 2020. Included patients were categorized as previously irradiated for PCa or radiation-naive. PRIMARY OUTCOME: differences in prevalence of aggressiveness features of bladder tumors (variant histology; high-grade tumors; muscle-invasive disease; criteria compliance for high or very-high risk of progression) between irradiated and radiation-naive patients at diagnosis of BCa. SECONDARY OUTCOMES: differences in eRFS and eCFS between groups. RESULTS: In total, 34 and 291 patients were included in the Irradiated and Radiation-naive groups, respectively. Mean age at the time of diagnosis of BCa was 72.7 years (CI 95% 71.6-73.8). Median follow-up of the overall cohort was 25 months (IQR 11-45.5). Concerning primary outcomes, no statistical differences were found except for a higher prevalence of low-grade tumors between irradiated patients and high-grade tumors between radiation-naive patients (P 0.018). Regarding secondary outcomes, prior RT did not increase neither eRFS nor eCFS in both univariate and multivariate analysis. CONCLUSIONS: BCa after RT for PCa has similar histological features and cystectomy free-survival compared to BCa in a radiation-naive population. For patients with non-muscle invasive BCa arising after prostate RT, the risk of recurrences appears to be similar to non-irradiated patients. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Schernuk, Jordan AU - Schernuk J AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. Electronic address: jordan.schernuk@gmail.com. FAU - Gonzalez, Matias I AU - Gonzalez MI AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. FAU - Vecchio, Florencia AU - Vecchio F AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. FAU - Alfieri, Andres G AU - Alfieri AG AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. FAU - Tobia, Ignacio P AU - Tobia IP AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. FAU - Tejerizo, Juan C AU - Tejerizo JC AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. FAU - Favre, Gabriel A AU - Favre GA AD - Bladder Oncology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires, Argentina. LA - eng PT - Journal Article DEP - 20220806 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Male MH - Adult MH - Humans MH - Aged MH - *Urinary Bladder Neoplasms/pathology MH - Neoplasm Recurrence, Local MH - Cystectomy MH - *Prostatic Neoplasms/pathology MH - Multivariate Analysis OTO - NOTNLM OT - Bladder cancer OT - Prostate cancer OT - Radiotherapy EDAT- 2022/08/10 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/08/09 22:05 PHST- 2022/05/08 00:00 [received] PHST- 2022/06/20 00:00 [revised] PHST- 2022/06/30 00:00 [accepted] PHST- 2022/08/10 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/08/09 22:05 [entrez] AID - S1078-1439(22)00240-X [pii] AID - 10.1016/j.urolonc.2022.06.021 [doi] PST - ppublish SO - Urol Oncol. 2022 Nov;40(11):492.e1-492.e6. doi: 10.1016/j.urolonc.2022.06.021. Epub 2022 Aug 6. PMID- 35937307 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220809 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 14 DP - 2022 TI - Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy. PG - 281-290 LID - 10.2147/RRU.S374068 [doi] AB - PURPOSE: Absence of tumor in the final histopathology after radical cystectomy (RC) is a rare but potentially favorable outcome. Therefore, we aimed to analyze outcomes and prognostic factors of patients with urothelial carcinoma (UC) undergoing RC and T0 in the final histology without neoadjuvant chemotherapy at a high-volume academic center. PATIENTS AND METHODS: We retrospectively analyzed patients undergoing RC for pure UC between 2004 and 2020. Cancer-specific survival (CSS) and overall survival (OS) were calculated using Kaplan-Meier analysis and group comparison by Log rank test. Potential prognostic factors were analyzed using univariate Cox regression models. RESULTS: A total of 1051 patients with UC underwent RC. 72 patients (6.7%) showed pT0 in the final histology. Across all T-stages, 5-year CSS was significantly different with 88% for pT0, 80% for pTa/pTis, 78% for pT1, 76% for pT2, 51% for pT3 and 27% for pT4 in our cohort (p=0.001). Neither instillation therapy (HR 0.31, 95% CI 0.07-1.43), number of TURB prior RC (HR 1.47, 95% CI 0.25-6.18), use of photodynamic diagnostics (PDD) (HR 0.64, 95% CI 0.14-3.02), performing a second resection (HR 0.87, 95% CI 0.27-2.86), muscle-invasive disease prior RC at any TURB (HR 0.7, 95% CI 0.2-2.39) or muscle-invasive disease in the TURB prior RC (HR 1.0, 0.31-3.29) were associated with CSS in univariate analysis. CONCLUSION: pT0 reveals a survival benefit in patients undergoing RC for UC and therefore presents a distinctive tumor entity. As clinical and cystoscopic characteristics do not improve patient stratification, further research is warranted to define risk groups in this specific tumor entity. CI - (c) 2022 Rodler et al. FAU - Rodler, Severin AU - Rodler S AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Buchner, Alexander AU - Buchner A AUID- ORCID: 0000-0001-7895-7070 AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Schulz, Gerald Bastian AU - Schulz GB AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Marcon, Julian AU - Marcon J AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Ledderose, Stephan AU - Ledderose S AD - Department of Pathology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Schlenker, Boris AU - Schlenker B AUID- ORCID: 0000-0001-6150-776X AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Stief, Christian G AU - Stief CG AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. FAU - Karl, Alexander AU - Karl A AD - Department of Urology, Barmherzige Bruder Krankenhaus Munchen, Munich, Germany. FAU - Jokisch, Jan-Friedrich AU - Jokisch JF AD - Department of Urology, Klinikum der Universitat Munchen, Munich, Germany. LA - eng PT - Journal Article DEP - 20220801 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC9355019 OTO - NOTNLM OT - bladder cancer OT - pT0 status after cystectomy OT - radical cystectomy COIS- The authors have no conflicts of interest to declare in this work. EDAT- 2022/08/09 06:00 MHDA- 2022/08/09 06:01 PMCR- 2022/08/01 CRDT- 2022/08/08 04:00 PHST- 2022/05/10 00:00 [received] PHST- 2022/07/26 00:00 [accepted] PHST- 2022/08/08 04:00 [entrez] PHST- 2022/08/09 06:00 [pubmed] PHST- 2022/08/09 06:01 [medline] PHST- 2022/08/01 00:00 [pmc-release] AID - 374068 [pii] AID - 10.2147/RRU.S374068 [doi] PST - epublish SO - Res Rep Urol. 2022 Aug 1;14:281-290. doi: 10.2147/RRU.S374068. eCollection 2022. PMID- 35935907 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240902 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 20 IP - 3 DP - 2022 TI - Diffusion of robot-assisted radical cystectomy: Nationwide trends, predictors, and association with continent urinary diversion. PG - 159-167 LID - 10.1080/2090598X.2022.2032562 [doi] AB - OBJECTIVES: To assess the utilisation trends of robot-assisted radical cystectomy (RARC), rates of performing continent urinary diversions (CUDs), and impact of diffusion of RARC on CUD rates. METHODS: We investigated the National Cancer Database for patients with muscle-invasive bladder cancer (MIBC) who underwent RC between 2004 and 2015. Patients were stratified by surgical technique into open (ORC) and RARC groups, and by type of urinary diversion into continent (CUD) and ileal conduit (ICUD) groups. Linear regression models were fitted to evaluate time trends for surgery and conversion techniques. Multivariate logistic regression models were utilised to identify independent predictors of RARC and CUD. RESULTS: A total of 14466 patients underwent RC for MIBC, of which 4914 (34%) underwent RARC. There was a significant increase in adoption of RARC from 22% in 2010 to 40% in 2015 (R(2) = 0.96, P < 0.001), this was not associated with a change in the rates of CUD over the same period (P = 0.22). Across all years, ICUD was the primary type of urinary diversion, CUD was only offered in 12% in 2010 compared to 9.9% in 2015 (R(2) = 0.33, P = 0.22). Multivariate analysis identified male gender (odds ratio [OR] 1.18, P = 0.03), academic centres (OR 1.74, P = 0.001), and lower T stage (T4 vs T2; OR 0.78, P = 0.03) as independent predictors of CUD, while surgical technique was not associated with odds of receiving CUD (P = 0.8). CONCLUSIONS: There is significant nationwide increasing trend of adoption of RARC. This diffusion was not associated with a decline in CUD, which remains significantly underutilised in both ORC and RARC groups. Abbreviations CUD: continent urinary diversion; ICD-O: International Classification of Diseases for Oncology; ICUD: ileal conduit urinary diversion; (N)MIBC: (non-)muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; NCDB: National Cancer Database; OR: odds ratio;(O)(RA)RC: (open) (robot-assisted) radical cystectomy. CI - (c) 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Elshabrawy, Ahmed AU - Elshabrawy A AUID- ORCID: 0000-0002-9742-6715 AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. FAU - Wang, Hanzhang AU - Wang H AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. FAU - Dursun, Furkan AU - Dursun F AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. FAU - Kaushik, Dharam AU - Kaushik D AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. AD - UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX, USA. FAU - Liss, Michael AU - Liss M AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. AD - UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX, USA. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. AD - UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX, USA. FAU - Mansour, Ahmed M AU - Mansour AM AD - Department of Urology, University of Texas (UT) Health, San Antonio, TX, USA. AD - UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX, USA. AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20220216 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC9354633 OTO - NOTNLM OT - Cystectomy OT - robotics OT - urinary bladder neoplasms OT - urinary diversion COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/08/09 06:00 MHDA- 2022/08/09 06:01 PMCR- 2022/02/16 CRDT- 2022/08/08 03:40 PHST- 2022/08/08 03:40 [entrez] PHST- 2022/08/09 06:00 [pubmed] PHST- 2022/08/09 06:01 [medline] PHST- 2022/02/16 00:00 [pmc-release] AID - 2032562 [pii] AID - 10.1080/2090598X.2022.2032562 [doi] PST - epublish SO - Arab J Urol. 2022 Feb 16;20(3):159-167. doi: 10.1080/2090598X.2022.2032562. eCollection 2022. PMID- 35934609 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221025 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 10 DP - 2022 Oct TI - Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomy. PG - 452.e17-452.e23 LID - S1078-1439(22)00229-0 [pii] LID - 10.1016/j.urolonc.2022.06.006 [doi] AB - INTRODUCTION: Perioperative intravesical chemotherapy (IVC) at or around the time of radical nephroureterectomy (RNU) reduces the risk of intravesical recurrence. Guidelines since 2013 have recommended its use. The objective of this study is to examine IVC utilization and determine predictors of its administration within a large international consortium. METHODS AND MATERIALS: Data was collected from 17 academic centers on patients who underwent robotic/laparoscopic RNU between 2006 and 2020. Patients who underwent concomitant radical cystectomy and cases in which IVC administration details were unknown were excluded. Univariate and multivariate analyses were utilized to determine predictors of IVC administration. A Joinpoint regression was performed to evaluate utilization by year. RESULTS: Six hundred and fifty-nine patients were included. A total of 512 (78%) did not receive IVC while 147 (22%) did. Non-IVC patients were older (P < 0.001), had higher ECOG scores (P = 0.003), and had more multifocal disease (23% vs. 12%, P = 0.005). Those in the IVC group were more likely to have higher clinical T stage disease (P = 0.008), undergone laparoscopic RNU (83% vs. 68%, P < 0.001), undergone endoscopic management of the bladder cuff (20% vs. 4%, P = 0.008). Multivariable regression showed that decreased age (OR 0.940, P < 0.001), laparoscopic approach (OR 2.403, P = 0.008), and endoscopic management of the bladder cuff (OR 7.619, P < 0.001) were significant predictors favoring IVC administration. Treatment at a European center was associated with lower IVC use (OR 0.278, P = 0.018). Overall utilization of IVC after the 2013 European Association of Urology (EAU) guideline was 24% vs. 0% prior to 2013 (P < 0.001). Limitations include limited data regarding IVC timing/agent and inclusion of minimally invasive RNU patients only. CONCLUSIONS: While IVC use has increased since being added to the EAU UTUC guidelines, its use remains low at academic centers, particularly within Europe. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Kenigsberg, Alexander P AU - Kenigsberg AP AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Carpinito, Gianpaolo AU - Carpinito G AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Gold, Samuel A AU - Gold SA AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Meng, Xiaosong AU - Meng X AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Ghoreifi, Alireza AU - Ghoreifi A AD - Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA. FAU - Minervini, Andrea AU - Minervini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, Florence, Italy. FAU - Jamil, Marcus AU - Jamil M AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Abdollah, Firas AU - Abdollah F AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Farrow, Jason M AU - Farrow JM AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Sundaram, Chandru AU - Sundaram C AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Uzzo, Robert AU - Uzzo R AD - Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy. FAU - Meagher, Margaret AU - Meagher M AD - Department of Urology, UCSD School of Medicine, La Jolla, CA. FAU - Derweesh, Ithaar AU - Derweesh I AD - Department of Urology, UCSD School of Medicine, La Jolla, CA. FAU - Wu, Zhenjie AU - Wu Z AD - Department of Urology, Changzheng Hospital, Second Military (Naval) Medical University, Shanghai, China. FAU - Porter, James AU - Porter J AD - Swedish Urology Group, Seattle, WA. FAU - Katims, Andrew AU - Katims A AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Mottrie, Alex AU - Mottrie A AD - Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. FAU - Reese, Adam C AU - Reese AC AD - Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. FAU - Eun, Daniel D AU - Eun DD AD - Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. FAU - Bhattu, Amit Satish AU - Bhattu AS AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL. FAU - Carbonara, Umberto AU - Carbonara U AD - Division of Urology and Massey Cancer Center, VCU Health System, Richmond, VA. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology and Massey Cancer Center, VCU Health System, Richmond, VA. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: vitaly.margulis@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20220804 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Administration, Intravesical MH - *Carcinoma, Transitional Cell/drug therapy/surgery MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Nephroureterectomy/methods MH - Retrospective Studies MH - *Ureteral Neoplasms/drug therapy/surgery MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - Intravesical chemotherapy OT - Nephroureterectomy OT - Practice trends OT - Upper tract urothelial carcinoma COIS- Conflict of interest The authors have no conflict of interest. EDAT- 2022/08/08 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/08/07 22:06 PHST- 2021/12/20 00:00 [received] PHST- 2022/06/03 00:00 [revised] PHST- 2022/06/12 00:00 [accepted] PHST- 2022/08/08 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/08/07 22:06 [entrez] AID - S1078-1439(22)00229-0 [pii] AID - 10.1016/j.urolonc.2022.06.006 [doi] PST - ppublish SO - Urol Oncol. 2022 Oct;40(10):452.e17-452.e23. doi: 10.1016/j.urolonc.2022.06.006. Epub 2022 Aug 4. PMID- 35922856 OWN - NLM STAT- MEDLINE DCOM- 20220805 LR - 20250728 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Aug 3 TI - Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma. PG - 120 LID - 10.1186/s12894-022-01074-9 [doi] LID - 120 AB - OBJECTIVE: To investigate the expression intensity of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma and its predictive value for the recurrence after transurethral resection of bladder tumor. METHODS: A retrospective analysis was made of 194 specimens who underwent transurethral resection of bladder tumors in our hospital from January 2014 to January 2016 and completed follow-up. The expression intensity of CA-IX and the clinical data of the patients were analyzed, and the subjects were divided into positive group and negative group according to the expression intensity of CA-IX. The age, gender, T stage, degree of differentiation, tumor number, tumor diameter, recurrence of each group was analyzed. Logistic univariate and multivariate analysis was used successively to find independent influencing factors for predicting the recurrence of bladder urothelial carcinoma after resection. The Kaplan-Meier survival curve was drawn according to the relationship between CA-IX expression intensity and postoperative recurrence. RESULTS: The positive expression rates of CA-IX in bladder urothelial carcinomas were 68.1% (132/194). The positive expression of CA-IX had no statistical significance with age, gender and tumor diameter (P > 0.05), while the positive expression of CA-IX had statistical significance with tumor T stage, tumor differentiation, tumor number and recurrence (P < 0.05); Logistic regression analysis showed that clinical T stage, tumor differentiation, tumor number, and CA-IX expression intensities were independent risk factors for predicting recurrence of bladder urothelial carcinoma after resection (P < 0.05); There were 59 cases of recurrence in the positive expression of CA-IX group, with a recurrence rate of 44.69% (59/132), and 17 cases of recurrence in the negative expression group, with a recurrence rate of 27.41% (17/62). The mean recurrence time of CA-IX positive group was 29.93 +/- 9.86 (months), and the mean recurrence time of CA-IX negative group was 34.02 +/- 12.44 (months). The Kaplan-Meier survival curve showed that the recurrence rate and recurrence time of patients with positive expression of CA-IX in bladder urothelial carcinomas were significantly higher than those of patients with negative expression of CA-IX. CONCLUSION: CA-IX is highly expressed in bladder urothelial carcinoma, is a good tumor marker, and can be used as a good indicator for predicting the recurrence of bladder urothelial carcinoma after transurethral resection of bladder tumor. CI - (c) 2022. The Author(s). FAU - Xiang, An-Ping AU - Xiang AP AD - Department of Urology, The First People's Hospital of Huzhou, #158, Square Road, Huzhou, 313000, China. anping108@163.com. FAU - Chen, Xiao-Nong AU - Chen XN AD - Department of Urology, The First People's Hospital of Huzhou, #158, Square Road, Huzhou, 313000, China. FAU - Xu, Peng-Fei AU - Xu PF AD - Department of Urology, The First People's Hospital of Huzhou, #158, Square Road, Huzhou, 313000, China. FAU - Shao, Si-Hai AU - Shao SH AD - Department of Urology, The First People's Hospital of Huzhou, #158, Square Road, Huzhou, 313000, China. FAU - Shen, Yue-Fan AU - Shen YF AD - Department of Urology, The First People's Hospital of Huzhou, #158, Square Road, Huzhou, 313000, China. LA - eng GR - 2019GY23/Huzhou Science and Technology Bureau Public welfare application research project of China/ PT - Journal Article DEP - 20220803 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - EC 4.2.1.1 (Carbonic Anhydrase IX) RN - EC 4.2.1.1 (Carbonic Anhydrases) SB - IM MH - Carbonic Anhydrase IX MH - *Carbonic Anhydrases/metabolism MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Humans MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9347144 OTO - NOTNLM OT - Bladder urothelial carcinoma OT - Carbonic anhydrase IX OT - Recurrence COIS- The authors declare that they have no competing interests. EDAT- 2022/08/04 06:00 MHDA- 2022/08/06 06:00 PMCR- 2022/08/03 CRDT- 2022/08/03 23:42 PHST- 2022/03/19 00:00 [received] PHST- 2022/07/19 00:00 [accepted] PHST- 2022/08/03 23:42 [entrez] PHST- 2022/08/04 06:00 [pubmed] PHST- 2022/08/06 06:00 [medline] PHST- 2022/08/03 00:00 [pmc-release] AID - 10.1186/s12894-022-01074-9 [pii] AID - 1074 [pii] AID - 10.1186/s12894-022-01074-9 [doi] PST - epublish SO - BMC Urol. 2022 Aug 3;22(1):120. doi: 10.1186/s12894-022-01074-9. PMID- 35909301 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230522 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 19 IP - 3 DP - 2023 Jun TI - Noninferior oncological outcomes in adults aged 80 years or older compared with younger patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma. PG - 305-311 LID - 10.1111/ajco.13835 [doi] AB - AIM: Radical nephroureterectomy (RNU) is the gold standard treatment for upper tract urothelial carcinoma (UTUC), but the usefulness of this surgery for older patients is rarely discussed. The prognosis following RNU for patients >/=80 years old remains controversial. We retrospectively investigated the prognosis of UTUC in patients >/=80 years old who underwent RNU. METHODS: Between January 1990 and December 2015, 451 patients with UTUC underwent RNU at six hospitals affiliated with Kitasato University (Kanagawa, Japan), eight patients who underwent neoadjuvant chemotherapy and two patients with metastases before surgery were excluded. Patients were divided into three groups according to their age at the time of RNU: /=80 years (n = 52). Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) curves were estimated using Kaplan-Meier analysis for all patients and each pT stage. Independent prognostic factors for survival were examined via multivariate analysis. RESULTS: RFS and CSS did not significantly differ between the three groups, but OS was significantly poorer in patients >/=80 years old. Stratification by pT stage (/=pT2, and >/=pT3) yielded the same results. In the multivariate analysis for OS, an age of >/=80 years was a significant independent risk factor (hazard ratio: 3.01, p = .01), but RFS and CSS did not significantly differ. CONCLUSION: Oncological outcomes showed the same anticancer effects in patients >/=80 years old who underwent RNU for UTUC compared with those of younger patients. Our study suggests that surgical treatment is a beneficial option for older patients who can tolerate radical surgery. CI - (c) 2022 John Wiley & Sons Australia, Ltd. FAU - Yamada, Yasufumi AU - Yamada Y AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. AD - Department of Urology, Sagamihara Kyodo Hospital, Sagamihara, Japan. FAU - Ikeda, Masaomi AU - Ikeda M AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Hirayama, Takahiro AU - Hirayama T AD - Department of Urology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Murakami, Yasukiyo AU - Murakami Y AUID- ORCID: 0000-0001-6071-218X AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Koguchi, Dai AU - Koguchi D AUID- ORCID: 0000-0003-0731-2579 AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Matsuda, Daisuke AU - Matsuda D AD - Department of Urology, Higashiyamato Hospital, Tokyo, Japan. FAU - Okuno, Norihiko AU - Okuno N AD - Department of Urology, Sagamihara Hospital, Sagamihara, Japan. FAU - Taoka, Yoshinori AU - Taoka Y AD - Department of Urology, Kitasato University Medical Center, Kitamoto, Japan. FAU - Utsunomiya, Takuji AU - Utsunomiya T AD - Department of Urology, Sagamihara Kyodo Hospital, Sagamihara, Japan. FAU - Irie, Akira AU - Irie A AD - Department of Urology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. LA - eng PT - Journal Article DEP - 20220731 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 SB - IM MH - Humans MH - Adult MH - Aged, 80 and over MH - Nephroureterectomy/methods MH - *Carcinoma, Transitional Cell/surgery/pathology MH - *Urinary Bladder Neoplasms/surgery MH - Retrospective Studies MH - Prognosis OTO - NOTNLM OT - cancer-specific survival OT - older patients OT - overall survival OT - radical nephroureterectomy OT - recurrence-free survival OT - upper tract urothelial carcinoma EDAT- 2022/08/02 06:00 MHDA- 2023/05/22 06:42 CRDT- 2022/08/01 01:32 PHST- 2022/01/15 00:00 [received] PHST- 2022/07/06 00:00 [accepted] PHST- 2023/05/22 06:42 [medline] PHST- 2022/08/02 06:00 [pubmed] PHST- 2022/08/01 01:32 [entrez] AID - 10.1111/ajco.13835 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2023 Jun;19(3):305-311. doi: 10.1111/ajco.13835. Epub 2022 Jul 31. PMID- 35903700 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240901 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer. PG - 937638 LID - 10.3389/fonc.2022.937638 [doi] LID - 937638 AB - The prognostic value of the lymphocyte-to-monocyte ratio during induction (ILMR) remains unclear in non-muscle-invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guerin (BCG). We aimed to determine and compare the prognostic value of the ILMR, preoperative lymphocyte-to-monocyte ratio (PLMR) and their dynamic changes (PILMR). This study collected the data from NMIBC patients receiving BCG treatment in our institution. The prognostic value of the PLMR, ILMR and PILMR was analyzed by the Kaplan-Meier method and Cox proportional hazard regression models. The concordance index and receiver operating characteristic curve analysis were employed to compare the prognostic value of these three factors. Our study enrolled 197 patients. These patients included 170 male patients, and the mean age was 64.17 years. During the follow-up time, 85 patients experienced recurrence, and 55 patients experienced progression. According to the results of COX multivariable analysis, PLMR (P=0.011) and ILMR (P<0.001) could independently predict the recurrence of NMIBC patients receiving BCG. Meanwhile, ILMR (P=0.001) and PILMR (P=0.036) were also the independent prognostic factors of progression. Compared with PLMR and PILMR, ILMR was associated with better accuracy for NMIBC patients receiving BCG. This study first found that the ILMR could independently predict the prognosis of NMIBC patients receiving BCG. Furthermore, we also identified that ILMR was associated with higher prognostic value than PLMR and PILMR, which might help to select an optimal treatment schedule for patients with NMIBC. CI - Copyright (c) 2022 Li, Wang, Feng, Zhang, Wu, Shi, Chen, Bai and Han. FAU - Li, Deng-Xiong AU - Li DX AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Xiao-Ming AU - Wang XM AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Feng, De-Chao AU - Feng DC AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Fa-Cai AU - Zhang FC AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wu, Rui-Cheng AU - Wu RC AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Shi, Xu AU - Shi X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Kai AU - Chen K AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Bai, Yunjin AU - Bai Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20220712 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9314647 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - LMR OT - immunotherapeutic OT - non-muscle-invasive bladder cancer OT - prognosis (carcinoma) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/07/30 06:00 MHDA- 2022/07/30 06:01 PMCR- 2022/01/01 CRDT- 2022/07/29 02:06 PHST- 2022/05/06 00:00 [received] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/07/29 02:06 [entrez] PHST- 2022/07/30 06:00 [pubmed] PHST- 2022/07/30 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.937638 [doi] PST - epublish SO - Front Oncol. 2022 Jul 12;12:937638. doi: 10.3389/fonc.2022.937638. eCollection 2022. PMID- 35901948 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1879-8519 (Electronic) IS - 1879-8500 (Linking) VI - 13 IP - 1 DP - 2023 Jan-Feb TI - The Rate of Prostatic Involvement in Men Treated With Radical Cystectomy for Muscle Invasive Bladder Cancer. PG - e68-e72 LID - S1879-8500(22)00193-X [pii] LID - 10.1016/j.prro.2022.06.001 [doi] AB - PURPOSE: Radical cystoprostatectomy (RC) is one standard treatment for muscle-invasive bladder cancer (MIBC) in male patients. Another therapeutic option is trimodal therapy. Including the prostate in the trimodal therapy radiation therapy volume is based on MIBC surgical series showing prostatic stromal (PS) involvement. Our aim was to establish the rate of pathologic PS involvement by preoperative T stage in men treated with RC for MIBC. METHODS AND MATERIALS: We conducted a retrospective review of men with MIBC treated with RC between 2006 and 2019. Electronic medical records were reviewed, and preoperative clinical staging data were collected. chi(2) test was done to test for a statistically significant difference in the rate of prostatic involvement between clinical tumor (cT) stages. Preoperatively identified carcinoma in situ, lymph node involvement, tumor location, and urethral involvement were also analyzed to see if they conferred a higher risk of PS involvement. Multivariate analysis using multiple logistic regression was performed. RESULTS: We identified 283 men with bladder cancer treated with RC. Patients with non-MIBC or incomplete medical data were excluded (n = 72). We analyzed 211 patients, and 46 (22%) had pathologic PS involvement. PS involvement by preoperative T stage was cT2 = 18%, cT3 = 23%, and cT4 = 48%. Twenty-nine (12%) patients had clinical lymph node involvement, of whom 19 (76%) had PS involvement. Thirty-four (16%) had urethral involvement, of whom 17 (50%) had PS involvement. Sixteen percent and 17% of percent of clinical T2 and T3 patients had bladder neck/trigone tumors, of whom 57% and 50% had prostatic involvement. Clinical T2 and T3 were not statistically different with regards to PS involvement (P = .385). Preoperative urethral involvement, lymph node involvement, cT4, and bladder neck/trigone location were statistically significant predictors of pathologic PS involvement (all P < .05). On multivariate analysis, only clinical urethral involvement was significant (P < .0001). CONCLUSIONS: The high rate of pathologic PS involvement seen in cT2 patients and the lack of ability of cT stage to predict PS involvement support routinely treating the prostate in trimodal therapy. Patients with preoperatively identified bladder neck/trigone tumors, urethral involvement, positive lymph nodes, or prostatic involvement are a subset at even higher risk of having pathologic PS involvement. CI - Copyright (c) 2022 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. FAU - Royal-Preyra, Benjamin AU - Royal-Preyra B AD - Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, Quebec. Electronic address: benpreyra@gmail.com. FAU - Cury, Fabio L AU - Cury FL AD - Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, Quebec. FAU - Katib, Yousef AU - Katib Y AD - Department of Radiology, Taibah University, Madinah, Saudi Arabia. FAU - Monsoor, Mehdi AU - Monsoor M AD - Department of Pathology, McGill University, Montreal, Quebec. FAU - Brimo, Fadi AU - Brimo F AD - Department of Pathology, McGill University, Montreal, Quebec. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Surgery, Division of Urology, McGill University, Montreal, Quebec. FAU - Souhami, Luis AU - Souhami L AD - Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, Quebec. LA - eng PT - Journal Article DEP - 20220726 PL - United States TA - Pract Radiat Oncol JT - Practical radiation oncology JID - 101558279 SB - IM MH - Humans MH - Male MH - *Urinary Bladder/pathology MH - Prostate/surgery/pathology MH - Cystectomy/methods MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Muscles/pathology MH - Retrospective Studies MH - Neoplasm Staging MH - Neoplasm Invasiveness/pathology EDAT- 2022/07/29 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/07/28 19:14 PHST- 2022/03/12 00:00 [received] PHST- 2022/06/03 00:00 [revised] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/07/29 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/07/28 19:14 [entrez] AID - S1879-8500(22)00193-X [pii] AID - 10.1016/j.prro.2022.06.001 [doi] PST - ppublish SO - Pract Radiat Oncol. 2023 Jan-Feb;13(1):e68-e72. doi: 10.1016/j.prro.2022.06.001. Epub 2022 Jul 26. PMID- 35897708 OWN - NLM STAT- MEDLINE DCOM- 20220729 LR - 20250728 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 15 DP - 2022 Jul 23 TI - Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification. LID - 10.3390/ijms23158133 [doi] LID - 8133 AB - Diagnosis and grading of non-invasive papillary urothelial tumors according to the current WHO classification poses some challenges for pathologists. The diagnostic reproducibility of separating low-grade and high-grade lesions is low, which impacts their clinical management. Whereas papillary urothelial neoplasms with low malignant potential (PUN-LMP) and low-grade papillary non-invasive carcinoma (LG-PUC) are comparable and show frequent local recurrence but rarely metastasize, high-grade papillary non-invasive carcinoma (HG-PUC) has a poor prognosis. The main objective of this work is to develop a multiparametric classification to unambiguously distinguish low-grade and high-grade tumors, considering immunohistochemical stains for p53, FGFR3, CK20, MIB-1, p16, p21 and p-HH3, and pathogenic mutations in TP53, FGFR3, TP53, ERCC2, PIK3CA, PTEN and STAG2. We reviewed and analyzed the clinical and histological data of 45 patients with a consensus diagnosis of PUN-LMP (n = 8), non-invasive LG-PUC (n = 23), and HG-PUC (n = 14). The proliferation index and mitotic count assessed with MIB-1 and P-HH3 staining, respectively correlated with grading and clinical behavior. Targeted sequencing confirmed frequent FGFR3 mutations in non-invasive papillary tumors and identified mutations in TP53 as high-risk. Cluster analysis of the different immunohistochemical and molecular parameters allowed a clear separation in two different clusters: cluster 1 corresponding to PUN-LMP and LG-PUC (low MIB-1 and mitotic count/FGFR3 and STAG2 mutations) and cluster 2, HG-PUC (high MIB-1 and mitosis count/CK20 +++ expression, FGFR3 WT and TP53 mutation). Further analysis is required to validate and analyze the reproducibility of these clusters and their biological and clinical implication. FAU - Montes-Mojarro, Ivonne A AU - Montes-Mojarro IA AUID- ORCID: 0000-0003-0636-7623 AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Hassas, Saki AU - Hassas S AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Staehle, Sina AU - Staehle S AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Sander, Philip AU - Sander P AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Harland, Niklas AU - Harland N AUID- ORCID: 0000-0002-5532-4868 AD - Department of Urology, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Serna-Higuita, Lina Maria AU - Serna-Higuita LM AUID- ORCID: 0000-0001-5182-8295 AD - Department of Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University, 72076 Tuebingen, Germany. FAU - Bonzheim, Irina AU - Bonzheim I AUID- ORCID: 0000-0002-7732-0788 AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Bosmuller, Hans AU - Bosmuller H AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AUID- ORCID: 0000-0003-4207-9928 AD - Department of Urology, Eberhard-Karls-University, 72076 Tuebingen, Germany. FAU - Fend, Falko AU - Fend F AUID- ORCID: 0000-0002-5496-293X AD - Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany. LA - eng GR - GRK2543/I, project ID 40947457/Deutsche Forschungsgemeinschaft/ PT - Journal Article PT - Review DEP - 20220723 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - EC 3.6.4.12 (Xeroderma Pigmentosum Group D Protein) RN - EC 5.99.- (ERCC2 protein, human) SB - IM MH - *Carcinoma, Papillary/metabolism MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Reproducibility of Results MH - Risk Assessment MH - *Urinary Bladder Neoplasms/metabolism MH - *Urologic Neoplasms/diagnosis/genetics MH - Xeroderma Pigmentosum Group D Protein PMC - PMC9330009 OTO - NOTNLM OT - classification OT - high-grade papillary urothelial carcinoma OT - non-invasive low-grade papillary urothelial carcinoma OT - urothelial neoplasm of low malignant potential COIS- The authors declare no conflict of interest. EDAT- 2022/07/29 06:00 MHDA- 2022/07/30 06:00 PMCR- 2022/07/23 CRDT- 2022/07/28 01:08 PHST- 2022/06/30 00:00 [received] PHST- 2022/07/20 00:00 [revised] PHST- 2022/07/21 00:00 [accepted] PHST- 2022/07/28 01:08 [entrez] PHST- 2022/07/29 06:00 [pubmed] PHST- 2022/07/30 06:00 [medline] PHST- 2022/07/23 00:00 [pmc-release] AID - ijms23158133 [pii] AID - ijms-23-08133 [pii] AID - 10.3390/ijms23158133 [doi] PST - epublish SO - Int J Mol Sci. 2022 Jul 23;23(15):8133. doi: 10.3390/ijms23158133. PMID- 35894701 OWN - NLM STAT- MEDLINE DCOM- 20221121 LR - 20230728 IS - 1551-4005 (Electronic) IS - 1538-4101 (Print) IS - 1551-4005 (Linking) VI - 21 IP - 23 DP - 2022 Dec TI - Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. PG - 2533-2549 LID - 10.1080/15384101.2022.2103898 [doi] AB - Bladder cancer can range from noninvasive to invasive tumors. When non-muscle invasive bladder cancer (NMIBC) recurs, patients could endure long-term invasive malignancies with a high disease-specific death rate. Immune escape frequently results in tumor development, metastases, unfavorable prognosis, and failure of immunotherapy. Based on the median immune score, this study used ESTIMATE scores to evaluate 411 bladder cancer cases from TCGA-BLCA. Two hundred two ncRNAs were differentially expressed in two groups, where 29 candidates appeared to be associated with the overall survival of bladder cancer patients. LASSO algorithm was performed to establish the risk score model of 13-ncRNA. Risk scores were computed for cases in the training set, validation set, and TCGA-BLCA set; Poor prognosis in cases with higher risk scores was based on the training set, validating set, and TCGA-BLCA set. Among the 13 ncRNAs, IGF2BP2-AS1, MAGF-AS1, ARHGAP5-AS1, and LINC00942 were significantly correlated with the overall survival of bladder cancer patients. Pearson's correlation analysis based on TCGA-BLCA identified 2093, 3107, 386, and 936 mRNAs co-expressed with IGF2BP2-AS1, MAGF-AS1, ARHGAP5-AS1, and LINC00942, respectively. Conclusively, the 13 ncRNA signature exhibited a feasible predictive prognostic value for bladder cancer patients. IGF2BP2-AS1 expression was higher in bladder cancer tissues and significantly correlated to immune-related factors, suggesting that IGF2BP2-AS1 represents a promising immune-related target for treating bladder cancer patients. FAU - Ding, Ke AU - Ding K AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, PR China. FAU - Zheng, Zhihuan AU - Zheng Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, PR China. FAU - Han, Yu AU - Han Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, PR China. FAU - Huang, Xiangyun AU - Huang X AD - Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, PR China. LA - eng PT - Journal Article DEP - 20220727 PL - United States TA - Cell Cycle JT - Cell cycle (Georgetown, Tex.) JID - 101137841 RN - 0 (RNA, Long Noncoding) RN - 0 (RNA, Untranslated) RN - 0 (IGF2BP2 protein, human) RN - 0 (RNA-Binding Proteins) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - *RNA, Long Noncoding/genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Prognosis MH - RNA, Untranslated/genetics MH - Tumor Microenvironment/genetics MH - RNA-Binding Proteins/genetics/metabolism PMC - PMC9677966 OTO - NOTNLM OT - Bladder cancer OT - ESTIMATE algorithm OT - IGF2BP2-AS1 OT - LASSO algorithm OT - non-coding RNA COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/07/28 06:00 MHDA- 2022/11/22 06:00 PMCR- 2023/07/27 CRDT- 2022/07/27 09:42 PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/11/22 06:00 [medline] PHST- 2022/07/27 09:42 [entrez] PHST- 2023/07/27 00:00 [pmc-release] AID - 2103898 [pii] AID - 10.1080/15384101.2022.2103898 [doi] PST - ppublish SO - Cell Cycle. 2022 Dec;21(23):2533-2549. doi: 10.1080/15384101.2022.2103898. Epub 2022 Jul 27. PMID- 35880441 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 18 IP - 26 DP - 2022 Aug TI - Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor. PG - 2933-2942 LID - 10.2217/fon-2022-0223 [doi] AB - Aim: To investigate the prognostic value of preoperative mean platelet volume (MPV), MPV/lymphocyte ratio (MPVLR), MPV/platelet count ratio and plasma fibrinogen in patients with non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). Methods: A total of 371 patients who underwent TURBT were enrolled. The main end points were disease-free survival (DFS) and overall survival (OS). Results: MPVLR, tumor size, tumor number and pathological grade were independent risk factors for postoperative DFS. Age and pathological grade were independent risk factors for postoperative OS. Conclusion: MPVLR is an independent risk factor for DFS in NMIBC patients and could be used as a parameter to predict postoperative tumor recurrence in patients after TURBT. FAU - Song, Yutong AU - Song Y AUID- ORCID: 0000-0003-3153-1018 AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Tian, Junqiang AU - Tian J AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Yang, Li AU - Yang L AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Zhang, Yunxin AU - Zhang Y AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Dong, Zhilong AU - Dong Z AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Ding, Hui AU - Ding H AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Wang, Juan AU - Wang J AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Wang, Yuhan AU - Wang Y AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. FAU - Wang, Hanzhang AU - Wang H AD - Department of Urology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. FAU - Wang, Zhiping AU - Wang Z AD - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Clinical Center of Gansu Province for Nephro-urology, Lanzhou University, Lanzhou, China. LA - eng PT - Journal Article DEP - 20220726 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 9001-32-5 (Fibrinogen) SB - IM MH - Cystectomy MH - Fibrinogen MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology OAB - The current study investigated the prognostic value of preoperative mean platelet volume (MPV), MPV/lymphocyte ratio (MPVLR), MPV/platelet count ratio (MPVPCR) and plasma fibrinogen (PF) in peripheral blood of patients with non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). Included were 371 patients who underwent TURBT and were followed up. A high level of PF indicated worse survival and age and pathological grade were independent risk factors for postoperative survival. High levels of MPV, MPVLR and MPVPCR were associated with recurrence. MPVLR, tumor size, tumor number and pathological grade were independent risk factors for postoperative recurrence. MPVLR could be used as a parameter to predict postoperative tumor recurrence in patients after TURBT. OABL- eng OTO - NOTNLM OT - bladder cancer OT - plasma fibrinogen OT - platelet OT - transurethral resection of bladder tumor EDAT- 2022/07/27 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/07/26 04:32 PHST- 2022/07/27 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/07/26 04:32 [entrez] AID - 10.2217/fon-2022-0223 [doi] PST - ppublish SO - Future Oncol. 2022 Aug;18(26):2933-2942. doi: 10.2217/fon-2022-0223. Epub 2022 Jul 26. PMID- 35871875 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20250728 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 4 DP - 2022 Aug TI - The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer. PG - e271-e275 LID - S1558-7673(22)00065-9 [pii] LID - 10.1016/j.clgc.2022.03.009 [doi] AB - INTRODUCTION: EpiCheck is a new urinary test that analyses DNA methylation biomarkers in order to identify high-risk urothelial cancer MATERIALS AND METHODS: A prospective single centre study was performed. We analysed Epicheck results in a population of 231 patients in follow-up for non-muscle invasive bladder cancer. The primary endpoint was to evaluate sensitivity and specificity of Epicheck in detecting any type of bladder cancer recurrence. The secondary endpoint was to evaluate specificity and sensitivity of Epicheck in patients with high-risk recurrence and in patients recently treated with endovesical therapy (< 3 months). RESULTS: Negative predictive value (NPV) for cytology was 83 % while for bladder Epicheck it was 89 %, while positive predictive value (PPV) was 67 % and 73 % for cytology and Epicheck respectively. Considering only high grade non muscle invasive bladder cancer the sensitivity of Epicheck was 91 % and for cytology was 81 %, specificity was 85 % and 83 % and negative predictive value of Epicheck outreached 96 % compared to 92 % of cytology. Among patients with an ongoing or recent endovesical treatment it appears that sensitivity of Epicheck was 88% % compared to 73 % of cytology, specificity was 97 % and 85 % and NPV was 92 % compared to 82 % for cytology. CONCLUSION: The EpiCheck (test showed very high diagnostic values, higher than the currently, gold standard. The test might clinically improve the BCa management in terms of, reduced number of inconclusive/suspicious reports of cytology and endoscopy, reduced number of further examinations, reduced associated patient and economic. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Ragonese, Mauro AU - Ragonese M AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. Electronic address: mauroragonese@yahoo.it. FAU - Gianfrancesco, Luca Di AU - Gianfrancesco LD AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. FAU - Pierconti, Francesco AU - Pierconti F AD - Unit of Pathology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, V, Italy. FAU - Martini, Maurizio AU - Martini M AD - Unit of Pathology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, V, Italy. FAU - Foti, Massimiliano AU - Foti M AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. FAU - Bassi, Pierfrancesco AU - Bassi P AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. FAU - Racioppi, Marco AU - Racioppi M AD - Unit of Urology, A.Gemelli Hospital - IRCCS, Catholic University of the Sacred Heart - Rome, Italy. LA - eng PT - Journal Article DEP - 20220316 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/genetics MH - Follow-Up Studies MH - Humans MH - Neoplasm Recurrence, Local/diagnosis MH - Prospective Studies MH - Sensitivity and Specificity MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/genetics OTO - NOTNLM OT - Epicheck OT - High risk OT - Methylation OT - NMIBC OT - Non-invasive test for bladder cancer EDAT- 2022/07/26 06:00 MHDA- 2022/07/27 06:00 CRDT- 2022/07/25 01:41 PHST- 2021/11/07 00:00 [received] PHST- 2022/03/14 00:00 [accepted] PHST- 2022/07/25 01:41 [entrez] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] AID - S1558-7673(22)00065-9 [pii] AID - 10.1016/j.clgc.2022.03.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Aug;20(4):e271-e275. doi: 10.1016/j.clgc.2022.03.009. Epub 2022 Mar 16. PMID- 35871040 OWN - NLM STAT- MEDLINE DCOM- 20221209 LR - 20260603 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 6 DP - 2022 Dec TI - Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. PG - e498-e505 LID - S1558-7673(22)00140-9 [pii] LID - 10.1016/j.clgc.2022.06.015 [doi] AB - BACKGROUND: Nonmuscle invasive bladder cancer (NMIBC) has an elevated risk of recurrence, and immediate postresection intravesical instillation of chemotherapy (IVC) significantly reduces the risk of recurrence. Questions remain about which subpopulation may maximally benefit from IVC. Our aim was to develop risk groups based on recurrence risk in NMIBC, and then evaluate the impact of a single, postoperative instillation of IVC on the subsequent risk of recurrence for each risk group. MATERIAL AND METHODS: Using the SWOG S0337 trial cohort, we performed a posthoc analysis of 345 patients who were diagnosed with suspected low-grade NMIBC, underwent transurethral resection of the bladder tumor (TURBT), and received post-operative IVC (gemcitabine vs. saline). Using regression tree analysis, the regression tree stratified patients based on their risk of recurrence into low-risk - single tumor and aged < 57 years, intermediate-risk - single tumor and aged >/= 57 years, and high-risk - multiple tumors. We used Cox proportional hazard models to test the impact of recurrence-free rate, and after adjustment to available covariates. RESULTS: Median age of the cohort was 66.5 (IQR: 59.7-75.8 years) with 85% of patients being males. Median overall follow-up time was 3.07 years (IQR: 0.75-4.01 years). When testing the impact of treatment in each risk group separately, we found that patients in the intermediate-risk treated with gemcitabine had a 24-month recurrence free rate of 77% (95% CI: 68%-86%) vs. 59% (95% CI: 49%-70%) in the saline group. This survival difference was confirmed on multivariable analysis (hazard ratio: 0.39, 95% CI: 23%-66%, P < 0.001). This group represented 53% of our cohort. Conversely, we did not observe a significant difference in recurrence-free survival among patients in the low- (P = 0.7) and high-risk (P = 0.4) groups. CONCLUSION: Our findings indicate that older patients with a single tumor of suspected low-grade NMIBC at TURBT maximally benefit from immediate postresection IVC (gemcitabine). CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Corsi, Nicholas J AU - Corsi NJ AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Wayne State University School of Medicine, Detroit, MI. FAU - Messing, Edward M AU - Messing EM AD - Department of Urology, University of Rochester, Rochester, NY. FAU - Sood, Akshay AU - Sood A AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Keeley, Jacob AU - Keeley J AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI. FAU - Bronkema, Chandler AU - Bronkema C AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. FAU - Rakic, Nikola AU - Rakic N AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Department of Urology, Baylor College of Medicine, Houston, TX. FAU - Jamil, Marcus AU - Jamil M AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Dalela, Deepansh AU - Dalela D AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Arora, Sohrab AU - Arora S AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Piontkowski, Austin J AU - Piontkowski AJ AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Wayne State University School of Medicine, Detroit, MI. FAU - Majdalany, Sami E AU - Majdalany SE AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI. FAU - Butaney, Mohit AU - Butaney M AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI. FAU - Rakic, Ivan AU - Rakic I AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Wayne State University School of Medicine, Detroit, MI. FAU - Li, Pin AU - Li P AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Menon, Mani AU - Menon M AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY. FAU - Rogers, Craig G AU - Rogers CG AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. FAU - Abdollah, Firas AU - Abdollah F AD - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation (VCORE), Henry Ford Hospital, Detroit, MI; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. Electronic address: fabdoll1@hfhs.org. LA - eng SI - ClinicalTrials.gov/NCT00445601 GR - U10 CA180819/CA/NCI NIH HHS/United States PT - Clinical Trial PT - Journal Article DEP - 20220625 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Administration, Intravesical MH - Cystectomy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/prevention & control/drug therapy MH - Survival Rate MH - *Urinary Bladder Neoplasms/drug therapy/surgery/pathology OTO - NOTNLM OT - Chemotherapy OT - Gemcitabine OT - Risk groups OT - TURBT EDAT- 2022/07/24 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/07/23 23:40 PHST- 2022/04/25 00:00 [received] PHST- 2022/06/03 00:00 [revised] PHST- 2022/06/20 00:00 [accepted] PHST- 2022/07/24 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/07/23 23:40 [entrez] AID - S1558-7673(22)00140-9 [pii] AID - 10.1016/j.clgc.2022.06.015 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Dec;20(6):e498-e505. doi: 10.1016/j.clgc.2022.06.015. Epub 2022 Jun 25. PMID- 35858936 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221005 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 5 DP - 2022 Oct TI - Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. PG - 482-487 LID - S1558-7673(22)00138-0 [pii] LID - 10.1016/j.clgc.2022.06.013 [doi] AB - BACKGROUND: Upper tract urothelial carcinomas (UTUCs) arise in the renal pelvis or the ureter, accounting for approximately 5% of all urothelial carcinomas. Recent years have witnessed the publication of several studies aimed at assessing the molecular, biologic, and clinical features of UTUC, reporting that FGFR3 mutations are the most observed genetic aberrations; however, several knowledge gaps persist in the understanding of the genomic landscape of this genitourinary malignancy with few treatment options. PATIENTS AND METHODS: In the current study, we aimed to comprehensively analyze clinicopathological features of FGFR3-mutated UTUCs patients in public datasets to increase the current knowledge of the molecular and biologic profile of UTUC. Data regarding clinical outcomes, mutational profiles, and copy number alterations in patients affected by UTUC were downloaded from the cBioPortal for Cancer Genomics Database. UTUC data were available from 4 studies, for a total number of 358 patients; among these, 150 UTUC patients presented FGFR3 mutations. RESULTS: The current database analysis of the mutational profile of 150 FGFR3-mutated UTUCs suggested that FGFR3 mutations may represent a prognostic factor in this disease, with a statistically longer overall survival compared to wild-type patients treated with radical surgery. In addition, FGFR3 mutations were more frequent in low-grade UTUCs with early-stage disease (pT1, pT2, and pT3). CONCLUSION: Genomic characterization of UTUC is destined to become increasingly important, and more efforts aimed at implementing UTUC genomics analysis are warranted. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Rizzo, Alessandro AU - Rizzo A AD - Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II," Bari, Italy. Electronic address: rizzo.alessandro179@gmail.com. FAU - Mollica, Veronica AU - Mollica V AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Santoni, Matteo AU - Santoni M AD - Oncology Unit, Macerata Hospital, Macerata, Italy. FAU - Massari, Francesco AU - Massari F AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. LA - eng PT - Journal Article DEP - 20220618 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biological Products) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - *Biological Products MH - *Carcinoma, Transitional Cell/pathology MH - Genomics MH - Humans MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - *Ureter/surgery MH - *Urinary Bladder Neoplasms/genetics/pathology OTO - NOTNLM OT - FGFR3 OT - KMT2D OT - UTUC OT - genomics OT - upper tract urothelial carcinoma COIS- Disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2022/07/21 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/07/20 23:41 PHST- 2022/04/28 00:00 [received] PHST- 2022/06/12 00:00 [revised] PHST- 2022/06/13 00:00 [accepted] PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/07/20 23:41 [entrez] AID - S1558-7673(22)00138-0 [pii] AID - 10.1016/j.clgc.2022.06.013 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Oct;20(5):482-487. doi: 10.1016/j.clgc.2022.06.013. Epub 2022 Jun 18. PMID- 35858755 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 10 DP - 2022 Oct TI - Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer. PG - 1195-1203 LID - 10.1111/iju.14976 [doi] AB - OBJECTIVE: To assess real-world oncological outcomes between the radical cystectomy (RC) group and non-RC group for early relapse and refractory disease. METHODS: We retrospectively analyzed 953 patients with recurrent non-muscle-invasive bladder cancer (NMIBC) who received bacillus Calmette-Guerin (BCG) at 31 affiliated hospitals from 2000 to 2019. Patients with missing data on the timing of failure were excluded and 871 patients remained eligible, of whom 447, 357, and 67 were classified as early relapse/refractory disease, intermediate/late relapse disease, and intolerant disease, respectively. For early relapse/refractory disease, patients were divided into two salvage treatment groups: RC and non-RC. The clinicopathological variables of each group were examined using Kaplan-Meier plots and proportional Cox hazard ratios with matched score analyses to compare oncological outcomes between the two groups. RESULTS: Significantly worse progression-free survival and cancer-specific survival (CSS) were confirmed in the early relapse/refractory disease group compared to the intermediate/late relapse group. Of the 88 salvage patients in the RC group with early relapse/refractory disease, /=pT3 in 28 (two patients with unknown pT category). In early relapse/refractory disease, the RC group showed significantly high-risk tumor compared to the non-RC group. However, no significant difference was observed in CSS after matched score analyses (p = 0.45) between the RC and non-RC groups. CONCLUSIONS: This study found that the RC group showed no significant superiority compared to the non-RC group in CSS for early relapse/refractory disease in terms of first salvage therapy. CI - (c) 2022 The Japanese Urological Association. FAU - Murakami, Yasukiyo AU - Murakami Y AUID- ORCID: 0000-0001-6071-218X AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Amano, Noriyuki AU - Amano N AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Shimura, Soichiro AU - Shimura S AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kota AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Abe, Takashige AU - Abe T AUID- ORCID: 0000-0002-5468-7632 AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Yamada, Takeshi AU - Yamada T AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. LA - eng PT - Journal Article DEP - 20220720 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Int J Urol. 2022 Oct;29(10):1204-1205. doi: 10.1111/iju.15000. PMID: 35858761 CIN - Int J Urol. 2022 Oct;29(10):1203-1204. doi: 10.1111/iju.14988. PMID: 35858763 CIN - Int J Urol. 2022 Oct;29(10):1205-1206. doi: 10.1111/iju.15037. PMID: 36094833 MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Cystectomy MH - Humans MH - *Mycobacterium bovis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/surgery MH - Recurrence MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - early radical cystectomy OT - salvage treatment EDAT- 2022/07/21 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/07/20 21:02 PHST- 2022/03/21 00:00 [received] PHST- 2022/06/14 00:00 [accepted] PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/07/20 21:02 [entrez] AID - 10.1111/iju.14976 [doi] PST - ppublish SO - Int J Urol. 2022 Oct;29(10):1195-1203. doi: 10.1111/iju.14976. Epub 2022 Jul 20. PMID- 35855578 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 32 IP - 5 DP - 2022 Sep 1 TI - Micropapillary bladder cancer: an evolving biology. PG - 504-510 LID - 10.1097/MOU.0000000000001023 [doi] AB - PURPOSE OF REVIEW: To summarize a comprehensive overview of more recent evidence on micropapillary bladder cancer (MPBC), focusing on actual incidence, clinical features, therapeutic strategies, and prognosis. RECENT FINDINGS: MPBC generally exhibits an aggressive behaviour compared with pure urothelial carcinoma (pUC) with advances in tumour stage and nodal and distant spread at diagnosis. Due to its rarity and presence of only small sample size and retrospective studies, no consensus currently exists regarding the most effective therapeutic strategy to be performed among nonmuscle-invasive (conservative treatment versus immediate radical cystectomy) and muscle-invasive MPBC (neoadjuvant therapy versus upfront radical cystectomy versus adjuvant chemotherapy). SUMMARY: The incidence of MPBC is recently increased according to latter literature, ranging from 2.9 to 7.6% of all bladder cancer. Despite its aggressive behaviour at time of presentation, more recent evidence fails to demonstrate a significant association between MPBC and worse outcomes compared with pUC when adjusted for clinical and pathological features. According to latter evidence, MPBC pathological response to NAC appears to be unsatisfactory compared with pUC patients while neoadjuvant immunotherapy with Pembrolizumab may represent an effective treatment among MPBC patients, based on PD-L1 and TMB expression. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lonati, Chiara AU - Lonati C AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia. FAU - Suardi, Nazareno AU - Suardi N AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele. AD - University Vita-Salute San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele. AD - University Vita-Salute San Raffaele, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele. LA - eng PT - Journal Article PT - Review DEP - 20220718 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Biology MH - *Carcinoma, Transitional Cell/pathology MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Neoadjuvant Therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/therapy EDAT- 2022/07/21 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/07/20 02:54 PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/07/20 02:54 [entrez] AID - 00042307-202209000-00013 [pii] AID - 10.1097/MOU.0000000000001023 [doi] PST - ppublish SO - Curr Opin Urol. 2022 Sep 1;32(5):504-510. doi: 10.1097/MOU.0000000000001023. Epub 2022 Jul 18. PMID- 35853574 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20250728 IS - 1943-7811 (Electronic) IS - 1525-1578 (Linking) VI - 24 IP - 9 DP - 2022 Sep TI - The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma. PG - 992-1008 LID - S1525-1578(22)00190-8 [pii] LID - 10.1016/j.jmoldx.2022.05.006 [doi] AB - The precise classification of tumors into relevant molecular subtypes will facilitate both future research and optimal treatment. Here, the Lund Taxonomy system for molecular classification of urothelial carcinoma was applied to two large and independent cohorts of non-muscle-invasive tumors. Of 752 tumors classified, close to 100% were of the luminal subtypes, 95% urothelial-like (Uro; UroA, UroB, or UroC) and 5% genomically unstable. The obtained subtype structure organized the tumors into groups with specific and coherent gene mutation, genomic, and clinical profiles. The intrasubtype variability in the largest group of tumors, UroA, was caused by infiltration and proliferation, not considered as cancer cell type-defining properties. Within the UroA subtype, a HOXB/late cell-cycle gene expression polarity was found, strongly associated with FGFR3, STAG2, and TP53 mutations, as well as with chromosome 9 losses. Kaplan-Meier analyses identified the genomically unstable subtype as a progression high-risk group, also valid in the subgroup of T1 tumors. Almost all progression events occurred within 12 months in this subtype. Also, a general progression gene signature was derived that identifies high- and low-risk tumors. All findings were demonstrated in two independent cohorts. The Lund Taxonomy system is applicable to both non-muscle- and muscle-invasive tumors and may be a useful biological framework for translational studies. CI - Copyright (c) 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. FAU - Marzouka, Nour-Al-Dain AU - Marzouka NA AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Eriksson, Pontus AU - Eriksson P AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Bernardo, Carina AU - Bernardo C AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Hurst, Carolyn D AU - Hurst CD AD - Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, United Kingdom. FAU - Knowles, Margaret A AU - Knowles MA AD - Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Leeds, United Kingdom. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Urology-Urothelial Cancer, Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Urology-Urothelial Cancer, Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: mattias.hoglund@med.lu.se. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220716 PL - United States TA - J Mol Diagn JT - The Journal of molecular diagnostics : JMD JID - 100893612 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/metabolism MH - *Carcinoma, Transitional Cell/genetics/metabolism/pathology MH - Humans MH - Immunohistochemistry MH - *Urinary Bladder Neoplasms/genetics/pathology MH - Urothelium/chemistry/metabolism/pathology EDAT- 2022/07/20 06:00 MHDA- 2022/09/14 06:00 CRDT- 2022/07/19 19:25 PHST- 2021/12/22 00:00 [received] PHST- 2022/04/29 00:00 [revised] PHST- 2022/05/16 00:00 [accepted] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/07/19 19:25 [entrez] AID - S1525-1578(22)00190-8 [pii] AID - 10.1016/j.jmoldx.2022.05.006 [doi] PST - ppublish SO - J Mol Diagn. 2022 Sep;24(9):992-1008. doi: 10.1016/j.jmoldx.2022.05.006. Epub 2022 Jul 16. PMID- 35853090 OWN - NLM STAT- MEDLINE DCOM- 20220912 LR - 20250728 IS - 1098-2825 (Electronic) IS - 0887-8013 (Print) IS - 0887-8013 (Linking) VI - 36 IP - 9 DP - 2022 Sep TI - An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer. PG - e24606 LID - 10.1002/jcla.24606 [doi] LID - e24606 AB - BACKGROUND: Several studies have interrogated the molecular pathways and their interacting genes underlying bladder cancer (BCa) tumorigenesis, yet, the role of homeobox genes is still poorly understood. Specifically, HOXA13, which plays an important role as a major actor in the urogenital tract's development. METHODS: Immunohistochemical (IHC) staining was performed to inspect the differential expression of HOXA13 protein in non-muscle-invasive bladder cancer (NMIBC) and non-tumoral tissues. A semiquantitative scoring system was adopted to evaluate the IHC labeling. Correlation to clinical parameters was performed by descriptive statistics. Overall survival was estimated by the Kaplan-Meier method and Cox regression model. The functional HOX A13 protein association networks (PPI) were obtained using String 11.0 database. RESULTS: HOX A13 exhibited cytoplasmic and nuclear staining. Its expression levels were lower in high-grade NMIBC (HG NMIBC) compared to low-grade ones (LG NMIBC). The expression of HOX A13 was correlated to tumor grade (LG/HG) (p = 0.036) and stage (TA/T1) (p = 0.036). Nevertheless, its expression was not correlated to clinical parameters and was not able to predict the overall survival of patients with HG NMIBC. Finally, PPI analysis revealed that HOX A13 seems to be a part of a molecular network holding mainly PBX1, MEIS, ALDH1A2, HOX A10, and HOX A11. CONCLUSION: The deregulation of HOX A13 is not associated with the prognosis of BCa. It seems to be rather implicated in the early initiation of urothelial tumorigenesis and thus may serve as a diagnostic marker in patients with NMIBC. Further experimentations on larger validation sets are mandatory. CI - (c) 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. FAU - Setti Boubaker, Nouha AU - Setti Boubaker N AUID- ORCID: 0000-0001-8342-6936 AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Gurtner, Aymone AU - Gurtner A AUID- ORCID: 0000-0002-7661-9059 AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. AD - Institute of Translational Pharmacology (IFT), National Research Council (CNR), Rome, Italy. FAU - Trabelsi, Nesrine AU - Trabelsi N AUID- ORCID: 0000-0003-1450-4659 AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. FAU - Manni, Isabella AU - Manni I AUID- ORCID: 0000-0003-4823-0596 AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Blel, Ahlem AU - Blel A AUID- ORCID: 0000-0001-6702-3889 AD - Pathology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis El Manar, Tunis, Tunisia. FAU - Saadi, Ahmed AU - Saadi A AUID- ORCID: 0000-0001-9206-4789 AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Chakroun, Marouene AU - Chakroun M AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Naimi, Zeineb AU - Naimi Z AUID- ORCID: 0000-0002-9511-5403 AD - Medical Oncology Department, Faculty of Medicine, Salah Azaiez Institute, University of Tunis-El Manar, Tunis, Tunisia. FAU - Zaghbib, Selim AU - Zaghbib S AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Ksontini, Meriam AU - Ksontini M AD - Pathology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis El Manar, Tunis, Tunisia. FAU - Meddeb, Khedija AU - Meddeb K AUID- ORCID: 0000-0002-3418-1749 AD - Medical Oncology Department, Faculty of Medicine, Salah Azaiez Institute, University of Tunis-El Manar, Tunis, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AUID- ORCID: 0000-0003-0366-4630 AD - Pathology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis El Manar, Tunis, Tunisia. FAU - Ayed, Haroun AU - Ayed H AUID- ORCID: 0000-0002-7365-0309 AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Chebil, Mohamed AU - Chebil M AUID- ORCID: 0000-0001-8387-7593 AD - Urology Department, Faculty of Medicine, Charles Nicolle Hospital, University of Tunis-El Manar, Tunis, Tunisia. FAU - Piaggio, Giulia AU - Piaggio G AUID- ORCID: 0000-0003-2114-1892 AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Ouerhani, Slah AU - Ouerhani S AUID- ORCID: 0000-0002-3651-4690 AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. LA - eng PT - Journal Article DEP - 20220719 PL - United States TA - J Clin Lab Anal JT - Journal of clinical laboratory analysis JID - 8801384 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/genetics/metabolism MH - Carcinogenesis MH - Humans MH - Neoplasm Invasiveness MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis/genetics/pathology PMC - PMC9459288 OTO - NOTNLM OT - HOXA13 OT - PPI OT - bladder cancer OT - diagnosis OT - prognosis COIS- The authors declare there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/07/20 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/07/19 CRDT- 2022/07/19 13:45 PHST- 2022/05/23 00:00 [revised] PHST- 2022/01/28 00:00 [received] PHST- 2022/06/14 00:00 [accepted] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/07/19 13:45 [entrez] PHST- 2022/07/19 00:00 [pmc-release] AID - JCLA24606 [pii] AID - 10.1002/jcla.24606 [doi] PST - ppublish SO - J Clin Lab Anal. 2022 Sep;36(9):e24606. doi: 10.1002/jcla.24606. Epub 2022 Jul 19. PMID- 35851185 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221201 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. PG - 491.e11-491.e19 LID - S1078-1439(22)00227-7 [pii] LID - 10.1016/j.urolonc.2022.06.008 [doi] AB - PURPOSE: Non-muscle-invasive bladder cancers (NMIBC) constitute 3-quarters of all primary diagnosed bladder tumors. For risk-adapted management of patients with NMIBC, different risk group systems and predictive models have been developed. This study aimed to externally validate EORTC2016, CUETO and novel EAU2021 risk scoring models in a multi-institutional retrospective cohort of patients with high-grade NMIBC who were treated with an adequate BCG immunotherapy. METHODS: The Kaplan-Meier estimates for recurrence-free survival and progression-free survival were performed, predictive abilities were assessed using the concordance index (C-index) and area under the curve (AUC). RESULTS: A total of 1690 patients were included and the median follow-up was 51 months. For the overall cohort, the estimates recurrence-free survival and progression-free survival rates at 5-years were 57.1% and 82.3%, respectively. The CUETO scoring model had poor discrimination for disease recurrence (C-index/AUC for G2 and G3 grade tumors: 0.570/0.493 and 0.559/0.492) and both CUETO (C-index/AUC for G2 and G3 grade tumors: 0.634/0.521 and 0.622/0.525) EAU2021 (c-index/AUC: 0.644/0.522) had poor discrimination for disease progression. CONCLUSION: Both the CUETO and EAU2021 scoring systems were able to successfully stratify risks in our population, but presented poor discriminative value in predicting clinical events. Due to the lack of data, model validation was not possible for EORTC2016. The CUETO and EAU2021 systems overestimated the risk, especially in highest-risk patients. The risk of progression according to EORTC2016 was slightly lower when compared with our population analysis. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. Electronic address: wk@softstar.pl. FAU - Aumatell, Julia AU - Aumatell J AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Departament of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Institute of Public Health, Opole University, Opole, Poland 68 Katowicka Street, 45-060 Opole, Poland. FAU - Moschini, Marco AU - Moschini M AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Basile, Giuseppe AU - Basile G AD - Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University Medical Center, Stanford, CA. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, Marche Polytechnic University, United Hospitals, Ancona, Italy. FAU - Galosi, Andrea Benedetto AU - Galosi AB AD - Division of Urology, Marche Polytechnic University, Ancona, Italy. FAU - Fave, Rocco Francesco Delle AU - Fave RFD AD - Division of Urology, Marche Polytechnic University, Ancona, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Hornak, Jakub AU - Hornak J AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Tafuri, Alessandro AU - Tafuri A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona,Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona,Verona, Italy. FAU - Panunzio, Andrea AU - Panunzio A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona,Verona, Italy. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology Hospital Universitario La Paz, Madrid, Spain. FAU - Simone, Giuseppe AU - Simone G AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Italy. FAU - Laszkiewicz, Jan AU - Laszkiewicz J AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Spedali Civili, Brescia, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Spedali Civili, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili, Brescia, Italy. FAU - Niedziela, Lukasz AU - Niedziela L AD - Holy Cross Cancer Center in Kielce, Kielce, Poland. FAU - Candela, Luigi AU - Candela L AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Macek, Petr AU - Macek P AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Italy. FAU - Hidalgo, Beatriz Gutierrez AU - Hidalgo BG AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Rivas, Juan Gomez AU - Rivas JG AD - Department of Urology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Sosnowski, Roman AU - Sosnowski R AD - Department of Urooncology, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mir, Carmen AU - Mir C AD - Department of Urology, Valencian Oncology Institute and Foundation (IVO), Valencia, Spain. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences Molinette Hospital University of Torino School of Medicine, Torino, Italy. FAU - Gonzalez-Padilla, Daniel A AU - Gonzalez-Padilla DA AD - Department of Urology, University Hospital Infanta Sofia, Madrid, Spain. FAU - Faba, Oscar Rodriguez AU - Faba OR AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Palou, Juan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Ploussard, Guillaume AU - Ploussard G AD - Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Halon, Agnieszka AU - Halon A AD - Department of Clinical and Experimental Pathology, Wroclaw Medical University, Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of urology, CHU Tours, Tours, France. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Burgos, Francisco Javier AU - Burgos FJ AD - Departament of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Cidre, Miguel Angel Jimenez AU - Cidre MAJ AD - Departament of Urology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Minimally Invasive Robotic Urology Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. CN - European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group LA - eng PT - Journal Article DEP - 20220716 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Invasiveness MH - Disease Progression MH - Risk Assessment MH - *Carcinoma, Transitional Cell/pathology OTO - NOTNLM OT - BCG OT - CUETO OT - EAU OT - EORTC OT - Non-muscle-invasive bladder cancer OT - Recurrence COIS- Conflicts of Interest The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/07/20 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/07/19 08:08 PHST- 2022/03/12 00:00 [received] PHST- 2022/05/20 00:00 [revised] PHST- 2022/06/12 00:00 [accepted] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/07/19 08:08 [entrez] AID - S1078-1439(22)00227-7 [pii] AID - 10.1016/j.urolonc.2022.06.008 [doi] PST - ppublish SO - Urol Oncol. 2022 Nov;40(11):491.e11-491.e19. doi: 10.1016/j.urolonc.2022.06.008. Epub 2022 Jul 16. PMID- 35850869 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20240901 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Jul 18 TI - The application value of multi-parameter cystoscope in improving the accuracy of preoperative bladder cancer grading. PG - 111 LID - 10.1186/s12894-022-01054-z [doi] LID - 111 AB - PURPOSE: To develop and validate a preoperative cystoscopic-based predictive model for predicting postoperative high-grade bladder cancer (BCa), which could be used to guide the surgical selection and postoperative treatment strategies. MATERIALS AND METHODS: We retrospectively recruited 366 patients with cystoscopy biopsy for pathology and morphology evaluation between October 2010 and January 2021. A binary logistic regression model was used to assess the risk factors for postoperative high-grade BCa. Diagnostic performance was analyzed by plotting receiver operating characteristic curve and calculating area under the curve (AUC), sensitivity, specificity. From January 2021 to July 2021, we collected 105 BCa prospectively to validate the model's accuracy. RESULTS: A total of 366 individuals who underwent transurethral resection of bladder tumor (TURBT) or radical cystectomy following cystoscopy biopsy were included for analysis. 261 (71.3%) had a biopsy pathology grade that was consistent with postoperative pathology grade. We discovered five cystoscopic parameters, including tumor diameter, site, non-pedicled, high-grade biopsy pathology, morphology, were associated with high-grade BCa. The established multi-parameter logistic regression model ("JSPH" model) revealed AUC was 0.917 (P < 0.001). Sensitivity and specificity were 86.2% and 84.0%, respectively. And the consistency of pre- and post-operative high-grade pathology was improved from biopsy-based 70.5% to JSPH model-based 85.2%. In a 105-patients prospective validation cohort, the consistency of pre- and post-operative high-grade pathology was increased from 63.1 to 84.2% after incorporation into JSPH model for prediction. CONCLUSION: The cystoscopic parameters based "JSPH model" is accurate at predicting postoperative pathological high-grade tumors prior to operations. CI - (c) 2022. The Author(s). FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Yuan, Baorui AU - Yuan B AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Bao, Meiling AU - Bao M AD - Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Wang, Zhen AU - Wang Z AD - Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Feng, Dexiang AU - Feng D AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Tao, Jun AU - Tao J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Shao, Qiang AU - Shao Q AD - Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215008, People's Republic of China. sq7166822@163.com. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. yangxiao2915@163.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. doctorlvqiang@sina.com. LA - eng GR - 82072832/National Natural Science Foundation of China/ PT - Journal Article DEP - 20220718 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Cystectomy MH - Cystoscopes MH - Humans MH - Retrospective Studies MH - Urinary Bladder/surgery MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9295426 OTO - NOTNLM OT - Bladder cancer OT - Cystoscopic biopsy OT - High grade OT - Pathological grade OT - Predictive model COIS- The authors declare no competing interests. The authors have no conflicts of interest to declare. EDAT- 2022/07/20 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/18 CRDT- 2022/07/19 07:50 PHST- 2022/04/12 00:00 [received] PHST- 2022/07/04 00:00 [accepted] PHST- 2022/07/19 07:50 [entrez] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/07/18 00:00 [pmc-release] AID - 10.1186/s12894-022-01054-z [pii] AID - 1054 [pii] AID - 10.1186/s12894-022-01054-z [doi] PST - epublish SO - BMC Urol. 2022 Jul 18;22(1):111. doi: 10.1186/s12894-022-01054-z. PMID- 35850759 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20220721 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Jul 18 TI - Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma. PG - 787 LID - 10.1186/s12885-022-09893-7 [doi] LID - 787 AB - BACKGROUND: Periostin is an extracellular matrix protein that has been known to be implicated in fibrillogenesis and cell migration, including cancer metastasis. Periostin overexpression in cancer cells and/or intervening stroma is usually related to tumor progression and poor patient outcomes in various human cancers; however, its role in urothelial carcinoma, especially upper urinary tract urothelial carcinomas (UTUCs), remains inconclusive. METHODS: Samples from 126 consecutive cases of invasive UTUC (69 renal pelvic cancers and 57 ureteral cancers) were histologically reviewed and analyzed for periostin expression using immunohistochemistry. The intensities of immunoreactivity and the fraction of positive cancer cells and stroma (i.e., epithelial and stromal expression, respectively) were classified into four categories each (intensity, 0-3; fraction, 0-25% = 1; 26-50% = 2; 51-75% = 3; and > 75% = 4). The overall score was determined by multiplying both scores, and overall scores >/= 6 were considered to indicate high periostin expression. RESULTS: Among 126 UTUCs, 55 (44%; 27 renal pelvic and 28 ureteral cancers) showed high stromal periostin expression. None of the cases were considered to have high epithelial periostin expression. High stromal periostin expression was associated with non-papillary gross findings, higher pathological T category, lymphovascular invasion, concomitant carcinoma in situ, subtype histology, lymph node metastasis, positive surgical margins, high tumor budding, and high tumor-associated immune cell status. Multivariate analysis revealed that high stromal periostin expression was an independent predictor of overall survival (p = 0.00072, hazard ratio = 3.62), and lymphovascular invasion and high stromal periostin expression were independent predictors of cancer-specific survival (p = 0.032 and 0.020, hazard ratio = 2.61 and 3.07, respectively). CONCLUSIONS: Stromal periostin expression was often observed in invasive UTUCs with adverse clinicopathological factors and may be a useful predictor of patient outcomes. CI - (c) 2022. The Author(s). FAU - Miyai, Kosuke AU - Miyai K AD - Department of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan. mykusu228@nifty.com. AD - Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan. mykusu228@nifty.com. FAU - Kawamura, Kazuki AU - Kawamura K AD - Department of Urology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan. FAU - Ito, Keiichi AU - Ito K AD - Department of Urology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan. FAU - Matsukuma, Susumu AU - Matsukuma S AD - Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan. FAU - Tsuda, Hitoshi AU - Tsuda H AD - Department of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan. LA - eng PT - Journal Article DEP - 20220718 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - *Kidney Neoplasms/pathology/surgery MH - Prognosis MH - *Ureteral Neoplasms/pathology/surgery MH - *Urinary Bladder Neoplasms/pathology MH - *Urinary Tract/pathology PMC - PMC9290244 OTO - NOTNLM OT - Immunohistochemistry OT - Periostin OT - Upper urinary tract OT - Urothelial carcinoma COIS- The authors declare that they have no competing interest. EDAT- 2022/07/20 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/18 CRDT- 2022/07/19 07:46 PHST- 2022/04/27 00:00 [received] PHST- 2022/07/12 00:00 [accepted] PHST- 2022/07/19 07:46 [entrez] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/07/18 00:00 [pmc-release] AID - 10.1186/s12885-022-09893-7 [pii] AID - 9893 [pii] AID - 10.1186/s12885-022-09893-7 [doi] PST - epublish SO - BMC Cancer. 2022 Jul 18;22(1):787. doi: 10.1186/s12885-022-09893-7. PMID- 35850465 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20260728 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 104 DP - 2022 Aug TI - Systematic review and meta-analysis of randomized controlled trials of perioperative outcomes and prognosis of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer. PG - 106777 LID - S1743-9191(22)00554-4 [pii] LID - 10.1016/j.ijsu.2022.106777 [doi] AB - OBJECTIVES: This article aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) of perioperative outcomes and prognosis of transurethral en-bloc resection versus conventional transurethral resection for non-muscle-invasive bladder cancer (NMIBC). METHODS: We searched MEDLINE, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) to find eligible RCTs. The studies were classified by version 2 of the Cochrane risk-of-bias tool for randomized trials. Review Manager 5.4.0 was used to evaluate the data. The certainty of the evidence was assessed using the Guideline Development Tool by GRADEpro GDT. RESULTS: Seven RCTs with 1142 patients was included in the present study. The results indicated that bladder perforation (OR = 0.17; 95% CI 0.05 to 0.67; P = 0.01), obturator nerve reflex (OR = 0.03; 95% CI 0.01 to 0.13; P < 0.00001), residual tumor (OR = 0.24; 95% CI 0.08 to 0.77; P = 0.02) and repeat transurethral resection of bladder tumor (re-TURBT) (OR = 0.54; 95% CI 0.34 to 0.85; P = 0.008) were significantly reduced in the en-bloc resection group than the conventional resection group. However, there were no significant differences in hemoglobin deficit (p = 0.31), urethral stricture (p = 0.47), and detrusor muscle presence (P = 0.16) between both groups. Besides, resection time (p = 0.25), operative time (p = 0.20), catheter dwell time (p = 0.24), and length of hospital stay (p = 0.16) were similar in the two groups. Meanwhile, en-bloc resection yielded no advantage for the 3-month (P = 0.11), 6-month (P = 0.05), 1-year (P = 0.61), 2-year (P = 0.53), and 3-year (P = 0.26) tumor recurrence rates. CONCLUSIONS: Our meta-analysis shows that transurethral en-bloc resection is associated with comparable outcomes to conventional transurethral resection for recurrence-free survival in NMIBC patients. En-bloc resection is more feasible and safer than conventional resection for NMIBC, with fewer intraoperative complications, less residual tumor, and less re-TURBT. CI - Copyright (c) 2022 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. FAU - Li, Zhouyue AU - Li Z AD - Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. FAU - Zhou, Zhongbao AU - Zhou Z AD - Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. FAU - Cui, Yuanshan AU - Cui Y AD - Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, Yantai, 264000, China. FAU - Zhang, Yong AU - Zhang Y AD - Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. Electronic address: jaccoli@ccmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220716 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM CIN - Int J Surg. 2023 Feb 01;109(2):208-210. doi: 10.1097/JS9.0000000000000097. PMID: 36799855 MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local MH - Neoplasm, Residual MH - Prognosis MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Conventional transurethral resection of bladder tumor OT - En-bloc resection of bladder tumor OT - Meta-analysis OT - Non-muscle-invasive bladder cancer EDAT- 2022/07/20 06:00 MHDA- 2022/08/31 06:00 CRDT- 2022/07/19 07:29 PHST- 2022/03/25 00:00 [received] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/07 00:00 [accepted] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2022/07/19 07:29 [entrez] AID - S1743-9191(22)00554-4 [pii] AID - 10.1016/j.ijsu.2022.106777 [doi] PST - ppublish SO - Int J Surg. 2022 Aug;104:106777. doi: 10.1016/j.ijsu.2022.106777. Epub 2022 Jul 16. PMID- 35849699 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 32 IP - 5 DP - 2022 Sep 1 TI - Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer. PG - 517-522 LID - 10.1097/MOU.0000000000001014 [doi] AB - PURPOSE OF REVIEW: To summarize the prognostic and predictive role of current clinical and biological markers in patients with T1 high-grade (T1HG) nonmuscle invasive bladder cancer (NMIBC). RECENT FINDINGS: Classical clinico-pathologic markers such as age, tumor size, focality, and location as well as the presence of concomitant carcinoma in situ, lymphovascular invasion, and histological variants at the time of transurethral resection (TUR) should be used in the risk-stratification of T1HG to improve patients' selection for early aggressive treatment. pathological T1 substaging has shown to predict disease progression and response to intravesical therapy, and should therefore be reported in the pathological assessment to improve clinical decision-making. Urinary inducible cytokines measured at different time points during Bacillus Calmette-Guerin therapy may be used to predict response to treatment, while urinary mRNA-based biomarkers may be of value to select patients for repeated TUR (reTUR). The advent of genomic classification in NMIBC and that of immune markers may improve current risk-stratification tools and pave the way toward personalized treatment. SUMMARY: The role of clinico-pathologic variables in the risk-stratification of T1HG NMIBC remains unaltered, despite insufficient. Urinary biomarkers and tissue-based immune markers hold the promise to revolutionize the paradigm of risk-stratification due to their potential role in predicting response to intravesical and systemic immunotherapy. However, to date, none of the investigated biomarkers is used in clinical practice to risk-stratify T1HG patients due to the lack of external and/or prospective validations. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Dutto, Daniele AU - Dutto D FAU - Gontero, Paolo AU - Gontero P LA - eng PT - Journal Article PT - Review DEP - 20220715 PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Biomarkers MH - *Carcinoma in Situ/drug therapy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology EDAT- 2022/07/19 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/07/18 14:29 PHST- 2022/07/19 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/07/18 14:29 [entrez] AID - 00042307-202209000-00015 [pii] AID - 10.1097/MOU.0000000000001014 [doi] PST - ppublish SO - Curr Opin Urol. 2022 Sep 1;32(5):517-522. doi: 10.1097/MOU.0000000000001014. Epub 2022 Jul 15. PMID- 35847838 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220719 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. PG - 907975 LID - 10.3389/fonc.2022.907975 [doi] LID - 907975 AB - BACKGROUND: Current guidelines recommend assessing the prognosis in high-risk upper tract urothelial carcinoma patients (UTUC) after surgery. However, no specific method is endorsed. Among the various prognostic models, nomograms represent an easy and accurate tool to predict the individual probability for a specific event. Therefore, identifying the best-suited nomogram for each setting seems of great interest to the patient and provider. OBJECTIVES: To identify, summarize and compare postoperative UTUC nomograms predicting oncologic outcomes. To estimate the overall performance of the nomograms and identify the most reliable predictors. To create a reference tool for postoperative UTUC nomograms, physicians can use in clinical practice. DESIGN: A systematic review was conducted following the recommendations of Cochrane's Prognosis Methods Group. Medline and EMBASE databases were searched for studies published before December 2021. Nomograms were grouped according to outcome measurements, the purpose of use, and inclusion and exclusion criteria. Random-effects meta-analyses were performed to estimate nomogram group performance and predictor reliability. Reference tables summarizing the nomograms' important characteristics were created. RESULTS: The systematic review identified 26 nomograms. Only four were externally validated. Study heterogeneity was significant, and the overall Risk of Bias (RoB) was high. Nomogram groups predicting overall survival (OS), recurrence-free survival (RFS), and intravesical recurrence (IVR) had moderate discrimination accuracy (c-Index summary estimate with 95% confidence interval [95% CI] and prediction interval [PI] > 0.6). Nomogram groups predicting cancer-specific survival (CSS) had good discrimination accuracy (c-Index summary estimate with 95% CI and PI > 0.7). Advanced pathological tumor stage (>/= pT3) was the most reliable predictor of OS. Pathological tumor stage (>/= pT2), age, and lymphovascular invasion (LVI) were the most reliable predictors of CSS. LVI was the most reliable predictor of RFS. CONCLUSIONS: Despite a moderate to good discrimination accuracy, severe heterogeneity discourages the uninformed use of postoperative prognostic UTUC nomograms. For nomograms to become of value in a generalizable population, future research must invest in external validation and assessment of clinical utility. Meanwhile, this systematic review serves as a reference tool for physicians choosing nomograms based on individual needs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=282596, identifier PROSPERO [CRD42021282596]. CI - Copyright (c) 2022 Pallauf, Konig, D'Andrea, Laukhtina, Mostafaei, Motlagh, Quhal, Aydh, Yanagisawa, Kawada, Rajwa, Lusuardi, Soria, Karakiewicz, Roupret, Rink, Lotan, Margulis, Singla, Xylinas, Shariat and Pradere. FAU - Pallauf, Maximilian AU - Pallauf M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. FAU - Konig, Frederik AU - Konig F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Motlagh, Reza Sari AU - Motlagh RS AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Aydh, Abdulmajeed AU - Aydh A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Faisal Medical City, Abha, Saudi Arabia. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Lusuardi, Lukas AU - Lusuardi L AD - Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie Salpetriere Hospital, Oncotype-Uro, Sorbonne University, Paris, France. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, TX, United States. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern, Dallas, TX, United States. FAU - Singla, Nirmish AU - Singla N AD - Departments of Urology and Oncology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, CHU Bichat, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, United States. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia. AD - Department of Urology, Weill Cornell Medical College, New York, NY, United States. AD - Karl Landsteiner Insitute of Urology and Andrology, Karl Landsteiner Society, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, La Croix du Sud Hopital, Quint Fonsegrives, France. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220701 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9283688 OTO - NOTNLM OT - UTUC OT - nomograms OT - oncologic outcome OT - prognostic models OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DE declared a shared affiliation with the author EL to the handling editor at the time of review. EDAT- 2022/07/19 06:00 MHDA- 2022/07/19 06:01 PMCR- 2022/01/01 CRDT- 2022/07/18 04:21 PHST- 2022/03/30 00:00 [received] PHST- 2022/05/02 00:00 [accepted] PHST- 2022/07/18 04:21 [entrez] PHST- 2022/07/19 06:00 [pubmed] PHST- 2022/07/19 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.907975 [doi] PST - epublish SO - Front Oncol. 2022 Jul 1;12:907975. doi: 10.3389/fonc.2022.907975. eCollection 2022. PMID- 35847448 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220719 IS - 2372-7705 (Print) IS - 2372-7705 (Electronic) IS - 2372-7705 (Linking) VI - 26 DP - 2022 Sep 15 TI - Lentiviral interferon: A novel method for gene therapy in bladder cancer. PG - 141-157 LID - 10.1016/j.omto.2022.06.005 [doi] AB - Interferon alpha (IFNalpha) gene therapy is emerging as a new treatment option for patients with non-muscle invasive bladder cancer (NMIBC). Adenoviral vectors expressing IFNalpha have shown clinical efficacy treating bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer (BLCA). However, transient transgene expression and adenoviral immunogenicity may limit therapeutic activity. Lentiviral vectors can achieve stable transgene expression and are less immunogenic. In this study, we evaluated lentiviral vectors expressing murine IFNalpha (LV-IFNalpha) and demonstrate IFNalpha expression by transduced murine BLCA cell lines, bladder urothelium, and within the urine following intravesical instillation. Murine BLCA cell lines (MB49 and UPPL1541) were sensitive to IFN-mediated cell death after LV-IFNalpha, whereas BBN975 was inherently resistant. Upregulation of interleukin-6 (IL-6) predicted sensitivity to IFN-mediated cell death mediated by caspase signaling, which when inhibited abrogated IFN-mediated cell killing. Intravesical therapy with LV-IFNalpha/Syn3 in a syngeneic BLCA model significantly improved survival, and molecular analysis of treated tumors revealed upregulation of apoptotic and immune-cell-mediated death pathways. In particular, biomarker discovery analysis identified three clinically actionable targets, PD-L1, epidermal growth factor receptor (EGFR), and ALDHA1A, in murine tumors treated with LV-IFNalpha/Syn3. Our findings warrant the comparison of adenoviral and LV-IFNalpha and the study of novel combination strategies with IFNalpha gene therapy for the BLCA treatment. CI - (c) 2022 The Author(s). FAU - Mokkapati, Sharada AU - Mokkapati S AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Narayan, Vikram M AU - Narayan VM AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Manyam, Ganiraju C AU - Manyam GC AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Lim, Amy H AU - Lim AH AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Duplisea, Jonathan J AU - Duplisea JJ AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Kokorovic, Andrea AU - Kokorovic A AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Miest, Tanner S AU - Miest TS AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Mitra, Anirban P AU - Mitra AP AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Plote, Devin AU - Plote D AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Anand, Selvalakshmi Selvaraj AU - Anand SS AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Metcalfe, Michael J AU - Metcalfe MJ AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Dunner, Kenneth Jr AU - Dunner K Jr AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Johnson, Burles A AU - Johnson BA AD - James Buchanan Brady Urological Institute, John Hopkins Greenberg Bladder Cancer Institute, John Hopkins University, School of Medicine, Baltimore, MD, USA. FAU - Czerniak, Bogdan A AU - Czerniak BA AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Nieminen, Tiina AU - Nieminen T AD - A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. FAU - Heikura, Tommi AU - Heikura T AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - Yla-Herttuala, Seppo AU - Yla-Herttuala S AD - A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. FAU - Parker, Nigel R AU - Parker NR AD - Middlesex, Hamesman, Ltd., Edgware, London, UK. FAU - Schluns, Kimberley S AU - Schluns KS AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. FAU - McConkey, David J AU - McConkey DJ AD - James Buchanan Brady Urological Institute, John Hopkins Greenberg Bladder Cancer Institute, John Hopkins University, School of Medicine, Baltimore, MD, USA. FAU - Dinney, Colin P AU - Dinney CP AD - University of Texas MD Anderson Cancer Center, Smith Research Building, 7777 Knight Road, Houston, TX 77584, USA. LA - eng PT - Journal Article DEP - 20220610 PL - United States TA - Mol Ther Oncolytics JT - Molecular therapy oncolytics JID - 101666776 PMC - PMC9251210 OTO - NOTNLM OT - IL-6 OT - MB49 OT - bladder cancer OT - gene therapy OT - interferon alpha OT - intravesical OT - lentiviral vector COIS- C.P.D. received personal compensation from FKD Therapies, Oy for consulting and advisory services, including serving as the Independent Chairman of steering committee for the phase 3 nadofaragene firadenovec (rAd-IFNalpha/Syn3) trial. EDAT- 2022/07/19 06:00 MHDA- 2022/07/19 06:01 PMCR- 2022/06/10 CRDT- 2022/07/18 04:15 PHST- 2021/12/08 00:00 [received] PHST- 2022/06/07 00:00 [accepted] PHST- 2022/07/18 04:15 [entrez] PHST- 2022/07/19 06:00 [pubmed] PHST- 2022/07/19 06:01 [medline] PHST- 2022/06/10 00:00 [pmc-release] AID - S2372-7705(22)00083-3 [pii] AID - 10.1016/j.omto.2022.06.005 [doi] PST - epublish SO - Mol Ther Oncolytics. 2022 Jun 10;26:141-157. doi: 10.1016/j.omto.2022.06.005. eCollection 2022 Sep 15. PMID- 35831215 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20260301 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience. PG - 491.e1-491.e9 LID - S1078-1439(22)00226-5 [pii] LID - 10.1016/j.urolonc.2022.06.007 [doi] AB - OBJECTIVES: To re-evaluate the treatment of T1HG bladder cancer by analyzing our experience over 18 years. METHODS AND MATERIALS: An IRB-approved, single-institution retrospective review was performed of all patients with T1HG bladder cancer between August 1999 and July 2017. We assessed clinicopathologic characteristics, treatment history (including intravesical therapy, cystectomy, systemic chemotherapy, and radiation), and oncologic outcomes. RESULTS: We identified 191 patients with T1HG. Five patients underwent cystectomy at diagnosis. The five-year recurrence-free survival (RFS) for the 186 patients who initially underwent bladder sparing treatments was 50% (95% CI: 41%-58%). There were 83 patients (45%) with disease recurrence; median time to recurrence was 6.7 months (IQR: 4.9-17.5). Disease characteristics at initial recurrence was T2 or greater in 8 patients (10%), T1HG in 19 (23%), CIS in 30 (36%), TaHG in 10 (12%), T1 low-grade (LG) in 1 (1%), and TaLG in 15 (18%). For patients with no prior recurrences, neither re-resection (P = 0.12), receipt of induction therapy (P = 0.81), prostatic urethra positivity (P = 0.51), or age (P = 0.34) were significantly associated with risk of recurrence. Similarly, patients with a single recurrence also fared well without identifiable risk factors. In fact, baseline hazard function analysis demonstrated no differences in RFS comparing patients stratified by 0, 1, and 2+ prior recurrences (P = 0.46). The five-year overall survival (OS) was 76% (95% CI: 68%-82%), and median OS was 127 months. The five-year cancer-specific survival was 86% (95% CI: 78%-91%) for the overall cohort. Five-year cystectomy-free survival for patients with BCG responsive disease and unresponsive disease was 95% (95% CI: 85%-98%) and 72% (95% CI: 52%-84%), respectively. CONCLUSION: For patients who recurred after intravesical therapy, including those with recurrent T1 disease, additional induction courses of intravesical therapy did not negatively affect oncologic outcomes. Pathology of initial recurrence was not found to be a statistically significant risk factor for future recurrence. These findings suggest that BCG-unresponsive disease does not necessarily require immediate cystectomy. A multicenter, pragmatically designed evaluation in a contemporary cohort would more validly interrogate this important patient population. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Yong, Courtney AU - Yong C AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center Biostatistics, College of Public Health Building, Iowa City, IA. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA. Electronic address: michael-odonnell@uiowa.edu. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20220710 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/pathology MH - BCG Vaccine/therapeutic use MH - Neoplasm Recurrence, Local/surgery MH - Cystectomy/methods MH - Retrospective Studies OTO - NOTNLM OT - BCG-unresponsive OT - Bladder preservation OT - Cystectomy OT - Intravesical therapy OT - Non-muscle invasive bladder cancer EDAT- 2022/07/14 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/07/13 22:03 PHST- 2022/03/22 00:00 [received] PHST- 2022/05/06 00:00 [revised] PHST- 2022/06/12 00:00 [accepted] PHST- 2022/07/14 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/07/13 22:03 [entrez] AID - S1078-1439(22)00226-5 [pii] AID - 10.1016/j.urolonc.2022.06.007 [doi] PST - ppublish SO - Urol Oncol. 2022 Nov;40(11):491.e1-491.e9. doi: 10.1016/j.urolonc.2022.06.007. Epub 2022 Jul 10. PMID- 35813257 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 41 DP - 2022 Jul TI - The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. PG - 74-80 LID - 10.1016/j.euros.2022.05.001 [doi] AB - BACKGROUND: There might be differential sensitivity to neoadjuvant chemotherapy (NAC) in patients with primary muscle-invasive bladder cancer (MIBC) in comparison to patients with secondary MIBC after a history of non-muscle-invasive disease. OBJECTIVE: To investigate pathologic response rates and survival associated with primary versus secondary MIBC among patients treated with cisplatin-based NAC for cT2-4N0M0 MIBC. DESIGN SETTING AND PARTICIPANTS: Oncologic outcomes were compared for 350 patients with primary MIBC and 64 with secondary MIBC treated with NAC and radical cystectomy between 1992 and 2021 at 11 academic centers. Genomic analyses were performed for 476 patients from the Memorial Sloan Kettering/The Cancer Genome Atlas cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome measures were pathologic objective response (pOR; 50%. Subgroup analyses illustrated that the association of tumor size with adverse prognosis in UTUC patients is not affected by treatment modalities. Segmental resection of ureter, whether receiving lymph node dissection, cutoff of tumor size, and region of population were potential sources of heterogeneity. The funnel plot test indicated no significant publication bias in the meta-analysis of survival outcomes. CONCLUSIONS: This study shows that larger tumor size is associated with an increased risk of overall and cancer-specific mortality, and disease recurrence in UTUC. Integration of tumor size with other prognostic indicators may help in risk stratification and individualized treatment of UTUC. PATIENT SUMMARY: Through a systematic review and meta-analysis, this study found that larger tumor size is associated with an increased risk of overall and cancer-specific mortality, and disease recurrence in patients with upper tract urothelial carcinoma. CI - (c) 2022 The Author(s). FAU - Ma, Runzhuo AU - Ma R AD - Department of Urology, Peking University Third Hospital, Beijing, China. AD - Center for Robotic Simulation & Education, Catherine & Joseph Aresty Department of Urology, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Liu, Zenan AU - Liu Z AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Cheng, Yinchu AU - Cheng Y AD - Department of Pharmacy, Peking University Third Hospital, Beijing, China. FAU - Zhou, Pengxiang AU - Zhou P AD - Department of Pharmacy, Peking University Third Hospital, Beijing, China. FAU - Pan, Yuting AU - Pan Y AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China. FAU - Bi, Hai AU - Bi H AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Tao, Liyuan AU - Tao L AD - Department of Biostatistics, Peking University Third Hospital, Beijing, China. FAU - Yang, Bin AU - Yang B AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Xia, Haizhui AU - Xia H AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Zhu, Xuehua AU - Zhu X AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - He, Jide AU - He J AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - He, Wei AU - He W AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Wang, Guoliang AU - Wang G AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Huang, Yi AU - Huang Y AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Ma, Lulin AU - Ma L AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Lu, Jian AU - Lu J AD - Department of Urology, Peking University Third Hospital, Beijing, China. LA - eng PT - Journal Article PT - Review DEP - 20220628 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC9244730 OTO - NOTNLM OT - Meta-analysis OT - Prognosis OT - Tumor size OT - Upper tract urothelial carcinoma EDAT- 2022/07/06 06:00 MHDA- 2022/07/06 06:01 PMCR- 2022/06/28 CRDT- 2022/07/05 10:18 PHST- 2022/06/09 00:00 [accepted] PHST- 2022/07/05 10:18 [entrez] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/07/06 06:01 [medline] PHST- 2022/06/28 00:00 [pmc-release] AID - S2666-1683(22)00717-0 [pii] AID - 10.1016/j.euros.2022.06.001 [doi] PST - epublish SO - Eur Urol Open Sci. 2022 Jun 28;42:19-29. doi: 10.1016/j.euros.2022.06.001. eCollection 2022 Aug. PMID- 35775336 OWN - NLM STAT- MEDLINE DCOM- 20220704 LR - 20220705 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 94 IP - 2 DP - 2022 Jun 29 TI - Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often? PG - 144-149 LID - 10.4081/aiua.2022.2.144 [doi] AB - INTRODUCTION AND OBJECTIVES: Radical cystectomy (RC) continues to be standard of care for muscle-invasive bladder cancer and recurrent or refractory nonmuscle invasive bladder cancer. Unfortunately, it has high rates of perioperative morbidity and mortality. One of the most important predictors of postoperative outcomes is frailty, while the majority of complications are diversion related. The aim of our study was to evaluate safety of extraperitoneal cystectomy with ureterocutaneostomy in patients considered as frail. MATERIALS AND METHODS: We retrospectively collected data of frail patients who underwent extraperitoneal cystectomy with ureterocutaneostomy from October 2018 to August 2020 in a single center. We evaluated frailty by assessing patients' age, body mass index (BMI), nutritional status by Malnutrition Universal Screening Tool, overall health by RAI (Risk Analysis Index) and ASA (American Society of Anaesthesiologists) score, and laboratory analyses. We observed intraoperative outcomes and rates of perioperative (within 30 days) and early postoperative (within 90 days) complications (Clavien-Dindo classification). We defined extraperitoneal cystectomy with ureterocutaneostomy as safe if patients did not develop Clavien Dindo IIIb, or worse, complication. RESULTS: A total of 34 patients, 3 female and 31 male, were analyzed. The median age was 77, BMI 26, RAI 28, ASA 3 and the majority had preexisting renal insufficiency. Blood analyses revealed presence of severe preoperative hypoalbuminemia and anemia in half of our cohort. Intraoperative median blood loss was 250 cc, whilst operative time 245 min. During perioperative period 60% of our cohort developed Clavien Dindo II complication and during early postoperative period 32% of patients required readmission. One death occurred during early postoperative period (2.9%). After 12 months of follow-up, we observed stability of the renal function for most patients. CONCLUSIONS: We believe that extraperitoneal cystectomy with ureterocutaneostomy could be considered as a treatment option for elderly and/or frail patients. FAU - Malinaric, Rafaela AU - Malinaric R AD - Department of Urology, San Martino Hospital, University of Genoa, Genoa. rafaela.malinaric@gmail.com. FAU - Mantica, Guglielmo AU - Mantica G AD - Department of Urology, San Martino Hospital, University of Genoa, Genoa. guglielmo.mantica@gmail.com. FAU - Balzarini, Federica AU - Balzarini F AD - Department of Urology, San Martino Hospital, University of Genoa, Genoa. balzarini.federica90@gmail.com. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, San Martino Hospital, University of Genoa, Genoa. carlo.terrone@med.unipo.it. FAU - Maffezzini, Massimo AU - Maffezzini M AD - Department of Urology, Hospitals of Legnano and Magenta, Milan. massimo.maffezzini@gmail.com. LA - eng PT - Journal Article DEP - 20220629 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Aged MH - Blood Loss, Surgical MH - Cystectomy/adverse effects MH - Female MH - *Frailty/complications/surgery MH - Humans MH - Male MH - Postoperative Complications/epidemiology/etiology MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder MH - *Urinary Bladder Neoplasms EDAT- 2022/07/02 06:00 MHDA- 2022/07/06 06:00 CRDT- 2022/07/01 04:31 PHST- 2022/01/14 00:00 [received] PHST- 2022/04/16 00:00 [accepted] PHST- 2022/07/01 04:31 [entrez] PHST- 2022/07/02 06:00 [pubmed] PHST- 2022/07/06 06:00 [medline] AID - 10.4081/aiua.2022.2.144 [doi] PST - epublish SO - Arch Ital Urol Androl. 2022 Jun 29;94(2):144-149. doi: 10.4081/aiua.2022.2.144. PMID- 35772481 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221206 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 168 DP - 2022 Oct TI - Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy. PG - 137-142 LID - S0090-4295(22)00514-3 [pii] LID - 10.1016/j.urology.2022.06.012 [doi] AB - OBJECTIVE: To compare pathologic and survival outcomes between primary muscle invasive (pMIBC) and secondary muscle invasive (sMIBC) bladder cancer patients who were treated with or without cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). METHODS: We reviewed cT2-T4/N0 MIBC patients at our institution between 2010-2019. pMIBC was defined as presenting with > cT2 disease on initial or restaging TURBT with no prior history of bladder cancer. sMIBC was defined as prior history of NMIBC that was treated with at least one induction course of BCG that progressed to MIBC. Outcomes analyzed included pathologic downstaging rates defined as pT2 and N+ disease were predictors of poorer CSS and OS. Separate analysis of sMIBC patients whom underwent RC only (N = 61), demonstrated inferior oncologic outcomes to other cohorts (P < .01). CONCLUSION: There were no differences in pathologic response or survival between pMIBC and sMIBC patients when managed with NAC and RC. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Benidir, Tarik AU - Benidir T AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Lone, Zaeem AU - Lone Z AD - Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Zhang, Ao AU - Zhang A AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Nowacki, Amy S AU - Nowacki AS AD - Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland, OH. FAU - Munoz-Lopez, Carlos AU - Munoz-Lopez C AD - Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Hegde, Pranay AU - Hegde P AD - Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Fung, Kevin AU - Fung K AD - Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Fajnzylber, Jesse AU - Fajnzylber J AD - Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Abouassaly, Robert AU - Abouassaly R AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Berglund, Ryan AU - Berglund R AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Klein, Eric A AU - Klein EA AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Eltemamy, Mohammed AU - Eltemamy M AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Kaouk, Jihad AU - Kaouk J AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Weight, Christopher J AU - Weight CJ AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Almassi, Nima AU - Almassi N AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Pascal-Haber, Georges AU - Pascal-Haber G AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Lee, Byron H AU - Lee BH AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: Leeb4@ccf.org. LA - eng PT - Journal Article DEP - 20220628 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (BCG Vaccine) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - BCG Vaccine/therapeutic use MH - Cisplatin/therapeutic use MH - *Cystectomy/methods MH - Muscles/pathology MH - Neoadjuvant Therapy/methods MH - *Urinary Bladder Neoplasms/drug therapy/surgery EDAT- 2022/07/01 06:00 MHDA- 2022/10/25 06:00 CRDT- 2022/06/30 19:22 PHST- 2022/04/10 00:00 [received] PHST- 2022/06/04 00:00 [revised] PHST- 2022/06/08 00:00 [accepted] PHST- 2022/07/01 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/06/30 19:22 [entrez] AID - S0090-4295(22)00514-3 [pii] AID - 10.1016/j.urology.2022.06.012 [doi] PST - ppublish SO - Urology. 2022 Oct;168:137-142. doi: 10.1016/j.urology.2022.06.012. Epub 2022 Jun 28. PMID- 35770498 OWN - NLM STAT- MEDLINE DCOM- 20220715 LR - 20220715 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 208 IP - 2 DP - 2022 Aug TI - All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors. PG - 284-291 LID - 10.1097/JU.0000000000002678 [doi] AB - PURPOSE: There is variation amongst guidelines with respect to risk stratification of Ta tumors, specifically high-grade (HG) Ta tumors. We sought to investigate the response of all Ta tumors to bacillus Calmette-Guerin (BCG) and compare response rates based on European Association of Urology (EAU) classification as intermediate- (IR) or high-risk (HR). MATERIALS AND METHODS: An institutional review of all patients who received adequate BCG from 2000-2018 was conducted. EAU 2021 prognostic risk groups were used to stratify patients including by the newly proposed adverse risk factors. RESULTS: When patient with Ta tumors were stratified into IR and HR, 37 (16%) had IR low-grade (LG) Ta, 92 (40%) had IR HG Ta and 101 (44%) had HR HG Ta tumors. BCG unresponsiveness developed in 13% of HR HG Ta tumors and 14% of IR HG Ta tumors compared to 0.0% of IR LG Ta tumors (p=0.003). While no patients with IR LG Ta tumors progressed, progression rates were similar in HR HG Ta and IR HG Ta tumors (>/=T2: 5.9% and 6.5%; [Formula: see text]T1: 13% and 13%, respectively). Rates of recurrence, BCG unresponsiveness and progression were similar, irrespective of number of EAU risk factors present (p=0.9, p=0.8 and p=0.9, respectively). CONCLUSIONS: All HG Ta tumors, regardless of EAU risk stratification, have inferior response to BCG and increased rates of progression compared to IR LG Ta tumors. EAU clinical risk factors did not improve prediction of oncologic outcomes among HG Ta patients who received adequate BCG. These data support consideration of all HG tumors as high risk. FAU - Bree, Kelly K AU - Bree KK AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Lobo, Niyati AU - Lobo N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Brooks, Nathan A AU - Brooks NA AD - UPMC Urology of Central Pennsylvania, Harrisburg, Pennsylvania. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220630 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2022 Aug;208(2):239-240. doi: 10.1097/JU.0000000000002731. PMID: 35499494 CIN - J Urol. 2022 Aug;208(2):290. doi: 10.1097/JU.0000000000002678.01. PMID: 35770499 MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - *Mycobacterium bovis MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Mycobacterium bovis OT - chemotherapy, adjuvant OT - practice guideline [publication type] OT - urinary bladder neoplasms EDAT- 2022/07/01 06:00 MHDA- 2022/07/16 06:00 CRDT- 2022/06/30 04:02 PHST- 2022/07/01 06:00 [pubmed] PHST- 2022/07/16 06:00 [medline] PHST- 2022/06/30 04:02 [entrez] AID - 10.1097/JU.0000000000002678 [doi] PST - ppublish SO - J Urol. 2022 Aug;208(2):284-291. doi: 10.1097/JU.0000000000002678. Epub 2022 Jun 30. PMID- 35764702 OWN - NLM STAT- MEDLINE DCOM- 20230427 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 149 IP - 6 DP - 2023 Jun TI - Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy. PG - 2537-2542 LID - 10.1007/s00432-022-04153-4 [doi] AB - PURPOSE: To identify pre-surgical imaging predictive value and factors associated with the clinicopathologic discrepancy for implication of definitive pelvic radiotherapy in clinically node-negative bladder cancer. METHOD: The documented data of bladder cancer patients who underwent radical cystectomy plus pelvic lymphadenectomy were collected retrospectively. Patients' characteristics, last imaging, pathology reports, disease-specific survival and overall survival were retrieved. RESULTS: From 142 patients, pre-surgical imaging had a sensitivity of 76.4%, specificity of 73.7%, positive predictive value (PPV) of 94.9%, and negative predictive value (NPV) of 32.6% (p value < 0.0001) for detection of muscle invasion. Also, for detection of positive lymph nodes, imaging had a sensitivity of 31.8%, specificity of 85.7%, PPV of 50%, and NPV of 73.7% (p value: 0.022). 44.4% of study population were upstaged after surgery (24.6% associated with N-upstaging) and 18.3% were downstaged (12% associated with N-downstaging). Receipt of neoadjuvant chemotherapy and T-stage were not correlated with N-upstaging. On multivariate analysis, lymphovascular invasion (LVI) maintained its significance for independent prediction of upstaging (OR 3.3, 95% CI 1.5-7.5, p value: 0.004) and inversely with downstaging (OR 0.34, 95% CI 0.12-0.96, p value: 0.04). Older age (OR 1.03, 95% CI 1.0-1.05, p value 0.047), positive margins (OR 2.1, 95% CI 1.2-3.8, p value 0.011), presence of LVI (OR 2.5, 95% CI 1.4-4.7, p value 0.003), perineural invasion (OR 2.0, 95% CI 1.2-3.4, p value 0.013), and lymph node ratio (OR 1.011, 95% CI 1.001-1.021, p value 0.03) were associated with worse survival. Also, N-upstaging independently predicted a worse survival after controlling for surgical pathology stage (OR 2.3, 95% CI 1.2-4.5, p value 0.011). CONCLUSIONS: The optimal target volume in definitive chemoradiotherapy of node-negative bladder cancer patients remains to be established. Since then, customizing the treatment is considered especially for positive LVI in TURBT specimen. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Saeedian, Arefeh AU - Saeedian A AUID- ORCID: 0000-0003-1999-5776 AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Qarib Street, Keshavarz Blvd., Tehran, Iran. FAU - Safaei, Afsaneh Maddah AU - Safaei AM AUID- ORCID: 0000-0001-7077-4712 AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. amaddahsafe@sina.tums.ac.ir. AD - Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Qarib Street, Keshavarz Blvd., Tehran, Iran. amaddahsafe@sina.tums.ac.ir. FAU - Azimi, Amirali AU - Azimi A AUID- ORCID: 0000-0001-7801-7855 AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. FAU - Kolahdouzan, Kasra AU - Kolahdouzan K AUID- ORCID: 0000-0003-1522-5619 AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Qarib Street, Keshavarz Blvd., Tehran, Iran. FAU - Tabatabaei, Fatemeh-Sadat AU - Tabatabaei FS AUID- ORCID: 0000-0003-2975-3543 AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. FAU - Esmati, Ebrahim AU - Esmati E AD - Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Qarib Street, Keshavarz Blvd., Tehran, Iran. LA - eng PT - Journal Article DEP - 20220628 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 SB - IM MH - Humans MH - Prognosis MH - Retrospective Studies MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/pathology MH - Lymph Nodes/pathology MH - Lymph Node Excision MH - Chemoradiotherapy MH - Cystectomy/methods MH - Muscles/pathology PMC - PMC11796696 OTO - NOTNLM OT - Bladder cancer OT - Chemoradiotherapy OT - Lymphovascular invasion OT - Pelvic lymph nodes COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2022/06/29 06:00 MHDA- 2023/04/27 06:42 PMCR- 2022/06/28 CRDT- 2022/06/28 23:24 PHST- 2022/05/03 00:00 [received] PHST- 2022/06/13 00:00 [accepted] PHST- 2023/04/27 06:42 [medline] PHST- 2022/06/29 06:00 [pubmed] PHST- 2022/06/28 23:24 [entrez] PHST- 2022/06/28 00:00 [pmc-release] AID - 10.1007/s00432-022-04153-4 [pii] AID - 4153 [pii] AID - 10.1007/s00432-022-04153-4 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 Jun;149(6):2537-2542. doi: 10.1007/s00432-022-04153-4. Epub 2022 Jun 28. PMID- 35763251 OWN - NLM STAT- MEDLINE DCOM- 20220805 LR - 20250728 IS - 1826-6983 (Electronic) IS - 0033-8362 (Print) IS - 0033-8362 (Linking) VI - 127 IP - 8 DP - 2022 Aug TI - A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. PG - 881-890 LID - 10.1007/s11547-022-01513-5 [doi] AB - PURPOSE: To determine the clinical, pathological, and radiological features, including the Vesical Imaging-Reporting and Data System (VI-RADS) score, independently correlating with muscle-invasive bladder cancer (BCa), in a multicentric national setting. METHOD AND MATERIALS: Patients with BCa suspicion were offered magnetic resonance imaging (MRI) before trans-urethral resection of bladder tumor (TURBT). According to VI-RADS, a cutoff of >/= 3 or >/= 4 was assumed to define muscle-invasive bladder cancer (MIBC). Trans-urethral resection of the tumor (TURBT) and/or cystectomy reports were compared with preoperative VI-RADS scores to assess accuracy of MRI for discriminating between non-muscle-invasive versus MIBC. Performance was assessed by ROC curve analysis. Two univariable and multivariable logistic regression models were implemented including clinical, pathological, radiological data, and VI-RADS categories to determine the variables with an independent effect on MIBC. RESULTS: A final cohort of 139 patients was enrolled (median age 70 [IQR: 64, 76.5]). MRI showed sensitivity, specificity, PPV, NPV, and accuracy for MIBC diagnosis ranging from 83-93%, 80-92%, 67-81%, 93-96%, and 84-89% for the more experienced readers. The area under the curve (AUC) was 0.95 (0.91-0.99). In the multivariable logistic regression model, the VI-RADS score, using both a cutoff of 3 and 4 (P < .0001), hematuria (P = .007), tumor size (P = .013), and concomitant hydronephrosis (P = .027) were the variables correlating with a bladder cancer staged as >/= T2. The inter-reader agreement was substantial (k = 0.814). CONCLUSIONS: VI-RADS assessment scoring proved to be an independent predictor of muscle-invasiveness, which might implicate a shift toward a more aggressive selection approach of patients' at high risk of MIBC, according to a novel proposed predictive pathway. CI - (c) 2022. The Author(s). FAU - Bicchetti, Marco AU - Bicchetti M AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, 'Regina Elena' National Cancer Institute, IRCCS, Rome, Italy. FAU - Giannarini, Gianluca AU - Giannarini G AD - Unit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy. FAU - Girometti, Rossano AU - Girometti R AD - Institute of Radiology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS Vita-Salute San Raffaele University, Milan, Italy. FAU - Brunocilla, Eugenio AU - Brunocilla E AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Cardone, Gianpiero AU - Cardone G AD - Department of Radiology, IRCCS Ospedale San Raffaele Di Turro, Milan, Italy. FAU - De Cobelli, Francesco AU - De Cobelli F AD - Department of Radiology, IRCSS Vita-Salute San Raffaele University, Milan, Italy. FAU - Gaudiano, Caterina AU - Gaudiano C AD - Department of Radiology, University of Bologna, Bologna, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Rome, Italy. FAU - Flammia, Simone AU - Flammia S AD - Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Rome, Italy. FAU - Leonardo, Costantino AU - Leonardo C AD - Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Rome, Italy. FAU - Pecoraro, Martina AU - Pecoraro M AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Catalano, Carlo AU - Catalano C AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy. FAU - Panebianco, Valeria AU - Panebianco V AUID- ORCID: 0000-0001-8466-918X AD - Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy. Valeria.panebianco@uniroma1.it. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220628 PL - Italy TA - Radiol Med JT - La Radiologia medica JID - 0177625 SB - IM MH - Aged MH - Humans MH - Magnetic Resonance Imaging/methods MH - Neoplasm Invasiveness/pathology MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery PMC - PMC9349064 OTO - NOTNLM OT - Hematuria OT - Magnetic resonance imaging OT - Muscle-invasive bladder cancer OT - Pathway OT - VI-RADS COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/06/29 06:00 MHDA- 2022/08/06 06:00 PMCR- 2022/06/28 CRDT- 2022/06/28 11:22 PHST- 2022/01/05 00:00 [received] PHST- 2022/06/01 00:00 [accepted] PHST- 2022/06/29 06:00 [pubmed] PHST- 2022/08/06 06:00 [medline] PHST- 2022/06/28 11:22 [entrez] PHST- 2022/06/28 00:00 [pmc-release] AID - 10.1007/s11547-022-01513-5 [pii] AID - 1513 [pii] AID - 10.1007/s11547-022-01513-5 [doi] PST - ppublish SO - Radiol Med. 2022 Aug;127(8):881-890. doi: 10.1007/s11547-022-01513-5. Epub 2022 Jun 28. PMID- 35752497 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20250623 IS - 1532-2157 (Electronic) IS - 0748-7983 (Linking) VI - 49 IP - 1 DP - 2023 Jan TI - Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis. PG - 29-38 LID - S0748-7983(22)00489-9 [pii] LID - 10.1016/j.ejso.2022.06.005 [doi] AB - BACKGROUND: To reduce recurrence or progression of tumor, NCCN guidelines recommend repeat transurethral resection of bladder tumors (reTURB) for non-muscle-invasive bladder cancer (NMIBC). The study aims to compare the impact of initial TURB and reTURB on the rate of residual or upstaging tumors and short-term and long-term survival outcomes of T1 bladder cancer (BC). MATERIALS AND METHODS: We searched through several public database, including PubMed, Embase, Ovid Medline and Ovid EBM Reviews - Cochrane Central Register of Controlled Trials. The latest search time was October 2021. RESULTS: In general, 68 articles were involved. Short-term RFS (1-year and 3-year) of reTURB group was better compared with TURB group in T1 patients. The pooled RR were 1.10 (95%CI: 1.01-1.19) and 1.15 (95%CI: 1.03-1.28), respectively. While reTURB did not improve long-term RFS (5-year, 10-year, 15-year) in T1 patients. The pooled RR were 1.12 (95%CI: 0.97-1.30), 1.11 (95%CI: 0.82-1.50) and 1.37 (95%CI: 0.50-3.74), respectively. Analysis of PFS, OS and CSS demonstrated similar outcomes with RFS. We found that about two-thirds of samples contained detrusor. The residual tumor rate in stage T1 was 0.48 (95%CI: 0.42-0.53). While the rate of upstaging in stage T1 was 0.10 (95%CI: 0.07-0.13). CONCLUSIONS: In conclusion, reTURB might provide short-term survival benefits for T1 BC, but it was not the same for long-term outcomes. The residual and upstaging rates of T1 BC in reTURB were around 50% and 10%, respectively. Our study might be conducive to clinically informed consents when patients expressed their concerns about the necessity of reTURB and its impact on diagnosis, treatment and prognosis. CI - Copyright (c) 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. FAU - Lin, Lede AU - Lin L AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Guo, Xiaotong AU - Guo X AD - Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Ma, Yucheng AU - Ma Y AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Zhu, Jiang AU - Zhu J AD - Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zhujiang@wchscu.cn. FAU - Li, Xiang AU - Li X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: xiangli.87@163.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220613 PL - England TA - Eur J Surg Oncol JT - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JID - 8504356 SB - IM MH - Humans MH - *Transurethral Resection of Bladder MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/diagnosis/surgery/pathology MH - Prognosis MH - Urologic Surgical Procedures MH - Cystectomy OTO - NOTNLM OT - Bladder cancer OT - CSS OT - OS OT - PFS OT - RFS OT - Transurethral resection of bladder tumors COIS- Declaration of competing interest All authors have no conflicts of interest or financial ties to disclose. EDAT- 2022/06/26 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/06/25 22:03 PHST- 2022/04/11 00:00 [received] PHST- 2022/05/26 00:00 [revised] PHST- 2022/06/04 00:00 [accepted] PHST- 2022/06/26 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/06/25 22:03 [entrez] AID - S0748-7983(22)00489-9 [pii] AID - 10.1016/j.ejso.2022.06.005 [doi] PST - ppublish SO - Eur J Surg Oncol. 2023 Jan;49(1):29-38. doi: 10.1016/j.ejso.2022.06.005. Epub 2022 Jun 13. PMID- 35749782 OWN - NLM STAT- MEDLINE DCOM- 20220628 LR - 20220818 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 32 IP - 4 DP - 2022 Jul 1 TI - Nonmuscle-invasive bladder cancer, old problems, new insights. PG - 352-357 LID - 10.1097/MOU.0000000000000997 [doi] AB - PURPOSE OF REVIEW: Nonmuscle-invasive bladder cancer (NMIBC) is the most frequent bladder cancer and represents around 75% of bladder cancers. This review will discuss known challenges and recent advances in staging, grading and treatment stratification based on pathology. RECENT FINDINGS: Pathological staging and grading in NMIBC remains challenging and different techniques exist. Substaging has been shown to be of prognostic relevance and to help predict treatment response in patients receiving Bacillus Calmette-Guerin (BCG) therapy, which is the treatment of choice for high-grade NMIBC. Recent advances in molecular classification and artificial intelligence were also able to show promising results in the stratification of patients. SUMMARY: Many challenges in the diagnosis of NMIBC are still unresolved and ask for more prospective research. New technologies, molecular insights and AI will help in the upcoming years to better stratify and manage these patients. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria. AD - Department of Pathology, Sorbonne University, Assistance Publique-Hopital de Paris, Hopital Tenon, Paris, France. FAU - Wasinger, Gabriel AU - Wasinger G AD - Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria. FAU - Oszwald, Andre AU - Oszwald A AD - Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh AU - Shariat S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Artificial Intelligence MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology EDAT- 2022/06/25 06:00 MHDA- 2022/06/29 06:00 CRDT- 2022/06/24 17:53 PHST- 2022/06/24 17:53 [entrez] PHST- 2022/06/25 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] AID - 00042307-202207000-00004 [pii] AID - 10.1097/MOU.0000000000000997 [doi] PST - ppublish SO - Curr Opin Urol. 2022 Jul 1;32(4):352-357. doi: 10.1097/MOU.0000000000000997. PMID- 35731280 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20261028 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 481 IP - 2 DP - 2022 Aug TI - Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice. PG - 191-200 LID - 10.1007/s00428-022-03361-0 [doi] AB - The preferred treatment of choice in muscle-invasive bladder cancer (MIBC) is usually transurethral resection followed by cystectomy, with neoadjuvant chemotherapy being a second option. As the treatment is associated with relevant side effects, a great effort is being made to improve the selection of patients, with molecular subtyping being one of the main strategies. Our aim was to develop an immunohistochemical algorithm for subtyping MIBCs. After a literature review, we have developed a simple algorithm to subtype MIBCs based on their morphology and three common antibodies: GATA3, CK5/6, and p16. We applied it to 113 muscle-invasive carcinomas. The positivity threshold for GATA3 and CK5/6 was 20% with at least moderate intensity, while p16 was 70% with moderate to intense nuclear and cytoplasmic staining. Cases GATA3 + CK5/6 - were considered luminal, while cases GATA3 - CK5/6 + were classified as nonluminal/basal squamous. Luminal p16 + cases were labeled as genomically unstable and luminal p16 - as Uro-like. Cases GATA3 + CK5/6 + with a predominantly basal pattern were labeled luminal, while diffuse cases were labeled nonluminal/basal squamous. All GATA3-CK5/6 - cases were considered nonluminal and were divided into mesenchymal-like or neuroendocrine, depending on the morphology. We were able to classify the 113 cases as: 82 (72.57%) were luminal, being 47 Uro-like (41.59%) and 35 (30.97%) genomically unstable; 31 (27.43%) were nonluminal, being 24 basal/squamous (21.24%), two (1.76%) mesenchymal-like, and five (4.42%) neuroendocrine like. We have achieved a feasible and cost-effective algorithm to subtype MIBCs from morphological features and the use of three common antibodies. Further studies in external cohorts are necessary to validate these results. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Queipo, Francisco Javier AU - Queipo FJ AD - Complejo Hospitalario Universitario A Coruna (CHUAC), A Coruna, Spain. patxiqueipo@gmail.com. FAU - Unamunzaga, Gorka Muniz AU - Unamunzaga GM AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Negro, Begona Fuertes AU - Negro BF AD - Hospital Universitario Josep Trueta, Girona, Spain. FAU - Fuertes, Sandra Gracia AU - Fuertes SG AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Cortes, Marina Alvarez AU - Cortes MA AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Tejedor, Elena Carceller AU - Tejedor EC AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Manas, Carmen Maria Bernal AU - Manas CMB AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Arino, Arceli Bono AU - Arino AB AD - Hospital Universitario San Jorge, Huesca, Spain. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Department of Translational Medicine, Lund University, Lund, Sweden. FAU - Beorlegui, Carmen AU - Beorlegui C AD - Hospital Universitario de Navarra, Pamplona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20220622 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - *Carcinoma, Squamous Cell MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Immunohistochemistry MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder carcinoma OT - CK 5/6 OT - GATA3 OT - Immunohistochemistry OT - Staining OT - Subtyping EDAT- 2022/06/23 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/06/22 11:25 PHST- 2021/12/28 00:00 [received] PHST- 2022/06/09 00:00 [accepted] PHST- 2022/04/19 00:00 [revised] PHST- 2022/06/23 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/06/22 11:25 [entrez] AID - 10.1007/s00428-022-03361-0 [pii] AID - 10.1007/s00428-022-03361-0 [doi] PST - ppublish SO - Virchows Arch. 2022 Aug;481(2):191-200. doi: 10.1007/s00428-022-03361-0. Epub 2022 Jun 22. PMID- 35725972 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 46 IP - 7 DP - 2022 Sep TI - The probability of residual tumor detection in the second transurethral resection of pT1 urothelial bladder cancer according to the risk factors. PG - 423-430 LID - S2173-5786(22)00045-2 [pii] LID - 10.1016/j.acuroe.2022.05.001 [doi] AB - OBJECTIVE: To analyze the predictive factors for residual tumors in the second resection after the initial transurethral resection of bladder tumor (TUR-BT) in patients with pT1 tumors and to develop a simple method to predict the probability of residual tumor detection. MATERIAL AND METHODS: Patients with pT1 bladder cancer who underwent a second resection within two to six weeks after the initial TUR-BT were included in our retrospective study. The patients' demographics and the tumor characteristics of the initial and second resections were recorded. RESULTS: A total of 144 patients were included in our analysis with a 53-month follow-up. In the univariate logistic regression analysis, tumor grade, concomitant carcinoma in situ (CIS), macroscopic appearance of the tumor (solid vs papillary), and presence of a variant histology, were significant risk factors for residual tumor. In the multivariate analysis, tumor grade was the only independent predictor of residual tumor at second TUR (OR: 5.62, 95% CI: 1.228-25.708, p = 0.026). According to our findings, the patients with the highest risk have a 90.9% residual tumor detection probability at the second resection, and the patients with the lowest risk have 25.4%. CONCLUSIONS: Tumor grade, macroscopic appearance of the tumor (solid vs papillary), and concomitant CIS, were important predictors of residual tumors at second resection of primary pT1 NMIBC patients. We were able to calculate the probability of residual tumor which helped us determine risk adapted strategies according to these probabilities. CI - Copyright (c) 2022. Published by Elsevier Espana, S.L.U. FAU - Culpan, M AU - Culpan M AD - Department of Urology, Istanbul Medeniyet University, Istanbul, Turkey. Electronic address: mculpan@gmail.com. FAU - Kazan, O AU - Kazan O AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Acar, H Cansu AU - Acar HC AD - Department of Public Health, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Iplikci, A AU - Iplikci A AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Atis, G AU - Atis G AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Yildirim, A AU - Yildirim A AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. LA - eng LA - spa PT - Journal Article DEP - 20220617 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - *Carcinoma in Situ MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Disease Progression MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Neoplasm, Residual/pathology/surgery MH - Retrospective Studies MH - Risk Factors MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - Cancer de vejiga OT - Factores predictivos OT - Predictive factors OT - Residual tumor OT - Second resection OT - Segunda reseccion OT - Tumor residual OT - re-RTU OT - re-TUR EDAT- 2022/06/22 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/06/21 00:08 PHST- 2021/05/07 00:00 [received] PHST- 2021/06/17 00:00 [revised] PHST- 2021/07/23 00:00 [accepted] PHST- 2022/06/22 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/06/21 00:08 [entrez] AID - S2173-5786(22)00045-2 [pii] AID - 10.1016/j.acuroe.2022.05.001 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2022 Sep;46(7):423-430. doi: 10.1016/j.acuroe.2022.05.001. Epub 2022 Jun 17. PMID- 35719953 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Could Metabolic Syndrome Be a Predictor of Survival Outcomes in Upper Tract Urothelial Carcinoma? A Propensity Score Matching Study in a Large Chinese Center. PG - 816915 LID - 10.3389/fonc.2022.816915 [doi] LID - 816915 AB - PURPOSE: To evaluate the prognostic value of metabolic syndrome (MetS) in upper tract urothelial carcinoma (UTUC) patients based on propensity score matching (PSM) analysis. PATIENTS AND METHODS: A total of 573 patients with UTUC after radical nephroureterectomy were included at Peking University People's Hospital from January 2007 to April 2021. MetS was diagnosed according to the criteria of Chinese Diabetes Society and was defined as the presence of 3 or more of the following 4 conditions (obesity, hyperglycemia, hypertension, high triglycerides and/or low high-density lipoprotein-cholesterol). Patients were divided into two groups based on whether they had MetS, whose variables were adjusted using 1:1 PSM analysis with a caliber of 0.02 to minimize selection bias. Univariate and multivariate Cox regression analysis were used to evaluate the association of MetS and its components with pathological outcomes after adjusting preoperative confounders by propensity score matching. The Kaplan-Meier method was used to estimate overall survival (OS), cancer-specific survival (CSS), and intravesical recurrence-free survival (IVRFS) after surgery. RESULTS: MetS was significantly correlated with older age, a history of coronary heart disease, high Charlson Comorbidity Index, low estimated Glomerular filtration rate, and low aspartate/alanine aminotransferase ratio (all P<0.05). Multivariate Cox regression analysis and Kaplan-Meier curves demonstrated that MetS showed no statistical correlation with lower OS or IVRFS and approaching significance with lower CSS (P=0.063) before PSM. After PSM, the 5-year OS, CSS, and IVRFS were 64.1%, 74.7%, and 77.2%, respectively, in the MetS group, compared with 67.4%, 78.8%, and 77.2%, respectively, in non-MetS group. Univariate Cox regression analyses showed that MetS and its components were not associated with decreased OS, CSS, or IVRFS (all P>0.05). CONCLUSION: In our study, no statistical difference was found between MetS and survival outcomes in UTUC, except a marginal association with lower CSS. Further studies are needed to evaluate the role of MetS and its each single component on UTUC. CI - Copyright (c) 2022 Dai, Wang, Du, Qin, Lai, Song, Huang, Han, Zhang and Xu. FAU - Dai, Xiang AU - Dai X AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Wang, Fei AU - Wang F AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Du, Yiqing AU - Du Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Qin, Caipeng AU - Qin C AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Song, Yuxuan AU - Song Y AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Huang, Zixiong AU - Huang Z AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Han, Songchen AU - Han S AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Zhang, Xiaopeng AU - Zhang X AD - Department of Urology, Peking University People's Hospital, Beijing, China. FAU - Xu, Tao AU - Xu T AD - Department of Urology, Peking University People's Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20220526 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9204272 OTO - NOTNLM OT - metabolic syndrome OT - prognosis OT - propensity score matching OT - survival OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/21 06:00 MHDA- 2022/06/21 06:01 PMCR- 2022/01/01 CRDT- 2022/06/20 03:36 PHST- 2021/11/17 00:00 [received] PHST- 2022/04/25 00:00 [accepted] PHST- 2022/06/20 03:36 [entrez] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/06/21 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.816915 [doi] PST - epublish SO - Front Oncol. 2022 May 26;12:816915. doi: 10.3389/fonc.2022.816915. eCollection 2022. PMID- 35719408 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 13 DP - 2022 TI - A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression. PG - 833989 LID - 10.3389/fgene.2022.833989 [doi] LID - 833989 AB - Non-muscle-invasive bladder cancer (NMIBC) accounts for more than 70% of urothelial cancer. More than half of NMIBC patients experience recurrence, progression, or metastasis, which essentially reduces life quality and survival time. Identifying the high-risk patients prone to progression remains the primary concern of risk management of NMIBC. In this study, we included 1370 NMIBC transcripts data from nine public datasets, identified nine tumor-infiltrating marker cells highly related to the survival of NMIBC, quantified the cells' proportion by self-defined differentially expressed signature genes, and established a robust immuno-prognostic model dividing NMIBC patients into low-risk versus high-risk progression groups. Our model implies that the loss of crosstalk between tumor cells and adjacent normal epithelium, along with enriched cell proliferation signals, may facilitate tumor progression. Thus, evaluating tumor progression should consider various components in the tumor immune microenvironment instead of the single marker in a single dimension. Moreover, we also appeal to the necessity of using appropriate meta-analysis methods to integrate the evidence from multiple sources in the feature selection step from large-scale heterogeneous omics data such as our study. CI - Copyright (c) 2022 Sun, Xu, Liu, Chen, Xu, Li and Liu. FAU - Sun, Xiaomeng AU - Sun X AD - Institutes of Biomedical Sciences and School of Basic Medical Sciences, Fudan University, Shanghai, China. AD - Research Institute, GloriousMed Clinical Laboratory Co., Ltd., Shanghai, China. FAU - Xu, Huilin AU - Xu H AD - Institutes of Biomedical Sciences and School of Basic Medical Sciences, Fudan University, Shanghai, China. FAU - Liu, Gang AU - Liu G AD - Institutes of Biomedical Sciences and School of Basic Medical Sciences, Fudan University, Shanghai, China. FAU - Chen, Jiani AU - Chen J AD - Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai, China. FAU - Xu, Jinrong AU - Xu J AD - Department of Electronic Engineering, Taiyuan Institute of Technology, Taiyuan, China. FAU - Li, Mingming AU - Li M AD - Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai, China. FAU - Liu, Lei AU - Liu L AD - Institutes of Biomedical Sciences and School of Basic Medical Sciences, Fudan University, Shanghai, China. LA - eng PT - Journal Article DEP - 20220603 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC9205430 OTO - NOTNLM OT - cancer-associated fibroblasts OT - collagen family OT - non-muscle-invasive bladder cancer OT - tumor immune microenvironment OT - tumor progression COIS- Author XS was employed by GloriousMed Clinical Laboratory Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/21 06:00 MHDA- 2022/06/21 06:01 PMCR- 2022/06/03 CRDT- 2022/06/20 03:29 PHST- 2021/12/12 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2022/06/20 03:29 [entrez] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/06/21 06:01 [medline] PHST- 2022/06/03 00:00 [pmc-release] AID - 833989 [pii] AID - 10.3389/fgene.2022.833989 [doi] PST - epublish SO - Front Genet. 2022 Jun 3;13:833989. doi: 10.3389/fgene.2022.833989. eCollection 2022. PMID- 35718695 OWN - NLM STAT- MEDLINE DCOM- 20221012 LR - 20260120 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 5 DP - 2022 Oct TI - Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. PG - 505-516 LID - S2588-9311(22)00088-8 [pii] LID - 10.1016/j.euo.2022.05.005 [doi] AB - CONTEXT: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease. OBJECTIVE: To update the International Bladder Cancer Group (IBCG) guidance and provide practical recommendations on IR NMIBC management. EVIDENCE ACQUISITION: A collaborative review of published randomized clinical trials, meta-analyses, systematic reviews, and clinical practice guidance on IR NMIBC published before January 2022 was undertaken using PubMed/Medline. EVIDENCE SYNTHESIS: Variation exists between guidelines in defining IR NMIBC. The IBCG recommends defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or has size >/=3 cm, OR any T1LG tumor. If the 3 tier grading system is used, than any TaG2 tumor would also be considered IR diease regardless of whether new diagnosis or recurrent. Accurate grading and staging of tumor, particularly in ruling out HG/G3 disease and/or carcinoma in situ, are crucial. The IBCG recommends that management of IR NMIBC should be further based on the following risk factors: multifocal tumor (more than one), early recurrence (<1 yr), frequent recurrence (>1/yr), tumor size (>/=3 cm), and failure of prior intravesical treatment. Patients with no risk factors are best managed by one dose of postoperative intravesical chemotherapy. Patients with one to two risk factors should be offered additional adjuvant induction intravesical chemotherapy (or bacillus Calmette-Guerin (BCG) if prior chemotherapy has been used). Patients with three or more risk factors should be offered induction plus 1-yr maintenance BCG. Where BCG is not available or recurrent disease following BCG is present, alternative intravesical treatments such as chemotherapy (single agent, combination, or chemohyperthermia) or a clinical trial are recommended. CONCLUSIONS: Standardizing the definition of IR NMIBC is critical for appropriate management of patients and for allowing a comparison of outcomes across clinical trials. The IBCG recommends defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or >/=3 cm, OR any T1LG tumor. If the 3 tier grading system is used, than any TaG2 tumor would also be considered IR disease regardless of whether new diagnosis or recurrent. Adjunctive management should then be based on established risk factors. PATIENT SUMMARY: Standardizing the definition of intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), which is a heterogeneous disease, is critical for appropriate management of patients. The International Bladder Cancer Group recommends classification of IR NMIBC tumors and personalized management based on the following risk factors: multifocal tumor (more than one), early recurrence (<1 yr), frequent recurrence (>1/yr), tumor size (>/=3 cm), and previous intravesical treatment. CI - Copyright (c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tan, Wei Shen AU - Tan WS AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals, London, UK. FAU - Steinberg, Gary AU - Steinberg G AD - Department of Urology, New York University, New York City, NY, USA. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC n degrees 5, Predictive ONCO-URO, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA. FAU - Psutka, Sarah P AU - Psutka SP AD - Department of Urology, University of Washington, Seattle, WA, USA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. FAU - Cookson, Michael S AU - Cookson MS AD - Department of Urology, The University of Oklahoma Health Sciences Center & The Stephenson Cancer Center, Oklahoma City, OK, USA. FAU - Palou, Juan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20220617 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol Oncol. 2022 Oct;5(5):517-518. doi: 10.1016/j.euo.2022.07.003. PMID: 35907762 CIN - Eur Urol Oncol. 2023 Jun;6(3):354. doi: 10.1016/j.euo.2023.03.007. PMID: 37031078 MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Chemotherapy OT - Guidelines OT - Intermediate risk OT - Intravesical EDAT- 2022/06/20 06:00 MHDA- 2022/10/13 06:00 CRDT- 2022/06/19 22:18 PHST- 2022/03/21 00:00 [received] PHST- 2022/04/22 00:00 [revised] PHST- 2022/05/19 00:00 [accepted] PHST- 2022/06/20 06:00 [pubmed] PHST- 2022/10/13 06:00 [medline] PHST- 2022/06/19 22:18 [entrez] AID - S2588-9311(22)00088-8 [pii] AID - 10.1016/j.euo.2022.05.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. PMID- 35718638 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20250728 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 9 DP - 2022 Sep TI - Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer. PG - 412.e1-412.e8 LID - S1078-1439(22)00189-2 [pii] LID - 10.1016/j.urolonc.2022.05.020 [doi] AB - PURPOSE: Serum biomarkers are valuable tools to predict the prognosis of anticancer therapies. This study aimed to evaluate the impact of serum interleukin-6 (IL-6) level on the clinical outcome of intravesical gemcitabine (GEM) therapy in non-muscle-invasive bladder cancer (NMIBC). METHODS: This retrospective study enrolled 71 patients initially diagnosed with T1 NMIBC who underwent intravesical GEM therapy between 2017 and 2019. The expression of IL-6 gene was examined by real-time PCR. Serum IL-6 level was determined by enzyme-linked immunosorbent assay (ELISA). The cell viability after gemcitabine treatment was measured by CCK-8 assay. The optimal serum IL-6 cutoff values for recurrence prediction were calculated using receiver-operating characteristic curve analysis with reference to cancer recurrence. Recurrence-free survival was compared by the log-rank test. Univariate and multivariate Cox regression analysis was conducted to identify the prognostic factors influencing recurrence-free survival after treatment with intravesical GEM. RESULTS: Increased expression and secretion of IL-6 were observed in GEM-resistant sublines compared with parental bladder cancer cell lines. Serum IL-6 level rendered a sensitivity of 82.6% and a specificity of 77.1% to correlate with the cancer recurrence after intravesical GEM. Patients with a high serum IL-6 level exhibited shorter recurrence-free survival after intravesical GEM. Moreover, serum IL-6 level in our NMIBC cohort was significantly associated with clinicopathological characteristics, such as tumor diameter, multifocality, concomitant CIS, and grade. Serum IL-6 level was an independent prognostic factor for recurrence-free survival in NMIBC patients treated with intravesical GEM. CONCLUSION: Given that it was significantly associated with clinical outcome of intravesical GEM therapy, serum IL-6 level might be used as a potential prognostic biomarker for intravesical GEM in T1 NMIBC. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Tong, Shiyu AU - Tong S AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. FAU - Hu, Xiheng AU - Hu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. FAU - Li, Yangle AU - Li Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. Electronic address: lyle2003@csu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220617 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Interleukin-6) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Administration, Intravesical MH - Deoxycytidine/analogs & derivatives MH - Humans MH - Interleukin-6 MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms MH - Gemcitabine OTO - NOTNLM OT - Bladder cancer OT - Cancer biomarker OT - Cancer recurrence OT - IL-6 OT - Non-muscle-invasive bladder cancer COIS- Conflict of Interest The authors declare that they have no competing interests. EDAT- 2022/06/20 06:00 MHDA- 2022/08/31 06:00 CRDT- 2022/06/19 22:15 PHST- 2021/12/22 00:00 [received] PHST- 2022/05/15 00:00 [revised] PHST- 2022/05/19 00:00 [accepted] PHST- 2022/06/20 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2022/06/19 22:15 [entrez] AID - S1078-1439(22)00189-2 [pii] AID - 10.1016/j.urolonc.2022.05.020 [doi] PST - ppublish SO - Urol Oncol. 2022 Sep;40(9):412.e1-412.e8. doi: 10.1016/j.urolonc.2022.05.020. Epub 2022 Jun 17. PMID- 35717533 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20221021 IS - 1879-4076 (Electronic) IS - 1879-4068 (Linking) VI - 13 IP - 7 DP - 2022 Sep TI - Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule. PG - 978-986 LID - S1879-4068(22)00135-7 [pii] LID - 10.1016/j.jgo.2022.05.014 [doi] AB - INTRODUCTION: Bladder cancer occurs mainly in older adults and surgery is not always possible when there are geriatric conditions and comorbidities. Trimodal treatment (TMT) combining trans-urethral resection of bladder tumour (TURBT) followed by concurrent chemoradiation (CRT) would be a curative alternative in such patients. MATERIALS AND METHODS: All consecutive patients 75 years of age and older with non-metastatic muscle-invasive bladder cancer (MIBC) treated with TMT by Georges Pompidou European Hospital team were retrospectively analysed. Induction CRT combined hypofractionated twice-daily radiotherapy targeting bladder and pelvis to a total dose of 24 Gy (Gy) with concurrent platinum salt and 5-fluorouracil. Consolidation CRT to a total dose of 44 Gy was proposed to patients with biopsy-proven complete response after induction phase and those with persistent tumour underwent salvage cystectomy. We assessed using Kaplan-Meier method overall survival (OS), cancer specific survival (CSS), invasive recurrence-free survival (IRFS), metastasis-free survival (MFS), survival with bladder preserved (SBP), and toxicities. With a Cox model for OS and the Fine Gray method of competing risk for secondary endpoints, we analysed in univariate (u) and multivariate (m) analysis the impact of tumour characteristics and patient profiles: gender, age, age-adjusted Charlson comorbidity index, polypharmacy, and malnutrition. RESULTS: From 1988 to 2017, 85 patients were included. After induction, complete response rate was 83.5%. With a median follow-up of 63 months, 5 year-OS, CSS, IRFS, MFS and SBP were 61.0%, 77.6%, 71%, 82.9%, and 70.2% respectively. A persistent tumour after induction impacted SBP (SHRm 3.61; p = 0.004), CSS (SHRm 3.27; p = 0.023), and MFS (SHRm 3.68; p = 0.018). Late grade 3 urinary and gastrointestinal toxicities were 3.5% and 1.2%. DISCUSSION: We report here the largest series of bladder preservation over 75 years in a curative intent. Outcomes and tolerance in selected older adults compared favourably with surgical series and with CRT studies using classical fractionation. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Alati, Aurelia AU - Alati A AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. Electronic address: alatiaurelia@hotmail.fr. FAU - Fabiano, Emmanuelle AU - Fabiano E AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Geiss, Romain AU - Geiss R AD - Geriatric Department, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Mareau, Alexis AU - Mareau A AD - Clinical Research Unit, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Charles-Nelson, Anais AU - Charles-Nelson A AD - Clinical Research Unit, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Bibault, Jean-Emmanuel AU - Bibault JE AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Giraud, Philippe AU - Giraud P AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Kreps, Sarah AU - Kreps S AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Mejean, Arnaud AU - Mejean A AD - Department of Urology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Housset, Martin AU - Housset M AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. FAU - Durdux, Catherine AU - Durdux C AD - Department of Radiation Oncology, Georges Pompidou European Hospital, University of Paris Descartes, Paris, France. LA - eng PT - Journal Article DEP - 20220616 PL - Netherlands TA - J Geriatr Oncol JT - Journal of geriatric oncology JID - 101534770 RN - 49DFR088MY (Platinum) RN - U3P01618RT (Fluorouracil) SB - IM MH - Aged MH - Combined Modality Therapy MH - Cystectomy/methods MH - Fluorouracil MH - Humans MH - Muscles/pathology MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/methods MH - Platinum MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology/therapy OTO - NOTNLM OT - Bladder sparing OT - Muscle-invasive bladder cancer OT - Older adults OT - Trimodal treatment EDAT- 2022/06/19 06:00 MHDA- 2022/09/21 06:00 CRDT- 2022/06/18 23:55 PHST- 2021/12/29 00:00 [received] PHST- 2022/05/24 00:00 [revised] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/06/19 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/06/18 23:55 [entrez] AID - S1879-4068(22)00135-7 [pii] AID - 10.1016/j.jgo.2022.05.014 [doi] PST - ppublish SO - J Geriatr Oncol. 2022 Sep;13(7):978-986. doi: 10.1016/j.jgo.2022.05.014. Epub 2022 Jun 16. PMID- 35711974 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 8 IP - 6 DP - 2022 Jun TI - Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. PG - e09643 LID - 10.1016/j.heliyon.2022.e09643 [doi] LID - e09643 AB - PURPOSE: This study aimed to detect the expression levels of topoisomerase IIalpha (TOP2A), ribonucleotide reductase catalytic subunit M1 (RRM1),c-erbB-2 (HER2) and excision repair cross complementing group 1 (ERCC1) in non-muscular invasive bladder cancer (NMIBC) and explore the correlation between the expression of these genes and NMBIC sensitivity to pirarubicin or gemcitabine treatment. MATERIALS AND METHODS: NMIBC patient tissues and the bladder cancer cell lines BIU-87 and KK47 were selected for the exploration of drug sensitivity in vitro. Immunohistochemistry was used to examine protein expression in tissues. Reverse transcription-polymerase chain reaction (RT-qPCR) and a Western blot assay were used to detect the mRNA and protein levels in cells. The cell IC50 value was evaluated by an MTT assay. Flow cytometry was used to sort the cell subpopulations. RESULTS: In the pirarubicin-treated group, the patients with high TOP2A expression experienced lower recurrence rates than those with low TOP2A expression, whereas TOP2A and HER2 co-expression resulted in higher recurrence rates. The patients with low RRM1 expression, especially those with low ERCC1 expression, experienced lower recurrence rates than the patients with high RRM1 expression in the gemcitabine-treated group. Tumour cells with high TOP2A expression were highly sensitive to pirarubicin, and TOP2A(+) HER2(-) cells were more sensitive to pirarubicin than TOP2A(+) HER2(+) cells. Cells with low RRM1 expression levels were sensitive to gemcitabine, and RRM1(-)ERCC1(-) cells were more sensitive to gemcitabine than RRM1(-)ERCC1(+) cells. CONCLUSION: High TOP2A expression or low RRM1 expression could predict the sensitivity of NMIBC to pirarubicin or gemcitabine treatment. HER2 and ERCC1 expression may affect the effect of TOP2A and RRM1, thus affecting the efficacy of chemotherapeutic drugs. CI - (c) 2022 The Author(s). FAU - Liu, Zhifei AU - Liu Z AD - Department of Urology, Tangshan People's Hospital, Hebei 063001, China. FAU - Xing, Liyong AU - Xing L AD - Department of Urology, Tangshan People's Hospital, Hebei 063001, China. FAU - Zhu, Yanfeng AU - Zhu Y AD - Department of Urology, Tangshan People's Hospital, Hebei 063001, China. FAU - Shi, Peng AU - Shi P AD - Department of Urology, Tangshan People's Hospital, Hebei 063001, China. FAU - Deng, Gang AU - Deng G AD - Department of Urology, Tangshan People's Hospital, Hebei 063001, China. LA - eng PT - Journal Article DEP - 20220608 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC9194599 OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - ERCC1 OT - RRM1 OT - TOP2A COIS- The authors declare no conflict of interest. EDAT- 2022/06/18 06:00 MHDA- 2022/06/18 06:01 PMCR- 2022/06/08 CRDT- 2022/06/17 02:35 PHST- 2022/01/27 00:00 [received] PHST- 2022/03/22 00:00 [revised] PHST- 2022/05/30 00:00 [accepted] PHST- 2022/06/17 02:35 [entrez] PHST- 2022/06/18 06:00 [pubmed] PHST- 2022/06/18 06:01 [medline] PHST- 2022/06/08 00:00 [pmc-release] AID - S2405-8440(22)00931-8 [pii] AID - e09643 [pii] AID - 10.1016/j.heliyon.2022.e09643 [doi] PST - epublish SO - Heliyon. 2022 Jun 8;8(6):e09643. doi: 10.1016/j.heliyon.2022.e09643. eCollection 2022 Jun. PMID- 35711476 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 14 IP - 2 DP - 2022 Apr-Jun TI - Clinical behavior and survival outcome of urothelial bladder cancer in young adults. PG - 162-166 LID - 10.4103/ua.ua_15_21 [doi] AB - BACKGROUND: Bladder cancer (BC) is rare in young adults and therefore natural history of BC is still debatable. This study aimed to determine clinical behavior and prognosis of BC in patients <40 years. MATERIALS AND METHODS: We reviewed patients (<40 years) managed with urothelial BC from 2003 to 2019. Patients with nonurothelial histology were excluded. Clinical behavior and prognosis such as recurrence, progression, and survival were assessed. The recurrence is defined as a newly diagnosed occurrence of BC at previous or new site(s). Cancer progression is defined as an increase in staging or grade. RESULTS: Fifty-five patients inclusive of 45 males and 10 females with a median age of 30.0 (interquartile range [IQR] 25.0-33.0) years were included. The median follow-up was 3.5 (IQR: 1.5-7.0) years. Fifty-one (92.72%) patients were diagnosed with nonmuscle-invasive BC while four (7.27%) patients were diagnosed with muscle-invasive disease. Three out of four patients with muscle-invasive BC died of metastatic disease. According to stage and grade, there were 42 (76.36%) Ta, 9 (16.36%) T1 and 4 (7.27%) having T2 stage while 41 (74.54%) low grade and 14 (25.45%) were having high grade disease. Thirty-six (65.45%) patients remained stable, 13 (26.63%) patients progressed, and 6 (10.90%) patients regressed to lower stage and grade. Higher stage and grade (P = 0.0431) and tumor size >3 cm (P = 0.0454) were significant for recurrence, and higher stage and grade (P = 0.0012) and tumor size >3 cm (P = 0.0055) were associated with tumor progression. CONCLUSION: BC in younger adults is mostly low stage and low grade. We should be vigilant in patients with higher stage and grade as it is related with recurrence, progression, and metastatic disease. CI - Copyright: (c) 2022 Urology Annals. FAU - Mehmood, Shahbaz AU - Mehmood S AD - King Faisal Specialist Hospital and Research Center, Riyadh, KSA. FAU - Alothman, Khalid Ibraheem AU - Alothman KI AD - King Faisal Specialist Hospital and Research Center, Riyadh, KSA. FAU - Al Rumayyan, Majed AU - Al Rumayyan M AD - King Faisal Specialist Hospital and Research Center, Riyadh, KSA. FAU - Altaweel, Waleed Mohammed AU - Altaweel WM AD - King Faisal Specialist Hospital and Research Center, Riyadh, KSA. FAU - Alhussain, Turki Omar AU - Alhussain TO AD - King Faisal Specialist Hospital and Research Center, Riyadh, KSA. LA - eng PT - Journal Article DEP - 20220418 PL - India TA - Urol Ann JT - Urology annals JID - 101510823 PMC - PMC9197011 OTO - NOTNLM OT - Bladder cancer OT - progression OT - recurrence OT - young adults COIS- There are no conflicts of interest. EDAT- 2022/06/18 06:00 MHDA- 2022/06/18 06:01 PMCR- 2022/04/01 CRDT- 2022/06/17 02:28 PHST- 2021/01/21 00:00 [received] PHST- 2021/09/22 00:00 [accepted] PHST- 2022/06/17 02:28 [entrez] PHST- 2022/06/18 06:00 [pubmed] PHST- 2022/06/18 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - UA-14-162 [pii] AID - 10.4103/ua.ua_15_21 [doi] PST - ppublish SO - Urol Ann. 2022 Apr-Jun;14(2):162-166. doi: 10.4103/ua.ua_15_21. Epub 2022 Apr 18. PMID- 35709298 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220716 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 6 DP - 2022 TI - A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. PG - e0266371 LID - 10.1371/journal.pone.0266371 [doi] LID - e0266371 AB - PURPOSE: Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OHD) in suspected BC patients presented by hematuria. METHODS: This prospective cohort study involved suspected patients of BC presented with hematuria. Patients were evaluated by CT urogram, office cystoscopy and urine cytology with subsequent inpatient biopsy for positive findings. Baseline blood samples were collected for measurement of 25(OHD) by electrochemiluminescence binding assay at the time of diagnosis. Patients with non-muscle-invasive BC (NMIBC) underwent transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or BCG instillation. Patients were followed up for their recurrence status during 10 to 24 months. Recurrence was defined as the first time of NMIBC pathological relapse during the follow up period. RESULTS: A total of 115 patients were included in the final analysis. Patients had proven pathological BC (64 with NMIBC, and 20 with muscle invasive) and 31 patients were considered as control group. Controls were those patients with BC-free workup (including cytology, cystoscopy, and upper tract imaging). BC group showed a lower level of 25(OHD) than control group 16.47+/-5.88 versus 28.99+/-3.19 ng/mL (p<0.001). In addition, muscle invasive group also showed a lower level than NMIBC group 13.17+/-4.5 versus 17.49+/-5.04 ng/mL (P = 0.003). During the follow-up period of, tumor recurrence occurred in 16 (25%) of NMIBC patients. The baseline 25(OHD) were decreased in patients who experienced early recurrence; without being statistically significant (15.99 +/- 5.17 vs. 18.38 +/- 5.14 ng/mL; p = 0.08). 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC patients, respectively, (odds-ratios (OR): 2.13; 95% confidence intervals (CI), 1.52-2.99; P < 0.0001). CONCLUSION: Serum 25(OHD) is significantly decreased in BC patients especially those with tumor muscle invasive group. However, the baseline serum 25(OHD) does not predict the recurrence in the NMIBC patients. FAU - Abdelgawad, Ahmed AU - Abdelgawad A AUID- ORCID: 0000-0003-2979-5997 AD - Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. FAU - Hashem, Abdelwahab AU - Hashem A AUID- ORCID: 0000-0002-0664-3504 AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Mosbah, Ahmed AU - Mosbah A AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Eissa, Laila A AU - Eissa LA AD - Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. LA - eng SI - figshare/10.6084/m9.figshare.19568467 PT - Clinical Trial PT - Journal Article DEP - 20220616 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 1406-16-2 (Vitamin D) RN - A288AR3C9H (25-hydroxyvitamin D) SB - IM MH - Administration, Intravesical MH - Hematuria/drug therapy MH - Humans MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Vitamin D/analogs & derivatives PMC - PMC9202854 COIS- The authors have declared that no competing interests exist. EDAT- 2022/06/17 06:00 MHDA- 2022/06/22 06:00 PMCR- 2022/06/16 CRDT- 2022/06/16 14:05 PHST- 2021/06/27 00:00 [received] PHST- 2022/03/19 00:00 [accepted] PHST- 2022/06/16 14:05 [entrez] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/06/16 00:00 [pmc-release] AID - PONE-D-21-21016 [pii] AID - 10.1371/journal.pone.0266371 [doi] PST - epublish SO - PLoS One. 2022 Jun 16;17(6):e0266371. doi: 10.1371/journal.pone.0266371. eCollection 2022. PMID- 35700751 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20230602 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 167 DP - 2022 Sep TI - Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG. PG - 158-164 LID - S0090-4295(22)00455-1 [pii] LID - 10.1016/j.urology.2022.05.034 [doi] AB - OBJECTIVE: To compare the therapeutic effect of Bacille Calmette-Guerin (BCG) intravesical instillation in older and younger patients with high-risk non-muscle-invasive bladder cancer. The comparison was performed with propensity score matching (PSM) without terminating the death of the older patients using relatively large-scale retrospective data from multiple institutes in Japan. MATERIALS AND METHODS: Overall, 3283 patients diagnosed with non-muscle-invasive bladder cancer treated with intravesical BCG instillation during 2000-2018 in 31 institutes were examined; 1437 and 602 patients with high-grade T1 and Tis tumors were divided into those aged >/=75 and <75 years. Multivariate analysis using the Fine-Gray competing risks regression model before PSM and survival analysis using the cumulative incidence method after PSM were performed. RESULTS: In the pre-PSM series of high-grade T1 tumors, age >/=75 years was an independent prognostic factor for both recurrence and progression in multivariate analysis (P = .015 and P = .013). In the pre-PSM series with Tis tumor, no variables to predict recurrence and progression was found. In the post-PSM series of 870 high-grade T1 tumors, cumulative probability of recurrence after BCG intravesical instillation were significantly higher in patients aged >/=75 years than in those aged <75 years (P = .008). The frequency of discontinuation of BCG instillation in patients aged >/=75 years with high-grade T1 and Tis was not significantly different from those in patients aged <75 years (P = .564 and P = .869). CONCLUSION: The cumulative probability of recurrence after intravesical BCG instillation was significantly higher in older than in younger patients with high-grade T1 bladder cancer. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Inoue, Takamitsu AU - Inoue T AD - Department of Renal and Urological Surgery, International University of Health and Welfare, Narita, Chiba, Japan; Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Electronic address: takmitz@gmail.com. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan. FAU - Onozawa, Mizuki AU - Onozawa M AD - Department of Renal and Urological Surgery, International University of Health and Welfare, Narita, Chiba, Japan. FAU - Kashima, Soki AU - Kashima S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Narita, Shintaro AU - Narita S AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University Graduate School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Kagawa University Faculty of Medicine, Takamatsu, Kagawa, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, University of Toyama Faculty of Medicine, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, University of Toyama Faculty of Medicine, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba Faculty of Medicine, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University Graduate School of Medicine, Kashihara, Nara, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. LA - eng PT - Journal Article DEP - 20220611 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Urology. 2023 Mar;173:229. doi: 10.1016/j.urology.2022.10.031. PMID: 36587796 MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/therapeutic use MH - Humans MH - Japan/epidemiology MH - Neoplasm Recurrence, Local/drug therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology EDAT- 2022/06/15 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/06/14 19:22 PHST- 2022/02/16 00:00 [received] PHST- 2022/04/09 00:00 [revised] PHST- 2022/05/30 00:00 [accepted] PHST- 2022/06/15 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/06/14 19:22 [entrez] AID - S0090-4295(22)00455-1 [pii] AID - 10.1016/j.urology.2022.05.034 [doi] PST - ppublish SO - Urology. 2022 Sep;167:158-164. doi: 10.1016/j.urology.2022.05.034. Epub 2022 Jun 11. PMID- 35690361 OWN - NLM STAT- MEDLINE DCOM- 20220622 LR - 20230302 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 103 DP - 2022 Jul TI - Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study. PG - 106693 LID - S1743-9191(22)00470-8 [pii] LID - 10.1016/j.ijsu.2022.106693 [doi] AB - INTRODUCTION: Although radical cystectomy is considered as the first choice for muscle-invasive bladder cancer (MIBC), there are also concerns regarding the cost of long-term morbidity, loss of body image, and compromised quality of life. Transurethral resection of bladder tumor (TURBT) is a candidate for bladder sparing treatments, but its viability as a substitute for radical cystectomy is questionable. Therefore, we conducted this population-based study to investigate the prevalence of TURBT in the treatments of T2-stage MIBC in the United States, and to compare its therapeutic efficiency with that of radical cystectomy. METHODS: Information on patients with T2-stage bladder cancer (BC) between 2000 and 2017 was extracted from the Surveillance, Epidemiology, and End Results program. The overall survival (OS) and disease-specific survival (DSS) of patients with different interventions were fitted. RESULTS: A total of 22,074 patients with T2-stage MIBC were enrolled, of whom 14,021 reached the main endpoint. Only 28% of the patients with T2-stage MIBC chose radical cystectomy as the initial surgical treatment, while TURBT was applied as the primary surgical treatment in 66.6% of the patients. The TURBT rate increased significantly with age at cancer diagnosis (40-44 years, 45.5% to > 85 years, 90.9%). The survival rate of patients undergoing TURBT was significantly lower than for those undergoing radical cystectomy (median OS: 1.5 versus 9.7 years; median DSS: 2.7 years versus not reached). Upon multivariable Cox analyses, the OS (HR: 2.34; p < 0.001) and DSS (HR: 2.68; p < 0.001) of TURBT were found to be significantly worse than those of radical cystectomy. CONCLUSION: Two-thirds of the patients with T2-stage MIBC were treated by TURBT in the United States. However, the long-term follow-up data indicate that the therapeutic efficiency of current TURBT techniques is far less effective than that of radical cystectomy. Further studies are urgently needed to devise the best management strategy for T2 stage bladder cancer. CI - Copyright (c) 2022 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. FAU - Zheng, Yongqiang AU - Zheng Y AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Ye, Yuzhong AU - Ye Y AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. FAU - Chen, Jiayuan AU - Chen J AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. FAU - Wei, Zhihao AU - Wei Z AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. FAU - Liu, Zekun AU - Liu Z AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. Electronic address: liuzk@sysucc.org.cn. FAU - Yu, Kai AU - Yu K AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. Electronic address: yukai@sysucc.org.cn. FAU - Zhang, Xiaoping AU - Zhang X AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Electronic address: xzhang@hust.edu.cn. LA - eng PT - Journal Article DEP - 20220609 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM CIN - Int J Surg. 2022 Aug;104:106802. doi: 10.1016/j.ijsu.2022.106802. PMID: 35964926 CIN - Int J Surg. 2022 Nov;107:106894. doi: 10.1016/j.ijsu.2022.106894. PMID: 36265779 MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscles/pathology MH - Neoplasm Invasiveness/pathology MH - Prevalence MH - Quality of Life MH - Retrospective Studies MH - Treatment Outcome MH - United States/epidemiology MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/epidemiology/pathology/surgery OTO - NOTNLM OT - Muscle-infiltrating bladder cancer OT - Prevalence OT - Prognosis OT - Radical cystectomy OT - Surveillance epidemiology and end results database OT - Transurethral resection of bladder tumor EDAT- 2022/06/12 06:00 MHDA- 2022/06/23 06:00 CRDT- 2022/06/11 19:28 PHST- 2021/11/30 00:00 [received] PHST- 2022/05/05 00:00 [revised] PHST- 2022/05/29 00:00 [accepted] PHST- 2022/06/12 06:00 [pubmed] PHST- 2022/06/23 06:00 [medline] PHST- 2022/06/11 19:28 [entrez] AID - S1743-9191(22)00470-8 [pii] AID - 10.1016/j.ijsu.2022.106693 [doi] PST - ppublish SO - Int J Surg. 2022 Jul;103:106693. doi: 10.1016/j.ijsu.2022.106693. Epub 2022 Jun 9. PMID- 35689462 OWN - NLM STAT- MEDLINE DCOM- 20230228 LR - 20230228 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 20 IP - 2 DP - 2023 Feb 27 TI - Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial. PG - 123-128 LID - 10.22037/uj.v19i.7194 [doi] AB - PURPOSE: The most common adjuvant therapy known for non-invasive muscle bladder cancer (NMIBC) is intravesical Bacillus Calmette-Guerin (BCG). Intravesical chemotherapy drugs like gemcitabine can also be used post-TURBT, which is considered as a good alternative for BCG, or can be used as a second-line treatment. Due to the common side effects of BCG, the use of chemotherapy drugs as intravesical treatments is currently increasing. MATERIALS AND METHODS: 117 intermediate-risk NMIBC cases were included in this study. All the patients underwent TURBT surgery and received 1 gr intravesical gemcitabine immediately after performing the surgery. The patients were then divided into two groups, either receiving intravesical gemcitabine or intravesical BCG weekly for 6 weeks. The patients were followed up with cystoscopy. RESULTS: Most patients were men who had smoking risk factors. The youngest patient was 36 years old and the oldest one was 88 years old. The rate of side effects in the group receiving gemcitabine (13.6%) was much lower than the group receiving BCG (44.8%). (P-value = 0.016). The recurrence rate during a one year period was lower in the group consisting of patients receiving gemcitabine compared to the group receiving BCG (19 patients vs. 23 patients) (p-value = 0.401) Conclusion: The efficacy of intravesical gemcitabine and intravesical BCG was almost equal in the treatment of intermediate-risk NMIBCs. The adverse effects of gemcitabine were found to be significantly lower than BCG. Due to causing fewer complications, gemcitabine can be known as a good alternative, especially among elderly patients with comorbidities. FAU - Ansari Djafari, Anahita AU - Ansari Djafari A AD - Urology Department , School of Medicine , Shahid Beheshti University of Medical Sciences, Tehran, Iran. d_ansary@yahoo.com. FAU - Javanmard, Babak AU - Javanmard B AD - Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drbabakjavanmard@gmail.com. FAU - Razzaghi, Mohammadreza AU - Razzaghi M AD - Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mohammadrezarazzaghi@yahoo.com. FAU - Hojjati, Seyyed Ali AU - Hojjati SA AD - Urology Department , School of Medicine , Shahid Beheshti University of Medical Sciences, Tehran, Iran. sah_hojjati@yahoo.com. FAU - Razzaghi, Zahra AU - Razzaghi Z AD - Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. z.razzaghi@sbmu.ac.ir. FAU - Faraji, Saba AU - Faraji S AD - Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. saba_faraji@yahoo.com. FAU - Rahavian, Amirhossein AU - Rahavian A AD - Andrology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. amirrahavian@yahoo.com. FAU - Garoosi, Maryam AU - Garoosi M AD - Radiation Oncology Department, Iran University of Medical Sciences, Tehran, Iran. garousi.m@iums.ac.ir. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20230227 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (Gemcitabine) RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Male MH - Humans MH - Aged MH - Adult MH - Aged, 80 and over MH - Female MH - Gemcitabine MH - BCG Vaccine/therapeutic use MH - *Non-Muscle Invasive Bladder Neoplasms MH - Adjuvants, Immunologic/therapeutic use MH - *Urinary Bladder Neoplasms/drug therapy MH - Administration, Intravesical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy EDAT- 2022/06/12 06:00 MHDA- 2023/03/03 06:00 CRDT- 2022/06/11 04:22 PHST- 2022/06/12 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/06/11 04:22 [entrez] AID - 7194 [pii] AID - 10.22037/uj.v19i.7194 [doi] PST - epublish SO - Urol J. 2023 Feb 27;20(2):123-128. doi: 10.22037/uj.v19i.7194. PMID- 35686410 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20220613 IS - 1681-7168 (Electronic) IS - 1022-386X (Linking) VI - 32 IP - 6 DP - 2022 Jun TI - Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C. PG - 768-772 LID - 10.29271/jcpsp.2022.06.768 [doi] AB - OBJECTIVE: To assess the effect of the urinary pH value on the efficacy of a postoperative single instillation of mitomycin-C. STUDY DESIGN: A descriptive study. PLACE AND DURATION OF STUDY: Department of Urology, Ankara Numune Training and Research Hospital, Ankara, Turkey from 2011 to 2016. METHODOLOGY: Patients newly diagnosed with low-risk non-muscle invasive bladder cancer and given a postoperative single instillation of mitomycin-C were retrospectively reviewed. The demographic data and pre-instillation urinary pH values of the patients were recorded. All patients included in the study (n=117) were followed up for five years. The primary outcome was the time to the first recurrence. The patients were divided into two groups: Group 1 consisted of 87 patients with no recurrence and Group 2 comprised 30 patients that had recurrence during the follow-up. RESULTS: The mean pre-instillation urinary pH value was significantly lower in Group 2 than in Group 1 (5.89 vs. 5.37, p <0.001). The receiver operating characteristic analysis revealed that the cut-off value of urinary pH in predicting recurrence was 5.25. The patients with a urinary pH value of 5.25 or greater had significantly higher recurrence-free survival rates. CONCLUSIONS: The patients with higher urinary pH before a single instillation of mitomycin-C had better recurrence-free survival. KEY WORDS: Bladder cancer, Mitomycin-C, Single instillation, Urinary pH. FAU - Senel, Cagdas AU - Senel C AD - Department of Urology, Balikesir University School of Medicine, Balikesir, Turkey. FAU - Asfuroglu, Ahmet AU - Asfuroglu A AD - Department of Urology, University of Health Sciences School of Medicine, Ankara State Hospital, Ankara, Turkey. FAU - Aykanat, Ibrahim Can AU - Aykanat IC AD - Department of Urology, Ministry of Health, Yozgat State Hospital, Yozgat, Turkey. FAU - Balci, Melih AU - Balci M AD - Department of Urology, University of Health Sciences School of Medicine, Ankara State Hospital, Ankara, Turkey. FAU - Aslan, Yilmaz AU - Aslan Y AD - Department of Urology, University of Health Sciences School of Medicine, Ankara State Hospital, Ankara, Turkey. FAU - Tuncel, Altug AU - Tuncel A AD - Department of Urology, University of Health Sciences School of Medicine, Ankara State Hospital, Ankara, Turkey. LA - eng PT - Journal Article PL - Pakistan TA - J Coll Physicians Surg Pak JT - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP JID - 9606447 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/therapeutic use MH - Humans MH - Hydrogen-Ion Concentration MH - *Mitomycin/therapeutic use MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery EDAT- 2022/06/11 06:00 MHDA- 2022/06/14 06:00 CRDT- 2022/06/10 03:24 PHST- 2021/11/14 00:00 [received] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/06/10 03:24 [entrez] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/14 06:00 [medline] AID - 040579197 [pii] AID - 10.29271/jcpsp.2022.06.768 [doi] PST - ppublish SO - J Coll Physicians Surg Pak. 2022 Jun;32(6):768-772. doi: 10.29271/jcpsp.2022.06.768. PMID- 35681556 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260730 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 11 DP - 2022 May 24 TI - Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. LID - 10.3390/cancers14112578 [doi] LID - 2578 AB - Within the last forty years, seminal contributions have been made in the areas of bladder cancer (BC) biology, driver genes, molecular profiling, biomarkers, and therapeutic targets for improving personalized patient care. This overview includes seminal discoveries and advances in the molecular oncology of BC. Starting with the concept of divergent molecular pathways for the development of low- and high-grade bladder tumors, field cancerization versus clonality of bladder tumors, cancer driver genes/mutations, genetic polymorphisms, and bacillus Calmette-Guerin (BCG) as an early form of immunotherapy are some of the conceptual contributions towards improving patient care. Although beginning with a promise of predicting prognosis and individualizing treatments, "-omic" approaches and molecular subtypes have revealed the importance of BC stem cells, lineage plasticity, and intra-tumor heterogeneity as the next frontiers for realizing individualized patient care. Along with urine as the optimal non-invasive liquid biopsy, BC is at the forefront of the biomarker field. If the goal is to reduce the number of cystoscopies but not to replace them for monitoring recurrence and asymptomatic microscopic hematuria, a BC marker may reach clinical acceptance. As advances in the molecular oncology of BC continue, the next twenty-five years should significantly advance personalized care for BC patients. FAU - Lokeshwar, Soum D AU - Lokeshwar SD AD - Department of Urology, Yale University School of Medicine, New Haven, CT 06520, USA. FAU - Lopez, Maite AU - Lopez M AD - Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. FAU - Sarcan, Semih AU - Sarcan S AUID- ORCID: 0000-0002-0237-0449 AD - Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. AD - Department of Urology, University Hospital Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany. FAU - Aguilar, Karina AU - Aguilar K AD - Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. FAU - Morera, Daley S AU - Morera DS AD - Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. FAU - Shaheen, Devin M AU - Shaheen DM AD - Yale School of Nursing, Yale University, New Haven, CT 06520, USA. FAU - Lokeshwar, Bal L AU - Lokeshwar BL AUID- ORCID: 0000-0002-1763-4718 AD - Georgia Cancer Center, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. AD - Research Service, Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. FAU - Lokeshwar, Vinata B AU - Lokeshwar VB AD - Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA. LA - eng GR - I01 BX003862/BX/BLRD VA/United States GR - R01 CA227277/CA/NCI NIH HHS/United States GR - 1R01CA227277-04;/NH/NIH HHS/United States PT - Journal Article PT - Review DEP - 20220524 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9179261 OTO - NOTNLM OT - bladder cancer stem cells OT - genomic/transcriptomic profiling OT - intra-tumor heterogeneity OT - lineage plasticity OT - molecular oncology OT - molecular subtypes OT - prognostic markers OT - urine biomarkers COIS- The authors declare no conflict of interest. EDAT- 2022/06/11 06:00 MHDA- 2022/06/11 06:01 PMCR- 2022/05/24 CRDT- 2022/06/10 01:08 PHST- 2022/04/14 00:00 [received] PHST- 2022/05/19 00:00 [revised] PHST- 2022/05/20 00:00 [accepted] PHST- 2022/06/10 01:08 [entrez] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/11 06:01 [medline] PHST- 2022/05/24 00:00 [pmc-release] AID - cancers14112578 [pii] AID - cancers-14-02578 [pii] AID - 10.3390/cancers14112578 [doi] PST - epublish SO - Cancers (Basel). 2022 May 24;14(11):2578. doi: 10.3390/cancers14112578. PMID- 35677889 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1687-8450 (Print) IS - 1687-8469 (Electronic) IS - 1687-8450 (Linking) VI - 2022 DP - 2022 TI - Assessment of Therapeutic Benefit and Option Strategy on Intravesical Instillation for Preventing Bladder Cancer Recurrence after Radical Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma. PG - 1755368 LID - 10.1155/2022/1755368 [doi] LID - 1755368 AB - OBJECTIVE: Upper urinary tract urothelial carcinoma (UUT-UC) is a very aggressive disease, characterized by 22%-50% of patients suffering from subsequent bladder recurrence after radical nephroureterectomy (RNU). Although the therapy of intravesical instillation is reported to be effective in preventing bladder recurrence, no study had been reported in Northeast China. The findings relating to the clinical effectiveness of intravesical instillation after RNU are somewhat controversial, and the best efficacy and least adverse effects of instillation drugs have not been widely accepted. Here, we aimed at evaluating the efficacy of intravesical instillation for the prevention intravesical recurrence systematically. METHODS: In this retrospective cohort study, from October 2006 to September 2017, 158 UUT-UC patients underwent RNU were divided into 4 groups: epirubicin (EPB) instillation group, hydroxycamptothecin (HCPT) instillation group, bacillus Calmette-Guerin (BCG) instillation group, and noninstillation group. Cox univariate and multivariate analyses were employed to identify the risk factors for intravesical recurrence-free survival (IVRFS). The nomogram model was also applied to predict patient outcomes. Subsequently, to evaluate the clinical significance of intravesical instillation comprehensively, several databases including PubMed, Ovid, and Embase were searched and data from published studies with our results were combined by direct meta-analysis. Moreover, a network meta-analysis comparing instillation therapies was conducted to evaluate the clinical efficacy of different instillation drugs. RESULTS: In our retrospective cohort study, the Kaplan-Meier survival curve demonstrated noninstillation groups were associated with worsened IVRFS. Meanwhile, multivariate analysis indicated that intravesical instillation was independent protective factors for IVRFS (hazard ratio [HR] = 0.731). Moreover, calibration plots, receiver operating characteristic (ROC) curves, area under the curve (AUC) values, and the C-index showed the priority of nomogram's predictive accuracy. Next, direct meta-analysis including 19 studies showed that intravesical instillation could prevent the recurrence of bladder cancer with a pooled risk ratio (RR) estimate of 0.53. Subgroup analysis by study type, year of intravesical recurrence, first instillation time, and instillation times also confirmed the robustness of the results. Moreover, intraoperative instillation was associated with a decrease in the risk of bladder recurrence compared with postoperative instillation. Then, a network meta-analysis including 7 studies indicated that pirarubicin (THP) (surface under the cumulative ranking curve [SUCRA] = 89.2%) is the most effective therapy to reduce the risk of bladder recurrence, followed by BCG (SUCRA = 83.5%), mitomycin C (MMC) (SUCRA = 53.6%), EPB (SUCRA = 52.6%), and HCPT (SUCRA = 5.1%) after the analysis of the value ranking. CONCLUSIONS: A maintenance schedule of intravesical instillation prevents the recurrence of bladder cancer after RNU in UUT-UC patients effectively. Large, prospective trials are needed to further confirm its value. Compared with other chemotherapy regimens, THP may be a promising drug with favorable efficacy to prevent bladder recurrence. As included studies had moderate risk of bias, the results of network meta-analysis should be applied with caution. CI - Copyright (c) 2022 Bo Fan et al. FAU - Fan, Bo AU - Fan B AUID- ORCID: 0000-0001-6598-3237 AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Teng, Qiliang AU - Teng Q AUID- ORCID: 0000-0002-8206-6278 AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Sun, Min AU - Sun M AUID- ORCID: 0000-0001-5883-0363 AD - Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442099, China. FAU - Wang, Yingzi AU - Wang Y AUID- ORCID: 0000-0002-6540-2428 AD - Department of International Medical, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Wang, Yutong AU - Wang Y AUID- ORCID: 0000-0002-2250-5670 AD - First Clinical College, Dalian Medical University, Dalian 116000, China. FAU - Lin, Zhe AU - Lin Z AUID- ORCID: 0000-0001-6743-3917 AD - Ethics Committee, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Wang, Yuchao AU - Wang Y AUID- ORCID: 0000-0001-9597-5289 AD - Second Clinical College, Dalian Medical University, Dalian 116000, China. FAU - Duan, Xu AU - Duan X AUID- ORCID: 0000-0002-6620-4108 AD - First Clinical College, Dalian Medical University, Dalian 116000, China. FAU - Zhang, Liren AU - Zhang L AUID- ORCID: 0000-0001-6814-1879 AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Chen, Tingyu AU - Chen T AUID- ORCID: 0000-0003-3369-3731 AD - Second Clinical College, Dalian Medical University, Dalian 116000, China. FAU - Chen, Sishan AU - Chen S AUID- ORCID: 0000-0001-9593-7039 AD - Department of Anesthesia, Dalian Medical University, Dalian 116000, China. FAU - Tai, Yu AU - Tai Y AUID- ORCID: 0000-0002-5367-2068 AD - Department of Anesthesia, Dalian Medical University, Dalian 116000, China. FAU - Zhang, Ce AU - Zhang C AUID- ORCID: 0000-0001-7350-4187 AD - Director of the Development Planning and Quality Management Department, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. FAU - Song, Xishuang AU - Song X AUID- ORCID: 0000-0001-5720-3077 AD - Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China. FAU - Liu, Zhiyu AU - Liu Z AUID- ORCID: 0000-0002-6024-7836 AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China. LA - eng PT - Journal Article DEP - 20220530 PL - Egypt TA - J Oncol JT - Journal of oncology JID - 101496537 PMC - PMC9170511 COIS- All authors declare that there are no conflicts in this study. EDAT- 2022/06/10 06:00 MHDA- 2022/06/10 06:01 PMCR- 2022/05/30 CRDT- 2022/06/09 02:24 PHST- 2022/01/08 00:00 [received] PHST- 2022/04/26 00:00 [revised] PHST- 2022/04/30 00:00 [accepted] PHST- 2022/06/09 02:24 [entrez] PHST- 2022/06/10 06:00 [pubmed] PHST- 2022/06/10 06:01 [medline] PHST- 2022/05/30 00:00 [pmc-release] AID - 10.1155/2022/1755368 [doi] PST - epublish SO - J Oncol. 2022 May 30;2022:1755368. doi: 10.1155/2022/1755368. eCollection 2022. PMID- 35677058 OWN - NLM STAT- MEDLINE DCOM- 20220610 LR - 20220716 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen. PG - 903297 LID - 10.3389/fimmu.2022.903297 [doi] LID - 903297 AB - Bacillus Calmette-Guerin (BCG) is the gold standard adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). However, given the current global shortage of BCG, new treatments are needed. We evaluated tumor microenvironment markers as potential BCG alternatives for NMIBC treatment. Programmed death-ligand 1, human epidermal growth factor receptor-2 (HER2), programmed cell death-1 (PD1), CD8, and Ki67 levels were measured in treatment-naive NMIBC and MIBC patients (pTa, pT1, and pT2 stages). Univariate and multivariate Cox proportional hazard models were used to determine the impact of these markers and other clinicopathological factors on survival, recurrence, and progression. EP263, IM142, PD1, and Ki67 levels were the highest in the T2 stage, followed by the T1 and Ta stages. HER2 and IM263 expressions were higher in the T1 and T2 stages than in the Ta stage. In NMIBC, the significant prognostic factors for recurrence-free survival were adjuvant therapy, tumor grade, and HER2 positivity, whereas those for progression-free survival included age, T-stage, and IM263. Age, T-stage, EP263, PD1, CD8, and Ki67 levels were significant factors associated with overall survival. IM263 and HER2 are potential biomarkers for progression and recurrence, respectively. Therefore, we propose HER2 as a potential target antigen for intravesical therapeutics as a BCG alternative. CI - Copyright (c) 2022 Chae, Nam, Kim, Lim, Noh, Kim, Kang, Park, Eom and Kim. FAU - Chae, Han Kyu AU - Chae HK AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Nam, Wook AU - Nam W AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Kim, Han Gwun AU - Kim HG AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Lim, Sharon AU - Lim S AD - Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Noh, Byeong-Joo AU - Noh BJ AD - Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Kim, So Won AU - Kim SW AD - Department of Parmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Kang, Gil Hyun AU - Kang GH AD - Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Park, Jong Yeon AU - Park JY AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Eom, Dae-Woon AU - Eom DW AD - Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. FAU - Kim, Sung Jin AU - Kim SJ AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220523 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) SB - IM MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor MH - Humans MH - Ki-67 Antigen MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9167936 OTO - NOTNLM OT - ADC (antibody-drug conjugate) OT - BCG (Bacillus Calmette-Guerin) OT - CD8 OT - HER2 (human epidermal growth factor receptor-2) OT - PD-L1 OT - PD1 OT - ki67 COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/10 06:00 MHDA- 2022/06/11 06:00 PMCR- 2022/01/01 CRDT- 2022/06/09 02:06 PHST- 2022/03/24 00:00 [received] PHST- 2022/04/25 00:00 [accepted] PHST- 2022/06/09 02:06 [entrez] PHST- 2022/06/10 06:00 [pubmed] PHST- 2022/06/11 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.903297 [doi] PST - epublish SO - Front Immunol. 2022 May 23;13:903297. doi: 10.3389/fimmu.2022.903297. eCollection 2022. PMID- 35676678 OWN - NLM STAT- MEDLINE DCOM- 20220610 LR - 20230916 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Jun 8 TI - Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor. PG - 631 LID - 10.1186/s12885-022-09733-8 [doi] LID - 631 AB - BACKGROUND: Non-muscle invasive bladder cancer can be controlled by transurethral resection of bladder (TURB), but suffers from frequent recurrences in 60-70% of cases. Although, recurrence interval after TURB influences treatment course and prognosis, its implication and risk factors have not been fully elucidated. We evaluated the risk factors of early (within 1 yr) and late (after 1 yr) recurrence of pTa bladder cancer and clinical significance of recurrence interval on disease progression and overall survival. METHODS: In this study, pTa bladder cancer patients enrolled in prospective patient registry system of Seoul National University, SUPER-UC, were retrospectively examined to determine the clinical risk factors for recurrence and its significance regarding to recurrence interval. A total of 1067 bladder cancer patients who underwent TURB between March 20 and June 2021 were included and classified into three groups of no recurrence, early, or late recurrence to be comparatively analyzed. RESULTS: Early recurrence was associated with poorer cystectomy-free survival and overall survival than late recurrence. Risk factors for early recurrence included a high number of previous TURB, tumor multiplicity, tumor location, tumor shape, incompleteness of TURB, and high tumor grade. Otherwise, late recurrence was associated with low-grade tumors with insufficient TURB depth. CONCLUSION: Patients with risk factors for early recurrence should be closely followed up with special cautions. CI - (c) 2022. The Author(s). FAU - Jeong, Seung-Hwan AU - Jeong SH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Han, Jang Hee AU - Han JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. armenia8@snu.ac.kr. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. armenia8@snu.ac.kr. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. kuuro70@snu.ac.kr. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. kuuro70@snu.ac.kr. LA - eng GR - 2018R1D1A1B07041191/Ministry of Education/ GR - 0320202190/Seoul National University Hospital/ PT - Journal Article DEP - 20220608 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9175350 OTO - NOTNLM OT - Recurrence OT - TURB OT - Ta bladder cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/09 06:00 MHDA- 2022/06/11 06:00 PMCR- 2022/06/08 CRDT- 2022/06/08 23:40 PHST- 2022/01/02 00:00 [received] PHST- 2022/05/25 00:00 [accepted] PHST- 2022/06/08 23:40 [entrez] PHST- 2022/06/09 06:00 [pubmed] PHST- 2022/06/11 06:00 [medline] PHST- 2022/06/08 00:00 [pmc-release] AID - 10.1186/s12885-022-09733-8 [pii] AID - 9733 [pii] AID - 10.1186/s12885-022-09733-8 [doi] PST - epublish SO - BMC Cancer. 2022 Jun 8;22(1):631. doi: 10.1186/s12885-022-09733-8. PMID- 35676172 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221201 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. PG - 490.e13-490.e20 LID - S1078-1439(22)00186-7 [pii] LID - 10.1016/j.urolonc.2022.05.016 [doi] AB - INTRODUCTION: Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis. MATERIALS AND METHODS: Patients with non-muscle invasive bladder cancer from 13 hospitals and academic institutions were identified and treated, from January 1, 2002, until December 31, 2012, with TURB and a subsequent re-TURB for restaging before receiving BCG. Follow-up was performed with urine cytology and cystoscopy every 3 months for 1 year and, successively every 6 months. Univariate and multivariate Cox regression models addressed the response to BCG therapy. Kaplan-Meier overall survival (OS) and cancer-specific survival (CSS) estimates were determined for BCG responsive vs. BCG unresponsive patients. RESULTS: A total of 1,228 patients with non-muscle invasive bladder cancer were enrolled. Of 257 (20.9%) patients were BCG unresponsive. Independent predictive factors for response to BCG were: multifocality (HR: 1.4; 95% CI 1.05-1.86; P = 0.019), lymphovascular invasion (HR: 1.75; 95% CI 1.22-2.49; P = 0.002) and high-grade on re-TURB (HR: 1.39; 95% CI 1.02-1.91; P = 0.037). Overall survival was significantly reduced in BCG-unresponsive patients compared to BCG-responsive patients at 5 years (82.9% vs. 92.4%, P < 0.0001) and at 10 years (44.2% vs. 74.4%, P < 0.0001). Similarly, cancer-specific survival was reduced in BCG-unresponsive patients at 5 years (90.6% vs. 97.3%, P < 0.0001) and at 10 years (72.3% vs. 87.2%, P < 0.0001). CONCLUSION: Multifocality, lymphovascular invasion, and high-grade on re-TURB were independent predictors for response to BCG treatment. BCG-unresponsive patients reported worse oncological outcomes. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Barone, Biagio AU - Barone B AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Bari, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Crocerossa, Fabio AU - Crocerossa F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Genoa, Italy. FAU - Bove, Pier Luigi AU - Bove PL AD - Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy. FAU - Papalia, Rocco AU - Papalia R AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, Chieti, Italy. FAU - La Civita, Evelina AU - La Civita E AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Piccinelli, Mattia AU - Piccinelli M AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy. FAU - Marmiroli, Andrea AU - Marmiroli A AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Schips, Luigi AU - Schips L AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, Chieti, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan IRCCS, Milan. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan IRCCS, Milan. FAU - Perdona, Sisto AU - Perdona S AD - Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Del Prete, Paola AU - Del Prete P AD - Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy. FAU - Tataru, Octavian Sabin AU - Tataru OS AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, Targu Mures, Romania. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, Targu Mures, Romania; Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20220605 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - BCG Vaccine/therapeutic use MH - Retrospective Studies MH - Neoplasm Recurrence, Local/diagnosis MH - Neoplasm Invasiveness MH - Disease Progression MH - Administration, Intravesical MH - Adjuvants, Immunologic/therapeutic use OTO - NOTNLM OT - BCG OT - Non-muscle invasive bladder cancer OT - re-TURB COIS- Conflict of interests The authors declare that they have no conflict of interest. EDAT- 2022/06/09 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/06/08 22:04 PHST- 2022/03/14 00:00 [received] PHST- 2022/04/05 00:00 [revised] PHST- 2022/05/10 00:00 [accepted] PHST- 2022/06/09 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/06/08 22:04 [entrez] AID - S1078-1439(22)00186-7 [pii] AID - 10.1016/j.urolonc.2022.05.016 [doi] PST - ppublish SO - Urol Oncol. 2022 Nov;40(11):490.e13-490.e20. doi: 10.1016/j.urolonc.2022.05.016. Epub 2022 Jun 5. PMID- 35675636 OWN - NLM STAT- MEDLINE DCOM- 20221010 LR - 20221207 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 52 IP - 10 DP - 2022 Oct 6 TI - The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study. PG - 1201-1207 LID - 10.1093/jjco/hyac095 [doi] AB - OBJECTIVE: Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer; however, a substantial number of patients with muscle-invasive bladder cancer are not appropriate candidates to radical cystectomy due to co-morbidities or anxiety regarding bladder preservation. Trimodal bladder-sparing therapy is an intelligent and attractive treatment option for such patients. We established a novel treatment strategy using trimodal treatment with gemcitabine and cisplatin. METHODS: Patients diagnosed with muscle-invasive bladder cancer by transurethral resection of bladder tumor and who wished for bladder preservation were recruited. The regimens were gemcitabine 300 mg/m2 and cisplatin 30 mg/m2 in day 1 and concomitant irradiation 1.8 Gy/Fr, five fractions per week. Irradiation was administered to the true pelvis up to 36 Gy and was then boosted to the entire bladder until a total of 54 Gy. Transurethral resection of bladder tumor was also performed after chemoradiotherapy to evaluate pathological response to treatment. We evaluated treatment efficacy and survival, safety of chemoradiotherapy with gemcitabine and cisplatin. RESULTS: Thirty-eight patients were enrolled, and three patients were excluded. Pathological complete response after chemoradiotherapy was observed in 31 patients, and the 5-year bladder-intact metastasis-free survival rate was 76%. The 5-year cancer-specific and overall survival rates for chemoradiotherapy were 85 and 75%, respectively, which were not significantly different from those for radical cystectomy (73 and 71%, respectively). Grade 3/4 adverse events included neutropenia (63%), anemia (18%) and thrombocytopenia (37%); however, treatment-related deaths were not observed. CONCLUSIONS: Chemoradiotherapy using gemcitabine and cisplatin for muscle-invasive bladder cancer is effective for local cancer control and shows no significant difference in oncological prognosis compared with radical cystectomy. CI - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Kobayashi, Keita AU - Kobayashi K AUID- ORCID: 0000-0001-9279-3156 AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AUID- ORCID: 0000-0003-0568-1258 AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. FAU - Misumi, Taku AU - Misumi T AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. FAU - Ito, Hideaki AU - Ito H AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. FAU - Hirata, Hiroshi AU - Hirata H AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Shuto General Hospital, Yanai city, Yamaguchi, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AUID- ORCID: 0000-0001-5607-7769 AD - Department of Urology, Graduate School of Medicine, Ymaguchi University, Ube sity, Yamaguchi, Japan. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols MH - Chemoradiotherapy/adverse effects MH - Cisplatin MH - Combined Modality Therapy MH - Cystectomy MH - Deoxycytidine/analogs & derivatives MH - Humans MH - Muscles/pathology MH - Neoplasm Invasiveness MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/drug therapy MH - Gemcitabine OTO - NOTNLM OT - bladder cancer OT - chemoradiotherapy OT - cisplatin OT - cystectomy OT - gemcitabine EDAT- 2022/06/09 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/06/08 16:42 PHST- 2022/03/09 00:00 [received] PHST- 2021/05/22 00:00 [accepted] PHST- 2022/06/09 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/06/08 16:42 [entrez] AID - 6604440 [pii] AID - 10.1093/jjco/hyac095 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2022 Oct 6;52(10):1201-1207. doi: 10.1093/jjco/hyac095. PMID- 35670714 OWN - NLM STAT- MEDLINE DCOM- 20220824 LR - 20250728 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 304 IP - 3 DP - 2022 Sep TI - Multiparametric MRI Evaluation of VI-RADS for Bladder Tumors Located at the Ureteral Orifice. PG - 593-599 LID - 10.1148/radiol.220028 [doi] AB - Background The Vesical Imaging Reporting and Data System (VI-RADS) based on multiparametric MRI scans standardizes preoperative bladder cancer staging. However, limitations have been reported for VI-RADS, particularly for ureteral orifice tumors. Purpose To investigate the diagnostic performance and interobserver agreement of VI-RADS in evaluating muscle invasion for bladder tumors located at the ureteral orifice. Materials and Methods In this retrospective study, patients with histopathologically confirmed bladder cancer occurring at the ureteral orifice from January 2012 to November 2021 were analyzed. Two blinded radiologists independently scored multiparametric MRI scans according to VI-RADS. Interobserver agreement of the VI-RADS scores was evaluated with weighted kappa analysis. Receiver operating characteristic curve analysis was used to evaluate the diagnostic performance of the VI-RADS scores in the prediction of muscle invasion. Results A total of 78 patients (mean age, 67 years +/- 7 [SD]; age range, 46-90 years; 67 men) were included in the final analysis: 25 with non-muscle-invasive bladder cancer and 53 with muscle-invasive bladder cancer (MIBCa). At consensus reading, one (1%) case was scored as VI-RADS 1, 27 cases (35%) were scored as VI-RADS 2, six (8%) were scored as VI-RADS 3, 10 (13%) were scored as VI-RADS 4, and 34 (44%) were scored as VI-RADS 5. On comparison of the VI-RADS score with histopathologic findings, it was confirmed that the presence of muscle invasion was 0% (zero of one) for VI-RADS 1, 15% (four of 27) for VI-RADS 2, 83% (five of six) for VI-RADS 3, 100% (10 of 10) for VI-RADS 4, and 100% (34 of 34) for VI-RADS 5. The area under the receiver operating characteristic curve of VI-RADS in the detection of MIBCa was 0.96 (95% CI: 0.92, 1.00). Conclusion The Vesical Imaging Reporting and Data System could be used to accurately predict muscle invasion for bladder tumors occurring at the ureteral orifice. (c) RSNA, 2022 Online supplemental material is available for this article. FAU - Cai, Qian AU - Cai Q AUID- ORCID: 0000-0001-5671-7885 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Ling, Jian AU - Ling J AUID- ORCID: 0000-0001-5493-486X AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Kong, Lingmin AU - Kong L AUID- ORCID: 0000-0003-4945-7127 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Huang, Yiping AU - Huang Y AUID- ORCID: 0000-0001-9884-9472 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Lin, Yingyu AU - Lin Y AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Wen, Zhihua AU - Wen Z AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Li, Meiqin AU - Li M AUID- ORCID: 0000-0002-3063-5758 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Guo, Yan AU - Guo Y AUID- ORCID: 0000-0002-0267-7328 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). FAU - Wang, Huanjun AU - Wang H AUID- ORCID: 0000-0001-9089-7736 AD - From the Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Rd 2, Guangzhou 510080, PR China (Q.C., L.K., Y.H., Y.L., Z.W., M.L., Y.G., H.W.); and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China (J.L.). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220607 PL - United States TA - Radiology JT - Radiology JID - 0401260 SB - IM MH - Aged MH - Aged, 80 and over MH - Data Systems MH - Humans MH - Magnetic Resonance Imaging/methods MH - Male MH - Middle Aged MH - *Multiparametric Magnetic Resonance Imaging MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology EDAT- 2022/06/08 06:00 MHDA- 2022/08/25 06:00 CRDT- 2022/06/07 10:31 PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/08/25 06:00 [medline] PHST- 2022/06/07 10:31 [entrez] AID - 10.1148/radiol.220028 [doi] PST - ppublish SO - Radiology. 2022 Sep;304(3):593-599. doi: 10.1148/radiol.220028. Epub 2022 Jun 7. PMID- 35665684 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20220719 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 81 DP - 2022 Jul TI - YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. PG - 104092 LID - S2352-3964(22)00273-0 [pii] LID - 10.1016/j.ebiom.2022.104092 [doi] LID - 104092 AB - BACKGROUND: Despite the availability of several treatments for non-muscle-invasive bladder cancer (NMIBC), many patients are still not responsive to treatments, and the disease progresses. A new prognostic classifier can differentiate between treatment response and progression, and it could be used as a very important tool in patient decision-making regarding treatment options. In this study, we focused on the activation of Yes-associated protein 1 (YAP1), which is known to play a pivotal role in tumour progression and serves as a factor contributing to the mechanism of resistance to various relevant therapeutic agents. We further evaluated its potential as a novel prognostic agent. METHODS: We identified YAP1-associated gene signatures based on UC3-siYAP1 cells (n=8) and NMIBC cohort (n=460). Cross-validation was performed using 5 independent bladder cancer patient cohorts (n=1006). We also experimentally validated the changes of gene expression levels representing each subgroup. FINDINGS: The 976-gene signature based on YAP1-activation redefined three subgroups and had the benefits of Bacillus Calmette-Guerin (BCG) treatment in patients with NMIBC (hazard ratio 3.32, 95% CI 1.29-8.56, p = 0.01). The integrated analysis revealed that YAP1 activation was associated with the characterization of patients with high-risk NMIBC and the response to immunotherapy. INTERPRETATION: This study suggests that YAP1 activation has an important prognostic effect on bladder cancer progression and might be useful in the selection of immunotherapy. FUNDING: A funding list that contributed to this research can be found in the Acknowledgements section. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Baek, Seung-Woo AU - Baek SW AD - Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea; Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Republic of Korea. FAU - Mun, Jeong-Yeon AU - Mun JY AD - Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea. FAU - Jang, In-Hwan AU - Jang IH AD - Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea; Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Republic of Korea. FAU - Yang, Gi-Eun AU - Yang GE AD - Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea; Department of Health Sciences, The Graduated of Dong-A University, Busan 49315, Republic of Korea. FAU - Jeong, Mi-So AU - Jeong MS AD - Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Republic of Korea; Personalized Genomic Medicine Research Center, KRIBB, Daejeon 34141, Republic of Korea. FAU - Nam, Jong-Kil AU - Nam JK AD - Department of Urology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea. FAU - Chu, In-Sun AU - Chu IS AD - Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea; Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Republic of Korea. Electronic address: chu@kribb.re.kr. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biomedical Sciences, Dong-A University, Busan 49315, Republic of Korea; Department of Health Sciences, The Graduated of Dong-A University, Busan 49315, Republic of Korea. Electronic address: shleem@dau.ac.kr. LA - eng PT - Journal Article DEP - 20220602 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Immunologic Factors) RN - 0 (YAP-Signaling Proteins) RN - 0 (YAP1 protein, human) SB - IM CIN - Nat Rev Urol. 2022 Jul;19(7):383. doi: 10.1038/s41585-022-00620-2. PMID: 35711060 MH - Adjuvants, Immunologic MH - BCG Vaccine MH - Humans MH - Immunologic Factors/therapeutic use MH - Immunotherapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Prognosis MH - *Urinary Bladder Neoplasms/drug therapy/therapy MH - YAP-Signaling Proteins PMC - PMC9166372 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Immunotherapy OT - Non-muscle-invasive bladder cancer (NMIBC) OT - Prognosis OT - YAP1 COIS- Declaration of interests All the authors have declared no conflicts of interests. EDAT- 2022/06/07 06:00 MHDA- 2022/07/20 06:00 PMCR- 2022/06/02 CRDT- 2022/06/06 14:51 PHST- 2021/08/31 00:00 [received] PHST- 2022/05/19 00:00 [revised] PHST- 2022/05/19 00:00 [accepted] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/06/06 14:51 [entrez] PHST- 2022/06/02 00:00 [pmc-release] AID - S2352-3964(22)00273-0 [pii] AID - 104092 [pii] AID - 10.1016/j.ebiom.2022.104092 [doi] PST - ppublish SO - EBioMedicine. 2022 Jul;81:104092. doi: 10.1016/j.ebiom.2022.104092. Epub 2022 Jun 2. PMID- 35665310 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2347-5625 (Print) IS - 2349-6673 (Electronic) IS - 2347-5625 (Linking) VI - 9 IP - 6 DP - 2022 Jun TI - Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis. PG - 100063 LID - 10.1016/j.apjon.2022.04.002 [doi] LID - 100063 AB - OBJECTIVE: This study identified group patterns in the quality of life (QOL), as well as examining factors associated with group membership, among non-muscle invasive bladder cancer (NMIBC) survivors. METHODS: This was a cross-sectional study involving 278 participating NMIBC survivors. Mplus version 7.2 was used to perform the latent profile analysis of QOL using the EORTC QLQ-NMIBC-24. The participants' social support, self-efficacy, knowledge level, depression, perceived severity of and susceptibility of cancer recurrence, and their demographic and clinical characteristics were compared between the subgroups, with a logistic regression analysis being adopted to examine the factors associated with the QOL subgroups. RESULTS: The NMIBC survivors based on the QOL were classified into two subgroups: "QOL-high" (81.3%) and "QOL-low" (18.7%). Having >/= 3 disease recurrences, perceived susceptibility toward and severity of cancer recurrence, and having depressive symptoms were significantly associated with the "QOL-low" group. CONCLUSIONS: Participants with frequent recurrences of NMIBC, higher perceived susceptibility and severity levels, and depressive symptoms had lower QOL. Therefore, it is necessary to develop intervention programs targeting participants with these characteristics to improve their QOL. CI - (c) 2022 The Authors. FAU - Park, Jeongok AU - Park J AD - College of Nursing and Mo-Im Kim Nursing Research Institute, Faculty of Nursing, Yonsei University, Seoul, Republic of Korea. FAU - Choi, Young Deuk AU - Choi YD AD - College of Medicine, Faculty of Medicine, Yonsei University, Seoul, Republic of Korea. FAU - Lee, Kyoungjin AU - Lee K AD - College of Nursing and Brain Korea 21 FOUR Project, Yonsei University, Seoul, South Korea and College of Nursing, Faculty of Nursing, Kyungbok University, Namyangju, Republic of Korea. FAU - Seo, Miae AU - Seo M AD - College of Nursing and Mo-Im Kim Nursing Research Institute, Research Assistant, Yonsei University, Seoul, South Korea and Division of Nursing, Registered Nurse, Severance Hospital, Seoul, Republic of Korea. FAU - Cho, Ahyoung AU - Cho A AD - College of Nursing and Mo-Im Kim Nursing Research Institute, Research Assistant, Yonsei University, Seoul, Republic of Korea. FAU - Lee, Sejeong AU - Lee S AD - College of Nursing and Brain Korea 21 FOUR Project, Graduate Student, Yonsei University, Seoul, Republic of Korea. FAU - Nam, Keum-Hee AU - Nam KH AD - College of Nursing, Faculty of Nursing, Kosin University, Busan, Republic of Korea. LA - eng PT - Journal Article DEP - 20220412 PL - United States TA - Asia Pac J Oncol Nurs JT - Asia-Pacific journal of oncology nursing JID - 101673157 PMC - PMC9157190 OTO - NOTNLM OT - Cancer recurrence OT - Cancer survivors OT - Depression OT - Latent profile analysis OT - Non-muscle invasive bladder cancer OT - Quality of life EDAT- 2022/06/07 06:00 MHDA- 2022/06/07 06:01 PMCR- 2022/04/12 CRDT- 2022/06/06 14:27 PHST- 2021/12/01 00:00 [received] PHST- 2022/04/05 00:00 [accepted] PHST- 2022/06/06 14:27 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/07 06:01 [medline] PHST- 2022/04/12 00:00 [pmc-release] AID - S2347-5625(22)00121-4 [pii] AID - 100063 [pii] AID - 10.1016/j.apjon.2022.04.002 [doi] PST - epublish SO - Asia Pac J Oncol Nurs. 2022 Apr 12;9(6):100063. doi: 10.1016/j.apjon.2022.04.002. eCollection 2022 Jun. PMID- 38993366 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 8 IP - 2 DP - 2022 TI - The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis. PG - 211-228 LID - 10.3233/BLC-211653 [doi] AB - BACKGROUND: Effective oral treatment options for urothelial bladder cancer (BC) are lacking. Metformin, the most frequently used oral drug in type II diabetes mellitus, has putative anticancer properties and could, therefore, influence BC incidence and treatment outcomes. We systematically reviewed the current literature regarding the effect of metformin on BC incidence and oncological outcomes in non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). METHODS: This review was conducted according to the PRISMA guidelines. Literature was gathered through a systematic search in PubMed/Medline, EMBASE and the Cochrane library. Risk of bias was determined using the Cochrane risk-of-bias tool for randomized trials and the Newcastle-Ottawa Scale for non-randomized trials. Hazard ratios (HRs) were extracted and pooled in a random-effects meta-analysis. RESULTS: We reviewed 13 studies, including 3,315,320 patients, considering the risk of developing BC after metformin exposure and 9 studies, including 4,006 patients, on oncological outcomes of patients with BC. Metformin did not affect BC incidence (HR 0.97, 95% CI 0.87 -1.09) or oncological outcomes for NMIBC but did show a reduced risk of recurrence (HR 0.52, 95% CI 0.32 -0.84), cancer-specific mortality (HR 0.58, 95% CI 0.43 -0.78) and overall mortality (HR 0.66, 95% CI 0.47 -0.92) in MIBC. CONCLUSIONS: The role of metformin in the prevention and treatment of BC in patients remains unclear. Although a beneficial effect of metformin on treatment outcomes of certain stages of BC may exist, a definitive conclusion cannot be drawn. Prospective clinical trials are needed to assess the efficacy of metformin for BC treatment. CI - (c) 2022 - The authors. Published by IOS Press. FAU - van Hattum, Jons W AU - van Hattum JW AD - Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. FAU - de Ruiter, Ben Max AU - de Ruiter BM AD - Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. FAU - de Reijke, Theo M AU - de Reijke TM AD - Department of Urology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. FAU - Wilmink, Johanna W AU - Wilmink JW AD - Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. FAU - Molenaar, Remco J AU - Molenaar RJ AD - Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220603 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181685 OTO - NOTNLM OT - Metformin OT - epidemiology OT - pharmacology OT - urinary bladder neoplasms COIS- The authors JH, BR, TR, JO, JW and RM declare no conflict of interest. EDAT- 2022/06/03 00:00 MHDA- 2022/06/03 00:01 PMCR- 2022/06/03 CRDT- 2024/07/12 04:37 PHST- 2021/12/16 00:00 [received] PHST- 2022/02/17 00:00 [accepted] PHST- 2022/06/03 00:01 [medline] PHST- 2022/06/03 00:00 [pubmed] PHST- 2024/07/12 04:37 [entrez] PHST- 2022/06/03 00:00 [pmc-release] AID - BLC211653 [pii] AID - 10.3233/BLC-211653 [doi] PST - epublish SO - Bladder Cancer. 2022 Jun 3;8(2):211-228. doi: 10.3233/BLC-211653. eCollection 2022. PMID- 38993361 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 8 IP - 2 DP - 2022 TI - Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study. PG - 129-138 LID - 10.3233/BLC-211583 [doi] AB - BACKGROUND: The role of smoking in the prognosis of bladder cancer may significantly impact clinical management. It is also a considerable burden to Taiwan's economy and health of its citizens. OBJECTIVE: To search Taiwan's National Health Insurance Research Database to determine whether smoking affected overall and cancer-specific mortality of patients with bladder cancer. METHODS: We collected data on basic information, tumor stage, and comorbidities. Each smoking case was propensity score-matched by age, sex, and diagnosis year to one control individual among bladder cancer patients. The study comprised a never-smoke and an ever-smoke group, with each group including 4,728 patients after matching. We evaluated the association between smoking and mortalities in patients with bladder cancer. Cox proportional regression modeling was used to estimate hazard ratios (HRs) of overall and cancer-specific mortality rates. Stratified analysis was also performed to estimate risk ratios of overall and cancer-specific mortalities in bladder cancer patients with and without a history of smoking history among different subgroups. RESULTS: The overall and specific mortality ratio of patients who were ever smokers were 1.15-fold and 1.16-fold, respectively, compared with those of never smokers (overall: 95% confidence interval [CI], 1.06-1.26, P = 0.0014; specific: 95% CI, 1.03-1. 03, P = 0.0176). Patients with bladder cancer who smoked and had significantly higher overall and specific mortality rates were those with Charlson Comorbidity Index (CCI)>/=3 (overall: P = 0.0119; specific: P = 0.0092), diabetes mellitus (DM; overall: P = 0.0046; specific: P = 0.0419), and non-muscle-invasive bladder cancer (NMIBC; overall: P = 0.0038; specific: P = 0.0014). CONCLUSIONS: Overall and specific mortality rates were significantly higher in the ever-smoke group than in the never-smoke group. The ever-smoke group with male sex, CCI>/=3, DM, and NMIBC had increased risks for overall and specific mortality. CI - (c) 2022 - The authors. Published by IOS Press. FAU - Ho, Chung-Han AU - Ho CH AD - Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan. AD - Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Tseng, Wen-Hsin AU - Tseng WH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Huang, Steven K AU - Huang SK AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Liu, Chien-Liang AU - Liu CL AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Wu, Yu-Cih AU - Wu YC AD - Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan. FAU - Chiu, Allen W AU - Chiu AW AD - Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan. AD - School of Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Ong, Khaa Hoo AU - Ong KH AD - Division of General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. AD - Institute of Biomedical Science, National SunYat-Sen University, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20220603 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181781 OTO - NOTNLM OT - Smoking OT - bladder cancer OT - overall mortality OT - specific mortality COIS- CH, WT, SH, CL, YW, AC and KO have no conflicts of interest to declare. EDAT- 2022/06/03 00:00 MHDA- 2022/06/03 00:01 PMCR- 2022/06/03 CRDT- 2024/07/12 04:37 PHST- 2021/07/13 00:00 [received] PHST- 2022/01/19 00:00 [accepted] PHST- 2022/06/03 00:01 [medline] PHST- 2022/06/03 00:00 [pubmed] PHST- 2024/07/12 04:37 [entrez] PHST- 2022/06/03 00:00 [pmc-release] AID - BLC211583 [pii] AID - 10.3233/BLC-211583 [doi] PST - epublish SO - Bladder Cancer. 2022 Jun 3;8(2):129-138. doi: 10.3233/BLC-211583. eCollection 2022. PMID- 35655252 OWN - NLM STAT- MEDLINE DCOM- 20220606 LR - 20250530 IS - 1756-994X (Electronic) IS - 1756-994X (Linking) VI - 14 IP - 1 DP - 2022 Jun 3 TI - Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. PG - 59 LID - 10.1186/s13073-022-01056-4 [doi] LID - 59 AB - BACKGROUND: Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage disease (muscle-invasive BC, stages T2+). We used exome and transcriptome sequencing to comprehensively characterise NMIBCs of all grades and stages to identify prognostic genes and pathways that could facilitate treatment decisions. Tumour grading is based upon microscopy and cellular appearances (grade 1 BCs are less aggressive, and grade 3 BCs are most aggressive), and we chose to also focus on the most clinically complex NMIBC subgroup, those patients with grade 3 pathological stage T1 (G3 pT1) disease. METHODS: Whole-exome and RNA sequencing were performed in total on 96 primary NMIBCs including 22 G1 pTa, 14 G3 pTa and 53 G3 pT1s, with both exome and RNA sequencing data generated from 75 of these individual samples. Associations between genomic alterations, expression profiles and progression-free survival (PFS) were investigated. RESULTS: NMIBCs clustered into 3 expression subtypes with different somatic alteration characteristics. Amplifications of ARNT and ERBB2 were significant indicators of worse PFS across all NMIBCs. High APOBEC mutagenesis and high tumour mutation burden were both potential indicators of better PFS in G3pT1 NMIBCs. The expression of individual genes was not prognostic in BCG-treated G3pT1 NMIBCs; however, downregulated interferon-alpha and gamma response pathways were significantly associated with worse PFS (adjusted p-value < 0.005). CONCLUSIONS: Multi-omic data may facilitate better prognostication and selection of therapeutic interventions in patients with G3pT1 NMIBC. These findings demonstrate the potential for improving the management of high-risk NMIBC patients and warrant further prospective validation. CI - (c) 2022. The Author(s). FAU - Goel, Anshita AU - Goel A AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Ward, Douglas G AU - Ward DG AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Noyvert, Boris AU - Noyvert B AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Centre for Computational Biology, University of Birmingham, Birmingham, UK. AD - CRUK Birmingham Centre, University of Birmingham, Birmingham, UK. FAU - Yu, Minghao AU - Yu M AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Gordon, Naheema S AU - Gordon NS AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Abbotts, Ben AU - Abbotts B AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Colbourne, John K AU - Colbourne JK AD - School of Biosciences, University of Birmingham, Birmingham, UK. FAU - Kissane, Stephen AU - Kissane S AD - School of Biosciences, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer Research, London, UK. AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - CAPHRI School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands. FAU - Cheng, Kar Keung AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - Cazier, Jean-Baptiste AU - Cazier JB AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Centre for Computational Biology, University of Birmingham, Birmingham, UK. FAU - Whalley, Celina M AU - Whalley CM AD - Genomics Birmingham, University of Birmingham, Birmingham, UK. FAU - Beggs, Andrew D AU - Beggs AD AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Genomics Birmingham, University of Birmingham, Birmingham, UK. FAU - Palles, Claire AU - Palles C AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Arnold, Roland AU - Arnold R AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. r.arnold.2@bham.ac.uk. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. r.arnold.2@bham.ac.uk. FAU - Bryan, Richard T AU - Bryan RT AUID- ORCID: 0000-0003-2853-4293 AD - Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. r.t.bryan@bham.ac.uk. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. r.t.bryan@bham.ac.uk. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom GR - C1343/A5738/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220603 PL - England TA - Genome Med JT - Genome medicine JID - 101475844 SB - IM MH - Disease Progression MH - Exome MH - Genomics MH - Humans MH - Transcriptome MH - *Urinary Bladder Neoplasms/genetics/pathology PMC - PMC9164468 OTO - NOTNLM OT - Bladder cancer OT - Exome OT - Mutations OT - Prognosis OT - Sequencing OT - Subtypes OT - Therapy OT - Transcriptome OT - Urothelial carcinoma COIS- ND James has contributed to the advisory boards for Merck USA and Pierre Fabre. RT Bryan has contributed to the advisory boards for Olympus Medical Systems, Janssen and Nonacus Limited and has undertaken research funded by UroGen Pharma, QED Therapeutics and Janssen. DG Ward has contributed to the advisory boards for Nonacus Limited. The remaining authors declare that they have no competing interests. EDAT- 2022/06/03 06:00 MHDA- 2022/06/07 06:00 PMCR- 2022/06/03 CRDT- 2022/06/02 23:45 PHST- 2021/12/21 00:00 [received] PHST- 2022/05/05 00:00 [accepted] PHST- 2022/06/02 23:45 [entrez] PHST- 2022/06/03 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/06/03 00:00 [pmc-release] AID - 10.1186/s13073-022-01056-4 [pii] AID - 1056 [pii] AID - 10.1186/s13073-022-01056-4 [doi] PST - epublish SO - Genome Med. 2022 Jun 3;14(1):59. doi: 10.1186/s13073-022-01056-4. PMID- 35634893 OWN - NLM STAT- MEDLINE DCOM- 20220610 LR - 20220915 IS - 1744-7682 (Electronic) IS - 1471-2598 (Linking) VI - 22 IP - 6 DP - 2022 Jun TI - Emerging treatment landscape of non-muscle invasive bladder cancer. PG - 717-734 LID - 10.1080/14712598.2022.2082869 [doi] AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) accounts for 70-75% of all bladder cancers and is a heterogeneous disease characterized by a wide spectrum of recurrences and progression. Adjuvant treatment for intermediate- and high-risk NMIBC is mainly represented by Bacillus Calmette Guerin (BCG). However, 20%-40% of patients develop disease recurrences or persistence following BCG treatment and are classified as "BCG unresponsive' (BCGu), thus representing a therapeutic challenge due to their worse prognosis and unavailability of effective intravesical treatments. AREAS COVERED: We provide an overview of completed and ongoing clinical trials assessing the role of innovative immunological and target agents in patients with BCGu and BCG naive (BCGn) NMIBCs. New treatment options are emerging, demonstrating promising clinical activity, namely, pembrolizumab, atezolizumab, oportuzumab monatox, nadofaragene firadenovec, and N-803. EXPERT OPINION: The increasing number of newer therapeutic agents for patients with NMIBC poses challenges regarding the choice of the most suited treatment option for each patient and the best treatment sequence, given their diverse mechanisms of action and varying degrees of activity. Tailored treatment approaches are advocated, based on a deeper comprehension of disease features, available therapies, patient's characteristics, and consequently, on the identification and validation of prognostic and predictive biomarkers. FAU - Valenza, Carmine AU - Valenza C AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy. AD - (DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy. FAU - Antonarelli, Gabriele AU - Antonarelli G AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy. AD - (DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy. FAU - Giugliano, Federica AU - Giugliano F AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy. AD - (DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy. FAU - Aurilio, Gaetano AU - Aurilio G AD - Division of Urogenital and Head and Neck Tumours, European Institute of Oncology, Milan, Italy. FAU - Verri, Elena AU - Verri E AD - Division of Urogenital and Head and Neck Tumours, European Institute of Oncology, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - San Raffaele Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific InstituteUniversity Vita-Salute, Milan, Italy. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy. AD - (DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - San Raffaele Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific InstituteUniversity Vita-Salute, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220531 PL - England TA - Expert Opin Biol Ther JT - Expert opinion on biological therapy JID - 101125414 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - BCG unresponsive OT - biomarkers OT - immunotherapy OT - non-muscle invasive bladder cancer OT - target therapies EDAT- 2022/06/01 06:00 MHDA- 2022/06/11 06:00 CRDT- 2022/05/31 10:33 PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/06/11 06:00 [medline] PHST- 2022/05/31 10:33 [entrez] AID - 10.1080/14712598.2022.2082869 [doi] PST - ppublish SO - Expert Opin Biol Ther. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. PMID- 35629309 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 5 DP - 2022 Apr 26 TI - Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors. LID - 10.3390/life12050641 [doi] LID - 641 AB - One pillar in treating non-muscle-invasive bladder cancer (NMIBC) is the complete and high-quality transurethral resection of the primary tumor (TURBT). However, even after a high-quality primary resection, the residual tumor risk is considerable, thus requiring a re-TURBT. Resections performed with the aid of a photodynamic diagnostics report improved recurrence-free survival rates and increased detection rates of carcinoma in situ (CIS). This monocentric retrospective study reports on patients treated with an extended TURBT procedure using conventional white-light cystoscopy or photodynamic diagnostics (PDD). Only patients undergoing a TURBT resection for their primary tumor were included in the statistical analysis. Recurrence-free survival and overall survival were the clinical endpoints. Mann-Whitney U tests and chi-squared tests were used for descriptive intergroup comparisons. The associations with overall survival and recurrence-free survival were determined by univariate and multivariate analyses. The test results were considered significant when p was < 0.05. In comparison to conventional white-light cystoscopy, PDD increased the detection rates of CIS (p = 0.004) and tumor multifocality (p = 0.005) and led to reduced residual tumor incidence at the primary resection site (p < 0.001). Likewise, tumor recurrence rates were reduced in the PDD cohort (p < 0.001). Patient age and the presence of residual tumor at the primary resection site were identified as independent predictors of overall survival. For recurrence-free survival, only the PDD resection method was an independent predictor (HR = 0.43; p < 0.001). In summary, we demonstrated that the utilization of PDD techniques was associated with improved detection rates of CIS and multifocal tumors and with reduced recurrence rates. The extended resection protocol allowed us to determine that PDD resections lead to a reduced residual tumor rate at the initial resection site. This residual tumor state at the resection site, determined by extended TURBT, became an independent predictor of long-term survival. On the other hand, the PDD technique was confirmed as the only independent predictor of recurrence-free survival. FAU - Marquardt, Alexander AU - Marquardt A AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. FAU - Richterstetter, Mario AU - Richterstetter M AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AUID- ORCID: 0000-0002-9077-1727 AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 8-10, 91054 Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Lieb, Verena AU - Lieb V AUID- ORCID: 0000-0001-6772-508X AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Bellut, Laura AU - Bellut L AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Apel, Hendrik AU - Apel H AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. LA - eng PT - Journal Article DEP - 20220426 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9143752 OTO - NOTNLM OT - photodynamic diagnostics OT - recurrence-free survival OT - transurethral resection COIS- The authors declare no conflict of interest. EDAT- 2022/05/29 06:00 MHDA- 2022/05/29 06:01 PMCR- 2022/04/26 CRDT- 2022/05/28 01:27 PHST- 2022/04/01 00:00 [received] PHST- 2022/04/19 00:00 [revised] PHST- 2022/04/24 00:00 [accepted] PHST- 2022/05/28 01:27 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/05/29 06:01 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - life12050641 [pii] AID - life-12-00641 [pii] AID - 10.3390/life12050641 [doi] PST - epublish SO - Life (Basel). 2022 Apr 26;12(5):641. doi: 10.3390/life12050641. PMID- 35626309 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 12 IP - 5 DP - 2022 May 6 TI - The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. LID - 10.3390/diagnostics12051154 [doi] LID - 1154 AB - Bladder cancer is a heterogeneous disease with variable natural history. Non-muscle-invasive bladder cancer has a favorable prognosis following transurethral resection, but the optimal adjuvant chemotherapy plan is still in debate. The aim of this study was to evaluate the effect of the adjuvant intravesical administration of a single dose of gemcitabine in the outcome of this disease. For that purpose, we performed a systematic review and meta-analysis on available randomized control trials on MEDLINE, EMBASE, Cochrane, Scopus, and Google Scholar databases. Ultimately, two studies were included with a total number of 654 patients. The statistical analysis performed showed that a single post-operative intravesical dose of gemcitabine does not affect the recurrence rate of non-muscle-invasive bladder cancer compared to placebo. Therefore, this therapeutic strategy does not offer any significant improvement on the outcomes of the disease. Nonetheless, due to the plethora of available therapeutic agents and treatment strategies, further research is needed to establish the optimal treatment in this category of patients. FAU - Koimtzis, Georgios AU - Koimtzis G AUID- ORCID: 0000-0002-0669-6980 AD - Cardiff Transplant Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff CF14 4XW, UK. FAU - Alexandrou, Vyron AU - Alexandrou V AD - Urology Department, General Hospital of Thessaloniki "G. Gennimata-Agios Dimitrios", Elenis Zografou 2, 546 34 Thessaloniki, Greece. FAU - Chalklin, Christopher G AU - Chalklin CG AUID- ORCID: 0000-0001-6206-8420 AD - Cardiff Transplant Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff CF14 4XW, UK. FAU - Carrington-Windo, Eliot AU - Carrington-Windo E AUID- ORCID: 0000-0003-2415-4533 AD - Cardiff Transplant Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff CF14 4XW, UK. FAU - Ramsden, Mark AU - Ramsden M AD - Cardiff Transplant Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff CF14 4XW, UK. FAU - Karakasis, Nikolaos AU - Karakasis N AD - Urology Department, General Hospital of Thessaloniki "G. Gennimata-Agios Dimitrios", Elenis Zografou 2, 546 34 Thessaloniki, Greece. FAU - Lam, Kit W AU - Lam KW AUID- ORCID: 0000-0003-1634-509X AD - Cardiff Transplant Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff CF14 4XW, UK. FAU - Tsakaldimis, Georgios AU - Tsakaldimis G AD - Urology Department, General Hospital of Thessaloniki "G. Gennimata-Agios Dimitrios", Elenis Zografou 2, 546 34 Thessaloniki, Greece. AD - Department of Medicine, Democritus University of Thrace, Administrative Building, 6th km, 681 00 Alexandroupoli, Greece. LA - eng PT - Journal Article PT - Review DEP - 20220506 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC9140686 OTO - NOTNLM OT - bladder cancer OT - gemcitabine OT - intravesical chemotherapy COIS- The authors declare no conflict of interest. EDAT- 2022/05/29 06:00 MHDA- 2022/05/29 06:01 PMCR- 2022/05/06 CRDT- 2022/05/28 01:10 PHST- 2022/02/10 00:00 [received] PHST- 2022/03/05 00:00 [revised] PHST- 2022/04/29 00:00 [accepted] PHST- 2022/05/28 01:10 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/05/29 06:01 [medline] PHST- 2022/05/06 00:00 [pmc-release] AID - diagnostics12051154 [pii] AID - diagnostics-12-01154 [pii] AID - 10.3390/diagnostics12051154 [doi] PST - epublish SO - Diagnostics (Basel). 2022 May 6;12(5):1154. doi: 10.3390/diagnostics12051154. PMID- 35618577 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20260728 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 40 IP - 9 DP - 2022 Sep TI - Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. PG - 410.e19-410.e27 LID - S1078-1439(22)00141-7 [pii] LID - 10.1016/j.urolonc.2022.04.013 [doi] AB - BACKGROUND: We sought to determine whether differences in subtype distribution and differentially expressed genes exist between African Americans (AAs) and European Americans (EAs) in patients with high-risk nonmuscle-invasive bladder cancer (NMIBC). METHODS: We performed a retrospective cohort study including 26 patients (14 AAs and 12 EAs) from the University of Texas Medical Branch and the Durham Veterans Affair Health Care System from 2010 to 2020 among treatment naive, high-risk NMIBC. Profiled gene expressions were performed using the UROMOL classification system. RESULTS: UROMOL racial subtype distributions were similar with class 2a being most common with 10 genes commonly upregulated in AAs compared to EAs including EFEMP1, S100A16, and MCL1 which are associated with progression to muscle-invasive bladder cancer, mitomycin C resistance, and bacillus Calmette-Guerin durability, respectively. We used single nuclei analysis to map the malignant cell heterogeneity in urothelial cancer which 5 distinct malignant epithelial subtypes whose presence has been associated with different therapeutic response prediction abilities. We mapped the expression of the 10 genes commonly upregulated by race as a function of the 5 malignant subtypes. This showed borderline (P = 0.056) difference among the subtypes suggesting AAs and EAs may be expected to have different therapeutic responses to treatments for bladder cancer. AAs were enriched with immune-related, inflammatory, and cellular regulation pathways compared to EAs, yet appeared to have reduced levels of the aggressive C3/CDH12 bladder tumor cell population. CONCLUSIONS: While premature, gene expression differed between AAs and EAs, supporting potential race-based etiologies for muscle-invasion, response to treatments, and transcriptome pathway regulations. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - You, Sungyong AU - You S AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Kim, Minhyung AU - Kim M AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Widen, Steven AU - Widen S AD - Department of Biochemistry and Molecular Biology, Next Generation Sequencing Core, The University of Texas Medical Branch, Galveston, TX. FAU - Yu, Alexander AU - Yu A AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX. FAU - Galvan, Gloria C AU - Galvan GC AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Choi-Kuaea, Yunhee AU - Choi-Kuaea Y AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Eyzaguirre, Eduardo J AU - Eyzaguirre EJ AD - Department of Pathology, The University of Texas Medical Branch, Galveston, TX. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Choi, Woonyoung AU - Choi W AD - Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Theodorescu, Dan AU - Theodorescu D AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Chan, Keith S AU - Chan KS AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Shan, Yong AU - Shan Y AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX. FAU - Tyler, Douglas S AU - Tyler DS AD - Department of Surgery, The University of Texas Medical Branch, Galveston, TX. FAU - De Hoedt, Amanda M AU - De Hoedt AM AD - Durham Veterans Affairs Health Care System, Durham, NC. FAU - Freedland, Stephen J AU - Freedland SJ AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; Durham Veterans Affairs Health Care System, Durham, NC; Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Williams, Stephen B AU - Williams SB AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX. Electronic address: stbwilli@utmb.edu. LA - eng GR - KL2 TR001441/TR/NCATS NIH HHS/United States GR - R01 CA075115/CA/NCI NIH HHS/United States GR - TL1 TR001440/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220523 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (EFEMP1 protein, human) RN - 0 (Extracellular Matrix Proteins) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Black or African American MH - BCG Vaccine MH - Extracellular Matrix Proteins MH - Humans MH - Mitomycin MH - Neoplasm Invasiveness MH - Retrospective Studies MH - *Urinary Bladder Neoplasms MH - White People PMC - PMC9741768 MID - NIHMS1852547 OTO - NOTNLM OT - Bladder cancer OT - High-risk OT - Noninvasive OT - Race OT - Subtypes COIS- Conflicts of interest The authors declare no potential conflicts of interest. EDAT- 2022/05/27 06:00 MHDA- 2022/08/31 06:00 PMCR- 2023/09/01 CRDT- 2022/05/26 22:07 PHST- 2022/01/03 00:00 [received] PHST- 2022/03/28 00:00 [revised] PHST- 2022/04/25 00:00 [accepted] PHST- 2022/05/27 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2022/05/26 22:07 [entrez] PHST- 2023/09/01 00:00 [pmc-release] AID - S1078-1439(22)00141-7 [pii] AID - 10.1016/j.urolonc.2022.04.013 [doi] PST - ppublish SO - Urol Oncol. 2022 Sep;40(9):410.e19-410.e27. doi: 10.1016/j.urolonc.2022.04.013. Epub 2022 May 23. PMID- 35602629 OWN - NLM STAT- MEDLINE DCOM- 20220524 LR - 20231221 IS - 1687-5273 (Electronic) IS - 1687-5265 (Print) VI - 2022 DP - 2022 TI - Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer. PG - 6044676 LID - 10.1155/2022/6044676 [doi] LID - 6044676 AB - Bladder cancer is the most prevalent tumor of the urinary tract, ranking seventh in males and seventeenth in women. The gold standard for the definitive diagnosis and initial treatment of non-muscle-invasive bladder cancer is transurethral resection (TUR) of the bladder tumor. The ability to accurately detect disease, typically in the presence of hematuria as well as to detect early recurrent tumors in patients with a history of NMIBC, is critical to the successful treatment of non-muscle-invasive bladder cancer (NMIBC). Unfortunately, the current biomarker landscape for NMIBC is still evolving. Cystoscopy remains the gold standard, but it can still miss 10% of tumors. As a result, physicians frequently employ additional diagnostic tools to aid in the diagnosis of bladder cancer. The efficacy of transurethral bipolar plasma needle electrodes and ring electrodes in the treatment of non-muscle-invasive bladder cancer was compared and analyzed in this study. During our study, 100 patients with non-muscle-invasive bladder cancer admitted to our hospital between June 2019 and June 2020 were randomly assigned to a control group and an observation group, with 50 cases in each group. The observation group was given a bipolar plasma needle electrode, while the control group was given a bipolar plasma ring. Patients continued to receive bladder irrigation chemotherapy as well as traditional Chinese medicine (TCM) treatment as part of our treatment plan, while the control group received only bladder irrigation chemotherapy. Clinical factors such as operational blood loss, catheter indention time, length of hospital stay, and others were compared between the two groups. When the risk grades in the two groups were compared, the observation group had fewer medium- and high-risk grades than the control group, but the control group had more low-risk grades, with statistical significance (P < 0.05). CI - Copyright (c) 2022 Pei Zheng et al. FAU - Zheng, Pei AU - Zheng P AUID- ORCID: 0000-0002-2406-3458 AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Zhang, Jianhua AU - Zhang J AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Zhu, Yahong AU - Zhu Y AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Guan, Xiaodong AU - Guan X AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Quan, Jianwen AU - Quan J AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Li, Qi AU - Li Q AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. FAU - Yi, Fen AU - Yi F AD - Yuncheng Central Hospital, Yanhu District, Yuncheng, Shanxi Province, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Retracted Publication DEP - 20220513 PL - United States TA - Comput Intell Neurosci JT - Computational intelligence and neuroscience JID - 101279357 SB - IM RIN - Comput Intell Neurosci. 2023 Dec 13;2023:9824189. doi: 10.1155/2023/9824189. PMID: 38124830 MH - Cystoscopy MH - Electrodes MH - Female MH - Humans MH - Male MH - *Urinary Bladder Neoplasms/diagnosis/pathology/therapy PMC - PMC9122689 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/05/24 06:00 MHDA- 2022/05/25 06:00 PMCR- 2022/05/13 CRDT- 2022/05/23 04:28 PHST- 2022/03/16 00:00 [received] PHST- 2022/04/10 00:00 [revised] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/23 04:28 [entrez] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/05/25 06:00 [medline] PHST- 2022/05/13 00:00 [pmc-release] AID - 10.1155/2022/6044676 [doi] PST - epublish SO - Comput Intell Neurosci. 2022 May 13;2022:6044676. doi: 10.1155/2022/6044676. eCollection 2022. PMID- 35600373 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231101 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Construction and Verification of Immunohistochemistry Parameters-Based Classifier to Predict Local-Recurrence of Upper Tract Urothelial Carcinoma After Kidney-Sparing Surgery. PG - 872432 LID - 10.3389/fonc.2022.872432 [doi] LID - 872432 AB - BACKGROUND: Kidney-sparing surgery (KSS) for upper tract urothelial carcinomas (UTUCs) has been gradually performed in selected patients beyond the recommendation of guidelines. However, there is still a lack of tools to evaluate postoperative local recurrence. Herein, a new nomogram was established to predict the local recurrence risk after KSS. METHODS: Patients were randomly divided into two cohorts (training: testing cohorts = 7:3). Cancer samples after KSS were used for immunohistochemical tests to detect molecules missing in previous pathology reports. Then, the total number of molecules were screened by the least absolute shrinkage and selection operator (LASSO) method to construct an IHCscore, which was further tested in the validation cohort. Finally, the IHCscore and other clinicopathologic parameters were combined to develop a more accurate model using univariate and multivariate Cox regression methods. RESULTS: In total, 200 patients were included. The Kaplan-Meier test showed that high Ki-67 and loss of Uroplakin III and E-cadherin were correlated with poor recurrence-free survival. The individual IHCscore was calculated based on the expression levels of Ki-67, Her2 and E-cadherin. Based on the IHC score, patients were further classified as low- or high-risk, and a significant difference in the recurrence-free survival was observed between the two groups. Then, the nomogram was developed based on Gender, surgical margin and IHCscore; this nomogram had a higher AUC (0.847) in predicting 3-year recurrence-free survival than the IHCscore alone (0.788). CONCLUSIONS: This easy-to-use nomogram shows better prediction accuracy in recurrence-free survival after KSS and may guide individualized intravesical chemotherapy. However, a larger sample is required for external validation. CI - Copyright (c) 2022 Cheng, Liu, Li and Wang. FAU - Cheng, Xu AU - Cheng X AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Liu, Wentao AU - Liu W AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Li, Yijian AU - Li Y AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Wang, Yinhuai AU - Wang Y AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. LA - eng PT - Journal Article DEP - 20220504 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9114713 OTO - NOTNLM OT - intravesical chemotherapy OT - kidney-sparing surgery OT - nomogram OT - recurrence OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/05/24 06:00 MHDA- 2022/05/24 06:01 PMCR- 2022/01/01 CRDT- 2022/05/23 03:53 PHST- 2022/02/10 00:00 [received] PHST- 2022/04/13 00:00 [accepted] PHST- 2022/05/23 03:53 [entrez] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/05/24 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.872432 [doi] PST - epublish SO - Front Oncol. 2022 May 4;12:872432. doi: 10.3389/fonc.2022.872432. eCollection 2022. PMID- 35598896 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1442-2042 (Electronic) IS - 0919-8172 (Print) IS - 0919-8172 (Linking) VI - 29 IP - 8 DP - 2022 Aug TI - Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer. PG - 807-815 LID - 10.1111/iju.14921 [doi] AB - Within the heterogeneous population of patients with bacillus Calmette-Guerin failure, there are clear differences in prognosis and therapy with regard to the timeline when bacillus Calmette-Guerin failure occurred. There are a variety of classifications which include bacillus Calmette-Guerin refractory disease, relapsing, unresponsive, and intolerant. Further profiling of these patients may help to shed light on other forms of therapy that are less radical. We hereby summarize the different biomarkers that predicts for response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer. CI - (c) 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association. FAU - Wang, Ziting AU - Wang Z AUID- ORCID: 0000-0003-4229-2702 AD - Department of Urology, National University Hospital, Singapore. FAU - So, Wei Zheng AU - So WZ AD - Department of Urology, National University Hospital, Singapore. FAU - Loh, Kep Yong AU - Loh KY AD - Department of Internal Medicine, Singapore General Hospital, Singapore. FAU - Lim, Yew Koon AU - Lim YK AD - Department of Urology, National University Hospital, Singapore. FAU - Mahendran, Ratha AU - Mahendran R AD - Department of Urology, National University Hospital, Singapore. FAU - Wu, Qing Hui AU - Wu QH AD - Department of Urology, National University Hospital, Singapore. FAU - Chiong, Edmund AU - Chiong E AUID- ORCID: 0000-0002-5241-5000 AD - Department of Urology, National University Hospital, Singapore. LA - eng PT - Journal Article PT - Review DEP - 20220522 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - 0 (Immunologic Factors) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Biomarkers MH - Humans MH - Immunologic Factors/therapeutic use MH - Immunotherapy/adverse effects MH - *Mycobacterium bovis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9543886 OTO - NOTNLM OT - bladder cancer OT - immunotherapy OT - recurrence COIS- None declared. EDAT- 2022/05/23 06:00 MHDA- 2022/08/05 06:00 PMCR- 2022/10/07 CRDT- 2022/05/22 20:52 PHST- 2021/12/17 00:00 [received] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/05/23 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/05/22 20:52 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - IJU14921 [pii] AID - 10.1111/iju.14921 [doi] PST - ppublish SO - Int J Urol. 2022 Aug;29(8):807-815. doi: 10.1111/iju.14921. Epub 2022 May 22. PMID- 35598096 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 10 DP - 2022 Oct TI - Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. PG - 1140-1146 LID - 10.1111/iju.14936 [doi] AB - OBJECTIVES: There is no consensus about the follow-up schedule after 5-year cancer-free periods. In this study, we aimed to elucidate the risk factors for the recurrence in patients with non-muscle-invasive bladder cancer who remained cancer free for more than 5 years. METHODS: Data from six Japanese institutions were retrospectively reviewed. Among the patients with non-muscle-invasive bladder cancer who were treated with transurethral resection of bladder tumor between 1990 and 2013, those who had no recurrence for more than 5 years were included in this study. The Kaplan-Meier method and Cox hazards model were used to estimate recurrence-free survival and to determine the pathologic and clinical factors affecting late recurrence. RESULTS: In total, 434 patients were enrolled in this study. Of these patients, 55 patients (12.7%) experienced late recurrence. The median follow-up time was 8.9 years (interquartile range 6.9-11.3 years). Prior history of bladder cancer before the most recent transurethral resection was a significant predictor for late recurrence (hazard ratio 1.99 [95% confidence interval 1.13-3.47], P = 0.019), although other clinical factors including tumor grade, pathologic stage, tumor multiplicity, and current risk classification systems were not associated with late recurrence. CONCLUSIONS: Late recurrence after a long tumor-free period is not rare and it was not predicted by current risk classification systems. Only prior history of bladder cancer was a significant predictor for late recurrence in this study. CI - (c) 2022 The Japanese Urological Association. FAU - Hirata, Yurie AU - Hirata Y AUID- ORCID: 0000-0002-3930-0233 AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Higuchi, Madoka AU - Higuchi M AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Hinotsu, Shiro AU - Hinotsu S AD - Department of Biostatistics, Sapporo Medical University, Sapporo, Japan. FAU - Harabayashi, Toru AU - Harabayashi T AD - Department of Urology, Hokkaido Cancer Center, Sapporo, Japan. FAU - Mochizuki, Tango AU - Mochizuki T AD - Department of Urology, Asahikawa City Hospital, Asahikawa, Japan. FAU - Enami, Nobuyasu AU - Enami N AD - Department of Urology, Nikko Memorial Hospital, Muroran, Japan. FAU - Nounaka, Osamu AU - Nounaka O AD - Department of Urology, Chitose City Hospital, Chitose, Japan. FAU - Shinno, Yuichiro AU - Shinno Y AD - Department of Urology, Otaru General Hospital, Otaru, Japan. FAU - Kikuchi, Hiroshi AU - Kikuchi H AUID- ORCID: 0000-0003-4999-8994 AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Matsumoto, Ryuji AU - Matsumoto R AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Abe, Takashige AU - Abe T AUID- ORCID: 0000-0002-5468-7632 AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Murai, Sachiyo AU - Murai S AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. LA - eng PT - Journal Article DEP - 20220521 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2022 Oct;29(10):1146. doi: 10.1111/iju.14967. PMID: 35718460 MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Retrospective Studies MH - Risk Factors MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - NMIBC OT - TURBT OT - bladder cancer OT - late recurrence OT - urothelial carcinoma EDAT- 2022/05/23 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/05/22 02:34 PHST- 2022/02/04 00:00 [received] PHST- 2022/05/05 00:00 [accepted] PHST- 2022/05/23 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/05/22 02:34 [entrez] AID - 10.1111/iju.14936 [doi] PST - ppublish SO - Int J Urol. 2022 Oct;29(10):1140-1146. doi: 10.1111/iju.14936. Epub 2022 May 21. PMID- 35593896 OWN - NLM STAT- MEDLINE DCOM- 20220725 LR - 20261028 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 49 IP - 8 DP - 2022 Aug TI - Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients. PG - 7541-7556 LID - 10.1007/s11033-022-07563-2 [doi] AB - BACKGROUND: Diagnostic and prognostic significance of epithelial-to-mesenchymal transition (EMT) associated biomarkers are evaluated in a cohort of NMIBC (non-muscle invasive bladder cancer) and MIBC (muscle invasive bladder cancer) patients. METHODS AND RESULTS: Real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical (IHC) staining were carried out in 100 tumor specimens (59 NMIBC and 41 MIBC). The expressions of the epithelial marker, mesenchymal markers and EMT-activating transcription factors (EMT-ATFs) were determined at transcriptome and protein level followed by their statistical associations with clinicohistopathological variables of the patients. Transcriptomic expression analysis showed statistical relevance of tumor stage with increased Twist and Zeb-1; tumor type with reduced E-cadherin and increased Snail; and smoking/tobacco chewing status (S/TC) of patients with increased N-cadherin and Snail in NMIBC patients. Tumor grade with reduced message E-cadherin, gain of N-cadherin, Snail, Twist and Zeb-1; patients' age with reduced E-cadherin and Twist gain; and tumor type with increased message N-cadherin exhibited associations in MIBC patients. Protein expression analysis identified statistical relevance of tumor grade with nuclear gain of Snail and Twist; and nuclear gain of Slug with S/TC status of NMIBC patients. Novel gain of membranous Vimentin deduced association with patients' age in MIBC patients. Survival analysis identified novel Vimentin as the positive predictor of short progression free survival (PFS) and short overall survival (OS) in MIBC patients. Study established altered EMT profile as the independent negative predictor of short recurrence free survival (RFS) in NMIBC patients and positive predictor of short PFS and OS in MIBC patients. CONCLUSIONS: EMT associated biomarkers could provide diagnostic and prognostic risk stratification and hence could be of importance in the clinical management of bladder cancer patients. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Singh, R AU - Singh R AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. FAU - Singh, U P AU - Singh UP AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India. FAU - Agrawal, V AU - Agrawal V AD - Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India. FAU - Garg, M AU - Garg M AUID- ORCID: 0000-0002-4069-8138 AD - Department of Biochemistry, University of Lucknow, Lucknow, 226007, India. minal14@yahoo.com. LA - eng GR - SR/SO/HS-0113/2010/Department of Science and Technology, Govt. of India/ PT - Journal Article PT - Retracted Publication DEP - 20220520 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Biomarkers, Tumor) RN - 0 (Cadherins) RN - 0 (Snail Family Transcription Factors) RN - 0 (Vimentin) SB - IM RIN - Mol Biol Rep. 2025 Mar 24;52(1):334. doi: 10.1007/s11033-025-10450-1. PMID: 40122981 MH - Biomarkers, Tumor/metabolism MH - Cadherins/genetics/metabolism MH - Disease Progression MH - Epithelial-Mesenchymal Transition/genetics MH - Humans MH - Prognosis MH - Snail Family Transcription Factors MH - *Urinary Bladder Neoplasms/metabolism MH - Vimentin/genetics OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Diagnosis and prognosis OT - Epithelial-to-mesenchymal transition OT - Survival probabilities EDAT- 2022/05/21 06:00 MHDA- 2022/07/26 06:00 CRDT- 2022/05/20 11:03 PHST- 2021/12/24 00:00 [received] PHST- 2022/05/04 00:00 [accepted] PHST- 2022/05/21 06:00 [pubmed] PHST- 2022/07/26 06:00 [medline] PHST- 2022/05/20 11:03 [entrez] AID - 10.1007/s11033-022-07563-2 [pii] AID - 10.1007/s11033-022-07563-2 [doi] PST - ppublish SO - Mol Biol Rep. 2022 Aug;49(8):7541-7556. doi: 10.1007/s11033-022-07563-2. Epub 2022 May 20. PMID- 35591971 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 75 IP - 1 DP - 2022 TI - Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer. PG - 41-46 LID - 10.5173/ceju.2022.0273 [doi] AB - INTRODUCTION: Neutrophil-to-lymphocyte ratio (NLR) has proven to be promising as a prognostic factor in many malignancies. We investigated the prognostic significance of NLR in patients undergoing radical cystectomy (RC) for bladder cancer (BC). MATERIAL AND METHODS: We retrospectively evaluated the data of 134 consecutive patients with BC who underwent RC between 2011 and 2017 at a single center. Overall survival (OS) was assessed using the Kaplan-Meier method and compared between NLR subpopulations using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to identify the variables affecting OS. RESULTS: At a median follow-up of 2.2 years, high NLR (>2.7) correlated with worse a survival outcome (p = 0.0345 in log-rank test), higher tumor stage (p = 0.0047), and higher frequency of positive lymph nodes (p = 0.0285). The univariate model showed that a high NLR (p = 0.038528), advanced pathological tumor stage (p = 0.000763), lymph node involvement (p = 0.013384), a high grade of cancer (p = 0.015611), lymphovascular invasion (LVI) (p = 0.001530), positive margins (p = 0.000890) and ureterocutaneostomy as urinary diversion (p = 0.038854) had a negative impact on OS. Tumor extending beyond the submucosa (>pT1) (hazard ratio 2.161, confidence interval 1058-4411, p = 0.0345) and lymphatic infiltration (hazard ratio 1.599, confidence interval 1028-2482, p = 0.037) have been recognized as independent risk factors of poor prognosis in multivariate Cox regression analysis. CONCLUSIONS: In our cohort, an elevated NLR is associated with worse OS and adverse histopathological findings. Consequently, the NLR is an easily acquired biomarker, which may be useful in pretreatment patient risk stratification. CI - Copyright by Polish Urological Association. FAU - Sudol, Damian AU - Sudol D AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Widz, Damian AU - Widz D AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Mitura, Przemyslaw AU - Mitura P AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Plaza, Pawel AU - Plaza P AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Godzisz, Michal AU - Godzisz M AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Kuliniec, Iga AU - Kuliniec I AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Yadlos, Andriy AU - Yadlos A AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Cabanek, Michal AU - Cabanek M AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Bar, Marek AU - Bar M AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. FAU - Bar, Krzysztof AU - Bar K AD - Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland. LA - eng PT - Journal Article DEP - 20220120 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC9074069 OTO - NOTNLM OT - bladder cancer OT - inflammation OT - neutrophil-lymphocyte ratio COIS- The authors declare no conflicts of interest. EDAT- 2022/05/21 06:00 MHDA- 2022/05/21 06:01 PMCR- 2022/01/01 CRDT- 2022/05/20 02:16 PHST- 2021/11/14 00:00 [received] PHST- 2021/12/30 00:00 [revised] PHST- 2022/01/03 00:00 [accepted] PHST- 2022/05/20 02:16 [entrez] PHST- 2022/05/21 06:00 [pubmed] PHST- 2022/05/21 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 0273 [pii] AID - 10.5173/ceju.2022.0273 [doi] PST - ppublish SO - Cent European J Urol. 2022;75(1):41-46. doi: 10.5173/ceju.2022.0273. Epub 2022 Jan 20. PMID- 35581143 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 4 DP - 2022 Aug TI - Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. PG - 403-411 LID - S2588-9311(22)00066-9 [pii] LID - 10.1016/j.euo.2022.04.008 [doi] AB - CONTEXT: Bladder cancer prognosis and treatment are heavily dependent on accurate staging. Traditional imaging and pathologic evaluation of transurethral resection (TUR) specimens have been associated with high rates of clinical understaging at the time of radical cystectomy (RC). OBJECTIVE: We describe current components and limitations of bladder cancer staging for muscle-invasive bladder cancer (MIBC), and discuss the rationale for inclusion of novel biomarkers and imaging modalities to improve diagnostic accuracy. EVIDENCE ACQUISITION: We summarize the data informing MIBC staging accuracy using a nonsystematic review of published literature and provide expert opinion on current and emerging standards in MIBC staging. EVIDENCE SYNTHESIS: Nearly 50% of patients undergoing RC are clinically understaged preoperatively. Components of clinical staging include TUR specimen evaluation, bimanual examination under anesthesia (EUA), and cross-sectional imaging of the chest, abdomen, and pelvis. Complete endoscopic resection of visible disease with sampling of muscularis propria is indicated. While histologic features such as tumor size, focality, variant histologic differentiation, and lymphovascular invasion have prognostic utility, insufficient evidence exists to incorporate them into current staging paradigms. For primary tumor staging, conventional computed tomography (CT) has limited accuracy in differentiating non-MIBC from MIBC. Magnetic resonance imaging (MRI) has exhibited superior pT staging accuracy with the validated Vesical Imaging Reporting and Data System. Positron emission tomography (PET)/CT does not increase clinical nodal staging accuracy beyond CT or MRI, and there exists no consensus role for the use of PET in routine clinical staging. CONCLUSIONS: In the absence of reliable biomarkers to serve as staging adjuncts, we continue to rely heavily on basic clinical staging components-TUR with accurate pathologic evaluation, EUA, and standard cross-sectional imaging modalities. MRI shows promising accuracy and interobserver reliability for primary tumor staging. PATIENT SUMMARY: Effective clinical staging for muscle-invasive bladder cancer estimates local and systemic disease burden and can dictate eligibility for systemic therapy and/or radical cystectomy. Herein, we review the accuracy and limitations of current and emerging staging modalities. CI - Copyright (c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Hensley, Patrick J AU - Hensley PJ AD - MD Anderson Cancer Center, Houston, TX, USA. FAU - Panebianco, Valeria AU - Panebianco V AD - Sapienza University, Rome, Italy. FAU - Pietzak, Eugene AU - Pietzak E AD - Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Kutikov, Alexander AU - Kutikov A AD - Fox Chase Cancer Center, Philadelphia, PA, USA. FAU - Vikram, Raghu AU - Vikram R AD - MD Anderson Cancer Center, Houston, TX, USA. FAU - Galsky, Matthew D AU - Galsky MD AD - Mount Sinai, New York, NY, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Departments of Urology, Weill Cornell Medical College, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, Texas, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Kamat, Ashish M AU - Kamat AM AD - MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article PT - Review DEP - 20220514 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Cystectomy MH - Humans MH - Magnetic Resonance Imaging/methods MH - Muscles/pathology MH - Reproducibility of Results MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery OTO - NOTNLM OT - Clinical staging OT - Examination under anesthesia OT - Muscle-invasive bladder cancer OT - Pathologic staging OT - Transurethral resection of bladder tumor OT - Vesical Imaging Reporting and Data System EDAT- 2022/05/18 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/05/17 22:07 PHST- 2021/12/28 00:00 [received] PHST- 2022/03/30 00:00 [revised] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/18 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/05/17 22:07 [entrez] AID - S2588-9311(22)00066-9 [pii] AID - 10.1016/j.euo.2022.04.008 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Aug;5(4):403-411. doi: 10.1016/j.euo.2022.04.008. Epub 2022 May 14. PMID- 35577750 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230124 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 6 DP - 2022 Nov TI - T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. PG - 1627-1634 LID - S2405-4569(22)00110-9 [pii] LID - 10.1016/j.euf.2022.04.014 [doi] AB - BACKGROUND: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports have consistently found a prevalence of 2-6% G1 in their T1 series. However, it remains unclear if T1G1 carcinomas have added value as a separate category to predict prognosis within the non-muscle-invasive bladder cancer (NMIBC) spectrum. OBJECTIVE: To evaluate the prognostic value of T1G1 carcinomas compared to TaG1 and T1G2 carcinomas within the NMIBC spectrum. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta and T1 bladder tumors from 17 hospitals in Europe and Canada were analyzed. Transurethral resection (TUR) was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox regression models stratified by institution. RESULTS AND LIMITATIONS: T1G1 represented 1.9% (99/5170) of all carcinomas and 5.3% (99/1859) of T1 carcinomas. According to primary TUR dates, the proportion of T1G1 varied between 0.9% and 3.5% per year, with similar percentages in the early and later calendar years. We found no difference in time to recurrence between T1G1 and TaG1 (p = 0.91) or between T1G1 and T1G2 (p = 0.30). Time to progression significantly differed between TaG1 and T1G1 (p < 0.001) but not between T1G1 and T1G2 (p = 0.30). Multivariable analyses for recurrence and progression showed similar results. CONCLUSIONS: The relative prevalence of T1G1 diagnosis was low and remained constant over the past three decades. Time to recurrence of T1G1 NMIBC was comparable to that for other stage/grade NMIBC combinations. Time to progression of T1G1 NMIBC was comparable to that for T1G2 but not for TaG1, suggesting that treatment and surveillance of T1G1 carcinomas should be more like the approaches for T1G2 NMIBC in accordance with the intermediate and/or high risk categories of the European Association of Urology NMIBC guidelines. PATIENT SUMMARY: Although rare, stage T1 grade 1 (T1G1) bladder cancer is still diagnosed in daily clinical practice. Using individual patient data from 17 centers in Europe and Canada, we found that time to progression of T1G1 cancer was comparable to that for T1G2 but not TaG1 cancer. Therefore, our results suggest that primary T1G1 bladder cancers should be managed with more aggressive treatment and more frequent follow-up than for low-risk bladder cancer. CI - Copyright (c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Beijert, Irene J AU - Beijert IJ AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Plass, Karin AU - Plass K AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Subiela Henriquez, Jose D AU - Subiela Henriquez JD AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Department of Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bauerova, Lenka AU - Bauerova L AD - Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Pesl, Michael AU - Pesl M AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Maxim Bruins, H AU - Maxim Bruins H AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Runneboom, Willemien AU - Runneboom W AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Calatrava, Ana AU - Calatrava A AD - Department of Pathology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Department of Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Ashabere, David AU - Ashabere D AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Huebner, Nicolai AU - Huebner N AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cotte, Juliette AU - Cotte J AD - Department of Urology, Pitie Salpetriere Hospital, AP-HP, GRC no. 5, Oncotype-Uro, Sorbonne University, Paris, France. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Liedberg, Fredrik AU - Liedberg F AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Lunelli, Luca AU - Lunelli L AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - El Sheikh, Soha AU - El Sheikh S AD - Department of Pathology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Volanis, Dimitrios AU - Volanis D AD - Department of Urology, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK. FAU - Cote, Jean-Francois AU - Cote JF AD - Department of Pathology, Pitie Salpetriere Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitie Salpetriere Hospital, AP-HP, GRC no. 5, Oncotype-Uro, Sorbonne University, Paris, France. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Hacek, Jaromir AU - Hacek J AD - Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - Evert, Matthias AU - Evert M AD - Department of Pathology, University of Regensburg, Regensburg, Germany. FAU - Hulsbergen-van de Kaa, Christina A AU - Hulsbergen-van de Kaa CA AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - A L M Kiemeney, Lambertus AU - A L M Kiemeney L AD - Department of Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Molinaro, Luca AU - Molinaro L AD - Department of Pathology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Llorente, Carlos AU - Llorente C AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - N'Dow, James AU - N'Dow J AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - Ribal, Maria J AU - Ribal MJ AD - European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: b.v.rhijn@nki.nl. LA - eng PT - Journal Article DEP - 20220514 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Non-Muscle Invasive Bladder Neoplasms MH - Europe OTO - NOTNLM OT - Bladder OT - Cancer OT - Carcinoma OT - G1 OT - Grade OT - Non-muscle-invasive OT - T1 OT - Urothelial OT - World Health Organization EDAT- 2022/05/17 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/05/16 22:08 PHST- 2022/03/04 00:00 [received] PHST- 2022/04/13 00:00 [revised] PHST- 2022/04/25 00:00 [accepted] PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/05/16 22:08 [entrez] AID - S2405-4569(22)00110-9 [pii] AID - 10.1016/j.euf.2022.04.014 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Nov;8(6):1627-1634. doi: 10.1016/j.euf.2022.04.014. Epub 2022 May 14. PMID- 35577732 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221006 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 5 DP - 2022 Oct TI - The Accuracy of Sequential Urethral Frozen Section and its Impact on Urethral Recurrence After Radical Cystectomy. PG - e390-e395 LID - S1558-7673(22)00083-0 [pii] LID - 10.1016/j.clgc.2022.04.007 [doi] AB - OBJECTIVE: To assess the accuracy of frozen section analysis (FSA) for detecting and eliminating malignant urethral margins during radical cystectomy (RC) for bladder cancer (BC) and its impact on urethral recurrence. METHODS: Urethral margins were initially examined by FSA in 217 patients at RC. When positive, additional resections were performed. Subsequently, all specimens were re-examined on formalin-fixed, paraffin-embedded sections (FFPE). Malignancy was defined as either the presence of carcinoma in situ, high-grade or invasive tumor cells at the urethral margin. Kaplan-Meier analysis was used to assess the impact of the final urethral margin status on urethral recurrence. Multinomial logistic regression addressed independent risk factors for a positive final urethral margin. RESULTS: At initial examination, urethral margins were positive on FSA and FFPE in 21 (9.7%) and 17 (7.8) patients, respectively. The corresponding sensitivity, specificity, positive and negative predictive values were 88.2%, 97.0%, 71.4% and 99.0% (overall accuracy: 96.3%). After initial FSA, 23 patients (including 2 with equivocal histological findings) received re-resections (median: 1, total range: 1-3). Persistent positive margins were detected on FSA in 10 (43.5%) while none of these margins were positive on FFPE (overall accuracy: 52.2%). A positive urethral FSA at initial assessment was the only independent risk for a positive final urethral margin. The 3-year urethral recurrence-free survival was 99.1% for patients with negative margins on initial assessment (I), 100% for those with negative final margins after re-resection (II) and 83.3% for patients with positive final margins (III; P= .013 for I/II vs. III). CONCLUSIONS: The accuracy of FSA for detecting malignant urethral margins is high on initial examination but drops considerably in case of re-resection while most positive margins at initial FSA are converted to negative final ones on FFPE. Conversion of a positive to a negative margin was associated with a lower risk of urethral recurrence. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Wurzburg, Germany; Department of Urology, University Hospital of Tubingen, Germany. Electronic address: georgios.gakis@web.de. FAU - Schmid, Manuel Alexander AU - Schmid MA AD - Department of Urology, University Hospital of Tubingen, Germany. FAU - Hassan, Fahmy AU - Hassan F AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Wurzburg, Germany; Department of Urology, University Hospital of Tubingen, Germany; King Salman Hospital (MOH), Riyadh, Saudi-Arabia. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital of Tubingen, Germany. FAU - Renninger, Markus AU - Renninger M AD - Department of Urology, University Hospital of Tubingen, Germany. LA - eng PT - Journal Article DEP - 20220422 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 1HG84L3525 (Formaldehyde) SB - IM MH - *Cystectomy MH - Formaldehyde MH - Frozen Sections MH - Humans MH - Margins of Excision MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Urethra/pathology/surgery MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - Final OT - Frozen section OT - Resection OT - Urethra EDAT- 2022/05/17 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/05/16 22:07 PHST- 2022/02/20 00:00 [received] PHST- 2022/04/10 00:00 [revised] PHST- 2022/04/15 00:00 [accepted] PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/05/16 22:07 [entrez] AID - S1558-7673(22)00083-0 [pii] AID - 10.1016/j.clgc.2022.04.007 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Oct;20(5):e390-e395. doi: 10.1016/j.clgc.2022.04.007. Epub 2022 Apr 22. PMID- 35577361 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 8 DP - 2022 Aug TI - Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy. PG - 867-875 LID - 10.1111/iju.14926 [doi] AB - OBJECTIVES: To investigate whether a single intravesical instillation of chemotherapy is associated with improved oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy. METHODS: This multi-institutional retrospective study included 205 patients with high-risk non-muscle-invasive bladder cancer who received adjuvant induction bacillus Calmette-Guerin therapy. Patients were divided into two groups: those who received the combined therapy of a single instillation of chemotherapy plus subsequent adjuvant induction bacillus Calmette-Guerin therapy (combined therapy group), and those who received adjuvant induction bacillus Calmette-Guerin therapy alone (bacillus Calmette-Guerin monotherapy group). Multivariable analyses using the inverse probability of treatment weighting method and Fine-Gray competing risk regression models were performed to evaluate the impact of a single instillation of chemotherapy on intravesical recurrence-free survival and muscle-invasive bladder cancer-free survival. RESULTS: Among the 205 patients, 130 (63%) and 75 (37%) were classified as the combined therapy and bacillus Calmette-Guerin monotherapy groups, respectively. Multivariable analyses using the inverse probability of treatment weighting method showed that a single instillation of chemotherapy was significantly associated with longer intravesical recurrence-free survival (hazard ratio 0.279; P < 0.001) and muscle-invasive bladder cancer-free survival (hazard ratio 0.078; P < 0.001). Fine-Gray competing risk regression model revealed that a single instillation of chemotherapy was associated with a significantly lower probability of intravesical recurrence and muscle-invasive bladder cancer progression, with an adjusted subdistribution hazard ratio of 0.477 (P = 0.008) and 0.261 (P = 0.043), respectively. CONCLUSION: A single intravesical instillation of chemotherapy may be a potential treatment option in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy. CI - (c) 2022 The Japanese Urological Association. FAU - Fujita, Naoki AU - Fujita N AUID- ORCID: 0000-0001-8284-9582 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Momota, Masaki AU - Momota M AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Narita, Takuma AU - Narita T AUID- ORCID: 0000-0003-2572-3590 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AUID- ORCID: 0000-0001-8026-9541 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AUID- ORCID: 0000-0002-1098-407X AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AUID- ORCID: 0000-0002-4557-0619 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AUID- ORCID: 0000-0003-0967-6835 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AUID- ORCID: 0000-0003-1550-8379 AD - Departments of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng GR - 19H05556/Japan Society for the Promotion of Science/ GR - 18K09157/Japan Society for the Promotion of Science/ GR - 17K11119/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20220516 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - *Mycobacterium bovis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/epidemiology/prevention & control MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - chemoinstillation OT - combined therapy OT - high-risk non-muscle-invasive bladder cancer OT - induction bacillus Calmette-Guerin therapy OT - single immediate instillation EDAT- 2022/05/17 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/05/16 20:33 PHST- 2022/01/23 00:00 [received] PHST- 2022/04/24 00:00 [accepted] PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/05/16 20:33 [entrez] AID - 10.1111/iju.14926 [doi] PST - ppublish SO - Int J Urol. 2022 Aug;29(8):867-875. doi: 10.1111/iju.14926. Epub 2022 May 16. PMID- 35575423 OWN - NLM STAT- MEDLINE DCOM- 20220630 LR - 20220630 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 3 DP - 2022 Jun TI - Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study. PG - 221-226 LID - 10.1080/21681805.2022.2062046 [doi] AB - OBJECTIVE: The most common form of urinary bladder cancer is the low and intermediate risk categories of stage Ta. This patient group has a high recurrence rate, but progression is rare. The aim of this study was to investigate recurrence and survival in a large population-based setting, with respect to possible prognostic factors and during different time periods. PATIENTS AND METHODS: BladderBaSe is a database which links information from the Swedish National Register of Urinary Bladder Cancer with national healthcare and demographic registers. Between 1997 and 2014, 16,599 were diagnosed with low and intermediate risk of Ta cancer in Sweden. The times to recurrence and cancer-specific death were analysed concerning the differences in age, gender, grade, region and hospital type. For temporal analysis, we divided the material into 6-year periods. RESULTS: The mean age was 70 years and 75% were males. Low risk according to grade constituted 56%, whilst 44% had intermediate risk. With a median follow-up time of 63 months the recurrence rates were 47% and 59% for the respective categories and overall 52%. The rate was similar between the first two time periods, but became substantially lower in the most recent period. Five percent of patients died of the disease and risk category was the main prognostic variable. CONCLUSIONS: The risk of recurrence decreased in the last time period. Risk category based on grade was the most important prognostic indicator for outcome. FAU - Wang, Eugen Y H AU - Wang EYH AUID- ORCID: 0000-0003-1825-8547 AD - Center for Clinical Research, Uppsala University, Sormland, Sweden. AD - Department of Surgical Sciences, Uppsala University, Urology, Sweden. FAU - Pihlstrom, Nicklas AU - Pihlstrom N AD - Center for Clinical Research, Uppsala University, Sormland, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Urology, Sweden. FAU - Gardmark, Truls AU - Gardmark T AUID- ORCID: 0000-0003-4610-0771 AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20220516 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - Sweden/epidemiology MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy OTO - NOTNLM OT - Bladder cancer OT - prognosis OT - recurrence OT - survival EDAT- 2022/05/17 06:00 MHDA- 2022/07/01 06:00 CRDT- 2022/05/16 08:13 PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/07/01 06:00 [medline] PHST- 2022/05/16 08:13 [entrez] AID - 10.1080/21681805.2022.2062046 [doi] PST - ppublish SO - Scand J Urol. 2022 Jun;56(3):221-226. doi: 10.1080/21681805.2022.2062046. Epub 2022 May 16. PMID- 35574612 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20251224 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 208 IP - 4 DP - 2022 Oct TI - Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. PG - 821-829 LID - 10.1097/JU.0000000000002778 [doi] AB - PURPOSE: We investigated the safety, preliminary efficacy, and immune effects of large surface area microparticle docetaxel (LSAM-DTX) administered by direct injection after transurethral resection of bladder tumor (TURBT), and by intravesical instillation in high-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: The trial followed an open-label 3+3 dose escalation with additional enrollment at the high dose. After TURBT, subjects received direct injection LSAM-DTX into the resection site and intravesical LSAM-DTX, followed by 6-week induction and 3-week maintenance intravesical LSAM-DTX courses. Tumor recurrence was evaluated by cytology, cystoscopy, or biopsy. Pharmacokinetic analysis of blood and multiplex immunofluorescence of tumor microenvironment occurred pre- and post-LSAM-DTX. RESULTS: Nineteen subjects were enrolled, 14 with prior bacillus Calmette-Guerin exposure and 16 with >/=1 prior TURBT. Direct injection and intravesical LSAM-DTX were well tolerated. In the 3 lowest dose escalation cohorts the median recurrence-free survival was 5.4 months (10 patients, median followup 8.6 months). In the high-dose and expansion cohorts median recurrence-free survival was significantly increased (p <0.05, hazard ratio 0.29) to 12.2 months (9 patients, median followup 12.4 months). Systemic docetaxel exposure was negligible and increases in antitumor immune cells were found in the tumor microenvironment along with elevations in the PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitor targets. CONCLUSIONS: Post-TURBT direct injection and intravesical LSAM-DTX were well tolerated and demonstrated clinical response for patients with high-risk nonmuscle-invasive bladder cancer. Favorable immune cell infiltration and checkpoint receptor increases following LSAM-DTX treatment warrants investigation alone as well as in combination with immune checkpoint inhibitor therapy. FAU - Kates, Max AU - Kates M AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland. FAU - Mansour, Ahmed M AU - Mansour AM AD - UT Health San Antonio, San Antonio, Texas. FAU - Lamm, Donald L AU - Lamm DL AD - BCG Oncology, PC, Phoenix, Arizona. FAU - Shore, Neal AU - Shore N AD - Carolina Urologic Research Center, Myrtle Beach, South Carolina. FAU - Maulhardt, Holly AU - Maulhardt H AD - US Biotest, Inc., San Luis Obispo, California. FAU - Wendt, Alison AU - Wendt A AD - US Biotest, Inc., San Luis Obispo, California. FAU - Verco, James AU - Verco J AD - US Biotest, Inc., San Luis Obispo, California. FAU - Marin, Alyson AU - Marin A AD - US Biotest, Inc., San Luis Obispo, California. FAU - Dewnani, Karan AU - Dewnani K AD - DFB Pharmaceuticals, Inc., Fort Worth, Texas. FAU - Verco, Shelagh AU - Verco S AD - US Biotest, Inc., San Luis Obispo, California. FAU - diZerega, Gere S AU - diZerega GS AD - US Biotest, Inc., San Luis Obispo, California. AD - NanOlogy, LLC., Fort Worth, Texas. LA - eng PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220516 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) RN - 15H5577CQD (Docetaxel) SB - IM CIN - J Urol. 2022 Oct;208(4):829. doi: 10.1097/JU.0000000000002778.02. PMID: 35830560 CIN - J Urol. 2022 Oct;208(4):828-829. doi: 10.1097/JU.0000000000002778.01. PMID: 35830563 MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Docetaxel/therapeutic use MH - Humans MH - Immune Checkpoint Inhibitors MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Treatment Outcome MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/surgery PMC - PMC12721687 OTO - NOTNLM OT - docetaxel OT - tumor microenvironment OT - urinary bladder neoplasms COIS- Conflict of Interest: Max Kates: NanOlogy, Janssen, Pacific Edge. EDAT- 2022/05/17 06:00 MHDA- 2022/09/14 06:00 PMCR- 2025/12/22 CRDT- 2022/05/16 05:01 PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/05/16 05:01 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - JU-22-177 [pii] AID - 10.1097/JU.0000000000002778 [doi] PST - ppublish SO - J Urol. 2022 Oct;208(4):821-829. doi: 10.1097/JU.0000000000002778. Epub 2022 May 16. PMID- 35563543 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220518 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 9 DP - 2022 May 5 TI - Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma. LID - 10.3390/ijms23095154 [doi] LID - 5154 AB - To evaluate biological characteristics and transitions of upper tract urothelial carcinoma (UTUC) through metachronous bladder tumors after radical nephroureterectomy (RNU), we conducted immunohistochemical (IHC) staining of tumor specimens of UTUC tumor origin, non-muscle-invasive bladder cancer (NMIBC) and MIBC progressed after intravesical recurrence (IVR), and bladder primary MIBC. Fibroblast growth factor receptor 3 (FGFR3), p53, cytokeratin 5/6 (CK5/6), and CK20 were stained to examine expression rates. After expression assessment with heatmap clustering, the overexpression of four biomarkers from UTUC origin to metachronous MIBC progression was analyzed with clinicopathological variables. We found that high CK20 and low CK5/6 expression were both observed in UTUC tumor origin and subsequent NMIBC after RNU. By investigating molecular expression in the IVR specimen, we observed that low pT stage bladder recurrence occupied the majority of CK20 high CK5/6 low expression, but would change to CK20 low CK5/6 high expression as it progressed to MIBC. UTUC metachronous MIBC has different characteristics compared with bladder primary MIBC, which comprises favorable biological features such as high FGFR3 expression, and follows favorable prognosis compared to those without FGFR3 expression. The present study demonstrated that the biological characteristics of UTUC tumor origin shifts from luminal to basal-like features with progression to MIBC, but FGFR3 expression taken over from UTUC origin may comprise a favorable entity compared to primary MIBC. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AUID- ORCID: 0000-0001-9222-0999 AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Mikami, Shuji AU - Mikami S AUID- ORCID: 0000-0002-2978-2187 AD - Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Kosaka, Takeo AU - Kosaka T AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Yasumizu, Yota AU - Yasumizu Y AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Takeda, Toshikazu AU - Takeda T AUID- ORCID: 0000-0003-1196-8642 AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa 216-8511, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan. LA - eng GR - JP18K09179/Japan Society for the Promotion of Science KAKENHI/ GR - JP 21K20811/the Japan Society for the Promotion of Science KAKENHI/ GR - 2020/Japanese Foundation for Research and Promotion of Endoscopy/ PT - Journal Article DEP - 20220505 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Female MH - Humans MH - Male MH - Muscles/pathology MH - Neoplasm Recurrence, Local/pathology MH - *Neoplasms, Second Primary/pathology MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology MH - *Urologic Neoplasms/pathology PMC - PMC9105227 OTO - NOTNLM OT - fibroblast growth factor receptor 3 OT - intravesical recurrence OT - molecular characteristic OT - muscle-invasive bladder carcinoma OT - upper tract urothelial carcinoma COIS- All authors state that there are no conflicts of interest in the subject matter or materials discussed in the manuscript. EDAT- 2022/05/15 06:00 MHDA- 2022/05/18 06:00 PMCR- 2022/05/05 CRDT- 2022/05/14 01:06 PHST- 2022/03/24 00:00 [received] PHST- 2022/04/27 00:00 [revised] PHST- 2022/04/29 00:00 [accepted] PHST- 2022/05/14 01:06 [entrez] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/05/05 00:00 [pmc-release] AID - ijms23095154 [pii] AID - ijms-23-05154 [pii] AID - 10.3390/ijms23095154 [doi] PST - epublish SO - Int J Mol Sci. 2022 May 5;23(9):5154. doi: 10.3390/ijms23095154. PMID- 35554648 OWN - NLM STAT- MEDLINE DCOM- 20221118 LR - 20230102 IS - 1432-1084 (Electronic) IS - 0938-7994 (Print) IS - 0938-7994 (Linking) VI - 32 IP - 11 DP - 2022 Nov TI - Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. PG - 7513-7521 LID - 10.1007/s00330-022-08813-4 [doi] AB - OBJECTIVES: To develop a modified Vesical Imaging Reporting and Data System (VI-RADS) without dynamic contrast-enhanced imaging (DCEI), termed "non-contrast-enhanced VI-RADS (NCE-VI-RADS)", and to assess the additive impact of denoising deep learning reconstruction (dDLR) on NCE-VI-RADS. METHODS: From January 2019 through December 2020, 163 participants who underwent high-gradient 3-T MRI of the bladder were prospectively enrolled. In total, 108 participants with pathologically confirmed bladder cancer by transurethral resection were analyzed. Tumors were evaluated based on VI-RADS (scores 1-5) by two readers independently: an experienced radiologist (reader 1) and a senior radiology resident (reader 2). Conventional VI-RADS assessment included all three imaging types (T2-weighted imaging [T2WI], diffusion-weighted imaging [DWI], and dynamic contrast-enhanced imaging [DCEI]). Also evaluated were NCE-VI-RADS comprising only non-contrast-enhanced imaging types (T2WI and DWI), and "NCE-VI-RADS with dDLR" comprising T2WI processed with dDLR and DWI. All systems were assessed using receiver-operating characteristic curve analysis and simple and/or weighted kappa statistics. RESULTS: Muscle invasion was identified in 23/108 participants (21%). Area under the curve (AUC) values for diagnosing muscle invasion were as follows: conventional VI-RADS, 0.94 and 0.91; NCE-VI-RADS, 0.93 and 0.91; and "NCE-VI-RADS with dDLR", 0.96 and 0.93, for readers 1 and 2, respectively. Simple kappa statistics indicated substantial agreement for NCE-VI-RADS and almost perfect agreement for conventional VI-RADS and "NCE-VI-RADS with dDLR" between the two readers. CONCLUSION: NCE-VI-RADS achieved predictive accuracy for muscle invasion comparable to that of conventional VI-RADS. Additional use of dDLR improved the diagnostic accuracy of NCE-VI-RADS. KEY POINTS: * Non-contrast-enhanced Vesical Imaging Reporting and Data System (NCE-VI-RADS) was developed to avoid risk related to gadolinium-based contrast agent administration. * NCE-VI-RADS had predictive accuracy for muscle invasion comparable to that of conventional VI-RADS. * The additional use of denoising deep learning reconstruction (dDLR) might further improve the diagnostic accuracy of NCE-VI-RADS. CI - (c) 2022. The Author(s). FAU - Watanabe, Masanaka AU - Watanabe M AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Machida, Haruhiko AU - Machida H AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. hmachida@ks.kyorin-u.ac.jp. AD - Department of Radiology, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa, Tokyo, 116-8567, Japan. hmachida@ks.kyorin-u.ac.jp. FAU - Tambo, Mitsuhiro AU - Tambo M AD - Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. tanbodes@ks.kyorin-u.ac.jp. FAU - Takeshita, Yuhei AU - Takeshita Y AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Kariyasu, Toshiya AU - Kariyasu T AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. AD - Department of Radiology, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa, Tokyo, 116-8567, Japan. FAU - Fukushima, Keita AU - Fukushima K AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Shimizu, Yuta AU - Shimizu Y AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Okegawa, Takatsugu AU - Okegawa T AD - Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. FAU - Yokoyama, Kenichi AU - Yokoyama K AD - Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. LA - eng PT - Journal Article DEP - 20220512 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Humans MH - *Data Systems MH - Urinary Bladder/diagnostic imaging/pathology MH - Prospective Studies MH - Retrospective Studies MH - Magnetic Resonance Imaging/methods MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology MH - Magnetic Fields PMC - PMC9668777 OTO - NOTNLM OT - Bladder cancer OT - Deep learning OT - Magnetic resonance imaging OT - Prospective OT - Vesical Imaging-Reporting and Data System (VI-RADS) COIS- The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. EDAT- 2022/05/14 06:00 MHDA- 2022/11/19 06:00 PMCR- 2022/05/12 CRDT- 2022/05/13 15:55 PHST- 2021/10/09 00:00 [received] PHST- 2022/04/12 00:00 [accepted] PHST- 2022/03/27 00:00 [revised] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/11/19 06:00 [medline] PHST- 2022/05/13 15:55 [entrez] PHST- 2022/05/12 00:00 [pmc-release] AID - 10.1007/s00330-022-08813-4 [pii] AID - 8813 [pii] AID - 10.1007/s00330-022-08813-4 [doi] PST - ppublish SO - Eur Radiol. 2022 Nov;32(11):7513-7521. doi: 10.1007/s00330-022-08813-4. Epub 2022 May 12. PMID- 35551661 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220517 IS - 0927-3042 (Print) IS - 0927-3042 (Linking) VI - 183 DP - 2022 TI - Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. PG - 201-223 LID - 10.1007/978-3-030-96376-7_7 [doi] AB - Immunotherapy, the 5th pillar of cancer care after surgery, radiotherapy, cytotoxic chemotherapy, and precision therapy (molecular targeted therapy), is revolutionizing the standard of care in certain patients with genitourinary malignancies. As modest clinical benefits of IL-2 for metastatic renal cell carcinoma and Bacillus Calmette-Guerin therapy for early-stage bladder cancers in the past years, immune checkpoint inhibitors therapies demonstrate meaningful survival benefit and durable clinical response in renal cell carcinoma, urothelial carcinoma, and some prostate cancer. Despite best efforts, the benefits are limited to a minority of unselected patients due to the complexities of biomarker development. Now come the next hurdles: figuring out which patients best respond to immune checkpoint inhibitors and which patients won't respond to immune checkpoint inhibitors? How best to approach immune checkpoint inhibitors therapies to extend/maximize the treatment response as long as possible? How to overcome therapeutic resistance by specific concurrent immunomodulators or targeted therapy or chemotherapy? The role of immune checkpoint inhibitors in combination or sequencing with chemotherapy or other targeted therapies or other immunomodulating therapeutics in the early disease, neoadjuvant, adjuvant, and metastatic setting is actively under exploration. Ideal strategy for cancer care is to provide not just more time, but more quality time: there remain unmet needs for novel therapies that exploit molecular or genetic pathways to extend survival without compromising health-related quality of life for patients with advanced genitourinary malignancies. Further research is needed to discover new therapeutic strategies, and validate efficacy and effectiveness in real-world settings. CI - (c) 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG. FAU - Lu, Kevin AU - Lu K AD - Division of Urology, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705. kevinlu0620@mail2000.com.tw. AD - Department of Surgery and Clinical Competences Center, Department of Medical Education, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705. kevinlu0620@mail2000.com.tw. AD - School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan. kevinlu0620@mail2000.com.tw. AD - Department of Urology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan. kevinlu0620@mail2000.com.tw. AD - School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. kevinlu0620@mail2000.com.tw. FAU - Chiu, Kun-Yuan AU - Chiu KY AD - Division of Urology, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705. AD - School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan. AD - Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan. FAU - Cheng, Chen-Li AU - Cheng CL AD - Division of Urology, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705. AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. LA - eng PT - Journal Article PL - United States TA - Cancer Treat Res JT - Cancer treatment and research JID - 8008541 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Immunologic Factors) SB - IM MH - *Carcinoma, Renal Cell MH - *Carcinoma, Transitional Cell MH - Female MH - Humans MH - Immune Checkpoint Inhibitors MH - Immunologic Factors MH - Immunotherapy MH - *Kidney Neoplasms MH - Male MH - Quality of Life MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Genitourinary cancer OT - Immune checkpoint inhibitors OT - Immunotherapy OT - Prostate cancer OT - Renal cell carcinoma OT - Urothelial cancer EDAT- 2022/05/14 06:00 MHDA- 2022/05/18 06:00 CRDT- 2022/05/13 13:45 PHST- 2022/05/13 13:45 [entrez] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] AID - 10.1007/978-3-030-96376-7_7 [doi] PST - ppublish SO - Cancer Treat Res. 2022;183:201-223. doi: 10.1007/978-3-030-96376-7_7. PMID- 35550107 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20220523 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 5 DP - 2021 May TI - Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer. PG - 286-290 LID - S1078-1439(20)30636-0 [pii] LID - 10.1016/j.urolonc.2020.12.007 [doi] AB - Papillary urothelial neoplasm of low malignant potential (PUNLMP) terminology remains controversial given its reported recurrence rate, its low interobserver diagnostic reproducibility, and its morphologic and molecular genetic overlap with low-grade noninvasive papillary urothelial carcinoma. By contrast, referring to any noninvasive tumor as a "carcinoma" is also controversial. PUNLMP and low-grade noninvasive papillary urothelial carcinomas cannot be reliably distinguished from one another even by experienced pathologists. As both tumors are treated in an identical manner and have similar rates of recurrence and progression, attempting to make this distinction is unnecessary and of little clinical value. These tumor types should therefore be combined into a single category for grading purposes. We propose that all tumors currently classified as either PUNLMP or low-grade noninvasive papillary urothelial carcinoma be termed low-grade noninvasive papillary urothelial neoplasms (NIPUN). This could improve interobserver reproducibility without sacrificing the prognostic utility of histologic grading. PUNLMP terminology should be discontinued and the term "carcinoma" should be reserved only for tumors showing histologic evidence of invasion. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Jones, Timothy D AU - Jones TD AD - Department of Pathology, Norton Healthcare/CPA Lab, Louisville, KY. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: liang_cheng@yahoo.com. LA - eng PT - Journal Article DEP - 20210101 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Carcinoma in Situ/pathology MH - *Carcinoma, Papillary/diagnosis/genetics/pathology MH - *Carcinoma, Transitional Cell/diagnosis/genetics/pathology MH - Humans MH - Reproducibility of Results MH - *Urinary Bladder Neoplasms/diagnosis/genetics/pathology MH - *Urologic Neoplasms/pathology MH - Urothelium/pathology OTO - NOTNLM OT - Bladder OT - Classification OT - Differential diagnosis OT - Histologic grading OT - Noninvasive papillary urothelial neoplasia (NIPUN) OT - PUNLMP OT - Papillary urothelial neoplasm of low malignant potential OT - Urothelial carcinoma EDAT- 2022/05/14 06:00 MHDA- 2022/05/20 06:00 CRDT- 2022/05/13 12:24 PHST- 2020/08/17 00:00 [received] PHST- 2020/11/11 00:00 [revised] PHST- 2020/12/09 00:00 [accepted] PHST- 2022/05/13 12:24 [entrez] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] AID - S1078-1439(20)30636-0 [pii] AID - 10.1016/j.urolonc.2020.12.007 [doi] PST - ppublish SO - Urol Oncol. 2021 May;39(5):286-290. doi: 10.1016/j.urolonc.2020.12.007. Epub 2021 Jan 1. PMID- 35549969 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220622 IS - 1521-0553 (Electronic) IS - 0894-1939 (Linking) VI - 35 IP - 7 DP - 2022 Jul TI - A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma. PG - 1610-1611 LID - 10.1080/08941939.2022.2071507 [doi] FAU - Tsapakidis, Konstantinos AU - Tsapakidis K AD - Department of Oncology, University Hospital of Larissa, Medical School, University of Thessaly, Larissa, Greece. FAU - Liontos, Michalis AU - Liontos M AD - Department of Clinical Therapeutics, "Alexandra" Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Tolia, Maria AU - Tolia M AD - Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece. FAU - Tsoukalas, Nikolaos AU - Tsoukalas N AD - Department of Oncology, 401 General Military Hospital of Athens, Athens, Greece. LA - eng PT - Journal Article DEP - 20220512 PL - United States TA - J Invest Surg JT - Journal of investigative surgery : the official journal of the Academy of Surgical Research JID - 8809255 SB - IM MH - *Carcinoma, Transitional Cell/diagnosis/pathology/surgery MH - Humans MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/diagnosis/pathology/prevention & control MH - *Nomograms MH - Retrospective Studies MH - Urinary Bladder EDAT- 2022/05/14 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/05/13 12:17 PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/05/13 12:17 [entrez] AID - 10.1080/08941939.2022.2071507 [doi] PST - ppublish SO - J Invest Surg. 2022 Jul;35(7):1610-1611. doi: 10.1080/08941939.2022.2071507. Epub 2022 May 12. PMID- 35528782 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 39 DP - 2022 May TI - Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. PG - 14-21 LID - 10.1016/j.euros.2022.02.011 [doi] AB - BACKGROUND: Radical cystectomy (RC) is indicated in primary or secondary muscle-invasive bladder cancer (primMIBC, secMIBC) and in primary or recurrent high- or very high-risk non-muscle-invasive bladder cancer (primHR-NMIBC, recHR-NMIBC). The optimal timing for RC along the disease spectrum of nonmetastatic urothelial carcinoma remains unclear. OBJECTIVE: To compare outcomes after RC between patients with primHR-NMIBC, recHR-NMIBC, primMIBC, and secMIBC. DESIGN SETTING AND PARTICIPANTS: This retrospective, multicenter study included patients with clinically nonmetastatic bladder cancer (BC) treated with RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed oncological outcomes for patients who underwent RC according to the natural history of their BC. primHR-NMIBC and primMIBC were defined as no prior history of BC, and recHR-NMIBC and secMIBC as previously treated NMIBC that recurred or progressed to MIBC, respectively. Log-rank analysis was used to compare survival outcomes, and univariable and multivariable Cox and logistic regression analyses were used to identify predictors for survival. RESULTS AND LIMITATIONS: Among the 908 patients included, 211 (23%) had primHR-NMIBC, 125 (14%) had recHR-NMIBC, 404 (44%) had primMIBC, and 168 (19%) had secMIBC. Lymph node involvement and pathological upstaging were more frequent in the secMIBC group than in the other groups (p < 0.001). The median follow-up was 37 mo. The 5-year recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were 77.9%, 83.2%, and 72.7% in primHR-NMIBC, 60.0%, 59%, and 48.9% in recHR-NMIBC, 60.9%, 64.5%, and 54.8% in primMIBC, and 41.3%, 46.5%, and 39% in secMIBC, respectively, with statistically significant differences across all survival outcomes except between recHR-NMIBC and primMIBC. On multivariable Cox regression, recHR-NMIBC was independently associated with shorter RFS (hazard ratio [HR] 1.64; p = 0.03), CSS (HR 1.79; p = 0.01), and OS (HR 1.45; p = 0.03), and secMIBC was associated with shorter CSS (HR 1.77; p = 0.01) and OS (HR 1.57; p = 0.006). Limitations include the biases inherent to the retrospective study design. CONCLUSIONS: Patients with recHR-NMIBC and primHR-MIBC had similar survival outcomes, while those with sec-MIBC had the worst outcomes. Therefore, early radical intervention may be indicated in selected patients, and potentially neoadjuvant systemic therapies in some patients with recHR-NMIBC. PATIENT SUMMARY: We compared cancer outcomes in different bladder cancer scenarios in a large, multinational series of patients who underwent removal of the bladder with curative intent. We found that patients who experienced recurrence of non-muscle-invasive bladder cancer (NMIBC) had similar survival outcomes to those with initial muscle-invasive bladder cancer (MIBC), while patients who experienced progression of NMIBC to MIBC had the worst outcomes. Selected patients with non-muscle-invasive disease may benefit from early radical surgery or from perioperative chemotherapy or immunotherapy. CI - (c) 2022 The Author(s). FAU - Grossmann, Nico C AU - Grossmann NC AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Konig, Frederik AU - Konig F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Katayama, Satoshi AU - Katayama S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Motlagh, Reza Sari AU - Motlagh RS AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Fankhauser, Christian D AU - Fankhauser CD AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Chlosta, Piotr AU - Chlosta P AD - Department of Urology, Jagiellonian University, Krakow, Poland. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Teoh, Jeremy Y C AU - Teoh JYC AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20220401 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC9068727 OTO - NOTNLM OT - Disease progression OT - Mycobacterium bovis OT - Recurrence OT - Survival OT - Urinary bladder neoplasms EDAT- 2022/05/10 06:00 MHDA- 2022/05/10 06:01 PMCR- 2022/04/01 CRDT- 2022/05/09 04:00 PHST- 2022/02/27 00:00 [accepted] PHST- 2022/05/09 04:00 [entrez] PHST- 2022/05/10 06:00 [pubmed] PHST- 2022/05/10 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - S2666-1683(22)00054-4 [pii] AID - 10.1016/j.euros.2022.02.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2022 Apr 1;39:14-21. doi: 10.1016/j.euros.2022.02.011. eCollection 2022 May. PMID- 35527047 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20220928 IS - 1465-3931 (Electronic) IS - 0031-3025 (Linking) VI - 54 IP - 6 DP - 2022 Oct TI - Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmette-Guerin instillation. PG - 700-706 LID - S0031-3025(22)00124-6 [pii] LID - 10.1016/j.pathol.2022.01.010 [doi] AB - Bacillus Calmette-Guerin (BCG) instillation is the gold standard for the treatment of patients with pT1 bladder cancer but causes severe adverse effects. Few predictive factors have been established for intravesical recurrence and/or stage progression in bladder cancer. We analysed 138 patients who underwent transurethral resection of bladder tumour and were pathologically confirmed to have stage pT1 bladder cancer. Of these, 72 patients (52.2%) received intravesical BCG instillation, 12 patients (8.7%) demonstrated stage progression, and five patients (3.6%) died of the disease. The number of patients who received BCG instillation was more in the group with multifocal tumours than that in the group with unifocal tumours (p=0.0034). Among 53 patients (38.4%) who demonstrated cytokeratin 5/6 (CK5/6) expression, 15 patients (28.3%) showed CK5/6 expression in more than 10% of tumour cells and 38 patients (71.7%) showed CK5/6 expression in 1-10% of tumour cells. CK5/6 expression was observed in both invasive and non-invasive components in 15 patients (28.3%), only in invasive components in 30 patients (56.6%), and only in non-invasive components in eight patients (15.1%). Furthermore, CK5/6 expression was observed in tumour cells only in front of the invasive component and stroma in 24 patients. The proportion of CK5/6-expressing tumour cells in the invasive component was significantly higher than that in the non-invasive component (p<0.001). The follow-up period for patients who received BCG tended to be shorter than that in the non-BCG patients. The CK5/6-positive group displayed significantly shorter recurrence-free survival (RFS) than the CK5/6-negative group (p=0.0412). Importantly, CK5/6 expression was a significant predictive factor of inferior RFS in the BCG instillation group (p=0.0197). In contrast, CK5/6 expression was not significantly associated with RFS in the non-BCG instillation group (p=0.841). Thus, CK5/6 expression can be a predictive marker for RFS in patients with pT1 bladder cancer and can provide critical information for patient care. CI - Copyright (c) 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved. FAU - Yamamoto, Yuuki AU - Yamamoto Y AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Takahara, Taishi AU - Takahara T AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Ohashi, Akiko AU - Ohashi A AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Taniguchi, Natsuki AU - Taniguchi N AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Ito, Takanori AU - Ito T AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Sassa, Naoto AU - Sassa N AD - Department of Urology, Aichi Medical University Hospital, Nagakute, Japan. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AD - Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan. Electronic address: tsuzuki@aichi-med-u.ac.jp. LA - eng PT - Journal Article DEP - 20220505 PL - England TA - Pathology JT - Pathology JID - 0175411 RN - 0 (BCG Vaccine) RN - 0 (Keratin-5) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Keratin-5 MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - CK5/6 OT - bacillus Calmette-Guerin OT - disease progression OT - intravesical recurrence OT - non-muscle-invasive bladder cancer OT - urothelial carcinoma EDAT- 2022/05/09 06:00 MHDA- 2022/09/24 06:00 CRDT- 2022/05/08 22:03 PHST- 2021/10/19 00:00 [received] PHST- 2022/01/22 00:00 [revised] PHST- 2022/01/28 00:00 [accepted] PHST- 2022/05/09 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/05/08 22:03 [entrez] AID - S0031-3025(22)00124-6 [pii] AID - 10.1016/j.pathol.2022.01.010 [doi] PST - ppublish SO - Pathology. 2022 Oct;54(6):700-706. doi: 10.1016/j.pathol.2022.01.010. Epub 2022 May 5. PMID- 35503263 OWN - NLM STAT- MEDLINE DCOM- 20220616 LR - 20241023 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 132 IP - 12 DP - 2022 Jun 15 TI - BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. LID - 10.1172/JCI145666 [doi] LID - e145666 AB - Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guerin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumors, and samples from cohorts of patients with bladder cancer before and after BCG therapy, we demonstrate 2 distinct patterns of immune subversion upon BCG relapse. In the first pattern, intracellular BCG infection of cancer cells induced a posttranscriptional downregulation of HLA-I membrane expression via inhibition of autophagy flux. Patients with HLA-I-deficient cancer cells following BCG therapy had a myeloid immunosuppressive tumor microenvironment (TME) with epithelial-mesenchymal transition (EMT) characteristics and dismal outcomes. Conversely, patients with HLA-I-proficient cancer cells after BCG therapy presented with CD8+ T cell tumor infiltrates, upregulation of inflammatory cytokines, and immune checkpoint-inhibitory molecules. The latter patients had a very favorable outcome. We surmise that HLA-I expression in bladder cancers at relapse following BCG does not result from immunoediting but rather from an immune subversion process directly induced by BCG on cancer cells, which predicts a dismal prognosis. HLA-I scoring of cancer cells by IHC staining can be easily implemented by pathologists in routine practice to stratify future treatment strategies for patients with urothelial cancer. FAU - Rouanne, Mathieu AU - Rouanne M AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. AD - Departement d'Urologie, Hopital Foch, UVSQ - Universite Paris-Saclay, Suresnes, France. FAU - Adam, Julien AU - Adam J AD - Departement de Biologie et Pathologie Medicales, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - INSERM U1186, Gustave Roussy, Villejuif, France. FAU - Radulescu, Camelia AU - Radulescu C AD - Departement de Pathologie, Hopital Foch, UVSQ - Universite Paris-Saclay, Suresnes, France. FAU - Letourneur, Diane AU - Letourneur D AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Master de Biologie, Ecole Normale Superieure de Lyon, Universite Claude Bernard Lyon I, Universite de Lyon, Lyon, France. FAU - Bredel, Delphine AU - Bredel D AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Mouraud, Severine AU - Mouraud S AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Goubet, Anne-Gaelle AU - Goubet AG AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Leduc, Marion AU - Leduc M AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, and. AD - Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Chen, Noah AU - Chen N AD - Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. FAU - Tan, Tuan Zea AU - Tan TZ AD - Genomics and Data Analytics Core (GeDaC), Cancer Science Institute of Singapore, National University of Singapore, Singapore. FAU - Signolle, Nicolas AU - Signolle N AD - INSERM U981, Gustave Roussy, Villejuif, France. FAU - Bigorgne, Amelie AU - Bigorgne A AD - INSERM U1163, Institut Imagine, Universite de Paris, Paris, France. AD - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Dussiot, Michael AU - Dussiot M AD - INSERM U1163, Institut Imagine, Universite de Paris, Paris, France. FAU - Tselikas, Lambros AU - Tselikas L AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Susini, Sandrine AU - Susini S AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Danlos, Francois-Xavier AU - Danlos FX AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Schneider, Anna K AU - Schneider AK AD - INSERM U981, Gustave Roussy, Villejuif, France. FAU - Chabanon, Roman AU - Chabanon R AD - ATIP-Avenir Group, INSERM U981, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. FAU - Vacher, Sophie AU - Vacher S AD - Service de Genetique, Institut Curie, PSL Research University, Paris, France. FAU - Bieche, Ivan AU - Bieche I AD - Service de Genetique, Institut Curie, PSL Research University, Paris, France. FAU - Lebret, Thierry AU - Lebret T AD - Departement d'Urologie, Hopital Foch, UVSQ - Universite Paris-Saclay, Suresnes, France. FAU - Allory, Yves AU - Allory Y AD - Departement de Pathologie, Hopital Foch, UVSQ - Universite Paris-Saclay, Suresnes, France. AD - Department de Pathologie, Institut Curie, Saint-Cloud, France. AD - CNRS UMR144, Paris, France. FAU - Soria, Jean-Charles AU - Soria JC AD - Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - INSERM U1163, Institut Imagine, Universite de Paris, Paris, France. FAU - Arpaia, Nicholas AU - Arpaia N AD - Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. AD - Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA. FAU - Kroemer, Guido AU - Kroemer G AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, and. AD - Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Centre de Recherche des Cordeliers, Universite de Paris, Sorbonne Universite, INSERM U1138, Institut Universitaire de France, Paris, France. AD - Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. FAU - Kepp, Oliver AU - Kepp O AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, and. AD - Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Thiery, Jean Paul AU - Thiery JP AD - INSERM U981, Gustave Roussy, Villejuif, France. AD - Guangzhou Laboratory, Guangzhou, China. FAU - Zitvogel, Laurence AU - Zitvogel L AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Centre d'Investigation Clinique de Biotherapies du Cancer (CICBT), Villejuif, France. FAU - Marabelle, Aurelien AU - Marabelle A AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Gustave Roussy, Universite Paris-Saclay, Villejuif, France. AD - Centre d'Investigation Clinique de Biotherapies du Cancer (CICBT), Villejuif, France. LA - eng GR - T32 GM145440/GM/NIGMS NIH HHS/United States GR - U01 CA247573/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Immunity MH - Immunotherapy MH - *Mycobacterium bovis MH - Neoplasm Recurrence, Local/metabolism MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC9197524 OTO - NOTNLM OT - Bacterial infections OT - Cancer OT - Immunology OT - MHC class 1 OT - Oncology COIS- Conflict of interest: Over the past 2 years, JCS has received consultancy fees and shares from Relay Therapeutics and Gritstone bio; was on the board of directors of Hookipa Pharmaceuticals (2018-2021); was full-time employee (2017-2019) at AstraZeneca; and has been a full-time employee at Amgen since August 2021. Over the past 7 years, AM has received institutional funding grants from AstraZeneca, Merus, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Transgene, Fondation MSD Avenir, and Sanofi; is member of the Clinical Trial Steering Committee for NCT02528357 (GlaxoSmithKline [GSK]), NCT03334617 (AstraZeneca); is a member of the Data Safety and Monitoring Board for NCT02423863 (sponsor: Oncovir) and NCT03818685 (sponsor: Centre Leon Berard); has participated on the scientific advisory boards of the following companies: Merck Serono, eTheRNA, Lytix Biopharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, AstraZeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX Pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD, Innate Pharma, and HotSpot Therapeutics; has received teaching/speaker honoraria from Roche/Genentech, BMS, Merck (MSD), Merck Serono, AstraZeneca/Medimmune, Amgen, Sanofi, and Servier; has received fees for scientific and medical consulting from Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, Benta Pharma Industries (BPI), and Faron; has received nonfinancial support (travel expenses) from AstraZeneca, BMS, Merck (MSD), and Roche; and is co-founder and shareholder of Centessa; holds a patent titled "Humanized and chimeric monoclonal antibodies to CD81" (US patent application serial no. 62/351,054). LZ is founder of EverImmune, a cancer/microbiome biotechnology company; is a member of the board of directors of Transgene; is a member of the scientific advisory board of Transgene, EpiVax, Lytix Biopharma; has received past research contracts with Merus, Roche, and Tusk and honoraria from Transgene; has current research contracts with Innovate Pharma, Kaleido, Pileje, Incyte, BMS, GSK, and Transgene; and is an employee of Gustave Roussy and the Faculte de Medecine Paris XI. GK is on the board of directors of the BMS Foundation (France); receives grants and research support form Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sotio, and Vasculox/Tioma; is founder and shareholder of EverImmune, Osasuna Therapeutics, Samsara Therapeutics, and Therafast Bio ; and is an employee of the University of Paris, AP-HP, Gustave Roussy. OK receives grant and research support from Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sotio, and Vasculox/Tioma; is founder and shareholder of Samsara Therapeutics; and is an employee of INSERM, Gustave Roussy. JPT is the scientific founder and chairman of BioCheetah Pte Ltd (Singapore), a company involved in urine-based bladder cancer diagnostics. LT has received research grants from the BMS Foundation and Terumo and honoraria or consulting fees from Boston Scientific, General Electric, and Ipsen. EDAT- 2022/05/04 06:00 MHDA- 2022/06/18 06:00 PMCR- 2022/06/15 CRDT- 2022/05/03 12:03 PHST- 2020/11/02 00:00 [received] PHST- 2022/04/26 00:00 [accepted] PHST- 2022/05/04 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2022/05/03 12:03 [entrez] PHST- 2022/06/15 00:00 [pmc-release] AID - 145666 [pii] AID - 10.1172/JCI145666 [doi] PST - ppublish SO - J Clin Invest. 2022 Jun 15;132(12):e145666. doi: 10.1172/JCI145666. PMID- 35495284 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 38 DP - 2022 Apr TI - STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. PG - 88-95 LID - 10.1016/j.euros.2022.02.004 [doi] AB - BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non-muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC. OBJECTIVE: To confirm the relationship between STAG2 protein expression and clinical outcomes and tumour characteristics in NMIBC. DESIGN SETTING AND PARTICIPANTS: IHC was used to determine STAG2 expression in 748 incident urothelial bladder cancers (UBCs) and recurrence-free, progression-free, and disease-specific survival were compared for patients with and without STAG2 loss. Exome and RNA sequencing were used to explore links between STAG2 loss and tumour molecular characteristics. RESULTS AND LIMITATIONS: STAG2 loss was observed in 19% of UBC patients and was 1.6-fold more common among female patients. Loss was frequent among grade 1 pTa tumours (40%), decreasing with stage and grade to only 5% among grade 3 pT2+ tumours. Loss was associated with fewer copy-number changes and less aggressive expression subtypes. In UBC, STAG2 loss was a highly significant prognostic indicator of better disease-free survival but was not independent of stage and grade. STAG2 loss was not a statistically significant predictor of NMIBC recurrence. STAG2 loss was significantly associated with better progression-free survival in NMIBC and appeared to be more prognostic for males than for females. CONCLUSIONS: A simple IHC-based STAG2 test shows promise for identifying NMIBC patients at lower risk of progression to MIBC for whom more conservative treatments may be suitable. PATIENT SUMMARY: A protein called STAG2 is frequently lost in early bladder cancers, most often in less aggressive tumours. STAG2 loss is easily measured and could be used as a biomarker to help guide treatment decisions. CI - (c) 2022 The Authors. FAU - Gordon, Naheema S AU - Gordon NS AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Humayun-Zakaria, Nada AU - Humayun-Zakaria N AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Goel, Anshita AU - Goel A AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Abbotts, Ben AU - Abbotts B AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Care and Public Health Research Institute, School of Nutrition and Translational Research in Metabolism, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer Research, London, UK. FAU - Arnold, Roland AU - Arnold R AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Ward, Douglas G AU - Ward DG AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article DEP - 20220304 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC9051973 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Prognosis OT - STAG2 EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/03/04 CRDT- 2022/05/02 06:39 PHST- 2022/02/15 00:00 [accepted] PHST- 2022/05/02 06:39 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/03/04 00:00 [pmc-release] AID - S2666-1683(22)00038-6 [pii] AID - 10.1016/j.euros.2022.02.004 [doi] PST - epublish SO - Eur Urol Open Sci. 2022 Mar 4;38:88-95. doi: 10.1016/j.euros.2022.02.004. eCollection 2022 Apr. PMID- 35494036 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Risk Factors for Unfavorable Pathological Types of Intravesical Recurrence in Patients With Upper Urinary Tract Urothelial Carcinoma Following Radical Nephroureterectomy. PG - 834692 LID - 10.3389/fonc.2022.834692 [doi] LID - 834692 AB - BACKGROUND: Numerous studies have investigated the risk factors of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) in patients with upper urinary tract urothelial carcinoma (UTUC). However, few studies explore the predictors for unfavorable pathological types of IVR following RNU. METHODS: We retrospectively reviewed 155 patients diagnosed with bladder cancer (BC) following RNU. Binary logistic regression was used for the univariable and multivariable analyses. Nomograms were developed based on the multivariable analysis. The concordance index (C-index) was used to assess the performance of the nomograms. We performed internal validation by generating calibration plots. RESULTS: Muscle-invasive BC (MIBC) was significantly correlated with operation interval (p = 0.004) and UTUC T-stage (p = 0.016). Operation interval (p = 0.002) and UTUC T-stage (p = 0.028) were also risk factors for BC > 3 cm. UTUC grade (p = 0.015), operation interval (p = 0.003), and hydronephrosis (p = 0.049) were independent predictors for high-grade BC (HGBC). MIBC (p = 0.018) and surgical approach (p = 0.003) were associated with multifocal IVR. Besides, MIBC and HGBC were associated with UTUC grade (p = 0.009), operation interval (p = 0.001), and hydronephrosis (p = 0.023). Moreover, only operation interval (p = 0.036) was a predictor for BC with at least one unfavorable pathological type. We developed nomograms for MIBC, HGBC, BC > 3 cm, and MIBC and/or HGBC. The calibration curves of the nomograms showed good agreement between the observation and prediction cases. The C-indexes of the nomograms were 0.820 (95% CI, 0.747-0.894), 0.728 (95% CI, 0.649-0.809), 0.770 (95% CI, 0.679-0.861), and 0.749 (95% CI, 0.671-0.827), respectively. CONCLUSIONS: The current study found that operation interval, UTUC T-stage, UTUC grade, surgical approach, and hydronephrosis are independent predictors for unfavorable pathological types of IVR following RNU. Nomograms based on these predictors were developed and internally validated to assess the risk of developing unfavorable pathological types of IVR. Furthermore, patients at high risk of developing unfavorable pathological types BC may benefit from more active follow-up 1 year after RNU by early detection of IVR. CI - Copyright (c) 2022 Zhu, Zhang, Yu, Li, He, Zhou, Zhang and Xiong. FAU - Zhu, Jun AU - Zhu J AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Zhang, Xiaoqing AU - Zhang X AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Yu, Wei AU - Yu W AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - He, Zhisong AU - He Z AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Zhang, Zhongyuan AU - Zhang Z AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20220413 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9043951 OTO - NOTNLM OT - bladder recurrence OT - nephroureterectomy OT - risk factors OT - upper urinary tract OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/01/01 CRDT- 2022/05/02 06:27 PHST- 2021/12/13 00:00 [received] PHST- 2022/02/15 00:00 [accepted] PHST- 2022/05/02 06:27 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.834692 [doi] PST - epublish SO - Front Oncol. 2022 Apr 13;12:834692. doi: 10.3389/fonc.2022.834692. eCollection 2022. PMID- 35490858 OWN - NLM STAT- MEDLINE DCOM- 20220812 LR - 20250728 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 126 DP - 2022 Aug TI - Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlates. PG - 2-8 LID - S0046-8177(22)00103-4 [pii] LID - 10.1016/j.humpath.2022.04.013 [doi] AB - While surveillance biopsies play a critical role in management of patients with muscle invasive bladder cancer (MIBC) treated with trimodal therapy (TMT), their assessment is often confounded by pronounced post-treatment changes. The aim of this study was to characterize these morphologic alterations and their clinical implications. A single-center retrospective analysis of surveillance transurethral resection of bladder tumor (TURBT) samples was undertaken, assessing for post-treatment morphologic changes in non-neoplastic and neoplastic tissue, as well as the correlation between these changes and cancer recurrence and cancer-specific survival. The cohort consisted of 73 patients with 56 males (76.7%), with a median age of 72 years and stage cT2 in 84.9%. The median follow-up was 28 months (4-207 months), with 34 patients (46.6%) dead during follow-up. A wide spectrum of morphologic characteristics was documented in all post-TMT TURBTs, with most common features including fibrosis (63.0%), inflammation (56.2%), and epithelial denudation (45.2%). Presence of fibrosis inversely correlated with cancer-specific death (n = 68, p = 0.027). Among the 18 cases with residual MIBC, 12 cases (66.7%) showed morphologic changes in the neoplastic cells that deviated from usual morphology of urothelial carcinoma. Presence of these changes was enriched in patients with subsequent disease recurrence (n = 18, p = 0.05). Secondary pathology review identified two cases (2.7%) with diagnostic discrepancy, both due to omission of in situ component. Post-treatment changes in post-TMT TURBTs must be recognized to avoid diagnostic misinterpretation and accurately guide patient management. Also, poor cellular preservation and severe cytologic changes in the residual carcinoma are not associated with a better prognosis. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Evaristo, Gertruda AU - Evaristo G AD - Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Khadang, Baharak AU - Khadang B AD - Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Kool, Ronald AU - Kool R AD - Experimental Surgery, Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada; Department of Urology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Marcq, Gautier AU - Marcq G AD - Experimental Surgery, Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada; Department of Urology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Farag, Mina S AU - Farag MS AD - Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Urology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. FAU - Brimo, Fadi AU - Brimo F AD - Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada. Electronic address: fadi.brimo@muhc.mcgill.ca. LA - eng PT - Journal Article DEP - 20220428 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 SB - IM MH - Aged MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Fibrosis MH - Humans MH - Male MH - Muscles/pathology MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Muscle-invasive OT - Radiotherapy OT - Trimodal therapy EDAT- 2022/05/02 06:00 MHDA- 2022/08/13 06:00 CRDT- 2022/05/01 19:25 PHST- 2022/02/07 00:00 [received] PHST- 2022/04/20 00:00 [revised] PHST- 2022/04/22 00:00 [accepted] PHST- 2022/05/02 06:00 [pubmed] PHST- 2022/08/13 06:00 [medline] PHST- 2022/05/01 19:25 [entrez] AID - S0046-8177(22)00103-4 [pii] AID - 10.1016/j.humpath.2022.04.013 [doi] PST - ppublish SO - Hum Pathol. 2022 Aug;126:2-8. doi: 10.1016/j.humpath.2022.04.013. Epub 2022 Apr 28. PMID- 35488409 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230626 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 131 IP - 2 DP - 2023 Feb TI - Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer? PG - 190-197 LID - 10.1111/bju.15760 [doi] AB - OBJECTIVES: To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc resection of bladder tumour (ERBT) for pathological T1 (pT1) bladder cancer. PATIENTS AND METHODS: We retrospectively analysed the record of 106 patients with pT1 high-grade bladder cancer who underwent ERBT between April 2013 and February 2021 at multiple institutions. All specimens were reviewed by a genitourinary pathologist. The primary outcome measures were recurrence-free survival (RFS) and progression-free survival (PFS) between patients with and those without reTUR. We also analysed the predictive value of surgical margin on the likelihood of residual tumour on reTUR. RESULTS: A reTUR was performed in 50 of the 106 patients. The 2-year RFS and 3-year PFS were comparable between patients who underwent reTUR and those who did not (55.1% vs 59.9%, P = 0.6, 80.6% vs 82.6%, P = 0.6, respectively). No patient was upstaged to pT2 on reTUR. Regarding the surgical margin status, there were no recurrences at the original site in 51 patients with negative horizontal margins. Cox proportional hazard analysis revealed that a positive vertical margin was an independent prognostic factor of worse PFS. On reTUR, six pTa/is residues were detected in patients with a positive horizontal margin, and three pT1 residues were detected in one patient with a positive vertical margin or other adverse pathological features. CONCLUSIONS: A reTUR after ERBT for pT1 bladder cancer appears not to improve either recurrence or progression. Surgical margin status affects prognosis and reTUR outcomes. A reTUR can be omitted after ERBT in patients with pT1 bladder cancer and negative margins; for those with positive horizontal or vertical margins, reTUR should remain the standard until proven otherwise. CI - (c) 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Sato, Shun AU - Sato S AUID- ORCID: 0000-0002-4852-7704 AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan. FAU - Okada, Yohei AU - Okada Y AD - Department of Urology, Saitama Medical Center, Saitama, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsukawa, Akihiro AU - Matsukawa A AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20220513 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - BJU Int. 2023 Jul;132(1):112. doi: 10.1111/bju.16005. PMID: 36896889 MH - Humans MH - Retrospective Studies MH - *Margins of Excision MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Urinary Bladder/pathology MH - Urologic Surgical Procedures MH - Neoplasm Recurrence, Local/pathology PMC - PMC10084154 OTO - NOTNLM OT - Bladder cancer OT - en bloc TUR OT - pT1 OT - progression OT - recurrence OT - repeat TURs COIS- Takahiro Kimura is a paid consultant/advisor of Astellas, Bayer, Janssen and Sanofi. Shahrokh F. Shariat received as follows: Honoraria: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, Takeda. Consulting or Advisory Role: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Takeda. Speakers Bureau: Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, Takeda. Shin Egawa is a paid consultant/advisor of Takeda, Astellas, AstraZeneca, Sanofi, Janssen, and Pfizer. The other authors declare no conflicts of interest associated with this manuscript. EDAT- 2022/05/01 06:00 MHDA- 2023/01/27 06:00 PMCR- 2023/04/10 CRDT- 2022/04/30 01:13 PHST- 2022/05/01 06:00 [pubmed] PHST- 2023/01/27 06:00 [medline] PHST- 2022/04/30 01:13 [entrez] PHST- 2023/04/10 00:00 [pmc-release] AID - BJU15760 [pii] AID - 10.1111/bju.15760 [doi] PST - ppublish SO - BJU Int. 2023 Feb;131(2):190-197. doi: 10.1111/bju.15760. Epub 2022 May 13. PMID- 35487092 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220517 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 151 DP - 2022 Jun TI - Detecting the muscle invasiveness of bladder cancer: An application of diffusion kurtosis imaging and tumor contact length. PG - 110329 LID - S0720-048X(22)00179-6 [pii] LID - 10.1016/j.ejrad.2022.110329 [doi] AB - PURPOSE: To evaluate the diagnostic efficacy of diffusion kurtosis imaging (DKI) parameters and tumor contact length (TCL) among clinical and radiological factors for preoperative prediction of muscle-invasive bladder cancer (MIBC). METHOD: A total of ninety-seven patients underwent 3.0 T MRI scan with propeller fast spin-echo T2WI, echo planar imaging diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE). Two radiologists independently viewed multiparametric MRI (mpMRI) of each patient, graded the VI-RADS, drew the region of interest (ROI) and measured TCL. Interclass correlation coefficients (ICCs), Kappa statistics, Kolmogorov-Smirnov test, Mann-Whitney U tests, chi-square tests, logistic regression analyses, Hosmer-Lemeshow tests, receiver operating characteristic curve (ROC) analysis, and area under the curve (AUC) were applied. RESULTS: The mean K(app) of NMIBC group (0.62 +/- 0.01) was significantly lower than that of MIBC group (0.79 +/- 0.08). The mean TCL of MIBC group (4.66 +/- 1.89) was significantly larger than TCL of NMIBC group (1.88 +/- 1.50) (all p < 0.01). At the corresponding cut-off, AUC of TCL, K(app), VI-RADS and the combination of K(app) and TCL were 0.87, 0.92, 0.90, and 0.95, respectively. TCL and K(app) were risk factors of BC muscle invasion at both univariate and multivariate analysis. CONCLUSIONS: K(app) performed better than conventional DWI in predicting MIBC. K(app) and TCL were independent risk factors of MIBC and could complement VI-RADS for predicting muscle invasion. The combination of K(app) and TCL had the largest AUC and highest accuracy among all parameters. CI - Copyright (c) 2022. Published by Elsevier B.V. FAU - Li, Qing AU - Li Q AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Cao, Bohong AU - Cao B AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Liu, Kai AU - Liu K AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Sun, Haitao AU - Sun H AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Ding, Yuqin AU - Ding Y AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Yan, Cheng AU - Yan C AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Wu, Pu-Yeh AU - Wu PY AD - GE Healthcare, MR Research China, Beijing, China. FAU - Dai, Chenchen AU - Dai C AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Rao, Shengxiang AU - Rao S AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Zeng, Mengsu AU - Zeng M AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Jiang, Shuai AU - Jiang S AD - Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Urology, Zhongshan Hospital Wusong Branch, Fudan University, Shanghai, China. FAU - Zhou, Jianjun AU - Zhou J AD - Department of Radiology, Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Radiology, Xiamen Branch, Zhongshan Hospital, Fudan University, Fujian Province, China. Electronic address: zhoujianjunzs@126.com. LA - eng PT - Journal Article DEP - 20220422 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Diffusion Magnetic Resonance Imaging MH - Diffusion Tensor Imaging MH - Female MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - *Multiparametric Magnetic Resonance Imaging MH - Muscles MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery OTO - NOTNLM OT - Diagnostic efficacy OT - Diffusion kurtosis imaging OT - Neoplasm invasiveness OT - Tumor contact length OT - Urinary bladder neoplasms EDAT- 2022/04/30 06:00 MHDA- 2022/05/18 06:00 CRDT- 2022/04/29 18:19 PHST- 2022/04/07 00:00 [received] PHST- 2022/04/17 00:00 [revised] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/04/30 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/04/29 18:19 [entrez] AID - S0720-048X(22)00179-6 [pii] AID - 10.1016/j.ejrad.2022.110329 [doi] PST - ppublish SO - Eur J Radiol. 2022 Jun;151:110329. doi: 10.1016/j.ejrad.2022.110329. Epub 2022 Apr 22. PMID- 35476175 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 54 IP - 7 DP - 2022 Jul TI - A comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy. PG - 1513-1519 LID - 10.1007/s11255-022-03216-2 [doi] AB - PURPOSE: To compare the population-based incidence of peritoneal carcinomatosis following open (ORC) vs. robotic-assisted radical cystectomy (RARC). METHODS: Using the Surveillance, Epidemiology and End Results Program (SEER)-Medicare linked data, we identified 1,621 patients who underwent radical cystectomy for bladder cancer during 2009 and 2014; 18.1% (n = 294) and 81.9% (n = 1327) underwent RARC and ORC, respectively. We subsequently evaluated the rates of peritoneal carcinomatosis at 6, 12, and 24 months following surgery. Multivariable proportional hazards regression was performed to determine factors associated with development of peritoneal carcinomatosis. RESULTS: Patients who underwent RARC vs. ORC were more likely to be male (p = 0.04); however, age at diagnosis, race, comorbidities, education, and marital status (all p > 0.05) did not differ by surgical approaches. Our findings showed that there were no significant differences in the rates of peritoneal carcinomatosis between ORC and RARC at 6, 12, and 24 months. In adjusted analyses, factors associated with peritoneal carcinomatosis were advanced N stage (N0 versus N2/3: HR 0.30, 95% CI 0.16-0.55, p < 0.01), preoperative hydronephrosis (HR 1.70, 95% CI 1.09-2.65, p = 0.04), higher T stage (T1 versus T4: HR 0.34, 95% CI 0.15-0.79, p < 0.01; T2 versus T4: HR 0.39, 95% CI 0.20-0.76, p < 0.01), and use of neoadjuvant chemotherapy (HR 1.78, 95% CI 1.11-2.84, p < 0.01). However, RARC was not associated with peritoneal carcinomatosis (HR 1.36, 95% CI 0.78-2.35). CONCLUSION: In this population-based analysis, we found no difference in peritoneal carcinomatosis between robotic or open approaches to radical cystectomy. These data should be reassuring to those utilizing robotic cystectomy. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Basourakos, Spyridon P AU - Basourakos SP AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. FAU - Al Hussein Al Awamlh, Bashir AU - Al Hussein Al Awamlh B AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. FAU - Borregales, Leonardo D AU - Borregales LD AUID- ORCID: 0000-0002-9280-3307 AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. FAU - Abrahimi, Parwiz AU - Abrahimi P AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. FAU - Sedrakyan, Art AU - Sedrakyan A AD - Department of Health Policy, Weill Cornell Medicine, New York, NY, USA. FAU - Shoag, Jonathan E AU - Shoag JE AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. AD - Department of Urology, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Hu, Jim C AU - Hu JC AD - Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, Starr 900, New York, NY, 10021, USA. jch9011@med.cornell.edu. LA - eng GR - U01 FD006936/FD/FDA HHS/United States GR - CER-2019C1-15682/PCORI/Patient-Centered Outcomes Research Institute/United States GR - CA241758/NH/NIH HHS/United States PT - Journal Article DEP - 20220427 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Medicare MH - *Peritoneal Neoplasms/complications/surgery MH - Postoperative Complications/epidemiology MH - *Robotic Surgical Procedures/adverse effects MH - Treatment Outcome MH - United States/epidemiology MH - *Urinary Bladder Neoplasms/complications OTO - NOTNLM OT - Bladder cancer OT - Open OT - Peritoneal carcinomatosis OT - Radical cystectomy OT - Robotic EDAT- 2022/04/28 06:00 MHDA- 2022/06/14 06:00 CRDT- 2022/04/27 12:21 PHST- 2022/01/07 00:00 [received] PHST- 2022/02/05 00:00 [accepted] PHST- 2022/04/28 06:00 [pubmed] PHST- 2022/06/14 06:00 [medline] PHST- 2022/04/27 12:21 [entrez] AID - 10.1007/s11255-022-03216-2 [pii] AID - 10.1007/s11255-022-03216-2 [doi] PST - ppublish SO - Int Urol Nephrol. 2022 Jul;54(7):1513-1519. doi: 10.1007/s11255-022-03216-2. Epub 2022 Apr 27. PMID- 35475152 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 3 IP - 1 DP - 2022 Jan TI - Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. PG - 37-44 LID - 10.1002/bco2.113 [doi] AB - OBJECTIVES: Multimodal kidney-preserving (MKP) strategies may be an option for patients with localised or locally advanced high-risk upper tract urothelial carcinoma (UTUC) who have a relative contraindication for nephroureterectomy (NU). MATERIALS AND METHODS: We studied patients with UTUC who were managed with MKP strategies, consisting of systemic anticancer therapy, with or without local/topical strategies after endoscopic control of intraluminal tumours. Primary end points were overall survival (OS) and progression-free survival (PFS). RESULTS: Fourteen patients received MKP treatment between August 2013 and April 2020. Median baseline estimated glomerular filtration rate was 43 mL/min/1.73m(2). MKP was mainly pursued to avoid dialysis (10/14, 71%), followed by low performance status and/or comorbidities (2/14, 14%). All patients had received systemic therapy: chemotherapy (64%) and immunotherapy (36%). Endoscopic control and/or laser ablation was feasible in 7 (50%) patients. Calculated overall risk of non-organ confined disease was 35%. Predicted 2-year and 5-year relapse-free probability (RFP) was 74% (24-92%) and 62% (10-85%), respectively. Median follow-up was 31 months (95% CI: 22.6, NE), median OS was 48.1 months (95% CI: 48.1, NE) and 2-year OS probability was 0.89 (95% CI: 0.71, 1). Median metastases-free survival was 48.1 months (95% CI: 26.8, NE), median PFS was 22.4 months (95% CI: 15.6, NE) and 2-year PFS probability was 0.48 (0.26, 0.89). CONCLUSION: Management of high-risk localised or locally advanced UTUC with MKP strategies was associated with good tolerance, preservation of renal function, and comparable PFS and OS to predicted in vulnerable patients. Prospective studies with more patients are needed to evaluate these possible benefits relative to current standards. CI - (c) 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Alhalabi, Omar AU - Alhalabi O AUID- ORCID: 0000-0002-9658-2206 AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Campbell, Matthew T AU - Campbell MT AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Xiao, Lianchun AU - Xiao L AD - Department of Biostatistics, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Adriazola, Ana C AU - Adriazola AC AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Wilson, Nathaniel R AU - Wilson NR AUID- ORCID: 0000-0002-9123-1781 AD - Department of Internal Medicine University of Texas Health Science Center at Houston Houston TX USA. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Corn, Paul G AU - Corn PG AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Zurita, Amado AU - Zurita A AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Jonasch, Eric AU - Jonasch E AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Gao, Jianjun AU - Gao J AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Adibi, Mehrad AU - Adibi M AUID- ORCID: 0000-0002-9351-5913 AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Pisters, Louis L AU - Pisters LL AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Dinney, Colin AU - Dinney C AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Matin, Surena F AU - Matin SF AUID- ORCID: 0000-0003-1638-1445 AD - Department of Urology, Division of Surgery University of Texas MD Anderson Cancer Center Houston TX USA. FAU - Shah, Amishi Y AU - Shah AY AD - Department of Genitourinary Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA. LA - eng PT - Journal Article DEP - 20211011 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC8988842 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - chemotherapy OT - endoscopic resection OT - immunotherapy OT - mitomycin OT - upper tract urothelial carcinoma COIS- The authors declare no relevant conflict of interest pertinent to this study. Full conflict of inflict disclosures include research funding from BMS, Eisai, EMD Serono for A.Y.S; Honoraria from Pfizer, Roche, BMS and Exelixis for A.Y.S; and Urogen Pharma (consultant) and Urology Education (speaker) for S.F.M. SFM: grant from QED therapeutics; consulting fees Merck, J&J; honoraria Ology education, Clinical Care Options. NN: consulting Schlesinger Group; Ad Board Aduro Bio Tech; Stock Allogene Therapeutics. AMK: grants Adolor, BMS, FKD Industries, FerGene, Heat Biologics, Merck, Photocure, SWOG, NIH/GU SPORE, AIBCCR, Janssen (+ Taris), Seattle Genetics; consulting Arquer Diagnostics. Asieris, Biological Dynamics, Bristol Myers Squibb, CG Oncology, H3 Biomedicine/Eisai, Engene, FerGene, Imagin Medical, Janssen, Medac, Merck, Photocure, ProTara, Seattle Genetics, Sessen Bio, Theralase, US Biotest, Urogen Inc., Roche, TMC Innovation; patents CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center; ad board: Arquer Diagnostics. Asieris, Biological Dynamics, Bristol Myers Squibb, CG Oncology, H3 Biomedicine/Eisai, Engene, FerGene, Imagin Medical, Janssen, Medac, Merck, Photocure, ProTara, Seattle Genetics, Sessen Bio, Theralase, US Biotest, Urogen Inc., Roche, TMC Innovation; leadership IBCG. MTC: grants or contracts ApricityHealth, Aravive, AstraZeneca, EMD Serono, Exelixis, Janssen, Pfizer; consulting Astellas, AXDev, AstraZeneca, Astellas, Exelixis, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, SeaGen; honoraria Bristol Myers Squibb, Merck, Roche, Pfizer. AZ: grants or contracts Infinity pharma; consulting Amedo, Astra Zeneca, Bayer; honoraria Biocept, CancerNet, Incyte; other Janssen-Cliag, McKesson Specialty Health, Pfizer. AOS: research grants or contracts: Basilea, Bristol Myers Squibb, Janssen, Merck Sharp and Dohme, Nektar Therapeutics; honoraria Janssen; Ad Board Astrazeneca, Basilea, Bavarian Nordic, Bristol-Myers Squibb, Genentech, Ideaya Biosciences, Immunomedics, Janssen, LOXO-Oncology, Merck sharp and Dohme, Mirati, Nektar Therapeutics, Seattle Genetics, Taiho. EDAT- 2022/04/28 06:00 MHDA- 2022/04/28 06:01 PMCR- 2021/10/11 CRDT- 2022/04/27 06:21 PHST- 2021/05/20 00:00 [received] PHST- 2021/08/11 00:00 [revised] PHST- 2021/08/25 00:00 [accepted] PHST- 2022/04/27 06:21 [entrez] PHST- 2022/04/28 06:00 [pubmed] PHST- 2022/04/28 06:01 [medline] PHST- 2021/10/11 00:00 [pmc-release] AID - BCO2113 [pii] AID - 10.1002/bco2.113 [doi] PST - epublish SO - BJUI Compass. 2021 Oct 11;3(1):37-44. doi: 10.1002/bco2.113. eCollection 2022 Jan. PMID- 35466036 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221025 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 10 DP - 2022 Oct TI - Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: A prospective study. PG - 454.e1-454.e7 LID - S1078-1439(22)00099-0 [pii] LID - 10.1016/j.urolonc.2022.03.008 [doi] AB - OBJECTIVES: To assess accuracy of vesical imaging-reporting and data system (VI-RADS) 5-point score in detection of muscle invasive bladder cancer and avoiding second look transurethral resection of the tumors (TURBT). Additionally, to assess safety and efficacy of bipolar en-block transurethral urethral resection of bladder tumor. METHODS: Patients with bladder mass up to 5 cm were included in the study. VI-RADS 5-point score was done preoperative for all cases and postoperatively before second look TURBT. Patients were followed up for 12 months. RESULTS: In all, 80 cases were eligible for the study. Preoperative VI-RADS score at cutoff of 3 had sensitivity of 89.3 %, specificity 83.3 %, postive predective value (PPV) 92.6 %, negative predictive value (NPV) 76.9 %, accuracy of 87.5 %, while at cutoff 2 sensitivity was 82.1%, specificity 91.7%, PPV 95.8%, NPV 68.8%, accuracy of 85.0%. Operative time 28.8 +/- 9.4 minutes, hemoglobin drop 0.3 +/- 0.05 g/dl, catheterization time 2.8 +/- 0.8 days, hospital stay 1.4 +/- 0.4 days. No complications occurred. Recurrence in field of resection 3.75%. Detrusor muscle was available in 76 cases (95%). Postoperative VI-RADS score at cutoff of 3 had sensitivity of 78.6%, specificity 77.8%, PPV 84.6%, NPV 70.0%, accuracy of 78.3%. At cutoff 2 VI-RADS score sensitivity was 71.4%, specificity 77.8%, PPV 83.3%, NPV 63.6%, accuracy of 73.9%. CONCLUSION: VI-RADS 5-point score showed high sensitivity and specificity in preoperative discrimination of non-muscle invasive bladder cancer (NMIBC) from muscle invasive bladder cancer cases and in avoiding unnecessary second look TURBT. Bipolar en-block TURBT technique is both safe and efficacious in resecting NMIBC cases with low recurrence rate. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - El-Karamany, Tarek M AU - El-Karamany TM AD - Department of Urology, Benha university, Benha, Egypt. FAU - Al-Adl, Ahmed M AU - Al-Adl AM AD - Department of Urology, Benha university, Benha, Egypt. FAU - Hosny, Mohamed M AU - Hosny MM AD - Radiology Department, Benha university, Benha, Egypt. FAU - A Eldeep, Helmy AU - A Eldeep H AD - Department of Urology, Benha university, Benha, Egypt. FAU - El-Hamshary, Salah A AU - El-Hamshary SA AD - Department of Urology, Benha university, Benha, Egypt. Electronic address: salah.abdelhamed@fmed.bu.edu.eg. LA - eng PT - Journal Article DEP - 20220422 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Hemoglobins) SB - IM MH - Data Systems MH - Hemoglobins MH - Humans MH - Prospective Studies MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery OTO - NOTNLM OT - (VI-RADS) OT - Bladder cancer OT - En bloc EDAT- 2022/04/26 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/04/25 05:58 PHST- 2022/02/16 00:00 [received] PHST- 2022/03/16 00:00 [revised] PHST- 2022/03/19 00:00 [accepted] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/04/25 05:58 [entrez] AID - S1078-1439(22)00099-0 [pii] AID - 10.1016/j.urolonc.2022.03.008 [doi] PST - ppublish SO - Urol Oncol. 2022 Oct;40(10):454.e1-454.e7. doi: 10.1016/j.urolonc.2022.03.008. Epub 2022 Apr 22. PMID- 35463353 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Preoperative Metabolic Syndrome and HDL-C Level Predict the Prognosis of Patients Following Radical Cystectomy: A Propensity Score Matching Study. PG - 833305 LID - 10.3389/fonc.2022.833305 [doi] LID - 833305 AB - OBJECTIVE: To investigate the prognostic significance of metabolic syndrome (MetS) and its components in patients with bladder cancer (BCa) treated with radical cystectomy (RC). METHODS: A total of 335 BCa patients who underwent RC between 2004 and 2019 at Peking University Third Hospital (PUTH) were analyzed retrospectively. The Kaplan-Meier method with the log-rank test was performed to assess overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox proportional hazard models were conducted to identify the prognostic factors of OS and PFS before and after propensity score matching (PSM). RESULTS: Enrolled patients were allocated into two groups according to the presence or absence of MetS (n=84 MetS vs n=251 non-MetS), and 82 new matched pairs were identified to balance the baseline characteristics after 1:1 PSM. In the Kaplan-Meier analysis, MetS was associated with better OS (P=0.031) than the group without MetS. In addition, a body mass index (BMI) >/= 25 was associated with better OS (P=0.011) and PFS (P=0.031), while low high-density lipoprotein cholesterol (HDL-C) was associated with worse OS (P=0.033) and PFS (P=0.010). In all patients, multivariate Cox analysis showed that hemoglobin, pathologic tumor stage and lymph node status were identified as independent prognostic factors for both OS and PFS, while age, MetS and HDL-C were independent prognostic factors only for OS. Reproducible results of multivariate analysis can still be observed in propensity matched patients. The results of further subgroup analysis revealed that the association of MetS with increased OS (P=0.043) and BMI >/=25 with increased OS (P=0.015) and PFS (P=0.029) was observed in non-muscle invasive bladder cancer (NMIBC) patients. CONCLUSIONS: MetS was independently associated with better OS in BCa patients after RC, and HDL-C was the only component of MetS that was independently associated with worse OS. MetS and HDL-C may become reliable prognostic biomarkers of OS in BCa patients after RC to provide individualized prognostication and assist in the formulation of clinical treatment strategies. CI - Copyright (c) 2022 Liu, Bi, He, Zhu, He, Lu and Lu. FAU - Liu, Zenan AU - Liu Z AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Bi, Hai AU - Bi H AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - He, Wei AU - He W AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Zhu, Xuehua AU - Zhu X AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - He, Jide AU - He J AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Lu, Min AU - Lu M AD - Department of Pathology, Peking University Third Hospital, Beijing, China. FAU - Lu, Jian AU - Lu J AD - Department of Urology, Peking University Third Hospital, Beijing, China. AD - NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, China. LA - eng PT - Journal Article DEP - 20220405 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9022107 OTO - NOTNLM OT - bladder cancer OT - high-density lipoprotein cholesterol (HDL-C) OT - metabolic syndrome OT - propensity score matching OT - radical cystectomy OT - survival outcome COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/26 06:00 MHDA- 2022/04/26 06:01 PMCR- 2022/01/01 CRDT- 2022/04/25 05:19 PHST- 2021/12/11 00:00 [received] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/04/25 05:19 [entrez] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/04/26 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.833305 [doi] PST - epublish SO - Front Oncol. 2022 Apr 5;12:833305. doi: 10.3389/fonc.2022.833305. eCollection 2022. PMID- 35462401 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20251031 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 52 IP - 8 DP - 2022 Aug 5 TI - Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer. PG - 944-949 LID - 10.1093/jjco/hyac068 [doi] AB - BACKGROUND: The objective of the present study was to evaluate the prognostic impact of the upper urinary tract cancer status on recurrence-free survival and progression-free survival, and to develop risk stratification systems that include the upper urinary tract cancer status for patients with non-muscle invasive bladder cancer. PATIENTS AND METHODS: The present study included 40 (upper urinary tract cancer-non-muscle invasive bladder cancer group) and 285 (non-muscle invasive bladder cancer alone group) patients with and without a history of prior or concomitant upper urinary tract cancer, respectively. Nine clinicopathological findings between the two groups were compared, and risk stratification systems for the recurrence and progression of non-muscle invasive bladder cancer were developed. RESULTS: Recurrence-free survival and progression-free survival in the upper urinary tract cancer-non-muscle invasive bladder cancer group were significantly inferior to those in the NMIBC alone group (P < 0.001 and P = 0.006, respectively). Multivariate analyses identified the following independent prognosticators: multiplicity and upper urinary tract cancer status for recurrence-free survival, and pT category and upper urinary tract cancer status for progression-free survival. Significant differences were noted by the risk stratification systems based on the positive number of independent predictors of recurrence-free survival and progression-free survival (P < 0.001 and P = 0.007, respectively). The concordance indices of recurrence-free survival were 0.627, 0.588 and 0.499 in this study stratification, EORTC risk table and CUETO model, respectively. Those of progression-free survival were 0.752, 0.740 and 0.714, respectively. CONCLUSION: The present results suggest the significant impact of a history of prior or concomitant UUTC on recurrence-free survival and progression-free survival in non-muscle invasive bladder cancer patients, and risk stratification systems that include the upper urinary tract cancer status for the recurrence and progression of non-muscle invasive bladder cancer are promising tools for predicting the outcomes of these patients. CI - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Matsushita, Yuto AU - Matsushita Y AUID- ORCID: 0000-0002-8159-9793 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Kawakami, Asuka AU - Kawakami A AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Sato, Ryo AU - Sato R AUID- ORCID: 0000-0002-1340-4739 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Watanabe, Kyohei AU - Watanabe K AUID- ORCID: 0000-0002-1171-9948 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Watanabe, Hiromitsu AU - Watanabe H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Tamura, Keita AU - Tamura K AUID- ORCID: 0000-0002-4305-7328 AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Motoyama, Daisuke AU - Motoyama D AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Ito, Toshiki AU - Ito T AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Sugiyama, Takayuki AU - Sugiyama T AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Otsuka, Atsushi AU - Otsuka A AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM EIN - Jpn J Clin Oncol. 2022 Nov 3;52(11):1358. doi: 10.1093/jjco/hyac156. PMID: 36124846 MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - *Urologic Neoplasms/pathology OTO - NOTNLM OT - progression-free survival OT - recurrence-free survival OT - renal pelvic cancer OT - risk stratification OT - ureter cancer EDAT- 2022/04/25 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/04/24 20:29 PHST- 2022/01/27 00:00 [received] PHST- 2022/04/06 00:00 [accepted] PHST- 2022/04/25 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/04/24 20:29 [entrez] AID - 6573315 [pii] AID - 10.1093/jjco/hyac068 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2022 Aug 5;52(8):944-949. doi: 10.1093/jjco/hyac068. PMID- 35459430 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220831 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 22 IP - 6 DP - 2022 Jun TI - Progress in the development of tissue-based biomarkers for urothelial cancer. PG - 605-619 LID - 10.1080/14737140.2022.2070154 [doi] AB - INTRODUCTION: As the understanding of molecular mechanisms of bladder cancer advances, molecularly-guided precision medicine becomes increasingly relevant. Biomarkers play a critical role in this setting, predicting treatment response and identifying candidates for targeted therapies. AREAS COVERED: Current literature on biomarkers in their role in disease prognosis and response to neoadjuvant and adjuvant therapies. In non-muscle invasive bladder cancer, particular focus is on markers of disease progression, and response to intravesical therapy. In muscle invasive and advanced bladder cancer, particular emphasis is on markers associated with neoadjuvant chemotherapy, as well as systemic immunotherapy. We discuss current shortcomings and pitfalls in contemporary markers, and future avenues of prospective research. EXPERT OPINION: The focus on biomarkers has moved from immunohistochemical analysis and tumor-related phenotypic changes to examining genetic alterations. Single marker analysis has been shown to be insufficient in predicting both disease course and response to therapy, and studies have shifted toward examining marker combinations and genetic classifiers. Ultimately, significant progress in implementing biomarkers into clinical guidelines remains elusive, largely due to lack of prospective studies in well-defined patient cohorts and with clinically meaningful endpoints. Until then, despite their promising value, tissue markers should be limited to experimental settings and clinical trials. FAU - Bhanvadia, Raj R AU - Bhanvadia RR AD - Department of Urology, University of Texas Southwestern, Dallas, Texas 75390. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, Texas 75390. LA - eng PT - Journal Article DEP - 20220429 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - *Carcinoma, Transitional Cell MH - Humans MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Prognosis MH - Prospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy OTO - NOTNLM OT - Biomarkers OT - bladder cancer OT - immunotherapy OT - muscle invasive bladder cancer OT - neoadjuvant chemotherapy OT - response to intravesical therapy EDAT- 2022/04/24 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/04/23 05:18 PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/04/23 05:18 [entrez] AID - 10.1080/14737140.2022.2070154 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2022 Jun;22(6):605-619. doi: 10.1080/14737140.2022.2070154. Epub 2022 Apr 29. PMID- 35449454 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20230422 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 127 IP - 2 DP - 2022 Jul TI - Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis. PG - 313-320 LID - 10.1038/s41416-022-01799-2 [doi] AB - BACKGROUND: Molecular subtyping of bladder cancer has revealed luminal tumors generally have a more favourable prognosis. However, some aggressive forms of variant histology, including micropapillary, are often classified luminal. In previous work, we found long non-coding RNA (lncRNA) expression profiles could identify a subgroup of luminal bladder tumors with less aggressive biology and better outcomes. OBJECTIVE: In the present study, we aimed to investigate whether lncRNA expression profiles could identify high-grade T1 micropapillary bladder cancer with differential outcome. DESIGN, SETTING, AND PARTICIPANTS: LncRNAs were quantified from RNA-seq data from a HGT1 bladder cancer cohort that was enriched for primary micropapillary cases (15/84). Unsupervised consensus clustering of variant lncRNAs identified a three-cluster solution, which was further characterised using a panel of micropapillary-associated biomarkers, molecular subtypes, gene signatures, and survival analysis. A single-sample genomic signature was trained using lasso-penalized logistic regression to classify micropapillary-like gene-expression, as characterised by lncRNA clustering. The genomic classifier (GC) was tested on luminal tumors derived from the TCGA cohort (N = 202). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient and tumor characteristics were compared between subgroups by using X(2) tests and two-sided Wilcoxon rank-sum tests. Primary endpoints were overall, progression-free and high-grade recurrence-free survival, calculated as the date of high-grade T1 disease at TURBT till date of death from any cause, progression, or recurrence, respectively. Survival rates were estimated using weighted Kaplan-Meier (KM) curves. RESULTS AND LIMITATIONS: Primary micropapillary HGT1 showed decreased FGFR3, SHH, and p53 pathway activity relative to tumors with conventional urothelial carcinoma. Many bladder cancer-associated lncRNAs were downregulated in micropapillary tumors, including UCA1, LINC00152, and MALAT1. Unsupervised consensus clustering resulted in a lncRNA cluster 1 (LC1) with worse prognosis that was enriched for primary micropapillary histology and the Luminal Unstable (LumU) molecular subtype. Interestingly, LC1 appeared to better identify aggressive HGT1 disease, compared to stratifying outcomes using primary histologic characteristics. A signature trained to identify LC1 cases showed good performance in the testing cohort, identifying seven cases with significantly worse survival (p < 0.001). Limitations include the retrospective nature of the study and the lack of a validation cohort. CONCLUSIONS: Using the lncRNA transcriptome we identified a subgroup of aggressive HGT1 bladder cancer that was enriched with micropapillary histology. These data suggest that lncRNAs can facilitate the identification of aggressive micropapillary-like tumors, potentially improving patient management. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature Limited. FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Valderrama, Begona P AU - Valderrama BP AD - Hospital Universitario Virgen del Rocio Sevilla, Sevilla, Spain. FAU - Perera, Julia AU - Perera J AD - IMIM-Hospital del Mar and GRIB, Barcelona, Spain. FAU - Juanpere, Nuria AU - Juanpere N AD - Department of Pathology, Parc de Salut Mar, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Cejas, Paloma AU - Cejas P AD - Center for functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA. FAU - Long, Henry AU - Long H AUID- ORCID: 0000-0001-6849-6629 AD - Center for functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA. FAU - Alba, M Mar AU - Alba MM AD - Evolutionary Genomics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute (IMIM) and Universitat Pompeu Fabra (UPF), Barcelona, Spain. AD - Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. FAU - Gibb, Ewan A AU - Gibb EA AUID- ORCID: 0000-0001-9836-1434 AD - Veracyte Inc., Vancouver, BC, Canada. ewan.gibb@veracyte.com. FAU - Bellmunt, Joaquim AU - Bellmunt J AUID- ORCID: 0000-0003-2328-3421 AD - Beth Israel Deaconess Medical Center, PSMAR-IMIM Lab, Harvard Medical School, Boston, MA, USA. jbellmun@bidmc.harvard.edu. LA - eng PT - Journal Article DEP - 20220421 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) SB - IM MH - Biomarkers, Tumor/analysis/genetics MH - *Carcinoma, Transitional Cell/genetics MH - Gene Expression Profiling/methods MH - Humans MH - Prognosis MH - *RNA, Long Noncoding/genetics MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9296664 COIS- Ewan Gibb is an employee of Veracyte, Inc. The remaining authors declare no competing interests. EDAT- 2022/04/23 06:00 MHDA- 2022/07/22 06:00 PMCR- 2023/04/21 CRDT- 2022/04/22 06:18 PHST- 2021/09/12 00:00 [received] PHST- 2022/03/18 00:00 [accepted] PHST- 2022/02/12 00:00 [revised] PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/04/22 06:18 [entrez] PHST- 2023/04/21 00:00 [pmc-release] AID - 10.1038/s41416-022-01799-2 [pii] AID - 1799 [pii] AID - 10.1038/s41416-022-01799-2 [doi] PST - ppublish SO - Br J Cancer. 2022 Jul;127(2):313-320. doi: 10.1038/s41416-022-01799-2. Epub 2022 Apr 21. PMID- 35435371 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20220419 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 65 IP - 2 DP - 2022 Apr-Jun TI - Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas. PG - 355-361 LID - 10.4103/IJPM.IJPM_914_20 [doi] AB - AIM: Superficial urothelial urinary bladder tumors are neoplasms that frequently recur and have a potential for invasion and metastasis. REG gene family is composed of various acute phase reactants, lectins, antiapoptotic factors, and growth factors that are effective on pancreatic island cells, neural cells, and epithelial cells. REG1A and REG1B are two forms of the human REG1 gene. It is reported that they are expressed in several cancers and are correlated with the prognosis of the patient. Claudins are integral transmembrane proteins that interconnect cells. However, their role in human tumorigenesis is extremely controversial. The aim of this study is to evaluate the relationship of REG1A, claudin 7 protein expressions, and Ki67 proliferation index in superficial urothelial urinary bladder tumors with well-known parameters of prognosis and tumor recurrence, and also to clarify whether these parameters are independent prognostic factors or not. MATERIALS AND METHODS: A hundred and eleven patients diagnosed with superficial urothelial carcinoma between 2011 and 2016 years in our hospital and followed up in our urology clinic were included in this study. The slides prepared from paraffin blocks were immunohistochemically stained with REG1A, claudin 7, and Ki67 antibodies. RESULTS: REG1A showed positive staining in 37 (33%) and negative staining in 74 (67%) of urothelial tumors. Claudin 7 was positive in 24 (22%) and negative in 87 (78%) cases. REG1A expression showed a positive correlation with tumor stage and tumor recurrence; a high Ki67 proliferation index was positively correlated with tumor stage and grade. The loss of claudin 7 expression was related to tumor recurrence. Besides, tumors with REG1A expression and claudin 7 loss had a shorter survival independent of recurrence. CONCLUSION: In urothelial tumors, REG1A expression and loss of claudin 7 might be significant markers of prognosis that predict tumor recurrence. FAU - Yamuc, Elif AU - Yamuc E AD - Pathology Clinic, Gebze Fatih State Hospital, Kocaeli, Turkey. FAU - Barisik, Nagehan Ozdemir AU - Barisik NO AD - Department of Pathology, Health Sciences University, Kartal Dr. Lutfi Kirdar City Hopital, Istanbul, Turkey. FAU - Sensu, Sibel AU - Sensu S AD - Department of Pathology, Istinye University, Medical Faculty, Istanbul, Turkey. FAU - Tarhan, Fatih AU - Tarhan F AD - Department of Urology, Health Sciences University, Kartal Dr. Lutfi Kirdar City Hopital, Istanbul, Turkey. FAU - Barisik, Cem Cahit AU - Barisik CC AD - Department of Radiology, Medipol University, Istanbul, Turkey. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Biomarkers, Tumor) RN - 0 (Claudins) RN - 0 (Ki-67 Antigen) RN - 0 (Lithostathine) RN - 0 (REG1A protein, human) SB - IM MH - Biomarkers, Tumor/genetics/metabolism MH - *Carcinoma, Transitional Cell/genetics MH - Claudins/genetics MH - Female MH - Humans MH - Ki-67 Antigen/genetics MH - Lithostathine MH - Male MH - Neoplasm Recurrence, Local MH - Prognosis MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/diagnosis/genetics OTO - NOTNLM OT - Claudin 7 OT - REG1A OT - prognosis OT - urothelial tumors COIS- None EDAT- 2022/04/19 06:00 MHDA- 2022/04/20 06:00 CRDT- 2022/04/18 08:42 PHST- 2022/04/18 08:42 [entrez] PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] AID - IndianJPatholMicrobiol_2022_65_2_355_343212 [pii] AID - 10.4103/IJPM.IJPM_914_20 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2022 Apr-Jun;65(2):355-361. doi: 10.4103/IJPM.IJPM_914_20. PMID- 35430138 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20220531 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 5 DP - 2022 May TI - Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909. PG - 197.e25-197.e35 LID - S1078-1439(22)00078-3 [pii] LID - 10.1016/j.urolonc.2022.03.004 [doi] AB - AIM: The exact role of androgen receptor (AR) and miR-2909 in non-muscle invasive bladder cancer (NMIBC) remains controversial. Our aim is to assess the relationship between NMIBC recurrences with AR expression and miRNA-2909. PATIENTS AND METHODS: This prospective controlled cohort study included 99 male patients with NMIBC (Ta-T1) who were treated by transurethral resection and 50 male patients as healthy control. We quantified blood AR messenger RNA variants 1 and 2 (AR1, AR2) and plasma miRNA-2909 with real-time quantitative polymerase chain reaction and the full length AR (AR-FL) using enzyme-linked immunosorbent assay in serum samples. In addition, AR1 and AR2 expression in tumor as well as normal tissues were analyzed. Kaplan-Meier survival curves and multivariate Cox analysis were used to identify independent predictors of recurrence-free survival. RESULTS: In comparison to control group, blood AR1, AR2, and serum AR-FL expression were significantly lower in the NMIBC group compared to plasma miRNA-2909 expression that was significantly higher in the control group. Blood AR1, AR2, and serum AR-FL were significantly correlated with higher tumor stage (pT1) while plasma miRNA-2909 was not. The median survival time (months) was significantly better for higher blood AR1 (34 vs. 21; P = 0.03), lower plasma miRNA-2909 (29 vs. 8; P <0.001), lower AR2 in normal tissues (32 vs. 22; P = 0.007). On multivariate analysis, serum free testosterone (hazards ratio [HR]: 8.9; 95% CI: 1.8-45.1; P = 0.008), serum AR1 (HR: 0.5; 95% CI: 0.3-0.9; P = 0.02), and plasma miRNA-2909 (HR: 5.8; 95% CI: 2.3-14.7; P = 0.0002), and tissue AR2 (HR: 2.6; 95% CI: 1.4-4.7; P = 0.002) were independent predictor for NMIBC recurrence. CONCLUSIONS: Blood and tissue levels of AR expression have a potential significant effect on NMIBC recurrence. Further studies are recommended to establish its exact role. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Muzaail, Hazim Hadi AU - Muzaail HH AD - Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt. FAU - El-Assmy, Ahmed AU - El-Assmy A AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Electronic address: a_assmy@yahoo.com. FAU - Harraz, Ahmed M AU - Harraz AM AD - Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Awadalla, Amira AU - Awadalla A AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AD - Center of Excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abdel-Aziz, A F AU - Abdel-Aziz AF AD - Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20220413 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (AR protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN2909 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Receptors, Androgen) SB - IM MH - Biomarkers, Tumor/genetics/metabolism MH - Cohort Studies MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - *MicroRNAs/genetics MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Prospective Studies MH - Receptors, Androgen/genetics/*metabolism MH - *Urinary Bladder Neoplasms/pathology EDAT- 2022/04/18 06:00 MHDA- 2022/05/11 06:00 CRDT- 2022/04/17 20:17 PHST- 2021/10/01 00:00 [received] PHST- 2022/03/07 00:00 [revised] PHST- 2022/03/10 00:00 [accepted] PHST- 2022/04/18 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/04/17 20:17 [entrez] AID - S1078-1439(22)00078-3 [pii] AID - 10.1016/j.urolonc.2022.03.004 [doi] PST - ppublish SO - Urol Oncol. 2022 May;40(5):197.e25-197.e35. doi: 10.1016/j.urolonc.2022.03.004. Epub 2022 Apr 13. PMID- 35413902 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20220506 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Apr 12 TI - Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study. PG - 59 LID - 10.1186/s12894-022-01000-z [doi] LID - 59 AB - BACKGROUND: The pathological grading system for non-muscle-invasive bladder cancer is based on the WHO 2004/2016 classification system (low-grade: LG/high-grade: HG) and the WHO 1973 classification system (Grade 1: G1/Grade 2: G2/Grade 3: G3). Recently, the usefulness of combining both systems and classifying the tumors as LG/G1, LG/G2, HG/G2, and HG/G3 has been demonstrated. In this study, we compared the prognosis of intravesical recurrence in relation to different treatment intensities between HG/G2 and HG/G3 bladder cancers. METHODS: We retrospectively evaluated the clinical and therapeutic outcomes of 145 patients diagnosed with T1 HG bladder cancer between 2000 and 2020. We classified 145 patients into three groups: (1) patients with T1 HG/G2 and HG/G3 who received intravesical instillation therapy (n = 76), (2) patients with T1 HG/G2 who did not receive intravesical instillation therapy (n = 32), and (3) patients with T1 HG/G3 who did not receive intravesical instillation therapy (n = 37). RESULTS: The median intravesical recurrence-free survival for all patients was 34.2 months. The number of tumors, the presence of intravesical instillation therapy, and tumor grade were significant prognostic factors for intravesical recurrence in all cases. Groups 2 and 3 showed significantly worse prognosis than group 1 in the multivariate analysis. CONCLUSIONS: Regarding intravesical recurrence, intravesical instillation therapy is necessary for both T1 HG/G3 and T1 HG/G2 bladder cancers. CI - (c) 2022. The Author(s). FAU - Yamamoto, Akinaru AU - Yamamoto A AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Kawashima, Atsunari AU - Kawashima A AUID- ORCID: 0000-0001-9369-4264 AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. kawashima@uro.med.osaka-u.ac.jp. FAU - Uemura, Toshihiro AU - Uemura T AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Yamamichi, Gaku AU - Yamamichi G AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Tomiyama, Eisuke AU - Tomiyama E AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Koh, Yoko AU - Koh Y AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Matsushita, Makoto AU - Matsushita M AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Kato, Taigo AU - Kato T AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Hatano, Koji AU - Hatano K AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. LA - eng PT - Journal Article DEP - 20220412 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Administration, Intravesical MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9006582 OTO - NOTNLM OT - Grade OT - Intravesical instillation therapy OT - Intravesical recurrence OT - Non-muscle-invasive bladder cancer OT - WHO 1973 classification system OT - WHO 2004/2016 classification system COIS- The authors declare that they have no competing interests. EDAT- 2022/04/14 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/04/12 CRDT- 2022/04/13 05:09 PHST- 2021/11/24 00:00 [received] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/04/13 05:09 [entrez] PHST- 2022/04/14 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/04/12 00:00 [pmc-release] AID - 10.1186/s12894-022-01000-z [pii] AID - 1000 [pii] AID - 10.1186/s12894-022-01000-z [doi] PST - epublish SO - BMC Urol. 2022 Apr 12;22(1):59. doi: 10.1186/s12894-022-01000-z. PMID- 35411173 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220413 IS - 1178-7074 (Print) IS - 1178-7074 (Electronic) IS - 1178-7074 (Linking) VI - 15 DP - 2022 TI - Development and Validation of a Prognostic Nomogram for Predicting Overall Survival for T1 High-Grade Patients After Radical Cystectomy: A Study Based on SEER. PG - 3753-3765 LID - 10.2147/IJGM.S354740 [doi] AB - OBJECTIVE: To construct a prognostic model that estimates the probability of overall survival for T1 high-grade bladder cancer patients after radical cystectomy. PATIENTS AND METHODS: We enrolled 801 patients diagnosed with T1 high grade and received radical cystectomy from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). All patients were randomly divided into the development group (n = 561) and validation group (n = 240) with the ratio of 7:3. Cox proportional hazards regression analyses were used to filter variables and the Kaplan-Meier method to evaluate survival outcomes. The results of sensitivity analysis determined the variables in the final model. The performance of the model was internally validated by calibration curves, the receiver operating characteristic (ROC) curves, and the concordance index (C-index). RESULTS: The mean survival months were 56.086 in the development group and 58.21 in the validation group. Six variables including age, marital status, tumour size, tumour sites, region nodes examined, and N stage were incorporated in the final nomogram. The accuracy of the nomogram for prediction of overall survival was estimated by C-index (0.732; 0.712-0.752) and AUC (0.771 for 3-year; 0.766 for 5-year) in the development group. In the validation group, the C-index of the nomogram was 0.752 (0.723-0.781), and AUC was 0.761 for 3-year as well as 0.793 for 5-year. These results all showed better performance than the AJCC stage. Calibration plots for 3- and 5-year overall survival presented good concordance in both the development and validation group. CONCLUSION: We have established a prognostic nomogram that provides a more accurate and relevant individualized probability of overall survival for patients with T1HG bladder transitional cell carcinoma after radical cystectomy. It can contribute to improving patient counselling and treatment selection. CI - (c) 2022 Zhan et al. FAU - Zhan, Xiangpeng AU - Zhan X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China. FAU - Chen, Luyao AU - Chen L AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China. FAU - Jiang, Ming AU - Jiang M AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China. FAU - Fu, Bin AU - Fu B AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China. LA - eng PT - Journal Article DEP - 20220405 PL - New Zealand TA - Int J Gen Med JT - International journal of general medicine JID - 101515487 PMC - PMC8994665 OTO - NOTNLM OT - SEER OT - T1 high-grade OT - bladder cancer OT - nomogram OT - prognosis OT - radical cystectomy COIS- The authors report no conflicts of interest in this work. EDAT- 2022/04/13 06:00 MHDA- 2022/04/13 06:01 PMCR- 2022/04/05 CRDT- 2022/04/12 05:30 PHST- 2021/12/24 00:00 [received] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/04/12 05:30 [entrez] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/04/13 06:01 [medline] PHST- 2022/04/05 00:00 [pmc-release] AID - 354740 [pii] AID - 10.2147/IJGM.S354740 [doi] PST - epublish SO - Int J Gen Med. 2022 Apr 5;15:3753-3765. doi: 10.2147/IJGM.S354740. eCollection 2022. PMID- 35410825 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20250530 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 6 IP - 1 DP - 2023 Feb TI - Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. PG - 67-75 LID - S2588-9311(22)00036-0 [pii] LID - 10.1016/j.euo.2022.03.005 [doi] AB - BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and monitoring bladder cancer (BC). Detection of BC-associated mutations in urinary DNA via targeted deep sequencing could meet this need. OBJECTIVE: To test the ability of mutational analysis of urinary DNA to noninvasively detect BC within the context of haematuria investigations and non-muscle-invasive BC (NMIBC) surveillance. DESIGN, SETTING, AND PARTICIPANTS: Capture-based ultra-deep sequencing was performed for 443 somatic mutations in 23 genes in 591 urine cell-pellet DNAs from haematuria clinic patients and 293 from NMIBC surveillance patients. Variant calling was optimised to minimise false positives using urine samples from 162 haematuria clinic patients without BC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The sensitivity and specificity for BC diagnosis were determined. RESULTS AND LIMITATIONS: Mutational analysis of urinary DNA detected 144 of the 165 haematuria patients diagnosed with incident BC from two independent cohorts, yielding overall sensitivity of 87.3% (95% confidence interval [CI] 81.2-92.0%) at specificity of 84.8% (95% CI 79.9-89.0%). The sensitivity was 97.4% for grade 3, 86.5% for grade 2, and 70.8% for grade 1 BC. Among NMIBC surveillance patients, 25 out of 29 recurrent BCs were detected, yielding sensitivity of 86.2% (95% CI 70.8-97.7%) at specificity of 62.5% (95% CI 56.1-68.0%); a positive urine mutation test in the absence of clinically detectable disease was associated with a 2.6-fold increase in the risk of future recurrence. The low number of recurrences in the NMIBC surveillance cohort and the lower sensitivity for detecting grade 1 pTa BC are limitations. CONCLUSIONS: Detection of mutations in a small panel of BC-associated genes could facilitate noninvasive BC testing and expedite haematuria investigations. Following further validation, the test could also play a role in NMIBC surveillance. PATIENT SUMMARY: Identification of alterations in genes that are frequently mutated in bladder cancer appears to be a promising strategy for detecting disease from urine samples and reducing reliance on examination of the bladder via a telescopic camera inserted through the urethra. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Ward, Douglas G AU - Ward DG AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Baxter, Laura AU - Baxter L AD - Bioinformatics Research Technology Platform, University of Warwick, Coventry, UK. FAU - Ott, Sascha AU - Ott S AD - Bioinformatics Research Technology Platform, University of Warwick, Coventry, UK; University of Warwick Medical School, University of Warwick, Coventry, UK. FAU - Gordon, Naheema S AU - Gordon NS AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Wang, Junhui AU - Wang J AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Patel, Prashant AU - Patel P AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Piechocki, Kim AU - Piechocki K AD - Nonacus Ltd., Birmingham Research Park, Birmingham, UK. FAU - Silcock, Lee AU - Silcock L AD - Nonacus Ltd., Birmingham Research Park, Birmingham, UK. FAU - Sale, Chris AU - Sale C AD - Nonacus Ltd., Birmingham Research Park, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Care and Public Health Research Institute, School of Nutrition and Translational Research in Metabolism, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer Research, London, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. Electronic address: r.t.bryan@bham.ac.uk. CN - BladderPath Trial Management Group LA - eng GR - 25354/CRUK_/Cancer Research UK/United Kingdom GR - C1343/A5738/CRUK_/Cancer Research UK/United Kingdom GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom GR - 14/08/60/DH_/Department of Health/United Kingdom GR - C16909/A23590/CRUK_/Cancer Research UK/United Kingdom GR - MC_PC_19029/MRC_/Medical Research Council/United Kingdom GR - MC_PC_18040/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220408 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 9007-49-2 (DNA) SB - IM CIN - Nat Rev Urol. 2022 Jul;19(7):383. doi: 10.1038/s41585-022-00620-2. PMID: 35711060 MH - Humans MH - *Hematuria/diagnosis/genetics MH - *Urinary Bladder Neoplasms/diagnosis/genetics/urine MH - Urinary Bladder MH - DNA MH - High-Throughput Nucleotide Sequencing OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - DNA OT - Diagnosis OT - Mutation OT - Sequencing OT - Urine EDAT- 2022/04/13 06:00 MHDA- 2023/02/11 06:00 CRDT- 2022/04/12 05:29 PHST- 2022/01/11 00:00 [received] PHST- 2022/03/03 00:00 [revised] PHST- 2022/03/17 00:00 [accepted] PHST- 2022/04/13 06:00 [pubmed] PHST- 2023/02/11 06:00 [medline] PHST- 2022/04/12 05:29 [entrez] AID - S2588-9311(22)00036-0 [pii] AID - 10.1016/j.euo.2022.03.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2023 Feb;6(1):67-75. doi: 10.1016/j.euo.2022.03.005. Epub 2022 Apr 8. PMID- 35404494 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 19 IP - 1 DP - 2023 Feb TI - A multi-institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence. PG - 71-78 LID - 10.1111/ajco.13684 [doi] AB - AIM: Intravesical recurrence (IVR) after nephroureterectomy for upper tract urothelial carcinoma (UTUC) is relatively frequent, occurring in about 30-50% of patients. The aim of this study was to investigate the differences of the prognosis and IVR between open and laparoscopic surgery and to elucidate the risk factor of IVR. PATIENTS AND METHODS: We retrospectively analyzed data from 403 patients with UTUC treated with laparoscopic or open nephroureterectomy at six affiliated hospitals between 1990 and 2015. The clinicopathological factors of each group were examined using Kaplan-Meier plots, and univariate and multivariate analyses. RESULTS: There was no difference in recurrence and cancer-specific mortality between open and laparoscopic surgery in univariate and multivariate analyses. There was no significant difference in IVR rate between the laparoscopic and open groups (p = .22). Among the patients with IVR, 84% of patients relapsed within 2 years. Univariate analysis of IVR showed a significant increase in patients with low-grade (p = .03, HR = 1.64) or low-stage urothelial carcinoma (pT1 or lower, p = .006, HR = 1.77) with no lymph node involvement (p = .002, HR = 10.3) or lymphovascular invasion (p = .009, HR = 1.79). Surgical modality was not an independent factor. In multivariate analysis, there was no independent predictive factor for IVR. CONCLUSIONS: There was no difference in recurrence, cancer-specific mortality, and IVR between open and laparoscopic surgery. On the other hand, our results suggested that the low malignant potential tumor may be a risk factor for IVR. This finding provides insight into IVR, which may help with the development of personalized prevention and treatment strategies. CI - (c) 2022 John Wiley & Sons Australia, Ltd. FAU - Shimura, Soichiro AU - Shimura S AUID- ORCID: 0000-0001-6798-7442 AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Ikeda, Masaomi AU - Ikeda M AUID- ORCID: 0000-0003-1017-9799 AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Moroo, Shigenori AU - Moroo S AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Koguchi, Dai AU - Koguchi D AUID- ORCID: 0000-0003-0731-2579 AD - Department of Urology, Kitasato University Medical Center, Kitamoto, Japan. FAU - Taoka, Yoshinori AU - Taoka Y AD - Department of Urology, Kitasato University Medical Center, Kitamoto, Japan. FAU - Hirayama, Takahiro AU - Hirayama T AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Murakami, Yasukiyo AU - Murakami Y AUID- ORCID: 0000-0001-6071-218X AD - Department of Urology, Kanagawa Prefectural Federation of Agricultural Cooperatives for Health and Welfare Sagamihara Kyodo Hospital, Sagamihara, Japan. FAU - Utsunomiya, Takuji AU - Utsunomiya T AD - Department of Urology, Kanagawa Prefectural Federation of Agricultural Cooperatives for Health and Welfare Sagamihara Kyodo Hospital, Sagamihara, Japan. FAU - Matsuda, Daisuke AU - Matsuda D AD - Department of Urology, Higashiyamato Hospital, Higashiyamato, Japan. FAU - Okuno, Norihiko AU - Okuno N AD - Department of Urology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan. FAU - Irie, Akira AU - Irie A AD - Department of Urology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. LA - eng GR - Parent's Association (Keyaki Kai) Grant of Kitasato University School of Medicine (S.S.)/ GR - JP18K09206/Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI)/ GR - 21K09355/Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI)/ GR - Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research/ PT - Journal Article PT - Multicenter Study DEP - 20220411 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 SB - IM MH - Humans MH - Nephroureterectomy MH - Retrospective Studies MH - *Carcinoma, Transitional Cell/pathology MH - *Urinary Bladder Neoplasms/pathology MH - Nephrectomy/adverse effects MH - *Laparoscopy/adverse effects MH - Neoplasm Recurrence, Local/epidemiology/surgery/etiology MH - *Ureteral Neoplasms/etiology/pathology/surgery OTO - NOTNLM OT - bladder cancer OT - intravesical recurrence OT - nephroureterectomy OT - upper tract urothelial carcinoma EDAT- 2022/04/12 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/04/11 12:15 PHST- 2020/08/20 00:00 [received] PHST- 2021/09/12 00:00 [accepted] PHST- 2022/04/12 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/04/11 12:15 [entrez] AID - 10.1111/ajco.13684 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2023 Feb;19(1):71-78. doi: 10.1111/ajco.13684. Epub 2022 Apr 11. PMID- 35400568 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220622 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 7 DP - 2022 Jul TI - Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: When and which patients can benefit most from it? PG - 344.e19-344.e25 LID - S1078-1439(22)00064-3 [pii] LID - 10.1016/j.urolonc.2022.02.013 [doi] AB - INTRODUCTION & OBJECTIVES: Radiation-induced haemorrhagic cystitis (RHC) is a frightening complication occurring after pelvic radiotherapy (PRT) which may significantly affect patients' quality of life. Bladder instillation with glycosaminoglycan replacement therapy (GRT) including hyaluronic acid +/- chondroitin sulphate has been proposed as an emerging alternative to prevent relapses of haematuria. Strong points in favour of using GRT for RHC are the ease of administration, cost, almost absence of side effects and possibility of administration to outpatients. We investigated the effectiveness of GRT in a cohort, single-centre, of patients with past-medical history of PRT attending the outpatient clinic and/or the accident & emergency department (A&E) for RHC. MATERIALS & METHODS: Patients with diagnosis of RHC, either with toxicity grade of 2 or 3, were deemed candidate for GRT as long as no active bleeding was occurring; in the case of non-self-limiting haematuria and/or anaemia for active bleeding, admission in the urology department was prompted for bleeding control prior to GRT instillation. An induction course of 6 weekly instillations was scheduled; if tolerated, patients were given a maintenance course with at least 6 monthly instillations. The primary end-point consisted in assessing the rate of haematuria remission (either partial or complete) defined as no need to readmission in the A&E and/or in the hospital. Secondary end-points included factors related to GRT failure. Univariate and multivariate analysis were undertaken to identify clinical independent variables associated to the events. RESULTS: Fifty-one patients with at least 1-year follow-up from the first GRT were included in the analysis. 88.2, 9.8 and 2% of patients had undergone PRT because affected by prostate, uterus and colorectal cancer, respectively. Median time-to-RHC was 31 months (IQR 21-90). Access to A&E and hospital admission were needed in 47 (92.1%) and 35 (68.6%) of the patients, respectively. Twenty-two (n = 22/35, 62.9%) patients required transurethral fulguration of the bladder, while the remainders could be managed with bladder wash-out. Median number of GRT instillations was 6 (IQR 3-7). Twenty-three (45.1%) patients needed to be readmitted to hospital a second time, receiving bladder wash-out (n = 7/23, 30.4%), transurethral fulguration of the bladder (n = 10/23, 43.5%) and/or cystectomy (n = 6/23, 26.1%). Ten (19.6%) patients received a second induction course of GRT. At the last follow-up, 36 (70.6%) patients did not required further hospital admission. Type of PRT and number of hospital admissions pre-GRT were the only variables statistically associated to the events at both univariate (P = 0.032 and P = 0.045) and multivariate analysis (P = 0.048 and P = 0.049). CONCLUSIONS: GRT should be prompted as soon as possible after diagnosis of the haematuria and settling of active bleeding. Patients who had undergone adjuvant PRT after radical prostatectomy are those at higher risk of GRT failure. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sanguedolce, Francesco AU - Sanguedolce F AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain; Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. FAU - Meneghetti, Iacopo AU - Meneghetti I AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: iacopo.meneghetti@uslnordovest.toscana.it. FAU - Bevilacqua, Giulio AU - Bevilacqua G AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Montano, Benjamin AU - Montano B AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Martinez, Christian AU - Martinez C AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Territo, Angelo AU - Territo A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Balana, Josep AU - Balana J AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20220408 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Glycosaminoglycans) SB - IM MH - Administration, Intravesical MH - *Cystitis/chemically induced/etiology MH - Female MH - Glycosaminoglycans/adverse effects MH - Hematuria/complications MH - Humans MH - Male MH - Quality of Life MH - *Radiation Injuries/drug therapy/etiology MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - Chondroitin sulphate OT - Cystitis OT - Haematuria OT - Hyaluronic acid OT - Radiotherapy COIS- Conflict of interests The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. EDAT- 2022/04/12 06:00 MHDA- 2022/06/15 06:00 CRDT- 2022/04/11 05:25 PHST- 2021/12/15 00:00 [received] PHST- 2022/02/13 00:00 [revised] PHST- 2022/02/15 00:00 [accepted] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/04/11 05:25 [entrez] AID - S1078-1439(22)00064-3 [pii] AID - 10.1016/j.urolonc.2022.02.013 [doi] PST - ppublish SO - Urol Oncol. 2022 Jul;40(7):344.e19-344.e25. doi: 10.1016/j.urolonc.2022.02.013. Epub 2022 Apr 8. PMID- 35393644 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 4 IP - 4 DP - 2022 Apr 8 TI - Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer. PG - CD014887 LID - 10.1002/14651858.CD014887.pub2 [doi] LID - CD014887 AB - BACKGROUND: Disease recurrence and progression remain major challenges for the treatment of non-muscle invasive bladder cancer. Narrow band imaging (NBI) is an optical enhancement technique that may improve resection of non-muscle invasive bladder cancer and thereby lead to better outcomes for people undergoing the procedure. OBJECTIVES: To assess the effects of NBI- and white light cystoscopy (WLC)-guided transurethral resection of bladder tumor (TURBT) compared to WLC-guided TURBT in the treatment of non-muscle invasive bladder cancer. SEARCH METHODS: We performed a comprehensive literature search of 10 databases, including the Cochrane Library, the Cochrane Database of Systematic Reviews, MEDLINE, Embase, several clinical trial registries, and grey literature for published and unpublished studies, irrespective of language. The search was performed per an a priori protocol on 3 December 2021. SELECTION CRITERIA: We included randomized controlled trials of participants with suspected or confirmed non-muscle invasive bladder cancer. Participants in the control group must have received WLC-guided TURBT alone (hereinafter simply referred to as 'WLC TURBT'). Participants in the intervention group had to have received NBI- and WLC-guided TURBT (hereinafter simply referred to as 'NBI + WLC TURBT'). DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion/exclusion, performed data extraction, and assessed risk of bias. We conducted meta-analysis on time-to-event and dichotomous data using a random-effects model in RevMan, according to Cochrane methods. We rated the certainty of evidence for each outcome according to the GRADE approach. Primary outcomes were time to recurrence, time to progression, and the occurrence of a major adverse event, defined as a Clavien-Dindo III, IV, or V complication. Secondary outcomes included time to death from bladder cancer and the occurrence of a minor adverse event, defined as a Clavien-Dindo I or II complication. MAIN RESULTS: We included eight studies with a total of 2152 participants randomized to the standard WLC TURBT or to NBI + WLC TURBT. A total of 1847 participants were included for analysis. Based on limited confidence in the time-to-event data, we found that participants who underwent NBI + WLC TURBT had a lower risk of disease recurrence over time compared to participants who underwent WLC TURBT (hazard ratio 0.63, 95% CI 0.45 to 0.89; I(2) = 53%; 6 studies, 1244 participants; low certainty of evidence). No studies examined disease progression as a time-to-event outcome or a dichotomous outcome. There was likely no difference in the risk of a major adverse event between participants who underwent NBI + WLC TURBT and those who underwent WLC TURBT (risk ratio 1.77, 95% CI 0.79 to 3.96; 4 studies, 1385 participants; low certainty of evidence). No studies examined death from bladder cancer as a time-to-event outcome or a dichotomous outcome. There was likely no difference in the risk of a minor adverse event between participants who underwent NBI + WLC TURBT and those who underwent WLC TURBT (risk ratio 0.88, 95% CI 0.49 to 1.56; I(2) = 61%; 4 studies, 1385 participants; low certainty of evidence). AUTHORS' CONCLUSIONS: Compared to WLC TURBT alone, NBI + WLC TURBT may lower the risk of disease recurrence over time while having little or no effect on the risks of major or minor adverse events. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Lai, Lillian Y AU - Lai LY AD - Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. FAU - Tafuri, Sean M AU - Tafuri SM AD - College of Medicine, California Northstate University, Elk Grove, California, USA. FAU - Ginier, Emily C AU - Ginier EC AD - Taubman Health Sciences Library, University of Michigan, Ann Arbor, Michigan, USA. FAU - Herrel, Lindsey A AU - Herrel LA AD - Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. FAU - Dahm, Philipp AU - Dahm P AD - Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. FAU - Maisch, Philipp AU - Maisch P AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. AD - Department of Urology, University of Ulm, Ulm, Germany. FAU - Lane, Giulia Ippolito AU - Lane GI AD - Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. LA - eng GR - F32 DK126232/DK/NIDDK NIH HHS/United States GR - K12 DK111011/DK/NIDDK NIH HHS/United States GR - T32 CA180984/CA/NCI NIH HHS/United States GR - T32 DK007782/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220408 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM CIN - World J Urol. 2023 Jul;41(7):1997-1999. doi: 10.1007/s00345-023-04435-7. PMID: 37311989 CIN - World J Urol. 2024 Jan 8;42(1):11. doi: 10.1007/s00345-023-04757-6. PMID: 38189985 MH - Cystoscopy MH - Humans MH - Narrow Band Imaging/methods MH - Neoplasm Recurrence, Local MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy/surgery PMC - PMC8990285 COIS- LL, ST, EG, LH, PD, PM, and GL report no conflicts of interest. EDAT- 2022/04/09 06:00 MHDA- 2022/04/12 06:00 PMCR- 2023/04/08 CRDT- 2022/04/08 05:32 PHST- 2022/04/08 05:32 [entrez] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2023/04/08 00:00 [pmc-release] AID - CD014887.pub2 [pii] AID - 10.1002/14651858.CD014887.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Apr 8;4(4):CD014887. doi: 10.1002/14651858.CD014887.pub2. PMID- 35393513 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20220520 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Apr 7 TI - mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis. PG - 5885 LID - 10.1038/s41598-022-09920-4 [doi] LID - 5885 AB - Bladder cancer (BC) is one of the most important cancers worldwide, and if it is diagnosed early, its progression in humans can be prevented and long-term survival will be achieved accordingly. This study aimed to identify novel micro-RNA (miRNA) and gene-based biomarkers for diagnosing BC. The microarray dataset of BC tissues (GSE13507) listed in the GEO database was analyzed for this purpose. The gene expression data from three BC tissues including 165 primary bladder cancer (PBC), 58 normal looking-bladder mucosae surrounding cancer (NBMSC), and 23 recurrent non-muscle invasive tumor tissues (RNIT) were used to reconstruct gene co-expression networks. After preprocessing and normalization, deferentially expressed genes (DEGs) were obtained and used to construct the weighted gene co-expression network (WGCNA). Gene co-expression modules and low-preserved modules were extracted among BC tissues using network clustering. Next, the experimentally validated mRNA-miRNA interaction information were used to reconstruct three mRNA-miRNA bipartite networks. Reactome pathway database and Gene ontology (GO) was subsequently performed for the extracted genes of three bipartite networks and miRNAs, respectively. To further analyze the data, ten hub miRNAs (miRNAs with the highest degree) were selected in each bipartite network to reconstruct three bipartite subnetworks. Finally, the obtained biomarkers were comprehensively investigated and discussed in authentic studies. The obtained results from our study indicated a group of genes including PPARD, CST4, CSNK1E, PTPN14, ETV6, and ADRM1 as well as novel miRNAs (e.g., miR-16-5p, miR-335-5p, miR-124-3p, and let-7b-5p) which might be potentially associated with BC and could be a potential biomarker. Afterward, three drug-gene interaction networks were reconstructed to explore candidate drugs for the treatment of BC. The hub miRNAs in the mRNA-miRNA bipartite network played a fundamental role in BC progression; however, these findings need further investigation. CI - (c) 2022. The Author(s). FAU - Abedi, Zahra AU - Abedi Z AD - Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. FAU - MotieGhader, Habib AU - MotieGhader H AD - Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran. habib_moti@ut.ac.ir. FAU - Hosseini, Sahar Sadat AU - Hosseini SS AD - Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. FAU - Sheikh Beig Goharrizi, Mohammad Ali AU - Sheikh Beig Goharrizi MA AD - Atherosclerosis Research Center, University of Medical Sciences Tehran, Tehran, Iran. FAU - Masoudi-Nejad, Ali AU - Masoudi-Nejad A AD - Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. amasoudin@ut.ac.ir. LA - eng PT - Journal Article DEP - 20220407 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (ADRM1 protein, human) RN - 0 (Biomarkers) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (MicroRNAs) RN - 0 (RNA, Messenger) RN - EC 3.1.3.48 (PTPN14 protein, human) RN - EC 3.1.3.48 (Protein Tyrosine Phosphatases, Non-Receptor) SB - IM MH - Biomarkers MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - Humans MH - Intracellular Signaling Peptides and Proteins/metabolism MH - *MicroRNAs/genetics/metabolism MH - Neoplasm Recurrence, Local/genetics MH - Protein Tyrosine Phosphatases, Non-Receptor/genetics MH - RNA, Messenger/genetics/metabolism MH - *Urinary Bladder Neoplasms/genetics PMC - PMC8991185 COIS- The authors declare no competing interests. EDAT- 2022/04/09 06:00 MHDA- 2022/04/12 06:00 PMCR- 2022/04/07 CRDT- 2022/04/08 05:31 PHST- 2021/11/06 00:00 [received] PHST- 2022/03/24 00:00 [accepted] PHST- 2022/04/08 05:31 [entrez] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2022/04/07 00:00 [pmc-release] AID - 10.1038/s41598-022-09920-4 [pii] AID - 9920 [pii] AID - 10.1038/s41598-022-09920-4 [doi] PST - epublish SO - Sci Rep. 2022 Apr 7;12(1):5885. doi: 10.1038/s41598-022-09920-4. PMID- 35390791 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20241101 IS - 1421-9794 (Electronic) IS - 0009-3157 (Print) IS - 0009-3157 (Linking) VI - 68 IP - 4 DP - 2023 TI - Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guerin Intravesical Instillation Therapy. PG - 190-196 LID - 10.1159/000524449 [doi] AB - BACKGROUND: There is a high incidence of intravesical recurrence after transurethral resection of bladder tumor for non-muscle-invasive bladder cancer (NMIBC). Intravesical instillation of bacillus Calmette-Guerin (BCG) is widely used to prevent recurrence and progression. There are two types of NMIBC: primary NMIBC and subsequent NMIBC after radical nephroureterectomy (RNU). We compared the clinical outcomes of BCG intravesical instillation therapy between the two types of NMIBC. PATIENTS AND METHODS: This study included a total of 357 patients, who received BCG intravesical instillation therapy to prevent recurrence of NMIBC (pTa/pT1) between 1991 and 2019. Among them, 34 patients had subsequent NMIBC after RNU, and the remaining 323 patients had primary NMIBC. This retrospective study analyzed 68 patients extracted by propensity score matching. Survival curves were estimated using the Kaplan-Meier method, and independent prognostic factors for survival were examined by the Cox proportional hazards model. RESULTS: The 3-year recurrence-free survival (RFS) rates in patients with primary NMIBC and subsequent NMIBC after RNU were 70.7% and 54.8%, respectively (p = 0.036). However, there were no significant differences between the two groups in progression-free survival and cancer-specific survival. Multivariate analysis of RFS showed that only a previous history of upper tract urothelial carcinoma was an independent prognostic and predictive factor. CONCLUSION: Patients with subsequent NMIBC after RNU treated with BCG intravesical instillation therapy have a higher risk of recurrence than those with primary NMIBC. Thus, stringent follow-up is necessary for patients with subsequent NMIBC after RNU. CI - (c) 2023 The Author(s). Published by S. Karger AG, Basel. FAU - Maeyama, Ryota AU - Maeyama R AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan, ryotadesu12@yahoo.co.jp. AD - Department of Urology, Musashimurayama Hospital, Musashimurayama, Japan, ryotadesu12@yahoo.co.jp. FAU - Ikeda, Masaomi AU - Ikeda M AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Shimura, Soichiro AU - Shimura S AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Amano, Noriyuki AU - Amano N AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Murakami, Yasukiyo AU - Murakami Y AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Yamada, Yasufumi AU - Yamada Y AD - Department of Urology, Sagamihara Kyodo Hospital, Sagamihara, Japan. FAU - Koguchi, Dai AU - Koguchi D AD - Department of Urology, Yokosuka City Uwamachi Hospital, Yokosuka, Japan. FAU - Tachibana, Takashi AU - Tachibana T AD - Department of Urology, Kitasato University Medical Center, Kitamoto, Japan. FAU - Kawamura, Mizuho AU - Kawamura M AD - Department of Urology, Sagamihara Hospital, Sagamihara, Japan. FAU - Sakata, Yusuke AU - Sakata Y AD - Department of Urology, International University of Health and Welfare Atami Hospital, Atami, Japan. FAU - Hagiwara, Masahiro AU - Hagiwara M AD - Department of Urology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. LA - eng PT - Journal Article DEP - 20220407 PL - Switzerland TA - Chemotherapy JT - Chemotherapy JID - 0144731 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - BCG Vaccine/therapeutic use MH - Nephroureterectomy MH - *Carcinoma, Transitional Cell/drug therapy MH - *Non-Muscle Invasive Bladder Neoplasms MH - Administration, Intravesical MH - Retrospective Studies MH - Neoplasm Recurrence, Local/drug therapy MH - Neoplasm Invasiveness PMC - PMC11524538 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Intravesical recurrence OT - Non-muscle-invasive bladder cancer OT - Radical nephroureterectomy OT - Recurrence-free survival COIS- The authors have no conflicts of interest to declare. EDAT- 2022/04/08 06:00 MHDA- 2023/12/17 09:43 PMCR- 2022/04/07 CRDT- 2022/04/07 20:17 PHST- 2022/01/15 00:00 [received] PHST- 2022/03/22 00:00 [accepted] PHST- 2023/12/17 09:43 [medline] PHST- 2022/04/08 06:00 [pubmed] PHST- 2022/04/07 20:17 [entrez] PHST- 2022/04/07 00:00 [pmc-release] AID - 000524449 [pii] AID - 524449 [pii] AID - 10.1159/000524449 [doi] PST - ppublish SO - Chemotherapy. 2023;68(4):190-196. doi: 10.1159/000524449. Epub 2022 Apr 7. PMID- 35387468 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20230410 IS - 0035-9351 (Print) IS - 0035-9351 (Linking) VI - 101 IP - 3 DP - 2022 Spring TI - Prognostic factors of early second transurethral resection of non-muscle invasive bladder cancer 10 years of experience of a referral center. PG - 119-128 LID - 10.33699/PIS.2022.101.3.119-128 [doi] AB - INTRODUCTION: Urothelial bladder cancer invading the submucosal layer (T1) is a tumor with a high risk of progression to invasive disease. In case of pT1 histology or absence of detrusor muscle in the specimen, an early second resection of the bladder tumor (reTUR) is indicated. According to retrospective studies, the histology finding of reTUR has a prognostic value. The aim of this study is to present the outcomes of second resection at a tertiary referral center. METHODS: In total, 146 patients with non-muscle invasive bladder cancer (NMIBC) were analyzed retrospectively. These patients underwent (the first) transurethral resection of their bladder tumor and an early reTUR between 3/2010 and 2/2021. Recurrence, progression and cystectomy free survival rates (RFS, PFS, CFS) were calculated using the Kaplan-Meier curves and the correlation of 7 clinical and pathologic factors (age, gender, muscle in specimen, presence of residual tumor and carcinoma in situ in reTUR, intravesical chemotherapy and BCG therapy) was evaluated using univariate and multivariate analyses. RESULTS: Median RFS was 2.15 years, 1-year RFS was 66.9% and 3-year RFS was 43.4%. One-year and 3-year PFS was 93.5% and 88.4%, respectively. One-year and 3-year CFS was 91.0% and 82.4%, respectively. Based on the multivariate analysis, presence of any residual tumor in reTUR was a negative prognostic marker for RFS, while intravesical chemotherapy and BCG therapy were positive prognostic markers. Presence of any residual tumor in reTUR was the only negative prognostic marker for PFS and CFS. CONCLUSION: The quality of the first resection of bladder tumor as determined by its completeness and presence of detrusor muscle in the histology specimen is the cornerstone of an adequate diagnosis and proper treatment. If an early reTUR is indicated, presence of any residual tumor in the histology specimen is a significant prognostic marker according to our findings. FAU - Zemlickova, B AU - Zemlickova B FAU - Brisuda, A AU - Brisuda A LA - eng PT - Journal Article TT - Prognosticke faktory v časne opakovane transuretralni resekci urotelialniho karcinomu močoveho měchyře bez invaze detruzoru 10lete zkušenosti referenčniho pracoviště. PL - Czech Republic TA - Rozhl Chir JT - Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti JID - 9815441 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine MH - Cystectomy MH - Disease Progression MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Neoplasm, Residual/surgery MH - Prognosis MH - Referral and Consultation MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Tumor of urinary bladder OT - early second resection (reTUR) OT - heart failure OT - urothelial carcinoma EDAT- 2022/04/08 06:00 MHDA- 2022/04/09 06:00 CRDT- 2022/04/07 05:26 PHST- 2022/04/07 05:26 [entrez] PHST- 2022/04/08 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] AID - 130382 [pii] AID - 10.33699/PIS.2022.101.3.119-128 [doi] PST - ppublish SO - Rozhl Chir. 2022 Spring;101(3):119-128. doi: 10.33699/PIS.2022.101.3.119-128. PMID- 35382986 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20220523 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 5 DP - 2022 May TI - Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. PG - 197.e1-197.e9 LID - S1078-1439(21)00557-3 [pii] LID - 10.1016/j.urolonc.2021.12.009 [doi] AB - Numerous biomarkers and risk tables can be used to predict recurrence or progression of patients with primary or recurrent non-muscle invasive bladder cancer (NMIBC) receiving Bacillus Calmette-Guerin (BCG). However, few are suitable for BCG-unresponsive disease (i.e., recurrence or progression after BCG treatment). Therefore, identification of a novel marker that allows accurate prediction of prognosis, particularly risk of recurrence, is critically important in clinical practice. In the current study, gene ontology and gene set enrichment analyses of microarray datasets (GSE13507, n = 47) revealed that differentially expressed genes in recurred NMIBC patients after BCG treatment were associated with virus and ribosomal pathways. Among the core-enrichment genes, the expression of RPL9, a putative tumor suppressor, was lower in recurred NMIBC patients after BCG therapy than in patients without recurrence (P = 0.033) from the E-MTAT-4321 European cohort (n = 84). Data from The Cancer Genome Atlas (n = 406) showed that bladder cancer patients with higher RPL9 expression had a longer overall survival probability than patients with lower RPL9 expression (P = 0.011). Moreover, we used the latest digital PCR platform to examine 59 NMIBC patients and identified downregulation of RPL9 in patients with recurrence after BCG therapy (P = 0.031). The Kaplan-Meier survival estimator showed that NMIBC patients with higher expression of RPL9 had longer recurrence-free survival (log-rank test, P = 0.015). Therefore, we conclude that RPL9 expression is a prospective predictor of recurrence after BCG therapy in NMIBC patients. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea. FAU - Kim, Yeong Uk AU - Kim YU AD - Department of Urology, College of medicine, Yeungnam University, Daegu, 42415, Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea. FAU - Zheng, Chuang-Ming AU - Zheng CM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea. FAU - Moon, Sung Min AU - Moon SM AD - Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Kim, Kyeong AU - Kim K AD - Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Lee, Hee Youn AU - Lee HY AD - Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Jeong, Pildu AU - Jeong P AD - Institute of Urotech, Cheongju 28120, Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Institute of Urotech, Cheongju 28120, Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, 28644, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, 28644, South Korea. Electronic address: sjyun@chungbuk.ac.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220402 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology OTO - NOTNLM OT - BCG-responsiveness OT - NMIBC recurrence OT - RPL9, digital PCR COIS- Conflict of Interest The authors declare no conflicts of interest. The funders played no role in the design of the study; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to publish. EDAT- 2022/04/07 06:00 MHDA- 2022/05/11 06:00 CRDT- 2022/04/06 05:22 PHST- 2021/10/19 00:00 [received] PHST- 2021/11/09 00:00 [revised] PHST- 2021/12/14 00:00 [accepted] PHST- 2022/04/07 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/04/06 05:22 [entrez] AID - S1078-1439(21)00557-3 [pii] AID - 10.1016/j.urolonc.2021.12.009 [doi] PST - ppublish SO - Urol Oncol. 2022 May;40(5):197.e1-197.e9. doi: 10.1016/j.urolonc.2021.12.009. Epub 2022 Apr 2. PMID- 35381368 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20220608 IS - 1873-1597 (Electronic) IS - 1572-1000 (Linking) VI - 38 DP - 2022 Jun TI - Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. PG - 102838 LID - S1572-1000(22)00127-2 [pii] LID - 10.1016/j.pdpdt.2022.102838 [doi] AB - BACKGROUND: 5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis. We aimed to clarify the therapeutic benefits of orally administered 5-aminolevulinic acid for photodynamic diagnosis in transurethral resection for non-muscle-invasive bladder cancer in a real-world setting. METHODS: From January 2009 to December 2020, patients with non-muscle-invasive bladder cancer who have undergone visually complete resection by initial transurethral surgery were included. Histopathologically confirmed residual and intravesical recurrent bladder cancer was retrospectively investigated and compared with transurethral resection using photodynamic diagnosis and conventional white light. RESULTS: One hundred and fifteen patients who underwent photodynamic diagnosis-transurethral resection were compared with 346 patients who underwent white light-transurethral resection. The second transurethral resection revealed that the proportion of residual T1 and Ta bladder cancer was lower in the photodynamic diagnosis group than in the white light group (10.3% vs. 33.8%, P = 0.001). Additionally, the proportion of intravesical recurrence was lower in the photodynamic diagnosis group than in the white light group (9.6% vs. 41.9%, P < 0.001). Using 5-aminolevulinic acid-photodynamic diagnosis during transurethral resection of bladder tumor improved the cumulative intravesical recurrence-free survival (log-rank test: P < 0.001). Furthermore, multivariate analyses indicated that not using 5-aminolevulinic acid-photodynamic diagnosis was an independent predictive factor for residual bladder cancer (odds ratio, 6.16; 95% confidence interval, 2.10-18.0; P < 0.001) and intravesical recurrence (hazard ratio, 2.01; 95% confidence interval, 1.05-3.83, P = 0.034). CONCLUSIONS: Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits. CI - Copyright (c) 2022. Published by Elsevier B.V. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. Electronic address: taoka.rikiya@kagawa-u.ac.jp. FAU - Matsuoka, Yuki AU - Matsuoka Y AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Yamasaki, Mari AU - Yamasaki M AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Kani, Naoya AU - Kani N AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Honda, Tomoko AU - Honda T AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Harada, Satoshi AU - Harada S AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Tohi, Yoichiro AU - Tohi Y AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Kato, Takuma AU - Kato T AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Okazoe, Homare AU - Okazoe H AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Tsunemori, Hiroyuki AU - Tsunemori H AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Ueda, Nobufumi AU - Ueda N AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University Japan, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. LA - eng PT - Journal Article DEP - 20220404 PL - Netherlands TA - Photodiagnosis Photodyn Ther JT - Photodiagnosis and photodynamic therapy JID - 101226123 RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Aminolevulinic Acid/therapeutic use MH - Disease Progression MH - Humans MH - Neoplasm Recurrence, Local MH - Neoplasm, Residual MH - *Photochemotherapy/methods MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/surgery OTO - NOTNLM OT - 5-aminolevulinic acid OT - Photodynamic diagnosis OT - Transurethral resection of bladder tumor OT - Urothelial carcinoma EDAT- 2022/04/06 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/04/05 20:09 PHST- 2022/01/21 00:00 [received] PHST- 2022/03/17 00:00 [revised] PHST- 2022/03/29 00:00 [accepted] PHST- 2022/04/06 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/04/05 20:09 [entrez] AID - S1572-1000(22)00127-2 [pii] AID - 10.1016/j.pdpdt.2022.102838 [doi] PST - ppublish SO - Photodiagnosis Photodyn Ther. 2022 Jun;38:102838. doi: 10.1016/j.pdpdt.2022.102838. Epub 2022 Apr 4. PMID- 35372015 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220405 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study. PG - 850874 LID - 10.3389/fonc.2022.850874 [doi] LID - 850874 AB - BACKGROUND: We aimed to evaluate the impact of tumor location on cancer outcomes in patients with pT3N0M0 upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU) with bladder cuff excision. MATERIALS AND METHODS: We retrospectively reviewed 302 patients with pT3N0M0 UTUC who underwent RNU with bladder cuff excision at our institution between 2005 and 2019, including 191 renal pelvis tumors and 111 ureteral tumors. Clinicopathologic characteristics were compared between renal pelvis and ureter urothelial carcinomas. Multivariate Cox proportional hazard regression was used to assess the association between outcomes and clinical factors. Outcomes of interest included intravesical recurrence-free survival (IVRFS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and cancer-specific survival (CSS), which were measured using the Kaplan-Meier curve with a log-rank test. RESULTS: A total of 302 patients underwent RNU with bladder cuff excision. During the median follow-up of 42.7 months, 70 (23.2%), 95 (31.5%), and 99 (32.8%) patients experienced intravesical recurrence, local recurrence, and distant metastasis, respectively. Seventy (23.2%) patients died from UTUC. Multivariate Cox regression analysis showed that tumor location was an independent predictor of local recurrence (HR = 2.05, p = 0.001), with borderline independent significance in intravesical recurrence (HR = 1.54, p = 0.074) and distant metastasis (HR = 1.45, p = 0.08). Kaplan-Meier analysis showed that ureter tumors had a worse 5-year local recurrence (log-rank p < 0.001) and borderline worse 5-year intravesical recurrence (log-rank p = 0.055) and 5-year distant metastasis (log-rank p = 0.073). CONCLUSION: Ureter tumors seem to be associated with worse oncological outcomes, especially with local recurrence in UTUC. Further large and long-term studies are warranted for investigating biological differences based on tumor location. CI - Copyright (c) 2022 Chen, Chen, Wang, Chiang, Yang, Lee, Chuang, Cheng, Kang, Lee, Chen, Shen, Liu, Liu, Chang, Su, Huang and Luo. FAU - Chen, Tzu Shuang AU - Chen TS AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yen Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wang, Hung Jen AU - Wang HJ AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chiang, Po Hui AU - Chiang PH AD - Jhong Siao Urological Hospital, Kaohsiung, Taiwan. FAU - Yang, Wen Chou AU - Yang WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lee, Wei Ching AU - Lee WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chuang, Yao Chi AU - Chuang YC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cheng, Yuan Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Kang, Chih Hsiung AU - Kang CH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lee, Wei Chia AU - Lee WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Chien Hsu AU - Chen CH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Shen, Yuan Chi AU - Shen YC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Liu, Yi Yang AU - Liu YY AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Liu, Hui Ying AU - Liu HY AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chang, Yin Lun AU - Chang YL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Su, Yu Li AU - Su YL AD - Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Huang, Chun Chieh AU - Huang CC AD - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Luo, Hao Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20220315 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8964942 OTO - NOTNLM OT - oncological outcomes OT - pT3N0M0 OT - radical nephroureterectomy OT - tumor location OT - upper urinary tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/05 06:00 MHDA- 2022/04/05 06:01 PMCR- 2022/01/01 CRDT- 2022/04/04 05:32 PHST- 2022/01/08 00:00 [received] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/04/04 05:32 [entrez] PHST- 2022/04/05 06:00 [pubmed] PHST- 2022/04/05 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.850874 [doi] PST - epublish SO - Front Oncol. 2022 Mar 15;12:850874. doi: 10.3389/fonc.2022.850874. eCollection 2022. PMID- 35351370 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220622 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 6 DP - 2022 Jun TI - Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. PG - 275.e1-275.e10 LID - S1078-1439(22)00039-4 [pii] LID - 10.1016/j.urolonc.2022.02.004 [doi] AB - BACKGROUND: To compare the overall survival (OS) outcomes of non-muscle invasive bladder cancer (NMIBC) patients with variant histology who underwent radical cystectomy (RC) vs. bladder preservation therapy (BPT). METHODS: We investigated the National Cancer Database for NMIBC patients with variant histological features. Patients diagnosed with micropapillary, sarcomatoid, neuroendocrine, squamous, and glandular variants were identified. Inverse probability weighting (IPW)-adjusted Kaplan Meier survival curves and Cox proportional hazard models were utilized to compare OS in the setting of RC versus BPT. RESULTS: A total of 8,920 (2.7%) NMIBC patients presented with variant histology, of whom 2,450 (27.5%) underwent RC, while 6,470 (72.5%) had BPT. When compared with BPT, patients who underwent RC had significantly higher 5-year OS rates for sarcomatoid (31.9% vs. 23.3%, P < 0.001) neuroendocrine (31% vs. 21.7%, P < 0.001), glandular (44% vs. 41%, P = 0.04) and squamous variants (39.7% vs 19.9%, P < 0.001). This OS benefit was not observed with micropapillary variant (43.9% vs. 53.2% P = 0.14). IPW-adjusted log-rank analysis identified RC as an independent predictor of OS for patients with sarcomatoid (hazards ratio [HR] 0.78, confidence interval [CI] 0.71-0.85, P < 0.001), squamous (HR 0.56, CI 0.53-0.59, P < 0.001), and neuroendocrine variants (HR 0.83, CI 0.76-0.91, P < 0.001), but not for micropapillary variant (HR 1.45, CI 1.24-1.7, P < 0.001). CONCLUSIONS: Among NMIBC patients presenting with variant histologies, RC was associated with better OS for sarcomatoid, squamous, glandular, and neuroendocrine variants when compared to BPT. This OS survival benefit was not observed in patients with micropapillary variant suggesting a potential role for bladder preservation in such population. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Dursun, Furkan AU - Dursun F AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX. FAU - Elshabrawy, Ahmed AU - Elshabrawy A AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX. FAU - Wang, Hanzhang AU - Wang H AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX. FAU - Wu, Shenghui AU - Wu S AD - Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX. FAU - Liss, Michael A AU - Liss MA AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX. FAU - Kaushik, Dharam AU - Kaushik D AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX. FAU - Grosser, Daniel AU - Grosser D AD - Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX. FAU - Mansour, Ahmed M AU - Mansour AM AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; UT Health San Antonio/MD Anderson Mays Cancer Center, San Antonio, TX; Urology and Nephrology Center, Mansoura University, Dakahlia Governorate, Egypt. Electronic address: ahmedmansour1st@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220327 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Carcinoma, Squamous Cell/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder preservation OT - Non-muscle invasive bladder cancer OT - Radical cystectomy OT - Survival OT - Variant histology EDAT- 2022/03/31 06:00 MHDA- 2022/05/18 06:00 CRDT- 2022/03/30 05:38 PHST- 2021/07/04 00:00 [received] PHST- 2022/01/27 00:00 [revised] PHST- 2022/02/06 00:00 [accepted] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/03/30 05:38 [entrez] AID - S1078-1439(22)00039-4 [pii] AID - 10.1016/j.urolonc.2022.02.004 [doi] PST - ppublish SO - Urol Oncol. 2022 Jun;40(6):275.e1-275.e10. doi: 10.1016/j.urolonc.2022.02.004. Epub 2022 Mar 27. PMID- 35351346 OWN - NLM STAT- MEDLINE DCOM- 20220602 LR - 20221129 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 81 IP - 6 DP - 2022 Jun TI - Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy. PG - 606-614 LID - S0302-2838(22)01670-0 [pii] LID - 10.1016/j.eururo.2022.02.028 [doi] AB - BACKGROUND: Limited data are available on the prognostic and predictive value of fibroblast growth factor receptor alterations (FGFRa) relative to clinical outcomes in patients with non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To determine whether FGFRa may be clinically useful in stratifying for treatment response in a real-world cohort of patients with pT1 NMIBC treated and untreated with bacillus Calmette-Guerin (BCG) instillation therapy. DESIGN, SETTING, AND PARTICIPANTS: A pooled dataset of matched clinical and genomic data (1992-2015) for pT1 NMIBC patients was assessed by the Bladder Cancer Research Initiative for Drug Targets in Germany consortium. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Key efficacy outcomes were recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS), which were estimated by Kaplan-Meier analysis, with hazard ratios calculated using a multivariate Cox proportional-hazard model. RESULTS AND LIMITATIONS: In this retrospective study of 263 patients with high-grade NMIBC, at a median follow-up of 63 mo, 32% showed recurrence and 15% progressed to muscle-invasive bladder cancer. FGFRa were found in 43% of patients, including 39% mutations and 5.7% fusions. FGFRa were associated with lower rates of concomitant carcinoma in situ. Among patients with or without FGFRa, there was no significant difference in PFS, RFS, and DSS in those who were BCG treated or BCG naive, or in the overall population. Limitations include the retrospective design from a single-center setting. CONCLUSIONS: In patients with high-risk NMIBC, FGFRa were frequently observed. Patients with FGFRa who often exhibit recurrence/relapse after BCG treatment have a high unmet need. PATIENT SUMMARY: Our retrospective study suggests that fibroblast growth factor receptor alterations (FGFRa) occur frequently in non-muscle-invasive bladder cancer (NMIBC). Outcomes were similar with or without FGFRa in patients with NMIBC, both overall and for standard bacillus Calmette-Guerin (BCG) treatment. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - Stratifyer Molecular Pathology GmbH, Cologne, Germany. FAU - Santiago-Walker, Ademi AU - Santiago-Walker A AD - Janssen Research & Development, Spring House, PA, USA. FAU - Baig, Mahadi AU - Baig M AD - Janssen Research & Development, Spring House, PA, USA. FAU - Sundaram, Ramesh AU - Sundaram R AD - Janssen Research & Development, Spring House, PA, USA. FAU - Carcione, Jenna Cody AU - Carcione JC AD - Janssen Research & Development, Spring House, PA, USA. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, University of Ulm, Ulm, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Electronic address: johannes.breyer@ukr.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220326 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Receptors, Fibroblast Growth Factor) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Humans MH - Immunotherapy MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/genetics/metabolism/pathology MH - Prognosis MH - *Receptors, Fibroblast Growth Factor/metabolism MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/genetics/metabolism/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - FGFR alterations OT - Fibroblast growth factor receptor OT - Non-muscle-invasive bladder cancer EDAT- 2022/03/31 06:00 MHDA- 2022/06/03 06:00 CRDT- 2022/03/30 05:38 PHST- 2021/09/17 00:00 [received] PHST- 2022/01/26 00:00 [revised] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/06/03 06:00 [medline] PHST- 2022/03/30 05:38 [entrez] AID - S0302-2838(22)01670-0 [pii] AID - 10.1016/j.eururo.2022.02.028 [doi] PST - ppublish SO - Eur Urol. 2022 Jun;81(6):606-614. doi: 10.1016/j.eururo.2022.02.028. Epub 2022 Mar 26. PMID- 35348732 OWN - NLM STAT- MEDLINE DCOM- 20220602 LR - 20221207 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 52 IP - 6 DP - 2022 May 31 TI - Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification. PG - 642-649 LID - 10.1093/jjco/hyac042 [doi] AB - OBJECTIVE: To investigate the relationships between non-muscle invasive bladder cancer molecular subtypes and predict the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine. METHODS: A total of 160 patients with T1 stage non-muscle invasive bladder cancer were enrolled in this study. Fifty-three patients underwent anthracycline (Pirarubicin and Pharmorubicin) therapy and 107 patients accepted gemcitabine therapy. Uroplakin II and CK20 were categorized as immunohistochemistry (IHC) markers for luminal subtype, whereas CK5/6 and CD44 were categorized as immunohistochemistry markers for basal subtype. The cluster results with immunohistochemical score indicated that non-muscle invasive bladder cancer can be subgrouped into three major classes. RESULTS: Class 2 showed the luminal-like characteristics, whereas class 3 showed the basal-like characteristics. Class 1 showed no high expression of luminal or basal-associated immunohistochemistry markers. The molecular subtype is an independent risk factor for recurrence-free survival (P = 0.030) and progression-free survival (P = 0.006) in patients with T1 stage non-muscle invasive bladder cancer. In class 1 and class 2 (luminal-like) subtypes, gemcitabine and anthracycline show no difference in recurrence-free survival and progression-free survival. Gemcitabine was associated with reduced recurrence compared with anthracycline (P = 0.039) in class 3 (basal-like) subtypes and show no difference in decreasing progression. CONCLUSIONS: The molecular classification based on immunohistochemical results is an independent risk factor for the prognosis of non-muscle invasive bladder cancer with T1 stage. Different therapeutic methods should be selected according to different molecular subtypes. CI - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Wang, Tianwei AU - Wang T AUID- ORCID: 0000-0003-4437-586X AD - Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China. FAU - Niu, Xiaobing AU - Niu X AD - Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China. FAU - Zhong, Bing AU - Zhong B AD - Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Anthracyclines) RN - 0 (Antibiotics, Antineoplastic) RN - 0W860991D6 (Deoxycytidine) RN - 3Z8479ZZ5X (Epirubicin) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) RN - 0 (Gemcitabine) SB - IM MH - Administration, Intravesical MH - Anthracyclines/therapeutic use MH - Antibiotics, Antineoplastic/therapeutic use MH - Deoxycytidine/analogs & derivatives MH - Doxorubicin/analogs & derivatives MH - Epirubicin/therapeutic use MH - Humans MH - Immunohistochemistry MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy MH - Gemcitabine OTO - NOTNLM OT - anthracycline OT - gemcitabine OT - intravesical chemotherapy OT - molecular classification OT - non-muscle invasive bladder cancer EDAT- 2022/03/30 06:00 MHDA- 2022/06/03 06:00 CRDT- 2022/03/29 12:20 PHST- 2021/11/01 00:00 [received] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/06/03 06:00 [medline] PHST- 2022/03/29 12:20 [entrez] AID - 6554952 [pii] AID - 10.1093/jjco/hyac042 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2022 May 31;52(6):642-649. doi: 10.1093/jjco/hyac042. PMID- 35347572 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20260213 IS - 1699-3055 (Electronic) IS - 1699-048X (Print) IS - 1699-048X (Linking) VI - 24 IP - 4 DP - 2022 Apr TI - SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). PG - 613-624 LID - 10.1007/s12094-022-02815-w [doi] AB - Most muscle-invasive bladder cancer (BC) are urothelial carcinomas (UC) of transitional origin, although histological variants of UC have been recognized. Smoking is the most important risk factor in developed countries, and the basis for prevention. UC harbors high number of genomic aberrations that make possible targeted therapies. Based on molecular features, a consensus classification identified six different MIBC subtypes. Hematuria and irritative bladder symptoms, CT scan, cystoscopy and transurethral resection are the basis for diagnosis. Radical cystectomy with pelvic lymphadenectomy is the standard approach for muscle-invasive BC, although bladder preservation is an option for selected patients who wish to avoid or cannot tolerate surgery. Perioperative cisplatin-based neoadjuvant chemotherapy is recommended for cT2-4aN0M0 tumors, or as adjuvant in patients with pT3/4 and or pN + after radical cystectomy. Follow-up is particularly important after the availability of new salvage therapies. It should be individualized and adapted to the risk of recurrence. Cisplatin-gemcitabine is considered the standard first line for metastatic tumors. Carboplatin should replace cisplatin in cisplatin-ineligible patients. According to the EMA label, pembrolizumab or atezolizumab could be an option in cisplatin-ineligible patients with high PD-L1 expression. For patients whose disease respond or did not progress after first-line platinum chemotherapy, maintenance with avelumab prolongs survival with respect to the best supportive care. Pembrolizumab also increases survival versus vinflunine or taxanes in patients with progression after chemotherapy who have not received avelumab, as well as enfortumab vedotin in those progressing to first-line chemotherapy followed by an antiPDL1/PD1. Erdafitinib may be considered in this setting in patients with FGFR alterations. An early onset of supportive and palliative care is always strongly recommended. CI - (c) 2022. The Author(s). FAU - Valderrama, Begona P AU - Valderrama BP AUID- ORCID: 0000-0003-0175-1263 AD - Medical Oncology Department, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain. bpvalderrama@gmail.com. FAU - Gonzalez-Del-Alba, Aranzazu AU - Gonzalez-Del-Alba A AD - Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. FAU - Morales-Barrera, Rafael AU - Morales-Barrera R AD - Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. FAU - Pelaez Fernandez, Ignacio AU - Pelaez Fernandez I AD - Medical Oncology Department, Hospital Universitario de Cabuenes, Gijon, Asturias, Spain. FAU - Vazquez, Sergio AU - Vazquez S AD - Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain. FAU - Caballero Diaz, Cristina AU - Caballero Diaz C AD - Medical Oncology Department, Hospital General Universitario de Valencia, CIBERONC (Centro de Investigacion Biomedica de Red en Cancer), Valencia, Spain. FAU - Domenech, Montserrat AU - Domenech M AD - Medical Oncology Department, Medical Oncology Service, Hospital Fundacio Althaia, Manresa, Spain. FAU - Fernandez Calvo, Ovidio AU - Fernandez Calvo O AD - Medical Oncology Department, Complejo Hospitalario Universitario, Ourense, Spain. FAU - Gomez de Liano Lista, Alfonso AU - Gomez de Liano Lista A AD - Medical Oncology Department, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas, Spain. FAU - Arranz Arija, Jose Angel AU - Arranz Arija JA AD - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20220326 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Carcinoma, Transitional Cell/pathology MH - Cisplatin/therapeutic use MH - Cystectomy MH - Humans MH - Muscles/pathology MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - *Urinary Bladder Neoplasms/pathology PMC - PMC8986688 OTO - NOTNLM OT - Bladder cancer OT - Muscle-invasive OT - Urothelial COIS- AGLL reports Advisory Board and Speaker from Roche, Pfizer and Astellas; Speaker from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board, Speaker and Other from Astellas, Roche, BMS and Merk-Pfizer; Advisory Board and Other from Ipsen; Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board, Speaker and Other from Pfizer; Speaker and Other from Ipsen and Roche; Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas; Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer and Ipsen and honoraria for speaker engagements, advisory boards and continuous medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Eisai and AstraZeneca. JAA reports honoraria from Astellas, Pfizer and BMS; conulting or advisory role from Pfizer, Astellas, Janssen-Cilag, MSD Oncology, BMS, Merck, AstraZeneca, Bayer and Eisai and Research Funding from BMS. RMB, SVE, CCD and MDS have nothing to disclose. EDAT- 2022/03/30 06:00 MHDA- 2022/04/09 06:00 PMCR- 2022/03/26 CRDT- 2022/03/29 05:48 PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2022/03/29 05:48 [entrez] PHST- 2022/03/26 00:00 [pmc-release] AID - 10.1007/s12094-022-02815-w [pii] AID - 2815 [pii] AID - 10.1007/s12094-022-02815-w [doi] PST - ppublish SO - Clin Transl Oncol. 2022 Apr;24(4):613-624. doi: 10.1007/s12094-022-02815-w. Epub 2022 Mar 26. PMID- 35346591 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20250728 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 4 DP - 2022 Aug TI - Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice. PG - e291-e295 LID - S1558-7673(22)00047-7 [pii] LID - 10.1016/j.clgc.2022.03.002 [doi] AB - Transurethral resection of bladder tumor (TURBT) is the essential first step in the current algorithm for the management of bladder cancer (BC). However, despite its necessity and significance, TURBT has several limitations, including cost, hospitalization, anesthesia, potential complications such as bladder perforation, and delay to radical cystectomy. The Vesical Imaging Reporting and Data System (VI-RADS) was developed to standardize the reporting of multiparametric magnetic resonance imaging for BC, and its diagnostic accuracy to predict muscle invasion has been validated. Given the high sensitivity of VI-RADS >/= 3 and high specificity of VI-RADS >/= 4 as clinically relevant cutoff values, we herein propose a new VI-RADS-based algorithm for the management of BC. Using this algorithm, patients with VI-RADS /= 4 may skip conventional TURBT aimed at pathologic confirmation of muscle invasion and immediately undergo radical cystectomy. Our newly proposed algorithm enables the avoidance of unnecessary deep resection or second TURBT as well as delay to radical cystectomy. The VI-RADS-based algorithm enables a paradigm shift from the current TURBT-dependent practice in the management of BC. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. Electronic address: satorutaguchi33@gmail.com. FAU - Watanabe, Masanaka AU - Watanabe M AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Tambo, Mitsuhiro AU - Tambo M AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Machida, Haruhiko AU - Machida H AD - Department of Radiology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan. FAU - Yokoyama, Kenichi AU - Yokoyama K AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. LA - eng SI - ISRCTN/ISRCTN35296862 PT - Journal Article DEP - 20220304 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Algorithms MH - *Cystectomy MH - Data Systems MH - Humans MH - Retrospective Studies MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery OTO - NOTNLM OT - Magnetic resonance imaging OT - Muscle invasion OT - Radical cystectomy OT - Staging OT - Urothelial carcinoma EDAT- 2022/03/30 06:00 MHDA- 2022/07/27 06:00 CRDT- 2022/03/29 05:42 PHST- 2022/01/29 00:00 [received] PHST- 2022/02/27 00:00 [revised] PHST- 2022/03/01 00:00 [accepted] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/03/29 05:42 [entrez] AID - S1558-7673(22)00047-7 [pii] AID - 10.1016/j.clgc.2022.03.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Aug;20(4):e291-e295. doi: 10.1016/j.clgc.2022.03.002. Epub 2022 Mar 4. PMID- 35337773 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20250623 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 6 DP - 2022 Nov TI - Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. PG - 1635-1642 LID - S2405-4569(22)00058-X [pii] LID - 10.1016/j.euf.2022.03.004 [doi] AB - CONTEXT: Surveillance of the urethra and management of urethral recurrence (UR) after radical cystectomy (RC) is an area with poor evidence. OBJECTIVE: We aimed to summarize the available evidence and provide clinicians with practical recommendations on how to prevent and manage UR after RC for bladder cancer. EVIDENCE ACQUISITION: The MEDLINE and EMBASE databases were searched during September 2021 for studies evaluating UR after RC. The primary endpoint was oncologic outcomes for patients who experienced UR depending on different surveillance and management approaches. EVIDENCE SYNTHESIS: Forty-three studies were included in the quantitative synthesis. According to the currently available literature, a tight-knitted surveillance protocol should be implemented for males treated with RC and nonorthotopic neobladder diversion as well as patients with prostatic involvement, tumor multifocality, bladder neck involvement, and concomitant carcinoma in situ. A survival benefit of a prophylactic urethrectomy has been reported only in patients at very high risk for UR based on clinical factors. Surveillance protocols were highly heterogeneous and poorly documented among included studies. Patients whose UR was diagnosed based on clinical symptoms had a poor prognosis. Only limited data were available on the comparative effectiveness of watchful waiting after RC versus clinical symptom screening as part of a follow-up strategy. However, the use of regular cytology and/or urethroscopy seems useful in select patients at high risk for UR. Despite limited data on the optimal management of UR, urethra-sparing approaches (transurethral resection of UR) seem to be an option for Ta (only) recurrences; a salvage urethrectomy with or without chemotherapy should be the standard for all others. CONCLUSIONS: Based on the currently available literature, we have proposed an algorithm to guide the decision-making process to help identify and treat UR after RC. Given the lack of evidence on how to deal with UR and surveil patients at risk for UR, this study may invigorate research in this area of unmet need. PATIENT SUMMARY: Early diagnosis and tailored management of urethral recurrence could help improve oncologic outcomes in these patients. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Torino, Italy. FAU - Andrea, David D AU - Andrea DD AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Albisinni, Simone AU - Albisinni S AD - Service d'Urologie, Hopital Erasme, Universite Libre de Bruxelles, Bruxelles, Belgium. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Hopital Foch, UVSQ-Paris-Saclay University, Suresnes, France. FAU - Giannarini, Gianluca AU - Giannarini G AD - Urology Unit, University Hospital Santa Maria della Misericordia, Udine, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris University, Paris, France. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA. FAU - Roupret, Morgan AU - Roupret M AD - GRC n degrees 5, Predictive Onco-Urology, Ap-Hp, Urology, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University, Nijmegen Heyendaal, The Netherlands. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: benjaminpradere@gmail.com. CN - European Association of Urology CN - Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group CN - European Association of Urology Section of Oncological Urology ESOU LA - eng PT - Journal Article PT - Systematic Review DEP - 20220323 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/surgery MH - Cystectomy/adverse effects MH - *Urinary Bladder Neoplasms/surgery MH - Urinary Bladder OTO - NOTNLM OT - Radical cystectomy OT - Urethral recurrence EDAT- 2022/03/27 06:00 MHDA- 2022/12/16 06:00 CRDT- 2022/03/26 05:28 PHST- 2021/12/26 00:00 [received] PHST- 2022/02/20 00:00 [revised] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/03/27 06:00 [pubmed] PHST- 2022/12/16 06:00 [medline] PHST- 2022/03/26 05:28 [entrez] AID - S2405-4569(22)00058-X [pii] AID - 10.1016/j.euf.2022.03.004 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Nov;8(6):1635-1642. doi: 10.1016/j.euf.2022.03.004. Epub 2022 Mar 23. PMID- 35332884 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20220401 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 75 IP - 2 DP - 2022 Mar TI - Optimization of the different therapeutic strategies in muscle invasive bladder cancer using biomarkers. PG - 144-155 AB - Predicting response to definitive treatmentsis a fascinating challenge which develops throughthe evolution of a panel of convincing molecularbiomarkers capable of adding in clinical decissionsdespite interpatient and intratumoral heterogenicity.Muscle-invasive bladder cancer (MIBC) can be locallytreated either with radical cystectomy (RC) with or withoutneoadyuvant chemotherapy or bladder preservationapproaches such as trimodal therapy (TMT) includingmaximal transurethral resection of bladder tumor(TURBt) followed by external beam radiotherapy withconcurrent systemic radio-sensitizing chemotherapy.Conventional or novel/targeted systemic agents areessential parts of perioperative multidisciplinary managementconsidering both neoadjuvant and adjuvantsetting. Advances in molecular biology such as next generation sequencing and whole genome or transcriptomicanalysis, provided novel insights to achieve a fullunderstanding of the biology behind MIBC helping toidentify emerging predictive signatures. Although severalprogresses have been made, real-world applicationof molecular biomarkers in MIBC scenario is hinderedby lack of standardization, and low reproducibility. Inthis review we aim to present the emerging role of novelmolecular biomarkers in predicting response to localtreatments and systemic agents in MIBC. FAU - Claps, Francesco AU - Claps F AD - Servicio de Urologia. Instituto Valenciano de Oncologia. Valencia. Espana. Servicio de Oncologia Quirurgica (Urologia). Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Amsterdam. Holanda. Clinica de Urologia. Departamento de Medicina. Cirugia y Ciencias de la Salud. Universidad de Trieste. Italia. FAU - Mir, Carmen AU - Mir C AD - Servicio de Urologia. Fundacion Investigacion Hospital IMED Valencia. Valencia. Espana. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Clinica de Urologia, Hospital VITHAS 9 de Octubre. Valencia. Espana. LA - eng LA - spa PT - Journal Article TT - Optimizacion de las diferentes estrategias terapeuticas en tumor vesical infi ltrante usando biomarcadores. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Biomarkers) SB - IM MH - Biomarkers MH - Humans MH - Muscles MH - Neoplasm Invasiveness MH - Reproducibility of Results MH - *Urinary Bladder Neoplasms/surgery/therapy OTO - NOTNLM OT - Adjuvant chemotherapy OT - Biomarcadores OT - Biomarkers OT - Bladder cancer OT - Cistectomia radical OT - Neoadjuvant chemotherapy OT - Quimioterapia neoadyuvante OT - Quimioterapia adyuvante OT - Radiation therapy OT - Radical cystectomy OT - Radioterapia adyuvante OT - Tumor vesical EDAT- 2022/03/26 06:00 MHDA- 2022/03/29 06:00 CRDT- 2022/03/25 08:37 PHST- 2022/03/25 08:37 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] AID - 2022-75-2-341b3d1bb3c98f469082cdb21b583dccbabe5e28 [pii] PST - ppublish SO - Arch Esp Urol. 2022 Mar;75(2):144-155. PMID- 35330146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240825 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 3 DP - 2022 Mar 9 TI - Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers. LID - 10.3390/life12030395 [doi] LID - 395 AB - Bladder cancer is the fourth most common cancer in men, and most cases are non-muscle-invasive. A high recurrence rate is a critical problem in non-muscle-invasive bladder cancer. The availability of few urine tests hinders the effective detection of superficial and small bladder tumors. Cystoscopy is the gold standard for diagnosis; however, it is associated with urinary tract infections, hematuria, and pain. Early detection is imperative, as intervention influences recurrence. Therefore, urinary biomarkers need to be developed to detect these bladder cancers. Recently, several protein candidates in the urine have been identified as biomarkers. In the present narrative review, the current status of the development of urinary protein biomarkers, including FDA-approved biomarkers, is summarized. Additionally, contemporary proteomic technologies, such as antibody-based methods, mass-spectrometry-based methods, and machine-learning-based diagnosis, are reported. Furthermore, new strategies for the rapid and correct profiling of potential biomarkers of bladder cancer in urine are introduced, along with their limitations. The advantages of urinary protein biomarkers and the development of several related technologies are highlighted in this review. Moreover, an in-depth understanding of the scientific background and available protocols in research and clinical applications of the surveillance of non-muscle bladder cancer is provided. FAU - Ahn, Jae-Hak AU - Ahn JH AUID- ORCID: 0000-0002-6125-9345 AD - Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Korea. FAU - Kang, Chan-Koo AU - Kang CK AD - Department of Advanced Convergence, Handong Global University, Pohang 37554, Gyeongbuk, Korea. AD - School of Life Science, Handong Global University, Pohang 37554, Gyungbuk, Korea. FAU - Kim, Eun-Mee AU - Kim EM AD - Department of Emergency Medical Technology, Korea Nazarene University, Cheonan 31172, Chungcheongnam-do, Korea. FAU - Kim, Ah-Ram AU - Kim AR AUID- ORCID: 0000-0001-8938-751X AD - Department of Advanced Convergence, Handong Global University, Pohang 37554, Gyeongbuk, Korea. AD - School of Life Science, Handong Global University, Pohang 37554, Gyungbuk, Korea. FAU - Kim, Aram AU - Kim A AD - Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Korea. LA - eng GR - This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2019R1I1A2A01063045)./Ah-Ram Kim/ PT - Journal Article PT - Review DEP - 20220309 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC8950253 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - proteomics OT - urine COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/03/09 CRDT- 2022/03/25 01:12 PHST- 2022/02/10 00:00 [received] PHST- 2022/02/25 00:00 [revised] PHST- 2022/03/03 00:00 [accepted] PHST- 2022/03/25 01:12 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/03/09 00:00 [pmc-release] AID - life12030395 [pii] AID - life-12-00395 [pii] AID - 10.3390/life12030395 [doi] PST - epublish SO - Life (Basel). 2022 Mar 9;12(3):395. doi: 10.3390/life12030395. PMID- 35328139 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 12 IP - 3 DP - 2022 Feb 25 TI - Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. LID - 10.3390/diagnostics12030586 [doi] LID - 586 AB - BACKGROUND: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette-Guerin (BCG) therapy. METHODS: We retrospectively reviewed patient's medical data from multicenter institutions. A total of 1382 patients with HG/G3 T1 NMIBC have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months. The analysis of mGPS for recurrence and progression was performed using multivariable and univariable Cox regression models. RESULTS: During follow-up, 659 patients (47.68%) suffered recurrence, 441 (31.91%) suffered progression, 156 (11.28%) died of all causes, and 67 (4.84%) died of bladder cancer. At multivariable analysis, neutrophil to lymphocyte ratio [hazard ratio (HR): 7.471; p = 0.0001] and erythrocyte sedimentation rate (ESR) (HR: 0.706; p = 0.006 were significantly associated with recurrence. mGPS has no statistical significance for progression (p = 0.076). Kaplan-Meier survival analysis showed a significant difference in survival among patients from different mGPS subgroups. Five-year OS was 93% (CI 95% 92-94), in patients with mGPS 0, 82.2% (CI 95% 78.9-85.5) in patients with mGPS 1 and 78.1% (CI 95% 60.4-70) in mGPS 2 patients. Five-year CSS was 98% (CI 95% 97-99) in patients with mGPS 0, 90% (CI 95% 87-94) in patients with mGPS 1, and 100% in mGPS 2 patients. Limitations are applicable to a retrospective study. CONCLUSIONS: mGPS may have the potential to predict recurrence in HG/G3 T1 NMIBC patients, but more prospective, with large cohorts, studies are needed to study the influence of systemic inflammatory markers in prediction of outcomes in NMIBC for a definitive conclusion. FAU - Ferro, Matteo AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Division of Urology, European Institute of Oncology, Milan IRCCS, 20141 Milan, Italy. FAU - Tataru, Octavian Sabin AU - Tataru OS AUID- ORCID: 0000-0001-7057-7815 AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, 540142 Targu Mures, Romania. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan IRCCS, 20141 Milan, Italy. AD - Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, 20133 Milan, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AUID- ORCID: 0000-0001-7807-1229 AD - Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, 70126 Bari, Italy. FAU - Abu Farhan, Abdal Rahman AU - Abu Farhan AR AUID- ORCID: 0000-0003-0665-3953 AD - Department of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan IRCCS, 20089 Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan IRCCS, 20089 Milan, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. AD - Urology Unit, University of Foggia, Bonomo Teaching Hospital, 76123 Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AUID- ORCID: 0000-0002-7899-8056 AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Fondazione "G. Pascale" IRCCS, 80131 Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, San Martino Policlinico Hospital, IRCCS for Oncology, 16132 Genoa, Italy. AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, 16132 Genoa, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, San Martino Policlinico Hospital, IRCCS for Oncology, 16132 Genoa, Italy. AD - Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, 16132 Genoa, Italy. FAU - La Civita, Evelina AU - La Civita E AUID- ORCID: 0000-0003-0543-9031 AD - Department of Translational Medical Sciences, University of Naples "Federico II", 80131 Naples, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Urology Department, San Carlo di Nancy Hospital, GVM Care and Research, 00165 Rome, Italy. AD - Urology Unit, Department of Surgery, Tor Vergata University of Rome, 00133 Rome, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, VCU Health, Richmond, VA 23298, USA. FAU - Muto, Matteo AU - Muto M AD - Radiotherapy Unit, "S.G. Moscati" Hospital, 74010 Avellino, Italy. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy of Cluj-Napoca, 400012 Cluj-Napoca, Romania. FAU - Marchioni, Michele AU - Marchioni M AUID- ORCID: 0000-0002-1702-4127 AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, 66100 Chieti, Italy. FAU - Schips, Luigi AU - Schips L AD - Urology Unit, Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, 66100 Chieti, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, 10126 Turin, Italy. FAU - Terracciano, Daniela AU - Terracciano D AUID- ORCID: 0000-0003-4296-429X AD - Department of Translational Medical Sciences, University of Naples "Federico II", 80131 Naples, Italy. FAU - Papalia, Rocco AU - Papalia R AD - Department of Urology, Campus Bio-Medico University, 00128 Rome, Italy. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Urology Unit, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples "Federico II", 80125 Naples, Italy. FAU - Barone, Biagio AU - Barone B AUID- ORCID: 0000-0003-4884-132X AD - Urology Unit, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples "Federico II", 80125 Naples, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, 95123 Catania, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Division of Urology, European Institute of Oncology, Milan IRCCS, 20141 Milan, Italy. AD - Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, 20133 Milan, Italy. FAU - Ludovico, Giuseppe Mario AU - Ludovico GM AD - Department of Urology, F. Miulli Regional Hospital, Acquaviva delle Fonti, 70021 Bari, Italy. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - I.O.S.U.D., George Emil Palade University of Medicine and Pharmacy, Science and Technology, 540142 Targu Mures, Romania. AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Division of Urology, European Institute of Oncology, Milan IRCCS, 20141 Milan, Italy. AD - Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, 20133 Milan, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Urology, University of Naples "Federico II", 80125 Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan IRCCS, 20141 Milan, Italy. AD - Department of Oncology and Hematology-Oncology, Universita degli Studi di Milano, 20133 Milan, Italy. LA - eng PT - Journal Article DEP - 20220225 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC8947693 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - modified Glasgow prognostic score OT - non muscle invasive bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/02/25 CRDT- 2022/03/25 01:06 PHST- 2022/02/05 00:00 [received] PHST- 2022/02/17 00:00 [revised] PHST- 2022/02/23 00:00 [accepted] PHST- 2022/03/25 01:06 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/02/25 00:00 [pmc-release] AID - diagnostics12030586 [pii] AID - diagnostics-12-00586 [pii] AID - 10.3390/diagnostics12030586 [doi] PST - epublish SO - Diagnostics (Basel). 2022 Feb 25;12(3):586. doi: 10.3390/diagnostics12030586. PMID- 35326643 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 6 DP - 2022 Mar 15 TI - The Prognostic Role of CDK9 in Bladder Cancer. LID - 10.3390/cancers14061492 [doi] LID - 1492 AB - Introduction: Most patients with urothelial carcinoma are diagnosed with non-invasive tumors, but the prognosis worsens with the progression of the disease. Overexpression of cyclin-dependent kinase 9 has been recently linked to increased cancer proliferation, faster progression, and worse prognosis. However, some cancers seem to contradict this rule. In this work, we explored the prognostic role of CDK9 expression in urothelial carcinoma. Materials and Methods: We performed immunohistochemical analysis on 72 bladder cancer samples. To assess a larger group of patients, the Cancer Genome Atlas (TCGA) database containing 406 cases and transcriptomics information through the Human Pathology Atlas were analyzed. Results: CDK9 is overexpressed in urothelial cancer tissues when compared to normal urothelial tissues (p < 0.05). High CDK9 expression was observed in low-stage, low-grade, and non-muscle-invasive tumors (p < 0.05). The patients with high CDK9 expression had a significantly higher 5-year overall survival rate than those with low CDK9 expression (77.54% vs. 53.6% in the TMA group and 57.75% vs. 35.44% in the TCGA group, respectively) (p < 0.05). The results were consistent in both cohorts. Multivariate Cox regression analysis indicated that low CDK9 status was an independent predictor for poor prognosis in the TCGA cohort (HR 1.60, CL95% 1.1-2.33, p = 0.014). Conclusions: High CDK9 expression predicts a favorable prognosis in urothelial carcinoma and is associated with clinicopathological features characteristic for early-stage disease. The decrease in CDK9 expression can be associated with the build-up of genetic instability and may indicate a key role for CDK9 in the early stages of urothelial carcinoma. FAU - Borowczak, Jedrzej AU - Borowczak J AUID- ORCID: 0000-0001-9873-3285 AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. FAU - Szczerbowski, Krzysztof AU - Szczerbowski K AUID- ORCID: 0000-0003-0722-7139 AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. FAU - Maniewski, Mateusz AU - Maniewski M AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. FAU - Zdrenka, Marek AU - Zdrenka M AUID- ORCID: 0000-0002-1574-0189 AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland. FAU - Slupski, Piotr AU - Slupski P AD - Department of Urology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, 85-168 Bydgoszcz, Poland. FAU - Antosik, Paulina AU - Antosik P AUID- ORCID: 0000-0002-7099-8115 AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. FAU - Kolodziejska, Sylwia AU - Kolodziejska S AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, 85-168 Bydgoszcz, Poland. FAU - Sekielska-Domanowska, Marta AU - Sekielska-Domanowska M AD - Department of Obstetrics, Gynecology and Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-168 Bydgoszcz, Poland. FAU - Dubiel, Mariusz AU - Dubiel M AD - Department of Obstetrics, Gynecology and Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-168 Bydgoszcz, Poland. FAU - Bodnar, Magdalena AU - Bodnar M AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, 85-168 Bydgoszcz, Poland. FAU - Szylberg, Lukasz AU - Szylberg L AUID- ORCID: 0000-0003-1349-5906 AD - Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland. AD - Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Lukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland. AD - Chair of Pathology, University Hospital No. 2 im. Dr. Jan Biziel in Bydgoszcz, 85-168 Bydgoszcz, Poland. LA - eng PT - Journal Article DEP - 20220315 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8945910 OTO - NOTNLM OT - CDK9 OT - bladder cancer OT - expression OT - prognosis OT - survival COIS- The authors have no conflicts of interest to declare that are relevant to the content of this article. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/03/15 CRDT- 2022/03/25 01:02 PHST- 2022/02/20 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/03/25 01:02 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/03/15 00:00 [pmc-release] AID - cancers14061492 [pii] AID - cancers-14-01492 [pii] AID - 10.3390/cancers14061492 [doi] PST - epublish SO - Cancers (Basel). 2022 Mar 15;14(6):1492. doi: 10.3390/cancers14061492. PMID- 35314138 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20250728 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 4 DP - 2022 Aug TI - Role of Renin-Angiotensin System Blockers on BCG Response in Nonmuscle Invasive, High Risk Bladder Cancer. PG - e303-e309 LID - S1558-7673(22)00044-1 [pii] LID - 10.1016/j.clgc.2022.02.007 [doi] AB - INTRODUCTION: The gold standard treatment for high-risk NMIBC is BCG immunotherapy. Some studies suggested an immomodulatory effects for commonly used drugs (ie, ACE-I and ARBs). We aimed to determine whether these drugs impact the prognosis of patients with high-risk NMIBC treated with BCG. MATERIALS AND METHODS: Retrospective analysis on 208 patients from a single academic center with primary high-risk NMIBC treated with transurethral resection followed by 6 weekly instillations of BCG and up to 12 monthly maintenance instillations. ARBs or ACE-I use at the time of treatment initiation was recorded. Inverse probability of treatment weighting (IPTW) was used to adjust for clinical and pathological covariates. IPTW-adjusted Kaplan-Meier curves and weighted Cox proportional hazards regression were used to compare 2-yr failure-free (2-yr FFS), failure-free (FFS), overall recurrence-free (RFS) and progression-free survival (PFS). RESULTS: A total of 68 patients were on ACE-I, and 38 on ARBs and treatment respectively. At a median follow-up of 26 months, ACE-I treatment had no significant impact on cancer-related outcomes. Conversely, patients treated with ARBs experienced significant improvements in 2-yr FFS (HR 0.3; 0.1-0.9, P = .004), FFS (HR 0.4, 0.1-0.9, P = .005), and PFS (HR 0.001; < 0.001-0.001, P < .001). No significant impact was found for ARB use in RFS (HR 0.6; P = .09). Sensitivity analyses confirmed these results. CONCLUSIONS: our findings support a potential role of the angiotensin-renin system in bladder cancer development. We identified ARBs as potential beneficial drugs that seems to act in synergy with BCG-immunotherapy. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Motterle, Giovanni AU - Motterle G AD - Department of Surgery- Urology, Piove di Sacco (PD) AULSS 6 Euganea, Padova, Italy. Electronic address: gio.motterle@gmail.com. FAU - Morlacco, Alessandro AU - Morlacco A AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Giovannini, Giulia AU - Giovannini G AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Vecchiato, Elia AU - Vecchiato E AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Iafrate, Massimo AU - Iafrate M AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Calpista, Arturo AU - Calpista A AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Prayer-Galetti, Tommaso AU - Prayer-Galetti T AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Martino, Francesca AU - Martino F AD - Department of Nephrology, Dialysis and Kidney Transplant, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy. FAU - Dal Moro, Fabrizio AU - Dal Moro F AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. FAU - Novara, Giacomo AU - Novara G AD - Department of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy. LA - eng PT - Journal Article DEP - 20220224 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Angiotensin Receptor Antagonists/therapeutic use MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - BCG Vaccine/therapeutic use MH - Disease-Free Survival MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Renin-Angiotensin System MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - ACE-inhibitors OT - Angiotensin receptor blockers OT - Cancer recurrence OT - Immunomodulatory OT - Instillations EDAT- 2022/03/23 06:00 MHDA- 2022/07/27 06:00 CRDT- 2022/03/22 05:33 PHST- 2021/10/07 00:00 [received] PHST- 2022/02/15 00:00 [revised] PHST- 2022/02/19 00:00 [accepted] PHST- 2022/03/23 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/03/22 05:33 [entrez] AID - S1558-7673(22)00044-1 [pii] AID - 10.1016/j.clgc.2022.02.007 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Aug;20(4):e303-e309. doi: 10.1016/j.clgc.2022.02.007. Epub 2022 Feb 24. PMID- 35313884 OWN - NLM STAT- MEDLINE DCOM- 20220329 LR - 20220329 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Mar 21 TI - External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center. PG - 41 LID - 10.1186/s12894-022-00987-9 [doi] LID - 41 AB - BACKGROUND: To investigate whether Pentafecta is suitable for bladder cancer patients receiving laparoscopic radical cystectomy (LRC). METHODS: From November 2013 to December 2020, muscle invasive Bladder Cancer (MIBC) and non-muscle invasive Bladder Cancer (NMIBC) patients who received LRC and urinary diversion were retrospectively analyzed. Pentafecta was defined as meeting five criteria: negative soft margin, >/= 16 lymph nodes (LNs) removed, major complications free, urinary diversion related sequelae free and clinical recurrence free within 1 year. Analyze the achievement of five criteria and compare the overall survival (OS) of Pentafecta group with non-attainment group. Multivariable Cox's regression was performed to evaluate the impact of Pentafecta on OS. Multivariable logistic regression was performed to explore the effect of surgical experience on Pentafecta attainment. RESULTS: A total of 340 patients were included, negative soft margin, >/= 16 lymph nodes (LNs) removed, major complications free, urinary diversion related sequelae free and clinical recurrence free within 1 year were observed in 95.3%, 30.3%, 83.8%, 75.0% and 85.6% of patients, respectively. Pentafecta group had a significantly longer OS than the non-attainment group (P = 0.027). The group with 10-15 LNs removed and meeting the other four criteria had a similar OS to group with >/= 16 LNs removed (Pentafecta group) (5-year OS: 67.3% vs 72.7%, P = 0.861). Pentafecta (HR = 0.33, P = 0.011), positive lymph nodes (HR = 2.08, P = 0.028) and MIBC (HR = 3.70, P < 0.001) were all significant predictors of OS in multivariable Cox's regression. Surgical experience (OR = 1.05, P < 0.001), conduit (OR = 2.09, P = 0.047) and neobladder (OR = 2.47, P = 0.048) were all independent predictors of Pentafecta attainment in multivariable logistic regression. CONCLUSIONS: Pentafecta is suitable for bladder cancer patients receiving LRC and has the potential to be a valuable tool for evaluating the quality of LRC. Based on Pentafecta analysis, removing 10 LNs instead of 16 LNs as the one of the five criteria may be more appropriate for bladder cancer patients. CI - (c) 2022. The Author(s). FAU - Li, Kai AU - Li K AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Zhuang, Juntao AU - Zhuang J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Cai, Lingkai AU - Cai L AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Han, Jie AU - Han J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Zhou, Zijian AU - Zhou Z AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Lv, Jianchen AU - Lv J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Feng, Dexiang AU - Feng D AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Yuan, Baorui AU - Yuan B AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. qiang_cao@126.com. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. doctorlvqiang@sina.com. LA - eng GR - 81772711/National Natural Science Foundation of China/ GR - 82072832/National Natural Science Foundation of China/ PT - Journal Article PT - Validation Study DEP - 20220321 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - *Laparoscopy MH - Logistic Models MH - *Lymph Node Excision MH - Male MH - Margins of Excision MH - Middle Aged MH - Outcome Assessment, Health Care/*methods/standards MH - Retrospective Studies MH - Urinary Bladder/pathology/*surgery MH - Urinary Bladder Neoplasms/mortality/*surgery PMC - PMC8939065 OTO - NOTNLM OT - Bladder cancer OT - Pelvic lymph node dissection OT - Pentafecta OT - Radical cystectomy COIS- The authors declare that they have no competing interests. EDAT- 2022/03/23 06:00 MHDA- 2022/03/30 06:00 PMCR- 2022/03/21 CRDT- 2022/03/22 05:31 PHST- 2021/12/04 00:00 [received] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/03/22 05:31 [entrez] PHST- 2022/03/23 06:00 [pubmed] PHST- 2022/03/30 06:00 [medline] PHST- 2022/03/21 00:00 [pmc-release] AID - 10.1186/s12894-022-00987-9 [pii] AID - 987 [pii] AID - 10.1186/s12894-022-00987-9 [doi] PST - epublish SO - BMC Urol. 2022 Mar 21;22(1):41. doi: 10.1186/s12894-022-00987-9. PMID- 35312783 OWN - NLM STAT- MEDLINE DCOM- 20220602 LR - 20220719 IS - 1538-8514 (Electronic) IS - 1535-7163 (Linking) VI - 21 IP - 6 DP - 2022 Jun 1 TI - Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway. PG - 1010-1019 LID - 10.1158/1535-7163.MCT-21-0725 [doi] AB - Cisplatin-based chemotherapy is the first-line therapy for bladder cancer. However, cisplatin resistance has been associated with the recurrence of bladder cancer. Previous studies have shown that activation of FGFR and HER2 signaling are involved in bladder cancer cell proliferation and drug resistance. Smoking is the most common etiologic risk factor for bladder cancer, and there is emerging evidence that smoking is associated with cisplatin resistance. However, the underlying mechanism remains elusive. Acrolein, a highly reactive aldehyde, is abundant in tobacco smoke, cooking fumes, and automobile exhaust fumes. Our previous studies have shown that acrolein contributes to bladder carcinogenesis through the induction of DNA damage and inhibition of DNA repair. In this study, we found that acrolein induced cisplatin resistance and tumor progression in both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) cell lines RT4 and T24, respectively. Activation of HER2 and FGFR3 signaling contributes to acrolein-induced cisplatin resistance in RT4 and T24 cells, respectively. Furthermore, trastuzumab, an anti-HER2 antibody, and PD173074, an FGFR inhibitor, reversed cisplatin resistance in RT4 and T24 cells, respectively. Using a xenograft mouse model with acrolein-induced cisplatin-resistant T24 clones, we found that cisplatin combined with PD173074 significantly reduced tumor size compared with cisplatin alone. These results indicate that differential molecular alterations behind cisplatin resistance in NMIBC and MIBC significantly alter the effectiveness of targeted therapy combined with chemotherapy. This study provides valuable insights into therapeutic strategies for cisplatin-resistant bladder cancer. CI - (c)2022 American Association for Cancer Research. FAU - Hong, Jian-Hua AU - Hong JH AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Tong, Zhen-Jie AU - Tong ZJ AD - Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Wei, Tung-En AU - Wei TE AD - Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Lu, Yu-Chuan AU - Lu YC AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. AD - National Taiwan University Cancer Center, Taipei, Taiwan. FAU - Huang, Cheng-Yu AU - Huang CY AUID- ORCID: 0000-0001-9070-2062 AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Huang, Chao-Yuan AU - Huang CY AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Chiang, Chih-Hung AU - Chiang CH AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Jaw, Fu-Shan AU - Jaw FS AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. FAU - Cheng, Hsiao-Wei AU - Cheng HW AD - Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Wang, Hsiang-Tsui AU - Wang HT AUID- ORCID: 0000-0003-4443-0670 AD - Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. AD - Institute of Food Safety and Health Risk Assessment, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. AD - PhD Program in Toxicology, Kaohsiung Medical University, Kaohsiung, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Mol Cancer Ther JT - Molecular cancer therapeutics JID - 101132535 RN - 0 (Antineoplastic Agents) RN - 7864XYD3JJ (Acrolein) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Acrolein/pharmacology/therapeutic use MH - Animals MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Cell Line, Tumor MH - *Cigarette Smoking MH - Cisplatin/pharmacology/therapeutic use MH - Drug Resistance, Neoplasm/genetics MH - Humans MH - Mice MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology EDAT- 2022/03/22 06:00 MHDA- 2022/06/03 06:00 CRDT- 2022/03/21 17:18 PHST- 2021/08/28 00:00 [received] PHST- 2021/12/03 00:00 [revised] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/03/22 06:00 [pubmed] PHST- 2022/06/03 06:00 [medline] PHST- 2022/03/21 17:18 [entrez] AID - 682320 [pii] AID - 10.1158/1535-7163.MCT-21-0725 [doi] PST - ppublish SO - Mol Cancer Ther. 2022 Jun 1;21(6):1010-1019. doi: 10.1158/1535-7163.MCT-21-0725. PMID- 35311085 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220322 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Bacillus Calmette-Guerin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer. PG - 842182 LID - 10.3389/fonc.2022.842182 [doi] LID - 842182 AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is currently the most effective intravesical therapy for non-muscle-invasive bladder cancer (NMIBC) as it can prevent disease recurrence and progression and lower mortality. However, the response rates to BCG vary widely and are dependent on a multitude of factors. METHODS: We performed a systematic discovery by analyzing the whole exome sequence, expression profile, and immune repertoire sequence of treatment-naive and 5-year time-serial relapsed tumors from 24 NMIBC patients. RESULTS: BCG therapy showed bidirectional effects on tumor evolution and immune checkpoint landscape, along with a significant reduction of the percentage of neoantigen burden. In addition, a remarkable proportion of subclonal mutations were unique to the matched pre- or post-treatment tumors, suggesting the presence of BCG-induced and/or spatial heterogeneity. In the relapsed tumors, we identified and validated a shift in the mutational signatures in which mutations associated with aristolochic acid (AA) exposure were enriched, implying AA may be associated with tumor recurrence. Enhanced expressions of immune checkpoint regulation genes were found in the relapsed tumors, suggesting that the combination of immune checkpoint with BCG treatment may be an effective strategy to treat NMIBC. TCR sequencing revealed treatment-associated changes in the T-cell repertoire in the primary and relapsed tumors. CONCLUSION: Our results provide insight into the genomic and immune dynamics of tumor evolution with BCG treatment, suggest new mechanisms of BCG resistance, and inform the development of clinically relevant biomarkers and trials of potential immune checkpoint inhibitor combination therapies. CI - Copyright (c) 2022 Su, Liu, Zhang, Tang, Zhang, Li, Zou, Zhang, Liu, Li, Ma, Zhang, Chen and Xiao. FAU - Su, Fei AU - Su F AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Wei AU - Zhang W AD - Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Tang, Min AU - Tang M AD - Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Jinsong AU - Zhang J AD - Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Hexin AU - Li H AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zou, Lihui AU - Zou L AD - The Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Rui AU - Zhang R AD - National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Liu, Yudong AU - Liu Y AD - The Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Lin AU - Li L AD - Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Ma, Jie AU - Ma J AD - Center for Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - State Key Lab of Molecular Oncology, National Cancer Center, Chinese Academy of Medical Sciences Cancer Hospital & Peking Union Medical College, Beijing, China. FAU - Zhang, Yaqun AU - Zhang Y AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Chen, Meng AU - Chen M AD - National Cancer Data Center, National Cancer Center, Chinese Academy of Medical Sciences Cancer Hospital & Peking Union Medical College, Beijing, China. FAU - Xiao, Fei AU - Xiao F AD - Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - The Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article DEP - 20220303 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8930202 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - immune checkpoint OT - neoantigen OT - non-muscle-invasive bladder cancer OT - tumor microenvironment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/22 06:00 MHDA- 2022/03/22 06:01 PMCR- 2022/01/01 CRDT- 2022/03/21 09:11 PHST- 2021/12/23 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/03/21 09:11 [entrez] PHST- 2022/03/22 06:00 [pubmed] PHST- 2022/03/22 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.842182 [doi] PST - epublish SO - Front Oncol. 2022 Mar 3;12:842182. doi: 10.3389/fonc.2022.842182. eCollection 2022. PMID- 35308527 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220322 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 9 DP - 2022 TI - Inflammatory Myofibroblastic Tumor of the Urinary Bladder: An 11-Year Retrospective Study From a Single Center. PG - 831952 LID - 10.3389/fmed.2022.831952 [doi] LID - 831952 AB - PURPOSE: To share our experience in the diagnosis and treatment of an inflammatory myofibroblastic tumor of the urinary bladder (IMTUB). MATERIALS AND METHODS: A database searches in the pathology archives by using the term "inflammatory myofibroblastic tumor" and" bladder" in our hospital department of pathology from 2010 to 2021. Patient characteristics, clinical features, histopathological results, immunohistochemical staining results, and treatment outcomes were reviewed. RESULTS: Fourteen cases of IMTUB were retrieved. The mean age was 44.7 +/- 18.9 years (range 12-74). Nine (64.3%) of the patients presented with hematuria, followed by seven (50%) with odynuria, five (35.7%) with urgent urination, and one (7.1%) with dysuria. Ten (71.4%) of the patients were treated with partial cystectomy (PC), three (21.4%) with transurethral resection of bladder tumor (TURBT), and one (7.1%) with radical cystectomy (RC). Histopathologically, eight (57.1%) had a compact spindle cell pattern. Anaplastic lymphoma kinase (ALK) staining was positive in six (75%) of 8 cases. During a mean follow-up period of 43.9 +/- 38 months (range 3-117), a patient had recurrence within half a month. Then, the patient was treated with further TURBT surgery and had no recurrence within 6 months. Thirteen of the patients had no local recurrence or distant metastasis. CONCLUSION: Inflammatory myofibroblastic tumor of the urinary bladder (IMTUB) is clinically rare and has a good prognosis. The disease is mainly treated with surgery to remove the tumor completely. It can easily be misdiagnosed as bladder urothelial carcinoma, leiomyosarcoma, or rhabdomyosarcoma, which may result in overtreatment and poor quality of life of patients. CI - Copyright (c) 2022 Chen, Huang, He, Wu, Liu, He, Zang and Xu. FAU - Chen, Can AU - Chen C AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Huang, Mengjun AU - Huang M AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - He, Haiqing AU - He H AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Wu, Shuiqing AU - Wu S AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Liu, Mingke AU - Liu M AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - He, Jun AU - He J AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Zang, Hongjing AU - Zang H AD - Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China. FAU - Xu, Ran AU - Xu R AD - Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. LA - eng PT - Journal Article DEP - 20220303 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC8928161 OTO - NOTNLM OT - bladder OT - diagnosis OT - inflammatory myofibroblastic tumor (IMT) OT - retrospective study OT - treatment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/22 06:00 MHDA- 2022/03/22 06:01 PMCR- 2022/03/03 CRDT- 2022/03/21 08:40 PHST- 2021/12/09 00:00 [received] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/03/21 08:40 [entrez] PHST- 2022/03/22 06:00 [pubmed] PHST- 2022/03/22 06:01 [medline] PHST- 2022/03/03 00:00 [pmc-release] AID - 10.3389/fmed.2022.831952 [doi] PST - epublish SO - Front Med (Lausanne). 2022 Mar 3;9:831952. doi: 10.3389/fmed.2022.831952. eCollection 2022. PMID- 35302627 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20230210 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 3 DP - 2022 Mar 1 TI - Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. PG - e223050 LID - 10.1001/jamanetworkopen.2022.3050 [doi] LID - e223050 AB - IMPORTANCE: Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment. OBJECTIVE: To describe current surveillance and treatment practices, cancer outcomes, and costs of care for low-grade papillary stage Ta (low-grade Ta) NMIBC and identify factors associated with increased cost of care. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study identified 13 054 older adults (aged 66-90 years) diagnosed with low-grade Ta tumors in the Surveillance, Epidemiology and End Results-linked Medicare database from January 1, 2004, through December 31, 2013. Medicare claims data through December 31, 2014, were also reviewed. Data were analyzed from April 1 to October 6, 2021. EXPOSURES: Surveillance testing and treatment among patients with low-grade Ta NMIBC. MAIN OUTCOMES AND MEASURES: The primary outcome was patterns in population-level surveillance and treatment practice over time among patients with low-grade Ta NMIBC. Secondary outcomes were recurrence (defined as receipt of subsequent transurethral resection of bladder tumor >3 months after index diagnosis of NMIBC and initial transurethral resection of bladder tumor), progression (defined as receipt of definitive treatment for bladder cancer), and costs of care. RESULTS: Among 13 054 patients who met inclusion criteria, 9596 (73.5%) were male and 3458 (26.5%) were female, with a median age of 76 years (IQR, 71-81 years). A total of 403 patients (3.1%) were Black, 120 (0.9%) were Hispanic, 12 123 (92.9%) were White, and 408 (3.1%) were of other races and/or ethnicities. Rates of surveillance cystoscopy increased over the study period (from 79.3% in 2004 to 81.5% in 2013; P = .007), with patients receiving a median of 3.0 cystoscopies per year (IQR, 2.0-4.0 per year). Rates of upper tract imaging (particularly computed tomography or magnetic resonance imaging) also increased over the study period (from 30.4% in 2004 to 47.0% in 2013; P < .001), with most patients receiving a median of 2.0 imaging tests per year (IQR, 1.0-2.0 per year). The use of urine cytologic testing or other urine biomarker assessment also increased (from 44.8% in 2004 to 54.9% in 2013; P < .001). Rates of adherence to current guidelines were similar over time (eg, a median of 4398 patients [55.2%] received /=2 (8.3% vs 33.3%, odds ratio 5.46 [1.81-22.28]). CONCLUSIONS: In high-risk non-muscle invasive bladder cancer cases, the odds of a residual tumor after initial photodynamic diagnosis-transurethral resection of bladder tumor were 0.39-fold that of the odds of those after initial white-light transurethral resection of bladder tumor. A risk stratification model could be used to omit the second transurethral resection of bladder tumor in 27% of the cases. CI - (c) 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. FAU - Kobayashi, Keita AU - Kobayashi K AUID- ORCID: 0000-0001-9279-3156 AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AUID- ORCID: 0000-0001-5607-7769 AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Ikeda, Atsushi AU - Ikeda A AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Nishimoto, Koshiro AU - Nishimoto K AUID- ORCID: 0000-0002-3952-5643 AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Osaka Medical and Pharmaceutical University Faculty of Medicine, Takatsuki, Japan. FAU - Abe, Takashige AU - Abe T AUID- ORCID: 0000-0002-5468-7632 AD - Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nangoku, Japan. FAU - Mitsui, Takahiko AU - Mitsui T AUID- ORCID: 0000-0003-0408-3678 AD - Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo, Japan. FAU - Kawakita, Mutsushi AU - Kawakita M AD - Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AUID- ORCID: 0000-0002-5643-2182 AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. FAU - Kuroiwa, Hajime AU - Kuroiwa H AD - Integrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nangoku, Japan. LA - eng GR - SBI Pharmaceutical/ GR - Chugai Pharmaceutical/ GR - Center for Clinical Research, Yamaguchi University Hospital/ PT - Journal Article DEP - 20220315 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2022 Jul;29(7):638-639. doi: 10.1111/iju.14883. PMID: 35362114 CIN - Int J Urol. 2022 Jul;29(7):639-640. doi: 10.1111/iju.14888. PMID: 35368133 CIN - Int J Urol. 2022 Jul;29(7):640. doi: 10.1111/iju.14895. PMID: 35384083 MH - Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm, Residual/surgery MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9542202 OTO - NOTNLM OT - 5-aminolevulinic acid OT - bladder cancer OT - high-risk NMIBC OT - photodynamic diagnosis OT - second TURBT COIS- H. Matsuyama reports personal fees as meeting lecture and grants from SBI Pharmaceuticals Co., Ltd. and Chugai Pharmaceuticals Co., Ltd. H. Nishiyama reports personal fees as consultant and grants from Chugai Pharmaceuticals Co., Ltd. The funding for this study was provided by Chugai Pharmaceutical Co., Ltd. and SBI Pharmaceuticals Co., Ltd. The funding source had no role in the design, practice, or analysis of this study. EDAT- 2022/03/17 06:00 MHDA- 2022/07/07 06:00 PMCR- 2022/10/07 CRDT- 2022/03/16 05:59 PHST- 2021/12/27 00:00 [received] PHST- 2022/02/21 00:00 [accepted] PHST- 2022/03/17 06:00 [pubmed] PHST- 2022/07/07 06:00 [medline] PHST- 2022/03/16 05:59 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - IJU14854 [pii] AID - 10.1111/iju.14854 [doi] PST - ppublish SO - Int J Urol. 2022 Jul;29(7):632-638. doi: 10.1111/iju.14854. Epub 2022 Mar 15. PMID- 35288995 OWN - NLM STAT- MEDLINE DCOM- 20220916 LR - 20220922 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 9 DP - 2022 Sep TI - Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer. PG - 968-976 LID - 10.1111/iju.14858 [doi] AB - OBJECTIVES: Radical cystectomy is the gold-standard treatment for muscle-invasive bladder cancer and aggressive non-muscle-invasive bladder cancer. To enhance clinical decision-making regarding patients with bladder cancer who underwent radical cystectomy, a recurrence prediction biomarker with high accuracy is urgently needed. In this study, we developed a model for the prediction of bladder cancer recurrence after radical cystectomy by combining serum microRNA and a pathological factor. METHODS: We retrospectively analyzed the clinical records of 81 patients with bladder cancer who underwent radical cystectomy between 2008 and 2016. The dataset was divided into two, and Fisher linear discriminant analysis was used to construct a prognostic model for future recurrence in the training set (n = 41). The performance of the model was evaluated in the validation set (n = 40). RESULTS: Thirty patients had recurrence after having undergone radical cystectomy. A prognostic model for recurrence was constructed by combining a pathological factor (i.e. positive pathological lymph node status) and three microRNAs (miR-23a-3p, miR-3679-3p, and miR-3195). The model showed a sensitivity of 0.87, a specificity of 0.80, and an area under the receiver operating characteristic curve of 0.88 (0.77-0.98) in the validation set. Furthermore, Kaplan-Meier analysis revealed that patients with a low prediction index have significantly longer overall survival than patients with a high prediction index (P = 0.041). CONCLUSION: A combination of serum microRNA profiles and lymph node statuses is useful for the prediction of oncological outcomes after radical cystectomy in patients with bladder cancer. CI - (c) 2022 The Japanese Urological Association. FAU - Urabe, Fumihiko AU - Urabe F AUID- ORCID: 0000-0002-2599-8183 AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsuzaki, Juntaro AU - Matsuzaki J AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. AD - Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan. FAU - Ito, Kagenori AU - Ito K AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takamori, Hajime AU - Takamori H AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Tsuzuki, Shunsuke AU - Tsuzuki S AUID- ORCID: 0000-0001-6164-4684 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AUID- ORCID: 0000-0002-4638-8640 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, The Jikei University Kashiwa Hospital, Chiba, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Nakamura, Eijiro AU - Nakamura E AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Fujimoto, Hiroyuki AU - Fujimoto H AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Yamamoto, Yusuke AU - Yamamoto Y AUID- ORCID: 0000-0002-5262-8479 AD - Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. FAU - Ochiya, Takahiro AU - Ochiya T AUID- ORCID: 0000-0002-0776-9918 AD - Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan. LA - eng GR - Japan Agency for Medical Research and Development/ GR - 21K16758/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20220314 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Biomarkers) RN - 0 (MicroRNAs) SB - IM MH - Biomarkers MH - Cystectomy MH - Humans MH - Liquid Biopsy MH - *MicroRNAs MH - Neoplasm Recurrence, Local/diagnosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/genetics/surgery OTO - NOTNLM OT - biomarker OT - bladder cancer OT - cystectomy OT - liquid biopsy OT - serum microRNA EDAT- 2022/03/16 06:00 MHDA- 2022/09/17 06:00 CRDT- 2022/03/15 05:47 PHST- 2022/01/05 00:00 [received] PHST- 2022/02/24 00:00 [accepted] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/09/17 06:00 [medline] PHST- 2022/03/15 05:47 [entrez] AID - 10.1111/iju.14858 [doi] PST - ppublish SO - Int J Urol. 2022 Sep;29(9):968-976. doi: 10.1111/iju.14858. Epub 2022 Mar 14. PMID- 35281100 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220316 IS - 2296-634X (Print) IS - 2296-634X (Electronic) IS - 2296-634X (Linking) VI - 10 DP - 2022 TI - Radiomics of Contrast-Enhanced Computed Tomography: A Potential Biomarker for Pretreatment Prediction of the Response to Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. PG - 814388 LID - 10.3389/fcell.2022.814388 [doi] LID - 814388 AB - Background: Bacillus Calmette-Guerin (BCG) instillation is recommended postoperatively after transurethral resection of bladder cancer (TURBT) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). An accurate prediction model for the BCG response can help identify patients with NMIBC who may benefit from alternative therapy. Objective: To investigate the value of computed tomography (CT) radiomics features in predicting the response to BCG instillation among patients with primary high-risk NMIBC. Methods: Patients with pathologically confirmed high-risk NMIBC were retrospectively reviewed. Patients who underwent contrast-enhanced CT examination within one to 2 weeks before TURBT and received >/=5 BCG instillation treatments in two independent hospitals were enrolled. Patients with a routine follow-up of at least 1 year at the outpatient department were included in the final cohort. Radiomics features based on CT images were extracted from the tumor and its periphery in the training cohort, and a radiomics signature was built with recursive feature elimination. Selected features further underwent an unsupervised radiomics analysis using the newly introduced method, non-negative matrix factorization (NMF), to compute factor factorization decompositions of the radiomics matrix. Finally, a robust component, which was most associated with BCG failure in 1 year, was selected. The performance of the selected component was assessed and tested in an external validation cohort. Results: Overall, 128 patients (training cohort, n = 104; external validation cohort, n = 24) were included, including 12 BCG failures in the training cohort and 11 failures in the validation cohort each. NMF revealed five components, of which component 3 was selected for the best discrimination of BCG failure; it had an area under the curve (AUC) of .79, sensitivity of .79, and specificity of .65 in the training set. In the external validation cohort, it achieved an AUC of .68, sensitivity of .73, and specificity of .69. Survival analysis showed that patients with higher component scores had poor recurrence-free survival (RFS) in both cohorts (C-index: training cohort, .69; validation cohort, .68). Conclusion: The study suggested that radiomics components based on NMF might be a potential biomarker to predict BCG response and RFS after BCG treatment in patients with high-risk NMIBC. CI - Copyright (c) 2022 Ye, Chen, Xu, Wang, Li, Qi, Wang, Yao, Liu and Song. FAU - Ye, Lei AU - Ye L AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Yuntian AU - Chen Y AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Xu, Hui AU - Xu H AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Zhaoxiang AU - Wang Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Haixia AU - Li H AD - Philips Healthcare, Chengdu, China. FAU - Qi, Jin AU - Qi J AD - University of Electronic Science and Technology of China, Chengdu, China. FAU - Wang, Jing AU - Wang J AD - University of Electronic Science and Technology of China, Chengdu, China. FAU - Yao, Jin AU - Yao J AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Jiaming AU - Liu J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Song, Bin AU - Song B AD - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20220225 PL - Switzerland TA - Front Cell Dev Biol JT - Frontiers in cell and developmental biology JID - 101630250 PMC - PMC8914064 OTO - NOTNLM OT - BCG immunotherapy OT - CECT images OT - NMF (nonnegative matrix factorization) OT - NMIBC (non-muscle-invasive bladder cancer) OT - radiomics analysis COIS- HL is employed by Philips Healthcare. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/15 06:00 MHDA- 2022/03/15 06:01 PMCR- 2022/01/01 CRDT- 2022/03/14 05:17 PHST- 2021/11/13 00:00 [received] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/03/14 05:17 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/15 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 814388 [pii] AID - 10.3389/fcell.2022.814388 [doi] PST - epublish SO - Front Cell Dev Biol. 2022 Feb 25;10:814388. doi: 10.3389/fcell.2022.814388. eCollection 2022. PMID- 35278613 OWN - NLM STAT- MEDLINE DCOM- 20220422 LR - 20220531 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 534 DP - 2022 May 28 TI - Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. PG - 215615 LID - S0304-3835(22)00090-8 [pii] LID - 10.1016/j.canlet.2022.215615 [doi] AB - Abnormal RNA methylation and dysregulation of miRNA are frequently occurred in bladder cancer. Melittin is a potential drug candidate for intravesical chemotherapy against bladder cancer. However, the underlying epigenetic mechanism by which melittin-induced anti-tumor effect remains unclear. Here, we showed that melittin selectively induced apoptosis of bladder cancer cells in a METTL3-dependent manner. Ectopic expression of METTL3 significantly blocked melittin-induced apoptosis in vitro and in vivo. MicroRNA-sequence analysis identified miR-146a-5p suppression contributed to the melittin-induced selective antitumor effect. Further investigation revealed that METTL3-guided m6A modification methylated pri-miR-146 at the flanking sequence, which was responsible for the pri-miR-146 maturation. Moreover, NUMB/NOTCH2 axis was identified as a downstream target signal that mediated the pro-survival role of miR-146a-5p in bladder cancer cells. Importantly, METTL3 and miR-146a-5p were positively correlated with recurrence and poor prognosis of patients with bladder cancer. Our study indicates that METTL3 acts as a fate determinant that controls the sensitivity of bladder cancer cells to melittin treatment. Moreover, METTL3/miR-146a-5p/NUMB/NOTCH2 axis plays an oncogenic role in bladder cancer pathogenesis and could be a potential therapeutic target for recurrent bladder cancer treatment. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Yan, Rucheng AU - Yan R AD - Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 131 Dong'an Road, Shanghai, 200032, PR China; Department of Urology, The First Affiliated Hospital (Yijishan Hospital) of Wannan Medical College, 2 Zheshan West Road, Wuhu, 241001, PR China. FAU - Dai, Weiwei AU - Dai W AD - Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 131 Dong'an Road, Shanghai, 200032, PR China. FAU - Wu, Ruixin AU - Wu R AD - Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 131 Dong'an Road, Shanghai, 200032, PR China. FAU - Huang, Houbao AU - Huang H AD - Department of Urology, The First Affiliated Hospital (Yijishan Hospital) of Wannan Medical College, 2 Zheshan West Road, Wuhu, 241001, PR China. Electronic address: hhb@wnmc.edu.cn. FAU - Shu, Minfeng AU - Shu M AD - Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 131 Dong'an Road, Shanghai, 200032, PR China; Ministry of Education (MOE) & Ministry of Health (MOH) Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 131 Dong'an Road, Shanghai, 200032, PR China. Electronic address: minfeng_shu@fudan.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220309 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 RN - 0 (MIRN146 microRNA, human) RN - 0 (MicroRNAs) RN - 20449-79-0 (Melitten) RN - EC 2.1.1.- (Methyltransferases) RN - EC 2.1.1.62 (METTL3 protein, human) SB - IM MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Melitten/pharmacology MH - Methyltransferases/metabolism MH - *MicroRNAs/genetics/metabolism MH - Neoplasm Recurrence, Local/genetics MH - *Urinary Bladder Neoplasms/drug therapy/genetics/pathology OTO - NOTNLM OT - Apoptosis OT - METTL3 OT - RNA methylation OT - Targeting therapy EDAT- 2022/03/13 06:00 MHDA- 2022/04/23 06:00 CRDT- 2022/03/12 20:10 PHST- 2021/12/29 00:00 [received] PHST- 2022/02/22 00:00 [revised] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/03/13 06:00 [pubmed] PHST- 2022/04/23 06:00 [medline] PHST- 2022/03/12 20:10 [entrez] AID - S0304-3835(22)00090-8 [pii] AID - 10.1016/j.canlet.2022.215615 [doi] PST - ppublish SO - Cancer Lett. 2022 May 28;534:215615. doi: 10.1016/j.canlet.2022.215615. Epub 2022 Mar 9. PMID- 38994519 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 8 IP - 1 DP - 2022 TI - Quality of Life and Health State Utilities in Bladder Cancer. PG - 55-70 LID - 10.3233/BLC-211615 [doi] AB - BACKGROUND: Bladder cancer treatments may variably impact health-related quality of life (QOL). OBJECTIVE: To characterize the quality of life of patients with bladder cancer at various time points across the continuum of bladder cancer care from non-muscle-invasive disease to metastatic bladder cancer and develop utility scores to inform cost-effective analyses. METHODS: We performed a cross-sectional survey of bladder cancer patients in the Bladder Cancer Advocacy Network Patient Survey Network. Participants were classified into mutually exclusive health states based upon non-muscle invasive (NMIBC), muscle-invasive (MIBC), or metastatic bladder cancer and completed surveys of generic cancer and bladder cancer-specific quality of life, financial toxicity, and work impairment. We constructed generalized linear mixed models to identify patient, clinical, and treatment factors associated with quality of life over time and derived health state utilities. RESULTS: Among 911 self-identified patients with bladder cancer, overall QOL scores and function domains were worse among those with advanced cancer. Financial toxicity was similar among non-metastatic disease states. Work and activity impairment increased with advancing disease (13%and 12%among non-recurrent NMIBC to 63%and 31%for metastatic disease respectively; p < 0.01). On multivariable analysis, bowel-related QOL was diminished among patients with MIBC, with urinary symptoms and physical function most diminished among patients with metastatic disease. Patients with metastatic and MIBC experienced worse emotional functioning (p = 0.04; p = 0.048). Health state utilities were calculated, highest among those with non-recurrent NMIBC and lowest among those with metastatic disease. CONCLUSION: Generic and bladder cancer-specific QOL diminishes with advancing disease. Health state utility estimates derived from this study can inform shared decision making with patients and may be used to inform future cost-effective analyses. CI - (c) 2022 - The authors. Published by IOS Press. FAU - Smith, Angela B AU - Smith AB AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - McCabe, Sean AU - McCabe S AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Deal, Allison M AU - Deal AM AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Guo, Amy AU - Guo A AD - Fergene, Boston, MA, USA. FAU - Gessner, Kathryn H AU - Gessner KH AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Lipman, Robert AU - Lipman R AD - Bladder Cancer Advocacy Network, Research Patient Advocate, Bethesda, MD, USA. FAU - Chisolm, Stephanie AU - Chisolm S AD - Bladder Cancer Advocacy Network, Director of Education & Research, Bethesda, MD, USA. FAU - Ahlschlager, Lauren AU - Ahlschlager L AD - Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Gore, John L AU - Gore JL AD - University of Washington, Seattle, WA, USA. LA - eng PT - Journal Article DEP - 20220311 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181821 OTO - NOTNLM OT - Urinary bladder neoplasms OT - patient-reported outcomes OT - quality of life OT - utility COIS- Angela Smith has funding from PCORI and BCAN and is a consultant for Merck, Fergene, Ambu, and Urogen. Amy Guo is a Senior Director at Fergene. Sean McCabe, Allison Deal, Stephanie Chisolm, Lauren Ahlschlager, Kathryn Gessner, John Gore, Robert Lipman have nothing to disclose. Angela Smith is an Associate Editor and John Gore is an Editorial Board member of this journal, but they were not involved in the peer-review process nor had access to any information regarding its peer-review. EDAT- 2022/03/11 00:00 MHDA- 2022/03/11 00:01 PMCR- 2022/03/11 CRDT- 2024/07/12 04:52 PHST- 2021/09/30 00:00 [received] PHST- 2021/11/17 00:00 [accepted] PHST- 2022/03/11 00:01 [medline] PHST- 2022/03/11 00:00 [pubmed] PHST- 2024/07/12 04:52 [entrez] PHST- 2022/03/11 00:00 [pmc-release] AID - BLC211615 [pii] AID - 10.3233/BLC-211615 [doi] PST - epublish SO - Bladder Cancer. 2022 Mar 11;8(1):55-70. doi: 10.3233/BLC-211615. eCollection 2022. PMID- 35268398 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 5 DP - 2022 Feb 27 TI - Outcome of Non-Muscle Invasive Upper Tract Urothelial Carcinoma Receiving Endoscopic Ablation: An Inverse Probability of Treatment Weighting Analysis. LID - 10.3390/jcm11051307 [doi] LID - 1307 AB - We compared the outcomes in early-stage upper tract urothelial carcinoma (UTUC) patients receiving endoscopic ablation (EA) with radical nephroureterectomy (RNU). From 2004 to 2018, cTa/T1N0M0 UTUC patients undergoing EA and RNU were enrolled. For reducing observational bias, propensity scores based on inverse probability of treatment weighting (IPTW) were utilized for comparing the oncologic outcomes and renal function changes. In total, 65 of 184 cTa/T1 UTUC patients were analyzed after exclusion of 119 patients with end-stage renal disease, and lack of previous ureteroscopic biopsy. The studied patients included 23 who received EA and 42 RNU, and both groups were well balanced after adjusting with IPTW. The median follow-up period was 43.6 months. There was no statistical difference between the two groups in terms of oncological outcome. The EA group exhibited less estimated glomerular filtration rate (eGFR) decline one year later (0.0% vs. 20.2%, p < 0.001) and less worsening of chronic kidney status (13.2% vs. 46.5%, p = 0.026). Among patients receiving EA, high-grade tumors exhibited higher subsequent recurrence in the residual urinary tract than did the low-grade ones. (p = 0.037). In summary, endoscopic ablation preserves renal function without compromising oncological outcome in selected UTUC patients. High-grade tumors should be strictly followed up following endoscopic ablation. FAU - Shen, Chih-Yu AU - Shen CY AUID- ORCID: 0000-0002-0642-3210 AD - Department of Urology, Tainan Hospital, Ministry of Health and Welfare, Tainan City 70043, Taiwan. FAU - Jou, Yeong-Chin AU - Jou YC AD - Department of Urology, Ditmanson Medical Foundation, Chiayi Christian Hospital, Chia-Yi 60002, Taiwan. FAU - Kan, Wei-Chih AU - Kan WC AD - Department of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan 710, Taiwan. AD - Department of Biological Science and Technology, Chung Hwa University of Medical Technology, Rende District, Tainan City 717, Taiwan. FAU - Tzai, Tzong-Shin AU - Tzai TS AD - Department of Urology, Tainan Municipal An-Nan Hospital, Tainan 709, Taiwan. FAU - Tsai, Yuh-Shyan AU - Tsai YS AUID- ORCID: 0000-0001-7613-3772 AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. LA - eng GR - NCKUH-10802035, NCKUH-10902045, NCKUH-11004022 and NCKUH-11104011/National Cheng Kung University Hospital/ PT - Journal Article DEP - 20220227 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8910842 OTO - NOTNLM OT - endoscopy OT - kidney sparing surgery OT - prognosis OT - upper tract urothelial carcinoma COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2022/03/11 06:00 MHDA- 2022/03/11 06:01 PMCR- 2022/02/27 CRDT- 2022/03/10 15:29 PHST- 2022/01/15 00:00 [received] PHST- 2022/02/19 00:00 [revised] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/10 15:29 [entrez] PHST- 2022/03/11 06:00 [pubmed] PHST- 2022/03/11 06:01 [medline] PHST- 2022/02/27 00:00 [pmc-release] AID - jcm11051307 [pii] AID - jcm-11-01307 [pii] AID - 10.3390/jcm11051307 [doi] PST - epublish SO - J Clin Med. 2022 Feb 27;11(5):1307. doi: 10.3390/jcm11051307. PMID- 35265660 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 9 DP - 2022 TI - Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review. PG - 762027 LID - 10.3389/fsurg.2022.762027 [doi] LID - 762027 AB - Early diagnosis of non-muscle-invasive bladder cancer (NMIBC) is of paramount importance to prevent morbidity and mortality due to bladder cancer. Although white light imaging (WLI) cystoscopy has long been considered the gold standard in the diagnosis of bladder cancer, it can miss lesions in a substantial percentage of patients and is very likely to miss carcinoma in situ and dysplasia. Tumor margin detection by WLI can be inaccurate. Moreover, WLI could, sometimes, be inadequate in distinguishing inflammation and malignancy. To improve the diagnostic efficacy of cystoscopy, various optical image enhancement modalities have been studied. These image enhancement modalities have been classified as macroscopic, microscopic, or molecular. Photodynamic diagnosis (PDD), narrow band imaging (NBI), and Storz image 1 S enhancement (formerly known as SPIES) are macroscopic image enhancement modalities. A relevant search was performed for literature describing macroscopic image enhancement modalities like PDD, NBI, and image 1 S enhancement. The advantages, limitations, and usefulness of each of these in the diagnosis of bladder cancer were studied. Photodynamic diagnosis requires intravesical instillation of a photosensitizing agent and a special blue light cystoscope system. PDD has been shown to be more sensitive than WLI in the detection of bladder cancer. It is superior to WLI in the detection of flat lesions. Bladder tumor resection (TURBT) by PDD results in more complete resection and reduced recurrence rates. PDD-guided TURBT may have some role in reducing the risk of progression. Narrow band imaging provides increased contrast between normal and abnormal tissues based on neovascularization, thereby augmenting WLI. NBI requires a special light source. There is no need for intravesical contrast instillation. NBI is superior to WLI in the detection of bladder cancer. The addition of NBI to WLI improves the detection of flat lesions like carcinoma in situ. NBI is not useful in predicting invasive tumors or grades of tumors. NBI-directed TURBT reduces recurrence rates and recurrence free survival. But its efficacy in retarding progression is unproven. Image 1 S-enhancement utilizes software-based image enhancement modes without the need for a special light source or intravesical contrast instillation. This system provides high-quality images and identifies additional abnormal-looking areas. Another advantage of this system is simultaneous side-by-side visualization of WLI and enhanced image, providing WLI images as the control for comparison. As with PDD, S-enhancement produces a lower rate of a missed bladder cancer diagnosis. The system significantly improves the diagnosis of NMIBC. The sensitivity and negative predictive value of image 1 S enhancement increase with the increase in cancer grade. A negative test by S-enhancement effectively rules out NMIBC. All the image enhancement modalities have proven their utility in improving detection and short-term cancer control. But none of these modalities have proven their utility in delaying progression, or in long-term cancer control. Cancer progression and long-term control are governed by the biological nature of cancer cells. Early detection by optical enhancement may not be of utility in this regard. Well-designed studies are needed to establish the efficacy of these modalities in the evaluation of patients with bladder cancer. The last word, in this regard, is yet to be written. CI - Copyright (c) 2022 Mulawkar, Sharma, Tamhankar, Shah and Raheem. FAU - Mulawkar, Prashant Motiram AU - Mulawkar PM AD - Department of Urology, Tirthankar Superspeciality Hospital, Akola, India. AD - Tutor in Urology, University of Edinburgh, Edinburgh, United Kingdom. FAU - Sharma, Gyanendra AU - Sharma G AD - Chitale Clinics Private Ltd., Solapur, India. FAU - Tamhankar, Ashwin AU - Tamhankar A AD - Apollo Hospital, Navi Mumbai, India. FAU - Shah, Utsav AU - Shah U AD - Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. FAU - Raheem, Rickaz AU - Raheem R AD - Milton Keynes University Hospital, Eaglestone, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20220221 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8898829 OTO - NOTNLM OT - bladder cancer OT - fluorescence cystoscopy OT - image 1 S OT - image enhancement OT - narrow band imaging COIS- GS was employed by Chitale Clinics Private Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/11 06:00 MHDA- 2022/03/11 06:01 PMCR- 2022/02/21 CRDT- 2022/03/10 05:46 PHST- 2021/08/20 00:00 [received] PHST- 2022/01/17 00:00 [accepted] PHST- 2022/03/10 05:46 [entrez] PHST- 2022/03/11 06:00 [pubmed] PHST- 2022/03/11 06:01 [medline] PHST- 2022/02/21 00:00 [pmc-release] AID - 10.3389/fsurg.2022.762027 [doi] PST - epublish SO - Front Surg. 2022 Feb 21;9:762027. doi: 10.3389/fsurg.2022.762027. eCollection 2022. PMID- 35261639 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220310 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 23 IP - 4 DP - 2022 Apr TI - Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer. PG - 126 LID - 10.3892/ol.2022.13246 [doi] LID - 126 AB - To analyze the risks and survival outcomes of non-definitive therapy (nDT) for muscle-invasive bladder cancer (MIBC), which may provide useful information for future treatment selection, the present study analyzed 124 patients who were diagnosed with MIBC (cT2-4aN1-2M0) and treated at Kurume University Hospital (Kurume, Japan) with definitive therapy (DT; including radical cystectomy and trimodal therapy) or nDT [transurethral resection of bladder tumor (TURBT) monotherapy or TURBT plus chemotherapy]. Differences in survival outcomes between the two groups were estimated using the Kaplan-Meier method and analyzed using the log-rank test. Cox proportional hazards regression models were used for multivariate analysis of each survival outcome. Of the 124 patients, 45% were treated with nDT, and among these, 50% were treated with TURBT monotherapy and 50% were treated with TURBT plus chemotherapy. Of the patients who chose definitive treatment, 69% were treated with radical cystectomy. The median age in the nDT group was 77 years, which was significantly higher than that in the DT group. Additionally, the proportion of patients with poor performance status, high Charlson comorbidity index and high neutrophil-lymphocyte ratio values was significantly higher in the nDT group. nDT was associated with significantly reduced overall survival, cancer-specific survival and progression-free survival rates, and was a poor prognostic factor for all survival outcomes compared with DT. In conclusion, nDT was associated with a high cancer-related mortality risk. The most appropriate treatment method should be discussed with the patients after providing them with sufficient information on the risks and benefits of each treatment method. CI - Copyright (c) 2022, Spandidos Publications. FAU - Nishihara, Kiyoaki AU - Nishihara K AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Ueda, Kosuke AU - Ueda K AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Kurose, Hirofumi AU - Kurose H AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Ogasawara, Naoyuki AU - Ogasawara N AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Hiroshige, Tasuku AU - Hiroshige T AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Chikui, Katsuaki AU - Chikui K AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Ejima, Kazuhisa AU - Ejima K AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Uemura, Keiichiro AU - Uemura K AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Nakiri, Makoto AU - Nakiri M AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Suekane, Shigetaka AU - Suekane S AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. FAU - Igawa, Tsukasa AU - Igawa T AD - Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan. LA - eng PT - Journal Article DEP - 20220217 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC8867182 OTO - NOTNLM OT - RC OT - TMT OT - TURBT OT - bladder-sparing therapy OT - health-related quality of life COIS- The authors declare that they have no competing interests. EDAT- 2022/03/10 06:00 MHDA- 2022/03/10 06:01 PMCR- 2022/02/17 CRDT- 2022/03/09 08:44 PHST- 2021/12/14 00:00 [received] PHST- 2022/01/20 00:00 [accepted] PHST- 2022/03/09 08:44 [entrez] PHST- 2022/03/10 06:00 [pubmed] PHST- 2022/03/10 06:01 [medline] PHST- 2022/02/17 00:00 [pmc-release] AID - OL-23-04-13246 [pii] AID - 10.3892/ol.2022.13246 [doi] PST - ppublish SO - Oncol Lett. 2022 Apr;23(4):126. doi: 10.3892/ol.2022.13246. Epub 2022 Feb 17. PMID- 35259936 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220309 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 207 IP - 4 DP - 2022 Apr TI - Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). Erratum. PG - 943 LID - 10.1097/JU.0000000000002483 [doi] LA - eng PT - Published Erratum DEP - 20220401 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM EFR - J Urol. 2021 Sep;206(3):568-576. doi: 10.1097/JU.0000000000001786. PMID: 33881931 EDAT- 2022/03/10 06:00 MHDA- 2022/03/10 06:01 CRDT- 2022/03/09 05:30 PHST- 2022/03/09 05:30 [entrez] PHST- 2022/03/10 06:00 [pubmed] PHST- 2022/03/10 06:01 [medline] AID - 10.1097/JU.0000000000002483 [doi] PST - ppublish SO - J Urol. 2022 Apr;207(4):943. doi: 10.1097/JU.0000000000002483. Epub 2022 Apr 1. PMID- 35249424 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20220506 IS - 1521-0553 (Electronic) IS - 0894-1939 (Linking) VI - 35 IP - 5 DP - 2022 May TI - Combining Clinical Parameters and Immunohistochemical Markers Might Strengthen Prediction of Recurrence of Non-Muscle Invasive Bladder Cancer. PG - 1195 LID - 10.1080/08941939.2022.2047244 [doi] FAU - Tonyali, Senol AU - Tonyali S AUID- ORCID: 0000-0003-1657-4044 AD - Department of Urology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20220306 PL - United States TA - J Invest Surg JT - Journal of investigative surgery : the official journal of the Academy of Surgical Research JID - 8809255 RN - 0 (Biomarkers) SB - IM UOF - J Invest Surg. 2022 May;35(5):1186-1194. doi: 10.1080/08941939.2021.2017080. PMID: 34913802 MH - Biomarkers MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - *Urinary Bladder Neoplasms/diagnosis/surgery EDAT- 2022/03/08 06:00 MHDA- 2022/04/28 06:00 CRDT- 2022/03/07 05:35 PHST- 2022/03/08 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] PHST- 2022/03/07 05:35 [entrez] AID - 10.1080/08941939.2022.2047244 [doi] PST - ppublish SO - J Invest Surg. 2022 May;35(5):1195. doi: 10.1080/08941939.2022.2047244. Epub 2022 Mar 6. PMID- 35248739 OWN - NLM STAT- MEDLINE DCOM- 20220628 LR - 20250623 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 83 DP - 2022 Jul TI - Systematic Review of Case Reports of Bacillus Calmette-Guerin Vascular Infections. PG - 369-377 LID - S0890-5096(22)00071-1 [pii] LID - 10.1016/j.avsg.2022.01.027 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that has been used as immunotherapy against several malignancies. In particular, intravesical instillation of BCG has become a well-accepted adjuvant treatment for bladder cancer. BCG vascular infections are a rare complication of BCG therapy. Many aspects of these infections, including the presentations, risk factors, and treatment strategies, are poorly understood. Through a systematic review of the existing literature, we aimed to identify potential associations between this condition and patient characteristics, presentations, its treatments, and outcomes. METHODS: We searched the PubMed, MEDLINE, and Embase databases for cases of BCG vascular infections from inception to June 2021. English-language reports of BCG vascular infections were included. RESULTS: A total of 74 cases of BCG vascular infections were included. Seventy-three (99%) cases were male patients, all of whom were exposed to BCG through bladder instillation. Fifty (68%) cases were diagnosed more than 12 months after exposure to BCG. Twenty-six (35%) cases presented with arterial rupture at the time of diagnosis. Concurrent BCG infections in nonvascular locations were present in 37 (50%) cases. The most common locations of BCG vascular infection were the abdominal aorta (57%), prosthetic grafts (15%), and thoracic aorta (12%). The most common treatment for BCG infection was open repair with synthetic graft in situ replacement for the abdominal aorta and endovascular repair for the thoracic aorta. The 30-day mortality, among the 59 cases where these data were reported, was 10%. CONCLUSIONS: We observed that many aspects of BCG vascular infections are similar to other forms of vascular infections. The high incidence of rupture or fistulation and the propensity toward abdominal aortic involvement and its prognosis are similar to those described in other vascular infections. However, our study also highlights 2 idiosyncratic features of BCG vascular infections: association with male sex and concurrent musculoskeletal infections. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Ho, Kelvin Kam Fai AU - Ho KKF AD - Department of Vascular Surgery, Mater Hospital Brisbane, South Brisbane, Queensland, Australia; Department of Vascular Surgery, Sunshine Coast University Hospital, Birtinya, Queensland, Australia. Electronic address: kho.kelvin@gmail.com. FAU - Lal, Vidushi AU - Lal V AD - Department of Vascular Surgery, Sunshine Coast University Hospital, Birtinya, Queensland, Australia. FAU - Hagley, Daniel AU - Hagley D AD - Department of Vascular Surgery, Mater Hospital Brisbane, South Brisbane, Queensland, Australia. FAU - Bingley, John AU - Bingley J AD - Department of Vascular Surgery, Mater Hospital Brisbane, South Brisbane, Queensland, Australia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220303 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/adverse effects MH - Female MH - Humans MH - Male MH - *Mycobacterium bovis MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2022/03/07 06:00 MHDA- 2022/06/29 06:00 CRDT- 2022/03/06 20:29 PHST- 2021/11/16 00:00 [received] PHST- 2022/01/16 00:00 [revised] PHST- 2022/01/19 00:00 [accepted] PHST- 2022/03/07 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] PHST- 2022/03/06 20:29 [entrez] AID - S0890-5096(22)00071-1 [pii] AID - 10.1016/j.avsg.2022.01.027 [doi] PST - ppublish SO - Ann Vasc Surg. 2022 Jul;83:369-377. doi: 10.1016/j.avsg.2022.01.027. Epub 2022 Mar 3. PMID- 35244987 OWN - NLM STAT- MEDLINE DCOM- 20220505 LR - 20250623 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 63 IP - 2 DP - 2022 Mar TI - Low-dose versus standard-dose bacille Calmette-Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. PG - 140-150 LID - 10.4111/icu.20210340 [doi] AB - PURPOSE: Intravesical BCG (bacille Calmette-Guerin) instillation in patients with non-muscle-invasive bladder cancer decreases the risk for tumor recurrence and progression. After one BCG product was discontinued, a chronic global BCG shortage occurred. We focused on identifying a reduced dose of BCG that could maintain efficacy and reduce adverse effects. MATERIALS AND METHODS: We conducted a comprehensive literature search of PubMed, Embase, the Cochrane Library, CINAHL, Web of Science, and Scopus to identify randomized controlled trials through April 2021. The odds ratios (ORs) and 95% confidence intervals (CIs) for the low and standard doses in nine studies were compared. A low dose was defined as a low volume of BCG compared with the standard BCG dose (Armand Frappier, 120 mg; Connaught, 81 mg; Danish 1331, 120 mg; modified Danish 1331, 120 mg; Tokyo 172, 80 mg). RESULTS: The low-dose group experienced aggravated recurrence (OR, 1.45; 95% CI, 1.09-1.94; p=0.01) but similar progression (OR, 1.11; 95% CI, 0.76-1.62; p=0.59), similar cancer-specific survival (OR, 1.02; 95% CI, 0.60-1.75; p=0.93), similar overall survival (OR, 1.09; 95% CI, 0.76-1.56; p=0.65), favorable adverse effects (OR, 0.41; 95% CI, 0.28-0.62; p<0.0001), and favorable withdrawal (OR, 0.42; 95% CI, 0.25-0.71; p=0.001). CONCLUSIONS: Low-dose BCG had more unfavorable outcomes than did standard-dose BCG in terms of recurrence. Tumor progression, cancer-specific survival, and overall survival were similar between the doses. Low-dose BCG improved adverse effects and withdrawal. In the setting of BCG shortage, low-dose BCG may have strong potential as an alternative. CI - (c) The Korean Urological Association. FAU - Choi, Se Young AU - Choi SY AUID- ORCID: 0000-0002-4615-0966 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. urosyc@cau.ac.kr. FAU - Ha, Moon Soo AU - Ha MS AUID- ORCID: 0000-0001-9735-4347 AD - Department of Urology, Hyundae General Hospital, Chung-Ang University College of Medicine, Namyangju, Korea. FAU - Kim, Jung Hoon AU - Kim JH AUID- ORCID: 0000-0002-0947-876X AD - Department of Urology, Hanil General Hospital, Seoul, Korea. FAU - Chi, Byung Hoon AU - Chi BH AUID- ORCID: 0000-0002-4184-7780 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Kim, Jin Wook AU - Kim JW AUID- ORCID: 0000-0003-4157-9365 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Chang, In Ho AU - Chang IH AUID- ORCID: 0000-0003-0240-1310 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Kim, Tae-Hyoung AU - Kim TH AUID- ORCID: 0000-0002-0257-3449 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Myung, Soon Chul AU - Myung SC AUID- ORCID: 0000-0002-6727-5450 AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (BCG Vaccine) SB - IM MH - *BCG Vaccine/adverse effects MH - Female MH - Humans MH - Male MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC8902423 OTO - NOTNLM OT - Administration, intravesical OT - Adverse effects OT - Recurrence OT - Urinary bladder neoplasms COIS- The authors have nothing to disclose. EDAT- 2022/03/05 06:00 MHDA- 2022/05/06 06:00 PMCR- 2022/03/01 CRDT- 2022/03/04 12:20 PHST- 2021/09/02 00:00 [received] PHST- 2021/11/09 00:00 [revised] PHST- 2021/12/07 00:00 [accepted] PHST- 2022/03/04 12:20 [entrez] PHST- 2022/03/05 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - 63.140 [pii] AID - 10.4111/icu.20210340 [doi] PST - ppublish SO - Investig Clin Urol. 2022 Mar;63(2):140-150. doi: 10.4111/icu.20210340. PMID- 35243387 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220502 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 37 DP - 2022 Mar TI - Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer. PG - 7-13 LID - 10.1016/j.euros.2021.12.008 [doi] AB - BACKGROUND: Bladder cancer imposes a significant public health burden on the European Union. There is a need for cost-effective treatment and follow-up regimens. OBJECTIVE: To assess the cost-effectiveness of immediate mitomycin C (MMC) instillation within 1 d after surgery compared to delayed MMC instillation within 2 wk after surgery with further adjuvant treatment, depending on the patient's risk group. DESIGN SETTING AND PARTICIPANTS: This economic evaluation was based on a randomized controlled trial among 2243 Dutch patients with non-muscle-invasive bladder cancer (NMIBC) patients from a health care perspective over a 3-yr time period. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The treatment effect was measured as time to recurrence and recurrence-free survival. Missing effect data were imputed with multiple imputation. Health care utilization and related costs were estimated on the basis of treatment protocols for NMIBC patients in the Netherlands. Statistical uncertainty was estimated using bootstrapping and is graphically presented using cost-effectiveness planes and cost-effectiveness acceptability curves. RESULTS AND LIMITATIONS: Time to recurrence was significantly longer for immediate MMC instillation (27.31 mo) than for delayed MMC instillation (24.97 mo), with an adjusted mean difference of 2.21 mo (95% confidence interval [CI] 1.58-2.84). The proportion of patients with recurrence-free survival was significantly higher after immediate MMC instillation (0.65) than after delayed MMC instillation (0.56), with an adjusted mean difference of 0.08 (95% CI 0.06-0.11). Total mean health care costs per patient were significantly lower for immediate MMC instillation (euro22 959) than for delayed MMC instillation (euro24 624), with an adjusted mean difference of -euro1350 (95% CI -euro1799 to -euro900). The study is limited by the retrospective estimation of costs. CONCLUSIONS: This trial-based cost-effectiveness analysis shows that from a health care perspective, immediate MMC instillation is more effective and less expensive compared to delayed MMC instillation. PATIENT SUMMARY: We assessed the cost-effectiveness of immediate bladder instillation of mitomycin C after surgery to reduce the risk of recurrence after removal of the bladder tumor as compared to delayed instillation in a large Dutch population of patients with non-muscle-invasive bladder cancer. We found that immediate instillation was more effective and less expensive than delayed instillation. We conclude that immediate mitomycin C instillation is a cost-effective treatment for non-muscle-invasive bladder cancer. CI - (c) 2021 The Author(s). FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Blankvoort, Christian J AU - Blankvoort CJ AD - Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Bosmans, Judith E AU - Bosmans JE AD - Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20220117 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8883187 OTO - NOTNLM OT - Cost-effectiveness OT - Intravesical chemotherapy OT - Mitomycin C OT - Non-muscle-invasive bladder cancer EDAT- 2022/03/05 06:00 MHDA- 2022/03/05 06:01 PMCR- 2022/01/17 CRDT- 2022/03/04 05:44 PHST- 2021/12/17 00:00 [accepted] PHST- 2022/03/04 05:44 [entrez] PHST- 2022/03/05 06:00 [pubmed] PHST- 2022/03/05 06:01 [medline] PHST- 2022/01/17 00:00 [pmc-release] AID - S2666-1683(21)03407-8 [pii] AID - 10.1016/j.euros.2021.12.008 [doi] PST - epublish SO - Eur Urol Open Sci. 2022 Jan 17;37:7-13. doi: 10.1016/j.euros.2021.12.008. eCollection 2022 Mar. PMID- 35238145 OWN - NLM STAT- MEDLINE DCOM- 20221111 LR - 20221114 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 130 IP - 6 DP - 2022 Dec TI - Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review. PG - 730-740 LID - 10.1111/bju.15723 [doi] AB - OBJECTIVES: To assess the effects of blue-light (BL)-enhanced transurethral resection of bladder tumour (TURBT) compared to white-light (WL)-based TURBT in the treatment of non-muscle-invasive bladder cancer (NMIBC). METHODS: Based on a published protocol, we performed a systematic search of multiple databases from their inception to March 2021. We included randomized controlled trials (RCTs) comparing blue-light (BL) TURBT to white-light (WL) TURBT. Our meta-analysis was based on a random-effects model. We assessed the quality of evidence on a per-outcome basis according to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included 16 RCTs involving a total of 4325 participants in this review. BL TURBT may reduce the risk of disease recurrence over time (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54-0.81; low-certainty evidence) depending on baseline risk. For participants with low-, intermediate- and high-risk NMIBC, this corresponded to 48 (66 fewer to 27 fewer), 109 (152 fewer to 59 fewer) and 147 (211 fewer to 76 fewer) fewer recurrences per 1000 participants when compared to WL TURBT, respectively. BL TURBT may also reduce the risk of disease progression over time (HR 0.65, 95% CI 0.50-0.84; low-certainty evidence) depending on baseline risk. For participants with low-, intermediate- and high-risk NMIBC, this corresponded to 1 (1 fewer to 0 fewer), 17 (25 fewer to 8 fewer), and 56 (81 fewer to 25 fewer) fewer progressions per 1000 participants when compared to WL TURBT, respectively. CONCLUSIONS: Our findings suggest a favourable impact of BL TURBT on the risk of disease recurrence and progression; however, whether this risk reduction is clinically relevant greatly depends on the baseline risk of patients. We did not find an increase in severe surgical complications with BL cystoscopy, and we did not find any trial evidence on other, non-surgical adverse events. CI - (c) 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Maisch, Philipp AU - Maisch P AUID- ORCID: 0000-0001-8104-167X AD - Department of Urology, University of Ulm, Ulm, Germany. AD - Department of Urology, Rechts der Isar Medical Centre, Technical University of Munich, Munich, Germany. FAU - Koziarz, Alex AU - Koziarz A AUID- ORCID: 0000-0002-3914-4373 AD - Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Vajgrt, Jon AU - Vajgrt J AD - University of Minnesota Medical School, Minneapolis, MN, USA. FAU - Narayan, Vikram AU - Narayan V AD - Department of Urology, Emory University, Atlanta, GA, USA. FAU - Kim, Myung Ha AU - Kim MH AD - Yonsei Wonju Medical Library, Yonsei University Wonju College of Medicine, Wonju, South Korea. FAU - Dahm, Philipp AU - Dahm P AUID- ORCID: 0000-0003-2819-2553 AD - Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA. AD - Department of Urology, University of Minnesota, Minneapolis, MN, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20220406 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Neoplasm Recurrence, Local/pathology MH - Cystectomy/methods MH - Cystoscopy/methods MH - Light OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - blue light OT - non-muscle-invasive bladder cancer OT - photodynamic diagnosis OT - transurethral resection of the bladder OT - white light EDAT- 2022/03/04 06:00 MHDA- 2022/11/15 06:00 CRDT- 2022/03/03 05:40 PHST- 2022/02/19 00:00 [revised] PHST- 2022/01/24 00:00 [received] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/03/03 05:40 [entrez] AID - 10.1111/bju.15723 [doi] PST - ppublish SO - BJU Int. 2022 Dec;130(6):730-740. doi: 10.1111/bju.15723. Epub 2022 Apr 6. PMID- 35235018 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 6 DP - 2022 Jun TI - Trends in the cause of death among patients with bladder cancer in the US SEER population, 1992-2018. PG - 1497-1503 LID - 10.1007/s00345-022-03971-y [doi] AB - BACKGROUND: Bladder cancer (BC) survival has shown no significant improvement. This study investigated the trends in the common causes of death among patients with BC to improve the management and survival of BC. METHOD: The Surveillance, Epidemiology, and End Results (SEER) (1992-2018) database was utilized to get the data of BC patients. We presented the proportion of six common causes of death in BC patients. We calculated the annual incidence of death due to the six most common causes and analyzed temporal trends in mortality rates using joinpoint regression. The competitive risk model was utilized to analyze the risk factors for death of BC and other causes. RESULTS: 198037 BC patients were enrolled. BC was the most common cause of death (30.62%), followed by other cancers (22.22%), circulatory diseases (20.28%), non-disease causes (11.58%), other non-cancer diseases (8.29%), and respiratory diseases (7.01%). However, the proportion of cases dying from BC gradually decreased from 44.87% in 1992-1996 to 26.74% in 2012-2018. The proportion of deaths due to BC decreased gradually with survival time from diagnosis. Age-standardized temporal trends present an initial increase in BC-specific and other-cause mortality rates. Advanced stage and older age were the most influential risk factors for BC-specific and other-cause death, respectively. CONCLUSION: Although BC was still the leading cause of death, other causes, especially other cancers and circulatory diseases, gradually became more critical. The management of other comorbid conditions will be a crucial part of the treatment for BC patients, especially for those with prolonged survival and NMIBC tumors. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Zhan, Xiangpeng AU - Zhan X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Chen, Luyao AU - Chen L AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Jiang, Ming AU - Jiang M AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Fu, Bin AU - Fu B AUID- ORCID: 0000-0001-6686-7561 AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. urofbin@163.com. LA - eng GR - 81960512/the National Natural Science Foundation of P.R. China/ PT - Journal Article DEP - 20220302 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Cause of Death MH - Humans MH - Incidence MH - Risk Factors MH - SEER Program MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - Cause of death OT - SEER OT - Temporal trends EDAT- 2022/03/03 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/03/02 12:20 PHST- 2022/01/04 00:00 [received] PHST- 2022/02/16 00:00 [accepted] PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/03/02 12:20 [entrez] AID - 10.1007/s00345-022-03971-y [pii] AID - 10.1007/s00345-022-03971-y [doi] PST - ppublish SO - World J Urol. 2022 Jun;40(6):1497-1503. doi: 10.1007/s00345-022-03971-y. Epub 2022 Mar 2. PMID- 35227680 OWN - NLM STAT- MEDLINE DCOM- 20220512 LR - 20220627 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 2 DP - 2022 Apr TI - Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. PG - 203-213 LID - S2588-9311(22)00009-8 [pii] LID - 10.1016/j.euo.2022.01.008 [doi] AB - BACKGROUND: An improved risk assessment of patients with bladder cancer (BC) is important to optimize clinical management. OBJECTIVE: To identify whether immune cell subpopulations and cancer cell-intrinsic features are associated with outcome and response to first-line chemotherapy in BC. DESIGN, SETTING, AND PARTICIPANTS: Primary tumor tissue from 785 patients with BC (stage Ta-T4b) were stained using multiplex immunofluorescence (CD3, CD8, FOXP3, CD20, CD68, CD163, and MHC-I) and immunohistochemistry (pancytokeratin, CK5/6, GATA3, programmed death 1 [PD-1], and programmed death ligand 1 [PD-L1]). A digital image analysis quantified staining results within the carcinoma cell and stromal part of the tumor. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoints were progression-free survival, recurrence-free survival, and response to first-line chemotherapy. Optimal cutoff values for investigated markers were estimated using maximally selected rank statistics and receiver operating characteristic for each primary endpoint. Time-to-event analyses were performed using Cox regression analyses. RESULTS AND LIMITATIONS: Several immune subpopulations were independently associated with clinical outcomes. Especially, high PD-1 and PD-L1 expression was independently associated with an increased risk of recurrence and progression in non-muscle-invasive tumors, but with a lower risk of recurrence in muscle-invasive tumors. Furthermore, we observed a lower likelihood of response to first-line chemotherapy in patients with basal differentiation features. Finally, a model combining clinical risk factors with our most evident prognosticator improved prediction accuracy compared with clinical risk factors alone for progression in non-muscle-invasive BC and recurrence in muscle-invasive BC. The use of tissue microarrays and a long inclusion period are limitations to this study. CONCLUSIONS: Immune cell subpopulations and cancer cell-intrinsic features are associated with different clinical outcomes in BC. PATIENT SUMMARY: Immune cells play an important role in cancer development and treatment outcomes. Infiltration with specific immune cells and the presence of markers associated with immune evasion in the tumor predict clinical outcomes in bladder cancer. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Taber, Ann AU - Taber A AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lamy, Philippe AU - Lamy P AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Agerbaek, Mads AU - Agerbaek M AD - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Steiniche, Torben AU - Steiniche T AD - Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: lars@clin.au.dk. LA - eng PT - Journal Article DEP - 20220225 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM CIN - Eur Urol Oncol. 2022 Apr;5(2):214-215. doi: 10.1016/j.euo.2022.03.001. PMID: 35337760 CIN - Nat Rev Urol. 2022 May;19(5):256. doi: 10.1038/s41585-022-00594-1. PMID: 35393567 MH - B7-H1 Antigen/metabolism MH - Humans MH - Programmed Cell Death 1 Receptor MH - Progression-Free Survival MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Chemotherapy OT - Immune contexture OT - Response EDAT- 2022/03/02 06:00 MHDA- 2022/05/14 06:00 CRDT- 2022/03/01 05:47 PHST- 2021/09/28 00:00 [received] PHST- 2021/12/10 00:00 [revised] PHST- 2022/01/28 00:00 [accepted] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2022/03/01 05:47 [entrez] AID - S2588-9311(22)00009-8 [pii] AID - 10.1016/j.euo.2022.01.008 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Apr;5(2):203-213. doi: 10.1016/j.euo.2022.01.008. Epub 2022 Feb 25. PMID- 35225148 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220502 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 2 DP - 2022 Apr TI - Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. PG - 137-146 LID - 10.1080/21681805.2022.2041086 [doi] AB - OBJECTIVE: To overview the updated Swedish National Guidelines on Urothelial Carcinoma 2021, with emphasis on non-muscle-invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC). METHODS: A narrative review of the updated version of the Swedish National Guidelines on Urothelial Carcinoma 2021 and highlighting new treatment recommendations, with comparison to the European Association of Urology (EAU) guidelines and current literature. RESULTS: For NMIBC the new EAU 2021 risk group stratification has been introduced for non-muscle invasive bladder cancer to predict risk of progression and the web-based application has been translated to Swedish (https://nmibc.net.). For patients with non-BCG -responsive disease treatment recommendations have been pinpointed, to guide patient counselling in this clinical situation. A new recommendation in the current version of the guidelines is the introduction of four courses of adjuvant platinum-based chemotherapy to patients with advanced disease in the nephroureterectomy specimen (pT2 or higher and/or N+). Patients with papillary urothelial neoplasms with low malignant potential (PUNLMP) can be discharged from follow-up already after 3 years based on a very low subsequent risk of further recurrences. CONCLUSIONS: The current version of the Swedish national guidelines introduces a new risk-stratification model and follow-up recommendation for NMIBC and adjuvant chemotherapy after radical surgery for UTUC. FAU - Liedberg, Fredrik AU - Liedberg F AUID- ORCID: 0000-0001-8193-0370 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Kjellstrom, Sofia AU - Kjellstrom S AD - Department of Oncology, Skane University Hospital, Sweden. FAU - Lind, Anna-Karin AU - Lind AK AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Department of Radiation Sciences, Umea University, Umea, Sweden. FAU - Falkman, Karin AU - Falkman K AD - Department of Urology, Sodersjukhuset, Stockholm, Sweden. FAU - Thulin, Helena AU - Thulin H AD - Genitourinary Oncology and Urology Unit, CLINTEC, Karolinska Institutet and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Papantonio, Dimitrious AU - Papantonio D AD - Department of Oncology, Ryhov County Hospital, Jonkoping, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden. FAU - Ofverholm, Elisabeth AU - Ofverholm E AD - Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, Sweden. FAU - Sandzen, Johan AU - Sandzen J AD - Department of Oncology, Karlstad County Hospital, Karlstad, Sweden. FAU - Verbiene, Ingrida AU - Verbiene I AD - Department of Oncology, Uppsala Akademiska Hospital, Uppsala, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Genitourinary Oncology and Urology Unit, Department of Oncology-Pathology, Karolinska Institutet and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. LA - eng PT - Journal Article PT - Review DEP - 20220228 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Nephroureterectomy MH - Sweden MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Swedish national guidelines OT - Urothelial carcinoma OT - non-muscle invasive bladder cancer OT - upper tract urothelial carcinoma EDAT- 2022/03/01 06:00 MHDA- 2022/04/30 06:00 CRDT- 2022/02/28 08:55 PHST- 2022/03/01 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2022/02/28 08:55 [entrez] AID - 10.1080/21681805.2022.2041086 [doi] PST - ppublish SO - Scand J Urol. 2022 Apr;56(2):137-146. doi: 10.1080/21681805.2022.2041086. Epub 2022 Feb 28. PMID- 35223454 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220502 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer. PG - 795242 LID - 10.3389/fonc.2021.795242 [doi] LID - 795242 AB - BACKGROUND: Tumor recurrence and progression in non-muscle invasive bladder cancer (NMIBC), therapy failure, and severe side effects in muscle invasive bladder cancer (MIBC) are the major challenges in the clinical management of bladder cancer (BC). Here, we identify new molecular targetable signatures to improve BC patients' stratification and the outcome of current immunotherapies. MATERIAL AND METHODS: In a prospective cohort of 70 BC patients, we assessed the genetic and molecular regulation of TERT in maintaining telomere length in parallel to immune checkpoint and microRNA expression. RESULTS: TERT was undetectable in healthy bladder tissues but upregulated in invasive BC stages and high tumor grade. Its expression was linked with the combined effect of the C250T mutation and THOR hypermethylation, associated with progressing tumors and maintaining of telomere length. In the same cohort, PD-L1 scored highest in NMIBC, while PD-L2 was upregulated in MIBC. We also show that miR-100-5p and 138-5p were highly expressed in healthy bladder specimens and cell line, while expression decreased in the BC tissues and BC cell lines. In line with the binding prediction for these miRNAs on target genes, miRs 100-5p and 138-5p expression strongly inverse correlated with TERT, PD-L1, and PD-L2 expression, but not PD1. CONCLUSION: We identify a loop involving TERT, PD1-ligands, and miR-138-5p in BC, that might represent not only a useful biomarker for improved diagnosis and patients' stratification but also as a promising axis that might be therapeutically targeted in situ. CI - Copyright (c) 2022 El Ahanidi, El Azzouzi, Hafidi Alaoui, Tetou, Bensaid, Chaoui, Benbacer, Hassan, Oukabli, Michaud, Ameur, Al Bouzidi, El Mzibri, Jandus and Attaleb. FAU - El Ahanidi, Hajar AU - El Ahanidi H AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. AD - Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. FAU - El Azzouzi, Meryem AU - El Azzouzi M AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. FAU - Hafidi Alaoui, Chaimae AU - Hafidi Alaoui C AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. AD - Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco. FAU - Tetou, Mohammed AU - Tetou M AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. AD - Military Hospital Mohammed V, Rabat, Morocco. FAU - Bensaid, Mounia AU - Bensaid M AD - Military Hospital Mohammed V, Rabat, Morocco. FAU - Chaoui, Imane AU - Chaoui I AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. FAU - Benbacer, Laila AU - Benbacer L AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. FAU - Hassan, Ilias AU - Hassan I AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. AD - Military Hospital Mohammed V, Rabat, Morocco. FAU - Oukabli, Mohamed AU - Oukabli M AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. AD - Military Hospital Mohammed V, Rabat, Morocco. FAU - Michaud, Katarzyna AU - Michaud K AD - University Center of Legal Medicine Lausanne-Geneva, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Ameur, Ahmed AU - Ameur A AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. AD - Military Hospital Mohammed V, Rabat, Morocco. FAU - Al Bouzidi, Abderrahmane AU - Al Bouzidi A AD - Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco. FAU - El Mzibri, Mohammed AU - El Mzibri M AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. FAU - Jandus, Camilla AU - Jandus C AD - Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. AD - Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland. FAU - Attaleb, Mohammed AU - Attaleb M AD - Biology and Medical Research Unit, Centre National de l'Energie, des Sciences et Techniques Nucleaires (CNESTEN), Rabat, Morocco. LA - eng PT - Journal Article DEP - 20220211 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8874320 OTO - NOTNLM OT - TERT OT - bladder cancer OT - immune checkpoint OT - immunotherapy OT - microRNAs COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/01 06:00 MHDA- 2022/03/01 06:01 PMCR- 2021/01/01 CRDT- 2022/02/28 05:38 PHST- 2021/10/19 00:00 [received] PHST- 2021/12/21 00:00 [accepted] PHST- 2022/02/28 05:38 [entrez] PHST- 2022/03/01 06:00 [pubmed] PHST- 2022/03/01 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.795242 [doi] PST - epublish SO - Front Oncol. 2022 Feb 11;11:795242. doi: 10.3389/fonc.2021.795242. eCollection 2021. PMID- 35219307 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20220307 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 22 IP - 1 DP - 2022 Feb 26 TI - Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). PG - 27 LID - 10.1186/s12894-022-00959-z [doi] LID - 27 AB - BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) fails in a considerable proportion of non-muscle invasive bladder cancer (NMIBC) patients despite treatment per recommended protocol. This real-world study aimed to understand the current patterns of treatment and disease management for the broad BCG-unresponsive NMIBC patient population, alongside collecting sufficient data on patients who do not undergo cystectomy. METHODS: This was a multicenter, retrospective survey of physicians treating BCG-unresponsive NMIBC patients. Data were collected in eight countries - France, Germany, Spain, Italy, United Kingdom, United States, China, and Japan - between January and May 2019. The study consisted of a short online physician survey and a retrospective chart review of eligible BCG-unresponsive NMIBC patients. Physicians abstracted chart data for the last 10 (five patients in Japan) eligible BCG-unresponsive NMIBC patients meeting the inclusion criteria, and the data were analysed for all countries combined using descriptive statistics. Country-specific analyses were also carried out, as appropriate. RESULTS: Overall, 508 physicians participated in the study. Almost one-quarter (22.9%) of physicians' current NMIBC patient caseload was BCG-unresponsive, whereby BCG therapy was no longer considered an option. Half of physicians (49.4%) did not regularly use biomarker tests in their practice, with particularly few physicians undertaking biomarker testing in Spain and Japan. Biomarker testing varied considerably, with the proportions of physicians selecting 'none' ranging from 11.4% in China to 70.3% in Japan. Physicians reported transurethral resection of the bladder tumor (TURBT) and BCG as the most common current treatments received by their patients. Chemotherapy and anti-PD-L1 treatment options were considered impactful new therapies by 94.7% and 90.0% of physicians surveyed in this study, respectively. CONCLUSIONS: The most common treatments received by patients in this study were TURBT and BCG. Emerging new treatments are driven by exploring biomarkers, but in real-world clinical practice only half of physicians or fewer regularly tested their NMIBC patients for biomarkers; PD-1/PD-L1 was the most common biomarker test used. Most physicians reported that, in addition to chemotherapy, anti-PD-L1 was an impactful new therapy. CI - (c) 2022. The Author(s). FAU - Broughton, Edward I AU - Broughton EI AD - Bristol Myers Squibb, Lawrence Township, NJ, USA. edwardbro@gmail.com. FAU - Gooden, Kyna M AU - Gooden KM AD - Bristol Myers Squibb, Lawrence Township, NJ, USA. FAU - Mycock, Katie L AU - Mycock KL AD - Adelphi Real World, Bollington, UK. FAU - Rajkovic, Ivana AU - Rajkovic I AD - Adelphi Real World, Bollington, UK. FAU - Taylor-Stokes, Gavin AU - Taylor-Stokes G AD - Adelphi Real World, Bollington, UK. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220226 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Aged MH - Antineoplastic Agents/therapeutic use MH - Attitude of Health Personnel MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor/*analysis MH - China MH - Europe MH - Female MH - Health Care Surveys MH - Humans MH - Immune Checkpoint Inhibitors/therapeutic use MH - Japan MH - Male MH - Oncologists/statistics & numerical data MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Retrospective Studies MH - United States MH - Urinary Bladder Neoplasms/pathology/*therapy MH - Urologists/statistics & numerical data PMC - PMC8882282 OTO - NOTNLM OT - Biomarkers OT - Clinical practice patterns OT - Disease management OT - Immunotherapy OT - Non-muscle invasive bladder cancer OT - Real-world evidence OT - Urinary bladder neoplasms COIS- Edward Broughton and Kyna M Gooden are employed by BMS. Ivana Rajkovic, Katie L Mycock, and Gavin Taylor-Stokes have no conflicts of interest to disclose. EDAT- 2022/02/28 06:00 MHDA- 2022/03/08 06:00 PMCR- 2022/02/26 CRDT- 2022/02/27 20:25 PHST- 2021/09/08 00:00 [received] PHST- 2022/01/18 00:00 [accepted] PHST- 2022/02/27 20:25 [entrez] PHST- 2022/02/28 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2022/02/26 00:00 [pmc-release] AID - 10.1186/s12894-022-00959-z [pii] AID - 959 [pii] AID - 10.1186/s12894-022-00959-z [doi] PST - epublish SO - BMC Urol. 2022 Feb 26;22(1):27. doi: 10.1186/s12894-022-00959-z. PMID- 35218372 OWN - NLM STAT- MEDLINE DCOM- 20220511 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 5 DP - 2022 May TI - Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. PG - 1167-1174 LID - 10.1007/s00345-022-03958-9 [doi] AB - PURPOSE: To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette-Guerin (BCG) immunotherapy for T1 squamous bladder cancer (BCa). METHODS: We retrospectively analysed 188 T1 high-grade squamous BCa patients treated between 1998 and 2019 at fifteen tertiary referral centres. Median follow-up time was 36 months (interquartile range: 19-76). The cumulative incidence and Kaplan-Meier curves were applied for CSM and OM, respectively, and compared with the Pepe-Mori and log-rank tests. Multivariable Cox models, adjusted for pathological findings at initial transurethral resection of bladder (TURB) specimen, were adopted to predict tumour recurrence and tumour progression after BCG immunotherapy. RESULTS: Immediate RC and conservative management were performed in 20% and 80% of patients, respectively. 5-year CSM and OM did not significantly differ between the two therapeutic strategies (Pepe-Mori test p = 0.052 and log-rank test p = 0.2, respectively). At multivariable Cox analyses, pure squamous cell carcinoma (SqCC) was an independent predictor of tumour progression (p = 0.04), while concomitant lympho-vascular invasion (LVI) was an independent predictor of both tumour recurrence and progression (p = 0.04) after BCG. Patients with neither pure SqCC nor LVI showed a significant benefit in 3-year recurrence-free survival and progression-free survival compared to individuals with pure SqCC or LVI (60% vs. 44%, p = 0.04 and 80% vs. 68%, p = 0.004, respectively). CONCLUSION: BCG could represent an effective treatment for T1 squamous BCa patients with neither pure SqCC nor LVI, while immediate RC should be preferred among T1 squamous BCa patients with pure SqCC or LVI at initial TURB specimen. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Lonati, Chiara AU - Lonati C AUID- ORCID: 0000-0003-0113-9920 AD - Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy. chiara.lonati@libero.it. AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. chiara.lonati@libero.it. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Schulz, Gerald B AU - Schulz GB AD - Department of Urology, Ludwig-Maximilians-University, Munich, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - University Vita-Salute San Raffaele, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. AD - University Vita-Salute San Raffaele, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Martini, Alberto AU - Martini A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - University Vita-Salute San Raffaele, Milan, Italy. AD - Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Umari, Paolo AU - Umari P AD - Division of Surgery and Interventional Science, University College London, London, UK. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, Prince of wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Charite, Universitatsmedizin Berlin, Berlin, Germany. FAU - Bajeot, Anne-Sophie AU - Bajeot AS AD - Department of Urology, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Sorbonne University, Pitie-Salpetriere Hospital, 75013, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - APHP, Department of Urology, Hopital Saint Louis, Universite de Paris, Paris, France. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Valiquette, Anne Sophie AU - Valiquette AS AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Mir, M Carmen AU - Mir MC AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Einerhand, Sarah M H AU - Einerhand SMH AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - Clinica S.Anna, Swiss Medical Group, Sorengo, Switzerland. AD - Clinica Santa Chiara, Locarno, Switzerland. FAU - Fankhauser, Christian D AU - Fankhauser CD AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Baumeister, Philipp AU - Baumeister P AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. CN - European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220226 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Squamous Cell/pathology/surgery MH - Cystectomy MH - Female MH - Humans MH - Immunotherapy MH - Male MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - CG OT - Immediate radical cystectomy OT - Immunotherapy OT - Non-muscle-invasive bladder cancer OT - T1 EDAT- 2022/02/27 06:00 MHDA- 2022/05/12 06:00 CRDT- 2022/02/26 12:06 PHST- 2021/08/26 00:00 [received] PHST- 2022/01/31 00:00 [accepted] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/05/12 06:00 [medline] PHST- 2022/02/26 12:06 [entrez] AID - 10.1007/s00345-022-03958-9 [pii] AID - 10.1007/s00345-022-03958-9 [doi] PST - ppublish SO - World J Urol. 2022 May;40(5):1167-1174. doi: 10.1007/s00345-022-03958-9. Epub 2022 Feb 26. PMID- 35216893 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20230224 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 40 IP - 6 DP - 2022 Jun TI - Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer. PG - 274.e1-274.e6 LID - S1078-1439(22)00028-X [pii] LID - 10.1016/j.urolonc.2022.01.010 [doi] AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about delaying treatment for localized cancer and its impact on long-term outcomes. OBJECTIVE: We aimed to investigate the impact of time to chemoradiation (CRT) on recurrence and survival outcomes for patients with muscle-invasive bladder cancer (MIBC). METHODS: In the national Veterans Affairs' database, we identified patients with urothelial histology, MIBC (T2-4a/N0-3/M0) diagnosed between 2000 to 2018 and treated with definitive CRT. Time to treatment was defined as the number of days between date of diagnosis and start date of CRT. The cohort was stratified into < 90 (early) or >/= 90 days (delayed) groups. Endpoints of locoregional failure (LRF), distant failure (DF), overall survival (OS), and bladder cancer-specific survival (BCS) were evaluated in multivariable Cox and Fine-Gray models. RESULTS: 305 patients with MIBC underwent CRT - 190 (62.3%) received early CRT, 115 (37.7%) received delayed CRT. Multivariable analysis (including success of transurethral resection of bladder tumor and type of chemotherapy) revealed no difference in recurrence between groups - LRF HR 1.12 (95%CI 0.76-1.67, P = 0.56) and DF HR 1.03 (95%CI 0.70-1.53, P = 0.88). Similarly, there were no differences in survival outcomes. The lack of association was maintained at both earlier and later time cutoffs (60-120 days). CONCLUSIONS: Our findings suggest that a short-term delay in definitive therapy may not affect long-term outcomes for patients with MIBC undergoing CRT. This study does not endorse delays in therapy, but rather provides information to aid patients and clinicians navigate the unique challenges of MIBC care in both pandemic and non-pandemic times. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Kotha, Nikhil V AU - Kotha NV AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - Kumar, Abhishek AU - Kumar A AD - Veterans Affairs San Diego Healthcare System, San Diego, CA; Department of Radiation Oncology, Duke University, Durham, NC. FAU - Nelson, Tyler J AU - Nelson TJ AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - Qiao, Edmund M AU - Qiao EM AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - Qian, Alex S AU - Qian AS AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - Voora, Rohith S AU - Voora RS AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - McKay, Rana R AU - McKay RR AD - Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA. FAU - Rose, Brent S AU - Rose BS AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA; Veterans Affairs San Diego Healthcare System, San Diego, CA. FAU - Stewart, Tyler F AU - Stewart TF AD - Veterans Affairs San Diego Healthcare System, San Diego, CA; Division of Hematology-Oncology, Department of Medicine, University of California San Diego, La Jolla, CA. Electronic address: tstewart@health.ucsd.edu. LA - eng GR - P30 CA023100/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20220223 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *COVID-19 MH - Cystectomy MH - Female MH - Humans MH - Male MH - Muscles/pathology MH - Neoplasm Invasiveness MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology PMC - PMC8863428 OTO - NOTNLM OT - COVID-19 pandemic OT - Chemoradiation OT - Muscle-invasive bladder cancer OT - Time to treatment OT - Veterans affairs (U.S.) COIS- Conflict of interest Dr. Rana McKay reports grants from Bayer, Pfizer, Tempus, personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pfizer, Sanofi, Tempus, Dendreon, Vividion, Caris, outside the submitted work. Dr. Tyler Stewart has served as a paid consultant for Seattle Genetics, outside the submitted work. All other authors have no conflicts of interest to report. EDAT- 2022/02/27 06:00 MHDA- 2022/05/18 06:00 PMCR- 2022/02/23 CRDT- 2022/02/26 05:32 PHST- 2021/09/02 00:00 [received] PHST- 2021/12/22 00:00 [revised] PHST- 2022/01/15 00:00 [accepted] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/02/26 05:32 [entrez] PHST- 2022/02/23 00:00 [pmc-release] AID - S1078-1439(22)00028-X [pii] AID - 10.1016/j.urolonc.2022.01.010 [doi] PST - ppublish SO - Urol Oncol. 2022 Jun;40(6):274.e1-274.e6. doi: 10.1016/j.urolonc.2022.01.010. Epub 2022 Feb 23. PMID- 35212590 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220601 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 22 IP - 4 DP - 2022 Apr TI - Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. PG - 361-370 LID - 10.1080/14737140.2022.2046466 [doi] AB - INTRODUCTION: Immunotherapy with intravesical bacillus Calmette-Guerin (BCG) has been the gold standard treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) for nearly half a century. Yet, many patients with high-risk disease will experience recurrence, including those who progress and eventually become unresponsive to BCG. For decades, apart from radical cystectomy, few therapeutic options existed for this at-risk population. However, the advent of novel immunotherapeutic agents has transformed treatment in a range of tumor types, including urothelial carcinoma. These immunotherapies have yielded promising results in the treatment of metastatic urothelial carcinoma and, as such, are also being investigated for use in NIMIBC. AREAS COVERED: This article provides an overview of the evolution of immunotherapy for NMIBC, beginning from the original immunotherapy-BCG - to current agents including checkpoint inhibitors, IL-15 agonists, viral gene therapies and therapeutic cancer vaccines. EXPERT OPINION: Emerging insights over the last decade have led to the development of novel immunotherapiesfor the treatment of NMIBC whilst providing new opportunities to enhance the anti-tumour activity of BCG. In particular, the KEYNOTE-057 trial represents a pivotal moment for immunotherapy in NMIBC, leading to approval of pembrolizumab by the US Food & Drug Administration for patients with BCG-unresponsive disease. However, patient selection and the development of biomarkers to guide the identification of patients who will benefit most from a particular immunotherapy remains critical. As research efforts come to fruition, these novel immunotherapies may become integrated into the standard treatment paradigm for intermediate- and high-risk NMBIC. FAU - Lobo, Niyati AU - Lobo N AUID- ORCID: 0000-0002-6505-8399 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220301 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Immunologic Factors) SB - IM MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - BCG Vaccine MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Immunologic Factors/therapeutic use MH - Immunotherapy/methods MH - Neoplasm Invasiveness MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - checkpoint inhibitors OT - immunotherapy OT - non-muscle-invasive bladder cancer OT - vaccines EDAT- 2022/02/26 06:00 MHDA- 2022/04/13 06:00 CRDT- 2022/02/25 12:15 PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/02/25 12:15 [entrez] AID - 10.1080/14737140.2022.2046466 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2022 Apr;22(4):361-370. doi: 10.1080/14737140.2022.2046466. Epub 2022 Mar 1. PMID- 35208878 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220301 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 10 IP - 2 DP - 2022 Feb 12 TI - Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer's Disease. LID - 10.3390/microorganisms10020424 [doi] LID - 424 AB - BCG vaccine has been used for 100 years to prevent tuberculosis. Not all countries, including the United States, adopted the initial World Health Organization recommendation to use BCG. Moreover, many Western countries that had routinely used BCG have discontinued its use. Recent population studies demonstrate lower prevalence of Alzheimer's disease (AD) in countries with high BCG coverage. Intravesicular instillation of BCG is also used to treat bladder cancer that has not invaded the bladder muscle wall and has been shown to reduce recurrence. Several retrospective studies of bladder cancer patients demonstrated that BCG treatment was associated with a significantly reduced risk of developing AD. Plasma amyloid beta assessment has become a fertile area of study for an AD biomarker that is predictive of a positive amyloid PET scan. Mass spectrometry-based plasma amyloid 42/40 ratio has proven to be accurate and robust, and when combined with age and ApoE, is shown to accurately predict current and future brain amyloid status. These parameters, amyloid 42/40 ratio, age and ApoE genotype are incorporated into an Amyloid Probability Score (APS)-a score that identifies low, intermediate or high risk of having a PET scan positive for cerebral amyloid. Community recruitment was used for this open-label pilot study. Forty-nine BCG-naive, immunocompetent individuals completed our study: prior to BCG prime and boost, as determined by the APS, 34 had low risk (APS 0-35), 5 had intermediate risk (APS 36-57) and 10 had high risk (APS 58-100). The APS range for the participant group was 0 to 94. Follow-up plasma amyloid testing 9 months after vaccination revealed a reduction in the APS in all the risk groups: low risk group (p = 0. 37), intermediate risk group (p = 0.13) and the high-risk group (statistically significant, p = 0.016). Greater benefit was seen in younger participants and those with the highest risk. The small number of participants and the nascent status of plasma amyloid testing will rightfully temper embracement of these results. However, both the favorable direction of change after BCG as well as the utility of the APS-a valuable surrogate AD biomarker-may prompt a definitive large-scale multicenter investigation of BCG and AD risk as determined by plasma amyloid peptide ratios and APS. FAU - Dow, Coad Thomas AU - Dow CT AD - Department of Ophthalmology and Visual Sciences, McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53706, USA. AD - Mindful Diagnostics and Therapeutics, Eau Claire, WI 54701, USA. FAU - Greenblatt, Charles L AU - Greenblatt CL AD - Department of Microbiology and Molecular Genetics, Hebrew University, Jerusalem 9103401, Israel. FAU - Chan, Edward D AU - Chan ED AUID- ORCID: 0000-0001-7612-7727 AD - Department of Academic Affairs, National Jewish Health, Denver, CO 80218, USA. AD - Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80217, USA. AD - Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO 80045, USA. FAU - Dow, Jordan F AU - Dow JF AD - Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA. AD - Northwestern Wisconsin Region Mayo Clinic Health System, Eau Claire, WI 54703, USA. LA - eng PT - Journal Article DEP - 20220212 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC8880735 OTO - NOTNLM OT - Alzheimer's OT - Alzheimer's biomarker OT - BCG OT - Bacillus Calmette-Guerin OT - CD4:CD8 OT - CMV OT - amyloid 42/40 OT - amyloid probability score (APS) OT - immune risk profile OT - non-specific effects of vaccines OT - plasma amyloid COIS- The authors declare no conflict of interest. EDAT- 2022/02/26 06:00 MHDA- 2022/02/26 06:01 PMCR- 2022/02/12 CRDT- 2022/02/25 01:16 PHST- 2021/12/29 00:00 [received] PHST- 2022/02/04 00:00 [revised] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/02/25 01:16 [entrez] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/02/26 06:01 [medline] PHST- 2022/02/12 00:00 [pmc-release] AID - microorganisms10020424 [pii] AID - microorganisms-10-00424 [pii] AID - 10.3390/microorganisms10020424 [doi] PST - epublish SO - Microorganisms. 2022 Feb 12;10(2):424. doi: 10.3390/microorganisms10020424. PMID- 35207416 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220301 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 4 DP - 2022 Feb 21 TI - A Comparison of the Anesthetic Methods for Recurrence Rates of Bladder Cancer after Transurethral Resection of Bladder Tumors Using National Health Insurance Claims Data of South Korea. LID - 10.3390/jcm11041143 [doi] LID - 1143 AB - Bladder cancers have high recurrence rates and are usually removed via transurethral resection of bladder tumor (TURBT). Recently, some reports showed that the anesthetic method may affect the recurrence rates of bladder cancers. The purpose of this population-based study was to compare the effect of anesthetic methods with the recurrence rates of bladder cancers in South Korea. A total of 4439 patients were reviewed retrospectively using the data of the Korean National Health Insurance (NHI) claims database from January 2007 to December 2011. Patients were divided into 2 groups who received general (n = 3767) and regional anesthesia (n = 582), and were followed up until September 2017. Propensity score matching was conducted to reduce the effect of confounding factors. After using propensity score matching with a multivariable Cox regression model, age (p < 0.001), sex (p < 0.001), hypertension (p = 0.003), diabetes mellitus (p = 0.001), and renal disease (p < 0.001) were significantly associated with bladder cancer recurrence. However, there were no significant differences in the recurrence rates of bladder cancers in patients who received general anesthesia and spinal anesthesia for TURBTs. This study revealed that there is no relationship between the anesthetic method and bladder cancer recurrence. Either general anesthesia or regional anesthesia can be used depending on the situation in patients receiving TURBT. Future prospective studies are warranted to confirm the association between the anesthetic method and the recurrence rates of bladder cancer. FAU - Lee, Sang Won AU - Lee SW AUID- ORCID: 0000-0001-9359-2639 AD - Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Tae, Bum Sik AU - Tae BS AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Choi, Yoon Ji AU - Choi YJ AUID- ORCID: 0000-0003-3031-357X AD - Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Yoon, Sang Min AU - Yoon SM AD - Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Lee, Yoon Sook AU - Lee YS AD - Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Kim, Jae Hwan AU - Kim JH AUID- ORCID: 0000-0002-1360-1708 AD - Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Shin, Hye Won AU - Shin HW AD - Department of Anesthesiology and Pain Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul 02841, Korea. FAU - Park, Jae Young AU - Park JY AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. FAU - Bae, Jae Hyun AU - Bae JH AUID- ORCID: 0000-0001-9862-3545 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Korea. LA - eng PT - Journal Article DEP - 20220221 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8878593 OTO - NOTNLM OT - bladder cancer OT - general anesthesia OT - regional anesthesia OT - transurethral resection of bladder tumor COIS- The authors declare no conflict of interest. EDAT- 2022/02/26 06:00 MHDA- 2022/02/26 06:01 PMCR- 2022/02/21 CRDT- 2022/02/25 01:12 PHST- 2022/02/05 00:00 [received] PHST- 2022/02/17 00:00 [revised] PHST- 2022/02/20 00:00 [accepted] PHST- 2022/02/25 01:12 [entrez] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/02/26 06:01 [medline] PHST- 2022/02/21 00:00 [pmc-release] AID - jcm11041143 [pii] AID - jcm-11-01143 [pii] AID - 10.3390/jcm11041143 [doi] PST - epublish SO - J Clin Med. 2022 Feb 21;11(4):1143. doi: 10.3390/jcm11041143. PMID- 35205635 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220228 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 4 DP - 2022 Feb 10 TI - Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. LID - 10.3390/cancers14040887 [doi] LID - 887 AB - BACKGROUND: Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. METHODS: Patients with NMIBCs underwent adjuvant induction +/- maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naive patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan-Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed. RESULTS: 852 Ta-T1 NMIBCs (n = 719, 84.4% on TICE; n = 133, 15.6% on RIVM) with a median of 53 (24-77) months of follow-up were reviewed. After PSM, no differences at 5-years RFS, PFS, and CSS at both Kaplan-Meier and Cox regression analyses were detected for the whole cohort. In the sub-group setting of full adherence to European/American Urology Guidelines (EAU/NCCN), BCG TICE demonstrated longer 5-years RFS compared to RIVM (68% vs. 43%, p = 0.008; HR: 0.45 95% CI 0.25-0.81). CONCLUSION: When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. AD - Department of Urology, Stanford Medical Center, Stanford, CA 94305, USA. FAU - Flammia, Rocco Simone AU - Flammia RS AUID- ORCID: 0000-0002-3129-0544 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford Medical Center, Stanford, CA 94305, USA. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, San Raffaele Hospital and Scientific Institute, 20132 Milan, Italy. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Mari, Andrea AU - Mari A AUID- ORCID: 0000-0001-9070-5706 AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, 50134 Florence, Italy. FAU - Soria, Francesco AU - Soria F AD - Urology Division, Department of Surgical Sciences, University of Studies of Torino, 10126 Turin, Italy. FAU - Albisinni, Simone AU - Albisinni S AD - Urology Department, Erasme Hospital, Universite Libre de Bruxelles, 1070 Brussels, Belgium. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - Department of Urology and Oncological Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, 19435 Moscow, Russia. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Gallioli, Andrea AU - Gallioli A AD - Unit of Urology, Fundacio Puigvert, 08025 Barcelona, Spain. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands. FAU - Maggi, Martina AU - Maggi M AUID- ORCID: 0000-0003-4672-850X AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AUID- ORCID: 0000-0002-7899-8056 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Salciccia, Stefano AU - Salciccia S AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Ferro, Matteo AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Division of Urology, European Institute of Oncology (IEO)-IRCCS, 20141 Milan, Italy. FAU - Scornajenghi, Carlo Maria AU - Scornajenghi CM AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Asero, Vincenzo AU - Asero V AUID- ORCID: 0000-0001-5293-9253 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Cattarino, Susanna AU - Cattarino S AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - De Angelis, Mario AU - De Angelis M AD - Department of Urology, San Raffaele Hospital and Scientific Institute, 20132 Milan, Italy. FAU - Cacciamani, Giovanni E AU - Cacciamani GE AD - USC Institute of Urology, University of Southern California, Los Angeles, CA 90089, USA. FAU - Autorino, Riccardo AU - Autorino R AUID- ORCID: 0000-0001-7045-7725 AD - Division of Urology, Department of Surgery, Virginia Commonwealth University, Richmond, VA 23284, USA. FAU - Pandolfo, Savio Domenico AU - Pandolfo SD AUID- ORCID: 0000-0001-9621-3059 AD - Division of Urology, Department of Surgery, Virginia Commonwealth University, Richmond, VA 23284, USA. AD - Department of Neurosciences, Sciences of Reproduction, and Odontostomatology, Fderico II University, 80131 Naples, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Neurosciences, Sciences of Reproduction, and Odontostomatology, Fderico II University, 80131 Naples, Italy. FAU - D'Altilia, Nicola AU - D'Altilia N AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Mancini, Vito AU - Mancini V AUID- ORCID: 0000-0003-3050-8748 AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Chirico, Marco AU - Chirico M AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cinelli, Francesco AU - Cinelli F AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Bettocchi, Carlo AU - Bettocchi C AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" Rome University, 00185 Rome, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Renal Transplantation, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy. FAU - On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party AU - On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party LA - eng PT - Journal Article DEP - 20220210 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8869903 OTO - NOTNLM OT - BCG strain OT - BCG-RIVM OT - BCG-TICE OT - bladder cancer OT - cancer-specific survival OT - progression-free survival OT - re-TUR OT - recurrence-free survival COIS- The authors declare no conflict of interest. EDAT- 2022/02/26 06:00 MHDA- 2022/02/26 06:01 PMCR- 2022/02/10 CRDT- 2022/02/25 01:07 PHST- 2022/01/06 00:00 [received] PHST- 2022/02/01 00:00 [revised] PHST- 2022/02/06 00:00 [accepted] PHST- 2022/02/25 01:07 [entrez] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/02/26 06:01 [medline] PHST- 2022/02/10 00:00 [pmc-release] AID - cancers14040887 [pii] AID - cancers-14-00887 [pii] AID - 10.3390/cancers14040887 [doi] PST - epublish SO - Cancers (Basel). 2022 Feb 10;14(4):887. doi: 10.3390/cancers14040887. PMID- 35204522 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220301 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 12 IP - 2 DP - 2022 Feb 7 TI - A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. LID - 10.3390/diagnostics12020431 [doi] LID - 431 AB - BACKGROUND: Lipid alterations may serve as potential tumour biomarkers. The ratio of triglycerides to HDL cholesterol (TG/HDL ratio) is associated with various cancers. Pseudocholinesterase (PChE) activity, involved in TG hydrolysis, plays an important role in the metabolism of lipoprotein. There is scarce data assessing the reliability of both the TG/HDL ratio and PChE levels in correctly classifying patients suffering from bladder cancer. METHODS: Three hundred and ninety-six patients undergoing cystoscopy or transurethral resection of the bladder (TURB), broken into two major groups, i.e., patients with histologically confirmed, non-metastatic bladder cancer (n = 208) and without bladder cancer (no bladder cancer, n = 188), formed the study population. The last group was split into two subgroups consisting of a cohort of patients never suffering from bladder cancer but with other bladder diseases (no CaBD, n = 100) and another cohort formed by patients characterised by eradicated bladder cancer after TURB with no recurrence during a three-month follow-up (previous bladder cancer, n = 88). Pieces of information by both metabolic derangement (the presence of type 2 diabetes mellitus), hypertension and lipid profile were retrieved from patient records upon entry to the study. Sensitivity, specificity, areas under the ROC (AUROC) of the TG/HDL ratio, and PChE levels were used in diagnostic decision making. RESULTS: The TG/HDL ratio as well as PChE concentrations of bladder cancer patients were significantly different when compared to those with previous bladder cancer and the no CaBD patients (p = 0.023 and 0.0004, respectively). There was an independent role of both the TG/HDL ratio and PChE levels in predicting the presence of bladder cancer (OR: 1.22 and 0.99, respectively), but the reliability of the TG/HDL ratio (AUROC: 0.587) was superior to that of PChE levels (AUROC: 0.374). The AUROC of a new parameter resulting from the combination of the TG/HDL ratio with PChE levels showed a further increment in the discriminant power of the bladder cancer presence (0.6298), interestingly with a negative predictive value (89%) according to the Bayesian approach. The cut-off of the TG/HDL ratio, the main marker of the present study that better distinguishes bladder cancer from no bladder cancer patients, was 2.147. DISCUSSION AND CONCLUSIONS: The reliability of the TG/HDL ratio is based on the fact that this parameter likely mirrors the insulin resistance (IR) underlying bladder cancer patients. Furthermore, PChE levels evidence both IR and the associated non-alcoholic fatty liver disease. The TG/HDL ratio and PChE levels as well as their combined use could help physicians to assess/confirm the presence of this very common cancer, where early detection is important to ensure the best therapeutical approach. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Pandolfo, Savio Domenico AU - Pandolfo SD AUID- ORCID: 0000-0001-9621-3059 AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. AD - Division of Urology, VCU Health, Richmond, VA 23219, USA. FAU - Aveta, Achille AU - Aveta A AUID- ORCID: 0000-0001-8470-1995 AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Martino, Raffaele AU - Martino R AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Trama, Francesco AU - Trama F AUID- ORCID: 0000-0001-9291-2426 AD - Andrology and UroGynecology Clinic, AOSP Santa Maria di Terni, 05100 Terni, Italy. FAU - Caputo, Vincenzo Francesco AU - Caputo VF AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Barone, Biagio AU - Barone B AUID- ORCID: 0000-0003-4884-132X AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Abate, Marco AU - Abate M AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Sicignano, Enrico AU - Sicignano E AUID- ORCID: 0000-0003-2725-8530 AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Cilio, Simone AU - Cilio S AUID- ORCID: 0000-0002-8431-9830 AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Russo, Gianluca AU - Russo G AUID- ORCID: 0000-0003-2698-9470 AD - Department of Public Health, University of Naples Federico II, 80138 Naples, Italy. FAU - Massanova, Matteo AU - Massanova M AD - Department of Urology, Queen Elizabeth, University Hospital, Glasgow G51 4TF, UK. FAU - Di Vito, Concetta AU - Di Vito C AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Imbimbo, Ciro AU - Imbimbo C AD - Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University, 80131 Naples, Italy. FAU - Tarantino, Giovanni AU - Tarantino G AUID- ORCID: 0000-0001-7751-2715 AD - Department of Clinical Medicine and Surgery, Federico II Medical School of Naples, 80138 Naples, Italy. LA - eng PT - Journal Article DEP - 20220207 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC8871224 OTO - NOTNLM OT - TG/HDL ratio OT - bladder cancer OT - pseudocholinesterase COIS- The authors declare no conflict of interest. EDAT- 2022/02/26 06:00 MHDA- 2022/02/26 06:01 PMCR- 2022/02/07 CRDT- 2022/02/25 01:04 PHST- 2022/01/08 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/02/25 01:04 [entrez] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/02/26 06:01 [medline] PHST- 2022/02/07 00:00 [pmc-release] AID - diagnostics12020431 [pii] AID - diagnostics-12-00431 [pii] AID - 10.3390/diagnostics12020431 [doi] PST - epublish SO - Diagnostics (Basel). 2022 Feb 7;12(2):431. doi: 10.3390/diagnostics12020431. PMID- 35186716 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity. PG - 802188 LID - 10.3389/fonc.2021.802188 [doi] LID - 802188 AB - PURPOSE: To investigate the role of circulating rare cells (CRCs), namely, circulating tumor cells (CTCs) and circulating endothelial cells (CECs), in aiding early intervention, treatment decision, and prognostication in bladder cancer. METHODS: A total of 196 patients with pathologically confirmed bladder cancer, namely, 141 non-muscle invasive bladder cancer (NMIBC) and 55 muscle invasive bladder cancer (MIBC) patients. There were 32 patients who received cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Subtraction enrichment combined with immunostaining-fluorescence in situ hybridization (SE-iFISH) strategy was used for CTC/CEC detection. Kaplan-Meier analysis and Cox regression were used to evaluate the overall survival (OS) and recurrence-free survival (RFS). Receiver operator characteristic analysis was used to discriminate NAC sensitivity. RESULTS: CTCs and CECs were related to clinicopathological characteristics. Triploid CTCs, tetraploid CTCs, and total CECs were found to be higher in incipient patients than in relapse patients (P = 0.036, P = 0.019, and P = 0.025, respectively). The number of total CECs and large cell CECs was also associated with advanced tumor stage (P = 0.028 and P = 0.033) and grade (P = 0.028 and P = 0.041). Remarkably, tumor-biomarker-positive CTCs were associated with worse OS and RFS (P = 0.026 and P = 0.038) in NMIBC patients underwent TURBT. CECs cluster was an independent predictor of recurrence in non-high-risk NMIBC patients underwent TURBT (HR = 9.21, P = 0.040). For NAC analysis, pre-NAC tetraploid CTCs and small cell CTCs demonstrated the capability in discriminating NAC-sensitive from insensitive patients. Additionally, tetraploid CTCs and single CTCs elevated post-NAC would indicate chemoresistance. CONCLUSION: CTCs and CECs may putatively guide in diagnosis, prognosis prediction, and therapeutic decision-making for bladder cancer. CI - Copyright (c) 2022 Yang, Lv, Zhou, Feng, Zhou, Yuan, Wu, Yu, Han, Cao, Gu, Li, Yang and Lu. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lv, Jiancheng AU - Lv J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhou, Zijian AU - Zhou Z AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Feng, Dexiang AU - Feng D AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhou, Rui AU - Zhou R AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. AD - Department of Pediatric Urology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. FAU - Yuan, Baorui AU - Yuan B AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wu, Qikai AU - Wu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Han, Jie AU - Han J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cao, Qiang AU - Cao Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Gu, Min AU - Gu M AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yang, Haiwei AU - Yang H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article DEP - 20220203 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8851236 OTO - NOTNLM OT - bladder cancer OT - circulating endothelial cells OT - circulating tumor cells OT - neoadjuvant chemosensitivity OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/22 06:00 MHDA- 2022/02/22 06:01 PMCR- 2021/01/01 CRDT- 2022/02/21 06:04 PHST- 2021/10/26 00:00 [received] PHST- 2021/12/28 00:00 [accepted] PHST- 2022/02/21 06:04 [entrez] PHST- 2022/02/22 06:00 [pubmed] PHST- 2022/02/22 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.802188 [doi] PST - epublish SO - Front Oncol. 2022 Feb 3;11:802188. doi: 10.3389/fonc.2021.802188. eCollection 2021. PMID- 35160003 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220219 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 3 DP - 2022 Jan 22 TI - The Accuracy of Transurethral Bladder Resection in Detecting Bladder Cancer Histological Variants and Their Prognostic Value at Radical Cystectomy. LID - 10.3390/jcm11030550 [doi] LID - 550 AB - OBJECTIVES: to investigate the accuracy of transurethral resection of bladder tumours (TURBT) in detecting histological variants (BHV) at radical cystectomy (RC) and to evaluate the impact of TURBT before cystectomy on oncological outcomes. METHODS: Data of 410 consecutive RCs were assessed. Positive and negative predictive values were used to assess the accuracy of TURBT in detecting BHV. Cohen's Kappa coefficient was used to calculate the agreement grade. Logistic regression analysis predicted features based on the presence of BHV at TURBT. Multivariable backward conditional Cox regression analysis was used to estimate oncological outcomes. RESULTS: A total of 73 patients (17.8%) showed BHV at TURBT as compared to 108 (26.3%) at RC. A moderate agreement in histological diagnosis was found between TURBT and RC (0.58). However, sensitivity and specificity in detecting BHV were 56% and 96%, respectively. Furthermore, positive predictive value (PPV) was 84.7% and negative predictive value (NPV) was 84.6%. Presence of BHV at TURBT was an independent predictor for pathologic upstage, albeit not a predictor for positive nodes or positive surgical margins. However, at multivariable analysis adjusted for all confounders, presence of BHV at TURBT was an independent predictor for recurrence after RC, but not for survival. Conversely, the presence of BHV at RC was an independent predictor for both recurrence and survival. CONCLUSION: There was a moderate agreement between TURBT and RC histopathological findings. TURBT, alone, could not provide an accurate and definitive histological diagnosis. Detection of BHV in TURBT specimens is not an independent predictor of oncological outcomes; indeed, only pathological features at RC are associated with worse survival. However, BHV presence in cystectomy specimens resulted as an independent predictor of both cancer-specific and overall mortality. FAU - La Croce, Giovanni AU - La Croce G AUID- ORCID: 0000-0001-6209-8670 AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Naspro, Richard AU - Naspro R AUID- ORCID: 0000-0003-2202-8939 AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Finati, Marco AU - Finati M AUID- ORCID: 0000-0002-7425-1166 AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Pellucchi, Federico AU - Pellucchi F AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Sodano, Mario AU - Sodano M AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Manica, Michele AU - Manica M AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Catellani, Michele AU - Catellani M AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Gianatti, Andrea AU - Gianatti A AUID- ORCID: 0000-0003-2303-7394 AD - Department of Pathology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Roscigno, Marco AU - Roscigno M AUID- ORCID: 0000-0002-5241-6767 AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Da Pozzo, Luigi Filippo AU - Da Pozzo LF AD - Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. AD - School of Medicine, University of Milano-Bicocca, 20126 Milan, Italy. LA - eng PT - Journal Article DEP - 20220122 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8836972 OTO - NOTNLM OT - bladder cancer OT - histological variants OT - transurethral resection COIS- The authors declare no conflict of interest. EDAT- 2022/02/16 06:00 MHDA- 2022/02/16 06:01 PMCR- 2022/01/22 CRDT- 2022/02/15 01:06 PHST- 2021/11/25 00:00 [received] PHST- 2021/12/30 00:00 [revised] PHST- 2022/01/18 00:00 [accepted] PHST- 2022/02/15 01:06 [entrez] PHST- 2022/02/16 06:00 [pubmed] PHST- 2022/02/16 06:01 [medline] PHST- 2022/01/22 00:00 [pmc-release] AID - jcm11030550 [pii] AID - jcm-11-00550 [pii] AID - 10.3390/jcm11030550 [doi] PST - epublish SO - J Clin Med. 2022 Jan 22;11(3):550. doi: 10.3390/jcm11030550. PMID- 35159947 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220219 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 3 DP - 2022 Jan 19 TI - Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. LID - 10.3390/jcm11030497 [doi] LID - 497 AB - Neoadjuvant chemotherapy followed by a cystectomy is the standard treatment in muscle-invasive bladder cancer (MIBC). However, the role of chemotherapy in the adjuvant setting remains controversial, and therefore new prognostic and predictive biomarkers are needed to improve the selection of MIBC patients. While lipid metabolism has been related to several biological processes in many tumours, including bladder cancer, no metabolic biomarkers have been identified as prognostic in routine clinical practice. In this multicentre, retrospective study of 198 patients treated with cystectomy followed by platinum-based adjuvant chemotherapy, we analysed the immunohistochemical expression of CD36 and correlated our findings with clinicopathological characteristics and survival. CD36 immunostaining was positive in 30 patients (15%) and associated with more advanced pathologic stages (pT3b-T4; p = 0.015). Moreover, a trend toward lymph node involvement in CD36-positive tumours, especially in earlier disease stages (pT1-T3; p = 0.101), was also observed. Among patients with tumour progression during the first 12 months after cystectomy, disease-free survival was shorter in CD36-positive tumours than in those CD36-negative (6.51 months (95% CI 5.05-7.96) vs. 8.74 months (95% CI 8.16-9.32); p = 0.049). Our results suggest an association between CD36 immunopositivity and more aggressive features of MIBC and lead us to suggest that CD36 could well be a useful prognostic marker in MIBC. FAU - Pardo, Juan Carlos AU - Pardo JC AD - Medical Oncology Department, Catalan Institute of Oncology, Ctra. Can Ruti- Cami de les Escoles s/n, 08916 Badalona, Spain. AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Sanhueza, Tamara AU - Sanhueza T AD - Pathology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain. FAU - Ruiz de Porras, Vicenc AU - Ruiz de Porras V AUID- ORCID: 0000-0002-4352-1784 AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Etxaniz, Olatz AU - Etxaniz O AUID- ORCID: 0000-0002-8856-5596 AD - Medical Oncology Department, Catalan Institute of Oncology, Ctra. Can Ruti- Cami de les Escoles s/n, 08916 Badalona, Spain. AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Rodriguez, Helena AU - Rodriguez H AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Martinez-Cardus, Anna AU - Martinez-Cardus A AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Grande, Enrique AU - Grande E AUID- ORCID: 0000-0002-0134-4732 AD - Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. AD - Medical Oncology Department, MD Anderson Cancer Center, 28033 Madrid, Spain. FAU - Castellano, Daniel AU - Castellano D AD - Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. FAU - Climent, Miquel A AU - Climent MA AD - Medical Oncology Department, Instituto Valenciano de Oncologia, 46009 Valencia, Spain. FAU - Lobato, Tania AU - Lobato T AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Estudillo, Lidia AU - Estudillo L AUID- ORCID: 0000-0003-3891-3713 AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, 28029 Madrid, Spain. FAU - Jorda, Mireia AU - Jorda M AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. FAU - Carrato, Cristina AU - Carrato C AD - Pathology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain. FAU - Font, Albert AU - Font A AD - Medical Oncology Department, Catalan Institute of Oncology, Ctra. Can Ruti- Cami de les Escoles s/n, 08916 Badalona, Spain. AD - Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO), 08916 Badalona, Spain. AD - Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. LA - eng GR - Grant Grupos coordinados estables de investigacion 2014/Asociacion Espanola Contra el Cancer/ PT - Journal Article DEP - 20220119 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8836680 OTO - NOTNLM OT - CD36 OT - MIBC OT - adjuvant chemotherapy OT - bladder cancer OT - fatty acid OT - lipid metabolism OT - prognostic biomarker COIS- The authors declare no conflict of interest. EDAT- 2022/02/16 06:00 MHDA- 2022/02/16 06:01 PMCR- 2022/01/19 CRDT- 2022/02/15 01:06 PHST- 2021/12/10 00:00 [received] PHST- 2022/01/17 00:00 [revised] PHST- 2022/01/18 00:00 [accepted] PHST- 2022/02/15 01:06 [entrez] PHST- 2022/02/16 06:00 [pubmed] PHST- 2022/02/16 06:01 [medline] PHST- 2022/01/19 00:00 [pmc-release] AID - jcm11030497 [pii] AID - jcm-11-00497 [pii] AID - 10.3390/jcm11030497 [doi] PST - epublish SO - J Clin Med. 2022 Jan 19;11(3):497. doi: 10.3390/jcm11030497. PMID- 35158886 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220219 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 3 DP - 2022 Jan 26 TI - The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT(c) Bladder Cancer Monitor and Narrow Band Imaging(c) Cystoscopy. LID - 10.3390/cancers14030618 [doi] LID - 618 AB - Follow-up is essential for the early detection of recurrent non-muscle invasive bladder cancers (NMIBC). This study investigates the clinical relevance of new diagnostic tools such as an mRNA-based urine test (XPERT(c) Bladder Cancer Monitor, XBCM) and Narrow Band Imaging(c) (NBI) and compares them with the established follow-up diagnostics (white-light cystoscopy (WLC) and urine cytology). This was a prospective, double-blind, single-center study that involved patients undergoing NMIBC screening at a tertiary care center. Enrollment occurred between January 2018 and March 2020. In addition to standard care (WLC, cytology, and ultrasound), patients underwent XBCM urine testing and NBI cystoscopy. In total, 301 WLCs were performed; through this, 49 patients demonstrated NMIBC recurrence. NBI cystoscopy was congruent with WLC in all patients. Cytology showed a sensitivity (SE) and specificity (SP) of 27% and 97% (PPV: 65%; NPV 87%), respectively, whereas XBCM showed SE and SP of 58% and 89%, respectively (PPV: 51%; NPV: 92%; AUC: 0.79 (0.716-0.871)). Subgroup analysis showed improved SE and similar SP (PPV, NPV) for high grade (HG) recurrence, with a SE of 74% and SP of 89% (39%, 97%). NBI cystoscopy does not necessarily provide additional benefit over standard WLC. However, the XBCM may provide better SE and a diagnostic advantage in instances of HG disease recurrence. FAU - Singer, Gad AU - Singer G AUID- ORCID: 0000-0001-8090-7267 AD - Institute of Pathology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Ramakrishnan, Venkat M AU - Ramakrishnan VM AD - Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Rogel, Uwe AU - Rogel U AD - Institute of Pathology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Schotzau, Andreas AU - Schotzau A AD - Eudox Statistics, CH-4000 Basel, Switzerland. FAU - Disteldorf, Daniel AU - Disteldorf D AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Maletzki, Philipp AU - Maletzki P AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Adank, Jean-Pascal AU - Adank JP AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Hofmann, Marc AU - Hofmann M AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Niemann, Tilo AU - Niemann T AUID- ORCID: 0000-0002-5384-2522 AD - Department of Radiology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Stadlmann, Sylvia AU - Stadlmann S AD - Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Nocito, Antonio AU - Nocito A AD - Department of Surgery, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Lehmann, Kurt AU - Lehmann K AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. FAU - Hefermehl, Lukas J AU - Hefermehl LJ AD - Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland. LA - eng PT - Journal Article DEP - 20220126 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8833571 OTO - NOTNLM OT - XPERT OT - biomarker OT - bladder carcinoma OT - mRNA OT - narrow band imaging OT - surveillance OT - test OT - urine COIS- The authors declare no conflict of interest. The funders had no role in study design, data collection, analyses, or interpretation, manuscript writing, or in the decision to publish the results. EDAT- 2022/02/16 06:00 MHDA- 2022/02/16 06:01 PMCR- 2022/01/26 CRDT- 2022/02/15 01:03 PHST- 2021/12/05 00:00 [received] PHST- 2022/01/16 00:00 [revised] PHST- 2022/01/19 00:00 [accepted] PHST- 2022/02/15 01:03 [entrez] PHST- 2022/02/16 06:00 [pubmed] PHST- 2022/02/16 06:01 [medline] PHST- 2022/01/26 00:00 [pmc-release] AID - cancers14030618 [pii] AID - cancers-14-00618 [pii] AID - 10.3390/cancers14030618 [doi] PST - epublish SO - Cancers (Basel). 2022 Jan 26;14(3):618. doi: 10.3390/cancers14030618. PMID- 35155263 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study. PG - 832835 LID - 10.3389/fonc.2022.832835 [doi] LID - 832835 AB - OBJECTIVES: To test the hypothesis that patients under active surveillance (AS) for Non-muscle Invasive Bladder Cancer (NMIBC) who were negative on longitudinal re-testing by the Xpert((R)) Bladder Cancer Monitor (Xpert BC Monitor) assay may avoid unnecessary cystoscopies and urine cytology (UC). SUBJECTS/PATIENTS OR MATERIALS AND METHODS: This is a prospective cohort study of patients enrolled in the AS protocol for recurrent NMIBC (Bladder Cancer Italian Active Surveillance, BIAS project), whose urine samples were analyzed by Xpert BC Monitor upon entry in the study (T0). Patients who had a negative Xpert test and did not fail AS, underwent additional Xpert tests after 4 (T1), 8 (T2), and 12 (T3) months. The clinical utility of Xpert was assessed by determining the number of cystoscopies and UC that could be avoided within 1 year. RESULTS: Overall, 139 patients were tested with Xpert at T0. Median follow-up was 23 (IQR 17-27) months. Sixty-eight (48.9%) patients failed AS, 65 (46.7%) are currently on AS, and 6 (4.3%) were lost at follow-up. At T0 57 (41.0%) patients had a negative test and 36 (63.2%) are still in AS. In patients with 2 consecutives negative Xpert tests, we could have avoided 73.9% of unnecessary cystoscopies, missing 26.4% failure, up to avoid all cystoscopies with 4 negative tests missing only 12% of failure. All the patients with negative Xpert had negative UC. Failure-free-survival at median follow-up (23 month) stratified for having 0, 1, or >/=2 negative tests was 67.0, 55.1. and 84.1, respectively. CONCLUSION: Our findings suggest that Xpert BC Monitor assay, when it is longitudinally repeated, could significantly reduce the number of unnecessary cystoscopies and UC during their follow-up. CI - Copyright (c) 2022 Fasulo, Paciotti, Lazzeri, Contieri, Casale, Saita, Lughezzani, Diana, Frego, Avolio, Colombo, Elefante, Guazzoni, Buffi, Bates and Hurle. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Diana, Pietro AU - Diana P AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Frego, Nicola AU - Frego N AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Avolio, Pier Paolo AU - Avolio PP AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Pathology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Elefante, Grazia Maria AU - Elefante GM AD - Department of Pathology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. FAU - Bates, Michael AU - Bates M AD - Medical and Scientific Affairs and Strategy, Oncology, Cepheid, Sunnyvale, CA, United States. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. LA - eng PT - Journal Article DEP - 20220127 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8830778 OTO - NOTNLM OT - BIAS OT - NMIBC OT - Xpert BC OT - active surveillance OT - biomarker OT - cystoscopies OT - urine cytology COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2022/01/01 CRDT- 2022/02/14 05:34 PHST- 2021/12/10 00:00 [received] PHST- 2022/01/03 00:00 [accepted] PHST- 2022/02/14 05:34 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.832835 [doi] PST - epublish SO - Front Oncol. 2022 Jan 27;12:832835. doi: 10.3389/fonc.2022.832835. eCollection 2022. PMID- 35152219 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 8 DP - 2022 TI - The Clinical Features of Incidentally Diagnosed Urothelial Bladder Cancer: A Retrospective Data Analysis. PG - 798-805 LID - 10.1159/000521684 [doi] AB - INTRODUCTION: The aim of this study was to evaluate the prevalence and clinical features of incidental bladder cancer (BC) diagnosis, with special emphasis on possible associations between incidental diagnosis and primary disease stage or grade. METHODS: We retrospectively included 501 consecutive patients who underwent transurethral resection of bladder tumor and were diagnosed with primary urothelial carcinoma of the bladder between January 2013 and February 2021 in a university hospital. The type of diagnosis (incidental or nonincidental), patient baseline characteristics and primary stage and grade were studied for interdependencies. RESULTS: 28.5% of all patients and 19.8% of high grade (HG) BC patients had been diagnosed incidentally, most commonly with ultrasound. Incidental diagnosis was associated with lower primary stage and grade of the disease. Most importantly, on multivariable analysis, which included baseline patient characteristics and type of diagnosis, in the subgroup of HG BC patients, muscle-invasive BC (MIBC) or metastatic disease was three times less likely to be diagnosed incidentally than non-MIBC (odds ratio: 0.31, 95% confidence interval: 0.14-0.71, p = 0.006). CONCLUSIONS: The study is first to demonstrate that incidental diagnosis of HG BC may be surprisingly prevalent and associated with lower rates of muscle invasion or metastatic disease. CI - (c) 2022 S. Karger AG, Basel. FAU - Kamecki, Hubert AU - Kamecki H AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. FAU - Debowska, Malgorzata AU - Debowska M AD - Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. AD - Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland. FAU - Nyk, Lukasz AU - Nyk L AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Przewor, Artur AU - Przewor A AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. FAU - Demkow, Tomasz AU - Demkow T AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. FAU - Sosnowski, Roman AU - Sosnowski R AD - Department of Urogenital Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20220211 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Data Analysis MH - Humans MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - Early detection of cancer OT - Incidental findings OT - Urinary bladder neoplasms EDAT- 2022/02/14 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/02/13 20:36 PHST- 2021/11/20 00:00 [received] PHST- 2021/12/20 00:00 [accepted] PHST- 2022/02/14 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/02/13 20:36 [entrez] AID - 000521684 [pii] AID - 10.1159/000521684 [doi] PST - ppublish SO - Urol Int. 2022;106(8):798-805. doi: 10.1159/000521684. Epub 2022 Feb 11. PMID- 35148949 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20220523 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 5 DP - 2022 May TI - Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort? PG - 196.e11-196.e16 LID - S1078-1439(21)00556-1 [pii] LID - 10.1016/j.urolonc.2021.12.008 [doi] AB - INTRODUCTION: Studies evaluating outcomes in bladder cancer sub stratified into T2a and T2b pathologic staging have demonstrated inconsistent results. Survival outcomes in a cohort of pure urothelial carcinoma patient undergoing radical cystectomy were evaluated to determine the prognostic value of T2 sub staging. METHODS: Using our prospectively maintained institutional cystectomy database, we identified patients with pure urothelial carcinoma of the bladder, either pT2aN0 or pT2bN0. We excluded any patients with variant histology, patients that underwent neoadjuvant chemotherapy, and patients that had margin positive disease. Demographic and clinicopathologic data were collected, and Cox proportional hazard regression assessed overall survival (OS), cancer specific survival (CSS), and recurrence free survival (RFS). RESULTS: From 2001 to 2019, we identified 1,929 patients that underwent radical cystectomy, 61 patients had pT2a and 65 had pT2b pure urothelial carcinoma that met inclusion criteria. Only age (P = 0.02) and the initial transurethral resection of bladder tumor pathology (P < 0.01) were notably different when comparing the clinical characteristics of patients with pT2a and pT2b. No differences were noted in OS, CSS, or RFS between the 2 groups on Kaplan-Meier analysis. On univariate Cox regression analysis, age, TURBT stage, cystectomy pathology stage, carcinoma in situ, and lymphovascular invasion status, and Bacillus Calmette-Guerin therapy status was not found to be significant factors for OS, CSS, or RFS between patients with pT2aN0 or pT2bN0 tumors. CONCLUSION: Prior studies have sub stratified pT2a and pT2b, studying survival outcomes with equivocal results. Many of these studies included variant histology or use of chemotherapy in the analysis. Here, we identified a pure urothelial cohort to compare survival outcomes between pT2a and pT2b and found no difference in OS, CSS, and RFS. CI - Published by Elsevier Inc. FAU - Tachibana, Isamu AU - Tachibana I AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: isatachi@iupui.edu. FAU - Mahmoud, Mohammad AU - Mahmoud M AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Abedali, Zain A AU - Abedali ZA AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Flack, Chandra AU - Flack C AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Adra, Nabil AU - Adra N AD - Department of Hematology & Medical Oncology, Indiana Unviersity School of Medicine, Indianapolis, IN. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, IN. FAU - Kaimaklitois, Hristos Z AU - Kaimaklitois HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. LA - eng PT - Journal Article DEP - 20220208 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Cohort Studies MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Neoplasm Staging MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Muscle invasive bladder cancer OT - Survival outcomes OT - Urothelial carcinoma EDAT- 2022/02/13 06:00 MHDA- 2022/05/11 06:00 CRDT- 2022/02/12 05:28 PHST- 2021/09/26 00:00 [received] PHST- 2021/11/15 00:00 [revised] PHST- 2021/12/12 00:00 [accepted] PHST- 2022/02/13 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/02/12 05:28 [entrez] AID - S1078-1439(21)00556-1 [pii] AID - 10.1016/j.urolonc.2021.12.008 [doi] PST - ppublish SO - Urol Oncol. 2022 May;40(5):196.e11-196.e16. doi: 10.1016/j.urolonc.2021.12.008. Epub 2022 Feb 8. PMID- 35142962 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20261010 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 27 IP - 5 DP - 2022 May TI - Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data. PG - 958-968 LID - 10.1007/s10147-022-02127-7 [doi] AB - BACKGROUND: This study investigated the clinical impact of carcinoma in situ (CIS) in intravesical Bacillus Calmette-Guerin (BCG) therapy for patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: This study retrospectively evaluated 3035 patients who were diagnosed with NMIBC and treated by intravesical BCG therapy between 2000 and 2019 at 31 institutions. Patients were divided into six groups according to the presence of CIS as follows: low-grade Ta without concomitant CIS, high-grade Ta without concomitant CIS, high-grade Ta with concomitant CIS, high-grade T1 without concomitant CIS, high-grade T1 with concomitant CIS, and pure CIS (without any papillary lesion). The endpoints were recurrence- and progression-free survival after the initiation of BCG therapy. We analyzed to identify factors associated with recurrence and progression. RESULTS: At a median follow-up of 44.4 months, recurrence and progression were observed in 955 (31.5%) and 316 (10.4%) patients, respectively. Comparison of six groups using univariate and multivariate analysis showed no significant association of CIS. However, CIS in the prostatic urethra was an independent factors associated with progression. CONCLUSION: Concomitant CIS did not show a significant impact in the analysis of Ta and T1 tumors which were treated using intravesical BCG. Concomitant CIS in the prostatic urethra was associated with high risk of progression. Alternative treatment approaches such as radical cystectomy should be considered for patients with NMIBC who have a risk of progression. CI - (c) 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. FAU - Tomida, Ryotaro AU - Tomida R AUID- ORCID: 0000-0002-2518-0197 AD - Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp. FAU - Minato, Ryoei AU - Minato R AD - Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan. FAU - Sawada, Yuichiro AU - Sawada Y AD - Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan. FAU - Matsumura, Masafumi AU - Matsumura M AD - Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Fukui, Shinji AU - Fukui S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan. FAU - Hongo, Fumiya AU - Hongo F AD - Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Metsuyama, Japan. CN - Japanese Urological Oncology Group LA - eng PT - Journal Article DEP - 20220210 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma in Situ/drug therapy/pathology MH - Cystectomy MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Carcinoma in situ OT - Non-muscle-invasive bladder cancer EDAT- 2022/02/11 06:00 MHDA- 2022/04/26 06:00 CRDT- 2022/02/10 12:15 PHST- 2021/09/06 00:00 [received] PHST- 2022/01/23 00:00 [accepted] PHST- 2022/02/11 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] PHST- 2022/02/10 12:15 [entrez] AID - 10.1007/s10147-022-02127-7 [pii] AID - 10.1007/s10147-022-02127-7 [doi] PST - ppublish SO - Int J Clin Oncol. 2022 May;27(5):958-968. doi: 10.1007/s10147-022-02127-7. Epub 2022 Feb 10. PMID- 35135701 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20220420 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 4 DP - 2022 Apr TI - Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons. PG - 165.e1-165.e8 LID - S1078-1439(21)00553-6 [pii] LID - 10.1016/j.urolonc.2021.12.006 [doi] AB - INTRODUCTION: A second transurethral resection of the bladder tumor (TURBT) within 2 - 6 weeks after initial TURBT is thought to have diagnostic, therapeutic, and prognostic benefits in T1 bladder cancer (BC). However, little is known about the real-world uptake of this guideline-endorsed intervention. We aimed (1) to measure re-resection rates over time, (2) to investigate if a guideline revision (April 2008) explicitly endorsing re-resection within 2 - 6 weeks in all T1 BC patients led to an increase in re-resection rates, and (3) to investigate the uptake among different groups of surgeons. METHODOLOGY: Province-wide BC pathology reports (January 2001 to December 2015; Ontario, Canada) were linked with health administrative data to (1) identify primary cases of T1 BC and to (2) ascertain whether these patients received re-resection. The resulting patients were then aggregated into quarterly time series and investigated by descriptive analysis, interventional autoregressive moving average (ARIMA) modeling, and Poisson regression analysis. RESULTS: A cohort of 7,373 patients was aggregated into a time series. We observed a linear increase in re-resection rates from 8.4% in 2001 to 28.3% in 2015. An actual effect of the guideline revision in April 2008 on re-resection rates could not be detected (P = 0.41). However, we observed a rather heterogeneous uptake behavior among different groups of surgeons. Specifically, female surgeons, more junior surgeons, high-volume surgeons, Canadian graduates, and surgeons without an academic affiliation were all independently more likely to re-resect their patients (all P-values < 0.05 in adjusted analysis). CONCLUSIONS: Re-resection rates in primary T1 BC increased between 2001 and 2015 in the province of Ontario regardless of the guideline revision in April 2008. Our study demonstrates that the uptake of this guideline-endorsed intervention varies among different groups of surgeons and therefore warrants further research to identify barriers to change that can be addressed by tailored interventions. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Wettstein, Marian S AU - Wettstein MS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto ON, Canada; ICES, Toronto, ON, Canada; Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Baxter, Nancy N AU - Baxter NN AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto ON, Canada; ICES, Toronto, ON, Canada. FAU - Sutradhar, Rinku AU - Sutradhar R AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto ON, Canada; ICES, Toronto, ON, Canada. FAU - Mamdani, Muhammad AU - Mamdani M AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto ON, Canada; ICES, Toronto, ON, Canada. FAU - Song, Pham AU - Song P AD - ICES, Toronto, ON, Canada. FAU - Qadri, Syed R AU - Qadri SR AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Li, Kathy AU - Li K AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Liu, Ning AU - Liu N AD - ICES, Toronto, ON, Canada. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto ON, Canada; ICES, Toronto, ON, Canada. Electronic address: girish.kulkarni@uhn.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220205 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Ontario MH - *Surgeons MH - Time Factors MH - *Urinary Bladder Neoplasms/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive bladder cancer OT - Population-based study OT - Re-resection OT - Time series analysis OT - Transurethral resection EDAT- 2022/02/10 06:00 MHDA- 2022/04/21 06:00 CRDT- 2022/02/09 05:41 PHST- 2021/08/06 00:00 [received] PHST- 2021/11/16 00:00 [revised] PHST- 2021/12/09 00:00 [accepted] PHST- 2022/02/10 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2022/02/09 05:41 [entrez] AID - S1078-1439(21)00553-6 [pii] AID - 10.1016/j.urolonc.2021.12.006 [doi] PST - ppublish SO - Urol Oncol. 2022 Apr;40(4):165.e1-165.e8. doi: 10.1016/j.urolonc.2021.12.006. Epub 2022 Feb 5. PMID- 35124930 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220208 IS - 1819-2718 (Electronic) IS - 1025-9589 (Linking) VI - 33 IP - 4 DP - 2021 Oct-Dec TI - Leiomyoma Urinary Bladder, Mimicking Urothelial Cancer. PG - 685-689 AB - Leiomyoma of the urinary bladder is a rare bladder tumour, which is benign in nature. On presentation, it resembles urothelial cancer but it has an excellent prognosis. We reported two cases of urinary bladder leiomyoma. Both the patients presented with lower urinary tract symptoms (LUTS) and the patient in the second case also had painless haematuria. Bladder mass was detected initially on ultrasound and confirmed on contrast-enhanced computed tomography (CT). Transurethral resection of bladder tumour was performed in both cases and no recurrence was found on initial follow-up. But the second case had haematuria and recurrence on subsequent follow-up and managed by performing a partial cystectomy. Endoscopic management of bladder leiomyoma is a safe treatment option for bladder leiomyoma and if multiple recurrences noted with symptoms, then partial cystectomy can be considered. Histopathology is the only definitive way of establishing the diagnosis. These patients can be followed up initially with cystoscopy, and if no recurrence is detected, subsequent follow-up can be carried out with ultrasound. FAU - Bangash, Muhibullah AU - Bangash M AD - Aga Khan University Hospital Karachi, Pakistan. FAU - Faruqui, Nuzhat AU - Faruqui N AD - Aga Khan University Hospital Karachi, Pakistan. FAU - Muhammad, Anis-Ul-Islam AU - Muhammad AU AD - Department of Urology, The Indus Hospital, Karachi, Pakistan. FAU - Uddin, Zeeshan AU - Uddin Z AD - Aga Khan University Hospital Karachi, Pakistan. LA - eng PT - Journal Article PL - Pakistan TA - J Ayub Med Coll Abbottabad JT - Journal of Ayub Medical College, Abbottabad : JAMC JID - 8910750 SB - IM MH - Cystectomy MH - Cystoscopy MH - Humans MH - *Leiomyoma/diagnostic imaging/surgery MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery OTO - NOTNLM OT - Transurethral resection of bladder tumour OT - Urinary bladder leiomyoma; Benign bladder lesion EDAT- 2022/02/07 06:00 MHDA- 2022/02/09 06:00 CRDT- 2022/02/06 20:41 PHST- 2022/02/06 20:41 [entrez] PHST- 2022/02/07 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] AID - 9180/3189 [pii] PST - ppublish SO - J Ayub Med Coll Abbottabad. 2021 Oct-Dec;33(4):685-689. PMID- 35124862 OWN - NLM STAT- MEDLINE DCOM- 20220916 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 9 DP - 2022 Sep TI - Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study. PG - 930-936 LID - 10.1111/iju.14808 [doi] AB - OBJECTIVES: Performing immediate radical cystectomy in all patients with the highest-risk non-muscle invasive bladder cancer results in overtreatment. We confirm whether the substratification of highest-risk patients can more effectively select suitable patients for radical cystectomy. METHODS: Patients with primary T1 high grade bladder cancer from two centers were included and roughly stratified into high-risk or highest-risk. The highest-risk patients were further substratified according to the number of risk factors. Endpoints were tumor recurrence and progression. The predictive accuracy was assessed with internal validation that consists of time-dependent receiver operating characteristic curve and calibration curves. RESULTS: A total of 262 patients were included. Although highest-risk patient had a poor prognosis, after further substratification, we found that those with only one factor showed the same prognosis with high-risk patients (recurrence: hazard ratio 1.79, P = 0.105; progression: hazard ratio 1.38, P = 0.532), while those with >/=2 factors had worst prognosis than high-risk patients. The 3-year area under the curve showed that the predictive accuracy of substratification in terms of recurrence and progression were superior to that of non-substratification (0.685 vs 0.622 and 0.666 vs 0.599, respectively). Additionally, calibration curves showed perfect agreement between the predicted and the actual recurrence and progression. CONCLUSIONS: Substratification of highest-risk enables us to further optimize the surgical decisions-making. Highest-risk patients with one factor show the similar outcomes as high-risk patients and deserve to try bladder-sparing treatment, whereas those with >/=2 risk factors were strongly recommended to undergo radical cystectomy. CI - (c) 2022 The Japanese Urological Association. FAU - Yang, Tao AU - Yang T AUID- ORCID: 0000-0002-3564-1495 AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Liang, Hua AU - Liang H AD - Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Pei, Xinqi AU - Pei X AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, China. FAU - Zhang, Nan AU - Zhang N AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Liang, Xiao AU - Liang X AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhang, Mengzhao AU - Zhang M AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Shao, Qiuya AU - Shao Q AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Lu AU - Wang L AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Ma, Minghai AU - Ma M AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Shi, Xinyu AU - Shi X AD - Department of Urology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Fan, Jinhai AU - Fan J AUID- ORCID: 0000-0002-0153-1159 AD - Departments of, Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. LA - eng GR - 2020SF-123/Key Research and Development Program of Department of Science and Technology of Shaanxi Province/ GR - 2019115713YX012SF048(4)/Medical Research Program of Department of Science and Technology of Xi'an/ PT - Journal Article DEP - 20220205 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2022 Sep;29(9):936-937. doi: 10.1111/iju.14828. PMID: 35170098 CIN - Int J Urol. 2022 Sep;29(9):937-938. doi: 10.1111/iju.14837. PMID: 35218081 MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy/methods MH - Humans MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - factor number OT - highest-risk OT - predictive accuracy OT - surgical decision-making OT - tumor outcomes EDAT- 2022/02/07 06:00 MHDA- 2022/09/17 06:00 CRDT- 2022/02/06 20:40 PHST- 2021/08/14 00:00 [received] PHST- 2022/01/13 00:00 [accepted] PHST- 2022/02/07 06:00 [pubmed] PHST- 2022/09/17 06:00 [medline] PHST- 2022/02/06 20:40 [entrez] AID - 10.1111/iju.14808 [doi] PST - ppublish SO - Int J Urol. 2022 Sep;29(9):930-936. doi: 10.1111/iju.14808. Epub 2022 Feb 5. PMID- 35124681 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 8 DP - 2022 TI - Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section. PG - 816-824 LID - 10.1159/000521804 [doi] AB - INTRODUCTION: Upper tract urinary cancer recurrence (UTUCR) after radical cystectomy (RC) is outcome-limiting. Surgical recommendations on intraoperative performance of frozen section analysis (FSA) and management of positive ureteral margin (PUM) are lacking. METHODS: 634 RC cases were identified (2010-2018). In patients with PUM, sequential ureteral resections up to a negative margin were performed. We investigated the accuracy of FSA, significance of PUM, and identified risk factors (RFs) to stratify patients for UTUCR. RESULTS: FSA was performed in 355 patients, including a total of 693 ureters. FSA sensitivity was 0.93 and specificity 0.99. PUM conversion was possible in 52 (91.2%) cases. UTUCR occurred in 17 (4.8%) patients. Identified UTUCR RFs are non-muscle invasive bladder carcinoma (NMIBC) (OR 3.8, 95% confidence intervals [CI] 1.4-10.2, p = 0.008), multifocal bladder cancer in cystectomy specimen (OR 4.7, CI 1.1-20.8, p = 0.042), and recurrent NMIBC (OR 4.1, CI 1.5-10.9, p = 0.006). Risk-group stratification showed a six-fold increase in UTUCR risk (low-to high-risk). CONCLUSION: FSA is a sensitive and specific method to identify PUM. UTUCR occurs significantly more often in patients with recurrent, multifocal NMIBC at the time of RC. Patients can be risk stratified for UTUCR. In case of NMIBC-PUM, surgeons can safely opt for a kidney preserving strategy. CI - (c) 2022 S. Karger AG, Basel. FAU - Nientiedt, Malin AU - Nientiedt M AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Waldbillig, Frank AU - Waldbillig F AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Stroop, Felix AU - Stroop F AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Nuhn, Philipp AU - Nuhn P AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Popovic, Zoran V AU - Popovic ZV AD - Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Weis, Cleo-Aron AU - Weis CA AD - Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Michel, Maurice Stephan AU - Michel MS AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Kriegmair, Maximilian C AU - Kriegmair MC AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. LA - eng PT - Journal Article DEP - 20220204 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - *Cystectomy/adverse effects/methods MH - Frozen Sections MH - Humans MH - Margins of Excision MH - Neoplasm Recurrence, Local/surgery MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Fresh frozen analysis OT - Surgical margin OT - Upper urinary tract carcinoma OT - Urothelial cancer EDAT- 2022/02/07 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/02/06 20:39 PHST- 2021/10/29 00:00 [received] PHST- 2021/12/27 00:00 [accepted] PHST- 2022/02/07 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/02/06 20:39 [entrez] AID - 000521804 [pii] AID - 10.1159/000521804 [doi] PST - ppublish SO - Urol Int. 2022;106(8):816-824. doi: 10.1159/000521804. Epub 2022 Feb 4. PMID- 35122124 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20240826 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 480 IP - 5 DP - 2022 May TI - T1 bladder carcinoma with variant histology: pathological features and clinical significance. PG - 989-998 LID - 10.1007/s00428-021-03264-6 [doi] AB - The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Overall, variant histology was identified as a significant predictor of disease-free survival (P = 0.035). The presence of any specific variant histology (squamous, glandular, micropapillary, nested, microcystic, inverted growth, villous-like, basaloid, and lymphoepithelioma-like) was identified as a significant predictor of disease-free survival (P = 0.008) and cancer-specific survival (P = 0.0001) in HGT1 bladder cancer. Therefore, our results support including micropapillary HGT1 urothelial carcinoma within the aggressive high-risk category, as suggested by some recent clinical guidelines, but also favor nested, glandular, and basaloid to be placed in the high-risk category due to their potential of aggressive, life-threatening behavior and their limited response to bacillus Calmette-Guerin therapy. Conversely, the low-risk category would include urothelial carcinomas with squamous, inverted growth, or microcystic morphology, all with limited life-threatening potential and good response to current therapy. A very low-risk category would finally include patients whose tumors present villous-like or lymphoepithelioma-like morphology. In conclusion, our findings support the value of reporting the variant histology as a feature of variable aggressiveness in HGT1 urothelial carcinoma of the bladder. CI - (c) 2022. The Author(s). FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AUID- ORCID: 0000-0003-3161-8164 AD - Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain. em1lobea@uco.es. FAU - Blanca, Ana AU - Blanca A AD - Maimonides Biomedical Research Institute of Cordoba, E-14004, Cordoba, Spain. FAU - Cimadamore, Alessia AU - Cimadamore A AUID- ORCID: 0000-0001-5981-3514 AD - Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy. FAU - Montironi, Rodolfo AU - Montironi R AUID- ORCID: 0000-0003-3938-610X AD - Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy. FAU - Luque, Rafael J AU - Luque RJ AUID- ORCID: 0000-0002-9808-784X AD - UGC Anatomia Patologica, Hospital Universitario de Jaen, Jaen, Spain. FAU - Volavsek, Metka AU - Volavsek M AUID- ORCID: 0000-0002-2878-4877 AD - Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Departments of Pathology and Laboratory Medicine and Urology, School of Medicine, Indiana University, Indianapolis, IN, USA. LA - eng GR - PI17/01981/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20220204 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM MH - *Carcinoma, Papillary/pathology MH - *Carcinoma, Squamous Cell/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Female MH - Humans MH - Male MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9033727 OTO - NOTNLM OT - Biomarker OT - Bladder OT - Staging OT - T1 urothelial carcinoma OT - Variant histology COIS- The authors declare no competing interests. EDAT- 2022/02/06 06:00 MHDA- 2022/04/27 06:00 PMCR- 2022/02/04 CRDT- 2022/02/05 05:50 PHST- 2021/10/29 00:00 [received] PHST- 2021/12/23 00:00 [accepted] PHST- 2021/12/13 00:00 [revised] PHST- 2022/02/06 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2022/02/05 05:50 [entrez] PHST- 2022/02/04 00:00 [pmc-release] AID - 10.1007/s00428-021-03264-6 [pii] AID - 3264 [pii] AID - 10.1007/s00428-021-03264-6 [doi] PST - ppublish SO - Virchows Arch. 2022 May;480(5):989-998. doi: 10.1007/s00428-021-03264-6. Epub 2022 Feb 4. PMID- 35116595 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 10 IP - 6 DP - 2021 Jun TI - Efficacy and toxicity in scheduled intravesical gemcitabine versus Bacille Calmette-Guerin for Ta and T1 bladder cancer: a systematic review and meta-analysis. PG - 2849-2858 LID - 10.21037/tcr-21-291 [doi] AB - BACKGROUND: We conducted a meta-analysis to compare the efficacy and toxicity of scheduled intravesical gemcitabine (GEM) and Bacille Calmette-Guerin (BCG) for Ta and T1 non-muscle invasive bladder cancer (NMIBC). METHODS: The database search was performed in Ovid Medline, Embase, Web of Science, Cochrane Library from the commencement of the database to July 7, 2020. Trials using immediate instillation were excluded and we present the included studies in accordance with the PRISMA 2020 reporting checklist. The data extracted was analyzed using Stata 11.0 software. RESULTS: Six studies of 466 patients comparing GEM and BCG were finally included. No significant difference was detected between GEM and BCG group in recurrence free survival [hazard ratio (HR) =0.80, 95% confidence interval (95% CI), 0.46-1.37, P=0.410], progression free survival (HR =0.82, 95% CI, 0.38-1.77, P=0.621), and total adverse events [odds ratio (OR) =0.70, 95% CI, 0.38-1.29, P=0.253). However, patients receiving GEM treatment are less likely to develop urinary adverse events, such as dysuria (OR =0.50, 95% CI, 0.29-0.87) and hematuria (OR =0.40, 95% CI, 0.18-0.91). We performed subgroup analysis and found that the effects of GEM and BCG were similar even on patients with high recurrence risk tumor. Sensitivity analysis showed the robustness of the results. DISCUSSION: Scheduled intravesical GEM instillation has a similar effect with BCG instillation in preventing NMIBC recurrence and progression, but GEM therapy causes a lower incidence of dysuria and hematuria than BCG. GEM may be an alternative therapy for BCG. However, the results should be treated with caution due to the low to moderate quality of the included studies. CI - 2021 Translational Cancer Research. All rights reserved. FAU - Lu, Jun-Lin AU - Lu JL AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Chen-Qian AU - Liu CQ AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Jian-Xuan AU - Sun JX AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Yang, Yuan-Yuan AU - Yang YY AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Heng-Long AU - Hu HL AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC8797991 OTO - NOTNLM OT - Bacille Calmette-Guerin (BCG) OT - Gemcitabine OT - meta-analysis OT - non-muscle invasive bladder cancer (NMIBC) OT - tumor recurrence COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tcr-21-291). The authors have no conflicts of interest to declare. EDAT- 2022/02/05 06:00 MHDA- 2022/02/05 06:01 PMCR- 2021/06/01 CRDT- 2022/02/04 05:49 PHST- 2021/02/16 00:00 [received] PHST- 2021/04/16 00:00 [accepted] PHST- 2022/02/04 05:49 [entrez] PHST- 2022/02/05 06:00 [pubmed] PHST- 2022/02/05 06:01 [medline] PHST- 2021/06/01 00:00 [pmc-release] AID - tcr-10-06-2849 [pii] AID - 10.21037/tcr-21-291 [doi] PST - ppublish SO - Transl Cancer Res. 2021 Jun;10(6):2849-2858. doi: 10.21037/tcr-21-291. PMID- 35109796 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20221207 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Feb 2 TI - Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. PG - 131 LID - 10.1186/s12885-021-09168-7 [doi] LID - 131 AB - BACKGROUND: The response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) is impaired in up to 50% of patients due to chemoresistance, with no predictive biomarkers in clinical use. The proto-oncogene RNA-binding motif protein 3 (RBM3) has emerged as a putative modulator of chemotherapy response in several solid tumours but has a hitherto unrecognized role in MIBC. METHODS: RBM3 protein expression level in tumour cells was assessed via immunohistochemistry in paired transurethral resection of the bladder (TURB) specimens, cystectomy specimens and lymph node metastases from a consecutive cohort of 145 patients, 65 of whom were treated with NAC. Kaplan-Meier and Cox regression analyses were applied to estimate the impact of RBM3 expression on time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) in strata according to NAC treatment. The effect of siRNA-mediated silencing of RBM3 on chemosensitivity was examined in RT4 and T24 human bladder carcinoma cells in vitro. Cellular functions of RBM3 were assessed using RNA-sequencing and gene ontology analysis, followed by investigation of cell cycle distribution using flow cytometry. RESULTS: RBM3 protein expression was significantly higher in TURB compared to cystectomy specimens but showed consistency between primary tumours and lymph node metastases. Patients with high-tumour specific RBM3 expression treated with NAC had a significantly reduced risk of recurrence and a prolonged CSS and OS compared to NAC-untreated patients. In high-grade T24 carcinoma cells, which expressed higher RBM3 mRNA levels compared to RT4 cells, RBM3 silencing conferred a decreased sensitivity to cisplatin and gemcitabine. Transcriptomic analysis revealed potential involvement of RBM3 in facilitating cell cycle progression, in particular G(1)/S-phase transition, and initiation of DNA replication. Furthermore, siRBM3-transfected T24 cells displayed an accumulation of cells residing in the G(1)-phase as well as altered levels of recognised regulators of G(1)-phase progression, including Cyclin D1/CDK4 and CDK2. CONCLUSIONS: The presented data highlight the potential value of RBM3 as a predictive biomarker of chemotherapy response in MIBC, which could, if prospectively validated, improve treatment stratification of patients with this aggressive disease. CI - (c) 2022. The Author(s). FAU - Wahlin, Sara AU - Wahlin S AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. Sara.wahlin@med.lu.se. FAU - Boman, Karolina AU - Boman K AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Moran, Bruce AU - Moran B AD - UCD School of Biomolecular and Biomedical Sciences, UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland. FAU - Nodin, Bjorn AU - Nodin B AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Gallagher, William M AU - Gallagher WM AD - UCD School of Biomolecular and Biomedical Sciences, UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland. FAU - Karnevi, Emelie AU - Karnevi E AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Jirstrom, Karin AU - Jirstrom K AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. LA - eng PT - Journal Article DEP - 20220202 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (RBM3 protein, human) RN - 0 (RNA-Binding Proteins) RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/*metabolism MH - Cell Line, Tumor MH - Cisplatin/therapeutic use MH - Cohort Studies MH - Deoxycytidine/analogs & derivatives/therapeutic use MH - Drug Resistance, Neoplasm/*drug effects MH - Female MH - Gene Expression Profiling MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - RNA-Binding Proteins/genetics/*metabolism MH - Resting Phase, Cell Cycle MH - Survival Analysis MH - Sweden MH - Urinary Bladder Neoplasms/metabolism/mortality/*pathology/therapy MH - Gemcitabine PMC - PMC8811987 OTO - NOTNLM OT - Biomarker OT - Cell cycle OT - Chemotherapy response OT - Muscle-invasive bladder cancer OT - Prediction OT - RBM3 COIS- W.M. Gallagher is a co-founder, shareholder and Chief Scientific Officer in OncoMark Limited, and reports receiving commercial research grants from and is an unpaid Scientific Advisory Board member with Carrick Therapeutics. The other authors declare no competing interest. EDAT- 2022/02/04 06:00 MHDA- 2022/03/08 06:00 PMCR- 2022/02/02 CRDT- 2022/02/03 05:27 PHST- 2021/05/16 00:00 [received] PHST- 2021/12/24 00:00 [accepted] PHST- 2022/02/03 05:27 [entrez] PHST- 2022/02/04 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2022/02/02 00:00 [pmc-release] AID - 10.1186/s12885-021-09168-7 [pii] AID - 9168 [pii] AID - 10.1186/s12885-021-09168-7 [doi] PST - epublish SO - BMC Cancer. 2022 Feb 2;22(1):131. doi: 10.1186/s12885-021-09168-7. PMID- 35105509 OWN - NLM STAT- MEDLINE DCOM- 20220530 LR - 20220601 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 3 DP - 2022 Jun TI - The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. PG - e190-e198 LID - S1558-7673(21)00236-6 [pii] LID - 10.1016/j.clgc.2021.12.006 [doi] AB - INTRODUCTION: The prognostic role of prior history of bladder cancer (BCa) among patients treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is poorly addressed. We aimed to investigate the role of prior BCa on any recurrence, distant metastases, and bladder recurrence following RNU among low-grade (LG) and high-grade (HG) UTUC patients. PATIENTS AND METHODS: We retrospectively analyzed 1,580 UTUC patients treated with RNU at 8 tertiary referral centers between 1992 and 2016. Any recurrence was defined as recurrence in the urinary tract, in the resection bed, or distant metastases (defined as disease outside the urinary tract and regional lymph nodes). Time to recurrence was computed from RNU. Multivariable Cox models were generated to predict risk of any recurrence, distant metastases, and bladder recurrence according to prior BCa history, coded as no prior BCa, non-muscle-invasive (NMIBC), and muscle-invasive BCa (MIBC). RESULTS: Median follow-up for survivors was 4 years. Overall, 71%, 25%, and 4% of patients had no prior BCa, NMIBC and MIBC. 5-year any recurrence-free survival was 61%, 41%, and 19% in LG (P < .001) and 42%, 34%, and 30% in HG patients (P = .1) with no prior BCa, NMIBC, and MIBC. On multivariable models, LG patients with NMIBC and MIBC showed a significantly higher risk of any recurrence compared to no prior BCa (both p .05) and 68%, 75%, and 45% in HG patients (P = .01) with no prior BCa, NMIBC, and MIBC. Previous NMIBC increased the risk of bladder recurrence among LG (P < .001) and HG (P = .003) patients. CONCLUSIONS: UTUC patients with prior history of BCa exhibit a higher risk of any recurrence after RNU. Our study provides important information which could address patient's counseling and decision-making process. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. Electronic address: a.martini.md@gmail.com. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Clinica Luganese Moncucco, Lugano, Switzerland; Clinica S.Anna, Swiss Medical Group, Sorengo, Switzerland; Clinica Santa Chiara, Locarno, Switzerland. FAU - Ploussard, Guillaume AU - Ploussard G AD - Department of Urology, CHU-Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; Department of Urology, La Croix du Sud Hospital, Toulouse, France. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, PARIS, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat Hospital, Paris Descartes University, Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; The National Center for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. LA - eng PT - Journal Article DEP - 20211211 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Neoplasm Recurrence, Local/pathology MH - Nephroureterectomy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder Cancer OT - Distant Metastasis OT - Recurrence OT - UTUC OT - Upper Tract Urothelial Carcinoma EDAT- 2022/02/03 06:00 MHDA- 2022/05/31 06:00 CRDT- 2022/02/02 05:31 PHST- 2021/05/27 00:00 [received] PHST- 2021/12/04 00:00 [revised] PHST- 2021/12/06 00:00 [accepted] PHST- 2022/02/03 06:00 [pubmed] PHST- 2022/05/31 06:00 [medline] PHST- 2022/02/02 05:31 [entrez] AID - S1558-7673(21)00236-6 [pii] AID - 10.1016/j.clgc.2021.12.006 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Jun;20(3):e190-e198. doi: 10.1016/j.clgc.2021.12.006. Epub 2021 Dec 11. PMID- 35098169 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220430 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 36 DP - 2022 Feb TI - Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. PG - 26-33 LID - 10.1016/j.euros.2021.11.011 [doi] AB - BACKGROUND: The role of serum lymphocyte-based biomarkers, such as the neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios, was previously studied in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy but remains underexplored in patients treated with trimodal therapy (TMT). OBJECTIVE: To analyze the impact of serum lymphocyte-based biomarkers on main oncological outcomes after TMT for MIBC. DESIGN SETTING AND PARTICIPANTS: A retrospective study, including 176 patients treated with TMT for nonmetastatic MIBC (cT2-4/cN0-2) between 2001 and 2017 at a tertiary academic center, was conducted. INTERVENTION: TMT, consisting of initial maximal transurethral resection of the bladder tumor, followed by radiotherapy with concurrent chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinicopathological characteristics, serum laboratory tests, and imaging reports were collected. NLR, LMR, and PLR were calculated before and at the end of TMT. Dynamic patterns of NLR, LMR, and PLR during TMT were studied. Multivariable regression models were performed to estimate the effect of these biomarkers on complete response (CR) to TMT and survival. RESULTS AND LIMITATIONS: The median age was 75 yr (interquartile range 66-82). Staging was cT2 in 156 (89%) and cN0 in 159 (90%) patients. A pretreatment NLR (pre-NLR) of >/=4.0 was independently associated with lower CR rates (odds ratio 0.32; p = 0.013). In addition, a pre-NLR of >/=4.0 was associated with worse cancer-specific survival (hazard ratio [HR] 1.88; p = 0.032) and overall survival (OS; HR 1.61; p = 0.033) together with other factors such as hydronephrosis, Eastern Cooperative Oncology Group performance status, and cT stage 3-4a. When both pre- and post-treatment variables were considered, an increase in NLR beyond 75% during TMT (HR 1.63; p = 0.035) was associated with worse OS. This study was limited by its retrospective design. CONCLUSIONS: A high pre-NLR value was independently associated with lower rates of CR and worse survival in MIBC patients undergoing TMT. Prospective validation is needed to implement NLR into clinical practice. PATIENT SUMMARY: In this study, we reported the oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal therapy. We found that the neutrophil-to-lymphocyte ratio, a cheap and available blood-derived biomarker, was associated with response to trimodal therapy and survival outcomes. CI - (c) 2021 The Authors. FAU - Kool, Ronald AU - Kool R AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Marcq, Gautier AU - Marcq G AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Shinde-Jadhav, Surashri AU - Shinde-Jadhav S AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Mansure, Jose Joao AU - Mansure JJ AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Saleh, Ramy AU - Saleh R AD - Division of Medical Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Rajan, Raghu AU - Rajan R AD - Division of Medical Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Aprikian, Armen AU - Aprikian A AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Tanguay, Simon AU - Tanguay S AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Cury, Fabio L AU - Cury FL AD - Experimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada. AD - Division of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Brimo, Fadi AU - Brimo F AD - Department of Pathology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Souhami, Luis AU - Souhami L AD - Division of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada. LA - eng PT - Journal Article DEP - 20211223 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8783035 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Prognosis OT - Radiotherapy EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2021/12/23 CRDT- 2022/01/31 06:04 PHST- 2021/11/25 00:00 [accepted] PHST- 2022/01/31 06:04 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2021/12/23 00:00 [pmc-release] AID - S2666-1683(21)03389-9 [pii] AID - 10.1016/j.euros.2021.11.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2021 Dec 23;36:26-33. doi: 10.1016/j.euros.2021.11.011. eCollection 2022 Feb. PMID- 35096575 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220430 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan. PG - 766576 LID - 10.3389/fonc.2021.766576 [doi] LID - 766576 AB - BACKGROUND: Taiwan is one of the endemic regions where upper tract urothelial carcinoma (UTUC) accounts for approximately a third of all urothelial tumors. Owing to its high prevalence, extensive experience has been accumulated in minimally invasive radical nephroureterectomy (RNU). Although a variety of predictive factors have been explored in numerous studies, most of them were on a single-center or limited institutional basis and data from a domestic cohort are lacking. OBJECTIVE: This study aims to identify significant predicting factors of oncological outcomes, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IVRFS), following RNU for UTUC in Taiwan. METHODS: A multicenter registry database, Taiwan UTUC Collaboration Group, was utilized to analyze oncological outcomes of 3,333 patients undergoing RNU from 1988 to 2021 among various hospitals in Taiwan. Clinicopathological parameters were recorded according to the principles established by consensus meetings. The Kaplan-Meier estimator was utilized to estimate the survival rates, and the curves were compared using the stratified log-rank test. Univariate and multivariate analyses were performed with the Cox proportional hazard model to explore potential predicting factors. RESULTS: With a median follow-up of 41.8 months in 1,808 patients with complete information, the 5-year IVRFS, DFS, CSS, and OS probabilities were 66%, 72%, 81%, and 70%, respectively. In total, 482 patients experienced intravesical recurrence, 307 died of UTUC, and 583 died of any cause. Gender predominance was female (57%). A total of 1,531 patients (84.7%) had high-grade tumors; preoperative hydronephrosis presented in 1,094 patients (60.5%). Synchronous bladder UC was identified in 292 patients (16.2%). Minimally invasive procedures accounted for 78.8% of all surgeries, including 768 hand-assisted laparoscopic (42.5%) and 494 laparoscopic (27.3%) approaches. Synchronous bladder UC was the dominant adverse predicting factor for all survival outcomes. Other independent predicting factors for OS, CSS, and DFS included age >==70, presence of preoperative hydronephrosis, positive surgical margin, LVI, pathological T and N staging, and laparoscopic RNU. CONCLUSION: Synchronous UC of the urinary bladder is an independent adverse prognostic factor for survival in UTUC. The presence of preoperative hydronephrosis was also corroborated as a disadvantageous prognostic factor. Our multivariate analysis suggested that laparoscopic RNU might provide better oncological control. CI - Copyright (c) 2022 Chen, Chang, Huang, Wu, Li, Chen, Huang, Lo, Yu, Tsai, Wu, Tseng, Lin, Jiang, Lee, Jou, Cheong, Hsueh, Chiu, Chen, Chen, Chiang, Tsai, Lin, Wu, Lin and Yu. FAU - Chen, I-Hsuan Alan AU - Chen IA AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. AD - Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. FAU - Chang, Chao-Hsiang AU - Chang CH AD - Department of Urology, China Medical University and Hospital, Taichung, Taiwan. AD - School of Medicine, China Medical University, Taichung, Taiwan. FAU - Huang, Chi-Ping AU - Huang CP AD - Department of Urology, China Medical University and Hospital, Taichung, Taiwan. AD - School of Medicine, China Medical University, Taichung, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Chen, Chung-Hsin AU - Chen CH AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Huang, Chao-Yuan AU - Huang CY AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Lo, Chi-Wen AU - Lo CW AD - Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan. FAU - Yu, Chih-Chin AU - Yu CC AD - Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan. AD - School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan. FAU - Tsai, Chung-You AU - Tsai CY AD - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan. AD - Department of Healthcare Information and Management, Ming Chuan University, Taipei, Taiwan. FAU - Wu, Wei-Che AU - Wu WC AD - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan. AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. FAU - Tseng, Jen-Shu AU - Tseng JS AD - Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, Mackay Medical College, Taipei, Taiwan. FAU - Lin, Wun-Rong AU - Lin WR AD - Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, Mackay Medical College, Taipei, Taiwan. FAU - Jiang, Yuan-Hong AU - Jiang YH AD - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan. FAU - Lee, Yu-Khun AU - Lee YK AD - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan. FAU - Jou, Yeong-Chin AU - Jou YC AD - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan. AD - Department of Health and Nutrition Biotechnology, Asian University, Taichung, Taiwan. FAU - Cheong, Ian-Seng AU - Cheong IS AD - Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan. FAU - Hsueh, Thomas Y AU - Hsueh TY AD - Division of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei, Taiwan. AD - Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Chiu, Allen W AU - Chiu AW AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Chen, Yung-Tai AU - Chen YT AD - Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan. FAU - Chen, Jih-Sheng AU - Chen JS AD - Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan. FAU - Chiang, Bing-Juin AU - Chiang BJ AD - College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan. AD - Department of Urology, Cardinal Tien Hospital, New Taipei City, Taiwan. AD - Department of Life Science, College of Science, National Taiwan Normal University, Taipei, Taiwan. FAU - Tsai, Yao-Chou AU - Tsai YC AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. AD - Department of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Lin, Wei Yu AU - Lin WY AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan. AD - Chang Gung University of Science and Technology, Chia-Yi, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Wu, Chia-Chang AU - Wu CC AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei, Taiwan. AD - TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan. FAU - Lin, Jen-Tai AU - Lin JT AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Yu, Chia-Cheng AU - Yu CC AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20220113 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8793058 OTO - NOTNLM OT - kidney pelvis OT - nephroureterectomy OT - risk factors OT - survival OT - ureter OT - urinary bladder OT - urinary tract OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2021/01/01 CRDT- 2022/01/31 05:59 PHST- 2021/09/17 00:00 [received] PHST- 2021/12/21 00:00 [accepted] PHST- 2022/01/31 05:59 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.766576 [doi] PST - epublish SO - Front Oncol. 2022 Jan 13;11:766576. doi: 10.3389/fonc.2021.766576. eCollection 2021. PMID- 35089812 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20261001 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 40 IP - 12 DP - 2022 Apr 20 TI - Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. PG - 1312-1322 LID - 10.1200/JCO.21.01485 [doi] AB - PURPOSE: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC. METHODS: Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non-muscle-invasive downstaging to < pT2N0. RESULTS: Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with >/= pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)-positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were >/= pT2N0 (P = .3 for association between PD-L1 and < pT2N0). CONCLUSION: Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker. FAU - Funt, Samuel A AU - Funt SA AUID- ORCID: 0000-0002-7235-6319 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Lattanzi, Michael AU - Lattanzi M AUID- ORCID: 0000-0002-6500-4753 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Whiting, Karissa AU - Whiting K AUID- ORCID: 0000-0002-4683-1868 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AUID- ORCID: 0000-0002-2938-6627 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Quinlan, Colleen AU - Quinlan C AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Teo, Min Yuen AU - Teo MY AUID- ORCID: 0000-0003-2511-6731 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Lee, Chung-Han AU - Lee CH AUID- ORCID: 0000-0001-5511-0635 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Aggen, David AU - Aggen D AUID- ORCID: 0000-0003-3963-5751 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Zimmerman, Danielle AU - Zimmerman D AUID- ORCID: 0000-0003-2189-2864 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - McHugh, Deaglan AU - McHugh D AUID- ORCID: 0000-0003-1477-0105 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Apollo, Arlyn AU - Apollo A AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Durdin, Trey D AU - Durdin TD AUID- ORCID: 0000-0003-3441-0799 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Truong, Hong AU - Truong H AUID- ORCID: 0000-0002-0225-0148 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Kamradt, Jeffrey AU - Kamradt J AD - Hartford Healthcare Medical Group, Hartford, CT. FAU - Khalil, Maged AU - Khalil M AD - Lehigh Valley Health Network, Allentown, PA. FAU - Lash, Bradley AU - Lash B AD - Lehigh Valley Health Network, Allentown, PA. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - McCoy, Asia S AU - McCoy AS AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Hettich, Grace AU - Hettich G AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Regazzi, Ashley AU - Regazzi A AUID- ORCID: 0000-0002-6019-1852 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Jihad, Marwah AU - Jihad M AUID- ORCID: 0000-0002-9121-8974 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Ratna, Neha AU - Ratna N AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Boswell, Abigail AU - Boswell A AUID- ORCID: 0000-0002-5245-6400 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Francese, Kaitlyn AU - Francese K AD - New York University Langone Medical Center, New York, NY. FAU - Yang, Yuanquan AU - Yang Y AD - Ohio State University Wexner Medical Center, Columbus, OH. FAU - Folefac, Edmund AU - Folefac E AUID- ORCID: 0000-0002-8753-2311 AD - Ohio State University Wexner Medical Center, Columbus, OH. FAU - Herr, Harry W AU - Herr HW AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Donat, S Machele AU - Donat SM AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Pietzak, Eugene AU - Pietzak E AUID- ORCID: 0000-0002-5121-5701 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Cha, Eugene K AU - Cha EK AUID- ORCID: 0000-0002-8807-2353 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Donahue, Timothy F AU - Donahue TF AUID- ORCID: 0000-0003-1855-1794 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Goh, Alvin C AU - Goh AC AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Huang, William C AU - Huang WC AUID- ORCID: 0000-0001-5261-0650 AD - New York University Langone Medical Center, New York, NY. FAU - Bajorin, Dean F AU - Bajorin DF AUID- ORCID: 0000-0003-4001-7088 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Iyer, Gopa AU - Iyer G AUID- ORCID: 0000-0002-5093-6099 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. FAU - Bochner, Bernard H AU - Bochner BH AUID- ORCID: 0000-0003-0846-0848 AD - Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Balar, Arjun V AU - Balar AV AUID- ORCID: 0000-0003-3949-5656 AD - New York University Langone Medical Center, New York, NY. FAU - Mortazavi, Amir AU - Mortazavi A AUID- ORCID: 0000-0002-2122-6805 AD - Ohio State University Wexner Medical Center, Columbus, OH. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AUID- ORCID: 0000-0003-2637-4249 AD - Memorial Sloan Kettering Cancer Center, New York, NY. AD - Weill Cornell Medical College, New York, NY. LA - eng SI - ClinicalTrials.gov/NCT02989584 GR - P30 CA008748/CA/NCI NIH HHS/United States GR - R25 CA068647/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - UL1 TR002384/TR/NCATS NIH HHS/United States GR - T32 CA082088/CA/NCI NIH HHS/United States GR - UL1 TR001873/TR/NCATS NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220128 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (B7-H1 Antigen) RN - 0W860991D6 (Deoxycytidine) RN - 52CMI0WC3Y (atezolizumab) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM CIN - J Clin Oncol. 2022 Aug 10;40(23):2656. doi: 10.1200/JCO.22.00420. PMID: 35609220 MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - B7-H1 Antigen/therapeutic use MH - Cisplatin/therapeutic use MH - Cystectomy MH - Deoxycytidine/analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Male MH - Muscles MH - *Neoadjuvant Therapy/adverse effects MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery MH - Gemcitabine PMC - PMC9797229 COIS- Samuel A. FuntEmployment: ByHeart (I)Stock and Other Ownership Interests: Kite, a Gilead company, Urogen pharma, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, Vida Ventures, IconOVir BioConsulting or Advisory Role: Merck, ImmunaiResearch Funding: Genentech/Roche (Inst), AstraZeneca (Inst), Decibel Therapeutics (Inst)Travel, Accommodations, Expenses: Bristol Myers Squibb, AstraZeneca/MedImmune Hikmat Al-AhmadieConsulting or Advisory Role: Bristol Myers Squibb, EMD Serono, AstraZeneca/MedImmune, Janssen Biotech, PAIGE.AI Min Yuen TeoConsulting or Advisory Role: Janssen OncologyResearch Funding: Bristol Myers Squibb (Inst), Clovis Oncology (Inst), Pharmacyclics (Inst) Chung-Han LeeHonoraria: Intellisphere, Research to Practice, American Institute of Continuing Medical EducationConsulting or Advisory Role: Eisai, Bristol Myers Squibb, Merck, Pfizer/EMD Serono, ExelixisResearch Funding: Eisai (Inst), Bristol Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst), Merck (Inst) David AggenConsulting or Advisory Role: Boehringer Ingelheim, Seattle Genetics, Astellas PharmaPatents, Royalties, Other Intellectual Property: University of Illinois-Urbana Champaign(OPTIONAL) Open Payments Link: https://openpaymentsdata.cms.gov/physician/4226107 Deaglan McHughConsulting or Advisory Role: Progenics Arlyn ApolloEmployment: Covera Health (I)Leadership: Covera Health (I)Stock and Other Ownership Interests: Covera Health (I)Consulting or Advisory Role: Covera Health (I)Travel, Accommodations, Expenses: Covera Health (I) Kaitlyn FranceseConsulting or Advisory Role: Seattle Genetics, Astellas Pharma Yuanquan YangStock and Other Ownership Interests: Bristol Myers Squibb, Pfizer, AstraZenecaConsulting or Advisory Role: The Whiteoak Group Eugene PietzakHonoraria: UpToDateConsulting or Advisory Role: Merck, Chugai Pharma, QED Therapeutics, Janssen Alvin C. GohConsulting or Advisory Role: MedtronicTravel, Accommodations, Expenses: Medtronic William C. HuangHonoraria: Urogen pharmaConsulting or Advisory Role: Intuitive SurgicalResearch Funding: SonaCare Medical, photocure, Storz, Storz, Merck (Inst), Intuitive Surgical (Inst)Travel, Accommodations, Expenses: Photocure Dean F. BajorinConsulting or Advisory Role: Merck, Dragonfly Therapeutics, Fidia Farmaceutici S. p. A, Bristol Myers Squibb FoundationResearch Funding: Novartis (Inst), Merck (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Astellas Pharma (Inst), Seattle Genetics/Astellas (Inst)Travel, Accommodations, Expenses: Merck Gopa IyerConsulting or Advisory Role: Bayer, Janssen, Mirati Therapeutics, Basilea, Flare Therapeutics, Loxo/LillySpeakers' Bureau: Gilead Sciences, The Lynx GroupResearch Funding: Mirati Therapeutics (Inst), Novartis (Inst), Debiopharm Group (Inst), Bayer (Inst), Janssen (Inst), Seattle Genetics (Inst) Bernard H. BochnerConsulting or Advisory Role: Olympus Arjun V. BalarLeadership: GT BiopharmaStock and Other Ownership Interests: GT BiopharmaHonoraria: Merck, Genentech/Roche, AstraZeneca/MedImmuneConsulting or Advisory Role: Genentech/Roche, Merck, Cerulean Pharma, AstraZeneca/MedImmune, Pfizer/EMD Serono, Incyte, Seattle Genetics/Astellas, Nektar, Dragonfly Therapeutics, GlaxoSmithKline, Bristol Myers Squibb/CelgeneResearch Funding: Merck (Inst), Genentech/Roche (Inst), AstraZeneca/MedImmune (Inst), Seattle Genetics, Gilead Sciences (Inst) Amir MortazaviHonoraria: Motive Medical IntelligenceConsulting or Advisory Role: Seattle Genetics, Debiopharm Group, PfizerResearch Funding: Acerta Pharma (Inst), Genentech/Roche (Inst), Merck (Inst), Novartis (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Bristol Myers Squibb (Inst), Roche (Inst), Astellas Pharma (Inst), Debiopharm Group (Inst), Debiopharm Group (Inst) Jonathan E. RosenbergHonoraria: UpToDate, Medscape, Peerview, Research To Practice, Intellisphere, Clinical Care Options, Physicans' Education Resource, MJH Life Sciences, EMD SeronoConsulting or Advisory Role: Lilly, Merck, Roche/Genentech, AstraZeneca/MedImmune, Bristol Myers Squibb, Seattle Genetics, Bayer, BioClin Therapeutics, QED Therapeutics, Adicet Bio, Pharmacyclics, western oncolytics, GlaxoSmithKline, Janssen Oncology, Astellas Pharma, Boehringer Ingelheim, Pfizer/EMD Serono, Mirati Therapeutics, Immunomedics, Tyra Biosciences, Infinity PharmaceuticalsResearch Funding: Genentech/Roche (Inst), Seattle Genetics (Inst), Bayer (Inst), AstraZeneca (Inst), QED Therapeutics (Inst), Astellas Pharma (Inst)Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity (Inst)No other potential conflicts of interest were reported. EDAT- 2022/01/29 06:00 MHDA- 2022/04/20 06:00 PMCR- 2023/04/20 CRDT- 2022/01/28 17:10 PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] PHST- 2022/01/28 17:10 [entrez] PHST- 2023/04/20 00:00 [pmc-release] AID - JCO.21.01485 [pii] AID - 10.1200/JCO.21.01485 [doi] PST - ppublish SO - J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. PMID- 35087575 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220129 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 12 DP - 2021 TI - Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. PG - 825109 LID - 10.3389/fgene.2021.825109 [doi] LID - 825109 AB - N6-methyladenosine (m6A) is a dynamic, reversible post-transcriptional modification, and the most common internal modification of eukaryotic messenger RNA (mRNA). Considerable evidence now shows that m6A alters gene expression, thereby regulating cell self-renewal, differentiation, invasion, and apoptotic processes. M6A methylation disorders are directly related to abnormal RNA metabolism, which may lead to tumor formation. M6A methyltransferase is the dominant catalyst during m6A modification; it removes m6A demethylase, promotes recognition by m6A binding proteins, and regulates mRNA metabolic processes. Bladder cancer (BC) is a urinary system malignant tumor, with complex etiology and high incidence rates. A well-differentiated or moderately differentiated pathological type at initial diagnosis accounts for most patients with BC. For differentiated superficial bladder urothelial carcinoma, the prognosis is normally good after surgery. However, due to poor epithelial cell differentiation, BC urothelial cell proliferation and infiltration may lead to invasive or metastatic BC, which lowers the 5-years survival rate and significantly affects clinical treatments in elderly patients. Here, we review the latest progress in m6A RNA methylation research and investigate its regulation on BC occurrence and development. CI - Copyright (c) 2022 Liu. FAU - Liu, Qiang AU - Liu Q AD - Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China. LA - eng PT - Journal Article PT - Review DEP - 20220111 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC8787278 OTO - NOTNLM OT - N6-methyladenosine OT - bladder cancer OT - methylation OT - "erasers" OT - "readers" OT - "writers" COIS- The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/01/29 06:00 MHDA- 2022/01/29 06:01 PMCR- 2022/01/11 CRDT- 2022/01/28 05:54 PHST- 2021/11/30 00:00 [received] PHST- 2021/12/22 00:00 [accepted] PHST- 2022/01/28 05:54 [entrez] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/01/29 06:01 [medline] PHST- 2022/01/11 00:00 [pmc-release] AID - 825109 [pii] AID - 10.3389/fgene.2021.825109 [doi] PST - epublish SO - Front Genet. 2022 Jan 11;12:825109. doi: 10.3389/fgene.2021.825109. eCollection 2021. PMID- 35084998 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20260906 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 207 IP - 6 DP - 2022 Jun TI - Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk. PG - 1200-1206 LID - 10.1097/JU.0000000000002449 [doi] AB - PURPOSE: Our goal was to determine the association between biochemically verified post-diagnosis smoking exposure and nonmuscle-invasive bladder cancer (NMIBC) recurrence risk. MATERIALS AND METHODS: We conducted a prospective study of 354 NMIBC patients with a smoking history undergoing care between 2015 and 2018. Patients contributed at least 2 biospecimens during followup which were tested for cotinine to determine biochemically verified post-diagnosis smoking exposure (yes/no). Our primary endpoint was time to first recurrence after study start date. We examined whether post-diagnosis smoking exposure was associated with recurrence risk in multivariable Cox proportional hazards models that accounted for demographics, clinicopathological variables, time since diagnosis and pack-years. RESULTS: Patients were predominantly White, male and had a median age of 68 years. Most patients had Ta disease (62%) and tumors of high grade (68%). Intravesical bacillus Calmette-Guerin was given to 63% of the cohort. Patients were followed for a median of 3.6 years since study start. Post-diagnosis smoking exposure was detected in 22% of patients, and 38.7% (137) of patients experienced a recurrence during followup. In multivariable models, only bacillus Calmette-Guerin treatment and prior recurrence rate were significantly associated with recurrence. There was no association between post-diagnosis smoking exposure and recurrence risk (HR: 0.73, 95% CI: 0.45-1.20). CONCLUSIONS: In a cohort of patients with predominantly high risk NMIBC, post-diagnosis smoking exposure was not associated with NMIBC recurrence. However, smoking cessation support remains a critical component of cancer care given that the benefits of quitting extend far beyond NMIBC recurrence. FAU - Furberg, Helena AU - Furberg H AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Petruzella, Stacey AU - Petruzella S AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Whiting, Karissa AU - Whiting K AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Stein, Emily AU - Stein E AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Orlow, Irene AU - Orlow I AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Kenney, Jessica AU - Kenney J AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Corrales-Guerrero, Sergio AU - Corrales-Guerrero S AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Benfante, Nicole AU - Benfante N AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Cha, Eugene K AU - Cha EK AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Donahue, Timothy F AU - Donahue TF AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Donat, Sherri M AU - Donat SM AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Herr, Harry W AU - Herr HW AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Matulewicz, Richard S AU - Matulewicz RS AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Pietzak, Eugene AU - Pietzak E AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Dalbagni, Guido AU - Dalbagni G AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Ostroff, Jamie AU - Ostroff J AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Bochner, Bernard H AU - Bochner BH AD - Memorial Sloan Kettering Cancer Center, New York, New York. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20220127 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2022 Jun;207(6):1178-1179. doi: 10.1097/JU.0000000000002649. PMID: 35289696 CIN - J Urol. 2022 Sep;208(3):561. doi: 10.1097/JU.0000000000002832. PMID: 35727617 MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - *Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/diagnosis/drug therapy/epidemiology MH - Prospective Studies MH - *Smoking/adverse effects/epidemiology MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/etiology PMC - PMC9472323 MID - NIHMS1826913 OTO - NOTNLM OT - cotinine OT - smoking OT - urinary bladder neoplasms EDAT- 2022/01/28 06:00 MHDA- 2022/05/11 06:00 PMCR- 2023/06/01 CRDT- 2022/01/27 17:13 PHST- 2022/01/28 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/01/27 17:13 [entrez] PHST- 2023/06/01 00:00 [pmc-release] AID - 10.1097/JU.0000000000002449 [doi] PST - ppublish SO - J Urol. 2022 Jun;207(6):1200-1206. doi: 10.1097/JU.0000000000002449. Epub 2022 Jan 27. PMID- 35083522 OWN - NLM STAT- MEDLINE DCOM- 20220511 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 5 DP - 2022 May TI - Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. PG - 1111-1124 LID - 10.1007/s00345-021-03908-x [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) represents a significant global therapeutic challenge, particularly in the era of Bacillus Calmette-Guerin (BCG) shortage. High-risk NMIBC can progress to muscle invasive or metastatic disease in 25% of patients. Optimal treatment selection, according to risk stratification, is imperative. International guidelines slightly differ in their categorisation of low, intermediate and high-risk NMIBC. Nonetheless, a single post-operative instillation of chemotherapy with Mitomycin C (MMC) or Gemcitabine improves relapse-free survival (RFS) in low-risk NMIBC. Induction and maintenance intravesical BCG remains the historical gold standard for patients with intermediate or high-risk NMIBC. However, clinicians may be forced to consider alternatives given the current BCG shortage. Both intravesical MMC and Gemcitabine have been associated with similar efficacy to BCG, albeit in smaller studies. MMC may also be manipulated using a variety of methods to potentiate its effects. BCG treatment delivery may also be modified without affecting efficacy through dose reduction and abbreviation or omission of maintenance therapy. Preliminary data also highlight that directly proceeding to radical cystectomy may not adversely affect long-term quality of life measures. Access to new systemic and intravesical therapies must be prioritised for patients with BCG recurrent or unresponsive disease. When used in conjunction with molecularly defined biomarkers, these agents herald the potential for improved survival outcomes and alleviation of the current BCG shortage. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Balasubramanian, Adithya AU - Balasubramanian A AD - Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia. FAU - Gunjur, Ashray AU - Gunjur A AD - Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia. FAU - Weickhardt, Andrew AU - Weickhardt A AD - Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia. FAU - Papa, Nathan AU - Papa N AD - Department of Surgery, Austin Health, University of Melbourne, Studley Road Heidelberg Vic 3088, Melbourne, Australia. FAU - Bolton, Damien AU - Bolton D AD - Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia. AD - Department of Surgery, Austin Health, University of Melbourne, Studley Road Heidelberg Vic 3088, Melbourne, Australia. FAU - Lawrentschuk, Nathan AU - Lawrentschuk N AD - Department of Urology, Royal Melbourne Hospital, Melbourne, Australia. FAU - Perera, Marlon AU - Perera M AUID- ORCID: 0000-0002-1138-6389 AD - Department of Surgery, Austin Health, University of Melbourne, Studley Road Heidelberg Vic 3088, Melbourne, Australia. marlonlperera@gmail.com. AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. marlonlperera@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20220127 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - Mitomycin/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Quality of Life MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - ADC OT - Antibody-drug conjugate OT - BCG OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Chemotherapy OT - Immunotherapy OT - Intravenous OT - Intravesical OT - Mitomycin OT - NMIBC OT - Non-muscle invasive EDAT- 2022/01/28 06:00 MHDA- 2022/05/12 06:00 CRDT- 2022/01/27 05:51 PHST- 2021/08/13 00:00 [received] PHST- 2021/12/07 00:00 [accepted] PHST- 2022/01/28 06:00 [pubmed] PHST- 2022/05/12 06:00 [medline] PHST- 2022/01/27 05:51 [entrez] AID - 10.1007/s00345-021-03908-x [pii] AID - 10.1007/s00345-021-03908-x [doi] PST - ppublish SO - World J Urol. 2022 May;40(5):1111-1124. doi: 10.1007/s00345-021-03908-x. Epub 2022 Jan 27. PMID- 35083068 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220430 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 74 IP - 4 DP - 2021 TI - The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer. PG - 496-502 LID - 10.5173/ceju.2021.0122 [doi] AB - INTRODUCTION: Expression level of the cell proliferation marker Ki-67 correlates with the degree of differentiation of tumor cells and stage in primary patients with non-muscle-invasive bladder cancer (NMIBC), but the marker is currently not used in assessing the efficacy of adjuvant intravesical therapy and risk stratification in patients with recurrent bladder tumors. MATERIAL AND METHODS: A retroprospective study included 107 patients with high-risk NMIBC; the patients were divided into 2 groups. The first group included patients who received adjuvant therapy after transurethral resection of the bladder using the Bacillus Calmette-Guerin (BCG) vaccine (BCG therapy group; n = 54), the second group consisted of patients who received hyperthermic intravesical chemotherapy (HIVEC((R)) therapy group; n = 53) using the device for local hyperthermia Combat BRS HIVEC((R)). RESULTS: Tumor recurrences were recorded in 21 (39%) patients receiving intravesical BCG therapy and in 9 (17%) patients after intravesical hyperthermic chemotherapy (p = 0.012). The expression level of Ki-67 in primary tumors did not differ; in recurrent tumors it was significantly different in both groups (32.05 +/-13.80 vs 11.00 +/- 6.86). The frequency of recurrence-free survival (RFS) in patients receiving chemohyperthermia was significantly higher than in patients after the BCG therapy (log-rank test result: p = 0.048). CONCLUSIONS: Assessment of Ki-67 expression in recurrent tumors can be a criterion for the effectiveness of intravesical bladder-preserving treatment. The use of hyperthermic chemotherapy can reduce the number of radical cystectomies in a separate group of patients with NMIBC. CI - Copyright by Polish Urological Association. FAU - Kostyev, Fedir AU - Kostyev F AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. FAU - Bondar, Oleksandr AU - Bondar O AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. FAU - Chystiakov, Roman AU - Chystiakov R AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. FAU - Lysenko, Viktoria AU - Lysenko V AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. FAU - Stavnychyi, Oleksiy AU - Stavnychyi O AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. FAU - Varbanets, Valeria AU - Varbanets V AD - Odessa National Medical University, Department of Urology and Nephrology, Odessa, Ukraine. LA - eng PT - Journal Article DEP - 20211022 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC8771141 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Ki-67 OT - hyperthermic intravesical chemotherapy OT - mitomycin-C OT - non-muscle invasive bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2022/01/28 06:00 MHDA- 2022/01/28 06:01 PMCR- 2021/01/01 CRDT- 2022/01/27 05:49 PHST- 2021/09/14 00:00 [received] PHST- 2021/08/25 00:00 [revised] PHST- 2021/10/04 00:00 [accepted] PHST- 2022/01/27 05:49 [entrez] PHST- 2022/01/28 06:00 [pubmed] PHST- 2022/01/28 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 0122 [pii] AID - 10.5173/ceju.2021.0122 [doi] PST - ppublish SO - Cent European J Urol. 2021;74(4):496-502. doi: 10.5173/ceju.2021.0122. Epub 2021 Oct 22. PMID- 35079236 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240405 IS - 1428-2526 (Print) IS - 1897-4309 (Electronic) IS - 1428-2526 (Linking) VI - 25 IP - 4 DP - 2021 TI - RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications. PG - 279-290 LID - 10.5114/wo.2021.112371 [doi] AB - AIM OF THE STUDY: The clinical significance and predictive and prognostic value of HuR, RBM3, and PODXL expression in patients with urothelial bladder cancer (UBC) are not clear yet. The aim of this study was to assess HuR, RBM3 and PODXL expression in muscle invasive and non-muscle invasive UBC tissues, and to investigate the clinicopathological correlations and their predictive and prognostic impact in patients with such type of cancer. MATERIAL AND METHODS: RBM-HuR, RBM3 and PODXL expression levels were evaluated in 70 patients with urothelial carcinoma by immunohistochemistry. The relationships between their expression, clinicopathological findings and prognostic data were analyzed. RESULTS: High RBM-HuR expression was related to muscle invasion (p = 0.008), metastasis to lymph nodes (p = 0.007), and presence of blood spread (p = 0.049). High RBM3 expression was associated with lower grade (p = 0.044), absence of distant metastasis (p = 0.025), and absence of lymph node metastasis (p = 0.018). High PODXL expression was significantly associated with advanced tumor stage (p < 0.001), larger tumor size (p = 0.050), lymphovascular invasion (p = 0.006), lymph node metastasis (p = 0.008), higher grade (p = 0.043) and distant metastasis (p = 0.002).Three-year overall survival rate was negatively associated with high expression of both RBM-HuR and PODXL while it was directly correlated with high expression of RBM3 (p = 0.008, 0.009 and 0.015 respectively). High RBM-HuR and PODXL expression and low expression of RBM3 were related to tumor recurrence (p = 0.022, 0.011 and 0.015). CONCLUSIONS: RBM-HuR and PODXL expressions are markers of poor prognosis while RBM3 is a good prognostic marker for urothelial carcinoma of the bladder. CI - Copyright (c) 2021 Termedia. FAU - Hafez, Abeer M AU - Hafez AM AD - Pathology Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Seleem, Mohammed M AU - Seleem MM AD - Pathology Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Alattar, Ahmed Z AU - Alattar AZ AD - Pathology Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Elshorbagy, Shereen AU - Elshorbagy S AD - Pathology Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Elsayed, Walid S H AU - Elsayed WSH AD - Pathology Faculty of Medicine, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article DEP - 20220105 PL - Poland TA - Contemp Oncol (Pozn) JT - Contemporary oncology (Poznan, Poland) JID - 101233223 PMC - PMC8768053 OTO - NOTNLM OT - PODXL OT - RBM-HuR OT - RBM3 OT - immunohistochemistry OT - prognosis OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2022/01/27 06:00 MHDA- 2022/01/27 06:01 PMCR- 2021/01/01 CRDT- 2022/01/26 05:30 PHST- 2021/10/28 00:00 [received] PHST- 2021/11/23 00:00 [accepted] PHST- 2022/01/26 05:30 [entrez] PHST- 2022/01/27 06:00 [pubmed] PHST- 2022/01/27 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 46079 [pii] AID - 10.5114/wo.2021.112371 [doi] PST - ppublish SO - Contemp Oncol (Pozn). 2021;25(4):279-290. doi: 10.5114/wo.2021.112371. Epub 2022 Jan 5. PMID- 35078711 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20230402 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 20 IP - 2 DP - 2022 Apr TI - Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. PG - 165-175 LID - S1558-7673(21)00242-1 [pii] LID - 10.1016/j.clgc.2021.12.012 [doi] AB - BACKGROUND: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without prior intravesical Bacillus Calmette-Guerin (BCG), who received ICI for aUC, hypothesizing that prior intravesical BCG would be associated with worse outcomes. PATIENTS AND METHODS: We performed a retrospective cohort study across 25 institutions in US and Europe. We compared observed response rate (ORR) using logistic regression; progression-free survival (PFS) and OS using Kaplan-Meier and Cox proportional hazards. Analyses were stratified by treatment line (first line/salvage) and included multivariable models adjusting for known prognostic factors. RESULTS: A total of 1026 patients with aUC were identified; 614, 617, and 638 were included in ORR, OS, PFS analyses, respectively. Overall, 150 pts had history of prior intravesical BCG treatment. ORR to ICI was similar between those with and without prior intravesical BCG exposure in both first line and salvage settings (adjusted odds radios 0.55 [P= .08] and 1.65 [P= .12]). OS (adjusted hazard ratios 1.05 [P= .79] and 1.13 [P= .49]) and PFS (adjusted hazard ratios 1.12 [P= .55] and 0.87 [P= .39]) were similar between those with and without intravesical BCG exposure in first line and salvage settings. CONCLUSION: Prior intravesical BCG was not associated with differences in response and survival in patients with aUC treated with ICI. Limitations include retrospective nature, lack of randomization, presence of selection and confounding biases. This study provides important preliminary data that prior intravesical BCG exposure may not impact ICI efficacy in aUC. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Talukder, Rafee AU - Talukder R AD - Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. FAU - Makrakis, Dimitrios AU - Makrakis D AD - Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. FAU - Diamantopoulos, Leonidas N AU - Diamantopoulos LN AD - Department of Medicine, University of Pittsburgh, Pittsburgh, PA. FAU - Carril-Ajuria, Lucia AU - Carril-Ajuria L AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Castellano, Daniel AU - Castellano D AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - De Kouchkovsky, Ivan AU - De Kouchkovsky I AD - Division of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA. FAU - Koshkin, Vadim S AU - Koshkin VS AD - Division of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA. FAU - Park, Joseph J AU - Park JJ AD - Division of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI. FAU - Alva, Ajjai AU - Alva A AD - Division of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI. FAU - Bilen, Mehmet A AU - Bilen MA AD - Winship Cancer Institute of Emory University, Atlanta, GA. FAU - Stewart, Tyler F AU - Stewart TF AD - Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA. FAU - McKay, Rana R AU - McKay RR AD - Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA. FAU - Santos, Victor S AU - Santos VS AD - Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT. FAU - Agarwal, Neeraj AU - Agarwal N AD - Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT. FAU - Jain, Jayanshu AU - Jain J AD - Department of Medicine, University of Iowa, Iowa City, IA. FAU - Zakharia, Yousef AU - Zakharia Y AD - Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA. FAU - Morales-Barrera, Rafael AU - Morales-Barrera R AD - Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Devitt, Michael E AU - Devitt ME AD - Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA. FAU - Grant, Michael AU - Grant M AD - Department of Surgery and Cancer, Imperial College London, London, UK. FAU - Lythgoe, Mark P AU - Lythgoe MP AD - Department of Surgery and Cancer, Imperial College London, London, UK. FAU - Pinato, David J AU - Pinato DJ AD - Department of Surgery and Cancer, Imperial College London, London, UK. FAU - Nelson, Ariel AU - Nelson A AD - Division of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Hoimes, Christopher J AU - Hoimes CJ AD - Division of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Medical Oncology, Duke University, Durham, NC. FAU - Shreck, Evan AU - Shreck E AD - Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY. FAU - Gartrell, Benjamin A AU - Gartrell BA AD - Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY. FAU - Sankin, Alex AU - Sankin A AD - Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY. FAU - Tripathi, Abhishek AU - Tripathi A AD - Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK. FAU - Zakopoulou, Roubini AU - Zakopoulou R AD - Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. FAU - Bamias, Aristotelis AU - Bamias A AD - 2nd Propaedeutic Dept of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. FAU - Murgic, Jure AU - Murgic J AD - Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, School of Dental Medicine, Zagreb, Croatia. FAU - Frobe, Ana AU - Frobe A AD - Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, School of Dental Medicine, Zagreb, Croatia. FAU - Rodriguez-Vida, Alejo AU - Rodriguez-Vida A AD - Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain. FAU - Drakaki, Alexandra AU - Drakaki A AD - Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA. FAU - Liu, Sandy AU - Liu S AD - Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA. FAU - Kumar, Vivek AU - Kumar V AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Lorenzo, Giuseppe Di AU - Lorenzo GD AD - Oncology University of Molise and ASL, Salerno, Italy. FAU - Joshi, Monika AU - Joshi M AD - Division of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA. FAU - Velho, Pedro Isaacsson AU - Velho PI AD - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. FAU - Buznego, Lucia Alonso AU - Buznego LA AD - Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain. FAU - Duran, Ignacio AU - Duran I AD - Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain. FAU - Moses, Marcus AU - Moses M AD - Deming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA. FAU - Barata, Pedro AU - Barata P AD - Deming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA. FAU - Sonpavde, Guru AU - Sonpavde G AD - Genitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. FAU - Yu, Evan Y AU - Yu EY AD - Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Wright, Jonathan L AU - Wright JL AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Urology, University of Washington, Seattle, WA. FAU - Grivas, Petros AU - Grivas P AD - Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: pgrivas@uw.edu. FAU - Khaki, Ali Raza AU - Khaki AR AD - Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Division of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu. LA - eng GR - P30 CA023100/CA/NCI NIH HHS/United States GR - T32 CA009515/CA/NCI NIH HHS/United States GR - CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211217 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/drug therapy MH - Humans MH - Immune Checkpoint Inhibitors/therapeutic use MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology PMC - PMC8995351 MID - NIHMS1767355 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Immunotherapy OT - Outcomes OT - Urinary tract neoplasms EDAT- 2022/01/27 06:00 MHDA- 2022/04/13 06:00 PMCR- 2023/04/01 CRDT- 2022/01/26 05:28 PHST- 2021/10/22 00:00 [received] PHST- 2021/12/11 00:00 [revised] PHST- 2021/12/13 00:00 [accepted] PHST- 2022/01/27 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/01/26 05:28 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - S1558-7673(21)00242-1 [pii] AID - 10.1016/j.clgc.2021.12.012 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2022 Apr;20(2):165-175. doi: 10.1016/j.clgc.2021.12.012. Epub 2021 Dec 17. PMID- 35074179 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20220603 IS - 1465-3931 (Electronic) IS - 0031-3025 (Linking) VI - 54 IP - 4 DP - 2022 Jun TI - The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes. PG - 425-433 LID - S0031-3025(21)00545-6 [pii] LID - 10.1016/j.pathol.2021.10.005 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) grade is a major determinant of progression risk. The most widely utilised grading systems are the World Health Organization (WHO) 1973 and 2004 schemes. Recent publications suggest the utility of combining both into a four-tier or a hybrid three-tier system, subdividing WHO 2004 high grade into two separate categories while maintaining low grade as a single group. We identified two retrospective cohorts of bladder resections/biopsies of papillary urothelial NMIBC with long term clinical follow-up. The sentinel specimen was assessed for WHO 2004 and 1973 grade, along with pathological stage and carcinoma in situ. Each case was additionally stratified into a hybrid three-tier system (low grade; high grade, grades 2 and 3) and a four-tier system (low grade, grades 1 and 2; high grade, grades 2 and 3). Uni- and multivariable analysis for progression and event free survival (PFS/EFS) were calculated along with the time dependent area under the curve (AUC) for each grading scheme. There were 609 cases (Cohort A, n=343; Cohort B, n=266), including 449 (74%) pTa, 156 pT1 (26%) and four pTx with 338 (56%) low grade (177, grade 1; 161, grade 2) and 271 (44%) high grade (137, grade 2; 134, grade 3). A total of 108 patients progressed (17.7%): 97 high grade, (grade 3, n=59; grade 2, n=38). Multivariable analyses of PFS with the hybrid 3- and 4-tier systems showed higher Harrell's concordance indices (0.851 and 0.853, respectively) than WHO 1973 (0.844) and WHO 2004 (0.846). In both cohorts AUC values were higher (0.77-0.85) for the two hybrid grading systems compared to WHO 1973 or WHO 2004 (0.72-0.82). Similar results were seen on analysis of EFS. The data support the use of a hybrid three-tier or four-tier grading system to improve stratification of NMIBC patients. CI - Copyright (c) 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved. FAU - Downes, Michelle R AU - Downes MR AD - Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address: michelle.downes@sunnybrook.ca. FAU - Lajkosz, Katherine AU - Lajkosz K AD - Division of Urology, Department of Surgery and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. FAU - Kuk, Cynthia AU - Kuk C AD - Division of Urology, Department of Surgery and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada. FAU - Gao, Bruce AU - Gao B AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20220122 PL - England TA - Pathology JT - Pathology JID - 0175411 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Disease Progression MH - Humans MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder cancer OT - WHO 1973 OT - WHO 2004 OT - grading system OT - non-muscle invasive OT - progression EDAT- 2022/01/26 06:00 MHDA- 2022/06/07 06:00 CRDT- 2022/01/25 05:38 PHST- 2021/08/27 00:00 [received] PHST- 2021/10/04 00:00 [revised] PHST- 2021/10/11 00:00 [accepted] PHST- 2022/01/26 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/01/25 05:38 [entrez] AID - S0031-3025(21)00545-6 [pii] AID - 10.1016/j.pathol.2021.10.005 [doi] PST - ppublish SO - Pathology. 2022 Jun;54(4):425-433. doi: 10.1016/j.pathol.2021.10.005. Epub 2022 Jan 22. PMID- 35073474 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220413 IS - 2702-3648 (Electronic) IS - 2702-3648 (Linking) VI - 122 IP - 4 DP - 2022 Jan 21 TI - Improving practice patterns in patients with newly diagnosed bladder masses treated with transurethral resection. PG - 169-173 LID - 10.1515/jom-2021-0157 [doi] AB - CONTEXT: Transurethral resection (TUR) is the mainstay for diagnosis, staging, and treatment of both high-grade and low-grade nonmuscle invasive bladder cancer (NMIBC). It is reported that 51% of initial transurethral resection of bladder tumors (iTURBT) does not contain muscle, which results in higher rates of clinical upstaging on repeat transurethral resection (reTUR) and worse oncologic outcomes. Presence of muscle on iTURBT specimen and performing reTUR within 6 weeks in high-risk NMIBC aids in accurate staging and, therefore, guides proper treatment. OBJECTIVES: This study aimed to assess and improve TURBT quality by making surgeons aware of their practice patterns and setting improvement goals. METHODS: Patients who received TURBT for a newly diagnosed bladder mass were analyzed by retrospective chart review for 9 months prior to quality improvement (QI) intervention. Data were collected pertaining to muscle presence/absence on biopsy, pathology of the tumor, risk stratification, whether reTUR was indicated, and time to reTUR. The primary endpoints were the presence of muscle on initial TURBT, whether a reTUR was performed when clinically indicated, and time to reTUR. Tumors requiring reTUR were defined as being HGT1 or HGTa >3 cm. The QI intervention, physician education, was then implemented by presenting initial performance results to the physicians, and a second dataset was then collected by prospective analysis for another 9 months to assess for changes in practice patterns. A total of 101 patients receiving TURBT were reviewed, including 52 patients prior to and 49 patients following QI intervention. Patients with a history of, or treatment for, bladder cancer were excluded, along with those without assessment of muscle on pathological analysis. Fisher's exact test was utilized to determine differences in categorical data by comparing each of the following groups prior to and following QI intervention: percent of muscle presence on iTURBT, percent reTUR performed when indicated, and mean time to reTUR in days. A p<0.05 was considered statistically significant. RESULTS: After comparing the TURBT results before and after our QI intervention, we found a significant improvement in the number of patients receiving a reTUR when indicated, with 5/13 (38.5%) before compared to 15/19 (78.9%) after, p=0.03. The number of specimens on iTURBT with muscle present were not significantly different, with 38/52 (73.1%) before and 33/49 (67.3%) after, p=0.66. The average time to reTUR before (32.4 days; n=5; range, 21-50 days) and after (42.4 days; n=15; range, 11-77 days) QI intervention was also not significantly different, p=0.28. CONCLUSIONS: Our data suggest that critical analysis of physician practice patterns followed by education and setting improvement goals can significantly impact clinical practices and improve quality of care. Future studies will be performed to determine the impact that these changes have on oncologic outcomes. CI - (c) 2022 Joshua Wilson et al., published by De Gruyter, Berlin/Boston. FAU - Wilson, Joshua AU - Wilson J AD - Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, IL, USA. FAU - Drach, Daniel AU - Drach D AD - Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, IL, USA. FAU - Zanghi, Joseph AU - Zanghi J AD - Department of Urology, Franciscan Health Olympia Fields, Olympia Fields, IL, USA. FAU - Siegert, James AU - Siegert J AD - Clinical Assistant Professor of Surgery, Department of Urology, Franciscan Health Olympia Fields, Olympia Fields, IL, USA. LA - eng PT - Journal Article DEP - 20220121 PL - Germany TA - J Osteopath Med JT - Journal of osteopathic medicine JID - 101776472 SB - IM MH - Cystectomy/methods MH - Humans MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/surgery OTO - NOTNLM OT - TURBT OT - bladder mass OT - practice patterns OT - quality improvement OT - surgery OT - transurethral resection OT - urology EDAT- 2022/01/25 06:00 MHDA- 2022/04/14 06:00 CRDT- 2022/01/24 17:15 PHST- 2021/07/18 00:00 [received] PHST- 2021/12/01 00:00 [accepted] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2022/01/24 17:15 [entrez] AID - jom-2021-0157 [pii] AID - 10.1515/jom-2021-0157 [doi] PST - epublish SO - J Osteopath Med. 2022 Jan 21;122(4):169-173. doi: 10.1515/jom-2021-0157. PMID- 35073149 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 2473-4276 (Electronic) IS - 2473-4276 (Linking) VI - 6 DP - 2022 Jan TI - Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing. PG - e2100097 LID - 10.1200/CCI.21.00097 [doi] AB - PURPOSE: Mortality from bladder cancer (BC) increases exponentially once it invades the muscle, with inherent challenges delineating at the population level. We sought to develop and validate a natural language processing (NLP) model for automatically identifying patients with muscle-invasive bladder cancer (MIBC). METHODS: All patients with a Current Procedural Terminology code for transurethral resection of bladder tumor (TURBT; n = 76,060) were selected from the Department of Veterans Affairs (VA) database. A sample of 600 patients (with 2,337 full-text notes) who had TURBT and confirmed pathology results were selected for NLP model development and validation. The NLP performance was assessed by calculating the sensitivity, specificity, positive predictive value, negative predictive value, F1 score, and overall accuracy at the individual note and patient levels. RESULTS: In the validation cohort, the NLP model had average overall accuracies of 94% and 96% at the note and patient levels. Specifically, the F1 score and overall accuracy for predicting muscle invasion at the patient level were 0.87% and 96%, respectively. The model classified nonmuscle-invasive bladder cancer (NMIBC) with overall accuracies of 90% and 93% at the note and patient levels. When applying the model to 71,200 patients VA-wide, the model classified 13,642 (19%) as having MIBC and 47,595 (66%) as NMIBC and was able to identify invasion status for 96% of patients with TURBT at the population level. Inherent limitations include a relatively small training set, given the size of the VA population. CONCLUSION: This NLP model, with high accuracy, may be a practical tool for efficiently identifying BC invasion status and aid in population-based BC research. FAU - Yang, Ruixin AU - Yang R AUID- ORCID: 0000-0002-2001-4202 AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. FAU - Zhu, Di AU - Zhu D AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. FAU - Howard, Lauren E AU - Howard LE AUID- ORCID: 0000-0003-3355-4483 AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. AD - Duke Cancer Institute, Duke University School of Medicine, Durham, NC. FAU - De Hoedt, Amanda AU - De Hoedt A AUID- ORCID: 0000-0002-3899-7702 AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. FAU - Schroeck, Florian R AU - Schroeck FR AUID- ORCID: 0000-0002-1860-2611 AD - White River Junction VA Medical Center, White River Junction, VT. AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH. FAU - Klaassen, Zachary AU - Klaassen Z AUID- ORCID: 0000-0001-7392-8916 AD - Division of Urology, Medical College of Georgia at Augusta University, Augusta, GA. AD - Georgia Cancer Center, Augusta, GA. FAU - Freedland, Stephen J AU - Freedland SJ AUID- ORCID: 0000-0002-8104-6419 AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. AD - Division of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. AD - Center for Integrated Research in Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Williams, Stephen B AU - Williams SB AUID- ORCID: 0000-0002-2683-2185 AD - Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. AD - Department of Surgery, Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - JCO Clin Cancer Inform JT - JCO clinical cancer informatics JID - 101708809 SB - IM MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Muscles/pathology MH - Natural Language Processing MH - Rare Diseases MH - *Urinary Bladder Neoplasms/pathology MH - Urologic Surgical Procedures COIS- Ruixin YangResearch Funding: Janssen, Merck Lauren E. HowardResearch Funding: Bayer (Inst), Merck (Inst), Ferring (Inst), MDxHealth (Inst), Sanofi (Inst), Diasorin (Inst), Myriad Genetics (Inst), LungLife AI (Inst) Amanda De HoedtStock and Other Ownership Interests: Myovant SciencesResearch Funding: Bayer (Inst), Ferring (Inst), Merck (Inst), Janssen (Inst), MDxHealth (Inst), Sanofi (Inst), Diasorin (Inst), Myriad Genetics (Inst), LungLife AI (Inst), Pfizer (Inst), Blue Earth Diagnostics (Inst) Florian R. SchroeckOther Relationship: Sesen Bio Zachary KlaassenHonoraria: Pfizer/Astellas, BayerConsulting or Advisory Role: Sesen Bio Stephen J. FreedlandEmployment: Genomic Health (I)Consulting or Advisory Role: Astellas Pharma, Janssen Biotech, Dendreon, Bayer, Pfizer, Ferring, AstraZeneca, Sanofi, Myovant Sciences, Clovis Oncology, Merck, Exact SciencesSpeakers' Bureau: Sanofi, AstraZenecaResearch Funding: Bayer (Inst), Janssen Biotech (Inst), Myriad Genetics (Inst), GenomeDx (Inst), Progenika (Inst), MDxHealth (Inst), OPKO Diagnostics (Inst), Diasorin, MerckTravel, Accommodations, Expenses: Sanofi Stephen B. WilliamsConsulting or Advisory Role: Taris BioMedical (Inst), Photocure, UroTodayTravel, Accommodations, Expenses: JanssenNo other potential conflicts of interest were reported. EDAT- 2022/01/25 06:00 MHDA- 2022/04/30 06:00 CRDT- 2022/01/24 17:13 PHST- 2022/01/24 17:13 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] AID - 10.1200/CCI.21.00097 [doi] PST - ppublish SO - JCO Clin Cancer Inform. 2022 Jan;6:e2100097. doi: 10.1200/CCI.21.00097. PMID- 35071834 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230224 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 7 IP - 1 DP - 2022 Jan-Feb TI - Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation. PG - 100836 LID - 10.1016/j.adro.2021.100836 [doi] LID - 100836 AB - PURPOSE: Chemoradiation (CRT) is a definitive treatment option for muscle-invasive bladder cancer (MIBC). Despite its effectiveness, CRT is underused, in part owing to concerns of tolerability and the need for integrated multidisciplinary care. We investigated factors associated with and the impact of treatment discontinuation in patients with MIBC treated with CRT. METHODS AND MATERIALS: In the US Veterans Affairs' national database, we identified patients with urothelial histology, MIBC (T2-4a/N0-3/M0) diagnosed between 2000 and 2018 and treated with definitive-intent CRT. The primary endpoint of discontinued radiation was evaluated in a multivariable logistic regression. Secondary endpoints of 30-day and 90-day mortality, overall mortality, and nonbladder cancer mortality were evaluated in multivariable models. RESULTS: Of 369 veterans with MIBC who underwent CRT, 30 patients (8.1%) did not complete radiation. The most common reasons for treatment discontinuation included comorbidities or infections necessitating hospital admission (63.3%) and treatment intolerance or declining performance status (26.7%). In multivariable logistic regression, variables associated with radiation discontinuation were creatinine clearance /= 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making bladder cancer the most expensive cancer to treat per capita. There is an urgent need to expand the understanding of markers related to recurrence and survival outcomes of NMIBC. METHODS AND RESULTS: We used the Illumina HumanMethylationEPIC array to measure peripheral blood DNA methylation profiles of NMIBC patients (N = 603) enrolled in a population-based cohort study in New Hampshire and applied cell type deconvolution to estimate immune cell-type proportions. Using Cox proportional hazard models, we identified that increasing CD4T and CD8T cell proportions were associated with a statistically significant decreased hazard of tumor recurrence or death (CD4T: HR = 0.98, 95% CI = 0.97-1.00; CD8T: HR = 0.97, 95% CI = 0.95-1.00), whereas increasing monocyte proportion and methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) were associated with the increased hazard of tumor recurrence or death (monocyte: HR = 1.04, 95% CI = 1.00-1.07; mdNLR: HR = 1.12, 95% CI = 1.04-1.20). Then, using an epigenome-wide association study (EWAS) approach adjusting for age, sex, smoking status, BCG treatment status, and immune cell profiles, we identified 2528 CpGs associated with the hazard of tumor recurrence or death (P < 0.005). Among these CpGs, the 1572 were associated with an increased hazard and were significantly enriched in open sea regions; the 956 remaining CpGs were associated with a decreased hazard and were significantly enriched in enhancer regions and DNase hypersensitive sites. CONCLUSIONS: Our results expand on the knowledge of immune profiles and methylation alteration associated with NMIBC outcomes and represent a first step toward the development of DNA methylation-based biomarkers of tumor recurrence. CI - (c) 2022. The Author(s). FAU - Chen, Ji-Qing AU - Chen JQ AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. FAU - Salas, Lucas A AU - Salas LA AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. FAU - Wiencke, John K AU - Wiencke JK AD - Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA. FAU - Koestler, Devin C AU - Koestler DC AD - Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS, 66160, USA. FAU - Molinaro, Annette M AU - Molinaro AM AD - Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA. FAU - Andrew, Angeline S AU - Andrew AS AD - Department of Neurology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. FAU - Seigne, John D AU - Seigne JD AD - Department of Surgery, Section of Urology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. FAU - Karagas, Margaret R AU - Karagas MR AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. FAU - Kelsey, Karl T AU - Kelsey KT AD - Departments of Epidemiology and Pathology and Laboratory Medicine, Brown University, Providence, RI, 02912, USA. FAU - Christensen, Brock C AU - Christensen BC AUID- ORCID: 0000-0003-3022-426X AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. Brock.Christensen@Dartmouth.edu. AD - Departments of Molecular and Systems Biology, and Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA. Brock.Christensen@Dartmouth.edu. AD - Dartmouth Hitchcock Medical Center, 1 Medical Center Dr, 660 Williamson Translation Research Building, Lebanon, NH, 03756, USA. Brock.Christensen@Dartmouth.edu. LA - eng GR - R01 CA253976/CA/NCI NIH HHS/United States GR - R01 CA207360/CA/NCI NIH HHS/United States GR - P50 CA097257/CA/NCI NIH HHS/United States GR - P20 GM130423/GM/NIGMS NIH HHS/United States GR - P20 GM104416/GM/NIGMS NIH HHS/United States GR - R01 CA216265/CA/NCI NIH HHS/United States GR - R01 CA057494/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220121 PL - Germany TA - Clin Epigenetics JT - Clinical epigenetics JID - 101516977 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/analysis/genetics MH - Cohort Studies MH - DNA Methylation/*genetics/physiology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Outcome Assessment, Health Care/methods/*statistics & numerical data MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/classification/*immunology PMC - PMC8783448 OTO - NOTNLM OT - DNA methylation OT - Immune profile OT - Immunomethylomic OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Survival COIS- The authors declare that they have no competing interests. JKW and KTK are co-founders of Cellintec which had no role in this work. EDAT- 2022/01/23 06:00 MHDA- 2022/02/24 06:00 PMCR- 2022/01/21 CRDT- 2022/01/22 05:32 PHST- 2021/09/15 00:00 [received] PHST- 2022/01/12 00:00 [accepted] PHST- 2022/01/22 05:32 [entrez] PHST- 2022/01/23 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] PHST- 2022/01/21 00:00 [pmc-release] AID - 10.1186/s13148-022-01234-6 [pii] AID - 1234 [pii] AID - 10.1186/s13148-022-01234-6 [doi] PST - epublish SO - Clin Epigenetics. 2022 Jan 21;14(1):14. doi: 10.1186/s13148-022-01234-6. PMID- 35060770 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220315 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 207 IP - 4 DP - 2022 Apr TI - En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. PG - 754-768 LID - 10.1097/JU.0000000000002444 [doi] AB - PURPOSE: En bloc resection for bladder tumors has been developed to overcome shortcomings of conventional transurethral resection of bladder tumors with regard to safety, pathological evaluation and oncologic outcomes. However, the potential benefits and utility compared to conventional transurethral resection of bladder tumors have not been conclusively demonstrated. We aimed to update the current evidence with focus on the pathological benefits of en bloc resection for nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: The PubMed(R), Web of Science and Scopus(R) databases were searched in August 2021 according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. Studies were deemed eligible if they compared safety, and pathological and clinical outcomes in patients who underwent en bloc resection with conventional transurethral resection of bladder tumors. RESULTS: Overall, 29 studies comprising 4,484 patients were eligible for this meta-analysis. Among 13 randomized controlled trials, the pooled 12- and 24-month recurrence risk ratios were not statistically different between the 2 surgical techniques (0.96, 95% CI 0.74-1.23 and 0.83, 95% CI 0.55-1.23, respectively). The pooled risk ratio for bladder perforation was 0.13 (95% CI 0.05-0.34) in favor of en bloc resection. In randomized controlled trials, the differential rates of detrusor muscle presence (pooled RR 1.31, 95% CI 1.19-1.43) and of detectable muscularis mucosae (pooled RR 2.69, 95% CI 1.81-3.97) were more likely in patients receiving en bloc resection. Patients who underwent en bloc resection had a lower rate of residual tumor at repeat transurethral resection than those treated with conventional transurethral resection of bladder tumors in 1 randomized controlled trial and 3 observational studies (pooled RR 0.47, 95% CI 0.31-0.71). CONCLUSIONS: En bloc resection for bladder tumors seems to be safer, and to yield superior histopathological information and performance compared to conventional transurethral resection of bladder tumors. Despite the failure to improve the recurrence rate, the more accurate histopathological analysis is likely to improve clinical decision making and care delivery in nonmuscle-invasive bladder cancer. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Motlagh, Reza Sari AU - Motlagh RS AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Kawada, Tatsushi AU - Kawada T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Aydh, Abdulmajeed AU - Aydh A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Faisal Medical City, Abha, Saudi Arabia. FAU - Konig, Frederik AU - Konig F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Pallauf, Maximilian AU - Pallauf M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Miki, Jun AU - Miki J AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Department of Urology, Weill Cornell Medical College, New York, New York. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220121 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Cystectomy/*adverse effects/methods MH - Disease Progression MH - Humans MH - Margins of Excision MH - Mucous Membrane/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm, Residual MH - Operative Time MH - Postoperative Complications MH - Risk Factors MH - Urinary Bladder/injuries MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Urinary Catheterization OTO - NOTNLM OT - pathology OT - recurrence OT - urinary bladder neoplasms EDAT- 2022/01/22 06:00 MHDA- 2022/03/16 06:00 CRDT- 2022/01/21 12:15 PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2022/01/21 12:15 [entrez] AID - 10.1097/JU.0000000000002444 [doi] PST - ppublish SO - J Urol. 2022 Apr;207(4):754-768. doi: 10.1097/JU.0000000000002444. Epub 2022 Jan 21. PMID- 35056397 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20230917 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 58 IP - 1 DP - 2022 Jan 7 TI - Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes? LID - 10.3390/medicina58010090 [doi] LID - 90 AB - Background and Objectives: To evaluate the oncological impact of squamous cell carcinoma (SCC) variant in patients submitted to intravesical therapy for non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: Between January 2015 and January 2020, patients with conventional urothelial NMIBC (TCC) or urothelial NMIBC with SCC variant (TCC + SCC) and submitted to adjuvant intravesical therapies were collected. Kaplan-Meier analyses targeted disease recurrence and progression. Uni- and multivariable Cox regression analyses were used to test the role of SCC on disease recurrence and/or progression. Results: A total of 32 patients out of 353 had SCC at diagnosis. Recurrence was observed in 42% of TCC and 44% of TCC + SCC patients (p = 0.88), while progression was observed in 12% of both TCC and TCC + SCC patients (p = 0.78). At multivariable Cox regression analyses, the presence of SCC variant was not associated with higher rates of neither recurrence (p = 0.663) nor progression (p = 0.582). Conclusions: We presented data from the largest series on patients with TCC and concomitant SCC histological variant managed with intravesical therapy (BCG or MMC). No significant differences were found in term of recurrence and progression between TCC and TCC + SCC. Despite the limited sample size, this study paves the way for a possible implementation of the use of intravesical BCG and MMC in NMIBC with histological variants. FAU - Mantica, Guglielmo AU - Mantica G AUID- ORCID: 0000-0003-4361-4523 AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Chierigo, Francesco AU - Chierigo F AUID- ORCID: 0000-0001-7357-0758 AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Malinaric, Rafaela AU - Malinaric R AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Smelzo, Salvatore AU - Smelzo S AD - Department of Urology, San Raffaele Turro Hospital, 20127 Milan, Italy. FAU - Ambrosini, Francesca AU - Ambrosini F AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Beverini, Martina AU - Beverini M AUID- ORCID: 0000-0001-5812-0900 AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Guano, Giovanni AU - Guano G AUID- ORCID: 0000-0003-3825-8149 AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Caviglia, Alberto AU - Caviglia A AUID- ORCID: 0000-0002-7414-1733 AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Rigatti, Lorenzo AU - Rigatti L AD - Department of Urology, San Raffaele Turro Hospital, 20127 Milan, Italy. FAU - De Rose, Aldo Franco AU - De Rose AF AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Tafuri, Alessandro AU - Tafuri A AD - Department of Urology, Vito Fazzi Hospital, 73110 Lecce, Italy. FAU - De Marchi, Davide AU - De Marchi D AD - Department of Urology, San Raffaele Turro Hospital, 20127 Milan, Italy. FAU - Gaboardi, Franco AU - Gaboardi F AD - Department of Urology, San Raffaele Turro Hospital, 20127 Milan, Italy. FAU - Suardi, Nazareno AU - Suardi N AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, 16132 Genova, Italy. LA - eng PT - Journal Article DEP - 20220107 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - *Carcinoma, Squamous Cell/drug therapy MH - *Carcinoma, Transitional Cell MH - Humans MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC8778404 OTO - NOTNLM OT - adjuvants OT - neoplasm recurrence OT - regression analysis OT - squamous cell carcinoma OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2022/01/22 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/07 CRDT- 2022/01/21 01:14 PHST- 2021/11/27 00:00 [received] PHST- 2021/12/26 00:00 [revised] PHST- 2022/01/01 00:00 [accepted] PHST- 2022/01/21 01:14 [entrez] PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/07 00:00 [pmc-release] AID - medicina58010090 [pii] AID - medicina-58-00090 [pii] AID - 10.3390/medicina58010090 [doi] PST - epublish SO - Medicina (Kaunas). 2022 Jan 7;58(1):90. doi: 10.3390/medicina58010090. PMID- 35045949 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20220420 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 4 DP - 2022 Apr TI - Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. PG - 164.e9-164.e16 LID - S1078-1439(21)00536-6 [pii] LID - 10.1016/j.urolonc.2021.11.021 [doi] AB - PURPOSE: To better define surrogate endpoints for neoadjuvant chemotherapy (NAC) trials in patients with muscle-invasive bladder cancer. We compared survival in patients with carcinoma in-situ (CIS) only vs. complete response following NAC and radical cystectomy (RC). MATERIALS AND METHODS: Patients with cT2-4N0M0 disease treated with NAC and RC between 2001 and 2018 were stratified by response: complete response (CR, pT0N0), partial response (PR, pTaN0, pT1N0+/-CIS), CIS-only (pTisN0), stable disease (SD, pT2N0), or progressive disease (PD, >pT2N0). Primary endpoints were overall survival (OS) and risk of recurrence in patients with CIS-only vs. CR. Multivariable Cox proportional hazards regression model was used for OS and a competing risks proportional hazards model was used for risk of recurrence. RESULTS: Of 1,406 patients in our institution cohort, 340 patients met inclusion criteria. Kaplan-Meier mean estimates of OS for CR and CIS-only were 108.9 months (95% CI 89.7-127.9) and 125.8 months (95% CI 112.3-139.3), respectively (P = 0.13). Cox proportional hazards model found no difference in OS between patients with PR (HR 1.06, 95% CI 0.33-2.58, P = 0.897) or CIS-only (HR 0.422, 95% CI 0.15-1.18, P = 0.101) when compared to CR. The risk of recurrence was similar between patients with CIS-only (HR 0.73, 95% 0.29-1.84, P = 0.49) and PR (HR 1.32, 95% CI 0.54-3.29, P = 0.54) when compared to CR on competing risks analysis. CONCLUSIONS: Residual CIS-only after NAC and RC demonstrated similar survival outcomes when compared to patients with pathologic CR. Further study in large multi-institutional cohorts may further validate CIS-only as an additional surrogate endpoint after NAC and may inform future trials. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Gabrielson, Andrew T AU - Gabrielson AT AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Daniels, Marcus J AU - Daniels MJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Rowe, Julian AU - Rowe J AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Alam, Ridwan AU - Alam R AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Lee, Esther J AU - Lee EJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Matoso, Andres AU - Matoso A AD - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - De Felice, Anthony AU - De Felice A AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Hahn, Noah AU - Hahn N AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. FAU - Hoffman-Censits, Jean AU - Hoffman-Censits J AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Kates, Max AU - Kates M AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: mkates@jhmi.edu. LA - eng PT - Journal Article DEP - 20220116 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Carcinoma in Situ/drug therapy MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Male MH - Muscles/pathology MH - Neoadjuvant Therapy/adverse effects MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Cystectomy OT - Surrogate endpoints COIS- Conflict of interest The authors declared no conflict interests. EDAT- 2022/01/21 06:00 MHDA- 2022/04/21 06:00 CRDT- 2022/01/20 05:40 PHST- 2021/08/18 00:00 [received] PHST- 2021/10/21 00:00 [revised] PHST- 2021/11/26 00:00 [accepted] PHST- 2022/01/21 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2022/01/20 05:40 [entrez] AID - S1078-1439(21)00536-6 [pii] AID - 10.1016/j.urolonc.2021.11.021 [doi] PST - ppublish SO - Urol Oncol. 2022 Apr;40(4):164.e9-164.e16. doi: 10.1016/j.urolonc.2021.11.021. Epub 2022 Jan 16. PMID- 35033480 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220601 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 2 DP - 2022 Apr TI - Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. PG - e166-e172 LID - S1558-7673(21)00234-2 [pii] LID - 10.1016/j.clgc.2021.12.005 [doi] AB - INTRODUCTION: The aim of this multicenter study was to investigate the role of age (cut-off 70 years) at diagnosis in predicting oncologic behavior of pure carcinoma in situ of the bladder. MATERIAL AND METHODS: Inclusion criteria were: patients with pure CIS confirmed and that followed intravesical BCG treatment. Pure CIS was defined at any CIS not associated with another urothelial cancer. Exclusion criteria were: any CIS associated with invasive urothelial carcinoma. A total of 172 with pure CIS treated between January 1, 2002 and December 31, 2012 at 8 academic institutions met the inclusion criteria. The maintenance schedule was generally according to the EAU guidelines at the time RESULTS: A total of 99 (57.6%) patients had an age >70 years prior to TURBT. There was no difference between clinico-pathologic features among groups (group 1, age 70 years), except that patients aged 800 was associated with a higher likelihood of durable response (p = 0.026). Peak post-treatment titers >800 were noted in 42 (89%) responders versus 26 (59%) nonresponders (p = 0.001; assay sensitivity, 89%; negative predictive value, 78%). Moreover, 22 (47%) responders compared with eight (18%) nonresponders had a combination of peak post-treatment titers >800 and peak antibody fold change >8 (p = 0.004; assay specificity, 82%; positive predictive value, 73%). A majority of responders continued to have post-treatment antibody titers >800 after the first 6 mo of therapy. In conclusion, serum antiadenovirus antibody quantification may serve as a novel predictive marker for nadofaragene firadenovec response durability. Future studies will focus on large-scale validation and clinical utility of the assay. PATIENT SUMMARY: This study reports on a planned secondary analysis of a phase 3 multicenter clinical trial that established the benefit of nadofaragene firadenovec, a novel intravesical gene therapeutic, for the treatment of patients with bacillus Calmette-Guerin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer. Prospective assessment of serum anti-human adenovirus type-5 antibody levels of patients in this trial indicated that a combination of post-treatment titers and fold change from baseline can predict treatment efficacy. While this merits additional validation, our findings suggest that serum antiadenovirus antibody levels can serve as an important predictive marker for the durability of therapeutic response to nadofaragene firadenovec. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Mitra, Anirban P AU - Mitra AP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Narayan, Vikram M AU - Narayan VM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Mokkapati, Sharada AU - Mokkapati S AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Miest, Tanner AU - Miest T AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Alemozaffar, Mehrdad AU - Alemozaffar M AD - Department of Urology, Kaiser Permanente Los Angeles, Los Angeles, CA, USA. FAU - Konety, Badrinath R AU - Konety BR AD - Department of Urology, Rush Medical College, Chicago, IL, USA. FAU - Shore, Neal D AU - Shore ND AD - Carolina Urologic Research Center, Myrtle Beach, SC, USA. FAU - Gomella, Leonard G AU - Gomella LG AD - Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. FAU - Montgomery, Jeffrey S AU - Montgomery JS AD - Department of Urology, University of Michigan, Ann Arbor, MI, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. FAU - Busby, J Erik AU - Busby JE AD - Department of Surgery, Prisma Health, University of South Carolina School of Medicine at Greenville, Greenville, SC, USA. FAU - Poch, Michael AU - Poch M AD - Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Crispen, Paul L AU - Crispen PL AD - Department of Urology, University of Florida, Gainesville, FL, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, New York University Langone Health, New York, NY, USA. FAU - Schuckman, Anne K AU - Schuckman AK AD - Institute of Urology, University of Southern California, Los Angeles, CA, USA. FAU - Downs, Tracy M AU - Downs TM AD - Department of Urology, University of Wisconsin, Madison, WI, USA. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. FAU - Mashni, Joseph AU - Mashni J AD - Department of Surgical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA. FAU - Lane, Brian R AU - Lane BR AD - Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, MI, USA. FAU - Guzzo, Thomas J AU - Guzzo TJ AD - Division of Urology, University of Pennsylvania, Philadelphia, PA, USA. FAU - Bratslavsky, Gennady AU - Bratslavsky G AD - Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA. FAU - Karsh, Lawrence I AU - Karsh LI AD - The Urology Center of Colorado, Denver, CO, USA. FAU - Woods, Michael E AU - Woods ME AD - Department of Urology, Loyola University, Maywood, IL, USA. FAU - Brown, Gordon A AU - Brown GA AD - New Jersey Urology, Bloomfield, NJ, USA. FAU - Canter, Daniel AU - Canter D AD - Georgia Urology, Atlanta, GA, USA. FAU - Luchey, Adam AU - Luchey A AD - Department of Urology, West Virginia University Cancer Institute, Morgantown, WV, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Krupski, Tracey AU - Krupski T AD - Department of Urology, University of Virginia, Charlottesville, VA, USA. FAU - Inman, Brant A AU - Inman BA AD - Division of Urology, Department of Surgery, Duke University, Durham, NC, USA. FAU - Williams, Michael B AU - Williams MB AD - Urology of Virginia, Virginia Beach, VA, USA. FAU - Cookson, Michael S AU - Cookson MS AD - Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. FAU - Keegan, Kirk A AU - Keegan KA AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Andriole, Gerald L AU - Andriole GL AD - Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine in St Louis, St Louis, MO, USA. FAU - Sankin, Alexander I AU - Sankin AI AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Boyd, Alan AU - Boyd A AD - Boyd Consultants Ltd, Crewe, UK. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Philipson, Richard AU - Philipson R AD - Trizell Ltd, Chinnor, UK. FAU - Yla-Herttuala, Seppo AU - Yla-Herttuala S AD - AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. FAU - Sawutz, David AU - Sawutz D AD - FKD Therapies Oy, Kuopio, Finland. FAU - Parker, Nigel R AU - Parker NR AD - AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: cdinney@mdanderson.org. LA - eng GR - P30 CA014236/CA/NCI NIH HHS/United States GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211218 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *Antineoplastic Agents/therapeutic use MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Prospective Studies MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC8891058 MID - NIHMS1763156 OTO - NOTNLM OT - Antiadenovirus antibody OT - Bladder cancer OT - Companion biomarker OT - Gene therapy OT - Treatment efficacy EDAT- 2021/12/23 06:00 MHDA- 2022/04/19 06:00 PMCR- 2023/03/01 CRDT- 2021/12/22 05:39 PHST- 2021/06/09 00:00 [received] PHST- 2021/11/04 00:00 [revised] PHST- 2021/12/02 00:00 [accepted] PHST- 2021/12/23 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2021/12/22 05:39 [entrez] PHST- 2023/03/01 00:00 [pmc-release] AID - S0302-2838(21)02217-X [pii] AID - 10.1016/j.eururo.2021.12.009 [doi] PST - ppublish SO - Eur Urol. 2022 Mar;81(3):223-228. doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18. PMID- 34931545 OWN - NLM STAT- MEDLINE DCOM- 20220520 LR - 20220616 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 36 IP - 5 DP - 2022 May TI - Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder Carcinoma. PG - 634-640 LID - 10.1089/end.2021.0617 [doi] AB - Purpose: To identify protective and risk factors of early postoperative complications after robot-assisted radical cystectomy (RARC) for urothelial bladder carcinoma. Methods: Data of all robot-assisted cystectomies performed in six French centers between February 2010 and December 2019 were retrospectively reviewed. All RARCs for bladder cancer (muscle-invasive and high-risk or Bacillus Calmette-Guerin-resistant nonmuscle-invasive bladder cancer) were included. Perioperative outcomes and early postoperative complications (in the first 30 days) were collected. Multivariable analysis was performed to identify factors associated with early postoperative complications. Results: Two hundred seventy patients were included. The overall incidence of early postoperative complications after RARC was 52.2% (27% of major complications). Most frequent complications were infectious complications (24.4%) and paralytic ileus (15.6%). Anticoagulant therapy (odds ratio [OR] = 2.909, 95% confidence interval [CI]: 1.003-8.432) and ureteroenteric anastomosis-type Wallace II (OR = 4.4, 95% CI: 1.435-13.489) were associated with a higher rate of overall complications. Complete intracorporeal diversion was a protective factor (OR = 0.399, 95% CI: 0.222-0.718). Tobacco consumption, anticoagulant therapy, and ureteroenteric anastomosis-type Wallace II were associated with a higher rate of minor complications (OR = 2.01, 95% CI: 1.079-3.744; OR = 2.495, 95% CI: 1.022-6.089; OR = 3.836, 95% CI: 1.384-10.63, respectively). Opioid-free analgesia (OFA) was associated with a lower rate of infectious complications (OR = 0.148, 95% CI: 0.034-0.644). Conclusion: Early postoperative complication rate after RARC for urothelial bladder carcinoma is high. Encouraging complete intracorporeal diversion and promoting OFA seem to reduce postoperative complications in the first 30 days. Prospective studies are needed to provide a high level of evidence. FAU - Mermier, Marie AU - Mermier M AUID- ORCID: 0000-0001-5279-3696 AD - Department of Urology, University of Rennes, Rennes, France. FAU - Baron, Pierre AU - Baron P AD - Department of Urology, University of Tours, Tours, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, University of Toulouse, Toulouse, France. FAU - Bajeot, Anne-Sophie AU - Bajeot AS AD - Department of Urology, University of Toulouse, Toulouse, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Urology, Paoli-Calmettes Institute, Marseille, France. FAU - Lannes, Francois AU - Lannes F AD - Department of Urology, University of Marseille, Marseille, France. FAU - Ploussard, Guillaume AU - Ploussard G AD - Department of Urology, La Croix du Sud Hospital, Toulouse, France. FAU - Gasmi, Anis AU - Gasmi A AD - Department of Urology, University of Rennes, Rennes, France. FAU - Bensalah, Karim AU - Bensalah K AD - Department of Urology, University of Rennes, Rennes, France. FAU - Perrot, Ophelie AU - Perrot O AD - Department of Urology, University of La Pitie-Salpetriere, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, University of La Pitie-Salpetriere, Paris, France. FAU - Bruyere, Franck AU - Bruyere F AD - Department of Urology, University of Tours, Tours, France. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - University of Medicine, Vienna, Austria. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, University of Rennes, Rennes, France. LA - eng PT - Journal Article DEP - 20220208 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 RN - 0 (Anticoagulants) SB - IM MH - Anticoagulants MH - *Carcinoma, Transitional Cell/surgery MH - Cystectomy/adverse effects MH - Humans MH - Postoperative Complications/epidemiology MH - Retrospective Studies MH - *Robotic Surgical Procedures/adverse effects MH - *Robotics MH - Treatment Outcome MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology/surgery MH - *Urinary Diversion/adverse effects OTO - NOTNLM OT - bladder cancer OT - cystectomy OT - postoperative complications OT - risk factors OT - robot-assisted radical cystectomy OT - urothelial bladder carcinoma EDAT- 2021/12/22 06:00 MHDA- 2022/05/21 06:00 CRDT- 2021/12/21 08:38 PHST- 2021/12/22 06:00 [pubmed] PHST- 2022/05/21 06:00 [medline] PHST- 2021/12/21 08:38 [entrez] AID - 10.1089/end.2021.0617 [doi] PST - ppublish SO - J Endourol. 2022 May;36(5):634-640. doi: 10.1089/end.2021.0617. Epub 2022 Feb 8. PMID- 34926567 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240819 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 8 DP - 2021 TI - Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View. PG - 754741 LID - 10.3389/fsurg.2021.754741 [doi] LID - 754741 AB - The aim of this narrative review is to provide adequate information on handling and reporting of the bladder cancer samples to improve the closely collaboration between pathologists and urologists. The main (but not exclusive) research tool used was PubMed and 87 references were selected and quoted in the text. We have considered handling of biopsies, transurethral resection (TUR), and cystectomy specimens to summarize the different methods of sampling and the related issues. Moreover, we considered and discussed the main prognostic factors, such as histological tumor type, grade, and stage of bladder cancer, that should be described in the pathological report. In addition, critical issues encountered in the interpretation of histological samples were discussed. CI - Copyright (c) 2021 Mazzucchelli, Marzioni, Tossetta, Pepi and Montironi. FAU - Mazzucchelli, Roberta AU - Mazzucchelli R AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, Universita Politecnica delle Marche, Ancona, Italy. FAU - Marzioni, Daniela AU - Marzioni D AD - Departement of Experimental and Clinical Medicine, Universita Politecnica delle Marche, Ancona, Italy. FAU - Tossetta, Giovanni AU - Tossetta G AD - Departement of Experimental and Clinical Medicine, Universita Politecnica delle Marche, Ancona, Italy. FAU - Pepi, Laura AU - Pepi L AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, Universita Politecnica delle Marche, Ancona, Italy. FAU - Montironi, Rodolfo AU - Montironi R AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, Universita Politecnica delle Marche, Ancona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20211202 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8674620 OTO - NOTNLM OT - bladder OT - carcinoma OT - cystectomy OT - handling OT - reporting OT - staging COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/21 06:00 MHDA- 2021/12/21 06:01 PMCR- 2021/12/02 CRDT- 2021/12/20 06:18 PHST- 2021/08/06 00:00 [received] PHST- 2021/10/15 00:00 [accepted] PHST- 2021/12/20 06:18 [entrez] PHST- 2021/12/21 06:00 [pubmed] PHST- 2021/12/21 06:01 [medline] PHST- 2021/12/02 00:00 [pmc-release] AID - 10.3389/fsurg.2021.754741 [doi] PST - epublish SO - Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021. PMID- 34922269 OWN - NLM STAT- MEDLINE DCOM- 20220216 LR - 20220216 IS - 2210-7762 (Print) VI - 260-261 DP - 2022 Jan TI - Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients. PG - 41-45 LID - S2210-7762(21)00234-9 [pii] LID - 10.1016/j.cancergen.2021.12.001 [doi] AB - Promoter hypermethylation have been reported to play a key role in bladder cancer development and progression. The aim of this study is to evaluate the methylation status of hTERT, TWIST1, VIM and NID2 genes in bladder cancer. The methylation status was evaluated using the Methylation-Specific PCR (MSP) approach on 70 tumour biopsies from Moroccan bladder cancer patients. Overall, methylation frequencies of hTERT, TWIST1, VIM and NID2 genes, were 90%, 85.71%, 67.14% and 67.14%, respectively. Hypermethylation of all studied genes was found in all pathological grades and stages of bladder cancer. Nevertheless, statistical analysis showed no significant association between promoter methylation of hTERT, TWIST1, VIM and NID2 genes and tumours stage/grade (p value >0.05). Moreover, we have investigated the association between the methylation pattern of selected genes and the treatment outcome in a sub-group of non-muscle-invasive bladder cancer cases (52/70). Hypermethylation of hTERT, TWIST1, VIM and NID2 was detected in 83.34%; 66.67%; 83.34% and 58.34% of recurrent cases, respectively, and in 80%; 80%; 80% and 60% of progressive cases, respectively. Statistical analysis highlighted a significant association between TWIST1 hypermethylation and tumour recurrence (p = 0.041<0.05). Our results indicate that hypermethylation of hTERT, TWIST1, VIM and NID2 genes is a frequent epigenetic event in bladder cancer and could be a promising therapeutic target to prevent bladder cancer progression and metastasis. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - El Azzouzi, Meryem AU - El Azzouzi M AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco; Faculty of Medicine and Pharmacy of Rabat. Mohammed V University in Rabat, Rabat, Morocco. FAU - El Ahanidi, Hajar AU - El Ahanidi H AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco; Faculty of Medicine and Pharmacy of Rabat. Mohammed V University in Rabat, Rabat, Morocco. FAU - Hafidi Alaoui, Chaimae AU - Hafidi Alaoui C AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco; Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco. FAU - Chaoui, Imane AU - Chaoui I AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco. FAU - Benbacer, Laila AU - Benbacer L AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco. FAU - Tetou, Mohamed AU - Tetou M AD - Mohammed V Military Hospital, Rabat, Morocco. FAU - Hassan, Ilias AU - Hassan I AD - Mohammed V Military Hospital, Rabat, Morocco. FAU - Bensaid, Mounia AU - Bensaid M AD - Mohammed V Military Hospital, Rabat, Morocco. FAU - Oukabli, Mohamed AU - Oukabli M AD - Faculty of Medicine and Pharmacy of Rabat. Mohammed V University in Rabat, Rabat, Morocco; Mohammed V Military Hospital, Rabat, Morocco. FAU - Ameur, Ahmed AU - Ameur A AD - Faculty of Medicine and Pharmacy of Rabat. Mohammed V University in Rabat, Rabat, Morocco; Mohammed V Military Hospital, Rabat, Morocco. FAU - Al Bouzidi, Abderrahmane AU - Al Bouzidi A AD - Faculty of Medicine and Pharmacy of Rabat. Mohammed V University in Rabat, Rabat, Morocco. FAU - El Mzibri, Mohammed AU - El Mzibri M AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco. FAU - Attaleb, Mohammed AU - Attaleb M AD - Biology and Medical Research Unit, CNESTEN, Rabat, Morocco. Electronic address: attaleb@cnesten.org.ma. LA - eng PT - Journal Article DEP - 20211206 PL - United States TA - Cancer Genet JT - Cancer genetics JID - 101539150 RN - 0 (Biomarkers, Tumor) RN - 0 (Calcium-Binding Proteins) RN - 0 (Cell Adhesion Molecules) RN - 0 (NID2 protein, human) RN - 0 (Nuclear Proteins) RN - 0 (TWIST1 protein, human) RN - 0 (Twist-Related Protein 1) RN - 0 (VIM protein, human) RN - 0 (Vimentin) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Calcium-Binding Proteins/*genetics MH - Cell Adhesion Molecules/*genetics MH - *DNA Methylation MH - Female MH - Genetic Association Studies MH - Humans MH - Male MH - Middle Aged MH - Morocco MH - Neoplasm Grading MH - Neoplasm Staging MH - Nuclear Proteins/*genetics MH - Promoter Regions, Genetic MH - Telomerase/*genetics MH - Twist-Related Protein 1/*genetics MH - Urinary Bladder Neoplasms/genetics/*pathology MH - Vimentin/*genetics OTO - NOTNLM OT - Bladder cancer OT - DNA methylation OT - Epigenetics OT - Methylation specific PCR OT - Recurrence COIS- Declaration of Competing Interest The authors declare that they have no conflict of interest. EDAT- 2021/12/19 06:00 MHDA- 2022/02/17 06:00 CRDT- 2021/12/18 20:29 PHST- 2021/07/16 00:00 [received] PHST- 2021/11/08 00:00 [revised] PHST- 2021/12/05 00:00 [accepted] PHST- 2021/12/19 06:00 [pubmed] PHST- 2022/02/17 06:00 [medline] PHST- 2021/12/18 20:29 [entrez] AID - S2210-7762(21)00234-9 [pii] AID - 10.1016/j.cancergen.2021.12.001 [doi] PST - ppublish SO - Cancer Genet. 2022 Jan;260-261:41-45. doi: 10.1016/j.cancergen.2021.12.001. Epub 2021 Dec 6. PMID- 34920986 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20250314 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 1 DP - 2022 Feb TI - Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. PG - 84-91 LID - S2588-9311(21)00216-9 [pii] LID - 10.1016/j.euo.2021.11.006 [doi] AB - BACKGROUND: The 2021 European Association of Urology (EAU) guidelines contain updated prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC). These groups are based on the following predictors of progression: tumour stage, grade, number, and size; concomitant carcinoma in situ; and age. However, the groups were derived from datasets excluding patients treated with bacillus Calmette-Guerin (BCG). OBJECTIVE: To determine the validity of the updated EAU prognostic factor risk groups in patients with NMIBC treated with BCG. DESIGN, SETTING, AND PARTICIPANTS: We reviewed patients treated with BCG at our institution between 2000 and 2018. Patients were analysed according to the receipt of "at least induction" and "adequate" BCG (as defined by the US Food and Drug Administration). Risk groups were assigned according to the 2021 EAU NMIBC risk calculator (https://nmibc.net/). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The Kaplan-Meier method was used to estimate the risks of progression at 1 and 5 yr. Probabilities of progression obtained with the updated prognostic factor risk groups in our series were compared with those reported by the EAU. Discrimination was assessed using the concordance index (c-index). RESULTS AND LIMITATIONS: A total of 529 patients received at least induction BCG with a median follow-up of 47.3 mo (interquartile range 25.3-86.9). Of these patients, 494 received adequate BCG. We found lower progression rates at 1 yr in the very-high-risk group patients receiving at least induction (6.9%) and adequate BCG (4.0%) versus 16.0% for the EAU predicted rates. Additionally, progression rates were also lower at 5 yr in the high-risk group-7.4% for at least induction and 5.3% for adequate BCG versus 9.6% for EAU predicted rates; the rates in the very-high-risk group were as follows: 16.7% for at least induction and 14.9% for adequate BCG versus 40.0% for EAU predicted rates. The c-index in our series was lower than that reported by the EAU (0.63 vs 0.80). Of interest, our multivariable analysis identified grade, stage, and age (p < 0.02) to be the predictors of progression after BCG therapy. CONCLUSIONS: While the 2021 EAU prognostic factor risk groups successfully stratified progression risks in our cohort, treatment with BCG reduced their discriminative ability. Furthermore, the groups overestimate progression risks in BCG-treated patients. These findings should be used in conjunction with the updated risk groups to counsel patients with higher-risk NMIBC about their risk of progression with and without BCG. PATIENT SUMMARY: Although the updated European Association of Urology prognostic factor risk groups are able to stratify patients with non-muscle-invasive bladder cancer according to their risk of progression to muscle-invasive bladder cancer, this risk is overestimated in patients treated with bacillus Calmette-Guerin (BCG). CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Lobo, Niyati AU - Lobo N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211215 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) SB - IM CIN - Nat Rev Urol. 2022 Feb;19(2):67. doi: 10.1038/s41585-022-00565-6. PMID: 35031786 MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Prognosis MH - United States MH - *Urinary Bladder Neoplasms/pathology MH - *Urology PMC - PMC11902298 MID - NIHMS2060425 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Progression OT - Risk stratification EDAT- 2021/12/19 06:00 MHDA- 2022/05/06 06:00 PMCR- 2025/03/12 CRDT- 2021/12/18 05:33 PHST- 2021/08/25 00:00 [received] PHST- 2021/11/07 00:00 [revised] PHST- 2021/11/17 00:00 [accepted] PHST- 2021/12/19 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2021/12/18 05:33 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - S2588-9311(21)00216-9 [pii] AID - 10.1016/j.euo.2021.11.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Feb;5(1):84-91. doi: 10.1016/j.euo.2021.11.006. Epub 2021 Dec 15. PMID- 34919338 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220526 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 130 IP - 4 DP - 2022 Apr TI - Impact of bacillus Calmette-Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with high-grade bladder cancer. PG - 294-302 LID - 10.1002/cncy.22539 [doi] AB - BACKGROUND: In high-grade urothelial carcinoma (UC) of the bladder, bacillus Calmette-Guerin (BCG) therapy is a therapeutic mainstay, and urinary cytology is recommended to detect recurrences. However, intravesical BCG instillations can induce morphologic changes in urothelial cells. The authors investigated the impact of BCG therapy on the efficacy of urinary cytology. METHODS: Matched pathology and cytology samples from patients undergoing transurethral resection of the bladder after BCG therapy were assessed. Cytology samples were graded according to The Paris System for Reporting Urinary Cytology. Diagnostic quality criteria were tested for different cutoff definitions, and the results were compared between those obtained <100 versus >/=100 days after the last BCG instillation. In addition, the oncologic outcome of false-positive results was assessed. RESULTS: In total, 389 matched cases from 197 patients who had a history of high-grade UC (HGUC) were identified. Sixty cases (15.7%) were diagnosed as high-grade urothelial bladder cancer. The cytology diagnoses were as follows: non-HGUC, 191 cases (49.1%); atypical urothelial cells, 80 cases (20.6%); suspicious for HGUC, 56 cases (14.4%); and HGUC, 56 cases (14.4%). Interrater reliability was substantial (kappa = 0.660). Sensitivity increased from 45% to 75% when cases diagnosed as suspicious for HGUC were also counted as positive. Notably, sensitivity was reduced within the first 100 days after BCG therapy (61.9%) compared with sensitivity at longer intervals (82.1%). Reactive atypia (odds ratio, 4.155; 95% confidence interval, 2.136-8.085; P < .001) and cellular degeneration (odds ratio, 5.050; 95% CI, 2.094-12.175; P < .001) of urothelial cells were associated with false-positive rates, and 44.7% of patients who had a false-positive cytology classification presented with HGUC during follow-up. CONCLUSIONS: BCG therapy has a short-term adverse impact on the efficacy of urinary cytology. After BCG therapy, cases classified as suspicious for HGUC should be considered positive. Importantly, patients with false-positive cytology findings should be closely monitored. CI - (c) 2021 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society. FAU - Hermans, Julian AU - Hermans J AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Jokisch, Friedrich AU - Jokisch F AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Volz, Yannic AU - Volz Y AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Pfitzinger, Paulo AU - Pfitzinger P AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Ebner, Benedikt AU - Ebner B AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Weinhold, Philipp AU - Weinhold P AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Schlenker, Boris AU - Schlenker B AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Stief, Christian G AU - Stief CG AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Tritschler, Stefan AU - Tritschler S AD - Department of Urology and Urologic Oncology, Loretto Hospital, Freiburg, Germany. FAU - Schulz, Gerald B AU - Schulz GB AUID- ORCID: 0000-0002-0340-0304 AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. LA - eng PT - Journal Article DEP - 20211217 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Reproducibility of Results MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy OTO - NOTNLM OT - administration, intravesical OT - bacillus Calmette-Guerin (BCG) therapy OT - carcinoma, transitional cell OT - cytologic techniques OT - immunotherapy OT - urinary bladder neoplasms EDAT- 2021/12/18 06:00 MHDA- 2022/04/06 06:00 CRDT- 2021/12/17 12:33 PHST- 2021/11/07 00:00 [revised] PHST- 2021/08/01 00:00 [received] PHST- 2021/11/18 00:00 [accepted] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/04/06 06:00 [medline] PHST- 2021/12/17 12:33 [entrez] AID - 10.1002/cncy.22539 [doi] PST - ppublish SO - Cancer Cytopathol. 2022 Apr;130(4):294-302. doi: 10.1002/cncy.22539. Epub 2021 Dec 17. PMID- 34913840 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220501 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 1 DP - 2022 Feb TI - Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety. PG - 39-46 LID - 10.1080/21681805.2021.2014562 [doi] AB - CONTEXT: Improving efficiency of follow-up for non-muscle invasive bladder tumours (NMIBC) without risking disease progression through delays of recurrence diagnosis, is a highly relevant field of research. OBJECTIVE: The aim of our systematic review was to investigate whether the available evidence support alternative follow-up cytoscopic schedules with respect to oncological safety, compared to those currently given in clinical guidelines for NMIBC. Evidence acquisition we included prospective studies investigating cystoscopy based follow-up schedules including, but not restricted to, comparison of two or more different follow-up schedules with respect to oncological safety measured by recurrence free survival, progression free survival, and overall survival. We allowed for supplementation of modalities such as urinary biomarkers. We screened 680 studies identified by a systematic literature search and, based on our inclusion and exclusion criteria, we included three studies for the narrative synthesis of evidence. CONCLUSION: In our systematic search of the literature, we found only low level evidence to support current or alternative cystoscopic follow-up schedules. Clinical trials directly aimed at investigating novel follow-up schedules for NMIBC are needed before substantial changes to existing clinical guidelines can be made. FAU - Dreyer, Thomas AU - Dreyer T AUID- ORCID: 0000-0002-3970-2961 AD - Department of Urology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Ernst, Andreas AU - Ernst A AUID- ORCID: 0000-0001-5533-8891 AD - Department of Urology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. AD - Department of Public Health, Research Unit for Epidemiology, Aarhus University, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AUID- ORCID: 0000-0002-4347-739X AD - Department of Urology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211216 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - *Cystoscopy MH - Follow-Up Studies MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/therapy OTO - NOTNLM OT - NMIBC OT - Non-muscle invasive bladder cancer OT - cystoscopy OT - follow-up EDAT- 2021/12/17 06:00 MHDA- 2022/02/09 06:00 CRDT- 2021/12/16 12:22 PHST- 2021/12/17 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] PHST- 2021/12/16 12:22 [entrez] AID - 10.1080/21681805.2021.2014562 [doi] PST - ppublish SO - Scand J Urol. 2022 Feb;56(1):39-46. doi: 10.1080/21681805.2021.2014562. Epub 2021 Dec 16. PMID- 34913802 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20220429 IS - 1521-0553 (Electronic) IS - 0894-1939 (Linking) VI - 35 IP - 5 DP - 2022 May TI - A Nomogram Model to Predict Recurrence of Non-Muscle Invasive Bladder Urothelial Carcinoma After Resection Based on Clinical Parameters and Immunohistochemical Markers. PG - 1186-1194 LID - 10.1080/08941939.2021.2017080 [doi] AB - OBJECTIVE: This study aims to establish a nomogram model by combining traditional clinical parameters with immunohistochemical markers to predict the recurrence of non-muscle invasive bladder urothelial carcinoma (NMIBUC) after resection. METHODS: In total, 504 patients were included in this study. Of these patients, 353 underwent transurethral resection of bladder tumor (TURBT) in the Yongchuan Hospital of Chongqing Medical University and were identified as a training cohort. Univariate and multivariate Cox regression analyses were used to determine the risk factors associated with recurrence in the training cohort and to establish a nomogram model. A total of 151 patients who were hospitalized in the Second Affiliated Hospital of Chongqing Medical University (validation cohort) were used for further validation. The calibration curve was generated for internal and external model validation. The clinical practicability of this model was further verified by comparing the consistency index (C-index) among various models. RESULTS: The mean follow-up time of the training cohort was 45.6 months (range 4-90). In total, 146 patients relapsed in training cohort. After univariate analysis, multivariate analysis further confirmed tumor grade (p=.034), immediate postoperative instillation therapy (p=.025), Ki67 (p=.047), P53 (p=.038) and CK20 (p=.049) as independent risk factors for recurrence, and these factors were included in the nomogram model. The model more accurately predicted recurrence compared with other models based on the highest C-index of 0.82 (95% CI, 0.78-0.86) in the training cohort and 0.80 (95% CI, 0.77-0.83) in the validation cohort. CONCLUSIONS: This proposed nomogram model based on traditional clinical parameters and immunohistochemical markers can more accurately predict postoperative recurrence in patients with NMIBUC. FAU - Pi, Jiangchuan AU - Pi J AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Xiong, Yongjiang AU - Xiong Y AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Liu, Chuan AU - Liu C AD - Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Liao, Juan AU - Liao J AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Liu, Jiaji AU - Liu J AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Li, Chuan AU - Li C AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Fu, Wenyu AU - Fu W AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. FAU - Zhao, Tao AU - Zhao T AD - Department of Urology, The Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China. LA - eng PT - Journal Article DEP - 20211216 PL - United States TA - J Invest Surg JT - Journal of investigative surgery : the official journal of the Academy of Surgical Research JID - 8809255 SB - IM UIN - J Invest Surg. 2022 May;35(5):1195. doi: 10.1080/08941939.2022.2047244. PMID: 35249424 MH - *Carcinoma, Transitional Cell/diagnosis/surgery MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/diagnosis/epidemiology/etiology MH - Nomograms MH - Retrospective Studies MH - Urinary Bladder/surgery MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/surgery OTO - NOTNLM OT - immunohistochemical markers OT - nomogram model OT - non-muscle invasive bladder urothelial carcinoma OT - prognosis OT - recurrence OT - traditional clinical parameters EDAT- 2021/12/17 06:00 MHDA- 2022/04/28 06:00 CRDT- 2021/12/16 12:20 PHST- 2021/12/17 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] PHST- 2021/12/16 12:20 [entrez] AID - 10.1080/08941939.2021.2017080 [doi] PST - ppublish SO - J Invest Surg. 2022 May;35(5):1186-1194. doi: 10.1080/08941939.2021.2017080. Epub 2021 Dec 16. PMID- 34902876 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20220307 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 29 IP - 3 DP - 2022 Mar TI - Prognostication in Japanese patients with bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy. PG - 242-249 LID - 10.1111/iju.14759 [doi] AB - OBJECTIVES: The US Food and Drug Administration recently defined the clinical term "bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer" as a disease state resistant to adequate bacillus Calmette-Guerin therapy. There is a significant lack of prognostication for this disease even in patients who have undergone early radical cystectomy. This study aimed to identify the clinical outcomes and prognostic factors in Japanese patients with bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer who underwent early radical cystectomy. METHODS: Data from a large-scale multicenter retrospective study included 2879 patients with highest-risk or high-risk non-muscle-invasive bladder cancer who received intravesical bacillus Calmette-Guerin induction therapy between January 2000 and December 2019. A total of 141 patients (4.3%) met the criteria for bacillus Calmette-Guerin-unresponsive disease, of whom 47 (33.3%) underwent early radical cystectomy. Prognostic factors for three clinical endpoints, namely, unresectable lesion-free survival, cancer-specific survival, and overall survival, were identified. RESULTS: The highest-risk status at induction bacillus Calmette-Guerin was associated with short unresectable lesion-free survival (hazard ratio 7.85; P < 0.05), cancer-specific survival (hazard ratio 12.24; P < 0.05), and overall survival (hazard ratio 9.25; P < 0.01). Moreover, extravesical tumors (pathological T3 or T4) on the radical cystectomy specimens were associated with poor prognosis and were found at a higher rate in patients with the highest-risk status at induction bacillus Calmette-Guerin than in those with high-risk status (35.7% vs 21.2%). CONCLUSIONS: The highest-risk status among the pre-bacillus Calmette-Guerin factors was associated with upstaging to extravesical tumors and poor prognosis despite early radical cystectomy procedures. Appropriate decision-making and the correct timing of radical cystectomy are vital to avoid treatment delays and improve outcomes. CI - (c) 2021 The Japanese Urological Association. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kota AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyamoto, Tatsuki AU - Miyamoto T AUID- ORCID: 0000-0002-0065-881X AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Tomida, Ryotaro AU - Tomida R AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan. FAU - Matsumura, Yoshiaki AU - Matsumura Y AD - Department of Urology, Nara Prefecture General Medical Center, Nara, Japan. FAU - Yajima, Shugo AU - Yajima S AD - Division of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. FAU - Masuda, Hitoshi AU - Masuda H AD - Division of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. FAU - Terada, Naoki AU - Terada N AD - Department of Urology, Miyazaki University, Miyazaki, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20211213 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Int J Urol. 2022 Mar;29(3):249-250. doi: 10.1111/iju.14770. PMID: 34908190 CIN - Int J Urol. 2022 Mar;29(3):250. doi: 10.1111/iju.14783. PMID: 34983081 MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Cystectomy/methods MH - Humans MH - Japan/epidemiology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/epidemiology/prevention & control MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery OTO - NOTNLM OT - bacillus Calmette-Guerin-unresponsive OT - early radical cystectomy OT - extravesical tumor OT - highest-risk EDAT- 2021/12/14 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/12/13 20:32 PHST- 2021/11/09 00:00 [revised] PHST- 2021/09/09 00:00 [received] PHST- 2021/11/18 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/12/13 20:32 [entrez] AID - 10.1111/iju.14759 [doi] PST - ppublish SO - Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13. PMID- 34901146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211215 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 8 DP - 2021 TI - Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC). PG - 790738 LID - 10.3389/fsurg.2021.790738 [doi] LID - 790738 AB - Purpose: Discordance between pre-operative biopsy and final pathology for Upper Tract Urothelial Carcinoma (UTUC) is high and optimal management remains controversial. The aim of this study is to evaluate the accuracy of pre-operative biopsy, to identify prognostic factors and to evaluate the effect of adjuvant chemotherapy on survival and oncologic outcome in UTUC. Methods: We analyzed records of patients receiving surgical treatment for UTUC. Pathology of pre-operative biopsy was compared to surgical specimen. We used Kaplan-Meier method to estimate survival probabilities and Cox's proportional hazards models to estimate the association between covariates and event times. Primary endpoint was overall survival (OS). A matched-pair analysis was performed to evaluate the effect of adjuvant chemotherapy. Results: 151 patients underwent surgical treatment (28% open, 36% laparoscopic, 17% robotic radical nephroureterectomy; 14% segmental ureteral resections and 5% palliative nephrectomy) for UTUC and were included in the analysis. Upstaging from /=pT1 in final pathology occurred in 61% of patients and upgrading from low-grade to high-grade occurred in 30% of patients. Five-year OS was 59.5%. In the univariate Cox-regression model pathological stage, grade, lymphovascular invasion and positive surgical margins were associated with OS. Matched pair analysis for stage (/=pT3; pN+) and age revealed a significant survival benefit for adjuvant chemotherapy (HR 0.40, 0.14-0.77, p < 0.018) in this cohort. Conclusion: UTUC is often underestimated in pre-operative biopsy, and it is associated with significant mortality. Pathological stage and grade, lymphovascular invasion and lymph node metastases are predictors of oncologic outcome and survival. CI - Copyright (c) 2021 Koll, Meisenzahl, Haller, Maisch, Kirchhoff, Horn, Gschwend and Schmid. FAU - Koll, Florestan J AU - Koll FJ AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. AD - Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. FAU - Meisenzahl, Eva AU - Meisenzahl E AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. FAU - Haller, Bernhard AU - Haller B AD - Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, Munich, Germany. FAU - Maisch, Philipp AU - Maisch P AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. AD - Department of Urology, University of Ulm, Ulm, Germany. FAU - Kirchhoff, Florian AU - Kirchhoff F AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. FAU - Horn, Thomas AU - Horn T AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. FAU - Gschwend, Jurgen E AU - Gschwend JE AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. FAU - Schmid, Sebastian C AU - Schmid SC AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, School of Medicine, Munich, Germany. LA - eng PT - Journal Article DEP - 20211125 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8655158 OTO - NOTNLM OT - UTUC OT - adjuvant chemotherapy OT - nephroureterectomy OT - segmental ureteral resection OT - upper tract urothelial carcinoma OT - ureteroscopy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/14 06:00 MHDA- 2021/12/14 06:01 PMCR- 2021/11/25 CRDT- 2021/12/13 18:09 PHST- 2021/10/07 00:00 [received] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/12/13 18:09 [entrez] PHST- 2021/12/14 06:00 [pubmed] PHST- 2021/12/14 06:01 [medline] PHST- 2021/11/25 00:00 [pmc-release] AID - 10.3389/fsurg.2021.790738 [doi] PST - epublish SO - Front Surg. 2021 Nov 25;8:790738. doi: 10.3389/fsurg.2021.790738. eCollection 2021. PMID- 34895996 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis. PG - 45-55 LID - S1078-1439(21)00504-4 [pii] LID - 10.1016/j.urolonc.2021.11.008 [doi] AB - OBJECTIVE: To investigate the accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) in detection of muscle-invasive bladder cancer (MIBC) we performed a systematic review and meta-analysis of the available literature. MATERIALS AND METHODS: Scopus, Web of Science, PubMed, and EMBASE were searched up to 8 March 2021 for the studies evaluating the diagnostic performance of VI-RADS for the detection of MIBC. Inclusion criteria were patients with bladder cancer; index test of VI-RADS based on multiparametric MRI; reference test of histopathological findings from TURBT, re-TURBT, or cystectomy and study design of cohort. Case reports, review articles, and editorials were eliminated, as well as studies with insufficient knowledge to acquire TP, FP, FN, and TN values of VI-RADS. The MIDAS module of STATA was for statistical analysis. The heterogeneity was explored using subgroup analysis and meta-regression analysis. RESULTS: Overall, 22 eligible studies, consisting of 2,576 participants and 5,414 MRI reports, were included in this meta-analysis. The area under curve (AUC) of VI-RADS at cut-point values of 3 and 4 were 0.93 (95%CI: 0.91, 0.95), 0.93 (95%CI: 0.90, 0.95), respectively. Based on Youden's J statistic, the optimal VI-RADS cutoff value for predicting MIBC was determined as 3 which granted a pooled sensitivity of 89% (95%CI: 87%, 91%; I(2)=48%) and a specificity of 84% (95%CI: 80%, 87%; I(2)=90%). Based on meta-regression, the sources of inter-study heterogeneity for VI-RADS >/= 3 were the sample size > 70, study design, single-center vs multi-center, patient population characteristics (i.e., gender, age), reference standard, histology, magnetic strength, T2WI slice thickness, and the number of radiologists reporting the MRI results (P value /=1.4 mm), largest invasive focus (>/=3.6 mm), aggregate linear length of invasion (>/=8.9 mm), and number of invasive foci (>/=3 foci) correlated significantly with progression and reduced progression-free survival, whereas invasion into muscularis mucosa or vascular plexus, or focal versus extensive invasion (focal when /=3) and/or measuring the largest contiguous focus of invasive carcinoma (>/=3.6 mm) are practical tools for prognostic substaging of T1 cancers. FAU - Budina, Anna AU - Budina A AD - From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak). FAU - Farahani, Sahar J AU - Farahani SJ AD - From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak). AD - Farahani is currently located at the Department of Pathology and Laboratory Medicine, Stony Brook University, Long Island, New York. FAU - Lal, Priti AU - Lal P AD - From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak). AD - The Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania (Lal, Nayak). FAU - Nayak, Anupma AU - Nayak A AD - From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak). AD - The Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania (Lal, Nayak). LA - eng PT - Journal Article PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 SB - IM MH - Biopsy MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology EDAT- 2021/12/07 06:00 MHDA- 2022/09/09 06:00 CRDT- 2021/12/06 17:27 PHST- 2021/08/10 00:00 [accepted] PHST- 2021/12/07 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2021/12/06 17:27 [entrez] AID - 474696 [pii] AID - 10.5858/arpa.2021-0175-OA [doi] PST - ppublish SO - Arch Pathol Lab Med. 2022 Sep 1;146(9):1131-1139. doi: 10.5858/arpa.2021-0175-OA. PMID- 34869576 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211207 IS - 2296-889X (Print) IS - 2296-889X (Electronic) IS - 2296-889X (Linking) VI - 8 DP - 2021 TI - Biological Functions and Prognostic Value of Ferroptosis-Related Genes in Bladder Cancer. PG - 631152 LID - 10.3389/fmolb.2021.631152 [doi] LID - 631152 AB - Background: Every year, nearly 170,000 people die from bladder cancer worldwide. A major problem after transurethral resection of bladder tumor is that 40-80% of the tumors recur. Ferroptosis is a type of regulatory necrosis mediated by iron-catalyzed, excessive oxidation of polyunsaturated fatty acids. Increasing the sensitivity of tumor cells to ferroptosis is a potential treatment option for cancer. Establishing a diagnostic and prognostic model based on ferroptosis-related genes may provide guidance for the precise treatment of bladder cancer. Methods: We downloaded mRNA data in Bladder Cancer from The Cancer Genome Atlas and analyzed differentially expressed genes based on and extract ferroptosis-related genes. We identified relevant pathways and annotate the functions of ferroptosis-related DEGs using Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis and Gene Ontology functions. On the website of Search Tool for Retrieving Interacting Genes database (STRING), we downloaded the protein-protein interactions of DEGs, which were drawn by the Cytoscape software. Then the Cox regression analysis were performed so that the prognostic value of ferroptosis-related genes and survival time are combined to identify survival- and ferroptosis-related genes and establish a prognostic formula. Survival analysis and receiver operating characteristic curvevalidation were then performed. Risk curves and nomograms were generated for both groups to predict survival. Finally, RT-qPCR was applied to analyze gene expression. Results: Eight ferroptosis-related genes with prognostic value (ISCU, NFE2L2, MAFG, ZEB1, VDAC2, TXNIP, SCD, and JDP2) were identified. With clinical data, we established a prognostic model to provide promising diagnostic and prognostic information of bladder cancer based on the eight ferroptosis-related genes. RT-qPCR revealed the genes that were differentially expressed between normal and cancer tissues. Conclusion: This study found that the ferroptosis-related genes is associated with bladder cancer, which may serve as new target for the treatment of bladder cancer. CI - Copyright (c) 2021 Yi, Liu, Rong, Wang, Tang, Zhang, Xiong and Wang. FAU - Yi, Kezhen AU - Yi K AD - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Liu, JingChong AU - Liu J AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Rong, Yuan AU - Rong Y AD - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Wang, Cheng AU - Wang C AD - Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, China. FAU - Tang, Xuan AU - Tang X AD - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Zhang, XiaoPing AU - Zhang X AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xiong, Yunhe AU - Xiong Y AD - Urology Department, Renmin Hospital of Wuhan University, Wuhan, China. FAU - Wang, Fubing AU - Wang F AD - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Center for Single-Cell Omics and Tumor Liquid Biopsy, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, China. LA - eng PT - Journal Article DEP - 20211117 PL - Switzerland TA - Front Mol Biosci JT - Frontiers in molecular biosciences JID - 101653173 PMC - PMC8635965 OTO - NOTNLM OT - bladder cancer OT - ferroptosis OT - mRNA OT - prognostic model construction OT - survival analysis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/07 06:00 MHDA- 2021/12/07 06:01 PMCR- 2021/01/01 CRDT- 2021/12/06 09:21 PHST- 2020/11/19 00:00 [received] PHST- 2021/10/15 00:00 [accepted] PHST- 2021/12/06 09:21 [entrez] PHST- 2021/12/07 06:00 [pubmed] PHST- 2021/12/07 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 631152 [pii] AID - 10.3389/fmolb.2021.631152 [doi] PST - epublish SO - Front Mol Biosci. 2021 Nov 17;8:631152. doi: 10.3389/fmolb.2021.631152. eCollection 2021. PMID- 34861847 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20220222 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Dec 3 TI - Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. PG - 1293 LID - 10.1186/s12885-021-08926-x [doi] LID - 1293 AB - BACKGROUND: Bladder cancer (BC) is one of the most common malignancies globally. Early diagnosis of it can significantly improve patients' survival and quality of life. Urinary exosomes (UEs)-derived miRNAs might be a promising biomarker for BC detection. METHOD: A total of 12 patients with BC and 4 non-cancerous participants (as healthy control) were recruited from a single center between March 2018 and December 2019 as the discovery set. Midstream urine samples from each participants were collected and high-throughput sequencing and differentially expression analysis were conducted. Combined with miRNA expression profile of BC tissue from The Cancer Genome Atlas (TCGA), miRNAs biomarkers for BC were determined. Candidate miRNAs as biomarkers were selected followed by verification with a quantitative reverse-transcription polymerase chain reaction assay in an independent validation cohort consisting of 53 BC patients and 51 healthy controls. The receiver-operating characteristic (ROC) curve was established to evaluate the diagnostic performance of UE-derived miRNAs. The possible mechanism of miRNAs were revealed by bioinformatic analysis and explored in vitro experiments. RESULTS: We identified that miR-93-5p, miR-516a-5p were simultaneously significantly increased both in UEs from BC compared with healthy control and BC tissue compared with normal tissue, which were verified by RT-qPCR in the validation cohort. Subsequently, the performance to discover BC of the miR-93-5p, miR-516a-5p was further verified with an area under ROC curve (AUC) of 0.838 and 0.790, respectively, which was significantly higher than that of urine cytology (AUC = 0.630). Moreover, miR-93-5p was significantly increased in muscle-invasive BC compared with non-muscle-invasive BC with an AUC of 0.769. Bioinformatic analysis revealed that B-cell translocation gene 2(BTG2) gene may be the hub target gene of miR-93-5p. In vitro experiments verified that miR-93-5p suppressed BTG2 expression and promoted BC cells proliferation, invasion and migration. CONCLUSION: Urine derived exosomes have a distinct miRNA profile in BC patients, and urinary exosomal miRNAs could be used as a promising non-invasive tool to detect BC. In vitro experiments suggested that miR-93-5p overexpression may contribute to BC progression via suppressing BTG2 expression. CI - (c) 2021. The Author(s). FAU - Lin, Hao AU - Lin H AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Shi, Xiaojun AU - Shi X AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Li, Haoran AU - Li H AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Hui, Jialiang AU - Hui J AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Liu, Ruiyu AU - Liu R AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Chen, Zihao AU - Chen Z AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Lu, Yuwen AU - Lu Y AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Tan, Wanlong AU - Tan W AD - Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. twl@smu.edu.cn. LA - eng PT - Journal Article DEP - 20211203 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (MIRN93 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Cell Line, Tumor MH - Exosomes/*metabolism MH - Female MH - High-Throughput Nucleotide Sequencing/*methods MH - Humans MH - Male MH - MicroRNAs/*metabolism MH - Middle Aged MH - Transfection MH - Urinary Bladder Neoplasms/*genetics PMC - PMC8641206 OTO - NOTNLM OT - BTG2 OT - Biomarker OT - Bladder cancer OT - Urinary exosomes OT - microRNA COIS- The authors declare that they have no competing interests. EDAT- 2021/12/05 06:00 MHDA- 2022/02/23 06:00 PMCR- 2021/12/03 CRDT- 2021/12/04 05:22 PHST- 2021/03/30 00:00 [received] PHST- 2021/10/27 00:00 [accepted] PHST- 2021/12/04 05:22 [entrez] PHST- 2021/12/05 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PHST- 2021/12/03 00:00 [pmc-release] AID - 10.1186/s12885-021-08926-x [pii] AID - 8926 [pii] AID - 10.1186/s12885-021-08926-x [doi] PST - epublish SO - BMC Cancer. 2021 Dec 3;21(1):1293. doi: 10.1186/s12885-021-08926-x. PMID- 34856960 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20220224 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 21 IP - 1 DP - 2021 Dec 2 TI - Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma. PG - 167 LID - 10.1186/s12894-021-00932-2 [doi] LID - 167 AB - BACKGROUND: One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after retroperitoneoscopic nephroureterectomy (RNU) for UTUC. METHODS: Clinicopathological and surgical information were collected from the medical records of 73 patients treated with RNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after RNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoretroperitoneum time, was analyzed using the Fisher exact test. RESULTS: During the median follow-up time of 39.1 months, 18 (24.7%) patients had subsequent IVR after RNU. The 1- and 3-year IVR-free survival rates were 85.9% and 76.5%, respectively. The Fisher exact test revealed that prolonged pneumoretroperitoneum time of >/= 210 min was a risk factor for IVR in 1 year after RNU (p = 0.0358) and positive urine cytology was a risk factor for IVR in 3 years after RNU (p = 0.0352). CONCLUSIONS: In UTUC, the occurrences of IVR in 1 and 3 years after RNU are highly probable when the pneumoretroperitoneum time is prolonged (>/= 210 min) and in patients with positive urine cytology, respectively. Strict follow-up after RNU is more probable recommended for these patients. CI - (c) 2021. The Author(s). FAU - Yanagi, Masato AU - Yanagi M AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. area-i@nms.ac.jp. FAU - Hamasaki, Tsutomu AU - Hamasaki T AD - Department of Urology, Nippon Medical School Musashikosugi Hospital, 1-396, Kosugityo, Nakahara-ku, Kawasaki city, Kanagawa, 211-8533, Japan. FAU - Akatsuka, Jun AU - Akatsuka J AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. FAU - Endo, Yuki AU - Endo Y AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. FAU - Takeda, Hayato AU - Takeda H AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. FAU - Kondo, Yukihiro AU - Kondo Y AD - Department of Urology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. LA - eng PT - Journal Article DEP - 20211202 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/*surgery MH - *Laparoscopy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasms, Second Primary/*epidemiology MH - Nephroureterectomy/*methods MH - Retroperitoneal Space MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder Neoplasms/*epidemiology PMC - PMC8638342 OTO - NOTNLM OT - Intravesical recurrence OT - Pneumoretroperitoneum time OT - Retroperitoneoscopic nephroureterectomy OT - Upper urinary tract OT - Urine cytology OT - Urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2021/12/04 06:00 MHDA- 2022/02/25 06:00 PMCR- 2021/12/02 CRDT- 2021/12/03 05:40 PHST- 2021/09/08 00:00 [received] PHST- 2021/11/24 00:00 [accepted] PHST- 2021/12/03 05:40 [entrez] PHST- 2021/12/04 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/12/02 00:00 [pmc-release] AID - 10.1186/s12894-021-00932-2 [pii] AID - 932 [pii] AID - 10.1186/s12894-021-00932-2 [doi] PST - epublish SO - BMC Urol. 2021 Dec 2;21(1):167. doi: 10.1186/s12894-021-00932-2. PMID- 34854189 OWN - NLM STAT- MEDLINE DCOM- 20220915 LR - 20250314 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 130 IP - 4 DP - 2022 Oct TI - Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guerin? PG - 463-469 LID - 10.1111/bju.15665 [doi] AB - OBJECTIVE: To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette-Guerin (BCG). PATIENTS AND METHODS: We performed an Institutional Review Board-approved review of patients with NMIBC treated with adequate intravesical BCG, at our institution between 2000 and 2018. FCI use at the time of BCG therapy was recorded for each patient. Patients were stratified according to use of FCI medication. Recurrence- and progression-free survival were analysed using Kaplan-Meier methods and Cox proportional hazard models. RESULTS: Overall, 226 of 526 patients (43.0%) used a FCI: aspirin (205), clopidogrel (38), warfarin (18) and novel oral anticoagulant (NOAC; seven). The use of FCIs did not adversely affect either recurrence- or progression-free survival (P = 0.385 and P = 0.131, respectively). These results did not change when the impact of aspirin, clopidogrel or warfarin/NOAC use on recurrence and progression was evaluated separately. On multivariate analysis, FCI use was neither associated with tumour recurrence nor progression. CONCLUSION: The use of FCIs was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. Based on these results, FCIs may be safely continued during BCG immunotherapy. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Lobo, Niyati AU - Lobo N AUID- ORCID: 0000-0002-6505-8399 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick J AU - Hensley PJ AUID- ORCID: 0000-0002-8098-901X AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211213 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (Anticoagulants) RN - 0 (BCG Vaccine) RN - 5Q7ZVV76EI (Warfarin) RN - 9001-31-4 (Fibrin) RN - A74586SNO7 (Clopidogrel) RN - R16CO5Y76E (Aspirin) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Anticoagulants/therapeutic use MH - Aspirin/pharmacology/therapeutic use MH - BCG Vaccine/therapeutic use MH - Clopidogrel/therapeutic use MH - Fibrin/therapeutic use MH - Humans MH - Neoplasm Recurrence, Local/drug therapy MH - *Thrombosis MH - *Urinary Bladder Neoplasms/pathology MH - Warfarin/pharmacology/therapeutic use PMC - PMC11902302 MID - NIHMS2060423 OTO - NOTNLM OT - #BladderCancer OT - #Urology OT - #blcsm OT - #uroonc OT - aspirin OT - bacille Calmette-Guerin OT - bladder cancer OT - clopidogrel OT - fibrin clot inhibitor OT - novel oral anticoagulant OT - warfarin COIS- The authors report the following financial interests: Colin P. Dinney: National Cancer Institutes and University of East Finland Faculty of Health Sciences research funding; grant and personal fees from FKD Therapies; creator of intellectual property owned by UT/MD Anderson Cancer Center related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovac. Ashish M. Kamat is a consultant or advisory board member for Abbott Molecular, Arquer Diagnostics, ArTara Therapeutics, Asieris Pharmaceuticals, AstraZeneca, BioClin Therapeutics, Bristol Myers Squibb, Cepheid, Cold Genesys, Eisai, Engene, Ferring Pharmaceuticals, FerGene, Imagine Pharma, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara Therapeutics, Roviant Sciences, Seattle Genetics, Sessen Bio, Theralase Technologies, TMC Innovation and US Biotest. A.M.K. has received grants and/or research support from Adolor Corporation, Bristol Myers Squibb, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH, Specialized Programs of Research Excellence (SPORE) and AIBCCR. A.M.K. also holds the patent for Cytokine Predictors of Response to Intravesical Therapy (CyPRIT) joint with UT MD Anderson Cancer Center. EDAT- 2021/12/03 06:00 MHDA- 2022/09/16 06:00 PMCR- 2025/03/12 CRDT- 2021/12/02 06:55 PHST- 2021/12/03 06:00 [pubmed] PHST- 2022/09/16 06:00 [medline] PHST- 2021/12/02 06:55 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - 10.1111/bju.15665 [doi] PST - ppublish SO - BJU Int. 2022 Oct;130(4):463-469. doi: 10.1111/bju.15665. Epub 2021 Dec 13. PMID- 34853164 OWN - NLM STAT- MEDLINE DCOM- 20230421 LR - 20230421 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 76 IP - 5 DP - 2023 May TI - Prognostic significance of tumour budding, tumour-stroma ratio and desmoplastic stromal reaction in gall bladder carcinoma. PG - 308-314 LID - 10.1136/jclinpath-2021-207957 [doi] AB - AIMS AND METHODS: The prognostic role of tumour budding (TBd) and its interaction with the stromal microenvironment has gained a lot of attention recently, but remains unexplored in gall bladder cancer (GBC). We aimed to study the interrelationship of TBd by International Tumour Budding Consensus Conference scoring system, tumour-stroma ratio (TSR) and desmoplastic stromal reaction (DSR) with the conventional clinicopathological prognostic factors, mortality and overall survival (OS) in 96 patients of operated GBC. RESULTS: Higher age, high TNM stage, lymphovascular and perineural invasion, positive resection margins, higher TBd score, low TSR and immature DSR were significantly associated with worse OS. However, on multivariate analysis, only metastases, positive resection margins and TSR <50% proved to be independent prognostic factors. The TBd score of stroma-rich tumour group (6.40+/-4.69) was significantly higher than that of stroma-poor group (2.77+/-3.79, p50%) express LRIG2 and LRIG3. Statistically significant association was observed between positivity for LRIG3 and muscle invasion (P = 0.001), high grade (P = 0.03), and female gender (P = 0.02). Moreover, positive LRIG2 staining was associated with early stage (T2) (P = 0.03), lymphovascular invasion (P = 0.004), and tendency to non-muscle invasive stage (P = 0.07). Grouping of cases according to positivity/negativity of both markers showed that cases with dual positivity for both proteins are associated with muscle invasion (P = 0.001) and paradoxically with prolonged overall survival (P = 0.037). We conclude that although the association of LRIG3 with MI and high-grade tumors, its expression is related to better survival. LRIG3 has the dominant role even if it coexists with LRIG2. The role of LRIG2 remains to be further investigated. FAU - M Serag El-Dien, Marwa AU - M Serag El-Dien M AUID- ORCID: 0000-0002-1554-9034 AD - Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - Fathy Mahmoud, Shereen AU - Fathy Mahmoud S AD - Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - Alhanafy, Alshimaa Mahmoud AU - Alhanafy AM AD - Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - Mohamed Zanaty, Fouad AU - Mohamed Zanaty F AD - Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - Shawky Holah, Nanis AU - Shawky Holah N AD - Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. LA - eng PT - Journal Article DEP - 20211129 PL - England TA - J Immunoassay Immunochem JT - Journal of immunoassay & immunochemistry JID - 100963688 RN - 0 (Biomarkers, Tumor) RN - 0 (LRIG2 protein, human) RN - 0 (LRIG3 protein, human) RN - 0 (Membrane Glycoproteins) RN - 0 (Membrane Proteins) SB - IM MH - Biomarkers, Tumor/metabolism MH - *Carcinoma MH - Female MH - Humans MH - Male MH - Membrane Glycoproteins MH - Membrane Proteins MH - Prognosis MH - Urinary Bladder/metabolism MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - LRIG2 OT - LRIG3 OT - immunohistochemistry OT - prognosis OT - urothelial bladder carcinoma EDAT- 2021/11/30 06:00 MHDA- 2022/05/19 06:00 CRDT- 2021/11/29 05:32 PHST- 2021/11/30 06:00 [pubmed] PHST- 2022/05/19 06:00 [medline] PHST- 2021/11/29 05:32 [entrez] AID - 10.1080/15321819.2021.2005623 [doi] PST - ppublish SO - J Immunoassay Immunochem. 2022 May 4;43(3):308-332. doi: 10.1080/15321819.2021.2005623. Epub 2021 Nov 29. PMID- 34830555 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 22 DP - 2021 Nov 12 TI - The Predictive Value of Systemic Immune-Inflammation Index on Bladder Recurrence on Upper Tract Urothelial Carcinoma Outcomes after Radical Nephroureterectomy. LID - 10.3390/jcm10225273 [doi] LID - 5273 AB - BACKGROUND: This study aimed to assess the prognostic significance of pre-treatment lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma (UTUC) patients. METHODS: This study included non-metastatic UTUC patients treated at our hospital between 2001 and 2013. The receiver operating characteristic curve was used to obtain the optimal neutrophile-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Multivariate logistic regression was performed to investigate the relationship between NLR, PLR, and SII and clinical pathologic characteristics. The Kaplan-Meier method was used to calculate the metastasis-free survival (MFS), cancer-specific survival (CSS), and bladder recurrence-free survival (BRFS), and the log-rank test was used to compare the survival rate. RESULTS: Overall, 376 patients were included in the current study. An elevated SII was associated with symptomatic hydronephrosis, bladder cancer history, advanced pathologic tumor stage, lymph node invasion, adjuvant chemotherapy and concomitant carcinoma in situ (CIS); high NLR was associated with older age, symptomatic hydronephrosis, hemodialysis status, anemia, multifocal tumor, advanced pathologic tumor stage, and adjuvant chemotherapy; and high PLR was associated with older age, anemia, advanced pathologic tumor stage, and adjuvant chemotherapy. The Kaplan-Meier analysis indicated that patients exhibiting higher NLR, PLR, and SII showed significantly poor MFS and CSS rates. Only high SII showed significantly worse BRFS rates. CONCLUSIONS: The NLR, PLR, and SII were independent predictive factors for both MFS and CSS in UTUC patients. Among the factors, only elevated SII can predict bladder recurrence. Therefore, the patients might need close bladder monitoring during the follow-up. FAU - Chien, Tsu-Ming AU - Chien TM AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan. AD - Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan. AD - Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. FAU - Lu, Yen-Man AU - Lu YM AD - Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan. FAU - Chou, Yii-Her AU - Chou YH AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan. AD - Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. FAU - Chang, Hsueh-Wei AU - Chang HW AUID- ORCID: 0000-0003-0068-2366 AD - Department of Biomedical Science and Environmental Biology, College of Life Science, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. AD - Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan. AD - Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan. AD - Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80756, Taiwan. LA - eng PT - Journal Article DEP - 20211112 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8623909 OTO - NOTNLM OT - bladder recurrence OT - neutrophile-lymphocyte OT - platelet-lymphocyte OT - survival OT - systemic immune-inflammation index OT - upper tract urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/11/12 CRDT- 2021/11/27 01:12 PHST- 2021/09/11 00:00 [received] PHST- 2021/11/07 00:00 [revised] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/11/27 01:12 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/11/12 00:00 [pmc-release] AID - jcm10225273 [pii] AID - jcm-10-05273 [pii] AID - 10.3390/jcm10225273 [doi] PST - epublish SO - J Clin Med. 2021 Nov 12;10(22):5273. doi: 10.3390/jcm10225273. PMID- 34829729 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 9 IP - 11 DP - 2021 Oct 20 TI - Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology. LID - 10.3390/biomedicines9111500 [doi] LID - 1500 AB - Urothelial bladder cancer (UBC) is one of the most prevalent and aggressive malignancies. Recent evidence indicates that the tumor microenvironment (TME), including a variety of immune cells, is a critical modulator of tumor initiation, progression, evolution, and treatment resistance. Mast cells (MCs) in UBC are possibly involved in tumor angiogenesis, tissue remodeling, and immunomodulation. Moreover, tumor-infiltration by MCs has been reported in early-stage UBC patients. This infiltration is linked with a favorable or unfavorable prognosis depending on the tumor type and location. Despite the discrepancy of MC function in tumor progression, MCs can modify the TME to regulate the immunity and infiltration of tumors by producing an array of mediators. Nonetheless, the precise role of MCs in UBC tumor progression and evolution remains unknown. Thus, this review discusses some critical roles of MCs in UBC. Patients with UBC are treated at both early and late stages by immunotherapeutic methods, including intravenous bacillus Calmette-Guerin instillation and immune checkpoint blockade. An understanding of the patient response and resistance mechanisms in UBC is required to unlock the complete potential of immunotherapy. Since MCs are pivotal to understand the underlying processes and predictors of therapeutic responses in UBC, our review also focuses on possible immunotherapeutic treatments that involve MCs. FAU - Choi, Hae Woong AU - Choi HW AUID- ORCID: 0000-0001-9372-1875 AD - Division of Life Sciences, Korea University, Seoul 02841, Korea. FAU - Naskar, Manisha AU - Naskar M AD - Division of Life Sciences, Korea University, Seoul 02841, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang 10408, Korea. AD - Division of Tumor Immunology, Department of Cancer Biomedical Science, Research Institute, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea. FAU - Lee, Hye Won AU - Lee HW AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang 10408, Korea. LA - eng GR - 2020R1C1C1003257/National Research Foundation of Korea/ PT - Journal Article PT - Review DEP - 20211020 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC8614912 OTO - NOTNLM OT - bladder cancer OT - mast cells OT - mucosal immune barrier OT - pro-tumor immunity immunotherapy OT - tumor microenvironment COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/10/20 CRDT- 2021/11/27 01:09 PHST- 2021/09/20 00:00 [received] PHST- 2021/10/14 00:00 [revised] PHST- 2021/10/16 00:00 [accepted] PHST- 2021/11/27 01:09 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/10/20 00:00 [pmc-release] AID - biomedicines9111500 [pii] AID - biomedicines-09-01500 [pii] AID - 10.3390/biomedicines9111500 [doi] PST - epublish SO - Biomedicines. 2021 Oct 20;9(11):1500. doi: 10.3390/biomedicines9111500. PMID- 34820417 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211126 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 8 DP - 2021 TI - Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy. PG - 759487 LID - 10.3389/fsurg.2021.759487 [doi] LID - 759487 AB - Background: Thulium laser resection of bladder tumors (TmLRBT) is recently considered as a common treatment option for non-muscle-invasive bladder cancers (NMIBC), but whether it is superior to Transurethral resection of bladder tumors (TURBT) are still undetermined. Materials and Methods: We retrospectively screened our institution database to identify patients who were treated by conventional TURBT or TmLRBT for NMIBC and followed by intravesical bacillus Calmette-Guerin (BCG) immunotherapy. The preoperative characteristics, perioperative outcomes, and recurrence-free survival were compared to assess the safety and efficacy of the two procedures. Results: Eventually, 90 patients who underwent TmLRBT (n = 37) or TURBT (n = 53) followed by intravesical BCG immunotherapy were included. Two groups were similar in baseline characteristics except for the smaller tumor size of the TmLRBT group(1.7 cm vs. 2.2 cm; P = 0.036). Obturator nerve reflex occurred in eight patients in the TURBT group and 3 of them suffered from bladder perforation while none happened in the TmLRBT group. The TmLRBT also had a shorter irrigation duration. In the multivariate Cox regression, the TmLRBT was related to less recurrence risk (HR: 0.268; 95% CI, 0.095-0.759; P = 0.013). Conclusion: Our results suggested that TmLRBT is safer than conventional TURBT with fewer perioperative complications, and it offers better cancer control, therefore might be a superior option for NMIBC patients with intermediate and high recurrence risk. CI - Copyright (c) 2021 Liu, Long, Zhang, Sun, Ouyang, Wang, Xu, Wang, Guan, Yu, Hu, Chen, Wang and Li. FAU - Liu, Zheng AU - Liu Z AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Long, Gongwei AU - Long G AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Yucong AU - Zhang Y AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Department of Geriatrics, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Guoliang AU - Sun G AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Ouyang, Wei AU - Ouyang W AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shen AU - Wang S AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Hao AU - Xu H AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Zhihua AU - Wang Z AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Guan, Wei AU - Guan W AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Yu, Xiao AU - Yu X AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Zhiquan AU - Hu Z AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Chen, Zhong AU - Chen Z AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shaogang AU - Wang S AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Li, Heng AU - Li H AD - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Hubei Institute of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20211108 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8606824 OTO - NOTNLM OT - bacillus Calmette-Guerin vaccine OT - en bloc resection of bladder tumor OT - non-muscle-invasive bladder cancer OT - thulium laser OT - transurethral resection of bladder tumors COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/26 06:00 MHDA- 2021/11/26 06:01 PMCR- 2021/11/08 CRDT- 2021/11/25 06:39 PHST- 2021/08/16 00:00 [received] PHST- 2021/10/18 00:00 [accepted] PHST- 2021/11/25 06:39 [entrez] PHST- 2021/11/26 06:00 [pubmed] PHST- 2021/11/26 06:01 [medline] PHST- 2021/11/08 00:00 [pmc-release] AID - 10.3389/fsurg.2021.759487 [doi] PST - epublish SO - Front Surg. 2021 Nov 8;8:759487. doi: 10.3389/fsurg.2021.759487. eCollection 2021. PMID- 34817753 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20220224 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 54 IP - 1 DP - 2022 Jan TI - Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. PG - 71-79 LID - 10.1007/s11255-021-03073-5 [doi] AB - PURPOSE: To compare clinical outcome and quality of life (QoL) in octogenarian patients with muscle-invasive urothelial carcinoma (MIBC) either treated by radical cystectomy (RC) or transurethral resection of the tumor (TURBT). METHODS: We identified octogenarian patients with MIBC in our institutions since 2005. Clinical treatment outcomes and QoL were analyzed. Uni- and multivariable Cox regression analyses, two-tailed Wilcoxon test, Mann-Whitney test and Fisher's exact test were assessed as appropriate. QoL was evaluated using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire. RESULTS: 143 patients were identified (RC: 51 cases, TURBT: 92 cases). Mean follow-up was 14 months (0-100 months). Median overall survival (OS) was 12 months in the RC group and 7 months in the TURBT group. TURBT and low preoperative hemoglobin were independent risk factors for reduced cancer-specific survival (CSS) (TURBT: p = 0.019, Hb: p = 0.008) and OS (TURBT: p = 0.026, Hb: p = 0.013) in multivariable analyses. Baseline QoL was low throughout the whole cohort. There was no difference in baseline FACT-G scoring comparing RC and TURBT (FACT-G total score (median): RC 43.7/108 vs. TURBT 44.0/108, p = 0.7144). Increased FACT-G questionnaire scoring was assessed for RC patients (median percentage score change RC 22.9%, TURBT 2.3%, p < 0.0001). CONCLUSION: RC and TURBT are feasible treatment options for MIBC in octogenarian patients. In our cohort, RC was associated with increased CSS, OS and QoL. QoL in general was low throughout the whole cohort. Interdisciplinary decision-making has to be improved for these critically ill patients. CI - (c) 2021. The Author(s). FAU - Rehme, Christian AU - Rehme C AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. FAU - Fritsch, Beatrix AU - Fritsch B AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. FAU - Thomas, Luca AU - Thomas L AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. FAU - Istin, Stefan AU - Istin S AD - Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. FAU - Burchert, Carolin AU - Burchert C AD - Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. FAU - Hummel, Bastian AU - Hummel B AD - Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. FAU - Baleanu-Curaj, Bogdan AU - Baleanu-Curaj B AD - Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. FAU - Reis, Henning AU - Reis H AD - Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. FAU - Szarvas, Tibor AU - Szarvas T AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Ruebben, Herbert AU - Ruebben H AD - Department of Urology, Helios Hospital Duisburg, Duisburg, Germany. FAU - Hadaschik, Boris AU - Hadaschik B AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. FAU - Niedworok, Christian AU - Niedworok C AUID- ORCID: 0000-0002-6796-9882 AD - Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. christian.niedworok@uni-due.de. AD - Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. christian.niedworok@uni-due.de. LA - eng PT - Comparative Study PT - Journal Article DEP - 20211124 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - *Quality of Life MH - Retrospective Studies MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC8732805 OTO - NOTNLM OT - Cystectomy OT - Muscle-invasive bladder cancer OT - Octogenarian OT - Transurethral resection OT - Urothelial carcinoma COIS- The authors have no conflicts of interest to declare that are relevant to the content of this article. We hereby confirm that all figures and tables in the present manuscript are originals, taken and/or generated by the team of authors and have not been published previously. EDAT- 2021/11/25 06:00 MHDA- 2022/02/25 06:00 PMCR- 2021/11/24 CRDT- 2021/11/24 12:28 PHST- 2021/08/31 00:00 [received] PHST- 2021/11/18 00:00 [accepted] PHST- 2021/11/25 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/11/24 12:28 [entrez] PHST- 2021/11/24 00:00 [pmc-release] AID - 10.1007/s11255-021-03073-5 [pii] AID - 3073 [pii] AID - 10.1007/s11255-021-03073-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2022 Jan;54(1):71-79. doi: 10.1007/s11255-021-03073-5. Epub 2021 Nov 24. PMID- 34816789 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20220308 IS - 1533-0338 (Electronic) IS - 1533-0346 (Print) IS - 1533-0338 (Linking) VI - 20 DP - 2021 Jan-Dec TI - The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer. PG - 15330338211062323 LID - 10.1177/15330338211062323 [doi] LID - 15330338211062323 AB - Objectives: To compare the efficacy of complete transurethral resection of bladder tumor combined with postoperative chemoradiotherapy and radical cystectomy (RC) in the treatment of muscle-invasive bladder cancer (MIBC). Methods: This is a single-center, retrospective study. Clinical data of 125 patients with MIBC admitted to the First Affiliated Hospital of Soochow University from December 2012 to December 2015 were retrospectively analyzed, in which 79 patients (tri-modality therapy [TMT] group) received TMT bladder-sparing treatment, and 41 patients (RC group) received RC. The differences of probabilities for 1-year, 2-year, 5-year, and comprehensive overall survival (OS), progress-free survival (PFS) between 2 groups were calculated using Kaplan-Meier product limited estimates. Univariate and multivariate analyses were performed to detect potential risk factors for OS and PFS. Results: There was no statistical difference between the TMT group and RC group in the 1-year, 2-year, 5-year, comprehensive OS rate, and PFS rate. And survival analysis found no significant difference in OS and PFS between the 2 groups. Univariate analysis showed that age, TNM staging, and prognostic nutritional index (PNI) were associated with OS, while PNI was connected to tumor recurrence. Multiple linear regression analysis indicated that TNM staging and PNI were independent risk factors for OS. Conclusions: TMT can be used as an alternative to RC for MIBC patients under the premise of strict control of indications, rigorous postoperative follow-up, and timely salvage cystectomy. PNI was negatively correlated with OS and PFS, while TNM staging was positively correlated with OS. FAU - Zhiyu, Zhang AU - Zhiyu Z AUID- ORCID: 0000-0001-5499-8011 AD - 74566The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Qi, Zhou AU - Qi Z AD - 74566The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Zhen, Song AU - Zhen S AD - 74566The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Jun, Ouyang AU - Jun O AD - 74566The First Affiliated Hospital of Soochow University, Suzhou, China. FAU - Jianglei, Zhang AU - Jianglei Z AD - 74566The First Affiliated Hospital of Soochow University, Suzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Technol Cancer Res Treat JT - Technology in cancer research & treatment JID - 101140941 SB - IM MH - Aged MH - Clinical Decision-Making MH - Combined Modality Therapy/adverse effects/methods MH - Cystectomy MH - Disease Management MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy PMC - PMC8649089 OTO - NOTNLM OT - MIBC OT - PNI OT - bladder-sparing OT - tri-modality therapy COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/11/25 06:00 MHDA- 2022/03/09 06:00 PMCR- 2021/11/24 CRDT- 2021/11/24 08:46 PHST- 2021/11/24 08:46 [entrez] PHST- 2021/11/25 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2021/11/24 00:00 [pmc-release] AID - 10.1177_15330338211062323 [pii] AID - 10.1177/15330338211062323 [doi] PST - ppublish SO - Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211062323. doi: 10.1177/15330338211062323. PMID- 34806518 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220501 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 1 DP - 2022 Feb TI - A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. PG - 20-26 LID - 10.1080/21681805.2021.2002402 [doi] AB - PURPOSE: To evaluate a method of transurethral visual response-staging in patients with urothelial muscle-invasive urinary bladder cancer (MIBC), undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). METHODS: A prospective study at four Swedish cystectomy centers, cystoscopy was performed after final NAC-cycle for MIBC. Fifty-six participants underwent cystoscopy for visual staging of the tumor immediately pre-RC. Visual assessments were correlated to pathoanatomical outcomes post-RC. RESULTS: Seventeen tumors were classified as complete response (CR), i.e. pT0. Twenty-five patients had residual MIBC and 14 had non-muscle invasive residual tumors (NMIBC). Of the 39 patients with residual tumor, 25 were correctly identified visually (64%). Eleven patients were pN+. The diagnostic accuracy of cystoscopy to correctly identify complete response or remaining tumor was 70% (CI = 56-81%) with a sensitivity of 64% (CI = 47-79%), specificity 82% (CI = 57-96%), PPV 89% (CI = 74-96%) and NPV 50% (CI =38-61%). Twenty-eight cystoscopy evaluations showed signs of residual tumors and 3/28 (11%) were false positive. In 4/14 patients assessed having residual NMIBC the estimates were correct, 8/14 had histopathological MIBC and 2/14 had CR. In 11/14 patients (79%), the suggested visual assessment of MIBC was correct, 2/14 had NMIBC and 1/14 had CR. Twenty-eight cystoscopies had negative findings, 14 were false negatives (50%), when cystoscopy falsely predicted pT0. Among them there were eight patients with pTa, pT1 or pTis and six MIBC-tumors. In 17 patients with histopathological pT0, 14 were correctly identified with cystoscopy (82%). CONCLUSION: Cystoscopy after the final NAC-cycle cannot robustly differentiate between NAC-responders and non-responders. Visually, negative MIBC-status cannot be determined safely. FAU - Asad, Danna AU - Asad D AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Styrke, Johan AU - Styrke J AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Hagsheno, Mohammad AU - Hagsheno M AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Johansson, Markus AU - Johansson M AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Huge, Ylva AU - Huge Y AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Svensson, Johan AU - Svensson J AD - Department of statistics, Umea School of Business, Economics and Statistics (USBE), Umea University, Umea, Sweden. FAU - Pelander, Sofia AU - Pelander S AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Lauer, Jan AU - Lauer J AD - Department of Surgery, Nykoping County Hospital, Nykoping, Sweden. FAU - Netterling, Hans AU - Netterling H AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Sherif, Amir AU - Sherif A AUID- ORCID: 0000-0002-3675-3050 AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20211121 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Cystectomy MH - *Cystoscopy MH - Humans MH - Muscles/pathology MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Prospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Cystectomy OT - neoadjuvant therapy OT - neoplasm staging OT - urinary bladder neoplasms EDAT- 2021/11/23 06:00 MHDA- 2022/02/09 06:00 CRDT- 2021/11/22 08:47 PHST- 2021/11/23 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] PHST- 2021/11/22 08:47 [entrez] AID - 10.1080/21681805.2021.2002402 [doi] PST - ppublish SO - Scand J Urol. 2022 Feb;56(1):20-26. doi: 10.1080/21681805.2021.2002402. Epub 2021 Nov 21. PMID- 34804825 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 10 DP - 2021 Oct TI - Effects of radical cystectomy, radiotherapy, and chemotherapy on the risk of long-term heart-specific death in bladder cancer patients. PG - 3826-3836 LID - 10.21037/tau-21-835 [doi] AB - BACKGROUND: At present, the low risk of bladder cancer (BCa)-specific death has allowed for investigation into treatment-related cardiotoxicity. To aid clinicians in selecting appropriate cardiovascular disease screening strategies and interventions, this study explored the heart-specific mortality and prognostic factors of patients with BCa after radical cystectomy (RC), radiotherapy (RT), or chemotherapy (CT), and compared their long-term heart-specific mortality with that of the general male population. METHODS: We identified three different treatments for BCa patients from the Surveillance, Epidemiology, and End Results (SEER) database: RC, RT, and CT. Patients were included from 2000 to 2012 and followed through 2015. A cumulative mortality curve and competitive risk regression model were applied to evaluate the prognostic factors of heart-specific mortality, and standardized mortality ratios (SMRs) were calculated. RESULTS: Of 39,500 men, 30.3%, 18.8%, and 50.9% received RC, RT, and CT, respectively. For patients with a survival period of less than 50 months, tumor-specific death exhibited a rapidly increasing trend, which subsequently flatlined. However, the rates heart-specific mortality and other causes exhibited a tendency to increase stably. The heart-specific and all-cause mortality rates of patients in any age group treated with the three abovementioned strategies were higher than those of the general population. The heart-specific mortality of patients with carcinoma in situ treated with RC and CT exceeded their all-cause mortality, while that of other tumor stages did not. The risks of heart-specific [sub-distribution hazard ratio (SHR) =1.38; 95% confidence interval (CI): 1.22-1.57] and tumor-specific (SHR =1.68; 95% CI: 1.60-1.77) deaths in patients who received RT were higher than those of patients who underwent CT. CONCLUSIONS: The risks of heart-specific and tumor-specific deaths in patients who received RT were higher than those of the RC and CT groups, especially in patients over 65 years of age who received RT. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Yang, Fuhan AU - Yang F AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Li, Cheng AU - Li C AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Guo, Yadong AU - Guo Y AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Yu, Yang AU - Yu Y AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Mao, Shiyu AU - Mao S AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Wang, Ruiliang AU - Wang R AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. FAU - Zhang, Aihong AU - Zhang A AD - Department of Medical Statistics, Tongji University School of Medicine, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. AD - Institute of Urologic Oncology, School of Medicine, Tongji University, Shanghai, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC8575595 OTO - NOTNLM OT - Bladder cancer (BCa) OT - Surveillance, Epidemiology, and End Results (SEER) OT - cardiovascular disease OT - competing risk COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tau-21-835). The authors have no conflicts of interest to declare. EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 PMCR- 2021/10/01 CRDT- 2021/11/22 06:51 PHST- 2021/08/26 00:00 [received] PHST- 2021/10/22 00:00 [accepted] PHST- 2021/11/22 06:51 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - tau-10-10-3826 [pii] AID - 10.21037/tau-21-835 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Oct;10(10):3826-3836. doi: 10.21037/tau-21-835. PMID- 34793662 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20220721 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 54 IP - 3 DP - 2022 Jul TI - Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. PG - 894-906 LID - 10.4143/crt.2021.854 [doi] AB - PURPOSE: This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI). MATERIALS AND METHODS: We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8). RESULTS: We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1-positive (PD-L1 combined positive score >/= 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1-negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1-positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1-positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment. CONCLUSION: Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC. FAU - Kim, Ryul AU - Kim R AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Hong, Jung Yong AU - Hong JY AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Jeeyun AU - Lee J AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kwon, Ghee Young AU - Kwon GY AD - Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Park, Se Hoon AU - Park SH AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng GR - OTA1602441/Samsung Medical Center/ GR - OTA1702441/Samsung Medical Center/ GR - Korea Health Industry Development Institute/ GR - HR20C0025/Ministry of Health and Welfare/ PT - Journal Article DEP - 20211117 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) SB - IM MH - B7-H1 Antigen/genetics/metabolism MH - Biomarkers, Tumor/genetics/metabolism MH - *Carcinoma, Transitional Cell MH - Genomics MH - Humans MH - Immunotherapy MH - Mutation MH - Tumor Microenvironment MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/genetics/therapy PMC - PMC9296940 OTO - NOTNLM OT - Dual blockade OT - Immunotherapy OT - Urinary bladder neoplasms OT - Whole-exome sequencing OT - Whole-transcriptome sequencing COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2021/11/19 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/01 CRDT- 2021/11/18 19:32 PHST- 2021/07/28 00:00 [received] PHST- 2021/11/12 00:00 [accepted] PHST- 2021/11/19 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2021/11/18 19:32 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - crt.2021.854 [pii] AID - crt-2021-854 [pii] AID - 10.4143/crt.2021.854 [doi] PST - ppublish SO - Cancer Res Treat. 2022 Jul;54(3):894-906. doi: 10.4143/crt.2021.854. Epub 2021 Nov 17. PMID- 34783981 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 54 IP - 1 DP - 2022 Jan TI - Is bladder preservation safe? The oncology outcomes of patients after 2-sided radical nephroureterectomies due to bilateral upper urinary tract urothelial carcinomas. PG - 63-69 LID - 10.1007/s11255-021-03005-3 [doi] AB - PURPOSE: The prognosis of patients undergoing 2-sided radical nephroureterectomies (RNUs) with a residual bladder due to bilateral upper tract urothelial carcinoma (UTUC) is poorly understood. This study was aimed toward surveying the oncology outcomes and prognostic factors that may help in shared decision-making related to bladder preservation in patients preparing to receive 2-sided RNUs. METHODS: Patients with synchronous or metachronous bilateral UTUC who received bilateral RNUs with a residual bladder in our hospital were retrospectively reviewed. Clinical and pathological data were analyzed for potential variables affecting the oncology outcomes. RESULTS: A total of 50 patients were included. The average age at completion of the 2-sided RNU was 62.7 +/- 12.4 years, with a mean follow-up of 88.4 +/- 59.3 months after the 2-sided RNUs. The medium overall survival was 13.4 +/- 1.8 years. Twenty-six patients (52%) had cancer recurrence in the residual bladder, but only 2 (8%) of the recurrences were muscle invasive. The highest UTUC stage was the only predictive factor for cancer-specific survival (CSS) rather than intravesical recurrence. The 5 year CSS rates in patients with the highest UTUC stage <== pT2 and >== pT3 were 90% and 51%, respectively (p = 0.007). CONCLUSIONS: Risk of cancer recurrence in the residual bladder is high, but does not affect survival outcomes. The highest UTUC stage plays a significant role in cancer-specific survival. With a careful patient surveillance, bladder preservation may be reasonable in patients with bilateral UTUC preparing for 2-sided RNUs. CI - (c) 2021. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Kao, Yao-Lin AU - Kao YL AUID- ORCID: 0000-0002-4147-9041 AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. FAU - Yang, Wen-Horng AU - Yang WH AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. FAU - Ou, Chien-Hui AU - Ou CH AUID- ORCID: 0000-0002-6555-0172 AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. donou1969@yahoo.com.tw. LA - eng GR - NCKUH-11003038/national cheng kung university hospital/ PT - Journal Article DEP - 20211116 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/mortality/pathology/*surgery MH - Male MH - Middle Aged MH - Nephroureterectomy/*methods MH - *Organ Sparing Treatments/adverse effects MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/pathology/*surgery MH - Urinary Bladder OTO - NOTNLM OT - Bilateral OT - Bladder OT - Nephroureterectomy OT - Upper tract OT - Urothelial carcinoma EDAT- 2021/11/17 06:00 MHDA- 2022/02/25 06:00 CRDT- 2021/11/16 12:29 PHST- 2021/07/14 00:00 [received] PHST- 2021/09/24 00:00 [accepted] PHST- 2021/11/17 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/11/16 12:29 [entrez] AID - 10.1007/s11255-021-03005-3 [pii] AID - 10.1007/s11255-021-03005-3 [doi] PST - ppublish SO - Int Urol Nephrol. 2022 Jan;54(1):63-69. doi: 10.1007/s11255-021-03005-3. Epub 2021 Nov 16. PMID- 34782748 OWN - NLM STAT- MEDLINE DCOM- 20220310 LR - 20230208 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 126 IP - 4 DP - 2022 Mar TI - Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. PG - 606-614 LID - 10.1038/s41416-021-01628-y [doi] AB - BACKGROUND: We examined the relationship between the tumour microenvironment and the clinical efficacy of neoadjuvant chemotherapy in patients with cT2-4aN0M0 bladder cancer using multiplex fluorescence immunohistochemistry. METHODS: The study retrospectively evaluated 51 patients who underwent radical cystectomy following neoadjuvant chemotherapy for cT2-4aN0M0 muscle-invasive bladder cancer. Patients were divided into responders (/=pT2). We assessed the density of each immune cell type in intratumoural and peritumoural areas in both groups via multiplex fluorescence immunohistochemical analysis. RESULTS: The median age was 69 years; 39 patients were male. Twelve (23.5%), 17 (33.3%), 10 (19.7%) and 12 (23.5%) patients were pT0, pT1, pT2 and >/=pT3, respectively. Responders had a significantly higher 5-year cancer-specific survival rate (96.6%) than non-responders (48.4%; p = 0.0018). CD8(+) T cell (p = 0.0056) and CD204(+) cell (p = 0.0394) densities were significantly higher in the intratumoural area in non-responders than in responders. Patients with higher CD204(+) cell densities in cancerous areas had worse prognosis. CONCLUSIONS: This comprehensive analysis of the immune microenvironment of a muscle-invasive bladder cancer specimen revealed that preexisting tumour-infiltrating proliferating CD8(+) T cells and CD204(+) cells are indicators of the response to neoadjuvant chemotherapy and that CD204(+) cells can be considered an unfavourable prognostic factor in these patients. CI - (c) 2021. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Ikarashi, Daiki AU - Ikarashi D AUID- ORCID: 0000-0001-8088-2848 AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. AD - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan. FAU - Kitano, Shigehisa AU - Kitano S AUID- ORCID: 0000-0002-4041-8298 AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp. FAU - Tsuyukubo, Takashi AU - Tsuyukubo T AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Takenouchi, Kazumasa AU - Takenouchi K AD - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan. FAU - Nakayama, Takayuki AU - Nakayama T AD - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan. FAU - Onagi, Hiroko AU - Onagi H AD - Department of Human Pathology, Juntendo University School of Medicine, Tokyo, 113-0033, Japan. FAU - Sakaguchi, Asumi AU - Sakaguchi A AD - Department of Human Pathology, Juntendo University School of Medicine, Tokyo, 113-0033, Japan. FAU - Yamashita, Makiko AU - Yamashita M AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. FAU - Mizugaki, Hidenori AU - Mizugaki H AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. FAU - Maekawa, Shigekatsu AU - Maekawa S AUID- ORCID: 0000-0003-4620-2831 AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Kato, Renpei AU - Kato R AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Kato, Yoichiro AU - Kato Y AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Sugai, Tamotsu AU - Sugai T AD - Department of Pathology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. FAU - Nakatsura, Tetsuya AU - Nakatsura T AD - Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. LA - eng PT - Journal Article DEP - 20211115 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (MSR1 protein, human) RN - 0 (Scavenger Receptors, Class A) SB - IM MH - Adult MH - Aged MH - CD8-Positive T-Lymphocytes/*metabolism MH - Cystectomy MH - Drug Therapy MH - Female MH - Fluorescent Antibody Technique MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Scavenger Receptors, Class A/*metabolism MH - Survival Analysis MH - Treatment Outcome MH - Tumor Microenvironment MH - Urinary Bladder Neoplasms/immunology/*pathology/*therapy PMC - PMC8854605 COIS- SK reports personal fees from Astra Zeneca, grants and personal fees from Chugai, personal fees from Pfizer, grants and personal fees from Boehringer Ingelheim, personal fees from Taiho, personal fees from Novartis, grants and personal fees from Daiichi-Sankyo, personal fees from MSD, personal fees from Sumitomo Dainippon Pharma, grants and personal fees from Eisai, grants from Astellas, grants from Gilead Sciences, grants and personal fees from Ono Pharmaceutical Co., Ltd, personal fees from Bristol-Myers Squibb, grants and personal fees from REGENERON, personal fees from AYUMI Pharmaceutical Corporation, personal fees from Rakuten Medical, grants from PACT Pharma, grants from Takara Bio Inc., personal fees from GSK, personal fees from ImmuniT Research Inc., grants and personal fees from Ono Pharmaceutical Co., Ltd, personal fees from PMDA (Pharmaceuticals and Medical Devices Agency), grants from AMED (Japan Agency for Medical Research and Development) and grants from JSPS (Japan Society for the Promotion of Science), outside the submitted work. The remaining authors declare no competing interests. EDAT- 2021/11/17 06:00 MHDA- 2022/03/11 06:00 PMCR- 2022/11/15 CRDT- 2021/11/16 06:47 PHST- 2021/06/25 00:00 [received] PHST- 2021/11/02 00:00 [accepted] PHST- 2021/10/29 00:00 [revised] PHST- 2021/11/17 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2021/11/16 06:47 [entrez] PHST- 2022/11/15 00:00 [pmc-release] AID - 10.1038/s41416-021-01628-y [pii] AID - 1628 [pii] AID - 10.1038/s41416-021-01628-y [doi] PST - ppublish SO - Br J Cancer. 2022 Mar;126(4):606-614. doi: 10.1038/s41416-021-01628-y. Epub 2021 Nov 15. PMID- 34775873 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220501 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 1 DP - 2022 Feb TI - Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. PG - 27-33 LID - 10.1080/21681805.2021.2002399 [doi] AB - INTRODUCTION AND OBJECTIVES: Bladder cancer is primarily a disease of older age and little is known about the differences between patients diagnosed with bladder cancer at a younger versus older age. Our objectives were to compare bladder cancer specific survival in patients aged <50 versus those aged 50-70 at time of diagnosis. MATERIALS AND METHODS: The Swedish bladder cancer database provided data on patient demographics, clinical characteristics and treatments for this observational study. Cox proportional hazard regression models were adjusted for appropriate variables. All analyses were stratified by disease stage (non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Furthermore, we compared the frequency of lower urinary tract infections within 24 months prior to bladder cancer diagnosis by sex and age groups. RESULTS: The study included 15,452 newly-diagnosed BC patients (1997-2014); 1,207 (8%) patients were <50 whilst 14,245 (92%) were aged 50-70. Patients aged <50 at diagnosis were at a decreased risk of bladder cancer death (HR = 0.82, 95%CI: 0.68-0.99) compared to those aged 50-70. When stratified by non-muscle-invasive and muscle-invasive bladder cancer, this association remained in non-muscle-invasive patients only (<50, HR = 0.43, 95% CI: 0.28-0.64). The frequency of lower urinary tract infection diagnoses did not differ between younger and older patients in either men or women. CONCLUSIONS: Patients diagnosed with non-muscle-invasive bladder cancer when aged <50 are at decreased risk of bladder cancer-specific death when compared to their older (50-70) counterparts. These observations raise relevant research questions about age-related differences in diagnostic procedures, clinical decision-making and, not least, potential differences in tumour biology. FAU - Russell, Beth AU - Russell B AUID- ORCID: 0000-0001-5640-8425 AD - Translational Oncology and Urology Research, King's College London, London, UK. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Ullen, Anders AU - Ullen A AD - Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. FAU - Soderkvist, Karin AU - Soderkvist K AD - Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Region Vastra Gotaland, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Orebro University, Orebro, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Translational Oncology and Urology Research, King's College London, London, UK. AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Enting, Deborah AU - Enting D AD - Department of Uro-Oncology, Guy's Hospital, Guy's St Thomas NHS Foundation Trust, London, United Kingdom. FAU - Van Hemelrijck, Mieke AU - Van Hemelrijck M AUID- ORCID: 0000-0002-7317-0858 AD - Translational Oncology and Urology Research, King's College London, London, UK. LA - eng PT - Journal Article PT - Observational Study DEP - 20211113 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscles MH - Neoplasm Invasiveness MH - Proportional Hazards Models MH - Urinary Bladder MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Age OT - MIBC OT - NMIBC OT - bladder cancer death OT - survival EDAT- 2021/11/16 06:00 MHDA- 2022/02/09 06:00 CRDT- 2021/11/15 05:35 PHST- 2021/11/16 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] PHST- 2021/11/15 05:35 [entrez] AID - 10.1080/21681805.2021.2002399 [doi] PST - ppublish SO - Scand J Urol. 2022 Feb;56(1):27-33. doi: 10.1080/21681805.2021.2002399. Epub 2021 Nov 13. PMID- 34775222 OWN - NLM STAT- MEDLINE DCOM- 20220223 LR - 20220223 IS - 1532-1983 (Electronic) IS - 0261-5614 (Linking) VI - 40 IP - 12 DP - 2021 Dec TI - Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer. PG - 5792-5801 LID - S0261-5614(21)00498-2 [pii] LID - 10.1016/j.clnu.2021.10.019 [doi] AB - OBJECTIVE: To investigate the predictors of response to intravesical Bacillus Calmette-Guerin (BCG) immunotherapy for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) patients. MATERIALS AND METHODS: We retrospectively analyzed the clinicopathological data of 184 intermediate and high risk NMIBC cases receiving transurethral resection of bladder tumor (TURBT) and intravesical BCG immunotherapy from December 2014 to April 2021 at our center. All patients were divided into BCG responders and non-responders. Multivariate Logistic regression analysis was performed to identify the independent predictors of response to intravesical BCG immunotherapy. Univariate and multivariate Cox regression analyses were applied to explore the independent prognostic factors of recurrence-free survival (RFS). Receiver operating characteristic (ROC) curve and Kaplan-Meier survival analysis were also utilized. RESULTS: The RFS of BCG responders was significantly increased compared with BCG non-responders. Multivariate Cox regression analysis demonstrated that low grade, pTa stage, non-CIS, lower relative visceral fat area (rVFA) and lower systemic immune inflammation index (SII) were independent prognostic factors of increased RFS after intravesical BCG immunotherapy. Multivariate Logistic regression analysis demonstrated that pTa stage, low grade, non-CIS, low rVFA, and low SII were independent predictors of response to intravesical BCG immunotherapy. Kaplan-Meier survival analysis indicated that the RFS of patients in low rVFA group or low SII group was significantly increased in comparison with those in high rVFA group or high SII group. ROC curve analysis showed that the area under ROC (AUC) of including SII and rVFA was significantly increased, indicating that the inclusion of preoperative SII and rVFA could significantly improve the predictive efficiency. CONCLUSIONS: Low grade, pTa stage, non-CIS, preoperative lower rVFA and lower SII were vital independent predictors of response to intravesical BCG immunotherapy and were associated with preferable prognosis in NMIBC patients. The inclusion of preoperative SII and rVFA could significantly improve the predictive efficiency. CI - Copyright (c) 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. FAU - Ke, Zhi-Bin AU - Ke ZB AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Chen, Hang AU - Chen H AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Chen, Jia-Yin AU - Chen JY AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Cai, Hai AU - Cai H AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Lin, Yun-Zhi AU - Lin YZ AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Sun, Xiong-Lin AU - Sun XL AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Huang, Jin-Bei AU - Huang JB AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Zheng, Qing-Shui AU - Zheng QS AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Wei, Yong AU - Wei Y AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. FAU - Xue, Xue-Yi AU - Xue XY AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. Electronic address: xuexueyi@fjmu.edu.cn. FAU - Xu, Ning AU - Xu N AD - Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. Electronic address: drxun@fjmu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211101 PL - England TA - Clin Nutr JT - Clinical nutrition (Edinburgh, Scotland) JID - 8309603 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Abdominal Fat/immunology MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*therapeutic use MH - Female MH - Humans MH - *Immunotherapy MH - Inflammation/immunology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/immunology MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Abdominal fat distribution OT - Bacillus calmette-guerin OT - Non-muscle invasive bladder cancer OT - Systemic immune inflammation index OT - Therapeutic response COIS- Conflict of interest All authors declare no conflict of interests. EDAT- 2021/11/15 06:00 MHDA- 2022/02/24 06:00 CRDT- 2021/11/14 21:02 PHST- 2021/06/08 00:00 [received] PHST- 2021/10/23 00:00 [revised] PHST- 2021/10/26 00:00 [accepted] PHST- 2021/11/15 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] PHST- 2021/11/14 21:02 [entrez] AID - S0261-5614(21)00498-2 [pii] AID - 10.1016/j.clnu.2021.10.019 [doi] PST - ppublish SO - Clin Nutr. 2021 Dec;40(12):5792-5801. doi: 10.1016/j.clnu.2021.10.019. Epub 2021 Nov 1. PMID- 34774000 OWN - NLM STAT- MEDLINE DCOM- 20220218 LR - 20220218 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Nov 13 TI - Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. PG - 1223 LID - 10.1186/s12885-021-08976-1 [doi] LID - 1223 AB - BACKGROUND: To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT). METHODS: Patients were categorized into two groups intraoperatively: a hypotensive group (minimum systolic blood pressure (SBP) 80 mmHg). We examined differences between the hypotensive group and non-hypotensive groups to identify clinical risk of ALA-induced hypotension using multivariate logistic regression analysis and decision tree analysis. RESULTS: Among 282 cases with ALA-PDD-assisted TURBT from three institutions who were screened, 245 patients were included in the final analysis. In total, 156 patients (63.7%) showed any grade of hypotension during ALA-PDD-assisted TURBT. General anesthesia and spinal anesthesia were induced intraoperatively in 113 patients (46.1%) and 132 patients (53.9%), respectively. Median SBP at baseline (before taking ALA) and at the beginning of anesthesia was 127 mmHg (range, 69-186 mmHg) and 124 mmHg (range, 69-186 mmHg), respectively. Median minimum SBP during ALA-PDD-assisted TURBT was 75 mmHg (range, 43-140 mmHg). Multivariate logistic regression analysis revealed that history of hypertension (odds ratio (OR) 7.568, p < 0.05) and general anesthesia (OR 14.435, p < 0.05) as significantly associated with an increased risk of hypotension incidence. Use of calcium antagonist showed significant negative associations with hypotension (OR 0.183, p < 0.05). Decision tree analysis showed presence of general anesthesia, age >/= 74 years and American Society of Anesthesiologists physical status (ASA-PS) >/=2 as the most important discriminators. CONCLUSIONS: General anesthesia and hypertension were independent risk factors related to ALA-induced hypotension. In contrast, use of calcium antagonists was identified as a factor associated with reduced risk of ALA-induced hypotension. CI - (c) 2021. The Author(s). FAU - Fukuhara, Hideo AU - Fukuhara H AD - Department of Urology and Center for Photodynamic Medicine, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. jm-fukuhara@kochi-u.ac.jp. FAU - Nohara, Takahiro AU - Nohara T AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan. FAU - Nishimoto, Koshiro AU - Nishimoto K AD - Department of Urology, Saitama Medical University International Medical, Center1397-1, Yamane, Hidaka, Saitama, 350-1298, Japan. FAU - Hatakeyama, Yutaka AU - Hatakeyama Y AD - Center of Medical Information Science, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. FAU - Hyodo, Yuki AU - Hyodo Y AD - Center of Medical Information Science, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. FAU - Okuhara, Yoshiyasu AU - Okuhara Y AD - Center of Medical Information Science, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Urology, Saitama Medical University International Medical, Center1397-1, Yamane, Hidaka, Saitama, 350-1298, Japan. FAU - Mizokami, Atsushi AU - Mizokami A AD - Department of Integrative Cancer Therapy and Urology, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology and Center for Photodynamic Medicine, Kochi Medical School, Kohasu, Oko, Nankoku, Kochi, 783-8505, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan. CN - Japan Urological Photodynamic Society LA - eng PT - Journal Article PT - Multicenter Study DEP - 20211113 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Calcium Channel Blockers) RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Aged MH - Aged, 80 and over MH - Aminolevulinic Acid/*adverse effects MH - Anesthesia, General/adverse effects MH - Anesthesia, Spinal MH - Calcium Channel Blockers/therapeutic use MH - Cystectomy/*methods MH - Decision Trees MH - Female MH - Humans MH - Hypotension/*chemically induced/epidemiology MH - Incidence MH - Male MH - Middle Aged MH - Photosensitizing Agents/*adverse effects MH - Regression Analysis MH - Retrospective Studies MH - Risk Factors MH - Systole/drug effects MH - Urinary Bladder Neoplasms/diagnosis/*surgery PMC - PMC8590750 OTO - NOTNLM OT - 5-aminolevulinic acid OT - Hypotension OT - Non-muscle invasive bladder cancer OT - Photodynamic diagnosis OT - Transurethral resection of bladder tumor COIS- The authors report the following financial interests; KI; Chugai Pharmaceutical Co., Ltd. - speaker fees. HM; Chugai Pharmaceutical Co., Ltd. - speaker fees. All other authors have nothing to disclose. Chugai Pharmaceutical Co., Ltd. played no role in the study design, data collection and analysis, decision to submit for publication, or preparation of the manuscript. EDAT- 2021/11/15 06:00 MHDA- 2022/02/19 06:00 PMCR- 2021/11/13 CRDT- 2021/11/14 20:25 PHST- 2021/04/24 00:00 [received] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/11/14 20:25 [entrez] PHST- 2021/11/15 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/11/13 00:00 [pmc-release] AID - 10.1186/s12885-021-08976-1 [pii] AID - 8976 [pii] AID - 10.1186/s12885-021-08976-1 [doi] PST - epublish SO - BMC Cancer. 2021 Nov 13;21(1):1223. doi: 10.1186/s12885-021-08976-1. PMID- 34768625 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211118 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 21 DP - 2021 Oct 30 TI - Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. LID - 10.3390/jcm10215105 [doi] LID - 5105 AB - (1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context of a relative BCG shortage. We aim to determine real-world data on the long-term treatment outcomes of adjunct hyperthermic intravesical chemotherapy (HIVEC) with MMC and a COMBAT(R) bladder recirculation system (BRS); (2) Methods: A prospective observational trial was performed on patients with NMIBC treated with HIVEC using BRS in nine academic institutions in Spain between 2012-2020 (HIVEC-E). Treatment effectiveness (recurrence, progression and overall mortality) was evaluated in patients treated with HIVEC MMC 40mg in the adjuvant setting, with baseline data and a clinical follow-up, that comprise the Full Analysis Set (FAS). Safety, according to the number and severity of adverse effects (AEs), was evaluated in the safety (SAF) population, composed by patients with at least one adjunct HIVEC MMC instillation; (3) Results: The FAS population (n = 502) received a median number of 8.78 +/- 3.28 (range 1-20) HIVEC MMC instillations. The median follow-up duration was 24.5 +/- 16.5 (range 1-81) months. Its distribution, based on EAU risk stratification, was 297 (59.2%) for intermediate and 205 (40.8%) for high-risk. The figures for five-year recurrence-free and progression-free survival were 50.37% (53.3% for intermediate and 47.14% for high-risk) and 89.83% (94.02% for intermediate and 84.23% for high-risk), respectively. A multivariate analysis identified recurrent tumors (HR 1.83), the duration of adjuvant HIVEC therapy <4 months (HR 1.72) and that high-risk group (HR 1.47) were at an increased risk of recurrence. Independent factors of progression were high-risk (HR 3.89), recurrent tumors (HR 3.32) and the induction of HIVEC therapy without maintenance (HR 2.37). The overall survival was determined by patient age at diagnosis (HR 3.36) and the treatment duration (HR 1.82). The SAF population (n = 592) revealed 406 (68.58%) patients without AEs and 186 (31.42%) with at least one AE: 170 (28.72%) of grade 1-2 and 16 (2.7%) of grade 3-4. The most frequent AEs were dysuria (10%), pain (7.1%), urgency (5.7%), skin rash (4.9%), spasms (3.7%) and hematuria (3.6%); (4) Conclusions: HIVEC using BRS is efficacious and well tolerated. A longer treatment duration, its use in naive patients and the intermediate-risk disease are independent determinants of success. Furthermore, a monthly maintenance of adjunct MMC HIVEC diminishes the progression rate of NMIBC. FAU - Plata, Ana AU - Plata A AD - Urology Department, Hospital Universitario de Canarias, Carretera Ofra s/n, 38320 San Cristobal de La Laguna, Spain. FAU - Guerrero-Ramos, Felix AU - Guerrero-Ramos F AUID- ORCID: 0000-0002-0767-3465 AD - Urology Department, Hospital Universitario 12 de Octubre, Avenida de Cordoba s/n, 28041 Madrid, Spain. FAU - Garcia, Carlos AU - Garcia C AD - Urology Department, Hospital Universitario de Canarias, Carretera Ofra s/n, 38320 San Cristobal de La Laguna, Spain. FAU - Gonzalez-Diaz, Alejandro AU - Gonzalez-Diaz A AUID- ORCID: 0000-0002-3581-7200 AD - Urology Department, Hospital Universitario 12 de Octubre, Avenida de Cordoba s/n, 28041 Madrid, Spain. FAU - Gonzalez-Valcarcel, Ignacio AU - Gonzalez-Valcarcel I AD - Urology Department, Hospital Universitario Infanta Sofia, Paseo de Europa 34, San Sebastian de los Reyes, 28702 Madrid, Spain. FAU - de la Morena, Jose Manuel AU - de la Morena JM AD - Urology Department, Hospital Universitario Infanta Sofia, Paseo de Europa 34, San Sebastian de los Reyes, 28702 Madrid, Spain. FAU - Diaz-Goizueta, Francisco Javier AU - Diaz-Goizueta FJ AD - Urology Department, Hospital Universitario Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain. FAU - Del Alamo, Julio Fernandez AU - Del Alamo JF AD - Urology Department, Hospital Universitario de Torrejon, Mateo Inurria, s/n, Torrejon de Ardoz, 28850 Madrid, Spain. FAU - Gonzalo, Victoria AU - Gonzalo V AD - Urology Department, Hospital Universitario de Burgos, Avenida Islas Baleares 3, 09006 Burgos, Spain. FAU - Montero, Javier AU - Montero J AD - Urology Department, Hospital Universitario de Burgos, Avenida Islas Baleares 3, 09006 Burgos, Spain. FAU - Sousa-Escandon, Alejandro AU - Sousa-Escandon A AD - Urology Department, Hospital Comarcal de Monforte, Rua Corredoira s/n, 27400 Monforte de Lemos, Spain. FAU - Leon, Juan AU - Leon J AUID- ORCID: 0000-0001-8162-0313 AD - Urology Department, Hospital Comarcal de Monforte, Rua Corredoira s/n, 27400 Monforte de Lemos, Spain. FAU - Pontones, Jose Luis AU - Pontones JL AD - Urology Department, Hospital Universitario La Fe, Avinguda de Fernando Abril Martorell 106, 46026 Valencia, Spain. FAU - Delgado, Francisco AU - Delgado F AD - Urology Department, Hospital Universitario La Fe, Avinguda de Fernando Abril Martorell 106, 46026 Valencia, Spain. FAU - Adriazola, Miguel AU - Adriazola M AD - Urology Department, Hospital General Rio Carrion, Avenida Donantes de Sangre s/n, 34005 Palencia, Spain. FAU - Pascual, Angela AU - Pascual A AD - Urology Department, Hospital General Rio Carrion, Avenida Donantes de Sangre s/n, 34005 Palencia, Spain. FAU - Calleja, Jesus AU - Calleja J AD - Urology Department, Hospital Clinico Universitario de Valladolid, Av. Ramon y Cajal 3, 47003 Valladolid, Spain. FAU - Ruano, Ana AU - Ruano A AD - Urology Department, Hospital Clinico Universitario de Valladolid, Av. Ramon y Cajal 3, 47003 Valladolid, Spain. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Urology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. FAU - Angulo, Javier C AU - Angulo JC AD - Urology Department, Hospital Universitario Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain. AD - Clinical Department, Facultad de Ciencias Biomedicas, Universidad Europea de Madrid, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain. LA - eng PT - Journal Article DEP - 20211030 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8584886 OTO - NOTNLM OT - bladder neoplasia OT - bladder recirculation system OT - hyperthermic intravesical chemotherapy OT - mitomycin-C COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/11/14 06:00 MHDA- 2021/11/14 06:01 PMCR- 2021/10/30 CRDT- 2021/11/13 01:02 PHST- 2021/10/17 00:00 [received] PHST- 2021/10/27 00:00 [revised] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/11/13 01:02 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/14 06:01 [medline] PHST- 2021/10/30 00:00 [pmc-release] AID - jcm10215105 [pii] AID - jcm-10-05105 [pii] AID - 10.3390/jcm10215105 [doi] PST - epublish SO - J Clin Med. 2021 Oct 30;10(21):5105. doi: 10.3390/jcm10215105. PMID- 34764423 OWN - NLM STAT- MEDLINE DCOM- 20220127 LR - 20240508 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Nov 11 TI - Metabolomic credentialing of murine carcinogen-induced urothelial cancer. PG - 22085 LID - 10.1038/s41598-021-99746-3 [doi] LID - 22085 AB - Bladder cancer (BCa) is the most common malignancy of the urinary system with increasing incidence, mortality, and limited treatment options. Therefore, it is imperative to validate preclinical models that faithfully represent BCa cellular, molecular, and metabolic heterogeneity to develop new therapeutics. We performed metabolomic profiling of premalignant and non-muscle invasive bladder cancer (NMIBC) that ensued in the chemical carcinogenesis N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model. We identified the enriched metabolic signatures that associate with premalignant and NMIBC. We found that enrichment of lipid metabolism is the forerunner of carcinogen-induced premalignant and NMIBC lesions. Cross-species analysis revealed the prognostic value of the enzymes associated with carcinogen-induced enriched metabolic in human disease. To date, this is the first study describing the global metabolomic profiles associated with early premalignant and NMIBC and provide evidence that these metabolomic signatures can be used for prognostication of human disease. CI - (c) 2021. The Author(s). FAU - Afify, Hesham AU - Afify H AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Ghoneum, Alia AU - Ghoneum A AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Almousa, Sameh AU - Almousa S AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Abdulfattah, Ammar Yasser AU - Abdulfattah AY AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Warren, Bailey AU - Warren B AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Langsten, Kendall AU - Langsten K AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Gonzalez, Daniela AU - Gonzalez D AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Casals, Randy AU - Casals R AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. AD - Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. FAU - Bharadwaj, Manish AU - Bharadwaj M AD - Cell Analysis Division, Agilent Technologies, Inc, Santa Clara, CA, 95051, USA. FAU - Kridel, Steven AU - Kridel S AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. AD - Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. AD - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, 27157, USA. FAU - Said, Neveen AU - Said N AD - Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. nsaid@wakehealth.edu. AD - Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. nsaid@wakehealth.edu. AD - Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA. nsaid@wakehealth.edu. AD - Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, 27157, USA. nsaid@wakehealth.edu. LA - eng GR - R01-CA193437/GF/NIH HHS/United States GR - R01 CA193437/CA/NCI NIH HHS/United States GR - T32 GM127261/GM/NIGMS NIH HHS/United States GR - T32 OD010957/OD/NIH HHS/United States GR - P30 CA012197/CA/NCI NIH HHS/United States GR - UL1 TR001420/TR/NCATS NIH HHS/United States GR - T32 GM127261/GF/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211111 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Carcinogens) RN - 3817-11-6 (Butylhydroxybutylnitrosamine) SB - IM MH - Animals MH - Butylhydroxybutylnitrosamine/*toxicity MH - Carcinogens/*toxicity MH - Cell Line MH - Humans MH - Male MH - *Metabolome/drug effects MH - Mice MH - Mice, Inbred C57BL MH - Neoplasms, Experimental/chemically induced/metabolism/pathology MH - Urinary Bladder Neoplasms/*chemically induced/metabolism/pathology MH - Urothelium/*drug effects/metabolism/pathology PMC - PMC8585868 COIS- The authors declare no competing interests. EDAT- 2021/11/13 06:00 MHDA- 2022/01/28 06:00 PMCR- 2021/11/11 CRDT- 2021/11/12 06:51 PHST- 2021/05/28 00:00 [received] PHST- 2021/09/28 00:00 [accepted] PHST- 2021/11/12 06:51 [entrez] PHST- 2021/11/13 06:00 [pubmed] PHST- 2022/01/28 06:00 [medline] PHST- 2021/11/11 00:00 [pmc-release] AID - 10.1038/s41598-021-99746-3 [pii] AID - 99746 [pii] AID - 10.1038/s41598-021-99746-3 [doi] PST - epublish SO - Sci Rep. 2021 Nov 11;11(1):22085. doi: 10.1038/s41598-021-99746-3. PMID- 34756696 OWN - NLM STAT- MEDLINE DCOM- 20220112 LR - 20220112 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 32 IP - 1 DP - 2022 Jan TI - Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy. PG - 53-60 LID - S1166-7087(21)00474-7 [pii] LID - 10.1016/j.purol.2021.09.010 [doi] AB - INTRODUCTION: Factors predicting response to adjuvant chemotherapy (AC) are required to identify patients who will most benefit from it. The aim of this study was to evaluate the impact of carcinoma in situ (CIS) at radical cystectomy (RC) on recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS) of patients treated by AC. MATERIALS AND METHODS: A single-center retrospective study was performed on patients who received AC after RC without pre-RC chemotherapy or trimodal therapy. RESULTS: Among the 150 patients analyzed, 52,7% had CIS on the RC specimens. Baseline characteristics were not significantly different between the CIS negative and positive groups. Most patients received a cisplatin-based AC (74%). The median follow-up of the cohort was 36,4 months. The presence of CIS was not significantly associated to disease-recurrence (OR=0.67; 95%CI=0.35-1.29; P=0.23), cancer related death (OR=0.70; 95%CI=0.36-1.33; P=0.27) or death by any cause (OR=0.80; 95%CI=0.42-1.52; P=0.50). The presence of CIS had no significant impact on RFS (HR=0.86; 95%CI=0.56-1.33; P=0.49), CSS (HR=0.85; 95%CI=0.53-1.36; P=0.50) or OS (HR=0.93; 95%CI=0.60-1.45; P=0.74). CONCLUSION: The presence of CIS on RC specimens did not have an impact on survival of patients treated by AC. CIS could be evaluated as a prognostic factor of response to novel adjuvant regimens such as immunotherapy. CI - Copyright (c) 2021 Elsevier Masson SAS. All rights reserved. FAU - Soorojebally, Y AU - Soorojebally Y AD - Department of Urology, Foch Hospital, Suresnes, France; University of Versailles-Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France. Electronic address: y.soorojebally@hopital-foch.com. FAU - Surlemont, L AU - Surlemont L AD - Department of Urology, Foch Hospital, Suresnes, France. FAU - Neuzillet, Y AU - Neuzillet Y AD - Department of Urology, Foch Hospital, Suresnes, France; University of Versailles-Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France. FAU - Lebret, T AU - Lebret T AD - Department of Urology, Foch Hospital, Suresnes, France; University of Versailles-Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France. LA - eng PT - Journal Article DEP - 20211028 PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 SB - IM MH - *Carcinoma in Situ/pathology MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Adjuvant chemotherapy OT - Cancer de vessie OT - Carcinoma in situ OT - Carcinome in situ OT - Chimiotherapie adjuvante OT - Cystectomie OT - Cystectomy OT - Survie OT - Survival OT - Urinary Bladder Neoplasms EDAT- 2021/11/11 06:00 MHDA- 2022/01/13 06:00 CRDT- 2021/11/10 14:08 PHST- 2021/07/19 00:00 [received] PHST- 2021/09/16 00:00 [revised] PHST- 2021/09/24 00:00 [accepted] PHST- 2021/11/11 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/11/10 14:08 [entrez] AID - S1166-7087(21)00474-7 [pii] AID - 10.1016/j.purol.2021.09.010 [doi] PST - ppublish SO - Prog Urol. 2022 Jan;32(1):53-60. doi: 10.1016/j.purol.2021.09.010. Epub 2021 Oct 28. PMID- 34756410 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20230228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 41 IP - 1 DP - 2023 Jan TI - Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. PG - 27-34 LID - S1078-1439(20)30477-4 [pii] LID - 10.1016/j.urolonc.2020.10.004 [doi] AB - Non-muscle-invasive bladder cancer is one of the most common malignancies. Patients with intermediate-risk or high-risk disease can be treated with intravesical Bacillus Calmette-Guerin, a vaccine against tuberculosis. However, many of these patients will experience tumor recurrence, despite appropriate treatment. 1 The standard of care in these patients is radical cystectomy (RC) with urinary diversion. 2 Patients diagnosed with muscle-invasive bladder cancer (MIBC) have traditionally faced 2 main treatment options: RC and urinary diversion, as in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive bladder cancer, or alternatively, trimodal therapy comprising maximal transurethral resection of bladder tumor plus chemoradiation. 3 For patients with MIBC and clinical (c)T2-T4a, neoadjuvant chemotherapy (NAC) preceding RC is supported by Level 1 evidence with a modest 5-year overall survival benefit of 5% with cisplatin-based regimens. 4-9 A number of factors preclude MIBC patients from standard treatment options. For example, patients with serious comorbidities might be unable to tolerate general anesthesia, while others might be unwilling to adapt to the lifestyle changes after RC. 10-12 Likewise, patients with extensive carcinoma in situ or poor bladder function might not be optimal candidates for trimodal therapy or be prepared for the ongoing risk that salvage RC might be ultimately required. Reasons for the underuse of NAC range from the fear of delaying potentially curative surgery in nonresponders to patient ineligibility to cisplatin-based NAC. 13,14 Despite best efforts, in both surgical and bladder-sparing approaches, the 5-year overall survival in treated patients with MIBC is only 35% to 50%. 3,15 Strategies to improve overall prognosis as well as to reduce the indications of RC are desperately needed. Trial results have demonstrated the unprecedented ability of immune-checkpoint inhibitors to induce durable remissions in some patients with metastatic urothelial carcinoma. 16-20 Furthermore, immune-checkpoint inhibitors have shown to be better tolerated than traditional chemotherapy. 16 These successful results have spearheaded the research on these agents in earlier curative settings, with the shared goal of improving overall outcomes, and potentially avoid surgery in patients who show complete response (pT0). Strategies to enhance the immune response by combining immunotherapy with immune sensitizers such as chemotherapy, immunotherapy, targeted therapy or radiation are on the rise. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Nadal, Rosa AU - Nadal R AD - Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, MD. FAU - Apolo, Andrea B AU - Apolo AB AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. FAU - Girardi, Daniel M AU - Girardi DM AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. FAU - Hahn, Noah M AU - Hahn NM AD - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: jbellmun@bidmc.harvard.edu. LA - eng PT - Journal Article PT - Review DEP - 20201023 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - Q20Q21Q62J (Cisplatin) RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Cisplatin/therapeutic use MH - BCG Vaccine/therapeutic use MH - Immune Checkpoint Inhibitors MH - Neoplasm Recurrence, Local/surgery MH - Cystectomy/methods MH - Neoadjuvant Therapy MH - Immunotherapy MH - Neoplasm Invasiveness OTO - NOTNLM OT - Bladder-sparing strategies OT - Immunotherapy OT - Nonmetastatic urothelial carcinoma EDAT- 2021/11/11 06:00 MHDA- 2022/11/30 06:00 CRDT- 2021/11/10 13:52 PHST- 2020/07/12 00:00 [received] PHST- 2020/09/01 00:00 [revised] PHST- 2020/10/07 00:00 [accepted] PHST- 2021/11/11 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2021/11/10 13:52 [entrez] AID - S1078-1439(20)30477-4 [pii] AID - 10.1016/j.urolonc.2020.10.004 [doi] PST - ppublish SO - Urol Oncol. 2023 Jan;41(1):27-34. doi: 10.1016/j.urolonc.2020.10.004. Epub 2020 Oct 23. PMID- 34753702 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20250623 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 4 IP - 6 DP - 2021 Dec TI - Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. PG - 927-942 LID - S2588-9311(21)00183-8 [pii] LID - 10.1016/j.euo.2021.10.003 [doi] AB - CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far. OBJECTIVE: To assess the diagnostic estimates of novel commercially available UBTs for diagnosis and surveillance of non-muscle-invasive bladder cancer (NMIBC) using diagnostic test accuracy (DTA) and network meta-analysis (NMA). EVIDENCE ACQUISITION: PubMed, Web of Science, and Scopus were searched up to April 2021 to identify studies addressing the diagnostic values of UBTs: Xpert bladder cancer, Adxbladder, Bladder EpiCheck, Uromonitor and Cxbladder Monitor, and Triage and Detect. The primary endpoint was to assess the pooled diagnostic values for disease recurrence in NMIBC patients using a DTA meta-analysis and to compare them with cytology using an NMA. The secondary endpoints were the diagnostic values for high-grade (HG) recurrence as well as for the initial detection of bladder cancer. EVIDENCE SYNTHESIS: Twenty-one studies, comprising 7330 patients, were included in the quantitative synthesis. In most of the studies, there was an unclear risk of bias. For NMIBC surveillance, novel UBTs demonstrated promising pooled diagnostic values with sensitivities up to 93%, specificities up to 84%, positive predictive values up to 67%, and negative predictive value up to 99%. Pooled estimates for the diagnosis of HG recurrence were similar to those for the diagnosis of any-grade recurrence. The analysis of the number of cystoscopies potentially avoided during the follow-up of 1000 patients showed that UBTs might be efficient in reducing the number of avoidable interventions with up to 740 cystoscopies. The NMA revealed that diagnostic values (except specificity) of the novel UBTs were significantly higher than those of cytology for the detection of NMIBC recurrence. There were too little data on UBTs in the primary diagnosis setting to allow a statistical analysis. CONCLUSIONS: Our analyses support high diagnostic accuracy of the studied novel UBTs, supporting their utility in the NMIBC surveillance setting. All of these might potentially help prevent unnecessary cystoscopies safely. There are not enough data to reliably assess their use in the primary diagnostic setting. These results have to be confirmed in a larger cohort as well as in head-to-head comparative studies. Nevertheless, our study might help policymakers and stakeholders evaluate the clinical and social impact of the implementation of these tests into daily practice. PATIENT SUMMARY: Novel urinary biomarker tests outperform cytology with the potential of improving routine clinical practice by preventing unnecessary cystoscopic examinations during the surveillance of non-muscle-invasive bladder cancer. CI - Copyright (c) 2021 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Shim, Sung Ryul AU - Shim SR AD - Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique-Hopitaux de Paris, Universite de Paris, Paris, France. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Palou, Juan AU - Palou J AD - Fundacio Puigvert, Department of Urology, Autonomous University of Barcelona, Barcelona, Spain. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University, Nijmegen Heyendaal, The Netherlands. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC n degrees 5, Predictive Onco-Urology, Ap-Hp, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Electronic address: shahrokh.shariat@meduniwien.ac.at. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. CN - European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20211106 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Biomarkers, Tumor) SB - IM EIN - Eur Urol Oncol. 2022 Aug;5(4):480-481. doi: 10.1016/j.euo.2022.01.003. PMID: 35063436 CIN - Eur Urol Oncol. 2022 Apr;5(2):263-264. doi: 10.1016/j.euo.2022.01.002. PMID: 35074283 MH - Biomarkers, Tumor MH - Cystoscopy MH - Humans MH - Neoplasm Recurrence, Local/diagnosis MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - Accuracy OT - Bladder cancer OT - Urinary biomarkers OT - Urine cytology EDAT- 2021/11/11 06:00 MHDA- 2022/02/03 06:00 CRDT- 2021/11/10 05:41 PHST- 2021/08/16 00:00 [received] PHST- 2021/09/23 00:00 [revised] PHST- 2021/10/05 00:00 [accepted] PHST- 2021/11/11 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/11/10 05:41 [entrez] AID - S2588-9311(21)00183-8 [pii] AID - 10.1016/j.euo.2021.10.003 [doi] PST - ppublish SO - Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. PMID- 34750054 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20230302 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 40 IP - 3 DP - 2022 Mar TI - Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival. PG - 108.e1-108.e10 LID - S1078-1439(21)00443-9 [pii] LID - 10.1016/j.urolonc.2021.09.017 [doi] AB - OBJECTIVES: Plasmacytoid urothelial carcinomas (PUC) of the bladder are rare variants known for diffuse and infiltrative spread, however their magnetic resonance imaging (MRI) features are not well established. We aimed to evaluate MRI features of PUC of the bladder and their association with survival. METHODS AND MATERIALS: This retrospective single-center study included 41 patients with pathologically-proven bladder PUC of the bladder that underwent pre-treatment MRI between January 2000 and March 2020. Two radiologists reviewed MRIs independently followed by consensus with a third radiologist. On MRI, tumor extent, size, Vesical Imaging-Reporting and Data System (VI-RADS) scores (>/=4, muscle-invasive; 5, extravesical extension [EVE]), pelvic peritoneal spread (PPS), hydronephrosis, pelvic adenopathy and clinicopathological factors of age, gender, pathological stage, and treatment type were extracted. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with survival. RESULTS: Thirty-two men and 9 women (median age 70 years, IQR 64-76) were included. Most were muscle-invasive (n = 30 [73.2%]). On MRI, most tumors were diffuse (n = 28 [68.3%]), >5 cm (n = 30 [73.2%]), VI-RADS 4 to 5 (n = 36 [87.8%]) with features of EVE and (n = 31 [75.6%]) and PPS (n = 25 [61.0%]). Variables associated with survival were: Larger tumors (>5 cm; hazard ratio [HR] = 5.0; 95% confidence interval [CI] 1.6-15.5; P < 0.01), diffuse extent (HR = 4.0; 95% CI 1.4-11.2; P = 0.01), EVE (HR = 4.5; 95% CI 1.5-13.6; P < 0.01), PPS (HR = 3.0; 95% CI 1.2-7.4; P = 0.01), hydronephrosis (HR = 13.7; 95% CI 3.1-60.9; P < 0.01), pathologic stage (>/=pT3 vs. pT1; HR = 5.6; 95% CI 1.3-22.0; P = 0.02), and margin positivity (HR = 4.4 [95% CI 1.2-16.4], P = 0.03). CONCLUSION: PUCs of the bladder are commonly large, diffuse VI-RADS score 4 to 5 tumors with MRI features of EVE and PPS. These features and pathological stage were associated with survival. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Woo, Sungmin AU - Woo S AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: woos@mskcc.org. FAU - Ghafoor, Soleen AU - Ghafoor S AD - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland. FAU - Das, Jeeban P AU - Das JP AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Gangai, Natalie AU - Gangai N AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Goh, Alvin C AU - Goh AC AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Vargas, Herbert Alberto AU - Vargas HA AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211105 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - *Carcinoma, Transitional Cell/pathology MH - Female MH - Humans MH - *Hydronephrosis MH - Magnetic Resonance Imaging MH - Male MH - *Multiparametric Magnetic Resonance Imaging MH - Retrospective Studies MH - Urinary Bladder/diagnostic imaging/pathology MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology PMC - PMC8885786 MID - NIHMS1745411 OTO - NOTNLM OT - Bladder OT - MRI OT - Plasmacytoid urothelial carcinoma OT - Survival OT - VI-RADS COIS- Declaration of interest This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Alvin C. Goh is a consultant to Medtronics for provision of Services for which he does not receive compensation. The other authors do not have anything to disclose. EDAT- 2021/11/10 06:00 MHDA- 2022/04/21 06:00 PMCR- 2023/03/01 CRDT- 2021/11/09 05:54 PHST- 2021/06/05 00:00 [received] PHST- 2021/08/20 00:00 [revised] PHST- 2021/09/26 00:00 [accepted] PHST- 2021/11/10 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2021/11/09 05:54 [entrez] PHST- 2023/03/01 00:00 [pmc-release] AID - S1078-1439(21)00443-9 [pii] AID - 10.1016/j.urolonc.2021.09.017 [doi] PST - ppublish SO - Urol Oncol. 2022 Mar;40(3):108.e1-108.e10. doi: 10.1016/j.urolonc.2021.09.017. Epub 2021 Nov 5. PMID- 34742742 OWN - NLM STAT- MEDLINE DCOM- 20211227 LR - 20211227 IS - 1090-2422 (Electronic) IS - 0014-4827 (Linking) VI - 409 IP - 2 DP - 2021 Dec 15 TI - Long noncoding RNA AK023096 interacts with hnRNP-K and contributes to the maintenance of self-renewal in bladder cancer stem-like cells. PG - 112909 LID - S0014-4827(21)00465-1 [pii] LID - 10.1016/j.yexcr.2021.112909 [doi] AB - LncRNA contribution to self-renewal of bladder cancer stem-like cells (CSLCs) remains largely unknown. We investigated the expression profile and biological function of lncRNAs in urothelial CSLCs by microarray analysis. Among these, lncRNA-AK023096 was identified as potentially playing a role in maintaining self-renewal of CSLCs. Knockdown of this transcript inhibited spheroid formation and tumor formation. We found that AK023096 mediates recruitment of hnRNP-K to SOX2 promoter and increases H3K4 trimethylation status on SOX2 promoter, leading to a robust change in SOX2 mRNA and protein levels. Moreover, AK023096 expression in primary tumors was found to be a powerful predictor of recurrence following transurethral resection in patients with nonmuscle-invasive bladder cancer, highlighting the critical role of lncRNA in the bladder cancer regulatory network. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Zhao, Fengjin AU - Zhao F AD - Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, No.621, Gangwan Road, Guangzhou, Guangdong, 510799, China. Electronic address: zhfj621@163.com. FAU - Qin, Shizhong AU - Qin S AD - Department of Urology, Liuzhou Maternity and Child Healthcare Hospital, No.621, Gangwan Road, Liuzhou, Guangxi, 545001, China. Electronic address: 976250600@qq.com. FAU - Huang, Li AU - Huang L AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107, Yanjiang Road, Guangzhou, Guangdong, 510120, China. Electronic address: huangli855@163.com. FAU - Ding, Langjin AU - Ding L AD - Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, No.621, Gangwan Road, Guangzhou, Guangdong, 510799, China. Electronic address: 917691775@qq.com. FAU - Shi, Xingyuan AU - Shi X AD - Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, Department of Oncology Radiotherapy, The Fifth Affiliated Hospital of Guangzhou Medical University, No.621, Gangwan Road, Guangzhou, Guangdong, 510799, China. Electronic address: shixingyuansums@qq.com. FAU - Zhong, Guangzheng AU - Zhong G AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107, Yanjiang Road, Guangzhou, Guangdong, 510120, China. Electronic address: zhonggzh3@mail.sysu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211104 PL - United States TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Biomarkers, Tumor) RN - 0 (Heterogeneous-Nuclear Ribonucleoprotein K) RN - 0 (RNA, Long Noncoding) RN - 0 (SOXB1 Transcription Factors) RN - 146410-60-8 (HNRNPK protein, human) SB - IM MH - Animals MH - Apoptosis MH - Biomarkers, Tumor/genetics/*metabolism MH - Cell Proliferation MH - *Cell Self Renewal MH - Gene Expression Regulation, Neoplastic MH - Heterogeneous-Nuclear Ribonucleoprotein K/genetics/*metabolism MH - Humans MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Neoplastic Stem Cells/metabolism/*pathology MH - Prognosis MH - Promoter Regions, Genetic MH - RNA, Long Noncoding/*genetics MH - SOXB1 Transcription Factors/genetics/*metabolism MH - Survival Rate MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/genetics/metabolism/*pathology MH - Xenograft Model Antitumor Assays OTO - NOTNLM OT - Bladder cancer OT - Cancer stem-like cells OT - SOX2 OT - hnRNP-K OT - lncRNA EDAT- 2021/11/08 06:00 MHDA- 2021/12/28 06:00 CRDT- 2021/11/07 20:34 PHST- 2021/06/10 00:00 [received] PHST- 2021/10/10 00:00 [revised] PHST- 2021/11/03 00:00 [accepted] PHST- 2021/11/08 06:00 [pubmed] PHST- 2021/12/28 06:00 [medline] PHST- 2021/11/07 20:34 [entrez] AID - S0014-4827(21)00465-1 [pii] AID - 10.1016/j.yexcr.2021.112909 [doi] PST - ppublish SO - Exp Cell Res. 2021 Dec 15;409(2):112909. doi: 10.1016/j.yexcr.2021.112909. Epub 2021 Nov 4. PMID- 34741631 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 40 IP - 3 DP - 2022 Mar TI - Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results. PG - 727-738 LID - 10.1007/s00345-021-03866-4 [doi] AB - PURPOSE: White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance. METHODS: Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses. RESULTS: 689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data. CONCLUSION: There was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients. REGISTRATION: ClinicalTrials.gov Identifier NCT02252549 (30-09-2014). CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - de la Rosette, Jean AU - de la Rosette J AUID- ORCID: 0000-0002-6308-1763 AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. j.j.delarosette@gmail.com. FAU - Martov, Alexey AU - Martov A AD - Department of Urology, Pletnew Moscow City Hospital, Moscow, Russia. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Favre, Gabriel AU - Favre G AD - Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Mamoulakis, Charalampos AU - Mamoulakis C AD - Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, Heraklion, Crete, Greece. FAU - Castanheira de Oliveira, Manuel AU - Castanheira de Oliveira M AD - Department of Urology, Centro Hospitalar Universitario Do Porto, Hospital de Santo Antonio, Porto, Portugal. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University of Tuebingen Medical Center, Tuebingen, Germany. FAU - Linares-Espinos, Estefania AU - Linares-Espinos E AD - Department of Urology, La Paz University Hospital, Madrid, Spain. FAU - Trelles Guzman, Carlos R AU - Trelles Guzman CR AD - Department of Urology, La Paz University Hospital, Madrid, Spain. FAU - Gravas, Stavros AU - Gravas S AD - Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. AD - Medical School, University of Cyprus, Nicosia, Cyprus. FAU - Knoll, Thomas AU - Knoll T AD - Department of Urology, Klinikum Sindelfingen-Boblingen, Germany. FAU - Boz, Mustafa Yucel AU - Boz MY AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. FAU - Herrmann, Thomas AU - Herrmann T AD - Department of Urology, Spital Thurgau, AG, Switzerland. AD - Department of Urology, Hannover Medical School (MHH), Hannover, Germany. FAU - Laguna, Pilar AU - Laguna P AD - Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. LA - eng SI - ClinicalTrials.gov/NCT02252549 PT - Clinical Trial Protocol PT - Journal Article DEP - 20211106 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Cystectomy/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Image 1S imaging OT - Non-muscle-invasive bladder OT - Transurethral resection of bladder tumour OT - Tumour recurrence OT - White light imaging EDAT- 2021/11/07 06:00 MHDA- 2022/03/29 06:00 CRDT- 2021/11/06 17:07 PHST- 2021/06/18 00:00 [received] PHST- 2021/10/16 00:00 [accepted] PHST- 2021/11/07 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] PHST- 2021/11/06 17:07 [entrez] AID - 10.1007/s00345-021-03866-4 [pii] AID - 10.1007/s00345-021-03866-4 [doi] PST - ppublish SO - World J Urol. 2022 Mar;40(3):727-738. doi: 10.1007/s00345-021-03866-4. Epub 2021 Nov 6. PMID- 34733784 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. PG - 741145 LID - 10.3389/fonc.2021.741145 [doi] LID - 741145 AB - BACKGROUND: Studies have reported that diabetes is related to the prognosis of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU), but this conclusion is still controversial. Here, we performed a meta-analysis to comprehensively explore the association between diabetes and UTUC prognosis. METHODS: In November 2020, we searched PubMed, Web of science and the Cochrane Library to find relevant studies that evaluated the effect of diabetes on the prognosis of UTUC. The Newcastle Ottawa Scale was used to assess the quality of the literature. Review Manager 5.3 was used to pool cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS) and intravesical recurrence (IVR). RESULTS: A total of 10 studies with 11,303 patients were included in this meta-analysis. Our pooled results showed that diabetes did not affect the survival outcome of UTUC, including CSS (HR: 1.33, 95% CI: 0.89-1.98; P = 0.16), OS (HR: 1.18, 95% CI: 0.77-1.80; P = 0.45) and RFS (HR: 1.37, 95% CI: 0.91-2.05; P = 0.13). However, diabetes increased the risk of IVR of UTUC patients (HR: 1.26, 95% CI: 1.11-1.43; P = 0.0004). CONCLUSION: Although diabetes has no significant impact on the survival outcomes of UTUC after RNU, it increases the risk of IVR. Therefore, special attention should be paid to monitoring the IVR for UTUC patients with diabetes and the necessity of appropriate intravesical adjuvant treatment when needed. CI - Copyright (c) 2021 Gao, Zhou, Ai, Wang, Di, Peng, Liao, Jin, Li and Wang. FAU - Gao, Xiaoshuai AU - Gao X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Zhou, Liang AU - Zhou L AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Ai, Jianzhong AU - Ai J AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Wei AU - Wang W AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Di, Xingpeng AU - Di X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Peng, Liao AU - Peng L AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Liao, Banghua AU - Liao B AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Jin, Xi AU - Jin X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Hong AU - Li H AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Kunjie AU - Wang K AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211018 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8558518 OTO - NOTNLM OT - diabetes OT - meta-analysis OT - prognosis OT - radical nephroureterectomy OT - upper tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/05 06:00 MHDA- 2021/11/05 06:01 PMCR- 2021/01/01 CRDT- 2021/11/04 06:27 PHST- 2021/08/11 00:00 [received] PHST- 2021/10/04 00:00 [accepted] PHST- 2021/11/04 06:27 [entrez] PHST- 2021/11/05 06:00 [pubmed] PHST- 2021/11/05 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.741145 [doi] PST - epublish SO - Front Oncol. 2021 Oct 18;11:741145. doi: 10.3389/fonc.2021.741145. eCollection 2021. PMID- 34733654 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 9 DP - 2021 Sep TI - The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders. PG - 3579-3590 LID - 10.21037/tau-21-400 [doi] AB - BACKGROUND: The incidence of bladder cancer (BCa) in male is approximately three to four times higher than in female, but the oncological outcomes in female patients with BCa are significantly worse than in male patients. Although many biomarkers have been identified in recent decades to predict the prognosis of BCa patients, few of them are able to distinguish the prognosis of BCa patients with gender difference. Aromatase encoded by the CYP19A1 gene catalyzes the conversion of androgens to estrogens. In this study, we investigate the prognosis significance of CYP19A1 expression considering the gender difference in BCa patients from four available public databases. METHODS: Four available public databases of BCa, including GSE13507, TCGA-BLCA, E-MTAB-4321, and E-MTAB-1803, were utilized in this analysis. The overall survival (OS) and progression-free survival (PFS) in different stages and genders were evaluated using the Kaplan-Meier analysis based on the optimal cut-off values of CYP19A1 expression. Then, Gene Set Enrichment Analysis (GSEA) were further performed to explore the potential biologic pathways by altering CYP19A1 expression in BCa patients. RESULTS: The results showed that patients with high CYP19A1 expression had a poorer outcome compared with those with low expression in both BCa cohorts in general. Higher CYP19A1 expression in male patients were significantly associated with shorter survival for either non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC). However, female NMIBC patients with high CYP19A1 expression were identified to have a better prognosis, whereas high CYP19A1 expression in female MIBC patients were significantly associated with poorer survival. The result of the GSEA showed that different outcomes in female and male patients with NMIBC were related to the interaction of CYP19A1 and the cell-cycle-related pathways. CONCLUSIONS: These findings demonstrated that CYP19A1 expression might have a potential role in distinguishing the prognosis of female BCa patients dependent on tumor stage. Our results provide new insights for aromatase-mediated BCa therapy. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Cai, Shanghua AU - Cai S AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. FAU - Feng, Yuanfa AU - Feng Y AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. FAU - Ye, Jianheng AU - Ye J AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. FAU - Deng, Yulin AU - Deng Y AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. FAU - Cai, Zhiduan AU - Cai Z AD - Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. FAU - Zhu, Xuejin AU - Zhu X AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. FAU - Liu, Ren AU - Liu R AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. FAU - Zhang, Yixun AU - Zhang Y AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. FAU - Zou, Zhihao AU - Zou Z AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. FAU - Tang, Zhenfeng AU - Tang Z AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. FAU - Han, Zhaodong AU - Han Z AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. FAU - Hon, Chi Tin AU - Hon CT AD - Macau Institute of Systems Engineering, Macau University of Science and Technology, Macau, China. FAU - Zhong, Weide AU - Zhong W AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. AD - Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. AD - Department of Urology, Huizhou Municipal Central Hospital, Huizhou, China. AD - Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China. FAU - He, Huichan AU - He H AD - Department of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC8511542 OTO - NOTNLM OT - CYP19A1 OT - bioinformatics analysis OT - bladder cancer (BCa) OT - gender difference OT - prognosis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tau-21-400). The authors have no conflicts of interest to declare. EDAT- 2021/11/05 06:00 MHDA- 2021/11/05 06:01 PMCR- 2021/09/01 CRDT- 2021/11/04 06:26 PHST- 2021/05/06 00:00 [received] PHST- 2021/08/02 00:00 [accepted] PHST- 2021/11/04 06:26 [entrez] PHST- 2021/11/05 06:00 [pubmed] PHST- 2021/11/05 06:01 [medline] PHST- 2021/09/01 00:00 [pmc-release] AID - tau-10-09-3579 [pii] AID - 10.21037/tau-21-400 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Sep;10(9):3579-3590. doi: 10.21037/tau-21-400. PMID- 34729964 OWN - NLM STAT- MEDLINE DCOM- 20220218 LR - 20220218 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 62 IP - 6 DP - 2021 Nov TI - Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer. PG - 641-649 LID - 10.4111/icu.20210278 [doi] AB - PURPOSE: Many studies identified that the preoperative neutrophil-to-lymphocyte ratio (PNLR) was associated with patient prognosis in non-muscle-invasive bladder cancer (NMIBC). We hypothesized that PNLR could be prognostic in patients with histological variants of NMIBC (VH-NMIBC). MATERIALS AND METHODS: This retrospective study included patients with VH-NMIBC admitted at our center between January 2009 and May 2019. The best cut-off value of NLR was measured by the receiver operating characteristic curve and Youden index. The Kaplan-Meier method and Cox proportional hazard regression models were employed to evaluate the association between PNLR and disease prognosis, including recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). RESULTS: A total of 243 patients with VH-NMIBC were enrolled in our study. According to the Kaplan-Meier method results, patients with PNLR >/=2.2 were associated with poor RFS (p<0.001), PFS (p<0.001), CSS (p<0.001), and OS (p<0.001). Multivariable analyses indicated that PNLR >/= 2.2 was an independent prognostic factor of RFS (hazard ratio [HR], 2.11; 95% confidence interval [CI, 1.57-1.83; p<0.001), PFS (HR, 2.34; 95% CI, 1.70-3.21; p<0.001), CCS (HR, 2.87; 95% CI, 1.96-4.18; p< 0.001), and OS (HR, 2.83; 95% CI, 1.96-4.07; p<0.001). CONCLUSIONS: This study identified that PNLR >/=2.2 was usually associated with a poor prognosis for patients with VH-NMIBC. CI - (c) The Korean Urological Association, 2021. FAU - Li, Deng-Xiong AU - Li DX AUID- ORCID: 0000-0002-1943-6758 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Xiao-Ming AU - Wang XM AUID- ORCID: 0000-0002-2288-4201 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Tang, Yin AU - Tang Y AUID- ORCID: 0000-0001-9600-955X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Yang, Yu-Bo AU - Yang YB AUID- ORCID: 0000-0002-0189-3256 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Feng, De-Chao AU - Feng DC AUID- ORCID: 0000-0002-8267-9920 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Ao AU - Li A AUID- ORCID: 0000-0001-7983-7062 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Fa-Cai AU - Zhang FC AUID- ORCID: 0000-0002-2562-4915 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Bai, Yun-Jin AU - Bai YJ AUID- ORCID: 0000-0001-6005-6725 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Ping AU - Han P AUID- ORCID: 0000-0002-9710-0037 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. hanpingwch@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - *Cystectomy/adverse effects/methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - *Lymphocyte Count/methods/statistics & numerical data MH - Lymphocytes/*pathology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neutrophils/*pathology MH - Predictive Value of Tests MH - Preoperative Care/methods MH - Prognosis MH - Proportional Hazards Models MH - *Urinary Bladder Neoplasms/diagnosis/mortality/pathology/surgery PMC - PMC8566785 OTO - NOTNLM OT - Bladder cancer OT - Histology OT - Lymphocyte OT - Neutrophil OT - Prognosis COIS- The authors have nothing to disclose. EDAT- 2021/11/04 06:00 MHDA- 2022/02/19 06:00 PMCR- 2021/11/01 CRDT- 2021/11/03 07:26 PHST- 2021/07/22 00:00 [received] PHST- 2021/08/18 00:00 [revised] PHST- 2021/09/07 00:00 [accepted] PHST- 2021/11/03 07:26 [entrez] PHST- 2021/11/04 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/11/01 00:00 [pmc-release] AID - 62.641 [pii] AID - 10.4111/icu.20210278 [doi] PST - ppublish SO - Investig Clin Urol. 2021 Nov;62(6):641-649. doi: 10.4111/icu.20210278. PMID- 34729225 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 74 IP - 3 DP - 2021 TI - Bladder cancer histological variants: which parameters could predict the concordance between transurethral resection of bladder tumor and radical cystectomy specimens? PG - 355-361 LID - 10.5173/ceju.2021.140.R1 [doi] AB - INTRODUCTION: The concordance rate of bladder cancer (BCa) histological variants (HV) between transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) is sub-optimal and is unclear which factors may influence it. The aim of this study was to identify factors that may be correlated to a higher TURBT-RC concordance rate. MATERIAL AND METHODS: Consecutive patients who had undergone RC between 2000 and 2019 at a single Institution with pathological evidence of HV were included. Patients with diagnosis of HV both at RC and at the previous TURBT were enlisted in the TURBT-RC Concordance Group (CG), whereas patients with only evidence of HV at RC in the TURBT-RC Non-Concordance Group (NCG). Surgical factors evaluated were the source of energy (mono- vs bipolar), surgeon's experience (/=100), execution of re-TURBT, number and size of specimens at TURBT. RESULTS: A total of 81 patients were included, 49 (60.5%) in the CG and 32 (39.5%) in the NCG. Among the surgical factors, maximal core length (MCL) was significantly higher in the CG (12.5 vs 10 mm, p = 0.014) (Table 1). At uni- and multivariable analyses, MCL>10 mm represented an independent predictor of concordance [OR 2.95; CI (1.01-8.61); p = 0.048]. Tumor recurrence, focality and dimension, source of energy, surgeon's experience, performance of re-TURBT and total number of specimens at TURBT did not significantly predict the concordance. CONCLUSIONS: Longer specimens at TURBT yield a higher chance to detect HV before RC. In this light, improving the quality of bladder resection means improving the management of BCa. CI - Copyright by Polish Urological Association. FAU - Mantica, Guglielmo AU - Mantica G AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Tappero, Stefano AU - Tappero S AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Parodi, Stefano AU - Parodi S AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Piol, Nataniele AU - Piol N AD - Department of Pathology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Spina, Bruno AU - Spina B AD - Department of Pathology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Malinaric, Rafaela AU - Malinaric R AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Balzarini, Federica AU - Balzarini F AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Van Der Merwe, Andre AU - Van Der Merwe A AD - Department of Urology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. FAU - Suardi, Nazareno AU - Suardi N AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy. LA - eng PT - Journal Article DEP - 20210909 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC8552936 OTO - NOTNLM OT - bladder cancer OT - histological variants OT - mixed variants OT - radical cystectomy OT - urothelial bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2021/11/04 06:00 MHDA- 2021/11/04 06:01 PMCR- 2021/01/01 CRDT- 2021/11/03 06:57 PHST- 2021/05/12 00:00 [received] PHST- 2021/08/10 00:00 [revised] PHST- 2021/08/11 00:00 [accepted] PHST- 2021/11/03 06:57 [entrez] PHST- 2021/11/04 06:00 [pubmed] PHST- 2021/11/04 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 140.R1 [pii] AID - 10.5173/ceju.2021.140.R1 [doi] PST - ppublish SO - Cent European J Urol. 2021;74(3):355-361. doi: 10.5173/ceju.2021.140.R1. Epub 2021 Sep 9. PMID- 34726625 OWN - NLM STAT- MEDLINE DCOM- 20211104 LR - 20220428 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 74 IP - 9 DP - 2021 Nov TI - The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial. PG - 883-893 AB - OBJECTIVE: Although an immediate postoperative instillation of chemotherapy (IPOIC) after transurethral resection of bladder tumors (TURBT) is recommended for the prevention of recurrences of non-muscleinvasive bladder cancer (NMIBC), evidence shows there is an important compliance failure worldwide. We believe that an immediate neoadjuvant instillation of chemotherapy (INAIC) can act similarly, reducing the recurrence risk of NMIBC. Here we present the interim analysis of the PRECAVE clinical trial. MATERIAL AND METHODS: Patients with clinically diagnosed NMIBC were randomized to receive an INAIC with mitomycin C before TURBT (Group A) or to a control group with TURBT only (Group B). Primary end point was to compare the efficacy of an INAIC in the early recurrence-free survival (RFS). Secondary end points were: RFS in patients who did not receive adjuvant treatments, toxicity, and feasibility. RESULTS: A total of 124 patients with Ta/T1 G1-G3NMIBC were included in the initial analysis (Group A:64, Group B: 60). Demographics, risk classification, complications, and adjuvant treatments were balanced between groups. Eighty-four patients (Group A: 45, Group B: 39) who completed a one-year follow-up were included in the efficacy analysis and no difference was observed in the RFS between groups (p=0.3). In the subgroup of patients who did not receive adjuvant treatments, we found a significant difference in favor of an INAIC (p=0.009) and an 80% reduction in the risk of early recurrences (Hazard Ratio: 0.20; 95% confidence interval: 0.05-0.81; p=0.0024). No differences were observed in adverse events. Only 4 patients did not receive an INAIC despite being planned. CONCLUSIONS: In this interim analysis, although we could not demonstrate a reduction in the RFS of all patients, we did find a significant decrease of recurrences in patients who did not receive adjuvant treatments. The administration of an INAIC seems to be safe and our protocol appears feasible and reproductive. FAU - Carrion, Diego M AU - Carrion DM AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. European Association of Urology - Young Academic Urologists (EAU-YAU). Urothelial Cancer Working Group. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. FAU - Aguilera Bazan, Alfredo AU - Aguilera Bazan A AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. FAU - Ballesteros Ruiz, Cristina AU - Ballesteros Ruiz C AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. FAU - Rios Gonzalez, Emilio AU - Rios Gonzalez E AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Department of Urology. La Paz University Hospital. Madrid. Spain. Autonomous University of Madrid. Madrid. Spain. La Paz University Hospital Institute of Health Research (IdiPAZ). Madrid. Spain. LA - eng LA - spa PT - Journal Article PT - Randomized Controlled Trial TT - El beneficio de una instilacion neoadyuvante de quimioterapia en el carcinoma vesical no musculo invasivo: analisis intermedio del ensayo clinico aleatorizado PRECAVE. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/therapeutic use MH - Cystectomy MH - Humans MH - Mitomycin/therapeutic use MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - Bladder carcinoma OT - Carcinoma urotelial OT - Carcinoma vesical OT - Intravesical chemotherapy OT - Mitomicina C OT - Mitomycin C OT - Neoadjuvant OT - Neoadyuvante OT - Quimioterapia intravesical OT - Recurrence OT - Recurrencia OT - Urotelial carcinoma EDAT- 2021/11/03 06:00 MHDA- 2021/11/05 06:00 CRDT- 2021/11/02 12:19 PHST- 2021/11/02 12:19 [entrez] PHST- 2021/11/03 06:00 [pubmed] PHST- 2021/11/05 06:00 [medline] AID - 2021-74-9-0cc610aa8043a2b2bdc34a6bc36a734d74b103a1 [pii] PST - ppublish SO - Arch Esp Urol. 2021 Nov;74(9):883-893. PMID- 34726624 OWN - NLM STAT- MEDLINE DCOM- 20211104 LR - 20220428 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 74 IP - 9 DP - 2021 Nov TI - Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer. PG - 875-882 AB - OBJECTIVES: To evaluate the oncological results of hyperthermic Mitomycin C (MMC) in adjuvant treatment of high-risk non-muscle invasive bladder cancer and to assess its side-effect profile. METHODS: Patients who were followed up in two reference university hospitals due to high-risk non-muscle invasive bladder tumors were included in the study. High-risk patients according to the EAU non-muscle invasive bladder cancer guideline, patients who were rejected early cystectomy, patients who could not be treated with BCG due to a shortage, and patients for whom the cystectomy would be too risky due to their comorbidities were included in the study. All patients were followed up forat least 24 months with physical examination, cystoscopy, and urine cytology at 3-month intervals. Transurethral tumor resection was performed in all patients and a non-muscle invasive urothelial carcinoma was diagnosed pathologically. Hyperthermic MMC was administered with Synergo system SB-TS 101. Records were kept prospectively and evaluated retrospectively. RESULTS: Fifty-eight high-risk group patients 18 (31%) of whom were at pTa stage and 40 (69%) at pT1 stage were included in the study. During a mean follow-up of 42 months, 34 (58%) patients had recurrence, while 5 (8%) patients progressed to muscle-invasive disease. Eleven (19%) of the patients under went radical cystectomy. The mean time to relapse was 10 months (3-34 months), and the mean time to progression was 41 months (6-87 months). Five-year overall survival, cancer-specific survival, progression-free survival, and relapse-free survival of the patients were 76%, 88%, 90% and 38%, respectively. Multifocality alone was found to be an independent risk factor (HR: 0.26; 95% Cl: 0.08-0.78; p=0.016) affecting recurrence. The observed side effects included tachycardia, cystitis, dysuria, macrohematuria, procedure-related pain, and allergic skin reactions. Treatment had to be discontinued in one patient due to a diffuse skin reaction. CONCLUSIONS: Thermal intravesical MMC therapyis a safe treatment and it could be effective treatment option in preventing disease progression in patients with high risk and non-muscle invasive bladder cancer with unsuccessful Bacillus Calmette-Guerin (BCG) or who could not be treated with BCG for other reasons. FAU - Efiloglu, Ozgur AU - Efiloglu O AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. FAU - Bayrak, Omer AU - Bayrak O AD - Department of Urology. Gaziantep University. School of Medicine. Gaziantep. Turkey. FAU - Turan, Turgay AU - Turan T AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. FAU - Kazan, Huseyin Ozgur AU - Kazan HO AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. FAU - Culpan, Meftun AU - Culpan M AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. FAU - Cakici, Mehmet Caglar AU - Cakici MC AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. FAU - Erturhan, Sakip AU - Erturhan S AD - Department of Urology. Gaziantep University. School of Medicine. Gaziantep. Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology. Istanbul Medeniyet University Faculty of Medicine. Istanbul. Turkey. LA - eng LA - spa PT - Journal Article TT - Quimioterapia intravesical termica como tratamiento adyuvante en pacientes de cancer de vejiga alto riesgo no-musculoinvasivos. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/adverse effects MH - *Carcinoma, Transitional Cell/drug therapy MH - Chemotherapy, Adjuvant MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - BCG OT - Cancer de vejiga invasivo en el musculo OT - Hipertermia OT - Hyperthermia OT - Intravesical chemotherapy OT - Mitomicina C OT - Mitomycin-C OT - Non-muscle invasive bladder cancer OT - Quimioterapia intravesical OT - Radiofrecuencia OT - Radiofrequency EDAT- 2021/11/03 06:00 MHDA- 2021/11/05 06:00 CRDT- 2021/11/02 12:19 PHST- 2021/11/02 12:19 [entrez] PHST- 2021/11/03 06:00 [pubmed] PHST- 2021/11/05 06:00 [medline] AID - 2021-74-9-c282ded6a9097565e7e07fd38cf88888ac60ce70 [pii] PST - ppublish SO - Arch Esp Urol. 2021 Nov;74(9):875-882. PMID- 34726325 OWN - NLM STAT- MEDLINE DCOM- 20220531 LR - 20220606 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 129 IP - 6 DP - 2022 Jun TI - Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study. PG - 744-751 LID - 10.1111/bju.15627 [doi] AB - OBJECTIVES: To evaluate the long-term oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU) and the impact of diagnostic ureteroscopy (URS) on survival outcomes. MATERIALS AND METHODS: A retrospective analysis of all consecutive patients undergoing RNU for suspected UTUC at a UK tertiary referral centre from a prospectively maintained database was conducted. The primary outcome measures were 5- and 10-year cancer-specific survival (CSS). The secondary outcomes were: overall survival (OS), recurrence-free survival (RFS), impact of prior diagnostic URS on OS, CSS and intravesical RFS (intravesical-RFS), and predictors of intravesical recurrence. Statistical analysis was performed in R using the 'survminer' and 'survival' packages. The Kaplan-Meier method was used to calculate survival functions and these were expressed in graphical form. Uni-/multivariate survival analyses were performed using the Cox proportional hazard regression model. Statistical significance in this study was set at P < 0.05. RESULTS: A total of 422 patients underwent RNU with confirmed UTUC. The median (interquartile range) follow-up of patients with confirmed UTUC was 9.2 (5.6-12.7) years. The 5- and 10-year CSS rates were 70.5% (95% confidence interval [CI] 65.9-74.9) and 67.1% (95% CI 62.4-71.6), respectively. OS (HR 1.04 [95% CI 0.78-1.38]; P = 0.46) and CSS (HR 0.96 [95% CI 0.68-1.34]; P = 0.81) were similar in the diagnostic URS and the direct RNU cohorts. intravesical RFS was superior for the direct RNU cohort (HR 1.94 [95% CI 1.19-3.17]; P = 0.008). In multivariate analysis, prior URS, T2 stage, proximal ureter tumour and bladder cancer history were predictors of metachronous bladder recurrence. CONCLUSION: This single-centre retrospective cohort study reports the long-term oncological outcomes of RNU with a median follow-up of 9.2 years, serving as a reference standard in counselling patients undergoing RNU. Stage and grade of the RNU specimen were the only two studied factors that appeared to adversely impact long-term CSS and OS. Our results suggest that the risk of intravesical recurrence is increased nearly twofold in patients who have undergone diagnostic URS prior to RNU. Prior URS, however, does not appear to adversely impact long-term CSS and OS. The authors suggest that a risk-stratified approach be adopted, wherein diagnostic URS is offered only in equivocal cases. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Veeratterapillay, Rajan AU - Veeratterapillay R AD - Freeman Hospital, Newcastle, UK. FAU - Geraghty, Robert AU - Geraghty R AUID- ORCID: 0000-0002-9128-5173 AD - Freeman Hospital, Newcastle, UK. FAU - Pandian, Rajadoss AU - Pandian R AD - Freeman Hospital, Newcastle, UK. FAU - Roy, Chloe AU - Roy C AD - Freeman Hospital, Newcastle, UK. FAU - Stenhouse, Georgie AU - Stenhouse G AD - Freeman Hospital, Newcastle, UK. FAU - Bird, Clare AU - Bird C AD - Freeman Hospital, Newcastle, UK. FAU - Soomro, Naeem AU - Soomro N AD - Freeman Hospital, Newcastle, UK. FAU - Paez, Edgar AU - Paez E AD - Freeman Hospital, Newcastle, UK. FAU - Rogers, Alistair AU - Rogers A AD - Freeman Hospital, Newcastle, UK. FAU - Johnson, Mark AU - Johnson M AD - Freeman Hospital, Newcastle, UK. FAU - Page, Toby AU - Page T AD - Freeman Hospital, Newcastle, UK. FAU - Rix, David AU - Rix D AD - Freeman Hospital, Newcastle, UK. FAU - Thomas, David AU - Thomas D AD - Freeman Hospital, Newcastle, UK. FAU - Rai, Bhavan Prasad AU - Rai BP AUID- ORCID: 0000-0002-6323-7246 AD - Freeman Hospital, Newcastle, UK. LA - eng PT - Journal Article PT - Observational Study DEP - 20211124 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - BJU Int. 2022 Jun;129(6):655-656. doi: 10.1111/bju.15745. PMID: 35633134 MH - *Carcinoma, Transitional Cell/diagnosis/pathology/surgery MH - Humans MH - Neoplasm Recurrence, Local MH - Nephroureterectomy MH - Retrospective Studies MH - *Ureteral Neoplasms/diagnosis/pathology/surgery MH - Ureteroscopy/adverse effects MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - bladder recurrence OT - nephroureterectomy OT - transitional cell carcinoma OT - upper tract OT - ureteroscopy OT - urothelial carcinoma EDAT- 2021/11/03 06:00 MHDA- 2022/06/01 06:00 CRDT- 2021/11/02 09:21 PHST- 2021/11/03 06:00 [pubmed] PHST- 2022/06/01 06:00 [medline] PHST- 2021/11/02 09:21 [entrez] AID - 10.1111/bju.15627 [doi] PST - ppublish SO - BJU Int. 2022 Jun;129(6):744-751. doi: 10.1111/bju.15627. Epub 2021 Nov 24. PMID- 34716417 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20230210 IS - 1530-0285 (Electronic) IS - 0893-3952 (Print) IS - 0893-3952 (Linking) VI - 35 IP - 4 DP - 2022 Apr TI - Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features. PG - 533-538 LID - 10.1038/s41379-021-00955-y [doi] AB - Non-muscle invasive bladder cancer (NMIBC) generally has a good prognosis; however, recurrence after transurethral resection (TUR), the standard primary treatment, is a major problem. Clinical management after TUR has been based on risk classification using clinicopathological factors, but these classifications are not complete. In this study, we attempted to predict early recurrence of NMIBC based on machine learning of quantitative morphological features. In general, structural, cellular, and nuclear atypia are evaluated to determine cancer atypia. However, since it is difficult to accurately quantify structural atypia from TUR specimens, in this study, we used only nuclear atypia and analyzed it using feature extraction followed by classification using Support Vector Machine and Random Forest machine learning algorithms. For the analysis, 125 patients diagnosed with NMIBC were used; data from 95 patients were randomly selected for the training set, and data from 30 patients were randomly selected for the test set. The results showed that the support vector machine-based model predicted recurrence within 2 years after TUR with a probability of 90% and the random forest-based model with probability of 86.7%. In the future, the system can be used to objectively predict NMIBC recurrence after TUR. CI - (c) 2021. The Author(s). FAU - Tokuyama, Naoto AU - Tokuyama N AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Saito, Akira AU - Saito A AD - Department of AI Applied Quantitative Clinical Science, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. AD - Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. FAU - Muraoka, Ryu AU - Muraoka R AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Matsubara, Shuya AU - Matsubara S AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Hashimoto, Takeshi AU - Hashimoto T AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Satake, Naoya AU - Satake N AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Matsubayashi, Jun AU - Matsubayashi J AD - Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Nagao, Toshitaka AU - Nagao T AD - Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. FAU - Mirza, Aashiq H AU - Mirza AH AD - Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. AD - Department of Pharmacology, Weill Cornell Medicine, New York, NY, 10065, USA. FAU - Graf, Hans-Peter AU - Graf HP AD - Department of Machine Learning, NEC Labs America Inc., Princeton, NJ, 08540, USA. FAU - Cosatto, Eric AU - Cosatto E AD - Department of Machine Learning, NEC Labs America Inc., Princeton, NJ, 08540, USA. FAU - Wu, Chin-Lee AU - Wu CL AD - Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA. FAU - Kuroda, Masahiko AU - Kuroda M AUID- ORCID: 0000-0001-7052-4289 AD - Department of AI Applied Quantitative Clinical Science, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. kuroda@tokyo-med.ac.jp. AD - Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. kuroda@tokyo-med.ac.jp. FAU - Ohno, Yoshio AU - Ohno Y AD - Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-0023, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211029 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 SB - IM MH - Humans MH - Machine Learning MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/pathology/surgery PMC - PMC8964412 COIS- The authors declare no competing interests. EDAT- 2021/10/31 06:00 MHDA- 2022/04/12 06:00 PMCR- 2021/10/29 CRDT- 2021/10/30 06:02 PHST- 2021/06/30 00:00 [received] PHST- 2021/10/12 00:00 [accepted] PHST- 2021/10/09 00:00 [revised] PHST- 2021/10/31 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2021/10/30 06:02 [entrez] PHST- 2021/10/29 00:00 [pmc-release] AID - S0893-3952(22)00298-8 [pii] AID - 955 [pii] AID - 10.1038/s41379-021-00955-y [doi] PST - ppublish SO - Mod Pathol. 2022 Apr;35(4):533-538. doi: 10.1038/s41379-021-00955-y. Epub 2021 Oct 29. PMID- 34715822 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20220207 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Oct 29 TI - Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial. PG - 1161 LID - 10.1186/s12885-021-08840-2 [doi] LID - 1161 AB - BACKGROUND: The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20-40% of patients experience a complete pathological response (pCR) in the RC specimen and these patients have excellent long-term overall survival. Subject to debate is, however, whether patients with a pCR to NAC benefit from RC, which is a major surgical procedure with substantial morbidity, and if these patients might be candidates for close surveillance instead. However, currently it is not possible to accurately identify patients with a pCR to NAC in whom RC might be withheld. The objective of this study is to assess whether pathological response in the RC specimen after NAC can be predicted based on clinical, radiological, and histological variables and on a wide set of molecular biomarkers assessed in tissue, blood and urine. METHODS: This is a multicentre, prospective cohort study, including patients with cT2a-T4a N0-N1 M0 urothelial cell MIBC who are scheduled to undergo cisplatin-based NAC followed by RC. Prior to start of therapy, a 2-Deoxy-2-[18F] fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) is performed. Response to NAC is evaluated by CT-scan. Blood and urine, including cytology, are prospectively collected for biomarker analyses before and after NAC. Immediately before RC, participants undergo cystoscopy with bimanual examination and a re-staging transurethral resection (TUR) of all visible cancerous lesions or with biopsies from scar tissue. Subsequently, RC is performed in all patients. Tissue from the diagnostic TUR, the re-staging TUR, and the RC specimen is examined for the presence of urothelial cancer carcinoma and DNA and RNA is isolated for molecular analysis. The primary endpoint is the pathological stage (ypTN) in the RC and ePLND specimen and its association with clinical response. DISCUSSION: If the PRE-PREVENCYS trial shows that the absence of residual disease after NAC in patients with MIBC is accurately predicted, a randomized controlled trial is scheduled comparing the overall survival of NAC plus RC versus NAC followed by close surveillance for patients with a clinically complete response (PREVENCYS trial). TRIAL REGISTRATION: Netherlands Trial Register: NL8678; Registered 20 May 2020 https://www.trialregister.nl/trial/8678. CI - (c) 2021. The Author(s). FAU - Hinsenveld, F J AU - Hinsenveld FJ AUID- ORCID: 0000-0002-8023-6640 AD - Department of Urology, Amsterdam University Medical Centers, VU University, Postbus 7057, 1007, MB, Amsterdam, internal post address 4F-28, The Netherlands. f.hinsenveld@amsterdamumc.nl. FAU - Noordman, B J AU - Noordman BJ AD - Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Boormans, J L AU - Boormans JL AD - Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Voortman, J AU - Voortman J AD - Department of Medical Oncology, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands. FAU - van Leenders, G J L H AU - van Leenders GJLH AD - Department of pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - van der Pas, S L AU - van der Pas SL AD - Department of Epidemiology and Biostatistics, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands. FAU - van Beek, S C AU - van Beek SC AD - Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Oprea-Lager, D E AU - Oprea-Lager DE AD - Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands. FAU - Vis, A N AU - Vis AN AD - Department of Urology, Amsterdam University Medical Centers, VU University, Postbus 7057, 1007, MB, Amsterdam, internal post address 4F-28, The Netherlands. LA - eng GR - 12432/KWF Kankerbestrijding/ PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20211029 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Algorithms MH - Carcinoma, Transitional Cell/diagnostic imaging/drug therapy/pathology/surgery MH - Chemotherapy, Adjuvant/methods MH - Cisplatin/administration & dosage MH - Combined Modality Therapy MH - *Cystectomy MH - Fluorodeoxyglucose F18 MH - Humans MH - Neoadjuvant Therapy/*methods MH - Neoplasm Invasiveness MH - Neoplasm, Residual MH - *Organ Sparing Treatments MH - Positron Emission Tomography Computed Tomography MH - Prospective Studies MH - Radiopharmaceuticals MH - Tomography, X-Ray Computed MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnostic imaging/*drug therapy/pathology/*surgery PMC - PMC8556888 OTO - NOTNLM OT - Bladder cancer OT - Bladder-sparing OT - Cancer biomarkers OT - Cystectomy OT - Neoadjuvant chemotherapy OT - Residual tumour COIS- BJN is Associate Editor of BMC Cancer. All other authors declare that they have no competing interests. EDAT- 2021/10/31 06:00 MHDA- 2022/02/08 06:00 PMCR- 2021/10/29 CRDT- 2021/10/30 05:22 PHST- 2021/06/08 00:00 [received] PHST- 2021/10/05 00:00 [accepted] PHST- 2021/10/30 05:22 [entrez] PHST- 2021/10/31 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2021/10/29 00:00 [pmc-release] AID - 10.1186/s12885-021-08840-2 [pii] AID - 8840 [pii] AID - 10.1186/s12885-021-08840-2 [doi] PST - epublish SO - BMC Cancer. 2021 Oct 29;21(1):1161. doi: 10.1186/s12885-021-08840-2. PMID- 34711530 OWN - NLM STAT- MEDLINE DCOM- 20221010 LR - 20221130 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 4 DP - 2022 Jul TI - Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States. PG - 968-971 LID - S2405-4569(21)00271-6 [pii] LID - 10.1016/j.euf.2021.09.025 [doi] AB - Blue light cystoscopy (BLC) during transurethral resection of bladder tumor (TURBT) is guideline-recommended as it improves cancer detection and decreases recurrence of the disease. However, the extent to which BLC is used has not been established. We studied BLC use in the Premier Healthcare Database, a large, national sample that captured 158 870 index TURBT procedures between January 2011 and March 2020. Billing data were queried for the administration of hexaminolevulinate at TURBT as a proxy for BLC, and logistic regression models were constructed to identify variables associated with BLC use. BLC was used in 1.2% of index TURBT procedures over the study period. Its use increased following the American Urological Association non-muscle-invasive bladder cancer guideline publication in October 2016 but plateaued in late 2018. After adjusting for patient characteristics, higher odds for BLC use were found for academic hospitals and hospitals with higher TURBT volumes and higher radical cystectomy volumes. Within hospitals with BLC capability, predictors of a surgeon never using BLC included low surgeon TURBT volumes, low surgeon radical cystectomy volumes, and lack of mitomycin C use. Our findings highlight a concerning underutilization and stagnation in the adoption of evidence and guideline-supported intervention. PATIENT SUMMARY: Use of blue light visualization of the bladder improves the detection of cancer during removal of bladder tumors via the urethra. We reviewed records in a large US database for use of this technique and found that it is being underutilized. Since this technique improves detection of cancer in the bladder so that it can be removed to reduce recurrence, blue light visualization should be more widely used. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Lewicki, Patrick AU - Lewicki P AD - Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA. FAU - Arenas-Gallo, Camilo AU - Arenas-Gallo C AD - Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. FAU - Qiu, Yuqing AU - Qiu Y AD - Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA. FAU - Venkat, Siv AU - Venkat S AD - Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA. FAU - Basourakos, Spyridon P AU - Basourakos SP AD - Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA. FAU - Scherr, Douglas AU - Scherr D AD - Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA. FAU - Shoag, Jonathan E AU - Shoag JE AD - Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA; Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address: jxs218@case.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211026 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 50SG953SK6 (Mitomycin) SB - IM MH - Cystectomy/methods MH - *Cystoscopy/methods MH - Humans MH - Mitomycin MH - United States MH - Urethra/pathology MH - *Urinary Bladder Neoplasms/diagnosis/pathology/surgery OTO - NOTNLM OT - Blue light cystoscopy OT - Cysview OT - Hexaminolevulinate OT - Non-muscle-invasive bladder cancer OT - Photodynamic diagnosis OT - Premier Healthcare Database OT - Transurethral resection of bladder tumor OT - Utilization EDAT- 2021/10/30 06:00 MHDA- 2022/10/12 06:00 CRDT- 2021/10/29 05:46 PHST- 2021/07/23 00:00 [received] PHST- 2021/09/21 00:00 [revised] PHST- 2021/09/30 00:00 [accepted] PHST- 2021/10/30 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2021/10/29 05:46 [entrez] AID - S2405-4569(21)00271-6 [pii] AID - 10.1016/j.euf.2021.09.025 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Jul;8(4):968-971. doi: 10.1016/j.euf.2021.09.025. Epub 2021 Oct 26. PMID- 34703308 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 13 DP - 2021 TI - MiR-10a-5p: A Promising Biomarker for Early Diagnosis and Prognosis Evaluation of Bladder Cancer. PG - 7841-7850 LID - 10.2147/CMAR.S326732 [doi] AB - INTRODUCTION: MiRNAs play a critical role in carcinogenesis, among which miR-10a-5p has been reported in several types of human cancer. Nevertheless, the role of miR-10a-5p remain uncovered in bladder cancer (BCa). METHODS: We recruited 88 BCa patients and 36 healthy controls (HC) to form the training cohort, and other 120 BCa patients to form the validation cohort. The clinical samples were collected for analysis. The expression level of miR-10a-5p was evaluated using RT-qPCR. Receiver operating characteristic (ROC) curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. CCK-8 and transwell assays were conducted to test the cell proliferation, migration, and invasion capacities. RESULTS: MiR-10a-5p was upregulated in human BCa tissues and closely associated with advanced clinicopathological features, including advanced tumor grade, histological grade, and T stage. High expression of miR-10a-5p was associated with worse survival outcomes in BCa patients. Circulating plasma miR-10a-5p expression had the great performance power to discriminate BCa patients form HC patients before surgery, and to differentiate muscle invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC). In addition, overexpression of miR-10a-5p could promote BCa cell proliferation, migration, and invasion. CONCLUSION: This study indicates that miR-10a-5p is a crucial diagnostic and prognostic biomarker for BCa patients, and miR-10a-5p exerted a tumor promoting role during BCa cell progression. CI - (c) 2021 Yang et al. FAU - Yang, Lei AU - Yang L AD - Department of Urology, Wuxi No.2 Chinese Medicine Hospital, Wuxi City, Jiangsu Province, 214121, People's Republic of China. FAU - Sun, Hong-Fang AU - Sun HF AD - Department of Urology, Wuxi No.2 Chinese Medicine Hospital, Wuxi City, Jiangsu Province, 214121, People's Republic of China. FAU - Guo, Lin-Qing AU - Guo LQ AD - Department of Urology, Wuxi No.2 Chinese Medicine Hospital, Wuxi City, Jiangsu Province, 214121, People's Republic of China. FAU - Cao, Hai-Bing AU - Cao HB AD - Department of Urology, Wuxi No.2 Chinese Medicine Hospital, Wuxi City, Jiangsu Province, 214121, People's Republic of China. LA - eng PT - Journal Article DEP - 20211014 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC8523317 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - diagnostic OT - miR-10a-5p OT - prognosis COIS- The authors report no conflicts of interest in this work. EDAT- 2021/10/28 06:00 MHDA- 2021/10/28 06:01 PMCR- 2021/10/14 CRDT- 2021/10/27 07:04 PHST- 2021/06/26 00:00 [received] PHST- 2021/08/02 00:00 [accepted] PHST- 2021/10/27 07:04 [entrez] PHST- 2021/10/28 06:00 [pubmed] PHST- 2021/10/28 06:01 [medline] PHST- 2021/10/14 00:00 [pmc-release] AID - 326732 [pii] AID - 10.2147/CMAR.S326732 [doi] PST - epublish SO - Cancer Manag Res. 2021 Oct 14;13:7841-7850. doi: 10.2147/CMAR.S326732. eCollection 2021. PMID- 34703177 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20230921 IS - 2413-7170 (Electronic) IS - 1029-1857 (Print) IS - 1029-1857 (Linking) VI - 31 IP - 4 DP - 2021 Jul TI - A Retrospective Analysis of Clinical and Pathologic Characteristics of Recurrent Bladder Tumor in a Tertiary Hospital in Addis Ababa, Ethiopia. PG - 779-784 LID - 10.4314/ejhs.v31i4.12 [doi] AB - BACKGROUND: Previous recurrences, tumor category (Ta, T1), the presence of CIS with superficial bladder tumors, the number of tumors, tumor size and multiplicity are predictors of bladder tumor recurrence. Recurrence is better predicted by multiplicity, size and previous recurrence. METHODS: This is retrospective descriptive study. All patients with urinary bladder tumor admitted to TASH from January 1st, 2018 to December 31st, 2019 is the study population. Information was retrieved using structured questionnaire. RESULTS: Most of the recurrent tumors 55 (76.4%) had huge size and were multiple 62 (86.1%) in the primary presentation. Most recurrent tumors 47 (65.3%) are low grade bladder tumors. About 17 (23.6%) were high grade tumor in their primary presentation. European studies showed size and multiplicity increase risk of recurrence. However, our patients have late presentations which probably made the proportion of recurrence higher. CONCLUSION: Most of the recurrent bladder tumors have huge size and multiple in number at their initial presentation. All histological variants of Urothelial carcinomas recur. CI - (c) 2021 Andualem Beyene. FAU - Beyene, Andualem AU - Beyene A AD - Dept. Surgery, School of Medicine, College of Health Sciences, Addis Ababa University. LA - eng PT - Journal Article PL - Ethiopia TA - Ethiop J Health Sci JT - Ethiopian journal of health sciences JID - 101224773 SB - IM MH - Ethiopia/epidemiology MH - Humans MH - Neoplasm Recurrence, Local/epidemiology MH - Retrospective Studies MH - Tertiary Care Centers MH - *Urinary Bladder Neoplasms/epidemiology PMC - PMC8512944 OTO - NOTNLM OT - Bladder Tumor OT - Clinical Character OT - Pathologic character OT - Recurrence EDAT- 2021/10/28 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/07/01 CRDT- 2021/10/27 07:03 PHST- 2020/12/08 00:00 [received] PHST- 2021/02/04 00:00 [accepted] PHST- 2021/10/27 07:03 [entrez] PHST- 2021/10/28 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - jEJHS.v31.i4.pg779 [pii] AID - 10.4314/ejhs.v31i4.12 [doi] PST - ppublish SO - Ethiop J Health Sci. 2021 Jul;31(4):779-784. doi: 10.4314/ejhs.v31i4.12. PMID- 34697907 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20220316 IS - 2056-4538 (Electronic) IS - 2056-4538 (Linking) VI - 8 IP - 2 DP - 2022 Mar TI - Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer. PG - 143-154 LID - 10.1002/cjp2.245 [doi] AB - Intrinsic molecular subtypes may explain marked variation between bladder cancer patients in prognosis and response to therapy. Complex testing algorithms and little attention to more prevalent, early-stage (non-muscle invasive) bladder cancers (NMIBCs) have hindered implementation of subtyping in clinical practice. Here, using a three-antibody immunohistochemistry (IHC) algorithm, we identify the diagnostic and prognostic associations of well-validated proteomic features of basal and luminal subtypes in NMIBC. By IHC, we divided 481 NMIBCs into basal (GATA3(-) /KRT5(+) ) and luminal (GATA3(+) /KRT5 variable) subtypes. We further divided the luminal subtype into URO (p16 low), URO-KRT5(+) (KRT5(+) ), and genomically unstable (GU) (p16 high) subtypes. Expression thresholds were confirmed using unsupervised hierarchical clustering. Subtypes were correlated with pathology and outcomes. All NMIBC cases clustered into the basal/squamous (basal) or one of the three luminal (URO, URO-KRT5(+) , and GU) subtypes. Although uncommon in this NMIBC cohort, basal tumors (3%, n = 16) had dramatically higher grade (100%, n = 16, odds ratio [OR] = 13, relative risk = 3.25) and stage, and rapid progression to muscle invasion (median progression-free survival = 35.4 months, p = 0.0001). URO, the most common subtype (46%, n = 220), showed rapid recurrence (median recurrence-free survival [RFS] = 11.5 months, p = 0.039) compared to its GU counterpart (29%, n = 137, median RFS = 16.9 months), even in patients who received intravesical immunotherapy (p = 0.049). URO-KRT5(+) tumors (22%, n = 108) were typically low grade (66%, n = 71, OR = 3.7) and recurred slowly (median RFS = 38.7 months). Therefore, a simple immunohistochemical algorithm can identify clinically relevant molecular subtypes of NMIBC. In routine clinical practice, this three-antibody algorithm may help clarify diagnostic dilemmas and optimize surveillance and treatment strategies for patients. CI - (c) 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons, Ltd. FAU - Jackson, Chelsea L AU - Jackson CL AUID- ORCID: 0000-0002-6784-5978 AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. AD - Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Chen, Lina AU - Chen L AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. FAU - Hardy, Celine Sc AU - Hardy CS AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. AD - Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Ren, Kevin Ym AU - Ren KY AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. FAU - Visram, Kash AU - Visram K AD - Department of Urology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Bratti, Vanessa F AU - Bratti VF AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. AD - Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Johnstone, Jeannette AU - Johnstone J AD - Department of Urology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Sjodahl, Gottfrid AU - Sjodahl G AUID- ORCID: 0000-0002-7869-0473 AD - Division of Urologic Research, Department of Translational Medicine, Lund University, Lund, Sweden. FAU - Siemens, David Robert AU - Siemens DR AD - Department of Urology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Gooding, Robert J AU - Gooding RJ AD - Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. FAU - Berman, David M AU - Berman DM AUID- ORCID: 0000-0001-5985-3698 AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. AD - Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211026 PL - England TA - J Pathol Clin Res JT - The journal of pathology. Clinical research JID - 101658534 RN - 0 (Biomarkers, Tumor) SB - IM MH - Algorithms MH - Biomarkers, Tumor/metabolism MH - Humans MH - Prognosis MH - Proteomics MH - *Urinary Bladder Neoplasms/diagnosis/pathology PMC - PMC8822375 OTO - NOTNLM OT - GATA3 OT - KRT5 OT - bladder cancer OT - immunohistochemistry OT - p16 EDAT- 2021/10/27 06:00 MHDA- 2022/03/17 06:00 PMCR- 2021/10/26 CRDT- 2021/10/26 06:44 PHST- 2021/08/25 00:00 [revised] PHST- 2021/05/13 00:00 [received] PHST- 2021/09/21 00:00 [accepted] PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/10/26 06:44 [entrez] PHST- 2021/10/26 00:00 [pmc-release] AID - CJP2245 [pii] AID - 10.1002/cjp2.245 [doi] PST - ppublish SO - J Pathol Clin Res. 2022 Mar;8(2):143-154. doi: 10.1002/cjp2.245. Epub 2021 Oct 26. PMID- 34694143 OWN - NLM STAT- MEDLINE DCOM- 20220228 LR - 20220228 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 207 IP - 3 DP - 2022 Mar TI - Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. PG - 551-558 LID - 10.1097/JU.0000000000002266 [doi] AB - PURPOSE: While lymph node dissection (LND) at radical cystectomy (RC) for muscle-invasive bladder cancer has been studied extensively, the role of LND for nonmuscle-invasive bladder cancer (NMIBC) remains incompletely defined. Herein, we aim to assess the association between extent of LND during RC for NMIBC and local pelvic recurrence-free survival (LPRS), cancer-specific survival (CSS) and overall survival (OS). MATERIALS AND METHODS: A multi-institutional retrospective review was performed of patients with NMIBC undergoing RC at 3 large tertiary referral centers. To identify a threshold for lymph node yield (LNY) to optimize LPRS, CSS and OS, separate Cox regression models were developed for each possible LNY threshold. Model performance including Q-statistics and hazard ratios (HRs) were used to identify optimal LNY thresholds. RESULTS: A total of 1,647 patients underwent RC for NMIBC, with a median LNY of 15 (quartiles 9,23). Model performance curves suggested LNY of 10 and 20 to optimize LPRS and CSS/OS, respectively. On multivariable regression, LNY >10 was associated with lower risk of LPR compared to LNY 20 was associated with improved CSS (HR 0.67, 95% CI 0.52-0.87, p=0.002) and OS (HR 0.75, 95% CI 0.64-0.88, p <0.001) compared to LNY /=36 months, there was no significant factor affecting IVR. CONCLUSIONS: Active IVR assessment is required until 36 months after RNUx. In addition, patient education and regular screening tests, such as urine analysis and cytology, are required for patients with IVRF for >/=36 months. CI - Copyright (c) 2021 Chung, Song, Kang, Jeon, Jeong, Seo, Jeon, Lee and Sung. FAU - Chung, Jae Hoon AU - Chung JH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Song, Wan AU - Song W AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Lee, Hyun Moo AU - Lee HM AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. LA - eng PT - Journal Article DEP - 20211007 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8529179 OTO - NOTNLM OT - bladder OT - nephroureterectomy OT - recurrence OT - risk OT - urothelium cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/26 06:00 MHDA- 2021/10/26 06:01 PMCR- 2021/01/01 CRDT- 2021/10/25 06:38 PHST- 2021/06/24 00:00 [received] PHST- 2021/09/16 00:00 [accepted] PHST- 2021/10/25 06:38 [entrez] PHST- 2021/10/26 06:00 [pubmed] PHST- 2021/10/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.730114 [doi] PST - epublish SO - Front Oncol. 2021 Oct 7;11:730114. doi: 10.3389/fonc.2021.730114. eCollection 2021. PMID- 34692255 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 2167-8359 (Print) IS - 2167-8359 (Electronic) IS - 2167-8359 (Linking) VI - 9 DP - 2021 TI - Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. PG - e12248 LID - 10.7717/peerj.12248 [doi] LID - e12248 AB - BACKGROUND: To summarize the current evidence on the effects of intra-arterial chemotherapy (IAC) on high-risk non-muscle invasive bladder cancer (NMIBC) and compare oncology results with intravesical chemotherapy (IVC). METHODS: We performed a systematic review and cumulative meta-analysis of the primary outcomes of interest by a systematical search of multiple scientific databases in February 2021. The mean difference (MD) and odds ratio (OR) were calculated for continuous and dichotomous variables respectively, with 95% confidence intervals (CIs). The hazard radio (HR) with 95% CIs was used for overall survival (OS), recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: A total of six studies with 866 patients were included. For IAC combined with IVC versus IVC alone, statistically significant differences were found regarding tumor recurrence rate (OR: 0.51, 95% CI [0.36 approximately 0.72], p = 0.0001), tumor progression rate (OR: 0.47, 95% CI [0.30 approximately 0.72], p = 0.0006), tumor-specific death rate (OR: 0.49, 95% CI [0.25 approximately 0.99], p = 0.05), PFS (HR: 0.47, 95% CI [0.23 approximately 0.96], p = 0.04) and RFS (HR: 0.60, 95% CI [0.41 approximately 0.87], p = 0.007). No significant difference between two groups was found for time to first recurrence (MD: 3.27, 95% CI [-2.37 approximately 8.92], p = 0.26) and OS (HR: 1.20, 95% CI [0.44 approximately 3.32], p = 0.72). For IAC alone versus IVC, There was no statistical difference in the terms of tumor-specific death rate (OR: 0.67, 95% CI [0.29 approximately 1.53], p = 0.34), RFS (HR: 0.90, 95% CI [0.56 approximately 1.46], p = 0.68) and PFS (HR: 0.71, 95% CI [0.32 approximately 1.55], p = 0.39). Adverse events mainly included nausea/vomiting (36.3%), hypoleukemia (19.4%), neutropenia (16.0%), increased creatinine (9.9%), increased alanine aminotransferase (18.7%), and thrombocytopenia (9.9%). CONCLUSION: The IAC combined with IVC is a safe and effective treatment for high risk NMIBC, with lower rates of recurrence, progression, tumor-specific death, PFS and RFS, and with minor and tolerable events. The effectiveness of the IAC alone is parallel to the IVC alone. CI - (c)2021 You et al. FAU - You, Chengyu AU - You C AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Li, Xianhui AU - Li X AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Du, Yuelin AU - Du Y AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Wang, Hui AU - Wang H AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Zhang, Xiaojun AU - Zhang X AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Wei, Tangqiang AU - Wei T AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. FAU - Wang, Anguo AU - Wang A AD - Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China. LA - eng PT - Journal Article DEP - 20210928 PL - United States TA - PeerJ JT - PeerJ JID - 101603425 PMC - PMC8485834 OTO - NOTNLM OT - Bladder cancer OT - Intra-arterial chemotherapy OT - Intravesical chemotherapy OT - Recurrence OT - Survival COIS- The authors declare there are no competing interests. EDAT- 2021/10/26 06:00 MHDA- 2021/10/26 06:01 PMCR- 2021/09/28 CRDT- 2021/10/25 06:35 PHST- 2021/05/20 00:00 [received] PHST- 2021/09/13 00:00 [accepted] PHST- 2021/10/25 06:35 [entrez] PHST- 2021/10/26 06:00 [pubmed] PHST- 2021/10/26 06:01 [medline] PHST- 2021/09/28 00:00 [pmc-release] AID - 12248 [pii] AID - 10.7717/peerj.12248 [doi] PST - epublish SO - PeerJ. 2021 Sep 28;9:e12248. doi: 10.7717/peerj.12248. eCollection 2021. PMID- 34683099 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211026 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 11 IP - 10 DP - 2021 Sep 26 TI - Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma. LID - 10.3390/jpm11100958 [doi] LID - 958 AB - PURPOSE: The survival effect of smoking-related chronic obstructive pulmonary disease (COPD) and COPD with acute exacerbation (COPDAE) on patients with muscle-invasive bladder urothelial carcinoma (MIBUC) receiving concurrent chemoradiotherapy (CCRT) for bladder preservation is unclear. METHODS: We recruited patients with MIBUC, clinical stages IIA-IVB, who had received maximal transurethral resection of bladder tumor (TURBT) followed by CCRT from the Taiwan Cancer Registry Database. The Cox proportional hazards model was used to analyze all-cause mortality. We categorized the patients into two groups by using propensity score matching based on the preexisting COPD status (within 1 year before CCRT) to compare overall survival outcomes: Group 1 (never smokers without COPD) and Group 2 (current smokers with COPD). RESULTS: In multivariate Cox regression analyses, the adjusted hazard ratio (aHR; 95% confidence interval (CI)) of all-cause mortality in Group 2 compared with Group 1 was 1.89 (1.12-3.18), p = 0.017. The aHRs (95% CIs) of all-cause mortality for >/=1 and >/=2 hospitalizations for COPDAE within 1 year before CCRT for bladder preservation were 3.26 (1.95-5.46) and 6.33 (3.55-11.281) compared with non-COPDAE patients with MIBUC undergoing CCRT for bladder preservation. CONCLUSIONS: Among patients with MIBUC undergoing TURBT followed by CCRT for bladder preservation, current smokers with smoking-related COPD had worse survival outcomes than did nonsmokers without COPD. CONDENSED ABSTRACT: This was the first study to estimate the survival impact of smoking-related chronic obstructive pulmonary disease (COPD) on patients with muscle-invasive bladder urothelial carcinoma (MIBUC) receiving maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy (CCRT) for bladder preservation. Smoking-related COPD was a significant independent risk factor for all-cause mortality in patients with clinical stages IIA-IVB receiving TURBT followed by CCRT. Hospitalization frequency for COPD with at least one acute exacerbation within 1 year before CCRT was highly associated with high mortality for patients with MIBUC receiving CCRT for bladder preservation. Not only all-cause death but also bladder cancer death and COPD death were significantly higher in the current-smoking COPD group than in the never-smoking non-COPD group. FAU - Zhang, Jiaqiang AU - Zhang J AD - Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450052, China. FAU - Chang, Shyh-Chyi AU - Chang SC AD - Department of Surgery, Division of Urology, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. AD - Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11221, Taiwan. FAU - Chiang, Ming-Feng AU - Chiang MF AUID- ORCID: 0000-0003-0940-0070 AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. FAU - Chiu, Kuo-Chin AU - Chiu KC AUID- ORCID: 0000-0001-5173-7852 AD - Division of Chest, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. FAU - Wu, Szu-Yuan AU - Wu SY AD - Division of Chest, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. AD - Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan. AD - Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. AD - Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. AD - Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung 413, Taiwan. AD - Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 256, Taiwan. AD - Graduate Institute of Business Administration, Fu Jen Catholic University, Taipei 242062, Taiwan. AD - Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan. LA - eng PT - Journal Article DEP - 20210926 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC8539205 OTO - NOTNLM OT - COPD OT - COPDAE OT - cigarette smoking OT - muscle-invasive bladder urothelial carcinoma OT - survival COIS- The authors have no potential conflict of interest to declare. The data sets supporting the study conclusions are included in the manuscript. EDAT- 2021/10/24 06:00 MHDA- 2021/10/24 06:01 PMCR- 2021/09/26 CRDT- 2021/10/23 01:14 PHST- 2021/08/22 00:00 [received] PHST- 2021/09/23 00:00 [revised] PHST- 2021/09/24 00:00 [accepted] PHST- 2021/10/23 01:14 [entrez] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/10/24 06:01 [medline] PHST- 2021/09/26 00:00 [pmc-release] AID - jpm11100958 [pii] AID - jpm-11-00958 [pii] AID - 10.3390/jpm11100958 [doi] PST - epublish SO - J Pers Med. 2021 Sep 26;11(10):958. doi: 10.3390/jpm11100958. PMID- 34683088 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211026 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 11 IP - 10 DP - 2021 Sep 23 TI - Low Preoperative Lymphocyte-to-Monocyte Ratio Is Predictive of the 5-Year Recurrence of Bladder Tumor after Transurethral Resection. LID - 10.3390/jpm11100947 [doi] LID - 947 AB - Many studies have investigated the prognostic significance of peripheral blood parameters-including lymphocyte-to-monocyte ratio (LMR)-in several cancers in recent decades. We evaluated the prognostic factors for five-year tumor recurrence after the transurethral resection of a bladder tumor (TURBT). In total, 151 patients with non-muscle invasive bladder tumors who underwent TURBT under spinal anesthesia were selected for this retrospective analysis. The time to tumor recurrence was determined by the number of days from surgery until there was a pathological confirmation of tumor recurrence. The preoperative and postoperative laboratory values were defined as results within one month prior to and one month after TURBT. Univariate and multivariate Cox regression analyses were performed. Seventy-one patients (47.0%) developed recurrent bladder tumors within five years after the first TURBT surgery. The multivariate Cox regression analysis revealed that preoperative LMR (hazard ratio, 0.839; 95% confidence interval, 0.739-0.952; p = 0.006) and multiple tumor sites (hazard ratio, 2.072; 95% confidence interval, 1.243-3.453; p = 0.005) were independent recurrence predictors in patients with recurrent bladder tumors within five years after the TURBT. A low preoperative LMR is an important predictor for the recurrence of a bladder tumor during a five-year follow-up period after surgery. FAU - Kim, Kyungmi AU - Kim K AUID- ORCID: 0000-0003-2833-1912 AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Yu, Jihion AU - Yu J AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Park, Jun-Young AU - Park JY AUID- ORCID: 0000-0003-4476-4945 AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Baek, Sungwoon AU - Baek S AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Hwang, Jai-Hyun AU - Hwang JH AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Choi, Woo-Jong AU - Choi WJ AUID- ORCID: 0000-0002-5392-398X AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. FAU - Kim, Young-Kug AU - Kim YK AUID- ORCID: 0000-0002-1982-3053 AD - Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. LA - eng PT - Journal Article DEP - 20210923 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC8540090 OTO - NOTNLM OT - bladder tumor OT - lymphocyte-to-monocyte ratio OT - peripheral blood parameters OT - transurethral resection OT - tumor recurrence COIS- The authors declare no conflict of interest. EDAT- 2021/10/24 06:00 MHDA- 2021/10/24 06:01 PMCR- 2021/09/23 CRDT- 2021/10/23 01:14 PHST- 2021/08/20 00:00 [received] PHST- 2021/09/17 00:00 [revised] PHST- 2021/09/20 00:00 [accepted] PHST- 2021/10/23 01:14 [entrez] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/10/24 06:01 [medline] PHST- 2021/09/23 00:00 [pmc-release] AID - jpm11100947 [pii] AID - jpm-11-00947 [pii] AID - 10.3390/jpm11100947 [doi] PST - epublish SO - J Pers Med. 2021 Sep 23;11(10):947. doi: 10.3390/jpm11100947. PMID- 34674366 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20230308 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 129 IP - 2 DP - 2022 Feb TI - Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study. PG - 258-268 LID - 10.1111/bju.15622 [doi] AB - OBJECTIVES: To quantify the real-world survival benefit of re-resection vs no re-resection in patients diagnosed with T1 bladder cancer (BC) at the population level. PATIENTS AND METHODS: Retrospective population-wide observational cohort study based on pathology reports linked to health administrative data. We identified patients who were diagnosed with T1 BC in the province of Ontario (01/2001-12/2015) and used billing claims to ascertain whether they received re-resection within 2-10 weeks. The time-dependent effect of re-resection on survival outcomes was modelled by Cox proportional hazards regression (unadjusted and adjusted for numerous assumed patient- and surgeon-level confounding variables). Effect measures were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: We identified 7666 patients of which 2162 (28.7%) underwent re-resection after a median (interquartile range) time of 45 (35-56) days. Patients who received re-resection were less likely to die from any causes (HR 0.68, 95% CI 0.63-0.74, P < 0.001) and from BC (HR 0.66, 95% CI 0.57-0.76, P < 0.001) during any time of follow-up. After adjusting for all assumed confounding variables, re-resection was still significantly associated with a lower overall mortality (HR 0.88, 95% CI 0.81-0.95, P < 0.001), while the association with cancer-specific survival marginally lost its statistical significance (HR 0.87, 95% CI 0.75-1.02, P = 0.08). CONCLUSIONS: A second transurethral resection within 2-6 weeks after the initial resection (i.e. re-resection) is recommended for patients diagnosed with primary T1 BC as prior studies suggest therapeutic, diagnostic, and prognostic benefits. However, results on survival endpoints are sparse, conflicting, and often affected by various biases. To the best of our knowledge, the present population-wide study represents the largest cohort of patients diagnosed with T1 BC and provides real-world evidence supporting the utilisation of re-resection in this group of patients. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Wettstein, Marian S AU - Wettstein MS AUID- ORCID: 0000-0003-1378-3625 AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Baxter, Nancy N AU - Baxter NN AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. FAU - Sutradhar, Rinku AU - Sutradhar R AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. FAU - Mamdani, Muhammad AU - Mamdani M AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. FAU - Song, Pham AU - Song P AD - ICES, Toronto, ON, Canada. FAU - Qadri, Syed R AU - Qadri SR AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Li, Kathy AU - Li K AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Liu, Ning AU - Liu N AD - ICES, Toronto, ON, Canada. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20211108 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - Eur Urol. 2023 Mar;83(3):297. doi: 10.1016/j.eururo.2022.11.011. PMID: 36463073 MH - Cystectomy/methods MH - Humans MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology MH - Urologic Surgical Procedures OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - bladder cancer OT - cohort study OT - comparative study OT - effectiveness OT - non-muscle-invasive bladder cancer OT - observational study OT - population-based study OT - re-resection OT - survival analysis OT - transurethral resection EDAT- 2021/10/22 06:00 MHDA- 2022/04/15 06:00 CRDT- 2021/10/21 21:41 PHST- 2021/10/22 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2021/10/21 21:41 [entrez] AID - 10.1111/bju.15622 [doi] PST - ppublish SO - BJU Int. 2022 Feb;129(2):258-268. doi: 10.1111/bju.15622. Epub 2021 Nov 8. PMID- 34673472 OWN - NLM STAT- MEDLINE DCOM- 20211104 LR - 20211104 IS - 1879-0534 (Electronic) IS - 0010-4825 (Linking) VI - 138 DP - 2021 Nov TI - A novel self-learning framework for bladder cancer grading using histopathological images. PG - 104932 LID - S0010-4825(21)00726-5 [pii] LID - 10.1016/j.compbiomed.2021.104932 [doi] AB - In recent times, bladder cancer has increased significantly in terms of incidence and mortality. Currently, two subtypes are known based on tumour growth: non-muscle invasive (NMIBC) and muscle-invasive bladder cancer (MIBC). In this work, we focus on the MIBC subtype because it has the worst prognosis and can spread to adjacent organs. We present a self-learning framework to grade bladder cancer from histological images stained by immunohistochemical techniques. Specifically, we propose a novel Deep Convolutional Embedded Attention Clustering (DCEAC) which allows for the classification of histological patches into different levels of disease severity, according to established patterns in the literature. The proposed DCEAC model follows a fully unsupervised two-step learning methodology to discern between non-tumour, mild and infiltrative patterns from high-resolution 512 x 512 pixel samples. Our system outperforms previous clustering-based methods by including a convolutional attention module, which enables the refinement of the features of the latent space prior to the classification stage. The proposed network surpasses state-of-the-art approaches by 2-3% across different metrics, reaching a final average accuracy of 0.9034 in a multi-class scenario. Furthermore, the reported class activation maps evidence that our model is able to learn by itself the same patterns that clinicians consider relevant, without requiring previous annotation steps. This represents a breakthrough in MIBC grading that bridges the gap with respect to training the model on labelled data. CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Garcia, Gabriel AU - Garcia G AD - Instituto de Investigacion e Innovacion en Bioingenieria, Universitat Politecnica de Valencia, 46022, Valencia, Spain. Electronic address: jogarpa7@i3b.upv.es. FAU - Esteve, Anna AU - Esteve A AD - Instituto de Investigacion e Innovacion en Bioingenieria, Universitat Politecnica de Valencia, 46022, Valencia, Spain; Hospital Universitario y Politecnico La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Spain. FAU - Colomer, Adrian AU - Colomer A AD - Instituto de Investigacion e Innovacion en Bioingenieria, Universitat Politecnica de Valencia, 46022, Valencia, Spain. FAU - Ramos, David AU - Ramos D AD - Hospital Universitario y Politecnico La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Spain. FAU - Naranjo, Valery AU - Naranjo V AD - Instituto de Investigacion e Innovacion en Bioingenieria, Universitat Politecnica de Valencia, 46022, Valencia, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211012 PL - United States TA - Comput Biol Med JT - Computers in biology and medicine JID - 1250250 SB - IM MH - Cluster Analysis MH - Humans MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - Deep clustering OT - Histopathological images OT - Immunohistochemical staining OT - Self-learning OT - Tumour budding OT - Unsupervised learning EDAT- 2021/10/22 06:00 MHDA- 2021/11/05 06:00 CRDT- 2021/10/21 21:05 PHST- 2021/06/15 00:00 [received] PHST- 2021/10/07 00:00 [revised] PHST- 2021/10/07 00:00 [accepted] PHST- 2021/10/22 06:00 [pubmed] PHST- 2021/11/05 06:00 [medline] PHST- 2021/10/21 21:05 [entrez] AID - S0010-4825(21)00726-5 [pii] AID - 10.1016/j.compbiomed.2021.104932 [doi] PST - ppublish SO - Comput Biol Med. 2021 Nov;138:104932. doi: 10.1016/j.compbiomed.2021.104932. Epub 2021 Oct 12. PMID- 34673209 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20221207 IS - 1879-0038 (Electronic) IS - 0378-1119 (Linking) VI - 809 DP - 2022 Jan 30 TI - Genetic variants in splicing factor genes and susceptibility to bladder cancer. PG - 146022 LID - S0378-1119(21)00617-X [pii] LID - 10.1016/j.gene.2021.146022 [doi] AB - BACKGROUND: Genome-wide association studies have demonstrated that genetic variants are closely related to tumorigenesis and progression of cancer. However, the correlation between genetic variants in splicing factor genes and bladder cancer susceptibility remains unclear. METHOD: A case-control study with 580 cases of bladder cancer and 1,101 controls was conducted to explore the association of single-nucleotide polymorphisms (SNPs) in splicing factors with bladder cancer susceptibility by logistic regression models, and multiple testing errors were justified by the false discovery rate (FDR) method. Next, we used the Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) datasets to further analyze the differential expression of candidate genes. RESULTS: We found that rs978416 G>A in RBFOX3 contributed to a reduced risk of bladder cancer [adjusted odds ratio (OR) = 0.72, 95% confidence internal (CI) = 0.62-0.84, P = 3.54 x 10(-5)], especially in individuals who never smoked (P = 7.83 x 10(-5)). Stratified analysis showed that the protective effect of rs978416 was more significant in the subgroup of low grade and non-muscle invasive bladder cancer. Furthermore, the RBFOX3 mRNA expression was decreased in bladder tumor tissues. However, the relatively high expression of RBFOX3 was related to a higher bladder cancer stage. CONCLUSIONS: Our findings indicated that SNP rs978416 G>A in RBFOX3 may be related to bladder cancer predisposition in Chinese population and might serve as a novel biomarker for bladder cancer risk. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Wang, Xi AU - Wang X AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Guo, Zheng AU - Guo Z AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Xuzhou Center for Disease Control and Prevention, Xuzhou, China. FAU - Zhu, Huanhuan AU - Zhu H AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Xin, Junyi AU - Xin J AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Yuan, Lin AU - Yuan L AD - Department of Urology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China. FAU - Qin, Chao AU - Qin C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medicial University, Nanjing, China. FAU - Wang, Meilin AU - Wang M AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Zhang, Zhengdong AU - Zhang Z AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. Electronic address: drzdzhang@njmu.edu.cn. FAU - Wang, Yunyan AU - Wang Y AD - Department of Urology, The Affiliated Huai'an No. 1 Hospital of Nanjing Medical University, Huai'an, China. Electronic address: hayywangyunyan@njmu.edu.cn. FAU - Chu, Haiyan AU - Chu H AD - Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. Electronic address: chy_grape@njmu.edu.cn. LA - eng PT - Journal Article DEP - 20211018 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - 0 (Antigens, Nuclear) RN - 0 (Biomarkers, Tumor) RN - 0 (Nerve Tissue Proteins) RN - 0 (RNA Splicing Factors) RN - 0 (neuronal nuclear antigen NeuN, human) SB - IM MH - Antigens, Nuclear/*genetics MH - Asian People/genetics MH - Biomarkers, Tumor/genetics MH - Case-Control Studies MH - Gene Expression Regulation, Neoplastic MH - Genetic Predisposition to Disease MH - Humans MH - Nerve Tissue Proteins/*genetics MH - *Polymorphism, Single Nucleotide MH - RNA Splicing Factors/*genetics MH - Urinary Bladder Neoplasms/*genetics/pathology OTO - NOTNLM OT - Bladder cancer susceptibility OT - Genetic variation OT - Molecular epidemiology OT - RBFOX3 OT - Splicing factor EDAT- 2021/10/22 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/10/21 20:51 PHST- 2021/06/10 00:00 [received] PHST- 2021/09/03 00:00 [revised] PHST- 2021/10/14 00:00 [accepted] PHST- 2021/10/22 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/21 20:51 [entrez] AID - S0378-1119(21)00617-X [pii] AID - 10.1016/j.gene.2021.146022 [doi] PST - ppublish SO - Gene. 2022 Jan 30;809:146022. doi: 10.1016/j.gene.2021.146022. Epub 2021 Oct 18. PMID- 34671552 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Influence of American Society of Anesthesiologists Score on Oncologic Outcomes in Patients With Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Large-Sample Study in Two Institutions. PG - 723669 LID - 10.3389/fonc.2021.723669 [doi] LID - 723669 AB - INTRODUCTION: As a research team of urologists and an anesthetist, we sought to investigate the prognostic significance of American Society of Anesthesiologists (ASA) score in patients with upper tract urothelial cancer (UTUC) after radical nephroureterectomy (RNU). ASA physical status (ASA-PS) classification not only was found to be associated with increased comorbidities but also independently factors for predicting morbidity and mortality. Accurate risk assessment was being particularly important for patients being considered for surgery. METHODS: Records for 958 patients with UTUC who underwent RNU were reviewed. Clinicopathologic variables, including ASA-PS, were assessed at two institutions. Overall survival (OS), cancer-specific survival (CSS), intravesical recurrence-free survival (IRFS), and metastasis-free survival (MFS) were estimated using the Kaplan-Meier method and Cox regression analyses. We measured the independent predictive value of ASA-PS for mortality by multivariate regression. Association of ASA-PS and clinicopathologic variables was assessed. RESULTS: The group of patients with ASA = 2/3 had a shorter 5-year OS (67.6% and 49.9%), CSS (72.9% and 58.1%), and MFS (75.1% and 58.5%). The median follow-up time was 39 months. Kaplan-Meier curves showed that the group with ASA = 2/3 had significantly poorer OS, CSS, and MFS. Adjusting for multiple potential confounding factors, multivariate analyses suggested that ASA score was an independent predictor of OS, CSS, and MFS (p = 0.004, p = 0.005, p < 0.001). CONCLUSION: Higher ASA scores were independently associated with lower survival rate. This capability, along with its simplicity, makes it a valuable prognostic metric. It should be seriously referenced in UTUC patients being considered for RNU. CI - Copyright (c) 2021 Yuan, Wang, Zhang, Mao, Huang, Huang and Ji. FAU - Yuan, Yichu AU - Yuan Y AD - Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Wang, Yiqiu AU - Wang Y AD - Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zhang, Nan AU - Zhang N AD - Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Mao, Xiawa AU - Mao X AD - Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Huang, Yiran AU - Huang Y AD - Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Huang, Jiwei AU - Huang J AD - Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ji, Na AU - Ji N AD - Department of Anesthesia, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. LA - eng PT - Journal Article DEP - 20211004 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8521060 OTO - NOTNLM OT - American Society of Anesthesiologists (ASA) score OT - prognosis OT - radical nephroureterectomy OT - survival OT - upper tract urothelial cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/22 06:00 MHDA- 2021/10/22 06:01 PMCR- 2021/01/01 CRDT- 2021/10/21 06:11 PHST- 2021/06/11 00:00 [received] PHST- 2021/09/09 00:00 [accepted] PHST- 2021/10/21 06:11 [entrez] PHST- 2021/10/22 06:00 [pubmed] PHST- 2021/10/22 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.723669 [doi] PST - epublish SO - Front Oncol. 2021 Oct 4;11:723669. doi: 10.3389/fonc.2021.723669. eCollection 2021. PMID- 34671381 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211022 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 12 DP - 2021 TI - Targeting Long Non-Coding RNA TTN-AS1 Suppresses Bladder Cancer Progression. PG - 704712 LID - 10.3389/fgene.2021.704712 [doi] LID - 704712 AB - Background: To explore the biological and clinical effects of titin-antisense RNA1 (TTN-AS1) in bladder cancer (BC) and the association between TTN-AS1 and activating transcription factor 2 (ATF2) in BC. Methods: The Kaplan-Meier method was performed to analyze the association between the expression of TTN-AS1 and prognosis of BC patients from TCGA data set and our institution. Quantitative real-time PCR (RT-PCR) was conducted to explore the expression of TTN-AS1 between the patients who underwent TURBT and Re-TURBT. MTT, colony formation, and tumor formation assays were conducted to evaluate the effect of TTN-AS1 on the ability of proliferation in BC cell lines. Transwell assay was performed to evaluate the effect of TTN-AS1 on the ability of invasion in BC cell lines. Bioinfomatics and immunohistochemical staining was used to identify the relationship between TTN-AS1 and ATF2. Results: The higher expression of TTN-AS1 was related to poorer disease-free survival (DFS) in patients with BC. The expression of TTN-AS1 was higher in BC patients who underwent Re-TURBT compared with BC patients who underwent TURBT. Knocking down TTN-AS1 resulted in inhibiting the ability of proliferation and invasion of BC cells. ATF2 may serve as a downstream target of TTN-AS1 in BC, and the high expression of ATF2 is also related to adverse DFS. Conclusion: Our study reveals that TTN-AS1 serves as an oncogene by activating ATF2 in BC. The findings suggest that TTN-AS1 may act as a novel therapeutic target for patients with BC. CI - Copyright (c) 2021 Xiao, Huang, Li, Zhang and Yang. FAU - Xiao, Huiyuan AU - Xiao H AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Huang, Wen AU - Huang W AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Li, Yanlei AU - Li Y AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Zhang, Rongxin AU - Zhang R AD - Department of Radiotherapy, Tianjin Medical University General Hospital, Tianjin, China. FAU - Yang, Long AU - Yang L AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. LA - eng PT - Journal Article DEP - 20211004 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC8522982 OTO - NOTNLM OT - bioinformactics OT - bladder cancer OT - long non-coding RNA OT - oncogene OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/22 06:00 MHDA- 2021/10/22 06:01 PMCR- 2021/10/04 CRDT- 2021/10/21 06:08 PHST- 2021/05/03 00:00 [received] PHST- 2021/08/26 00:00 [accepted] PHST- 2021/10/21 06:08 [entrez] PHST- 2021/10/22 06:00 [pubmed] PHST- 2021/10/22 06:01 [medline] PHST- 2021/10/04 00:00 [pmc-release] AID - 704712 [pii] AID - 10.3389/fgene.2021.704712 [doi] PST - epublish SO - Front Genet. 2021 Oct 4;12:704712. doi: 10.3389/fgene.2021.704712. eCollection 2021. PMID- 34667220 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20220125 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Oct 19 TI - Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history. PG - 20675 LID - 10.1038/s41598-021-00184-y [doi] LID - 20675 AB - Limited information is currently available on predictors of upper tract urothelial carcinoma (UTUC) recurrence in non-muscle-invasive bladder cancer (NMIBC) patients according to smoking history, although smoking probably contributes to urothelial carcinogenesis. Therefore, the present study aimed to identify independent predictors of UTUC recurrence in all patients and those with a smoking history. Our study population comprised 1190 NMIBC patients who underwent transurethral resection of bladder tumor. UTUC developed in 43 patients during the follow-up. A history of bacillus Calmette-Guerin (BCG) therapy was independently associated with a lower incidence of UTUC (HR = 0.43; P = 0.011). In a subgroup of NMIBC patients with a smoking history, concomitant carcinoma in situ (CIS) and a lower urinary pH (< 6) were independently associated with a higher incidence of UTUC recurrence (HR = 3.34, P = 0.006 and HR = 3.73, P = 0.008, respectively). Among patients with a longer smoking duration (>/= 20 years) or larger smoking intensity (>/= 20 cigarettes per day), those with lower urinary pH (< 6) had a significantly higher UTUC recurrence rate than their counterparts. These results suggest that BCG instillation may prevent UTUC recurrence in NMIBC patients, while a lower urinary pH and concomitant CIS increase the risk of UTUC recurrence in those with a smoking history. CI - (c) 2021. The Author(s). FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Masuda, Tsukasa AU - Masuda T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Baba, Yuto AU - Baba Y AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20211019 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/pathology MH - Female MH - Humans MH - Hydrogen-Ion Concentration MH - Male MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*pathology MH - Risk Factors MH - Smoking/*pathology MH - Ureteral Neoplasms/*pathology MH - Urinary Bladder Neoplasms/*pathology PMC - PMC8526685 COIS- The authors declare no competing interests. EDAT- 2021/10/21 06:00 MHDA- 2022/01/27 06:00 PMCR- 2021/10/19 CRDT- 2021/10/20 06:26 PHST- 2021/08/17 00:00 [received] PHST- 2021/10/01 00:00 [accepted] PHST- 2021/10/20 06:26 [entrez] PHST- 2021/10/21 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/10/19 00:00 [pmc-release] AID - 10.1038/s41598-021-00184-y [pii] AID - 184 [pii] AID - 10.1038/s41598-021-00184-y [doi] PST - epublish SO - Sci Rep. 2021 Oct 19;11(1):20675. doi: 10.1038/s41598-021-00184-y. PMID- 34660642 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211022 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 8 DP - 2021 TI - Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and miRNAs in Bladder Cancer: Implications for Personalized Medicine. PG - 735590 LID - 10.3389/fmed.2021.735590 [doi] LID - 735590 AB - Bladder cancer (BC) is the ninth most common cancer and the thirteenth most common cause of mortality worldwide. Bacillus Calmette Guerin (BCG) instillation is a common treatment option for BC. BCG therapy is associated with the less adversary effects, compared to chemotherapy, radiotherapy, and other conventional treatments. BCG could inhibit the progression and recurrence of BC by triggering apoptosis pathways, arrest cell cycle, autophagy, and neutrophil extracellular traps (NETs) formation. However, BCG therapy is not efficient for metastatic cancer. NETs and autophagy were induced by BCG and help to suppress the growth of tumor cells especially in the primary stages of BC. Activated neutrophils can stimulate autophagy pathway and release NETs in the presence of microbial pathogenesis, inflammatory agents, and tumor cells. Autophagy can also regulate NETs formation and induce production of reactive oxygen species (ROS) and NETs. Moreover, miRNAs are important regulator of gene expression. These small non-coding RNAs are also considered as an essential factor to control the levels of tumor development. However, the interaction between BCG and miRNAs has not been well-understood yet. Therefore, the present study discusses the roles of miRNAs in regulations of autophagy and NETs formation in BCG therapy in the treatment of BC. The roles of autophagy and NETs formation in BC treatment and efficiency of BCG are also discussed. CI - Copyright (c) 2021 Mao, Xu, Ding and Xu. FAU - Mao, Chenyu AU - Mao C AD - Department of Medical Oncology Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Xu, Xin AU - Xu X AD - Department of Medical Oncology Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Ding, Yongfeng AU - Ding Y AD - Department of Medical Oncology Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Xu, Nong AU - Xu N AD - Department of Medical Oncology Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20210930 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC8514698 OTO - NOTNLM OT - Bacillus Calmette Guerin OT - autophagy OT - biomarkers OT - bladder cancer OT - miRNAs OT - neutrophil extracellular traps COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/19 06:00 MHDA- 2021/10/19 06:01 PMCR- 2021/09/30 CRDT- 2021/10/18 09:08 PHST- 2021/07/02 00:00 [received] PHST- 2021/08/05 00:00 [accepted] PHST- 2021/10/18 09:08 [entrez] PHST- 2021/10/19 06:00 [pubmed] PHST- 2021/10/19 06:01 [medline] PHST- 2021/09/30 00:00 [pmc-release] AID - 10.3389/fmed.2021.735590 [doi] PST - epublish SO - Front Med (Lausanne). 2021 Sep 30;8:735590. doi: 10.3389/fmed.2021.735590. eCollection 2021. PMID- 34660295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Predictive Value of Preoperative Positive Urine Cytology for Development of Bladder Cancer After Nephroureterectomy in Patients With Upper Urinary Tract Urothelial Carcinoma: A Prognostic Nomogram Based on a Retrospective Multicenter Cohort Study and Systematic Meta-Analysis. PG - 731318 LID - 10.3389/fonc.2021.731318 [doi] LID - 731318 AB - BACKGROUND: Upper urinary tract urothelial carcinoma (UUT-UC) is a rare and severe urinary malignancy. Several studies have explored the relationship between preoperative urine cytology and intravesical recurrence (IVR) in patients with UUT-UC. However, the results of these studies are controversial or even contradictory, and investigations with UUT-UC patients in northeast China are rare. METHODS: We first estimated the prognostic significance of preoperative urine cytology in the outcomes of intravesical recurrence in 231 UUT-UC patients (training cohort = 142, validation cohort = 89) after radical nephroureterectomy (RNU) by the nomogram model. Subsequently, we quantitatively combined our results with the published data after searching several databases to assess whether preoperative positive urine cytology was associated with poor intravesical recurrence-free survival and a high risk of tumor malignant biological behavior. RESULTS: Firstly, the multicenter retrospective cohort study demonstrated that preoperative positive urine cytology correlated with poor intravesical recurrence-free survival and can serve as significant independent predictors of IVR by Kaplan-Meier curves and Cox regression analysis. The construction of the nomogram demonstrated that predictive efficacy and accuracy were significantly improved when preoperative urine cytology was combined. Meanwhile, meta-analysis showed that preoperative positive urine cytology was associated with a 49% increased risk of IVR. In the subgroup analysis by region, study type, and sample size, the pooled hazard ratios (HRs) were statistically significant for the Japan subgroup (HR 1.32), China subgroup (HR 1.88), cohort study subgroup (HR 1.45), and the single-arm study subgroup (HR 1.63). CONCLUSIONS: Preoperative urine cytology was validated as a potential predictor of intravesical recurrence in patients with UUT-UC after RNU, although these results need to be generalized with caution. Large, prospective trials are required to further confirm its significance in prognosis and tumor malignant biological behavior. CI - Copyright (c) 2021 Fan, Huang, Wen, Teng, Yang, Sun, Chen, Huang, Wang and Liu. FAU - Fan, Bo AU - Fan B AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Huang, Yuanbin AU - Huang Y AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, China. AD - Department of Clinical Medicine, Dalian Medical University, Dalian, China. FAU - Wen, Shuang AU - Wen S AD - Department of Pathology, Dalian Friendship Hospital, Dalian, China. FAU - Teng, Qiliang AU - Teng Q AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Yang, Xinrui AU - Yang X AD - Department of Clinical Medicine, Dalian Medical University, Dalian, China. FAU - Sun, Man AU - Sun M AD - Department of Clinical Medicine, Dalian Medical University, Dalian, China. FAU - Chen, Tingyu AU - Chen T AD - Department of Clinical Medicine, Dalian Medical University, Dalian, China. FAU - Huang, Yan AU - Huang Y AD - Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China. FAU - Wang, Yumei AU - Wang Y AD - Department of Clinical Laboratory, Second Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Liu, Zhiyu AU - Liu Z AD - Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian, China. LA - eng PT - Journal Article DEP - 20211001 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8519510 OTO - NOTNLM OT - cohort study OT - intravesical recurrence OT - meta-analysis OT - nomogram OT - preoperative urine cytology OT - upper urinary tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/19 06:00 MHDA- 2021/10/19 06:01 PMCR- 2021/10/01 CRDT- 2021/10/18 09:06 PHST- 2021/06/26 00:00 [received] PHST- 2021/09/08 00:00 [accepted] PHST- 2021/10/18 09:06 [entrez] PHST- 2021/10/19 06:00 [pubmed] PHST- 2021/10/19 06:01 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.731318 [doi] PST - epublish SO - Front Oncol. 2021 Oct 1;11:731318. doi: 10.3389/fonc.2021.731318. eCollection 2021. PMID- 34655075 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20220923 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 19 IP - 4 DP - 2021 Oct 16 TI - Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guerin and the Relationship with the CUETO Scoring Model. PG - 281-288 LID - 10.22037/uj.v18i.6765 [doi] AB - PURPOSE: In this study, we evaluated the predictability of a modified Club Urologico Espanol de Tratamiento Oncologico (CUETO) scoring model and preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: From August 2005 to May 2016, a total of 281 patients received intravesical bacillus Calmette-Guerin therapy after transurethral resection of a bladder tumor. The pathologic stage of all patients was Ta or T1. Of 281 patients, 84 (29.9%) experienced recurrence and 14 (5.0%) developed progression. The mean follow-up period was 46 months. The cut-off value for NLRs was 2.29. RESULTS: One hundred-eight patients (38.4%) displayed a high NLR (> 2.29). In Kaplan-Meier curve analysis, a high NLR was associated with lower recurrence-free survival (RFS) (P < .001) and progression-free survival (PFS) (P = .002). CUETO scores were associated with RFS (P < .001), but not with PFS (P = .423). A combination of NLRs and the CUETO risk model correlated with RFS (P < .001) and PFS (P = .002). In multivariate analysis, female gender, concomitant carcinoma in situ (CIS), tumor number >3, recurrent tumors, and a high NLR were independent factors predicting recurrence (all P < .05). Concomitant CIS, recurrent tumors, and a high NLR were independent factors for predicting progression (all P < .05). CONCLUSION: In patients with NMIBC, an NLR >2.29 was identified as a significant factor for predicting tumor recurrence and progression. Inclusion of preoperative NLR enhanced the accuracy of the CUETO model to predict disease progression. FAU - Chung, Jae-Wook AU - Chung JW AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. jeus119@hanmail.net. FAU - Kim, Jin Woo AU - Kim JW AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. jinu1723@naver.com. FAU - Lee, Eun Hye AU - Lee EH AD - Joint Institute for Regenerative Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea. eun90hye@gmail.com. FAU - Chun, So Young AU - Chun SY AD - BioMedical Research Institute, Kyungpook National University Hospital, Daegu, Republic of Korea. soyachun99@naver.com. FAU - Park, Dong Jin AU - Park DJ AD - Department of Urology, Dongguk University School of Medicine, Gyeongju, Korea. parkdj0510@gmail.com. FAU - Byeon, Kyeong Hyeon AU - Byeon KH AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. qosrod@naver.com. FAU - Choi, Seock Hwan AU - Choi SH AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of KoreaDepartment of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea. skhwan@gmail.com. FAU - Lee, Jun Nyung AU - Lee JN AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. ljnlover@gmail.com. FAU - Kim, Bum Soo AU - Kim BS AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea. urokbs@knu.ac.kr. FAU - Kim, Hyun Tae AU - Kim HT AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea. ht-kim1212@hanmail.net. FAU - Yoo, Eun Sang AU - Yoo ES AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea. uroyoo@knu.ac.kr. FAU - Kwon, Tae Gyun AU - Kwon TG AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. tgkwon@knu.ac.kr. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. yunsokha@gmail.com. FAU - Kim, Tae-Hwan AU - Kim TH AD - Department of Urology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. doctork@knu.ac.kr. LA - eng PT - Journal Article DEP - 20211016 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - Disease Progression MH - Female MH - Humans MH - Lymphocytes/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Neutrophils/pathology MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/pathology EDAT- 2021/10/17 06:00 MHDA- 2022/09/24 06:00 CRDT- 2021/10/16 06:05 PHST- 2021/10/17 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2021/10/16 06:05 [entrez] AID - 6765 [pii] AID - 10.22037/uj.v18i.6765 [doi] PST - epublish SO - Urol J. 2021 Oct 16;19(4):281-288. doi: 10.22037/uj.v18i.6765. PMID- 34624323 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 1090-2422 (Electronic) IS - 0014-4827 (Linking) VI - 408 IP - 2 DP - 2021 Nov 15 TI - HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells. PG - 112860 LID - S0014-4827(21)00414-6 [pii] LID - 10.1016/j.yexcr.2021.112860 [doi] AB - Our previous that HMMR upregulation independently predicts poor survival in patients with papillary muscle-invasive bladder cancer (MIBC). In this study, we explored its downstream regulations and the potential transcriptional factors activating its expression. MIBC derived T24 cells, and non-MIBC (NMIBC) derived RT4 cells were used for in vitro and in vivo studies. HMMR expression enhanced cell proliferation, the expression of mesenchymal markers, and cell invasion. It induced the nuclear entry of beta-catenin, increased its active form in the nuclear part, and elevated the relative TOP/FOP activity. The promoter region of HMMR has a canonical FKH motif. FOXM1 bound to this site and activated HMMR transcription. HMMR knockdown significantly weakened FOXM1 overexpression induced bladder cancer growth, invasion, partial epithelial-to-mesenchymal transition (pEMT), as well as the activation of the Wnt/beta-catenin signaling pathway. In conclusion, the findings in this study expanded our understanding of the mechanisms underlying HMMR dysregulation and the functional role of the FOXM1-HMMR axis in bladder cancer. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Yang, Dong AU - Yang D AD - Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. FAU - Ma, Yan AU - Ma Y AD - Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. FAU - Zhao, Pengcheng AU - Zhao P AD - Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. FAU - Ma, Jing AU - Ma J AD - Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. FAU - He, Chaohong AU - He C AD - Department of Urology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. Electronic address: hechaohong11@hotmail.com. LA - eng PT - Journal Article DEP - 20211005 PL - United States TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (CTNNB1 protein, human) RN - 0 (Extracellular Matrix Proteins) RN - 0 (FOXM1 protein, human) RN - 0 (Forkhead Box Protein M1) RN - 0 (Hyaluronan Receptors) RN - 0 (beta Catenin) RN - 0 (hyaluronan-mediated motility receptor) SB - IM MH - Cell Line, Tumor MH - Cell Proliferation/genetics MH - Epithelial-Mesenchymal Transition/genetics MH - Extracellular Matrix Proteins/*genetics MH - Forkhead Box Protein M1/*genetics MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Hyaluronan Receptors/*genetics MH - Urinary Bladder Neoplasms/*genetics/pathology MH - Wnt Signaling Pathway/genetics MH - beta Catenin/*genetics OTO - NOTNLM OT - Bladder cancer OT - Epithelial-to-mesenchymal transition OT - FOXM1 OT - HMMR EDAT- 2021/10/09 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/10/08 20:13 PHST- 2021/07/19 00:00 [received] PHST- 2021/09/26 00:00 [revised] PHST- 2021/10/04 00:00 [accepted] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/08 20:13 [entrez] AID - S0014-4827(21)00414-6 [pii] AID - 10.1016/j.yexcr.2021.112860 [doi] PST - ppublish SO - Exp Cell Res. 2021 Nov 15;408(2):112860. doi: 10.1016/j.yexcr.2021.112860. Epub 2021 Oct 5. PMID- 34623216 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220501 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 56 IP - 1 DP - 2022 Feb TI - Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study. PG - 14-18 LID - 10.1080/21681805.2021.1987980 [doi] AB - OBJECTIVE: Papillary urothelial neoplasm of low malignant potential (PUNLMP) and stage TaG1 non-muscle invasive bladder cancer (NMIBC) represent separate categories in current WHO 1999 grade definitions. Similarly, PUNLMP and Ta low-grade are separate entities in the WHO 2004/2016 grading system. However, this classification is currently questioned by reports showing a similar risk of recurrence and progression for both categories. PATIENTS AND METHODS: In this population-based study, risk estimates were evaluated in patients diagnosed with PUNLMP (n = 135) or stage TaG1 (n = 2176) NMIBC 2004-2008 with 5-year follow-up registration in the nation-wide Bladder Cancer Data Base Sweden (BladderBaSe). The risk of recurrence was assessed using multivariable Cox regression with adjustment for multiple confounders (age, gender, marital status, comorbidity, educational level, and health care region). RESULTS: At five years, 28/135 (21%) patients with PUNLMP and 922/2176 (42%) with TaG1 had local recurrence. The corresponding progression rates were 0.7% (1/135) and 4.0% (86/2176), respectively. A higher relative risk of recurrence was detected in patients with TaG1 tumours compared to PUNLMP (Hazard Ratio 1.6, 95% CI 1.2-2.0) at 5-year follow-up, while progression events were too few to compare. CONCLUSIONS: The difference in risk of recurrence between primary stage TaG1 and PUNLMP stands in contrast to the recently adapted notion that treatment and follow-up strategies can be merged into one low-risk group of NMIBC. FAU - Bobjer, Johannes AU - Bobjer J AUID- ORCID: 0000-0001-8495-3498 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Orebro University, Orebro, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Simoulis, Athanasious AU - Simoulis A AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Clinical Pathology, Skane University Hospital, Malmo, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Department of Public Health and Clinical Medicine, Northern Registre Centre, Umea University, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. FAU - Liedberg, Fredrik AU - Liedberg F AUID- ORCID: 0000-0001-8193-0370 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. LA - eng PT - Journal Article DEP - 20211008 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - *Carcinoma, Transitional Cell/epidemiology MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Risk Factors MH - *Urinary Bladder Neoplasms/epidemiology MH - World Health Organization OTO - NOTNLM OT - PUNLMP OT - Papillary urothelial neoplasm of low malignant potential OT - bladder cancer OT - grade 1 OT - recurrence EDAT- 2021/10/09 06:00 MHDA- 2022/02/09 06:00 CRDT- 2021/10/08 12:14 PHST- 2021/10/09 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] PHST- 2021/10/08 12:14 [entrez] AID - 10.1080/21681805.2021.1987980 [doi] PST - ppublish SO - Scand J Urol. 2022 Feb;56(1):14-18. doi: 10.1080/21681805.2021.1987980. Epub 2021 Oct 8. PMID- 34606878 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 159 DP - 2022 Jan TI - Association Between Surgical Volume and Survival Among Patients With Variant Histologies of Bladder Cancer. PG - 100-106 LID - S0090-4295(21)00884-0 [pii] LID - 10.1016/j.urology.2021.09.009 [doi] AB - OBJECTIVE: To examine the relationship between hospital volume and the management of bladder cancer variant histology. Variant histologies of bladder cancer are rare which limits the ability for providers to develop expertise however there is a clear hospital and/or surgeon-volume relationship for management of rare or complex surgical and/or medical diseases. METHODS: We queried the National Cancer Database from 2004-2016 for all cases of bladder cancer, identifying cases of variant histology. Our primary outcome was overall survival while secondary outcomes included identifying treatment patterns. Hospitals were stratified into those that managed 2-4, >4-6, and >/=6 cases per year of variant histology. RESULTS: We identified 23,284 patients with bladder cancer of variant histology who were treated at 1301 hospitals. Few institutions had high volume experience with this disease: 18.5% (n = 241) treated >2 patients annually and 5.7% (n = 76) treated >4 cases annually. Hospital volume positively correlated with utilization of early radical cystectomy (RC) in non-muscle invasive disease and neoadjuvant chemotherapy in muscle-invasive disease. On multivariable analysis, increased hospital volume was associated with improved survival. After stratifying by sub-type, hospital volume continued to be associated with improved survival for squamous, small cell, and sarcomatoid cancers. CONCLUSION: Management of variant histology urothelial carcinoma at high-volume centers is associated with improved overall survival. The mechanisms of this are multifactorial, and future research should focus on improvement opportunities for low-volume hospitals, centralization of care, and/or increased access to care at high-volume centers. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Sui, Wilson AU - Sui W AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Hall, Mary E AU - Hall ME AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Barocas, Daniel A AU - Barocas DA AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Luckenbaugh, Amy N AU - Luckenbaugh AN AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Moses, Kelvin A AU - Moses KA AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Penson, David F AU - Penson DF AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Laviana, Aaron A AU - Laviana AA AD - Department of Surgery & Perioperative Care, Dell Medical School at the University of Texas at Austin, Austin, TX. Electronic address: aaron.laviana@austin.utexas.edu. LA - eng PT - Journal Article DEP - 20211001 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - *Carcinoma, Renal Cell/mortality/pathology/therapy MH - *Cystectomy/adverse effects/methods/statistics & numerical data MH - Female MH - Hospitals, High-Volume/*statistics & numerical data MH - Hospitals, Low-Volume/statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/methods/statistics & numerical data MH - Neoplasm Invasiveness MH - Outcome Assessment, Health Care/methods/statistics & numerical data MH - *Postoperative Complications/epidemiology MH - Procedures and Techniques Utilization/statistics & numerical data MH - Professional Competence/*standards MH - Survival Analysis MH - United States/epidemiology MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy EDAT- 2021/10/05 06:00 MHDA- 2022/02/03 06:00 CRDT- 2021/10/04 20:14 PHST- 2021/05/10 00:00 [received] PHST- 2021/08/14 00:00 [revised] PHST- 2021/09/06 00:00 [accepted] PHST- 2021/10/05 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/10/04 20:14 [entrez] AID - S0090-4295(21)00884-0 [pii] AID - 10.1016/j.urology.2021.09.009 [doi] PST - ppublish SO - Urology. 2022 Jan;159:100-106. doi: 10.1016/j.urology.2021.09.009. Epub 2021 Oct 1. PMID- 34603020 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211005 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 12 DP - 2021 TI - Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis. PG - 707271 LID - 10.3389/fphar.2021.707271 [doi] LID - 707271 AB - Background: The treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) remains highly debated for its high recurrence and progression risk. This work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Methods: A comprehensive online literature search was conducted in three databases to select researches related to IAC + IVC for high-risk NMIBC. All data were analyzed using the Review Manager software version 5.3. And we used the Cochrane Risk of Bias tool to assessed the quality of these enrolled researches. Results: Seven eligible original publications were enrolled in our studies with a total of 1,247 patients. Compared with the intravesical instillation, IAC + IVC therapy showed a better therapeutic effect. The total odds ratio for tumor recurrence rate, tumor progression rate, survival rate, and tumor-specific death rate was calculated as 0.51 (95% CI: 0.36-0.72; p < 0.05), 0.51 (95% CI: 0.36-0.72; p < 0.05), 1.75 (95% CI: 1.09-2.81; p < 0.05), and 0.48 (95% CI: 0.28-0.84; p < 0.05), respectively. In patients who received IAC, most of the adverse events (AEs)in the treatment were Grade I and II. Conclusion: IAC + IVC regimen for high-risk NMIBC could effectively reduce recurrence and progression and provide a better prognosis than intravesical instillation. The adverse events of IAC were mild and acceptable. CI - Copyright (c) 2021 Cheng, Qiu, Chen, Zu, Liu, Li, Hu, Yi, He, Chen and Cui. FAU - Cheng, Chunliang AU - Cheng C AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Qiu, Dongxu AU - Qiu D AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Chen, Jinbo AU - Chen J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Zu, Xiongbing AU - Zu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Liu, Jinhui AU - Liu J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Li, Huihuang AU - Li H AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Hu, Jiao AU - Hu J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Yi, Zhenglin AU - Yi Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - He, Tongchen AU - He T AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Chen, Zhi AU - Chen Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Cui, Yu AU - Cui Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article DEP - 20210916 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC8481664 OTO - NOTNLM OT - high-risk non-muscle-invasive bladder cancer OT - intra-arterial chemotherapy OT - intravesical chemotherapy OT - progression OT - recurrence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/05 06:00 MHDA- 2021/10/05 06:01 PMCR- 2021/09/16 CRDT- 2021/10/04 05:56 PHST- 2021/05/09 00:00 [received] PHST- 2021/07/30 00:00 [accepted] PHST- 2021/10/04 05:56 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/05 06:01 [medline] PHST- 2021/09/16 00:00 [pmc-release] AID - 707271 [pii] AID - 10.3389/fphar.2021.707271 [doi] PST - epublish SO - Front Pharmacol. 2021 Sep 16;12:707271. doi: 10.3389/fphar.2021.707271. eCollection 2021. PMID- 34593956 OWN - NLM STAT- MEDLINE DCOM- 20211228 LR - 20211228 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Sep 30 TI - Effects of robot-assisted versus hand-assisted nephroureterectomy on circulating tumor cells for upper urinary tract urothelial carcinoma. PG - 19499 LID - 10.1038/s41598-021-99092-4 [doi] LID - 19499 AB - To compare perioperative circulating tumor cells (CTC) in primary upper tract urothelial carcinoma (UTUC) patients who underwent hand-assisted retroperitoneoscopic nephroureterectomy (HANU) or robotic-assisted nephroureterectomy (RANU). A total of 29 patients received RANU (n = 10) or HANU (n = 19). Peripheral blood samples were collected before, 24 h after surgery (POh24) and on postoperative day 28 (POD28). The demographic and pathologic data are similar in both groups. RANU had a longer operative time (p = 0.031), less bleeding volume (p = 0.004), and comparable pain sore (p = 0.169). The mean CTC numbers before surgery (2.4 vs. 2.3, p = 0.482), POh24 (2.4 vs. 1.9, p = 0.668) and POD28 (0.5 vs. 0.6, p = 0.280) were not significant different among groups. The amount of CTCs in both groups decreased and reached similar level on POD28. No significant difference of overall and intravesical recurrence rate between the two approaches. In comparison to RANU, more surgical manipulation does not affect tumor cell translocation into the bloodstream in UTUC patients who received HANU. However, a longer follow-up would be needed for the final comparison of tumor recurrence. CI - (c) 2021. The Author(s). FAU - Ting, Hui-Kung AU - Ting HK AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Cha, Tai-Lung AU - Cha TL AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. AD - Graduate School of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. FAU - Tsai, Yi-Ta AU - Tsai YT AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. AD - Graduate School of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. FAU - Liu, Shu-Yu AU - Liu SY AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Wu, Sheng-Tang AU - Wu ST AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. doc20283@gmail.com. FAU - Meng, En AU - Meng E AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Tsao, Chih-Wei AU - Tsao CW AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Kao, Chien-Chang AU - Kao CC AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. AD - Graduate School of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. FAU - Chen, Chin-Li AU - Chen CL AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Sun, Guang-Huan AU - Sun GH AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Yu, Dah-Shyong AU - Yu DS AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. FAU - Yang, Ming-Hsin AU - Yang MH AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec 2, Neihu 114, Taipei, Taiwan. msy681028@gmail.com. AD - Graduate School of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. msy681028@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210930 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor MH - Disease Management MH - Female MH - Humans MH - Immunophenotyping MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplastic Cells, Circulating/metabolism/*pathology MH - Nephroureterectomy/adverse effects/*methods MH - Prognosis MH - Robotic Surgical Procedures/adverse effects/*methods MH - Treatment Outcome MH - Urologic Neoplasms/*pathology/*surgery PMC - PMC8484450 COIS- The authors declare no competing interests. EDAT- 2021/10/02 06:00 MHDA- 2021/12/29 06:00 PMCR- 2021/09/30 CRDT- 2021/10/01 07:10 PHST- 2021/07/09 00:00 [received] PHST- 2021/09/17 00:00 [accepted] PHST- 2021/10/01 07:10 [entrez] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/12/29 06:00 [medline] PHST- 2021/09/30 00:00 [pmc-release] AID - 10.1038/s41598-021-99092-4 [pii] AID - 99092 [pii] AID - 10.1038/s41598-021-99092-4 [doi] PST - epublish SO - Sci Rep. 2021 Sep 30;11(1):19499. doi: 10.1038/s41598-021-99092-4. PMID- 34589112 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220603 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 12 DP - 2021 TI - Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer. PG - 694777 LID - 10.3389/fgene.2021.694777 [doi] LID - 694777 AB - Background: Bladder cancer has become the tenth most diagnosed cancer worldwide. The prognosis has been shown to differ between non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). We aimed to identify signature genes that are associated with the invasiveness and survival of bladder cancer and to identify potential treatments. Methods: We downloaded gene expression profiles of bladder cancer from the Gene Expression Omnibus database to identify differentially expressed genes and perform weighted gene co-expression network analysis. Functional enrichment was analyzed by GO and KEGG analyses. Hub genes were identified from the significant module. Another dataset was also acquired to verify the expression of hub genes. Univariate and multivariate Cox regression analyses were applied to the dataset downloaded from The Cancer Genome Atlas database. Risk scores were calculated and the effect was evaluated by Kaplan-Meier survival analysis. A nomogram was constructed and validated using training and testing samples, respectively. Analysis of the tumor immune microenvironment was conducted with the CIBERSORT algorithm. Results: In total, 1,245 differentially expressed genes (DEGs) were identified. A distinct module was identified that was significantly correlated to invasiveness. The genes within this module were found to be significantly associated with extracellular exosomes, GTPase activity, metabolic pathways, etc. Three hub genes (VSIG2, PPFIBP2, and DENND2D) were identified as biomarkers of invasiveness; two of these (PPFIBP2 and DENND2D) were closely associated with prognosis. The risk score was regarded as an independent prognostic factor. The nomogram was associated with acceptable accuracy for predicting 1- and 5-year overall survival. The infiltrating levels of resting NK cells, activated natural killer (NK) cells, CD8(+) T cells, activated memory CD4(+) T cells, and T follicular helper cells, were significantly higher in the group with lower risk scores. The group with higher risk scores showed predominant infiltration by regulatory T cells (Tregs). Conclusion: We successfully identified three signature genes related to invasiveness and constructed a nomogram of bladder cancer with acceptable performance. Differences suggested by risk scores between groups of patients showing diverse patterns of immune cell infiltration may be beneficial for selecting therapeutic approaches and predicting prognosis. CI - Copyright (c) 2021 He, Wu, Liu, Li, Jiang, Xu and Xu. FAU - He, Yang AU - He Y AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Wu, Yongxin AU - Wu Y AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Liu, Zhe AU - Liu Z AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Li, Boping AU - Li B AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Jiang, Ning AU - Jiang N AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Xu, Peng AU - Xu P AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. FAU - Xu, Abai AU - Xu A AD - Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. AD - Department of Urology, The First People's Hospital of Kashgar Prefecture, Kashgar, China. LA - eng PT - Journal Article DEP - 20210913 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 EIN - Front Genet. 2022 May 17;13:880633. doi: 10.3389/fgene.2022.880633. PMID: 35656317 PMC - PMC8473900 OTO - NOTNLM OT - bladder cancer OT - invasiveness OT - nomogram OT - tumor immune microenvironment OT - weighted gene co-expression network analysis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/01 06:00 MHDA- 2021/10/01 06:01 PMCR- 2021/09/13 CRDT- 2021/09/30 07:12 PHST- 2021/04/13 00:00 [received] PHST- 2021/08/25 00:00 [accepted] PHST- 2021/09/30 07:12 [entrez] PHST- 2021/10/01 06:00 [pubmed] PHST- 2021/10/01 06:01 [medline] PHST- 2021/09/13 00:00 [pmc-release] AID - 10.3389/fgene.2021.694777 [doi] PST - epublish SO - Front Genet. 2021 Sep 13;12:694777. doi: 10.3389/fgene.2021.694777. eCollection 2021. PMID- 34579695 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220217 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 21 IP - 1 DP - 2021 Sep 27 TI - Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study. PG - 136 LID - 10.1186/s12894-021-00901-9 [doi] LID - 136 AB - PURPOSE: To evaluate the prognostic value of the aspartate transaminase/alanine transaminase (AST/ALT) ratio in primary non-muscle-invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. METHODS: We retrospectively collected the clinical and pathological data from 314 patients with primary NMIBC who underwent transurethral resection of bladder tumor. The full cohorts were divided into a low AST/ALT ratio group and a high AST/ALT ratio group according to the optimal cut-off value which was obtained based on the analysis of the receiver operating characteristic curve for the 3-year recurrence-free survival (RFS). After 1:1 PSM, the correlation between preoperative AST/ALT ratio and survival prognosis was evaluated by Kaplan-Meier analysis with log-rank tests. The independent prognostic factors for RFS and progression-free survival (PFS) were also analyzed. RESULTS: The optimum cutoff value of the preoperative AST/ALT ratio was 1.40. Before PSM, a high AST/ALT ratio was correlated with the larger proportion of age > 60 years (P = 0.007) and the worse pathological T stage (P < 0.001). After PSM, patients with a high AST/ALT ratio had poorer RFS and PFS than patients with a low AST/ALT ratio (all P < 0.001). In addition, multivariate Cox regression analysis indicated that preoperative AST/ALT ratio was considered as an independent prognostic factor of RFS (HR 2.865; 95%CI 1.873-4.381; P < 0.001) and PFS (HR 4.771; 95%CI 2.607-8.734; P < 0.001) in patients with primary NMIBC. CONCLUSIONS: The high AST/ALT ratio group tended to have poorer RFS and PFS than the low AST/ALT ratio group. Our results also indicated that the elevated preoperative AST/ALT ratio could be seen as a useful prognostic biomarker for predicting early disease recurrence and progression in patients with primary NMIBC. CI - (c) 2021. The Author(s). FAU - Cheng, Xiaofeng AU - Cheng X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. FAU - Zhou, Xiaochen AU - Zhou X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. FAU - Yi, Ming AU - Yi M AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. FAU - Xu, Song AU - Xu S AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. FAU - Zhang, Cheng AU - Zhang C AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. FAU - Wang, Gongxian AU - Wang G AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang City, 330000, Jiangxi Province, China. wanggx-mr@126.com. LA - eng PT - Journal Article DEP - 20210927 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers, Tumor) RN - EC 2.6.1.1 (Aspartate Aminotransferases) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alanine Transaminase/*blood MH - Aspartate Aminotransferases/*blood MH - Biomarkers, Tumor/*blood MH - Female MH - Humans MH - Male MH - Middle Aged MH - Preoperative Period MH - Prognosis MH - Propensity Score MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*blood/mortality/surgery PMC - PMC8474786 OTO - NOTNLM OT - Alanine transaminase OT - Aspartate transaminase OT - Primary non-muscle-invasive bladder cancer OT - Survival prognosis COIS- The authors declare that they have no competing interests. EDAT- 2021/09/29 06:00 MHDA- 2022/02/19 06:00 PMCR- 2021/09/27 CRDT- 2021/09/28 05:34 PHST- 2021/05/18 00:00 [received] PHST- 2021/09/21 00:00 [accepted] PHST- 2021/09/28 05:34 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/09/27 00:00 [pmc-release] AID - 10.1186/s12894-021-00901-9 [pii] AID - 901 [pii] AID - 10.1186/s12894-021-00901-9 [doi] PST - epublish SO - BMC Urol. 2021 Sep 27;21(1):136. doi: 10.1186/s12894-021-00901-9. PMID- 34578700 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211001 IS - 2079-4991 (Print) IS - 2079-4991 (Electronic) IS - 2079-4991 (Linking) VI - 11 IP - 9 DP - 2021 Sep 13 TI - Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS. LID - 10.3390/nano11092384 [doi] LID - 2384 AB - Because cystoscopy is expensive and invasive, a new method of detecting non-invasive muscular bladder cancer (NMIBC) is needed. This study aims to identify potential serum protein markers for NMIBC to improve diagnosis and to find treatment approaches that avoid disease progression to a life-threatening phenotype (muscle-invasive bladder cancer, MIBC). Here, silver nanoparticles (AgNPs, 9.73 +/- 1.70 nm) as a scavenging device together with sequential window acquisition of all theoretical mass spectra (SWATH-MS) were used to quantitatively analyze the blood serum protein alterations in two NMIBC subtypes, T1 and Ta, and they were compared to normal samples (HC). NMIBC's analysis of serum samples identified three major groups of proteins, the relative content of which is different from the HC content: proteins implicated in the complement and coagulation cascade pathways and apolipoproteins. In conclusion, many biomarker proteins were identified that merit further examination to validate their useful significance and utility within the clinical management of NMIBC patients. FAU - Gomez, Benito Blanco AU - Gomez BB AD - Urology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Lopez-Cortes, Ruben AU - Lopez-Cortes R AUID- ORCID: 0000-0001-7143-0663 AD - Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Casas-Nebra, Francisco Javier AU - Casas-Nebra FJ AUID- ORCID: 0000-0002-9346-0799 AD - Urology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Vazquez-Estevez, Sergio AU - Vazquez-Estevez S AD - Oncology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Perez-Fentes, Daniel AU - Perez-Fentes D AD - Urology Division, University Clinical Hospital of Santiago de Compostela (CHUS), Servizo Galego de Saude (SERGAS), ES15706 Santiago de Compostela, Spain. FAU - Chantada-Vazquez, Maria Del Pilar AU - Chantada-Vazquez MDP AUID- ORCID: 0000-0001-8652-4961 AD - Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. AD - Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), ES15706 Santiago de Compostela, Spain. FAU - Bravo, Susana B AU - Bravo SB AUID- ORCID: 0000-0001-7615-3079 AD - Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela (CHUS), ES15706 Santiago de Compostela, Spain. FAU - Nunez, Cristina AU - Nunez C AUID- ORCID: 0000-0003-1554-9891 AD - Research Unit, Lucus Augusti University Hospital (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. LA - eng GR - CP16/00139/Instituto de Salud Carlos III/ GR - CD20/00112/Instituto de Salud Carlos III/ GR - IN607B 2021/002/Xunta de Galicia/ PT - Journal Article DEP - 20210913 PL - Switzerland TA - Nanomaterials (Basel) JT - Nanomaterials (Basel, Switzerland) JID - 101610216 PMC - PMC8467878 OTO - NOTNLM OT - SWATH-MS OT - biomarkers OT - bladder cancer (BC) OT - fingerprinting OT - protein corona (PC) OT - silver nanoparticles (AgNPs) COIS- The authors declare no conflict of interest. EDAT- 2021/09/29 06:00 MHDA- 2021/09/29 06:01 PMCR- 2021/09/13 CRDT- 2021/09/28 01:27 PHST- 2021/07/22 00:00 [received] PHST- 2021/09/07 00:00 [revised] PHST- 2021/09/09 00:00 [accepted] PHST- 2021/09/28 01:27 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2021/09/29 06:01 [medline] PHST- 2021/09/13 00:00 [pmc-release] AID - nano11092384 [pii] AID - nanomaterials-11-02384 [pii] AID - 10.3390/nano11092384 [doi] PST - epublish SO - Nanomaterials (Basel). 2021 Sep 13;11(9):2384. doi: 10.3390/nano11092384. PMID- 34576020 OWN - NLM STAT- MEDLINE DCOM- 20211021 LR - 20240226 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 18 DP - 2021 Sep 12 TI - Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma. LID - 10.3390/ijms22189856 [doi] LID - 9856 AB - BACKGROUND: The possible involvement of p53 signaling, FGFR3 expression, and FGFR3 mutation rates in the prediction of the NMIBC anti-PD-L1 treatment response needs to be clarified. The main aim of our study was to explore predictive value of p53 expression, FGFR3 expression, and its gene mutation status for the therapeutic success of anti-PD-L1 treatment in the patient-derived murine model of recurrent high-PD-L1(+) GATA3(-)/CR5/6(-) high-grade and low-grade NMIBC. METHODS: twenty lines of patient-derived xenografts (PDXs) of relapsed high-PD-L1(+) double-negative NMIBC were developed, of which 10 lines represented high-grade tumors and the other ones-low-grade bladder cancer. Acceptors of each grade-related branch received specific anti-PD-L1 antibodies. Animals' survival, tumor-doubling time, and remote metastasis were followed during the post-interventional period. PD-L1, GATA3, CR5/6, and p53 protein expressions in engrafted tumors were assessed by immunohistochemistry. The FGFR3 expression and FGFR3 mutations in codons 248 and 249 were detected by real-time polymerase chain reaction. RESULTS: The expression of p53 protein is an independent factor affecting the animals' survival time [HR = 0.036, p = 0.031] of anti-PD-L1-treated mice with low-grade high-PD-L1(+) double-negative NMIBC PDX. The FGFR3 expression and FGFR3 mutation rate have no impact on the anti-PD-L1 treatment response in the interventional groups. CONCLUSIONS: p53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)-relapsed noninvasive bladder cancer. FAU - Blinova, Ekaterina AU - Blinova E AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. AD - Department of Fundamental Medicine, National Research Nuclear University MEPHI, 31, Kashirskoe Highway, 115409 Moscow, Russia. FAU - Samishina, Elena AU - Samishina E AD - Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia. FAU - Deryabina, Olga AU - Deryabina O AD - Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia. FAU - Blinov, Dmitry AU - Blinov D AUID- ORCID: 0000-0002-8385-4356 AD - Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia. AD - Laboratory of Molecular Pharmacology, Department of Clinical Trials and Scientific Research, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela Street, 117997 Moscow, Russia. FAU - Roshchin, Dmitry AU - Roshchin D AD - Department of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia. FAU - Shich, Evgeniia AU - Shich E AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Tumutolova, Oxana AU - Tumutolova O AD - Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia. FAU - Fedoseykin, Ilya AU - Fedoseykin I AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Epishkina, Anna AU - Epishkina A AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Barakat, Haydar AU - Barakat H AUID- ORCID: 0000-0003-0911-3063 AD - Department of Propaedeutic of Dental Diseases, People's Friendship University of Russia, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia. FAU - Kaprin, Andrey AU - Kaprin A AD - Department of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia. FAU - Zhandarov, Kirill AU - Zhandarov K AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Perepechin, Dmitrij AU - Perepechin D AD - Department of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia. FAU - Merinov, Dmitrij AU - Merinov D AD - Department of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia. FAU - Brykin, Gordey AU - Brykin G AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Arutiunian, Karen AU - Arutiunian K AD - Department of Urology, Andrology and Oncology, Pirogov Russian National Research Medical University, 1 Ostrovityanova Street, 117997 Moscow, Russia. FAU - Serebrianyi, Stanislav AU - Serebrianyi S AD - Department of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia. FAU - Mirontsev, Artem AU - Mirontsev A AD - Department of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia. FAU - Kozdoba, Andrew AU - Kozdoba A AD - Department of Urology, Andrology and Oncology, Pirogov Russian National Research Medical University, 1 Ostrovityanova Street, 117997 Moscow, Russia. LA - eng GR - 2020/15/Sechenov University internal grant/ PT - Journal Article DEP - 20210912 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Tumor Suppressor Protein p53) RN - 28X28X9OKV (durvalumab) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Aged MH - Animals MH - Antibodies, Monoclonal/*therapeutic use MH - Antineoplastic Agents, Immunological/*therapeutic use MH - Carcinoma/*drug therapy/genetics/metabolism/mortality MH - Female MH - Humans MH - Male MH - Mice, SCID MH - Middle Aged MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Tumor Suppressor Protein p53/*metabolism MH - Urinary Bladder Neoplasms/*drug therapy/genetics/metabolism/mortality MH - Xenograft Model Antitumor Assays MH - Mice PMC - PMC8465184 OTO - NOTNLM OT - FGFR3 expression OT - FGFR3 mutations OT - anti-PD-L1 therapy OT - double-negative molecular subtype OT - human-derived xenograft model OT - mice OT - nonmuscular invasive bladder cancer OT - p53 expression OT - response COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/09/29 06:00 MHDA- 2023/02/25 06:00 PMCR- 2021/09/12 CRDT- 2021/09/28 01:17 PHST- 2021/08/26 00:00 [received] PHST- 2021/09/07 00:00 [revised] PHST- 2021/09/09 00:00 [accepted] PHST- 2021/09/28 01:17 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2021/09/12 00:00 [pmc-release] AID - ijms22189856 [pii] AID - ijms-22-09856 [pii] AID - 10.3390/ijms22189856 [doi] PST - epublish SO - Int J Mol Sci. 2021 Sep 12;22(18):9856. doi: 10.3390/ijms22189856. PMID- 34575374 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211001 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 18 DP - 2021 Sep 20 TI - Intravesical Prostatic Protrusion and Prognosis of Non-Muscle Invasive Bladder Cancer: Analysis of Long-Term Data over 5 Years with Machine-Learning Algorithms. LID - 10.3390/jcm10184263 [doi] LID - 4263 AB - We aim to investigate the significance of intravesical prostate protrusion (IPP) on the prognosis of non-muscle invasive bladder cancer (NMIBC) after the transurethral resection of bladder tumors (TURBT). For newly diagnosed NMIBC, we retrospectively analyzed the association between prognosis and IPP for at least a 5-year follow-up. A degree of IPP over 5 mm in a preoperative CT scan was classified as severe. The primary endpoint was recurrence-free survival, and the secondary endpoint was progression-free survival. The machine learning (ML) algorithm of a support vector machine was used for predictive model development. Of a total of 122 patients, ultimately, severe IPP was observed in 33 patients (27.0%). IPP correlated positively with age, BPH, recurrence, and prognosis. Severe IPP was significantly higher in the recurrence group and reduced in the recurrence-free survival group (p = 0.038, p = 0.032). Severe IPP independently increased the risk of intravesical recurrence by 2.6 times. The addition of IPP to the known oncological risk factors in the prediction model using the ML algorithm improved the predictability of cancer recurrence by approximately 6%, to 0.803. IPP was analyzed as a potential independent risk factor for NMIBC recurrence and progression after TURBT. This anatomical feature of the prostate could affect the recurrence of bladder tumors. FAU - Lee, Junghoon AU - Lee J AUID- ORCID: 0000-0002-8330-0329 AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. FAU - Choo, Min Soo AU - Choo MS AUID- ORCID: 0000-0002-7852-5822 AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. FAU - Yoo, Sangjun AU - Yoo S AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. FAU - Cho, Min Chul AU - Cho MC AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. FAU - Son, Hwancheol AU - Son H AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. FAU - Jeong, Hyeon AU - Jeong H AD - Department of Urology, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul 07061, Korea. LA - eng GR - 2018R1C1B5046263/Ministry of Science and ICT/ PT - Journal Article DEP - 20210920 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8468209 OTO - NOTNLM OT - benign prostatic hyperplasia OT - bladder cancer OT - intravesical prostatic protrusion OT - machine learning OT - recurrence COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/09/29 06:00 MHDA- 2021/09/29 06:01 PMCR- 2021/09/20 CRDT- 2021/09/28 01:15 PHST- 2021/08/26 00:00 [received] PHST- 2021/09/14 00:00 [revised] PHST- 2021/09/16 00:00 [accepted] PHST- 2021/09/28 01:15 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2021/09/29 06:01 [medline] PHST- 2021/09/20 00:00 [pmc-release] AID - jcm10184263 [pii] AID - jcm-10-04263 [pii] AID - 10.3390/jcm10184263 [doi] PST - epublish SO - J Clin Med. 2021 Sep 20;10(18):4263. doi: 10.3390/jcm10184263. PMID- 34575307 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211210 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 18 DP - 2021 Sep 16 TI - The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. LID - 10.3390/jcm10184197 [doi] LID - 4197 AB - BACKGROUND: The incidence of intravesical recurrence (IVR) following radical nephroureterectomy (RNU) is reported in up to 50% of patients with upper tract urothelial carcinoma (UTUC). It was suggested that preoperative diagnostic ureteroscopy (URS) could increase the IVR rate after RNU. However, the available data are often conflicting. Thus, in this systematic review and meta-analysis we sought to synthesize available data for the impact of pre-RNU URS for UTUC on IVR and other oncological outcomes. MATERIALS AND METHODS: A systematic literature search of the PubMed, Embase, and Cochrane Library databases was performed in June 2021. Cumulative analyses of hazard ratios (HRs) and their corresponding 95% confidence intervals (CI) were conducted. The primary endpoint was intravesical recurrence-free survival (IVRFS), with the secondary endpoints being cancer-specific survival (CSS), overall survival (OS), and metastasis-free survival (MFS). RESULTS: Among a total of 5489 patients included in the sixteen selected papers, 2387 (43.4%) underwent diagnostic URS before RNU and 3102 (56.6%) did not. Pre-RNU diagnostic URS was significantly associated with worse IVRFS after RNU (HR = 1.44, 95% CI: 1.29-1.61, p < 0.001) than RNU alone. However, subgroup analysis including patients without biopsy during URS revealed no significant impact of diagnostic URS on IVRFS (HR = 1.28, 95% CI: 0.90-1.80, p = 0.16). The results of other analyses showed no significant differences in CSS (HR = 0.94, p = 0.63), OS (HR: 0.94, p = 0.56), and MFS (HR: 0.91, p = 0.37) between patients who underwent URS before RNU and those who did not. CONCLUSIONS: The results of this meta-analysis confirm that diagnostic URS prior to RNU is significantly associated with worse IVRFS, albeit with no concurrent impact on the other long-term survival outcomes. Our results indicate that URS has a negative impact on IVRFS only when combined with endoscopic biopsy. Future studies are warranted to assess the role of immediate postoperative intravesical chemotherapy in patients undergoing biopsy during URS for suspected UTUC. FAU - Nowak, Lukasz AU - Nowak L AUID- ORCID: 0000-0003-4273-8196 AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kielb, Pawel AU - Kielb P AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Sut, Michal AU - Sut M AD - Department of Urology, Ministry of Interior and Administration Hospital in Gdansk, 80-104 Gdansk, Poland. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, 6004 Lucerne, Switzerland. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Mori, Keiichiro AU - Mori K AD - Comprehensive Cancer Center, Department of Urology, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090 Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo 105-8461, Japan. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Comprehensive Cancer Center, Department of Urology, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090 Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, 119146 Moscow, Russia. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Spedali Civili of Brescia, 25123 Brescia, Italy. FAU - Kaliszewski, Krzysztof AU - Kaliszewski K AUID- ORCID: 0000-0002-3291-5294 AD - Department of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AUID- ORCID: 0000-0002-5933-3753 AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Szydelko, Tomasz AU - Szydelko T AD - University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20210916 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8465597 OTO - NOTNLM OT - oncological outcomes OT - radical nephroureterectomy OT - upper tract urothelial carcinoma OT - ureteroscopy COIS- The authors declare no conflict of interest. EDAT- 2021/09/29 06:00 MHDA- 2021/09/29 06:01 PMCR- 2021/09/16 CRDT- 2021/09/28 01:15 PHST- 2021/07/16 00:00 [received] PHST- 2021/09/09 00:00 [revised] PHST- 2021/09/14 00:00 [accepted] PHST- 2021/09/28 01:15 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2021/09/29 06:01 [medline] PHST- 2021/09/16 00:00 [pmc-release] AID - jcm10184197 [pii] AID - jcm-10-04197 [pii] AID - 10.3390/jcm10184197 [doi] PST - epublish SO - J Clin Med. 2021 Sep 16;10(18):4197. doi: 10.3390/jcm10184197. PMID- 34572901 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211001 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 18 DP - 2021 Sep 17 TI - Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. LID - 10.3390/cancers13184673 [doi] LID - 4673 AB - Approximately 80% of all new bladder cancer patients are diagnosed with non-muscle invasive bladder cancer (NMIBC). However, approximately 15% of them progress to muscle-invasive bladder cancer (MIBC), for which prognosis is poor. The current study aimed to improve diagnostic accuracy associated with clinical outcomes in NMIBC patients. Nevertheless, it has been challenging to identify molecular biomarkers that accurately predict MIBC progression because this disease is complex and heterogeneous. Through integrative transcriptome profiling, we showed that high SKA3 expression is associated with poor clinical outcomes and MIBC progression. We performed RNA sequencing on human tumor tissues to identify candidate biomarkers in NMIBC. We then selected genes with prognostic significance by analyzing public datasets from multiple cohorts of bladder cancer patients. We found that SKA3 was associated with NMIBC pathophysiology and poor survival. We analyzed public single-cell RNA-sequencing (scRNA-seq) data for bladder cancer to dissect transcriptional tumor heterogeneity. SKA3 was expressed in an epithelial cell subpopulation expressing genes regulating the cell cycle. Knockdown experiments confirmed that SKA3 promotes bladder cancer cell proliferation by accelerating G2/M transition. Hence, SKA3 is a new prognostic marker for predicting NMIBC progression. Its inhibition could form part of a novel treatment lowering the probability of bladder cancer progression. FAU - You, Chaelin AU - You C AD - Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea. FAU - Kang, Keunsoo AU - Kang K AD - Department of Microbiology, College of Science & Technology, Dankook University, Cheonan 31116, Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea. FAU - Kang, Kyuho AU - Kang K AUID- ORCID: 0000-0003-3448-5336 AD - Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea. LA - eng PT - Journal Article DEP - 20210917 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8470398 OTO - NOTNLM OT - SKA3 OT - non-muscle invasive bladder cancer OT - prognostic marker OT - survival OT - transcriptomics OT - tumor progression COIS- The authors declare no conflict of interest. EDAT- 2021/09/29 06:00 MHDA- 2021/09/29 06:01 PMCR- 2021/09/17 CRDT- 2021/09/28 01:07 PHST- 2021/07/15 00:00 [received] PHST- 2021/09/03 00:00 [revised] PHST- 2021/09/14 00:00 [accepted] PHST- 2021/09/28 01:07 [entrez] PHST- 2021/09/29 06:00 [pubmed] PHST- 2021/09/29 06:01 [medline] PHST- 2021/09/17 00:00 [pmc-release] AID - cancers13184673 [pii] AID - cancers-13-04673 [pii] AID - 10.3390/cancers13184673 [doi] PST - epublish SO - Cancers (Basel). 2021 Sep 17;13(18):4673. doi: 10.3390/cancers13184673. PMID- 34568079 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210929 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression? PG - 754649 LID - 10.3389/fonc.2021.754649 [doi] LID - 754649 FAU - Ferro, Matteo AU - Ferro M AD - Department of Urology, IRCCS European Institute of Oncology (IEO), Milan, Italy. FAU - Caputo, Vincenzo Francesco AU - Caputo VF AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Barone, Biagio AU - Barone B AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Imbimbo, Ciro AU - Imbimbo C AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, IRCCS European Institute of Oncology (IEO), Milan, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. LA - eng PT - Journal Article DEP - 20210909 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8458796 OTO - NOTNLM OT - MIBC (muscle-invasive bladder cancer) OT - NMIBC (non-muscle-invasive bladder cancer) OT - bladder cancer OT - lymphocyte to monocyte ratio (LMR) OT - prognostic factor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/28 06:00 MHDA- 2021/09/28 06:01 PMCR- 2021/01/01 CRDT- 2021/09/27 06:15 PHST- 2021/08/06 00:00 [received] PHST- 2021/08/20 00:00 [accepted] PHST- 2021/09/27 06:15 [entrez] PHST- 2021/09/28 06:00 [pubmed] PHST- 2021/09/28 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.754649 [doi] PST - epublish SO - Front Oncol. 2021 Sep 9;11:754649. doi: 10.3389/fonc.2021.754649. eCollection 2021. PMID- 34567184 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 1735-5303 (Print) IS - 2345-3656 (Electronic) IS - 1735-5303 (Linking) VI - 16 IP - 4 DP - 2021 Fall TI - Significance of Vascular Endothelial Growth Factor Expression in the Bladder Urothelial Carcinoma and Its Association with Tumor Grade and Invasiveness. PG - 362-369 LID - 10.30699/IJP.20201.138671.2518 [doi] AB - BACKGROUND & OBJECTIVE: Vascular Endothelial Growth Factor (VEGF) is one of the newer molecular markers that acts as a central mediator of tumor angiogenesis and is essential for tumor growth, progression, and metastasis. So anti-angiogenic drugs can be used as anticancer therapy. Treatments with anti-VEGF (Bevacizumab) therapy have been proved to improve relapse-free survival in many tumors. Urinary bladder tumor has become emerging cancer globally among elderly individuals. So, the identification and development of novel biomarkers for effective treatment of urinary bladder carcinoma is essential. The present study aimed to investigate the immunohistochemical expression of VEGF in urothelial carcinoma of urinary bladder and to assess its association with tumor grade and muscle invasiveness. METHODS: This cross-sectional study was conducted in the Department of Pathology, Chittagong Medical College, Chattogram from September 2018 to August 2020. Fifty-six formalin-fixed paraffin-embedded tissue blocks of urinary bladder carcinoma were prepared for both histopathological and immunohistochemical examination. Each slide was evaluated by at least two pathologists. RESULTS: Weak to strong positive expression of VEGF were observed in 52 cases (92.86%). The proportion of tumors positive for VEGF expression was higher among patients with high grade and non-muscle invasive bladder carcinoma. CONCLUSION: We found that VEGF expression has a significant association with tumor grade and an inverse association with muscle invasion. These findings may be useful for selecting the subset of patients likely to respond to anti-VEGF targeted therapy. FAU - Sadaf, Anika AU - Sadaf A AD - Department of Pathology, Chittagong Medical College, Chattogram, Bangladesh. FAU - Rahman, Md Zillur AU - Rahman MZ AD - Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. FAU - Bhattacharjee, Pradip AU - Bhattacharjee P AD - Department of Pathology, Chittagong Medical College, Chattogram, Bangladesh. FAU - Ahamad, M Shahab Uddin AU - Ahamad MSU AD - Department of Pathology, Chittagong Medical College, Chattogram, Bangladesh. FAU - Nasreen, Sayeeda AU - Nasreen S AD - Department of Pathology, Chittagong Medical College, Chattogram, Bangladesh. LA - eng PT - Journal Article DEP - 20210706 PL - Iran TA - Iran J Pathol JT - Iranian journal of pathology JID - 101515128 PMC - PMC8463759 OTO - NOTNLM OT - Angiogenesis OT - Bevacizumab OT - Muscle-invasion OT - Urothelial carcinoma OT - Vascular endothelial growth factor COIS- The authors declared no conflict of interest. EDAT- 2021/09/28 06:00 MHDA- 2021/09/28 06:01 PMCR- 2021/09/01 CRDT- 2021/09/27 06:05 PHST- 2020/10/27 00:00 [received] PHST- 2021/06/10 00:00 [accepted] PHST- 2021/09/27 06:05 [entrez] PHST- 2021/09/28 06:00 [pubmed] PHST- 2021/09/28 06:01 [medline] PHST- 2021/09/01 00:00 [pmc-release] AID - 10.30699/IJP.20201.138671.2518 [doi] PST - ppublish SO - Iran J Pathol. 2021 Fall;16(4):362-369. doi: 10.30699/IJP.20201.138671.2518. Epub 2021 Jul 6. PMID- 34563358 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20220615 IS - 1531-5037 (Electronic) IS - 0022-3468 (Linking) VI - 57 IP - 7 DP - 2022 Jul TI - Bladder urothelial cell carcinoma as a rare cause of haematuria in children: Our experience and review of current literature. PG - 1409-1413 LID - S0022-3468(21)00600-X [pii] LID - 10.1016/j.jpedsurg.2021.09.007 [doi] AB - OBJECTIVES: To report our experience of bladder urothelial cell carcinoma (UCC) in children and review contemporary management and follow-up of paediatric UCC. PATIENTS AND METHODS: Between 2004 and 2020, five patients (4 boys and 1 girl) were managed at our centre for urothelial cell carcinoma of the bladder. Data was collected by note review for age at presentation, symptoms, clinical findings, investigations, treatment and follow-up. RESULTS: All five patients presented with visible haematuria, two had dysuria and one had suprapubic pain. Bladder ultrasound scan (USS) showed exophytic bladder lesions in only 4 patients. Definitive diagnosis and treatment were achieved by cystoscopic excision. Four patients had PUNLMP while one had Grade 3 pTa UCC of the bladder which required further cystoscopic excision and intravesical Mitomycin C (MMC) instillation. All patients were followed up clinically, with renal USS and cystoscopy. We have observed recurrence of the carcinoma in two patients requiring further cystoscopic excision and intravesical MMC. CONCLUSION: Bladder urothelial cell carcinoma in children should be suspected in children presenting with haematuria. If renal USS is normal, cystoscopy should be considered for diagnosis and treatment. Compared to adults, children with bladder UCC often have favourable histopathology and prognosis. Close follow-up is necessary with renal USS and cystoscopy to detect recurrence even in PUNLMP. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - ElSharnoby, Osama AU - ElSharnoby O AD - Paediatric Surgery Registrar at Queens Medical Centre, Nottingham University Hospitals, NHS. Derby Road, Nottingham NG71RU, United Kingdom. Electronic address: usama_hamdi@hotmail.com. FAU - Fraser, Nia AU - Fraser N AD - Paediatric Urology Consultant at Queens Medical Centre, Nottingham University Hospitals, NHS. Derby Road, Nottingham NG71RU, United Kingdom. FAU - Williams, Alun AU - Williams A AD - Paediatric Urology Consultant at Queens Medical Centre, Nottingham University Hospitals, NHS. Derby Road, Nottingham NG71RU, United Kingdom. FAU - Scriven, Sharon AU - Scriven S AD - Urology Consultant at Nottingham City Hospital, Nottingham University Hospitals, NHS. Hucknall Road, Nottingham NG51PB, United Kingdom. FAU - Shenoy, Manoj AU - Shenoy M AD - Paediatric Urology Consultant at Queens Medical Centre, Nottingham University Hospitals, NHS. Derby Road, Nottingham NG71RU, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20210917 PL - United States TA - J Pediatr Surg JT - Journal of pediatric surgery JID - 0052631 SB - IM MH - Adult MH - *Carcinoma, Transitional Cell/complications/diagnosis/pathology MH - Child MH - Cystoscopy MH - Female MH - Hematuria/etiology MH - Humans MH - Male MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/complications/diagnosis/therapy MH - Urothelium/pathology OTO - NOTNLM OT - Bladder cancer paediatric OT - Epithelial tumour of the bladder pediatric OT - Papillary urothelial neoplasia of low malignant potential children OT - Papillary urothelial neoplasm case report and review of literature OT - Transitional cell carcinoma of the bladder OT - Urothelial cell carcinoma children COIS- Declarations of Competing Interest None EDAT- 2021/09/27 06:00 MHDA- 2022/06/16 06:00 CRDT- 2021/09/26 20:34 PHST- 2021/03/30 00:00 [received] PHST- 2021/08/30 00:00 [revised] PHST- 2021/09/06 00:00 [accepted] PHST- 2021/09/27 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2021/09/26 20:34 [entrez] AID - S0022-3468(21)00600-X [pii] AID - 10.1016/j.jpedsurg.2021.09.007 [doi] PST - ppublish SO - J Pediatr Surg. 2022 Jul;57(7):1409-1413. doi: 10.1016/j.jpedsurg.2021.09.007. Epub 2021 Sep 17. PMID- 34561545 OWN - NLM STAT- MEDLINE DCOM- 20211230 LR - 20211230 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Sep 24 TI - Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy. PG - 19059 LID - 10.1038/s41598-021-98696-0 [doi] LID - 19059 AB - Tumor multifocality and location are prognostic factors for upper tract urothelial carcinoma (UTUC). However, confounding effects can appear when these two factors are analyzed together. Therefore, we aimed to investigate the impact of tumor distribution on the outcomes of multifocal UTUC after radical nephroureterectomy. From the 2780 UTUC patients in the Taiwan UTUC Collaboration Group, 685 UTUC cases with multifocal tumors (defined as more than one tumor lesion in unilateral upper urinary tract) were retrospectively included and divided into three groups: multiple renal pelvic tumors, multiple ureteral tumors, and synchronous renal pelvic and ureteral tumors included 164, 152, and 369 patients, respectively. We found the prevalence of carcinoma in situ was the highest in the synchronous group. In multivariate survival analyses, tumor distribution showed no difference in cancer-specific and disease-free survival, but there was a significant difference in bladder recurrence-free survival. The synchronous group had the highest bladder recurrence rate. In summary, tumor distribution did not influence the cancer-specific outcomes of multifocal UTUC, but synchronous lesions led to a higher rate of bladder recurrence than multiple renal pelvic tumors. We believe that the distribution of tumors reflects the degree of malignant involvement within the urinary tract, but has little significance for survival or disease progression. CI - (c) 2021. The Author(s). FAU - Sheu, Zai-Lin AU - Sheu ZL AD - School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Huang, Chi-Ping AU - Huang CP AD - Department of Urology, China Medical University and Hospital, Taichung, Taiwan. FAU - Chang, Chao-Hsiang AU - Chang CH AD - Department of Urology, China Medical University and Hospital, Taichung, Taiwan. FAU - Chen, Chung-Hsin AU - Chen CH AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Hong, Jian-Hua AU - Hong JH AD - Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. FAU - Weng, Han-Yu AU - Weng HY AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Tai, Ta-Yao AU - Tai TY AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chung, Shiu-Dong AU - Chung SD AD - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Taipei, Taiwan. FAU - Lo, Chi-Wen AU - Lo CW AD - Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. AD - Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan. FAU - Hsueh, Thomas Y AU - Hsueh TY AD - Division of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei, Taiwan. AD - Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Tsai, Yao-Chou AU - Tsai YC AD - Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan. AD - Department of Urology, Taipei Medical University Hospital, Taipei, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. FAU - Jiang, Yuan-Hong AU - Jiang YH AD - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan. FAU - Chiang, Bing-Juin AU - Chiang BJ AD - College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan. AD - Department of Urology, Cardinal Tien Hospital, New Taipei City, Taiwan. AD - Department of Life Science, College of Science, National Taiwan Normal University, Taipei, Taiwan. FAU - Chen, Yung-Tai AU - Chen YT AD - Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan. FAU - Lin, Jen-Tai AU - Lin JT AD - Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Lin, Wei-Yu AU - Lin WY AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan. AD - Chang Gung University of Science and Technology, Chia-Yi, Taiwan. AD - Department of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Jou, Yeong-Chin AU - Jou YC AD - Department of Urology, Ditmanson Medical Foundation, Chiayi Christian Hospital, Chiayi, Taiwan. AD - Department of Health and Nutrition Biotechnology, Asian University, Taichung, Taiwan. FAU - Tseng, Jen-Shu AU - Tseng JS AD - Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan. FAU - Wu, Chia-Chang AU - Wu CC AD - Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. AD - Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. AD - TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Yeh, Hsin-Chih AU - Yeh HC AD - Department of Urology, Kaohsiung Medical University Hospital, No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan. patrick1201.tw@yahoo.com.tw. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. patrick1201.tw@yahoo.com.tw. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. patrick1201.tw@yahoo.com.tw. AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. patrick1201.tw@yahoo.com.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210924 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - *Neoplasm Recurrence, Local MH - Nephroureterectomy/*methods MH - Survival Analysis MH - Taiwan MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC8463529 COIS- The authors declare no competing interests. EDAT- 2021/09/26 06:00 MHDA- 2021/12/31 06:00 PMCR- 2021/09/24 CRDT- 2021/09/25 06:14 PHST- 2021/06/19 00:00 [received] PHST- 2021/09/14 00:00 [accepted] PHST- 2021/09/25 06:14 [entrez] PHST- 2021/09/26 06:00 [pubmed] PHST- 2021/12/31 06:00 [medline] PHST- 2021/09/24 00:00 [pmc-release] AID - 10.1038/s41598-021-98696-0 [pii] AID - 98696 [pii] AID - 10.1038/s41598-021-98696-0 [doi] PST - epublish SO - Sci Rep. 2021 Sep 24;11(1):19059. doi: 10.1038/s41598-021-98696-0. PMID- 34561265 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20220531 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 9 DP - 2021 Sep 24 TI - Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial. PG - e055782 LID - 10.1136/bmjopen-2021-055782 [doi] LID - e055782 AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) accounts for about 75% of newly diagnosed bladder cancers. The treatment for NMIBC involves surgical removal of the tumour followed by 6 weekly instillations of immunotherapy or chemotherapy directly into the bladder (ie, intravesical therapy). NMIBC has a high rate of recurrence (31%-78%) and progression (15%). Moreover, bladder cancer and its treatment may affect patient functioning and quality of life. Exercise is a safe and effective intervention for many patient with cancer groups, however, no studies have examined exercise during intravesical therapy for NMIBC. The primary objective of the Bladder cancer and exeRcise trAining during intraVesical thErapy (BRAVE) trial is to examine the safety and feasibility of an exercise intervention in patients with bladder cancer undergoing intravesical therapy. The secondary objectives are to investigate the preliminary efficacy of exercise on health-related fitness and patient-reported outcomes; examine the social cognitive predictors of exercise adherence; and explore the potential effects of exercise on tumour recurrence and progression. METHODS AND ANALYSIS: BRAVE is a phase II randomised controlled trial that aims to include 66 patients with NMIBC scheduled to receive intravesical therapy. Participants will be randomly assigned to the exercise intervention or usual care. The intervention consists of three supervised, high-intensity interval training sessions per week for 12 weeks. Feasibility will be evaluated by eligibility, recruitment, adherence and attrition rates. Preliminary efficacy will focus on changes in cardiorespiratory fitness and patient-reported outcomes from baseline (prior to intravesical therapy) to pre-cystoscopy (3 months). Cancer outcomes will be tracked at 3 months, and 1-year follow-up by cystoscopy. Analysis of covariance will compare between-group differences at post-intervention (pre-cystoscopy) for all health-related fitness and patient-reported outcomes. ETHICS AND DISSEMINATION: The study was approved by the Health Research Ethics Board of Alberta-Cancer Committee (#20-0184). Dissemination will include publication and presentations at scientific conferences and public channels. TRIAL REGISTRATION NUMBER: NCT04593862; Pre-results. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Arthuso, Fernanda Z AU - Arthuso FZ AUID- ORCID: 0000-0003-1262-9036 AD - Faculty of Kinesiology, Sport, and Recreation, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada. FAU - Fairey, Adrian S AU - Fairey AS AD - Division of Urology, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. FAU - Boule, Normand G AU - Boule NG AD - Faculty of Kinesiology, Sport, and Recreation, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada. FAU - Courneya, Kerry S AU - Courneya KS AD - Faculty of Kinesiology, Sport, and Recreation, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada kerry.courneya@ualberta.ca. LA - eng SI - ClinicalTrials.gov/NCT04593862 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210924 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Administration, Intravesical MH - Clinical Trials, Phase II as Topic MH - Exercise MH - Humans MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC8475156 OTO - NOTNLM OT - bladder disorders OT - clinical trials OT - oncology COIS- Competing interests: None declared. EDAT- 2021/09/26 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/09/24 CRDT- 2021/09/25 05:35 PHST- 2021/09/25 05:35 [entrez] PHST- 2021/09/26 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/09/24 00:00 [pmc-release] AID - bmjopen-2021-055782 [pii] AID - 10.1136/bmjopen-2021-055782 [doi] PST - epublish SO - BMJ Open. 2021 Sep 24;11(9):e055782. doi: 10.1136/bmjopen-2021-055782. PMID- 34552102 OWN - NLM STAT- MEDLINE DCOM- 20211217 LR - 20211217 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Sep 22 TI - Prognostic value of prostate volume in non-muscle invasive bladder cancer. PG - 18784 LID - 10.1038/s41598-021-98045-1 [doi] LID - 18784 AB - There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with 30 mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52 months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, p = 0.002). Further, cox-regression analysis showed that tumor size (HR = 1.292 p < 0.001), multifocal tumor (HR = 1.993, p < 0.001), adjuvant intravesical therapy (chemotherapy: HR = 0.580, p = 0.037 and bacillus Calmette-Guerin: HR = 0.542, p = 0.004) and prostate volume (HR = 2.326, p < 0.001) were significant predictors of recurrence-free survival. Prostate volume (HR = 2.886, p = 0.014) was also associated with PFS with age (HR = 1.043, p = 0.044) and tumor grade (HR = 3.822, p = 0.013). We conclude higher prostate volume is associated with worse recurrence and progression-free survival in non-muscle invasive bladder cancer. CI - (c) 2021. The Author(s). FAU - Ham, Won Sik AU - Ham WS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea. FAU - Park, Jee Soo AU - Park JS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea. AD - Department of Urology, Sorokdo National Hospital, Goheung, South Korea. FAU - Jang, Won Sik AU - Jang WS AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea. FAU - Choi, Young Deuk AU - Choi YD AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea. FAU - Kim, Jongchan AU - Kim J AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea. lumpakcef@yuhs.ac. AD - Department of Urology, Yongin Severance Hospital, Yonsei University Health System, 363, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do, 16995, South Korea. lumpakcef@yuhs.ac. LA - eng PT - Journal Article DEP - 20210922 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Humans MH - Male MH - Middle Aged MH - Organ Size MH - Prognosis MH - Propensity Score MH - Prostate/diagnostic imaging/*pathology MH - Prostatic Hyperplasia/mortality/pathology MH - Survival Analysis MH - Tomography, X-Ray Computed MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/mortality/pathology PMC - PMC8458356 COIS- The authors declare no competing interests. EDAT- 2021/09/24 06:00 MHDA- 2021/12/18 06:00 PMCR- 2021/09/22 CRDT- 2021/09/23 06:11 PHST- 2021/06/23 00:00 [received] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/23 06:11 [entrez] PHST- 2021/09/24 06:00 [pubmed] PHST- 2021/12/18 06:00 [medline] PHST- 2021/09/22 00:00 [pmc-release] AID - 10.1038/s41598-021-98045-1 [pii] AID - 98045 [pii] AID - 10.1038/s41598-021-98045-1 [doi] PST - epublish SO - Sci Rep. 2021 Sep 22;11(1):18784. doi: 10.1038/s41598-021-98045-1. PMID- 34548821 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1179-1349 (Print) IS - 1179-1349 (Electronic) IS - 1179-1349 (Linking) VI - 13 DP - 2021 TI - Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort. PG - 801-811 LID - 10.2147/CLEP.S319620 [doi] AB - PURPOSE: Circulating 25-hydroxyvitamin D (25(OH)D) is inversely associated with overall cancer mortality and selected cancers, while for urothelial bladder cancer (BC) this relationship is unclear. We aimed to examine the association between 25(OH)D and BC mortality. MATERIALS AND METHODS: We used prediagnostic serum from 378 BC cases within the population-based Janus Cohort. Cox regression models estimated hazard ratios (HRs), with 95% confidence intervals (CIs), for the association between 25(OH)D and BC-specific and all-cause mortality. Restricted cubic splines were assessed to examine non-linear risk associations. Analyses were stratified by tumor invasiveness (non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC)). Additionally, the association between 25(OH)D and all-cause mortality was assessed for 378 cancer-free matched controls. RESULTS: 25(OH)D deficiency (<50 nmol/L) was associated with higher BC-specific mortality (HR 1.87, 95% CI 1.10-3.20), when compared with insufficient levels (50-74 nmol/L). Stratification by tumor invasiveness revealed that this result was evident for NMIBC only, both with respect to BC-specific mortality (HR 2.84, 95% CI 1.14-7.12) and all-cause mortality (HR 1.97, 95% CI 1.06-3.65). No association between 25(OH)D levels and all-cause mortality was found in cancer-free controls. CONCLUSION: 25(OH)D deficiency (<50 nmol/L) prior to a BC diagnosis was associated with increased risk of BC-specific mortality, when compared to insufficient levels (50-74 nmol/L). The results were evident among NMIBC patients only, suggesting a more critical role of vitamin D deficiency in an early stage of the disease. CI - (c) 2021 Hektoen et al. FAU - Hektoen, Helga H AU - Hektoen HH AUID- ORCID: 0000-0002-2002-0944 AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. FAU - Gislefoss, Randi E AU - Gislefoss RE AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. FAU - Stenehjem, Jo S AU - Stenehjem JS AUID- ORCID: 0000-0002-1964-5410 AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. FAU - Langseth, Hilde AU - Langseth H AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. FAU - Axcrona, Karol AU - Axcrona K AD - Department of Urology, Akershus University Hospital, Lorenskog, Norway. FAU - Mondul, Alison M AU - Mondul AM AD - Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. FAU - Robsahm, Trude E AU - Robsahm TE AUID- ORCID: 0000-0002-1652-7734 AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. FAU - Andreassen, Bettina K AU - Andreassen BK AD - Department of Research, Cancer Registry of Norway, Oslo, Norway. LA - eng PT - Journal Article DEP - 20210914 PL - New Zealand TA - Clin Epidemiol JT - Clinical epidemiology JID - 101531700 PMC - PMC8449552 OTO - NOTNLM OT - cancer OT - cancer death OT - mortality OT - prospective study OT - vitamin D COIS- Dr Jo S Stenehjem reports grants from Research Council of Norway, outside the submitted work. The authors report no conflicts of interest in this work. EDAT- 2021/09/23 06:00 MHDA- 2021/09/23 06:01 PMCR- 2021/09/14 CRDT- 2021/09/22 07:08 PHST- 2021/05/13 00:00 [received] PHST- 2021/07/12 00:00 [accepted] PHST- 2021/09/22 07:08 [entrez] PHST- 2021/09/23 06:00 [pubmed] PHST- 2021/09/23 06:01 [medline] PHST- 2021/09/14 00:00 [pmc-release] AID - 319620 [pii] AID - 10.2147/CLEP.S319620 [doi] PST - epublish SO - Clin Epidemiol. 2021 Sep 14;13:801-811. doi: 10.2147/CLEP.S319620. eCollection 2021. PMID- 34547923 OWN - NLM STAT- MEDLINE DCOM- 20220126 LR - 20220126 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 207 IP - 2 DP - 2022 Feb TI - Factors Associated with Re-Resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level. PG - 314-323 LID - 10.1097/JU.0000000000002229 [doi] AB - PURPOSE: Prior research has shown that concordance with the guideline-endorsed recommendation to re-resect patients diagnosed with primary T1 bladder cancer (BC) is suboptimal. Therefore, the aim of this population-based study was to identify factors associated with re-resection in T1 BC. MATERIALS AND METHODS: We linked province-wide BC pathology reports (January 2001 to December 2015) with health administrative data sources to derive an incident cohort of patients diagnosed with T1 BC in the province of Ontario, Canada. Re-resection was ascertained by a billing claim for transurethral resection within 2 to 8 weeks after the initial resection, accounting for system-related wait times. Multivariable logistic regression analysis accounting for the clustered nature of the data was used to identify various patient-level and surgeon-level factors associated with re-resection. P values <0.05 were considered statistically significant (2-sided). RESULTS: We identified 7,373 patients who fulfilled the inclusion criteria. Overall, 1,678 patients (23%) underwent re-resection. Patients with a more aggressive tumor profile and individuals without sufficiently sampled muscularis propria as well as younger, healthier and socioeconomically advantaged patients were more likely to receive re-resection (all p <0.05). In addition, more senior, lower volume and male surgeons were less likely to perform re-resection for their patients (all p <0.05). CONCLUSIONS: Only a minority of all patients received re-resection within 2 to 8 weeks after initial resection. To improve the access to care for potentially underserved patients, we suggest specific knowledge translation/exchange interventions that also include equity aspects besides further promotion of evidence-based instead of eminence-based medicine. FAU - Wettstein, Marian S AU - Wettstein MS AUID- ORCID: 0000-0003-1378-3625 AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Baxter, Nancy N AU - Baxter NN AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. FAU - Sutradhar, Rinku AU - Sutradhar R AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. FAU - Mamdani, Muhammad AU - Mamdani M AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. FAU - Song, Pham AU - Song P AD - ICES, Toronto, Ontario, Canada. FAU - Qadri, Syed R AU - Qadri SR AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Bhalla, Girima AU - Bhalla G AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Li, Kathy AU - Li K AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Liu, Ning AU - Liu N AD - ICES, Toronto, Ontario, Canada. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20210922 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/diagnosis/epidemiology/pathology/*surgery MH - Cystectomy/standards/*statistics & numerical data MH - Female MH - Humans MH - Male MH - Medical Oncology/standards MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/pathology/prevention & control/*surgery MH - Neoplasm Staging MH - Ontario/epidemiology MH - Practice Guidelines as Topic MH - Reoperation/standards/*statistics & numerical data MH - Retrospective Studies MH - Time Factors MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/epidemiology/pathology/*surgery MH - Urology/standards OTO - NOTNLM OT - endoscopy OT - urinary bladder neoplasms EDAT- 2021/09/23 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/09/22 05:35 PHST- 2021/09/23 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/09/22 05:35 [entrez] AID - 10.1097/JU.0000000000002229 [doi] PST - ppublish SO - J Urol. 2022 Feb;207(2):314-323. doi: 10.1097/JU.0000000000002229. Epub 2021 Sep 22. PMID- 34547921 OWN - NLM STAT- MEDLINE DCOM- 20220126 LR - 20220126 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 207 IP - 2 DP - 2022 Feb TI - Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy. PG - 284-292 LID - 10.1097/JU.0000000000002211 [doi] AB - PURPOSE: The incidence and risk factors for metachronous upper tract urothelial carcinoma (UTUC) following radical cystectomy (RC) remain incompletely defined, which has limited the ability to individualize postoperative surveillance. MATERIALS AND METHODS: A retrospective review of 2 institutional registries was performed to identify patients undergoing RC for urothelial carcinoma. Multivariable Cox proportional hazard models for metachronous post-RC UTUC were developed in one institutional data set and validated in the second institutional data set. A post-RC UTUC risk score was then developed from these models. RESULTS: A total of 3,170 RC patients were included from the training cohort and 959 RC patients from the validation cohort. At a median followup after RC of 4.6 years (IQR 2.1-8.7), 167 patients were diagnosed with UTUC. On multivariable analysis in the training cohort, risk factors for metachronous UTUC were the presence of positive urothelial margin (HR 2.60, p <0.01), history of bacillus Calmette-Guerin treatment prior to RC (HR 2.20, p <0.01), carcinoma in situ at RC (HR 2.01, p <0.01) and pre-RC hydronephrosis (HR 1.48, p=0.04). These factors had similar discriminative capacity in the training and validation cohorts (C-statistic 0.71 and 0.73, respectively). A UTUC risk score was developed with these variables which stratified patients into low (0 points), intermediate (1-3 points), and high risk (4+ points) for post-RC UTUC, with respective 5-year UTUC-free survivals of 99%, 96%, 89% in the training cohort and 98%, 96%, and 91% in the validation cohort. CONCLUSIONS: We developed and validated a risk score for post-RC UTUC that may optimize UTUC surveillance protocols after RC. FAU - Miest, T AU - Miest T AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Khanna, A AU - Khanna A AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Sharma, V AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Hensley, P J AU - Hensley PJ AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Campbell, R AU - Campbell R AD - Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Thapa, P AU - Thapa P AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Zganjar, A AU - Zganjar A AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tollefson, M K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Thompson, R H AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Frank, I AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Karnes, R J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Potretzke, A AU - Potretzke A AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Matin, S F AU - Matin SF AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Murthy, P B AU - Murthy PB AD - Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Haber, G P AU - Haber GP AD - Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Lee, B AU - Lee B AD - Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Boorjian, S A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. LA - eng PT - Journal Article PT - Validation Study DEP - 20210922 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2022 Feb;207(2):291-292. doi: 10.1097/JU.0000000000002211.01. PMID: 34814737 MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/therapy MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Kidney Neoplasms/diagnosis/*epidemiology MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasms, Second Primary/diagnosis/*epidemiology MH - Postoperative Period MH - Registries/statistics & numerical data MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Ureteral Neoplasms/diagnosis/*epidemiology MH - Ureteroscopy/statistics & numerical data MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - carcinoma, transitional cell OT - cystectomy OT - recurrence OT - ureteral neoplasms OT - urinary bladder neoplasms EDAT- 2021/09/23 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/09/22 05:35 PHST- 2021/09/23 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/09/22 05:35 [entrez] AID - 10.1097/JU.0000000000002211 [doi] PST - ppublish SO - J Urol. 2022 Feb;207(2):284-292. doi: 10.1097/JU.0000000000002211. Epub 2021 Sep 22. PMID- 34541363 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2424-810X (Electronic) IS - 2382-6533 (Print) IS - 2382-6533 (Linking) VI - 7 IP - 4 DP - 2021 Aug 26 TI - Immune escape mechanisms and immunotherapy of urothelial bladder cancer. PG - 485-500 AB - BACKGROUND AND AIM: Urothelial bladder cancer (UBC) is a common malignant tumor of the urogenital system with a high rate of recurrence. Due to the sophisticated and largely unexplored mechanisms of tumorigenesis of UBC, the classical therapeutic approaches including transurethral resection and radical cystectomy combined with chemotherapy have remained unchanged for decades. However, with increasingly in-depth understanding of the microenvironment and the composition of tumor-infiltrating lymphocytes of UBC, novel immunotherapeutic strategies have been developed. Bacillus Calmette-Guerin (BCG) therapy, immune checkpoint blockades, adoptive T cell immunotherapy, dendritic cell (DC) vaccines, etc., have all been intensively investigated as immunotherapies for UBC. This review will discuss the recent progress in immune escape mechanisms and immunotherapy of UBC. METHODS: Based on a comprehensive search of the PubMed and ClinicalTrials.gov database, this review included the literature reporting the immune escape mechanisms of UBC and clinical trials assessing the effect of immunotherapeutic strategies on tumor or immune cells in UBC patients published in English between 1999 and 2020. RESULTS: Immune surveillance, immune balance, and immune escape are the three major processes that occur during UBC tumorigenesis. First, the role of immunosuppressive cells, immunosuppressive molecules, immunosuppressive signaling molecules, and DCs in tumor microenvironment is introduced elaborately in the immune escape mechanisms of UBC section. In addition, recent progress of immunotherapies including BCG, checkpoint inhibitors, cytokines, adoptive T cell immunotherapy, DCs, and macrophages on UBC patients are summarized in detail. Finally, the need to explore the mechanisms, molecular characteristics and immune landscape during UBC tumorigenesis and development of novel and robust immunotherapies for UBC are also proposed and discussed. CONCLUSION: At present, BCG and immune checkpoint blockades have been approved by the US Food and Drug Administration for the treatment of UBC patients and have achieved encouraging therapeutic results, expanding the traditional chemotherapy and surgery-based treatment for UBC. RELEVANCE FOR PATIENTS: Immunotherapy has achieved desirable results in the treatment of UBC, which not only improve the overall survival but also reduce the recurrence rate and the occurrence of treatment-related adverse events of UBC patients. In addition, the indicators to predict the effectiveness and novel therapy strategies, such as combination regimen of checkpoint inhibitor with checkpoint inhibitor or chemotherapy, should be further studied. CI - Copyright: (c) Whioce Publishing Pte. Ltd. FAU - Yang, Zhao AU - Yang Z AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. AD - Department of Bioscience, College of Life Science, Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin of Xinjiang Production and Construction Corps, Tarim University, Alar 843300, Xinjiang, China. FAU - Xu, Yinyan AU - Xu Y AD - Department of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. FAU - Bi, Ying AU - Bi Y AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Zhang, Nan AU - Zhang N AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wang, Haifeng AU - Wang H AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China. FAU - Xing, Tianying AU - Xing T AD - Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. FAU - Bai, Suhang AU - Bai S AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Shen, Zongyi AU - Shen Z AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Naz, Faiza AU - Naz F AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Zhang, Zichen AU - Zhang Z AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Yin, Liqi AU - Yin L AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Shi, Mengran AU - Shi M AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wang, Luyao AU - Wang L AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wang, Lei AU - Wang L AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wang, Shihui AU - Wang S AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Xu, Lida AU - Xu L AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Su, Xin AU - Su X AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wu, Song AU - Wu S AD - Department of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China. FAU - Yu, Changyuan AU - Yu C AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. LA - eng PT - Journal Article PT - Review DEP - 20210730 PL - Singapore TA - J Clin Transl Res JT - Journal of clinical and translational research JID - 101667205 PMC - PMC8445627 OTO - NOTNLM OT - immune cells OT - immune checkpoints OT - immune escape OT - immunotherapy OT - urothelial bladder cancer COIS- All authors declare no conflict of interest. EDAT- 2021/09/21 06:00 MHDA- 2021/09/21 06:01 PMCR- 2021/07/30 CRDT- 2021/09/20 06:19 PHST- 2020/11/12 00:00 [received] PHST- 2021/05/12 00:00 [revised] PHST- 2021/06/25 00:00 [accepted] PHST- 2021/09/20 06:19 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/21 06:01 [medline] PHST- 2021/07/30 00:00 [pmc-release] AID - jctres.07.202104.009 [pii] PST - epublish SO - J Clin Transl Res. 2021 Jul 30;7(4):485-500. eCollection 2021 Aug 26. PMID- 34539184 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1178-7074 (Print) IS - 1178-7074 (Electronic) IS - 1178-7074 (Linking) VI - 14 DP - 2021 TI - STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer. PG - 5505-5516 LID - 10.2147/IJGM.S329723 [doi] AB - BACKGROUND: Stanniocalcin-1 (STC1) is a well-studied oncogene that promotes different types of cancer progression. However, the expression status of STC1, the values of STC1 on prognosis, and its immune characteristic in bladder cancer (BLCA) have not been well examined. METHODS: The expression of STC1 and its clinicopathological as well as immune characteristics in BLCA samples were firstly identified in The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) performed on the tissue microarray (TMA) slide was further used to validate the expression of STC1 and its relationship with immune features in 16 non-muscle invasive bladder cancer (NMIBC) samples and 42 muscle invasive bladder cancer (MIBC) samples. RESULTS: The expression of STC1 was upregulated in higher stage BLCA. High STC1 expression also predicted poor prognosis in BLCA. Subsequently, the TMA validated the expression and prognostic value of STC1 in BLCA. Bioinformatics analysis demonstrated that STC1 and common immune checkpoints as well as immune markers of various immune cells were positively correlated in TCGA. In addition, IHC data from the TMA further validated that tumor cells with higher STC1 level tended to express higher PDL1 as well as increased infiltration of CD3+ T cells. CONCLUSION: To our knowledge, this is the first comprehensive study that investigates the clinical and immune characteristics of STC1 in BLCA. It may provide new insight into the function of STC1 in regulating tumor immune microenvironment. Further studies are warranted to uncover the potential mechanisms that mediate STC1 expression and tumor immunity in BLCA. CI - (c) 2021 Sun et al. FAU - Sun, Jiale AU - Sun J AUID- ORCID: 0000-0002-8040-6267 AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - Wei, Xuedong AU - Wei X AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - You, Jiawei AU - You J AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - Yue, Wenchang AU - Yue W AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - Ouyang, Jun AU - Ouyang J AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - Ling, Zhixin AU - Ling Z AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. FAU - Hou, Jianquan AU - Hou J AD - Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. AD - Department of Urology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20210911 PL - New Zealand TA - Int J Gen Med JT - International journal of general medicine JID - 101515487 PMC - PMC8445105 OTO - NOTNLM OT - STC1 OT - bladder cancer OT - immune characteristics OT - immune checkpoints OT - tissue microarray COIS- The authors report no conflicts of interest in this work. EDAT- 2021/09/21 06:00 MHDA- 2021/09/21 06:01 PMCR- 2021/09/11 CRDT- 2021/09/20 05:57 PHST- 2021/07/21 00:00 [received] PHST- 2021/09/01 00:00 [accepted] PHST- 2021/09/20 05:57 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/21 06:01 [medline] PHST- 2021/09/11 00:00 [pmc-release] AID - 329723 [pii] AID - 10.2147/IJGM.S329723 [doi] PST - epublish SO - Int J Gen Med. 2021 Sep 11;14:5505-5516. doi: 10.2147/IJGM.S329723. eCollection 2021. PMID- 34535354 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20220420 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 4 DP - 2022 Apr TI - Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis. PG - 163.e1-163.e9 LID - S1078-1439(21)00380-X [pii] LID - 10.1016/j.urolonc.2021.08.017 [doi] AB - INTRODUCTION: There is a need for sensitive and specific biomarkers for detecting recurrences in patients with non-muscle invasive bladder cancer (NMIBC) on surveillance. Xpert bladder cancer (BC) monitor is the latest rapid in vitro qualitative test that detects expression of 5 mRNAs using a GeneXpert instrument. The primary aim of this review was to systematically review and pool the data regarding the diagnostic performance of Xpert BC in patients with NMIBC. METHODS: Systematic literature search using 4 electronic databases (PubMed, EMbase, Scopus and Web of science) was performed. Pooled sensitivity, specificity and diagnostic odds ratio (DOR) were estimated using DerSimonian-Laird random-effects model. Standard Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines were followed and the study protocol was registered with PROSPERO (CRD42021249762). RESULTS: In this review, 11 prospective studies with 2,896 patients were included. Pooled sensitivity and specificity for Xpert BC were 73% (95% confidence interval (CI) 65%-80%) and 77% (95% CI 69%-84%) respectively. Area under curve (AUC) for Xpert BC monitor was 0.81 (0.78-0.84) respectively. Subgroup analysis from 7 studies for patients with high-grade recurrence revealed sensitivity, specificity and AUC of 0.86 (0.77-0.92), 0.78 (0.75-0.81) and 0.87 (0.84-0.90) respectively. Similar analysis for patients with low-grade recurrence revealed sensitivity, specificity and AUC of 0.58 (0.47-0.68), 0.79 (0.75-0.82) and 0.79 (0.75-0.82) respectively. CONCLUSION: Xpert BC monitor has overall acceptable diagnostic accuracy. Sensitivity is higher for high-grade disease for detecting recurrences in patients with NMIBC on surveillance. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Sharma, Gopal AU - Sharma G AD - Department of Urology, PGIMER, Chandigarh, India. Electronic address: gopal.26669192@gmail.com. FAU - Sharma, Abhay AU - Sharma A AD - University College of Medical Sciences, New Delhi, India. FAU - Krishna, Murali AU - Krishna M AD - Department of Urology, PGIMER, Chandigarh, India. FAU - Devana, Sudheer Kumar AU - Devana SK AD - Department of Urology, PGIMER, Chandigarh, India. FAU - Singh, Shrawan Kumar AU - Singh SK AD - Department of Urology, PGIMER, Chandigarh, India. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20210914 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Urol Oncol. 2022 Feb;40(2):68-69. doi: 10.1016/j.urolonc.2021.10.001. PMID: 34848123 MH - Area Under Curve MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/diagnosis MH - Prospective Studies MH - Recurrence MH - Sensitivity and Specificity MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Diagnostic accuracy OT - Systematic review OT - Xpert EDAT- 2021/09/19 06:00 MHDA- 2022/04/21 06:00 CRDT- 2021/09/18 05:35 PHST- 2021/06/08 00:00 [received] PHST- 2021/08/04 00:00 [revised] PHST- 2021/08/16 00:00 [accepted] PHST- 2021/09/19 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2021/09/18 05:35 [entrez] AID - S1078-1439(21)00380-X [pii] AID - 10.1016/j.urolonc.2021.08.017 [doi] PST - ppublish SO - Urol Oncol. 2022 Apr;40(4):163.e1-163.e9. doi: 10.1016/j.urolonc.2021.08.017. Epub 2021 Sep 14. PMID- 34525114 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 9 DP - 2021 TI - Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer. PG - e0257195 LID - 10.1371/journal.pone.0257195 [doi] LID - e0257195 AB - Fibroblast activation protein-alpha (FAP) is a transmembrane peptidase and a surrogate marker for cancer-associated fibroblasts (CAFs). FAP has been linked to worse prognosis and therapy resistance in several cancers. We hypothesised that FAP might have a prognostic 3biomarker potential to stratify patients with high-grade (HG) T1 non-muscle-invasive bladder cancer (NMIBC). We selected 30 patients with HG T1 NMIBC that progressed to >/=T2 disease which were pair-matched based on CUETO progression score variables with 90 patients that did not progress. After revision a final cohort of 86 patients was retained. Slides were stained for FAP, the luminal marker GATA3 and the basal marker CK5. All HG T1 tumour regions of interest (ROIs) within each patient were annotated, analysed and scored using image analysis software. FAP expression in HG T1 ROIs was significantly higher in progressors vs. non-progressors and was prognostic for recurrence-free survival, progression-free survival, cancer-specific survival, and overall survival. FAP expression in HG T1 ROIs remained strongly prognostic for these outcomes in a bivariable model corrected for adequate BCG per FDA definition. Expression of GATA3 and CK5 did not differ between progressors vs. non-progressors, and were not prognostic for these outcomes. FAP might serve as an easily applicable prognostic biomarker to risk-stratify patients with HG T1 NMIBC if these results are prospectively validated in a larger series. FAU - Muilwijk, Tim AU - Muilwijk T AUID- ORCID: 0000-0002-6965-389X AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Daelemans, Sofie AU - Daelemans S AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. AD - Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium. FAU - Marien, Koen AU - Marien K AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Waumans, Yannick AU - Waumans Y AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Kockx, Mark AU - Kockx M AD - Pathology - Histology, Imaging and Quantification, CellCarta, Antwerp, Belgium. FAU - Baekelandt, Loic AU - Baekelandt L AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van den Broeck, Thomas AU - Van den Broeck T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Gevaert, Thomas AU - Gevaert T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. AD - Department of Pathology, AZ Klina, Brasschaat, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210915 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/diagnosis/*metabolism/pathology MH - Disease Progression MH - Female MH - Fibroblasts/*metabolism MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk MH - Software MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*metabolism/pathology PMC - PMC8443055 COIS- The authors have declared that no competing interests exist. The above does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2021/09/16 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/09/15 CRDT- 2021/09/15 17:19 PHST- 2021/06/27 00:00 [received] PHST- 2021/08/25 00:00 [accepted] PHST- 2021/09/15 17:19 [entrez] PHST- 2021/09/16 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/09/15 00:00 [pmc-release] AID - PONE-D-21-20985 [pii] AID - 10.1371/journal.pone.0257195 [doi] PST - epublish SO - PLoS One. 2021 Sep 15;16(9):e0257195. doi: 10.1371/journal.pone.0257195. eCollection 2021. PMID- 34511488 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20260830 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 33 IP - 1 DP - 2022 TI - Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. PG - 151-157 LID - 10.3233/CBM-210221 [doi] AB - BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80-0.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment. FAU - Murakami, Kaoru AU - Murakami K AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Dai, Yunfeng AU - Dai Y AD - Department of Epidemiology, University of Florida, Gainesville, FL, USA. FAU - Pagano, Ian AU - Pagano I AD - Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI, USA. FAU - Chen, Runpu AU - Chen R AD - Department of Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY, USA. FAU - Sun, Yijun AU - Sun Y AD - Department of Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY, USA. AD - Department of Computer Science and Engineering, The State University of New York at Buffalo, Buffalo, NY, USA. AD - Department of Biostatistics, The State University of New York at Buffalo, Buffalo, NY, USA. FAU - Gupta, Amit AU - Gupta A AD - Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Goodison, Steve AU - Goodison S AD - Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA. FAU - Rosser, Charles J AU - Rosser CJ AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. AD - Nonagen Bioscience Corp., Los Angeles, CA, USA. FAU - Furuya, Hideki AU - Furuya H AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. LA - eng GR - R01 CA198887/CA/NCI NIH HHS/United States GR - R01 CA241123/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Recurrence, Local/drug therapy MH - Pilot Projects MH - Urinalysis MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy PMC - PMC8925124 OTO - NOTNLM OT - BCG OT - Biomarkers OT - bladder cancer OT - multiplex OT - protein COIS- CJR is an officer of Nonagen Bioscience Corporation. EDAT- 2021/09/14 06:00 MHDA- 2022/04/05 06:00 PMCR- 2022/02/14 CRDT- 2021/09/13 06:29 PHST- 2021/09/14 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2021/09/13 06:29 [entrez] PHST- 2022/02/14 00:00 [pmc-release] AID - CBM210221 [pii] AID - 10.3233/CBM-210221 [doi] PST - ppublish SO - Cancer Biomark. 2022;33(1):151-157. doi: 10.3233/CBM-210221. PMID- 34511303 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220429 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 81 IP - 1 DP - 2022 Jan TI - European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). PG - 75-94 LID - S0302-2838(21)01978-3 [pii] LID - 10.1016/j.eururo.2021.08.010 [doi] AB - CONTEXT: The European Association of Urology (EAU) has released an updated version of the guidelines on non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To present the 2021 EAU guidelines on NMIBC. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines since the 2020 version was performed. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1 and carcinoma in situ (CIS) are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of tissue obtained via transurethral resection of the bladder (TURB) for papillary tumours or via multiple bladder biopsies for CIS. For papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. In cases for which the initial resection is incomplete, there is no muscle in the specimen, or a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risk of progression may be estimated for individual patients using the 2021 EAU scoring model. On the basis of their individual risk of progression, patients are stratified as having low, intermediate, high, or very high risk, which is pivotal to recommending adjuvant treatment. For patients with tumours presumed to be at low risk and for small papillary recurrences detected more than 1 yr after a previous TURB, one immediate chemotherapy instillation is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose intravesical bacillus Calmette-Guerin (BCG) immunotherapy or instillations of chemotherapy for a maximum of 1 yr. For patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. For patients at very high risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is also recommended for BCG-unresponsive tumours. The extended version of the guidelines is available on the EAU website at https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology has released updated guidelines on the classification, risk factors, diagnosis, prognostic factors, and treatment of non-muscle-invasive bladder cancer. The recommendations are based on the literature up to 2020, with emphasis on the highest level of evidence. Classification of patients as having low, intermediate, or and high risk is essential in deciding on suitable treatment. Surgical removal of the bladder should be considered for tumours that do not respond to bacillus Calmette-Guerin (BCG) treatment and tumours with the highest risk of progression. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. Electronic address: marek.babjuk@fnmotol.cz. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Dominguez Escrig, Jose L AU - Dominguez Escrig JL AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Lund University, Malmo, Sweden; Department of Urology, Skane University Hospital, Malmo, Sweden. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology, Universite de Paris, APHP, Saint Louis Hospital, Paris, France. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, Department of Urology, Sorbonne University, AP-HP, Pitie Salpetriere Hospital, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Seisen, Thomas AU - Seisen T AD - GRC 5 Predictive Onco-Uro, Department of Urology, Sorbonne University, AP-HP, Pitie Salpetriere Hospital, Paris, France. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology, Arnhem, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20210910 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma in Situ/diagnosis/therapy MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - *Urinary Bladder Neoplasms/diagnosis/pathology/therapy MH - *Urology OTO - NOTNLM OT - *BCG unresponsive OT - *Bacillus Calmette-Guerin (BCG) OT - *Bladder cancer OT - *Cystoscopy OT - *Diagnosis OT - *European Association of Urology (EAU) OT - *Follow-up OT - *Guidelines OT - *Intravesical chemotherapy OT - *Prognosis OT - *Radical cystectomy OT - *Transurethral resection (TUR) OT - *Urothelial carcinoma EDAT- 2021/09/14 06:00 MHDA- 2022/04/19 06:00 CRDT- 2021/09/13 05:49 PHST- 2021/08/04 00:00 [received] PHST- 2021/08/15 00:00 [accepted] PHST- 2021/09/14 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2021/09/13 05:49 [entrez] AID - S0302-2838(21)01978-3 [pii] AID - 10.1016/j.eururo.2021.08.010 [doi] PST - ppublish SO - Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10. PMID- 34510192 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20220104 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 52 IP - 1 DP - 2022 Jan 3 TI - Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. PG - 65-72 LID - 10.1093/jjco/hyab143 [doi] AB - BACKGROUND: The ureterovesical junction is the boundary between the urinary bladder and upper urinary tract. Because treatment strategies for bladder cancer and upper tract urothelial carcinoma are entirely different, urothelial carcinoma involving the ureterovesical junction requires special attention. Nevertheless, studies focusing on the disease are lacking. METHODS: We reviewed consecutive patients with urothelial carcinoma treated via either transurethral resection of bladder tumor (n = 2791) or radical nephroureterectomy (n = 292) between 2000 and 2020 and identified those with bladder cancer involving the ureteral orifice (n = 64) and those with upper tract urothelial carcinoma involving the intramural ureter (/=T2) as an independent predictor of shorter cancer-specific survival. CONCLUSIONS: Given the positional property of urothelial carcinoma involving the ureterovesical junction, the profiles of patients with the disease were highly heterogeneous. Further optimization of treatment strategies for urothelial carcinoma involving the ureterovesical junction is urgently warranted for better clinical outcomes. CI - (c) The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Oshina, Takahiro AU - Oshina T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Taguchi, Satoru AU - Taguchi S AUID- ORCID: 0000-0002-1291-4294 AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Miyakawa, Jimpei AU - Miyakawa J AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Akiyama, Yoshiyuki AU - Akiyama Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Sato, Yusuke AU - Sato Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - Nephrectomy MH - Nephroureterectomy MH - Retrospective Studies MH - *Ureter/surgery MH - *Ureteral Neoplasms/surgery MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - bladder cancer OT - radical cystectomy OT - radical nephroureterectomy OT - upper tract urothelial carcinoma OT - ureterovesical junction EDAT- 2021/09/13 06:00 MHDA- 2022/01/05 06:00 CRDT- 2021/09/12 21:07 PHST- 2021/07/10 00:00 [received] PHST- 2021/08/26 00:00 [accepted] PHST- 2021/09/13 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] PHST- 2021/09/12 21:07 [entrez] AID - 6369005 [pii] AID - 10.1093/jjco/hyab143 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2022 Jan 3;52(1):65-72. doi: 10.1093/jjco/hyab143. PMID- 34504238 OWN - NLM STAT- MEDLINE DCOM- 20211117 LR - 20211117 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Sep 9 TI - Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. PG - 17981 LID - 10.1038/s41598-021-97500-3 [doi] LID - 17981 AB - Tumor budding is defined as a single cell or a cluster of up to 5 tumor cells at the invasion front. Due to the difficulty of identifying patients at high risk for pT1 non-muscle-invasive bladder cancer (NMIBC) and the difficulties in T1 substaging, tumor budding was evaluated as a potential alternative and prognostic parameter in these patients. Tumor budding as well as growth pattern, invasion pattern and lamina propria infiltration were retrospectively evaluated in transurethral resection of the bladder (TURB) specimens from 92 patients with stage pT1 NMIBC. The presence of tumor budding correlated with multifocal tumors (p = 0.003), discontinuous invasion pattern (p = 0.039), discohesive growth pattern (p < 0.001) and extensive lamina propria invasion (p < 0.001). In Kaplan-Meier analysis, tumor budding was associated with significantly worse RFS (p = 0.005), PFS (p = 0.017) and CSS (p = 0.002). In patients who received BCG instillation therapy (n = 65), the absence of tumor budding was associated with improved RFS (p = 0.012), PFS (p = 0.011) and CSS (p = 0.022), with none of the patients suffering from progression or dying from the disease. Tumor budding is associated with a more aggressive and invasive stage of pT1 NMIBC and a worse outcome. This easy-to-assess parameter could help stratify patients into BCG therapy or early cystectomy treatment groups. CI - (c) 2021. The Author(s). FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Kimmel, Charlotte AU - Kimmel C AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Bruendl, Johannes AU - Bruendl J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Weber, Florian AU - Weber F AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210909 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Immunotherapy/methods MH - Kaplan-Meier Estimate MH - Male MH - Mucous Membrane/*pathology MH - Mycobacterium bovis/immunology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery PMC - PMC8429693 COIS- The authors declare no competing interests. EDAT- 2021/09/11 06:00 MHDA- 2021/11/18 06:00 PMCR- 2021/09/09 CRDT- 2021/09/10 06:40 PHST- 2021/06/09 00:00 [received] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/10 06:40 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/11/18 06:00 [medline] PHST- 2021/09/09 00:00 [pmc-release] AID - 10.1038/s41598-021-97500-3 [pii] AID - 97500 [pii] AID - 10.1038/s41598-021-97500-3 [doi] PST - epublish SO - Sci Rep. 2021 Sep 9;11(1):17981. doi: 10.1038/s41598-021-97500-3. PMID- 34503220 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20261001 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 17 DP - 2021 Aug 31 TI - Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. LID - 10.3390/cancers13174411 [doi] LID - 4411 AB - Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was based on the use of chemotherapy alone. Since 2016, five immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administration (FDA) in different settings, i.e., first-line, maintenance and second-line treatment, while several trials are still ongoing in the perioperative context. Lately, pembrolizumab, a programmed death-1 (PD-1) inhibitor, has been approved for Bacillus Calmette-Guerin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), using immunotherapy at an early stage of the disease. This review investigates the current state and future perspectives of immunotherapy in BC, focusing on the rationale and results of combining immunotherapy with other therapeutic strategies. FAU - Roviello, Giandomenico AU - Roviello G AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Catalano, Martina AU - Catalano M AUID- ORCID: 0000-0003-1856-2848 AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Santi, Raffaella AU - Santi R AD - Histopathology and Molecular Diagnostics, Careggi Teaching Hospital, 50139 Florence, Italy. FAU - Palmieri, Valeria Emma AU - Palmieri VE AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Vannini, Gianmarco AU - Vannini G AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Galli, Ilaria Camilla AU - Galli IC AD - Histopathology and Molecular Diagnostics, Careggi Teaching Hospital, 50139 Florence, Italy. FAU - Buttitta, Eleonora AU - Buttitta E AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Villari, Donata AU - Villari D AD - Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy. FAU - Rossi, Virginia AU - Rossi V AD - Clinical Oncology Unit, Careggi Teaching Hospital, 50139 Florence, Italy. FAU - Nesi, Gabriella AU - Nesi G AUID- ORCID: 0000-0002-2614-944X AD - Department of Health Sciences, University of Florence, 50139 Florence, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210831 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8431680 OTO - NOTNLM OT - PD-1 OT - PD-L1 OT - biomarkers OT - bladder cancer OT - immune checkpoint blockade OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/11 06:01 PMCR- 2021/08/31 CRDT- 2021/09/10 01:11 PHST- 2021/07/28 00:00 [received] PHST- 2021/08/26 00:00 [revised] PHST- 2021/08/28 00:00 [accepted] PHST- 2021/09/10 01:11 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/11 06:01 [medline] PHST- 2021/08/31 00:00 [pmc-release] AID - cancers13174411 [pii] AID - cancers-13-04411 [pii] AID - 10.3390/cancers13174411 [doi] PST - epublish SO - Cancers (Basel). 2021 Aug 31;13(17):4411. doi: 10.3390/cancers13174411. PMID- 34501211 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210913 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 17 DP - 2021 Aug 24 TI - Pyuria as a Predictive Marker of Bacillus Calmette-Guerin Unresponsiveness in Non-Muscle Invasive Bladder Cancer. LID - 10.3390/jcm10173764 [doi] LID - 3764 AB - This study aims to investigate the clinical role of preoperative pyuria for predicting bacillus Calmette-Guerin (BCG) unresponsiveness in non-muscle invasive bladder cancer (NMIBC). We performed a logistic regression analysis on 453 patients with NMIBC who were treated with BCG immunotherapy after a transurethral resection of bladder tumours, to evaluate predictive factors of BCG unresponsiveness. We also analysed univariate and multivariable survival data to estimate the prognostic impact of pyuria. Of the total study population, 37.6% (170/453) of patients had BCG unresponsiveness. A multivariable logistic regression analysis revealed that a history of upper urinary tract cancer (odds ratio (OR): 1.86, 95% confidence interval (CI): 1.04-3.32, p-value = 0.035) and the presence of pyuria (OR: 1.51, 95% CI: 1.01-2.27, p = 0.047) and tumour multiplicity (OR: 1.80, 95% CI: 1.18-2.75, p-value < 0.001) were significant predictors of BCG unresponsiveness. A Cox proportional hazards analysis model showed that pyuria was a significant prognostic factor for progression-free survival (hazard ratio: 4.51, 95% CI: 1.22-16.66, p = 0.024). A history of upper urinary tract cancer and the presence of pyuria and tumour multiplicity are predictive markers of BCG unresponsiveness. For patients with NMIBC who have preoperative pyuria, treatment using BCG should be considered cautiously. FAU - Suh, Jungyo AU - Suh J AUID- ORCID: 0000-0002-3867-4778 AD - Department of Urology, Asan Medical Centre, Seoul 05505, Korea. FAU - Yuk, Hyeong Dong AU - Yuk HD AUID- ORCID: 0000-0002-5874-9167 AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AUID- ORCID: 0000-0002-2200-5019 AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea. LA - eng PT - Journal Article DEP - 20210824 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8432248 OTO - NOTNLM OT - BCG immunotherapy OT - non-muscle invasive bladder cancer OT - pyuria COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/11 06:01 PMCR- 2021/08/24 CRDT- 2021/09/10 01:03 PHST- 2021/06/07 00:00 [received] PHST- 2021/08/10 00:00 [revised] PHST- 2021/08/19 00:00 [accepted] PHST- 2021/09/10 01:03 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/11 06:01 [medline] PHST- 2021/08/24 00:00 [pmc-release] AID - jcm10173764 [pii] AID - jcm-10-03764 [pii] AID - 10.3390/jcm10173764 [doi] PST - epublish SO - J Clin Med. 2021 Aug 24;10(17):3764. doi: 10.3390/jcm10173764. PMID- 34499690 OWN - NLM STAT- MEDLINE DCOM- 20211116 LR - 20211116 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 9 DP - 2021 TI - Survival of bladder or renal cancer in patients with CHEK2 mutations. PG - e0257132 LID - 10.1371/journal.pone.0257132 [doi] LID - e0257132 AB - PURPOSE: The purpose of this study was to compare the clinical characteristics and the survival of CHEK2 mutation positive and CHEK2 mutation negative patients diagnosed with bladder or kidney cancer. MATERIALS AND METHODS: 1016 patients with bladder and 402 cases with kidney cancer and 8302 controls were genotyped for four CHEK2 variants: 1100delC, del5395, IVS2+1G>A and I157T. Predictors of survival were determined among CHEK2 pathogenic variant carriers using the Cox proportional hazards model. The median follow-up was 17.5 years. Covariates included age (61 years), sex (female; male), clinical characteristics (stage: TNM, grade, histopathological type), smoking status (non-smoking; smoking) and cancer family history (negative; positive). RESULTS: We found no impact of CHEK2 mutations on bladder or kidney cancer survival. However, we observed a possible increased survival in the subgroup of patients with stage T1 bladder cancer with CHEK2 mutations but this did not meet statistical significance (HR = 0.14; 95% CI 0.02-1.04; p = 0.055). Moreover, we observed that the missense mutations were more frequent in the low grade invasive bladder cancer patient group (OR = 7.9; 95% CI 1.50-42.1; p = 0.04) and in patients with bladder cancer with stage Ta (OR = 2.4; 95% CI 1.30-4.55; p = 0.006). The different results where missense mutations occurs less often we observed among patients with high grade invasive bladder cancer (OR = 0.12; 95% CI 0.02-0.66; p = 0.04) and those with stage T1 disease (OR = 0.2; 95% CI 0.07-0.76; p = 0.01). Our investigations revealed that any mutation in CHEK2 occurs more often among patients with stage Ta bladder cancer (OR = 2.0; 95% CI 1.19-3.47; p = 0.01) and less often in patients with stage T1 disease (OR = 0.31; 95% CI 0.12-0.78; p = 0.01). In the kidney cancer patients, truncating mutations were present more often in the group with clear cell carcinoma GII (OR = 8.0; 95% CI 0.95-67.7; p = 0.05). The 10-year survival for all CHEK2 mutation carriers with bladder cancer was 33% and for non-carriers 11% (p = 0.15). The 10-year survival for CHEK2 mutation carriers with kidney cancer 34% and for non-carriers 20% (p = 0.5). CONCLUSION: CHEK2 mutations were not associated with any change in bladder or kidney cancer survival regardless of their age, sex, smoking status and family history. We observed a potentially protective effect of CHEK2 mutations on survival for patients with stage T1 bladder cancer. CHEK2 missense mutations were more common among patients with low grade invasive bladder cancer and in patients with stage Ta diease. The frequencies of the I157T CHEK2 pathogenic variant were less in patients with high grade invasive bladder cancer and those with stage T1 disease. Among patients with bladder cancer with stage Ta disease, the OR for any mutation in CHEK2 was 2.0 but for those with stage T1 disease, the OR was 0.3. We observed truncating CHEK2 mutations were associated with kidney cancer patients with GII clear cell carcinoma. FAU - Zlowocka-Perlowska, Elzbieta AU - Zlowocka-Perlowska E AUID- ORCID: 0000-0002-5143-6387 AD - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. FAU - Debniak, Tadeusz AU - Debniak T AD - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. FAU - Slojewski, Marcin AU - Slojewski M AD - Department of Urology and Oncological Urology Clinic, Pomeranian Medical University, Szczecin, Poland. FAU - van de Wetering, Thierry AU - van de Wetering T AUID- ORCID: 0000-0002-3910-649X AD - Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland. FAU - Toloczko-Grabarek, Aleksandra AU - Toloczko-Grabarek A AD - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. FAU - Cybulski, Cezary AU - Cybulski C AD - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. FAU - Scott, Rodney J AU - Scott RJ AD - School of Biomedical Sciences & Pharmacy, Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, Newcastle, NSW, Australia. AD - Division of Molecular Medicine, Pathology North, NSW Pathology, Newcastle, NSW, Australia. FAU - Lubinski, Jan AU - Lubinski J AD - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210909 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 2.7.1.11 (Checkpoint Kinase 2) RN - EC 2.7.11.1 (CHEK2 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alleles MH - Checkpoint Kinase 2/*genetics MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/*enzymology/*genetics MH - Male MH - Middle Aged MH - Mutation/*genetics MH - Survival Analysis MH - Urinary Bladder Neoplasms/*enzymology/*genetics PMC - PMC8428549 COIS- The authors have declared that no competing interests exist. EDAT- 2021/09/10 06:00 MHDA- 2021/11/17 06:00 PMCR- 2021/09/09 CRDT- 2021/09/09 17:20 PHST- 2021/01/22 00:00 [received] PHST- 2021/08/25 00:00 [accepted] PHST- 2021/09/09 17:20 [entrez] PHST- 2021/09/10 06:00 [pubmed] PHST- 2021/11/17 06:00 [medline] PHST- 2021/09/09 00:00 [pmc-release] AID - PONE-D-21-02204 [pii] AID - 10.1371/journal.pone.0257132 [doi] PST - epublish SO - PLoS One. 2021 Sep 9;16(9):e0257132. doi: 10.1371/journal.pone.0257132. eCollection 2021. PMID- 34498951 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20220429 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 55 IP - 6 DP - 2021 Dec TI - Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers. PG - 448-454 LID - 10.1080/21681805.2021.1962403 [doi] AB - PURPOSE: To investigate the role of clinical parameters and immunohistochemical (IHC) biomarkers in their feasibility to predict the effect of neo-adjuvant chemotherapy (NAC) in patients with muscle-invasive urothelial bladder cancer (MIBC). MATERIALS AND METHODS: The first 76 consecutive patients with MIBC treated with NAC and radical cystectomy in two University hospitals in Finland between 2008 and 2013 were chosen for this study. After excluding patients with non-urothelial cancer, less than two cycles of chemotherapy, no tissue material for IHC analysis or non-muscle-invasive bladder cancer in re-review, 59 patients were included in the final analysis. A tissue microarray block was constructed from the transurethral resection samples and IHC stainings of Ki-67, p53, Her-2 and EGFR were made. The correlations between histological features in transurethral resection samples and immune-histochemical stainings were calculated. The associations of clinicopathological parameters and IHC stainings with NAC response were evaluated. Factors affecting survival were estimated. RESULTS: The complete response rate after NAC was 44%. A higher number of chemotherapy cycles was associated with better response to neo-adjuvant chemotherapy. No response to neo-adjuvant chemotherapy and female gender was associated with decreased cancer-specific survival. The IHC stainings used failed to show an association with neo-adjuvant chemotherapy response and overall or cancer specific survival. CONCLUSIONS: Patients who do not respond to neo-adjuvant chemotherapy do significantly worse than responders. This study could not find clinical tools to distinguish responders from non-responders. Further studies preferably with larger cohorts addressing this issue are warranted to improve the selection of patients for neo-adjuvant chemotherapy. FAU - Koskinen, I AU - Koskinen I AD - Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Bostrom, P J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Taimen, P AU - Taimen P AD - Institute of Biomedicine, University of Turku, Turku, Finland. AD - Department of Pathology, Turku University Hospital, Turku, Finland. FAU - Salminen, A AU - Salminen A AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Tervahartiala, M AU - Tervahartiala M AD - Department of Surgery, Lohja Regional Hospital, Lohja, Finland. FAU - Sairanen, J AU - Sairanen J AD - Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Erickson, A AU - Erickson A AD - Department of Pathology (HUSLAB), Helsinki University Hospital and University of Helsinki, Helsinki, Finland and FIMM. AD - Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. FAU - Mirtti, T AU - Mirtti T AUID- ORCID: 0000-0003-0455-9891 AD - Department of Pathology (HUSLAB), Helsinki University Hospital and University of Helsinki, Helsinki, Finland and FIMM. LA - eng PT - Journal Article DEP - 20210909 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Female MH - Humans MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Urothelium OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - cystectomy OT - immunohistochemistry OT - neo-adjuvant chemotherapy EDAT- 2021/09/10 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/09/09 12:16 PHST- 2021/09/10 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/09/09 12:16 [entrez] AID - 10.1080/21681805.2021.1962403 [doi] PST - ppublish SO - Scand J Urol. 2021 Dec;55(6):448-454. doi: 10.1080/21681805.2021.1962403. Epub 2021 Sep 9. PMID- 34497827 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210910 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 8 DP - 2021 TI - T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram. PG - 704902 LID - 10.3389/fsurg.2021.704902 [doi] LID - 704902 AB - Background: The T1 substaging of bladder cancer (BCa) potentially impacts disease progression. The objective of the study was to compare the prognostic accuracy of two substaging systems on the recurrence and progression of primary pathologic T1 (pT1) BCa and to test a nomogram based on pT1 substaging for predicting recurrence-free survival (RFS) and progression-free survival (PFS). Methods: The medical records of 204 patients affected by pT1 BCa were retrospectively reviewed. Substaging was defined according to the depth of lamina propria invasion in T1(a-c) and the extension of the lamina propria invasion to T1-microinvasive (T1(m)) or T1-extensive (T1(e)). Uni- and multivariable Cox regression models evaluated the independent variables correlated with recurrence and progression. The predictive accuracies of the two substaging systems were compared by Harrell's C index. Multivariate Cox regression models for the RFS and PFS were also depicted by a nomogram. Results: The 5-year RFS was 47.5% with a significant difference between T1(c) and T1(a) (p = 0.02) and between T1(e) and T1(m) (p < 0.001). The 5-year PFS was 75.9% with a significant difference between T1(c) and T1(a) (p = 0.011) and between T1(e) and T1(m) (p < 0.001). Model T1(m-e) showed a higher predictive power than T1(a-c) for predicting RFS and PFS. In the univariate and multivariate model subcategory T1e, the diameter, location, and number of tumors were confirmed as factors influencing recurrence and progression after adjusting for the other variables. The nomogram incorporating the T1(m-e) model showed a satisfactory agreement between model predictions at 5 years and actual observations. Conclusions: Substaging is significantly associated with RFS and PFS for patients affected by T1 BCa and should be included in innovative prognostic nomograms. CI - Copyright (c) 2021 Asimakopoulos, Colalillo, Telesca, Mauriello, Miano, Di Stasi, Germani, Finazzi Agro, Petrozza, Caruso, Carbone, Pastore and Fuschi. FAU - Asimakopoulos, Anastasios D AU - Asimakopoulos AD AD - Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy. FAU - Colalillo, Gaia AU - Colalillo G AD - Division of Urology, Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Telesca, Rossana AU - Telesca R AD - Pathology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. FAU - Mauriello, Alessandro AU - Mauriello A AD - Pathology, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. FAU - Miano, Roberto AU - Miano R AD - Division of Urology, Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Di Stasi, Savino Mauro AU - Di Stasi SM AD - Division of Urology, Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Germani, Stefano AU - Germani S AD - Division of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy. FAU - Finazzi Agro, Enrico AU - Finazzi Agro E AD - Division of Urology, Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy. FAU - Petrozza, Vincenzo AU - Petrozza V AD - Pathology, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. FAU - Caruso, Gianluca AU - Caruso G AD - Pathology, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. FAU - Carbone, Antonio AU - Carbone A AD - Urology Unit ICOT, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Latina, Italy. FAU - Pastore, Antonio Luigi AU - Pastore AL AD - Urology Unit ICOT, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Latina, Italy. FAU - Fuschi, Andrea AU - Fuschi A AD - Urology Unit ICOT, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Latina, Italy. LA - eng PT - Journal Article DEP - 20210823 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8419324 OTO - NOTNLM OT - bladder cancer OT - lamina propria OT - prognosis OT - staging OT - urinary bladder neoplasms OT - urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/10 06:00 MHDA- 2021/09/10 06:01 PMCR- 2021/08/23 CRDT- 2021/09/09 06:53 PHST- 2021/05/04 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/09/09 06:53 [entrez] PHST- 2021/09/10 06:00 [pubmed] PHST- 2021/09/10 06:01 [medline] PHST- 2021/08/23 00:00 [pmc-release] AID - 10.3389/fsurg.2021.704902 [doi] PST - epublish SO - Front Surg. 2021 Aug 23;8:704902. doi: 10.3389/fsurg.2021.704902. eCollection 2021. PMID- 34493171 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20220531 IS - 2046-0236 (Electronic) IS - 0147-8885 (Linking) VI - 45 IP - 1 DP - 2022 Mar TI - Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study. PG - 21-28 LID - 10.1080/01478885.2021.1973309 [doi] AB - Enhancer of zeste homolog 2 (EZH2) and AT-rich interactive domain 1A (ARID1A) expression in urothelial carcinoma (UC) has not been well studied. ARID1A is a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in urinary bladder cancer. The enhancer of zeste homolog 2 (EZH2) is a transcriptional repressor involved in gene silencing. Amplification of EZH2 has been reported in several malignancies. This study analyzed the immunohistochemical expression of EZH2 and ARID1A in 56 cases of UC that included (n = 21) cases of radical cystectomy and (n = 35) cases of transurethral resections of bladder tumor (TURBT) with muscle fibers and immunotherapy with adjuvant intravesical bacillus Calmette-Guerin (BCG). The predicting role of both markers for tumor recurrence and recurrence-free survival (RFS) was also analyzed. High EZH2 marker expression was observed in 75% of cases while 78.6% of cases had low ARID1A marker expression. There was a significant negative correlation between the two markers where high EZH2 and low ARID1A expression was significantly associated with higher tumor grade, stage, presence of muscle invasion, lymph node metastasis, presence of concomitant carcinoma in situ (CIS) and higher incidence of recurrence with shorter RFS rate. It was concluded that EZH2 and ARID1A play a role in tumor carcinogenesis and differentiation and could be considered as independent prognostic factors in UC and for use as a potential therapeutic target. FAU - Sameh, Reham AU - Sameh R AUID- ORCID: 0000-0002-2936-5631 AD - Pathology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Mostafa, Naglaa AU - Mostafa N AD - Pathology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Ramadan, Mohamed AU - Ramadan M AD - Pathology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - AbdelRaouf, Samar AU - AbdelRaouf S AD - Pathology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Abdelwahab, Khaled AU - Abdelwahab K AD - Urology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article DEP - 20210908 PL - England TA - J Histotechnol JT - Journal of histotechnology JID - 8003807 RN - 0 (ARID1A protein, human) RN - 0 (DNA-Binding Proteins) RN - 0 (Transcription Factors) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) SB - IM MH - *Carcinoma, Transitional Cell/metabolism MH - Cystectomy MH - DNA-Binding Proteins/genetics MH - Enhancer of Zeste Homolog 2 Protein/genetics/metabolism MH - Female MH - Humans MH - Male MH - Prognosis MH - Transcription Factors/genetics MH - *Urinary Bladder Neoplasms/diagnosis/genetics/pathology OTO - NOTNLM OT - ARID1A OT - EZH2 OT - immunohistochemistry OT - prognosis OT - urinary bladder cancer OT - urothelial carcinoma EDAT- 2021/09/09 06:00 MHDA- 2022/05/06 06:00 CRDT- 2021/09/08 05:37 PHST- 2021/09/09 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2021/09/08 05:37 [entrez] AID - 10.1080/01478885.2021.1973309 [doi] PST - ppublish SO - J Histotechnol. 2022 Mar;45(1):21-28. doi: 10.1080/01478885.2021.1973309. Epub 2021 Sep 8. PMID- 34492655 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 2 DP - 2022 TI - Prognostic Analysis of Diagnostic Ureteroscopic Biopsy for Intravesical Recurrence of Upper Urinary Tract Urothelial Carcinoma. PG - 186-194 LID - 10.1159/000517789 [doi] AB - OBJECTIVE: The aim of this study was to investigate whether diagnostic ureteroscopy (URS) biopsy is unfavourable for bladder tumour recurrence in upper urinary tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: We performed a retrospective analysis of 195 patients diagnosed with UTUC, who were divided into a diagnostic URS group (URS+) and a nondiagnostic URS group (URS-) according to whether diagnostic ureteroscopic biopsy was performed. A Cox regression model was used to analyse the risk factors for intravesical recurrence (IVR)-free survival (IRFS) and overall survival (OS) in UTUC after radical nephroureterectomy (RNU). Kaplan-Meier analysis was used to estimate the influence of factors on the incidence of IVR and the cumulative survival rate of UTUC. RESULTS: Patients with a maximum tumour diameter of less than 3.1 cm, low-stage tumours, and ureteral tumours were more likely to undergo diagnostic URS before radical surgery. Multivariate Cox regression analysis showed that tumour pathological stage and diagnostic ureteroscopic biopsy can be used as predictors of IVR after RNU (p = 0.019, 0.033). Kaplan-Meier survival analysis found that diagnostic ureteroscopic biopsy was a high-risk factor for IRFS (p = 0.034). Subcomponent analysis showed that pTa/Tis/T1, pT2, pT3/pT4 stage, and diagnostic ureteroscopic biopsy with pTa/Tis/T1 stage were unfavourable for IVR (p = 0.047). CONCLUSION: Diagnostic ureteroscopic biopsy before RNU should be carefully selected for patients with atypical preoperative UTUC. We believe that intravesical chemotherapy drug perfusion can be used after surgery to prevent IVR if biopsy is unavoidable, but this still requires further prospective studies. CI - (c) 2021 S. Karger AG, Basel. FAU - Chen, Han AU - Chen H AD - Department of Urology, Chengdu Second People's Hospital, Chengdu, China, hjdchcz@qq.com. FAU - Wang, Ming AU - Wang M AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Weng, Tonghui AU - Weng T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Wei, Yu AU - Wei Y AD - Department of Master, The Chongqing Medical University, Chongqing, China. FAU - Yang, Lei AU - Yang L AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Ren, Ke AU - Ren K AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Tang, Zhaobing AU - Tang Z AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Gou, Xin AU - Gou X AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20210907 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Biopsy/methods MH - Carcinoma, Transitional Cell/mortality/*pathology/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/mortality/*pathology/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/mortality/*pathology MH - *Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Ureteral Neoplasms/mortality/*pathology/*surgery MH - *Ureteroscopy MH - Urinary Bladder Neoplasms/mortality/*pathology OTO - NOTNLM OT - Intravesical recurrence OT - Tumour stage OT - Upper urinary tract urothelial carcinoma OT - Ureteroscopic biopsy EDAT- 2021/09/08 06:00 MHDA- 2022/03/04 06:00 CRDT- 2021/09/07 20:27 PHST- 2021/03/20 00:00 [received] PHST- 2021/06/02 00:00 [accepted] PHST- 2021/09/08 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2021/09/07 20:27 [entrez] AID - 000517789 [pii] AID - 10.1159/000517789 [doi] PST - ppublish SO - Urol Int. 2022;106(2):186-194. doi: 10.1159/000517789. Epub 2021 Sep 7. PMID- 34484309 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 12 DP - 2021 TI - Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer. PG - 731625 LID - 10.3389/fgene.2021.731625 [doi] LID - 731625 AB - BACKGROUND: Bladder cancer (BC) is the most common tumor of the urinary system. Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate after surgery, and patients with muscle-invasive bladder cancer (MIBC) have poor quality of life after radical surgery. Understanding the molecular mechanism of bladder cancer is helpful for providing a more appropriate treatment approach. Annexins are calcium-binding proteins and play an important role in different tumor cells. However, the role of the annexin family in bladder cancer has not been studied in detail. METHODS: ONCOMINE, UALCAN, TIMER2.0, Kaplan-Meier Plotter, cBioPortal, and WebGestalt were utilized in this study. RESULTS: ANXA2, ANXA3, ANXA4, ANXA8, and ANXA9 were significantly increased in bladder tumor tissues, while ANXA6, ANXA7, and ANXA11 were significantly decreased. ANXA1, ANXA2, ANXA3, ANXA5, ANXA6, ANXA7, and ANXA9 had prognostic value in bladder cancer. In addition, specific annexins were specifically expressed in different subtypes of MIBC and were related to the histological morphology of bladder tumors. ANXA1, ANXA2, ANXA3, ANXA5, ANXA6, ANXA7, and ANXA8 were highly expressed in basal-subtype MIBC, while ANXA4, ANXA9, ANXA10, and ANXA11 were mainly expressed in luminal-subtype MIBC. Finally, we analyzed the possible mechanisms of ANXAs in different subtypes of bladder cancer through GO and KEGG analyses and the correlation between ANXAs and immune infiltration in the tumor microenvironment. CONCLUSION: Taken together, our results indicate that annexins might play important roles in BC and have the potential to be used as markers for subtype classification. CI - Copyright (c) 2021 Wu, Jia, Chen, Liu and Xia. FAU - Wu, WenBo AU - Wu W AD - Department of Urology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Jia, GaoZhen AU - Jia G AD - Department of Urology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Chen, Lei AU - Chen L AD - Department of Urology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Liu, HaiTao AU - Liu H AD - Department of Urology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xia, ShuJie AU - Xia S AD - Department of Urology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20210813 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC8414640 OTO - NOTNLM OT - MIBC OT - NMIBC OT - annexin OT - prognosis OT - public databases COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/07 06:00 MHDA- 2021/09/07 06:01 PMCR- 2021/08/13 CRDT- 2021/09/06 05:56 PHST- 2021/06/27 00:00 [received] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/09/06 05:56 [entrez] PHST- 2021/09/07 06:00 [pubmed] PHST- 2021/09/07 06:01 [medline] PHST- 2021/08/13 00:00 [pmc-release] AID - 10.3389/fgene.2021.731625 [doi] PST - epublish SO - Front Genet. 2021 Aug 13;12:731625. doi: 10.3389/fgene.2021.731625. eCollection 2021. PMID- 34475999 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210904 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 12 IP - 19 DP - 2021 TI - Prognostic Value of Preoperative Albumin-to-Fibrinogen Ratio in Patients with Bladder Cancer. PG - 5864-5873 LID - 10.7150/jca.61068 [doi] AB - Background: Both nutritional status and coagulation function are closely associated with prognosis in patients with bladder cancer (BC). This study aimed to investigate the prognostic value of albumin-to-fibrinogen ratio (AFR) for BC patients underwent radical cystectomy (RC) or transurethral resection of bladder tumor (TURBT), and develop predictive nomograms based on AFR. Methods: We retrospectively collected medical records of 358 BC patients who underwent RC or TURBT between January 2012 and December 2018. The whole cohort was divided into the training (215 patients, 60.06%) and validation cohorts (143 patients, 39.94%) based on surgery dates. The training cohort was applied to select characteristics and construct nomograms, while the validation cohort was used to verify the nomograms independently. Endpoints of the current study included overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS). Prognostic values of AFR and other characteristics were evaluated using univariate and multivariate Cox regression analyses and compared using the concordance-index (C-index). Nomograms for OS, DSS and DFS were constructed based on both-directional stepwise Cox proportional hazards regression analysis and evaluated by the receiver operating characteristic (ROC) curve, the C-index and calibration plot. Results: In whole cohort, 86 patients (24.02%) were classified into low AFR group and had worse OS (hazard ratio [HR]: 4.079, 95% confidence interval [CI]: 2.085-7.982, P < 0.001), DSS (HR: 3.012, 95% CI: 1.302-6.966, P = 0.010) and DFS (HR: 1.863, 95% CI: 1.204-2.883, P = 0.005) compared to BC patients in high AFR group. Meanwhile, the AFR processed better prognostic power than albumin and fibrinogen, individually. Multivariate Cox analysis indicated that AFR was an independent prognostic factor for OS (HR: 2.601, 95% CI: 1.057-6.395, P = 0.037) and DFS (HR: 1.971, 95% CI: 1.049-3.703, P = 0.035). Novel nomograms, incorporating AFR, tumor grade and tumor multifocality, were constructed and successfully validated for predictions of OS, DSS and DFS in BC. Conclusions: Preoperative AFR was identified as an independent prognostic predictor for OS and DFS of BC patients underwent surgery. The nomograms incorporating AFR provided accurate predictions for OS, DSS and DFS, which could help urologists in better clinical decision-making. CI - (c) The author(s). FAU - Li, Shuai AU - Li S AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Zhang, Di AU - Zhang D AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Zeng, Song AU - Zeng S AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Wu, Tianjun AU - Wu T AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Wang, Yicun AU - Wang Y AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Zhang, He AU - Zhang H AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Wang, Biao AU - Wang B AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. FAU - Hu, Xiaopeng AU - Hu X AD - Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. AD - Institute of Urology, Capital Medical University, Beijing, China. LA - eng PT - Journal Article DEP - 20210804 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC8408123 OTO - NOTNLM OT - albumin-to-fibrinogen ratio OT - biomarker OT - bladder cancer OT - nomogram OT - nutrition OT - prognosis COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2021/09/04 06:00 MHDA- 2021/09/04 06:01 PMCR- 2021/01/01 CRDT- 2021/09/03 06:49 PHST- 2021/03/30 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/09/03 06:49 [entrez] PHST- 2021/09/04 06:00 [pubmed] PHST- 2021/09/04 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - jcav12p5864 [pii] AID - 10.7150/jca.61068 [doi] PST - epublish SO - J Cancer. 2021 Aug 4;12(19):5864-5873. doi: 10.7150/jca.61068. eCollection 2021. PMID- 34470779 OWN - NLM STAT- MEDLINE DCOM- 20220106 LR - 20231108 IS - 1538-7445 (Electronic) IS - 0008-5472 (Print) IS - 0008-5472 (Linking) VI - 81 IP - 20 DP - 2021 Oct 15 TI - Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. PG - 5161-5175 LID - 10.1158/0008-5472.CAN-21-1254 [doi] AB - To study the progression of bladder cancer from non-muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urothelium in vivo, thereby allowing us to generate a new series of genetically engineered mouse models (GEMM) of bladder cancer. One method is based on the delivery of adenoviruses that express Cre recombinase in selected cell types in the urothelium, and a second uses transgenic drivers in which activation of inducible Cre alleles can be limited to the bladder urothelium by intravesicular delivery of tamoxifen. Using both approaches, targeted deletion of the Pten and p53 tumor suppressor genes specifically in basal urothelial cells gave rise to muscle-invasive bladder tumors. Furthermore, preinvasive lesions arising in basal cells displayed upregulation of molecular pathways related to bladder tumorigenesis, including proinflammatory pathways. Cross-species analyses comparing a mouse gene signature of early bladder cancer with a human signature of bladder cancer progression identified a conserved 28-gene signature of early bladder cancer that is associated with poor prognosis for human bladder cancer and that outperforms comparable gene signatures. These findings demonstrate the relevance of these GEMMs for studying the biology of human bladder cancer and introduce a prognostic gene signature that may help to stratify patients at risk for progression to potentially lethal muscle-invasive disease. SIGNIFICANCE: Analyses of bladder cancer progression in a new series of genetically engineered mouse models has identified a gene signature of poor prognosis in human bladder cancer. CI - (c)2021 American Association for Cancer Research. FAU - Park, Soonbum AU - Park S AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Rong, Lijie AU - Rong L AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Owczarek, Tomasz B AU - Owczarek TB AUID- ORCID: 0000-0002-5095-8642 AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. FAU - Bernardo, Matteo Di AU - Bernardo MD AUID- ORCID: 0000-0002-7574-1941 AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Shoulson, Rivka L AU - Shoulson RL AD - Institute of Comparative Medicine, Columbia University, New York, New York. FAU - Chua, Chee-Wai AU - Chua CW AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. AD - Department of Medicine, Columbia University Irving Medical Center, New York, New York. AD - Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York. AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, New York. FAU - Kim, Jaime Y AU - Kim JY AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Lankarani, Amir AU - Lankarani A AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Chakrapani, Prithi AU - Chakrapani P AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. FAU - Syed, Talal AU - Syed T AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. AD - Department of Medicine, Columbia University Irving Medical Center, New York, New York. AD - Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York. AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, New York. AD - Department of Biological Sciences, Columbia University, New York, New York. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. AD - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. FAU - Solit, David B AU - Solit DB AUID- ORCID: 0000-0002-6614-802X AD - Departments of Human Oncology and Pathogenesis and Medicine, Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. AD - Weill Medical College, Cornell University, New York, New York. FAU - Shen, Michael M AU - Shen MM AUID- ORCID: 0000-0002-4042-1657 AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. AD - Department of Medicine, Columbia University Irving Medical Center, New York, New York. AD - Department of Genetics & Development, Columbia University Irving Medical Center, New York, New York. AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, New York. AD - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AUID- ORCID: 0000-0002-2938-6627 AD - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York. FAU - Abate-Shen, Cory AU - Abate-Shen C AD - Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York. cabateshen@columbia.edu. AD - Department of Urology, Columbia University Irving Medical Center, New York, New York. AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, New York. AD - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - P30 CA013696/CA/NCI NIH HHS/United States GR - R01 CA193442/CA/NCI NIH HHS/United States GR - P01 CA221757/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210901 PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (Biomarkers, Tumor) RN - 0 (Trp53 protein, mouse) RN - 0 (Tumor Suppressor Protein p53) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - EC 3.1.3.67 (Pten protein, mouse) SB - IM MH - Animals MH - Biomarkers, Tumor/genetics/*metabolism MH - *Disease Models, Animal MH - Disease Progression MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Neoplasm Invasiveness MH - PTEN Phosphohydrolase/*physiology MH - Prognosis MH - RNA-Seq MH - Survival Rate MH - Tumor Cells, Cultured MH - Tumor Suppressor Protein p53/*physiology MH - Urinary Bladder Neoplasms/genetics/metabolism/*pathology PMC - PMC8609963 MID - NIHMS1739244 COIS- Conflict of interest statement: H. Al-Ahmadie is a Consultant for Bristol-Myers-Squibb, AstraZeneca, Janssen Biotech and Paige.ai. The other authors have no conflicts to report. EDAT- 2021/09/03 06:00 MHDA- 2022/01/07 06:00 PMCR- 2022/04/15 CRDT- 2021/09/02 05:59 PHST- 2021/04/22 00:00 [received] PHST- 2021/07/11 00:00 [revised] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/03 06:00 [pubmed] PHST- 2022/01/07 06:00 [medline] PHST- 2021/09/02 05:59 [entrez] PHST- 2022/04/15 00:00 [pmc-release] AID - 0008-5472.CAN-21-1254 [pii] AID - 10.1158/0008-5472.CAN-21-1254 [doi] PST - ppublish SO - Cancer Res. 2021 Oct 15;81(20):5161-5175. doi: 10.1158/0008-5472.CAN-21-1254. Epub 2021 Sep 1. PMID- 34468956 OWN - NLM STAT- MEDLINE DCOM- 20240725 LR - 20240725 IS - 1559-0283 (Electronic) IS - 1085-9195 (Print) IS - 1085-9195 (Linking) VI - 79 IP - 4 DP - 2021 Dec TI - Advances in Research on Bladder Cancer Targeting Peptides: a Review. PG - 711-718 LID - 10.1007/s12013-021-01019-3 [doi] AB - Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past 30 years due to the lack of early theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for bladder cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the wide use of the targeting peptides for intravesical theranostic techniques in bladder cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical application. CI - (c) 2021. The Author(s). FAU - Zheng, Bin AU - Zheng B AUID- ORCID: 0000-0002-9984-4136 AD - Zhejiang Chinese Medical University, 310053, HangZhou, China. AD - Zhejiang Provincial People's Hospital, Hangzhou Medical College, 310014, Hangzhou, China. FAU - Zhang, Pu AU - Zhang P AUID- ORCID: 0000-0001-9670-4237 AD - Zhejiang Provincial People's Hospital, Hangzhou Medical College, 310014, Hangzhou, China. FAU - Wang, Heng AU - Wang H AD - Zhejiang Provincial People's Hospital, Hangzhou Medical College, 310014, Hangzhou, China. FAU - Wang, Jinxue AU - Wang J AD - Handan Central hospital, 056001, Handan, China. FAU - Liu, Zheng Hong AU - Liu ZH AD - Zhejiang Chinese Medical University, 310053, HangZhou, China. FAU - Zhang, DaHong AU - Zhang D AUID- ORCID: 0000-0001-6990-4487 AD - Zhejiang Chinese Medical University, 310053, HangZhou, China. zhangdahong88@126.com. LA - eng PT - Journal Article PT - Review DEP - 20210901 PL - United States TA - Cell Biochem Biophys JT - Cell biochemistry and biophysics JID - 9701934 RN - 0 (Peptides) MH - Humans MH - *Urinary Bladder Neoplasms/metabolism/drug therapy/pathology MH - *Peptides/therapeutic use/chemistry MH - Animals PMC - PMC8558283 OTO - NOTNLM OT - Bladder tumor OT - Diagnosis OT - Peptides targeting OT - Research progress OT - Treatment COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/09/02 06:00 MHDA- 2022/01/29 06:00 PMCR- 2021/09/01 CRDT- 2021/09/01 12:39 PHST- 2021/06/27 00:00 [accepted] PHST- 2021/09/02 06:00 [pubmed] PHST- 2022/01/29 06:00 [medline] PHST- 2021/09/01 12:39 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - 10.1007/s12013-021-01019-3 [pii] AID - 1019 [pii] AID - 10.1007/s12013-021-01019-3 [doi] PST - ppublish SO - Cell Biochem Biophys. 2021 Dec;79(4):711-718. doi: 10.1007/s12013-021-01019-3. Epub 2021 Sep 1. PMID- 34467237 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 31 DP - 2021 Sep TI - Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer. PG - 17-27 LID - 10.1016/j.euros.2021.06.011 [doi] AB - CONTEXT: White light (WL) cystoscopy and transurethral resection of bladder tumour (TURBT) comprise the current gold standard technique for detecting and grading bladder cancer. However, with WL cystoscopy, recurrence following initial TURBT is high, and identification of smaller tumours and carcinoma in situ is poor. Photodynamic diagnosis (PDD) has been developed to improve the detection of bladder. OBJECTIVE: To assess the effect of PDD-guided TURBT compared with WL on recurrence rates (RRs) in non-muscle-invasive bladder cancer (NMIBC). EVIDENCE ACQUISITION: A systematic review of the literature from inception to April 2020 using Medline, EMBASE, and CENTRAL was undertaken. Randomised control trials comparing TURBT undertaken with PDD to WL that reported RRs of at least 12 mo were included in the analysis. The primary outcomes were RRs at 12 and 24 mo. The secondary outcomes were reported adverse effects. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of the evidence. EVIDENCE SYNTHESIS: Twelve randomised controlled trials (2288 patients) were included for the meta-analysis. PDD was found to reduce RRs at 12 mo (RR 0.73, confidence interval [CI] 0.60-0.88) and 24 mo (RR 0.75, CI 0.62-0.91). There was an increased risk of recurrence for patients undergoing WL at 12 mo (hazard ratio [HR] 1.14, CI 1.05-1.23) and 24 mo (HR 1.25, CI 1.15-1.35). Two studies reported recurrence data at 60 mo showing statistically significant outcomes in favour of PDD: one showed lower RRs for PDD (49% PDD vs 68% WL), whilst the other showed increased recurrence-free survival (68.2% PDD vs 57.3% WL). Adverse effects appeared to be minimal, though poorly reported. A GRADE analysis showed the evidence to be of moderate certainty overall. CONCLUSIONS: This systematic review found that PDD reduced RRs and improved recurrence-free survival compared with WL in NMIBC over at least 2-yr follow-up. These effects may persist up to 5 yr. Further research in a pragmatic study looking at longer-term outcomes beyond 24 mo will help guide recommendations on clinical adoption. PATIENT SUMMARY: This review suggests that photodynamic diagnosis, compared with white light cystoscopy, improves recurrence-free survival in non-muscle-invasive bladder cancer over at least 2 yr of follow-up. However, confirmatory pragmatic studies with longer-term outcomes are required for its clinical adoption. CI - (c) 2021 The Authors. FAU - Veeratterapillay, Rajan AU - Veeratterapillay R AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Gravestock, Paul AU - Gravestock P AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Nambiar, Arjun AU - Nambiar A AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Gupta, Ameet AU - Gupta A AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Aboumarzouk, Omar AU - Aboumarzouk O AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Rai, Bhavan AU - Rai B AD - Department of Urology, Freeman Hospital, Newcastle, UK. FAU - Vale, Luke AU - Vale L AD - Health Economics Group, Population Health Sciences Institute, Newcastle University, Newcastle, UK. FAU - Heer, Rakesh AU - Heer R AD - Department of Urology, Freeman Hospital, Newcastle, UK. LA - eng PT - Journal Article PT - Review DEP - 20210722 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8385287 OTO - NOTNLM OT - Cystoscopy OT - Fluorescence OT - Recurrence rate OT - Recurrence-free survival OT - Urinary bladder neoplasms EDAT- 2021/09/02 06:00 MHDA- 2021/09/02 06:01 PMCR- 2021/07/22 CRDT- 2021/09/01 07:32 PHST- 2021/06/28 00:00 [accepted] PHST- 2021/09/01 07:32 [entrez] PHST- 2021/09/02 06:00 [pubmed] PHST- 2021/09/02 06:01 [medline] PHST- 2021/07/22 00:00 [pmc-release] AID - S2666-1683(21)00128-2 [pii] AID - 10.1016/j.euros.2021.06.011 [doi] PST - epublish SO - Eur Urol Open Sci. 2021 Jul 22;31:17-27. doi: 10.1016/j.euros.2021.06.011. eCollection 2021 Sep. PMID- 34458203 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 13 DP - 2021 TI - Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. PG - 603-611 LID - 10.2147/RRU.S326249 [doi] AB - PURPOSE: L-type amino acid transporter 1 (LAT1), a Na(+)-independent amino acid transporter, is highly expressed in various cancer types. We evaluated the prognostic value of LAT1 expression in non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We retrospectively reviewed 119 consecutive patients who underwent initial transurethral resection of bladder tumor. Of these, 75 patients with NMIBC were included in this study. Patients were classified into two groups according to the proportion of LAT1-positive cells, as determined by immunohistochemistry. Associations between LAT1 expression and clinicopathological factors were analyzed. Cox multivariate analyses were performed to identify independent predictors of intravesical recurrence (IVR). The LAT1 integrated risk model was compared with the European Organization for Research and Treatment of Cancer (EORTC) risk model to evaluate the predictive ability for IVR based on the c-index. RESULTS: The median follow-up was 37 months. Twenty-eight patients (37.3%) had IVR. LAT1 expression was not correlated with any other clinicopathological factors. Patients with high LAT1 expression had a worse IVR-free survival than that of patients with low LAT1 expression (P = 0.038). Cox multivariate analyses indicated that tumor multiplicity and high LAT1 expression were independent predictors of IVR. The LAT1 integrated risk model had a significantly improved performance over the EORTC model for assessing recurrence risk (c-index: 0.695, improvement: 0.091, P = 0.001). When patients were stratified into three groups according to the score calculated by the LAT1 integrated risk model, the 2-year IVR-free survival rates were 93.3% in patients with 0 points, 66.9% for those with 2 points, and 37.5% for those with 4 points. CONCLUSION: High LAT1 expression was an independent predictor of IVR in patients with NMIBC. The LAT1 integrated risk model had good predictability for IVR. CI - (c) 2021 Sawazaki et al. FAU - Sawazaki, Harutake AU - Sawazaki H AUID- ORCID: 0000-0002-8161-7664 AD - Department of Urology, Tama-Hokubu Medical Center, Higashimurayama, Japan. AD - Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Japan. FAU - Arai, Yuichi AU - Arai Y AD - Department of Urology, National Defense Medical College, Tokorozawa, Japan. FAU - Ito, Yuji AU - Ito Y AD - Department of Pathology, Tama-Hokubu Medical Center, Higashimurayama, Japan. FAU - Sato, Kimiya AU - Sato K AD - Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan. FAU - Tsuda, Hitoshi AU - Tsuda H AD - Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan. FAU - Yamaga, Takashi AU - Yamaga T AD - Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Japan. FAU - Sakurai, Hiroyuki AU - Sakurai H AD - Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Japan. LA - eng PT - Journal Article DEP - 20210821 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC8387640 OTO - NOTNLM OT - L-type amino acid transporter 1 OT - intravesical recurrence OT - non-muscle-invasive bladder cancer OT - transurethral resection of bladder tumor COIS- The authors report no conflicts of interest in this work. EDAT- 2021/08/31 06:00 MHDA- 2021/08/31 06:01 PMCR- 2021/08/21 CRDT- 2021/08/30 06:01 PHST- 2021/06/23 00:00 [received] PHST- 2021/08/14 00:00 [accepted] PHST- 2021/08/30 06:01 [entrez] PHST- 2021/08/31 06:00 [pubmed] PHST- 2021/08/31 06:01 [medline] PHST- 2021/08/21 00:00 [pmc-release] AID - 326249 [pii] AID - 10.2147/RRU.S326249 [doi] PST - epublish SO - Res Rep Urol. 2021 Aug 21;13:603-611. doi: 10.2147/RRU.S326249. eCollection 2021. PMID- 34448679 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20220531 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 55 IP - 5 DP - 2021 Oct TI - Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). PG - 354-360 LID - 10.1080/21681805.2021.1971290 [doi] AB - BACKGROUND: Multiparametric Magnetic Resonance Imaging (mpMRI) has been proposed to add value in the diagnostic pathway of bladder cancer (BC). We wanted to evaluate the performance of mpMRI for muscle-invasion detection in BC patients using a subjective MRI visual T-category and the Vesical Imaging-Reporting and Data System (VI-RADS) score. METHODS: This single centre clinical trial included 45 patients with suspected BC (ClinicalTrials.gov Identifier: NCT02662166). All patients had mpMRI prior to transurethral resection of bladder tumour (TUR-BT). The imaging was correlated to histopathological findings. Two individual radiologists evaluated all the mpMRI images. A binary cut-off point for the detection of muscle-invasion in the MRI visual T-category was defined between T1 and T2 and the VI-RADS cut-off score was 3. Cohen's Kappa values were used to evaluate the agreement between the two radiologists. Sensitivity, Specificity, Area Under Receiver Operator Characteristics Curve (AUC), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were calculated to evaluate the performance of both radiologists separately. RESULTS: AUC values for reader A and B using the MRI visual T-category were 0.76 and 0.56, while the corresponding values for VI-RADS were 0.63 and 0.57, respectively. There was no statistically significant difference between the radiologists nor the reporting systems (p > .05) in the detection of muscle-invasion. The inter-reader agreement was substantial (0.61-0.80). CONCLUSION: Both the subjective MRI visual T-category and VI-RADS score had only a low to moderate accuracy for the detection of muscle-invasion in BC with no statistically significant difference between the reporting systems. FAU - Nikulainen, Ilkka AU - Nikulainen I AUID- ORCID: 0000-0002-6065-4087 AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Salminen, Antti P AU - Salminen AP AUID- ORCID: 0000-0001-6081-7686 AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Jambor, Ivan AU - Jambor I AUID- ORCID: 0000-0001-6305-3570 AD - Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. AD - Department of Radiology, University of Turku, Turku, Finland. AD - Medical Imaging Centre of Southwest Finland, Turku University Hospital, Turku, Finland. FAU - Merisaari, Harri AU - Merisaari H AUID- ORCID: 0000-0002-8515-5399 AD - Department of Radiology, University of Turku, Turku, Finland. AD - Medical Imaging Centre of Southwest Finland, Turku University Hospital, Turku, Finland. AD - Department of Future Technologies, University of Turku, Turku, Finland. AD - Institute of Biomedicine, University of Turku, Turku, Finland. FAU - Tammilehto, Ville AU - Tammilehto V AD - Department of Radiology, University of Turku, Turku, Finland. FAU - Taimen, Pekka AU - Taimen P AUID- ORCID: 0000-0001-8849-4604 AD - Department of Pathology, Turku University Hospital, Turku, Finland. FAU - Seikkula, Heikki AU - Seikkula H AUID- ORCID: 0000-0001-9942-1582 AD - Department of Surgery, Central Hospital of Central Finland, Jyvaskyla, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AUID- ORCID: 0000-0003-3647-0015 AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. LA - eng SI - ClinicalTrials.gov/NCT02662166 PT - Clinical Trial PT - Journal Article DEP - 20210827 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - *Multiparametric Magnetic Resonance Imaging MH - Muscles MH - *Prostatic Neoplasms MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging OTO - NOTNLM OT - Bladder cancer OT - T-stage OT - VI-RADS OT - multiparametric MRI OT - single centre clinical trial EDAT- 2021/08/28 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/08/27 12:17 PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/08/27 12:17 [entrez] AID - 10.1080/21681805.2021.1971290 [doi] PST - ppublish SO - Scand J Urol. 2021 Oct;55(5):354-360. doi: 10.1080/21681805.2021.1971290. Epub 2021 Aug 27. PMID- 34448522 OWN - NLM STAT- MEDLINE DCOM- 20220915 LR - 20220929 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 130 IP - 4 DP - 2022 Oct TI - Predictive value of immunological markers after bacille Calmette-Guerin induction in bladder cancer. PG - 444-453 LID - 10.1111/bju.15582 [doi] AB - OBJECTIVES: To investigate the predictive value of different immunological markers on treatment outcomes after bacille Calmette-Guerin (BCG) induction in high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients who underwent transurethral resection of bladder tumour for NMIBC were assessed for study eligibility. Urine and blood samples were taken from patients at baseline (immediately before first dose of induction) and after induction (4 h after last [sixth] dose). Urine samples were evaluated for interleukin (IL)-2 and IL-10 by solid-phase enzyme-linked immunosorbent assay. Blood samples were evaluated for tumour necrosis factor alpha (TNF-alpha), cytotoxic T-lymphocyte antigen 4 (CTLA-4) and transcription factors (TFs) (GATA-binding protein 3 [GATA3], T-box expressed in T cells [T-bet], and forkhead box protein 3 [FoxP3]) using quantitative reverse transcriptase-polymerase chain reaction analysis. Change pattern and fold change of each evaluable marker was assessed in relation to different treatment outcomes (initial complete response [ICR]/recurrence/progression). RESULTS: Between July 2013 and May 2019, 204 patients were included. Among evaluable markers, urinary IL-2 and serum TNF-alpha increased in all patients, serum CTLA-4 and FoxP3(+) showed a predominant decreased pattern in 188 (92.2%) and 192 (94.1%) patients, respectively. An ICR was achieved in 186 (91.2%) patients. Serum TNF-alpha fold change and urinary IL-10 change pattern were significantly associated with an ICR (P = 0.001 and P = 0.03, respectively). At a median (range) follow-up of 37 (20-88) months, 104 (56%) patients developed recurrence. Urinary IL-10, serum CTLA-4, T-bet(+) , FoxP3(+) change patterns and GATA3(+) /T-bet(+) ratio were significantly associated with tumour recurrence (P = 0.001, P = 0.001, P = 0.02, P = 0.009 and P = 0.001, respectively). Tumour progression occurred in 34 (18.3%) patients. Urinary IL-10, serum CTLA-4, serum T-bet(+) change patterns and GATA3(+) /T-bet(+) ratio were independent predictors of tumour progression (P = 0.001, P = 0.001, P = 0.02 and P = 0.001, respectively). CONCLUSIONS: Urinary IL-10 and serum TNF-alpha can significantly predict ICR. Moreover, change pattern of urinary IL-10, serum CTLA-4, TFs (GATA3, T-bet and FoxP3) and GATA3(+) /T-bet(+) ratio after BCG induction can independently predict further BCG response. These markers could be implemented in clinical practice when management options are discussed or in systems with severe BCG shortage. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Elsawy, Amr A AU - Elsawy AA AUID- ORCID: 0000-0001-7077-8094 AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abol-Enein, Hassan AU - Abol-Enein H AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Laymon, Mahmoud AU - Laymon M AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Ahmed, Asmaa E AU - Ahmed AE AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Essam, Ahmed AU - Essam A AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Hamam, Eman T AU - Hamam ET AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Zidan, Abdel-Aziz A AU - Zidan AA AD - Department of Zoology, Faculty of Science, Damanhour University, Damanhour, Egypt. FAU - Zahran, Mohamed H AU - Zahran MH AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AUID- ORCID: 0000-0003-2699-2629 AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Awadalla, Amira AU - Awadalla A AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210913 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - 0 (CTLA-4 Antigen) RN - 0 (Forkhead Transcription Factors) RN - 0 (Tumor Necrosis Factor-alpha) RN - 130068-27-8 (Interleukin-10) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Biomarkers MH - CTLA-4 Antigen MH - Forkhead Transcription Factors/therapeutic use MH - Humans MH - Interleukin-10/therapeutic use MH - Neoplasm Recurrence, Local/drug therapy MH - Tumor Necrosis Factor-alpha MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - T cells OT - bacille Calmette-Guerin response OT - bladder cancer OT - prediction OT - progression OT - recurrence OT - urinary cytokines EDAT- 2021/08/28 06:00 MHDA- 2022/09/16 06:00 CRDT- 2021/08/27 08:44 PHST- 2021/08/09 00:00 [revised] PHST- 2021/05/26 00:00 [received] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/08/28 06:00 [pubmed] PHST- 2022/09/16 06:00 [medline] PHST- 2021/08/27 08:44 [entrez] AID - 10.1111/bju.15582 [doi] PST - ppublish SO - BJU Int. 2022 Oct;130(4):444-453. doi: 10.1111/bju.15582. Epub 2021 Sep 13. PMID- 34447272 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 13 DP - 2021 TI - The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. PG - 6567-6578 LID - 10.2147/CMAR.S318893 [doi] AB - PURPOSE: Fibroblast growth factor receptor 3 (FGFR3) alterations are frequent in non-muscle-invasive bladder cancer (NMIBC), although current data regarding the prognostic and therapeutic relevance are inconsistent. We analyzed the prognostic role of FGFR3 mRNA expression in stage T1 NMIBC. PATIENTS AND METHODS: The mRNA expression of FGFR3 and cyclin-dependent kinase inhibitor 2A (CDKN2A) was measured by RT-qPCR in 80 patients with stage T1 NMIBC treated with transurethral resection of the bladder and correlated with clinical data and KRT5 and KRT20 expression, used as surrogate markers for basal and luminal subtypes, respectively. RESULTS: FGFR3 and CDKN2A transcript levels were not correlated. FGFR3 expression was associated with the expression of KRT5 (p=0.002) and KRT20 (p < 0.001). CDKN2A expression was negatively correlated with KRT5 (p=0.030). In Kaplan-Meier analysis and univariable Cox regression analysis, high FGFR3 expression was associated with significantly reduced recurrence-free survival (RFS) (HR=3.78; p < 0.001) and improved overall survival (OS) (HR=0.50; p=0.043), while high CDKN2A expression was associated with reduced OS (HR=2.34; p=0.034). Patient age was the only clinicopathological parameter associated with reduced OS (HR=2.29; p=0.022). No parameter was an independent prognostic factor in multivariable analysis. Next, we stratified the patients depending on their lineage differentiation. In univariable analysis, the prognostic effect of FGFR3 and CDKN2A was observed primarily in patients demonstrating high expression of KRT5 or KRT20, whereas high FGFR3 expression was associated with significantly reduced RFS, irrespective of instillation therapy. CONCLUSION: Stage T1 NMIBC patients with high FGFR3 expression show shorter RFS but better OS than patients with low FGFR3 expression. CI - (c) 2021 Sikic et al. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AUID- ORCID: 0000-0002-9077-1727 AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Kubon, Jennifer AU - Kubon J AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Worst, Thomas S AU - Worst TS AD - Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Kriegmair, Maximilian C AU - Kriegmair MC AD - Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AUID- ORCID: 0000-0002-0665-6604 AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. LA - eng PT - Journal Article DEP - 20210820 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC8384147 OTO - NOTNLM OT - CDKN2A OT - FGFR3 OT - NMIBC OT - biomarker OT - prognosis COIS- DS, HT, JB, ME, VW, BK, WO, TSW, MCK, PE, AH, BW, RMW and SW are members of the BRIDGE Consortium e.V., 68167 Mannheim, Germany. ME reports grants, personal fees, and/or non-financial support from AstraZeneca, Janssen, Cepheid, MSD, Roche, Astellas, GenomicHealth, Diaceutics, and STRATIFYER, outside the submitted work. JK reports grants from ELAN Fund, during the conduct of the study. AH reports personal fees from BMS, MSD, Roche, Janssen, Pfizer, AstraZeneca, Cepheid, and Qiagen, during the conduct of the study; personal fees from BMS, MSD, Roche, AstraZeneca, Janssen, Qiagen, and Cepheid, outside the submitted work. RMW reports fee for service research cooperation from Janssen Research & Development LLC, fee for master research and testing service collaboration from Qiagen GmbH, during the conduct of the study; is employee and reports stocks from STRATIFYER Molecular Pathology, fee for strategic framework collaboration from BioNTech Diagnostics GmbH, outside the submitted work; In addition, RMW has a patent "Method of classifying a sample based on determination of FGFR" (PCT/EP2020/060456) licensed to Qiagen GmbH. The authors report no other conflicts of interest in this work. EDAT- 2021/08/28 06:00 MHDA- 2021/08/28 06:01 PMCR- 2021/08/20 CRDT- 2021/08/27 06:52 PHST- 2021/05/06 00:00 [received] PHST- 2021/07/28 00:00 [accepted] PHST- 2021/08/27 06:52 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/08/28 06:01 [medline] PHST- 2021/08/20 00:00 [pmc-release] AID - 318893 [pii] AID - 10.2147/CMAR.S318893 [doi] PST - epublish SO - Cancer Manag Res. 2021 Aug 20;13:6567-6578. doi: 10.2147/CMAR.S318893. eCollection 2021. PMID- 34441434 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210830 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 11 IP - 8 DP - 2021 Aug 20 TI - Mitofusin-2 Down-Regulation Predicts Progression of Non-Muscle Invasive Bladder Cancer. LID - 10.3390/diagnostics11081500 [doi] LID - 1500 AB - Identification of markers predicting disease outcome is a major clinical issue for non-muscle invasive bladder cancer (NMIBC). The present study aimed to determine the role of the mitochondrial proteins Mitofusin-2 (Mfn2) and caseinolytic protease P (ClpP) in predicting the outcome of NMIBC. The study population consisted of patients scheduled for transurethral resection of bladder tumor upon the clinical diagnosis of bladder cancer (BC). Samples of the main bladder tumor and healthy-looking bladder wall from patients classified as NMIBC were tested for Mfn2 and ClpP. The expression levels of these proteins were correlated to disease recurrence, progression. Mfn2 and ClpP expression levels were significantly higher in lesional than in non-lesional tissue. Low-risk NMIBC had significantly higher Mfn2 expression levels and significantly lower ClpP expression levels than high-risk NMIBC; there were no differences in non-lesional levels of the two proteins. Lesional Mfn2 expression levels were significantly lower in patients who progressed whereas ClpP levels had no impact on any survival outcome. Multivariable analysis adjusting for the EORTC scores showed that Mfn2 downregulation was significantly associated with disease progression. In conclusion, Mfn2 and ClpP proteins were found to be overexpressed in BC as compared to non-lesional bladder tissue and Mfn2 expression predicted disease progression. FAU - Cormio, Antonella AU - Cormio A AUID- ORCID: 0000-0002-6029-1722 AD - Department of Biosciences, Biotechnologies, and Biofarmaceutical, University of Bari, 70126 Bari, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AUID- ORCID: 0000-0002-7291-0316 AD - Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Musicco, Clara AU - Musicco C AUID- ORCID: 0000-0003-4359-4403 AD - CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), 70126 Bari, Italy. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University of Foggia, 71122 Foggia, Italy. FAU - Calo, Beppe AU - Calo B AD - Department of Urology, Bonomo Hospital, 76123 Andria, Italy. FAU - Chirico, Marco AU - Chirico M AD - Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Falagario, Ugo Giovanni AU - Falagario UG AD - Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy. FAU - Piccoli, Claudia AU - Piccoli C AD - Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy. AD - Department of Urology, Bonomo Hospital, 76123 Andria, Italy. LA - eng PT - Journal Article DEP - 20210820 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC8394056 OTO - NOTNLM OT - ClpP OT - Mfn2 OT - NMIBC OT - bladder cancer OT - disease progression OT - disease recurrence COIS- The authors declare no conflict of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/08/28 06:01 PMCR- 2021/08/20 CRDT- 2021/08/27 01:09 PHST- 2021/08/02 00:00 [received] PHST- 2021/08/17 00:00 [revised] PHST- 2021/08/18 00:00 [accepted] PHST- 2021/08/27 01:09 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/08/28 06:01 [medline] PHST- 2021/08/20 00:00 [pmc-release] AID - diagnostics11081500 [pii] AID - diagnostics-11-01500 [pii] AID - 10.3390/diagnostics11081500 [doi] PST - epublish SO - Diagnostics (Basel). 2021 Aug 20;11(8):1500. doi: 10.3390/diagnostics11081500. PMID- 34440955 OWN - NLM STAT- MEDLINE DCOM- 20210831 LR - 20240814 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 8 DP - 2021 Jul 24 TI - Bladder Cancer: Current Challenges and Future Directions. LID - 10.3390/medicina57080749 [doi] LID - 749 AB - Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BCa-specific mortality started to decrease in the regions with a wide range of activities leading to greater social awareness of the risk factors and the decline in carcinogenic exposure. The urologic community refines the role of transurethral surgery towards more rigorous and high-quality techniques. New agents have been approved for patients with BCG failure who faced radical cystectomy so far. Although radical removal of the bladder is the gold standard for muscle invasive cancer management, the extent and clinical value of lymphadenectomy is currently heavily challenged in randomized trials. Furthermore, alternatives to perioperative chemotherapy have arisen to increase the likelihood of complete treatment delivery and successful oncological outcomes. Finally, improvements in molecular biology and our understanding of tumorigenesis open the era of personalized medicine in bladder cancer. In the present review, the status and future directions in bladder cancer epidemiology, diagnosis and management are thoroughly discussed. FAU - Dobruch, Jakub AU - Dobruch J AD - Centre of Postgraduate Medical Education, Department of Urology, 00-416 Warsaw, Poland. FAU - Oszczudlowski, Maciej AU - Oszczudlowski M AD - Centre of Postgraduate Medical Education, Department of Urology, 00-416 Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20210724 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Cystectomy MH - Humans MH - Lymph Node Excision MH - Neoplasm Invasiveness MH - Risk Factors MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy PMC - PMC8402079 OTO - NOTNLM OT - BCG failure OT - perioperative chemotherapy OT - surgical treatment OT - urinary bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/09/01 06:00 PMCR- 2021/07/24 CRDT- 2021/08/27 01:08 PHST- 2021/05/16 00:00 [received] PHST- 2021/07/18 00:00 [revised] PHST- 2021/07/20 00:00 [accepted] PHST- 2021/08/27 01:08 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/01 06:00 [medline] PHST- 2021/07/24 00:00 [pmc-release] AID - medicina57080749 [pii] AID - medicina-57-00749 [pii] AID - 10.3390/medicina57080749 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Jul 24;57(8):749. doi: 10.3390/medicina57080749. PMID- 34440262 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210830 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 9 IP - 8 DP - 2021 Aug 20 TI - Prognostic Significance of ROR2 Expression in Patients with Urothelial Carcinoma. LID - 10.3390/biomedicines9081054 [doi] LID - 1054 AB - We investigated the association of receptor tyrosine kinase-like orphan receptor 2 (ROR2) expression with clinicopathological features and oncologic outcomes in large urothelial carcinoma (UC) of the upper tract (UTUC) and urinary bladder (UBUC) cohorts. Through transcriptomic profiling of a published dataset (GSE31684), ROR2 was discovered to be the most upregulated gene during UC progression, focusing on the JNK cascade (GO:0007254). Initially, the evaluation of ROR2 mRNA expression in 50 frozen UBUCs showed significantly upregulated levels in high-stage UC. Moreover, high ROR2 immunoexpression significantly correlated with high tumor stage, high tumor grade, lymph node metastasis, and vascular invasion (all p < 0.05). In multivariate analysis, after adjusting for standard clinicopathological features, ROR2 expression status was an independent prognosticator of cancer-specific survival and metastasis-free survival in UTUC and UBUC (all p < 0.01). In the subgroup analysis, it also significantly predicted bladder tumor recurrence in non-muscle invasive UBUC. Furthermore, the GO enrichment analysis showed that fatty acid, monocarboxylic acid, carboxylic acid metabolic processes, negative regulation of neutrophil migration, and negative regulation of granulocyte and neutrophil chemotaxis were significantly enriched by ROR2 dysregulation. In conclusion, high ROR2 immunoexpression was associated with aggressive pathological characteristics in UC and independently predicted worse prognosis, suggesting it could play roles in clinical risk stratification and therapy decisions. FAU - Yeh, Cheng-Fa AU - Yeh CF AD - Division of General Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan. AD - Department of Environment Engineering and Science, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan. FAU - Chan, Ti-Chun AU - Chan TC AD - Department of Medical Research, Chi Mei Medical Center, Tainan 710, Taiwan. AD - National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan. FAU - Ke, Hung-Lung AU - Ke HL AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. FAU - Chen, Tzu-Ju AU - Chen TJ AD - Department of Clinical Pathology, Chi Mei Medical Center, Tainan 710, Taiwan. FAU - Wu, Li-Ching AU - Wu LC AD - Department of Clinical Pathology, Chi Mei Medical Center, Tainan 710, Taiwan. FAU - Lee, Hsiang-Ying AU - Lee HY AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. FAU - Wei, Yu-Ching AU - Wei YC AD - Department of Pathology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Pathology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Li, Chien-Feng AU - Li CF AD - Department of Medical Research, Chi Mei Medical Center, Tainan 710, Taiwan. AD - National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung 900, Taiwan. LA - eng GR - KMUH107-7R58, KMUH108-8M53, KMUH-DK(C)-110006/Kaohsiung Medical University Hospital, Taiwan/ GR - MOST109-2314-B-037-110-MY3, MOST110-2321-B-037-002/Ministry of Science and Technology, Taiwan/ PT - Journal Article DEP - 20210820 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC8392262 OTO - NOTNLM OT - ROR2 OT - bladder cancer OT - prognosis OT - survival OT - upper tract urothelial carcinoma COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/08/28 06:00 MHDA- 2021/08/28 06:01 PMCR- 2021/08/20 CRDT- 2021/08/27 01:06 PHST- 2021/07/18 00:00 [received] PHST- 2021/08/16 00:00 [revised] PHST- 2021/08/17 00:00 [accepted] PHST- 2021/08/27 01:06 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/08/28 06:01 [medline] PHST- 2021/08/20 00:00 [pmc-release] AID - biomedicines9081054 [pii] AID - biomedicines-09-01054 [pii] AID - 10.3390/biomedicines9081054 [doi] PST - epublish SO - Biomedicines. 2021 Aug 20;9(8):1054. doi: 10.3390/biomedicines9081054. PMID- 34438192 OWN - NLM STAT- MEDLINE DCOM- 20220126 LR - 20220126 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 54 DP - 2021 Oct TI - The diagnostic applicability of A-type Lamin in non-muscle invasive bladder cancer. PG - 151808 LID - S1092-9134(21)00108-8 [pii] LID - 10.1016/j.anndiagpath.2021.151808 [doi] AB - PURPOSE: Lamin A is a major component of the nuclear lamina maintaining nuclear integrity, regulation of gene expression, cell proliferation, and apoptosis. Its deregulation in cancer has been recently reported to be associated with its prognosis. However, its clinical significance in non-muscle invasive bladder cancer (NMIBC) remains to be defined. MATERIAL/METHODS: Immunohistochemical staining and RT-qPCR were performed to screen the expression patterns of Lamin A/C protein and Lamin A mRNA respectively in 58 high and low grade NMIBC specimens. RESULTS: Lamin A/C protein was expressed only in the nucleus and less exhibited in NMIBC tissues compared to non-tumoral ones. On the other side, Lamin A mRNA was up-regulated in NMIBC compared to controls. Nevertheless, both expression patterns (protein and mRNA) were not correlated to clinical prognosis factors and were not able to predict the overall survival of patients with high-grade NMIBC. CONCLUSIONS: The deregulation of A-type Lamin is not associated with the prognosis of NMIBC, but it could serve as a diagnostic biomarker distinguishing NMIBC patients from healthy subjects suggesting its involvement as an initiator event of tumorigenesis in our cohort. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Setti Boubaker, Nouha AU - Setti Boubaker N AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia; UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. Electronic address: nouha.setti@hotmail.fr. FAU - Gurtner, Aymone AU - Gurtner A AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy; Institute of Translational Pharmacology, National Research Council, Rome, Italy. Electronic address: aymone.gurtner@ifo.gov.it. FAU - Trabelsi, Nesrine AU - Trabelsi N AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. Electronic address: nesrine.trabelsi.n@ieee.org. FAU - Manni, Isabella AU - Manni I AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. Electronic address: isabella.manni@ifo.gov.it. FAU - Ayed, Haroun AU - Ayed H AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: ayedharoun@yahoo.fr. FAU - Saadi, Ahmed AU - Saadi A AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: dr.saadi.ahmed@gmail.com. FAU - Zaghbib, Selim AU - Zaghbib S AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: selim.zaghbib@gmail.com. FAU - Naimi, Zeineb AU - Naimi Z AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: zeinebnaimi89@gmail.com. FAU - Sahraoui, Ghada AU - Sahraoui G AD - Pathology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: ghada_sahraoui@yahoo.com. FAU - Zouari, Skander AU - Zouari S AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: zouari.skander@gmail.com. FAU - Meddeb, Khedija AU - Meddeb K AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: khedijameddeb@gmail.com. FAU - Mrad, Karima AU - Mrad K AD - Pathology Department, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: karima.mrad@rns.tn. FAU - Chebil, Mohamed AU - Chebil M AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia. Electronic address: mohamed.chebil.uro@gmail.com. FAU - Piaggio, Giulia AU - Piaggio G AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. Electronic address: giulia.piaggio@ifo.gov.it. FAU - Ouerhani, Slah AU - Ouerhani S AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. Electronic address: slah_mekni@yahoo.fr. LA - eng PT - Journal Article DEP - 20210817 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 RN - 0 (Biomarkers, Tumor) RN - 0 (Lamins) RN - 0 (RNA, Messenger) SB - IM MH - Biomarkers, Tumor/metabolism MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Lamins/genetics/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*genetics/*pathology MH - Neoplasm Recurrence, Local/diagnosis/*genetics/pathology MH - Prognosis MH - RNA, Messenger/genetics MH - *Urinary Bladder Neoplasms/diagnosis/genetics/metabolism OTO - NOTNLM OT - Diagnosis OT - LMNA OT - Lamin A/C OT - NMIBC OT - Prognosis EDAT- 2021/08/27 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/08/26 20:19 PHST- 2021/06/09 00:00 [received] PHST- 2021/07/04 00:00 [revised] PHST- 2021/08/10 00:00 [accepted] PHST- 2021/08/27 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/08/26 20:19 [entrez] AID - S1092-9134(21)00108-8 [pii] AID - 10.1016/j.anndiagpath.2021.151808 [doi] PST - ppublish SO - Ann Diagn Pathol. 2021 Oct;54:151808. doi: 10.1016/j.anndiagpath.2021.151808. Epub 2021 Aug 17. PMID- 34433303 OWN - NLM STAT- MEDLINE DCOM- 20220120 LR - 20251224 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 207 IP - 1 DP - 2022 Jan TI - Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. PG - 61-69 LID - 10.1097/JU.0000000000002186 [doi] AB - PURPOSE: Low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG IR NMIBC) is a recurrent disease, thus requiring repeated transurethral resection of bladder tumor under general anesthesia. We evaluated the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, as a primary chemoablative therapeutic alternative to transurethral resection of bladder tumor for patients with LG IR NMIBC. MATERIALS AND METHODS: This prospective, phase 2b, open-label, single-arm trial recruited patients with biopsy-proven LG IR NMIBC to receive 6 once-weekly instillations of UGN-102. The primary end point was complete response (CR) rate, defined as the proportion of patients with negative endoscopic examination, negative cytology and negative for-cause biopsy 3 months after treatment initiation. Patients with CR were followed quarterly up to 12 months to assess durability of treatment effect. Safety and adverse events were monitored throughout the trial. RESULTS: A total of 63 patients (38 males and 25 females 33-96 years old) enrolled and received >/=1 instillation of UGN-102. Among the patients 41 (65%) achieved CR at 3 months, of whom 39 (95%), 30 (73%) and 25 (61%) remained disease-free at 6, 9 and 12 months after treatment initiation, respectively. A total of 13 patients had documented recurrences. The probability of durable response 9 months after CR (12 months after treatment initiation) was estimated to be 73% by Kaplan-Meier analysis. Common adverse events (incidence >/=10%) included dysuria, urinary frequency, hematuria, micturition urgency, urinary tract infection and fatigue. CONCLUSIONS: Nonsurgical primary chemoablation of LG IR NMIBC using UGN-102 resulted in significant treatment response with sustained durability. UGN-102 may provide an alternative to repetitive surgery for patients with LG IR NMIBC. FAU - Chevli, K Kent AU - Chevli KK AD - State University of New York at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York. FAU - Shore, Neal D AU - Shore ND AD - Atlantic Urology Clinics, Carolina Urologic Research Center, Myrtle Beach, South Carolina. FAU - Trainer, Andrew AU - Trainer A AD - Adult Paediatrics Urology & Urogynecology, Omaha, Nebraska. FAU - Smith, Angela B AU - Smith AB AD - University of North Carolina School of Medicine, Chapel Hill, North Carolina. FAU - Saltzstein, Daniel AU - Saltzstein D AD - Urology San Antonio, San Antonio, Texas. FAU - Ehrlich, Yaron AU - Ehrlich Y AD - Rabin Medical Center, Petah-Tikva, Israel. FAU - Raman, Jay D AU - Raman JD AD - Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Friedman, Boris AU - Friedman B AD - Lady Davis Carmel Medical Center, Technicon-Israel Institute of Technology, Haifa, Israel. FAU - D'Anna, Richard AU - D'Anna R AD - Arkansas Urology, Little Rock, Arkansas. FAU - Morris, David AU - Morris D AD - Urology Associates, Nashville, Tennessee. FAU - Hu, Brian AU - Hu B AD - Loma Linda University, Loma Linda, California. FAU - Tyson, Mark AU - Tyson M AD - Mayo Clinic, Scottsdale, Arizona. FAU - Sankin, Alexander AU - Sankin A AD - Albert Einstein College of Medicine, Bronx, New York. FAU - Kates, Max AU - Kates M AD - Brady Urological Institute, Johns Hopkins Medicine, Baltimore, Maryland. FAU - Linehan, Jennifer AU - Linehan J AD - John Wayne Cancer Institute, Santa Monica, California. FAU - Scherr, Douglas AU - Scherr D AD - Weill Medical College of Cornell University, New York, New York. FAU - Kester, Steven AU - Kester S AD - Urology Center of Florida, Pompano Beach, Florida. FAU - Verni, Michael AU - Verni M AD - Urology Center of Las Vegas, Las Vegas, Nevada. FAU - Chamie, Karim AU - Chamie K AD - UCLA, Los Angeles, California. FAU - Karsh, Lawrence AU - Karsh L AD - The Urology Center of Colorado, Denver, Colorado. FAU - Cinman, Arnold AU - Cinman A AD - Tower Urology, Los Angeles, California. FAU - Meads, Andrew AU - Meads A AD - UroGen Pharma, New York, New York. FAU - Lahiri, Soumi AU - Lahiri S AD - UroGen Pharma, New York, New York. FAU - Malinowski, Madlen AU - Malinowski M AD - UroGen Pharma, New York, New York. FAU - Gabai, Nimrod AU - Gabai N AD - UroGen Pharma, New York, New York. FAU - Raju, Sunil AU - Raju S AD - UroGen Pharma, New York, New York. FAU - Schoenberg, Mark AU - Schoenberg M AD - Albert Einstein College of Medicine, Bronx, New York. AD - UroGen Pharma, New York, New York. FAU - Seltzer, Elyse AU - Seltzer E AD - UroGen Pharma, New York, New York. FAU - Huang, William C AU - Huang WC AUID- ORCID: 0000-0001-5261-0650 AD - NYU Langone Urology Associates, New York, New York. LA - eng SI - ClinicalTrials.gov/NCT03558503 PT - Clinical Trial, Phase II PT - Journal Article DEP - 20210826 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Hydrogels) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - J Urol. 2022 Jan;207(1):69. doi: 10.1097/JU.0000000000002186.01. PMID: 34661456 CIN - J Urol. 2022 Jan;207(1):69. doi: 10.1097/JU.0000000000002186.02. PMID: 34661457 MH - Ablation Techniques MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/adverse effects/*therapeutic use MH - Female MH - Humans MH - Hydrogels/adverse effects/*therapeutic use MH - Male MH - Middle Aged MH - Mitomycin/adverse effects/*therapeutic use MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Prospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC8667793 OTO - NOTNLM OT - clinical trial OT - mitomycin OT - phase II OT - urinary bladder neoplasms COIS- JL, DM, JDR and DSa report acting as investigators and consultants/advisors for UroGen Pharma; KC, BH, NDS and ABS report serving as consultants/advisors for UroGen Pharma; NG, SL, MM, AM, SR, MS and ES are full-time employees of UroGen Pharma; MT reports serving as an assistant editor for The Journal of Urology(R); KKC, AC, RD'A, YE, BF, WCH, LK, MK, SK, AS, DSc, AT and MV report no direct or indirect commercial financial incentive associated with publishing the article. EDAT- 2021/08/27 06:00 MHDA- 2022/01/21 06:00 PMCR- 2021/12/13 CRDT- 2021/08/26 05:24 PHST- 2021/08/27 06:00 [pubmed] PHST- 2022/01/21 06:00 [medline] PHST- 2021/08/26 05:24 [entrez] PHST- 2021/12/13 00:00 [pmc-release] AID - JU-21-929 [pii] AID - 10.1097/JU.0000000000002186 [doi] PST - ppublish SO - J Urol. 2022 Jan;207(1):61-69. doi: 10.1097/JU.0000000000002186. Epub 2021 Aug 26. PMID- 34430403 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 7 DP - 2021 Jul TI - Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients. PG - 2998-3009 LID - 10.21037/tau-21-158 [doi] AB - BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selection. We performed genomic analysis on high-grade (HG) T1 NMIBCs to determine if response to therapy is predicted by certain mutational and/or expressional changes. METHODS: Patients with HG T1 NMIBC treated with induction BCG were stratified by response into durable and non-durable responders. Baseline tumor samples were subjected to targeted DNA sequencing and whole-exome RNAseq. Genomic variants differing significantly between response groups were analyzed using Ingenuity Pathway Analysis (IPA) software. Variant selection was refined to target potential biomarker candidates for responsiveness to BCG. RESULTS: Among 42 patients, the median follow-up was 51.7 months and 40.5% (n=17) were durable BCG responders. Deleterious mutations in the RNA sequence of JCHAIN, S100A7, CLEC2B, and ANXA10 were more common in non-durable responders. Mutations in MCL1 and MSH6 detected on targeted sequencing were more commonly found in durable responders. Of all deleterious DNA and RNA mutations identified, only MCL1 was significantly associated with longer recurrence free survival (RFS) (P=0.031). CONCLUSIONS: Differences in the genomic profiles of HG T1 NMIBC tumors exist between those who show durable response to BCG and those who do not. Using pathway analysis, those differences imply upregulation of several interconnected inflammatory pathways among responders. Specific variants identified here, namely MCL1, are candidates for further study and, if clinically validated, may serve as useful biomarkers in the future. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Sanders, J Alexa AU - Sanders JA AD - Department of Bioinformatics & Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA. AD - Bioinformatics Services Division, University of North Carolina at Charlotte, Kannapolis, NC, USA. FAU - Frasier, Connor AU - Frasier C AD - Department of Bioinformatics & Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA. AD - Bioinformatics Services Division, University of North Carolina at Charlotte, Kannapolis, NC, USA. FAU - Matulay, Justin T AU - Matulay JT AD - Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Steuerwald, Nury M AU - Steuerwald NM AD - Molecular Biology and Microarray Core Facilities, Atrium Health, Charlotte, NC, USA. FAU - Zhu, Jason AU - Zhu J AD - Department of Medical Oncology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Grigg, Claud M AU - Grigg CM AD - Department of Medical Oncology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Kearns, James T AU - Kearns JT AD - Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Riggs, Stephen B AU - Riggs SB AD - Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Gaston, Kris E AU - Gaston KE AD - Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Brouwer, Cory R AU - Brouwer CR AD - Department of Bioinformatics & Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA. AD - Bioinformatics Services Division, University of North Carolina at Charlotte, Kannapolis, NC, USA. FAU - Burks, R Tucker AU - Burks RT AD - Carolinas Pathology, Charlotte, NC, USA. FAU - Hartman, Aaron L AU - Hartman AL AD - Carolinas Pathology, Charlotte, NC, USA. FAU - Foureau, David M AU - Foureau DM AD - Immune Monitoring Core Laboratory, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Burgess, Earle F AU - Burgess EF AD - Department of Medical Oncology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. FAU - Clark, Peter E AU - Clark PE AD - Department of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC8350238 OTO - NOTNLM OT - Non-muscle invasive bladder cancer (NMIBC) OT - bacillus Calmette-Guerin (BCG) OT - genomics OT - intravesical therapy COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tau-21-158). The authors have no conflicts of interest to declare. EDAT- 2021/08/26 06:00 MHDA- 2021/08/26 06:01 PMCR- 2021/07/01 CRDT- 2021/08/25 06:26 PHST- 2021/02/24 00:00 [received] PHST- 2021/06/16 00:00 [accepted] PHST- 2021/08/25 06:26 [entrez] PHST- 2021/08/26 06:00 [pubmed] PHST- 2021/08/26 06:01 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - tau-10-07-2998 [pii] AID - 10.21037/tau-21-158 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Jul;10(7):2998-3009. doi: 10.21037/tau-21-158. PMID- 34429654 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 13 DP - 2021 TI - Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score. PG - 6473-6487 LID - 10.2147/CMAR.S323844 [doi] AB - BACKGROUND: Bladder cancer is the second most prevalent neoplasm in the urogenital system in terms of morbidity and mortality, and there is an urgent need for a more accurate assessment of individual prognosis in patients with primary non-muscle-invasive bladder cancer (NMIBC). The Controlling Nutritional Status (CONUT) score is an emerging biomarker score which has been confirmed to have prognostic value in various malignant tumors. The study attempted to systematically identify the prognostic role of preoperative CONUT score on posttreatment recurrence-free survival (RFS) in patients with NMIBC, and determine the predictive value and feasibility of the new prognostic prediction model. METHODS: A total of 94 patients with NMIBC were analyzed retrospectively between January 2011 and December 2015. Statistical analysis was conducted using the nonparametric method. The Kaplan--Meier method was used to assess recurrence-free survival (RFS), and Log rank tests was used to analyze the equivalences of survival curves. We used univariate and multivariate Cox proportional hazards regression model to identify important predictors of RFS. Discrimination of nomogram was measured by the concordance index. Predictive accuracy of the model was evaluated using the internal validation. RESULTS: In univariate analysis, age, history of smoking, pathological T stage, tumor grade, tumor size, and CONUT score were significantly correlated with RFS. Multivariate analysis indicated that CONUT score (HR =3.855, 95% CI 1.242-11.970, p=0.020) was an independent predictor of RFS in patients with NMIBC. Based on significant parameters in multivariate analysis and reliable recurrence predictors determined in predictive models and relevant guidelines, a new age-, history of smoking-, pathologic factors- and the CONUT score-based scoring model was developed to predict recurrence of NMBIC. In addition, we internally validated the nomogram using the consistency index and calibration plots, which demonstrated that the model has high prediction accuracy (c-index= 0.851). CONCLUSION: The development of a new nomogram based on CONUT score could increase the accuracy of recurrence prediction and improve individualized treatment plans for patients with NMIBC. CI - (c) 2021 Zhao et al. FAU - Zhao, Liwei AU - Zhao L AD - Department of Urology, School of Medicine, Hangzhou Normal University, Hangzhou, 311121, Zhejiang Province, People's Republic of China. AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Sun, Ji AU - Sun J AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Wang, Kai AU - Wang K AD - Department of Urology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang Province, People's Republic of China. FAU - Tai, Shengcheng AU - Tai S AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Hua, Runmiao AU - Hua R AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Yu, Yufu AU - Yu Y AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Fan, Yi AU - Fan Y AD - Department of Urology, School of Medicine, Hangzhou Normal University, Hangzhou, 311121, Zhejiang Province, People's Republic of China. AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. FAU - Huang, Jiaguo AU - Huang J AD - Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, Zhejiang Province, People's Republic of China. LA - eng PT - Journal Article DEP - 20210816 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC8379392 OTO - NOTNLM OT - CONUT score OT - bladder cancer OT - nomogram OT - recurrence-free survival OT - the EORTC scoring system COIS- Authors declare no conflicts of interest for this article. EDAT- 2021/08/26 06:00 MHDA- 2021/08/26 06:01 PMCR- 2021/08/16 CRDT- 2021/08/25 06:21 PHST- 2021/06/18 00:00 [received] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/08/25 06:21 [entrez] PHST- 2021/08/26 06:00 [pubmed] PHST- 2021/08/26 06:01 [medline] PHST- 2021/08/16 00:00 [pmc-release] AID - 323844 [pii] AID - 10.2147/CMAR.S323844 [doi] PST - epublish SO - Cancer Manag Res. 2021 Aug 16;13:6473-6487. doi: 10.2147/CMAR.S323844. eCollection 2021. PMID- 34423585 OWN - NLM STAT- MEDLINE DCOM- 20220302 LR - 20220302 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 10 IP - 19 DP - 2021 Oct TI - Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients. PG - 6868-6880 LID - 10.1002/cam4.4219 [doi] AB - PURPOSE: To study prognostic values of bladder neck involvement (BNI) and survival outcomes in non-muscle-invasive bladder cancer (NMIBC). METHOD AND MATERIALS: The national Surveillance, Epidemiology, and End Results database (2004-2015) was applied to gain further insight into the prognostic values of BNI and 19,919 patients diagnosed with NMIBC were included in our study. We used the Kaplan-Meier method with the log-rank test and subgroup analyses to evaluate cancer-specific survival (CSS) and overall survival (OS). In addition, the multivariable Cox proportional hazard model and propensity score matching (PSM) were utilized. RESULTS: In all, 3446 patients with BNI and 16,473 patients with sites except for bladder neck were enrolled in our study. Compared with other sites, a tendency toward a higher proportion of higher grade (p < 0.001), bigger tumor size (p < 0.001), and more patients with T1 and Tis stage (p < 0.001) was seen in BNI group. After 1:1 PSM, 3425 matched pairs were selected. Under the survival analyses, the BNI group had a lower survival probability in both OS (p = 0.0056) and CSS analyses (p < 0.0001) in NMIBC patients. However, in the subgroup analysis, only observed in the Ta and T1 stage in terms of CSS (all p < 0.05), and patients with Tis stage failed to show statistical survival differences (p > 0.05). In addition, subgroups stratified by tumor size and grade all revealed poor prognosis of BNI in NMIBC patients. Moreover, better survival outcomes of OS were observed in BNI patients who received radical cystectomy (p = 0.02) or chemotherapy (p < 0.001) multivariable Cox regression after PSM revealed that the BNI group had a higher risk of overall mortality (OM) (BNI vs. other sites hazards ratios [HR]: 1.127, 95% CI: 1.154-1.437, p < 0.001) and cancer-specific mortality (CSM) (BNI vs. other sites HR: 1.127, 95% CI: 1.039-1.223, p < 0.001), while before PSM, similar situations were only existed in CSM (BNI vs. other sites HR: 1.288, 95% CI: 1.154-1.437, p < 0.001). CONCLUSIONS: The prognosis of BNI was poorer than that of the other sites. BNI was an independent risk factor for OM and CSM in patients with NMIBC, especially for those with Ta or T1 stage. CI - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Zhan, Xiangpeng AU - Zhan X AUID- ORCID: 0000-0001-6872-3705 AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Guo, Ju AU - Guo J AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Chen, Luyao AU - Chen L AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. FAU - Deng, Wen AU - Deng W AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Liu, Xiaoqiang AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Zhu, Ke AU - Zhu K AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Liu, Weipeng AU - Liu W AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. FAU - Fu, Bin AU - Fu B AUID- ORCID: 0000-0001-6686-7561 AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. AD - Jiangxi Inst Urol, Nanchang, Jiangxi, P. R. China. LA - eng GR - 81960512/National Natural Science Foundation of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210823 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Aged MH - Databases, Factual MH - Female MH - Humans MH - Male MH - Prognosis MH - Risk Factors MH - SEER Program/*standards MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/*physiopathology PMC - PMC8495274 OTO - NOTNLM OT - SEER database OT - bladder neck involvement OT - prognosis OT - urinary bladder COIS- The authors declare no conflict of interest. EDAT- 2021/08/24 06:00 MHDA- 2022/03/03 06:00 PMCR- 2021/08/23 CRDT- 2021/08/23 06:59 PHST- 2021/07/22 00:00 [revised] PHST- 2021/06/26 00:00 [received] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/08/24 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2021/08/23 06:59 [entrez] PHST- 2021/08/23 00:00 [pmc-release] AID - CAM44219 [pii] AID - 10.1002/cam4.4219 [doi] PST - ppublish SO - Cancer Med. 2021 Oct;10(19):6868-6880. doi: 10.1002/cam4.4219. Epub 2021 Aug 23. PMID- 34419381 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20221214 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 5 DP - 2022 Sep TI - Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guerin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. PG - 1270-1277 LID - S2405-4569(21)00195-4 [pii] LID - 10.1016/j.euf.2021.07.015 [doi] AB - BACKGROUND: Literature lacks clear evidence regarding the optimal treatment for non-muscle-invasive micropapillary bladder cancer (MPBC) due to its rarity and the presence of only small sample size and single-centre studies. OBJECTIVE: To assess cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and conservative management among T1 high-grade (HG) MPBC. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analysed a multicentre dataset including 119 T1 HG MPBC patients treated between 2005 and 2019 at 15 tertiary referral centres. The median follow-up time was 35 mo (interquartile range: 19-64). INTERVENTION: Patients underwent immediate RC versus conservative management with bacillus Calmette-Guerin. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidence functions and Kaplan-Meier methods were applied to estimate survival outcomes. Multivariable Cox analyses were performed to assess independent predictors of disease recurrence and disease progression after conservative management; covariates consisted of pure MPBC, concomitant lymphovascular invasion (LVI), and carcinoma in situ at initial diagnosis. RESULTS AND LIMITATIONS: Immediate RC and conservative management were performed in 27% and 73% of patients, respectively. CSM and OM did not differ significantly among patient treated with immediate RC versus conservative management (Pepe-Mori test p = 0.5 and log-rank test p = 0.9, respectively). Overall, 66.7% and 34.5% of patients experienced disease recurrence and disease progression after conservative management, respectively. At multivariable Cox analyses, concomitant LVI was an independent predictor of disease recurrence (p = 0.01) and progression (p = 0.03), while pure MPBC was independently associated with disease progression (p = 0.03). The absence of a centralised re-review and the retrospective design represent the main limitations of our study. CONCLUSIONS: Conservative management could achieve satisfactory results among T1 HG MPBC patients with neither pure MPBC nor LVI at initial diagnosis. PATIENT SUMMARY: Bacillus Calmette-Guerin seems to be an effective therapy for T1 micropapillary bladder cancer patients with neither pure micropapillary disease nor lymphovascular invasion at initial diagnosis. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Spedali Civili di Brescia, Brescia, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: chiara.lonati@libero.it. FAU - Baumeister, Philipp AU - Baumeister P AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Azizi, Sosan AU - Azizi S AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Martini, Alberto AU - Martini A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Tafuri, Alessandro AU - Tafuri A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Cerruto, Maria Angela AU - Cerruto MA AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Roupret, Morgan AU - Roupret M AD - GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - APHP, Department of Urology, Hopital Saint Louis, Universite de Paris, Paris, France. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy. FAU - Contieri, Roberto AU - Contieri R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Valiquette, Anne Sophie AU - Valiquette AS AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Mir, M Carmen AU - Mir MC AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Spedali Civili di Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili di Brescia, Brescia, Italy. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Yushima, Bunkyo-ku, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Yushima, Bunkyo-ku, Tokyo, Japan. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Clinica Luganese Moncucco, Lugano, Switzerland; Clinica S. Anna, Swiss Medical Group, Sorengo, Switzerland; Clinica Santa Chiara, Locarno, Switzerland. FAU - Schulz, Gerald B AU - Schulz GB AD - Department of Urology, Ludwig-Maximilians-University, Munich, Germany. FAU - Mordasini, Livio AU - Mordasini L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. CN - European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210819 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Cystectomy MH - *Urinary Bladder Neoplasms/surgery/pathology MH - Retrospective Studies MH - BCG Vaccine/therapeutic use MH - Conservative Treatment MH - Neoplasm Staging MH - Neoplasm Recurrence, Local/pathology MH - *Carcinoma, Papillary/surgery/pathology MH - Disease Progression OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Conservative management OT - Immediate radical cystectomy OT - Micropapillary OT - Variant histology EDAT- 2021/08/23 06:00 MHDA- 2022/12/06 06:00 CRDT- 2021/08/22 20:40 PHST- 2021/05/03 00:00 [received] PHST- 2021/07/12 00:00 [revised] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/08/23 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2021/08/22 20:40 [entrez] AID - S2405-4569(21)00195-4 [pii] AID - 10.1016/j.euf.2021.07.015 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Sep;8(5):1270-1277. doi: 10.1016/j.euf.2021.07.015. Epub 2021 Aug 19. PMID- 34407681 OWN - NLM STAT- MEDLINE DCOM- 20210820 LR - 20210825 IS - 1473-2300 (Electronic) IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 49 IP - 8 DP - 2021 Aug TI - Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study. PG - 3000605211037478 LID - 10.1177/03000605211037478 [doi] LID - 03000605211037478 AB - OBJECTIVE: To investigate if the use of therapeutic agents for dysuria is a risk factor for the primary recurrence of non-muscle invasive bladder cancer (NMIBC). METHODS: First, patients with NMIBC were divided into two groups: the non-recurrence group and the recurrence group. Patient characteristics were compared between both groups. The risk factors of recurrence that were statistically different between the two groups were identified by multivariate analysis. Second, we divided the patients into risk and non-risk groups, and differences in the recurrence-free survival (RFS) between the two groups were analyzed before and after propensity score matching (PSM). RESULTS: A total of 162 patients were included, with 84 patients in the non-recurrence group and 78 patients in the recurrence group. In the multivariate analysis, the intake of dysuria agents and bacillus Calmette-Guerin (BCG) therapy were independent factors. The RFS results in terms of the intake of dysuria agents were statistically significant before and after PSM analysis, but no factors were significantly different between the BCG and non-BCG groups after PSM. CONCLUSIONS: Therapeutic agents for dysuria might be at an independent risk factor for NMIBC recurrence. This trial is registered with the UMIN Clinical Trials Registry under the number UMIN000036097 (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno = R000041122). FAU - Kato, Yoichiro AU - Kato Y AUID- ORCID: 0000-0003-3778-9300 AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Ikarashi, Daiki AU - Ikarashi D AUID- ORCID: 0000-0001-8088-2848 AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Kikuchi, Daichi AU - Kikuchi D AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Takayama, Misato AU - Takayama M AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Kanzaki, Seiko AU - Kanzaki S AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Ito, Akito AU - Ito A AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Tamura, Daichi AU - Tamura D AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Matsuura, Tomohiko AU - Matsuura T AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Maekawa, Shigekatsu AU - Maekawa S AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Kato, Renpei AU - Kato R AUID- ORCID: 0000-0001-6089-7620 AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Kanehira, Mitsugu AU - Kanehira M AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Takata, Ryo AU - Takata R AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Sugimura, Jun AU - Sugimura J AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University, Yahaba-cho, Iwate, Japan. LA - eng PT - Journal Article PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 RN - 0 (Adjuvants, Immunologic) SB - IM MH - Adjuvants, Immunologic MH - Dysuria/etiology MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Prognosis MH - Propensity Score MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC8381433 OTO - NOTNLM OT - Bladder cancer OT - dysuria OT - non-muscle invasive OT - propensity score matching study OT - recurrence OT - residual urine COIS- Declaration of conflicting interest: The authors declare that there is no conflict of interest. EDAT- 2021/08/20 06:00 MHDA- 2021/08/21 06:00 PMCR- 2021/08/19 CRDT- 2021/08/19 05:31 PHST- 2021/08/19 05:31 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2021/08/21 06:00 [medline] PHST- 2021/08/19 00:00 [pmc-release] AID - 10.1177_03000605211037478 [pii] AID - 10.1177/03000605211037478 [doi] PST - ppublish SO - J Int Med Res. 2021 Aug;49(8):3000605211037478. doi: 10.1177/03000605211037478. PMID- 34393538 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 1179-5549 (Print) IS - 1179-5549 (Electronic) IS - 1179-5549 (Linking) VI - 15 DP - 2021 TI - Bilateral Nephroureterectomy Versus Unilateral Nephroureterectomy for Treating De Novo Upper Tract Urothelial Carcinoma After Renal Transplantation: A Comparison of Surgical and Oncological outcomes. PG - 11795549211035541 LID - 10.1177/11795549211035541 [doi] LID - 11795549211035541 AB - BACKGROUND: There is currently no consensus on the optimal management of de novo unilateral upper tract urothelial carcinoma (UTUC) in renal transplant recipients. We aimed to compare the surgical and oncological outcomes of simultaneous bilateral radical nephroureterectomy (SBRNU) and unilateral radical nephroureterectomy (URNU) to determine the appropriate surgical method. METHODS: Patients who developed de novo UTUC after renal transplantation and underwent surgical treatment at our center were included in the study. Outcomes were compared between the SBRNU group (underwent bilateral RNU within 3 months) and the URNU group using the Mann-Whitney U-test for continuous variables, Pearson's chi-square test for categorical variables, and the log-rank test for survival data. RESULTS: A total of 48 patients were identified, including 21 and 27 patients in the SBRNU and URNU groups, respectively. Comparison of perioperative data showed that the SBRNU group had a significantly longer operative time (P < .001) and hospital stay (P = .040) than the URNU group but no statistically significant difference in the blood loss (P = .171) and morbidity rate (P = .798). After a median follow-up of 65 months, the SBRNU group had a significantly longer disease-free survival (P = .009), longer cancer-specific survival (P = .032), marginally longer overall survival (P = .066), and similar intravesical recurrence-free survival (P = .274) than the URNU group. CONCLUSIONS: Our data suggest that SBRNU contributes to improved survival without significantly compromising the perioperative outcomes compared with URNU. SBRNU can be considered a feasible option for de novo UTUC after renal transplantation in specialized centers. Prospective studies should be conducted to further explore the best treatment options for this group of patients. CI - (c) The Author(s) 2021. FAU - Zhang, Qiming AU - Zhang Q AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Ma, Runzhuo AU - Ma R AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Li, Youzhao AU - Li Y AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Lu, Min AU - Lu M AD - Department of Pathology, Peking University Third Hospital, Beijing, China. FAU - Zhang, Hongxian AU - Zhang H AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Qiu, Min AU - Qiu M AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Zhao, Lei AU - Zhao L AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Zhang, Shudong AU - Zhang S AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Huang, Yi AU - Huang Y AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Hou, Xiaofei AU - Hou X AD - Department of Urology, Peking University Third Hospital, Beijing, China. FAU - Ma, Lulin AU - Ma L AUID- ORCID: 0000-0003-2141-9348 AD - Department of Urology, Peking University Third Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20210805 PL - United States TA - Clin Med Insights Oncol JT - Clinical Medicine Insights. Oncology JID - 101525771 PMC - PMC8358578 OTO - NOTNLM OT - Upper tract urothelial carcinoma OT - kidney transplantation OT - nephroureterectomy OT - prognosis OT - treatment outcome COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/08/17 06:00 MHDA- 2021/08/17 06:01 PMCR- 2021/08/05 CRDT- 2021/08/16 05:44 PHST- 2021/01/10 00:00 [received] PHST- 2021/07/08 00:00 [accepted] PHST- 2021/08/16 05:44 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/08/17 06:01 [medline] PHST- 2021/08/05 00:00 [pmc-release] AID - 10.1177_11795549211035541 [pii] AID - 10.1177/11795549211035541 [doi] PST - epublish SO - Clin Med Insights Oncol. 2021 Aug 5;15:11795549211035541. doi: 10.1177/11795549211035541. eCollection 2021. PMID- 34393098 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 20 IP - 1 DP - 2022 Feb TI - Histological Variants of Urothelial Carcinoma Predict No Response to Neoadjuvant Chemotherapy. PG - e1-e6 LID - S1558-7673(21)00150-6 [pii] LID - 10.1016/j.clgc.2021.07.011 [doi] AB - BACKGROUND: Platinum-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIBC) has been adopted as a standard of care related to better survival outcomes. However, there is a considerable number of patients who do not respond, experiencing toxicity and delay in the surgical treatment. Our aim is to find biomarkers of response that could be easily adopted in the clinical practice. METHODS: Between January 2009 and July 2016, 52 patients with MIBC were submitted to radical cystectomy after NAC. A tissue microarray containing 25 cases, who met the inclusion criteria was built for immunohistochemical analysis of Cytokeratins 5/6, 7, and 20, GATA3, Her2, EGFR, p63, p53, Carbonic-anhydrase IX (CAIX), MLH1, MSH2, MSH6, and PMS2. The surgery was performed in a mean time of 58.7 (+/- 21) days after the end of the NAC. Fisher's exact test was used to analyze the relationship between response (7.0 in the MMC and MMC + Ara-C groups was 6.3% and 26.7%, respectively (P < 0.001). Multivariate analysis models including clinicopathological features and second transurethral resection demonstrated that increased urinary pH was associated with better outcomes (hazard ratio 0.18, 95% confidential interval 0.18-0.038; P < 0.001). In all, there were 14 and 10 adverse events in the MMC and MMC + Ara-C groups, respectively, without a significant difference (P = 0.113). CONCLUSIONS: Our randomised clinical trial suggested that intravesical therapy with MMC and Ara-C is useful and safe for patients with intermediate-risk NMIBC. Increase in urinary pH with Ara-C is speculated as a mechanism for increased anti-cancer effects. CI - (c) 2021 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Miyata, Yasuyoshi AU - Miyata Y AUID- ORCID: 0000-0001-6272-6657 AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Japan. FAU - Tsurusaki, Toshifumi AU - Tsurusaki T AD - Department of Urology, The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. FAU - Hayashida, Yasushi AU - Hayashida Y AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan. FAU - Imasato, Yushi AU - Imasato Y AD - Department of Urology, The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. FAU - Takehara, Kosuke AU - Takehara K AD - Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan. FAU - Aoki, Daiyu AU - Aoki D AD - Department of Urology, Japan Community Health care Organization Isahaya General Hospital, Isahaya, Japan. FAU - Nishikido, Masaharu AU - Nishikido M AD - Department of Urology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan. FAU - Watanabe, Junichi AU - Watanabe J AD - Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan. FAU - Mitsunari, Kensuke AU - Mitsunari K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Japan. FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Japan. FAU - Ohba, Kojiro AU - Ohba K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Japan. FAU - Taniguchi, Keisuke AU - Taniguchi K AD - Department of Urology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan. FAU - Sakai, Hideki AU - Sakai H AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Japan. CN - Nagasaki University Urological Oncology Research Group LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20210824 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Antibiotics, Antineoplastic) RN - 04079A1RDZ (Cytarabine) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Nat Rev Urol. 2021 Oct;18(10):576. doi: 10.1038/s41585-021-00516-7. PMID: 34453153 MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/therapeutic use MH - Cytarabine/therapeutic use MH - Female MH - Humans MH - Male MH - *Mitomycin/therapeutic use MH - *Urinary Bladder Neoplasms/surgery PMC - PMC9290455 OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - cytosine arabinoside OT - intravesical therapy OT - mitomycin C OT - non-muscle-invasive bladder cancer OT - randomised trial OT - urinary pH COIS- All authors have declared no competing interests. EDAT- 2021/08/13 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/07/18 CRDT- 2021/08/12 12:40 PHST- 2021/07/29 00:00 [revised] PHST- 2021/06/18 00:00 [received] PHST- 2021/08/07 00:00 [accepted] PHST- 2021/08/13 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2021/08/12 12:40 [entrez] PHST- 2022/07/18 00:00 [pmc-release] AID - BJU15571 [pii] AID - 10.1111/bju.15571 [doi] PST - ppublish SO - BJU Int. 2022 Apr;129(4):534-541. doi: 10.1111/bju.15571. Epub 2021 Aug 24. PMID- 34381563 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210813 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 12 IP - 16 DP - 2021 Aug 3 TI - High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer. PG - 1580-1586 LID - 10.18632/oncotarget.28029 [doi] AB - BACKGROUND: An accurate prediction of progression is critical to define the management of bladder cancer (BC). The ectonucleotidases CD39 and CD73 play strategic roles in calibrating purinergic signals via an extracellular balance between ATP and adenosine. The altered expression of these enzymes plays a potential role in tumor invasion and metastasis, therefore, has been proposed to be used for prognosis of solid tumor. In BC this is not yet clear. OBJECTIVE: This study aimed to evaluate CD39 and CD73 expression in a cohort of patients with non-muscle-invasive (NMI) and muscle-invasive (MI) BC regard to its association with clinicopathological features. MATERIALS AND METHODS: Retrospective clinical follow-up data and primary urothelial BC specimens of 162 patients were used (87 from patients who underwent transurethral resection and 75 from cystectomized patients). Tissue microarrays were constructed, and immunohistochemistry for CD39 and CD73 was performed to make associations with clinicopathological data. RESULTS: Overall, 96 were NMI (59.3%) and 66 MI (40.7%). CD39 immunoreactivity in BC cells was found in 72% of the cases, while CD73 was found in 97%. High CD39 expression alone was more frequent in NMI BC (p < 0.001), while CD73 expression was not powerful to predict the stage of BC. The association of both markers confirmed that only CD39 has potential in BC prognosis. CONCLUSIONS: The altered expression of CD39 presented herein supports the idea that this ectonucleotidase may be involved in bladder tumorigenesis. High expression of CD39 in tumor cells is correlated with the early stage of BC. CI - Copyright: (c) 2021 Ferreira et al. FAU - Ferreira, Janaina Mendes AU - Ferreira JM AD - Postgraduate Program in Medicine, Universidade Nove de Julho, Sao Paulo, Brazil. FAU - Matheus, Luiz Henrique Gomes AU - Matheus LHG AD - Postgraduate Program in Medicine, Universidade Nove de Julho, Sao Paulo, Brazil. FAU - de Almeida, Renato Vasconcelos Souza AU - de Almeida RVS AD - Divisao de Urologia do Centro de Saude Masculina do Hospital Brigadeiro, Sao Paulo, Brazil. FAU - Melo, Petronio Augusto de Souza AU - Melo PAS AD - Divisao de Urologia do Centro de Saude Masculina do Hospital Brigadeiro, Sao Paulo, Brazil. FAU - Leite, Katia Ramos Moreira AU - Leite KRM AD - Laboratory of Medical Investigation, Urology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil. FAU - Murta, Claudio Bovolenta AU - Murta CB AD - Divisao de Urologia do Centro de Saude Masculina do Hospital Brigadeiro, Sao Paulo, Brazil. FAU - Claro, Joaquim Francisco de Almeida AU - Claro JFA AD - Divisao de Urologia do Centro de Saude Masculina do Hospital Brigadeiro, Sao Paulo, Brazil. FAU - Camacho, Cleber Pinto AU - Camacho CP AD - Postgraduate Program in Medicine, Universidade Nove de Julho, Sao Paulo, Brazil. FAU - Pontes-Junior, Jose AU - Pontes-Junior J AD - Laboratory of Medical Investigation, Urology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil. AD - Divisao de Urologia do Centro de Saude Masculina do Hospital Brigadeiro, Sao Paulo, Brazil. FAU - Delle, Humberto AU - Delle H AD - Postgraduate Program in Medicine, Universidade Nove de Julho, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20210803 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC8351603 OTO - NOTNLM OT - CD39 OT - bladder cancer OT - ectonucleotidases OT - purinergic signaling COIS- CONFLICTS OF INTEREST Authors have no conflicts of interest to declare. EDAT- 2021/08/13 06:00 MHDA- 2021/08/13 06:01 PMCR- 2021/08/03 CRDT- 2021/08/12 06:34 PHST- 2021/04/21 00:00 [received] PHST- 2021/07/13 00:00 [accepted] PHST- 2021/08/12 06:34 [entrez] PHST- 2021/08/13 06:00 [pubmed] PHST- 2021/08/13 06:01 [medline] PHST- 2021/08/03 00:00 [pmc-release] AID - 28029 [pii] AID - 10.18632/oncotarget.28029 [doi] PST - epublish SO - Oncotarget. 2021 Aug 3;12(16):1580-1586. doi: 10.18632/oncotarget.28029. eCollection 2021 Aug 3. PMID- 34379177 OWN - NLM STAT- MEDLINE DCOM- 20220228 LR - 20241117 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 71 IP - 3 DP - 2022 Mar TI - Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer. PG - 727-736 LID - 10.1007/s00262-021-03032-0 [doi] AB - The intravesical administration of bacillus Calmette-Guerin (BCG) is widely used to control the intravesical recurrence of non-muscle-invasive bladder cancer (NMIBC). This study aimed to reveal the effects of zygosity on human leukocyte antigen (HLA) genes and individual HLA genotypes on intravesical recurrence after intravesical BCG therapy for NMIBC. This study included Japanese patients who had received intravesical BCG for NMIBC. HLA genotyping of HLA-A, B, C, and DRB1 was performed. The effect of HLA zygosity and HLA genotype on intravesical recurrence was evaluated. Among 195 patients, those homozygous for the HLA-B supertype were more likely than those heterozygous for the HLA-B supertype to experience intravesical recurrence by univariate analysis (hazard ratio [HR], 95% confidence interval [CI]; 1.87, 1.14-3.05, P = 0.012) and multivariate analysis (HR, 95% CI; 2.26, 1.02-5.01, P = 0.045). Patients with B07 or B44 had a decreased risk of intravesical recurrence by univariate analysis (HR, 95% CI; 0.43, 0.24-0.78, P = 0.0056) and multivariate analysis (HR, 95% CI; 0.36, 0.16-0.82, P = 0.016). This study suggests the importance of the diversity and specificity of HLA-B loci in the antitumor effect of BCG immunotherapy for NMIBC. These findings may contribute to the delineation of risk strata for BCG therapy and improve the medical management of NMIBC. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kobayashi, Mizuki AU - Kobayashi M AD - Department of Urology, Graduate School of Medicine, Akita University, Akita, 010-8543, Japan. FAU - Fujiyama, Nobuhiro AU - Fujiyama N AD - Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, 010-8543, Japan. FAU - Tanegashima, Tokiyoshi AU - Tanegashima T AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. FAU - Narita, Shintaro AU - Narita S AD - Department of Urology, Graduate School of Medicine, Akita University, Akita, 010-8543, Japan. FAU - Yamamoto, Yoshiaki AU - Yamamoto Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, 755-8505, Japan. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, 807-8556, Japan. FAU - Ueda, Shohei AU - Ueda S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. FAU - Numakura, Kazuyuki AU - Numakura K AD - Department of Urology, Graduate School of Medicine, Akita University, Akita, 010-8543, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Graduate School of Medicine, Akita University, Akita, 010-8543, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, 755-8505, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. FAU - Shiota, Masaki AU - Shiota M AUID- ORCID: 0000-0002-3306-4858 AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp. LA - eng GR - 21K06592/Japan Society for the Promotion of Science/ GR - 19K18551/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20210811 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - 0 (HLA Antigens) SB - IM MH - Alleles MH - BCG Vaccine/therapeutic use MH - Biomarkers MH - Biopsy MH - Disease Management MH - Disease Susceptibility MH - *Genotype MH - HLA Antigens/*genetics/immunology MH - Homozygote MH - Humans MH - Kaplan-Meier Estimate MH - Liquid Biopsy MH - Neoplasm Invasiveness MH - Prognosis MH - Recurrence MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*genetics/mortality/*pathology/therapy PMC - PMC10991975 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Human leukocyte antigen OT - Immunotherapy OT - Intravesical recurrence OT - Non-muscle-invasive bladder cancer COIS- Shintaro Narita received honoraria from Janssen Pharmaceutical, Bayer Yakuhin, AstraZeneca, Takeda Pharmaceutical, Sanofi, and Astellas Pharma. Tomonori Habuchi received honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, AstraZeneca, Sanofi, and Bayer Yakuhin, and research funding support from Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Sanofi, and Bayer Yakuhin. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, and Merck Biopharma, and research funding support from Sanofi, Bayer Yakuhin, Astellas Pharma., Ono Pharmaceutical., and Takeda Pharmaceutical. Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma, and research funding support from Daiichi Sankyo. EDAT- 2021/08/12 06:00 MHDA- 2022/03/01 06:00 PMCR- 2021/08/11 CRDT- 2021/08/11 12:22 PHST- 2021/06/03 00:00 [received] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/08/12 06:00 [pubmed] PHST- 2022/03/01 06:00 [medline] PHST- 2021/08/11 12:22 [entrez] PHST- 2021/08/11 00:00 [pmc-release] AID - 10.1007/s00262-021-03032-0 [pii] AID - 3032 [pii] AID - 10.1007/s00262-021-03032-0 [doi] PST - ppublish SO - Cancer Immunol Immunother. 2022 Mar;71(3):727-736. doi: 10.1007/s00262-021-03032-0. Epub 2021 Aug 11. PMID- 34375494 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220415 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 129 IP - 4 DP - 2022 Apr TI - Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy. PG - 542-550 LID - 10.1111/bju.15567 [doi] AB - OBJECTIVE: To assess whether bacillus Calmette-Guerin (BCG) responsiveness after initiation of an adequate BCG treatment (at least five of six instillations of induction and at least two of three instillations of maintenance) impacts oncological outcomes in patients with carcinoma in situ (CIS) of the bladder treated with BCG immunotherapy. PATIENTS AND METHODS: Data were available for 193 patients with bladder CIS with or without associated cTa/cT1 disease who received an adequate BCG treatment between 2008 and 2015. Bladder biopsies were taken at 6 months and patients were then stratified as either BCG responsive (negative biopsies) or BCG unresponsive (positive biopsies). Inverse probability weighting (IPW)-adjusted Kaplan-Meier and IPW-adjusted Cox regression were performed to compare progression-free survival (PFS), radical cystectomy-free survival (RCFS), overall survival OS, and cancer-specific survival (CSS) in the two groups. RESULTS AND LIMITATIONS: Comparing the BCG-responsive and BCG-unresponsive groups, IPW-adjusted Kaplan-Meier analysis revealed, respectively, a median (interquartile range) of PFS of 9 (5-15) vs 48.5 (28-77) months (P = 0.001), a RCFS of 11 (9-15) vs 49 (24-76) months (P < 0.001), and a CSS of 25 (13-60) vs 109 (78-307) months (P = 0.004). On IPW-adjusted Cox regression analysis, BCG-unresponsive patients had a worse PFS (hazard ratio [HR] 3.40, 95% confidence interval [CI] 1.59-7.27), RCFS (HR 3.52, 95% CI 1.77-7), and CSS (HR 4.42, 95% CI 1.95-10.01). We found no significant differences for OS. CONCLUSION: Using an IPW method we found that lack of response after initiation of an adequate BCG treatment has prognostic implications beyond identification of complete response in patients with CIS. BCG-unresponsive patients, satisfying the novel definition of BCG unresponsive, showed a poor PFS, RCFS, and CSS. In this setting, the patients should be counselled regarding RC as a first option or enrolled in a clinical trial if they refuse RC or are unfit for surgery. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Subiela, Jose Daniel AU - Subiela JD AUID- ORCID: 0000-0003-4176-8174 AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Oncological and Functional Bladder Pathology Unit, Department of Urology, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Rodriguez Faba, Oscar AU - Rodriguez Faba O AUID- ORCID: 0000-0001-6668-4423 AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Calderon, Julio AU - Calderon J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Mercade, Asier AU - Mercade A AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Balana, Josep AU - Balana J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Esquinas, Cristina AU - Esquinas C AD - Statistics Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210823 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Immunologic Factors) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma in Situ/drug therapy MH - Female MH - Humans MH - Immunologic Factors/therapeutic use MH - Immunotherapy MH - Male MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - BCG vaccine OT - BCG-unresponsive OT - bladder biopsy OT - carcinoma in situ OT - urinary bladder neoplasms EDAT- 2021/08/11 06:00 MHDA- 2022/04/16 06:00 CRDT- 2021/08/10 17:23 PHST- 2021/07/10 00:00 [revised] PHST- 2021/05/14 00:00 [received] PHST- 2021/08/03 00:00 [accepted] PHST- 2021/08/11 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2021/08/10 17:23 [entrez] AID - 10.1111/bju.15567 [doi] PST - ppublish SO - BJU Int. 2022 Apr;129(4):542-550. doi: 10.1111/bju.15567. Epub 2021 Aug 23. PMID- 34353775 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20250530 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 1 DP - 2022 Feb TI - Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. PG - 70-83 LID - S2588-9311(21)00120-6 [pii] LID - 10.1016/j.euo.2021.07.001 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed. OBJECTIVE: To identify single nucleotide polymorphisms (SNPs) associated with recurrence-free (RFS) and progression-free (PFS) survival in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed outcome data from 3400 newly diagnosed NMIBC patients from the Netherlands, the UK, Canada, and Spain. We generated genome-wide germline SNP data using Illumina OmniExpress and Infinium Global Screening Array in combination with genotype imputation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cohort-specific genome-wide association studies (GWASs) for RFS and PFS were performed using a Cox proportional hazard model. Results were combined in a fixed-effect inverse-variance weighted meta-analysis. Candidate genes for the identified SNP associations were prioritized using functional annotation, gene-based analysis, expression quantitative trait locus analysis, and transcription factor binding site databases. Tumor expression levels of prioritized genes were tested for association with RFS and PFS in an independent NMIBC cohort. RESULTS AND LIMITATIONS: This meta-analysis revealed a genome-wide significant locus for RFS on chromosome 14 (lead SNP rs12885353, hazard ratio [HR] C vs T allele 1.55, 95% confidence interval [CI] 1.33-1.82, p = 4.0 x 10(-8)), containing genes G2E3 and SCFD1. Higher expression of SCFD1 was associated with increased RFS (HR 0.70, 95% CI 0.59-0.84, p(FDR) = 0.003). Twelve other loci were suggestively associated with RFS (p < 10(-5)), pointing toward 18 additional candidate genes. For PFS, ten loci showed suggestive evidence of association, indicating 36 candidate genes. Expression levels of ten of these genes were statistically significantly associated with PFS, of which four (IFT140, UBE2I, FAHD1, and NME3) showed directional consistency with our meta-analysis results and published literature. CONCLUSIONS: In this first prognostic GWAS in NMIBC, we identified several novel candidate loci and five genes that showed convincing associations with recurrence or progression. PATIENT SUMMARY: In this study, we searched for inherited DNA changes that affect the outcome of non-muscle-invasive bladder cancer (NMIBC). We identified several genes that are associated with disease recurrence and progression. The roles and mechanisms of these genes in NMIBC prognosis should be investigated in future studies. CI - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Galesloot, Tessel E AU - Galesloot TE AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands. Electronic address: Tessel.Galesloot@radboudumc.nl. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands. FAU - Kolev, Dimitar AU - Kolev D AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands. FAU - Aben, Katja K AU - Aben KK AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK; Bladder Cancer Research Centre, University of Birmingham, Birmingham, UK. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Cheng, Kar K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - Conroy, Samantha AU - Conroy S AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Fleshner, Neil E AU - Fleshner NE AD - Department of Urology, Princess Margaret Cancer Centre, Toronto, Canada. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Lamy, Philippe AU - Lamy P AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Lindskrog, Sia Viborg AU - Lindskrog SV AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain; CIBERONC, Madrid, Spain. FAU - Mengual, Lourdes AU - Mengual L AD - Department and Laboratory of Urology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. FAU - Verhaegh, Gerald AU - Verhaegh G AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; CAPHRI School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands; Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands. LA - eng GR - RDSDIA-2022/100001/CRUK_/Cancer Research UK/United Kingdom GR - C1343/A5738/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20210802 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - EC 3.- (FAHD1 protein, human) RN - EC 3.- (Hydrolases) SB - IM MH - Female MH - Genome-Wide Association Study MH - Humans MH - Hydrolases MH - Male MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Genome-wide association study OT - Meta-analysis OT - Non-muscle-invasive bladder cancer OT - Prognosis OT - Progression OT - Recurrence EDAT- 2021/08/07 06:00 MHDA- 2022/05/06 06:00 CRDT- 2021/08/06 05:49 PHST- 2021/06/09 00:00 [received] PHST- 2021/06/15 00:00 [revised] PHST- 2021/07/01 00:00 [accepted] PHST- 2021/08/07 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2021/08/06 05:49 [entrez] AID - S2588-9311(21)00120-6 [pii] AID - 10.1016/j.euo.2021.07.001 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Feb;5(1):70-83. doi: 10.1016/j.euo.2021.07.001. Epub 2021 Aug 2. PMID- 34352790 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 2 DP - 2022 TI - Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer? PG - 154-162 LID - 10.1159/000517543 [doi] AB - Background & Objectives: We aimed to evaluate the risk of progression in high-grade T1 (HGT1) tumors using tumor budding (TB) and other standard clinical and histological features. TB is defined as an isolated cancer cell or a cluster composed of fewer than 5 cells scattered in the stroma and is usually used as a strong predictor of lymph node metastasis in T1 colorectal cancer. METHODS: This is an observational longitudinal cohort study involving 168 consecutive patients with HGT1 between 2013 and 2016. Cox regression was performed to analyze the relationship between the clinical and histological features and progression. All slides were blindly assessed by 2 genitourinary pathologists. Budding was determined to be positive when the number of buds was equal to or greater than 6. RESULTS: The median age was 75 years; 152 (90.5%) patients were men, and 49 (29.2%) were positive for TB. At a median follow-up time of 35 months, 33 patients (19.6%) showed progression. Progression was observed in 32.7% of the patients positive for TB and in only 14.3% of those who were negative (p = 0.006). TB was significantly associated with the endoscopic tumor pattern (TP) (papillary/solid) and lymphovascular invasion (LVI). Univariate analysis showed that TB, carcinoma in situ (CIS), TP, LVI, sub-staging, and BCG induction predict progression. The multivariate analysis showed that TB (p = 0.032, hazard ratio 2.1), CIS, TP, and lack of BCG induction were significant for progression. CONCLUSIONS: TB is a new and significant pathological variable for predicting progression in HGT1 tumors and can be easily introduced in clinical practice. Its inclusion in the TNM system should be carefully considered, as it may aid early cystectomy decisions. CI - (c) 2021 S. Karger AG, Basel. FAU - Raventos Busquets, Carles X AU - Raventos Busquets CX AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Semidey, M Eugenia AU - Semidey ME AD - Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Lozano Palacio, Fernando AU - Lozano Palacio F AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Carrion Puig, Albert AU - Carrion Puig A AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Aula Olivar, Ana AU - Aula Olivar A AD - Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - De Torres Ramirez, Ines M AU - De Torres Ramirez IM AD - Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Trilla Herrera, Enrique AU - Trilla Herrera E AD - Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20210805 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Cohort Studies MH - *Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Neoplasm Grading MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - High risk OT - Prognostic factors OT - Progression OT - Staging OT - T1HG bladder Cancer EDAT- 2021/08/06 06:00 MHDA- 2022/03/04 06:00 CRDT- 2021/08/05 20:34 PHST- 2021/01/11 00:00 [received] PHST- 2021/05/24 00:00 [accepted] PHST- 2021/08/06 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2021/08/05 20:34 [entrez] AID - 000517543 [pii] AID - 10.1159/000517543 [doi] PST - ppublish SO - Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5. PMID- 34348860 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. PG - 62.e1-62.e11 LID - S1078-1439(21)00336-7 [pii] LID - 10.1016/j.urolonc.2021.07.018 [doi] AB - PURPOSE: Clinical node-positive urothelial carcinoma of the bladder (cN+UCaB) is a rapidly fatal disease with limited information on comparative-effectiveness of available treatment options. We sought to examine the impact of high-intensity vs. conservative local treatment (LT) regimens in management of these patients alongside systemic chemotherapy. MATERIALS AND METHODS: We identified 3,227 patients within the National Cancer Data Base who underwent multiagent systemic chemotherapy along with either high-intensity or conservative LT for primary cN+UCaB between 2004-2016. Patients who received no LT, TURBT alone, or <50 Gy radiation therapy to the bladder were included in the conservative group, while patients that received radical cystectomy with pelvic lymphadenectomy or >/=50 Gy radiation therapy with TURBT were included in the high-intensity group. Inverse probability of treatment weighting (IPTW) adjusted Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS). Additionally, to assess whether the benefit of high-intensity LT differs by baseline mortality risk, we tested an interaction between 5-year predicted life-expectancy and the LT type. RESULTS: Overall, 784 (24.3%) and 2,443 (75.7%) cN+UCaB patients underwent high-intensity and conservative LT, respectively. IPTW-adjusted Kaplan-Meier analysis demonstrated OS to be significantly higher in the high-intensity group compared to the conservative group: 5-year OS 28.4% vs. 18.3%, respectively (Log-rank P<0.001). IPTW-adjusted multivariable Cox regression analysis confirmed the benefit of high-intensity LT in prolonging OS (HR 0.63, P<0.001). Interaction analysis showed that high-intensity LT approach was associated with longer OS in all patients regardless of their baseline 5-year life-expectancy (P(interaction)=0.79). CONCLUSION: Eligible patients with cN+UCaB should be considered for aggressive local treatment alongside multiagent systemic chemotherapy. Prospective trials are needed to validate these preliminary findings. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Sood, Akshay AU - Sood A AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: akshaysood@outlook.com. FAU - Keeley, Jacob AU - Keeley J AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan. FAU - Palma-Zamora, Isaac AU - Palma-Zamora I AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Novara, Giacomo AU - Novara G AD - Department of Surgery, Oncology and Gastroenterology-Urology, University Hospital of Padova, Padova, Italy. FAU - Elshaikh, Mohamed AU - Elshaikh M AD - Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan. FAU - Jeong, Wooju AU - Jeong W AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Hensley, Patrick AU - Hensley P AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Peabody, James O AU - Peabody JO AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusettsa. FAU - Rogers, Craig G AU - Rogers CG AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Menon, Mani AU - Menon M AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Abdollah, Firas AU - Abdollah F AD - VCORE - Vattikuti Urology Institute Center for Outcomes Research, Analytics and Evaluation, Henry Ford Hospital, Detroit, Michigan; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. LA - eng PT - Journal Article DEP - 20210802 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Survival Analysis MH - Urinary Bladder Neoplasms/*drug therapy/mortality OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Lymph-node dissection OT - Radiation therapy OT - Radical cystectomy EDAT- 2021/08/06 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/08/05 05:40 PHST- 2021/05/23 00:00 [received] PHST- 2021/07/05 00:00 [revised] PHST- 2021/07/14 00:00 [accepted] PHST- 2021/08/06 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/08/05 05:40 [entrez] AID - S1078-1439(21)00336-7 [pii] AID - 10.1016/j.urolonc.2021.07.018 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):62.e1-62.e11. doi: 10.1016/j.urolonc.2021.07.018. Epub 2021 Aug 2. PMID- 34342065 OWN - NLM STAT- MEDLINE DCOM- 20211105 LR - 20211105 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 28 IP - 11 DP - 2021 Nov TI - Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study. PG - 1136-1142 LID - 10.1111/iju.14657 [doi] AB - OBJECTIVES: To evaluate the risk factors for intravesical recurrence in patients with newly diagnosed Ta high-grade non-muscle-invasive bladder cancer and the optimal management to reduce the risk of recurrence. METHODS: We retrospectively evaluated Ta high-grade bladder cancer in patients who were newly diagnosed by transurethral resection from January 2007 through October 2018. Using multivariate analyses, we evaluated the risk factors and therapeutic options affecting intravesical recurrence and stratified the patients according to the risk numbers. RESULTS: We included 390 patients and the median follow-up period was 31 months after the initial transurethral resection. According to multivariate analysis, having a previous history of upper urinary tract carcinoma, and multiple and sessile tumors were risk factors for intravesical recurrence (P = 0.001, P = 0.02 and P = 0.01, respectively). Risk groups were stratified according to these risk factors into favorable, intermediate and poor. In the entire cohort, induction and immediate intravesical instillation therapy were treatment options to reduce intravesical recurrence (P < 0.01 and P = 0.02, respectively). Analyses in each risk group showed that a second transurethral resection was the only therapeutic option to reduce intravesical recurrence in the favorable group (P = 0.048), whereas induction intravesical instillation therapy was effective in the intermediate and poor risk groups (P = 0.01 and P < 0.01, respectively), as was immediate intravesical instillation for the poor risk group (P < 0.001). CONCLUSIONS: Sessile, multiple tumors and a history of upper urinary tract carcinoma are risk factors for intravesical recurrence in Ta high-grade bladder cancer patients. CI - (c) 2021 The Japanese Urological Association. FAU - Shindo, Tetsuya AU - Shindo T AUID- ORCID: 0000-0002-4990-8330 AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. AD - Department of Urology, Hakodate Koseiin Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Hashimoto, Kohei AU - Hashimoto K AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Tanaka, Toshiaki AU - Tanaka T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Taguchi, Keisuke AU - Taguchi K AD - Department of Urology, Oji General Hospital, Tomakomai, Japan. FAU - Takahashi, Atsushi AU - Takahashi A AD - Department of Urology, Hakodate Koseiin Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Itoh, Naoki AU - Itoh N AD - Department of Urology, NTT East Corporation Sapporo Hospital, Sapporo, Japan. FAU - Okada, Manabu AU - Okada M AD - Department of Urology, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Japan. FAU - Hotta, Hiroshi AU - Hotta H AD - Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan. FAU - Kunishima, Yasuharu AU - Kunishima Y AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan. FAU - Hirose, Takaoki AU - Hirose T AD - Department of Urology, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan. FAU - Matsukawa, Masanori AU - Matsukawa M AD - Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan. FAU - Tachiki, Hitoshi AU - Tachiki H AD - Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan. FAU - Kato, Ryuichi AU - Kato R AD - Department of Urology, Muroran City General Hospital, Muroran, Japan. FAU - Hinotsu, Shiro AU - Hinotsu S AD - Department of Biostatistics, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210803 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Administration, Intravesical MH - Humans MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/therapy OTO - NOTNLM OT - Ta high-grade OT - intravesical instillation OT - intravesical recurrence OT - non-muscle-invasive bladder cancer EDAT- 2021/08/04 06:00 MHDA- 2021/11/06 06:00 CRDT- 2021/08/03 06:54 PHST- 2020/12/16 00:00 [received] PHST- 2021/07/04 00:00 [accepted] PHST- 2021/08/04 06:00 [pubmed] PHST- 2021/11/06 06:00 [medline] PHST- 2021/08/03 06:54 [entrez] AID - 10.1111/iju.14657 [doi] PST - ppublish SO - Int J Urol. 2021 Nov;28(11):1136-1142. doi: 10.1111/iju.14657. Epub 2021 Aug 3. PMID- 34337540 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 30 DP - 2021 Aug TI - Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans. PG - 1-10 LID - 10.1016/j.euros.2021.05.009 [doi] AB - BACKGROUND: Muscle-invasive bladder cancer (MIBC) remains undertreated despite multiple potentially curative options. Both radical cystectomy (RC) with or without neoadjuvant chemotherapy and trimodal therapy (TMT), including transurethral resection of bladder tumor followed by chemoradiotherapy, are standard treatments. OBJECTIVE: To evaluate real-world clinical outcomes of RC with neoadjuvant chemotherapy (RC-NAC), RC without NAC, TMT with National Comprehensive Cancer Network guideline-preferred radiosensitizing chemotherapy including cisplatin or mitomycin-C and 5-fluorouracil (pTMT), and TMT with nonpreferred chemotherapy (npTMT). DESIGN SETTING AND PARTICIPANTS: US veterans with nonmetastatic MIBC (T2-4aN0-3M0) were studied. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall mortality (OM) was evaluated with multivariable Cox proportional hazard model. Bladder cancer-specific mortality (BCSM) was evaluated with multivariable Fine-Gray regression. Salvage cystectomy rates were obtained by chart review. RESULTS AND LIMITATIONS: Overall 2306 patients were included: 1472 (64%) with RC without NAC, 506 (22%) with RC-NAC, 163 (7%) with pTMT, and 165 (7%) with npTMT. On multivariable analysis, pTMT was associated with similar OM (hazard ratio [HR] 1.19; 95% confidence interval [CI] 0.94-1.50; p = 0.15) and BCSM (HR 1.34; 95% CI 0.99-1.83; p = 0.06) to RC-NAC; npTMT was associated with worse OM (HR 1.30; 95% CI 1.04-1.61; p = 0.02) and BCSM (HR 1.45; 95% CI 1.09-1.94; p = 0.01). RC without NAC was associated with similar OM (HR 1.08; 95% CI 0.95-1.24; p = 0.24) and BCSM (HR 1.02; 95% CI 0.86-1.21; p = 0.79). When stratified by age, among patients >/=65 yr of age, treatment with pTMT was associated with similar OM (HR 1.14; 95% CI 0.87-1.50; p = 0.35) and BCSM (HR 1.11; 95% CI 0.76-1.62; p = 0.60). Among patients <65 yr of age, pTMT was associated with worse OM (HR 1.82; 95% CI 1.14-2.91; p = 0.01) and BCSM (HR 2.51; 95% CI 1.52-4.13; p < 0.01). The 5-yr cumulative incidence of salvage cystectomy in the TMT group was 3.6%. CONCLUSIONS: In MIBC, patients receiving pTMT have comparable survival in RC-NAC patients >/=65 yr and inferior survival in RC-NAC patients <65 yr. Salvage cystectomy rates were low. PATIENT SUMMARY: Management of muscle-invasive bladder cancer is a multidisciplinary effort requiring thoughtful discussions with patients about treatment options, including trimodal therapy, which is an effective treatment option. CI - (c) 2021 The Authors. FAU - Kumar, Abhishek AU - Kumar A AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Cherry, Daniel R AU - Cherry DR AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Courtney, Patrick T AU - Courtney PT AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Nalawade, Vinit AU - Nalawade V AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Kotha, Nikhil AU - Kotha N AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Riviere, Paul J AU - Riviere PJ AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Efstathiou, Jason AU - Efstathiou J AD - Department of Radiation Oncology, Harvard, Cambridge, MA, USA. FAU - McKay, Rana R AU - McKay RR AD - Division of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA. FAU - Karim Kader, A AU - Karim Kader A AD - Department of Urology, University of California San Diego, La Jolla, CA, USA. FAU - Rose, Brent S AU - Rose BS AD - Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. FAU - Stewart, Tyler F AU - Stewart TF AD - Division of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20210609 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8317783 OTO - NOTNLM OT - Bladder preservation OT - Chemoradiotherapy OT - Muscle-invasive bladder cancer OT - Radical cystectomy OT - Treatment OT - Trimodal therapy EDAT- 2021/08/03 06:00 MHDA- 2021/08/03 06:01 PMCR- 2021/06/09 CRDT- 2021/08/02 06:17 PHST- 2021/05/19 00:00 [accepted] PHST- 2021/08/02 06:17 [entrez] PHST- 2021/08/03 06:00 [pubmed] PHST- 2021/08/03 06:01 [medline] PHST- 2021/06/09 00:00 [pmc-release] AID - S2666-1683(21)00101-4 [pii] AID - 10.1016/j.euros.2021.05.009 [doi] PST - epublish SO - Eur Urol Open Sci. 2021 Jun 9;30:1-10. doi: 10.1016/j.euros.2021.05.009. eCollection 2021 Aug. PMID- 34337512 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 27 DP - 2021 May TI - The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guerin Therapy in Patients with Non-muscle‑invasive Bladder Cancer. PG - 10-18 LID - 10.1016/j.euros.2021.02.005 [doi] AB - BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) instillation is a standard treatment for non-muscle-invasive bladder cancer (NMIBC); however, not all patients benefit from BCG therapy. Currently, no surrogate marker exists to predict BCG efficacy, and thereby, identify patients who will benefit from this treatment. OBJECTIVE: To evaluate the utility of urine Mycobacterium tuberculosis complex polymerase chain reaction (MTC-PCR) assay as a predictive marker for recurrence and progression following BCG therapy. DESIGN SETTING AND PARTICIPANTS: A prospective analysis was carried out for of intermediate- or high-risk NMIBC patients who received BCG instillation for the first time. Urine samples, for MTC-PCR assay, were collected at baseline and annually for up to 10 yr after the last BCG instillation, including induction and maintenance therapy. The first postoperative sample for MTC-PCR was taken at 1 yr from the last instillation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence and progression after BCG treatment were assessed using Cox regression analysis. RESULTS AND LIMITATIONS: During follow-up (median: 57 mo), 468/521 samples (89.8%) were MTC-PCR positive, and 108/123 patients (87.8%) exhibited MTC-PCR positivity at least once. Five-year recurrence- and progression-free survival in patients who were not MTC-PCR positive was significantly lower than in patients who were MTC-PCR positive at least once (p < 0.001). Using multivariable Cox regression analysis, MTC-PCR positivity at least once was a significant prognostic factor for recurrence (hazard ratio [HR]: 36.782, p < 0.001) and progression (HR: 47.209, p < 0.001). CONCLUSIONS: Patients who were not MTC-PCR positive, even once after BCG therapy, were extremely likely to exhibit recurrence and progression. Urine MTC-PCR may be an extremely useful, noninvasive surrogate marker to predict recurrence and progression following BCG therapy. PATIENT SUMMARY: Urine Mycobacterium tuberculosis complex polymerase chain reaction may be a novel biomarker capable of identifying patients at risk of recurrence and progression after bacillus Calmette-Guerin (BCG) immunotherapy. CI - (c) 2021 The Author(s). FAU - Muto, Satoru AU - Muto S AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. AD - Department of Advanced Informatics for Genetic Disease, Juntendo University School of Medicine, Tokyo, Japan. FAU - Lu, Yan AU - Lu Y AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Ide, Hisamitsu AU - Ide H AD - Department of Urology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan. FAU - Yamaguchi, Raizo AU - Yamaguchi R AD - Department of Urology, Kobe Minimally Invasive Cancer Center, Kobe, Japan. FAU - Saito, Keisuke AU - Saito K AD - Department of Urology, Juntendo University Shizuoka Hospital, Shizuoka, Japan. FAU - Kitamura, Kousuke AU - Kitamura K AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Noma, Yasuhiro AU - Noma Y AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Koyasu, Hiroki AU - Koyasu H AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Hirano, Hisashi AU - Hirano H AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Ashizawa, Takeshi AU - Ashizawa T AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Isotani, Shuji AU - Isotani S AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Nagata, Masayoshi AU - Nagata M AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Horie, Shigeo AU - Horie S AD - Department of Urology, Juntendo University School of Medicine, Tokyo, Japan. AD - Department of Advanced Informatics for Genetic Disease, Juntendo University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20210311 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8317891 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Mycobacterium tuberculosis complex polymerase chain reaction OT - Non-muscle invasive EDAT- 2021/08/03 06:00 MHDA- 2021/08/03 06:01 PMCR- 2021/03/11 CRDT- 2021/08/02 06:16 PHST- 2021/02/18 00:00 [accepted] PHST- 2021/08/02 06:16 [entrez] PHST- 2021/08/03 06:00 [pubmed] PHST- 2021/08/03 06:01 [medline] PHST- 2021/03/11 00:00 [pmc-release] AID - S2666-1683(21)00040-9 [pii] AID - 10.1016/j.euros.2021.02.005 [doi] PST - epublish SO - Eur Urol Open Sci. 2021 Mar 11;27:10-18. doi: 10.1016/j.euros.2021.02.005. eCollection 2021 May. PMID- 34337469 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 2666-1683 (Electronic) IS - 2666-1691 (Print) IS - 2666-1683 (Linking) VI - 21 DP - 2020 Oct TI - Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. PG - 61-68 LID - 10.1016/j.euros.2020.08.008 [doi] AB - BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. OBJECTIVE: We aimed to study the association between FGFR3 mutations and survival in urothelial carcinoma. DESIGN SETTING AND PARTICIPANTS: We performed a systematic literature search of PubMed, Cochrane, Ovid, and Web of Science from January 1985 to October 2018. The search terms were as follows: targeted therapies, FGFR and its subtypes, urothelial, bladder, and cancer. We included case-control or cohort studies of FGFR3 mutations in urothelial carcinoma. We included studies reporting hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes comparing FGFR3 mutations with FGFR3 wild type. Two reviewers performed article selection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed heterogeneity among study-specific HRs using I (2) statistic. We used a random effect model to obtain HR and 95% CI for event-free survival (EFS), composed of recurrence-free and progression-free survival. Statistical tests were two sided. RESULTS AND LIMITATIONS: Eleven studies (seven retrospective and four prospective) comprising 2162 patients were included. Analysis was performed for two groups. The first group included 1651 patients with non-muscle-invasive (NMI) urothelial carcinomas (886 [53.6%] had FGFR3 mutations). Compared with FGFR3 wild type, FGFR3 mutation did not influence EFS (HR = 0.99, CI = 0.77-1.28, p =  0.96). There was no significant heterogeneity (I (2) = 25%). The second group included 511 patients with NMI and muscle-invasive (MI) urothelial carcinomas (151 [30%] had FGFR3 mutations). FGFR3 mutation was not prognostic (HR = 1.54, CI = 0.41-5.81, p =  0.52). There was heterogeneity (I (2) = 91%). CONCLUSIONS: There is no association between FGFR3 mutation and EFS in NMI urothelial carcinoma, and in NMI and MI urothelial carcinoma groups. PATIENT SUMMARY: Fibroblast growth factor receptor 3 (FGFR3) mutation is not associated with a worse survival outcome in urothelial carcinoma. This is important as FGFR inhibitors are emerging as a new treatment option. CI - (c) 2020 Published by Elsevier B.V. on behalf of European Association of Urology. FAU - Khalid, Sidra AU - Khalid S AD - Department of Oncology, Queen's University, Kingston, ON, Canada. FAU - Basulaiman, Bassam Mohammed AU - Basulaiman BM AD - Department of Oncology, Queen's University, Kingston, ON, Canada. AD - Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada. FAU - Emack, Jeffrey AU - Emack J AD - Department of Oncology, Queen's University, Kingston, ON, Canada. FAU - Booth, Christopher M AU - Booth CM AD - Department of Oncology, Queen's University, Kingston, ON, Canada. AD - Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, ON, Canada. FAU - Duran, Ignacio AU - Duran I AD - Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain. FAU - Robinson, Andrew G AU - Robinson AG AD - Department of Oncology, Queen's University, Kingston, ON, Canada. FAU - Berman, David AU - Berman D AD - Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. FAU - Smoragiewicz, Martin AU - Smoragiewicz M AD - Department of Oncology, Queen's University, Kingston, ON, Canada. AD - Division of Medical Oncology, Department of Medicine, University of Toronto, Sunnybrook Health Sciences Center, Toronto, ON, Canada. FAU - Amir, Eitan AU - Amir E AD - Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Vera-Badillo, Francisco E AU - Vera-Badillo FE AD - Department of Oncology, Queen's University, Kingston, ON, Canada. LA - eng PT - Journal Article DEP - 20201013 PL - Netherlands TA - Eur Urol Open Sci JT - European urology open science JID - 101771568 PMC - PMC8317902 OTO - NOTNLM OT - Fibroblast growth factor receptor 3 mutation OT - Muscle invasive OT - Non-muscle invasive OT - Progression-free survival OT - Recurrence-free survival OT - Urothelial carcinoma EDAT- 2021/08/03 06:00 MHDA- 2021/08/03 06:01 PMCR- 2020/10/13 CRDT- 2021/08/02 06:16 PHST- 2020/08/26 00:00 [accepted] PHST- 2021/08/02 06:16 [entrez] PHST- 2021/08/03 06:00 [pubmed] PHST- 2021/08/03 06:01 [medline] PHST- 2020/10/13 00:00 [pmc-release] AID - S2666-1683(20)35317-9 [pii] AID - 10.1016/j.euros.2020.08.008 [doi] PST - epublish SO - Eur Urol Open Sci. 2020 Oct 13;21:61-68. doi: 10.1016/j.euros.2020.08.008. eCollection 2020 Oct. PMID- 34336691 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer. PG - 704039 LID - 10.3389/fonc.2021.704039 [doi] LID - 704039 AB - Urinary bladder cancer (BCa) is a highly prevalent disease among aged males. Precise diagnosis of tumor phenotypes and recurrence risk is of vital importance in the clinical management of BCa. Although imaging modalities such as CT and multiparametric MRI have played an essential role in the noninvasive diagnosis and prognosis of BCa, radiomics has also shown great potential in the precise diagnosis of BCa and preoperative prediction of the recurrence risk. Radiomics-empowered image interpretation can amplify the differences in tumor heterogeneity between different phenotypes, i.e., high-grade vs. low-grade, early-stage vs. advanced-stage, and nonmuscle-invasive vs. muscle-invasive. With a multimodal radiomics strategy, the recurrence risk of BCa can be preoperatively predicted, providing critical information for the clinical decision making. We thus reviewed the rapid progress in the field of medical imaging empowered by the radiomics for decoding the phenotype and recurrence risk of BCa during the past 20 years, summarizing the entire pipeline of the radiomics strategy for the definition of BCa phenotype and recurrence risk including region of interest definition, radiomics feature extraction, tumor phenotype prediction and recurrence risk stratification. We particularly focus on current pitfalls, challenges and opportunities to promote massive clinical applications of radiomics pipeline in the near future. CI - Copyright (c) 2021 Xu, Wang, Guo, Zhang, Li, Du, Liu and Lu. FAU - Xu, Xiaopan AU - Xu X AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. FAU - Wang, Huanjun AU - Wang H AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Guo, Yan AU - Guo Y AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Zhang, Xi AU - Zhang X AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. FAU - Li, Baojuan AU - Li B AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. FAU - Du, Peng AU - Du P AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. FAU - Liu, Yang AU - Liu Y AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. FAU - Lu, Hongbing AU - Lu H AD - School of Biomedical Engineering, Air Force Medical University, Xi'an, China. LA - eng PT - Journal Article PT - Review DEP - 20210715 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8321511 OTO - NOTNLM OT - histopathological phenotype OT - multimodal imaging OT - radiomics OT - recurrence OT - urinary bladder cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/08/03 06:00 MHDA- 2021/08/03 06:01 PMCR- 2021/07/15 CRDT- 2021/08/02 06:07 PHST- 2021/05/01 00:00 [received] PHST- 2021/06/30 00:00 [accepted] PHST- 2021/08/02 06:07 [entrez] PHST- 2021/08/03 06:00 [pubmed] PHST- 2021/08/03 06:01 [medline] PHST- 2021/07/15 00:00 [pmc-release] AID - 10.3389/fonc.2021.704039 [doi] PST - epublish SO - Front Oncol. 2021 Jul 15;11:704039. doi: 10.3389/fonc.2021.704039. eCollection 2021. PMID- 34334293 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants. PG - 61.e9-61.e19 LID - S1078-1439(21)00310-0 [pii] LID - 10.1016/j.urolonc.2021.07.009 [doi] AB - INTRODUCTION: The presence of carcinoma in situ at transurethral resection is known to increase the risk of recurrence and progression to invasive disease. However, the evidence regarding the prognostic role of concomitant carcinoma in situ after radical cystectomy due to bladder cancer is controversial. Moreover, concomitant carcinoma in situ was found to be significantly associated with bladder histological variants. The aim of our study is to evaluate whether the presence of concomitant carcinoma in situ at radical cystectomy, impacts on recurrence and survival outcomes in pure urothelial bladder cancer, compared to histological variants. METHODS: We evaluated 410 consecutive patients diagnosed with non-metastatic bladder cancer and treated with radical cystectomy at a single tertiary referral centre between January 2009 and May 2019. Patients were stratified according to the presence of carcinoma in situ. The Kaplan-Meier method was used to compare recurrence free, cancer specific and overall survival in pure urothelial and histological variants. Cox proportional hazards regression analyses model was used to predict recurrence, cancer specific and overall mortality in pure urothelial and histological variants bladder cancer, according to pathological stage. RESULTS: Median age was 71 years. 340 patients (82%) were male. At a median follow-up of 32 months, disease recurrence, cancer specific mortality and overall mortality were, 37% (155 patients), 32.9% (135 patients) and 46.6% (191 patients), respectively. Concomitant and pure carcinoma in situ were found in 39% and 19% of radical cystectomy specimens, respectively. Concomitant carcinoma in situ was more frequent in patients with histological variants (50.9%) compared to pure urothelial bladder cancer (35.4%) (P-value <.001) and was associated with worst pathological features (lymphovascular invasion, lymph node involvement and non-organ confined disease). Recurrence free survival at Kaplan-Meyer analyses was significantly higher in patients with pure carcinoma in situ compared to those with concomitant or no carcinoma in situ (all P <.001), similarly for patients without carcinoma in situ compared with those with concomitant Cis (P =.02) at radical cystectomy. Cancer specific and overall survival were significantly higher in patients with pure carcinoma in situ compared to those with concomitant or no carcinoma in situ (all P <.001). Conversely no significant difference was found between patients without carcinoma in situ and with concomitant carcinoma in situ (P>0.1) at radical cystectomy Moreover, concomitant carcinoma in situ at radical cystectomy in histological variants is associated with higher free recurrence rate compared to the other groups. At multivariate Cox proportional hazards regression analyses the presence of carcinoma in situ at radical cystectomy was not associated with any survival effect or recurrence (all P > .05) in the overall population and when patients are stratified according to histology. However, concomitant carcinoma in situ represents an independent predictor of recurrence in the subgroup of patients with organ confined disease in case of urothelial bladder cancer and histological variants. CONCLUSION: Concomitant carcinoma in situ should be considered a proxy of aggressiveness in bladder cancer after radical cystectomy. Based on its prognostic implications, concomitant carcinoma in situ should be considered for strict follow-up in patients with organ confined disease which may deserve adjuvant treatment both in pure urothelial bladder cancer and histological variants. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Naspro, Richard AU - Naspro R AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. Electronic address: nasprorichard@gmail.com. FAU - La Croce, Giovanni AU - La Croce G AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Finati, Marco AU - Finati M AD - University of Milano-Bicocca, Milan, Italy. FAU - Roscigno, Marco AU - Roscigno M AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Pellucchi, Federico AU - Pellucchi F AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Sodano, Mario AU - Sodano M AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Manica, Michele AU - Manica M AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Gianatti, Andrea AU - Gianatti A AD - Department of Pathology, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Da Pozzo, Luigi F AU - Da Pozzo LF AD - Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy; University of Milano-Bicocca, Milan, Italy. LA - eng PT - Journal Article DEP - 20210729 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Histological variants OT - Radical cystectomy OT - Transurethral resection OT - Urothelial carcinoma EDAT- 2021/08/03 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/08/02 05:36 PHST- 2021/04/10 00:00 [received] PHST- 2021/06/14 00:00 [revised] PHST- 2021/07/02 00:00 [accepted] PHST- 2021/08/03 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/08/02 05:36 [entrez] AID - S1078-1439(21)00310-0 [pii] AID - 10.1016/j.urolonc.2021.07.009 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):61.e9-61.e19. doi: 10.1016/j.urolonc.2021.07.009. Epub 2021 Jul 29. PMID- 34334292 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. PG - 60.e11-60.e16 LID - S1078-1439(21)00304-5 [pii] LID - 10.1016/j.urolonc.2021.07.003 [doi] AB - OBJECTIVE: To investigate the outcomes of mixed-grade non-muscle invasive bladder cancer (NMIBC) based on the degree of high-grade predominance. METHODS: We identified patients in our institutional database who had a transurethral resection of bladder tumor(s) for NMIBC. Tumors with mixed-grade features on pathology report were reanalyzed, assigned the percentage high-grade component, and stratified into 5% high-grade groups. All others were classified as low-grade or high-grade NMIBC. Differences in recurrence-free survival were assessed by log-rank test. A multivariable Cox regression model was used to evaluate the impact of tumor grade on recurrence, controlling for tumor stage, size, multifocality, and intravesical therapy. RESULTS: Two hundred and twenty patients were followed for a median of 2 years; 127 (58%) had low-grade NMIBC, 66 (30%) had high-grade NMIBC, and 27 (12%) had mixed-grade NMIBC. Of the mixed-grade patients, 14 had a 5% high-grade component. Recurrence rates across all groups ranged from 42% to 79%. There was no significant difference in intravesical recurrence-free survival among the grade categories as assessed by log-rank test. On multivariable Cox regression analysis, grade category was not significantly associated with likelihood of recurrence. CONCLUSIONS: The prognosis of mixed-grade histology in NMIBC has not previously been well defined. Although grade category was not found to be an independent significant predictor of recurrence, the recurrence rate for mixed-grade tumors was quite high overall. Further studies are required to better understand appropriate risk stratification and treatment of mixed-grade NMIBC. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Ho, Patrick AU - Ho P AD - Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Moran, George W AU - Moran GW AD - Columbia University Irving Medical Center, Department of Urology, New York, NY. FAU - Wang, Vinson AU - Wang V AD - Columbia University Irving Medical Center, Department of Urology, New York, NY. FAU - Li, Gen AU - Li G AD - University of Michigan, Department of Biostatistics, Ann Arbor, MI. FAU - Virk, Renu K AU - Virk RK AD - Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, NY. FAU - McKiernan, James M AU - McKiernan JM AD - Columbia University Irving Medical Center, Department of Urology, New York, NY. FAU - Anderson, Christopher B AU - Anderson CB AD - Columbia University Irving Medical Center, Department of Urology, New York, NY. Electronic address: cba2125@cumc.columbia.edu. LA - eng PT - Journal Article DEP - 20210730 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*pathology MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - mixed-grade EDAT- 2021/08/03 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/08/02 05:36 PHST- 2021/03/18 00:00 [received] PHST- 2021/06/11 00:00 [revised] PHST- 2021/07/02 00:00 [accepted] PHST- 2021/08/03 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/08/02 05:36 [entrez] AID - S1078-1439(21)00304-5 [pii] AID - 10.1016/j.urolonc.2021.07.003 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):60.e11-60.e16. doi: 10.1016/j.urolonc.2021.07.003. Epub 2021 Jul 30. PMID- 34333899 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 1738-3684 (Print) IS - 1976-3026 (Electronic) IS - 1738-3684 (Linking) VI - 18 IP - 8 DP - 2021 Aug TI - Increased Risk of Recurrence of Non-Muscle Invasive Bladder Cancer Associated With Psychological Distress: A Prospective Cohort Study. PG - 718-727 LID - 10.30773/pi.2021.0022 [doi] AB - OBJECTIVE: The primary aim was to evaluate the influence of depressive and anxiety symptoms on the 1-year recurrence rate of non-muscle invasive bladder cancer (NMIBC) patients. The secondary aim was to examine the risk factors leading to psychological distress. METHODS: A total of 104 NMIBC patients were enrolled for interviews, and the Hospital Anxiety and Depression Scale (HADS) questionnaire survey was administered 1 month after their operation. Their cystoscopy results were followed up. The risk factors affecting their 1-year recurrence rate were evaluated through univariate analysis, Cox regression and Kaplan-Meier analysis. The risk factors causing depressive and anxiety symptoms were evaluated through univariate analysis and logistic regression. RESULTS: In addition to American Urological Association risk stratification, depressive symptoms were another independent risk factor for recurrence in NMIBC patients (HR: 2.493, 95% CI: 1.048-5.930, p=0.039), and the increase in the recurrence rate was highly significant in intermediate-risk patients (HR: 8.496, 95% CI: 2.178-33.138, p=0.019). Anxiety symptoms were not an independent risk factor for recurrence (HR: 1.655, 95% CI: 0.714-3.837, p=0.240). We also observed that the burden of medical expenses of NMIBC on the family was an independent risk factor for depressive symptoms (p=0.029) and anxiety symptoms (p=0.048); chronic pain was an independent risk factor for anxiety symptoms (OR: 3.447, 95% CI: 1.182-10.052, p=0.023). CONCLUSION: Depression symptoms are an independent risk factor for recurrence in NMIBC patients. Moreover, the burden of medical expenses on the family is an independent risk factor for depressive and anxiety symptoms in NMIBC patients. Additionally, chronic pain is a risk factor for anxiety symptoms in NMIBC patients. This study provided a theoretical foundation for clinical oncologists to pay more attention to the mental health of NMIBC patients. FAU - Qian, Zhiyu AU - Qian Z AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Ding, Weihong AU - Ding W AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Zhou, Qidong AU - Zhou Q AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Ge, Shengyang AU - Ge S AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Sun, Chuanyu AU - Sun C AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Xu, Ke AU - Xu K AD - Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China. LA - eng GR - 19ZR1408000/Science and Technology Commission of Shanghai Municipality/ PT - Journal Article DEP - 20210802 PL - Korea (South) TA - Psychiatry Investig JT - Psychiatry investigation JID - 101242994 PMC - PMC8390949 OTO - NOTNLM OT - Anxiety symptoms OT - Depressive symptoms OT - Non-muscle invasive bladder cancer OT - Recurrence COIS- The authors have no potential conflicts of interest to disclose. EDAT- 2021/08/03 06:00 MHDA- 2021/08/03 06:01 PMCR- 2021/08/01 CRDT- 2021/08/02 00:11 PHST- 2021/01/20 00:00 [received] PHST- 2021/05/14 00:00 [accepted] PHST- 2021/08/03 06:00 [pubmed] PHST- 2021/08/03 06:01 [medline] PHST- 2021/08/02 00:11 [entrez] PHST- 2021/08/01 00:00 [pmc-release] AID - pi.2021.0022 [pii] AID - pi-2021-0022 [pii] AID - 10.30773/pi.2021.0022 [doi] PST - ppublish SO - Psychiatry Investig. 2021 Aug;18(8):718-727. doi: 10.30773/pi.2021.0022. Epub 2021 Aug 2. PMID- 34330653 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma. PG - 743-753 LID - S1078-1439(21)00257-X [pii] LID - 10.1016/j.urolonc.2021.05.039 [doi] AB - OBJECTIVE: Upper urinary tract urothelial carcinoma (UTUC) is a relatively uncommon disease with few reported molecular markers. This study evaluated Tim-3 and PD-1 expression in primary UTUC and its impact on patients' clinical outcomes. METHODS: Tim-3 and PD-1 protein expression was detected by immunohistochemistry in paraffin-embedded sections from 101 UTUC patients. The H-score was correlated with clinicopathologic outcomes and the long-term recurrence and survival rates. RESULTS: T cell immunoglobulin mucin-3 (Tim-3) protein was overexpressed in UTUC cells, especially tumour-infiltrating lymphocytes (TILs) and endothelial cells. We found that 95% (95/101) of UTUC tissues had dysregulated Tim-3 expression, of which 44% (44/101) showed high expression. High Tim-3 expression (H-score>/=100) was significantly correlated with advanced pathological grade, advanced T stage and tumour recurrence (P=0.016, 0.001 and < 0.001, respectively) and with poor intravesical recurrence-free survival (IRFS) and overall survival (OS) (P< 0.001 and 0.003). Moreover, another immune checkpoint molecule, programmed death receptor-1 (PD-1), was also assessed in our study. Among patients in the low Tim-3 expression subgroup, those with high PD-1 expression experienced intravesical recurrence (IVR) more often than those with low PD-1 expression (P< 0.001). However, the PD-1 expression level had no effect on prognosis in the high Tim-3 expression subgroup. CONCLUSION: We confirmed that high Tim-3 protein expression can be used as an indicator of earlier IVR and shorter OS in patients with UTUC, while high expression of PD-1 is only related to earlier IVR. We showed that Tim-3 plays a more important role in tumour recurrence and progression than PD-1. Collectively, our findings support the use of Tim-3 and PD-1 as clinical prognostic factors indicating poor patient survival. Tim-3, alone or in combination with PD-1, could become a target for future UTUC therapies, but further prospective studies are needed. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Chen, Han AU - Chen H AD - Department of Urology, Chengdu Second People's Hospital (Chengdu Third Clinical College Affiliated to Chongqing Medical University), Chengdu, China. FAU - Wang, Ming AU - Wang M AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: wangm20201028@163.com. FAU - Weng, Tonghui AU - Weng T AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Wei, Yu AU - Wei Y AD - Department of Master, The Chongqing Medical University, Chongqing, China. FAU - Liu, Chuan AU - Liu C AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Yang, Lei AU - Yang L AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Ren, Ke AU - Ren K AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Tang, Yi AU - Tang Y AD - Department of Pathology, The Chongqing Medical University, Chongqing, China. FAU - Tang, Zhaobing AU - Tang Z AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Gou, Xin AU - Gou X AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Review DEP - 20210728 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (HAVCR2 protein, human) RN - 0 (Hepatitis A Virus Cellular Receptor 2) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Hepatitis A Virus Cellular Receptor 2/*metabolism MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Programmed Cell Death 1 Receptor/*metabolism MH - Urinary Bladder Neoplasms/*genetics/pathology OTO - NOTNLM OT - PD-1 OT - Tim-3 OT - intravesical recurrence OT - tumor stage OT - upper urinary tract urothelial carcinoma COIS- Conflict of interest All authors do not have any financial, personal relationships and potential conflicts of interest with others or organizations, such as employment, consulting, equity, remuneration, paid expert testimony, patent application/registration, and grants or other funds. EDAT- 2021/08/01 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/07/31 06:27 PHST- 2021/02/24 00:00 [received] PHST- 2021/05/06 00:00 [revised] PHST- 2021/05/30 00:00 [accepted] PHST- 2021/08/01 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/07/31 06:27 [entrez] AID - S1078-1439(21)00257-X [pii] AID - 10.1016/j.urolonc.2021.05.039 [doi] PST - ppublish SO - Urol Oncol. 2021 Nov;39(11):743-753. doi: 10.1016/j.urolonc.2021.05.039. Epub 2021 Jul 28. PMID- 34330652 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. PG - 63.e9-63.e18 LID - S1078-1439(21)00297-0 [pii] LID - 10.1016/j.urolonc.2021.06.021 [doi] AB - INTRODUCTION: Molecular markers associated with breast cancer are assumed to be associated with outcome in non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively investigated the association of the mRNA expression of estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR), MKI67, and HER2 (ERBB2) with recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) in 80 patients with stage T1 NMIBC. RESULTS: High expression of ESR2 (P = 0.003), ERBB2 (P < 0.001), and MKI67 (P = 0.029) was associated with shorter RFS. Only high ERBB2 was an independent prognostic factor for reduced RFS (HR = 2.98; P = 0.009). When sub stratifying the cohort, high ESR2 was associated with reduced RFS (P < 0.001), CSS (P = 0.037) and OS (P = 0.006) in patients without instillation therapy. High ESR2 was associated with reduced CSS (P = 0.018) and OS (P = 0.029) in females and with shorter RFS in both sexes (males: P = 0.035; females: P = 0.010). Patients with high ERBB2 showed reduced CSS (P = 0.011) and OS (P = 0.042) in females and reduced CSS (P = 0.012) in those without instillation, while RFS was significantly reduced irrespective of sex or instillation. CONCLUSION: High mRNA expression of ERBB2 is an independent predictor of reduced RFS in patients with stage T1 NMIBC. High ERBB2 and ESR2 are associated with reduced outcomes, especially in females and patients without instillation therapy. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Electronic address: danijel.sikic@uk-erlangen.de. FAU - Eckstein, Markus AU - Eckstein M AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Kubon, Jennifer AU - Kubon J AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany. FAU - Kunath, Frank AU - Kunath F AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210728 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality OTO - NOTNLM OT - ERBB2 OT - Estrogen receptor OT - HER2 OT - Non-muscle-invasive bladder cancer OT - Urothelial carcinoma COIS- Conflict of interest All authors declare no conflicts of interest. EDAT- 2021/08/01 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/07/31 06:27 PHST- 2021/04/26 00:00 [received] PHST- 2021/06/13 00:00 [revised] PHST- 2021/06/25 00:00 [accepted] PHST- 2021/08/01 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/07/31 06:27 [entrez] AID - S1078-1439(21)00297-0 [pii] AID - 10.1016/j.urolonc.2021.06.021 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):63.e9-63.e18. doi: 10.1016/j.urolonc.2021.06.021. Epub 2021 Jul 28. PMID- 34313904 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20261010 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 26 IP - 11 DP - 2021 Nov TI - Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. PG - 2104-2112 LID - 10.1007/s10147-021-01988-8 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) is a newly defined subtype that is unlikely to benefit from BCG rechallenge. Radical cystectomy is currently recommended for BCG-unresponsive NMIBC; however, a certain proportion of these patients can be managed with treatments other than that. Herein, we conducted a multicenter retrospective study to analyze the clinical outcomes of BCG-unresponsive NMIBC patients who did not receive radical cystectomy. METHODS: Of the 141 BCG-unresponsive NMIBC patients, 94 (66.7%) received treatment except radical cystectomy. Survival outcomes were calculated from the date of diagnosis using the Kaplan-Meier method and compared using the log-rank test. Prognostic factors were identified using the multivariate Cox regression model. This group was further classified into three groups according to the number of risk factors, and survival outcomes were compared. RESULTS: Multivariate analyses identified low estimated glomerular filtration rate (< 45 ml/min/1.73 m(2)) and large tumor size (>/= 30 mm) before BCG induction as independent poor prognostic factors for progression-free survival and overall survival, while the latter was also an independent factor for cancer-specific survival. The presence of variant histology was an independent poor prognostic factor for overall survival. The high-risk non-cystectomy group showed a significantly poor prognosis for progression-free survival (hazard ratio: 7.61, 95% confidence interval: 2.11-27.5), cancer-specific survival (10.4, 0.54-70.02), and overall survival (8.28, 1.82-37.7). CONCLUSIONS: Our findings suggest that patients with renal impairment and large tumors should undergo radical cystectomy if the complications and intentions of the patients allow so. CI - (c) 2021. Japan Society of Clinical Oncology. FAU - Iida, Kota AU - Iida K AUID- ORCID: 0000-0001-7804-9128 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp. FAU - Murakami, Kaoru AU - Murakami K AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Komiyama, Motokiyo AU - Komiyama M AD - Department of Urology, National Cancer Center Hospital, Tokyo, Japan. FAU - Okajima, Eijiro AU - Okajima E AD - Department of Urology, Nara City Hospital, Nara, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Yasumoto, Hiroaki AU - Yasumoto H AD - Department of Urology, Shimane University, Izumo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University School of Medicine, Aoba-ku, Sendai, Miyagi, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Yamagishi, Atsushi AU - Yamagishi A AD - Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan. FAU - Kikuchi, Hiroshi AU - Kikuchi H AD - Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210727 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 RN - 0 (BCG Vaccine) SB - IM MH - *BCG Vaccine/therapeutic use MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - Bacillus Calmette-Guerin-unresponsive OT - Estimated glomerular filtration rate OT - Non-muscle invasive bladder cancer OT - Tumor size EDAT- 2021/07/28 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/07/27 12:32 PHST- 2021/03/01 00:00 [received] PHST- 2021/07/07 00:00 [accepted] PHST- 2021/07/28 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/07/27 12:32 [entrez] AID - 10.1007/s10147-021-01988-8 [pii] AID - 10.1007/s10147-021-01988-8 [doi] PST - ppublish SO - Int J Clin Oncol. 2021 Nov;26(11):2104-2112. doi: 10.1007/s10147-021-01988-8. Epub 2021 Jul 27. PMID- 34303597 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 2 DP - 2022 Feb TI - Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. PG - 60.e1-60.e9 LID - S1078-1439(21)00277-5 [pii] LID - 10.1016/j.urolonc.2021.06.018 [doi] AB - BACKGROUND: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited. OBJECTIVE: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice. METHODS AND MATERIALS: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RARC (n = 386) between January 1, 2012 and December 31, 2015. Primary and secondary outcome measures were median OS and RFS, respectively. Survival outcomes were estimated using Kaplan-Meier curves. A multivariable Cox regression model was developed to adjust for possible confounders and to assess prognostic factors for survival including clinical variables, clinical and pathological disease stage, neoadjuvant therapy and surgical margin status. RESULTS: The median follow-up was 5.1 years (95% confidence interval ([95%CI] 5.0-5.2). The median OS after ORC was 5.0 years (95%CI 4.3-5.6) versus 5.8 years after RARC (95%CI 5.1-6.5). The median RFS was 3.8 years (95%CI 3.1-4.5) after ORC versus 5.0 years after RARC (95%CI 3.9-6.0). After multivariable adjustment, the hazard ratio for OS was 1.00 (95%CI 0.84-1.20) and for RFS 1.08 (95%CI 0.91-1.27) of ORC versus RARC. Patients who underwent ORC were older, had higher preoperative serum creatinine levels and more advanced clinical and pathological disease stage. CONCLUSION: ORC and RARC resulted in similar intermediate-term OS and RFS in a cohort of almost 1500 MIBC and high-risk NMIBC. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Hinsenveld, Florentien J AU - Hinsenveld FJ AD - Department of Urology, Amsterdam University Medical Centres location Vrije University Medical Centre, Amsterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands. Electronic address: j.boormans@erasmusmc.nl. FAU - van der Poel, Henk G AU - van der Poel HG AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - van der Schoot, Deric K E AU - van der Schoot DKE AD - Department of Urology, Amphia Hospital, Breda, The Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, Amsterdam University Medical Centres location Vrije University Medical Centre, Amsterdam, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Arends, T J AU - Arends TJ AD - Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. FAU - Ausems, P J AU - Ausems PJ AD - Department of Urology, HagaZiekenuis, Den Haag, The Netherlands. FAU - Baselmans, D AU - Baselmans D AD - Department of Urology, Maxima Medical Centre, Veldhoven, The Netherlands. FAU - Berger, Cpam AU - Berger C AD - Department of Urology, Haaglanden Medical Centre, Den Haag, The Netherlands. FAU - Berrens, A AU - Berrens A AD - Department of Urology, Franciscus Hospital, Rotterdam, The Netherlands. FAU - Bickerstaffe, H AU - Bickerstaffe H AD - Department of Urology, Bravis Hospital, Bergen op Zoom, Roosendaal, The Netherlands. FAU - Bos, S D AU - Bos SD AD - Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. FAU - Braam, M AU - Braam M AD - Department of Urology, Martini Hospital, Groningen, The Netherlands. FAU - Buddingh, K T AU - Buddingh KT AD - Department of Urology, HagaZiekenuis, Den Haag, The Netherlands. FAU - Claus, S AU - Claus S AD - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands. FAU - Dekker, K AU - Dekker K AD - Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands. FAU - van Doeveren, T AU - van Doeveren T AD - Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Einerhand, Smh AU - Einerhand S AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Fossion, Lmcl AU - Fossion L AD - Department of Urology, Maxima Medical Centre, Veldhoven, The Netherlands. FAU - van Gennep, E J AU - van Gennep EJ AD - Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands. FAU - van Ginkel, N AU - van Ginkel N AD - Department of Urology, Spaarne Gasthuis, Haarlem, Hoofddorp, The Netherlands. FAU - Palacios, LA Grondhuis AU - Palacios G AD - Department of Urology, Haaglanden Medical Centre, Den Haag, The Netherlands. FAU - Hermans, Tjn AU - Hermans T AD - Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Hobijn, M M AU - Hobijn MM AD - Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - van Huystee, S H AU - van Huystee SH AD - Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. FAU - Jaspers-Valentijn, M AU - Jaspers-Valentijn M AD - Department of Urology, Bravis Hospital, Bergen op Zoom, Roosendaal, The Netherlands. FAU - Klaver, O S AU - Klaver OS AD - Department of Urology, Maasstad Hospital, Rotterdam, The Netherlands. FAU - Koldewijn, E L AU - Koldewijn EL AD - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands. FAU - Korsten, L AU - Korsten L AD - Department of Urology, Elisabeth TweeSteden Hospital, Tilburg, The Netherland. FAU - Lenting, A AU - Lenting A AD - Department of Urology, Franciscus Hospital, Rotterdam, The Netherlands. FAU - Lentjes, K J AU - Lentjes KJ AD - Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands. FAU - Luiting, H B AU - Luiting HB AD - Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - van der Meer, S AU - van der Meer S AD - Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands. FAU - Nieuwenhuijzen, J A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Centres location Vrije University Medical Centre, Amsterdam, The Netherlands. FAU - Noordzij, M A AU - Noordzij MA AD - Department of Urology, Spaarne Gasthuis, Haarlem, Hoofddorp, The Netherlands. FAU - Nooter, R I AU - Nooter RI AD - Department of Urology, Franciscus Hospital, Rotterdam, The Netherlands. FAU - Notenboom, Caw AU - Notenboom C AD - Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Oomen, Rja AU - Oomen R AD - Department of Urology, Elisabeth TweeSteden Hospital, Tilburg, The Netherland. FAU - van Roermund, Jgh AU - van Roermund J AD - Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - de Rooij, J AU - de Rooij J AD - Department of Urology, Maxima Medical Centre, Veldhoven, The Netherlands. FAU - Roshani, H AU - Roshani H AD - Department of Urology, HagaZiekenuis, Den Haag, The Netherlands. FAU - Schrier, B P AU - Schrier BP AD - Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands. FAU - van der Slot, M A AU - van der Slot MA AD - Department of Urology, Maasstad Hospital, Rotterdam, The Netherlands. FAU - Somford, D M AU - Somford DM AD - Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. FAU - Stelwagen, P J AU - Stelwagen PJ AD - Department of Urology, Amsterdam University Medical Centres location Vrije University Medical Centre, Amsterdam, The Netherlands. FAU - Stroux, Ama AU - Stroux A AD - Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - van der West, A AU - van der West A AD - Department of Urology, Spaarne Gasthuis, Haarlem, Hoofddorp, The Netherlands. FAU - Wijsman, B P AU - Wijsman BP AD - Department of Urology, Elisabeth TweeSteden Hospital, Tilburg, The Netherland. FAU - Windt, Wakm AU - Windt W AD - Department of Urology, Martini Hospital, Groningen, The Netherlands. FAU - van Zanten, P AU - van Zanten P AD - Department of Urology, HagaZiekenuis, Den Haag, The Netherlands. FAU - van Beek, Sytse C AU - van Beek SC AD - Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands. CN - Dutch Cystectomy Snapshot Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210722 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Netherlands MH - Retrospective Studies MH - Robotic Surgical Procedures/*methods MH - Robotics/*methods MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Muscle invasive OT - Robot OT - Survival COIS- Conflict of interest All authors declare no conflicts of interest. EDAT- 2021/07/26 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/07/25 20:25 PHST- 2021/04/01 00:00 [received] PHST- 2021/05/31 00:00 [revised] PHST- 2021/06/21 00:00 [accepted] PHST- 2021/07/26 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/07/25 20:25 [entrez] AID - S1078-1439(21)00277-5 [pii] AID - 10.1016/j.urolonc.2021.06.018 [doi] PST - ppublish SO - Urol Oncol. 2022 Feb;40(2):60.e1-60.e9. doi: 10.1016/j.urolonc.2021.06.018. Epub 2021 Jul 22. PMID- 34301456 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220217 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 10 DP - 2021 Oct TI - Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. PG - 734.e11-734.e17 LID - S1078-1439(21)00270-2 [pii] LID - 10.1016/j.urolonc.2021.06.011 [doi] AB - PURPOSE: Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether patients with HG clinical T1 or T2 bladder urothelial carcinoma (UC) have profiles that predict the potential effectiveness of immune-checkpoint inhibitors (ICI). MATERIALS AND METHODS: Data from transurethral resection of bladder tumor (TURBT) specimens from 2 studies was evaluated. The molecular upstaging (MOL) cohort included HG cT1N0M0 (n = 87) and cT2N0M0 (n = 119) bladder UC who underwent radical cystectomy (RC) without any neoadjuvant therapy. The PURE-01 cohort (n = 102) was used as ICI-treated reference. Specimen collection and sample processing were conducted using a clinical-grade whole-transcriptome assay (Decipher). Immune-signatures scores and molecular subtyping were evaluated. Kaplan-Meier curves and log-rank tests were used for exploratory analyses of recurrence-free survival (RFS) and overall survival (OS). RESULTS: In both the PURE-01 and MOL cohorts, the Immune190 signature, stratified by subtype, showed the highest scores in basal-type, but also in luminal-infiltrated tumors, but the lowest scores in the luminal tumors. However, in HG cT1 tumors the Immune190 scores were the lowest for luminal papillary tumors (Consensus, TCGA) and luminal tumors (GSC), with less distinct differences between other subtypes. RFS was significantly longer for luminal vs non-luminal tumors in MOL (P = 0.04) but not in PURE-01 (P = 0.8). In the MOL cohort, OS was inferior in HG cT1 tumors for Immune190-high vs low tumors (median split, P = 0.042). CONCLUSION: We identified a population of cT1-T2N0M0 tumors in the MOL cohort that shared molecular features with tumors included in PURE-01. These profiles suggest that treatment with ICI could be proposed to more selected HG cT1N0M0 tumors, identified with a gene expression assay. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Necchi, Andrea AU - Necchi A AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy. Electronic address: necchi.andrea@hsr.it. FAU - Raggi, Daniele AU - Raggi D AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Bandini, Marco AU - Bandini M AD - Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Marandino, Laura AU - Marandino L AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Montorsi, Francesco AU - Montorsi F AD - Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Davicioni, Elai AU - Davicioni E AD - Decipher Urologic Cancers, Veracyte, Vancouver, British Columbia, Canada. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Gibb, Ewan A AU - Gibb EA AD - Decipher Urologic Cancers, Veracyte, Vancouver, British Columbia, Canada. Electronic address: ewan.gibb@decipherbio.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210721 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Aged MH - Female MH - Gene Expression Profiling/*methods MH - Humans MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use MH - Male MH - Middle Aged MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Immunotherapy OT - Muscle-invasive bladder cancer OT - Neoadjuvant pembrolizumab OT - Radical cystectomy OT - Tumor biomarkers COIS- Conflict of interest Elai Davicioni and Ewan Gibb are employees of Veracyte, Inc. A Necchi: Consulting: Merck, Astra Zeneca, Janssen, Incyte, Roche, Rainier Therapeutics, Clovis Oncology, Bayer, and Astellas/Seattle Genetics, Ferring, Immunomedics. Grant/Research support: Merck, Ipsen, and Astra Zeneca. Travel expenses/Honoraria: Roche, Merck, Astra Zeneca, and Janssen. The remaining authors have no direct or indirect commercial financial incentive associated with publishing the article. EDAT- 2021/07/25 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/07/24 05:34 PHST- 2021/03/03 00:00 [received] PHST- 2021/06/07 00:00 [revised] PHST- 2021/06/17 00:00 [accepted] PHST- 2021/07/25 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/07/24 05:34 [entrez] AID - S1078-1439(21)00270-2 [pii] AID - 10.1016/j.urolonc.2021.06.011 [doi] PST - ppublish SO - Urol Oncol. 2021 Oct;39(10):734.e11-734.e17. doi: 10.1016/j.urolonc.2021.06.011. Epub 2021 Jul 21. PMID- 34298186 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20211022 IS - 1876-7737 (Electronic) IS - 1874-3919 (Linking) VI - 247 DP - 2021 Sep 15 TI - Blood-based protein biomarkers in bladder urothelial tumors. PG - 104329 LID - S1874-3919(21)00228-1 [pii] LID - 10.1016/j.jprot.2021.104329 [doi] AB - Bladder cancer (BC) is the fifth most common cancer with a high prevalence rate. It is classically classified in two groups, namely non-muscle invasive (NMIBC) and muscle invasive (MIBC). NMIBC accounts for 75% of cases and has a better prognosis than MIBC. However, 30-50% of the NMIBC patients will show recurrences throughout their lives, and about 10-20% of them will progress to MIBC, with frequent metastasis and a reduced survival rate. The diagnosis of bladder cancer is confirmed by direct visualization of the tumour and other mucosal abnormalities with endoscopic excision using cystoscopy and transurethral resection of the bladder (TURBT). An adequate TURBT requires complete resection of all visible tumour with appropriate sampling of the bladder to assess the depth of invasion. However, for many years, researchers have attempted to identify and utilise urinary markers for bladder cancer detection. Voided urine cytology has been the mainstay of urine-based diagnosis of bladder cancer since originally described by Papanicolau and Marshall. Nonetheless, urine cytology has several drawbacks, including a poor sensitivity for low-grade/stage tumours, a lack of interobserver consistency and a variable range of readings (e.g., atypical, atypical-suspicious, non-diagnostic). These shortcomings have inspired the search for more sensitive bladder cancer biomarkers. To bring precision medicine to genitourinary oncology, the analysis of the plasma/serum wide genome and proteome offers promising possibilities. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Lopez-Cortes, Ruben AU - Lopez-Cortes R AD - Research Unit, Hospital Universitario Lucus Augusti (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Gomez, Benito Blanco AU - Gomez BB AD - Urology Division, Hospital Universitario Lucus Augusti (HULA), Servizo Galego de Saude (SERGAS), ES27002, Lugo, Spain. FAU - Vazquez-Estevez, Sergio AU - Vazquez-Estevez S AD - Oncology Division, Hospital Universitario Lucus Augusti (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. FAU - Perez-Fentes, Daniel AU - Perez-Fentes D AD - Urology Division, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Servizo Galego de Saude (SERGAS), ES15706 Santiago de Compostela, Spain. FAU - Nunez, Cristina AU - Nunez C AD - Research Unit, Hospital Universitario Lucus Augusti (HULA), Servizo Galego de Saude (SERGAS), ES27002 Lugo, Spain. Electronic address: cristina.nunez.gonzalez@sergas.es. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210721 PL - Netherlands TA - J Proteomics JT - Journal of proteomics JID - 101475056 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - Cystectomy MH - Cystoscopy MH - Humans MH - Neoplasm Invasiveness MH - *Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Glycoproteomics OT - Molecular subtypes OT - Proteomics OT - Urothelial cancer EDAT- 2021/07/24 06:00 MHDA- 2023/02/25 06:00 CRDT- 2021/07/23 20:15 PHST- 2021/03/05 00:00 [received] PHST- 2021/07/15 00:00 [accepted] PHST- 2021/07/24 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2021/07/23 20:15 [entrez] AID - S1874-3919(21)00228-1 [pii] AID - 10.1016/j.jprot.2021.104329 [doi] PST - ppublish SO - J Proteomics. 2021 Sep 15;247:104329. doi: 10.1016/j.jprot.2021.104329. Epub 2021 Jul 21. PMID- 34295585 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 13 IP - 6 DP - 2021 Jun TI - Diagnostic Ureteroscopy in CT Urography-Diagnosed Upper Tract Urothelial Carcinoma: Delay in Definitive Treatment and Increased Intravesical Recurrence. PG - e15775 LID - 10.7759/cureus.15775 [doi] LID - e15775 AB - Purpose To investigate the effect of diagnostic ureteroscopy (URS) on the delay to surgical treatment of upper tract urothelial carcinoma (UTUC) detected by imaging and the risk of intravesical recurrence. Materials and methods We undertook a retrospective case-note analysis of all patients who underwent radical nephroureterectomy (NUU) from November 2012 to July 2019. We identified those who underwent diagnostic ureteroscopy prior to NUU as Group 1 and those who did not undergo diagnostic URS as Group 2. Perioperative and pathological parameters were compared between both groups. Kaplan-Meier and Log-Rank analyses were used to compare delay to NUU and the intravesical recurrence (IVR) free survival. Cox regression models were employed to analyze the risk factors of intravesical recurrence. Results Out of 69 patients with a mean age of 71.3 years and a mean follow-up of 48.5 months, 49 (71%) underwent URS while 20 (29%) did not. The mean time between the computerized tomography urography (CTU) and surgery was 86 days with URS and 59 days in the control groups(p=0.007). Intravesical recurrence in year one postoperatively was 28.2 % in the URS group vs 5.9% in the control group (p=0.04). The Kaplan-Meier curve showed improved, yet insignificant, IVR-free survival for the control group (Log-Rank p-value=0.21). In multivariate Cox regression analysis, concomitant bladder carcinoma was an independent risk factor for IVR (HR, 15.01; 95%CI, 3.311 - 68.07; p=0.0004). Intravesical mitomycin-c was a protective factor (HR 0.154; 95%CI 0.025 - 0.922; p=0.040). Conclusion In our retrospective single-unit study, diagnostic ureteroscopy for CTU-detected upper tract urothelial carcinoma delayed definitive surgical treatment. Furthermore, it was associated with a significantly increased risk of early intravesical recurrence. URS can provide useful information and reassurance prior to major surgery but must be used with caution in light of these findings. CI - Copyright (c) 2021, SHSM et al. FAU - Shsm, Hadi AU - Shsm H AD - Urology, Cornwall Royal Hospital, Truro, GBR. FAU - Bright, Elizabeth AU - Bright E AD - Urology, Cornwall Royal Hospital, Truro, GBR. FAU - Mantle, Mark AU - Mantle M AD - Urology, Cornwall Royal Hospital, Truro, GBR. FAU - Munro, Nicholas AU - Munro N AD - Urology, Cornwall Royal Hospital, Truro, GBR. FAU - Fahmy, Omar AU - Fahmy O AD - Urology, Universiti Putra Malaysia, Serdang, MYS. LA - eng PT - Journal Article DEP - 20210620 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8291344 OTO - NOTNLM OT - bladder cancer OT - intravesical recurrence OT - nephroureterectomy OT - upper tract urothelial carcinoma OT - ureteroscopy COIS- The authors have declared that no competing interests exist. EDAT- 2021/07/24 06:00 MHDA- 2021/07/24 06:01 PMCR- 2021/06/20 CRDT- 2021/07/23 06:49 PHST- 2021/06/20 00:00 [accepted] PHST- 2021/07/23 06:49 [entrez] PHST- 2021/07/24 06:00 [pubmed] PHST- 2021/07/24 06:01 [medline] PHST- 2021/06/20 00:00 [pmc-release] AID - 10.7759/cureus.15775 [doi] PST - epublish SO - Cureus. 2021 Jun 20;13(6):e15775. doi: 10.7759/cureus.15775. eCollection 2021 Jun. PMID- 34286545 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20220531 IS - 2282-4197 (Electronic) IS - 1124-3562 (Linking) VI - 93 IP - 2 DP - 2021 Jun 28 TI - Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer. PG - 143-147 LID - 10.4081/aiua.2021.2.143 [doi] AB - OBJECTIVE: To conduct a prospective study of the potential prognostic role of endothelin-1 (ET-1) in a cohort of primary high-grade non-muscle-invasive urothelial bladder cancer patients, who were treated with adjuvant intravesical Bacillus Calmette-Guerin (BCG). MATERIAL AND METHODS: Patients with primary high-grade nonmuscle- invasive urothelial bladder cancer, who received postoperatively induction and maintenance BCG therapy, were prospectively included. Recurrence and progression were histologically proven. Immunohistochemical staining for ET-1 was assessed. Epidemiological, pathological and clinical parameters as well as the expression of ET-1 in tumor specimens were statistically analyzed for recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: ET-1 associates significantly with recurrence (p = 0.000), progression (p = 0.000), RFS (p = 0.000) and PFS (p = 0.000). The patient's age is also significant for recurrence (p = 0.003, OR = 1.273 95% CI: 1.086-1.492) and RFS (p = 0.013). CONCLUSIONS: ET-1 seems to deteriorate prognosis in patients suffering from primary high-grade non-muscle-invasive urothelial bladder cancer, who are treated with adjuvant BCG instillations. Furthermore, the patient's age associates with an increased likelihood for recurrence. FAU - Mitrakas, Lampros AU - Mitrakas L AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. lamprosmit@gmail.com. FAU - Gravas, Stavros AU - Gravas S AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. sgravas2002@yahoo.com. FAU - Karasavvidou, Foteini AU - Karasavvidou F AD - Department of Pathology and Cytology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa. fotkarasa@yahoo.gr. FAU - Zachos, Ioannis AU - Zachos I AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. johnbzac@yahoo.gr. FAU - Karatzas, Anastasios AU - Karatzas A AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. adkaratzas@yahoo.gr. FAU - Oeconomou, Athanasios AU - Oeconomou A AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. thaoik@hotmail.com. FAU - Koukoulis, Georgios AU - Koukoulis G AD - Department of Pathology and Cytology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa. gnkouk@med.uth.gr. FAU - Tzortzis, Vasilios AU - Tzortzis V AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Greece. tzorvas@otenet.gr. FAU - Papandreou, Christos AU - Papandreou C AD - Department of Oncology, School of Medicine, Aristotle University of Thessaloniki, "N.Papageorgiou" Hospital of Thessaloniki, Ring Road of Thessaloniki. cpapandreou@auth.gr. LA - eng PT - Journal Article DEP - 20210628 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Endothelin-1) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine MH - *Carcinoma, Transitional Cell/therapy MH - Endothelin-1 MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Prospective Studies MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2021/07/22 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/07/21 06:55 PHST- 2020/11/17 00:00 [received] PHST- 2021/01/23 00:00 [accepted] PHST- 2021/07/21 06:55 [entrez] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - 10.4081/aiua.2021.2.143 [doi] PST - epublish SO - Arch Ital Urol Androl. 2021 Jun 28;93(2):143-147. doi: 10.4081/aiua.2021.2.143. PMID- 34286164 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 6 IP - 5 DP - 2021 Sep-Oct TI - Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience. PG - 100718 LID - 10.1016/j.adro.2021.100718 [doi] LID - 100718 AB - PURPOSE: As an alternative to radical cystectomy, tri-modality treatment (TMT) is an effective treatment approach for selected patients with muscle-invasive bladder cancer (MIBC). The purpose of this report is to contribute to the literature by summarizing institutional outcomes of a bladder-preserving TMT approach for patients with MIBC. METHODS AND MATERIALS: Patients treated with TMT for MIBC from 1998 to 2019 were identified. Patient, disease, and treatment factors were recorded. Overall survival (OS), disease-free survival (DFS), and bladder-preserved DFS were estimated with the Kaplan-Meier method. Prognostic factors were evaluated with Cox proportional hazards regression. RESULTS: Thirty-two patients treated with TMT to a median dose of 64.8 Gy for T2 (78%), T3 (19%), and T4 (3%) disease were followed for a median of 19 months (mean, 36; range, 6-213); 31% had associated carcinoma in situ; 25% had associated hydronephrosis. Cisplatin was the most commonly used chemotherapeutic agent. OS rates were 84% at 1 year and 61% at 5 years. DFS rates were 84% and 61% and bladder-preserved DFS rates were 84% and 60% at 1 year and 5 years, respectively. Salvage cystectomy rates at 1 year and 5 years were 4% and 9%, respectively. Four patients had locally invasive recurrences at 8, 11, 34, and 37 months after initial MIBC diagnosis, 2 of whom underwent salvage radical cystectomy. Ten (31%) patients developed distant disease at a median of 13 months after diagnosis. Unlike local recurrence, distant recurrences were associated with worse OS and hazard ratios of 3.4 (P = 0.039). CONCLUSIONS: OS and DFS were comparable to those of published data. Our outcomes support TMT as an effective option for carefully selected patients with MIBC. CI - (c) 2021 The Authors. FAU - Polineni, Praneet AU - Polineni P AD - Departments of Radiation Oncology. FAU - Ashack, Laura AU - Ashack L AD - Departments of Radiation Oncology. FAU - Kalapurakal, John AU - Kalapurakal J AD - Departments of Radiation Oncology. FAU - Morgans, Alicia AU - Morgans A AD - Medicine, Hematology and Oncology Division. FAU - VanderWeele, David AU - VanderWeele D AD - Medicine, Hematology and Oncology Division. FAU - Kundu, Shilajit AU - Kundu S AD - Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Hussain, Maha AU - Hussain M AD - Medicine, Hematology and Oncology Division. FAU - Meeks, Joshua AU - Meeks J AD - Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Sachdev, Sean AU - Sachdev S AD - Departments of Radiation Oncology. LA - eng PT - Journal Article DEP - 20210520 PL - United States TA - Adv Radiat Oncol JT - Advances in radiation oncology JID - 101677247 PMC - PMC8273199 EDAT- 2021/07/22 06:00 MHDA- 2021/07/22 06:01 PMCR- 2021/05/20 CRDT- 2021/07/21 06:39 PHST- 2020/12/06 00:00 [received] PHST- 2021/04/07 00:00 [revised] PHST- 2021/04/27 00:00 [accepted] PHST- 2021/07/21 06:39 [entrez] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/07/22 06:01 [medline] PHST- 2021/05/20 00:00 [pmc-release] AID - S2452-1094(21)00076-2 [pii] AID - 100718 [pii] AID - 10.1016/j.adro.2021.100718 [doi] PST - epublish SO - Adv Radiat Oncol. 2021 May 20;6(5):100718. doi: 10.1016/j.adro.2021.100718. eCollection 2021 Sep-Oct. PMID- 34281841 OWN - NLM STAT- MEDLINE DCOM- 20210729 LR - 20210729 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 41 IP - 8 DP - 2021 Aug TI - Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer. PG - 3815-3823 LID - 10.21873/anticanres.15174 [doi] AB - BACKGROUND/AIM: A previous report showed that immune complex-ceruloplasmin (CP) in urine is associated with carcinogenesis and malignant behavior in bladder cancer (BC). We investigated the pathological significance and prognostic roles of urine and tissue levels of CP protein in BC patients. MATERIALS AND METHODS: Urine CP levels were measured using an enzyme-linked immunosorbent assay in 97 patients. CP expression in BC tissues was evaluated by immunohistochemical analysis in 176 patient samples. RESULTS: Urine CP levels were positively associated with tumor grade and pT stage in non-muscle invasive BC (NMIBC). CP expression in BC tissues was positively associated with tumor growth and progression. Multivariate analysis demonstrated that high urine CP levels was an independent predictor of recurrence in the urinary tract in NMIBC (hazard ratio=2.87, p=0.016). CONCLUSION: CP-related markers, especially urine CP levels, are useful biomarkers of malignant potential and prognosis in NMIBC. CI - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Mukae, Yuta AU - Mukae Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Ito, Hidenori AU - Ito H AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Miyata, Yasuyoshi AU - Miyata Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan yasu-myt@nagasaki-u.ac.jp. FAU - Araki, Kyohei AU - Araki K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Matsuda, Tsuyoshi AU - Matsuda T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Aibara, Nozomi AU - Aibara N AD - Department of Pharmacy Practice, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Nakamura, Yuichiro AU - Nakamura Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Sakai, Hideki AU - Sakai H AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Ohyama, Kaname AU - Ohyama K AD - Department of Pharmacy Practice, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Biomarkers, Tumor) RN - EC 1.16.3.1 (Ceruloplasmin) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism/urine MH - Ceruloplasmin/*metabolism/urine MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Urinary Bladder Neoplasms/metabolism/*mortality/*pathology OTO - NOTNLM OT - Ceruloplasmin OT - bladder cancer OT - immunohistochemistry OT - recurrence OT - urine levels EDAT- 2021/07/21 06:00 MHDA- 2021/07/30 06:00 CRDT- 2021/07/20 06:09 PHST- 2021/06/02 00:00 [received] PHST- 2021/06/19 00:00 [revised] PHST- 2021/06/22 00:00 [accepted] PHST- 2021/07/20 06:09 [entrez] PHST- 2021/07/21 06:00 [pubmed] PHST- 2021/07/30 06:00 [medline] AID - 41/8/3815 [pii] AID - 10.21873/anticanres.15174 [doi] PST - ppublish SO - Anticancer Res. 2021 Aug;41(8):3815-3823. doi: 10.21873/anticanres.15174. PMID- 34274387 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20230110 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 157 DP - 2021 Nov TI - Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-risk Non-muscle-invasive Bladder Cancer. PG - 197-200 LID - S0090-4295(21)00642-7 [pii] LID - 10.1016/j.urology.2021.06.032 [doi] AB - OBJECTIVE: To test whether 2 sequential BCG-induction courses improve the response of high-risk non-muscle invasive bladder cancer. Achieving a complete response (CR) to BCG is critical to disease-free survival. Patients with preexisting BCG-specific immunity owing to prior exposure to BCG have longer disease-free survival than BCG-naive patients likely due to heterologous immunity from the initial priming of the immune system. We evaluated this hypothesis in a phase II prospective clinical trial. METHODS: From 2015 to 2018, we recruited patients with primary or recurrent NMIBC (high-grade Ta, T1 tumors, with or without CIS) to receive 2-induction courses (12 intra-vesical instillations) of BCG. The primary aim of the study was CR rate 6 months after start of the first BCG induction. CR was defined as no tumor at cystoscopy or TURB biopsy. No maintenance BCG was given. We targeted at least 75 evaluable patients, and a CR of 80% or better was deemed significant. RESULTS: Eighty-one patients agreed to participate. Five withdrew before starting BCG, leaving 76 evaluable patients. Sixty-three patients (83%) completed the 12 instillations on schedule. Of these, 62 patients (91%) had a CR at 6 months. None of the patients had tumor progression. Serious adverse event was seen in 1 patient (1%). Recurrence-free survival at 2 years after complete response was 85% (95% CI 77%, 95%). CONCLUSION: The high response rate in patients with high-risk non-muscle-invasive bladder cancer justifies 2 BCG induction cycles in current practice. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Herr, Harry AU - Herr H AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: herrh@mskcc.org. FAU - Vertosick, Emily A AU - Vertosick EA AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Dalbagni, Guido AU - Dalbagni G AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Cha, Eugene K AU - Cha EK AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Smith, Robert AU - Smith R AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Benfante, Nicole AU - Benfante N AD - Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sjoberg, Daniel D AU - Sjoberg DD AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article DEP - 20210715 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2023 Feb;209(2):443-444. doi: 10.1097/JU.0000000000003057. PMID: 36382508 MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC9428818 MID - NIHMS1826103 EDAT- 2021/07/19 06:00 MHDA- 2022/02/25 06:00 PMCR- 2022/11/01 CRDT- 2021/07/18 20:35 PHST- 2021/04/15 00:00 [received] PHST- 2021/06/06 00:00 [revised] PHST- 2021/06/30 00:00 [accepted] PHST- 2021/07/19 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/07/18 20:35 [entrez] PHST- 2022/11/01 00:00 [pmc-release] AID - S0090-4295(21)00642-7 [pii] AID - 10.1016/j.urology.2021.06.032 [doi] PST - ppublish SO - Urology. 2021 Nov;157:197-200. doi: 10.1016/j.urology.2021.06.032. Epub 2021 Jul 15. PMID- 34269918 OWN - NLM STAT- MEDLINE DCOM- 20220223 LR - 20261010 IS - 1534-6269 (Electronic) IS - 1523-3790 (Linking) VI - 23 IP - 9 DP - 2021 Jul 16 TI - Approaches to Non-Muscle-Invasive Bladder Cancer. PG - 105 LID - 10.1007/s11912-021-01091-1 [doi] AB - PURPOSE OF REVIEW: Non-muscle-invasive bladder cancer (NMIBC) is a heterogenous malignancy with high recurrence and progression rates, which necessitate uniform recommendations for diagnosis and management. Herein, we review the literature, with an emphasis on guidelines and contemporary diagnostic techniques and interventions. RECENT FINDINGS: Guidelines around the world have adopted a schema which risk-stratify cases at diagnosis, to offer evidence-based treatment and surveillance recommendations. Enhanced endoscopic technologies can improve detection of NMIBC and reduce recurrence. The present Bacillus Calmette-Guerin (BCG) shortage in the USA has led to new strategies to prioritize the most high-risk cases. The entity of BCG-unresponsive high-risk NMIBC remains a challenge to manage, with multiple novel treatments under investigation; fortunately, new therapies have been approved, such as immune checkpoint inhibitors, and others are showing tremendous promise. The standardization of NMIBC management, with evolving detection techniques and therapeutics, offers great potential to improve patient outcomes and survivorship. CI - (c) 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. FAU - Slovacek, Hannah AU - Slovacek H AD - Loyola University Chicago Stritch School of Medicine, Chicago, IL, USA. FAU - Zhuo, Jerry AU - Zhuo J AD - Department of Urology, Baylor College of Medicine, 7200 Cambridge St, Ste 10B, Houston, TX, 77030, USA. FAU - Taylor, Jennifer M AU - Taylor JM AUID- ORCID: 0000-0001-8595-8805 AD - Department of Urology, Baylor College of Medicine, 7200 Cambridge St, Ste 10B, Houston, TX, 77030, USA. Jennifer.Taylor@bcm.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210716 PL - United States TA - Curr Oncol Rep JT - Current oncology reports JID - 100888967 SB - IM MH - Clinical Trials as Topic MH - Cystoscopy/*methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Patient Care Team MH - Practice Guidelines as Topic MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Intravesical therapy OT - Non-muscle-invasive bladder cancer OT - Survivorship EDAT- 2021/07/17 06:00 MHDA- 2022/02/24 06:00 CRDT- 2021/07/16 12:30 PHST- 2021/05/20 00:00 [accepted] PHST- 2021/07/16 12:30 [entrez] PHST- 2021/07/17 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] AID - 10.1007/s11912-021-01091-1 [pii] AID - 10.1007/s11912-021-01091-1 [doi] PST - epublish SO - Curr Oncol Rep. 2021 Jul 16;23(9):105. doi: 10.1007/s11912-021-01091-1. PMID- 34269291 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20220424 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 17 IP - 3 DP - 2021 Jul TI - The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin vaccine therapy in patients with nonmuscle invasive bladder cancer. PG - 625-629 LID - 10.4103/jcrt.JCRT_1684_20 [doi] AB - AIMS: This study aimed to evaluate the role of serum prostate-specific antigen (PSA) levels and multiparametric magnetic resonance imaging (mpMRI) in the diagnosis of granulomatous prostatitis (GP) induced by intravesical Bacillus Calmette-Guerin vaccine (BCG) therapy in patients with nonmuscle invasive bladder cancer (NMIBC). SUBJECTS AND METHODS: We retrospectively analyzed eight patients with bladder cancer who underwent intravesical BCG therapy after transurethral resection of bladder tumor (TURBt) cancer. All these eight patients received 12-core transrectal ultrasound-guided prostate systemic biopsies. Clinical data on PSA with T1-weighted imaging (T1WI), T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) on mpMRI were enrolled in the study. H and E and acid-fast staining was performed to pathologically prove GP. RESULTS: Four of all eight cases were above 4 ng/ml total PSA (tPSA) levels and four cases were within normal ranges, while free PSA/tPSA levels decreased to lower than 16% in all patients. Every patient had hard prostatic nodules through digital rectal examination (DRE). All characters of prostate mpMRI did not show signal intensity (SI) of prostate cancer before BCG therapy but showed abnormal signals after BCG therapy. All nodular lesions showed equal SI on T1WI, lower SI on T2WI, higher SI on DWI, and lower SI on ADC after BCG therapy. Pathologic results were GP and acid-fast staining outcomes were positive in all biopsies. CONCLUSIONS: Perioperative serum PSA levels, prostate magnetic resonance imaging, and DRE may help in the diagnosis of GP induced by intravesical BCG therapy. In general, male patients with middle- and high-risk NMIBC are recommended to undertake DRE, PSA, and prostate mpMRI, if possible, before and after TURBt." FAU - Wang, Zilong AU - Wang Z AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. FAU - Han, Chenglin AU - Han C AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. FAU - Xu, Yingkun AU - Xu Y AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. FAU - Yu, Xiao AU - Yu X AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Kang, Weiting AU - Kang W AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. FAU - Xiang, Yuzhu AU - Xiang Y AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Yuan, Yanhua AU - Yuan Y AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Li, Lianjun AU - Li L AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Wang, Muwen AU - Wang M AD - Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - EC 3.4.21.- (KLK3 protein, human) RN - EC 3.4.21.- (Kallikreins) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage/*adverse effects MH - Biomarkers/blood MH - Biopsy MH - Cystectomy MH - Digital Rectal Examination MH - Humans MH - Immunotherapy/adverse effects/methods MH - Kallikreins/*blood MH - Male MH - Middle Aged MH - Multiparametric Magnetic Resonance Imaging MH - Prostate/*diagnostic imaging/pathology MH - Prostate-Specific Antigen/*blood MH - Prostatitis/blood/*diagnosis/immunology/pathology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin vaccine OT - granulomatous prostatitis OT - magnetic resonance imaging OT - prostate cancer OT - prostate-specific antigen COIS- None EDAT- 2021/07/17 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/07/16 08:48 PHST- 2021/07/16 08:48 [entrez] PHST- 2021/07/17 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - JCanResTher_2021_17_3_625_321016 [pii] AID - 10.4103/jcrt.JCRT_1684_20 [doi] PST - ppublish SO - J Cancer Res Ther. 2021 Jul;17(3):625-629. doi: 10.4103/jcrt.JCRT_1684_20. PMID- 34268374 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 9 IP - 9 DP - 2021 May TI - CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers. PG - 761 LID - 10.21037/atm-19-4511 [doi] LID - 761 AB - BACKGROUND: The biological behaviors, clinical treatment, prognosis of non-muscle-invasive bladder cancers (NMIBCs) and muscle-invasive bladder cancers (MIBCs) are distinct. Accurate staging is pivotal in optimal therapy planning for bladder cancers (BCs). However, it is insufficient for urologists in preoperative determining whether the tumor has invaded within the muscularis propria through cystoscope and imaging methods (CT or MRI). Therefore, searching for ideal biomarkers from the tumor tissues and urine is important for identifying the MIBCs preoperatively. METHODS: Differentially expressed genes between NMIBCs and MIBCs were identified by microarray analysis and validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemical analysis. The correlation between cysteine-rich angiogenic inducer 61 (CYR61) expression and Kaplan-Meier test evaluated patients' overall survival (OS). CYR61 protein levels were measured using enzyme-linked immunosorbent assay (ELISA) in preoperatively collected urine samples from BC patients. The receiver-operating characteristic (ROC) curve analyzed the diagnostic accuracy of uric CYR61. The siRNA mediated silencing of CYR61 in bladder carcinoma cells was performed using Lipofectamine 2000. Cell migration and invasion were assessed using wound healing and transwell assay, respectively. RESULTS: Differential gene expression analysis using microarray between 14 MIBCs and 16 NMIBCs human tumor samples revealed a significant increase (P<0.001) in the expression of CYR61 in MIBCs compared with NMIBCs. Higher expression of CYR61 in MIBCs was found in additional 54 tumor samples using qRT-PCR. Therefore, the overexpression of CYR61 in MIBCs could be used as a potential biomarker to distinguish between MIBCs and NMIBCs. ELISA detected elevated levels of CYR61 in the urine samples of MIBC patients (average 2.5-fold) compared with NMIBCs, with 72.7% sensitivity and 86.0% specificity to distinguish MIBCs from NMIBCs. Wound healing and transwell assays using CYR61-silenced carcinoma cells indicated the role of CYR61 in cell migration and invasion. CONCLUSIONS: CYR61 expression is higher in MIBCs compared with NMIBCs and can serve as a promising biomarker for the preoperative diagnosis of MIBCs with prognostic value; however, multicentric prospective validation is essential for the further evaluation of CYR61. CI - 2021 Annals of Translational Medicine. All rights reserved. FAU - Chen, Huang AU - Chen H AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Yu AU - Liu Y AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Cao, Chuanzhen AU - Cao C AD - Department of Urology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Xi, Hao AU - Xi H AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Chen, Wenting AU - Chen W AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Wei AU - Zheng W AD - Department of Urology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Dong, Xin AU - Dong X AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Shan AU - Zheng S AD - Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Lin AU - Li L AD - Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Ma, Jianhui AU - Ma J AD - Department of Urology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Gao, Yanning AU - Gao Y AD - State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Shou, Jianzhong AU - Shou J AD - Department of Urology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC8246191 OTO - NOTNLM OT - Bladder cancer (BC) OT - biomarker OT - cysteine-rich angiogenic inducer 61 (CYR61) OT - muscle-invasive bladder cancers (MIBCs) OT - non-muscle-invasive bladder cancers (NMIBCs) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-19-4511). The authors have no conflicts of interest to declare. EDAT- 2021/07/17 06:00 MHDA- 2021/07/17 06:01 PMCR- 2021/05/01 CRDT- 2021/07/16 06:42 PHST- 2019/12/22 00:00 [received] PHST- 2021/02/28 00:00 [accepted] PHST- 2021/07/16 06:42 [entrez] PHST- 2021/07/17 06:00 [pubmed] PHST- 2021/07/17 06:01 [medline] PHST- 2021/05/01 00:00 [pmc-release] AID - atm-09-09-761 [pii] AID - 10.21037/atm-19-4511 [doi] PST - ppublish SO - Ann Transl Med. 2021 May;9(9):761. doi: 10.21037/atm-19-4511. PMID- 34268106 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260930 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer. PG - 632459 LID - 10.3389/fonc.2021.632459 [doi] LID - 632459 AB - The progression from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) increases the risk of death. It is therefore important to find new relevant molecular models that will allow for effective prediction of the progression and prognosis of bladder cancer (BC). Using RNA-Sequence data of 49 BC patients in Shanghai tenth people's hospital (STPH) and weighted gene co-expression network analysis methods, a co-expression network of genes was developed and three key modules associated with malignant progression were selected. Based on the genes in three key modules, an eight-gene risk signature was established using univariate Cox regression and the Least absolute shrinkage and selection operator Cox model in The Cancer Genome Atlas Program (TCGA) and validated in validation sets. Subsequently, a nomogram based on the risk signature was constructed for prognostic prediction. The mRNA and protein expression levels of eight genes in cell lines and tissues were further investigated. The novel eight-gene risk signature was closely related to the malignant clinical features of BC and could predict the prognosis of patients in the training dataset (TCGA) and four validation sets (GSE32894, GSE13507, IMvigor210 trial, and STPH). The nomogram showed good prognostic prediction and calibration. The mRNA and protein expression levels of the eight genes were differentially expressed in cell lines and tissues. In our study, we established a novel eight-gene risk signature that could predict the progression and prognoses of BC patients. CI - Copyright (c) 2021 Wang, Zheng, Mao, Zhang, Liu, Li, Liu and Yao. FAU - Wang, Ruiliang AU - Wang R AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Zheng, Zongtai AU - Zheng Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Mao, Shiyu AU - Mao S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, Ji AU - Liu J AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Li, Cheng AU - Li C AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, Shenghua AU - Liu S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20210629 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8276675 OTO - NOTNLM OT - LASSO OT - WGCNA OT - bladder cancer OT - malignant progression OT - nomogram OT - prognosis OT - risk signature COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/17 06:00 MHDA- 2021/07/17 06:01 PMCR- 2021/01/01 CRDT- 2021/07/16 06:40 PHST- 2020/11/23 00:00 [received] PHST- 2021/06/07 00:00 [accepted] PHST- 2021/07/16 06:40 [entrez] PHST- 2021/07/17 06:00 [pubmed] PHST- 2021/07/17 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.632459 [doi] PST - epublish SO - Front Oncol. 2021 Jun 29;11:632459. doi: 10.3389/fonc.2021.632459. eCollection 2021. PMID- 34264569 OWN - NLM STAT- MEDLINE DCOM- 20220126 LR - 20220126 IS - 0890-9091 (Print) IS - 0890-9091 (Linking) VI - 35 IP - 7 DP - 2021 Jul 15 TI - Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook. PG - 410-420 LID - 10.46883/ONC.2021.3507.0410 [doi] AB - Bladder cancer is the sixth most common cancer in the United States, with an estimated 81,400 new cases in 2020. Although bladder cancer has 4 stages, for systemic treatment we recognize 3 clinical stages: non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and locally advanced/metastatic urothelial carcinoma (mUC). Approximately 70% to 80% of patients present with NMIBC at diagnosis and have an excellent 5-year overall survival (OS) of 69.2% to 95.8%.1 About 10% to 15% of patients present with MIBC at the time of diagnosis and have about a 50% chance of progressing to metastatic disease.2 mUC accounts for 10% to 15% of all bladder cancers at diagnosis, with a 5-year OS for patients of fewer than 10% with platinum-based chemotherapy. FAU - Feng, Zizhen AU - Feng Z AD - Knight Cancer Institute of the Oregon Health & Science University, Portland, OR. FAU - Vuky, Jacqueline AU - Vuky J AD - Knight Cancer Institute of the Oregon Health & Science University, Portland, OR. LA - eng PT - Journal Article PT - Review DEP - 20210715 PL - United States TA - Oncology (Williston Park) JT - Oncology (Williston Park, N.Y.) JID - 8712059 RN - 0 (Biomarkers, Tumor) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Immunoconjugates) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use MH - Biomarkers, Tumor MH - Humans MH - Immune Checkpoint Inhibitors/administration & dosage/adverse effects/*therapeutic use MH - Immunoconjugates/administration & dosage/adverse effects/*therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*drug therapy/pathology EDAT- 2021/07/16 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/07/15 14:43 PHST- 2021/07/15 14:43 [entrez] PHST- 2021/07/16 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] AID - 10.46883/ONC.2021.3507.0410 [doi] PST - epublish SO - Oncology (Williston Park). 2021 Jul 15;35(7):410-420. doi: 10.46883/ONC.2021.3507.0410. PMID- 34263743 OWN - NLM STAT- MEDLINE DCOM- 20220922 LR - 20260331 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 74 IP - 5 DP - 2022 Oct TI - Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. PG - 570-580 LID - 10.23736/S2724-6051.21.04436-0 [doi] AB - INTRODUCTION: Despite bladder perforation (BP) is a frequent complication during transurethral resection of bladder (TURB) for bladder cancer (BCa), literature lacks systematic reviews focusing on this issue. We aimed to investigate incidence, diagnosis, therapy, and prognosis after BP during TURB for BCa; therapy was distinguished between conservative (without the need for bladder repair) and surgical management (requiring bladder wall closure). EVIDENCE ACQUISITION: A systematic search was conducted up to April 2021 using PubMed, Scopus, Cochrane Database of Systematic Reviews, and Web of Science to identify articles focusing on incidence, detection, management, or survival outcomes after iatrogenic BP. The selection of articles followed the preferred reporting items for systematic review and meta-analyses process. EVIDENCE SYNTHESIS: We included 41 studies, involving 21,174 patients. Overall, 521 patients experienced BP during TURB for BCa, with a mean incidence of 2.4%, up to 58.3% when postoperative cystography is routinely performed after all TURB procedures. Risk factors were low body mass index (BMI) (P=0.01), resection depth (P=0.006 and P=0.03), and low surgical experience (P=0.006). Extraperitoneal BP (68.5%) were treated conservatively in 97.5% of patients; intraperitoneal BP were managed with surgical bladder closure in 56% of cases. Overall, three immediate BP-related deaths were recorded due to septic complications. Extravesical tumor seeding was observed after 6 intraperitoneal and 1 extraperitoneal BP (median time: 6.2 months). Intraperitoneal BP (P=0.0003) and bladder closure (P<0.001) were found as independent predictors of extravesical tumor recurrence. CONCLUSIONS: BP is more frequent than expected when proper diagnosis is routinely performed after all TURB procedures. Risk factors include low BMI, resection depth, and unexperienced surgeon. The risk of sepsis after BP suggests empirical antibiotic prophylaxis after BP. FAU - Lonati, Chiara AU - Lonati C AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy - chiara.lonati@libero.it. AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland - chiara.lonati@libero.it. FAU - Esperto, Francesco AU - Esperto F AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Scarpa, Roberto M AU - Scarpa RM AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Papalia, Rocco AU - Papalia R AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AD - Department of Urology, La Paz University Hospital, Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, La Paz University Hospital, Madrid, Spain. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Fankhauser, Christian D AU - Fankhauser CD AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - S. Anna Clinic, Swiss Medical Group, Sorengo, Switzerland. AD - Santa Chiara Clinic, Locarno, Switzerland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Teo, Jeremy Yuen-Chun AU - Teo JY AD - Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili of Brescia, Brescia, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. CN - European Association of Urology - Young Academic Urologists (EAU-YA U): Urothelial Carcinoma Working Group; European Association of Urology - European Society of Resident Urologists (EAU-ESRU) LA - eng PT - Journal Article PT - Systematic Review DEP - 20210715 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 SB - IM MH - Humans MH - *Abdominal Injuries/pathology MH - Algorithms MH - Follow-Up Studies MH - Neoplasm Recurrence, Local/prevention & control MH - Urinary Bladder/diagnostic imaging/surgery MH - *Urinary Bladder Diseases/pathology EDAT- 2021/07/16 06:00 MHDA- 2022/09/23 06:00 CRDT- 2021/07/15 09:06 PHST- 2021/07/16 06:00 [pubmed] PHST- 2022/09/23 06:00 [medline] PHST- 2021/07/15 09:06 [entrez] AID - S2724-6051.21.04436-0 [pii] AID - 10.23736/S2724-6051.21.04436-0 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2022 Oct;74(5):570-580. doi: 10.23736/S2724-6051.21.04436-0. Epub 2021 Jul 15. PMID- 34257543 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20240812 IS - 1532-2807 (Electronic) IS - 1219-4956 (Print) IS - 1219-4956 (Linking) VI - 27 DP - 2021 TI - Upregulation of Fatty Acid Transporters is Associated With Tumor Progression in Non-Muscle-Invasive Bladder Cancer. PG - 594705 LID - 10.3389/pore.2021.594705 [doi] LID - 594705 AB - As patients with non-muscle-invasive bladder cancer (NMIBC) show a high degree of heterogeneity in tumor recurrence or progression, many clinicians demand a detailed risk stratification. Although modified fatty acid metabolism in cancer cells is reported to reflect malignant phenotypes such as metastasis, the impact of fatty acid transporters on NMIBC has never been investigated. This study examined the clinicopathologic implications of fatty acid transporters such as fatty acid transport protein 4 (FATP4), cluster of differentiation 36/fatty acid translocase (CD36/FAT), and long chain acyl CoA synthetase 1 (ACSL1) in 286 NMIBC cases. This study revealed that FATP4, CD36, and ACSL1 were overexpressed in 123 (43.0%), 43 (15.0%), and 35 (12.2%) NMIBC cases, respectively. High FATP4 in tumor cells was associated with high grade (p = 0.004) and high stage (p = 0.039). High CD36 was related to high grade (p < 0.001), high stage (p = 0.002), and non-papillary growth type (p = 0.004). High ACSL1 showed an association with high grade (p < 0.001), high stage (p = 0.01), non-papillary growth type (p = 0.002), and metastasis (p = 0.033). High FATP4 was an independent factor predicting short overall survival (OS) (hazard ratio = 3.32; 95% confidence interval, 1.07-10.31; p = 0.038). In conclusion, upregulation of FATP4, CD36, and ACSL1 might promote the NMIBC progression and could be exploited in clinical risk stratification and targeted therapy. CI - Copyright (c) 2021 Jeong, Oh, Kim, Lee, Lee, Kim and Choi. FAU - Jeong, Hoiseon AU - Jeong H AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Oh, Hwa Eun AU - Oh HE AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Kim, Hyesun AU - Kim H AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Lee, Ju-Han AU - Lee JH AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Lee, Eung Seok AU - Lee ES AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Kim, Young-Sik AU - Kim YS AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. FAU - Choi, Jung-Woo AU - Choi JW AD - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea. LA - eng PT - Journal Article DEP - 20210330 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (CD36 Antigens) RN - 0 (CD36 protein, human) RN - 0 (Fatty Acid Transport Proteins) RN - 0 (SLC27A4 protein, human) RN - EC 6.2.1.- (Coenzyme A Ligases) RN - EC 6.2.1.3 (ACSL1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - CD36 Antigens/metabolism MH - Coenzyme A Ligases/metabolism MH - Fatty Acid Transport Proteins/*metabolism MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Up-Regulation MH - Urinary Bladder Neoplasms/*metabolism/pathology PMC - PMC8262182 OTO - NOTNLM OT - ACSL1 OT - CD36 OT - FATP4 OT - Fatty acid OT - bladder cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/15 06:00 MHDA- 2021/12/24 06:00 PMCR- 2021/03/30 CRDT- 2021/07/14 07:01 PHST- 2020/08/14 00:00 [received] PHST- 2021/02/12 00:00 [accepted] PHST- 2021/07/14 07:01 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/03/30 00:00 [pmc-release] AID - 594705 [pii] AID - 10.3389/pore.2021.594705 [doi] PST - epublish SO - Pathol Oncol Res. 2021 Mar 30;27:594705. doi: 10.3389/pore.2021.594705. eCollection 2021. PMID- 34252867 OWN - NLM STAT- MEDLINE DCOM- 20210825 LR - 20210825 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 142 DP - 2021 Sep TI - Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC? PG - 109829 LID - S0720-048X(21)00310-7 [pii] LID - 10.1016/j.ejrad.2021.109829 [doi] AB - PURPOSE: To investigate the diagnostic performance of the overall Vesical Imaging Reporting and Data System (VI-RADS) score and its individual magnetic resonance imaging (MRI) parameters in assessing grade and muscle invasiveness of bladder cancer (BC). METHODS: This IRB-approved retrospective, single-center, cross-sectional study included patients with BC wo underwent 3 Tesla preoperative multiparametric (mp)-MRI including T2-weighted (T2w), diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) sequences. An independent evaluation according to VI-RADS was performed by two radiologists in separate sessions, blinded to histological findings. RESULTS: The mean age of 59 included patients was 68.2 (+/-13.6 standard deviation) years. Among bladder cancer patients, 26 (51%) were identified as high grade and 14 (27.5%) as muscle invasive urothelial carcinomas in histological sections. The area under the curve (AUC) for the overall VI-RADS score to predict muscle invasion was 0.986 (R1) and 0.992 (R2). The AUC to diagnose high grade bladder cancer was 0.908 (R1) and 0.905 (R2). There was no significance difference between the AUC of single parameters (T2w, DWI and DCE) compared to the total VI-RADS score (P > 0.05, respectively). Upon multivariate logistic regression, only the T2w VI-RADS score contributed independently to the diagnosis of high grade and muscle invasive bladder cancer (P = 0.001 (R1) and P = 0.0022 (R2) for high grade cancer; P = 0.0007 (R1) and P = 0.0019 (R2) for muscle invasiveness). CONCLUSION: VI-RADS provides high diagnostic accuracy to diagnose high grade and muscle invasive BC. Our results suggest, that mp-MRI parameters provide overlapping information and for sake of clinical simplicity, a biparametric, contrast free image acquisition may be approached without sacrificing diagnostic accuracy. CI - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Gmeiner, Jasmin AU - Gmeiner J AD - Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Garstka, Nathalie AU - Garstka N AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Helbich, Thomas H AU - Helbich TH AD - Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Baltzer, Pascal A AU - Baltzer PA AD - Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. Electronic address: pascal.baltzer@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20210624 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Aged MH - Aged, 80 and over MH - Cross-Sectional Studies MH - Diffusion Magnetic Resonance Imaging MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - *Multiparametric Magnetic Resonance Imaging MH - *Prostatic Neoplasms MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging OTO - NOTNLM OT - Multiparametric magnetic resonance imaging OT - Urinary bladder neoplasms OT - Vesical imaging and reporting system EDAT- 2021/07/13 06:00 MHDA- 2021/08/26 06:00 CRDT- 2021/07/12 20:32 PHST- 2021/05/09 00:00 [received] PHST- 2021/06/16 00:00 [revised] PHST- 2021/06/18 00:00 [accepted] PHST- 2021/07/13 06:00 [pubmed] PHST- 2021/08/26 06:00 [medline] PHST- 2021/07/12 20:32 [entrez] AID - S0720-048X(21)00310-7 [pii] AID - 10.1016/j.ejrad.2021.109829 [doi] PST - ppublish SO - Eur J Radiol. 2021 Sep;142:109829. doi: 10.1016/j.ejrad.2021.109829. Epub 2021 Jun 24. PMID- 34244567 OWN - NLM STAT- MEDLINE DCOM- 20211108 LR - 20211108 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Jul 9 TI - Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment. PG - 14251 LID - 10.1038/s41598-021-93414-2 [doi] LID - 14251 AB - To detect muscle-invasive upper tract urothelial carcinoma, we evaluated the internal texture of the tumor using texture analysis of computed tomography images in 86 cases of upper tract urothelial carcinoma. The internal texture of the tumor was evaluated as the value of computed tomography attenuation number of the unenhanced image, and the median, standard deviation, skewness and kurtosis were calculated. Each parameter was compared with clinicopathological factors, and their associations with postoperative prognosis were investigated. Immunohistochemistry was performed to investigate the histological and molecular mechanisms of the inflammatory tumor microenvironment. The histogram of computed tomography attenuation number in non-muscle invasive tumor was single-peaked, whereas muscle invasive tumor showed a multi-peaked shape. In the parameters obtained by texture analysis, standard deviation was significantly associated with pathological stage (p < 0.0001), tumor grade (p = 0.0053), lymphovascular invasion (p = 0.0078) and concomitant carcinoma in situ (p = 0.0177) along with recurrence-free (p = 0.0191) and overall survival (p = 0.0184). The standard deviation value correlated with the amount of stromal components (p < 0.0001) and number of tumor-infiltrating macrophages (p < 0.0001). In addition, higher expression of high mobility group box 1 was found in heterogeneous tumor. Tumor heterogeneity evaluated by texture analysis was associated with muscle-invasive upper tract urothelial carcinoma and represented an inflammatory tumor microenvironment and useful as the clinical assessment to differentiate muscle invasive tumor. CI - (c) 2021. The Author(s). FAU - Goto, Keisuke AU - Goto K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. keigoto@hirodhima-u.ac.jp. FAU - Honda, Yukiko AU - Honda Y AD - Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Ikeda, Kenichiro AU - Ikeda K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Takemoto, Kenshiro AU - Takemoto K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Higaki, Toru AU - Higaki T AD - Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Hayashi, Tetsutaro AU - Hayashi T AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Kobatake, Kohei AU - Kobatake K AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Nakamura, Yuko AU - Nakamura Y AD - Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Sekino, Yohei AU - Sekino Y AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Inoue, Shogo AU - Inoue S AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. FAU - Awai, Kazuo AU - Awai K AD - Department of Diagnostic Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Yasui, Wataru AU - Yasui W AD - Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Teishima, Jun AU - Teishima J AD - Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210709 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/*diagnostic imaging MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prognosis MH - Retrospective Studies MH - Tomography, X-Ray Computed/*methods MH - Tumor Microenvironment/physiology MH - Urinary Bladder Neoplasms/*diagnostic imaging PMC - PMC8271017 COIS- The authors declare no competing interests. EDAT- 2021/07/11 06:00 MHDA- 2021/11/09 06:00 PMCR- 2021/07/09 CRDT- 2021/07/10 06:03 PHST- 2021/03/22 00:00 [received] PHST- 2021/06/22 00:00 [accepted] PHST- 2021/07/10 06:03 [entrez] PHST- 2021/07/11 06:00 [pubmed] PHST- 2021/11/09 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - 10.1038/s41598-021-93414-2 [pii] AID - 93414 [pii] AID - 10.1038/s41598-021-93414-2 [doi] PST - epublish SO - Sci Rep. 2021 Jul 9;11(1):14251. doi: 10.1038/s41598-021-93414-2. PMID- 34237155 OWN - NLM STAT- MEDLINE DCOM- 20220309 LR - 20220309 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 127 IP - 21 DP - 2021 Nov 1 TI - The impact of the social construct of race on outcomes among bacille Calmette-Guerin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting. PG - 3998-4005 LID - 10.1002/cncr.33792 [doi] AB - BACKGROUND: The objective of this study was to describe bladder cancer outcomes as a function of race among patients with high-risk non-muscle-invasive bladder cancer (NMIBC) in an equal-access setting. METHODS: A total of 412 patients with high-risk NMIBC who received bacille Calmette-Guerin (BCG) from January 1, 2010, to December 31, 2015, were assessed. The authors used the Kaplan-Meier method to estimate event-free survival and Cox regression to determine the association between race and recurrence, progression, disease-specific, and overall survival outcomes. RESULTS: A total of 372 patients who had complete data were included in the analysis; 48 (13%) and 324 (87%) were Black and White, respectively. There was no difference in age, sex, smoking status, or Charlson Comorbidity Index by race. White patients had a higher socioeconomic status with a greater percentage of patients living above the poverty level in comparison with Black patients (median, 85% vs 77%; P < .001). A total of 360 patients (97%) received adequate induction BCG, and 145 patients (39%) received adequate maintenance BCG therapy. There was no significant difference in rates of adequate induction or maintenance BCG therapy according to race. There was no significant difference in recurrence (hazard ratio [HR], 1.53; 95% confidence interval [CI], 0.64-3.63), progression (HR, 0.77; 95% CI, 0.33-1.82), bladder cancer-specific survival (HR, 1.01; 95% CI, 0.30-3.46), or overall survival (HR, 0.97; 95% CI, 0.56-1.66) according to Black race versus White race. CONCLUSIONS: In this small study from an equal-access setting, there was no difference in the receipt of BCG or any differences in bladder cancer outcomes according to race. CI - (c) 2021 American Cancer Society. FAU - Lawler, Corinne AU - Lawler C AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Gu, Lin AU - Gu L AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina. FAU - Howard, Lauren E AU - Howard LE AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina. FAU - Branche, Brandee AU - Branche B AD - Department of Urology, Virginia Commonwealth University School of Medicine, Richmond, Virginia. FAU - Wiggins, Emily AU - Wiggins E AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Srinivasan, Aditya AU - Srinivasan A AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Division of Urology, The University of Texas Medical Branch, Galveston, Texas. FAU - Foster, Meagan L AU - Foster ML AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Klaassen, Zachary AU - Klaassen Z AUID- ORCID: 0000-0001-7392-8916 AD - Section of Urology, Department of Surgery, Augusta University-Medical College of Georgia, Augusta, Georgia. FAU - De Hoedt, Amanda M AU - De Hoedt AM AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Gingrich, Jeffrey R AU - Gingrich JR AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Theodorescu, Dan AU - Theodorescu D AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Freedland, Stephen J AU - Freedland SJ AUID- ORCID: 0000-0002-8104-6419 AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California. AD - Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Williams, Stephen B AU - Williams SB AUID- ORCID: 0000-0002-2683-2185 AD - Department of Surgery, Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Division of Urology, The University of Texas Medical Branch, Galveston, Texas. LA - eng GR - W81XWH1710576/U.S. Department of Defense/ PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210708 PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Progression-Free Survival MH - Proportional Hazards Models MH - Urinary Bladder MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - bladder cancer OT - disparities OT - noninvasive OT - progression OT - race OT - recurrence OT - survival OT - treatment EDAT- 2021/07/09 06:00 MHDA- 2022/03/11 06:00 CRDT- 2021/07/08 17:48 PHST- 2021/05/24 00:00 [revised] PHST- 2021/04/05 00:00 [received] PHST- 2021/06/04 00:00 [accepted] PHST- 2021/07/09 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2021/07/08 17:48 [entrez] AID - 10.1002/cncr.33792 [doi] PST - ppublish SO - Cancer. 2021 Nov 1;127(21):3998-4005. doi: 10.1002/cncr.33792. Epub 2021 Jul 8. PMID- 34235972 OWN - NLM STAT- MEDLINE DCOM- 20211231 LR - 20211231 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 35 IP - 12 DP - 2021 Dec TI - Clinical Outcomes of Reresection in Patients with High-Risk Nonmuscle-Invasive Bladder Cancer Treated with En Bloc Transurethral Resection: A Retrospective Study with a 1-Year Follow-Up. PG - 1801-1807 LID - 10.1089/end.2021.0008 [doi] AB - Purpose: To evaluate the impact of reresection on the clinical outcome in patients with primary high-risk nonmuscle-invasive bladder cancer (NMIBC) who initially received en bloc transurethral resection. Methods: A retrospective analysis of data on eligible high-risk NMIBC with en bloc resection from June 2015 to June 2019 was performed. Patients were divided into two groups based on the presence or absence of reresection after the initial en bloc resection. In the first group (reresection group), patients underwent en bloc reresection within 6 weeks. In the second group (non-reresection group), patients did not undergo en bloc reresection. Pathologic findings in patients with reresection and cystoscopic findings in all patients 3 months after initial resection were recorded. The primary study endpoint was recurrence-free survival (RFS). The secondary outcomes were the residual rate of the tumor after initial en bloc resection, tumor upstaging rate, and progression-free survival. Results: We identified 115 eligible patients, including 51 (44.3%) who underwent reresection within 6 weeks of the initial en bloc resection and 64 (55.7%) who did not undergo en bloc reresection after the initial en bloc resection. The clinicopathologic features were similar in patients with or without reresection. On finding tumor residues after the first en bloc resection, there were three cases (5.9%) in the reresection group compared with two cases (3.1%) in the non-reresection group (p = 0.473). Two patients (3.9%) in the reresection group had tumor progression to muscle-invasive bladder cancer, whereas one patient (1.6%) in the non-reresection group exhibited tumor progression (p = 0.430). The 1-year RFS rate was 94.1% in the reresection group and 90.6% in the non-reresection group (p = 0.269). In multivariate analysis, multifocality and T1 staging were independent prognostic factors for recurrence in patients with high-risk NMIBC who underwent en bloc resection. Conclusion: In patients with high-risk NMIBC not exceeding 4 cm in diameter with no more than four lesions and not in the anterior bladder wall, reresection after en bloc resection seems to have failed to improve the patient's prognosis. We predict that the future trend in the treatment of patients with high-risk NMIBC is from reresection to en bloc resection. However, a randomized controlled clinical study is required to confirm this hypothesis. FAU - Xu, Sheng AU - Xu S AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Cao, Peng AU - Cao P AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Wang, Kuanyin AU - Wang K AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Wu, Tingming AU - Wu T AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Hu, Xinming AU - Hu X AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Chen, Hualei AU - Chen H AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Xu, Lei AU - Xu L AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Gu, Jun AU - Gu J AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Wu, Shuling AU - Wu S AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Zhu, Lingfeng AU - Zhu L AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Che, Xianping AU - Che X AUID- ORCID: 0000-0002-8601-6614 AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. LA - eng PT - Journal Article PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Cystectomy MH - Follow-Up Studies MH - Humans MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - clinical outcomes OT - high-risk OT - nonmuscle-invasive bladder cancer OT - reresection OT - transurethral en bloc resection of bladder tumor EDAT- 2021/07/09 06:00 MHDA- 2022/01/01 06:00 CRDT- 2021/07/08 08:39 PHST- 2021/07/09 06:00 [pubmed] PHST- 2022/01/01 06:00 [medline] PHST- 2021/07/08 08:39 [entrez] AID - 10.1089/end.2021.0008 [doi] PST - ppublish SO - J Endourol. 2021 Dec;35(12):1801-1807. doi: 10.1089/end.2021.0008. PMID- 34235072 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette-Guerin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 614041 LID - 10.3389/fonc.2021.614041 [doi] LID - 614041 AB - OBJECTIVE: To assess the effect of fibrin clot inhibitors (aspirin, clopidogrel, and warfarin) and statins on intravesical BCG therapy. METHOD: A systematic literature search was carried out through PubMed, Embase, and the Cochrane Central Search Library in March 2020. Accumulative analyses of odds ratios (ORs), hazard ratio (HR), and corresponding 95% confidence intervals (CIs) were performed. All analyses were performed by using Review Manager software version 5.3 and Stata 15.1. RESULTS: Four cohort studies and nine case-control studies containing 3,451 patients were included. The pooled analysis indicated that statins (HR = 1.00; 95%CI, 0.82 to 1.22; p = 1.00) and fibrin clot inhibitors (HR = 1.01; 95%CI, 0.64 to 1.59; p = 0.98) did not affect the efficacy of BCG on recurrence-free survival. The cumulative analysis showed that statins (HR = 0.79; 95%CI, 0.41 to 1.49; p = 0.46) and fibrin clot inhibitors (HR = 1.62; 95%CI, 0.90 to 2.91; p = 0.11) did not affect the efficacy of BCG on progression-free survival. There were no differences on cancer-specific survival (HR = 1.68; 95%CI, 0.64 to 4.40; p = 0.29) and overall survival (HR = 1.13; 95%CI, 0.73 to 1.78; p = 0.58) after taking statins. CONCLUSION: The present study shows that the application of fibrin clot inhibitors and statins do not influence the efficacy of BCG on oncological prognosis. Consequently, we do not need to stop using them or change to other drugs during intravesical BCG treatment. However, large-scale multi-center prospective research is still needed to confirm the above conclusions. CI - Copyright (c) 2021 Cai, Hu, Othmane, Li, Qiu, Yi, Chen and Zu. FAU - Cai, Zhiyong AU - Cai Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Hu, Jiao AU - Hu J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Othmane, Belaydi AU - Othmane B AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Li, Huihuang AU - Li H AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Qiu, Dongxu AU - Qiu D AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Yi, Zhenglin AU - Yi Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Chen, Jinbo AU - Chen J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Zu, Xiongbing AU - Zu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210621 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8256157 OTO - NOTNLM OT - Bacille Calmette-Guerin OT - bladder cancer OT - fibrin clot inhibitors OT - prognosis OT - statins COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/09 06:00 MHDA- 2021/07/09 06:01 PMCR- 2021/01/01 CRDT- 2021/07/08 06:43 PHST- 2020/10/05 00:00 [received] PHST- 2021/06/01 00:00 [accepted] PHST- 2021/07/08 06:43 [entrez] PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/07/09 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.614041 [doi] PST - epublish SO - Front Oncol. 2021 Jun 21;11:614041. doi: 10.3389/fonc.2021.614041. eCollection 2021. PMID- 34232958 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20240531 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 7 DP - 2021 TI - Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations. PG - e0253178 LID - 10.1371/journal.pone.0253178 [doi] LID - e0253178 AB - Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a staggering molecular complexity. Despite a plethora of diagnostic tools and therapies, it is hard to outline the key steps leading up to the transition from high-risk non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Carcinogen-induced murine models can recapitulate urothelial carcinogenesis and natural anti-tumor immunity. Herein, we have developed and profiled a novel model of progressive NMIBC based on 10 weeks of OH-BBN exposure in hepatocyte growth factor/cyclin dependent kinase 4 (R24C) (Hgf-Cdk4R24C) mice. The profiling of the model was performed by histology grading, single cell transcriptomic and proteomic analysis, while the derivation of a tumorigenic cell line was validated and used to assess in vivo anti-tumor effects in response to immunotherapy. Established NMIBC was present in females at 10 weeks post OH-BBN exposure while neoplasia was not as advanced in male mice, however all mice progressed to MIBC. Single cell RNA sequencing analysis revealed an intratumoral heterogeneity also described in the human disease trajectory. Moreover, although immune activation biomarkers were elevated in urine during carcinogen exposure, anti-programmed cell death protein 1 (anti-PD1) monotherapy did not prevent tumor progression. Furthermore, anti-PD1 immunotherapy did not control the growth of subcutaneous tumors formed by the newly derived urothelial cancer cell line. However, treatment with CpG-oligodeoxynucleotides (ODN) significantly decreased tumor volume, but only in females. In conclusion, the molecular map of this novel preclinical model of bladder cancer provides an opportunity to further investigate pharmacological therapies ahead with regards to both targeted drugs and immunotherapies to improve the strategies of how we should tackle the heterogeneous tumor microenvironment in urothelial bladder cancer to improve responses rates in the clinic. FAU - Kerzeli, Iliana K AU - Kerzeli IK AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Lord, Martin AU - Lord M AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Doroszko, Milena AU - Doroszko M AD - Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Elgendy, Ramy AU - Elgendy R AUID- ORCID: 0000-0002-2592-3448 AD - Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Chourlia, Aikaterini AU - Chourlia A AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Stepanek, Ivan AU - Stepanek I AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Larsson, Elinor AU - Larsson E AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - van Hooren, Luuk AU - van Hooren L AD - Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Nelander, Sven AU - Nelander S AD - Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Dragomir, Anca AU - Dragomir A AD - Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Mangsbo, Sara M AU - Mangsbo SM AUID- ORCID: 0000-0002-1355-2678 AD - Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210707 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Carcinogens) RN - 3817-11-6 (Butylhydroxybutylnitrosamine) SB - IM EIN - PLoS One. 2024 May 31;19(5):e0304890. doi: 10.1371/journal.pone.0304890. PMID: 38820327 MH - Animals MH - Butylhydroxybutylnitrosamine/pharmacology MH - Carcinogens/pharmacology MH - Cell Line, Tumor MH - Disease Models, Animal MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Polymerase Chain Reaction MH - Proteinuria/urine MH - Proteomics/methods MH - Sequence Analysis, RNA MH - Single-Cell Analysis MH - Urinary Bladder/drug effects/metabolism/pathology MH - Urinary Bladder Calculi/chemically induced/*metabolism/urine MH - Urothelium/drug effects/metabolism/pathology PMC - PMC8262791 COIS- SM is the founder and shareholder of Immuneed AB, Vivologica AB and Strike pharma AB and is the Chief Development Officer and shareholder of Ultimovacs ASA/AB. None of the mentioned companies have had any financial or working impact on the work presented herein. None of the other authors have any competing interests to declare. The above disclosure statement does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2021/07/08 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/07/07 CRDT- 2021/07/07 17:19 PHST- 2020/12/15 00:00 [received] PHST- 2021/05/28 00:00 [accepted] PHST- 2021/07/07 17:19 [entrez] PHST- 2021/07/08 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/07/07 00:00 [pmc-release] AID - PONE-D-20-39368 [pii] AID - 10.1371/journal.pone.0253178 [doi] PST - epublish SO - PLoS One. 2021 Jul 7;16(7):e0253178. doi: 10.1371/journal.pone.0253178. eCollection 2021. PMID- 34232194 OWN - NLM STAT- MEDLINE DCOM- 20210713 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 27 DP - 2021 Jul 9 TI - The prognostic value of preoperative serum albumin in patients with bladder urothelial carcinoma undergoing transurethral resection of bladder tumor: A prospective cohort study. PG - e26548 LID - 10.1097/MD.0000000000026548 [doi] LID - e26548 AB - BACKGROUND: To evaluate whether the preoperative serum albumin level can predict the survival outcome in patients with bladder urothelial carcinoma (BUC) undergoing transurethral resection of bladder tumor (TURBT). METHODS: Four hundred fifty six newly diagnosed patients with BUC who underwent TURBT between January 2014 and December 2017 were retrospectively enrolled. Patients were categorized into low albumin (<40 g/L) and high albumin (>/=40 g/L) groups. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional analyses were used to determine the hazard ratios (HRs) for overall survival (OS). Of patients with available data, 108 (24%) and 348 (76%) patients were classified into the low albumin (<40 g/L) and high albumin (>/=40 g/L) groups, respectively. RESULTS: The results of the Kaplan-Meier analysis and log-rank test showed a significantly worse 5-year OS (P = .003) in the low albumin group than in the high albumin group. In the multivariate Cox regression analysis, after adjusting for confounding variables, the preoperative albumin level remained an independent predictor for 5-year OS (HR: 0.434, 95% confidence interval: 0.221-0.852; P = .015). CONCLUSION: Our study determined that a low preoperative albumin level predicted poor OS in patients with BUC who underwent TURBT. Preoperative serum albumin is an inexpensive and easily available marker that has the potential to be a good prognostic factor for predicting mortality in patients with BUC treated with TURBT. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Shen, Chen AU - Shen C AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. AD - Department of Urology, the Second Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Zhou, Kechong AU - Zhou K AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Wang, Wei AU - Wang W AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. AD - Department of Urology, the Second Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Zhang, Yue AU - Zhang Y AD - Department of Urology, the Second Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Liu, Xiaoqiang AU - Liu X AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Biomarkers, Tumor) RN - 0 (Serum Albumin) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/blood MH - Carcinoma, Transitional Cell/*blood/diagnosis/surgery MH - *Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Serum Albumin/*metabolism MH - Urinary Bladder Neoplasms/*blood/diagnosis/surgery PMC - PMC8270602 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2021/07/08 06:00 MHDA- 2021/07/14 06:00 PMCR- 2021/07/09 CRDT- 2021/07/07 12:16 PHST- 2021/04/02 00:00 [received] PHST- 2021/05/25 00:00 [accepted] PHST- 2021/07/07 12:16 [entrez] PHST- 2021/07/08 06:00 [pubmed] PHST- 2021/07/14 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - 00005792-202107090-00032 [pii] AID - MD-D-21-01458 [pii] AID - 10.1097/MD.0000000000026548 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Jul 9;100(27):e26548. doi: 10.1097/MD.0000000000026548. PMID- 34215507 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220217 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 10 DP - 2021 Oct TI - The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer in a genome-wide association study. PG - 733.e17-733.e24 LID - S1078-1439(21)00254-4 [pii] LID - 10.1016/j.urolonc.2021.05.034 [doi] AB - OBJECTIVE: Bacillus Calmette-Guerin (BCG) instillation therapy is widely used to reduce intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). In this study, we aimed to reveal the genetic variations associated with intravesical recurrence after BCG therapy for NMIBC in a genome-wide association study (GWAS). MATERIALS AND METHODS: This study included Japanese patients with NMIBC, in whom genomic DNA was obtained from whole blood samples. The association between genetic variation and treatment failure was analyzed by GWAS in 44 patients treated with BCG instillation as a discovery cohort. Candidate single-nucleotide polymorphisms (SNPs) were examined separately in 47 patients treated with BCG instillation and in 62 patients treated with chemotherapeutic agent instillation as validation studies. RESULTS: Among the 44 patients in the discovery cohort, 14 cases experienced intravesical recurrent diseases. GWAS identified 12 candidate SNPs (rs9374832, rs35176001, rs363765, rs2127120, rs4277759, rs73664140, rs1607282, rs12141654, rs4541358, rs6986852, rs12373386, and rs17637903). In the validation study, a genetic risk stratification model using the number of risk alleles in rs363765 and rs6986852 discriminated the risk of intravesical recurrence after BCG therapy, but not after non-BCG therapy. CONCLUSION: This study suggested that several SNPs were associated with intravesical recurrence after BCG therapy for NMIBC. A genetic risk model may be useful to predict intravesical recurrence after BCG therapy, warranting further research and development for clinical application. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Nagakawa, Shohei AU - Nagakawa S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: shiota.masaki.101@m.kyushu-u.ac.jp. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Yamamoto, Yoshiaki AU - Yamamoto Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Blas, Leandro AU - Blas L AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tsukahara, Shigehiro AU - Tsukahara S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Matsumoto, Takashi AU - Matsumoto T AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Kashiwagi, Eiji AU - Kashiwagi E AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Uchiumi, Takeshi AU - Uchiumi T AD - Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210629 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/pharmacology/*therapeutic use MH - Female MH - Genome-Wide Association Study/*methods MH - Humans MH - Male MH - Middle Aged MH - Polymorphism, Single Nucleotide/*genetics MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Genome-wide association study OT - Immunotherapy OT - Intravesical recurrence OT - Non-muscle invasive bladder cancer OT - Single-nucleotide polymorphism COIS- Conflict of interest The authors declare no conflict of interest. EDAT- 2021/07/04 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/07/03 05:34 PHST- 2021/04/19 00:00 [received] PHST- 2021/05/25 00:00 [revised] PHST- 2021/05/27 00:00 [accepted] PHST- 2021/07/04 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/07/03 05:34 [entrez] AID - S1078-1439(21)00254-4 [pii] AID - 10.1016/j.urolonc.2021.05.034 [doi] PST - ppublish SO - Urol Oncol. 2021 Oct;39(10):733.e17-733.e24. doi: 10.1016/j.urolonc.2021.05.034. Epub 2021 Jun 29. PMID- 34211078 OWN - NLM STAT- MEDLINE DCOM- 20211108 LR - 20211108 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Jul 1 TI - Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. PG - 13684 LID - 10.1038/s41598-021-93245-1 [doi] LID - 13684 AB - Transurethral resection of bladder tumor (TUR-BT) and radical cystectomy (RC) are standard treatment options for bladder cancer (BC). Neoadjuvant chemotherapy (NAC) prior to RC improves outcome of some patients but currently there are no valid biomarkers to identify patients who benefit from NAC. Presence of cancer stem cells (CSC) has been associated with poor outcome and resistance to chemotherapy in various cancers. Here we studied the expression of stem cell markers ALDH1, SOX2 and SSEA-4 with immunohistochemistry in tissue microarray material consisting of 195 BC patients treated with RC and 74 patients treated with TUR-BT followed by NAC and RC. Post-operative follow-up data of up to 22 years was used. Negative to weak cytoplasmic SOX2 staining was associated with lymphovascular invasion and non-organ confined disease. It was also associated with shortened cancer-specific survival, but the finding was not statistically significant. Contrary to previous reports, none of the other tested biomarkers were associated with cancer-specific mortality or clinicopathological characteristics. Neither were they associated with response to NAC. Despite the promising results of previously published studies, our results suggest that CSC markers ALDH1, SOX2 and SSEA-4 have little if any prognostic or predictive value in BC treated with RC. FAU - Blomqvist, Matias AU - Blomqvist M AD - Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland. FAU - Koskinen, Ilmari AU - Koskinen I AD - Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Loyttyniemi, Eliisa AU - Loyttyniemi E AD - Department of Biostatistics, University of Turku, Turku, Finland. FAU - Mirtti, Tuomas AU - Mirtti T AD - Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology and FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland. FAU - Taimen, Pekka AU - Taimen P AD - Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland. pepeta@utu.fi. AD - Department of Pathology, Turku University Hospital, Turku, Finland. pepeta@utu.fi. LA - eng PT - Journal Article DEP - 20210701 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (SOX2 protein, human) RN - 0 (SOXB1 Transcription Factors) RN - 0 (Stage-Specific Embryonic Antigens) RN - 0 (stage-specific embryonic antigen-4) RN - EC 1.2.1 (Aldehyde Dehydrogenase 1 Family) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Aldehyde Dehydrogenase 1 Family/*analysis MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/diagnosis/pathology MH - Prognosis MH - SOXB1 Transcription Factors/*analysis MH - Stage-Specific Embryonic Antigens/*analysis MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery PMC - PMC8249395 COIS- The authors declare no competing interests. EDAT- 2021/07/03 06:00 MHDA- 2021/11/09 06:00 PMCR- 2021/07/01 CRDT- 2021/07/02 06:23 PHST- 2021/02/05 00:00 [received] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/07/02 06:23 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/11/09 06:00 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - 10.1038/s41598-021-93245-1 [pii] AID - 93245 [pii] AID - 10.1038/s41598-021-93245-1 [doi] PST - epublish SO - Sci Rep. 2021 Jul 1;11(1):13684. doi: 10.1038/s41598-021-93245-1. PMID- 34209360 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210727 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 11 IP - 7 DP - 2021 Jun 30 TI - High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/life11070642 [doi] LID - 642 AB - The role of the androgen receptor (AR) in non-muscle-invasive bladder cancer (NMIBC) remains controversial. We retrospectively analyzed the mRNA expression of AR using RT-qPCR in 95 patients with high-risk NMIBC treated with a bladder-sparing approach and correlated AR with clinical data and recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). The mRNA expression of AR and KRT5, i.e., the basal-like subtype, was strongly correlated (rs = 0.456; p < 0.001). AR (p = 0.053) and KRT5 (p = 0.029) mRNA expression was negatively correlated with tumor grade. Kaplan-Meier analyses indicated significantly prolonged CSS (p = 0.020) and OS (p = 0.015) and a trend towards longer RFS (p = 0.051) in patients with high AR expression. High KRT5 expression was associated with significantly longer RFS (p = 0.033), CSS (p = 0.029) and OS (p = 0.030), while high KRT20 expression was associated with reduced RFS (p = 0.042). In multivariable analysis, none of the molecular markers was an independent prognostic factor. When performing a substratification with regard to molecular markers and clinicopathological parameters, high AR expression showed improved OS in patients with high KRT20 mRNA expression (p = 0.041). Women showed significantly longer OS in cases with high AR expression (p = 0.011). High AR was associated with significantly improved CSS in males (p = 0.044) and patients with instillation therapy (p = 0.040), while OS was improved regardless of instillation therapy. Younger patients with high AR expression had significantly improved RFS (p = 0.021), CSS (p = 0.014) and OS (p = 0.007). RFS was also improved in patients with high AR and low expression of either KRT5 (p = 0.003) or KRT20 (p = 0.014), but not in patients with high expression of KRT5 or KRT20. In conclusion, high AR mRNA expression is correlated with KRT5 mRNA expression and is associated with an improved outcome in high-risk NMIBC. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AUID- ORCID: 0000-0002-9077-1727 AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, 541713 Cologne, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AUID- ORCID: 0000-0001-5919-7651 AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Kubon, Jennifer AU - Kubon J AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Erben, Philipp AU - Erben P AUID- ORCID: 0000-0002-8279-7636 AD - Department of Urology and Urosurgery, University Medical Centre Mannheim, 68167 Mannheim, Germany. AD - Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany. FAU - Burger, Maximilian AU - Burger M AD - Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. LA - eng GR - ELAN 18-08-18-1-Sikic/Friedrich-Alexander-Universitat Erlangen-Nurnberg/ PT - Journal Article DEP - 20210630 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC8306811 OTO - NOTNLM OT - KRT20 OT - KRT5 OT - NMIBC OT - PCR OT - androgen receptor OT - bladder cancer OT - mRNA COIS- The authors declare no conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/07/03 06:01 PMCR- 2021/06/30 CRDT- 2021/07/02 01:38 PHST- 2021/06/08 00:00 [received] PHST- 2021/06/24 00:00 [revised] PHST- 2021/06/28 00:00 [accepted] PHST- 2021/07/02 01:38 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/03 06:01 [medline] PHST- 2021/06/30 00:00 [pmc-release] AID - life11070642 [pii] AID - life-11-00642 [pii] AID - 10.3390/life11070642 [doi] PST - epublish SO - Life (Basel). 2021 Jun 30;11(7):642. doi: 10.3390/life11070642. PMID- 34199766 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20220716 IS - 1467-3045 (Electronic) IS - 1467-3037 (Print) IS - 1467-3037 (Linking) VI - 43 IP - 1 DP - 2021 Jun 4 TI - Differentially Expressed Extracellular Vesicle-Contained microRNAs before and after Transurethral Resection of Bladder Tumors. PG - 286-300 LID - 10.3390/cimb43010024 [doi] AB - Bladder cancer (BC) is currently diagnosed and monitored by cystoscopy, a costly and invasive procedure. Potential biomarkers in urine, blood, and, more recently, extracellular vesicles (EVs), have been explored as non-invasive alternatives for diagnosis and surveillance of BC. EVs are nanovesicles secreted by most cell types containing diverse molecular cargo, including different types of small RNAs, such as microRNA (miRNA). In this study, we performed next-generation sequencing of EV-contained miRNA isolated from urine and serum of 41 patients with non-muscle invasive BC (27 stage Ta, 14 stage T1) and 15 non-cancer patients (NCP) with benign cystoscopy findings. MiRNA sequencing was also performed on serum supernatant samples for T1 patients. To identify potential BC-specific biomarkers, expression levels of miRNA in presurgery samples were compared to those at postsurgery check-ups, and to NCPs. Results showed that two miRNAs, urinary EV-contained miR-451a and miR-486-5p, were significantly upregulated in presurgery samples from T1 patients compared to postsurgery check-up samples. This was confirmed in a replica EV/RNA isolation and sequencing run of 10 T1 patients from the primary run; however, analyses revealed no differential expression of miRNAs in serum EVs, serum supernatant, or when comparing BC patients to NCPs. This is the first study to investigate EV-containing miRNA sequencing in pre- and postsurgery BC patient samples and our findings suggest that urinary EV-contained miR-451a and miR-486-5p may be potential biomarkers for recurrence-free survival of BC patients with stage T1 disease. FAU - Stromme, Olaf AU - Stromme O AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. FAU - Heck, Kathleen A AU - Heck KA AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. FAU - Brede, Gaute AU - Brede G AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. FAU - Lindholm, Havard T AU - Lindholm HT AD - CEMIR-Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. FAU - Otterlei, Marit AU - Otterlei M AUID- ORCID: 0000-0002-5232-1186 AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. FAU - Arum, Carl-Jorgen AU - Arum CJ AD - Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway. AD - Department of Urology, St. Olav's University Hospital, 7030 Trondheim, Norway. LA - eng GR - 2017/22110/Liaison Committee between the central Norway Regional Health Authority (RHA) and the Norwegian University of Science and technology (NTNU) (SO)/ GR - 2019/38882/The Joint Research Committee between St. Olav's Hospital and the Faculty of Medicine and Health Sciences, NTNU (FFU)/ GR - 2016/43/16/Kreftfondet (Cancer Research Fund), St. Olav's Hospital/ GR - NA/Olav Raagholt og Gerd Meidel Raagholts stiftelse/ PT - Journal Article DEP - 20210604 PL - Switzerland TA - Curr Issues Mol Biol JT - Current issues in molecular biology JID - 100931761 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN451 microRNA, human) RN - 0 (MIRN486 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Aged, 80 and over MH - Apoptosis/genetics MH - Biomarkers, Tumor/blood/*genetics/urine MH - Cell Differentiation/genetics MH - Extracellular Vesicles/*genetics MH - Female MH - Gene Expression Profiling/*methods MH - *Gene Expression Regulation, Neoplastic MH - Gene Ontology MH - Humans MH - Male MH - MicroRNAs/blood/*genetics/urine MH - Middle Aged MH - Signal Transduction/genetics MH - Urinary Bladder Neoplasms/*genetics/surgery PMC - PMC8929081 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - exosome OT - extracellular vesicles OT - liquid biopsy OT - miRNA OT - non-muscle invasive bladder cancer OT - pre/postsurgery OT - transurethral resection of bladder tumor COIS- The authors claim no conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/06/04 CRDT- 2021/07/02 01:05 PHST- 2021/04/23 00:00 [received] PHST- 2021/05/26 00:00 [revised] PHST- 2021/06/02 00:00 [accepted] PHST- 2021/07/02 01:05 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/04 00:00 [pmc-release] AID - cimb43010024 [pii] AID - cimb-43-00024 [pii] AID - 10.3390/cimb43010024 [doi] PST - epublish SO - Curr Issues Mol Biol. 2021 Jun 4;43(1):286-300. doi: 10.3390/cimb43010024. PMID- 34196758 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 12 DP - 2021 Dec TI - Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. PG - 4363-4371 LID - 10.1007/s00345-021-03776-5 [doi] AB - PURPOSE: To evaluate the risk factors associated with positive surgical margins' (PSMs) location and their impact on disease-specific survival (DSS) in patients with bladder cancer (BCa) undergoing radical cystectomy (RC). METHODS: We analyzed a large multi-institutional cohort of patients treated with upfront RC for non-metastatic (cT1-4aN0M0) BCa. Multivariable binomial logistic regression analyses were used to assess the risk of PSMs at RC for each location after adjusting for clinicopathological covariates. The Kaplan-Meier method was used to estimate DSS stratified by margins' status and location. Log-rank statistics and Cox' regression models were used to determine significance. RESULTS: A total of 1058 patients were included and 108 (10.2%) patients had PSMs. PSMs were located at soft-tissue, ureter(s), and urethra in 57 (5.4%), 30 (2.8%) and 21 (2.0%) patients, respectively. At multivariable analysis, soft-tissue PSMs were independently associated with pathological stage T4 (pT4) (Odds ratio (OR) 6.20, p < 0.001) and lymph-node metastases (OR 1.86, p = 0.04). Concomitant carcinoma-in-situ (CIS) was an independent risk factor for ureteric PSMs (OR 6.31, p = 0.003). Finally, urethral PSMs were independently correlated with pT4-stage (OR 5.10, p = 0.01). The estimated 3-years DSS rates were 58.2%, 32.4%, 50.1%, and 40.3% for negative SMs, soft-tissue-, ureteric- and urethral PSMs, respectively (log-rank; p < 0.001). CONCLUSIONS: PSMs' location represents distinct risk factors' patterns. Concomitant CIS was associated with ureteric PSMs. Urethral and soft-tissue PSM showed worse DSS rates. Our results suggest that clinical decision-making paradigms on adjuvant treatment and surveillance might be adapted based on PSM and their location. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Claps, Francesco AU - Claps F AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. AD - Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy. FAU - van de Kamp, Maaike W AU - van de Kamp MW AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Surgical Oncology (Urology), Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. FAU - Boeve, Egbert R AU - Boeve ER AD - Department of Urology, St Franciscus Hospital, Rotterdam, The Netherlands. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. AD - Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, 75005, Paris, France. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Pouessel, Damien AU - Pouessel D AD - Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, 75005, Paris, France. AD - Department of Medical Oncology, Claudius Regaud Institute, Toulouse University Cancer Center (IUCT) Oncopole, 31000, Toulouse, France. FAU - Trombetta, Carlo AU - Trombetta C AD - Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Department of Pathology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. FAU - Allory, Yves AU - Allory Y AD - Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, 75005, Paris, France. AD - Department of Pathology, Institut Curie, 75005, Paris, France. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. FAU - Mir, M Carmen AU - Mir MC AD - Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.v.rhijn@nki.nl. AD - Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. b.v.rhijn@nki.nl. AD - Department of Surgical Oncology (Urology), Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada. b.v.rhijn@nki.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210701 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Cohort Studies MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - *Margins of Excision MH - Middle Aged MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - Bladder OT - Cancer OT - Cystectomy OT - Margin OT - Soft tissue OT - Ureter OT - Urethra OT - Urothelial carcinoma EDAT- 2021/07/02 06:00 MHDA- 2022/02/25 06:00 CRDT- 2021/07/01 12:22 PHST- 2021/05/05 00:00 [received] PHST- 2021/06/23 00:00 [accepted] PHST- 2021/07/02 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/07/01 12:22 [entrez] AID - 10.1007/s00345-021-03776-5 [pii] AID - 10.1007/s00345-021-03776-5 [doi] PST - ppublish SO - World J Urol. 2021 Dec;39(12):4363-4371. doi: 10.1007/s00345-021-03776-5. Epub 2021 Jul 1. PMID- 34190435 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 62 IP - 4 DP - 2021 Jul TI - Stratifying risk for multiple, recurrent, and large (>/=3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer. PG - 408-415 LID - 10.4111/icu.20210017 [doi] AB - PURPOSE: The current stratification of risk groups regarding recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) is problematic. We aimed to assess the long-term outcome and risk of multiple, recurrent, and large (>/=3 cm) Ta, G1/G2 tumors after transurethral resection of the bladder tumor (TURBT). MATERIALS AND METHODS: We categorized 1,621 patients with NMIBC who underwent TURBT into four risk groups according to the European Association of Urology (EAU) guidelines as follows: low-risk, intermediate-risk, high-risk, and study group. The overall, cancer-specific, disease recurrence-free, and disease progression-free survival rates were estimated by using the Kaplan-Meier method. Then, the impact of risk group was assessed by using a multivariable Cox regression model. RESULTS: The study group comprised 52 patients (3.2%) within a mean follow-up of 64.8 months. The disease recurred and progressed in 41 (78.8%) and 7 (13.5%) patients, respectively. Among the four groups, the study group showed the highest risk for 10-year recurrence after TURBT. The disease progression risk in the study group was between that of the intermediate- and high-risk groups. Cancer-specific and all-cause deaths occurred in one and four patients in the study group, respectively. The study group had a higher risk for disease recurrence than did the high-risk group; however, it did not have a higher risk for disease progression than in the high-risk group. CONCLUSIONS: Multiple, recurrent, and large (>/=3 cm) Ta, G1/G2 tumors carry a higher risk for disease recurrence, but not progression, than in the EAU high-risk group of NMIBC. CI - (c) The Korean Urological Association, 2021. FAU - Suh, Jungyo AU - Suh J AUID- ORCID: 0000-0002-3867-4778 AD - Department of Urology, Asan Medical Center, Seoul, Korea. FAU - Jung, Jae Hyun AU - Jung JH AUID- ORCID: 0000-0002-2844-8697 AD - Seoul Leaders Urology Clinic, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AUID- ORCID: 0000-0002-1987-2111 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AUID- ORCID: 0000-0001-6600-4539 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. randyku@hanmail.net. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Aged MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/drug therapy/*pathology/surgery MH - Chemotherapy, Adjuvant MH - *Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Myalgia/pathology MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - Neoplasms, Second Primary/*pathology MH - Progression-Free Survival MH - Proportional Hazards Models MH - Risk Assessment/methods MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/drug therapy/*pathology/surgery PMC - PMC8246012 OTO - NOTNLM OT - Outcome OT - Risk assessment OT - Urinary bladder neoplasms COIS- The authors have nothing to disclose. EDAT- 2021/07/01 06:00 MHDA- 2022/02/03 06:00 PMCR- 2021/07/01 CRDT- 2021/06/30 09:26 PHST- 2021/01/11 00:00 [received] PHST- 2021/03/10 00:00 [revised] PHST- 2021/03/21 00:00 [accepted] PHST- 2021/06/30 09:26 [entrez] PHST- 2021/07/01 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - 62.408 [pii] AID - 10.4111/icu.20210017 [doi] PST - ppublish SO - Investig Clin Urol. 2021 Jul;62(4):408-415. doi: 10.4111/icu.20210017. PMID- 34189951 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20211220 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 17 IP - 22 DP - 2021 Aug TI - High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. PG - 2893-2905 LID - 10.2217/fon-2021-0092 [doi] AB - Aims: To explore the prognostic value of high PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (TIIC) in urothelial carcinoma (UC). Patients & methods: 162 UC specimens were evaluated for PD-L1 expression on TIIC and TC with the SP263 assay. High PD-L1 expression was defined as >/=25% staining. Results: High PD-L1 expression on TC in UC patients with stage T1-4 disease was associated with poor overall survival. However, high PD-L1 expression on TIIC in UC patients with stage T1-4 disease revealed favorable disease-free and overall survival; more significant differences were observed in patients with stages T2-4. Multivariate analysis revealed that high PD-L1 expression on TIIC was an independent prognostic predictor for better disease-free and overall survival. Conclusion: High PD-L1 expression on TIIC, but not on TC, is a favorable prognostic factor in UC. FAU - Zhong, Qiaofeng AU - Zhong Q AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Shou, Jianzhong AU - Shou J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Ying, Jianming AU - Ying J AD - Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Ling, Yun AU - Ling Y AD - Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Yu, Yue AU - Yu Y AD - Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Shen, Zhirong AU - Shen Z AD - BeiGene (Beijing) Co., Ltd, Beijing, 102206, China. FAU - Zhang, Yun AU - Zhang Y AD - BeiGene (Beijing) Co., Ltd, Beijing, 102206, China. FAU - Li, Ning AU - Li N AD - BeiGene (Beijing) Co., Ltd, Beijing, 102206, China. FAU - Shi, Yuankai AU - Shi Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. FAU - Zhou, Aiping AU - Zhou A AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. LA - eng PT - Journal Article DEP - 20210630 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) SB - IM MH - Adult MH - Aged MH - B7-H1 Antigen/analysis/*metabolism MH - Biomarkers, Tumor/analysis/*metabolism MH - Biopsy MH - Carcinoma, Transitional Cell/diagnosis/immunology/*mortality/surgery MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocytes, Tumor-Infiltrating/immunology/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*epidemiology MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Risk Assessment/methods MH - Tumor Microenvironment/immunology MH - Urinary Bladder/immunology/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/immunology/*mortality/surgery OAB - Lay abstract Bladder cancer is the tenth most common form of cancer worldwide, and urothelial carcinoma is the most common type of bladder cancer. PD-L1 is a protein that can be expressed on the surface of many tissue types, including tumor cells (TC) and tumor-infiltrating immune cells (TIIC). PD-L1 can help the tumor evade the body's natural immune defense system. The expression of PD-L1 not only related to the response of immunotherapy but is also associated with the prognosis in bladder cancer. However, the prognostic significance of PD-L1 expression on TC and TIIC remains controversial. This study drew a conclusion that high PD-L1 expression on TIIC, but not on TC, is a favorable prognostic factor in urothelial carcinoma. OABL- eng OTO - NOTNLM OT - PD-L1 OT - prognosis OT - tumor cells OT - tumor-infiltrating immune cells OT - urothelial carcinoma EDAT- 2021/07/01 06:00 MHDA- 2021/12/21 06:00 CRDT- 2021/06/30 08:46 PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] PHST- 2021/06/30 08:46 [entrez] AID - 10.2217/fon-2021-0092 [doi] PST - ppublish SO - Future Oncol. 2021 Aug;17(22):2893-2905. doi: 10.2217/fon-2021-0092. Epub 2021 Jun 30. PMID- 34184926 OWN - NLM STAT- MEDLINE DCOM- 20211027 LR - 20250314 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 206 IP - 5 DP - 2021 Nov TI - Progression of Disease after Bacillus Calmette-Guerin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. PG - 1258-1267 LID - 10.1097/JU.0000000000001943 [doi] AB - PURPOSE: Data from the pre-neoadjuvant chemotherapy (NAC) era suggests patients who progress on bacillus Calmette-Guerin (BCG) to muscle-invasive bladder cancer (P-MIBC) exhibit worse outcomes compared to de novo MIBC (D-MIBC). Herein, we investigate whether P-MIBC is an independent poor risk factor in the setting of contemporary NAC use. MATERIALS AND METHODS: A review of patients who underwent radical cystectomy (RC) for cT2-3 MIBC from 2005 to 2018 was performed. Patients were stratified into high risk (lymphovascular invasion, variant histology, hydronephrosis, cT3b) vs low risk (no risk factors) and P-MIBC (/=cT2) vs D-MIBC. RESULTS: Among 801 patients who underwent RC 20.3% had P-MIBC and 79.7% had D-MIBC. In low-risk patients treated without NAC, P-MIBC was associated with pathological upstaging (64.9% vs 42.7%, p=0.004) and worse overall (OS, p=0.006) and cancer-specific survival (CSS, p=0.001) compared to D-MIBC. P-MIBC status conferred uniformly poor survival outcomes to patients who did not receive NAC compared to D-MIBC without NAC (median OS 51.5 months [95% CI 40.0-81.0] vs 85.1 months [95% CI 62.8-96.0], p=0.040; median CSS not reached, p=0.014). However, P-MIBC status did not remain a negative prognostic factor in the setting of NAC (median OS 90.5 months [95% CI 34.0-not estimable] vs 87.8 months [95% CI 68.7-not estimable], p=0.606; median CSS not reached, p=0.448). CONCLUSIONS: P-MIBC confers a poor prognosis when managed with RC alone. Treatment with NAC results in equivalent pathological response and survival outcomes compared to D-MIBC. P-MIBC should be included in risk-stratified approaches to NAC selection. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Campbell, Matthew T AU - Campbell MT AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Alhalabi, Omar AU - Alhalabi O AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Kokorovic, Andrea AU - Kokorovic A AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Miest, Tanner AU - Miest T AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Gao, Jianjun AU - Gao J AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, University of Texas MD Anderson Cancer Center,Houston, Texas. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Kamat, Ashish M AU - Kamat AM AUID- ORCID: 0000-0002-8098-901X AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210629 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2021 Nov;206(5):1266-1267. doi: 10.1097/JU.0000000000001943.01. PMID: 34372684 MH - Aged MH - BCG Vaccine/*administration & dosage MH - Chemotherapy, Adjuvant/methods/statistics & numerical data MH - *Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Neoplasm Staging MH - Patient Selection MH - Retrospective Studies MH - Risk Assessment/statistics & numerical data MH - Risk Factors MH - Urinary Bladder/drug effects/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/mortality/pathology/*therapy PMC - PMC11902300 MID - NIHMS2059846 OTO - NOTNLM OT - cystectomy OT - mycobacterium bovis OT - neoadjuvant therapy OT - urinary bladder neoplasms EDAT- 2021/06/30 06:00 MHDA- 2021/10/28 06:00 PMCR- 2025/03/12 CRDT- 2021/06/29 12:11 PHST- 2021/06/30 06:00 [pubmed] PHST- 2021/10/28 06:00 [medline] PHST- 2021/06/29 12:11 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - 10.1097/JU.0000000000001943 [doi] PST - ppublish SO - J Urol. 2021 Nov;206(5):1258-1267. doi: 10.1097/JU.0000000000001943. Epub 2021 Jun 29. PMID- 34184816 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220217 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 25 IP - 16 DP - 2021 Aug TI - Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer. PG - 7890-7900 LID - 10.1111/jcmm.16712 [doi] AB - Cytokeratin 5 is a marker of basal molecular subtypes of muscle-invasive bladder cancer (MIBC), which correlates with worse overall survival compared to luminal subtypes. Our observations have not confirmed CK5 as a marker of high-grade (HG) disease in Ta non-muscle-invasive bladder cancer (NMIBC). Therefore, to understand the basal-luminal immunohistochemistry profile in Ta NMIBC, we performed immunohistochemistry for CK5, P40, P63 (basal), GATA3 and CK20 (luminal) and studied the correlation with HG and clinical outcome in 109 patients with Ta NMIBC. HG and low-grade (LG) diseases were scored in each patient. Four different CK5 patterns were evaluated: absent (median 41.3%), normal (72.5%), rising (84.4%) and full thickness (23.9%). The median percentage of GATA3 was 100%. HG disease and CK5 expression and rising CK5 pattern had a significant inverse correlation, whereas HG disease and CK20 expression had a significant positive correlation. We also found a significant inverse correlation between CK5 expression and CK20 expression. Quantitative PCR confirmed that the presence of CK5 correlated with up-regulation of CK5 RNA. None of the markers could differentiate patients with regard to clinical outcome. Our results suggest a role for CK5 and CK20 in differentiating between LG and HG disease in Ta NMIBC. CI - (c) 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Muilwijk, Tim AU - Muilwijk T AUID- ORCID: 0000-0002-6965-389X AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Akand, Murat AU - Akand M AUID- ORCID: 0000-0001-8840-5771 AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Organ Systems, KU Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AUID- ORCID: 0000-0002-4617-3666 AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - De Coninck, Vincent AU - De Coninck V AUID- ORCID: 0000-0002-4983-5055 AD - Department of Urology, AZ Klina, Brasschaat, Belgium. FAU - Claessens, Marc AU - Claessens M AD - Department of Urology, AZ Klina, Brasschaat, Belgium. FAU - Hente, Robert AU - Hente R AD - Department of Urology, AZ Klina, Brasschaat, Belgium. FAU - Eckstein, Markus AU - Eckstein M AUID- ORCID: 0000-0001-5418-3349 AD - Department of Pathology, University Hospital Erlangen, Erlangen, Germany. FAU - Allory, Yves AU - Allory Y AUID- ORCID: 0000-0002-4406-3316 AD - Department of Pathology, Curie Institute, Paris, France. FAU - Libbrecht, Louis AU - Libbrecht L AUID- ORCID: 0000-0002-9453-3355 AD - Department of Pathology, AZ Groeninge, Kortrijk, Belgium. AD - Department of Pathology, University Hospital Saint-Luc, Brussels, Belgium. FAU - Joniau, Steven AU - Joniau S AUID- ORCID: 0000-0003-3195-9890 AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Gevaert, Thomas AU - Gevaert T AUID- ORCID: 0000-0001-6880-7183 AD - Organ Systems, KU Leuven, Leuven, Belgium. AD - Department of Pathology, AZ Klina, Brasschaat, Belgium. LA - eng PT - Journal Article DEP - 20210629 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Biomarkers, Tumor) RN - 0 (KRT20 protein, human) RN - 0 (KRT5 protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Keratin-20/metabolism MH - Keratin-5/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/metabolism/*pathology PMC - PMC8358875 OTO - NOTNLM OT - CK20 OT - CK5 OT - GATA3 OT - basal OT - immunohistochemistry OT - luminal OT - non-muscle-invasive bladder cancer COIS- The authors declare that they have no conflicts of interest related to this manuscript. EDAT- 2021/06/30 06:00 MHDA- 2022/02/19 06:00 PMCR- 2021/08/01 CRDT- 2021/06/29 09:29 PHST- 2021/04/24 00:00 [revised] PHST- 2021/02/15 00:00 [received] PHST- 2021/05/13 00:00 [accepted] PHST- 2021/06/30 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/06/29 09:29 [entrez] PHST- 2021/08/01 00:00 [pmc-release] AID - JCMM16712 [pii] AID - 10.1111/jcmm.16712 [doi] PST - ppublish SO - J Cell Mol Med. 2021 Aug;25(16):7890-7900. doi: 10.1111/jcmm.16712. Epub 2021 Jun 29. PMID- 34184796 OWN - NLM STAT- MEDLINE DCOM- 20220110 LR - 20240403 IS - 1098-2825 (Electronic) IS - 0887-8013 (Print) IS - 0887-8013 (Linking) VI - 35 IP - 8 DP - 2021 Aug TI - The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence. PG - e23883 LID - 10.1002/jcla.23883 [doi] LID - e23883 AB - PURPOSE: The purpose of this study was to explore the predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes (NHL) in patients with non-muscular invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively collected clinical and pathological data of patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) at our hospital between 2013 and 2018. The ratio of neutrophils to lymphocytes (NLR), the Systemic Immune Inflammation Index (SII), and NHL were obtained based on routine blood settlement within a week before surgery. The receiver operating characteristic curve was used to determine the optimal cutoff value of each index, and different groups were grouped accordingly. Kaplan-Meier survival curve and Cox regression model were used to study the factors affecting the prognosis of NMIBC patients. RESULTS: There was significant difference in recurrence-free survival (RFS) rate between the high NLR group and the low NLR group, the high SII group and the low SII group, and the high NHL group and the low NHL group. Cox univariate regression analysis showed that tumor number, tumor size, tumor pathological grade, tumor pathological stage, NLR, SII, and NHL were related to postoperative RFS in patients with NMIBC. The tumor number, tumor pathological grade, SII, and NHL were independent predictors of RFS in multivariate analysis. CONCLUSIONS: The preoperative clinical inflammatory indexes NLR, SII, and NHL have certain predictive value for postoperative RFS in NMIBC patients. CI - (c) 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. FAU - Zhao, Ruining AU - Zhao R AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Shan, Jiahao AU - Shan J AD - Ningxia Medical University, Yinchuan, China. FAU - Nie, Lihong AU - Nie L AD - Department of Physiology, Ningxia Medical University, Yinchuan, China. FAU - Yang, Xiaobo AU - Yang X AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, China. FAU - Yuan, Zhongyu AU - Yuan Z AD - Ningxia Medical University, Yinchuan, China. FAU - Xu, Haoran AU - Xu H AD - Ningxia Medical University, Yinchuan, China. FAU - Liu, Ziyang AU - Liu Z AD - Ningxia Medical University, Yinchuan, China. FAU - Zhou, Xiaojie AU - Zhou X AD - Ningxia Medical University, Yinchuan, China. FAU - Ma, Wenzhuo AU - Ma W AD - Ningxia Medical University, Yinchuan, China. FAU - Shi, Hongbin AU - Shi H AUID- ORCID: 0000-0001-7082-7327 AD - Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, China. LA - eng GR - 2020BFH03001/Ningxia Hui Autonomous Region Focus on Research and Development projects/ GR - NZ17166/Natural Science Foundation of Ningxia/ GR - NZ17164/Natural Science Foundation of Ningxia/ GR - 2020AAC03155/Natural Science Foundation of Ningxia/ GR - 81460148/National Natural Science Foundation of China/ GR - 31560288/National Natural Science Foundation of China/ PT - Journal Article DEP - 20210629 PL - United States TA - J Clin Lab Anal JT - Journal of clinical laboratory analysis JID - 8801384 RN - 0 (Hemoglobins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Hemoglobins/*analysis MH - Humans MH - Kaplan-Meier Estimate MH - *Leukocyte Count MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - *Neutrophils MH - Preoperative Period MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*blood/mortality/*pathology/surgery PMC - PMC8373351 OTO - NOTNLM OT - neutrophil-lymphocyte ratio OT - non-muscular invasive bladder cancer OT - recurrence OT - systemic immune inflammation index COIS- None. EDAT- 2021/06/30 06:00 MHDA- 2022/01/11 06:00 PMCR- 2021/06/29 CRDT- 2021/06/29 09:27 PHST- 2021/05/20 00:00 [revised] PHST- 2021/05/04 00:00 [received] PHST- 2021/06/11 00:00 [accepted] PHST- 2021/06/30 06:00 [pubmed] PHST- 2022/01/11 06:00 [medline] PHST- 2021/06/29 09:27 [entrez] PHST- 2021/06/29 00:00 [pmc-release] AID - JCLA23883 [pii] AID - 10.1002/jcla.23883 [doi] PST - ppublish SO - J Clin Lab Anal. 2021 Aug;35(8):e23883. doi: 10.1002/jcla.23883. Epub 2021 Jun 29. PMID- 34184561 OWN - NLM STAT- MEDLINE DCOM- 20220201 LR - 20220201 IS - 1750-7448 (Electronic) IS - 1750-743X (Linking) VI - 13 IP - 11 DP - 2021 Aug TI - Urothelial carcinoma in the era of immune checkpoint inhibitors. PG - 953-964 LID - 10.2217/imt-2021-0042 [doi] AB - Bladder cancer is the seventh most frequent cancer worldwide. The majority of patients present with nonmuscle invasive disease, while 20% of the patients are diagnosed with muscle-invasive bladder cancer. The treatment of nonmuscle invasive disease is endoscopic resection followed by intravesical adjuvant treatment for high risk patients. The standard treatment of localized muscle-invasive disease is neoadjuvant chemotherapy followed by radical cystectomy. Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma as second-line treatment or first-line in platinum-ineligible patients. Recently, pembrolizumab have been approved in bacillus Calmette-Guerin (BCG)-refractory nonmuscle invasive bladder cancer. This review summarizes the current evidence concerning immunotherapy in the treatment of urothelial carcinoma. FAU - Khalife, Nadine AU - Khalife N AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France. FAU - Chahine, Claude AU - Chahine C AD - International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France. FAU - Kordahi, Manal AU - Kordahi M AD - National Institute of Pathology, Baabda, 1003, Lebanon. FAU - Felefly, Tony AU - Felefly T AD - Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon. FAU - Kourie, Hampig Raphael AU - Kourie HR AD - Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 1100, Lebanon. FAU - Saleh, Khalil AU - Saleh K AUID- ORCID: 0000-0002-2985-2202 AD - Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France. LA - eng PT - Journal Article PT - Review DEP - 20210629 PL - England TA - Immunotherapy JT - Immunotherapy JID - 101485158 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Carcinoma, Transitional Cell/*drug therapy MH - Humans MH - Immune Checkpoint Inhibitors/*therapeutic use MH - Immunotherapy/*methods MH - Urinary Bladder Neoplasms/*drug therapy OAB - Lay abstract Bladder cancer is one of the most frequent cancers worldwide with multiple known risk factors such as cigarette smoking and occupational exposures. The majority of patients present with a superficial disease treated with endoscopic resection and intravesical treatment if needed. The localized form of bladder cancer is treated with chemotherapy followed by radical cystectomy. Metastatic bladder cancer is an incurable disease and historic treatment remains on chemotherapy. Recently, immunotherapy has been approved for the treatment of bladder cancer after progression on chemotherapy. In this article we reviewed the most recent available data concerning immunotherapy for the treatment of early-stage and advanced disease. OABL- eng OTO - NOTNLM OT - atezolizumab OT - avelumab OT - durvalumab OT - immune checkpoint inhibitors OT - metastatic urothelial carcinoma OT - muscle-invasive bladder cancer OT - nivolumab OT - nonmuscle invasive bladder cancer OT - pembrolizumab EDAT- 2021/06/30 06:00 MHDA- 2022/02/02 06:00 CRDT- 2021/06/29 08:46 PHST- 2021/06/30 06:00 [pubmed] PHST- 2022/02/02 06:00 [medline] PHST- 2021/06/29 08:46 [entrez] AID - 10.2217/imt-2021-0042 [doi] PST - ppublish SO - Immunotherapy. 2021 Aug;13(11):953-964. doi: 10.2217/imt-2021-0042. Epub 2021 Jun 29. PMID- 34183505 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20221013 IS - 1533-4058 (Electronic) IS - 1533-4058 (Linking) VI - 30 IP - 1 DP - 2022 Jan 1 TI - PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage. PG - 56-61 LID - 10.1097/PAI.0000000000000957 [doi] AB - BACKGROUND: Upper tract urothelial carcinomas (UTUCs) are a rare and unique subset of urothelial carcinoma (UC). Patients with UTUC may qualify for treatment with immune checkpoint inhibitors if their tumor cells express programmed death ligand-1 (PD-L1). While several large studies have looked at PD-L1 expression in UC, most have not investigated UTUC as a separate group, and most have not used Food and Drug Administration approved PD-L1 stains and scoring systems. Moreover, comparison between studies of PD-L1 expression is challenging as a wide variety of different PD-L1 antibody clones, testing platforms, and cutoff values have been used in the literature. METHODS: This is a retrospective study of 37 cases of resected UTUC. Representative tissue from each case was compiled into tissue microarrays and immunohistochemical stains for PD-L1 (Dako antibody clones 22C3 and 28-8) were performed. PD-L1 staining was evaluated using several established Food and Drug Administration approved scoring systems: tumor proportion score (TPS), combined positive score, and immune cell score. Associations between PD-L1 expression and clinicopathologic features were investigated. RESULTS: Overall expression of PD-L1 in UTUC was 29.7% when using a TPS cutoff of >/=1%. Total of, 55.6% of cases with higher pathologic stage (pT3 or pT4) were positive for PD-L1, compared with only 5.3% of cases with lower pathologic stage (pTis, pT1, or pT2; P=0.0011). When using a combined positive score cutoff of >/=10, there was no significant association between tumor stage and PD-L1 expression. There was no association between PD-L1 positivity and tumor grade, tumor location, sex, or age. There was 100% concordance between 22C3 and 28-8 in terms of positivity rate. CONCLUSIONS: Our study using approved testing methods shows that PD-L1 expression in UTUC is more often associated with high pathologic stage, which may reflect an immune response evasion mechanism that UC cells acquire later in disease progression. In addition we show that 29.7% of UTUCs are positive for PD-L1 TPS expression, comparable to the 20% to 30% reported in UC literature. Finally, PD-L1 22C3 and 28-8 clones show similar overall patterns of staining in this setting. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Ward, Michael AU - Ward M AD - Department of Pathology, University of Utah. AD - ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. FAU - Albertson, Daniel AU - Albertson D AD - Department of Pathology, University of Utah. AD - ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. FAU - Furtado, Larissa V AU - Furtado LV AD - Department of Pathology, University of Utah. AD - ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. AD - Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN. FAU - Deftereos, Georgios AU - Deftereos G AD - Department of Pathology, University of Utah. AD - ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Appl Immunohistochem Mol Morphol JT - Applied immunohistochemistry & molecular morphology : AIMM JID - 100888796 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) SB - IM MH - B7-H1 Antigen/metabolism MH - Biomarkers, Tumor/metabolism MH - *Carcinoma, Transitional Cell/metabolism/pathology MH - Humans MH - Neoplasm Staging MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/metabolism/pathology COIS- The authors declare no conflict of interest. EDAT- 2021/06/30 06:00 MHDA- 2022/03/17 06:00 CRDT- 2021/06/29 05:55 PHST- 2020/09/08 00:00 [received] PHST- 2021/05/23 00:00 [accepted] PHST- 2021/06/30 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/06/29 05:55 [entrez] AID - 00129039-202201000-00009 [pii] AID - 10.1097/PAI.0000000000000957 [doi] PST - ppublish SO - Appl Immunohistochem Mol Morphol. 2022 Jan 1;30(1):56-61. doi: 10.1097/PAI.0000000000000957. PMID- 34182482 OWN - NLM STAT- MEDLINE DCOM- 20210630 LR - 20210803 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 35 IP - 4 DP - 2021 Jul-Aug TI - Detection of Novel Urine Markers Using Immune Complexome Analysis in Bladder Cancer Patients: A Preliminary Study. PG - 2073-2080 LID - 10.21873/invivo.12476 [doi] AB - BACKGROUND/AIM: Little is known on urine biomarkers that are associated with malignant behavior in patients with bladder cancer (BC). Our aim was to identify BC-related factors in urine samples using our original method "immune complexome analysis", based on detecting the immune complex (IC). PATIENTS AND METHODS: Immune complexome analysis was performed using urine samples from 97 BC patients, including 67 with non-muscle invasive BC (NMIBC). RESULTS: Eight IC-antigens were recognized as candidates for BC-related factors from 20,165 proteins. IC-serum albumin, -fibrinogen gamma chain, -hemoglobin subunit alpha, -hemoglobin subunit beta, -ceruloplasmin, and fibrinogen beta chain were significantly associated with either pathological features and/or outcome. IC-ceruloplasmin was most widely associated with pathological features in all BC patients and lamina propria invasion and urinary tract recurrence in NMIBC. CONCLUSION: Based on detection of IC-antigens it was demonstrated that six IC-antigens, especially IC-ceruloplasmin, are potential urine biomarkers in BC. CI - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Aibara, Nozomi AU - Aibara N AD - Department of Pharmacy Practice, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Miyata, Yasuyoshi AU - Miyata Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan yasu-myt@nagasaki-u.ac.jp. FAU - Araki, Kyohei AU - Araki K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Sagara, Yuji AU - Sagara Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Mitsunari, Kensuke AU - Mitsunari K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Ohba, Kojiro AU - Ohba K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Mochizuki, Yasushi AU - Mochizuki Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Sakai, Hideki AU - Sakai H AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. FAU - Ohyama, Kaname AU - Ohyama K AD - Department of Pharmacy Practice, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - Humans MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/diagnosis PMC - PMC8286497 OTO - NOTNLM OT - Immune complexome analysis OT - bladder cancer OT - invasion OT - recurrence OT - urine marker COIS- The Authors have no conflicts of interest regarding this study. EDAT- 2021/06/29 06:00 MHDA- 2021/07/01 06:00 PMCR- 2021/07/03 CRDT- 2021/06/28 20:31 PHST- 2021/03/13 00:00 [received] PHST- 2021/03/26 00:00 [revised] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/06/28 20:31 [entrez] PHST- 2021/06/29 06:00 [pubmed] PHST- 2021/07/01 06:00 [medline] PHST- 2021/07/03 00:00 [pmc-release] AID - 35/4/2073 [pii] AID - 10.21873/invivo.12476 [doi] PST - ppublish SO - In Vivo. 2021 Jul-Aug;35(4):2073-2080. doi: 10.21873/invivo.12476. PMID- 34178700 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer. PG - 701298 LID - 10.3389/fonc.2021.701298 [doi] LID - 701298 AB - Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment strategies need to be based on an accurate risk stratification, in which muscle invasiveness and tumor grade represent the two most important factors. Traditional imaging techniques provide preliminary information about muscle invasiveness but are lacking in terms of accuracy. Although as the gold standard, pathological biopsy is only available after the surgery and cannot be performed longitudinally for long-term surveillance. In this work, we developed a microfluidic approach that interrogates circulating tumor cells (CTCs) in the peripheral blood of bladder cancer patients to reflect the risk stratification of the disease. In a cohort of 48 bladder cancer patients comprising 33 non-muscle invasive bladder cancer (NMIBC) cases and 15 muscle invasive bladder cancer (MIBC) cases, the CTC count was found to be considerably higher in the MIBC group compared with the NMIBC group (4.67 vs. 1.88 CTCs/3 mL, P=0.019), and was significantly higher in high-grade bladder cancer patients verses low-grade bladder cancer patients (3.69 vs. 1.18 CTCs/3mL, P=0.024). This microfluidic assay of CTCs is believed to be a promising complementary tool for the risk stratification of bladder cancer. CI - Copyright (c) 2021 Fu, Cheng, Chen, Xu, Chen, Tian, Xu, Sun, Neoh, Dai, Han and Jin. FAU - Fu, Guanghou AU - Fu G AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Cheng, Kok Suen AU - Cheng KS AD - Jiangzhong Cancer Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, China. AD - Department of Material Science and Engineering, College of Engineering, Peking University, Beijing, China. FAU - Chen, Anqi AU - Chen A AD - Department of Material Science and Engineering, College of Engineering, Peking University, Beijing, China. FAU - Xu, Zhijie AU - Xu Z AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Chen, Xiaoyi AU - Chen X AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Tian, Junjie AU - Tian J AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Xu, Congcong AU - Xu C AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Sun, Yukun AU - Sun Y AD - Department of Material Science and Engineering, College of Engineering, Peking University, Beijing, China. FAU - Neoh, Kuang Hong AU - Neoh KH AD - Department of Material Science and Engineering, College of Engineering, Peking University, Beijing, China. FAU - Dai, Yun AU - Dai Y AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Han, Ray P S AU - Han RPS AD - Jiangzhong Cancer Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, China. FAU - Jin, Baiye AU - Jin B AD - Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. LA - eng PT - Journal Article DEP - 20210610 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8222714 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - circulating tumor cells OT - microfluidics OT - risk stratification COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/29 06:00 MHDA- 2021/06/29 06:01 PMCR- 2021/01/01 CRDT- 2021/06/28 06:04 PHST- 2021/04/27 00:00 [received] PHST- 2021/05/20 00:00 [accepted] PHST- 2021/06/28 06:04 [entrez] PHST- 2021/06/29 06:00 [pubmed] PHST- 2021/06/29 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.701298 [doi] PST - epublish SO - Front Oncol. 2021 Jun 10;11:701298. doi: 10.3389/fonc.2021.701298. eCollection 2021. PMID- 34178641 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Deep Learning on Enhanced CT Images Can Predict the Muscular Invasiveness of Bladder Cancer. PG - 654685 LID - 10.3389/fonc.2021.654685 [doi] LID - 654685 AB - BACKGROUND: Clinical treatment decision making of bladder cancer (BCa) relies on the absence or presence of muscle invasion and tumor staging. Deep learning (DL) is a novel technique in image analysis, but its potential for evaluating the muscular invasiveness of bladder cancer remains unclear. The purpose of this study was to develop and validate a DL model based on computed tomography (CT) images for prediction of muscle-invasive status of BCa. METHODS: A total of 441 BCa patients were retrospectively enrolled from two centers and were divided into development (n=183), tuning (n=110), internal validation (n=73) and external validation (n=75) cohorts. The model was built based on nephrographic phase images of preoperative CT urography. Receiver operating characteristic (ROC) curves were performed and the area under the ROC curve (AUC) for discrimination between muscle-invasive BCa and non-muscle-invasive BCa was calculated. The performance of the model was evaluated and compared with that of the subjective assessment by two radiologists. RESULTS: The DL model exhibited relatively good performance in all cohorts [AUC: 0.861 in the internal validation cohort, 0.791 in the external validation cohort] and outperformed the two radiologists. The model yielded a sensitivity of 0.733, a specificity of 0.810 in the internal validation cohort and a sensitivity of 0.710 and a specificity of 0.773 in the external validation cohort. CONCLUSION: The proposed DL model based on CT images exhibited relatively good prediction ability of muscle-invasive status of BCa preoperatively, which may improve individual treatment of BCa. CI - Copyright (c) 2021 Zhang, Wu, Xu, Zhang, Zhang, Mao, Li, Xiao, Guo, Ji, Sun and Jin. FAU - Zhang, Gumuyang AU - Zhang G AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Wu, Zhe AU - Wu Z AD - Department of Radiology, Fushun Central Hospital of Liaoning Province, Fushun, China. FAU - Xu, Lili AU - Xu L AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Xiaoxiao AU - Zhang X AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Daming AU - Zhang D AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Mao, Li AU - Mao L AD - Deepwise Artificial Intelligence (AI) Lab, Deepwise Inc., Beijing, China. FAU - Li, Xiuli AU - Li X AD - Deepwise Artificial Intelligence (AI) Lab, Deepwise Inc., Beijing, China. FAU - Xiao, Yu AU - Xiao Y AD - Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Guo, Jun AU - Guo J AD - Department of Radiology, Fushun Central Hospital of Liaoning Province, Fushun, China. FAU - Ji, Zhigang AU - Ji Z AD - Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Sun, Hao AU - Sun H AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Jin, Zhengyu AU - Jin Z AD - Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article DEP - 20210611 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8226179 OTO - NOTNLM OT - artificial intelligence OT - bladder cancer OT - computed tomography OT - computed-assisted OT - deep learning OT - diagnosis COIS- LM and XL are employees of Deepwise AI Lab, Deepwise Inc., which contributed to the development of radiomics models described in the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/29 06:00 MHDA- 2021/06/29 06:01 PMCR- 2021/01/01 CRDT- 2021/06/28 06:04 PHST- 2021/01/17 00:00 [received] PHST- 2021/05/27 00:00 [accepted] PHST- 2021/06/28 06:04 [entrez] PHST- 2021/06/29 06:00 [pubmed] PHST- 2021/06/29 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.654685 [doi] PST - epublish SO - Front Oncol. 2021 Jun 11;11:654685. doi: 10.3389/fonc.2021.654685. eCollection 2021. PMID- 34172421 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20221214 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 5 DP - 2022 Sep TI - Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer. PG - 1226-1237 LID - S2405-4569(21)00169-3 [pii] LID - 10.1016/j.euf.2021.06.007 [doi] AB - BACKGROUND: Delay in treatment is a prognostic factor in muscle-invasive bladder cancer. OBJECTIVE: To evaluate clinical outcomes associated with delays in diagnosis and treatment for patients with non-muscle invasive bladder cancer (NMIBC). DESIGN, SETTING, AND PARTICIPANTS: In this retrospective study we analyzed data for patients treated at our center between November 2008 and December 2016 for intermediate risk (IR) or high risk (HR) NMIBC with an additional intravesical treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time delays from diagnosis to first transurethral resection (TT-TUR), from resection to restaging resection (TT-reTUR), and from the last resection to first instillation (TT-INST) of bacillus Calmette-Guerin (BCG) or mitomycin C (MMC) were documented. To identify the interval of time from which recurrence rates significantly increased, we used nonparametric series regression. Recurrence-free survival (RFS) and progression-free survival for patients in each time delay category were compared using the Kaplan-Meier method. Factors associated with tumor recurrence were analyzed in a multivariable model. RESULTS AND LIMITATIONS: A total of 434 patients were included, of whom 168 (38.7%) had IR and 266 (61.3%) had HR NMIBC. Among the patients, 34.6% had reTUR, 63.6% received BCG, and 36.4% received MMC. The median TT-TUR, TT-reTUR, and TT-INST was 4.0 wk, 6.5 wk, and 7.0 wk, respectively. At 40 mo the rate of recurrence was 28.4% and the rate of progression was 7.3%. Nonparametric analysis revealed that each week in delay increased the risk of recurrence, starting from week 6 for TT-TUR for IR and HR cases, and starting from week 7 for TT-INST for IR cases. RFS was significantly lower with TT-TUR > 6 wk among patients in the IR (p < 0.001) and HR (p = 0.04) groups, and with TT-INST >7 wk for patients in the IR group (p = 0.001). TT-reTUR >7 wk had a significant negative impact on progression (p < 0.017). Multivariable analysis revealed that for IR and HR cases, multifocality (p = 0.02 and p = 0.007) and TT-TUR >6 wk (p = 0.001 and p = 0.03) were independent predictors of recurrence, while TT-INST >7 wk predicted recurrence (p = 0.04) for IR NMIBC. CONCLUSIONS: Our results suggest that delays of >6 wk to first TUR in IR and HR NMIBC, and >7 wk to first instillation in IR cases are associated with increases in the risk of recurrence. TT-reTUR of >7 wk is also associated with higher risk of progression. PATIENT SUMMARY: We evaluated the impact of treatment delays on outcomes for patients with intermediate- and high-risk bladder cancer not invading the bladder wall muscle. We found that delays from diagnosis to first bladder resection, from first resection to repeat resection, and from last resection to bladder instillation treatment increase the rates of cancer recurrence and progression. The medical team should avoid delays in treatment, even for low-grade bladder cancer. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Ourfali, Said AU - Ourfali S AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France. Electronic address: said.ourfali@chu-lyon.fr. FAU - Matillon, Xavier AU - Matillon X AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France. FAU - Ricci, Estelle AU - Ricci E AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France. FAU - Fassi-Fehri, Hakim AU - Fassi-Fehri H AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France. FAU - Benoit-Janin, Melanie AU - Benoit-Janin M AD - Service d'Anatomo-Cyto-Pathologie, Hopital Louis Pradel, Hospices Civils de Lyon, Bron, France. FAU - Badet, Lionel AU - Badet L AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France. FAU - Colombel, Marc AU - Colombel M AD - Service d'Urologie et Chirurgie de la Transplantation, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard-Lyon 1, Lyon, France. LA - eng PT - Journal Article DEP - 20210623 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Humans MH - *Urinary Bladder Neoplasms/drug therapy/surgery MH - Retrospective Studies MH - Prognosis MH - BCG Vaccine/therapeutic use MH - Time-to-Treatment MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Invasiveness MH - Mitomycin/therapeutic use OTO - NOTNLM OT - Intravesical therapy OT - Non muscle invasive bladder cancer OT - Progression rate OT - Recurrence rate OT - Treatment delays EDAT- 2021/06/27 06:00 MHDA- 2022/12/06 06:00 CRDT- 2021/06/26 05:39 PHST- 2021/03/16 00:00 [received] PHST- 2021/05/13 00:00 [revised] PHST- 2021/06/10 00:00 [accepted] PHST- 2021/06/27 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2021/06/26 05:39 [entrez] AID - S2405-4569(21)00169-3 [pii] AID - 10.1016/j.euf.2021.06.007 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Sep;8(5):1226-1237. doi: 10.1016/j.euf.2021.06.007. Epub 2021 Jun 23. PMID- 34160681 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria. PG - 4159-4165 LID - 10.1007/s00345-021-03765-8 [doi] AB - INTRODUCTION: Transurethral resection of bladder tumor (TURBT) is a fundamental but challenging step in the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). The first- and second-look TURBT are central in the management of T1 tumors. MATERIALS AND METHODS: We retrospectively reviewed all patients treated with TURBT for T1 urothelial cell carcinoma (UCC) of the bladder in one academic institution between 2007 and 2017. Quality of TURBT was evaluated based on the presence/absence of muscle on pathology report, the presence/absence of residual tumor on the second look and the occurrence of complications. Patient-, surgeon- and tumor-related factors were investigated for their association with TURBT quality. RESULTS: 283 patients were included. Second-look resection was performed after a mean delay of 54 days. Muscle was observed in 85.9% of the samples on the first TURBT. On the second-look resection, UCC was observed in 52.3% of the samples. 38 complications were reported after the first TURBT (13.4%). Surgeon's experience was the only factor significantly associated with occurrence of post-operative complications (OR = 0.40; p = 0.04). Location of the tumor at the bottom of the bladder was a risk factor for not finding muscle at pathological analysis (OR = 0.20; p = 0.06). Male gender, multiplicity and tumor located at the bottom of the bladder were significantly associated with residual disease on reTURBT. In multivariate analysis, only male gender (OR = 4.71; p = 0.02) and tumor multiplicity remained significant (OR for unique tumor = 0.36; p = 0.02). CONCLUSION: TURBT is a challenging procedure and surgeon's experience is crucial in reducing the rate of post-operative complications. Technical difficulties resulting from patient's gender, tumor location or number of tumors may be as important as oncological factors in deciding whether or not to perform a second-look resection. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Bebane, Sonia AU - Bebane S AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. FAU - Denize, Justine AU - Denize J AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. FAU - Goujon, Annabelle AU - Goujon A AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. FAU - Meria, Paul AU - Meria P AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. FAU - Verine, Jerome AU - Verine J AD - Pathology Department, Saint Louis Hospital, APHP, Paris, France. FAU - Mongiat-Artus, Pierre AU - Mongiat-Artus P AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. AD - Universite de Paris, Paris, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. AD - Universite de Paris, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AUID- ORCID: 0000-0001-8591-3236 AD - Service D'Urologie, Hopital Saint Louis, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. amassonlecomte@gmail.com. AD - Universite de Paris, Paris, France. amassonlecomte@gmail.com. LA - eng PT - Journal Article DEP - 20210623 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - *Cystectomy/methods/standards MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Neoplasm, Residual MH - Quality of Health Care MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Second look OT - TURB OT - Teaching program EDAT- 2021/06/24 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/06/23 12:30 PHST- 2021/03/31 00:00 [received] PHST- 2021/06/11 00:00 [accepted] PHST- 2021/06/24 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/06/23 12:30 [entrez] AID - 10.1007/s00345-021-03765-8 [pii] AID - 10.1007/s00345-021-03765-8 [doi] PST - ppublish SO - World J Urol. 2021 Nov;39(11):4159-4165. doi: 10.1007/s00345-021-03765-8. Epub 2021 Jun 23. PMID- 34156341 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210727 IS - 2369-1999 (Print) IS - 2369-1999 (Electronic) IS - 2369-1999 (Linking) VI - 7 IP - 2 DP - 2021 Jun 22 TI - Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guerin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study. PG - e25800 LID - 10.2196/25800 [doi] LID - e25800 AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is currently the most clinically effective intravesical treatment for non-muscle-invasive bladder cancer (NMIBC), particularly for patients with high-risk NMIBC such as those with carcinoma in situ. BCG treatments could be optimized to improve patient safety and conserve supply by predicting BCG efficacy based on tumor characteristics or clinicopathological criteria. OBJECTIVE: The aim of this study is to assess the ability of specific clinicopathological criteria to predict tumor recurrence in patients with NMIBC who received BCG therapy along various treatment timelines. METHODS: A total of 1331 patients (stage Ta, T1, or carcinoma in situ) who underwent transurethral resection of a bladder tumor between 2006 and 2017 were included. Univariate analysis, including laboratory tests (eg, complete blood panels, creatinine levels, and hemoglobin A(1c) levels) within 180 days of BCG therapy initiation, medications, and clinical and demographic variables to assess their ability to predict NMIBC recurrence, was completed. This was followed by multivariate regression that included the elements of the Club Urologico Espanol de Tratamiento Oncologico (CUETO) scoring model and variables that were significant predictors of recurrence in univariate analysis. RESULTS: BCG was administered to 183 patients classified as intermediate or high risk, and 76 (41.5%) experienced disease recurrence. An abnormal neutrophil-to-lymphocyte ratio measured within 180 days of induction BCG therapy was a significant predictor (P=.047) of future cancer recurrence and was a stronger predictor than the CUETO score or the individual variables included in the CUETO scoring model through multivariate analysis. CONCLUSIONS: An abnormal neutrophil-to-lymphocyte ratio within 180 days of BCG therapy initiation is predictive of recurrence and could be suggestive of additional or alternative interventions. CI - (c)Joseph Plasek, John Weissert, Tracy Downs, Kyle Richards, Kourosh Ravvaz. Originally published in JMIR Cancer (https://cancer.jmir.org), 22.06.2021. FAU - Plasek, Joseph AU - Plasek J AUID- ORCID: 0000-0002-9686-3876 AD - Advocate Aurora Research Institute, Milwaukee, WI, United States. FAU - Weissert, John AU - Weissert J AUID- ORCID: 0000-0001-9444-163X AD - Advocate Aurora Research Institute, Milwaukee, WI, United States. FAU - Downs, Tracy AU - Downs T AUID- ORCID: 0000-0001-8161-8926 AD - School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Richards, Kyle AU - Richards K AUID- ORCID: 0000-0001-8773-6413 AD - School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Ravvaz, Kourosh AU - Ravvaz K AUID- ORCID: 0000-0002-6530-9506 AD - Advocate Aurora Research Institute, Milwaukee, WI, United States. LA - eng PT - Journal Article DEP - 20210622 PL - Canada TA - JMIR Cancer JT - JMIR cancer JID - 101666844 PMC - PMC8277393 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - recurrence OT - risk factor OT - urinary bladder neoplasms COIS- Conflicts of Interest: None declared. EDAT- 2021/06/23 06:00 MHDA- 2021/06/23 06:01 PMCR- 2021/06/22 CRDT- 2021/06/22 12:13 PHST- 2020/11/16 00:00 [received] PHST- 2021/03/28 00:00 [accepted] PHST- 2021/03/25 00:00 [revised] PHST- 2021/06/22 12:13 [entrez] PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/06/23 06:01 [medline] PHST- 2021/06/22 00:00 [pmc-release] AID - v7i2e25800 [pii] AID - 10.2196/25800 [doi] PST - epublish SO - JMIR Cancer. 2021 Jun 22;7(2):e25800. doi: 10.2196/25800. PMID- 34147429 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20250623 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 45 IP - 6 DP - 2021 Jul-Aug TI - Risk factors, management, and survival of bladder cancer after kidney transplantation. PG - 427-438 LID - S2173-5786(21)00075-5 [pii] LID - 10.1016/j.acuroe.2020.09.009 [doi] AB - INTRODUCTION AND OBJECTIVES: Kidney transplantation is associated with an increased risk of bladder cancer; however guidelines have not been established on the management of bladder cancer after kidney transplantation. MATERIALS AND METHODS: A systematic literature review using PubMed was performed in accordance with the PRISMA statement to identify studies concerning the prevalence and survival of bladder cancer after kidney transplantation. The risk factors and management of bladder cancer after kidney transplantation were also reviewed and discussed. RESULTS: A total of 41 studies, published between 1996 and 2018, reporting primary data on bladder cancer after kidney transplantation were identified. Marked heterogeneity in bladder cancer prevalence, time to diagnosis, non-muscle invasive/muscle-invasive bladder cancer prevalence, and survival was noted. Four studies, published between 2003 and 2017, reporting primary data on bladder cancer treated with Bacillus Calmette-Guerin (BCG) after kidney transplantation were identified. Disease-free survival, cancer-specific survival, and overall survival were similar between BCG studies (75-100%). CONCLUSIONS: Carcinogen exposure that led to ESRD, BKV, HPV, immunosuppressive agents, and the immunosuppressed state likely contribute to the increased risk of bladder cancer after renal transplantation. Non-muscle invasive disease should be treated with transurethral resection. BCG can be safely used in transplant recipients and likely improves the disease course. Muscle-invasive disease should be treated with radical cystectomy, with special consideration to the dissection and urinary diversion choice. Chemotherapy and immune checkpoint inhibitors can be safely used in regionally advanced bladder cancer with potential benefit. mTOR inhibitors may reduce the risk of developing bladder cancer, and immunosuppression medications should be reduced if malignancy develops. CI - Copyright (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Jue, J S AU - Jue JS AD - Department of Urology, Lenox Hill Hospital, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, New York, United States; Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. Electronic address: jjue@northwell.edu. FAU - Alameddine, M AU - Alameddine M AD - Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Miami Transplant Institute, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Gonzalez, J AU - Gonzalez J AD - Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Ciancio, G AU - Ciancio G AD - Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Department of Urology, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Miami Transplant Institute, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States; Department of Urology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Systematic Review DEP - 20210617 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Adjuvants, Immunologic) SB - IM MH - Adjuvants, Immunologic MH - Cystectomy MH - Humans MH - *Kidney Transplantation/adverse effects MH - Risk Factors MH - *Urinary Bladder Neoplasms/epidemiology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Cancer vesical OT - Kidney transplantation OT - Trasplante renal EDAT- 2021/06/21 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/06/20 20:33 PHST- 2020/09/20 00:00 [received] PHST- 2020/09/22 00:00 [accepted] PHST- 2021/06/21 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/06/20 20:33 [entrez] AID - S2173-5786(21)00075-5 [pii] AID - 10.1016/j.acuroe.2020.09.009 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2021 Jul-Aug;45(6):427-438. doi: 10.1016/j.acuroe.2020.09.009. Epub 2021 Jun 17. PMID- 34147426 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 45 IP - 6 DP - 2021 Jul-Aug TI - Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. PG - 473-478 LID - S2173-5786(21)00071-8 [pii] LID - 10.1016/j.acuroe.2020.08.014 [doi] AB - INTRODUCTION AND OBJECTIVES: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR. MATERIAL AND METHODS: In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions. RESULTS: The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors > 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, while the presence of CIS only remained significant in the model with tumor size, p < 0.001. CONCLUSIONS: The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumors and tumors more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease. CI - Copyright (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Pisano, F AU - Pisano F AD - Citta della Salute e della Scienza di Torino, University of Studies of Turin; Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. Electronic address: francescapisano85@gmail.com. FAU - Gontero, P AU - Gontero P AD - Citta della Salute e della Scienza di Torino, University of Studies of Turin. FAU - Sylvester, R AU - Sylvester R AD - Formerly Department of Biostatistics, EORTC Headquarters. FAU - Joniau, S AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Serretta, V AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Larre, S AU - Larre S AD - Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK. FAU - Di Stasi, S AU - Di Stasi S AD - Policlinico Tor Vergata-University of Rome, Rome, Italy. FAU - van Rhijn, B AU - van Rhijn B AD - Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Witjes, A AU - Witjes A AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Grotenhuis, A AU - Grotenhuis A AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Colombo, R AU - Colombo R AD - Dipartimento di Urologia, Universita Vita-Salute, Ospedale S. Raffaele, Milan, Italy. FAU - Briganti, A AU - Briganti A AD - Dipartimento di Urologia, Universita Vita-Salute, Ospedale S. Raffaele, Milan, Italy. FAU - Babjuk, M AU - Babjuk M AD - Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic. FAU - Soukup, V AU - Soukup V AD - Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic. FAU - Malmstrom, P U AU - Malmstrom PU AD - Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden. FAU - Irani, J AU - Irani J AD - Department of Urology, Hospital Bicetre, France. FAU - Malats, N AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO). FAU - Baniel, J AU - Baniel J AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Mano, R AU - Mano R AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Cai, T AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - Cha, E AU - Cha E AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Ardelt, P AU - Ardelt P AD - University Hospital Basel, Urological University Clinic Basel-Liestal, Basel, Switzerland. FAU - Varkarakis, J AU - Varkarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Bartoletti, R AU - Bartoletti R AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Dalbagni, G AU - Dalbagni G AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Shariat, S F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, 1190, Austria; Department of Urology, Cochin Hospital, Paris, France. FAU - Xylinas, E AU - Xylinas E AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Karnes, R J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Palou, J AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. LA - eng LA - spa PT - Journal Article DEP - 20210617 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Factors MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Cancer de vejiga no musculo-invasivo OT - Enfermedad residual OT - Non-muscle invasive bladder cancer OT - Progresion OT - Progression OT - Re-reseccion transuretral de la vejiga OT - Re-transurethral resection of the bladder OT - Recurrence OT - Recurrencia OT - Residual disease EDAT- 2021/06/21 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/06/20 20:33 PHST- 2020/06/30 00:00 [received] PHST- 2020/08/22 00:00 [accepted] PHST- 2021/06/21 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/06/20 20:33 [entrez] AID - S2173-5786(21)00071-8 [pii] AID - 10.1016/j.acuroe.2020.08.014 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2021 Jul-Aug;45(6):473-478. doi: 10.1016/j.acuroe.2020.08.014. Epub 2021 Jun 17. PMID- 34143284 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20220224 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 12 DP - 2021 Dec TI - Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. PG - 4355-4361 LID - 10.1007/s00345-021-03740-3 [doi] AB - PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC. CI - (c) 2021. The Author(s). FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Motlagh, Reza Sari AU - Motlagh RS AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Grossmann, Nico C AU - Grossmann NC AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Medical University of Silesia, 41-800, Zabrze, Poland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, 2 Rue Henri le Guilloux, 35000, Rennes, France. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Comperat, Eva AU - Comperat E AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Haydter, Martin AU - Haydter M AD - Department of Urology, Landesklinikum Wiener Neustadt, Vienna, Austria. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Nasu, Yasutomo AU - Nasu Y AD - Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. CN - European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210618 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Female MH - Humans MH - Inflammation/*etiology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*complications/*immunology/pathology PMC - PMC8602174 OTO - NOTNLM OT - Biomarker OT - Intermediate-risk OT - NMIBC OT - SII OT - Survival COIS- All authors state that they have no conflict of interest that might bias this work. EDAT- 2021/06/19 06:00 MHDA- 2022/02/25 06:00 PMCR- 2021/06/18 CRDT- 2021/06/18 12:24 PHST- 2021/03/24 00:00 [received] PHST- 2021/05/19 00:00 [accepted] PHST- 2021/06/19 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2021/06/18 12:24 [entrez] PHST- 2021/06/18 00:00 [pmc-release] AID - 10.1007/s00345-021-03740-3 [pii] AID - 3740 [pii] AID - 10.1007/s00345-021-03740-3 [doi] PST - ppublish SO - World J Urol. 2021 Dec;39(12):4355-4361. doi: 10.1007/s00345-021-03740-3. Epub 2021 Jun 18. PMID- 34142438 OWN - NLM STAT- Publisher LR - 20240222 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 25 IP - 13 DP - 2021 Jun 17 TI - Thrombospondin-4 promotes bladder cancer cell migration and invasion via MMP2 production. PG - 6046-55 LID - 10.1111/jcmm.16463 [doi] AB - Bladder cancer (BC) is the second most common urological tumour in Western countries. Approximately, 80% of patients with BC will present with non-muscle invasive bladder cancer (NMIBC), whereas a quarter will have muscle invasive disease (MIBC) at the time of BC diagnosis. However, patients with NMIBC are at risk of BC recurrence or progression into MIBC, and an MIBC prognosis is determined by the presence of progression and metastasis. Matrix metalloproteinase 2 (MMP2), a type of matrix metalloproteinase (MMP), plays a major role in tumour invasion and is well-characterized in BC prognosis. In BC, the mechanisms regulating MMP2 expression, and, in turn, promote cancer invasion, have hardly been explored. Thrombospondin-4 (THBS4/TSP4) is a matricellular glycoprotein that regulates multiple biological functions, including proliferation, angiogenesis, cell adhesion and extracellular matrix modelling. Based on the results of a meta-analysis in the Gene Expression Profiling Interactive Analysis 2 database, we observed that TSP4 expression levels were consistent with overall survival (OS) rate and BC progression, with the highest expression levels observed in the advanced stages of BC and associated with poor OS rate. In our pilot experiments, incubation with recombinant TSP4 promoted the migration and invasion in BC cells. Furthermore, MMP2 expression levels increased after recombinant TSP4 incubation. TSP4-induced-MMP2 expression and cell motility were regulated via the AKT signalling pathway. Our findings facilitate further investigation into TSP4 silencing-based therapeutic strategies for BC. CI - (c) 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Chou, Kuang-Yu AU - Chou KY AD - Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan. FAU - Chang, An-Chen AU - Chang AC AUID- ORCID: 0000-0002-9544-9980 AD - Translational Medicine Center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. FAU - Ho, Chao-Yen AU - Ho CY AD - Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - School of Medicine, Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Tsai, Te-Fu AU - Tsai TF AD - Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan. FAU - Chen, Hung-En AU - Chen HE AD - Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. FAU - Chen, Po-Chun AU - Chen PC AUID- ORCID: 0000-0002-6325-3668 AD - Translational Medicine Center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan. AD - Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan. FAU - Hwang, Thomas I-Sheng AU - Hwang TI AD - Division of Urology, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan. AD - Department of Urology, Taipei Medical University, Taipei, Taiwan. LA - eng GR - MOST-108-2314-B-341-001-/Ministry of Science and Technology, Taiwan/ GR - SKH-8302-106-DR-09/Shin Kong Wu Ho-Su Memorial Hospital/ GR - 2018SKHADR010/Shin Kong Wu Ho-Su Memorial Hospital/ GR - 2020SKHBDR005/Shin Kong Wu Ho-Su Memorial Hospital/ PT - Journal Article DEP - 20210617 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 SB - IM PMC - PMC8406484 OTO - NOTNLM OT - MMP2 OT - TSP4 OT - bladder cancer OT - invasion OT - migration COIS- The authors of this article declare no conflicts of interest. EDAT- 2021/06/19 06:00 MHDA- 2021/06/19 06:00 PMCR- 2021/07/01 CRDT- 2021/06/18 07:08 PHST- 2021/02/01 00:00 [revised] PHST- 2020/08/03 00:00 [received] PHST- 2021/03/03 00:00 [accepted] PHST- 2021/06/18 07:08 [entrez] PHST- 2021/06/19 06:00 [pubmed] PHST- 2021/06/19 06:00 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - JCMM16463 [pii] AID - 10.1111/jcmm.16463 [doi] PST - aheadofprint SO - J Cell Mol Med. 2021 Jun 17;25(13):6046-55. doi: 10.1111/jcmm.16463. PMID- 34141706 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2296-634X (Print) IS - 2296-634X (Electronic) IS - 2296-634X (Linking) VI - 9 DP - 2021 TI - Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis. PG - 651560 LID - 10.3389/fcell.2021.651560 [doi] LID - 651560 AB - BACKGROUND: The toll-like receptor 4 (TLR4) agonist, Bacille Calmette-Guerin, has exhibited gratifying effects in treating bladder cancer. The study aims to explore the expression pattern, prognostic value, and potential mechanism of TLR4 in bladder cancer. METHODS: The transcriptome file from the GSE13507 dataset in the Gene Expression Omnibus database and the promoter methylation file from the bladder cancer dataset in The Cancer Genome Atlas database were downloaded for analysis. The prognostic value of the TLRs was assessed by univariate Cox regression. Immunohistochemistry was applied to verify the expression of TLR4 in bladder cancer. The drug response is estimated through the R package "pRRophetic." The CIBERSORT algorithm was carried out to estimate the infiltrating immune cells of samples. Gene Set Enrichment Analysis (GSEA) was performed to identify the pathways involved under varied TLR4 expression levels. RESULTS: TLR4 is decreased in tumor tissues compared with surrounding tumor tissues or normal tissue, which is also positively correlated to the overall survival rate (hazard ratio [HR] = 0.38) and cancer-specific survival rate (HR = 0.15) of patients with bladder cancer. Low expression of TLR4 is observed in tumors with malignant performance (high pathological grade, higher tumor stage, and progression). Patients with low TLR4 levels are more sensitive to gemcitabine rather than cisplatin. The promoter methylation level of TLR4 is positively associated with TLR4 expression (P < 0.001). The cg14629571 methylation site largely contributes to the overall methylation level. The CIBERSORT analysis shows that high TLR4 expression is associated with lower levels of plasma cells, M0 macrophages, and M1 macrophages. The GSEA results indicate that the TGF-beta pathway and apoptosis are activated in high TLR4 bladder cancer, while G2M checkpoint and E2F targets pathways are enriched in low TLR4 bladder cancer. CONCLUSION: This research discusses the abnormal expression and prognostic value of TLR4 in bladder cancer. The TLR4 expression can effectively predict oncological outcomes and drug sensitivity of bladder cancer patients. TLR4 is also associated with infiltrating immune cell variation and cancer pathway dysregulation. The results provide a novel prognostic marker and potential drug targets for bladder cancer. CI - Copyright (c) 2021 Lu, Xia, Sun, Xun, Hu, Liu, Sun, Xu, Hu and Wang. FAU - Lu, Jun-Lin AU - Lu JL AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Yi AU - Sun Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xun, Yang AU - Xun Y AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Heng-Long AU - Hu HL AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Chen-Qian AU - Liu CQ AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Jian-Xuan AU - Sun JX AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xu, Jin-Zhou AU - Xu JZ AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Jia AU - Hu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20210601 PL - Switzerland TA - Front Cell Dev Biol JT - Frontiers in cell and developmental biology JID - 101630250 PMC - PMC8204102 OTO - NOTNLM OT - bioinformatics OT - bladder cancer OT - innate immunity OT - methylation OT - prognosis OT - toll-like receptor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/19 06:00 MHDA- 2021/06/19 06:01 PMCR- 2021/01/01 CRDT- 2021/06/18 06:48 PHST- 2021/01/10 00:00 [received] PHST- 2021/04/07 00:00 [accepted] PHST- 2021/06/18 06:48 [entrez] PHST- 2021/06/19 06:00 [pubmed] PHST- 2021/06/19 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcell.2021.651560 [doi] PST - epublish SO - Front Cell Dev Biol. 2021 Jun 1;9:651560. doi: 10.3389/fcell.2021.651560. eCollection 2021. PMID- 34140244 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220217 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 1 DP - 2022 Jan TI - Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG. PG - 9.e9-9.e17 LID - S1078-1439(21)00211-8 [pii] LID - 10.1016/j.urolonc.2021.05.006 [doi] AB - OBJECTIVE: Some attempts have previously been made to stratify patients with CIS for the purpose of risk-adapted clinical management and clinical trial design. In particular, two classification systems have been proposed: clinical classification, comprising primary (P-CIS), concomitant (C-CIS), and secondary (S-CIS) disease, and pathological classification, comprising P-CIS, cTa-CIS, and cT1-CIS. The aim of the present study was to assess the impact of both classifications on BCG response, recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS). PATIENTS AND METHODS: We performed a retrospective analysis of 386 patients with bladder CIS, with or without associated cTa/cT1 disease, treated with BCG instillations between 2008 and 2015. Patients were stratified according to the two classification systems. Cox multivariate regression models were used to assess the impact of these subtypes on BCG response, RFS, PFS, OS, and CSS. We also performed a cumulative meta-analysis according to PRISMA guidelines. RESULTS: The median follow-up was 70.5 months. According to the clinical classification, 34 (8.8%) patients had P-CIS, 81 (21%) S-CIS, and 271 (70.2%) C-CIS. The pathological classification showed 34 (8.8%) patients to have P-CIS, 190 (49.2%) cTa-CIS, and 162 (42%) cT1-CIS. In the overall cohort, BCG response was reported in 296 (76.7%); 159 (41.2%) had recurrence, 55 (14.2%) had progression, and 67 (17.4%) underwent radical cystectomy. Death from any cause was recorded in 135 (35%) and death from urothelial carcinoma in 38 (9.9%). Cox multivariate regression analysis showed that neither clinical classification nor pathological classification is an independent predictive factor for BCG response, RFS, PFS, OS, or CSS after adjusting for confounders. In the pooled meta-analysis, two studies and the present series were included for evidence synthesis, recruiting a total of 941 patients. We found no statistically significant difference across the groups for both classifications with respect to BCG response, RFS, PFS, and CSS. CONCLUSIONS: Currently, the supporting evidence for an impact of clinical classification and pathological classification on oncological outcomes of CIS of the bladder is insufficient to justify their use to guide clinical management or follow-up. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. Electronic address: jdsubiela@gmail.com. FAU - Faba, Oscar Rodriguez AU - Faba OR AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Aumatell, Julia AU - Aumatell J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Morphological Sciences, Barcelona, Spain. FAU - Calderon, Julio AU - Calderon J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Parada, Ruben AU - Parada R AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Huguet, Jorge AU - Huguet J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Department of Urology and Oncological Urology, Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Breda, Alberto AU - Breda A AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Urooncology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Department of Surgery, Barcelona, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20210616 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*classification/diagnosis/*drug therapy/mortality MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*classification/diagnosis/*drug therapy/mortality OTO - NOTNLM OT - BCG immunotherapy OT - Carcinoma in situ OT - Non-muscle-invasive bladder cancer EDAT- 2021/06/19 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/06/18 05:45 PHST- 2021/02/11 00:00 [received] PHST- 2021/04/14 00:00 [revised] PHST- 2021/05/03 00:00 [accepted] PHST- 2021/06/19 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/06/18 05:45 [entrez] AID - S1078-1439(21)00211-8 [pii] AID - 10.1016/j.urolonc.2021.05.006 [doi] PST - ppublish SO - Urol Oncol. 2022 Jan;40(1):9.e9-9.e17. doi: 10.1016/j.urolonc.2021.05.006. Epub 2021 Jun 16. PMID- 34139890 OWN - NLM STAT- MEDLINE DCOM- 20211026 LR - 20211026 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 35 IP - 10 DP - 2021 Oct TI - Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. PG - 1541-1547 LID - 10.1089/end.2021.0013 [doi] AB - Introduction: We sought to describe the incidence, risk factors, and survival outcomes associated with pathologic upstaging from non-muscle invasive bladder cancer (NMIBC) to muscle invasive bladder cancer (MIBC) after robot-assisted radical cystectomy (RARC). Methods: We reviewed the International Robotic Cystectomy Consortium database between 2004 and 2020. Upstaging was defined as >/=pT(2) or pathologic node positive (pN+) at final pathology analysis from clinical /=3; 55% vs 44%, p = 0.04), and had higher rate of preoperative hydronephrosis (26% vs 10%, p < 0.01). They were more likely to have positive surgical margins (10% vs 3%, p = 0.01), recurrences (28% vs 9%, p < 0.01), and to receive adjuvant/salvage treatment (26% vs 3%, p < 0.01). On multivariate analysis, upstaging was associated with older age (odds ratio [OR] 1.04; confidence interval [CI] 1.01-1.07, p < 0.01), cT(1) vs cTis (OR 4.25; CI 1.57-11.48, p < 0.01), cT(1) vs cTa (OR 2.92; CI 1.40-6.06, p < 0.01), and preoperative hydronephrosis (OR 3.18; CI 1.60-6.32, p < 0.01). Upstaged patients had worse 5-year RFS (53% vs 85%, log rank p < 0.01), DSS (66% vs 93%, log rank p < 0.01), and OS (49% vs 74%, log rank p < 0.01). The rate of upstaging did not significantly change over time (38% in 2004 to 27% in 2019, p = 0.17). Conclusion: Upstaging to MIBC occurred in a significant proportion of patients after RARC for NMIBC and was associated with worse survival outcomes. Older patients, those with cT(1) disease and hydronephrosis were more likely to upstage. FAU - Iqbal, Umar AU - Iqbal U AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Elsayed, Ahmed S AU - Elsayed AS AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Jing, Zhe AU - Jing Z AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Stockle, Michael AU - Stockle M AD - UKS Saarland, Homburg, Germany. FAU - Wijburg, Carl AU - Wijburg C AD - Rijnstate Hospital-Stichting, Arnhem, the Netherlands. FAU - Wiklund, Peter AU - Wiklund P AD - Department of Urology, Karolinska Institute, Stockholm, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Urology, Karolinska Institute, Stockholm, Sweden. FAU - Dasgupta, Prokar AU - Dasgupta P AD - Guy's Hospital, London, United Kingdom. FAU - Khan, Mohammad Shamim AU - Khan MS AD - Guy's Hospital, London, United Kingdom. FAU - Hemal, Ashok AU - Hemal A AD - Wake Forest Medical Center, Winston-Salem, North Carolina, USA. FAU - Kim, Eric AU - Kim E AD - Department of Urology, Washington University in St. Louis, Missouri, USA. FAU - Wagner, Andrew A AU - Wagner AA AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - Gaboardi, Franco AU - Gaboardi F AD - Luigi Sacco (San Raffaele Turro), Milan, Italy. FAU - Rha, Koon Ho AU - Rha KH AD - Yonsei Medical Health Care System, Severance Hospital, Seoul, South Korea. FAU - Maatman, Thomas J AU - Maatman TJ AD - Metro Health Hospital, Wyoming, Michigan, USA. FAU - Balbay, Derya AU - Balbay D AD - Koc University Hospital, Istanbul, Turkey. FAU - Li, Qiang AU - Li Q AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Hussein, Ahmed A AU - Hussein AA AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. FAU - Guru, Khurshid A AU - Guru KA AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. LA - eng PT - Journal Article PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Aged MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Robotic Surgical Procedures MH - *Robotics MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - bladder cancer OT - non-muscle invasive OT - pathologic discrepancy OT - radical cystectomy OT - robot-assisted OT - upstaging EDAT- 2021/06/19 06:00 MHDA- 2021/10/27 06:00 CRDT- 2021/06/18 05:29 PHST- 2021/06/19 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/06/18 05:29 [entrez] AID - 10.1089/end.2021.0013 [doi] PST - ppublish SO - J Endourol. 2021 Oct;35(10):1541-1547. doi: 10.1089/end.2021.0013. PMID- 34125951 OWN - NLM STAT- MEDLINE DCOM- 20210803 LR - 20231222 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 6 IP - 6 DP - 2021 Jun 14 TI - Intravesical gemcitabine for non-muscle invasive bladder cancer. PG - CD009294 LID - 10.1002/14651858.CD009294.pub3 [doi] LID - CD009294 AB - BACKGROUND: It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. This is an update of a Cochrane Review first published in 2012. Since that time, several randomized controlled trials (RCTs) have been reported, making this update relevant. OBJECTIVES: To assess the comparative effectiveness and toxicity of intravesical gemcitabine instillation for NMIBC. SEARCH METHODS: We performed a comprehensive literature search of the Cochrane Library, MEDLINE, Embase, four other databases, trial registries, and conference proceedings to 11 September 2020, with no restrictions on the language or status of publication. SELECTION CRITERIA: We included RCTs in which participants received intravesical gemcitabine for primary or recurrent NMIBC. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the included studies and extracted data for the primary outcomes: time to recurrence, time to progression, grade III to V adverse events determined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), and the secondary outcomes: time to death from bladder cancer, time to death from any cause, grade I or II adverse events determined by the CTCAE v5.0 and disease-specific quality of life. We performed statistical analyses using a random-effects model and rated the certainty of the evidence using GRADE. MAIN RESULTS: We included seven studies with 1222 participants with NMIBC across five comparisons. This abstract focuses on the primary outcomes of the three most clinically relevant comparisons. 1. Gemcitabine versus saline: based on two years' to four years' follow-up, gemcitabine may reduce the risk of recurrence over time compared to saline (39% versus 47% recurrence rate, hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.54 to 1.09; studies = 2, participants = 734; I(2) = 49%; low-certainty evidence), but the CI included the possibility of no effect. Gemcitabine may result in little to no difference in the risk of progression over time compared to saline (4.6% versus 4.8% progression rate, HR 0.96, 95% CI 0.19 to 4.71; studies = 2, participants = 654; I(2) = 53%; low-certainty evidence). Gemcitabine may result in little to no difference in the CTCAE grade III to V adverse events compared to saline (5.9% versus 4.7% adverse events rate, risk ratio [RR] 1.26, 95% CI 0.58 to 2.75; studies = 2, participants = 668; I(2) = 24%; low-certainty evidence). 2. Gemcitabine versus mitomycin: based on three years' follow-up (studies = 1, participants = 109), gemcitabine may reduce the risk of recurrence over time compared to mitomycin (17% versus 40% recurrence rate, HR 0.36, 95% CI 0.19 to 0.69; low-certainty evidence). Gemcitabine may reduce the risk of progression over time compared to mitomycin (11% versus 18% progression rate, HR 0.57, 95% CI 0.32 to 1.01; low-certainty evidence), but the CI included the possibility of no effect. We are very uncertain about the effect of gemcitabine on the CTCAE grade III to V adverse events compared to mitomycin (RR 0.51, 95% CI 0.13 to 1.93; very low-certainty evidence). The analysis was only based on recurrent NMIBC. 3. Gemcitabine versus Bacillus Calmette-Guerin (BCG) for recurrent (one-course BCG failure) high-risk NMIBC: based on 6 months' to 22 months' follow-up (studies = 1, participants = 80), gemcitabine may reduce the risk of recurrence compared to BCG (41% versus 97% recurrence rate, HR 0.15, 95% CI 0.09 to 0.26; low-certainty evidence) and progression over time (16% versus 33% progression rate, HR 0.45, 95% CI 0.27 to 0.76; low-certainty evidence). We are very uncertain about the effect of gemcitabine on the CTCAE grade III to V adverse events compared to BCG (RR 1.00, 95% CI 0.21 to 4.66; very low-certainty evidence). In addition, the review provides information on the comparison of gemcitabine versus BCG and gemcitabine versus one-third dose BCG. AUTHORS' CONCLUSIONS: Based on findings of this review, gemcitabine may have a more favorable impact on recurrence and progression-free survival than mitomycin but we are very uncertain as to how major adverse events compare. The same is true when comparing gemcitabine to BCG in individuals with high risk disease who have previously failed BCG. The underlying low- to very low-certainty evidence indicates that our confidence in these results is limited; the true effects may be substantially different from these findings; therefore, better quality studies are needed. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Han, Mi Ah AU - Han MA AD - Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, Korea, South. FAU - Maisch, Philipp AU - Maisch P AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. FAU - Jung, Jae Hung AU - Jung JH AD - Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea, South. AD - Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Korea, South. FAU - Hwang, Jun Eul AU - Hwang JE AD - Department of Hematology-Oncology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South. FAU - Narayan, Vikram AU - Narayan V AD - Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA. FAU - Cleves, Anne AU - Cleves A AD - Velindre NHS Trust, Cardiff University Library Services, Cardiff, UK. FAU - Hwang, Eu Chang AU - Hwang EC AD - Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South. FAU - Dahm, Philipp AU - Dahm P AD - Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. LA - eng SI - ClinicalTrials.gov/NCT00191477 SI - ClinicalTrials.gov/NCT00192049 SI - ClinicalTrials.gov/NCT02695771 SI - ClinicalTrials.gov/NCT04172675 PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210614 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (BCG Vaccine) RN - 0 (Saline Solution) RN - 0W860991D6 (Deoxycytidine) RN - 50SG953SK6 (Mitomycin) RN - 0 (Gemcitabine) SB - IM UOF - Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. PMID: 22259002 MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/administration & dosage/adverse effects MH - Antimetabolites, Antineoplastic/*administration & dosage/adverse effects MH - BCG Vaccine/administration & dosage MH - Bias MH - Cause of Death MH - Confidence Intervals MH - Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives MH - Disease Progression MH - Drug Administration Schedule MH - Humans MH - Mitomycin/administration & dosage/adverse effects MH - Neoplasm Recurrence, Local/*drug therapy/mortality/prevention & control MH - Randomized Controlled Trials as Topic MH - Saline Solution/administration & dosage MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/prevention & control MH - Gemcitabine PMC - PMC8202966 COIS- MAH: none. PM: none. JHJ: none. JEH: none. VN: none. AC: none. ECH: none. PD: serves as Co-ordinating Editor of Cochrane Urology. However, he was not involved in the editorial processing or decision-making for this review. Other editors of Cochrane Urology managed the editorial process, including final sign-off for this review. EDAT- 2021/06/15 06:00 MHDA- 2021/08/04 06:00 PMCR- 2022/06/14 CRDT- 2021/06/14 17:30 PHST- 2021/06/14 17:30 [entrez] PHST- 2021/06/15 06:00 [pubmed] PHST- 2021/08/04 06:00 [medline] PHST- 2022/06/14 00:00 [pmc-release] AID - CD009294.pub3 [pii] AID - 10.1002/14651858.CD009294.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3. PMID- 34123803 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study. PG - 651657 LID - 10.3389/fonc.2021.651657 [doi] LID - 651657 AB - BACKGROUND: Due to the poor prognosis, the treatment of high-risk bladder cancer (HRBC) remains controversial. This meta-analysis aims to access the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IC) versus IC alone after bladder-sparing surgery in HRBC. METHODS: A systematic search of PubMed, Cochrane Library databases, EMBASE (until June 2020) was conducted. PRISMA checklist was followed. The data were analyzed by RevMan v5.3.0. RESULTS: A total of five articles including 843 patients were studied. The analysis demonstrated that the IAC + IC group had a greater improvement of overall survival (P = 0.02) and significant reduction in terms of tumor recurrence rate (P = 0.0006) and tumor progression rate (P = 0.008) compared with the IC group. The recurrence-free survival in the IAC + IC group was significantly higher than that in the IC group (P = 0.004), but there was no significant difference in progression-free survival between the two groups (P = 0.32). In addition, the combination of IAC and IC significantly extended tumor recurrence interval (P = 0.0001) and reduced tumor-specific death rate (P = 0.01) for patients with HRBC compared with IC alone. For side effects related with IAC, although about half of the patients experienced some toxicities, most of them were mild and reversible (grades 1-2, 22.3% vs. grade 3-4, 2.7%), mainly including nausea/vomiting (P = 0.0001), neutropenia (P = 0.002), and alanine aminotransferase (P = 0.0001). CONCLUSION: Patients with HRBC treated with IAC + IC after bladder-sparing surgery had a marked improvement in the overall survival, recurrence-free survival, time interval to first recurrence, tumor recurrence rate, tumor progression rate, and tumor-specific death rate than patients treated with IC alone. However, progression-free survival was not significantly correlated with treatment strategy. In addition, patients seemed to tolerate well the toxicities related with IAC. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42021232679. CI - Copyright (c) 2021 Zhou, Cui, Huang, Chen and Zhang. FAU - Zhou, Zhongbao AU - Zhou Z AD - Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China. FAU - Cui, Yuanshan AU - Cui Y AD - Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China. AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. FAU - Huang, Shuangfeng AU - Huang S AD - Second Clinical Medical College, Binzhou Medical University, Yantai, China. FAU - Chen, Zhipeng AU - Chen Z AD - Department of Urology, Weifang People's Hospital, Weifang, China. FAU - Zhang, Yong AU - Zhang Y AD - Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210527 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8190377 OTO - NOTNLM OT - bladder-sparing surgery OT - high-risk bladder cancer OT - intra-arterial chemotherapy OT - intravesical chemotherapy OT - meta-analysis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/15 06:00 MHDA- 2021/06/15 06:01 PMCR- 2021/01/01 CRDT- 2021/06/14 09:49 PHST- 2021/01/10 00:00 [received] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/06/14 09:49 [entrez] PHST- 2021/06/15 06:00 [pubmed] PHST- 2021/06/15 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.651657 [doi] PST - epublish SO - Front Oncol. 2021 May 27;11:651657. doi: 10.3389/fonc.2021.651657. eCollection 2021. PMID- 34121689 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20220423 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 17 IP - 2 DP - 2021 Apr-Jun TI - Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer. PG - 434-442 LID - 10.4103/jcrt.JCRT_408_19 [doi] AB - PURPOSE: To investigate the prognostic and clinicopathologic value of Ki-67 and profilin 1 immunohistochemical expression in primary pT1 papillary urothelial bladder cancer. MATERIALS AND METHODS: This study included 88 male and 13 female pT1 primary bladder cancer patients. Demographic characteristics, tumor histological grade, tumor number, presence of concomitant carcinoma in situ, tumor size, and status of recurrence or progression were recorded for each patient. Expression of Ki-67 and profilin 1 was evaluated by immunohistochemical analysis of paraffin-embedded tumor tissues. The Pearson's Chi-square test was used for the analysis of qualitative data, and the Kaplan-Meier method and the log-rank test were used for the survival analysis. RESULTS: In the mean follow-up period of 52 months, 52 (51.5%) patients experienced recurrence, 24 (23.8%) patients experienced progression, and 17 (16.8%) patients died from bladder cancer-related causes. Ki-67 expression was significantly associated with tumor histological grade (P = 0.001). In multivariate analysis, Ki-67 positivity had significantly worse outcome for recurrence (P = 0.006) and mortality (P = 0.022). Ki-67-positive (Ki-67 index >/=15%) patients had shorter recurrence-free (P = 0.003), progression-free (P = 0.002), and cancer-specific (P = 0.003) survival. However, no statistically significant relationship was found between profilin 1 expression and clinicopathologic features and prognosis. CONCLUSIONS: Ki-67 is a highly predictive biomarker for recurrence-free, progression-free, and cancer-specific survival in pT1 bladder cancer patients, in whom prediction of recurrence and progression are difficult. Ki-67 expression can be safely combined with other prognostic factors. However, in pT1 bladder cancer patients, no significant relationship was found between profilin 1 expression and tumor characteristics or prognostic parameters. FAU - Culpan, Meftun AU - Culpan M AD - Department of Urology, Okan University Hospital, Istanbul, Turkey. FAU - Turan, Turgay AU - Turan T AD - Department of Urology, Turgutlu State Hospital, Manisa, Turkey. FAU - Ozkanli, Sidika Seyma AU - Ozkanli SS AD - Department of Pathology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Zenginkinet, Tulay AU - Zenginkinet T AD - Department of Pathology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Kazan, Ozgur AU - Kazan O AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Ucar, Taha AU - Ucar T AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Atis, Gokhan AU - Atis G AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Caskurlu, Turhan AU - Caskurlu T AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 RN - 0 (BCG Vaccine) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (PFN1 protein, human) RN - 0 (Profilins) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/administration & dosage MH - Carcinoma, Transitional Cell/diagnosis/*mortality/pathology/therapy MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/analysis/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Neoplasm Staging MH - Profilins/analysis/*metabolism MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/*mortality/pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - Ki-67 OT - profilin 1 OT - progression OT - recurrence COIS- None EDAT- 2021/06/15 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/06/14 09:29 PHST- 2021/06/14 09:29 [entrez] PHST- 2021/06/15 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - JCanResTher_2021_17_2_434_299887 [pii] AID - 10.4103/jcrt.JCRT_408_19 [doi] PST - ppublish SO - J Cancer Res Ther. 2021 Apr-Jun;17(2):434-442. doi: 10.4103/jcrt.JCRT_408_19. PMID- 34117914 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20250330 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. PG - 4143-4149 LID - 10.1007/s00345-021-03755-w [doi] AB - PURPOSE: Female sex has been implicated with higher stage at diagnosis and as a negative prognostic factor amongst patients with non-muscle invasive bladder cancer (NMIBC). Whether this holds true with contemporary management paradigms is unknown. We analyzed a cohort of patients treated with adequate bacillus Calmette-Guerin (BCG) for NMIBC in an effort to identify sex-specific influence on BCG response. METHODS: An IRB-approved review of patients with NMIBC treated at our institution with at least 'adequate BCG', as defined by the US FDA and EAU, from 2000 to 2018 was performed. Patients were then stratified by sex and response to BCG. Non-parametric tests were used to summarize the data overall and by groups. The Kaplan-Meier product limit method was used to calculate median survival endpoints. RESULTS: Of the 541 patients treated with adequate BCG, 111 (20.5%) were female and 430 (79.5%) were male. Female patients were younger (median 66 vs. 69, p = 0.071), had a lower BMI (median 27.3 vs. 28.8, p = 0.010) and were more likely to have no smoking history (49.5% vs. 27.0%, p < 0.001). Tumor characteristics with respect to stage, size, multifocality, presence of carcinoma in situ, and presence of variant histology were similar between sexes. While rates of recurrence were higher in females than in males this, was not statistically significant (44.1% vs. 34.7%, p = 0.064) and Kaplan-Meier estimates of recurrence-free, progression-free and overall survival demonstrated no significant difference between sexes (p = 0.409, p = 0.253, p = 0.171, respectively). CONCLUSION: In a contemporary cohort of patients with NMIBC treated with adequate BCG, female sex was not associated with adverse oncologic outcomes. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Brooks, Nathan AU - Brooks N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matulay, Justin AU - Matulay J AD - Department of Urology, Atrium Health Levine Cancer Institute, Charlotte, NC, USA. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. akamat@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States GR - P50CA091846/NIH/NCI UTMD Anderson SPORE in Genitourinary Cancer (Bladder)/ PT - Journal Article DEP - 20210612 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - World J Urol. 2022 May;40(5):1245-1246. doi: 10.1007/s00345-021-03775-6. PMID: 34196757 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Sex Factors MH - Tertiary Care Centers MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC11951177 MID - NIHMS2065955 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Gender OT - Non-muscle invasive bladder cancer COIS- KK Bree: Stratify genomics - consultant CP Dinney: National Cancer Institutes research funding, University of East Finland Faculty of Health Sciences (UEFHS) research funding, grant and personal fees from FKD Therapies, creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovac. AM Kamat: personal fees and other from Merck, personal fees from Abbott Molecular, personal fees from Arquer, personal fees from ArTara, personal fees from Asieris, personal fees and other from Photocure, personal fees from Astra Zeneca, personal fees from BioClin Therapeutics, personal fees and other from BMS, personal fees from Cepheid, personal fees from Cold Genesys, other from FKD Industries, personal fees from Eisai, personal fees from Engene, Inc., personal fees from Ferring, personal fees from FerGene, personal fees from Imagin, personal fees from Janssen, personal fees from MDxHealth, personal fees from Medac, personal fees from Pfizer, personal fees from Roviant, personal fees from Sessen Bio, personal fees from ProTara, personal fees from Nucleix, personal fees from Seattle Genetics, grants from CEC Oncology, personal fees from Theralase, personal fees from TMC Innovation, personal fees from US Biotest, other from Adolor, other from Heat Biologics, patent for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy pending. EDAT- 2021/06/13 06:00 MHDA- 2022/02/19 06:00 PMCR- 2025/03/28 CRDT- 2021/06/12 12:07 PHST- 2021/04/05 00:00 [received] PHST- 2021/06/05 00:00 [accepted] PHST- 2021/06/13 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/06/12 12:07 [entrez] PHST- 2025/03/28 00:00 [pmc-release] AID - 10.1007/s00345-021-03755-w [pii] AID - 10.1007/s00345-021-03755-w [doi] PST - ppublish SO - World J Urol. 2021 Nov;39(11):4143-4149. doi: 10.1007/s00345-021-03755-w. Epub 2021 Jun 12. PMID- 34117682 OWN - NLM STAT- MEDLINE DCOM- 20210817 LR - 20240403 IS - 1742-1241 (Electronic) IS - 1368-5031 (Print) IS - 1368-5031 (Linking) VI - 75 IP - 9 DP - 2021 Sep TI - Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic. PG - e14490 LID - 10.1111/ijcp.14490 [doi] LID - e14490 AB - PURPOSE: To evaluate the impact of delay in cystoscopic surveillance on recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A total of 407 patients from four high-volume centres with NMIBC that applied for follow-up cystoscopy were included in our study prospectively. Patients' demographics and previous tumour characteristics, the presence of tumour in follow-up cystoscopy, the pathology results of the latest transurethral resection of bladder tumour (if tumour was detected) and the delay in cystoscopy time were recorded. Our primary outcomes were tumour recurrences detected by follow-up cystoscopy and progression. Multivariate logistic regression analysis was performed using the possible factors identified with univariate analyses (P values 147 days, OR: 4.883, P < .001) were significant risk factors for tumour recurrence on follow-up cystoscopy; the number of recurrences (OR: 1.255, P = .024) and cystoscopy delay time (>90 days, OR: 6.704, P = .002) were significant risk factors for tumour progression. CONCLUSIONS: This study showed that a 2-5 months of delay in follow-up cystoscopy increases the risk of recurrence by 2.4-fold, and delay in cystoscopy for more than 3 months increases the probability of progression by 6.7-fold. We suggest that cystoscopic surveillance should be done during the COVID-19 pandemic according to the schedule set by relevant guidelines. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Culpan, Meftun AU - Culpan M AUID- ORCID: 0000-0001-8573-1192 AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Keser, Ferhat AU - Keser F AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Acar, Hazal Cansu AU - Acar HC AD - Department of Public Health, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Otunctemur, Alper AU - Otunctemur A AD - Department of Urology, Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Kucuk, Eyup Veli AU - Kucuk EV AD - Department of Urology, Istanbul Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Erdem, Selcuk AU - Erdem S AUID- ORCID: 0000-0002-3514-1394 AD - Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Ozer, Murat AU - Ozer M AD - Department of Urology, Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Sen, Ugur Tolga AU - Sen UT AD - Department of Urology, Istanbul Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Degirmenci, Enes AU - Degirmenci E AD - Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Ergul, Rifat AU - Ergul R AD - Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Atis, Ramazan Gokhan AU - Atis RG AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20210622 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 SB - IM MH - *COVID-19 MH - Cystoscopy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Pandemics MH - SARS-CoV-2 MH - *Urinary Bladder Neoplasms/epidemiology/surgery PMC - PMC8420249 COIS- All authors declare that they have no conflict of interest. EDAT- 2021/06/13 06:00 MHDA- 2021/08/18 06:00 PMCR- 2021/06/22 CRDT- 2021/06/12 06:25 PHST- 2021/03/29 00:00 [received] PHST- 2021/06/09 00:00 [accepted] PHST- 2021/06/13 06:00 [pubmed] PHST- 2021/08/18 06:00 [medline] PHST- 2021/06/12 06:25 [entrez] PHST- 2021/06/22 00:00 [pmc-release] AID - IJCP14490 [pii] AID - 10.1111/ijcp.14490 [doi] PST - ppublish SO - Int J Clin Pract. 2021 Sep;75(9):e14490. doi: 10.1111/ijcp.14490. Epub 2021 Jun 22. PMID- 34117034 OWN - NLM STAT- MEDLINE DCOM- 20220401 LR - 20240211 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 27 IP - 16 DP - 2021 Aug 15 TI - Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. PG - 4599-4609 LID - 10.1158/1078-0432.CCR-21-0205 [doi] AB - PURPOSE: Improved risk stratification and predictive biomarkers of treatment response are needed for non-muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC. EXPERIMENTAL DESIGN: Gene expression in NMIBC samples was profiled by NanoString nCounter, an RNA quantification platform, from two independent cohorts (n = 28, n = 50); targeted panel sequencing was performed in a subgroup (n = 50). Gene signatures were externally validated using two RNA sequencing datasets of NMIBC tumors (n = 438, n = 73). Established molecular subtype classifiers and novel gene expression signatures were assessed for associations with clinicopathologic characteristics, somatic tumor mutations, and treatment outcomes. RESULTS: Molecular subtypes distinguished between low-grade Ta tumors with FGFR3 mutations and overexpression (UROMOL-class 1) and tumors with more aggressive clinicopathologic characteristics (UROMOL-classes 2 and 3), which were significantly enriched with TERT promoter mutations. However, UROMOL subclasses were not associated with recurrence after bacillus Calmette-Guerin (BCG) immunotherapy in two independent cohorts. In contrast, a novel expression signature of an inflamed tumor microenvironment (TME) was associated with improved recurrence-free survival after BCG. Expression of immune checkpoint genes (PD-L1/PD-1/CTLA-4) was associated with an inflamed TME, but not with higher recurrence rates after BCG. FGFR3 mutations and overexpression were both associated with low immune signatures. CONCLUSIONS: Assessment of the immune TME, rather than molecular subtypes, is a promising predictive biomarker of BCG response. Modulating the TME in an immunologically "cold" tumor warrants further investigation. Integrated transcriptomic and exome sequencing should improve treatment selection in NMIBC. CI - (c)2021 The Authors; Published by the American Association for Cancer Research. FAU - Damrauer, Jeffrey S AU - Damrauer JS AUID- ORCID: 0000-0001-8148-0285 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. FAU - Roell, Kyle R AU - Roell KR AUID- ORCID: 0000-0001-7491-6095 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Smith, Markia A AU - Smith MA AUID- ORCID: 0000-0002-7114-3776 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Sun, Xuezheng AU - Sun X AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Kirk, Erin L AU - Kirk EL AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Hoadley, Katherine A AU - Hoadley KA AUID- ORCID: 0000-0002-1216-477X AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Benefield, Halei C AU - Benefield HC AUID- ORCID: 0000-0003-1400-5374 AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Iyer, Gopakumar AU - Iyer G AD - Department of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, New York. AD - Department of Medicine, Weill Cornell Medicine, New York, New York. FAU - Solit, David B AU - Solit DB AUID- ORCID: 0000-0002-6614-802X AD - Department of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, New York. AD - Department of Medicine, Weill Cornell Medicine, New York, New York. AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Milowsky, Matthew I AU - Milowsky MI AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Kim, William Y AU - Kim WY AUID- ORCID: 0000-0001-7922-2156 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Wobker, Sara E AU - Wobker SE AUID- ORCID: 0000-0001-5324-4197 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. AD - Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Dalbagni, Guido AU - Dalbagni G AD - Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York. AD - Department of Urology, Weill Cornell Medicine, New York, New York. FAU - Al-Ahmadie, Hikmat A AU - Al-Ahmadie HA AUID- ORCID: 0000-0002-2938-6627 AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Olshan, Andrew F AU - Olshan AF AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Bochner, Bernard H AU - Bochner BH AD - Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York. AD - Department of Urology, Weill Cornell Medicine, New York, New York. FAU - Furberg, Helena AU - Furberg H AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Troester, Melissa A AU - Troester MA AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. AD - Department of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, New York. AD - Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York. pietzake@mskcc.org. AD - Department of Urology, Weill Cornell Medicine, New York, New York. LA - eng GR - P30 ES010126/ES/NIEHS NIH HHS/United States GR - T32 ES007018/ES/NIEHS NIH HHS/United States GR - P50 CA058223/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - UL1 TR002384/TR/NCATS NIH HHS/United States GR - F30 CA236199/CA/NCI NIH HHS/United States GR - K12 CA184746/CA/NCI NIH HHS/United States GR - T32 CA057726/CA/NCI NIH HHS/United States GR - R01 CA253450/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210611 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2023 Oct;210(4):715-716. doi: 10.1097/JU.0000000000003630. PMID: 37527370 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Female MH - Humans MH - Inflammation MH - Male MH - Middle Aged MH - Mutation MH - Neoplasm Invasiveness MH - *Transcriptome MH - Treatment Outcome MH - *Tumor Microenvironment MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology PMC - PMC8416390 MID - NIHMS1715684 EDAT- 2021/06/13 06:00 MHDA- 2022/04/02 06:00 PMCR- 2022/08/24 CRDT- 2021/06/12 05:38 PHST- 2021/01/19 00:00 [received] PHST- 2021/03/24 00:00 [revised] PHST- 2021/06/10 00:00 [accepted] PHST- 2021/06/13 06:00 [pubmed] PHST- 2022/04/02 06:00 [medline] PHST- 2021/06/12 05:38 [entrez] PHST- 2022/08/24 00:00 [pmc-release] AID - 1078-0432.CCR-21-0205 [pii] AID - CCR-21-0205 [pii] AID - 10.1158/1078-0432.CCR-21-0205 [doi] PST - ppublish SO - Clin Cancer Res. 2021 Aug 15;27(16):4599-4609. doi: 10.1158/1078-0432.CCR-21-0205. Epub 2021 Jun 11. PMID- 34116955 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 6 DP - 2021 Dec TI - Intravesical Bacillus Calmette-Guerin Treatment Is Inversely Associated With the Risk of Developing Alzheimer Disease or Other Dementia Among Patients With Non-muscle-invasive Bladder Cancer. PG - e409-e416 LID - S1558-7673(21)00096-3 [pii] LID - 10.1016/j.clgc.2021.05.001 [doi] AB - BACKGROUND: The immune system plays an important role in the pathogenesis of Alzheimer disease (AD), but it remains unclear whether bacillus Calmette-Guerin (BCG) may affect the risk of AD or not. METHODS: Using retrospective chart review, we collected data regarding demographics, comorbidities, cancer diagnosis, BCG treatment, and subsequent diagnosis of AD or other dementia in a racially/ethnically diverse cohort of patients with non-muscle-invasive bladder cancer (NIMBC) receiving treatment between 1984 and 2020 in the Bronx, New York. We used Cox proportional hazard models to examine association between BCG treatment and risk of incident AD or other dementia, adjusting for age, gender, race/ethnicity, and major comorbidities. RESULTS: In our cohort of 1290 patients with NMIBC, a total of 99 (7.7%) patients developed AD or other dementia during follow-up. Patients who received BCG treatment (25%) had a 60% lowered incidence of AD or other dementia (adjusted hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21-0.80) in comparison to those who did not receive BCG. There was also suggestive evidence that the reduction in risk of AD or other dementia associated with BCG treatment was stronger in men (adjusted HR, 0.34; 95% CI, 0.15-0.81) but not in women (adjusted HR, 0.75; 95% CI 0.25-2.24). When we stratified the patients who received BCG by type of treatments, patients who received both induction and maintenance rounds of BCG had a further lowered incidence of AD or other dementia (HR, 0.23; 95% CI, 0.06-0.96) than patients who did not receive BCG. CONCLUSIONS: To our knowledge, our study is one of the first to suggest that BCG treatment is associated with a reduced risk of developing AD or other dementia in a multiethnic population, independent of significant comorbidities. Larger cohort studies are needed to corroborate our findings. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Kim, Joseph I AU - Kim JI AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. FAU - Zhu, Denzel AU - Zhu D AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. FAU - Barry, Emily AU - Barry E AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. FAU - Kovac, Evan AU - Kovac E AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. FAU - Aboumohamed, Ahmed AU - Aboumohamed A AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. FAU - Agalliu, Ilir AU - Agalliu I AD - Department of Epidemiology and Population Health/Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY. FAU - Sankin, Alex AU - Sankin A AD - Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx NY. Electronic address: asankin@montefiore.org. LA - eng PT - Journal Article DEP - 20210517 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic MH - Administration, Intravesical MH - *Alzheimer Disease/epidemiology MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/epidemiology OTO - NOTNLM OT - Aging OT - BCG OT - Dementia OT - Immunotherapy OT - Intravesical Therapy COIS- Declaration of Competing Interest The authors have no interests to declare. EDAT- 2021/06/13 06:00 MHDA- 2022/02/03 06:00 CRDT- 2021/06/12 05:36 PHST- 2021/01/21 00:00 [received] PHST- 2021/04/15 00:00 [revised] PHST- 2021/05/03 00:00 [accepted] PHST- 2021/06/13 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/06/12 05:36 [entrez] AID - S1558-7673(21)00096-3 [pii] AID - 10.1016/j.clgc.2021.05.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Dec;19(6):e409-e416. doi: 10.1016/j.clgc.2021.05.001. Epub 2021 May 17. PMID- 34106817 OWN - NLM STAT- MEDLINE DCOM- 20220304 LR - 20220304 IS - 1532-4230 (Electronic) IS - 1532-1819 (Linking) VI - 42 IP - 6 DP - 2021 Nov 2 TI - Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6. PG - 662-678 LID - 10.1080/15321819.2021.1937212 [doi] AB - Bladder urothelial carcinoma (BUC) has two pathways with distinct molecular features and prognosis, non-muscle invasive (NMI) and muscle invasive (MI) tumors. The aim is to investigate the expression of GATA3 and CK5/6 in BUC with correlation to clinicopathologic parameters, including their impact on survival beside their potential use to stratify cases into prognostic subgroups. This study included 80 cases of BUC stained immunohistochemically by GATA3 and CK5/6. The cases were divided into four groups regarding expression status of both markers (luminal, basal, mixed, and null). GATA3 percentage of expression decreased in urothelial carcinoma with squamous differentiation, MI tumors, high-grade tumors, tumors with involved lymph nodes, presence of perineural invasion, presence of bilharziasis, presence of lympho-vascular invasion, and high mitotic count. CK5/6 positivity was higher in urothelial carcinoma cases with squamous differentiation, MI tumors, and presence of perineural invasion. Pure urothelial carcinoma and NMI were in favor of luminal group (GATA3 +ve/CK5/6 -ve). Univariate analysis showed that the presence of bilharziasis was associated with shorter PFS (p = .04). GATA3 and CK5/6 could be used for the stratification of urothelial bladder carcinoma into subtypes with different characteristics. Luminal bladder cancer represents the most common type (60%) that carries favorable features. Bilharziasis-associated urothelial carcinoma carries poor outcome manifested by short PFS. FAU - Serag Eldien, Marwa Mohammed AU - Serag Eldien MM AD - Pathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. FAU - Abdou, Asmaa Gaber AU - Abdou AG AD - Pathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. FAU - Elghrabawy, Gehad Raafat Amein AU - Elghrabawy GRA AD - Pathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. FAU - Alhanafy, Alshimaa Mahmoud AU - Alhanafy AM AD - Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. FAU - Mahmoud, Shereen Fathy AU - Mahmoud SF AD - Pathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. LA - eng PT - Journal Article DEP - 20210609 PL - England TA - J Immunoassay Immunochem JT - Journal of immunoassay & immunochemistry JID - 100963688 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) SB - IM MH - Biomarkers, Tumor MH - Carcinoma, Squamous Cell MH - *Carcinoma, Transitional Cell/diagnosis MH - GATA3 Transcription Factor MH - Humans MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - CK5/6 OT - GATA3 OT - bilharziasis OT - stratification OT - urothelial carcinoma EDAT- 2021/06/10 06:00 MHDA- 2022/03/05 06:00 CRDT- 2021/06/09 17:20 PHST- 2021/06/10 06:00 [pubmed] PHST- 2022/03/05 06:00 [medline] PHST- 2021/06/09 17:20 [entrez] AID - 10.1080/15321819.2021.1937212 [doi] PST - ppublish SO - J Immunoassay Immunochem. 2021 Nov 2;42(6):662-678. doi: 10.1080/15321819.2021.1937212. Epub 2021 Jun 9. PMID- 34098901 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20211018 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Jun 7 TI - Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival. PG - 676 LID - 10.1186/s12885-021-08418-y [doi] LID - 676 AB - BACKGROUND: Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers. METHODS: Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. INCLUSION CRITERIA: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis. RESULTS: One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival. CONCLUSION: Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival. FAU - Ripoll, J AU - Ripoll J AD - Primary Care Research Unit of Mallorca, Balearic Health Service, Palma, Spain. AD - Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, 07120, Illes Balears, Spain. FAU - Ramos, M AU - Ramos M AUID- ORCID: 0000-0002-0903-5264 AD - Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, 07120, Illes Balears, Spain. mramos@dgsanita.caib.es. AD - Mallorca Cancer Registry, Balearic Islands Public Health Department, Palma, Spain. mramos@dgsanita.caib.es. FAU - Montano, J AU - Montano J AD - Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, 07120, Illes Balears, Spain. AD - University of the Balearic Islands, Palma, Spain. FAU - Pons, J AU - Pons J AD - Mallorca Cancer Registry, Balearic Islands Public Health Department, Palma, Spain. FAU - Ameijide, A AU - Ameijide A AD - Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service. Sant Joan de Reus University Hospital, IISPV., Reus, Spain. FAU - Franch, P AU - Franch P AD - Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, 07120, Illes Balears, Spain. AD - Mallorca Cancer Registry, Balearic Islands Public Health Department, Palma, Spain. LA - eng GR - PI14/01199/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20210607 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM EIN - BMC Cancer. 2021 Aug 26;21(1):956. doi: 10.1186/s12885-021-08694-8. PMID: 34445985 MH - Adolescent MH - Adult MH - Age Factors MH - Aged MH - Carcinoma in Situ/diagnosis/*mortality/pathology MH - Carcinoma, Papillary/diagnosis/*mortality/pathology MH - Carcinoma, Transitional Cell/diagnosis/*mortality/pathology MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Registries/statistics & numerical data MH - Retrospective Studies MH - Risk Assessment/statistics & numerical data MH - Risk Factors MH - Spain/epidemiology MH - Survival Rate MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/diagnosis/*mortality/pathology MH - Young Adult PMC - PMC8186217 OTO - NOTNLM OT - Bladder neoplasms OT - Multiple imputation OT - Stage OT - Survival COIS- We declare that we have no competing interests. EDAT- 2021/06/09 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/06/07 CRDT- 2021/06/08 05:34 PHST- 2020/01/28 00:00 [received] PHST- 2021/05/27 00:00 [accepted] PHST- 2021/06/08 05:34 [entrez] PHST- 2021/06/09 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/06/07 00:00 [pmc-release] AID - 10.1186/s12885-021-08418-y [pii] AID - 8418 [pii] AID - 10.1186/s12885-021-08418-y [doi] PST - epublish SO - BMC Cancer. 2021 Jun 7;21(1):676. doi: 10.1186/s12885-021-08418-y. PMID- 34097440 OWN - NLM STAT- MEDLINE DCOM- 20210831 LR - 20241005 IS - 2473-4276 (Electronic) IS - 2473-4276 (Linking) VI - 5 DP - 2021 Jun TI - Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries. PG - 641-653 LID - 10.1200/CCI.20.00170 [doi] LID - CCI.20.00170 AB - PURPOSE: Population-based cancer incidence rates of bladder cancer may be underestimated. Accurate estimates are needed for understanding the burden of bladder cancer in the United States. We developed and evaluated the feasibility of a machine learning-based classifier to identify bladder cancer cases missed by cancer registries, and estimated the rate of bladder cancer cases potentially missed. METHODS: Data were from population-based cohort of 37,940 bladder cancer cases 65 years of age and older in the SEER cancer registries linked with Medicare claims (2007-2013). Cases with other urologic cancers, abdominal cancers, and unrelated cancers were included as control groups. A cohort of cancer-free controls was also selected using the Medicare 5% random sample. We used five supervised machine learning methods: classification and regression trees, random forest, logic regression, support vector machines, and logistic regression, for predicting bladder cancer. RESULTS: Registry linkages yielded 37,940 bladder cancer cases and 766,303 cancer-free controls. Using health insurance claims, classification and regression trees distinguished bladder cancer cases from noncancer controls with very high accuracy (95%). Bacille Calmette-Guerin, cystectomy, and mitomycin were the most important predictors for identifying bladder cancer. From 2007 to 2013, we estimated that up to 3,300 bladder cancer cases in the United States may have been missed by the SEER registries. This would result in an average of 3.5% increase in the reported incidence rate. CONCLUSION: SEER cancer registries may potentially miss bladder cancer cases during routine reporting. These missed cases can be identified leveraging Medicare claims and data analytics, leading to more accurate estimates of bladder cancer incidence. FAU - Noone, Anne-Michelle AU - Noone AM AUID- ORCID: 0000-0001-6997-4004 AD - Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD. FAU - Lam, Clara J K AU - Lam CJK AD - Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD. FAU - Smith, Angela B AU - Smith AB AUID- ORCID: 0000-0003-2423-1834 AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. AD - Biostatistics and Clinical Data Management Core, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Nielsen, Matthew E AU - Nielsen ME AD - University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. AD - Biostatistics and Clinical Data Management Core, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Boyd, Eric AU - Boyd E AD - Information Management Services Inc, Calverton, MD. FAU - Mariotto, Angela B AU - Mariotto AB AD - Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD. FAU - Banerjee, Mousumi AU - Banerjee M AD - University of Michigan, Ann Arbor, MI. LA - eng PT - Journal Article PL - United States TA - JCO Clin Cancer Inform JT - JCO clinical cancer informatics JID - 101708809 SB - IM MH - Aged MH - Humans MH - Machine Learning MH - Medicare MH - Registries MH - SEER Program MH - United States/epidemiology MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology PMC - PMC8462616 COIS- Angela B. SmithConsulting or Advisory Role: Merck, Photocure, Urogen Pharma, Fergene, Ambu Matthew E. NielsenStock and Other Ownership Interests: Grand Rounds HealthNo other potential conflicts of interest were reported. EDAT- 2021/06/08 06:00 MHDA- 2021/09/01 06:00 PMCR- 2022/06/07 CRDT- 2021/06/07 17:10 PHST- 2021/06/07 17:10 [entrez] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/09/01 06:00 [medline] PHST- 2022/06/07 00:00 [pmc-release] AID - CCI.20.00170 [pii] AID - 10.1200/CCI.20.00170 [doi] PST - ppublish SO - JCO Clin Cancer Inform. 2021 Jun;5:641-653. doi: 10.1200/CCI.20.00170. PMID- 34092528 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20220504 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 1 DP - 2022 Feb TI - Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. PG - 109-112 LID - S2588-9311(21)00112-7 [pii] LID - 10.1016/j.euo.2021.05.006 [doi] AB - Despite being standard tools for decision-making, the European Organisation for Research and Treatment of Cancer (EORTC), European Association of Urology (EAU), and Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk groups provide moderate performance in predicting recurrence-free survival (RFS) and progression-free survival (PFS) in non-muscle-invasive bladder cancer (NMIBC). In this retrospective combined-cohort data-mining study, the training group consisted of 3570 patients with de novo diagnosed NMIBC. Predictors included gender, age, T stage, histopathological grading, tumor burden and diameter, EORTC and CUETO scores, and type of intravesical treatment. The models developed were externally validated using an independent cohort of 322 patients. Models were trained using Cox proportional-hazards deep neural networks (deep learning; DeepSurv) with a proprietary grid search of hyperparameters. For patients treated with surgery and bacillus Calmette-Guerin-treated patients, the models achieved a c index of 0.650 (95% confidence interval [CI] 0.649-0.650) for RFS and 0.878 (95% CI 0.873-0.874) for PFS in the training group. In the validation group, the c index was 0.651 (95% CI 0.648-0.654) for RFS and 0.881 (95% CI 0.878-0.885) for PFS. After inclusion of patients treated with mitomycin C, the c index for RFS models was 0.6415 (95% CI 0.6412-0.6417) for the training group and 0.660 (95% CI 0.657-0.664) for the validation group. Models for PFS achieved a c index of 0.885 (95% CI 0.885-0.885) for the training set and 0.876 (95% CI 0.873-0.880) for the validation set. Our tool outperformed standard-of-care risk stratification tools and showed no evidence of overfitting. The application is open source and available at https://biostat.umed.pl/deepNMIBC/. PATIENT SUMMARY: We created and validated a new tool to predict recurrence and progression of early-stage bladder cancer. The application uses advanced artificial intelligence to combine state-of-the-art scales, outperforms these scales for prediction, and is freely available online. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Jobczyk, Mateusz AU - Jobczyk M AD - Department of Urology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland; Department of Urology, The Hospital Ministry of the Interior and Administration, Lodz, Poland. FAU - Stawiski, Konrad AU - Stawiski K AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. Electronic address: konrad@konsta.com.pl. FAU - Kaszkowiak, Marcin AU - Kaszkowiak M AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Medical University of Silesia, Zabrze, Poland; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Rozanski, Waldemar AU - Rozanski W AD - Department of Urology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Fendler, Wojciech AU - Fendler W AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210603 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Artificial Intelligence MH - *Deep Learning MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Data mining OT - Deep learning OT - Nomogram OT - Non-muscle-invasive bladder cancer OT - Prediction EDAT- 2021/06/08 06:00 MHDA- 2022/05/06 06:00 CRDT- 2021/06/07 05:36 PHST- 2021/02/27 00:00 [received] PHST- 2021/05/11 00:00 [revised] PHST- 2021/05/21 00:00 [accepted] PHST- 2021/06/08 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2021/06/07 05:36 [entrez] AID - S2588-9311(21)00112-7 [pii] AID - 10.1016/j.euo.2021.05.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Feb;5(1):109-112. doi: 10.1016/j.euo.2021.05.006. Epub 2021 Jun 3. PMID- 34092482 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20240925 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 1 DP - 2022 Jan TI - Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. PG - 9.e1-9.e7 LID - S1078-1439(21)00134-4 [pii] LID - 10.1016/j.urolonc.2021.03.024 [doi] AB - INTRODUCTION: Repeat BCG induction remains an option for select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated. We aimed to compare the efficacy BCG plus interferon a-2b (BCG/IFN) and Gem/Doce in patients with recurrent NMIBC after a single prior BCG course. METHODS: The National Phase II BCG/IFN trial database and multi-institutional Gem/Doce database were queried for patients with recurrent NMIBC after one prior BCG induction course, excluding those with BCG unresponsive disease. Stabilized inverse probability treatment weighted survival curves were estimated using the Kaplan-Meier method and compared. Propensity scores were derived from a logistic regression model. The primary outcome was recurrence free survival (RFS); secondary outcomes were high-grade (HG) RFS and risk factors for treatment failure. RESULTS: We identified 197 BCG/IFN and 93 Gem/Doce patients who met study criteria. Patients receiving Gem/Doce were older and more likely to have HG disease, CIS, and persistent disease following induction BCG (all P < 0.01). After propensity score-based weighting, the adjusted 1- and 2-year RFS was 61% and 53% after BCG/IFN versus 68% and 46% after Gem/Doce (P = 0.95). Adjusted 1- and 2-year HG-RFS was 60% and 51% after BCG/IFN versus 63% and 42% after Gem/Doce (P = 0.68). Multivariable Cox regression revealed that Gem/Doce treatment was not associated with an increased risk of failure (HR = 0.97, P = 0.89) as compared to BCG/IFN. CONCLUSION: Patients with recurrent NMIBC after a single induction BCG failure and not deemed BCG unresponsive had similar oncologic outcomes with Gem/Doce and BCG/IFN in a post-hoc analysis. Additional prospective studies are needed. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Thomas, Lewis J AU - Thomas LJ AD - Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO. FAU - Brooks, Nathan AU - Brooks N AD - UPMC Pinnacle, Harrisburg, PA. FAU - Vitale, Andrew AU - Vitale A AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - Crump, Trafford AU - Crump T AD - Department of Urology, University of Calgary, Calgary, Alberta, Canada. FAU - Wang, Jonathan AU - Wang J AD - Beth Israel Deaconess Medical Center, Boston, MA. FAU - DeWolf, William C AU - DeWolf WC AD - Beth Israel Deaconess Medical Center, Boston, MA. FAU - Lamm, Donald L AU - Lamm DL AD - University of Arizona School of Medicine, Phoenix, Az; BCG Oncology, Phoenix, Az. FAU - Kates, Max AU - Kates M AD - Department of Urology, Johns Hopkins University, Baltimore, MD. FAU - Hyndman, M Eric AU - Hyndman ME AD - Department of Urology, University of Calgary, Calgary, Alberta, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - MD Anderson Cancer Center, Houston, TX. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, Johns Hopkins University, Baltimore, MD. FAU - Nepple, Kenneth G AU - Nepple KG AD - Department of Urology, University of Iowa, Iowa City, IA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. Electronic address: Michael-ODonnell@UIowa.edu. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210604 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Interferon alpha-2) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Antineoplastic Agents/*administration & dosage MH - BCG Vaccine/*administration & dosage MH - Cohort Studies MH - Deoxycytidine/administration & dosage/*analogs & derivatives MH - Docetaxel/*administration & dosage MH - Female MH - Humans MH - Induction Chemotherapy MH - Interferon alpha-2/*administration & dosage MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Gemcitabine OTO - NOTNLM OT - Administration, Intravesical OT - Chemotherapy OT - Docetaxel OT - Gemcitabine OT - Immunotherapy OT - Mycobacterium bovis OT - Urinary bladder neoplasms COIS- Conflict of interest AMK reports financial interest and/or other relationship with Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Medac, Asieris, Abbott Molecular and US Biotest. MAO reports financial interest and/or other relationship with Abbott Molecular, Photocure, UroGen, Tocogen, Cold Genesys, Medical Enterprises, Fidia Pharmaceuticals, Vaxiion Pharmaceuticals, Ferring Pharmaceuticals, Sesen Bio, Urovant and Theralase. VTP reports financial interest and/or other relationship with Cold Genesys. MK reports being an advisory boards member for Genesis Biotech and Janssen; consultant for Pacific Edge, Fergene. All other authors declare no conflict of interest. EDAT- 2021/06/08 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/06/07 05:35 PHST- 2021/02/17 00:00 [received] PHST- 2021/03/18 00:00 [revised] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/06/08 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/06/07 05:35 [entrez] AID - S1078-1439(21)00134-4 [pii] AID - 10.1016/j.urolonc.2021.03.024 [doi] PST - ppublish SO - Urol Oncol. 2022 Jan;40(1):9.e1-9.e7. doi: 10.1016/j.urolonc.2021.03.024. Epub 2021 Jun 4. PMID- 34084119 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 1661-7649 (Print) IS - 1661-7657 (Electronic) IS - 1661-7649 (Linking) VI - 15 IP - 1 DP - 2021 Mar TI - Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure. PG - 33-38 LID - 10.1097/CU9.0000000000000010 [doi] AB - BACKGROUND: There are limited bladder-preserving therapeutic options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) after failed Bacillus Calmette-Guerin (BCG) therapy. Salvage intravesical docetaxel therapy was described in 2006 but has not been validated outside of the original institution. In this study, we presented the first external report on the oncologic outcomes of intravesical docetaxel. MATERIALS AND METHODS: We identified 13 patients with high-risk NMIBC treated with >/=1 course of intravesical BCG who received salvage intravesical docetaxel. Recurrence-free survival (RFS) was estimated using the Kaplan-Meier method. Associations of clinicopathologic features with RFS were evaluated using Cox regression. RESULTS: Median age was 75.2 years, and 46.2% of patients were male. Of the patients 92.3% had a prior diagnosis of high-grade T1 disease, 38.5% had a prior diagnosis of carcinoma in situ, and 46.2% had received >/=2 courses of BCG. Only 1 (7.7%) patient experienced docetaxel-related toxicity. Nine (69.2%) patients had a complete response at initial post-docetaxel cystoscopy. During a median follow-up of 12.0 (interquartile range 5.0-18.1) months, a total of 7 (53.8%) patients developed recurrence. Median time to recurrence was 10.1 (interquartile range 4.8-11.6) months. Estimated RFS at 6-, 12-, 18-, and 24-months was 75%, 50%, 50%, and 25%. Three (23.1%) patients ultimately underwent cystectomy. On univariable analysis, multiple courses of induction BCG were associated with decreased RFS, although this did not reach statistical significance (hazard ratio 4.69, p = 0.08). CONCLUSIONS: In this first external validation study, intravesical docetaxel was associated with excellent response rates and intermediate-term RFS among patients with high-risk NMIBC after failed BCG therapy. CI - Copyright (c) 2021 The Authors. Published by Wolters Kluwer Health, Inc. FAU - Shantharam, Govind AU - Shantharam G AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. FAU - Amin, Ali AU - Amin A AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. AD - Department of Pathology and Laboratory Medicine, The Miriam Hospital, Providence, RI, USA. FAU - Pereira, Jorge AU - Pereira J AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA. AD - Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA. FAU - Kott, Ohad AU - Kott O AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA. AD - Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA. FAU - Mueller-Leonhard, Catrina AU - Mueller-Leonhard C AD - Lifespan Oncology Clinical Research, The Miriam Hospital, Providence, RI, USA. FAU - Mega, Anthony AU - Mega A AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. AD - Department of Hematology/Oncology, The Miriam Hospital, Providence, RI, USA. FAU - Golijanin, Dragan AU - Golijanin D AD - Warren Alpert School of Medicine of Brown University, Providence, RI, USA. AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA. AD - Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA. FAU - Gershman, Boris AU - Gershman B AD - Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20210329 PL - United States TA - Curr Urol JT - Current urology JID - 101471188 PMC - PMC8137085 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Docetaxel OT - Intravesical instillation OT - Nonmuscle invasive bladder cancer COIS- The authors declare that they have no financial conflict of interest with regard to the content of this report. EDAT- 2021/06/05 06:00 MHDA- 2021/06/05 06:01 PMCR- 2021/03/01 CRDT- 2021/06/04 07:02 PHST- 2019/10/07 00:00 [received] PHST- 2019/10/15 00:00 [accepted] PHST- 2021/06/04 07:02 [entrez] PHST- 2021/06/05 06:00 [pubmed] PHST- 2021/06/05 06:01 [medline] PHST- 2021/03/01 00:00 [pmc-release] AID - Curr-Urol-21-0021 [pii] AID - 10.1097/CU9.0000000000000010 [doi] PST - ppublish SO - Curr Urol. 2021 Mar;15(1):33-38. doi: 10.1097/CU9.0000000000000010. Epub 2021 Mar 29. PMID- 34080067 OWN - NLM STAT- MEDLINE DCOM- 20210709 LR - 20260103 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 147 IP - 8 DP - 2021 Aug TI - High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence. PG - 2309-2322 LID - 10.1007/s00432-021-03661-z [doi] AB - PURPOSE: Our study was aimed to understand the importance of LIMD1-VHL-HIF1alpha pathway in development of bladder carcinoma (BlCa) in association with arsenic prevalence. METHODS: At first, the mRNA expression pattern of the genes of this pathway (LIMD1, VHL and HIF1alpha) was checked in GEO datasets and in our samples. Next, genetic and epigenetic profiling of LIMD1 and VHL was done in our sample pool, validated in T24 BlCa cell line. The results were next correlated with various clinico-pathological parameters. RESULTS: Differential under-expression of LIMD1 and VHL genes was found in muscle-invasive BlCa (MIBC) in comparison to non-muscle-invasive BlCa (NMIBC). However, HIF1alpha protein, but mRNA, was found to be overexpressed among the MIBC samples; depicting the probability of HIF1alpha protein stabilization. Analysis of genetic and epigenetic profiles of LIMD1 and VHL exposed a frequent promoter methylation of LIMD1 gene in MIBC samples. Further, in-depth look into the results unveiled that the high nuclear expression of HIF1alpha was significantly correlated with genetic alterations of LIMD1, alone or in combination with VHL. Moreover, treating the T24 cells with a de-methylating agent (5-aza-2'-deoxycytidine) re-expressed the methylated LIMD1 and VHL genes, which in turn, reduced the HIF1alpha protein level significantly. Additionally, patients with high arsenic content (> 112 ng/g, AsH) seemed to have recurrent promoter methylation in LIMD1, as well as co-methylation/alteration of LIMD1 and VHL gene. Lastly, high nuclear expression of HIF1alpha in association with co-alteration of VHL and LIMD1 showed the worst overall survival (OS) among the patients. CONCLUSION: To conclude, MIBC samples portrayed higher alterations in VHL and LIMD1, thereby, stabilizing HIF1alpha protein and lowering the OS of patients. FAU - Basu, Mukta AU - Basu M AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37 S. P. Mukherjee Road, Kolkata, West Bengal, 700026, India. FAU - Chatterjee, Amvrin AU - Chatterjee A AD - Department of Urology, IPGMER, SSKM, 244 A.J.C. Bose Road, Kolkata, 700020, India. FAU - Chakraborty, Balarko AU - Chakraborty B AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37 S. P. Mukherjee Road, Kolkata, West Bengal, 700026, India. FAU - Chatterjee, Essha AU - Chatterjee E AD - National Institute of Pharmaceutical Education and Research, Kukatpally Industrial Estate, Balanagar, Hyderabad, Telangana, 500037, India. FAU - Ghosh, Sabnam AU - Ghosh S AD - Department of Life Science, Presidency University, 86/1, College Street, Kolkata, 700073, India. FAU - Samadder, Sudip AU - Samadder S AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37 S. P. Mukherjee Road, Kolkata, West Bengal, 700026, India. FAU - Pal, Dilip Kumar AU - Pal DK AD - Department of Urology, IPGMER, SSKM, 244 A.J.C. Bose Road, Kolkata, 700020, India. FAU - Roy, Anup AU - Roy A AD - Nil Ratan Sarkar Medical College and Hospital, Kolkata, West Bengal, India. FAU - Chakrabarti, Jayanta AU - Chakrabarti J AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37 S. P. Mukherjee Road, Kolkata, West Bengal, 700026, India. FAU - Ghosh, Amlan AU - Ghosh A AD - Department of Life Science, Presidency University, 86/1, College Street, Kolkata, 700073, India. FAU - Panda, Chinmay Kumar AU - Panda CK AUID- ORCID: 0000-0002-0854-6978 AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37 S. P. Mukherjee Road, Kolkata, West Bengal, 700026, India. ckpanda.cnci@gmail.com. LA - eng GR - Sr. No. 2061430780, Ref No.: 22/06/2014(i)EU-V/University Grants Commission/ GR - 923/ (Sanc.)-BT (Estt.) RD 13/13F/Department of Biotechnology, Government of West Bengal/ PT - Journal Article PT - Retracted Publication DEP - 20210602 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (LIM Domain Proteins) RN - 0 (LIMD1 protein, human) RN - EC 2.3.2.27 (Von Hippel-Lindau Tumor Suppressor Protein) RN - EC 6.3.2.- (VHL protein, human) SB - IM RIN - J Cancer Res Clin Oncol. 2026 Jan 3;152(1):26. doi: 10.1007/s00432-025-06417-1. PMID: 41483015 MH - Adult MH - Aged MH - Aged, 80 and over MH - Arsenic Poisoning/diagnosis/epidemiology MH - Biomarkers, Tumor/genetics/metabolism MH - Carcinoma, Transitional Cell/*diagnosis/epidemiology/genetics/pathology MH - Cell Line, Tumor MH - Cell Nucleus/genetics/metabolism/pathology MH - Comorbidity MH - DNA Methylation MH - Datasets as Topic MH - Female MH - Gene Expression Regulation, Neoplastic MH - Gene Silencing MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism MH - Intracellular Signaling Peptides and Proteins/*genetics/metabolism MH - LIM Domain Proteins/*genetics/metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prevalence MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/genetics/pathology MH - Von Hippel-Lindau Tumor Suppressor Protein/*genetics/metabolism PMC - PMC11801887 OTO - NOTNLM OT - Bladder carcinoma OT - HIF1alpha OT - Kaplan-Meier survival analysis OT - LIMD1 OT - VHL COIS- The authors declare no potential conflict of interest. EDAT- 2021/06/04 06:00 MHDA- 2021/07/10 06:00 PMCR- 2021/06/02 CRDT- 2021/06/03 06:50 PHST- 2020/11/10 00:00 [received] PHST- 2021/05/05 00:00 [accepted] PHST- 2021/06/04 06:00 [pubmed] PHST- 2021/07/10 06:00 [medline] PHST- 2021/06/03 06:50 [entrez] PHST- 2021/06/02 00:00 [pmc-release] AID - 10.1007/s00432-021-03661-z [pii] AID - 3661 [pii] AID - 10.1007/s00432-021-03661-z [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2021 Aug;147(8):2309-2322. doi: 10.1007/s00432-021-03661-z. Epub 2021 Jun 2. PMID- 34075770 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1840-2879 (Electronic) IS - 1840-1848 (Linking) VI - 50 IP - 1 DP - 2021 Apr TI - New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer. PG - 143-156 LID - 10.5644/ama2006-124.332 [doi] AB - This review aims to emphasize new insights into the diagnosis, classification, and therapy of bladder cancer (BC). Bladder cancer is a heterogeneous, complex disease on a morphological, molecular, diagnostic, and prognostic level. Cancer stage is still the most important attribute for prognosis and treatment, while early detection with optimal and rapid individual therapeutic and surveillance approach is crucial. The vast majority of patients have a superficial, non-muscle-invasive tumor associated with a good prognosis after resection and adjuvant intravesical maintenance immuno or chemotherapy if needed. On the other hand, muscle-invasive bladder cancer is a highly aggressive disease with high morbidity and mortality. However, it has become a model for oncology success over the last five years with many available targeted therapeutic modalities. Metastatic BC is now amenable to multimodal treatment combining cystectomy and neoadjuvant chemotherapy and immunotherapy and is a target for precision medicine. CONCLUSION: A new molecular taxonomy for bladder cancer has been proposed and provided insight into BC's carcinogenesis, with some possible effects on therapy decisions. However, this classification is still not applicable in routine clinical practice. It opens new questions regarding the interplay between tumor genetic signature, intratumoral heterogeneity, therapy implications, and tumor progression. CI - Copyright (c) 2021 by Academy of Sciences and Arts of Bosnia and Herzegovina. FAU - Ulamec, Monika AU - Ulamec M AD - Department of Pathology and Cytology "Ljudevit Jurak", University Hospital Center "Sestre milosrdnice", Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb, Croatia. monika.ulamec@gmail.com. FAU - Murgic, Jure AU - Murgic J AD - Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. FAU - Novosel, Luka AU - Novosel L AD - Department of Radiology, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. FAU - Tomic, Miroslav AU - Tomic M AD - Department of Urology, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. FAU - Terlevic, Robert AU - Terlevic R AD - Department of Pathology and Cytology, Pula General Hospital, Pula, Croatia. FAU - Tomaskovic, Igor AU - Tomaskovic I AD - Department of Urology, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia; Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia. FAU - Jazvic, Marijana AU - Jazvic M AD - Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. FAU - Froebe, Ana AU - Froebe A AD - School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia. FAU - Kruslin, Bozo AU - Kruslin B AD - Department of Pathology and Cytology "Ljudevit Jurak", University Hospital Center "Sestre milosrdnice", Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb, Croatia. LA - eng PT - Journal Article PT - Review PL - Bosnia and Herzegovina TA - Acta Med Acad JT - Acta medica academica JID - 101587903 SB - IM MH - Combined Modality Therapy MH - Cystectomy MH - Humans MH - Immunotherapy MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy OTO - NOTNLM OT - Bladder Cancer Genetics OT - Bladder Cancer Pathology OT - Bladder Cancer Therapy EDAT- 2021/06/03 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/06/02 08:47 PHST- 2021/02/11 00:00 [received] PHST- 2021/03/04 00:00 [accepted] PHST- 2021/06/02 08:47 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] AID - ama2006-124.332 [pii] AID - 10.5644/ama2006-124.332 [doi] PST - ppublish SO - Acta Med Acad. 2021 Apr;50(1):143-156. doi: 10.5644/ama2006-124.332. PMID- 34074810 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20230922 IS - 1532-0979 (Electronic) IS - 0147-5185 (Print) IS - 0147-5185 (Linking) VI - 45 IP - 10 DP - 2021 Oct 1 TI - Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. PG - 1399-1408 LID - 10.1097/PAS.0000000000001740 [doi] AB - Large cell neuroendocrine carcinoma (LCNEC) of the urinary tract is a rare disease. We present a relatively large retrospective cohort of urinary LCNEC, 20 from the urinary bladder, and 2 from the ureter, from a single institution. The patients included 16 men and 6 women with a median age of 74.5 years. Most LCNEC presented at an advanced stage with tumors invading the muscularis propria and beyond (21/22). Eight cases were pure LCNEC, while 14 cases were mixed with other histologic types, including conventional urothelial carcinoma (n=9), carcinoma in situ (n=7), small cell carcinoma (n=6), and urothelial carcinoma with glandular (n=3) features. Most LCNEC expressed neuroendocrine markers synaptophysin (22/22), chromogranin (13/16), CD56 (7/7), TTF1 (8/8), and INSM1 (2/3). They were negative for common urothelial markers including HMWCK (0/3), p40/p63 (0/6), CK20 (0/10), and had variable GATA3 staining (4/8). Ki-67 stained 25% to nearly 100% tumor cell nuclei. Patient survival was associated with cancer stage, and pure LCNEC showed worse survival than mixed LCNEC. Compared with small cell carcinoma at similar stages from a prior study, LCNEC had a worse prognosis only when patients developed metastatic disease. For organ-confined LCNEC, neoadjuvant chemotherapy followed by radical resection is the treatment option to achieve long-term survival. CI - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Wang, Gang AU - Wang G AD - Departments of Pathology. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Yuan, Ren AU - Yuan R AD - Radiology. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Zhou, Chen AU - Zhou C AD - Departments of Pathology. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Guo, Charles AU - Guo C AD - Department of Pathology, MD Anderson Cancer Center, Houston, TX. FAU - Villamil, Carlos AU - Villamil C AD - Departments of Pathology. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Hayes, Malcolm AU - Hayes M AD - Departments of Pathology. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Eigl, Bernhard J AU - Eigl BJ AD - Medical Oncology, British Columbia Cancer Vancouver Centre. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Black, Peter AU - Black P AD - Department of Urology, Vancouver General Hospital. AD - Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Carcinoma, Large Cell/chemistry/mortality/*pathology/therapy MH - Carcinoma, Neuroendocrine/chemistry/mortality/*pathology/therapy MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Databases, Factual MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Treatment Outcome MH - Ureteral Neoplasms/chemistry/mortality/*pathology/therapy MH - Urinary Bladder Neoplasms/chemistry/mortality/*pathology/therapy PMC - PMC8428850 COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. EDAT- 2021/06/03 06:00 MHDA- 2021/10/05 06:00 PMCR- 2021/09/09 CRDT- 2021/06/02 05:59 PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2021/06/02 05:59 [entrez] PHST- 2021/09/09 00:00 [pmc-release] AID - 00000478-202110000-00012 [pii] AID - 10.1097/PAS.0000000000001740 [doi] PST - ppublish SO - Am J Surg Pathol. 2021 Oct 1;45(10):1399-1408. doi: 10.1097/PAS.0000000000001740. PMID- 34073436 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210615 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 11 DP - 2021 May 26 TI - Intravesical Bacillus Calmette-Guerin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies. LID - 10.3390/cancers13112615 [doi] LID - 2615 AB - The 2016 World Health Organization classification newly described infiltrating urothelial carcinoma (UC) with divergent differentiation (DD) or variant morphologies (VMs). Data comparing oncological outcomes after bladder-preservation therapy using intravesical Bacillus Calmette-Guerin (BCG) treatment among T1 bladder pure UC (pUC), UC with DD (UC-DD), and UC with VMs (UC-VM) are limited. We evaluated 1490 patients with T1 high-grade bladder UC who received intravesical BCG during 2000-2019. They were classified into three groups: 93.6% with pUC, 4.4% with UC-DD, and 2.0% with UC-VM. Recurrence-free, progression-free, and cancer-specific survival following intravesical BCG were compared among the groups using multivariate Cox regression analysis, also used to estimate inverse probability of treatment weighting-adjusted hazard ratio and 95% confidence interval for the outcomes. Glandular differentiation and micropapillary variant were the most common forms in the UC-DD and UC-VM groups, respectively. Of 1490 patients, 31% and 13% experienced recurrence and progression, respectively, and 5.0% died of bladder cancer. Survival analyses revealed the impact of concomitant VMs was significant for cancer-specific survival, but not recurrence-free and progression-free survival compared with that of pUC. Our analysis clearly demonstrated that concomitant VMs were associated with aggressive behavior in contrast to concomitant DD in patients treated with intravesical BCG. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Fujii, Tomomi AU - Fujii T AUID- ORCID: 0000-0002-7207-4127 AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Nishikawa, Ryoma AU - Nishikawa R AD - Department of Urology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan. FAU - Teraoka, Shogo AU - Teraoka S AD - Department of Urology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan. FAU - Takenaka, Atsushi AU - Takenaka A AD - Department of Urology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan. FAU - Kikuchi, Hiroshi AU - Kikuchi H AUID- ORCID: 0000-0003-4999-8994 AD - Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan. FAU - Okajima, Eijiro AU - Okajima E AD - Department of Urology, Nara City Hospital, Nara 630-8305, Japan. FAU - Shimizu, Takuto AU - Shimizu T AD - Department of Urology, Saiseikai Chuwa Hospital, Nara 633-0054, Japan. FAU - Hori, Shunta AU - Hori S AUID- ORCID: 0000-0001-9514-9964 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. AD - Department of Urology, Saiseikai Chuwa Hospital, Nara 633-0054, Japan. FAU - Tsuchiya, Norihiko AU - Tsuchiya N AD - Department of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Murakami, Yasukiyo AU - Murakami Y AD - Department of Urology, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan. FAU - Taoka, Rikiya AU - Taoka R AUID- ORCID: 0000-0003-3243-499X AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AUID- ORCID: 0000-0003-1069-2816 AD - Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama 633-0054, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Faculty of Medicine, University of Toyama, Toyama 633-0054, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. LA - eng PT - Journal Article DEP - 20210526 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8198171 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - divergent differentiation OT - immunotherapy OT - survival OT - urinary bladder neoplasms OT - variant morphology COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/26 CRDT- 2021/06/02 01:38 PHST- 2021/04/22 00:00 [received] PHST- 2021/05/24 00:00 [revised] PHST- 2021/05/25 00:00 [accepted] PHST- 2021/06/02 01:38 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/26 00:00 [pmc-release] AID - cancers13112615 [pii] AID - cancers-13-02615 [pii] AID - 10.3390/cancers13112615 [doi] PST - epublish SO - Cancers (Basel). 2021 May 26;13(11):2615. doi: 10.3390/cancers13112615. PMID- 34073233 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210627 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 11 IP - 6 DP - 2021 May 26 TI - KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. LID - 10.3390/jpm11060473 [doi] LID - 473 AB - Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival, especially those with pathological complete response (pCR). The response to NAC according to molecular subtypes has been discussed. Molecular targets such as estrogen receptor (ESR1) and human epidermal growth factor receptor 2 (ERBB2) play an important role in breast cancer management and have also been associated with urothelial bladder cancer. Hence, the association of Keratin 20 (KRT20) Keratin 5 (KRT5), ESR1, and ERBB2 mRNA expression in MIBC at transurethral resection (TUR-BT) with pCR after NAC was analyzed retrospectively. Formalin-fixed paraffin-embedded tumour tissue samples from TUR-BT of 54 patients (42 males, 12 females, median age of 64) with MIBC were analyzed for KRT20, KRT5, ESR1, and ERBB2 mRNA expression. After NAC, RC was performed, and the specimens were evaluated for pCR. Statistical analyses comprised nonparametric and chi(2) testing, partition models, and Spearman correlation analyses. After NAC, 22 out of 54 patients (40.7%) had pCR. Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009). Elevated ERBB2 expression was positively correlated with luminal expression features such as KRT20, and negatively with basal characteristics such as KRT5. Patients with MIBC showing a high expression of ERBB2, ESR1, or KRT20 have a significantly higher chance of pCR following NAC. These findings might improve patient selection for NAC in MIBC. FAU - Jutte, Hendrik AU - Jutte H AD - Institute of Pathology, Ruhr-University Bochum, 44789 Bochum, Germany. FAU - Reike, Moritz AU - Reike M AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - Stratifyer Molecular Pathology GmbH, 50935 Cologne, Germany. FAU - Kriegmair, Maximilian AU - Kriegmair M AD - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Tully, Karl AU - Tully K AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Eidt, Sebastian AU - Eidt S AUID- ORCID: 0000-0003-0891-1936 AD - Institute of Pathology, St. Elisabeth Hospital, 50935 Cologne, Germany. FAU - Wezel, Felix AU - Wezel F AUID- ORCID: 0000-0003-0675-181X AD - Department of Urology, University Hospital Ulm, University of Ulm, 89081 Ulm, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, University Hospital Ulm, University of Ulm, 89081 Ulm, Germany. FAU - Tannapfel, Andrea AU - Tannapfel A AD - Institute of Pathology, Ruhr-University Bochum, 44789 Bochum, Germany. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany. LA - eng PT - Journal Article DEP - 20210526 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC8229873 OTO - NOTNLM OT - bladder cancer OT - chemotherapy OT - muscle invasive OT - risk stratification OT - subtype COIS- H.J. reports personal fees from Roche, personal fees from AstraZeneca, personal fees from Bristol Myers Squibb, personal fees from Merck Sharp Dohme, personal fees from Ipsen, personal fees from AMGEN, outside the submitted work. M.R. has nothing to disclose. R.M.W. reports grants from Janssen, during the conduct of the study; other from Stratifyer, outside the submitted work. M.K. has nothing to disclose. P.E. reports grants from Janssen, during the conduct of the study. K.T. has nothing to disclose. V.W. has nothing to disclose. M.E. reports grants and personal fees from AstraZeneca, personal fees from Roche, personal fees from Astellas, personal fees from Cepheid, personal fees from GenomicHealth, personal fees from Diaceutics, grants and personal fees from Stratifyer, during the conduct of the study. A.H. reports grants and personal fees from Janssen, grants and personal fees from AstraZeneca, grants and personal fees from Nanostring, grants and personal fees from Cepheid, grants and personal fees from Roche, grants from BioNTech, from Illumina, personal fees from BMS, personal fees from MSD, personal fees from Qiagen, personal fees from Ipsen, personal fees from Abbvie, personal fees from Diaceutics, personal fees from Boehringer Ingelheim, personal fees from 3D Histech, during the conduct of the study. S.E. has nothing to disclose. C.B. reports personal fees from Janssen-Cilag, personal fees from AstraZeneca, personal fees from Medac, personal fees from Takeda, personal fees from Roche, during the conduct of the study. A.T. has nothing to disclose. J.N. has nothing to disclose. F.R. reports grants and personal fees from Janssen, personal fees from Pfizer, personal fees from Roche, personal fees from Merck, during the conduct of the study. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/26 CRDT- 2021/06/02 01:37 PHST- 2021/03/30 00:00 [received] PHST- 2021/05/17 00:00 [revised] PHST- 2021/05/18 00:00 [accepted] PHST- 2021/06/02 01:37 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/26 00:00 [pmc-release] AID - jpm11060473 [pii] AID - jpm-11-00473 [pii] AID - 10.3390/jpm11060473 [doi] PST - epublish SO - J Pers Med. 2021 May 26;11(6):473. doi: 10.3390/jpm11060473. PMID- 34065365 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210605 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 10 DP - 2021 May 20 TI - Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. LID - 10.3390/cancers13102496 [doi] LID - 2496 AB - To evaluate oncological outcomes of primary versus secondary muscle-invasive bladder cancer treated with radical cystectomy. Medline, Embase, Scopus and Cochrane Library were searched for eligible studies. Hazard ratios for overall survival (OS), cancer specific survival (CSS) and progression free survival (PFS) were calculated using survival data extracted from Kaplan-Meier curves. A total of 16 studies with 5270 patients were included. Pooled analysis showed similar 5-year and 10-year OS (HR 1, p = 0.96 and HR 1, p = 0.14) and CSS (HR 1.02, p = 0.85 and HR 0.99, p = 0.93) between primMIBC and secMIBC. Subgroup analyses according to starting point of follow-up and second-look transurethral resection revealed similar results. Subgroup analyses of studies in which neoadjuvant chemotherapy was administered demonstrated significantly worse 5-year CSS (HR 1.5, p = 0.04) but not 10-year CSS (HR 1.36, p = 0.13) in patients with secMIBC. Patients with secMIBC had significantly worse PFS at 5-year (HR 1.41, p = 0.002) but not at 10-year follow-up (HR 1.25, p = 0.34). This review found comparable oncologic outcomes between primMIBC and secMIBC patients treated with RC regarding OS and CSS. Subgroup analysis showed worse 5-year CSS but not 10-year CSS for neoadjuvant chemotherapy in the secMIBC group. Prospective clinical trials incorporating molecular markers, that allow precise risk stratification of secMIBC and further research uncovering underlying molecular and clinical drivers of the heterogeneous group of secMIBC is needed. FAU - Pones, Mario AU - Pones M AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo 3-25-8, Japan. FAU - Abufraj, Mohammad AU - Abufraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, University of Jordan, Amman 11942, Jordan. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, 6000 Luzern, Switzerland. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AUID- ORCID: 0000-0002-6627-6179 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria. AD - Comprehensive Cancer Center, Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Institute of Urology and Reproductive Health, Imperial Moscow Sechenov First Moscow State Medical University, 119992 Moscow, Russia. AD - Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX 5323, USA. AD - Karl Landsteiner Institute of Urology and Andrology, 1090 Vienna, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic. AD - European Association of Urology Research Foundation, 6803 Arnhem, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20210520 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8160701 OTO - NOTNLM OT - CSS OT - OS OT - PFS OT - neoadjuvant chemotherapy OT - outcome OT - primary MIBC OT - secondary MIBC COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/20 CRDT- 2021/06/02 01:12 PHST- 2021/04/07 00:00 [received] PHST- 2021/04/30 00:00 [revised] PHST- 2021/05/13 00:00 [accepted] PHST- 2021/06/02 01:12 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/20 00:00 [pmc-release] AID - cancers13102496 [pii] AID - cancers-13-02496 [pii] AID - 10.3390/cancers13102496 [doi] PST - epublish SO - Cancers (Basel). 2021 May 20;13(10):2496. doi: 10.3390/cancers13102496. PMID- 34063088 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231101 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 9 DP - 2021 May 5 TI - Nanotechnology in Bladder Cancer: Diagnosis and Treatment. LID - 10.3390/cancers13092214 [doi] LID - 2214 AB - Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumor cells mostly cause tumor recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumor therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In order to reduce this challenge, anti-cancer drugs can be loaded into NPs that can improve water solubility. In our review, we state several nanosystem, which can effective and useful for the diagnosis, treatment of BC. We investigate the function of metal NPs, polymeric NPs, liposomes, and exosomes accompanied therapeutic agents for BC Therapy, and then focused on the potential of nanotechnology to improve conventional approaches in sensing. FAU - Barani, Mahmood AU - Barani M AUID- ORCID: 0000-0002-1711-2522 AD - Department of Chemistry, Shahid Bahonar University of Kerman, Kerman 76169-14111, Iran. FAU - Hosseinikhah, Seyedeh Maryam AU - Hosseinikhah SM AUID- ORCID: 0000-0001-9565-3730 AD - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 91886-17871, Iran. FAU - Rahdar, Abbas AU - Rahdar A AUID- ORCID: 0000-0003-4766-9214 AD - Department of Physics, Faculty of Science, University of Zabol, Zabol 98613-35856, Iran. FAU - Farhoudi, Leila AU - Farhoudi L AD - Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 91886-17871, Iran. FAU - Arshad, Rabia AU - Arshad R AUID- ORCID: 0000-0001-7654-3456 AD - Department of Pharmacy, Quaid-I-Azam University, Islamabad 45320, Pakistan. FAU - Cucchiarini, Magali AU - Cucchiarini M AUID- ORCID: 0000-0003-0323-8922 AD - Center of Experimental Orthopaedics, Saarland University Medical Center, 66421 Homburg/Saar, Germany. FAU - Pandey, Sadanand AU - Pandey S AUID- ORCID: 0000-0003-2065-897X AD - Department of Chemistry, College of Natural Science, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Korea. AD - Particulate Matter Research Center, Research Institute of Industrial Science & Technology (RIST), 187-12, Geumho-ro, Gwangyang-si 57801, Korea. LA - eng PT - Journal Article PT - Review DEP - 20210505 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8125468 OTO - NOTNLM OT - bladder cancer OT - diagnosis OT - nanoparticles OT - therapy COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/05 CRDT- 2021/06/02 01:05 PHST- 2021/03/31 00:00 [received] PHST- 2021/04/29 00:00 [revised] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/06/02 01:05 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/05 00:00 [pmc-release] AID - cancers13092214 [pii] AID - cancers-13-02214 [pii] AID - 10.3390/cancers13092214 [doi] PST - epublish SO - Cancers (Basel). 2021 May 5;13(9):2214. doi: 10.3390/cancers13092214. PMID- 34060373 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20220423 IS - 1526-2359 (Electronic) IS - 1073-2748 (Print) IS - 1073-2748 (Linking) VI - 28 DP - 2021 Jan-Dec TI - Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer. PG - 10732748211021078 LID - 10.1177/10732748211021078 [doi] LID - 10732748211021078 AB - OBJECTIVE: We investigated the clinical value of the Controlling Nutritional Status score in evaluating the prognosis of patients with non-muscle invasive bladder cancer. METHODS: We conducted a retrospective analysis of the clinical data of 88 patients with non-muscle invasive bladder cancer who underwent transurethral resection of bladder tumor or partial cystectomy between January 2011 and May 2015 in a single center. The patients were divided into groups base on high (>1) and low (18 mo. A multivariable Cox regression model confirmed that patients with a history of multiple TURs (hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.01-2.51) and those with more than one lesion at AS entry (HR 1.63, 95% CI 1.05-2.54) were significantly more likely to experience AS failure. Our results confirm that well-selected patients with NMIBC can safely remain on AS for a long period of time. Multiple TURs and multiple lesions at AS enrollment are associated with a higher risk of AS failure. PATIENT SUMMARY: Active surveillance has been proposed as an alternative to surgery for patients with recurrent low-risk superficial bladder cancer. Our report confirms that well-selected patients can safely avoid or postpone surgery. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Contieri, Roberto AU - Contieri R AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Buffi, Nicolo M AU - Buffi NM AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Frego, Nicola AU - Frego N AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Diana, Pietro AU - Diana P AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: massimo.lazzeri@humanitas.it. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. LA - eng PT - Journal Article DEP - 20210528 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Recurrence, Local/epidemiology MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy MH - Watchful Waiting OTO - NOTNLM OT - Active surveillance OT - Follow-up OT - Non-muscle-invasive bladder cancer OT - Outcome OT - Predictors of failure EDAT- 2021/06/02 06:00 MHDA- 2022/05/14 06:00 CRDT- 2021/06/01 05:57 PHST- 2021/03/06 00:00 [received] PHST- 2021/04/12 00:00 [revised] PHST- 2021/05/12 00:00 [accepted] PHST- 2021/06/02 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2021/06/01 05:57 [entrez] AID - S2588-9311(21)00108-5 [pii] AID - 10.1016/j.euo.2021.05.002 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Apr;5(2):251-255. doi: 10.1016/j.euo.2021.05.002. Epub 2021 May 28. PMID- 34059435 OWN - NLM STAT- MEDLINE DCOM- 20220209 LR - 20220209 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 12 DP - 2021 Dec TI - The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer. PG - 833.e9-833.e17 LID - S1078-1439(21)00183-6 [pii] LID - 10.1016/j.urolonc.2021.04.027 [doi] AB - BACKGROUND: Accurate Lymph node (LN) staging before radical cystectomy (RC) in patients with bladder cancer (BC) is crucial to improve patient's management. 18F-fluorodeoxyglucose positron-emission tomography-computed tomography (FDG-PET-CT) become widely used in the loco-regional staging of BC. The diagnostic performance of PET-CT in preoperative LN staging of BC is still unknown due to lacking large trials. OBJECTIVES: We aim to evaluate the diagnostic value of PET-CT scan, compared with CT scan alone for preoperative LN staging of BC. PATIENTS AND METHODS: From January 2010 to November 2020, we retrospectively reviewed the records of 300 patients undergoing RC for muscle-invasive BC and high-risk non-muscle-invasive BC. All patients had PET-CT and CT of abdomen and pelvis to assess for pelvic LN metastases before RC. Patients were excluded from analysis if they had neoadjuvant chemotherapy (NAC). Sensitivity, specificity, and accuracy for detecting pelvic LN metastases were determined by comparing the results of the FDG PET-CT and CT alone to the final histopathology reports obtained after RC. RESULTS: LN metastasis was confirmed histology in 134 patients (44.7%). On a patient-based analysis, PET-CT, and CT showed a sensitivity of 40.3% and 13.4 %, respectively, a specificity of 79.5% and 86.7 %, respectively, positive predictive value (PPV) of 61.4% and 45%, respectively, and negative predictive value (NPV) of 62.3% and 55.4%, respectively. The diagnostic accuracy of PET-CT scan depends on multiple preoperative and postoperative factors. CONCLUSION: PET-CT is more accurate than CT-scan alone for preoperative LN staging in patients with BC. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Moussa, Mohamad AU - Moussa M AD - Chairman of Urology department, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon. FAU - Chakra, Mohamad Abou AU - Chakra MA AD - Urology Department, Lebanese University, Faculty of Medicine, Beirut, Lebanon. Electronic address: mohamedabouchakra@hotmail.com. FAU - Saad, Wajih AU - Saad W AD - Head of Oncology department, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon. FAU - Dellis, Athanasios AU - Dellis A AD - Department of Urology/General Surgery, Areteion Hospital, Athens, Greece. FAU - Papatsoris, Athanasios AU - Papatsoris A AD - 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece. LA - eng PT - Journal Article DEP - 20210529 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Cystectomy/*methods MH - Female MH - Fluorodeoxyglucose F18/*metabolism MH - Humans MH - Lymph Nodes/pathology MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Positron Emission Tomography Computed Tomography/*methods MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnostic imaging/*surgery OTO - NOTNLM OT - 18F-fluorodeoxyglucose positron emission tomography-computed tomography OT - Bladder cancer OT - Computed tomography OT - Pelvic lymph node OT - Radical cystectomy EDAT- 2021/06/02 06:00 MHDA- 2022/02/10 06:00 CRDT- 2021/06/01 05:55 PHST- 2021/02/01 00:00 [received] PHST- 2021/04/09 00:00 [revised] PHST- 2021/04/17 00:00 [accepted] PHST- 2021/06/02 06:00 [pubmed] PHST- 2022/02/10 06:00 [medline] PHST- 2021/06/01 05:55 [entrez] AID - S1078-1439(21)00183-6 [pii] AID - 10.1016/j.urolonc.2021.04.027 [doi] PST - ppublish SO - Urol Oncol. 2021 Dec;39(12):833.e9-833.e17. doi: 10.1016/j.urolonc.2021.04.027. Epub 2021 May 29. PMID- 34055868 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240810 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 8 DP - 2021 TI - Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study. PG - 659292 LID - 10.3389/fsurg.2021.659292 [doi] LID - 659292 AB - Purpose: Guidelines advocate cystoscopy surveillance (CS) for non-muscle invasive bladder cancer (NMIBC) post-resection. However, cystoscopy is operator dependent and may miss upper tract lesions or carcinoma in-situ (CIS). Urine cytology is a common adjunct but lacks sensitivity and specificity in detecting recurrence. A new mRNA biomarker (CxBladder) was compared with urine cytology as an adjunct to cystoscopy in detecting a positive cystoscopy findings during surveillance cystoscopy in our center. Materials and Methods: Consented patients older than 18, undergoing CS for NMIBC, provide paired urine samples for cytology and CxBladder test. Patients with positive cystoscopy findings would undergo re-Trans Urethral Resection of Bladder Tumor (TURBT). Results: Thirty-five patients were enrolled from April to June 2019. Seven contaminated urine samples were excluded. The remaining cohort of 23 (82%) and 5 (18%) females had a mean age of 66.69 (36-89). Eight (29%) patients with positive cystoscopy finding underwent TURBT. All 8 patients also had positive CxBladder result. This shows that CxBladder has a sensitivity and negative predictive value (NPV) of 100%, specificity of 75% and positive predictive value (PPV) of 62% in predicting a positive cystoscopy finding. TURBT Histo-pathological findings showed Low-grade Ta NMIBC in one patient (4%), and 7 (25%) patients had inflammatory changes. Urine cytology was only positive in one patient with a positive cystoscopy finding. This led to a sensitivity of merely 13% and NPV of 74%, while specificity and PPV was 100% in predicting a positive cystoscopy finding. Conclusion: CxBladder had high NPV and sensitivity which accurately predicted suspicious cystoscopy findings leading to further investigation. It has great potential for use as adjunct to cystoscopy for surveillance of NMIBC. CI - Copyright (c) 2021 Chai, Yeoh, Rajandram, Aung, Ong, Kuppusamy, Nazran, Kumaran, Razack and Teoh. FAU - Chai, C A AU - Chai CA AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Yeoh, W S AU - Yeoh WS AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Rajandram, R AU - Rajandram R AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Aung, K P AU - Aung KP AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Ong, T A AU - Ong TA AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Kuppusamy, S AU - Kuppusamy S AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Nazran, A AU - Nazran A AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Kumaran, K AU - Kumaran K AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Razack, A H A AU - Razack AHA AD - Urology Division, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Teoh, J Y AU - Teoh JY AD - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. LA - eng PT - Journal Article DEP - 20210513 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC8155709 OTO - NOTNLM OT - CxBladder OT - bladder cancer OT - cystoscopy OT - non-muscle invasive bladder cancer OT - urine cytology COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/01 06:00 MHDA- 2021/06/01 06:01 PMCR- 2021/05/13 CRDT- 2021/05/31 06:18 PHST- 2021/01/27 00:00 [received] PHST- 2021/04/07 00:00 [accepted] PHST- 2021/05/31 06:18 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/01 06:01 [medline] PHST- 2021/05/13 00:00 [pmc-release] AID - 10.3389/fsurg.2021.659292 [doi] PST - epublish SO - Front Surg. 2021 May 13;8:659292. doi: 10.3389/fsurg.2021.659292. eCollection 2021. PMID- 34055600 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer. PG - 619893 LID - 10.3389/fonc.2021.619893 [doi] LID - 619893 AB - BACKGROUND: The treatment and prognosis for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC) are different. We aimed to construct a nomogram based on the multiparametric MRI (mpMRI) radiomics signature and the Vesical Imaging-Reporting and Data System (VI-RADS) score for the preoperative differentiation of MIBC from NMIBC. METHOD: The retrospective study involved 185 pathologically confirmed bladder cancer (BCa) patients (training set: 129 patients, validation set: 56 patients) who received mpMRI before surgery between August 2014 to April 2020. A total of 2,436 radiomics features were quantitatively extracted from the largest lesion located on the axial T2WI and from dynamic contrast-enhancement images. The minimum redundancy maximum relevance (mRMR) algorithm was used for feature screening. The selected features were introduced to construct radiomics signatures using three classifiers, including least absolute shrinkage and selection operator (LASSO), support vector machines (SVM) and random forest (RF) in the training set. The differentiation performances of the three classifiers were evaluated using the area under the curve (AUC) and accuracy. Univariable and multivariable logistic regression were used to develop a nomogram based on the optimal radiomics signature and clinical characteristics. The performance of the radiomics signatures and the nomogram was assessed and validated in the validation set. RESULTS: Compared to the RF and SVM classifiers, the LASSO classifier had the best capacity for muscle invasive status differentiation in both the training (accuracy: 90.7%, AUC: 0.934) and validation sets (accuracy: 87.5%, AUC: 0.906). Incorporating the radiomics signature and VI-RADS score, the nomogram demonstrated better discrimination and calibration both in the training set (accuracy: 93.0%, AUC: 0.970) and validation set (accuracy: 89.3%, AUC: 0.943). Decision curve analysis showed the clinical usefulness of the nomogram. CONCLUSIONS: The mpMRI radiomics signature may be useful for the preoperative differentiation of muscle-invasive status in BCa. The proposed nomogram integrating the radiomics signature with the VI-RADS score may further increase the differentiation power and improve clinical decision making. CI - Copyright (c) 2021 Zheng, Xu, Gu, Yan, Xu, Liu and Yao. FAU - Zheng, Zongtai AU - Zheng Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Xu, Feijia AU - Xu F AD - Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Gu, Zhuoran AU - Gu Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Yan, Yang AU - Yan Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Xu, Tianyuan AU - Xu T AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, Shenghua AU - Liu S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20210513 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8155615 OTO - NOTNLM OT - Vesical Imaging-Reporting and Data System OT - bladder cancer OT - multiparametric magnetic resonance imaging OT - muscle-invasive status OT - nomogram OT - radiomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/01 06:00 MHDA- 2021/06/01 06:01 PMCR- 2021/01/01 CRDT- 2021/05/31 06:17 PHST- 2020/10/21 00:00 [received] PHST- 2021/04/26 00:00 [accepted] PHST- 2021/05/31 06:17 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/01 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.619893 [doi] PST - epublish SO - Front Oncol. 2021 May 13;11:619893. doi: 10.3389/fonc.2021.619893. eCollection 2021. PMID- 34055072 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210601 IS - 1792-0981 (Print) IS - 1792-1015 (Electronic) IS - 1792-0981 (Linking) VI - 22 IP - 1 DP - 2021 Jul TI - Tumoral markers in bladder cancer (Review). PG - 773 LID - 10.3892/etm.2021.10205 [doi] LID - 773 AB - Bladder tumors are frequently diagnosed urologic malignant diseases with an extremely high recurrence rate compared to other neoplastic tumors. Urothelial bladder carcinomas are mostly identified in their incipient form, as non-muscle invasive, but despite that, a third of them develop into aggressive recurrent disease. The diagnosis of bladder carcinoma at this moment is established using cytology and cystoscopy and is a great challenge for clinicians due to the lack of sensitivity. Urinary biomarkers could improve and enhance the diagnosis and screening techniques and determine a more accurate recurrence rate. However, bladder cancer is a heterogeneous disease and the existence of a single marker test with reduced cost is unlikely; thus, until then, the use of a panel of markers to obtain valuable information is inevitable even though suboptimal for use. To improve this deadlock, new biomarker panels should be identified and prepared to equalize the cost-efficiency balance. The present paper is a literature review concerning the most commonly used tumor markers in urinary bladder cancer as well as the most commonly encountered genetic modifications in such patients. CI - Copyright (c) 2020, Spandidos Publications. FAU - Bratu, Ovidiu AU - Bratu O AD - Department of Urology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. AD - Department of Urology, Academy of Romanian Scientists, 020021 Bucharest, Romania. FAU - Marcu, Dragos AU - Marcu D AD - Department of Urology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. FAU - Anghel, Radu AU - Anghel R AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. FAU - Spinu, Dan AU - Spinu D AD - Department of Urology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. FAU - Iorga, Lucian AU - Iorga L AD - Department of Urology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. FAU - Balescu, Irina AU - Balescu I AD - Department of Visceral Surgery, 'Ponderas' Academic Hospital, 021188 Bucharest, Romania. FAU - Bacalbasa, Nicolae AU - Bacalbasa N AD - Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, 023991 Bucharest, Romania. AD - Department of Visceral Surgery, Center of Excellence in Translational Medicine, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania. AD - Department of Obstetrics and Gynecology, 'I. Cantacuzino' Clinical Hospital, 030167 Bucharest, Romania. FAU - Diaconu, Camelia AU - Diaconu C AD - Department of Internal Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania. FAU - Savu, Cornel AU - Savu C AD - Department of Thoracic Surgery, 'Marius Nasta' National Institute of Pneumophtisiology, 050159 Bucharest, Romania. AD - Department of Thoracic Surgery, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Savu, Carmen AU - Savu C AD - Department of Anesthesiology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania. FAU - Cherciu, Alexandru AU - Cherciu A AD - Department of Urology, University Emergency Central Military Hospital, 010825 Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20210518 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC8145526 OTO - NOTNLM OT - cystoscopy OT - cytology OT - non-muscle invasive OT - urinary biomarkers OT - urothelial bladder carcinoma COIS- There are no competing interests to declare regarding this study. EDAT- 2021/06/01 06:00 MHDA- 2021/06/01 06:01 PMCR- 2021/05/18 CRDT- 2021/05/31 06:10 PHST- 2021/02/10 00:00 [received] PHST- 2021/03/12 00:00 [accepted] PHST- 2021/05/31 06:10 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/01 06:01 [medline] PHST- 2021/05/18 00:00 [pmc-release] AID - ETM-0-0-10205 [pii] AID - 10.3892/etm.2021.10205 [doi] PST - ppublish SO - Exp Ther Med. 2021 Jul;22(1):773. doi: 10.3892/etm.2021.10205. Epub 2021 May 18. PMID- 34048174 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20260127 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 22 IP - 5 DP - 2021 May 1 TI - Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin. PG - 1459-1466 LID - 89595 [pii] LID - 10.31557/APJCP.2021.22.5.1459 [doi] AB - OBJECTIVE: Immediate single instillation of chemotherapy following transurethral resection of bladder tumor (TURBT) is suggested for non-muscle invasive bladder cancer (NMIBC) patients. However, no study has evaluated molecular marker that was involved in intravesical recurrence (IVR) after single instillation of chemotherapy. Therefore, this study aimed to evaluate whether P-glycoprotein, multidrug resistance protein 1 (MRP1), Annexin A2 (ANXA2) or nucleophosmin (NPM) expression predicts IVR after initial TURBT and immediate single intravesical adriamycin instillation. METHODS: We retrospectively reviewed consecutive 443 patients who underwent TURBT. Of these, 54 patients who underwent initial TURBT and single instillation of adriamycin for NMIBC were included. The expressions of P-glycoprotein, MRP1, ANXA2 and NPM were evaluated immunohistochemically and were divided into 2 groups (low or high) according to the staining intensity and/or proportion of positive cells. IVR was assessed by Kaplan-Meier method. Cox;s multivaritate analyses were performed to identify independent predictors for IVR. RESULTS: Nineteen patients (35.1%) had IVR. High P-glycoprotein expression was significantly correlated with multiplicity, pT stage and high grade. High ANXA2 expression was significantly correlated with high grade. MRP1 and NPM were not correlated with any clinicopathological variables. MRP1 expression and ANXA2 expression were significantly correlated with P-glycoprotein expression. Patients with high P-glycoprotein expression had significantly worse IVR-free survival (IVRFS) than those with low P-glycoprotein expression (P =0.015). The difference in IVRFS rates between patients with high ANXA2 expression and those with low ANXA2 expression was nearly significant (P =0.057). Univariate analyses indicated multiplicity, high grade and high P-glycoprotein expression were significant predictors for IVR. Multivariate analysis indicated high grade was an independent predictor for IVR. CONCLUSIONS: High P-glycoprotein expression was associated with IVR. Further study was needed to determine significance of P-glycoprotein expression in IVR after single intravesical adriamycin instillation. FAU - Sawazaki, Harutake AU - Sawazaki H AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. FAU - Ito, Keiichi AU - Ito K AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. FAU - Asano, Takako AU - Asano T AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. FAU - Kuroda, Kenji AU - Kuroda K AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. FAU - Horiguchi, Akio AU - Horiguchi A AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. FAU - Tsuda, Hitoshi AU - Tsuda H AD - Department of Basic Pathology, National Defense Medical College Tokorozawa, Japan. FAU - Asano, Tomohiko AU - Asano T AD - Department of Urology, National Defense Medical College Tokorozawa, Japan. LA - eng PT - Journal Article DEP - 20210501 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (ATP Binding Cassette Transporter, Subfamily B) RN - 0 (Annexin A2) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Biomarkers, Tumor) RN - 80168379AG (Doxorubicin) RN - 0 (ATP-Binding Cassette, Sub-Family C Proteins) RN - 0 (Nuclear Proteins) RN - 117896-08-9 (Nucleophosmin) RN - 0 (ABCB1 protein, human) RN - 0 (ANXA2 protein, human) RN - 0 (NPM1 protein, human) RN - Y49M64GZ4Q (multidrug resistance-associated protein 1) SB - IM MH - ATP Binding Cassette Transporter, Subfamily B/metabolism MH - Aged MH - Annexin A2/*metabolism MH - Antibiotics, Antineoplastic/administration & dosage MH - Biomarkers, Tumor/metabolism MH - Combined Modality Therapy MH - Cystectomy/*mortality MH - Doxorubicin/*administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - ATP-Binding Cassette, Sub-Family C Proteins/*metabolism MH - Neoplasm Recurrence, Local/metabolism/*pathology/therapy MH - Nuclear Proteins/metabolism MH - Nucleophosmin MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/metabolism/*pathology/therapy PMC - PMC8408374 OTO - NOTNLM OT - adriamycin OT - bladder cancer OT - intravesical recurrence OT - p-glycoprotein COIS- All the authors declare they have no conflict of interest. EDAT- 2021/05/29 06:00 MHDA- 2021/11/26 06:00 PMCR- 2021/07/01 CRDT- 2021/05/28 13:26 PHST- 2021/01/25 00:00 [received] PHST- 2021/05/28 13:26 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - 89595 [pii] AID - 10.31557/APJCP.2021.22.5.1459 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2021 May 1;22(5):1459-1466. doi: 10.31557/APJCP.2021.22.5.1459. PMID- 34046347 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231111 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. PG - 651745 LID - 10.3389/fonc.2021.651745 [doi] LID - 651745 AB - BACKGROUND: Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes. METHODS: Patients with histologically confirmed muscle-invasive UBC included in this retrospective study had to be treated with either 3 (cohort A) or 4 (cohort B) cycles of cisplatin-gemcitabine as neoadjuvant therapy before undergoing radical cystectomy with lymphadenectomy. Outcomes including pathologic downstaging to non-muscle invasive disease, pathologic complete response (defined as absence of disease -ypT0), overall- and cancer-specific- survival as well as time to recurrence were compared between cohorts A vs. B. RESULTS: A total of 219 patients treated at 14 different high-volume Institutions were included in this retrospective study. Patients who received 3 (cohort A) vs. 4 (cohort B) cycles of neoadjuvant cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%).At univariate analysis, the number of neoadjuvant cycles was not associated with either pathologic complete response, pathologic downstaging, time to recurrence, cancer specific, and overall survival. Of note, patients in cohort B vs. A showed a worse non-cancer specific overall survival at univariate analysis (HR= 2.53; 95 CI= 1.05 - 6.10; p=0.046), although this finding was not confirmed at multivariate analysis. CONCLUSIONS: Our findings suggest that 3 cycles of cisplatin-gemcitabine may be equally effective, with less long-term toxicity, compared to 4 cycles in the neoadjuvant setting. CI - Copyright (c) 2021 Ferro, de Cobelli, Musi, Lucarelli, Terracciano, Pacella, Muto, Porreca, Busetto, Del Giudice, Soria, Gontero, Cantiello, Damiano, Crocerossa, Farhan, Autorino, Vartolomei, Muto, Marchioni, Mari, Scafuri, Minervini, Longo, Chiancone, Perdona, De Placido, Verde, Catellani, Luzzago, Mistretta, Ditonno, Caputo, Battaglia, Zamboni, Antonelli, Greco, Russo, Hurle, Crisan, Manfredi, Porpiglia, Di Lorenzo, Crocetto and Buonerba. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. AD - Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, School of Medicine, University of Bari Aldo Moro, Bari, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Pacella, Daniela AU - Pacella D AD - Department of Public Health, University of Naples Federico II, Naples, Italy. FAU - Muto, Tommaso AU - Muto T AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Oncological Urology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology and Renal Transplantation, University of Foggia Policlinico Riuniti of Foggia, Foggia, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza, Torino School of Medicine, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza, Torino School of Medicine, Turin, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, University of Catanzaro, UNIVERSITA "MAGNA GRAECIA" di Catanzaro, Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, University of Catanzaro, UNIVERSITA "MAGNA GRAECIA" di Catanzaro, Catanzaro, Italy. FAU - Crocerossa, Fabio AU - Crocerossa F AD - Department of Urology, University of Catanzaro, UNIVERSITA "MAGNA GRAECIA" di Catanzaro, Catanzaro, Italy. FAU - Farhan, Abdal Rahman Abu AU - Farhan ARA AD - Department of Urology, University of Catanzaro, UNIVERSITA "MAGNA GRAECIA" di Catanzaro, Catanzaro, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University Health System, Richmond, VA, United States. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Department of Urology, Vienna General Hospital, Vienna, Austria. AD - Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Tirgu Mures, Romania. FAU - Muto, Matteo AU - Muto M AD - Department of Hematology, Oncology and Radiotherapy Azienda ospedaliera San Giuseppe Moscati, Avellino, Avelino, Italy. FAU - Marchioni, Michele AU - Marchioni M AD - Department of Urology, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy. FAU - Scafuri, Luca AU - Scafuri L AD - Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy. FAU - Longo, Nicola AU - Longo N AD - Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy. FAU - Chiancone, Francesco AU - Chiancone F AD - Division of Urology, Hospital Antonio Cardarelli, Naples, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Division of Urology, Istituto Nazionale Tumori Fondazione G. Pascale (IRCCS), Naples, Italy. FAU - De Placido, Pietro AU - De Placido P AD - Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Verde, Antonio AU - Verde A AD - Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Catellani, Michele AU - Catellani M AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy. FAU - Ditonno, Pasquale AU - Ditonno P AD - Department of Emergency and Organ Transplantation, School of Medicine, University of Bari Aldo Moro, Bari, Italy. FAU - Caputo, Vincenzo Francesco AU - Caputo VF AD - Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, School of Medicine, University of Bari Aldo Moro, Bari, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology, Civil Hospital of Brescia, Brescia, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, Civil Hospital of Brescia, Brescia, Italy. AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona - Polo Chirurgico Confortini - Borgo Trento, Verona, Italy. FAU - Greco, Francesco AU - Greco F AD - Department of Urology, Humanitas Gavazzeni, IRRCS, Bergamo, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, Iuliu Hatieganu University of Medicine and Pharmacy, Ciuj Napoca, Romania. FAU - Manfredi, Matteo AU - Manfredi M AD - Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy. FAU - Di Lorenzo, Giuseppe AU - Di Lorenzo G AD - Department of Urology, Humanitas Research Hospital Milano, Milan, Italy. AD - Department of Medicine and Health Science, University of Molise, Campobasso, Italy. FAU - Crocetto, Felice AU - Crocetto F AD - Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy. FAU - Buonerba, Carlo AU - Buonerba C AD - Rare Tumor Reference Center, Federico II University Hospital, Naples, Italy. AD - Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy. LA - eng PT - Journal Article DEP - 20210511 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8144638 OTO - NOTNLM OT - bladder cancer OT - cisplatin-based chemotherapy OT - neoadjuvant chemotherapy OT - observational study OT - radical cystectomy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/29 06:00 MHDA- 2021/05/29 06:01 PMCR- 2021/01/01 CRDT- 2021/05/28 07:28 PHST- 2021/01/10 00:00 [received] PHST- 2021/03/02 00:00 [accepted] PHST- 2021/05/28 07:28 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/05/29 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.651745 [doi] PST - epublish SO - Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021. PMID- 34041036 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer. PG - 674933 LID - 10.3389/fonc.2021.674933 [doi] LID - 674933 AB - BACKGROUND: Finding effective prognostic signatures is of great urgency due to the high risk of recurrence and progression of bladder cancer (BC). Although a lot of genetic alterations are involved in the carcinogenesis, none of them were referred in the current risk group stratifications. In this study, we aimed to find significant copy number variations (CNVs) to predict prognosis for BC patients. METHODS: CNVs with high aberration frequencies in BC were explored by array-based comparative genomic hybridization in 65 tumor samples. Candidates were validated in independent groups of BC tumor samples (n=219) and urine samples (n=123). 3D digital PCR was applied for detecting accurate gene copy numbers in BC urine. In order to explore the prognostic value of candidate CNVs, all enrolled patients were followed up for the disease-free survival (DFS). Cox proportional hazards regression analysis was performed to find the independent prognostic factors for DFS. RESULTS: CNVs of CEP63, FOSL2 and PAQR6 with high aberration frequencies (67.7%, 56.9% and 60.0%, respectively) were found in BC tumors. Copy numbers of CEP63, FOSL2 and PAQR6 were gained in 219 tumor samples. CNVs of CEP63 and FOSL2 were correlated with advanced tumor stage and high grade. Retrospective analysis (median follow-up time: 69 months) revealed that CNVs of CEP63 and FOSL2 were independent prognostic factors for DFS of non-muscle-invasive bladder cancer (NMIBC) patients, while CNVs of FOSL2 and PAQR6 were independent prognostic factors for DFS of muscle-invasive bladder cancer (MIBC) patients. Models for predicting DFS were constructed based on CNVs of three genes. Patients with high prognostic indexes tended to have poor DFS. Prognostic index can also help to identify those with worse outcomes among high risk NMIBC patients. Copy number gains of CEP63 and FOSL2 in urine were found to be significantly correlated with poor DFS of NMIBC patients. CONCLUSIONS: CNVs of CEP63, FOSL2 and PAQR6 were capable of predicting DFS and may serve as promising signatures for prognosis of BC. CI - Copyright (c) 2021 Cai, Chen, Bai, Zheng, Ma, Cai, Liu, Zhang, Shou and Gao. FAU - Cai, Zhao AU - Cai Z AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Chen, Huang AU - Chen H AD - Department of Pathology, China-Japan Friendship Hospital, Beijing, China. FAU - Bai, Jingqiao AU - Bai J AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Yang AU - Zheng Y AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Ma, Jianhui AU - Ma J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Cai, Xiongwei AU - Cai X AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Yu AU - Liu Y AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zhang, Kaitai AU - Zhang K AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Shou, Jianzhong AU - Shou J AD - Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Gao, Yanning AU - Gao Y AD - State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article DEP - 20210510 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8141655 OTO - NOTNLM OT - CEP63 OT - FOSL2 OT - PAQR6 OT - bladder cancer OT - copy number variation OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/28 06:00 MHDA- 2021/05/28 06:01 PMCR- 2021/01/01 CRDT- 2021/05/27 06:47 PHST- 2021/03/02 00:00 [received] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/05/27 06:47 [entrez] PHST- 2021/05/28 06:00 [pubmed] PHST- 2021/05/28 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.674933 [doi] PST - epublish SO - Front Oncol. 2021 May 10;11:674933. doi: 10.3389/fonc.2021.674933. eCollection 2021. PMID- 34034567 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20220428 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 89 IP - 2 DP - 2022 May TI - Incidental prostate cancer in patients who underwent radical cystectomy for high risk non muscle invasive bladder cancer: Is it clinically significant? PG - 216-220 LID - 10.1177/03915603211019989 [doi] AB - INTRODUCTION AND OBJECTIVE: Non muscle invasive, high-risk, bladder cancer is an entity which is usually treated with radical cystectomy. Incidental prostate cancer refers to prostate cancer detected in radical cystectomy specimens in patients with no signs of the disease. Objective of this study is to report the prevalence, characteristics, and clinical significance of incidental prostate cancer in non-muscle invasive bladder cancer patients treated with radical cystectomy in our department. MATERIAL AND METHODS: We retrospectively reviewed data from 41 patients who underwent radical cystectomy for non-muscle invasive, high risk, bladder cancer during the years 2016-2020 in our department. Prostate cancer was described as clinically significant when there were positive surgical margins, extraprostatic extension, Gleason score >6, or tumor volume ⩾0.5 cm(3). Two groups of patients were formed according to the presence or absence of clinically significant prostate cancer. RESULTS: Incidental prostate cancer in the cystectomy specimens was detected in 21 of the 35 patients investigated. Clinically significant prostate cancer was detected in five patients. Positive surgical margins and extraprostatic extension were present in one patient, respectively. Gleason score was more than six in four of the five patients and PCa tumor volume was above 0.5 cm(3) in three patients. Two patients with clinically significant prostate cancer were diagnosed with biochemical recurrence during their follow up. CONCLUSIONS: In non-muscle invasive, high-risk patients undergoing radical cystectomy, clinically significant incidental PCa is an important issue as it may affect prognosis, quality of life, metastasis free survival, and overall survival. FAU - Fragkoulis, Charalampos AU - Fragkoulis C AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Glykas, Ioannis AU - Glykas I AUID- ORCID: 0000-0002-0681-8685 AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Mari, Victoria AU - Mari V AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Lamprou, Stavros AU - Lamprou S AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Tzelves, Lazaros AU - Tzelves L AD - Second Department of Urology, National and Kapodistrian University of Athens, School of Medicine, Sismanoglio Hospital, Athens, Greece. FAU - Stathouros, Georgios AU - Stathouros G AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Papadopoulos, Georgios AU - Papadopoulos G AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. FAU - Ntoumas, Konstantinos AU - Ntoumas K AD - Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. LA - eng PT - Journal Article DEP - 20210525 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Cystectomy MH - Female MH - Humans MH - Incidental Findings MH - Male MH - Margins of Excision MH - Prostatectomy MH - *Prostatic Neoplasms/pathology MH - Quality of Life MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/epidemiology/pathology/surgery OTO - NOTNLM OT - clinically significant incidental prostate cancer OT - clinically significant incidental prostate cancer in high risk NMIBC OT - clinically significant incidental prostate cancer in radical cystectomies OT - incidental prostate cancer EDAT- 2021/05/27 06:00 MHDA- 2022/04/29 06:00 CRDT- 2021/05/26 05:35 PHST- 2021/05/27 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] PHST- 2021/05/26 05:35 [entrez] AID - 10.1177/03915603211019989 [doi] PST - ppublish SO - Urologia. 2022 May;89(2):216-220. doi: 10.1177/03915603211019989. Epub 2021 May 25. PMID- 34032500 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 206 IP - 4 DP - 2021 Oct TI - A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy. PG - 970-977 LID - 10.1097/JU.0000000000001842 [doi] AB - PURPOSE: Oncologic outcomes following urethral recurrence (UR) remain incompletely described, with reports limited by small cohort sizes. We evaluated risk factors for UR as well as cancer-specific survival (CSS) and overall survival (OS) among patients with UR. MATERIALS AND METHODS: We reviewed our institutional radical cystectomy (RC) registry to identify patients with UR. Cox proportional hazards regression was used to assess risk factors for UR. Kaplan-Meier and Cox models were used to assess the relationship between UR and CSS/OS as well as to compare outcomes following symptomatic vs asymptomatic presentation of UR. RESULTS: Overall, 2,930 patients underwent RC from 1980 to 2018, with a median postoperative followup of 7.1 years (IQR 2.8-13.1), of whom 144 (4.9%) were subsequently diagnosed with UR. Carcinoma in situ (HR 1.98, 95% CI 1.30-3.04), multifocal disease (HR 1.59, 95% CI 1.07-2.36) and prostatic urethral involvement at RC (HR 3.01, 95% CI 1.98-4.57) were associated with increased risk of UR. UR was associated with decreased CSS (HR 7.30, 95% CI 5.46-9.76) and OS (HR 1.86, 95% CI 1.54-2.24). A total of 63/144 patients were diagnosed with UR based on symptoms, while 104/144 patients with UR underwent urethrectomy. Patients with symptomatic UR had higher tumor stage at urethrectomy (>/=pT2 in 13.1% vs 3.1%, p=0.007), while patients with asymptomatic UR experienced longer median CSS (12.1 vs 6.1 years) and OS (8.30 vs 4.82 years; p=0.05 for both). CONCLUSIONS: We identified pathological risk factors for UR after RC and report adverse subsequent survival outcomes for these patients. Presentation with symptomatic UR was associated with higher tumor stage and poorer prognosis, supporting a value to continued urethral surveillance after RC. FAU - Khanna, Abhinav AU - Khanna A AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Zganjar, Andrew AU - Zganjar A AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Lyon, Timothy AU - Lyon T AD - Department of Urology, Mayo Clinic, Jacksonville, Florida. FAU - Shah, Paras AU - Shah P AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tarrell, Robert AU - Tarrell R AD - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. FAU - Thapa, Prabin AU - Thapa P AD - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. FAU - Thompson, R Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. LA - eng PT - Journal Article DEP - 20210525 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Oct;206(4):977. doi: 10.1097/JU.0000000000001842.01. PMID: 34387507 MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/secondary MH - *Cystectomy MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prospective Studies MH - Retrospective Studies MH - Risk Factors MH - Urethra/pathology MH - Urethral Neoplasms/*epidemiology/secondary MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - cell biology OT - cystectomy OT - recurrence OT - urinary bladder neoplasms EDAT- 2021/05/26 06:00 MHDA- 2021/09/30 06:00 CRDT- 2021/05/25 13:43 PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/05/25 13:43 [entrez] AID - 10.1097/JU.0000000000001842 [doi] PST - ppublish SO - J Urol. 2021 Oct;206(4):970-977. doi: 10.1097/JU.0000000000001842. Epub 2021 May 25. PMID- 38994538 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 7 IP - 2 DP - 2021 TI - A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. PG - 221-241 LID - 10.3233/BLC-201510 [doi] AB - BACKGROUND: Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-analyses, and evidence-based decision-making for patients and clinicians. OBJECTIVE: We aimed to systematically review the extent of reporting and definition heterogeneity. METHODS: We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma in situ) published between 2000-2020. Abstracts and full texts were screened independently by two reviewers. Data were extracted by one reviewer and checked by another. RESULTS: We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident throughout, particularly in the definitions of progression and recurrence, and how CIS patients were handled in the analysis of studies with predominantly papillary patients, highlighting further issues with the definition of recurrence and progression vs treatment response for CIS patients. Data reporting was also inconsistent, with some trials reporting event rates at various time-points and others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently reported. QoL data was absent in most trials. CONCLUSIONS: Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core outcome set is required to reduce heterogeneity. PATIENT SUMMARY: This systematic review found inconsistencies in outcome definitions and reporting, pointing out the urgent need for a core outcome set to help improve evidence-based treatment decisions. CI - (c) 2021 - IOS Press. All rights reserved. FAU - Veskimae, Erik AU - Veskimae E AD - Department of Urology, Tampere University Hospital, Tampere, Finland. FAU - Subbarayan, Selvarani AU - Subbarayan S AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. FAU - Campi, Riccardo AU - Campi R AD - Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Carron, Domitille AU - Carron D AD - Inspiring-health GmbH, Munich, Germany. FAU - Omar, Muhammad Imran AU - Omar MI AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. FAU - Yuan, Cathy AU - Yuan C AD - Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada. FAU - Dimitropoulos, Konstantinos AU - Dimitropoulos K AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. AD - Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK. FAU - Van Hemelrijck, Mieke AU - Van Hemelrijck M AD - King's College London, Faculty of Life Sciences and Medicine, Translational and Oncology Research (TOUR), London, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - N'Dow, James AU - N'Dow J AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. AD - Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic. FAU - Alfred Witjes, J AU - Alfred Witjes J AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Sylvester, Richard AU - Sylvester R AD - EAU NMIBC Guidelines Panel, Brussels, Belgium. FAU - MacLennan, Steven AU - MacLennan S AD - Academic Urology Unit, University of Aberdeen, Aberdeen, UK. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210525 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181687 OTO - NOTNLM OT - Outcome reporting heterogeneity OT - TURBT OT - core outcome sets OT - non-muscle-invasive bladder cancer (NMIBC) OT - systematic review COIS- Erik Veskimae - Has no conflict of interest to report. Selvarani Subbarayan - Has no conflict of interest to report. Riccardo Campi - Has no conflict of interest to report. Domitille Carron - Has no conflict of interest to report. Muhammad Imran Omar - Has no conflict of interest to report. Cathy Yuan - Has no conflict of interest to report. Konstantinos Dimitropoulos - Has no conflict of interest to report. Mieke Van Hemelrijck - Has no conflict of interest to report. Richard T. Bryan - Reports other from Janssen EMEA, grants from UroGen Pharma, grants from QED Therapeutics, outside the submitted work. James N'Dow - Has no conflict of interest to report. Marek Babjuk - Has no conflict of interest to report. J. Alfred Witjes - Has no conflict of interest to report. Richard Sylvester - Has no conflict of interest to report. Steven MacLennan - Has no conflict of interest to report. EDAT- 2021/05/25 00:00 MHDA- 2021/05/25 00:01 PMCR- 2021/05/25 CRDT- 2024/07/12 04:52 PHST- 2020/11/19 00:00 [received] PHST- 2021/02/28 00:00 [accepted] PHST- 2021/05/25 00:01 [medline] PHST- 2021/05/25 00:00 [pubmed] PHST- 2024/07/12 04:52 [entrez] PHST- 2021/05/25 00:00 [pmc-release] AID - BLC201510 [pii] AID - 10.3233/BLC-201510 [doi] PST - epublish SO - Bladder Cancer. 2021 May 25;7(2):221-241. doi: 10.3233/BLC-201510. eCollection 2021. PMID- 38994534 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 7 IP - 2 DP - 2021 TI - Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly -An International Multicenter Study. PG - 173-185 LID - 10.3233/BLC-200391 [doi] AB - BACKGROUND: Radical cystectomy (RC) is the standard treatment for muscle invasive bladder cancer, but approximately half of all patients will ultimately succumb to disease progression despite apparent cure with extirpative surgery. Elderly patients are at especially high risk of advanced disease and may benefit from perioperative systemic therapy. OBJECTIVE: To assess the real-world benefit of adjuvant chemotherapy (AC) in patients >/=75 years old. METHODS: We retrospectively reviewed patients who underwent RC for non-metastatic urothelial carcinoma of the bladder (UCB) from 12 participating international medical institutions. Kaplan-Meier survival curves and Cox regression models were used to assess the association between age groups, administration of AC and oncological outcome parameters such as recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). RESULTS: 4,335 patients were included in the analyses, of which 820 (18.9%) were >/=75 years old. These elderly patients had a higher rate of adverse pathologic features. In an univariable subgroup analysis in patients >/=75 years with lymph node metastasis, 5-year OS was significantly higher in patients who had received AC (41% vs. 30.9%, p = 0.02). In a multivariable Cox model that was adjusted for several established outcome predictors, there was a significant favorable association between the administration of AC in elderly patients and OS, but no RFS or CSS. CONCLUSIONS: In this large observational study, the administration of AC was associated with improved OS, but not RFS or CSS, in elderly patients treated with RC for UCB. This is of clinical importance, as elderly patients are more likely to have adverse pathologic features and experience worse survival outcomes. Treatment of UCB should include both a multidisciplinary approach and a geriatric evaluation to identify patients who are most likely to tolerate and benefit from AC. CI - (c) 2021 - The authors. Published by IOS Press. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital of Tours, Tours, France. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Motlagh, Reza Sari AU - Motlagh RS AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Deuker, Marina AU - Deuker M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Department of Urology, Institut Mutualiste Montsouris, Paris, France. AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Stolzenbach, Lara Franziska AU - Stolzenbach LF AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - European Association of Urology Research Foundation, Arnhem, Netherlands. LA - eng PT - Journal Article DEP - 20210525 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181794 OTO - NOTNLM OT - MIBC OT - NMIBC OT - adjuvant chemotherapy OT - bladder cancer OT - elderly OT - systemic therapy OT - transitional cell carcinoma COIS- S.F. Shariat reports advisory board of/and or speaker for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lissy, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia and Sanofi. Victor Schuettfort, Benjamin Pradere, Hadi Mostafaei, Ekaterina Laukhtina, Keiichiro Mor, Fahad Quhal, Reza Sari Motlagh, Michael Rink, Pierre Karakiewicz, Marina Deuker, Marco Moschini, Lara Stolzenbach, Quoc-Dien Trinh, Alberto Briganti and David D'Andrea have no conflicts of interest. EDAT- 2021/05/25 00:00 MHDA- 2021/05/25 00:01 PMCR- 2021/05/25 CRDT- 2024/07/12 04:52 PHST- 2020/09/11 00:00 [received] PHST- 2021/01/03 00:00 [accepted] PHST- 2021/05/25 00:01 [medline] PHST- 2021/05/25 00:00 [pubmed] PHST- 2024/07/12 04:52 [entrez] PHST- 2021/05/25 00:00 [pmc-release] AID - BLC200391 [pii] AID - 10.3233/BLC-200391 [doi] PST - epublish SO - Bladder Cancer. 2021 May 25;7(2):173-185. doi: 10.3233/BLC-200391. eCollection 2021. PMID- 38994530 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 7 IP - 2 DP - 2021 TI - Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra. PG - 213-220 LID - 10.3233/BLC-201516 [doi] AB - BACKGROUND: In patients with non-invasive urothelial carcinoma of the prostatic urethra (PUC), treatment with Bacillus Calmette-Guerin (BCG) could be beneficial. OBJECTIVE: To assess the response rates to BCG in the different tumor stages, to describe the clinical impact of transurethral resection of the prostate (TURP) before BCG treatment, and to review the side effects of BCG treatment for PUC. METHODS: A systematic search was conducted using the PubMed database to identify original studies between 1977 and 2019 reporting on PUC and BCG. RESULTS: Of a total of 865 studies, ten were considered for evidence synthesis. An indication for BCG treatment was found in non-stromal invasive stages (Tis pu, Tis pd) and in stromal infiltrating cases (T1) of primary and secondary PUC when transitional cell carcinoma was the histology of origin. Studies including patients treated with TURP before BCG showed a better local response in the prostatic urethra with a higher disease free survival (DFS) (80-100% vs. 63-89%) and progression free survival (PFS) (90-100% vs. 75-94%) than patients in studies in which no TURP was performed. However, this difference in recurrence and progression in the prostate neither affected the total PFS (57-75% vs. 58-93%), nor the disease specific survival (70-100% vs. 66-100%). CONCLUSIONS: The use of resection loop biopsies of the prostatic urethra in appropriate cases during the primary work-up for suspected PUC, as well as the use of the current TNM classification for PUC, need to be improved. BCG therapy for non-stromal invasive stages of PUC show a good local response. Local response is further improved by a TURP before BCG therapy, although the overall prognosis does not seem to be affected. Further evidence for BCG treatment in the rare cases of stromal invasive PUC is needed. Specific side effects of BCG treatment for PUC are not reported. CI - (c) 2021 - The authors. Published by IOS Press. FAU - Patschan, Oliver AU - Patschan O AUID- ORCID: 0000-0001-5788-794X AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of GU Oncology and Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, University Hospital Inselspital, Bern, Switzerland. FAU - Redorta, Joan Palou AU - Redorta JP AD - Department of Urology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Fundatio Puigvert, Barcelona, Spain. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Wurzburg, Germany. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210525 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181694 OTO - NOTNLM OT - BCG OT - prostatic urethra OT - transitional carcinoma COIS- Georgios Gakis receives honoraria for advisory board activities: MSD, Astellas, Ferring, BMS, Bayer, Leo Pharma, medac, Merck, and he receives speaker honoraria/travel grants: Roche, MSD, IPSEN, Erbe, medac. Philippe E Spiess is the vice chair of the NCCN bladder and penile cancer panel; he is as well the president of the Global Society of Rare GU Tumors. Joan Palou Redorta reports trial participation: Cepheid, Presurgery, Ipsen, Combat, Storz, Archer, IDL Biotech, Palex and receives honoraria or consultation fees from Combat BRS, Olympus, Sanofi, Cepheid, Ipsen, Fidia Farmaceutici, and fees for Advisory/Scientific Board activities from: Pfizer, Astra Zeneca, Merck, Janssen, Ferring. Oliver Patschan and George N Thalmann have no conflict of interest to declare. EDAT- 2021/05/25 00:00 MHDA- 2021/05/25 00:01 PMCR- 2021/05/25 CRDT- 2024/07/12 04:52 PHST- 2020/11/16 00:00 [received] PHST- 2021/02/28 00:00 [accepted] PHST- 2021/05/25 00:01 [medline] PHST- 2021/05/25 00:00 [pubmed] PHST- 2024/07/12 04:52 [entrez] PHST- 2021/05/25 00:00 [pmc-release] AID - BLC201516 [pii] AID - 10.3233/BLC-201516 [doi] PST - epublish SO - Bladder Cancer. 2021 May 25;7(2):213-220. doi: 10.3233/BLC-201516. eCollection 2021. PMID- 34027701 OWN - NLM STAT- MEDLINE DCOM- 20211011 LR - 20211011 IS - 1552-695X (Electronic) IS - 1534-7354 (Print) IS - 1534-7354 (Linking) VI - 20 DP - 2021 Jan-Dec TI - Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. PG - 15347354211019483 LID - 10.1177/15347354211019483 [doi] LID - 15347354211019483 AB - INTRODUCTION: Radical cystectomy (RC) is the gold standard treatment for patients with muscle-invasive or refractory non-muscle invasive bladder cancer. It is estimated that approximately 64% and 13% of RC patients experience any complication and major complications, respectively. Specialized immunonutrition (SIM) aims to reduce the rates of complications after RC. We reported surgical complication rates in RC patients who received (SIM group) versus who did not receive (no-SIM group) perioperative SIM. Moreover, we investigated factors associated with complications after RC. MATERIAL AND METHODS: This is a retrospective cohort study of 52 patients who underwent RC between April 2016 and December 2017. Overall, 26 (50%) patients received perioperative SIM. We recorded age, gender, Charlson Comorbidity Index (CCI), body mass index (BMI), Malnutrition Universal Screening Tool (MUST) score, unintentional weight loss (UWL), SIM drinks consume, surgical approach, urinary diversion, neoadjuvant chemotherapy (NAC), use of total parenteral nutrition (TPN), final pathology, length of stay (LOS), and complications. RESULTS: SIM was associated with higher rates of documented infections (P = .03). Conversely, post-operative ileus was associated with higher rates of overall infections (P = .03). Median LOS was comparable within the 2 groups. Overall, 4 (15.38%) versus 0 (0%) patients in SIM versus no-SIM group were readmitted to hospital (P = .03). Age, CCI, NAC, and TPN were not associated with complication rates. CONCLUSIONS: SIM is not associated with lower rates of post-operative complications in RC candidates. Moreover, higher rates of documented infections were observed in the SIM group. Patients with post-operative ileus experienced more infections. Age, CCI, NAC, and TPN were not predictive of complications. FAU - Cozzi, Gabriele AU - Cozzi G AUID- ORCID: 0000-0001-6386-7013 AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Musi, Gennaro AU - Musi G AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Universita degli Studi di Milano, Milan, Italy. FAU - Milani, Martina AU - Milani M AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Jemos, Costantino AU - Jemos C AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Gandini, Sara AU - Gandini S AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Universita degli Studi di Milano, Milan, Italy. FAU - Mazzoleni, Ludovica AU - Mazzoleni L AD - Universita degli Studi di Pavia, Pavia, Italy. FAU - Ferro, Matteo AU - Ferro M AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Universita degli Studi di Milano, Milan, Italy. FAU - Bianchi, Roberto AU - Bianchi R AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Omodeo Sale, Emanuela AU - Omodeo Sale E AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Universita degli Studi di Milano, Milan, Italy. LA - eng PT - Journal Article PL - United States TA - Integr Cancer Ther JT - Integrative cancer therapies JID - 101128834 SB - IM MH - *Cystectomy/adverse effects MH - Humans MH - Length of Stay MH - Neoadjuvant Therapy MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery PMC - PMC8142230 OTO - NOTNLM OT - bladder cancer OT - complications OT - enhanced recovery after surgery OT - immunonutrition OT - infections OT - radical cystectomy COIS- Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/05/25 06:00 MHDA- 2021/10/12 06:00 PMCR- 2021/05/22 CRDT- 2021/05/24 09:17 PHST- 2021/05/24 09:17 [entrez] PHST- 2021/05/25 06:00 [pubmed] PHST- 2021/10/12 06:00 [medline] PHST- 2021/05/22 00:00 [pmc-release] AID - 10.1177_15347354211019483 [pii] AID - 10.1177/15347354211019483 [doi] PST - ppublish SO - Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019483. doi: 10.1177/15347354211019483. PMID- 34017909 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2352-0779 (Print) IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 8 IP - 1 DP - 2021 Jan TI - OUTCOMES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN IN A MULTIRACIAL COHORT WITH NON-MUSCLE-INVASIVE BLADDER CANCER. PG - 100-105 LID - 10.1097/upj.0000000000000154 [doi] AB - INTRODUCTION: We sought to determine if outcomes of Bacillus Calmette-Guerin (BCG) therapy in patients with non-muscle-invasive bladder cancer (NMIBC) vary by race. METHODS: A retrospective chart review was conducted on 149 patients treated with BCG for intermediate- and high-risk NMIBC between 2001 and 2018, and who were followed up for cancer recurrence through March 2019.The primary outcomes were disease-free survival (DFS), low-grade disease-free survival (LGDFS), high-grade disease-free survival (HGDFS), and progression-free survival (PFS) at five years. Kaplan-Meier survival curves stratified by race (African American vs non-African American) were analyzed for all the above outcomes and multivariate Cox regression analyses were also performed to compare recurrence differences by race, after adjusting for age, sex, initial stage and grade. RESULTS: Of the 149 patients, 37.6% were Caucasian, 24.8% were African American, 26.8% were Hispanic, and 10.7% were of other/unknown race. Disease stage at initial presentation was 65.1% Ta, 34.9% T1, and 18.1% CIS. African American patients (N=37) did not have evidence for worse outcomes compared to non-African American patients when considering DFS (54.1% vs. 65.7%, p = 0.202), HGDFS (58.8% vs. 71.7%, p = 0.158), and PFS (83.8% vs. 92.6%, p = 0.117) at five years. Multivariate analysis did not reveal statistically significant racial differences in recurrence or progression. CONCLUSIONS: African Americans with NMIBC did not have worse disease recurrence and progression after receiving intravesical BCG treatment. Although there did appear to be a trend towards worse oncologic outcomes in African Americans, larger studies are needed to validate this finding. FAU - Barry, Emily AU - Barry E AD - Albert Einstein College of Medicine; Bronx, NY. FAU - Agalliu, Ilir AU - Agalliu I AD - Department of Epidemiology and Population Health, Albert Einstein College of Medicine; Bronx, NY. AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. FAU - Maiman, Richard AU - Maiman R AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. FAU - Shreck, Evan AU - Shreck E AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. FAU - Kovac, Evan AU - Kovac E AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. FAU - Aboumohamed, Ahmed AU - Aboumohamed A AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. FAU - Sankin, Alexander AU - Sankin A AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Bronx, NY. LA - eng GR - L30 CA220768/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20210101 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 PMC - PMC8130652 MID - NIHMS1652751 OTO - NOTNLM OT - African Americans OT - Disease-Free Survival OT - Mycobacterium bovis OT - Progression-Free Survival OT - Urinary Bladder Neoplasms EDAT- 2021/05/22 06:00 MHDA- 2021/05/22 06:01 PMCR- 2022/01/01 CRDT- 2021/05/21 06:35 PHST- 2021/05/21 06:35 [entrez] PHST- 2021/05/22 06:00 [pubmed] PHST- 2021/05/22 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.1097/upj.0000000000000154 [doi] PST - ppublish SO - Urol Pract. 2021 Jan;8(1):100-105. doi: 10.1097/upj.0000000000000154. Epub 2021 Jan 1. PMID- 34009374 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20211019 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 51 IP - 8 DP - 2021 Aug 1 TI - Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients. PG - 1303-1312 LID - 10.1093/jjco/hyab060 [doi] AB - BACKGROUND: The relationship between guideline adherence for radical cystectomy of non-muscle-invasive bladder cancer and patient prognoses currently remains unclear. We investigated whether guideline adherence at the time of non-muscle-invasive bladder cancer affects the oncological outcomes of bladder cancer patients who underwent radical cystectomy. METHODS: Among 267 cTa-4N0-2M0 bladder cancer patients, 70 who underwent radical cystectomy under the non-muscle-invasive bladder cancer or muscle-invasive bladder cancer status that progressed from non-muscle-invasive bladder cancer were identified. Patients who followed the guidelines from initial transurethral resection of bladder tumors to radical cystectomy were defined as the guideline adherent group (n = 52), while those who did not were the guideline non-adherent group (n = 18). RESULTS: In the guideline non-adherent group, 8 (44.4%) out of 18 were diagnosed with highest risk non-muscle-invasive bladder cancer for Bacillus Calmette Guerin-naive patients and 7 (38.9%) had a Bacillus Calmette Guerin unresponsive tumor status. Five-year recurrence-free survival and cancer-specific survival rates for the guideline non-adherent group vs guideline adherent group were 38.9% vs 69.8% (P = 0.018) and 52.7% vs 80.1% (P = 0.006), respectively. A multivariate analysis identified guideline non-adherence as one of independent indicators for disease recurrence (hazard ratio = 2.81, P = 0.008) and cancer-specific death (hazard ratio = 4.04, P = 0.003). In a subgroup analysis of 49 patients with cT1 or less non-muscle-invasive bladder cancer at the time of radical cystectomy, guideline non-adherence remained an independent prognostic factor for cancer-specific survival (hazard ratio = 3.46, P = 0.027). CONCLUSIONS: Guideline adherence during the time course of the non-muscle-invasive bladder cancer stage may result in a favorable prognosis of patients who receive radical cystectomy. Even under non-muscle-invasive bladder cancer status, radical cystectomy needs to be performed with adequate timing under guideline recommendations. CI - (c) The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Kayama, Emina AU - Kayama E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Hakozaki, Kyohei AU - Hakozaki K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Iwasawa, Tomohiro AU - Iwasawa T AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Kamisawa, Ken AU - Kamisawa K AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Kanai, Kunimitsu AU - Kanai K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Hara, Satoshi AU - Hara S AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - *Cystectomy/methods/standards MH - Disease Progression MH - Guideline Adherence MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/surgery MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology/surgery OTO - NOTNLM OT - BCG failure OT - EAU guideline OT - intravesical therapy OT - radical surgery OT - urothelial carcinoma EDAT- 2021/05/20 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/05/19 12:38 PHST- 2021/01/14 00:00 [received] PHST- 2021/04/09 00:00 [accepted] PHST- 2021/05/20 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/05/19 12:38 [entrez] AID - 6261378 [pii] AID - 10.1093/jjco/hyab060 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2021 Aug 1;51(8):1303-1312. doi: 10.1093/jjco/hyab060. PMID- 34003609 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20250623 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 48 IP - 3 DP - 2022 May-Jun TI - Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis. PG - 406-455 LID - 10.1590/S1677-5538.IBJU.2020.1032 [doi] AB - INTRODUCTION: There is an ongoing need to identify various pathological factors that can predict various survival parameters in patients with upper tract urothelial carcinoma (UTUC). With this review, we aim to scrutinize the impact of several pathological factors on recurrence free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) in patients with UTUC. MATERIALS AND METHODS: Systematic electronic literature search of various databases was conducted for this review. Studies providing multivariate hazard ratios (HR) for various pathological factors such as tumor margin, necrosis, stage, grade, location, architecture, lymph node status, lymphovascular invasion (LVI), carcinoma in situ (CIS), multifocality and variant histology as predictor of survival parameters were included and pooled analysis of HR was performed. RESULTS: In this review, 63 studies with 35.714 patients were included. For RFS, all except tumor location (HR 0.94, p=0.60) and necrosis (HR 1.00, p=0.98) were associated with worst survival. All the pathological variables except tumor location (HR 0.95, p=0.66) were associated with worst CSS. For OS, only presence of CIS (HR 1.03, p=0.73) and tumor location (HR 1.05, p=0.74) were not predictor of survival. CONCLUSIONS: We noted tumor grade, stage, presence of LVI, lymph node metastasis, hydronephrosis, variant histology, sessile architecture, margin positivity and multifocality were associated with poor RFS, CSS and OS. Presence of CIS was associated with poor RFS and CSS but not OS. Tumor necrosis was associated with worst CSS and OS but not RFS. Tumor location was not a predictor of any of the survival parameters. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Sharma, Gopal AU - Sharma G AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Yadav, Anuj Kumar AU - Yadav AK AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Pareek, Tarun AU - Pareek T AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Kaundal, Pawan AU - Kaundal P AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Tyagi, Shantanu AU - Tyagi S AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Devana, Sudheer Kumar AU - Devana SK AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Singh, Shrawan Kumar AU - Singh SK AD - Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Prognosis MH - Retrospective Studies MH - *Ureteral Neoplasms MH - *Urinary Bladder Neoplasms MH - *Urologic Neoplasms/pathology PMC - PMC9060157 OTO - NOTNLM OT - Carcinoma, Transitional Cell OT - Pathology OT - Prognosis COIS- None declared. EDAT- 2021/05/19 06:00 MHDA- 2022/04/07 06:00 PMCR- 2021/04/20 CRDT- 2021/05/18 13:47 PHST- 2020/11/20 00:00 [received] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/05/19 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2021/05/18 13:47 [entrez] PHST- 2021/04/20 00:00 [pmc-release] AID - IBJU20201032 [pii] AID - S1677-5538.IBJU.2020.1032 [pii] AID - 10.1590/S1677-5538.IBJU.2020.1032 [doi] PST - ppublish SO - Int Braz J Urol. 2022 May-Jun;48(3):406-455. doi: 10.1590/S1677-5538.IBJU.2020.1032. PMID- 34002265 OWN - NLM STAT- MEDLINE DCOM- 20220118 LR - 20220218 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 10 DP - 2021 Oct TI - The HELENA study: Hexvix((R))-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study. PG - 3799-3805 LID - 10.1007/s00345-021-03719-0 [doi] AB - PURPOSE: Photodynamic diagnosis and white-light TURB with adjuvant intravesical chemotherapy (ICT) is widely used in treatment of bladder cancer. This non-inferiority trial is designed to demonstrate non-inferiority regarding recurrence-free survival (RFS) of Hexvix((R)) TURB followed by immediate instillation compared to white-light TURB with immediate instillation followed by maintenance ICT. METHODS: Between 07/2010 and 12/2016, 129 patients with EORTC intermediate risk non-muscle invasive bladder cancer treated with TURB were included in this multicentre phase III study. Patients were randomized and received either white-light TURB with immediate ICT followed by maintenance ICT (n = 62, 20 mg Mitomycin weekly for 6 weeks as induction phase, afterwards 20 mg/month for 6 months) or Hexvix((R)) TURB with immediate ICT only (n = 67, 40 mg Mitomycin). Primary study endpoint was RFS after 12 months. Hexvix((R)) TURB was counted as non-inferior to white light alone if the upper limit of the one-sided 95% confidence interval of hazard ratio was lower than 1.676. Due to the non-inferiority design, the per-protocol population was used as the primary analysis population (n = 113) RESULTS: Median follow-up was 1.81 years. Hexvix((R)) group showed more events (recurrence or death) than white-light group (19 vs. 10) resulting in a HR of 1.29 (upper limit of one-sided 95%-CI = 2.45; p(non-inferiority) = 0.249). The ITT population yielded similar results (HR = 1.67); 3.18], p(non-inferiority) = 0.493). There was no significant difference in overall survival between both groups (p = 0.257). CONCLUSION: Non-inferiority of Hexvix((R)) TURB relative to white-light TURB with maintenance Mitomycin instillation in intermediate risk urothelial carcinoma of the bladder was not proven. Hence a higher effect of maintenance ICT is to assume compared to a Hexvix((R))-improved TURB only, confirming its important role in patient treatment. CI - (c) 2021. The Author(s). FAU - Gierth, M AU - Gierth M AUID- ORCID: 0000-0001-6393-5899 AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. Michael.Gierth@gmx.de. FAU - Breyer, J AU - Breyer J AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. FAU - Zeman, F AU - Zeman F AD - Center for Statistics and Clinical Studies, University of Regensburg, Regensburg, Germany. FAU - Fritsche, H M AU - Fritsche HM AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. FAU - Cordes, J AU - Cordes J AD - Department of Urology, University Hospital of Schleswig-Holstein, Lubeck, Germany. FAU - Karl, A AU - Karl A AD - Department of Urology, Barmherzige Bruder Hospital Munchen, Munich, Germany. FAU - Zaak, D AU - Zaak D AD - Department of Urology, Traunstein Medical Center, Traunstein, Germany. FAU - Stenzl, A AU - Stenzl A AD - Department of Urology, University of Tubingen, Tubingen, Germany. FAU - von Schmeling, I Kausch AU - von Schmeling IK AD - Department of Urology, Medical Center of Westerstede, Westerstede, Germany. FAU - Sommerhuber, A AU - Sommerhuber A AD - Department of Urology, Medical Center Linz, Linz, Austria. FAU - Zierer, T AU - Zierer T AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. FAU - Burger, M AU - Burger M AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. FAU - Mayr, R AU - Mayr R AD - Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstrasse 65, 93053, Regensburg, Germany. LA - eng PT - Clinical Trial, Phase III PT - Comparative Study PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20210517 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 0 (Photosensitizing Agents) RN - 50SG953SK6 (Mitomycin) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Aminolevulinic Acid/administration & dosage/*analogs & derivatives MH - Antineoplastic Agents/*administration & dosage MH - Carcinoma/mortality/pathology/*therapy MH - Chemotherapy, Adjuvant MH - *Cystectomy MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - Photochemotherapy MH - Photosensitizing Agents/*administration & dosage MH - Prospective Studies MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy PMC - PMC8521513 OTO - NOTNLM OT - Bladder cancer OT - Intravesical chemotherapy OT - Transurethral resection OT - Urothelial carcinoma COIS- All other authors declare that they have no conflict of interest. EDAT- 2021/05/19 06:00 MHDA- 2022/01/19 06:00 PMCR- 2021/05/17 CRDT- 2021/05/18 07:13 PHST- 2021/02/22 00:00 [received] PHST- 2021/04/30 00:00 [accepted] PHST- 2021/05/19 06:00 [pubmed] PHST- 2022/01/19 06:00 [medline] PHST- 2021/05/18 07:13 [entrez] PHST- 2021/05/17 00:00 [pmc-release] AID - 10.1007/s00345-021-03719-0 [pii] AID - 3719 [pii] AID - 10.1007/s00345-021-03719-0 [doi] PST - ppublish SO - World J Urol. 2021 Oct;39(10):3799-3805. doi: 10.1007/s00345-021-03719-0. Epub 2021 May 17. PMID- 33998957 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20220425 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 55 IP - 4 DP - 2021 Aug TI - The use of reTURB in T1 bladder cancer: a Norwegian population-based study. PG - 268-274 LID - 10.1080/21681805.2021.1917652 [doi] AB - AIM: To evaluate the use of repeat transurethral resection of the bladder (reTURB) in stage T1 bladder cancer and its impact on treatment and survival in a Norwegian population-based cohort. MATERIAL AND METHODS: 1130 patients registered at the Cancer Registry of Norway between 2008 and 2012 with primary urothelial T1 cancer were included. Information on surgical and medical procedures was provided by the Norwegian Patient Registry. Descriptive statistics were used to evaluate characteristics of patients receiving reTURB or not within 12 weeks from primary TURB (primTURB). Survival models identified risk factors and estimated cause-specific survival rates (CSS) adjusted for sex, age, WHO grade, concomitant cis and detrusor muscle at primTURB and treatment. RESULTS: The 648 (57%) T1 patients with reTURB were significantly younger and had more WHO high grade tumors compared to those without reTURB. Of 275 patients without detrusor muscle at primTURB 114 (41%) had no reTURB. Of reTURB patients, 45 (7%) had muscle invasive tumor, 110 (17%) T1 and 378 (58%) Ta, cis or T0. Two-thirds of 81 patients receiving early cystectomy after reTURB had T1 or muscle invasive bladder cancer at reTURB. ReTURB did not impact adjusted CSS, but patients with T1 at reTURB had significantly lower CSS than those with < T1 conditions. CONCLUSIONS: Almost half of the T1 patients did not undergo reTURB as recommended in guidelines. We show that reTURB makes the histology result more reliable with impact on both treatment and survival. Our results support the use of reTURB as recommended by EAU guidelines. FAU - Blindheim, Augun Jodis AU - Blindheim AJ AD - Department of Clinical and Molecular Medicine, St. Olavs Hospital, Trondheim, Norway. AD - Norwegian University of Science and Technology (NTNU), Trondheim, Norway. AD - Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. FAU - Fossa, Sophie Dorothea AU - Fossa SD AD - Department of Oncology, Medical Faculty, Oslo University Hospital & University of Oslo, Oslo, Norway. FAU - Babigumira, Ronnie AU - Babigumira R AD - Department of Research, Cancer Registry of Norway, Institute for Population-based Research, Oslo, Norway. FAU - Andreassen, Bettina Kulle AU - Andreassen BK AD - Department of Research, Cancer Registry of Norway, Institute for Population-based Research, Oslo, Norway. LA - eng PT - Journal Article DEP - 20210517 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Cystectomy MH - Humans MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/epidemiology/pathology/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - T1 OT - TURB OT - Urothelial carcinoma OT - repeated TURB OT - survival OT - urinary bladder cancer EDAT- 2021/05/18 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/05/17 12:21 PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/05/17 12:21 [entrez] AID - 10.1080/21681805.2021.1917652 [doi] PST - ppublish SO - Scand J Urol. 2021 Aug;55(4):268-274. doi: 10.1080/21681805.2021.1917652. Epub 2021 May 17. PMID- 33998725 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 1522-2586 (Electronic) IS - 1053-1807 (Linking) VI - 54 IP - 4 DP - 2021 Oct TI - Detecting Muscle Invasion of Bladder Cancer Using a Proposed Magnetic Resonance Imaging Strategy. PG - 1212-1221 LID - 10.1002/jmri.27676 [doi] AB - BACKGROUND: Accurate evaluation of the invasion depth of tumors with a Vesical Imaging-Reporting and Data System (VI-RADS) score of 3 is difficult. PURPOSE: To evaluate the diagnostic performance of a new magnetic resonance imaging (MRI) strategy based on the integration of the VI-RADS and tumor contact length (TCL) for the diagnosis of muscle-invasive bladder cancer (MIBC). STUDY TYPE: Single center, retrospective. SUBJECTS: A group of 179 patients with a mean age of 67 years (range, 24.0-96.0) underwent multiparametric MRI (mpMRI) before surgery, including 147 (82.1%) males and 32 (17.9%) females. Twenty-four (13.4%), 90 (50.3%), 43 (24.0%), 15 (8.4%), and 7 (3.9%) cases were Ta, T1, T2, T3, and T4, respectively. FIELD STRENGTH/SEQUENCE: A 1.5 T and 3.0 T, T2-weighted turbo spin-echo (TSE), single-shot echo-planar (SS-EPI), diffusion-weighted imaging (DWI), and T1-weighted volumetric interpolated breath-hold examination (T1-VIBE). ASSESSMENT: Three radiologists independently graded the VI-RADS score and measured the TCL on index lesion images. A proposed MRI strategy called VI-RADS_TCL was introduced by modifying the VI-RADS score, which was downgraded to VI-RADS 3F (equal to a VI-RADS score of 2) if VI-RADS = 3 and TCL < 3 cm. STATISTICAL TESTS: Intraclass correlation coefficients (ICCs), Mann-Whitney U test, chi-square tests, receiver operating characteristic (ROC) curves, and 2 x 2 contingency tables were applied. RESULTS: Inter-reader agreement values were 0.941 (95% CI, 0.924-0.955) and 0.934 (95% CI, 0.916-0.948) for the TCL and VI-RADS score. The TCL was significantly increased in the MIBC group (6.40-6.85 cm) compared with the NMIBC group (1.98-2.45 cm) (P < 0.05). The specificity and positive predictive values (PPV) of VI-RADS_TCL were 82.46%-87.72% and 90.91%-91.59%, which were significantly greater than VI-RADS score (P < 0.05). Additionally, 52.17%-55.88% NMIBC lesions with VI-RADS 3 were downgraded to 3F by using VI-RADS_TCL. DATA CONCLUSION: The proposed MRI strategy could reduce the false-positive rate of lesions with a VI-RADS score of 3 while retaining sensitivity. EVIDENCE LEVEL: 4 TECHNICAL EFFICACY: 2. CI - (c) 2021 International Society for Magnetic Resonance in Medicine. FAU - Wang, Xiangyu AU - Wang X AUID- ORCID: 0000-0002-2906-9875 AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, 518035, China. FAU - Tu, Ning AU - Tu N AD - PET-CT/MRI Center & Molecular Imaging Center, Wuhan University Renmin Hospital, Wuhan, 430060, China. FAU - Sun, Feng AU - Sun F AD - Department of Radiology, Shijiazhuang General Hospital, Shijiazhuang, 050000, China. FAU - Wen, Zhi AU - Wen Z AD - Department of Radiology, Wuhan University Renmin Hospital, Wuhan, 430060, China. FAU - Lan, Xinxin AU - Lan X AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, 518035, China. FAU - Lei, Yi AU - Lei Y AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, 518035, China. FAU - Cui, Enming AU - Cui E AUID- ORCID: 0000-0003-0634-822X AD - Department of Radiology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun YAT-SEN University, Jiangmen, 529030, China. FAU - Lin, Fan AU - Lin F AUID- ORCID: 0000-0003-1595-2736 AD - Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, 518035, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210517 PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - *Multiparametric Magnetic Resonance Imaging MH - Muscles MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging MH - Young Adult OTO - NOTNLM OT - Vesical Imaging-Reporting and Data System OT - muscle-invasive bladder cancer OT - nonmuscle-invasive bladder cancer OT - tumor contact length EDAT- 2021/05/18 06:00 MHDA- 2021/09/30 06:00 CRDT- 2021/05/17 08:57 PHST- 2021/04/16 00:00 [revised] PHST- 2021/02/10 00:00 [received] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/05/17 08:57 [entrez] AID - 10.1002/jmri.27676 [doi] PST - ppublish SO - J Magn Reson Imaging. 2021 Oct;54(4):1212-1221. doi: 10.1002/jmri.27676. Epub 2021 May 17. PMID- 33998240 OWN - NLM STAT- MEDLINE DCOM- 20210806 LR - 20210806 IS - 0028-2685 (Print) IS - 0028-2685 (Linking) VI - 68 IP - 4 DP - 2021 Jul TI - Morbidity and mortality after open radical cystectomy and ileal diversion - 10 years experience and a comprehensive assessment in a single tertiary center. PG - 882-891 LID - 210202N161 [pii] LID - 10.4149/neo_2021_210202N161 [doi] AB - Open radical cystectomy (ORC) remains the gold standard for the treatment of muscle-invasive and high-risk non-muscle invasive bladder cancer unsuitable for bladder preservation techniques. Despite improvements in operative technique and perioperative care, it continues to be associated with significant complications. We analyzed our series of prospectively collected data of patients who underwent ORC at a tertiary referral academic center and evaluated early and late postoperative complications and mortality. The records of 391 ORCs with ileal diversion performed at our institution between January 2008 and July 2018 for non-metastatic transitional bladder carcinoma and other distinct pathological types were analyzed. Perioperative mortality was determined and 30-day and 90-day complications were reported according to the Martin Criteria and the European Association of Urology and graded according to the five-grade Clavien-Dindo classification. Univariate and multivariate analyses were used to evaluate predictors of complications and mortality. Gastrointestinal and infectious complications represented 41% and 43% of the total complications observed at 30 and 90 days after the surgery, respectively. The strongest predictor of infectious complications was the choice of ileal neobladder as the urinary diversion (p/=75 was the single predictor of mortality at both 30-days (p-value 0.003) and 90-days (p-value 0.01) in univariate and multivariate analyses. ORC is a morbid procedure, associated with a high mortality rate. Elderly patients should have proper counseling before the indication of this procedure. Gastrointestinal and infectious complications represent the most common and serious complications, and the study of their predictors is of the utmost importance. FAU - Do Carmo Silva, Joana AU - Do Carmo Silva J AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Vesely, Stepan AU - Vesely S AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. FAU - Dusek, Pavel AU - Dusek P AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. FAU - Jarolim, Ladislav AU - Jarolim L AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, University Hospital of Motol , Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. LA - eng PT - Journal Article DEP - 20210517 PL - Slovakia TA - Neoplasma JT - Neoplasma JID - 0377266 SB - IM MH - Aged MH - *Cystectomy/adverse effects MH - Humans MH - Morbidity MH - Postoperative Complications MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery EDAT- 2021/05/18 06:00 MHDA- 2021/08/07 06:00 CRDT- 2021/05/17 08:40 PHST- 2021/02/02 00:00 [received] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/08/07 06:00 [medline] PHST- 2021/05/17 08:40 [entrez] AID - 210202N161 [pii] AID - 10.4149/neo_2021_210202N161 [doi] PST - ppublish SO - Neoplasma. 2021 Jul;68(4):882-891. doi: 10.4149/neo_2021_210202N161. Epub 2021 May 17. PMID- 33996580 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210518 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer. PG - 657483 LID - 10.3389/fonc.2021.657483 [doi] LID - 657483 AB - Circulating tumor DNA (ctDNA) can be a prognostic biomarker for non-muscle-invasive bladder cancer (NMIBC); however, targeted sequencing has not been performed to detect ctDNA in NMIBC. We applied targeted sequencing based on an 861-gene panel to determine mutations in tumor tissue DNA and plasma ctDNA in 82 NMIBC patients receiving transurethral resection (TUR) of bladder followed by immunotherapy. We detected 476 and 165 somatic variants in tumor DNA from 82 NMIBC patients (100%) and ctDNA from 54 patients (65.85%), respectively. Patients with high heterogeneity in tumor DNA had a significantly shorter disease-free survival than those with low heterogeneity. Tumor-derived alterations were detectable in plasma of 43 patients (52.44%). The concordance of somatic variants between tumor DNA and plasma ctDNA were higher in patients with T1 stage (p < 0.0001) and tumor size >/=3 cm (p = 0.0002). Molecular tumor burden index (mTBI) in ctDNA positively correlated with larger tumor size (p = 0.0020). A higher mTBI was an independent predictor of recurrence after TUR of bladder followed by immunotherapy. Analysis of ctDNA based on targeted sequencing is a promising approach to predict disease recurrence for NMIBC patients receiving TUR of bladder followed by immunotherapy. CI - Copyright (c) 2021 Zhang, Dai, Tian, Li, Bai, Xu, Wang and Tang. FAU - Zhang, Jinghua AU - Zhang J AD - College of Life Sciences, Henan Agricultural University, Zhengzhou, China. AD - Health Science Center, The First Affiliated Hospital of Shenzhen University, and Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, Shenzhen, China. FAU - Dai, Daofeng AU - Dai D AD - Health Science Center, The First Affiliated Hospital of Shenzhen University, and Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, Shenzhen, China. AD - Jiangxi Otorhinolaryngology Head and Neck Surgery Institute, Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China. FAU - Tian, Junqiang AU - Tian J AD - Key Laboratory of Gansu Province for Urological Diseases, Department of Urology of Lanzhou University Second Hospital, Urology Institute of Lanzhou University Second Hospital, Lanzhou, China. FAU - Li, Lifeng AU - Li L AD - Geneplus-Beijing Institute, Beijing, China. FAU - Bai, Jing AU - Bai J AD - Geneplus-Beijing Institute, Beijing, China. FAU - Xu, Yaping AU - Xu Y AD - Geneplus-Beijing Institute, Beijing, China. FAU - Wang, Zhiping AU - Wang Z AD - Key Laboratory of Gansu Province for Urological Diseases, Department of Urology of Lanzhou University Second Hospital, Urology Institute of Lanzhou University Second Hospital, Lanzhou, China. FAU - Tang, Aifa AU - Tang A AD - Health Science Center, The First Affiliated Hospital of Shenzhen University, and Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, Shenzhen, China. AD - Shenzhen Luohu Hospital Group, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China. LA - eng PT - Journal Article DEP - 20210428 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8114939 OTO - NOTNLM OT - chemotherapy OT - circulating tumor DNA OT - molecular tumor burden index OT - non-muscle-invasive bladder cancer OT - prognostic biomarker OT - targeted sequencing COIS- Authors LL, JB and YX were employed by company Geneplus-Beijing Institute, Beijing, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/18 06:00 MHDA- 2021/05/18 06:01 PMCR- 2021/01/01 CRDT- 2021/05/17 06:15 PHST- 2021/01/23 00:00 [received] PHST- 2021/03/15 00:00 [accepted] PHST- 2021/05/17 06:15 [entrez] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/05/18 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.657483 [doi] PST - epublish SO - Front Oncol. 2021 Apr 28;11:657483. doi: 10.3389/fonc.2021.657483. eCollection 2021. PMID- 33982770 OWN - NLM STAT- MEDLINE DCOM- 20211208 LR - 20211214 IS - 1791-2423 (Electronic) IS - 1019-6439 (Linking) VI - 59 IP - 1 DP - 2021 Jul TI - Collagen type VI‑alpha1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. LID - 37 [pii] LID - 10.3892/ijo.2021.5217 [doi] AB - The bladder cancer (BCa) microenvironment comprises heterogeneous tumor cell populations, the surrounding stroma and the extracellular matrix (ECM). Collagen, the scaffold of the tumor microenvironment, regulates ECM remodeling to promote tumor infiltration, angiogenesis, invasion and migration. The present study examined how collagen type VI‑alpha (COL6A) 1 and 2 function during BCa pathogenesis and progression, with the aim of facilitating the development of precision therapeutics, risk stratification and molecular diagnosis. COL6A1 and COL6A2 mRNA expression in non‑muscle invasive BCa (NMIBC) and MIBC tissue samples was measured using reverse transcription‑quantitative PCR. In addition, the tumor‑suppressive effects of COL6A1 and COL6A2 in human BCa EJ cells (MGH‑U1) were assessed. Compared with normal controls, COL6A1 and COL6A2 mRNA expression was downregulated in both NMIBC and MIBC tissue samples (P<0.05, respectively). COL6A1 and COL6A2 effectively inhibited the proliferation of human BCa EJ cells (MGH‑U1) and induced cell cycle arrest at the G(1) phase. Additionally, COL6A1 and COL6A2 served roles in MAPK and AKT signaling by increasing p38 MAPK phosphorylation and decreasing AKT phosphorylation. Finally, COL6A1 and COL6A2 inhibited wound healing and invasion by suppressing the activity of matrix metalloproteinase (MMP)‑2 and MMP‑9. In conclusion, COL6A1 and COL6A2 may act as classical collagens by forming a physical barrier to inhibit BCa tumor growth and invasion. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Hwang, Byungdoo AU - Hwang B AD - Department of Food Science and Technology, Chung‑Ang University, Anseong, Gyeonggi 456‑756, Republic of Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Seo, Sung Phil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Lee, Jong-Young AU - Lee JY AD - Oneomics Institute, Seoul 04158, Republic of Korea. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu 41566, Republic of Korea. FAU - Lee, Young-Suk AU - Lee YS AD - Department of Urology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Gyeongsangnam 51353, Republic of Korea. FAU - Kim, Isaac Y AU - Kim IY AD - Section of Urologic Oncology and Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ 08903‑2681, USA. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biochemistry, College of Oriental Medicine, Dong‑Eui University, Busan 614‑052, Republic of Korea. FAU - Cha, Eun-Jong AU - Cha EJ AD - Department of Biomedical Engineering, Chungbuk National University College of Medicine, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food Science and Technology, Chung‑Ang University, Anseong, Gyeonggi 456‑756, Republic of Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk 28644, Republic of Korea. LA - eng PT - Journal Article DEP - 20210513 PL - Greece TA - Int J Oncol JT - International journal of oncology JID - 9306042 RN - 0 (COL6A2 protein, human) RN - 0 (Col6a1 protein, human) RN - 0 (Collagen Type VI) RN - 0 (Transcription Factors) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cell Line, Tumor MH - Cell Movement/genetics MH - Cell Proliferation/genetics MH - Collagen Type VI/*genetics/metabolism MH - G1 Phase Cell Cycle Checkpoints MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Middle Aged MH - Phosphorylation MH - Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction MH - Transcription Factors/genetics/metabolism MH - Urinary Bladder Neoplasms/*genetics/metabolism/*pathology MH - p38 Mitogen-Activated Protein Kinases/metabolism OTO - NOTNLM OT - BCa OT - COL6A OT - pathogenesis OT - progression OT - tumor suppressor EDAT- 2021/05/14 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/05/13 08:52 PHST- 2020/10/28 00:00 [received] PHST- 2021/04/16 00:00 [accepted] PHST- 2021/05/13 08:52 [entrez] PHST- 2021/05/14 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - 37 [pii] AID - 10.3892/ijo.2021.5217 [doi] PST - ppublish SO - Int J Oncol. 2021 Jul;59(1):37. doi: 10.3892/ijo.2021.5217. Epub 2021 May 13. PMID- 33981633 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 13 DP - 2021 TI - Evaluation of the Expression of HER2 and c-KIT Proteins as Prognostic Markers in Superficial Bladder Urothelial Carcinoma. PG - 197-206 LID - 10.2147/RRU.S296974 [doi] AB - BACKGROUND: The roles of c-KIT and HER2 protein expression in bladder cancer are still debated, and the prognostic value of these proteins as markers of tumor progression is inconclusive. OBJECTIVE: To assess the impact of HER2 and c-KIT protein expressions in the progression of non-muscle-invasive bladder cancer. METHODS: All patients undergoing transurethral resection of bladder tumors for non-muscle-invasive urothelial carcinoma, with standard regimen of BCG, between January 2017 and November 2019, were evaluated pathologically and immunohistochemically for HER1 and c-KIT proteins in urothelial carcinoma cells. Follow-up cystoscopy was performed for 100 patients every 3 months for the first 2-years and any recurred tumors were excised and examined pathologically, as well as stained for HER2 and c-KIT protein expression. RESULTS: HER2 and c-KIT positive expressions were detected in 49% and 38% of cases, respectively. After a mean follow-up of 26.4+/-7.2 months, the overall recurrence and progression rates were significantly correlated with overexpression of HER2 and c-KIT. In high-grade non-invasive muscle neoplasms, tumor cells showed weak expression for both HER2 and c-KIT proteins, but with progression to muscle-invasion, tumor cells strongly expressed HER2 and lost expression to c-KIT. In the multivariate model, overexpression of HER2 rather than c-KIT protein significantly predicted increased progression. CONCLUSION: Recurrence and progression of non-muscle-invasive bladder cancer correlate with overexpression of HER2 and c-KIT proteins in tumor cells. CI - (c) 2021 Abdou Hassan et al. FAU - Abdou Hassan, Wael AU - Abdou Hassan W AD - Department of Basic Sciences, College of Medicine, Suliman Al Rajhi University, Al Bukayriyah, Kingdom of Saudi Arabia. FAU - Shalaby, Essam AU - Shalaby E AUID- ORCID: 0000-0001-8340-5668 AD - Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. FAU - Abo-Hashesh, Mona AU - Abo-Hashesh M AD - Faculty of Science, Port Said University, Port Said, Egypt. FAU - Ibrahim Ali, Rehab AU - Ibrahim Ali R AD - Department of Pathology, College of Medicine, El-Jouf University, Sakaka, Kingdom of Saudi Arabia. AD - Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. LA - eng PT - Journal Article DEP - 20210505 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC8109022 OTO - NOTNLM OT - HER2 OT - c- KIT OT - non-muscle-invasive OT - urothelial carcinoma COIS- None of the contributing authors have any conflict of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. EDAT- 2021/05/14 06:00 MHDA- 2021/05/14 06:01 PMCR- 2021/05/05 CRDT- 2021/05/13 06:29 PHST- 2020/12/11 00:00 [received] PHST- 2021/02/04 00:00 [accepted] PHST- 2021/05/13 06:29 [entrez] PHST- 2021/05/14 06:00 [pubmed] PHST- 2021/05/14 06:01 [medline] PHST- 2021/05/05 00:00 [pmc-release] AID - 296974 [pii] AID - 10.2147/RRU.S296974 [doi] PST - epublish SO - Res Rep Urol. 2021 May 5;13:197-206. doi: 10.2147/RRU.S296974. eCollection 2021. PMID- 33979097 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20230922 IS - 1533-4058 (Electronic) IS - 1533-4058 (Linking) VI - 29 IP - 9 DP - 2021 Oct 1 TI - E-cadherin and N-cadherin Immunohistochemical Expression in Proliferating Urothelial Lesions: Potential Novel Cancer Predictive EMT Profiles. PG - 657-666 LID - 10.1097/PAI.0000000000000940 [doi] AB - Cadherin switch (CS) outlined by downregulation of E-cadherin and upregulation of N-cadherin is an established epithelial-mesenchymal transition (EMT) hallmark, being a common signature in wound healing and carcinogenesis. It is intriguing to explore the EMT-associated CS pattern in precancerous phases as well as variably aggressive bladder cancer categories. In this study, we tested CS signified by a reduction in urothelial cells E-cadherin expression and/or aberrant N-cadherin expression in proliferative epithelial changes (PEC) associating inflammation, non-muscle-invasive bladder cancer (NMIBC), and muscle-invasive bladder cancer (MIBC). Immunohistochemical study of both E-cadherin and N-cadherin was performed for 60 cases: 15 PEC, 8 NMIBC, and 37 MIBC. CS patterns were analyzed: abnormal CS patterns were expressed as deviated, hybrid, co-negative, and full CS patterns. E-cadherin expression was significantly preserved in PEC (86.7%) followed by NMIBC (62.5%) and then MIBC (37.8%) (P=0.004), whereas N-cadherin showed obvious aberrant expression in MIBC (51.4%) as compared with PEC (33.3%) and NMIBC (25%). In the MIBC group, abnormal cadherin patterns were the highest (70.3%) and was associated with adverse prognostic indicators. In the context of NMIBC progression to MIBC, combined E and N-cadherin evaluation showed highest sensitivity (70.3%) and NPV (31.3%), whereas aberrant expression of N-cadherin presented highest specificity (75%) and positive predictive value (90.5%). For cancer prediction, combined E-cadherin and N-cadherin evaluation showed the highest sensitivity (64.4%); abnormal E-cadherin offered highest specificity (86.7%), positive predictive value (92.9%), and negative predictive value (40.6%). In posttherapy follow-up setting, a metastable EMT signature in the form of partial CS was noted and might reflect resistant dormant populations. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Shash, Lobna S AU - Shash LS AD - Surgical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Ibrahim, Riham A AU - Ibrahim RA FAU - Elgohary, Shimaa A AU - Elgohary SA LA - eng PT - Journal Article PL - United States TA - Appl Immunohistochem Mol Morphol JT - Applied immunohistochemistry & molecular morphology : AIMM JID - 100888796 RN - 0 (Antigens, CD) RN - 0 (CDH1 protein, human) RN - 0 (CDH2 protein, human) RN - 0 (Cadherins) RN - 0 (Neoplasm Proteins) SB - IM MH - Antigens, CD/*biosynthesis MH - Cadherins/*biosynthesis MH - *Cell Proliferation MH - *Epithelial-Mesenchymal Transition MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Neoplasm Proteins/*biosynthesis MH - *Urinary Bladder Neoplasms/metabolism/pathology MH - *Urothelium/metabolism/pathology COIS- The authors declare no conflict of interest. EDAT- 2021/05/13 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/05/12 16:35 PHST- 2020/10/28 00:00 [received] PHST- 2021/03/08 00:00 [accepted] PHST- 2021/05/13 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/05/12 16:35 [entrez] AID - 00129039-202110000-00004 [pii] AID - 10.1097/PAI.0000000000000940 [doi] PST - ppublish SO - Appl Immunohistochem Mol Morphol. 2021 Oct 1;29(9):657-666. doi: 10.1097/PAI.0000000000000940. PMID- 33976912 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220422 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 74 IP - 1 DP - 2021 TI - Evaluation of comorbidity indices in determining the most suitable candidates for uro-oncological surgeries in elderly men. PG - 24-38 LID - 10.5173/ceju.2021.0246 [doi] AB - INTRODUCTION: We aimed to evaluate the superiority of different comorbidity indices in determining the most suitable elderly male candidates for uro-oncological operations. While making this assessment, we also aimed to determine the risk factors that may affect surgery-related major complications and overall survival. MATERIAL AND METHODS: Data of 543 male patients, 60 years or older, who underwent uro-oncological surgery (radical cystectomy, radical prostatectomy, radical or partial nephrectomy, transurethral resection of bladder tumor) between September 2009 and January 2019 were retrospectively evaluated. Demographic, clinical and pathological characteristics of the patients, preoperative comorbidity indices, postoperative complications, length of hospitalization, re-admission rates within 90 days and postoperative follow-up outcomes were recorded. Patients in similar tumor stages were divided into different subgroups. All subgroups were divided into two main categories: middle age (60-69 years-old) and elderly age (>/=70-years-old). RESULTS: No significant difference was found for all types of surgery in terms of postoperative outcomes in both age groups (p >0.05). Age-adjusted Charlson Comorbidity Index (ACCI), Preoperative Score to Predict Postoperative Mortality (POSPOM), Rockwood Frailty Index (RFI) and tumor characteristics were found to be more significant predictors for postoperative major complications and overall mortality than Eastern Cooperative Oncology Group (ECOG), American Society of Anesthesiologists (ASA) and New York Heart Association (NYHA) functional classification. CONCLUSIONS: Our findings show that patient age alone is not a risk factor for increased postoperative complications and overall mortality. Although many different comorbidity indices have been used in urological practice, ACCI, POSPOM and RFI are more valuable predictors. Uro-oncological surgeries may be performed safely in elderly males after a good clinical decision based on these indices. CI - Copyright by Polish Urological Association. FAU - Selvi, Ismail AU - Selvi I AD - Basaksehir Cam ve Sakura City Hospital, Department of Urology, Istanbul, Turkey. FAU - Arik, Ali Ihsan AU - Arik AI AD - Health Science University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Urology, Ankara, Turkey. FAU - Baydilli, Numan AU - Baydilli N AD - Erciyes University Medical School, Department of Urology, Kayseri, Turkey. FAU - Basay, Mehmet Sinan AU - Basay MS AD - Health Science University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Urology, Ankara, Turkey. FAU - Basar, Halil AU - Basar H AD - Health Science University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Urology, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20210305 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC8097655 OTO - NOTNLM OT - aging male OT - comorbidity indices OT - overall survival OT - postoperative complications OT - uro-oncological surgeries COIS- The authors declare no conflicts of interest. EDAT- 2021/05/13 06:00 MHDA- 2021/05/13 06:01 PMCR- 2021/01/01 CRDT- 2021/05/12 07:05 PHST- 2020/08/20 00:00 [received] PHST- 2020/10/01 00:00 [revised] PHST- 2021/02/10 00:00 [accepted] PHST- 2021/05/12 07:05 [entrez] PHST- 2021/05/13 06:00 [pubmed] PHST- 2021/05/13 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 0246 [pii] AID - 10.5173/ceju.2021.0246 [doi] PST - ppublish SO - Cent European J Urol. 2021;74(1):24-38. doi: 10.5173/ceju.2021.0246. Epub 2021 Mar 5. PMID- 33975782 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 4 IP - 6 DP - 2021 Dec TI - Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. PG - 893-903 LID - S2588-9311(21)00079-1 [pii] LID - 10.1016/j.euo.2021.04.005 [doi] AB - CONTEXT: Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. OBJECTIVE: To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitoring, and prognostication of bladder and kidney cancer. EVIDENCE ACQUISITION: A literature review was conducted through August 15, 2020 including prospective and retrospective studies. Keywords included "cell-free DNA", "circulating tumor DNA", "kidney cancer", "renal cell carcinoma", "bladder cancer", "upper tract urothelial carcinoma", and "urothelial carcinoma". EVIDENCE SYNTHESIS: Urine tumor DNA (utDNA) has sensitivity of 91% and specificity of 96% for detecting bladder cancer, outperforming cystoscopy and cytology. Increased utDNA and ctDNA are associated with progression from non-muscle-invasive to muscle-invasive disease. In patients undergoing cystectomy, ctDNA detection is associated with worse overall survival and disease recurrence, and with persistent tumor on surgical pathology in those who received neoadjuvant chemotherapy. cfDNA is significantly higher in patients with kidney cancer than in healthy controls or in those with benign lesions, and detectable ctDNA and increased cfDNA are associated with decreased survival. CONCLUSIONS: Combined data from small studies provide evidence that cfDNA and ctDNA may have the ability to detect, monitor, and prognosticate in patients with bladder, upper tract urothelial, and kidney cancers. PATIENT SUMMARY: In this review, we looked at the work that has been published so far on cell-free and circulating tumor DNA in bladder and kidney cancers. We found that while many of the studies were small, there is evidence that cell-free tumor DNA can emerge as a tool for the diagnosis and monitoring of treatment response for patients with these cancers. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Green, Elizabeth A AU - Green EA AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Roger.Li@moffitt.org. FAU - Albiges, Laurence AU - Albiges L AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. FAU - Choueiri, Toni K AU - Choueiri TK AD - Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. FAU - Freedman, Matthew AU - Freedman M AD - Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. FAU - Pal, Sumanta AU - Pal S AD - Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center Duarte, Duarte, CA, USA. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20210508 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Circulating Tumor DNA) SB - IM MH - *Carcinoma, Transitional Cell/diagnosis/genetics/therapy MH - *Circulating Tumor DNA/genetics MH - Humans MH - Kidney MH - *Kidney Neoplasms/diagnosis/genetics/therapy MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/genetics OTO - NOTNLM OT - Bladder cancer OT - Cell-free DNA OT - Circulating tumor DNA OT - Kidney cancer OT - Renal cell carcinoma OT - Urine tumor DNA OT - Urothelial carcinoma EDAT- 2021/05/13 06:00 MHDA- 2022/02/03 06:00 CRDT- 2021/05/12 05:59 PHST- 2020/12/21 00:00 [received] PHST- 2021/03/28 00:00 [revised] PHST- 2021/04/15 00:00 [accepted] PHST- 2021/05/13 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/05/12 05:59 [entrez] AID - S2588-9311(21)00079-1 [pii] AID - 10.1016/j.euo.2021.04.005 [doi] PST - ppublish SO - Eur Urol Oncol. 2021 Dec;4(6):893-903. doi: 10.1016/j.euo.2021.04.005. Epub 2021 May 8. PMID- 33973537 OWN - NLM STAT- MEDLINE DCOM- 20210625 LR - 20230917 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 31 IP - 4 DP - 2021 Jul 1 TI - Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. PG - 291-296 LID - 10.1097/MOU.0000000000000895 [doi] AB - PURPOSE OF REVIEW: The purpose of this article was to identify quality indicators for an optimized management of high-risk upper tract urothelial carcinoma (UTUC) requiring radical nephroureterectomy (RNU). RECENT FINDINGS: RNU with bladder cuff resection is the standard treatment of high-risk UTUC. For the bladder cuff resection, two main approaches are accepted: transvesical and extravesical. Lymph node dissection following a dedicated template should be performed in all high-risk patients undergoing RNU as it improves tumour staging and possibly survival. Postoperative bladder instillation of single-dose chemotherapy should be administered after RNU to decrease the risk of intravesical tumour recurrence. Perioperative systemic chemotherapy should always be considered for advanced cancers. Although level-1 evidence is available for adjuvant platinum-based chemotherapy, neoadjuvant regimens are still being evaluated. SUMMARY: Optimal management of high-risk UTUC requires evidence-based reproducible quality indicators in order to allow guidance and frameworks for clinical practices. Adherence to quality indicators allows for the measurement and comparison of outcomes that are likely to improve prognosis. Based on the literature, we found four evidence-based accepted quality indicators that are easily implementable to improve the management of high-risk UTUC patients treated with RNU: adequate management of the distal ureter/ bladder cuff, template-based lymph node dissection, single-shot postoperative intravesical chemotherapy, and perioperative systemic treatment. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Konig, Frederik AU - Konig F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, New York. AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. FAU - Mun, Dong-Ho AU - Mun DH AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - *Kidney Neoplasms/surgery MH - Neoplasm Recurrence, Local/epidemiology MH - Nephroureterectomy MH - Quality Indicators, Health Care MH - Retrospective Studies MH - *Ureter/surgery MH - *Ureteral Neoplasms/surgery EDAT- 2021/05/12 06:00 MHDA- 2021/06/29 06:00 CRDT- 2021/05/11 09:27 PHST- 2021/05/12 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/05/11 09:27 [entrez] AID - 00042307-202107000-00003 [pii] AID - 10.1097/MOU.0000000000000895 [doi] PST - ppublish SO - Curr Opin Urol. 2021 Jul 1;31(4):291-296. doi: 10.1097/MOU.0000000000000895. PMID- 33965961 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 2 DP - 2022 TI - Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival. PG - 130-137 LID - 10.1159/000515650 [doi] AB - INTRODUCTION: Limitations in tumor staging and the heterogeneous natural evolution of pT1 urothelial bladder carcinoma (UBC) make the choice of treatment challenging. We evaluated if histopathological substaging (pT1a, pT1b, and pT1c) helps predict disease recurrence, progression, and overall survival following transurethral resection of the bladder (TURB). METHODS: We included 239 consecutive patients diagnosed with pT1 UBC at TURB in a single institution since 2001. Each sample was interpreted by our specialized uropathologists trained to subclassify pT1 stage. Three groups were distinguished according to the degree of invasion: T1a (up to the muscularis mucosae [MM]), T1b (into the MM), and T1c (beyond the MM). RESULTS: T1 substaging was possible in 217/239 (90%) patients. pT1a, b, and c occurred in 124 (57), 59 (27), and 34 (16%), respectively. The median follow-up was 3.1 years, with a cumulative recurrence rate of 52%, progression rate of 20%, and survival rate of 54%. Recurrence was not significantly associated with tumor substage (p = 0.61). However, the Kaplan-Meier survival analysis showed a significantly higher progression rate among T1b (31) and T1c (26%) tumors than T1a (13%) (log-rank test: p = 0.001) stages. In a multivariable model including gender, age, ASA score, smoking, tumor grade, and presence of carcinoma in situ, T1 substage was the single variable significantly associated with progression-free survival (HR 1.7, p = 0.005). Nineteen patients (9%) needed radical cystectomy; among them, 12/19 (63%) had an invasive tumor. Overall survival was significantly associated with tumor substaging (p = 0.001). CONCLUSION: Histopathological substaging of pT1 UBC is significantly associated with tumor progression and overall survival and therefore appears to be a useful prognostic tool to counsel patients about treatment options. CI - (c) 2021 S. Karger AG, Basel. FAU - Grobet-Jeandin, Elisabeth AU - Grobet-Jeandin E AD - Urology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Wirth, Gregory Johannes AU - Wirth GJ AD - Urology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Benamran, Daniel AU - Benamran D AD - Urology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Dupont, Amandine AU - Dupont A AD - Pathology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Tille, Jean-Christophe AU - Tille JC AD - Pathology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Iselin, Christophe Emmanuel AU - Iselin CE AD - Urology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. LA - eng PT - Journal Article DEP - 20210507 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/*pathology/surgery MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - Predictive Value of Tests MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Pathology OT - Progression OT - Recurrence OT - Substaging system OT - Survival EDAT- 2021/05/10 06:00 MHDA- 2022/03/04 06:00 CRDT- 2021/05/09 20:55 PHST- 2020/11/26 00:00 [received] PHST- 2021/02/02 00:00 [accepted] PHST- 2021/05/10 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2021/05/09 20:55 [entrez] AID - 000515650 [pii] AID - 10.1159/000515650 [doi] PST - ppublish SO - Urol Int. 2022;106(2):130-137. doi: 10.1159/000515650. Epub 2021 May 7. PMID- 33960102 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20211223 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 Suppl 1 DP - 2021 Oct TI - A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol. PG - 9-17 LID - 10.1111/bju.15365 [doi] AB - OBJECTIVES: This article presents the clinical trial protocol for a phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (NMIBC), the SUB-urothelial DUrvalumab injection-1 study (SUBDUE-1). The primary objectives of this study are to assess the safety of sub-urothelial injection of durvalumab using patient reported outcome measures and observed local or systemic adverse events. The secondary objectives are to examine the local immunological efficacy of sub-urothelial administration of durvalumab. PATIENTS AND METHODS: The SUBDUE-1 trial will include adult patients with either high-risk NMIBC or MIBC, who are scheduled for radical cystectomy or who have refused or are unsuitable for systemic neoadjuvant chemotherapy. Three fixed total dose levels of durvalumab (25, 75, 150 mg) will be studied to identify a dose suitable to be taken forward into phase II trials. The primary endpoint is to evaluate the safety and tolerability of the trial intervention in terms of the incidence and severity of adverse events and the potential establishment of dose-limiting toxicities. The secondary efficacy endpoints include rates of pT0 status at resection, lymph node status, as well as the change in distribution of tumour-infiltrating lymphocytes and tumour-activated macrophages between pre- and post-injection bladder biopsies. Translational studies will focus on bladder tumour molecular sub-typing, immune infiltrate characterisation, and immune checkpoint protein expression relative to efficacy end-points. OUTCOME AND SIGNIFICANCE: If proven safe and effective, this novel strategy comprising sub-urothelial durvalumab injections aimed at promoting an anti-tumour immune reaction, will provide additional treatment options for reducing tumour recurrence and progression in treatment-naive patients with high-risk NMIBC or in patients with bacille Calmette-Guerin-refractory NMIBC. Local administration of durvalumab may be associated with a reduced rate of immunological side-effects and lower costs when compared to systemic delivery. CI - (c) 2021 The Authors. BJU International (c) 2021 BJU International. FAU - Moe, Andrew AU - Moe A AUID- ORCID: 0000-0001-6323-6238 AD - University of Western Australia (UWA) Medical School, University of Western Australia, Perth, WA, Australia. AD - Urology and Medical Oncology Departments, South Metropolitan Health Service, Perth, WA, Australia. AD - Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia. FAU - Liow, Elizabeth AU - Liow E AD - Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia. FAU - Redfern, Andrew AU - Redfern A AD - University of Western Australia (UWA) Medical School, University of Western Australia, Perth, WA, Australia. AD - Urology and Medical Oncology Departments, South Metropolitan Health Service, Perth, WA, Australia. AD - Cancer Division, Harry Perkins Institute of Medical Research, Perth, WA, Australia. FAU - Swarbrick, Nicole AU - Swarbrick N AD - Department of Anatomical Pathology, PathWest Laboratory Medicine WA, Perth, WA, Australia. AD - Division of Pathology and Laboratory Medicine, UWA Medical School, University of Western Australia, Perth, WA, Australia. FAU - Ferguson, Tom AU - Ferguson T AD - Urology and Medical Oncology Departments, South Metropolitan Health Service, Perth, WA, Australia. FAU - Davis, Ian D AU - Davis ID AD - Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia. AD - Eastern Health Clinical School, Monash University, Melbourne, Vic., Australia. AD - Department of Oncology, Eastern Health, Melbourne, Vic., Australia. FAU - Hayne, Dickon AU - Hayne D AD - University of Western Australia (UWA) Medical School, University of Western Australia, Perth, WA, Australia. AD - Urology and Medical Oncology Departments, South Metropolitan Health Service, Perth, WA, Australia. AD - Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia. LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210506 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents, Immunological) RN - 28X28X9OKV (durvalumab) SB - IM MH - Adult MH - Antibodies, Monoclonal/*administration & dosage/adverse effects MH - Antineoplastic Agents, Immunological/*administration & dosage/adverse effects MH - Clinical Trials, Phase I as Topic MH - Humans MH - Injections, Intralesional MH - Neoplasm Invasiveness MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Urothelium OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - anti-PD-L1 OT - clinical trial OT - durvalumab OT - immunotherapy OT - sub-urothelial injection OT - urothelial carcinoma EDAT- 2021/05/08 06:00 MHDA- 2021/12/24 06:00 CRDT- 2021/05/07 07:41 PHST- 2021/05/08 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/05/07 07:41 [entrez] AID - 10.1111/bju.15365 [doi] PST - ppublish SO - BJU Int. 2021 Oct;128 Suppl 1:9-17. doi: 10.1111/bju.15365. Epub 2021 May 6. PMID- 33958148 OWN - NLM STAT- MEDLINE DCOM- 20220304 LR - 20220304 IS - 1558-1977 (Electronic) IS - 0889-8588 (Linking) VI - 35 IP - 3 DP - 2021 Jun TI - Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. PG - 513-529 LID - S0889-8588(21)00021-6 [pii] LID - 10.1016/j.hoc.2021.02.003 [doi] AB - Transurethral resection of bladder tumor remains the cornerstone of non-muscle invasive bladder cancer management, proper risk stratification, and appropriate selection of adjuvant therapy. A single, postoperative dose of intravesical chemotherapy is used for low-risk patients; patients with high-grade, high-risk disease should receive intravesical bacillus Calmette-Guerin (BCG) induction and maintenance therapy. For patients who develop BCG-unresponsive disease, cystectomy remains the standard of care. Pembrolizumab and valrubicin are approved in the BCG failure setting and as alternative treatments to cystectomy. Nadofaragene firadenovec, vicinium, hyperthermic chemotherapy, and various combination therapies are under investigation as treatment options for patients in the salvage setting. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. FAU - Brooks, Nathan A AU - Brooks NA AD - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: AKamat@MDAnderson.org. LA - eng PT - Journal Article PT - Review DEP - 20210418 PL - United States TA - Hematol Oncol Clin North Am JT - Hematology/oncology clinics of North America JID - 8709473 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Salvage Therapy MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - BCG failure OT - BCG naive OT - Intravesical therapy OT - Non-muscle invasive bladder cancer COIS- Disclosure A.M. Kamat has served as a consultant or sat on the advisory board of the following: Abbott Molecular, Arquer, ArTara, Asieris, Astra Zeneca, BioClin Therapeutics, BMS, Cepheid, Cold Genesys, Eisai, Engene, Inc, Ferring, FerGene, Imagin, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara, Roviant, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, and US Biotest. He has received grant funding or research support from: Adolor, BMS, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH, SPORE, and AIBCCR. EDAT- 2021/05/08 06:00 MHDA- 2022/03/05 06:00 CRDT- 2021/05/07 06:25 PHST- 2021/05/07 06:25 [entrez] PHST- 2021/05/08 06:00 [pubmed] PHST- 2022/03/05 06:00 [medline] AID - S0889-8588(21)00021-6 [pii] AID - 10.1016/j.hoc.2021.02.003 [doi] PST - ppublish SO - Hematol Oncol Clin North Am. 2021 Jun;35(3):513-529. doi: 10.1016/j.hoc.2021.02.003. Epub 2021 Apr 18. PMID- 33953845 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210508 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 12 IP - 9 DP - 2021 Apr 27 TI - A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer. PG - 917-922 LID - 10.18632/oncotarget.27944 [doi] AB - BACKGROUND: High-risk non-muscle invasive bladder cancer (NMIBC) is thought to be associated with a higher risk of recurrence and progression. A recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies. This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC. MATERIALS AND METHODS: A total of 138 patients who were initially diagnosed with high-risk NMIBC between January 2012 to December 2016 were enrolled in this study. The criteria for the high-risk classification followed the EAU guidelines. The recurrence-free and progression-free survival of the higher and lower De Ritis ratio groups were compared. The cut-off value of the De Ritis ratio was set at 1.35, based on a receiver operator curve analysis. RESULTS: The median observation period was 50.3 months. Among these patients, 32 (23.1%) patients developed recurrent disease and 15 (10.9%) patients showed progression. A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression. CONCLUSIONS: The De Ritis ratio might be a risk factor for progression in high-risk NMIBC. CI - Copyright: (c) 2021 Fukui-Kawaura et al. FAU - Fukui-Kawaura, Sachi AU - Fukui-Kawaura S AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Araki, Yushi AU - Araki Y AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Nishimura, Reona AU - Nishimura R AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Uemura, Koichi AU - Uemura K AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Namura, Kazuhiro AU - Namura K AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Mizuno, Nobuhiko AU - Mizuno N AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. FAU - Yao, Masahiro AU - Yao M AD - Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan. FAU - Uemura, Hiroji AU - Uemura H AD - Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Ikeda, Ichiro AU - Ikeda I AD - Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan. LA - eng PT - Journal Article DEP - 20210427 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC8092343 OTO - NOTNLM OT - ALT OT - AST OT - De Ritis OT - high risk NMIBC COIS- CONFLICTS OF INTEREST Authors have no conflicts of interest to declare. EDAT- 2021/05/07 06:00 MHDA- 2021/05/07 06:01 PMCR- 2021/04/27 CRDT- 2021/05/06 07:04 PHST- 2020/10/26 00:00 [received] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/05/06 07:04 [entrez] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/05/07 06:01 [medline] PHST- 2021/04/27 00:00 [pmc-release] AID - 27944 [pii] AID - 10.18632/oncotarget.27944 [doi] PST - epublish SO - Oncotarget. 2021 Apr 27;12(9):917-922. doi: 10.18632/oncotarget.27944. eCollection 2021 Apr 27. PMID- 33948507 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220422 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 7 IP - 4 DP - 2021 Apr TI - APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival. PG - e06756 LID - 10.1016/j.heliyon.2021.e06756 [doi] LID - e06756 AB - BACKGROUND: Human apurinic/apyrimidinic (AP) endonuclease 1 (APE1) plays a critical role in DNA base excision repair (BER) pathway and has been reported to be overexpressed in multiple cancers. Previously, we have shown that histone chaperone FACT complex (Facilitates Chromatin Transcription, a heterodimer of SSRP1 and SPT16 proteins) facilitates the chromatin access and DNA repair function of APE1, and their expression levels are correlated with promoting drug resistance in cancer. FACT inhibitor has been introduced in phase I and II clinical trials for chemosensitization of advanced solid cancers. However, the expression profile and prognostic significance of APE1 and FACT complex in bladder cancer remains largely unknown. METHODS: Retrospectively, 69 bladder cancer samples were retrieved and submitted for immunohistochemical staining of APE1 and SSRP1. Expression profile including cytoplasmic and nuclear staining of APE1 and expression level of SSRP1 was examined and semi-quantified to render a H-score. The prognostic significance of APE1 and SSRP1 was evaluated by Kaplan-Meier survival analysis in our cohort and R2 database. RESULTS: APE1 expression is elevated in bladder cancer compared to normal adjacent tissues. Compared with low grade tumors, high grade tumors show a shift in the staining pattern including higher intensity and positive cytoplasmic staining. Carcinoma in situ has a similar staining pattern to high grade tumors. APE1 and SSRP1 staining intensity increases as tumor progresses with stage. There is a correlation between APE1 and SSRP1 staining in invasive bladder cancer (Spearman r = 0.5466, p < 0.0001). The increased expression of APE1 and SSRP1 is associated with poor survival in Kaplan-Meier analysis in our cohort and in R2-TCGA bladder cancer database. CONCLUSIONS: The expression levels of APE1 and SSRP1 are significantly elevated in bladder cancer as compared to normal adjacent tissues. APE1 correlates with SSRP1 expression in high grade tumors. Overexpression of APE1 and SSRP1 is associated with poor survival in bladder cancer. This suggests the usage of FACT inhibitor curaxins in muscle invasive bladder cancer to target FACT complex and APE1 to improve chemosensitization after further validation. CI - (c) 2021 The Author(s). FAU - Song, Heyu AU - Song H AD - Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, United States. FAU - Zeng, Jiping AU - Zeng J AD - College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States. AD - Department of Urology, University of Arizona College of Medicine, Tucson, AZ, United States. FAU - Lele, Subodh AU - Lele S AD - Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States. FAU - LaGrange, Chad A AU - LaGrange CA AD - Division of Urologic Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, United States. AD - Fred & Pamela Buffett Cancer Center, Omaha, NE, United States. FAU - Bhakat, Kishor K AU - Bhakat KK AD - Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, United States. AD - Fred & Pamela Buffett Cancer Center, Omaha, NE, United States. LA - eng PT - Journal Article DEP - 20210416 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC8080038 OTO - NOTNLM OT - APE1 OT - Bladder cancer OT - SSRP1 COIS- The authors declare no conflict of interest. EDAT- 2021/05/06 06:00 MHDA- 2021/05/06 06:01 PMCR- 2021/04/16 CRDT- 2021/05/05 06:27 PHST- 2020/12/24 00:00 [received] PHST- 2021/03/18 00:00 [revised] PHST- 2021/04/06 00:00 [accepted] PHST- 2021/05/05 06:27 [entrez] PHST- 2021/05/06 06:00 [pubmed] PHST- 2021/05/06 06:01 [medline] PHST- 2021/04/16 00:00 [pmc-release] AID - S2405-8440(21)00859-8 [pii] AID - e06756 [pii] AID - 10.1016/j.heliyon.2021.e06756 [doi] PST - epublish SO - Heliyon. 2021 Apr 16;7(4):e06756. doi: 10.1016/j.heliyon.2021.e06756. eCollection 2021 Apr. PMID- 42877699 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261015 LR - 20261015 IS - 1734-1922 (Print) IS - 1896-9151 (Electronic) IS - 1734-1922 (Linking) VI - 22 IP - 4 DP - 2026 TI - Blood count-derived inflammatory markers predict time to Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer. PG - 2175-2183 LID - 10.5114/aoms/130303 [doi] AB - INTRODUCTION: Bacillus Calmette-Guerin (BCG) treatment failure remains a significant clinical problem in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) risk scores remain the most commonly used models in the prediction of NMIBC recurrence and progression. On the other hand, well-established predictors of BCG failure are still lacking. Our aim was to evaluate the utility of blood count-derived inflammatory markers for BCG failure prediction in patients with high-risk NMIBC. MATERIAL AND METHODS: One hundred and eighty-three consecutive patients with high-risk NMIBC, who underwent transurethral resection of the bladder tumour (TURBT) and were further treated with BCG instillations were included in the study. Bacillus Calmette-Guerin failure was retrospectively determined based on European Association of Urology 2019 guidelines. Differences in BCG failure-free survival were assessed using the log-rank test. Logistic regression was utilized for uni- and multivariate analysis. RESULTS: Kaplan-Meier analysis revealed that patients with a high preoperative neutrophil-to-lymphocyte ratio (NLR > 2.3), platelet-to-lymphocyte ratio (PLR > 147), neutrophil-to-erythrocyte ratio (NER > 0.93), higher systemic inflammatory marker (SIM) score and with a low lymphocyte-to-monocyte ratio (LMR < 2.55) had shorter time to BCG failure (p < 0.05). In the multivariate model, all markers except for LMR remained a significant adjunct to the CUETO recurrence risk score when predicting BCG failure. CONCLUSIONS: Our study demonstrates the utility of blood count-derived inflammatory markers in the prediction of BCG failure in high-risk NMIBC. Implementation of NLR, PLR, NER and SIM score might be of clinical value especially when combined with the CUETO scoring system. CI - Copyright: (c) 2021 Termedia & Banach. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. FAU - Garbas, Karolina AU - Garbas K AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. FAU - Borkowski, Tomasz AU - Borkowski T AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland. LA - eng PT - Journal Article DEP - 20210505 PL - Poland TA - Arch Med Sci JT - Archives of medical science : AMS JID - 101258257 PMC - PMC13663636 OTO - NOTNLM OT - BCG failure OT - BCG unresponsive OT - neutrophil-to-lymphocyte ratio OT - non-muscle-invasive bladder cancer OT - systemic inflammatory markers COIS- The authors declare no conflict of interest. EDAT- 2021/05/05 00:00 MHDA- 2021/05/05 00:01 PMCR- 2021/05/05 CRDT- 2026/10/15 15:58 PHST- 2020/09/01 00:00 [received] PHST- 2020/11/08 00:00 [accepted] PHST- 2021/05/05 00:01 [medline] PHST- 2021/05/05 00:00 [pubmed] PHST- 2026/10/15 15:58 [entrez] PHST- 2021/05/05 00:00 [pmc-release] AID - 130303 [pii] AID - 10.5114/aoms/130303 [doi] PST - epublish SO - Arch Med Sci. 2021 May 5;22(4):2175-2183. doi: 10.5114/aoms/130303. eCollection 2026. PMID- 33945147 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20261010 IS - 2092-9293 (Electronic) IS - 1976-9571 (Linking) VI - 43 IP - 11 DP - 2021 Nov TI - Adhesion GPR123 is an indicator for recurrence and prognosis in bladder cancer. PG - 1317-1325 LID - 10.1007/s13258-021-01108-w [doi] AB - BACKGROUND: Bladder cancer is a common urinary cancer, and most patients suffer tumor recurrence after surgery. Identifying more prognostic biomarkers is an essential task for precious treatment. OBJECTIVE: To evaluate the expression and clinical significance of GPR123, Angiotensin-I a type of adhesion G protein-coupled receptors (aGPCRs), in bladder cancer. METHODS: The expressions of GPR123 in two retrospective cohorts comprised of 150 and 56 patients with bladder cancer respectively, were detected with and immunohistochemistry (IHC). Moreover, GPR123 mRNAs in 11 non-muscle-invasive bladder cancers (NMIBCs) and 11 muscle-invasive bladder cancers (MIBCs) were detected with qRT-PCR. The correlation between GPR123 and the clinicopathological characters was estimated by Chi-square test. The significance of GPR123 and other clinicopathological characters in recurrence and prognosis of bladder cancer was evaluated by univariate and multivariate analyses. RESULTS: GPR123 was mainly expressed in the cell membrane of bladder cancer. The percentages of high GPR123 expression in NMIBC and MIBC were 38.32 and 55.81 % in cohort 1, and 16.00 and 43.90 % in cohort 2. With qRT-PCR and IHC, we showed that GPR123 expression in MIBC was significantly higher than that in NMIBC. GPR123 was significantly associated with T and M stage of bladder cancer. GPR123 expression was all correlated with recurrence (disease-free survival rate), and prognosis (overall survival rate). High GPR123 expression was identified as independent biomarker indicating easier recurrence and poorer prognosis. CONCLUSIONS: GPR123 was an independent biomarker of bladder cancer for recurrence and prognosis, indicating that GPR123 detection with IHC after operation could help find the high-risk patients and direct the post-operational surveillance. CI - (c) 2021. The Genetics Society of Korea. FAU - Liu, Yaming AU - Liu Y AD - Department of Urinary Surgery, Yidu Central Hospital of Weifang City, Weifang, China. FAU - Wang, Guodong AU - Wang G AD - Department of Vascular Surgery, Yidu Central Hospital of Weifang City, Weifang, China. FAU - Cui, Tongwei AU - Cui T AD - Department of Urinary Surgery, Yidu Central Hospital of Weifang City, Weifang, China. FAU - Lv, Lin AU - Lv L AD - Department of Health Care, Jinan Municipal Hospital of Traditional Chinese Medicine, 76 Gongqingtuan road, Jinan, Shandong, China. lujiubin9208@163.com. LA - eng PT - Journal Article DEP - 20210504 PL - Korea (South) TA - Genes Genomics JT - Genes & genomics JID - 101481027 RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, G-Protein-Coupled) SB - IM MH - Biomarkers, Tumor/genetics/*metabolism MH - *Disease Progression MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Receptors, G-Protein-Coupled/genetics/*metabolism MH - Retrospective Studies MH - Urinary Bladder Neoplasms/genetics/*metabolism/pathology OTO - NOTNLM OT - Bladder cancer OT - GPR123 OT - Prognosis OT - Recurrence EDAT- 2021/05/05 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/05/04 12:42 PHST- 2021/01/22 00:00 [received] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/05/05 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/05/04 12:42 [entrez] AID - 10.1007/s13258-021-01108-w [pii] AID - 10.1007/s13258-021-01108-w [doi] PST - ppublish SO - Genes Genomics. 2021 Nov;43(11):1317-1325. doi: 10.1007/s13258-021-01108-w. Epub 2021 May 4. PMID- 33943049 OWN - NLM STAT- MEDLINE DCOM- 20220208 LR - 20220208 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 62 IP - 3 DP - 2021 May TI - Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer. PG - 274-281 LID - 10.4111/icu.20200425 [doi] AB - PURPOSE: A readily accessible biomarker to identify which patients with bladder cancer are more likely to respond to neoadjuvant chemotherapy (NAC) could help clinicians avoid unnecessary chemotherapy and prevent its subsequent complications in some patients. The primary objective of this study was to investigate the association of immunohistochemical markers of tumor subtype with response to NAC and survival of patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: MIBC patients treated with NAC were retrospectively included. The tissue microarrays were assembled from transurethral resection of bladder tumor (TURBT) specimens and immunohistochemistry (IHC) was performed. The association of independent variables, including IHC markers, and clinical covariates with clinical complete response to NAC and with overall survival was assessed by using logistic regression and Cox proportional hazard regression analysis, respectively. Kaplan-Meier curves were plotted for different IHC-based tumor subtypes. RESULTS: Data from 140 MIBC patients treated with NAC were retrospectively reviewed. A total of 63 patients with available TURBT specimens were eligible to be included in the analysis. Our results showed that the IHC signature of KRT5/6(+)/KRT20(-), as a combined marker of basal subtype, was the only covariate significantly associated with complete response to NAC (p=0.037). Moreover, we found no statistically significant differences in overall survival between different IHC-based subtypes (p=0.721). CONCLUSIONS: The IHC expression of KRT5/6 and KRT20, as a readily accessible combined marker, may help us to identify the patients most likely to benefit from chemotherapy. The clinical utility of this marker needs to be established in larger prospective studies. CI - (c) The Korean Urological Association, 2021. FAU - Razzaghdoust, Abolfazl AU - Razzaghdoust A AUID- ORCID: 0000-0002-2619-3774 AD - Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Ghajari, Mahdi AU - Ghajari M AUID- ORCID: 0000-0002-2298-5731 AD - Department of Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Basiri, Abbas AU - Basiri A AUID- ORCID: 0000-0002-8101-8151 AD - Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Torbati, Peyman Mohammadi AU - Torbati PM AUID- ORCID: 0000-0002-7495-6764 AD - Department of Pathology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Jafari, Anya AU - Jafari A AUID- ORCID: 0000-0001-7175-0034 AD - Department of Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Fattahi, Mohammad Reza AU - Fattahi MR AUID- ORCID: 0000-0002-5619-396X AD - Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. FAU - Salahi, Maryam AU - Salahi M AUID- ORCID: 0000-0002-9401-829X AD - Department of Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Mofid, Bahram AU - Mofid B AUID- ORCID: 0000-0003-2151-3510 AD - Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mofid429@sbmu.ac.ir. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) RN - 0 (KRT20 protein, human) RN - 0 (KRT5 protein, human) RN - 0 (KRT6A protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (Keratin-6) SB - IM MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers/metabolism MH - *Chemotherapy, Adjuvant MH - *Cystectomy MH - Female MH - Humans MH - Immunohistochemistry MH - Keratin-20/metabolism MH - Keratin-5/metabolism MH - Keratin-6/metabolism MH - Logistic Models MH - Male MH - Middle Aged MH - *Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Proportional Hazards Models MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*metabolism/mortality/*therapy PMC - PMC8100015 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Chemotherapy OT - Immunohistochemistry COIS- The authors have nothing to disclose. EDAT- 2021/05/05 06:00 MHDA- 2022/02/09 06:00 PMCR- 2021/05/01 CRDT- 2021/05/04 08:55 PHST- 2020/09/27 00:00 [received] PHST- 2020/12/23 00:00 [revised] PHST- 2020/12/31 00:00 [accepted] PHST- 2021/05/04 08:55 [entrez] PHST- 2021/05/05 06:00 [pubmed] PHST- 2022/02/09 06:00 [medline] PHST- 2021/05/01 00:00 [pmc-release] AID - 62.274 [pii] AID - 10.4111/icu.20200425 [doi] PST - ppublish SO - Investig Clin Urol. 2021 May;62(3):274-281. doi: 10.4111/icu.20200425. PMID- 33935020 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20250728 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 5 IP - 3 DP - 2022 Jun TI - Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guerin Therapy Outcomes. PG - 347-356 LID - S2588-9311(21)00077-8 [pii] LID - 10.1016/j.euo.2021.04.003 [doi] AB - BACKGROUND: Guideline indications for restaging transurethral resection (reTUR) for high-grade (HG) Ta bladder tumors vary due to a paucity of data. OBJECTIVE: To investigate guideline-based, risk-adapted approaches to reTUR for HG Ta lesions. DESIGN, SETTING, AND PARTICIPANTS: An institutional review of HG Ta patients who received adequate bacillus Calmette-Guerin (BCG) from 2000 to 2019 was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Guideline criteria for reTUR were used to stratify patients. Kaplan-Meier product limits estimated survival. Cox regression and log-rank tests identified association of variables with survival. RESULTS AND LIMITATIONS: Of the 209 patients with HG Ta bladder cancer, 104 (50%) underwent reTUR, which identified residual disease in 39 patients (38%). Only one patient (1%) was upstaged to pT1 on reTUR. In all unstratified HG Ta patients, reTUR was associated with improved progression-free survival (p = 0.050) and recurrence-free survival (RFS; p = 0.003). The 5-yr RFS for patients who underwent versus those who did not undergo reTUR based on AUA guidelines was 73% (95% confidence interval 63-81%) versus 52% (40-62%), and for those who underwent versus those who did not undergo reTUR based on EAU guidelines was 76% (61-86%) versus 22% (4-49%). In 45 patients meeting both AUA high-risk criteria (large, multifocal tumors) and EAU criteria (lack of detrusor muscle) for reTUR, lack of restaging was associated with over a two-fold increase in recurrence (67% vs 15%, p = 0.002) and progression (25% vs 6%, p = 0.109). Data were limited by selection bias unaccounted for in selecting candidates for reTUR. CONCLUSIONS: Restaging TUR in all HG Ta patients, regardless of risk stratification, was associated with improved outcomes. The benefit of reTUR was most notable in high-risk patients without muscle in the index specimen, consistent with components of both AUA and EAU guidelines. These data support a non-risk-adapted approach to reTUR for all HG Ta lesions. PATIENT SUMMARY: Restaging bladder tumor resection improves outcomes in patients with high-grade Ta tumors treated with bacillus Calmette-Guerin (BCG). CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Brooks, Nathan AU - Brooks N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matulay, Justin AU - Matulay J AD - Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Nogueras-Gonzalez, Graciela M AU - Nogueras-Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nagaraju, Supriya AU - Nagaraju S AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States GR - R03 CA109917/CA/NCI NIH HHS/United States GR - T32 CA079449/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210429 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/drug therapy/surgery MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery PMC - PMC8553807 MID - NIHMS1701237 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle invasive bladder cancer OT - Restaging transurethral resection EDAT- 2021/05/04 06:00 MHDA- 2022/06/09 06:00 PMCR- 2023/06/01 CRDT- 2021/05/03 05:53 PHST- 2021/02/23 00:00 [received] PHST- 2021/03/20 00:00 [revised] PHST- 2021/04/13 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2021/05/03 05:53 [entrez] PHST- 2023/06/01 00:00 [pmc-release] AID - S2588-9311(21)00077-8 [pii] AID - 10.1016/j.euo.2021.04.003 [doi] PST - ppublish SO - Eur Urol Oncol. 2022 Jun;5(3):347-356. doi: 10.1016/j.euo.2021.04.003. Epub 2021 Apr 29. PMID- 33934964 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20211223 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. PG - 434.e23-434.e29 LID - S1078-1439(21)00136-8 [pii] LID - 10.1016/j.urolonc.2021.03.026 [doi] AB - BACKGROUND: Optical coherence tomography (OCT) is a novel imaging modality that provides microstructural information of different tissue layers using near-infrared light. This prospective, multicenter phase II trial aimed to assess the accuracy of OCT-assisted cystoscopy for bladder tumor staging. METHODS: Patients with primary or recurrent bladder tumors (Ta,T1) identified by outpatient cystoscopy were included. The primary objective was to assess the accuracy and positive predictive value of for determining tumor stage >/=T1 correlated by histopathology. 72 suspicious lesions from 63 patients were eligible to analyze in the study. All suspected lesions were evaluated with conventional cystoscopy, interpreted in real-time using OCT, and then resected. All results were compared to pathology. A total of 363 OCT images of tumor and normal mucosa in 25 patients were obtained to evaluate diagnostic efficacy of the computer-aided texture analysis algorithm. RESULTS: Sensitivity and specificity for predicting invasive tumors (>/= T1, n = 17) were 58.8% and 92.7% for cystoscopy, 64.7% and 100% for OCT-assisted cystoscopy, respectively. Accuracy of cystoscopy and OCT-assisted cystoscopy for predicting invasive tumor was 84.7% and 91.7% (P = 0.063), respectively. Cystoscopy and OCT-assisted cystoscopy correctly predicted T stage in 52/72 and 59/72 cases, respectively (P = 0.016). Cystoscopy missed 2 more invasive tumors than OCT-assisted cystoscopy. Cystoscopy (14.3%, 1/7) and OCT-assisted cystoscopy (28.6%, 2/7) showed relatively low sensitivity in detecting muscle invasion. Computer aided texture analysis demonstrated 75.1% sensitivity, 64.0% specificity, and 74.4% accuracy for differentiating tumor and normal urothelium. CONCLUSION: OCT-assisted cystoscopy is a real time noninvasive and simple procedure that enhanced the accuracy of staging bladder tumors and prediction of any tumor invasion. Though the study did not meet the prespecified primary endpoint, OCT imaging is a promising adjunct to cystoscopy that may supplement intraoperative decision-making during transurethral resection of bladder tumors and additional prospective studies are warranted. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX. FAU - Scherr, Douglas S AU - Scherr DS AD - Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY. FAU - Slaton, Joel AU - Slaton J AD - Department of Urology, University of Minnesota, Minneapolis, MIN. FAU - Liu, Hao AU - Liu H AD - Department of Biostatistics, Indiana University School of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN. FAU - Feeny, Katy Ledford AU - Feeny KL AD - Department of Bioengineering, University of Toledo, Toledo, OH. FAU - Lingley-Papadopoulos, Colleen AU - Lingley-Papadopoulos C AD - School of Engineering & Applied Science, The George Washington University, Washington, DC. FAU - Gearheart, John AU - Gearheart J AD - School of Engineering & Applied Science, The George Washington University, Washington, DC. FAU - Zara, Jason M AU - Zara JM AD - School of Engineering & Applied Science, The George Washington University, Washington, DC. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX. Electronic address: slerner@bcm.edu. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study DEP - 20210429 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - *Cystoscopy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Predictive Value of Tests MH - Prospective Studies MH - Reproducibility of Results MH - *Tomography, Optical Coherence MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Optical coherence tomography OT - Optical imaging OT - Staging EDAT- 2021/05/04 06:00 MHDA- 2021/12/24 06:00 CRDT- 2021/05/03 05:51 PHST- 2020/07/08 00:00 [received] PHST- 2021/03/14 00:00 [revised] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/05/03 05:51 [entrez] AID - S1078-1439(21)00136-8 [pii] AID - 10.1016/j.urolonc.2021.03.026 [doi] PST - ppublish SO - Urol Oncol. 2021 Jul;39(7):434.e23-434.e29. doi: 10.1016/j.urolonc.2021.03.026. Epub 2021 Apr 29. PMID- 33932015 OWN - NLM STAT- MEDLINE DCOM- 20220211 LR - 20220211 IS - 1314-2143 (Electronic) IS - 0204-8043 (Linking) VI - 63 IP - 2 DP - 2021 Apr 30 TI - Age and sex do not affect first year recurrence in patients with non-muscle invasive bladder cancer. PG - 242-246 LID - 10.3897/folmed.63.e53234 [doi] AB - INTRODUCTION: Although demographic heterogeneity in the management of patients with non-muscle invasive bladder tumor (NMIBT) is an important factor, there are only minimal evidence-based recommendations that adjust for patient age and gender. The relationship and impact of age and gender on the recurrence in NBIMT is poorly investigated and understood. AIM: The aim of the study was to evaluate the impact of age and sex on the recurrence of non-muscle invasive bladder cancer. MATERIALS AND METHODS: Patients treated with transurethral resection (TUR) of primary NMIBT were included in the study. Risk calculation was made according to the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Prognostic factors for predicting tumor recurrence up to 5 years including age and sex were analyzed. The Mann-Whitney U test was used for comparison of non-parametric variables in independent groups. Kaplan-Meier method, with log rank (Mantel-Cox) analyses applied for comparison of mean duration of remission by sex and age, was used to calculate mean duration of remission. Results: A total of 81 patients, 68 males (mean age 59.03 years) and 13 females (mean age 58.13 years) were eligible for final analysis. Mean survival time of patients. CI - This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Kocan, Huseyin AU - Kocan H AUID- ORCID: 0000-0002-0670-8080 AD - Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. FAU - Kadihasanoglu, Mustafa AU - Kadihasanoglu M AD - Istanbul Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article PL - Bulgaria TA - Folia Med (Plovdiv) JT - Folia medica JID - 2984761R SB - IM MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Survival Rate MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - age OT - bladder tumor OT - recurrence OT - sex OT - transurethral resection EDAT- 2021/05/02 06:00 MHDA- 2022/02/12 06:00 CRDT- 2021/05/01 06:32 PHST- 2020/04/14 00:00 [received] PHST- 2020/09/11 00:00 [accepted] PHST- 2021/05/01 06:32 [entrez] PHST- 2021/05/02 06:00 [pubmed] PHST- 2022/02/12 06:00 [medline] AID - 10.3897/folmed.63.e53234 [doi] PST - ppublish SO - Folia Med (Plovdiv). 2021 Apr 30;63(2):242-246. doi: 10.3897/folmed.63.e53234. PMID- 33931844 OWN - NLM STAT- MEDLINE DCOM- 20220322 LR - 20220322 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 19 IP - 1 DP - 2021 Apr 28 TI - Prognostic value of HPV DNA in Urothelial Carcinoma of the Bladder: A Preliminary Report of 2-Year Follow-up Results. PG - 45-49 LID - 10.22037/uj.v18i.6429 [doi] AB - PURPOSE: The association between the human papillomavirus (HPV) and anogenital carcinomas is well established. However, despite its anatomic adjacency, the relationship between HPV and urothelial carcinoma of the bladder (UCB) is less clear. Recent meta-analysis and case-control studies demonstrated a significant relationship between the presence of HPV DNA and UCB. The aim of this clinical study was to compare the 2-year follow-up results of HPV-positive and HPV-negative UCB patients to evaluate the prognostic value of HPV DNA positivity in UCB. METHODS: The study included patients with stage pTa and pT1 UCB who underwent polymerase chain reaction (PCR) analysis of HPV DNA between January 1 and November 30, 2018. Based on their PCR results, 19 HPV-positive and 38 HPV-negative UCB patients who had regular follow-up in our clinic were evaluated in terms of tumor recurrence and disease progression over a 2-year follow-up period. RESULTS: There was no significant difference between the groups in terms of age, follow-up time, smoking, or tumor grade (P= .576, P= .368, P= .080, and P= .454). Tumor recurrence was observed at least once in 47.3% (n=9) of the 19 HPV-positive patients and 36.8% (n=14) of the 38 HPV-negative patients (P= .445). There was no difference in disease progression between the groups during follow-up. CONCLUSION: In our sample of UCB patients, the presence of HPV DNA was associated with a trend toward higher recurrence rate during the 2-year follow-up, though the difference was not statistically significant. No difference in disease progression was observed based on HPV DNA positivity. FAU - Sarier, Mehmet AU - Sarier M AD - Department of Urology, Istinye University Istanbul Turkey drsarier@gmail.com. FAU - Usta, Sibel Surmen AU - Usta SS AD - Department of Obstetrics and Gynaecology, Medical Park Hospital Antalya Turkey . sibelsurmenusta@hotmail.com. FAU - Turgut, Hasan AU - Turgut H AD - Facult of Health Sciences, Avrasya University, Trabzon, Turkey. drhasanturgut@hotmail.com. FAU - Ozturk, Sefa Alperen AU - Ozturk SA AD - Department of Urology, Suleyman Demirel University, Isparta, Turkey. dr.sefa.alperen@gmail.com. FAU - Soylu, Ahmet AU - Soylu A AD - Department of Urology, Atlas University, Istanbul, Turkey. drsoylu@gmail.com. FAU - Emek, Mestan AU - Emek M AD - Department of Public Health, Akdeniz University, Antalya, Turkey. emekms@gmail.com. FAU - Kukul, Erdal AU - Kukul E AD - Department of Urology, Medical Park Hospital, Antalya, Turkey. erdal.kukul@medicalpark.com.tr. FAU - Bozcuk, Hakan AU - Bozcuk H AD - Department of Oncology, Medical Park Hospital, Antalya, Turkey. hakan.bozcuk@medicalpark.com.tr. FAU - Sepin, Nevgun AU - Sepin N AD - Department of Clinical Microbiology and Infectious Disease, Training and Research Hospital Antalya, Turkey. nevgun@gmail.com. LA - eng PT - Journal Article DEP - 20210428 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (DNA, Viral) SB - IM MH - *Carcinoma, Transitional Cell/complications MH - DNA, Viral/analysis MH - Follow-Up Studies MH - Humans MH - *Papillomavirus Infections/complications MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology EDAT- 2021/05/02 06:00 MHDA- 2022/03/23 06:00 CRDT- 2021/05/01 06:23 PHST- 2021/05/02 06:00 [pubmed] PHST- 2022/03/23 06:00 [medline] PHST- 2021/05/01 06:23 [entrez] AID - 6429 [pii] AID - 10.22037/uj.v18i.6429 [doi] PST - epublish SO - Urol J. 2021 Apr 28;19(1):45-49. doi: 10.22037/uj.v18i.6429. PMID- 33922894 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210527 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 5 DP - 2021 Apr 25 TI - The Usefulness of Lymphadenectomy in Bladder Cancer-Current Status. LID - 10.3390/medicina57050415 [doi] LID - 415 AB - The purpose of this review is to present the current status of lymph node dissection (LND) during radical cystectomy in patients with bladder cancer (BCa). Despite the growing body of evidence of LND utility at the time of radical cystectomy (RC) in high-risk nonmuscle-invasive and muscle-invasive BCa (MIBC), therapeutic and prognostic value and optimal extent of LND remain unsolved issues. Recently published results of the first prospective, a randomized trial assessing the therapeutic benefit of extended versus limited LND during RC, failed to demonstrate survival improvement with the extended template. Although LND is the most accurate staging procedure, the direct therapeutic effect is still not evident from the current literature, limiting the possibility of establishing clear recommendations. This indicates the need for robust and adequately powered clinical trials. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AUID- ORCID: 0000-0002-5933-3753 AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kielb, Pawel AU - Kielb P AUID- ORCID: 0000-0002-2291-2217 AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Gurwin, Adam AU - Gurwin A AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Knecht, Klaudia AU - Knecht K AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Wilk, Karol AU - Wilk K AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - First Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20210425 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Cystectomy MH - Humans MH - Lymph Node Excision MH - Neoplasm Staging MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery PMC - PMC8145304 OTO - NOTNLM OT - bladder cancer OT - lymph node dissection OT - lymphadenectomy OT - staging OT - surgery COIS- The authors declare no conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/04/25 CRDT- 2021/04/30 01:23 PHST- 2021/03/14 00:00 [received] PHST- 2021/04/19 00:00 [revised] PHST- 2021/04/23 00:00 [accepted] PHST- 2021/04/30 01:23 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/04/25 00:00 [pmc-release] AID - medicina57050415 [pii] AID - medicina-57-00415 [pii] AID - 10.3390/medicina57050415 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Apr 25;57(5):415. doi: 10.3390/medicina57050415. PMID- 33909149 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20220218 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 479 IP - 4 DP - 2021 Oct TI - PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. PG - 705-713 LID - 10.1007/s00428-021-03094-6 [doi] AB - Urothelial bladder cancer (UBC) patients ineligible to platinum-based chemotherapy can be treated with immune-checkpoint inhibitors (ICI) in Programmed Death Ligand 1 (PD-L1) positive cases. Although concordance exists between different PD-L1 assays, little is known on PD-L1 expression variability in matched UBC samples. We compared PD-L1 expression in whole slides of matched transurethral resections (TURBT), radical cystectomies (RC), and lymph node metastasis (LN). Immunohistochemistry using the VENTANA PD-L1 (SP263) assay was performed on 115 patients and scored positive if expression occurred in >/=25% immune cells (IC), >/=25% tumour cells (TC), or both. PD-L1 was positive in 42.7% TURBT, 39.8% RC, and 27.3% LN specimens. Concordance was moderate (kappa=0.52; P<0.001) between TURBT and RC, and fair between LN and TURBT (kappa=0.31; P=0.048) or RC (kappa=0.25; P=0.075). Comparison with the VENTANA PD-L1 (SP142) assay which had been performed previously on the same cohort showed moderate to substantial inter-assay agreement (kappa=0.42-0.66). Although TC staining is not part of the SP142 scoring algorithm, discordant PD-L1 assay outcome could be attributed to SP263 TC>/=25% staining in only 41% of cases. These results show that PD-L1 expression variability between matched specimens is higher than that between individual assays. Optimal specimen determination for PD-L1 testing needs to be addressed in future studies. CI - (c) 2021. The Author(s). FAU - de Jong, Joep J AU - de Jong JJ AUID- ORCID: 0000-0003-2378-367X AD - Department of Urology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. j.j.dejong@erasmusmc.nl. FAU - Stoop, Hans AU - Stoop H AD - Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. FAU - van Leenders, Geert J L H AU - van Leenders GJLH AD - Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20210428 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) SB - IM MH - Aged MH - B7-H1 Antigen/*genetics/metabolism MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/pathology MH - Cohort Studies MH - Female MH - Gene Expression/genetics MH - Gene Expression Profiling/methods MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Immunohistochemistry MH - Lymph Nodes/metabolism MH - Lymphatic Metastasis/pathology MH - Male MH - Middle Aged MH - Transcriptome/*genetics MH - Urinary Bladder/metabolism MH - Urinary Bladder Neoplasms/*genetics/pathology MH - Urologic Neoplasms/pathology MH - Urothelium/pathology PMC - PMC8516767 OTO - NOTNLM OT - Bladder OT - Concordance OT - Immunohistochemistry OT - PD-L1 OT - Urothelial cancer COIS- Each author has made a substantial contribution to the article, and has read and approved the final version of the manuscript. JLB is consultant for Bristol-Myers Squibb (BMS), MSD and Roche. GvL has been consultant for Roche and AstraZeneca. The other authors have no conflict of interest to disclose. EDAT- 2021/04/29 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/04/28 CRDT- 2021/04/28 12:24 PHST- 2020/10/19 00:00 [received] PHST- 2021/03/30 00:00 [accepted] PHST- 2021/03/22 00:00 [revised] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/04/28 12:24 [entrez] PHST- 2021/04/28 00:00 [pmc-release] AID - 10.1007/s00428-021-03094-6 [pii] AID - 3094 [pii] AID - 10.1007/s00428-021-03094-6 [doi] PST - ppublish SO - Virchows Arch. 2021 Oct;479(4):705-713. doi: 10.1007/s00428-021-03094-6. Epub 2021 Apr 28. PMID- 33909091 OWN - NLM STAT- MEDLINE DCOM- 20210831 LR - 20220707 IS - 2366-0058 (Electronic) VI - 46 IP - 9 DP - 2021 Sep TI - Combining volumetric apparent diffusion coefficient histogram analysis with vesical imaging reporting and data system to predict the muscle invasion of bladder cancer. PG - 4301-4310 LID - 10.1007/s00261-021-03091-y [doi] AB - OBJECTIVE: The objective of this study was to explore whether volumetric apparent diffusion coefficient (ADC) histogram analysis can provide additional value to Vesical Imaging Reporting and Data System (VI-RADS) in differentiating muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: 80 patients were retrospectively reviewed with pathologically proven NMIBC (n = 53) or MIBC (n = 27). All patients underwent MRI including diffusion-weighted imaging (DWI) (b = 0, 800 s/mm(2)), and the VI-RADS score was evaluated based on DWI. Volumetric ADC histogram parameters were calculated from the volumetric of interest (VOI) on DWI, including the min ADC, mean ADC, median ADC, max ADC, 10th, 25th, 75th, 90th percentiles ADC, skewness, kurtosis, and entropy. The Mann-Whitney U-test was used to compare histogram parameters between NMIBC and MIBC. Receiver operating characteristic analysis was used to evaluate the diagnostic value of each significant parameter. RESULTS: Among all parameters, the VI-RADS yield the highest Area Under the Curve (AUC, 0.88; sensitivity, 88.89%; specificity, 83.61%). MIBC had significantly lower min ADC, mean ADC, median ADC, 10th, 25th, 75th, and 90th percentiles ADC than NMIBC (p = 0.002, p < 0.001, p < 0.001, p = 0.003, p = 0.004, p < 0.001, p < 0.001). Skewness and kurtosis of MIBC were significantly higher than those of NMIBC (p < 0.001, p < 0.001). The combination of VI-RADS and skewness showed significantly higher AUC (AUC 0.923; 95% CI 0.847-0.969) than only with VI-RADS (AUC 0.880; 95% CI 0.793-0.940). CONCLUSION: Volumetric ADC histogram analysis and VI-RADS are both useful methods in differentiating MIBC from NMIBC, and the volumetric ADC histogram analysis can provide additional value to VI-RADS. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Li, Shichao AU - Li S AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Liang, Ping AU - Liang P AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Wang, Yanchun AU - Wang Y AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Feng, Cui AU - Feng C AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Shen, Yaqi AU - Shen Y AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Hu, Xuemei AU - Hu X AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Hu, Daoyu AU - Hu D AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. FAU - Meng, Xiaoyan AU - Meng X AUID- ORCID: 0000-0002-3424-6928 AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. xymeng@hust.edu.cn. FAU - Li, Zhen AU - Li Z AD - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, Hubei, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210428 PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Diffusion Magnetic Resonance Imaging MH - Humans MH - Magnetic Resonance Imaging MH - Muscles MH - Retrospective Studies MH - Sensitivity and Specificity MH - *Urinary Bladder Neoplasms/diagnostic imaging OTO - NOTNLM OT - Apparent diffusion coefficient OT - Bladder cancer OT - Diffusion-weighted magnetic resonance imaging OT - Vesical imaging reporting and data system EDAT- 2021/04/29 06:00 MHDA- 2021/09/01 06:00 CRDT- 2021/04/28 12:22 PHST- 2021/02/25 00:00 [received] PHST- 2021/04/10 00:00 [accepted] PHST- 2021/04/06 00:00 [revised] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/09/01 06:00 [medline] PHST- 2021/04/28 12:22 [entrez] AID - 10.1007/s00261-021-03091-y [pii] AID - 10.1007/s00261-021-03091-y [doi] PST - ppublish SO - Abdom Radiol (NY). 2021 Sep;46(9):4301-4310. doi: 10.1007/s00261-021-03091-y. Epub 2021 Apr 28. PMID- 33908802 OWN - NLM STAT- MEDLINE DCOM- 20210830 LR - 20240925 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 206 IP - 3 DP - 2021 Sep TI - The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. PG - 558-567 LID - 10.1097/JU.0000000000001834 [doi] AB - PURPOSE: Diagnostic ureteroscopic biopsy for upper tract urothelial carcinoma (UTUC) has been hypothesized to increase intravesical recurrence of urothelial carcinoma after radical nephroureterectomy (RNU). Moreover, the impact of ureteroscopy without biopsy or percutaneous biopsy on intravesical recurrence remains unknown. Herein, we compared post-RNU intravesical recurrences across UTUC diagnostic modalities. MATERIALS AND METHODS: Patients undergoing RNU at our institution between 1995 and 2019 were categorized by UTUC diagnostic modality: 1) no ureteroscopy or percutaneous biopsy; 2) percutaneous biopsy; 3) ureteroscopy without biopsy; 4) ureteroscopic biopsy. Intravesical recurrences were compared using Kaplan-Meier analyses and Cox-proportional hazard models. Results of group 4 vs 1 were pooled with the literature using a fixed effects meta-analysis. RESULTS: In a cohort of 834 RNU patients, 210 (25.2%) had undergone no ureteroscopy, 57 (6.6%) percutaneous biopsy, 125 (15.0%) ureteroscopy without biopsy, and 442 (53.0%) ureteroscopic biopsy. Two-year intravesical recurrence rates were 15.0%, 12.7%, 18.4%, and 21.9% for groups 1 through 4, respectively (p=0.09). Multivariable analysis found that group 4 had increased intravesical recurrences (HR 1.40, p=0.04) relative to group 1 while group 2 (HR 1.07, p=0.87) and group 3 (HR 1.15, p=0.54) did not. Group 4 remained associated with intravesical recurrence on subset analyses accounting for post-RNU surveillance cystoscopy frequency. On meta-analysis including 11 other series, ureteroscopic biopsy was associated with intravesical recurrence (HR 1.47, p <0.01). CONCLUSIONS: Ureteroscopic biopsy before RNU, but not percutaneous biopsy or ureteroscopy without biopsy, was associated with increased intravesical recurrence. Clinical trials of intravesical chemotherapy after ureteroscopic biopsy are warranted to reduce intravesical recurrences. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. AD - Department of Urology, University of California, Los Angeles, California. AD - Greater Los Angeles VA, Health Services Research and Development Program, Los Angeles, California. FAU - Miest, Tanner S AU - Miest TS AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Juvet, Tristan S AU - Juvet TS AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Toussi, Amir AU - Toussi A AD - Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. FAU - Packiam, Vignesh AU - Packiam V AD - Department of Urology, University of Iowa Medical Center, Iowa City, Iowa. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, University of California, Los Angeles, California. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Thompson, R Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Potretzke, Aaron M AU - Potretzke AM AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20210428 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Sep;206(3):567. doi: 10.1097/JU.0000000000001834.01. PMID: 34121428 CIN - J Urol. 2021 Oct;206(4):1071. doi: 10.1097/JU.0000000000001928. PMID: 34228502 CIN - J Urol. 2022 Apr;207(4):937. doi: 10.1097/JU.0000000000002430. PMID: 35015562 MH - Aged MH - Biopsy/adverse effects/methods/statistics & numerical data MH - Carcinoma, Transitional Cell/diagnosis/*epidemiology/secondary/surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/diagnosis/pathology/*surgery MH - Male MH - Neoplasm Seeding MH - Nephroureterectomy/*adverse effects MH - Proportional Hazards Models MH - Retrospective Studies MH - Ureteral Neoplasms/diagnosis/pathology/*surgery MH - Ureteroscopy/adverse effects/statistics & numerical data MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/diagnosis/*epidemiology/secondary OTO - NOTNLM OT - carcinoma, transitional cell OT - recurrence OT - ureteral neoplasms OT - ureteroscopy OT - urinary bladder neoplasms EDAT- 2021/04/29 06:00 MHDA- 2021/08/31 06:00 CRDT- 2021/04/28 12:11 PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/08/31 06:00 [medline] PHST- 2021/04/28 12:11 [entrez] AID - 10.1097/JU.0000000000001834 [doi] PST - ppublish SO - J Urol. 2021 Sep;206(3):558-567. doi: 10.1097/JU.0000000000001834. Epub 2021 Apr 28. PMID- 33905290 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20210914 IS - 1744-7666 (Electronic) IS - 1465-6566 (Linking) VI - 22 IP - 13 DP - 2021 Sep TI - Advances in the management of urothelial carcinoma: is immunotherapy the answer? PG - 1743-1759 LID - 10.1080/14656566.2021.1921149 [doi] AB - Introduction: Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary system in the US, but mortality rate has not significantly improved despite advances in therapy. Over the past few years, the treatment landscape of non-muscle-invasive, muscle-invasive and metastatic UC (mUC) has evolved with the advent of immunotherapy.Areas covered: This paper summarizes current data and ongoing research into the use of immune checkpoint inhibitors (ICIs) in various settings of UC, including as maintenance therapy in chemotherapy-responsive mUC (with recent approval for avelumab in this setting) and as neoadjuvant and adjuvant therapies in localized and non-muscle-invasive disease. In addition, the authors review the combination of ICIs with chemotherapy, radiation and targeted therapies in an effort to increase response durability and efficacy.Expert opinion: While there has been a rapid expansion in clinical trials, platinum-based chemotherapy remains standard treatment in perioperative and first-line metastatic UC. The identification of biomarkers that can identify patients who will respond to ICIs has yielded conflicting results and has been largely non-generalizable to clinical practice. Further research into novel strategies and combinations with ICIs is needed to better characterize the role of immunotherapy in UC. FAU - Santopietro, Ariana L AU - Santopietro AL AD - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Einstein, David AU - Einstein D AD - Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20210520 PL - England TA - Expert Opin Pharmacother JT - Expert opinion on pharmacotherapy JID - 100897346 RN - 0 (Immunologic Factors) SB - IM MH - *Carcinoma, Transitional Cell/drug therapy MH - Humans MH - Immunologic Factors MH - Immunotherapy MH - Neoadjuvant Therapy MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - Biomarkers OT - immune checkpoint inhibitor OT - immunotherapy OT - targeted therapies OT - urothelial carcinoma EDAT- 2021/04/28 06:00 MHDA- 2021/09/15 06:00 CRDT- 2021/04/27 17:12 PHST- 2021/04/28 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2021/04/27 17:12 [entrez] AID - 10.1080/14656566.2021.1921149 [doi] PST - ppublish SO - Expert Opin Pharmacother. 2021 Sep;22(13):1743-1759. doi: 10.1080/14656566.2021.1921149. Epub 2021 May 20. PMID- 33900566 OWN - NLM STAT- MEDLINE DCOM- 20211208 LR - 20211214 IS - 1573-2584 (Electronic) IS - 0301-1623 (Print) IS - 0301-1623 (Linking) VI - 53 IP - 8 DP - 2021 Aug TI - Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians. PG - 1591-1597 LID - 10.1007/s11255-021-02870-2 [doi] AB - PURPOSE: To evaluate the outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment (NMIBC) in elderly patients over 80 years of age. METHODS: This is a retrospective single tertiary-centre study. Medical records of patients with T1 high-grade NMIBC treated with transurethral resection of the bladder tumour (TURBT) were reviewed. Among 269 patients with high-grade T1 NMIBC, 74 individuals were over 80 years of age at the time of surgery. Finally, 67 patients met the inclusion criteria. RESULTS: Only 47.8% of patients (N = 32) received at least five of the six instillations of the BCG immunotherapy induction course. Oncological outcomes were compared between patients who received at least the induction course of BCG and non-BCG-treated patients matched to each other based on age and Charlson comorbidity index. Thirty case-control pairs were included in the final analysis. Rates of disease recurrence (80% vs. 53%) and cancer-specific mortality (40% vs. 10%) were significantly higher in the group of patients who did not receive BCG. BCG therapy, Charlson comorbidity index, haemoglobin concentration and the number of tumours > 3 in TURBT constituted independent prognostic factors for cancer-specific survival (CSS). CONCLUSION: BCG should be strongly recommended to patients with T1HG NMIBC despite advanced age and comorbidities. Already BCG induction improves CSS and reduces the recurrence rate in octogenarians with T1HG bladder cancer. CI - (c) 2021. The Author(s). FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Garbas, Karolina AU - Garbas K AUID- ORCID: 0000-0002-2671-3610 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. kgarbas98@gmail.com. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20210426 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged, 80 and over MH - Case-Control Studies MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC8072304 OTO - NOTNLM OT - Advanced age OT - BCG therapy OT - Elderly patients OT - Non-muscle-invasive bladder cancer OT - Survival COIS- The authors declare that they have no conflict of interest. EDAT- 2021/04/27 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/04/26 CRDT- 2021/04/26 12:29 PHST- 2021/01/29 00:00 [received] PHST- 2021/04/20 00:00 [accepted] PHST- 2021/04/27 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/26 12:29 [entrez] PHST- 2021/04/26 00:00 [pmc-release] AID - 10.1007/s11255-021-02870-2 [pii] AID - 2870 [pii] AID - 10.1007/s11255-021-02870-2 [doi] PST - ppublish SO - Int Urol Nephrol. 2021 Aug;53(8):1591-1597. doi: 10.1007/s11255-021-02870-2. Epub 2021 Apr 26. PMID- 33890701 OWN - NLM STAT- MEDLINE DCOM- 20211221 LR - 20250623 IS - 1445-2197 (Electronic) IS - 1445-1433 (Linking) VI - 91 IP - 12 DP - 2021 Dec TI - Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review. PG - 2592-2598 LID - 10.1111/ans.16740 [doi] AB - BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) can recur despite transurethral resection of bladder tumour (TURBT) that clears macroscopic disease, partly from re-implantation of exfoliated cells. Immediate instillation of intravesical chemotherapy (IC) can reduce recurrence, is guideline-recommended but is under-utilized. Continuous bladder irrigation (CBI) immediately post-TURBT is postulated to prevent re-implantation, and may provide a simple, cheap and practical alternative. We undertook a systematic review to assess the effect of CBI on NMIBC recurrence. METHODS: Following PRISMA guidelines, relevant publications were identified by online search of databases, including Ovid Medline and EMBASE (1980-2019). All published prospective randomized controlled trials comparing CBI post-TURBT to a control group were included. The primary end-point was recurrence. RESULTS: Our search yielded 514 studies, of which six met inclusion criteria. Two studies (935 participants), albeit without peer-reviewed publication, comparing CBI to no CBI both showed a reduction in recurrence at 2 years. Four publications from three trials (331 participants) compared CBI to IC, showing similar recurrence rates at 1 year (odds ratio 1.29, 95% confidence interval 0.78-2.13) but a lower risk of adverse events (6-34% versus 27-48%). CONCLUSION: CBI post-TURBT appears to yield 1-year recurrence rates of NMIBC comparable to immediate IC. However, existing studies are small and of heterogenous design, precluding definitive conclusions. Further trials are required to determine if CBI can be implemented routinely to reduce NMIBC recurrence, as well as the optimal irrigant, volume and duration. CI - (c) 2021 Royal Australasian College of Surgeons. FAU - Li, Mo AU - Li M AUID- ORCID: 0000-0003-2444-4784 AD - Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. AD - Department of Urology, Eastern Health, Melbourne, Victoria, Australia. FAU - Toniolo, Jason AU - Toniolo J AUID- ORCID: 0000-0002-1002-7878 AD - Department of Urology, Eastern Health, Melbourne, Victoria, Australia. FAU - Nandurkar, Ruchira AU - Nandurkar R AD - Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. FAU - Papa, Nathan AU - Papa N AUID- ORCID: 0000-0002-3188-1803 AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. AD - Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. FAU - Lawrentschuk, Nathan AU - Lawrentschuk N AD - Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. FAU - Davis, Ian D AU - Davis ID AD - Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. AD - Cancer Services, Eastern Health, Melbourne, Victoria, Australia. FAU - Sengupta, Shomik AU - Sengupta S AUID- ORCID: 0000-0003-3357-1216 AD - Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. AD - Department of Urology, Eastern Health, Melbourne, Victoria, Australia. AD - Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. LA - eng GR - APP1102604/NHMRC Practitioner Fellowship/ PT - Journal Article PT - Systematic Review DEP - 20210423 PL - Australia TA - ANZ J Surg JT - ANZ journal of surgery JID - 101086634 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Peer Review MH - Prospective Studies MH - Urinary Bladder MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - bladder cancer OT - intravesical chemotherapy OT - irrigation OT - randomized controlled trial OT - recurrence EDAT- 2021/04/24 06:00 MHDA- 2021/12/22 06:00 CRDT- 2021/04/23 08:53 PHST- 2021/02/17 00:00 [revised] PHST- 2020/11/01 00:00 [received] PHST- 2021/02/23 00:00 [accepted] PHST- 2021/04/24 06:00 [pubmed] PHST- 2021/12/22 06:00 [medline] PHST- 2021/04/23 08:53 [entrez] AID - 10.1111/ans.16740 [doi] PST - ppublish SO - ANZ J Surg. 2021 Dec;91(12):2592-2598. doi: 10.1111/ans.16740. Epub 2021 Apr 23. PMID- 33883080 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1535-6345 (Electronic) IS - 0147-0272 (Linking) VI - 45 IP - 6 DP - 2021 Dec TI - Prognostic significance of tumor multifocality on outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy: A cohort study. PG - 100747 LID - S0147-0272(21)00054-4 [pii] LID - 10.1016/j.currproblcancer.2021.100747 [doi] AB - To identify the prognostic impact of tumor multifocality on upper tract urothelial carcinoma (UTUC) outcomes in patients treated with radical nephroureterectomy (RNU). Study included 342 consecutive patients with UTUC. Tumor multifocality was defined as the synchronous presence of 2 or more pathologically confirmed tumors in any upper urinary tract location. Cox regression analyses were used to address recurrence-free (RFS) and cancer-specific survival (CSS) estimates. Tumor multifocality was significantly associated with a history of previous non-muscle invasive bladder cancer (P < 0.001), tumor size (P < 0.001), gender (P = 0.009), tumor location (P = 0.005), and anemia (P = 0.01). The Kaplan-Meier method showed that tumor multifocality was significantly associated with worse recurrence-free survival (P < 0.001, log rank). Using multivariate analysis, tumor multifocality (HR, 2.86; 95% CI, 2.06 - 3.99; P < 0.001) was independently associated with recurrence free survival. During the follow-up, a total of 128 (37.4%) patients died, including 92 (28.2%) from UTUC. However, tumor multifocality was not associated with CSS (HR, 1.29; 95% CI, 0.89 - 1.96; P = 0.21) in univariate Cox regression analyses. Tumor stage (HR, 11.1; 95% CI, 3.64 - 33.8; P < 0.001), lymph node status (HR, 2.04, 95% CI, 1.05 - 3.94; P = 0.03) and preoperative anemia (HR, 3.50, 95% CI, 2.02 - 6.08; P < 0.001) were the only independent predictors associated with worse cancer-specific survival. Tumor multifocality is an independent prognostic factor of disease recurrence in patients treated with RNU for UTUC. Tumor multifocality is unable to predict cancer specific survival in a single-center series of consecutive patients who were treated with RNU. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Milojevic, Bogomir AU - Milojevic B AD - Clinic of Urology, Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: em2bogomir@yahoo.com. FAU - Bumbasirevic, Uros AU - Bumbasirevic U AD - Clinic of Urology, Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Santric, Veljko AU - Santric V AD - Clinic of Urology, Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Kajmakovic, Boris AU - Kajmakovic B AD - Clinic of Urology, Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Dragicevic, Dejan AU - Dragicevic D AD - Clinic of Urology, Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Radisavcevic, Djordje AU - Radisavcevic D AD - Clinic of Urology, Clinical Center of Serbia. FAU - Sretenovic, Milan AU - Sretenovic M AD - Clinic of Urology, Clinical Center of Serbia. FAU - Grujicic, Sandra Sipetic AU - Grujicic SS AD - Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210415 PL - United States TA - Curr Probl Cancer JT - Current problems in cancer JID - 7702986 SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Nephroureterectomy MH - Prognosis MH - Serbia/epidemiology MH - Survival Rate MH - Urologic Neoplasms/*mortality/*pathology/surgery OTO - NOTNLM OT - Radical nephroureterectomy OT - Recurrence OT - Survival OT - Tumor multifocality OT - Upper tract urothelial carcinoma COIS- Declaration of Competing Interest The authors declare that they have no conflict of interest. EDAT- 2021/04/23 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/04/22 05:47 PHST- 2021/02/14 00:00 [received] PHST- 2021/03/12 00:00 [revised] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/04/23 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/04/22 05:47 [entrez] AID - S0147-0272(21)00054-4 [pii] AID - 10.1016/j.currproblcancer.2021.100747 [doi] PST - ppublish SO - Curr Probl Cancer. 2021 Dec;45(6):100747. doi: 10.1016/j.currproblcancer.2021.100747. Epub 2021 Apr 15. PMID- 33882992 OWN - NLM STAT- MEDLINE DCOM- 20220121 LR - 20240809 IS - 1868-7083 (Electronic) IS - 1868-7075 (Print) IS - 1868-7075 (Linking) VI - 13 IP - 1 DP - 2021 Apr 21 TI - Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. PG - 84 LID - 10.1186/s13148-021-01029-1 [doi] LID - 84 AB - BACKGROUND: Bladder cancer (BC) is the 5th most common cancer in the USA. Non-muscle invasive bladder cancer represents about 70% of all cases and has generally a favorable outcome. However, recurrence rates as high as 60 to 70% and progression rates of 10 to 20% necessitate intensive surveillance with cystoscopy. The invasiveness and high cost of cystoscopy poses significant burden on BC patients as well as on the healthcare system. In this study we test the feasibility of a simple, sensitive, and non-invasive detection of BC using Bladder CARE test in urine samples. RESULTS: Urine from 136 healthy and 77 BC subjects was collected using the at-home Bladder CARE Urine Collection Kit and analyzed with Bladder CARE test. The test measures the methylation level of three BC-specific biomarkers and two internal controls using methylation-sensitive restriction enzymes coupled with qPCR. Bladder CARE showed an overall sensitivity of 93.5%, a specificity of 92.6%, and a PPV and NPV of 87.8% and 96.2%, respectively. Bladder CARE has an LOD as low as 0.046%, which equates to detecting 1 cancer cell for every 2,200 cells analyzed. We also provided evidence that bisulfite-free methods to assess DNA methylation, like Bladder CARE, are advantageous compared to conventional methods that rely on bisulfite conversion of the DNA. CONCLUSION: Highly sensitive detection of BC in urine samples is possible using Bladder CARE. The low LOD of the test and the measurement of epigenetic biomarkers make Bladder CARE a good candidate for the early detection of BC and possibly for the routine screening and surveillance of BC patients. Bladder CARE and the at-home urine sample collection system have the potential to (1) reduce unnecessary invasive testing for BC (2) reduce the burden of surveillance on patients and on the healthcare system, (3) improve the detection of early stage BC, and (4) allow physicians to streamline the monitoring of patients. FAU - Piatti, Paolo AU - Piatti P AD - Zymo Research Corp, Irvine, CA, USA. FAU - Chew, Yap Ching AU - Chew YC AD - Zymo Research Corp, Irvine, CA, USA. FAU - Suwoto, Michiko AU - Suwoto M AD - Zymo Research Corp, Irvine, CA, USA. FAU - Yamada, Taikun AU - Yamada T AD - Zymo Research Corp, Irvine, CA, USA. FAU - Jara, Benjamin AU - Jara B AD - Zymo Research Corp, Irvine, CA, USA. FAU - Jia, Xi-Yu AU - Jia XY AD - Zymo Research Corp, Irvine, CA, USA. AD - Pangea Laboratory LLC, Costa Mesa, CA, USA. FAU - Guo, Wei AU - Guo W AD - Zymo Research Corp, Irvine, CA, USA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Ahmadi, Hamed AU - Ahmadi H AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Rice, Jeffrey AU - Rice J AD - Zymo Research Corp, Irvine, CA, USA. FAU - Bhasin, Jeffrey AU - Bhasin J AD - Zymo Research Corp, Irvine, CA, USA. FAU - Holloway, Faith AU - Holloway F AD - Zymo Research Corp, Irvine, CA, USA. FAU - Tsai, Yvonne AU - Tsai Y AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Chihara, Yoshitomo AU - Chihara Y AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Liang, Gangning AU - Liang G AUID- ORCID: 0000-0001-8664-922X AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. gliang@usc.edu. LA - eng GR - P30 CA014089/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210421 PL - Germany TA - Clin Epigenetics JT - Clinical epigenetics JID - 101516977 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/urine MH - DNA Methylation/*genetics MH - Epigenesis, Genetic/*genetics MH - Epigenomics/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*genetics/*urine MH - Young Adult PMC - PMC8059345 OTO - NOTNLM OT - At-home sample collection OT - Bladder cancer OT - DNA methylation OT - Non-invasive testing OT - Urine COIS- G. Liang certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patent applications that are pending or issued as patents), are the following: P. Piatti is named, along with W. Guo, X.Y. Jia (Jia), and G. Liang in US and foreign equivalent pending patent applications and issued patents for "Assays to Determine DNA Methylation and DNA Methylation Markers of Cancer" held by Zymo Research Corp. an associate of Pangea Laboratory, LLC. X.Y. Jia is an employee at Zymo Research Corp. and Pangea Laboratory, LLC. Dr. P. Piatti, Dr. Y.C. Chew, M. Suwoto, and T. Yamada are employees at Zymo Research Corp. and independent contractors with Pangea Laboratory, LLC. The remaining authors have nothing to disclose. EDAT- 2021/04/23 06:00 MHDA- 2022/01/22 06:00 PMCR- 2021/04/21 CRDT- 2021/04/22 05:42 PHST- 2020/09/16 00:00 [received] PHST- 2021/02/14 00:00 [accepted] PHST- 2021/04/22 05:42 [entrez] PHST- 2021/04/23 06:00 [pubmed] PHST- 2022/01/22 06:00 [medline] PHST- 2021/04/21 00:00 [pmc-release] AID - 10.1186/s13148-021-01029-1 [pii] AID - 1029 [pii] AID - 10.1186/s13148-021-01029-1 [doi] PST - epublish SO - Clin Epigenetics. 2021 Apr 21;13(1):84. doi: 10.1186/s13148-021-01029-1. PMID- 33882936 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20210426 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 19 IP - 1 DP - 2021 Apr 21 TI - Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis. PG - 129 LID - 10.1186/s12957-021-02236-z [doi] LID - 129 AB - BACKGROUND: During the past two decades, laparoscopic radical nephroureterectomy (LRNU) has been proposed as an alternative technique to open radical nephroureterectomy (ORNU) and has become increasingly accepted for the treatment of patients with upper tract urothelial carcinoma (UTUC). Nevertheless, the oncologic efficacy of LRNU remains controversial, especially for the treatment of locally advanced (T3/T4 and/or N+) UTUC. In this meta-analysis, we aimed to cumulatively compare the oncological outcomes of LRNU versus ORNU. MATERIALS AND METHODS: The present meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A search was conducted of three electronic databases, namely, Medline, Embase, and Cochrane Library. Outcome measurements of cancer-specific survival (CSS), overall survival (OS), intravesical recurrence-free survival (IVRFS), and recurrence-free survival (RFS), including hazard ratios (HRs) and 95% confidence intervals (CIs), were extracted and pooled. RESULTS: Eighteen articles published from 2007 to 2020 were included in the final quantitative analysis. One study was a randomized controlled trial (RCT), and the remaining articles had a retrospective design. Among a total of 10,730 participants in the selected papers, 5959 (55.5%) and 4771 (44.5%) underwent ORNU and LRNU, respectively. The results of pooled analyses revealed no significant differences in CSS (HR 0.84, 95% CI 0.60-1.19, p = 0.33), OS (HR 0.84, 95% CI 0.62-1.13, p = 0.25), IVRFS (HR 1.08, 95% CI 0.85-1.39, p = 0.52), and RFS (HR 1.09, 95% CI 0.94-1.25, p = 0.26) between LRNU and ORNU groups. Furthermore, the results of subgroup analyses for pT3/T4 and pTany N+ populations did not confirm any statistically significant differences between LRNU and ORNU in terms of any survival parameter. CONCLUSIONS: Our present meta-analysis of current evidence suggests that LRNU and ORNU have comparable oncological outcomes in patients with UTUC, even in those with locally advanced disease. Further multicenter RCTs with large sample sizes and uniform data regarding specific surgical procedures, such as bladder cuff excision, are required to establish definitive conclusions. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncologic Urology, Lower Silesian Specialist Hospital, Fieldorfa 2 Street, 50-556, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AUID- ORCID: 0000-0003-4273-8196 AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Borowska 213 Street, 50-556, Wroclaw, Poland. lllukasz.nowak@gmail.com. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Borowska 213 Street, 50-556, Wroclaw, Poland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Borowska 213 Street, 50-556, Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Centre of Postgraduate Medical Education, Marymonecka 99/813 Street, 01-813, Warsaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, Spitalstrasse, 6004, 16, Lucerne, Switzerland. FAU - Kaliszewski, Krzysztof AU - Kaliszewski K AD - Department of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska 213 Street, 50-556, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Borowska 213 Street, 50-556, Wroclaw, Poland. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20210421 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Cystectomy/methods MH - Humans MH - Kidney Neoplasms/*surgery MH - *Laparoscopy MH - Nephroureterectomy/*methods MH - Prognosis MH - Randomized Controlled Trials as Topic MH - Ureteral Neoplasms/*surgery PMC - PMC8061074 OTO - NOTNLM OT - Laparoscopic nephroureterectomy OT - Open nephroureterectomy OT - Upper tract urothelial carcinoma COIS- None of the contributing authors has any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. EDAT- 2021/04/23 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/04/21 CRDT- 2021/04/22 05:40 PHST- 2020/12/29 00:00 [received] PHST- 2021/04/07 00:00 [accepted] PHST- 2021/04/22 05:40 [entrez] PHST- 2021/04/23 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2021/04/21 00:00 [pmc-release] AID - 10.1186/s12957-021-02236-z [pii] AID - 2236 [pii] AID - 10.1186/s12957-021-02236-z [doi] PST - epublish SO - World J Surg Oncol. 2021 Apr 21;19(1):129. doi: 10.1186/s12957-021-02236-z. PMID- 33882561 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20230917 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 31 IP - 4 DP - 2021 Jul 1 TI - Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine. PG - 404-408 LID - 10.1097/MOU.0000000000000882 [doi] AB - PURPOSE OF REVIEW: This review aims to provide an update of the results of studies published in the last 2 years involving the use of artificial intelligence in bladder cancer (BCa) prognosis. RECENT FINDINGS: Recently, many studies evaluated various artificial intelligence models to predict BCa evolution using either deep learning or machine learning. Many trials evidenced a better prediction of recurrence-free survival and overall survival for muscle invasive BCa (MIBC) for deep learning-based models compared with clinical stages. Improvements in imaging associated with the development of deep learning neural networks and radiomics seem to improve post neo-adjuvant chemotherapy response. One study showed that digitalized histology could predict nonmuscle invasive BCa recurrence. SUMMARY: BCa prognosis could be better assessed using artificial intelligence models not only in the case of MIBC but also NMIBC. Many studies evaluated its role for the prediction of overall survival and recurrence-free survival but there is still little data in the case of NMIBC. Recent findings showed that artificial intelligence could lead to a better assessment of BCa prognosis before treatment and to personalized medicine. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Pinar, Ugo AU - Pinar U AD - Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitie-Salpetriere Hopital, Urology, Paris, France. FAU - Pradere, Benjamin AU - Pradere B AD - Comprehensive Cancer Center, Medical University of Vienna, Department of Urology, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitie-Salpetriere Hopital, Urology, Paris, France. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Artificial Intelligence MH - Humans MH - Neoplasm Recurrence, Local MH - Precision Medicine MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy EDAT- 2021/04/22 06:00 MHDA- 2021/06/29 06:00 CRDT- 2021/04/21 20:19 PHST- 2021/04/22 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/04/21 20:19 [entrez] AID - 00042307-202107000-00019 [pii] AID - 10.1097/MOU.0000000000000882 [doi] PST - ppublish SO - Curr Opin Urol. 2021 Jul 1;31(4):404-408. doi: 10.1097/MOU.0000000000000882. PMID- 33882245 OWN - NLM STAT- MEDLINE DCOM- 20210531 LR - 20220716 IS - 1748-880X (Electronic) IS - 0007-1285 (Print) IS - 0007-1285 (Linking) VI - 94 IP - 1122 DP - 2021 Jun 1 TI - Utility of first order MRI-Texture analysis parameters in the prediction of histologic grade and muscle invasion in urinary bladder cancer: a preliminary study. PG - 20201114 LID - 10.1259/bjr.20201114 [doi] LID - 20201114 AB - OBJECTIVE: To explore the utility of first-order MRI-texture analysis (TA) parameters in predicting histologic grade and muscle invasion in urinary bladder cancer (UBC). METHODS: After ethical clearance, 40 patients with UBC, who were imaged on a 3.0-Tesla scanner, were retrospectively included. Using the TexRAD(TM) platform, two readers placed freehand ROI on the sections demonstrating the largest dimension of the tumor, evaluating only one tumor per patient. Interobserver reproducibility was assessed using the intraclass correlation coefficient (ICC). Mann-Whitney U test and ROC curve analysis were used to identify statistical significance and select parameters with high class separation capacity (AUC >0.8), respectively. Pearson's test was used to identify redundancy in the results. RESULTS: All texture parameters showed excellent ICC. The best parameters in differentiating high and low-grade tumors were mean/ mean of positive pixels (MPP) at SSF 0 (AUC: 0.897) and kurtosis at SSF 5 (AUC: 0.828) on the ADC images. In differentiating muscle invasive from non-muscle invasive tumors, mean/ MPP at SSF 0 on the ADC images showed AUC >0.8; however, this finding resulted from the confounding effect of high-grade histology on the ADC values of muscle invasive tumors. CONCLUSION: MRI-TA generated few parameters which were reproducible and useful in predicting histologic grade. No independent parameters predicted muscle invasion. ADVANCES IN KNOWLEDGE: There is lacuna in the literature concerning the role of MRI-TA in the prediction of histologic grade and muscle invasion in UBC. Our study generated a few first-order parameters which were useful in predicting high-grade histology. FAU - Razik, Abdul AU - Razik A AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Das, Chandan J AU - Das CJ AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Sharma, Raju AU - Sharma R AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Malla, Sundeep AU - Malla S AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Sharma, Sanjay AU - Sharma S AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Seth, Amlesh AU - Seth A AD - Departments of Urology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. FAU - Srivastava, Deep Narayan AU - Srivastava DN AD - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. LA - eng PT - Journal Article DEP - 20210429 PL - England TA - Br J Radiol JT - The British journal of radiology JID - 0373125 SB - IM MH - Aged MH - Female MH - Humans MH - Image Interpretation, Computer-Assisted/methods MH - Magnetic Resonance Imaging/methods MH - Male MH - Middle Aged MH - Muscle, Skeletal/pathology MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Reproducibility of Results MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology PMC - PMC8173695 EDAT- 2021/04/22 06:00 MHDA- 2021/06/01 06:00 PMCR- 2022/06/01 CRDT- 2021/04/21 20:06 PHST- 2021/04/22 06:00 [pubmed] PHST- 2021/06/01 06:00 [medline] PHST- 2021/04/21 20:06 [entrez] PHST- 2022/06/01 00:00 [pmc-release] AID - 10.1259/bjr.20201114 [doi] PST - ppublish SO - Br J Radiol. 2021 Jun 1;94(1122):20201114. doi: 10.1259/bjr.20201114. Epub 2021 Apr 29. PMID- 33881931 OWN - NLM STAT- MEDLINE DCOM- 20210830 LR - 20220309 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 206 IP - 3 DP - 2021 Sep TI - Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). PG - 568-576 LID - 10.1097/JU.0000000000001786 [doi] AB - PURPOSE: Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) has an incidence of approximately 20%-50%. Studies to date have been composed of mixed treatment cohorts-open, laparoscopic and robotic. The objective of this study is to assess clinicopathological risk factors for intravesical recurrence after RNU for UTUC in a completely minimally invasive cohort. MATERIALS AND METHODS: We performed a multicenter, retrospective analysis of 485 patients with UTUC without prior or concurrent bladder cancer who underwent robotic or laparoscopic RNU. Patients were selected from an international cohort of 17 institutions across the United States, Europe and Asia. Univariate and multiple Cox regression models were used to identify risk factors for bladder recurrence. RESULTS: A total of 485 (396 robotic, 89 laparoscopic) patients were included in analysis. Overall, 110 (22.7%) of patients developed IVR. The average time to recurrence was 15.2 months (SD 15.5 months). Hypertension was a significant risk factor on multiple regression (HR 1.99, CI 1.06; 3.71, p=0.030). Diagnostic ureteroscopic biopsy incurred a 50% higher chance of developing IVR (HR 1.49, CI 1.00; 2.20, p=0.048). Treatment specific risk factors included positive surgical margins (HR 3.36, CI 1.36; 8.33, p=0.009) and transurethral resection for bladder cuff management (HR 2.73, CI 1.10; 6.76, p=0.031). CONCLUSIONS: IVR after minimally invasive RNU for UTUC is a relatively common event. Risk factors include a ureteroscopic biopsy, transurethral resection of the bladder cuff, and positive surgical margins. When possible, avoidance of transurethral resection of the bladder cuff and alternative strategies for obtaining biopsy tissue sample should be considered. FAU - Katims, Andrew B AU - Katims AB AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Say, Rollin AU - Say R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Derweesh, Ithaar AU - Derweesh I AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, California. FAU - Uzzo, Robert AU - Uzzo R AD - Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Minervini, Andrea AU - Minervini A AD - Department of Urology, University of Florence, Florence, Italy. FAU - Wu, Zhenjie AU - Wu Z AD - Department of Urology, Changzheng Hospital, Second Military (Naval) Medical University, Shanghai, China. FAU - Abdollah, Firas AU - Abdollah F AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Sundaram, Chandru AU - Sundaram C AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Rha, Koon AU - Rha K AD - Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Mottrie, Alex AU - Mottrie A AD - Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, Regina Elena National Cancer Institute, Rome, Italy. FAU - Eun, Daniel D AU - Eun DD AD - Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Reese, Adam AU - Reese A AD - Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Kidd, Laura C AU - Kidd LC AD - Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Porter, James AU - Porter J AD - Swedish Urology Group, Seattle, Washington. FAU - Bhattu, Amit Satish AU - Bhattu AS AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Marcus, Jamil AU - Marcus J AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Danno, Alyssa AU - Danno A AD - Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Meagher, Margaret AU - Meagher M AD - Department of Urology, University of California San Diego School of Medicine, La Jolla, California. FAU - Tellini, Riccardo AU - Tellini R AD - Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Mari, Andrea AU - Mari A AD - Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania. FAU - Veccia, Alessandro AU - Veccia A AD - Division of Urology, VCU Health System, Richmond, Virginia. FAU - Ghoreifi, Alireza AU - Ghoreifi A AD - Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, VCU Health System, Richmond, Virginia. FAU - Djaladat, Hooman AU - Djaladat H AD - Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210421 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Sep;206(3):575-576. doi: 10.1097/JU.0000000000001786.01. PMID: 34105989 CIN - J Urol. 2021 Sep;206(3):576. doi: 10.1097/JU.0000000000001786.02. PMID: 34105990 EIN - J Urol. 2022 Apr;207(4):943. doi: 10.1097/JU.0000000000002483. PMID: 35259936 MH - Aged MH - Biopsy/adverse effects/methods MH - Carcinoma, Transitional Cell/diagnosis/*epidemiology/secondary/surgery MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney/pathology/surgery MH - Kidney Neoplasms/diagnosis/mortality/*surgery MH - Male MH - Margins of Excision MH - Middle Aged MH - Neoplasm Seeding MH - Nephroureterectomy/*adverse effects/methods MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Robotic Surgical Procedures/*adverse effects MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/diagnosis/mortality/*surgery MH - Ureteroscopy/adverse effects MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/diagnosis/*epidemiology/secondary OTO - NOTNLM OT - robotic surgical procedures OT - ureteral neoplasms OT - urinary bladder neoplasms EDAT- 2021/04/22 06:00 MHDA- 2021/08/31 06:00 CRDT- 2021/04/21 17:12 PHST- 2021/04/22 06:00 [pubmed] PHST- 2021/08/31 06:00 [medline] PHST- 2021/04/21 17:12 [entrez] AID - 10.1097/JU.0000000000001786 [doi] PST - ppublish SO - J Urol. 2021 Sep;206(3):568-576. doi: 10.1097/JU.0000000000001786. Epub 2021 Apr 21. PMID- 33881556 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220218 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification? PG - 4021-4027 LID - 10.1007/s00345-021-03697-3 [doi] AB - PURPOSE: The value of bladder cancer (BC) substaging into macroscopic (pT3b) and microscopic (pT3a) perivesical fat extension in lymph node (Ln)-negative patients is controversially discussed and limited evidence for prognostic relevance of additional histopathological factors in pT3 BC exists. We evaluated the prognostic value of pT3 substaging and established pathological and clinical parameters with focus on tumor invasive front (TIF) and tumor size. METHODS: Specimens of 52 patients treated with radical cystectomy (RC) for pT3 a/b muscle-invasive BC were reviewed and re-evaluated by a pathologist specialized in uropathology. Clinical variables and standard histopathologic characteristics were assessed including TIF and tumor size. Their value as prognosticators for overall survival (OS) and recurrence-free survival (RFS) was evaluated. RESULTS: Mean age of patients was 67.55 years. Tumors were staged pT3a in 28 patients (53.8%) and pT3b in 24 (46.8%). Median OS was 34.51 months. Median tumor size was 3.2 cm, median TIF was 11.0 mm. Differences in OS between pT3a and pT3b were not significant (p = 0.45). Carcinoma in situ (CIS) and lymphovascular invasion (LVI) were significantly associated with pT3b tumors. Univariate analysis could not identify pathological prognosticators like TIF or tumor size for OS and RFS (p for all > 0.05). CONCLUSION: No significant differences in OS or RFS were observed comparing Ln-negative pT3 BC following radical cystectomy. Additional pathologic variables like TIF could not be identified as prognosticator. Relevance of pT3 BC substaging needs reevaluation in larger prospective cohorts. CI - (c) 2021. The Author(s). FAU - Maas, Moritz AU - Maas M AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Mischinger, Johannes AU - Mischinger J AD - Department of Urology, University Hospital, Graz, Austria. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, University Hospital, Wien, Austria. FAU - Scharpf, Marcus AU - Scharpf M AD - Department of Pathology, University Hospital, Tubingen, Germany. FAU - Fend, Falko AU - Fend F AD - Department of Pathology, University Hospital, Tubingen, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Clinical Trials Unit, Studienpraxis Urologie, Nurtingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital Wurzburg, Oberdurrbacher Strasse 6, 97080, Wurzburg, Germany. georgios.gakis@gmail.com. FAU - Rausch, Steffen AU - Rausch S AD - Department of Urology, University Hospital, Tubingen, Germany. LA - eng PT - Journal Article DEP - 20210421 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/classification/mortality/*pathology MH - Female MH - Humans MH - Lymph Nodes MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/classification/mortality/*pathology PMC - PMC8571207 OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - Pathological staging OT - Patient outcome OT - Perivesical extension OT - Tumor invasion front COIS- The authors have no relevant conflict of interest in the context of the work presented. EDAT- 2021/04/22 06:00 MHDA- 2022/02/19 06:00 PMCR- 2021/04/21 CRDT- 2021/04/21 12:19 PHST- 2020/11/01 00:00 [received] PHST- 2021/04/08 00:00 [accepted] PHST- 2021/04/22 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/04/21 12:19 [entrez] PHST- 2021/04/21 00:00 [pmc-release] AID - 10.1007/s00345-021-03697-3 [pii] AID - 3697 [pii] AID - 10.1007/s00345-021-03697-3 [doi] PST - ppublish SO - World J Urol. 2021 Nov;39(11):4021-4027. doi: 10.1007/s00345-021-03697-3. Epub 2021 Apr 21. PMID- 33868985 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220422 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. PG - 570077 LID - 10.3389/fonc.2021.570077 [doi] LID - 570077 AB - OBJECTIVE: To investigate the association between antibiotic therapy and the efficacy of intravesical BCG therapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). METHODS: This study involved the retrospective review of medical records of patients who underwent transurethral resection of bladder tumors for high-risk NMIBC followed by intravesical BCG therapy between 2008 and 2017. Patients were categorized as none, short- (2-6 days), and long-course use (>/=7 days) based on the duration of antibiotic treatment concurrent with or initiated /=cT2 to /=T2 vs 62%; P < 0.001) and were, therefore, more likely to receive NAC (29% vs 18%; P = 0.003). We found no evidence to support a difference in partial (24% vs 31%) or complete (20% vs 24%) response between patients with sarcomatoid histology and those with pure UC at TUR (P = 0.6). Among patients with sarcomatoid differentiation, 5-year recurrence-free survival was 55% (95% confidence interval [CI] 41-74) among patients receiving NAC and 40% (95% CI 31-52) among patients undergoing cystectomy alone (P = 0.1). Adjusting for stage, nodal involvement, margin status and receipt of NAC, sarcomatoid differentiation was associated with worse recurrence-free (hazard ratio [HR] 1.82, 95% CI 1.39-2.39), disease-specific (HR 1.66, 95% CI 1.23-2.22), and overall survival (HR 1.37, 95% CI 1.06-1.78). CONCLUSIONS: Sarcomatoid differentiation was associated with higher stage at presentation and independently associated with worse survival. Given similar pathological response rates if sarcomatoid differentiation is detected at initial resection, and greater survival among patients receiving NAC, treatment with NAC appears warranted. Other drivers of the poor outcomes of this histology must be investigated. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Almassi, Nima AU - Almassi N AUID- ORCID: 0000-0002-6307-9268 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Vertosick, Emily A AU - Vertosick EA AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Sjoberg, Daniel D AU - Sjoberg DD AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Wong, Nathan C AU - Wong NC AUID- ORCID: 0000-0001-6174-1046 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Huang, Chun AU - Huang C AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Cha, Eugene K AU - Cha EK AUID- ORCID: 0000-0002-8807-2353 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Donahue, Timothy F AU - Donahue TF AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Dalbagni, Guido AU - Dalbagni G AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Iyer, Gopa AU - Iyer G AUID- ORCID: 0000-0002-5093-6099 AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Bajorin, Dean F AU - Bajorin DF AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Department of Pathology, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. FAU - Goh, Alvin C AU - Goh AC AUID- ORCID: 0000-0003-3092-9024 AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - UL1 TR002384/TR/NCATS NIH HHS/United States GR - T32 CA082088/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210524 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology PMC - PMC8522172 MID - NIHMS1726104 OTO - NOTNLM OT - #BladderCancer OT - #scmsm OT - #uroonc OT - bladder cancer OT - neoadjuvant therapy OT - pathological outcomes OT - sarcomatoid differentiation OT - survival OT - urothelial carcinoma COIS- Conflicts of Interest Nima Almassi, Emily A. Vertosick, Daniel D. Sjoberg, Nathan C. Wong, Chun Huang, Eugene K. Cha, Timothy F. Donahue, Guido Dalbagni, and Alvin C. Goh have no conflicts of interest to report. Eugene J. Pietzak reports honoraria from UpToDate, consulting or advisory role at Merck and Chugai Pharma. Bernard H. Bochner serves as consultant for Olympus. Gopa Iyer reports personal fees from Mirati Therapeutics and Janssen and research support from Novartis. Jonathan E. Rosenberg reports stock and other ownership Interests in Merck, Illumina; honoraria from UpToDate, Bristol-Myers Squibb, AstraZeneca, Medscape, Vindico, Peerview, Chugai Pharma; consulting or advisory role for Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Seattle Genetic, Bayer, Inovio Pharmaceuticals, BioClin Therapeutics, QED Therapeutic, Adicet Bio, Sensei Biotherapeutics; patents, royalties, other intellectual property for Predictor of platinum sensitivity; research funding from Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genentech/Roche, Incyte, Seattle Genetics, Bayer; travel, accommodations, expenses from Genentech/Roche, Bristol-Myers Squibb. Dean F. Bajorin reports honoraria from the speaker's bureau of Merck; lecture fees and travel support from Merck; and Consultant/advisory board: Merck, Pfizer, Bristol-Myers Squibb, Urogen, Genentech, Eli Lilly. Hikmat Al-Ahmadie reports personal fees from AstraZeneca and Bristol-Myers Squibb. EDAT- 2021/04/19 06:00 MHDA- 2022/04/05 06:00 PMCR- 2023/04/01 CRDT- 2021/04/18 21:11 PHST- 2021/04/19 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2021/04/18 21:11 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - 10.1111/bju.15428 [doi] PST - ppublish SO - BJU Int. 2022 Apr;129(4):463-469. doi: 10.1111/bju.15428. Epub 2021 May 24. PMID- 33865688 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20250512 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. PG - 787.e9-787.e15 LID - S1078-1439(21)00135-6 [pii] LID - 10.1016/j.urolonc.2021.03.025 [doi] AB - OBJECTIVES: Prior studies have shown that pathologic complete response at radical cystectomy, a significant prognostic factor, can be attributed to both neoadjuvant chemotherapy (NAC) and high-quality transurethral resections (TURBT) prior to NAC. It remains unclear whether the visual completeness of TURBT prior to NAC plays an important role in subsequent outcomes. We sought to assess the association of completeness of TURBT prior to NAC with response and survival outcomes. METHODS AND MATERIALS: We retrospectively reviewed all patients with clinically localized muscle-invasive bladder cancer at our institution who received NAC from 2000 to 2017. Complete TURBT was defined as resection of all visible tumor in entirety, resection to normal-appearing muscle, and/or repeat pre-NAC TURBT revealing cT0. Patients who were restaged as cT0 after NAC and refused cystectomy were placed on an active surveillance/delayed intervention (ASDI) protocol. The primary endpoints were overall and cancer-specific survival. The secondary endpoints were recurrence-free and muscle-invasive recurrence-free survival. RESULTS: Of 93 patients, 62 (67%) underwent complete TURBT prior to chemotherapy. Compared to patients with incomplete TURBT, those with complete TURBT had lower rates of variant histology (13% vs. 32%) and hydronephrosis (15% vs. 39%). Also, 36% of patients with incomplete TURBT had >/=cT3 disease prior to NAC, compared to none in the complete TURBT cohort. Patients with complete TURBT were more likely to defer RC and pursue ASDI (61% vs. 32%). Those with complete TURBT had lower rates of pT2 or higher disease at cystectomy (48% vs. 75%), with a lower rate of N+ disease trending towards significance (17% vs. 37%). Patients with complete TURBT had higher 5-year overall (77% vs. 46%, P = 0.003) and cancer-specific (85% vs. 50%, P = 0.001) survival. On Cox regression analysis, complete TURBT was significantly associated with superior cancer-specific, recurrence-free, and muscle-invasive recurrence-free survival. CONCLUSIONS: A complete TURBT prior to NAC is associated with improved survival and oncologic outcomes in this cohort with muscle-invasive bladder cancer. The extent to which complete TURBT simply represents a proxy for less aggressive disease or is actually a beneficial therapeutic intervention which improves response to chemotherapy is difficult to define retrospectively. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Pak, Jamie S AU - Pak JS AD - Department of Urology, Columbia University Irving Medical Center,NY. Electronic address: Jsp2187@cumc.columbia.edu. FAU - Haas, Christopher R AU - Haas CR AD - Department of Urology, Columbia University Irving Medical Center,NY. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Columbia University Irving Medical Center,NY. FAU - DeCastro, G Joel AU - DeCastro GJ AD - Department of Urology, Columbia University Irving Medical Center,NY. FAU - Benson, Mitchell C AU - Benson MC AD - Department of Urology, Columbia University Irving Medical Center,NY. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Irving Medical Center,NY. LA - eng PT - Journal Article DEP - 20210414 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Neoadjuvant Therapy/*methods MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*drug therapy/mortality/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Cystectomy OT - Neoadjuvant therapy OT - Recurrence OT - Survival analysis OT - Urinary bladder neoplasms EDAT- 2021/04/19 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/04/18 20:33 PHST- 2020/10/28 00:00 [received] PHST- 2021/03/15 00:00 [revised] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/04/19 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/04/18 20:33 [entrez] AID - S1078-1439(21)00135-6 [pii] AID - 10.1016/j.urolonc.2021.03.025 [doi] PST - ppublish SO - Urol Oncol. 2021 Nov;39(11):787.e9-787.e15. doi: 10.1016/j.urolonc.2021.03.025. Epub 2021 Apr 14. PMID- 33863885 OWN - NLM STAT- MEDLINE DCOM- 20210503 LR - 20240212 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 12 IP - 1 DP - 2021 Apr 16 TI - An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. PG - 2301 LID - 10.1038/s41467-021-22465-w [doi] LID - 2301 AB - The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials. FAU - Lindskrog, Sia Viborg AU - Lindskrog SV AUID- ORCID: 0000-0001-5280-7306 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Lamy, Philippe AU - Lamy P AUID- ORCID: 0000-0003-1347-7724 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. FAU - Taber, Ann AU - Taber A AUID- ORCID: 0000-0002-0516-9564 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Groeneveld, Clarice S AU - Groeneveld CS AUID- ORCID: 0000-0001-5222-2586 AD - Cartes d'Identite des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France. AD - Oncologie Moleculaire, UMR144, Institut Curie, Paris, France. FAU - Birkenkamp-Demtroder, Karin AU - Birkenkamp-Demtroder K AUID- ORCID: 0000-0001-8057-6277 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Strandgaard, Trine AU - Strandgaard T AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Nordentoft, Iver AU - Nordentoft I AUID- ORCID: 0000-0003-4856-4086 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. FAU - Christensen, Emil AU - Christensen E AUID- ORCID: 0000-0001-7201-3933 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Sokac, Mateo AU - Sokac M AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Birkbak, Nicolai J AU - Birkbak NJ AUID- ORCID: 0000-0003-1613-9587 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Maretty, Lasse AU - Maretty L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Hermann, Gregers G AU - Hermann GG AD - Department of Urology, Herlev hospital, Copenhagen University, Copenhagen, Denmark. FAU - Petersen, Astrid C AU - Petersen AC AD - Department of Pathology, Aalborg University Hospital, Aalborg, Denmark. FAU - Weyerer, Veronika AU - Weyerer V AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. FAU - Grimm, Marc-Oliver AU - Grimm MO AD - Department of Urology, Jena University Hospital, Jena, Germany. FAU - Horstmann, Marcus AU - Horstmann M AD - Department of Urology, Jena University Hospital, Jena, Germany. AD - Department of Urology, Malteser Hospital St. Josephshospital, Krefeld Uerdingen, Krefeld, Germany. FAU - Sjodahl, Gottfrid AU - Sjodahl G AUID- ORCID: 0000-0002-7869-0473 AD - Division of Urological Research, Department of Translational Medicine, Lund University, Skane University Hospital, Malmo, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Steiniche, Torben AU - Steiniche T AD - Department of Pathology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Mogensen, Karin AU - Mogensen K AD - Department of Urology, Herlev hospital, Copenhagen University, Copenhagen, Denmark. FAU - de Reynies, Aurelien AU - de Reynies A AD - Cartes d'Identite des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France. FAU - Nawroth, Roman AU - Nawroth R AD - Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany. FAU - Jordan, Brian AU - Jordan B AD - Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine, Chicago, IL, USA. FAU - Lin, Xiaoqi AU - Lin X AD - Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine, Chicago, IL, USA. FAU - Dragicevic, Dejan AU - Dragicevic D AD - Clinic of Urology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Ward, Douglas G AU - Ward DG AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Goel, Anshita AU - Goel A AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Hurst, Carolyn D AU - Hurst CD AD - Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. FAU - Raman, Jay D AU - Raman JD AD - Department of Surgery, Division of Urology, Pennsylvania State University, Hershey, PA, USA. FAU - Warrick, Joshua I AU - Warrick JI AUID- ORCID: 0000-0001-6149-1331 AD - Department of Pathology and Laboratory Medicine, Division of Urology, Department of Biochemistry and Molecular Biology, Pennsylvania State University, Hershey, PA, USA. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. FAU - van Kessel, Kim E M AU - van Kessel KEM AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Maurer, Tobias AU - Maurer T AD - Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany. AD - Department of Urology and Martini-Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Meeks, Joshua J AU - Meeks JJ AD - Departments of Pathology, Urology, Biochemistry and Molecular Genetics, Northwestern University School of Medicine, Chicago, IL, USA. FAU - DeGraff, David J AU - DeGraff DJ AD - Department of Pathology and Laboratory Medicine, Division of Urology, Department of Biochemistry and Molecular Biology, Pennsylvania State University, Hershey, PA, USA. FAU - Bryan, Richard T AU - Bryan RT AD - Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Knowles, Margaret A AU - Knowles MA AD - Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. FAU - Simic, Tatjana AU - Simic T AD - Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Malats, Nuria AU - Malats N AUID- ORCID: 0000-0003-2538-3784 AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), CIBERONC, Madrid, Spain. FAU - Real, Francisco X AU - Real FX AUID- ORCID: 0000-0001-9501-498X AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain. AD - Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, CIBERONC, Barcelona, Spain. FAU - Dyrskjot, Lars AU - Dyrskjot L AUID- ORCID: 0000-0001-7061-9851 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark. lars@clin.au.dk. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. lars@clin.au.dk. LA - eng GR - I01 BX003692/BX/BLRD VA/United States GR - I01 BX005599/BX/BLRD VA/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210416 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM CIN - J Urol. 2022 Mar;207(3):733-734. doi: 10.1097/JU.0000000000002358. PMID: 34905949 MH - Aged MH - BCG Vaccine/administration & dosage MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell/*genetics/immunology/mortality/therapy MH - Chromosomal Instability MH - Cystectomy/methods MH - Denmark/epidemiology MH - Female MH - Follow-Up Studies MH - Gene Expression Regulation, Neoplastic MH - Genomics MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mutation MH - Neoplasm Recurrence, Local/*epidemiology/genetics MH - Prognosis MH - Progression-Free Survival MH - RNA-Seq MH - Urinary Bladder/immunology/pathology/surgery MH - Urinary Bladder Neoplasms/*genetics/immunology/mortality/therapy PMC - PMC8052448 COIS- L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J.J.M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix. R.T.B. has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma and QED Therapeutics. The following authors declare no competing interests: S.V.L., F.P., P.L., A.T., C.S.G., K.B.D., T.S., I.N., E.C., M.S., N.J.B., L.M., G.G.H., A.C.P., V.W., M.O.G., M.H., G.S., M.H., T.S., K.M., A.R., R.M., B.J., X.L., D.D., D.G.W., A.G., C.D.H., J.I.W., U.S., D.S., K.E.M.K., T.M., D.J.D., M.A.K., T.S., A.H., E.C.Z., P.U.M., N.M., and F.X.R. EDAT- 2021/04/18 06:00 MHDA- 2021/05/04 06:00 PMCR- 2021/04/16 CRDT- 2021/04/17 05:43 PHST- 2020/06/11 00:00 [received] PHST- 2021/03/09 00:00 [accepted] PHST- 2021/04/17 05:43 [entrez] PHST- 2021/04/18 06:00 [pubmed] PHST- 2021/05/04 06:00 [medline] PHST- 2021/04/16 00:00 [pmc-release] AID - 10.1038/s41467-021-22465-w [pii] AID - 22465 [pii] AID - 10.1038/s41467-021-22465-w [doi] PST - epublish SO - Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID- 33850786 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210416 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 3 DP - 2021 Mar TI - Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. PG - 1521-1529 LID - 10.21037/tau-20-1436 [doi] AB - Over the last few years efficacy of immunotherapy using immune checkpoint inhibitors (ICI) has been investigated in patients with bladder cancer (BC) at all stages. The present article aims to assess new therapeutic options with emerging agents in BC patients, shedding light on ICI-based treatments encompassing all disease stages, from non-muscle invasive (NMIBC) to muscle-invasive (MIBC) BC, concluding with metastatic MIBC. In bacillus Calmette-Guerin (BCG) unresponsive patients with carcinoma in situ, pembrolizumab has been recently approved. In the neoadjuvant setting, results from two clinical trials seem to identify pathological and genomic features of highly responsive tumors. Squamous cells and lymphoepithelioma/like histotypes, programmed cell-death ligand 1 (PD-L1) expression and high levels of activate T cells have been associated with higher response rate. In the metastatic setting, only 30% of patient may respond to ICI. A panel of biomarkers for patient selection is an actual need since the correlation between response and PD-L1 expression seem inconsistent across clinical trials, with some exceptions. Molecular characterization of BC, tumor mutation burden and immune-gene expression profiling might introduce new molecular biomarkers, hopefully transferable into the clinical-pathological practice. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Aurilio, Gaetano AU - Aurilio G AD - Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, United Hospitals, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Surgery, Cordoba University Medical School, Cordoba, Spain. FAU - Scarpelli, Marina AU - Scarpelli M AD - Section of Pathological Anatomy, United Hospitals, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Massari, Francesco AU - Massari F AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Verri, Elena AU - Verri E AD - Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Santoni, Matteo AU - Santoni M AD - Oncology Unit, Macerata Hospital, Macerata, Italy. FAU - Montironi, Rodolfo AU - Montironi R AD - Section of Pathological Anatomy, United Hospitals, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC8039606 OTO - NOTNLM OT - Urothelial carcinoma OT - bladder cancer (BC) OT - clinical trials OT - immune checkpoint inhibitors (ICIs) OT - immunotherapy OT - predictive biomarkers OT - programmed cell-death ligand 1 (PD-L1) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1436). The series "Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors" was commissioned by the editorial office without any funding or sponsorship. AC, ALB, MS, LC and RM served as the unpaid Guest Editors of the series. LC serves as an unpaid editorial board member of Translational Andrology and Urology from Dec 2018 to Nov 2022. The authors have no other conflicts of interest to declare. EDAT- 2021/04/15 06:00 MHDA- 2021/04/15 06:01 PMCR- 2021/03/01 CRDT- 2021/04/14 06:35 PHST- 2021/04/14 06:35 [entrez] PHST- 2021/04/15 06:00 [pubmed] PHST- 2021/04/15 06:01 [medline] PHST- 2021/03/01 00:00 [pmc-release] AID - tau-10-03-1521 [pii] AID - 10.21037/tau-20-1436 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Mar;10(3):1521-1529. doi: 10.21037/tau-20-1436. PMID- 33842371 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220422 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer. PG - 655000 LID - 10.3389/fonc.2021.655000 [doi] LID - 655000 AB - INTRODUCTION: Transurethral resection of bladder tumor with subsequent BCG immunotherapy is the current gold standard in the treatment of high risk and some medium-risk non-muscle invasive bladder cancer. Clinical factors like stage, grade, age and gender are well-know predictors of progression to muscle-invasive bladder cancer. In recent years novel hematological biomarkers were shown to be independent predictors of progression. This study aimed to evaluate which of these novel markers has the highest prognostic value of progression in patients with bladder cancer receiving BCG immunotherapy. MATERIALS AND METHODS: We retrospectively analyzed the data of 125 patients with non-muscle invasive bladder cancer who received BCG immunotherapy. Of these, 61 progressed to muscle-invasive disease or had high-grade recurrence. These patients were compared with the group who did not progress (n = 64). Clinical data including stage, grade, age, gender, smoking status and observational time was collected. Besides, information on blood count analysis was obtained from ambulatory digital charts. On this basis neutrophil-to-lymphocyte ratio (NLR), platelet-to lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) was counted and compared between groups. RESULTS: NLR, PLR and LMR were shown to be independent prognostic markers of progression in multivariable analysis. The model with stage, grade, age, gender, smoking status and LMR had the highest prognostic values of all models (area under curve [AUC] = 0.756). The cut-off point according to ROC curves for LMR was 3.25. Adding LMR to the baseline model including clinical variables significantly increased area under curve by 0.08 (p = 0.001). NLR and PLR did not increase areas under curve significantly to baseline model. CONCLUSIONS: LMR outperformed NLR and PLR for prediction of progression in patients with non-muscle-invasive bladder cancer receiving BCG immunotherapy. LMR, as an easily obtainable biomarker, should be incorporated to the present risk stratification models. CI - Copyright (c) 2021 Adamkiewicz, Bryniarski, Kowalik, Burzynski, Rajwa and Paradysz. FAU - Adamkiewicz, Mateusz AU - Adamkiewicz M AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Bryniarski, Piotr AU - Bryniarski P AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Kowalik, Maksymilian AU - Kowalik M AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Burzynski, Bartlomiej AU - Burzynski B AD - Department of Rehabilitation, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. FAU - Paradysz, Andrzej AU - Paradysz A AD - Department of Urology, Medical University of Silesia, Zabrze, Poland. LA - eng PT - Journal Article DEP - 20210326 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC8033152 OTO - NOTNLM OT - Bacillus Calmet-Guiren immunotherapy OT - bladder cancer OT - lymphocyte-to-monocyte ratio OT - neutrophil-to-lymphocyte ratio OT - platelet-to-lymphocyte ratio OT - transurethral resection of bladder tumor COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/04/13 06:00 MHDA- 2021/04/13 06:01 PMCR- 2021/01/01 CRDT- 2021/04/12 06:23 PHST- 2021/01/18 00:00 [received] PHST- 2021/03/09 00:00 [accepted] PHST- 2021/04/12 06:23 [entrez] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/04/13 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.655000 [doi] PST - epublish SO - Front Oncol. 2021 Mar 26;11:655000. doi: 10.3389/fonc.2021.655000. eCollection 2021. PMID- 33839041 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 4 DP - 2021 Aug TI - Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette-Guerin Responders in T1HG/NMIBC: Prospective Cohort Study. PG - e248-e254 LID - S1558-7673(21)00064-1 [pii] LID - 10.1016/j.clgc.2021.03.001 [doi] AB - BACKGROUND: Prediction of recurrence and progression and the choice of type of management are largely based on stage and grade; however, these prognostic features are limited in the prediction of clinical outcomes. The objective was to investigate the relation between the apparent diffusion coefficient (ADC) value and recurrence and progression of T1G3 of urothelial carcinoma after transurethral resection of the bladder tumor (TURBT) and Bacillus Calmette-Guerin instillation. MATERIALS AND METHODS: This prospective study included 65 patients with single bladder mass T1G3 less than 3 cm without carcinoma in situ or lymphovascular invasion. Mean ADC values of the tumors were compared between patients with and without recurrence and progression following TURBT. The relation of ADC value and other factors were determined by univariate and multivariate analyses. The following tests were used to test differences for significance: difference and association of qualitative variable by chi(2) test; differences between quantitative independent groups by t-test or Mann-Whitney U test; survival by Kaplan-Meier; Cox regression (or Cox proportional hazards model) was used to analyze the effect of several risk factors on time until event (recurrence and progression); correlation by Pearson or Spearman, and we calculated the most suitable cutoff and validity by receiver operating characteristic curve. RESULTS: In relation to recurrence, smoking, nonpapillary shape and higher size, and lower ADC were significant predictors for recurrence. In relation to progression, female sex, nonpapillary shape, and lower ADC were significant predictors for progression. Multivariate analysis showed that ADC < 1.09 was the only significant independent predictors for recurrence. Also, it showed that ADC < 0.98 was the only significant independent predictors for progression. CONCLUSION: Low ADC value group of T1G3 bladder cancer showed significant recurrence and progression than high ADC value group of T1G3 bladder cancer. ADC value in conjunction with other risk stratifications will have a promising role in stratifying patients with T1G3 who need to proceed to early radical cystectomy versus conservative treatment. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Abd Elwahab, Khaled M AU - Abd Elwahab KM AD - Urology Department, Zagazig University, Zagazig, Egypt. Electronic address: khaledabdelwahab1966@gmail.com. FAU - Desky, Esam A E AU - Desky EAE AD - Urology Department, Zagazig University, Zagazig, Egypt. Electronic address: prof_esam_desoky@yahoo.com. FAU - Eldery, Mohamed S AU - Eldery MS AD - Urology Department, Zagazig University, Zagazig, Egypt. Electronic address: mohamed.salah.urology@gmail.com. FAU - Mohammad, Faten Fawzy AU - Mohammad FF AD - Radiology Department, Zagazig University, Zagazig, Egypt. FAU - Seleem, Mohammed M AU - Seleem MM AD - Urology Department, Zagazig University, Zagazig, Egypt. Electronic address: drseleem2007@yahoo.com. FAU - El-Babouly, Islam M AU - El-Babouly IM AD - Urology Department, Zagazig University, Zagazig, Egypt. Electronic address: islammohiedden@gmail.com. LA - eng PT - Journal Article DEP - 20210317 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma, Transitional Cell/diagnostic imaging/drug therapy/surgery MH - Disease Progression MH - Female MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy/surgery OTO - NOTNLM OT - Bladder tumor OT - MRI, NMIBC EDAT- 2021/04/12 06:00 MHDA- 2021/09/11 06:00 CRDT- 2021/04/11 20:27 PHST- 2020/11/23 00:00 [received] PHST- 2021/02/19 00:00 [revised] PHST- 2021/03/03 00:00 [accepted] PHST- 2021/04/12 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] PHST- 2021/04/11 20:27 [entrez] AID - S1558-7673(21)00064-1 [pii] AID - 10.1016/j.clgc.2021.03.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Aug;19(4):e248-e254. doi: 10.1016/j.clgc.2021.03.001. Epub 2021 Mar 17. PMID- 33833577 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 13 DP - 2021 TI - The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer. PG - 2937-2945 LID - 10.2147/CMAR.S299148 [doi] AB - PURPOSE: Non-muscle invasive bladder cancer (NMIBC) is a potentially curable or controllable disease if strict adherence to a surveillance protocol is followed. Management and surveillance of NMIBC begins at the time of diagnosis up to a few years thereafter. There is scanty data in the literature evaluating the impact of non-compliance with the surveillance protocols on progression, recurrence, and mortality rate. PATIENTS AND METHODS: An observational, retrospective cohort study recruited data between 2012 and 2017 at two tertiary hospitals. Data were collected consecutively. NMIBC patients who had at least 3 years of follow-up data were included. Patients were divided into different groups based on their compliance with the cystoscopy follow-up protocol as recommended by the European guidelines. We compared the cystoscopy compliant group with the non-compliant group in view of recurrence, progression, and mortality. In addition, missing variable items during surveillance were calculated using a new scoring model to predict adverse outcomes. RESULTS: Eighty-eight NMIBC patients met our criteria. Recurrence rate (RR), progression rate (PR), metastasis rate (MsR), and mortality rate (MR) are significantly higher in non-compliant group, RR: (92.6%) (P<0.001), PR: (54.1%) (P<0.001), MsR: (37.7%) (P<0.001), MR: (23.5%) (P= 0.002) respectively. In the subgroup analysis, intermediate and high-risk groups have a PR rate of zero in the compliant group, while it is 100% (P<0.001) and 56.4% (P=0.001) in the non-compliant group, respectively. Use of a Kaplan Meier (KM) graph shows that compliant patients had a better survival in comparison to non-compliant patients. Scoring there or more is statistically and clinically significantly associated with higher recurrence, progression, and mortality. RR: (94%) (P=0.016), PR: 49% (P<0.001) and MR (26%) (P=0.012). CONCLUSION: Non-compliance to a standardized surveillance protocol in NMIBC is associated statistically and clinically with adverse outcomes in comparison to a compliant group. This mandates strict adherence to surveillance guidelines particularly in patients with high-risk disease. CI - (c) 2021 Abushamma et al. FAU - Abushamma, Faris AU - Abushamma F AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. AD - Department of Urology, An-Najah National University Hospital, Nablus, 44839, Palestine. AD - Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK. FAU - Khayyat, Zain AU - Khayyat Z AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. FAU - Soroghle, Aya AU - Soroghle A AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. FAU - H Zyoud, Sa'ed AU - H Zyoud S AD - Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, an-Najah National University, Nablus, 44839, Palestine. AD - Clinical Research Center, an-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Jaradat, Ahmad AU - Jaradat A AUID- ORCID: 0000-0002-6537-2943 AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. AD - Department of Urology, An-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Akkawi, Maha AU - Akkawi M AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. AD - Department of Pathology, An-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Aburass, Hanood AU - Aburass H AUID- ORCID: 0000-0003-1949-4883 AD - Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. AD - Department of Pathology, An-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Qaddumi, Iyad K K AU - Qaddumi IKK AD - Department of Urology, Rafedia General Hospital, Nablus, 44839, Palestine. FAU - Odeh, Razan AU - Odeh R AD - Department of Oncology, An-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Salameh, Husam AU - Salameh H AD - Department of Oncology, An-Najah National University Hospital, Nablus, 44839, Palestine. FAU - Albuheissi, Salah AU - Albuheissi S AD - Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK. LA - eng PT - Journal Article DEP - 20210331 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC8020126 OTO - NOTNLM OT - COVID-19 OT - NMIBC OT - haematuria OT - urological malignancies COIS- The authors report no conflicts of interest for this work. EDAT- 2021/04/10 06:00 MHDA- 2021/04/10 06:01 PMCR- 2021/03/31 CRDT- 2021/04/09 06:24 PHST- 2021/01/10 00:00 [received] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/04/09 06:24 [entrez] PHST- 2021/04/10 06:00 [pubmed] PHST- 2021/04/10 06:01 [medline] PHST- 2021/03/31 00:00 [pmc-release] AID - 299148 [pii] AID - 10.2147/CMAR.S299148 [doi] PST - epublish SO - Cancer Manag Res. 2021 Mar 31;13:2937-2945. doi: 10.2147/CMAR.S299148. eCollection 2021. PMID- 33808614 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260928 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 6 DP - 2021 Mar 19 TI - Imaging and Management of Bladder Cancer. LID - 10.3390/cancers13061396 [doi] LID - 1396 AB - METHODS: Keyword searches of Medline, PubMed, and the Cochrane Library for manuscripts published in English, and searches of references cited in selected articles to identify additional relevant papers. Abstracts sponsored by various societies including the American Urological Association (AUA), European Association of Urology (EAU), and European Society for Medical Oncology (ESMO) were also searched. BACKGROUND: Bladder cancer is the sixth most common cancer in the United States, and one of the most expensive in terms of cancer care. The overwhelming majority are urothelial carcinomas, more often non-muscle invasive rather than muscle-invasive. Bladder cancer is usually diagnosed after work up for hematuria. While the workup for gross hematuria remains CT urography and cystoscopy, the workup for microscopic hematuria was recently updated in 2020 by the American Urologic Association with a more risk-based approach. Bladder cancer is confirmed and staged by transurethral resection of bladder tumor. One of the main goals in staging is determining the presence or absence of muscle invasion by tumor which has wide implications in regards to management and prognosis. CT urography is the main imaging technique in the workup of bladder cancer. There is growing interest in advanced imaging techniques such as multiparametric MRI for local staging, as well as standardized imaging and reporting system with the recently created Vesicle Imaging Reporting and Data System (VI-RADS). Therapies for bladder cancer are rapidly evolving with immune checkpoint inhibitors, particularly programmed death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) inhibitors, as well as another class of immunotherapy called an antibody-drug conjugate which consists of a cytotoxic drug conjugated to monoclonal antibodies against a specific target. CONCLUSION: Bladder cancer is a complex disease, and its management is evolving. Advances in therapy, understanding of the disease, and advanced imaging have ushered in a period of rapid change in the care of bladder cancer patients. FAU - Wong, Vincenzo K AU - Wong VK AD - Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Ganeshan, Dhakshinamoorthy AU - Ganeshan D AD - Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Jensen, Corey T AU - Jensen CT AD - Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Devine, Catherine E AU - Devine CE AD - Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20210319 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8003397 OTO - NOTNLM OT - CT OT - MRI OT - bladder cancer OT - imaging OT - management OT - urography OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/04/04 06:01 PMCR- 2021/03/19 CRDT- 2021/04/03 01:30 PHST- 2021/03/09 00:00 [received] PHST- 2021/03/16 00:00 [accepted] PHST- 2021/04/03 01:30 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/04 06:01 [medline] PHST- 2021/03/19 00:00 [pmc-release] AID - cancers13061396 [pii] AID - cancers-13-01396 [pii] AID - 10.3390/cancers13061396 [doi] PST - epublish SO - Cancers (Basel). 2021 Mar 19;13(6):1396. doi: 10.3390/cancers13061396. PMID- 33806392 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210408 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 5 DP - 2021 Mar 4 TI - Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. LID - 10.3390/jcm10051055 [doi] LID - 1055 AB - PURPOSE: To assess the diagnostic performance of urine telomerase activity (TA) in detecting bladder cancer (BCa) using the modified Telomeric Repeat Amplification Protocol (TRAP) and the Real Time Telomeric Repeat Amplification Protocol with double Polymerase Chain Reaction (RT-TRAP-2PCR). METHODS: In this case-control study, matching urine (in the pre- and post-surgical period) and tissue samples from 68 patients with BCa were assessed for TA. As a control, 45 urine samples were examined from non-BCa patients. TA levels were measured using TRAP and RT-TRAP-2 PCR methods. RESULTS: Preoperative urinary TA was elevated in 64 (94.1%) of the 68 BCa patients. Urine TA was undetectable in 44 control patients, while TA was detected in one patient with histologically verified cystitis. Sensitivity for BCa detection of 94.1% and specificity of 97.8% were observed for urinary TA, while tissue TA had 100% sensitivity and 97.8% specificity. Both urine and tissue TA levels were not significantly higher in patients with muscle-invasive disease compared to those with non-muscle invasive BCa (p > 0.05). Urine and tissue TA levels were not associated with higher tumor grade, stage, and number of tumors (p > 0.05). However, the association was found between higher urinary and tissue TA levels with tumor size >/= 3 cm (p = 0.02 and p = 0.01, respectively). During the first postoperative year, 17 BCa patients experienced disease recurrence, and urinary TA was present in 14 (82.4%) of these patients. The sensitivity and specificity of urinary TA levels for BCa recurrence in patients with non-muscle invasive bladder cancer (NMIBC) during follow-up were 82% and 94.4%, respectively. CONCLUSIONS: This pilot study demonstrates a high diagnostic performance of urinary and tissue TA levels measured by a new RT-TRAP-2PCR method for detecting and monitoring BCa. Additionally, the association was found between higher urinary and tissue TA levels with tumor size >/= 3 cm; however, higher TA levels failed for significant correlation with advanced tumor stage and grade. Our study could serve as a benchmark for the evaluation of novel biomarkers using the RT-TRAP-2PCR method. FAU - Glukhov, Alexander AU - Glukhov A AD - Department of Biochemistry, Sechenov University, 119146 Moscow, Russia. AD - Faculty of Biology, Moscow State University, 119192 Moscow, Russia. FAU - Potoldykova, Natalya AU - Potoldykova N AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. FAU - Taratkin, Mark AU - Taratkin M AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. FAU - Gordeev, Sergey AU - Gordeev S AD - Faculty of Biology, Moscow State University, 119192 Moscow, Russia. FAU - Polyakovsky, Konstantin AU - Polyakovsky K AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, 6000 Lucerne, Switzerland. AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, 20132 Milano, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Urology, The University of Jordan, 11942 Amman, Jordan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Urology, The University of Jordan, 11942 Amman, Jordan. FAU - Sekacheva, Marina AU - Sekacheva M AD - Computational Oncology Group, Sechenov University, 119435 Moscow, Russia. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. FAU - Glybochko, Petr AU - Glybochko P AD - Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia. LA - eng PT - Journal Article DEP - 20210304 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC7961950 OTO - NOTNLM OT - RT-TRAP-2PCR OT - bladder cancer OT - non-invasive diagnosis of bladder cancer OT - non-isotopic TRAP assay OT - urine biomarker COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/04/04 06:01 PMCR- 2021/03/04 CRDT- 2021/04/03 01:23 PHST- 2021/02/08 00:00 [received] PHST- 2021/02/26 00:00 [revised] PHST- 2021/02/27 00:00 [accepted] PHST- 2021/04/03 01:23 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/04 06:01 [medline] PHST- 2021/03/04 00:00 [pmc-release] AID - jcm10051055 [pii] AID - jcm-10-01055 [pii] AID - 10.3390/jcm10051055 [doi] PST - epublish SO - J Clin Med. 2021 Mar 4;10(5):1055. doi: 10.3390/jcm10051055. PMID- 33804350 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 3 DP - 2021 Mar 1 TI - Imaging of Bladder Cancer: Standard Applications and Future Trends. LID - 10.3390/medicina57030220 [doi] LID - 220 AB - The evolution in imaging has had an increasing role in the diagnosis, staging and follow up of bladder cancer. Conventional cystoscopy is crucial in the diagnosis of bladder cancer. However, a cystoscopic procedure cannot always depict carcinoma in situ (CIS) or differentiate benign from malignant tumors prior to biopsy. This review will discuss the standard application, novel imaging modalities and their additive role in patients with bladder cancer. Staging can be performed with CT, but distinguishing between T1 and T2 BCa (bladder cancer) cannot be assessed. MRI can distinguish muscle-invasive from non-muscle-invasive tumors with accurate local staging. Vesical Imaging-Reporting and Data System (VI-RADS) score is a new diagnostic modality used for the prediction of tumor aggressiveness and therapeutic response. Bone scintigraphy is recommended in patients with muscle-invasive BCa with suspected bony metastases. CT shows low sensitivity for nodal staging; however, PET (Positron Emission Tomography)/CT is superior and highly recommended for restaging and determining therapeutic effect. PET/MRI is a new imaging technique in bladder cancer imaging and its role is promising. Texture analysis has shown significant steps in discriminating low-grade from high-grade bladder cancer. Radiomics could be a reliable method for quantitative assessment of the muscle invasion of bladder cancer. FAU - Abouelkheir, Rasha Taha AU - Abouelkheir RT AUID- ORCID: 0000-0002-4250-8772 AD - Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Abdelhamid, Abdalla AU - Abdelhamid A AD - Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - Abou El-Ghar, Mohamed AU - Abou El-Ghar M AUID- ORCID: 0000-0003-2713-4394 AD - Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. FAU - El-Diasty, Tarek AU - El-Diasty T AD - Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt. LA - eng PT - Journal Article PT - Review DEP - 20210301 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - Magnetic Resonance Imaging MH - Neoplasm Staging MH - Positron-Emission Tomography MH - Tomography, X-Ray Computed MH - *Urinary Bladder Neoplasms/diagnostic imaging PMC - PMC8000909 OTO - NOTNLM OT - CT OT - MRI OT - bladder OT - cancer OT - diagnosis OT - imaging COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/03/01 CRDT- 2021/04/03 01:17 PHST- 2021/01/25 00:00 [received] PHST- 2021/02/20 00:00 [revised] PHST- 2021/02/23 00:00 [accepted] PHST- 2021/04/03 01:17 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/03/01 00:00 [pmc-release] AID - medicina57030220 [pii] AID - medicina-57-00220 [pii] AID - 10.3390/medicina57030220 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Mar 1;57(3):220. doi: 10.3390/medicina57030220. PMID- 33802033 OWN - NLM STAT- MEDLINE DCOM- 20210503 LR - 20240331 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 6 DP - 2021 Mar 10 TI - Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. LID - 10.3390/ijms22062800 [doi] LID - 2800 AB - In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to Bacillus-Calmette Guerin (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibility reduces successful treatment outcomes in muscle-invasive bladder cancer (MIBC) patients. The effectiveness of PD-1/PD-L1 immune checkpoint inhibitors (ICI) in metastatic disease has stimulated its evaluation as a treatment option in HR-NMIBC and MIBC patients. However, the observed responses, immune-related adverse events and high costs associated with ICI have provided impetus for the development of methods to improve patient stratification, enhance anti-tumorigenic effects and reduce toxicity. Here, we review the challenges and opportunities offered by PD-1/PD-L1 inhibition in HR-NMIBC and MIBC. We highlight the gaps in the field that need to be addressed to improve patient outcome including biomarkers for response stratification and potentially synergistic combination therapy regimens with PD-1/PD-L1 blockade. FAU - de Jong, Florus C AU - de Jong FC AUID- ORCID: 0000-0001-6853-5982 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. FAU - Rutten, Vera C AU - Rutten VC AUID- ORCID: 0000-0003-2452-5357 AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands. FAU - Theodorescu, Dan AU - Theodorescu D AD - Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. AD - Departments of Surgery (Urology) and Pathology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. LA - eng PT - Journal Article PT - Review DEP - 20210310 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Antibodies, Monoclonal, Humanized/immunology/*therapeutic use MH - B7-H1 Antigen/*antagonists & inhibitors/immunology MH - Drug Synergism MH - Humans MH - Immune Checkpoint Inhibitors/immunology/therapeutic use MH - Outcome Assessment, Health Care/methods/statistics & numerical data MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology MH - Risk Factors MH - Urinary Bladder/*drug effects/immunology/pathology MH - Urinary Bladder Neoplasms/*drug therapy/immunology PMC - PMC7998260 OTO - NOTNLM OT - BCG-unresponsive OT - PD-1 OT - PD-L1 OT - bladder cancer OT - immune checkpoint inhibition OT - neoadjuvant chemotherapy COIS- None of the contributing authors have any conflict of interest, including specific financial interests and relationships and affiliations relevant to the subject matter in the manuscript. EDAT- 2021/04/04 06:00 MHDA- 2021/05/04 06:00 PMCR- 2021/03/10 CRDT- 2021/04/03 01:10 PHST- 2021/02/11 00:00 [received] PHST- 2021/02/25 00:00 [revised] PHST- 2021/03/02 00:00 [accepted] PHST- 2021/04/03 01:10 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/05/04 06:00 [medline] PHST- 2021/03/10 00:00 [pmc-release] AID - ijms22062800 [pii] AID - ijms-22-02800 [pii] AID - 10.3390/ijms22062800 [doi] PST - epublish SO - Int J Mol Sci. 2021 Mar 10;22(6):2800. doi: 10.3390/ijms22062800. PMID- 33799514 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20210426 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 6 DP - 2021 Mar 11 TI - Biomarker-Oriented Therapy in Bladder and Renal Cancer. LID - 10.3390/ijms22062832 [doi] LID - 2832 AB - Treatment of patients with urothelial carcinoma (UC) of the bladder or renal cancer has changed significantly during recent years and efforts towards biomarker-directed therapy are being investigated. Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle invasive bladder cancer (NMIBC) patients, as well as muscle-invasive bladder cancer (MIBC) patients. Meanwhile, efforts to predict tumor response to neoadjuvant chemotherapy (NAC) are still ongoing, and genomic biomarkers are being evaluated in prospective clinical trials. Currently, patients with metastatic UC (mUC) are usually treated with second-line ICI, while cisplatin-ineligible patients with programmed death-ligand 1 (PD-L1) positive tumors can benefit from first-line ICI. Platinum-relapsed UC patients harboring FGFR2/3 mutations can be treated with erdafitinib, while enfortumab vedotin has emerged as a novel third-line treatment option for mUC. In metastatic (clear cell) renal cell carcinoma (RCC), ICI was first introduced as second-line treatment after vascular endothelial growth factor receptor-tyrosine kinase inhibition (VEGFR-TKI). Currently, ICIs have also been introduced as first-line treatment in metastatic RCC. Although there is no evidence up to now for beneficial adjuvant treatment after surgery with VEGFR-TKIs in high-risk non-metastatic RCC, several trials are underway investigating the potential beneficial effect of ICIs in this setting. FAU - Scholtes, Mathijs P AU - Scholtes MP AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. FAU - Alberts, Arnout R AU - Alberts AR AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. FAU - Ifle, Iris G AU - Ifle IG AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. FAU - Verhagen, Paul C M S AU - Verhagen PCMS AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. FAU - van der Veldt, Astrid A M AU - van der Veldt AAM AD - Department of Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. AD - Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20210311 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents) RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) RN - 890E37NHMV (erdafitinib) RN - DLE8519RWM (enfortumab vedotin) RN - EC 2.7.10.1 (FGFR2 protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Antibodies, Monoclonal/therapeutic use MH - Antineoplastic Agents/*therapeutic use MH - B7-H1 Antigen/antagonists & inhibitors/genetics/immunology MH - Biomarkers, Tumor/*genetics/immunology MH - Carcinoma, Renal Cell/*drug therapy/genetics/immunology/pathology MH - Cisplatin/therapeutic use MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immune Checkpoint Inhibitors/*therapeutic use MH - Kidney Neoplasms/*drug therapy/genetics/immunology/pathology MH - Lymphatic Metastasis MH - Mutation MH - Protein Kinase Inhibitors/therapeutic use MH - Pyrazoles/therapeutic use MH - Quinoxalines/therapeutic use MH - Receptor, Fibroblast Growth Factor, Type 2/antagonists & inhibitors/genetics/immunology MH - Receptor, Fibroblast Growth Factor, Type 3/antagonists & inhibitors/genetics/immunology MH - Recurrence MH - Urinary Bladder Neoplasms/*drug therapy/genetics/immunology/pathology PMC - PMC7999814 OTO - NOTNLM OT - biomarker guided therapy OT - bladder cancer OT - immune checkpoint inhibitor OT - renal cancer OT - targeted therapy COIS- A.A.M.v.d.V. has done consultancy (paid to the institute) for BMS, MSD, Merck, Eisai, Sanofi, Pfizer, Ipsen, Novartis, Roche, and Pierre Fabre. EDAT- 2021/04/04 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/03/11 CRDT- 2021/04/03 01:02 PHST- 2021/02/08 00:00 [received] PHST- 2021/03/03 00:00 [revised] PHST- 2021/03/04 00:00 [accepted] PHST- 2021/04/03 01:02 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2021/03/11 00:00 [pmc-release] AID - ijms22062832 [pii] AID - ijms-22-02832 [pii] AID - 10.3390/ijms22062832 [doi] PST - epublish SO - Int J Mol Sci. 2021 Mar 11;22(6):2832. doi: 10.3390/ijms22062832. PMID- 33793062 OWN - NLM STAT- MEDLINE DCOM- 20220103 LR - 20220812 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 128 IP - 6 DP - 2021 Dec TI - Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert((R)) Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer. PG - 713-721 LID - 10.1111/bju.15418 [doi] AB - OBJECTIVE: To evaluate the performance of the Xpert Bladder Cancer Monitor (Xpert; Cepheid, Sunnyvale, CA, USA) test as a predictor of tumour recurrence in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients (n = 429) undergoing surveillance for NMIBC underwent Xpert, cytology, and UroVysion testing. Patients with a positive Xpert and a negative cystoscopy result (positive-negative [PN] group, n = 66) and a control group of double negative patients (negative Xpert and cystoscopy results [NN] group) were followed for 12 months (+/-90 days). RESULTS: Histology-confirmed recurrences were detected in 58 patients (13.5%). Xpert had an overall sensitivity of 60.3% and a specificity of 76.5%. The sensitivity for high-grade (HG) cancer was 87% with a negative predictive value (NPV) of 99%. Urine cytology showed an overall sensitivity of 23.2% (47.6% sensitivity for HG tumours) and a specificity of 88.3%. In the PN group, 32% (n = 21) developed a recurrence within 12 months, 11 of which were HG tumours. In the NN control group, 14% (n = 9) developed a recurrence and only two were HG tumours. The hazard ratio for developing recurrence in the PN group was 2.68 for all tumours and 6.84 for HG cancer. CONCLUSIONS: The Xpert test has a high sensitivity for detecting the recurrence of cancer and a high NPV for excluding HG cancer. In addition, the data suggest that patients with a positive Xpert assay in the setting of negative cystoscopy are at high risk for recurrence and need close surveillance. CI - (c) 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Cowan, Barrett AU - Cowan B AD - Urology Associates, Englewood, CO, USA. FAU - Klein, Eric AU - Klein E AD - Idaho Urologic Institute, Meridian, ID, USA. FAU - Jansz, Ken AU - Jansz K AD - Jansz Medicine Professional Corp, Burlington, ON, Canada. FAU - Westenfelder, Karl AU - Westenfelder K AD - Five Valleys Urology, Missoula, MT, USA. FAU - Bradford, Timothy AU - Bradford T AD - Virginia Urology, Richmond, VA, USA. FAU - Peterson, Chad AU - Peterson C AD - North Idaho Urology, Coeur d Alene, ID, USA. FAU - Scherr, Douglas AU - Scherr D AD - Weill Cornell Medicine, New York, NY, USA. FAU - Karsh, Lawrence I AU - Karsh LI AD - The Urology Centre of Colorado, Denver, CO, USA. FAU - Egerdie, Blair AU - Egerdie B AD - Urology Associates/Urology Medical Research, Kitchener, ON, Canada. FAU - Witjes, Alfred AU - Witjes A AD - Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Trainer, Andrew AU - Trainer A AD - Adult and Paediatric Urology, Omaha, NE, USA. FAU - Harris, Richard AU - Harris R AD - UroPartners, Melrose Park, IL, USA. FAU - Goldfarb, Bernard AU - Goldfarb B AD - Medical Offices, North Bay, ON, Canada. FAU - Flax, Stanley AU - Flax S AD - Urology Clinic, North York, ON, Canada. FAU - Kroeger, Robert AU - Kroeger R AD - Urology Centre, St. Omaha, NE, USA. FAU - Boyd, Buffi AU - Boyd B AD - Urology Associates of Savannah, Savannah, GA, USA. FAU - Liao, Joseph AU - Liao J AD - VA Palo Alto Health Care System, Palo Alto, CA, USA. FAU - Patel, Sanjay AU - Patel S AD - Stephenson Cancer Centre, Oklahoma City, OK, USA. FAU - Bridge, Julia AU - Bridge J AD - University of Nebraska Medical Centre, Omaha, NE, USA. FAU - Reuter, Victor AU - Reuter V AD - MSKCC, New York, NY, USA. FAU - Quigley, Neil AU - Quigley N AD - Geneuity Clinical Research Services, Maryville, TN, USA. FAU - Brown, Sarah AU - Brown S AD - Cepheid, Sunnyvale, CA, USA. FAU - Zhao, Suling AU - Zhao S AD - Cepheid, Sunnyvale, CA, USA. FAU - Satya, Malini AU - Satya M AD - Cepheid, Sunnyvale, CA, USA. FAU - Bates, Michael AU - Bates M AD - Cepheid, Sunnyvale, CA, USA. FAU - Simon, Iris M AU - Simon IM AD - Cepheid, Sunnyvale, CA, USA. FAU - Campbell, Scott AU - Campbell S AD - Cepheid, Sunnyvale, CA, USA. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - UT Southwestern, Dallas, TX, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Validation Study DEP - 20210505 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystoscopy MH - Female MH - Follow-Up Studies MH - Humans MH - In Situ Hybridization, Fluorescence MH - Liquid Biopsy MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis/pathology/*urine MH - Predictive Value of Tests MH - Prospective Studies MH - RNA, Messenger/*urine MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery/*urine MH - Urine/chemistry/cytology PMC - PMC9292663 OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - anticipatory positive OT - liquid biopsy OT - molecular diagnostic OT - non-muscle-invasive bladder cancer OT - surveillance COIS- Dr Lotan reports personal fees from fergene, Ferring Research, Merck, C2I genomics, photocure, Astra Zeneca, AbbVie, Cleveland Diagnostics, BMS, Nucleix, Ambu, Seattle Genetics and Hitachi, outside the submitted work and grants from Abbott, Cepheid, Pacific Edge, and GenomeDx Biosciences, Inc., outside the submitted work. Dr Bridge reports grants from Cepheid, during the conduct of the study, and other from Merck and Bayer, outside the submitted work. Dr Quigley works for Genuity. Geneuity received payment from Cepheid for performing testing on this study. Ms Brown reports personal fees from Cepheid, during the conduct of the study, personal fees from Cepheid, outside the submitted work, and is an employee of a company who sponsored the study. Mrs Zhao reports other from Cepheid (study sponsor and funding source), outside the submitted work. Ms Satya reports other from Cepheid, outside the submitted work. Dr Bates reports personal fees from Cepheid and Danaher, during the conduct of the study, personal fees from Cepheid and Danaher, outside the submitted work. Dr Campbell reports other from Cepheid (study sponsor and funding source), outside the submitted work. All other authors have nothing to declare. EDAT- 2021/04/02 06:00 MHDA- 2022/01/04 06:00 PMCR- 2022/07/18 CRDT- 2021/04/01 12:52 PHST- 2021/04/02 06:00 [pubmed] PHST- 2022/01/04 06:00 [medline] PHST- 2021/04/01 12:52 [entrez] PHST- 2022/07/18 00:00 [pmc-release] AID - BJU15418 [pii] AID - 10.1111/bju.15418 [doi] PST - ppublish SO - BJU Int. 2021 Dec;128(6):713-721. doi: 10.1111/bju.15418. Epub 2021 May 5. PMID- 33787908 OWN - NLM STAT- MEDLINE DCOM- 20210608 LR - 20220428 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 3 DP - 2021 Mar 1 TI - Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System. PG - e213800 LID - 10.1001/jamanetworkopen.2021.3800 [doi] LID - e213800 AB - IMPORTANCE: Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guerin (BCG) therapy. OBJECTIVE: To describe real-world patient characteristics, long-term outcomes, and the economic burden in a population with high-risk NMIBC treated with BCG therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015. Adequate induction BCG therapy was defined as at least 5 installations, and adequate maintenance BCG therapy was defined as at least 7 installations. Data were analyzed from January 2, 2020, to January 20, 2021. EXPOSURES: Intravesical BCG therapy, including adequate induction BCG therapy, was defined as at least 5 intravesical instillations of BCG within 70 days from BCG therapy start date. Adequate maintenance BCG therapy was defined as at least 7 installations of BCG within 274 days of the start (the first instillation) of adequate induction BCG therapy (ie, adequate induction BCG plus some form of additional BCG). MAIN OUTCOMES AND MEASURES: The Kaplan-Meier method was used to estimate outcomes, including event-free survival. All-cause expenditures were summarized as medians with corresponding interquartile ranges (IQRs) and adjusted to 2019 USD. RESULTS: Of the 412 patients who met inclusion criteria, 335 (81%) were male and 77 (19%) were female, with a median age of 67 (IQR, 61-74) years. Follow-up was 2694 person-years. A total of 392 patients (95%) received adequate induction BCG therapy, and 152 (37%) received adequate BCG therapy. For all patients with high-risk NMIBC, the 10-year progression-free survival rate and disease-specific death rate were 78% and 92%, respectively. Patients with carcinoma in situ (Cis) had worse disease-free survival than those without Cis (hazard ratio [HR], 1.85; 95% CI, 1.34-2.56). Total median costs at 1 year were $29 459 (IQR, $14 991-$52 060); at 2 years, $55 267 (IQR, $28 667-$99 846); and at 5 years, $117 361 (IQR, $59 680-$211 298). Patients with progressive disease had significantly higher median 5-year costs ($232 729 [IQR, $151 321-$341 195] vs $94 879 [IQR, $52 498-$172 631]; P < .001), with outpatient care, pharmacy, and surgery-related costs contributing. CONCLUSIONS AND RELEVANCE: Despite adequate induction BCG therapy, only 37% of patients received adequate BCG therapy. Patients with Cis had increased risk of progression, and progression regardless of Cis was associated with significantly increased costs relative to patients without progression. Extrapolating cost figures, regardless of progression, resulted in nationwide costs at 1 year of $373 million for patients diagnosed with high-risk NMIBC in 2019. FAU - Williams, Stephen B AU - Williams SB AD - Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston. FAU - Howard, Lauren E AU - Howard LE AD - Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina. FAU - Foster, Meagan L AU - Foster ML AD - Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Klaassen, Zachary AU - Klaassen Z AD - Section of Urology, Department of Surgery, Augusta University, Medical College of Georgia, Augusta. FAU - Sieluk, Jan AU - Sieluk J AD - Merck & Co, Inc, Kenilworth, New Jersey. FAU - De Hoedt, Amanda M AU - De Hoedt AM AD - Durham Veterans Affairs Health Care System, Durham, North Carolina. FAU - Freedland, Stephen J AU - Freedland SJ AD - Durham Veterans Affairs Health Care System, Durham, North Carolina. AD - Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. AD - Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210301 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - JAMA Netw Open. 2021 Mar 1;4(3):e213816. doi: 10.1001/jamanetworkopen.2021.3816. PMID: 33787916 CIN - J Urol. 2022 May;207(5):1153-1155. doi: 10.1097/JU.0000000000002460. PMID: 35139651 MH - Adjuvants, Immunologic/economics/therapeutic use MH - Aged MH - BCG Vaccine/economics/*therapeutic use MH - Disease-Free Survival MH - Drug Administration Schedule MH - *Drug Costs MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Time Factors MH - United States MH - United States Department of Veterans Affairs/*statistics & numerical data MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/economics MH - Veterans/*statistics & numerical data PMC - PMC8013821 COIS- Conflict of Interest Disclosures: Dr Williams reported receiving grants from the Department of Defense, consulting for Digital Science Press and Photocure, and receiving travel fees from Janssen Global Services, LLC, outside the submitted work. Dr Sieluk reported being a stockowner of Merck & Co, Inc. Ms DeHoedt reported receiving grants from Merck & Co, Inc, during the conduct of the study. Dr Freedland reported receiving grants from Merck & Co, Inc, during the conduct of the study and personal fees from Merck & Co, Inc, outside the submitted work. No other disclosures were reported. EDAT- 2021/04/01 06:00 MHDA- 2021/06/09 06:00 PMCR- 2021/03/31 CRDT- 2021/03/31 13:23 PHST- 2021/03/31 13:23 [entrez] PHST- 2021/04/01 06:00 [pubmed] PHST- 2021/06/09 06:00 [medline] PHST- 2021/03/31 00:00 [pmc-release] AID - 2777975 [pii] AID - zoi210138 [pii] AID - 10.1001/jamanetworkopen.2021.3800 [doi] PST - epublish SO - JAMA Netw Open. 2021 Mar 1;4(3):e213800. doi: 10.1001/jamanetworkopen.2021.3800. PMID- 33785220 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20211223 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker. PG - 437.e11-437.e19 LID - S1078-1439(21)00070-3 [pii] LID - 10.1016/j.urolonc.2021.02.009 [doi] AB - OBJECTIVES: To prospectively investigate the role of a urinary mRNA biomarker (Xpert Test) after initial complete resection of T1 bladder cancer (BC) for the prediction of positive repeat biopsy for malignancy. METHODS: Patients who underwent TURBT for NMIBC between September 2018 and April 2020 were included. Patients with benign pathology, incomplete resection, concomitant CIS/upper tract urothelial tumor or muscle invasive BC, were excluded. 2 to 6 weeks after primary TURBT, voided urine sample was retrieved for Xpert analysis and patients were scheduled for repeat biopsy. The primary outcome was to determine the role of positive Xpert test to predict positive repeat biopsy for malignancy. RESULTS: During the study period, 254 patients met the study inclusion criteria of which 61 (24%) patients had recurrent NMIBC. Complete resection was censured by the presence of detrusor muscle in the specimen with documented T1 disease in all study participants. Xpert test was positive in 128 patients; of whom 85 (66.4%) showed positive repeat biopsy (HR=6.2, 95%CI=3.46-9.4, P = 0.002). The sensitivity, specificity, positive and negative predictive values of Xpert test for repeat biopsy were 85.9% (95%CI: 82-89), 72.3% (95%CI: 68-76), 66.4% (95%CI: 62-71) and 88.9% (95%CI: 85-94), respectively. On median (range) follow up of 12(3-25) months, tumor recurrence was encountered in 84 (35%) patients. On multivariate Cox regression analysis, Xpert test was significantly associated with tumor recurrence (HR= 9.7, 95%CI=5-18, P <0.001). CONCLUSIONS: Positive Xpert test after primary complete resection of T1 BC is significantly associated with positive repeat biopsy for malignancy. In addition, Xpert test is an independent predictor of early tumor recurrence. Xpert test might be applied after initial complete resection of NMIBC to minimize unnecessary repeat biopsy with potential saving of healthcare costs and reduction in patient morbidity. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Elsawy, Amr A AU - Elsawy AA AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. Electronic address: amrelsawy.unc@hotmail.com. FAU - Awadalla, Amira AU - Awadalla A AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Abdullateef, Muhammed AU - Abdullateef M AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Ahmed, Asmaa E AU - Ahmed AE AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Abol-Enein, Hassan AU - Abol-Enein H AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. LA - eng SI - ClinicalTrials.gov/NCT04603612 PT - Journal Article DEP - 20210327 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Biomarkers, Tumor/*urine MH - Biopsy MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prospective Studies MH - RNA, Messenger/*urine MH - Urinary Bladder Neoplasms/*pathology/surgery/*urine OTO - NOTNLM OT - Non-muscle invasive bladder cancer/T1/TURBT/ mRNA/Xpert/ Repeat biopsy/Recurrence COIS- Conflict of interest The authors have nothing to declare. EDAT- 2021/04/01 06:00 MHDA- 2021/12/24 06:00 CRDT- 2021/03/31 05:48 PHST- 2021/01/13 00:00 [received] PHST- 2021/02/05 00:00 [revised] PHST- 2021/02/07 00:00 [accepted] PHST- 2021/04/01 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/03/31 05:48 [entrez] AID - S1078-1439(21)00070-3 [pii] AID - 10.1016/j.urolonc.2021.02.009 [doi] PST - ppublish SO - Urol Oncol. 2021 Jul;39(7):437.e11-437.e19. doi: 10.1016/j.urolonc.2021.02.009. Epub 2021 Mar 27. PMID- 33783950 OWN - NLM STAT- MEDLINE DCOM- 20220103 LR - 20250723 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 IP - 5 DP - 2021 Nov TI - Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response. PG - 634-641 LID - 10.1111/bju.15413 [doi] AB - OBJECTIVES: To investigate bacille Calmette-Guerin (BCG) tolerability and response with respect to the timing of BCG administration after transurethral resection of bladder tumour (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A review of patients with NMIBC at our institution managed with at least 'adequate BCG' (defined by the United States Food and Drug Administration as at least five of six induction instillations, with two additional instillations comprising either maintenance or repeat induction) at our institution from 2000 to 2018 was performed. Time from TURBT to first instillation of induction BCG was stratified by quartile and analysed as a continuous variable. Kaplan-Meier and log-rank tests analysed differences in recurrence-free (RFS) and progression-free survival (PFS). Cox proportional hazards regression models identified associations between risk factors and survival outcomes. RESULTS: A total of 518 patients received adequate BCG at a median (range) of 26 (6-188) days from TURBT. Overall, 45 patients (9%) developed BCG intolerance at a median (range) 12 (7-33) instillations. When time from TURBT to BCG was stratified into quartiles, there was no difference with respect BCG intolerance (P = 0.966), RFS (P = 0.632) or PFS (P = 0.789). On both uni- and multivariate regression analysis for RFS and PFS, time from TURBT to BCG was not a significant predictor when analysed by quartile or as a continuous variable (the hazard ratio for RFS was 1.00, 95% confidence interval [CI] 0.99-1.00, P = 0.449; and for PFS was 0.99, 95% CI 0.98-1.00, P = 0.074). CONCLUSION: The rates of tolerability and response to adequate BCG are not predicated by the timing of induction BCG instillation after TURBT. Early administration in properly selected patients is safe and delays do not affect therapeutic response. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Hensley, Patrick J AU - Hensley PJ AUID- ORCID: 0000-0002-8098-901X AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bree, Kelly K AU - Bree KK AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Brooks, Nathan AU - Brooks N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matulay, Justin AU - Matulay J AD - Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Nogueras Gonzalez, Graciela M AU - Nogueras Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, Herbert B AU - Grossman HB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States GR - P50CA091846/NIH)/National Cancer Institute (NCI) University of Texas MD Anderson Specialized Programs of Research Excellence (SPORE) in Genitourinary Cancer (Bladder)/ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210505 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage/*adverse effects MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*administration & dosage/*adverse effects MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Progression-Free Survival MH - Proportional Hazards Models MH - Survival Rate MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - BCG-unresponsive OT - bacille Calmette-Guerin OT - bladder cancer OT - intravesical therapy OT - transurethral resection of bladder tumour EDAT- 2021/03/31 06:00 MHDA- 2022/01/04 06:00 CRDT- 2021/03/30 12:47 PHST- 2021/03/31 06:00 [pubmed] PHST- 2022/01/04 06:00 [medline] PHST- 2021/03/30 12:47 [entrez] AID - 10.1111/bju.15413 [doi] PST - ppublish SO - BJU Int. 2021 Nov;128(5):634-641. doi: 10.1111/bju.15413. Epub 2021 May 5. PMID- 33780049 OWN - NLM STAT- MEDLINE DCOM- 20211123 LR - 20211123 IS - 1098-2825 (Electronic) IS - 0887-8013 (Print) IS - 0887-8013 (Linking) VI - 35 IP - 5 DP - 2021 May TI - The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis. PG - e23765 LID - 10.1002/jcla.23765 [doi] LID - e23765 AB - BACKGROUND: Bladder cancer is one of the most common urological cancers all over the world, and NMIBC occupies almost 80% of recently diagnosed bladder cancer cases. Progress and recurrence of bladder cancer are the main problems during the disease. The level of TP53 mutation is obviously higher in the high stage than the lower. This meta-analysis is to evaluate the potential diagnosis feature of TP53 mutation by the expression of TP53 mutation of Ta stage vs high stage in bladder cancer. METHODS: A systematic search of databases was conducted, and some relevant articles were selected. Next, the meta-analysis was carried out according to the standard guidelines. RESULTS: There were seven researches in which 677 participants were selected at the basis of inclusion standard. TP53 mutation was associated highly with increased diagnosis of bladder cancer. We found that the high stage of bladder cancer has obviously higher level of TP53 mutation than the lower stage, and these patients of MIBC have higher expression of TP53 mutation compared with NMIBC. No significant publication bias has been observed in this meta-analysis. The expression of TP53 mutation might be a diagnose-related biomarker for lots of patients with bladder cancer. CONCLUSIONS: The results of this meta-analysis provided further evidences that the expression of TP53 mutation was associated with the diagnosis efficiency of advanced bladder cancer. Higher expression of TP53 mutation was observed in the high stage of bladder cancer or the MIBC, and lower expression of TP53 mutation in the Ta stage of bladder cancer or the NMIBC. The expression level of TP53 mutation was probably a critical diagnosed biomarker in advanced bladder cancer. CI - (c) 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. FAU - Liao, Yihao AU - Liao Y AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Tang, Huiqin AU - Tang H AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wang, Miaomiao AU - Wang M AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wang, Keke AU - Wang K AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Wang, Youzhi AU - Wang Y AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Jiang, Ning AU - Jiang N AUID- ORCID: 0000-0002-9851-0863 AD - Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. LA - eng GR - 16JCZDJC34400/Science Foundation of Tianjin/ GR - 81572538/National Natural Science Foundation of China/ GR - 81872079/National Natural Science Foundation of China/ PT - Journal Article PT - Meta-Analysis DEP - 20210329 PL - United States TA - J Clin Lab Anal JT - Journal of clinical laboratory analysis JID - 8801384 RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Humans MH - Mutation/*genetics MH - Neoplasm Staging MH - Publication Bias MH - Tumor Suppressor Protein p53/*genetics MH - Urinary Bladder Neoplasms/*genetics/*pathology PMC - PMC8128305 OTO - NOTNLM OT - TP53 OT - bladder cancer OT - meta-analysis OT - mutation COIS- The authors have no conflicts of interest to declare. EDAT- 2021/03/30 06:00 MHDA- 2021/11/24 06:00 PMCR- 2021/03/29 CRDT- 2021/03/29 13:47 PHST- 2021/03/05 00:00 [revised] PHST- 2021/01/15 00:00 [received] PHST- 2021/03/09 00:00 [accepted] PHST- 2021/03/30 06:00 [pubmed] PHST- 2021/11/24 06:00 [medline] PHST- 2021/03/29 13:47 [entrez] PHST- 2021/03/29 00:00 [pmc-release] AID - JCLA23765 [pii] AID - 10.1002/jcla.23765 [doi] PST - ppublish SO - J Clin Lab Anal. 2021 May;35(5):e23765. doi: 10.1002/jcla.23765. Epub 2021 Mar 29. PMID- 33779053 OWN - NLM STAT- MEDLINE DCOM- 20210720 LR - 20221207 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 10 IP - 9 DP - 2021 May TI - Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study. PG - 3004-3012 LID - 10.1002/cam4.3835 [doi] AB - INTRODUCTION: In surgical series of muscle-invasive bladder cancer (MIBC), women have higher recurrence rates, disease progression, and mortality following radical cystectomy than men. Similar reports of oncologic differences between men and women following trimodality therapy (TMT) are rare. Our hypothesis was that there would be no difference in overall survival (OS) between sexes receiving TMT. METHODS: We queried the National Cancer Database (NCDB) for patients diagnosed with clinical stage T2-T4aN0 M0 MIBC between 2004-2016. We considered patients to have received TMT if they received 55 Gy in 20 fractions or 59.4-70.2 Gy of radiotherapy with concurrent chemotherapy following a transurethral resection of bladder tumor (TURBT). We used multivariable Cox proportional hazard models to determine whether sex was associated with risk of mortality. In addition to OS, we calculated relative survival (RS) to adjust for the fact that females generally survive longer than males. RESULTS: Of the patients, 1960 underwent TMT and had survival data. Less than one quarter were female. In the first year following treatment, women had worse OS and RS than men (p = 0.093 and p = 0.030, respectively). However, overall and relative survival differences between sexes were not statistically significantly different in Years 2 and later. Unlike with OS, the RS between sexes remained significant at 9 years; in multivariable analysis based on RS, women were 43% more likely to die than men (p < 0.001). CONCLUSIONS: Women had a higher initial risk of death than men in the first year following TMT. However, long-term survival between sexes was similar. TMT is an important treatment option in both men and women seeking bladder preservation. CI - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Ballas, Leslie K AU - Ballas LK AUID- ORCID: 0000-0001-5510-1691 AD - Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Navarro, Stephanie AU - Navarro S AD - Department of Preventative Medicine, Keck School of Medicine, University of Southern CA, Los Angeles, CA, USA. FAU - Luo, Chunqiao AU - Luo C AD - Department of Preventative Medicine, Keck School of Medicine, University of Southern CA, Los Angeles, CA, USA. FAU - Fossum, Croix C AU - Fossum CC AD - Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Farias, Albert AU - Farias A AUID- ORCID: 0000-0002-6463-7831 AD - Department of Preventative Medicine, Keck School of Medicine, University of Southern CA, Los Angeles, CA, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Groshen, Susan AU - Groshen S AD - Department of Preventative Medicine, Keck School of Medicine, University of Southern CA, Los Angeles, CA, USA. LA - eng GR - P30 CA014089/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210328 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Aged MH - Black People/statistics & numerical data MH - Carcinoma, Transitional Cell/*mortality/pathology/*therapy MH - Combined Modality Therapy/mortality/statistics & numerical data MH - Cystectomy/mortality MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Neoplasm Recurrence, Local MH - *Organ Sparing Treatments MH - Proportional Hazards Models MH - Retrospective Studies MH - Sex Factors MH - Socioeconomic Factors MH - Survival Analysis MH - Time Factors MH - Treatment Outcome MH - *Urinary Bladder MH - Urinary Bladder Neoplasms/*mortality/pathology/*therapy MH - White People/statistics & numerical data PMC - PMC8085939 OTO - NOTNLM OT - bladder preservation OT - muscle-invasive bladder cancer OT - sex-based disparities OT - trimodality therapy COIS- All authors have completed a conflict of interest disclosure and have no conflicts of interest that pertain to this study. EDAT- 2021/03/30 06:00 MHDA- 2021/07/21 06:00 PMCR- 2021/03/28 CRDT- 2021/03/29 07:00 PHST- 2021/01/15 00:00 [revised] PHST- 2020/10/17 00:00 [received] PHST- 2021/02/25 00:00 [accepted] PHST- 2021/03/30 06:00 [pubmed] PHST- 2021/07/21 06:00 [medline] PHST- 2021/03/29 07:00 [entrez] PHST- 2021/03/28 00:00 [pmc-release] AID - CAM43835 [pii] AID - 10.1002/cam4.3835 [doi] PST - ppublish SO - Cancer Med. 2021 May;10(9):3004-3012. doi: 10.1002/cam4.3835. Epub 2021 Mar 28. PMID- 33776408 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 1110-5704 (Print) IS - 2090-2379 (Electronic) IS - 1110-5704 (Linking) VI - 27 IP - 1 DP - 2021 TI - Early radical cystectomy with negative margins in a 57-year-old female with myxoid/round cell liposarcoma of the bladder suggests prolonged overall survival. PG - 52 LID - 10.1186/s12301-021-00152-y [doi] LID - 52 AB - BACKGROUND: Bladder cancer is the 17th most common cancer in the female population. Most bladder cancers are of urothelial origin. Sarcomas of the bladder are very uncommon. CASE PRESENTATION: This case concerns a 57-year-old female from a rural town in the Eastern Cape who was diagnosed with myxoid/round cell liposarcoma of the bladder. After the initial transurethral resection of the bladder tumour, she underwent an anterior exenteration with Bricker's diversion (ileal conduit) and negative margins were achieved. CONCLUSIONS: Sarcomas of the bladder are known to have a poor prognosis. Our patient is alive with good stoma function more than 24 months since her radical surgery. We are of the opinion that her favourable overall survival is attributable to early radical surgical intervention with negative margins. CI - (c) The Author(s) 2021. FAU - Delport, Johannes Eduard AU - Delport JE AUID- ORCID: 0000-0002-1635-0879 AD - Medical Officer, Department of Urology, Port Elizabeth Provincial Hospital, Buckingham Road, Mount Croix, Port Elizabeth, Eastern Cape South Africa. GRID: grid.440248.e FAU - Makamba, Khanyisa AU - Makamba K AD - Head of Clinical Unit, Department of Urology, Port Elizabeth Provincial Hospital, Buckingham Road, Mount Croix, Port Elizabeth, Eastern Cape South Africa. GRID: grid.440248.e LA - eng PT - Journal Article DEP - 20210323 PL - England TA - Afr J Urol JT - African journal of urology : the official journal of the Pan African Urological Surgeons' Association (PAUSA) JID - 9612042 PMC - PMC7985921 OTO - NOTNLM OT - Bladder cancer OT - Liposarcoma OT - Oncology COIS- Competing interestsNone. EDAT- 2021/03/30 06:00 MHDA- 2021/03/30 06:01 PMCR- 2021/03/23 CRDT- 2021/03/29 06:18 PHST- 2020/06/05 00:00 [received] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/03/29 06:18 [entrez] PHST- 2021/03/30 06:00 [pubmed] PHST- 2021/03/30 06:01 [medline] PHST- 2021/03/23 00:00 [pmc-release] AID - 152 [pii] AID - 10.1186/s12301-021-00152-y [doi] PST - ppublish SO - Afr J Urol. 2021;27(1):52. doi: 10.1186/s12301-021-00152-y. Epub 2021 Mar 23. PMID- 33774705 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 9 DP - 2021 Sep TI - En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. PG - 3353-3358 LID - 10.1007/s00345-021-03675-9 [doi] AB - PURPOSE: To investigate the technical success rate and 30-day complications of en-bloc resection of bladder tumour (ERBT) upon routine implementation regardless of tumour size. METHODS: This is a prospective, multi-centre, study on routine implementation of ERBT for patients with bladder tumours requiring transurethral surgery. Surgeons were allowed to cross over to conventional transurethral resection of bladder tumour (TURBT) when necessary. We performed an analysis for patients who had ERBT/TURBT as the definitive treatment. Study outcomes included the technical success rate of ERBT and 30-day complication rate. Multivariate logistic regression analysis was performed to investigate for predictors of a successful ERBT and factors associated with 30-day complications. RESULTS: A total of 135 patients were included in this study. The majority of the patients (80.0%) had bladder tumours of 3 cm respectively. Upon multivariate analysis, tumour size was the only significant factor predicting the success of ERBT (OR 0.920, 95% CI 0.882-0.960, p < 0.001). Moreover, ERBT was not a significant factor associated with 30-day complications. CONCLUSION: EBRT achieved a good technical success rate for the majority of patients with bladder tumours 1/year (P = 0.046). Lower post-HIVEC inflammatory indices [C-reactive protein (P = 0.021), erythrocyte sedimentation rate (P = 0.027)] and lower pre- (P = 0.014) and post-treatment (P = 0.004) neutrophil-to-lymphocyte ratio (NLR) values were significantly associated with the response to the HIVEC regimen (no bladder cancer recurrence or progression). In the multivariate analysis, patients with a recurrence rate of >1/year were eight-times more likely to experience failure of HIVEC (P = 0.007). Higher pre- (P = 0.023) and post-treatment NLR values (P = 0.046) were associated with a worse response to the HIVEC regimen. Conclusions: The recurrence rate and systemic inflammatory response markers could be useful tools to predict the likelihood of obtaining a response with the HIVEC regimen. These markers might help to guide patients about the behaviour of the tumour after BCG failure, predicting failure or success of a conservative treatment. Abbreviations: CHT: chemo-hyperthermia; CIS: carcinoma in situ; CRP: C-reactive protein; EAU: European Association of Urology; ESR: erythrocyte sedimentation rate; HG: high grade; HIVEC: Hyperthermic IntraVEsical Chemotherapy; ICD: immunogenic cell death; IL: interleukin; MMC: Mitomycin-C; NK: natural killer; NLR: neutrophil-to-lymphocyte ratio; NMIBC: non-muscle-invasive bladder cancer; PLR: platelet-to-lymphocyte ratio; RC: radical cystectomy; SIR: systemic inflammatory response; TURB: transurethral resection of bladder. CI - (c) 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Chiancone, Francesco AU - Chiancone F AUID- ORCID: 0000-0001-8648-3557 AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. FAU - Fabiano, Marco AU - Fabiano M AUID- ORCID: 0000-0003-1280-8798 AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. FAU - Carrino, Maurizio AU - Carrino M AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. FAU - Fedelini, Maurizio AU - Fedelini M AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. FAU - Meccariello, Clemente AU - Meccariello C AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. FAU - Fedelini, Paolo AU - Fedelini P AD - Department of Urology, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Antonio Cardarelli, Naples, Italy. LA - eng PT - Journal Article DEP - 20210113 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954479 OTO - NOTNLM OT - BCG failure OT - bladder cancer OT - chemo-hyperthermia OT - neutrophil-to-lymphocyte ratio OT - systemic inflammatory response COIS- No potential conflict of interest was reported by the authors. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1874627 [pii] AID - 10.1080/2090598X.2021.1874627 [doi] PST - epublish SO - Arab J Urol. 2021 Jan 13;19(1):86-91. doi: 10.1080/2090598X.2021.1874627. PMID- 33763252 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2021 Jan 13 TI - Assessment of the oncological outcomes of three different bacillus Calmette-Guerin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. PG - 78-85 LID - 10.1080/2090598X.2021.1874628 [doi] AB - OBJECTIVE: : To determine whether there are significant differences in oncological outcomes between three different bacillus Calmette-Guerin (BCG) strains used for adjuvant intravesical immunotherapy in patients with high-grade T1 (T1HG) non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: : Data of 590 patients with a diagnosis of primary T1HG NMIBC were retrospectively reviewed. The study included 138 (23.4%) patients who were treated with the Moreau, 272 (46.1%) with the TICE, and 180 (30.5%) with the RIVM strains. All patients included in the analysis received at least five instillations of an induction course and at least two installations of a maintenance course. Due to existing differences in baseline patient characteristics, the association between oncological outcomes and strain groups was investigated by complementary analysis with the implementation of inverse probability weighting (IPW). RESULTS: : The 5-year recurrence-free survival (RFS) rate was 70.5%, 66.7% and 55.2% for the Moreau, TICE and RIVM groups, respectively (P = 0.016). The 5-year progression-free survival (PFS) rates were 84.4%, 85% and 77.8% in the Moreau, TICE and RIVM groups, respectively (P = 0.215). The IPW-adjusted Cox proportional hazard regression analysis did not show any differences in RFS between the Moreau and TICE groups (P = 0.69), whereas the RIVM strain was significantly associated with worse RFS compared to the Moreau (hazard ratio [HR] 1.69 for RIVM; P = 0.034) and TICE (HR 1.87 for RIVM; P = 0.002) strains. The IPW-adjusted analysis did not show any significant differences between study groups in terms of PFS. CONCLUSIONS: : The results of the present study suggest that the Moreau and TICE strains might be superior to the RIVM strain in terms of RFS in patients with T1HG NMIBC.Abbreviations: CIS: carcinoma in situ; IPW: inverse probability weighting; IQR: interquartile range; HR: hazard ratio; HG: high grade; LVI: lymphovascular invasion; MP: muscularis priopria; NMIBC: non-muscle-invasive bladder cancer; PFS: progression-free survival; RCT: randomised controlled trial; RFS: recurrence-free survival; T1HG, high-grade T1; (re-)TURB: (re-staging) transurethral resection of bladder; VH: variant histology. CI - (c) 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Nowak, Lukasz AU - Nowak L AUID- ORCID: 0000-0003-4273-8196 AD - Department of Urology and Oncologic Urology, Wroclaw Medical Univeristy, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AUID- ORCID: 0000-0003-1727-2283 AD - Department of Urology and Oncologic Urology, Wroclaw Medical Univeristy, Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Klinik Fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Urology and Oncologic Urology, Wroclaw Medical Univeristy, Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Tafuri, Alessandro AU - Tafuri A AUID- ORCID: 0000-0003-1404-2925 AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Orlando, Rossella AU - Orlando R AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Di Trapani, Ettore AU - Di Trapani E AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology , Hospital Universitario La Paz, Madrid, Spain. FAU - Simone, Giuseppe AU - Simone G AD - Oncologic Urology, 'Regina Elena' National Cancer Institute, Department of Urology, Rome, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Marconi, Maria Cristina AU - Marconi MC AD - Urology Unit, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Oncologic Urology, 'Regina Elena' National Cancer Institute, Department of Urology, Rome, Italy. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncologic Urology, Lowersilesian Specialistic Hospital, Wroclaw, Poland. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux De Paris, Paris Descartes University, Paris, France. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncologic Urology, Wroclaw Medical Univeristy, Wroclaw, Poland. CN - European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group LA - eng PT - Journal Article DEP - 20210113 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954505 OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - bacillus Calmette-Guerin OT - progression OT - recurrence OT - strain COIS- The authors declare no conflict of interest. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1874628 [pii] AID - 10.1080/2090598X.2021.1874628 [doi] PST - epublish SO - Arab J Urol. 2021 Jan 13;19(1):78-85. doi: 10.1080/2090598X.2021.1874628. PMID- 33763251 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Aug 31 TI - Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients. PG - 71-77 LID - 10.1080/2090598X.2020.1816150 [doi] AB - OBJECTIVE: To evaluate the effectiveness of electro-mediated drug administration of mitomycin C (EMDA/MMC) after transurethral resection of the bladder tumour (TURBT) in preventing non-muscle-invasive bladder cancer (NMIBC) recurrence and progression and to explore clinical and demographic factors associated with treatment response. PATIENTS AND METHODS: Between April 2016 and August 2019, 112 patients diagnosed with intermediate- or high-risk NMIBC underwent a TURBT followed by an EMDA/MMC treatment. The percentage of treatment responders and progression-free survivors at 3 and 6 months were evaluated. RESULTS: Follow-up data were available for 101 patients (90%) at 3 months and 92 (82%) at 6 months. Response rates to EMDA/MMC treatment were 85% at 3 months and 75% at 6 months, and progression-free rates were 94% and 90%, respectively. No statistically significant differences were seen between intermediate- and high-risk patients. A higher risk of tumour recurrence and progression was associated with previous Bacillus Calmette-Guerin (BCG) failure. According to the Clavien-Dindo classification, only low-grade complications were observed. CONCLUSIONS: EMDA/MMC after TURBT was associated with high response and progression-free rates at 3 and 6 months, with only low-grade adverse events. These results confirm the efficacy and safety of EMDA/MMC as a therapeutic option for both intermediate- and high-risk patients. However, patients with BCG failure responded poorly to EMDA/MMC.Abbreviations: ACCI: age-adjusted Charlson Comorbidity Index; CHT: chemohyperthermia; CIS: carcinoma in situ; EMDA: electro-mediated drug administration; EORTC: European Organisation for Research and Treatment of Cancer; IQR: interquartile range; (N)MIBC: (non-)muscle-invasive bladder cancer; MMC: mitomycin C; OR, odds ratio; TURBT: transurethral resection of the bladder tumour. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Carando, Roberto AU - Carando R AUID- ORCID: 0000-0003-3773-3171 AD - Klinik fur Urologie, Luzerner Kantonsspital, Luzern, Switzerland. AD - Clinica Luganese Moncucco, Lugano, Switzerland. AD - Clinica S. Anna, Sorengo, Switzerland. AD - Clinica S. Chiara, Locarno, Switzerland. FAU - Soldini, Emiliano AU - Soldini E AUID- ORCID: 0000-0002-9577-5567 AD - Department of Business Economics, Health and Social Care, Research Methodology Competence Centre, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland. FAU - Cotrufo, Simone AU - Cotrufo S AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. FAU - Zazzara, Michele AU - Zazzara M AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. FAU - Ludovico, Giuseppe M AU - Ludovico GM AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. LA - eng PT - Journal Article DEP - 20200831 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954506 OTO - NOTNLM OT - Bladder cancer OT - electro-mediated drug administration OT - intermediate and high risk OT - mitomycin C OT - non-muscle invasive OT - transurethral resection COIS- The authors declare that they have no competing interests. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1816150 [pii] AID - 10.1080/2090598X.2020.1816150 [doi] PST - epublish SO - Arab J Urol. 2020 Aug 31;19(1):71-77. doi: 10.1080/2090598X.2020.1816150. PMID- 33763250 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Jul 16 TI - The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guerin immunotherapy: Current status. PG - 67-70 LID - 10.1080/2090598X.2020.1791562 [doi] AB - OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette-Guerin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Nowak, Lukasz AU - Nowak L AUID- ORCID: 0000-0003-4273-8196 AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AUID- ORCID: 0000-0003-1727-2283 AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Poterek, Adrian AU - Poterek A AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Sliwa, Anna AU - Sliwa A AUID- ORCID: 0000-0002-8388-4379 AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20200716 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954482 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - NMIBC OT - PD-L1 OT - immunotherapy COIS- No potential conflict of interest was reported by the authors. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1791562 [pii] AID - 10.1080/2090598X.2020.1791562 [doi] PST - epublish SO - Arab J Urol. 2020 Jul 16;19(1):67-70. doi: 10.1080/2090598X.2020.1791562. PMID- 33763248 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2021 Feb 16 TI - Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe? PG - 46-58 LID - 10.1080/2090598X.2021.1883810 [doi] AB - INTRODUCTION: The European Association of Urology guidelines recommend offering kidney-sparing surgery (KSS) as a primary treatment option to patients with low-risk tumours. Cystoscopy, urinary cytology, and computed tomography urography (CTU) do not always allow correct disease staging and grading, and sometimes there is even a lack of certainty regarding the diagnosis of UTUC. Diagnostic ureteroscopy (d-URS) may therefore be of crucial importance within the diagnostic framework and fundamental in establishing the appropriate therapeutic approach. EVIDENCE ACQUISITION AND SYNTHESIS: A systematic review of the literature was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Risk of bias was assessed using Risk of Bias in Non-randomized Studies of interventions (ROBINS-I). Overall, from 3791 identified records, 186 full-text articles were assessed for eligibility. Finally, after a quantitative review of the selected literature, with the full agreement of all authors, 62 studies were considered relevant for this review. RESULTS: CTU has a sensitivity and specificity for UTUC of 92% and 95% respectively, but is not able to detect small or flat lesions with adequate accuracy. The sensitivity of voided urinary cytology for UTUC is around 67-76% and ranges from 43% to 78% for selective ureteric urine collection. As no technique offers a diagnosis of certainty, d-URS can allow an increase in diagnostic accuracy. In the present review the pros and cons of d-URS were analysed. This technique may provide additional information in the selection of patients suitable for neoadjuvant chemotherapy or KSS, distinguishing between normal tissue and low- and high-grade UTUC thanks to the emerging technologies. CONCLUSIONS: Information obtainable from d-URS and ureteroscopic-guided biopsy can prove extremely valuable when the diagnosis of UTUC is doubtful or KSS is being considered. Notwithstanding concerns remain regarding the potential risk of bladder recurrence, cancer dissemination, and/or delay in radical treatment.Abbreviations: CLE: confocal laser endomicroscopy; CSS: cancer-specific survival; CTU: CT urography; d-URS: diagnostic ureteroscopy; EAU: European Association of Urology; HR: hazard ratio; IMAGE1S: Storz professional imaging enhancement system; IVR: intravesical recurrence; KSS: kidney-sparing surgery; MFS: Metastasis-free survival; NAC: neoadjuvant chemotherapy; NBI: narrow-band imaging; OCT: optical coherence tomography; RFS: Recurrence-free survival; RNU: radical nephroureterectomy; ROBINS-I: Risk of Bias in Non-randomized Studies of interventions; URS(-GB): Ureteroscopy(-guided biopsy); UTUC: upper tract urothelial carcinoma; UUT: upper urinary tract. CI - (c) 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Territo, Angelo AU - Territo A AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Gallioli, Andrea AU - Gallioli A AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Meneghetti, Iacopo AU - Meneghetti I AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Fontana, Matteo AU - Fontana M AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Huguet, Jordi AU - Huguet J AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Urology Department, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20210216 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954478 OTO - NOTNLM OT - Diagnostic biopsy OT - diagnosis OT - radical nephroureterectomy OT - upper tract urothelial carcinoma OT - ureteroscopy COIS- No potential conflict of interest was reported by the authors. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1883810 [pii] AID - 10.1080/2090598X.2021.1883810 [doi] PST - epublish SO - Arab J Urol. 2021 Feb 16;19(1):46-58. doi: 10.1080/2090598X.2021.1883810. PMID- 33763247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Jul 27 TI - Lymph node dissection for upper tract urothelial carcinoma: A systematic review. PG - 37-45 LID - 10.1080/2090598X.2020.1791563 [doi] AB - OBJECTIVE: To perform a systematic review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, investigating the role of lymph node dissection (LND) during nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC); focussing on survival and complication outcomes. METHODS: A comprehensive systematic search was completed using a combination of Medical Subject Headings terms and keywords related to UTUC and LND on multiple databases. Meta-analyses were performed when outcomes were reported under the same definition in two or more studies. Where meta-analysis was not possible, outcomes were reviewed in a narrative manner. RESULTS: A total of 21 studies were included in the qualitative analysis and 11 cohort studies in the quantitative analysis. Our review did not detect significant improvement in recurrence-free survival (RFS) (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.41-1.92), cancer-specific survival (CSS) (HR 0.89, 95% CI 0.54-1.46) and overall survival (OS) (HR 1.10, 95% CI 0.93-1.30). However, when focussing on studies only including patients with pT2/pT3 UTUC, not performing LND significantly worsened RFS (HR 2.83, 95% CI 1.72-4.66). Reports of removing more than eight lymph nodes may also provide prognostic benefits in pN0 patients. The performance of LND was not associated with a higher rate of postoperative complications (risk ratio 1.06, 95% CI 1.00-1.13). CONCLUSION: Overall, LND did not provide additional benefit in RFS, CSS and OS. However, there was a potential benefit in RFS in patients with muscle-invasive and advanced UTUC. LND was also not associated with increased risks of postoperative complications.Abbreviations: CIS: carcinoma in situ; CSS: cancer-specific survival; HR: hazard ratio; LND: lymph node dissection; NU: nephroureterectomy; OS: overall survival; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RFS: recurrence-free survival; RoB, risk of bias; RR: risk ratio; (UT)UC: (upper tract) urothelial carcinoma. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Chan, Vinson Wai-Shun AU - Chan VW AUID- ORCID: 0000-0002-6108-9315 AD - School of Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, UK. FAU - Wong, Chris Ho Ming AU - Wong CHM AD - Department of Surgery, Prince of Wales Hospital, Hong Kong, China. FAU - Yuan, Yuhong AU - Yuan Y AUID- ORCID: 0000-0003-4374-3042 AD - Department of Medicine, McMaster University, Hamilton, ON, Canada. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AUID- ORCID: 0000-0002-9361-2342 AD - S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, China. LA - eng PT - Journal Article PT - Review DEP - 20200727 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954472 OTO - NOTNLM OT - UTUC OT - Urothelial carcinoma OT - lymph node dissection OT - nephroureterectomy COIS- The authors report no conflict of interest. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1791563 [pii] AID - 10.1080/2090598X.2020.1791563 [doi] PST - epublish SO - Arab J Urol. 2020 Jul 27;19(1):37-45. doi: 10.1080/2090598X.2020.1791563. PMID- 33763246 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Sep 4 TI - Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. PG - 31-36 LID - 10.1080/2090598X.2020.1817720 [doi] AB - OBJECTIVES: To compare oncological outcomes of open (ORNU) and laparoscopic radical nephroureterectomy (LRNU) after controlling for preoperative patient-derived factors. PATIENTS AND METHODS: We evaluated a multi-institutional collaborative database composed of 3984 patients diagnosed with upper tract urothelial carcinoma (UTUC) treated with RNU between 2006 and 2018. To adjust for potential selection bias, propensity score matching adjusted for age, gender and American society Anesthesiology (ASA) score was performed with one ORNU patient matched to one LRNU patient. Uni- and multivariable Cox regression evaluating the risk of overall recurrence, cancer-specific mortality (CSM) and overall mortality (OM) in the overall population and after propensity matching were performed. RESULTS: In total, 3984 patients underwent RNU, of these 3227 (81%) patients were treated with ORNU and 757 (19%) patients with LRNU. Within a median follow-up of 62 months, 1276 recurrences, 844 CSMs and 1128 OMs were recorded. On multivariable analyses, the LRNU approach was associated with an increased risk of overall recurrence (hazard ratio [HR] 1.26, 95% confidence interval [CI] 1.03-1.54; P = 0.02), but on the other hand LRNU was associated with a protective effect on CSM (HR 0.74, 95% CI 0.56-0.98; P = 0.04). After propensity matching analyses adjusted for age, gender and ASA score, 757 patients treated with LRNU and 757 patients treated with ORNU were available for the analyses. On multivariable Cox regression, LRNU vs ORNU was not associated with any difference in overall recurrence (P = 0.08), CSM (P = 0.1) or OM (P = 0.9). CONCLUSION: Our present data suggest that even if the type of approach to RNU was associated with different survival outcomes considering the overall population, this difference vanished when adjusted for potential confounders in propensity matching analyses. Therefore, we found that LRNU is not inferior to the ORNU approach for the treatment of UTUC. ABBREVIATIONS: ASA: American Society of Anesthesiology; CIS: carcinoma in situ; CSM: cancer-specific mortality; HR: hazard ratio; IQR: interquartile range; LN: lymph node; LNI: lymph node invasion; LVI: lymphovascular invasion; OM: overall mortality; pT: pathological tumour stage; RCT: randomised controlled trial; (L)(O)RNU: (laparoscopic) (open) radical nephroureterectomy; UTUC: upper tract urothelial carcinoma. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, ASST Spedali Civili, Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, the University of Jordan, Amman, Jordan. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Urology, Assistance Publique-Hopitaux De Paris (AP-HP), Sorbonne University, Hopital Pitie Salpetriere, Paris, France. FAU - De la Taille, Alexandre AU - De la Taille A AD - Department of Urology, Assistance Publique-Hopitaux De Paris (AP-HP) CHU Mondor, Faculte De Medecine, Henri Mondor Hospital, Creteil, France. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili, Brescia, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Mathieu, Romain AU - Mathieu R AD - Urology, Rennes University Hospital (France), Rennes, France. FAU - Bensalah, Karim AU - Bensalah K AD - Urology, Rennes University Hospital (France), Rennes, France. FAU - Wirth, Manfred Peter AU - Wirth MP AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Urology, 'Regina Elena' National Cancer Institute, Rome, Italy. FAU - Di Bona, Carlo AU - Di Bona C AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Di Trapani, Ettore AU - Di Trapani E AD - Department of Urology, European Institute of Oncology (IEO), Milan, Italy. FAU - Alvarez Maestro, Mario AU - Alvarez Maestro M AD - Department of Urology, La Paz University Hospital, Madrid, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Motol Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, CHU Bichat, Paris, France. FAU - Baumeister, Philipp AU - Baumeister P AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. LA - eng PT - Journal Article DEP - 20200904 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954493 OTO - NOTNLM OT - RNU OT - UTUC OT - Upper tract urothelial carcinoma OT - laparoscopic OT - open OT - radical nephroureterectomy COIS- The authors declare that they have no conflict of interest. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1817720 [pii] AID - 10.1080/2090598X.2020.1817720 [doi] PST - epublish SO - Arab J Urol. 2020 Sep 4;19(1):31-36. doi: 10.1080/2090598X.2020.1817720. PMID- 33763245 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210422 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Dec 10 TI - Prognostic impact of perioperative blood transfusions on oncological outcomes of patients with bladder cancer undergoing radical cystectomy: A systematic review. PG - 24-30 LID - 10.1080/2090598X.2020.1859055 [doi] AB - Objective: To conduct a systematic review of whether blood transfusions may be associated with worse outcomes for patients with bladder cancer treated with radical cystectomy (RC), as there has been a recent increase in studies addressing this clinically relevant topic. Methods: PubMed, Ovid Medical Literature Analysis and Retrieval System Online (MEDLINE), Google Scholar, and the ClinicalTrials.gov databases were searched with pre-specified search terms for studies published between January 2010 and May 2020. The systemic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 17 studies with 19 627 patients were included after 183 records were screened for eligibility. In all, 10 studies proposed perioperative blood transfusion to be associated with impaired prognosis regarding overall survival, nine studies regarding cancer-specific and four studies regarding recurrence-free survival. The timing of blood transfusion might affect patient outcomes. Notably, several studies did not find a significant correlation between blood transfusions and prognosis. As all studies to date are of retrospective design, the grade of evidence is still limited. Conclusions: Despite the lack of prospective trials, perioperative blood transfusion may lead to worse oncological outcomes. These results, as well as known non-oncological side-effects and associated costs, are important arguments to carefully consider the indication for blood transfusion. Abbreviations BCa: bladder cancer; CSS: cancer-specific survival; HR: hazard ratio; (N)MIBC: (non-) muscle-invasive BCa; OS: overall survival; PBT, perioperative blood transfusion; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RC: radical cystectomy; RFS: recurrence-free survival. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Volz, Yannic AU - Volz Y AUID- ORCID: 0000-0002-5468-9398 AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Eismann, Lennert AU - Eismann L AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Pfitzinger, Paulo L AU - Pfitzinger PL AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Jokisch, Jan-Friedrich AU - Jokisch JF AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Buchner, Alexander AU - Buchner A AUID- ORCID: 0000-0001-7895-7070 AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Schlenker, Boris AU - Schlenker B AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Stief, Christian G AU - Stief CG AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. FAU - Schulz, Gerald B AU - Schulz GB AD - Department of Urology, Ludwig-Maximilians University, Munich, Germany. LA - eng PT - Journal Article PT - Review DEP - 20201210 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954477 OTO - NOTNLM OT - Bladder cancer OT - blood transfusion OT - cystectomy OT - oncology OT - prognostic marker OT - urothelial carcinoma COIS- The authors report no conflict of interests. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1859055 [pii] AID - 10.1080/2090598X.2020.1859055 [doi] PST - epublish SO - Arab J Urol. 2020 Dec 10;19(1):24-30. doi: 10.1080/2090598X.2020.1859055. PMID- 33763243 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 19 IP - 1 DP - 2020 Aug 26 TI - Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer. PG - 2-8 LID - 10.1080/2090598X.2020.1814974 [doi] AB - OBJECTIVE: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged >/=75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). PATIENTS AND METHODS: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Multivariable regression models were built for the prediction of major postoperative surgical complications, disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM). RESULTS: The median (interquartile range [IQR]) age at surgery was 79 (75-83) years. Major postoperative surgical complications were registered in 41.9% of the patients. The 5-year overall survival, cancer-specific survival and recurrence-free survival rates were 42.4% (95% confidence interval [CI] 34.7-49.9%), 70.3% (95% CI 62.3-76.9%), and 59.8% (95% CI 52.4-66.5), respectively. At multivariable analysis, higher levels of fibrinogen and a modified Glasgow Prognostic Score (mGPS) of 1 and 2 at baseline were independently associated with higher risk of major postoperative complications and of CSM. The inclusion of mGPS and fibrinogen to a standard multivariable model for recurrence and for CSM increased discrimination from 69.4% to 73.0% and from 71.3% to 73.9%, respectively. Preoperative neutrophil-to-lymphocyte ratio of >3 was independently associated with OM (hazard ratio 1.38, 95% CI 1.01-1.77; P = 0.01). CONCLUSIONS: In a cohort of elderly patients with UBC treated with RC, fibrinogen and mGPS appeared to be the most relevant prognostic measurements and increased the accuracy of clinicopathological preoperative models to predict major postoperative complications, disease recurrence and mortality. ABBREVIATIONS: ASA: American Society of Anesthesiologists; CCI: Charlson Comorbidity Index; CIS: carcinoma in situ; CRP: C-reactive protein; CSM: cancer-specific mortality; CSS: cancer-specific survival; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HDL: high-density lipoprotein; (S)HR: (subdistribution) hazard ratio; LND: lymphadenectomy; LVI: lymphovascular invasion; mGPS: modified Glasgow Prognostic Score; NLR: neutrophil-to-lymphocyte ratio; NOC: non-organ-confined; OM: overall mortality; OR: odds ratio; OS: overall survival; RC: radical cystectomy; RNU: radical nephroureterectomy; UBC: urothelial bladder cancer; UTUC: upper urinary tract urothelial carcinoma. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Muto, Gianluca AU - Muto G AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Tellini, Riccardo AU - Tellini R AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Bossa, Riccardo AU - Bossa R AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Bisegna, Claudio AU - Bisegna C AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Campi, Riccardo AU - Campi R AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Cocci, Andrea AU - Cocci A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Viola, Lorenzo AU - Viola L AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Grosso, Antonio AU - Grosso A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Scelzi, Sabino AU - Scelzi S AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Lapini, Alberto AU - Lapini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Carini, Marco AU - Carini M AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. LA - eng PT - Journal Article DEP - 20200826 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7954471 OTO - NOTNLM OT - Urothelial bladder cancer OT - biomarkers OT - mortality OT - radical cystectomy OT - recurrence OT - systemic inflammation COIS- The authors declare that they have no competing interests. EDAT- 2021/03/26 06:00 MHDA- 2021/03/26 06:01 PMCR- 2021/01/01 CRDT- 2021/03/25 06:29 PHST- 2021/03/25 06:29 [entrez] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/03/26 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 1814974 [pii] AID - 10.1080/2090598X.2020.1814974 [doi] PST - epublish SO - Arab J Urol. 2020 Aug 26;19(1):2-8. doi: 10.1080/2090598X.2020.1814974. PMID- 33762203 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20250623 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 2 DP - 2022 Mar TI - Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. PG - 447-456 LID - S2405-4569(21)00095-X [pii] LID - 10.1016/j.euf.2021.03.016 [doi] AB - CONTEXT: Patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) may pose a clinical dilemma without an agreed evidence-based decision tree for personalized treatment. OBJECTIVE: To perform a systematic review and network meta-analysis (NMA) to summarize available evidence on the oncologic outcomes of intravesical therapy in patients with intermediate-risk NMIBC. EVIDENCE ACQUISITION: The MEDLINE, EMBASE, and ClinicalTrials.gov databases were searched in October 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Studies were deemed eligible if they reported on oncologic outcomes in patients with intermediate-risk NMIBC treated with transurethral resection of bladder tumor with and without intravesical chemotherapy or bacillus Calmette-Guerin (BCG) immunotherapy. EVIDENCE SYNTHESIS: Twelve studies were included in a qualitative synthesis (systematic review); three were deemed eligible for a quantitative synthesis (NMA). An NMA of five different regimens was conducted for the association of treatment with the 5-yr recurrence risk. Chemotherapy with maintenance was associated with a lower likelihood of 5-yr recurrence than chemotherapy without maintenance (odds ratio [OR] 0.51, 95% credible interval [CI] 0.26-1.03). Immunotherapy, regardless of whether a full- or reduced-dose regimen, was not associated with a significantly lower likelihood of 5-yr recurrence when compared with chemotherapy without maintenance (OR 0.90, 95% CI 0.39-2.11 vs OR 0.93, 95% CI 0.40-2.19). Analysis of the treatment ranking revealed that chemotherapy with maintenance had the lowest 5-yr recurrence risk (P score 0.9666). CONCLUSIONS: Our analysis indicates that chemotherapy with a maintenance regimen confers a superior oncologic benefit in terms of 5-yr recurrence risk compared to chemotherapy without maintenance in patients with intermediate-risk NMIBC. Regardless of the dose regimen, immunotherapy with BCG does not appear to be superior to chemotherapy in patients with intermediate-risk NMIBC in term of disease recurrence. However, owing to the lack of comparative studies, there is an unmet need for well-designed, large-scale trials to validate our findings and generate robust evidence on disease recurrence and progression. PATIENT SUMMARY: A maintenance schedule of chemotherapy reduces the rate of long-term recurrence of bladder cancer that has not invaded the bladder muscle. Chemotherapy inserted directly into the bladder and immunotherapy without maintenance schedules seem to have limited benefit in preventing cancer recurrence. CI - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Al-Ani, Abdallah AU - Al-Ani A AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Ali, Mustafa Rami AU - Ali MR AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Katayama, Satoshi AU - Katayama S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Grossmann, Nico C AU - Grossmann NC AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: shahrokh.shariat@meduniwien.ac.at. CN - European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20210321 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Recurrence, Local/prevention & control MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - Bladder cancer OT - Intermediate risk OT - Intravesical therapy OT - Network meta-analysis OT - Non-muscle-invasive bladder cancer COIS- Declaration of Competing Interest The authors report no declarations of interest. EDAT- 2021/03/26 06:00 MHDA- 2022/06/09 06:00 CRDT- 2021/03/25 05:49 PHST- 2021/01/20 00:00 [received] PHST- 2021/02/11 00:00 [revised] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/03/26 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2021/03/25 05:49 [entrez] AID - S2405-4569(21)00095-X [pii] AID - 10.1016/j.euf.2021.03.016 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Mar;8(2):447-456. doi: 10.1016/j.euf.2021.03.016. Epub 2021 Mar 21. PMID- 33747959 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210323 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes. PG - 636870 LID - 10.3389/fonc.2021.636870 [doi] LID - 636870 AB - Bladder cancer (BLCA) represents the ninth most common malignant tumor in the world and is characterized by high recurrence risk. Tumor microenvironment (TME) plays an important role in regulating the progression of BLCA. Immunotherapy, including Bacillus Calmette-Guerin (BCG) and programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1), is closely associated with TME and is widely used for treating BLCA. But parts of BLCA patients have no response to these treatment ways, thus a better understanding of the complex TME of BLCA is still needed. We downloaded the gene expression profile and corresponding clinical information of 414 BLCA patients from the TCGA database. Via the ESTIMATE and CIBERSORT algorithm, we identified the two hub genes (CXCL12 and CD3E) and explored their correlations with immune infiltration. We found that BLCA patients with higher expression of CXCL12 and lower expression of CD3E had prolonged survival. Gene set enrichment analysis (GSEA) revealed that both CXCL12 and CD3E were enriched in immune-related pathways. We also discovered that stromal score and the level of CXCL12 were higher in luminal subtype, and immune score and the level of CD3E were higher in the basal subtype. Furtherly, we found that CXCL12 was associated with naive B cells, resting mast cell, M2 macrophages, follicular helper T cells, and dendritic cells. CD8(+) T cells, CD4(+) T cells, regulatory T cells (Tregs), and macrophages were correlated with CD3E. In conclusions, we found that CXCL12 and CD3E might serve as indicators of TME modulation in BLCA. Therapy targeting CXCL12 and CD3E had the potential as novel therapeutic strategy. CI - Copyright (c) 2021 Liu, Wu, Zhang, Xu, Liu, He, Liu and Kang. FAU - Liu, Yi AU - Liu Y AD - Department of Urology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - Wu, YuCai AU - Wu Y AD - Department of Urology, Peking University First Hospital, Beijing, China. FAU - Zhang, PeiPei AU - Zhang P AD - Department of Pediatrics, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - Xu, ChaoJie AU - Xu C AD - Department of Urology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - Liu, ZeSen AU - Liu Z AD - Department of General Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - He, ChaoJie AU - He C AD - Department of General Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - Liu, YiMing AU - Liu Y AD - Department of General Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. FAU - Kang, ZhengJun AU - Kang Z AD - Department of Urology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. LA - eng PT - Journal Article DEP - 20210304 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7971116 OTO - NOTNLM OT - CD3E OT - CXCL12 OT - bladder cancer OT - molecular subtype OT - prognosis OT - tumor microenvironment OT - tumor-infiltrating immune cells COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/03/23 06:00 MHDA- 2021/03/23 06:01 PMCR- 2021/01/01 CRDT- 2021/03/22 08:20 PHST- 2020/12/02 00:00 [received] PHST- 2021/01/18 00:00 [accepted] PHST- 2021/03/22 08:20 [entrez] PHST- 2021/03/23 06:00 [pubmed] PHST- 2021/03/23 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.636870 [doi] PST - epublish SO - Front Oncol. 2021 Mar 4;11:636870. doi: 10.3389/fonc.2021.636870. eCollection 2021. PMID- 33747133 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240807 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 13 DP - 2021 Jan-Dec TI - Diagnostic value of Xpert((R)) Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update. PG - 1756287221997183 LID - 10.1177/1756287221997183 [doi] LID - 1756287221997183 AB - AIMS: Xpert((R)) Bladder Cancer Monitor is a urinary marker based on the evaluation of five target mRNAs overexpressed in patients with bladder cancer (BC). The aim of our study is to update our results regarding the diagnostic accuracy of the Xpert((R)) Bladder Cancer Monitor test in the follow-up of patients with non-muscle invasive bladder cancer (NMIBC). METHODS: We conducted a prospective study on 1015 samples of 416 patients (mean age 72.2 +/- 10.3 years) under follow-up for NMIBC. Patients underwent voided urinary cytology, the Xpert((R)) Bladder Cancer Monitor test and cystoscopy and, if positive, a transurethral resection of the bladder. Xpert((R)) Bladder Cancer Monitor was reported as negative or positive: cut-off total Linear Discriminant Analysis (LDA) = 0.5. RESULTS: We identified 168 recurrent tumours: 126 (75%) were low-grade (LG) and 42 (25%) high-grade (HG). Overall sensitivity was 17.9% for cytology, 52.4% for Xpert((R)) Bladder Cancer Monitor and 54.2% for the two tests combined. The sensitivity of cytology increased from 6.3% in LG to 52.4% in HG tumours whereas Xpert((R)) Bladder Cancer Monitor showed a sensitivity ranging from 42.9% in LG to 80.9% in HG tumours. Combined cytology and Xpert((R)) Bladder Cancer Monitor yielded an overall sensitivity of 45.2% for LG and 80.9% for HG tumours. Overall specificity was 98.5% for cytology and 78.4% for Xpert((R)) Bladder Cancer Monitor and 78.2% for the two tests combined. The area under the curve (AUC) for Xpert((R)) Bladder Cancer Monitor was 0.71; stratifying the patients according to the European Association of Urology risk groups, the AUC was 0.69, 0.67 and 0.85 for low, intermediate and high risk, respectively (p = 0.0003). CONCLUSION: Our data confirm a significantly higher sensitivity of Xpert((R)) Bladder Cancer Monitor than for cytology in a larger patient cohort. The test performed very well in terms of specificity but could not reach the high value of cytology. Along with voided urinary cytology the test could allow to reduce cystoscopies in follow-up patients, reducing discomfort to the patients and costs. CI - (c) The Author(s), 2021. FAU - D'Elia, Carolina AU - D'Elia C AUID- ORCID: 0000-0002-8227-9978 AD - Department of Urology, Hospital of Bolzano, Bolzano, Italy. FAU - Folchini, Decio M AU - Folchini DM AD - Department of Urology, Hospital of Bolzano, Bolzano, Italy. FAU - Mian, Christine AU - Mian C AD - Department of Pathology, Hospital of Bolzano, Bolzano, Italy. FAU - Hanspeter, Esther AU - Hanspeter E AD - Department of Pathology, Hospital of Bolzano, Bolzano, Italy. FAU - Schwienbacher, Christine AU - Schwienbacher C AD - Department of Pathology, Hospital of Bolzano, Bolzano, Italy. FAU - Spedicato, Giorgio Alfredo AU - Spedicato GA AUID- ORCID: 0000-0002-0315-8888 AD - Data Science Management, Unipol Group, Bologna, Italy. FAU - Pycha, Stefan AU - Pycha S AD - Department of Urology, Riga Stradins University Hospital, Riga, Latvia. FAU - Vjaters, Egils AU - Vjaters E AD - Department of Urology, Riga Stradins University Hospital, Riga, Latvia. FAU - Degener, Stephan AU - Degener S AD - Department of Urology, Helios-Klinikum Wuppertal, Witten Herdecke University, Wuppertal, Germany. FAU - Kafka, Mona AU - Kafka M AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, Hospital of Bolzano, Bolzano, Italy. FAU - Trenti, Emanuela AU - Trenti E AUID- ORCID: 0000-0003-3034-531X AD - Department of Urology, Bolzano General Hospital, Lorenz Bohler St 5, Bolzano, 39100, Italy. LA - eng PT - Journal Article DEP - 20210305 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC7940738 OTO - NOTNLM OT - bladder cancer OT - cystoscopy OT - follow-up OT - urinary markers COIS- Conflict of interest statement: The authors declare that there is no conflict of interest. EDAT- 2021/03/23 06:00 MHDA- 2021/03/23 06:01 PMCR- 2021/03/05 CRDT- 2021/03/22 08:11 PHST- 2021/01/18 00:00 [received] PHST- 2021/01/27 00:00 [accepted] PHST- 2021/03/22 08:11 [entrez] PHST- 2021/03/23 06:00 [pubmed] PHST- 2021/03/23 06:01 [medline] PHST- 2021/03/05 00:00 [pmc-release] AID - 10.1177_1756287221997183 [pii] AID - 10.1177/1756287221997183 [doi] PST - epublish SO - Ther Adv Urol. 2021 Mar 5;13:1756287221997183. doi: 10.1177/1756287221997183. eCollection 2021 Jan-Dec. PMID- 33742465 OWN - NLM STAT- MEDLINE DCOM- 20210727 LR - 20210727 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 28 IP - 7 DP - 2021 Jul TI - Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. PG - 727-732 LID - 10.1111/iju.14548 [doi] AB - OBJECTIVE: To elucidate the therapeutic benefits of using a surgical checklist during transurethral resection for non-muscle-invasive bladder cancer. METHODS: A nine-item surgical checklist was established in January 2016 to assess disease risk and resection adequacy, and it was prospectively implemented into clinical practice. Patients diagnosed with non-muscle-invasive bladder cancer who underwent complete resection from January 2009 to August 2019 were included in this study. The presence of detrusor muscle in the transurethral resection specimen and the intravesical recurrence-free survival were compared between patients who underwent transurethral resection before and after surgical checklist implementation. RESULTS: A total of 125 patients who underwent transurethral resection after surgical checklist implementation were reviewed and compared with 125 patients who underwent transurethral resection before surgical checklist implementation. The use of the surgical checklist led to an increase in the proportion of transurethral resection specimens containing detrusor muscle (92% vs 69.6%, P < 0.01) and a decrease in the recurrence rate (19.2% vs 49.6%, P < 0.01). Multivariate analysis showed that transurethral resection without a surgical checklist was an independent predictive factor influencing the absence of detrusor muscle in the transurethral resection specimen (odds ratio 4.78, P < 0.01) and intravesical recurrence (hazard ratio 1.92, 95% confidence interval 1.14-3.23; P = 0.01). Kaplan-Meier plots showed that the recurrence-free survival rate was significantly lower when the surgical checklist was not used (log-rank test result P < 0.01). CONCLUSIONS: This study shows the therapeutic benefits of surgical checklist in improving the quality of resection during transurethral resection and reducing the recurrence rate in patients with non-muscle-invasive bladder cancer. CI - (c) 2021 The Japanese Urological Association. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Tsunemori, Hiroyuki AU - Tsunemori H AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Matsuoka, Yuki AU - Matsuoka Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kohashiguchi, Kana AU - Kohashiguchi K AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Miura, Takayoshi AU - Miura T AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Tohi, Yoichiro AU - Tohi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Miyauchi, Yasuyuki AU - Miyauchi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Kato, Takuma AU - Kato T AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Ueda, Nobufumi AU - Ueda N AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. LA - eng PT - Journal Article DEP - 20210319 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2021 Jul;28(7):732-733. doi: 10.1111/iju.14563. PMID: 33778990 CIN - Int J Urol. 2021 Jul;28(7):733. doi: 10.1111/iju.14588. PMID: 33881194 MH - Checklist MH - Humans MH - Muscles MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - *Urinary Bladder Neoplasms/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - recurrence-free survival OT - surgical checklist OT - transurethral resection of bladder tumor EDAT- 2021/03/21 06:00 MHDA- 2021/07/28 06:00 CRDT- 2021/03/20 06:53 PHST- 2020/06/22 00:00 [received] PHST- 2021/02/14 00:00 [accepted] PHST- 2021/03/21 06:00 [pubmed] PHST- 2021/07/28 06:00 [medline] PHST- 2021/03/20 06:53 [entrez] AID - 10.1111/iju.14548 [doi] PST - ppublish SO - Int J Urol. 2021 Jul;28(7):727-732. doi: 10.1111/iju.14548. Epub 2021 Mar 19. PMID- 38993218 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240714 IS - 2352-3735 (Electronic) IS - 2352-3727 (Print) IS - 2352-3727 (Linking) VI - 7 IP - 1 DP - 2021 TI - Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer. PG - 71-78 LID - 10.3233/BLC-200400 [doi] AB - BACKGROUND: AQP proteins show a variety of functions in human cell metabolism. The role of different AQP subtypes in tumor metabolism and prognosis are subject of ongoing research. OBJECTIVE: To investigate the mRNA expression of Aquaporin (AQP) 3, 4, 7 and 9 in pT1 non-muscle-invasive bladder cancer (NMIBC) and its prognostic value in therapeutic decision making. METHODS: Formalin-fixed-paraffin-embedded (FFPE) tissues from transurethral resection of the bladder (TURB) from 112 patients with initial diagnosis of stage pT1 NMIBC were analyzed retrospectively together with clinical data and therapeutic approaches. mRNA expression of AQP3, 4, 7 and 9 was measured and quantified using RT-qPCR. RESULTS: Of the 112 patients (83.9%male, median age 72 years), 40 had a recurrence (35.7%), 16 a progression (14.3%) and 14 patients (12.5%) died tumor-related. mRNA expression for AQP3 was detected in 99.1%, AQP4 in 46.4%, AQP7 in 86.6%and AQP9 in 97.3%. Spearman analysis revealed statistically significant correlations between AQP3, AQP7 and AQP9 mRNA expression with adverse clinical and histopathological parameters (WHO1973 grade 3, concomitant Cis or multifocality). High AQP9 mRNA expression was associated with worse PFS in the total cohort (p = 0.034) and in Grade 3 tumors (p = 0.003) in Kaplan-Meier analysis. In patients with bladder sparing approach, high AQP3 mRNA expression was significantly associated with worse CSS in patients receiving BCG therapy (p = 0.029). CONCLUSIONS: mRNA expression of AQP3, 7 and 9 correlates with adverse clinical and pathological parameters. AQP3 and 9 may help to identify a subgroup of highest risk patients who may be considered for early cystectomy. CI - (c) 2021 - The authors. Published by IOS Press. FAU - Reiss, Julian AU - Reiss J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Kalble, Sebastian AU - Kalble S AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Rosenhammer, Bernd AU - Rosenhammer B AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Weber, Florian AU - Weber F AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Wirtz, Ralph Markus AU - Wirtz RM AD - Stratifyer Molecular Pathology GmbH, Cologne, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20210319 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC11181798 OTO - NOTNLM OT - AQP OT - NMIBC OT - Non-muscle-invasive bladder cancer OT - aquaporin COIS- RMW is founder and employee of STRATIFYER Molecular Pathology GmbH. JR, SK, JB (Brundl), BR, MG, FW, ME, SD, MB, WO and JB (Breyer) have no conflict of interest to declare. EDAT- 2021/03/19 00:00 MHDA- 2021/03/19 00:01 PMCR- 2021/03/19 CRDT- 2024/07/12 04:35 PHST- 2020/09/09 00:00 [received] PHST- 2020/11/25 00:00 [accepted] PHST- 2021/03/19 00:01 [medline] PHST- 2021/03/19 00:00 [pubmed] PHST- 2024/07/12 04:35 [entrez] PHST- 2021/03/19 00:00 [pmc-release] AID - BLC200400 [pii] AID - 10.3233/BLC-200400 [doi] PST - epublish SO - Bladder Cancer. 2021 Mar 19;7(1):71-78. doi: 10.3233/BLC-200400. eCollection 2021. PMID- 33735905 OWN - NLM STAT- MEDLINE DCOM- 20210602 LR - 20210602 IS - 1423-0232 (Electronic) IS - 0030-2414 (Linking) VI - 99 IP - 6 DP - 2021 TI - Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications. PG - 345-358 LID - 10.1159/000514759 [doi] AB - BACKGROUND: The most common bladder cancer (BC) histotype is pure urothelial carcinoma (UC), which may undergo divergent differentiation in some cases. Variant histology (VH) presents along variable morphologies, either single or combined between them or with pure UC. From a clinical standpoint, the vast majority of BC is diagnosed at non-invasive or minimally invasive stages, namely as non-muscle invasive BC (NMIBC). There is a wide range of therapeutic options for patients with NMIBC, according to their clinical and pathological features. However, current risk stratification models do not show optimal effectiveness. Evidence from the literature suggests that VH has peculiar biological features, and may be associated with poorer survival outcomes compared to pure UC. SUMMARY: In order to describe the biological features and prognostic/predictive role of VH in NMIBC, and to discuss current treatment options, we performed a systematic literature search through multiple databases (PubMed/Medline, Google Scholar) for relevant articles according to the following terms, single and/or in combination: "non-muscle invasive bladder cancer," "variant histology," "micropapillary variant," "glandular differentiation," "squamous differentiation," "nested variant," "plasmacytoid variant," and "sarcomatoid variant." We extracted 99 studies including original articles, reviews, and systematic reviews, and subsequently analyzed data from 16 studies reporting on the outcome of NMIBC with VH. We found that the relative rarity of these forms as well as the heterogeneity in study populations and therapeutic protocols results in conflicting findings overall. Key Messages: The presence of VH should be taken into account when counseling a patient with NMIBC, since it may upgrade the disease to high-risk tumor and thus warrant a more aggressive treatment. CI - (c) 2021 S. Karger AG, Basel. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Pathology Unit, University Hospital OO.RR, Foggia, Italy, fradolce@hotmail.com. FAU - Calo, Beppe AU - Calo B AD - Urology Unit, University of Foggia, Bonomo Teaching Hospital, Foggia, Italy. FAU - Mancini, Vito AU - Mancini V AD - Urology and Renal Transplantation Unit, University of Foggia, Foggia, Italy. FAU - Zanelli, Magda AU - Zanelli M AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Palicelli, Andrea AU - Palicelli A AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Zizzo, Maurizio AU - Zizzo M AD - Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. AD - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. FAU - Ascani, Stefano AU - Ascani S AD - Pathology Unit, Azienda Ospedaliera S. Maria di Terni, University of Perugia, Terni, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Urology and Renal Transplantation Unit, University of Foggia, Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Urology Unit, University of Foggia, Bonomo Teaching Hospital, Foggia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210318 PL - Switzerland TA - Oncology JT - Oncology JID - 0135054 SB - IM MH - Carcinoma, Transitional Cell/*pathology/*therapy MH - Combined Modality Therapy MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*pathology/*therapy OTO - NOTNLM OT - Micropapillary OT - Non-muscle invasive bladder cancer OT - Pathology OT - Risk stratification OT - Variant histology EDAT- 2021/03/19 06:00 MHDA- 2021/06/03 06:00 CRDT- 2021/03/18 20:28 PHST- 2020/11/21 00:00 [received] PHST- 2020/12/30 00:00 [accepted] PHST- 2021/03/19 06:00 [pubmed] PHST- 2021/06/03 06:00 [medline] PHST- 2021/03/18 20:28 [entrez] AID - 000514759 [pii] AID - 10.1159/000514759 [doi] PST - ppublish SO - Oncology. 2021;99(6):345-358. doi: 10.1159/000514759. Epub 2021 Mar 18. PMID- 33734503 OWN - NLM STAT- MEDLINE DCOM- 20210727 LR - 20210727 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 28 IP - 7 DP - 2021 Jul TI - Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. PG - 720-726 LID - 10.1111/iju.14545 [doi] AB - OBJECTIVE: To assess the clinical outcomes of highest-risk non-muscle-invasive bladder cancer patients treated with intravesical bacillus Calmette-Guerin. METHODS: The medical charts of patients with non-muscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guerin between 2000 and 2018 at a single institution were retrospectively reviewed. Patients were stratified into three groups (intermediate-, high- and highest-risk groups) according to the risk classification of the updated Japanese Urological Association guidelines 2019. Among the three groups, the intravesical recurrence-free survival and progression-free survival were estimated and compared, respectively. Furthermore, the different types of risk factors in the highest-risk group were analyzed. RESULTS: Of the 165 patients, 49 (30%) patients had intravesical recurrence and 23 (14%) patients showed progression to muscle-invasive disease during a median follow-up period of 53 months. Significant differences were not noted in the recurrence-free survival and progression-free survival among the three groups. Multivariable survival analysis of 74 patients in the highest-risk group showed that carcinoma in situ in the prostatic urethra was a significant predictor associated with recurrence (hazard ratio 3.20, P = 0.026) and progression (hazard ratio 4.36, P = 0.013). CONCLUSIONS: Intravesical bacillus Calmette-Guerin can control highest-risk non-muscle-invasive bladder cancer in most patients. Our findings might aid in decision-making regarding the treatment of this subset of patients who require intensive treatment, such as intravesical therapy with bacillus Calmette-Guerin and radical cystectomy. CI - (c) 2021 The Japanese Urological Association. FAU - Miyamoto, Tatsuki AU - Miyamoto T AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Toyoshima, Yuta AU - Toyoshima Y AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of, Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, Nara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Iida, Kota AU - Iida K AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakahama, Tomonori AU - Nakahama T AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. FAU - Ohbayashi, Chiho AU - Ohbayashi C AD - Department of, Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Departments of, Department of, Urology and, Nara Medical University, Kashihara, Nara, Japan. LA - eng GR - 16K20159/JSPS KAKENHI/ GR - 26861290/JSPS KAKENHI/ GR - Fiscal Years 2015-2016 Nara Medical University Grant-in-Aid for Collaborative Research Projects/ PT - Journal Article DEP - 20210318 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - *BCG Vaccine/therapeutic use MH - Disease Progression MH - Humans MH - Japan/epidemiology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - Japanese Urological Association OT - bacillus Calmette-Guerin OT - highest risk OT - non-muscle-invasive bladder cancer OT - risk classification EDAT- 2021/03/19 06:00 MHDA- 2021/07/28 06:00 CRDT- 2021/03/18 12:55 PHST- 2020/06/20 00:00 [received] PHST- 2021/02/14 00:00 [accepted] PHST- 2021/03/19 06:00 [pubmed] PHST- 2021/07/28 06:00 [medline] PHST- 2021/03/18 12:55 [entrez] AID - 10.1111/iju.14545 [doi] PST - ppublish SO - Int J Urol. 2021 Jul;28(7):720-726. doi: 10.1111/iju.14545. Epub 2021 Mar 18. PMID- 33718167 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis. PG - 613696 LID - 10.3389/fonc.2021.613696 [doi] LID - 613696 AB - PURPOSE: To assess the association of tumor architecture with cancer recurrence, metastasis, and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) in Taiwan. MATERIALS AND METHODS: Data were collected from 857 patients treated with RNU between January 2005 and August 2016 in our hospital. Pathologic slides were reviewed by genitourinary pathologists. Propensity score weighting was performed for data analysis. RESULTS: Sessile growth pattern was observed in 212 patients (24.7%). Tumor architecture exhibited a significant association with bladder cancer history, chronic kidney disease (CKD), tumor stage, lymph node status, histological grade, lymphovascular invasion, concomitant carcinoma in situ, and the variant type [standardized mean difference (SMD) > 0.1 for all variables before weighting]. In the propensity score analysis, 424 papillary and sessile tumor architecture were analyzed to balance the baseline characteristics between the groups. Tumor architecture was an independent predictor of metastatic disease and CSS (p = 0.033 and p = 0.002, respectively). However, the associations of tumor architecture with bladder and contralateral recurrence were nonsignificant (p = 0.956 and p = 0.844, respectively). CONCLUSIONS: Tumor architecture of UTUC after RNU is associated with established features of aggressive disease and predictors of metastasis and CSS. Assessment of tumor architecture may help identify patients who could benefit from close follow-up or early administration of systemic therapy after RNU. Tumor architecture should be included in UTUC staging after further confirmation. CI - Copyright (c) 2021 Liu, Chen, Huang, Wang, Cheng, Kang, Lee, Su, Huang, Chang, Chuang, Luo and Chiang. FAU - Liu, Hui-Ying AU - Liu HY AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yen Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Huang, Shun-Chen AU - Huang SC AD - Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wang, Hung-Jen AU - Wang HJ AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cheng, Yuan-Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Kang, Chih Hsiung AU - Kang CH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lee, Wei Ching AU - Lee WC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Su, Yu-Li AU - Su YL AD - Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Huang, Chun-Chieh AU - Huang CC AD - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chang, Yin-Lun AU - Chang YL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chuang, Yao-Chi AU - Chuang YC AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Luo, Hao Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chiang, Po Hui AU - Chiang PH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20210225 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7947797 OTO - NOTNLM OT - cancer-specific survival OT - metastasis OT - papillary OT - sessile OT - tumor architecture OT - upper urinary tract urothelial carcinoma COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/03/16 06:00 MHDA- 2021/03/16 06:01 PMCR- 2021/01/01 CRDT- 2021/03/15 07:07 PHST- 2020/10/03 00:00 [received] PHST- 2021/01/04 00:00 [accepted] PHST- 2021/03/15 07:07 [entrez] PHST- 2021/03/16 06:00 [pubmed] PHST- 2021/03/16 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.613696 [doi] PST - epublish SO - Front Oncol. 2021 Feb 25;11:613696. doi: 10.3389/fonc.2021.613696. eCollection 2021. PMID- 33718075 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 2 DP - 2021 Feb TI - Recurrence factors in patients with Keratinizing squamous metaplasia of the bladder after surgical management: a single-center retrospective study. PG - 734-740 LID - 10.21037/tau-20-948 [doi] AB - BACKGROUND: Keratinizing squamous metaplasia (KSM) is a clinically heterogeneous disease that lacks research that provide definitive recurrent risk factors. Therefore, we identified the recurrence factors in patients with KSM of the bladder after transurethral resection (TUR). We also attempted to investigate the association between KSM and bladder cancer. METHODS: Clinical information of 257 patients diagnosed with KSM who underwent TUR in Xiangya Hospital from January 2010 to November 2018 were retrospectively collected. Clinical information was available for follow-up of 223 patients. To determine the risk factors for recurrence, we conducted univariate and multivariate cox regression analysis respectively. To explore the association between KSM and bladder cancer, we used clinical follow-up data. RESULTS: The median follow-up time is 49 (IQR, 12-121) months. Five-year recurrence-free rate (RFR) and 1-year RFR were 86.1% and 91.9%, respectively. Thirty-one patients (13.9%) relapsed of KSM after a median follow-up of 49 months (range, 12-121 months), and none of them developed subsequent bladder cancer. Univariate Cox analysis indicated that urinary tract infection [hazard ratio (HR) =2.111; 95% confidence interval (CI): 1.043-4.271; P=0.038], and atypical urothelial hyperplasia of the bladder (HR =4.191; 95% CI: 2.006-8.756; P<0.001) were significant recurrence factors. Multivariate Cox analysis suggested that atypical urothelial hyperplasia of the bladder (HR =3.506; 95% CI: 1.663-7.392; P=0.001) was the independent risk factor for postoperative recurrence of KSM. CONCLUSIONS: The recurrence rate in patients with KSM was about 13.9%, and atypical urothelial hyperplasia of the bladder was the independent risk factor in patients with KSM recurrence. In cases with bladder atypical urothelial hyperplasia, close follow-ups are necessary. Also, we demonstrated that KSM did not increase the subsequent risk of bladder cancer. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Yi, Zhenglin AU - Yi Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Ou, Zhenyu AU - Ou Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Guo, Xi AU - Guo X AD - Department of Urology, Hunan Provincial People's Hospital, Changsha, China. FAU - Othmane, Belaydi AU - Othmane B AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Hu, Jiao AU - Hu J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Ren, Wenbiao AU - Ren W AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Li, Huihuang AU - Li H AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - He, Tongchen AU - He T AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Qiu, Dongxu AU - Qiu D AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Cai, Zhiyong AU - Cai Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Chen, Jinbo AU - Chen J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Zu, Xiongbing AU - Zu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7947458 OTO - NOTNLM OT - Atypical urothelial hyperplasia OT - recurrence OT - squamous metaplasia OT - transurethral resection (TUR) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-948). XZ serves as an unpaid editorial board member of Translational Andrology and Urology. The other authors have no conflicts of interest to declare. EDAT- 2021/03/16 06:00 MHDA- 2021/03/16 06:01 PMCR- 2021/02/01 CRDT- 2021/03/15 07:07 PHST- 2021/03/15 07:07 [entrez] PHST- 2021/03/16 06:00 [pubmed] PHST- 2021/03/16 06:01 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - tau-10-02-734 [pii] AID - 10.21037/tau-20-948 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Feb;10(2):734-740. doi: 10.21037/tau-20-948. PMID- 33718065 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 10 IP - 2 DP - 2021 Feb TI - Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. PG - 626-635 LID - 10.21037/tau-20-1272 [doi] AB - BACKGROUND: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. METHODS: A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3). RESULTS: After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression. CONCLUSIONS: The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality. CI - 2021 Translational Andrology and Urology. All rights reserved. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Di Mauro, Marina AU - Di Mauro M AD - Urology Section, Department of Surgery, University of Catania, Catania, Italy. FAU - Cimino, Sebastiano AU - Cimino S AD - Urology Section, Department of Surgery, University of Catania, Catania, Italy. FAU - Morgia, Giuseppe AU - Morgia G AD - Urology Section, Department of Surgery, University of Catania, Catania, Italy. AD - Urology Section, Istituto Oncologico Del Mediterraneo (IOM), Viagrande, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Abu Farhan, Abdal Rahman AU - Abu Farhan AR AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Abano Terme Hospital, Padua, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy of Cluj-Napoca, Cluj-Napoca, Romania. FAU - Marchioni, Michele AU - Marchioni M AD - Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, Urology Unit, Chieti, Italy. FAU - Schips, Luigi AU - Schips L AD - Department of Medical, Oral and Biotechnological Sciences, "SS. Annunziata" Hospital, Urology Unit, Chieti, Italy. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Division of Urology, Department of Experimental Medicine and Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, ASST Ospedali Civili, University of Brescia, Brescia, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Cordima, Giovanni AU - Cordima G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Muto, Matteo AU - Muto M AD - Radiotherapy Unit, "S.G. Moscati" Hospital, Avellino, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Urology Section, Department of Surgery, University of Catania, Catania, Italy. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7947442 OTO - NOTNLM OT - Bladder cancer (BC) OT - immune system OT - inflammation OT - outcomes OT - prognosis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1272). The authors have no conflicts of interest to declare. EDAT- 2021/03/16 06:00 MHDA- 2021/03/16 06:01 PMCR- 2021/02/01 CRDT- 2021/03/15 07:07 PHST- 2021/03/15 07:07 [entrez] PHST- 2021/03/16 06:00 [pubmed] PHST- 2021/03/16 06:01 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - tau-10-02-626 [pii] AID - 10.21037/tau-20-1272 [doi] PST - ppublish SO - Transl Androl Urol. 2021 Feb;10(2):626-635. doi: 10.21037/tau-20-1272. PMID- 33713162 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20220423 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 9 DP - 2021 Sep TI - Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guerin immunotherapy for T1G3/HG bladder cancer. PG - 3337-3344 LID - 10.1007/s00345-021-03653-1 [doi] AB - PURPOSE: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guerin (BCG) for T1G3/HG urinary bladder cancer (UBC). MATERIALS AND METHODS: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients' sex with HG-recurrence and disease progression. RESULTS: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01-1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92-1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients' sex was not associated with recurrence (HR 0.99, 95%CI 0.80-1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78-1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78-1.60, p = 0.55). CONCLUSION: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response. CI - (c) 2021. The Author(s). FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. dd.dandrea@gmail.com. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, University of the Studies of Turin, AOU Citta Della Salute e Della Scienza di Torino, Presidio Molinette, Turin, Italy. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Cha, Eugene K AU - Cha EK AD - Department of Urology, Weill Medical College of Cornell, University, New York, NY, USA. AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Di Stasi, Savino AU - Di Stasi S AD - Department of Urology, Policlinico Tor Vergata-University of Rome, Rome, Italy. FAU - Joniau, Steven AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Cai, Tommaso AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Irani, Jaques AU - Irani J AD - Department of Urology, Centre Hospitalier Universitaire La Miletrie, University of Poitiers, Poitiers, France. FAU - Karnes, Jeffrey AU - Karnes J AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Varkarakis, John AU - Varkarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Baniel, Jack AU - Baniel J AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic. FAU - Spahn, Martin AU - Spahn M AD - Department of Urology, University Hospital of Wuerzburg, Wuertzburg, Germany. FAU - Ardelt, Peter AU - Ardelt P AD - Department of Urology, Universitatsklinik Freiburg, Freiburg, Germany. FAU - Colombo, Renzo AU - Colombo R AD - Departement of Urology, Universita Vita Salute, Ospedale S. Raffaele, Milan, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Dalbagni, Guido AU - Dalbagni G AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, University of the Studies of Turin, AOU Citta Della Salute e Della Scienza di Torino, Presidio Molinette, Turin, Italy. FAU - Bartoletti, Riccardo AU - Bartoletti R AD - Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy. FAU - Larre, Stephane AU - Larre S AD - Department of Urology, CHU de Reims, Reims, France. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden. FAU - Sylvester, Richard AU - Sylvester R AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Brussels, Belgium. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Medical College of Cornell, University, New York, NY, USA. AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. AD - Department of Urology, University of Jordan, Amman, Jordan. AD - European Association of Urology Research Foundation, Arnhem, The Netherlands. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20210313 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Female MH - Humans MH - *Immunotherapy MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Retrospective Studies MH - Sex Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*pathology PMC - PMC8510956 OTO - NOTNLM OT - Age OT - BCG OT - Bladder cancer OT - Progression OT - Recurrence OT - Response COIS- All authors declare that they have no conflict of interest for this manuscript. EDAT- 2021/03/14 06:00 MHDA- 2022/02/01 06:00 PMCR- 2021/03/13 CRDT- 2021/03/13 12:07 PHST- 2020/11/14 00:00 [received] PHST- 2021/02/28 00:00 [accepted] PHST- 2021/03/14 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/03/13 12:07 [entrez] PHST- 2021/03/13 00:00 [pmc-release] AID - 10.1007/s00345-021-03653-1 [pii] AID - 3653 [pii] AID - 10.1007/s00345-021-03653-1 [doi] PST - ppublish SO - World J Urol. 2021 Sep;39(9):3337-3344. doi: 10.1007/s00345-021-03653-1. Epub 2021 Mar 13. PMID- 33712344 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. PG - 438.e1-438.e9 LID - S1078-1439(21)00069-7 [pii] LID - 10.1016/j.urolonc.2021.02.007 [doi] AB - OBJECTIVE: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC. MATERIALS AND METHODS: STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models. RESULTS: STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC. CONCLUSIONS: STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Taber, Ann AU - Taber A AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Park, Youngrok AU - Park Y AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC; Tumor Biology Training Program, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Lelo, Alana AU - Lelo A AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC; Tumor Biology Training Program, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Xiao, Jerry AU - Xiao J AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC; Tumor Biology Training Program, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Berry, Deborah L AU - Berry DL AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Chaldekas, Krysta AU - Chaldekas K AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus N, Denmark. FAU - Philips, George AU - Philips G AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Kim, Jung-Sik AU - Kim JS AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Harris, Brent T AU - Harris BT AD - Departments of Pathology and Neurology , Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: lars@clin.au.dk. FAU - Waldman, Todd AU - Waldman T AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. Electronic address: waldmant@georgetown.edu. LA - eng GR - R01 DK131437/DK/NIDDK NIH HHS/United States GR - R01 CA169345/CA/NCI NIH HHS/United States GR - R01 CA267872/CA/NCI NIH HHS/United States GR - P30 CA051008/CA/NCI NIH HHS/United States GR - T32 CA009686/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210310 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Cycle Proteins) RN - 0 (STAG2 protein, human) RN - 0 (Cohesins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Cell Cycle Proteins/*analysis MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Urinary Bladder Neoplasms/*chemistry/mortality/pathology MH - Cohesins PMC - PMC8286298 MID - NIHMS1677853 OTO - NOTNLM OT - Bladder cancer OT - Bladder cancer recurrence and progression OT - Risk stratification guidelines OT - STAG2 EDAT- 2021/03/14 06:00 MHDA- 2021/12/24 06:00 PMCR- 2022/07/01 CRDT- 2021/03/13 05:45 PHST- 2020/11/07 00:00 [received] PHST- 2021/01/20 00:00 [revised] PHST- 2021/02/04 00:00 [accepted] PHST- 2021/03/14 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/03/13 05:45 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - S1078-1439(21)00069-7 [pii] AID - 10.1016/j.urolonc.2021.02.007 [doi] PST - ppublish SO - Urol Oncol. 2021 Jul;39(7):438.e1-438.e9. doi: 10.1016/j.urolonc.2021.02.007. Epub 2021 Mar 10. PMID- 33710533 OWN - NLM STAT- MEDLINE DCOM- 20211130 LR - 20261010 IS - 1776-260X (Electronic) IS - 1776-2596 (Linking) VI - 16 IP - 3 DP - 2021 May TI - Coming of Age of Immunotherapy of Urothelial Cancer. PG - 283-294 LID - 10.1007/s11523-021-00804-7 [doi] AB - Following platinum-based regimens becoming the reference standard of care, it has taken almost four decades to find a systemic treatment that improved overall survival in metastatic urothelial tumors. Single-agent immune checkpoint inhibitors have not only improved overall survival but also the quality of life of patients with metastatic urothelial tumors after failure of platinum-based regimens and as a maintenance therapy after four to six cycles of standard first-line chemotherapy. In addition, very promising data are emerging when single-agent immunotherapy is offered as adjuvant or neoadjuvant treatment for patients with muscle-invasive disease and also in the non-muscle-invasive setting. There is an extensive debate about the role of PD-L1 expression as a reliable biomarker to predict the activity of immune-based regimens. Furthermore, the lack of consensus concerning its utility means that there is a need for more and better tools to identify patients who are likely to benefit from these novel approaches. The field of urothelial tumors now additionally exploits novel antibody-drug conjugates and fibroblast growth factor-receptor inhibitors that are being tested in combination with immunotherapy. This added complexity contributes to an enormous increase in the challenges that will be faced shortly. FAU - Grande, Enrique AU - Grande E AD - Medical Oncology Department, MD Anderson Cancer Center Madrid, C/Arturo Soria 270, 28033, Madrid, Spain. egrande@oncomadrid.com. FAU - Molina-Cerrillo, Javier AU - Molina-Cerrillo J AD - Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Necchi, Andrea AU - Necchi A AD - Vita-Salute San Raffaele University, Milan, Italy. AD - IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy. AD - Urological Research Institute (URI)-IRCCS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210312 PL - France TA - Target Oncol JT - Targeted oncology JID - 101270595 SB - IM MH - Aged MH - Female MH - Humans MH - Immunotherapy/*methods MH - Male MH - Urologic Neoplasms/*drug therapy EDAT- 2021/03/13 06:00 MHDA- 2021/12/01 06:00 CRDT- 2021/03/12 12:49 PHST- 2021/02/20 00:00 [accepted] PHST- 2021/03/13 06:00 [pubmed] PHST- 2021/12/01 06:00 [medline] PHST- 2021/03/12 12:49 [entrez] AID - 10.1007/s11523-021-00804-7 [pii] AID - 10.1007/s11523-021-00804-7 [doi] PST - ppublish SO - Target Oncol. 2021 May;16(3):283-294. doi: 10.1007/s11523-021-00804-7. Epub 2021 Mar 12. PMID- 33706705 OWN - NLM STAT- MEDLINE DCOM- 20210503 LR - 20210503 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 21 IP - 1 DP - 2021 Mar 11 TI - Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. PG - 266 LID - 10.1186/s12885-021-07966-7 [doi] LID - 266 AB - BACKGROUND: To explore possible solutions to overcome chronic Bacillus Calmette-Guerin (BCG) shortage affecting seriously the management of non-muscle invasive bladder cancer (NMIBC) in Europe and throughout the world, we investigated whether non-maintenance eight-dose induction BCG (iBCG) was comparable to six-dose iBCG plus maintenance BCG (mBCG). METHODS: This observational study evaluated 2669 patients with high- or highest-risk NMIBC who treated with iBCG with or without mBCG during 2000-2019. The patients were classified into five groups according to treatment pattern: 874 (33%) received non-maintenance six-dose iBCG (Group A), 405 (15%) received six-dose iBCG plus mBCG (Group B), 1189 (44%) received non-maintenance seven-/eight-dose iBCG (Group C), 60 (2.2%) received seven-/eight-dose iBCG plus mBCG, and 141 (5.3%) received only 3 (33% vs 16%) postoperative complications (all p<0.05). Moreover, the positive surgical margin (PSM) rate after RARC was higher in the PPS group (14% vs 4%; p=0.03). On multivariable analyses, PPS at RARC independently predicted higher risk of intraoperative (odds ratio [OR] 2.10, 95% confidence interval [CI] 1.04-6.21; p=0.01) and 30-d complications (OR 2.26, 95% CI 1.05-5.22; p=0.02), as well as longer OT (relative risk [RR] 1.03, 95% CI 1.00-1.05; p=0.02) and length of stay (RR 1.13, 95% CI 1.02-1.26; p=0.02). Lack of randomization represents the main limitation. CONCLUSIONS: RARC in patients with a history of PPS is feasible, but it is associated with a higher risk of complications and longer OT and length of stay. Moreover, higher PSM rates have been reported for these patients. Thus, measures aimed at improving surgical outcomes appear to be warranted. PATIENT SUMMARY: We investigated the effect of previous prostate surgery (PPS) on surgical outcomes after robot-assisted removal of the bladder. We found that patients with PPS have a higher risk of complications and longer hospitalization after bladder removal. These patients deserve closer evaluation before this type of bladder operation. CI - Copyright (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Department of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. Electronic address: giusepperosiello@hotmail.it. FAU - Piazza, Pietro AU - Piazza P AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, University of Bologna, Bologna, Italy. FAU - Tames, Victor AU - Tames V AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, Bellvitge University Hospital, Barcelona, Spain. FAU - Farinha, Rui AU - Farinha R AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Paludo, Artur AU - Paludo A AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, Clinic Hospital of Porto Alegre, Porto Alegre, Brazil. FAU - Puliatti, Stefano AU - Puliatti S AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Amato, Marco AU - Amato M AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Mazzone, Elio AU - Mazzone E AD - Department of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - De Groote, Ruben AU - De Groote R AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Berquin, Camille AU - Berquin C AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Develtere, Dries AU - Develtere D AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Veys, Ralf AU - Veys R AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Sinatti, Celine AU - Sinatti C AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - De Naeyer, Geert AU - De Naeyer G AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Schatteman, Peter AU - Schatteman P AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Carpentier, Paul AU - Carpentier P AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - D'Hondt, Frederiek AU - D'Hondt F AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. FAU - Mottrie, Alexandre AU - Mottrie A AD - Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium. LA - eng PT - Clinical Study PT - Journal Article DEP - 20210227 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Aged MH - *Cystectomy/adverse effects/methods MH - Feasibility Studies MH - Humans MH - Male MH - Margins of Excision MH - Middle Aged MH - Postoperative Complications/epidemiology/etiology MH - Prostate/pathology/surgery MH - *Prostatectomy/adverse effects/methods MH - *Prostatic Neoplasms/pathology/surgery MH - *Robotic Surgical Procedures/adverse effects/methods MH - Transurethral Resection of Prostate/adverse effects/methods MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Minimally invasive surgery OT - Radical prostatectomy OT - Transurethral resection of the prostate EDAT- 2021/03/04 06:00 MHDA- 2022/03/15 06:00 CRDT- 2021/03/03 05:37 PHST- 2020/12/27 00:00 [received] PHST- 2021/02/12 00:00 [accepted] PHST- 2021/03/04 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2021/03/03 05:37 [entrez] AID - S0302-2838(21)00149-4 [pii] AID - 10.1016/j.eururo.2021.02.029 [doi] PST - ppublish SO - Eur Urol. 2021 Sep;80(3):358-365. doi: 10.1016/j.eururo.2021.02.029. Epub 2021 Feb 27. PMID- 33650265 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20220731 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 129 IP - 2 DP - 2022 Feb TI - A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. PG - 182-193 LID - 10.1111/bju.15379 [doi] AB - OBJECTIVES: To determine the predictive and prognostic value of a panel of systemic inflammatory response (SIR) biomarkers relative to established clinicopathological variables in order to improve patient selection and facilitate more efficient delivery of peri-operative systemic therapy. MATERIALS AND METHODS: The preoperative serum levels of a panel of SIR biomarkers, including albumin-globulin ratio, neutrophil-lymphocyte ratio, De Ritis ratio, monocyte-lymphocyte ratio and modified Glasgow prognostic score were assessed in 4199 patients treated with radical cystectomy for clinically non-metastatic urothelial carcinoma of the bladder. Patients were randomly divided into a training and a testing cohort. A machine-learning-based variable selection approach (least absolute shrinkage and selection operator regression) was used for the fitting of several multivariable predictive and prognostic models. The outcomes of interest included prediction of upstaging to carcinoma invading bladder muscle (MIBC), lymph node involvement, pT3/4 disease, cancer-specific survival (CSS) and recurrence-free survival (RFS). The discriminatory ability of each model was either quantified by area under the receiver-operating curves or by the C-index. After validation and calibration of each model, a nomogram was created and decision-curve analysis was used to evaluate the clinical net benefit. RESULTS: For all outcome variables, at least one SIR biomarker was selected by the machine-learning process to be of high discriminative power during the fitting of the models. In the testing cohort, model performance evaluation for preoperative prediction of lymph node metastasis, >/=pT3 disease and upstaging to MIBC showed a 200-fold bootstrap-corrected area under the curve of 67.3%, 73% and 65.8%, respectively. For postoperative prognosis of CSS and RFS, a 200-fold bootstrap corrected C-index of 73.3% and 72.2%, respectively, was found. However, even the most predictive combinations of SIR biomarkers only marginally increased the discriminative ability of the respective model in comparison to established clinicopathological variables. CONCLUSION: While our machine-learning approach for fitting of the models with the highest discriminative ability incorporated several previously validated SIR biomarkers, these failed to improve the discriminative ability of the models to a clinically meaningful degree. While the prognostic and predictive value of such cheap and readily available biomarkers warrants further evaluation in the age of immunotherapy, additional novel biomarkers are still needed to improve risk stratification. CI - (c) 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Schuettfort, Victor M AU - Schuettfort VM AUID- ORCID: 0000-0002-7114-0508 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Mostafaei, Hadi AU - Mostafaei H AUID- ORCID: 0000-0001-5596-1771 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Konig, Frederik AU - Konig F AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, QC, Canada. FAU - Luzzago, Stefano AU - Luzzago S AUID- ORCID: 0000-0002-9373-1413 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, QC, Canada. AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology, Predictive Onco-Urology, AP-HP, Urology Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Enikeev, Dmitry AU - Enikeev D AUID- ORCID: 0000-0001-7169-2209 AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Zimmermann, Kristin AU - Zimmermann K AUID- ORCID: 0000-0002-6654-9886 AD - Clinic for Urology, Central Military Hospital Koblenz, Koblenz, Germany. FAU - Deuker, Marina AU - Deuker M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Centre, Montreal, QC, Canada. AD - Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AUID- ORCID: 0000-0002-3819-9911 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Grossmann, Nico C AU - Grossmann NC AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital of Tours, Tours, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan. AD - Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - European Association of Urology Research Foundation, Arnhem, The Netherlands. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20210407 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers) SB - IM MH - Biomarkers MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Humans MH - Prognosis MH - Retrospective Studies MH - Systemic Inflammatory Response Syndrome/diagnosis/etiology MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology PMC - PMC9291893 OTO - NOTNLM OT - #uroonc OT - #utuc OT - adjuvant chemotherapy OT - biomarker OT - bladder cancer OT - muscle-invasive bladder cancer OT - non-muscle invasive bladder cancer OT - systemic therapy OT - transitional cell carcinoma COIS- All authors have no conflict of interest. EDAT- 2021/03/03 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/07/18 CRDT- 2021/03/02 06:27 PHST- 2021/01/27 00:00 [revised] PHST- 2020/12/11 00:00 [received] PHST- 2021/02/23 00:00 [accepted] PHST- 2021/03/03 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2021/03/02 06:27 [entrez] PHST- 2022/07/18 00:00 [pmc-release] AID - BJU15379 [pii] AID - 10.1111/bju.15379 [doi] PST - ppublish SO - BJU Int. 2022 Feb;129(2):182-193. doi: 10.1111/bju.15379. Epub 2021 Apr 7. PMID- 33650041 OWN - NLM STAT- MEDLINE DCOM- 20210909 LR - 20220218 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 479 IP - 2 DP - 2021 Aug TI - Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. PG - 325-335 LID - 10.1007/s00428-021-03054-0 [doi] AB - Reliable factors predicting the disease course of non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) are unavailable. Molecular subtypes have potential for prognostic stratification of muscle-invasive bladder cancer, while their value for CIS patients is unknown. Here, the prognostic impact of both clinico-pathological parameters, including CIS focality, and immunohistochemistry-based surrogate subtypes was analyzed in a cohort of high-risk NMIBC patients with CIS. In 128 high-risk NMIBC patients with CIS, luminal (KRT20, GATA3, ERBB2) and basal (KRT5/6, KRT14) surrogate markers as well as p53 were analyzed in 213-231 biopsies. To study inter-lesional heterogeneity of CIS, marker expression in independent CIS biopsies from different bladder localizations was analyzed. Clinico-pathological parameters and surrogate subtypes were correlated with recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Forty-six and 30% of CIS patients exhibited a luminal-like (KRT20-positive, KRT5/6-negative) and a null phenotype (KRT20-negative, KRT5/6-negative), respectively. A basal-like subtype (KRT20-negative, KRT5/6-positive) was not observed. A significant degree of inter-lesional CIS heterogeneity was noted, reflected by 23% of patients showing a mixed subtype. Neither CIS surrogate subtype nor CIS focality was associated with patient outcome. Patient age and smoking status were the only potentially independent prognostic factors predicting RFS, PFS, OS, and PFS, respectively. In conclusion, further clarification of heterogeneity of surrogate subtypes in HR NMIBC and their prognostic value is of importance with regard to potential implementation of molecular subtyping into clinical routine. The potential prognostic usefulness of patient age and smoking status for high-risk NMIBC patients with CIS needs further validation. CI - (c) 2021. The Author(s). FAU - Garczyk, Stefan AU - Garczyk S AUID- ORCID: 0000-0001-5447-3207 AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. sgarczyk@ukaachen.de. FAU - Bischoff, Felix AU - Bischoff F AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. FAU - Schneider, Ursula AU - Schneider U AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. FAU - Golz, Reinhard AU - Golz R AD - Institute of Pathology, Helios University Hospital Wuppertal, Wuppertal, Germany. FAU - von Rundstedt, Friedrich-Carl AU - von Rundstedt FC AD - Department of Urology, Helios University Hospital Wuppertal, Wuppertal, Germany. FAU - Knuchel, Ruth AU - Knuchel R AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. FAU - Degener, Stephan AU - Degener S AD - Department of Urology, Helios University Hospital Wuppertal, Wuppertal, Germany. LA - eng PT - Journal Article DEP - 20210301 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma in Situ/*chemistry/mortality/pathology/therapy MH - Female MH - Humans MH - *Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Progression-Free Survival MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Smoking/adverse effects MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/*chemistry/mortality/pathology/therapy MH - Urothelium/*chemistry/pathology PMC - PMC8364543 OTO - NOTNLM OT - Bladder cancer OT - CIS OT - Carcinoma in situ OT - Intratumoral heterogeneity OT - Molecular subtypes OT - NMIBC COIS- The authors declare that they have no conflict of interest. EDAT- 2021/03/03 06:00 MHDA- 2021/09/10 06:00 PMCR- 2021/03/01 CRDT- 2021/03/02 06:23 PHST- 2020/11/13 00:00 [received] PHST- 2021/02/07 00:00 [accepted] PHST- 2021/01/20 00:00 [revised] PHST- 2021/03/03 06:00 [pubmed] PHST- 2021/09/10 06:00 [medline] PHST- 2021/03/02 06:23 [entrez] PHST- 2021/03/01 00:00 [pmc-release] AID - 10.1007/s00428-021-03054-0 [pii] AID - 3054 [pii] AID - 10.1007/s00428-021-03054-0 [doi] PST - ppublish SO - Virchows Arch. 2021 Aug;479(2):325-335. doi: 10.1007/s00428-021-03054-0. Epub 2021 Mar 1. PMID- 33648348 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20211029 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 17 IP - 11 DP - 2021 Apr TI - Arsenic level in bladder tumor of patients from an exposed population: association with progression and prognosis. PG - 1311-1323 LID - 10.2217/fon-2020-0154 [doi] AB - Aims: To elucidate the impact of arsenic on progression and prognosis of bladder cancer. Patients & methods: Total arsenic in 145 tumors (80 non-muscle-invasive [NMIBC] and 65 muscle-invasive bladder cancer [MIBC]) was measured and associated with Ki67 expression, tumor-clinicopathological parameters and patient outcome. Results: Tumor arsenic concentration was higher in exposed than unexposed patients (256 mug/kg vs 77 mug/kg; p < 0.0001) and positively correlated (r = 0.65; p < 0.0001) with arsenic content of patient's drinking water. Arsenic concentration showed significant association with Ki67-overexpression (p = 0.001) and advanced tumor stages (NMIBC vs MIBC; p = 0.0009). In NMIBC, high tumor arsenic (>100 mug/kg) and Ki67 overexpression was established as predictors for recurrence (hazard ratio [HR]: 4.68; p = 0.005 and HR: 3.91; p = 0.018) and progression (HR: 6.04; p = 0.023 and HR: 6.87; p = 0.013). In MIBC, association of high arsenic remained significant with increased risk of recurrence (HR: 4.58; p = 0.04). Conclusion: In NMIBC, high arsenic and Ki67 overexpression and in MIBC, only high arsenic showed prognostic importance in predicting poor patient outcome. FAU - Ghosh, Sabnam AU - Ghosh S AD - Department of Life Sciences, Presidency University, Kolkata, West Bengal, 700073, India. FAU - Basu, Mukta AU - Basu M AUID- ORCID: 0000-0002-5479-1018 AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, West Bengal, 700026, India. FAU - Banerjee, Kalyan AU - Banerjee K AD - Department of Life Sciences, Presidency University, Kolkata, West Bengal, 700073, India. FAU - Chaudhury, Snigdha Pal AU - Chaudhury SP AD - Department of Geology, Presidency University, Kolkata West Bengal, 700073, India. FAU - Paul, Tanmoy AU - Paul T AD - Department of Microbiology, University of Kalyani, West Bengal, 741235, India. FAU - Bera, Dipak Kumar AU - Bera DK AD - Department of Urology, IPGME&R, Kolkata, West Bengal, 700020, India. FAU - Pal, Dilip Kumar AU - Pal DK AUID- ORCID: 0000-0002-9356-642X AD - Department of Urology, IPGME&R, Kolkata, West Bengal, 700020, India. FAU - Sk, Ugir Hossain AU - Sk UH AD - Department of Clinical & Translational Research, Chittaranjan National Cancer Institute, Kolkata, West Bengal, 700026, India. FAU - Panda, Chinmay Kumar AU - Panda CK AUID- ORCID: 0000-0002-0854-6978 AD - Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, West Bengal, 700026, India. FAU - Ghosh, Amlan AU - Ghosh A AUID- ORCID: 0000-0001-9334-5152 AD - Department of Life Sciences, Presidency University, Kolkata, West Bengal, 700073, India. LA - eng GR - 922/(Sanc)-BT (Estt.) RD-13/13F dt.09.09.14/Department of Biotechnology, West Bengal, India/ PT - Journal Article DEP - 20210302 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (Water Pollutants) RN - N712M78A8G (Arsenic) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Arsenic/*metabolism MH - Biomarkers, Tumor/metabolism MH - Dietary Exposure/*adverse effects/analysis MH - Disease Progression MH - Female MH - Humans MH - India MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*metabolism/pathology MH - Water Pollutants/*metabolism OAB - Lay abstract Research work suggests arsenic as risk factor for bladder cancer. In developing countries such as India, arsenic contamination of underground drinking water is a major health problem. The present study aimed to evaluate impact of arsenic on parameters of bladder cancer aggressiveness and clinical outcome of patients from West Bengal, India. Our data showed accumulation of arsenic in bladder tumor of patients exposed mainly through contaminated drinking water. Arsenic content in tumor favored aggressive phenotypes in bladder cancer (higher cell proliferation and advanced tumor stages) and was found to be a potential predictor for cases of death and disease recurrence in patients after receiving primary treatment measures. Therefore, arsenic content in bladder tumor may be used to improve existing protocols for better prediction of patient outcomes in populations with a similar type of exposure. OABL- eng OTO - NOTNLM OT - West Bengal OT - bladder cancer OT - patient outcome OT - proliferation potential OT - tumor arsenic EDAT- 2021/03/03 06:00 MHDA- 2021/10/30 06:00 CRDT- 2021/03/02 05:42 PHST- 2021/03/03 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/03/02 05:42 [entrez] AID - 10.2217/fon-2020-0154 [doi] PST - ppublish SO - Future Oncol. 2021 Apr;17(11):1311-1323. doi: 10.2217/fon-2020-0154. Epub 2021 Mar 2. PMID- 33642228 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20211223 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. PG - 409-421 LID - S1078-1439(21)00048-X [pii] LID - 10.1016/j.urolonc.2021.01.025 [doi] AB - To evaluate the oncologic prognostic value of fibroblast growth factor receptor (FGFR) and to assess the safety and efficacy of its inhibitors in patients with urothelial bladder carcinoma. A literature search using PubMed, Scopus, and Cochrane Library was conducted on June 2020 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. The pooled recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS) were calculated using a fixed or random effects model in patients with nonmuscle invasive bladder cancer (NMIBC). Overall, 62 studies comprising 9,229 patients were eligible and included in this systematic review and meta-analysis. Both FGFR3 mutation and protein overexpression were significantly associated with RFS, PFS, CSS, and overall survival. FGFR3 mutation was associated with worse RFS and better PFS (pooled hazard ratio: 1.30; 95% confidence interval: 1.08-1.57, and pooled hazard ratio: 0.62; 95% confidence interval: 0.42-0.92, respectively) in patients with NMIBC. In 11 studies reporting on the response to FGFR inhibitors, complete response rates, disease control rates, and overall response rate of 0% to 8%, 59.3% to 64.2%, and 40% were reported for dovitinib, infigratinib, and erdafitinib, respectively. Based on this study, FGFR3 mutation is a statistically significant prognostic factor for RFS in NMIBC. FGFR inhibitors have measurable benefit in patients with advanced and metastatic urothelial carcinoma. However, the results of ongoing RCTs and future well-designed studies are awaited to capture the differential biologic and clinical behavior of tumors harboring FGFR while helping to identify those who are most likely to benefit from FGFR inhibitors. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AD - Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; European Association of Urology research foundation, Arnhem, The Netherlands. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20210226 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Receptors, Fibroblast Growth Factor) SB - IM MH - Carcinoma, Transitional Cell/*drug therapy MH - Humans MH - Prognosis MH - Receptors, Fibroblast Growth Factor/*antagonists & inhibitors MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Bladder cancer OT - FGFR OT - FGFR inhibitors OT - FGFR3 OT - Prognosis OT - Progression OT - Urothelial carcinoma COIS- Conflict of interest The authors declare that they have no conflict of interest. EDAT- 2021/03/02 06:00 MHDA- 2021/12/24 06:00 CRDT- 2021/03/01 05:32 PHST- 2020/09/28 00:00 [received] PHST- 2020/12/16 00:00 [revised] PHST- 2021/01/21 00:00 [accepted] PHST- 2021/03/02 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/03/01 05:32 [entrez] AID - S1078-1439(21)00048-X [pii] AID - 10.1016/j.urolonc.2021.01.025 [doi] PST - ppublish SO - Urol Oncol. 2021 Jul;39(7):409-421. doi: 10.1016/j.urolonc.2021.01.025. Epub 2021 Feb 26. PMID- 33636055 OWN - NLM STAT- MEDLINE DCOM- 20210518 LR - 20210518 IS - 1742-1241 (Electronic) IS - 1368-5031 (Linking) VI - 75 IP - 6 DP - 2021 Jun TI - Prognostic value of preoperative inflammation markers in non-muscle invasive bladder cancer. PG - e14118 LID - 10.1111/ijcp.14118 [doi] AB - PURPOSE: To investigate the prediction values of the preoperative neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV) and red cell distribution width (RDW) for recurrence and progression of patients with non-muscle invasive bladder cancer (NMIBC). METHODS: In this prospective study, 94 consecutive patients newly diagnosed with NMIBC between July 2017 and August 2018 were included. The blood samples were collected from patients before transurethral resection of bladder tumour (TURB) and NLR, LMR, PLR, RDW and MPV values were calculated. The effect of these preoperative inflammatory parameters and other clinicopathological parameters on recurrence and progression rates was evaluated. Kaplan-Meier and multivariate Cox regression analyses were performed to identify significant prognostic variables. RESULTS: The mean follow-up was 11 +/- 6.4 months. Recurrence was observed in 35.1% and progression was detected in 7.4% of the patients. NLR was statistically significantly associated with both recurrence (P = .01) and progression (P = .035), whereas LMR was only associated with recurrence (P = .038). In the survival analyses, the relationship between recurrence and LMR was confirmed in both univariate (P = .021) and multivariate (P = .022) analyses. The relationship between NLR and recurrence was confirmed in univariate analysis (P = .019); however; in multivariate analysis, it was found to be statistically insignificant (P = .051). CONCLUSIONS: LMR might be an easy obtainable, non-invasive and cost-effective method for predicting recurrence of disease in patients with NMIBC. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Yildiz, Huseyin Alperen AU - Yildiz HA AUID- ORCID: 0000-0002-7423-4585 AD - Department of Urology, Malazgirt State Hospital, Mus, Turkey. FAU - Deger, Muslim Dogan AU - Deger MD AUID- ORCID: 0000-0002-5095-7770 AD - Department of Urology, Edirne State Hospital, Edirne, Turkey. FAU - Aslan, Guven AU - Aslan G AUID- ORCID: 0000-0003-3715-1761 AD - Department of Urology, School of Medicine, Dokuz Eylul University, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20210305 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 SB - IM MH - Humans MH - Inflammation MH - Neoplasm Recurrence, Local MH - Neutrophils MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery EDAT- 2021/02/27 06:00 MHDA- 2021/05/19 06:00 CRDT- 2021/02/26 17:10 PHST- 2021/02/17 00:00 [revised] PHST- 2020/11/28 00:00 [received] PHST- 2021/02/24 00:00 [accepted] PHST- 2021/02/27 06:00 [pubmed] PHST- 2021/05/19 06:00 [medline] PHST- 2021/02/26 17:10 [entrez] AID - 10.1111/ijcp.14118 [doi] PST - ppublish SO - Int J Clin Pract. 2021 Jun;75(6):e14118. doi: 10.1111/ijcp.14118. Epub 2021 Mar 5. PMID- 33634310 OWN - NLM STAT- MEDLINE DCOM- 20210707 LR - 20221207 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 51 IP - 7 DP - 2021 Jul 1 TI - Developing a nomogram for predicting intravesical recurrence after radical nephroureterectomy: a retrospective cohort study of mainland Chinese patients. PG - 1132-1141 LID - 10.1093/jjco/hyab017 [doi] AB - OBJECTIVE: To evaluate the role of Ki-67 in predicting subsequent intravesical recurrence following radical nephroureterectomy and to develop a predictive nomogram for upper tract urothelial carcinoma patients. METHODS: This retrospective analysis involved 489 upper tract urothelial carcinoma patients who underwent radical nephroureterectomy with bladder cuff excision. The data set was randomly split into a training cohort of 293 patients and a validation cohort of 196 patients. Immunohistochemical analysis was used to assess the immunoreactivity of the biomarker Ki-67 in the tumor tissues. A multivariable Cox regression model was utilized to identify independent intravesical recurrence predictors after radical nephroureterectomy before constructing a nomographic model. Predictive accuracy was quantified using time-dependent receiver operating characteristic curve. Decision curve analysis was performed to evaluate the clinical benefit of models. RESULTS: With a median follow-up of 54 months, intravesical recurrence developed in 28.2% of this sample (n = 137). Tumor location, multifocality, pathological T stage, surgical approach, bladder cancer history and Ki-67 expression levels were independently associated with intravesical recurrence (all P < 0.05). The full model, which intercalated Ki-67 with traditional clinicopathological parameters, outperformed both the basic model and Xylinas' model in terms of discriminative capacity (all P < 0.05). Decision-making analysis suggests that the more comprehensive model can also improve patients' net benefit. CONCLUSIONS: This new model, which intercalates the Ki-67 biomarker with traditional clinicopathological factors, appears to be more sensitive than nomograms previously tested across mainland Chinese populations. The findings suggest that Ki-67 could be useful for determining risk-stratified surveillance protocols following radical nephroureterectomy and in generating an individualized strategy based around intravesical recurrence predictions. CI - (c) The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Lai, Shicong AU - Lai S AUID- ORCID: 0000-0003-2172-6583 AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Long, Xingbo AU - Long X AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Seery, Samuel AU - Seery S AD - School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK. FAU - Hou, Huimin AU - Hou H AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Yuan AU - Li Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Wang, Jianye AU - Wang J AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. LA - eng GR - Z201100005620007/Beijing Municipal Science and Technology Project/ GR - BJ-2018-090/Beijing Hospital Clinical Research 121 Project/ GR - 81874094/National Natural Science Foundation of China/ GR - 2019-1002-69/Peking Union Medical College/ PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Biomarkers) RN - 0 (Ki-67 Antigen) SB - IM MH - Aged MH - Asian People MH - Biomarkers/metabolism MH - China MH - Female MH - Humans MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - *Neoplasm Recurrence, Local MH - *Nephroureterectomy MH - *Nomograms MH - Proportional Hazards Models MH - Retrospective Studies MH - Urinary Bladder/metabolism/surgery MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - intravesical recurrence OT - prediction model OT - radical nephroureterectomy OT - upper urinary tract urothelial carcinoma EDAT- 2021/02/27 06:00 MHDA- 2021/07/08 06:00 CRDT- 2021/02/26 06:05 PHST- 2020/12/12 00:00 [received] PHST- 2021/02/27 06:00 [pubmed] PHST- 2021/07/08 06:00 [medline] PHST- 2021/02/26 06:05 [entrez] AID - 6150030 [pii] AID - 10.1093/jjco/hyab017 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2021 Jul 1;51(7):1132-1141. doi: 10.1093/jjco/hyab017. PMID- 33632097 OWN - NLM STAT- MEDLINE DCOM- 20220617 LR - 20220922 IS - 1875-5666 (Electronic) IS - 1566-5240 (Linking) VI - 22 IP - 10 DP - 2022 TI - The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder Cancer. PG - 941-949 LID - 10.2174/1566524021666210225100041 [doi] AB - BACKGROUND: Expression levels of collagens have been implicated in the progression of various cancers and interaction with cytokeratins but are not well studied in bladder cancer (BC). Therefore, we analyzed the gene and protein expression levels of collagen 1A1 (Col1a1/COL1A1), collagen 3A1 (col3a1/COL3A1), collagen 5A2 (col5a2/COL5A2), cytokeratin 14 (krt14/CK14), and cytokeratin 17 (krt17/CK17) in urothelial BC samples of different stages. METHODS: In total, 102 fresh frozen and 190 formalin-fixed and paraffin-embedded (FFPE) samples were tested using immunohistochemistry and RT-qPCR. Expression levels were correlated with clinicopathological and follow-up data. RESULTS: Col1a1, col3a1, col5a2 and krt14 mRNA levels were significantly overexpressed in high-grade and muscle-invasive BC (MIBC) compared to low-grade and non-muscle invasive BC (NMIBC) cases. Disease-specific survival (DSS) was shorter in patients with high expression levels of col1a1 (p = 0.004), col3a1 (p = 0.004), and col5a2 (p = 0.028). CK14 (p = 0.020), COL3A1 (p = 0.006), and Col5A2 (p = 0.006) protein expression levels were significantly higher and protein expression levels of CK17 (p = 0.05) were significantly lower in MIBC compared to NMIBC. Furthermore, CK14 (p = 0.002) and COL5A2 (p = 0.006) protein expression level were significantly higher in high-grade compared to low-grade BC. DSS was shorter in patients with high expression levels of COL5A2 (p = 0.033) and CK14 (p = 0.042). CONCLUSION: Expression changes of collagens and cytokeratins are univariable prognostic markers in BC. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Ingenwerth, Marc AU - Ingenwerth M AD - Institute of Pathology, Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, 1082 Budapest, Hungary. FAU - Hadaschik, Boris AU - Hadaschik B AD - Department of Urology, Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Szarvas, Tibor AU - Szarvas T AD - Department of Urology, Semmelweis University, 1082 Budapest, Hungary. AD - Department of Urology, Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Reis, Henning AU - Reis H AD - Institute of Pathology, Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Curr Mol Med JT - Current molecular medicine JID - 101093076 RN - 0 (Biomarkers, Tumor) RN - 68238-35-7 (Keratins) RN - 9007-34-5 (Collagen) SB - IM MH - Biomarkers, Tumor/genetics MH - *Carcinoma, Transitional Cell/genetics/pathology MH - Collagen/genetics MH - Humans MH - Keratins MH - Prognosis MH - *Urinary Bladder Neoplasms/genetics/pathology OTO - NOTNLM OT - CK14 OT - CK17 OT - COL1A1 OT - COL3A1 OT - COL5A2 OT - bladder cancer OT - epithelial-mesenchymal-transition EDAT- 2021/02/27 06:00 MHDA- 2022/06/18 06:00 CRDT- 2021/02/26 05:37 PHST- 2020/10/04 00:00 [received] PHST- 2021/01/28 00:00 [revised] PHST- 2021/02/01 00:00 [accepted] PHST- 2021/02/27 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2021/02/26 05:37 [entrez] AID - CMM-EPUB-114544 [pii] AID - 10.2174/1566524021666210225100041 [doi] PST - ppublish SO - Curr Mol Med. 2022;22(10):941-949. doi: 10.2174/1566524021666210225100041. PMID- 33627018 OWN - NLM STAT- MEDLINE DCOM- 20210705 LR - 20210705 IS - 1464-5157 (Electronic) IS - 0265-6736 (Linking) VI - 38 IP - 1 DP - 2021 TI - Quantification of thermal dose in moderate clinical hyperthermia with radiotherapy: a relook using temperature-time area under the curve (AUC). PG - 296-307 LID - 10.1080/02656736.2021.1875060 [doi] AB - BACKGROUND: Thermal dose in clinical hyperthermia reported as cumulative equivalent minutes (CEM) at 43 degrees C (CEM43) and its variants are based on direct thermal cytotoxicity assuming Arrhenius 'break' at 43 degrees C. An alternative method centered on the actual time-temperature plot during each hyperthermia session and its prognostic feasibility is explored. METHODS AND MATERIALS: Patients with bladder cancer treated with weekly deep hyperthermia followed by radiotherapy were evaluated. From intravesical temperature (T) recordings obtained every 10 secs, the area under the curve (AUC) was computed for each session for T > 37 degrees C (AUC > 37 degrees C) and T >/= 39 degrees C (AUC >/= 39 degrees C). These along with CEM43, CEM43(>37 degrees C), CEM43(>/=39 degrees C), T(mean), T(min) and T(max) were evaluated for bladder tumor control. RESULTS: Seventy-four hyperthermia sessions were delivered in 18 patients (median: 4 sessions/patient). Two patients failed in the bladder. For both individual and summated hyperthermia sessions, the T(mean), CEM43, CEM43(>37 degrees C), CEM43(>/=39 degrees C), AUC > 37 degrees C and AUC >/= 39 degrees C were significantly lower in patients who had a local relapse. Individual AUC >/= 39 degrees C for patients with/without local bladder failure were 105.9 +/- 58.3 degrees C-min and 177.9 +/- 58.0 degrees C-min, respectively (p = 0.01). Corresponding summated AUC >/= 39 degrees C were 423.7 +/- 27.8 degrees C-min vs. 734.1 +/- 194.6 degrees C-min (p < 0.001), respectively. The median AUC >/= 39 degrees C for each hyperthermia session in patients with bladder tumor control was 190 degrees C-min. CONCLUSION: AUC >/= 39 degrees C for each hyperthermia session represents the cumulative time-temperature distribution at clinically defined moderate hyperthermia in the range of 39 degrees C to 45 degrees C. It is a simple, mathematically computable parameter without any prior assumptions and appears to predict treatment outcome as evident from this study. However, its predictive ability as a thermal dose parameter merits further evaluation in a larger patient cohort. FAU - Datta, Niloy R AU - Datta NR AUID- ORCID: 0000-0003-1680-5578 AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Marder, Dietmar AU - Marder D AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Datta, Sneha AU - Datta S AUID- ORCID: 0000-0003-4201-3822 AD - Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria. FAU - Meister, Andreas AU - Meister A AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Puric, Emsad AU - Puric E AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Stutz, Emanuel AU - Stutz E AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Rogers, Susanne AU - Rogers S AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Eberle, Brigitte AU - Eberle B AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Timm, Olaf AU - Timm O AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Staruch, Michal AU - Staruch M AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. FAU - Riesterer, Oliver AU - Riesterer O AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. AD - Department of Radiation Oncology, University Hospital Zurich, Switzerland. FAU - Bodis, Stephan AU - Bodis S AUID- ORCID: 0000-0003-1078-8711 AD - Department of Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. AD - Department of Radiation Oncology, University Hospital Zurich, Switzerland. LA - eng PT - Journal Article PL - England TA - Int J Hyperthermia JT - International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group JID - 8508395 SB - IM MH - Area Under Curve MH - Combined Modality Therapy MH - Humans MH - *Hyperthermia MH - *Hyperthermia, Induced MH - Neoplasm Recurrence, Local/therapy MH - Temperature OTO - NOTNLM OT - AUC OT - CEM OT - Thermal dose OT - area under the curve OT - hyperthermia OT - thermometry EDAT- 2021/02/26 06:00 MHDA- 2021/07/06 06:00 CRDT- 2021/02/25 05:31 PHST- 2021/02/25 05:31 [entrez] PHST- 2021/02/26 06:00 [pubmed] PHST- 2021/07/06 06:00 [medline] AID - 10.1080/02656736.2021.1875060 [doi] PST - ppublish SO - Int J Hyperthermia. 2021;38(1):296-307. doi: 10.1080/02656736.2021.1875060. PMID- 33626547 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 106 IP - 2 DP - 2022 TI - Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes. PG - 122-129 LID - 10.1159/000512053 [doi] AB - OBJECTIVES: The objective of this study was to assess the impact of complete transurethral resection of bladder tumors (TURBTs) before radical cystectomy on pathological and oncological outcomes of patients with muscle-invasive bladder cancer (MIBC) and high-risk non-MIBC. MATERIALS AND METHODS: The charts of all patients who underwent radical cystectomy for bladder cancer in 2 academic departments of urology between 1996 and 2016 were retrospectively reviewed. Patients were divided into 2 groups according to the completeness of the last endoscopic resection before radical cystectomy: macroscopically complete transurethral resection (complete) or macroscopically incomplete transurethral resection (incomplete). The primary end point was the recurrence-free survival (RFS). Secondary end points included cancer-specific survival (CSS) and rates of pT0 and downstaging. RESULTS: Out of 486 patients included for analysis, the TURBT immediately preceding radical cystectomy was considered macroscopically complete in 253 patients (52.1%) and incomplete in 233 patients (47.9%). In multivariate analysis, macroscopically complete TURBT was the strongest predictor of both pT0 disease (OR = 3.1; p = 0.02) and downstaging (OR = 7.1; p < 0.0001). After a median follow-up of 41 months, macroscopically complete TURBT was associated with better RFS (5-year RFS: 57 vs. 37%; p < 0.0001) and CSS (5-year CSS: 70.8 vs. 54.5%; p = 0.002). In multivariate analysis adjusting for multifocality, weight of endoscopic resection specimen, cT4 stage on preoperative imaging, interval between endoscopic resection and radical cystectomy, neoadjuvant chemotherapy, pT stage, and associated carcinoma in situ, macroscopically complete endoscopic resection remained the main predictor of better RFS (HR = 0.4; p = 0.0003) and the only preoperative factor associated with CSS (HR = 0.5; p = 0.01). CONCLUSION: A macroscopically complete TURBT immediately preceding radical cystectomy may improve pathological and oncological outcomes in patients with MIBC and high-risk MIBC. CI - (c) 2021 S. Karger AG, Basel. FAU - Graffeille, Vivien AU - Graffeille V AD - Department of Urology, University Hospital of Rennes, Rennes, France, graffeillevivien@gmail.com. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Gryn, Alexandre AU - Gryn A AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Kammerer-Jacquet, Solene-Florence AU - Kammerer-Jacquet SF AD - Department of Radiology, University Hospital of Rennes, Rennes, France. FAU - Alimi, Quentin AU - Alimi Q AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Beauval, Jean-Baptiste AU - Beauval JB AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Beuzit, Luc AU - Beuzit L AD - Department of Radiology, University Hospital of Rennes, Rennes, France. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Thoulouzan, Matthieu AU - Thoulouzan M AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Khene, Zine Eddine AU - Khene ZE AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Guille, Francois AU - Guille F AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Rioux-Leclercq, Nathalie AU - Rioux-Leclercq N AD - Department of Radiology, University Hospital of Rennes, Rennes, France. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Game, Xavier AU - Game X AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Bensalah, Karim AU - Bensalah K AD - Department of Urology, University Hospital of Rennes, Rennes, France. FAU - Soulie, Michel AU - Soulie M AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department of Urology, University Hospital of Toulouse, Toulouse, France. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Department of Urology, University Hospital of Rennes, Rennes, France. LA - eng PT - Journal Article DEP - 20210224 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Cystectomy OT - MeSH OT - Neoplasm OT - Survival OT - Transurethral resection OT - Urinary bladder EDAT- 2021/02/25 06:00 MHDA- 2022/03/04 06:00 CRDT- 2021/02/24 20:09 PHST- 2020/06/21 00:00 [received] PHST- 2020/10/04 00:00 [accepted] PHST- 2021/02/25 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2021/02/24 20:09 [entrez] AID - 000512053 [pii] AID - 10.1159/000512053 [doi] PST - ppublish SO - Urol Int. 2022;106(2):122-129. doi: 10.1159/000512053. Epub 2021 Feb 24. PMID- 33626220 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20220414 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 129 IP - 2 DP - 2022 Feb TI - Complete metabolic response with [(18) F]fluorodeoxyglucose-positron emission tomography/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer. PG - 174-181 LID - 10.1111/bju.15374 [doi] AB - OBJECTIVE: To determine whether repeated [(18) F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT) scans can predict increased cancer-specific survival (CSS) after induction chemotherapy followed by radical cystectomy (RC). PATIENTS AND METHODS: Between 2007 and 2018, 86 patients with clinically lymph node (LN)-positive bladder cancer (T1-T4, N1-N3, M0-M1a) were included and underwent a repeated FDG-PET-CT during cisplatin-based induction chemotherapy. The 71 patients that had a response to chemotherapy underwent RC. Response to chemotherapy was evaluated in LNs through repeated FDG-PET-CT and stratified as partial response or complete response using three different methods: maximum standardised uptake value (SUV(max) ), adapted Deauville criteria, and total lesion glycolysis (TLG). Progression-free survival (PFS) and CSS were analysed for all three methods by Cox regression analysis. RESULTS: After a median follow-up of 40 months, 15 of the 71 patients who underwent RC had died from bladder cancer. Using SUV(max) and the adapted Deauville criteria, multivariable Cox regression analyses adjusting for age, clinical tumour stage and LN stage showed that complete response was associated with increased PFS (hazard ratio [HR] 3.42, 95% confidence interval [CI] 1.20-9.77) and CSS (HR 3.30, 95% CI 1.02-10.65). Using TLG, a complete response was also associated with increased PFS (HR 5.17, 95% CI 1.90-14.04) and CSS (HR 6.32, 95% CI 2.06-19.41). CONCLUSIONS: Complete metabolic response with FDG-PET-CT predicts survival after induction chemotherapy followed by RC in patients with LN-positive bladder cancer and comprises a novel tool in evaluating response to chemotherapy before surgery. This strategy has the potential to tailor treatment in individual patients by identifying significant response to chemotherapy, which motivates the administration of a full course of induction chemotherapy with a higher threshold for suspending treatment due to toxicity and side-effects. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International Published by John Wiley & Sons Ltd. FAU - Abrahamsson, Johan AU - Abrahamsson J AUID- ORCID: 0000-0003-4854-1896 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Kollberg, Petter AU - Kollberg P AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Almquist, Helen AU - Almquist H AD - Department of Medical Imaging and Physiology, Skane University Hospital, Lund, Sweden. FAU - Blackberg, Mats AU - Blackberg M AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Brandstedt, Johan AU - Brandstedt J AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Lyttkens, Kerstin AU - Lyttkens K AD - Department of Medical Imaging and Physiology, Skane University Hospital, Lund, Sweden. FAU - Simoulis, Athanasios AU - Simoulis A AUID- ORCID: 0000-0001-6669-9481 AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Pathology, Skane University Hospital, Malmo, Sweden. FAU - Sjodahl, Gottfrid AU - Sjodahl G AUID- ORCID: 0000-0002-7869-0473 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Sorenby, Anne AU - Sorenby A AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Tragardh, Elin AU - Tragardh E AD - Department of Medical Imaging and Physiology, Skane University Hospital, Malmo, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AUID- ORCID: 0000-0001-8193-0370 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210423 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Cystectomy MH - Fluorodeoxyglucose F18/pharmacology MH - Humans MH - Induction Chemotherapy MH - Lymph Nodes/diagnostic imaging/pathology MH - Lymphatic Metastasis/pathology MH - *Positron Emission Tomography Computed Tomography/methods MH - Prognosis MH - Radiopharmaceuticals/therapeutic use MH - *Urinary Bladder Neoplasms/diagnostic imaging/drug therapy/surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - FDG-PET-CT OT - bladder cancer OT - induction chemotherapy OT - lymph node positive OT - radical cystectomy OT - survival EDAT- 2021/02/25 06:00 MHDA- 2022/04/15 06:00 CRDT- 2021/02/24 17:10 PHST- 2021/02/25 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2021/02/24 17:10 [entrez] AID - 10.1111/bju.15374 [doi] PST - ppublish SO - BJU Int. 2022 Feb;129(2):174-181. doi: 10.1111/bju.15374. Epub 2021 Apr 23. PMID- 33622868 OWN - NLM STAT- MEDLINE DCOM- 20210618 LR - 20220531 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 35 IP - 2 DP - 2021 Mar-Apr TI - Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer. PG - 753-759 LID - 10.21873/invivo.12316 [doi] AB - BACKGROUND/AIM: The role of glutathione peroxidase 2 (GPX2) expression in urothelial carcinoma (UC) is rarely reported. The aim of this study was to assess the expression status of GPX2 in UC of the bladder. MATERIALS AND METHODS: We collected samples from 112 patients treated with radical cystectomy for immunohistochemical study. RESULTS: Following immunohistochemical analysis of the specimens, 86 (76.8%) had weak GPX2 expression. In cases with consistent GPX2 expression within the same lesion, the levels of GPX2 showed significant decreases from pTa to pT1 (47.1%) compared to those from pT1 to pT2 (5.9%) (p=0.017). Specimens obtained with transurethral resection before cancer progressed to muscle invasive bladder cancer showed that pT1 had a lower expression for GPX2 than that of pTa (63.3% vs. 93.3%; p=0.009). CONCLUSION: The decrease in GPX2 expression among those with UC of the bladder may be involved in the early step of cancer invasion. CI - Copyright(c) 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Minato, Akinori AU - Minato A AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; a-minato@med.uoeh-u.ac.jp. FAU - Noguchi, Hirotsugu AU - Noguchi H AD - Department of Pathology, Field of Oncology Graduate School of Medical and Dental Science, Kagoshima, Japan. FAU - Ohnishi, Rei AU - Ohnishi R AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Tomisaki, Ikko AU - Tomisaki I AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Nakayama, Toshiyuki AU - Nakayama T AD - Department of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 RN - EC 1.11.1.- (GPX2 protein, human) RN - EC 1.11.1.9 (Glutathione Peroxidase) SB - IM MH - *Carcinoma, Transitional Cell/pathology MH - Cystectomy MH - Glutathione Peroxidase/genetics MH - Humans MH - Neoplasm Staging MH - Prognosis MH - *Urinary Bladder Neoplasms/genetics/pathology/surgery PMC - PMC8045116 OTO - NOTNLM OT - Urothelial carcinoma OT - bladder cancer OT - glutathione peroxidase 2 (GPX2) OT - immunohistochemistry OT - invasion COIS- The Authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/02/25 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/03/03 CRDT- 2021/02/24 05:37 PHST- 2020/12/26 00:00 [received] PHST- 2021/01/16 00:00 [revised] PHST- 2021/01/25 00:00 [accepted] PHST- 2021/02/24 05:37 [entrez] PHST- 2021/02/25 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/03/03 00:00 [pmc-release] AID - 35/2/753 [pii] AID - 10.21873/invivo.12316 [doi] PST - ppublish SO - In Vivo. 2021 Mar-Apr;35(2):753-759. doi: 10.21873/invivo.12316. PMID- 33622681 OWN - NLM STAT- MEDLINE DCOM- 20220422 LR - 20220422 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 75 IP - 5 DP - 2022 May TI - Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. PG - 333-337 LID - 10.1136/jclinpath-2021-207400 [doi] AB - AIMS: To compare the 1973 WHO and the 2004/2016 WHO grading systems in patients with urothelial carcinoma of urinary bladder (UCUB), since no consensus has been made which classification should supersede the other and since both are recommended in clinical practice. METHODS: Newly diagnosed patients with Ta UCUB treated with transurethral resection of bladder tumour were abstracted from the Surveillance, Epidemiology and End Results database (2010-2016). Kaplan-Meier plots and multivariable Cox regression models (CRMs) tested cancer-specific mortality (CSM), according to 1973 WHO (G1 vs G2 vs G3) and to 2004/2016 WHO (low-grade vs high-grade) grading systems. RESULTS: Of 35 986 patients, according to 1973 WHO grading system, 8165 (22.7%) were G1, 17 136 (47.6%) were G2 and 10 685 (29.7%) were G3. According to 2004/2016 WHO grading system, 24 961 (69.4%) were low-grade versus 11 025 (30.6%) high-grade. In multivariable CRMs, G3 (HR: 2.05, p<0.001), relative to G1, and high-grade(HR: 2.13, p<0.001), relative to low-grade, predicted higher CSM. Conversely, G2 (p=0.8) was not an independent predictor. The multivariable models without consideration of either grading system were 74% accurate in predicting 5-year CSM. After addition of 1973 WHO or 2004/2016 WHO grade, the accuracy increased to 76% and 77%, respectively. CONCLUSIONS: From a statistical standpoint, it appears that the 2004/2016 WHO grading system holds a small, although measurable advantage over the 1973 WHO grading system. Other considerations, such as intraobserver and interobserver variability may represent an additional matric to consider in deciding which grading system is better. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Colla Ruvolo, Claudia AU - Colla Ruvolo C AUID- ORCID: 0000-0001-8110-7341 AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada c.collaruvolo@gmail.com. AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Campania, Italy. FAU - Wurnschimmel, Christoph AU - Wurnschimmel C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. AD - Martini-Klinik Prostate Cancer Center, University of Hamburg Faculty of Medicine, Hamburg, Germany. FAU - Wenzel, Mike AU - Wenzel M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. AD - Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Faculty 16 Medicine, Frankfurt am Main, Hessen, Germany. FAU - Nocera, Luigi AU - Nocera L AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. AD - Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Lombardia, Italy. FAU - Califano, Gianluigi AU - Califano G AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Campania, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Departments of Urology, Weill Cornell Medical College, New York, New York, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M, Sechenov First Moscow State Medical University, Moscow, Russia. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Faculty 16 Medicine, Frankfurt am Main, Hessen, Germany. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Lombardia, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Fisciano, Campania, Italy. FAU - Imbimbo, Ciro AU - Imbimbo C AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Campania, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Campania, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, CRCHUM, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20210223 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 SB - IM MH - *Carcinoma, Transitional Cell MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Proportional Hazards Models MH - Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology MH - World Health Organization OTO - NOTNLM OT - urinary bladder OT - urologic diseases OT - urologic neoplasms COIS- Competing interests: None declared. EDAT- 2021/02/25 06:00 MHDA- 2022/04/23 06:00 CRDT- 2021/02/24 05:36 PHST- 2021/01/06 00:00 [received] PHST- 2021/01/27 00:00 [revised] PHST- 2021/01/29 00:00 [accepted] PHST- 2021/02/25 06:00 [pubmed] PHST- 2022/04/23 06:00 [medline] PHST- 2021/02/24 05:36 [entrez] AID - jclinpath-2021-207400 [pii] AID - 10.1136/jclinpath-2021-207400 [doi] PST - ppublish SO - J Clin Pathol. 2022 May;75(5):333-337. doi: 10.1136/jclinpath-2021-207400. Epub 2021 Feb 23. PMID- 33617331 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20210715 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 206 IP - 1 DP - 2021 Jul TI - Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy. PG - 22-28 LID - 10.1097/JU.0000000000001689 [doi] AB - PURPOSE: We sought to determine the optimal cystoscopic interval for intermediate risk, nonmuscle invasive bladder cancer. MATERIALS AND METHODS: A retrospective analysis of patients with intermediate risk, nonmuscle invasive bladder cancer (2010-2017) was performed and 3 hypothetical models of surveillance intensity were applied: model 1: high (3 months), model 2: moderate (6 months) and model 3: low intensity (12 months) over a 2-year period. We compared timing of actual detection of recurrence and progression to proposed cystoscopy timing between each model. We calculated number of avoidable cystoscopies and associated costs. RESULTS: Of 107 patients with median followup of 37 months, 66/107 (77.6%) developed recurrence and 12/107(14.1%) had progression. Relative to model 1, there were 33 (50%) delayed detection of recurrences in model 2 and 41 (62%) in model 3. There was a 1.7-month mean delay in detection of recurrence for model 1 vs 3.2, and a 7.6-month delay for models 2 and 3 (p <0.001 model 1 vs 2; p <0.001 model 2 vs 3). Relative to model 1, there were 8 (67%) and 9 (75%) delayed detection of progression events in model 2 and 3. There were no progression-related bladder cancer deaths or radical cystectomies due to delayed detection. Mean number of avoidable cystoscopies was higher in model 1 (2) vs model 2 (1) and 3 (0). Model 1 had the highest aggregate cost of surveillance ($46,262.52). CONCLUSIONS: High intensity (3-month) surveillance intervals provide faster detection of recurrences but with increased cost and more avoidable cystoscopies without clear oncologic benefit. Moderate intensity (6-month) intervals in intermediate risk, nonmuscle invasive bladder cancer allows timely detection without oncologic compromise and is less costly with fewer cystoscopies. FAU - Bhat, Abhishek AU - Bhat A AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Kwon, Deukwoo AU - Kwon D AD - Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida. AD - Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. FAU - Soodana-Prakash, Nachiketh AU - Soodana-Prakash N AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Mouzannar, Ali AU - Mouzannar A AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Punnen, Sanoj AU - Punnen S AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. FAU - Parekh, Dipen J AU - Parekh DJ AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. FAU - Ritch, Chad R AU - Ritch CR AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210222 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Jul;206(1):27. doi: 10.1097/JU.0000000000001689.01. PMID: 33835847 MH - Aged MH - Cystoscopy/*statistics & numerical data MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*pathology MH - Watchful Waiting/*standards/*statistics & numerical data OTO - NOTNLM OT - cystoscopy OT - urinary bladder neoplasms EDAT- 2021/02/23 06:00 MHDA- 2021/07/16 06:00 CRDT- 2021/02/22 17:10 PHST- 2021/02/23 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2021/02/22 17:10 [entrez] AID - 10.1097/JU.0000000000001689 [doi] PST - ppublish SO - J Urol. 2021 Jul;206(1):22-28. doi: 10.1097/JU.0000000000001689. Epub 2021 Feb 22. PMID- 33617327 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20210715 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 206 IP - 1 DP - 2021 Jul TI - Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. PG - 29-36 LID - 10.1097/JU.0000000000001696 [doi] AB - PURPOSE: Salvage cystectomy is required for some patients with intravesical recurrence after trimodality therapy. We compared postoperative outcomes between salvage cystectomy post-trimodality therapy, primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. MATERIALS AND METHODS: We included 265 patients who underwent radical cystectomy at Massachusetts General Hospital for cT1-T4 bladder cancer between 2003 and 2013. Patients were grouped as salvage cystectomy post-trimodality therapy, primary cystectomy or primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. Early (90 days) complications were compared. Disease-specific survival and overall survival were calculated using a Cox regression model, and adjusted survival curves were generated. RESULTS: The median followup from the time of cystectomy was 65.5 months. There was no difference in intraoperative and early complications between the groups. The detection of late complications was higher in salvage cystectomy post-trimodality therapy compared to primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy (p=0.03). In multivariable Cox regression analysis, salvage cystectomy post-trimodality therapy was associated with a higher incidence of any late (HR 2.3, p=0.02) and major late complications (HR 2.1, p <0.05). There was no difference in disease-specific survival (p=0.8) or overall survival (p=0.9) between the groups. CONCLUSIONS: Salvage cystectomy post-trimodality therapy for intravesical recurrence post-trimodality therapy has an intraoperative and early complication rate comparable to primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. Salvage cystectomy post-trimodality therapy is associated with a higher risk of overall and major late complications than primary cystectomy. The disease-specific survival and overall survival of patients who require salvage cystectomy post-trimodality therapy are comparable to both groups. FAU - Pieretti, Alberto AU - Pieretti A AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Krasnow, Ross AU - Krasnow R AD - Department of Urology, MedStar Washington Hospital Center, Washington, D.C. FAU - Drumm, Michael AU - Drumm M AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Gusev, Andrew AU - Gusev A AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Dahl, Douglas M AU - Dahl DM AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - McGovern, Francis AU - McGovern F AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Blute, Michael L AU - Blute ML AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Shipley, William U AU - Shipley WU AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Feldman, Adam S AU - Feldman AS AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Wszolek, Matthew F AU - Wszolek MF AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. LA - eng PT - Journal Article DEP - 20210222 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Jul;206(1):35-36. doi: 10.1097/JU.0000000000001696.01. PMID: 33835845 MH - Aged MH - Combined Modality Therapy MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*surgery MH - Postoperative Complications/*epidemiology MH - Retrospective Studies MH - Salvage Therapy MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery/therapy OTO - NOTNLM OT - cystectomy OT - postoperative complications OT - salvage therapy OT - urinary bladder neoplasms EDAT- 2021/02/23 06:00 MHDA- 2021/07/16 06:00 CRDT- 2021/02/22 17:10 PHST- 2021/02/23 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2021/02/22 17:10 [entrez] AID - 10.1097/JU.0000000000001696 [doi] PST - ppublish SO - J Urol. 2021 Jul;206(1):29-36. doi: 10.1097/JU.0000000000001696. Epub 2021 Feb 22. PMID- 33612088 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20220531 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 88 IP - 3 DP - 2021 Aug TI - Expression of aquaporins 3 in low grade risk of recurrence primary bladder cancer. PG - 190-193 LID - 10.1177/0391560321993588 [doi] AB - INTRODUCTION: Bladder cancer (BC) is one of the most frequent malignancy of the urinary tract. Recent studies demonstrated the role of aquaporins urothelial tumor cells (AQPs) as potential prognostic factor for tumor progression and invasion. In this study we investigated the AQP3 expression levels inside primary superficial (pTa) low grade bladder cancer, correlating with pathological parameters and clinical outcomes. MATERIALS AND METHODS: We retrospectively analyzed tumor samples of 66 patients with diagnosis of superficial urothelial (pTa) bladder cancer between 1997 and 2007. All patients underwent transurethral bladder resection (TURB) and immediate single instillation of mitomycin C. All tumors samples were blindly reviewed by two expert anatomopathologists and only pTa low grade urothelial bladder cancer were included. Cancer recurrence was defined as the detection of bladder lesions during follow-up cystoscopy. AQP3-immunoreactive areas detected at immunohistochemical analysis were classified as AQP3 positive. RESULTS: Of these 60.6% of patients was detected as negative for AQP3 expression. Forty-two patients develop cancer recurrence during follow-up with a mean progression free survival of 16.44 months. The absence of reaction for AQP3 was observed 56% (9/16) tumor grading G1 and 62% (31/50) tumor grading G2. No correlation was observed with sexual gender, grading of tumor differentiation, and recurrence of cancer disease. Kaplan-Meier curves of disease-free survival (DFS) showed a significant separation (p = 0.028) between patients AQP3-positive and AQP3-negative. It was observed a mean DFS of 23.83 and 14.43 months respectively in absence and presence of AQP3 expression. CONCLUSION: AQP3 expression is related to disease-free interval (DFI) and the absence of AQP3 expression correlates with a late relapse. The expression of AQP3 does not provide a reproducible quantitative aspect. AQP3 are not suitable to forecast tumor cell behavior but they perform a role as regulator for tumor cell homeostasis and for additional therapeutic developments. FAU - Ticonosco, Marco AU - Ticonosco M AUID- ORCID: 0000-0001-9295-7456 AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Assumma, Simone AU - Assumma S AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Iseppi, Andrea AU - Iseppi A AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Benedetti, Mattia AU - Benedetti M AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Sarchi, Luca AU - Sarchi L AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Ferrari, Riccardo AU - Ferrari R AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Calcagnile, Tommaso AU - Calcagnile T AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Rocco, Bernardo AU - Rocco B AUID- ORCID: 0000-0001-7211-0485 AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Sighinolfi, Maria Chiara AU - Sighinolfi MC AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Alriyalat, Sulieman AU - Alriyalat S AD - AlBalqa' Applied University, As-Salt, Jordan. FAU - Reggiani Bonetti, Luca AU - Reggiani Bonetti L AD - Department of Pathology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Migaldi, Mario AU - Migaldi M AD - Department of Pathology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Micali, Salvatore AU - Micali S AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. LA - eng PT - Journal Article DEP - 20210221 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - 158801-98-0 (Aquaporin 3) SB - IM MH - Aquaporin 3 MH - *Carcinoma, Transitional Cell MH - Humans MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms OTO - NOTNLM OT - Bladder cancer OT - aquaporin 3 OT - low grade OT - pTa EDAT- 2021/02/23 06:00 MHDA- 2021/10/29 06:00 CRDT- 2021/02/22 05:44 PHST- 2021/02/23 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/02/22 05:44 [entrez] AID - 10.1177/0391560321993588 [doi] PST - ppublish SO - Urologia. 2021 Aug;88(3):190-193. doi: 10.1177/0391560321993588. Epub 2021 Feb 21. PMID- 33606105 OWN - NLM STAT- MEDLINE DCOM- 20210824 LR - 20261010 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 31 IP - 9 DP - 2021 Sep TI - The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. PG - 6949-6961 LID - 10.1007/s00330-021-07765-5 [doi] AB - OBJECTIVE: To assess diagnostic validity and reliability of VI-RADS in predicting muscle invasion by bladder cancer (BCa) and evaluate reviewer acceptance of VI-RADS for clinical routine. METHODS: A prospective multicenter study enrolled 331 patients with suspected/untreated BCa who underwent preoperative multiparametric MRI examination (mp-MRI) of the urinary bladder. Four experienced radiologists independently evaluated all mp-MRI using VI-RADS. The diagnostic validity of VI-RADS for predicting muscle invasion by BCa was calculated using histopathology of the first transurethral resection bladder tumor (TURBT) and second TURBT as the reference standards. The kappa statistics (kappa) were applied to assess the interreader agreement (IRA). Reviewer acceptance was evaluated with questionnaires. RESULTS: The risk of muscle invasion in VI-RADS 2, 3, 4, and 5 after the first and second TURBT was 21.8%, 45.8%, 69.6%, and 96.4% and 24.4%, 58.3%, 87%, and 99.2%, respectively. The overall diagnostic validity of VI-RADS was high. The optimal cut-off value for predicting muscle invasion after first TURBT was > VI-RADS 3 (sensitivity = 84.1% and specificity = 92.3%), and after second TURBT was > VI-RADS 2 (sensitivity = 89.9% and specificity = 90.1%). VI-RADS categorization showed a very good IRA (kappa = 0.93). Reviewers fully agreed with the statement, "The application of structured reporting of bladder tumor should be encouraged" (score = 20). CONCLUSIONS: VI-RADS showed high diagnostic validity and reliability for predicting muscle invasion by BCa, especially VI-RADS 4 and 5. However, VI-RADS 2 and 3 require further modifications to enhance their diagnostic validity. VI-RADS is highly encouraged to be used in daily practice. KEY POINTS: * VI-RADS showed high diagnostic validity and reliability in predicting BCa muscle invasion, especially VI-RADS 4 and 5. * In VI-RADS 2 and 3, we observed a notable percentage of BCa with muscle invasion and this would require further modifications to enhance the diagnostic validity for these scores. * Overall VI-RADS is well-accepted by radiologists who recommend it for daily practice. CI - (c) 2021. European Society of Radiology. FAU - Metwally, Maha Ibrahim AU - Metwally MI AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Zeed, Nesma Adel AU - Zeed NA AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Hamed, Enas Mahmoud AU - Hamed EM AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Elshetry, Al Shaimaa Fathi AU - Elshetry ASF AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Elfwakhry, Rabab Mahmoud AU - Elfwakhry RM AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Alaa Eldin, Ahmed M AU - Alaa Eldin AM AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Sakr, Ahmed AU - Sakr A AD - Department of Urology, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Aly, Sameh Abdelaziz AU - Aly SA AD - Department of Radio-diagnosis, Faculty of Human Medicine, Benha University, Benha, Egypt. FAU - Mosallam, Walid AU - Mosallam W AD - Department of Radio-diagnosis, Faculty of Human Medicine, Suez Canal University, Ismailia, Egypt. FAU - Ziada, Yara Mohammed Ahmad AU - Ziada YMA AD - Department of Radio-diagnosis, Al-Ahrar Teaching Hospital, Zagazig, Egypt. FAU - Balata, Rawda AU - Balata R AD - Department of Clinical Oncology, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Harb, Ola A AU - Harb OA AD - Department of Pathology, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. FAU - Basha, Mohammad Abd Alkhalik AU - Basha MAA AUID- ORCID: 0000-0002-9075-8020 AD - Department of Radio-diagnosis, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt. Mohammad_basha76@yahoo.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210219 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Cystectomy MH - Humans MH - Magnetic Resonance Imaging MH - Muscles MH - Prospective Studies MH - Reproducibility of Results MH - *Urinary Bladder Neoplasms/diagnostic imaging/surgery OTO - NOTNLM OT - Diffusion magnetic resonance imaging OT - Multiparametric magnetic resonance imaging OT - Reproducibility of results OT - Urinary bladder neoplasms EDAT- 2021/02/20 06:00 MHDA- 2021/08/25 06:00 CRDT- 2021/02/19 12:13 PHST- 2020/11/24 00:00 [received] PHST- 2021/02/08 00:00 [accepted] PHST- 2021/02/03 00:00 [revised] PHST- 2021/02/20 06:00 [pubmed] PHST- 2021/08/25 06:00 [medline] PHST- 2021/02/19 12:13 [entrez] AID - 10.1007/s00330-021-07765-5 [pii] AID - 10.1007/s00330-021-07765-5 [doi] PST - ppublish SO - Eur Radiol. 2021 Sep;31(9):6949-6961. doi: 10.1007/s00330-021-07765-5. Epub 2021 Feb 19. PMID- 33592141 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20221207 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 53 IP - 4 DP - 2021 Oct TI - Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. PG - 1156-1165 LID - 10.4143/crt.2020.1356 [doi] AB - PURPOSE: Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC. This research aimed to assess real NAC efficacy without interference from TURBT and apply combined modality therapies guided by NAC efficacy. MATERIALS AND METHODS: Patients with cT2-4aN0M0 MIBC were confirmed by cystoscopic biopsy and imaging. NAC efficacy was assessed by imaging, urine cytology, and cystoscopy with multidisciplinary team discussion. Definite responders (250 ng/ml had a sensitivity of 100% and specificity of 50%, resulting in a negative predictive value of 100% and positive predictive value of 14.8% for preoperative deep vein thrombosis. Increasing the D-dimer threshold to >1000 ng/ml created a sensitivity of 50% and specificity of 85%, resulting in a negative predictive value of 92% and positive predictive value of 33%. D-dimer values did not significantly vary with neoadjuvant chemotherapy or days since transurethral resection. CONCLUSIONS: Approximately 8% of patients had an occult deep vein thrombosis prior to radical cystectomy. D-dimer can provide sensitive diagnostic utility for deep vein thrombosis in the pre-radical cystectomy setting and could help guide use of preoperative lower extremity ultrasound in this high-risk patient population. FAU - Miest, Tanner S AU - Miest TS AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. AD - Department of Urology, UCLA, Los Angeles, CA, United States. AD - VA Health Services Research and Development Fellowship, United States. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. FAU - Thompson, R Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN, United States. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC8490096 COIS- Competing Interests: The authors do not report any competing personal or financial interests related to this work. EDAT- 2021/02/17 06:00 MHDA- 2021/02/17 06:01 PMCR- 2021/09/01 CRDT- 2021/02/16 17:10 PHST- 2021/02/17 06:00 [pubmed] PHST- 2021/02/17 06:01 [medline] PHST- 2021/02/16 17:10 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - cuaj.6852 [pii] AID - cuaj-9-e471 [pii] AID - 10.5489/cuaj.6852 [doi] PST - ppublish SO - Can Urol Assoc J. 2021 Sep;15(9):E471-E475. doi: 10.5489/cuaj.6852. PMID- 33591855 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1563-5244 (Electronic) IS - 0883-0185 (Linking) VI - 40 IP - 5 DP - 2021 TI - Chemokines as the critical factors during bladder cancer progression: an overview. PG - 344-358 LID - 10.1080/08830185.2021.1877287 [doi] AB - Bladder cancer (BCa) is one of the most frequent urogenital malignancies which is mainly observed among men. There are various genetic and environmental risk factors associated with BCa progression. Transurethral endoscopic resection and open ablative surgery are the main treatment options for muscle invasive BCa. BCG therapy is also employed following the endoscopic resection to prevent tumor relapse. The tumor microenvironment is the main interaction site of tumor cells and immune system in which the immune cells are recruited via chemokines and chemokine receptors. In present review we summarized the main chemokines and chemokine receptors which have been associated with histopathological features of BCa patients in the world. This review highlights the chemokines and chemokine receptors as critical markers in early detection and therapeutic purposes among BCa patients and clarifies their molecular functions during BCa progression and metastasis. FAU - Zangouei, Amir Sadra AU - Zangouei AS AD - Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Hamidi, Amir Abbas AU - Hamidi AA AD - Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Rahimi, Hamid Reza AU - Rahimi HR AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Saburi, Ehsan AU - Saburi E AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Mojarrad, Majid AU - Mojarrad M AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Moghbeli, Meysam AU - Moghbeli M AUID- ORCID: 0000-0001-9680-0309 AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. LA - eng PT - Journal Article PT - Review DEP - 20210216 PL - England TA - Int Rev Immunol JT - International reviews of immunology JID - 8712260 RN - 0 (Chemokines) SB - IM MH - Chemokines MH - Disease Progression MH - Humans MH - Male MH - Neoplasm Recurrence, Local MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/therapy OTO - NOTNLM OT - Bladder cancer OT - chemokine OT - diagnosis OT - immune system OT - prognosis EDAT- 2021/02/17 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/02/16 17:09 PHST- 2021/02/17 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/02/16 17:09 [entrez] AID - 10.1080/08830185.2021.1877287 [doi] PST - ppublish SO - Int Rev Immunol. 2021;40(5):344-358. doi: 10.1080/08830185.2021.1877287. Epub 2021 Feb 16. PMID- 33586577 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20241108 IS - 1651-226X (Electronic) IS - 0284-186X (Linking) VI - 60 IP - 6 DP - 2021 Jun TI - Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses. PG - 704-713 LID - 10.1080/0284186X.2021.1886323 [doi] AB - BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) has been studied as a biomarker for cancer prognosis, predicting survival in many tumors. The aim of this umbrella review was to combine the results from all systematic reviews and meta-analyses related to the prognostic role of the NLR in patients with urological tumors. METHODS: A PubMed, Scopus, Embase and Cochrane search was undergone from inception through September 2020 for systematic reviews and meta-analyses investigating the prognostic value of NLR in urological tumors, subdivided into prostate cancer, renal cell carcinoma, urothelial bladder and upper tract carcinomas PROSPERO (CRD42020216310). RESULTS: The results have shown, with a high level of evidence, that an elevated NLR predicts worse overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS) in prostate cancer, worse OS, PFS and RFS in renal cell carcinoma, worse OS, PFS, RFS and cancer-specific survival (CSS) in muscle invasive bladder cancer, worse PFS and RFS in non-muscle invasive bladder cancer, and worse OS, PFS, RFS and CSS in urothelial upper tract carcinoma. CONCLUSION: NLR has a significant prognostic value in urological tumors and should be included in prognostic scores of these cancers. FAU - Mjaess, Georges AU - Mjaess G AUID- ORCID: 0000-0002-8703-4611 AD - Department of Urology, University Clinics of Brussels, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Chebel, Roy AU - Chebel R AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Karam, Aya AU - Karam A AUID- ORCID: 0000-0003-3105-1604 AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Moussa, Ilan AU - Moussa I AD - Department of Urology, University Clinics of Brussels, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Pretot, Dominique AU - Pretot D AD - Department of Urology, University Clinics of Brussels, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Abi Tayeh, Georges AU - Abi Tayeh G AUID- ORCID: 0000-0003-3179-1290 AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Sarkis, Julien AU - Sarkis J AUID- ORCID: 0000-0002-5060-0819 AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Semaan, Albert AU - Semaan A AUID- ORCID: 0000-0001-8915-5970 AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. FAU - Peltier, Alexandre AU - Peltier A AD - Department of Urology, Institut Jules Bordet, Brussels, Belgium. FAU - Aoun, Fouad AU - Aoun F AUID- ORCID: 0000-0002-8291-4302 AD - Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. AD - Department of Urology, Institut Jules Bordet, Brussels, Belgium. FAU - Albisinni, Simone AU - Albisinni S AUID- ORCID: 0000-0001-5529-3064 AD - Department of Urology, University Clinics of Brussels, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Roumeguere, Thierry AU - Roumeguere T AUID- ORCID: 0000-0002-5377-8137 AD - Department of Urology, University Clinics of Brussels, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium. AD - Department of Urology, Institut Jules Bordet, Brussels, Belgium. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210215 PL - Sweden TA - Acta Oncol JT - Acta oncologica (Stockholm, Sweden) JID - 8709065 SB - IM MH - Humans MH - *Kidney Neoplasms MH - Lymphocyte Count MH - Lymphocytes MH - Male MH - Meta-Analysis as Topic MH - Neoplasm Recurrence, Local MH - Neutrophils MH - Prognosis MH - Systematic Reviews as Topic MH - *Urologic Neoplasms OTO - NOTNLM OT - Neutrophil-to-lymphocyte ratio OT - bladder cancer OT - kidney cancer OT - prostate cancer OT - upper tract carcinoma EDAT- 2021/02/16 06:00 MHDA- 2021/08/19 06:00 CRDT- 2021/02/15 08:43 PHST- 2021/02/16 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2021/02/15 08:43 [entrez] AID - 10.1080/0284186X.2021.1886323 [doi] PST - ppublish SO - Acta Oncol. 2021 Jun;60(6):704-713. doi: 10.1080/0284186X.2021.1886323. Epub 2021 Feb 15. PMID- 33584702 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 11 DP - 2020 TI - Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. PG - 615091 LID - 10.3389/fimmu.2020.615091 [doi] LID - 615091 AB - Intravesical Bacillus Calmette-Guerin (BCG) is an effective immunotherapy for non-muscle invasive bladder cancer (NMIBC). However, recurrence and progression remain frequent warranting deeper insights into its mechanism. We herein comprehensively profiled blood and tissues obtained from NMIBC patients before, during and after BCG treatment using cytometry by time-of-flight (CyTOF) and RNA sequencing to identify the key immune subsets crucial for anti-tumor activity. We observed the temporal changes of peripheral immune subsets including NKT cells, central memory CD4(+) T cells, CD8(+) T cells and regulatory T cells (Treg) during the course of BCG. Gene expression analysis revealed enriched immune pathways involving in T cell activation and chemotaxis, as well as a more diversified T cell receptor repertoire in post-BCG tissues. Moreover, tissue multiplexed-immunofluorescence (mIF) showed baseline densities of non-Treg and CD8(+)PD-1(+) T cells were predictive of response and better recurrence-free survival after BCG. Remarkably, post-BCG tissues from responders were found to be infiltrated with more active CD8(+)PD-1(-) T cells and non-Treg CD4(+)FOXP3(-) T cells; but increased exhausted CD8(+)PD-1(+) T cells were found in non-responders. Taken together, we identified predictive biomarkers for response and uncovered the post-treatment expansion of exhausted PD-1(+)CD8(+) T cells as key to BCG resistance, which could potentially be restored by combining with anti-PD-1 immunotherapy. CI - Copyright (c) 2021 Lim, Nguyen, Wasser, Kumar, Lee, Nasir, Chua, Lai, Hazirah, Loh, Khor, Yeong, Lim, Low, Albani, Chong and Chew. FAU - Lim, Chun Jye AU - Lim CJ AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Nguyen, Phuong Hoang Diem AU - Nguyen PHD AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Wasser, Martin AU - Wasser M AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Kumar, Pavanish AU - Kumar P AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Lee, Yun Hua AU - Lee YH AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Nasir, Nurul Jannah Mohamed AU - Nasir NJM AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. AD - Duke-NUS Medical School, Singapore, Singapore. FAU - Chua, Camillus AU - Chua C AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Lai, Liyun AU - Lai L AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Hazirah, Sharifah Nur AU - Hazirah SN AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Loh, Josh Jie Hua AU - Loh JJH AD - Division of Pathology, Singapore General Hospital, Singapore, Singapore. FAU - Khor, Li Yan AU - Khor LY AD - Duke-NUS Medical School, Singapore, Singapore. AD - Division of Pathology, Singapore General Hospital, Singapore, Singapore. FAU - Yeong, Joe AU - Yeong J AD - Division of Pathology, Singapore General Hospital, Singapore, Singapore. AD - Institute of Molecular Cell Biology (IMCB), Agency of Science, Technology and Research (ASTAR), Singapore, Singapore. FAU - Lim, Tony Kiat Hon AU - Lim TKH AD - Duke-NUS Medical School, Singapore, Singapore. AD - Division of Pathology, Singapore General Hospital, Singapore, Singapore. FAU - Low, Alvin Wei Xiang AU - Low AWX AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Albani, Salvatore AU - Albani S AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. FAU - Chong, Tsung Wen AU - Chong TW AD - Duke-NUS Medical School, Singapore, Singapore. AD - Department of Urology, Singapore General Hospital, Singapore, Singapore. FAU - Chew, Valerie AU - Chew V AD - Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210129 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BCG Vaccine) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Receptors, Antigen, T-Cell) SB - IM MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/immunology/therapy MH - Chemotaxis MH - Drug Resistance, Neoplasm MH - Gene Expression Regulation, Neoplastic/drug effects MH - High-Throughput Nucleotide Sequencing MH - Humans MH - Image Cytometry/instrumentation/methods MH - Immune Checkpoint Inhibitors/therapeutic use MH - Immunotherapy MH - *Immunotherapy, Active MH - Lymphocyte Activation MH - Lymphocyte Count MH - Lymphocyte Subsets/drug effects/*immunology MH - Programmed Cell Death 1 Receptor/analysis/antagonists & inhibitors MH - Receptors, Antigen, T-Cell/analysis MH - Single-Cell Analysis MH - T-Lymphocyte Subsets/chemistry/immunology MH - Time Factors MH - Transcriptome MH - Tumor Escape MH - Urinary Bladder Neoplasms/*drug therapy/immunology/therapy PMC - PMC7879685 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Immunotherapy OT - PD-1 OT - biomarkers OT - bladder cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/02/16 06:00 MHDA- 2021/06/29 06:00 PMCR- 2020/01/01 CRDT- 2021/02/15 06:08 PHST- 2020/10/08 00:00 [received] PHST- 2020/12/10 00:00 [accepted] PHST- 2021/02/15 06:08 [entrez] PHST- 2021/02/16 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2020.615091 [doi] PST - epublish SO - Front Immunol. 2021 Jan 29;11:615091. doi: 10.3389/fimmu.2020.615091. eCollection 2020. PMID- 33580627 OWN - NLM STAT- MEDLINE DCOM- 20211129 LR - 20211129 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 IP - 2 DP - 2021 Aug TI - Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. PG - 244-253 LID - 10.1111/bju.15368 [doi] AB - OBJECTIVES: To evaluate the diagnostic performance of fluorescent voided urine cytology (FVUC) using a novel automated detection technology to screen for primary bladder cancer and for surveillance of recurrent bladder tumour. PATIENTS AND METHODS: We created a rapid, objective, automated, and high-throughput detection device for hexylaminolevulinate-mediated FVUC, named the cellular fluorescence analysis unit-II (CFAU-II). Two different cohorts were used in this study: (i) screening test for primary bladder cancer (165 patients with bladder cancer and 52 controls), and (ii) surveillance test for detecting intravesical recurrent tumour (192 patients with treated non-muscle-invasive bladder cancer and 15 with post-nephroureterectomy upper urinary tract cancer). Voided urine samples were subjected to urine analysis, conventional VUC (cVUC), and FVUC. Diagnostic performance was compared between cVUC, FVUC, and a combination of the two. RESULTS: A total of 614 urine samples were successfully collected, processed, and analysed. Comparative analysis of the screening test cohort demonstrated that the overall sensitivity of FVUC (63%, P < 0.001) and combination testing (72%, P < 0.001) was significantly higher than that of cVUC (29%). FVUC was found to be superior in most of the subgroups, especially in low-grade, Ta, and small tumours. Analysis of the surveillance test cohort showed that combination testing achieved a sensitivity of 82% and a negative predictive value of 98%, whereas those of cVUC were 39% and 96%, respectively. According to the pathological finding of recurrent tumours presenting false-negative result in the FVUC, the majority of the overlooked recurrent diseases were Ta low-grade tumours. Logistic regression analysis suggested an association between the risk of false-positive results and high density of urine white blood cells and alkaluria. CONCLUSION: The present findings clearly demonstrate that FVUC using the newly developed automation technology has superior sensitivity to cVUC for both screening for primary bladder cancer and recurrent tumour detection. It is essential to confirm the clinical usefulness of this method via further large-scale studies, in addition to ensuring its affordability and availability. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International Published by John Wiley & Sons Ltd. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AUID- ORCID: 0000-0002-7579-0372 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Ohnishi, Sayuri AU - Ohnishi S AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Oda, Yuki AU - Oda Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AUID- ORCID: 0000-0002-6056-3820 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AUID- ORCID: 0000-0001-9242-7877 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. AD - Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, Japan. FAU - Hirao, Yoshihiko AU - Hirao Y AD - Department of Urology, Osaka Gyoumeikan Hospital, Konohana-ku, Osaka, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210416 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Aminolevulinic Acid/*analogs & derivatives MH - Cytodiagnosis/methods MH - Early Detection of Cancer/*methods MH - Humans MH - Optical Imaging MH - Population Surveillance MH - Prospective Studies MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - 5-aminolevulinic acid OT - bladder cancer OT - fluorescence OT - follow-up OT - hexylaminolevulinate OT - photodynamic diagnosis OT - recurrence OT - screening OT - urine biomarker OT - urine cytology EDAT- 2021/02/14 06:00 MHDA- 2021/11/30 06:00 CRDT- 2021/02/13 05:57 PHST- 2021/02/14 06:00 [pubmed] PHST- 2021/11/30 06:00 [medline] PHST- 2021/02/13 05:57 [entrez] AID - 10.1111/bju.15368 [doi] PST - ppublish SO - BJU Int. 2021 Aug;128(2):244-253. doi: 10.1111/bju.15368. Epub 2021 Apr 16. PMID- 33579627 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20220104 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 8 DP - 2021 Aug TI - The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study. PG - 497.e1-497.e8 LID - S1078-1439(21)00054-5 [pii] LID - 10.1016/j.urolonc.2021.01.028 [doi] AB - BACKGROUND AND OBJECTIVE: The presence of carcinoma in situ (Cis) in association with bladder cancer is associated with a poor prognosis. However, the prognosis associated with the presence of Cis in ureteral margins (CUM) during radical cystectomy has been poorly defined. To assess the prognosis associated with the presence of Cis in ureteral margins in patients with pM0 bladder cancer who have not undergone neoadjuvant chemotherapy. MATERIALS AND METHODS: A retrospective case-control study was conducted between 2001 and 2016 using data from one academic center in France. From 1,450 radical cystectomies, 122 patients (case) who had CUM were matched according to age, sex, pTNM stage and urinary diversion method with a population sample of 122 patients (controls) who did not have Cis in ureteral margins during radical cystectomy. The survival analysis was performed by Kaplan-Meier using a (95%) CI. Multivariate Cox regression analysis was used to test the effect of CUM on cancer-specific survival. Recurrence-free survival was defined as a recurrence of urothelial carcinoma in the upper urinary tract. RESULTS AND LIMITATIONS: The mean follow-up period was 55.43 +/- 39.6 months. The rate of Cis in the bladder in the CUM cases group was evaluated at 11.47%. The median overall and specific survival was inferior in the CUM cases group estimated at 43.3 [35.33-56.93] months, 52.43 [42.16-68.93] months respectively compared to the control group with a significant difference (P= 0.001, P= 0.0039). The cumulative probability of urothelial recurrence-free survival was decreased in the case group compared with the control group (63.9% vs. 92.6%, P = 0.0001). Multivariate analysis shown that urothelial recurrence was associated with CUM [(P <0.001), (HR adjusted =11.31), (95% CI): (3.38-37.77)] and the macroscopic appearance of the ureter (thickened, dilated) [(P= 0.003), (HR adjusted =4.62), (95% CI): (3.31-8.84)]. CONCLUSION: CUM is a poor prognostic factor that impacts cancer-specific survival and Recurrence-free survival. The presence of CUM has been independently associated with a significant increase in the risk of urothelial recurrence, and a decrease in both overall and specific survival. This supports the use of frozen section analysis to complete radical cystectomy without CUM. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Kerroumi, S AU - Kerroumi S AD - Department of urology, EHU Oran, health and environment research laboratory, Faculty de medicine of Oran, university Oran1 Algeria. Electronic address: kerroumi.slimane@univ-oran1.dz. FAU - Neuzillet, Y AU - Neuzillet Y AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Soorojebally, Y AU - Soorojebally Y AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Radulescu, C AU - Radulescu C AD - Department of pathology, hospital Foch, Suresnes. France. FAU - Talhi, R AU - Talhi R AD - Department of statistical epidemiology, faculty of medicine, university Oran1 Algeria. FAU - Taleb, S AU - Taleb S AD - Department of urology, EHU Oran, health and environment research laboratory, Faculty de medicine of Oran, university Oran1 Algeria. FAU - Herve, C J AU - Herve CJ AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Rouanne, M AU - Rouanne M AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Abdou, A AU - Abdou A AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Bosset, P AU - Bosset P AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. FAU - Bazzi, A AU - Bazzi A AD - Department of urology, EHU Oran, health and environment research laboratory, Faculty de medicine of Oran, university Oran1 Algeria. FAU - Yousfi, M J AU - Yousfi MJ AD - Department of urology, EHU Oran, health and environment research laboratory, Faculty de medicine of Oran, university Oran1 Algeria. FAU - Lebret, T AU - Lebret T AD - Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France. LA - eng PT - Journal Article DEP - 20210209 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma in Situ/*pathology MH - Case-Control Studies MH - Cystectomy/*adverse effects MH - Female MH - Follow-Up Studies MH - France/epidemiology MH - Humans MH - Male MH - *Margins of Excision MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/etiology/*pathology MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Ureter/*pathology/surgery MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Cis OT - Radical cystectomy OT - Recurrence-free survival OT - Ureteral margins EDAT- 2021/02/14 06:00 MHDA- 2022/01/05 06:00 CRDT- 2021/02/13 05:39 PHST- 2020/12/02 00:00 [received] PHST- 2021/01/10 00:00 [revised] PHST- 2021/01/25 00:00 [accepted] PHST- 2021/02/14 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] PHST- 2021/02/13 05:39 [entrez] AID - S1078-1439(21)00054-5 [pii] AID - 10.1016/j.urolonc.2021.01.028 [doi] PST - ppublish SO - Urol Oncol. 2021 Aug;39(8):497.e1-497.e8. doi: 10.1016/j.urolonc.2021.01.028. Epub 2021 Feb 9. PMID- 33568346 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20230210 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 27 IP - 9 DP - 2021 May 1 TI - A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). PG - 2435-2441 LID - 10.1158/1078-0432.CCR-20-2409 [doi] AB - PURPOSE: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC) and gemcitabine-cisplatin (GC) are accepted neoadjuvant regimens for muscle-invasive bladder cancer. The aim of this study was to validate the score from a coexpression extrapolation (COXEN) algorithm-generated gene expression model (GEM) as a biomarker in patients undergoing radical cystectomy. PATIENTS AND METHODS: Eligibility included cT2-T4a N0 M0, urothelial bladder cancer, >/= 5 mm of viable tumor, cisplatin eligible, with plan for cystectomy; 237 patients were randomized between ddMVAC, given every 14 days for four cycles, and GC, given every 21 days for four cycles. The primary objective assessed prespecified dichotomous treatment-specific COXEN score as predictive of pT0 rate or /=cT3, metastasis and LVI at first TURBT as factors significantly associated with overall survival (OS) and cancer-specific survival (CSS). Multivariate analysis identified metastasis (hazard ratio (HR) 6.560, p = 0.009) and LVI at first TURBT (HR 9.205, p = 0.003) as significant predictors of CSS. On the other hand, in patients who underwent RC, >/=pT3, presence of G3 and LVI was significantly associated with OS and CSS in univariate analysis. Multivariate analysis identified inclusion of G3 as a significant predictor of OS and CSS. The concordance rate between LVI at first TURBT and RC was 48.0%. Patients with positive results for LVI at first TURBT and RC displayed poorer prognosis than other patients (p < 0.05). (4) Conclusions: We found that the combination of LVI at first TURBT and RC was likely to provide a more significant prognostic factor. FAU - Yoneda, Kei AU - Yoneda K AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-city, Chiba 260-8687, Japan. FAU - Kamiya, Naoto AU - Kamiya N AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Utsumi, Takanobu AU - Utsumi T AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Wakai, Ken AU - Wakai K AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-city, Chiba 260-8687, Japan. FAU - Oka, Ryo AU - Oka R AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Endo, Takumi AU - Endo T AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Yano, Masashi AU - Yano M AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Hiruta, Nobuyuki AU - Hiruta N AD - Department of Surgical Pathology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-city, Chiba 260-8687, Japan. FAU - Suzuki, Hiroyoshi AU - Suzuki H AD - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan. LA - eng GR - 15k11030/Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology/ PT - Journal Article DEP - 20210204 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC7915441 OTO - NOTNLM OT - bladder cancer OT - lymphovascular invasion OT - neoadjuvant chemotherapy OT - radical cystectomy OT - transurethral resection of bladder tumor COIS- The authors declare no conflict of interest. EDAT- 2021/02/10 06:00 MHDA- 2021/02/10 06:01 PMCR- 2021/02/04 CRDT- 2021/02/09 01:03 PHST- 2020/11/19 00:00 [received] PHST- 2021/01/28 00:00 [revised] PHST- 2021/02/02 00:00 [accepted] PHST- 2021/02/09 01:03 [entrez] PHST- 2021/02/10 06:00 [pubmed] PHST- 2021/02/10 06:01 [medline] PHST- 2021/02/04 00:00 [pmc-release] AID - diagnostics11020244 [pii] AID - diagnostics-11-00244 [pii] AID - 10.3390/diagnostics11020244 [doi] PST - epublish SO - Diagnostics (Basel). 2021 Feb 4;11(2):244. doi: 10.3390/diagnostics11020244. PMID- 33552566 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220420 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 73 IP - 4 DP - 2020 TI - Preoperative pyuria predicts the presence of high-grade bladder carcinoma in patients with bladder tumors. PG - 423-436 LID - 10.5173/ceju.2020.0289 [doi] AB - INTRODUCTION: Preoperative identification of high-grade bladder cancer presence can optimize patient management. The aim of this study was to assess the association between preoperative pyuria and the pathological features of bladder cancer. MATERIAL AND METHODS: This retrospective analysis enrolled 943 patients undergoing transurethral resection of a bladder tumor. Patients were divided into two study groups based on the presence of pyuria in preoperative urine analysis, defined as the presence of >5 leukocytes in the high power field. Pyuria status as a potential predictive factor was then confronted with pathological features based on standard microscopic examination of the surgical specimen. RESULTS: Among 943 recruited patients, 294 (31.2%) presented with pyuria. Patients with pyuria were older (71 vs. 68 years, p <0.05), had higher rates of large (>/=3 cm) tumors (37% vs. 26%, p <0.05), and more frequently presented concomitant hematuria (58% vs. 24%, p <0.05). In case of recurrent tumors patients with pyuria more often received intravesical chemotherapy in the past (4.8% vs. 1.4%, p <0.05). Regarding oncological data, patients with pyuria had significantly higher tumor stage and grade. On multivariable analysis pyuria was independently associated with high-grade tumors (OR 1.97, 95% CI 1.45-2.67). Specificity and negative predictive value of pyuria as a biomarker of high-grade tumors were 76% and 68%, respectively. CONCLUSIONS: Preoperative pyuria can be regarded as a predictor of the presence of high-grade bladder carcinoma in patients with bladder tumors. CI - Copyright by Polish Urological Association. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Gajewska, Dominika AU - Gajewska D AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Kaczmarek, Krystian AU - Kaczmarek K AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Lykowski, Marcin AU - Lykowski M AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Sondka-Migdalska, Joanna AU - Sondka-Migdalska J AD - I Department of Urology, Medical University in Lodz, Lodz, Poland. FAU - Borowik, Michal AU - Borowik M AD - Department of Urology, University of Warmia and Mazury, Olsztyn, Poland. FAU - Buraczynski, Pawel AU - Buraczynski P AD - Department of Urology and Urologic Oncology, Medical University of Lublin, Lublin, Poland. FAU - Dziegala, Mateusz AU - Dziegala M AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Przudzik, Maciej AU - Przudzik M AD - Department of Urology, University of Warmia and Mazury, Olsztyn, Poland. FAU - Slojewski, Marcin AU - Slojewski M AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Kryst, Piotr AU - Kryst P AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20201203 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC7848834 OTO - NOTNLM OT - bladder cancer OT - pyuria OT - transurethral resection COIS- The authors declare no conflicts of interest. EDAT- 2021/02/09 06:00 MHDA- 2021/02/09 06:01 PMCR- 2020/01/01 CRDT- 2021/02/08 05:38 PHST- 2020/10/09 00:00 [received] PHST- 2020/11/16 00:00 [revised] PHST- 2020/11/16 00:00 [accepted] PHST- 2021/02/08 05:38 [entrez] PHST- 2021/02/09 06:00 [pubmed] PHST- 2021/02/09 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 0289 [pii] AID - 10.5173/ceju.2020.0289 [doi] PST - ppublish SO - Cent European J Urol. 2020;73(4):423-436. doi: 10.5173/ceju.2020.0289. Epub 2020 Dec 3. PMID- 33551309 OWN - NLM STAT- MEDLINE DCOM- 20211221 LR - 20211221 IS - 0929-6646 (Print) IS - 0929-6646 (Linking) VI - 121 IP - 1 Pt 1 DP - 2022 Jan TI - Outcomes of stratified transurethral resection of bladder tumor: A propensity score-matched analysis. PG - 73-80 LID - S0929-6646(21)00034-6 [pii] LID - 10.1016/j.jfma.2021.01.012 [doi] AB - BACKGROUND/PURPOSE: Several strategies have been reported for improving the integrity of transurethral resection of bladder tumor (TURBT). However, no standard has been established. Stratified TURBT (SR) is one of protocols for TURBT, wherein exophytic tumors are first resected and retrieved, and tumor bases are then resected. In this study, we aimed to evaluate the outcomes of SR in patients with nonmuscle invasive bladder cancer (NMIBC). METHODS: From January 2012 to December 2017, patients newly diagnosed as having NMIBC with a follow-up period of more than 2 years were enrolled and categorized into SR and conventional TURBT (CR) groups. Propensity score matching at a 2:1 ratio was performed. Outcomes were the detrusor muscle sampling rate, recurrence-free survival (RFS), and progression-free survival (PFS). RESULTS: In total, 205 patients were included in our study. The detrusor muscle sampling rate was higher in the SR group (P = 0.043). After propensity score matching, 162 patients were selected for outcome analysis, with 108 and 54 patients undergoing SR and CR, respectively. Compared with the CR group, the SR group showed a lower recurrence rate (P = 0.015) and better RFS in univariate (P = 0.010) and multivariate (P = 0.006) Cox proportional hazards regression. Progression rate and PFS were not significantly different between the two groups. CONCLUSION: SR results in a higher detrusor muscle sampling rate and better disease outcomes. Our findings suggest that SR is a promising strategy for TURBT in patients with NMIBC. CI - Copyright (c) 2021 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. FAU - Huang, Wei-Lun AU - Huang WL AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. FAU - Huang, Chao-Yuan AU - Huang CY AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. FAU - Huang, Kuo-How AU - Huang KH AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. FAU - Pu, Yeong-Shiau AU - Pu YS AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. FAU - Chang, Hong-Chiang AU - Chang HC AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. FAU - Chow, Po-Ming AU - Chow PM AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. Electronic address: meow1812@gmail.com. LA - eng PT - Journal Article DEP - 20210205 PL - Singapore TA - J Formos Med Assoc JT - Journal of the Formosan Medical Association = Taiwan yi zhi JID - 9214933 SB - IM MH - Cystectomy MH - Humans MH - Progression-Free Survival MH - Propensity Score MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - Bladder tumors OT - Cystoscopic surgery OT - Cystoscopy OT - Recurrence COIS- Declarations of competing interest The authors have no conflicts of interest relevant to this article. EDAT- 2021/02/09 06:00 MHDA- 2021/12/22 06:00 CRDT- 2021/02/08 05:30 PHST- 2020/08/29 00:00 [received] PHST- 2020/12/01 00:00 [revised] PHST- 2021/01/13 00:00 [accepted] PHST- 2021/02/09 06:00 [pubmed] PHST- 2021/12/22 06:00 [medline] PHST- 2021/02/08 05:30 [entrez] AID - S0929-6646(21)00034-6 [pii] AID - 10.1016/j.jfma.2021.01.012 [doi] PST - ppublish SO - J Formos Med Assoc. 2022 Jan;121(1 Pt 1):73-80. doi: 10.1016/j.jfma.2021.01.012. Epub 2021 Feb 5. PMID- 33542658 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220420 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 13 DP - 2021 TI - Clinical Value of Postoperative Neutrophil-to-Lymphocyte Ratio Change as a Detection Marker of Bladder Cancer Recurrence. PG - 849-860 LID - 10.2147/CMAR.S289986 [doi] AB - PURPOSE: This study investigated the clinical significance of postoperative neutrophil-to-lymphocyte ratio (NLR) changes in bladder cancer recurrence. PATIENTS AND METHODS: For evaluating the predictive value of postoperative dynamic change of NLR, a retrospective cohort study was performed to analyze 213 patients with bladder cancer who underwent surgical treatment from January 2013 to December 2019 at the Affiliated Tumor Hospital of Guangxi Medical University. Baseline characteristics and recurrence-free survival (RFS) were statistically compared, and a multivariate analysis was used to identify prognostic factors. RESULTS: Compared with preoperative NLR levels, postoperative decreased NLR in 130 patients and postoperative increased NLR in 83 patients were detected. The 1-, 3- and 5-year RFS rates were 88.0%, 75.4% and 75.4% in the decreased postoperative NLR group, respectively, and 51.2%, 25.8% and 16.1% in the increased postoperative NLR group, respectively (P < 0.05). Kaplan-Meier curves showed that the cumulative DFS rate in the increased group was significantly lower than that in the decreased group (P < 0.05). The preoperative NLR showed significant difference with postoperative NLR in the total cohort, high-grade non-muscle-invasive bladder cancer (HG-NMIBC) and muscle-invasive bladder cancer (MIBC) group, while there was no significant difference between postoperative NLR and NLR of recurrence or last follow-up. Multivariate analysis suggested that postoperative-preoperative NLR was an independent predictor for RFS (HR=6.206, 95% CI: 3.826-10.067, P < 0.001) in the total cohort, RFS (HR=9.373, 95% CI: 2.724-32.245, P < 0.001) in the LG-NMIBC group, RFS rates (HR=6.873, 95% CI: 2.486-18.999, P < 0.001) in the HG-NMIBC group and RFS rates (HR=6.109, 95% CI: 2.847-13.109, P < 0.001) in the MIBC group. CONCLUSION: The dynamic change of postoperative NLR is a potential marker for the early detection of bladder cancer recurrence. Patients with increased NLR after surgery tend to have higher risk of recurrence. CI - (c) 2021 Zhang et al. FAU - Zhang, Qingyun AU - Zhang Q AD - Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. AD - Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. FAU - Lai, Qinqiao AU - Lai Q AD - Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. FAU - Wang, Shan AU - Wang S AD - Department of Research, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. FAU - Meng, Qinggui AU - Meng Q AD - Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. FAU - Mo, Zengnan AU - Mo Z AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. AD - Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, People's Republic of China. LA - eng PT - Journal Article DEP - 20210129 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7853415 OTO - NOTNLM OT - NLR dynamic change OT - bladder cancer OT - prognosis OT - recurrence COIS- All of the authors declare that they have no conflicts of interest for this work. EDAT- 2021/02/06 06:00 MHDA- 2021/02/06 06:01 PMCR- 2021/01/29 CRDT- 2021/02/05 05:58 PHST- 2020/11/10 00:00 [received] PHST- 2021/01/13 00:00 [accepted] PHST- 2021/02/05 05:58 [entrez] PHST- 2021/02/06 06:00 [pubmed] PHST- 2021/02/06 06:01 [medline] PHST- 2021/01/29 00:00 [pmc-release] AID - 289986 [pii] AID - 10.2147/CMAR.S289986 [doi] PST - epublish SO - Cancer Manag Res. 2021 Jan 29;13:849-860. doi: 10.2147/CMAR.S289986. eCollection 2021. PMID- 33539743 OWN - NLM STAT- MEDLINE DCOM- 20210218 LR - 20250530 IS - 1474-5488 (Electronic) IS - 1470-2045 (Print) IS - 1470-2045 (Linking) VI - 22 IP - 2 DP - 2021 Feb TI - Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. PG - 246-255 LID - S1470-2045(20)30607-0 [pii] LID - 10.1016/S1470-2045(20)30607-0 [doi] AB - BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6.5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term outcomes of these schedules in several cohort studies and case series suggest that response, survival, and toxicity are similar, but no direct comparison has been published. The present study aimed to assess the non-inferiority of 55 Gy in 20 fractions to 64 Gy in 32 fractions in terms of invasive locoregional control and late toxicity in patients with locally advanced bladder cancer. METHODS: We did a meta-analysis of individual patient data from patients (age >/=18 years) with locally advanced bladder cancer (T1G3 [high-grade non-muscle invasive] or T2-T4, N0M0) enrolled in two multicentre, randomised, controlled, phase 3 trials done in the UK: BC2001 (NCT00024349; assessing addition of chemotherapy to radiotherapy) and BCON (NCT00033436; assessing hypoxia-modifying therapy combined with radiotherapy). In each trial, the fractionation schedule was chosen according to local standard practice. Co-primary endpoints were invasive locoregional control (non-inferiority margin hazard ratio [HR]=1.25); and late bladder or rectum toxicity, assessed with the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic tool (non-inferiority margin for absolute risk difference [RD]=10%). If non-inferiority was met for invasive locoregional control, superiority could be considered if the 95% CI for the treatment effect excluded the null effect (HR=1). One-stage individual patient data meta-analysis models for the time-to-event and binary outcomes were used, accounting for trial differences, within-centre correlation, randomised treatment received, baseline variable imbalances, and potential confounding from relevant prognostic factors. FINDINGS: 782 patients with known fractionation schedules (456 from the BC2001 trial and 326 from the BCON trial; 376 (48%) received 64 Gy in 32 fractions and 406 (52%) received 55 Gy in 20 fractions) were included in our meta-analysis. Median follow-up was 120 months (IQR 99-159). Patients who received 55 Gy in 20 fractions had a lower risk of invasive locoregional recurrence than those who received 64 Gy in 32 fractions (adjusted HR 0.71 [95% CI 0.52-0.96]). Both schedules had similar toxicity profiles (adjusted RD -3.37% [95% CI -11.85 to 5.10]). INTERPRETATION: A hypofractionated schedule of 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard to both invasive locoregional control and toxicity, and is superior with regard to invasive locoregional control. 55 Gy in 20 fractions should be adopted as a standard of care for bladder preservation in patients with locally advanced bladder cancer. FUNDING: Cancer Research UK. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Choudhury, Ananya AU - Choudhury A AD - Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: ananya.choudhury@nhs.net. FAU - Porta, Nuria AU - Porta N AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Hall, Emma AU - Hall E AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Song, Yee Pei AU - Song YP AD - Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. FAU - Owen, Ruth AU - Owen R AD - Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK. FAU - MacKay, Ranald AU - MacKay R AD - Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK. FAU - West, Catharine M L AU - West CML AD - Division of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Lewis, Rebecca AU - Lewis R AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. FAU - Hussain, Syed A AU - Hussain SA AD - Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. FAU - James, Nicholas D AU - James ND AD - Radiotherapy and Imaging Division, The Institute of Cancer Research, London, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Huddart, Robert AU - Huddart R AD - Radiotherapy and Imaging Division, The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. FAU - Hoskin, Peter AU - Hoskin P AD - Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Mount Vernon Cancer Centre, Northwood, UK. CN - BC2001 and BCON investigators LA - eng SI - ClinicalTrials.gov/NCT00024349 SI - ClinicalTrials.gov/NCT00033436 GR - C1491/A25351/CRUK_/Cancer Research UK/United Kingdom GR - DH_/Department of Health/United Kingdom GR - C2094/A11365/CRUK_/Cancer Research UK/United Kingdom GR - 25351/CRUK_/Cancer Research UK/United Kingdom GR - C1467/A7286/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 SB - IM CIN - Strahlenther Onkol. 2021 Sep;197(9):854-856. doi: 10.1007/s00066-021-01804-2. PMID: 34228169 CIN - Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):113-116. doi: 10.1016/j.ijrobp.2021.04.048. PMID: 34348106 CIN - Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1097-1100. doi: 10.1016/j.ijrobp.2021.09.021. PMID: 34793725 MH - Disease-Free Survival MH - *Dose Fractionation, Radiation MH - Humans MH - Neoplasm Recurrence, Local/epidemiology/pathology/*radiotherapy MH - Radiation Dose Hypofractionation/*standards MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy PMC - PMC7851111 EDAT- 2021/02/05 06:00 MHDA- 2021/02/20 06:00 PMCR- 2021/02/01 CRDT- 2021/02/04 20:11 PHST- 2020/07/08 00:00 [received] PHST- 2020/08/28 00:00 [revised] PHST- 2020/09/29 00:00 [accepted] PHST- 2021/02/04 20:11 [entrez] PHST- 2021/02/05 06:00 [pubmed] PHST- 2021/02/20 06:00 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - S1470-2045(20)30607-0 [pii] AID - 10.1016/S1470-2045(20)30607-0 [doi] PST - ppublish SO - Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0. PMID- 33535799 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20220414 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 205 IP - 6 DP - 2021 Jun TI - Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. PG - 1605-1611 LID - 10.1097/JU.0000000000001602 [doi] AB - PURPOSE: Concern for discordance between clinical staging and final pathology drives current management of patients deemed appropriate candidates for radical cystectomy. Therefore, we set out to prospectively investigate reliability and shortcomings of cystoscopic evaluation in radical cystectomy candidates. MATERIALS AND METHODS: Patients undergoing radical cystectomy for urothelial carcinoma were enrolled in a prospective single-arm study to evaluate reliability of Systematic Endoscopic Evaluation in predicting pT0 urothelial carcinoma (NCT02968732). Systematic Endoscopic Evaluation consisted of cystoscopy and tissue sampling at the time of radical cystectomy. Systematic Endoscopic Evaluation results were compared to radical cystectomy pathology. The primary end point was the negative predictive value of Systematic Endoscopic Evaluation findings in predicting radical cystectomy pathology. RESULTS: A total of 61 patients underwent Systematic Endoscopic Evaluation and radical cystectomy. Indications included muscle invasive bladder cancer in 42 (68.9%) and high risk nonmuscle invasive bladder cancer in 19 (31.1%). In all, 38 (62.3%, 90.5% of patients with muscle invasive bladder cancer) received neoadjuvant chemotherapy. On Systematic Endoscopic Evaluation, 31 (50.8%) patients demonstrated no visual nor biopsy-based evidence of disease (seeT0), yet 16/31 (51.6%) harbored residual disease (>pT0), including 8 (8/31, 25.8%) with residual >/=pT2 disease upon radical cystectomy. The negative predictive value of Systematic Endoscopic Evaluation predicting a pT0 bladder was 48.4% (CI 30.2-66.9), which was below our prespecified hypothesis. Therefore, the trial was stopped for futility. CONCLUSIONS: Approximately 1 of 4 patients with seeT0 at the time of radical cystectomy harbored residual muscle invasive bladder cancer. These prospective data definitively confirm major limitations of endoscopic assessment for pT0 bladder cancer. Future work should focus on novel imaging and biomarker strategies to optimize evaluations before radical cystectomy for improved decision making regarding bladder preservation. FAU - Zibelman, Matthew AU - Zibelman M AD - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Asghar, Aeen M AU - Asghar AM AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Parker, Daniel C AU - Parker DC AD - Department of Urology, University of Oklahoma, Oklahoma City, Oklahoma. FAU - O'Neill, John AU - O'Neill J AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Wei, Shuanzeng AU - Wei S AD - Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Greenberg, Richard E AU - Greenberg RE AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Smaldone, Marc C AU - Smaldone MC AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Chen, David Y T AU - Chen DYT AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Viterbo, Rosalia AU - Viterbo R AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Uzzo, Robert G AU - Uzzo RG AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Bloom, Evan AU - Bloom E AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Kokate, Rutika AU - Kokate R AD - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Geynisman, Daniel M AU - Geynisman DM AD - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Ghatalia, Pooja AU - Ghatalia P AD - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Deng, Mengying AU - Deng M AD - Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Ross, Eric A AU - Ross EA AD - Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Plimack, Elizabeth AU - Plimack E AD - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Abbosh, Philip H AU - Abbosh PH AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Kutikov, Alexander AU - Kutikov A AD - Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. LA - eng GR - P30 CA006927/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210204 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Cystectomy MH - *Cystoscopy MH - Female MH - Humans MH - Male MH - Neoplasm Staging MH - Predictive Value of Tests MH - Prospective Studies MH - Reproducibility of Results MH - Specimen Handling MH - Urinary Bladder Neoplasms/*pathology/surgery PMC - PMC9006869 MID - NIHMS1784565 OTO - NOTNLM OT - cystectomy OT - cystoscopy OT - neoadjuvant therapy OT - urinary bladder neoplasms EDAT- 2021/02/05 06:00 MHDA- 2021/07/16 06:00 PMCR- 2022/04/13 CRDT- 2021/02/04 05:31 PHST- 2021/02/05 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2021/02/04 05:31 [entrez] PHST- 2022/04/13 00:00 [pmc-release] AID - 10.1097/JU.0000000000001602 [doi] PST - ppublish SO - J Urol. 2021 Jun;205(6):1605-1611. doi: 10.1097/JU.0000000000001602. Epub 2021 Feb 4. PMID- 33535616 OWN - NLM STAT- MEDLINE DCOM- 20210913 LR - 20240806 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 3 DP - 2021 Feb 1 TI - A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guerin Therapy. LID - 10.3390/ijms22031450 [doi] LID - 1450 AB - Non-muscle-invasive bladder cancer (NMIBC) is clinically heterogeneous; thus, many patients fail to respond to treatment and relapse. Here, we identified a molecular signature that is both prognostic and predictive for NMIBC heterogeneity and responses to Bacillus Calmette-Guerin (BCG) therapy. Transcriptomic profiling of 948 NMIBC patients identified a signature-based subtype predictor, MSP888, along with three distinct molecular subtypes: DP.BCG+ (related to progression and response to BCG treatment), REC.BCG+ (related to recurrence and response to BCG treatment), and EP (equivocal prognosis). Patients with the DP.BCG+ subtype showed worse progression-free survival but responded to BCG treatment, whereas those with the REC.BCG+ subtype showed worse recurrence-free survival but responded to BCG treatment. Multivariate analyses revealed that MSP888 showed independent clinical utility for predicting NMIBC prognosis (each p = 0.001 for progression and recurrence, respectively). Comparative analysis of this classifier and previously established molecular subtypes (i.e., Lund taxonomy and UROMOL class) revealed that a great proportion of patients were similar between subtypes; however, the MSP888 predictor better differentiated biological activity or responsiveness to BCG treatment. Our data increase our understanding of the mechanisms underlying the poor prognosis of NMIBC and the effectiveness of BCG therapy, which should improve clinical practice and complement other diagnostic tools. FAU - Kim, Seon-Kyu AU - Kim SK AUID- ORCID: 0000-0002-4176-5187 AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. AD - Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Korea. FAU - Park, Seong-Hwan AU - Park SH AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. AD - Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Korea. FAU - Kim, Yeong Uk AU - Kim YU AD - Department of Urology, College of Medicine, Yeungnam University, Daegu 38541, Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. FAU - Piao, Xuan-Mei AU - Piao XM AUID- ORCID: 0000-0001-6847-7743 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. FAU - Kim, Kyeong AU - Kim K AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Lee, Hee Youn AU - Lee HY AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Seo, Sung Pil AU - Seo SP AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food and Nutrition, College of Biotechnology & Natural Resource, Chung-Ang University, Anseong 06974, Korea. FAU - Choi, Yung Hyun AU - Choi YH AUID- ORCID: 0000-0002-1454-3124 AD - Department of Urology, Personalized Tumor Engineering Research Center, Chungbuk National University College of Medicine, Cheongju 28644, Korea. FAU - Kim, Wun-Jae AU - Kim WJ AUID- ORCID: 0000-0002-8060-8926 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. FAU - Kim, Seon-Young AU - Kim SY AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. AD - Korea Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. FAU - Yun, Seok Joong AU - Yun SJ AUID- ORCID: 0000-0001-7737-4746 AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea. LA - eng GR - 2014M3C9A306855423/National Research Foundation of Korea/ GR - 2020R1F1A1068488/National Research Foundation of Korea/ GR - 2020R1I1A3062508/National Research Foundation of Korea/ GR - AG200904005 and AG200902001/Osong Medical Innovation Foundation, funded by Chungcheongbuk-do/ PT - Journal Article DEP - 20210201 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - *Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Transcriptome MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/*immunology MH - Young Adult PMC - PMC7867154 OTO - NOTNLM OT - BCG OT - gene signature OT - molecular subtypes OT - non-muscle-invasive bladder cancer OT - prognosis COIS- The authors declare no conflict of interest. EDAT- 2021/02/05 06:00 MHDA- 2021/09/14 06:00 PMCR- 2021/02/01 CRDT- 2021/02/04 01:01 PHST- 2021/01/09 00:00 [received] PHST- 2021/01/26 00:00 [revised] PHST- 2021/01/28 00:00 [accepted] PHST- 2021/02/04 01:01 [entrez] PHST- 2021/02/05 06:00 [pubmed] PHST- 2021/09/14 06:00 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - ijms22031450 [pii] AID - ijms-22-01450 [pii] AID - 10.3390/ijms22031450 [doi] PST - epublish SO - Int J Mol Sci. 2021 Feb 1;22(3):1450. doi: 10.3390/ijms22031450. PMID- 33525423 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210316 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 11 IP - 2 DP - 2021 Jan 28 TI - Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method. LID - 10.3390/diagnostics11020185 [doi] LID - 185 AB - Clinical evidence regarding risk reduction of repeated bladder recurrence after initial photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) is still limited in patients with non-muscle-invasive bladder cancer (NMIBC). We analyzed patients with primary NMIBC undergoing TURBT without any adjuvant treatment to compare the risk of cumulative recurrence between the conventional white-light (WL)-TURBT and PDD-TURBT. Out of 430 patients diagnosed with primary NMIBC from 2010 to 2019, 40 undergoing WL-TURBT and 60 undergoing PDD-TURBT were eligible. Multivariate Cox regression analysis for time to the first recurrence demonstrated that PDD assistance was an independent prognostic factor with better outcome (p = 0.038, hazard ratio = 0.39, and 95% confidence interval 0.16-0.95). While no patient experienced more than one recurrence within 1000 postoperative days in the PDD-TURBT group, five out of 40 patients treated by WL-TURBT experienced repeated recurrence. The comparison of cumulative incidence per 10,000 person-days between the two groups revealed that PDD assistance decreased by 6.6 recurrences per 10,000 person-days (exact p = 0.011; incidence rate ratio 0.37, Clopper-Pearson confidence interval 0.15-0.82). This is the first study addressing PDD assistance-induced risk reduction of repeated bladder recurrence using the person-time method. Our findings could support clinical decision making, especially on adjuvant therapy after TURBT. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Nishimura, Nobutaka AU - Nishimura N AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Fujii, Tomomi AU - Fujii T AUID- ORCID: 0000-0002-7207-4127 AD - Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AUID- ORCID: 0000-0001-7142-5901 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Prostate Brachytherapy Nara Medical University, Kashihara, Nara 634-8522, Japan. FAU - Hirao, Yoshihiko AU - Hirao Y AD - Department of Urology, Osaka Gyoumeikan Hospital, Konohana-ku, Osaka 554-0012, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan. LA - eng PT - Journal Article DEP - 20210128 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC7911613 OTO - NOTNLM OT - 5-aminolevulinic acid OT - bladder cancer OT - fluorescence OT - person-time method OT - photodynamic diagnosis OT - prognosis OT - repeated recurrence OT - transurethral resection OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2021/02/03 06:00 MHDA- 2021/02/03 06:01 PMCR- 2021/01/28 CRDT- 2021/02/02 01:03 PHST- 2021/01/01 00:00 [received] PHST- 2021/01/20 00:00 [revised] PHST- 2021/01/26 00:00 [accepted] PHST- 2021/02/02 01:03 [entrez] PHST- 2021/02/03 06:00 [pubmed] PHST- 2021/02/03 06:01 [medline] PHST- 2021/01/28 00:00 [pmc-release] AID - diagnostics11020185 [pii] AID - diagnostics-11-00185 [pii] AID - 10.3390/diagnostics11020185 [doi] PST - epublish SO - Diagnostics (Basel). 2021 Jan 28;11(2):185. doi: 10.3390/diagnostics11020185. PMID- 33502235 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20210715 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 205 IP - 6 DP - 2021 Jun TI - Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer. PG - 1622-1628 LID - 10.1097/JU.0000000000001630 [doi] AB - PURPOSE: T1 bladder cancer is characterized by high recurrence and aggressive progression. Muscularis mucosae invasion may be a prognostic factor for progression, but the limitations of conventional transurethral resection of bladder tumors make diagnosis difficult. We correlated degree of invasion with oncologic outcome and evaluated the utility of pathological diagnosis following en bloc resection of bladder tumors. MATERIALS AND METHODS: We retrospectively analyzed the records of 123 consecutive patients diagnosed with pT1 bladder cancer between November 2013 and December 2018. Transurethral resection was conducted in 91 patients, and en bloc resection in 32 patients. All specimens were analyzed for invasion depth and pT1 substaging (T1a/b: invasion above or into/beyond muscularis mucosae, pT1m/e: microinvasive or extensively invasive). Primary end points were prognostic values of pT1 substaging and invasion depth. The secondary end point was the pathological diagnostic utility of en bloc resection. RESULTS: Median followup was 23 months. Three-year progression-free survival rate differed significantly depending on muscularis mucosae invasion (pT1a: 97.3%, pT1b: 72.8%; p=0.003) and invasion depth from basal membrane (<2 mm: 90.6%, >/=2 mm: 77.9%; p=0.03). Multivariate analysis showed that sessile tumor and invasion depth from basal membrane >/=2 mm were independent prognostic factors for progression. Diagnostic rates for pT1a/b and invasion depth were 77.6% and 85.9%, respectively, with transurethral resection, but 100% and 100% with en bloc resection (p=0.01 and p=0.03). CONCLUSIONS: Vertical lamina propria invasion is predictive of progression in T1 bladder cancer, underlining the importance of accurately diagnosing the degree of vertical lamina propria invasion with en bloc resection. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AD - Department of Urology, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan. AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan. AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Yorozu, Takashi AU - Yorozu T AD - Department of Pathology, The Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Obayashi, Koki AU - Obayashi K AD - Department of Urology, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan. AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210127 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Cystectomy/*methods MH - Disease Progression MH - Female MH - Humans MH - Male MH - Mucous Membrane/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Predictive Value of Tests MH - Retrospective Studies MH - Urethra MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - neoplasm staging OT - urinary bladder neoplasms OT - urologic surgical procedures EDAT- 2021/01/28 06:00 MHDA- 2021/07/16 06:00 CRDT- 2021/01/27 12:13 PHST- 2021/01/28 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2021/01/27 12:13 [entrez] AID - 10.1097/JU.0000000000001630 [doi] PST - ppublish SO - J Urol. 2021 Jun;205(6):1622-1628. doi: 10.1097/JU.0000000000001630. Epub 2021 Jan 27. PMID- 33498535 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210218 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 3 DP - 2021 Jan 20 TI - Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. LID - 10.3390/cancers13030377 [doi] LID - 377 AB - BACKGROUND: The recurrence rate of non-muscle invasive bladder cancer (NMIBC) is high, despite intravesical treatments. Importantly, patients are frequently unfit or unwilling to undergo a recommended radical cystectomy when standard intravesical treatments fail, due to the substantial risk of morbidity and mortality. For these patients, radiofrequency-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results. We aim to determine treatment outcomes and assess the effect of (ablative) dose. METHODS: 299 intensively pretreated patients treated with RF-CHT were included in safety analysis. Of these, 274 patients who fulfilled induction treatments were included in efficacy analysis. Six-month complete response (CR) and durable response were reported for (concomitant) carcinoma in situ (CIS) patients and recurrence-free survival (RFS) for papillary patients. RESULTS: For CIS, six-month CR-rate was 56.0%; and durable response rates were 79.7%, 66.5%, and 40.3% at one-, two- and five-year, respectively. RFS rates for papillary patients were 77.9%, 57.5%, and 37.2%, respectively. Patients treated with ablative dose are less likely to develop recurrence (adjusted Hazard Ratio 0.54, p = 0.01), compared to adjuvant dose. CONCLUSIONS: RF-CHT is effective in NMIBC patients in whom standard intravesical treatments have failed and should be considered in patients who are unwilling or unfit to undergo radical cystectomy. Patients with CIS or residual papillary tumor at baseline benefit from ablative dose. FAU - Brummelhuis, Iris S G AU - Brummelhuis ISG AD - Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. FAU - Wimper, Yvonne AU - Wimper Y AD - Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. FAU - Witjes-van Os, Hilde G J M AU - Witjes-van Os HGJM AD - Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. FAU - Arends, Tom J H AU - Arends TJH AD - Department of Urology, Meander Medical Centre Amersfoort, 3813 TZ Amersfoort, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AUID- ORCID: 0000-0002-8839-8601 AD - Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20210120 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7864165 OTO - NOTNLM OT - NMIBC OT - RITE OT - Synergo OT - bladder cancer OT - chemohyperthermia OT - chemosensitization OT - epirubicin OT - hyperthermia OT - mitomycin-C COIS- J.A.W. receives honoraria as advisor and/or for lecturing for Tocagen, Roche, Sanofi, MSD, BMS, Ipsen, Nucleix Ltd. Israel, Astellas, OncoDiag, Janssen and BeiGene: none of these firms have a relation to data of this paper. The other authors declare no conflict of interest. EDAT- 2021/01/28 06:00 MHDA- 2021/01/28 06:01 PMCR- 2021/01/20 CRDT- 2021/01/27 01:06 PHST- 2020/11/30 00:00 [received] PHST- 2021/01/05 00:00 [revised] PHST- 2021/01/13 00:00 [accepted] PHST- 2021/01/27 01:06 [entrez] PHST- 2021/01/28 06:00 [pubmed] PHST- 2021/01/28 06:01 [medline] PHST- 2021/01/20 00:00 [pmc-release] AID - cancers13030377 [pii] AID - cancers-13-00377 [pii] AID - 10.3390/cancers13030377 [doi] PST - epublish SO - Cancers (Basel). 2021 Jan 20;13(3):377. doi: 10.3390/cancers13030377. PMID- 33496841 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20220218 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 9 DP - 2021 Sep TI - Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. PG - 3345-3352 LID - 10.1007/s00345-020-03586-1 [doi] AB - PURPOSE: To investigate the prognostic value of preoperative serum albumin to globulin ratio (AGR) in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of bladder tumor (TURB) with or without intravesical therapy (IVT). MATERIALS AND METHODS: We retrospectively reviewed 1,096 consecutive patients with NMIBC. Levels of albumin and globulin were obtained before TURB and used to calculate the preoperative AGR level. Multivariable Cox regression analyses were performed to assess the prognostic effect of preoperative AGR on oncologic outcomes. Subgroup analyses were performed in patients based on the European Association of Urology (EAU) risk groups for NMIBC. RESULTS: Low AGR levels were observed in 389 (35.5%) patients. The median follow-up was 63.7 months (IQR 25.3-111). On multivariable Cox regression analysis, low AGR was associated with increased risk of progression to muscle-invasive BCa (MIBC) (HR 1.81, 95% CI 1.22-2.68, P = 0.003). The addition of AGR only minimally improved the discrimination ability of a base model that included established clinicopathologic features (C-index = 0.7354 vs. C-index = 0.7162). Low preoperative AGR was not significantly associated with the risk of disease recurrence (P = 0.31). In subgroup analyses based on patients' EAU risk groups, low preoperative AGR was not associated with recurrence-free survival (RFS) (P = 0.59) or progression-free survival (PFS) (P = 0.22) in any of the risk groups. Additionally, in patients treated with Bacillus Calmette-Guerin (BCG) for intermediate- or high-risk NMIBC, low AGR failed to predict disease recurrence or progression. CONCLUSION: Preoperative serum AGR levels independently predicted the risk of disease progression in patients with NMIBC. However, it was not found to be associated with either RFS or PFS in NMIBC patients based on their EAU risk group. This marker seems to have a limited role in NMIBC at the present time. However, further research is needed to investigate this marker in combination with other systemic inflammatory markers to help improve prediction in this heterogeneous group of patients. CI - (c) 2021. The Author(s). FAU - Quhal, Fahad AU - Quhal F AUID- ORCID: 0000-0002-8163-6953 AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital of Tours, Tours, France. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada. FAU - Roupret, Morgan AU - Roupret M AD - Predictive onco-uro, AP-HP, Urology Hopital Pitie-Salpetriere, Sorbonne Universite, GRC n degrees 5, 75013, Paris, France. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac. AD - European Association of Urology Research Foundation, Arnhem, Netherlands. shahrokh.shariat@meduniwien.ac. AD - Karl Landsteiner Institute, Wahringer Gurtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac. LA - eng PT - Journal Article DEP - 20210126 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Serum Albumin) RN - 0 (Serum Globulins) SB - IM MH - Aged MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Preoperative Period MH - Prognosis MH - Retrospective Studies MH - Serum Albumin/*analysis MH - Serum Globulins/*analysis MH - Urethra MH - Urinary Bladder Neoplasms/*blood/pathology/*surgery PMC - PMC8510920 OTO - NOTNLM OT - AGR OT - Albumin OT - BCG OT - Bladder cancer OT - Globulin OT - Non-muscle-invasive OT - Progression COIS- The authors declare that they have no conflict of interest. EDAT- 2021/01/27 06:00 MHDA- 2022/02/01 06:00 PMCR- 2021/01/26 CRDT- 2021/01/26 12:11 PHST- 2020/09/13 00:00 [received] PHST- 2020/12/29 00:00 [accepted] PHST- 2021/01/27 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/01/26 12:11 [entrez] PHST- 2021/01/26 00:00 [pmc-release] AID - 10.1007/s00345-020-03586-1 [pii] AID - 3586 [pii] AID - 10.1007/s00345-020-03586-1 [doi] PST - ppublish SO - World J Urol. 2021 Sep;39(9):3345-3352. doi: 10.1007/s00345-020-03586-1. Epub 2021 Jan 26. PMID- 33488094 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220420 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 14 DP - 2021 TI - Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. PG - 315-324 LID - 10.2147/OTT.S242248 [doi] AB - PURPOSE: The Plasminogen Activation System (PAS) plays a role in tumor growth, invasion and metastasis and has been associated with oncological outcomes in urinary bladder carcinoma (UBC). The use of the different components of this system as molecular markers could improve our understanding of the heterogeneous behavior of UBC and might enable earlier disease detection, individual risk stratification, more accurate outcome prediction and be a rationale for new targeted therapies. METHODS: A comprehensive literature search including relevant articles up to October 2020 was performed using the MEDLINE/PubMed database. RESULTS: The components of the PAS axis are involved in tumor progression through their signaling processes during angiogenesis, cell migration, metastasis and adhesion. The body of evidence shows an association of PAS component overexpression with adverse pathological features and clinical outcome in UBC. Overexpressed PAS components correlate with a higher pathological tumor grade and advanced tumor stage. In non-muscle-invasive bladder cancer (NMIBC), the PAS components were associated with disease outcome while in muscle-invasive bladder cancer (MIBC), it was associated with disease outcome and pathological features. Possible therapeutic approaches in the PAS for the treatment of UBC have only been sparsely investigated in in vitro and in vivo studies. Intravesical plasminogen activator inhibitor 1 (PAI-1) instillation in animal models yielded interesting results and warrant further exploration in Phase II studies. CONCLUSION: The overexpression of PAS components in UBC tumor tissue is associated with adverse pathological features and worse oncological outcomes. These findings are mainly based on preclinical studies and retrospective series, which requires further prospective studies to translate the PAS into clinically useful biomarkers and therapeutic targets. CI - (c) 2021 Grossmann et al. FAU - Grossmann, Nico C AU - Grossmann NC AUID- ORCID: 0000-0001-8698-6461 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Schuettfort, Victor M AU - Schuettfort VM AUID- ORCID: 0000-0002-7114-0508 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Hospital of Tours, Tours, France. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Quhal, Fahad AU - Quhal F AUID- ORCID: 0000-0002-8163-6953 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Mostafaei, Hadi AU - Mostafaei H AUID- ORCID: 0000-0001-5596-1771 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Department of Urology, Molinette Hospital, University of Turin, Turin, Italy. FAU - Katayama, Satoshi AU - Katayama S AUID- ORCID: 0000-0002-8377-2457 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AUID- ORCID: 0000-0002-3819-9911 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Poyet, Cedric AU - Poyet C AUID- ORCID: 0000-0002-3648-6941 AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AUID- ORCID: 0000-0002-6627-6179 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - European Association of Urology Research Foundation, Arnhem, Netherlands. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review DEP - 20210113 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC7814246 OTO - NOTNLM OT - PAI OT - review OT - therapy OT - uPA OT - uPAR OT - urothelial cancer COIS- The authors report no financial interests or other conflicts of interest in this work. EDAT- 2021/01/26 06:00 MHDA- 2021/01/26 06:01 PMCR- 2021/01/13 CRDT- 2021/01/25 05:37 PHST- 2020/12/01 00:00 [received] PHST- 2020/12/29 00:00 [accepted] PHST- 2021/01/25 05:37 [entrez] PHST- 2021/01/26 06:00 [pubmed] PHST- 2021/01/26 06:01 [medline] PHST- 2021/01/13 00:00 [pmc-release] AID - 242248 [pii] AID - 10.2147/OTT.S242248 [doi] PST - epublish SO - Onco Targets Ther. 2021 Jan 13;14:315-324. doi: 10.2147/OTT.S242248. eCollection 2021. PMID- 33485764 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20220112 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. PG - 436.e1-436.e8 LID - S1078-1439(21)00003-X [pii] LID - 10.1016/j.urolonc.2021.01.004 [doi] AB - INTRODUCTION: While numerous current clinical trials are testing novel salvage therapies (ST) for patients with recurrent nonmuscle invasive bladder cancer (NMIBC) after bacillus Calmette-Guerin (BCG), the natural history of this disease state has been poorly defined to date. Herein, we evaluated oncologic outcomes in patients previously treated with BCG and ST who subsequently underwent radical cystectomy (RC). METHODS: We identified 378 patients with high-grade NMIBC who received at least one complete induction course of BCG (n = 378) with (n = 62) or without (n = 316) additional ST and who then underwent RC between 2000 and 2018. Oncologic outcomes were compared using the Kaplan-Meier method and Cox proportional hazards models. Sensitivity analyses were conducted stratifying by presenting tumor stage, matched 1:3 for receipt vs. no receipt of ST. RESULTS: Patients receiving ST were more likely to initially present with CIS (26% vs. 17%) and less likely with T1 disease (34% vs. 50%, P = 0.06) compared to patients not treated with ST. Receipt of ST was not associated with increased risk of adverse pathology (>/=pT2 or pN+) at RC (31% vs. 41%, P = 0.14). Likewise, 5-year cancer-specific survival did not significantly differ between groups on univariable Kaplan-Meier analysis (73% for ST and 74% for no ST, P = 0.7). Moreover, on multivariable analysis, receipt of ST was not significantly associated the risk of death from bladder cancer (HR 1.12; 95% CI 0.60-2.09, P = 0.7). Results were unchanged on sensitivity analysis. CONCLUSIONS: These data suggest that, in carefully selected patients, ST following BCG for high grade NMIBC does not compromise oncologic outcomes for patients who ultimately undergo RC. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Urology, University of Iowa, Iowa City, IA. FAU - Labbate, Craig V AU - Labbate CV AD - Division of Urology, Department of Surgery, University of Chicago Medicine, Chicago, IL. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tarrell, Robert AU - Tarrell R AD - Department of Health Sciences Research, Mayo Clinic, Rochester, MN. FAU - Cheville, John C AU - Cheville JC AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. FAU - Avulova, Svetlana AU - Avulova S AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tsivian, Matvey AU - Tsivian M AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Adamic, Brittany AU - Adamic B AD - Division of Urology, Department of Surgery, University of Chicago Medicine, Chicago, IL. FAU - Mahmoud, Mohammad AU - Mahmoud M AD - Division of Urology, Department of Surgery, University of Chicago Medicine, Chicago, IL. FAU - Werntz, Ryan P AU - Werntz RP AD - Division of Urology, Department of Surgery, Prisma Health-Upstate, University of South Carolina-Greenville, Greenville, SC. FAU - Smith, Norm D AU - Smith ND AD - Division of Urology, Department of Surgery, Northshore University Health System, Evanston, IL. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, New York University, New York, NY. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Frank.igor@mayo.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210121 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Nat Rev Urol. 2021 Jun;18(6):323-324. doi: 10.1038/s41585-021-00457-1. PMID: 33772157 MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine/therapeutic use MH - Combined Modality Therapy MH - *Cystectomy/methods MH - Humans MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Salvage Therapy MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery/therapy OTO - NOTNLM OT - BCG OT - Bladder sparing OT - Chemotherapy OT - Immunotherapy OT - Intravesical OT - Nonmuscle invasive bladder cancer OT - Urothelial neoplasms COIS- Declaration of competing interest The authors have no conflict of interest to declare. EDAT- 2021/01/25 06:00 MHDA- 2021/12/24 06:00 CRDT- 2021/01/24 20:32 PHST- 2020/09/03 00:00 [received] PHST- 2020/12/13 00:00 [revised] PHST- 2021/01/03 00:00 [accepted] PHST- 2021/01/25 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/01/24 20:32 [entrez] AID - S1078-1439(21)00003-X [pii] AID - 10.1016/j.urolonc.2021.01.004 [doi] PST - ppublish SO - Urol Oncol. 2021 Jul;39(7):436.e1-436.e8. doi: 10.1016/j.urolonc.2021.01.004. Epub 2021 Jan 21. PMID- 33485761 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20220104 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 8 DP - 2021 Aug TI - Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. PG - 498.e13-498.e20 LID - S1078-1439(20)30654-2 [pii] LID - 10.1016/j.urolonc.2020.12.025 [doi] AB - PURPOSE: Intravesical Bacillus Calmette-Guerin (BCG) is the gold standard for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC), but availability is limited by global shortages. We present the first North American clinical experience using intravesical hyperthermia (HIVEC) with high-dose mitomycin C (MMC) during BCG shortage. MATERIALS AND METHODS: Single arm intermediate size expanded access protocol for high dose HIVEC MMC in patients with intermediate and high-risk NMIBC during BCG shortage. Patients received 120 mg intravesical MMC using the Combat BRS to achieve 43 degrees C HIVEC. Primary outcome was a safety assessment of adverse events, with recurrence-free survival and a descriptive analysis of hematologic impacts as secondary outcomes. RESULTS: Fourteen patients were treated from May 2019 to June 2020, 4 (29%) intermediate and 10 (71%) high risk. The cohort is heavily pretreated, only 2 (14%) BCG naive and median 6 BCG instillations (IQR 5.25, 8.25), with median 3.5 recurrences per patient (IQR 1.00, 5.25) 67% with >1 per year. Patients underwent a median 6 instillations (IQR 3.25, 9.25) which were well tolerated in 11/14 (79%). Seven patients (50%) experienced 10 adverse events, all grades 1 or 2. Most common was MMC allergy (4/14, 29%), followed by bladder spasm (3/14, 21%). Two had recurrences at median 11 months follow up, but both discontinued HIVEC after only 2 treatments. CONCLUSIONS: High dose MMC HIVEC is a safe and well-tolerated substitute for BCG during global shortages. The higher rate of systemic effects implies increased drug delivery, which may improve efficacy. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Grimberg, Dominic C AU - Grimberg DC AD - Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC. FAU - Dudinec, John AU - Dudinec J AD - Duke University School of Medicine, Duke University, Durham, NC. FAU - Shah, Ankeet AU - Shah A AD - Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC. FAU - Inman, Brant A AU - Inman BA AD - Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address: brant.inman@duke.edu. LA - eng PT - Journal Article DEP - 20210121 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/administration & dosage MH - BCG Vaccine/*administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - Hyperthermia, Induced/*methods MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - Neoplasm Invasiveness MH - Prognosis MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - BCG shortage OT - Intravesical hyperthermia OT - Mitomycin C OT - Non-muscle invasive bladder cancer EDAT- 2021/01/25 06:00 MHDA- 2022/01/05 06:00 CRDT- 2021/01/24 20:32 PHST- 2020/11/01 00:00 [received] PHST- 2020/12/06 00:00 [revised] PHST- 2020/12/23 00:00 [accepted] PHST- 2021/01/25 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] PHST- 2021/01/24 20:32 [entrez] AID - S1078-1439(20)30654-2 [pii] AID - 10.1016/j.urolonc.2020.12.025 [doi] PST - ppublish SO - Urol Oncol. 2021 Aug;39(8):498.e13-498.e20. doi: 10.1016/j.urolonc.2020.12.025. Epub 2021 Jan 21. PMID- 33484074 OWN - NLM STAT- MEDLINE DCOM- 20220103 LR - 20250723 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 IP - 5 DP - 2021 Nov TI - Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. PG - 568-574 LID - 10.1111/bju.15344 [doi] AB - OBJECTIVE: To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin (BCG) response and progression in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We performed an institutional review board-approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US Food and Drug Administration, at our institution between 2000 and 2018. Patients were stratified by presence of any UTUC and time of UTUC diagnosis (preceding vs synchronous to NMIBC diagnosis or metachronous disease after NMIBC diagnosis). Descriptive statistics were used to summarize the data overall and by groups, and t-tests or Wilcoxon's rank sum tests and Pearson's chi-squared or Fisher's exact tests were used to analyse continuous and categorical data, respectively. RESULTS: Of 541 patients with NMIBC treated with adequate BCG, 59 (10.9 %) were diagnosed with UTUC. Of these, 34 had a history of UTUC prior to NMIBC (UTUC-P; median [interquartile range IQR] 13.1 [7.4-27.6] months prior), while 25 developed UTUC after diagnosis of NMIBC (six synchronous and 19 metachronous; median [IQR] 12.1 [1.7-28.1] months after). Compared to the non-UTUC group, patients with UTUC-P were more likely to exhibit Tis without papillary tumour in the bladder (20.6% vs 5.0%; P < 0.001), but were less likely to have T1 disease on index transurethral resection (8.8% vs 49.4%; P < 0.001). Patients with UTUC-P developed more recurrences (55.9% vs 34.0%; P = 0.010), any stage/grade progression (23.5% vs 9.8%; P = 0.012) and progression to muscle-invasive or metastatic disease (17.6% vs 6.4%; P = 0.014). The presence of high-grade UTUC-P compared to low-grade UTUC-P was associated with increased NMIBC recurrence (68.2% vs 25.0%; P = 0.049). There was no significant difference in rates of recurrence or progression based on timing of UTUC with respect to the index bladder tumour, although this analysis was limited by small numbers. CONCLUSIONS: Presence of UTUC prior to a diagnosis of NMIBC was associated with an almost twofold increased recurrence and progression rates after adequate BCG therapy. This should be considered when counselling patients and designing cohorts for clinical trials. CI - (c) 2021 The Authors BJU International (c) 2021 BJU International. FAU - Bree, Kelly K AU - Bree KK AUID- ORCID: 0000-0003-4532-7763 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Brooks, Nathan A AU - Brooks NA AUID- ORCID: 0000-0002-5111-6914 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matulay, Justin AU - Matulay J AD - Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Nogueras Gonzalez, Graciela M AU - Nogueras Gonzalez GM AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, Herbert Barton AU - Grossman HB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matin, Surena F AU - Matin SF AUID- ORCID: 0000-0003-1638-1445 AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States GR - P50CA091846/NIH/NCI UTMD Anderson SPORE in Genitourinary Cancer (Bladder)/ GR - NCI Grant P30 CA016672/Cancer Center Support Grant/ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210215 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Nat Rev Urol. 2021 Apr;18(4):190. doi: 10.1038/s41585-021-00451-7. PMID: 33692495 CIN - J Urol. 2022 Dec;208(6):1347-1349. doi: 10.1097/JU.0000000000002965. PMID: 36111981 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/*pathology/secondary/surgery MH - Disease Progression MH - Female MH - Humans MH - Kidney Neoplasms/*pathology MH - Kidney Pelvis MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasms, Second Primary/*pathology MH - Risk Factors MH - Time Factors MH - Ureteral Neoplasms/*pathology MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - #utuc OT - To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin OT - bacillus Calmette-Guerin OT - bladder cancer OT - intravesical BCG OT - non-muscle-invasive bladder cancer OT - upper tract urothelial carcinoma EDAT- 2021/01/24 06:00 MHDA- 2022/01/04 06:00 CRDT- 2021/01/23 05:43 PHST- 2021/01/24 06:00 [pubmed] PHST- 2022/01/04 06:00 [medline] PHST- 2021/01/23 05:43 [entrez] AID - 10.1111/bju.15344 [doi] PST - ppublish SO - BJU Int. 2021 Nov;128(5):568-574. doi: 10.1111/bju.15344. Epub 2021 Feb 15. PMID- 33472889 OWN - NLM STAT- MEDLINE DCOM- 20210625 LR - 20260127 IS - 1538-7445 (Electronic) IS - 0008-5472 (Linking) VI - 81 IP - 6 DP - 2021 Mar 15 TI - Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling. PG - 1552-1566 LID - 10.1158/0008-5472.CAN-20-2336 [doi] AB - Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictive impacts for patients. However, it remains unclear whether tumor subtype commitment occurs in noninvasive urothelial lesions or in carcinoma in situ (CIS) and which gene pathways are important for bladder tumor progression. To understand the timing of this commitment, we used gene expression and protein analysis to create a global overview of 36 separate tissues excised from a whole bladder encompassing urothelium, noninvasive urothelial lesions, CIS, and invasive carcinomas. Additionally investigated were matched CIS, noninvasive urothelial lesions, and muscle-invasive bladder cancers (MIBC) from 22 patients. The final stage of subtype commitment to either a luminal or basal MIBC occurred at the CIS transition. For all tissues combined, hierarchical clustering of subtype gene expression revealed three subtypes: "luminal," "basal," and a "luminal p53-/extracellular matrix (ECM)-like" phenotype of ECM-related genes enriched in tumor-associated urothelium, noninvasive urothelial lesions, and CIS, but rarely invasive, carcinomas. A separate cohort of normal urothelium from noncancer patients showed significantly lower expression of ECM-related genes compared with tumor-associated urothelium, noninvasive urothelial lesions, and CIS. A PanCancer Progression Panel of 681 genes unveiled pathways specific for the luminal p53-/ECM-like cluster, for example, ECM remodeling, angiogenesis, epithelial-to-mesenchymal transition, cellular discohesion, cell motility involved in tumor progression, and cell proliferation and oncogenic ERBB2/ERBB3 signaling for invasive carcinomas. In conclusion, this study provides insights into bladder cancer subtype commitment and associated signaling pathways, which could help predict therapy response and enhance our understanding of therapy resistance. SIGNIFICANCE: This study demonstrates that CIS is the stage of commitment for determining MIBC tumor subtype, which is relevant for patient prognosis and therapy response. CI - (c)2021 American Association for Cancer Research. FAU - Wullweber, Adrian AU - Wullweber A AD - Department of Internal Medicine, Evangelisches Krankenhaus Dusseldorf, Dusseldorf, Germany. AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Strick, Reiner AU - Strick R AD - Translational Research Centre (TRC), University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. AD - Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Lange, Fabienne AU - Lange F AUID- ORCID: 0000-0003-2707-7676 AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Taubert, Helge AU - Taubert H AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. FAU - Strissel, Pamela L AU - Strissel PL AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. AD - Translational Research Centre (TRC), University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AUID- ORCID: 0000-0001-5418-3349 AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. markus.eckstein@uk-erlangen.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210120 PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (Receptor, ErbB-3) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (ERBB3 protein, human) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/pharmacology/therapeutic use MH - BCG Vaccine/pharmacology/therapeutic use MH - Biomarkers, Tumor/analysis/genetics MH - Carcinoma in Situ/*diagnosis/genetics/pathology/therapy MH - Carcinoma, Transitional Cell/*diagnosis/genetics/pathology/therapy MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Drug Resistance, Neoplasm/genetics MH - Epithelial-Mesenchymal Transition/drug effects/genetics MH - Extracellular Matrix/*pathology MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoadjuvant Therapy/methods MH - Neoplasm Invasiveness/pathology/prevention & control MH - Neoplasm Staging MH - Prognosis MH - RNA-Seq MH - Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Receptor, ErbB-3/metabolism MH - Signal Transduction/drug effects/genetics MH - Urinary Bladder/cytology/*pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology/therapy MH - Urothelium/cytology/*pathology MH - Whole Genome Sequencing EDAT- 2021/01/22 06:00 MHDA- 2021/06/29 06:00 CRDT- 2021/01/21 05:27 PHST- 2020/07/15 00:00 [received] PHST- 2020/11/24 00:00 [revised] PHST- 2021/01/13 00:00 [accepted] PHST- 2021/01/22 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/01/21 05:27 [entrez] AID - 0008-5472.CAN-20-2336 [pii] AID - 10.1158/0008-5472.CAN-20-2336 [doi] PST - ppublish SO - Cancer Res. 2021 Mar 15;81(6):1552-1566. doi: 10.1158/0008-5472.CAN-20-2336. Epub 2021 Jan 20. PMID- 33457279 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210119 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 6 DP - 2020 Dec TI - Transurethral resection of bladder tumour (TURBT). PG - 3056-3072 LID - 10.21037/tau.2019.09.38 [doi] AB - The goals of transurethral resection of bladder tumour (TURBT) are to identify and eradicate visualized bladder tumour if technically safe and feasible and to obtain a specimen of satisfactory quality to enable accurate histological diagnosis. In the setting of high grade bladder tumour this generally entails the inclusion of detrusor muscle and assessment for the presence of associated carcinoma in situ (CIS), lymphovascular involvement or any variant form of bladder cancer. This will assist in determining risk stratification and prognostication of the bladder cancer and guides further treatment planning. Conversely, if suboptimal TURBT is performed there will be detrimental consequences on patient outcomes in regards to undergrading or understaging, increased recurrence or progression, and subsequently need for further treatments including more invasive interventions. This review article firstly summarises the key principles and complications of TURBT, as well as significance of re-TURBT. We also discuss a number of modifications and advances in detection technology and resection techniques that have shown to improve perioperative as well as pathological and oncological outcomes of bladder cancer. They include enhanced cystoscopy such as blue light cystoscopy (BLC), narrow band imaging (NBI) and en bloc resection of bladder tumour (ERBT) technique using various types of energy source. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Kim, Lawrence H C AU - Kim LHC AD - Department of Urology, Westmead Hospital, Sydney, Australia. AD - Discipline of Surgery, Sydney Medical School, University of Sydney, Sydney, Australia. FAU - Patel, Manish I AU - Patel MI AD - Department of Urology, Westmead Hospital, Sydney, Australia. AD - Discipline of Surgery, Sydney Medical School, University of Sydney, Sydney, Australia. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7807319 OTO - NOTNLM OT - Transurethral resection of bladder tumour (TURBT) OT - blue light cystoscopy (BLC) OT - carcinoma in situ (CIS) OT - en bloc resection of bladder tumour technique (ERBT technique) OT - narrow beam imaging (NBI) OT - non-muscle invasive bladder cancer (NMIBC) COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2019.09.38). The series "Surgery for Urologic Cancers" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2021/01/19 06:00 MHDA- 2021/01/19 06:01 PMCR- 2020/12/01 CRDT- 2021/01/18 05:32 PHST- 2021/01/18 05:32 [entrez] PHST- 2021/01/19 06:00 [pubmed] PHST- 2021/01/19 06:01 [medline] PHST- 2020/12/01 00:00 [pmc-release] AID - tau-09-06-3056 [pii] AID - 10.21037/tau.2019.09.38 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Dec;9(6):3056-3072. doi: 10.21037/tau.2019.09.38. PMID- 33457265 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230916 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 6 DP - 2020 Dec TI - Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer. PG - 2920-2937 LID - 10.21037/tau.2020.02.10 [doi] AB - Bladder-sparing protocols (BSP) have been gaining widespread popularity as an attractive alternative to radical cystectomy (RC) for muscle-invasive bladder cancer. Unimodal therapies are inferior to multimodal regimens. The most promising regimen is trimodal therapy (TMT), which is a combination of maximal transurethral resection of bladder tumor (TURBT), radiotherapy, and chemotherapy. In appropriately selected patients (low volume unifocal T2 disease, complete TURBT, no hydronephrosis and no carcinoma-in-situ), comparable oncological outcomes to RC have been reported in large retrospective studies, with a potential improvement in overall quality of life (QOL). TMT also offers the possibility for definitive therapy for patients who are not surgically fit to undergo RC. Routine biopsy of previous tumor resection is recommended to assess response. Prompt salvage RC is required in non-responders and for recurrent muscle-invasive disease, while non-muscle-invasive recurrence can be managed conservatively with TURBT +/- intravesical BCG. Long-term follow-up consisting of routine cystoscopy, urine cytology, and cross-section imaging is required. Further studies are warranted to better define the role of neoadjuvant or adjuvant chemotherapy in the setting of TMT. Finally, future research on predictive markers of response to TMT and on the integration of immunotherapy in bladder sparing protocols is ongoing and is highly promising. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Tholomier, Come AU - Tholomier C AD - Department of Surgery, Division of Urology, McGill University, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Souhami, Luis AU - Souhami L AD - Department of Radiation Oncology, McGill University, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Surgery, Division of Urology, McGill University, McGill University Health Centre, Montreal, Quebec, Canada. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7807363 OTO - NOTNLM OT - Muscle-invasive bladder cancer OT - bladder preservation therapy OT - bladder-sparing protocols (BSP) OT - chemoradiation OT - transurethral resection of bladder tumor (TURBT) OT - trimodal therapy (TMT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.02.10). The series "Muscle-Invasive Bladder Cancer" was commissioned by the editorial office without any funding or sponsorship. Dr. Souhami reports other from Varian Medical Systems, other from Janssen, other from AbbVie, outside the submitted work. The authors have no other conflicts of interest to declare. EDAT- 2021/01/19 06:00 MHDA- 2021/01/19 06:01 PMCR- 2020/12/01 CRDT- 2021/01/18 05:32 PHST- 2021/01/18 05:32 [entrez] PHST- 2021/01/19 06:00 [pubmed] PHST- 2021/01/19 06:01 [medline] PHST- 2020/12/01 00:00 [pmc-release] AID - tau-09-06-2920 [pii] AID - 10.21037/tau.2020.02.10 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Dec;9(6):2920-2937. doi: 10.21037/tau.2020.02.10. PMID- 33457228 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240902 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 6 DP - 2020 Dec TI - Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. PG - 2541-2554 LID - 10.21037/tau-20-713 [doi] AB - BACKGROUND: Radical cystectomy (RC) and urinary diversion (UD), with either an ileal conduit (IC) or an orthotopic neobladder (NB), is a complex surgery, in which various complications can occur. In this study, we compared postoperative complication rates after a RC and UD performed for the treatment of muscle-invasive bladder cancer or recurring high-risk non-muscle-invasive bladder cancer in our center. METHODS: We retrospectively included 604 patients that underwent UDs from December 1996 to August 2015. Complications were classified by type and severity according to the Clavien-Dindo classification (CDC). Univariate and multivariate analyses were performed to identify predictive factors of short-term (90 d) complications. RESULTS: Four hundred and forty-five (74%) and 159 (26%) patients received ICs and NBs, respectively. These groups had significantly different long-term complication rates (IC: 39.7% vs. NB: 49%, P=0.046), but similar short-term (P=0.319) and intermediate-term complication rates (P=0.397). Short-term complications (CDC I-V) were predicted by male gender, age-adjusted Charlson comorbidity index (aCCI) >/=3, and American Society of Anesthesiologists (ASA) score >/=3. Compared to minor short-term complications (CDC I-II), major short-term complications (CDC III-V) were predicted by male gender and a previous abdominal/pelvic surgery, and long-term major complications were predicted by the type of UD (NB). CONCLUSIONS: The increasing risk of short-term complications with increasing aCCI and ASA score can be used when counseling the patients who are planned to undergo a RC with UD. Patients that receive NBs should be informed of the increased risk of reoperations compared to an IC. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Demaegd, Liesbeth AU - Demaegd L AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Albersen, Maarten AU - Albersen M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Milenkovic, Uros AU - Milenkovic U AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Moris, Lisa AU - Moris L AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Everaerts, Wouter AU - Everaerts W AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van Poppel, Hendrik AU - Van Poppel H AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Akand, Murat AU - Akand M AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. AD - Department of Urology, School of Medicine, Selcuk University, Konya, Turkey. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7807350 OTO - NOTNLM OT - Bladder cancer (BC) OT - complication OT - ileal conduit (IC) OT - neobladder (NB) OT - radical cystectomy (RC) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-713). The authors have no conflicts of interest to declare. EDAT- 2021/01/19 06:00 MHDA- 2021/01/19 06:01 PMCR- 2020/12/01 CRDT- 2021/01/18 05:32 PHST- 2021/01/18 05:32 [entrez] PHST- 2021/01/19 06:00 [pubmed] PHST- 2021/01/19 06:01 [medline] PHST- 2020/12/01 00:00 [pmc-release] AID - tau-09-06-2541 [pii] AID - 10.21037/tau-20-713 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Dec;9(6):2541-2554. doi: 10.21037/tau-20-713. PMID- 33455057 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20250530 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 10 IP - 4 DP - 2021 Feb TI - Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts. PG - 1431-1438 LID - 10.1002/cam4.3721 [doi] AB - BACKGROUND: The relation between obesity, blood pressure (BP) and bladder cancer (BC) risk and mortality remains unclear, partially due to potential confounding by smoking, the strongest risk factor for BC, and not accounting for tumor stage and grade in such studies. We investigated body mass index (BMI) and BP in relation to BC risk by stage and grade, and BC-specific mortality, including separately among never-smokers aimed at minimizing confounding by smoking. METHODS: We analyzed 338,910 men from three Swedish cohorts, with 4895 incident BC's (940 among never-smokers) during follow-up. Cox regression was used to calculate hazard ratios (HR) and 95% confidence intervals adjusted for smoking status. HRs for BMI and BP were corrected for their regression dilution ratios, calculated from 280,456 individuals with 758,641 observations. RESULTS: Body mass index was positively associated with non-muscle invasive BC (NMIBC, HR per 5 kg/m(2) , 1.10 [1.02-1.19]) and NMIBC grade 3 (HR 1.17 [1.01-1.34]) in the full cohort, with similar effect sizes, albeit non-significant, among never-smokers. Systolic BP was positively associated with muscle-invasive BC (MIBC, HR per 10 mmHg, 1.25 [1.00-1.55]) and BC-specific mortality (HR 1.10 [1.01-1.20]) among never-smokers, with weaker and non-significant associations in the full cohort. CONCLUSIONS: In an analyses of BMI, BP and BC risk by stage and grade among men, we found modest positive associations between BMI and NMIBC and NMIBC grade 3. SBP was positively associated with MIBC and BC-specific mortality in an analysis of never-smokers, which may reflect the association, un-confounded by smoking, also in a broader population. CI - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Teleka, Stanley AU - Teleka S AUID- ORCID: 0000-0002-9343-8399 AD - Department of Clinical Sciences in Lund, Lund University, Lund, Sweden. FAU - Jochems, Sylvia H J AU - Jochems SHJ AUID- ORCID: 0000-0001-7676-1488 AD - Department of Clinical Sciences in Lund, Lund University, Lund, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AUID- ORCID: 0000-0001-6808-4405 AD - Department of Biobank Research, Umea University, Umea, Sweden. AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Wood, Angela M AU - Wood AM AD - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. FAU - Jarvholm, Bengt AU - Jarvholm B AD - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. FAU - Orho-Melander, Marju AU - Orho-Melander M AD - Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Division of Urological Research, Institution of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Skane, Sweden. FAU - Stocks, Tanja AU - Stocks T AD - Department of Clinical Sciences in Lund, Lund University, Lund, Sweden. LA - eng GR - G0701619/MRC_/Medical Research Council/United Kingdom GR - MR/K014811/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210116 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Adult MH - *Blood Pressure MH - *Body Mass Index MH - Cohort Studies MH - Follow-Up Studies MH - Humans MH - Male MH - Prognosis MH - Risk Factors MH - Survival Rate MH - Sweden/epidemiology MH - Urinary Bladder Neoplasms/*epidemiology/*mortality/pathology PMC - PMC7926028 OTO - NOTNLM OT - bladder cancer OT - blood pressure OT - body mass index OT - confounding OT - survival analysis COIS- None declared. EDAT- 2021/01/18 06:00 MHDA- 2021/08/06 06:00 PMCR- 2021/01/16 CRDT- 2021/01/17 20:37 PHST- 2020/10/08 00:00 [received] PHST- 2020/12/22 00:00 [revised] PHST- 2020/12/24 00:00 [accepted] PHST- 2021/01/18 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2021/01/17 20:37 [entrez] PHST- 2021/01/16 00:00 [pmc-release] AID - CAM43721 [pii] AID - 10.1002/cam4.3721 [doi] PST - ppublish SO - Cancer Med. 2021 Feb;10(4):1431-1438. doi: 10.1002/cam4.3721. Epub 2021 Jan 16. PMID- 33445605 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210126 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 2 DP - 2021 Jan 12 TI - Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies. LID - 10.3390/cancers13020260 [doi] LID - 260 AB - Urothelial carcinoma (UC) is the most frequent malignancy of the urinary system and is ranked the sixth most diagnosed cancer in men worldwide. Around 70-75% of newly diagnosed UC manifests as the non-muscle invasive bladder cancer (NMIBC) subtype, which can be treated by a transurethral resection of the tumor. However, patients require life-long monitoring due to its high rate of recurrence. The current gold standard for UC diagnosis, prognosis, and disease surveillance relies on a combination of cytology and cystoscopy, which is invasive, costly, and associated with comorbidities. Hence, there is considerable interest in the development of highly specific and sensitive urinary biomarkers for the non-invasive early detection of UC. In this review, we assess the performance of current diagnostic assays for UC and highlight some of the most promising biomarkers investigated to date. We also highlight some of the recent advances in single-cell technologies that may offer a paradigm shift in the field of UC biomarker discovery and precision diagnostics. FAU - Hong, Michelle AU - Hong M AD - A. Menarini Biomarkers Singapore Pte Ltd., Singapore 117440, Singapore. FAU - He, George AU - He G AD - Department of Pathology, Singapore General Hospital, Singapore 169856, Singapore. FAU - Goh, Siting AU - Goh S AD - Department of Pathology, Singapore General Hospital, Singapore 169856, Singapore. FAU - Low, Alvin Wei Xiang AU - Low AWX AD - Department of Urology, Singapore General Hospital, Singapore 169854, Singapore. FAU - Tay, Kae Jack AU - Tay KJ AD - Department of Urology, Singapore General Hospital, Singapore 169854, Singapore. FAU - Lim, Tony Kiat Hon AU - Lim TKH AD - Department of Pathology, Singapore General Hospital, Singapore 169856, Singapore. FAU - Yeong, Joe AU - Yeong J AUID- ORCID: 0000-0002-6674-7153 AD - Department of Pathology, Singapore General Hospital, Singapore 169856, Singapore. AD - Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore. FAU - Khor, Li Yan AU - Khor LY AD - Department of Pathology, Singapore General Hospital, Singapore 169856, Singapore. FAU - Lim, Tong Seng AU - Lim TS AD - A. Menarini Biomarkers Singapore Pte Ltd., Singapore 117440, Singapore. LA - eng PT - Journal Article PT - Review DEP - 20210112 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7827267 OTO - NOTNLM OT - biomarker OT - circulating tumor cells OT - cystoscopy OT - cytology OT - diagnostics OT - non-invasive OT - single cell OT - urothelial carcinoma COIS- M.H. and T.S.L. are full-time employees of A. Menarini Biomarkers Singapore Pte Ltd. The rest of the authors declare no conflict of interest. EDAT- 2021/01/16 06:00 MHDA- 2021/01/16 06:01 PMCR- 2021/01/12 CRDT- 2021/01/15 01:01 PHST- 2020/12/08 00:00 [received] PHST- 2020/12/30 00:00 [revised] PHST- 2021/01/08 00:00 [accepted] PHST- 2021/01/15 01:01 [entrez] PHST- 2021/01/16 06:00 [pubmed] PHST- 2021/01/16 06:01 [medline] PHST- 2021/01/12 00:00 [pmc-release] AID - cancers13020260 [pii] AID - cancers-13-00260 [pii] AID - 10.3390/cancers13020260 [doi] PST - epublish SO - Cancers (Basel). 2021 Jan 12;13(2):260. doi: 10.3390/cancers13020260. PMID- 33439571 OWN - NLM STAT- MEDLINE DCOM- 20220214 LR - 20220214 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 73 IP - 6 DP - 2021 Dec TI - Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. PG - 796-802 LID - 10.23736/S2724-6051.20.04076-X [doi] AB - BACKGROUND: We aimed to test the hypothesis that the immune-modulatory effect of statins may improve survival outcomes in patients with non-muscle invasive bladder cancer (NMIBC). We focused on a cohort of patients diagnosed with high risk NMIBC, that were treated with intravesical BCG immunotherapy. METHODS: We included patients at first diagnosis of T1 high grade NMIBC after transurethral resection of bladder (TURB). All procedures were performed at 18 different tertiary institutions between January 2002 and December 2012. Univariable and multivariable models were used to test differences in terms of residual tumor, disease recurrence, disease progression and overall mortality (OM) rates. RESULTS: Overall, 1510 patients with T1 high grade NMIBC at TURB were included in our analyses. Of these, 402 (26.6%) were statin users. At multivariable analysis, statin use was associated with a higher rate of high-grade BC at re-TURB (OR: 1.37, 95%CI: 1.04-1.78; P=0.022), while at follow-up it was not independently associated with OM (HR: 0.71, 95%CI: 0.50-1.03; P=0.068) and disease progression rates (HR: 0.97, 95%CI: 0.79-1.19; P=0.753). Conversely, statin use has been shown to be independently associated with a lower risk of recurrence (HR:0.80, 95%CI: 0.67-0.95; P=0.009). The median recurrence-free survival was 47 (95%CI 40-49) months for those classified as non-statin users vs. 53 (95%CI 48-68) months in those classified as statin users. CONCLUSIONS: Statin daily intake do not compromise oncological outcomes in high risk NMIBC patients treated with BCG. Moreover, statin may have a beneficial effect on recurrence rates in this cohort of patients. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy - matteo.ferro@ieo.it. FAU - Marchioni, Michele AU - Marchioni M AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Section of Urology, Unit of Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, Targu Mures, Romania. FAU - Soria, Francesco AU - Soria F AD - School of Medicine, Division of Urology, Department of Surgical Sciences, Turin, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Mistretta, Francesco A AU - Mistretta FA AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy. FAU - Buonerba, Carlo AU - Buonerba C AD - CRTR Rare Tumors Reference Center, University of Naples Federico II, Naples, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Mari, Andrea AU - Mari A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, University of Florence, Careggi Hospital, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Urology, University of Florence, Careggi Hospital, Florence, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Division of Urology, Department of Surgery, VCU Health System, Richmond, VA, USA. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Verona, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - IRCCS Humanitas Clinic, Rozzano, Milan, Italy. FAU - Busetto, Gian M AU - Busetto GM AD - Department of Urology, Sapienza University, Rome, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Sapienza University, Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - School of Medicine, Stanford University, Stanford, CA, USA. FAU - Berardinelli, Francesco AU - Berardinelli F AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Department Uro-Gynecology, IRCCS G. Pascale Foundation, National Institute for the Study and Treatment of Cancer, Naples, Italy. FAU - Del Prete, Paola AU - Del Prete P AD - Scientific Directorate, IRCCS G. Pascale Foundation, National Institute for the Study and Treatment of Cancer, Naples, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Unit of Urology, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Department of Robotic Urologic Surgery, Abano Terme Hospital, Abano Terme, Padua, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Department of Surgery, VCU Health System, Richmond, VA, USA. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. FAU - Abu Farhan, Abdal R AU - Abu Farhan AR AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Section of Urology, Unit of Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Ditonno, Pasquale AU - Ditonno P AD - Section of Urology, Unit of Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Russo, Giorgio I AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Muto, Matteo AU - Muto M AD - Unit of Radiotherapy, Moscati University Hospital, Avellino, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University, Catanzaro, Italy. FAU - Manfredi, Matteo AU - Manfredi M AD - School of Medicine, Division of Urology, Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - School of Medicine, Division of Urology, Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy. FAU - DE Cobelli, Ottavio AU - DE Cobelli O AD - Division of Urology, IRCCS European Institute of Oncology, Milan, Italy. FAU - Schips, Luigi AU - Schips L AD - Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210113 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - *Carcinoma, Transitional Cell/drug therapy MH - Disease Progression MH - Humans MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2021/01/14 06:00 MHDA- 2022/02/15 06:00 CRDT- 2021/01/13 12:41 PHST- 2021/01/14 06:00 [pubmed] PHST- 2022/02/15 06:00 [medline] PHST- 2021/01/13 12:41 [entrez] AID - S0393-2249.20.04076-X [pii] AID - 10.23736/S2724-6051.20.04076-X [doi] PST - ppublish SO - Minerva Urol Nephrol. 2021 Dec;73(6):796-802. doi: 10.23736/S2724-6051.20.04076-X. Epub 2021 Jan 13. PMID- 33434860 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20210414 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 136 DP - 2021 Mar TI - Prediction of muscle invasion of bladder cancer: A comparison between DKI and conventional DWI. PG - 109522 LID - S0720-048X(21)00002-4 [pii] LID - 10.1016/j.ejrad.2021.109522 [doi] AB - OBJECTIVES: To prospectively compare the diagnostic efficacy of conventional diffusion-weighted imaging (DWI) and diffusion kurtosis imaging (DKI) in differentiating between muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). METHODS: Multiple b value DWIs were performed using a 3-T magnetic resonance (MR) imaging unit in fifty-one patients with bladder cancer including MIBC and NMIBC confirmed by histopathological findings. DWI data were postprocessed using mono-exponential and DKI models to calculate the apparent diffusion coefficient (ADC), apparent diffusional kurtosis (K(app)), and kurtosis-corrected diffusion coefficient (D(app)). Receiver-operating characteristic (ROC) analysis was performed to compare the diagnostic efficacy of all diffusion parameters. RESULTS: All parameters differed significantly between MIBC and NIMBC including increased K(app), decreased D(app) and ADC (all p < 0.001). Only the combination of D(app) and K(app) was significantly higher than ADC (p < 0.05), whilst D(app) and K(app) were not statistically different from ADC. CONCLUSIONS: Both conventional DWI and DKI models are beneficial in differentiating between MIBC and NMIBC, whilst the combination of D(app) and K(app) can produce a more robust value than conventional ADC value in evaluating aggressiveness of bladder cancer. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Li, Qing AU - Li Q AD - Department of Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China. Electronic address: liqing_0413@163.com. FAU - Cao, Bohong AU - Cao B AD - Department of Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China. Electronic address: cao.bohong@zs-hospital.sh.cn. FAU - Tan, Qinxuan AU - Tan Q AD - Department of Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China. Electronic address: tanqinxuan1994@163.com. FAU - Liu, Kai AU - Liu K AD - Department of Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China. Electronic address: 195347478@qq.com. FAU - Jiang, Shuai AU - Jiang S AD - Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China. Electronic address: jiang.shuai@zs-hospital.sh.cn. FAU - Zhou, Jianjun AU - Zhou J AD - Department of Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Fudan University, 180 Fenglin Road, Shanghai, Xuhui District, 200032, People's Republic of China; Department of Radiology, Xiamen Branch, Zhongshan Hospital, Fudan University, 668 Jinhu Road, Huli District, Xiamen City 361015, Fujian Province, People's Republic of China. Electronic address: zhoujianjunzs@126.com. LA - eng PT - Journal Article DEP - 20210106 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Diffusion Magnetic Resonance Imaging MH - Diffusion Tensor Imaging MH - Humans MH - Magnetic Resonance Imaging MH - Muscles MH - *Urinary Bladder Neoplasms/diagnostic imaging OTO - NOTNLM OT - Diagnostic efficacy OT - Diffusion kurtosis imaging OT - Diffusion-weighted MRI OT - Urinary bladder neoplasms EDAT- 2021/01/13 06:00 MHDA- 2021/04/15 06:00 CRDT- 2021/01/12 20:12 PHST- 2020/10/25 00:00 [received] PHST- 2020/12/10 00:00 [revised] PHST- 2021/01/04 00:00 [accepted] PHST- 2021/01/13 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2021/01/12 20:12 [entrez] AID - S0720-048X(21)00002-4 [pii] AID - 10.1016/j.ejrad.2021.109522 [doi] PST - ppublish SO - Eur J Radiol. 2021 Mar;136:109522. doi: 10.1016/j.ejrad.2021.109522. Epub 2021 Jan 6. PMID- 33423944 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20260518 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 4 IP - 2 DP - 2021 Apr TI - Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. PG - 182-191 LID - S2588-9311(20)30210-8 [pii] LID - 10.1016/j.euo.2020.12.002 [doi] AB - BACKGROUND: In the current European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016. OBJECTIVE: To compare the prognostic value of these WHO systems. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and 2019. The median follow-up was 3.9 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariable analyses of WHO1973 and WHO2004/2016 stratified by center were performed for time to recurrence, progression (primary endpoint), cystectomy, and duration of survival, taking into account age, concomitant carcinoma in situ, gender, multiplicity, tumor size, initial treatment, and tumor stage. Harrell's concordance (C-index) was used for prognostic accuracy of classification systems. RESULTS AND LIMITATIONS: The median age was 68 yr; 3292 (64%) patients had Ta tumors. Neither classification system was prognostic for recurrence. For a four-tier combination of both WHO systems, progression at 5-yr follow-up was 1.4% in low-grade (LG)/G1, 3.8% in LG/G2, 7.7% in high grade (HG)/G2, and 18.8% in HG/G3 (log-rank, p < 0.001). In multivariable analyses with WHO1973 and WHO2004/2016 as independent variables, WHO1973 was a significant prognosticator of progression (p < 0.001), whereas WHO2004/2016 was not anymore (p = 0.067). C-indices for WHO1973, WHO2004, and the WHO systems combined for progression were 0.71, 0.67, and 0.73, respectively. Prognostic analyses for cystectomy and survival showed results similar to those for progression. CONCLUSIONS: In this large prognostic factor study, both classification systems were prognostic for progression but not for recurrence. For progression, the prognostic value of WHO1973 was higher than that of WHO 2004/2016. The four-tier combination (LG/G1, LG/G2, HG/G2, and HG/G3) of both WHO systems proved to be superior, as it divides G2 patients into two subgroups (LG and HG) with different prognoses. Hence, the current EAU-NMIBC guideline recommendation to use both WHO classification systems remains correct. PATIENT SUMMARY: At present, two classification systems are used in parallel to grade non-muscle-invasive bladder tumors. Our data on a large number of patients showed that the older classification system (WHO1973) performed better in terms of assessing progression than the more recent (WHO2004/2016) one. Nevertheless, we conclude that the current guideline recommendation for the use of both classification systems remains correct, since this has the advantage of dividing the large group of WHO1973 G2 patients into two subgroups (low and high grade) with different prognoses. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: basvanrhijn@hotmail.com. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bruins, H Maxim AU - Bruins HM AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Royal Free London - NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Pitie Salpetriere Hospital, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Zigeuner, Richard AU - Zigeuner R AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Burger, Maximilian AU - Burger M AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Palou, Joan AU - Palou J AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. CN - Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973 WHO 2004 2016 Classification Systems for Grade LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210108 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM CIN - Eur Urol Oncol. 2021 Aug;4(4):671-673. doi: 10.1016/j.euo.2021.06.002. PMID: 34144939 MH - Aged MH - Cystectomy MH - Humans MH - Neoplasm Grading MH - Prognosis MH - *Urinary Bladder Neoplasms/surgery/therapy MH - *Urology OTO - NOTNLM OT - 1973 OT - 2004 OT - 2016 OT - Bladder OT - Cancer OT - Carcinoma OT - European Association of Urology OT - Grade OT - Guideline OT - Non-muscle invasive OT - Progression OT - Stage OT - Urothelial OT - World Health Organization FIR - van Rhijn, Bas W G IR - van Rhijn BWG FIR - Hentschel, Anouk E IR - Hentschel AE FIR - Brundl, Johannes IR - Brundl J FIR - Comperat, Eva M IR - Comperat EM FIR - Plass, Karin IR - Plass K FIR - Rodriguez, Oscar IR - Rodriguez O FIR - Subiela Henriquez, Jose D IR - Subiela Henriquez JD FIR - Hernandez, Virginia IR - Hernandez V FIR - de la Pena, Enrique IR - de la Pena E FIR - Alemany, Isabel IR - Alemany I FIR - Turturica, Diana IR - Turturica D FIR - Pisano, Francesca IR - Pisano F FIR - Soria, Francesco IR - Soria F FIR - Capoun, Otakar IR - Capoun O FIR - Bauerova, Lenka IR - Bauerova L FIR - Pesl, Michael IR - Pesl M FIR - Bruins, H Maxim IR - Bruins HM FIR - Runneboom, Willemien IR - Runneboom W FIR - Herdegen, Sonja IR - Herdegen S FIR - Breyer, Johannes IR - Breyer J FIR - Brisuda, Antonin IR - Brisuda A FIR - Calatrava, Ana IR - Calatrava A FIR - Rubio-Briones, Jose IR - Rubio-Briones J FIR - Seles, Maximilian IR - Seles M FIR - Mannweiler, Sebastian IR - Mannweiler S FIR - Bosschieter, Judith IR - Bosschieter J FIR - Kusuma, Venkata R M IR - Kusuma VRM FIR - Ashabere, David IR - Ashabere D FIR - Huebner, Nicolai IR - Huebner N FIR - Cotte, Juliette IR - Cotte J FIR - Mertens, Laura S IR - Mertens LS FIR - Cohen, Daniel IR - Cohen D FIR - Lunelli, Luca IR - Lunelli L FIR - Cussenot, Olivier IR - Cussenot O FIR - El Sheikh, Soha IR - El Sheikh S FIR - Volanis, Dimitrios IR - Volanis D FIR - Cote, Jean-Francois IR - Cote JF FIR - Roupret, Morgan IR - Roupret M FIR - Haitel, Andrea IR - Haitel A FIR - Shariat, Shahrokh F IR - Shariat SF FIR - Mostafid, A Hugh IR - Mostafid AH FIR - Nieuwenhuijzen, Jakko A IR - Nieuwenhuijzen JA FIR - Zigeuner, Richard IR - Zigeuner R FIR - Dominguez-Escrig, Jose L IR - Dominguez-Escrig JL FIR - Hacek, Jaromir IR - Hacek J FIR - Zlotta, Alexandre R IR - Zlotta AR FIR - Burger, Maximilian IR - Burger M FIR - Evert, Matthias IR - Evert M FIR - Hulsbergen-van de Kaa, Christina A IR - Hulsbergen-van de Kaa CA FIR - van der Heijden, Antoine G IR - van der Heijden AG FIR - Kiemeney, Lambertus A L M IR - Kiemeney LALM FIR - Soukup, Viktor IR - Soukup V FIR - Molinaro, Luca IR - Molinaro L FIR - Gontero, Paolo IR - Gontero P FIR - Llorente, Carlos IR - Llorente C FIR - Algaba, Ferran IR - Algaba F FIR - Palou, Joan IR - Palou J FIR - N'Dow, James IR - N'Dow J FIR - van der Kwast, Theo H IR - van der Kwast TH FIR - Babjuk, Marko IR - Babjuk M FIR - Sylvester, Richard J IR - Sylvester RJ EDAT- 2021/01/12 06:00 MHDA- 2021/11/23 06:00 CRDT- 2021/01/11 05:27 PHST- 2020/10/15 00:00 [received] PHST- 2020/11/23 00:00 [revised] PHST- 2020/12/01 00:00 [accepted] PHST- 2021/01/12 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2021/01/11 05:27 [entrez] AID - S2588-9311(20)30210-8 [pii] AID - 10.1016/j.euo.2020.12.002 [doi] PST - ppublish SO - Eur Urol Oncol. 2021 Apr;4(2):182-191. doi: 10.1016/j.euo.2020.12.002. Epub 2021 Jan 8. PMID- 33421984 OWN - NLM STAT- MEDLINE DCOM- 20211217 LR - 20211217 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 53 IP - 3 DP - 2021 Jul TI - Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. PG - 795-802 LID - 10.4143/crt.2020.919 [doi] AB - PURPOSE: This study aimed to evaluate the effects of bladder cuff method on oncological outcomes in patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. MATERIALS AND METHODS: The records of 1,095 patients treated with RNU performed at our hospital between 1994 and 2018 were retrospectively reviewed; 856 patients with no bladder tumor history were enrolled in the present study. The management of bladder cuff was divided into two categories: extravesical ligation (EL) or transvesical resection (TR). Survival was analyzed using the Kaplan-Meier method and Cox regression analyses were performed to determine which factors were associated with intravesical recurrence (IVR)-free survival (IVRFS), cancer-specific survival (CSS), and overall survival (OS). RESULTS: The mean patient age was 64.8 years and the median follow-up was 37.7 months. Among the 865 patients, 477 (55.7%) underwent the TR and 379 (44.3%) the EL. Significantly higher IVRFS (p=0.001) and OS (p=0.013) were observed in the TR group. In multivariable analysis, IVR, CSS, and OS were independently associated with the EL. Among 379 patients treated with the EL, eight underwent remnant ureterectomy. Based on radical cystectomy-free survival, significant difference was not observed between the two groups. However, significantly higher IVRFS was observed in the TR group when the tumor was located in the renal pelvis. CONCLUSION: Intramural complete excision of the distal ureter during RNU should be the gold standard approach compared with EL for the management of distal ureter in terms of oncological outcomes. FAU - Ryoo, Hyunsoo AU - Ryoo H AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Jungyu AU - Kim J AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Taejin AU - Kim T AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Hyun Moo AU - Lee HM AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Journal Article DEP - 20201228 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/secondary/*surgery MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney/pathology/surgery MH - Kidney Neoplasms/mortality/pathology/*surgery MH - Male MH - Middle Aged MH - Nephroureterectomy/*methods MH - Retrospective Studies MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/mortality/pathology/*surgery MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*epidemiology/prevention & control/secondary PMC - PMC8291174 OTO - NOTNLM OT - Bladder cuff method OT - Oncological outcome OT - Upper tract urothelial carcinoma COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2021/01/11 06:00 MHDA- 2021/12/18 06:00 PMCR- 2021/07/01 CRDT- 2021/01/10 18:20 PHST- 2020/09/11 00:00 [received] PHST- 2020/12/25 00:00 [accepted] PHST- 2021/01/11 06:00 [pubmed] PHST- 2021/12/18 06:00 [medline] PHST- 2021/01/10 18:20 [entrez] PHST- 2021/07/01 00:00 [pmc-release] AID - crt.2020.919 [pii] AID - crt-2020-919 [pii] AID - 10.4143/crt.2020.919 [doi] PST - ppublish SO - Cancer Res Treat. 2021 Jul;53(3):795-802. doi: 10.4143/crt.2020.919. Epub 2020 Dec 28. PMID- 33419683 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20230225 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 79 IP - 4 DP - 2021 Apr TI - European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. PG - 480-488 LID - S0302-2838(20)31019-8 [pii] LID - 10.1016/j.eururo.2020.12.033 [doi] AB - BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT +/- intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary. PATIENT SUMMARY: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule. CI - Copyright (c) 2020 European Association of Urology. All rights reserved. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: richard.sylvester@skynet.be. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Bauerova, Lenka AU - Bauerova L AD - Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bruins, Harman Max AU - Bruins HM AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Huebner, Nicolai AU - Huebner N AD - Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cotte, Juliette AU - Cotte J AD - Department of Urology, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Volanis, Dimitrios AU - Volanis D AD - Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Cussenot, Olivier AU - Cussenot O AD - Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Subiela Henriquez, Jose D AU - Subiela Henriquez JD AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Pisano, Francesca AU - Pisano F AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Pesl, Michael AU - Pesl M AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Hacek, Jaromir AU - Hacek J AD - Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Calatrava, Ana AU - Calatrava A AD - Department of Pathology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Department of Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Ashabere, David AU - Ashabere D AD - Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cote, Jean-Francois AU - Cote JF AD - Department of Pathology, Pitie Salpetriere Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - El Sheikh, Soha AU - El Sheikh S AD - Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Lunelli, Luca AU - Lunelli L AD - Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Algaba, Ferran AU - Algaba F AD - Department of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Department of Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Runneboom, Willemien AU - Runneboom W AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands. FAU - Llorente, Carlos AU - Llorente C AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Molinaro, Luca AU - Molinaro L AD - Department of Pathology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Hulsbergen-van de Kaa, Christina A AU - Hulsbergen-van de Kaa CA AD - Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Evert, Matthias AU - Evert M AD - Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - N'Dow, James AU - N'Dow J AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Plass, Karin AU - Plass K AD - European Association of Urology Guidelines Office, Arnhem, The Netherlands. FAU - Capoun, Otakar AU - Capoun O AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Soukup, Viktor AU - Soukup V AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Cohen, Daniel AU - Cohen D AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Palou, Joan AU - Palou J AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Gontero, Paolo AU - Gontero P AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Citta della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. FAU - Burger, Maximilian AU - Burger M AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Zigeuner, Richard AU - Zigeuner R AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria. FAU - Mostafid, Amir Hugh AU - Mostafid AH AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. FAU - Shariat, Shahrokh F AU - Shariat SF AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitie Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Comperat, Eva M AU - Comperat EM AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Babjuk, Marko AU - Babjuk M AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. LA - eng PT - Journal Article DEP - 20210106 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2021 Apr;79(4):489-491. doi: 10.1016/j.eururo.2021.01.005. PMID: 33478775 EIN - Eur Urol. 2023 May;83(5):e140-e141. doi: 10.1016/j.eururo.2023.02.007. PMID: 36841687 MH - Humans MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/therapy MH - *Urology MH - World Health Organization OTO - NOTNLM OT - Grade OT - Guidelines OT - Non-muscle-invasive bladder cancer OT - Prognostic factors OT - Progression OT - Risk groups OT - WHO 1973 2004/2016 EDAT- 2021/01/10 06:00 MHDA- 2022/02/23 06:00 CRDT- 2021/01/09 05:30 PHST- 2020/09/18 00:00 [received] PHST- 2020/12/17 00:00 [accepted] PHST- 2021/01/10 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PHST- 2021/01/09 05:30 [entrez] AID - S0302-2838(20)31019-8 [pii] AID - 10.1016/j.eururo.2020.12.033 [doi] PST - ppublish SO - Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6. PMID- 33415006 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240330 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 10 IP - 12 DP - 2020 TI - Effects of alpha(1)-adrenergic receptor antagonists on the development and progression of urothelial cancer. PG - 4386-4398 AB - We recently demonstrated that silodosin, a selective alpha(1)-blocker often prescribed for the symptomatic treatment of benign prostatic hyperplasia (BPH), could inactivate a c-fos proto-oncogene regulator ELK1 in bladder cancer cells possessing a functional androgen receptor (AR). However, the clinical impact of alpha(1)-blockers on the development and progression of bladder cancer remained poorly understood. In the present study, we investigated if alpha(1)-blockers clinically used, including silodosin, tamsulosin, and naftopidil, could prevent the neoplastic/malignant transformation and cell growth, using non-neoplastic urothelial SVHUC sublines with carcinogen/MCA challenge and bladder cancer lines, respectively. Bladder cancers in men treated with silodosin, tamsulosin, or naftopidil for their BPH were then compared. Silodosin at 1-10 microM significantly inhibited the neoplastic transformation of MCA-SVHUC-AR cells, but not that of AR-negative MCA-SVHUC-control cells. In MCA-SVHUC-AR, silodosin significantly reduced the expression levels of oncogenes (c-fos/NF-kappaB1) and induced those of tumor suppressors (p27/PTEN). However, tamsulosin (up to 1 microM) or naftopidil (up to 10 microM) failed to significantly inhibit the neoplastic transformation of AR-positive or AR-negative urothelial cells. Similarly, cell proliferation/migration of AR-positive bladder cancer lines was considerably inhibited only by silodosin. Meanwhile, the incidence of bladder cancer in patients with silodosin [49/540 (9.1%)] was marginally lower, compared to those with tamsulosin [64/523 (12.2%); P=0.094] or tamsulosin or naftopidil [64+28/523+236 (12.1%); P=0.082]. There were no significant differences in tumor grade/stage among the 3 cohorts. Outcome analysis revealed lower risks for disease progression of non-muscle-invasive bladder tumors in the silodosin group than in the naftopidil group (P=0.011) or tamsulosin+naftopidil groups (P=0.035). Similarly, silodosin patients with muscle-invasive tumor had lower risks for disease progression, compared with tamsulosin (P=0.006) or tamsulosin+naftopidil (P=0.028) patients. Multivariate analysis further showed that silodosin treatment in those with non-muscle-invasive tumor was associated with improved progression-free survival, compared with naftopidil (hazard ratio=0.086; 95% confidence interval=0.008-0.905; P=0.041) or tamsulosin/naftopidil (hazard ratio=0.128; 95% confidence interval=0.016-1.036; P=0.054) treatment. Our in vitro studies thus indicate that both urothelial tumorigenesis and tumor growth are inhibited by silodosin, but not by tamsulosin or naftopidil. Clinical data further suggest that even pharmacological doses (e.g. 0.1 microM) of silodosin contribute to preventing bladder cancer progression. CI - AJCR Copyright (c) 2020. FAU - Nagata, Yujiro AU - Nagata Y AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. AD - Department of Urology, University of Occupational and Environmental Health School of Medicine Kitakyushu, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center Yokohama, Japan. FAU - Goto, Takuro AU - Goto T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Inoue, Satoshi AU - Inoue S AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Teramoto, Yuki AU - Teramoto Y AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Jiang, Guiyang AU - Jiang G AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - Department of Urology, University of Occupational and Environmental Health School of Medicine Kitakyushu, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA. AD - James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY, USA. AD - Department of Urology, University of Rochester Medical Center Rochester, NY, USA. LA - eng PT - Journal Article DEP - 20201201 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC7783756 OTO - NOTNLM OT - androgen receptor OT - bladder cancer OT - naftopidil OT - silodosin OT - tamsulosin OT - alpha1-blocker COIS- Hiroshi Miyamoto has received research funding from Astellas Scientific and Medical Affairs, Ferring Research Institute, and Bristol-Myers Squibb. EDAT- 2021/01/09 06:00 MHDA- 2021/01/09 06:01 PMCR- 2020/12/01 CRDT- 2021/01/08 06:12 PHST- 2020/07/28 00:00 [received] PHST- 2020/11/09 00:00 [accepted] PHST- 2021/01/08 06:12 [entrez] PHST- 2021/01/09 06:00 [pubmed] PHST- 2021/01/09 06:01 [medline] PHST- 2020/12/01 00:00 [pmc-release] PST - epublish SO - Am J Cancer Res. 2020 Dec 1;10(12):4386-4398. eCollection 2020. PMID- 33410746 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210911 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 15 IP - 8 DP - 2021 Aug TI - Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guerin. PG - E412-E417 LID - 10.5489/cuaj.7066 [doi] AB - INTRODUCTION: While studies suggest that innate immune memory acquired by circulating monocytes may mediate the benefit of bacillus Calmette-Guerin (BCG) in the treatment of patients with high-risk non-muscle-invasive bladder cancer (NMIBC), prospective studies are lacking. Innate immune memory is defined by enhanced release of pro-inflammatory cytokines by innate immune cells following a secondary challenge with pattern recognition receptor (PRR) ligands. METHODS: Peripheral blood monocytes isolated from 33 patients with intermediate- or high-risk NMIBC before and after two or five induction BCG instillations were stimulated with the PRR ligand lipopolysaccharide (LPS). Inflammatory cytokine levels in the culture medium were measured. Extent of innate immune memory acquisition was determined by dividing the levels of cytokines released after BCG instillation by the levels released prior to BCG therapy. RESULTS: Monocytes secreted variable levels of TNFalpha, IL-1beta, IL-6, IFNgamma, IL-12, and IL-10. Compared with patients with recurrences, the post-BCG:pre-BCG ratio of IL-12 in monocyte cultures from patients without recurrences after five BCG instillations was significantly increased. Patients with no innate immune memory (based on IL-12 ratios) had significantly shorter time to recurrence than patients with innate immune memory (p<0.001). Eighty-four percent (16/19) of patients with innate immune memory vs. only 22% (2/9) of patients without memory had disease-free survival of over 500 days. CONCLUSIONS: Results demonstrate a potential link between BCG-induced innate immune memory peripherally and local anti-tumor responses. Further validation will increase our understanding of the mode of action of BCG and, therefore, will be used to enhance its effectiveness. FAU - Graham, Charles H AU - Graham CH AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Urology, Queen's University, Kingston, ON, Canada. FAU - Pare, Jean-Francois AU - Pare JF AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Cotechini, Tiziana AU - Cotechini T AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Hopman, Wilma AU - Hopman W AD - Department of Public Health Sciences, Queen's University, Kingston, ON, Canada. FAU - Hindmarch, Charles C T AU - Hindmarch CCT AD - Department of Medicine, Queen's University, Kingston, ON, Canada. FAU - Ghaffari, Abdi AU - Ghaffari A AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Marginean, Diana AU - Marginean D AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Chenard, Stephen AU - Chenard S AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. FAU - Koti, Madhuri AU - Koti M AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Urology, Queen's University, Kingston, ON, Canada. FAU - Siemens, D Robert AU - Siemens DR AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. AD - Department of Urology, Queen's University, Kingston, ON, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC8418256 COIS- Competing interests: The authors do not report any competing personal or financial interests related to this work. EDAT- 2021/01/08 06:00 MHDA- 2021/01/08 06:01 PMCR- 2021/08/01 CRDT- 2021/01/07 12:14 PHST- 2021/01/08 06:00 [pubmed] PHST- 2021/01/08 06:01 [medline] PHST- 2021/01/07 12:14 [entrez] PHST- 2021/08/01 00:00 [pmc-release] AID - cuaj.7066 [pii] AID - cuaj-8-e412 [pii] AID - 10.5489/cuaj.7066 [doi] PST - ppublish SO - Can Urol Assoc J. 2021 Aug;15(8):E412-E417. doi: 10.5489/cuaj.7066. PMID- 33407469 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210111 IS - 1475-2867 (Print) IS - 1475-2867 (Electronic) IS - 1475-2867 (Linking) VI - 21 IP - 1 DP - 2021 Jan 6 TI - Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing. PG - 23 LID - 10.1186/s12935-020-01731-9 [doi] LID - 23 AB - OBJECTIVE: To investigate the genetic prognostic factors for the recurrence of non-muscle invasive bladder cancer. MATERIALS AND METHODS: The patients underwent transurethral resection of bladder tumor and received bacillus Calmette-Guerin (BCG) or epirubicin. Next-generation sequencing was performed and alterations of genes, pathways, and tumor mutation burden were recorded. Associations between these clinicopathological and genetic variants were estimated, and prognostic factor identified. RESULTS: A total of 58 cases were included in our study, and 46 patients underwent treatment with BCG. FGFR3 was the most frequently altered gene (48%), and more commonly detected in intermediate-risk patients. Univariate Cox analysis demonstrated that 10 genes were significantly correlated with BCG failure, while NEB, FGFR1 and SDHC were independent recurrence predictors. Besides, epigenetic-related gene pathway mutations were negatively correlated with recurrence (hazard ratio: 0.198, P = 0.023). DNA damage response and repair gene alterations were positively correlated with tumor burden, while altered TP53 was most frequent among these genes and significant correlated with high tumor burden. CONCLUSION: BCG instillation significantly reduced the rate of recurrence compared with epirubicin in this population. Potential biomarkers and therapeutic targets were found with the help of next-generation sequencing; correlations between DDR genes alterations and high tumor mutation burden were also demonstrated. FAU - Shao, Yanxiang AU - Shao Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Hu, Xu AU - Hu X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Yang, Zhen AU - Yang Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. AD - Department of Urology, Chengdu Second People's Hospital, Chengdu, People's Republic of China. FAU - Lia, Thongher AU - Lia T AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Yang, Weixiao AU - Yang W AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Wu, Kan AU - Wu K AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Ren, Shangqing AU - Ren S AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. AD - Robot Minimally Invasive Center, Sichuan Provincial People's Hospital, Chengdu, People's Republic of China. FAU - Xiong, Sanchao AU - Xiong S AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Dou, Weichao AU - Dou W AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Feng, Shuyang AU - Feng S AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Wang, Yaohui AU - Wang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Liu, Yang AU - Liu Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Wu, Kang AU - Wu K AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. FAU - Li, Xiang AU - Li X AUID- ORCID: 0000-0001-8471-0015 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 GuoXueXiang, Chengdu, 610041, People's Republic of China. xiangli.87@163.com. LA - eng GR - 81672552/National Natural Science Foundation of China (CN)/ GR - ZY2016104/the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University/ PT - Journal Article DEP - 20210106 PL - England TA - Cancer Cell Int JT - Cancer cell international JID - 101139795 PMC - PMC7789352 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - DNA damage response and repair OT - Next-generation sequencing OT - Predictive model COIS- The authors declare that they have no competing interests. EDAT- 2021/01/08 06:00 MHDA- 2021/01/08 06:01 PMCR- 2021/01/06 CRDT- 2021/01/07 05:46 PHST- 2020/10/14 00:00 [received] PHST- 2020/12/21 00:00 [accepted] PHST- 2021/01/07 05:46 [entrez] PHST- 2021/01/08 06:00 [pubmed] PHST- 2021/01/08 06:01 [medline] PHST- 2021/01/06 00:00 [pmc-release] AID - 10.1186/s12935-020-01731-9 [pii] AID - 1731 [pii] AID - 10.1186/s12935-020-01731-9 [doi] PST - epublish SO - Cancer Cell Int. 2021 Jan 6;21(1):23. doi: 10.1186/s12935-020-01731-9. PMID- 33396795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240805 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 1 DP - 2020 Dec 30 TI - Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. LID - 10.3390/cancers13010087 [doi] LID - 87 AB - Bladder cancer is among the top ten most common cancer types in the world. Around 25% of all cases are muscle-invasive bladder cancer, for which the gold standard treatment in the absence of metastasis is the cystectomy. In recent years, trimodality treatment associating maximal transurethral resection and radiotherapy combined with concurrent chemotherapy is increasingly used as an organ-preserving alternative. However, the use of this treatment is still limited by the lack of biomarkers predicting tumour response and by a lack of targeted radiosensitising drugs that can improve the therapeutic index, especially by limiting side effects such as bladder fibrosis. In order to improve the bladder-preserving treatment, experimental studies addressing these main issues ought to be considered (both in vitro and in vivo studies). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews, we conducted a literature search in PubMed on experimental studies investigating how to improve bladder cancer radiotherapy with different radiosensitising agents using a comprehensive search string. We made comments on experimental model selection, experimental design and results, formulating the gaps of knowledge still existing: such as the lack of reliable predictive biomarkers of tumour response to chemoradiation according to the molecular tumour subtype and lack of efficient radiosensitising agents specifically targeting bladder tumour cells. We provided guidance to improve forthcoming studies, such as taking into account molecular characteristics of the preclinical models and highlighted the value of using patient-derived xenografts as well as syngeneic models. Finally, this review could be a useful tool to set up new radiation-based combined treatments with an improved therapeutic index that is needed for bladder preservation. FAU - Silina, Linda AU - Silina L AUID- ORCID: 0000-0002-2382-3400 AD - French League Against Cancer Team, CNRS UMR144, Curie Institute and PSL Research University, 75005 Paris, France. AD - CNRS UMR 9187, INSERM U1196, Curie Institute, PSL Research University and Paris-Saclay University, Rue H. Becquerel, 91405 Orsay, France. FAU - Maksut, Fatlinda AU - Maksut F AD - CNRS UMR 9187, INSERM U1196, Curie Institute, PSL Research University and Paris-Saclay University, Rue H. Becquerel, 91405 Orsay, France. FAU - Bernard-Pierrot, Isabelle AU - Bernard-Pierrot I AD - French League Against Cancer Team, CNRS UMR144, Curie Institute and PSL Research University, 75005 Paris, France. FAU - Radvanyi, Francois AU - Radvanyi F AD - French League Against Cancer Team, CNRS UMR144, Curie Institute and PSL Research University, 75005 Paris, France. FAU - Crehange, Gilles AU - Crehange G AD - Radiation Oncology Department, Curie Institute, 75005 Paris, France. FAU - Megnin-Chanet, Frederique AU - Megnin-Chanet F AD - CNRS UMR 9187, INSERM U1196, Curie Institute, PSL Research University and Paris-Saclay University, Rue H. Becquerel, 91405 Orsay, France. FAU - Verrelle, Pierre AU - Verrelle P AD - CNRS UMR 9187, INSERM U1196, Curie Institute, PSL Research University and Paris-Saclay University, Rue H. Becquerel, 91405 Orsay, France. AD - Radiation Oncology Department, Curie Institute, 75005 Paris, France. AD - Clermont Auvergne University, 63000 Clermont-Ferrand, France. LA - eng GR - FDT201904008237/Fondation pour la Recherche Medicale/ GR - D4008/10.11.16/532/Electricite de France/ GR - INCa-DGOS- 4654/SIRIC-Curie/ GR - 666003/H2020 Marie Sklodowska-Curie Actions/ PT - Journal Article PT - Review DEP - 20201230 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7795454 OTO - NOTNLM OT - bladder cancer OT - bladder cancer cell lines OT - molecular subtypes OT - preclinical studies OT - radiosensitisation OT - radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2021/01/06 06:00 MHDA- 2021/01/06 06:01 PMCR- 2020/12/30 CRDT- 2021/01/05 01:17 PHST- 2020/11/30 00:00 [received] PHST- 2020/12/22 00:00 [revised] PHST- 2020/12/22 00:00 [accepted] PHST- 2021/01/05 01:17 [entrez] PHST- 2021/01/06 06:00 [pubmed] PHST- 2021/01/06 06:01 [medline] PHST- 2020/12/30 00:00 [pmc-release] AID - cancers13010087 [pii] AID - cancers-13-00087 [pii] AID - 10.3390/cancers13010087 [doi] PST - epublish SO - Cancers (Basel). 2020 Dec 30;13(1):87. doi: 10.3390/cancers13010087. PMID- 33392066 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220419 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer. PG - 542492 LID - 10.3389/fonc.2020.542492 [doi] LID - 542492 AB - OBJECTIVE: The malignant progression from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is common and has detrimental effect on patients. We aimed to elucidate the underlying mechanisms of the malignant progression from an immunological perspective and establish a reliable signature for prognostic prediction and immunotherapeutic strategies. METHODS: The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts algorithm was applied to the GSE32894 data set to identify the different tumor-infiltrating immune cells involved in NMIBC and MIBC. Using weighted gene correlation network analysis, survival analysis and least absolute shrinkage and selection operator Cox analysis, we established an immune prognostic signature (IPS) based on 14 overall survival-associated immune genes in The Cancer Genome Atlas (TCGA). Functional enrichment analyses and nomogram were performed to explore the potential effects and prognostic performance of the IPS. Furthermore, the RNA-sequence data from our center were used to validate the expression levels of the selected immune genes in BLCA samples. RESULTS: Diverse proportions of macrophage subtypes were observed between NMIBC and MIBC. Patients with high risk scores had a worse prognosis than patients with low risk scores in training (TCGA) and validation data sets (GSE32894, GSE13507, and GSE48277). The IPS was a useful prognostic factor for patients treated with immunotherapy in the IMvigor210 trial. Hallmarks of multiple oncogenic pathways were significantly enriched in the high risk group. A novel nomogram model was established for prognostic predictions. The dysregulated expression of the selected immune genes between NMIBC and MIBC was also validated in BLCA samples. CONCLUSION: Dysregulation of the immune microenvironment promoted the malignant progression from NMIBC to MIBC. The IPS can stratify patients into different risk groups with distinct prognoses and immunotherapeutic susceptibility, thus facilitating personalized immunotherapy. CI - Copyright (c) 2020 Zheng, Mao, Zhang, Liu, Li, Wang and Yao. FAU - Zheng, Zongtai AU - Zheng Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Mao, Shiyu AU - Mao S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, Ji AU - Liu J AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Li, Cheng AU - Li C AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Wang, Ruiliang AU - Wang R AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20201216 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7773013 OTO - NOTNLM OT - Cell Type Identification by Estimating Relative Subsets of RNA Transcripts OT - bladder cancer OT - immune OT - nomogram OT - prognostic signature COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/01/05 06:00 MHDA- 2021/01/05 06:01 PMCR- 2020/01/01 CRDT- 2021/01/04 05:30 PHST- 2020/03/13 00:00 [received] PHST- 2020/11/16 00:00 [accepted] PHST- 2021/01/04 05:30 [entrez] PHST- 2021/01/05 06:00 [pubmed] PHST- 2021/01/05 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.542492 [doi] PST - epublish SO - Front Oncol. 2020 Dec 16;10:542492. doi: 10.3389/fonc.2020.542492. eCollection 2020. PMID- 33387223 OWN - NLM STAT- MEDLINE DCOM- 20211006 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 53 IP - 6 DP - 2021 Jun TI - Prognosis of patients with T1 bladder cancer after en bloc transurethral resection of bladder tumor stratified by invasion to the level of the muscularis mucosa. PG - 1105-1109 LID - 10.1007/s11255-020-02772-9 [doi] AB - PURPOSE: To evaluate the prognosis of patients with pT1 bladder cancer who underwent en bloc resection of bladder tumors (ERBTs), stratified by invasion to the muscularis mucosa (MM) level. METHODS: Among 64 specimens obtained by ERBT with bipolar energy from patients with pT1 bladder cancer, MM was detected in 61 specimens. Thus, 61 specimens were included in this retrospective study. Patients were stratified by invasion to the MM level (pT1a, invasion above the MM level; pT1b, invasion within the MM level; and pT1c, invasion beyond the MM level). In specimens with discontinuous MM, invasion to the MM level was predicted from the dispersed MM in the specimen. The primary endpoints were progression-free survival (PFS) and cancer-specific survival (CSS). RESULTS: Progression occurred in 2/39 patients with pT1a (5.1%), 1/6 patients with pT1b (16.7%), and 6/16 patients with pT1c cancer (37.5%). Cancer death occurred in 1/39 patients with pT1a (2.6%), 0/7 patients with pT1b, and 3/16 patients with pT1c cancer (18.8%). Patients with pT1a or pT1b cancer had a significantly better prognosis than those with pT1c cancer. On univariate analysis, tumor size >/= 3 cm and pT1c were significantly associated with shorter PFS. On multivariate analysis, only pT1c was independently associated with shorter PFS. CONCLUSION: This is the first study evaluating the prognosis by T1 substaging based on invasion to the MM level using ERBT specimens. ERBT provided high-quality specimens for diagnosing the MM and showed poor prognosis in pT1c bladder cancer. ERBT could be an appropriate surgical approach for an accurate diagnosis and prognosis of the T1 bladder cancer substage. FAU - Yasui, Masato AU - Yasui M AUID- ORCID: 0000-0003-4216-9421 AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. yabomabo@gmail.com. FAU - Ohta, Jun-Ichi AU - Ohta JI AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Aoki, Shuntaro AU - Aoki S AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Tajirika, Hironao AU - Tajirika H AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Terao, Hideyuki AU - Terao H AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Funahashi, Makoto AU - Funahashi M AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Moriyama, Masatoshi AU - Moriyama M AD - Department of Urology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa-ku, Yokohama, 221-0855, Japan. FAU - Hayashi, Hiroyuki AU - Hayashi H AD - Department of Pathology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. LA - eng PT - Journal Article DEP - 20210102 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mucous Membrane/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - En bloc resection of bladder tumor OT - Endourology OT - Muscularis mucosa OT - Non-muscle-invasive bladder cancer OT - T1 substaging EDAT- 2021/01/03 06:00 MHDA- 2021/10/07 06:00 CRDT- 2021/01/02 12:10 PHST- 2020/11/05 00:00 [received] PHST- 2020/12/22 00:00 [accepted] PHST- 2021/01/03 06:00 [pubmed] PHST- 2021/10/07 06:00 [medline] PHST- 2021/01/02 12:10 [entrez] AID - 10.1007/s11255-020-02772-9 [pii] AID - 10.1007/s11255-020-02772-9 [doi] PST - ppublish SO - Int Urol Nephrol. 2021 Jun;53(6):1105-1109. doi: 10.1007/s11255-020-02772-9. Epub 2021 Jan 2. PMID- 33386289 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220428 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 5 DP - 2021 Sep TI - Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial. PG - 1035-1043 LID - S2405-4569(20)30303-5 [pii] LID - 10.1016/j.euf.2020.12.003 [doi] AB - BACKGROUND: En-bloc resection of bladder tumors achieves complete tumor removal, improves the quality of resection, decreases perioperative complication, and potentially improves recurrence rates. OBJECTIVE: To assess the efficacy and safety of holmium laser en-bloc resection (HolERBT) versus conventional transurethral resection of bladder tumor (cTURBT). DESIGN, SETTING, AND PARTICIPANTS: Between September 2015 and September 2018, 100 patients with non-muscle-invasive bladder cancer were randomly allocated to cTURBT or HolERBT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was detection of residual tumor in reTURBT specimens at 4 wk after the primary resection. Operative parameters, specimen quality, perioperative complications, and recurrence-free survival (RFS) were compared. Independent sample t tests, chi(2) tests, and Kaplan-Meier curves were used, as appropriate. RESULTS AND LIMITATIONS: The patient and tumor baseline characteristics were comparable between the groups. Residual tumors were detected in 7% and 27.7% of cases after HolERBT and cTURBT, respectively (p=0.01). Detrusor muscle was sampled in 98% of HolERBT and 62% of cTURBT cases (p<0.001). Lamina propria invasion substaging was feasible in only 68.2% of HolERBT and 18.4% of cTURBT cases (p<0.001). Following HolERBT, catheterization time (p<0.001) and hospital stay (p=0.001) were shorter when compared to cTURBT. Immediate postoperative instillation of chemotherapy in indicated cases was feasible for 100% of the HolERBT group and 91.5% of the cTURBT group (p=0.04). After follow-up of 20 +/- 9.9 mo (13-36), RFS was 31.76 mo (95% confidence interval [CI] 28.67-34.86) in the HolERBT group and 28.25 mo (95% CI 24.87-31.64) in the cTURBT group (hazard ratio 0.43, 95% CI 0.17-1.1; p=0.07). However, this study was not powered to detect a difference in RFS. CONCLUSIONS: Compared to cTURBT, HolERBT is a safer procedure for bladder tumor resection. It fulfills the oncological criteria of optimized resection with less residual tumor and better specimen quality. PATIENT SUMMARY: En-bloc resection of bladder cancer tumors using a holmium laser is safer than the conventional technique. It has the advantages of less residual tumor and better specimen quality, with a similar tumor recurrence rate. This study is registered at ClinicalTrials.gov as NCT02555163. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Hashem, Abdelwahab AU - Hashem A AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Mosbah, Ahmed AU - Mosbah A AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Tabey, Nasr A AU - El-Tabey NA AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Laymon, Mahmoud AU - Laymon M AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Ibrahiem, El-Houssieny AU - Ibrahiem EH AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Elhamid, Mohamed Abd AU - Elhamid MA AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Elshal, Ahmed M AU - Elshal AM AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. Electronic address: elshalam@hotmail.com. LA - eng SI - ClinicalTrials.gov/NCT02555163 PT - Journal Article PT - Randomized Controlled Trial DEP - 20201230 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Cystectomy/methods MH - Humans MH - *Lasers, Solid-State/therapeutic use MH - Neoplasm, Residual/surgery MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Urologic Surgical Procedures/methods OTO - NOTNLM OT - *Bladder tumor OT - *Laser OT - *Non-muscle-invasive bladder cancer OT - *Resection OT - *Transurethral resection of bladder tumor EDAT- 2021/01/03 06:00 MHDA- 2022/04/14 06:00 CRDT- 2021/01/02 05:15 PHST- 2020/08/22 00:00 [received] PHST- 2020/11/01 00:00 [revised] PHST- 2020/12/05 00:00 [accepted] PHST- 2021/01/03 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2021/01/02 05:15 [entrez] AID - S2405-4569(20)30303-5 [pii] AID - 10.1016/j.euf.2020.12.003 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Sep;7(5):1035-1043. doi: 10.1016/j.euf.2020.12.003. Epub 2020 Dec 30. PMID- 33376063 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 3 DP - 2021 Mar TI - Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review. PG - 161-170 LID - S1078-1439(20)30583-4 [pii] LID - 10.1016/j.urolonc.2020.11.014 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is accompanied with high incidence and recurrence rates. The extensive need for cystoscopic follow up causes substantial patient discomfort and leads to a high economic burden. Cytology of exfoliated tumor cells in urine is not able to safely reduce or replace the amount of cystoscopies. Here, we give a short overview of established urinary biomarkers and review 2 novel urinary biomarkers, ADXBLADDER and Bladder EpiCheck, for their clinical utility in NMIBC. A Pubmed literature search was performed on the subject of urinary biomarkers for NMIBC. The performance of urinary cytology and established biomarkers Nuclear matrix proteins (NMP22), BTA, UroVysion, and ImmunoCyt was evaluated. The performance of novel biomarkers ADXBLADDER and Bladder EpiCheck was critically reviewed. Based on available clinical studies, established urinary biomarkers have no clear role in the diagnosis or follow-up of NMIBC. Three available prospective studies of ADXBLADDER (2 studying initial diagnosis and 1 follow-up study) reported overall sensitivity (45%-73%) and negative predictive values (NPV) (74%-100%) superior to cytology, with reasonable specificity (70%-73%). Four follow-up Bladder EpiCheck studies reported overall sensitivity (62%-90%) and NPV (79%-97%) superior to cytology, with a high specificity (82%-88%). For detection of high grade recurrences, sensitivity, and NPV of both novel biomarkers were even higher, with a sensitivity and NPV of 76% to 88% and 99% respectively for ADXBLADDER and 79% to 95% and 99% respectively for Bladder EpiCheck - Novel urinary biomarkers ADXBLADDER and Bladder EpiCheck have better sensitivity and NPV, but worse specificity than cytology in the follow-up of NMIBC. In the future, these biomarkers might reduce the amount of follow-up cystoscopies, for instance via an intermittent follow-up scheme alternating between cystoscopy and biomarker testing. The main biomarker objective should be to rule out high grade tumor recurrence without the need for any invasive procedures. Nevertheless, the clinical implementation of these biomarkers in the follow up of NMIBC has to be further investigated in prospective randomized trials for low as well as high grade tumors. CI - Copyright (c) 2020. Published by Elsevier Inc. FAU - Wolfs, Jur Robert Erica AU - Wolfs JRE AD - Eindhoven University of Technology, Eindhoven, The Netherlands. FAU - Hermans, Tom Johannes Noel AU - Hermans TJN AD - Catharina Hospital Eindhoven, Eindhoven, The Netherlands. FAU - Koldewijn, Evert Louwerens AU - Koldewijn EL AD - Catharina Hospital Eindhoven, Eindhoven, The Netherlands. FAU - van de Kerkhof, Daan AU - van de Kerkhof D AD - Catharina Hospital Eindhoven, Eindhoven, The Netherlands; Expert Center Clinical Chemistry Eindhoven, Eindhoven, The Netherlands. Electronic address: daan.vd.kerkhof@catharinaziekenhuis.nl. LA - eng PT - Journal Article PT - Review DEP - 20201226 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*urine MH - Humans MH - Neoplasm Invasiveness MH - Urinalysis/methods MH - Urinary Bladder Neoplasms/pathology/*urine OTO - NOTNLM OT - ADXBLADDER OT - Bladder EpiCheck OT - Follow-up OT - Nonmuscle invasive bladder cancer OT - Recurrence EDAT- 2020/12/31 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/12/30 05:17 PHST- 2020/09/23 00:00 [received] PHST- 2020/11/02 00:00 [revised] PHST- 2020/11/09 00:00 [accepted] PHST- 2020/12/31 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/12/30 05:17 [entrez] AID - S1078-1439(20)30583-4 [pii] AID - 10.1016/j.urolonc.2020.11.014 [doi] PST - ppublish SO - Urol Oncol. 2021 Mar;39(3):161-170. doi: 10.1016/j.urolonc.2020.11.014. Epub 2020 Dec 26. PMID- 33369059 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20210426 IS - 1742-1241 (Electronic) IS - 1368-5031 (Linking) VI - 75 IP - 5 DP - 2021 May TI - Do urinary mast cell mediators predict immune response to BCG in patients with primary high-grade non-muscle invasive bladder cancer? PG - e13959 LID - 10.1111/ijcp.13959 [doi] AB - BACKGROUND: Mast cells play a critical role in cancer-associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) immunotherapy. METHODS: In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N-methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed. RESULTS: The average age was 56.1 +/- 10.5 years in Group 1 and 52.6 +/- 9.7 years in Group 2. Fourteen patients had high-grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N-methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N-methylhistamine levels significantly decreased when immunotherapy was terminated (P < .05). The pre-BCG estimated marginal mean values of N-methylhistamine were significantly higher in Group 1 than in Group 2 (P < .05). CONCLUSIONS: Our study is the first to identify the changes in mast cell mediators with the onset of immunotherapy and in presence of bladder cancer. However, these mediators cannot predict patients' response to immunotherapy. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Simsekoglu, Muhammed Fatih AU - Simsekoglu MF AUID- ORCID: 0000-0001-7577-7955 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Kaleler, Islim AU - Kaleler I AUID- ORCID: 0000-0002-2712-7955 AD - Department of Biochemistry, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Onal, Bulent AU - Onal B AUID- ORCID: 0000-0003-0540-2693 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Demirdag, Cetin AU - Demirdag C AUID- ORCID: 0000-0002-8912-9155 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Citgez, Sinharib AU - Citgez S AUID- ORCID: 0000-0002-3897-2951 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Uslu, Ezel AU - Uslu E AUID- ORCID: 0000-0003-3925-0851 AD - Department of Biochemistry, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Erozenci, Ahmet AU - Erozenci A AUID- ORCID: 0000-0002-6389-5353 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. FAU - Talat, Zubeyr AU - Talat Z AUID- ORCID: 0000-0003-0645-4129 AD - Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey. LA - eng GR - 30651/Bilimsel Arastirma Projeleri Birimi, Istanbul Universitesi/ PT - Journal Article DEP - 20210105 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/therapeutic use MH - Humans MH - Immunity MH - Mast Cells MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2020/12/29 06:00 MHDA- 2021/04/27 06:00 CRDT- 2020/12/28 12:40 PHST- 2020/11/17 00:00 [received] PHST- 2020/12/21 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2020/12/28 12:40 [entrez] AID - 10.1111/ijcp.13959 [doi] PST - ppublish SO - Int J Clin Pract. 2021 May;75(5):e13959. doi: 10.1111/ijcp.13959. Epub 2021 Jan 5. PMID- 33368857 OWN - NLM STAT- MEDLINE DCOM- 20210317 LR - 20250515 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) VI - 112 IP - 3 DP - 2021 Mar TI - The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma. PG - 1084-1094 LID - 10.1111/cas.14782 [doi] AB - This study aimed to clarify the clinical characteristics and oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) who developed muscle-invasive bladder cancer (MIBC) after radical nephroureterectomy (RNU). We identified 966 pTa-4N0-2M0 patients with UTUC who underwent RNU and clarified the risk factors for MIBC progression after initial intravesical recurrence (IVR). We also identified 318 patients with primary pT2-4N0-2M0 MIBC to compare the oncological outcomes with those of patients with UTUC who developed or progressed to MIBC. Furthermore, immunohistochemical examination of p53 and FGFR3 expression in tumor specimens was performed to compare UTUC of MIBC origin with primary MIBC. In total, 392 (40.6%) patients developed IVR after RNU and 46 (4.8%) developed MIBC at initial IVR or thereafter. As a result, pT1 stage on the initial IVR specimen, concomitant carcinoma in situ on the initial IVR specimen, and no intravesical adjuvant therapy after IVR were independent factors for MIBC progression. After propensity score matching adjustment, primary UTUC was a favorable indicator for cancer-specific death compared with primary MIBC. Subgroup molecular analysis revealed high FGFR3 expression in non-MIBC and MIBC specimens from primary UTUC, whereas low FGFR3 but high p53 expression was observed in specimens from primary MIBC tissue. In conclusion, our study demonstrated that patients with UTUC who develop MIBC recurrence after RNU exhibited the clinical characteristics of subsequent IVR more than those of primary UTUC. Of note, MIBC subsequent to UTUC may have favorable outcomes, probably due to the different molecular biological background compared with primary MIBC. CI - (c) 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. FAU - Shigeta, Keisuke AU - Shigeta K AUID- ORCID: 0000-0002-9405-9446 AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AUID- ORCID: 0000-0001-9222-0999 AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Murakami, Tetsushi AU - Murakami T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Anno, Tadatsugu AU - Anno T AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Umeda, Kota AU - Umeda K AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Izawa, Mizuki AU - Izawa M AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. AD - Department of Urology, Saitama Medical University Hospital, Saitama, Japan. FAU - Baba, Yuto AU - Baba Y AD - Department of Urology, International University of Health and Welfare Mita Hospital, Tokyo, Japan. FAU - Sanjo, Tansei AU - Sanjo T AD - Department of Urology, Isehara Kyodo Hospital, Kanagawa, Japan. FAU - Shojo, Kazunori AU - Shojo K AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Takeda, Toshikazu AU - Takeda T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kosaka, Takeo AU - Kosaka T AUID- ORCID: 0000-0002-4371-4594 AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mikami, Shuji AU - Mikami S AUID- ORCID: 0000-0002-2978-2187 AD - Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AUID- ORCID: 0000-0002-1624-6676 AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Oya, Mototsugu AU - Oya M AUID- ORCID: 0000-0002-2048-4263 AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Comparative Study PT - Journal Article DEP - 20210111 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 RN - 0 (Antineoplastic Agents) SB - IM EIN - Cancer Sci. 2025 Aug;116(8):2323. doi: 10.1111/cas.70101. PMID: 40369799 MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Carcinoma, Transitional Cell/*mortality/secondary/therapy MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/mortality/*pathology/therapy MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology/surgery MH - Neoadjuvant Therapy MH - Neoplasm Recurrence, Local/*epidemiology/pathology MH - Nephroureterectomy MH - Propensity Score MH - Retrospective Studies MH - Risk Factors MH - Ureteral Neoplasms/mortality/*pathology/therapy MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*mortality/secondary/therapy PMC - PMC7935810 OTO - NOTNLM OT - immunohistochemistry OT - intravesical recurrence OT - muscle-invasive bladder cancer OT - non-muscle-invasive bladder cancer OT - upper tract urothelial carcinoma COIS- All authors state that there are no conflict of interests in the subject matter or materials discussed in the manuscript. EDAT- 2020/12/29 06:00 MHDA- 2021/03/18 06:00 PMCR- 2021/03/01 CRDT- 2020/12/28 12:36 PHST- 2020/10/18 00:00 [received] PHST- 2020/12/09 00:00 [revised] PHST- 2020/12/22 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2021/03/18 06:00 [medline] PHST- 2020/12/28 12:36 [entrez] PHST- 2021/03/01 00:00 [pmc-release] AID - CAS14782 [pii] AID - 10.1111/cas.14782 [doi] PST - ppublish SO - Cancer Sci. 2021 Mar;112(3):1084-1094. doi: 10.1111/cas.14782. Epub 2021 Jan 11. PMID- 33367941 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220218 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - Follow-up in non-muscle invasive bladder cancer: facts and future. PG - 4047-4053 LID - 10.1007/s00345-020-03569-2 [doi] AB - Patients with non-muscle invasive bladder cancer (NMIBC) have high recurrence and progression rates in spite of tumor resection and adjuvant instillation therapy. To detect recurrences and progression, these patients remain under frequent follow-up. Follow-up, however, is not well defined. Frequency and duration of follow recommendations are based on low levels of evidence, which is illustrated by clear differences in these recommendations per guideline, even when specified per risk group. Additionally, follow-up is recommended with cystoscopy and cytology in selected patients, which both have clear limitations. Fact is that follow-up in NMIBC is too frequent, with low levels of evidence and suboptimal tools, and it is patient unfriendly and costly. Improved cystoscopy techniques are unproven or impractical in the outpatient follow-up setting. Urinary markers have been around for decades, but never widely used in clinical practice. New (epi)genetic markers, however, could play a significant role in future follow-up of NMIBC. They have been shown to have very high negative predictive values for recurrences in follow-up of NMIBC, especially high-grade recurrences. Several studies suggested that these markers could be used to adapt follow-up cystoscopy frequency. What still needs study and confirmation is the cost-effectiveness of the use of these markers, which is highly dependent on health care costs per country and marker price. In all, however, implementation of these new urinary markers after confirmation of current results might significantly reduce patient burden and health care costs in the near future without reducing quality. CI - (c) 2020. The Author(s). FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, University Medical Center Nijmegen, Radboudumc (610), P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Fred.witjes@radboudumc.nl. LA - eng PT - Journal Article PT - Review DEP - 20201226 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/urine MH - Cystoscopy MH - Follow-Up Studies MH - Humans MH - Neoplasm Invasiveness MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/pathology/therapy/urine PMC - PMC8571151 OTO - NOTNLM OT - Costs OT - Follow-up OT - Non-muscle invasive bladder cancer OT - Risk groups OT - Urinary markers COIS- Ipsen, Nucleix, OncoDiag, Astellas, Janssen, Sanofi, MSD, BMS. EDAT- 2020/12/29 06:00 MHDA- 2022/02/19 06:00 PMCR- 2020/12/26 CRDT- 2020/12/28 12:18 PHST- 2020/10/21 00:00 [received] PHST- 2020/12/12 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2020/12/28 12:18 [entrez] PHST- 2020/12/26 00:00 [pmc-release] AID - 10.1007/s00345-020-03569-2 [pii] AID - 3569 [pii] AID - 10.1007/s00345-020-03569-2 [doi] PST - ppublish SO - World J Urol. 2021 Nov;39(11):4047-4053. doi: 10.1007/s00345-020-03569-2. Epub 2020 Dec 26. PMID- 33358490 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 2 DP - 2021 Apr TI - Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. PG - 117-124 LID - S1558-7673(20)30265-2 [pii] LID - 10.1016/j.clgc.2020.11.004 [doi] AB - PURPOSE: To evaluate stage at presentation and cancer-specific mortality (CSM) in upper urinary tract tumors according to histologic subtype. METHODS: Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), we identified patients with upper urinary tract tumors with pure variant histology (UTVH) and pure upper urinary tract urothelial carcinoma (UTUC). Cumulative incidence plots, after propensity score matching for tumor and patient characteristics, addressed CSM. Subgroup analyses addressed efficacy of radical nephroureterectomy (RNU) in stage T1-2 and of chemotherapy in metastatic UTVH patients. RESULTS: Of all 11,809 upper urinary tract tumor patients, 154 (1.3%) harbored squamous cell carcinoma (SCC), 86 (0.7%) adenocarcinoma, 39 (0.3%) neuroendocrine carcinoma, 38 (0.3%) other UTVH, and 11,492 (97.3%) UTUC. UTVH patients were more likely to exhibit metastatic stage disease at diagnosis than UTUC (odds ratio, 1.9; 95% confidence interval, 1.3-2.8; P < .01). After detailed matching for performance status, only SCC showed significantly higher CSM than UTUC (multivariate HR = 1.71; P < .01). Subgroup analyses in stage T1-2 RNU patients showed, relative to UTUC patients, no CSM differences for SCC or adenocarcinoma patients. No significant survival benefit for chemotherapy administration was identified in patients with metastatic SCC or metastatic adenocarcinoma. This study is limited by its sample size and the missing centralized pathologic review. CONCLUSIONS: Disease stage at diagnosis is more advanced in UTVH patients than UTUC. Across all stages, CSM is higher for SCC than for UTUC. However, in T1-2 stage disease, RNU results in similar survival in SCC or adenocarcinoma versus UTUC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Deuker, Marina AU - Deuker M AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: marina.deuker@kgu.de. FAU - Stolzenbach, L Franziska AU - Stolzenbach LF AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Colla Ruvolo, Claudia AU - Colla Ruvolo C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, University of Naples Federico II, Naples, Italy. FAU - Nocera, Luigi AU - Nocera L AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Roos, Frederik C AU - Roos FC AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Becker, Andreas AU - Becker A AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Tilki, Derya AU - Tilki D AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, University of Jordan, Amman, Jordan. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20201202 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Humans MH - Nephroureterectomy MH - Retrospective Studies MH - *Ureteral Neoplasms/pathology/surgery MH - *Urinary Bladder Neoplasms MH - *Urologic Neoplasms/pathology/surgery OTO - NOTNLM OT - Neuroendocrine carcinoma OT - Radical nephroureterectomy OT - Renal pelvis OT - Squamous cell carcinoma OT - Ureter EDAT- 2020/12/29 06:00 MHDA- 2021/08/10 06:00 CRDT- 2020/12/28 10:36 PHST- 2020/09/13 00:00 [received] PHST- 2020/11/04 00:00 [revised] PHST- 2020/11/18 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/12/28 10:36 [entrez] AID - S1558-7673(20)30265-2 [pii] AID - 10.1016/j.clgc.2020.11.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Apr;19(2):117-124. doi: 10.1016/j.clgc.2020.11.004. Epub 2020 Dec 2. PMID- 33358370 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220502 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 8 IP - 1 DP - 2022 Jan TI - Deep Learning-based Recurrence Prediction in Patients with Non-muscle-invasive Bladder Cancer. PG - 165-172 LID - S2405-4569(20)30310-2 [pii] LID - 10.1016/j.euf.2020.12.008 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrence of the disease, which is difficult to predict. OBJECTIVE: To combine digital histopathology slides with clinical data to predict 1- and 5-yr recurrence-free survival of NMIBC patients using deep learning. DESIGN, SETTING, AND PARTICIPANTS: Data of patients undergoing a transurethral resection of a bladder tumor between 2000 and 2018 at a Dutch academic medical center were selected. Corresponding histological slides were digitized. A three-step approach was used to predict 1- and 5-yr recurrence-free survival. First, a segmentation network was used to detect the urothelium on the digital histopathology slides. Second, a selection network was trained for the selection of patches associated with recurrence. Third, a classification network, combining the information of the selection network with clinical data, was trained to give the probability of 1- and 5-yr recurrence-free survival. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The accuracy of the deep learning-based model was compared with a multivariable logistic regression model using clinical data only. RESULTS AND LIMITATIONS: In the 1- and 5-yr follow-up cohorts, 359 and 281 patients were included with recurrence rates of 27% and 63%, respectively. The areas under the curve (AUCs) of the model combining digital histopathology slide data with clinical data were 0.62 and 0.76 for 1- and 5-yr recurrence predictions, respectively, which were higher than those of the model using digital histopathology slide data only (AUCs of 0.56 and 0.72, respectively) and the multivariable logistic regression (AUCs of 0.58 and 0.57, respectively). CONCLUSIONS: In our population, the deep learning-based model combining digital histopathology slides and clinical data enhances the prediction of recurrence (within 5 yr) compared with models using clinical data or image data only. PATIENT SUMMARY: By combining histopathology images and patient record data using deep learning, the prediction of recurrence in bladder cancer patients is enhanced. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Lucas, Marit AU - Lucas M AD - Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: m.lucas@amsterdamumc.nl. FAU - Jansen, Ilaria AU - Jansen I AD - Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - van Leeuwen, Ton G AU - van Leeuwen TG AD - Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - de Bruin, Daniel M AU - de Bruin DM AD - Department of Biomedical Engineering and Physics, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Marquering, Henk A AU - Marquering HA AD - Department of Biomedical Engineering and Physics, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Biomedical Engineering and Physics, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201224 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - *Deep Learning MH - Humans MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - *Bladder cancer OT - *Deep learning OT - *Disease recurrence OT - *Prediction EDAT- 2020/12/29 06:00 MHDA- 2022/04/14 06:00 CRDT- 2020/12/28 10:34 PHST- 2020/10/05 00:00 [received] PHST- 2020/11/10 00:00 [revised] PHST- 2020/12/10 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2020/12/28 10:34 [entrez] AID - S2405-4569(20)30310-2 [pii] AID - 10.1016/j.euf.2020.12.008 [doi] PST - ppublish SO - Eur Urol Focus. 2022 Jan;8(1):165-172. doi: 10.1016/j.euf.2020.12.008. Epub 2020 Dec 24. PMID- 33356484 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20260906 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 205 IP - 5 DP - 2021 May TI - Examining the Accuracy of Self-Reported Smoking-Related Exposure among Recently Diagnosed Nonmuscle Invasive Bladder Cancer Patients. PG - 1321-1325 LID - 10.1097/JU.0000000000001571 [doi] AB - PURPOSE: Cigarette smoking is a risk factor for developing nonmuscle invasive bladder cancer, and continued smoking exposure after diagnosis may increase the likelihood of adverse clinical outcomes. We compare self-reported vs biochemically verified nicotine exposure to determine the accuracy of self-report among recently diagnosed nonmuscle invasive bladder cancer patients. MATERIALS AND METHODS: This cross-sectional analysis consisted of 517 nonmuscle invasive bladder cancer patients who contributed a urine or saliva specimen the same day as self-reporting their smoking, use of e-cigarettes, nicotine replacement therapy and whether they lived with a smoker. Cotinine, the primary metabolite of nicotine, was used as an objective biomarker of recent nicotine exposure. RESULTS: The prevalence of high, low and no cotinine exposure was 13%, 54% and 33%, respectively. Overall, 7.3% of patients (38/517) reported being a current cigarette smoker, while 13% (65/517) had cotinine levels consistent with active smoking exposure. Of these 65 patients 27 denied current smoking, resulting in a sensitivity of self-reported current smoking of 58%. After considering other sources of nicotine exposure such as e-cigarettes, cigars, nicotine replacement therapy and living with a smoker, the sensitivity was higher, at 82%. Nearly all patients with low cotinine denied any smoking-related exposure. CONCLUSIONS: Our findings suggest either biochemical verification with cotinine or additional questions about other sources of nicotine are needed to accurately identify nonmuscle invasive bladder cancer patients who have smoking-related exposures. Accurate classification of active and passive smoking exposure is essential to allow clinicians to advise cessation and help researchers estimate the association between post-diagnosis smoking-related exposure and nonmuscle invasive bladder cancer recurrence risk. FAU - Petruzella, Stacey AU - Petruzella S AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Bochner, Bernard H AU - Bochner BH AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Kenney, Jessica AU - Kenney J AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Whiting, Karissa AU - Whiting K AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Sadeghi, Keimya AU - Sadeghi K AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Benfante, Nicole AU - Benfante N AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Cha, Eugene K AU - Cha EK AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Dalbagni, Guido AU - Dalbagni G AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Donahue, Timothy AU - Donahue T AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Donat, Sherri M AU - Donat SM AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Herr, Harry W AU - Herr HW AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Pietzak, Eugene AU - Pietzak E AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Orlow, Irene AU - Orlow I AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Ostroff, Jamie S AU - Ostroff JS AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Furberg, Helena AU - Furberg H AD - Memorial Sloan Kettering Cancer Center, New York, New York. LA - eng GR - K12 CA184746/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20201224 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers) RN - K5161X06LL (Cotinine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers/analysis MH - Cotinine/*blood/*urine MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Reproducibility of Results MH - *Self Report MH - Smoking/*blood/*urine MH - Urinary Bladder Neoplasms/*blood/diagnosis/pathology/*urine MH - Young Adult PMC - PMC9262154 MID - NIHMS1817399 OTO - NOTNLM OT - cotinine OT - smoking OT - urinary bladder neoplasms EDAT- 2020/12/29 06:00 MHDA- 2021/07/16 06:00 PMCR- 2022/07/07 CRDT- 2020/12/28 10:07 PHST- 2020/12/29 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2020/12/28 10:07 [entrez] PHST- 2022/07/07 00:00 [pmc-release] AID - 10.1097/JU.0000000000001571 [doi] PST - ppublish SO - J Urol. 2021 May;205(5):1321-1325. doi: 10.1097/JU.0000000000001571. Epub 2020 Dec 24. PMID- 33339725 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 4 DP - 2021 Apr TI - A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. PG - 237.e21-237.e29 LID - S1078-1439(20)30603-7 [pii] LID - 10.1016/j.urolonc.2020.11.017 [doi] AB - BACKGROUND: There is an increasing demand for prognostic immune biomarkers of cancer. The prognostic significance of immune markers has been shown for various cancers, but biomarkers of bladder cancer (BCa) have not been fully evaluated. To clarify the role of human leukocyte antigen DR alpha chain (HLA-DRA) in BCa development, we examined expression of HLA-DRA mRNA in tissue samples of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MATERIALS AND METHODS: Tissues of 96 NMIBC, 43 MIBC and 59 controls comprising noncancerous BCa surrounding tissues were used to examine the expression of HLA-DRA gene by real-time polymerase chain reaction. The expression of up-stream genes regulating HLA-DRA were also measured to explain the role of HLA-DRA in BCa. RESULTS: Patients with high grade NMIBC showed higher expression of HLA-DRA than those with low grade NMIBC (P < 0.05). In addition, NMIBC patients who progressed to MIBC showed high expression of HLA-DRA mRNA. Kaplan-Meier analysis showed that NMIBC patients with low expression of HLA-DRA had better progression-free survival than those with high expression (P = 0.004). Moreover, the expression of genes regulating HLA-DRA varied in NMIBC and MIBC, indicating a different immunoregulation effect of HLA-DRA in both cancers. CONCLUSIONS: High expression of HLA-DRA in NMIBC patients has implications for patient stratification strategies, as well as for BCa tumor immunology. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Lee, Hee Youn AU - Lee HY AD - Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Kim, Kyeong AU - Kim K AD - Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Seo, Sung Phil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Lee, Jong-Young AU - Lee JY AD - Oneomics Institute, Seoul, South Korea. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea; Department of Urology, Kyungpook National University Hospital, Daegu, South Korea. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan, South Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food Science and Technology, Chung-Ang University, Ansung, South Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. Electronic address: sjyun@chungbuk.ac.kr. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Institute of Urotech, Cheongju, South Korea. Electronic address: wjkim@chungbuk.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201215 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (HLA-DR alpha-Chains) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/*immunology MH - Female MH - Gene Expression Regulation, Neoplastic MH - HLA-DR alpha-Chains/genetics/*immunology MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Urinary Bladder Neoplasms/genetics/*immunology/*pathology OTO - NOTNLM OT - HLA-DRA OT - Immune biomarker OT - Muscle invasive bladder cancer OT - Nonmuscle invasive bladder cancer OT - Prognosis COIS- Conflict of interest None. EDAT- 2020/12/20 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/12/19 05:22 PHST- 2020/08/24 00:00 [received] PHST- 2020/11/10 00:00 [revised] PHST- 2020/11/11 00:00 [accepted] PHST- 2020/12/20 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/12/19 05:22 [entrez] AID - S1078-1439(20)30603-7 [pii] AID - 10.1016/j.urolonc.2020.11.017 [doi] PST - ppublish SO - Urol Oncol. 2021 Apr;39(4):237.e21-237.e29. doi: 10.1016/j.urolonc.2020.11.017. Epub 2020 Dec 15. PMID- 33319245 OWN - NLM STAT- MEDLINE DCOM- 20210323 LR - 20221207 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 51 IP - 3 DP - 2021 Mar 3 TI - Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment. PG - 424-433 LID - 10.1093/jjco/hyaa219 [doi] AB - OBJECTIVE: To explore the immunohistochemistry-based molecular subtypes of bladder cancer, and their impact on the prognosis and the chemotherapy response between gemcitabine plus cisplatin intra-arterial chemotherapy and epirubicin-inducted intravesical chemotherapy, in patients with T1 stage bladder cancer after bladder-preserving treatment. METHODS: One hundred and seventy-six patients with T1 stage bladder cancer were selected for this study. Thirty-three patients underwent radical cystectomy, 43 received gemcitabine plus cisplatin intra-arterial chemotherapy and 100 received intravesical chemotherapy. The markers labeled with luminal (GATA3, Uroplakin II, CK20) and basal (CK5/6, CK14, CD44) phenotypes were chosen as candidate markers. RESULTS: One hundred and seventy-six patients were divided into 76 patients as basal/squamous (BASQ), 45 as the luminal A and 55 as the luminal B. Compared with the luminal B and BASQ tumors, the luminal A tumors showed a trend for better recurrence-free survival (P = 0.105) and progression-free survival (P = 0.093). The combination of CK20 and GATA3 was practical to identify the molecular phenotypes with total 84.9% accuracy and significantly associated with recurrence-free survival (P = 0.025) and progression-free survival (P = 0.004). The patient with BASQ tumors who received intravesical chemotherapy showed a trend for worse progression-free survival than the patient who received gemcitabine plus cisplatin intra-arterial chemotherapy or radical cystectomy. Furthermore, the patients with BASQ tumors experienced a significant improvement in progression-free survival after gemcitabine plus cisplatin intra-arterial chemotherapy compared with the patients who received intravesical chemotherapy (P = 0.011). CONCLUSIONS: The immunohistochemistry-based molecular subtypes could predict the patient's prognosis and clinically different chemotherapeutic survival outcomes in patients with T1 stage bladder cancer after bladder-preserving treatment. CI - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Lu, Jiangli AU - Lu J AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. FAU - Zhang, Yijun AU - Zhang Y AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. FAU - Wu, Chenyan AU - Wu C AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. FAU - Chu, Chengbiao AU - Chu C AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. FAU - Liu, Zhuowei AU - Liu Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. FAU - Cao, Yun AU - Cao Y AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, P. R. China. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Biomarkers, Tumor) RN - 0W860991D6 (Deoxycytidine) RN - 3Z8479ZZ5X (Epirubicin) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Biomarkers, Tumor/metabolism MH - Cisplatin/therapeutic use MH - Deoxycytidine/analogs & derivatives/therapeutic use MH - Epirubicin/therapeutic use MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Organ Sparing Treatments MH - Prognosis MH - Progression-Free Survival MH - Treatment Outcome MH - Urinary Bladder Neoplasms/classification/*drug therapy/*pathology MH - Gemcitabine OTO - NOTNLM OT - bladder cancer OT - gemcitabine plus cisplatin intra-arterial chemotherapy OT - immunohistochemistry OT - molecular subtype OT - survival EDAT- 2020/12/16 06:00 MHDA- 2021/03/24 06:00 CRDT- 2020/12/15 06:06 PHST- 2020/08/13 00:00 [received] PHST- 2020/10/22 00:00 [accepted] PHST- 2020/12/16 06:00 [pubmed] PHST- 2021/03/24 06:00 [medline] PHST- 2020/12/15 06:06 [entrez] AID - 6034414 [pii] AID - 10.1093/jjco/hyaa219 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2021 Mar 3;51(3):424-433. doi: 10.1093/jjco/hyaa219. PMID- 33316558 OWN - NLM STAT- MEDLINE DCOM- 20211117 LR - 20211117 IS - 2468-2942 (Electronic) IS - 2468-2942 (Linking) VI - 25 DP - 2020 TI - Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer. PG - 100264 LID - S2468-2942(20)30099-X [pii] LID - 10.1016/j.ctarc.2020.100264 [doi] AB - BACKGROUND: Despite treatment with radical cystectomy, patients with muscle invasive bladder cancer (MIBC) have a poor survival. It has been reported that survival is worse in NMIBC patients who progressed to MIBC in comparison to patients with de novo MIBC. The objective of this study was to compare survival of progressive versus de novo MIBC. Secondary objective was to explain this difference in survival by clinicopathological factors. METHODS: 431 patients with MIBC who underwent radical cystectomy between 1998 and 2016 in the Radboudumc, Nijmegen, were retrospectively analyzed. 313 patients were identified with de novo MIBC and 118 with progressive MIBC. RESULTS: 5- and 10-year overall survival (OS) of patients with progressive MIBC was 37% and 20%, respectively. Patients with de novo MIBC had significantly better survival, with a 5- and 10-year OS of 49% and 39%, respectively. Patients with progressive MIBC were more frequently diagnosed with concomitant carcinoma in situ and positive surgical margins in bladder, ureters or urethra. In multivariable analysis that adjusted for these factors, progressive MIBC was associated with a hazard ratio of 1.40 (0.99 - 1.98). Kaplan-Meier survival curves show a detrimental effect of progressive MIBC in patients with pT2 versus pT3-4 tumors and in patients with negative versus positive surgical margins. In multivariable analysis, this effect modification disappeared. CONCLUSIONS: Progressive MIBC is associated with poorer survival than de novo MIBC. Because most patients with progressive MIBC had a history of high risk NMIBC, considering radical cystectomy is most important in the highest risk NMIBC. CI - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Vlaming, Michiel AU - Vlaming M AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands; Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. Electronic address: toine.vanderheijden@radboudumc.nl. LA - eng PT - Journal Article DEP - 20201204 PL - England TA - Cancer Treat Res Commun JT - Cancer treatment and research communications JID - 101694651 SB - IM MH - Aged MH - Cystectomy/methods/*mortality MH - Disease Progression MH - Female MH - Humans MH - Male MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/*surgery OTO - NOTNLM OT - Clinicopathological factors OT - Cystectomy OT - Disease progression OT - Mibc EDAT- 2020/12/15 06:00 MHDA- 2021/11/18 06:00 CRDT- 2020/12/14 20:10 PHST- 2020/09/12 00:00 [received] PHST- 2020/11/23 00:00 [revised] PHST- 2020/12/02 00:00 [accepted] PHST- 2020/12/15 06:00 [pubmed] PHST- 2021/11/18 06:00 [medline] PHST- 2020/12/14 20:10 [entrez] AID - S2468-2942(20)30099-X [pii] AID - 10.1016/j.ctarc.2020.100264 [doi] PST - ppublish SO - Cancer Treat Res Commun. 2020;25:100264. doi: 10.1016/j.ctarc.2020.100264. Epub 2020 Dec 4. PMID- 33312739 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220418 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 18 IP - 4 DP - 2020 Sep 2 TI - Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy. PG - 267-272 LID - 10.1080/2090598X.2020.1814183 [doi] AB - OBJECTIVES: To evaluate human epidermal growth factor receptor 2 (HER2) protein overexpression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridisation (FISH) in urothelial non-muscle-invasive bladder carcinoma (NMIBC), as HER2 is a potential therapeutic target in muscle-invasive bladder carcinoma (MIBC) and HER2 expression and gene amplification in low/high-grade and pTa/pT1 NMIBC is not clear. PATIENTS AND METHODS: The study included 93 bladder cancers; 25 MIBC and 68 NMIBC (37 low- and 31 high-grade). All HER2 positive (3+) and equivocal (2+) cases were subjected to FISH using a HER2/CEN 17 dual-colour probe kit. IHC and FISH were scored as per the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2013 Guidelines for breast cancers. Based on the number of signals/nuclei, amplification was categorised as low (>/=6-10) and high-level (>/=10). RESULTS: HER2 2-3+ expression was seen in 29% of NMIBCs (10.8% low- and 51.6% high-grade). HER2 3+ expression was seen in high-grade NMIBC (nine of 31; 29%) and MIBC (nine of 25; 36%). In all, 87% of high-grade NMIBCs were lamina invasive (pT1). Gene amplification was found in 45% (eight of 18) of 3+ tumours. None of the HER2 2+ tumours showed gene amplification. IHC and FISH results were in closest agreement when >/=50% of tumour cells showed 3+ expressions. High-level amplification correlated with increased gene expression on reverse transcriptase-polymerase chain reaction. On multivariate analysis, lower stage, grade, and HER2 expression significantly correlated with progression-free survival. HER2 3+ expression in NMIBC correlated significantly with time to recurrence and progression. CONCLUSION: Our present results show that HER2 FISH should not be performed for HER2 2 + and low-grade NMIBC. This contrasts with breast cancers where it is recommended for equivocal 2+ tumours. About 50% of HER2 3+ MIBC and high-grade NMIBC show HER2 gene amplification and can be potential candidates for HER2-targeted therapy. ABBREVIATIONS: ASCO/CAP: American Society of Clinical Oncology/College of American Pathologists; DAB: 3,3'-diaminobenzidine; FISH: fluorescent in situ hybridisation; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry;(N)MIBC: (non-) muscle-invasive bladder carcinoma; MPUC: micropapillary variant of urothelial bladder cancer; PFS: progression-free survival; TURBT: transurethral resection of bladder tumour. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Agrawal, Vinita AU - Agrawal V AUID- ORCID: 0000-0003-1806-7142 AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Bharti, Niharika AU - Bharti N AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. FAU - Pandey, Rakesh AU - Pandey R AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. LA - eng PT - Journal Article DEP - 20200902 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 CIN - Arab J Urol. 2020 Nov 9;18(4):273-274. doi: 10.1080/2090598X.2020.1835439. PMID: 33425393 PMC - PMC7717524 OTO - NOTNLM OT - Bladder carcinoma OT - HER2 oncogene OT - fluorescent in situ hybridisation OT - gene amplification OT - immunohistochemistry OT - non-invasive bladder carcinoma EDAT- 2020/12/15 06:00 MHDA- 2020/12/15 06:01 PMCR- 2020/01/01 CRDT- 2020/12/14 10:58 PHST- 2020/12/14 10:58 [entrez] PHST- 2020/12/15 06:00 [pubmed] PHST- 2020/12/15 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 1814183 [pii] AID - 10.1080/2090598X.2020.1814183 [doi] PST - epublish SO - Arab J Urol. 2020 Sep 2;18(4):267-272. doi: 10.1080/2090598X.2020.1814183. PMID- 33309565 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 2 DP - 2021 Apr TI - Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. PG - e100-e119 LID - S1558-7673(20)30252-4 [pii] LID - 10.1016/j.clgc.2020.11.002 [doi] AB - INTRODUCTION: In cases of recurrent high-risk non-muscle-invasive bladder cancer, radical cystectomy (RC) is recommended. We compared oncologic and treatment-related outcomes of second-line conservative device-assisted therapy to RC. PATIENTS AND METHODS: In a retrospective cohort study, we analyzed 209 consecutive patients with recurrent bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer; 107 subjects refused RC and were offered electromotive drug administration (n = 44) or chemohyperthermia (n = 63) (group A), and 102 patients underwent RC (group B). In group A, patients who did not benefit from device-assisted treatment underwent RC. The endpoints were high-grade disease-free survival, progression-free survival, cancer-specific survival, overall survival, and treatment-related complications. Follow-up was based on international guideline recommendations. Analyses were performed with log-rank and Fisher exact tests. RESULTS: The median follow-up was 59 months (SD +/- 5.3). When comparing group A to B, overall survival rates were 91.6% and 90.2%, respectively (P > .05); cancer-specific survival was 94.4% and 96.1%, respectively (P > .05); high-grade disease-free survival was 43% and 74.5%, respectively (P < .05); and progression-free survival was 59.8% and 75.5%, respectively (P < .05). Patients with carcinoma-in-situ had worse oncologic outcomes compared to patients with papillary disease. In the multivariate analysis, multifocality, disease recurrence, and progression risk group were independently associated with device treatment failure. The 90-day RC-related overall complications rates were 63.9% in group A and 66.6% in group B (P = .63); grade 3 to 5 complications were 9.8% in group A and 9.8% in group B(P = .99). Complications within group A were comparable (P > .05). CONCLUSION: Device-assisted treatment may a represent a valid second-line conservative tool in selected patients with recurrent high-risk non-muscle-invasive bladder cancer. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. Electronic address: luca.digian@libero.it. FAU - Ragonese, Mauro AU - Ragonese M AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. FAU - Sacco, Emilio AU - Sacco E AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. FAU - Bassi, PierFrancesco AU - Bassi P AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. FAU - Racioppi, Marco AU - Racioppi M AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Universita Cattolica del Sacro Cuore di Roma, Rome, Italy. LA - eng PT - Journal Article DEP - 20201113 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/surgery MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Conservative treatment OT - Decision making process OT - Device-assisted therapy OT - Outcomes OT - Radical cystectomy EDAT- 2020/12/15 06:00 MHDA- 2021/08/10 06:00 CRDT- 2020/12/14 10:14 PHST- 2020/07/01 00:00 [received] PHST- 2020/10/31 00:00 [revised] PHST- 2020/11/02 00:00 [accepted] PHST- 2020/12/15 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/12/14 10:14 [entrez] AID - S1558-7673(20)30252-4 [pii] AID - 10.1016/j.clgc.2020.11.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Apr;19(2):e100-e119. doi: 10.1016/j.clgc.2020.11.002. Epub 2020 Nov 13. PMID- 33308977 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20211214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 5 DP - 2021 May TI - The natural history of muscle-invasive bladder cancer in geriatric patients undergoing transurethral resection only: Outcome and cost. PG - 300.e7-300.e13 LID - S1078-1439(20)30619-0 [pii] LID - 10.1016/j.urolonc.2020.11.034 [doi] AB - PURPOSE: Bladder cancer is predominant in the elderly. Up to 70% of geriatric patients with muscle-invasive bladder cancer do not receive curative treatment. We analyzed the outcome of patients managed only by transurethral resection of bladder tumor (TURBT) without chemo- or radio-therapy, and performed a cost analysis of the cumulative inpatient interventions throughout the course of the disease. METHODS: From 2010 to 2016 81 patients >/=75 years with de novo muscle-invasive bladder cancer who were not eligible for curative treatment options were analyzed retrospectively. All patients were treated only with TURBT. Overall survival (OS) was measured by Kaplan-Meier plots (log-rank test) and clinical parameters predicting OS by a multivariate analysis. The cost analysis was based on actual billing from the hospital provider and referenced standardized pricing in Germany for bladder cancer treatment. RESULTS: The median age was 83 years. The OS was 11 months, the 1-year OS was 42%. In the multivariate model Charlson Comorbidity Index <8 (P = 0.016), tumor size /= stage pT3 (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.64-2.59; p < 0.001) and a lower rate of concomitant carcinoma in situ (OR, 0.25; 95% CI, 0.09-0.72; p = 0.010). The other clinicopathological variables were similar between SV-UCB and C-UCB. With unadjusted data, patients with SV-UCB had a significant inferior OS (HR, 1.24; 95% CI, 1.07-1.44; p = 0.004) and CSS (HR, 2.08; 95% CI, 1.63-2.66; p < 0.001). However, after adjusted, SV-UCB had worse OS (HR, 1.41; 95% CI, 0.95-2.08; p = 0.090) and CSS (HR, 1.54; 95% CI, 0.95-2.52; p = 0.080) approaching the borderline of significance. For SV-UCB, NAC (HR, 0.73; 95% CI, 0.51-1.05; p = 0.090) and AC (HR, 0.88; 95% CI, 0.66-1.17; p = 0.370) seemed to have no benefit on OS. CONCLUSIONS: Compared to C-UCB, SV-UCB was associated with more advanced disease and more inferior OS and CSS. NAC and AC had no survival benefit for SV-UCB. FAU - Gu, Liangyou AU - Gu L AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Ai, Qing AU - Ai Q AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Cheng, Qiang AU - Cheng Q AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Ma, Xin AU - Ma X AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Wang, Baojun AU - Wang B AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Huang, Qingbo AU - Huang Q AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Li, Xintao AU - Li X AD - Department of Urology, Air force specialty medical center, Beijing, China. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Liu, Kan AU - Liu K AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. FAU - Zhao, Xupeng AU - Zhao X AD - School of Medicine, Nankai University, Tianjin, China. FAU - Li, Hongzhao AU - Li H AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. urolancet@126.com. FAU - Zhang, Xu AU - Zhang X AUID- ORCID: 0000-0002-6908-6768 AD - Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China. xzhang@foxmail.com. LA - eng PT - Journal Article PT - Review DEP - 20201114 PL - England TA - Cancer Cell Int JT - Cancer cell international JID - 101139795 PMC - PMC7666462 OTO - NOTNLM OT - Bladder cancer OT - Sarcomatoid OT - Survival OT - Urothelial carcinoma OT - Variant histology COIS- The authors declare that they have no competing interests. EDAT- 2020/12/10 06:00 MHDA- 2020/12/10 06:01 PMCR- 2020/11/14 CRDT- 2020/12/09 05:42 PHST- 2020/08/04 00:00 [received] PHST- 2020/10/26 00:00 [accepted] PHST- 2020/12/09 05:42 [entrez] PHST- 2020/12/10 06:00 [pubmed] PHST- 2020/12/10 06:01 [medline] PHST- 2020/11/14 00:00 [pmc-release] AID - 10.1186/s12935-020-01626-9 [pii] AID - 1626 [pii] AID - 10.1186/s12935-020-01626-9 [doi] PST - epublish SO - Cancer Cell Int. 2020 Nov 14;20(1):550. doi: 10.1186/s12935-020-01626-9. PMID- 33291319 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201226 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 12 IP - 12 DP - 2020 Dec 6 TI - tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5'-tRF-LysCTT Results in Disease Early Progression and Patients' Poor Treatment Outcome. LID - 10.3390/cancers12123661 [doi] LID - 3661 AB - The heterogeneity of bladder cancer (BlCa) prognosis and treatment outcome requires the elucidation of tumors' molecular background towards personalized patients' management. tRNA-derived fragments (tRFs), although originally considered as degradation debris, represent a novel class of powerful regulatory non-coding RNAs. In silico analysis of the TCGA-BLCA project highlighted 5'-tRF-LysCTT to be significantly deregulated in bladder tumors, and 5'-tRF-LysCTT levels were further quantified in our screening cohort of 230 BlCa patients. Recurrence and progression for non-muscle invasive (NMIBC) patients, as well as progression and patient's death for muscle-invasive (MIBC) patients, were used as clinical endpoint events. TCGA-BLCA were used as validation cohort. Bootstrap analysis was performed for internal validation and the clinical net benefit of 5'-tRF-LysCTT on disease prognosis was assessed by decision curve analysis. Elevated 5'-tRF-LysCTT was associated with unfavorable disease features, and significant higher risk for early progression (multivariate Cox: HR = 2.368; p = 0.033) and poor survival (multivariate Cox: HR = 2.151; p = 0.032) of NMIBC and MIBC patients, respectively. Multivariate models integrating 5'-tRF-LysCTT with disease established markers resulted in superior risk-stratification specificity and positive prediction of patients' progression. In conclusion, increased 5'-tRF-LysCTT levels were strongly associated with adverse disease outcome and improved BlCa patients' prognostication. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 157 01 Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AUID- ORCID: 0000-0002-2135-9886 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 157 01 Athens, Greece. AD - Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Levis, Panagiotis AU - Levis P AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Papasotiriou, Evangelia Ch AU - Papasotiriou EC AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 157 01 Athens, Greece. FAU - Kotronopoulos, Georgios AU - Kotronopoulos G AUID- ORCID: 0000-0002-8157-1029 AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 157 01 Athens, Greece. LA - eng GR - T2EDK-02196/This research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE (proj/ PT - Journal Article DEP - 20201206 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7762106 OTO - NOTNLM OT - 5'-tRFs OT - bladder cancer OT - bladder tumors OT - bladder urothelial carcinoma OT - ncRNAs OT - non coding RNAs OT - tRNA fragments OT - tRNA-Lys-CTT OT - tRNA-derived fragments OT - tRNALysCTT COIS- The authors declare no conflict of interest. EDAT- 2020/12/10 06:00 MHDA- 2020/12/10 06:01 PMCR- 2020/12/06 CRDT- 2020/12/09 01:01 PHST- 2020/10/11 00:00 [received] PHST- 2020/11/24 00:00 [revised] PHST- 2020/12/02 00:00 [accepted] PHST- 2020/12/09 01:01 [entrez] PHST- 2020/12/10 06:00 [pubmed] PHST- 2020/12/10 06:01 [medline] PHST- 2020/12/06 00:00 [pmc-release] AID - cancers12123661 [pii] AID - cancers-12-03661 [pii] AID - 10.3390/cancers12123661 [doi] PST - epublish SO - Cancers (Basel). 2020 Dec 6;12(12):3661. doi: 10.3390/cancers12123661. PMID- 33288580 OWN - NLM STAT- MEDLINE DCOM- 20201221 LR - 20201221 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 40 IP - 12 DP - 2020 Dec TI - Chloride Intracellular Channel Protein 1 (CLIC1) Iotas Over-expressed in Muscle Invasive Urinary Bladder Cancer. PG - 6879-6884 LID - 10.21873/anticanres.14710 [doi] AB - BACKGROUND/AIM: Invasive bladder cancer mortality remains high despite progresses made in early diagnosis and surgical procedures. Thus, there is a need to define new markers for bladder cancer. CLIC1 has not been previously studied in bladder cancer and thus, we aimed to assess its immunohistochemical expression in relation to different stages of bladder cancer development. MATERIALS AND METHODS: Immunohistochemistry for CLIC1 was applied in 50 cases of muscle invasive bladder cancer. RESULTS: CLIC1 was not expressed in the normal urothelium, but a strong reaction was observed in dysplastic urothelium, carcinoma in situ and in 94% of the cases with invasive urothelial carcinoma; however, it was not expressed in squamous cell carcinoma cases. No correlation was found between the immunohistochemical expression of CLIC1 and the stage and grade of the tumour. CONCLUSION: CLIC1 was overexpressed in urinary bladder dysplastic epithelium, carcinoma in situ and invasive carcinoma. CLIC1 constitutes a new potential marker of invasive bladder cancer. CI - Copyright (c) 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Adelmann, Tiberiu Gabriel AU - Adelmann TG AD - Department of Microscopic Morphology/Histology, Angiogenesis Research Center Timisoara, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. FAU - Camerota, Tommaso Ciro AU - Camerota TC AD - Urology, IRCCS ICS Maugeri of Pavia, Pavia, Italy. FAU - Ceausu, Amalia Raluca AU - Ceausu AR AD - Department of Microscopic Morphology/Histology, Angiogenesis Research Center Timisoara, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. FAU - Cimpean, Anca Maria AU - Cimpean AM AD - Department of Microscopic Morphology/Histology, Angiogenesis Research Center Timisoara, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. FAU - Mazzanti, Michele AU - Mazzanti M AD - Department of Biosciences, Laboratory of Cellular and Molecular Physiology, University of Milano, Milan, Italy. FAU - Raica, Marius AU - Raica M AD - Department of Microscopic Morphology/Histology, Angiogenesis Research Center Timisoara, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania marius.raica@umft.ro mraica1@umft.ro. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Biomarkers, Tumor) RN - 0 (CLIC1 protein, human) RN - 0 (Chloride Channels) SB - IM MH - Aged MH - Biomarkers, Tumor MH - Chloride Channels/*genetics/metabolism MH - Female MH - *Gene Expression MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/*genetics/metabolism/mortality/*pathology OTO - NOTNLM OT - Bladder cancer OT - chloride intracellular channel protein 1 (CLIC1) OT - immunohistochemistry OT - potential therapeutic target OT - prognosis EDAT- 2020/12/09 06:00 MHDA- 2020/12/22 06:00 CRDT- 2020/12/08 05:39 PHST- 2020/10/08 00:00 [received] PHST- 2020/10/28 00:00 [revised] PHST- 2020/10/29 00:00 [accepted] PHST- 2020/12/08 05:39 [entrez] PHST- 2020/12/09 06:00 [pubmed] PHST- 2020/12/22 06:00 [medline] AID - 40/12/6879 [pii] AID - 10.21873/anticanres.14710 [doi] PST - ppublish SO - Anticancer Res. 2020 Dec;40(12):6879-6884. doi: 10.21873/anticanres.14710. PMID- 33283389 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20260518 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 28 IP - 2 DP - 2021 Feb TI - Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer. PG - 208-214 LID - 10.1111/iju.14435 [doi] AB - OBJECTIVES: To investigate the impact on intravesical recurrence and prognosis according to the ureteral ligation timing during radical nephroureterectomy for upper urinary tract urothelial carcinoma. METHODS: We carried out a retrospective chart review of 664 patients with non-metastatic upper urinary tract urothelial carcinoma who underwent radical nephroureterectomy with ureteral ligation (supplementary analysis of JCOG1110A). We excluded patients with previous and/or synchronous bladder cancer, clinically node-positive disease, no ureteral ligation data, those without ureteral ligation and those with any missing data. We investigated the cumulative incidence of intravesical recurrence and cancer-specific mortality, and overall survival between patients with ureteral ligation before renovascular ligation (early ureteral ligation), or ureteral ligation after renovascular ligation (late ureteral ligation). RESULTS: Early and late ureteral ligation was carried out in 243 patients (36.6%) and 421 patients (63.4%), respectively. Intravesical recurrence occurred in 218 patients (32.8%) during follow up (median 3.9 years). No significant difference in the intravesical recurrence was found between early and late ureteral ligation groups. Meanwhile, survival in the early ureteral ligation group was significantly worse compared with the late ureteral ligation group. Multivariable analysis showed that early ureteral ligation was an independent prognostic factor for overall survival (hazard ratio 1.88, 95% confidence interval 1.24-2.85, P = 0.003) and cancer-specific mortality (hazard ratio 1.93, 95% confidence interval 1.14-3.25, P = 0.014). CONCLUSIONS: Our findings suggest that the incidence of intravesical recurrence is not affected by the timing of ureteral ligation during radical nephroureterectomy. However, early ureteral ligation might have a negative impact on survival outcomes. CI - (c) 2020 The Japanese Urological Association. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Kuroiwa, Kentaro AU - Kuroiwa K AD - Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba, Tsukuba, Japan. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, University of Tsukuba, Tsukuba, Japan. FAU - Kakehi, Yoshiyuki AU - Kakehi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Takenaka, Atsushi AU - Takenaka A AD - Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Yamaguchi, Raizo AU - Yamaguchi R AD - Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. FAU - Hashine, Katsuyoshi AU - Hashine K AD - Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. FAU - Mizusawa, Junki AU - Mizusawa J AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Eba, Junko AU - Eba J AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. FAU - Naito, Seiji AU - Naito S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. AD - Department of Urology, Harasanshin Hospital, Fukuoka, Japan. CN - Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG) LA - eng GR - 23-A-20/National Cancer Center Research and Development Fund/ GR - 26-A-4/National Cancer Center Research and Development Fund/ GR - 29-A-3/National Cancer Center Research and Development Fund/ PT - Journal Article DEP - 20201129 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2021 Feb;28(2):215. doi: 10.1111/iju.14453. PMID: 33280177 MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - Neoplasm Recurrence, Local/epidemiology/surgery MH - Nephrectomy MH - Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - *Ureteral Neoplasms/surgery MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - intravesical recurrence OT - prognosis OT - radical nephroureterectomy OT - upper urinary tract urothelial cancer OT - ureteral ligation FIR - Shinohara, N IR - Shinohara N FIR - Masumori, N IR - Masumori N FIR - Ohyama, C IR - Ohyama C FIR - Ito, A IR - Ito A FIR - Kawamura, S IR - Kawamura S FIR - Tsuchiya, N IR - Tsuchiya N FIR - Ito, K IR - Ito K FIR - Ichikawa, T IR - Ichikawa T FIR - Fujimoto, H IR - Fujimoto H FIR - Egawa, S IR - Egawa S FIR - Iwamura, M IR - Iwamura M FIR - Tanigawa, T IR - Tanigawa T FIR - Ishizuka, O IR - Ishizuka O FIR - Miyake, H IR - Miyake H FIR - Niwakawa, M IR - Niwakawa M FIR - Gotoh, M IR - Gotoh M FIR - Inoue, T IR - Inoue T FIR - Ogawa, O IR - Ogawa O FIR - Nishumura, K IR - Nishumura K FIR - Matsuyama, H IR - Matsuyama H FIR - Eto, M IR - Eto M FIR - Yokomizo, A IR - Yokomizo A FIR - Kamba, T IR - Kamba T EDAT- 2020/12/08 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/12/07 05:42 PHST- 2020/06/26 00:00 [received] PHST- 2020/10/13 00:00 [accepted] PHST- 2020/12/08 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/12/07 05:42 [entrez] AID - 10.1111/iju.14435 [doi] PST - ppublish SO - Int J Urol. 2021 Feb;28(2):208-214. doi: 10.1111/iju.14435. Epub 2020 Nov 29. PMID- 33269720 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20201214 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 73 IP - 10 DP - 2020 Dec TI - Precision medicine in localized bladder cancer: Personalizing therapies to improve outcomes. PG - 1016-1022 AB - In the last decades, only few improvements have been made in the comprehension of bladder cancer tumor leading to few improvements in the development of new diagnostic and therapeutic approaches.However, in the last years several step forwards in the field of precision medicine have been made. In this review we focused on some of these elements such as the available biomarkers, the role of enhanced transurethral resection of the bladder and the role of the molecular classification in defining prognosis and therapeutic approaches in bladder cancer patients. Although several progresses have been made, at the time none of the existing biomarkers appear to be able to safely avoid the need of cystoscopy during the follow up of bladder cancer patients. However, these biomarkers representan important tool to follow up patients with a less invasive methods and in the near future might be able to substitute the need of cystoscopy. Enhanced transurethral resection technique can in some cases reduce the risk of recurrence during follow up, although its impact on survival outcomes is still under debate. Transurethral resection of the bladder represents a fundamental diagnostic and therapeutic step in the management of bladder cancer and these techniques can successfully improve its outcomes. Finally, the molecular classification of the bladder cancer represents one of the most exciting novelty in this field, improving consistently the knowledge of bladder cancer. Improvements regarding prognoses and therapeutics can be achieved although data stil need validation. FAU - Carando, Roberto AU - Carando R AD - Clinica Luganese Moncucco. Lugano. Switzerland. Clinica S. Anna. Swiss Medical Group. Sorengo. Switzerland. Clinica Santa Chiara. Locarno. Switzerland. Department of Urology. Luzerner Kantonsspital. Spitalstrasse. Luzern. Switzerland. FAU - Ludovico, Giuseppe Mario AU - Ludovico GM AD - Urology Department. Ospedale Generale Regionale "F. Miulli". Acquaviva delle Fonti (BA). FAU - Zazzara, Michele AU - Zazzara M AD - Urology Department. Ospedale Generale Regionale "F. Miulli". Acquaviva delle Fonti (BA). FAU - Zamboni, Stefania AU - Zamboni S AD - Department of Urology. Spedali Civili Hospital of Brescia. University of Brescia. Brescia. Italy. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology. Luzerner Kantonsspital. Spitalstrasse. Luzern. Switzerland. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology. Spedali Civili Hospital of Brescia. University of Brescia. Brescia. Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology. Wroclaw Medical University. Wroclaw. Poland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology. Luzerner Kantonsspital. Spitalstrasse. Luzern. Switzerland. LA - eng PT - Journal Article PT - Review TT - Medicina de precision en cancer de vejiga localizado: terapias personalizadas para mejorar los resultados. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Precision Medicine MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - Cistectomia radical OT - Cancer urotelial OT - Cancer de vejiga OT - Medicina de precision OT - Precision medicine OT - Radical cystectomy OT - Reseccion transuretral de vejiga OT - Transurethral resection of the bladder OT - Urothelial carcinoma EDAT- 2020/12/04 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/12/03 08:34 PHST- 2020/12/03 08:34 [entrez] PHST- 2020/12/04 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] AID - 2021-73-10-b11726ea774381a981ee6c670e5a593093d5000f [pii] PST - ppublish SO - Arch Esp Urol. 2020 Dec;73(10):1016-1022. PMID- 33269713 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20201214 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 73 IP - 10 DP - 2020 Dec TI - New immunotherapy treatments in non-muscle invasive bladder cancer. PG - 945-953 AB - Non-muscle invasive bladder cancer (NMIBC) is a highly heterogeneous disease that hides classes of patients who behave significantly differently under a favorable overall prognosis facade. Individual risk stratification and good decision making improve the patient outcomes. To date, radical cystectomy remains the treatment of choice in particularly aggressive subsets of disease, also due to the lack of proven alternative bladder-sparing strategies.Cancer immunotherapy, by inhibiting the PD-1/PD-L1axis, has shown durable efficacy in the treatment of advanced and metastatic unresectable urothelial carcinoma, and is studied with great interest in early disease settings. The updated data of the KEYNOTE-057 study have recently promoted the United States (US) Food and Drug Administration (FDA) approval of pembrolizumabin patients with CIS-containing BCG-unresponsive NMIBC. This significant step forward paves the way to a new window of therapeutic opportunities, while underlining new needs and questions to be addressed. FAU - Califano, Gianluigi AU - Califano G AD - Urology Unit. Department of Neurosciences. Reproductive Sciences and Odontostomatology. Federico II University of Naples. Naples. Italy. Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique Hopitaux de Paris. Paris University. Paris. France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique Hopitaux de Paris. Paris University. Paris. France. FAU - Verze, Paolo AU - Verze P AD - Urology Unit. Department of Medicine and Surgery "Scuola Medica Salernitana". University of Salerno. Salerno. Italy. FAU - Stivalet, Nadja AU - Stivalet N AD - Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique Hopitaux de Paris. Paris University. Paris. France. FAU - Hermieu, Jean-Francois AU - Hermieu JF AD - Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique Hopitaux de Paris. Paris University. Paris. France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique Hopitaux de Paris. Paris University. Paris. France. LA - eng PT - Journal Article TT - Nuevos tratamientos de immunoterapia en cancer de vejiga no musculoinvasivo. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 SB - IM MH - *Carcinoma, Transitional Cell/therapy MH - Cystectomy MH - Humans MH - Immunotherapy MH - *Urinary Bladder Neoplasms/therapy OTO - NOTNLM OT - BCG unresponsive OT - Cancer de vejiga no musculo invasivo OT - Immune checkpoint inhibitors OT - Immunotherapy OT - Inhibicion de PD-1/PD-L1 OT - Inhibidores de checkpoint OT - Inmunoterapia OT - No respondedores a BCG OT - Non-muscle invasive bladder cancer OT - PD-1/PDL1 inhibition OT - Pembrolizumab EDAT- 2020/12/04 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/12/03 08:34 PHST- 2020/12/03 08:34 [entrez] PHST- 2020/12/04 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] AID - 2021-73-10-1107d278d40557e8ef8ddddd4d722253b51ef94f [pii] PST - ppublish SO - Arch Esp Urol. 2020 Dec;73(10):945-953. PMID- 33269247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201207 IS - 2307-8960 (Print) IS - 2307-8960 (Electronic) IS - 2307-8960 (Linking) VI - 8 IP - 21 DP - 2020 Nov 6 TI - Oncological impact of different distal ureter managements during radical nephroureterectomy for primary upper urinary tract urothelial carcinoma. PG - 5104-5115 LID - 10.12998/wjcc.v8.i21.5104 [doi] AB - BACKGROUND: The current standard surgical treatment for non-metastatic upper urinary tract urothelial carcinoma (UTUC) is radical nephroureterectomy (RNU) with bladder cuff excision (BCE). Typically, BCE techniques are classified in one of the following three categories: An open technique described as intrasvesical incision of the bladder cuff, a transurethral incision of the bladder cuff (TUBC), and an extravesical incision of the bladder cuff (EVBC) method. Even though each of these management techniques are widely used, there is no consensus about which surgical intervention is superior, with the best oncologic outcomes. AIM: To investigate the oncological outcomes of three BCE methods during RNU for primary UTUC patients. METHODS: We retrospectively analyzed the data of 248 primary UTUC patients, who underwent RNU with BCE between January 2004 to December 2018. Patients were analyzed according to each BCE method. Data extracted included patient demographics, perioperative parameters, and oncological outcomes. Statistical analyses were performed using chi-square and log-rank tests. The Cox proportional hazards regression model was utilized to identify independent predictors. P < 0.05 was considered statistically significant. RESULTS: Of the 248 participants, 39.9% (n = 99) underwent intrasvesical incision of the bladder cuff, 38.7% (n = 96) EVBC, and 21.4% (n = 53) TUBC. At a median follow-up of 44.2 mo, bladder recurrence developed in 17.2%, 12.5%, and 13.2% of the cases, respectively. Cancer-specific deaths occurred in 11.1%, 5.2%, and 7.5% of patients, respectively. Kaplan-Meier survival curves with a log-rank test highlighted no significant differences in intravesical recurrence-free survival, cancer-specific survival, and overall survival among these approaches with P values of 0.987, 0.825, and 0.497, respectively. Multivariate analysis showed that the lower ureter location appears to have inferior intravesical recurrence-free survival (P = 0.042). However, cancer-specific survival and overall survival were independently influenced by tumor stage (hazard ratio [HR] = 8.439; 95% con fi dence interval: 2.424-29.377; P = 0.001) and lymph node status (HR = 14.343; 95%CI: 5.176-39.745; P < 0.001). CONCLUSION: All three techniques had comparable outcomes; although, EVBC and TUBC are minimally invasive. While based upon rather limited data, these findings will support urologists in blending experience with evidence to inform patient choices. However, larger, rigorously designed, multicenter studies with long term outcomes are still required. CI - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Lai, Shi-Cong AU - Lai SC AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Wu, Peng-Jie AU - Wu PJ AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Liu, Jian-Yong AU - Liu JY AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Seery, Samuel AU - Seery S AD - School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. FAU - Liu, Sheng-Jie AU - Liu SJ AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Long, Xing-Bo AU - Long XB AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Wang, Jian-Ye AU - Wang JY AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. LA - eng PT - Journal Article PL - United States TA - World J Clin Cases JT - World journal of clinical cases JID - 101618806 PMC - PMC7674733 OTO - NOTNLM OT - Bladder cuff excision OT - Prognosis OT - Radical nephroureterectomy OT - Survival OT - Technique OT - Upper urinary tract urothelial carcinoma COIS- Conflict-of-interest statement: All authors report no conflicts of interest regarding this study or report. EDAT- 2020/12/04 06:00 MHDA- 2020/12/04 06:01 PMCR- 2020/11/06 CRDT- 2020/12/03 05:47 PHST- 2020/05/15 00:00 [received] PHST- 2020/09/14 00:00 [revised] PHST- 2020/09/23 00:00 [accepted] PHST- 2020/12/03 05:47 [entrez] PHST- 2020/12/04 06:00 [pubmed] PHST- 2020/12/04 06:01 [medline] PHST- 2020/11/06 00:00 [pmc-release] AID - 10.12998/wjcc.v8.i21.5104 [doi] PST - ppublish SO - World J Clin Cases. 2020 Nov 6;8(21):5104-5115. doi: 10.12998/wjcc.v8.i21.5104. PMID- 33264798 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 105 IP - 3-4 DP - 2021 TI - The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma. PG - 291-297 LID - 10.1159/000511650 [doi] AB - OBJECTIVE: The objective of this study is to evaluate the effect of diagnostic ureterorenoscopy (URS) prior to radical nephroureterectomy (RNU) on intravesical recurrence (IVR), in patients with primary upper urinary tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: Retrospective analysis of 354 patients, who underwent RNU for UTUC from 10 urology centers between 2005 and 2019, was performed. The primary endpoint was the occurrence of IVR after RNU. Patients were divided into URS prior to RNU (Group 1) and no URS prior to RNU (Group 2). Rates of IVR after RNU were compared, and a Cox proportional hazards model was used to evaluate potential predictors of IVR. RESULTS: After exclusion, a total of 194 patients were analyzed: Group 1 n = 95 (49.0%) and Group 2 n = 99 (51.0%). In Group 1, a tumor biopsy and histopathological confirmation during URS were performed in 58 (61.1%). The mean follow-up was 39.17 +/- 39.3 (range 12-250) months. In 54 (27.8%) patients, IVR was recorded after RNU, and the median recurrence time within the bladder was 10.0 (3-144) months. IVR rate was 38.9% in Group 1 versus 17.2% in Group 2 (p = 0.001). In Group 1, IVR rate was 43.1% in those undergoing intraoperative biopsy versus 32.4% of patients without biopsy during diagnostic URS (p =0.29). Intravesical recurrence-free survival (IRFS) was longer in Group 2 compared to Group 1 (median IRFS was 111 vs. 60 months in Groups 2 and 1, respectively (p< 0.001)). Univariate analysis revealed that IRFS was significantly associated with URS prior to RNU (HR: 2.9, 95% CI 1.65-5.41; p < 0.001). In multivariate analysis, URS prior to RNU (HR: 3.5, 95% CI 1.74-7.16; p < 0.001) was found to be an independent prognostic factor for IRFS. CONCLUSION: Diagnostic URS was associated with the poor IRFS following RNU for primary UTUC. The decision for a diagnostic URS with or without tumor biopsy should be reserved for cases where this information might influence further treatment decisions. CI - (c) 2020 S. Karger AG, Basel. FAU - Izol, Volkan AU - Izol V AD - Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey. FAU - Deger, Mutlu AU - Deger M AD - Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey, drmutludeger@gmail.com. FAU - Ozden, Ender AU - Ozden E AD - Department of Urology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey. FAU - Bolat, Deniz AU - Bolat D AD - Department of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Argun, Burak AU - Argun B AD - Department of Urology, Acibadem University, Istanbul, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Celik, Orcun AU - Celik O AD - Department of Urology, Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Akgul, Haci Murat AU - Akgul HM AD - Department of Urology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey. FAU - Tinay, Ilker AU - Tinay I AD - Department of Urology, School of Medicine, Marmara University, Istanbul, Turkey. FAU - Bayazit, Yildirim AU - Bayazit Y AD - Department of Urology, Faculty of Medicine, Cukurova University, Adana, Turkey. CN - Bladder Cancer Study Group of Association of Urooncology, Turkey LA - eng PT - Journal Article PT - Multicenter Study DEP - 20201202 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*diagnosis/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/*diagnosis/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - *Nephroureterectomy MH - Retrospective Studies MH - Ureteral Neoplasms/*diagnosis/*surgery MH - *Ureteroscopy MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Diagnostic ureterorenoscopy OT - Intravesical recurrence OT - Radical nephroureterectomy OT - Upper urinary tract OT - Urothelial carcinoma EDAT- 2020/12/03 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/12/02 20:07 PHST- 2020/06/22 00:00 [received] PHST- 2020/09/08 00:00 [accepted] PHST- 2020/12/03 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/12/02 20:07 [entrez] AID - 000511650 [pii] AID - 10.1159/000511650 [doi] PST - ppublish SO - Urol Int. 2021;105(3-4):291-297. doi: 10.1159/000511650. Epub 2020 Dec 2. PMID- 33260285 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210403 IS - 2383-7837 (Print) IS - 2383-7845 (Electronic) IS - 2383-7837 (Linking) VI - 55 IP - 2 DP - 2021 Mar TI - Histologically confirmed distant metastatic urothelial carcinoma from the urinary bladder: a retrospective review of one institution's 20-year experience. PG - 94-101 LID - 10.4132/jptm.2020.10.19 [doi] AB - BACKGROUND: Urothelial carcinoma (UC) accounts for roughly 90% of bladder cancer, and has a high propensity for diverse differentiation. Recently, certain histologic variants of UC have been recognized to be associated with unfavorable clinical outcomes. Several UC studies have also suggested that tumor budding is a poor prognostic marker. Distant metastasis of UC after radical cystectomy is not uncommon. However, these metastatic lesions are not routinely confirmed with histology. METHODS: We investigated the histopathologic features of 13 cases of UC with biopsy-proven distant metastases, with a special emphasis on histologic variants and tumor budding. RESULTS: Lymph nodes (6/13, 46%) were the most common metastatic sites, followed by the lung (4/13, 31%), liver (4/13, 31%), and the adrenal gland (2/13, 15%). The histologic variants including squamous (n=1), micropapillary (n=4), and plasmacytoid (n=1) variants in five cases of UC. Most histologic variants (4/5, 80%) of primary UCs appeared in the metastatic lesions. In contrast, high-grade tumor budding was detected in six cases (46%), including one case of non-muscle invasive UC. Our study demonstrates that histologic variants are not uncommonly detected in distant metastatic UCs. Most histologic variants seen in primary UCs persist in the distant metastatic lesions. In addition, high-grade tumor budding, which occurs frequently in primary tumors, may contribute to the development of distant metastasis. CONCLUSIONS: Therefore, assessing the presence or absence of histologic variants and tumor budding in UCs of the urinary bladder, even in non-muscle invasive UCs, may be useful to predict distant metastasis. FAU - Yoo, Youngeun AU - Yoo Y AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Lee, Junghye AU - Lee J AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Park, Heae Surng AU - Park HS AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Cho, Min-Sun AU - Cho MS AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Sung, Sun Hee AU - Sung SH AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Park, Sanghui AU - Park S AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. FAU - Choi, Euno AU - Choi E AD - Department of Pathology, Ewha Womans University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article DEP - 20201203 PL - Korea (South) TA - J Pathol Transl Med JT - Journal of pathology and translational medicine JID - 101650151 PMC - PMC7987521 OTO - NOTNLM OT - Bladder neoplasms OT - Distant metastasis OT - Histologic variant OT - Tumor budding OT - Urothelial carcinoma COIS- Conflicts of Interest The authors declare that they have no potential conflicts of interest. EDAT- 2020/12/03 06:00 MHDA- 2020/12/03 06:01 PMCR- 2021/03/01 CRDT- 2020/12/02 00:15 PHST- 2020/09/25 00:00 [received] PHST- 2020/10/19 00:00 [accepted] PHST- 2020/12/03 06:00 [pubmed] PHST- 2020/12/03 06:01 [medline] PHST- 2020/12/02 00:15 [entrez] PHST- 2021/03/01 00:00 [pmc-release] AID - jptm.2020.10.19 [pii] AID - jptm-2020-10-19 [pii] AID - 10.4132/jptm.2020.10.19 [doi] PST - ppublish SO - J Pathol Transl Med. 2021 Mar;55(2):94-101. doi: 10.4132/jptm.2020.10.19. Epub 2020 Dec 3. PMID- 33250346 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20221207 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 4 DP - 2021 Apr TI - Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients. PG - 238.e1-238.e7 LID - S1078-1439(20)30602-5 [pii] LID - 10.1016/j.urolonc.2020.11.015 [doi] AB - OBJECTIVES: Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer. Intravesical BCG therapy is widely-used for bladder cancer. However, tumor recurrence and progression are very common. Stratification based on germline polymorphisms may contribute to circumvent this clinical challenge. Autophagy pathway plays an important role in the nonspecific protective effects of BCG. Patients that carry C allele of rs3759601 in autophagy gene ATG2B showed increased risk of recurrence and progression in European population. We thus sought to analyze rs3759601 and its relevance in BCG response in Asian NMIBC patients. METHOD: Functional impact of rs3759601 ATG2B (p.Gln1383Glu) was analyzed by bioinformatics programs including NCBI Conserved Domain Search, Clustal Omega, Polyphen and SIFT. NMIBC patients who received intravesical BCG at multiple hospitals in Singapore from 1995 to 2016 were included. These patients were genotyped for rs3759601 using high resolution melt analysis. The rs3759601 polymorphism was studied in correlation with the bladder cancer recurrence rate and disease progression rate in our cohort. Statistical analysis was conducted using Kaplan-Meier plots and the Chi-squared analysis. RESULTS: In total, 307 individules were included in the study including 161 NMIBC patients and 146 healthy controls, predominately Chinese. The rs3759601 genotype distributions in our NMIBC patients were (GG 72.1%; GC 27.9%; CC 0%), which were distinct from the Dutch report (GG 32.8%; GC 47.4% and CC 19.8%, Buffen K et al, 2014). Consistently, the C allele frequencies of rs3759601 are 0.171 in our controls and 0.177 in East Asians from 1,000 Genome, but 0.406 in Europeans from 1,000 Genome. In silico analysis suggested rs3759601 ATG2B (p.Gln1383Glu) alteration is unlikely to be functionally deleterious. Statistical analysis revealed no significant association between ATG2B rs3759601 C allele and risk of bladder cancer recurrence (P= 0.353, GC vs. GG: hazard ratio [HR]= 1.324), or cancer progression (P= 0.454, GC vs. GG: HR = 0.658). CONCLUSION: In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients. CI - Copyright (c) 2020. Published by Elsevier Inc. FAU - Zang, Zhijiang AU - Zang Z AD - Department of Urology, National University Hospital, National University Health System, Singapore. Electronic address: zhijiang_zang@nuhs.edu.sg. FAU - Lim, Yew Koon AU - Lim YK AD - Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Chan, Yiong Huak AU - Chan YH AD - Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Raman, Lata AU - Raman L AD - Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Esuvaranathan, Kesavan AU - Esuvaranathan K AD - Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Chiong, Edmund AU - Chiong E AD - Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Mahendran, Ratha AU - Mahendran R AD - Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. LA - eng PT - Journal Article DEP - 20201126 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (ATG2B protein, human) RN - 0 (Adjuvants, Immunologic) RN - 0 (Autophagy-Related Proteins) RN - 0 (BCG Vaccine) RN - 0 (Vesicular Transport Proteins) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - Asian People MH - Autophagy-Related Proteins/*genetics MH - BCG Vaccine/*administration & dosage MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*drug therapy/*genetics MH - *Polymorphism, Genetic MH - Urinary Bladder Neoplasms/*drug therapy/*genetics MH - Vesicular Transport Proteins/*genetics OTO - NOTNLM OT - ATG2B OT - Autophagy OT - BCG OT - Bladder cancer OT - Polymorphism OT - Recurrence OT - SNP EDAT- 2020/12/01 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/11/30 05:32 PHST- 2019/11/18 00:00 [received] PHST- 2020/10/08 00:00 [revised] PHST- 2020/11/10 00:00 [accepted] PHST- 2020/12/01 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/11/30 05:32 [entrez] AID - S1078-1439(20)30602-5 [pii] AID - 10.1016/j.urolonc.2020.11.015 [doi] PST - ppublish SO - Urol Oncol. 2021 Apr;39(4):238.e1-238.e7. doi: 10.1016/j.urolonc.2020.11.015. Epub 2020 Nov 26. PMID- 33245791 OWN - NLM STAT- MEDLINE DCOM- 20211123 LR - 20211123 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 78 IP - 7 DP - 2021 Jun TI - Feasibility and accuracy of pathological diagnosis in en-bloc transurethral resection specimens versus conventional transurethral resection specimens of bladder tumour: evaluation with pT1 substaging by 10 pathologists. PG - 943-950 LID - 10.1111/his.14307 [doi] AB - AIMS: En-bloc transurethral resection (TUR) of bladder tumour (ERBT) is designed to provide more accurate pathological diagnosis of specimens than conventional TUR of bladder tumour (cTURBT). Some studies have reported that T1 bladder cancer substage could be a prognostic factor in assessing tumour progression, but such substaging has not been widely adopted because of problems with pathological diagnosis using cTURBT specimens. The aim of this study was to evaluate the possible advantages of en-bloc TUR specimens in T1 substaging following assessment by a panel of 10 pathologists. METHODS AND RESULTS: We assessed the substages in 123 patients (cTURBT, n = 91; ERBT, n = 32) who were diagnosed with pT1 bladder cancer. We randomly selected 10 ERBT specimens and 10 cTURBT specimens with cancer invasion areas equivalent to those of their corresponding ERBT specimens. Ten pathologists performed pT1 substaging for pT1a/b/c and pT1m/e in 20 patients (cTURBT, n = 10; ERBT, n = 10). We evaluated diagnostic times and rates of diagnostic concordance among these pathologists, comparing cTURBT and ERBT. The median diagnostic times per slide were 87.7 s [interquartile range (IQR) 71.9-109.2 s) for cTURBT and 54.7 s (IQR 46.0-59.6 s) for ERBT (P = 0.009). The rate of diagnostic concordance was significantly better for ERBT specimens. For pT1a/b/c, the median concordance rates were 50% for cTURBT and 80% for ERBT (P = 0.02); for pT1m/e, the median concordance rates were 70% for cTURBT and 90% for ERBT (P = 0.05). For pT1a/b/c, the average kappa-values between the pathologist and the standard diagnosis were 0.04 for cTURBT and 0.47 for ERBT. CONCLUSIONS: The use of ERBT specimens shortened the diagnostic time and minimised interobserver variability for T1 substaging compared with the use of cTURBT specimens. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yorozu, Takashi AU - Yorozu T AD - Department of Pathology, The Kyorin University School of Medicine, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Iwatani, Kosuke AU - Iwatani K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Obayashi, Koki AU - Obayashi K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sato, Shun AU - Sato S AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20210326 PL - England TA - Histopathology JT - Histopathology JID - 7704136 SB - IM MH - Female MH - Humans MH - Male MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/*pathology/surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - bladder cancer OT - diagnosis OT - en-bloc TURBT EDAT- 2020/11/28 06:00 MHDA- 2021/11/24 06:00 CRDT- 2020/11/27 17:05 PHST- 2020/08/28 00:00 [received] PHST- 2020/11/22 00:00 [accepted] PHST- 2020/11/28 06:00 [pubmed] PHST- 2021/11/24 06:00 [medline] PHST- 2020/11/27 17:05 [entrez] AID - 10.1111/his.14307 [doi] PST - ppublish SO - Histopathology. 2021 Jun;78(7):943-950. doi: 10.1111/his.14307. Epub 2021 Mar 26. PMID- 33238953 OWN - NLM STAT- MEDLINE DCOM- 20210603 LR - 20210603 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 20 IP - 1 DP - 2020 Nov 25 TI - The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients. PG - 187 LID - 10.1186/s12894-020-00759-3 [doi] LID - 187 AB - BACKGROUND: Bladder cancer (BC) is the 10th most common cancer in the UK, with about 10,000 new cases annually. About 75-85% of BC are non-muscle invasive (NMIBC), which is associated with high recurrence and progression rates (50-60% within 7-10 years). There are no routine biomarkers currently available for identifying BC patients at increased risk of developing recurrence. The focus of this research study was to evaluate antibody expression in BC patients and their association with cancer recurrence. METHODS: 35 patients scheduled for TURBT were recruited after written informed consent. Ethical approval for the project was granted via IRAS (REC4: 14/WA/0033). Following surgical procedure, tissues were preserved in 10% buffered formalin and processed within 24 h in FFPE blocks. 7 sections (4 microm each) were cut from each block and stained for CD31, Human epidermal growth factor receptor-2 (HER-2), S100P, Cyclooxygenase-2 (COX-2), VEGFR-3 thrombomodulin and CEACAM-1 using immunohistochemistry. Clinical outcome measures (obtained via cystoscopy) were monitored for up to 6 months following surgical procedure. RESULTS: There was significantly increased expression of CD31 (p < 0.001), HER-2 (p = 0.032), S100P (p < 0.001), COX-2 (p < 0.001), VEGFR-3 (p < 0.001) and decreased expression of thrombomodulin (p = 0.010) and CEACAM-1 (p < 0.001) in bladder tumours compared to normal bladder tissues. HER-2 expression was also significantly associated with cancer grade (p = 0.003), especially between grade 1 and grade 2 (p = 0.002) and between grade 1 and grade 3 (p = 0.004). There was also a significant association between cancer stage and HER-2 expression (p < 0.001). Although recurrence was significantly associated with cancer grade, there was no association with antibody expression. CONCLUSION: Findings from the present study may indicate an alternative approach in the monitoring and management of patients with BC. It is proposed that by allowing urological surgeons access to laboratory markers such as HER-2, Thrombomodulin and CD31 (biomarker profile), potentially, in the future, these biomarkers may be used in addition to, or in combination with, currently used scoring systems to predict cancer recurrence. However, verification and validation of these biomarkers are needed using larger cohorts. FAU - Ella-Tongwiis, Peter AU - Ella-Tongwiis P AD - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK. AD - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK. FAU - Lamb, Rebecca May AU - Lamb RM AD - Department of Biological Sciences, University of Chester, Chester, UK. FAU - Makanga, Alexander AU - Makanga A AD - Department of Histopathology, Ysbyty Glan Clwd, Betsi Cadwaladr University Health Board (BCUHB), Wrexham, UK. FAU - Shergill, Iqbal AU - Shergill I AD - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK. AD - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK. AD - Department of Urology, BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK. FAU - Hughes, Stephen Fon AU - Hughes SF AUID- ORCID: 0000-0001-6558-9037 AD - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK. Stephen.hughes6@wales.nhs.uk. AD - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK. Stephen.hughes6@wales.nhs.uk. LA - eng PT - Clinical Study PT - Journal Article DEP - 20201125 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Antibody Formation MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*immunology MH - Pilot Projects MH - Prospective Studies MH - Urinary Bladder Neoplasms/*immunology PMC - PMC7690172 OTO - NOTNLM OT - Biomarkers OT - Bladder OT - Immunohistochemistry OT - Recurrence COIS- The authors declare that they have no competing interests. EDAT- 2020/11/27 06:00 MHDA- 2021/06/04 06:00 PMCR- 2020/11/25 CRDT- 2020/11/26 05:29 PHST- 2020/08/19 00:00 [received] PHST- 2020/11/18 00:00 [accepted] PHST- 2020/11/26 05:29 [entrez] PHST- 2020/11/27 06:00 [pubmed] PHST- 2021/06/04 06:00 [medline] PHST- 2020/11/25 00:00 [pmc-release] AID - 10.1186/s12894-020-00759-3 [pii] AID - 759 [pii] AID - 10.1186/s12894-020-00759-3 [doi] PST - epublish SO - BMC Urol. 2020 Nov 25;20(1):187. doi: 10.1186/s12894-020-00759-3. PMID- 33238591 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201201 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 10 IP - 11 DP - 2020 Nov 23 TI - Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma. LID - 10.3390/life10110305 [doi] LID - 305 AB - BACKGROUND: bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a, FGFR3 gene expression, and mutation status in tissue specimens of the luminal subtype of newly diagnosed high and low grade NMIBC. METHODS: twenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and FGFR3. We detected FGFR3 hotspot mutations in codons 248 and 249 by Sanger sequencing. RESULTS: high grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher FGFR3 expression and hotspot mutation rate. The tumor grade (HR = 571.72 [11.03-2.96] p = 0.002), PD-L1 expression (HR = 2.33 [0.92-1.92] p = 0.012), and FGFR3 expression (HR = 0.08 [0.17-0.42] p = 0.003) were associated with relapse-free survival. CONCLUSIONS: tumor grade in association with PD-L1 and FGFR3 expression can be considered as a complex predictor for primary luminal NMIBC progression. FAU - Blinova, Ekaterina AU - Blinova E AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Buzdin, Anton AU - Buzdin A AD - Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia. AD - Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. FAU - Enikeev, Dmitry AU - Enikeev D AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Roshchin, Dmitry AU - Roshchin D AD - Department of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia. FAU - Suntsova, Maria AU - Suntsova M AD - Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia. FAU - Samyshina, Elena AU - Samyshina E AD - Laboratory of Molecular Pharmacology and Drug Design, All-Union Research Center for Biological Active Compounds Safety, 142450 Staraja Kupavna, Russia. FAU - Drobyshev, Aleksey AU - Drobyshev A AD - Laboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia. FAU - Deryabina, Olga AU - Deryabina O AD - Department of Oncology, Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia. FAU - Demura, Tatiana AU - Demura T AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Blinov, Dmitry AU - Blinov D AUID- ORCID: 0000-0002-8385-4356 AD - Laboratory of Molecular Pharmacology and Drug Design, All-Union Research Center for Biological Active Compounds Safety, 142450 Staraja Kupavna, Russia. FAU - Shich, Evgenia AU - Shich E AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Barakat, Haydar AU - Barakat H AD - Department of Propaedeutics of Dental Diseases, People's Friendship University of Russia, 117198 Moscow, Russia. FAU - Borger, Pieter AU - Borger P AD - Laboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Center, Department of Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. FAU - Merinov, Dmitrij AU - Merinov D AD - Department of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia. FAU - Kachmazov, Aleksandr AU - Kachmazov A AD - Department of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia. FAU - Serebrianyi, Stanislav AU - Serebrianyi S AD - Department of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia. FAU - Tumutolova, Oxana AU - Tumutolova O AD - Department of Oncology, Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia. FAU - Potoldykova, Natalia AU - Potoldykova N AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Zhdanov, Pavel AU - Zhdanov P AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Grigoryan, Vagarshak AU - Grigoryan V AD - Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia. FAU - Perepechin, Dmitrij AU - Perepechin D AD - Department of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia. LA - eng GR - 1/15/Russian academic excellence project "5-100" for Sechenov First Moscow State Medical University/ PT - Journal Article DEP - 20201123 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC7700587 OTO - NOTNLM OT - PD-L1 OT - cancer progression OT - expression OT - fibroblast growth factor receptor 3 OT - microRNA OT - mutation OT - non-muscular invasive bladder carcinoma OT - prognosis OT - tumor relapse COIS- The authors declare no conflict of interest. EDAT- 2020/11/27 06:00 MHDA- 2020/11/27 06:01 PMCR- 2020/11/01 CRDT- 2020/11/26 01:01 PHST- 2020/10/10 00:00 [received] PHST- 2020/11/10 00:00 [revised] PHST- 2020/11/22 00:00 [accepted] PHST- 2020/11/26 01:01 [entrez] PHST- 2020/11/27 06:00 [pubmed] PHST- 2020/11/27 06:01 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - life10110305 [pii] AID - life-10-00305 [pii] AID - 10.3390/life10110305 [doi] PST - epublish SO - Life (Basel). 2020 Nov 23;10(11):305. doi: 10.3390/life10110305. PMID- 33237904 OWN - NLM STAT- MEDLINE DCOM- 20201229 LR - 20250530 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 15 IP - 11 DP - 2020 TI - Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis. PG - e0241711 LID - 10.1371/journal.pone.0241711 [doi] LID - e0241711 AB - The association between blood pressure (BP) and bladder cancer (BC) risk remains unclear with confounding by smoking being of particular concern. We investigated the association between BP and BC risk among men using conventional survival-analysis, and by Mendelian Randomization (MR) analysis in an attempt to disconnect the association from smoking. We additionally investigated the interaction between BP and N-acetyltransferase-2 (NAT2) rs1495741, an established BC genetic risk variant, in the association. Populations consisting of 188,167 men with 502 incident BC's in the UK-biobank and 27,107 men with 928 incident BC's in two Swedish cohorts were used for the analysis. We found a positive association between systolic BP and BC risk in Cox-regression survival analysis in the Swedish cohorts, (hazard ratio [HR] per standard deviation [SD]: 1.14 [95% confidence interval 1.05-1.22]) and MR analysis (odds ratio per SD: 2-stage least-square regression, 7.70 [1.92-30.9]; inverse-variance weighted estimate, 3.43 [1.12-10.5]), and no associations in the UK-biobank (HR systolic BP: 0.93 [0.85-1.02]; MR OR: 1.24 [0.35-4.40] and 1.37 [0.43-4.37], respectively). BP levels were positively associated with muscle-invasive BC (MIBC) (HRs: systolic BP, 1.32 [1.09-1.59]; diastolic BP, 1.27 [1.04-1.55]), but not with non-muscle invasive BC, which could be analyzed in the Swedish cohorts only. There was no interaction between BP and NAT2 in relation to BC on the additive or multiplicative scale. These results suggest that BP might be related to BC, more particularly MIBC. There was no evidence to support interaction between BP and NAT2 in relation to BC in our study. FAU - Teleka, Stanley AU - Teleka S AUID- ORCID: 0000-0002-9343-8399 AD - Department of Clinical Sciences in Lund, Lund University, Lund, Sweden. FAU - Hindy, George AU - Hindy G AUID- ORCID: 0000-0002-7257-9299 AD - Department of Population Medicine, College of Medicine Qatar University, Doha, Qatar. AD - Broad Institute, Cambridge, Massachusetts, United States of America. FAU - Drake, Isabel AU - Drake I AD - Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden. FAU - Poveda, Alaitz AU - Poveda A AD - Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden. FAU - Melander, Olle AU - Melander O AD - Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Division of Urological Research, Institution of Translational Medicine, Lund University, Malmo, Sweden. AD - Department of Urology, Skane University Hospital, Skane, Sweden. FAU - Orho-Melander, Marju AU - Orho-Melander M AD - Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden. FAU - Stocks, Tanja AU - Stocks T AD - Department of Clinical Sciences in Lund, Lund University, Lund, Sweden. LA - eng GR - MC_PC_17228/MRC_/Medical Research Council/United Kingdom GR - MC_QA137853/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201125 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 2.3.1.5 (Arylamine N-Acetyltransferase) RN - EC 2.3.1.5 (NAT2 protein, human) SB - IM MH - Aged MH - Arylamine N-Acetyltransferase/*genetics MH - Blood Pressure/*physiology MH - Female MH - Genotype MH - Humans MH - Male MH - Mendelian Randomization Analysis MH - Middle Aged MH - Polymorphism, Single Nucleotide MH - Proportional Hazards Models MH - Risk Factors MH - Smoking MH - Survival Analysis MH - Urinary Bladder Neoplasms/genetics/mortality/*pathology PMC - PMC7688142 COIS- The authors have declared that no competing interests exist. EDAT- 2020/11/26 06:00 MHDA- 2020/12/30 06:00 PMCR- 2020/11/25 CRDT- 2020/11/25 17:25 PHST- 2020/06/23 00:00 [received] PHST- 2020/10/20 00:00 [accepted] PHST- 2020/11/25 17:25 [entrez] PHST- 2020/11/26 06:00 [pubmed] PHST- 2020/12/30 06:00 [medline] PHST- 2020/11/25 00:00 [pmc-release] AID - PONE-D-20-19309 [pii] AID - 10.1371/journal.pone.0241711 [doi] PST - epublish SO - PLoS One. 2020 Nov 25;15(11):e0241711. doi: 10.1371/journal.pone.0241711. eCollection 2020. PMID- 33230694 OWN - NLM STAT- MEDLINE DCOM- 20210305 LR - 20220107 IS - 1573-7225 (Electronic) IS - 0957-5243 (Print) IS - 0957-5243 (Linking) VI - 32 IP - 2 DP - 2021 Feb TI - Bladder cancer stage and mortality: urban vs. rural residency. PG - 139-145 LID - 10.1007/s10552-020-01366-1 [doi] AB - OBJECTIVE: Relative to urban populations, rural patients may have more limited access to care, which may undermine timely bladder cancer (BCa) diagnosis and even survival. METHODS: We tested the effect of residency status (rural areas [RA < 2500 inhabitants] vs. urban clusters [UC >/= 2500 inhabitants] vs. urbanized areas [UA, >/=50,000 inhabitants]) on BCa stage at presentation, as well as on cancer-specific mortality (CSM) and other cause mortality (OCM), according to the US Census Bureau definition. Multivariate competing risks regression (CRR) models were fitted after matching of RA or UC with UA in stage-stratified analyses. RESULTS: Of 222,330 patients, 3496 (1.6%) resided in RA, 25,462 (11.5%) in UC and 193,372 (87%) in UA. Age, tumor stage, radical cystectomy rates or chemotherapy use were comparable between RA, UC and UA (all p > 0.05). At 10 years, RA was associated with highest OCM followed by UC and UA (30.9% vs. 27.7% vs. 25.6%, p < 0.01). Similarly, CSM was also marginally higher in RA or UC vs. UA (20.0% vs. 20.1% vs. 18.8%, p = 0.01). In stage-stratified, fully matched CRR analyses, increased OCM and CSM only applied to stage T1 BCa patients. CONCLUSION: We did not observe meaningful differences in access to treatment or stage distribution, according to residency status. However, RA and to a lesser extent UC residency status, were associated with higher OCM and marginally higher CSM in T1N0M0 patients. This observation should be further validated or refuted in additional epidemiological investigations. FAU - Deuker, Marina AU - Deuker M AUID- ORCID: 0000-0002-1219-387X AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. Marina.Deuker@kgu.de. AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Marina.Deuker@kgu.de. FAU - Stolzenbach, L Franziska AU - Stolzenbach LF AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Colla Ruvolo, Claudia AU - Colla Ruvolo C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Urology, University of Naples Federico II, Naples, Italy. FAU - Nocera, Luigi AU - Nocera L AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. AD - Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Roos, Frederik C AU - Roos FC AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Becker, Andreas AU - Becker A AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Tilki, Derya AU - Tilki D AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. AD - Department of Urology, University of Jordan, Amman, Jordan. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Chun, Felix K H AU - Chun FKH AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Comparative Study PT - Journal Article DEP - 20201123 PL - Netherlands TA - Cancer Causes Control JT - Cancer causes & control : CCC JID - 9100846 SB - IM CIN - J Urol. 2022 Jan;207(1):228-229. doi: 10.1097/JU.0000000000002268. PMID: 34661437 MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Rural Population MH - Urban Population MH - Urinary Bladder Neoplasms/*mortality/*pathology PMC - PMC7810614 OTO - NOTNLM OT - Bladder cancer OT - Geographical disparities OT - Social differences OT - Stage at presentation OT - Treatment rates COIS- Our research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2020/11/25 06:00 MHDA- 2021/03/06 06:00 PMCR- 2020/11/23 CRDT- 2020/11/24 06:06 PHST- 2020/08/16 00:00 [received] PHST- 2020/11/06 00:00 [accepted] PHST- 2020/11/25 06:00 [pubmed] PHST- 2021/03/06 06:00 [medline] PHST- 2020/11/24 06:06 [entrez] PHST- 2020/11/23 00:00 [pmc-release] AID - 10.1007/s10552-020-01366-1 [pii] AID - 1366 [pii] AID - 10.1007/s10552-020-01366-1 [doi] PST - ppublish SO - Cancer Causes Control. 2021 Feb;32(2):139-145. doi: 10.1007/s10552-020-01366-1. Epub 2020 Nov 23. PMID- 33230571 OWN - NLM STAT- MEDLINE DCOM- 20220111 LR - 20220111 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. PG - 2545-2552 LID - 10.1007/s00345-020-03522-3 [doi] AB - PURPOSE: This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette-Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data on 429 patients from 13 tertiary care centers with primary T1HG NMIBC treated with reTURB and maintenance BCG between 2001 and 2019 were retrospectively reviewed. Change-point regression was applied following Muggeo's approach. The population was divided into subgroups according to TTBCG, whereas the recurrence-free survival (RFS) and progression-free survival (PFS) were estimated with log-rank tests. Additionally, Cox regression analyses were performed. Due to differences in baseline patient characteristics, propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. RESULTS: The median TTBCG was 95 days (interquartile range (IQR): 71-127). The change-point regression analysis revealed a gradually increasing risk of recurrence with growing TTBCG. The risk of tumor progression gradually increased until a TTBCG of approximately 18 weeks. When the study population was divided into two subgroups (time intervals: 101 days), statistically significant differences were found for both RFS (p = 0.029) and PFS (p = 0.005). Furthermore, in patients with a viable tumor at reTURB, there were no differences in RFS and PFS. After both PSM and IPW, statistically significant differences were found for both RFS and PFS, with worse results for longer TTBCG. CONCLUSION: This study shows that delaying BCG immunotherapy after TURB of T1HG NMIBC is associated with an increased risk of tumor recurrence and progression. CI - (c) 2020. The Author(s). FAU - Krajewski, Wojciech AU - Krajewski W AUID- ORCID: 0000-0003-1727-2283 AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. wk@softstar.pl. FAU - Moschini, Marco AU - Moschini M AD - Klinik Fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Chorbinska, Joanna AU - Chorbinska J AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Afferi, Luca AU - Afferi L AD - Klinik Fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - S.H.Ho Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Tafuri, Alessandro AU - Tafuri A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Cianflone, Francesco AU - Cianflone F AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Di Trapani, Ettore AU - Di Trapani E AD - Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology Hospital, Universitario La Paz Madrid, Madrid, Spain. FAU - Rodriguez-Serrano, Andrea AU - Rodriguez-Serrano A AD - Department of Urology Hospital, Universitario La Paz Madrid, Madrid, Spain. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, Oncologic Urology "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Zamboni, Stefania AU - Zamboni S AD - Urology Unit, ASST Spedali Civili, Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili, Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Marconi, Maria Cristina AU - Marconi MC AD - Urology Unit, ASST Spedali Civili, Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, Oncologic Urology "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Ploussard, Guillaume AU - Ploussard G AD - Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewska, Joanna AU - Krajewska J AD - Department and Clinic of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wroclaw, Poland. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncologic Urology, Lowersilesian Specialistic Hospital, Wroclaw, Poland. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris, France. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. CN - European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20201123 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Combined Modality Therapy MH - Cystectomy/methods MH - Female MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*drug therapy/*mortality/pathology/surgery PMC - PMC8332577 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Delay OT - Survival OT - Time COIS- The authors declare that they have no conflict of interest. EDAT- 2020/11/25 06:00 MHDA- 2022/01/12 06:00 PMCR- 2020/11/23 CRDT- 2020/11/24 06:05 PHST- 2020/08/20 00:00 [received] PHST- 2020/11/04 00:00 [accepted] PHST- 2020/11/25 06:00 [pubmed] PHST- 2022/01/12 06:00 [medline] PHST- 2020/11/24 06:05 [entrez] PHST- 2020/11/23 00:00 [pmc-release] AID - 10.1007/s00345-020-03522-3 [pii] AID - 3522 [pii] AID - 10.1007/s00345-020-03522-3 [doi] PST - ppublish SO - World J Urol. 2021 Jul;39(7):2545-2552. doi: 10.1007/s00345-020-03522-3. Epub 2020 Nov 23. PMID- 33222014 OWN - NLM STAT- MEDLINE DCOM- 20210525 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 147 IP - 6 DP - 2021 Jun TI - Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor. PG - 1781-1788 LID - 10.1007/s00432-020-03453-x [doi] AB - OBJECTIVE: To compare the efficacy and safety of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IVC) against intravesical BCG immunotherapy in high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of the bladder tumor (TURBT). MATERIALS AND METHODS: 130 patients with high-risk NMIBC who had underwent TURBT were divided into two groups, of which IAC + IVC group received four courses of IAC (cisplatin and epirubicin) combined with IVC (epirubicin or pirarubicin) after surgery and BCG group received intravesical BCG immunotherapy. Recurrence rate and progression rate were assessed by Chi-square test, while recurrence-free survival and progression-free survival were calculated using the Kaplan-Meier method. RESULTS: In this study, the recurrence rate was 27.9% (12/43) in IAC + IVC group and 26.4% (14/53) in BCG group, while progression rate was 9.3% (4/43) in IAC + IVC group and 9.4% (5/53) in BCG group. Both of the recurrence and progression rate did not show a significant difference. In the Kaplan-Meier plot, no difference was found with respect to recurrence-free survival and progression-free survival. Moreover, 46.5% (20/43) patients suffered from adverse events of IAC and 83.1% (49/59) patients suffered from adverse events associated with BCG, of which 6 patients discontinued treatment due to serious adverse events of BCG. Univariate analysis suggested that only recurrent tumor could be an independent risk factor related to recurrence. CONCLUSIONS: IAC combined with IVC used in high-risk NMIBC could reduce the recurrence and progression as effective as BCG instillation with lower adverse events. FAU - Huang, Bin AU - Huang B AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Huang, Gaowei AU - Huang G AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Li, Wenji AU - Li W AD - Surgical Anesthesia Center, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Chen, Lingwu AU - Chen L AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. chenlingwu@hotmail.com. FAU - Mao, Xiaopeng AU - Mao X AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. mxpzc1979@aliyun.com. FAU - Chen, Junxing AU - Chen J AUID- ORCID: 0000-0002-7264-5110 AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. cjxsysums@163.com. LA - eng GR - No.81402116/National Natural Science Foundation of China/ GR - No. 2019A1515010285/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20201122 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 3Z8479ZZ5X (Epirubicin) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage MH - BCG Vaccine/*administration & dosage MH - Carcinoma, Transitional Cell/*drug therapy/pathology/*surgery MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage MH - Combined Modality Therapy MH - Cystectomy/methods MH - Doxorubicin/administration & dosage/analogs & derivatives MH - Epirubicin/administration & dosage MH - Female MH - Humans MH - Immunotherapy/methods MH - Infusions, Intra-Arterial MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery PMC - PMC11801937 OTO - NOTNLM OT - BCG OT - High-risk non-muscle-invasive bladder cancer OT - Intra-arterial chemotherapy OT - Intravesical chemotherapy COIS- The authors declare that they have no conflicts of interest. EDAT- 2020/11/23 06:00 MHDA- 2021/05/26 06:00 PMCR- 2020/11/22 CRDT- 2020/11/22 20:43 PHST- 2020/08/20 00:00 [received] PHST- 2020/11/04 00:00 [accepted] PHST- 2020/11/23 06:00 [pubmed] PHST- 2021/05/26 06:00 [medline] PHST- 2020/11/22 20:43 [entrez] PHST- 2020/11/22 00:00 [pmc-release] AID - 10.1007/s00432-020-03453-x [pii] AID - 3453 [pii] AID - 10.1007/s00432-020-03453-x [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2021 Jun;147(6):1781-1788. doi: 10.1007/s00432-020-03453-x. Epub 2020 Nov 22. PMID- 33214030 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 3 DP - 2021 Mar TI - Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study. PG - 195.e1-195.e6 LID - S1078-1439(20)30424-5 [pii] LID - 10.1016/j.urolonc.2020.09.006 [doi] AB - PURPOSE: To assess whether progressive and primary muscle invasive bladder cancer (MIBC) have different prognosis after radical cystectomy or not. To date only a few data are available on this topic with conflicting results. Further studies on large cohort are needed to clarify these outcomes that may influence bladder cancer management for these patients. MATERIAL AND METHODS: A multicentre retrospective study was conducted on patient treated for MIBC at 5 centres between 2005 and 2015 by radical cystectomy. Patients' outcomes were compared between patients with primary MIBC vs. progressive MIBC subsequent to a history of non-muscle invasive bladder cancer (NMIBC). RESULTS: A total of 1197 patients were included. Median (IQ) age was 65 (58-72) years and median follow-up was 65 months. Baseline characteristics were similar between the groups as well as the Tumour pT stage, N status and positive surgical margins. Patients with progressive MIBC had worse overall survival (OS) (hazard ratio [HR] 1.36, [95%CI 1.10-1.76]; P = 0.004), cancer specific survival (CSS) (HR 1.41 [1.13-1.78]; P = 0.002), and recurrence-free survival (RFS) (HR 1.21 [1.01-1.49]; P = 0.05). Pathological stage >/=pT3, positive surgical margins, and positive lymph nodes status (pN+) were also found as predictors of OS, CSS, and RFS. CONCLUSIONS: Our results suggest that patient having a progressive BC have a worse prognosis in terms of OS, PFS, and CSS than patient with primary disease. These 2 groups may require different management and patients with high risk NMIBC should be assessed properly to avoid progression and be offered early cystectomy. CI - Copyright (c) 2020. Published by Elsevier Inc. FAU - Nouhaud, Francois-Xavier AU - Nouhaud FX AD - Department of Urology, Rouen University Hospital, Rouen, France. Electronic address: fx_nouhaud@hotmail.fr. FAU - Chakroun, Marouene AU - Chakroun M AD - Department of Urology, Tunis University Hospital, Tunis, Tunisia. FAU - Lenormand, Claire AU - Lenormand C AD - Department of Urology, Rouen University Hospital, Rouen, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Bichat University Hospital, Paris, France. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Gryn, Alexandre AU - Gryn A AD - Department, of Urology, Toulouse University Hospital, Toulouse, France. FAU - Prudhomme, Thomas AU - Prudhomme T AD - Department, of Urology, Toulouse University Hospital, Toulouse, France. FAU - Grafeille, Vivien AU - Grafeille V AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Soulie, Michel AU - Soulie M AD - Department, of Urology, Toulouse University Hospital, Toulouse, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Department, of Urology, Toulouse University Hospital, Toulouse, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat University Hospital, Paris, France. FAU - Bouzouita, Abderrazak AU - Bouzouita A AD - Department of Urology, Tunis University Hospital, Tunis, Tunisia. FAU - Chebil, Mohamed AU - Chebil M AD - Department of Urology, Tunis University Hospital, Tunis, Tunisia. FAU - Pfister, Christian AU - Pfister C AD - Department of Urology, Rouen University Hospital, Rouen, France. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20201116 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - *Cystectomy/methods MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Progression OT - Radical Cystectomy OT - Survival EDAT- 2020/11/21 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/11/20 05:35 PHST- 2020/05/18 00:00 [received] PHST- 2020/08/03 00:00 [revised] PHST- 2020/09/04 00:00 [accepted] PHST- 2020/11/21 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/11/20 05:35 [entrez] AID - S1078-1439(20)30424-5 [pii] AID - 10.1016/j.urolonc.2020.09.006 [doi] PST - ppublish SO - Urol Oncol. 2021 Mar;39(3):195.e1-195.e6. doi: 10.1016/j.urolonc.2020.09.006. Epub 2020 Nov 16. PMID- 33210440 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20250912 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 IP - 1 DP - 2021 Jul TI - The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin. PG - 65-71 LID - 10.1111/bju.15296 [doi] AB - OBJECTIVES: To evaluate if the obesity paradox, wherein obesity portends worse overall prognosis for a disease but improved outcomes for patients receiving immunotherapy, exists for patients receiving bacillus Calmette-Guerin (BCG) in a contemporary cohort. PATIENTS AND METHODS: We performed an Institutional Review Board-approved database review to identify patients with non-muscle-invasive bladder cancer (NMIBC) completing at least an induction course of BCG. Clinicopathological variables collected included: body mass index (BMI), medications, and diabetes mellitus (DM). Outcomes of interest included: recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Univariate and multivariate modelling were used to evaluate the association between outcomes and clinical factors. RESULTS: A total of 579 patients (median follow-up 4.6 years) received BCG induction for NMIBC; 90% had high-grade disease (47.2% clinical stage T1). In all, 75.7% of patients were overweight or obese and 18% had DM. Aspirin, statins, metformin and beta-blockers were used in 34%, 42%, 11%, and 29% of patients, respectively. Overweight and obese patients had improved PFS, CSS and OS. DM was associated with worse RFS. Medications of interest had no association with outcomes. CONCLUSION: Elevated BMI is associated with improved outcomes in patients with NMIBC treated with BCG immunotherapy. Patients with DM are at increased risk of recurrence. These findings support a potential obesity paradox in bladder cancer. Evaluation of the underlying mechanism and the role of global patient assessment, counselling, and risk factor modification are warranted. CI - (c) 2020 The Authors BJU International (c) 2020 BJU International. FAU - Brooks, Nathan A AU - Brooks NA AUID- ORCID: 0000-0002-5111-6914 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kokorovic, Andrea AU - Kokorovic A AUID- ORCID: 0000-0002-1957-7999 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Xiao, Lianchen AU - Xiao L AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Matulay, Justin T AU - Matulay JT AUID- ORCID: 0000-0002-2467-5710 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Ranasinghe, Weranja K B AU - Ranasinghe WKB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nagaraju, Supriya AU - Nagaraju S AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Shen, Yu AU - Shen Y AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Gao, Jianjun AU - Gao J AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20201205 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - *Body Mass Index MH - Diabetes Complications/*complications MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Obesity/*complications MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*complications/*drug therapy/pathology OTO - NOTNLM OT - #Bladder Cancer OT - #blcsm OT - #uroonc OT - Bacillus Calmette-Guerin OT - body mass index OT - diabetes mellitus OT - non-muscle-invasive bladder cancer OT - obesity paradox EDAT- 2020/11/20 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/11/19 05:56 PHST- 2020/11/20 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/11/19 05:56 [entrez] AID - 10.1111/bju.15296 [doi] PST - ppublish SO - BJU Int. 2021 Jul;128(1):65-71. doi: 10.1111/bju.15296. Epub 2020 Dec 5. PMID- 33208770 OWN - NLM STAT- MEDLINE DCOM- 20210422 LR - 20210422 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Nov 18 TI - Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. PG - 20135 LID - 10.1038/s41598-020-76904-7 [doi] LID - 20135 AB - No consensus currently exist on the optimal treatment of patients with high-risk nonmuscle invasive (HGT1) micropapillary variant of bladder cancer (MPBC). Transcripsome analysis may allow stratification of MPBC-HGT1 enabling prediction of recurrence and guide therapeutic management for individual patients. Whole transcriptome RNA-Sequencing of tumors from 23 patients with MPBC-HGT1 and 64 conventional urothelial carcinomas (cUC) (reference set) was performed. Differentially expressed genes between MPBC-HGT1 and cUC-HGT1 were explored. Cox proportional hazard models and Kapplan-Meier methods were used to assess the relation between time to progression (TTP) and individual gene expression adjusting for clinical covariates. Over 3000 genes were differentially expressed in MPBC-HGT1 as compared with cUC-HGT1 and a 26-gene signature is characteristic of MPBC within HGT1. A set of three genes; CD36, FAPB3 and RAETE1; were significantly associated with TTP. High expression of FABP3 and CD36 were associated with shorter TTP (p = 0.045 and p = 0.08) as was low expression of RAET1E (p = 0.01). Our study suggest that a 26-gene signature can define MPBC-HGT1 within conventional urothelial carcinomas. A prognostic risk index of three genes (FABP3, CD36 and RAET1E) was found to be associated with shorter TTP and may help classify a group of patients with MPBC-HGT1 with high-risk of early progression. These observations might have implications in terms of radical cystectomy recommendation in MPBC patients. FAU - Bowden, Michaela AU - Bowden M AD - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. mbowde01@gmail.com. FAU - Nadal, Rosa AU - Nadal R AD - Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, MD, USA. FAU - Zhou, Chensheng W AU - Zhou CW AD - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. FAU - Werner, Lillian AU - Werner L AD - Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Barletta, Justine AU - Barletta J AD - Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. FAU - Juanpere, Nuria AU - Juanpere N AD - Department of Pathology, PSMAR-IMIM Research Institute, Barcelona, Spain. AD - Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Lloreta, Josep AU - Lloreta J AD - Department of Pathology, PSMAR-IMIM Research Institute, Barcelona, Spain. AD - Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Hernandez-Llodra, Silvia AU - Hernandez-Llodra S AD - Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Morote, Juan AU - Morote J AD - Department of Urology, Hospital Vall D'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - de Torres, Ines AU - de Torres I AD - Department of Pathology, Hospital Vall D'Hebron, Barcelona, Spain. FAU - Orsola, Anna AU - Orsola A AD - PSMAR-IMIM Research Institute, Barcelona, Spain. FAU - Cejas, Paloma AU - Cejas P AD - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA. FAU - Long, Henry AU - Long H AD - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. jbellmun@bidmc.harvard.edu. AD - PSMAR-IMIM Research Institute, Barcelona, Spain. jbellmun@bidmc.harvard.edu. AD - Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Av, Boston, 02215, USA. jbellmun@bidmc.harvard.edu. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20201118 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (CD36 Antigens) RN - 0 (Carrier Proteins) RN - 0 (FABP3 protein, human) RN - 0 (Fatty Acid Binding Protein 3) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Membrane Proteins) RN - 0 (RAET1E protein, human) SB - IM MH - CD36 Antigens/genetics MH - Carrier Proteins/genetics MH - Fatty Acid Binding Protein 3/genetics MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Histocompatibility Antigens Class I/genetics MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Membrane Proteins/genetics MH - Neoplasm Staging MH - Sequence Analysis, RNA MH - Urinary Bladder Neoplasms/*genetics/mortality/*pathology PMC - PMC7675970 COIS- M. Bowden and J. Bellmunt have applied for a patent based on the genomic findings for the diagnosis and/or the prediction of the progression of high grade T1 micropapillary bladder cancer. The method comprises quantifying the expression product of each one of FABP3, CD36 and RAET1E genes in an isolated sample from the subject. The analysis of these 3 differentially expressed genes (FABP3, CD36 and RAET1E) allowed to create a risk index that could help to identify patients with micropapillary variant of high grade T1 with a higher risk of progression. The other authors do not have any conflicts of interest to declare. EDAT- 2020/11/20 06:00 MHDA- 2021/04/23 06:00 PMCR- 2020/11/18 CRDT- 2020/11/19 05:36 PHST- 2020/03/24 00:00 [received] PHST- 2020/10/20 00:00 [accepted] PHST- 2020/11/19 05:36 [entrez] PHST- 2020/11/20 06:00 [pubmed] PHST- 2021/04/23 06:00 [medline] PHST- 2020/11/18 00:00 [pmc-release] AID - 10.1038/s41598-020-76904-7 [pii] AID - 76904 [pii] AID - 10.1038/s41598-020-76904-7 [doi] PST - epublish SO - Sci Rep. 2020 Nov 18;10(1):20135. doi: 10.1038/s41598-020-76904-7. PMID- 33204366 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20221207 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2020 DP - 2020 TI - Associations between Interleukin-32 Gene Polymorphisms rs12934561 and rs28372698 and Susceptibilities to Bladder Cancer and the Prognosis in Chinese Han Population. PG - 8860445 LID - 10.1155/2020/8860445 [doi] LID - 8860445 AB - The proinflammatory chemokine interleukin-32 is related to various diseases, including cancer. However, it has never been associated with bladder cancer (BC). To detect whether there is a relationship between the IL-32 gene polymorphisms (rs12934561 C/T and rs28372698 T/A) and BC, the study enrolled 170 non-muscle-invasive bladder cancer (NMIBC) patients, 151 muscle-invasive bladder cancer (MIBC) patients, and 437 healthy controls. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for the IL-32 single-nucleotide polymorphism (SNP) genotyping. Statistical analysis was performed using SNPstats online analysis software and SPSS software. Our data revealed that the CC homozygous genotype of rs12934561 in BC patients was significantly higher than that in controls (P = 0.03, OR = 1.47, 95%CI = 1.04-2.08), and the percentage of TC genotype carriers was relatively less than that of controls (P = 0.001, OR = 0.61, 95%CI = 0.45-0.82). Furthermore, the TT homozygous genotype of rs28372698 was associated with a significantly lower overall survival rate in MIBC patients (P = 0.028, OR = 2.77, 95%CI = 1.11-6.90). The IL-32 gene polymorphism rs12934561 might be associated with increased BC risk, and the rs28372698 might participate in the prognosis of BC patients. Therefore, they could be potential forecasting factors for the prognosis of MIBC patients. CI - Copyright (c) 2020 Jie Yang et al. FAU - Yang, Jie AU - Yang J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. AD - Department of Urology, Chengdu First People's Hospital, Chengdu, Sichuan 610041, China. FAU - Jian, Zhongyu AU - Jian Z AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Shen, Pengfei AU - Shen P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Bai, Yunjin AU - Bai Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Tang, Yin AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. FAU - Wang, Jia AU - Wang J AUID- ORCID: 0000-0002-6957-9810 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. LA - eng PT - Journal Article DEP - 20201105 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (IL32 protein, human) RN - 0 (Interleukins) SB - IM MH - Aged MH - Asian People/ethnology/*genetics MH - Case-Control Studies MH - China/ethnology MH - Early Detection of Cancer MH - Female MH - Genetic Association Studies MH - Genetic Predisposition to Disease MH - Humans MH - Interleukins/*genetics MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - *Polymorphism, Single Nucleotide MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/genetics PMC - PMC7661138 COIS- The authors declare that they have no conflict of interest. EDAT- 2020/11/19 06:00 MHDA- 2021/08/10 06:00 PMCR- 2020/11/05 CRDT- 2020/11/18 05:58 PHST- 2020/04/20 00:00 [received] PHST- 2020/07/20 00:00 [revised] PHST- 2020/10/24 00:00 [accepted] PHST- 2020/11/18 05:58 [entrez] PHST- 2020/11/19 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/11/05 00:00 [pmc-release] AID - 10.1155/2020/8860445 [doi] PST - epublish SO - Dis Markers. 2020 Nov 5;2020:8860445. doi: 10.1155/2020/8860445. eCollection 2020. PMID- 33201207 OWN - NLM STAT- MEDLINE DCOM- 20210105 LR - 20220418 IS - 1538-3598 (Electronic) IS - 0098-7484 (Linking) VI - 324 IP - 19 DP - 2020 Nov 17 TI - Bladder Cancer: A Review. PG - 1980-1991 LID - 10.1001/jama.2020.17598 [doi] AB - IMPORTANCE: Bladder cancer is a common malignancy in women and is the fourth most common malignancy in men. Bladder cancer ranges from unaggressive and usually noninvasive tumors that recur and commit patients to long-term invasive surveillance, to aggressive and invasive tumors with high disease-specific mortality. OBSERVATIONS: Advanced age, male sex, and cigarette smoking contribute to the development of bladder cancer. Bladder tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper tract imaging depending on the degree of hematuria and risk of malignancy. Non-muscle-invasive tumors are treated with endoscopic resection and adjuvant intravesical therapy, depending on the risk classification. Enhanced cystoscopy includes technology used to improve the detection of tumors and can reduce the risk of recurrence. Patients with high-risk non-muscle invasive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy, bacille Calmette-Guerin (BCG), constitute a challenging patient population to manage and many alternative therapies are being studied. For patients with muscle-invasive disease, more aggressive therapy with radical cystectomy and urinary diversion or trimodal therapy with maximal endoscopic resection, radiosensitizing chemotherapy, and radiation is warranted to curb the risk of metastasis and disease-specific mortality. Treatment of patients with advanced disease is undergoing rapid changes as immunotherapy with checkpoint inhibitors, targeted therapies, and antibody-drug conjugates have become options for certain patients with various stages of disease. CONCLUSIONS AND RELEVANCE: Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates. FAU - Lenis, Andrew T AU - Lenis AT AD - Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles. FAU - Lec, Patrick M AU - Lec PM AD - Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles. FAU - Chamie, Karim AU - Chamie K FAU - Mshs, M D AU - Mshs MD AD - Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles. LA - eng PT - Journal Article PT - Review PL - United States TA - JAMA JT - JAMA JID - 7501160 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM SPIN- JAMA. 2020 Nov 17;324(19):2006. doi: 10.1001/jama.2020.17601. PMID: 33201205 MH - Administration, Intravesical MH - Antineoplastic Agents/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Combined Modality Therapy MH - *Cystectomy/adverse effects/methods MH - Cystoscopy MH - Female MH - Humans MH - *Immunotherapy MH - Male MH - Mutation MH - Neoplasm Invasiveness MH - Risk Factors MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/diagnosis/genetics/pathology/*therapy EDAT- 2020/11/18 06:00 MHDA- 2021/01/06 06:00 CRDT- 2020/11/17 12:16 PHST- 2020/11/17 12:16 [entrez] PHST- 2020/11/18 06:00 [pubmed] PHST- 2021/01/06 06:00 [medline] AID - 2772966 [pii] AID - 10.1001/jama.2020.17598 [doi] PST - ppublish SO - JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598. PMID- 33198698 OWN - NLM STAT- MEDLINE DCOM- 20210419 LR - 20210419 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 20 IP - 1 DP - 2020 Nov 16 TI - Preoperative positive voided urine cytology predicts poor clinical outcomes in patients with upper tract urothelial carcinoma undergoing nephroureterectomy. PG - 1113 LID - 10.1186/s12885-020-07623-5 [doi] LID - 1113 AB - BACKGROUND: Performance of urinary cytology is recommended as the part of a standard diagnostic workup and base surveillance regimens in upper tract urothelial carcinoma (UTUC). However, the effect of positive voided urine cytology (VUC) on UTUC prognosis, compared with negative VUC, has not been fully demonstrated. This study aimed to evaluate the impact of preoperative VUC on predicting intravesical recurrence, disease recurrence, and mortality in patients with UTUC who underwent nephroureterectomy (RNU). METHODS: Clinicopathological information was collected from 315 UTUC patients treated with RNU. The association between VUC and oncological outcomes was analyzed using the Kaplan-Meier method with log-rank test and Cox proportional hazards regression models. Multiple logistic regression analysis was performed to identify the influence of VUC on tumor grade. RESULTS: Preoperative positive VUC, presenting in 101 patients (32%), was significantly associated with tumor multifocality (P = 0.017) and higher tumor grade (P = 0.010). On multivariable Cox regression analyses, preoperative positive VUC was an independent prognostic factor of intravesical recurrence-free survival (RFS) (hazard ratio [HR] = 2.21, 95% confidence interval [CI] 1.06-4.64; P = 0.035), RFS (HR = 1.80, 95% CI 1.08-2.99; P = 0.023), and cancer-specific survival (CSS) (HR = 1.87, 95% CI 1.10-3.18; P = 0.020), but not overall survival (HR = 1.32, 95% CI 0.80-2.18; P = 0.28). Logistic regression analysis revealed that VUC was related to high tumor grade in UTUC (odds ratio = 2.23, 95%CI 1.15-4.52). CONCLUSION: Preoperative positive VUC significantly increases the risk of intravesical recurrence in UTUC patients undergoing RNU. In addition, positive VUC is an adverse predictor of RFS and CSS, which might be due to the association between positive VUC and high tumor grade. FAU - Liu, Wen AU - Liu W AD - Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Rd, Qingdao, 266003, China. FAU - Wang, Zhankun AU - Wang Z AD - Department of Urology, Qingdao Eighth People's Hospital, Qingdao, China. FAU - Liu, Shuai AU - Liu S AD - Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Rd, Qingdao, 266003, China. FAU - Yao, Yu AU - Yao Y AD - Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Rd, Qingdao, 266003, China. FAU - Liu, Yong AU - Liu Y AD - Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Rd, Qingdao, 266003, China. FAU - Zhang, Guiming AU - Zhang G AUID- ORCID: 0000-0002-5856-5325 AD - Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Rd, Qingdao, 266003, China. zhangguiming9@126.com. LA - eng GR - 81502195/Young Scientists Fund/ PT - Clinical Trial PT - Journal Article DEP - 20201116 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Aged MH - Cytodiagnosis/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*mortality/pathology/surgery/urine MH - Nephroureterectomy/*mortality MH - *Preoperative Care MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinalysis/*methods MH - Urologic Neoplasms/*mortality/pathology/surgery/urine PMC - PMC7670807 OTO - NOTNLM OT - Nephroureterectomy OT - Recurrence OT - Survival OT - Upper urinary tract OT - Urine cytology OT - Urothelial carcinoma COIS- None declared. EDAT- 2020/11/18 06:00 MHDA- 2021/04/20 06:00 PMCR- 2020/11/16 CRDT- 2020/11/17 05:43 PHST- 2020/03/10 00:00 [received] PHST- 2020/11/10 00:00 [accepted] PHST- 2020/11/17 05:43 [entrez] PHST- 2020/11/18 06:00 [pubmed] PHST- 2021/04/20 06:00 [medline] PHST- 2020/11/16 00:00 [pmc-release] AID - 10.1186/s12885-020-07623-5 [pii] AID - 7623 [pii] AID - 10.1186/s12885-020-07623-5 [doi] PST - epublish SO - BMC Cancer. 2020 Nov 16;20(1):1113. doi: 10.1186/s12885-020-07623-5. PMID- 33195885 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220418 IS - 2468-3574 (Electronic) IS - 2468-3574 (Linking) VI - 24 DP - 2020 TI - Precave: Immediate neoadjuvant instillation of chemotherapy for the prevention of non-muscle invasive bladder carcinoma recurrence: A prospective randomized clinical trial protocol. PG - 21-26 LID - 10.1016/j.isjp.2020.10.001 [doi] AB - INTRODUCTION AND OBJECTIVES: Recurrence rates for patients presenting with non-muscle invasive bladder carcinoma (NMIBC) can be as high as 60% during the first year after a transurethral resection of bladder tumor (TURBT). Currently, an immediate postoperative instillation of chemotherapy (IPOIC) is recommended for the prevention of recurrences in patients with low to intermediate risk disease. Although in real clinical practice this specific instillation of chemotherapy has many difficulties to be standardized, including its contraindications (suspected or confirmed bladder perforation, wide or extensive resection and, continuous bladder irrigation requirement), which will only make it feasible for around 30% of patients.We propose in this controlled study, to administer an immediate neoadjuvant instillation of chemotherapy (INAIC), which can be applied technically to all patients, no matter the surgical outcomes and compare it with a control group. We expect to find a reduction in the recurrence rate in the experimental group of at least 15%. METHODS: We designed a phase IV, randomized, controlled, open label clinical trial. Main inclusion criteria are: patients with a clinical diagnosis of localized, papillary-type bladder cancer (suspected low to intermediate risk) with a disease-free interval of at least 6 months. Eligible patients will be allocated into group A (INAIC plus TURBT) or group B (TURBT) using a computer-generated block randomization sequence/ratio 1:1. Time to recurrence of both groups will be analyzed and compared using Kaplan-Meier estimates, log-rank tests and, Cox-regression. Univariate and multivariate analyzes will be performed to determine factors which influence recurrence. The study has received the approval of the Ethics Committee for Drug Research (CEIm) of La Paz University Hospital and the Spanish Agency for Medicines and Health Products. CI - (c) 2020 The Author(s). FAU - Carrion, Diego M AU - Carrion DM AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. FAU - Gomez Rivas, Juan AU - Gomez Rivas J AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. FAU - Ballesteros Ruiz, Cristina AU - Ballesteros Ruiz C AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. FAU - Aguilera Bazan, Alfredo AU - Aguilera Bazan A AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Department of Urology, La Paz University Hospital, Madrid, Spain. AD - Autonomous University of Madrid, Madrid, Spain. AD - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain. LA - eng PT - Journal Article DEP - 20201017 PL - England TA - Int J Surg Protoc JT - International journal of surgery protocols JID - 101758186 PMC - PMC7644741 OTO - NOTNLM OT - Bladder carcinoma OT - Intravesical chemotherapy OT - Mitomycin c OT - Recurrence OT - Urothelial carcinoma COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2020/11/17 06:00 MHDA- 2020/11/17 06:01 PMCR- 2020/10/17 CRDT- 2020/11/16 08:56 PHST- 2020/09/28 00:00 [received] PHST- 2020/10/06 00:00 [accepted] PHST- 2020/11/16 08:56 [entrez] PHST- 2020/11/17 06:00 [pubmed] PHST- 2020/11/17 06:01 [medline] PHST- 2020/10/17 00:00 [pmc-release] AID - S2468-3574(20)30030-9 [pii] AID - 10.1016/j.isjp.2020.10.001 [doi] PST - epublish SO - Int J Surg Protoc. 2020 Oct 17;24:21-26. doi: 10.1016/j.isjp.2020.10.001. eCollection 2020. PMID- 33191862 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20210414 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 205 IP - 3 DP - 2021 Mar TI - T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guerin Failure and Improves Patient Stratification at Diagnosis. PG - 701-708 LID - 10.1097/JU.0000000000001422 [doi] AB - PURPOSE: Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guerin treatment. Therefore, we evaluated the prognostic value of T1 substaging in patients with primary high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Patients with primary high risk nonmuscle invasive bladder cancer who received >/=5 bacillus Calmette-Guerin induction instillations were included. All tumors were centrally reviewed, which included T1 substaging (microinvasion vs extensive invasion of the lamina propria). T1 patients were stratified into high risk or highest risk subgroups according to major urology guidelines. Primary end point was bacillus Calmette-Guerin failure, defined as development of a high grade recurrence. Secondary end points were high grade recurrence-free survival, defined as time from primary diagnosis to biopsy-proven high grade recurrence and progression-free survival. Time-to-event analyses were used to predict survival. RESULTS: A total of 264 patients with high risk nonmuscle invasive bladder cancer had tumor invasion of the lamina propria, of which 73% were classified as extensive invasion and 27% as microinvasion. Median followup was 68 months (IQR 43-98) and bacillus Calmette-Guerin failure was more common among patients with extensive vs microinvasive tumors (41% vs 21%, p=0.002). The 3-year high grade recurrence-free survival (defined as bacillus Calmette-Guerin failure) for patients with extensive vs microinvasive tumors was 64% vs 83% (p=0.004). In multivariate analysis, T1 substaging was an independent predictor of high grade recurrence-free survival (HR 3.2, p=0.005) and progression-free survival (HR 3.0, p=0.009). Patients with highest risk/microinvasive disease have an improved progression-free survival as compared to highest risk/T1e disease (p.adj=0.038). CONCLUSIONS: T1 substaging provides important prognostic information on patients with primary high risk nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin. The risk of bacillus Calmette-Guerin failure is higher in extensive vs microinvasive tumors. Substaging of T1 high risk nonmuscle invasive bladder cancer has the potential to guide treatment decisions on bacillus Calmette-Guerin vs alternative strategies at diagnosis. FAU - de Jong, Florus C AU - de Jong FC AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Hoedemaeker, Robert F AU - Hoedemaeker RF AD - Pathan BV, Pathological Laboratory, Rotterdam, The Netherlands. FAU - Kvikstad, Vebjorn AU - Kvikstad V AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway. FAU - Mensink, Jolien T M AU - Mensink JTM AD - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - de Jong, Joep J AU - de Jong JJ AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Boeve, Egbert R AU - Boeve ER AD - Department of Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. FAU - van der Schoot, Deric K E AU - van der Schoot DKE AD - Department of Urology, Amphia, Breda, The Netherlands. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20201116 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Staging MH - Netherlands MH - Norway MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Treatment Failure MH - Urinary Bladder Neoplasms/*drug therapy/mortality/*pathology OTO - NOTNLM OT - BCG vaccine OT - carcinoma, transitional cell OT - neoplasm staging OT - prognosis OT - urinary bladder neoplasms EDAT- 2020/11/17 06:00 MHDA- 2021/04/15 06:00 CRDT- 2020/11/16 08:42 PHST- 2020/11/17 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2020/11/16 08:42 [entrez] AID - 10.1097/JU.0000000000001422 [doi] PST - ppublish SO - J Urol. 2021 Mar;205(3):701-708. doi: 10.1097/JU.0000000000001422. Epub 2020 Nov 16. PMID- 33189530 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 4 DP - 2021 Apr TI - Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. PG - 235.e5-235.e14 LID - S1078-1439(20)30574-3 [pii] LID - 10.1016/j.urolonc.2020.11.005 [doi] AB - INTRODUCTION: The Albumin-Globulin Ratio (AGR; albumin/total protein - albumin) has been associated with oncological outcome in various malignancies. However, its role in urothelial carcinoma of the bladder (UCB) has not been clearly established. In this study, we assessed the association of preoperative AGR (pAGR) with survival in patients who underwent radical cystectomy (RC) for UCB. MATERIAL AND METHODS: We conducted a retrospective analysis of an established multicenter database of 4.335 patients who were treated with RC for UCB. The cohort was divided into 2 groups according to the pAGR status. Binominal logistic regression as well as uni- and multivariable Cox regression analyses were used. The predictive value of the models was assessed by calculating receiver operating characteristics curves and concordance-indices (C-Index). The additional clinical value was assessed using the decision curve analysis (DCA). RESULTS: Overall, 1.670 patients (38.5%) had a low pAGR. On multivariable logistic regression analyses, low pAGR was associated with an increased risk of >/=pT3 disease at RC (odds ratio [OR] 1.15, 95% confidence interval [CI] 1.01-1.31, P= 0.04). On multivariable Cox regression analyses, low pAGR remained associated with worse recurrence-free survival (RFS, HR 1.24, 95% CI 1.1-1.37, P< 0.001), cancer-specific survival (CSS, HR 1.23, 95% CI 1.1-1.38, P< 0.001) and overall survival (OS, HR 1.17, 95% CI 1.07-1.28, P< 0.001). The addition of pAGR to multiple prognostic models that were respectively fitted for clinical and postoperative variables did not improve the predictive accuracy. CONCLUSION: pAGR status is an independent predictor of >/=pT3 disease, therefore it could help identify patients who have a higher likelihood to benefit from neoadjuvant systemic therapy. While pAGR was independently associated with RFS, CSS, and OS, it did not improve the predictive accuracy and clinical value beyond obtained by information already available. The predictive value of this biomarker in the age of immunotherapy needs further evaluation. CI - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - D Andrea, David AU - D Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada. FAU - Luzzago, Stefano AU - Luzzago S AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, GRC n degrees 5, Predictive Onco-Urology, Ap-Hp, Urology, Hopital Pitie-Salpetriere, Urology, Paris. FAU - Chlosta, Piotr AU - Chlosta P AD - Department of Urology, Jagiellonian University, Medical College, Krakow, Poland. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. FAU - Deuker, Marina AU - Deuker M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Institut Mutualiste Montsouris, Paris, France; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; European Association of Urology Research Foundation, Arnhem, Netherlands. Electronic address: shahrokh.shariat@meduniwien.ac.at. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital of Tours, Tours, France. LA - eng PT - Journal Article PT - Review DEP - 20201111 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Serum Albumin) RN - 0 (Serum Globulins) SB - IM MH - Carcinoma, Transitional Cell/*blood/*surgery MH - *Cystectomy/methods MH - Humans MH - Preoperative Period MH - Serum Albumin/*analysis MH - Serum Globulins/*analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*blood/*surgery OTO - NOTNLM OT - AGR OT - Biomarker OT - Bladder cancer OT - MIBC OT - NMIBC OT - Transitional cell carcinoma COIS- Conflicts of interest All authors have no conflict of interest. EDAT- 2020/11/16 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/11/15 20:23 PHST- 2020/06/22 00:00 [received] PHST- 2020/10/16 00:00 [revised] PHST- 2020/11/02 00:00 [accepted] PHST- 2020/11/16 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/11/15 20:23 [entrez] AID - S1078-1439(20)30574-3 [pii] AID - 10.1016/j.urolonc.2020.11.005 [doi] PST - ppublish SO - Urol Oncol. 2021 Apr;39(4):235.e5-235.e14. doi: 10.1016/j.urolonc.2020.11.005. Epub 2020 Nov 11. PMID- 33189528 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20221207 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes? PG - 368.e19-368.e29 LID - S1078-1439(20)30575-5 [pii] LID - 10.1016/j.urolonc.2020.11.006 [doi] AB - PURPOSE: Cisplatin based chemoradiation has been commonly used as a definitive treatment for muscle-invasive bladder cancer (MIBC). The aim of the current study is to evaluate oncologic results and toxicity profile of bladder-sparing treatment with external beam radiotherapy (EBRT) and gemcitabine chemotherapy (ChT) in patients with MIBC. MATERIALS AND METHODS: Between April 2005 and November 2018 44 patients with nonmetastatic and N0 MIBC were treated with transurethral resection of bladder (TURB), EBRT and concurrent gemcitabine. All patients were staged using thorax-abdomen-pelvic CT and pelvic MRI. EBRT was delivered using 3D conformal technique or intensity modulated radiotherapy. Patients received 50 Gy in 25 to 28 fractions to full bladder followed by a boost dose of 10 Gy in 5 fractions to empty bladder with weekly concurrent gemcitabine of 50 mg/m(2). All patients were evaluated for age, gender, smoking status, neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) at diagnosis, presence of hydroureteronephrosis (HUN), preoperative tumor size, tumor multifocality, presence of CIS, clinical tumor stage. Acute/late genitourinary (GUS) and gastrointestinal (GIS) toxicity, recurrence status, cancer specific survival (CSS) and overall survival (OS) were evaluated. Statistical analysis was performed using SPSS v21.0. Kaplan-Meier survival estimates were calculated to describe CSS and OS. The effect of different parameters on survival was investigated using the log rank test. RESULTS: Median age of the patients was 72 years (interquartile [IQR]; 66-80). The median tumor size was 30 mm (IQR, 15-59 mm). Thirty-two (77%) patients had T2, 6 (14%) patients had T3, and 4 (9%) patients had T4a disease. Median NLR was 2.6 (IQR, 1.7-3.8) and median PLR was 126.47 (IQR, 77.4-184.8). Median follow-up time was 21 months (range, 6-153 months). At the first TURB performed 6 weeks after CRT, complete response, partial response, stable disease, and progression was detected in 37 (84%), 3 (7%), 1 (2%), and 3 (7%) patients, respectively. One- and 2-year OS, CSS, LRFS, and DMFS rates were 86% and 64%; 88% and 66%; 65% and 44%; 68% and 48%, respectively. In univariate analysis; prognostic factors were age and presence of HUN for OS and DMFS; age, HUN, presence of CIS, NLR, and PLR for DSS; HUN, NLR, and PLR for LRFS, respectively. In multivariate analysis, the independent predictor was the presence of HUN for OS, LRFS, and DMFS; NLR for DSS; PLR for LRFS and age for DMSF. For a subgroup of 17 patients with complete TURB and no CIS and HUN symptoms, 2-year OS, DSS, LRFS, and DMFS rates were 88%, 88%, 72%, and 79%, respectively. The treatment was well-tolerated and all patients completed the planned EBRT and ChT. No acute or late >/= grade 3 toxicity was observed. Grade II acute GIS toxicity was detected in 3 (7%) patients and grade II acute GUS toxicity was detected in 9 (21%) patients, respectively. Grade II late GUS toxicity was observed in 2 (5%) patients. CONCLUSION: Gemcitabine based trimodality treatment is well-tolerated with similar oncologic outcomes reported in the literature. Older age, presence of CIS and high NLR and PLR values seem to deteriorate DSS. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Hurmuz, Pervin AU - Hurmuz P AD - Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: phurmuz@yahoo.com. FAU - Ozyigit, Gokhan AU - Ozyigit G AD - Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. FAU - Kilickap, Saddettin AU - Kilickap S AD - Department of Preventive Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. FAU - Esen, Caglayan Selenge Beduk AU - Esen CSB AD - Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. FAU - Akdogan, Bulent AU - Akdogan B AD - Department of Urology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. FAU - Ozen, Haluk AU - Ozen H AD - Department of Urology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. FAU - Akyol, Fadil AU - Akyol F AD - Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20201111 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antimetabolites, Antineoplastic) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Aged, 80 and over MH - Antimetabolites, Antineoplastic/*therapeutic use MH - *Blood Platelets MH - Combined Modality Therapy MH - Deoxycytidine/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Leukocyte Count MH - *Lymphocytes MH - Male MH - Neoplasm Invasiveness MH - *Neutrophils MH - Platelet Count MH - Predictive Value of Tests MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*blood/*drug therapy/pathology/radiotherapy MH - Gemcitabine OTO - NOTNLM OT - Bladder cancer OT - Gemcitabine OT - Trimodality therapy COIS- Conflicts of Interest Any actual or potential conflicts of interest do not exist. EDAT- 2020/11/16 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/11/15 20:23 PHST- 2020/09/02 00:00 [received] PHST- 2020/10/07 00:00 [revised] PHST- 2020/11/02 00:00 [accepted] PHST- 2020/11/16 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/11/15 20:23 [entrez] AID - S1078-1439(20)30575-5 [pii] AID - 10.1016/j.urolonc.2020.11.006 [doi] PST - ppublish SO - Urol Oncol. 2021 Jun;39(6):368.e19-368.e29. doi: 10.1016/j.urolonc.2020.11.006. Epub 2020 Nov 11. PMID- 33187904 OWN - NLM STAT- MEDLINE DCOM- 20210301 LR - 20210301 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 19 IP - 1 DP - 2021 Feb TI - Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. PG - 41-46.e1 LID - S1558-7673(20)30144-0 [pii] LID - 10.1016/j.clgc.2020.06.005 [doi] AB - INTRODUCTION: During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making to ensure that the benefit of early intervention for muscle-invasive bladder cancer exceeds the risk of contracting COVID-19 in the clinical setting. It is unknown whether treatment delays for patients eligible for curative chemoradiation (CRT) compromise long-term outcomes. PATIENTS AND METHODS: We used the National Cancer Data Base to investigate whether there is an association between a >/= 90-day delay from transurethral resection of bladder tumor (TURBT) in initiating CRT and overall survival. We included patients with cT2-4N0M0 muscle-invasive bladder cancer from 2004 to 2015 who underwent TURBT and curative-intent concurrent CRT. Patients were grouped on the basis of timing of CRT: /= 90 and < 180 days after TURBT (delayed). RESULTS: A total of 1387 (87.5%) received earlier CRT (median, 45 days after TURBT; interquartile range, 34-59 days), and 197 (12.5%) received delayed CRT (median, 111 days after TURBT; interquartile range, 98-130 days). Median overall survival was 29.0 months (95% CI, 26.0-32.0) versus 27.0 months (95% CI, 19.75-34.24) for earlier and delayed CRT (P = .94). On multivariable analysis, delayed CRT was not associated with an overall survival difference (hazard ratio, 1.05; 95% CI, 0.87-1.27; P = .60). CONCLUSION: Although these results are limited and require validation, short, strategic treatment delays during a pandemic can be considered on the basis of clinician judgment. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fischer-Valuck, Benjamin W AU - Fischer-Valuck BW AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. FAU - Michalski, Jeff M AU - Michalski JM AD - Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Harton, Joanna G AU - Harton JG AD - Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. FAU - Birtle, Alison AU - Birtle A AD - Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University of Manchester, Manchester, UK. FAU - Christodouleas, John P AU - Christodouleas JP AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA. FAU - Arora, Vivek K AU - Arora VK AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Kim, Eric H AU - Kim EH AD - Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Knoche, Eric M AU - Knoche EM AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Pachynski, Russell K AU - Pachynski RK AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Picus, Joel AU - Picus J AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Rao, Yuan James AU - Rao YJ AD - Department of Radiation Oncology, George Washington University, Washington D.C. FAU - Reimers, Melissa AU - Reimers M AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Roth, Bruce J AU - Roth BJ AD - Division of Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Sargos, Paul AU - Sargos P AD - Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada; Department of Radiotherapy, Institut Bergonie, Bordeaux, France. FAU - Smith, Zachary L AU - Smith ZL AD - Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Zaghloul, Mohamed S AU - Zaghloul MS AD - Radiation Oncology Department, Children's Cancer Hospital, Cairo, Egypt; Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt. FAU - Gay, Hiram A AU - Gay HA AD - Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO. FAU - Patel, Sagar A AU - Patel SA AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. FAU - Baumann, Brian C AU - Baumann BC AD - Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: Brian.Baumann@wustl.edu. LA - eng PT - Journal Article PT - Observational Study DEP - 20200622 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/epidemiology/*prevention & control/transmission MH - Chemoradiotherapy, Adjuvant/*standards/statistics & numerical data MH - Cystectomy MH - *Decision Making, Shared MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Pandemics/prevention & control MH - Time Factors MH - Time-to-Treatment/*standards/statistics & numerical data MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Young Adult PMC - PMC7306737 OTO - NOTNLM OT - COVID-19 bladder cancer OT - ChemoRT MIBC OT - Delays in chemoRT MIBC OT - MIBC OT - Pandemic treatment delays MIBC EDAT- 2020/11/15 06:00 MHDA- 2021/03/02 06:00 PMCR- 2020/06/22 CRDT- 2020/11/14 05:23 PHST- 2020/05/13 00:00 [received] PHST- 2020/06/15 00:00 [revised] PHST- 2020/06/15 00:00 [accepted] PHST- 2020/11/15 06:00 [pubmed] PHST- 2021/03/02 06:00 [medline] PHST- 2020/11/14 05:23 [entrez] PHST- 2020/06/22 00:00 [pmc-release] AID - S1558-7673(20)30144-0 [pii] AID - 10.1016/j.clgc.2020.06.005 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Feb;19(1):41-46.e1. doi: 10.1016/j.clgc.2020.06.005. Epub 2020 Jun 22. PMID- 33183321 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20220418 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 15 IP - 1 DP - 2020 Nov 12 TI - Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells. PG - 136 LID - 10.1186/s13000-020-01054-3 [doi] LID - 136 AB - BACKGROUND: Bladder cancer (BCa) is the ninth frequent and 13th leading cause of cancer related deaths in the world which is mainly observed among men. There is a declining mortality rates in developed countries. Although, the majority of BCa patients present Non-Muscle-Invasive Bladder Cancer (NMIBC) tumors, only 30% of patients suffer from muscle invasion and distant metastases. Radical cystoprostatectomy, radiation, and chemotherapy have proven to be efficient in metastatic tumors. However, tumor relapse is observed in a noticeable ratio of patients following the chemotherapeutic treatment. Non-coding RNAs (ncRNAs) are important factors during tumor progression and chemo resistance which can be used as diagnostic and prognostic biomarkers of BCa. MAIN BODY: In present review we summarized all of the lncRNAs and miRNAs associated with chemotherapeutic resistance in bladder tumor cells. CONCLUSIONS: This review paves the way of introducing a prognostic panel of ncRNAs for the BCa patients which can be useful to select a proper drug based on the lncRNA profiles of patients to reduce the cytotoxic effects of chemotherapy in such patients. FAU - Zangouei, Amir Sadra AU - Zangouei AS AD - Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Rahimi, Hamid Reza AU - Rahimi HR AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Mojarrad, Majid AU - Mojarrad M AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Moghbeli, Meysam AU - Moghbeli M AUID- ORCID: 0000-0001-9680-0309 AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. moghbelim@mums.ac.ir. LA - eng PT - Journal Article PT - Review DEP - 20201112 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (RNA, Long Noncoding) SB - IM MH - Biomarkers, Tumor/genetics MH - Drug Resistance, Neoplasm/*genetics MH - Humans MH - MicroRNAs/*genetics MH - RNA, Long Noncoding/*genetics MH - Urinary Bladder Neoplasms/*genetics/*pathology PMC - PMC7659041 OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Drug resistance OT - LncRNA OT - Marker OT - MiRNA OT - Prognosis COIS- The authors declare that they have no competing interests. EDAT- 2020/11/14 06:00 MHDA- 2021/09/28 06:00 PMCR- 2020/11/12 CRDT- 2020/11/13 05:33 PHST- 2020/06/19 00:00 [received] PHST- 2020/11/05 00:00 [accepted] PHST- 2020/11/13 05:33 [entrez] PHST- 2020/11/14 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/11/12 00:00 [pmc-release] AID - 10.1186/s13000-020-01054-3 [pii] AID - 1054 [pii] AID - 10.1186/s13000-020-01054-3 [doi] PST - epublish SO - Diagn Pathol. 2020 Nov 12;15(1):136. doi: 10.1186/s13000-020-01054-3. PMID- 33182484 OWN - NLM STAT- MEDLINE DCOM- 20210302 LR - 20240803 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 21 DP - 2020 Nov 9 TI - High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer. LID - 10.3390/ijms21218407 [doi] LID - 8407 AB - Stage pT1 bladder cancer (BC) shows highly diverse outcomes. Predictive markers are required to stratify patients for personalized treatment. The present study aimed to validate immune response quantification as a prognostic marker. Patients with pT1 BC (n = 167) treated by transurethral resection of the bladder (TURB) were enrolled. Formaldehyde-fixed paraffin-embedded material was stained for CD3 and CD8. Corresponding T cells were counted in three regions with the highest immune response. Numbers of tertiary lymphoid structures (TLS) and lymphocyte aggregates (LA) were quantified. High CD3(+) stroma T-cell infiltration was associated with improved survival (p = 0.045), especially in the G3 subgroup (p = 0.01). Cluster with higher immune response showed less recurrence (p = 0.034) and favorable overall survival (OS) (p = 0.019). In contrast, higher CD3(+) and CD8(+) tumor T-cell infiltration seemed to have a negative impact on prognosis. TLS and LA were more frequently observed in G3 tumors, indicating an increased anti-tumoral immune response. We proved the role of immune cell infiltration and showed that higher infiltration numbers of CD3(+) (not CD8(+)) lymphocytes in the stroma are associated with favorable outcome. Immune cell quantification could be used as a marker to help stratify patients' risk and therefore, to optimize patients' management and follow-up examination as well as possible therapies. FAU - Hulsen, Sabine AU - Hulsen S AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Lippolis, Eleonora AU - Lippolis E AD - Institute of Human Genetics, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Ferrazzi, Fulvia AU - Ferrazzi F AUID- ORCID: 0000-0003-4011-4638 AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Institute of Human Genetics, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. AD - Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany. FAU - Distel, Luitpold AU - Distel L AUID- ORCID: 0000-0002-8040-3226 AD - Department of Radiation Therapy, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Fietkau, Rainer AU - Fietkau R AD - Department of Radiation Therapy, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany. FAU - Bertz, Simone AU - Bertz S AUID- ORCID: 0000-0003-0458-7075 AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Ebner, Annette AU - Ebner A AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AUID- ORCID: 0000-0002-4860-4626 AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Geppert, Carol-I AU - Geppert CI AD - Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nurnberg, 91054 Erlangen, Germany. LA - eng PT - Journal Article DEP - 20201109 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers) RN - 0 (CD3 Complex) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers/metabolism MH - CD3 Complex/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Female MH - Humans MH - Lymphocytes, Tumor-Infiltrating/*immunology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/immunology/metabolism/pathology MH - Neoplasm Staging/methods MH - Prognosis MH - Tumor Microenvironment/immunology MH - Urinary Bladder Neoplasms/*immunology/metabolism/*pathology PMC - PMC7665154 OTO - NOTNLM OT - CD8+ lymphocytes OT - immunoscore OT - pT1 bladder cancer OT - progression OT - survival OT - tumor-infiltrating lymphocytes (TILs), CD3+ lymphocytes COIS- All authors declare no conflicts of interest. EDAT- 2020/11/14 06:00 MHDA- 2021/03/03 06:00 PMCR- 2020/11/01 CRDT- 2020/11/13 01:03 PHST- 2020/09/13 00:00 [received] PHST- 2020/10/30 00:00 [revised] PHST- 2020/11/04 00:00 [accepted] PHST- 2020/11/13 01:03 [entrez] PHST- 2020/11/14 06:00 [pubmed] PHST- 2021/03/03 06:00 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - ijms21218407 [pii] AID - ijms-21-08407 [pii] AID - 10.3390/ijms21218407 [doi] PST - epublish SO - Int J Mol Sci. 2020 Nov 9;21(21):8407. doi: 10.3390/ijms21218407. PMID- 33174397 OWN - NLM STAT- MEDLINE DCOM- 20211129 LR - 20211129 IS - 2573-8348 (Electronic) IS - 2573-8348 (Linking) VI - 4 IP - 2 DP - 2021 Apr TI - Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial transurethral resection for non-muscle-invasive bladder cancer under white light cystoscopy. PG - e1321 LID - 10.1002/cnr2.1321 [doi] LID - e1321 AB - BACKGROUND: Although few studies evaluated the significance of random biopsies under white light cystoscopy (WLC) in patients with non-muscle-invasive bladder cancer (NMIBC), the findings are controversial. AIM: This aim of this study was to evaluate what kind of preoperative covariates were useful as predictive factors in detecting carcinoma in situ (CIS) from normal-appearing mucosa using random bladder biopsies under WLC. METHODS AND RESULTS: A total of 229 patients with NMIBC underwent initial TUR followed by random biopsies under WLC at Red Cross Takayama Hospital between 2007 and 2016. These patients underwent TUR with complete resection of intravesical visible tumors followed by random biopsies of normal-appearing mucosa. In this study, random bladder biopsies of normal-appearing urothelial mucosa, excluding abnormal mucosa, were carried out with a cold punch in the selected intravesical sites. The covariates included age, gender, the urine cytology result, presence of an abnormal mucosa, number of tumors, size of the largest tumors, configuration of the tumor, and tumor type. Abnormal mucosa was defined as reddish or mossy areas at the time of TUR under WLC. The primary endpoint was to determine what kind of preoperative covariates were useful as predictive factors in detecting CIS from normal-appearing mucosa using random bladder biopsies under WLC. Finally, 212 patients were evaluated, and 67 patients (31.6%) were diagnosed with CIS from normal-appearing mucosa. In univariate analysis, positive urine cytology, abnormal mucosa, and the number of tumors were significantly associated with concomitant CIS. On multivariate analysis, positive urine cytology and abnormal mucosa were significantly associated with CIS. CONCLUSION: The patients who were diagnosed with positive urine cytology or abnormal mucosa by WLC are ideal candidates for TUR followed by random biopsy of normal-appearing mucosa. CI - (c) 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC. FAU - Iinuma, Koji AU - Iinuma K AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Yuhara, Kazuya AU - Yuhara K AD - Department of Urology, Japanese Red Cross Takayama Hospital, Takayama, Japan. FAU - Kotaka, Hiroto AU - Kotaka H AD - Department of Urology, Japanese Red Cross Takayama Hospital, Takayama, Japan. FAU - Ozawa, Kaori AU - Ozawa K AD - Department of Urology, Japanese Red Cross Takayama Hospital, Takayama, Japan. FAU - Kato, Daiki AU - Kato D AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Takai, Manabu AU - Takai M AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Nakane, Keita AU - Nakane K AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Mizutani, Kosuke AU - Mizutani K AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Tsuchiya, Tomohiro AU - Tsuchiya T AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. FAU - Koie, Takuya AU - Koie T AUID- ORCID: 0000-0002-2980-127X AD - Department of Urology, Gifu University Graduate, School of Medicine, Gifu, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201111 PL - United States TA - Cancer Rep (Hoboken) JT - Cancer reports (Hoboken, N.J.) JID - 101747728 SB - IM MH - Aged MH - Biopsy/methods/statistics & numerical data MH - Carcinoma in Situ/*diagnosis/pathology/surgery MH - *Cystectomy MH - Cystoscopy/methods/*statistics & numerical data MH - Feasibility Studies MH - Female MH - Humans MH - Light MH - Male MH - Mucous Membrane/diagnostic imaging/pathology/surgery MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Preoperative Period MH - Prognosis MH - Retrospective Studies MH - Risk Assessment/methods/statistics & numerical data MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery MH - Urothelium/diagnostic imaging/pathology/surgery PMC - PMC8451375 OTO - NOTNLM OT - carcinoma in situ OT - non-muscle-invasive bladder cancer OT - random biopsy OT - white light cystoscopy COIS- The authors have stated explicitly that there are no conflicts of interest in connection with this article. EDAT- 2020/11/12 06:00 MHDA- 2021/11/30 06:00 PMCR- 2020/11/11 CRDT- 2020/11/11 06:05 PHST- 2020/10/18 00:00 [revised] PHST- 2020/08/27 00:00 [received] PHST- 2020/10/27 00:00 [accepted] PHST- 2020/11/12 06:00 [pubmed] PHST- 2021/11/30 06:00 [medline] PHST- 2020/11/11 06:05 [entrez] PHST- 2020/11/11 00:00 [pmc-release] AID - CNR21321 [pii] AID - 10.1002/cnr2.1321 [doi] PST - ppublish SO - Cancer Rep (Hoboken). 2021 Apr;4(2):e1321. doi: 10.1002/cnr2.1321. Epub 2020 Nov 11. PMID- 33160889 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20250530 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 19 IP - 2 DP - 2021 Apr TI - Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. PG - 144-154 LID - S1558-7673(20)30229-9 [pii] LID - 10.1016/j.clgc.2020.10.002 [doi] AB - BACKGROUND: Micropapillary urothelial carcinoma (MPC) is a rare urothelial carcinoma variant with conflicting data guiding clinical practice. In this study, we explored oncologic outcomes in relation to neoadjuvant chemotherapy (NAC) in a retrospective cohort of patients with MPC, alongside data from Surveillance, Epidemiology, and End Results (SEER)-Medicare. PATIENTS AND METHODS: We retrospectively identified patients with MPC or conventional urothelial carcinoma (CUC) without any variant histology undergoing radical cystectomy (RC) in our institution (2003-2018). SEER-Medicare was also queried to identify patients diagnosed with MPC (2004-2015). Clinicopathologic data and treatment modalities were extracted. Overall survival (OS) was estimated with the Kaplan-Meier method. Mann-Whitney-Wilcoxon and chi-square tests were used for comparative analysis and Cox regression for identifying clinical covariates associated with OS. RESULTS: Our institutional database yielded 46 patients with MPC and 457 with CUC. In SEER-Medicare, 183 patients with MPC were identified, and 63 (34%) underwent RC. In the institutional cohort, patients with MPC had significantly higher incidence of cN+ (17% vs. 8%), pN+ stage (30% vs. 17%), carcinoma-in-situ (43% vs. 25%), and lymphovascular invasion (30% vs. 16%) at RC versus those with CUC (all P < .05). Pathologic complete response (ypT0N0) to NAC was 33% for MPC and 35% for CUC (P = .899). Median OS was lower for institutional MPC versus CUC in univariate analysis (43.6 vs. 105.3 months, P = .006); however, MPC was not independently associated with OS in the multivariate model. Median OS was 25 months in the SEER MPC cohort for patients undergoing RC, while NAC was not associated with improved OS in that group. CONCLUSION: Pathologic response to NAC was not significantly different between MPC and CUC, while MPC histology was not an independent predictor of OS. Further studies are needed to better understand biological mechanisms behind its aggressive features as well as the role of NAC in this histology variant. CI - Published by Elsevier Inc. FAU - Diamantopoulos, Leonidas N AU - Diamantopoulos LN AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA. FAU - Holt, Sarah K AU - Holt SK AD - Department of Urology, University of Washington, Seattle, WA. FAU - Khaki, Ali R AU - Khaki AR AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA. FAU - Sekar, Rishi R AU - Sekar RR AD - Department of Urology, University of Washington, Seattle, WA. FAU - Gadzinski, Adam AU - Gadzinski A AD - Department of Urology, University of Washington, Seattle, WA. FAU - Nyame, Yaw A AU - Nyame YA AD - Department of Urology, University of Washington, Seattle, WA. FAU - Vakar-Lopez, Funda AU - Vakar-Lopez F AD - Department of Pathology, University of Washington, Seattle, WA. FAU - Tretiakova, Maria S AU - Tretiakova MS AD - Department of Pathology, University of Washington, Seattle, WA. FAU - Psutka, Sarah P AU - Psutka SP AD - Department of Urology, University of Washington, Seattle, WA. FAU - Gore, John L AU - Gore JL AD - Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Lin, Daniel W AU - Lin DW AD - Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Schade, George R AU - Schade GR AD - Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Hsieh, Andrew C AU - Hsieh AC AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Lee, John K AU - Lee JK AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Yezefski, Todd AU - Yezefski T AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA. FAU - Schweizer, Michael T AU - Schweizer MT AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Cheng, Heather H AU - Cheng HH AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Yu, Evan Y AU - Yu EY AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - True, Lawrence D AU - True LD AD - Department of Pathology, University of Washington, Seattle, WA. FAU - Montgomery, Robert B AU - Montgomery RB AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Grivas, Petros AU - Grivas P AD - Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: pgrivas@uw.edu. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: jlwright@uw.edu. LA - eng GR - T32 CA009515/CA/NCI NIH HHS/United States GR - VA999999/ImVA/Intramural VA/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20201014 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - *Carcinoma, Transitional Cell/pathology/therapy MH - Cystectomy MH - Female MH - Humans MH - Infant, Newborn MH - Male MH - Medicare MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Retrospective Studies MH - Tertiary Care Centers MH - United States MH - *Urinary Bladder Neoplasms/pathology/therapy PMC - PMC8044249 MID - NIHMS1667633 OTO - NOTNLM OT - Cystectomy OT - Neoadjuvant therapy OT - Pathologic response OT - SEER program OT - Urinary bladder neoplasms COIS- Disclosure S.P.P. reports honoraria, travel, accommodations, and expenses from Prime Education. J.L.G. reports research grant funding from Ferring Pharmaceuticals. D.W.L. reports DSMB for the POTOMAC study with AstraZeneca; consulting or advisory role for Astellas Pharma, Clovis Oncology, and Dendreon; and research funding form GenomeDx, Genomic Health, and MDxHealth. R.S. reports patents, royalties, other intellectual property from Global Cancer Technology. A.C.H. reports honoraria from Hotspot Therapeutics; research funding from eFFECTOR Inc; patents, royalties, or other intellectual property regarding mTOR modulators and uses thereof (patent 9629843; and "use of translational profiling to identify target molecules for therapeutic treatment," publication 20140288097. J.K.L. reports research funding from Immunomedics. M.T.S. reports research grant funding to University of Washington from Janssen, AstraZeneca, Zenith, Pfizer, Immunomedics, Madison Vaccines, and Hoffman-La Roche. H.H.C. reports research funding from Astellas Medivation, Clovis Oncology, Color Foundation, INOVIO Pharmaceuticals, Janssen, and Sanofi; and royalties from UpToDate. E.Y.Y. reports consulting for Amgen, AstraZeneca, Bayer, Churchill, Dendreon, EMD Serono, Incyte, Janssen, Merck, Pharmacyclics, QED, Seattle Genetics, and Tolmar; institutional research support from Bayer, Daiichi-Sankyo, Dendreon, Merck, Taiho, and Seattle Genetics; and personal fees from Clovis (last 3 years). L.D.T. reports stock and other ownership interests in Lightspeed Micro research funding and Ventana Medical Systems; and patents, royalties, other intellectual property for using a lens on an open-top lightsheet microscope. R.B.M. reports research funding from AstraZeneca, ESSA, Ferring, and Janssen Oncology. P.G. reports consulting for AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Driver, EMD Serono, Exelixis, Foundation Medicine, GlaxoSmithKline, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck, Mirati Therapeutics, Pfizer, Roche, Seattle Genetics, and QED Therapeutics; participation in educational program for Bristol-Myers Squibb; institutional research funding from AstraZeneca, Bayer, Genentech, Merck, Mirati Therapeutics, Oncogenex, Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb, QED Therapeutics, GlaxoSmithKline, and Kure It Cancer Research, all unrelated to this study, within the last 3 years. J.L.W. reports royalties from UpToDate; clinical trials for Movember Foundation, Merck, Nucleix, and Altor Biosciences; and consulting for Sanofi Genzyme. The other authors have stated that they have no conflict of interest. EDAT- 2020/11/09 06:00 MHDA- 2021/08/10 06:00 PMCR- 2022/04/01 CRDT- 2020/11/08 20:26 PHST- 2020/04/21 00:00 [received] PHST- 2020/10/01 00:00 [revised] PHST- 2020/10/04 00:00 [accepted] PHST- 2020/11/09 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/11/08 20:26 [entrez] PHST- 2022/04/01 00:00 [pmc-release] AID - S1558-7673(20)30229-9 [pii] AID - 10.1016/j.clgc.2020.10.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Apr;19(2):144-154. doi: 10.1016/j.clgc.2020.10.002. Epub 2020 Oct 14. PMID- 33153725 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20211004 IS - 1465-3931 (Electronic) IS - 0031-3025 (Linking) VI - 53 IP - 1 DP - 2021 Jan TI - Stage T1 bladder cancer: diagnostic criteria and pitfalls. PG - 67-85 LID - S0031-3025(20)30943-0 [pii] LID - 10.1016/j.pathol.2020.09.014 [doi] AB - Accurate pathological staging is crucial for patient management. Patients with T1 bladder cancer are at risk of recurrence, progression, and death of cancer. Recognition of early invasion (stage T1 disease) in urothelial carcinoma remains one of the most challenging areas in urological surgical pathology practice. A logical roadmap to T1 diagnosis would include careful evaluation of histological grade, stromal epithelial interface, characteristics of the invading epithelium, and the stroma associated responses. Tangential sectioning, crush and cautery artifacts, and associated inflammatory infiltrate are commonly encountered problems and the source of pitfalls. In this review, we outline diagnostic criteria, common pitfalls, and different histological patterns of invasion into the lamina propria. Current recommendations on reporting of biopsy and transurethral resection specimens, molecular biomarkers, clinical implications of T1 cancer diagnosis and recent developments on the T1 substaging are also discussed. Most T1 bladder cancer patients will benefit from conservative management after restaging transurethral resection of bladder and bacillus Calmette-Guerin maintenance. Patients with high risk features, such as concurrent urothelial carcinoma in situ, increased depth of invasion, lymphovascular invasion, and variant histology among others, should be considered for early cystectomy. CI - Copyright (c) 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Morphological Sciences, Cordoba University Medical School, Cordoba, Spain. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, USA. Electronic address: liang_cheng@yahoo.com. LA - eng PT - Journal Article PT - Review DEP - 20201103 PL - England TA - Pathology JT - Pathology JID - 0175411 SB - IM MH - Carcinoma, Transitional Cell/diagnosis/*pathology MH - Humans MH - Neoplasm Staging/*methods MH - Urinary Bladder Neoplasms/diagnosis/*pathology OTO - NOTNLM OT - Urinary bladder OT - diagnostic criteria OT - differential diagnosis OT - molecular biomarkers OT - pathological stage T1 OT - staging classification OT - urothelial carcinoma EDAT- 2020/11/07 06:00 MHDA- 2021/10/05 06:00 CRDT- 2020/11/06 05:41 PHST- 2020/08/19 00:00 [received] PHST- 2020/08/31 00:00 [revised] PHST- 2020/09/02 00:00 [accepted] PHST- 2020/11/07 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2020/11/06 05:41 [entrez] AID - S0031-3025(20)30943-0 [pii] AID - 10.1016/j.pathol.2020.09.014 [doi] PST - ppublish SO - Pathology. 2021 Jan;53(1):67-85. doi: 10.1016/j.pathol.2020.09.014. Epub 2020 Nov 3. PMID- 33152179 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 128 IP - 1 DP - 2021 Jul TI - Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. PG - 79-87 LID - 10.1111/bju.15289 [doi] AB - OBJECTIVES: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. PATIENTS AND METHODS: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathological complete response and downstaging at RC, while IPTW-adjusted Kaplan-Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS). RESULTS: After IPTW-adjusted analysis, standardised differences between groups were <15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and nine (3%) undergoing upfront RC. Downstaging to non-muscle-invasive disease (/=3 cm (p = .029), recurrence rate >1/year (p = .034), concomitant carcinoma in situ (CIS) during transurethral resection of bladder (TURB) (p = .039) and BCG-unresponsive status (p = .048) were associated with a worse response to chemohyperthermia. The use of MMC or EPI did not influence the response to treatment (p = .157). A slightly significant higher rate of overall complications (p = .0488) was observed in Group B. A significantly higher rate of Grade 3 frequency/urgency (p = .0064) contributed to this difference. The use of EPI was the only independent factor associated with severe urinary frequency/urgency (p = .017). No patients experienced Grade 4/5 adverse events. CONCLUSIONS: HIVEC can be considered a feasible option in BCG failure/intolerant NMIBC patients, avoiding or postponing radical cystectomy in some particular subclasses of patients. CI - Copyright by Polish Urological Association. FAU - Chiancone, Francesco AU - Chiancone F AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. FAU - Fabiano, Marco AU - Fabiano M AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. FAU - Fedelini, Maurizio AU - Fedelini M AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. FAU - Meccariello, Clemente AU - Meccariello C AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. FAU - Carrino, Maurizio AU - Carrino M AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. FAU - Fedelini, Paolo AU - Fedelini P AD - AORN A. Cardarelli, Department of Urology, Naples, Italy. LA - eng PT - Journal Article DEP - 20200806 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC7587473 OTO - NOTNLM OT - BCG failure OT - bladder cancer OT - chemohyperthermia OT - complications OT - epirubicin OT - mitomycin C COIS- The authors declare no conflicts of interest. EDAT- 2020/11/03 06:00 MHDA- 2020/11/03 06:01 PMCR- 2020/01/01 CRDT- 2020/11/02 06:18 PHST- 2020/05/30 00:00 [received] PHST- 2020/07/07 00:00 [revised] PHST- 2020/07/16 00:00 [accepted] PHST- 2020/11/02 06:18 [entrez] PHST- 2020/11/03 06:00 [pubmed] PHST- 2020/11/03 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 0148 [pii] AID - 10.5173/ceju.2020.0148 [doi] PST - ppublish SO - Cent European J Urol. 2020;73(3):287-294. doi: 10.5173/ceju.2020.0148. Epub 2020 Aug 6. PMID- 33132108 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20250522 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 5 DP - 2021 Sep TI - Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. PG - 1044-1051 LID - S2405-4569(20)30286-8 [pii] LID - 10.1016/j.euf.2020.10.002 [doi] AB - CONTEXT: Bladder cancer demonstrates striking gender-based differences in incidence, with a role for androgens possibly implicated in the development and progression of the disease. Emerging preclinical and clinical evidence suggests that there may be a role for antiandrogen therapy in bladder cancer. OBJECTIVE: This systematic review assessed the current clinical evidence evaluating androgen suppressive therapy (AST) for the treatment or prevention of bladder cancer. EVIDENCE ACQUISITION: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, MEDLINE was searched for full-text articles detailing clinical outcomes or incidence of bladder cancer among patients who received AST, defined as gonadotropin-releasing hormone agonists or equivalent, androgen receptor antagonists, or 5-alpha reductase inhibitors. EVIDENCE SYNTHESIS: A total of 12 studies were included. Five studies focused on prostate cancer patients, with one study in men with lower urinary tract symptoms. Among these studies, a lower incidence of bladder cancer was observed in five, with adjusted risk reduction estimates ranging from 7% to 47%. Six studies evaluating 11 820 bladder cancer patients investigated clinical outcomes among men who received a form of AST. Three out of four studies evaluating recurrence-free survival found a benefit for AST, with adjusted hazard ratios for recurrence of non-muscle-invasive cancer ranging from 0.29 to 0.53. Limitations included large variability in data sources and methodologies, as well as no data on tolerability. CONCLUSIONS: Current evidence indicates that antiandrogen therapies exert a favorable influence on bladder tumors. Further prospective studies are needed to assess their therapeutic potential. PATIENT SUMMARY: Androgen suppressive therapy is commonly prescribed for the treatment of prostate-related problems. Prior research indicates that there may be a role for these treatments in patients with bladder cancer. In this review, we evaluate the current evidence that strongly suggests that these agents may be effective against bladder cancer. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kourbanhoussen, Kassim AU - Kourbanhoussen K AD - Department of Surgery, Faculty of Medicine, Universite Laval, Quebec City, Quebec, Canada. FAU - McMartin, Catherine AU - McMartin C AD - Department of Surgery, Faculty of Medicine, Universite Laval, Quebec City, Quebec, Canada. FAU - Lodde, Michele AU - Lodde M AD - Department of Surgery, Faculty of Medicine, Universite Laval, Quebec City, Quebec, Canada; Oncology Division, Centre de Recherche du CHU de Quebec-Universite Laval, Quebec City, QC, Canada. FAU - Zlotta, Alexandre AU - Zlotta A AD - Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Toren, Paul AU - Toren P AD - Department of Surgery, Faculty of Medicine, Universite Laval, Quebec City, Quebec, Canada; Oncology Division, Centre de Recherche du CHU de Quebec-Universite Laval, Quebec City, QC, Canada. Electronic address: paul.toren@crchudequebec.ulaval.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20201031 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (5-alpha Reductase Inhibitors) RN - 0 (Androgen Antagonists) RN - 0 (Androgens) SB - IM MH - 5-alpha Reductase Inhibitors/therapeutic use MH - Androgen Antagonists/therapeutic use MH - Androgens/therapeutic use MH - *Carcinoma in Situ MH - Humans MH - Male MH - *Prostatic Neoplasms/pathology MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - *Androgen suppression therapy OT - *Androgens OT - *Bladder cancer OT - *Incidence OT - *Recurrence OT - *Systematic review EDAT- 2020/11/03 06:00 MHDA- 2022/04/14 06:00 CRDT- 2020/11/02 05:39 PHST- 2020/08/29 00:00 [received] PHST- 2020/09/30 00:00 [revised] PHST- 2020/10/12 00:00 [accepted] PHST- 2020/11/03 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2020/11/02 05:39 [entrez] AID - S2405-4569(20)30286-8 [pii] AID - 10.1016/j.euf.2020.10.002 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Sep;7(5):1044-1051. doi: 10.1016/j.euf.2020.10.002. Epub 2020 Oct 31. PMID- 35117333 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220205 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 9 IP - 11 DP - 2020 Nov TI - Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review. PG - 7323-7336 LID - 10.21037/tcr-20-2257 [doi] AB - The majority of patients with bladder cancer are diagnosed in non-muscle invasive stage. Most of them will experience recurrence or progression to more aggressive disease during follow-up. That raises the need for improvements with regard to risk assessment. Current risk stratification, based only on clinicopathologic features, does not fully reflect biological heterogeneity of the cancer and its role in prognosis. Many studies addressed the topic of variant histology and its influence on treatment and outcomes. It has been shown that accurate identification of variant histology implicates patient prognosis and inform right treatment decisions. Most studies on histological variants of bladder cancer suggest a more aggressive clinical course, with higher risk of recurrence and progression than in conventional urothelial cancer, even when diagnosed in non-muscle invasive stage. That prompts early aggressive treatment approach whenever variant histology is detected. Emerging genomic information are expected to complement clinical and pathological data and change the paradigms in the management of bladder cancer. Several reports highlighted the clinical significance of molecular stratification of bladder cancer, but the available evidence is based on retrospective data. Molecular subtyping gives promise not only for improving risk assessment, but also in predicting response to Bacillus Calmette-Guerin (BCG) or chemotherapy. Finally, molecular alterations might become targets for novel drugs to improve the overall response of these patients. However, its implementation into clinical practice requires further validation in prospective trials, especially in the context of non-muscle invasive bladder cancer. CI - 2020 Translational Cancer Research. All rights reserved. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncological Urology, Lower-Silesian Specialistic Hospital, A.E. Fieldorfa 2, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Borowska 213, Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Spitalstrasse 6004 Luzern, Switzerland. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Borowska 213, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Borowska 213, Wroclaw, Poland. FAU - Poterek, Adrian AU - Poterek A AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Borowska 213, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Borowska 213, Wroclaw, Poland. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC8798016 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - molecular variants OT - variant histology COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-2257). The authors have no conflicts of interest to declare. EDAT- 2020/11/01 00:00 MHDA- 2020/11/01 00:01 PMCR- 2020/11/01 CRDT- 2022/02/04 05:50 PHST- 2020/06/04 00:00 [received] PHST- 2020/10/09 00:00 [accepted] PHST- 2022/02/04 05:50 [entrez] PHST- 2020/11/01 00:00 [pubmed] PHST- 2020/11/01 00:01 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - tcr-09-11-7323 [pii] AID - 10.21037/tcr-20-2257 [doi] PST - ppublish SO - Transl Cancer Res. 2020 Nov;9(11):7323-7336. doi: 10.21037/tcr-20-2257. PMID- 33128684 OWN - NLM STAT- MEDLINE DCOM- 20210524 LR - 20261010 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 47 IP - 11 DP - 2020 Nov TI - Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer. PG - 8819-8830 LID - 10.1007/s11033-020-05932-3 [doi] AB - BACKGROUND: Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa. METHODS AND RESULTS: The expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2(-DeltaDeltaCT) method. Correlation to clinical characteristics of the patients was performed using descriptive statistics and the receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic value of all miRNAs. MiR-27a, miR-205 and miR-369 were down-regulated whereas miR-182 was up-regulated in patients compared to controls (p < 0.001). MiR-205 and miR-182 positively segregate between NMIBC and MIBC (p = 0.002 and p = 0.000 respectively) whereas the distribution of miR-27a's expression among these tumor groups was almost significant (p = 0.05) and that of miR-369's expression was irrelevant (p = 0.618). Interestingly, miR-182 was discriminative between LG NMIBC and HG NMIBC (p < 0.001) and Ta/T1 tumors (p = 0.000). Furthermore, high levels of miR-182 were potentially predictive of progression in NMIBC patients (p = 0.01). CONCLUSION: Collectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings. FAU - Setti Boubaker, Nouha AU - Setti Boubaker N AUID- ORCID: 0000-0001-8342-6936 AD - Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. nouha.setti@hotmail.fr. AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. nouha.setti@hotmail.fr. FAU - Gurtner, Aymone AU - Gurtner A AUID- ORCID: 0000-0002-7661-9059 AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. AD - Institute of Translational Pharmacology, National Research Council, Rome, Italy. FAU - Trabelsi, Nesrine AU - Trabelsi N AD - Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. FAU - Manni, Isabella AU - Manni I AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Ayed, Haroun AU - Ayed H AD - Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Saadi, Ahmed AU - Saadi A AUID- ORCID: 0000-0002-5361-9005 AD - Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Naimi, Zeineb AU - Naimi Z AUID- ORCID: 0000-0002-9511-5403 AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Ksontini, Meriem AU - Ksontini M AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Ayadi, Mouna AU - Ayadi M AD - Medical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Blel, Ahlem AU - Blel A AUID- ORCID: 0000-0001-6702-3889 AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AUID- ORCID: 0000-0003-0366-4630 AD - Pathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Chebil, Mohamed AU - Chebil M AUID- ORCID: 0000-0001-8387-7593 AD - Urology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia. FAU - Piaggio, Giulia AU - Piaggio G AUID- ORCID: 0000-0003-2114-1892 AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. giulia.piaggio@ifo.gov.it. FAU - Ouerhani, Slah AU - Ouerhani S AUID- ORCID: 0000-0002-3651-4690 AD - Laboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. LA - eng PT - Journal Article DEP - 20201031 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (MicroRNAs) RN - 0 (MIR205, human) RN - 0 (MIRN27 microRNA, human) RN - 0 (MIRN369 microRNA, human) RN - 0 (Mirn182 microRNA, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Gene Expression Profiling/*methods MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prognosis MH - ROC Curve MH - Urinary Bladder Neoplasms/diagnosis/*genetics OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Epigenetic OT - Expression profiles OT - MicroRNA OT - Prognosis EDAT- 2020/11/01 06:00 MHDA- 2021/05/25 06:00 CRDT- 2020/10/31 17:08 PHST- 2020/08/19 00:00 [received] PHST- 2020/10/17 00:00 [accepted] PHST- 2020/11/01 06:00 [pubmed] PHST- 2021/05/25 06:00 [medline] PHST- 2020/10/31 17:08 [entrez] AID - 10.1007/s11033-020-05932-3 [pii] AID - 10.1007/s11033-020-05932-3 [doi] PST - ppublish SO - Mol Biol Rep. 2020 Nov;47(11):8819-8830. doi: 10.1007/s11033-020-05932-3. Epub 2020 Oct 31. PMID- 33128085 OWN - NLM STAT- MEDLINE DCOM- 20210405 LR - 20261010 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 478 IP - 4 DP - 2021 Apr TI - A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. PG - 637-645 LID - 10.1007/s00428-020-02951-0 [doi] AB - Urothelial carcinoma of the bladder (UC) has a poor prognosis, partly because of chemotherapy resistance. Molecular classifications have shown their interest and can help to offer personalized treatment. In this study, we evaluated the feasibility of an immunohistochemical study to divide advanced UC into clinico-pathological-molecular subgroups and evaluate phenotypic correspondence between primary UC and matched lymph node metastases (LMN). An eight-antibody immunohistochemical panel was performed on UC and matched LMN from patients treated with radical cystectomy. One hundred eighty-seven UCs (100 pN0 tumor and 87 pN+ tumor) were tested. Multiple correspondence analysis showed that UC expressing GATA3 also expressed FOXA1 (p = 0.010) and did not stain for CK5/6 (p = 0.031) nor CK14 (p = 0.003). UC expressing CK14 coexpressed CK5/6 (p < 0.0001), had high Ki67 (p = 0.010) and no GATA3 (p = 0.003) nor FOXA1 (p = 0.011) expression. Loss of expression of STAG2 was associated with high Ki67 (p = 0.001). Sixty-seven percent of [CK5/6 CK14]+ [GATA3 FOAXA1]- patients had high Ki67 expression vs 37% of [GATA3 FOXA1]+ [CK5/6 CK14]- patients (p = 0.024). The majority of [CK5/6 CK14]+ [GATA3 FOAXA1]- patients (92%) had advanced disease (pT3-pT4) whilst 86% of pT1-T2 cases were [GATA3 FOXA1]+ [CK5/6 CK14]- (p = 0.041). Differential antigen expression between 63 pN+ primary tumors and their corresponding LNM showed the following concordance percentages: p53 (76%), p63 (75%), CK5/6 (65%), CK14 (89%), GATA3 (75%), FOXA1 (68%), STAG2 (65%), and Ki-67 (71%). These results support the interest of immunohistochemistry for subtype profiling in metastatic UC, using CK5/6, CK14, GATA3, and FOXA1, highlighting also few phenotypical modifications when tumor spreads to lymph nodes. FAU - Bontoux, Christophe AU - Bontoux C AD - Department of Pathology, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne University, 4 rue de la Chine, 75020, Paris, France. FAU - Rialland, Thomas AU - Rialland T AD - Department of Pathology, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne University, 4 rue de la Chine, 75020, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Department of Urology, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne University, Paris, France. AD - GRC5 Predictive Onco-urology, Sorbonne University, Paris, France. FAU - Comperat, Eva AU - Comperat E AUID- ORCID: 0000-0001-8488-543X AD - Department of Pathology, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne University, 4 rue de la Chine, 75020, Paris, France. eva.comperat@aphp.fr. AD - GRC5 Predictive Onco-urology, Sorbonne University, Paris, France. eva.comperat@aphp.fr. LA - eng PT - Journal Article DEP - 20201030 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Transitional Cell/diagnosis/*metabolism/*pathology MH - Case-Control Studies MH - Feasibility Studies MH - Female MH - Humans MH - Immunohistochemistry MH - Lymph Nodes/*pathology MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/diagnosis/*metabolism/*pathology OTO - NOTNLM OT - Bladder cancer OT - Immunohistochemistry OT - Lymph node metastases OT - Molecular classification OT - Subtype profiling OT - Urothelial carcinoma EDAT- 2020/11/01 06:00 MHDA- 2021/04/07 06:00 CRDT- 2020/10/31 05:35 PHST- 2020/06/26 00:00 [received] PHST- 2020/10/14 00:00 [accepted] PHST- 2020/10/08 00:00 [revised] PHST- 2020/11/01 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2020/10/31 05:35 [entrez] AID - 10.1007/s00428-020-02951-0 [pii] AID - 10.1007/s00428-020-02951-0 [doi] PST - ppublish SO - Virchows Arch. 2021 Apr;478(4):637-645. doi: 10.1007/s00428-020-02951-0. Epub 2020 Oct 30. PMID- 33123248 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201031 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 20 IP - 6 DP - 2020 Dec TI - Mucinous tubular and spindle cell carcinoma of the kidney: Five case reports and review of the literature. PG - 337 LID - 10.3892/ol.2020.12201 [doi] LID - 337 AB - Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney is a rare and polymorphic tumor, which has been previously considered to be a low-grade malignancy, predominantly occurring in women. To the best of our knowledge, MTSCC with bladder metastasis has never been reported. The current study presents five adult cases of MTSCC that included three male and two female patients. Among the male cases, two were of advanced stage, one with MTSCC and renal chromophobe cell carcinoma with bladder metastasis and the other with MTSCC with invasion of the renal vein. The other three cases with small masses were at an early stage. All five cases had a good prognosis and were without recurrence after several years of follow-up. A 70-year-old male with intermittent gross hematuria, intermittent renal colic, and groin radiation pain for a year (case 1), was incidentally detected to have a left renal density mass by total abdominal enhanced computed tomography scans. In the other four cases, renal masses were found by B-ultrasound. The patient in case 1 underwent a retroperitoneal laparoscopic radical nephroureterectomy with bladder cuff resection and transurethral resection of the bladder tumor, and received gemcitabine hydrochloride via intravesical instillation therapy plus cisplatin chemotherapy every 3 months. The patient in case 2 underwent an open left radical nephrectomy and renal pedicle lymph node dissection. The other three patients underwent a laparoscopic radical nephrectomy. All five patients had no recurrence or new metastasis in other organs after follow-up. In conclusion, the incidence of MTSCC in men and women is not as disparate as reported in previous publications. The characteristics of the images of the five adult cases in the present study showed a considerable consistency, with only minor differences. The malignancy and prognosis of MTSCC are still controversial, and thus inclusion and review of more cases is required to reach a definite final conclusion. Sunitinib and gemcitabine chemotherapy in combination with cisplatin may be effective for the therapy of MTSCC patients with metastasis, but a larger range of treatments needs to be identified. CI - Copyright: (c) Gong et al. FAU - Gong, Pengfeng AU - Gong P AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - Zhuang, Qianfeng AU - Zhuang Q AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - Wang, Xiaogang AU - Wang X AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - Xu, Renfang AU - Xu R AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - Ding, Tao AU - Ding T AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - Yin, Shuai AU - Yin S AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. FAU - He, Xiaozhou AU - He X AD - Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003 P.R. China. LA - eng PT - Journal Article DEP - 20201007 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC7583836 OTO - NOTNLM OT - imaging features OT - mucinous tubular and spindle cell carcinoma OT - origin OT - renal cell carcinoma EDAT- 2020/10/31 06:00 MHDA- 2020/10/31 06:01 PMCR- 2020/10/07 CRDT- 2020/10/30 05:54 PHST- 2019/10/24 00:00 [received] PHST- 2020/09/01 00:00 [accepted] PHST- 2020/10/30 05:54 [entrez] PHST- 2020/10/31 06:00 [pubmed] PHST- 2020/10/31 06:01 [medline] PHST- 2020/10/07 00:00 [pmc-release] AID - OL-0-0-12201 [pii] AID - 10.3892/ol.2020.12201 [doi] PST - ppublish SO - Oncol Lett. 2020 Dec;20(6):337. doi: 10.3892/ol.2020.12201. Epub 2020 Oct 7. PMID- 33122913 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 13 DP - 2020 TI - Co-Expression of Stem Cell and Epithelial Mesenchymal Transition Markers in Circulating Tumor Cells of Bladder Cancer Patients. PG - 10739-10748 LID - 10.2147/OTT.S259240 [doi] AB - OBJECTIVE: Cancer cells with stemness and epithelial-to-mesenchymal transition (EMT) features display enhanced malignant and metastatic potential. This study aimed to introduce a new methodology developed in order to investigate the co-expression of a stemness (OCT4) and EMT markers on single circulating tumor cells (CTCs) of patients with localized urinary bladder cancer and their potential prognostic prediction value. METHODS AND MATERIALS: Between April 2015 and July 2015, blood samples of 51 consecutive patients diagnosed with high risk bladder cancer (cT(1-3)N(0)M(0)) were prospectively investigated for CTCs. Peripheral blood (5 mL) was drawn before primary transurethral resection. Detection of CTCs was performed using the CanPatrol(TM) system. Nucleic acid probes were used to identify CTCs, and expression levels of epithelial and mesenchymal genes in CTCs were examined by situ hybridization assay. RESULTS: All patients received radical cystectomy with pelvic lymph nodes dissection. CTCs were detected in 44 of 51 (86.3%) patients, respectively. The overall mean number of CTCs was 6.1 (range: 0~29; median: 4). A total of 311 CTCs were detected in PB. High OCT4 expression (OCT4(high)) was detected more frequently in Epi(-)Mes(+) cells (p=0.001). Patients with pathological confirmed muscle-invasive bladder cancer (MIBC) had higher Epi(-)Mes(+) CTCs positive rates (p=0.001) and OCT4(high) CTCs positive rates (p=0.019) than pathological confirmed non muscle-invasive bladder cancer (NMIBC). Regarding co-expression of these markers, Epi(-)Mes(+)/OCT4(high) CTCs were more frequently evident in the MIBC setting (30.4% vs 3.6% of patients, p = 0.016). CONCLUSION: A differential expression pattern for these markers was observed both in NMIBC and MIBC disease. A subgroup of CTCs showed a CTCs expressing high OCT4, along with Mes were more frequently detected in patients with MIBC, suggesting that these cells may prevail during tumor muscle invasion and disease progression. CI - (c) 2020 Zhang et al. FAU - Zhang, Ruiyun AU - Zhang R AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Xia, Jun AU - Xia J AD - Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Wang, Yiqiu AU - Wang Y AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Cao, Ming AU - Cao M AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Jin, Di AU - Jin D AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Xue, Wei AU - Xue W AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Huang, Yiran AU - Huang Y AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. FAU - Chen, Haige AU - Chen H AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. LA - eng GR - EP-C-17-017/EPA/EPA/United States PT - Journal Article DEP - 20201022 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC7588836 OTO - NOTNLM OT - OCT4 OT - circulating tumor cells OT - epithelial-to-mesenchymal transition OT - muscle-invasive bladder cancer COIS- The authors report no conflicts of interest in this work. EDAT- 2020/10/31 06:00 MHDA- 2020/10/31 06:01 PMCR- 2020/10/22 CRDT- 2020/10/30 05:52 PHST- 2020/04/28 00:00 [received] PHST- 2020/08/28 00:00 [accepted] PHST- 2020/10/30 05:52 [entrez] PHST- 2020/10/31 06:00 [pubmed] PHST- 2020/10/31 06:01 [medline] PHST- 2020/10/22 00:00 [pmc-release] AID - 259240 [pii] AID - 10.2147/OTT.S259240 [doi] PST - epublish SO - Onco Targets Ther. 2020 Oct 22;13:10739-10748. doi: 10.2147/OTT.S259240. eCollection 2020. PMID- 33121908 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 3 DP - 2021 Jun TI - Preoperative Monocyte-to-lymphocyte Ratio Predicts for Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract After Radical Nephroureterectomy Without a History of Bladder Cancer. PG - e156-e165 LID - S1558-7673(20)30220-2 [pii] LID - 10.1016/j.clgc.2020.09.004 [doi] AB - BACKGROUND: This study aimed to investigate the preoperative monocyte-to-lymphocyte ratio (MLR) as a biomarker for intravesical recurrence (IVR) in upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) for the first time. PATIENTS AND METHODS: This study involved the clinical data of 255 patients with UTUC without a history of bladder cancer who had undergone RNU from March 2004 to February 2019 at an academic institution. The associations between MLR and IVR were assessed with Kaplan-Meier method and Cox regression analysis. RESULTS: The median follow-up was 43.93 months. Of the 255 patients, 37 developed IVR during the follow-up period. Kaplan-Meier analysis revealed that patients with high MLR (> 0.22) had poor IVR-free survival (P = .001); this prognostic value was in accordance with patients with high grade and more advanced stage UTUC. Cox regression preoperative models showed that ureteral tumor site (hazard ratio [HR], 2.784; P = .005), surgical approach (HR, 2.745; P = .008), and high MLR (HR, 4.085; P < .001) were an independent risk factor for IVR. These factors were used as a signature to establish a prognostic risk model, which revealed significant differences among the 3 subgroups of patients with low, intermediate, and high risk (P < .001). CONCLUSION: Ureteral tumor site, surgical approach, and preoperative MLR are significant predictors for IVR in patients with UTUC after RNU. MLR may become a useful biomarker to predict IVR in patients with UTUC after RNU. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Song, Xinda AU - Song X AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Fu, Chunlong AU - Fu C AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Wang, Xuan AU - Wang X AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Liu, Shengjie AU - Liu S AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Hou, Huimin AU - Hou H AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. Electronic address: liumingbjh@126.com. FAU - Wang, Jianye AU - Wang J AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of the Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P. R. China. Electronic address: wangjy@bjhmoh.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200918 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - Kidney Pelvis MH - Lymphocytes MH - Monocytes MH - Neoplasm Recurrence, Local MH - Nephrectomy MH - Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - *Ureteral Neoplasms/surgery MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Intravesical recurrence OT - Monocyte-to-lymphocyte ratio OT - Nephroureterectomy OT - Upper urinary tract OT - Urothelial carcinoma EDAT- 2020/10/31 06:00 MHDA- 2021/08/19 06:00 CRDT- 2020/10/30 05:35 PHST- 2020/04/16 00:00 [received] PHST- 2020/08/28 00:00 [revised] PHST- 2020/09/07 00:00 [accepted] PHST- 2020/10/31 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2020/10/30 05:35 [entrez] AID - S1558-7673(20)30220-2 [pii] AID - 10.1016/j.clgc.2020.09.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Jun;19(3):e156-e165. doi: 10.1016/j.clgc.2020.09.004. Epub 2020 Sep 18. PMID- 33117464 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1920-454X (Electronic) IS - 1920-4531 (Print) IS - 1920-4531 (Linking) VI - 11 IP - 5 DP - 2020 Oct TI - Fluorescence Emitted by Papanicolaou-Stained Urothelial Cells Improves Sensitivity of Urinary Conventional Cytology for Detection of Urothelial Tumors. PG - 204-215 LID - 10.14740/wjon1305 [doi] AB - BACKGROUND: Urinary conventional cytology (UCCy) is easy to perform, but its low sensitivity, especially for low-grade urothelial neoplasms (LGUNs), limits its indications in the management of patients at risk of bladder cancer. The authors aim at obtaining a complementary test that would effectively increase the sensitivity of UCCy on voided urines by analyzing fluorescence of Papanicolaou-stained urothelial cells with no change of method in slide preparation. METHODS: In this retrospective study of 155 patients, 91 Papanicolaou-stained voided urines were considered satisfactory under fluorescence microscopy (FMi). The results of FMi were compared with UCCy (using transmission microscopy) and correlated to cystoscopy, histology and follow-up data. RESULTS: The results are given for all patients and for two groups of them according to the patients' main complaints (group 1: 33 patients followed up for a previously treated bladder tumor; group 2: 58 patients with persistent urinary symptoms). Overall negative predictive value (NPV) and sensitivity of FMi were 100% vs. 73.7% and 64.3% respectively for UCCy (P = 0.0001). Sensitivity of FMi for LGUN was unexpectedly high with a value of 100% vs. 46.2% for UCCy (P = 0.0002). FMi was significantly superior to UCCy for detecting urothelial tumors in every group of patients and would allow a better characterization of atypical urothelial cells (AUCs) defined by the Paris System for Reporting Urine Cytology (TPS). CONCLUSIONS: Because of its sensitivity and NPV of 100%, FMi could complement UCCy to screen voided urines allowing a better detection of primary urothelial tumors or early recurrences of previously treated urothelial carcinoma. Moreover, this "dual screening" would allow completing efficiently cystoscopy to detect flat dysplasia, carcinoma in situ (CIS) and extra bladder carcinoma. CI - Copyright 2020, Alsibai et al. FAU - Alsibai, Kinan Drak AU - Alsibai KD AD - Service d'Anatomie Pathologique, Centre des Ressources Biologiques, Centre Hospitalier de Cayenne, 97306 Cayenne Cedex, France. AD - These authors should be considered joint first authors. FAU - Daste, Ghislaine AU - Daste G AD - Centre de Pathologie Cellulaire et Moleculaire (CPCM-Labs), 31750 Escalquens, France. AD - These authors should be considered joint first authors. FAU - Ferlicot, Sophie AU - Ferlicot S AD - Service d'Anatomo-Pathologie, Universite Paris-Sud, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, 94276 Le Kremlin-Bicetre Cedex, France. FAU - Fabre, Monique AU - Fabre M AD - Service d'Anatomie Pathologique, Universite Paris-Descartes, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 75743 Paris Cedex, France. FAU - Steenkeste, Karine AU - Steenkeste K AD - Institut des Sciences Moleculaires d'Orsay (ISMO), CNRS, Universite et Paris-Saclay, 91405 Orsay Cedex, France. FAU - Salleron, Julia AU - Salleron J AD - Service de Biostatistiques, Institut de Cancerologie de Lorraine, 54519 Vandoeuvre-les-Nancy Cedex, France. FAU - Hammoudi, Yacine AU - Hammoudi Y AD - Service d'Urologie, Universite Paris-Sud, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, 94276 Le Kremlin-Bicetre Cedex, France. FAU - Fontaine-Aupart, Marie-Pierre AU - Fontaine-Aupart MP AD - Institut des Sciences Moleculaires d'Orsay (ISMO), CNRS, Universite et Paris-Saclay, 91405 Orsay Cedex, France. FAU - Eschwege, Pascal AU - Eschwege P AD - Service d'Urologie, Universite de Lorraine, CNRS UMR 7039 CRAN, Centre Hospitalier Regional Universitaire, 54035 Nancy Cedex, France. LA - eng PT - Journal Article DEP - 20201015 PL - Canada TA - World J Oncol JT - World journal of oncology JID - 101564097 PMC - PMC7575278 OTO - NOTNLM OT - Cytology OT - Fluorescence OT - Papanicolaou stain OT - Urothelial tumors OT - Voided urines COIS- This method of detecting tumor cells by fluorescence signals is protected by the United States Patent US8597905 B2 2013.2. The owners are Fabre M, Ferlicot S, Fontaine Aupart MP, Steenkeste K, Eschwege P. EDAT- 2020/10/30 06:00 MHDA- 2020/10/30 06:01 PMCR- 2020/10/15 CRDT- 2020/10/29 05:52 PHST- 2020/06/11 00:00 [received] PHST- 2020/08/12 00:00 [accepted] PHST- 2020/10/29 05:52 [entrez] PHST- 2020/10/30 06:00 [pubmed] PHST- 2020/10/30 06:01 [medline] PHST- 2020/10/15 00:00 [pmc-release] AID - 10.14740/wjon1305 [doi] PST - ppublish SO - World J Oncol. 2020 Oct;11(5):204-215. doi: 10.14740/wjon1305. Epub 2020 Oct 15. PMID- 33116841 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. PG - 9825-9836 LID - 10.2147/CMAR.S267969 [doi] AB - PURPOSE: To analyze the effect of preoperative serum sodium and hemoglobin on oncologic outcomes in upper tract urothelial carcinoma (UTUC) based on a multi-center cohort from China and the United States (U.S.). METHODS: We retrospectively reviewed the records of 775 patients with UTUC treated surgically at tertiary care medical facilities in China or the US from 1998 to 2015. We analyzed associations of preoperative serum sodium and hemoglobin with clinicopathological characteristics, overall survival (OS), cancer-specific survival (CSS) and intravesical recurrence free survival (IVRFS). RESULTS: The US patients had comparatively lower serum sodium and similar hemoglobin at baseline. Preoperative low serum sodium value was associated with tumor multifocality, lymph node metastasis (LNM) and lymphovascular invasion (LVI); preoperative anemia was associated with advanced age, tumor multifocality, high tumor grade and LVI. Preoperative low serum sodium was an independent predictor of worse OS in the entire cohort; preoperative anemia was an independent predictor of worse OS and CSS in the US cohort alone, Chinese cohort alone and the combined cohort. We developed a predictive nomogram for OS which exhibited better prognostic value when it included the values of sodium and anemia, and successfully validated it in different cohorts. CONCLUSION: Preoperative low serum sodium and anemia could be informative in predicting worse pathologic and survival outcomes in different UTUC patient ethnic groups. CI - (c) 2020 Fang et al. FAU - Fang, Dong AU - Fang D AUID- ORCID: 0000-0001-6746-6559 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Bao, Zhengqing AU - Bao Z AUID- ORCID: 0000-0003-0602-089X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. AD - Department of Urology, Beijing Jishuitan Hospital, The Fourth Medical College of Peking University, Beijing, People's Republic of China. FAU - Jafri, Syed M AU - Jafri SM AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. FAU - Su, Xiaohong AU - Su X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Cao, Zhenpeng AU - Cao Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Xiong, Gengyan AU - Xiong G AUID- ORCID: 0000-0003-1385-5297 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Woldu, Solomon AU - Woldu S AUID- ORCID: 0000-0003-3282-7670 AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Hutchinson, Ryan AU - Hutchinson R AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Sagalowsky, Arthur AU - Sagalowsky A AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Zhou, Liqun AU - Zhou L AUID- ORCID: 0000-0003-2795-9038 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20201008 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7549885 OTO - NOTNLM OT - China OT - anemia OT - serum sodium OT - survival OT - the United States OT - upper tract urothelial carcinoma COIS- The authors declare that they have no conflicting interests for this work. EDAT- 2020/10/30 06:00 MHDA- 2020/10/30 06:01 PMCR- 2020/10/08 CRDT- 2020/10/29 05:49 PHST- 2020/06/27 00:00 [received] PHST- 2020/09/08 00:00 [accepted] PHST- 2020/10/29 05:49 [entrez] PHST- 2020/10/30 06:00 [pubmed] PHST- 2020/10/30 06:01 [medline] PHST- 2020/10/08 00:00 [pmc-release] AID - 267969 [pii] AID - 10.2147/CMAR.S267969 [doi] PST - epublish SO - Cancer Manag Res. 2020 Oct 8;12:9825-9836. doi: 10.2147/CMAR.S267969. eCollection 2020. PMID- 33116823 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China. PG - 9635-9641 LID - 10.2147/CMAR.S269065 [doi] AB - OBJECTIVE: To investigate the clinical characteristics and prognosis of patients with rare histological variants of bladder cancer (RHV-BC) in China. MATERIALS AND METHODS: Patients diagnosed as bladder carcinoma with RHV in our center, from March 2009 and April 2019, were included. The univariate and multivariate COX regression model were used to evaluate the association between clinical characteristics and overall survival (OS). RESULTS: A total of 54 (1.4%) patients with RVH-BC were identified from 3803 potential patients with bladder cancer. The RHV classifications included micropapillary variant (MPV), sarcomatoid variant (SAV), neuroendocrine variant (NEV), nested variant (NV), plasmacytoid variant (PCV), and lymphoepithelioma-like variant (LEV), which were found in 19, 18, seven, six, three, and one patient, respectively. The mean of recurrence-free survival (RFS), cancer-specific survival (CSS), and OS of patients were 18.8 months, 37.0 months and 36.0 months, respectively. The multivariable analyses indicated that metastasis and T >/=2 were independent risk factors of OS. Besides, 84.4% (27/32) of patients who were receiving intravesical therapies (IVT) suffered recurrence. Patients with adjuvant chemotherapy (AC) had a recurrence rate of 64.7% (11/17). CONCLUSION: T>/=2 and metastasis were independent risk factors of OS in patients with RHV-BC. Considering a high recurrence following transurethral resection of bladder tumor (TURBT) and IVT, early radical cystectomy (RC) might be performed for patients with RHV-BC. CI - (c) 2020 Li et al. FAU - Li, Dengxiong AU - Li D AUID- ORCID: 0000-0002-1943-6758 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Li, Ao AU - Li A AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Yang, Yubo AU - Yang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Feng, Dechao AU - Feng D AUID- ORCID: 0000-0002-8267-9920 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Zhang, Facai AU - Zhang F AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Wang, Xiaoming AU - Wang X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Bai, Yunjin AU - Bai Y AUID- ORCID: 0000-0001-6005-6725 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Tang, Yin AU - Tang Y AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. FAU - Han, Ping AU - Han P AUID- ORCID: 0000-0002-9710-0037 AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, People's Republic of China. LA - eng PT - Journal Article DEP - 20201007 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7548230 OTO - NOTNLM OT - bladder cancer OT - histologic variants OT - overall survival OT - prognosis COIS- The authors report no conflicts of interest for this work. EDAT- 2020/10/30 06:00 MHDA- 2020/10/30 06:01 PMCR- 2020/10/07 CRDT- 2020/10/29 05:49 PHST- 2020/06/23 00:00 [received] PHST- 2020/08/28 00:00 [accepted] PHST- 2020/10/29 05:49 [entrez] PHST- 2020/10/30 06:00 [pubmed] PHST- 2020/10/30 06:01 [medline] PHST- 2020/10/07 00:00 [pmc-release] AID - 269065 [pii] AID - 10.2147/CMAR.S269065 [doi] PST - epublish SO - Cancer Manag Res. 2020 Oct 7;12:9635-9641. doi: 10.2147/CMAR.S269065. eCollection 2020. PMID- 33114616 OWN - NLM STAT- MEDLINE DCOM- 20210303 LR - 20231104 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 21 DP - 2020 Oct 26 TI - Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? LID - 10.3390/ijms21217935 [doi] LID - 7935 AB - Urothelial bladder cancer is one of the most lethal cancers worldwide with barely 5% five-year survival in patients with metastatic disease. Intravesical immunotherapy with Bacillus Calmette-Guerin and platinum-based chemotherapy are currently the standard of care for non-muscle invasive and advanced or metastatic urothelial cancer (mUC), respectively. Recently, a subset of patients with locally advanced or mUC has shown to be responsive to immune checkpoint inhibitors (ICIs), e.g., the anti-cytotoxic T-lymphocyte-associated protein 4 and programmed cell death -1/programmed death-ligand1 (PD-1/PD-L1) antibodies. Due to the relevant clinical benefit of immunotherapy for mUC, in 2016, the United States Food and Drug Administration (FDA) approved five immunotherapeutic agents as second-line or first-line treatments for patients with advanced bladder cancer who did not profit from or were ineligible for standard therapy. In this review, we discuss the role of immunotherapy in bladder cancer and recent clinical applications of PD-1/PD-L1 blockade in mUC. Furthermore, we evaluate a variable response rate to ICIs treatment and outline potential biomarkers predictive of immunotherapy response. FAU - Roviello, Giandomenico AU - Roviello G AD - Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy. FAU - Catalano, Martina AU - Catalano M AD - School of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. FAU - Nobili, Stefania AU - Nobili S AUID- ORCID: 0000-0003-4731-9169 AD - Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy. FAU - Santi, Raffaella AU - Santi R AD - Department of Pathology, Careggi University Hospital, University of Firenze, 50139 Firenze, Italy. FAU - Mini, Enrico AU - Mini E AD - Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy. FAU - Nesi, Gabriella AU - Nesi G AD - Department of Health Sciences, University of Florence, Section of Pathological Anatomy, University Hospital of Florence, 50139 Florence, Italy. LA - eng PT - Journal Article PT - Review DEP - 20201026 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (CTLA-4 Antigen) RN - 0 (CTLA4 protein, human) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use MH - B7-H1 Antigen/metabolism MH - CTLA-4 Antigen/metabolism MH - Carcinoma, Transitional Cell/*drug therapy/metabolism MH - Clinical Trials as Topic MH - Gene Expression Regulation, Neoplastic/drug effects MH - Humans MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use MH - Neoplasm Metastasis MH - Programmed Cell Death 1 Receptor/metabolism MH - Treatment Outcome MH - United States MH - United States Food and Drug Administration MH - Urinary Bladder Neoplasms/*drug therapy/metabolism PMC - PMC7662285 OTO - NOTNLM OT - PD-1 OT - PD-L1 OT - biomarkers OT - bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2020/10/30 06:00 MHDA- 2021/03/04 06:00 PMCR- 2020/11/01 CRDT- 2020/10/29 01:04 PHST- 2020/09/09 00:00 [received] PHST- 2020/10/13 00:00 [revised] PHST- 2020/10/22 00:00 [accepted] PHST- 2020/10/29 01:04 [entrez] PHST- 2020/10/30 06:00 [pubmed] PHST- 2021/03/04 06:00 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - ijms21217935 [pii] AID - ijms-21-07935 [pii] AID - 10.3390/ijms21217935 [doi] PST - epublish SO - Int J Mol Sci. 2020 Oct 26;21(21):7935. doi: 10.3390/ijms21217935. PMID- 33105025 OWN - NLM STAT- MEDLINE DCOM- 20210802 LR - 20210802 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 148 IP - 8 DP - 2021 Apr 15 TI - Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation. PG - 1808-1820 LID - 10.1002/ijc.33359 [doi] AB - Aging is associated with an insufficient immune response that may lead to the initiation and progression of various malignancies. Bladder cancer (BC), prevalent in elderly patients, predominantly presents as recurrent nonmuscle invasive BC that requires further treatment. There is much interest in the activation of patients' immune cells with the focus on CD8+ T cells. Successful therapy should also ensure the efficient presentation of BC antigens by major histocompatibility complex (MHC) class I molecules. The purpose of this systematic review is to present the existing literature on the role of MHC class I in BC research and therapy. The bibliographic databases PubMed and Web of Science were searched for articles published between January 2009 and September 2020 that addressed MHC class I relationship to BC. We searched for available relevant publications on MHC class I and its role and regulation in BC, aging and MHC class I importance in BC immunotherapy. Based on the provided evidence, we propose that the loss of MHC class I expression in BC may lead to its recurrence after the transurethral resection and unresponsiveness to Bacillus Calmette-Guerin immunotherapy. We discuss different ways to enhance MHC class I antigen presentation to CD8+ T cells in BC treatment. The immune status characterized by MHC class I expression patterns and cancer-infiltrating immune cells may provide valuable prognostic information about which patients may benefit from transurethral resection of BC and additional immunotherapy. CI - (c) 2020 Union for International Cancer Control. FAU - Wieczorek, Edyta AU - Wieczorek E AUID- ORCID: 0000-0002-4390-2042 AD - Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, Lodz, Poland. FAU - Garstka, Malgorzata A AU - Garstka MA AUID- ORCID: 0000-0003-2896-7275 AD - Core Research Laboratory, the Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China. AD - Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China. AD - Department of Tumor and Immunology, Precision Medical Institute, Western China Science and Technology Innovation Port, School of Medicine, Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20201119 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Histocompatibility Antigens Class I) SB - IM MH - Aged MH - Aging/*immunology MH - Antigen Presentation/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - Histocompatibility Antigens Class I/*immunology MH - Humans MH - Immunotherapy/methods MH - Models, Immunological MH - Neoplasm Recurrence, Local MH - Urinary Bladder Neoplasms/*immunology/pathology/therapy OTO - NOTNLM OT - BCG immunotherapy OT - MHC class I OT - TURBT OT - aging OT - bladder cancer EDAT- 2020/10/27 06:00 MHDA- 2021/08/03 06:00 CRDT- 2020/10/26 17:15 PHST- 2020/09/23 00:00 [received] PHST- 2020/10/20 00:00 [revised] PHST- 2020/10/21 00:00 [accepted] PHST- 2020/10/27 06:00 [pubmed] PHST- 2021/08/03 06:00 [medline] PHST- 2020/10/26 17:15 [entrez] AID - 10.1002/ijc.33359 [doi] PST - ppublish SO - Int J Cancer. 2021 Apr 15;148(8):1808-1820. doi: 10.1002/ijc.33359. Epub 2020 Nov 19. PMID- 33094476 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20210414 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 38 IP - 1 DP - 2021 Jan TI - Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario. PG - 258-267 LID - 10.1007/s12325-020-01529-1 [doi] AB - INTRODUCTION: For risk stratification of non-muscle invasive bladder cancer (NMIBC), the depth of stromal invasion can be further classified, where the lamina muscularis mucosae (MM) serves as a reference structure. While the overall identifiability of MM in standard transurethral specimens is low, en bloc resection may help in identification and overall orientation. The aims of this study were to report the detection rate of MM in en bloc resected bladder tumors (ERBT) and to provide real-world information on tissue stability and preservation of en bloc architecture during recovery and processing for histopathologic evaluation. METHODS: Thirty-four ERBT specimens were histologically re-evaluated with regard to MM detectability and structure as well as the presence of en bloc architecture and further histologic features. Associations with tumor size and energy source and within histologic parameters were assessed by standard Pearson's chi-squared analyses and Cramer's V effect size testing (V). RESULTS: The first parameter assessed was MM detection rate. In 19 out of 34 samples (56%) MM was detectable: scattered in 9 cases (26%), interrupted in 8 cases (24%) and continuous in 2 cases (6%). The second parameter assessed was preservation of en bloc architecture. In 11 out of 34 samples (32%), en bloc architecture could not be confirmed, and these samples served as a reference group for the detection of MM. Preservation of en bloc architecture was associated with an increased MM detection rate (MM in en bloc preserved 16/23, 70% vs. non-preserved 3/11, 27%; p = 0.020; V = 0.398) and with tumor size (p = 0.005; V = 0.595). Medium-sized tumors (1.1-2 cm) were best preserved. The choice of energy source did not show relevant association with en bloc architecture (p = n.s.). CONCLUSIONS: In line with recent publications, ERBT increases the MM detection rate considerably. However, a third of the ERBT specimens lost en bloc architecture during sample recovery and processing. Tumor size is a relevant factor, with optimal architecture preservation between 1 and 2 cm. Optimizing resection techniques, recovery, transport, and diagnostic processing of ERBT samples is warranted to verify the diagnostic value of MM-based substaging. FAU - Struck, Julian P AU - Struck JP AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. julian.struck@uksh.de. FAU - Kramer, Mario W AU - Kramer MW AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - Katzendorn, Olga AU - Katzendorn O AD - Department of Urology and Urologic Oncology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Hupe, Marie C AU - Hupe MC AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - Ozimek, Tomasz AU - Ozimek T AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - Hennig, Martin J P AU - Hennig MJP AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - Wiessmeyer, Judith R AU - Wiessmeyer JR AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - von Klot, Christoph A J AU - von Klot CAJ AD - Department of Urology and Urologic Oncology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Kuczyk, Markus A AU - Kuczyk MA AD - Department of Urology and Urologic Oncology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Kreipe, Hans H AU - Kreipe HH AD - Institute of Pathology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Merseburger, Axel S AU - Merseburger AS AD - Department of Urology, University-Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. FAU - Perner, Sven AU - Perner S AD - Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. AD - Institute of Pathology, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40, 23845, Borstel, Germany. FAU - Dressler, Franz F AU - Dressler FF AD - Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. LA - eng PT - Journal Article DEP - 20201022 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 MH - Cystectomy MH - Humans MH - Mucous Membrane MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery PMC - PMC7854421 OTO - NOTNLM OT - Bladder cancer OT - ERBT OT - En bloc OT - Histopathologic stratification OT - Substaging EDAT- 2020/10/24 06:00 MHDA- 2021/04/15 06:00 PMCR- 2020/10/22 CRDT- 2020/10/23 06:00 PHST- 2020/08/30 00:00 [received] PHST- 2020/10/08 00:00 [accepted] PHST- 2020/10/24 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2020/10/23 06:00 [entrez] PHST- 2020/10/22 00:00 [pmc-release] AID - 10.1007/s12325-020-01529-1 [pii] AID - 1529 [pii] AID - 10.1007/s12325-020-01529-1 [doi] PST - ppublish SO - Adv Ther. 2021 Jan;38(1):258-267. doi: 10.1007/s12325-020-01529-1. Epub 2020 Oct 22. PMID- 33090031 OWN - NLM STAT- MEDLINE DCOM- 20210708 LR - 20210708 IS - 1940-2465 (Electronic) IS - 1066-8969 (Linking) VI - 29 IP - 1 DP - 2021 Feb TI - Analysis of Tumor Depth Invasion With Anti-Smoothelin Antibody in Equivocal Transurethral Resection of Urinary Bladder Tumor Surgical Specimens. PG - 54-63 LID - 10.1177/1066896920967762 [doi] AB - OBJECTIVE: To examine the expression and value of the smoothelin marker in control cases, to standardize the working method, and to analyze its application in pathologic staging process of problematic transurethral resection of bladder tumor (TURBT) cases. MATERIAL AND METHODS: Immunohistochemical (IHC) staining was performed on tumor-free bladder wall sections, tumor-free large bowel sections, TURBTs with unequivocal tumor stage, and TURBTs with equivocal stage. The IHC staining of muscularis mucosa (MM), muscularis propria (MP), and blood vessels was evaluated semiquantitatively. RESULTS: Smoothelin IHC staining pattern ranged from negative (30% to 67% cases) to 2+ (0% to 15% cases) in MM and from 1+ (10% to 50% cases) to 3+ (9% to 48% cases) in MP. When compared on the same slide, the smoothelin expression of MP showed a stronger staining intensity than the one of the MM in all the analyzed cases. Blood vessel muscle cells stained in a constant intensity as the MM (r = 0.9808; r = 0.9604). Smoothelin determined restaging of 33% of the problematic TURBT cases. CONCLUSION: Smoothelin is an IHC marker that shows differential staining between coexistent MM and MP; however, variations in staining intensity and pattern may occur, aspects that can be influenced by different technique variables. We recommend using this marker as a diagnostic tool in problematic TURBT cases only when there is sufficient experience in control cases with this antibody. FAU - Mihai, Ioana Maria AU - Mihai IM AUID- ORCID: 0000-0003-0617-4178 AD - Department of Microscopic Morphology - Pathology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania. FAU - Olteanu, Gheorghe-Emilian AU - Olteanu GE AUID- ORCID: 0000-0001-5921-4634 AD - Department of Microscopic Morphology - Pathology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania. AD - Centre for Gene and Cellular Therapies in Cancer-Oncogen, Timisoara, Romania. FAU - Herman, Diana AU - Herman D AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. FAU - Anderco, Denisa AU - Anderco D AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. FAU - Iacob, Mihaela AU - Iacob M AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. FAU - Nataras, Bianca AU - Nataras B AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. FAU - Cumpanas, Alin Adrian AU - Cumpanas AA AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. AD - Department of Urology - "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania. FAU - Bardan, Razvan AU - Bardan R AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. AD - Department of Urology - "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania. FAU - Dema, Alis AU - Dema A AD - Department of Microscopic Morphology - Pathology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania. AD - Emergency County Hospital "Pius Brinzeu," Timisoara, Romania. LA - eng PT - Journal Article DEP - 20201022 PL - United States TA - Int J Surg Pathol JT - International journal of surgical pathology JID - 9314927 RN - 0 (Biomarkers, Tumor) RN - 0 (Cytoskeletal Proteins) RN - 0 (Muscle Proteins) RN - 0 (SMTN protein, human) SB - IM MH - Aged MH - Biomarkers, Tumor/*analysis MH - Case-Control Studies MH - Cystectomy MH - Cytoskeletal Proteins/*analysis/metabolism MH - Feasibility Studies MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Muscle Proteins/*analysis/metabolism MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery OTO - NOTNLM OT - TURBT OT - immunohistochemistry OT - muscularis mucosae OT - muscularis propria OT - smoothelin OT - urinary bladder cancer EDAT- 2020/10/23 06:00 MHDA- 2021/07/09 06:00 CRDT- 2020/10/22 12:15 PHST- 2020/10/23 06:00 [pubmed] PHST- 2021/07/09 06:00 [medline] PHST- 2020/10/22 12:15 [entrez] AID - 10.1177/1066896920967762 [doi] PST - ppublish SO - Int J Surg Pathol. 2021 Feb;29(1):54-63. doi: 10.1177/1066896920967762. Epub 2020 Oct 22. PMID- 33086575 OWN - NLM STAT- MEDLINE DCOM- 20210223 LR - 20240803 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 20 DP - 2020 Oct 19 TI - Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression. LID - 10.3390/ijms21207726 [doi] LID - 7726 AB - Non-muscle-invasive bladder cancer (NMIBC) consists of transcriptional subtypes that are distinguishable from those of muscle-invasive cancer. We aimed to identify genetic signatures of NMIBC related to basal (K5/6) and luminal (K20) keratin expression. Based on immunohistochemical staining, papillary high-grade NMIBC was classified into K5/6-only (K5/6(High)-K20(Low)), K20-only (K5/6(Low)-K20(High)), double-high (K5/6(High)-K20(High)), and double-low (K5/6(Low)-K20(Low)) groups (n = 4 per group). Differentially expressed genes identified between each group using RNA sequencing were subjected to functional enrichment analyses. A public dataset was used for validation. Machine learning algorithms were implemented to predict our samples against UROMOL subtypes. Transcriptional investigation demonstrated that the K20-only group was enriched in the cell cycle, proliferation, and progression gene sets, and this result was also observed in the public dataset. The K5/6-only group was closely regulated by basal-type gene sets and showed activated invasive or adhesive functions. The double-high group was enriched in cell cycle arrest, macromolecule biosynthesis, and FGFR3 signaling. The double-low group moderately expressed genes related to cell cycle and macromolecule biosynthesis. All K20-only group tumors were classified as UROMOL "class 2" by the machine learning algorithms. K5/6 and K20 expression levels indicate the transcriptional subtypes of NMIBC. The K5/6(Low)-K20(High) expression is a marker of high-risk NMIBC. FAU - Jung, Minsun AU - Jung M AD - Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea. FAU - Jang, Insoon AU - Jang I AD - Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea. FAU - Kim, Kwangsoo AU - Kim K AD - Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul 03080, Korea. FAU - Moon, Kyung Chul AU - Moon KC AD - Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea. AD - Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul 03080, Korea. LA - eng GR - 2018R1D1A1B07045763/National Research Foundation of Korea/ PT - Comparative Study PT - Journal Article DEP - 20201019 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Aged MH - Aged, 80 and over MH - Databases, Genetic MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Gene Ontology MH - Humans MH - Male MH - Middle Aged MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Reproducibility of Results MH - Up-Regulation/genetics MH - Urinary Bladder Neoplasms/genetics/*metabolism/*pathology PMC - PMC7589917 OTO - NOTNLM OT - biomarkers OT - gene expression profiling OT - keratin-20 OT - keratin-5/6 OT - non-muscle-invasive bladder cancer OT - urinary bladder neoplasms COIS- The authors declare no conflict of interest. EDAT- 2020/10/23 06:00 MHDA- 2021/02/24 06:00 PMCR- 2020/10/01 CRDT- 2020/10/22 01:01 PHST- 2020/09/22 00:00 [received] PHST- 2020/10/08 00:00 [revised] PHST- 2020/10/13 00:00 [accepted] PHST- 2020/10/22 01:01 [entrez] PHST- 2020/10/23 06:00 [pubmed] PHST- 2021/02/24 06:00 [medline] PHST- 2020/10/01 00:00 [pmc-release] AID - ijms21207726 [pii] AID - ijms-21-07726 [pii] AID - 10.3390/ijms21207726 [doi] PST - epublish SO - Int J Mol Sci. 2020 Oct 19;21(20):7726. doi: 10.3390/ijms21207726. PMID- 33076249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201103 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 9 IP - 10 DP - 2020 Oct 15 TI - Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. LID - 10.3390/jcm9103306 [doi] LID - 3306 AB - BACKGROUND AND PURPOSE: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2-6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guerin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. MATERIALS AND METHODS: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon's discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients' characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. RESULTS: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. CONCLUSIONS: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, 6004 Lucerne, Switzerland. FAU - Nowak, Lukasz AU - Nowak L AUID- ORCID: 0000-0003-4273-8196 AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AUID- ORCID: 0000-0001-7664-9816 AD - Second Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Public Health, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Afferi, Luca AU - Afferi L AUID- ORCID: 0000-0002-5472-1933 AD - Klinik fur Urologie, Luzerner Kantonsspital, 6004 Lucerne, Switzerland. FAU - Teoh, Jeremy AU - Teoh J AUID- ORCID: 0000-0002-9361-2342 AD - S.H.Ho Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AUID- ORCID: 0000-0003-3195-9890 AD - Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium. FAU - Tafuri, Alessandro AU - Tafuri A AUID- ORCID: 0000-0003-1404-2925 AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy. FAU - Gozzo, Alessandra AU - Gozzo A AD - Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, 37129 Verona, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, 50139 Florence, Italy. FAU - Di Trapani, Ettore AU - Di Trapani E AD - Department of Urology, European Institute of Oncology, 20143 Milan, Italy. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AUID- ORCID: 0000-0003-0705-7643 AD - Department of Urology Hospital Universitario La Paz, 28046 Madrid, Spain. FAU - Serrano, Andrea Rodriguez AU - Serrano AR AD - Department of Urology Hospital Universitario La Paz, 28046 Madrid, Spain. FAU - Simone, Giuseppe AU - Simone G AD - IRCCS "Regina Elena" National Cancer Institute, Department of Urology, 00144 Rome, Italy. FAU - Zamboni, Stefania AU - Zamboni S AUID- ORCID: 0000-0002-6244-4120 AD - Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy. FAU - Marconi, Maria Cristina AU - Marconi MC AD - Urology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili of Brescia, Brescia 25123, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - IRCCS "Regina Elena" National Cancer Institute, Department of Urology, 00144 Rome, Italy. FAU - Ploussard, Guillaume AU - Ploussard G AUID- ORCID: 0000-0002-6004-2152 AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Rajwa, Pawel AU - Rajwa P AD - Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800 Zabrze, Poland. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Institute for Urology and Reproductive Health, Sechenov University, 119146 Moscow, Russia. AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, 1090 Vienna, Austria. FAU - Zdrojowy-Welna, Aleksandra AU - Zdrojowy-Welna A AD - Department of Endocrinology, Diabetes and Isothope Therapy, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Paradysz, Andrzej AU - Paradysz A AD - Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800 Zabrze, Poland. FAU - Tully, Karl AU - Tully K AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, 44625 Herne, Germany. FAU - Krajewska, Joanna AU - Krajewska J AD - Department and Clinic of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncologic Urology, Lower Silesian Specialist Hospital, 50-556 Wroclaw, Poland. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, 75018 Paris, France. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20201015 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC7602446 OTO - NOTNLM OT - BCG OT - bladder cancer OT - reTURB COIS- The authors declare no conflict of interest. EDAT- 2020/10/21 06:00 MHDA- 2020/10/21 06:01 PMCR- 2020/10/15 CRDT- 2020/10/20 01:02 PHST- 2020/09/17 00:00 [received] PHST- 2020/10/09 00:00 [revised] PHST- 2020/10/10 00:00 [accepted] PHST- 2020/10/20 01:02 [entrez] PHST- 2020/10/21 06:00 [pubmed] PHST- 2020/10/21 06:01 [medline] PHST- 2020/10/15 00:00 [pmc-release] AID - jcm9103306 [pii] AID - jcm-09-03306 [pii] AID - 10.3390/jcm9103306 [doi] PST - epublish SO - J Clin Med. 2020 Oct 15;9(10):3306. doi: 10.3390/jcm9103306. PMID- 35474659 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2688-4526 (Electronic) IS - 2688-4526 (Linking) VI - 2 IP - 1 DP - 2021 Jan TI - The role of URO17 biomarker to enhance diagnosis of urothelial cancer in new hematuria patients-First European Data. PG - 46-52 LID - 10.1002/bco2.50 [doi] AB - INTRODUCTION AND OBJECTIVES: Novel biomarker research is vital for the progression of safe and thorough diagnostic medicine. There is now a need to improve the diagnosis of bladder cancer via a noninvasive urine test while balancing the risks of harm from investigational procedures, such as cystoscopy and radiological tests, against the likelihood of malignancy. We evaluate the diagnostic accuracy and sensitivity of Uro17 urinary biomarker for the detection of urothelial cancer in hematuria patients in a prospective blinded validation study. Uro17 is an immunobiomarker which binds to the oncoprotein Keratin 17, which is involved in the replication cycle of malignant cells. This study compared cystoscopic and histological investigations against Uro17 results in patients being investigated for symptoms of urothelial cancer. MATERIALS AND METHODS: After receiving both local and national ethics/protocol approval, 71 patients were consented and recruited into the study. All patients were scheduled to undergo cystoscopic investigation, and following recruitment, a urine sample was collected. Urine samples were anonymized and processed as per standard cytology protocols and stained using Uro17 immunobiomarker. The pathologists assessing the results were blinded to the patient and background history, and the results were compared to the biopsy histology. RESULTS: The full cohort of enrolled patients consisted of 71 participants included. There were 55 males and 16 females, with an average age of 70. Thirteen were current smokers, 42 ex-smokers, and 16 nonsmokers. The malignancies detected included both muscle-invasive (n = 6) and non-muscle-invasive tumors (n = 38), and tumors of all grades and carcinoma in situ. Uro17 was shown to have an overall sensitivity of 100% and a specificity of 92.6%, with a positive predictive value of 0.957 and negative predictive value of 1. Uro17 investigation was positive in every case of urothelial malignancy. CONCLUSIONS: Our current data indicates Uro17 is a highly sensitive noninvasive bladder cancer urine detection test that can improve the diagnosis of Bladder cancer. This can further improve diagnostic capabilities in primary care, reduce the number of referrals to Urology department, and reduce the number of unnecessary invasive procedures for new patients with a suspected urinary bladder cancer. CI - (c) 2020 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. FAU - Vasdev, Nikhil AU - Vasdev N AUID- ORCID: 0000-0002-3966-5734 AD - Hertfordshire and Bedfordshire Urological Cancer Centre Department of Urology Lister Hospital Stevenage UK. AD - School of Life and Medical Sciences University of Hertfordshire Hatfield UK. FAU - Hampson, Alexander AU - Hampson A AUID- ORCID: 0000-0003-3517-2534 AD - Hertfordshire and Bedfordshire Urological Cancer Centre Department of Urology Lister Hospital Stevenage UK. FAU - Agarwal, Samita AU - Agarwal S AD - Department of Pathology Lister Hospital Stevenage UK. FAU - Swamy, Rajiv AU - Swamy R AD - Department of Pathology Lister Hospital Stevenage UK. FAU - Chilvers, Michael AU - Chilvers M AD - Department of Anaesthetics Lister Hospital Stevenage UK. FAU - Hampson, Amy AU - Hampson A AD - Hertfordshire and Bedfordshire Urological Cancer Centre Department of Urology Lister Hospital Stevenage UK. FAU - Jahanfard, Sholeh AU - Jahanfard S AD - KDx Diagnostics Inc Campbell CA USA. FAU - Kim, Nam AU - Kim N AD - KDx Diagnostics Inc Campbell CA USA. LA - eng PT - Journal Article DEP - 20201020 PL - United States TA - BJUI Compass JT - BJUI compass JID - 101764975 PMC - PMC8988772 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - cytology OT - diagnostic OT - oncology EDAT- 2020/10/20 00:00 MHDA- 2020/10/20 00:01 PMCR- 2020/10/20 CRDT- 2022/04/27 06:13 PHST- 2020/08/19 00:00 [received] PHST- 2020/09/14 00:00 [revised] PHST- 2020/09/26 00:00 [accepted] PHST- 2022/04/27 06:13 [entrez] PHST- 2020/10/20 00:00 [pubmed] PHST- 2020/10/20 00:01 [medline] PHST- 2020/10/20 00:00 [pmc-release] AID - BCO250 [pii] AID - 10.1002/bco2.50 [doi] PST - epublish SO - BJUI Compass. 2020 Oct 20;2(1):46-52. doi: 10.1002/bco2.50. eCollection 2021 Jan. PMID- 33074725 OWN - NLM STAT- MEDLINE DCOM- 20210304 LR - 20210304 IS - 1532-4192 (Electronic) IS - 0735-7907 (Linking) VI - 39 IP - 3 DP - 2021 Mar TI - Prognostic Significance of Plasma Folate and Cobalamin Concentrations in Non-Muscle-Invasive Bladder Cancer: A Prospective Cohort Study. PG - 240-250 LID - 10.1080/07357907.2020.1839760 [doi] AB - This cohort study aimed to investigate prognostic significance of plasma folate and cobalamin in non-muscle-invasive bladder cancer (NMIBC). A total of 177 NMIBC patients were followed over a period extending to 6 years. Cox regression models were applied to estimate risks for recurrence and progression according to plasma vitamins tertiles. Compared to first tertile, third tertile of plasma folate [HR (95% CI), 10.5 (1.32-83.4); p = 0.026] was associated, and of plasma cobalamin [2.12 (0.63-7.25); p = 0.116] tended to be associated with higher risk for progression. NIMBC patients with high folate/cobalamin statuses should make the physician more alert for a likely poor outcome. FAU - Ben Fradj, Mohamed Kacem AU - Ben Fradj MK AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia. FAU - Ouanes, Yassine AU - Ouanes Y AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Department of Urology, Rabta Hospital, Tunis, Tunisia. FAU - Hadj-Taeib, Sameh AU - Hadj-Taeib S AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia. FAU - Mrad Dali, Kheireddine AU - Mrad Dali K AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Department of Urology, Rabta Hospital, Tunis, Tunisia. FAU - Bibi, Mokhtar AU - Bibi M AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Department of Urology, Rabta Hospital, Tunis, Tunisia. FAU - Jmal, Khalil AU - Jmal K AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia. FAU - Sanhaji, Haifa AU - Sanhaji H AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia. FAU - Nouira, Yassine AU - Nouira Y AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Department of Urology, Rabta Hospital, Tunis, Tunisia. FAU - Feki, Moncef AU - Feki M AD - Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. AD - Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia. LA - eng PT - Journal Article DEP - 20210215 PL - England TA - Cancer Invest JT - Cancer investigation JID - 8307154 RN - 0 (Biomarkers, Tumor) RN - 935E97BOY8 (Folic Acid) RN - P6YC3EG204 (Vitamin B 12) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*blood MH - Female MH - Folic Acid/*blood MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Urinary Bladder Neoplasms/*blood/*pathology MH - Vitamin B 12/*blood OTO - NOTNLM OT - Bladder cancer OT - cobalamin OT - folate OT - poor outcome OT - recurrence EDAT- 2020/10/20 06:00 MHDA- 2021/03/05 06:00 CRDT- 2020/10/19 17:10 PHST- 2020/10/20 06:00 [pubmed] PHST- 2021/03/05 06:00 [medline] PHST- 2020/10/19 17:10 [entrez] AID - 10.1080/07357907.2020.1839760 [doi] PST - ppublish SO - Cancer Invest. 2021 Mar;39(3):240-250. doi: 10.1080/07357907.2020.1839760. Epub 2021 Feb 15. PMID- 33073457 OWN - NLM STAT- MEDLINE DCOM- 20211007 LR - 20211007 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 127 IP - 6 DP - 2021 Jun TI - Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. PG - 617-625 LID - 10.1111/bju.15276 [doi] AB - OBJECTIVE: To investigate the predictive value of tumour-infiltrating immune cells (TIICs) on oncological outcomes and response to BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A systematic review and meta-analysis was performed using PubMed, Scopus and the Cochrane Library in July 2020 to identify relevant studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The pooled recurrence-free survival (RFS) rate was calculated using a fixed-effect model. RESULTS: We retrieved 15 studies (including 791 patients) evaluating the effect of TIICs on oncological outcomes in patients with NMIBC treated with intravesical BCG. TIICs were reported to be a significant predictor of oncological outcomes and response to BCG treatment in 10 studies. Tumour-associated macrophages were associated with worse RFS (pooled hazard ratio 2.30, 95% confidence interval 1.64-3.22). CONCLUSIONS: Based on these data, TIICs are significant predictors of RFS and response to BCG treatment in patients with NMIBC; therefore, incorporation of TIICs into risk stratification models may help patients and physicians in the clinical decision-making process in order to achieve the maximum possible benefit from BCG treatment. CI - (c) 2020 The Authors BJU International (c) 2020 BJU International Published by John Wiley & Sons Ltd. FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AUID- ORCID: 0000-0002-9380-8492 AD - Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AUID- ORCID: 0000-0002-6627-6179 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - European Association of Urology Research Foundation, Arnhem, The Netherlands. FAU - Margulis, Vitaly AU - Margulis V AUID- ORCID: 0000-0002-5837-4561 AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Mori, Keiichiro AU - Mori K AUID- ORCID: 0000-0002-6147-6569 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Lotan, Yair AU - Lotan Y AUID- ORCID: 0000-0001-5692-2723 AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20201109 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage MH - Humans MH - *Lymphocytes, Tumor-Infiltrating MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/immunology/*pathology EDAT- 2020/10/20 06:00 MHDA- 2021/10/08 06:00 CRDT- 2020/10/19 06:03 PHST- 2020/09/28 00:00 [revised] PHST- 2020/09/01 00:00 [received] PHST- 2020/10/13 00:00 [accepted] PHST- 2020/10/20 06:00 [pubmed] PHST- 2021/10/08 06:00 [medline] PHST- 2020/10/19 06:03 [entrez] AID - 10.1111/bju.15276 [doi] PST - ppublish SO - BJU Int. 2021 Jun;127(6):617-625. doi: 10.1111/bju.15276. Epub 2020 Nov 9. PMID- 33072593 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201022 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. PG - 564714 LID - 10.3389/fonc.2020.564714 [doi] LID - 564714 AB - Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis. Recently, the programmed death-1 (PD-1) inhibitor pembrolizumab provided a better survival benefit with a complete response rate (9.2%) for chemoresistatant urothelial carcinoma. However, the dynamic changes of the cancer microenvironment about the cases of complete response are still unknown. We herein report a case of a 57-year-old man who had been diagnosed with localized, non-muscle-invasive bladder cancer (pT1N0M0, high grade), for which he underwent transurethral resection of the bladder cancer twice. Given that gemcitabine plus carboplatin as first-line neoadjuvant chemotherapy was unable to control left vesico-ureteral junction recurrence with muscle invasion (T3N0M0, high grade), the patient received the PD-1 inhibitor pembrolizumab as second-line neoadjuvant therapy in an attempt to stop tumor growth, which promoted dramatic tumor shrinkage without serious adverse effects and allowed subsequent nephroureterectomy and lymphadenectomy. To the best of our knowledge, this has been the first study to report that pembrolizumab administration before surgery for chemotherapy-resistant ureteral carcinoma promoted a pathological complete response, providing a better understanding of the cancer microenvironment after immunotherapy. CI - Copyright (c) 2020 Ikarashi, Kitano, Ishida, Nakatsura, Shimodate, Tsuyukubo, Tamura, Kato, Sugai and Obara. FAU - Ikarashi, Daiki AU - Ikarashi D AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research Ariake, Tokyo, Japan. AD - Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan. FAU - Kitano, Shigehisa AU - Kitano S AD - Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research Ariake, Tokyo, Japan. FAU - Ishida, Kazuyuki AU - Ishida K AD - Department of Pathology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Nakatsura, Tetsuya AU - Nakatsura T AD - Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan. FAU - Shimodate, Hitoshi AU - Shimodate H AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Tsuyukubo, Takashi AU - Tsuyukubo T AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Tamura, Daichi AU - Tamura D AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Kato, Renpei AU - Kato R AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Sugai, Tamotsu AU - Sugai T AD - Department of Pathology, Iwate Medical University School of Medicine, Iwate, Japan. FAU - Obara, Wataru AU - Obara W AD - Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan. LA - eng PT - Journal Article DEP - 20200924 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7541700 OTO - NOTNLM OT - chemoresistant OT - neoadjuvant OT - pathological complete response OT - pembrolizumab OT - ureteral carcinoma EDAT- 2020/10/20 06:00 MHDA- 2020/10/20 06:01 PMCR- 2020/01/01 CRDT- 2020/10/19 05:58 PHST- 2020/05/22 00:00 [received] PHST- 2020/08/28 00:00 [accepted] PHST- 2020/10/19 05:58 [entrez] PHST- 2020/10/20 06:00 [pubmed] PHST- 2020/10/20 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.564714 [doi] PST - epublish SO - Front Oncol. 2020 Sep 24;10:564714. doi: 10.3389/fonc.2020.564714. eCollection 2020. PMID- 33061634 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study. PG - 9471-9483 LID - 10.2147/CMAR.S259117 [doi] AB - PURPOSE: This study aimed to investigate the associations between the preoperative prognostic nutritional index (PNI), systemic immune-inflammation index (SII) and overall survival (OS) and cancer-specific survival (CSS) in high-risk non-muscle-invasive bladder cancer (NMIBC) patients who received intravesical instillation of Bacillus Calmette-Guerin (BCG) after transurethral resection of bladder tumour (TURBT). PATIENTS AND METHODS: We retrospectively collected data from 387 high-risk NMIBC patients between January 2004 and December 2014. PNI was calculated as total lymphocyte count (10(9)/L)x5+albumin concentration (g/L). SII was calculated as neutrophil count (10(9)/L)xplatelet count (10(9)/L)/lymphocyte count (10(9)/L). The cutoff values of PNI and SII were determined through receiver operating characteristic (ROC) analysis. OS and CSS were estimated by Kaplan-Meier analysis. The Log rank test was used to compare differences between the groups. Univariate and multivariate Cox regression analyses were performed to assess the predictive values of PNI and SII for OS and CSS. Additionally, highest-risk NMIBC patients were also divided into low or high groups according to PNI and SII. The OS and CSS of highest-risk NMIBC patients were estimated using Kaplan-Meier analysis with the Log rank test. RESULTS: The patients were divided into two groups according to the cutoff values of PNI (<50.17 vs >/=50.17) and SII (<467.76 vs >/=467.76). Kaplan-Meier analysis revealed that low PNI and high SII were associated with poorer OS and CSS in high-risk NMIBC patients. Univariate and multivariate Cox regression analyses revealed that PNI and SII were independent predictive factors for OS and CSS. Kaplan-Meier analysis also revealed that low PNI and high SII were related to poorer OS and CSS in highest-risk NMIBC patients. CONCLUSION: These results suggest that preoperative PNI and SII, based on standard laboratory measurements, may be useful noninvasive, inexpensive and simple tools for predicting the long-term survival of high-risk NMIBC patients who received intravesical instillation of BCG after TURBT. CI - (c) 2020 Bi et al. FAU - Bi, Huifeng AU - Bi H AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. AD - Department of Urology, Jincheng General Hospital, Jincheng, Shanxi Province, People's Republic of China. FAU - Shang, Zhenhua AU - Shang Z AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Jia, Chunsong AU - Jia C AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Wu, Jiangtao AU - Wu J AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Cui, Bo AU - Cui B AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Ou, Tongwen AU - Ou T AUID- ORCID: 0000-0001-8055-9418 AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20201001 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7534864 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - cancer-specific survival OT - non-muscle-invasive bladder cancer OT - overall survival OT - prognostic nutritional index OT - systemic immune-inflammation index COIS- The authors report grants from Beijing Municipal People's Government, during the conduct of the study; and grants from Beijing Municipal People's Government, outside the submitted work. The authors declare that there are no other conflicts of interest in this study. EDAT- 2020/10/17 06:00 MHDA- 2020/10/17 06:01 PMCR- 2020/10/01 CRDT- 2020/10/16 05:51 PHST- 2020/04/21 00:00 [received] PHST- 2020/08/26 00:00 [accepted] PHST- 2020/10/16 05:51 [entrez] PHST- 2020/10/17 06:00 [pubmed] PHST- 2020/10/17 06:01 [medline] PHST- 2020/10/01 00:00 [pmc-release] AID - 259117 [pii] AID - 10.2147/CMAR.S259117 [doi] PST - epublish SO - Cancer Manag Res. 2020 Oct 1;12:9471-9483. doi: 10.2147/CMAR.S259117. eCollection 2020. PMID- 33057888 OWN - NLM STAT- MEDLINE DCOM- 20210930 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 5 DP - 2021 May TI - Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. PG - 1319-1329 LID - 10.1007/s00345-020-03474-8 [doi] AB - PURPOSE: Patients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresponsive disease. The purpose of this review is to present the current status and describe future directions of immunotherapy in NMIBC. METHODS: The PubMed and Google Scholar databases were searched for articles pertaining to immunotherapy in NMIBC. Relevant planned and ongoing clinical trials were identified using www.ClinicalTrials.gov . Published randomized control trials, reviews, other retrospective and prospective studies deemed relevant were used in this review paper. RESULTS: Novel immunotherapies used in the treatment of high-grade NMIBC and BCG-unresponsive disease allow patients more options and have the potential to reduce the need for radical cystectomy. Currently, several options target the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis as this mechanism of immunotherapy has been shown to be effective in several cancers, including bladder, melanoma, and lung cancers. In addition, other immunotherapy options for the treatment of NMIBC include viral gene therapies, interleukin-15 superagonists, small molecule inhibitors of indoleamine (2,3)-dioxygenase 1, and vaccines. CONCLUSIONS: The current landscape of immunotherapy in bladder cancer is rapidly evolving, with much literature pertaining to muscle-invasive and metastatic disease. However, the implementation of these treatment options in high-grade NMIBC may allow patients to avoid life-altering surgery. Reliable biomarkers for response are needed to further select patients who may benefit from such therapies. FAU - Pfail, John L AU - Pfail JL AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Avenue, 6th Floor, New York City, NY, 10029, USA. FAU - Katims, Andrew B AU - Katims AB AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Avenue, 6th Floor, New York City, NY, 10029, USA. FAU - Alerasool, Parissa AU - Alerasool P AD - School of Medicine, New York Medical College, Valhalla, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, 1425 Madison Avenue, 6th Floor, New York City, NY, 10029, USA. John.Sfakianos@icahn.mssm.edu. LA - eng PT - Journal Article PT - Review DEP - 20201015 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Forecasting MH - Humans MH - Immunotherapy/*trends MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - Checkpoint inhibitors OT - Immunotherapy OT - Pembrolizumab OT - Recurrence OT - Urinary bladder neoplasms EDAT- 2020/10/16 06:00 MHDA- 2021/10/01 06:00 CRDT- 2020/10/15 17:38 PHST- 2020/07/17 00:00 [received] PHST- 2020/10/01 00:00 [accepted] PHST- 2020/10/16 06:00 [pubmed] PHST- 2021/10/01 06:00 [medline] PHST- 2020/10/15 17:38 [entrez] AID - 10.1007/s00345-020-03474-8 [pii] AID - 10.1007/s00345-020-03474-8 [doi] PST - ppublish SO - World J Urol. 2021 May;39(5):1319-1329. doi: 10.1007/s00345-020-03474-8. Epub 2020 Oct 15. PMID- 33049910 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201110 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 12 IP - 10 DP - 2020 Oct 8 TI - Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. LID - 10.3390/cancers12102882 [doi] LID - 2882 AB - Numerous pan-genomic studies identified alterations in protein-coding genes and signaling pathways involved in bladder carcinogenesis, while non-coding somatic alterations remain weakly explored. The goal of this study was to identify clinical biomarkers in non-coding regions for bladder cancer patients. We have previously identified in bladder tumors two non-coding mutational hotspots occurring at high frequencies (>/=30%). These mutations are located close to the GPR126 and PLEKHS1 genes, at the guanine or the cytosine of a TGAACA core motif flanked, on both sides, by a stretch of palindromic sequences. Here, we hypothesize that such a pattern of recurrent non-coding mutations could be a signature of somatic genomic instability specifically involved in bladder cancer. We analyzed 26 additional mutable non-coding sites with the same core motif in a cohort of 103 bladder cancers composed of 44 NMIBC cases and 59 MIBC cases using high-resolution melting (HRM) and Sanger sequencing. Five bladder cancers were additionally analyzed for protein-coding gene mutations using a targeted NGS panel composed of 571 genes. Expression levels of three members of the APOBEC3 family genes were assessed using real-time quantitative RT-PCR. Non-coding somatic mutations were observed for at least one TGAACA core motif locus in 62.1% (64/103) of bladder tumor samples. These non-coding mutations co-occurred in the bladder tumors but were absent in prostate tumor, HPV-positive Head and Neck Squamous Cell Carcinoma, and high microsatellite instability (MSI-H) colorectal tumor series. This signature of palindromic non-coding somatic mutations, specific to bladder tumors, was not associated with patients' outcome and was more frequent in females. Interestingly, this signature was associated with high tumor mutational burden (TMB) and high expression levels of APOBEC3B and interferon inducible genes. We identified a new type of somatic genomic instability targeting the TGAACA core motif loci flanked by palindromic sequences in bladder cancer. This mutational signature is a promising candidate clinical biomarker for the early detection of relapse and a major low-cost alternative to the TMB to monitor the response to immunotherapy for bladder cancer patients. FAU - Vacher, Sophie AU - Vacher S AUID- ORCID: 0000-0002-0042-6023 AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Suybeng, Voreak AU - Suybeng V AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Girard, Elodie AU - Girard E AD - Plateforme de Bioinformatique, Centre de Recherche de l'Institut Curie, F-75005 Paris, France. AD - INSERM U900 (Institut National de la Sante et de la Recherche Medicale), F-75005 Paris, France. FAU - Masliah Planchon, Julien AU - Masliah Planchon J AD - Unite de Genetique Somatique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Thomson, Gregory AU - Thomson G AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Le Goux, Constance AU - Le Goux C AUID- ORCID: 0000-0002-8543-4320 AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Garinet, Simon AU - Garinet S AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Schnitzler, Anne AU - Schnitzler A AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Chemlali, Walid AU - Chemlali W AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. FAU - Firlej, Virginie AU - Firlej V AUID- ORCID: 0000-0003-4132-0695 AD - TRePCa, Universite Paris Est Creteil, F-94010 Creteil, France. AD - Plateforme de ressources biologiques, AP-HP, Hopital Henri Mondor, F-94010 Creteil, France. FAU - Damotte, Diane AU - Damotte D AD - Service d'Anatomopathologie, Hopital Cochin, F-75014 Paris, France. AD - INSERM U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, F-75005 Paris, France. FAU - Allory, Yves AU - Allory Y AD - Departement de Pathologie, Institut Curie, F-92210 Saint-Cloud, France. FAU - Kamal, Maud AU - Kamal M AD - Institut Curie, Department of Drug Development and Innovation (D3i), Institut Curie Paris & Saint Cloud, F-75005 Paris, France. FAU - Pignot, Geraldine AU - Pignot G AD - Departement d'Urologie, Unite de Chirurgie Oncologique, Institut Paoli-Calmettes, F-13009 Marseille, France. FAU - Bieche, Ivan AU - Bieche I AD - Unite de Pharmacogenomique, Service de Genetique, Institut Curie, F-75005 Paris, France. AD - INSERM U1016, Universite Paris Descartes, F-75005 Paris, France. LA - eng PT - Journal Article DEP - 20201008 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7650671 OTO - NOTNLM OT - bladder cancer OT - clinical biomarkers OT - genomic instability signature OT - non-coding mutation COIS- The authors declare no potential conflicts of interest. EDAT- 2020/10/15 06:00 MHDA- 2020/10/15 06:01 PMCR- 2020/10/08 CRDT- 2020/10/14 01:02 PHST- 2020/09/24 00:00 [received] PHST- 2020/10/01 00:00 [revised] PHST- 2020/10/03 00:00 [accepted] PHST- 2020/10/14 01:02 [entrez] PHST- 2020/10/15 06:00 [pubmed] PHST- 2020/10/15 06:01 [medline] PHST- 2020/10/08 00:00 [pmc-release] AID - cancers12102882 [pii] AID - cancers-12-02882 [pii] AID - 10.3390/cancers12102882 [doi] PST - epublish SO - Cancers (Basel). 2020 Oct 8;12(10):2882. doi: 10.3390/cancers12102882. PMID- 33042546 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 2050-7771 (Print) IS - 2050-7771 (Electronic) IS - 2050-7771 (Linking) VI - 8 DP - 2020 TI - Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer. PG - 51 LID - 10.1186/s40364-020-00232-1 [doi] LID - 51 AB - BACKGROUND: Screening across a multitude of normal and malignant tissues revealed an enhanced expression of lymphocyte antigen 6 superfamily member D (LY6D) in squamous epithelium and urothelium, as well as in malignancies derived therefrom. The aim of this study was to further delineate the protein expression of LY6D in urothelial bladder cancer, with particular attention to its relationship with clinicopathological characteristics and patient outcome. METHODS: Immunohistochemical expression of LY6D was assessed in tissue microarrays with urothelial bladder cancer tumours from three independent patient cohorts; one with transurethral resection of the bladder (TURB) specimens of mixed tumour stages from 110 consecutive cases, one with tumours of mixed stages from 260 incident cases in a population-based cohort, and one with paired TURB specimens, resected tumours and a subset of lymph node metastases from 145 patients with muscle-invasive bladder cancer (MIBC). Chi-square and non-parametric tests were applied to examine associations of LY6D expression with clinicopathological characteristics. Kaplan-Meier and Cox regression analyses were applied to examine 5-year overall survival (OS) and recurrence free survival (RFS) in relation to LY6D expression. RESULTS: In the two cohorts with mixed stages, positive LY6D expression was denoted in 63 and 64% of the cases, respectively, and found to be significantly higher in low-grade and less invasive tumours. Negative LY6D expression was significantly associated with a reduced 5-year OS, although not independently of established prognostic factors. In the population-based cohort, LY6D expression was higher in tumours with squamous differentiation and lower in other variant histologies compared to pure urothelial tumours, and the association of LY6D expression with survival was somewhat enhanced after exclusion of the former. LY6D expression was generally lower in the MIBC cohort, and even more reduced in resected tumours compared to TURB specimens in patients who had not received neoadjuvant chemotherapy. There were no significant associations between LY6D expression and RFS, neither allover nor in relation to neoadjuvant chemotherapy. CONCLUSION: LY6D is a marker of urothelial and squamous differentiation that may add useful diagnostic and prognostic information to better guide the clinical management of bladder cancer, given that the presence of variant histology is taken into account. CI - (c) The Author(s) 2020. FAU - Andersson, Nina AU - Andersson N AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Ohlsson, Johan AU - Ohlsson J AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Wahlin, Sara AU - Wahlin S AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Nodin, Bjorn AU - Nodin B AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Boman, Karolina AU - Boman K AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Lundgren, Sebastian AU - Lundgren S AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 FAU - Jirstrom, Karin AU - Jirstrom K AUID- ORCID: 0000-0003-2257-5000 AD - Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund, Lund University, SE-221 85 Lund, Sweden. GRID: grid.4514.4. ISNI: 0000 0001 0930 2361 LA - eng PT - Journal Article DEP - 20201007 PL - England TA - Biomark Res JT - Biomarker research JID - 101607860 PMC - PMC7539380 OTO - NOTNLM OT - Differentiation OT - Lymphocyte antigen 6 superfamily member D OT - Prognosis OT - Urinary bladder cancer OT - Urothelial cancer COIS- Competing interestsThe authors declare that they have no competing interests. EDAT- 2020/10/13 06:00 MHDA- 2020/10/13 06:01 PMCR- 2020/10/07 CRDT- 2020/10/12 05:30 PHST- 2020/07/07 00:00 [received] PHST- 2020/09/30 00:00 [accepted] PHST- 2020/10/12 05:30 [entrez] PHST- 2020/10/13 06:00 [pubmed] PHST- 2020/10/13 06:01 [medline] PHST- 2020/10/07 00:00 [pmc-release] AID - 232 [pii] AID - 10.1186/s40364-020-00232-1 [doi] PST - epublish SO - Biomark Res. 2020 Oct 7;8:51. doi: 10.1186/s40364-020-00232-1. eCollection 2020. PMID- 33040478 OWN - NLM STAT- MEDLINE DCOM- 20210719 LR - 20250623 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 9 IP - 21 DP - 2020 Nov TI - Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. PG - 7800-7809 LID - 10.1002/cam4.3513 [doi] AB - Intravesical instillation therapy is the mainstay of prophylaxis of tumor recurrence and progression in non-muscle-invasive bladder cancer. However, there is no study evaluating the superiority of monotherapy. The aim of this study is to compare the efficacy of preventing recurrence and progression of intravesical monotherapies via network meta-analysis (NMA) of randomized controlled trials. Database searches were conducted on Embase, Ovid Medline, Web of Science, ScienceDirect, Cochrane Library, and ClinicalTrials.com from the time of establishment to February 6, 2020. The monotherapies included Bacille Calmette-Guerin (BCG), mitomycin C (MMC), interferon (IFN), adriamycin, epirubicin, gemcitabine (GEM), and thiotepa (THP). A Bayesian consistency network model was generated under a random-effects model. The superiority of therapy was identified based on the surface under the cumulative ranking curve (SUCRA). Fifty-seven studies with 12462 patients are included. NMA shows that GEM (SUCRA = 0.92), BCG (SUCRA = 0.82), and IFN (SUCRA = 0.78) are the top three effective drugs to reduce recurrence. GEM (SUCRA = 0.87) is the most effective therapy to prevent progress, followed by BCG, MMC, THP, and IFN with similar efficacy. Subgroup analysis of pairwise meta-analysis and NMA was performed on publication year, trial initiation year, study origin, center involvement, sample size, drug schedule, tumor characteristics, and trial quality to address confounding factors, which suggests the robustness of the results with stable effect sizes. Network meta-regression also indicates consistent rank by analyzing year, sample size, and quality. Compared with BCG, GEM is also a promising therapy with favorable efficacy to reduce tumor recurrence and progression. IFN and MMC could be alternative therapies for BCG with slightly inferior efficacy in recurrence prevention and similar efficacy in progression prevention. However, the results of this study should be treated with caution since most of the included studies are of moderate to high risk of bias. CI - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Lu, Jun-Lin AU - Lu JL AUID- ORCID: 0000-0002-3438-0297 AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xia, Qi-Dong AU - Xia QD AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Lu, Ying-Hong AU - Lu YH AD - Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China. FAU - Liu, Zheng AU - Liu Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhou, Peng AU - Zhou P AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Heng-Long AU - Hu HL AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Shao-Gang AU - Wang SG AUID- ORCID: 0000-0002-3206-1495 AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20201011 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Antineoplastic Agents) SB - IM EIN - Cancer Med. 2021 Aug;10(16):5722. doi: 10.1002/cam4.4174. PMID: 34397156 MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - Clinical Trials as Topic MH - Disease Progression MH - Humans MH - Neoplasm Metastasis MH - *Neoplasm Recurrence, Local MH - Progression-Free Survival MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology PMC - PMC7643689 COIS- The authors have no conflict of interest to disclose. EDAT- 2020/10/12 06:00 MHDA- 2021/07/20 06:00 PMCR- 2020/10/11 CRDT- 2020/10/11 20:38 PHST- 2020/07/31 00:00 [received] PHST- 2020/09/16 00:00 [revised] PHST- 2020/09/17 00:00 [accepted] PHST- 2020/10/12 06:00 [pubmed] PHST- 2021/07/20 06:00 [medline] PHST- 2020/10/11 20:38 [entrez] PHST- 2020/10/11 00:00 [pmc-release] AID - CAM43513 [pii] AID - 10.1002/cam4.3513 [doi] PST - ppublish SO - Cancer Med. 2020 Nov;9(21):7800-7809. doi: 10.1002/cam4.3513. Epub 2020 Oct 11. PMID- 33032922 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20211214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 5 DP - 2021 May TI - Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-Does it complicate surgery and adversely impact oncological outcome? PG - 300.e15-300.e20 LID - S1078-1439(20)30438-5 [pii] LID - 10.1016/j.urolonc.2020.09.016 [doi] AB - INTRODUCTION: The standard intravesical treatment for high risk non muscle invasive bladder cancer (HRNMIBC) is Bacillus Calmette-Guerin (BCG), with failure often resulting in cystectomy. Radiofrequency-Induced Thermo-chemotherapeutic Effect Mitomycin (RITE-MMC) can be an alternative in BCG failure. There has been concern that RITE-MMC may delay an inevitable cystectomy, make it more technically challenging and worsen prognosis. The aim of this study was to assess operative challenges and oncological outcome in patients undergoing cystectomy for HRNMIBC who received RITE-MMC, and contrast them with those that did not. PATIENTS AND METHODS: A retrospective study of a prospective cystectomy database was conducted. Patients treated from April 2011 to June 2017 were looked at. Inclusion criteria were HRNMIBC with BCG failure undergoing cystectomy. Patient demographics and tumour characteristics were analysed. Intraoperative blood loss and length of stay were used as surrogate markers for intra-operative difficulty. Kaplan-Meier curves were constructed to analyse all-cause mortality, cancer specific mortality and time to recurrence between the RITE-MMC treatment group and those that did not receive RITE-MMC. A multivariate analysis was conducted to assess factors that may influence readmission. RESULTS: Thirty-six patients who received RITE-MMC underwent cystectomy, compared to 102 that did not. Median ages were comparable at 72 and 69 years, respectively. Patients were followed up for a median of 24 months across the 2 groups. The commonest histological stage in both groups was CIS. There were no significant differences in intraoperative blood loss, length of stay and 90-day readmission between the 2 groups. There were proportionally fewer recurrences in the RITE-MMC group (16% vs. 19%) and median time to recurrence was longer in the RITE-MMC group (37 months vs. 24 months). Multivariate analysis did not reveal a significant correlation between pre-op RITE-MMC and post-operative readmission (P = 0.606). Survival curves show no significant difference in time to recurrence across both groups (P = 0.513), and no overall (P = 0.069) or cancer specific mortality (P = 0.129) dis-advantage was noted in the RITE-MMC group. CONCLUSION: We have found that RITE-MMC treatment does not result in a technically more challenging cystectomy and does not compromise oncological outcome compared to those patients undergoing cystectomy immediately post-BCG failure. We feel RITE-MMC remains a useful tool in a carefully selected group of patients who may not be willing to accept the morbidity of a cystectomy at the time, without significantly compromising their long-term outcome. CI - Crown Copyright (c) 2020. Published by Elsevier Inc. All rights reserved. FAU - Sri, Denosshan AU - Sri D AD - St George's University Hospitals NHS Foundation Trust, London. Electronic address: denosshansri@gmail.com. FAU - Lee, Hack Jae AU - Lee HJ AD - St George's University Hospitals NHS Foundation Trust, London. FAU - El-Gemmal, Sarah AU - El-Gemmal S AD - St George's University Hospitals NHS Foundation Trust, London. FAU - Backhouse, Chris AU - Backhouse C AD - St George's University Hospitals NHS Foundation Trust, London. FAU - Tay, Andrea AU - Tay A AD - St George's University Hospitals NHS Foundation Trust, London. FAU - John, Babbin AU - John B AD - St George's University Hospitals NHS Foundation Trust, London. FAU - Perry, Matthew J AU - Perry MJ AD - St George's University Hospitals NHS Foundation Trust, London. FAU - Ayres, Benjamin E AU - Ayres BE AD - St George's University Hospitals NHS Foundation Trust, London. FAU - Issa, Rami AU - Issa R AD - St George's University Hospitals NHS Foundation Trust, London. LA - eng PT - Journal Article DEP - 20201006 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/therapeutic use MH - Combined Modality Therapy MH - *Cystectomy MH - Female MH - Humans MH - Hyperthermia, Induced MH - Male MH - Middle Aged MH - Mitomycin/therapeutic use MH - Neoplasm Invasiveness MH - Radiofrequency Therapy MH - Retrospective Studies MH - Risk Assessment MH - Treatment Failure MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery/therapy OTO - NOTNLM OT - CIS OT - Cystectomy OT - HRNMIBC OT - Hyperthermic mitomycin OT - RITE-mitomycin OT - Radiofrequency-induced hyperthermic effect EDAT- 2020/10/10 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/10/09 05:30 PHST- 2020/07/14 00:00 [received] PHST- 2020/09/02 00:00 [revised] PHST- 2020/09/19 00:00 [accepted] PHST- 2020/10/10 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/10/09 05:30 [entrez] AID - S1078-1439(20)30438-5 [pii] AID - 10.1016/j.urolonc.2020.09.016 [doi] PST - ppublish SO - Urol Oncol. 2021 May;39(5):300.e15-300.e20. doi: 10.1016/j.urolonc.2020.09.016. Epub 2020 Oct 6. PMID- 33029425 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 18 IP - 3 DP - 2020 Apr 17 TI - Can frozen-section analysis of ureteric margins at the time of radical cystectomy predict upper tract recurrence? PG - 155-162 LID - 10.1080/2090598X.2020.1751923 [doi] AB - OBJECTIVE: To summarise the currently available literature and analyse available results of the outcome of intraoperative frozen-section analysis (FSA) on upper urinary tract recurrence (UUTR) after radical cystectomy (RC). MATERIALS AND METHODS: A systematic review of the literature was performed according to the Cochrane Reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Articles discussing ureteric FSA with RC were identified. RESULTS: The literature search yielded 21 studies, on which the present analysis was done. The studies were published between 1997 and 2019. There were 10 010 patients with an age range between 51 and 95 years. Involvement of the ureteric margins was noted in 2-9% at RC. The sensitivity and specificity of FSA were ~75% and 99%, respectively. Adverse pathology on FSA and on permanent section, prostatic urothelial carcinoma involving the stroma but not prostatic duct, and ureteric involvement on permanent section were all more likely to develop UUTR. Neither evidence of ureteric involvement nor ureteric margin status on permanent section were significant predictors of overall survival. CONCLUSION: Routine FSA is mandatory for a tumour-free uretero-enteric anastomosis and is predictive of UUTR. To lower the UUTR, FSA is not necessary if the ureters are resected at the level where they cross the common iliac vessels. FSA is indicated whenever the surgeon encounters findings suspicious of malignancy, e.g. ureteric obstruction, periureteric fibrosis, diffuse carcinoma in situ, induration or frank tumour infiltration of the distal ureter is discovered unexpectedly during surgery, and prostatic urethral involvement. ABBREVIATIONS: CIS: carcinoma in situ; FSA: frozen-section analysis; HR: hazard ratio; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RC: radical cystectomy; (UT)UC: (upper tract) urothelial carcinoma; UUT(R): upper urinary tract (recurrence). CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Soliman, Karim AU - Soliman K AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Taha, Diaa-Eldin AU - Taha DE AD - Department of Urology, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt. FAU - Aboumarzouk, Omar M AU - Aboumarzouk OM AD - Glasgow Urological Research Unit, Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK. AD - School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK. FAU - Koraiem, Islam Osama AU - Koraiem IO AD - Department of Urology, Damanhour International Medical Institute, Beheira, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20200417 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7473000 OTO - NOTNLM OT - Bladder cancer OT - frozen-section analysis OT - radical cystectomy OT - upper urinary tract recurrence COIS- The authors declare that they have no competing interests. EDAT- 2020/10/09 06:00 MHDA- 2020/10/09 06:01 PMCR- 2020/01/01 CRDT- 2020/10/08 05:33 PHST- 2020/10/08 05:33 [entrez] PHST- 2020/10/09 06:00 [pubmed] PHST- 2020/10/09 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 1751923 [pii] AID - 10.1080/2090598X.2020.1751923 [doi] PST - epublish SO - Arab J Urol. 2020 Apr 17;18(3):155-162. doi: 10.1080/2090598X.2020.1751923. PMID- 33029409 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 18 IP - 2 DP - 2020 Mar 1 TI - The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review. PG - 67-71 LID - 10.1080/2090598X.2020.1733818 [doi] AB - OBJECTIVE: To evaluate the role of the Vesical Imaging-Reporting and Data System (VI-RADS) score in the diagnostic pathway of bladder cancer. METHODS: A systemic search of the contemporary literature was performed in December 2019 using the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), and Web of Science databases focussing on all available articles on VI-RADS. RESULTS: Overall, six of 15 articles were included. All the available articles evaluated the ability of radiologists to use the VI-RADS score for discriminating non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC). Considering a cut-off VI-RADS score of >2, the sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were 78-91.9%, 85-91%.1, 69-78%, and 88-97.1%, respectively. Considering a VI-RADS score cut-off of >3, the sensitivity, specificity, PPV and NPV were 77-94.6%, 43.9-96.5%, 51.6-86%, and 63.7-93%, respectively. Good interobserver agreement was demonstrated in the evaluated studies with a kappa score of 0.73-0.89. Only one study evaluated the utility of VI-RADS in determining the presence of MIBC in patients treated with transurethral resection of the bladder diagnosed with high-grade T1 before the second transurethral resection using a VI-RADS score cut-off of >2; the sensitivity, specificity, PPV and NPV were 85%, 93.6%, 74.5%, and 96.6%, respectively. CONCLUSION: The VI-RADS score, using multiparametric magnetic resonance imaging, showed excellent results in discriminating MIBC from NMIBC. Preliminary results have been reported for its use in patients with high-grade T1 bladder cancer. These results need to be validated in high-quality real-world settings. ABBREVIATIONS: DCE: dynamic contrast enhancement; DWI: diffusion-weighted imaging; (N)MIBC: (non-)muscle-invasive bladder cancer; mpMRI: multiparametric MRI; TURBT: transurethral resection of bladder tumour; (N)(P)PV: (negative) (positive) predictive value; SC: structural category; T2W: T2-weighted; VI-RADS: vesical imaging-reporting and data system. CI - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Carando, Roberto AU - Carando R AD - Department of Urology, Clinica Luganese Moncucco, Lugano, Switzerland. AD - Clinica S. Anna, Swiss Medical Group, Sorengo, Switzerland. AD - Ward of Surgery and Urology, Clinica S. Chiara, Locarno, Switzerland. AD - Department of Urology, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Pagliarulo, Vincenzo AU - Pagliarulo V AD - Department of Urology, University "Aldo Moro", Bari, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology Bichat Hospital, Paris Descartes University, Paris, France. FAU - Cathelineau, Xavier AU - Cathelineau X AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Sanchez-Salas, Rafael AU - Sanchez-Salas R AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Moschini, Marco AU - Moschini M AUID- ORCID: 0000-0002-3084-2458 AD - Department of Urology, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20200301 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC7473244 OTO - NOTNLM OT - Radical cystectomy OT - VI-RADS OT - muscle-invasive bladder cancer OT - urothelial carcinoma COIS- The authors declare that they have no conflicts of interest. EDAT- 2020/10/09 06:00 MHDA- 2020/10/09 06:01 PMCR- 2020/01/01 CRDT- 2020/10/08 05:33 PHST- 2020/10/08 05:33 [entrez] PHST- 2020/10/09 06:00 [pubmed] PHST- 2020/10/09 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 1733818 [pii] AID - 10.1080/2090598X.2020.1733818 [doi] PST - epublish SO - Arab J Urol. 2020 Mar 1;18(2):67-71. doi: 10.1080/2090598X.2020.1733818. PMID- 33025406 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 53 IP - 3 DP - 2021 Mar TI - Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ? PG - 465-469 LID - 10.1007/s11255-020-02667-9 [doi] AB - PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) is the standard of care for bladder carcinoma in situ (CIS). The response to BCG therapy against CIS is generally assessed by random bladder biopsy (RBB). In this study, we examined the necessity of routine RBB after BCG therapy. METHODS: We retrospectively identified 102 patients who were initially diagnosed with CIS with or without papillary tumor and received subsequent 6-8-week BCG therapy. Thereafter, all patients underwent voiding cytology analysis, cystoscopy, and RBB to evaluate the effects of BCG therapy. We evaluated the association between clinical parameters (voiding cytology and cystoscopy findings) and the final pathological results by RBB specimens. RESULTS: According to the pathological results of RBB, 30 (29%) patients had BCG-unresponsive disease (remaining urothelial carcinoma was confirmed pathologically) and 20 were diagnosed with CIS. Positive/suspicious voiding cytology and positive cystoscopy findings were well observed in patients who had BCG-unresponsive disease compared with their counterparts (p = 0.116, and p < 0.001, respectively). The sensitivity (Sen.), specificity (Spe.), positive predictive value (PPV), and negative predictive value (NPV) of voiding cytology were 50%, 68%, 39%, and 77%, respectively. The values for cystoscopy findings were as follows: Sen.: 87%, Spe.: 57%, PPV: 46%, and NPV: 91%. The values for their combination (having either of them) were as follows: Sen.: 100%, Spe.: 44%, PPV: 43%, and NPV: 100%. CONCLUSION: RBB after BCG therapy for patients with negative voiding cytology and negative cystoscopy may be omitted because their risk of BCG-unresponsive disease is significantly low (NPV: 100%). FAU - Takamatsu, Kimiharu AU - Takamatsu K AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AUID- ORCID: 0000-0001-9222-0999 AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. kazz_matsumoto@yahoo.co.jp. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Hayakawa, Nozomi AU - Hayakawa N AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Takeda, Toshikazu AU - Takeda T AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Morita, Shinya AU - Morita S AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Kosaka, Takeo AU - Kosaka T AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Asanuma, Hiroshi AU - Asanuma H AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. FAU - Mikami, Shuji AU - Mikami S AD - Department of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 1608582, Japan. LA - eng GR - JP18K09179/the Japan Society for the Promotion of Science KAKENHI/ PT - Journal Article DEP - 20201006 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Biopsy/methods MH - Carcinoma in Situ/*drug therapy/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/*pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Carcinoma in situ OT - Voiding cytology EDAT- 2020/10/08 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/10/07 05:54 PHST- 2020/07/07 00:00 [received] PHST- 2020/09/25 00:00 [accepted] PHST- 2020/10/08 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/10/07 05:54 [entrez] AID - 10.1007/s11255-020-02667-9 [pii] AID - 10.1007/s11255-020-02667-9 [doi] PST - ppublish SO - Int Urol Nephrol. 2021 Mar;53(3):465-469. doi: 10.1007/s11255-020-02667-9. Epub 2020 Oct 6. PMID- 33024200 OWN - NLM STAT- MEDLINE DCOM- 20210308 LR - 20211006 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Oct 6 TI - Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. PG - 16641 LID - 10.1038/s41598-020-73642-8 [doi] LID - 16641 AB - This study evaluated the prognostic value of a panel of 29 oncogenes derived from the analysis of The Cancer Genome Atlas (TCGA data) or from the recent literature on bladder tumors on a well-characterized series of muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) samples and tried to identify molecular prognostic markers. Mutations of HRAS, FGFR3, PIK3CA and TERT were found in 2.9%, 27.2%, 14.9% and 76.7% of tumor samples, respectively. Concerning NMIBC, on multivariate analysis, RXRA and FGFR3 levels were associated with recurrence-free survival (RFS) (p = 0.0022 and p = 0.0069) and RXRA level was associated with progression to muscle-invasive disease (p = 0.0068). We identified a 3-gene molecular signature associated with NMIBC prognosis. FGFR3 overexpression was associated with reduced response to Bacillus Calmette-Guerin treatment (p = 0.037). As regards MIBC, on multivariate analysis, ERCC2 overexpression was associated with RFS (p = 0.0011) and E2F3 and EGFR overexpression were associated with overall survival (p = 0.014 and p = 0.035). RT-PCR findings were confirmed by IHC for FGFR3. Genomic alterations in MIBC revealed in TCGA data also concern NMIBC and seem to be associated with prognosis in terms of recurrence and progression. Correcting these alterations by targeted therapies seems a promising pharmacological approach. FAU - Le Goux, Constance AU - Le Goux C AD - Pharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France. constance.legoux@gmail.com. AD - Department of Urology, Bicetre Hospital, Paris Sud University, 78 rue du General Leclerc, 94270, Le Kremlin-Bicetre, France. constance.legoux@gmail.com. FAU - Vacher, Sophie AU - Vacher S AD - Pharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France. FAU - Schnitzler, Anne AU - Schnitzler A AD - Pharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France. FAU - Barry Delongchamps, Nicolas AU - Barry Delongchamps N AD - Department of Urology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Zerbib, Marc AU - Zerbib M AD - Department of Urology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Peyromaure, Michael AU - Peyromaure M AD - Department of Urology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Sibony, Mathilde AU - Sibony M AD - Department of Pathology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Curie Institute, Paris, France. FAU - Bieche, Ivan AU - Bieche I AD - Pharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France. AD - Inserm U1016, Cochin Institute, University Paris Descartes, Paris, France. FAU - Damotte, Diane AU - Damotte D AD - Department of Pathology, Cochin Hospital, Paris Descartes University, Paris, France. AD - Cancer, Immune Control, and Escape, INSERM U1138, Cordeliers Research Center, Paris, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. LA - eng PT - Journal Article DEP - 20201006 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) RN - 0 (RXRA protein, human) RN - 0 (Retinoid X Receptor alpha) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) RN - EC 3.6.5.2 (HRAS protein, human) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) SB - IM MH - Aged MH - BCG Vaccine/therapeutic use MH - Class I Phosphatidylinositol 3-Kinases/*genetics/metabolism MH - *Databases, Genetic MH - Disease Progression MH - Female MH - Gene Expression/*genetics MH - Humans MH - Male MH - Middle Aged MH - Mutation/*genetics MH - Neoplasm Invasiveness/genetics MH - Neoplasm Recurrence, Local/*genetics MH - *Oncogenes MH - Prognosis MH - Proto-Oncogene Proteins p21(ras)/*genetics/metabolism MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics/metabolism MH - Retinoid X Receptor alpha/genetics/metabolism MH - Survival Rate MH - Telomerase/genetics/metabolism MH - Urinary Bladder Neoplasms/*genetics/mortality/*pathology/therapy PMC - PMC7538919 COIS- The authors declare no competing interests. EDAT- 2020/10/08 06:00 MHDA- 2021/03/09 06:00 PMCR- 2020/10/06 CRDT- 2020/10/07 05:46 PHST- 2019/11/11 00:00 [received] PHST- 2020/09/17 00:00 [accepted] PHST- 2020/10/07 05:46 [entrez] PHST- 2020/10/08 06:00 [pubmed] PHST- 2021/03/09 06:00 [medline] PHST- 2020/10/06 00:00 [pmc-release] AID - 10.1038/s41598-020-73642-8 [pii] AID - 73642 [pii] AID - 10.1038/s41598-020-73642-8 [doi] PST - epublish SO - Sci Rep. 2020 Oct 6;10(1):16641. doi: 10.1038/s41598-020-73642-8. PMID- 33021430 OWN - NLM STAT- MEDLINE DCOM- 20210401 LR - 20210401 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 205 IP - 3 DP - 2021 Mar TI - Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer. PG - 693-700 LID - 10.1097/JU.0000000000001372 [doi] AB - PURPOSE: The presence of detrusor muscle is essential for accurate staging of T1 cancers. Detrusor muscle presence can be a quality indicator of transurethral resection of bladder tumor for nonmuscle invasive bladder cancer. We hypothesized that increasing surgeon awareness of personal and institutional detrusor muscle sampling rates could improve resection quality and long-term oncologic outcomes. MATERIALS AND METHODS: A retrospective review of transurethral resections of bladder tumor from 1/2006 to 2/2018 was performed. The presence of detrusor muscle in the pathology report and transurethral resection specimen were extracted from records. Individual surgeon scorecards were created and distributed. Rates of detrusor muscle sampling were compared prior to and 12 months after distribution. Chart review was done to compare 3-year recurrence and progression outcomes before and after distribution of scorecards. RESULTS: The rate of detrusor muscle sampling increased from 36% (1,250/3,488) to 54% (202/373) (p=0.001) in the 12 months after scorecard distribution, ie from 30% (448/1,500) to 55% (91/165) (p <0.001) in Ta tumors and from 47% (183/390) to 72% (42/58) (p <0.001) in T1 tumors. Pathological reporting of muscle also improved for all samples (73%, 2,530/3,488 to 90%, 334/373, p <0.001), Ta (75%, 1,127/1,500 to 94%, 155/165, p <0.001) and T1 (93%, 362/390 to 100%, 58/58, p=0.04). On multivariate Cox regression analysis, the surgeon scorecard was associated with decreased 3-year risk of recurrence (HR 0.63, 95% CI 0.40-0.99). CONCLUSIONS: Creation and distribution of individual surgeon scorecards improved detrusor muscle sampling on transurethral resection and was associated with decreased risk of disease recurrence. Quality evaluation of transurethral resection of bladder tumor may contribute to improved outcomes of patients with nonmuscle invasive bladder cancer. FAU - Das, Arighno AU - Das A AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. AD - Department of Urology, Northwestern University Feinberg School of Medicine, Jesse Brown VAMC, Chicago, Illinois. FAU - Cohen, Jason E AU - Cohen JE AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Ko, Oliver S AU - Ko OS AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Jordan, Brian J AU - Jordan BJ AD - Department of Urology, University of Washington, Seattle, Washington. FAU - Glaser, Alexander P AU - Glaser AP AD - Division of Urology, Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois. FAU - Auffenberg, Gregory B AU - Auffenberg GB AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. LA - eng PT - Comparative Study PT - Journal Article DEP - 20201006 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2021 Mar;205(3):700. doi: 10.1097/JU.0000000000001372.01. PMID: 33369508 CIN - J Urol. 2021 Mar;205(3):717. doi: 10.1097/JU.0000000000001412.01. PMID: 33399490 MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Muscle, Smooth/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Specimen Handling/*standards MH - Time Factors MH - Treatment Outcome MH - Urethra MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Urology/*standards OTO - NOTNLM OT - cystoscopy OT - neoplasm staging OT - quality improvement OT - urinary bladder neoplasms EDAT- 2020/10/07 06:00 MHDA- 2021/04/02 06:00 CRDT- 2020/10/06 12:17 PHST- 2020/10/07 06:00 [pubmed] PHST- 2021/04/02 06:00 [medline] PHST- 2020/10/06 12:17 [entrez] AID - 10.1097/JU.0000000000001372 [doi] PST - ppublish SO - J Urol. 2021 Mar;205(3):693-700. doi: 10.1097/JU.0000000000001372. Epub 2020 Oct 6. PMID- 33021428 OWN - NLM STAT- MEDLINE DCOM- 20210401 LR - 20210401 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 205 IP - 3 DP - 2021 Mar TI - Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful? PG - 686-692 LID - 10.1097/JU.0000000000001373 [doi] AB - PURPOSE: The Vesical Imaging Reporting and Data System (VI-RADS) was launched in 2018 to standardize reporting of magnetic resonance imaging for bladder cancer. This study aimed to prospectively validate VI-RADS using a next-generation magnetic resonance imaging scanner and to investigate the usefulness of denoising deep learning reconstruction. MATERIALS AND METHODS: We prospectively enrolled 98 patients who underwent bladder multiparametric magnetic resonance imaging using a next-generation magnetic resonance imaging scanner before transurethral resection of bladder tumor. Tumors were categorized according to VI-RADS, and we ultimately analyzed 68 patients with pathologically confirmed urothelial bladder cancer. We used receiving operating characteristic curve analyses to assess the predictive accuracy of VI-RADS for muscle invasion. Sensitivity, specificity, positive/negative predictive value, accuracy and area under the curve were calculated for different VI-RADS score cutoffs. RESULTS: Muscle invasion was detected in the transurethral resection of bladder tumor specimens of 18 patients (26%). The optimal cutoff value of the VI-RADS score was determined as >/=4 based on the receiver operating curve analyses. The accuracy of diagnosing muscle invasion using a cutoff of VI-RADS >/=4 was 94% (AUC 0.92). Additionally, we assessed the utility of denoising deep learning reconstruction. Combination with denoising deep learning reconstruction significantly improved the AUC of category by T2-weighted imaging, and of the 4 patients who were misdiagnosed by the final VI-RADS score 3 were correctly diagnosed by T2-weighted imaging+denoising deep learning reconstruction. CONCLUSIONS: In this prospective validation study with a next-generation magnetic resonance imaging scanner, VI-RADS showed high predictive accuracy for muscle invasion in patients with bladder cancer before transurethral resection of bladder tumor. Combining T2-weighted imaging with denoising deep learning reconstruction might further improve the diagnostic accuracy of VI-RADS. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Tambo, Mitsuhiro AU - Tambo M AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Watanabe, Masanaka AU - Watanabe M AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Machida, Haruhiko AU - Machida H AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Kariyasu, Toshiya AU - Kariyasu T AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Fukushima, Keita AU - Fukushima K AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Shimizu, Yuta AU - Shimizu Y AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Okegawa, Takatsugu AU - Okegawa T AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Yokoyama, Kenichi AU - Yokoyama K AD - Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20201006 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*diagnostic imaging MH - *Deep Learning MH - Female MH - Humans MH - Male MH - *Multiparametric Magnetic Resonance Imaging/instrumentation MH - Noise MH - Predictive Value of Tests MH - Prospective Studies MH - Research Design MH - Urinary Bladder Neoplasms/*diagnostic imaging OTO - NOTNLM OT - deep learning OT - magnetic resonance imaging OT - prospective studies OT - urinary bladder neoplasms EDAT- 2020/10/07 06:00 MHDA- 2021/04/02 06:00 CRDT- 2020/10/06 12:17 PHST- 2020/10/07 06:00 [pubmed] PHST- 2021/04/02 06:00 [medline] PHST- 2020/10/06 12:17 [entrez] AID - 10.1097/JU.0000000000001373 [doi] PST - ppublish SO - J Urol. 2021 Mar;205(3):686-692. doi: 10.1097/JU.0000000000001373. Epub 2020 Oct 6. PMID- 33020030 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220428 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 5 DP - 2021 Sep TI - Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. PG - 1067-1074 LID - S2405-4569(20)30268-6 [pii] LID - 10.1016/j.euf.2020.09.009 [doi] AB - BACKGROUND: A prospective randomized trial (LEA AUO AB 25/02) found no survival benefit in extended compared with limited pelvic lymph node dissection (PLND) templates in bladder cancer (BCa) patients treated with radical cystectomy (RC). However, the rate of lymph node invasion (LNI) in the standard and extended templates was lower than estimated. OBJECTIVE: To assess the accuracy of preoperative clinical and pathological parameters to predict LNI and to develop a model to preoperatively select candidates for the extended PLND templates. DESIGN, SETTING, AND PARTICIPANTS: A total of 903 BCa patients treated at a single institution were retrospectively identified. The primary outcome was to identify preoperatively the risk of LNI to tailor the type of PLND. The extended PLND templates consisted in the removal of pelvic lymph nodes together with the common iliac, presacral, para-aortocaval, interaortocaval, and paracaval sites up to the inferior mesenteric artery. INTERVENTION: A total of 903 BCa patients were treated with RC and bilateral extended PLND templates. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Several models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots and decision curve analyses. A nomogram predicting LNI in the extended pattern was developed and validated internally. RESULTS AND LIMITATIONS: Overall, 55 patients (6.1%) had LNI in the extended PLND templates at RC. The median number of nodes removed was 19 (interquartile range: 13-26). A model including age, clinical T stage, clinical node stage, lymphovascular invasion, and presence of carcinoma in situ at the last transurethral resection before RC was developed. The AUC of this model is 73%. Using a cutoff of 3%, 108 extended PLNDs (12%) would be spared and only two LNIs (3%) would be missed. The main limitations of our model are the retrospective nature of the data, lack of external validation, and low rate of LNI. CONCLUSIONS: This is the first proposed model to predict LNI in the extended PLND templates. This model might help urologists identify which patients might benefit from an extended PLND at the time of RC, reserving a standard PLND for all the others. PATIENT SUMMARY: We developed the first nomogram to predict lymph node invasion (LNI) in the extended pelvic lymph node dissection templates in bladder cancer patients treated with radical cystectomy. The adoption of our model to identify candidates for the extended pelvic lymph node dissection templates could avoid up to 12% of these procedures at the cost of missing only 3% of patients with LNI. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: marco.moschini87@gmail.com. FAU - Afferi, Luca AU - Afferi L AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Zamboni, Stefania AU - Zamboni S AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Di Bona, Carlo AU - Di Bona C AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mordasini, Livio AU - Mordasini L AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Baumeister, Philipp AU - Baumeister P AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Martini, Alberto AU - Martini A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Burgio, Giusy AU - Burgio G AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Sanchez-Salas, Rafael AU - Sanchez-Salas R AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Cathelineau, Xavier AU - Cathelineau X AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Stabile, Armando AU - Stabile A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Zaffuto, Emanuele AU - Zaffuto E AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Necchi, Andrea AU - Necchi A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20201002 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - *Cystectomy MH - Humans MH - Lymph Node Excision/methods MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/pathology/surgery OTO - NOTNLM OT - *Bladder cancer OT - *Extended lymph node dissection OT - *Lymph node dissection OT - *Nomogram OT - *Radical cystectomy OT - *Urothelial cancer EDAT- 2020/10/07 06:00 MHDA- 2022/04/14 06:00 CRDT- 2020/10/06 05:25 PHST- 2020/06/14 00:00 [received] PHST- 2020/09/07 00:00 [revised] PHST- 2020/09/18 00:00 [accepted] PHST- 2020/10/07 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2020/10/06 05:25 [entrez] AID - S2405-4569(20)30268-6 [pii] AID - 10.1016/j.euf.2020.09.009 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Sep;7(5):1067-1074. doi: 10.1016/j.euf.2020.09.009. Epub 2020 Oct 2. PMID- 33008753 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 4 DP - 2021 Apr TI - Setting the stage for bladder preservation. PG - 209-212 LID - S1078-1439(20)30421-X [pii] LID - 10.1016/j.urolonc.2020.09.001 [doi] AB - There is an underutilization of potentially curative treatments for patients with muscle-invasive bladder cancer. Contemporary trimodality bladder-preservation therapy - which includes a maximally safe transurethral resection of the bladder tumor followed by concurrent chemoradiation and close cystoscopic surveillance with salvage cystectomy reserved for invasive tumor recurrence - can help fulfill this unmet need. Over the past few decades, cumulative published data from prospective clinical trials and large institutional series have established trimodality therapy (TMT) for select patients as a safe and effective alternative to upfront cystectomy. Indeed, TMT is now supported as an accepted option for muscle-invasive bladder cancer patients by numerous clinical guidelines. Following TMT, the vast majority of long-term survivors maintain their native bladders, which tend to function well with relatively low rates of long-term toxicity and good long-term quality of life. There is the potential to further improve outcomes by optimizing systemic therapy integration and by validating predictive biomarkers for improved patient and treatment selection. TMT offers a unique opportunity for urologic surgeons, radiation oncologists and medical oncologists to work hand-in-hand in a multidisciplinary effort to deliver such therapy optimally, to support its research, to promote informed decision-making and ultimately to preserve the autonomy of patients with bladder cancer. The third annual meeting of the Johns Hopkins Greenberg Bladder Cancer Institute/American Urological Association Translational Research Collaboration allowed bladder cancer experts to meet and advance this mission. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: pblack@mail.ubc.ca. FAU - Efstathiou, Jason AU - Efstathiou J AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. LA - eng PT - Journal Article PT - Review DEP - 20200930 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Carcinoma, Transitional Cell/*surgery MH - *Cystectomy MH - Humans MH - *Organ Sparing Treatments OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Quality of life OT - Radiation therapy OT - Radical cystectomy EDAT- 2020/10/04 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/10/03 05:25 PHST- 2020/08/12 00:00 [received] PHST- 2020/09/02 00:00 [accepted] PHST- 2020/10/04 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/10/03 05:25 [entrez] AID - S1078-1439(20)30421-X [pii] AID - 10.1016/j.urolonc.2020.09.001 [doi] PST - ppublish SO - Urol Oncol. 2021 Apr;39(4):209-212. doi: 10.1016/j.urolonc.2020.09.001. Epub 2020 Sep 30. PMID- 33004944 OWN - NLM STAT- MEDLINE DCOM- 20210101 LR - 20211001 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Oct 1 TI - Non-muscle invasive bladder cancer tissues have increased base excision repair capacity. PG - 16371 LID - 10.1038/s41598-020-73370-z [doi] LID - 16371 AB - The molecular mechanisms underlying the development and progression of bladder cancer (BC) are complex and have not been fully elucidated. Alterations in base excision repair (BER) capacity, one of several DNA repair mechanisms assigned to preserving genome integrity, have been reported to influence cancer susceptibility, recurrence, and progression, as well as responses to chemotherapy and radiotherapy. We report herein that non-muscle invasive BC (NMIBC) tissues exhibit increased uracil incision, abasic endonuclease and gap-filling activities, as well as total BER capacity in comparison to normal bladder tissue from the same patient (p < 0.05). No significant difference was detected in 8-oxoG incision activity between cancer and normal tissues. NMIBC tissues have elevated protein levels of uracil DNA glycosylase, 8-oxoguanine DNA glycosylase, AP endonuclease 1 and DNA polymerase beta protein. Moreover, the fold increase in total BER and the individual BER enzyme activities were greater in high-grade tissues than in low-grade NMIBC tissues. These findings suggest that enhanced BER activity may play a role in the etiology of NMIBC and that BER proteins could serve as biomarkers in disease prognosis, progression or response to genotoxic therapeutics, such as Bacillus Calmette-Guerin. FAU - Somuncu, Berna AU - Somuncu B AD - Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University, 34752, Atasehir, Istanbul, Turkey. FAU - Keskin, Selcuk AU - Keskin S AD - Department of Urology, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. FAU - Antmen, Fatma Merve AU - Antmen FM AD - Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University, 34752, Atasehir, Istanbul, Turkey. FAU - Saglican, Yesim AU - Saglican Y AD - Department of Pathology, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. FAU - Ekmekcioglu, Aysegul AU - Ekmekcioglu A AD - Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University, 34752, Atasehir, Istanbul, Turkey. FAU - Ertuzun, Tugce AU - Ertuzun T AD - Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University, 34752, Atasehir, Istanbul, Turkey. FAU - Tuna, Mustafa Bilal AU - Tuna MB AD - Department of Urology, Acibadem Maslak Hospital, Istanbul, Turkey. FAU - Obek, Can AU - Obek C AD - Department of Urology, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. AD - Department of Urology, Acibadem Taksim Hospital, Istanbul, Turkey. FAU - Wilson, David M 3rd AU - Wilson DM 3rd AD - Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium. FAU - Ince, Umit AU - Ince U AD - Department of Pathology, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. FAU - Kural, Ali Riza AU - Kural AR AD - Department of Urology, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. FAU - Muftuoglu, Meltem AU - Muftuoglu M AD - Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University, 34752, Atasehir, Istanbul, Turkey. meltem.muftuoglu@acibadem.edu.tr. AD - Department of Molecular Biology and Genetics, Acibadem Mehmet Ali Aydinlar University, 34752, Istanbul, Turkey. meltem.muftuoglu@acibadem.edu.tr. LA - eng PT - Journal Article DEP - 20201001 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - EC 3.2.2.- (DNA Glycosylases) RN - EC 3.2.2.- (oxoguanine glycosylase 1, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*genetics/pathology MH - DNA Glycosylases/genetics MH - *DNA Repair MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC7529820 COIS- The authors declare no competing interests. EDAT- 2020/10/03 06:00 MHDA- 2021/01/02 06:00 PMCR- 2020/10/01 CRDT- 2020/10/02 05:40 PHST- 2020/02/04 00:00 [received] PHST- 2020/09/15 00:00 [accepted] PHST- 2020/10/02 05:40 [entrez] PHST- 2020/10/03 06:00 [pubmed] PHST- 2021/01/02 06:00 [medline] PHST- 2020/10/01 00:00 [pmc-release] AID - 10.1038/s41598-020-73370-z [pii] AID - 73370 [pii] AID - 10.1038/s41598-020-73370-z [doi] PST - epublish SO - Sci Rep. 2020 Oct 1;10(1):16371. doi: 10.1038/s41598-020-73370-z. PMID- 33003392 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240803 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 12 IP - 10 DP - 2020 Sep 29 TI - Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. LID - 10.3390/cancers12102794 [doi] LID - 2794 AB - Non-muscle invasive bladder cancer (NMIBC), which is characterized by a recurrence rate of approximately 30% and very long treatment times, remains a major unresolved problem for patients and the health care system. The immunological interplay between tumor cells and the immune environment is important for tumor development. Therefore, we analyzed the mRNA of three immune markers, CXCL9, PD1 and PD-L1, in NMIBC by qRT-PCR. The results were subsequently correlated with clinicopathological parameters and prognostic data. Altogether, as expected, higher age was an independent prognostic factor for overall survival (OS) and disease-specific survival (DSS), but not for recurrence-free survival (RFS). Lower CXCL9 mRNA was observed in multivariate Cox's regression analysis to be an independent prognostic parameter for reduced OS (relative risk; RR = 2.08; p = 0.049), DSS (RR = 4.49; p = 0.006) and RFS (RR = 2.69; p = 0.005). In addition, PD-L1 mRNA was an independent prognostic factor for DSS (RR = 5.02; p = 0.042) and RFS (RR = 2.07; p = 0.044). Moreover, in univariate Cox's regression analysis, the stratification of patients revealed that low CXCL9 or low PD1 mRNA was associated with reduced RFS in the younger patient group (71 years). In addition, low CXCL9 or low PD-L1 was associated with shorter RFS in patients with higher tumor cell proliferation and in patients without instillation therapy. In conclusion, the characterization of mRNA levels of immune markers differentiates NIMBC patients with respect to prognosis. FAU - Kubon, Jennifer AU - Kubon J AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Weyerer, Veronika AU - Weyerer V AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Neumann, Angela AU - Neumann A AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany. FAU - Taubert, Helge AU - Taubert H AUID- ORCID: 0000-0002-9077-1727 AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universitat Erlangen-Nurnberg, 91054 Erlangen, Germany. LA - eng GR - ELAN 18-08-18-1-Sikic/ELAN Fund/ GR - none/Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander University Erlangen-Nuremberg/ GR - none/Rudolf und Irmgard Kleinknecht-Stiftung/ GR - none/Johannes und Frieda Marohn-Stiftung/ GR - Forderantrag Nr. 2015.171.1/Wilhelm Sander-Stiftung/ PT - Journal Article DEP - 20200929 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7601021 OTO - NOTNLM OT - CXCL9 OT - PD-L1 OT - PD1 OT - prognosis OT - stage T1 NMIBC COIS- The authors declare that there are no financial and/or nonfinancial conflicts of interest. EDAT- 2020/10/03 06:00 MHDA- 2020/10/03 06:01 PMCR- 2020/09/29 CRDT- 2020/10/02 01:01 PHST- 2020/09/03 00:00 [received] PHST- 2020/09/23 00:00 [revised] PHST- 2020/09/24 00:00 [accepted] PHST- 2020/10/02 01:01 [entrez] PHST- 2020/10/03 06:00 [pubmed] PHST- 2020/10/03 06:01 [medline] PHST- 2020/09/29 00:00 [pmc-release] AID - cancers12102794 [pii] AID - cancers-12-02794 [pii] AID - 10.3390/cancers12102794 [doi] PST - epublish SO - Cancers (Basel). 2020 Sep 29;12(10):2794. doi: 10.3390/cancers12102794. PMID- 33000460 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 18 IP - 4 DP - 2020 Oct 1 TI - Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer. PG - 411-416 LID - 10.22037/uj.v16i7.5965 [doi] AB - PURPOSE: To compare the influence of three operative approaches [transurethral en bloc resection of bladder tumor by pin-shaped electrode (pin-ERBT), transurethral resection of bladder tumor (TURBT) and transurethral holmium laser resection of bladder tumor (HoLRBT)] on the recurrence rate of non-muscle-invasive bladder cancer (NMIBC) at low dimension (i.e. diameter below 3 cm). MATERIALS AND METHODS: A retrospective analysis was conducted for a total of 115 patients affected by solitary NMIBC, with a diameter <3 cm, who were submitted to operation between March 2013 to May 2017. The patients were divided according to the operative method applied (pin-ERBT, TURBT and HoLRBT groups, respectively). The 2-year recurrence rate was compared among the three groups, and multivariat Cox hazard model analysis was applied to analyze the influencing factor(s) for postoperative recurrence. RESULTS: The 2-year recurrence rate was 10.0% in ERBT, 38.5% in TURBT and 40.0% in HoLRBT group, with a significant difference (P =0.014). According to the Cox hazard model analysis, age(HR=1.058, 95% CI: 1.019~1.098，P=0.003), operative method(HR=2.974,6.508, 95% CI: 0.862~10.255,1.657~25.566, P=0.023), smoking(HR=2.399, 95% CI: 1.147~5.017, P=0.020) and pathological grade(HR=2.012,95% CI: 1.279~3.165, P=0.002) were risk factors for postoperative recurrence of bladder cancer. CONCLUSION: Pin-ERBT can prominently decrease the postoperative recurrence rate of solitary NMIBC with a diameter <3 cm. FAU - Li, Shoubin AU - Li S AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. lishoubin@163.com. FAU - Jia, Yi AU - Jia Y AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. jia930529@vip.qq.com. FAU - Yu, Chunhong AU - Yu C AD - Department of Medical Checkup Centre, Hebei General Hospital,, Shijiazhuang, Hebei, China. sdyuchunhong@163.com. FAU - Xiao, Helong AU - Xiao H AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. egone1989@sina.com. FAU - Guo, Liuxiong AU - Guo L AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. 175629871@qq.com. FAU - Sun, Fuzhen AU - Sun F AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. sfz20050122@sina.com. FAU - Wei, Dong AU - Wei D AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. weidong051222@163.com. FAU - Zhang, Panying AU - Zhang P AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. zhangpy666@126.com. FAU - Li, Jingpo AU - Li J AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. 1265038353@qq.com. FAU - Liu, Junjiang AU - Liu J AD - Department of Urology, Hebei General Hospital, , Shijiazhuang, Hebei, China. liujunjiang67@163.com. LA - eng PT - Journal Article DEP - 20201001 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 SB - IM MH - Cystectomy MH - Humans MH - *Lasers, Solid-State MH - Neoplasm Recurrence, Local/epidemiology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery MH - Urologic Surgical Procedures EDAT- 2020/10/02 06:00 MHDA- 2022/01/18 06:00 CRDT- 2020/10/01 05:41 PHST- 2020/10/02 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2020/10/01 05:41 [entrez] AID - 5965 [pii] AID - 10.22037/uj.v16i7.5965 [doi] PST - epublish SO - Urol J. 2020 Oct 1;18(4):411-416. doi: 10.22037/uj.v16i7.5965. PMID- 35117271 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220205 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 9 IP - 10 DP - 2020 Oct TI - The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. PG - 6609-6623 LID - 10.21037/tcr-20-1243 [doi] AB - Urothelial cell carcinoma (UCC) of the bladder and upper urinary tract is a heterogeneous disease with distinct biologic features resulting in different clinical behaviors. Bladder cancer (BC) is classified into non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). NMIBC is associated with high recurrence rates and risk of progression to invasive disease, whereas MIBC is complicated by systemic recurrence after radical cystectomy because of the limited efficacy of available therapies. UCC of the upper urinary tract (UUT-UCC) is a rare but aggressive urologic cancer characterized by multifocality, local recurrence, and metastasis. Conventional histopathologic evaluation of UCC, including tumor stage and grade, cannot accurately predict the behavior of BC and UUT-UCC. Recent clinical and preclinical studies aimed at understanding the molecular landscape of UCC have provided insight into molecular subtyping, inter- or intratumoral heterogeneity, and potential therapeutic targets. Combined analysis of molecular markers and standard pathological features may improve risk stratification and help monitor tumor progression and treatment response, ultimately improving patient outcomes. This review discusses prognostic and therapeutic biomarkers for BC and UUT-UCC, and describes recent advances in molecular stratification that may guide prognosis, patient stratification, and treatment selection. CI - 2020 Translational Cancer Research. All rights reserved. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South Korea. AD - Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC8798786 OTO - NOTNLM OT - Urothelial cell carcinoma (UCC) OT - biomarkers OT - liquid biopsy OT - prognosis OT - tumor heterogeneity COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-1243). The series "Urothelial Carcinoma" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2020/10/01 00:00 MHDA- 2020/10/01 00:01 PMCR- 2020/10/01 CRDT- 2022/02/04 05:50 PHST- 2020/02/28 00:00 [received] PHST- 2020/04/20 00:00 [accepted] PHST- 2022/02/04 05:50 [entrez] PHST- 2020/10/01 00:00 [pubmed] PHST- 2020/10/01 00:01 [medline] PHST- 2020/10/01 00:00 [pmc-release] AID - tcr-09-10-6609 [pii] AID - 10.21037/tcr-20-1243 [doi] PST - ppublish SO - Transl Cancer Res. 2020 Oct;9(10):6609-6623. doi: 10.21037/tcr-20-1243. PMID- 32991771 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1742-1241 (Electronic) IS - 1368-5031 (Linking) VI - 75 IP - 4 DP - 2021 Apr TI - Comparison of De Ritis Ratio and other systemic inflammatory parameters for the prediction of prognosis of patients with transitional cell bladder cancer. PG - e13743 LID - 10.1111/ijcp.13743 [doi] AB - OBJECTIVE: To investigate the clinical value of preoperative De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) (DRR) in patients with transitional cell bladder cancer (TCBC) at initial diagnosis. The secondary objective was to investigate the status of systemic inflammatory parameters, such as neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR) and platelet-monocyte ratio (PMR). MATERIALS AND METHODS: The records of patients with primary TCBC who underwent transurethral resection were retrospectively evaluated. The relationship of DRR and systemic inflammatory parameters with clinicopathological findings, recurrence and progression status was evaluated separately. RESULTS: There was no significant difference in the DRR according to the clinicopathological findings, recurrence and progression. Significant differences were found between the NLR and the patient groups for tumour diameter, tumour stage, tumour grade and progression. In univariate analysis, the LMR was found to be associated with progression, and also the PLR and LMR were found to be associated with recurrence. Decrease in LMR and increase in LMR score demonstrated by multiple analysis was shown as independent predictors of progression and recurrence development. CONCLUSIONS: This paper shows a positive correlation between poor prognosis in TCBC and the systemic inflammatory markers, namely NLR, LMR, PLR and PMR, but not DRR. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Batur, Ali Furkan AU - Batur AF AUID- ORCID: 0000-0001-7945-7326 AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Aydogan, Muhammed Furkan AU - Aydogan MF AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Kilic, Ozcan AU - Kilic O AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Korez, Muslu Kazim AU - Korez MK AUID- ORCID: 0000-0001-9524-6115 AD - Department of Biostatistics, Selcuk University School of Medicine, Konya, Turkey. FAU - Gul, Murat AU - Gul M AUID- ORCID: 0000-0002-6657-6227 AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Kaynar, Mehmet AU - Kaynar M AUID- ORCID: 0000-0002-6957-9060 AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Goktas, Serdar AU - Goktas S AUID- ORCID: 0000-0001-6538-7187 AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. FAU - Akand, Murat AU - Akand M AD - Department of Urology, Selcuk University School of Medicine, Konya, Turkey. LA - eng PT - Journal Article DEP - 20201101 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - Lymphocytes MH - Neoplasm Recurrence, Local MH - Prognosis MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/surgery EDAT- 2020/09/30 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/09/29 17:15 PHST- 2020/09/13 00:00 [revised] PHST- 2020/08/17 00:00 [received] PHST- 2020/09/23 00:00 [accepted] PHST- 2020/09/30 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/09/29 17:15 [entrez] AID - 10.1111/ijcp.13743 [doi] PST - ppublish SO - Int J Clin Pract. 2021 Apr;75(4):e13743. doi: 10.1111/ijcp.13743. Epub 2020 Nov 1. PMID- 32987933 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201103 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 10 IP - 10 DP - 2020 Sep 24 TI - Clinical Validation of a Urine Test (Uromonitor-V2((R))) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. LID - 10.3390/diagnostics10100745 [doi] LID - 745 AB - The costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder cancer (NMIBC) drives the development of new methods that may alternate with regular cystoscopy and urine cytology. The Uromonitor-V2((R)) is a new urine-based assay in the detection of hotspot mutations in three genes (TERT, FGFR3, and KRAS) for evaluation of disease recurrence. The aim of this study was to investigate the Uromonitor-V2((R))'s performance in detecting NMIBC recurrence and compare it with urine cytology. From February 2018 to September 2019 patients were enrolled. All subjects underwent a standard-of-care (SOC) cystoscopy, either as part of their follow-up for NMIBC or for a nonmalignant urological pathology. Urine cytology was performed in NMIBC patients. Out of the 105 patients enrolled, 97 were eligible for the study. Twenty patients presented nonmalignant lesions, 29 had a history of NMIBC with disease recurrence, and 49 had a history of NMIBC without recurrence. In NMIBC, the Uromonitor-V2((R)) displayed a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 93.1%, 85.4%, 79.4%, and 95.3%, respectively. Urine cytology was available for 52 patients, and the sensitivity, specificity, PPV, and NPV were 26.3%, 90.9%, 62.5%, and 68.2%, respectively. With its high NPV of 95.3%, the Uromonitor-V2((R)) revealed promising properties for the follow-up of patients with NMIBC. FAU - Sieverink, Caroline A AU - Sieverink CA AD - Department of Urology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. FAU - Batista, Rui P M AU - Batista RPM AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. AD - U-Monitor Lda, Rua Alfredo Allen, N masculine 461 Paranhos, 4200-461 Porto, Portugal. AD - Department of Pathology, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. FAU - Prazeres, Hugo J M AU - Prazeres HJM AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. AD - U-Monitor Lda, Rua Alfredo Allen, N masculine 461 Paranhos, 4200-461 Porto, Portugal. FAU - Vinagre, Joao AU - Vinagre J AUID- ORCID: 0000-0002-0871-1427 AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. AD - U-Monitor Lda, Rua Alfredo Allen, N masculine 461 Paranhos, 4200-461 Porto, Portugal. AD - Department of Pathology, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. FAU - Sampaio, Cristina AU - Sampaio C AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. FAU - Leao, Ricardo R AU - Leao RR AD - Department of Urology, Hospital de Braga, Sete Fontes-Sao Victor, 4710-243 Braga, Portugal. AD - Department of Urology, Hospital CUF Coimbra, Rua Camilo Pessanha 1, 3000-600 Coimbra, Portugal. AD - Faculdade de Medicina de Coimbra (FMUC), Rua Larga 2, 3000-370 Coimbra, Portugal. FAU - Maximo, Valdemar AU - Maximo V AUID- ORCID: 0000-0002-8631-8356 AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. AD - Department of Pathology, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. FAU - Soares, Paula AU - Soares P AUID- ORCID: 0000-0001-9607-6998 AD - i3S-Instituto de Investigacao e Inovacao em Saude, R. Alfredo Allen 208, 4200-135 Porto; Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Rua Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal. AD - U-Monitor Lda, Rua Alfredo Allen, N masculine 461 Paranhos, 4200-461 Porto, Portugal. AD - Department of Pathology, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. LA - eng PT - Journal Article DEP - 20200924 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC7599569 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - cystoscopy OT - cytology OT - follow-up OT - non-muscle-invasive bladder cancer OT - recurrence OT - urine test COIS- Authors R.P.M.B.; J.V.; P.S. and H.J.M.P. are partners of U-Monitor Lda, the company owing the Uromonitor-V2((R)). Author F.W. is advisor for Nucleix Ltd. All other authors have no conflicts of interest to declare. The funding sponsor of this research, U-Monitor Lda, had a role in the choice of research project; design of the study; in the collection, analyses and interpretation of data, in the writing of the manuscript and in the decision to publish. EDAT- 2020/09/30 06:00 MHDA- 2020/09/30 06:01 PMCR- 2020/09/24 CRDT- 2020/09/29 01:03 PHST- 2020/08/14 00:00 [received] PHST- 2020/09/14 00:00 [revised] PHST- 2020/09/22 00:00 [accepted] PHST- 2020/09/29 01:03 [entrez] PHST- 2020/09/30 06:00 [pubmed] PHST- 2020/09/30 06:01 [medline] PHST- 2020/09/24 00:00 [pmc-release] AID - diagnostics10100745 [pii] AID - diagnostics-10-00745 [pii] AID - 10.3390/diagnostics10100745 [doi] PST - epublish SO - Diagnostics (Basel). 2020 Sep 24;10(10):745. doi: 10.3390/diagnostics10100745. PMID- 32987034 OWN - NLM STAT- MEDLINE DCOM- 20210329 LR - 20240804 IS - 1532-8392 (Electronic) IS - 0046-8177 (Print) IS - 0046-8177 (Linking) VI - 106 DP - 2020 Dec TI - Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. PG - 54-61 LID - S0046-8177(20)30182-9 [pii] LID - 10.1016/j.humpath.2020.09.010 [doi] AB - Several molecular subtypes of bladder cancer were identified with differing clinical behavior and responses to platinum-based chemotherapy. But so far, their urothelial histomorphologic features, besides association with some variant histologies, have remained fully undefined. We sought to characterize the histological features of genomically classified bladder cancers more extensively to tumor in radical cystectomy (RC) specimens. Forty-eight bladder cancers submitted to The Cancer Genome Atlas (TCGA) were classified using the BASE47 genomic classifier into luminal subtype (LS) (14 cases), basal subtype (BS) (18 cases), and claudin-low subtype (CLS) (16 cases), and TCGA samples and the corresponding RC specimens were histologically assessed. Marked pleomorphism was more extensive in CLS tumors (87.5% had >15% extent) than in LS tumors (21.4%) (p = 0.0006), whereas the extent in BS tumors was in between LS and CLS tumors. Pleomorphism in distant carcinoma in situ appeared to correlate with that in the main tumor. Ki-67 proliferation was higher in CLS tumors (mean = 61%) than in LS tumors (mean = 29%) or BS (mean = 30%) (p < 0.001). Squamous differentiation was more extensive in BS and CLS tumors (38.2% of BS and CLS tumors versus 7.1% of LS tumors had >30% squamous, p = 0.040). Sarcomatoid change was present in BS and CLS tumors only. The micropapillary variant was identified in LS (3/14) and BS (4/18) tumors only. Histologic features associated with aggressiveness (eg, marked pleomorphism, high proliferation, and sarcomatoid change) are enriched in CLS tumors, correlating with its known poorer outcome that may provide hints in their microscopic distinction. Features more associated with BS than with LS tumors (eg, squamous, marked pleomorphism, and sarcomatoid change) are also identified or enhanced in CLS tumors, supporting the genomic findings suggesting CLS tumor as a hyperbasal form of BS tumor. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Han, Lisa AU - Han L AD - Department of Pathology, University of Chicago, Chicago, IL, USA. FAU - Gallan, Alexander J AU - Gallan AJ AD - Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, New York University Langone Health, New York, NY, USA. FAU - Sweis, Randy F AU - Sweis RF AD - Department of Medicine (Hematology-Oncology), University of Chicago, Chicago, IL, USA. Electronic address: rsweis@bsd.uchicago.edu. FAU - Paner, Gladell P AU - Paner GP AD - Department of Pathology, University of Chicago, Chicago, IL, USA; Department of Surgery (Urology), University of Chicago, Chicago, IL, USA. Electronic address: Gladell.Paner@uchospitals.edu. LA - eng GR - K08 CA234392/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20200926 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) SB - IM MH - Aged MH - Biomarkers, Tumor/analysis/*genetics MH - Cell Proliferation MH - Cystectomy MH - Databases, Genetic MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/analysis MH - Male MH - Neoplasm Staging MH - Phenotype MH - RNA-Seq MH - Urinary Bladder Neoplasms/chemistry/*genetics/*pathology/surgery PMC - PMC7746505 MID - NIHMS1644773 OTO - NOTNLM OT - Basal OT - Bladder OT - Claudin-low OT - Luminal OT - Molecular OT - Morphology COIS- The authors have no conflicts of interest to declare EDAT- 2020/09/29 06:00 MHDA- 2021/03/30 06:00 PMCR- 2021/12/01 CRDT- 2020/09/28 20:08 PHST- 2020/08/10 00:00 [received] PHST- 2020/09/16 00:00 [revised] PHST- 2020/09/21 00:00 [accepted] PHST- 2020/09/29 06:00 [pubmed] PHST- 2021/03/30 06:00 [medline] PHST- 2020/09/28 20:08 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - S0046-8177(20)30182-9 [pii] AID - 10.1016/j.humpath.2020.09.010 [doi] PST - ppublish SO - Hum Pathol. 2020 Dec;106:54-61. doi: 10.1016/j.humpath.2020.09.010. Epub 2020 Sep 26. PMID- 32985754 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 27 IP - 12 DP - 2020 Dec TI - Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer. PG - 1130-1135 LID - 10.1111/iju.14372 [doi] AB - OBJECTIVES: To clarify the potential therapeutic benefit of a second transurethral resection for high-grade Ta bladder cancer. METHODS: From January 2009 to August 2019, 521 patients with bladder tumors underwent initial transurethral resection procedures at Kagawa University Hospital. Patients diagnosed with high-grade Ta bladder cancer considered to have been resected completely were included in this study. Recurrence and progression rates were compared between patients who received a second transurethral resection and those who did not. RESULTS: We identified 97 eligible patients, including 22 patients who received a second transurethral resection. In terms of clinical characteristics, the proportion of patients with bladder cancer and upper urinary tract tumor history was lower in the second transurethral resection group than in the no second transurethral resection group (P < 0.01 and P = 0.03, respectively). The histopathological findings of 22 transurethral resection procedures were no cancer in 13 (59.2%), Ta in six (27.2%) and carcinoma in situ in three patients (13.6%). After the second transurethral resection, one patient (4.6%) had recurrent high-grade T1 bladder cancer. The no second transurethral resection group showed a 44% recurrence rate (33 patients), including five patients (6.7%) with progression, and consequently, had a higher rate of recurrence than in the second transurethral resection group (P < 0.01). Multivariate analysis showed that no second transurethral resection was the independent predictive factor influencing recurrence (hazard ratio 8.662, P = 0.04). The Kaplan-Meier curve showed that a second transurethral resection significantly decreased the recurrence rate than that of patients without a second transurethral resection (P < 0.01). CONCLUSIONS: A second transurethral resection can reduce the recurrence rate in high-grade Ta bladder cancer, showing a possible therapeutic benefit of this procedure. CI - (c) 2020 The Japanese Urological Association. FAU - Taoka, Rikiya AU - Taoka R AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Matsuoka, Yuki AU - Matsuoka Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Kohashiguchi, Kana AU - Kohashiguchi K AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Miura, Takayoshi AU - Miura T AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Tohi, Yoichiro AU - Tohi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Miyauchi, Yasuyuki AU - Miyauchi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Kato, Takuma AU - Kato T AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Tsunemori, Hiroyuki AU - Tsunemori H AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Ueda, Nobufumi AU - Ueda N AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Kakehi, Yoshiyuki AU - Kakehi Y AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. FAU - Sugimoto, Mikio AU - Sugimoto M AD - Department of Urology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan. LA - eng PT - Journal Article DEP - 20200928 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasm Staging MH - *Urinary Bladder Neoplasms/pathology/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - high-grade Ta OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence OT - second transurethral resection EDAT- 2020/09/29 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/09/28 08:47 PHST- 2020/05/23 00:00 [received] PHST- 2020/08/13 00:00 [accepted] PHST- 2020/09/29 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/09/28 08:47 [entrez] AID - 10.1111/iju.14372 [doi] PST - ppublish SO - Int J Urol. 2020 Dec;27(12):1130-1135. doi: 10.1111/iju.14372. Epub 2020 Sep 28. PMID- 32976177 OWN - NLM STAT- MEDLINE DCOM- 20210218 LR - 20210218 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 43 IP - 12 DP - 2020 Dec 1 TI - Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. PG - 880-888 LID - 10.1097/COC.0000000000000766 [doi] AB - OBJECTIVE: The objective of the study is to test the effect of age on cancer-specific mortality (CSM) in patients with urothelial carcinoma of the urinary bladder (UCUB), across all disease stages. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) registry (2004-2016), we identified 207,714 patients. Age was categorized as: below 60 versus 60 to 69 versus 70 to 79 versus 80 years and above. Multivariable competing-risks regression (CRR) models were used according to disease stage (low-risk nonmuscle invasive: TaN0M0 low grade, high-risk nonmuscle invasive: Ta high grade or Tis-1N0M0, muscle invasive: T2-3N0M0, regional: T4N0M0/TanyN1-3M0, and metastatic: TanyNanyM1). RESULTS: Overall, 33,970 (16.4%) versus 52,173 (25.1%) versus 64,537 (31.1%) versus 57,034 (27.4%) patients were below 60 versus 60 to 69 versus 70 to 79 versus 80 years and above, respectively. In multivariable CRR models that focused on low-risk nonmuscle invasive UCUB, advanced age was associated with higher CSM rates (hazard ratio [HR]: 7.04 in patients aged 80 y and above, relative to below 60 y; P<0.001). Moreover, advanced age was also associated with higher CSM rates in high-risk nonmuscle invasive UCUB (HR: 2.77 in patients aged 80 y and above, relative to below 60 y; P<0.001) and in muscle invasive UCUB patients (HR: 1.38 in patients aged 80 y and above, relative to below 60 y; P<0.001). Conversely, lower CSM rates with advanced age were observed in multivariable CRR that focused on regional (HR: 0.91 for patients aged 80 y and above, relative to below 60 y; P=0.02) or metastatic UCUB (HR: 0.75 for patients aged 80 y and above, relative to below 60 y; P<0.001). CONCLUSIONS: The direction and the magnitude of the association between advanced age and CSM in UCUB patients changes according to tumor stage. In low-risk nonmuscle invasive, high-risk nonmuscle invasive, and muscle invasive UCUB, more advanced age is associated with higher CSM rates. Conversely, in regional and metastatic UCUB patients, more advanced age is associated with lower CSM rates. CI - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved. FAU - Luzzago, Stefano AU - Luzzago S AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, European Institute of Oncology, IRCCS. FAU - Knipper, Sophie AU - Knipper S AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg. FAU - Palumbo, Carlotta AU - Palumbo C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Urology Unit, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute. FAU - Pecoraro, Angela AU - Pecoraro A AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. FAU - Deuker, Marina AU - Deuker M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Mistretta, Francesco A AU - Mistretta FA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, European Institute of Oncology, IRCCS. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, European Institute of Oncology, IRCCS. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, NY. AD - Department of Urology, University of Texas Southwestern, Dallas, TX. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, European Institute of Oncology, IRCCS. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. LA - eng PT - Journal Article PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Age Distribution MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Regression Analysis MH - SEER Program MH - United States/epidemiology MH - Urinary Bladder Neoplasms/*mortality/pathology/therapy MH - Urothelium/pathology COIS- The authors declare no conflicts of interest. EDAT- 2020/09/26 06:00 MHDA- 2021/02/20 06:00 CRDT- 2020/09/25 17:10 PHST- 2020/09/26 06:00 [pubmed] PHST- 2021/02/20 06:00 [medline] PHST- 2020/09/25 17:10 [entrez] AID - 00000421-202012000-00009 [pii] AID - 10.1097/COC.0000000000000766 [doi] PST - ppublish SO - Am J Clin Oncol. 2020 Dec 1;43(12):880-888. doi: 10.1097/COC.0000000000000766. PMID- 32974145 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. PG - 1400 LID - 10.3389/fonc.2020.01400 [doi] LID - 1400 AB - Background: Several studies investigating the role of PD-L1 in upper tract urothelial carcinoma (UTUC) patients after radical nephroureterectomy (RNU) to predict prognosis had been published and great controversy existed among them. We, therefore, in the meta-analysis, reported the association between PD-L1 and survival in UTUC patients who underwent RNU. Methods: We searched the PubMed, Cochrane Library, EMBASE, and Web of Science by April 1, 2020. Hazard ratio (HR) and odds ratio (OR) were adopted to evaluate relationships between PD-L1 and survival outcomes, and tumor features, respectively. We formulated clinical questions and organized following the PICOS strategy. Results: Eight retrospective studies incorporating 1406 patients were included. The pooled positive rate of PD-L1 in UTUC patients was 21.0% (95% CI = 13.0-30.0%, I (2) = 95.3%). Furthermore, higher PD-L1 in tumor tissues was related to shorter cancer-specific survival (CSS) in radically resected UTUC patients (HR = 1.63, 95% CI = 1.17-2.26, I (2) = 0.0%), but was not associated with overall survival (OS) (HR = 1.49, 95% CI = 0.76-2.91, I (2) = 74.9%). Subgroup analyses indicated associations between higher PD-L1 and shorter CSS in both Caucasus (HR = 1.72, 95% CI = 1.02-2.92, I (2) = 0.0%) and Asian (HR = 1.57, 95% CI = 1.03-2.39, I (2) = 23.1%) UTUC patients. Furthermore, PD-L1 was related to tumor grade of UTUC (High vs. Low, OR = 3.56, 95% CI = 1.82-6.97, P = 0.000) and invasive depth (pT3+pT4+pT2 vs. pT1+pTa/pTis, OR = 2.53, 95% CI = 1.07-5.96, P = 0.001). In the cumulative meta-analysis, results indicated that the 95% CIs narrowed as the pooled results gradually moved near the null. Conclusions: PD-L1 overexpression was related to worse survival outcomes in UTUC patients after RNU. It may be useful to incorporate PD-L1 into prognostic tools to select appropriate treatment strategies for UTUC. PD-L1 can also be clinically used for survival anticipation, risk stratification, and patient counseling. However, the pooled findings should be considered tentative until ascertained by more researches. CI - Copyright (c) 2020 Lu, Kang, Luo, Song, Tian, Li, Wang, Liu, Yang and Liu. FAU - Lu, Yi AU - Lu Y AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Kang, Jiaqi AU - Kang J AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Luo, Zhiwen AU - Luo Z AD - Department of Hepatology, National Clinical Research Center for Cancer and Cancer Hospital, Beijing, China. FAU - Song, Yuxuan AU - Song Y AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Tian, Jia AU - Tian J AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Li, Zhongjia AU - Li Z AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Wang, Xiao AU - Wang X AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Liu, Li AU - Liu L AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. FAU - Yang, Yongjiao AU - Yang Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liu, Xiaoqiang AU - Liu X AD - Department of Urology, Tianjin Medical University General Hospital, Tianjin, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20200821 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7472102 OTO - NOTNLM OT - PD-L1 OT - immune checkpoint OT - meta-analysis OT - prognostic biomarker OT - upper tract urothelial carcinoma (UTUC) EDAT- 2020/09/26 06:00 MHDA- 2020/09/26 06:01 PMCR- 2020/01/01 CRDT- 2020/09/25 06:03 PHST- 2020/04/23 00:00 [received] PHST- 2020/07/02 00:00 [accepted] PHST- 2020/09/25 06:03 [entrez] PHST- 2020/09/26 06:00 [pubmed] PHST- 2020/09/26 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.01400 [doi] PST - epublish SO - Front Oncol. 2020 Aug 21;10:1400. doi: 10.3389/fonc.2020.01400. eCollection 2020. PMID- 32960495 OWN - NLM STAT- MEDLINE DCOM- 20210719 LR - 20240330 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 9 IP - 22 DP - 2020 Nov TI - Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate? PG - 8491-8497 LID - 10.1002/cam4.3478 [doi] AB - The reported results of trimodal treatment (TMT) in muscle-invasive bladder cancer vary widely. We attempted to characterize the profile of ideal candidates for this approach. Between 2000 and 2019, 105 patients (median age 78 years) with T2-4aN0M0 bladder cancer were treated with TMT and analyzed retrospectively. Mean radiotherapy dose was 62 Gy (SD 8.4). Ten pretreatment prognostic parameters were evaluated including tumor diameter on pre-TURBT CT. Multivariate analyses was performed and combination of parameters was studied. After a median follow-up of 29 months, 53 patients (50.5%) developed recurrence and 70 patients (67.7%) died. Death was disease-specific in 46 patients (65.7%). Tumor diameter was the most significant prognostic parameter with p < 0.0001 for overall, disease-specific and recurrence-free survivals. For every 1 cm increase in tumor diameter, the risk of disease-specific mortality increased by 1.57. Age, cisplatin eligibility and the Charlson Comorbidity Index were significant predictors of overall survival but not of disease-specific or recurrence-free survival. Patients who were cisplatin-eligible with a tumor diameter 5 cm TMT renders unacceptably poor treatment outcomes. CI - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Gofrit, Ofer N AU - Gofrit ON AUID- ORCID: 0000-0001-8815-6488 AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Meirovitz, Amichay AU - Meirovitz A AUID- ORCID: 0000-0001-7479-2926 AD - Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Frank, Stephen AU - Frank S AD - Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Rabinovich, Igal AU - Rabinovich I AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Luwisch, Hemda AU - Luwisch H AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Yutkin, Vladimir AU - Yutkin V AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Neuman, Tzahi AU - Neuman T AD - Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Hidas, Guy AU - Hidas G AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Duvdevani, Mordechai AU - Duvdevani M AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Wygoda, Marc AU - Wygoda M AD - Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200922 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Antineoplastic Agents) RN - BG3F62OND5 (Carboplatin) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/adverse effects/*therapeutic use MH - Carboplatin/adverse effects/*therapeutic use MH - *Chemoradiotherapy, Adjuvant/adverse effects/mortality MH - Cisplatin/adverse effects/*therapeutic use MH - *Clinical Decision-Making MH - *Cystectomy/adverse effects/mortality MH - Disease Progression MH - Dose Fractionation, Radiation MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Patient Selection MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Tumor Burden MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy PMC - PMC7666756 OTO - NOTNLM OT - muscle-invasive bladder cancer OT - patient selection OT - trimodal therapy OT - tumor diameter COIS- None. EDAT- 2020/09/23 06:00 MHDA- 2021/07/20 06:00 PMCR- 2020/09/22 CRDT- 2020/09/22 12:14 PHST- 2020/07/03 00:00 [received] PHST- 2020/09/05 00:00 [revised] PHST- 2020/09/07 00:00 [accepted] PHST- 2020/09/23 06:00 [pubmed] PHST- 2021/07/20 06:00 [medline] PHST- 2020/09/22 12:14 [entrez] PHST- 2020/09/22 00:00 [pmc-release] AID - CAM43478 [pii] AID - 10.1002/cam4.3478 [doi] PST - ppublish SO - Cancer Med. 2020 Nov;9(22):8491-8497. doi: 10.1002/cam4.3478. Epub 2020 Sep 22. PMID- 32959230 OWN - NLM STAT- MEDLINE DCOM- 20210215 LR - 20261012 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 26 IP - 1 DP - 2021 Jan TI - UroVysion((R)) predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study. PG - 178-185 LID - 10.1007/s10147-020-01785-9 [doi] AB - BACKGROUND: Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UCUUT) is common. One of the mechanisms driving this is the implantation of cancer cells from the UCUUT at the RNUs. Therefore, their detection after RNU can assist in predicting IVR. This study aimed to examine the utility of UroVysion((R)) as a tool for predicting bladder recurrence after RNU for UCUUT. METHODS: We prospectively enrolled 65 patients who received RNU for high-grade UCUUT between October 2013 and April 2017. RESULTS: Of the 65 patients, 54 (83.1%) who had both bladder urine samples available immediately after RNU (0 postoperative days: POD) and 5 days after RNU (5POD) were selected. We performed UroVysion((R)) and cytology. Twenty-two patients showed IVR with 32 foci. UroVysion((R)) results at 0POD (26 patients, 48.1%) and/or 5POD (31 patients, 57.4%) were positive in 42 (77.8%) patients. The sensitivity, specificity, positive predictive value, and negative predictive value of UroVysion((R)) for included cases were measured for both 0POD and 5POD samples; they were determined to be 95.5% (21/22), 34.4% (11/32), 50.0% (21/42), and 91.7% (11/12), respectively. For cytology, these values were 75.0% (15/20), 52.9% (18/34), 48.4% (15/31), and 78.3% (18/23), respectively. Forty-two (64.6%) patients who were UroVysion((R))-positive demonstrated IVR. The IVR rate between the group positive for either 0POD or 5POD and that negative for both significantly differed for both UroVysion((R)) (p = 0.019) and cytology (p = 0.046). CONCLUSION: Multiple urine tests using UroVysion((R)) after RNU could be a useful predictor for IVR. FAU - Iwata, Hidehiro AU - Iwata H AD - Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. AD - Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myoken-Cho, Showa-Ku, Nagoya, 466-8650, Japan. FAU - Sassa, Naoto AU - Sassa N AD - Department of Urology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. AD - Department of Urology, Nagoya University Graduate School of Medicine, Tsuruma-Cho, Showa-Ku, Nagoya, 466-0065, Japan. FAU - Kato, Masashi AU - Kato M AD - Department of Urology, Nagoya University Graduate School of Medicine, Tsuruma-Cho, Showa-Ku, Nagoya, 466-0065, Japan. FAU - Murase, Yota AU - Murase Y AD - Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. AD - Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myoken-Cho, Showa-Ku, Nagoya, 466-8650, Japan. FAU - Seko, Shuko AU - Seko S AD - Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myoken-Cho, Showa-Ku, Nagoya, 466-8650, Japan. FAU - Kawanishi, Hideji AU - Kawanishi H AD - Department of Urology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. AD - Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, 3-35 Douge-Cho, Nakamura-Ku, Nagoya, 453-8511, Japan. FAU - Hattori, Ryohei AU - Hattori R AD - Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, 3-35 Douge-Cho, Nakamura-Ku, Nagoya, 453-8511, Japan. FAU - Gotoh, Momokazu AU - Gotoh M AD - Department of Urology, Nagoya University Graduate School of Medicine, Tsuruma-Cho, Showa-Ku, Nagoya, 466-0065, Japan. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AUID- ORCID: 0000-0002-4855-4366 AD - Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. tsuzuki@aichi-med-u.ac.jp. LA - eng PT - Journal Article DEP - 20200921 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - *Carcinoma, Transitional Cell/surgery MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Nephrectomy MH - Nephroureterectomy MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/surgery MH - *Urinary Tract OTO - NOTNLM OT - Intravesicular recurrence OT - Nephroureterectomy OT - Urine cytology OT - UroVysion OT - Urothelial carcinoma of the upper urinary tract EDAT- 2020/09/23 06:00 MHDA- 2021/02/16 06:00 CRDT- 2020/09/22 05:44 PHST- 2020/06/04 00:00 [received] PHST- 2020/09/06 00:00 [accepted] PHST- 2020/09/23 06:00 [pubmed] PHST- 2021/02/16 06:00 [medline] PHST- 2020/09/22 05:44 [entrez] AID - 10.1007/s10147-020-01785-9 [pii] AID - 10.1007/s10147-020-01785-9 [doi] PST - ppublish SO - Int J Clin Oncol. 2021 Jan;26(1):178-185. doi: 10.1007/s10147-020-01785-9. Epub 2020 Sep 21. PMID- 32955679 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20261012 IS - 1432-1440 (Electronic) IS - 0946-2716 (Linking) VI - 98 IP - 11 DP - 2020 Nov TI - Relevance of iNOS expression in tumor growth and maintenance of cancer stem cells in a bladder cancer model. PG - 1615-1627 LID - 10.1007/s00109-020-01973-0 [doi] AB - The expression of inducible nitric oxide (NO) synthase (iNOS) in human bladder cancer (BC) is a poor prognostic factor associated with invasion and tumor recurrence. Here, we evaluated the relevance of iNOS expression in BC progression and in cancer stem cell (CSC) maintenance in a murine BC model. Also, iNOS expression and CSC markers were analyzed in human BC samples. iNOS inhibitors (L-NAME or 1400W) or shRNA were used on murine BC model with different iNOS expressions and invasiveness grades: MB49 (iNOS+, non-muscle invasive (NMI)) and MB49-I (iNOS++, muscle invasive (MI)), in order to analyzed cell proliferation, tumor growth, angiogenesis, number of CSC, and pluripotential marker expression. iNOS, SOX2, Oct4, and Nanog expressions were also analyzed in human BC samples by qPCR and immunohistochemistry. iNOS inhibtion reduced parameters associated with tumor progression and reduced the number of CSC, wich resulted higher in MB49-I than in MB49, in concordance with the higher expression of SOX2, Oct4, and Nanog. The expression of SOX2 was notoriously diminished, when iNOS was inhibited only in the MI cell line. Similar results were observed in human samples, where MI tumors expressed higher levels of iNOS and pluripotential genes, in comparison to NMI tumors with a positive correlation between those and iNOS, suggesting that iNOS expression is associated with CSC. iNOS plays an important role in BC progression and CSC maintenance. Its inhibition could be a potential therapeutic target to eradicate CSC, responsible for tumor recurrences. KEY MESSAGES: * iNOS expression is involved in bladder tumor development, growth, and angiogenesis. * iNOS expression is involved in bladder cancer stem cell generation and maintenance, playing an important role regulating their self-renewal capacity, especially in muscle invasive murine bladder cancer cells. * iNOS expression is higher in human muscle invasive tumors, in association with a high expression of pluripotential genes, especially of SOX2. FAU - Belgorosky, Denise AU - Belgorosky D AD - Research Area, Instituto de Oncologia Angel H. Roffo (IOAHR), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. FAU - Girouard, Julie AU - Girouard J AD - Medical Biology Department, Groupe de Recherche en Signalisation Cellulaire (GRSC), Universite du Quebec a Trois-Rivieres, Trois-Rivieres, QC, Canada. FAU - Langle, Yanina Veronica AU - Langle YV AD - Research Area, Instituto de Oncologia Angel H. Roffo (IOAHR), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. FAU - Hamelin-Morrissete, Jovane AU - Hamelin-Morrissete J AD - Medical Biology Department, Groupe de Recherche en Signalisation Cellulaire (GRSC), Universite du Quebec a Trois-Rivieres, Trois-Rivieres, QC, Canada. FAU - Marino, Lina AU - Marino L AD - Pathology Department, IOAHR, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. FAU - Aguero, Eduardo Imanol AU - Aguero EI AD - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Buenos Aires, Argentina. FAU - Malagrino, Hector AU - Malagrino H AD - Urology Department, IOAHR, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. FAU - Reyes-Moreno, Carlos AU - Reyes-Moreno C AD - Medical Biology Department, Groupe de Recherche en Signalisation Cellulaire (GRSC), Universite du Quebec a Trois-Rivieres, Trois-Rivieres, QC, Canada. FAU - Eijan, Ana Maria AU - Eijan AM AUID- ORCID: 0000-0002-2723-0194 AD - Research Area, Instituto de Oncologia Angel H. Roffo (IOAHR), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. anamariaeijan@gmail.com. AD - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Buenos Aires, Argentina. anamariaeijan@gmail.com. AD - Area Investigaciones, Instituto de Oncologia "Angel H. Roffo", Av. San Martin 5481, CP1417DTB, Buenos Aires, Argentina. anamariaeijan@gmail.com. LA - eng GR - 392334/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200916 PL - Germany TA - J Mol Med (Berl) JT - Journal of molecular medicine (Berlin, Germany) JID - 9504370 RN - 0 (Biomarkers, Tumor) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (NOS2 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) SB - IM MH - *Biomarkers, Tumor MH - Cell Line, Tumor MH - Disease Progression MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - Neoplastic Stem Cells/*metabolism MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase Type II/*genetics/metabolism MH - Organ Specificity/genetics MH - Oxidation-Reduction MH - Urinary Bladder Neoplasms/*genetics/*metabolism/pathology OTO - NOTNLM OT - Bladder cancer OT - Cancer stem cells OT - Nitric oxide OT - iNOS EDAT- 2020/09/22 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/09/21 12:13 PHST- 2020/04/28 00:00 [received] PHST- 2020/08/27 00:00 [accepted] PHST- 2020/08/10 00:00 [revised] PHST- 2020/09/22 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/09/21 12:13 [entrez] AID - 10.1007/s00109-020-01973-0 [pii] AID - 10.1007/s00109-020-01973-0 [doi] PST - ppublish SO - J Mol Med (Berl). 2020 Nov;98(11):1615-1627. doi: 10.1007/s00109-020-01973-0. Epub 2020 Sep 16. PMID- 32944553 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 4 DP - 2020 Aug TI - Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract. PG - 1891-1896 LID - 10.21037/tau.2020.03.47 [doi] AB - Upper tract urothelial carcinoma (UTUC) is a relatively uncommon and poorly investigated malignancy, however, bladder recurrence after radical nephroureterectomy (RNU) is a frequent event. In this review, we summarize the current knowledge on risk prediction of bladder tumor recurrence after RNU, including surgical strategies and adjuvant intravesical treatments to reduce the risk of recurrence. Finally, we outline some of the more recent advances in genomics that will likely lead to new prognostic markers and risk stratification tools that may refine UTUC treatment in the future. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Lonergan, Peter E AU - Lonergan PE AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7475654 OTO - NOTNLM OT - Upper tract urothelial carcinoma (UTUC) OT - intravesical recurrence OT - nephroureterectomy OT - surveillance COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.03.47). The series "Upper-Tract Urothelial Carcinoma: current state and future directions" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2020/09/19 06:00 MHDA- 2020/09/19 06:01 PMCR- 2020/08/01 CRDT- 2020/09/18 05:51 PHST- 2020/09/18 05:51 [entrez] PHST- 2020/09/19 06:00 [pubmed] PHST- 2020/09/19 06:01 [medline] PHST- 2020/08/01 00:00 [pmc-release] AID - tau-09-04-1891 [pii] AID - 10.21037/tau.2020.03.47 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Aug;9(4):1891-1896. doi: 10.21037/tau.2020.03.47. PMID- 32944548 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240902 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 4 DP - 2020 Aug TI - Oncologic outcomes of radical nephroureterectomy (RNU). PG - 1841-1852 LID - 10.21037/tau.2019.12.29 [doi] AB - Radical nephroureterectomy is the mainstay of surgical treatment for upper tract urothelial carcinoma (UTUC), a disease which comprises approximately 5% of urothelial malignancies. Minimally-invasive and nephron-sparing interventions have been explored, although thus far have not shown comparable oncologic outcomes except in a relatively narrow set of patients. Due to the relative rarity of the disease, it has taken decades and multi-disciplinary efforts to sufficiently identify prognostic factors of oncologic outcomes. Despite these efforts, however, oncologic outcomes of nephroureterectomy have remained remarkably stable over the past 30 years. New techniques, such as laparoscopic and robotic surgery, have been applied to this procedure. High level evidence regarding equivalent oncologic outcomes is lacking and open surgery remains the standard of care for high-stage disease, although there is a role for laparoscopic and robotic nephroureterectomy. The importance of bladder cuff removal in improving oncologic outcomes has been broadly accepted, although there is no consensus as to the most oncologically appropriate technique. There does appear to be evidence that endoscopic techniques confer worse oncologic control. The role of lymphadenectomy remains controversial, although there is evidence that increased nodal yield could have oncologic benefit. Given disease heterogeneity and varied technical approaches to the procedure, no consensus standardized template has been identified. There is level 1 evidence for the use of intravesical chemotherapy peri-operatively and that this intervention can improve the risk of intravesical recurrence. Advances in systemic neoadjuvant and adjuvant chemotherapy have yielded promising results and are likely to become standard of care for patients without contraindications. Immunotherapy and targeted biologic agents are also likely to improve the surgical efficacy of radical nephroureterectomy as well. Ultimately, more high level evidence is needed to identify successful surgical and medical approaches to UTUC and multi-institutional collaboration is critical to this progress. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Kenigsberg, Alexander P AU - Kenigsberg AP AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Meng, Xiaosong AU - Meng X AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Ghandour, Rashed AU - Ghandour R AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7475687 OTO - NOTNLM OT - Nephroureterectomy OT - laparoscopic surgery OT - neoadjuvant chemotherapy OT - robotic surgery COIS- Conflicts of Interest: The series "Upper-Tract Urothelial Carcinoma: Current State and Future Directions" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2020/09/19 06:00 MHDA- 2020/09/19 06:01 PMCR- 2020/08/01 CRDT- 2020/09/18 05:51 PHST- 2020/09/18 05:51 [entrez] PHST- 2020/09/19 06:00 [pubmed] PHST- 2020/09/19 06:01 [medline] PHST- 2020/08/01 00:00 [pmc-release] AID - tau-09-04-1841 [pii] AID - 10.21037/tau.2019.12.29 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Aug;9(4):1841-1852. doi: 10.21037/tau.2019.12.29. PMID- 32943344 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 3 DP - 2021 Mar TI - Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer. PG - 194.e9-194.e16 LID - S1078-1439(20)30395-1 [pii] LID - 10.1016/j.urolonc.2020.08.026 [doi] AB - OBJECTIVES: To evaluate the impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We retrospectively evaluated 428 patients with primary high-risk NMIBC who underwent TURBT from November 1993 to April 2019. Of the 428 patients, 140 had experienced recurrence at any site and were divided into 2 groups: patients who had experienced recurrence detected by the surveillance (asymptomatic group) and patients who had experienced recurrence detected by a symptom-driven investigation (symptomatic group). Background-adjusted multivariable analyses with the inverse probability of treatment weighting method were performed to evaluate the impact of symptomatic recurrence on cancer-specific survival and overall survival after first recurrence in patients who had experienced recurrence. Moreover, multivariable analysis was performed to identify predictive factors of symptomatic recurrence in the entire cohort. RESULTS: Median age and follow-up periods were 72 (interquartile range [IQR] 64-79) years and 55 (IQR 29-96) months, respectively. Of the 140 patients who experienced recurrence, 106 (76%) were diagnosed by the surveillance (asymptomatic group) and 34 (24%) were diagnosed by a symptom-driven investigation (symptomatic group). In the background-adjusted multivariable analyses with the inverse probability of treatment weighting model, symptomatic recurrence was significantly associated with shorter cancer-specific survival along with shorter overall survival after first recurrence. In the multivariable analysis, only tumor grade was selected as a significant predictive factor of symptomatic recurrence after TURBT. CONCLUSIONS: Symptomatic recurrence was significantly associated with poor oncological outcomes in patients with primary high-risk NMIBC. Patients with grade 3 tumors may require more intensive surveillance after TURBT. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article DEP - 20200915 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local MH - Retrospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - High-risk OT - Non-muscle-invasive bladder cancer OT - Surveillance OT - Symptomatic recurrence OT - Transurethral resection of bladder tumor EDAT- 2020/09/19 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/09/18 05:38 PHST- 2020/04/30 00:00 [received] PHST- 2020/08/04 00:00 [revised] PHST- 2020/08/17 00:00 [accepted] PHST- 2020/09/19 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/09/18 05:38 [entrez] AID - S1078-1439(20)30395-1 [pii] AID - 10.1016/j.urolonc.2020.08.026 [doi] PST - ppublish SO - Urol Oncol. 2021 Mar;39(3):194.e9-194.e16. doi: 10.1016/j.urolonc.2020.08.026. Epub 2020 Sep 15. PMID- 32924986 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 30 IP - 2 DP - 2021 TI - MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study. PG - 139-143 LID - 10.3233/CBM-200316 [doi] AB - BACKGROUND: Mini Chromosome Maintenance 5 (MCM5) is considered as a urinary biomarker of bladder cancer. ADXBLADDER is a commercially available test to detect MCM5 antibodies. OBJECTIVE: External validation of ADXBLADDER test as a urinary biomarker of histopathologically confirmed non-muscle invasive bladder cancer (NMIBC) recurrence. METHODS: The study enrolled 119 consecutive patients with a history of NMIBC and 37 healthy volunteers matched as controls. Single, full-void urine samples were collected from patients before cystoscopy +/- TUR. To measure MCM5 expression, Arquer Diagnostics ADXBLADDER test was used. The study protocol was registered within the clinical trials database (NCT03796299). RESULTS: Among patients with NMIBC history, recurrence was diagnosed in 83 patients (69.7%). ADXBLADDER demonstrated sensitivity of 73.5% (95% confidence interval (CI) 62.7%-82.6%), specificity of 33.3% (95% CI 18.6% to 51%), overall negative predictive value (NPV) of 35.3% (95% CI 23.3% to 49.5%) and overall positive predictive value of 71.8% (95% CI 66.1% to 76.8%) for detecting recurrence. In a control group, false positive ADXBLADDER results were noticed in 18 patients (48.6%). The sensitivity and NPV were the highest in invasive tumors (100% and 100%, respectively) and in high-grade recurrences (81.8% and 94.1%, respectively). CONCLUSIONS: ADXBLADDER has a moderate sensitivity and poor specificity in detecting NMIBC recurrence. However, it properly diagnoses patients with T1+ stage recurrence or high-grade tumors. FAU - Bialek, Lukasz AU - Bialek L AD - First Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Czerwinska, Katarzyna AU - Czerwinska K AD - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland. FAU - Fus, Lukasz AU - Fus L AD - Department of Pathology, Medical University of Warsaw, Warsaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department and Clinic of Urology, Medical University of Wroclaw, Wroclaw, Poland. FAU - Sadowska, Anna AU - Sadowska A AD - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - First Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Kryst, Piotr AU - Kryst P AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. LA - eng SI - ClinicalTrials.gov/NCT03796299 PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Cycle Proteins) RN - 0 (MCM5 protein, human) SB - IM MH - Aged MH - Biomarkers, Tumor/urine MH - Case-Control Studies MH - Cell Cycle Proteins/*urine MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*urine MH - Prospective Studies MH - Urinary Bladder Neoplasms/diagnosis/pathology/*urine PMC - PMC12499985 OTO - NOTNLM OT - ADXBLADDER OT - MCM5 OT - Urothelial cancer OT - biomarker EDAT- 2020/09/15 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/02/22 CRDT- 2020/09/14 15:42 PHST- 2020/09/15 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2020/09/14 15:42 [entrez] PHST- 2021/02/22 00:00 [pmc-release] AID - CBM200316 [pii] AID - 10.3233/CBM-200316 [doi] PST - ppublish SO - Cancer Biomark. 2021;30(2):139-143. doi: 10.3233/CBM-200316. PMID- 32923138 OWN - NLM STAT- MEDLINE DCOM- 20210702 LR - 20210702 IS - 2162-4011 (Print) IS - 2162-402X (Electronic) IS - 2162-4011 (Linking) VI - 9 IP - 1 DP - 2020 Jun 27 TI - Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. PG - 1776060 LID - 10.1080/2162402X.2020.1776060 [doi] LID - 1776060 AB - The prediction of the response to Bacillus Calmette-Guerin (BCG) can help identify non-muscle-invasive bladder cancer (NMIBC) patients that may be better served with alternative therapy. Several cytokine profiles present promising results, but they are difficult to use in clinical practice. In this prospective, longitudinal study, we tried to identify reliable serum cytokines/chemokines to predict the response to BCG using samples collected before and during BCG induction therapy. We used the Bio-plex multiplex assays to identify potential BCG failure-related serum cytokines/chemokines in the discovery set (n = 13). After screening, we identified CCL27 as the top candidate biomarker for predicting the response to BCG (P = .003). In the validation set, we found that the AUC of the baseline CCL27 was 0.730 (95% CI 0.515-0.945, P = .040) along with 67% sensitivity, 78% specificity. The changes from baseline to last timepoint can also distinguish BCG responders from non-responders (AUC: 0.726, 95% CI 0.474-0.979, P = .044). Moreover, the combination score of serum CCL27 (CS(CCL27)), based on the baseline and changes of CCL27, could further improve the predictive accuracy with an AUC of 0.897 (95% CI 0.790-1.000, P < .001). The correlations between CCL27 and local/systemic immunologic parameters were further analyzed. The level of serum CCL27 was strongly correlated with regulatory T cells (Tregs) in the tumor microenvironment (P = .002), indicating that CCL27 may promote the recruitment of Tregs into the tumor microenvironment. Our results show that serum CCL27 may represent a practical and reliable marker for the prediction of the response to BCG in NMIBC. CI - (c) 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. FAU - Zhong, Wenlong AU - Zhong W AUID- ORCID: 0000-0001-5343-4652 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Wang, Bo AU - Wang B AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Lin, Jianxun AU - Lin J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Xia, Kun AU - Xia K AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Hou, Weibin AU - Hou W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Yang, Meihua AU - Yang M AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Chen, Junyu AU - Chen J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Yang, Meng AU - Yang M AD - Department of Urology, Yan' an Hospital of Kunming City, Kunming Medical University, Kunming, PR China. FAU - Wang, Xiaofei AU - Wang X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200627 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 RN - 0 (BCG Vaccine) RN - 0 (CCL27 protein, human) RN - 0 (Chemokine CCL27) MH - BCG Vaccine/therapeutic use MH - Chemokine CCL27 MH - Female MH - Humans MH - Immunotherapy MH - Longitudinal Studies MH - Male MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC7458591 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - CCL27 OT - non-muscle-invasive bladder cancer (NMIBC) OT - regulatory T cells (Tregs) OT - response EDAT- 2020/09/15 06:00 MHDA- 2020/09/15 06:01 PMCR- 2020/06/27 CRDT- 2020/09/14 05:53 PHST- 2020/09/14 05:53 [entrez] PHST- 2020/09/15 06:00 [pubmed] PHST- 2020/09/15 06:01 [medline] PHST- 2020/06/27 00:00 [pmc-release] AID - 1776060 [pii] AID - 10.1080/2162402X.2020.1776060 [doi] PST - epublish SO - Oncoimmunology. 2020 Jun 27;9(1):1776060. doi: 10.1080/2162402X.2020.1776060. PMID- 32922663 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260330 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 11 IP - 34 DP - 2020 Aug 25 TI - Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1. PG - 3244-3255 LID - 10.18632/oncotarget.27696 [doi] AB - Clinical management of bladder carcinomas (BC) remains a major challenge and demands comprehensive multi-omics analysis for better stratification of the disease. Identification of patients on risk requires identification of signatures predicting prognosis risk of the patients. Understanding the molecular alterations associated with the disease onset and progression could improve the routinely used diagnostic and therapy procedures. In this study, we investigated the aberrant changes in N-glycosylation pattern of proteins associated with tumorigenesis as well as disease progression in bladder cancer. We integrated and compared global N-glycoproteomic and proteomic profile of urine samples from bladder cancer patients at different clinicopathological stages (non-muscle invasive and muscle-invasive patients [n = 5 and 4 in each cohort]) with healthy subjects (n = 5) using SPEG method. We identified 635 N-glycopeptides corresponding to 381 proteins and 543 N-glycopeptides corresponding to 326 proteins in NMIBC and MIBC patients respectively. Moreover, we identified altered glycosylation in 41 NMIBC and 21 MIBC proteins without any significant change in protein abundance levels. In concordance with the previously published bladder cancer cell line N-glycoproteomic data, we also observed dysregulated glycosylation in ECM related proteins. Further, we identified distinct N-glycosylation pattern of CD44, MGAM, and GINM1 between NMIBC and MIBC patients, which may be associated with disease progression in bladder cancer. These aberrant protein glycosylation events would provide a novel approach for bladder carcinoma diagnosis and further define novel mechanisms of tumor initiation and progression. FAU - Sathe, Gajanan AU - Sathe G AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - Manipal Academy of Higher Education (MAHE), Manipal 576104, India. AD - Center for Molecular Medicine, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India. AD - These authors contributed equally to this work and share the first authorship. FAU - George, Irene A AU - George IA AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - Manipal Academy of Higher Education (MAHE), Manipal 576104, India. AD - These authors contributed equally to this work and share the first authorship. FAU - Deb, Barnali AU - Deb B AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - Manipal Academy of Higher Education (MAHE), Manipal 576104, India. AD - These authors contributed equally to this work and share the second authorship. FAU - Jain, Ankit P AU - Jain AP AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - These authors contributed equally to this work and share the second authorship. FAU - Patel, Krishna AU - Patel K AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India. FAU - Nayak, Brusabhanu AU - Nayak B AD - Department of Urology, All India Institute of Medical Sciences, New Delhi 110070, India. FAU - Karmakar, Subhradip AU - Karmakar S AD - Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110070, India. FAU - Seth, Amlesh AU - Seth A AD - Department of Urology, All India Institute of Medical Sciences, New Delhi 110070, India. FAU - Pandey, Akhilesh AU - Pandey A AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - Manipal Academy of Higher Education (MAHE), Manipal 576104, India. AD - Center for Molecular Medicine, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India. AD - Department of Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA. FAU - Kumar, Prashant AU - Kumar P AD - Institute of Bioinformatics, International Technology Park, Bangalore 560066, India. AD - Manipal Academy of Higher Education (MAHE), Manipal 576104, India. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20200825 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC7456616 OTO - NOTNLM OT - MIBC OT - N-linked glycoproteomics OT - NMIBC OT - urine proteomics OT - urothelial carcinoma COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest. EDAT- 2020/09/15 06:00 MHDA- 2020/09/15 06:01 PMCR- 2020/08/25 CRDT- 2020/09/14 05:51 PHST- 2020/06/01 00:00 [received] PHST- 2020/07/14 00:00 [accepted] PHST- 2020/09/14 05:51 [entrez] PHST- 2020/09/15 06:00 [pubmed] PHST- 2020/09/15 06:01 [medline] PHST- 2020/08/25 00:00 [pmc-release] AID - 27696 [pii] AID - 10.18632/oncotarget.27696 [doi] PST - epublish SO - Oncotarget. 2020 Aug 25;11(34):3244-3255. doi: 10.18632/oncotarget.27696. eCollection 2020 Aug 25. PMID- 32922074 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Development and Validation of a Model for Predicting Urethral Recurrence in Male Patients with Muscular Invasive Bladder Cancer After Radical Cystectomy Combined with Urinary Diversion. PG - 7649-7657 LID - 10.2147/CMAR.S261809 [doi] AB - PURPOSE: Radical cystectomy (RC) is the primary treatment strategy for patients with muscular invasive bladder cancer (MIBC). However, the prognosis is poor and tumor recurrence is not rare, in particular, urethral recurrence (UR) in male patients who underwent RC combined with urinary diversion. Here, we have developed and validated a model for predicting UR in these patients. PATIENTS AND METHODS: The development cohort comprised 310 patients who underwent RC combined with urinary diversion at our center between 1 January 2007 and 31 December 2015. Clinicopathologic data of patients were comprehensively recorded. Multivariate Cox proportional hazard regression was used for building a predictive model with regression coefficients and backward stepwise selection applied by utilizing the likelihood ratio test with Akaike's information criterion as the stopping rule. An independent cohort consisting of 131 consecutive patients treated from 1 January 2016 to 31 December 2017 was used for validation. The performance of this predictive model was assessed with respect to discrimination, calibration, and clinical usefulness. RESULTS: The predictors of this model included body mass index, history of transurethral resection of bladder tumor, tumor grade, tumor stage, and concomitant carcinoma in situ. In the validation cohort, the model showed good discrimination with a concordance index of 0.777 (95% CI, 0.618 to 0.937) and calibration. Decision curve analysis also demonstrated the clinical utility of the model. CONCLUSION: The predictive model facilitated postoperative individualized prediction of UR in male patients with MIBC after RC combined with urinary diversion and it may therefore serve to improve follow-up strategies. CI - (c) 2020 Liu et al. FAU - Liu, Zeqi AU - Liu Z AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China. FAU - Zhang, Xuanyu AU - Zhang X AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China. FAU - Wu, Bin AU - Wu B AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China. FAU - Zhao, Yueyang AU - Zhao Y AD - Department of Library and Statistics, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China. FAU - Bai, Song AU - Bai S AUID- ORCID: 0000-0002-6073-145X AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China. LA - eng PT - Journal Article DEP - 20200824 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7457729 OTO - NOTNLM OT - male OT - muscle invasive bladder cancer OT - predictive model OT - radical cystectomy OT - urethral recurrence COIS- The authors (Zeqi Liu, Xuanyu Zhang, Bin Wu, Yueyang Zhao, Song Bai) declare that they have no competing interests for this work. Song Bai certifies that all conflicts of interest, including specific financial interests, relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending) are none. There was no role in this study of funding source. EDAT- 2020/09/15 06:00 MHDA- 2020/09/15 06:01 PMCR- 2020/08/24 CRDT- 2020/09/14 05:49 PHST- 2020/05/12 00:00 [received] PHST- 2020/08/02 00:00 [accepted] PHST- 2020/09/14 05:49 [entrez] PHST- 2020/09/15 06:00 [pubmed] PHST- 2020/09/15 06:01 [medline] PHST- 2020/08/24 00:00 [pmc-release] AID - 261809 [pii] AID - 10.2147/CMAR.S261809 [doi] PST - epublish SO - Cancer Manag Res. 2020 Aug 24;12:7649-7657. doi: 10.2147/CMAR.S261809. eCollection 2020. PMID- 32915676 OWN - NLM STAT- MEDLINE DCOM- 20210415 LR - 20210415 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 20 IP - 11 DP - 2020 Nov TI - Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. PG - 965-983 LID - 10.1080/14737140.2020.1822743 [doi] AB - INTRODUCTION: Many patients with non-muscle-invasive bladder cancer (NMIBC) failed intravesical BCG therapy. Currently, radical cystectomy is the recommended standard of care for those patients. There is unfortunately no effective other second-line therapy recommended. AREAS COVERED: In this review, we present the topics of BCG unresponsive NMIBC; definition, prognosis, and further treatment options: immunotherapy, intravesical chemotherapy, gene therapy, and targeted individualized therapy. EXPERT OPINION: There are major challenges of the management of NMIBC who failed BCG therapy as many patients refuse or are unfit for radical cystectomy. Multiple new modalities currently under investigation in ongoing clinical trials to better treat this category of patients. Immunotherapy, especially PD-1/PD-L1 inhibitors, offers exciting and potentially effective strategies for the treatment of BCG unresponsive NMIBC. As the data expands, it is sure that soon there will be established new guidelines for NMIBC. FAU - Moussa, Mohamad AU - Moussa M AD - Head of Urology Department, Zahraa Hospital, University Medical Center, Lebanese University , Beirut, Lebanon. FAU - Papatsoris, Athanasios G AU - Papatsoris AG AD - 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens , Athens, Greece. FAU - Dellis, Athanasios AU - Dellis A AD - Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens , Athens, Greece. FAU - Abou Chakra, Mohamed AU - Abou Chakra M AD - Faculty of Medical Sciences, Department of Urology, Lebanese University , Beirut,Lebanon. FAU - Saad, Wajih AU - Saad W AD - Head of Oncology Department, Zahraa Hospital, University Medical Center, Lebanese University , Beirut, Lebanon. LA - eng PT - Journal Article PT - Review DEP - 20200920 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Animals MH - BCG Vaccine/*administration & dosage MH - Cystectomy/*methods MH - Genetic Therapy/methods MH - Humans MH - Immunotherapy/methods MH - Prognosis MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG therapy OT - BCG unresponsive OT - Bladder cancer OT - gene therapy OT - immunotherapy OT - new therapy OT - non-muscle invasive OT - targeted therapy EDAT- 2020/09/12 06:00 MHDA- 2021/04/16 06:00 CRDT- 2020/09/11 17:11 PHST- 2020/09/12 06:00 [pubmed] PHST- 2021/04/16 06:00 [medline] PHST- 2020/09/11 17:11 [entrez] AID - 10.1080/14737140.2020.1822743 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2020 Nov;20(11):965-983. doi: 10.1080/14737140.2020.1822743. Epub 2020 Sep 20. PMID- 32900676 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220429 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 6 DP - 2021 Nov TI - Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival. PG - 1324-1331 LID - S2405-4569(20)30220-0 [pii] LID - 10.1016/j.euf.2020.08.007 [doi] AB - BACKGROUND: Obtaining detrusor muscle (DM) in transurethral resection of bladder tumor (TURBt) specimen is considered a surrogate marker of resection quality. However, evidence was principally investigated in high-risk tumors. Therefore, DM sampling for low-grade (LG) urothelial carcinoma (UC) remains poorly investigated and certainly requires further investigation. OBJECTIVE: To assess whether the absence of DM in TURBt specimen has a negative impact on recurrence-free survival (RFS) in patients with a Ta LG UC. DESIGN, SETTING, AND PARTICIPANTS: A multicenter TURBt database was queried for "LG, Ta, UC of the bladder." All patients treated between 1996 and 2018 with tumor grade assessed according to both 1973 World Health Organization and 2004 WHO/International Society of Urological Pathology grading classifications and with a minimum follow-up of 1 yr were included. Patients with a previous history of high-grade UC, upper urinary tract UC, or bladder tumor differentiations other than UC were excluded. INTERVENTION: TURBt. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline demographic, clinical, and pathologic data were analyzed. The European Organization for Research and Treatment of Cancer (EORTC) risk group was recorded. Kaplan-Meier analysis was performed to assess the predictive role of clinical and pathologic data for RFS. Univariable and multivariable Cox regression analyses were performed to identify the predictors of recurrence. RESULTS AND LIMITATIONS: Overall, 521 patients were included. At Kaplan-Meier analysis, the low-risk cohort displayed significantly higher RFS than the intermediate-risk cohort (1-yr RFS 87% vs 79%; log-rank p = 0.007). At univariable Cox regression analysis, only gender, multiple tumors, tumor diameter >/=3 cm, and EORTC risk group were significant predictors of recurrence. Absence of DM had no impact on RFS. Multivariable Cox regression analysis confirmed gender and EORTC risk group as independent predictors of recurrence. CONCLUSIONS: Absence of DM in TURBt specimen has negligible role in RFS of patients with Ta LG tumors of the bladder. PATIENT SUMMARY: In this study, we assessed the role that detrusor muscle (DM) in transurethral resection of bladder tumor specimen has in recurrence-free survival, in patients with a Ta low-grade urothelial carcinoma of the bladder. Absence of DM has no impact on tumor recurrence; therefore, it does not require additional attention. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy; Department of Urology, "Sapienza" University, Rome, Italy. Electronic address: ric.mastroianni@libero.it. FAU - Brassetti, Ado AU - Brassetti A AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Salhi, Yazan Al AU - Salhi YA AD - Department of Medico Surgical Sciences and Biotechnologies-Urology Unit, "Sapienza" University-I.C.O.T., Latina, Italy. FAU - Anceschi, Umberto AU - Anceschi U AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Bove, Alfredo Maria AU - Bove AM AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Carbone, Antonio AU - Carbone A AD - Department of Medico Surgical Sciences and Biotechnologies-Urology Unit, "Sapienza" University-I.C.O.T., Latina, Italy. FAU - De Nunzio, Cosimo AU - De Nunzio C AD - Department of Urology, "Sant'Andrea" Hospital, Rome, Italy. FAU - Fuschi, Andrea AU - Fuschi A AD - Department of Medico Surgical Sciences and Biotechnologies-Urology Unit, "Sapienza" University-I.C.O.T., Latina, Italy. FAU - Ferriero, Mariaconsiglia AU - Ferriero M AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Nacchia, Antonio AU - Nacchia A AD - Department of Urology, "Sant'Andrea" Hospital, Rome, Italy. FAU - Pastore, Antonio Luigi AU - Pastore AL AD - Department of Medico Surgical Sciences and Biotechnologies-Urology Unit, "Sapienza" University-I.C.O.T., Latina, Italy. FAU - Tema, Giorgia AU - Tema G AD - Department of Urology, "Sant'Andrea" Hospital, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Urology, "Sapienza" University, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200906 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - *Carcinoma, Transitional Cell/pathology/surgery MH - Humans MH - Muscles/pathology MH - Neoplasm Recurrence, Local/epidemiology/surgery MH - Urinary Bladder/pathology/surgery MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - *Detrusor muscle OT - *Intermediate-risk bladder cancer OT - *Low-grade bladder cancer OT - *Low-risk bladder cancer OT - *Non-muscle-invasive bladder cancer OT - *Recurrence-free survival OT - *Transurethral resection of the bladder EDAT- 2020/09/10 06:00 MHDA- 2022/04/14 06:00 CRDT- 2020/09/09 05:24 PHST- 2020/07/06 00:00 [received] PHST- 2020/07/27 00:00 [revised] PHST- 2020/08/25 00:00 [accepted] PHST- 2020/09/10 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2020/09/09 05:24 [entrez] AID - S2405-4569(20)30220-0 [pii] AID - 10.1016/j.euf.2020.08.007 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Nov;7(6):1324-1331. doi: 10.1016/j.euf.2020.08.007. Epub 2020 Sep 6. PMID- 32900630 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 2 DP - 2021 Feb TI - Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage. PG - 132.e13-132.e26 LID - S1078-1439(20)30375-6 [pii] LID - 10.1016/j.urolonc.2020.08.008 [doi] AB - OBJECTIVES: To evaluate the prognostic impact of lymphovascular invasion (LVI) on node-negative upper tract urothelial carcinoma (UTUC) in patients treated with radical nephroureterectomy (RNU). MATERIALS AND METHODS: A retrospective study was performed in single tertiary referral center of middle Taiwan between 2001 and 2015. Seven hundred and twenty-eight patients were diagnosed of UTUC and underwent RNU with ipsilateral bladder cuff excision including 303 and 195 patients with N0 and Nx status respectively. LVI status was assessed as a prognostic factor for cancer-specific (CSS) and overall survival (OS) using univariate and multivariate Cox regression analysis. RESULTS: LVI was observed in 82 patients (16.5%). LVI presentation associated with smoking status, advanced tumor stage, high tumor grade, positive surgical margin, and consequence lung/liver/bone metastasis. In the multivariate analysis, LVI was failed to predict CSS, OS, and disease-free survival (DFS) (hazard ratio [HR] [95% confidence interval [CI]: 1.07 [0.55-2.09], 1.05 [0.62-1.79], 1.15 [0.69-1.92], in CSS, OS, DFS, respectively). In the subgroup analysis of pT1-2 disease, the CSS, OS, and DFS were associated with LVI status (HR [95% CI]: 2.29 [0.44-11.84], 3.17 [1.16-8.67], 2.66 [1.04-6.79], in CSS, OS, DFS, respectively). In contrast, there was no difference in pT3 disease. CONCLUSION: In conclusion, LVI status was not associated with survival outcomes of node-negative UTUC in our study. The subgroup analysis showed different prognostic impacts of LVI status in node-negative UTUC with T1-2 and T3 stage. Further evidence to clarify the prognostic effect is needed to make LVI became a practical factor in clinical decision-making. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Chen, Chuan-Shu AU - Chen CS AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Lin, Chia-Yen AU - Lin CY AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan; Division of Surgical Critical Care, Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Wang, Chun-Li AU - Wang CL AD - Department of Family Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Wang, Shian-Shiang AU - Wang SS AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan. FAU - Li, Jian-Ri AU - Li JR AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Yang, Chun-Kuang AU - Yang CK AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Cheng, Chen-Li AU - Cheng CL AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Chiu, Kun-Yuan AU - Chiu KY AD - Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan. Electronic address: kychiu37782002@gmail.com. FAU - Yang, Shun-Fa AU - Yang SF AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. Electronic address: ysf@csmu.edu.tw. LA - eng PT - Journal Article DEP - 20200906 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*pathology/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Kidney Neoplasms/mortality/*pathology/*surgery MH - Lymphatic Vessels/*pathology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/*pathology/*surgery OTO - NOTNLM OT - Lymphovascular invasion OT - Nephroureterectomy OT - Node negative OT - Survival OT - Upper tract OT - Urothelial carcinoma EDAT- 2020/09/10 06:00 MHDA- 2021/08/13 06:00 CRDT- 2020/09/09 05:24 PHST- 2020/03/23 00:00 [received] PHST- 2020/07/29 00:00 [revised] PHST- 2020/08/03 00:00 [accepted] PHST- 2020/09/10 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/09/09 05:24 [entrez] AID - S1078-1439(20)30375-6 [pii] AID - 10.1016/j.urolonc.2020.08.008 [doi] PST - ppublish SO - Urol Oncol. 2021 Feb;39(2):132.e13-132.e26. doi: 10.1016/j.urolonc.2020.08.008. Epub 2020 Sep 6. PMID- 32893303 OWN - NLM STAT- MEDLINE DCOM- 20210224 LR - 20210224 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 51 IP - 2 DP - 2021 Feb 8 TI - Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. PG - 287-295 LID - 10.1093/jjco/hyaa168 [doi] AB - BACKGROUND: Prophylactic urethrectomy at the time of radical cystectomy is frequently recommended for patients with bladder cancer at a high risk of urethral recurrence without definitive evidence. The present study attempted to clarify the survival benefits of performing prophylactic urethrectomy. METHODS: We identified 214 male patients who were treated by radical cystectomy with an incontinent urinary diversion in our seven institutions between 2004 and 2017. We used propensity score matching and ultimately identified 114 patients, 57 of whom underwent prophylactic urethrectomy (prophylactic urethrectomy group) and 57 who did not (non-prophylactic urethrectomy group). RESULTS: No significant differences were observed in the 5-year overall survival rate between the prophylactic urethrectomy and non-prophylactic urethrectomy groups in the overall. However, the local recurrence rate was significantly lower in the prophylactic urethrectomy group than in the non-prophylactic urethrectomy group (P = 0.015). In the subgroup of 58 patients with multiple tumours and/or concomitant carcinoma in situ at the time of transurethral resection of bladder tumour, the 5-year overall survival rate was significantly higher in the prophylactic urethrectomy group than in the non-prophylactic urethrectomy group (P = 0.021). A multivariate analysis revealed that performing prophylactic urethrectomy was the only independent predictor of the overall survival rate (P = 0.016). In those patients who were treated without neoadjuvant chemotherapy (n = 38), the 5-year overall survival rate was significantly higher in the prophylactic urethrectomy group than in the non-prophylactic urethrectomy group (P = 0.007). CONCLUSIONS: Prophylactic urethrectomy at the time of radical cystectomy may have a survival benefit in patients with multiple tumours and/or concomitant carcinoma in situ, particularly those who do not receive neoadjuvant chemotherapy. CI - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Hakozaki, Kyohei AU - Hakozaki K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Abe, Takayuki AU - Abe T AD - Department of Clinical and Translational Research Center, Keio University School of Medicine, Tokyo. AD - Yokohama City University, School of Data Science, Kanagawa. FAU - Miyazaki, Yasumasa AU - Miyazaki Y AD - Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa. FAU - Kaneko, Gou AU - Kaneko G AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama. FAU - Maeda, Takahiro AU - Maeda T AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa. FAU - Yoshimine, Shunsuke AU - Yoshimine S AD - Department of Urology, Saitama City Hospital, Saitama. FAU - Kanai, Kunimitsu AU - Kanai K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama. FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Saiseikai Central Hospital, Tokyo. FAU - Shirotake, Suguru AU - Shirotake S AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - Carcinoma in Situ/drug therapy/pathology/surgery MH - *Cystectomy MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoadjuvant Therapy MH - Neoplasm Metastasis MH - Neoplasm Recurrence, Local/pathology MH - Postoperative Complications/etiology MH - Propensity Score MH - Proportional Hazards Models MH - Survival Rate MH - Urethra/pathology/*surgery MH - Urinary Bladder Neoplasms/drug therapy/pathology/*surgery MH - *Urologic Surgical Procedures/adverse effects OTO - NOTNLM OT - bladder cancer OT - neoadjuvant chemotherapy OT - propensity score matching OT - radical cystectomy OT - urethrectomy EDAT- 2020/09/08 06:00 MHDA- 2021/02/25 06:00 CRDT- 2020/09/07 05:59 PHST- 2020/06/11 00:00 [received] PHST- 2020/08/17 00:00 [accepted] PHST- 2020/09/08 06:00 [pubmed] PHST- 2021/02/25 06:00 [medline] PHST- 2020/09/07 05:59 [entrez] AID - 5901982 [pii] AID - 10.1093/jjco/hyaa168 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2021 Feb 8;51(2):287-295. doi: 10.1093/jjco/hyaa168. PMID- 32891505 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20220420 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 31 IP - 2 DP - 2021 Feb TI - TFPI-2 inhibits the invasion and metastasis of bladder cancer cells. PG - 71-77 LID - S1166-7087(20)30479-6 [pii] LID - 10.1016/j.purol.2020.07.243 [doi] AB - INTRODUCTION: Bladder cancer metastasis seriously affects the prognosis of patients, but its molecular mechanism is unclear. This study sought to explore the roles of tissue factor pathway inhibitor-2 (TFPI-2) gene overexpression in the infiltration and metastasis of bladder cancer. MATERIALS: Firstly, real-time PCR and immunohistochemistry were used to compare the mRNA and protein expression levels, respectively, of TFPI-2 and matrix metalloproteinase-1 (MMP-1) in adjacent non-tumoral tissues, muscle-invasive bladder cancer (MIBC) tissues, and non-muscle-invasive bladder cancer (NMIBC) tissues. BIU-87-TFPI-2 cells that stably expressed TFPI-2 were generated by transfection with pcDNA3.1-TFPI-2. Real-time PCR and western blotting were performed to determine the mRNA and protein expression levels, respectively, of TFPI-2 and MMP-1 in BIU-87-TFPI-2 cells. The invasion and migration abilities of BIU-87-TFPI-2 cells were investigated using the Transwell chamber method. RESULTS: TFPI-2 was found to be significantly downregulated in bladder cancer tissue. The expression of MMP-1 was increased with the progression of bladder cancer. BIU-87 cells that overexpressed TFPI-2 were successfully generated by transfection with pcDNA3.1-TFPI-2. TFPI-2 overexpression in BIU-87 cells significantly inhibited cancer cell invasion and metastasis. Furthermore, the mRNA and protein expression levels of MMP-1 were significantly reduced in TFPI-2-overexpressing cells. CONCLUSION: Decreased TFPI-2 expression in bladder tissue was correlated with invasion and metastasis in bladder cancer. TFPI-2 overexpression could inhibit bladder cancer cell invasion and migration in vitro by inhibiting MMP-1 protein expression. LEVEL OF PROOF: 3. CI - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved. FAU - Liu, J AU - Liu J AD - Department of Urology, The Affiliated Hospital of Putian University, 351100 Putian, Fujian, China. FAU - Xie, J AU - Xie J AD - Department of Urology, The Affiliated Hospital of Putian University, 351100 Putian, Fujian, China. Electronic address: shashou027027@163.com. FAU - Huang, Y AU - Huang Y AD - Department of Ophthalmology, Jinjiang Hospital, 362200 Jinjiang, China. FAU - Xie, J AU - Xie J AD - Department of Urology, The Affiliated Hospital of Putian University, 351100 Putian, Fujian, China. FAU - Yan, X AU - Yan X AD - Department of Urology, The Affiliated Hospital of Putian University, 351100 Putian, Fujian, China. LA - eng PT - Journal Article DEP - 20200903 PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 RN - 0 (Glycoproteins) RN - 0 (tissue-factor-pathway inhibitor 2) SB - IM MH - Adult MH - Aged MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Glycoproteins/*genetics MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/genetics MH - Neoplasm Metastasis/genetics MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/*genetics/*pathology OTO - NOTNLM OT - Bladder cancer OT - Cancer de la vessie OT - Invasion OT - MMP-1 OT - Migration OT - TFPI-2 EDAT- 2020/09/07 06:00 MHDA- 2021/08/10 06:00 CRDT- 2020/09/06 20:23 PHST- 2020/03/01 00:00 [received] PHST- 2020/06/19 00:00 [revised] PHST- 2020/07/08 00:00 [accepted] PHST- 2020/09/07 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/09/06 20:23 [entrez] AID - S1166-7087(20)30479-6 [pii] AID - 10.1016/j.purol.2020.07.243 [doi] PST - ppublish SO - Prog Urol. 2021 Feb;31(2):71-77. doi: 10.1016/j.purol.2020.07.243. Epub 2020 Sep 3. PMID- 32891350 OWN - NLM STAT- MEDLINE DCOM- 20210708 LR - 20210708 IS - 1879-3320 (Electronic) IS - 0960-7404 (Linking) VI - 34 DP - 2020 Sep TI - The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. PG - 312-317 LID - S0960-7404(20)30333-9 [pii] LID - 10.1016/j.suronc.2020.06.006 [doi] AB - OBJECTIVE: To prospectively study the impact of smoking on pathological response to neoadjuvant chemotherapy (NAC) in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB). MATERIALS & METHODS: We collected standard clinicopathological variables, including smoking status (never, former, current) in patients undergoing NAC and RC for UCB at 12 European tertiary care centers between 12/2013-12/2015. Clinicopathological variables were compared according to smoking status. Multivariable logistic regression models were built to assess the association of smoking status and a) complete (no residual disease), b) partial (residual, non-muscle invasive disease), c) no pathological response (residual muscle invasive or lymph node positive disease). Kaplan-Meier and Cox regression analyses were employed to study the impact of response to NAC on survival. RESULTS AND LIMITATIONS: Our final cohort consisted of 167 NAC patients with a median follow-up of 15 months (interquartile range (IQR) 9-26 months) of whom 48 (29%), 69 (41%), and 50 (30%) where never, former, and current smokers, respectively. Smoking was significantly associated with advanced age (p = 0.013), worse ECOG performance status (p = 0.049), and decreased pathological response to NAC (p = 0.045). On multivariable logistic regression analyses, former and current smoking status was significantly associated with lower odds of complete pathological response (odds ratio (OR) 0.37, 95% confidence interval (CI) 0.16-0.87, p = 0.023, and OR 0.34, 95% CI 0.13-0.85, p = 0.021), while current smoking status was significantly associated with a greater likelihood of no pathological response (OR 2.49, 95% CI 1.02-6.06, p = 0.045). Response to NAC was confirmed as powerful predictor of survival. CONCLUSIONS: Smoking status is adversely associated with pathological response to NAC. Smokers should be informed about these adverse effects, counseled regarding smoking cessation, and possibly be considered for immunotherpeutics as they may be more effective in smokers. CI - Copyright (c) 2020 Elsevier Ltd. All rights reserved. FAU - Gild, Philipp AU - Gild P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Germany. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Germany. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, University Hospital Berne, Berne, Switzerland. FAU - Necchi, Andrea AU - Necchi A AD - Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Mertens, Laura S AU - Mertens LS AD - Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. FAU - Landenberg, Nicolas V AU - Landenberg NV AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, University of Torino, Italy. FAU - Cumberbatch, Marcus AU - Cumberbatch M AD - Department of Academic Urology, University of Sheffield, Sheffield, UK. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Seisen, Thomas AU - Seisen T AD - Department of Urology, University Paris Sorbonne, France. FAU - Grande, Pietro AU - Grande P AD - Department of Urology, University Paris Sorbonne, France. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Anract, Julien AU - Anract J AD - Department of Urology, Bichat-Claude Bernard Hospital, Paris Descartes University, Paris, France. FAU - Comploj, Evi AU - Comploj E AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy; Department of Research, College of Health Care Professions, Claudiana, Bozen, Italy. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy; Medical School, Sigmund Freud University, Vienna, Austria. FAU - Saba, Karim AU - Saba K AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - van Rhijn, Bas W AU - van Rhijn BW AD - Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Noon, Aidan P AU - Noon AP AD - Department of Urology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, University Paris Sorbonne, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Germany. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Paris Descartes University, Paris, France. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Germany. Electronic address: m.rink@uke.de. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20200630 PL - Netherlands TA - Surg Oncol JT - Surgical oncology JID - 9208188 SB - IM MH - Aged MH - Algorithms MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Cigarette Smoking/*mortality MH - Combined Modality Therapy MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*mortality MH - Neoplasm Recurrence, Local/drug therapy/pathology MH - *Patient Selection MH - Prognosis MH - Prospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*pathology/therapy MH - Urologists OTO - NOTNLM OT - Bladder cancer OT - Cisplatin OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Smoking EDAT- 2020/09/07 06:00 MHDA- 2021/07/09 06:00 CRDT- 2020/09/06 20:21 PHST- 2020/04/20 00:00 [received] PHST- 2020/06/18 00:00 [accepted] PHST- 2020/09/06 20:21 [entrez] PHST- 2020/09/07 06:00 [pubmed] PHST- 2021/07/09 06:00 [medline] AID - S0960-7404(20)30333-9 [pii] AID - 10.1016/j.suronc.2020.06.006 [doi] PST - ppublish SO - Surg Oncol. 2020 Sep;34:312-317. doi: 10.1016/j.suronc.2020.06.006. Epub 2020 Jun 30. PMID- 32885299 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20261010 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 31 IP - 3 DP - 2021 Mar TI - Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the vesical imaging-reporting and data system. PG - 1656-1666 LID - 10.1007/s00330-020-07224-7 [doi] AB - OBJECTIVES: To examine the diagnostic performance of Vesical Imaging-Reporting and Data System (VIRADS) and to find a quantitative indicator for predicting muscle layer invasion of bladder cancer. METHODS: 3-T MRI of 82 patients performed before transurethral resection of bladder tumors or radical cystectomy between July 2018 and June 2019 were retrospectively analyzed. For one index lesion of each patient, two radiologists independently assigned VIRADS score and measured tumor-wall interface (contact length between tumor and bladder wall) on T2-weighted, diffusion-weighted, and dynamic contrast-enhanced MRI. Inter-reader agreement was assessed, and logistic regression analysis was performed to find indicators of muscle layer invasion. Comparison of indicators' diagnostic performance was done with receiver operating characteristic (ROC) curve and generalized linear model analyses. Optimal cutoff point was determined by the Youden index J. RESULTS: Inter-reader agreement was at least substantial for VIRADS categorization (kappa 0.77-0.81), and almost perfect for tumor-wall interface (intraclass correlation coefficient 0.88-0.90). Tumor-wall interface (odds ratio [OR] 1.90-2.00) and VIRADS score (OR 8.59-8.89) were independently associated with muscle layer invasion (p 0.10), except as measured on diffusion-weighted images (p = 0.01). CONCLUSIONS: VIRADS is a good predictor of muscle layer invasion. As an independent quantitative indicator, tumor-wall interface may complement VIRADS to enhance prediction. KEY POINTS: * Vesical Imaging-Reporting and Data System (VIRADS) is a promising predictor of muscle invasion of bladder cancer with good reproducibility, as suggested by previous studies. * VIRADS score and the tumor-wall interface (curvilinear contact length between the tumor and the bladder wall) are independent predictors of muscle layer invasion. * As an easy-to-use quantitative indicator, tumor-wall interface is expected to be used as an indicator complementary to VIRADS, a qualitative indicator. FAU - Ahn, Hyungwoo AU - Ahn H AD - Department of Radiology, Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. FAU - Hwang, Sung Il AU - Hwang SI AUID- ORCID: 0000-0001-7516-5369 AD - Department of Radiology, Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. hwangsi49@gmail.com. FAU - Lee, Hak Jong AU - Lee HJ AD - Department of Radiology, Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. FAU - Choe, Gheeyoung AU - Choe G AD - Department of Pathology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. FAU - Jeong, Seong Jin AU - Jeong SJ AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. FAU - Byun, Seok-Soo AU - Byun SS AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. FAU - Kim, Jung Kwon AU - Kim JK AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. LA - eng GR - NRF-2013R1A1A2011398/Ministry of Science, Information and Communications Technology, Republic of Korea/ GR - 11-2010-008/Seoul National University Bundang Hospital Research Fund/ PT - Journal Article DEP - 20200904 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Humans MH - Muscles/pathology MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Reproducibility of Results MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology OTO - NOTNLM OT - Carcinoma OT - Magnetic resonance imaging OT - Neoplasm staging OT - Urinary bladder neoplasms OT - transitional cell EDAT- 2020/09/05 06:00 MHDA- 2021/04/15 06:00 CRDT- 2020/09/05 06:00 PHST- 2020/05/27 00:00 [received] PHST- 2020/08/21 00:00 [accepted] PHST- 2020/07/21 00:00 [revised] PHST- 2020/09/05 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2020/09/05 06:00 [entrez] AID - 10.1007/s00330-020-07224-7 [pii] AID - 10.1007/s00330-020-07224-7 [doi] PST - ppublish SO - Eur Radiol. 2021 Mar;31(3):1656-1666. doi: 10.1007/s00330-020-07224-7. Epub 2020 Sep 4. PMID- 32884355 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Predictors of Intravesical Recurrence After Radical Nephroureterectomy and Prognosis in Patients with Upper Tract Urothelial Carcinoma. PG - 7439-7450 LID - 10.2147/CMAR.S261087 [doi] AB - PURPOSE: We investigate factors that may contribute individually to bladder recurrence and find out the potential candidate to receive postoperative single dose intravesical chemotherapy. MATERIALS AND METHODS: A total of 217 patients who were diagnosed with upper tract urothelial carcinoma (UTUC) underwent radical nephroureterectomy (RNU) between 2012 and 2016 in a single hospital. The possible risk factors that may contribute to development of bladder recurrence and overall survival were analysed. In order to find out the relationship between 1st bladder recurrence timing and outcome, we divided the 54 of 56 patients (2 patients with prophylactic intravesical chemotherapy excluded) with bladder recurrence after RNU into 2 groups, using the median time of 1st bladder recurrence and confirmed with the "minimum P-value" approach. The primary endpoint was the development of relapsing high-risk non-muscle invasive bladder cancer (NMIBC). The predictive factors of early recurrence and prognostic factors of survival were also analysed. RESULTS: Among 217 patients with UTUC under RNU, intravesical recurrence occurred in 56 (25.8%) patients after a median follow-up of 35.2 (1.18-83.34) months. On multivariable analysis, the preoperative ureter manipulation (p=0.009) was a significant predictor for the development of bladder tumours. As for overall survival, renal rein invasion (p=0.017), neutrophil to lymphocyte ratio (p=0.021), and main tumour size (p=0.015) were significant predictors. For 54 patients who developed bladder recurrence, the optimal cut-off point of early recurrence was determined to be 10 months after surgery (p=0.042). Preoperative ureter manipulation (p=0.005) and tumour located both pelvicalyceally and ureterically (P=0.042) were identified as independent factors associated with early recurrence. An end-stage renal disease history and surgical margin positive patient has more late bladder recurrence. CONCLUSION: Bladder recurrence was common in UTUC after RNU. Early bladder recurrence was associated with more relapsing high-risk NMIBC and preoperative ureter manipulation was identified as an independent factor associated with early recurrence. CI - (c) 2020 Li et al. FAU - Li, Yun-Ren AU - Li YR AUID- ORCID: 0000-0001-8473-9336 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Yu, Kai-Jie AU - Yu KJ AUID- ORCID: 0000-0003-3656-8856 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Chang, Ying-Hsu AU - Chang YH AD - Department of Urology, New Taipei Municipal Tu Cheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan. FAU - Lin, Po-Hung AU - Lin PH AUID- ORCID: 0000-0001-8245-4302 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Shao, I-Hung AU - Shao IH AUID- ORCID: 0000-0002-4832-0113 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Kan, Hung-Cheng AU - Kan HC AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Chu, Yuan-Cheng AU - Chu YC AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Chuang, Cheng-Keng AU - Chuang CK AUID- ORCID: 0000-0001-6154-1220 AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Pang, See-Tong AU - Pang ST AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. FAU - Liu, Chung-Yi AU - Liu CY AUID- ORCID: 0000-0002-6579-4775 AD - Department of Urology, New Taipei Municipal Tu Cheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan. LA - eng PT - Journal Article DEP - 20200819 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7443413 OTO - NOTNLM OT - intravesical recurrence OT - prognosis OT - radical nephroureterectomy OT - upper tract urothelial carcinoma COIS- The authors report no conflicts of interest in this work. EDAT- 2020/09/05 06:00 MHDA- 2020/09/05 06:01 PMCR- 2020/08/19 CRDT- 2020/09/05 06:00 PHST- 2020/05/03 00:00 [received] PHST- 2020/07/29 00:00 [accepted] PHST- 2020/09/05 06:00 [entrez] PHST- 2020/09/05 06:00 [pubmed] PHST- 2020/09/05 06:01 [medline] PHST- 2020/08/19 00:00 [pmc-release] AID - 261087 [pii] AID - 10.2147/CMAR.S261087 [doi] PST - epublish SO - Cancer Manag Res. 2020 Aug 19;12:7439-7450. doi: 10.2147/CMAR.S261087. eCollection 2020. PMID- 32875619 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20241017 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 27 IP - 11 DP - 2020 Nov TI - Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma. PG - 1024-1030 LID - 10.1111/iju.14352 [doi] AB - OBJECTIVES: To evaluate the relationship between residual urine volume, pyuria and bladder carcinoma recurrence. METHODS: The clinical data of 305 patients who had post-void residual urine volume measured and preoperative pyuria were retrospectively collected. The patients were classified into three risk groups based on the presence of residual urine and pyuria: good (negative residual urine and pyuria), intermediate (positive residual urine or pyuria) and poor (positive residual urine and pyuria). Predictive factors for intravesical recurrence-free survival were statistically analyzed using Cox proportional hazard models and Kaplan-Meier methods. The propensity score matching method was used to adjust the patients' backgrounds. RESULTS: The median follow-up period for all patients was 44 months. The presence of residual urine (P = 0.0164) and pyuria (P = 0.0233) were two independent prognostic factors for recurrence. After patients were classified into risk groups, the poor-risk group showed significantly shorter recurrence-free survival compared with that of the good- (P = 0.0002) and intermediate-risk groups (P = 0.0090). Even after matching, the presence of residual urine was related to short recurrence-free survival in male patients (P = 0.0012). When stratified by European Organization for Research and Treatment of Cancer risk groups, the presence of pyuria was related to short recurrence-free survival, especially for intermediate-risk patients without bacillus Calmette-Guerin treatment. CONCLUSIONS: Post-void residual urine and preoperative pyuria are two risks for recurrence-free survival in non-muscle-invasive bladder cancer. CI - (c) 2020 The Japanese Urological Association. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Sakamoto, Shinichi AU - Sakamoto S AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Imamura, Yusuke AU - Imamura Y AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Nakamura, Kazuyoshi AU - Nakamura K AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Yamamoto, Satoshi AU - Yamamoto S AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Arai, Takayuki AU - Arai T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Takeuchi, Nobuyoshi AU - Takeuchi N AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Komiya, Akira AU - Komiya A AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Teishima, Jun AU - Teishima J AD - Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. LA - eng PT - Journal Article DEP - 20200901 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) SB - IM CIN - Int J Urol. 2020 Nov;27(11):1030-1031. doi: 10.1111/iju.14365. PMID: 32914469 CIN - Int J Urol. 2020 Nov;27(11):1031. doi: 10.1111/iju.14395. PMID: 32990342 MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Carcinoma MH - Humans MH - Male MH - Neoplasm Recurrence, Local/epidemiology MH - *Pyuria/epidemiology/etiology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/surgery OTO - NOTNLM OT - bladder carcinoma OT - intravesical recurrence OT - non-muscle-invasive bladder cancer OT - pyuria OT - residual urine volume EDAT- 2020/09/03 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/09/03 06:00 PHST- 2020/04/19 00:00 [received] PHST- 2020/07/13 00:00 [accepted] PHST- 2020/09/03 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/09/03 06:00 [entrez] AID - 10.1111/iju.14352 [doi] PST - ppublish SO - Int J Urol. 2020 Nov;27(11):1024-1030. doi: 10.1111/iju.14352. Epub 2020 Sep 1. PMID- 32868381 OWN - NLM STAT- MEDLINE DCOM- 20210210 LR - 20220810 IS - 1538-7445 (Electronic) IS - 0008-5472 (Print) IS - 0008-5472 (Linking) VI - 80 IP - 20 DP - 2020 Oct 15 TI - Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. PG - 4476-4486 LID - 10.1158/0008-5472.CAN-20-0977 [doi] AB - High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer with unpredictable outcome and poorly understood risk factors. Here, we examined the association of somatic mutation profiles with nonrecurrent disease (GO, good outcome), recurrence (R), or progression (PD) in a cohort of HGT1 patients. Exome sequencing was performed on 62 HGT1 and 15 matched normal tissue samples. Both tumor only (TO) and paired analyses were performed, focusing on 95 genes known to be mutated in bladder cancer. Somatic mutations, copy-number alterations, mutation load, and mutation signatures were studied. Thirty-three GO, 10 R, 18 PD, and 1 unknown outcome patients were analyzed. Tumor mutational burden (TMB) was similar to muscle-invasive disease and was highest in GO, intermediate in PD, and lowest in R patients (P = 0.017). DNA damage response gene mutations were associated with higher TMB (P < 0.0001) and GO (P = 0.003). ERCC2 and BRCA2 mutations were associated with GO. TP53, ATM, ARID1A, AHR, and SMARCB1 mutations were more frequent in PD. Focal copy-number gain in CCNE1 and CDKN2A deletion was enriched in PD or R (P = 0.047; P = 0.06). APOBEC (46%) and COSMIC5 (34%) signatures were most frequent. APOBEC-A and ERCC2 mutant tumors (COSMIC5) were associated with GO (P = 0.047; P = 0.0002). pT1b microstaging was associated with a genomic cluster (P = 0.05) with focal amplifications of E2F3/SOX4, PVRL4, CCNE1, and TP53 mutations. Findings were validated using external public datasets. These findings require confirmation but suggest that management of HGT1 bladder cancer may be improved via molecular characterization to predict outcome. SIGNIFICANCE: Detailed genetic analyses of HGT1 bladder tumors identify features that correlate with outcome, e.g., high mutational burden, ERCC2 mutations, and high APOBEC-A/ERCC2 mutation signatures were associated with good outcome. CI - (c)2020 American Association for Cancer Research. FAU - Bellmunt, Joaquim AU - Bellmunt J AUID- ORCID: 0000-0003-2328-3421 AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. jbellmun@bidmc.harvard.edu dk@rics.bwh.harvard.edu. AD - Harvard Medical School University, Boston, Massachusetts. AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. AD - IMIM-Hospital del Mar Medical Research Institute; Hospital del Mar, Barcelona, Spain. FAU - Kim, Jaegil AU - Kim J AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. FAU - Reardon, Brendan AU - Reardon B AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Perera-Bel, Julia AU - Perera-Bel J AUID- ORCID: 0000-0002-6809-132X AD - IMIM-Hospital del Mar Medical Research Institute; Hospital del Mar, Barcelona, Spain. FAU - Orsola, Anna AU - Orsola A AD - IMIM-Hospital del Mar Medical Research Institute; Hospital del Mar, Barcelona, Spain. FAU - Rodriguez-Vida, Alejo AU - Rodriguez-Vida A AD - IMIM-Hospital del Mar Medical Research Institute; Hospital del Mar, Barcelona, Spain. FAU - Wankowicz, Stephanie A AU - Wankowicz SA AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Bowden, Michaela AU - Bowden M AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Barletta, Justine A AU - Barletta JA AD - Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Morote, Juan AU - Morote J AD - Department of Urology, University Hospital Valle de Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - de Torres, Ines AU - de Torres I AUID- ORCID: 0000-0002-5495-9140 AD - Department of Pathology, University Hospital Valle de Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Juanpere, Nuria AU - Juanpere N AD - Department of Pathology, University Hospital del Mar, Pompeu Fabra University, Barcelona, Spain. FAU - Lloreta-Trull, Josep AU - Lloreta-Trull J AUID- ORCID: 0000-0003-1644-9470 AD - Department of Pathology, University Hospital del Mar, Pompeu Fabra University, Barcelona, Spain. FAU - Hernandez, Silvia AU - Hernandez S AD - Department of Pathology, University Hospital del Mar, Pompeu Fabra University, Barcelona, Spain. FAU - Mouw, Kent W AU - Mouw KW AD - Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts. FAU - Taplin, Mary-Ellen AU - Taplin ME AD - Harvard Medical School University, Boston, Massachusetts. AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Cejas, Paloma AU - Cejas P AD - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, Massachusetts. FAU - Long, Henry W AU - Long HW AD - Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, Massachusetts. FAU - Van Allen, Eliezer M AU - Van Allen EM AD - Harvard Medical School University, Boston, Massachusetts. AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Getz, Gad AU - Getz G AUID- ORCID: 0000-0002-0936-0753 AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. AD - Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. AD - Department of Pathology, Harvard Medical School, Boston, Massachusetts. FAU - Kwiatkowski, David J AU - Kwiatkowski DJ AUID- ORCID: 0000-0002-5668-5219 AD - Harvard Medical School University, Boston, Massachusetts. jbellmun@bidmc.harvard.edu dk@rics.bwh.harvard.edu. AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. LA - eng GR - P01 CA240239/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200831 PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (CCNE1 protein, human) RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin E) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Oncogene Proteins) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - EC 3.6.4.12 (Xeroderma Pigmentosum Group D Protein) RN - EC 5.99.- (ERCC2 protein, human) SB - IM CIN - Eur Urol. 2021 Mar;79(3):428-429. doi: 10.1016/j.eururo.2020.10.020. PMID: 33158662 CIN - Eur Urol. 2021 Apr;79(4):e119-e120. doi: 10.1016/j.eururo.2020.12.038. PMID: 33419679 MH - Cyclin E/genetics MH - Cyclin-Dependent Kinase Inhibitor p16/genetics MH - Female MH - Follow-Up Studies MH - Gene Dosage MH - Humans MH - Male MH - Muscles/pathology MH - *Mutation MH - Neoplasm Recurrence, Local/pathology MH - Oncogene Proteins/genetics MH - Tumor Suppressor Protein p53/genetics MH - Urinary Bladder Neoplasms/*genetics/mortality/*pathology MH - Xeroderma Pigmentosum Group D Protein/genetics PMC - PMC9361191 MID - NIHMS1826770 EDAT- 2020/09/02 06:00 MHDA- 2021/02/11 06:00 PMCR- 2022/08/09 CRDT- 2020/09/02 06:00 PHST- 2020/03/27 00:00 [received] PHST- 2020/06/27 00:00 [revised] PHST- 2020/08/20 00:00 [accepted] PHST- 2020/09/02 06:00 [pubmed] PHST- 2021/02/11 06:00 [medline] PHST- 2020/09/02 06:00 [entrez] PHST- 2022/08/09 00:00 [pmc-release] AID - 0008-5472.CAN-20-0977 [pii] AID - 10.1158/0008-5472.CAN-20-0977 [doi] PST - ppublish SO - Cancer Res. 2020 Oct 15;80(20):4476-4486. doi: 10.1158/0008-5472.CAN-20-0977. Epub 2020 Aug 31. PMID- 36238040 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221015 IS - 2288-2928 (Electronic) IS - 1738-2637 (Print) IS - 1738-2637 (Linking) VI - 81 IP - 5 DP - 2020 Sep TI - T1-Staging for Urinary Bladder Cancer with the Stalk and Inchworm Signs with 3.0 Tesla MRI. PG - 1194-1203 LID - 10.3348/jksr.2019.0149 [doi] AB - PURPOSE: To evaluate the diagnostic utility of the stalk and the inchworm sign on preoperative MRI for detecting superficial bladder cancers, and to compare the diagnostic performance between the stalk and the inchworm sign. MATERIALS AND METHODS: We retrospectively reviewed 240 patients (505 tumors) who had undergone radical cystectomy. The tumors were classified as follows: superficial or invasive tumors indicated by the stalk or inchworm sign on 3.0 Tesla MRI. We evaluated the diagnostic accuracy of the stalk and inchworm signs, by comparing each finding with the postoperative pathologic T stage. We compared diagnostic performance between them statistically. RESULTS: The stalk and inchworm signs showed high specificity (93% and 91%, respectively), positive predictive values (89% and 90%, respectively), and acceptable accuracy (70% and 74%, respectively), but low sensitivity (54% and 61%, respectively) and negative predictive values (60% and 63%, respectively). There was no statistically significant difference between the two signs (p > 0.05). CONCLUSION: Superficial bladder cancers could be differentiated from invasive tumors using the stalk or inchworm sign on MRI. CI - Copyrights (c) 2020 The Korean Society of Radiology. FAU - Kim, Da-Hoon AU - Kim DH AUID- ORCID: 0000-0001-6961-018X FAU - Kang, Byung Chul AU - Kang BC AUID- ORCID: 0000-0001-8939-3514 FAU - Chung, Jin AU - Chung J AUID- ORCID: 0000-0001-9990-3768 LA - eng PT - Journal Article DEP - 20200928 PL - Korea (South) TA - Taehan Yongsang Uihakhoe Chi JT - Taehan Yongsang Uihakhoe chi JID - 101479271 PMC - PMC9431854 OTO - NOTNLM OT - Cystectomy OT - Urinary Bladder Cancer OT - Urology COIS- Conflicts of Interest: The authors have no potential conflicts of interest to disclose. EDAT- 2020/09/01 00:00 MHDA- 2020/09/01 00:01 PMCR- 2020/09/01 CRDT- 2022/10/14 02:59 PHST- 2019/08/08 00:00 [received] PHST- 2019/09/16 00:00 [revised] PHST- 2019/10/27 00:00 [accepted] PHST- 2022/10/14 02:59 [entrez] PHST- 2020/09/01 00:00 [pubmed] PHST- 2020/09/01 00:01 [medline] PHST- 2020/09/01 00:00 [pmc-release] AID - 10.3348/jksr.2019.0149 [doi] PST - ppublish SO - Taehan Yongsang Uihakhoe Chi. 2020 Sep;81(5):1194-1203. doi: 10.3348/jksr.2019.0149. Epub 2020 Sep 28. PMID- 32861170 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 216 IP - 11 DP - 2020 Nov TI - Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. PG - 153186 LID - S0344-0338(20)32041-0 [pii] LID - 10.1016/j.prp.2020.153186 [doi] AB - FGFR3 mutations are frequently mutually exclusive of TP53 mutations in invasive high grade urothelial carcinoma (HGUC) and p53 immunohistochemistry is often used as a surrogate for TP53 mutations. A 10 % staining cut off has been used in HGUC for designation as p53 positive or negative however, a novel contemporary method we have previously proposed (0% or >50 % - abnormal vs. 1-49 % - wild type) has shown significant correlation with oncologic outcome as well. We aimed to compare how a >/=10 % vs. 0 % and >/= 50 % cut off p53 assessment method correlates with TP53 and FGFR3 mutation status. Tissue microarrays created from three retrospective cohorts (two cystectomy cohorts (cohort A, n = 206 and cohort B, n = 91; one T1 transurethral resection cohort (cohort C, n = 47)) were stained with p53 and scored by two blinded reviewers using both p53 scoring schemes. 50 cases from cohort A were assessed for TP53 and FGFR3 mutation status using next generation sequencing and FGFR3 mutation status was separately assessed in cohorts B and C using SNaPshot methodology. 202 (58.7 %) and 142 (41.3 %) cases showed abnormal and wild type p53 staining, respectively. Using the 10 % cut off, 254 cases were positive (73.8 %) and 90 cases were negative (26.2 %). 27 (14.4 %) and 15 (30 %) assessed cases demonstrated FGFR3 and TP53 mutations, respectively; 19/27 FGFR3 mutated showed a wild type pattern of p53 expression while 15/15 TP53 mutated tumours showed an abnormal pattern of p53 expression. There was a significant correlation between the contemporary p53 scoring scheme and TP53 and FGFR3 mutations (p < 0.0001 and p = 0.002, respectively). Improved sensitivity, specificity, positive predictive value, and negative predictive value for TP53 mutation was also seen compared to the 10 % cut off; specifically, the sensitivity and negative predictive value were 100 %. These findings might be of clinical relevance in the era of precision medicine. CI - Copyright (c) 2020 Elsevier GmbH. All rights reserved. FAU - Hodgson, Anjelica AU - Hodgson A AD - Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Kim, Sung Sun AU - Kim SS AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, Anatomic Pathology, St Michael's Hospital, Toronto, ON, Canada; Department of Pathology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Ding, Colleen AU - Ding C AD - Li Ka Shing Knowledge Institute, Anatomic Pathology, St Michael's Hospital, Toronto, ON, Canada. FAU - Saleeb, Rola AU - Saleeb R AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, Anatomic Pathology, St Michael's Hospital, Toronto, ON, Canada. FAU - Vesprini, Danny AU - Vesprini D AD - Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue, Toronto ON M4N 3M5, Canada. FAU - Liu, Stanley K AU - Liu SK AD - Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue, Toronto ON M4N 3M5, Canada. FAU - Yousef, George M AU - Yousef GM AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, Anatomic Pathology, St Michael's Hospital, Toronto, ON, Canada; Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, ON, Canada. FAU - van der Kwast, Theodorus H AU - van der Kwast TH AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. FAU - Xu, Bin AU - Xu B AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Downes, Michelle R AU - Downes MR AD - Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address: michelle.downes@sunnybrook.ca. LA - eng PT - Journal Article DEP - 20200823 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Biomarkers, Tumor) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/metabolism MH - Carcinoma, Transitional Cell/genetics/*metabolism/pathology MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - *Mutation MH - Receptor, Fibroblast Growth Factor, Type 3/genetics/*metabolism MH - Retrospective Studies MH - Tumor Suppressor Protein p53/genetics/*metabolism MH - Urinary Bladder Neoplasms/genetics/*metabolism/pathology OTO - NOTNLM OT - Bladder cancer OT - FGFR3 mutation OT - TP53 mutation OT - Urothelial carcinoma OT - p53 immunohistochemistry EDAT- 2020/08/30 06:00 MHDA- 2021/09/11 06:00 CRDT- 2020/08/30 06:00 PHST- 2020/06/26 00:00 [received] PHST- 2020/08/16 00:00 [revised] PHST- 2020/08/17 00:00 [accepted] PHST- 2020/08/30 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] PHST- 2020/08/30 06:00 [entrez] AID - S0344-0338(20)32041-0 [pii] AID - 10.1016/j.prp.2020.153186 [doi] PST - ppublish SO - Pathol Res Pract. 2020 Nov;216(11):153186. doi: 10.1016/j.prp.2020.153186. Epub 2020 Aug 23. PMID- 32851811 OWN - NLM STAT- MEDLINE DCOM- 20210519 LR - 20231112 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 9 IP - 20 DP - 2020 Oct TI - A mediation analysis to explain socio-economic differences in bladder cancer survival. PG - 7477-7487 LID - 10.1002/cam4.3418 [doi] AB - INTRODUCTION: This study aims to disentangle heterogeneity in the survival of bladder cancer (BC) patients of different socioeconomic status (SES) by identifying potential mediators of the relationship. METHODS: The Bladder Cancer Database Sweden (BladderBaSe) was used to select patients diagnosed between 1997 and 2014 with Tis/Ta-T4 disease. The education level was used as a proxy for SES. Accelerated failure time models were used to investigate the association between SES and survival. Mediation analysis was used to investigate potential mediators of the association also accounting for interaction. RESULTS: The study included 37 755 patients from the BladderBaSe. Patients diagnosed with both non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) who had high SES were found to have increased overall and BC-specific survival, when compared to those with low SES. In the NMIBC patients, Charlson Comorbidity Index was found to mediate this relationship by 10% (percentage of the total effect explained by the mediator) and hospital type by 4%. The time from referral to TURBT was a considerable mediator (14%) in the MIBC patients only. CONCLUSIONS: Mediation analysis suggests that the association between SES and BC survival can be explained by several factors. The mediators identified were not, however, able to fully explain the theoretical causal pathway between SES and survival, therefore, future studies should also include the investigation of other possible mediators to help explain this relationship further. These results highlight the importance of standardization of clinical care across SES groups. CI - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Russell, Beth AU - Russell B AUID- ORCID: 0000-0001-5640-8425 AD - Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. FAU - Hemelrijck, Mieke V AU - Hemelrijck MV AUID- ORCID: 0000-0002-7317-0858 AD - Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Kumar, Pardeep AU - Kumar P AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Bellavia, Andrea AU - Bellavia A AD - Department of Environmental Health, Harvard T.H. Chan School of Public Health. FAU - Haggstrom, Christel AU - Haggstrom C AUID- ORCID: 0000-0001-6808-4405 AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Department of Biobank Research, Umea University, Umea, Sweden. LA - eng PT - Journal Article DEP - 20200826 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Comorbidity MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mediation Analysis MH - Middle Aged MH - Public Health Surveillance MH - Registries MH - Risk Factors MH - *Social Class MH - Socioeconomic Factors MH - Sweden/epidemiology MH - Urinary Bladder Neoplasms/diagnosis/epidemiology/*mortality/therapy PMC - PMC7571835 OTO - NOTNLM OT - bladder cancer OT - education level OT - socioeconomic status OT - survival COIS- There are no conflicts of interest to declare. EDAT- 2020/08/28 06:00 MHDA- 2021/05/20 06:00 PMCR- 2020/08/26 CRDT- 2020/08/28 06:00 PHST- 2020/03/04 00:00 [received] PHST- 2020/08/07 00:00 [revised] PHST- 2020/08/08 00:00 [accepted] PHST- 2020/08/28 06:00 [pubmed] PHST- 2021/05/20 06:00 [medline] PHST- 2020/08/28 06:00 [entrez] PHST- 2020/08/26 00:00 [pmc-release] AID - CAM43418 [pii] AID - 10.1002/cam4.3418 [doi] PST - ppublish SO - Cancer Med. 2020 Oct;9(20):7477-7487. doi: 10.1002/cam4.3418. Epub 2020 Aug 26. PMID- 32850635 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2296-2646 (Print) IS - 2296-2646 (Electronic) IS - 2296-2646 (Linking) VI - 8 DP - 2020 TI - New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis. PG - 600 LID - 10.3389/fchem.2020.00600 [doi] LID - 600 AB - About 70% of bladder cancers (BCs) are diagnosed as non-muscle-invasive BCs (NMIBCs), while the remaining are muscle-invasive BCs (MIBCs). The European Association of Urology (EAU) guidelines stratify NMIBCs into low, intermediate, and high risk for treatment options. Low-risk NMIBCs undergo only the transurethral resection of the bladder (TURB), whereas for intermediate-risk and high-risk NMIBCs, the transurethral resection of the bladder (TURB) with or without Bacillus Calmette-Guerin (BCG) immune or chemotherapy is the standard treatment. A minority of NMIBCs show unfavorable prognosis. High-risk NMIBCs have a high rate of disease recurrence and/or progression to muscle-invasive tumor and BCG treatment failure. The heterogeneous nature of NMIBCs poses challenges for clinical decision-making. In 2020, the EAU made some changes to NMIBCs BCG failure definitions and treatment options, highlighting the need for reliable molecular markers for improving the predictive accuracy of currently available risk tables. Nowadays, next-generation sequencing (NGS) has revolutionized the study of cancer biology, providing diagnostic, prognostic, and therapy response biomarkers in support of precision medicine. Integration of NGS with other cutting-edge technologies might help to decipher also bladder tumor surrounding aspects such as immune system, stromal component, microbiome, and urobiome; altogether, this might impact the clinical outcomes of NMBICs especially in the BCG responsiveness. This review focuses on NMIBCs with unfavorable prognoses, providing molecular prognostic factors from tumor immune and stromal cells, and the perspective of urobiome and microbiome profiling on therapy response. We provide information on the cornerstone of immunotherapy and new promising bladder-preserving treatments and ongoing clinical trials for BCG-unresponsive NMIBCs. CI - Copyright (c) 2020 Pane, Mirabelli, Coppola, Illiano, Salvatore and Franzese. FAU - Pane, Katia AU - Pane K AD - IRCCS SDN, Naples, Italy. FAU - Mirabelli, Peppino AU - Mirabelli P AD - IRCCS SDN, Naples, Italy. FAU - Coppola, Luigi AU - Coppola L AD - IRCCS SDN, Naples, Italy. FAU - Illiano, Ester AU - Illiano E AD - Andrological and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, Italy. FAU - Salvatore, Marco AU - Salvatore M AD - IRCCS SDN, Naples, Italy. FAU - Franzese, Monica AU - Franzese M AD - IRCCS SDN, Naples, Italy. LA - eng PT - Journal Article PT - Review DEP - 20200731 PL - Switzerland TA - Front Chem JT - Frontiers in chemistry JID - 101627988 PMC - PMC7413024 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - biomarker OT - bladder cancer OT - immunotherapy OT - microbiome OT - non-muscle-invasive bladder cancer OT - omics OT - prognostic factor EDAT- 2020/08/28 06:00 MHDA- 2020/08/28 06:01 PMCR- 2020/01/01 CRDT- 2020/08/28 06:00 PHST- 2020/02/14 00:00 [received] PHST- 2020/06/09 00:00 [accepted] PHST- 2020/08/28 06:00 [entrez] PHST- 2020/08/28 06:00 [pubmed] PHST- 2020/08/28 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fchem.2020.00600 [doi] PST - epublish SO - Front Chem. 2020 Jul 31;8:600. doi: 10.3389/fchem.2020.00600. eCollection 2020. PMID- 32848456 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 12 DP - 2020 TI - Risk Factors for Urethral Recurrence in Men After Radical Cystectomy with Orthotopic Urinary Diversion for Urothelial Carcinoma: A Retrospective Cohort Study. PG - 6739-6746 LID - 10.2147/CMAR.S260979 [doi] AB - PURPOSE: To evaluate the risk factors affecting urethral recurrence (UR) in men after radical cystectomy (RC) with ileal orthotopic neobladder (IONB). MATERIALS AND METHODS: We retrospectively reviewed 348 men who underwent RC with IONB for bladder cancer between January 2010 and December 2017. Clinicopathologic characteristics, including tumor location (trigone and/or bladder neck), prostatic urethral and/or stromal involvement, presence of carcinoma in situ (CIS), pathologic T and N stage, and urethral resection margin status, were identified. Kaplan-Meier survival analysis was used to illustrate urethral recurrence-free survival (URFS), and Cox proportional hazard models were applied to identify factors predicting UR. RESULTS: Of the 348 patients, UR was identified in 7 (2.0%) patients during the mean follow-up of 33.3 months. The 2-, 3-, and 5-year URFS rates were 97.6%, 96.3%, and 93.8%, respectively. On multivariable analysis, prostatic urethral involvement (P = 0.033, hazard ratio: 6.25, 95% confidence interval: 1.06-36.96) was an independent predictor of UR. When patients were divided according to prostatic urethral involvement (negative vs positive), the 2- and 3-year URFS rates were significantly different (93.8% and 96.8%, respectively, vs 92.0% and 92.0%, respectively; P = 0.020). All 7 patients with UR underwent transurethral surgery and maintained their IONB. CONCLUSION: In this series, UR occurred in approximately 2% of men after RC with IONB. Prostatic urethral involvement was the only significant prognostic factor for UR. Follow-up strategies considering UR risk should be adopted to facilitate early detection in those at high risk of UR. CI - (c) 2020 Lee and Song. FAU - Lee, Dong Hyeon AU - Lee DH AD - Department of Urology, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, Korea. FAU - Song, Wan AU - Song W AUID- ORCID: 0000-0003-0971-1805 AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Journal Article DEP - 20200803 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC7425095 OTO - NOTNLM OT - bladder cancer OT - neobladder OT - radical cystectomy OT - risk factor OT - urethral recurrence COIS- The authors declare that they have no conflicts of interest in this work. EDAT- 2020/08/28 06:00 MHDA- 2020/08/28 06:01 PMCR- 2020/08/03 CRDT- 2020/08/28 06:00 PHST- 2020/05/02 00:00 [received] PHST- 2020/07/16 00:00 [accepted] PHST- 2020/08/28 06:00 [entrez] PHST- 2020/08/28 06:00 [pubmed] PHST- 2020/08/28 06:01 [medline] PHST- 2020/08/03 00:00 [pmc-release] AID - 260979 [pii] AID - 10.2147/CMAR.S260979 [doi] PST - epublish SO - Cancer Manag Res. 2020 Aug 3;12:6739-6746. doi: 10.2147/CMAR.S260979. eCollection 2020. PMID- 32842545 OWN - NLM STAT- MEDLINE DCOM- 20210310 LR - 20210310 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 17 DP - 2020 Aug 23 TI - Mutational Landscape and Environmental Effects in Bladder Cancer. LID - 10.3390/ijms21176072 [doi] LID - 6072 AB - Bladder cancer is the most common cancer of the urinary tract. Although nonmuscle-invasive bladder cancers have a good prognosis, muscle-invasive bladder cancers promote metastases and have a poor prognosis. Comprehensive analyses using RNA sequence of clinical tumor samples in bladder cancer have been reported. These reports implicated the candidate genes and pathways that play important roles in carcinogenesis and/or progression of bladder cancer. Further investigations for the function of each mutation are warranted. There is suggestive evidence for several environmental factors as risk factors of bladder cancer. Environmental factors such as cigarette smoking, exposure to chemicals and gases, bladder inflammation due to microbial and parasitic infections, diet, and nutrition could induce several genetic mutations and alter the tumor microenvironment, such as immune cells and fibroblasts. The detailed mechanism of how these environmental factors induce carcinogenesis and/or progression of bladder cancer remains unclear. To identify the relationship between the mutations and the lifestyle could be useful for prevention and treatment of bladder cancer. FAU - Hayashi, Takuji AU - Hayashi T AUID- ORCID: 0000-0003-2030-3087 AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. AD - Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MA 21287-2101, USA. FAU - Fujita, Kazutoshi AU - Fujita K AUID- ORCID: 0000-0002-6774-7497 AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. AD - Department of Urology, Faculty of Medicine, Kindai University, Ohno-higashi, Osakasayama, Osaka 589-8511, Japan. FAU - Hayashi, Yujiro AU - Hayashi Y AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Hatano, Koji AU - Hatano K AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Kawashima, Atsunari AU - Kawashima A AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - McConkey, David J AU - McConkey DJ AD - Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, MA 21287-2101, USA. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. LA - eng GR - 201840069/Uehara Memorial Foundation/ GR - 659224/Urology Care Foundation/ PT - Journal Article PT - Review DEP - 20200823 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Cyclin-Dependent Kinase Inhibitor p16/genetics MH - Cystitis/complications MH - Diet MH - Environmental Exposure/*adverse effects MH - Humans MH - Life Style MH - Metabolic Syndrome/complications MH - *Mutation MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Risk Factors MH - Smoking/adverse effects MH - Telomerase/genetics MH - Urinary Bladder Neoplasms/*etiology/genetics PMC - PMC7503658 OTO - NOTNLM OT - bladder cancer OT - diet OT - inflammation OT - lifestyle OT - mutation OT - smoking COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2020/08/28 06:00 MHDA- 2021/03/11 06:00 PMCR- 2020/09/01 CRDT- 2020/08/27 06:00 PHST- 2020/07/31 00:00 [received] PHST- 2020/08/20 00:00 [revised] PHST- 2020/08/21 00:00 [accepted] PHST- 2020/08/27 06:00 [entrez] PHST- 2020/08/28 06:00 [pubmed] PHST- 2021/03/11 06:00 [medline] PHST- 2020/09/01 00:00 [pmc-release] AID - ijms21176072 [pii] AID - ijms-21-06072 [pii] AID - 10.3390/ijms21176072 [doi] PST - epublish SO - Int J Mol Sci. 2020 Aug 23;21(17):6072. doi: 10.3390/ijms21176072. PMID- 32840743 OWN - NLM STAT- MEDLINE DCOM- 20210310 LR - 20210310 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 28 IP - 1 DP - 2021 Jan TI - Evaluating the Oncological Outcomes of Pure Laparoscopic Radical Nephroureterectomy Performed for Upper-Tract Urothelial Carcinoma Patients: A Multicenter Cohort Study Adjusted by Propensity Score Matching. PG - 465-473 LID - 10.1245/s10434-020-09046-9 [doi] AB - PURPOSE: To evaluate the oncological feasibility of pure laparoscopic radical nephroureterectomy (p-LRNU) for upper tract urothelial carcinoma (UTUC) compared with conventional LRNU (c-LRNU) using a propensity-adjusted multi-institutional collaboration dataset. METHODS: Among the 503 UTUC patients who underwent RNU, we identified 219 who underwent c-LRNU (laparoscopic nephrectomy with open bladder cuff resection) and 72 who underwent p-LRNU (dissecting the kidney, ureter, and bladder cuff under complete laparoscopy). We adopted a propensity score (PS) matching method to achieve homogeneity with respect to patient backgrounds. PS matching-adjusted Cox-regression analysis was performed to evaluate the risk factors that influenced oncological outcomes. RESULTS: Sixty-eight p-LRNU and 68 c-LRNU patients were matched. Overall, 51 (37.0%) developed intravesical recurrence (IVR), 21 (15.4%) had disease recurrence, and 20 (14.7%) died. Patients who underwent p-LRNU had a significantly shorter operation time and less blood loss than those who underwent c-LRNU. Although no significant differences in 3-year recurrence-free survival were found between the two methods, atypical recurrence sites were observed in the p-LRNU group, including the brain, sigmoid colon, vagina, and peritoneum. Regarding IVR, the 3-year IVR-free survival rate was 41.8% in the p-LRNU group, which was significantly lower than that in the c-LRNU group (66.6%, p = 0.004). Multivariate analysis demonstrated that a history of bladder cancer, ureteral cancer, and p-LRNU were independent risk factors for subsequent IVR. CONCLUSION: Although p-LRNU is less invasive, the current technique may increase the incidence of atypical disease recurrence and subsequent IVR due to extravesical and intravesical tumor dissemination. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AUID- ORCID: 0000-0002-9405-9446 AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. kazz_matsumoto@yahoo.co.jp. FAU - Takeda, Toshikazu AU - Takeda T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Hattori, Seiya AU - Hattori S AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Kaneko, Gou AU - Kaneko G AD - Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Matsushima, Masashi AU - Matsushima M AD - Department of Urology, Ogikubo Hospital, Tokyo, Japan. FAU - Abe, Takayuki AU - Abe T AD - Department of Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Asanuma, Hiroshi AU - Asanuma H AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200825 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Cohort Studies MH - Female MH - Humans MH - Laparoscopy MH - *Nephroureterectomy MH - Propensity Score MH - Retrospective Studies MH - *Ureteral Neoplasms/surgery MH - *Urologic Neoplasms/surgery EDAT- 2020/08/26 06:00 MHDA- 2021/03/11 06:00 CRDT- 2020/08/26 06:00 PHST- 2020/02/24 00:00 [received] PHST- 2020/07/15 00:00 [accepted] PHST- 2020/08/26 06:00 [pubmed] PHST- 2021/03/11 06:00 [medline] PHST- 2020/08/26 06:00 [entrez] AID - 10.1245/s10434-020-09046-9 [pii] AID - 10.1245/s10434-020-09046-9 [doi] PST - ppublish SO - Ann Surg Oncol. 2021 Jan;28(1):465-473. doi: 10.1245/s10434-020-09046-9. Epub 2020 Aug 25. PMID- 32839927 OWN - NLM STAT- MEDLINE DCOM- 20210917 LR - 20261010 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 23 IP - 4 DP - 2021 Apr TI - Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications. PG - 840-845 LID - 10.1007/s12094-020-02476-7 [doi] AB - PURPOSE: To determine the presence of a group of mutations, and establish the prognostic value for recurrence and progression. MATERIALS AND METHODS: Prospective observational study. Intermediate-to-high-risk non-muscle invasive bladder cancer (NMIBC) was evaluated. Data from genetic analyses were included in a database along with clinicopathological variables of interest. RESULTS: Seventy-four patients. Twenty-five (33.8%) recurred and 3 (4.1%) progressed. Median time to recurrence: 8 months (5.7-12.7). Median time to progression: 14 months (P75: 12). Mutation distribution: KRAS codon 12: one patient (1.4%), BAT25: five patients (6.8%), BAT-26: four patients (5.4%), and D2S123: 6 patients (8.1%). Arg72Pro polymorphism: 50 patients (67.6%) exhibited homozygous mutations, 23 (31.1%) were heterozygous, and 1 patient (1.4%) did not present the mutation. We found an association between presence of MSI at BAT26 and female sex (p < 0.05) and tumor stage and the TP53 Arg72Pro polymorphism. Recurrence-free survival (RFS) was significantly associated with presence of MSI at D2S123, with a HR of 5.44 for patients presenting the mutation (95% CI 1.83-16.16). On multivariate analysis, we found a statistically significant increase in risk of recurrence among patients with MSI at D2S123 (HR 5.15; p < 0.05) and more than 2 previous transurethral bladder resections (TURBs) (HR 5.07; p < 0.05) adjusted for tumor stage and grade. Harrell's concordance index revealed an accuracy of 0.74 (p < 0.05). CONCLUSION: An association was found between presence BAT26 MSI and female sex, Arg72Pro polymorphism with tumor stage and D2S123 and more than 2 TUR procedures were associated with RFS adjusted to tumor stage and grade. FAU - Garde-Garcia, H AU - Garde-Garcia H AUID- ORCID: 0000-0001-5272-9846 AD - Servicio de Urologia, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. hector.gardegarcia@gmail.com. FAU - Redondo-Gonzalez, E AU - Redondo-Gonzalez E AD - Servicio de Urologia y Unidad de Biologia Molecular del Servicio de Analisis Clinicos, Instituto de Investigacion Sanitaria (IdISSC), Hospital Clinico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. FAU - Maestro-de Las Casas, M AU - Maestro-de Las Casas M AD - Servicio de Urologia y Unidad de Biologia Molecular del Servicio de Analisis Clinicos, Instituto de Investigacion Sanitaria (IdISSC), Hospital Clinico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. FAU - Fernandez-Perez, C AU - Fernandez-Perez C AD - Servicio de Urologia y Unidad de Biologia Molecular del Servicio de Analisis Clinicos, Instituto de Investigacion Sanitaria (IdISSC), Hospital Clinico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. FAU - Moreno-Sierra, J AU - Moreno-Sierra J AD - Servicio de Urologia y Unidad de Biologia Molecular del Servicio de Analisis Clinicos, Instituto de Investigacion Sanitaria (IdISSC), Hospital Clinico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20200824 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (BAT26 microsatellite DNA) RN - 0 (Biomarkers, Tumor) RN - 0 (Codon) RN - 0 (Dipeptides) RN - 0 (Genetic Markers) RN - 2418-69-1 (arginylproline) SB - IM MH - Aged MH - Analysis of Variance MH - Biomarkers, Tumor/*genetics MH - Codon/genetics MH - Dipeptides/genetics MH - *Disease Progression MH - Female MH - Genes, p53/genetics MH - Genes, ras MH - Genetic Markers/genetics MH - Humans MH - Male MH - Microsatellite Instability MH - Microsatellite Repeats/genetics MH - Neoplasm Recurrence, Local/*genetics MH - *Point Mutation MH - Prognosis MH - Prospective Studies MH - Sex Factors MH - Time Factors MH - Urinary Bladder Neoplasms/*genetics/pathology/surgery OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Molecular biology OT - Prognosis EDAT- 2020/08/26 06:00 MHDA- 2021/09/18 06:00 CRDT- 2020/08/26 06:00 PHST- 2020/06/13 00:00 [received] PHST- 2020/08/06 00:00 [accepted] PHST- 2020/08/26 06:00 [pubmed] PHST- 2021/09/18 06:00 [medline] PHST- 2020/08/26 06:00 [entrez] AID - 10.1007/s12094-020-02476-7 [pii] AID - 10.1007/s12094-020-02476-7 [doi] PST - ppublish SO - Clin Transl Oncol. 2021 Apr;23(4):840-845. doi: 10.1007/s12094-020-02476-7. Epub 2020 Aug 24. PMID- 32814637 OWN - NLM STAT- MEDLINE DCOM- 20220209 LR - 20220209 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 79 IP - 3 DP - 2021 Mar TI - Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. PG - 364-371 LID - S0302-2838(20)30564-9 [pii] LID - 10.1016/j.eururo.2020.07.016 [doi] AB - BACKGROUND: Standard of care for patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by consolidative therapy with either chemoradiation or radical cystectomy (RC). Some patients experience robust pathologic responses to NAC, and these have been reported to associate with somatic mutations in specific gene pathways including DNA damage response genes. OBJECTIVE: To evaluate the ability of post-NAC clinical restaging, with or without tumor sequencing, to predict final RC pathologic staging. DESIGN, SETTING, AND PARTICIPANTS: We reviewed our institutional review board-approved institutional database to identify patients with MIBC who underwent NAC followed by RC from 2003 to 2016. Following NAC prior to RC, cystoscopy was performed routinely, with resection of residual visible tumor and/or tumor base (transurethral resection [TUR]). For patients with pre-NAC tumor tissue available, tumor sequencing was performed. Outcome measurements and statistical analysis: Clinical restaging and tumor sequencing were evaluated for their ability to predict the final pathologic stage accurately at RC using chi-square or Fisher's exact test. RESULTS AND LIMITATIONS: A total of 114 patients underwent restaging TUR following NAC and prior to RC. The diagnostic accuracy of post-NAC clinical restaging including TUR was poor, with 32% of patients being downstaged falsely when compared with their final RC pathology. Forty-nine patients had sequencing of pre-NAC tumor tissue, of whom 32 showed at least one mutation of interest. However, NAC responses and rates of false downstaging did not differ significantly according to tumor mutation status. CONCLUSIONS: This study highlights the inaccuracy of post-NAC clinical restaging TUR with or without adjunctive tumor mutation analysis, to assess pathologic residual disease accurately. Caution must be taken when performing post-NAC restaging, especially when considering conservative management strategies such as active surveillance on this basis. Patient summary: Several groups are evaluating whether certain patients, whose bladder cancer responds well to upfront chemotherapy, may be able to forego cystectomy safely. We demonstrate that currently available staging tools and tumor DNA sequencing cannot identify such patients reliably and accurately. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Becker, Russell E N AU - Becker REN AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. Electronic address: rbecker@jhmi.edu. FAU - Meyer, Alexa R AU - Meyer AR AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Brant, Aaron AU - Brant A AD - Department of Urology, Weill Cornell Medicine, New York, NY, USA. FAU - Reese, Adam C AU - Reese AC AD - Department of Urology, Temple Health, Philadelphia, PA, USA. FAU - Biles, Michael J AU - Biles MJ AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Harris, Kelly T AU - Harris KT AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Netto, George AU - Netto G AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Matoso, Andres AU - Matoso A AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Hoffman-Censits, Jean AU - Hoffman-Censits J AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Hahn, Noah M AU - Hahn NM AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Choi, Woonyoung AU - Choi W AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - McConkey, David AU - McConkey D AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Pierorazio, Phillip M AU - Pierorazio PM AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Johnson, Michael H AU - Johnson MH AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Schoenberg, Mark P AU - Schoenberg MP AD - Department of Urology, Montefiore Medical Center, Bronx, NY, USA. FAU - Kates, Max R AU - Kates MR AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Baras, Alex AU - Baras A AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. LA - eng PT - Journal Article DEP - 20200817 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2021 Mar;79(3):372-373. doi: 10.1016/j.eururo.2020.09.019. PMID: 32980169 CIN - Eur Urol. 2021 Feb;79(2):e58-e59. doi: 10.1016/j.eururo.2020.11.006. PMID: 33218822 CIN - Eur Urol. 2021 Feb;79(2):e56-e57. doi: 10.1016/j.eururo.2020.11.007. PMID: 33218823 MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Muscles MH - *Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm, Residual MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/genetics/surgery OTO - NOTNLM OT - Bladder cancer OT - Neoadjuvant chemotherapy OT - Postchemotherapy restaging OT - Radical cystectomy OT - Transurethral resection of bladder tumor OT - Tumor mutation analysis EDAT- 2020/08/21 06:00 MHDA- 2022/02/10 06:00 CRDT- 2020/08/21 06:00 PHST- 2020/04/27 00:00 [received] PHST- 2020/07/16 00:00 [accepted] PHST- 2020/08/21 06:00 [pubmed] PHST- 2022/02/10 06:00 [medline] PHST- 2020/08/21 06:00 [entrez] AID - S0302-2838(20)30564-9 [pii] AID - 10.1016/j.eururo.2020.07.016 [doi] PST - ppublish SO - Eur Urol. 2021 Mar;79(3):364-371. doi: 10.1016/j.eururo.2020.07.016. Epub 2020 Aug 17. PMID- 32808107 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20210927 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). PG - 1961-1968 LID - 10.1007/s00345-020-03384-9 [doi] AB - PURPOSE: The De Ritis ratio (aspartate aminotransferase/alanine aminotransferase, DRR) has been linked to oncological outcomes in several cancers. We aimed to assess the association of DRR with recurrence-free survival (RFS) and progression-free survival (PFS) in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: We conducted a retrospective analysis of 1117 patients diagnosed with NMIBC originating from an established multicenter database. To define the optimal pretreatment DRR cut-off value, we determined a value of 1.2 as having a maximum Youden index value. The overall population was therefore divided into two De Ritis ratio groups using this cut-off (lower, < 1.2 vs. higher, >/= 1.2). Univariable and multivariable Cox regression analyses were used to investigate the association of DRR with RFS and PFS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). RESULTS: Overall, 405 (36%) patients had a DRR >/= 1.2. On univariable Cox regression analysis, DRR was significantly associated with RFS (HR: 1.23, 95% CI 1.02-1.47, p = 0.03), but not with PFS (HR: 0.96, 95% CI 0.65-1.44, p = 0.9). On multivariable Cox regression analysis, which adjusted for the effect of established clinicopathologic features, DRR >/= 1.2 remained significantly associated with worse RFS (HR:1.21, 95% CI 1.00-1.46, p = 0.04). The addition of DRR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index = 0.683 vs. C-index = 0.681). On DCA the inclusion of DRR did not improve the net-benefit of the prognostic model. CONCLUSION: Despite the statistically significant association of the DRR with RFS in patients with NMIBC, it does not seem to add any prognostic or clinical benefit beyond that of currently available clinical factors. FAU - Laukhtina, Ekaterina AU - Laukhtina E AUID- ORCID: 0000-0002-8953-0272 AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University Hospital of Tours, Tours, France. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miura, Noriyoshi AU - Miura N AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan. FAU - Schuettfort, Victor M AU - Schuettfort VM AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Aydh, Abdulmajeed AU - Aydh A AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - King Faisal Medical City, Abha, Saudi Arabia. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - The National Center for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Vienna General Hospital Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - European Association of Urology Research Foundation, Arnhem, The Netherlands. shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20200817 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - EC 2.6.1.1 (Aspartate Aminotransferases) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Aged MH - Alanine Transaminase/*blood MH - Aspartate Aminotransferases/*blood MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*blood/pathology/*surgery PMC - PMC8217037 OTO - NOTNLM OT - Bladder cancer OT - De Ritis ratio OT - NMIBC OT - PFS OT - RFS COIS- All authors state that they have no conflict of interest that might bias this work. EDAT- 2020/08/19 06:00 MHDA- 2021/09/28 06:00 PMCR- 2020/08/17 CRDT- 2020/08/19 06:00 PHST- 2020/05/11 00:00 [received] PHST- 2020/07/22 00:00 [accepted] PHST- 2020/08/19 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/08/19 06:00 [entrez] PHST- 2020/08/17 00:00 [pmc-release] AID - 10.1007/s00345-020-03384-9 [pii] AID - 3384 [pii] AID - 10.1007/s00345-020-03384-9 [doi] PST - ppublish SO - World J Urol. 2021 Jun;39(6):1961-1968. doi: 10.1007/s00345-020-03384-9. Epub 2020 Aug 17. PMID- 32805763 OWN - NLM STAT- MEDLINE DCOM- 20211007 LR - 20211007 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 127 IP - 4 DP - 2021 Apr TI - Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. PG - 473-485 LID - 10.1111/bju.15209 [doi] AB - OBJECTIVES: To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), and to examine the predictive factors for recurrence at different time points by assessing conditional RFS and PFS. PARTICIPANTS AND METHODS: A cohort of 602 patients treated with transurethral resection of bladder tumour and histopathologically diagnosed with IR NMIBC was included in this retrospective study. RESULTS: The conditional RFS rate at 1, 2, 3, 4 and 5 years improved with increased duration of RFS; however, the conditional PFS rate did not improve over time. Multivariable analyses showed that recurrent tumour, multiple tumours, tumour size (>3 cm), immediate postoperative instillation of chemotherapy, and administration of BCG were independent predictive factors for recurrence at baseline. The predictive ability of these factors disappeared with increasing recurrence-free survivorship. Subclassification of these patients with IR NMIBC into three groups using clinicopathological factors (recurrent tumour, multiple tumours, tumour size) demonstrated that the high IR group (two factors) had significantly worse RFS than the intermediate (one factor, P < 0.001) and low IR groups (no factor, P = 0.005) at baseline. This subclassification stratified conditional risk of RFS also at 1, 3 and 5 years, which provides the basis for distinct surveillance protocols among patients with IR NMIBC. CONCLUSION: Conditional survival analyses of patients with IR NMIBC demonstrate that RFS changes over time, while PFS does not change. These data support distinct surveillance protocols based on the subclassification of IR NMIBC. CI - 2020 The Authors BJU International (c) 2020 BJU International Published by John Wiley & Sons Ltd. FAU - Kohada, Yuki AU - Kohada Y AUID- ORCID: 0000-0002-6510-7461 AD - Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan. AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Hayashi, Tetsutaro AU - Hayashi T AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Hsi, Ryan S AU - Hsi RS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Yukihiro, Kazuma AU - Yukihiro K AD - Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan. FAU - Sentani, Kazuhiro AU - Sentani K AD - Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. FAU - Goto, Keisuke AU - Goto K AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Inoue, Shogo AU - Inoue S AUID- ORCID: 0000-0001-7996-0685 AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Ohara, Shinya AU - Ohara S AD - Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan. FAU - Teishima, Jun AU - Teishima J AUID- ORCID: 0000-0001-8429-1607 AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. FAU - Kajiwara, Mitsuru AU - Kajiwara M AD - Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan. FAU - Nishisaka, Takashi AU - Nishisaka T AD - Department of Pathology, Hiroshima Prefectural Hospital, Hiroshima, Japan. FAU - Yasui, Wataru AU - Yasui W AD - Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Matsubara, Akio AU - Matsubara A AD - Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. LA - eng PT - Journal Article DEP - 20200921 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Progression-Free Survival MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*classification/diagnosis/epidemiology/*surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - #utuc OT - conditional survival OT - progression OT - recurrence OT - surveillance OT - urinary bladder cancer EDAT- 2020/08/18 06:00 MHDA- 2021/10/08 06:00 CRDT- 2020/08/18 06:00 PHST- 2020/08/18 06:00 [pubmed] PHST- 2021/10/08 06:00 [medline] PHST- 2020/08/18 06:00 [entrez] AID - 10.1111/bju.15209 [doi] PST - ppublish SO - BJU Int. 2021 Apr;127(4):473-485. doi: 10.1111/bju.15209. Epub 2020 Sep 21. PMID- 32805294 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20220224 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 147 DP - 2021 Jan TI - Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era? PG - 199-204 LID - S0090-4295(20)30983-3 [pii] LID - 10.1016/j.urology.2020.08.004 [doi] AB - OBJECTIVE: To examine recent treatment trends for non-muscle-invasive bladder cancer (NMIBC), and specifically, to assess whether there was a change in use radical cystectomy (RC) between 2008 and 2015 using data from the Surveillance, Epidemiology, and End Results database. METHODS: We identified patients presenting with high-grade T1 (T1HG) NMIBC at diagnosis during the study period. Treatment was dichotomized into "RC" and "local treatment" (which included transurethral resection and intravesical therapies). We then employed multivariable logistic regression models to assess the odds of undergoing RC across the study period. Additionally we examined the rates of RC for T1HG NMIBC during the period of BCG-shortage, defined as 2012-2015. RESULTS: We identified 21,817 individuals diagnosed with T1HG bladder cancer during the study period. The majority of patients underwent local treatment (94.5%). During the shortage period, the rate of RC for T1HG NMIBC was significantly lower compared to the preshortage era (5.1% vs 5.9%, P = .007). Across the study period, the utilization of RC for T1HG NMIBC decreased significantly (odds ratio 0.99 per quarter, 95% confidence interval 0.98-0.99, P = .017). CONCLUSION: In our cohort of patients diagnosed with T1HG bladder cancer, we found a significant decrease in the use of radical cystectomy across the study period. Contrary to the hypothesis of increasing rates of RC in the face of BCG shortage, the rate of RC was significantly higher in the pre-shortage era. Further examination of NMIBC treatment patterns will be necessary to assess the impact of BCG availability on therapeutic pathways and oncologic outcomes in patients with high-grade NMIBC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Tully, Karl H AU - Tully KH AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Cole, Alexander P AU - Cole AP AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Krimphove, Marieke J AU - Krimphove MJ AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Friedlander, David F AU - Friedlander DF AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Mossanen, Matthew AU - Mossanen M AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Herzog, Peter AU - Herzog P AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Sonpavde, Guru P AU - Sonpavde GP AD - Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard, Medical School, Boston, MA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: Trinh.qd@gmail.com. LA - eng PT - Journal Article DEP - 20200814 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*supply & distribution/therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*supply & distribution/therapeutic use MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/drug therapy/pathology/*surgery EDAT- 2020/08/18 06:00 MHDA- 2022/02/25 06:00 CRDT- 2020/08/18 06:00 PHST- 2020/03/19 00:00 [received] PHST- 2020/07/31 00:00 [revised] PHST- 2020/08/04 00:00 [accepted] PHST- 2020/08/18 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2020/08/18 06:00 [entrez] AID - S0090-4295(20)30983-3 [pii] AID - 10.1016/j.urology.2020.08.004 [doi] PST - ppublish SO - Urology. 2021 Jan;147:199-204. doi: 10.1016/j.urology.2020.08.004. Epub 2020 Aug 14. PMID- 32800441 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 1 DP - 2021 Jan TI - Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer. PG - 77.e9-77.e16 LID - S1078-1439(20)30335-5 [pii] LID - 10.1016/j.urolonc.2020.07.013 [doi] AB - OBJECTIVES: To assess the clinical performance characteristics of Xpert Monitor test for recurrence detection during surveillance of patients with non muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patient with previous history of NMIBC were included in the study. Voided urine specimens were collected for Xpert monitor analysis and cytology. Office cystoscopy was performed for all study participants with in patient biopsy specimen retrieval for positive or suspicious cases. Test characteristics were calculated based on cystoscopy/biopsy results and compared between Xpert and cytology. RESULTS: Between March 2018 and May 2019, 181 patients including 168 (92.8%) males fulfilled the study criteria with median age 61 years, Primary tumors were low, intermediate, high risk in 2.8%, 22.7% and 74.5% of patients respectively. Biopsy proven recurrence was detected in 19 patients (10.4%). Xpert Monitor had a sensitivity of 73.7% with a negative predictive value (NPV) of 96.3%. Xpert Monitor was positive in all cases with high grade tumors (9 patients). Urine cytology showed sensitivity of 47% and an NPV of 93.2%. During follow up surveillance, out of 162 cystoscopy negative patients (CNP), 9.3% developed recurrence within 8 months. Xpert Monitor was found to be an independent predictor of early recurrence in CNP (HR=2.8, 95%CI=1.1-7.2, p=0.01). CONCLUSIONS: Xpert Monitor urine test has a superior diagnostic performance for recurrence detection in NMIBC patients compared to urine cytology. It might be a helpful tool not only for excluding bladder cancer recurrence in those patients, but also for prediction of possible future early recurrence. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Elsawy, Amr A AU - Elsawy AA AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. Electronic address: amrelsawy.unc@hotmail.com. FAU - Awadalla, Amira AU - Awadalla A AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Elsayed, Asmaa AU - Elsayed A AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Abdullateef, Muhammad AU - Abdullateef M AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. FAU - Abol-Enein, Hassan AU - Abol-Enein H AD - Urology and Nephrology Center, Mansoura University, Mansoura-Egypt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20200813 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*urine MH - Population Surveillance/methods MH - Prospective Studies MH - RNA, Messenger/*urine MH - Urinalysis/*methods MH - Urinary Bladder Neoplasms/pathology/*urine OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Recurrence OT - Surveillance OT - Urine cytology OT - mRNA COIS- Conflict of interest The authors have nothing to declare. EDAT- 2020/08/18 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/08/18 06:00 PHST- 2020/06/12 00:00 [received] PHST- 2020/07/08 00:00 [revised] PHST- 2020/07/10 00:00 [accepted] PHST- 2020/08/18 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/08/18 06:00 [entrez] AID - S1078-1439(20)30335-5 [pii] AID - 10.1016/j.urolonc.2020.07.013 [doi] PST - ppublish SO - Urol Oncol. 2021 Jan;39(1):77.e9-77.e16. doi: 10.1016/j.urolonc.2020.07.013. Epub 2020 Aug 13. PMID- 32800440 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 11 DP - 2020 Nov TI - Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study. PG - 851.e11-851.e17 LID - S1078-1439(20)30338-0 [pii] LID - 10.1016/j.urolonc.2020.07.014 [doi] AB - OBJECTIVE: To examine the association between Bacillus Calmette-Guerin (BCG) shortage and bladder cancer recurrence in high-risk non-muscle-invasive bladder cancer (NMIBC) patients. MATERIALS AND METHODS: This retrospective study included 333 BCG-naive patients who underwent transurethral resection of bladder tumor for high-risk NMIBC between January 2014 and December 2017. The primary outcome was disease recurrence after operation. The secondary outcomes were trends in BCG shortages and differences in post-transurethral resection of bladder tumor intravesical treatments according to shortage. Multivariable Cox regression modeling was used to assess outcomes. RESULTS: Among 333 patients (median age, 67 years; men, 270 [81.1%]), 94 (28.2%) experienced BCG shortage (BCG shortage group). Eleven episodes of BCG shortage occurred during the study period (median 10 days, range 2-97 days). Although we observed no statistically significant differences in clinical and pathological characteristics, there were significant differences in post-transurethral resection of bladder tumor intravesical treatments between the shortage and control groups (BCG: 28.7% vs. 68.1%, mitomycin/epirubicin: 27.7% vs. 1.7%, P < 0.001). The 3-year recurrence-free survival rate was significantly lower in the shortage group than that in the control group (38.0% vs. 60.2%, log-rank test, P = 0.010). In multivariable analysis, shortage (hazard ratio [HR] = 1.55, 95% confidence interval [CI] 1.09-2.21, P = 0.016) and tumor multiplicity (HR = 1.55, 95% CI 1.05-2.29, P = 0.028) were independent factors associated with the recurrence of bladder cancer. CONCLUSIONS: High-risk NMIBC patients who experienced BCG shortage had a high risk of bladder cancer recurrence. Clinical trials of alternative treatment strategies and efforts to increase BCG supply are required. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Lee, Sangmin AU - Lee S AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Lim, Bumjin AU - Lim B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: igjeong@amc.seoul.kr. LA - eng PT - Journal Article DEP - 20200813 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*supply & distribution/*therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*supply & distribution/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*drug therapy/*epidemiology/pathology OTO - NOTNLM OT - Immunotherapy OT - Recurrence OT - Urinary bladder neoplasms EDAT- 2020/08/18 06:00 MHDA- 2021/08/13 06:00 CRDT- 2020/08/18 06:00 PHST- 2020/03/15 00:00 [received] PHST- 2020/06/29 00:00 [revised] PHST- 2020/07/12 00:00 [accepted] PHST- 2020/08/18 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/08/18 06:00 [entrez] AID - S1078-1439(20)30338-0 [pii] AID - 10.1016/j.urolonc.2020.07.014 [doi] PST - ppublish SO - Urol Oncol. 2020 Nov;38(11):851.e11-851.e17. doi: 10.1016/j.urolonc.2020.07.014. Epub 2020 Aug 13. PMID- 32798360 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20220716 IS - 2737-5935 (Electronic) IS - 0037-5675 (Print) IS - 0037-5675 (Linking) VI - 63 IP - 4 DP - 2022 Apr TI - Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. PG - 209-213 LID - 10.11622/smedj.2020121 [doi] AB - INTRODUCTION: Usage of metformin is associated with improved survival in lung, breast and prostate cancer, and metformin has been shown to inhibit cancer cell growth and proliferation in in vitro studies. Given the lack of clinical data on metformin use in patients with bladder cancer, we aimed to evaluate the role of metformin in their oncological outcomes. METHODS: Medication use data from a prospectively maintained database of 122 patients with non-muscle-invasive bladder cancer treated with intravesical Bacille Calmette-Guerin (BCG), who were recruited under a randomised, double-blinded, controlled clinical trial, was collected and analysed. Kaplan-Meier curves were used to assess overall survival (OS) and disease-specific survival (DSS). RESULTS: At a median follow-up duration of 102 (range 3-357) months, 53 (43.4%) patients experienced disease recurrence and 21 (17.2%) experienced disease progression. There was no significant difference in mortality between patients with and without diabetes mellitus. There was significant difference in OS between patients without diabetes mellitus, patients with diabetes mellitus on metformin and patients with diabetes mellitus but not on metformin (p = 0.033); patients with diabetes mellitus on metformin had the best prognosis. Metformin use was associated with significantly lower DSS (p = 0.042). Other oral hypoglycaemic agents, insulin or statins were not associated with disease recurrence or progression. CONCLUSION: Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG. Prospective studies with larger patient populations are needed to validate the role of metformin as potential therapy for bladder cancer. CI - Copyright: (c) Singapore Medical Association. FAU - Wang, Ziting AU - Wang Z AD - Department of Urology, National University Hospital, Singapore. FAU - Ong, Wilson Ying Fa AU - Ong WYF AD - Department of Urology, National University Hospital, Singapore. FAU - Shen, Tong AU - Shen T AD - Department of Urology, National University Hospital, Singapore. FAU - Sng, Jen-Hwei AU - Sng JH AD - Department of Urology, National University of Singapore, Singapore. FAU - Lata, Raman Mani AU - Lata RM AD - Department of Urology, National University Hospital, Singapore. FAU - Mahendran, Ratha AU - Mahendran R AD - Department of Urology, National University of Singapore, Singapore. FAU - Kesavan, Esuvaranathan AU - Kesavan E AD - Department of Urology, National University Hospital, Singapore. FAU - Chiong, Edmund AU - Chiong E AD - Department of Urology, National University Hospital, Singapore. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20200817 PL - India TA - Singapore Med J JT - Singapore medical journal JID - 0404516 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 9100L32L2N (Metformin) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - *Diabetes Mellitus MH - Disease Progression MH - Humans MH - Male MH - *Metformin/therapeutic use MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy PMC - PMC9251265 OTO - NOTNLM OT - bladder carcinoma OT - diabetes mellitus OT - metformin OT - recurrences EDAT- 2020/08/18 06:00 MHDA- 2022/06/16 06:00 PMCR- 2022/04/01 CRDT- 2020/08/18 06:00 PHST- 2020/08/18 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2020/08/18 06:00 [entrez] PHST- 2022/04/01 00:00 [pmc-release] AID - j63/4/209 [pii] AID - SMJ-63-209 [pii] AID - 10.11622/smedj.2020121 [doi] PST - ppublish SO - Singapore Med J. 2022 Apr;63(4):209-213. doi: 10.11622/smedj.2020121. Epub 2020 Aug 17. PMID- 32797169 OWN - NLM STAT- MEDLINE DCOM- 20201208 LR - 20201214 IS - 1573-4935 (Electronic) IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 40 IP - 9 DP - 2020 Sep 30 TI - Predictive value of beta-catenin in bladder cancer: a systematic review and meta-analysis. LID - 10.1042/BSR20202127 [doi] LID - BSR20202127 AB - Recently, some studies have suggested that the abnormal expression of beta-catenin in bladder cancer (BC) is associated with the progression and survival of BC, but there are still some controversies. Hence, we elaborated on the relationship between beta-catenin expression and BC through a systematic literature review and meta-analysis. As of March 2020, Embase, PubMed, the Cochrane Library, Science Direct/Elsevier, Medline and CNKI were used for systematic literature retrieval to investigate the correlation between beta-catenin expression and BC. Meta-analysis was performed using Review Manager and Stata software. Fourteen studies were included, including 865 BC tissues and 106 controls. Combined ORs were identified with 95% confidence intervals (95% CIs) in a random- or fixed-effects model. We illustrated that there was a significant correlation between beta-catenin and BC, that there was abnormally high expression of beta-catenin in BC tissues compared with normal bladder tissues (P<0.05), and that the combined OR was 14.69 [5.73, 37.65]. Furthermore, the aberrant expression rates of beta-catenin in high-grade and invasive bladder neoplasm tissues were greater than those in low-grade and non-muscle-invasive bladder tissues (P<0.05), and the combined ORs were 0.31 [0.23, 0.43] and 0.21 [0.15, 0.29]. Finally, we found through meta-analysis that the higher the expression level of beta-catenin, the shorter was the progression-free survival (PFS) of patients with BC (P<0.05), and the combined OR was 2.74 [1.22, 6.14]. The present study suggests that the abnormal expression of beta-catenin is associated with aggressive behavior and poor prognosis of BC, and beta-catenin may be a molecular marker of the malignant degree and poor prognosis of BC. CI - (c) 2020 The Author(s). FAU - Ren, Jin AU - Ren J AD - Department of Urology, The First People's Hospital of Chongqing Liangjiang New Area, Chongqing 400000, China. FAU - Yang, Yaodong AU - Yang Y AD - Department of Urology, 958 Hospital of PLA Army, Chongqing 400000, China. FAU - Peng, Taifang AU - Peng T AD - Department of Urology, Qianjiang Central Hospital of Chongqing, Chongqing 409000, China. FAU - Xu, Dong AU - Xu D AD - Department of Urology, Qianjiang Central Hospital of Chongqing, Chongqing 409000, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - 0 (CTNNB1 protein, human) RN - 0 (beta Catenin) SB - IM MH - Case-Control Studies MH - Humans MH - Prognosis MH - Urinary Bladder Neoplasms/*metabolism/*mortality/pathology MH - beta Catenin/*metabolism PMC - PMC7475297 OTO - NOTNLM OT - Meta-Analysis OT - bladder cancer OT - high grade cancer OT - beta-catenin COIS- The authors declare that there are no competing interests associated with the manuscript. EDAT- 2020/08/17 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/09/04 CRDT- 2020/08/16 06:00 PHST- 2020/06/20 00:00 [received] PHST- 2020/08/06 00:00 [revised] PHST- 2020/08/12 00:00 [accepted] PHST- 2020/08/17 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/08/16 06:00 [entrez] PHST- 2020/09/04 00:00 [pmc-release] AID - 226086 [pii] AID - BSR20202127 [pii] AID - 10.1042/BSR20202127 [doi] PST - ppublish SO - Biosci Rep. 2020 Sep 30;40(9):BSR20202127. doi: 10.1042/BSR20202127. PMID- 32794294 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 27 IP - 11 DP - 2020 Nov TI - Reduced recurrence of low-risk non-muscle-invasive bladder cancer is associated with low urine-specific gravity. PG - 1019-1023 LID - 10.1111/iju.14351 [doi] AB - OBJECTIVE: To investigate the association between urine-specific gravity and oncological outcomes in patients with non-muscle-invasive bladder cancer. METHODS: We identified 433 primary non-muscle-invasive bladder cancer patients who underwent transurethral resection between 2002 and 2016. The association between urine-specific gravity and tumor recurrence was statistically evaluated. RESULTS: A total of 211 (48.7%) patients received adjuvant bacillus Calmette-Guerin therapy. During the median follow-up period of 60 months, 155 (35.8%) patients experienced at least one tumor recurrence. Of them all, 95 (21.9%) and 338 (78.1%) patients had high (>1.020) and low (70 years (hazard ratio 1.69, P = 0.02), grade 3 tumor (hazard ratio 1.81, P = 0.03) and high urine-specific gravity (hazard ratio 1.87, P < 0.01) were independent risk factors for tumor recurrence. CONCLUSION: High urine-specific gravity is an independent risk factor for tumor recurrence in non-muscle-invasive bladder cancer patients who have not received bacillus Calmette-Guerin therapy. Our results suggest that hydration status might have some clinical impacts on bladder tumor recurrence. CI - (c) 2020 The Japanese Urological Association. FAU - Iwasawa, Tomohiro AU - Iwasawa T AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Komatsuda, Akari AU - Komatsuda A AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20200813 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/therapeutic use MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Retrospective Studies MH - Specific Gravity MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - bladder cancer OT - fluid intake OT - hydration OT - urinary marker OT - urine-specific gravity EDAT- 2020/08/15 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/08/15 06:00 PHST- 2020/01/24 00:00 [received] PHST- 2020/07/13 00:00 [accepted] PHST- 2020/08/15 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/08/15 06:00 [entrez] AID - 10.1111/iju.14351 [doi] PST - ppublish SO - Int J Urol. 2020 Nov;27(11):1019-1023. doi: 10.1111/iju.14351. Epub 2020 Aug 13. PMID- 32792215 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 2 DP - 2021 Feb TI - Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer. PG - 132.e1-132.e6 LID - S1078-1439(20)30337-9 [pii] LID - 10.1016/j.urolonc.2020.07.016 [doi] AB - OBJECTIVE: To identify the optimal selection criteria for bladder sparing strategy with transurethral resection of bladder tumor (TURBT) and systemic chemotherapy in patients with muscle-invasive bladder cancer (MIBC). METHODS: We conducted a retrospective cohort study in 71 patients with MIBC (T2-4aN0M0) who desire to bladder preservation received neoadjuvant chemotherapy (NAC) after maximal TURBT, followed by clinical restaging and second-TURBT. Fifty-eight of 71 patients with no residual tumor on the second-TURBT were placed on conservative management for bladder sparing (BS). Noninvasive down-staging (NID) was defined as cT0/Ta/Tis/T1N0 at first-TURBT after NAC and no residual tumor on second-TURBT. Overall survival (OS) and cystectomy-free survival (CFS) were assessed according to the response of NAC in the BS group by using Kaplan-Meier methods. Cox proportional hazards regression model was used to identify independent variables predicting OS. RESULTS: At a median follow-up of 40 months 5-year OS and CFS in patients with NID and non-NID were 89.1% versus 20.8% and 84.8% versus 16.7%, respectively. Multivariate analysis showed that the >/=3 cycles of NAC (hazard ratio [HR] 0.14, 95% confidential index [CI] 0.03-0.7; P = 0.017) and achievement of NID (HR 0.11, 95% CI 0.03-0.46, P = 0.002) favorably associated with OS. CONCLUSIONS: Patients who achieved NID might be optimal candidates for the bladder sparing strategy with maximum TURBT plus NAC followed by second-TURBT. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Onishi, Takehisa AU - Onishi T AD - Department of Urology, Ise Red Cross hospital, Ise, Mie, Japan. Electronic address: takehisa@ise.jrc.or.jp. FAU - Sekito, Sho AU - Sekito S AD - Department of Urology, Ise Red Cross hospital, Ise, Mie, Japan. FAU - Shibahara, Takuji AU - Shibahara T AD - Department of Urology, Ise Red Cross hospital, Ise, Mie, Japan. FAU - Yabana, Tadashi AU - Yabana T AD - Department of Pathology, Ise Red Cross hospital, Ise, Japan. LA - eng PT - Journal Article DEP - 20200810 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Combined Modality Therapy MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Muscle invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Transurethral resection, Bladder preservation COIS- Conflict of interest All authors declare that they have no conflicts of interest EDAT- 2020/08/15 06:00 MHDA- 2021/08/13 06:00 CRDT- 2020/08/15 06:00 PHST- 2020/04/22 00:00 [received] PHST- 2020/07/10 00:00 [revised] PHST- 2020/07/12 00:00 [accepted] PHST- 2020/08/15 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/08/15 06:00 [entrez] AID - S1078-1439(20)30337-9 [pii] AID - 10.1016/j.urolonc.2020.07.016 [doi] PST - ppublish SO - Urol Oncol. 2021 Feb;39(2):132.e1-132.e6. doi: 10.1016/j.urolonc.2020.07.016. Epub 2020 Aug 10. PMID- 32791287 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20220203 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 145 DP - 2020 Nov TI - The Remaining Ipsilateral Ureteral Orifice Provokes Intravesical Tumor Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Study With a Mid-Term Follow-Up. PG - 166-171 LID - S0090-4295(20)30974-2 [pii] LID - 10.1016/j.urology.2020.06.083 [doi] AB - OBJECTIVES: To investigate the impact of the remnant ureteral orifice (RUO) on the prognosis of upper tract urothelial carcinoma (UTUC), because the presence of an ipsilateral intact ureteral orifice is not an uncommon finding during follow-up cystoscopy despite the clinical relevance of bladder cuffing during radical nephroureterectomy (RNU) for the management of UTUC. METHODS: The records of patients who underwent RNU in all tertiary hospitals in Daegu province (2011-2018) were retrospectively reviewed. Subjects were allocated to RUO or non-RUO groups. Cox proportional hazard models were used to identify variables. The primary endpoint was a 5-year intravesical recurrence-free survival (RFS). RESULTS: Of the 164 patients enrolled, 45 (27.4%) had an RUO by postoperative cystoscopy. The characteristics of the RUO and non-RUO groups were similar. During mean follow-up of 76.4 months (range: 69.5-83.4), 21 (46.7%) subjects in the RUO group and 25 (21.0%) in the non-RUO group experienced intravesical recurrence (P = .001). Among them, 3 (6.7%) and 14 (8.5%) developed distant metastasis (P = .339), and 3 (6.7%) and 9 (7.6%) succumbed to UTUC (P = .844), respectively. The 5-year RFS was lower in the RUO group than in the non-RUO counterpart (45.6% vs 77.8%, P = .003). Multivariate analysis showed lymphovascular invasion (hazard ratio [HR] = 3.593, P = .002), lymph nodal involvement (HR = 2.336, P = .038), and the presence of RUO (HR = 2.058, P = .026) predicted 5-year RFS. CONCLUSION: The presence of RUO after RNU was found to be significantly associated with intravesical tumor recurrence, and this finding emphasizes the quality of bladder cuffing during RNU, which could be assessed by complete removal of the natural orifice. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Kwon, Se Yun AU - Kwon SY AD - Department of Urology, Dongguk University College of Medicine, Seoul, South Korea. FAU - Ko, Young Hwii AU - Ko YH AD - Department of Urology, Yeungnam University College of Medicine, Daegu, South Korea. Electronic address: urokyh@naver.com. FAU - Song, Phil Hyun AU - Song PH AD - Department of Urology, Yeungnam University College of Medicine, Daegu, South Korea. FAU - Kim, Byung Hoon AU - Kim BH AD - Department of Urology, Keimyung University Dongsan Medical Center, Daegu, South Korea. FAU - Kim, Bum Soo AU - Kim BS AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea. FAU - Kim, Tae-Hwan AU - Kim TH AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea. CN - KYUS group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200811 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2020 Nov;145:171. doi: 10.1016/j.urology.2020.06.086. PMID: 33167175 MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/diagnosis/*epidemiology/secondary/surgery MH - Cystoscopy MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Male MH - Middle Aged MH - Nephroureterectomy/*adverse effects/methods MH - Retrospective Studies MH - Ureteral Neoplasms/pathology/*surgery MH - Urinary Bladder/diagnostic imaging/pathology MH - Urinary Bladder Neoplasms/diagnosis/*epidemiology/secondary EDAT- 2020/08/14 06:00 MHDA- 2022/02/04 06:00 CRDT- 2020/08/14 06:00 PHST- 2020/04/09 00:00 [received] PHST- 2020/06/26 00:00 [revised] PHST- 2020/06/30 00:00 [accepted] PHST- 2020/08/14 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2020/08/14 06:00 [entrez] AID - S0090-4295(20)30974-2 [pii] AID - 10.1016/j.urology.2020.06.083 [doi] PST - ppublish SO - Urology. 2020 Nov;145:166-171. doi: 10.1016/j.urology.2020.06.083. Epub 2020 Aug 11. PMID- 32784716 OWN - NLM STAT- MEDLINE DCOM- 20210218 LR - 20231112 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 16 DP - 2020 Aug 7 TI - Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. LID - 10.3390/ijms21165670 [doi] LID - 5670 AB - Bladder cancer is a heterogeneous disease that is not depicted by current classification systems. It was originally classified into non-muscle invasive and muscle invasive. However, clinically and genetically variable tumors are summarized within both classes. A definition of three groups may better account for the divergence in prognosis and probably also choice of treatment. The first group represents mostly non-invasive tumors that reoccur but do not progress. Contrarily, the second group represent non-muscle invasive tumors that likely progress to the third group, the muscle invasive tumors. High throughput tumor profiling improved our understanding of the biology of bladder cancer. It allows the identification of molecular subtypes, at least three for non-muscle invasive bladder cancer (Class I, Class II and Class III) and six for muscle-invasive bladder cancer (luminal papillary, luminal non-specified, luminal unstable, stroma-rich, basal/squamous and neuroendocrine-like) with distinct clinical and molecular phenotypes. Molecular subtypes can be potentially used to predict the response to treatment (e.g., neoadjuvant chemotherapy and immune checkpoint inhibitors). Moreover, they may allow to characterize the evolution of bladder cancer through different pathways. However, to move towards precision medicine, the understanding of the biological meaning of these molecular subtypes and differences in the composition of cell subpopulations will be mandatory. FAU - Minoli, Martina AU - Minoli M AD - Department of BioMedical Research, Urology Research Laboratory, University of Bern, 3008 Bern, Switzerland. FAU - Kiener, Mirjam AU - Kiener M AD - Department of BioMedical Research, Urology Research Laboratory, University of Bern, 3008 Bern, Switzerland. FAU - Thalmann, George N AU - Thalmann GN AD - Department of BioMedical Research, Urology Research Laboratory, University of Bern, 3008 Bern, Switzerland. AD - Department of Urology, Inselspital, Bern University Hospital, 3008 Bern, Switzerland. FAU - Kruithof-de Julio, Marianna AU - Kruithof-de Julio M AUID- ORCID: 0000-0002-6085-7706 AD - Department of BioMedical Research, Urology Research Laboratory, University of Bern, 3008 Bern, Switzerland. AD - Department of Urology, Inselspital, Bern University Hospital, 3008 Bern, Switzerland. FAU - Seiler, Roland AU - Seiler R AUID- ORCID: 0000-0002-3529-2088 AD - Department of BioMedical Research, Urology Research Laboratory, University of Bern, 3008 Bern, Switzerland. AD - Department of Urology, Inselspital, Bern University Hospital, 3008 Bern, Switzerland. LA - eng GR - 310030/SNSF_/Swiss National Science Foundation/Switzerland PT - Journal Article PT - Review DEP - 20200807 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers, Tumor) SB - IM MH - Animals MH - Biomarkers, Tumor/genetics MH - Humans MH - Muscles/pathology MH - Treatment Failure MH - Urinary Bladder Neoplasms/*classification/*genetics/therapy MH - Urothelium/*pathology PMC - PMC7461199 OTO - NOTNLM OT - bladder cancer OT - classification OT - evolution OT - molecular subtypes OT - muscle invasive OT - non-muscle invasive OT - targeted therapy COIS- The authors declare no conflict of interest. EDAT- 2020/08/14 06:00 MHDA- 2021/02/20 06:00 PMCR- 2020/08/01 CRDT- 2020/08/14 06:00 PHST- 2020/07/15 00:00 [received] PHST- 2020/08/05 00:00 [revised] PHST- 2020/08/05 00:00 [accepted] PHST- 2020/08/14 06:00 [entrez] PHST- 2020/08/14 06:00 [pubmed] PHST- 2021/02/20 06:00 [medline] PHST- 2020/08/01 00:00 [pmc-release] AID - ijms21165670 [pii] AID - ijms-21-05670 [pii] AID - 10.3390/ijms21165670 [doi] PST - epublish SO - Int J Mol Sci. 2020 Aug 7;21(16):5670. doi: 10.3390/ijms21165670. PMID- 32783347 OWN - NLM STAT- MEDLINE DCOM- 20210205 LR - 20220107 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 126 IP - 5 DP - 2020 Nov TI - Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? PG - 610-619 LID - 10.1111/bju.15188 [doi] AB - OBJECTIVES: (I) To determine Vesical Imaging-Reporting and Data System (VI-RADS) score 5 accuracy in predicting locally advanced bladder cancer (BCa), so as to potentially identify those patients who could avoid the morbidity of deep transurethral resection of bladder tumour (TURBT) in favour of histological sampling-TUR prior to radical cystectomy (RC). (II) To explore the predictive value of VI-RADS score 5 on time-to-cystectomy (TTC) outcomes. PATIENTS AND METHODS: We retrospectively reviewed patients' ineligible or refusing cisplatin-based combination neoadjuvant chemotherapy who underwent multiparametric magnetic resonance imaging (mpMRI) of the bladder prior to staging TURBT followed by RC for muscle-invasive BCa. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for VI-RADS score 5 vs. score 2-4 cases to assess the accuracy of mpMRI for extravesical BCa detection (>/=pT3). VI-RADS score performance was assessed by receiver operating characteristics curve analysis. A Kappa statistic was calculated to estimate mpMRI and pathological diagnostic agreement. The risk of delayed TTC (i.e. time from initial BCa diagnosis of >3 months) was assessed using multivariable logistic regression model. RESULTS: A total of 149 T2-T4a, cN0-M0 patients (VI-RADS score 5, n = 39 vs VI-RADS score 2-4, n = 110) were examined. VI-RADS score 5 demonstrated sensitivity, specificity, PPV and NPV, in detecting extravesical disease of 90.2% (95% confidence interval [CI] 84-94.3), 98.1% (95% CI 94-99.6), 94.9% (95% CI 89.6-97.6) and 96.4% (95% CI 91.6-98.6), respectively. The area under the curve was 94.2% (95% CI 88.7-99.7) and inter-reader agreement was excellent (Kappa(inter) 0.89). The mean (SD) TTC was 4.2 (2.3) and 2.8 (1.1) months for score 5 vs 2-4, respectively (P < 0.001). VI-RADS score 5 was found to independently increase risk of delayed TTC (odds ratio 2.81, 95% CI 1.20-6.62). CONCLUSION: The VI-RADS is valid and reliable in differentiating patients with extravesical disease from those with muscle-confined BCa before TURBT. Detection of VI-RADS score 5 was found to predict significant delay in TTC independently from other clinicopathological features. In the future, higher VI-RADS scores could potentially avoid the morbidity of extensive primary resections in favour of sampling-TUR for histology. Further prospective, larger, and multi-institutional trials are required to validate clinical applicability of our findings. CI - (c) 2020 The Authors BJU International (c) 2020 BJU International Published by John Wiley & Sons Ltd. FAU - Del Giudice, Francesco AU - Del Giudice F AUID- ORCID: 0000-0003-3865-5988 AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. AD - Department of Urology, Stanford University, School of Medicine, Stanford, CA, USA. FAU - Leonardo, Costantino AU - Leonardo C AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, "Regina Elena" National Cancer Institute, IRCCS, Rome, Italy. FAU - Pecoraro, Martina AU - Pecoraro M AD - Department of Radiological Sciences, Oncology & Pathology, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Cipollari, Stefano AU - Cipollari S AD - Department of Radiological Sciences, Oncology & Pathology, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Flammia, Simone AU - Flammia S AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Bicchetti, Marco AU - Bicchetti M AUID- ORCID: 0000-0002-0396-3203 AD - Department of Radiological Sciences, Oncology & Pathology, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University, School of Medicine, Stanford, CA, USA. FAU - Gallucci, Michele AU - Gallucci M AD - Department of, Departments of, Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Catalano, Carlo AU - Catalano C AD - Department of Radiological Sciences, Oncology & Pathology, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. FAU - Panebianco, Valeria AU - Panebianco V AUID- ORCID: 0000-0001-8466-918X AD - Department of Radiological Sciences, Oncology & Pathology, "Sapienza" University of Rome, Policlinico Umberto, Hospital, Rome, Italy. LA - eng PT - Journal Article DEP - 20200817 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - J Urol. 2022 Jan;207(1):228-229. doi: 10.1097/JU.0000000000002268. PMID: 34661437 MH - Aged MH - Cystectomy/*methods MH - Cystoscopy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiparametric Magnetic Resonance Imaging MH - Neoplasm Staging MH - Predictive Value of Tests MH - Preoperative Care MH - Retrospective Studies MH - Time-to-Treatment/*statistics & numerical data MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - *Urinary Bladder Neoplasms/diagnostic imaging/pathology/surgery OTO - NOTNLM OT - #BladderCancer OT - #VIRADS OT - #uroonc OT - bladder cancer OT - bladder cancer staging OT - blcsm OT - extravesical bladder cancer OT - multiparametric magnetic resonance imaging OT - muscle-invasive bladder cancer OT - radical cystectomy OT - transurethral resection of bladder tumour EDAT- 2020/08/13 06:00 MHDA- 2021/02/07 06:00 CRDT- 2020/08/13 06:00 PHST- 2020/08/13 06:00 [pubmed] PHST- 2021/02/07 06:00 [medline] PHST- 2020/08/13 06:00 [entrez] AID - 10.1111/bju.15188 [doi] PST - ppublish SO - BJU Int. 2020 Nov;126(5):610-619. doi: 10.1111/bju.15188. Epub 2020 Aug 17. PMID- 32782604 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 20 IP - 3 DP - 2020 Sep TI - Correlation of APE1 with VEGFA and CD163(+) macrophage infiltration in bladder cancer and their prognostic significance. PG - 2881-2887 LID - 10.3892/ol.2020.11814 [doi] AB - The present study sought to estimate the applicability of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), vascular endothelial growth factor A (VEGFA) expression and CD163(+) tumor-associated macrophage (TAM) ratio as prognostic factors in bladder cancer (BCa). A total of 127 patients with bladder urothelial cancer who underwent radical cystectomy at Daping Hospital were recruited between January 2013 and January 2017, including 45 cases of non-muscle invasive BCa (NMIBC) and 82 of MIBC. Immunohistochemical detection of APE1, VEGFA and CD163, as well as multiple immunofluorescence staining for APE1, VEGFA, CD163 and CD34, were performed on tissue samples. For APE1 and VEGFA, the staining was graded based on intensity (0-3), while CD163 was graded (0-3) based on the percentage of positively stained cells. The prognostic value of APE1, VEGF and CD163 was assessed using Kaplan-Meier and Cox regression analysis. The results suggested that in BCa, high APE1 expression was associated with high VEGFA expression and more infiltration of CD163(+) TAM. Furthermore, high expression of APE1 was associated with lymphovascular invasion of BCa, as well as reduced survival time. This indicates that APE1 may be associated with CD163(+) TAM infiltration in BCa, with VEGFA as a possible influencing factor. CI - Copyright: (c) Wang et al. FAU - Wang, Lin-Ang AU - Wang LA AD - Department of Urology, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Yang, Bo AU - Yang B AD - Cancer Center, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Tang, Tang AU - Tang T AD - Department of Urology, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Yang, Yuxin AU - Yang Y AD - Cancer Center, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Zhang, Dianzheng AU - Zhang D AD - Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA 19131, USA. FAU - Xiao, Hualiang AU - Xiao H AD - Department of Pathology, Daping Hospital/Army Medical Center of PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Xu, Jing AU - Xu J AD - Department of Urology, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Wang, Luofu AU - Wang L AD - Department of Urology, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Lin, Li AU - Lin L AD - Department of Pathology, Daping Hospital/Army Medical Center of PLA, Army Medical University, Chongqing 400042, P.R. China. FAU - Jiang, Jun AU - Jiang J AD - Department of Urology, Daping Hospital/Army Medical Center of the PLA, Army Medical University, Chongqing 400042, P.R. China. LA - eng PT - Journal Article DEP - 20200706 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC7401005 OTO - NOTNLM OT - CD163 OT - apurinic/apyrimidinic endodeoxyribonuclease 1 OT - bladder cancer OT - tumor-associated macrophage OT - vascular endothelial growth factor A EDAT- 2020/08/13 06:00 MHDA- 2020/08/13 06:01 PMCR- 2020/07/06 CRDT- 2020/08/13 06:00 PHST- 2020/01/07 00:00 [received] PHST- 2020/05/27 00:00 [accepted] PHST- 2020/08/13 06:00 [entrez] PHST- 2020/08/13 06:00 [pubmed] PHST- 2020/08/13 06:01 [medline] PHST- 2020/07/06 00:00 [pmc-release] AID - OL-0-0-11814 [pii] AID - 10.3892/ol.2020.11814 [doi] PST - ppublish SO - Oncol Lett. 2020 Sep;20(3):2881-2887. doi: 10.3892/ol.2020.11814. Epub 2020 Jul 6. PMID- 32782133 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 19 IP - 1 DP - 2021 Feb TI - Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. PG - 60-68.e1 LID - S1558-7673(20)30171-3 [pii] LID - 10.1016/j.clgc.2020.07.011 [doi] AB - BACKGROUND: The purpose of this study was to evaluate stage at presentation, treatment rates, and cancer-specific mortality (CSM) of non-urothelial variant histology (VH) bladder cancer (BCa) relative to urothelial carcinoma of the urinary bladder (UCUB). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), patients with VH BCa and UCUB were identified. Stage at presentation and treatment rates, as well as multivariably adjusted and matched CSM rates according to TNM stage within each histologic subtype, were reported. RESULTS: Of all 222,435 eligible patients with BCa, 11,147 (5.0%) harbored VH. Among those, squamous cell carcinoma accounted for 3666 (1.6%) patients, adenocarcinoma for 1862 (0.8%), neuroendocrine carcinoma for 1857 (0.8%), and other VH BCa for 3762 (1.7%) of the study cohort. Patients with VH BCa showed invariably more advanced TNM stage at presentation compared with patients with UCUB. Treatment rates according to TNM stages showed similar distribution of cystectomy rates in VH BCa and UCUB. However, important differences in the distribution of radiotherapy and chemotherapy rates existed within VH BCa and in comparison with UCUB. Furthermore, even after multivariable adjustment and matching with UCUB, squamous cell carcinoma exhibited higher CSM (hazard ratios, 1.43-1.95; all P < .01) across all stages. All other VH predominantly exhibited higher CSM than UCUB in either non-muscle-invasive or muscle-invasive nonmetastatic stages. CONCLUSION: TNM stage at diagnosis is invariably more advanced in all patients with VH BCa versus patients with UCUB. Of all VH BCa, in multivariably adjusted stage for stage analyses, squamous cell carcinoma appears to have the worst natural history. All other VH subgroups exhibited more aggressive natural history than UCUB in nonmetastatic stages only. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Deuker, Marina AU - Deuker M AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: marina.deuker@kgu.de. FAU - Martin, Thomas AU - Martin T AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Stolzenbach, Franziska AU - Stolzenbach F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Colla Ruvolo, Claudia AU - Colla Ruvolo C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, University of Naples Federico II, Naples, Italy. FAU - Nocera, Luigi AU - Nocera L AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Becker, Andreas AU - Becker A AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Kluth, Luis AU - Kluth L AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Roos, Frederik C AU - Roos FC AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Tilki, Derya AU - Tilki D AD - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, University of Jordan, Amman, Jordan. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Colombia, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Urology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Chun, Felix AU - Chun F AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20200718 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - *Carcinoma, Squamous Cell MH - *Carcinoma, Transitional Cell/surgery/therapy MH - Cystectomy MH - Humans MH - *Urinary Bladder Neoplasms/surgery/therapy OTO - NOTNLM OT - Adenocarcinoma OT - Neuroendocrine carcinoma OT - Radical cystectomy OT - Rare histology OT - Squamous cell Carcinoma EDAT- 2020/08/13 06:00 MHDA- 2021/08/19 06:00 CRDT- 2020/08/13 06:00 PHST- 2020/04/25 00:00 [received] PHST- 2020/06/13 00:00 [revised] PHST- 2020/07/12 00:00 [accepted] PHST- 2020/08/13 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2020/08/13 06:00 [entrez] AID - S1558-7673(20)30171-3 [pii] AID - 10.1016/j.clgc.2020.07.011 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2021 Feb;19(1):60-68.e1. doi: 10.1016/j.clgc.2020.07.011. Epub 2020 Jul 18. PMID- 32773232 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 2 DP - 2021 Feb TI - Primary Ta high grade bladder tumors: Determination of the risk of progression. PG - 132.e7-132.e11 LID - S1078-1439(20)30339-2 [pii] LID - 10.1016/j.urolonc.2020.07.017 [doi] AB - PURPOSE: TaG3 bladder cancer is an under-investigated disease and because of its rarity it is commonly studies together with T1G3 disease. We sought to exclusively study TaG3 disease and to determine the factors associated with disease progression. MATERIAL AND METHOD: We retrospectively studied patients with primary TaG3 bladder cancer. Progression to >/=pT1 and pT2 were analyzed using Cox and competing-risk regression analyses. RESULTS: Of 3,505 consecutive patients with nonmuscle invasive bladder cancer, 285 patients had primary TaG3 without concomitant carcinoma in-situ. Progression to >/=pT1 occurred in 21 patients (7.4%). In a multivariable competing-risk regression analysis, intravesical Bacillus Calmette-Guerin (BCG) was significantly associated with a lower risk of progression to >/=pT1 (HR 0.23, 95%CI 0.08-0.64, P = 0.005). Recurrence in the first year of diagnosis was significantly associated with an increased risk of stage progression to >/=pT1 (HR 7.81, 95%CI 2.50-24.44, P < 0.001). Progression to >/=T2 was observed in 9 patients (3.2%). In univariable competing-risk regression analyses, intravesical BCG was significantly associated with a lower risk of progression to >/=pT2 (HR 0.11, 95%CI 0.04-0.47, P = 0.003). On the other hand, recurrence in the first year of diagnosis was significantly associated with an increased risk of stage progression to >/=T2 (HR 7.12, 95%CI 1.50-33.77, P = 0.013). In a subgroup of 199 patients who were treated with BCG, there was no statistically significant association between tumor recurrence in the 1(st) year of diagnosis and stage progression to >/=pT1 (P = 0.14) or >/=pT2(P = 0.19). CONCLUSION: Patients with TaG3 bladder cancer are considered high risk but if appropriately treated with BCG that risk is considerably mitigated. Our data support that TaG3 without concomitant carcinoma in-situ should not be considered as aggressive as T1G3 as it has a lower risk of progression to muscle-invasive bladder cancer. Recurrence in the first year after diagnosis is the strongest predictor of progression to muscle-invasive bladder cancer. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Urology Hopital Pitie-Salpetriere, Paris, France. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Yang, Lin AU - Yang L AD - Department of Epidemiology, Medical University of Vienna, Vienna, Austria; Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Canada. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Laukhtina, Ekaterina AU - Laukhtina E AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Departments of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; European Association of Urology Research Foundation, Arnhem, Netherlands; Karl Landsteiner Institute, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20200807 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Bladder cancer OT - NMIBC OT - TaG3 OT - progression OT - recurrence EDAT- 2020/08/11 06:00 MHDA- 2021/08/13 06:00 CRDT- 2020/08/11 06:00 PHST- 2020/04/14 00:00 [received] PHST- 2020/07/09 00:00 [revised] PHST- 2020/07/13 00:00 [accepted] PHST- 2020/08/11 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/08/11 06:00 [entrez] AID - S1078-1439(20)30339-2 [pii] AID - 10.1016/j.urolonc.2020.07.017 [doi] PST - ppublish SO - Urol Oncol. 2021 Feb;39(2):132.e7-132.e11. doi: 10.1016/j.urolonc.2020.07.017. Epub 2020 Aug 7. PMID- 32764425 OWN - NLM STAT- MEDLINE DCOM- 20210310 LR - 20210310 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 9 IP - 8 DP - 2020 Aug 5 TI - Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. LID - 10.3390/cells9081839 [doi] LID - 1839 AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecular markers to help guide responses are scarce and currently not used in the clinical setting. METHODS: To identify novel biomarkers and pathways involved in response to BCG immunotherapy, we performed a genome-wide DNA methylation analysis of NMIBCs before BCG therapy. Genome-wide DNA methylation profiles of DNA isolated from tumors of 26 BCG responders and 27 failures were obtained using the Infinium MethylationEPIC BeadChip. RESULTS: Distinct DNA methylation patterns were found by genome-wide analysis in the two groups. Differentially methylated CpG sites were predominantly located in gene promoters and gene bodies associated with bacterial invasion of epithelial cells, chemokine signaling, endocytosis, and focal adhesion. In total, 40 genomic regions with a significant difference in methylation between responders and failures were detected. The differential methylation state of six of these regions, localized in the promoters of the genes GPR158, KLF8, C12orf42, WDR44, FLT1, and CHST11, were internally validated by bisulfite-sequencing. GPR158 promoter hypermethylation was the best predictor of BCG failure with an AUC of 0.809 (p-value < 0.001). CONCLUSIONS: Tumors from BCG responders and BCG failures harbor distinct DNA methylation profiles. Differentially methylated DNA regions were detected in genes related to pathways involved in bacterial invasion of cells or focal adhesion. We identified candidate DNA methylation biomarkers that may help to predict patient prognosis after external validation in larger, well-designed cohorts. FAU - Ilijazi, Dafina AU - Ilijazi D AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Pulverer, Walter AU - Pulverer W AD - AIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, 1210 Vienna, Austria. FAU - Ertl, Iris E AU - Ertl IE AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Lemberger, Ursula AU - Lemberger U AUID- ORCID: 0000-0003-2019-6111 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Urology, Jikei University School of Medicine, Tokyo 105-8461, Japan. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman 11942, Jordan. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Urology, CHRU Tours, Francois Rabelais University, 37000 Tours, France. FAU - Bruchbacher, Andreas AU - Bruchbacher A AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Graf, Anna AU - Graf A AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, 10124 Turin, Italy. FAU - Susani, Martin AU - Susani M AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria. FAU - Haitel, Andrea AU - Haitel A AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria. FAU - Molinaro, Luca AU - Molinaro L AD - Division of Pathology, Department of Medical Sciences, University of Studies of Torino, 10124 Turin, Italy. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, Central Hospital of Bolzano/Bozen, 39100 Bozen, Italy. AD - Sigmund Freud Private University, Medical University, 1020 Vienna, Austria. FAU - Comploj, Evi AU - Comploj E AD - Department of Urology, Central Hospital of Bolzano/Bozen, 39100 Bozen, Italy. AD - College of Health-Care Professions, Claudiana Research, Claudiana, 39100 Bolzano, Italy. FAU - Pabinger, Stephan AU - Pabinger S AD - AIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, 1210 Vienna, Austria. FAU - Weinhausel, Andreas AU - Weinhausel A AUID- ORCID: 0000-0002-9318-1204 AD - AIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, 1210 Vienna, Austria. FAU - Egger, Gerda AU - Egger G AUID- ORCID: 0000-0003-2489-155X AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna 1090, Austria. AD - Ludwig Boltzmann Institute Applied Diagnostics, Wahringer Gurtel 18-20, 1090 Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman 11942, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA. AD - Karl Landsteiner Institute of Urology and Andrology, 3100 St. Poelten, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia. AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. FAU - Hassler, Melanie R AU - Hassler MR AD - Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200805 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Heterochromatin) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/genetics MH - CpG Islands MH - *DNA Methylation MH - Female MH - Genome-Wide Association Study MH - Heterochromatin MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - Promoter Regions, Genetic MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology PMC - PMC7464079 OTO - NOTNLM OT - BCG refractory OT - Bacillus Calmette-Guerin OT - DNA methylation marker OT - Illumina MethylationEPIC BeadChip OT - bladder cancer OT - high-risk bladder cancer OT - urothelial cancer COIS- SFS: Honoraria for lectures/consulting boards for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf Roche, Sanochemia, Sanofi, Takeda, Urogen; patents: method to determine prognosis after therapy for prostate cancer granted 2002-09-06, methods to determine prognosis after therapy for bladder cancer granted 2003-06-19, prognostic methods for patients with prostatic disease granted 2004-08-05 and soluble Fas urinary marker for the detection of bladder transitional cell carcinoma granted 2010-07-20. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2020/08/09 06:00 MHDA- 2021/03/11 06:00 PMCR- 2020/08/01 CRDT- 2020/08/09 06:00 PHST- 2020/07/15 00:00 [received] PHST- 2020/07/31 00:00 [revised] PHST- 2020/08/03 00:00 [accepted] PHST- 2020/08/09 06:00 [entrez] PHST- 2020/08/09 06:00 [pubmed] PHST- 2021/03/11 06:00 [medline] PHST- 2020/08/01 00:00 [pmc-release] AID - cells9081839 [pii] AID - cells-09-01839 [pii] AID - 10.3390/cells9081839 [doi] PST - epublish SO - Cells. 2020 Aug 5;9(8):1839. doi: 10.3390/cells9081839. PMID- 32760227 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1523-6161 (Print) IS - 2153-8182 (Electronic) IS - 1523-6161 (Linking) VI - 22 IP - 2 DP - 2020 TI - Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies. PG - 43-51 AB - Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. Risk stratification by American Urological Association (AUA) and European Association of Urology (EAU) guidelines or by using nomograms/risk calculators developed from clinical trial data can help inform patient treatment decisions but may not accurately classify all patients. Risk-adapted adjuvant (post-transurethral resection of bladder tumor [TURBT]) treatment strategies using intravesical therapies are an important means of balancing disease control with potential adverse effects. Adjuvant intravesical instillation with various chemotherapy agents and bacillus Calmette-Guerin (BCG) is well studied and associated with excellent outcomes for most patients. However, upwards of 40% of patients recur within 2 years and roughly 10% progress to muscle-invasive bladder cancer. Novel approaches and agents that aim to reduce the treatment burden associated with NMIBC are increasingly needed. We review the current landscape of NMIBC as it pertains to the use of and rationale for emerging neoadjuvant chemoablative therapies. CI - (c) 2020 MedReviews(R), LLC. FAU - Matulewicz, Richard S AU - Matulewicz RS AD - Department of Urology, NYU Grossman School of Medicine, NYU Langone Health New York, NY. AD - Department of Population Health, NYU Grossman School of Medicine, NYU Langone Health New York, NY. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, NYU Grossman School of Medicine, NYU Langone Health New York, NY. LA - eng PT - Journal Article PL - United States TA - Rev Urol JT - Reviews in urology JID - 100889067 PMC - PMC7393683 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Mitomycin OT - Non-muscle invasive bladder cancer OT - Urothelial carcinoma EDAT- 2020/08/08 06:00 MHDA- 2020/08/08 06:01 PMCR- 2020/01/01 CRDT- 2020/08/08 06:00 PHST- 2020/08/08 06:00 [entrez] PHST- 2020/08/08 06:00 [pubmed] PHST- 2020/08/08 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] PST - ppublish SO - Rev Urol. 2020;22(2):43-51. PMID- 32758253 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20231111 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 18 IP - 1 DP - 2020 Aug 5 TI - Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. PG - 303 LID - 10.1186/s12967-020-02475-w [doi] LID - 303 AB - BACKGROUND: Bladder cancer (BlCa) taxonomy has proved its impact in patient outcome and selection for targeted therapies, but such transcriptomic-based classification has not yet translated to routine practice. Moreover, epithelial-to-mesenchymal transition (EMT) has shown relevance in acquisition of more aggressive BlCa phenotype. We aimed to test the usefulness of the molecular classification, as defined by immunohistochemistry (a routinely performed and easy-to-implement technique), in a well-defined BlCa cohort of both non-muscle invasive (NMIBC) and muscle invasive (MIBC) disease. Also, we aimed to assess the additional prognostic value of the mesenchymal marker vimentin to the stratification strategy. METHODS: A total of 186 samples were available. Immunohistochemistry/RT-qPCR for luminal markers GATA3/FOXA1, basal markers KRT5/KRT6A and vimentin were performed. RESULTS: mRNA expression levels of the markers positively correlated with immunoexpression scores. We found substantial overlapping in immunoexpression of luminal and basal markers, evidencing tumor heterogeneity. In MIBC, basal tumors developed recurrence more frequently. NMIBC patients with higher vimentin immunoexpression endured poorer disease-free survival, and increased expression was observed from normal bladder-NMIBC-MIBC-metastases. CONCLUSIONS: The classification has the potential to be implemented in routine, but further adjustments in practical scoring should be defined; focusing on additional markers, including those related to EMT, may further refine BlCa molecular taxonomy. FAU - Lobo, Joao AU - Lobo J AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal. FAU - Monteiro-Reis, Sara AU - Monteiro-Reis S AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal. FAU - Guimaraes-Teixeira, Catarina AU - Guimaraes-Teixeira C AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Lopes, Paula AU - Lopes P AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Carneiro, Isa AU - Carneiro I AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. FAU - Jeronimo, Carmen AU - Jeronimo C AUID- ORCID: 0000-0003-4186-5345 AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt. AD - Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt. FAU - Henrique, Rui AU - Henrique R AD - Cancer Biology and Epigenetics Group IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. henrique@ipoporto.min-saude.pt. AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Antonio Bernardino de Almeida, 4200-072, Porto, Portugal. henrique@ipoporto.min-saude.pt. AD - Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513, Porto, Portugal. henrique@ipoporto.min-saude.pt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200805 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (Biomarkers, Tumor) RN - 0 (Vimentin) SB - IM MH - Biomarkers, Tumor/genetics MH - Epithelial-Mesenchymal Transition/genetics MH - Humans MH - Neoplasm Recurrence, Local MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis/genetics MH - Vimentin/genetics PMC - PMC7405371 OTO - NOTNLM OT - Basal OT - Bladder cancer OT - EMT OT - Luminal OT - Molecular classification OT - Pathology OT - Vimentin COIS- The authors declare that they have no competing interests. EDAT- 2020/08/08 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/08/05 CRDT- 2020/08/08 06:00 PHST- 2020/04/13 00:00 [received] PHST- 2020/07/30 00:00 [accepted] PHST- 2020/08/08 06:00 [entrez] PHST- 2020/08/08 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/08/05 00:00 [pmc-release] AID - 10.1186/s12967-020-02475-w [pii] AID - 2475 [pii] AID - 10.1186/s12967-020-02475-w [doi] PST - epublish SO - J Transl Med. 2020 Aug 5;18(1):303. doi: 10.1186/s12967-020-02475-w. PMID- 32758196 OWN - NLM STAT- MEDLINE DCOM- 20210506 LR - 20210506 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 20 IP - 1 DP - 2020 Aug 5 TI - Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. PG - 117 LID - 10.1186/s12894-020-00684-5 [doi] LID - 117 AB - BACKGROUND: Hyperglycemia is associated with series of process leading to oncogenesis. Evidence has shown that diabetes mellitus (DM) seems to be associated with poor prognosis in patients with bladder cancer. However, evidence on the effect of glycemic control on the outcomes of bladder cancer is still limited. In the current study, we aimed to investigate the effect of DM and glycemic control on the prognosis of bladder cancer. METHODS: We conducted a retrospective chart review of a prospective database from January 2012 to December 2017. Patients with newly diagnosed non-muscle invasive bladder cancer (NMIBC) were included. They were classified into the DM and non-DM groups. Prognosis including recurrence rate, progression rate, recurrence-free survival (RFS), and progression-free survival was compared between the two groups. Subgroup analysis of the DM subgroup, in which patients were classified by HbA1C level, was conducted to investigate the effect of glycemic control. RESULTS: A total of 287 patients were included in our study, with 61 patients in the DM group and 226 patients in the non-DM group. No statistically significant difference was found in the prognosis between the DM and non-DM groups. Subgroup analysis revealed higher recurrence rate (P = 0.037) and worse RFS (log-rank P = 0.019) in patients with HbA1C >/= 7. CONCLUSIONS: DM is not a risk factor for recurrence and progression in patients with NMIBC. However, poor glycemic control is associated with poor prognosis in patients with both DM and NMIBC. Further prospective studies are needed to confirm current results. FAU - Huang, Wei-Lun AU - Huang WL AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. FAU - Huang, Kuo-How AU - Huang KH AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. FAU - Huang, Chao-Yuan AU - Huang CY AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. FAU - Pu, Yeong-Shiau AU - Pu YS AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. FAU - Chang, Hong-Chiang AU - Chang HC AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. FAU - Chow, Po-Ming AU - Chow PM AUID- ORCID: 0000-0002-3183-1830 AD - Department of Urology, National Taiwan University Hospital, National Taiwan University, College of Medicine, No.7, Chung-Shan South Road, Zhongzheng District, Taipei, 100, Taiwan. meow1812@gmail.com. LA - eng PT - Journal Article DEP - 20200805 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Aged MH - Diabetes Complications/blood/*complications/*therapy MH - Female MH - *Glycemic Control MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*complications/mortality/pathology PMC - PMC7409398 OTO - NOTNLM OT - Bladder cancer OT - Diabetes mellitus OT - Glycemic control OT - Prognosis OT - Recurrence OT - Urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2020/08/08 06:00 MHDA- 2021/05/07 06:00 PMCR- 2020/08/05 CRDT- 2020/08/08 06:00 PHST- 2020/03/12 00:00 [received] PHST- 2020/07/23 00:00 [accepted] PHST- 2020/08/08 06:00 [entrez] PHST- 2020/08/08 06:00 [pubmed] PHST- 2021/05/07 06:00 [medline] PHST- 2020/08/05 00:00 [pmc-release] AID - 10.1186/s12894-020-00684-5 [pii] AID - 684 [pii] AID - 10.1186/s12894-020-00684-5 [doi] PST - epublish SO - BMC Urol. 2020 Aug 5;20(1):117. doi: 10.1186/s12894-020-00684-5. PMID- 32754330 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 13 IP - 3 DP - 2020 Sep TI - Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: A single institution retrospective study. PG - 16 LID - 10.3892/mco.2020.2086 [doi] LID - 16 AB - The aims of the current study were to analyze the oncological outcomes of patients with high-risk non-invasive bladder cancer (NMIBC) and to identify prognostic factors in these patients. The present study included 186 consecutive patients who underwent transurethral resection of the bladder tumor (TURBT) between January 2007 and June 2017 at Hamamatsu University School of Medicine and were subsequently diagnosed with high-risk NMIBC according to the classification of the European Urological Association guidelines. The oncological outcomes, including recurrence-free survival (RFS), progression-free survival (PFS) and overall survival (OS) in the 186 patients were evaluated. Additionally, the effects of several clinicopathologiocal parameters on these outcomes were investigated. After the initial TURBT, the second transurethral resection and intravesical bacillus of Calmette-Guerin (BCG) therapy were performed for 47 (25.3%) and 108 (58.1%) patients, respectively. During the observation period of the current study, disease recurrence, disease progression and overall deaths occurred in 54 (29.0%), 14 (7.5%) and 19 (10.2%) patients, respectively. The 5-year RFS, PFS and OS rates in the 186 patients were 66.6, 90.2 and 87.2%, respectively. Multivariate analyses using the Cox proportional hazards regression model identified the following independent factors for the oncological outcomes: Tumor multiplicity and introduction of BCG therapy for RFS (P=0.018 and P<0.008, respectively), tumor multiplicity and recurrence status for PFS (P=0.043 and P=0.029, respectively), and age and tumor multiplicity for OS (P<0.008 and P=0.041, respectively). Although management following initial TURBT was insufficient, the oncological outcomes in the present series were comparable to those in previous studies targeting high-risk patients with NMIBC. However, attention should be paid to patients with factors independently associated with poor prognostic outcomes, particularly those with multiple tumors. CI - Copyright (c) 2020, Spandidos Publications. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Tamura, Keita AU - Tamura K AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Motoyama, Daisuke AU - Motoyama D AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Ito, Toshiki AU - Ito T AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Sugiyama, Takayuki AU - Sugiyama T AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Otsuka, Atsushi AU - Otsuka A AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan. LA - eng PT - Journal Article DEP - 20200706 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC7391835 OTO - NOTNLM OT - high-risk non-muscle-invasive bladder cancer OT - overall survival OT - progression-free survival OT - recurrence-free survival OT - tumor multiplicity EDAT- 2020/08/06 06:00 MHDA- 2020/08/06 06:01 PMCR- 2020/07/06 CRDT- 2020/08/06 06:00 PHST- 2019/06/01 00:00 [received] PHST- 2020/06/01 00:00 [accepted] PHST- 2020/08/06 06:00 [entrez] PHST- 2020/08/06 06:00 [pubmed] PHST- 2020/08/06 06:01 [medline] PHST- 2020/07/06 00:00 [pmc-release] AID - MCO-0-0-02086 [pii] AID - 10.3892/mco.2020.2086 [doi] PST - ppublish SO - Mol Clin Oncol. 2020 Sep;13(3):16. doi: 10.3892/mco.2020.2086. Epub 2020 Jul 6. PMID- 32753285 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20220510 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 78 IP - 6 DP - 2020 Dec TI - Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. PG - 907-915 LID - S0302-2838(20)30566-2 [pii] LID - 10.1016/j.eururo.2020.07.018 [doi] AB - BACKGROUND: Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in approximately 15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs). OBJECTIVE: To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC. DESIGN, SETTING, AND PARTICIPANTS: The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA). INTERVENTION: Platinum-based chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response, recurrence-free (RFS) or progression-free (PFS) survival, and overall survival (OS) were compared between patients with FGFR3 alteration (FGFR3alt) and those without it (FGFR3wild type [FGFR3wt]) in the three cohorts. RESULTS AND LIMITATIONS: Nine of 72 NAC patients (13%) had FGFR3alt, of whom none had pathologic complete response and three had residual non-MIBC (carcinoma in situ, n = 1; pT1, n = 2). FGFR3alt was associated with shorter RFS (hazard ratio, 2.74; p = 0.044) but not OS. Among TCGA patients who underwent adjuvant chemotherapy (n = 74), FGFR3alt patients had shorter RFS as well. Conversely, among chemotherapy-naive TCGA patients, FGFR3alt was associated with longer RFS and OS. In the M1 cohort (FGFR3alt, n = 27; FGFR3wt, n = 81), FGFR3alt was associated with higher rates of pulmonary metastases and nonregional lymphadenopathy. Despite lower response rates among FGFR3alt patients (37% vs 49%; p = 0.056), PFS and OS were not significantly different from FGFR3wt patients. CONCLUSIONS: FGFR3 status is associated with lower responses to platinum-based chemotherapy, which may prompt exploration of nonchemotherapeutic approaches for perioperative management of FGFR3alt urothelial cancers. PATIENT SUMMARY: Approximately 15% of bladder cancers harbor mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Our findings suggest that FGFR3 mutations might be associated with lower responses and shorter time to recurrence among patients with muscle-invasive bladder cancer who received perioperative platinum-based chemotherapy. FGFR3 status does not significantly impact response to chemotherapy among those with metastatic urothelial cancers. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Teo, Min Yuen AU - Teo MY AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. FAU - Mota, Jose Mauricio AU - Mota JM AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Whiting, Karissa A AU - Whiting KA AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Li, Han A AU - Li HA AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Funt, Samuel A AU - Funt SA AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. FAU - Lee, Chung-Han AU - Lee CH AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. FAU - Solit, David B AU - Solit DB AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Milowsky, Matthew I AU - Milowsky MI AD - Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Balar, Arjun V AU - Balar AV AD - Department of Medical Oncology, NYU Langone Health, New York, NY, USA. FAU - Pietzak, Eugene AU - Pietzak E AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Dalbagni, Guido AU - Dalbagni G AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bajorin, Dean F AU - Bajorin DF AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. FAU - Iyer, Gopa AU - Iyer G AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: iyerg@mskcc.org. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20200801 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 49DFR088MY (Platinum) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM EIN - Eur Urol. 2021 May;79(5):e158-e159. doi: 10.1016/j.eururo.2021.01.031. PMID: 33579575 CIN - Eur Urol. 2021 Jun;79(6):e182-e183. doi: 10.1016/j.eururo.2021.03.028. PMID: 33838962 CIN - J Urol. 2022 Jun;207(6):1346-1348. doi: 10.1097/JU.0000000000002650. PMID: 35319252 MH - Aged MH - Carcinoma, Transitional Cell/*drug therapy/*genetics/secondary MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Mutation MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Platinum/*therapeutic use MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology PMC - PMC8215618 MID - NIHMS1618823 OTO - NOTNLM OT - Chemotherapy OT - FGFR3 OT - Platinum OT - Urothelial cancer COIS- Financial disclosures: Gopa Iyer certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. EDAT- 2020/08/06 06:00 MHDA- 2021/07/23 06:00 PMCR- 2021/12/01 CRDT- 2020/08/06 06:00 PHST- 2020/03/03 00:00 [received] PHST- 2020/07/16 00:00 [accepted] PHST- 2020/08/06 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/08/06 06:00 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - S0302-2838(20)30566-2 [pii] AID - 10.1016/j.eururo.2020.07.018 [doi] PST - ppublish SO - Eur Urol. 2020 Dec;78(6):907-915. doi: 10.1016/j.eururo.2020.07.018. Epub 2020 Aug 1. PMID- 32745350 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20220112 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 127 IP - 2 DP - 2021 Feb TI - Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. PG - 198-204 LID - 10.1111/bju.15194 [doi] AB - OBJECTIVE: To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences. BACKGROUND: ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. Expression is usually restricted to the basal stem cell compartment; however, in malignancy, MCM5-expressing cells can be found throughout the epithelium. Detection of MCM5 in urine sediment can be indicative of the presence of a bladder tumour. PATIENTS AND METHODS: A multicentre prospective, blinded study was carried out from August 2017 and July 2019 at 21 European Union centres, 14 of which collected matching cytology data. Urine was collected from patients prior to cystoscopy. Urine cytology and ADXBLADDER were performed and compared to the diagnosis obtained by cystoscopy. The performance of cytology and ADXBLADDER were then compared. RESULTS: The overall performance of ADXBLADDER demonstrated a sensitivity of 51.9%, a specificity of 66.4%, and a negative predictive value (NPV) of 92%. The sensitivity of ADXBLADDER for low- and high-grade recurrences was 44.1% and 58.8%, respectively. By contrast, cytology sensitivity was 16.7%, specificity was 98% and NPV was 90.7%. Cytology sensitivity for both low- and high-grade disease was 17.6%. CONCLUSIONS: ADXBLADDER detection of both low- and high-grade NMIBC recurrence is superior to that of cytology, with ADXBLADDER able to exclude the presence of high-grade recurrence in 97.8% of cases compared to 97.1% with cytology. These results show that ADXBLADDER has promise as a more reliable alternative to urine cytology in the follow-up of NMIBC. CI - (c) 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Gontero, Paulo AU - Gontero P AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology Department, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, F-75013, France. FAU - Longo, Fabrizio AU - Longo F AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Stockley, Jacqueline AU - Stockley J AUID- ORCID: 0000-0001-6601-5107 AD - Arquer Diagnostics, R&D, Sunderland, UK. FAU - Kennedy, Ashleigh AU - Kennedy A AD - Arquer Diagnostics, R&D, Sunderland, UK. FAU - Rodriguez, Oscar AU - Rodriguez O AUID- ORCID: 0000-0001-6668-4423 AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - McCracken, Stuart R C AU - McCracken SRC AD - Sunderland Royal Hospital, Sunderland, UK. FAU - Dudderidge, Tim AU - Dudderidge T AD - University Hospital Southampton, Southampton, UK. FAU - Sieverink, Caroline AU - Sieverink C AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Vanie, Felicien AU - Vanie F AD - Urology Department, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, F-75013, France. FAU - Allasia, Marco AU - Allasia M AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Sylvester, Richard AU - Sylvester R AD - EAU Non-muscle-Invasive Guidelines Panel, EAU Guidelines Office, Brussels, Belgium. FAU - Colombel, Marc AU - Colombel M AD - Department of Urology, Hopital Edouard Herriot, Lyon, France. FAU - Palou, Juan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. LA - eng GR - Arquer DIagnostics Ltd/ PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20200829 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Nat Rev Urol. 2020 Sep;17(9):486. doi: 10.1038/s41585-020-0368-y. PMID: 32782362 MH - Aged MH - Biomarkers, Tumor/urine MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Prospective Studies MH - Reproducibility of Results MH - Urinalysis/*methods MH - Urinary Bladder Neoplasms/diagnosis/*urine PMC - PMC7891338 OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - #utuc OT - biomarker OT - bladder cancer OT - cytology MCM5 OT - follow-up OT - non-muscle-invasive bladder cancer OT - surveillance COIS- This was a commercially sponsored study by Arquer Diagnostics Ltd. M. Roupret, P. Gontero, S. R. C. McCracken, T. Dudderidge, M. Colombel, F. Longo, E. Montanari and J. Palou are paid consultants to Arquer Diagnostics. J. A. Witjes has received fees for lecture honorarium for Nucleix. None has any shareholding in Arquer Diagnostics or any related company. J. Stockley and A. Kennedy are employees of Arquer Diagnostics holding share options in the company. The funder of the study assisted the authors in study design, data collection, data analysis, data interpretation, writing of the report, and the decision to submit the paper for publication. P. Gontero, M. Roupret, E. Montanari, F. Longo, T. Dudderidge, J. Palou and S. R. C. McCracken, had access to the raw data. The corresponding author had full access to all the data and had the final responsibility to submit for publication. EDAT- 2020/08/04 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/02/18 CRDT- 2020/08/04 06:00 PHST- 2020/08/04 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2020/08/04 06:00 [entrez] PHST- 2021/02/18 00:00 [pmc-release] AID - BJU15194 [pii] AID - 10.1111/bju.15194 [doi] PST - ppublish SO - BJU Int. 2021 Feb;127(2):198-204. doi: 10.1111/bju.15194. Epub 2020 Aug 29. PMID- 32739227 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 11 DP - 2020 Nov TI - Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. PG - 851.e19-851.e25 LID - S1078-1439(20)30321-5 [pii] LID - 10.1016/j.urolonc.2020.06.034 [doi] AB - PURPOSE: To examine survival rates and to calculate the risk of disease recurrence, progression, overall, and cancer-specific mortality in patients diagnosed with high-risk NMIBC using a multi-institutional dataset to evaluate differences between the guidelines of the European Association of Urology and the guidelines of the National Comprehensive Cancer Network (NCCN) with regard to tumor size in risk stratification. METHODS AND MATERIAL: In total 1,116 individuals diagnosed with high-risk NMIBC between 2001 and 2013 were included in the analysis. Patients were stratified to NCCN guideline recommendations (high-grade T1, high-grade Ta 3 cm). Recurrence and progression rates were calculated. Kaplan-Meier curves were fitted to examine differences in recurrence-free (RFS) and progression-free survival (PFS). Multivariable Cox proportional hazards regression models were employed to calculate differences in the RFS, PFS, overall, and cancer-specific survival (CSS). RESULTS: The majority of patients were diagnosed with high-grade T1 disease (N = 576, 51.6%), while 34.2% and 14.2% of patients were diagnosed with high-grade Ta 3 cm NMIBC, respectively. The 1- and 5-year RFS (1-year: 80.5% vs. 64.9%; 5-year: 58.6% vs. 48.3%, P = 0.048) and PFS (1-year: 99.1% vs. 98.6%; 5-year: 97.7% vs. 92.4%, P = 0.054) rates were higher in patients with Ta 3 cm experienced unfavorable progression-free, and cancer-specific survival compared to high-grade Ta 3 cm and high-grade T1 NMIBC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Tully, Karl H AU - Tully KH AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. FAU - Moschini, Marco AU - Moschini M AD - Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - von Rundstedt, Friedrich-Carl E AU - von Rundstedt FE AD - Department of Urology, Jena University Hospital, Friedrich-Schiller- University, Jena, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, Munchen Klinik Bogenhausen, Munich, Germany. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Necchi, Andrea AU - Necchi A AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Itlay. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Sargos, Paul AU - Sargos P AD - Division of Radiation Oncology, McGill University, Montreal, QC, Canada. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwest, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique Hopitaux de Paris, Paris Descartes University, Paris, France. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: f.roghmann@gmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200729 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Practice Guidelines as Topic MH - Retrospective Studies MH - Risk Assessment MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/classification/*mortality/*pathology OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive OT - Outcome OT - Recurrence and progression OT - Risk stratification OT - Urothelial carcinoma EDAT- 2020/08/03 06:00 MHDA- 2021/08/13 06:00 CRDT- 2020/08/03 06:00 PHST- 2020/03/12 00:00 [received] PHST- 2020/06/21 00:00 [revised] PHST- 2020/06/28 00:00 [accepted] PHST- 2020/08/03 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/08/03 06:00 [entrez] AID - S1078-1439(20)30321-5 [pii] AID - 10.1016/j.urolonc.2020.06.034 [doi] PST - ppublish SO - Urol Oncol. 2020 Nov;38(11):851.e19-851.e25. doi: 10.1016/j.urolonc.2020.06.034. Epub 2020 Jul 29. PMID- 32737581 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. PG - 1911-1916 LID - 10.1007/s00345-020-03376-9 [doi] AB - PURPOSE: To evaluate the clinical, pathological, and survival outcomes of bladder cancer in patients aged 18-40 years. METHODS: We identified 362,091 bladder cancer patients from the National Cancer Database between 2004-2013 and compared patients aged 18-40 years to those > 40 years of age with univariate analysis using Chi-square tests. A subset analysis was performed on patients who underwent cystectomy. Multivariable Cox regression was used for overall survival analysis. RESULTS: Our final analysis included 314,177 patients with 3314 (1.1%) patients aged 18-40 years. Patients aged 18-40 years had a lower male-to-female ratio (2.4 versus 3.0), a greater proportion of low-grade tumors (72.7% versus 48.3%, p < 0.001), non-muscle invasive tumors (90.3% versus 81.2%, p < 0.001), and variant histology (4.0% versus 3.3%, p < 0.001). Similar trends were observed at cystectomy including lower male-to-female ratio in the 18-40 years group (1.7 versus 3.1), a greater proportion of variant histology (25.0% versus 10.0%, p < 0.001); and 53.3% of those younger patients with variant histology were women. Patients aged 18-40 years who underwent cystectomy had a higher proportion of locally advanced disease (pT4 19.2% versus 14.6%, p = 0.004). Multivariable analyses in both cohorts demonstrated that variant histology was a predictor of worse overall survival. CONCLUSION: The majority of patients aged 18-40 years with bladder cancer present with low-grade, non-muscle-invasive disease associated with better survival. However, a subset of younger patients with a higher proportion of women presents with aggressive bladder cancer which may be partly explained by a higher prevalence of variant histology. FAU - de la Calle, Claire M AU - de la Calle CM AUID- ORCID: 0000-0003-1770-7953 AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, 1825 4th Street, San Francisco, CA, 94158, USA. claire.delacalle@ucsf.edu. FAU - Washington, Samuel L 3rd AU - Washington SL 3rd AUID- ORCID: 0000-0002-2467-6115 AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, 1825 4th Street, San Francisco, CA, 94158, USA. FAU - Lonergan, Peter E AU - Lonergan PE AUID- ORCID: 0000-0001-7233-8156 AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, 1825 4th Street, San Francisco, CA, 94158, USA. FAU - Meng, Maxwell V AU - Meng MV AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, 1825 4th Street, San Francisco, CA, 94158, USA. FAU - Porten, Sima P AU - Porten SP AUID- ORCID: 0000-0002-3948-4968 AD - Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, 1825 4th Street, San Francisco, CA, 94158, USA. LA - eng PT - Journal Article DEP - 20200731 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Adolescent MH - Adult MH - *Cystectomy MH - Databases, Factual MH - Female MH - Humans MH - Male MH - Retrospective Studies MH - Survival Rate MH - United States/epidemiology MH - Urinary Bladder Neoplasms/*mortality/*surgery MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Survival OT - Variant histology EDAT- 2020/08/02 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/08/02 06:00 PHST- 2020/04/04 00:00 [received] PHST- 2020/07/20 00:00 [accepted] PHST- 2020/08/02 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/08/02 06:00 [entrez] AID - 10.1007/s00345-020-03376-9 [pii] AID - 10.1007/s00345-020-03376-9 [doi] PST - ppublish SO - World J Urol. 2021 Jun;39(6):1911-1916. doi: 10.1007/s00345-020-03376-9. Epub 2020 Jul 31. PMID- 32734459 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Bladder lesions as incidental findings during transurethral resection of the prostate: prevalence, diagnosis, and pathological findings. PG - 1955-1960 LID - 10.1007/s00345-020-03389-4 [doi] AB - PURPOSE: The purpose of this study was to determine the prevalence of bladder lesions diagnosed during transurethral resection of the prostate (TURP), to identify the associated risk factors, and to correlate the macroscopic descriptions with the pathological findings. METHODS: This was a single-center retrospective case series conducted at a hospital in the city of Sao Paulo, Brazil. We reviewed the medical and surgical records of patients who underwent TURP between January 2012 and December 2017. RESULTS: The final sample comprised 513 patients, with a mean age of 70.8 years. Bladder lesions were identified during TURP in 109 (21.2%) of the patients, and 90 of those lesions were submitted for pathological examination. The most common macroscopic finding was bullous edema, which was seen in 57 (63.3%) of the 90 lesions examined. The pathological analysis revealed chronic cystitis in 61 lesions (67.8%) and malignant lesions in 16 (17.8%). Of the 57 lesions described as bullous edema, 5 (8.8%) were found to be malignant. CONCLUSIONS: Alterations in the bladder mucosa appear to be more common among elderly patients who use an indwelling urinary catheter for a prolonged period and among patients with recurrent urinary tract infections. In addition, the risk of a bladder lesion being malignant is apparently higher in current and former smokers than in never smokers. Our findings suggest that at-risk patients should undergo biopsy or resection of incidental bladder lesions even if those lesions seem to be benign, due to the low level of agreement between the visual analysis and the pathological examination. FAU - de Cunto Romero, Rafael AU - de Cunto Romero R AUID- ORCID: 0000-0002-5203-6342 AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. rafaelromero.urologia@gmail.com. AD - Hospital do Servidor Publico Estadual de Sao Paulo, Avenida Ibirapuera, 981, Sao Paulo, SP, 04029-000, Brazil. rafaelromero.urologia@gmail.com. FAU - Franca, Wagner A AU - Franca WA AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. FAU - Dias, Cristiane B AU - Dias CB AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. FAU - Pascini, Conrado G AU - Pascini CG AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. FAU - Amin, Estevao C AU - Amin EC AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. FAU - Rios, Luis A S AU - Rios LAS AD - Institute for the Medical Care of Civil Servants, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20200730 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Correlation of Data MH - Humans MH - *Incidental Findings MH - Male MH - Middle Aged MH - Prevalence MH - Prostatic Hyperplasia/*surgery MH - Retrospective Studies MH - Risk Factors MH - *Transurethral Resection of Prostate MH - Urinary Bladder Diseases/*diagnosis/*epidemiology/pathology OTO - NOTNLM OT - Benign prostatic hyperplasia OT - Bladder cancer OT - Bladder lesions OT - Transurethral resection of the prostate EDAT- 2020/08/01 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/08/01 06:00 PHST- 2020/04/04 00:00 [received] PHST- 2020/07/22 00:00 [accepted] PHST- 2020/08/01 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/08/01 06:00 [entrez] AID - 10.1007/s00345-020-03389-4 [pii] AID - 10.1007/s00345-020-03389-4 [doi] PST - ppublish SO - World J Urol. 2021 Jun;39(6):1955-1960. doi: 10.1007/s00345-020-03389-4. Epub 2020 Jul 30. PMID- 32734304 OWN - NLM STAT- MEDLINE DCOM- 20210323 LR - 20221207 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 51 IP - 3 DP - 2021 Mar 3 TI - Does Xylinas' nomogram accurately predict intravesical recurrence risk after radical nephroureterectomy for primary upper urinary tract urothelial carcinoma when applied to Asian populations? PG - 469-477 LID - 10.1093/jjco/hyaa138 [doi] AB - OBJECTIVE: To validate a prognostic nomogram (Xylinas' nomogram) for intravesical recurrence after radical nephroureterectomy for primary upper urinary tract urothelial carcinoma patients of Asian descent. METHODS: Clinicopathological and survival data from 243 primary urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy with bladder cuff excision between January 2004 and May 2017 were collated. Univariate and multivariable Cox regression analyses were performed to identify independent risk factors associated with intravesical recurrence-free survival. External validation was determined using regression coefficients abstracted from previously published data. Performance was then quantified through calibration and discrimination, according to concordance indexes (c-index) in receiver operating characteristic curves. RESULTS: 163 patients met our eligibility criteria and were finally included in this study. At a median follow-up of 60 months, intravesical recurrence occurred in 29.4% (n = 48). Multivariable analysis revealed that being male, ureteral tumor location, tumor multifocality and previous bladder cancer were independent prognostic factors of intravesical recurrence-free survival. When Xylinas' nomogram was applied to our cohort, the discriminatory power was found to be roughly equivalent with a c-index of 68.3% for the reduced model and 68.4% for the full model. Calibration plots also revealed intravesical recurrence predictions at 3, 6, 12, 18, 24 and 36 months had relative concordance. Contrasting the respective performances of the reduced and full model suggests there is no significant difference between the two (all P > 0.05). CONCLUSIONS: This nomogram appears accurate at predicting intravesical recurrence after radical nephroureterectomy for primary urinary tract urothelial carcinoma in Asian populations. However, it remains necessary to data mine for unknown prognostic factors for optimization. Further external validation is required across larger, ethically diverse populations before applying this nomogram in clinical practice. CI - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Diao, Tongxiang AU - Diao T AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Peking University Fifth School of Clinical Medicine, Beijing, China. FAU - Seery, Samuel AU - Seery S AD - School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Hou, Huimin AU - Hou H AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Jianye AU - Wang J AD - Department of Urology, Beijing Hospital, Beijing, China. AD - National Center of Gerontology, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. AD - Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - *Asian People MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*pathology MH - *Nephroureterectomy MH - *Nomograms MH - Outcome Assessment, Health Care MH - Prognosis MH - Proportional Hazards Models MH - ROC Curve MH - Regression Analysis MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urothelium/*pathology OTO - NOTNLM OT - intravesical recurrence OT - nomogram OT - prognosis OT - radical nephroureterectomy (RNU) OT - upper urinary tract urothelial carcinoma (UTUC) EDAT- 2020/08/01 06:00 MHDA- 2021/03/24 06:00 CRDT- 2020/08/01 06:00 PHST- 2020/05/29 00:00 [received] PHST- 2020/07/10 00:00 [accepted] PHST- 2020/08/01 06:00 [pubmed] PHST- 2021/03/24 06:00 [medline] PHST- 2020/08/01 06:00 [entrez] AID - 5879064 [pii] AID - 10.1093/jjco/hyaa138 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2021 Mar 3;51(3):469-477. doi: 10.1093/jjco/hyaa138. PMID- 32725305 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomy? PG - 1941-1945 LID - 10.1007/s00345-020-03375-w [doi] AB - PURPOSE: Imaging characteristics in bladder cancer (BC), such as hydronephrosis, are predictive of >/= pT3 disease at time of radical cystectomy (RC). The predictive capacity of other findings, such as perivesical stranding (PS), remains unclear. We investigated whether PS was associated with >/= pT3 BC in patients who did not receive neoadjuvant chemotherapy (NAC). METHODS: We identified 433 patients with BC who underwent RC from 2003 to 2018 of which 128 did not receive NAC. Evidence of PS on pre-TURBT imaging was determined by radiologist review and a stranding grading system was created. Factors associated with PS and hydronephrosis were identified. Multivariable logistic regressions evaluated PS and hydronephrosis as predictors for >/= pT3 BC. RESULTS: Of the 128 patients who did not receive NAC, 48 (38%) had pT3 and 12 (9%) had pT4 BC. 125 (98%) patients had CT and three (2%) had MRI. PS and hydronephrosis on imaging were identified in 19 (15%) and 45 (35%) patients. PS was not associated with imaging type (p = 0.38), BMI (p = 0.18), or pathologic T stage (p = 0.24). Hydronephrosis was more frequently associated with higher pathologic T stage (p = 0.034). Multivariable analysis demonstrated that PS was not predictive of >/= pT3 BC (p = 0.457), while hydronephrosis was positively associated (p = 0.003). Stratification by grade of stranding did not improve the predictive capacity of PS (p = 0.667). CONCLUSION: While hydronephrosis is an indicator of higher stage BC, PS failed to be a reliable predictor of >/= pT3 stage. These observations should give pause in using PS on imaging to guide decisions until further investigations can be explored. FAU - Fuletra, Jay G AU - Fuletra JG AD - Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. FAU - Watts, Andrew AU - Watts A AD - College of Medicine, The Pennsylvania State University, Hershey, PA, USA. FAU - Kaag, Matthew G AU - Kaag MG AD - Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. FAU - Lehman, Erik AU - Lehman E AD - Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA, USA. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. FAU - Merrill, Suzanne B AU - Merrill SB AD - Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. smerrill1@pennstatehealth.psu.edu. LA - eng PT - Journal Article DEP - 20200728 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - *Cystectomy MH - Humans MH - Hydronephrosis/diagnostic imaging/etiology MH - *Magnetic Resonance Imaging MH - Middle Aged MH - Neoplasm Staging MH - Predictive Value of Tests MH - Preoperative Period MH - Retrospective Studies MH - *Tomography, X-Ray Computed MH - Urinary Bladder Neoplasms/complications/*diagnostic imaging/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Imaging OT - Perivesical stranding OT - Staging EDAT- 2020/07/30 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/07/30 06:00 PHST- 2020/05/27 00:00 [received] PHST- 2020/07/18 00:00 [accepted] PHST- 2020/07/30 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/07/30 06:00 [entrez] AID - 10.1007/s00345-020-03375-w [pii] AID - 10.1007/s00345-020-03375-w [doi] PST - ppublish SO - World J Urol. 2021 Jun;39(6):1941-1945. doi: 10.1007/s00345-020-03375-w. Epub 2020 Jul 28. PMID- 32724417 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 20 IP - 2 DP - 2020 Aug TI - MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway. PG - 1743-1751 LID - 10.3892/ol.2020.11741 [doi] AB - Mitogen activated protein kinase phosphatase-1 (MKP-1) has been revealed to be overexpressed in bladder cancer, particularly in non-muscle invasive bladder cancer. MKP-1 may also be associated with chemotherapy resistance. However, the underlying mechanism is yet to be elucidated. The current study investigated the expression of MKP-1 by performing immunohistochemistry in surgically resected specimens obtained from primary and recurrent patients with bladder cancer. The results revealed that MKP-1 expression increased in recurrent patients. Additionally, a 3D model of the human bladder cancer cell line, RT112, was established to determine the role of MKP-1 in drug resistance. The results demonstrated that MKP-1 overexpression protected bladder cancer cells against cell death. Contrarily, MKP-1 knockdown was revealed to sensitize cells to death. In addition, the application of MAPK inhibitors effectively increased RT112 cell sensitivity to pirarubicin. In conclusion, the results of the current study indicated that MKP-1 treatment resulted in bladder cancer cell chemoresistance via JNK, ERK and p38 pathways. MKP-1 may also serve as a potential therapeutic target for chemoresistance in patients with bladder cancer. CI - Copyright: (c) Lei et al. FAU - Lei, Siyu AU - Lei S AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. AD - Department of Surgery, The 2nd Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China. FAU - Xu, Hong AU - Xu H AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. AD - Department of Surgery, The 2nd Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China. FAU - Chen, Naiwen AU - Chen N AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. AD - Department of Surgery, The 2nd Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China. FAU - Pan, Huan AU - Pan H AD - Department of Central Laboratory, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. FAU - Xie, Wenhua AU - Xie W AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. FAU - He, Yi AU - He Y AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. FAU - Jin, Jing AU - Jin J AD - Department of Urology, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China. LA - eng PT - Journal Article DEP - 20200616 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC7377201 OTO - NOTNLM OT - 3D model OT - RT112 cell OT - bladder cancer OT - fibroblast growth factor 3 OT - mitogen activated protein kinase phosphatase-1 OT - resistance EDAT- 2020/07/30 06:00 MHDA- 2020/07/30 06:01 PMCR- 2020/06/16 CRDT- 2020/07/30 06:00 PHST- 2019/07/26 00:00 [received] PHST- 2020/01/14 00:00 [accepted] PHST- 2020/07/30 06:00 [entrez] PHST- 2020/07/30 06:00 [pubmed] PHST- 2020/07/30 06:01 [medline] PHST- 2020/06/16 00:00 [pmc-release] AID - OL-0-0-11741 [pii] AID - 10.3892/ol.2020.11741 [doi] PST - ppublish SO - Oncol Lett. 2020 Aug;20(2):1743-1751. doi: 10.3892/ol.2020.11741. Epub 2020 Jun 16. PMID- 32717243 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20220203 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 145 DP - 2020 Nov TI - Increased Bacillus Calmette-Guerin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-invasive Bladder Cancer in United States Clinical Practice. PG - 172-180 LID - S0090-4295(20)30884-0 [pii] LID - 10.1016/j.urology.2020.07.023 [doi] AB - OBJECTIVE: To characterize Bacillus Calmette-Guerin (BCG) treatment patterns and associated outcomes in a large cohort of patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: Our retrospective analysis of patients aged >/=66 years with stage 0-1 urothelial bladder carcinoma diagnosed between 2000 and 2012 in the United States Surveillance, Epidemiology, and End Results-Medicare database estimated proxies for recurrence and secondary events and both all-cause and bladder cancer-specific mortality. Proportional hazards models were used in conditional landmark analyses to compare adequate (>/=5 induction instillations and >/=2 maintenance instillations) and inadequate BCG, stratified by National Comprehensive Cancer Network risk group. RESULTS: Of 39,532 patients who met the selection criteria, 16,225 (41.0%) received BCG; of them, 4602 (28.4%; 11.6% overall) received adequate treatment. Adequately treated patients were slightly younger and healthier than inadequately treated patients. Half of patients with intermediate- and high-risk NMIBC did not receive BCG; few received adequate treatment. At the 12-month landmark, adequate BCG treatment was associated with decreased risks of recurrence and of cancer-specific and all-cause mortality in patients with intermediate- and high-risk disease. CONCLUSION: We observed lower than expected use of adequate BCG treatment in patients with intermediate- to high-risk NMIBC despite evidence of improved outcomes, which suggested that practice patterns may not be in line with management recommendations in this population. CI - Published by Elsevier Inc. FAU - Richards, Kyle A AU - Richards KA AD - University of Wisconsin-Madison, Madison, WI. Electronic address: richardsk@urology.wisc.edu. FAU - Lin, Shih-Wen AU - Lin SW AD - Genentech, Inc., South San Francisco, CA. FAU - Chuo, Ching-Yi AU - Chuo CY AD - Genentech, Inc., South San Francisco, CA. FAU - Derleth, Christina L AU - Derleth CL AD - Genentech, Inc., South San Francisco, CA. FAU - Yi, Jingbo AU - Yi J AD - Genesis Research, Hoboken, NJ. FAU - Zivkovic, Marko AU - Zivkovic M AD - Genesis Research, Hoboken, NJ. FAU - Ogale, Sarika AU - Ogale S AD - Genentech, Inc., South San Francisco, CA. FAU - Prasad, Sandip AU - Prasad S AD - Garden State Urology, Whippany, NJ. FAU - Decastro, G Joel AU - Decastro GJ AD - Columbia University Medical Center, New York, NY. FAU - Steinberg, Gary D AU - Steinberg GD AD - New York University Langone Health, New York, NY. LA - eng PT - Journal Article DEP - 20200724 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2021 Jul;206(1):136-139. doi: 10.1097/JU.0000000000001802. PMID: 33881341 MH - Administration, Intravesical MH - Age Factors MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*administration & dosage MH - Carcinoma, Transitional Cell/*drug therapy/mortality/pathology MH - Drug Administration Schedule MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Practice Patterns, Physicians'/*statistics & numerical data/trends MH - Retrospective Studies MH - Risk Factors MH - United States/epidemiology MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology EDAT- 2020/07/28 06:00 MHDA- 2022/02/04 06:00 CRDT- 2020/07/28 06:00 PHST- 2020/03/19 00:00 [received] PHST- 2020/06/22 00:00 [revised] PHST- 2020/07/15 00:00 [accepted] PHST- 2020/07/28 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2020/07/28 06:00 [entrez] AID - S0090-4295(20)30884-0 [pii] AID - 10.1016/j.urology.2020.07.023 [doi] PST - ppublish SO - Urology. 2020 Nov;145:172-180. doi: 10.1016/j.urology.2020.07.023. Epub 2020 Jul 24. PMID- 32713622 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 3 DP - 2021 Mar TI - Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guerin therapy. PG - 191.e9-191.e16 LID - S1078-1439(20)30319-7 [pii] LID - 10.1016/j.urolonc.2020.06.032 [doi] AB - OBJECTIVES: To investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who underwent adjuvant induction bacillus Calmette-Guerin (BCG) therapy after transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We conducted a multi-institutional retrospective study assessing 209 patients with high-risk NMIBC who underwent TURBT and subsequent adjuvant induction BCG therapy from December 1998 to April 2019. Patients were divided into 2 groups: those with preoperative estimated glomerular filtration rate (eGFR) >/= 60 ml/min/1.73 m(2) (non-CKD group), and those with eGFR < 60 ml/min/1.73 m(2) (CKD group). Primary endpoints were intravesical recurrence-free survival (RFS) and muscle-invasive bladder cancer (MIBC)-free survival. Background-adjusted multivariate analyses with the inverse probability of treatment weighting (IPTW) method using the propensity score were performed to evaluate the impact of CKD on intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. Moreover, multivariable analyses were performed to assess the impact of CKD on intravesical recurrence and MIBC progression, adjusting for the competing risk of death using the Fine-Gray competing risk regression model. RESULTS: Median age and follow-up period after TURBT were 72 years and 45 months, respectively. Of 209 patients, 71 (34%) were diagnosed with CKD before TURBT. Background-adjusted multivariate analyses with the IPTW method indicated that CKD was significantly associated with shorter intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. In the Fine-Gray competing risk regression model, CKD showed significantly higher probabilities of intravesical recurrence and MIBC progression, with an adjusted subdistribution hazard ratio of 1.886 (95% confidence interval 1.069-3.330, P = 0.028) and 3.740 (95% confidence interval 1.060-13.20, P = 0.040), respectively. CONCLUSIONS: CKD presents a risk factor of poor oncological outcomes in patients with high-risk NMIBC who underwent adjuvant induction BCG therapy after TURBT. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Okita, Kazutaka AU - Okita K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Narita, Takuma AU - Narita T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200723 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Chemotherapy, Adjuvant MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Renal Insufficiency, Chronic/*complications MH - Retrospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*complications/*drug therapy/pathology/surgery OTO - NOTNLM OT - Chronic kidney disease OT - High-risk OT - Immune dysfunction OT - Non-muscle-invasive bladder cancer OT - Oncological outcomes OT - bacillus Calmette-Guerin EDAT- 2020/07/28 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/07/28 06:00 PHST- 2020/05/13 00:00 [received] PHST- 2020/06/25 00:00 [revised] PHST- 2020/06/28 00:00 [accepted] PHST- 2020/07/28 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/07/28 06:00 [entrez] AID - S1078-1439(20)30319-7 [pii] AID - 10.1016/j.urolonc.2020.06.032 [doi] PST - ppublish SO - Urol Oncol. 2021 Mar;39(3):191.e9-191.e16. doi: 10.1016/j.urolonc.2020.06.032. Epub 2020 Jul 23. PMID- 32701723 OWN - NLM STAT- MEDLINE DCOM- 20201217 LR - 20210206 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 30 IP - 5 DP - 2020 Sep TI - Smoking and bladder cancer: review of the recent literature. PG - 720-725 LID - 10.1097/MOU.0000000000000804 [doi] AB - PURPOSE OF REVIEW: This review summarizes the current knowledge regarding the relationship between smoking and bladder cancer (BCa), especially with respect to treatment outcomes for muscle and nonmuscle-invasive BCa (MIBC/NMIBC). RECENT FINDINGS: PubMed/Medline databases were searched for recent reports investigating the association of smoking with BCa. Smoking is associated with an increased risk of recurrence in patients with NMIBC and may impair Bacillus Calmette-Guerin treatment efficacy. Moreover, smoking is associated with poor responses to neoadjuvant chemotherapy, poor survival outcomes and high complication rates in patients undergoing radical cystectomy. Smoking cessation mitigates these negative effects, especially. However, the amount of patient counselling provided regarding this important matter and patient knowledge regarding smoking and BCa risk are inadequate. Currently, the impact of secondhand smoke on BCa risk remains uncertain. SUMMARY: Tobacco smoking is responsible for approximately half of BCa cases, and is associated with poor oncological outcomes for both NMIBC and MIBC. Despite smoking being a well known risk factor, counselling and knowledge in this area are insufficient. Appropriate smoking cessation interventions and patient information are required to improve patient health and optimize BCa survival. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mostafaei, Hadi AU - Mostafaei H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. FAU - Yang, Lin AU - Yang L AD - Department of Cancer Epidemiology and Prevention Research, Alberta Health Services. AD - Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. AD - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. AD - Department of Urology, Weill Cornell Medical College, New York, New York. AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - European Association of Urology Research Foundation, Arnhem, Netherlands. LA - eng PT - Journal Article PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Tobacco Smoke Pollution) SB - IM MH - Carcinoma, Transitional Cell/*diagnosis/mortality/*therapy MH - *Cystectomy MH - Humans MH - *Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Smoking Cessation MH - Survival Rate MH - Tobacco Smoke Pollution MH - Tobacco Smoking/*adverse effects MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/mortality/*therapy EDAT- 2020/07/24 06:00 MHDA- 2020/12/18 06:00 CRDT- 2020/07/24 06:00 PHST- 2020/07/24 06:00 [pubmed] PHST- 2020/12/18 06:00 [medline] PHST- 2020/07/24 06:00 [entrez] AID - 00042307-202009000-00016 [pii] AID - 10.1097/MOU.0000000000000804 [doi] PST - ppublish SO - Curr Opin Urol. 2020 Sep;30(5):720-725. doi: 10.1097/MOU.0000000000000804. PMID- 32700089 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20240426 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 70 IP - 1 DP - 2021 Jan TI - Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report. PG - 245-252 LID - 10.1007/s00262-020-02673-x [doi] AB - OBJECTIVES: To determine whether there is an association between blood eosinophil count and percentage with the recurrence of nonmuscle invasive bladder cancer (NMIBC) during Bacillus Calmette-Guerin (BCG) maintenance therapy with our preliminary results. METHODS: A total of 53 patients with NMIBC underwent BCG immunotherapy between January 2015 and September 2018, and met our inclusion criteria were included in the study. The parameters age, gender, smoking status, comorbidity, blood neutrophil, lymphocyte and eosinophil counts, blood eosinophil percentage, previous single postoperative intravesical chemotherapy instillation, tumor characteristic, and total and maintenance dose numbers of BCG were extracted from our medical records and compared between patients with response and with recurrence. RESULTS: Blood eosinophil count and percentage were significantly higher in patients with recurrence compared to patients with response (0.263 +/- 0.37 vs. 0.0134 +/- 0.021, p = 0.01 and 0.31 +/- 0.29 vs. 0.17 +/- 0.27, p = 0.01). Other parameters were similar in patients with recurrence and response. Receiver-operating characteristic analysis showed a considerable diagnostic value of blood eosinophil count and percentage in the prediction of bladder cancer recurrence during BCG immunotherapy. CONCLUSION: Blood eosinophil count and percentage in patients with NMIBC can predict the disease recurrence during the BCG immunotherapy. Our research raised new questions and assumptions about the role of eosinophils during BCG immunotherapy. FAU - Temiz, Mustafa Zafer AU - Temiz MZ AUID- ORCID: 0000-0002-5736-5495 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. dr_mustafazafertemiz@hotmail.com. FAU - Colakerol, Aykut AU - Colakerol A AUID- ORCID: 0000-0002-5076-5306 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Ulus, Ismail AU - Ulus I AUID- ORCID: 0000-0002-2005-9734 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Kilic, Enes AU - Kilic E AUID- ORCID: 0000-0002-3235-3025 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Paslanmaz, Filip AU - Paslanmaz F AUID- ORCID: 0000-0003-4556-5518 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Sahin, Sergen AU - Sahin S AUID- ORCID: 0000-0003-2951-5991 AD - Department of Urology, Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Yuruk, Emrah AU - Yuruk E AUID- ORCID: 0000-0002-2343-8828 AD - Department of Urology, University of Health Sciences/Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Kandirali, Engin AU - Kandirali E AUID- ORCID: 0000-0003-0580-2144 AD - Department of Urology, University of Health Sciences/Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Semercioz, Atilla AU - Semercioz A AUID- ORCID: 0000-0001-8688-4772 AD - Department of Urology, University of Health Sciences/Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. FAU - Muslumanoglu, Ahmet Yaser AU - Muslumanoglu AY AUID- ORCID: 0000-0002-8691-0886 AD - Department of Urology, University of Health Sciences/Bagcilar Training and Research Hospital, Merkez Mh, Dr. Sadik Ahmet Caddesi, Bagcilar, 34100, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20200722 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*immunology MH - Comorbidity MH - Disease Progression MH - Drug Administration Schedule MH - Eosinophils/*immunology MH - Female MH - Humans MH - Immunotherapy/methods MH - Lymphocytes/immunology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*immunology/*pathology MH - Neutrophils/immunology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*immunology/*pathology PMC - PMC10991931 OTO - NOTNLM OT - BCG OT - Eosinophils OT - Local neoplasm recurrence OT - Urinary bladder neoplasms COIS- The authors declare that they have no conflict of interest. EDAT- 2020/07/24 06:00 MHDA- 2021/01/30 06:00 PMCR- 2020/07/22 CRDT- 2020/07/24 06:00 PHST- 2020/05/21 00:00 [received] PHST- 2020/07/15 00:00 [accepted] PHST- 2020/07/24 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2020/07/24 06:00 [entrez] PHST- 2020/07/22 00:00 [pmc-release] AID - 10.1007/s00262-020-02673-x [pii] AID - 2673 [pii] AID - 10.1007/s00262-020-02673-x [doi] PST - ppublish SO - Cancer Immunol Immunother. 2021 Jan;70(1):245-252. doi: 10.1007/s00262-020-02673-x. Epub 2020 Jul 22. PMID- 32696127 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre. PG - 1917-1926 LID - 10.1007/s00345-020-03364-z [doi] AB - OBJECTIVES: To evaluate the impact of histological variants on oncological outcomes of patients with muscle-invasive bladder cancer treated with open radical cystectomy and furthermore to determine any association between survival and each histotype of bladder cancer. MATERIALS AND METHODS: Data from 525 consecutive patients with muscle-invasive bladder cancer treated with radical cystectomy between January 2008 and May 2019 were collected retrospectively. The Kaplan-Meier curves and multivariable analysis addressed the role of histological variants in recurrence, cancer-specific and overall mortality between all subgroups. RESULTS: Of 525 patients, 131 (25.0%) showed a histological variant at radical cystectomy. With a median follow-up of 31 months, 209 (39.8%) recurrences, 184 (35.0%) cancer-related deaths and 260 (49.5%) overall deaths were reported. The presence of histological variant was associated with advanced tumour stage, the presence of concomitant carcinoma in situ, lymph node metastasis, lymphovascular invasion and positive surgical margins compared to pure urothelial bladder cancer (all p values < .008) and resulted as an independent risk factor for cancer-specific mortality (p = 0.001). Patients with a histological variant were at significantly higher risk for recurrence, cancer-specific mortality and overall mortality (all p values pT2 disease. Mean tumor size was 5.6 +/- 3.0 cm and 36/207 (17%) patients had lymph node positive disease. p16 immunohistochemistry was positive in 52/204 (25%) cases but high-risk HPV was identified with in situ hybridization in only 1 (0.5%) case. Tumor size, stage, number of lymph nodes removed, number of positive lymph nodes, lymphovascular invasion, perineural invasion, and positive margins each were associated with cancer-specific mortality when adjusted for demographic factors. A multivariate analysis of variable importance further revealed sex and race as important factors in predicting cancer-specific mortality. CONCLUSION: SCC of the bladder is an aggressive histologic subtype. Although bladder SCC can express p16, it is not typically associated with high-risk HPV, although rare cases can occur. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Gordetsky, Jennifer AU - Gordetsky J AD - Department of Pathology, Vanderbilt University Medical Center, Nashville, TN; Department of Urology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: jennifer.b.gordetsky@vumc.org. FAU - Spieker, Andrew J AU - Spieker AJ AD - Department of Biostatistics, Vanderbilt University, Nashville, TN. FAU - Pena, Maria Del Carmen Rodriguez AU - Pena MDCR AD - Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. FAU - Kamanda, Sonia AU - Kamanda S AD - Department of Pathology, Vanderbilt University Medical Center, Nashville, TN. FAU - Anderson, Michele R AU - Anderson MR AD - Department of Pathology, Vanderbilt University Medical Center, Nashville, TN. FAU - Cheville, John AU - Cheville J AD - Department of Pathology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Steve AU - Boorjian S AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Granada, Carlos Prieto AU - Granada CP AD - Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Tenon Hospital, Sorbonne University, Paris, France. FAU - Hirsch, Michelle S AU - Hirsch MS AD - Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. FAU - Iczkowski, Kenneth A AU - Iczkowski KA AD - Department of Pathology, Medical College of Wisconsin, Milwaukee, WI. FAU - Imblum, Brittney AU - Imblum B AD - Department of Pathology, University of Pennsylvania, Philadelphia, PA. FAU - Schwartz, Lauren AU - Schwartz L AD - Department of Pathology, University of Pennsylvania, Philadelphia, PA. FAU - Giannico, Giovanna A AU - Giannico GA AD - Department of Pathology, Vanderbilt University Medical Center, Nashville, TN. FAU - Rais-Bahrami, Soroush AU - Rais-Bahrami S AD - Department of Urology, University of Alabama at Birmingham, Birmingham, AL; Department of Radiology, University of Alabama at Birmingham, Birmingham, AL; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL. LA - eng PT - Journal Article DEP - 20200716 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alphapapillomavirus/*isolation & purification MH - Carcinoma, Squamous Cell/epidemiology/pathology/*virology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Papillomavirus Infections/diagnosis/*epidemiology/pathology/virology MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder/pathology/virology MH - Urinary Bladder Neoplasms/epidemiology/pathology/*virology EDAT- 2020/07/19 06:00 MHDA- 2022/02/04 06:00 CRDT- 2020/07/19 06:00 PHST- 2020/05/12 00:00 [received] PHST- 2020/06/28 00:00 [revised] PHST- 2020/06/30 00:00 [accepted] PHST- 2020/07/19 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2020/07/19 06:00 [entrez] AID - S0090-4295(20)30832-3 [pii] AID - 10.1016/j.urology.2020.06.065 [doi] PST - ppublish SO - Urology. 2020 Oct;144:158-163. doi: 10.1016/j.urology.2020.06.065. Epub 2020 Jul 16. PMID- 32680493 OWN - NLM STAT- MEDLINE DCOM- 20201216 LR - 20201216 IS - 1472-6947 (Electronic) IS - 1472-6947 (Linking) VI - 20 IP - 1 DP - 2020 Jul 17 TI - Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches. PG - 162 LID - 10.1186/s12911-020-01185-z [doi] LID - 162 AB - BACKGROUND: One of the most challenging tasks for bladder cancer diagnosis is to histologically differentiate two early stages, non-invasive Ta and superficially invasive T1, the latter of which is associated with a significantly higher risk of disease progression. Indeed, in a considerable number of cases, Ta and T1 tumors look very similar under microscope, making the distinction very difficult even for experienced pathologists. Thus, there is an urgent need for a favoring system based on machine learning (ML) to distinguish between the two stages of bladder cancer. METHODS: A total of 1177 images of bladder tumor tissues stained by hematoxylin and eosin were collected by pathologists at University of Rochester Medical Center, which included 460 non-invasive (stage Ta) and 717 invasive (stage T1) tumors. Automatic pipelines were developed to extract features for three invasive patterns characteristic to the T1 stage bladder cancer (i.e., desmoplastic reaction, retraction artifact, and abundant pinker cytoplasm), using imaging processing software ImageJ and CellProfiler. Features extracted from the images were analyzed by a suite of machine learning approaches. RESULTS: We extracted nearly 700 features from the Ta and T1 tumor images. Unsupervised clustering analysis failed to distinguish hematoxylin and eosin images of Ta vs. T1 tumors. With a reduced set of features, we successfully distinguished 1177 Ta or T1 images with an accuracy of 91-96% by six supervised learning methods. By contrast, convolutional neural network (CNN) models that automatically extract features from images produced an accuracy of 84%, indicating that feature extraction driven by domain knowledge outperforms CNN-based automatic feature extraction. Further analysis revealed that desmoplastic reaction was more important than the other two patterns, and the number and size of nuclei of tumor cells were the most predictive features. CONCLUSIONS: We provide a ML-empowered, feature-centered, and interpretable diagnostic system to facilitate the accurate staging of Ta and T1 diseases, which has a potential to apply to other types of cancer. FAU - Yin, Peng-Nien AU - Yin PN AD - Thomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 1 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Kc, Kishan AU - Kc K AD - Golisano College of Computing and Information Sciences, Rochester Institute of Technology, 20 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Wei, Shishi AU - Wei S AD - Golisano College of Computing and Information Sciences, Rochester Institute of Technology, 20 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Yu, Qi AU - Yu Q AD - Golisano College of Computing and Information Sciences, Rochester Institute of Technology, 20 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Li, Rui AU - Li R AD - Golisano College of Computing and Information Sciences, Rochester Institute of Technology, 20 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Haake, Anne R AU - Haake AR AD - Golisano College of Computing and Information Sciences, Rochester Institute of Technology, 20 Lomb Memorial Drive, Rochester, NY, 14623, USA. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY, 14642, USA. hiroshi_miyamoto@urmc.rochester.edu. FAU - Cui, Feng AU - Cui F AUID- ORCID: 0000-0002-5186-5720 AD - Thomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, 1 Lomb Memorial Drive, Rochester, NY, 14623, USA. fxcsbi@rit.edu. LA - eng GR - R15 GM116102/GM/NIGMS NIH HHS/United States GR - GM116102/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20200717 PL - England TA - BMC Med Inform Decis Mak JT - BMC medical informatics and decision making JID - 101088682 SB - IM MH - Humans MH - Image Processing, Computer-Assisted MH - Machine Learning MH - Neoplasm Staging MH - Neural Networks, Computer MH - *Urinary Bladder Neoplasms/pathology PMC - PMC7367328 OTO - NOTNLM OT - Bladder cancer OT - Deep learning OT - Histopathology images OT - Machine learning COIS- The authors declare that they have no competing interests. EDAT- 2020/07/19 06:00 MHDA- 2020/12/17 06:00 PMCR- 2020/07/17 CRDT- 2020/07/19 06:00 PHST- 2019/12/27 00:00 [received] PHST- 2020/07/13 00:00 [accepted] PHST- 2020/07/19 06:00 [entrez] PHST- 2020/07/19 06:00 [pubmed] PHST- 2020/12/17 06:00 [medline] PHST- 2020/07/17 00:00 [pmc-release] AID - 10.1186/s12911-020-01185-z [pii] AID - 1185 [pii] AID - 10.1186/s12911-020-01185-z [doi] PST - epublish SO - BMC Med Inform Decis Mak. 2020 Jul 17;20(1):162. doi: 10.1186/s12911-020-01185-z. PMID- 32676741 OWN - NLM STAT- MEDLINE DCOM- 20210930 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 5 DP - 2021 May TI - Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. PG - 1549-1558 LID - 10.1007/s00345-020-03358-x [doi] AB - PURPOSE: The impact of sex hormones on cancer immunotherapy remains controversial. Androgens, via the androgen receptor (AR), may impact the success of immune checkpoint blockade. This study characterizes AR and programmed death ligand-1 (PD-L1) expression in bladder tumors with long clinical follow-up. METHODS: AR and PD-L1 expression was analyzed using immunohistochemistry on 143 transurethral resection (TUR) and 203 radical cystectomy (RC) specimens. Descriptive statistics and survival analyses assessed the relationship of AR and PD-L1 staining with clinical outcomes of tumor recurrence, progression, and overall survival. RESULTS: AR expression was observed in a higher proportion of TUR than RC specimens (59% vs 35%, p < 0.001). High immune cell (IC) PD-L1 expression was associated with higher stage and grade. Patients with the combination of an absence of AR expression and the highest (> 10%) IC PD-L1 expression in TUR tumors had an increased risk of recurrence and progression. In RC specimens, the expression of AR increased the risk of local recurrence (adjusted hazard ratio (HR) 2.09, 95% CI 0.98-4.45), which was even higher among patients who also had IC PD-L1 expression (HR 4.16, 95% CI 1.28-13.52). For 28 paired metastatic lymph nodes among RC patients, tumor cell PD-L1 expression was significantly correlated (r = 0.48, p = 0.01), while no relationship with IC PD-L1 expression was observed. CONCLUSIONS: The expression of AR and its relationship to clinical outcomes appears to vary between non-muscle invasive and muscle-invasive bladder cancer. Our results support the role of IC PD-L1 expression as an independent risk factor for bladder cancer outcomes. FAU - Toren, Paul AU - Toren P AUID- ORCID: 0000-0002-5762-5787 AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. paul.toren@crchudequebec.ulaval.ca. AD - Centre de recherche sur le cancer, Universite Laval, Quebec, QC, Canada. paul.toren@crchudequebec.ulaval.ca. FAU - Brisson, Herve AU - Brisson H AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. FAU - Simonyan, David AU - Simonyan D AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. FAU - Hovington, Helene AU - Hovington H AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. FAU - Lacombe, Louis AU - Lacombe L AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. AD - Centre de recherche sur le cancer, Universite Laval, Quebec, QC, Canada. FAU - Bergeron, Alain AU - Bergeron A AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. AD - Centre de recherche sur le cancer, Universite Laval, Quebec, QC, Canada. FAU - Fradet, Yves AU - Fradet Y AD - Centre de Recherche du CHU de Quebec, Oncology Division, CHU de Quebec-Universite Laval, Quebec, QC, Canada. AD - Centre de recherche sur le cancer, Universite Laval, Quebec, QC, Canada. LA - eng GR - 32774/Fonds de Recherche du Quebec - Sante/ PT - Journal Article DEP - 20200716 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (AR protein, human) RN - 0 (B7-H1 Antigen) RN - 0 (Receptors, Androgen) SB - IM MH - Aged MH - B7-H1 Antigen/*biosynthesis MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Prognosis MH - Receptors, Androgen/*biosynthesis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*epidemiology/*metabolism OTO - NOTNLM OT - Androgen receptor OT - Bladder cancer OT - Immunohistochemistry OT - Programmed death ligand 1 EDAT- 2020/07/18 06:00 MHDA- 2021/10/01 06:00 CRDT- 2020/07/18 06:00 PHST- 2020/04/04 00:00 [received] PHST- 2020/07/08 00:00 [accepted] PHST- 2020/07/18 06:00 [pubmed] PHST- 2021/10/01 06:00 [medline] PHST- 2020/07/18 06:00 [entrez] AID - 10.1007/s00345-020-03358-x [pii] AID - 10.1007/s00345-020-03358-x [doi] PST - ppublish SO - World J Urol. 2021 May;39(5):1549-1558. doi: 10.1007/s00345-020-03358-x. Epub 2020 Jul 16. PMID- 32676418 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220415 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 3 DP - 2020 Jun TI - Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy. PG - 1338-1344 LID - 10.21037/tau.2020.03.40 [doi] AB - BACKGROUND: The carcinoma in situ (CIS) of urinary bladder is a flat, high-grade and aggressive manifestation of urothelial cancer which carries a great risk for progression to muscle invasive disease and metastatic spread. The aim of the study was to analyse the clinical history and survival differences between primary, secondary and concomitants CIS of the bladder. METHODS: We analysed a database of 301 patients who were treated between 1998 and 2017 in university BCG outpatient department. Primary, secondary and concomitants CIS cases were included in the study with minimum follow-up of 12 months. Recurrence-free survival (RSF), progression-free survival (PFS) and cancer specific survival (CSS) were analysed by Kaplan-Meier curves and log-rank test. Additionally, Cox regression models were performed. RESULTS: Seventy-two patients with primary, 58 with secondary and 171 with CIS concomitants were analysed. The patients were followed from mean 61,9 months. RFS rates at 5-years follow-up were 54.9%, 55.3% and 60.4% for primary, concomitants and secondary CIS (P>0.05). PFS rates at 5-years follow-up were 65.8%, 72.1% and 77% for primary, concomitants and secondary CIS (P>0.05). CSS rates at 5-years follow-up were 83.1%, 81.9% and 90.1% for primary, concomitants and secondary CIS (P>0.05). There were no statistically significant differences between any CIS subtype in any of analysed endpoints in multivariate analysis. Female gender was associated with worse RFS and the instillation number was positively associated with all analysed survival rates. On contrary, age was not statistically related to RFS, PFS nor CSS. CONCLUSIONS: In this study it was shown that when compared with secondary and concomitants CIS, primary CIS presented the worst RFS and PFS, however, the differences between subgroups were not statistically significant. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Piszczek, Radoslaw AU - Piszczek R AD - Department of Urology and Oncologic Urology, Lowersilesian Specialistic Hospital, Wroclaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Malkiewicz, Bartosz AU - Malkiewicz B AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewski, Piotr AU - Krajewski P AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7354324 OTO - NOTNLM OT - Bladder cancer (BC) OT - carcinoma in situ (CIS) OT - progression OT - recurrence COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.03.40). The authors have no conflicts of interest to declare. EDAT- 2020/07/18 06:00 MHDA- 2020/07/18 06:01 PMCR- 2020/06/01 CRDT- 2020/07/18 06:00 PHST- 2020/07/18 06:00 [entrez] PHST- 2020/07/18 06:00 [pubmed] PHST- 2020/07/18 06:01 [medline] PHST- 2020/06/01 00:00 [pmc-release] AID - tau-09-03-1338 [pii] AID - 10.21037/tau.2020.03.40 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Jun;9(3):1338-1344. doi: 10.21037/tau.2020.03.40. PMID- 32676410 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220415 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 3 DP - 2020 Jun TI - Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy. PG - 1270-1277 LID - 10.21037/tau-19-705 [doi] AB - BACKGROUND: To evaluate the survival benefit of neoadjuvant chemotherapy (NAC) in pathologic T2N0 or less patients. METHODS: A total of 526 patients with less than pT2N0 underwent radical cystectomy. Patients were divided into three groups: non-NAC, those who did not receive NAC; partial NAC, those who received less 3 cycles of NAC; and complete NAC, those who received 3 cycles of NAC. RESULTS: Median follow up was 74.6 (range, 24-311) months. Recurrent-free survival (RFS) was significantly (P=0.041) higher in the non-NAC group than that in the complete NAC group. Overall survival (OS) was significantly (P=0.039) higher in the non-NAC group than that in the complete NAC group. There was no significant difference between the partial NAC group and the complete NAC group. In patients with pT0, the NAC group had higher pT0 ratio than the non-NAC group (33.3% vs. 21.1%). A total of 66.6% of NAC patients were down-staged to less than T2. In univariate and multivariate analyses, recurrence was significantly related to pathologic T stage (P<0.001), concurrent carcinoma in situ (CIS) (P=0.002), and the number of removed lymph nodes (LNs) (P=0.001). Survival was significantly related to pathologic T stage (P<0.001), lymphovascular invasion (LVI) (P=0.002), the number of removed LNs (P<0.001), and the presence of NAC (P=0.047). CONCLUSIONS: Patients with pT2 or lower underwent NAC showed similar prognosis as patients with pT2 or lower who did not undergo NAC. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7354338 OTO - NOTNLM OT - Bladder cancer OT - chemotherapy OT - neoadjuvant chemotherapy (NAC) OT - radical cystectomy OT - urothelial carcinoma (UC) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-19-705). JHK serves as an unpaid editorial board member of Translational Andrology and Urology from Jan 2020 to Dec 2021. The other authors have no other conflicts of interest to declare. EDAT- 2020/07/18 06:00 MHDA- 2020/07/18 06:01 PMCR- 2020/06/01 CRDT- 2020/07/18 06:00 PHST- 2020/07/18 06:00 [entrez] PHST- 2020/07/18 06:00 [pubmed] PHST- 2020/07/18 06:01 [medline] PHST- 2020/06/01 00:00 [pmc-release] AID - tau-09-03-1270 [pii] AID - 10.21037/tau-19-705 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Jun;9(3):1270-1277. doi: 10.21037/tau-19-705. PMID- 32672109 OWN - NLM STAT- MEDLINE DCOM- 20210730 LR - 20210730 IS - 1532-7914 (Electronic) IS - 0163-5581 (Linking) VI - 73 IP - 1 DP - 2021 TI - Low Plasma 25-Hydoxyvitamin D at Diagnosis Predicts Poor Outcomes in Patients with Bladder Cancer: A Prospective Cohort Study. PG - 55-61 LID - 10.1080/01635581.2020.1737150 [doi] AB - This study aimed to investigate whether plasma 25-hydroxyvitamin D (25-OHD) at diagnosis predicts poor outcomes in patients with urothelial bladder cancer. A total of 177 patients with non-muscle-invasive bladder cancer (NMIBC) were prospectively followed up over a period extending beyond 6 years. Data on poor outcomes (ie., recurrence, progression, and mortality) were collected. Plasma 25-OHD was measured by immunoassay. Cutoff-Finder web application was used to determine the best 25-OHD cutoff point to predict a specific poor outcome. Cox-hazard models were applied to test how plasma 25-OHD affect patients outcome while adjusting for potential confounding factors. During the follow-up period, tumor recurrence and progression occurred in 40.7% and 14.1% of patients, respectively and 11.3% of patients died. Baseline 25-OHD was lower in patients who experienced poor outcome (12.2 +/- 7.44 vs. 16.7 +/- 10.6 ng/mL; p < 0.001). Multi-adjusted HR (95% CI) for vitamin D deficiency (25-OHD < 12 ng/mL) was 2.09 (1.27-3.44) for recurrence, 2.63 (1.06-6.49) for progression and 2.93 (1.04-8.25) for mortality in patients with NMIBC. Low plasma 25-OHD in NMIBC patients is associated with higher risk of poor outcome. Future work is required to test whether correction of vitamin D deficiency will improve quality of life and extend survival in these patients. FAU - Ben Fradj, Mohamed Kacem AU - Ben Fradj MK AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Laboratory of Biochemistry, LR99ES11, Rabta University Hospital, Tunis, Tunisia. FAU - Bibi, Mokhtar AU - Bibi M AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Department of Urology, UR12SP041007, Rabta University Hospital, Tunis, Tunisia. FAU - Hammami, Mohamed Bassem AU - Hammami MB AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Laboratory of Biochemistry, LR99ES11, Rabta University Hospital, Tunis, Tunisia. FAU - Kallel, Amani AU - Kallel A AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Laboratory of Biochemistry, LR99ES11, Rabta University Hospital, Tunis, Tunisia. FAU - Nouira, Yassine AU - Nouira Y AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Department of Urology, UR12SP041007, Rabta University Hospital, Tunis, Tunisia. FAU - Feki, Moncef AU - Feki M AD - University of Tunis El Manar, Faculty of Medicine of Tunis, Tunis, Tunisia. AD - Laboratory of Biochemistry, LR99ES11, Rabta University Hospital, Tunis, Tunisia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200716 PL - United States TA - Nutr Cancer JT - Nutrition and cancer JID - 7905040 RN - 1406-16-2 (Vitamin D) SB - IM MH - Humans MH - Prognosis MH - Prospective Studies MH - Quality of Life MH - *Urinary Bladder Neoplasms/diagnosis MH - Vitamin D MH - *Vitamin D Deficiency/complications EDAT- 2020/07/17 06:00 MHDA- 2021/07/31 06:00 CRDT- 2020/07/17 06:00 PHST- 2020/07/17 06:00 [pubmed] PHST- 2021/07/31 06:00 [medline] PHST- 2020/07/17 06:00 [entrez] AID - 10.1080/01635581.2020.1737150 [doi] PST - ppublish SO - Nutr Cancer. 2021;73(1):55-61. doi: 10.1080/01635581.2020.1737150. Epub 2020 Jul 16. PMID- 32669107 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 18 IP - 1 DP - 2020 Jul 15 TI - Transurethral needle electrode resection and transurethral holmium laser resection of bladder cancer. PG - 166 LID - 10.1186/s12957-020-01943-3 [doi] LID - 166 AB - PURPOSE: The aim of the present study was to explore the efficacy and safety of transurethral needle electrode resection and transurethral holmium laser resection of non-muscular invasive bladder cancer (NMIBC). PATIENTS AND METHODS: In this prospective, case-control study, patients from the Urinary Surgery or Oncology Department who met the inclusion and exclusion criteria received transurethral needle electrode resection (n = 52) or transurethral holmium laser resection (n = 51). RESULTS: A total of 103 patients with NMIBC were included in the present study, with 68 males and 35 females. Their mean age was 57.3 years. Sixty-two patients had Ta, 15 patients had T1, and 26 patients had Tis. Operative time, intraoperative blood loss, postoperative gross hematuria time, bladder irrigation time, and postoperative hospitalization time were all significantly lower in the transurethral holmium laser resection group than the transurethral needle electrode resection group. After resection, transurethral holmium laser resection significantly decreased the value of HGF, TSH, and TNF-alpha versus the transurethral needle electrode resection group. The incidence of obturator reflex was significantly lower in the transurethral holmium laser resection group than the transurethral needle electrode resection group. There was no significant difference in disease-free survival rate and progression-free survival rate between the two groups. CONCLUSIONS: Transurethral holmium laser resection has clinical advantages in the treatment of NMIBC. FAU - Zhou, Yu AU - Zhou Y AD - Department of Urology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, China. FAU - Zhang, Zheng-Long AU - Zhang ZL AD - Department of Urology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, China. FAU - Luo, Mao-Hua AU - Luo MH AD - Department of Urology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, China. FAU - Yang, Hua AU - Yang H AUID- ORCID: 0000-0001-5385-8148 AD - Department of Urology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, China. chufeng323@126.com. LA - eng PT - Journal Article DEP - 20200715 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Case-Control Studies MH - Electrodes MH - Female MH - Humans MH - *Laser Therapy MH - *Lasers, Solid-State/therapeutic use MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery PMC - PMC7364503 OTO - NOTNLM OT - Non-muscular invasive bladder cancer OT - Transurethral holmium laser resection OT - Transurethral needle electrode resection COIS- The authors declare that they have no competing interests. EDAT- 2020/07/17 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/07/15 CRDT- 2020/07/17 06:00 PHST- 2020/03/31 00:00 [received] PHST- 2020/07/03 00:00 [accepted] PHST- 2020/07/17 06:00 [entrez] PHST- 2020/07/17 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/07/15 00:00 [pmc-release] AID - 10.1186/s12957-020-01943-3 [pii] AID - 1943 [pii] AID - 10.1186/s12957-020-01943-3 [doi] PST - epublish SO - World J Surg Oncol. 2020 Jul 15;18(1):166. doi: 10.1186/s12957-020-01943-3. PMID- 32666225 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20261012 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 11 DP - 2021 Nov TI - PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. PG - 4055-4065 LID - 10.1007/s00345-020-03329-2 [doi] AB - PURPOSE: To assess the association between PD-L1 expression and disease-free survival (DFS) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) patients treated with intravesical Bacillus Calmette-Guerin (BCG) instillations (IBI). METHODS: Retrospective study in five French centres between 2001 and 2015. Participants were 140 patients with histologically confirmed HR-NMIBC. All patients received induction and maintenance IBI. Pathological stage/grade, concomitant carcinoma in situ, lesion number and tumour size were recorded. CD3, CD8 and PD-L1 expression in tumour cells and in T cells in the tumour microenvironment (TME) was determined immunohistochemically. Median follow-up was 54.2 months. The primary outcome measure was DFS. Univariable and multivariable analyses were performed using the log rank test and Cox proportional hazards model. RESULTS: Of the 140 NMIBC, 52 (37.1%) were Ta, 88 (62.9%) were T1 and 100% were high grade. Median number of maintenance IBI was six (range 1-30). Twenty-five (17.9%) patients had recurrence/progression. In multivariable analysis, age (HR 1.07 [95% CI 1.02-1.13], p = 0.009), PD-L1 expression in tumour cells (HR per 10 units = 1.96 [95% CI 1.28-3.00], p = 0.02) and CD3/CD8 ratio (HR per 10 units = 3.38 [95% CI 1.61-7.11], p = 0.01) were significantly associated with DFS. However, using the cut-off corresponding for each PD-L1 antibodies, PD-L1 + status was not associated with DFS. CONCLUSION: Despite an association between PD-L1 expression and BCG failure in HR-NMIBC, the PD-L1 + status was not a prognostic factor in the response of BCG. Moreover, we confirmed the key role played by the IC within the microenvironment in BCG treatment. These findings highlighted the rationale to combine BCG and PD-L1/PD-1 antibodies in early bladder cancer. CI - (c) 2020. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology, Institut Universitaire du Cancer de Toulouse Oncopole, Rangueil University Hospital, 31059, Toulouse, France. roumiguie_mathieu@yahoo.fr. FAU - Comperat, Eva AU - Comperat E AD - GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP Service de Pathology, Tenon Hospital, Sorbonne University, 75020, Paris, France. FAU - Chaltiel, Leonor AU - Chaltiel L AD - Biostatistics Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France. FAU - Nouhaud, Francois Xavier AU - Nouhaud FX AD - Urology Department, Rouen University Hospital, Rouen, France. AD - UNIROUEN, IRON Group, Rouen University Hospital, Normandy University, Rouen, France. FAU - Verhoest, Gregory AU - Verhoest G AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Urology Department, Saint-Louis Hospital, Paris-Diderot University, 75010, Paris, France. FAU - Colin, Pierre AU - Colin P AD - Urology Department, Hopital prive de la Louviere, 59042, Lille, France. FAU - Audenet, Francois AU - Audenet F AD - Urology Department, Georges Pompidou European Hospital, University Paris Descartes, AP-HP, 75015, Paris, France. FAU - Houede, Nadine AU - Houede N AD - Department of Medical Oncology, CHU Caremeau, Montpellier University, 30029, Nimes, France. FAU - Larre, Stephane AU - Larre S AD - Urology Department, CHU de Reims, 51100, Reims, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Urology Department, Bichat-Claude Bernard Hospital, Paris Descartes University, AP-HP, 75018, Paris, France. FAU - Brunelle, Serge AU - Brunelle S AD - Department of Radiology, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Piana-Thomassin, Jeanne AU - Piana-Thomassin J AD - Department of Pathology, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Cotte, Juliette AU - Cotte J AD - Urology Department, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne University, 75013, Paris, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Surgical Oncology 2, Institut Paoli-Calmettes, 13009, Marseille, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Urology Department, Foch Hospital, Versailles-Saint-Quentin-en-Yvelines University, 92150, Suresnes, France. FAU - Roupret, Morgan AU - Roupret M AD - Urology Department, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne University, 75013, Paris, France. mroupret@gmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200714 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (CD274 protein, human) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - *B7-H1 Antigen/biosynthesis MH - BCG Vaccine/*administration & dosage MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Risk Assessment MH - T-Lymphocytes/metabolism MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/*drug therapy/*immunology/metabolism/pathology OTO - NOTNLM OT - BCG OT - Immunotherapy OT - Non-muscle invasive bladder cancer OT - PD-L1/PD-1 checkpoint inhibitor EDAT- 2020/07/16 06:00 MHDA- 2022/02/19 06:00 CRDT- 2020/07/16 06:00 PHST- 2020/04/01 00:00 [received] PHST- 2020/06/23 00:00 [accepted] PHST- 2020/07/16 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2020/07/16 06:00 [entrez] AID - 10.1007/s00345-020-03329-2 [pii] AID - 10.1007/s00345-020-03329-2 [doi] PST - ppublish SO - World J Urol. 2021 Nov;39(11):4055-4065. doi: 10.1007/s00345-020-03329-2. Epub 2020 Jul 14. PMID- 32665123 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 39 IP - 1 DP - 2021 Jan TI - Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer. PG - 75.e9-75.e16 LID - S1078-1439(20)30278-7 [pii] LID - 10.1016/j.urolonc.2020.06.011 [doi] AB - OBJECTIVES: To evaluate the impact of intraoperative upper urinary tract (UUT) cytology examination in patients with non-muscle-invasive bladder cancer (NMIBC) who had undergone transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We retrospectively evaluated 414 patients with NMIBC who had undergone transurethral resection of bladder tumor between November 1993 and April 2019. Patients with simultaneous UUT urothelial carcinoma (UC) detected via computed tomography were excluded. Patients were divided into 2 groups: those who had undergone intraoperative bilateral UUT cytology examination via retrograde catheterization (study group) and those who had not (control group). We evaluated the utility of intraoperative UUT cytology examination, comparing surgical outcomes and perioperative complications between the 2 groups. In addition, we evaluated the impact of UUT cytology examination on UUT recurrence using background-adjusted multivariate analysis. RESULTS: We obtained 292 UUT urine samples from 146 patients with a median age of 72 years. Of 292 UUT urine samples, 11 (3.7%) were positive and 3 were finally diagnosed as UUT UC. Positive predictive value and false positive rate were 18% and 3.1%, respectively. Operative time for the study group was significantly longer than for the control group. Rate of perioperative complications were not significantly different between the 2 groups. However, in background-adjusted multivariate analysis, intraoperative UUT cytology examination was associated with significantly shorter UUT recurrence-free survival. CONCLUSION: Intraoperative UUT cytology examination may not be recommended as a result of low positive predictive value due to contamination and UUT recurrence risk in patients with NMIBC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Okita, Kazutaka AU - Okita K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article DEP - 20200712 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - *Cystectomy/methods MH - Female MH - Humans MH - Intraoperative Period MH - Kidney Neoplasms/*pathology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology/*surgery MH - Retrospective Studies MH - Risk Factors MH - Ureteral Neoplasms/*pathology MH - Urethra MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - Retrograde catheterization OT - Upper urinary tract cytology OT - Upper urinary tract recurrence OT - Utility EDAT- 2020/07/16 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/07/16 06:00 PHST- 2020/03/24 00:00 [received] PHST- 2020/05/16 00:00 [revised] PHST- 2020/06/13 00:00 [accepted] PHST- 2020/07/16 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/07/16 06:00 [entrez] AID - S1078-1439(20)30278-7 [pii] AID - 10.1016/j.urolonc.2020.06.011 [doi] PST - ppublish SO - Urol Oncol. 2021 Jan;39(1):75.e9-75.e16. doi: 10.1016/j.urolonc.2020.06.011. Epub 2020 Jul 12. PMID- 32655828 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1943-8141 (Print) IS - 1943-8141 (Electronic) IS - 1943-8141 (Linking) VI - 12 IP - 6 DP - 2020 TI - The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. PG - 3033-3045 AB - Adipocytokines such as leptin and adiponectin have functions in metabolism as well as the development and progression of various types of malignancies. However, little is known about their role in bladder cancer. In this study, we investigated whether leptin, adiponectin, and their receptors have an impact on bladder cancer outgrowth and the mechanisms involved. We performed immunohistochemistry for leptin, leptin receptor (Ob-R), adiponectin, and adiponectin receptors (AdipoR1, AdipoR2) in bladder cancer tissue microarrays. Wound healing assay and western blot were then performed in human bladder cancer lines. The positive rates (0 vs 1+/2+/3+) of Ob-R (P=0.004), adiponectin (P<0.001), AdipoR1 (P=0.016), and AdipoR2 (P<0.001) expression were significantly higher in bladder tumors than in benign urothelial tissues. Strong (3+) leptin expression tended to be present more often in tumors (10.2%; P=0.079) than in benign tissues (3.2%). Multivariate analysis revealed a lower risk of recurrence (hazard ratio [HR]=0.432; 95% confidence interval [CI]=0.198-0.942; P=0.034) in patients with an adiponectin-positive non-muscle-invasive tumor and a higher risk of progression (HR=5.148, 95% CI=1.190-22.273; P=0.028) in patients with a leptin-positive muscle-invasive tumor. Treatment of two bladder cancer cell lines with a synthetic adiponectin inhibited their migration and the expressions of phospho-NF-kappaB, NF-kappaB, snail, slug, Y-box-binding protein 1, and COX-2, whereas leptin showed reverse effects. Downregulation of adiponectin expression and upregulation of leptin expression were independent predictors for the recurrence of non-muscle-invasive bladder tumors and progression of muscle-invasive bladder tumors, respectively. In summary, synthetic adiponectin might exhibit antitumor activity against bladder cancer. CI - AJTR Copyright (c) 2020. FAU - Kashiwagi, Eiji AU - Kashiwagi E AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine Baltimore, MD 21287, USA. FAU - Abe, Tatsuro AU - Abe T AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Kinoshita, Fumio AU - Kinoshita F AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Ushijima, Miho AU - Ushijima M AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Masaoka, Hiroyuki AU - Masaoka H AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Netto, George J AU - Netto GJ AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine Baltimore, MD 21287, USA. AD - Department of Pathology, University of Alabama at Birmingham Birmingham, AL 35233, USA. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine Baltimore, MD 21287, USA. AD - Departments of Pathology & Laboratory Medicine and Urology, and James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, NY 14642, USA. LA - eng PT - Journal Article DEP - 20200615 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC7344091 OTO - NOTNLM OT - Bladder cancer OT - adiponectin OT - epithelial-to-mesenchymal transition OT - immunohistochemistry OT - leptin COIS- None. EDAT- 2020/07/14 06:00 MHDA- 2020/07/14 06:01 PMCR- 2020/06/15 CRDT- 2020/07/14 06:00 PHST- 2019/11/22 00:00 [received] PHST- 2020/05/28 00:00 [accepted] PHST- 2020/07/14 06:00 [entrez] PHST- 2020/07/14 06:00 [pubmed] PHST- 2020/07/14 06:01 [medline] PHST- 2020/06/15 00:00 [pmc-release] PST - epublish SO - Am J Transl Res. 2020 Jun 15;12(6):3033-3045. eCollection 2020. PMID- 32654947 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20210805 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 12 DP - 2020 Dec TI - Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study. PG - 935.e1-935.e8 LID - S1078-1439(20)30279-9 [pii] LID - 10.1016/j.urolonc.2020.06.012 [doi] AB - OBJECTIVES: To prospectively evaluate the value of early urine cytology (EUC) after the primary transurethral resection of bladder tumor (TURBT) of nonmuscle invasive bladder cancer (NMIBC) for the prediction of positive biopsy findings on repeat TURBT. METHODS: After approval of institutional review board, patients who underwent TURBT for NMIBC between February 2014 and July 2018 were included in the study. Patients with concomitant Carcinoma in Situ (CIS), upper tract urothelial tumors, biopsy proven muscle invasion, or low-risk NMIBC (single, primary, Ta, and G1 tumor) were excluded. Forty-eight hours after primary TURBT, EUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive EUC to predict positive biopsy findings on repeat TURBT. RESULTS: During the study period, 198 patients fulfilled the study inclusion criteria of which 49 (25%) had recurrent NMIBC. Primary TURBT pathology results showed T1 stage in 195 (98.5%) patients and high-grade malignancy in 158 (79.8%). Intermediate- and high-risk NMIBC were defined in 49 (25%) and 149 (75%) patients, respectively. EUC was positive in 114 patients; of whom 78 (68.4%) showed positive biopsy findings on repeat TURBT (P = 0.001). The sensitivity, specificity, negative, and positive predictive values of EUC for biopsy findings at repeat TURBT were 90% (95%CI: 87-94), 75% (95%CI: 71-79), 89% (95%CI: 85-94), and 68% (95%CI: 62-74), respectively. On mean (+/-SD) follow-up of 42(+/-13) months, tumor recurrence was encountered in 101 (53%) patients. On multivariate Cox regression analysis, EUC was significantly associated with tumor recurrence (HR = 4.6, 95%CI: 2.37-8.9, P < 0.001). CONCLUSIONS: Positive EUC after primary TURBT for NMIBC is significantly associated with positive repeat TURBT for malignancy. EUC is an independent predictor of tumor recurrence. EUC might be implemented after primary TURBT to help refining indications of repeat biopsy and planning of further intervention. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Elsawy, Amr A AU - Elsawy AA AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. Electronic address: amrelsawy.unc@hotmail.com. FAU - Harraz, Ahmed M AU - Harraz AM AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Ghobrial, Fady K AU - Ghobrial FK AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abdullatef, Muhammed AU - Abdullatef M AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Ali-El-Dein, Bedeir AU - Ali-El-Dein B AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20200709 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Prospective Studies MH - Time Factors MH - Urethra MH - Urinary Bladder Neoplasms/*pathology/surgery/*urine MH - Urine/cytology OTO - NOTNLM OT - Early urine cytology OT - Nonmuscle invasive bladder cancer OT - Repeat TURBT OT - Transurethral resection of bladder tumor COIS- Conflict of interest The authors have nothing to declare. EDAT- 2020/07/14 06:00 MHDA- 2021/08/06 06:00 CRDT- 2020/07/14 06:00 PHST- 2020/03/14 00:00 [received] PHST- 2020/05/31 00:00 [revised] PHST- 2020/06/13 00:00 [accepted] PHST- 2020/07/14 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2020/07/14 06:00 [entrez] AID - S1078-1439(20)30279-9 [pii] AID - 10.1016/j.urolonc.2020.06.012 [doi] PST - ppublish SO - Urol Oncol. 2020 Dec;38(12):935.e1-935.e8. doi: 10.1016/j.urolonc.2020.06.012. Epub 2020 Jul 9. PMID- 32641241 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 9 DP - 2020 Sep TI - Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. PG - 737.e11-737.e16 LID - S1078-1439(20)30196-4 [pii] LID - 10.1016/j.urolonc.2020.05.002 [doi] AB - PURPOSE: Single, postoperative instillation of prophylactic intravesical chemotherapy (pIVC) is effective in reducing bladder cancer recurrences following radical nephroureterectomy (RNU). Despite high level evidence, pIVC is underutilized. Intraoperative pIVC (I-pIVC) may be easier and safer to implement than postoperative pIVC (P-pIVC). We aimed to evaluate the efficacy of I-pIVC during RNU. MATERIALS AND METHODS: Retrospective analysis of patients undergoing RNU and I-pIVC or postoperative pIVC (P-pVC) with 20 to 40 mg mitomycin-C or 1 to 2 g gemcitabine. Recurrence rates were evaluated using the Kaplan-Meier curves and log rank test. Cox regression was used for univariable and multivariable analysis. RESULTS: One hundred and thirty-seven patients were included in the final analysis. 81% (111/137) had I-pIVC and 19% (26/137) had P-pIVC. In the I-pIVC group higher rates of HG, muscle invasive disease and gemcitabine use were observed. Overall, 74% (101/137) and 26% (36/137) had mitomycin-C and gemcitabine instillations, respectively. Within 12 months 14% (19/137) of the patients experienced bladder recurrence. Median time to bladder recurrence was 7 months (range 3-27). Twelve months bladder recurrence-free survival rates were 82% for the I-pIVC group, and 72% for the P-pIVC group ((log rank P = 0.365). CONCLUSIONS: I-pIVC during RNU may reduce bladder recurrence rates. Bladder recurrence rates are comparable to those reported using postoperative instillations. Intraoperative instillations may be easier to implement and may increase usage rates. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Freifeld, Yuval AU - Freifeld Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Ghandour, Rashed AU - Ghandour R AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Woldu, Solomon AU - Woldu S AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Rapoport, Leonid M AU - Rapoport LM AD - Research institute of Uronephrology and Human Reproductive Health, I.M Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Gazimiev, Magomet AU - Gazimiev M AD - Research institute of Uronephrology and Human Reproductive Health, I.M Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Delafuente, Karen AU - Delafuente K AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Kulangara, Rohan AU - Kulangara R AD - University of Texas Southwestern Medical School, Dallas, TX. FAU - Robyak, Haley AU - Robyak H AD - Division of Urology, Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Petros, Firas G AU - Petros FG AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Research institute of Uronephrology and Human Reproductive Health, I.M Sechenov First Moscow State Medical University, Moscow, Russia. Electronic address: Vitaly.Margulis@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20200705 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Humans MH - Intraoperative Period MH - Kidney Neoplasms/*surgery MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - Neoplasm Recurrence, Local/*prevention & control MH - *Nephroureterectomy/methods MH - Retrospective Studies MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder Neoplasms/*prevention & control OTO - NOTNLM OT - Bladder cancer OT - Intravesical chemotherapy OT - Mitomycin C OT - Nephroureterectomy OT - Recurrence OT - Upper tract urothelial carcinoma EDAT- 2020/07/10 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/07/10 06:00 PHST- 2019/12/24 00:00 [received] PHST- 2020/04/30 00:00 [revised] PHST- 2020/05/01 00:00 [accepted] PHST- 2020/07/10 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/07/10 06:00 [entrez] AID - S1078-1439(20)30196-4 [pii] AID - 10.1016/j.urolonc.2020.05.002 [doi] PST - ppublish SO - Urol Oncol. 2020 Sep;38(9):737.e11-737.e16. doi: 10.1016/j.urolonc.2020.05.002. Epub 2020 Jul 5. PMID- 32641099 OWN - NLM STAT- MEDLINE DCOM- 20210319 LR - 20210319 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 20 IP - 1 DP - 2020 Jul 8 TI - Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study. PG - 91 LID - 10.1186/s12894-020-00642-1 [doi] LID - 91 AB - BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) therapy is the treatment of choice for patients with T1 or high-grade superficial bladder cancer or those with carcinoma in situ after transurethral resection. A personal history of tuberculosis infection has been viewed as a relative contraindication for BCG therapy, because it may increase the risk of complications or decrease the treatment effectiveness. We determined the safety and efficacy of intravesical BCG treatment for patients with prior tuberculosis infection by analyzing the data obtained from the National Health Insurance Research Database in Taiwan. METHODS: We included patients who were newly diagnosed with bladder cancer from 2000 to 2009 and who received adjuvant intravesical BCG therapy within 3 months after the surgery. We excluded those who developed upper urinary tract cancer during the study period. Disease recurrence, disease progression, and major adverse effects were compared between patients with and without a prior diagnosis of tuberculosis infection until December 31, 2011. RESULTS: Among the 3915 patients included, 187 (4.8%) had been previously diagnosed with tuberculosis infection. The proportion of men (84.0% versus 76.9%) and older patients was higher in the group with a prior tuberculosis infection than in those without a prior tuberculosis infection. Significant differences in disease recurrence (20.3% versus 22.8%; hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.63-1.21, p = 0.404) or disease progression (10.2% versus 12.8%, HR, 0.74; 95% CI, 0.46-1.17, p = 0.191) were not observed between the two groups. None of the patients with a prior tuberculosis infection had severe urinary tract infections, whereas four (0.1%) patients without such an infection developed severe urinary tract infections. CONCLUSION: A prior tuberculosis infection did not affect the treatment efficacy or safety of intravesical BCG treatment. The efficacy and safety of intravesical BCG therapy are comparable between bladder cancer patients with and without prior tuberculosis infections. FAU - Hsu, Che-Wei AU - Hsu CW AD - Division of Urology, Department of Surgery, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan. FAU - Chiu, Yi-Chun AU - Chiu YC AD - Division of Urology, Department of Surgery, Taipei City Hospital Heping Fuyou Branch, Taipei, Taiwan. AD - Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Hu, Hsiao-Yun AU - Hu HY AD - Department of Education and Research, Taipei City Hospital, Taipei, Taiwan. AD - Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. FAU - Fan, Yu-Hua AU - Fan YH AD - Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan. AD - Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Hong, Shih-Chi AU - Hong SC AD - Division of Urology, Department of Surgery, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan. DAH79@tpech.gov.tw. FAU - Cheng, Wei-Ming AU - Cheng WM AD - Division of Urology, Department of Surgery, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan. guwmcheng@gmail.com. AD - Department of Urology, School of Medicine, National Yang-Ming University, Taipei, Taiwan. guwmcheng@gmail.com. LA - eng PT - Journal Article DEP - 20200708 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Risk Factors MH - Taiwan MH - Treatment Outcome MH - Tuberculosis MH - Urinary Bladder Neoplasms/*drug therapy PMC - PMC7346498 OTO - NOTNLM OT - Bacillus Calmette-Guerin instillation OT - Bladder cancer OT - Intravesical immunotherapy OT - Tuberculosis infection OT - Urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2020/07/10 06:00 MHDA- 2021/03/20 06:00 PMCR- 2020/07/08 CRDT- 2020/07/10 06:00 PHST- 2020/03/25 00:00 [received] PHST- 2020/06/17 00:00 [accepted] PHST- 2020/07/10 06:00 [entrez] PHST- 2020/07/10 06:00 [pubmed] PHST- 2021/03/20 06:00 [medline] PHST- 2020/07/08 00:00 [pmc-release] AID - 10.1186/s12894-020-00642-1 [pii] AID - 642 [pii] AID - 10.1186/s12894-020-00642-1 [doi] PST - epublish SO - BMC Urol. 2020 Jul 8;20(1):91. doi: 10.1186/s12894-020-00642-1. PMID- 32623385 OWN - NLM STAT- MEDLINE DCOM- 20210608 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 29 IP - 1 DP - 2020 TI - Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer. PG - 101-110 LID - 10.3233/CBM-191322 [doi] AB - BACKGROUND: Among patients diagnosed with non-muscle invasive bladder cancer (NMIBC), 30% to 70% experience recurrences within 6 to 12 years of diagnosis. The need to screen for these events every 3 to 6 months and ultimately annually by cystoscopy makes bladder cancer one of the most expensive malignancies to manage. OBJECTIVE: The purpose of this study was to identify reproducible prognostic microRNAs in resected non-muscle invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype as potential biomarkers and molecular therapeutic targets. METHODS: Two independent cohorts of NMIBC patients were analyzed using a biomarker discovery and validation approach, respectively. RESULTS: miRNA Let-7f-5p showed the strongest association with recurrence across both cohorts. Let-7f-5p levels in urine and plasma were both found to be significantly correlated with levels in tumor tissue. We assessed the therapeutic potential of targeting Lin28, a negative regulator of Let-7f-5p, with small-molecule inhibitor C1632. Lin28 inhibition significantly increased levels of Let-7f-5p expression and led to significant inhibition of viability and migration of HTB-2 cells. CONCLUSIONS: We have identified Let-7f-5p as a miRNA biomarker of recurrence in NMIBC tumors. We further demonstrate that targeting Lin28, a negative regulator of Let-7f-5p, represents a novel potential therapeutic opportunity in NMIBC. FAU - Shee, Kevin AU - Shee K AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Seigne, John D AU - Seigne JD AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Karagas, Margaret R AU - Karagas MR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Marsit, Carmen J AU - Marsit CJ AD - Department of Environmental Health and of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. FAU - Hinds, John W AU - Hinds JW AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. AD - Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Schned, Alan R AU - Schned AR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Pettus, Jason R AU - Pettus JR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Armstrong, David A AU - Armstrong DA AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Miller, Todd W AU - Miller TW AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. AD - Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. FAU - Andrew, Angeline S AU - Andrew AS AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA. LA - eng GR - K07 CA102327/CA/NCI NIH HHS/United States GR - R21 CA182659/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (Lin28A protein, human) RN - 0 (MicroRNAs) RN - 0 (RNA-Binding Proteins) RN - 0 (mirnlet7 microRNA, human) SB - IM MH - Biomarkers, Tumor/genetics MH - Cell Movement/genetics MH - Cell Proliferation/genetics MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Neoplasm Invasiveness/genetics MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Prognosis MH - RNA-Binding Proteins/genetics MH - Urinary Bladder Neoplasms/*genetics PMC - PMC12662509 OTO - NOTNLM OT - bladder cancer OT - miR OT - miRNA OT - recurrence OT - urothelial carcinoma COIS- The authors have no conflicts of interest to disclose. EDAT- 2020/07/06 06:00 MHDA- 2021/06/09 06:00 PMCR- 2020/09/25 CRDT- 2020/07/06 06:00 PHST- 2020/07/06 06:00 [pubmed] PHST- 2021/06/09 06:00 [medline] PHST- 2020/07/06 06:00 [entrez] PHST- 2020/09/25 00:00 [pmc-release] AID - CBM191322 [pii] AID - 10.3233/CBM-191322 [doi] PST - ppublish SO - Cancer Biomark. 2020;29(1):101-110. doi: 10.3233/CBM-191322. PMID- 32620920 OWN - NLM STAT- MEDLINE DCOM- 20201208 LR - 20210703 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Jul 3 TI - Circulating proteomic signature for detection of biomarkers in bladder cancer patients. PG - 10999 LID - 10.1038/s41598-020-67929-z [doi] LID - 10999 AB - The identification of clinically-relevant early diagnostic and prognostic protein biomarkers is essential to maximize therapeutic efficacy and prevent cancer progression. The aim of the current study is to determine whether aberrant plasma protein profile can be applied as a surrogate tool for early diagnosis of bladder carcinoma. Plasma samples from patients with low grade non-muscle invasive bladder cancer and healthy controls were analyzed using combined 2D-DIGE and mass-spectrometry to identify differentially expressed proteins. Validation was performed using western blotting analysis in an independent cohort of cancer patients and controls. Fifteen differentially-expressed proteins were identified of which 12 were significantly up-regulated and three were significantly down-regulated in tumors compared to controls. The Ingenuity Pathways Analysis revealed functional connection between the differentially-expressed proteins and immunological disease, inflammatory disease and cancer mediated through chemokine and cytokine signaling pathway and NF-kB transcription factor. Among the three validated proteins, haptoglobin was able to distinguish between patients with low grade bladder cancer and the controls with high sensitivity and specificity (AUC > 0.87). In conclusion, several biomarker proteins were identified in bladder cancer. Haptoglobin is a potential candidate that merit further investigation to validate its usefulness and functional significance as potential biomarkers for early detection of bladder cancer. FAU - Nedjadi, Taoufik AU - Nedjadi T AD - King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, PO Box 9515, Jeddah, 21423, Saudi Arabia. nedjadita@ngha.med.sa. FAU - Benabdelkamal, Hicham AU - Benabdelkamal H AD - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - Albarakati, Nada AU - Albarakati N AD - King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, PO Box 9515, Jeddah, 21423, Saudi Arabia. FAU - Masood, Afshan AU - Masood A AD - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - Al-Sayyad, Ahmed AU - Al-Sayyad A AD - Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Alfadda, Assim A AU - Alfadda AA AD - Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - Alanazi, Ibrahim O AU - Alanazi IO AD - National Center for Biotechnology (NCBT), Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia. FAU - Al-Ammari, Adel AU - Al-Ammari A AD - Department of Urology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. FAU - Al-Maghrabi, Jaudah AU - Al-Maghrabi J AD - Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200703 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (Haptoglobins) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*blood MH - Case-Control Studies MH - Electrophoresis, Gel, Two-Dimensional MH - Female MH - Gene Expression Regulation, Neoplastic MH - Haptoglobins/*metabolism MH - Humans MH - Male MH - Middle Aged MH - Proteomics/*methods MH - Sensitivity and Specificity MH - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MH - Urinary Bladder Neoplasms/blood/*diagnosis PMC - PMC7335182 COIS- The authors declare no competing interests. EDAT- 2020/07/06 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/07/03 CRDT- 2020/07/05 06:00 PHST- 2020/01/16 00:00 [received] PHST- 2020/06/15 00:00 [accepted] PHST- 2020/07/05 06:00 [entrez] PHST- 2020/07/06 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/07/03 00:00 [pmc-release] AID - 10.1038/s41598-020-67929-z [pii] AID - 67929 [pii] AID - 10.1038/s41598-020-67929-z [doi] PST - epublish SO - Sci Rep. 2020 Jul 3;10(1):10999. doi: 10.1038/s41598-020-67929-z. PMID- 32610323 OWN - NLM STAT- MEDLINE DCOM- 20210422 LR - 20210422 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 104 IP - 7-8 DP - 2020 TI - Sub-Staging-Specific Differences in Recurrence-Free, Progression-Free, and Cancer-Specific Survival for Patients with T1 Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 580-586 LID - 10.1159/000506238 [doi] AB - INTRODUCTION: The efficiency of the T1 sub-staging system on categorizing bladder cancer (BC) patients into subgroups with different clinical outcomes was unclear. We summarized relevant evidences, including recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS), to analyze the prognostic significance of T1 sub-stage. METHODS: Systematic literature searches of MEDLINE, EMBASE, and the Cochrane Library were performed. We pooled data on recurrence, progression, and CSS from 35 studies. RESULTS: The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) indicated the difference in RFS between T1a sub-stage and T1b sub-stage (HR 1.28, 95% CI 1.14-1.43, p < 0.001). The significant difference was observed in PFS between the 2 arms (HR 2.18, 95% CI 1.95-2.44, p < 0.001). Worse CSS was found in T1b patients than in T1a patients (HR 1.36, 95% CI 1.21-1.54, p < 0.001). CONCLUSIONS: T1 sub-staging system based on the invasion depth into muscularis mucosae can be a significant prognostic factor for RFS, PFS, and CSS of patients with T1 BC. Urologists and pathologists are encouraged to work together to give a precise sub-stage classification of T1 BC, and T1 sub-staging system should be a routine part of any histopathological report when possible. Different treatment strategies need to be developed for both T1a BC and T1b BC. CI - (c) 2020 S. Karger AG, Basel. FAU - Chen, Guanqiu AU - Chen G AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Yang, Tao AU - Yang T AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Shao, Qiuya AU - Shao Q AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhang, Mengzhao AU - Zhang M AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Yang, Bo AU - Yang B AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhang, Pu AU - Zhang P AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Fan, Jinhai AU - Fan J AD - Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, jinhaif029@126.com. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200701 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Disease Progression MH - Humans MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology OTO - NOTNLM OT - Cancer-specific survival OT - Muscularis mucosa OT - Progression OT - Recurrence OT - Sub-staging OT - Urinary bladder neoplasms EDAT- 2020/07/02 06:00 MHDA- 2021/04/23 06:00 CRDT- 2020/07/02 06:00 PHST- 2019/11/05 00:00 [received] PHST- 2020/01/27 00:00 [accepted] PHST- 2020/07/02 06:00 [pubmed] PHST- 2021/04/23 06:00 [medline] PHST- 2020/07/02 06:00 [entrez] AID - 000506238 [pii] AID - 10.1159/000506238 [doi] PST - ppublish SO - Urol Int. 2020;104(7-8):580-586. doi: 10.1159/000506238. Epub 2020 Jul 1. PMID- 32601273 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 2058-6124 (Electronic) IS - 2058-6124 (Linking) VI - 6 IP - 1 DP - 2020 Jun 29 TI - Incidental bladder cancer at initial urological workup of spinal cord injury patients. PG - 55 LID - 10.1038/s41394-020-0307-4 [doi] LID - 55 AB - STUDY DESIGN: Retrospective descriptive study. OBJECTIVES: To compare histopathological findings and the long-term course of SCI patients with bladder cancer found incidentally at the initial urological workup to those diagnosed with bladder cancer many years after the onset of SCI. SETTING: Spinal cord injury center in Germany. METHODS: Data and follow-up of consecutive in- and out-patients with SCI admitted at a tertiary spinal cord injury center between January 1, 1998 and December 31, 2018 were screened retrospectively. All patients with acquired SCI were evaluated for pathological findings in the urinary bladder present at the time of SCI on the initial urological workup. Data of 37 long-term SCI patients from the same center with diagnosed bladder cancer and data of the general German population served as reference groups. Descriptive statistics were applied. RESULTS: In total, four patients with bladder cancer at initial urological workup were assessed. They all had non-muscle invasive bladder cancer. Two of the patients were cystectomized 34 and 106 months after first bladder cancer diagnosis, due to relapsing tumor and progressive renal failure, respectively. In both cases no tumor was found in the resected bladder. All four patients are currently alive with no tumor and a mean follow-up of 105 months. CONCLUSIONS: In incidental bladder cancer observed at the initial urological workup after acquired SCI, the duration of SCI, at least in the first 5 years, does not noticeably contribute to a poor prognosis, i.e., progression to muscle invasive bladder cancer (>/=T2) or a higher grading (G3). FAU - Bothig, Ralf AU - Bothig R AUID- ORCID: 0000-0003-3037-8066 AD - Department of Neuro-Urology, Centre for Spinal Cord Injuries, BG Klinikum Hamburg, Hamburg, Germany. R.Boethig@bgk-hamburg.de. FAU - Golka, Klaus AU - Golka K AD - Clinical Occupational Medicine, Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Dortmund, Germany. FAU - Tiburtius, Christian AU - Tiburtius C AD - Department of Neuro-Urology, Centre for Spinal Cord Injuries, BG Klinikum Hamburg, Hamburg, Germany. FAU - Balzer, Oliver AU - Balzer O AD - Department of Neuro-Urology, Centre for Spinal Cord Injuries, BG Klinikum Hamburg, Hamburg, Germany. FAU - Kowald, Birgitt AU - Kowald B AD - Biomechanical Laboratory, BG Klinikum Hamburg, Hamburg, Germany. FAU - Hirschfeld, Sven AU - Hirschfeld S AD - Centre for Spinal Cord Injuries, BG Klinikum Hamburg, Hamburg, Germany. FAU - Kurze, Ines AU - Kurze I AD - Department of Paraplegiology and Neuro-Urology, Centre for Spinal Cord Injuries, Zentralklinik Bad Berka, Bad Berka, Germany. FAU - Schops, Wolfgang AU - Schops W AD - Urological Practice, Sankt Augustin, Germany. FAU - Kadhum, Thura AU - Kadhum T AD - Specialist Clinic for Psychosomatic Rehabilitation, Mittelrheinklinik, Boppard-Bad Salzig, Germany. FAU - Thietje, Roland AU - Thietje R AD - Centre for Spinal Cord Injuries, BG Klinikum Hamburg, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20200629 PL - England TA - Spinal Cord Ser Cases JT - Spinal cord series and cases JID - 101680856 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Retrospective Studies MH - Spinal Cord Injuries/*complications MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*complications/*epidemiology MH - Urinary Bladder, Neurogenic/*complications/epidemiology PMC - PMC7324388 COIS- The authors declare that they have no conflict of interest. EDAT- 2020/07/01 06:00 MHDA- 2021/08/10 06:00 PMCR- 2021/06/29 CRDT- 2020/07/01 06:00 PHST- 2020/04/29 00:00 [received] PHST- 2020/06/16 00:00 [accepted] PHST- 2020/06/13 00:00 [revised] PHST- 2020/07/01 06:00 [entrez] PHST- 2020/07/01 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2021/06/29 00:00 [pmc-release] AID - 10.1038/s41394-020-0307-4 [pii] AID - 307 [pii] AID - 10.1038/s41394-020-0307-4 [doi] PST - epublish SO - Spinal Cord Ser Cases. 2020 Jun 29;6(1):55. doi: 10.1038/s41394-020-0307-4. PMID- 32593530 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20210927 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 79 IP - 1 DP - 2021 Jan TI - European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. PG - 62-79 LID - S0302-2838(20)30427-9 [pii] LID - 10.1016/j.eururo.2020.05.042 [doi] AB - CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract carcinoma, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, adjuvant treatment, instillation, recurrence, risk factors, and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification as well as for radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumour and two functional kidneys. After radical nephroureterectomy, cisplatin-based chemotherapy is indicated in locally advanced UTUC. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC n degrees 5, Predictive ONCO-URO, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. Electronic address: morgan.roupret@aphp.fr. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Capoun, Otakar AU - Capoun O AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Sorbonne University, Assistance Publique-Hopitaux de Paris, Hopital Tenon, Paris, France. FAU - Cowan, Nigel C AU - Cowan NC AD - Department of Radiology, The Queen Alexandra Hospital, Portsmouth, UK. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Molinette Hospital, University of Torino School of Medicine, Torino, Italy. FAU - Hugh Mostafid, A AU - Hugh Mostafid A AD - Royal Surrey Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Department of urology, university of Rennes, Rennes, France. FAU - Seisen, Thomas AU - Seisen T AD - Urology, GRC n degrees 5, Predictive ONCO-URO, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France. FAU - Soukup, Viktor AU - Soukup V AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EAU Guidelines Office, Arnhem, The Netherlands. FAU - Rhijn, Bas W G van AU - Rhijn BWGV AD - Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20200624 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2021 Jan;79(1):80-81. doi: 10.1016/j.eururo.2020.09.045. PMID: 33039204 MH - Carcinoma, Transitional Cell/*diagnosis/*therapy MH - Humans MH - Kidney Neoplasms/*diagnosis/*therapy MH - *Kidney Pelvis MH - Ureteral Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - Chemotherapy OT - Cytology OT - Diagnosis OT - Follow-up OT - Guidelines OT - Management OT - Neoplasm OT - Nephroureterectomy OT - Renal pelvis OT - Risk factors OT - Survival OT - Systemic treatment OT - Upper tract OT - Ureter OT - Ureteroscopy OT - Urothelial carcinoma EDAT- 2020/07/01 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/06/29 06:00 PHST- 2020/05/19 00:00 [received] PHST- 2020/05/28 00:00 [accepted] PHST- 2020/07/01 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/06/29 06:00 [entrez] AID - S0302-2838(20)30427-9 [pii] AID - 10.1016/j.eururo.2020.05.042 [doi] PST - ppublish SO - Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24. PMID- 32585894 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 9 IP - 6 DP - 2020 Jun 23 TI - Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. LID - 10.3390/jcm9061962 [doi] LID - 1962 AB - BACKGROUND: To compare overall survival (OS) outcomes in pN1-3 disease at the time of radical cystectomy (RC) for muscle invasive bladder according to the neoadjuvant chemotherapy (NAC) status. MATERIALS AND METHODS: This multicenter study included 450 consecutive patients undergoing RC for muscle-invasive urothelial bladder cancer with pN1-3 pM0 disease from 2010 to 2019. NAC consisted in platinum-based chemotherapy. The primary endpoint was the comparison between NAC and non-NAC in terms of death from any cause. OS was assessed using the Kaplan-Meier method and multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios. RESULTS: Median age was 69 years. Patients receiving NAC were younger (p = 0.051), and more likely had downstaging to non-muscle invasive disease (10.7% versus 4.3%, p = 0.042). Median OS was 26.6 months. NAC patients had poorer OS compared with those who did receive NAC (Hazard ratio (HR) 1.6; p = 0.019). The persistence of muscle-invasive bladder in RC specimens was also significantly associated with OS (HR 2.40). In the NAC cohort, the two factors independently correlated with OS were the number of positive lymph nodes (p = 0.013) and adjuvant chemotherapy (AC) (HR 0.31; p = 0.015). CONCLUSIONS: Persistent nodal disease in RC specimens after NAC was associated with poor prognosis and lower OS rates compared with pN1-3 disease after upfront RC. In this sub-group of NAC patients, AC was independently associated with better OS. FAU - Ploussard, Guillaume AU - Ploussard G AUID- ORCID: 0000-0002-6004-2152 AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Pradere, Benjamin AU - Pradere B AUID- ORCID: 0000-0002-7768-8558 AD - Department of Urology, Bretonneau Hospital, 37000 Tours, France. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. FAU - Beauval, Jean-Baptiste AU - Beauval JB AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Chevreau, Christine AU - Chevreau C AD - Department of Oncology, IUCT-O, 31000 Toulouse, France. FAU - Almeras, Christophe AU - Almeras C AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Suc, Etienne AU - Suc E AD - Department of Oncology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Gautier, Jean-Romain AU - Gautier JR AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Laurenty, Anne-Pascale AU - Laurenty AP AD - Department of Oncology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Roumiguie, Mathieu AU - Roumiguie M AUID- ORCID: 0000-0002-2412-146X AD - Department of Urology, CHU-IUC, 31000 Toulouse, France. FAU - Loison, Guillaume AU - Loison G AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Tollon, Christophe AU - Tollon C AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Mourey, Loic AU - Mourey L AD - Department of Oncology, IUCT-O, 31000 Toulouse, France. FAU - Salin, Ambroise AU - Salin A AD - Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris University, 75018 Paris, France. FAU - Pouessel, Damien AU - Pouessel D AD - Department of Oncology, IUCT-O, 31000 Toulouse, France. LA - eng PT - Journal Article DEP - 20200623 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC7356776 OTO - NOTNLM OT - adjuvant OT - bladder cancer OT - chemotherapy OT - neoadjuvant OT - nodal disease OT - pN1 OT - radical cystectomy COIS- The authors declare no conflict of interest. EDAT- 2020/06/27 06:00 MHDA- 2020/06/27 06:01 PMCR- 2020/06/23 CRDT- 2020/06/27 06:00 PHST- 2020/05/26 00:00 [received] PHST- 2020/06/11 00:00 [revised] PHST- 2020/06/22 00:00 [accepted] PHST- 2020/06/27 06:00 [entrez] PHST- 2020/06/27 06:00 [pubmed] PHST- 2020/06/27 06:01 [medline] PHST- 2020/06/23 00:00 [pmc-release] AID - jcm9061962 [pii] AID - jcm-09-01962 [pii] AID - 10.3390/jcm9061962 [doi] PST - epublish SO - J Clin Med. 2020 Jun 23;9(6):1962. doi: 10.3390/jcm9061962. PMID- 32584153 OWN - NLM STAT- MEDLINE DCOM- 20210422 LR - 20210422 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 54 IP - 4 DP - 2020 Aug TI - Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study. PG - 281-289 LID - 10.1080/21681805.2020.1782978 [doi] AB - Purpose: To investigate the effect of repeated transurethral procedures under general anesthesia on overall mortality in patients with non-invasive bladder cancer.Materials and methods: All Danish residents with non-invasive papillary urothelial carcinoma or primary urothelial carcinoma in situ diagnosed between 1 January 2000 and 1 January 2011 were included and followed until death or 31 March 2017. All transurethral procedures under general anesthesia, intravesical instillation therapy, recurrences and progression to invasive disease or cystectomy were recorded during follow-up. Associations between treatments and overall mortality were evaluated using multivariable regression analysis adjusted for age, gender, comorbidities and socioeconomic status. The effect of disease progression on mortality was removed by censoring patients at the time of progression or cystectomy.Results: Risk of death increased with the number of transurethral procedures under general anesthesia for Ta low- and high-grade tumors compared to patients who had only one procedure; after eight or more procedures the risk of death increased by 28% and 83%, respectively. There was no similar relationship for carcinomas in situ. In total, 36-52% of procedures under general anesthesia did not identify urothelial neoplasia.Conclusions: Repeated transurethral procedures under general anesthesia appear to be associated with increased risk of death in patients with primary non-invasive papillary urothelial carcinoma. Furthermore, a substantial number of procedures were without findings of neoplasia, indicating that too many patients are admitted for transurethral procedures under GA. Attempts should be taken to reduce unnecessary transurethral procedures under GA, e.g. by improved outpatient diagnosis of urothelial neoplasia. FAU - Erikson, Marie Schmidt AU - Erikson MS AD - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. FAU - Petersen, Astrid Christine AU - Petersen AC AD - Department of Pathology, Aalborg University Hospital, Aalborg, Denmark. FAU - Andersen, Klaus Kaae AU - Andersen KK AD - Department of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark. FAU - Jacobsen, Frederik Krogsdal AU - Jacobsen FK AD - Department of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark. FAU - Mogensen, Karin AU - Mogensen K AD - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. FAU - Hermann, Gregers Gautier AU - Hermann GG AD - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. LA - eng PT - Journal Article DEP - 20200625 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Aged, 80 and over MH - *Anesthesia, General MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - Cohort Studies MH - Cystectomy/*methods MH - Denmark MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Reoperation MH - Urethra MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - NMIBC OT - Non-invasive bladder cancer OT - TUR-BT OT - mortality OT - progression OT - recurrence EDAT- 2020/06/26 06:00 MHDA- 2021/04/23 06:00 CRDT- 2020/06/26 06:00 PHST- 2020/06/26 06:00 [pubmed] PHST- 2021/04/23 06:00 [medline] PHST- 2020/06/26 06:00 [entrez] AID - 10.1080/21681805.2020.1782978 [doi] PST - ppublish SO - Scand J Urol. 2020 Aug;54(4):281-289. doi: 10.1080/21681805.2020.1782978. Epub 2020 Jun 25. PMID- 32569566 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201207 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 14 IP - 12 DP - 2020 Dec TI - Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. PG - 404-410 LID - 10.5489/cuaj.6459 [doi] AB - INTRODUCTION: Bladder preservation with trimodal therapy (TMT) has emerged as a feasible alternative to radical cystectomy in patients with muscle-invasive bladder cancer. Neoadjuvant chemotherapy (NAC) was proven to cause pathological downstaging. For this reason, we evaluated whether receipt of NAC decreases local bladder recurrences in TMT patients. METHODS: We retrospectively analyzed our TMT database for all patients treated between 2003 and 2017. Patients were treated with maximal transurethral resection of bladder tumor (TURBT) followed by chemotherapy/radiotherapy with or without NAC. Baseline demographic and tumor characteristics were recorded. Rates of local and systemic recurrence were analyzed per receipt of NAC. Overall recurrence-free survival (RFS) and bladder (b)RFS were analyzed using the Kaplan-Meier method and Cox proportional hazards modelling. RESULTS: Median age and followup periods were 72 years and 3.6 years, respectively. Fifty-four patients had NAC and concurrent chemoradiation (NAC-TMT) vs. 70 patients who had concurrent chemoradiation only (TMT). Carcinoma in situ (CIS) was present in 31% of the patients in NAC-TMT group compared to 24% in TMT group (p=0.40). After treatment, 24 (44%) and 31 (44%) patients in NAC-TMT and TMT groups, respectively, had bladder tumor recurrence. Overall RFS at three years was 46% and 50% in NAC-TMT and TMT groups, respectively (p=0.70). BRFS at three years was 55% and 69% in NAC-TMT and TMT groups, respectively (p=0.27). Multivariable analyses found that the presence of concomitant CIS (hazard ratio [HR] 2.13; 95% confidence interval CI 1.06-4.27; p=0.0036) was the primary factor associated with local bladder recurrence. CONCLUSIONS: Receipt of NAC does not obviate the risk of bladder recurrence post-TMT. Patients with CIS should be monitored especially closely for local recurrence. FAU - Ajib, Khaled AU - Ajib K AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Tjong, Michael C AU - Tjong MC AD - Department of Radiation Oncology of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Tan, Guan Hee AU - Tan GH AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Nason, Gregory J AU - Nason GJ AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Berjaoui, Mohamad Baker AU - Berjaoui MB AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Erlich, Annette AU - Erlich A AD - Division of Urology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. FAU - Maganti, Manjula AU - Maganti M AD - Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Sridhar, Srikala S AU - Sridhar SS AD - Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. FAU - Catton, Charles AU - Catton C AD - Department of Radiation Oncology of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Berlin, Alejandro AU - Berlin A AD - Department of Radiation Oncology of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Chung, Peter AU - Chung P AD - Department of Radiation Oncology of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC7704086 COIS- Competing interests: Dr. Sridhar has been an advisory board member for Astellas, Janssen, Pfizer, Roche, and Sanofi; has received grants/honoraria from Astellas, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Bayer, Janssen, and Roche. Dr. Fleshner has been a consultant or advisory board member for AbbVie, Amgen, Astellas, Bayer, Ferring, Hybridyne Health, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Medivalion, Nucleix, Progenics Pharmaceutical, Sanofi, and Spectracure AB. Dr. Zlotta has been an advisory board member for Janssen, Rho Inc., and Sanofi. Dr. Catton has been an advisory board member for and received honoraria from AbbVie, Bayer, Janssen, and Sanofi; has received institutional grant support for fellowship programs from AbbVie; and has participated in several clinical trials with OCOG, CCTG, and NRG. Dr. Berlin was a member of the board of directors of Vaccinex Inc. until May 2020; and has received honoraria for research grants and advisory board participation from AbbVie, Astellas, Bayer, Ferring, Janssen, and TerSera. Dr. Chung has received honoraria from Sanofi; and has participated in clinical trials supported by AbbVie. Dr. Kulkarni has been an advisory board member for Ferring, Janssen, Merck, and Theralase; has received honoraria from AbbVie, Amgen, Astellas, Biosyent, Ferring, Janssen, Merck, Roche, and TerSera; and has participated in clinical trials supported by AbbVie, Bristol Myers Squibb, Eleven Biotherapeutics, Merck, and Theralase. The remaining authors report no competing personal or financial interests related to this work. EDAT- 2020/06/23 06:00 MHDA- 2020/06/23 06:01 PMCR- 2020/12/01 CRDT- 2020/06/23 06:00 PHST- 2020/06/23 06:00 [pubmed] PHST- 2020/06/23 06:01 [medline] PHST- 2020/06/23 06:00 [entrez] PHST- 2020/12/01 00:00 [pmc-release] AID - cuaj.6459 [pii] AID - cuaj-12-404 [pii] AID - 10.5489/cuaj.6459 [doi] PST - ppublish SO - Can Urol Assoc J. 2020 Dec;14(12):404-410. doi: 10.5489/cuaj.6459. PMID- 32566010 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 20 IP - 1 DP - 2020 Jul TI - Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer. PG - 828-840 LID - 10.3892/ol.2020.11597 [doi] AB - In patients with bladder cancer (BC), the association between ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5) expression and clinical outcomes, particularly regarding muscle-invasive disease, high tumor grade and prognosis, remain unknown. In the present study, the expression of ST3GAL5 and its association with clinical outcomes in patients with BC was analyzed using various public bioinformatics databases. The difference in ST3GAL5 expression between BC and healthy bladder tissues was also evaluated using data from the Oncomine database, The Cancer Genome Atlas and Gene Expression Omnibus database. The differences in ST3GAL5 expression between muscle invasive BC (MIBC) and non-muscle invasive BC (NMIBC), and high- and low-grade BC were also analyzed. Furthermore, genes that were positively co-expressed with ST3GAL5 in patients with BC were identified from the intersection between the Oncomine, Gene Expression Profiling Interactive Analysis 2 and UALCAN databases. Enrichment analysis by Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Reactome pathway enrichment analyses and a gene-concept network was performed using R package. Gene set enrichment analysis was also performed to assess the signaling pathways influenced by the high and low expression of ST3GAL5 in BC. The results indicated that ST3GAL5 expression was significantly lower in BC tissues compared with normal bladder tissues (P<0.05). Furthermore, ST3GAL5 expression in MIBC and high-grade BC was significantly lower compared with NMIBC and low-grade BC (P<0.05), respectively. The results from Kaplan-Meier survival analysis result demonstrated that ST3GAL5 downregulation was associated with poor survival in patients with BC (P<0.05). Taken together, these findings suggested that ST3GAL5 may be considered as an anti-oncogene in BC, could represent a potential predictive and prognostic biomarker for BC and may be a molecular target for tumor therapy. CI - Copyright: (c) Ouyang et al. FAU - Ouyang, Song AU - Ouyang S AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China. AD - Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, P.R. China. FAU - Liu, Ji-Hong AU - Liu JH AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China. FAU - Ni, Zhao AU - Ni Z AD - Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, P.R. China. FAU - Ding, Guo-Fu AU - Ding GF AD - Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, P.R. China. FAU - Wang, Qin-Zhang AU - Wang QZ AD - Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, P.R. China. LA - eng PT - Journal Article DEP - 20200507 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC7285741 OTO - NOTNLM OT - ST3 beta-galactoside alpha-2,3-sialyltransferase 5 OT - bladder cancer OT - high grade OT - methylation OT - muscle invasive OT - prognosis EDAT- 2020/06/23 06:00 MHDA- 2020/06/23 06:01 PMCR- 2020/05/07 CRDT- 2020/06/23 06:00 PHST- 2019/11/30 00:00 [received] PHST- 2020/04/07 00:00 [accepted] PHST- 2020/06/23 06:00 [entrez] PHST- 2020/06/23 06:00 [pubmed] PHST- 2020/06/23 06:01 [medline] PHST- 2020/05/07 00:00 [pmc-release] AID - OL-0-0-11597 [pii] AID - 10.3892/ol.2020.11597 [doi] PST - ppublish SO - Oncol Lett. 2020 Jul;20(1):828-840. doi: 10.3892/ol.2020.11597. Epub 2020 May 7. PMID- 32555265 OWN - NLM STAT- MEDLINE DCOM- 20201208 LR - 20210617 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Jun 17 TI - Analysis of risk factors for post-bacillus Calmette-Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer. PG - 9763 LID - 10.1038/s41598-020-66952-4 [doi] LID - 9763 AB - The objective of this study was to evaluate risk factors for bacillus Calmette-Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer following bacillus Calmette-Guerin therapy. Clinical findings from patients with non-muscle invasive bladder cancer who underwent multi-parametric magnetic resonance imaging before transurethral resection of bladder tumor and post-bacillus Calmette-Guerin therapy from March 2004 to August 2018 were evaluated. The population was grouped into patients with or without newly developed lesions on multi-parametric magnetic resonance imaging performed 3 months after bacillus Calmette-Guerin instillation. Patients with prostate-specific antigen levels >/= 4 ng/mL or prostate cancer were excluded. Univariable and multivariable analyses were performed to determine the predictors of prostate lesions in patients with prior bacillus Calmette-Guerin exposure. Post bacillus Calmette-Guerin-induced prostatitis was found in 50 of the 194 patients (25.8%). No significant differences were observed between the groups except for prostate volumes (33.8 mL vs. 30.8 mL, P = 0.012) and body mass index (25.2 kg/m(2) vs. 24.1 kg/m(2), P = 0.044). After bacillus Calmette-Guerin exposure, no significant differences in prostate-specific antigen levels, international prostate symptom scores, or post-voiding residual volume were noted. Multivariable regression analysis showed that body mass index (odds ratio, OR = 1.115, P = 0.038) and prostate volume (OR = 3.080, P = 0.012) were significant predictors of post-bacillus Calmette-Guerin prostate lesions. Body mass index and prostate volume may be clinical predictors of prostate lesions after bacillus Calmette-Guerin exposure. Awareness of potential risk factors for this entity should contribute to the clinical decision-making process for patients following bacillus Calmette-Guerin therapy. FAU - Kim, Tae Jin AU - Kim TJ AD - Department of Urology, CHA University College of Medicine, CHA Bundang Hospital, Seoul, Korea. FAU - Yu, Young Dong AU - Yu YD AD - Department of Urology, CHA University College of Medicine, CHA Bundang Hospital, Seoul, Korea. FAU - Hwang, Sung Il AU - Hwang SI AD - Department of Radiology, Seoul National University Bundang Hospital, Seoul, Korea. FAU - Lee, Hak Jong AU - Lee HJ AD - Department of Radiology, Seoul National University Bundang Hospital, Seoul, Korea. FAU - Hong, Sung Kyu AU - Hong SK AD - Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea. FAU - Lee, Sang Eun AU - Lee SE AD - Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea. bebsuzzang@naver.com. LA - eng PT - Journal Article DEP - 20200617 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage/*adverse effects MH - Disease Progression MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Prostatitis/etiology/*pathology MH - Risk Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC7300010 COIS- The authors declare no competing interests. EDAT- 2020/06/20 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/06/17 CRDT- 2020/06/20 06:00 PHST- 2019/12/06 00:00 [received] PHST- 2020/06/01 00:00 [accepted] PHST- 2020/06/20 06:00 [entrez] PHST- 2020/06/20 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/06/17 00:00 [pmc-release] AID - 10.1038/s41598-020-66952-4 [pii] AID - 66952 [pii] AID - 10.1038/s41598-020-66952-4 [doi] PST - epublish SO - Sci Rep. 2020 Jun 17;10(1):9763. doi: 10.1038/s41598-020-66952-4. PMID- 32541139 OWN - NLM STAT- MEDLINE DCOM- 20210422 LR - 20210422 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 104 IP - 7-8 DP - 2020 TI - Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy. PG - 567-572 LID - 10.1159/000507100 [doi] AB - OBJECTIVE: To investigate the capability of a modified self-administrable comorbidity index recommended in the standard sets for neoplastic diseases published by the International Consortium for Health Outcomes Measurement (ICHOM) to predict 90-day and long-term mortality after radical cystectomy. METHODS: A single-center series of 1,337 consecutive patients who underwent radical cystectomy for muscle-invasive or high-risk non-muscle-invasive urothelial or undifferentiated bladder cancer were stratified by the modified self-administrable comorbidity index and Charlson score, respectively. Multivariate logit models (for 90-day mortality) and proportional-hazards models (for overall and non-bladder cancer mortality) were used for statistical workup. RESULTS: Considering 90-day mortality, both comorbidity indexes contributed independent information when analyzed together with age (p < 0.0001). The Charlson score performed slightly better (area under the curve [AUC] 0.74 vs. 0.72 for the ICHOM-recommended comorbidity index). Considering 5-year overall mortality in 727 patients with complete observation, the performance of both measures was similar (AUC 0.63 vs. 0.62, including age AUC 0.66 for both indexes). With 6-sided stratifications, the modified self-administrable comorbidity index separated the risk groups slightly better (p values for directly neighboring curves: 0.0068-0.1043 vs. 0.0001-0.8100). CONCLUSION: The ICHOM-recommended modified self-administrable comorbidity index is capable of predicting 90-day mortality and long-term non-bladder cancer mortality after radical cystectomy similarly to the commonly used Charlson score. CI - (c) 2020 S. Karger AG, Basel. FAU - Froehner, Michael AU - Froehner M AD - Department of Urology, Zeisigwaldkliniken Bethanien Chemnitz, Chemnitz, Germany, michael.froehner@ediacon.de. AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany, michael.froehner@ediacon.de. FAU - Koch, Rainer AU - Koch R AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. FAU - Heberling, Ulrike AU - Heberling U AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. FAU - Borkowetz, Angelika AU - Borkowetz A AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. FAU - Hubler, Matthias AU - Hubler M AD - Department of Anesthesiology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. FAU - Novotny, Vladimir AU - Novotny V AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. AD - Department of Urology, Stadtisches Klinikum Gorlitz, Gorlitz, Germany. FAU - Wirth, Manfred P AU - Wirth MP AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. FAU - Thomas, Christian AU - Thomas C AD - Department of Urology, University Hospital "Carl Gustav Carus", Technische Universitat Dresden, Dresden, Germany. LA - eng PT - Journal Article PT - Validation Study DEP - 20200615 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Prognosis MH - Retrospective Studies MH - *Self Report MH - Time Factors MH - Urinary Bladder Neoplasms/*complications/diagnosis/mortality/*surgery OTO - NOTNLM OT - Bladder OT - Comorbidity OT - Cystectomy OT - International Consortium for Health Outcomes Measurement OT - Logit model OT - Proportional hazards model OT - Standard set EDAT- 2020/06/17 06:00 MHDA- 2021/04/23 06:00 CRDT- 2020/06/17 06:00 PHST- 2019/10/24 00:00 [received] PHST- 2020/03/08 00:00 [accepted] PHST- 2020/06/17 06:00 [pubmed] PHST- 2021/04/23 06:00 [medline] PHST- 2020/06/17 06:00 [entrez] AID - 000507100 [pii] AID - 10.1159/000507100 [doi] PST - ppublish SO - Urol Int. 2020;104(7-8):567-572. doi: 10.1159/000507100. Epub 2020 Jun 15. PMID- 32539252 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20210124 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 46 IP - 5 DP - 2020 Sep-Oct TI - Retrograde pyelography before radical nephroureterectomy for upper tract urothelial carcinoma is associated with intravesical tumor recurrence. PG - 778-785 LID - 10.1590/S1677-5538.IBJU.2019.0503 [doi] AB - PURPOSE: To investigate the association between preoperative retrograde pyelography (RGP), conducted to evaluate upper tract urothelial carcinoma (UTUC), and intravesical recurrence (IVR) after radical nephroureterectomy (RNU). MATERIALS AND METHODS: Of 114 patients that underwent RNU, 72 patients without preoperative ureteroscopy and a history of bladder tumor were selectively enrolled. Variables associated with IVR were identified. RESULTS: RGP was performed at a mean duration of 24.9 days prior to RNU in 41 (56.1%) of study subjects. During the mean follow-up period of 64.5 months, IVRs were identified in 32 (44.4%) patients at 22.3+/-18.8 (mean+/-SD) months after RNU. Despite similar tumor characteristics in the RGP and non-RGP groups, the incidence of IVR was considerably higher in the RGP group (63.4%) than in the non-RGP group (19.4%, p <0.001). The following variables differed significantly between the IVR and non-IVR groups: age (64.6+/-8.51 vs. 59.6+/-9.65 years), tumor location (lower or upper; 53.1% vs. 20%), tumor invasiveness (> pT2; 53.1% vs. 17.5%), preoperative hemoglobin (12.8+/-1.36 vs. 13.9+/-1.65), preoperative creatinine (1.29+/-0.32 vs. 1.11+/-0.22), and preoperative RGP (81.3% vs. 37.5%), respectively. Multivariate Cox regression model showed that tumor location (p=0.020, HR=2.742), preoperative creatinine level (p=0.004, HR=6.351), and preoperative RGP (p=0.045, HR=3.134) independently predicted IVR. CONCLUSION: Given the limitations of retrospective single-center series, performance of RGP before RNU was shown to have a negative effect on IVR after surgery. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Ko, Young Hwii AU - Ko YH AD - Department of Urology, College of Medicine, Yeungnam University, Daegu, Republic of Korea. FAU - Song, Phil Hyun AU - Song PH AD - Department of Urology, College of Medicine, Yeungnam University, Daegu, Republic of Korea. FAU - Park, Taeyong AU - Park T AD - Department of Urology, Pusan Paik Hospital, Inje University, Busan, Republic of Korea. FAU - Choi, Jae Young AU - Choi JY AD - Department of Urology, College of Medicine, Yeungnam University, Daegu, Republic of Korea. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - *Carcinoma, Transitional Cell/diagnostic imaging/surgery MH - Humans MH - Neoplasm Recurrence, Local/diagnostic imaging MH - Nephrectomy MH - *Nephroureterectomy MH - Retrospective Studies MH - Urography MH - Urologic Neoplasms/*diagnostic imaging PMC - PMC7822386 OTO - NOTNLM OT - Nephroureterectomy OT - Neoplasms OT - Urography COIS- None declared. EDAT- 2020/06/17 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/07/31 CRDT- 2020/06/17 06:00 PHST- 2019/08/07 00:00 [received] PHST- 2020/01/26 00:00 [accepted] PHST- 2020/06/17 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/06/17 06:00 [entrez] PHST- 2020/07/31 00:00 [pmc-release] AID - IBJU20190503 [pii] AID - S1677-5538.IBJU.2019.0503 [pii] AID - 10.1590/S1677-5538.IBJU.2019.0503 [doi] PST - ppublish SO - Int Braz J Urol. 2020 Sep-Oct;46(5):778-785. doi: 10.1590/S1677-5538.IBJU.2019.0503. PMID- 32533903 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20231112 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 14 IP - 10 DP - 2020 Oct TI - TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. PG - 2375-2383 LID - 10.1002/1878-0261.12746 [doi] AB - Telomerase reverse transcriptase (TERT) promoter mutations are frequently found in tumors or urine from patients with urothelial carcinoma (UC). TERT promoter mutations are also detected in urine from patients with no evidence of cancer but are associated with subsequent UC development. Mutations in the TERT promoter are thought to be present in nonmalignant urothelium (NMU) during early stages of tumor formation prior to pathological change, but this has not been proven directly. In this proof-of-concept study, we investigated the clinical utility of TERT promoter mutation analysis in NMU of patients with non-muscle-invasive bladder cancer (NMIBC). This single-institute study included 53 primary tumors and 428 systematic bladder biopsy specimens from 54 patients with NMIBC. All patients underwent systematic random biopsy and transurethral resection of the bladder tumor. Genomic DNA was analyzed for TERT C228T and C250T mutations using droplet digital PCR (ddPCR). The association between TERT promoter mutation of NMU and bladder recurrence was examined by the Kaplan-Meier method and Cox proportional hazards model. Of the 54 patients, 16 (29.6%) had a TERT C228T mutation and three (5.6%) had a TERT C250T mutation in NMU. Of 428 biopsy specimens, the TERT C228T mutation was detected in 9% (31/364) of normal urothelium, 27% (4/15) of urothelial dysplasia (UD), 50% (9/18) of UD suspicious for carcinoma in situ (CIS), and 58% (18/31) of CIS. During follow-up (median: 3.7 years), 22 (40.7%) patients experienced bladder recurrence and five (9.3%) experienced disease progression. Cox proportional hazard analysis showed that TERT C228T mutation in NMU was significantly associated with bladder recurrence after adjustment for cofounding factors (P = 0.0128). Thus, TERT C228T mutation was detected in NMU, which was a reliable independent prognostic factor of bladder tumor recurrence. CI - (c) 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. FAU - Hayashi, Yujiro AU - Hayashi Y AUID- ORCID: 0000-0002-4701-5635 AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Fujita, Kazutoshi AU - Fujita K AUID- ORCID: 0000-0002-6774-7497 AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. AD - Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan. FAU - Nojima, Satoshi AU - Nojima S AD - Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Tomiyama, Eisuke AU - Tomiyama E AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Matsushita, Makoto AU - Matsushita M AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Koh, Yoko AU - Koh Y AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Nakano, Kosuke AU - Nakano K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Wang, Cong AU - Wang C AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Ishizuya, Yu AU - Ishizuya Y AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Kato, Taigo AU - Kato T AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. AD - Department of Urological Immuno-oncology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Hatano, Koji AU - Hatano K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Kawashima, Atsunari AU - Kawashima A AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Ujike, Takeshi AU - Ujike T AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Uemura, Motohide AU - Uemura M AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. AD - Department of Urological Immuno-oncology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Imamura, Ryoichi AU - Imamura R AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Morii, Eiichi AU - Morii E AD - Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200627 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Muscles/*pathology MH - Mutation/*genetics MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Promoter Regions, Genetic MH - Telomerase/*genetics MH - Urinary Bladder Neoplasms/*enzymology/*genetics/pathology MH - Urothelium/pathology PMC - PMC7530786 OTO - NOTNLM OT - TERT promoter OT - bladder cancer OT - field change OT - prognosis COIS- The authors declare no conflict of interest. EDAT- 2020/06/14 06:00 MHDA- 2021/09/11 06:00 PMCR- 2020/10/01 CRDT- 2020/06/14 06:00 PHST- 2020/04/13 00:00 [received] PHST- 2020/05/28 00:00 [revised] PHST- 2020/06/05 00:00 [accepted] PHST- 2020/06/14 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] PHST- 2020/06/14 06:00 [entrez] PHST- 2020/10/01 00:00 [pmc-release] AID - MOL212746 [pii] AID - 10.1002/1878-0261.12746 [doi] PST - ppublish SO - Mol Oncol. 2020 Oct;14(10):2375-2383. doi: 10.1002/1878-0261.12746. Epub 2020 Jun 27. PMID- 32532704 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220424 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 3 DP - 2021 May TI - Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. PG - 566-573 LID - S2405-4569(20)30115-2 [pii] LID - 10.1016/j.euf.2020.05.004 [doi] AB - BACKGROUND: There is an urgent need to provide a risk-stratification tool for intermediate-risk non-muscle-invasive bladder cancer (NMIBC), especially at the time of bacillus Calmette-Guerin (BCG) shortage. OBJECTIVE: To assess whether patients with intermediate-risk NMIBC can be stratified into different risk groups, thereby providing a practical tool for the selection of the optimal adjuvant therapy, based on the individualized risk of disease progression. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of 636 patients with intermediate-risk NMIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A multivariable Cox-regression model was built to evaluate the impact of each variable on recurrence and progression to muscle-invasive disease. A Cox-based nomogram to predict patient-specific probability of disease progression was performed, and the decision curve analysis (DCA) was used to evaluate its clinical benefit. RESULTS AND LIMITATIONS: Within a median follow-up of 92 mo (interquartile range 56-118), disease recurrence and progression occurred in 346 (54%) and 91 (14%) patients, respectively. On multivariable analysis, age, early recurrence (<12 mo), and tumor size>/=3cm were found to be independent predictors of progression. The Harrell C-index of the model for the prediction of progression was 0.75 and exceeded that of the model proposed by the International Bladder Consultation Group. DCA showed superior net benefits for the nomogram compared with the strategies of treating all/none and previous predictive models. Limitations are inherent to the retrospective design. CONCLUSIONS: We provided a risk-stratification tool that helps identify individual risk of disease progression in patients with intermediate-risk NMIBC. This tool outperforms standard strategies in the threshold probability range of interest and could help select the optimal intravesical therapy regimen based on the individual risk of disease progression. PATIENT SUMMARY: In this study, we provided a practical tool for risk stratification in patients with intermediate-risk non-muscle-invasive bladder cancer. This tool may help select the most appropriate adjuvant therapy (either bacillus Calmette-Guerin [BCG] or chemotherapy) based on patient and tumor characteristics, thus making a step forward toward the era of personalized medicine. CI - Copyright (c) 2020. Published by Elsevier B.V. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Giordano, Andrea AU - Giordano A AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Division of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20200609 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - *BCG Vaccine/therapeutic use MH - Disease Progression MH - Humans MH - Neoplasm Recurrence, Local/drug therapy/epidemiology MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/drug therapy/pathology OTO - NOTNLM OT - *Bacillus Calmette-Guerin OT - *Intermediate risk OT - *Non-muscle-invasive bladder cancer OT - *Progression OT - *Risk stratification EDAT- 2020/06/14 06:00 MHDA- 2022/04/14 06:00 CRDT- 2020/06/14 06:00 PHST- 2020/04/01 00:00 [received] PHST- 2020/04/27 00:00 [revised] PHST- 2020/05/12 00:00 [accepted] PHST- 2020/06/14 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2020/06/14 06:00 [entrez] AID - S2405-4569(20)30115-2 [pii] AID - 10.1016/j.euf.2020.05.004 [doi] PST - ppublish SO - Eur Urol Focus. 2021 May;7(3):566-573. doi: 10.1016/j.euf.2020.05.004. Epub 2020 Jun 9. PMID- 32532529 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20250530 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 9 DP - 2020 Sep TI - Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. PG - 737.e1-737.e10 LID - S1078-1439(20)30216-7 [pii] LID - 10.1016/j.urolonc.2020.05.012 [doi] AB - OBJECTIVES: Real-time monitoring of disease status would be beneficial for timely decision making in the treatment of urothelial cancer (UC), and may accelerate the evaluation of clinical trials. Use of cell free tumor DNA (cftDNA) as a biomarker in liquid biopsy is minimally invasive and its successful use has been reported in various cancer types, including UC. The objective of this study was to evaluate the use of digital droplet PCR (ddPCR)-based assays to monitor UC after treatment. METHOD AND MATERIALS: Blood, urine and matching formalin fixed, paraffin embedded diagnostic specimens were collected from 20 patients diagnosed with stage T1 (n = 2) and T2/T3 (n = 18) disease. SNaPshot assays, Sanger sequencing and whole exome sequencing were used to identify tumor-specific mutations, and somatic mutation status was confirmed using patient-matched DNAs extracted from buffy coats and peripheral blood mononucleocytes. The ddPCR assays of the tumor-specific mutations were used to detect the fractional abundance of cftDNA in plasma and urine. RESULTS: SNaPshot and Sanger sequencing identified point mutations in 70% of the patients that were assayable by ddPCR. Cases of remission and relapse monitored by assays for PIK3CA E542K and TP53 Y163C mutations in plasma and urine concurred with clinical observations up to 48 months from the start of chemotherapy. A new ddPCR assay for the telomerase reverse transcriptase (TERT) promoter (-124) mutation was developed. The TERT assay was able to detect mutations in cases below the limit of detection by SNaPshot. Whole exome sequencing identified a novel mutation, CNTNAP4 G727*. A ddPCR assay designed to detect this mutation was able to distinguish mutant from wild-type alleles. CONCLUSIONS: The study demonstrated that ddPCR assays could be used to detect cftDNA in liquid biopsy monitoring of the post-therapy disease status in patients with UC. Overall, 70% of the patients in our study harbored mutations that were assayable by ddPCR. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Pritchard, John J G AU - Pritchard JJG AD - School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. FAU - Hamilton, Graham AU - Hamilton G AD - Glasgow Polyomics, University of Glasgow, Glasgow, United Kingdom. FAU - Hurst, Carolyn D AU - Hurst CD AD - Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom. FAU - Fraser, Sioban AU - Fraser S AD - Department of Pathology, Queen Elizabeth University Hospital, Glasgow, United Kingdom. FAU - Orange, Clare AU - Orange C AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. FAU - Knowles, Margaret A AU - Knowles MA AD - Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom. FAU - Jones, Robert J AU - Jones RJ AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Cancer Research UK Beatson Institute, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. FAU - Leung, Hing Y AU - Leung HY AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Cancer Research UK Beatson Institute, Glasgow, United Kingdom. FAU - Iwata, Tomoko AU - Iwata T AD - School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. Electronic address: Tomoko.Iwata@glasgow.ac.uk. LA - eng GR - 22904/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200610 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (Circulating Tumor DNA) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/chemistry/*genetics/metabolism/*pathology MH - Circulating Tumor DNA/*analysis/blood/urine MH - Feasibility Studies MH - Female MH - Humans MH - Liquid Biopsy MH - Male MH - Middle Aged MH - Mutation MH - Polymerase Chain Reaction/*methods MH - Urinary Bladder Neoplasms/chemistry/*genetics/metabolism/*pathology OTO - NOTNLM OT - Cell free DNA OT - Circulating tumor DNA OT - Digital droplet PCR OT - Molecular diagnosis OT - Urothelial carcinoma OT - Whole exome sequencing EDAT- 2020/06/14 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/06/14 06:00 PHST- 2019/12/04 00:00 [received] PHST- 2020/04/12 00:00 [revised] PHST- 2020/05/10 00:00 [accepted] PHST- 2020/06/14 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/06/14 06:00 [entrez] AID - S1078-1439(20)30216-7 [pii] AID - 10.1016/j.urolonc.2020.05.012 [doi] PST - ppublish SO - Urol Oncol. 2020 Sep;38(9):737.e1-737.e10. doi: 10.1016/j.urolonc.2020.05.012. Epub 2020 Jun 10. PMID- 32516772 OWN - NLM STAT- MEDLINE DCOM- 20200814 LR - 20231111 IS - 1423-0399 (Electronic) IS - 0042-1138 (Print) IS - 0042-1138 (Linking) VI - 104 IP - 7-8 DP - 2020 TI - SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features? PG - 510-522 LID - 10.1159/000509065 [doi] AB - BACKGROUND: The new severe acute respiratory syndrome virus (SARS-CoV-2) outbreak is a huge health, social and economic issue and has been declared a pandemic by the World Health Organization. Bladder cancer, on the contrary, is a well-known disease burdened by a high rate of affected patients and risk of recurrence, progression and death. SUMMARY: The coronavirus disease (COVID-19 or 2019-nCoV) often involves mild clinical symptoms but in some cases, it can lead to pneumonia with acute respiratory distress syndrome and multiorgan dysfunction. Factors associated with developing a more severe disease are increased age, obesity, smoking and chronic underlying comorbidities (including diabetes mellitus). High-risk non-muscle-invasive bladder cancer (NMIBC) progression and worse prognosis are also characterized by a higher incidence in patients with risk factors similar to COVID-19. Immune system response and inflammation have been found as a common hallmark of both diseases. Most severe cases of COVID-19 and high-risk NMIBC patients at higher recurrence and progression risk are characterized by innate and adaptive immune activation followed by inflammation and cytokine/chemokine storm (interleukin [IL]-2, IL-6, IL-8). Alterations in neutrophils, lymphocytes and platelets accompany the systemic inflammatory response to cancer and infections. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for example have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer, and their role has been found important even for the prognosis of SARS-CoV-2 infection. Key Messages: All these mechanisms should be further analyzed in order to find new therapeutic agents and new strategies to block infection and cancer progression. Further than commonly used therapies, controlling cytokine production and inflammatory response is a promising field. CI - (c) 2020 S. Karger AG, Basel. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, gianmaria.busetto@uniroma1.it. FAU - Porreca, Angelo AU - Porreca A AD - Department of Urology, Abano Terme Policlinic, Abano Terme, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Maggi, Martina AU - Maggi M AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - D'Agostino, Daniele AU - D'Agostino D AD - Department of Urology, Abano Terme Policlinic, Abano Terme, Italy. FAU - Romagnoli, Daniele AU - Romagnoli D AD - Department of Urology, Abano Terme Policlinic, Abano Terme, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Palmer, Katie AU - Palmer K AD - Department of Internal Medicine and Geriatrics, Cattolica del Sacro Cuore University, Rome, Italy. FAU - Colonna di Paliano, Ascanio AU - Colonna di Paliano A AD - Digital Design Kingdom, Rome, Italy. FAU - Muto, Matteo AU - Muto M AD - Radiotherapy Unit, S.G. Moscati Hospital, Avellino, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Research Hospital, Milan, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20200609 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aging MH - Betacoronavirus MH - Body Mass Index MH - COVID-19 MH - Cellular Senescence MH - Comorbidity MH - Coronavirus Infections/complications/*physiopathology MH - Diabetes Complications MH - Disease Progression MH - Humans MH - Inflammation MH - Neoplasm Recurrence, Local MH - Obesity/complications MH - Pandemics MH - Pneumonia, Viral/complications/*physiopathology MH - Prevalence MH - Prognosis MH - Recurrence MH - Risk MH - SARS-CoV-2 MH - Smoking/adverse effects MH - Urinary Bladder Neoplasms/complications/*physiopathology PMC - PMC7316644 OTO - NOTNLM OT - Aging OT - Bladder cancer OT - COVID-19 OT - Diabetes OT - Inflammation OT - Interleukin-6 OT - Obesity OT - Smoking COIS- The authors have nothing to disclose. EDAT- 2020/06/10 06:00 MHDA- 2020/08/15 06:00 PMCR- 2020/06/26 CRDT- 2020/06/10 06:00 PHST- 2020/05/10 00:00 [received] PHST- 2020/05/31 00:00 [accepted] PHST- 2020/06/10 06:00 [pubmed] PHST- 2020/08/15 06:00 [medline] PHST- 2020/06/10 06:00 [entrez] PHST- 2020/06/26 00:00 [pmc-release] AID - 000509065 [pii] AID - uin-0001 [pii] AID - 10.1159/000509065 [doi] PST - ppublish SO - Urol Int. 2020;104(7-8):510-522. doi: 10.1159/000509065. Epub 2020 Jun 9. PMID- 32512320 OWN - NLM STAT- MEDLINE DCOM- 20200904 LR - 20200904 IS - 1872-9142 (Electronic) IS - 0161-5890 (Linking) VI - 124 DP - 2020 Aug TI - Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2. PG - 35-41 LID - S0161-5890(20)30351-5 [pii] LID - 10.1016/j.molimm.2020.05.010 [doi] AB - BACKGROUND: Bladder cancer (BC) can be successfully treated by manipulating immune responses with intravesical Bacillus Calmette-Guerin instillation or targeting the PD-1/PD-L signaling pathway. In the present study we investigated the prognostic significance of the immune checkpoint inhibitor PD-1 and its ligands PD-L1 and PD-L2 on tumor cells and infiltrating lymphocytes, in the tumor microenvironment and draining lymph nodes in patients with non-metastatic BC. PATIENTS AND METHODS: Cells were mechanically isolated from tissues and draining lymph nodes from 58 patients, and surface-stained for CD45, PD-1, PD-L1 and PD-L2. The cells were then analyzed with a flow cytometric method. RESULTS: Approximately 2% of CD45-negative tumor and stromal cells expressed PD-L1. Expression was not associated with the main clinicopathological characteristics of the disease or with survival. However, as tumors progressed the frequency of PD-L1(+)CD45(hi) cells and the mean expression of PD-1 on CD45(hi) cells increased remarkably on immune cells in tumor tissues and draining lymph nodes. In addition, frequency analysis showed that cell percentages as well as mean expression of PD-L2 on total CD45(+) lymphocytes and their CD45(hi) subpopulation in tumor-draining lymph nodes was significantly associated with cancer-related death (P < 0.05). Multiple Cox regression also revealed that while CD45(+) (hazard ratio: 0.596, 95 % CI 0.439-0.809, P = 0.001) was associated with improved survival, CD45(neg) (HR: 0.615, 95 % CI 0.454-0.831, P = 0.002), and PD-L2(+)CD45(+) cells (hazard ratio: 1.472, 95 % CI 1.023-2.120, P = 0.038) in draining lymph nodes were associated with lower survival. CONCLUSION: Our results suggest that in patients with BC, PD-1 and PD-L expression on immune cells, especially in draining lymph nodes, is valuable for predicting prognosis and survival, and possibly responsiveness to immunotherapy. However, expression of the inhibitor molecule or its ligands on tumor cells was not associated with prognosis. The results highlight the significance of PD-L2 as a second important suppressive molecule in tumors. CI - Copyright (c) 2020 Elsevier Ltd. All rights reserved. FAU - Ariafar, Ali AU - Ariafar A AD - Urology-Oncology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ghaedi, Meisam AU - Ghaedi M AD - Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Rezaeifard, Somayeh AU - Rezaeifard S AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Shahriari, Shadab AU - Shahriari S AD - Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Zeighami, Shahryar AU - Zeighami S AD - Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ghaderi, Abbas AU - Ghaderi A AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Faghih, Zahra AU - Faghih Z AD - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: faghihz@sums.ac.ir. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200605 PL - England TA - Mol Immunol JT - Molecular immunology JID - 7905289 RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (PDCD1 protein, human) RN - 0 (PDCD1LG2 protein, human) RN - 0 (Programmed Cell Death 1 Ligand 2 Protein) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Aged MH - B7-H1 Antigen/*immunology MH - Carcinoma, Transitional Cell/immunology/metabolism/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Programmed Cell Death 1 Ligand 2 Protein/*immunology MH - Programmed Cell Death 1 Receptor/*immunology MH - Urinary Bladder Neoplasms/immunology/metabolism/*pathology OTO - NOTNLM OT - Bladder cancer OT - PD-1 OT - PD-L1 OT - PD-L2 OT - Survival COIS- Declaration of Competing Interest None. EDAT- 2020/06/09 06:00 MHDA- 2020/09/05 06:00 CRDT- 2020/06/09 06:00 PHST- 2019/11/05 00:00 [received] PHST- 2020/05/08 00:00 [revised] PHST- 2020/05/12 00:00 [accepted] PHST- 2020/06/09 06:00 [pubmed] PHST- 2020/09/05 06:00 [medline] PHST- 2020/06/09 06:00 [entrez] AID - S0161-5890(20)30351-5 [pii] AID - 10.1016/j.molimm.2020.05.010 [doi] PST - ppublish SO - Mol Immunol. 2020 Aug;124:35-41. doi: 10.1016/j.molimm.2020.05.010. Epub 2020 Jun 5. PMID- 32497002 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 46 IP - 5 DP - 2020 Sep TI - Transurethral resection of bladder and radical cystectomy: Concordance of histology. Are we good enough? PG - 354-359 LID - 10.5152/tud.2020.20121 [doi] AB - OBJECTIVE: Urothelial carcinoma (UC) is heterogeneous, and variant histologies (VH) are more frequent than initially reported. Reporting VH is recommended by several guidelines because of prognostic and therapeutic implications. We evaluated the concordance of VH between the first transurethral resections of the bladder (TURBs) and the following radical cystectomy (RC). This paper is the first to compare VH with a central pathology review between TURB and RC. MATERIAL AND METHODS: In this retrospective study, we only included those patients who underwent TURB with VH and then RC between 01/2010 and 12/2013 at our institution. The presence of VH in both TURB and RC was assessed and compared according to the 2016 World Health Organization (WHO) classification by a central pathology review. RESULTS: Among 110 patients who had the initial TURB/RC, 54 (49.1%) were diagnosed with VH, 48 (43%) had a single pattern, and six had (5%) multiple histological patterns. Squamous differentiation was the most common single VH (31%). Twenty patients with UC (18%) showed discordance between TURB and RC, especially in micropapillary versus nested (n=3) cases. Concordant histology between TURB/RC was seen in 82% of the cases. CONCLUSION: Discrepancies can be seen between TURB and RC when reporting VH, which can be problematic for selection of therapy and management. TURB alone might be insufficient to evaluate the presence of VH, especially in VH with heavy therapeutic implications, such as micropapillary carcinomas. Nevertheless, concordance with a central review by an experienced uropathologist when applying the WHO 2016 classification is 82%. FAU - Ngo, Carine AU - Ngo C AUID- ORCID: 0000-0002-8172-5876 AD - Department of Pathology, Tenon Hospital, APHP, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AUID- ORCID: 0000-0002-9912-0533 AD - Department of Urology, Tenon Hospital, APHP, Sorbonne University, Paris, France. FAU - Comperat, Eva AU - Comperat E AUID- ORCID: 0000-0001-8488-543X AD - Department of Pathology, Tenon Hospital, APHP, Sorbonne University, Paris, France. LA - eng PT - Journal Article DEP - 20200601 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC7483458 COIS- Conflict of Interest: The authors have no conflicts of interest to declare. EDAT- 2020/06/05 06:00 MHDA- 2020/06/05 06:01 PMCR- 2020/09/01 CRDT- 2020/06/05 06:00 PHST- 2020/04/14 00:00 [received] PHST- 2020/05/07 00:00 [accepted] PHST- 2020/06/05 06:00 [pubmed] PHST- 2020/06/05 06:01 [medline] PHST- 2020/06/05 06:00 [entrez] PHST- 2020/09/01 00:00 [pmc-release] AID - tud.2020.20121 [pii] AID - tju-46-5-354 [pii] AID - 10.5152/tud.2020.20121 [doi] PST - ppublish SO - Turk J Urol. 2020 Sep;46(5):354-359. doi: 10.5152/tud.2020.20121. Epub 2020 Jun 1. PMID- 32493345 OWN - NLM STAT- MEDLINE DCOM- 20201201 LR - 20210110 IS - 2662-7671 (Electronic) IS - 2662-7671 (Linking) VI - 20 IP - 1 DP - 2020 Jun 3 TI - Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy. PG - 166 LID - 10.1186/s12906-020-2861-5 [doi] LID - 166 AB - BACKGROUND: The purpose of this study was to identify the clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma (UTUC) patients complicated with aristolochic acid nephropathy(AAN) after radical nephroureterectomy (RNU). METHODS: The clinical data of 42 UTUC patients with AAN (AAN group) and 238 UTUC patients without AAN (Non-AAN group) were retrospectively reviewed. All patients received a RNU with excision of bladder cuff. Demographic and clinical data, including preoperative indexes, intraoperative indexes and surgical outcomes were compared. RESULTS: There were no significant differences in age, tumor location, surgery approach, tumor pathologic grade, stage, the mean operative time and estimated blood loss between the two groups (all p > 0.05). There were more female patients in the AAN group (p < 0.001), and 57.1% were high grade tumors. The AAN group showed a higher complications rate (p = 0.003). The median follow-up time was 43.2 months. The AAN group showed a worse estimated 5-year overall survival rate (35.1% vs. 63.0%, p = 0.014), however, no significant difference was found between the two groups with regard to disease specific survival (63.5% vs. 81.5%, p = 0.091). Multivariate binary logistic regression analysis showed that AAN was an independent factor related with overall and disease specific survival. 38.9% of all patients experienced any types of recurrence, and the estimated 5-year recurrence-free survival rate was lower in the AAN group (37.1% vs. 63.7%, p = 0.001). In the comparison of subgroups stratified by recurrence type, the AAN group had a higher intravesical (p = 0.030) and contralateral recurrence rate (p = 0.040). CONCLUSION: UTUC with AAN occurred more frequently in female patients who were more likely to develop high-grade tumors. However, these patients showed a worse overall survival and a lower recurrence-free survival rate than the other patients. AA-related UTUC might be associate with an increased risk of intravesical and contralateral recurrence after RUN. FAU - Shan, Hongli AU - Shan H AD - Department of clinical laboratory, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. FAU - Tian, Wen AU - Tian W AD - Department of Blood Transfusion, The Second Hospital of Jinlin University, Changchun, 131000, People's Republic of China. FAU - Hong, Yazhao AU - Hong Y AD - Department of urology, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. FAU - Xu, Bo AU - Xu B AD - Department of urology, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. FAU - Wang, Chunxi AU - Wang C AD - Department of urology, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. FAU - Yu, Bing AU - Yu B AD - Department of urology, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. 1161449482@qq.com. FAU - Wang, Xiaoqing AU - Wang X AUID- ORCID: 0000-0001-9317-9983 AD - Department of urology, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China. wangxiaoq@jlu.edu.cn. LA - eng GR - 201806175061/Chinese Government Scholarship/ PT - Journal Article DEP - 20200603 PL - England TA - BMC Complement Med Ther JT - BMC complementary medicine and therapies JID - 101761232 RN - 0 (Aristolochic Acids) RN - 0 (Drugs, Chinese Herbal) RN - 94218WFP5T (aristolochic acid I) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Aristolochic Acids/*adverse effects MH - Drugs, Chinese Herbal/*adverse effects MH - Female MH - Humans MH - Kidney Diseases/*chemically induced/surgery MH - Male MH - Middle Aged MH - *Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*chemically induced/surgery PMC - PMC7268428 OTO - NOTNLM OT - Aristolochic acid OT - Carcinogenesis OT - Nephroureterectomy OT - Survival OT - Upper tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2020/06/05 06:00 MHDA- 2020/12/02 06:00 PMCR- 2020/06/03 CRDT- 2020/06/05 06:00 PHST- 2019/10/19 00:00 [received] PHST- 2020/02/20 00:00 [accepted] PHST- 2020/06/05 06:00 [entrez] PHST- 2020/06/05 06:00 [pubmed] PHST- 2020/12/02 06:00 [medline] PHST- 2020/06/03 00:00 [pmc-release] AID - 10.1186/s12906-020-2861-5 [pii] AID - 2861 [pii] AID - 10.1186/s12906-020-2861-5 [doi] PST - epublish SO - BMC Complement Med Ther. 2020 Jun 3;20(1):166. doi: 10.1186/s12906-020-2861-5. PMID- 32486251 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 12 IP - 6 DP - 2020 May 30 TI - Fanconi Anemia Pathway Activation by FOXM1 Is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance. LID - 10.3390/cancers12061417 [doi] LID - 1417 AB - Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1 and FANCD2 were involved in recurrence. Therefore, we investigated how these genes were involved in the mechanism of recurrence and confirmed their usefulness as biomarkers. Investigation have shown that FOXM1 directly regulated the transcription of FANCD2, which is the key gene of the Fanconi anemia (FA) pathway. Depletion of FOXM1 resulted in DNA repair defects in the FA pathway and in decreased resistance to chemotherapy. Thus, the FANCD2-associated FA pathway activated by FOXM1 is an important mechanism involved in chemotherapy-related recurrence. In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients. FAU - Roh, Yun-Gil AU - Roh YG AD - Department of Biological Science, Dong-A University, Busan 49315, Korea. FAU - Mun, Jeong-Yeon AU - Mun JY AD - Department of Biological Science, Dong-A University, Busan 49315, Korea. FAU - Kim, Seon-Kyu AU - Kim SK AUID- ORCID: 0000-0002-4176-5187 AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. AD - Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Korea. FAU - Park, Wonyoung AU - Park W AD - Department of Pathology, Medical Research Institute, Pusan National University Hospital, Busan 49241, Korea. FAU - Jeong, Mi-So AU - Jeong MS AD - Department of Biological Science, Dong-A University, Busan 49315, Korea. FAU - Kim, Tae Nam AU - Kim TN AD - Department of Urology, Medical Research Institute, Pusan National University Hospital, Busan 49241, Korea. FAU - Kim, Won-Tae AU - Kim WT AD - Department of Biological Science, Dong-A University, Busan 49315, Korea. FAU - Choi, Yung Hyun AU - Choi YH AUID- ORCID: 0000-0002-1454-3124 AD - Department of Biochemistry, University College of Korean Medicine, Busan 47227, Korea. FAU - Chu, In-Sun AU - Chu IS AD - Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, Korea. AD - Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biological Science, Dong-A University, Busan 49315, Korea. LA - eng GR - 2017R1A2B2007836/National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning/ PT - Journal Article DEP - 20200530 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7352315 OTO - NOTNLM OT - DNA repair OT - FANCD2 OT - FOXM1 OT - Fanconi anemia pathway OT - bladder cancer OT - cancer recurrence COIS- The authors declare no conflict of interest. EDAT- 2020/06/04 06:00 MHDA- 2020/06/04 06:01 PMCR- 2020/05/30 CRDT- 2020/06/04 06:00 PHST- 2020/04/27 00:00 [received] PHST- 2020/05/15 00:00 [revised] PHST- 2020/05/28 00:00 [accepted] PHST- 2020/06/04 06:00 [entrez] PHST- 2020/06/04 06:00 [pubmed] PHST- 2020/06/04 06:01 [medline] PHST- 2020/05/30 00:00 [pmc-release] AID - cancers12061417 [pii] AID - cancers-12-01417 [pii] AID - 10.3390/cancers12061417 [doi] PST - epublish SO - Cancers (Basel). 2020 May 30;12(6):1417. doi: 10.3390/cancers12061417. PMID- 32484812 OWN - NLM STAT- MEDLINE DCOM- 20200820 LR - 20200820 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 15 IP - 6 DP - 2020 TI - Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer. PG - e0233676 LID - 10.1371/journal.pone.0233676 [doi] LID - e0233676 AB - In urothelial cell type non-muscle invasive urinary bladder carcinoma, TNM stage and WHO grade are widely used to classify patients into low and high‑risk groups for prognostic and therapeutic decision-making. However, stage and grade reproducibility and prediction accuracy are wanting. This may lead to suboptimal treatment. We evaluated whether proliferation features, nuclear area of the epithelial cancer cells and the composition of stromal and tumor infiltrating lymphocytes have independent prognostic value. In 183 primary non-muscle invasive bladder cancer patients with long follow-up (median for stage progression cohort: 119 months, range 5-173; median for tumor recurrence cohort: 82, range 3-165) proliferation features Ki67, PPH3 and Mitotic Activity Index (MAI), Mean Nuclear Area (MNA), lymphocyte subsets (CD8+, CD4+, CD25+) and plasma cells (CD138+) were assessed on consecutive sections. Post-resection instillation treatments (none, mitomycin, BCG) were strictly standardized during the intake period. Risk of recurrence was associated with expression of Ki67 ( 39) and Multifocality (p = 0.01). Patients with low Ki67 had a higher recurrence rate than those with high Ki67. Lymphocyte composition did not predict recurrence. Stage progression was strongly associated with high values for MAI (>15) and CD25+ (>0.2%). In a multivariate analysis the combination of MAI and CD25+ was the single most prognostic feature (p<0.001). Validation of these results in additional, independent studies is warranted. FAU - Lillesand, Melinda AU - Lillesand M AUID- ORCID: 0000-0001-8898-1330 AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Kvikstad, Vebjorn AU - Kvikstad V AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway. FAU - Mangrud, Ok Malfrid AU - Mangrud OM AD - Department of Pathology, Innlandet Hospital, Lillehammer, Norway. FAU - Gudlaugsson, Einar AU - Gudlaugsson E AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - van Diermen-Hidle, Bianca AU - van Diermen-Hidle B AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Skaland, Ivar AU - Skaland I AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Baak, Jan P A AU - Baak JPA AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Jan Baak AS, Tananger, Norway. FAU - Janssen, Emiel A M AU - Janssen EAM AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway. LA - eng PT - Journal Article DEP - 20200602 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (IL2RA protein, human) RN - 0 (Interleukin-2 Receptor alpha Subunit) RN - 0 (Ki-67 Antigen) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/genetics/immunology/*pathology MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Interleukin-2 Receptor alpha Subunit/metabolism MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/metabolism MH - Lymphocytes, Tumor-Infiltrating/*immunology/metabolism MH - Male MH - Middle Aged MH - *Mitotic Index MH - Neoplasm Recurrence, Local/*diagnosis/epidemiology/genetics/immunology MH - Neoplasm Staging MH - Prognosis MH - Reproducibility of Results MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/genetics/immunology/mortality/*pathology PMC - PMC7266352 COIS- Jan Baak AS, Norway commercial affiliation not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2020/06/03 06:00 MHDA- 2020/08/21 06:00 PMCR- 2020/06/02 CRDT- 2020/06/03 06:00 PHST- 2019/12/20 00:00 [received] PHST- 2020/05/10 00:00 [accepted] PHST- 2020/06/03 06:00 [entrez] PHST- 2020/06/03 06:00 [pubmed] PHST- 2020/08/21 06:00 [medline] PHST- 2020/06/02 00:00 [pmc-release] AID - PONE-D-19-35258 [pii] AID - 10.1371/journal.pone.0233676 [doi] PST - epublish SO - PLoS One. 2020 Jun 2;15(6):e0233676. doi: 10.1371/journal.pone.0233676. eCollection 2020. PMID- 32484710 OWN - NLM STAT- MEDLINE DCOM- 20200914 LR - 20200914 IS - 0006-9248 (Print) IS - 0006-9248 (Linking) VI - 121 IP - 6 DP - 2020 TI - The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non-muscle invasive bladder cancer. PG - 444-449 LID - 10.4149/BLL_2020_072 [doi] AB - OBJECTIVES: The objectives of this study were to determine the prognostic value of expression levels of selected biomarkers and their statistical analysis in relation to survival and standard histopathologic examination and other clinicopathologic variables in non-muscle invasive bladder cancer (NMIBC). BACKGROUND: Worldwide, bladder cancer is a frequent malignant disease with rising incidence. Characteristic invasiveness and high recurrence rates call for more diagnostic methods to obtain more accurate information. Prognosis is affected by a significant interpersonal variability of the disease. For this reason, constant search for alternative and better diagnostic methods is essential. METHODS: We analysed cancer tissue from patients with Ta and T1 bladder cancer. E-cadherin and Ki-67 expression levels were analysed using immunohistochemical staining. The expression levels quantified to a percentual amount were statistically analysed in relation to survival and their frequency distribution in the study group. RESULTS: E-cadherin and Ki-67 expression levels show high association with tumor stage and grade (p<0.001), in contrast, the association with recurrence has proven insignificant. Patients with non-aberrant biomarker expression levels have much higher survival rates than the cases with aberrant expression. CONCLUSION: Low expression levels of Ki-67 and high expression levels of E-cadherin positively affect survival of patients, whereas aberrant expressions pose poorer prognosis (Tab. 2, Fig. 2, Ref. 33). FAU - Harsanyi, S AU - Harsanyi S FAU - Ziaran, S AU - Ziaran S FAU - Bevizova, K AU - Bevizova K FAU - Varchulova Novakova, Z AU - Varchulova Novakova Z FAU - Trebaticky, B AU - Trebaticky B FAU - Bujdak, P AU - Bujdak P FAU - Galbavy, S AU - Galbavy S FAU - Danisovic, L AU - Danisovic L LA - eng PT - Journal Article PL - Germany TA - Bratisl Lek Listy JT - Bratislavske lekarske listy JID - 0065324 RN - 0 (Biomarkers, Tumor) RN - 0 (Cadherins) RN - 0 (Ki-67 Antigen) SB - IM MH - *Biomarkers, Tumor/analysis MH - *Cadherins/analysis MH - *Carcinoma, Transitional Cell MH - Disease Progression MH - Disease-Free Survival MH - Humans MH - *Ki-67 Antigen/analysis MH - Neoplasm Recurrence, Local MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis OTO - NOTNLM OT - E-cadherin OT - Ki-67 OT - NMIBC OT - survival prognosis. EDAT- 2020/06/03 06:00 MHDA- 2020/09/15 06:00 CRDT- 2020/06/03 06:00 PHST- 2020/06/03 06:00 [entrez] PHST- 2020/06/03 06:00 [pubmed] PHST- 2020/09/15 06:00 [medline] AID - 10.4149/BLL_2020_072 [doi] PST - ppublish SO - Bratisl Lek Listy. 2020;121(6):444-449. doi: 10.4149/BLL_2020_072. PMID- 32460737 OWN - NLM STAT- MEDLINE DCOM- 20210304 LR - 20210304 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 20 IP - 1 DP - 2020 May 27 TI - Risk assessment of neuromuscular stimulation by energy-based transurethral resection devices: an ex vivo test standard. PG - 59 LID - 10.1186/s12894-020-00630-5 [doi] LID - 59 AB - BACKGROUND: During transurethral resection of bladder tumours (TURB), radio-frequency (RF) currents can lead to adverse neuromuscular stimulation (NMS). Here we present a novel ex vivo method to determine the risk of RF generators and their bipolar TURB modes to cause NMS. We aimed to develop an experimental platform for safety evaluation of new RF generators and their modes with a newly established test standard, suitable for replacement or reduction of animal testing. METHODS: We tested four contemporary RF generators with their bipolar modes for TURB in saline. A two-stage ex vivo approach was pursued: First, we recorded voltages at possible positions of the obturator nerve behind a porcine bladder wall in a TURB model using 18 RF applications per generator. Second, these voltage records were used as stimuli to evoke nerve compound action potentials (CAPs) in isolated porcine axillary nerves. The NMS potential was defined as the ratio between the observed area under the CAPs and the theoretical CAP area at maximum response and a firing rate of 250 Hz, which would reliably induce tetanic muscle responses in most human subjects. The measurement protocol was tailored to optimise reproducibility of the obtained NMS potentials and longevity of the nerve specimens. RESULTS: As prerequisite for the clinical translation of our results, the robustness of our test method and reproducibility of the NMS potential are demonstrated with an excellent correlation (r = 0.93) between two sets of identical stimuli (n = 72 each) obtained from 16 nerve segments with similar diameters (4.2 +/- 0.37 mm) in the nerve model. The RF generators differed significantly (p < 0.0001) regarding NMS potential (medians: 0-3%). CONCLUSIONS: Our test method is suitable for quantifying the NMS potential of different electrosurgical systems ex vivo with high selectivity at a reasonable degree of standardization and with justifiable effort. Our results suggest that the clinical incidence of NMS is considerably influenced by the type of RF generator. Future generations of RF generators take advantage from the proposed test standard through higher safety and less animal testing. Health professionals and treated patients will benefit most from improved RF surgery using generators with a low NMS risk. FAU - Biber, Ulrich AU - Biber U AUID- ORCID: 0000-0001-9788-1761 AD - Erbe Elektromedizin GmbH, Waldhoernlestrasse 17, 72072, Tuebingen, Germany. ulrich.biber@erbe-med.com. FAU - Jurjut, Ovidiu AU - Jurjut O AD - Erbe Elektromedizin GmbH, Waldhoernlestrasse 17, 72072, Tuebingen, Germany. FAU - Enderle, Markus D AU - Enderle MD AD - Erbe Elektromedizin GmbH, Waldhoernlestrasse 17, 72072, Tuebingen, Germany. FAU - Aicher, Wilhelm K AU - Aicher WK AD - Department of Urology, University Hospital Tuebingen, Tuebingen, Germany. LA - eng PT - Journal Article DEP - 20200527 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Animals MH - Cystectomy/methods MH - Electric Stimulation MH - Male MH - Muscle, Smooth MH - Neuromuscular Junction MH - Prostate/innervation/*surgery MH - Prostatectomy/methods MH - Radiofrequency Ablation/*adverse effects/*instrumentation/methods MH - Risk Assessment MH - Swine MH - Urethra MH - Urinary Bladder/innervation/*surgery PMC - PMC7254752 OTO - NOTNLM OT - Bipolar loop electrode OT - Bladder OT - Compound action potential OT - Electrical stimulation OT - Electrosurgical unit OT - Obturator nerve OT - Prostate OT - Radio-frequency current OT - TURB OT - TURP COIS- UB, OJ and MDE are employees of Erbe Elektromedizin GmbH (Sponsor). Otherwise, the authors declare that they have no competing interests. EDAT- 2020/05/29 06:00 MHDA- 2021/03/05 06:00 PMCR- 2020/05/27 CRDT- 2020/05/29 06:00 PHST- 2019/06/19 00:00 [received] PHST- 2020/05/18 00:00 [accepted] PHST- 2020/05/29 06:00 [entrez] PHST- 2020/05/29 06:00 [pubmed] PHST- 2021/03/05 06:00 [medline] PHST- 2020/05/27 00:00 [pmc-release] AID - 10.1186/s12894-020-00630-5 [pii] AID - 630 [pii] AID - 10.1186/s12894-020-00630-5 [doi] PST - epublish SO - BMC Urol. 2020 May 27;20(1):59. doi: 10.1186/s12894-020-00630-5. PMID- 32457017 OWN - NLM STAT- MEDLINE DCOM- 20210422 LR - 20211104 IS - 1532-2157 (Electronic) IS - 0748-7983 (Linking) VI - 47 IP - 2 DP - 2021 Feb TI - Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. PG - 463-469 LID - S0748-7983(20)30459-5 [pii] LID - 10.1016/j.ejso.2020.05.006 [doi] AB - BACKGROUND: Radical cystectomy (RC) is often performed for T1 variant histology bladder cancer (VHBC), based on weak clinical evidence. We tested for cancer specific survival (CSS) differences after RC between T1 VHBC vs. urothelial carcinoma of the urinary bladder (UBC). METHODS: Within the Surveillance, Epidemiology and End Results registry (SEER, 2001-2016), we retrospectively identified T1N0M0 VHBC (adenocarcinoma, squamous cell carcinoma [SqCC], neuroendocrine carcinoma and other VHBC) and UBC patients. Kaplan-Meier plots, multivariate Cox regression models (CRM) with inverse probability treatment weighting (IPTW) and competing risks regression (CRR) tested CSS rates after RC in stage T1 vs. no-RC according to VHBC type and UBC. RESULTS: Of all 37,528 T1N0M0 bladder cancer patients, 1726 (4.6%) harboured VHBC. Of those, 598 (1.6%) had SqCC, 409 (1.1%) adenocarcinoma, 249 (0.7%) neuroendocrine carcinoma and 470 (1.3%) other VHBC. RC was performed in 7.4-11.0% of VHBC vs. 5.1% of high grade UBC patients. In patients with neuroendocrine and SqCC, RC was associated with higher CSS rates than any other surgical treatment modality (both p /= T2 and toxicity. RESULTS AND LIMITATIONS: In total, 170 patients were randomised to reduced frequency and 175 to standard BCG. Prognostic factors at initial resection were as follows: Ta/T1: 46/54%; primary/recurrent: 92/8%; single/multiple: 57/43%; and concomitant carcinoma in situ: 27%. After 12 mo of median follow-up, the intention-to-treat analysis showed a safety-relevant difference in recurrences between treatment arms: 46/170 (reduced frequency) versus 21/175 patients (standard). Additional safety analyses showed a hazard ratio of 0.40 with the upper part of the one-sided 97.5% confidence interval of 0.68, meeting a predefined stopping criterion for inferiority. CONCLUSIONS: The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence. Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm. PATIENT SUMMARY: After surgical removal of the tumour, patients with high-grade non-muscle-invasive bladder cancer are treated with bacillus Calmette-Guerin to prevent recurrence and progression. This is associated with significant side effects. We report the results of a clinical trial showing a reduction in the number of instillations (from 15 to nine in total) being inferior to the standard protocol. From today's perspective, complete tumour resection and a standard number of instillations remain the standard of care. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Grimm, Marc-Oliver AU - Grimm MO AD - Department of Urology, Jena University Hospital, Jena, Germany. Electronic address: marc-oliver.grimm@med.uni-jena.de. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud UMC, Nijmegen, The Netherlands. FAU - Colombel, Marc AU - Colombel M AD - Department of Urology, Hospital Edouard Herriot, Lyon, France. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Babjuk, Marko M AU - Babjuk MM AD - Department of Urology, Hospital Motol, Charles University, Prague, Czech Republic. FAU - Turkeri, Levent N AU - Turkeri LN AD - Department of Urology, Acibadem University, Istanbul, Turkey. FAU - Palou, Joan AU - Palou J AD - Urology Department, Fundacio Puigvert, Barcelona, Spain. FAU - Patel, Anup AU - Patel A AD - London, UK. FAU - Bjartell, Anders S AU - Bjartell AS AD - EAU Research Foundation, Arnhem, The Netherlands; Skane University Hospital, Lund University, Sweden. FAU - Caris, Christien AU - Caris C AD - EAU Research Foundation, Arnhem, The Netherlands. FAU - Schipper, Raymond G AU - Schipper RG AD - EAU Research Foundation, Arnhem, The Netherlands. FAU - Witjes, Wim P J AU - Witjes WPJ AD - EAU Research Foundation, Arnhem, The Netherlands. CN - EAU Research Foundation NIMBUS Study Group LA - eng PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20200520 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2020 Nov;78(5):699-700. doi: 10.1016/j.eururo.2020.05.021. PMID: 32532515 CIN - Eur Urol. 2020 Oct;78(4):e161-e162. doi: 10.1016/j.eururo.2020.06.060. PMID: 32682616 CIN - Eur Urol. 2020 Oct;78(4):e163-e164. doi: 10.1016/j.eururo.2020.07.004. PMID: 32693930 MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Prospective Studies MH - Reference Standards MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Instillation therapy OT - Non-muscle-invasive bladder cancer OT - Reduced frequency FIR - Horstmann, Jorg IR - Horstmann J FIR - Machtens, Stefan IR - Machtens S FIR - Mumperow, Eberhard IR - Mumperow E FIR - Ghazal, Andreas Al IR - Ghazal AA FIR - Pulte, Thomas IR - Pulte T FIR - Stephan-Odenthal, Michael IR - Stephan-Odenthal M FIR - Gakis, Georgios IR - Gakis G FIR - Kramer, Mario IR - Kramer M FIR - Grimm, Marc-Oliver IR - Grimm MO FIR - Zaak, Dirk IR - Zaak D FIR - Schmitz-Drager, Bernd IR - Schmitz-Drager B FIR - Schreier, Holger IR - Schreier H FIR - Lehmann, Jan IR - Lehmann J FIR - Werner, Torsten IR - Werner T FIR - Klier, Jorg IR - Klier J FIR - Marin, Jan IR - Marin J FIR - Rulf, Wolfgang IR - Rulf W FIR - Hellmis, Eva IR - Hellmis E FIR - Schneider, Andreas IR - Schneider A FIR - Spiegelhalder IR - Spiegelhalder FIR - Wirth, Manfred IR - Wirth M FIR - Klotz, Theodor IR - Klotz T FIR - Suttmann, Henrik IR - Suttmann H FIR - Siebels, Michael IR - Siebels M FIR - Rodemer, Gerd IR - Rodemer G FIR - Rudolph, Robert IR - Rudolph R FIR - Zillmann, Roger IR - Zillmann R FIR - de Bruin, M IR - de Bruin M FIR - Bos, S IR - Bos S FIR - van Moorselaar, R IR - van Moorselaar R FIR - de Reijke, T IR - de Reijke T FIR - Boormans, J IR - Boormans J FIR - Wijsman, B IR - Wijsman B FIR - van Melick, H H E IR - van Melick HHE FIR - van Boven, E IR - van Boven E FIR - Meijer, R P IR - Meijer RP FIR - van der Heijden, A G IR - van der Heijden AG FIR - Vergunst, H IR - Vergunst H FIR - Te Slaa, E IR - Te Slaa E FIR - Leliveld-Kors, A M IR - Leliveld-Kors AM FIR - Colombel, Marc IR - Colombel M FIR - Ruffion, Alain IR - Ruffion A FIR - Pfister, Christian IR - Pfister C FIR - Roupret, Morgan IR - Roupret M FIR - Irani, Jacques IR - Irani J FIR - Stoica, Gabriel IR - Stoica G FIR - Van Bruwaene, Siska IR - Van Bruwaene S FIR - Ameye, Filip IR - Ameye F FIR - Arentsen, Harm IR - Arentsen H FIR - Joniau, Steven IR - Joniau S FIR - Beardo, Pastora IR - Beardo P EDAT- 2020/05/25 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/05/25 06:00 PHST- 2020/01/16 00:00 [received] PHST- 2020/04/26 00:00 [accepted] PHST- 2020/05/25 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/05/25 06:00 [entrez] AID - S0302-2838(20)30334-1 [pii] AID - 10.1016/j.eururo.2020.04.066 [doi] PST - ppublish SO - Eur Urol. 2020 Nov;78(5):690-698. doi: 10.1016/j.eururo.2020.04.066. Epub 2020 May 20. PMID- 32446641 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 10 DP - 2020 Oct TI - Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival. PG - 796.e7-796.e14 LID - S1078-1439(20)30182-4 [pii] LID - 10.1016/j.urolonc.2020.04.027 [doi] AB - INTRODUCTION: Radical cystectomy (RC) is the standard of care for refractory high-risk non-muscle invasive bladder cancer (NMIBC). We aim to identify predictors of adequate lymph node dissection (LND) in a cohort of NMIBC patients undergoing RC, as well as its impact on clinical outcomes. METHODS: The National Cancer Database was queried for patients who underwent RC for urothelial cell carcinoma for clinical stage Tis/a/1 N0M0 disease between 2004 and 2013. Patients were stratified by LND: none, inadequate (<10) or adequate (>/=10 nodes). Factors associated with LND were analyzed. Inverse-probability weighted propensity score matching was used to assess the impact of adequate LND on overall survival. RESULTS: The final cohort of 3,226 patients had a median follow-up of 39.0 months, had a mean age of 65.3 years, was 70% male, and was 81% Caucasian. Overall, 16.6% received no LND, 28.5% inadequate LND, and 55.0% adequate LND. Treatment at an academic facility, Charlson-Deyo Comorbidity score of 1, and later year of treatment were significantly associated with adequate LND. Overall survival was significantly higher with adequate LND compared to a matched-cohort of inadequate LND patients (68.7% vs. 60.6% at 5 years, P < 0.01). CONCLUSIONS: Nearly half of NMIBC patients undergoing RC do not receive an adequate LND, despite an association with increased overall survival. Treatment at an academic facility was associated with increased likelihood of adequate LND. Initiatives to improve adequate LND in this population may be warranted. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Lenis, Andrew T AU - Lenis AT AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. Electronic address: andrewlenis@gmail.com. FAU - Lec, Patrick M AU - Lec PM AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. FAU - Michel, Joaquin AU - Michel J AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. FAU - Brisbane, Wayne AU - Brisbane W AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. FAU - Golla, Vishnukamal AU - Golla V AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. FAU - Gollapudi, Kiran AU - Gollapudi K AD - Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA. FAU - Blumberg, Jeremy AU - Blumberg J AD - Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, David Geffen School of Medicine, Institute of Urologic Oncology (IUO), University of California, Los Angeles, CA. LA - eng PT - Journal Article DEP - 20200520 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Age Factors MH - Aged MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Cystectomy/methods/*statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Lymph Node Excision/methods/*statistics & numerical data MH - Lymph Nodes/pathology/surgery MH - Lymphatic Metastasis/*prevention & control MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology/surgery MH - Neoplasm Staging MH - Prognosis MH - Propensity Score MH - Registries/statistics & numerical data MH - Risk Factors MH - Treatment Outcome MH - United States/epidemiology MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Bladder neoplasms OT - Lymphadenectomy OT - Nonmuscle invasive bladder cancer OT - Radical cystectomy OT - Survival analysis EDAT- 2020/05/25 06:00 MHDA- 2021/06/29 06:00 CRDT- 2020/05/25 06:00 PHST- 2020/01/23 00:00 [received] PHST- 2020/03/27 00:00 [revised] PHST- 2020/04/24 00:00 [accepted] PHST- 2020/05/25 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/05/25 06:00 [entrez] AID - S1078-1439(20)30182-4 [pii] AID - 10.1016/j.urolonc.2020.04.027 [doi] PST - ppublish SO - Urol Oncol. 2020 Oct;38(10):796.e7-796.e14. doi: 10.1016/j.urolonc.2020.04.027. Epub 2020 May 20. PMID- 32445767 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20220124 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 147 DP - 2021 Jan TI - High-Risk Nonmuscle Invasive Bladder Cancer: Selecting the Appropriate Patient for Timely Cystectomy. PG - 7-13 LID - S0090-4295(20)30573-2 [pii] LID - 10.1016/j.urology.2020.05.023 [doi] AB - The heterogenous nature of high-risk nonmuscle invasive bladder cancer encompasses a wide range of tumor biologies with varying recurrence and progression risks. Radical cystectomy provides excellent oncologic outcomes but is often underutilized. Timing for these patients is critical, however, to its effectiveness. Certain unfavorable tumor characteristics predict worse outcomes and may help select the most appropriate patients for more aggressive initial therapy. This manuscript aims to outline factors that predict worse outcomes in high-risk nonmuscle invasive bladder cancer and proposes which patients may benefit most from a timely radical cystectomy. CI - Copyright (c) 2020. Published by Elsevier Inc. FAU - Koch, George E AU - Koch GE AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Luckenbaugh, Amy N AU - Luckenbaugh AN AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: sam.chang@vanderbilt.edu. LA - eng PT - Journal Article PT - Review DEP - 20200520 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Cystectomy/*adverse effects/*methods MH - Disease Progression MH - Epigenesis, Genetic MH - Humans MH - Medical Oncology/*standards MH - Neoplasm Invasiveness MH - Patient Selection MH - Risk MH - Surgical Oncology/*methods/standards MH - Treatment Outcome MH - United States MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/genetics/*surgery MH - Urology/*standards EDAT- 2020/05/24 06:00 MHDA- 2022/01/27 06:00 CRDT- 2020/05/24 06:00 PHST- 2020/03/05 00:00 [received] PHST- 2020/04/18 00:00 [revised] PHST- 2020/05/10 00:00 [accepted] PHST- 2020/05/24 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2020/05/24 06:00 [entrez] AID - S0090-4295(20)30573-2 [pii] AID - 10.1016/j.urology.2020.05.023 [doi] PST - ppublish SO - Urology. 2021 Jan;147:7-13. doi: 10.1016/j.urology.2020.05.023. Epub 2020 May 20. PMID- 32443178 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 77 IP - 5 DP - 2020 Nov TI - Non-invasive papillary urothelial carcinoma with 'micropapillary' architecture: clinicopathological study of 18 patients emphasising clinical outcomes. PG - 728-733 LID - 10.1111/his.14161 [doi] AB - AIMS: Invasive micropapillary carcinoma is a recognised aggressive urothelial carcinoma variant. One prior study focusing on non-invasive (pTa) high-grade papillary urothelial carcinoma with micropapillary architecture has been reported. METHODS AND RESULTS: We collected bladder transurethral resection specimens showing non-invasive high-grade papillary urothelial carcinoma with non-hierarchical secondary papillae lacking fibrovascular cores (i.e. micropapillary architecture). Cases with any invasive component or any prior history of invasive urothelial carcinoma were excluded. Twenty cases were identified from 16 male and two female patients (aged 55-86 years). Micropapillary architecture comprised from 10 to 95% (mean = 31%), but non-invasive cribriform (15 cases, comprising 5-60%, mean = 19%) and villoglandular patterns (nine cases, comprising 5-60%, mean = 24%) were commonly admixed. Treatment data were available for 16 patients: surveillance (n = 13), cystoprostatectomy (n = 1), BCG plus mitomycin (n = 1) and BCG (n = 1). Follow-up data were available from 16 patients (range = 1-128 months, mean = 50 months): 13 patients had no new occurrences to date (81%), two had stage progression to pT1 papillary urothelial carcinoma (13%) with one dying of other causes, and one died of other causes with no evidence of disease (6%). CONCLUSION: Non-invasive urothelial carcinomas with micropapillary architecture are often admixed with non-invasive cribriform and villoglandular patterns. Stage progression to lamina propria invasion in only two of 16 patients (13%) is not higher than expected for otherwise typical pTa high-grade urothelial carcinomas and no progression to invasive micropapillary carcinoma was identified, adding further support to the current World Health Organisation recommendation excluding use of the term 'micropapillary' for pTa urothelial carcinoma. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Sangoi, Ankur R AU - Sangoi AR AUID- ORCID: 0000-0003-0874-8964 AD - Pathology, El Camino Hospital, Mountain View, CA, USA. FAU - Cox, Roni M AU - Cox RM AD - Pathology, Cleveland Clinic, Cleveland, OH, USA. FAU - Higgins, John P AU - Higgins JP AD - Pathology, Stanford Medical Center, Stanford, CA, USA. FAU - Quick, Charles M AU - Quick CM AD - Pathology, University for Arkansas Medical Sciences, Little Rock, AR, USA. FAU - McKenney, Jesse K AU - McKenney JK AUID- ORCID: 0000-0003-0851-1465 AD - Pathology, Cleveland Clinic, Cleveland, OH, USA. LA - eng PT - Journal Article DEP - 20200927 PL - England TA - Histopathology JT - Histopathology JID - 7704136 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Papillary/mortality/*pathology MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Urinary Bladder Neoplasms/mortality/*pathology OTO - NOTNLM OT - bladder OT - carcinoma OT - micropapillary OT - non-invasive OT - urothelial EDAT- 2020/05/23 06:00 MHDA- 2021/08/10 06:00 CRDT- 2020/05/23 06:00 PHST- 2020/04/28 00:00 [received] PHST- 2020/05/17 00:00 [accepted] PHST- 2020/05/23 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/05/23 06:00 [entrez] AID - 10.1111/his.14161 [doi] PST - ppublish SO - Histopathology. 2020 Nov;77(5):728-733. doi: 10.1111/his.14161. Epub 2020 Sep 27. PMID- 32434491 OWN - NLM STAT- MEDLINE DCOM- 20210202 LR - 20260518 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 20 IP - 1 DP - 2020 May 20 TI - Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). PG - 455 LID - 10.1186/s12885-020-06954-7 [doi] LID - 455 AB - BACKGROUND: Despite the embedding of bladder cancer management in European guidelines, large variation in clinical practice exists for applied diagnostics and treatments. This variation may affect patients' outcomes including complications, disease recurrence, progression, survival, and health-related quality of life (HRQL). Lack of detailed clinical data and HRQL data hampers a comprehensive evaluation of bladder cancer care. Through prospective data registration, this study aims to provide insight in bladder cancer care in the Netherlands and to identify barriers and modulators of optimal bladder cancer care. METHODS: This study is a nationwide prospective cohort study including all patients who were newly diagnosed with high-risk non-muscle invasive bladder cancer (HR-NMIBC; Tis and/or T1, N0, M0/x) or non-metastatic muscle invasive bladder cancer (MIBC; >/=T2, N0/x-3, M0/x) in the Netherlands between November 1st 2017 and October 31st 2019. Extensive data on patient- and tumor characteristics, diagnostics, treatment and follow-up up to 2 years after diagnosis will be collected prospectively from electronic health records in the participating hospitals by data managers of the Netherlands Cancer Registry (NCR). Additionally, patients will be requested to participate in a HRQL survey shortly after diagnosis and subsequently at 6, 12 and 24 months. The HRQL survey includes six standardized questionnaires, e.g. SCQ Comorbidity score, EQ-5D-5 L, EORTC-QLQ-C30, EORTC-QLQ-BLM30, EORTC-QLQ-NMIBC24 and BCI. Variation in care and deviation from the European guidelines will be assessed through descriptive analyses and multivariable multilevel analyses. Survival analyses will be used to assess the association between variation in care and relevant outcomes such as survival. DISCUSSION: The results of this observational study will guide modifications of clinical practice and/or adaptation of guidelines and may set the agenda for new specific research questions in the management of bladder cancer. TRIAL REGISTRATION: Retrospectively registered in the Netherlands Trial Register. Trial identification number: NL8106. Registered on October 22nd 2019. FAU - Ripping, T M AU - Ripping TM AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. FAU - Kiemeney, L A AU - Kiemeney LA AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. AD - Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - van Hoogstraten, L M C AU - van Hoogstraten LMC AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. FAU - Witjes, J A AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Aben, K K H AU - Aben KKH AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. katja.aben@radboudumc.nl. AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. katja.aben@radboudumc.nl. CN - BlaZIB study group LA - eng GR - IKNL 2015-7914/KWF Kankerbestrijding/ PT - Journal Article DEP - 20200520 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Follow-Up Studies MH - Humans MH - Needs Assessment/*standards MH - Netherlands MH - Practice Guidelines as Topic/*standards MH - Prognosis MH - Prospective Studies MH - Quality of Health Care/*standards MH - *Quality of Life MH - Urinary Bladder Neoplasms/*therapy PMC - PMC7240996 OTO - NOTNLM OT - Bladder cancer OT - Guidelines OT - Prospective cohort study OT - Quality of care OT - Quality of life OT - Study protocol COIS- The authors declare that they have no conflicts of interest. FIR - Boormans, Joost IR - Boormans J FIR - de Reijke, Theo IR - de Reijke T FIR - Goossens, Catharina A IR - Goossens CA FIR - Helder, Sipke IR - Helder S FIR - Hulshof, Maarten C C M IR - Hulshof MCCM FIR - van Leenders, Geert J L H IR - van Leenders GJLH FIR - van Leliveld, Annemarie M IR - van Leliveld AM FIR - Meijer, Richard P IR - Meijer RP FIR - Mulder, Sasja IR - Mulder S FIR - Nooter, Ronald I IR - Nooter RI FIR - Noteboom, Juus L IR - Noteboom JL FIR - Oddens, Jorg R IR - Oddens JR FIR - Smilde, Tineke J IR - Smilde TJ FIR - Vanderbosch, Guus W J IR - Vanderbosch GWJ FIR - van der Heijden, Antoine G IR - van der Heijden AG FIR - van der Heijden, Michiel S IR - van der Heijden MS FIR - van Moorselaar, Reindert J A IR - van Moorselaar RJA FIR - van Rhijn, Bas W G IR - van Rhijn BWG FIR - van Roermund, Joep G H IR - van Roermund JGH FIR - Wijsman, Bart P IR - Wijsman BP EDAT- 2020/05/22 06:00 MHDA- 2021/02/03 06:00 PMCR- 2020/05/20 CRDT- 2020/05/22 06:00 PHST- 2020/04/08 00:00 [received] PHST- 2020/05/12 00:00 [accepted] PHST- 2020/05/22 06:00 [entrez] PHST- 2020/05/22 06:00 [pubmed] PHST- 2021/02/03 06:00 [medline] PHST- 2020/05/20 00:00 [pmc-release] AID - 10.1186/s12885-020-06954-7 [pii] AID - 6954 [pii] AID - 10.1186/s12885-020-06954-7 [doi] PST - epublish SO - BMC Cancer. 2020 May 20;20(1):455. doi: 10.1186/s12885-020-06954-7. PMID- 32430255 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 10 DP - 2020 Oct TI - Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. PG - 796.e1-796.e6 LID - S1078-1439(20)30181-2 [pii] LID - 10.1016/j.urolonc.2020.04.026 [doi] AB - PURPOSE: The American Urological Association (AUA) introduced evidence-based guidelines for the management of nonmuscle invasive bladder cancer (NMIBC) in 2016. We sought to assess the implementation of these guidelines among members of the Society of Urologic Oncology (SUO) with an aim to identifying addressable gaps. METHODS AND MATERIALS: An SUO approved survey was distributed to 747 members from December 28, 2018 to February 2, 2019. This 14-question online survey (Qualtrics, SAP SE, Germany) consisted of 38 individual items addressing specific statements from the AUA NMIBC guidelines within 3 broad categories - initial diagnosis, surveillance, and imaging/biomarkers. Adherence to guidelines was assessed by dichotomizing responses to each item that was related to recommended action statement within the guidelines. Statistical analysis was applied using Pearson's chi-squared test, where a P-value of <0.05 was considered statistically significant. RESULTS: A total of 121 (16.2%) members completed the survey. Members reported a mean of 71% guidelines adherence; adherence was higher for the intermediate- and high-risk subgroups (82% and 76%, respectively) compared to low-risk (58%). Specifically, adherence to guideline recommended cystoscopic surveillance intervals for low-risk disease differed based on clinical experience (60.9% [<10 years] vs. 36.8% [>/=10 years], P = 0.01) and type of fellowship training (55.2% [urologic oncology] vs. 28.0% [none/other], P = 0.02). CONCLUSION: Adherence to guidelines across risk-categories was higher for intermediate- and high-risk patients. Decreased adherence observed for low-risk patients resulted in higher than recommended use of cytology, imaging, and surveillance cystoscopy. These results identify addressable gaps and provide impetus for targeted interventions to support high-value care, especially for low-risk patients. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Matulay, Justin T AU - Matulay JT AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Tabayoyong, William AU - Tabayoyong W AD - Department of Urology, University of Rochester Medical Center, Rochester, NY. FAU - Duplisea, Jonathan J AU - Duplisea JJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Chang, Courtney AU - Chang C AD - Division of Urology, Department of Surgery, UTHealth McGovern Medical School, Houston, TX. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC Institute of Urology, University of Southern California, Los Angeles, CA. FAU - Gore, John L AU - Gore JL AD - Department of Urology, University of Washington School of Medicine, Seattle, WA. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - Department of Urology, University of Kansas Medical Center, Kansas City, KS. FAU - Karsh, Lawrence I AU - Karsh LI AD - The Urology Center of Colorado, Denver, CO. FAU - Kim, Simon P AU - Kim SP AD - Division of Urology, University of Colorado, Aurora, CO. FAU - Konety, Badrinath R AU - Konety BR AD - Department of Urology, University of Minnesota, Minneapolis, MN. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Irving Medical Center, New York, NY. FAU - Messing, Edward M AU - Messing EM AD - Department of Urology, University of Rochester Medical Center, Rochester, NY. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Urology, New York University Langone Medical Center, New York, NY. FAU - Williams, Stephen B AU - Williams SB AD - Division of Urology, Department of Surgery, University of Texas Medical Branch-Galveston, Galveston, TX. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article DEP - 20200517 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/analysis MH - Cystectomy MH - Cystoscopy/standards/statistics & numerical data MH - Disease Progression MH - Evidence-Based Medicine/standards/statistics & numerical data MH - Guideline Adherence/*statistics & numerical data MH - Humans MH - Medical Oncology/standards/statistics & numerical data MH - Medical Overuse/*statistics & numerical data MH - Muscle, Smooth/diagnostic imaging/pathology/surgery MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*diagnosis/pathology/prevention & control MH - Neoplasm Staging MH - Practice Guidelines as Topic MH - Practice Patterns, Physicians'/standards/*statistics & numerical data MH - Risk Assessment MH - Societies, Medical/standards/statistics & numerical data MH - Surveys and Questionnaires/statistics & numerical data MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/pathology/*therapy MH - Urology/standards/statistics & numerical data MH - Watchful Waiting/standards/statistics & numerical data OTO - NOTNLM OT - Bladder cancer OT - Guidelines OT - Society of urologic oncology OT - Survey EDAT- 2020/05/21 06:00 MHDA- 2021/06/29 06:00 CRDT- 2020/05/21 06:00 PHST- 2020/02/06 00:00 [received] PHST- 2020/03/25 00:00 [revised] PHST- 2020/04/24 00:00 [accepted] PHST- 2020/05/21 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/05/21 06:00 [entrez] AID - S1078-1439(20)30181-2 [pii] AID - 10.1016/j.urolonc.2020.04.026 [doi] PST - ppublish SO - Urol Oncol. 2020 Oct;38(10):796.e1-796.e6. doi: 10.1016/j.urolonc.2020.04.026. Epub 2020 May 17. PMID- 32430254 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20231127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 38 IP - 12 DP - 2020 Dec TI - Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. PG - 933.e7-933.e12 LID - S1078-1439(20)30180-0 [pii] LID - 10.1016/j.urolonc.2020.04.025 [doi] AB - OBJECTIVE: Whether pathologic stage at radical nephroureterectomy (RNU) can serve as an appropriate surrogate for oncologic outcomes in patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) treated with neoadjuvant chemotherapy (NAC) is not defined. We sought to determine whether patients who achieve pathologically non-muscle-invasive (ypT0, ypTa, ypT1, ypTis) HG UTUC after receipt of NAC exhibit oncologic outcomes comparable to those who are inherently low stage without chemotherapy. METHODS: We identified 647 UTUC patients who underwent RNU among 3 institutions from 1993to2016. Patients with low or unknown grade, pathologic muscle invasion, or receipt of adjuvant chemotherapy were excluded. We compared clinicopathologic data and oncologic outcomes between pT0-1 and ypT0-1 patients. Kaplan-Meier analysis was used to assess overall (OS), cancer-specific (CSS), and systemic recurrence-free (RFS) survival. Predictors of these endpoints were identified using Cox regression. RESULTS: 234 (43 ypT0-1, 191 pT0-1) patients with HG UTUC were included. Two patients exhibited pathologic complete response after NAC. OS (P = 0.055), CSS (P = 0.152), and RFS (P = 0.098) were similar between ypT0-1 and pT0-1 patients. Predictors of worse outcomes included African-American race (RFS, CSS, and OS), Charlson score (OS), and systemic recurrence (OS and CSS). CONCLUSIONS: Patients with HG UTUC who achieve ypT0-1 stage after NAC exhibit favorable oncologic outcomes comparable to those inherently non-muscle-invasive who do not receive chemotherapy. Improvements in clinical staging will play an important role in better defining candidacy for NAC in treating HG UTUC while minimizing overtreatment. Furthermore, pathologic stage may serve as an appropriate early surrogate for oncologic endpoints in designing clinical trials. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Christie, Alana AU - Christie A AD - Division of Biostatistics, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Freifeld, Yuval AU - Freifeld Y AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Ghandour, Rashed A AU - Ghandour RA AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Woldu, Solomon L AU - Woldu SL AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Clinton, Timothy N AU - Clinton TN AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Petros, Firas G AU - Petros FG AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Robyak, Haley AU - Robyak H AD - Division of Urology, Department of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA. FAU - Yeh, Hsin-Chih AU - Yeh HC AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Sagalowsky, Arthur I AU - Sagalowsky AI AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Department of Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. Electronic address: vitaly.margulis@utsouthwestern.edu. LA - eng GR - L30 CA129564/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20200516 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*drug therapy/*pathology/surgery MH - Chemotherapy, Adjuvant MH - Cohort Studies MH - Female MH - Humans MH - Kidney Neoplasms/*drug therapy/*pathology/surgery MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Grading MH - Neoplasm Staging MH - Treatment Outcome MH - Ureteral Neoplasms/*drug therapy/*pathology/surgery PMC - PMC10676742 MID - NIHMS1588615 OTO - NOTNLM OT - Neoadjuvant chemotherapy OT - Pathologic response OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2020/05/21 06:00 MHDA- 2021/08/06 06:00 PMCR- 2023/11/26 CRDT- 2020/05/21 06:00 PHST- 2020/03/02 00:00 [received] PHST- 2020/03/26 00:00 [revised] PHST- 2020/04/24 00:00 [accepted] PHST- 2020/05/21 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2020/05/21 06:00 [entrez] PHST- 2023/11/26 00:00 [pmc-release] AID - S1078-1439(20)30180-0 [pii] AID - 10.1016/j.urolonc.2020.04.025 [doi] PST - ppublish SO - Urol Oncol. 2020 Dec;38(12):933.e7-933.e12. doi: 10.1016/j.urolonc.2020.04.025. Epub 2020 May 16. PMID- 32428277 OWN - NLM STAT- MEDLINE DCOM- 20201208 LR - 20211204 IS - 1749-6632 (Electronic) IS - 0077-8923 (Linking) VI - 1473 IP - 1 DP - 2020 Aug TI - Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. PG - 48-61 LID - 10.1111/nyas.14358 [doi] AB - Changes in the cellular microenvironment play a critical role in the development of bladder cancer (BC). Yes-associated protein (YAP), a central mediator of the Hippo pathway, functions as a nuclear sensor of mechanotransduction that can be induced by stiffness of the extracellular matrix (ECM), including stiffness resulting from surgical manipulations. We aimed to clarify the possible association between surgically-related ECM stiffness and YAP activation in BC patients. We compared 30 bladder cancer tissues with grade II (n = 15 recurrent and n = 15 newly diagnosed) with 30 adjacent healthy tissues. Atomic force microscopy showed that patients with recurrent BC had stiffer ECM than newly diagnosed patients (P < 0.05). Gene expression profiles showed that beta1 integrin (ITGB1), focal adhesion kinase (FAK), CDC42, and YAP were upregulated in cancerous tissues (P < 0.05); additionally, beta1 integrin activation was confirmed using a specific antibody. Nuclear localization of YAP was higher in recurrent cancerous tissues compared with newly diagnosed and it was positively associated with higher stiffness (P < 0.05). Our results suggest that postsurgery-induced ECM stiffness can influence integrin-FAK-YAP activity and thereby YAP trafficking to the nucleus where it contributes to BC progression and relapse. CI - (c) 2020 New York Academy of Sciences. FAU - Ghasemi, Hadi AU - Ghasemi H AD - Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Mousavibahar, Seyed Habibollah AU - Mousavibahar SH AD - Urology & Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Hashemnia, Mohammad AU - Hashemnia M AD - Department of Pathobiology, Veterinary Medicine Faculty Razi University, Kermanshah, Iran. FAU - Karimi, Jamshid AU - Karimi J AD - Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Khodadadi, Iraj AU - Khodadadi I AD - Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Mirzaei, Fatemeh AU - Mirzaei F AD - Department of Anatomy, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Tavilani, Heidar AU - Tavilani H AD - Urology & Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200519 PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Biomarkers, Tumor) RN - 0 (Transcription Factors) RN - 0 (YAP-Signaling Proteins) RN - 0 (YAP1 protein, human) SB - IM MH - Adaptor Proteins, Signal Transducing/chemistry/*metabolism MH - Aged MH - Biomarkers, Tumor/chemistry/*metabolism MH - Extracellular Matrix/metabolism/pathology MH - Female MH - Humans MH - Male MH - Mechanotransduction, Cellular/*physiology MH - Middle Aged MH - Protein Structure, Secondary MH - Protein Structure, Tertiary MH - Transcription Factors/chemistry/*metabolism MH - Tumor Microenvironment/*physiology MH - Urinary Bladder Neoplasms/*metabolism/pathology/*surgery MH - YAP-Signaling Proteins OTO - NOTNLM OT - ECM OT - Hippo pathway OT - Yes-associated protein (YAP) OT - bladder cancer OT - tissue stiffness OT - beta1 integrin EDAT- 2020/05/20 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/05/20 06:00 PHST- 2020/01/18 00:00 [received] PHST- 2020/03/21 00:00 [revised] PHST- 2020/04/13 00:00 [accepted] PHST- 2020/05/20 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/05/20 06:00 [entrez] AID - 10.1111/nyas.14358 [doi] PST - ppublish SO - Ann N Y Acad Sci. 2020 Aug;1473(1):48-61. doi: 10.1111/nyas.14358. Epub 2020 May 19. PMID- 32425678 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220414 IS - 1426-3912 (Print) IS - 1644-4124 (Electronic) IS - 1426-3912 (Linking) VI - 45 IP - 1 DP - 2020 TI - Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy. PG - 37-47 LID - 10.5114/ceji.2020.94674 [doi] AB - INTRODUCTION: The present study investigated the association of cytokines genes polymorphisms (IL-2, IL-8 and IL-18) and polymorphisms in genes encoding molecules related to the differentiation of Th17 subpopulation (IL-17 and IL-23R) with the risk of bladder cancer (BC) and response to BCG immunotherapy. MATERIAL AND METHODS: Altogether, 175 BC patients treated with BCG due to high-grade non-muscle invasive tumors and 207 healthy individuals were genotyped for the following polymorphisms: IL-17A-197G>A (rs2275913); IL-17F+7488T>C (rs763780); IL-23Rc.309C>A (rs10889677);IL-23Rc.1142G>A (rs11209026); IL-2-330T>G (rs2069762), IL-8-251A>T (rs4073), and IL-18-137G>C (rs187238) using the TaqMan SNP genotyping assays. RESULTS: The IL-23Rc.-309C>A[A] allele was associated with the risk of BC (OR: 1.42, p = 0.03). Moreover, heterozygocities for IL-17A-197G>A[GA] and IL-18-137G>C[GC] increased the risk of BC, as compared to both homozygotes (OR: 1.67, p = 0.01 and OR: 1.84, p = 0.008, respectively). The IL-18-137G>C[GC] heterozygous patients had the highest risk of tumor recurrence and progression, and the worst recurrence-free and progression-free survival. Homozygous IL-17A-197G>A[GG] patients presented the best recurrence-free survival, while IL-17A-197G>A[AA] patients had 1.8-fold higher risk of recurrence. CONCLUSIONS: The present study highlighted the importance of IL-17, IL-18, and IL-23R gene polymorphisms for BC susceptibility and BCG immunotherapy outcomes. It may help to identify appropriate candidates for early radical treatment. CI - Copyright (c) 2020 Termedia. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Karabon, Lidia AU - Karabon L AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. AD - Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland. FAU - Partyka, Anna AU - Partyka A AD - Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland. FAU - Tomkiewicz, Anna AU - Tomkiewicz A AD - Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Social Medicine, Wroclaw Medical University, Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article PL - Poland TA - Cent Eur J Immunol JT - Central-European journal of immunology JID - 9702239 PMC - PMC7226548 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - gene polymorphisms OT - non-muscle-invasive bladder cancer OT - progression OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2020/05/20 06:00 MHDA- 2020/05/20 06:01 PMCR- 2020/01/01 CRDT- 2020/05/20 06:00 PHST- 2018/12/25 00:00 [received] PHST- 2019/04/23 00:00 [accepted] PHST- 2020/05/20 06:00 [entrez] PHST- 2020/05/20 06:00 [pubmed] PHST- 2020/05/20 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 94674 [pii] AID - 10.5114/ceji.2020.94674 [doi] PST - ppublish SO - Cent Eur J Immunol. 2020;45(1):37-47. doi: 10.5114/ceji.2020.94674. PMID- 32420968 OWN - NLM STAT- MEDLINE DCOM- 20210329 LR - 20240329 IS - 2531-6745 (Electronic) IS - 0392-4203 (Print) IS - 0392-4203 (Linking) VI - 91 IP - 2 DP - 2020 May 11 TI - Second-look TURBT: evaluation of anatomopatological and oncologic results in a single center. PG - 322-325 LID - 10.23750/abm.v91i2.8618 [doi] AB - INTRODUCTION: T1 bladder cancer is associated with a high risk of recurrence and progression; concomitant carcinoma in situ and/or multifocality are negative prognostic factors. Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, and after resection of High-grade (HG) Ta tumour in 41,4%. It has been demonstrated that a second TURB can increase recurrence-free survival and it can make a restaging of the cancer. PATIENTS AND METHODS: From January 2011 to December 2016, 87 patients with superficial bladder tumor (Ta-T1), undergoing TURB and routine repeat TURB (Re-TURB) 4-6 weeks after the initial resection, were included in the study. Re-TURB was applied to the scar of the first resection and other suspicious lesions in the bladder. After the second-look, we studied the follow-up of each patient. RESULTS: Specimens obtained during the second TURBT showed no tumor in 47 (54,02%) patients; 40 (45,98%) patients had residual cancer: 34 of them had cancer of the same stage, 6 patients of pT1 had a lower stage, and 3 had a higher stage. 5 patient underwent radical cistectomy immediatly after re-TURBT. During the first year of follow up, 15 patients had a recurrent bladder cancer; 2 of them underwent radical cistectomy. CONCLUSIONS: T1 bladder cancer is an high risk tumor, so that second-look TURBT is a valuable procedure for accurate staging of nonmuscle-invasive bladder cancer and it can guarantee a better eradication of the neoplasm. FAU - Maltagliati, Matteo AU - Maltagliati M AD - . matteo.maltagliati90@gmail.com. FAU - Varca, Virginia AU - Varca V AD - . v.varca@fastwebnet.it. FAU - Milandri, Riccardo AU - Milandri R AD - Universita di Modena e Reggio Emilia. riccardomilandri85@gmail.com. FAU - Micali, Salvatore AU - Micali S AD - . salvatore.micali@unimore.it. FAU - Bocchialini, Tommaso AU - Bocchialini T AD - . tommaso.bocchialini@libero.it. FAU - Rocco, Bernardo Maria Cesare AU - Rocco BMC AD - . bernardo.rocco@gmail.com. FAU - Gregori, Andrea AU - Gregori A AD - . gregori.andrea@asst-rhodense.it. LA - eng PT - Journal Article DEP - 20200511 PL - Italy TA - Acta Biomed JT - Acta bio-medica : Atenei Parmensis JID - 101295064 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - *Second-Look Surgery MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*pathology/*surgery PMC - PMC7569633 COIS- Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article EDAT- 2020/05/19 06:00 MHDA- 2021/03/30 06:00 PMCR- 2020/01/01 CRDT- 2020/05/19 06:00 PHST- 2019/06/23 00:00 [received] PHST- 2019/07/11 00:00 [accepted] PHST- 2020/05/19 06:00 [entrez] PHST- 2020/05/19 06:00 [pubmed] PHST- 2021/03/30 06:00 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - ACTA-91-322 [pii] AID - 10.23750/abm.v91i2.8618 [doi] PST - epublish SO - Acta Biomed. 2020 May 11;91(2):322-325. doi: 10.23750/abm.v91i2.8618. PMID- 32420150 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220414 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 2 DP - 2020 Apr TI - Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. PG - 445-451 LID - 10.21037/tau.2020.02.16 [doi] AB - BACKGROUND: To investigate the accuracy of using the Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in prediction preoperative muscle invasion of bladder cancer. METHODS: The study retrospectively reviewed consecutive patients with bladder cancer who received multiparametric magnetic resonance imaging (MRI) between January 2017 and June 2019. Clinical and pathological parameters were collected. Bladder tumors were re-evaluated with 5-point VI-RADS scoring system by two experienced radiologists independently. The VI-RADS score was compared with postoperative pathology for each tumor for determining muscle invasion. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for each VI-RADS cutoff. RESULTS: A total of 126 patients were included in analysis, with 82 patients received transurethral resection of bladder tumor (TURBt) while 44 underwent radical cystectomy. Fifty patients were muscle-invasive bladder cancer and 76 were non-muscle invasive tumor confirmed pathologically. VI-RADS score was only predictive factor to muscle invasion in multivariate analysis. Setting VI-RADS score greater than or equal to 4 reached the best sensitivity and specificity of 94.00% and 92.11%, with PPV and NPV value of 88.68% and 95.89%. CONCLUSIONS: VI-RADS score system is a promising and effective modality in determining detrusor muscle invasion of bladder cancer preoperatively. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Liu, Shenghua AU - Liu S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. FAU - Xu, Feijia AU - Xu F AD - Department of Radiology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. FAU - Xu, Tianyuan AU - Xu T AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. FAU - Yan, Yang AU - Yan Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. FAU - Yao, Xudong AU - Yao X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. FAU - Tang, Guangyu AU - Tang G AD - Department of Radiology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7215047 OTO - NOTNLM OT - Bladder cancer OT - Vesical Imaging-Reporting and Data System (VI-RADS) OT - multiparametric magnetic resonance imaging (mpMRI) OT - muscle invasion OT - prediction COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.02.16). The authors have no conflicts of interest to declare. EDAT- 2020/05/19 06:00 MHDA- 2020/05/19 06:01 PMCR- 2020/04/01 CRDT- 2020/05/19 06:00 PHST- 2020/05/19 06:00 [entrez] PHST- 2020/05/19 06:00 [pubmed] PHST- 2020/05/19 06:01 [medline] PHST- 2020/04/01 00:00 [pmc-release] AID - tau-09-02-445 [pii] AID - 10.21037/tau.2020.02.16 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Apr;9(2):445-451. doi: 10.21037/tau.2020.02.16. PMID- 32420148 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220414 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 9 IP - 2 DP - 2020 Apr TI - Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma. PG - 428-436 LID - 10.21037/tau.2020.02.12 [doi] AB - BACKGROUND: Non-schistosoma-associated urinary bladder squamous cell carcinoma (SqCC) has low incidence and is associated with chronic inflammation. Due to its unique etiology and pathology, expression of programmed cell death ligand 1 (PD-L1) in SqCC could be different from that of urothelial carcinoma, which may contribute to different responses to immunotherapy. In this study, we intended to explore the expression profile and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder SqCC under the consideration of tumor-infiltrating lymphocytes' (TILs) density. METHODS: We conducted a retrospective study to review 604 bladder cancer patients who received radical cystectomy (RC) from 2009 to 2013 in Peking University First Hospital. We enrolled 67 bladder SqCC patients in total, including pure SqCC (n=19) and mixed SqCC (n=48, with urothelial carcinoma). PD-L1 protein expression and TILs density were evaluated by immunohistochemistry. RESULTS: Nine female and 58 male patients (median age 67.4 years) were enrolled in the present study. There were 15 stage T1-2 patients and 52 stage T3-4 patients. 27 patients had N1-2 lymph node metastasis. Overall, 61.2% cases were PD-L1-positive. Dense TILs coincided with higher PD-L1 expression rate. Median survival time of PD-L1 positive cases was significantly higher than negative cases (P=0.026). During multivariate analysis, positive PD-L1 expression and dense TILs were independent protective factors affecting overall survival (OS, PD-L1: P=0.022; TILs: P=0.010) and progression free survival (PFS, PD-L1: P=0.018; TILs: P=0.009). CONCLUSIONS: PD-L1 expression and dense TILs were frequently detected in urinary bladder SqCC tumors. Positive PD-L1 expression and dense TILs were correlated with better survival outcomes in non-schistosoma-associated urinary bladder SqCC. The immunotherapy targeting PD-L1 might be helpful to bladder SqCC patients. CI - 2020 Translational Andrology and Urology. All rights reserved. FAU - Liu, Zhenhua AU - Liu Z AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Meng, Yisen AU - Meng Y AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Cao, Yudong AU - Cao Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China. FAU - Chen, Yuke AU - Chen Y AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Fan, Yu AU - Fan Y AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Li, Shaobo AU - Li S AD - School of Basic Medicine, Fudan University, Shanghai 200032, China. FAU - He, Qun AU - He Q AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Wu, Shiliang AU - Wu S AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Yu, Wei AU - Yu W AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. FAU - Jin, Jie AU - Jin J AD - Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC7215043 OTO - NOTNLM OT - Bladder cancer OT - programmed death ligand-1 OT - squamous cell carcinoma (SqCC) OT - survival OT - tumor-infiltrating lymphocytes (TILs) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.02.12). The authors have no conflicts of interest to declare. EDAT- 2020/05/19 06:00 MHDA- 2020/05/19 06:01 PMCR- 2020/04/01 CRDT- 2020/05/19 06:00 PHST- 2020/05/19 06:00 [entrez] PHST- 2020/05/19 06:00 [pubmed] PHST- 2020/05/19 06:01 [medline] PHST- 2020/04/01 00:00 [pmc-release] AID - tau-09-02-428 [pii] AID - 10.21037/tau.2020.02.12 [doi] PST - ppublish SO - Transl Androl Urol. 2020 Apr;9(2):428-436. doi: 10.21037/tau.2020.02.12. PMID- 32417111 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 10 DP - 2020 Oct TI - Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. PG - 795.e9-795.e17 LID - S1078-1439(20)30178-2 [pii] LID - 10.1016/j.urolonc.2020.04.023 [doi] AB - OBJECTIVES: To validate the substratification of high-risk in the European Association of Urology (EAU) guidelines and to develop the simplified substratification to improve usefulness and predictive accuracy on oncological outcomes in patients with primary high-risk nonmuscle-invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We retrospectively evaluated 428 patients with primary high-risk NMIBC who underwent TURBT from November 1993 to April 2019. First, the efficacy of the EAU highest-risk on intravesical recurrence-free survival (RFS) and muscle-invasive bladder cancer (MIBC)-free survival was evaluated with univariate analyses. Second, we developed our simplified substratification based on multivariate analysis for intravesical RFS (lower- and higher-risk). We compared predictive accuracy on oncological outcomes using the receiver operating characteristic curve between the EAU and the simplified substratifications. RESULTS: Median age and median follow-up periods were 72 years and 51 months, respectively. The EAU highest-risk was not associated with shorter intravesical RFS and MIBC-free survival (P = 0.054 and P = 0.350, respectively). In multivariate analysis, tumor size, grade 3, and chronic kidney disease were significantly associated with shorter intravesical RFS, and we developed the simplified substratification including those 3 factors. Of 428 patients, 89 (21%) were substratified into the simplified higher-risk. The predictive accuracy of the simplified substratification on intravesical recurrence, MIBC and metastasis progression, and cancer-specific mortality was significantly superior to the EAU substratification. CONCLUSION: Our simplified substratification might contribute to improving predictive accuracy on intravesical recurrence, MIBC and metastasis progression, and cancer-specific mortality in patients with primary high-risk NMIBC who underwent TURBT. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article PT - Validation Study DEP - 20200514 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/diagnosis/mortality/pathology/*surgery MH - Cystectomy/*methods MH - Disease Progression MH - Disease-Free Survival MH - Feasibility Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Muscle, Smooth/pathology/surgery MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis/*epidemiology/pathology/prevention & control MH - Practice Guidelines as Topic MH - Predictive Value of Tests MH - Prognosis MH - Retrospective Studies MH - Risk Assessment/methods/standards MH - Societies, Medical/standards MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/mortality/pathology/*surgery MH - Urology/standards OTO - NOTNLM OT - Chronic kidney disease OT - High-risk OT - Non-muscle-invasive bladder cancer OT - Substratification OT - Transurethral resection of bladder tumor EDAT- 2020/05/18 06:00 MHDA- 2021/06/29 06:00 CRDT- 2020/05/18 06:00 PHST- 2020/01/03 00:00 [received] PHST- 2020/04/06 00:00 [revised] PHST- 2020/04/22 00:00 [accepted] PHST- 2020/05/18 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/05/18 06:00 [entrez] AID - S1078-1439(20)30178-2 [pii] AID - 10.1016/j.urolonc.2020.04.023 [doi] PST - ppublish SO - Urol Oncol. 2020 Oct;38(10):795.e9-795.e17. doi: 10.1016/j.urolonc.2020.04.023. Epub 2020 May 14. PMID- 32414626 OWN - NLM STAT- MEDLINE DCOM- 20200713 LR - 20250530 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 78 IP - 1 DP - 2020 Jul TI - Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. PG - 29-42 LID - S0302-2838(20)30331-6 [pii] LID - 10.1016/j.eururo.2020.04.063 [doi] AB - CONTEXT: The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. OBJECTIVE: To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage. EVIDENCE ACQUISITION: A collaborative review using literature published as of April 2, 2020. EVIDENCE SYNTHESIS: Patients with low-grade non-muscle-invasive bladder cancer are unlikely to suffer from a 3-6-month delay. Patients with muscle-invasive bladder cancer are at risk of disease progression, with radical cystectomy delays beyond 12 wk from diagnosis or completion of neoadjuvant chemotherapy. Prioritization of these patients for surgery or management with radiochemotherapy is encouraged. Active surveillance should be used for low-risk prostate cancer (PCa). Treatment of most patients with intermediate- and high-risk PCa can be deferred 3-6 mo without change in outcomes. The same may be true for cancers with the highest risk of progression. With radiotherapy, neoadjuvant androgen deprivation therapy (ADT) is the standard of care. For surgery, although the added value of neoadjuvant ADT is questionable, it may be considered if a patient is interested in such an approach. Intervention may be safely deferred for T1/T2 renal masses, while locally advanced renal tumors (>/=T3) should be treated expeditiously. Patients with metastatic renal cancer may consider vascular endothelial growth factor targeted therapy over immunotherapy. Risks for delay in the treatment of upper tract urothelial cancer depend on grade and stage. For patients with high-grade disease, delays of 12 wk in nephroureterectomy are not associated with adverse survival outcomes. Expert guidance recommends expedient local treatment of testis cancer. In penile cancer, adverse outcomes have been observed with delays of >/=3 mo before inguinal lymphadenectomy. Limitations include a paucity of data and methodologic variations for many cancers. CONCLUSIONS: Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system. PATIENT SUMMARY: The coronavirus disease 2019 pandemic has led to delays in the treatment of patients with urologic malignancies. Based on a review of the literature, patients with high-grade urothelial carcinoma, advanced kidney cancer, testicular cancer, and penile cancer should be prioritized for treatment during these challenging times. CI - Copyright (c) 2020. Published by Elsevier B.V. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Novara, Giacomo AU - Novara G AD - Department of Surgery, Oncology, and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy. FAU - Marandino, Laura AU - Marandino L AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Bex, Axel AU - Bex A AD - Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science, London, UK. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Morgan, Todd M AU - Morgan TM AD - Department of Urology, University of Michigan, Ann Arbor, MI, USA. FAU - Mottet, Nicolas AU - Mottet N AD - Department of Urology, University hospital Nord, St Etienne, France. FAU - Gillessen, Silke AU - Gillessen S AD - Department of Medical Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland. FAU - Bossi, Alberto AU - Bossi A AD - Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. FAU - Roupret, Morgan AU - Roupret M AD - Urology, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Pitie Salpetriere Hospital, Sorbonne University, Paris, France; European Section of Onco Urology, EAU. FAU - Powles, Thomas AU - Powles T AD - Barts Cancer Center, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk. FAU - Klaassen, Zachary AU - Klaassen Z AD - Department of Surgery, Division of Urology, Augusta University-Medical College of Georgia, Augusta, GA, USA; Georgia Cancer Center, Augusta, GA, USA. Electronic address: zklaassen19@gmail.com. LA - eng GR - NIHR300047/DH_/Department of Health/United Kingdom PT - Journal Article PT - Review DEP - 20200503 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2020 Sep;78(3):478-481. doi: 10.1016/j.eururo.2020.04.070. PMID: 32416977 MH - *Betacoronavirus MH - COVID-19 MH - Combined Modality Therapy/methods MH - Coronavirus Infections/*complications/epidemiology MH - *Disease Management MH - Humans MH - *Pandemics MH - Pneumonia, Viral/*complications/epidemiology MH - Risk Factors MH - SARS-CoV-2 MH - Time-to-Treatment/*organization & administration MH - Triage/*organization & administration MH - Urogenital Neoplasms/complications/diagnosis/*therapy PMC - PMC7196384 OTO - NOTNLM OT - Bladder cancer OT - Coronavirus OT - Coronavirus disease 2019 OT - Delayed treatment OT - Kidney cancer OT - Penile cancer OT - Prostate cancer OT - Sstemic therapy OT - Surgery OT - Testicular cancer OT - Upper tract urothelial carcinoma EDAT- 2020/05/18 06:00 MHDA- 2020/07/14 06:00 PMCR- 2020/05/03 CRDT- 2020/05/17 06:00 PHST- 2020/04/15 00:00 [received] PHST- 2020/04/24 00:00 [accepted] PHST- 2020/05/18 06:00 [pubmed] PHST- 2020/07/14 06:00 [medline] PHST- 2020/05/17 06:00 [entrez] PHST- 2020/05/03 00:00 [pmc-release] AID - S0302-2838(20)30331-6 [pii] AID - 10.1016/j.eururo.2020.04.063 [doi] PST - ppublish SO - Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3. PMID- 32409197 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20211109 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 38 IP - 9 DP - 2020 Sep TI - Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults. PG - 737.e17-737.e23 LID - S1078-1439(20)30150-2 [pii] LID - 10.1016/j.urolonc.2020.04.010 [doi] AB - BACKGROUND: Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. METHODS: We identified 1,485 older (age >/=60 years) NMIBC patients (American Joint Committee on Cancer Stage 30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. RESULTS: Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70-1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. CONCLUSION: We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Garg, Tullika AU - Garg T AD - Department of Urology, Geisinger, Danville, PA; Department of Population Health Sciences, Geisinger, Danville, PA. Electronic address: tgarg@geisinger.edu. FAU - Young, Amanda J AU - Young AJ AD - Biostatistics Core, Geisinger, Danville, PA. FAU - O'Keeffe-Rosetti, Maureen AU - O'Keeffe-Rosetti M AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - McMullen, Carmit K AU - McMullen CK AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Department of Urology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Department of Epidemiology, Health Policy, and Management, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC. FAU - Murphy, Terrence E AU - Murphy TE AD - Section of Geriatrics, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT. FAU - Kirchner, H Lester AU - Kirchner HL AD - Department of Population Health Sciences, Geisinger, Danville, PA. LA - eng GR - P30 AG021342/AG/NIA NIH HHS/United States GR - R03 AG064382/AG/NIA NIH HHS/United States GR - R21 CA191610/CA/NCI NIH HHS/United States GR - R24 AG045050/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20200512 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - J Urol. 2021 Mar;205(3):906-909. doi: 10.1097/JU.0000000000001542. PMID: 33356457 MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Metabolic Syndrome/*complications MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*complications/pathology PMC - PMC7438276 MID - NIHMS1586774 OTO - NOTNLM OT - Bladder cancer;Geriatric oncology;Outcomes;Metabolic syndrome;Multiplechronic conditions COIS- CONFLICT OF INTEREST: Matthew E. Nielsen serves as a paid consultant to the American College of Physicians High Value Care Task Force and as a consultant/advisor to Grand Rounds for which he is paid via stock options. All other authors report No Conflict of Interest. EDAT- 2020/05/16 06:00 MHDA- 2021/07/23 06:00 PMCR- 2021/09/01 CRDT- 2020/05/16 06:00 PHST- 2020/01/05 00:00 [received] PHST- 2020/04/06 00:00 [revised] PHST- 2020/04/10 00:00 [accepted] PHST- 2020/05/16 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/05/16 06:00 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - S1078-1439(20)30150-2 [pii] AID - 10.1016/j.urolonc.2020.04.010 [doi] PST - ppublish SO - Urol Oncol. 2020 Sep;38(9):737.e17-737.e23. doi: 10.1016/j.urolonc.2020.04.010. Epub 2020 May 12. PMID- 32397531 OWN - NLM STAT- MEDLINE DCOM- 20210216 LR - 20210216 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 9 DP - 2020 May 9 TI - Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. LID - 10.3390/ijms21093360 [doi] LID - 3360 AB - The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice. FAU - Matuszczak, Milena AU - Matuszczak M AD - Department of Urology, Collegium Medicum, University of Zielona Gora, 65-046 Zielona Gora, Poland. FAU - Salagierski, Maciej AU - Salagierski M AUID- ORCID: 0000-0001-8646-1219 AD - Department of Urology, Collegium Medicum, University of Zielona Gora, 65-046 Zielona Gora, Poland. LA - eng PT - Journal Article PT - Review DEP - 20200509 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 0 (DNA-Binding Proteins) RN - 0 (Keratin-19) RN - 0 (Neoplasm Proteins) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (antigen CYFRA21.1) RN - 50936-63-5 (Trypsin Inhibitor, Kazal Pancreatic) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 3.1.- (ERCC1 protein, human) RN - EC 3.1.- (Endonucleases) SB - IM MH - Antigens, Neoplasm/*analysis MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/*chemistry/diagnosis MH - DNA-Binding Proteins/*analysis MH - Endonucleases/*analysis MH - Humans MH - Keratin-19/*analysis MH - Neoplasm Proteins/*analysis MH - Prognosis MH - Receptor, Fibroblast Growth Factor, Type 3/*analysis MH - Trypsin Inhibitor, Kazal Pancreatic/*analysis MH - Tumor Suppressor Protein p53/*analysis MH - Urinary Bladder Neoplasms/*chemistry/diagnosis PMC - PMC7247579 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - prognosis OT - tumor markers COIS- The authors declare no conflict of interest. EDAT- 2020/05/14 06:00 MHDA- 2021/02/17 06:00 PMCR- 2020/05/01 CRDT- 2020/05/14 06:00 PHST- 2020/04/16 00:00 [received] PHST- 2020/05/04 00:00 [revised] PHST- 2020/05/05 00:00 [accepted] PHST- 2020/05/14 06:00 [entrez] PHST- 2020/05/14 06:00 [pubmed] PHST- 2021/02/17 06:00 [medline] PHST- 2020/05/01 00:00 [pmc-release] AID - ijms21093360 [pii] AID - ijms-21-03360 [pii] AID - 10.3390/ijms21093360 [doi] PST - epublish SO - Int J Mol Sci. 2020 May 9;21(9):3360. doi: 10.3390/ijms21093360. PMID- 32391563 OWN - NLM STAT- MEDLINE DCOM- 20210323 LR - 20210323 IS - 1573-4935 (Electronic) IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 40 IP - 5 DP - 2020 May 29 TI - Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study. LID - 10.1042/BSR20194192 [doi] LID - BSR20194192 AB - Bladder cancer is the 11th most common cancer in the world. Bladder cancer can be roughly divided into muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). The aim of the present study was to identify the key genes and pathways associated with the progression of NMIBC to MIBC and to further analyze its molecular mechanism and prognostic significance. We analyzed microarray data of NMIBC and MIBC gene expression datasets (GSE31684) listed in the Gene Expression Omnibus (GEO) database. After the dataset was analyzed using R software, differentially expressed genes (DEGs) of NMIBC and MIBC were identified. These DEGs were analyzed using Gene Ontology (GO) enrichment, KOBAS-Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) analysis. The effect of these hub genes on the survival of bladder cancer patients was analyzed in The Cancer Genome Atlas (TCGA) database. A total of 389 DEGs were obtained, of which 270 were up-regulated and 119 down-regulated. GO and KEGG pathway enrichment analysis revealed that DEGs were mainly involved in the pathway of protein digestion and absorption, extracellular matrix (ECM) receiver interaction, phantom, toll-like receptor (TLR) signaling pathway, focal adhesion, NF-kappaB signaling pathway, PI3K/Akt signaling pathway, and other signaling pathways. Top five hub genes COL1A2, COL3A1, COL5A1, POSTN, and COL12A1 may be involved in the development of MIBC. These results may provide us with a further understanding of the occurrence and development of MIBC, as well as new targets for the diagnosis and treatment of MIBC in the future. CI - (c) 2020 The Author(s). FAU - Zhang, Heng AU - Zhang H AD - Medical School of Guizhou University, Jiaxiu South road, Guiyang, Guizhou Province, P.R. China. FAU - Shan, Gang AU - Shan G AD - Department of Urology Surgery, Guizhou Province People's Hospital, No. 83 East Zhongshan Road, Guiyang, Guizhou Province, P.R. China. FAU - Song, Jukun AU - Song J AD - Department of Oral and Maxillofacial Surgery, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, Guizhou Province, P.R. China. FAU - Tian, Ye AU - Tian Y AD - Department of Urology Surgery, Guizhou Province People's Hospital, No. 83 East Zhongshan Road, Guiyang, Guizhou Province, P.R. China. FAU - An, Ling-Yue AU - An LY AD - Guangzhou Medical University, New town, Panyu district, Guangzhou Province, P.R. China. FAU - Ban, Yong AU - Ban Y AD - Department of Urology Surgery, Guizhou Province People's Hospital, No. 83 East Zhongshan Road, Guiyang, Guizhou Province, P.R. China. FAU - Luo, Guang-Heng AU - Luo GH AD - Medical School of Guizhou University, Jiaxiu South road, Guiyang, Guizhou Province, P.R. China. AD - Department of Urology Surgery, Guizhou Province People's Hospital, No. 83 East Zhongshan Road, Guiyang, Guizhou Province, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - 0 (Extracellular Matrix Proteins) SB - IM MH - *Computational Biology MH - Databases, Genetic MH - Disease Progression MH - Extracellular Matrix/*genetics/metabolism/pathology MH - Extracellular Matrix Proteins/*genetics/metabolism MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - Humans MH - Neoplasm Invasiveness MH - Protein Interaction Maps MH - Signal Transduction MH - Transcriptome MH - Urinary Bladder Neoplasms/*genetics/metabolism/mortality/pathology PMC - PMC7251326 OTO - NOTNLM OT - Bladder cancer OT - Extracellular matrix OT - GEO COIS- The authors declare that there are no competing interests associated with the manuscript. EDAT- 2020/05/12 06:00 MHDA- 2021/03/24 06:00 PMCR- 2020/05/26 CRDT- 2020/05/12 06:00 PHST- 2019/12/10 00:00 [received] PHST- 2020/04/22 00:00 [revised] PHST- 2020/05/07 00:00 [accepted] PHST- 2020/05/12 06:00 [pubmed] PHST- 2021/03/24 06:00 [medline] PHST- 2020/05/12 06:00 [entrez] PHST- 2020/05/26 00:00 [pmc-release] AID - 224101 [pii] AID - BSR20194192 [pii] AID - 10.1042/BSR20194192 [doi] PST - ppublish SO - Biosci Rep. 2020 May 29;40(5):BSR20194192. doi: 10.1042/BSR20194192. PMID- 32391279 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma. PG - 623 LID - 10.3389/fonc.2020.00623 [doi] LID - 623 AB - Object: CK14 expression is an important marker of basal/squamous-like (BASQ)-type muscle-invasive bladder carcinoma, and this molecularly defined subtype has a poor prognosis and a distinct response to chemotherapy. However, CK14 expression and its clinicopathological and molecular significance in papillary non-muscle-invasive upper tract urothelial carcinoma (NMIUTUC) remain unknown. Herein, we investigated the prognostic implications of immunohistochemical (IHC) staining for CK14 and the transcriptional characteristics associated with CK14 expression in papillary NMIUTUC. Materials and Methods: IHC staining for CK14 was conducted in 204 papillary NMIUTUC specimens. Positive CK14 IHC staining was defined as a positive signal in >0% of tumor cells. RNA sequencing data were analyzed from 8 papillary high-grade NMIUTUC specimens consisting of 4 CK14-positive and 4 CK14-negative tumors. Results: CK14 positivity was associated with a high TNM stage (p < 0.001) and a high World Health Organization grade (p = 0.003). Survival analysis showed that CK14 positivity was significantly associated with poor progression-free survival (p = 0.015; hazard ratio [HR] = 2.990; 95% confidence interval [CI] = 1.180-7.580) and was marginally associated with poor cancer-specific survival (p = 0.052; HR = 3.77; 95% CI = 0.900-15.780). Gene set enrichment analysis demonstrated that the CK14-positive tumors were associated with a basal subtype of breast cancer, squamous cell carcinoma development, p40, tumor necrosis factor alpha-nuclear factor-kappaB, and p53 pathways, and embryonic stem cells; these characteristics are reminiscent of the BASQ subtype. In addition, with a p < 0.05 and |fold change| >/=2 as the cutoffs, we identified 178 differentially expressed genes when comparing CK14-positive and CK14-negative tumors. Functional analysis of these genes revealed several networks and gene ontology terms related to the positive regulation of cellular proliferation in CK14-positive tumors. Consistent with these results, we demonstrated that the mean Ki-67 proliferative index was higher in CK14-positive tumors than it was in CK14-negative tumors (2.3 vs. 0.8%, respectively, p = 0.002). Conclusion: CK14-positive papillary NMIUTUC is an aggressive subtype with BASQ-like molecular characteristics and dynamic proliferative activity. We propose that CK14 IHC staining can be a useful biomarker of BASQ-type papillary NMIUTUC that can be applied in daily practice with the aim of precision oncology. CI - Copyright (c) 2020 Jung, Jang, Kim and Moon. FAU - Jung, Minsun AU - Jung M AD - Department of Pathology, Seoul National University Hospital, Seoul, South Korea. FAU - Jang, Insoon AU - Jang I AD - Division of Clinical Bioinformatics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea. FAU - Kim, Kwangsoo AU - Kim K AD - Division of Clinical Bioinformatics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea. FAU - Moon, Kyung Chul AU - Moon KC AD - Department of Pathology, Seoul National University Hospital, Seoul, South Korea. AD - Medical Research Center, Kidney Research Institute, Seoul National University College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article DEP - 20200424 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7193093 OTO - NOTNLM OT - Cytokeratin 14 OT - basal/squamous-like OT - carcinoma OT - gene expression profiling OT - high-throughput nucleotide sequencing OT - prognosis OT - transitional cell OT - upper tract urothelial carcinoma EDAT- 2020/05/12 06:00 MHDA- 2020/05/12 06:01 PMCR- 2020/01/01 CRDT- 2020/05/12 06:00 PHST- 2020/01/16 00:00 [received] PHST- 2020/04/03 00:00 [accepted] PHST- 2020/05/12 06:00 [entrez] PHST- 2020/05/12 06:00 [pubmed] PHST- 2020/05/12 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.00623 [doi] PST - epublish SO - Front Oncol. 2020 Apr 24;10:623. doi: 10.3389/fonc.2020.00623. eCollection 2020. PMID- 32389427 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20210805 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 12 DP - 2020 Dec TI - The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome. PG - 933.e1-933.e6 LID - S1078-1439(20)30140-X [pii] LID - 10.1016/j.urolonc.2020.04.012 [doi] AB - OBJECTIVES: The utility of frozen section analysis (FSA) during partial cystectomy has not been established. We assessed the impact of intraoperative FSA in partial cystectomy cases on surgical margin (SM) status and patient outcome. SUBJECTS AND METHODS: A retrospective review identified 76 consecutive patients who underwent partial cystectomy for bladder carcinoma with (n = 66; 87%) or without (n = 10; 13%) FSA for SMs at our institution from 2004 to 2018. FSA was correlated with the diagnosis of the frozen section control, the status of final SM, and the prognosis. RESULTS: Final SM was positive in 9 (12%) cystectomies, including 6 (9%) FSA vs. 3 (30%) non-FSA cases (P = 0.091). There were no significant differences in tumor size, histology, or tumor grade/stage between the 2 cohorts. FSAs were reported as positive (n = 7; 11%), atypical (n = 10; 15%), and negative (n = 49; 74%). All of the positive and negative FSA diagnoses were confirmed accurate on the frozen section controls, whereas atypical diagnoses were revised to benign (n = 4), atypical (n = 4), and carcinoma (n = 2) on the controls. Ten (77%) of 13 initial FSA-positive (6 of 7)/atypical (4 of 6; excluding benign diagnoses on the controls) cases achieved negative conversion by excision of additional tissue. Thus, final SM was positive in 1 (14%) FSA-positive case, 3 (30%) FSA-atypical cases (including one at the SM where FSA was not sampled), and 2 (4%) FSA-negative cases (at the SM where FSA was not sampled). Kaplan-Meier analysis and log-rank test revealed an association of performing FSA with the risk of disease progression (P = 0.021), but not intravesical recurrence (P = 0.434) or cancer-specific mortality (P = 0.560). Initial positive/atypical FSA, as an independent prognosticator, was associated with reduced progression-free (P = 0.002) and cancer-specific (P = 0.004) survival rates, compared with initial negative FSA. Positive SM was also associated with a larger tumor size (P < 0.05) and a higher risk of intravesical recurrence (P = 0.070) or disease progression (P = 0.096). CONCLUSIONS: Performing FSA during partial cystectomy may contribute to preventing positive SM and disease progression. Additionally, as seen in most of initial FSA-positive/atypical cases that achieved negative conversion, select patients may benefit from the routine FSA. Meanwhile, positive or atypical FSA was associated with significantly poorer prognosis. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Sharma, Meenal AU - Sharma M AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY. FAU - Nagata, Yujiro AU - Nagata Y AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. FAU - Yang, Zhiming AU - Yang Z AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; Department of Urology, University of Rochester Medical Center, Rochester, NY. Electronic address: hiroshi_miyamoto@urmc.rochester.edu. LA - eng PT - Journal Article DEP - 20200508 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - *Frozen Sections MH - Humans MH - Intraoperative Period MH - Male MH - *Margins of Excision MH - Middle Aged MH - Retrospective Studies MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Frozen section assessment OT - Prognosis OT - Surgical margin EDAT- 2020/05/12 06:00 MHDA- 2021/08/06 06:00 CRDT- 2020/05/12 06:00 PHST- 2020/02/17 00:00 [received] PHST- 2020/03/23 00:00 [revised] PHST- 2020/04/05 00:00 [accepted] PHST- 2020/05/12 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2020/05/12 06:00 [entrez] AID - S1078-1439(20)30140-X [pii] AID - 10.1016/j.urolonc.2020.04.012 [doi] PST - ppublish SO - Urol Oncol. 2020 Dec;38(12):933.e1-933.e6. doi: 10.1016/j.urolonc.2020.04.012. Epub 2020 May 8. PMID- 32374509 OWN - NLM STAT- MEDLINE DCOM- 20211013 LR - 20250530 IS - 2056-4538 (Electronic) IS - 2056-4538 (Linking) VI - 6 IP - 4 DP - 2020 Oct TI - Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer. PG - 238-251 LID - 10.1002/cjp2.167 [doi] AB - Approximately 75% of bladder cancers are non-muscle invasive (NMIBC). Of these, up to 53% of cases progress to life-threatening muscle-invasive bladder cancer (MIBC). Patients with high-grade stage T1 (HGT1) NMIBC frequently undergo radical cystectomy (RC), although this represents overtreatment for many. Identification of progressors versus non-progressors could spare unnecessary treatment. Recent studies have confirmed that urothelial carcinoma is composed of two main molecular subtypes, basal and luminal, with 12% of basal tumours exhibiting epithelial-to-mesenchymal transition (EMT). Levels of immune cell infiltration have been shown to be subtype-specific. Here, we performed immunohistochemistry (IHC) for 11 antibodies relating to molecular subtypes or EMT in 26 cases of HGT1 urothelial carcinoma cases with 6 matched samples subsequently obtained at cystectomy (n = 6; 1 muscle-invasive, 5 non-muscle-invasive; 3 = pTis, 1 = pT1, 1 = pTa) and at recurrence (n = 2, pT2). RNAScope was also conducted in a subset. Expression patterns in HGT1 specimens versus MIBC (pT2+) were examined, and correlated with disease-specific survival (DSS). Levels of stromal tumour-infiltrating lymphocytes (sTILs) were assessed manually to determine whether lymphocyte infiltration was associated with DSS and whether differences existed between HGT1 and MIBC. Molecular subtype markers demonstrated increased prognostic potential compared to the EMT markers assessed. Increased expression of the luminal markers FOXA1 and SCUBE2, were found to be significantly associated with better DFS. No EMT markers were significantly associated with DFS. In areas of non-invasive papillary urothelial carcinoma, but not invasive carcinoma, sTIL levels were found to be significantly associated with DFS. While differences were observed between HGT1 cases that progressed versus those that did not, a larger cohort study is required for validation of these findings. Taken together, an emphasis on molecular subtype markers, rather than EMT markers, may be preferable when studying biomarkers of HGT1 urothelial carcinoma in the future. CI - (c) 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. FAU - Ottley, Edward C AU - Ottley EC AD - CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. FAU - Pell, Robert AU - Pell R AD - CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. FAU - Brazier, Benedict AU - Brazier B AD - CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. FAU - Hollidge, Julianne AU - Hollidge J AD - Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. FAU - Kartsonaki, Christiana AU - Kartsonaki C AD - Department of Population Health, University of Oxford, Oxford, UK. FAU - Browning, Lisa AU - Browning L AD - Department of Cellular Pathology, and the NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK. FAU - O'Neill, Eric AU - O'Neill E AD - CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. FAU - Kiltie, Anne E AU - Kiltie AE AUID- ORCID: 0000-0001-7208-2912 AD - CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. LA - eng GR - 23279/CRUK_/Cancer Research UK/United Kingdom GR - C5255/A23755/CRUK_/Cancer Research UK/United Kingdom PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200506 PL - England TA - J Pathol Clin Res JT - The journal of pathology. Clinical research JID - 101658534 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Eur Urol. 2020 Nov;78(5):764. doi: 10.1016/j.eururo.2020.06.019. PMID: 32631743 MH - Biomarkers, Tumor/*analysis/genetics MH - Carcinoma/*chemistry/genetics/immunology/*pathology MH - Cystectomy MH - Disease Progression MH - *Epithelial-Mesenchymal Transition MH - Humans MH - Immunohistochemistry MH - Lymphocytes, Tumor-Infiltrating/immunology MH - Neoplasm Invasiveness MH - Phenotype MH - Pilot Projects MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/*chemistry/genetics/immunology/*pathology PMC - PMC7578305 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - epithelial-to-mesenchymal transition OT - immunohistochemistry OT - molecular subtypes EDAT- 2020/05/07 06:00 MHDA- 2021/10/14 06:00 PMCR- 2020/05/06 CRDT- 2020/05/07 06:00 PHST- 2019/12/04 00:00 [received] PHST- 2020/03/10 00:00 [revised] PHST- 2020/03/20 00:00 [accepted] PHST- 2020/05/07 06:00 [pubmed] PHST- 2021/10/14 06:00 [medline] PHST- 2020/05/07 06:00 [entrez] PHST- 2020/05/06 00:00 [pmc-release] AID - CJP2167 [pii] AID - 10.1002/cjp2.167 [doi] PST - ppublish SO - J Pathol Clin Res. 2020 Oct;6(4):238-251. doi: 10.1002/cjp2.167. Epub 2020 May 6. PMID- 32374123 OWN - NLM STAT- MEDLINE DCOM- 20201201 LR - 20201230 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 46 IP - 4 DP - 2020 Jul-Aug TI - The relation between the storage symptoms before and after transurethral resection of the prostate, analysis of the risk factors and the prevention of the symptoms with solifenacin. PG - 575-584 LID - 10.1590/S1677-5538.IBJU.2019.0227 [doi] AB - OBJECTIVE AND HYPOTHESIS: We aimed to investigate the reasons of storage symptoms ( SS) after transurethral resection of the prostate (TURP). The hypothesis was that a positive correlation would be identified between preoperative and postoperative SS in patients with undergoing TURP and starting early solifenacin treatment in patients with high preoperative SS would be reasonable. In addition, we aimed to analyze multiple other risk factors for post-TURP SS. MATERIALS AND METHODS: A total of 160 patients undergoing TURP were prospectively evaluated and divided into two groups according to their OABS. Those with a score of >/=10 points were Group 1 (G1), and those with < 10 points Group 2 (G2). In addition, patients in each group were randomly further divided into two subgroups: those who were started on 5 mg solifenacin succinate in the early postoperative period (G1/G2 A) and those who were not (G1/G2 B). In additions to SS Preop, perop and at the 3rd-month of postoperatively 14 variable were evaluated. The effects of these factors, surgery and the efficacy of an early medical treatment on the postoperative SS were investigated. LUTS were assessed by International Prostate Symptom Score (IPSS) and SS were assessed by sum of IPSS 2, 4 and 7 questionnaires (Storage, S- IPSS). RESULTS: Preoperative IPSS and S-IPSS were significantly higher in G1 (p< 0.001); there was a significant improvement at IPSS, S-IPSS, QoL score, Qmax, and PVR for all groups after surgery. Only preoperative S-IPSS was found to have significant effect on postoperative SS (p< 0.001). There was a significant difference between G1A and G1B but no significant difference between G2A and G2B in terms of SS at postoperatively. In addition to this, prostatic volume was found smaller than non-symptomatic patients in de novo SS patients. CONCLUSION: TURP provides significant improvement in both storage and voiding symptoms. The predictive value of the preoperative S-IPSS on postop SS is significant. These results suggest that 5 mg solifenacin succinate treatment in the early postoperative period may be beneficial for patients with high preoperative SS and may not be beneficial in others. Small prostatic volume may bode ill for postoperative SS in the patients with de novo SS. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Sipal, Timucin AU - Sipal T AD - Depertment of Urology, Cerkezkoy State Hospital, Tekirdag, Turkey. FAU - Akdere, Hakan AU - Akdere H AD - Depertmen of Urology, Trakya University Medical Faculty, Edirne, Turkey. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - KKA5DLD701 (Solifenacin Succinate) SB - IM MH - Aged MH - Humans MH - Male MH - Middle Aged MH - *Prostatic Hyperplasia/drug therapy/surgery MH - Risk Factors MH - Solifenacin Succinate/therapeutic use MH - *Transurethral Resection of Prostate MH - Treatment Outcome PMC - PMC7239300 OTO - NOTNLM OT - Cystectomy OT - Urinary Bladder Neoplasms OT - Urinary Diversion COIS- None declared. EDAT- 2020/05/07 06:00 MHDA- 2020/12/02 06:00 PMCR- 2020/12/30 CRDT- 2020/05/07 06:00 PHST- 2019/04/04 00:00 [received] PHST- 2019/10/13 00:00 [accepted] PHST- 2020/05/07 06:00 [entrez] PHST- 2020/05/07 06:00 [pubmed] PHST- 2020/12/02 06:00 [medline] PHST- 2020/12/30 00:00 [pmc-release] AID - IBJU20190227 [pii] AID - S1677-5538.IBJU.2019.0227 [pii] AID - 10.1590/S1677-5538.IBJU.2019.0227 [doi] PST - ppublish SO - Int Braz J Urol. 2020 Jul-Aug;46(4):575-584. doi: 10.1590/S1677-5538.IBJU.2019.0227. PMID- 32373518 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - Perioperative Chemotherapy on Survival in Patients With Upper Urinary Tract Urothelial Carcinoma Undergoing Nephroureterectomy: A Population-Based Study. PG - 481 LID - 10.3389/fonc.2020.00481 [doi] LID - 481 AB - Objectives: To estimate the stage-specific impact of perioperative chemotherapy on survival for upper urinary tract urothelial carcinoma (UTUC) patients treated with nephroureterectomy (NU). Methods: Overall, 7,278 UTUC patients treated with NU from 2004 to 2015 were identified within the SEER database. Kaplan-Meier plots were used to elucidate overall survival (OS) and cancer-specific survival (CSS) rates. Multivariable Cox regression analyses were used to test the impact of chemotherapy on survival rates, after stratifying according to pathological stage. Results: Chemotherapy was performed in 17.3% of patients and in 5.7, 11.5, 25.4, and 51.3% of patients with, respectively, pT1, pT2, pT3, and pT4 disease (P < 0.001). In multivariable analyses, perioperative chemotherapy was associated with a lower OS in pT2 patients and a lower CSS in pT1 disease (both P < 0.05), while predisposed to a higher OS in pT3 and pT4 patients (both P < 0.01). Moreover, perioperative chemotherapy was prone to a higher OS or CSS in pN+ disease compared to no chemotherapy (both P < 0.01). Conclusion: Perioperative chemotherapy was more frequently performed in locally advanced UTUC patients. The beneficial effect of chemotherapy on OS was evident in pT3/pT4 and pN+ patients. In addition, a clear CSS benefit was observed in patients who received chemotherapy for pN+ UTUC, while perioperative chemotherapy may reduce CSS for pT1 and OS for pT2 patients following NU. CI - Copyright (c) 2020 Zhai, Jin, Feng, Zhou, Liu, Liu, Ma, Lu, Chen, Yao and Ye. FAU - Zhai, Ting-Shuai AU - Zhai TS AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Jin, Liang AU - Jin L AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Feng, Li-Ming AU - Feng LM AD - Department of Urology, Shawan People's Hospital, Tacheng, China. FAU - Zhou, Zhen AU - Zhou Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Department of Urology, First Clinical Medical College, Nanjing Medical University, Nanjing, China. FAU - Liu, Xiang AU - Liu X AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Department of Urology, Shanghai Putuo District People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, Huan AU - Liu H AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Ma, Wei-Guo AU - Ma WG AD - Department of Urology, Karamay Central Hospital, Karamay, China. AD - Department of Urology, Tongxin People's Hospital, Wuzhong, China. FAU - Lu, Jing-Yi AU - Lu JY AD - Department of Urology, Karamay Central Hospital, Karamay, China. FAU - Chen, Wei AU - Chen W AD - Department of Urology, Shawan People's Hospital, Tacheng, China. FAU - Yao, Xu-Dong AU - Yao XD AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Ye, Lin AU - Ye L AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Department of Urology, Karamay Central Hospital, Karamay, China. LA - eng PT - Journal Article DEP - 20200421 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7186446 OTO - NOTNLM OT - Epidemiology and End Results (SEER) program OT - Surveillance OT - chemotherapy OT - neoplasm staging OT - survival analysis OT - upper urinary tract urothelial carcinoma EDAT- 2020/05/07 06:00 MHDA- 2020/05/07 06:01 PMCR- 2020/01/01 CRDT- 2020/05/07 06:00 PHST- 2019/06/01 00:00 [received] PHST- 2020/03/17 00:00 [accepted] PHST- 2020/05/07 06:00 [entrez] PHST- 2020/05/07 06:00 [pubmed] PHST- 2020/05/07 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.00481 [doi] PST - epublish SO - Front Oncol. 2020 Apr 21;10:481. doi: 10.3389/fonc.2020.00481. eCollection 2020. PMID- 32369816 OWN - NLM STAT- MEDLINE DCOM- 20210304 LR - 20210304 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 104 IP - 5-6 DP - 2020 TI - Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. PG - 396-401 LID - 10.1159/000507122 [doi] AB - INTRODUCTION: Evidence that smoking cessation at first diagnosis of nonmuscle-invasive bladder cancer (NMIBC) reduces the risk of recurrence is lacking. The aim of our prospective study was to analyze the association between patients' changes in smoking habits after diagnosis and recurrence-free survival (RFS). PATIENTS: After transurethral resection of primary NMIBC, patients were classified as "ex-smokers," i.e., those definitively stopping, and as "active smokers," i.e., those continuing or restarting to smoke. Smoking status was reassessed every 3 months during the first year and every 6 months thereafter. Data on patients' demographics, smoking status, tumor characteristics, treatments, and follow-up were collected. Statistical analysis was performed adopting SPSS 15.0.1 and R3.4.2 software. RESULTS: Out of 194 patients, 67 (34.5%) quit smoking after the diagnosis, while 127 (65.5%) did not. The clinical and pathological characteristics were homogeneously distributed. At a median follow-up of 38 months, 106 patients (54.6%) recurred, 33 (49.2%) ex- and 73 (60.3%) active smokers with a 3-year RFS of 42.3 and 50.7%, respectively (p = 0.55). No statistically significant association between recurrence, pathological features of the primary tumor, and patient smoking habits after diagnosis was detected. Results were not statistically influenced by the intensity (cigarette/day) and duration (years) of smoking. In multivariate analysis, cigarette smoking cessation at diagnosis did not significantly reduce tumor recurrence. CONCLUSION: In our prospective study, more than half of our patients recurred at 3 years. In multivariate analysis, smoking cessation did not significantly reduce tumor recurrence. However, the 8.4% reduction in favor of the ex-smokers suggests the need of larger studies with longer follow-ups. Surprisingly, only 35% of smokers definitively quit after diagnosis. The urologists should play a more active role to persuade the patients to stop smoking at first cancer diagnosis. CI - (c) 2020 S. Karger AG, Basel. FAU - Serretta, Vincenzo AU - Serretta V AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy, vserretta@libero.it. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Baiamonte, Davide AU - Baiamonte D AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Vella, Marco AU - Vella M AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Pavone, Carlo AU - Pavone C AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Cacciatore, Loris AU - Cacciatore L AD - Division of Urology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Valerio, Maria Rosaria AU - Valerio MR AD - Division of Medical Oncology, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Scalici Gesolfo, Cristina AU - Scalici Gesolfo C AD - Division of Urology, Paolo Borsellino Hospital, Marsala, Italy. FAU - Sanfilippo, Chiara AU - Sanfilippo C AD - Statistics, GSTU Foundation, Palermo, Italy. LA - eng PT - Journal Article DEP - 20200505 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Disease-Free Survival MH - Humans MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control MH - Prospective Studies MH - *Smoking Cessation MH - Urinary Bladder Neoplasms/pathology/*prevention & control/*surgery OTO - NOTNLM OT - Cigarette smoking OT - Nonmuscle-invasive bladder cancer OT - Recurrence EDAT- 2020/05/06 06:00 MHDA- 2021/03/05 06:00 CRDT- 2020/05/06 06:00 PHST- 2020/01/19 00:00 [received] PHST- 2020/03/10 00:00 [accepted] PHST- 2020/05/06 06:00 [pubmed] PHST- 2021/03/05 06:00 [medline] PHST- 2020/05/06 06:00 [entrez] AID - 000507122 [pii] AID - 10.1159/000507122 [doi] PST - ppublish SO - Urol Int. 2020;104(5-6):396-401. doi: 10.1159/000507122. Epub 2020 May 5. PMID- 32364756 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20221207 IS - 1557-8852 (Electronic) IS - 1084-9785 (Linking) VI - 35 IP - 8 DP - 2020 Oct TI - Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy. PG - 563-569 LID - 10.1089/cbr.2019.3455 [doi] AB - Objective: To prevent postoperative relapse after HOLRBT, we compared postoperative adjuvant therapies. Methods: One hundred fifty patients with non-muscle invasive bladder cancer (NMIBC) were meanly divided into three groups: A, B, and C. Group A patients only took sunitinib, group B patients underwent TGC perfusion chemotherapy, and group C patients took sunitinib and underwent TGC chemotherapy. Results: It was discovered that TGC perfusion chemotherapy combined with taking sunitinib can significantly reduce the relapse rate. Most of the tumor relapse period was assembled at 9 months after the operation. No-tumor relapse survival rate and no-fluorescence in situ hybridization positive survival rate in Group C were significantly higher than those of Group A and Group B. Conclusion: Therefore, the combined application of taking sunitinib drug and going through TGC perfusion chemotherapy after secondary HOLRBT will evidently improve the prognosis of patients with a glorious applicated prospect. FAU - Li, Songjiang AU - Li S AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Zhao, Kai AU - Zhao K AD - Department of Urology, Gaotang People's Hospital, Gaotang, China. FAU - Jin, Yueli AU - Jin Y AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Ma, Zheng AU - Ma Z AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Sun, Rong AU - Sun R AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Zhao, Wei AU - Zhao W AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Yan, Huilei AU - Yan H AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. FAU - Li, Yuqiao AU - Li Y AD - Department of Urology, Liaocheng People's Hospital, Liaocheng City, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20200501 PL - United States TA - Cancer Biother Radiopharm JT - Cancer biotherapy & radiopharmaceuticals JID - 9605408 RN - 0W860991D6 (Deoxycytidine) RN - P88XT4IS4D (Paclitaxel) RN - Q20Q21Q62J (Cisplatin) RN - V99T50803M (Sunitinib) RN - 0 (Gemcitabine) SB - IM MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects MH - Chemotherapy, Adjuvant/adverse effects/methods MH - Chemotherapy, Cancer, Regional Perfusion/adverse effects/methods MH - Cisplatin/administration & dosage/adverse effects MH - Cystectomy/*methods MH - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives MH - Disease-Free Survival MH - Double-Blind Method MH - Female MH - Humans MH - Lasers, Solid-State/*therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Paclitaxel/administration & dosage/adverse effects MH - Prognosis MH - Sunitinib/administration & dosage/adverse effects MH - Survival Rate MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Gemcitabine OTO - NOTNLM OT - HOLRBT OT - NMIBC OT - TGC OT - chemotherapy OT - relapse OT - sunitinib EDAT- 2020/05/05 06:00 MHDA- 2021/06/29 06:00 CRDT- 2020/05/05 06:00 PHST- 2020/05/05 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/05/05 06:00 [entrez] AID - 10.1089/cbr.2019.3455 [doi] PST - ppublish SO - Cancer Biother Radiopharm. 2020 Oct;35(8):563-569. doi: 10.1089/cbr.2019.3455. Epub 2020 May 1. PMID- 32364521 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20210621 IS - 2501-062X (Electronic) IS - 1220-4749 (Linking) VI - 58 IP - 3 DP - 2020 Sep 1 TI - Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer. PG - 146-152 LID - 10.2478/rjim-2020-0008 [doi] AB - INTRODUCTION: Bladder cancer is the most common malignancy involving the urinary system. Recent research tends to emphasize the role of oxidative stress products in the carcinogenesis of bladder cancer. The level of oxidative stress can be measured by assessing the MDA levels. This study aimed to evaluate serum MDA levels in patients with bladder cancer, as well as to determine its potential role as a biomarker in the diagnosis of the disease and progression risk considerations. METHODS: The study was designed as a cross-sectional study and included 90 patients, divided into three groups with 30 patients each: Ta, T1and T2-T4 group, based on histopathological findings after transurethral resection of the tumor. The control group included 30 healthy volunteers. MDA level was determined using the spectrophotometric method. RESULTS: Serum MDA level in patients with bladder cancer [0.86 (0.78-1.05) mumol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69-0.72) mumol/L] (p < 0.001). Serum MDA level in Ta group [0.73 (0.70-1.05) mumol/L], T1 group [0.85 (0.80-1.12) mumol/L] and in T2-T4 group [0.91 (0.84-1.04) mumol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69-0.72) mumol/L] (p < 0.01). MDA level in T1 and T2-T4 group was significantly higher than the MDA level in Ta group (p < 0.01). No significant difference was observed in MDA level between T1 and T2-T4 group (p = NS). A statistically significant positive correlation was found between tumor size and serum MDA level in patients with bladder cancer (rho = 0.254 p < 0.01). CONCLUSIONS: The results of the present study suggest that MDA serum level might play a significant role as a biomarker in the diagnosis of bladder cancer, as well as in the monitoring of its progression. FAU - Lepara, Zahid AU - Lepara Z AD - Urology Clinic, Clinical Center University of Sarajevo, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina. FAU - Lepara, Orhan AU - Lepara O AD - Department of Physiology, Faculty of Medicine, University of Sarajevo, Cekalusa 90, 71 000 Sarajevo, Bosnia and Herzegovina. FAU - Fajkic, Almir AU - Fajkic A AD - Department of Pathophysiology, Faculty of Medicine, University of Sarajevo, Cekalusa 90, 71 000 Sarajevo, Bosnia and Herzegovina. FAU - Rebic, Damir AU - Rebic D AD - Nephrology Clinic, Clinical Center University of Sarajevo, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina. FAU - Alic, Jasmin AU - Alic J AD - Urology Clinic, Clinical Center University of Sarajevo, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina. FAU - Spahovic, Hajrudin AU - Spahovic H AD - Urology Clinic, Clinical Center University of Sarajevo, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina. LA - eng PT - Journal Article PL - Germany TA - Rom J Intern Med JT - Romanian journal of internal medicine = Revue roumaine de medecine interne JID - 9304507 RN - 0 (Biomarkers, Tumor) RN - 4Y8F71G49Q (Malondialdehyde) SB - IM MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor MH - Case-Control Studies MH - Cross-Sectional Studies MH - Disease Progression MH - Female MH - Humans MH - Male MH - Malondialdehyde/*blood MH - Middle Aged MH - ROC Curve MH - Tumor Burden MH - Urinary Bladder Neoplasms/*blood/diagnosis/*pathology OTO - NOTNLM OT - biomarker OT - bladder cancer OT - cancer progression OT - malondialdehyde OT - oxidative stress EDAT- 2020/05/05 06:00 MHDA- 2021/06/22 06:00 CRDT- 2020/05/05 06:00 PHST- 2020/02/14 00:00 [received] PHST- 2020/05/05 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/05/05 06:00 [entrez] AID - /j/rjim.ahead-of-print/rjim-2020-0008/rjim-2020-0008.xml [pii] AID - 10.2478/rjim-2020-0008 [doi] PST - ppublish SO - Rom J Intern Med. 2020 Sep 1;58(3):146-152. doi: 10.2478/rjim-2020-0008. PMID- 32360052 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20220428 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 79 IP - 1 DP - 2021 Jan TI - European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. PG - 82-104 LID - S0302-2838(20)30230-X [pii] LID - 10.1016/j.eururo.2020.03.055 [doi] AB - CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). OBJECTIVE: To provide practical evidence-based recommendations and consensus statements on the clinical management of MMIBC with a focus on diagnosis and treatment. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the MMIBC guideline has been performed annually since its 2017 publication (based on the 2016 guideline). Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. A level of evidence and a grade of recommendation were assigned. Additionally, the results of a collaborative multistakeholder consensus project on advanced bladder cancer (BC) have been incorporated in the 2020 guidelines, addressing those areas where it is unlikely that prospective comparative studies will be conducted. EVIDENCE SYNTHESIS: Variant histologies are increasingly reported in invasive BC and are relevant for treatment and prognosis. Staging is preferably done with (enhanced) computerised tomography scanning. Treatment decisions are still largely based on clinical factors. Radical cystectomy (RC) with lymph node dissection remains the recommended treatment in highest-risk non-muscle-invasive and muscle-invasive nonmetastatic BC, preceded by cisplatin-based neoadjuvant chemotherapy (NAC) for invasive tumours in "fit" patients. Selected men and women benefit from sexuality sparing RC, although this is not recommended as standard therapy. Open and robotic RC show comparable outcomes, provided the procedure is performed in experienced centres. For open RC 10, the minimum selected case load is 10 procedures per year. If bladder preservation is considered, chemoradiation is an alternative in well-selected patients without carcinoma in situ and after maximal resection. Adjuvant chemotherapy should be considered if no NAC was given. Perioperative immunotherapy can be offered in clinical trial setting. For fit metastatic patients, cisplatin-based chemotherapy remains the first choice. In cisplatin-ineligible patients, immunotherapy in Programmed Death Ligand 1 (PD-L1)-positive patients or carboplatin in PD-L1-negative patients is recommended. For second-line treatment in metastatic disease, pembrolizumab is recommended. Postchemotherapy surgery may prolong survival in responders. Quality of life should be monitored in all phases of treatment and follow-up. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/. CONCLUSIONS: This summary of the 2020 EAU MMIBC guideline provides updated information on the diagnosis and treatment of MMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Muscle-invasive and Metastatic Bladder Cancer (MMIBC) Panel has released an updated version of their guideline, which contains information on histology, staging, prognostic factors, and treatment of MMIBC. The recommendations are based on the current literature (until the end of 2019), with emphasis on high-level data from randomised clinical trials and meta-analyses and on the findings of an international consensus meeting. Surgical removal of the bladder and bladder preservation are discussed, as well as the use of chemotherapy and immunotherapy in localised and metastatic disease. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: Fred.Witjes@radboudumc.nl. FAU - Bruins, Harman Max AU - Bruins HM AD - Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, The Netherlands. FAU - Cathomas, Richard AU - Cathomas R AD - Department of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Sorbonne University, Assistance Publique-Hopitaux de Paris, Hopital Tenon, Paris, France. FAU - Cowan, Nigel C AU - Cowan NC AD - Department of Radiology, The Queen Alexandra Hospital, Portsmouth, UK. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology and Pediatric Urology, University of Wurzburg, Wurzburg, Germany. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Linares Espinos, Estefania AU - Linares Espinos E AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Lorch, Anja AU - Lorch A AD - Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Rouanne, Mathieu AU - Rouanne M AD - Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, Inselspital, University Hospital Bern, Switzerland. FAU - Veskimae, Erik AU - Veskimae E AD - Department of Urology, Tampere University Hospital, Tampere, Finland. FAU - Ribal, Maria J AU - Ribal MJ AD - Department of Urology, Hospital Clinic, University of Barcelona, Barcelona, Spain. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20200429 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2021 Jan;79(1):105-106. doi: 10.1016/j.eururo.2020.04.054. PMID: 32360051 CIN - Eur Urol. 2020 Oct;78(4):492-493. doi: 10.1016/j.eururo.2020.07.006. PMID: 32693931 CIN - Eur Urol. 2020 Oct;78(4):489-491. doi: 10.1016/j.eururo.2020.06.035. PMID: 32736929 CIN - Eur Urol. 2021 Jan;79(1):e29. doi: 10.1016/j.eururo.2020.08.003. PMID: 32819787 CIN - J Urol. 2022 May;207(5):1153-1155. doi: 10.1097/JU.0000000000002460. PMID: 35139651 MH - Decision Trees MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Urinary Bladder Neoplasms/*diagnosis/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Diagnosis OT - European Association of Urology OT - Follow-up OT - Guidelines OT - Management OT - Metastatic OT - Multimodality OT - Muscle invasive OT - Quality of life EDAT- 2020/05/04 06:00 MHDA- 2021/09/28 06:00 CRDT- 2020/05/04 06:00 PHST- 2020/03/24 00:00 [received] PHST- 2020/03/31 00:00 [accepted] PHST- 2020/05/04 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2020/05/04 06:00 [entrez] AID - S0302-2838(20)30230-X [pii] AID - 10.1016/j.eururo.2020.03.055 [doi] PST - ppublish SO - Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29. PMID- 32340875 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 6 DP - 2020 Dec TI - Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. PG - 500-508 LID - S1558-7673(20)30053-7 [pii] LID - 10.1016/j.clgc.2020.03.004 [doi] AB - BACKGROUND: Myeloid-derived suppressor cells (MDSC) have immunosuppressive activity and enhance tumor progression. We hypothesized that lower blood MDSC would correlate with pathologic complete response and better outcomes in nonmetastatic urothelial carcinoma (UC). PATIENTS AND METHODS: Before cystectomy, blood MDSC were measured in whole blood (WB) and peripheral blood mononuclear cells using flow cytometry. MDSC were defined as CD33(+)/HLA-DR(-). MDSC subtypes were polymorphonuclear MDSC (CD15(+)/CD14(-)), monocytic (M)-MDSC (CD15(-)/CD14(+)), and uncommitted (UnC) MDSC (CD15(-)/CD14(-)). The Wilcoxon rank sum test was used to compare MDSC between pathologic complete response groups. The optimal cutoff points for MDSC were identified using recursive partitioning analysis with cross-validation. The Cox proportional hazard model was used to associate MDSC and other clinical factors with recurrence-free survival and overall survival (OS). RESULTS: Overall, 109 patients were included: 86% men with median (range) age of 67 (30-88) years, 76% with pure UC, 29% intravesical therapy, and 41% neoadjuvant chemotherapy. Twenty-one patients (19%) had pT0N0 and 23 (24%) < pT2N0. Median (range) follow-up time was 17.4 (0.4-42.4) months. Total MDSC and polymorphonuclear MDSC percentage in peripheral blood mononuclear cells was significantly lower in patients with pT0N0 disease (P = .03). One- and 2-year OS rates were 94% (95% confidence interval [CI], 90-99) and 83% (95% CI, 75-93), respectively. In the multivariate Cox model after adjusting for age and gender, patients with higher WB M-MDSC and UnC-MDSC had shorter OS (optimal cutoff points by recursive partitioning analysis, hazard ratio = 7.5 [95% CI, 2.5-22.8], P = .0004; hazard ratio = 3.4 [95% CI, 1.0-11.0], P = .046, respectively). CONCLUSION: In patients with nonmetastatic UC of bladder, higher WB M-MDSC and UnC-MDSC before cystectomy had negative prognostic value. Prospective validation is warranted. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fallah, Jaleh AU - Fallah J AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Diaz-Montero, Claudia Marcela AU - Diaz-Montero CM AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Rayman, Patricia AU - Rayman P AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Wei, Wei AU - Wei W AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Finke, James H AU - Finke JH AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Kim, Jin S AU - Kim JS AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Pavicic, Paul G Jr AU - Pavicic PG Jr AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Lamenza, Marcelo AU - Lamenza M AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Dann, Priscilla AU - Dann P AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Company, Donna AU - Company D AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Stephenson, Andrew AU - Stephenson A AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Campbell, Steven AU - Campbell S AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Haber, George AU - Haber G AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Lee, Byron AU - Lee B AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Mian, Omar AU - Mian O AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Gilligan, Timothy AU - Gilligan T AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Garcia, Jorge A AU - Garcia JA AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Rini, Brian AU - Rini B AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Division of Hematology & Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN. FAU - Ornstein, Moshe C AU - Ornstein MC AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: ornstem@ccf.org. FAU - Grivas, Petros AU - Grivas P AD - Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: pgrivas@uw.edu. LA - eng GR - L30 CA220908/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20200319 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Aged, 80 and over MH - *Carcinoma, Transitional Cell MH - Female MH - Humans MH - Leukocytes, Mononuclear MH - Male MH - *Myeloid-Derived Suppressor Cells MH - *Urinary Bladder Neoplasms/drug therapy OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Cystectomy OT - Immune system OT - Immunosuppression EDAT- 2020/04/29 06:00 MHDA- 2021/08/19 06:00 CRDT- 2020/04/29 06:00 PHST- 2019/12/22 00:00 [received] PHST- 2020/03/02 00:00 [revised] PHST- 2020/03/03 00:00 [accepted] PHST- 2020/04/29 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2020/04/29 06:00 [entrez] AID - S1558-7673(20)30053-7 [pii] AID - 10.1016/j.clgc.2020.03.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Dec;18(6):500-508. doi: 10.1016/j.clgc.2020.03.004. Epub 2020 Mar 19. PMID- 32336149 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 34 IP - 8 DP - 2020 Aug TI - The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. PG - 795-804 LID - 10.1089/end.2020.0301 [doi] AB - Background: T1, high-grade, nonmuscle-invasive bladder cancer (NMIBC) is characterized by a high recurrence rate and progression to muscle-invasive disease concerns a significant number of patients. To overcome limitations of initial transurethral resection of bladder tumor (TURBT), various strategies are proposed in the literature. One of them is performance of restaging TURBT (re-TURBT). In recent years, it has been shown that re-TURBT can provide valuable additional pathologic information. However, its potential effect on survival improvement is debatable and benefits from this procedure have been suggested to be dependent on several clinicopathological factors (e.g., the presence of detrusor muscle in initial TURBT). Evidence Acquisition: A systematic search was conducted within the three electronic databases, including Medline, Scopus, and Embase. The following outcomes were retrieved: outcome measurements of recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), including hazard ratios and 95% confidence intervals. Initially, a main analysis for each outcome (RFS, PFS, CSS, and OS) was performed. Subsequently, we conducted subgroup analyses for the following factors: T1 grade, presence of detrusor muscle in initial TURBT, and type of adjuvant intravesical therapy. Evidence Synthesis: Finally, six studies with overall 3257 participants were identified for this meta-analysis. A significant impact of re-TURBT on RFS, PFS, CSS, and OS was not found in the overall analysis that included all patients with T1 bladder tumors. On the other hand, subgroup analyses, including studies reporting cohorts with mixed T1 tumor grading, revealed that re-TURBT was associated with significantly better RFS, PFS, and OS. Conclusions: This meta-analysis shows that re-TURBT does not improve survival outcomes in patients with T1 tumors; however, results of some particular subgroup analyses indicate its potential positive impact on the subsequent course of the disease. Furthermore, high-quality, prospective, randomized controlled trials are necessary to make a final statement about the therapeutic role of re-TURBT in T1 NMIBC. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Nowak, Lukasz AU - Nowak L AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Tukiendorf, Andrzej AU - Tukiendorf A AD - Department of Public Health, Wroclaw Medical University, Wroclaw, Poland. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Di Trapani, Ettore AU - Di Trapani E AD - European Institute of Oncology, Milan, Italy. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris, France. FAU - Kielb, Pawel AU - Kielb P AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. FAU - Welna, Marek AU - Welna M AD - Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200603 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local/surgery MH - Prospective Studies MH - *Urinary Bladder Neoplasms/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - bladder cancer OT - repeat OT - restaging OT - second look OT - transurethral resection EDAT- 2020/04/28 06:00 MHDA- 2021/04/28 06:00 CRDT- 2020/04/28 06:00 PHST- 2020/04/28 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/04/28 06:00 [entrez] AID - 10.1089/end.2020.0301 [doi] PST - ppublish SO - J Endourol. 2020 Aug;34(8):795-804. doi: 10.1089/end.2020.0301. Epub 2020 Jun 3. PMID- 32335060 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 6 DP - 2020 Dec TI - Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. PG - e651-e659 LID - S1558-7673(20)30075-6 [pii] LID - 10.1016/j.clgc.2020.03.013 [doi] AB - INTRODUCTION: The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or immunotherapy. PATIENTS AND METHODS: We identified 4900 patients with histologically confirmed, clinically non-metastatic high-grade T1 bladder cancer undergoing surgical intervention using the National Cancer Database for the period 2010 to 2015. Multivariable logistic regression was used to examine predictors for the receipt of early radical cystectomy (defined as radical cystectomy within 90 days of diagnosis). We then employed multivariable Cox proportional hazards regression models and Kaplan-Meier curves to evaluate the OS according to surgical treatment (early radical cystectomy vs. local treatment). RESULTS: A minority (23.7%) of patients underwent early radical cystectomy. Independent predictors of undergoing early radical cystectomy included lower age, White race, and lower comorbidity status. The median OS was 74.0 months for patients diagnosed with high-grade T1 bladder cancer. The 1- and 5-year survival rates of patients undergoing early radical cystectomy were 94.8% and 71.0%, whereas they were 85.2% and 52.4%, for patients undergoing initial local treatment, respectively (P < .001). Compared with patients undergoing local treatment, patients undergoing early radical cystectomy had a lower risk of all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.67-0.91; P = .002). CONCLUSION: In this cohort of patients presenting with high-grade T1 non-muscle-invasive bladder cancer, we found that early radical cystectomy was associated with an OS benefit compared with initial local treatment. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Tully, Karl H AU - Tully KH AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Chen, Xi AU - Chen X AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Hauser, Lorine AU - Hauser L AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Kibel, Adam S AU - Kibel AS AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Sonpavde, Guru P AU - Sonpavde GP AD - Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA. FAU - Mossanen, Matthew AU - Mossanen M AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: trinh.qd@gmail.com. LA - eng PT - Journal Article DEP - 20200331 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - *Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - NMIBC OT - Pelvic lymph node dissection OT - Radical Cystectomy OT - Transurethral resection EDAT- 2020/04/27 06:00 MHDA- 2021/08/19 06:00 CRDT- 2020/04/27 06:00 PHST- 2019/11/06 00:00 [received] PHST- 2020/03/20 00:00 [revised] PHST- 2020/03/22 00:00 [accepted] PHST- 2020/04/27 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2020/04/27 06:00 [entrez] AID - S1558-7673(20)30075-6 [pii] AID - 10.1016/j.clgc.2020.03.013 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Dec;18(6):e651-e659. doi: 10.1016/j.clgc.2020.03.013. Epub 2020 Mar 31. PMID- 32322885 OWN - NLM STAT- MEDLINE DCOM- 20200706 LR - 20200706 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 50 IP - 6 DP - 2020 Jun 10 TI - Second transurethral resection for high-risk non-muscle invasive bladder cancer patients: a propensity score matched analysis. PG - 718-721 LID - 10.1093/jjco/hyaa041 [doi] AB - OBJECTIVES: Second transurethral resection is recommended for patients diagnosed with high-risk non-muscle invasive bladder cancer; however, there have been several studies showing conflicting findings regarding the advantage of second transurethral resection. The objective of this study was to investigate the prognostic significance of second transurethral resection using propensity score matched analysis. PATIENTS AND METHODS: This study retrospectively included 164 consecutive patients who underwent initial transurethral resection and were diagnosed with high-risk non-muscle invasive bladder cancer. Of these, 56 subsequently received second transurethral resection, and the remaining 108 underwent initial transurethral resection alone. RESULTS: After adjusting patient variables by propensity score matching, 44 patients were included in each group. There was no significant difference in recurrence-free, progression-free or overall survival between these two groups. CONCLUSIONS: These findings suggested no significant impact of second transurethral resection on the prognosis of high-risk non-muscle invasive bladder cancer patients; therefore, it may be necessary to perform a reassessment focusing on the indication for second transurethral resection by conducting a large-scale prospective study. CI - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Matsushita, Yuto AU - Matsushita Y AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Watanabe, Kyohei AU - Watanabe K AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Watanabe, Hiromitsu AU - Watanabe H AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Tamura, Keita AU - Tamura K AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Motoyama, Daisuke AU - Motoyama D AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Ito, Toshiki AU - Ito T AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Sugiyama, Takayuki AU - Sugiyama T AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Otsuka, Atsushi AU - Otsuka A AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. FAU - Miyake, Hideaki AU - Miyake H AD - Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Prognosis MH - Progression-Free Survival MH - Propensity Score MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*surgery MH - *Urologic Surgical Procedures OTO - NOTNLM OT - high-risk non-muscle invasive bladder cancer OT - prognosis OT - propensity score matched analysis OT - second TUR EDAT- 2020/04/24 06:00 MHDA- 2020/07/07 06:00 CRDT- 2020/04/24 06:00 PHST- 2020/01/30 00:00 [received] PHST- 2020/03/09 00:00 [revised] PHST- 2020/03/12 00:00 [accepted] PHST- 2020/04/24 06:00 [pubmed] PHST- 2020/07/07 06:00 [medline] PHST- 2020/04/24 06:00 [entrez] AID - 5823898 [pii] AID - 10.1093/jjco/hyaa041 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2020 Jun 10;50(6):718-721. doi: 10.1093/jjco/hyaa041. PMID- 32318846 OWN - NLM STAT- MEDLINE DCOM- 20210118 LR - 20261010 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 30 IP - 9 DP - 2020 Sep TI - Elaboration of a multisequence MRI-based radiomics signature for the preoperative prediction of the muscle-invasive status of bladder cancer: a double-center study. PG - 4816-4827 LID - 10.1007/s00330-020-06796-8 [doi] AB - OBJECTIVES: To develop a multisequence MRI-based radiomics signature for the preoperative prediction of the muscle-invasive status of bladder cancer (BCa). METHODS: This retrospective study involved 106 eligible patients from two independent clinical centers. All patients underwent a preoperative 3.0 T MRI scan with T2-weighted image (T2WI) and multi-b-value diffusion-weighted image (DWI) sequences. In total, 1404 radiomics features were extracted from the largest region of the reported tumor locations on the T2WI, DWI, and corresponding apparent diffusion coefficient map (ADC) of each patient. A radiomics signature, namely the Radscore, was then generated using the recursive feature elimination approach and a logistic regression algorithm in a training cohort (n = 64). Its performance was then validated in an independent validation cohort (n = 42). The primary imaging and clinical factors in conjunction with the Radscore were used to determine whether the performance could be further improved. RESULTS: The Radscore, generated by 36 selected radiomics features, demonstrated a favorable ability to predict muscle-invasive BCa status in both the training (AUC 0.880) and validation (AUC 0.813) cohorts. Subsequently, integrating the two independent predictors (including the Radscore and MRI-determined tumor stalk) into a nomogram exhibited more favorable discriminatory performance, with the AUC improved to 0.924 and 0.877 in both cohorts, respectively. CONCLUSIONS: The proposed multisequence MRI-based radiomics signature alone could be an effective tool for quantitative prediction of muscle-invasive status of BCa. Integrating the Radscore with MRI-determined tumor stalk could further improve the discriminatory power, realizing more accurate prediction of nonmuscle-invasive and muscle-invasive BCa. KEY POINTS: * DWI is superior to T2WI sequence in reflecting the heterogeneous differences between NMIBC and MIBC, and multisequence MRI helps in the preoperative prediction of muscle-invasive status of BCa. * Co-occurrence (CM), run-length matrix (RLM), and gray-level size zone matrix (GLSZM) features were the favorable feature categories for the prediction of muscle-invasive status of BCa. * The Radscore (proposed multisequence MRI-based radiomics signature) helps predict preoperatively muscle invasion. Combination with the MRI-determined tumor stalk further improves prediction. FAU - Wang, Huanjun AU - Wang H AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, People's Republic of China. FAU - Xu, Xiaopan AU - Xu X AD - School of Biomedical Engineering, Air Force Medical University (Fourth Military Medical University), No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China. FAU - Zhang, Xi AU - Zhang X AD - School of Biomedical Engineering, Air Force Medical University (Fourth Military Medical University), No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China. FAU - Liu, Yang AU - Liu Y AD - School of Biomedical Engineering, Air Force Medical University (Fourth Military Medical University), No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China. FAU - Ouyang, Longyuan AU - Ouyang L AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, People's Republic of China. FAU - Du, Peng AU - Du P AD - School of Biomedical Engineering, Air Force Medical University (Fourth Military Medical University), No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China. FAU - Li, Shurong AU - Li S AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, People's Republic of China. FAU - Tian, Qiang AU - Tian Q AD - Department of Radiology, Tangdu Hospital, Air Force Medical University (Fourth Military Medical University), Xi'an, Shaanxi, People's Republic of China. FAU - Ling, Jian AU - Ling J AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, People's Republic of China. FAU - Guo, Yan AU - Guo Y AD - Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, People's Republic of China. dr.guoyan@163.com. FAU - Lu, Hongbing AU - Lu H AD - School of Biomedical Engineering, Air Force Medical University (Fourth Military Medical University), No. 169 Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China. luhb@fmmu.edu.cn. LA - eng GR - 81701747/National Natural Science Foundation of China/ GR - 81871424/National Natural Science Foundation of China/ GR - 81901698/National Natural Science Foundation of China/ GR - 2017YFC0107400/National Key Research and Development Program of China/ GR - 2017A030313902/Natural Science Foundation of Guangdong Province/ PT - Journal Article PT - Multicenter Study DEP - 20200421 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - *Algorithms MH - Diffusion Magnetic Resonance Imaging/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Nomograms MH - Predictive Value of Tests MH - Preoperative Period MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/surgery MH - *Urologic Surgical Procedures OTO - NOTNLM OT - Apparent diffusion coefficient OT - Bladder cancer OT - Diffusion-weighted image OT - Logistic regression algorithm OT - MRI EDAT- 2020/04/23 06:00 MHDA- 2021/01/20 06:00 CRDT- 2020/04/23 06:00 PHST- 2019/09/02 00:00 [received] PHST- 2020/03/06 00:00 [accepted] PHST- 2019/12/19 00:00 [revised] PHST- 2020/04/23 06:00 [pubmed] PHST- 2021/01/20 06:00 [medline] PHST- 2020/04/23 06:00 [entrez] AID - 10.1007/s00330-020-06796-8 [pii] AID - 10.1007/s00330-020-06796-8 [doi] PST - ppublish SO - Eur Radiol. 2020 Sep;30(9):4816-4827. doi: 10.1007/s00330-020-06796-8. Epub 2020 Apr 21. PMID- 32314931 OWN - NLM STAT- MEDLINE DCOM- 20201029 LR - 20201029 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 204 IP - 4 DP - 2020 Oct TI - Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. PG - 685-690 LID - 10.1097/JU.0000000000001084 [doi] AB - PURPOSE: Detection of MCM5 containing cells in urine has been shown to be indicative of the presence of a bladder tumor on primary diagnosis. In this study we evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in nonmuscle invasive bladder cancer followup. MATERIALS AND METHODS: A multicenter prospective blinded study was performed at 21 European centers with patients undergoing cystoscopy for nonmuscle invasive bladder cancer surveillance, diagnosed in the preceding 2 years. Urine was collected from all eligible patients and ADXBLADDER-MCM5 testing was performed. Performance characteristics were calculated by comparing MCM5 results to the outcome of cystoscopy plus pathological assessment. RESULTS: Of 1,431 eligible patients enrolled 127 were diagnosed with a bladder cancer recurrence. The overall sensitivity for the ADXBLADDER-MCM5 test in detecting bladder cancer recurrence was 44.9% (95% CI 36.1-54) with a 75.6% sensitivity for nonpTaLG tumors (95% CI 59.7-87.6). Specificity was 71.1% (95% CI 68.5-73.5). The overall negative predictive value was 93% (95% CI 91.2-94.5). However, ADXBLADDER was able to rule out the presence of a nonpTaLG recurrent tumor with a negative predictive value of 99.0% (95% CI 98.2-99.5). No statistically significant differences in the performance of ADXBLADDER were observed as a result of age or sex. CONCLUSIONS: This large blinded prospective study demonstrates that in the followup of patients with nonmuscle invasive bladder cancer ADXBLADDER is able to exclude the presence of the most aggressive tumors with a negative predictive value of 99%. These results indicate that ADXBLADDER could be incorporated in the followup strategy of nonmuscle invasive bladder cancer. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Urology department, Hopital Pitie-Salpetriere, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - McCracken, Stuart R C AU - McCracken SRC AD - Department of Urology, Sunderland Royal Hospital, Sunderland, United Kingdom. FAU - Dudderidge, Tim AU - Dudderidge T AD - Department of Urology, University Hospital Southampton, Southampton, United Kingdom. FAU - Stockley, Jacqueline AU - Stockley J AD - Arquer Diagnostics, R&D, Sunderland, United Kingdom. FAU - Kennedy, Ashleigh AU - Kennedy A AD - Arquer Diagnostics, R&D, Sunderland, United Kingdom. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Sieverink, Caroline AU - Sieverink C AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Vanie, Felicien AU - Vanie F AD - Sorbonne Universite, GRC n degrees 5, PREDICTIVE ONCO-URO, AP-HP, Urology department, Hopital Pitie-Salpetriere, Paris, France. FAU - Allasia, Marco AU - Allasia M AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Colombel, Marc AU - Colombel M AD - Department of Urology, Hopital Edouard Herriot, Lyon, France. FAU - Sylvester, Richard AU - Sylvester R AD - EAU Non-muscle Invasive Bladder Cancer Guidelines Panel, EAU Guidelines Office, Brussels, Belgium. FAU - Longo, Fabrizio AU - Longo F AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200421 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Cell Cycle Proteins) RN - 0 (MCM5 protein, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Cell Cycle Proteins/*urine MH - Cohort Studies MH - Cross-Sectional Studies MH - Europe MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*urine MH - Predictive Value of Tests MH - Prospective Studies MH - Reproducibility of Results MH - Single-Blind Method MH - Urinary Bladder Neoplasms/*pathology/*urine OTO - NOTNLM OT - MCM5 protein. OT - biomarkers OT - urinary bladder neoplasms OT - watchful waiting EDAT- 2020/04/22 06:00 MHDA- 2020/10/30 06:00 CRDT- 2020/04/22 06:00 PHST- 2020/04/22 06:00 [pubmed] PHST- 2020/10/30 06:00 [medline] PHST- 2020/04/22 06:00 [entrez] AID - 10.1097/JU.0000000000001084 [doi] PST - ppublish SO - J Urol. 2020 Oct;204(4):685-690. doi: 10.1097/JU.0000000000001084. Epub 2020 Apr 21. PMID- 32312640 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20210429 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 8 DP - 2020 Aug TI - A novel diagnostic tool for the detection of bladder cancer: Measurement of urinary high mobility group box-1. PG - 685.e11-685.e16 LID - S1078-1439(20)30131-9 [pii] LID - 10.1016/j.urolonc.2020.03.025 [doi] AB - OBJECTIVE: We aimed to investigate the diagnostic value of urinary High Mobility Group Box-1 (HMGB1) level as a noninvasive tool that can be potentially used for diagnosis and during follow-up in patients with bladder cancer patients. METHOD: The study was conducted in a total of 121 participants including 61 patients diagnosed with primary bladder cancer, 30 patients with an acute urinary tract infection and 30 healthy controls. Age, gender and urinary HMGB1 levels of the study groups were evaluated. The association of clinical features (tumor diameter, number of foci, pathological grade, muscle invasion) with urinary HMGB1 levels was investigated in patients with bladder cancer. RESULTS: All 3 groups showed a normal age and gender distribution with no significant difference among them (P = 0.775 and P = 0.967, respectively). A significant difference was detected in urinary HMGB1 levels among the 3 groups (P < 0.001). When urinary HMGB1 levels were compared between patients with high grade vs. low grade tumors, the mean HMGB1 level was 44.39 pg/ml (12.1-505.2) in patients with low grade tumors and 280 pg/ml (18.7-2685.3) in patients with high grade tumors (P < 0.001). Patients with a greater number of tumor foci had higher HMGB1 levels in comparison to patients with a single tumor focus (P = 0.008). Urinary HMGB1 levels were higher in patients with a tumor diameter of >/=3 cm than in patients with a tumor diameter less than 3 cm (P = 0.001). Patients with muscle-invasive bladder cancer exhibited higher urinary HMGB1 levels compared to patients with non-muscle-invasive bladder cancer (P = 0.033). The cut-off values derived from the ROC analysis were 63.30 pg/ml for distinguishing bladder cancer from urinary tract infection, 30.94 pg/ml for urinary tract infection versus control group and 38.70 pg/ml for bladder cancer vs. control group, respectively. Sensitivity was 59% and specificity was found 77%. CONCLUSION: In future controlled studies involving larger patient groups, urinary HMGB1 levels can be used for diagnostic and screening purposes in bladder cancer patients. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Benlier, Necla AU - Benlier N AD - Sanko University School of Medicine, Department of Medical Pharmacology, Gaziantep, Turkey. FAU - Solakhan, Mehmet AU - Solakhan M AD - Bahcesehir University School of Medicine, Department of Urology, Istanbul, Turkey. Electronic address: msolakhan@hotmail.com. FAU - Yildirim, Zeliha AU - Yildirim Z AD - Gaziantep University, Islahiye Vocational School, Department of Veterinary, Gaziantep, Turkey. FAU - Kaya, Vildan AU - Kaya V AD - Medstar Antalya Hospital, Department of Radiation Oncology, Antalya, Turkey. FAU - Yildirim, Omer Aydin AU - Yildirim OA AD - Medicalpark Gaziantep Hospital, Department of Internal Medicine, Gaziantep, Turkey. FAU - Orhan, Nuri AU - Orhan N AD - Medicalpark Gaziantep Hospital, Department of Biochemistry, Gaziantep, Turkey. FAU - Cicek, Hulya AU - Cicek H AD - Gaziantep University School of Medicine, Department of Medical Biochemistry, Gaziantep, Turkey. FAU - Yildirim, Mustafa AU - Yildirim M AD - Bahcesehir University School of Medicine, Department of Internal Medicine, Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200417 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (HMGB1 Protein) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*urine MH - Female MH - HMGB1 Protein/*urine MH - Humans MH - Male MH - Middle Aged MH - Urinary Bladder Neoplasms/*diagnosis/*urine OTO - NOTNLM OT - Bladder cancer OT - Noninvasive screening test OT - Tumor marker OT - Urinary HMGB1 OT - Urine marker EDAT- 2020/04/22 06:00 MHDA- 2021/04/30 06:00 CRDT- 2020/04/22 06:00 PHST- 2020/01/22 00:00 [received] PHST- 2020/03/17 00:00 [revised] PHST- 2020/03/25 00:00 [accepted] PHST- 2020/04/22 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/04/22 06:00 [entrez] AID - S1078-1439(20)30131-9 [pii] AID - 10.1016/j.urolonc.2020.03.025 [doi] PST - ppublish SO - Urol Oncol. 2020 Aug;38(8):685.e11-685.e16. doi: 10.1016/j.urolonc.2020.03.025. Epub 2020 Apr 17. PMID- 32304379 OWN - NLM STAT- MEDLINE DCOM- 20201217 LR - 20210625 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 30 IP - 4 DP - 2020 Jul TI - Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? PG - 584-593 LID - 10.1097/MOU.0000000000000792 [doi] AB - PURPOSE OF REVIEW: Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) is a new definition including patients who failed intravesical BCG therapy and should not receive more BCG because of the very low efficacy and disproportionately poor prognosis. Radical cystectomy as the standard of care for these patients is associated with significant morbidity and altered quality of life. Therefore, the FDA has accepted phase II single-arm studies as a threshold to approve new agents in this setting. RECENT FINDINGS: Efforts to find an effective and safe bladder sparing strategy for BCG unresponsive patients have not been successful yet. Studies that assess nanoparticle-bound, combination or device-assisted intravesical chemotherapy to increase drug delivery and efficacy have been partly promising but suffer from limitations. Systemic immunotherapy such as checkpoint inhibitors therapy PD1/PDL1 and intravesical immunotherapy such as rAd-IFN/Syn3 have shown satisfactory efficacy so far. SUMMARY: Although this is much effort and enthusiasm, no bladder-sparing strategy has met the criteria set for the successful alternative to radical cystectomy in BCG unresponsive NMIBC. For BCG unresponsive patients who refuse or are unfit for radical cyctectomy, there is new hope arising with novel strategies limiting the threshold for clinical use and a multitude of promising agents in clinical trials. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Miura, Noriyoshi AU - Miura N AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - The National Center for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. AD - Department of Urology, Weil Cornell Medical College, New York, New York. AD - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. AD - European Association of Urology Research Foundation, Arnhem, Netherlands. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM EIN - Curr Opin Urol. 2020 Sep;30(5):746. doi: 10.1097/ACI.0000000000000662. PMID: 32740140 EIN - Curr Opin Urol. 2021 Jul 1;31(4):436. doi: 10.1097/MOU.0000000000000880. PMID: 34024897 MH - Administration, Intravesical MH - Antineoplastic Agents/administration & dosage/*pharmacology MH - BCG Vaccine/*therapeutic use MH - Drug Therapy MH - Humans MH - Immunotherapy/*methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Quality of Life MH - Urinary Bladder Neoplasms/immunology/pathology/*therapy EDAT- 2020/04/19 06:00 MHDA- 2020/12/18 06:00 CRDT- 2020/04/19 06:00 PHST- 2020/04/19 06:00 [pubmed] PHST- 2020/12/18 06:00 [medline] PHST- 2020/04/19 06:00 [entrez] AID - 00042307-202007000-00018 [pii] AID - 10.1097/MOU.0000000000000792 [doi] PST - ppublish SO - Curr Opin Urol. 2020 Jul;30(4):584-593. doi: 10.1097/MOU.0000000000000792. PMID- 32303246 OWN - NLM STAT- MEDLINE DCOM- 20210121 LR - 20210121 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 39 IP - 1 DP - 2020 Apr 17 TI - Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study. PG - 68 LID - 10.1186/s13046-020-01550-w [doi] LID - 68 AB - BACKGROUND: High grade non-muscle-invasive bladder cancer (HG-NMIBC) is a heterogeneous disease with variable risk of progression. Urinary microRNAs are promising biomarkers for BC detection and surveillance. Let-7c-5p miRNA, clustered with miR-99a-5p and -125b-5p, is deregulated in cancer, including BC. The aim of this study is to evaluate urinary let-7c cluster expression in Ta/T1 HG-NMIBC patients and its impact on progression-free survival (PFS). METHODS: Quantitative Real-Time-Polymerase-Chain-Reaction (qRT-PCR) was used to analyze the let-7c cluster expression in 57 urine and 49 neoplastic paired tissue samples prospectively collected from transurethral resection (TUR) HG-NMIBC patients. Twenty urine and 10 bladder tissue samples were collected and analyzed as normal controls. QRT-PCR was also used to detect intra-/extra-cellular let-7c cluster in BC cells. Receiver Operating Characteristic (ROC) curves were used to identify urinary miRNAs cut-off values predicting T-stage and PFS. Uni/multivariable Cox regression was performed to identify predictors of PFS. A nomogram predicting progression risk and a decision curve analysis (DCA) were performed. RESULTS: Urinary let-7c was significantly up-regulated in patients compared with controls, while the whole cluster was down-regulated in tumor tissues. Supporting these findings, in vitro comparison of extra-/intra-cellular ratios of cluster levels between BC cells, showed a higher ratio for let-7c in HG-NMIBC versus low-grade cells. Urinary let-7c cluster expression was increased in higher T-stage and was an independent predictor of progression. Lower EORTC-score and downregulation of urinary cluster were predictors of higher PFS on univariable Cox regression, while on multivariable analysis only cluster expression was an independent progression predictor. On DCA, a benefit was evident for patients with a PFS probability > 20%. CONCLUSIONS: Urinary let-7c cluster evaluation may improve prognosis, identifying patients at risk of progression and addressing early radical treatment. FAU - Spagnuolo, Manuela AU - Spagnuolo M AD - Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Costantini, Manuela AU - Costantini M AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Ferriero, Mariaconsiglia AU - Ferriero M AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Varmi, Marco AU - Varmi M AD - Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Sperduti, Isabella AU - Sperduti I AD - Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Regazzo, Giulia AU - Regazzo G AD - Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Cicchillitti, Lucia AU - Cicchillitti L AD - Department of Experimental Clinical Oncology, Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Diaz Mendez, Ana Belen AU - Diaz Mendez AB AD - Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. FAU - Cigliana, Giovanni AU - Cigliana G AD - Department of Research, Advanced Diagnostics and Technological Innovation, Clinical Pathology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Pompeo, Vincenzo AU - Pompeo V AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Russo, Andrea AU - Russo A AD - Department of Research, Advanced Diagnostics and Technological Innovation, Pathology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Laquintana, Valentina AU - Laquintana V AD - Department of Research, Advanced Diagnostics and Technological Innovation, Pathology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Mastroianni, Riccardo AU - Mastroianni R AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Piaggio, Giulia AU - Piaggio G AD - Department of Research, Advanced Diagnostics and Technological Innovation, SAFU Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Anceschi, Umberto AU - Anceschi U AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Brassetti, Aldo AU - Brassetti A AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Bove, Alfredo AU - Bove A AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Tuderti, Gabriele AU - Tuderti G AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Flammia, Rocco Simone AU - Flammia RS AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. AD - Department of Urology, "Sapienza" University, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Experimental Clinical Oncology, Urology Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi 53, 00144, Rome, Italy. giuseppe.simone@ifo.gov.it. AD - Department of Clinical and Experimental Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. giuseppe.simone@ifo.gov.it. FAU - Rizzo, Maria Giulia AU - Rizzo MG AD - Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. maria.rizzo@ifo.gov.it. LA - eng PT - Journal Article DEP - 20200417 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (mirnlet7 microRNA, human) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/urine MH - Disease Progression MH - Female MH - Humans MH - Male MH - MicroRNAs/*urine MH - Neoplasm Grading MH - Pilot Projects MH - Progression-Free Survival MH - Urinary Bladder Neoplasms/genetics/pathology/*urine PMC - PMC7164295 OTO - NOTNLM OT - Let-7c cluster, urinary biomarkers, progression free survival OT - Non-muscle-invasive bladder cancer OT - microRNA COIS- The authors declare that they have no competing interests. EDAT- 2020/04/19 06:00 MHDA- 2021/01/22 06:00 PMCR- 2020/04/17 CRDT- 2020/04/19 06:00 PHST- 2020/01/04 00:00 [received] PHST- 2020/02/19 00:00 [accepted] PHST- 2020/04/19 06:00 [entrez] PHST- 2020/04/19 06:00 [pubmed] PHST- 2021/01/22 06:00 [medline] PHST- 2020/04/17 00:00 [pmc-release] AID - 10.1186/s13046-020-01550-w [pii] AID - 1550 [pii] AID - 10.1186/s13046-020-01550-w [doi] PST - epublish SO - J Exp Clin Cancer Res. 2020 Apr 17;39(1):68. doi: 10.1186/s13046-020-01550-w. PMID- 32298067 OWN - NLM STAT- MEDLINE DCOM- 20201112 LR - 20260414 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 72 IP - 3 DP - 2020 Jun TI - Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. PG - 265-278 LID - 10.23736/S0393-2249.20.03786-8 [doi] AB - INTRODUCTION: The European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) scoring systems show limited accuracy for the prediction of disease recurrence and progression of non-muscle-invasive bladder cancer (NMIBC). This aspect is even more relevant in the category of HR NMIBC. Biomarkers might potentially help to further categorize the outcomes of these patients. Therefore, we sought to review the evidence available on tissue-based, urinary, and serum biomarkers for the prediction of recurrence, progression, and survival in HR NMIBC. EVIDENCE ACQUISITION: A systematic literature review without time restrictions was performed using PubMed/EMBASE, Web of Science, SCOPUS, and the Cochrane Libraries. The search was filtered for articles in the English, Italian, German, French, and Spanish languages, involving patients with more than 18 years of age. Relevant papers on tissue-based, serum and urinary biomarkers related to the prediction of oncological outcomes for high-risk bladder cancer patients were included in the analyses. EVIDENCE SYNTHESIS: Overall, 71 studies were eligible for inclusion in this review. The majority of the investigations performed so far focused on immunohistochemical analyses on tumoral tissue. Overall, p53 was the most studied biomarker, but results regarding its prognostic and predictive role were contradictory. Ki67 seems to be a promising biomarker in the prediction of recurrence. Recently, PD-L1 has been associated with the prediction of recurrence free survival and of treatment-refractory disease. Markers developed un urine samples are focused on commercially available kits, which currently do not unequivocally show strongly superior levels of accuracy to cytology. However, they have demonstrated to be potentially helpful in the prediction of recurrence. Blood-based biomarkers represent an emerging reality with promising future applications. CONCLUSIONS: Despite a long history of attempts to discover accurate biomarkers predicting oncological outcomes for HR NMIBC, contradictory or uncertain findings render the adoption of this ancillary techniques in clinical practice still unlikely. Future attempts should be directed to the development of prospective trials and the definition of standardized cut-off levels to render findings worthy of comparison. FAU - Afferi, Luca AU - Afferi L AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland - marco.moschini87@gmail.com. AD - Department of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Cumberbatch, Marcus G AU - Cumberbatch MG AD - Unit of Academic Urology, University of Sheffield, Sheffield, UK. FAU - Catto, James W AU - Catto JW AD - Unit of Academic Urology, University of Sheffield, Sheffield, UK. FAU - Scarpa, Roberto M AU - Scarpa RM AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. FAU - Porpiglia, Francesco AU - Porpiglia F AD - Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Sanchez-Salas, Rafael AU - Sanchez-Salas R AD - Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France. FAU - Esperto, Francesco AU - Esperto F AD - Department of Urology, Campus Bio-Medico University, Rome, Italy. CN - European Association of Urology - European Society of Resident Urologists (EAU-ESRU) LA - eng PT - Journal Article PT - Systematic Review DEP - 20200416 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 RN - 0 (Biomarkers) SB - IM MH - *Biomarkers MH - Humans MH - Predictive Value of Tests MH - Prognosis MH - Risk Assessment/methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/psychology/surgery/*therapy EDAT- 2020/04/17 06:00 MHDA- 2020/11/13 06:00 CRDT- 2020/04/17 06:00 PHST- 2020/04/17 06:00 [pubmed] PHST- 2020/11/13 06:00 [medline] PHST- 2020/04/17 06:00 [entrez] AID - S0393-2249.20.03786-8 [pii] AID - 10.23736/S0393-2249.20.03786-8 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2020 Jun;72(3):265-278. doi: 10.23736/S0393-2249.20.03786-8. Epub 2020 Apr 16. PMID- 32296929 OWN - NLM STAT- MEDLINE DCOM- 20200709 LR - 20261010 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 477 IP - 1 DP - 2020 Jul TI - pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. PG - 3-16 LID - 10.1007/s00428-020-02808-6 [doi] AB - Most patients with bladder carcinoma are diagnosed with non-muscle-invasive disease, stage Ta, and pT1. Stage remains as the single most important prognostic indicator in urothelial carcinoma. Among the pT1 bladder cancer patients, recurrence and progression of disease occur in 50% and 10%, respectively. The identification of high-risk patients within the pT1 subgroup remains an important clinical goal and an active field of research. Substaging of pT1 disease has been claimed as important histologic discriminator by the 2016 World Health Organization (WHO) classification of the genitourinary tract tumors and by the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual supporting its implementation in clinical practice. Interobserver variation in pT1 diagnosis and the associated pitfalls in pT1 assessment are the critical pathological issues. The aim of this review paper is to provide the practicing pathologist with the state of the art of morphological and immunohistochemical features useful for the diagnosis of early invasive bladder carcinomas, including practical clues on how to avoid relevant interpretative pitfalls, and to summarize the current status of pT1 substaging. FAU - Raspollini, Maria Rosaria AU - Raspollini MR AD - Histopathology and Molecular Diagnostics, University Hospital Careggi, Viale Pieraccini, 6, 50139, Florence, Italy. mariarosaria.raspollini@unifi.it. FAU - Montironi, Rodolfo AU - Montironi R AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. FAU - Mazzucchelli, Roberta AU - Mazzucchelli R AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Unit of Anatomic Pathology, Department of Surgery, Cordoba University Medical School, Cordoba, Spain. AD - Champalimaud Clinical Center, Lisbon, Portugal. LA - eng PT - Journal Article PT - Review DEP - 20200415 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM MH - Animals MH - Carcinoma, Transitional Cell/*pathology MH - Humans MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Bladder cancer OT - Pitfalls, OT - Stage OT - pT1 sub-staging EDAT- 2020/04/17 06:00 MHDA- 2020/07/10 06:00 CRDT- 2020/04/17 06:00 PHST- 2020/01/27 00:00 [received] PHST- 2020/03/25 00:00 [accepted] PHST- 2020/03/18 00:00 [revised] PHST- 2020/04/17 06:00 [pubmed] PHST- 2020/07/10 06:00 [medline] PHST- 2020/04/17 06:00 [entrez] AID - 10.1007/s00428-020-02808-6 [pii] AID - 10.1007/s00428-020-02808-6 [doi] PST - ppublish SO - Virchows Arch. 2020 Jul;477(1):3-16. doi: 10.1007/s00428-020-02808-6. Epub 2020 Apr 15. PMID- 32285440 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20250530 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 147 IP - 8 DP - 2020 Oct 15 TI - Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. PG - 2091-2100 LID - 10.1002/ijc.33008 [doi] AB - While the association between fruit consumption and bladder cancer risk has been extensively reported, studies have had inadequate statistical power to investigate associations between types of fruit and bladder cancer risk satisfactorily. Fruit consumption in relation to bladder cancer risk was investigated by pooling individual data from 13 cohort studies. Cox regression models with attained age as time scale were used to estimate hazard ratios (HRs) for intakes of total fruit and citrus fruits, soft fruits, stone fruits, tropical fruits, pome fruits and fruit products. Analyses were stratified by sex, smoking status and bladder cancer subtype. During on average 11.2 years of follow-up, 2836 individuals developed incident bladder cancer. Increasing fruit consumption (by 100 g/day) was inversely associated with the risk of bladder cancer in women (HR = 0.92; 95% CI 0.85-0.99). Although in women the association with fruit consumption was most evident for higher-risk nonmuscle invasive bladder cancer (NMIBC; HR = 0.72; 95% CI 0.56-0.92), the test for heterogeneity by bladder cancer subtype was nonsignificant (P-heterogeneity = .14). Increasing fruit consumption (by 100 g/day) was not associated with bladder cancer risk in men (HR = 0.99; 95% CI 0.94-1.03), never smokers (HR = 0.96; 95% CI 0.88-1.05), former smokers (HR = 0.98; 95% CI 0.92-1.05) or current smokers (HR = 0.95; 95% CI 0.89-1.01). The consumption of any type of fruit was not found to be associated with bladder cancer risk (P values > .05). Our study supports no evidence that the consumption of specific types of fruit reduces the risk of bladder cancer. However, increasing total fruit consumption may reduce bladder cancer risk in women. CI - (c) 2020 UICC. FAU - Jochems, Sylvia H J AU - Jochems SHJ AUID- ORCID: 0000-0001-7676-1488 AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Reulen, Raoul C AU - Reulen RC AUID- ORCID: 0000-0002-7328-0467 AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - van Osch, Frits H M AU - van Osch FHM AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Witlox, Willem J A AU - Witlox WJA AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - Maastricht University Medical Centre+, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands. FAU - Goossens, Maria E AU - Goossens ME AD - Cancer Centre of Sciensano, OD Public Health and Surveillance, Brussels, Belgium. FAU - Brinkman, Maree AU - Brinkman M AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - Department of Clinical Studies and Nutritional Epidemiology, Nutrition Biomed Research Institute, Melbourne, Australia. AD - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Giles, Graham G AU - Giles GG AD - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia. AD - Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. AD - Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. FAU - Milne, Roger L AU - Milne RL AD - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia. AD - Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. AD - Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. FAU - van den Brandt, Piet A AU - van den Brandt PA AUID- ORCID: 0000-0001-8781-8099 AD - Department of Epidemiology, Schools for Oncology and Developmental Biology and Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - White, Emily AU - White E AD - Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. FAU - Weiderpass, Elisabete AU - Weiderpass E AUID- ORCID: 0000-0003-2237-0128 AD - International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. FAU - Huybrechts, Inge AU - Huybrechts I AD - International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. FAU - Hemon, Bertrand AU - Hemon B AD - International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. FAU - Agudo, Antonio AU - Agudo A AD - Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Bueno-de-Mesquita, Bas AU - Bueno-de-Mesquita B AD - Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. AD - Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. AD - Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, UK. AD - Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Cheng, Kar K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - van Schooten, Frederik J AU - van Schooten FJ AD - Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Wesselius, Anke AU - Wesselius A AUID- ORCID: 0000-0003-4474-9665 AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - CAPHRI School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200428 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 SB - IM MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Fruit MH - Humans MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - Risk Factors MH - Smoking/adverse effects MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*epidemiology/*etiology/pathology OTO - NOTNLM OT - bladder cancer OT - fruit OT - pooled analysis OT - prospective cohort EDAT- 2020/04/15 06:00 MHDA- 2021/04/13 06:00 CRDT- 2020/04/15 06:00 PHST- 2019/09/21 00:00 [received] PHST- 2020/01/14 00:00 [revised] PHST- 2020/02/03 00:00 [accepted] PHST- 2020/04/15 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2020/04/15 06:00 [entrez] AID - 10.1002/ijc.33008 [doi] PST - ppublish SO - Int J Cancer. 2020 Oct 15;147(8):2091-2100. doi: 10.1002/ijc.33008. Epub 2020 Apr 28. PMID- 32278732 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20210429 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 8 DP - 2020 Aug TI - Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guerin in patients with high-risk non-muscle-invasive bladder cancer. PG - 684.e17-684.e24 LID - S1078-1439(20)30093-4 [pii] LID - 10.1016/j.urolonc.2020.03.009 [doi] AB - OBJECTIVES: To evaluate the safety and efficacy of intensive intravesical instillation of low-dose pirarubicin (THP) for 6 times vs. bacillus Calmette-Guerin (BCG) without maintenance therapy after transurethral resection of bladder tumor (TURBT) in patients with primary high-risk non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively evaluated 370 patients with primary high-risk NMIBC who underwent TURBT from November 1993 to April 2019. The patients were divided into 2 groups: patients treated with intravesical instillation of BCG without maintenance therapy (BCG group) and intensive intravesical instillation of low-dose (20 mg) THP for 6 times within 10 days after TURBT (THP group). Safety was assessed using the Common Terminology Criteria for Adverse Events version 5.0. Background-adjusted multivariate analyses were performed to evaluate the effect of intensive intravesical instillation of low-dose THP on oncological outcomes, including intravesical recurrence-free survival (RFS), upper urinary tract RFS, muscle-invasive bladder cancer-free survival, metastasis-free survival, cancer-specific survival, and overall survival. RESULTS: Of the 370 patients with primary high-risk NMIBC, 180 (49%) and 190 (51%) were stratified into the BCG and THP groups, respectively. The incidence rate of adverse events of any grade in the BCG group was significantly higher than that in the THP group (P < 0.001). In the background-adjusted multivariate analyses, no significant differences were observed in oncological outcomes between the BCG and THP groups. CONCLUSIONS: Intensive intravesical instillation of low-dose THP for 6 times may be one of the treatment options in view of safety and efficacy after TURBT in patients with primary high-risk NMIBC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kido, Koichi AU - Kido K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Narita, Takuma AU - Narita T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200409 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Adjuvants, Immunologic/*administration & dosage/adverse effects MH - Administration, Intravesical MH - Aged MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - BCG Vaccine/*administration & dosage/adverse effects MH - Combined Modality Therapy MH - Cystectomy/methods MH - Doxorubicin/administration & dosage/adverse effects/*analogs & derivatives MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*drug therapy/epidemiology/pathology/surgery OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - High-risk OT - Low-dose OT - Non-muscle-invasive bladder cancer OT - Pirarubicin OT - Six-times intensive instillation EDAT- 2020/04/13 06:00 MHDA- 2021/04/30 06:00 CRDT- 2020/04/13 06:00 PHST- 2019/12/13 00:00 [received] PHST- 2020/02/21 00:00 [revised] PHST- 2020/03/14 00:00 [accepted] PHST- 2020/04/13 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/04/13 06:00 [entrez] AID - S1078-1439(20)30093-4 [pii] AID - 10.1016/j.urolonc.2020.03.009 [doi] PST - ppublish SO - Urol Oncol. 2020 Aug;38(8):684.e17-684.e24. doi: 10.1016/j.urolonc.2020.03.009. Epub 2020 Apr 9. PMID- 32273049 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20210429 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 6 DP - 2020 Jun TI - Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysis. PG - 574-581 LID - S1078-1439(20)30061-2 [pii] LID - 10.1016/j.urolonc.2020.02.020 [doi] AB - PURPOSE: Some excised specimens of upper tract urothelial carcinoma (UTUC) are concomitant carcinoma in situ (CIS). However, whether concomitant CIS affects the prognosis of UTUC is controversial. The objective of this study was to provide a comprehensive association between CIS and the prognosis of UTUC. MATERIALS AND METHODS: Web of Science, PubMed, and Embase were searched to identify clinical studies about CIS and UTUC before July 2019. Newcastle Ottawa Scale was used to evaluate the quality of the literature. We calculated hazard ratios (HRs) and 95% CIs to evaluate the relationship between concomitant CIS and survival outcomes. Z test was used to pooled HRs, if P < 0.05, the difference was considered statistically significant. RESULTS: Total of 7,852 patients with UTUC were included, of which 1,004 (12.79%) concomitant CIS. In univariate analysis, our meta-analysis shows that concomitant CIS is associated with worse cancer-specific survival (HR: 1.54; P < 0.00001), worse recurrence-free survival (RFS) (HR: 1.42; P < 0.00001) and worse overall survival (OS; HR: 1.41; P = 0.04). In multivariate analysis, concomitant CIS is associated with worse cancer-specific survival (HR: 1.25; P = 0.004), worse recurrence-free survival (HR: 1.24; P = 0.006), and worse OS (HR: 1.12; P = 0.25), however, there was no statistical difference in the effect of CIS on OS (P > 0.05). CONCLUSIONS: Our meta-analysis shows that concomitant CIS is associated with worse survival outcomes in UTUC after radical nephroureterectomy. CIS is an independent prognostic risk factor in UTUC. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Gao, Xiaoshuai AU - Gao X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Ma, Yucheng AU - Ma Y AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Chen, Guo AU - Chen G AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Chen, Jixiang AU - Chen J AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Li, Hao AU - Li H AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Li, Hong AU - Li H AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Wei, Xin AU - Wei X AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. FAU - Wang, Kunjie AU - Wang K AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. Electronic address: wangkj@scu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20200406 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Carcinoma in Situ/*mortality/*surgery MH - Carcinoma, Transitional Cell/*mortality/*surgery MH - Humans MH - Kidney Neoplasms/*mortality/*surgery MH - Neoplasms, Multiple Primary/*mortality/*surgery MH - *Nephroureterectomy MH - Prognosis MH - Survival Rate MH - Ureteral Neoplasms/*mortality/*surgery OTO - NOTNLM OT - Carcinoma in situ OT - Meta-analysis OT - Prognosis OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2020/04/11 06:00 MHDA- 2021/04/30 06:00 CRDT- 2020/04/11 06:00 PHST- 2019/10/08 00:00 [received] PHST- 2020/02/01 00:00 [revised] PHST- 2020/02/17 00:00 [accepted] PHST- 2020/04/11 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/04/11 06:00 [entrez] AID - S1078-1439(20)30061-2 [pii] AID - 10.1016/j.urolonc.2020.02.020 [doi] PST - ppublish SO - Urol Oncol. 2020 Jun;38(6):574-581. doi: 10.1016/j.urolonc.2020.02.020. Epub 2020 Apr 6. PMID- 32268173 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20260512 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 142 DP - 2020 Aug TI - Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. PG - 155-160 LID - S0090-4295(20)30330-7 [pii] LID - 10.1016/j.urology.2020.03.021 [doi] AB - OBJECTIVES: To evaluate the risk of occult nodal metastasis in patients with muscle invasive bladder cancer who exhibit a complete or partial clinical response to neoadjuvant chemotherapy (NAC) and assess a potential role for "bladder sparing" management given that the gold standard treatment, radical cystectomy (RC), is associated with high morbidity. METHODS: We queried the National Cancer Database for bladder cancer from 2004 to 2013 including patients with cT2-4aN0M0 bladder cancer who underwent multiagent NAC followed by RC and pelvic lymphadenectomy and excluding patients with nonurothelial predominant histology and those undergoing partial cystectomy. Student's t test was used to evaluate patients' demographics, presence of co-morbid conditions, and pathologic findings, notably the presence of lymphovascular invasion and variant histology. RESULTS: We identified 17,917 patients who underwent RC. Of these, 14.9% (n = 2673) received NAC before RC. About 13.1% and 14.5% of patients had complete (ypT0) and partial (ypTa, Tis, and T1) pathologic response, respectively. These 14.7% of cT2, 9.0% of cT3, and 6.9% of cT4 patients exhibited pT0 status on final pathology. And 4.9% of complete and 5.4% of partial responders demonstrated occult nodal metastases. Age, sex, ethnicity, the presence of co-morbidities, LVI, and variant histology were not significantly associated with occult nodal metastasis. CONCLUSION: While bladder preservation may be a viable option in patients who are carefully selected and closely followed after NAC, patients undergoing NAC may be at risk of occult disease outside of the bladder despite an otherwise clinical complete response diagnosed with cross-sectional imaging, cystoscopy, TURBT, and cytology. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Nassiri, Nima AU - Nassiri N AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Maas, Marissa AU - Maas M AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Nazemi, Azadeh AU - Nazemi A AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Asanad, Kian AU - Asanad K AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Pearce, Shane AU - Pearce S AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Bhanvadia, Sumeet S AU - Bhanvadia SS AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Schuckman, Anne AU - Schuckman A AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Institute of Urology and USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA. Electronic address: daneshma@med.usc.edu. LA - eng PT - Journal Article DEP - 20200405 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Age Factors MH - Chemotherapy, Adjuvant/methods MH - Cystectomy/*statistics & numerical data MH - Humans MH - Lymph Nodes/pathology MH - Lymphatic Metastasis/*diagnosis/pathology MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Risk Factors MH - Sex Factors MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/pathology/*therapy MH - Female EDAT- 2020/04/09 06:00 MHDA- 2022/02/03 06:00 CRDT- 2020/04/09 06:00 PHST- 2020/01/21 00:00 [received] PHST- 2020/03/01 00:00 [revised] PHST- 2020/03/12 00:00 [accepted] PHST- 2020/04/09 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2020/04/09 06:00 [entrez] AID - S0090-4295(20)30330-7 [pii] AID - 10.1016/j.urology.2020.03.021 [doi] PST - ppublish SO - Urology. 2020 Aug;142:155-160. doi: 10.1016/j.urology.2020.03.021. Epub 2020 Apr 5. PMID- 32266509 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 39 IP - 2 DP - 2021 Feb TI - Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. PG - 425-431 LID - 10.1007/s00345-020-03180-5 [doi] AB - PURPOSE: Paucity of reliable long-term data on the prognostic implications of the 2004 WHO bladder cancer classification system necessitates utilisation of both this and the 1973 grading systems. This study evaluated, in noninvasive (pTa) bladder tumours, the prognostic value of the 2004 system independently and in combination with the 1973 system while establishing concordance between tertiary centre uropathologists. METHODS: We used a cohort of non-muscle invasive bladder cancer (NMIBC) patients diagnosed between 1991 and 93 where tumour features were gathered prospectively with detailed cystoscopic follow-up data recorded over 15 years. Initial grading was by one senior expert uropathologist (UP1) using the 1973 WHO classification alone. Subsequently, two other expert uropathologists (UP2 and UP3), blinded to the previous grading, re-evaluated the pathology slides and graded the tumours using both the 1973 and 2004 systems. Association between grade and recurrence/progression was analysed and the Cohen Kappa test assessed concordance between pathologists. RESULTS: Of 370 new NMIBC, 229 were staged noninvasive (pTa). Recurrence rates were 46.2% and 50.0% for LGPUC (low-grade papillary urothelial carcinoma) and HGPUC (high-grade papillary urothelial carcinoma), respectively, while progression was seen in 3.9% and 10.0% of LGPUC and HGPUC, respectively. Concordance between uropathologists UP2 and UP3 for the 2004 and 1973 systems was good (Kappa = 0.69) and fair (Kappa = 0.25), respectively. CONCLUSIONS: With good inter-observer concordance, the 2004 WHO classification system of noninvasive bladder tumours appears to accurately predict recurrence and progression risks. The combination of both grading systems to low-grade tumours allows further refinement of the natural history. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. param.mariappan@nhs.net. AD - University of Edinburgh, Edinburgh, UK. param.mariappan@nhs.net. FAU - Fineron, Paul AU - Fineron P AD - Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK. FAU - O'Donnell, Marie AU - O'Donnell M AD - Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK. FAU - Gailer, Ruth M AU - Gailer RM AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. FAU - Watson, David J AU - Watson DJ AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. FAU - Smith, Gordon AU - Smith G AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. FAU - Grigor, Kenneth M AU - Grigor KM AD - University of Edinburgh, Edinburgh, UK. AD - Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK. LA - eng PT - Journal Article DEP - 20200407 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Observer Variation MH - Prognosis MH - Prospective Studies MH - Reproducibility of Results MH - Time Factors MH - United Kingdom MH - Urinary Bladder Neoplasms/*classification/*pathology MH - World Health Organization PMC - PMC7910375 OTO - NOTNLM OT - Bladder cancer OT - ISUP classification OT - Long-term follow-up OT - Non-muscle invasive bladder cancer (NMIBC) OT - Prognosis OT - WHO classification COIS- All the authors have no conflicts of interest to declare. EDAT- 2020/04/09 06:00 MHDA- 2021/07/23 06:00 PMCR- 2020/04/07 CRDT- 2020/04/09 06:00 PHST- 2020/01/03 00:00 [received] PHST- 2020/03/23 00:00 [accepted] PHST- 2020/04/09 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/04/09 06:00 [entrez] PHST- 2020/04/07 00:00 [pmc-release] AID - 10.1007/s00345-020-03180-5 [pii] AID - 3180 [pii] AID - 10.1007/s00345-020-03180-5 [doi] PST - ppublish SO - World J Urol. 2021 Feb;39(2):425-431. doi: 10.1007/s00345-020-03180-5. Epub 2020 Apr 7. PMID- 32264924 OWN - NLM STAT- MEDLINE DCOM- 20210318 LR - 20210318 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 15 IP - 1 DP - 2020 Apr 7 TI - ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients. PG - 33 LID - 10.1186/s13000-020-00947-7 [doi] LID - 33 AB - BACKGROUND: Bladder cancer (BC) is one of the most common malignancies in Egypt, representing about 8.7% of cancers in both sexes with more predominance in males, making identification of valuable predictive and prognostic markers, mandatory. Cullin-RING ligases (CRL) play an important role in the ubiquitination of cell cycle-related proteins or other proteins (e.g., DNA replication protein, signal transduction protein). Regulator of Cullins-1 (ROC-1) is a key subunit of CRL. P21 belongs to the family of cyclin dependent kinase inhibitors (CKIs) which regulates cell cycle by inactivating Cyclin- Dependent Kinases key regulators of the cell cycle. CAIX a highly active member of the family of carbonic anhydrases has gained much interest as a hypoxic marker. Hypoxia is a consequence of the rapid growth of many tumors, including bladder cancer, and is an important regulator of gene expression and resistance to chemotherapy and radiotherapy. Therefore the purpose of this study is to evaluate the role of ROC-1, CAIX and P21 and its relationship with the clinico-pathological features of bladder cancer in Egyptian patients. METHODS: Using the standard immunohistochemical technique, ROC-1, CAIX and P21 expression in 80 primary bladder carcinomas and 15 normal bladder specimens as control group were assessed. The bladder carcinoma cases included 50 cases with muscle invasive bladder cancer and 30 cases with non-muscle invasive bladder cancer. RESULTS: Over expression of ROC-1, CAIX and P21 in BC were significantly associated with muscularis propria invasion and high grade BC. ROC-1, CAIX and P21, showed significant inverse relationship in primary BC cases. CAIX expression was significantly higher in BC compared with controls. Regarding the survival analysis, expression of ROC-1, CAIX and P21 didn't affect the survival of BC patients. CONCLUSIONS: High expression of ROC-1, CAIX and P21 could be promising potential biomarkers for identifying patients with poor prognostic factors in bladder cancer serving as potential targets for cancer therapy. FAU - Al-Sharaky, Dalia Rifaat AU - Al-Sharaky DR AD - Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia Governorate, 35211, Egypt. daliah_alsharaky@yahoo.com. FAU - Kandil, Mona Abd El-Halim AU - Kandil MAE AD - Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia Governorate, 35211, Egypt. FAU - Aiad, Hayam Abdel Samie AU - Aiad HAS AD - Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia Governorate, 35211, Egypt. FAU - El-Hosary, Enas Megahed AU - El-Hosary EM AD - General hospital, Shebin El-Kom, Menoufia Governorate, Egypt. FAU - Alagizy, Hagar Abdelmagied AU - Alagizy HA AD - Clinical oncology & Nuclear medicine Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - Elshenawy, Mahmoud Abdel-Sattar AU - Elshenawy MA AD - Clinical oncology & Nuclear medicine Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. FAU - El-Rebey, Hala Said AU - El-Rebey HS AD - Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia Governorate, 35211, Egypt. LA - eng PT - Journal Article DEP - 20200407 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Biomarkers, Tumor) RN - 0 (Carrier Proteins) RN - 0 (RBX1 protein, human) RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - EC 4.2.1.1 (Carbonic Anhydrase IX) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carbonic Anhydrase IX/analysis/*biosynthesis MH - Carcinoma, Transitional Cell/*pathology MH - Carrier Proteins/analysis/*biosynthesis MH - Egypt MH - Female MH - Humans MH - Male MH - Middle Aged MH - Proto-Oncogene Proteins p21(ras)/analysis/*biosynthesis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology PMC - PMC7137342 OTO - NOTNLM OT - BC OT - CAIX OT - Immunohistochemistry OT - P21 OT - Prognosis OT - ROC-1 COIS- The authors declare that they have no competing interests. EDAT- 2020/04/09 06:00 MHDA- 2021/03/19 06:00 PMCR- 2020/04/07 CRDT- 2020/04/09 06:00 PHST- 2019/10/30 00:00 [received] PHST- 2020/03/19 00:00 [accepted] PHST- 2020/04/09 06:00 [entrez] PHST- 2020/04/09 06:00 [pubmed] PHST- 2021/03/19 06:00 [medline] PHST- 2020/04/07 00:00 [pmc-release] AID - 10.1186/s13000-020-00947-7 [pii] AID - 947 [pii] AID - 10.1186/s13000-020-00947-7 [doi] PST - epublish SO - Diagn Pathol. 2020 Apr 7;15(1):33. doi: 10.1186/s13000-020-00947-7. PMID- 32256273 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231113 IS - 1611-2156 (Print) IS - 1611-2156 (Electronic) IS - 1611-2156 (Linking) VI - 19 DP - 2020 TI - Involvement of haptoglobin phenotypes and genotypes in non-muscle invasive bladder cancer: A possible prognostic marker for risk stratification. PG - 351-359 LID - 10.17179/excli2019-1768 [doi] AB - The association of haptoglobin (Hp) with various cancers has been reported and also it has been documented that the Hp phenotypes/genotypes have different functional ability. So, we examined phenotypes/genotypes of Hp in newly diagnosed, untreated non-muscle invasive bladder cancer (NMIBC) patients and investigated its prognostic value for risk stratification of the cancer. In eighty NMIBC patients and 80 healthy individuals the Hp genotypes and phenotypes were analyzed using polymerase chain reaction (PCR) and two-dimensional gel electrophoresis (2D-GE), respectively. Besides, the presence of the Hpalpha1, alpha2, and beta chains in the sera was confirmed by Mass Spectrometry (MS). The frequencies of the 1-1 and 2-2 genotypes/phenotypes were respectively higher and lower in healthy subjects compared to the patients. Our results revealed that the 2-2 genotype/phenotype could increase the risk of NMIBC. There was a positive association between the 2-2 genotype/phenotype with the T category/grade of cancer (p<0.05). The present study implied a strong association between the Hp phenotypes and genotypes with NMIBC. It was found that the 2-2 genotype and phenotype could be a risk factor for NMIBC incidence, as well as, progression. This study introduced Hp genotyping as a possible cost-effective and precise method for prognosis of individuals at the risk of NMIBC. CI - Copyright (c) 2020 Aghaalikhani et al. FAU - Aghaalikhani, Nazi AU - Aghaalikhani N AD - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Zamani, Mojtaba AU - Zamani M AD - Department of Agronomy and Plant Breeding, School of Agriculture, University of Tehran, Karaj, Iran. FAU - Allameh, Abdolamir AU - Allameh A AD - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Mashayekhi, Amir AU - Mashayekhi A AD - Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran. FAU - Shadpour, Pejman AU - Shadpour P AD - Hasheminejad Kidney Center (HKC), Hospital Management Research Center (HMRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. FAU - Mahmoodi, Marzieh AU - Mahmoodi M AD - Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran. FAU - Rashtchizadeh, Nadereh AU - Rashtchizadeh N AD - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Journal Article DEP - 20200310 PL - Germany TA - EXCLI J JT - EXCLI journal JID - 101299402 PMC - PMC7105941 OTO - NOTNLM OT - acute-phase protein OT - biomarkers OT - electrophoresis OT - haptoglobin OT - non-muscle invasive bladder cancer EDAT- 2020/04/08 06:00 MHDA- 2020/04/08 06:01 PMCR- 2020/03/10 CRDT- 2020/04/08 06:00 PHST- 2019/08/28 00:00 [received] PHST- 2020/03/02 00:00 [accepted] PHST- 2020/04/08 06:00 [entrez] PHST- 2020/04/08 06:00 [pubmed] PHST- 2020/04/08 06:01 [medline] PHST- 2020/03/10 00:00 [pmc-release] AID - 2019-1768 [pii] AID - Doc351 [pii] AID - 10.17179/excli2019-1768 [doi] PST - epublish SO - EXCLI J. 2020 Mar 10;19:351-359. doi: 10.17179/excli2019-1768. eCollection 2020. PMID- 32253580 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 39 IP - 2 DP - 2021 Feb TI - Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer. PG - 453-459 LID - 10.1007/s00345-020-03188-x [doi] AB - PURPOSE: To perform a feasibility phase study of a panel of putative protein biomarkers and determine whether it can identify and predict tumor recurrence in patients with non-muscle-invasive bladder cancer (NMIBC) on follow-up. METHODS: We prospectively analyzed the urine of 152 patients previously treated for NMIBC. Quantitative expression of plasminogen activator inhibitor-1 (PAI-1), DJ-1, apolipoprotein A-I (apoA-1), matrix metallopeptidase-9 (MMP-9), and interleukin-8 (IL-8) was assessed by enzyme-linked immunosorbent assay and compared amongst patients with and without bladder cancer recurrence at urine collection and during 3 years of follow-up. Tumor recurrence was confirmed by pathologic analysis. We performed a prediction analysis, excluding patients with recurrence at the start of the study, and assessed the influence of previous use of intravesical BCG on the level of biomarkers. RESULTS: Median follow-up time was 47 months (interquartile range 39-50 months). Sixteen patients (10.5%) were diagnosed with recurrence at the start of the study, and 21 (15.4%) were diagnosed during the study. Three biomarker proteins (apoA-1, MMP-9, and IL-8) appear to hold diagnostic potential [odds ratio (OR) = 12.9; 95% CI 3.5-47.4]; while, PAI-1 and IL-8 predict recurrence (OR = 4.1; 95% CI 1.4-11.4). Previous use of intravesical BCG did not affect biomarker levels. CONCLUSION: In the feasibility phase, the panel of urine biomarkers analyzed detected and predicted recurrence of NMIBC and provided reliable results in patients who had previously used intravesical BCG. Validation studies are required to confirm the panel clinical utility. FAU - Srougi, Victor AU - Srougi V AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. vsrougi@gmail.com. FAU - Reis, Sabrina T AU - Reis ST AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. AD - Faculdade Atenas, Campos Passos, Rua Oscar Candido Monteiro, 1000, Passos, MG, 37900-380, Brazil. FAU - Viana, Nayara AU - Viana N AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. FAU - Gallucci, Fabio P AU - Gallucci FP AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. FAU - Leite, Katia R AU - Leite KR AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. FAU - Srougi, Miguel AU - Srougi M AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. FAU - Nahas, William C AU - Nahas WC AD - Division of Urology, University of Sao Paulo Medical School, Hospital das Clinicas de Sao Paulo, Av Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. LA - eng GR - 2016/07917-5/FAPESP/ PT - Journal Article DEP - 20200406 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/*urine MH - Feasibility Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*urine MH - Predictive Value of Tests MH - Prospective Studies MH - Urinary Bladder Neoplasms/pathology/*urine OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Diagnosis OT - Recurrence OT - Urothelial carcinoma EDAT- 2020/04/08 06:00 MHDA- 2021/07/23 06:00 CRDT- 2020/04/08 06:00 PHST- 2019/10/18 00:00 [received] PHST- 2020/03/27 00:00 [accepted] PHST- 2020/04/08 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/04/08 06:00 [entrez] AID - 10.1007/s00345-020-03188-x [pii] AID - 10.1007/s00345-020-03188-x [doi] PST - ppublish SO - World J Urol. 2021 Feb;39(2):453-459. doi: 10.1007/s00345-020-03188-x. Epub 2020 Apr 6. PMID- 32248340 OWN - NLM STAT- MEDLINE DCOM- 20200408 LR - 20261011 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 21 IP - 5 DP - 2020 Apr 4 TI - Blue Light Cystoscopy: Indications and Outcomes. PG - 19 LID - 10.1007/s11934-020-0966-5 [doi] AB - PURPOSE OF REVIEW: It has been firmly established that hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) reduces cancer recurrence rates. This review explores the impact of HAL-BLC on other meaningful outcomes in patients with bladder cancer, including disease progression, and earlier detection of disease at the time of surveillance cystoscopy. RECENT FINDINGS: A randomized clinical trial confirmed earlier implementation of HAL-BLC at the time of surveillance cystoscopy increased identification of cancerous lesions, including those of high grade, when compared with white light cystoscopy. In addition, the evidence is evolving that the use of HAL-BLC at the time of endoscopic treatment of high-risk tumors may lead to lower rates of progression to muscle invasion, and this in part may be due to better risk stratification leading to changes in treatment plan. The clinical contexts for the use of HAL-BLC are broader than prior knowledge. It is also becoming more clear that the positive impact of HAL-BLC is likely more than just reducing cancer recurrence rates, and patients would benefit from the technology at many time points in the management and follow-up of their disease. FAU - Pohar, Kamal S AU - Pohar KS AD - Department of Urology, The Ohio State University, Suite 3000, 915 Olentangy River Rd, Columbus, OH, 43212, USA. kamal.pohar@osumc.edu. LA - eng PT - Journal Article PT - Review DEP - 20200404 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Administration, Intravesical MH - Aminolevulinic Acid/administration & dosage/*analogs & derivatives MH - Cystoscopy/*methods MH - Disease Progression MH - Humans MH - Light MH - Neoplasm Recurrence, Local/prevention & control MH - Neoplasm Staging MH - Photosensitizing Agents/*administration & dosage MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery/*therapy OTO - NOTNLM OT - Blue light cystoscopy OT - Enhanced cystoscopy OT - Hexaminolevulinate OT - Non-muscle invasive bladder cancer OT - Surveillance cystoscopy EDAT- 2020/04/06 06:00 MHDA- 2020/04/09 06:00 CRDT- 2020/04/06 06:00 PHST- 2020/04/06 06:00 [entrez] PHST- 2020/04/06 06:00 [pubmed] PHST- 2020/04/09 06:00 [medline] AID - 10.1007/s11934-020-0966-5 [pii] AID - 10.1007/s11934-020-0966-5 [doi] PST - epublish SO - Curr Urol Rep. 2020 Apr 4;21(5):19. doi: 10.1007/s11934-020-0966-5. PMID- 32239282 OWN - NLM STAT- MEDLINE DCOM- 20200713 LR - 20240730 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 146 IP - 8 DP - 2020 Aug TI - Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer. PG - 2099-2108 LID - 10.1007/s00432-020-03202-0 [doi] AB - INTRODUCTION: After transurethral resection of a bladder tumor, patients frequently have a recurrence of the disease, thereby requiring adjuvant therapy. PURPOSE: The study aimed to determine the prognostic value of expression levels of p53, Ki-67, and survivin, and to develop a new prognostic model for patients with non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of a bladder tumor. METHODS: The study group consisted of 101 patients with primary NMIBC. Univariate followed by multivariate Cox proportional hazard regression analysis was performed to obtain a model including the smallest possible number of descriptive variables with the highest statistical significance and impact on risk. RESULTS: The RECINT model (RECurrence In Not Treated) including factors independently associated with cancer recurrence (tumor size [HR 1.148; p = 0.034], intensity of the color reaction for p53 [HR 1.716; p = 0.008], Ki-67 [HR 3.001; p = 0.022], and survivin [HR 1.461; p = 0.021]) adequately stratified recurrence free-survival (R(2) = 0.341, p < 0.001) in patients with primary NMIBC. Patients with the lowest RECINT score (0-6) had the lowest probability of cancer recurrence (1- and 5-year recurrence of 16%) in comparison with other groups (p < 0.001). CONCLUSIONS: The RECINT model may be useful for stratifying the risk of recurrence in patients with non-muscle-invasive bladder cancer and may allow for identification of those who may benefit the most from adjuvant BCG immunotherapy. FAU - Semeniuk-Wojtas, Aleksandra AU - Semeniuk-Wojtas A AD - Oncology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. osemeniuk@wp.pl. FAU - Lubas, Arkadiusz AU - Lubas A AD - Internal Diseases, Nephrology and Dialysis Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Cierniak, Szczepan AU - Cierniak S AD - Patomorphology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Brzoskowska, Urszula AU - Brzoskowska U AD - Patomorphology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Syrylo, Tomasz AU - Syrylo T AD - General, Functional and Oncological Urology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Zielinski, Henryk AU - Zielinski H AD - General, Functional and Oncological Urology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Stec, Rafal AU - Stec R AD - Oncology Department, Medical University of Warsaw, 19/25 Stepinska St., 00-739, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20200401 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (BIRC5 protein, human) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (Survivin) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Decision Support Systems, Clinical MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/*biosynthesis MH - Male MH - *Models, Statistical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/metabolism/pathology MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Survivin/*biosynthesis MH - Tumor Suppressor Protein p53/*biosynthesis MH - Urinary Bladder Neoplasms/*metabolism/pathology/surgery PMC - PMC7324417 OTO - NOTNLM OT - Bladder cancer OT - Ki-67 OT - NMIBC OT - RECINT model OT - Surviving OT - p53 COIS- None declared. EDAT- 2020/04/03 06:00 MHDA- 2020/07/14 06:00 PMCR- 2020/04/01 CRDT- 2020/04/03 06:00 PHST- 2019/12/10 00:00 [received] PHST- 2020/03/24 00:00 [accepted] PHST- 2020/04/03 06:00 [pubmed] PHST- 2020/07/14 06:00 [medline] PHST- 2020/04/03 06:00 [entrez] PHST- 2020/04/01 00:00 [pmc-release] AID - 10.1007/s00432-020-03202-0 [pii] AID - 3202 [pii] AID - 10.1007/s00432-020-03202-0 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2020 Aug;146(8):2099-2108. doi: 10.1007/s00432-020-03202-0. Epub 2020 Apr 1. PMID- 32235285 OWN - NLM STAT- MEDLINE DCOM- 20201214 LR - 20210206 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 30 IP - 3 DP - 2020 May TI - Management of de-novo urothelial carcinoma in transplanted patients. PG - 467-474 LID - 10.1097/MOU.0000000000000749 [doi] AB - PURPOSE OF REVIEW: The aim of this article is to review incidence, risk factors, and optimal management of de-novo urothelial carcinoma in transplant recipients. RECENT FINDINGS: There is a two to three-fold increased risk for de-novo malignant tumors after solid-organ transplantation, but there is currently no consensus regarding optimal management of de-novo urothelial carcinoma in transplanted patients. Known risk factors include polyomavirus BK, aristolochic acid, and smoking. Data suggest a higher rate of high-grade tumors, as well as predominantly higher stage at primary diagnosis, for both NMIBC and muscle-invasive bladder cancer (MIBC). Treatment for NMIBC includes TURB, mitomycin, and Bacille de Calmette-Guerin instillation with special concern to the immunosuppressive regime. Treatment of MIBC or advanced urothelial carcinoma includes radical cystectomy with chemotherapy if the patient is eligible. A screening should be performed in all transplant recipients, to allow early diagnosis. SUMMARY: De-novo urothelial carcinoma in transplant recipients is more frequent than in the general population and these tumors were more likely to be high-grade tumors and diagnosed at an advanced stage. There is very little information available on the optimal treatment for these patients. However, aggressive treatment and a strict management according the given recommendations are of the utmost importance. FAU - Pradere, Benjamin AU - Pradere B AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France. FAU - Schuettfort, Victor AU - Schuettfort V AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Quhal, Fahad AU - Quhal F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Fahad Specialist Hospital, Dammam. FAU - Aydh, Abdulmajeed AU - Aydh A AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, King Faisal Medical City, Abha, Saudi Arabia. FAU - Sari Motlagh, Reza AU - Sari Motlagh R AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Cystectomy MH - Humans MH - Kidney Transplantation/*adverse effects MH - Transplant Recipients MH - Urinary Bladder Neoplasms/pathology/*therapy MH - Urothelium/pathology EDAT- 2020/04/03 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/04/03 06:00 PHST- 2020/04/03 06:00 [entrez] PHST- 2020/04/03 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] AID - 00042307-202005000-00028 [pii] AID - 10.1097/MOU.0000000000000749 [doi] PST - ppublish SO - Curr Opin Urol. 2020 May;30(3):467-474. doi: 10.1097/MOU.0000000000000749. PMID- 32232691 OWN - NLM STAT- MEDLINE DCOM- 20200916 LR - 20261010 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 25 IP - 7 DP - 2020 Jul TI - A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. PG - 1364-1376 LID - 10.1007/s10147-020-01654-5 [doi] AB - BACKGROUND: The aim of this study is to establish new risk tables for the current clinical setting, enabling short- and long-term risk stratification for recurrence, progression, and cancer-specific death after transurethral resection in non-muscle invasive bladder cancer (NMIBC). Currently available risk tables lack input from the 2004 World Health Organization grading system and risk prediction for cancer-specific death. METHODS: This was a multi-institutional database study of 1490 patients diagnosed with NMIBC (the development cohort). A multivariate Fine and Gray subdistribution hazard model was used to assess the prognostic impact of various factors. Patients were classified into low-, intermediate-, and high-risk groups according to a sum of the weight of selected factors, and predicted cumulative rates were calculated. Internal validation was conducted using 200 bootstrap resamples to assess the optimism for the c-index and estimate a bias-corrected c-index. External validation of the developed risk table was performed on an independent dataset of 91 patients. RESULTS: The Japanese NIshinihon uro-onCology Extensive collaboration group (J-NICE) risk stratification table was derived from six, five, and two factors for recurrence, progression, and cancer-specific death, respectively. The internal validation bias-corrected c-index values were 0.619, 0.621, and 0.705, respectively. The application of the J-NICE table to an external dataset resulted in c-indices for recurrence, progression, and cancer-specific death of 0.527, 0.691, and 0.603, respectively. CONCLUSIONS: We propose a novel risk stratification model that predicts outcomes of treated NMIBC and may overcome the shortcomings of existing risk models. Further external validation is required to strengthen its clinical impact. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, 755-8505, Japan. FAU - Teramukai, Satoshi AU - Teramukai S AD - Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan. FAU - Kinoshita, Fumie AU - Kinoshita F AD - Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan. FAU - Yokota, Isao AU - Yokota I AD - Department of Biostatistics, Graduate of Medicine, Hokkaido University, Kita15 Nishi7, Kita-ku, Sapporo, 060-8638, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, 755-8505, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, 1501 Higashi kidera-cho, Nara-shi, Nara, 630-8305, Japan. FAU - Kinjyo, Mitsuru AU - Kinjyo M AD - Department of Pathology, Steel Memorial Yawata Hospital, 1-1-1 Harunomachi, Yahatahigashi-ku, Kitakyushu-shi, Fukuoka, 805-0050, Japan. FAU - Shimokama, Tatsuro AU - Shimokama T AD - Department of Pathology, Steel Memorial Yawata Hospital, 1-1-1 Harunomachi, Yahatahigashi-ku, Kitakyushu-shi, Fukuoka, 805-0050, Japan. FAU - Okumura, Koji AU - Okumura K AD - Department of Urology, Steel Memorial Yawata Hospital, 1-1-1 Harunomachi, Yahatahigashi-ku, Kitakyushu-shi, Fukuoka, 805-0050, Japan. FAU - Yomenori, Masaya AU - Yomenori M AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. FAU - Enokida, Hideki AU - Enokida H AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. FAU - Nakagawa, Masayuki AU - Nakagawa M AD - Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. kiyokun@naramed-u.ac.jp. CN - Nishinihon Uro-oncology Extensive Collaboration group LA - eng PT - Journal Article DEP - 20200330 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prognosis MH - Proportional Hazards Models MH - Reproducibility of Results MH - Risk Factors MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery MH - Young Adult OTO - NOTNLM OT - Prediction OT - Prognosis OT - Progression OT - Recurrence OT - Risk OT - Urinary bladder neoplasms EDAT- 2020/04/02 06:00 MHDA- 2020/09/17 06:00 CRDT- 2020/04/02 06:00 PHST- 2019/11/01 00:00 [received] PHST- 2020/03/04 00:00 [accepted] PHST- 2020/04/02 06:00 [pubmed] PHST- 2020/09/17 06:00 [medline] PHST- 2020/04/02 06:00 [entrez] AID - 10.1007/s10147-020-01654-5 [pii] AID - 10.1007/s10147-020-01654-5 [doi] PST - ppublish SO - Int J Clin Oncol. 2020 Jul;25(7):1364-1376. doi: 10.1007/s10147-020-01654-5. Epub 2020 Mar 30. PMID- 32216043 OWN - NLM STAT- MEDLINE DCOM- 20210513 LR - 20240328 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 9 IP - 11 DP - 2020 Jun TI - Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis. PG - 4014-4025 LID - 10.1002/cam4.3007 [doi] AB - The results demonstrate that the European Organisation for Research and Treatment of Cancer (EORTC) scale provides the best recurrence and progression prediction in comparison with European Association of Urology (EAU) and Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk scores among a mixed population of patients with non-muscle-invasive bladder who were treated with, or without, Bacillus Calmette-Guerin (BCG) and without any immediate postoperative chemotherapy. The study highlights the role of tumor diameter and extent in transition prediction. This retrospective cohort analysis of 322 patients with newly diagnosed non-muscle-invasive bladder cancer (NMIBC) assesses the concordance and accuracy of predicting recurrence and progression by EAU-recommended tools (EAU risk groups, EORTC, and CUETO). One-year and five-year c-indices ranged from 0.55 to 0.66 for recurrence and from 0.72 to 0.82 for progression. AUCROC of predictions ranged from 0.46 for 1-year recurrence risk based on CUETO groups, to 0.82 for 1-year progression risk based on EAU risk groups. Diameter (HR: 1.91; 95% CI: 1.39-2.61) and tumor extent (HR: 1.21; 95% CI: 1.01-1.46 for recurrence; HR: 3.1; 95% CI: 1.40-6.87 for progression) were shown to be significant predictors in multistate analysis. Lower accuracy of prediction was observed for patients treated with BCG maintenance immunotherapy. The EORTC model (overall c-index c = 0.64; 95% CI: 0.61-0.68) was superior to the EAU (P = .035; .62; 95% CI: 0.59-0.66) and CUETO (P < .001; c = 0.53; 95% CI: 0.50-0.56) models in predicting recurrence. The EORTC model (c = 0.82; 95% CI: 0.77-0.86) also performed better than CUETO (P = .008; c = 0.73; 95% CI: 0.66-0.81) but there was no sufficient evidence that it performed better than EAU (P = .572; c = 0.81; 95% CI: 0.77-0.84) for predicting progression. EORTC and CUETO gave similar predictions for progression in BCG-treated EAU high-risk patients (P = .48). We share anonymized individual patient data. In conclusion, despite moderate accuracy, EORTC provided the best recurrence and progression prediction for a mixed population of patients treated with, or without BCG, and without immediate postoperative chemotherapy. CI - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Jobczyk, Mateusz AU - Jobczyk M AUID- ORCID: 0000-0001-8615-5940 AD - Department of Urology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland. AD - Department of Urology, The Hospital Ministry of the Interior and Administration, Lodz, Poland. FAU - Stawiski, Konrad AU - Stawiski K AUID- ORCID: 0000-0002-6550-3384 AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. FAU - Fendler, Wojciech AU - Fendler W AUID- ORCID: 0000-0002-5083-9168 AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. FAU - Rozanski, Waldemar AU - Rozanski W AD - Department of Urology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20200326 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Aged MH - Cystectomy/*mortality MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*mortality/pathology/surgery MH - Practice Guidelines as Topic/*standards MH - Prognosis MH - Retrospective Studies MH - Risk Assessment/*methods/*standards MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/surgery PMC - PMC7286464 OTO - NOTNLM OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - prediction OT - risk stratification OT - systematic review COIS- None declared. EDAT- 2020/03/28 06:00 MHDA- 2021/05/14 06:00 PMCR- 2020/03/26 CRDT- 2020/03/28 06:00 PHST- 2019/10/27 00:00 [received] PHST- 2020/02/25 00:00 [revised] PHST- 2020/03/01 00:00 [accepted] PHST- 2020/03/28 06:00 [pubmed] PHST- 2021/05/14 06:00 [medline] PHST- 2020/03/28 06:00 [entrez] PHST- 2020/03/26 00:00 [pmc-release] AID - CAM43007 [pii] AID - 10.1002/cam4.3007 [doi] PST - ppublish SO - Cancer Med. 2020 Jun;9(11):4014-4025. doi: 10.1002/cam4.3007. Epub 2020 Mar 26. PMID- 32214283 OWN - NLM STAT- MEDLINE DCOM- 20201109 LR - 20201109 IS - 2038-8306 (Electronic) IS - 1121-760X (Print) IS - 1121-760X (Linking) VI - 64 IP - 2 DP - 2020 Mar 26 TI - Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. LID - 10.4081/ejh.2020.3098 [doi] LID - 3098 AB - Although the incidence varies with age and gender, urothelial bladder cancer is a relatively frequently occurring malignancy with variable clinical behavior that often has high recurrence rates. In this study, we analyzed the tumor tissues of 224 patients with pTa, pT1, and pT2 urinary bladder cancer. We performed a histomorphologic analysis and immunohistochemistry for p53, Ki-67, and E-cadherin, which were selected as markers of the malignant process. For pTa and pT1, univariate analyses of cancer-specific survival (CSS), progression-free survival (PFS), and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method, the log-rank test and Cox regression. Multivariate analysis was performed by a Cox regression analysis. Ki-67 (P<0.001) was significantly associated with CSS, but the highest association was shown for E-cadherin (P<0.001). For pT1 and pTa, the Kaplan-Meier analysis and the log-rank test revealed significantly worse PFS for patients with higher levels of Ki-67 (P<0.001) and lower levels of E-cadherin (P<0.001). Based on these obtained results, it can be clearly stated that Ki-67 and E-cadherin expression levels are associated with CSS, PFS and RFS. The clinical utility of these markers is valuable for pTa and pT1 urinary bladder cancer and should be further verified with prospective multi-center trials. FAU - Ziaran, Stanislav AU - Ziaran S AD - Department of Urology, Faculty of Medicine, Comenius University, Bratislava. stanoziaran@gmail.com. FAU - Harsanyi, Stefan AU - Harsanyi S FAU - Bevizova, Katarina AU - Bevizova K FAU - Varchulova Novakova, Zuzana AU - Varchulova Novakova Z FAU - Trebaticky, Branislav AU - Trebaticky B FAU - Bujdak, Peter AU - Bujdak P FAU - Galbavy, Stefan AU - Galbavy S FAU - Danisovic, Lubos AU - Danisovic L LA - eng PT - Journal Article DEP - 20200326 PL - Italy TA - Eur J Histochem JT - European journal of histochemistry : EJH JID - 9207930 RN - 0 (Antigens, CD) RN - 0 (Biomarkers, Tumor) RN - 0 (CDH1 protein, human) RN - 0 (Cadherins) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, CD/*metabolism MH - Biomarkers, Tumor/*metabolism MH - Cadherins/*metabolism MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/*metabolism MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Prognosis MH - Progression-Free Survival MH - Recurrence MH - Tumor Suppressor Protein p53/*metabolism MH - Urinary Bladder/metabolism/pathology MH - Urinary Bladder Neoplasms/diagnosis/*metabolism/mortality/pathology PMC - PMC7118433 COIS- Conflict of interest: The authors declare that they have no competing interests, and all authors confirm accuracy. EDAT- 2020/03/28 06:00 MHDA- 2020/11/11 06:00 PMCR- 2020/03/26 CRDT- 2020/03/28 06:00 PHST- 2019/12/03 00:00 [received] PHST- 2020/02/19 00:00 [accepted] PHST- 2020/03/28 06:00 [entrez] PHST- 2020/03/28 06:00 [pubmed] PHST- 2020/11/11 06:00 [medline] PHST- 2020/03/26 00:00 [pmc-release] AID - 10.4081/ejh.2020.3098 [doi] PST - epublish SO - Eur J Histochem. 2020 Mar 26;64(2):3098. doi: 10.4081/ejh.2020.3098. PMID- 32210471 OWN - NLM STAT- MEDLINE DCOM- 20200612 LR - 20200612 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 15 IP - 3 DP - 2020 TI - No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PG - e0229384 LID - 10.1371/journal.pone.0229384 [doi] LID - e0229384 AB - BACKGROUND: Non-muscle invasive bladder cancer patients are at high risk for tumour recurrence and progression, hence an intensive follow-up procedure is recommended which is costly. Identification of factors that are associated with the risk of recurrence and progression may enable personalized follow-up schedules. Obesity and diabetes mellitus may be associated with a worse prognosis, but the evidence is limited and inconsistent. Our objective was to determine the associations of BMI and diabetes mellitus with risks of recurrence and progression among non-muscle invasive bladder cancer patients. METHODS: A population-based cohort of patients diagnosed with non-muscle invasive bladder cancer between 1995 and 2010 was retrospectively identified from the Netherlands Cancer Registry and invited to participate in the Nijmegen Bladder Cancer Study (n = 1,433). Average weight during adult life, height, and diabetes mellitus diagnosis were self-reported by use of a questionnaire. Clinical follow-up data were retrieved from medical files. Associations were quantified using proportional hazard analyses. For all analyses, minimal adjustment sets were selected using a Directed Acyclic Graph. RESULTS: Fourteen percent of the patients indicated to be diagnosed with diabetes mellitus, and more than half was overweight (45%) or obese (9%). Compared to healthy weight, overweight and obesity were not associated with risk of recurrence (adjusted hazard ratio (HR) = 1.02; 95% confidence interval (CI): 0.86-1.22, and HR = 1.02; 95% CI: 0.76-1.38, respectively) and overall progression (HR = 1.04; 95% CI: 0.74-1.44, and HR = 1.20; 95% CI: 0.69-2.09, respectively). Also, no clear associations of diabetes mellitus with risk of recurrence (HR = 1.22; 95% CI: 0.98-1.54) and overall progression (HR = 1.16; 95% CI: 0.76-1.76) were found. CONCLUSION: Average BMI during adult life and diabetes mellitus were not clearly associated with risk of recurrence or progression in non-muscle invasive bladder cancer. Prospective cohort studies with detailed information on BMI and diabetes mellitus before and after diagnosis are needed to confirm these findings. FAU - Evers, Jelle AU - Evers J AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aben, Katja K H AU - Aben KKH AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20200325 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - *Body Mass Index MH - Diabetes Mellitus, Type 1/*complications MH - Diabetes Mellitus, Type 2/*complications MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology/etiology/pathology MH - Netherlands/epidemiology MH - Obesity/*complications MH - Overweight/*complications MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*epidemiology/etiology/pathology PMC - PMC7094867 COIS- The authors have declared that no competing interests exist. EDAT- 2020/03/27 06:00 MHDA- 2020/06/13 06:00 PMCR- 2020/03/25 CRDT- 2020/03/27 06:00 PHST- 2019/06/13 00:00 [received] PHST- 2020/02/05 00:00 [accepted] PHST- 2020/03/27 06:00 [entrez] PHST- 2020/03/27 06:00 [pubmed] PHST- 2020/06/13 06:00 [medline] PHST- 2020/03/25 00:00 [pmc-release] AID - PONE-D-19-16781 [pii] AID - 10.1371/journal.pone.0229384 [doi] PST - epublish SO - PLoS One. 2020 Mar 25;15(3):e0229384. doi: 10.1371/journal.pone.0229384. eCollection 2020. PMID- 32207064 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20210110 IS - 1776-260X (Electronic) IS - 1776-2596 (Linking) VI - 15 IP - 2 DP - 2020 Apr TI - Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. PG - 211-220 LID - 10.1007/s11523-020-00707-z [doi] AB - BACKGROUND: Myeloid-derived suppressor cells (MDSCs) were linked to pathologic stage in bladder urothelial carcinoma (UC). Neutrophil lymphocyte ratio (NLR) is an inflammatory biomarker with a prognostic role in metastatic (m)UC. OBJECTIVE: We hypothesized that MDSC levels correlate with NLR and overall survival (OS) in mUC. PATIENTS AND METHODS: MDSCs were measured in blood samples from patients with mUC in fresh unfractionated whole blood (WB) and peripheral blood mononuclear cells (PBMC) by flow cytometry and defined as LinloCD33+/HLADR- (Total MDSC). MDSC subsets were defined as polymorphonuclear (PMN-MDSC: CD15+/CD14-), monocytic (M-MDSC: CD15-/CD14+), and uncommitted (UNC-MDSC: CD15-/CD14-). MDSC populations were presented as a percentage of live nucleated blood cells. Spearman's rank correlation assessed correlations between MDSC and NLR. Kaplan-Meier curves and log-rank test estimated OS from the time of MDSC collection to last follow-up or date of death. RESULTS: Of the 76 patients, 78% were men and 43% were never smokers with a median age of 69 years (range 31-83); 72% had pure UC and 76% had lower tract UC. Prior therapies included intravesical therapy (22%), neoadjuvant chemotherapy (30%), cystectomy or nephroureterectomy (55%). Median follow-up for all patients was 12 months (0.6-36.5). PMN-MDSC was the predominant subset in WB and PBMC. There was significant correlation between individual MDSC subsets in WB and PBMC (p /=60 ml/min/1.73 m(2) (non-CKD group) and <60 ml/min/1.73 m(2) (CKD group). Background-adjusted multivariate analyses were performed to evaluate the effect of preoperative CKD on oncological outcomes, including intravesical recurrence-free survival, muscle-invasive bladder cancer-free survival, upper urinary tract (UUT) recurrence-free survival, metastasis-free survival, cancer-specific survival, and overall survival. We evaluated predictive accuracy of CKD on prognosis using the receiver operating characteristic curve and compared between risk factors in the European Organization for Research and Treatment of Cancer scoring system and CKD plus those risk factors. RESULTS: The median age and median follow-up period were 72 years and 51 months, respectively. Of 434 patients, 141 (32%) were diagnosed with CKD before TURBT. In background-adjusted multivariate analyses, CKD was an independent risk factor for those oncological outcomes, except for UUT recurrence. The predictive accuracy of CKD plus risk factors in the European Organization for Research and Treatment of Cancer scoring system on oncological outcomes was significantly improved compared with those risk factors alone, except for UUT recurrence. CONCLUSION: Preoperative CKD was a risk factor and might improve predictive accuracy on poor prognosis in patients with primary NMIBC who underwent TURBT. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: shingoh@hirosaki-u.ac.jp. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Imai, Atsushi AU - Imai A AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200320 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Renal Insufficiency, Chronic/*complications MH - Retrospective Studies MH - Risk Factors MH - Urethra MH - Urinary Bladder Neoplasms/*complications/pathology/*surgery OTO - NOTNLM OT - Chronic kidney disease OT - Non-muscle-invasive bladder cancer OT - Oncological outcome OT - Predictor OT - Transurethral resection of bladder tumor EDAT- 2020/03/24 06:00 MHDA- 2021/04/30 06:00 CRDT- 2020/03/24 06:00 PHST- 2019/12/11 00:00 [received] PHST- 2020/01/28 00:00 [revised] PHST- 2020/02/02 00:00 [accepted] PHST- 2020/03/24 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/03/24 06:00 [entrez] AID - S1078-1439(20)30042-9 [pii] AID - 10.1016/j.urolonc.2020.02.001 [doi] PST - ppublish SO - Urol Oncol. 2020 Aug;38(8):684.e1-684.e8. doi: 10.1016/j.urolonc.2020.02.001. Epub 2020 Mar 20. PMID- 32199915 OWN - NLM STAT- MEDLINE DCOM- 20210531 LR - 20260106 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 3 IP - 3 DP - 2020 Jun TI - Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PG - 306-315 LID - S2588-9311(20)30032-8 [pii] LID - 10.1016/j.euo.2020.02.007 [doi] AB - CONTEXT: A noninvasive multiparametric magnetic resonance imaging (MRI)-based scoring system for predicting muscle-invasive bladder cancer (MIBC), the "Vesical Imaging Reporting and Data System" (VI-RADS), was recently developed by an international multidisciplinary panel. Since then, a few studies evaluating the value of VI-RADS for predicting MIBC have been published. OBJECTIVE: To review the diagnostic performance of VI-RADS for the prediction of MIBC. EVIDENCE ACQUISITION: PubMed and EMBASE databases were searched up to November 10, 2019. We included diagnostic accuracy studies using VI-RADS to predict MIBC using cystectomy or transurethral resection as the reference standard. Methodological quality was evaluated with Quality Assessment of Diagnostic Accuracy Studies-2. Sensitivity and specificity were pooled and plotted using hierarchical summary receiver operating characteristics (HSROC) modeling. Meta-regression analyses were done to explore heterogeneity. EVIDENCE SYNTHESIS: Six studies (1770 patients) were included. Pooled sensitivity and specificity were 0.83 (95% confidence interval [CI] 0.70-0.90) and 0.90 (95% CI 0.83-0.95), and the area under the HSROC curve was 0.94 (95% CI 0.91-0.95). Heterogeneity was present among the studies (Q = 29.442, p <  0.01; I(2) = 87.93%, and 90.99% for sensitivity and specificity). Meta-regression analyses showed that the number of patients (>205 vs /=3 vs >/=4) were significant factors affecting heterogeneity (p /= 14.5% was classified as high. In the multivariable analysis, a high RDW could independently predict shorter TTR (subdistribution hazard ratio [SHR]: 2.65, 95% confidence interval [CI]: 1.83-3.84, P < 0.001), irrespective of tumor characteristics. No significant relationship was observed between RDW and time to progression (SHR: 1.75, 95% CI: 0.76-4.08, P = 0.19). Adding binary-coded RDW to the EORTC risk scoring model significantly improved its discriminatory performance in assessing recurrence risk (c-index: 0.62, improvement: 0.052, P < 0.001). High RDW was associated with shorter TTR in patients treated with bacillus Calmette-Guerin in the multivariable analysis (SHR: 2.0, 95% CI: 1.01-3.98, P = 0.047). CONCLUSIONS: RDW was an independent, significant prognostic factor of TTR in patients with primary NMIBC. Adding RDW to the EORTC risk model significantly improved the model's predictability for tumor recurrence. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan; Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. Electronic address: wfukuokaya@gmail.com. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Watanabe, Hisaki AU - Watanabe H AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan; Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Bo, Fan AU - Bo F AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Okada, Daigo AU - Okada D AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Aikawa, Koichi AU - Aikawa K AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan; Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Ochi, Atsuhiko AU - Ochi A AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Suzuki, Koichiro AU - Suzuki K AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Shiga, Naoki AU - Shiga N AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Abe, Hirokazu AU - Abe H AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20200315 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Erythrocyte Indices/*physiology MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*blood MH - Retrospective Studies MH - Urinary Bladder Neoplasms/blood/*complications OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Non-muscular-invasive bladder cancer OT - Prognostic model OT - Red cell distribution width EDAT- 2020/03/19 06:00 MHDA- 2021/04/02 06:00 CRDT- 2020/03/19 06:00 PHST- 2019/11/01 00:00 [received] PHST- 2020/01/22 00:00 [revised] PHST- 2020/01/27 00:00 [accepted] PHST- 2020/03/19 06:00 [pubmed] PHST- 2021/04/02 06:00 [medline] PHST- 2020/03/19 06:00 [entrez] AID - S1078-1439(20)30036-3 [pii] AID - 10.1016/j.urolonc.2020.01.016 [doi] PST - ppublish SO - Urol Oncol. 2020 Jul;38(7):638.e15-638.e23. doi: 10.1016/j.urolonc.2020.01.016. Epub 2020 Mar 15. PMID- 32173242 OWN - NLM STAT- MEDLINE DCOM- 20210506 LR - 20210506 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 5 DP - 2020 May TI - Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guerin after transurethral resection of the bladder tumor. PG - 459-464 LID - S1078-1439(20)30057-0 [pii] LID - 10.1016/j.urolonc.2020.02.016 [doi] AB - OBJECTIVES: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). MATERIALS AND METHODS: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guerin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. RESULTS: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5% in patients with T2DM compared to 36% in patients without T2DM, P < 0.0001. Five-year PFS estimates were 60.5% in patients with T2DM compared to 70.2% in patients without T2DM, P = 0.003. T2DM was independently associated with disease recurrence (hazard ratio = 1.41; 95% confidence interval = 1.20-1.66, P < 0.001) and progression (hazard ratio = 1.27; 95% confidence interval = 0.99-1.63, P < 0.001), after adjusting for other known predictive factors such as tumor size, multifocality, T1G3 on re-TURB, body mass index, lymphovascular invasion, and neutrophil-to-lymphocytes ratio. CONCLUSIONS: Given the potential implications for management, prospective validation of this finding along with translational studies designed to investigate the underlying biology of such an association are warranted. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Katalin, Martha Orsolya AU - Katalin MO AD - Department of Urology, University of Medicine, Pharmacy, Sciences and Technology, Tirgu Mures, Romania. FAU - Buonerba, Carlo AU - Buonerba C AD - CRTR Rare Tumors Reference Center, AOU Federico II, Napoli, Italy; Environment & Health Operational Unit, Zoo-prophylactic Institute of Southern Italy, Portici, Italy. FAU - Marian, Raluca AU - Marian R AD - Department of Cell and Molecular Biology, University of Medicine, Pharmacy, Sciences and Technology, Tirgu Mures, Romania. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy. FAU - Di Stasi, Savino AU - Di Stasi S AD - Department of Experimental Medicine and Surgery, Tor Vegata University, Rome, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, La Sapienza University of Rome, Rome, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Urology, La Sapienza University of Rome, Rome, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Del Prete, Paola AU - Del Prete P AD - Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University Federico II, Napoli, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Porreca, Angelo AU - Porreca A AD - Department of Robotic Urologic Surgery, Abano Terme Hospital, Abano Terme, Italy. FAU - Artibani, Walter AU - Artibani W AD - Department of Robotic Urologic Surgery, Abano Terme Hospital, Abano Terme, Italy. FAU - Bove, Pierluigi AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. FAU - Lima, Estevao AU - Lima E AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. FAU - Abu Farhan, Abdal Rahman AU - Abu Farhan AR AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Ditonno, Pasquale AU - Ditonno P AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University Federico II, Napoli, Italy. FAU - di Lorenzo, Giuseppe AU - di Lorenzo G AD - Department of Clinical Medicine and Surgery, University Federico II, Napoli, Italy; Department of Medicine, University of Molise, Campobasso, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Sonpavde, Guru AU - Sonpavde G AD - Genitourinary Oncology Section, Dana Farber Cancer Institute, Boston, MA. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy; Department of Cell and Molecular Biology, University of Medicine, Pharmacy, Sciences and Technology, Tirgu Mures, Romania. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy; Universita degli Studi di Milano, Milan, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20200312 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Chemotherapy, Adjuvant MH - *Cystectomy/methods MH - Diabetes Mellitus, Type 2/*complications MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/*complications/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Diabetes mellitus OT - High grade OT - High risk OT - Progression OT - Recurrence EDAT- 2020/03/17 06:00 MHDA- 2021/05/07 06:00 CRDT- 2020/03/17 06:00 PHST- 2019/07/11 00:00 [received] PHST- 2020/01/05 00:00 [revised] PHST- 2020/02/11 00:00 [accepted] PHST- 2020/03/17 06:00 [pubmed] PHST- 2021/05/07 06:00 [medline] PHST- 2020/03/17 06:00 [entrez] AID - S1078-1439(20)30057-0 [pii] AID - 10.1016/j.urolonc.2020.02.016 [doi] PST - ppublish SO - Urol Oncol. 2020 May;38(5):459-464. doi: 10.1016/j.urolonc.2020.02.016. Epub 2020 Mar 12. PMID- 32164441 OWN - NLM STAT- MEDLINE DCOM- 20210423 LR - 20220112 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 34 IP - 5 DP - 2020 May TI - Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. PG - 573-580 LID - 10.1089/end.2019.0750 [doi] AB - Purpose: To address the safety and feasibility of adjuvant single-dose upper urinary tract instillation of mitomycin (ASDM) immediately after therapeutic ureteroscopy for upper tract urothelial carcinoma (UTUC) and to compare urothelial (ipsilateral or bladder) recurrence rates in the ASDM group and controls. Materials and Methods: Between April 2015 and August 2018, 52 patients affected by UTUC were treated by endoscopic ablation, of whom 26 were selected for ASDM. Clinical and perioperative data and 30-day complications were recorded. Urothelial recurrence-free survival (URFS) was evaluated with second-look ureteroscopy (URS) and CT scan/URS every 6 months. Results: ASDM was administered through a Single-J (19/25, 76%) or a Double-J (6/25, 24%) in 25/26 (96%) patients. Median follow-up was 18 months (IQR 10-29). The urothelial recurrence rate was 23.5% and 55.5% in the ASDM group and controls, respectively (p = 0.086). Mean URFS was 28.8 months in the ASDM group vs 18.8 months in controls (log-rank p = 0.067). On multivariate Cox regression, ASDM was associated with a 7.7-fold lower risk of urothelial recurrence (HR = 0.13; 95% CI 0.03-0.65; p = 0.01). Clavien grade 90%) and alveolar histology (<10%). Pre-treatment imaging should be carried out by computed tomography (CT) or at present is more likely with magnetic resonance imaging of the pelvis. Chest CT and bone scintigraphy are used to screen for metastases. In selected cases, a positron emission tomography scan may be recommended to evaluate suspicious lesions. The current prognostic classification considers age, histologic subtype, tumor site, size, and extent (nodal or distant metastases). Staging is based on pre-operative findings, group is based on intra-operative findings and pathology, and risk stratification is derived from both stage and group data. Pre-operative chemotherapy is the most common first-line intervention for bladder/prostate RMS, before surgery or radiation therapy. Collaborative groups such as the Soft Tissue Sarcoma Committee of the Children's Oncology Group and the European Pediatric Soft Tissue Sarcoma Study Group endorse this therapy. PUNLMPs are generally solitary, small (1-2 cm), non-invasive lesions that do not metastasize. Therapy is usually limited to a transurethral resection of the bladder tumor. About 35% are recurrent and around 10% of them increase in size if they are not treated. CI - Copyright: (c) 2020 Lopes RI et al. FAU - Lopes, Roberto Iglesias AU - Lopes RI AD - Pediatric Urology Unit, Division of Urology, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, 05402-000, Brazil. FAU - Mello, Marcos Figueiredo AU - Mello MF AUID- ORCID: 0000-0002-6816-9254 AD - Pediatric Urology Unit, Division of Urology, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, 05402-000, Brazil. FAU - Lorenzo, Armando J AU - Lorenzo AJ AD - Division of Urology, The Hospital for Sick Children and Department of Surgery, University of Toronto, Toronto, ON, Canada. LA - eng GR - U10 CA180886/CA/NCI NIH HHS/United States GR - U10 CA180899/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20200225 PL - England TA - F1000Res JT - F1000Research JID - 101594320 SB - IM MH - Child MH - Humans MH - Male MH - Prognosis MH - Prostatic Neoplasms MH - *Rhabdomyosarcoma MH - *Urinary Bladder Neoplasms PMC - PMC7043112 OTO - NOTNLM OT - BLADDER MALIGNANCIES OT - PEDIATRIC COIS- No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed. EDAT- 2020/03/10 06:00 MHDA- 2020/08/28 06:00 PMCR- 2020/02/25 CRDT- 2020/03/10 06:00 PHST- 2020/02/20 00:00 [accepted] PHST- 2020/03/10 06:00 [entrez] PHST- 2020/03/10 06:00 [pubmed] PHST- 2020/08/28 06:00 [medline] PHST- 2020/02/25 00:00 [pmc-release] AID - F1000 Faculty Rev-147 [pii] AID - 10.12688/f1000research.19396.1 [doi] PST - epublish SO - F1000Res. 2020 Feb 25;9:F1000 Faculty Rev-147. doi: 10.12688/f1000research.19396.1. eCollection 2020. PMID- 32147582 OWN - NLM STAT- MEDLINE DCOM- 20201229 LR - 20201229 IS - 1089-8611 (Electronic) IS - 1089-8603 (Linking) VI - 98 DP - 2020 May 1 TI - Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment. PG - 50-59 LID - S1089-8603(20)30004-5 [pii] LID - 10.1016/j.niox.2020.03.003 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is the standard treatment for patients with high-risk non-muscle invasive bladder cancer (BC). Despite its success, about 30-50% of patients are refractory. It was reported that inducible nitric oxide synthase (iNOS) tumor expression is presented in 50% of human BC, associated with bad prognosis and BCG failure. OBJECTIVE: to evaluate in human bladder tumors the association between iNOS expression and the tumor microenvironment focusing on the immunosuppressive protein S100A9. Also, investigate in a preclinical murine MB49-BC model the tumor immunoresponse induced by BCG in combination with the nitric oxide production inhibitor l-NAME. RESULTS: In human bladder tumors, we detected a positive association between iNOS and S100A9 tumor expression, suggesting a relationship between both immunomodulatory proteins. We also found a positive correlation between iNOS tumor expression and the presence of S100A9(+) tumor-infiltrating cells, suggesting an immunosuppressive tumor microenvironment induced by the nitric oxide production. Using the subcutaneous murine BC model, we show that similarly to the human pathology, MB49 tumors constitutively expressed iNOS and S100A9 protein. MB49 tumor-bearing mice presented an immunosuppressive systemic profile characterized by fewer cytotoxic cells (CD8(+) and NK) and higher suppressor cells (Treg and myeloid-derived suppressor cells -MDSC-) compared to normal mice. BCG treatment reduced tumor growth, increasing local CD8(+)-infiltrating cells and induced a systemic increase in CD8(+) and a reduction in Treg. BCG combined with l-NAME, significantly reduced tumor growth compared to BCG alone, diminishing iNOS and S100A9 tumor expression and increasing CD8(+)-infiltrating cells in tumor microenvironment. This local response was accompanied by the systemic increase in CD8(+) and NK cells, and the reduction in Treg and MDSC, even more than BCG alone. Similar results were obtained using the orthotopic BC model, where an increase in specific cytotoxicity against MB49 tumor cells was detected. CONCLUSION: The present study provides preclinical information where NO inhibition in iNOS-expressing bladder tumors could contribute to improve BCG antitumor immune response. The association between iNOS and S100A9 in human BC supports the hypothesis that iNOS expression is a negative prognostic factor and a promising therapeutic target. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Langle, Yanina Veronica AU - Langle YV AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina. Electronic address: yaninalangle@yahoo.com.ar. FAU - Balarino, Natalia Patricia AU - Balarino NP AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina. Electronic address: natybalarino@hotmail.com. FAU - Belgorosky, Denise AU - Belgorosky D AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina. Electronic address: d_belgo@hotmail.com. FAU - Cresta Morgado, Pablo Damian AU - Cresta Morgado PD AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina. Electronic address: pablo_crestam@hotmail.com. FAU - Sandes, Eduardo Omar AU - Sandes EO AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina. Electronic address: eosandes@yahoo.com.ar. FAU - Marino, Lina AU - Marino L AD - Universidad de Buenos Aires, Facultad de Medicina, IOAHR, Diagnostic Area, Argentina. Electronic address: lina.marino@hotmail.com. FAU - Bilbao, Erica Rojas AU - Bilbao ER AD - Universidad de Buenos Aires, Facultad de Medicina, IOAHR, Diagnostic Area, Argentina. Electronic address: ericarbilbao_2008@yahoo.com.ar. FAU - Zambrano, Macarena AU - Zambrano M AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina; Fellow of Universidad de Buenos Aires, Argentina. Electronic address: maca.2291@gmail.com. FAU - Lodillinsky, Catalina AU - Lodillinsky C AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina; Members of Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Argentina. Electronic address: catalina.lodillinsky@gmail.com. FAU - Eijan, Ana Maria AU - Eijan AM AD - Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncologia Angel H. Roffo (IOAHR), Research Area, Argentina; Members of Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Argentina. Electronic address: grupoeijan@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200306 PL - United States TA - Nitric Oxide JT - Nitric oxide : biology and chemistry JID - 9709307 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (BCG Vaccine) RN - 0 (Calgranulin B) RN - 0 (S100A9 protein, human) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (NOS2 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - V55S2QJN2X (NG-Nitroarginine Methyl Ester) SB - IM MH - Adjuvants, Immunologic/administration & dosage/*pharmacology MH - Animals MH - Antineoplastic Agents, Immunological/administration & dosage/*pharmacology MH - BCG Vaccine/administration & dosage/immunology/*pharmacology MH - Calgranulin B/biosynthesis MH - Cell Proliferation/drug effects MH - Drug Screening Assays, Antitumor MH - Humans MH - Injections, Subcutaneous MH - Mice MH - Mice, Inbred C57BL MH - NG-Nitroarginine Methyl Ester/pharmacology MH - Neoplasms, Experimental/drug therapy/metabolism/pathology MH - Nitric Oxide/*antagonists & inhibitors/metabolism MH - Nitric Oxide Synthase Type II/biosynthesis MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/*drug therapy/metabolism/pathology OTO - NOTNLM OT - Bacillus calmette-Guerin (BCG) OT - Bladder cancer OT - Immunotherapy OT - Nitric oxide COIS- Declaration of competing interest The authors have no conflict of interest to declare. EDAT- 2020/03/10 06:00 MHDA- 2020/12/30 06:00 CRDT- 2020/03/10 06:00 PHST- 2020/01/05 00:00 [received] PHST- 2020/02/24 00:00 [revised] PHST- 2020/03/03 00:00 [accepted] PHST- 2020/03/10 06:00 [pubmed] PHST- 2020/12/30 06:00 [medline] PHST- 2020/03/10 06:00 [entrez] AID - S1089-8603(20)30004-5 [pii] AID - 10.1016/j.niox.2020.03.003 [doi] PST - ppublish SO - Nitric Oxide. 2020 May 1;98:50-59. doi: 10.1016/j.niox.2020.03.003. Epub 2020 Mar 6. PMID- 32144049 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20250530 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 18 IP - 4 DP - 2020 Aug TI - Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. PG - e418-e442 LID - S1558-7673(19)30377-5 [pii] LID - 10.1016/j.clgc.2019.12.004 [doi] AB - BACKGROUND: Limited evidence exists regarding the cost and health-related quality of life (HRQoL) effects of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression to muscle-invasive bladder cancer (MIBC). We examined these effects using evidence from a recent randomized control trial. MATERIAL AND METHODS: The costs and HRQoL associated with bladder cancer were assessed using data from the BOXIT trial (bladder COX-2 inhibition trial; n = 472). The cost and HRQoL effects from clinical events were estimated using generalized estimating equations. The costs were derived from the recorded resource usage and UK unit costs. HRQoL was assessed using the EQ-5D-3L and reported UK preference tariffs. The events were categorized using the TMN classification. RESULTS: Cases of grade 3 recurrence and progression were associated with statistically significant HRQoL decrements (-0.08; 95% confidence interval [CI], -0.13 to -0.03; and -0.10; 95% CI, -0.17 to -0.03, respectively). The 3-year average cost per NMIBC patient was estimated at pound8735 (95% CI, 8325-9145). Cases of grade 1, 2, and 3 recurrence were associated with annual cost effects of pound1218 (95% CI, 403-2033), pound1677 (95% CI, 920-2433), and pound3957 (95% CI, 2332-5583), respectively. Progression to MIBC was associated with an average increase in costs of pound5407 (95% CI, 2663-8152). CONCLUSION: Evidence from the BOXIT trial suggests that patients with NMIBC will both experience decrements in HRQoL and incur significant costs, especially in the event of a grade 3 recurrence or a progression to MIBC. CI - Copyright (c) 2019 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Cox, Edward AU - Cox E AD - Centre for Health Economics, University of York, York, United Kingdom. Electronic address: edward.cox@york.ac.uk. FAU - Saramago, Pedro AU - Saramago P AD - Centre for Health Economics, University of York, York, United Kingdom. FAU - Kelly, John AU - Kelly J AD - Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, University College London Hospital, London, United Kingdom. FAU - Porta, Nuria AU - Porta N AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom. FAU - Hall, Emma AU - Hall E AD - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom. FAU - Tan, Wei Shen AU - Tan WS AD - Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, Imperial College Healthcare, London, United Kingdom. FAU - Sculpher, Mark AU - Sculpher M AD - Centre for Health Economics, University of York, York, United Kingdom. FAU - Soares, Marta AU - Soares M AD - Centre for Health Economics, University of York, York, United Kingdom. LA - eng GR - 25351/CRUK_/Cancer Research UK/United Kingdom GR - 5669/CRUK_/Cancer Research UK/United Kingdom GR - CRUK 07/004/CRUK_/Cancer Research UK/United Kingdom GR - C8262/A5669/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191214 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Clinical Trials, Phase III as Topic MH - Female MH - Follow-Up Studies MH - *Health Care Costs MH - Health Resources MH - Humans MH - Male MH - Neoplasm Recurrence, Local/drug therapy/*economics/physiopathology MH - Prognosis MH - *Quality of Life MH - Randomized Controlled Trials as Topic MH - United Kingdom MH - Urinary Bladder Neoplasms/drug therapy/*economics/physiopathology PMC - PMC7427321 OTO - NOTNLM OT - Cost OT - HRQoL OT - NMIBC OT - QALY OT - RCT EDAT- 2020/03/08 06:00 MHDA- 2021/06/16 06:00 PMCR- 2020/08/01 CRDT- 2020/03/08 06:00 PHST- 2019/10/06 00:00 [received] PHST- 2019/12/01 00:00 [revised] PHST- 2019/12/09 00:00 [accepted] PHST- 2020/03/08 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2020/03/08 06:00 [entrez] PHST- 2020/08/01 00:00 [pmc-release] AID - S1558-7673(19)30377-5 [pii] AID - 10.1016/j.clgc.2019.12.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Aug;18(4):e418-e442. doi: 10.1016/j.clgc.2019.12.004. Epub 2019 Dec 14. PMID- 32141938 OWN - NLM STAT- MEDLINE DCOM- 20201214 LR - 20210206 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 30 IP - 3 DP - 2020 May TI - Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn in the last 24 months: a critical review. PG - 387-391 LID - 10.1097/MOU.0000000000000741 [doi] AB - PURPOSE OF REVIEW: Patients with nonmuscle invasive bladder cancer (NMIBC) have a high risk of recurrent tumors, even in spite of contemporary guideline recommended therapy. Follow-up recommendations are also clear (cystoscopy with cytology and upper urinary tract imaging in high-risk patients), but frequency and duration of follow-up are well defined. However, recent developments in follow-up tools might be of interest for clinical practice. RECENT FINDINGS: Enhanced endoscopy improves detection and treatment of recurrences, and it can help in tailoring follow-up. However, it remains an invasive procedure. Most recently cystoscopy augmented with artificial intelligence has shown some promising results. Active surveillance, frequently done in prostate cancer patients, is also gaining attention in NMIBC follow-up. Finally markers are being studied and launched. Although not recommended by guidelines, and not used in clinical practice, recent studies have shown marker combinations with very high negative predictive values for (high risk) recurrences in follow-up of NMIBC patients. SUMMARY: New tools for follow-up such as enhanced cystoscopy and urinary markers might help to individualize follow-up, which will result in decreasing patient discomfort, workload and costs while quality of care is maintained. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboudumc Nijmegen, Nijmegen, The Netherlands. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - *Artificial Intelligence MH - *Cystoscopy MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis MH - Urinary Bladder Neoplasms/*diagnosis EDAT- 2020/03/07 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/03/07 06:00 PHST- 2020/03/07 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/03/07 06:00 [entrez] AID - 00042307-202005000-00018 [pii] AID - 10.1097/MOU.0000000000000741 [doi] PST - ppublish SO - Curr Opin Urol. 2020 May;30(3):387-391. doi: 10.1097/MOU.0000000000000741. PMID- 32139301 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 3 DP - 2020 Jun TI - High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test. PG - 210-221 LID - S1558-7673(19)30311-8 [pii] LID - 10.1016/j.clgc.2019.10.007 [doi] AB - INTRODUCTION: Cystoscopy and transurethral resection are the current reference standard tests to diagnose and histologically confirm non-muscle-invasive bladder cancer (NMIBC). In other tumor entities (ie, colon carcinoma, cervical cancer), DNA methylation markers have been approved as diagnostic tests with high diagnostic power. In our case-control study, we used an approved molecular cervical cancer diagnostics test that includes 6 DNA methylation markers (GynTect) for the detection of bladder cancer. PATIENTS AND METHODS: We included samples from 40 patients with bladder cancer and 34 control subjects. In a pilot study, we analyzed DNA methylation in 38 tumor tissues and 4 healthy ureters using methylation-specific polymerase chain reaction. Subsequently, we determined the sensitivity and specificity of the GynTect for the detection of bladder cancer in urine sediments from 40 patients with bladder cancer and 30 control subjects with benign prostatic hyperplasia or urolithiasis. RESULTS: The markers showed very different methylation rates in the NMIBC tissues, ranging from 2.6% to 78.9%. No methylation of any of the markers was detectable in the healthy ureters. Using the urine sediments from the patients with cancer and control subjects, we found surprisingly high sensitivity and specificity for the GynTect assay (60% and 96.7%, respectively). The application of different algorithms for evaluation of the markers included in GynTect resulted in a sensitivity of 6-12 weeks; group C: > 12-18 weeks). Kaplan-Meier plots were used to estimate differences in RFS, PFS, and CSS. Multivariate Cox regression analysis was used to assess the impact of time to Re-TUR on oncological outcomes. RESULTS: Overall, 269 high-grade T1 BC patients were eligible for the analysis. Nineteen (7.1%) had concomitant CIS. Median follow-up was 49.3 (IQR 25-65) months. Kaplan-Meier plots showed no differences in RFS, PFS, and CSS between the three groups. Multivariate Cox regression analysis showed that Group B had a slightly better RFS, while the other outcomes were not affected by time to Re-TUR. CONCLUSIONS: This is the first study testing the role of time to Re-TUR in a homogeneous population of patients with high-grade T1 BC who received complete BCG treatment. The study challenged the concept the sooner the Re-TUR the better, since time to Re-TUR did not significantly affect oncological outcomes. FAU - Calo, Beppe AU - Calo B AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. b.calo@hotmail.it. AD - Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal. b.calo@hotmail.it. FAU - Falagario, Ugo AU - Falagario U AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University of Foggia, Foggia, Italy. FAU - Veccia, Alessandro AU - Veccia A AD - Division of Urology, Department of Surgery, VCU Health, Richmond, VA, USA. FAU - Chirico, Marco AU - Chirico M AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Carvalho-Diaz, Emanuel AU - Carvalho-Diaz E AD - Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal. FAU - Mota, Paulo AU - Mota P AD - Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal. FAU - Lima, Estevao AU - Lima E AD - Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Department of Surgery, VCU Health, Richmond, VA, USA. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. LA - eng PT - Journal Article DEP - 20200215 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Combined Modality Therapy MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Progression-Free Survival MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery OTO - NOTNLM OT - High-grade OT - Non muscle-invasive bladder cancer OT - Oncological outcomes OT - Restaging transurethral resection OT - Time to re-TUR EDAT- 2020/02/18 06:00 MHDA- 2021/06/25 06:00 CRDT- 2020/02/17 06:00 PHST- 2019/11/12 00:00 [received] PHST- 2020/01/27 00:00 [accepted] PHST- 2020/02/18 06:00 [pubmed] PHST- 2021/06/25 06:00 [medline] PHST- 2020/02/17 06:00 [entrez] AID - 10.1007/s00345-020-03108-z [pii] AID - 10.1007/s00345-020-03108-z [doi] PST - ppublish SO - World J Urol. 2020 Dec;38(12):3161-3167. doi: 10.1007/s00345-020-03108-z. Epub 2020 Feb 15. PMID- 32061496 OWN - NLM STAT- MEDLINE DCOM- 20201210 LR - 20201214 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 30 IP - 2 DP - 2020 Feb TI - Reduced E-cadherin expression as a prognostic factor in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. PG - 66-74 LID - S1166-7087(19)30651-7 [pii] LID - 10.1016/j.purol.2019.12.004 [doi] AB - INTRODUCTION AND OBJECTIVES: The exact role of E-cadherin in non-muscle-invasive bladder cancer (NMIBC) is still unknown, and the aims of this study were to prove whether reduced E-cadherin expression can be a prognostic factor in patients with NMIBC. MATERIALS AND METHODS: A meta-analysis was conducted to assess the prognostic value of reduced E-cadherin expression in NMIBC. The PubMed, Embase and Web of Science databases were included in the study search. RESULTS: Fifteen studies with a total of 1538 NMIBC patients were included. The results showed that reduced E-cadherin expression was significantly associated with poor recurrence-free survival (RFS) (pooled HR 2.16, 95% CI 1.22-3.85) and progression-free survival (PFS) (pooled HR 1.91, 95% CI 1.52-2.40) in NMIBC patients. CONCLUSION: E-cadherin can be a prognostic factor for patients with NMIBC. CI - Copyright (c) 2019 Elsevier Masson SAS. All rights reserved. FAU - Yang, T AU - Yang T AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. FAU - Fan, J AU - Fan J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. FAU - Liang, H AU - Liang H AD - Department of Pathology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. FAU - He, D AU - He D AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. FAU - Zeng, X AU - Zeng X AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, 430071 Wuhan, PR China. FAU - Fan, J AU - Fan J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. FAU - Wu, K AU - Wu K AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, PR China. Electronic address: kaijie_wu@163.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200212 PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 RN - 0 (Antigens, CD) RN - 0 (CDH1 protein, human) RN - 0 (Cadherins) SB - IM MH - Antigens, CD/*genetics MH - Cadherins/*genetics MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Prognosis MH - Progression-Free Survival MH - Urinary Bladder Neoplasms/genetics/*pathology OTO - NOTNLM OT - Bladder cancer OT - Cancer de la vessie OT - E-cadherin OT - E-cadherine OT - Facteur pronostique OT - Meta-analysis OT - Meta-analyse OT - Prognostic factor EDAT- 2020/02/18 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/02/17 06:00 PHST- 2019/09/27 00:00 [received] PHST- 2019/12/04 00:00 [revised] PHST- 2019/12/14 00:00 [accepted] PHST- 2020/02/18 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/02/17 06:00 [entrez] AID - S1166-7087(19)30651-7 [pii] AID - 10.1016/j.purol.2019.12.004 [doi] PST - ppublish SO - Prog Urol. 2020 Feb;30(2):66-74. doi: 10.1016/j.purol.2019.12.004. Epub 2020 Feb 12. PMID- 32057720 OWN - NLM STAT- MEDLINE DCOM- 20210728 LR - 20260127 IS - 1879-4076 (Electronic) IS - 1879-4068 (Linking) VI - 11 IP - 7 DP - 2020 Sep TI - Management of bladder cancer in older patients: Position paper of a SIOG Task Force. PG - 1043-1053 LID - S1879-4068(19)30481-3 [pii] LID - 10.1016/j.jgo.2020.02.001 [doi] AB - Median age at bladder cancer (BC) diagnosis is older than for other major tumours. Age should not determine treatment, and patients should be fully involved in decisions. Patients should be screened with Mini-Cog for cognitive impairment and the G8 to ascertain need for comprehensive geriatric assessment. In non-muscle invasive disease, older adult patients should have standard therapy. Age does not contraindicate intravesical therapy. Independent of age and fitness, patients with muscle-invasive BC should have at least cross-sectional imaging. Data suggest extensive undertreatment in older adult patients, leading to poor outcomes. Standard treatment for a fit patient differs between countries. Radical cystectomy and trimodality therapy are first-line options. Radical cystectomy patients should be referred to an experienced centre and prehabilitation is mandatory. Older adult patients should be considered for neoadjuvant and adjuvant therapy, according to guidelines. In urinary diversion, avoiding bowel surgery for reconstruction of the lower urinary tract significantly reduces complications. If a patient is unfit for or refuses standard treatment, RT alone, or TURBT in selected cases should be considered. In metastatic BC, older adult patients should receive standard systemic therapy, depending on fitness for cisplatin and prognosis. Efficacy and tolerability of immunotherapy (IO) appears similar to younger patients. Second line IO is standard in platinum pre-treated patients, with benefit and tolerability in the older adult similar to younger patients. The toxicity profile seems to favour IO in the older adult but more data are needed. Patients progressing on IO may respond to further systemic treatment. In metastatic disease, palliative care should begin early. CI - Copyright (c) 2020. Published by Elsevier Ltd. FAU - Mottet, Nicolas AU - Mottet N AD - University Jean Monnet, St Etienne, France. Electronic address: nicolas.mottet@wanadoo.fr. FAU - Ribal, Maria J AU - Ribal MJ AD - Hospital Clinic, University of Barcelona, Spain. FAU - Boyle, Helen AU - Boyle H AD - Centre Leon Berard, Lyon, France. FAU - De Santis, Maria AU - De Santis M AD - Charite University Hospital, Berlin, Germany; Department of Urology, Medical University of Vienna, Austria. FAU - Caillet, Philippe AU - Caillet P AD - Department of Geriatric Medicine, European Georges Pompidou Hospital, Paris, France; Department of Geriatric Medicine, Hopital Henri Mondor, Creteil, France. FAU - Choudhury, Ananya AU - Choudhury A AD - Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9PL, UK. FAU - Garg, Tullika AU - Garg T AD - Department of Urology, Epidemiology and Health Services Research, Geisinger, Danville, PA, USA. FAU - Nielsen, Matthew AU - Nielsen M AD - University of North Carolina, USA. FAU - Wuthrich, Patrick AU - Wuthrich P AD - Department of Anesthesiology and Pain Medicine, University Hospital Bern, Switzerland. FAU - Gust, Kilian M AU - Gust KM AD - Medical University of Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Departments of Urology, Weill Cornell Medical College, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology and Paediatric Urology, University Hospital of Wurzburg, Germany. LA - eng GR - DH_/Department of Health/United Kingdom PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20200210 PL - Netherlands TA - J Geriatr Oncol JT - Journal of geriatric oncology JID - 101534770 SB - IM CIN - J Urol. 2021 Mar;205(3):906-909. doi: 10.1097/JU.0000000000001542. PMID: 33356457 MH - Aged MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - *Urinary Bladder Neoplasms/drug therapy MH - *Urinary Diversion EDAT- 2020/02/15 06:00 MHDA- 2021/07/29 06:00 CRDT- 2020/02/15 06:00 PHST- 2019/10/15 00:00 [received] PHST- 2020/01/31 00:00 [revised] PHST- 2020/02/01 00:00 [accepted] PHST- 2020/02/15 06:00 [pubmed] PHST- 2021/07/29 06:00 [medline] PHST- 2020/02/15 06:00 [entrez] AID - S1879-4068(19)30481-3 [pii] AID - 10.1016/j.jgo.2020.02.001 [doi] PST - ppublish SO - J Geriatr Oncol. 2020 Sep;11(7):1043-1053. doi: 10.1016/j.jgo.2020.02.001. Epub 2020 Feb 10. PMID- 32053096 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 46 IP - 3 DP - 2020 May TI - Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer. PG - 206-212 LID - 10.5152/tud.2020.19186 [doi] AB - OBJECTIVE: The current study aimed to examine the correlation between serum and urine transforming growth factor beta 1 (TGF-beta1), matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinase 2 (TIMP-2), and nerve growth factor beta (NGF-beta) levels and serum neutrophil-to-lymphocyte ratio (NLR) as well as the recurrence and progression risks of non-muscle invasive bladder cancer (NMIBC). MATERIAL AND METHODS: The current study included 89 individuals: n=47, patients with primary NMIBC (patient group) and n=42, healthy controls (control group). The TGF-beta1, MMP-9, TIMP-2, and NGF-beta levels in the blood and urine samples were assessed using an enzyme-linked immunosorbent assay. Moreover, the serum NLR was evaluated. For the statistical analysis, a generalized linear model was used to compare the groups. In the analysis, gender and use of cigarettes were used as the secondary factors, and age was included as the covariate in the generalized linear model set for the intergroup evaluations. Meanwhile, a logistic regression model was utilized to evaluate the impact of the biomarkers on the risk of recurrence and progression. RESULTS: The serum NLR was higher in the patient group than in the control group (p=0.033). The patients with disease recurrence had higher body mass index and MMP-9 levels, but the results were not statistically significant. Moreover, the patients with a high NLR had a high risk of disease progression (odds ratio [OR]=13.046, 95% confidence interval [CI]=1.057-161.18, p=0.045), whereas the patients with a high serum TGF-beta1 level (OR=0.972, 95% CI=0.945-0.999, p=0.047) had a low risk of disease progression. CONCLUSION: High NLR and low TGF-beta1 values were associated with an increased risk of disease progression in patients with NMIBC. However, no relationships were found between TGF-beta1, MMP-9, TIMP-2, and NGF-beta values and the recurrence of NMIBC. FAU - Efiloglu, Ozgur AU - Efiloglu O AUID- ORCID: 0000-0003-4757-803X AD - Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey. FAU - Basok, Banu Isbilen AU - Basok BI AUID- ORCID: 0000-0002-1483-997X AD - Department of Medical Biochemistry, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Turan, Turgay AU - Turan T AUID- ORCID: 0000-0002-4951-6396 AD - Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey. FAU - Toprak, Tuncay AU - Toprak T AUID- ORCID: 0000-0003-1348-5273 AD - Department of Urology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey. FAU - Erol, Bulent AU - Erol B AUID- ORCID: 0000-0003-2402-3373 AD - Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey. FAU - Caskurlu, Turhan AU - Caskurlu T AUID- ORCID: 0000-0002-4471-2670 AD - Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AUID- ORCID: 0000-0002-3386-971X AD - Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20200207 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC7219974 COIS- Conflict of Interest: The authors have no conflicts of interest to declare. EDAT- 2020/02/14 06:00 MHDA- 2020/02/14 06:01 PMCR- 2020/05/01 CRDT- 2020/02/14 06:00 PHST- 2019/09/18 00:00 [received] PHST- 2019/12/23 00:00 [accepted] PHST- 2020/02/14 06:00 [pubmed] PHST- 2020/02/14 06:01 [medline] PHST- 2020/02/14 06:00 [entrez] PHST- 2020/05/01 00:00 [pmc-release] AID - tud.2020.19186 [pii] AID - tju-46-3-206 [pii] AID - 10.5152/tud.2020.19186 [doi] PST - epublish SO - Turk J Urol. 2020 Feb 7;46(3):206-212. doi: 10.5152/tud.2020.19186. Print 2020 May. PMID- 32041630 OWN - NLM STAT- MEDLINE DCOM- 20201124 LR - 20210110 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 18 IP - 1 DP - 2020 Feb 10 TI - Retrograde en bloc resection for non-muscle invasive bladder tumor can reduce the risk of seeding cancer cells into the peripheral circulation. PG - 33 LID - 10.1186/s12957-020-1808-0 [doi] LID - 33 AB - OBJECTIVE: To ascertain whether en bloc resection could reduce the risk of seeding cancer cells into the circulation during the resection of non-muscle invasive bladder cancer (NMIBC). METHODS: Patients with primary NMIBC were enrolled in this prospective study from October 2017 to May 2018. Patients were allocated to receive conventional transurethral resection of the bladder (TURB) or retrograde en bloc resection technique of the bladder tumor (RERBT). Blood samples (1 ml) for circulating tumor cell (CTC) enumeration were drawn from the peripheral vein prior to resection (PV1), immediately after resection of the tumor base (PV2), and at 12 h after resection (PV3). Intra-group comparisons of the changes in the number of CTCs identified among the PV1, PV2, and PV3 blood samples were performed in each group. RESULTS: A total of 21 patients (12 in the RERBT group and 9 in the TURB group) were recruited. For patients receiving TURB, the level of CTCs identified in PV3 was significantly higher than that in PV1 (p = 0.047). However, there was no significant difference in CTC counts before and after resection in the RERBT group. CONCLUSION: RERBT did not increase the number of tumor cells in the bloodstream. FAU - Huang, Haichao AU - Huang H AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. FAU - Wang, Tao AU - Wang T AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. FAU - Ahmed, Metages Gashaw AU - Ahmed MG AD - MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Collaborative Innovation Center of Chemistry for Energy Materials, Department of Chemical and Biochemical Engineering, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361003, Fujian, China. FAU - Zhu, Lin AU - Zhu L AD - MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Collaborative Innovation Center of Chemistry for Energy Materials, Department of Chemical and Biochemical Engineering, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361003, Fujian, China. FAU - Yang, Chaoyong AU - Yang C AD - MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Collaborative Innovation Center of Chemistry for Energy Materials, Department of Chemical and Biochemical Engineering, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361003, Fujian, China. FAU - Li, Wei AU - Li W AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. FAU - Wu, Zhun AU - Wu Z AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. FAU - Wang, Xuegang AU - Wang X AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. FAU - Zhang, Kaiyan AU - Zhang K AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. kaiyanzhang_xmu@163.com. FAU - Xing, Jinchun AU - Xing J AD - Department of Urology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. xmcua_2007@163.com. LA - eng GR - 2016D009/Fujian Provincial Department of Science and Technology/ GR - 3502Z20184014/Xiamen Science and Technology Plan/ PT - Journal Article PT - Video-Audio Media DEP - 20200210 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Cell Count MH - Cystectomy/adverse effects/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - *Neoplasm Seeding MH - Neoplastic Cells, Circulating/*pathology MH - Postoperative Period MH - Preoperative Period MH - Prognosis MH - Prospective Studies MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/blood/pathology/*surgery PMC - PMC7011233 OTO - NOTNLM OT - Bladder tumor OT - Circulating tumor cells OT - Resection COIS- The authors declare that they have no competing interests. EDAT- 2020/02/12 06:00 MHDA- 2020/11/25 06:00 PMCR- 2020/02/10 CRDT- 2020/02/12 06:00 PHST- 2019/10/22 00:00 [received] PHST- 2020/01/27 00:00 [accepted] PHST- 2020/02/12 06:00 [entrez] PHST- 2020/02/12 06:00 [pubmed] PHST- 2020/11/25 06:00 [medline] PHST- 2020/02/10 00:00 [pmc-release] AID - 10.1186/s12957-020-1808-0 [pii] AID - 1808 [pii] AID - 10.1186/s12957-020-1808-0 [doi] PST - epublish SO - World J Surg Oncol. 2020 Feb 10;18(1):33. doi: 10.1186/s12957-020-1808-0. PMID- 32038994 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240422 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Linking NRP2 With EMT and Chemoradioresistance in Bladder Cancer. PG - 1461 LID - 10.3389/fonc.2019.01461 [doi] LID - 1461 AB - Neuropilin-2 (NRP2) is a prognostic indicator for reduced survival in bladder cancer (BCa) patients. Together with its major ligand, vascular endothelial growth factor (VEGF)-C, NRP2 expression is a predictive factor for treatment outcome in response to radiochemotherapy in BCa patients who underwent transurethral resection. Therefore, we investigated the benefit of combining cisplatin-based chemotherapy with irradiation treatment in the BCa cell line RT112 exhibiting or lacking endogenous NRP2 expression in order to evaluate NRP2 as potential therapeutic target. We have identified a high correlation of NRP2 and the glioma-associated oncogene family zinc finger 2 (GLI2) transcripts in the cancer genome atlas (TCGA) cohort of BCa patients and a panel of 15 human BCa cell lines. Furthermore, we used in vitro BCa models to show the transforming growth factor-beta 1 (TGFbeta1)-dependent regulation of NRP2 and GLI2 expression levels. Since NRP2 was shown to bind TGFbeta1, associate with TGFbeta receptors, and enhance TGFbeta1 signaling, we evaluated downstream signaling pathways using an epithelial-to-mesenchymal transition (EMT)-assay in combination with a PCR profiling array containing 84 genes related to EMT. Subsequent target validation in NRP2 knockout and knockdown models revealed secreted phosphoprotein 1 (SPP1/OPN/Osteopontin) as a downstream target positively regulated by NRP2. CI - Copyright (c) 2020 Schulz, Gorodetska, Behrendt, Fuessel, Erdmann, Foerster, Datta, Mayr, Dubrovska and Muders. FAU - Schulz, Alexander AU - Schulz A AD - Faculty of Medicine and University Hospital Carl Gustav Carus, OncoRay-National Center for Radiation Research in Oncology, Technische Universitat Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. FAU - Gorodetska, Ielizaveta AU - Gorodetska I AD - Faculty of Medicine and University Hospital Carl Gustav Carus, OncoRay-National Center for Radiation Research in Oncology, Technische Universitat Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. FAU - Behrendt, Rayk AU - Behrendt R AD - Faculty of Medicine, Institute for Immunology, Technische Universitat Dresden, Dresden, Germany. FAU - Fuessel, Susanne AU - Fuessel S AD - Department of Urology, Technische Universitat Dresden, Dresden, Germany. FAU - Erdmann, Kati AU - Erdmann K AD - Department of Urology, Technische Universitat Dresden, Dresden, Germany. FAU - Foerster, Sarah AU - Foerster S AD - Rudolf Becker Laboratory for Prostate Cancer Research, Center of Pathology, University of Bonn Medical Center, Bonn, Germany. FAU - Datta, Kaustubh AU - Datta K AD - Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States. FAU - Mayr, Thomas AU - Mayr T AD - Rudolf Becker Laboratory for Prostate Cancer Research, Center of Pathology, University of Bonn Medical Center, Bonn, Germany. FAU - Dubrovska, Anna AU - Dubrovska A AD - Faculty of Medicine and University Hospital Carl Gustav Carus, OncoRay-National Center for Radiation Research in Oncology, Technische Universitat Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. AD - Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany. AD - German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany. AD - German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Muders, Michael H AU - Muders MH AD - Rudolf Becker Laboratory for Prostate Cancer Research, Center of Pathology, University of Bonn Medical Center, Bonn, Germany. LA - eng GR - P30 DK017047/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20200121 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6986262 OTO - NOTNLM OT - J82 OT - Neuropilin-2 (NRP2) OT - RT112 OT - bladder cancer OT - epithelial-to-mesenchymal transition (EMT) OT - glioma-associated oncogene family zinc finger 2 (GLI2) OT - osteopontin (OPN) OT - secreted phosphoprotein 1 (SPP1) EDAT- 2020/02/11 06:00 MHDA- 2020/02/11 06:01 PMCR- 2019/01/01 CRDT- 2020/02/11 06:00 PHST- 2019/08/02 00:00 [received] PHST- 2019/12/05 00:00 [accepted] PHST- 2020/02/11 06:00 [entrez] PHST- 2020/02/11 06:00 [pubmed] PHST- 2020/02/11 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.01461 [doi] PST - epublish SO - Front Oncol. 2020 Jan 21;9:1461. doi: 10.3389/fonc.2019.01461. eCollection 2019. PMID- 32038960 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240725 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 6 DP - 2019 Dec TI - Prevalence, clinicopathological features, and prognosis in upper tract urinary carcinoma patients with severe preoperative chronic kidney disease. PG - 641-650 LID - 10.21037/tau.2019.11.19 [doi] AB - BACKGROUND: Studies regarding the prevalence and factors associated with severe pre-operative chronic kidney disease (CKD) in upper tract urinary carcinoma (UTUC) patients were rare due to the low prevalence of UTUC. We conducted the present study to investigate the prevalence, clinicopathological features, and prognosis in UTUC patients with severe preoperative CKD. METHODS: The study included 731 patients with UTUC treated with radical nephroureterectomy (RNU) in a large Chinese center. Estimated glomerular filtration rate (eGFR) was calculated by re-expressed Modification of Diet in Renal Disease (MDRD) formulas for the Chinese population. Severe preoperative CKD was defined as CKD stage 4-5 (eGFR <30 mL/min). Relationships of CKD stage 4-5 with clinicopathological characteristics, overall survival (OS), cancer-specific survival (CSS), contralateral recurrence-free survival and intravesical recurrence (IVR)-free survival were analyzed. RESULTS: A total of 73 (10.0%) patients presented severe preoperative CKD in this cohort. Multivariate logistic analysis indicated that female gender (OR =1.791; 95% CI: 1.018-3.150; P=0.043), lower BMI (OR =0.452; 95% CI: 0.262-0.778; P=0.004), concomitant bladder tumor (OR =2.944; 95% CI: 1.360-6.373; P=0.006), lower pathological T stage (OR =0.578; 95% CI: 0.339-0.984; P=0.043), tumor necrosis (OR =2.764; 95% CI: 1.411-5.416; P=0.003), and exposure of aristolochic acid (AA) (OR =3.115; 95% CI: 1.536-6.316; P=0.002) were significantly related to severe CKD. Multivariate Cox's regression analysis showed that severe preoperative CKD was significantly associated with worse OS (HR =1.840; 95% CI: 1.150-2.944; P=0.011) and worse contralateral recurrence-free survival (HR =3.269; 95% CI: 1.607-6.650; P=0.001), while no statistical difference in terms of CSS or IVR-free survival were noticed. CONCLUSIONS: Female gender, lower BMI, concomitant bladder tumor, lower pathological T stage, exposure of AA, and tumor necrosis were independently associated with severe preoperative CKD in UTUC patients. UTUC patients with severe preoperative CKD possess worse OS and higher possibility of contralateral upper urinary tract recurrence. CI - 2019 Translational Andrology and Urology. All rights reserved. FAU - Bao, Zhengqing AU - Bao Z AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Du, Yicong AU - Du Y AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Yuan, Yiming AU - Yuan Y AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. AD - Andrology Center, Peking University First Hospital, Beijing 100034, China. FAU - Zhu, Yuze AU - Zhu Y AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110000, China. FAU - Qian, Cheng AU - Qian C AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Zhan, Yonghao AU - Zhan Y AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. AD - Andrology Center, Peking University First Hospital, Beijing 100034, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Beijing 100034, China. AD - Institute of Urology, Peking University, Beijing 100034, China. AD - National Urological Cancer Center, Beijing 100034, China. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6987590 OTO - NOTNLM OT - Chronic kidney disease (CKD) OT - contralateral recurrence-free survival OT - overall survival (OS) OT - radical nephroureterectomy (RNU) OT - upper tract urinary carcinoma (UTUC) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2020/02/11 06:00 MHDA- 2020/02/11 06:01 PMCR- 2019/12/01 CRDT- 2020/02/11 06:00 PHST- 2020/02/11 06:00 [entrez] PHST- 2020/02/11 06:00 [pubmed] PHST- 2020/02/11 06:01 [medline] PHST- 2019/12/01 00:00 [pmc-release] AID - tau-08-06-641 [pii] AID - 10.21037/tau.2019.11.19 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Dec;8(6):641-650. doi: 10.21037/tau.2019.11.19. PMID- 32035800 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 2 DP - 2020 Apr TI - Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. PG - 117-128.e5 LID - S1558-7673(19)30320-9 [pii] LID - 10.1016/j.clgc.2019.10.016 [doi] AB - BACKGROUND: The present study tested cancer-specific (CSM) and overall mortality (OM) after partial cystectomy (PC) for variant histology bladder cancer (non-urothelial carcinoma of the urinary bladder UCUB), relative to UCUB and relative to radical cystectomy (RC). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results registry (2001-2016), we identified patients with stage T1-T2N0M0 non-UCUB and UCUB who had undergone PC or RC. Non-UCUB included adenocarcinoma, squamous carcinoma, neuroendocrine carcinoma, and other histologic subtypes. First, CSM and OM after PC were compared between the non-UCUB and UCUB groups. Second, CSM and OM after PC were compared with RC in the non-UCUB group. Kaplan Meier plots and multivariable Cox regression models were used before and after inverse probability of treatment weighting. RESULTS: Overall, 248 patients (16.3%) treated with PC had had non-UCUB. Of the 248 cases, 115 (46.5%), 50 (20%), 34 (14%), and 49 (19.5%) were adenocarcinoma, squamous carcinoma, neuroendocrine carcinoma, and other histologic subtypes, respectively. The comparison between PC in the non-UCUB and PC in the UCUB group showed higher CSM (hazard ratio, 1.4; P = .03) but the same OM rates (hazard ratio, 1.1; P = .7) in the non-UCUB group. The comparison between PC and RC for the non-UCUB group showed no CSM or OM differences. CONCLUSIONS: PC for non-UCUB was associated with higher CSM compared with PC for UCUB. However, PC instead of RC for select patients with non-UCUB appears not to undermine cancer-control outcomes. Thus, the excess CSM is probably unrelated to cystectomy type but could originate from differences in the tumor biology. These results could act as hypothesis generating for the design of future trials. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Luzzago, Stefano AU - Luzzago S AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: stefanoluzzago@gmail.com. FAU - Palumbo, Carlotta AU - Palumbo C AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Rosiello, Giuseppe AU - Rosiello G AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Knipper, Sophie AU - Knipper S AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. FAU - Pecoraro, Angela AU - Pecoraro A AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. FAU - Deuker, Marina AU - Deuker M AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Mistretta, Francesco Alessandro AU - Mistretta FA AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Saad, Fred AU - Saad F AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. LA - eng PT - Comparative Study PT - Journal Article DEP - 20191016 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Clinical Decision-Making MH - Cystectomy/*methods/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Patient Selection MH - Retrospective Studies MH - SEER Program/statistics & numerical data MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Adenocarcinoma OT - Inverse probability of treatment weighting OT - Neuroendocrine carcinoma OT - Other histologic subtypes OT - Squamous carcinoma EDAT- 2020/02/10 06:00 MHDA- 2021/01/30 06:00 CRDT- 2020/02/10 06:00 PHST- 2019/08/08 00:00 [received] PHST- 2019/10/01 00:00 [revised] PHST- 2019/10/06 00:00 [accepted] PHST- 2020/02/10 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2020/02/10 06:00 [entrez] AID - S1558-7673(19)30320-9 [pii] AID - 10.1016/j.clgc.2019.10.016 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Apr;18(2):117-128.e5. doi: 10.1016/j.clgc.2019.10.016. Epub 2019 Oct 16. PMID- 32034486 OWN - NLM STAT- MEDLINE DCOM- 20200729 LR - 20261010 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 477 IP - 2 DP - 2020 Aug TI - PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. PG - 269-277 LID - 10.1007/s00428-020-02755-2 [doi] AB - Carcinoma in situ (CIS) is believed to be a precursor of muscle-invasive carcinomas that may arise from these flat high-grade, superficial urothelial lesions. CIS accounts for approximately 10% of all bladder tumors. Therapeutic options for urothelial CIS are limited, and in order to inhibit disease progression and recurrence, current guidelines recommend transurethral resection (TURBT) followed by intravesical administration of Bacillus of Calmette-Guerin (BCG). Approximately 30-40% of patients fail the BCG therapy with recurrence and progression of disease. In the present study, we examined the expression of PD-L1 both in neoplastic epithelial cells and in stromal inflammatory cells in patients with diagnosis of CIS primary responders and not responders to BCG therapy, in order to verify if the PD-L1 expression could identify patients resistant to BCG treatment. Moreover, we analyzed on the same cases the immunoreactivities of anti-PD-L1 MoAbs such as SP263, C23, and SP142. Our results have showed that PD-L1 expression in tumor cells and in immune cell compartment is higher in BCG-unresponsive group than in BCG responders, but only the PD-L1 22C3 expression in tumor cells seems to be associated with recurrence of disease (p = 0.035; OR 0.1204; CI 95% from 0.0147 to 1.023). Hence, our data suggest that the PD-L1 22C3 expression could help to identify CIS that fail the BCG therapy, supporting the hypothesis that enhanced levels of intratumoral PD-L1 22C3 expressed by the tumor cells may explain the failure of BCG immunotherapy. FAU - Pierconti, Francesco AU - Pierconti F AD - Department of Pathology, Catholic University of Sacred Heart, Fondazione Policlinico A. Gemelli, L.go A. Gemelli, 8, 00141, Rome, Italy. francesco.pierconti@unicatt.it. FAU - Raspollini, Maria Rosaria AU - Raspollini MR AD - Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy. FAU - Martini, Maurizio AU - Martini M AD - Department of Pathology, Catholic University of Sacred Heart, Fondazione Policlinico A. Gemelli, L.go A. Gemelli, 8, 00141, Rome, Italy. FAU - Larocca, Luigi Maria AU - Larocca LM AD - Department of Pathology, Catholic University of Sacred Heart, Fondazione Policlinico A. Gemelli, L.go A. Gemelli, 8, 00141, Rome, Italy. FAU - Bassi, Pier Francesco AU - Bassi PF AD - Department of Urology, Catholic University of Sacred Heart, Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Bientinesi, Riccardo AU - Bientinesi R AD - Department of Urology, Catholic University of Sacred Heart, Fondazione Policlinico A. Gemelli, Rome, Italy. FAU - Baroni, Gianna AU - Baroni G AD - Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Urology, University Hospital Careggi, Florence, Italy. FAU - Petracco, Guido AU - Petracco G AD - Department of Pathology, Azienda ospedaliera Lariana, Ospedale St Anna, Como, Italy. FAU - Pini, Giacomo Maria AU - Pini GM AD - Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy. FAU - Patriarca, Carlo AU - Patriarca C AD - Department of Pathology, Azienda ospedaliera Lariana, Ospedale St Anna, Como, Italy. LA - eng PT - Journal Article DEP - 20200207 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Antibodies, Monoclonal) RN - 0 (Biomarkers, Tumor) SB - IM EIN - Virchows Arch. 2020 Aug;477(2):327. doi: 10.1007/s00428-020-02791-y. PMID: 32157466 MH - Aged MH - Antibodies, Monoclonal/therapeutic use MH - Biomarkers, Tumor/metabolism MH - Carcinoma in Situ/metabolism/pathology MH - Carcinoma, Transitional Cell/metabolism/pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*metabolism/pathology MH - Urinary Bladder/*metabolism/pathology MH - Urinary Bladder Neoplasms/*metabolism/pathology MH - Urologic Neoplasms/*metabolism/pathology OTO - NOTNLM OT - BCG failure OT - Bladder carcinoma OT - Carcinoma in situ (CIS) OT - Immunotherapy OT - PD-L1 EDAT- 2020/02/09 06:00 MHDA- 2020/07/30 06:00 CRDT- 2020/02/09 06:00 PHST- 2019/09/20 00:00 [received] PHST- 2020/01/14 00:00 [accepted] PHST- 2020/01/10 00:00 [revised] PHST- 2020/02/09 06:00 [pubmed] PHST- 2020/07/30 06:00 [medline] PHST- 2020/02/09 06:00 [entrez] AID - 10.1007/s00428-020-02755-2 [pii] AID - 10.1007/s00428-020-02755-2 [doi] PST - ppublish SO - Virchows Arch. 2020 Aug;477(2):269-277. doi: 10.1007/s00428-020-02755-2. Epub 2020 Feb 7. PMID- 32026665 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 2724-6442 (Electronic) IS - 2724-6051 (Linking) VI - 73 IP - 5 DP - 2021 Oct TI - Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis. PG - 572-580 LID - 10.23736/S2724-6051.19.03657-9 [doi] AB - BACKGROUND: We compared survival outcomes among patients who received either NAC or AC and RC. METHODS: We identified patients in the National Cancer Data Base (NCDB) diagnosed with clinical T2-T4, N0, M0 urothelial carcinoma who underwent RC. Patients who received NAC were propensity matched by age, race, ethnicity, sex, insurance type, academic/research program, comorbidity, and clinical stage to patients receiving AC within 90 days of RC. Median survival was calculated using Kaplan-Meier analysis. Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) were calculated from multivariable Cox regression models to compare overall survival (OS), downstaging to non-MIBC (NMIBC), and N upstaging. RESULTS: A total of 417 patients treated with NAC and 272 patients treated with AC were identified from 2004-2013. Patients who received NAC had better 5-year OS (46.2%, 95% CI: 39.2-53.0%) compared to patients who received AC (37.6%, 95% CI: 31.5-43.7%). NAC was a significant predictor of decreased mortality, decreased progression to node positivity, and downstaging to NMIBC (0.76, 0.60-0.96, P=0.023; 0.19, 0.13-0.28, P<0.001; 23.96, 8.91-64.42, P<0.001). CONCLUSIONS: The use of NAC+RC was associated with improved OS compared to RC+AC for patients diagnosed with T2-T4, N0, M0 bladder cancer. The increased survival benefit associated with NAC compared to AC among patients undergoing RC may be due to decreased progression to node positivity and pathological downstaging. FAU - Jue, Joshua S AU - Jue JS AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA - jjue@northwell.edu. FAU - Koru-Sengul, Tulay AU - Koru-Sengul T AD - Miller School of Medicine, Department of Public Health Sciences, University of Miami, Miami, FL, USA. AD - Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. FAU - Miao, Feng AU - Miao F AD - Miller School of Medicine, Department of Public Health Sciences, University of Miami, Miami, FL, USA. FAU - Velasquez, Maria C AU - Velasquez MC AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Savio, Luis F AU - Savio LF AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Alameddine, Mahmoud AU - Alameddine M AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Kroeger, Zachary A AU - Kroeger ZA AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Punnen, Sanoj AU - Punnen S AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Parekh, Dipen J AU - Parekh DJ AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. AD - Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. FAU - Ritch, Chad R AU - Ritch CR AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Miller School of Medicine, Department of Urology, University of Miami, Miami, FL, USA. AD - Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. LA - eng PT - Journal Article DEP - 20200130 PL - Italy TA - Minerva Urol Nephrol JT - Minerva urology and nephrology JID - 101777299 SB - IM MH - *Carcinoma, Transitional Cell/drug therapy MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Muscles MH - Neoadjuvant Therapy MH - *Urinary Bladder Neoplasms/drug therapy EDAT- 2020/02/07 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/02/07 06:00 PHST- 2020/02/07 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/02/07 06:00 [entrez] AID - S0393-2249.19.03657-9 [pii] AID - 10.23736/S2724-6051.19.03657-9 [doi] PST - ppublish SO - Minerva Urol Nephrol. 2021 Oct;73(5):572-580. doi: 10.23736/S2724-6051.19.03657-9. Epub 2020 Jan 30. PMID- 32023888 OWN - NLM STAT- MEDLINE DCOM- 20201113 LR - 20201113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 3 DP - 2020 Jan 31 TI - TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. LID - 10.3390/ijms21030947 [doi] LID - 947 AB - Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette-Guerin (BCG) intravesical therapy. Methods - 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, TERT rs2853669 single nucleotide polymorphism, and Fibroblast Growth Factor Receptor 3 (FGFR3) hotspot mutations. Results - TERTp mutations were found in 56.0% of BCG-NMIBC and were not associated with tumor stage or grade. FGFR3 mutations were found in 44.9% of the cases and were not associated with tumor stage or grade nor with TERTp mutations. The TERT rs2853669 single nucleotide polymorphism was associated with tumors of higher grade. The specific c.1-146G>A TERTp mutation was an independent predictor of nonrecurrence after BCG therapy (hazard ratio-0.382; 95% confidence interval-0.150-0.971, p = 0.048). Conclusions - TERTp mutations are frequent in BCG-NMIBC and -146G>A appears to be an independent predictive marker of response to BCG treatment with an impact in recurrence-free survival. FAU - Batista, Rui AU - Batista R AD - Instituto de Investigacao e Inovacao em Saude (i3S), 4200-135 Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. FAU - Lima, Luis AU - Lima L AD - Grupo de Patologia e Terapeutica Experimental, Instituto Portugues de Oncologia do Porto FG, EPE (IPO-Porto), 4200-072 Porto, Portugal. FAU - Vinagre, Joao AU - Vinagre J AUID- ORCID: 0000-0002-0871-1427 AD - Instituto de Investigacao e Inovacao em Saude (i3S), 4200-135 Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. FAU - Pinto, Vasco AU - Pinto V AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. FAU - Lyra, Joana AU - Lyra J AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. FAU - Maximo, Valdemar AU - Maximo V AUID- ORCID: 0000-0002-8631-8356 AD - Instituto de Investigacao e Inovacao em Saude (i3S), 4200-135 Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. FAU - Santos, Lucio AU - Santos L AD - Grupo de Patologia e Terapeutica Experimental, Instituto Portugues de Oncologia do Porto FG, EPE (IPO-Porto), 4200-072 Porto, Portugal. FAU - Soares, Paula AU - Soares P AUID- ORCID: 0000-0001-9607-6998 AD - Instituto de Investigacao e Inovacao em Saude (i3S), 4200-135 Porto, Portugal. AD - Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal. AD - Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal. LA - eng GR - CEECIND/00201/2017/Fundacao para a Ciencia e a Tecnologia/ GR - SFRH/BD/111321/2015/Fundacao para a Ciencia e a Tecnologia/ GR - NORTE-01-0145-FEDER-000029/Norte 2020 -Programa Operacional Regional do Norte/ GR - PTDC/MED-ONC/31438/2017/Fundacao para a Ciencia e a Tecnologia/ GR - POCI-01-0145-FEDER-016390/Fundacao para a Ciencia e a Tecnologia/ PT - Journal Article DEP - 20200131 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage/pharmacology MH - Biomarkers, Tumor/*genetics MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Staging MH - *Polymorphism, Single Nucleotide MH - Prognosis MH - Promoter Regions, Genetic MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Telomerase/*genetics MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/genetics/pathology PMC - PMC7037401 OTO - NOTNLM OT - BCG therapy OT - FGFR3 OT - TERT promoter mutations OT - non muscle invasive bladder cancer COIS- The authors declare no conflict of interest. EDAT- 2020/02/07 06:00 MHDA- 2020/11/18 06:00 PMCR- 2020/02/01 CRDT- 2020/02/07 06:00 PHST- 2019/12/28 00:00 [received] PHST- 2020/01/27 00:00 [revised] PHST- 2020/01/30 00:00 [accepted] PHST- 2020/02/07 06:00 [entrez] PHST- 2020/02/07 06:00 [pubmed] PHST- 2020/11/18 06:00 [medline] PHST- 2020/02/01 00:00 [pmc-release] AID - ijms21030947 [pii] AID - ijms-21-00947 [pii] AID - 10.3390/ijms21030947 [doi] PST - epublish SO - Int J Mol Sci. 2020 Jan 31;21(3):947. doi: 10.3390/ijms21030947. PMID- 32021250 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231113 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 13 DP - 2020 TI - Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives. PG - 1-15 LID - 10.2147/OTT.S225301 [doi] AB - INTRODUCTION: Upper tract urothelial carcinoma (UTUC) is a relatively uncommon urologic malignancy for which there has not been significant improvement in survival over the past few decades, highlighting the need for optimal multi-modality management. METHODS: A non-systematic review of the latest literature was performed to include relevant articles up to June 2019. It summarizes the epidemiologic risk factors associated with UTUC, including smoking, carcinogenic aromatic amines, arsenic, aristolochic acid, and Lynch syndrome. Molecular pathways underlying UTUC and potential druggable targets are outlined. RESULTS: Surgical management for UTUC includes kidney-sparing surgery (KSS) for low-risk disease and radical nephroureterectomy (RNU) for high-risk disease. Endoscopic management of UTUC may include ureteroscopic or percutaneous resection. Topical instillation therapy post-KSS aims to reduce recurrence, progression and to treat carcinoma-in-situ; this may be achieved retrogradely (via ureteric catheterization), antegradely (via percutaneous nephrostomy) or via reflux through double-J stent. RNU, which may be performed via open, laparoscopic or robot-assisted approaches, is the gold standard treatment for high-risk UTUC. The distal cuff may be dealt with extravesical, transvesical or endoscopic techniques. Peri-operative chemotherapy and immunotherapy are increasingly utilized; level 1 evidence exists for adjuvant chemotherapy, but neoadjuvant chemotherapy is favored as kidney function is better prior to RNU. Immunotherapy is primarily reserved for metastatic UTUC but is currently being investigated in the perioperative setting. CONCLUSION: The optimal management of UTUC includes a firm understanding of the epidemiological factors and molecular pathways. Surgical management includes KSS for low-risk disease and RNU for high-risk disease. Peri-operative immunotherapy and chemotherapy may be considered as evidence mounts. CI - (c) 2020 Leow et al. FAU - Leow, Jeffrey J AU - Leow JJ AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. FAU - Liu, Zhenbang AU - Liu Z AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. AD - Department of Surgery, Woodlands Health Campus, Singapore. FAU - Tan, Teck Wei AU - Tan TW AUID- ORCID: 0000-0003-1376-7908 AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. FAU - Lee, Yee Mun AU - Lee YM AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. FAU - Yeo, Eu Kiang AU - Yeo EK AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. FAU - Chong, Yew-Lam AU - Chong YL AD - Department of Urology, Tan Tock Seng Hospital, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. LA - eng PT - Journal Article PT - Review DEP - 20200106 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC6954076 OTO - NOTNLM OT - carcinoma OT - chemotherapy OT - immunotherapy OT - nephroureterectomy OT - transitional cell OT - upper tract urothelial carcinoma OT - ureteral neoplasms COIS- The authors report no conflicts of interest in this work. EDAT- 2020/02/06 06:00 MHDA- 2020/02/06 06:01 PMCR- 2020/01/06 CRDT- 2020/02/06 06:00 PHST- 2019/07/30 00:00 [received] PHST- 2019/12/12 00:00 [accepted] PHST- 2020/02/06 06:00 [entrez] PHST- 2020/02/06 06:00 [pubmed] PHST- 2020/02/06 06:01 [medline] PHST- 2020/01/06 00:00 [pmc-release] AID - 225301 [pii] AID - 10.2147/OTT.S225301 [doi] PST - epublish SO - Onco Targets Ther. 2020 Jan 6;13:1-15. doi: 10.2147/OTT.S225301. eCollection 2020. PMID- 32020826 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20220422 IS - 1473-0790 (Electronic) IS - 1368-5538 (Linking) VI - 23 IP - 5 DP - 2020 Dec TI - Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. PG - 1182-1193 LID - 10.1080/13685538.2020.1718637 [doi] AB - OBJECTIVE: In this study, we aimed to examine the clinical efficacy of simultaneous transurethral resection of bladder cancer and the prostate (TURBT + TURP) in non-muscle invasive bladder cancer (NMIBC) and benign prostatic hyperplasia (BPH) patients. METHOD: We conducted systematic research in PubMed, EMBASE, and Cochrane Library databases to identify retrospective studies and prospective randomized controlled trials (RCTs) comparing patient outcomes between TURBT + TURP and TURBT-only patients. The meta-analysis was conducted using Review Manager 5.3. RESULTS: We identified eight relevant studies involving a total of 1032 patients. We found that patients that underwent TURBT + TURP exhibited significantly lower recurrence rates [odds ratio (OR), 0.70; 95% confidence interval (CI), 0.53-0.93; p = .01] and increased maximal urinary flow rate (Qmax) (WMD, 5.92; 95% CI, 4.67-7.16; p < .001) compared with patients that underwent TURBT-only. However, rates of recurrence at the prostatic urethra/bladder neck and bladder tumor progression, as well as the time to recurrence did not differ significantly between these two groups. CONCLUSIONS: Simultaneous TURBT + TURP can be safely performed in patients with NMIBC and BPH and improves patient quality of life, without any risk of increasing tumor recurrence or metastasis rates. Comprehensive RCTs are needed to confirm the results of this study. FAU - Zhou, Li AU - Zhou L AD - Department of Urology, Maoming People's Hospital, Maoming, China. FAU - Liang, Xinglong AU - Liang X AD - Department of Dermatology, Maoming People's Hospital, Maoming, China. FAU - Zhang, Kaizhong AU - Zhang K AD - Department of Urology, Maoming People's Hospital, Maoming, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200205 PL - England TA - Aging Male JT - The aging male : the official journal of the International Society for the Study of the Aging Male JID - 9808210 SB - IM MH - Cystectomy MH - Humans MH - Male MH - Prostate MH - *Prostatic Hyperplasia/surgery MH - *Transurethral Resection of Prostate MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bladder cancer OT - benign prostatic hypertrophy OT - prostate cancer OT - transurethral resection EDAT- 2020/02/06 06:00 MHDA- 2021/10/26 06:00 CRDT- 2020/02/06 06:00 PHST- 2020/02/06 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2020/02/06 06:00 [entrez] AID - 10.1080/13685538.2020.1718637 [doi] PST - ppublish SO - Aging Male. 2020 Dec;23(5):1182-1193. doi: 10.1080/13685538.2020.1718637. Epub 2020 Feb 5. PMID- 32015903 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220412 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 72 IP - 4 DP - 2019 TI - Efficacy of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer and quality of surgery: post-hoc analysis of small a, Cyrillic prospective randomized study. PG - 351-356 LID - 10.5173/ceju.2019.0003 [doi] AB - INTRODUCTION: This paper aims to evaluate the influence of quality of transurethral resection in patients with non-muscle invasive bladder cancer on the benefit of fluorescent cystoscopy-assisted transurethral resection in the post hoc analysis of the single-center randomized controlled trial. MATERIAL AND METHODS: We retrospectively analyzed the results of the prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection. The quality of transurethral resection was defined on the basis of a separate retrospective study estimating the variability in recurrence risk for the individual surgeon. The subgroup analysis of fluorescent cystoscopy-assisted transurethral resection efficacy depending on surgical experience was performed. RESULTS: Of 377 eligible patients, transurethral resection was performed in 365 (97%) by surgeons with available grading information. Two 'experienced' surgeons performed 238 (63%) of all transurethral resections and three 'less experienced' surgeons completed 127 (34%) surgeries. The two surgical groups were comparable with respect to basic prognostic factors and subsequent therapy. The median follow-up was 56 months.In the total cohort of patients, fluorescent cystoscopy significantly decreased the risk of recurrence with hazard ratio 0.58 (p = 0.004). In the 'experienced surgeons' subgroup the benefit of fluorescent cystoscopy was not significant (hazard ratio 0.81, p = 0.34), whereas the 'less experienced' subgroup showed a marked difference in favor of fluorescent cystoscopy-assisted transurethral resection (hazard ratio 0.31, p = 0.001), with a P-value for interaction of 0.021. CONCLUSIONS: Baseline quality of surgery may be a significant interacting factor affecting the magnitude of the benefit of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer. CI - Copyright by Polish Urological Association. FAU - Rolevich, Alexander AU - Rolevich A AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. AD - Department of Radiation Molecular Epidemiology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan. FAU - Minich, Alexander AU - Minich A AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Vasilevich, Vladimir AU - Vasilevich V AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Zhegalik, Alexander AU - Zhegalik A AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Mokhort, Andrey AU - Mokhort A AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Nabebina, Tatiana AU - Nabebina T AD - Department of Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Krasny, Sergey AU - Krasny S AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Polyakov, Sergey AU - Polyakov S AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. FAU - Sukonko, Oleg AU - Sukonko O AD - Department of Urology and Pathology, N.N. Alexandrov National Research Cancer Center, Minsk, Belarus. LA - eng PT - Journal Article DEP - 20190926 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC6979560 OTO - NOTNLM OT - cystoscopy OT - neoplasm recurrence OT - optical imaging OT - retrospective studies OT - urinary bladder neoplasm COIS- The authors declare no conflicts of interest. EDAT- 2020/02/06 06:00 MHDA- 2020/02/06 06:01 PMCR- 2019/01/01 CRDT- 2020/02/05 06:00 PHST- 2019/07/20 00:00 [received] PHST- 2019/08/26 00:00 [revised] PHST- 2019/09/22 00:00 [accepted] PHST- 2020/02/05 06:00 [entrez] PHST- 2020/02/06 06:00 [pubmed] PHST- 2020/02/06 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 0003 [pii] AID - 10.5173/ceju.2019.0003 [doi] PST - ppublish SO - Cent European J Urol. 2019;72(4):351-356. doi: 10.5173/ceju.2019.0003. Epub 2019 Sep 26. PMID- 32012137 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20220310 IS - 1473-5709 (Electronic) IS - 0959-8278 (Linking) VI - 29 IP - 2 DP - 2020 Mar TI - Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. PG - 110-118 LID - 10.1097/CEJ.0000000000000525 [doi] AB - OBJECTIVE: Between 10 and 20% of bladder cancer patients who are diagnosed with nonmuscle-invasive bladder cancer will progress to muscle-invasive disease. Risk of progression depends on several factors at diagnosis including age, tumour stage, grade, size and number, and the presence or absence of carcinoma in situ. Fluid intake may be related to these factors. METHODS: Data of 1123 participants from the West Midlands Bladder Cancer Prognosis Programme were used. Data collection was via a semistructured questionnaire, and case report forms were used to collect clinicopathological data. Fluid intake was measured for six main categories: alcoholic fluids, hot fluids, fruit fluids, milk, fizzy drinks, and water, and converted into quintile variables. Multilevel mixed-effects linear regression was performed for every beverage category per clinicopathological variable and corrected for age, gender, and smoking status. RESULTS: Age at diagnosis was distributed differently amongst those in different total fluid intake quintiles (predicted means 71.5, 70.9, 71.5, 69.9, and 67.4, respectively) and showed a significant inverse linear trend in alcohol (P < 0.01), hot fluids (P < 0.01), and total fluids intake (P < 0.01), in nonmuscle-invasive bladder cancer patients. CONCLUSION: Our results suggest an inverse association for alcohol intake and total fluid intake with age at diagnosis. These results should be confirmed by future studies, alongside a possible (biological) mechanism that could influence tumour growth, and the effect of micturition frequency. FAU - van Hensbergen, Mitch AU - van Hensbergen M AD - Departments of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism. FAU - van Osch, Frits H M AU - van Osch FHM AD - Departments of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism. AD - Institute of Cancer and Genomic Sciences. FAU - Jochems, Sylvia AU - Jochems S AD - Departments of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism. AD - Institute of Cancer and Genomic Sciences. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences. FAU - Wallace, D Michael A AU - Wallace DMA AD - Institute of Cancer and Genomic Sciences. FAU - Wesselius, Anke AU - Wesselius A AD - Departments of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism. FAU - Cheng, K K AU - Cheng KK AD - Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences. FAU - Zeegers, M P AU - Zeegers MP AD - Departments of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism. AD - Public Health and Primary Care (School CAPHRI), Maastricht University, Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - Eur J Cancer Prev JT - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JID - 9300837 SB - IM CIN - J Urol. 2022 Apr;207(4):926-928. doi: 10.1097/JU.0000000000002398. PMID: 34983188 MH - Aged MH - Alcohol Drinking/adverse effects/*epidemiology MH - Beverages/*statistics & numerical data MH - Carcinoma in Situ/*diagnosis/pathology/physiopathology MH - Case-Control Studies MH - Diet Surveys/statistics & numerical data MH - Disease Progression MH - Drinking/*physiology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Prospective Studies MH - Risk Factors MH - United Kingdom/epidemiology MH - Urinary Bladder/pathology/physiopathology MH - Urinary Bladder Neoplasms/*diagnosis/pathology/physiopathology MH - Urination/physiology EDAT- 2020/02/06 06:00 MHDA- 2021/06/16 06:00 CRDT- 2020/02/04 06:00 PHST- 2020/02/04 06:00 [entrez] PHST- 2020/02/06 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] AID - 00008469-202003000-00003 [pii] AID - 10.1097/CEJ.0000000000000525 [doi] PST - ppublish SO - Eur J Cancer Prev. 2020 Mar;29(2):110-118. doi: 10.1097/CEJ.0000000000000525. PMID- 32003203 OWN - NLM STAT- MEDLINE DCOM- 20210322 LR - 20210322 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 72 IP - 6 DP - 2020 Dec TI - En-bloc resection of bladder tumors for pathological staging: the value of lateral margins analysis. PG - 763-769 LID - 10.23736/S0393-2249.20.03551-1 [doi] AB - BACKGROUND: In endoscopic resection of colorectal tumors, the pathological assessment of the lateral margins is a strong predictor of tumor recurrence after resection. The aim of the current study is to evaluate the value of the peritumoral margins assessment in ERBT on tumor recurrence. METHODS: We retrospectively analyzed the data of 50 consecutive patients with NMIBC and treated by ERBT between January and December 2017. RESULTS: The lateral margins showed dysplasia in 16 patients and malignancy in three patients. Local recurrence occurred in 14 (28%) patients. It was noted that 57% of patients with recurrence showed some degree of dysplasia or malignancy in the lateral margin; however, on multivariate logistic regression lateral margins lesions were not significantly associated with recurrence (OR 2.175, 95% CI: 0.430-10.996, P=0.35). CONCLUSIONS: ERBT may improve the pathological report of bladder tumor. There was a trend toward increased rate of recurrence in patients with dysplasia or malignancy in their lateral margins; however, this was not statistically significant on multivariate analysis. Further studies with larger sample sizes are required to assess the value of lateral margin analysis. FAU - Eissa, Ahmed AU - Eissa A AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. AD - Department of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Zoeir, Ahmed AU - Zoeir A AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. AD - Department of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Ciarlariello, Silvia AU - Ciarlariello S AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Sarchi, Luca AU - Sarchi L AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Sighinolfi, Maria C AU - Sighinolfi MC AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Ghaith, Ahmed AU - Ghaith A AD - Department of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt. FAU - Puliatti, Stefano AU - Puliatti S AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Inzillo, Raffaele AU - Inzillo R AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Reggiani Bonetti, Luca AU - Reggiani Bonetti L AD - Section of Pathology, Department of Diagnostic Medicine and Public Health, University of Modena and Reggio Emilia, Modena, Italy. FAU - Rizzo, Mino AU - Rizzo M AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Rocco, Bernardo AU - Rocco B AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy. FAU - Micali, Salvatore AU - Micali S AD - Department of Urology, University of Modena and Reggio Emilia, Modena, Italy - salvatore.micali@unimore.it. LA - eng PT - Journal Article DEP - 20200129 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 SB - IM MH - Humans MH - Margins of Excision MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/pathology/surgery EDAT- 2020/02/01 06:00 MHDA- 2021/03/23 06:00 CRDT- 2020/02/01 06:00 PHST- 2020/02/01 06:00 [pubmed] PHST- 2021/03/23 06:00 [medline] PHST- 2020/02/01 06:00 [entrez] AID - S0393-2249.20.03551-1 [pii] AID - 10.23736/S0393-2249.20.03551-1 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2020 Dec;72(6):763-769. doi: 10.23736/S0393-2249.20.03551-1. Epub 2020 Jan 29. PMID- 31997062 OWN - NLM STAT- MEDLINE DCOM- 20210226 LR - 20261010 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 52 IP - 6 DP - 2020 Jun TI - Gender effect on the oncologic outcomes of upper urinary tract urothelial carcinoma in Taiwan. PG - 1043-1048 LID - 10.1007/s11255-020-02396-z [doi] AB - PURPOSE: Upper urinary tract urothelial carcinoma (UTUC) is a relatively uncommon malignancy in Western countries, affecting more men than women. By contrast, UTUC is relatively common in Taiwan and diagnosed more often in women than in men. Previous studies regarding the gender effect on cancer behaviour with UTUC have been controversial. Investigation of female predominance of UTUC in Taiwan may help improve UTUC management in Taiwan as well as understand the gender effect on urothelial carcinoma. METHODS: Between January 2005 and December 2015, 828 patients with localized UTUC treated with radical nephroureterectomy were enrolled. Cox regression analysis was performed to assess the independent roles of perioperative factors on local recurrence and systemic recurrence. RESULTS: Multivariate analysis revealed the male gender had a trend associated with higher systemic recurrence (P = 0.096) and independently associated with higher bladder recurrence (P = 0.011) and cancer-specific mortality (P = 0.014), even after taking smoking and other established prognostic factors into consideration. Bladder cancer history and multifocal disease are strongly associated with bladder recurrence. CONCLUSION: Compared with female UTUC patients, male UTUC patients in Taiwan were associated with more bladder recurrences and higher cancer-specific mortality and had a trend associated with more systemic recurrences. FAU - Wu, Yen-Ting AU - Wu YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. FAU - Luo, Hao Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. alesy1980@gmail.com. FAU - Wang, Hung Jen AU - Wang HJ AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. FAU - Chen, Yen Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. FAU - Cheng, Yuan Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. FAU - Chiang, Po Hui AU - Chiang PH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Niaosung District, No. 123, Dapi Road, Kaohsiung, Taiwan. cphtem@yahoo.com.tw. AD - Kaohsiung Medical University, Kaohsiung, Taiwan. cphtem@yahoo.com.tw. LA - eng PT - Comparative Study PT - Journal Article DEP - 20200129 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - *Nephroureterectomy MH - Retrospective Studies MH - Sex Factors MH - Taiwan MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/*surgery MH - Urinary Bladder Neoplasms/mortality/*surgery OTO - NOTNLM OT - Gender OT - Intravesical recurrence OT - Nephroureterectomy OT - Prognosis OT - Risk factor OT - Upper urinary tract urothelial carcinoma EDAT- 2020/01/31 06:00 MHDA- 2021/02/27 06:00 CRDT- 2020/01/31 06:00 PHST- 2019/12/03 00:00 [received] PHST- 2020/01/20 00:00 [accepted] PHST- 2020/01/31 06:00 [pubmed] PHST- 2021/02/27 06:00 [medline] PHST- 2020/01/31 06:00 [entrez] AID - 10.1007/s11255-020-02396-z [pii] AID - 10.1007/s11255-020-02396-z [doi] PST - ppublish SO - Int Urol Nephrol. 2020 Jun;52(6):1043-1048. doi: 10.1007/s11255-020-02396-z. Epub 2020 Jan 29. PMID- 31987764 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20220328 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 2 DP - 2021 Mar TI - Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer. PG - 366-372 LID - S2405-4569(20)30022-5 [pii] LID - 10.1016/j.euf.2020.01.006 [doi] AB - BACKGROUND: Intermediate-risk non-muscle-invasive bladder cancer (NMIBC) involves heterogeneous patients, resulting in uncertainty regarding its prognosis and the indication of adjuvant therapy. Previous studies suggested a correlation between tumor location, especially bladder neck involvement (BNI), and patient prognosis of NMIBC. OBJECTIVE: We investigated the role of BNI in risk substratification of intermediate-risk NMIBC patients. DESIGN, SETTING, AND PARTICIPANTS: This single-institutional study included 436 primary or recurrent intermediate-risk NMIBC patients based on risk stratification in the European Association of Urology guidelines. INTERVENTION: All patients underwent transurethral resection of the bladder tumor. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary and secondary endpoints were progression and recurrence, respectively. The associations of BNI with the endpoints were examined using the Kaplan-Meier method and the Cox proportional hazards model. RESULTS AND LIMITATIONS: Overall, 205 (47%) patients had multiple tumors and 276 (63%) underwent intravesical therapy. BNI was observed in 53 (12%) patients. During the median follow-up of 42 mo, 12 (3%) and 211 (48%) patients experienced progression and recurrence, respectively. Multivariate analysis showed that BNI was an independent predictor for both progression (hazard ratio 10.98, p < 0.001) and recurrence (hazard ratio 2.12, p < 0.001). The progression rate was significantly higher in patients with BNI compared with those without BNI (13% vs 1% at 3 yr and 20% vs 1% at 6 yr; p < 0.001). Analogous findings were observed for recurrence. The progression rate was more remarkably stratified by BNI in 103 recurrent cases (17% vs 3% at 3 yr and 34% vs 3% at 6 yr in patients with vs without BNI; p < 0.001). A limitation of this study was its retrospective nature. CONCLUSIONS: BNI substratified intermediate-risk NMIBC patients well regarding their risks of progression and recurrence, which could help determine follow-up and therapeutic strategies for these patients. PATIENT SUMMARY: The associations of bladder neck involvement with progression and recurrence were evaluated in patients with intermediate-risk non-muscle-invasive bladder cancer. We found that bladder neck involvement was a good factor for substratifying patients based on their risks of progression and recurrence. Bladder neck involvement can be useful in determining follow-up and therapeutic strategies for intermediate-risk non-muscle-invasive bladder cancer. CI - Copyright (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Fukushima, Hiroshi AU - Fukushima H AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Moriyama, Shingo AU - Moriyama S AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Waseda, Yuma AU - Waseda Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fukuda, Shohei AU - Fukuda S AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Uehara, Sho AU - Uehara S AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Kijima, Toshiki AU - Kijima T AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Matsuoka, Yoh AU - Matsuoka Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: y-fujii.uro@tmd.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200125 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Neoplasm Recurrence, Local/pathology MH - Retrospective Studies MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Bladder neck involvement OT - Non-muscle-invasive bladder cancer OT - Progression OT - Risk substratification EDAT- 2020/01/29 06:00 MHDA- 2022/03/29 06:00 CRDT- 2020/01/29 06:00 PHST- 2019/11/07 00:00 [received] PHST- 2019/12/18 00:00 [revised] PHST- 2020/01/16 00:00 [accepted] PHST- 2020/01/29 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] PHST- 2020/01/29 06:00 [entrez] AID - S2405-4569(20)30022-5 [pii] AID - 10.1016/j.euf.2020.01.006 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Mar;7(2):366-372. doi: 10.1016/j.euf.2020.01.006. Epub 2020 Jan 25. PMID- 31983531 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20210412 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 4 DP - 2020 Apr TI - Prediction of recurrence and progression in patients with T1G3 bladder cancer by gene expression of circulating tumor cells. PG - 278-285 LID - S1078-1439(19)30489-2 [pii] LID - 10.1016/j.urolonc.2019.12.002 [doi] AB - OBJECTIVE: To investigate the role of gene expression of circulating tumor cells (CTCs) as noninvasive prognostic markers in patients with high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODS: We identified all patients with TIG3 urothelial bladder cancer (UBC) at our institution since 2016.The study included 100 patients with T1G3 UBC and 50 healthy volunteers. CTCs were isolated from blood using immunomagnetic separation and gene expression was performed using 10 bladder cancer associated genes, namely; KRAS, EPCAM, CD133, CD44, mTOR, SURVIVIN, AKT, PI3K, VEGF, and TP53. Gene expression of CTCs was correlated to time to first recurrence and time to progression using Kaplan-Meier curves. RESULTS: There was strong negative correlation between CTCs-positive patients and time to first recurrence and time to progression. Significant differences in expression levels of specific genes were observed that can predict recurrence and progression of T1G3 UBC. CONCLUSION: CTCs appear to be noninvasive methods of predicting disease recurrence and progression in patients with high- risk nonmuscle invasive bladder cancer; therefore, studying their molecular profiling may improve prediction of recurrence and progression. Further studies are invited for more in-depth investigation to consolidate our initial results. CI - Copyright (c) 2019. Published by Elsevier Inc. FAU - Awadalla, Amira AU - Awadalla A AD - Center of Excellence for Genome and Caner Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abol-Enein, H AU - Abol-Enein H AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Gabr, Mahmoud M AU - Gabr MM AD - Center of Excellence for Genome and Caner Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Hamam, Eman T AU - Hamam ET AD - Center of Excellence for Genome and Caner Research, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Shokeir, Ahmed A AU - Shokeir AA AD - Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. Electronic address: ahmed.shokeir@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200123 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Gene Expression/*genetics MH - Humans MH - Male MH - Neoplasm Recurrence, Local MH - Neoplastic Cells, Circulating/*pathology MH - Urinary Bladder Neoplasms/*genetics OTO - NOTNLM OT - CTC OT - Progression OT - Recurrence OT - UBC COIS- Conflict of interest The authors do not disclose any conflict of interest. EDAT- 2020/01/28 06:00 MHDA- 2021/04/13 06:00 CRDT- 2020/01/28 06:00 PHST- 2019/07/11 00:00 [received] PHST- 2019/11/27 00:00 [revised] PHST- 2019/12/02 00:00 [accepted] PHST- 2020/01/28 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2020/01/28 06:00 [entrez] AID - S1078-1439(19)30489-2 [pii] AID - 10.1016/j.urolonc.2019.12.002 [doi] PST - ppublish SO - Urol Oncol. 2020 Apr;38(4):278-285. doi: 10.1016/j.urolonc.2019.12.002. Epub 2020 Jan 23. PMID- 31978650 OWN - NLM STAT- MEDLINE DCOM- 20200819 LR - 20200819 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 75 DP - 2020 Mar TI - Assessing the impact of different distal ureter management techniques during radical nephroureterectomy for primary upper urinary tract urothelial carcinoma on oncological outcomes: A systematic review and meta-analysis. PG - 165-173 LID - S1743-9191(20)30026-1 [pii] LID - 10.1016/j.ijsu.2020.01.016 [doi] AB - OBJECTIVES: To assess the oncological outcomes of several distal ureter management techniques in patients administered with radical nephroureterectomy (RNU) for primary upper urinary tract urothelial carcinoma (UTUC). METHODS: A systematic search of PubMed, EMBASE, and the Cochrane Library was conducted to identify studies comparing outcomes following RNU under various surgical methods for bladder cuff management. Standard cumulative analyses of hazard ratios (HRs) with 95% confidence intervals (CIs) were performed using Review Manager (5.3). RESULTS: Nine studies involving 4683 patients were selected based upon eligibility criteria. Meta-analysis of cancer-specific survival (CSS) and overall survival (OS) revealed no significant differences among intravesical incision of the bladder cuff (IVBC), extravesical incision of the bladder cuff (EVBC) and transurethral incision of the bladder cuff (TUBC) techniques. However, the IVBC technique appeared to have better recurrence-free survival (RFS) (HR = 1.37, p < 0.01) and intravesical recurrence-free survival (IRFS) (HR = 1.45, p < 0.01) compared with non-IVBC methods, including both TUBC and EVBC. When studies involving patients with bladder tumour history were excluded, the pooled statistic appeared to confirm that IVBC was associated with improved IRFS (HR = 1.25, p = 0.03) compared with EVBC and TUBC. No significant difference was found between the EVBC and TUBC groups (HR = 1.81, p = 0.32). CONCLUSIONS: The findings suggest that IVBC is associated with improved oncologic outcomes and that it may be recommended for distal ureter management. However, caution must be taken because this recommendation is based upon a very limited number of clinical studies. Further research with enhanced outcome data collection and improved reporting is required to confirm these findings. CI - Copyright (c) 2020. Published by Elsevier Ltd. FAU - Lai, Shicong AU - Lai S AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Guo, Runqi AU - Guo R AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China. FAU - Seery, Samuel AU - Seery S AD - School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Liu, Jianyong AU - Liu J AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Zhang, Yaoguang AU - Zhang Y AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Zhu, Shengcai AU - Zhu S AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Li, Xiaoguang AU - Li X AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China. FAU - Liu, Ming AU - Liu M AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China. Electronic address: liuming3222@bjhmoh.cn. FAU - Wang, Jianye AU - Wang J AD - Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China. Electronic address: wangjy@bjhmoh.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200121 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM CIN - Int J Surg. 2020 Apr;76:5-6. doi: 10.1016/j.ijsu.2020.02.006. PMID: 32070731 MH - Humans MH - Nephroureterectomy/*methods MH - Retrospective Studies MH - Ureter/*surgery MH - Urologic Neoplasms/mortality/*surgery OTO - NOTNLM OT - Distal ureter management OT - Prognosis OT - Radical nephroureterectomy (RNU) OT - Systematic review and meta-analysis OT - Upper urinary tract urothelial carcinoma (UTUC) COIS- Declaration of competing interest The authors declared that no conflicts of interest exit. EDAT- 2020/01/25 06:00 MHDA- 2020/08/20 06:00 CRDT- 2020/01/25 06:00 PHST- 2019/09/05 00:00 [received] PHST- 2020/01/15 00:00 [revised] PHST- 2020/01/16 00:00 [accepted] PHST- 2020/01/25 06:00 [pubmed] PHST- 2020/08/20 06:00 [medline] PHST- 2020/01/25 06:00 [entrez] AID - S1743-9191(20)30026-1 [pii] AID - 10.1016/j.ijsu.2020.01.016 [doi] PST - ppublish SO - Int J Surg. 2020 Mar;75:165-173. doi: 10.1016/j.ijsu.2020.01.016. Epub 2020 Jan 21. PMID- 31977307 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201114 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 14 IP - 6 DP - 2020 Jun TI - Emerging intravesical therapies for the management of bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward. PG - 204-213 LID - 10.5489/cuaj.6101 [doi] AB - Management of patients with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle-invasive bladder cancer (NMIBC) presents a formidable clinical challenge that requires urologists to weigh the competing risks of progression during further intravesical therapy vs. the morbidity of radical cystectomy. The prognosis of high-risk NMIBC recurring after BCG depends on the adequacy of prior BCG, timing of recurrence, and tumor histology. The standard of care is currently radical cystectomy, as effective salvage intravesical therapy has not been established. The development of bladder-sparing treatments has been hampered to date by inconsistent definitions of BCG failure and difficulties in identifying appropriate control treatments in clinical trials. Despite these limitations, the spectrum of salvage therapy is expanding to include enhanced intravesical chemo-, gene, and immuno-therapies. In this review, we provide an overview of these emerging agents in the context of our current understanding of BCG failure and the unique considerations for clinical trial design in this disease state. FAU - Chehroudi, Ali Cyrus AU - Chehroudi AC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Review PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC7654668 COIS- Competing interests: Dr. Black has been an advisory board member or equivalent for Abbvie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, Janssen, Lilly, Merck, Roche, Sanofi, and Urogen; a speakers' bureau member for Abbvie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received grants and/or honoraria from Bayer, GenomeDx Biosciences, iProgen, and Sanofi; has participated in clinical trials supported by Astellas, Ferring, Genentech, Janssen, MDx Health, and Sitka; and shares a patent with GenomeDx. Dr. Chehroudi reports no competing personal or financial interests related to this work. EDAT- 2020/01/25 06:00 MHDA- 2020/01/25 06:01 PMCR- 2020/06/01 CRDT- 2020/01/25 06:00 PHST- 2020/01/25 06:00 [pubmed] PHST- 2020/01/25 06:01 [medline] PHST- 2020/01/25 06:00 [entrez] PHST- 2020/06/01 00:00 [pmc-release] AID - cuaj.6101 [pii] AID - cuaj-6-204 [pii] AID - 10.5489/cuaj.6101 [doi] PST - ppublish SO - Can Urol Assoc J. 2020 Jun;14(6):204-213. doi: 10.5489/cuaj.6101. PMID- 31970565 OWN - NLM STAT- MEDLINE DCOM- 20201016 LR - 20261010 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 35 IP - 8 DP - 2020 Oct TI - The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer. PG - 1695-1701 LID - 10.1007/s10103-020-02960-0 [doi] AB - The objective of this study was to evaluate which patients might benefit from a single immediate postoperative intravesical instillation (SII) compared to maintenance intravesical instillations (MII) in primary non-muscle-invasive bladder cancer (NMIBC) after transurethral en bloc resection of bladder tumors (ERBT). A total of 141 patients with primary NMIBC who underwent ERBT with thulium laser between January 2012 and May 2016 were retrospectively enrolled. All the patients were categorized into two groups based on the duration of postoperative intravesical instillation of pirarubicin (THP): single intravesical instillation (SII) group, patients received a single immediate postoperative intravesical instillation of THP (30 mg), and maintenance intravesical instillations (MII) group, patients received a 1-year MII of THP (30 mg). Prognosis and recurrence data of each group were analyzed. One hundred and four (73.8%) patients received MII, and other 37 (26.2%) patients received SII. There was no significant difference in recurrence-free survival (RFS) between the two groups (P = 0.105). Following recurrence risk-stratified analysis, patients with high recurrence risk who accepted SII had a significantly lower RFS rate than those who received MII (P = 0.027). However, there were no significant differences in RFS rate between the two groups in patients with low and intermediate recurrence risk. In the multivariate analysis, the number of tumors was found to be an independent prognostic factor for RFS in NMIBC patients [hazard ratio, 5.665; 95% confidence interval (CI), 2.577-12.454; P < 0.001]. SII seems not to be inferior to MII in patients with initial low-risk and intermediate-risk NMIBC after ERBT. FAU - Xu, Sheng AU - Xu S AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368, Yehai Road, Longhua District, Haikou, 570311, China. FAU - Tan, Shaoying AU - Tan S AD - Department of Nursing, Haikou Fourth People's Hospital, No. 65, Yehai Road, Qiongshan District, Haikou, 571100, China. FAU - Wu, Tingming AU - Wu T AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368, Yehai Road, Longhua District, Haikou, 570311, China. FAU - Gu, Jun AU - Gu J AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368, Yehai Road, Longhua District, Haikou, 570311, China. FAU - Xu, Lei AU - Xu L AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368, Yehai Road, Longhua District, Haikou, 570311, China. FAU - Che, Xianping AU - Che X AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368, Yehai Road, Longhua District, Haikou, 570311, China. chexianpinghainan@163.com. LA - eng PT - Journal Article DEP - 20200122 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 RN - 80168379AG (Doxorubicin) RN - 8RKC5ATI4P (Thulium) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Doxorubicin/administration & dosage/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - *Lasers MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Muscles/*pathology MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Thulium/*therapeutic use MH - Urethra/*surgery MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - En bloc resection OT - Non-muscle-invasive bladder cancer OT - Pirarubicin OT - RFS OT - Single immediate postoperative intravesical instillation EDAT- 2020/01/24 06:00 MHDA- 2020/10/21 06:00 CRDT- 2020/01/24 06:00 PHST- 2019/07/03 00:00 [received] PHST- 2020/01/10 00:00 [accepted] PHST- 2020/01/24 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2020/01/24 06:00 [entrez] AID - 10.1007/s10103-020-02960-0 [pii] AID - 10.1007/s10103-020-02960-0 [doi] PST - ppublish SO - Lasers Med Sci. 2020 Oct;35(8):1695-1701. doi: 10.1007/s10103-020-02960-0. Epub 2020 Jan 22. PMID- 31966059 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240724 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 19 IP - 2 DP - 2020 Feb TI - Bone morphogenic proteins-2, -4, -6 and 7 in non-muscle invasive bladder cancer. PG - 1291-1297 LID - 10.3892/ol.2019.11218 [doi] AB - Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-beta) family and may play an important role in the regulation of malignant cells in bladder cancer. The aim of the present study was to investigate BMP expression in non-muscle invasive bladder cancer. Tumor tissue samples from 71 patients treated with transurethral resection and 10 samples of normal bladder tissue were stained using immunohistochemistry for BMP-2, -4, -6 and -7. The levels of BMP were correlated with the number and size of tumors in the bladder, the pathohistological findings as well as with tumor recurrence and progression. The results of the present study demonstrated that BMP-2 and -7 are highly expressed in normal bladder tissue, but significantly downregulated in cancer samples. This reduction correlates with a faster rate of tumor recurrence as well as with an increase in the number of recurrent tumors. There was no evident interrelation between BMP-2 and -7 reduction and changes in tumor grade and stage. In conclusion, BMP-2 and -7 are potential prognostic factors for tumor recurrence and further studies on BMP and bladder cancer are needed to confirm these results. CI - Copyright: (c) Hudolin et al. FAU - Hudolin, Tvrtko AU - Hudolin T AD - Department of Urology, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - Kastelan, Zeljko AU - Kastelan Z AD - Department of Urology, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - El-Saleh, Ahmad AU - El-Saleh A AD - Department of Urology, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - Bakula, Mirko AU - Bakula M AD - Department of Urology, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - Coric, Marijana AU - Coric M AD - Department of Pathology, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - Kes, Petar AU - Kes P AD - Department of Dialysis, University Hospital Center Zagreb, 10000 Zagreb, Croatia. FAU - Tomas, Davor AU - Tomas D AD - Department of Pathology, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia. FAU - Basic-Jukic, Nikolina AU - Basic-Jukic N AD - Department of Dialysis, University Hospital Center Zagreb, 10000 Zagreb, Croatia. LA - eng PT - Journal Article DEP - 20191213 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6956307 OTO - NOTNLM OT - bone morphogenic protein-2 OT - bone morphogenic protein-4 OT - bone morphogenic protein-6 OT - bone morphogenic protein-7 OT - non-muscle invasive bladder cancer OT - prognostic factor OT - tumor recurrence EDAT- 2020/01/23 06:00 MHDA- 2020/01/23 06:01 PMCR- 2019/12/13 CRDT- 2020/01/23 06:00 PHST- 2018/11/27 00:00 [received] PHST- 2019/03/12 00:00 [accepted] PHST- 2020/01/23 06:00 [entrez] PHST- 2020/01/23 06:00 [pubmed] PHST- 2020/01/23 06:01 [medline] PHST- 2019/12/13 00:00 [pmc-release] AID - OL-0-0-11218 [pii] AID - 10.3892/ol.2019.11218 [doi] PST - ppublish SO - Oncol Lett. 2020 Feb;19(2):1291-1297. doi: 10.3892/ol.2019.11218. Epub 2019 Dec 13. PMID- 31965287 OWN - NLM STAT- MEDLINE DCOM- 20210617 LR - 20210617 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 38 IP - 11 DP - 2020 Nov TI - Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection. PG - 2849-2856 LID - 10.1007/s00345-020-03092-4 [doi] AB - OBJECTIVE: Slingshot homolog-1 (SSH-1) shows an important role in the occurrence and development in various tumors. While, the expression and prognostic implications of SSH-1 in bladder urothelial carcinoma (UC) remain unclear and thus were addressed in this study. METHODS: Immunohistochemistry (IHC) was performed on tissue microarrays composed of 624 bladder UC specimens after transurethral resection of bladder tumor (TUR-BT) to detect SSH-1 expression. The clinic-pathological features were compared between SSH-1( +) and SSH-1(-) subgroups. The Kaplan-Meier curve with log-rank test and univariate/multivariate Cox regression model with stepwise backward elimination methods were performed for survival analyses. RESULTS: In this study, 359 (57.53%) specimens were detected with SSH-1 expression. SSH-1 positivity was significantly associated with higher pathological grade (p = 0.020), lymphovascular invasion (p = 0.006), tumor recurrence (p < 0.001) and progression (p < 0.001) in bladder UC. Besides, SSH-1 positivity predicted a shorter overall survival (OS, p = 0.024), recurrence-free survival (RFS, p < 0.001), progression-free survival (PFS, p = 0.002) and cancer-specific survival (CSS, p = 0.047). Multivariate Cox proportional hazard analysis showed that tumor size (p = 0.007), lymphovascular invasion (p = 0.003), recurrence (p < 0.001), progression (p < 0.001) and SSH-1 expression (p = 0.015) were predictors of poor prognosis in bladder UC patients. CONCLUSIONS: SSH-1 expression was associated with undesirable clinic-pathological characteristics and poor post-operative prognosis in bladder UC patients. SSH-1 might play an important role in bladder UC and serve as a promising predictor of oncological outcomes in patients with bladder UC. FAU - Luo, Qiang AU - Luo Q AD - Department of Urology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, No.163, Shoushan Rd, Jiangyin, 214400, Jiangsu Province, China. FAU - Liu, Yanxia AU - Liu Y AD - Department of Pathology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, Jiangyin, 214400, Jiangsu Province, China. FAU - Zhao, Hu AU - Zhao H AD - Department of Urology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, No.163, Shoushan Rd, Jiangyin, 214400, Jiangsu Province, China. FAU - Guo, Peng AU - Guo P AD - Department of Urology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, No.163, Shoushan Rd, Jiangyin, 214400, Jiangsu Province, China. FAU - Wang, Qianwen AU - Wang Q AD - Department of Pathology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, Jiangyin, 214400, Jiangsu Province, China. FAU - Li, Wenjun AU - Li W AD - Department of Urology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, No.163, Shoushan Rd, Jiangyin, 214400, Jiangsu Province, China. FAU - Li, Gang AU - Li G AD - Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Wu, Bin AU - Wu B AUID- ORCID: 0000-0003-4483-5707 AD - Department of Urology, Jiangyin People's Hospital, Affiliated Jiangyin Hospital of the Southeast University Medical College, No.163, Shoushan Rd, Jiangyin, 214400, Jiangsu Province, China. 13182796779@163.com. LA - eng GR - 81772756/National Natural Science Foundation of China/ PT - Journal Article DEP - 20200121 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - EC 3.1.3.16 (Phosphoprotein Phosphatases) RN - EC 3.1.3.16 (SSH1 protein, human) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*metabolism/mortality/pathology/*surgery MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Phosphoprotein Phosphatases/*biosynthesis MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urethra MH - Urinary Bladder Neoplasms/*metabolism/mortality/pathology/*surgery PMC - PMC7644478 OTO - NOTNLM OT - Bladder urothelial carcinoma OT - Prognostic factor OT - Slingshot homolog-1 OT - Transurethral resection OT - pT1 COIS- The authors declare they have no conflict of interest. EDAT- 2020/01/23 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/01/21 CRDT- 2020/01/23 06:00 PHST- 2019/10/11 00:00 [received] PHST- 2020/01/10 00:00 [accepted] PHST- 2020/01/23 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/01/23 06:00 [entrez] PHST- 2020/01/21 00:00 [pmc-release] AID - 10.1007/s00345-020-03092-4 [pii] AID - 3092 [pii] AID - 10.1007/s00345-020-03092-4 [doi] PST - ppublish SO - World J Urol. 2020 Nov;38(11):2849-2856. doi: 10.1007/s00345-020-03092-4. Epub 2020 Jan 21. PMID- 31961624 OWN - NLM STAT- MEDLINE DCOM- 20200522 LR - 20201002 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 46 IP - 2 DP - 2020 Mar-Apr TI - Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. PG - 169-184 LID - 10.1590/S1677-5538.IBJU.2020.99.01 [doi] AB - BACKGROUND: Standard management of muscle-invasive bladder cancer involves radical cystectomy with pelvic lymph node dissection. However, patients may be ineligible for surgery or may wish to avoid the morbidity of cystectomy due to quality of life concerns. Bladder preservation therapies have emerged as alternatives treatment options that can provide comparable oncologic outcomes while maintaining patients' quality of life. OBJECTIVE: To review bladder preservation therapies, patient selection criteria, and functional and oncologic outcomes for BPT in muscle-invasive bladder cancer. MATERIALS AND METHODS: We conducted a comprehensive literature review of bladder preservation therapies in Pubmed and Embase. DISCUSSION: The ideal patient for BPT has low-volume T2 disease, absence of CIS, absence of hydronephrosis, and a maximal TURBT with regular surveillance. Technological advancements involving cancer staging, TURBT technique, and chemotherapy and radiation therapy regimens have improved BPT outcomes, with oncologic outcomes now comparable to those of radical cystectomy. Advancements in BPT also includes a heightened focus on improving quality of life for patients undergoing bladder preservation. Preservation strategies with most evidence for use include trimodality therapy and partial cystectomy with pelvic lymph node dissection. CONCLUSIONS: This review highlights the breadth of strategies that aim to preserve a patient's bladder while still optimizing local tumor control and overall survival. Future areas for innovation include the use of predictive biomarkers and implementation of immunotherapy, moving the field towards patient-tailored care. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Hamad, Judy AU - Hamad J AD - University of North Carolina at Chapel Hill School of Medicine; Chapel Hill, NC, USA. FAU - McCloskey, Hannah AU - McCloskey H AD - 2 Department of Urology, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA. FAU - Milowsky, Matthew I AU - Milowsky MI AD - Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA. FAU - Royce, Trevor AU - Royce T AD - Department of Radiation Oncology, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA. FAU - Smith, Angela AU - Smith A AD - Department of Urology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA. LA - eng PT - Journal Article PT - Review PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Combined Modality Therapy MH - Cystectomy/*methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC7025842 OTO - NOTNLM OT - Cystectomy OT - Therapeutics OT - Urinary Bladder Neoplasms COIS- None declared. EDAT- 2020/01/22 06:00 MHDA- 2020/05/23 06:00 PMCR- 2020/01/10 CRDT- 2020/01/22 06:00 PHST- 2019/12/20 00:00 [received] PHST- 2020/01/02 00:00 [accepted] PHST- 2020/01/22 06:00 [pubmed] PHST- 2020/05/23 06:00 [medline] PHST- 2020/01/22 06:00 [entrez] PHST- 2020/01/10 00:00 [pmc-release] AID - IBJU20209901 [pii] AID - S1677-5538.IBJU.2020.99.01 [pii] AID - 10.1590/S1677-5538.IBJU.2020.99.01 [doi] PST - ppublish SO - Int Braz J Urol. 2020 Mar-Apr;46(2):169-184. doi: 10.1590/S1677-5538.IBJU.2020.99.01. PMID- 31959070 OWN - NLM STAT- MEDLINE DCOM- 20210217 LR - 20220415 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 87 IP - 3 DP - 2020 Aug TI - How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices. PG - 142-148 LID - 10.1177/0391560319899303 [doi] AB - OBJECTIVE: The aim of this study was to assess the quality of TURBT (transurethral resection of bladder tumor) using surrogate parameters and evaluate adherence to the guidelines regarding the management of bladder tumors. MATERIALS AND METHODS: A clinical audit of all new diagnosis of bladder cancer was undertaken from January 2016 to January 2017. A total of 101 new bladder cancer cases were included. Surrogates of TURBT quality including presence of detrusor in the specimen, rate of re-TUR, presence of carcinoma in situ, and 3-month recurrence rates were analyzed. Adherence to guidelines regarding management of non-muscle invasive bladder cancer including time to re-TUR and utilization of single instillation chemotherapy was evaluated. RESULTS: Absence of detrusor muscle in the specimen of the initial TURBT was noted in 22.8% of the cases. The chance of including muscle in the specimen was almost four-fold for tumors larger than 3 cm. A single instillation of intravesical chemotherapy following TURBT was administered in only 40% of eligible patients; 54.3% of patients had a re-TUR, the majority (61.3%) for high-grade non-muscle invasive bladder cancer on initial TURBT. Re-TUR was done on average 10 weeks after initial TURBT. The 3-month recurrence rate was 36.0% with larger tumors (>3 cm) being more prone to early recurrences. Early recurrences were not affected by intravesical instillations with bacillus Calmette-Guerin or mitomycin C although there was a positive association between the presence of carcinoma in situ on initial resection and early recurrences. DISCUSSION AND CONCLUSION: One in two patients will have a re-TUR, and approximately one in two patients will have tumor on re-TUR. Single immediate chemotherapy instillations after TURBT are underutilized. The presence of carcinoma in situ on initial TURBT and tumor size were predictors of early recurrences. FAU - Sountoulides, Petros AU - Sountoulides P AUID- ORCID: 0000-0003-2671-571X AD - Urology Department, The Pennine Acute Hospitals NHS Trust, Manchester, UK. FAU - Mutomba, Wilbert Fana AU - Mutomba WF AD - 1st Urology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Bouras, Emmanouil AU - Bouras E AUID- ORCID: 0000-0003-1489-5506 AD - Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Lim, Jieqi AU - Lim J AD - Urology Department, The Pennine Acute Hospitals NHS Trust, Manchester, UK. FAU - Bourdoumis, Andreas AU - Bourdoumis A AD - Urology Department, The Pennine Acute Hospitals NHS Trust, Manchester, UK. FAU - Jain, Arun AU - Jain A AD - Urology Department, The Pennine Acute Hospitals NHS Trust, Manchester, UK. LA - eng PT - Journal Article DEP - 20200121 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Aged MH - Carcinoma in Situ/*epidemiology/pathology/*surgery MH - Cystectomy/*standards MH - Guideline Adherence/*statistics & numerical data MH - Humans MH - *Medical Audit MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - United Kingdom MH - Urinary Bladder Neoplasms/*epidemiology/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - TURBT OT - guidelines OT - re-TUR OT - recurrences EDAT- 2020/01/22 06:00 MHDA- 2021/02/18 06:00 CRDT- 2020/01/22 06:00 PHST- 2020/01/22 06:00 [pubmed] PHST- 2021/02/18 06:00 [medline] PHST- 2020/01/22 06:00 [entrez] AID - 10.1177/0391560319899303 [doi] PST - ppublish SO - Urologia. 2020 Aug;87(3):142-148. doi: 10.1177/0391560319899303. Epub 2020 Jan 21. PMID- 31955206 OWN - NLM STAT- MEDLINE DCOM- 20200710 LR - 20200710 IS - 1465-3621 (Electronic) IS - 0368-2811 (Print) IS - 0368-2811 (Linking) VI - 50 IP - 5 DP - 2020 May 5 TI - The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer. PG - 609-616 LID - 10.1093/jjco/hyz211 [doi] AB - OBJECTIVE: Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system. METHODS: Thirty-eight patients who were diagnosed with T2-T4N0M0 bladder cancer between 1998 and 2016 and had clinically inoperable disease or refused to undergo surgery were enrolled. The treatment protocol included maximal transurethral resection followed by whole-bladder radiotherapy (40 Gy). Concurrent nedaplatin-based chemotherapy was administered to patients with adequate renal function. At the time of the first evaluation (via transurethral resection of the tumor bed), fiducial markers were endoscopically inserted into the bladder wall around the tumor. A boost of 25 Gy was administered using the real-time tumor-tracking radiotherapy system. The second evaluation (via transurethral resection of the tumor bed) was performed 6 months after the start of treatment. The Kaplan-Meier method and Cox hazards analysis were used to analyze overall survival and cancer-specific survival. RESULTS: The median duration of the follow-up period was 28 months (range: 3-161 months). The 5- and 10-year overall survival rates were 54.9 and 41.2%, respectively. Twenty-five (65.8%) and twenty (74.1%) patients had achieved complete responses to chemoradiation at the first and second evaluations, respectively. In univariate and multivariate analyses, performance status was found to be significantly associated with overall survival [P = 0.03, hazard ratio: 3.48, 95% confidence interval: 1.15-10.6] and cancer-specific survival [P = 0.02, hazard ratio: 4.57, 95% confidence interval: 1.32-16.9], and sex was shown to be significantly associated with cancer-specific survival [P = 0.03, hazard ratio: 3.07, 95% confidence interval: 1.09-8.30]. CONCLUSIONS: Our bladder-preserving trimodal therapy protocol, which involves the use of a real-time tumor-tracking radiotherapy system, produced an acceptable overall survival rate. This therapy is a reasonable alternative for patients that are medically unfit for or do not want to undergo cystectomy. CI - (c) The Author(s) 2020. Published by Oxford University Press. FAU - Miyata, Haruka AU - Miyata H AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Abe, Takashige AU - Abe T AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Kikuchi, Hiroshi AU - Kikuchi H AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Matsumoto, Ryuji AU - Matsumoto R AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Maruyama, Satoru AU - Maruyama S AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. FAU - Nishioka, Kentaro AU - Nishioka K AD - Department of Radiation Medical Science and Engineering, Hokkaido University, Sapporo, Japan. FAU - Shimizu, Shinichi AU - Shimizu S AD - Department of Radiation Medical Science and Engineering, Hokkaido University, Sapporo, Japan. AD - Global Station for Quantum Biomedical Science and Engineering, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Japan. FAU - Hashimoto, Takayuki AU - Hashimoto T AD - Department of Radiation Medicine, Hokkaido University, Sapporo, Japan. FAU - Shirato, Hiroki AU - Shirato H AD - Global Station for Quantum Biomedical Science and Engineering, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Japan. FAU - Shinohara, Nobuo AU - Shinohara N AD - Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Female MH - Humans MH - Induction Chemotherapy MH - Kaplan-Meier Estimate MH - Male MH - Multivariate Analysis MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Prognosis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*radiotherapy PMC - PMC7202139 OTO - NOTNLM OT - bladder cancer OT - chemoradiation OT - complications OT - mortality OT - trimodal therapy EDAT- 2020/01/20 06:00 MHDA- 2020/07/11 06:00 PMCR- 2020/01/19 CRDT- 2020/01/20 06:00 PHST- 2019/11/09 00:00 [received] PHST- 2019/10/13 00:00 [revised] PHST- 2019/12/20 00:00 [accepted] PHST- 2020/01/20 06:00 [pubmed] PHST- 2020/07/11 06:00 [medline] PHST- 2020/01/20 06:00 [entrez] PHST- 2020/01/19 00:00 [pmc-release] AID - 5709020 [pii] AID - hyz211 [pii] AID - 10.1093/jjco/hyz211 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2020 May 5;50(5):609-616. doi: 10.1093/jjco/hyz211. PMID- 31950596 OWN - NLM STAT- MEDLINE DCOM- 20200806 LR - 20200806 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 125 IP - 4 DP - 2020 Apr TI - Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). PG - 497-505 LID - 10.1111/bju.14995 [doi] AB - OBJECTIVE: To provide a contemporary update and recommendations for the diagnosis and management of low-grade non-muscle-invasive bladder cancer (BCa) based on current literature and expert consensus of the International Bladder Cancer Group. METHODS: We reviewed published trials, guidelines, meta-analyses and reviews (up to March 2019) and provide recommendations on baseline evaluations, treatment, endpoints, study design and surveillance protocols. RESULTS: Low-grade Ta BCa poses minimal risk to patients in terms of progression and disease-specific survival. Thus, to minimize patient morbidity, this entity should be managed appropriately. After initial diagnosis of low-grade Ta tumour, subsequent stable, low-grade-appearing recurrences can be managed conservatively with office cystoscopy and fulguration or even followed using an active surveillance protocol. Intravesical therapy other than single-dose peri-operative chemotherapy instillation should be used judiciously, and only after assigning appropriate risk points. Routine use of urinary cytology - other than at initial risk stratification, or for patients on active surveillance without therapy - is not recommended; and surveillance cystoscopy may be discontinued after 5 years. Clinical studies in this group of patients should focus on recurrence rates, and time to recurrence, rather than progression events. CONCLUSIONS: The International Bladder Cancer Group has developed formal recommendations regarding the diagnosis, treatment and surveillance of low-grade non-muscle-invasive BCa to minimize morbidity and encourage uniformity among studies in this disease. CI - (c) 2020 The Authors BJU International (c) 2020 BJU International Published by John Wiley & Sons Ltd. FAU - Matulay, Justin T AU - Matulay JT AUID- ORCID: 0000-0002-2467-5710 AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Soloway, Mark AU - Soloway M AD - Memorial Cancer Institute, Memorial Hospital, Hollywood, FL, USA. FAU - Witjes, J Alfred AU - Witjes JA AD - Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. FAU - Buckley, Roger AU - Buckley R AD - North York General Hospital, Toronto, Ontario, Canada. FAU - Persad, Raj AU - Persad R AD - Bristol Royal Infirmary and Bristol Urological Institute, Bristol, UK. FAU - Lamm, Donald L AU - Lamm DL AD - University of Arizona and BCG Oncology, Phoenix, AZ, USA. FAU - Boehle, Andreas AU - Boehle A AD - University of Luebeck, Luebeck, Germany. FAU - Palou, Joan AU - Palou J AD - Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Colombel, Marc AU - Colombel M AD - Claude Bernard University, Hopital Edouard Herriot, Lyon, France. FAU - Brausi, Maurizio AU - Brausi M AD - Azienda Unita Sanitaria Locale di Modena, Modena, Italy. FAU - Kamat, Ashish M AU - Kamat AM AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20200208 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Humans MH - Neoplasm Grading MH - Risk Assessment MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - cystoscopy OT - low grade OT - papillary OT - surveillance EDAT- 2020/01/18 06:00 MHDA- 2020/08/07 06:00 CRDT- 2020/01/18 06:00 PHST- 2019/09/17 00:00 [received] PHST- 2019/12/29 00:00 [revised] PHST- 2020/01/08 00:00 [accepted] PHST- 2020/01/18 06:00 [pubmed] PHST- 2020/08/07 06:00 [medline] PHST- 2020/01/18 06:00 [entrez] AID - 10.1111/bju.14995 [doi] PST - ppublish SO - BJU Int. 2020 Apr;125(4):497-505. doi: 10.1111/bju.14995. Epub 2020 Feb 8. PMID- 31942812 OWN - NLM STAT- MEDLINE DCOM- 20210126 LR - 20210126 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 54 IP - 1 DP - 2020 Feb TI - Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark. PG - 58-64 LID - 10.1080/21681805.2019.1710562 [doi] AB - Objective: To report the oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in a large study sample.Materials and methods: This was a nationwide multicenter registry-based cohort study of all patients with upper urinary tract urothelial neoplasia in Denmark found to be eligible for nephroureterectomy between April 2004 and April 2017 (N = 1384). Primary endpoints were intravesical recurrence-free survival and overall survival. Survival probabilities were estimated with Kaplan-Meier and the log-rank test to compare survival curves. Association with clinical outcomes was studied using univariate and multivariate Cox proportional hazards.Results: Intravesical recurrence-free survival was 72% [95% confidence interval (CI) 69-75%] at 5 years and 70% (95% CI 67-73%) at 10 years. Patients with muscle-invasive disease had a significantly lower rate of intravesical recurrence [hazard ratio (HR) = 0.46, p < 0.0001] and patients with high-grade tumors had a significantly higher rate of incident intravesical recurrence compared to low-grade tumors (HR = 1.65, p = 0.001). The overall survival was 76% (95% CI 74-79%) at 5 years and 64% (95% CI 60-70%) at 10 years. Patients with higher age (p = 0.008) and muscle-invasive disease (p < 0.0001) had worse overall survival. When comparing surgical approaches, laparoscopic nephroureterectomy versus open nephroureterectomy did not differ in intravesical recurrence-free survival but was associated with shorter postoperative hospital stay (p < 0.0001) and better overall survival (p = 0.02).Conclusions: We report the oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in a large sample and give insights into predictive factors with significant impact. FAU - Azawi, Nessn H AU - Azawi NH AUID- ORCID: 0000-0001-7519-8654 AD - Department of Urology, Zealand University Hospital, Roskilde, Denmark. AD - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Naeraa, Sara Haunstrup AU - Naeraa SH AD - Department of Urology, Zealand University Hospital, Roskilde, Denmark. FAU - Subhi, Yousif AU - Subhi Y AUID- ORCID: 0000-0001-6620-5365 AD - Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark. FAU - Vasquez, Juan Luis AU - Vasquez JL AD - Department of Urology, Zealand University Hospital, Roskilde, Denmark. FAU - Norus, Thomas AU - Norus T AD - Department of Urology, Zealand University Hospital, Roskilde, Denmark. FAU - Dahl, Claus AU - Dahl C AD - Department of Urology, Zealand University Hospital, Roskilde, Denmark. FAU - Thind, Peter AU - Thind P AD - Department of Urology, Rigshospitalet, Copenhagen, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AUID- ORCID: 0000-0002-4347-739X AD - Department of Urology, Regionshospitalet Holstebro, Holstebro, Denmark. AD - Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark. LA - eng PT - Journal Article DEP - 20200116 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Denmark MH - Disease-Free Survival MH - Female MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Kidney Pelvis MH - Laparoscopy MH - Length of Stay/statistics & numerical data MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - *Nephroureterectomy MH - Proportional Hazards Models MH - Treatment Outcome MH - Ureteral Neoplasms/pathology/*surgery MH - Urinary Bladder Neoplasms/*epidemiology OTO - NOTNLM OT - Denmark OT - Nephroureterectomy OT - laparoscopy OT - surgical oncology EDAT- 2020/01/17 06:00 MHDA- 2021/01/27 06:00 CRDT- 2020/01/17 06:00 PHST- 2020/01/17 06:00 [pubmed] PHST- 2021/01/27 06:00 [medline] PHST- 2020/01/17 06:00 [entrez] AID - 10.1080/21681805.2019.1710562 [doi] PST - ppublish SO - Scand J Urol. 2020 Feb;54(1):58-64. doi: 10.1080/21681805.2019.1710562. Epub 2020 Jan 16. PMID- 31942463 OWN - NLM STAT- MEDLINE DCOM- 20201218 LR - 20201218 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 61 IP - 1 DP - 2020 Jan TI - Preoperative sterile pyuria as a prognostic biomarker for intravesical recurrence in upper urinary tract urothelial carcinoma. PG - 51-58 LID - 10.4111/icu.2020.61.1.51 [doi] AB - PURPOSE: To evaluate if preoperative sterile pyuria can be a prognostic factor for intravesical recurrence (IVR) and overall survival (OS)in patients with upper tract urothelial carcinoma (UTUC) undergoing surgery. MATERIALS AND METHODS: We retrospectively reviewed the medical records of patients who were diagnosed with UTUC from October 2003 to December 2016 at Korea University Medical Center. Sterile pyuria was defined as urine containing five or more white blood cells per high-power field in the absence of bacteria in urine culture. We used a stepwise multivariable Cox proportional hazards model to assess the independent effects of the prognostic factors for IVR and OS. RESULTS: We investigated a total of 176 patients who were diagnosed with UTUC. Among them, 91 (51.7%) patients had preoperative sterile pyuria. There were no significant differences in the baseline characteristics between the pyuria and non-pyuria groups concerning tumor grade, T stage, tumor multiplicity, and recurrence history. However, there was a significant difference in the IVR between the two groups. In the multivariable analysis, preoperative sterile pyuria, diabetes mellitus, high-grade tumor, and lymphovascular invasion were revealed as independent risk factors for IVR, and only lymphovascular invasion was identified as an independent risk factor for OS. CONCLUSIONS: Preoperative sterile pyuria is significantly associated with IVR in patients with UTUC undergoing surgery, but it is not associated with OS. Furthermore, diabetes mellitus, high-grade tumor, and lymphovascular invasion are also independent prognostic factors for these patients. CI - (c) The Korean Urological Association, 2020. FAU - Jeon, Byeong Jo AU - Jeon BJ AUID- ORCID: 0000-0002-8598-6635 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. FAU - Tae, Bum Sik AU - Tae BS AUID- ORCID: 0000-0003-2963-7366 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. FAU - Choi, Hoon AU - Choi H AUID- ORCID: 0000-0002-8481-8103 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. FAU - Bae, Jae Hyun AU - Bae JH AUID- ORCID: 0000-0001-9862-3545 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. FAU - Kim, Jong Wook AU - Kim JW AUID- ORCID: 0000-0003-2228-0640 AD - Department of Urology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Park, Hong Seok AU - Park HS AUID- ORCID: 0000-0001-7287-2682 AD - Department of Urology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Park, Jae Young AU - Park JY AUID- ORCID: 0000-0002-6664-6846 AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191219 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Aged MH - *Carcinoma, Transitional Cell/pathology/surgery/urine MH - Female MH - Humans MH - *Leukocyte Count/methods/statistics & numerical data MH - Male MH - Middle Aged MH - Neoplasm Grading MH - *Neoplasm Recurrence, Local/diagnosis/etiology MH - Neoplasm Staging MH - Outcome Assessment, Health Care MH - Perioperative Period MH - Predictive Value of Tests MH - Prognosis MH - *Pyuria/diagnosis/urine MH - Risk Assessment/methods MH - *Urologic Neoplasms/pathology/surgery/urine MH - Urologic Surgical Procedures/*adverse effects/methods PMC - PMC6946823 OTO - NOTNLM OT - Prognosis OT - Pyuria OT - Recurrence OT - Urinary bladder OT - Urologic neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2020/01/17 06:00 MHDA- 2020/12/19 06:00 PMCR- 2020/01/01 CRDT- 2020/01/17 06:00 PHST- 2019/05/26 00:00 [received] PHST- 2019/09/08 00:00 [accepted] PHST- 2020/01/17 06:00 [entrez] PHST- 2020/01/17 06:00 [pubmed] PHST- 2020/12/19 06:00 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.4111/icu.2020.61.1.51 [doi] PST - ppublish SO - Investig Clin Urol. 2020 Jan;61(1):51-58. doi: 10.4111/icu.2020.61.1.51. Epub 2019 Dec 19. PMID- 31941594 OWN - NLM STAT- MEDLINE DCOM- 20201026 LR - 20201026 IS - 0219-3108 (Electronic) IS - 1015-9584 (Linking) VI - 43 IP - 10 DP - 2020 Oct TI - Single-docking robotic-assisted nephroureterectomy and extravesical bladder cuff excision without intraoperative repositioning: The technique and oncological outcomes. PG - 978-985 LID - S1015-9584(19)30854-1 [pii] LID - 10.1016/j.asjsur.2019.11.009 [doi] AB - BACKGROUND: /Objective: Currently there are few report of oncologic outcomes following robotic-assisted radical nephroureterectomy (RRNU) based on long-term follow-up. To evaluate the therapeutic effect of RRNU for upper tract urothelial carcinoma (UTUC), a technique of single-docking RRNU was described and its oncological outcomes was evaluated. PATIENTS AND METHODS: The data of 29 patients underwent RRNU for UTUC of Ta-T3 from July 2013 to June 2016 was analyzed. The data of 131 patients of UTUC underwent laparoscopic radical nephroureterectomy (LRNU) over the same period was analyzed as control. Kaplan-Meier analysis and Cox regression were used for prognosis evaluation. RESULTS: The median follow-up time was 40.5 and 40.4 months in RRNU cohort and LRNU cohort. No difference in 5-year intravesical recurrence-free survival (IVRFS) (88.0% vs. 85.5%, p = 0.611) or distant metastasis-free survival (93.1% vs.96.7%, p = 0.323) between RRNU cohort and LRNU cohort. The 5-year retroperitoneal recurrence-free survival and cancer-specific survival (CS) were lower in RRNU cohort than in LRNU cohort (77.3% vs. 87.7%, and 71.2% v.s. 84.7%, respectively). CONCLUSION: The single-docking RRNU is an effective treatment for UTUC, avoiding the re-docking of patient-side cart or the intraoperative reposition of patient, and bringing equivalent 5-year IVRFS compared to LRNU. However, the lower 5-year retroperitoneal recurrence-free survival and CS in RRNU cohort warned the concern of higher chance of local tumor spillage during RRNU. The noninferiority of RRNU to LRNU still needed the confirmation of large sample sized, prospective randomized controlled study. CI - Copyright (c) 2020. Published by Elsevier Taiwan LLC. FAU - Ye, Huamao AU - Ye H AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: changhaimiwai@qq.com. FAU - Feng, Xiang AU - Feng X AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: 13621951368@163.com. FAU - Wang, Yang AU - Wang Y AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: oceansayhello@126.com. FAU - Chen, Rui AU - Chen R AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: drchenrui@foxmail.com. FAU - Zhang, Chao AU - Zhang C AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: tonyzhangchanghai@163.com. FAU - Zhang, Wei AU - Zhang W AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: weizhangchanghai@163.com. FAU - Guo, Fei AU - Guo F AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: 172715957@qq.com. FAU - Wang, Zeyu AU - Wang Z AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: zeyuwangchanghai@163.com. FAU - Fang, Yu AU - Fang Y AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: 13916943129@163.com. FAU - Wu, Zhenjie AU - Wu Z AD - Department of Urology, Shanghai Changzheng Hospital, The Second Military Medical University, PR China. Electronic address: wuzhenjie17@163.com. FAU - Yang, Qing AU - Yang Q AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: qingyangchanghai@163.com. FAU - Yang, Bo AU - Yang B AD - Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: boyangchanghai@163.com. FAU - Lu, Chen AU - Lu C AD - Department of Urology, Shanghai East Hospital Affiliated to Shanghai Tongji University, PR China; Department of Urology, Shanghai Changhai Hospital, The Second Military Medical University, PR China. Electronic address: chenlouie@live.com. FAU - Wang, Linhui AU - Wang L AD - Department of Urology, Shanghai Changzheng Hospital, The Second Military Medical University, PR China. Electronic address: wanglinhuicz@163.com. LA - eng PT - Journal Article DEP - 20200112 PL - Netherlands TA - Asian J Surg JT - Asian journal of surgery JID - 8900600 SB - IM MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Laparoscopy/*methods MH - Male MH - Middle Aged MH - Nephroureterectomy/*methods MH - Patient Positioning MH - Prognosis MH - Robotic Surgical Procedures/*methods MH - Urinary Bladder/*surgery MH - Urologic Neoplasms/mortality/*surgery OTO - NOTNLM OT - Laparoscopic surgery OT - Radical nephroureterectomy OT - Robotic surgery OT - Upper tract urothelial carcinoma COIS- Declaration of competing interest All authors have declared that no conflict of interest exists. EDAT- 2020/01/17 06:00 MHDA- 2020/10/27 06:00 CRDT- 2020/01/17 06:00 PHST- 2019/07/23 00:00 [received] PHST- 2019/11/09 00:00 [revised] PHST- 2019/11/24 00:00 [accepted] PHST- 2020/01/17 06:00 [pubmed] PHST- 2020/10/27 06:00 [medline] PHST- 2020/01/17 06:00 [entrez] AID - S1015-9584(19)30854-1 [pii] AID - 10.1016/j.asjsur.2019.11.009 [doi] PST - ppublish SO - Asian J Surg. 2020 Oct;43(10):978-985. doi: 10.1016/j.asjsur.2019.11.009. Epub 2020 Jan 12. PMID- 31937798 OWN - NLM STAT- MEDLINE DCOM- 20201110 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 10 IP - 1 DP - 2020 Jan 14 TI - Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. PG - 281 LID - 10.1038/s41598-019-55013-0 [doi] LID - 281 AB - Little attention was given to the interaction between tumor and stromal cells in urothelial bladder carcinoma (UBC). While recent studies point towards the existence of different fibroblast subsets, no comprehensive analyses linking different fibroblast markers to UBC patient survival have been performed so far. Through immunohistochemical analysis of five selected fibroblast markers, namely alpha smooth muscle actin (ASMA), CD90/Thy-1, fibroblast activation protein (FAP), platelet derived growth factor receptor-alpha and -beta (PDGFRa,-b), this study investigates their association with survival and histopathological characteristics in a cohort of 344 UBC patients, involving both, muscle-invasive and non-muscle-invasive cases. The data indicates that combinations of stromal markers are more suited to identify prognostic patient subgroups than single marker analysis. Refined stroma-marker-based patient stratification was achieved through cluster analysis and identified a FAP-dominant patient cluster as independent marker for shorter 5-year-survival (HR(95% CI)2.25(1.08-4.67), p = 0.030). Analyses of interactions between fibroblast and CD8a-status identified a potential minority of cases with CD90-defined stroma and high CD8a infiltration showing a good prognosis of more than 80% 5-year-survival. Presented analyses point towards the existence of different stroma-cell subgroups with distinct tumor-modulatory properties and motivate further studies aiming to better understand the molecular tumor-stroma crosstalk in UBC. FAU - Mezheyeuski, Artur AU - Mezheyeuski A AD - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Leiss, Lina Wik AU - Leiss LW AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Hatina, Jiri AU - Hatina J AD - Charles University, Faculty of Medicine in Pilsen, Institut of Biology, Plzen, Czech Republic. FAU - Ostman, Arne AU - Ostman A AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. FAU - Strell, Carina AU - Strell C AD - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. carina.strell@igp.uu.se. AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. carina.strell@igp.uu.se. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200114 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Actins) RN - 0 (Biomarkers, Tumor) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.24.- (Gelatinases) RN - 0 (Membrane Proteins) RN - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha) RN - EC 3.4.21.- (Serine Endopeptidases) RN - 0 (Thy-1 Antigens) RN - EC 3.4.21.- (Fibroblast Activation Protein Alpha) SB - IM MH - Actins/metabolism MH - Aged MH - Biomarkers, Tumor/metabolism MH - CD8-Positive T-Lymphocytes/cytology/immunology/metabolism MH - Cluster Analysis MH - Endopeptidases MH - Female MH - Fibroblasts/cytology/*metabolism MH - Gelatinases/metabolism MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Membrane Proteins/metabolism MH - Phenotype MH - Prognosis MH - Proportional Hazards Models MH - Receptor, Platelet-Derived Growth Factor alpha/metabolism MH - Serine Endopeptidases/metabolism MH - Thy-1 Antigens/metabolism MH - Urinary Bladder Neoplasms/metabolism/mortality/*pathology MH - Fibroblast Activation Protein Alpha PMC - PMC6959241 COIS- The authors declare no competing interests. EDAT- 2020/01/16 06:00 MHDA- 2020/11/11 06:00 PMCR- 2020/01/14 CRDT- 2020/01/16 06:00 PHST- 2019/07/12 00:00 [received] PHST- 2019/11/20 00:00 [accepted] PHST- 2020/01/16 06:00 [entrez] PHST- 2020/01/16 06:00 [pubmed] PHST- 2020/11/11 06:00 [medline] PHST- 2020/01/14 00:00 [pmc-release] AID - 10.1038/s41598-019-55013-0 [pii] AID - 55013 [pii] AID - 10.1038/s41598-019-55013-0 [doi] PST - epublish SO - Sci Rep. 2020 Jan 14;10(1):281. doi: 10.1038/s41598-019-55013-0. PMID- 31937176 OWN - NLM STAT- MEDLINE DCOM- 20201211 LR - 20260127 IS - 1473-2300 (Electronic) IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 48 IP - 1 DP - 2020 Jan TI - HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy. PG - 300060519895847 LID - 10.1177/0300060519895847 [doi] LID - 0300060519895847 AB - OBJECTIVE: HER-2 is overexpressed in a variety of human malignant tumors and has been widely used in the prognosis and treatment of breast cancer. In urothelial cell carcinoma of the bladder, some reports have shown an association between HER-2 overexpression and worse outcomes. The aim of this study was to examine the association between HER-2 expression and other clinicopathologic parameters in 48 patients treated for primary non-muscle-invasive transitional cell carcinoma of the bladder. METHODS: The initial expression of HER-2 in tumor specimens and its expression upon disease recurrence following instillation therapy (BCG, Mitomycin, or Epirubicin) were studied. RESULTS: HER-2 expression was significantly increased between these two timepoints. In multivariate analysis, HER-2 expression at the time of diagnosis was found to be the only independent factor and was associated with reduced recurrence free survival. CONCLUSIONS: HER-2 status could be an additional biomarker for predicting the outcome of non-muscle-invasive bladder cancer, which could help identify high-risk patients for recurrence and possible progression who require close observation and perhaps radical treatment, such as early cystectomy. FAU - Moustakas, Georgios AU - Moustakas G AD - Department of Urology, Theagenio Cancer Hospital, Thessaloniki, Greece. FAU - Kampantais, Spyridon AU - Kampantais S AUID- ORCID: 0000-0001-5743-0333 AD - Department of Urology, Saint Luke's Private Hospital of Thessaloniki, Thessaloniki, Greece. FAU - Nikolaidou, Anastasia AU - Nikolaidou A AD - Department of Pathology, Theagenio Cancer Hospital, Thessaloniki, Greece. FAU - Vakalopoulos, Ioannis AU - Vakalopoulos I AD - 1st Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Tzioufa, Valentini AU - Tzioufa V AD - Department of Pathology, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Dimitriadis, Georgios AU - Dimitriadis G AD - 1st Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece. LA - eng PT - Journal Article PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Transitional Cell/*metabolism/pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*metabolism/pathology PMC - PMC7112244 OTO - NOTNLM OT - Bladder cancer OT - HER-2 OT - erbB2 OT - human epidermal growth factor receptor OT - immunohistochemistry OT - non-muscle-invasive bladder cancer EDAT- 2020/01/16 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/01/15 CRDT- 2020/01/16 06:00 PHST- 2020/01/16 06:00 [entrez] PHST- 2020/01/16 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/01/15 00:00 [pmc-release] AID - 10.1177_0300060519895847 [pii] AID - 10.1177/0300060519895847 [doi] PST - ppublish SO - J Int Med Res. 2020 Jan;48(1):300060519895847. doi: 10.1177/0300060519895847. PMID- 31921631 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240723 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Clinical Significance of Pre-treated Neutrophil-Lymphocyte Ratio in the Management of Urothelial Carcinoma: A Systemic Review and Meta-Analysis. PG - 1365 LID - 10.3389/fonc.2019.01365 [doi] LID - 1365 AB - Purpose: We performed a study-level meta-analysis to summarize the current evidence on the correlation between pretreatment neutrophil-to-lymphocyte ratios (NLR) and oncological outcomes in each type of management for urothelial carcinoma. Method: All articles published until February 2017 in PubMed, Scopus, and EMBASE database were collected and reviewed. The current evidence on correlations between pretreatment NLR and oncological outcomes in each type of management for urothelial carcinoma, including transurethral resection of bladder tumor (TURBT), radical cystectomy (RCx), chemotherapy (CTx), and nephroureterectomy (NUx), were summarized. Results: Thirty-eight studies containing clinical information on 16,379 patients were analyzed in this study. Pooled hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals were calculated after weighing each study. Heterogeneity among the studies and publication bias were assessed. Pretreatment NLR was significantly associated with muscle invasiveness (OR: 4.27), recurrence free survival (RFS, HR: 2.32), and progression-free survival (PFS, HR: 2.45) in TURBT patients. In the RCx patients, high NLR was negatively associated with both disease status (extravesical extension and lymph-node positivity, OR: 1.14 and 1.43, respectively) and oncological outcomes [overall survival (OS), PFS], and cancer specific survival (CSS, HR: 1.18, 1.12, and 1.35, respectively). Pretreatment NLR was negatively correlated with pathologic downstaging (OR: 0.79) and positively correlated with PFS (HR: 1.30) and OS (HR: 1.44) in CTx patients. For patients who underwent NUx, pretreatment NLR was significantly associated with OS (HR: 1.72), PFS (HR: 1.63), and CSS (HR: 1.68). Conclusions: Pretreatment NLR is a useful biomarker for disease aggressiveness, oncological outcome, and treatment response in the management of patients with urothelial carcinoma. More evidence is needed to clarify these results. CI - Copyright (c) 2019 Suh, Jung, Jeong, Kwak, Kim and Ku. FAU - Suh, Jungyo AU - Suh J AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Urology, Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea. FAU - Jung, Jae Hyun AU - Jung JH AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article PT - Systematic Review DEP - 20191216 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6927426 OTO - NOTNLM OT - chemotherapy OT - cystectomy OT - neutrophil-lymphocyte ratio OT - oncological outcome OT - trans-urethral resection of bladder tumor OT - urothelial carcinoma EDAT- 2020/01/11 06:00 MHDA- 2020/01/11 06:01 PMCR- 2019/01/01 CRDT- 2020/01/11 06:00 PHST- 2019/07/30 00:00 [received] PHST- 2019/11/19 00:00 [accepted] PHST- 2020/01/11 06:00 [entrez] PHST- 2020/01/11 06:00 [pubmed] PHST- 2020/01/11 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.01365 [doi] PST - epublish SO - Front Oncol. 2019 Dec 16;9:1365. doi: 10.3389/fonc.2019.01365. eCollection 2019. PMID- 31921291 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1664-8021 (Print) IS - 1664-8021 (Electronic) IS - 1664-8021 (Linking) VI - 10 DP - 2019 TI - Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. PG - 1237 LID - 10.3389/fgene.2019.01237 [doi] LID - 1237 AB - Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most prevalent cancer worldwide. Of all newly diagnosed patients with BC, 70-75% will present disease confined to the mucosa or submucosa, the non-muscle-invasive BC (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to high rate of recurrence, patients are submitted to an intensive follow-up program maintained throughout many years, or even throughout life, resulting in an expensive follow-up, with cystoscopy being the most cost-effective procedure for NMIBC screening. Currently, the gold standard procedure for detection and follow-up of NMIBC is based on the association of cystoscopy and urine cytology. As cystoscopy is a very invasive approach, over the years, many different noninvasive assays (both based in serum and urine samples) have been developed in order to search genetic and protein alterations related to the development, progression, and recurrence of BC. TERT promoter mutations and FGFR3 hotspot mutations are the most frequent somatic alterations in BC and constitute the most reliable biomarkers for BC. Based on these, we developed an ultra-sensitive, urine-based assay called Uromonitor((R)), capable of detecting trace amounts of TERT promoter (c.1-124C > T and c.1-146C > T) and FGFR3 (p.R248C and p.S249C) hotspot mutations, in tumor cells exfoliated to urine samples. Cells present in urine were concentrated by the filtration of urine through filters where tumor cells are trapped and stored until analysis, presenting long-term stability. Detection of the alterations was achieved through a custom-made, robust, and highly sensitive multiplex competitive allele-specific discrimination PCR allowing clear interpretation of results. In this study, we validate a test for NMIBC recurrence detection, using for technical validation a total of 331 urine samples and 41 formalin-fixed paraffin-embedded tissues of the primary tumor and recurrence lesions from a large cluster of urology centers. In the clinical validation, we used 185 samples to assess sensitivity/specificity in the detection of NMIBC recurrence vs. cystoscopy/cytology and in a smaller cohort its potential as a primary diagnostic tool for NMIBC. Our results show this test to be highly sensitive (73.5%) and specific (93.2%) in detecting recurrence of BC in patients under surveillance of NMIBC. CI - Copyright (c) 2019 Batista, Vinagre, Prazeres, Sampaio, Peralta, Conceicao, Sismeiro, Leao, Gomes, Furriel, Oliveira, Torres, Eufrasio, Azinhais, Almeida, Gonzalez, Bidovanets, Ecke, Stinjs, Pascual, Abdelmalek, Villafruela, Beardo-Villar, Fidalgo, Ozturk, Gonzalez-Enguita, Monzo, Lopes, Alvarez-Maestro, Servan, De La Cruz, Perez, Maximo and Soares. FAU - Batista, Rui AU - Batista R AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. AD - U-Monitor Lda, Porto, Portugal. AD - Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Vinagre, Joao AU - Vinagre J AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. AD - U-Monitor Lda, Porto, Portugal. AD - Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Prazeres, Hugo AU - Prazeres H AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. AD - U-Monitor Lda, Porto, Portugal. AD - Department of Molecular Pathology, Portuguese Institute of Oncology, Coimbra, Portugal. FAU - Sampaio, Cristina AU - Sampaio C AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. FAU - Peralta, Pedro AU - Peralta P AD - Department of Urology Service, Portuguese Institute of Oncology, Coimbra, Portugal. FAU - Conceicao, Paulo AU - Conceicao P AD - Department of Urology Service, Portuguese Institute of Oncology, Coimbra, Portugal. FAU - Sismeiro, Amilcar AU - Sismeiro A AD - Department of Urology Service, Portuguese Institute of Oncology, Coimbra, Portugal. FAU - Leao, Ricardo AU - Leao R AD - Department of Urology, Hospital de Braga, Braga, Portugal. AD - Department of Urology, Hospital CUF Coimbra, Coimbra, Portugal. FAU - Gomes, Andreia AU - Gomes A AD - Department of Urology, Hospital de Braga, Braga, Portugal. FAU - Furriel, Frederico AU - Furriel F AD - Department of Urology, Hospital CUF Coimbra, Coimbra, Portugal. FAU - Oliveira, Carlos AU - Oliveira C AD - Department of Urology, Hospital de Braga, Braga, Portugal. FAU - Torres, Joao Nuno AU - Torres JN AD - Department of Urology, Hospital de Braga, Braga, Portugal. FAU - Eufrasio, Pedro AU - Eufrasio P AD - Department of Urology, Hospital CUF Coimbra, Coimbra, Portugal. FAU - Azinhais, Paulo AU - Azinhais P AD - Department of Urology, Hospital CUF Coimbra, Coimbra, Portugal. FAU - Almeida, Fabio AU - Almeida F AD - Department of Urology, Hospital Universitario Fernando Pessoa, Porto, Portugal. FAU - Gonzalez, Edwin Romero AU - Gonzalez ER AD - Department of Urology, Hospital Zafra-Llerena, Badajoz, Spain. FAU - Bidovanets, Bohdan AU - Bidovanets B AD - Department of Surgery, Ternopil Regional Oncology Center, Ternopil, Ukraine. FAU - Ecke, Thorsten AU - Ecke T AD - Department of Urology, Helios Hospital, Bad Saarow, Germany. FAU - Stinjs, Pascal AU - Stinjs P AD - Department of Urology, St. Antonius Hospital, Nieuwegein, Netherlands. FAU - Pascual, Alvaro Serrano AU - Pascual AS AD - Servicio de Urologia, Hospital Clinico San Carlos, Madrid, Spain. FAU - Abdelmalek, Rabehi AU - Abdelmalek R AD - Independent Researcher, El-Eulma, Algeria. FAU - Villafruela, Ainara AU - Villafruela A AD - Department of Urology, Hospital Universitario Donostia, San Sebastian, Spain. FAU - Beardo-Villar, Pastora AU - Beardo-Villar P AD - Department of Urology, Hospital Universitario de Araba, Vitoria, Spain. FAU - Fidalgo, Nuno AU - Fidalgo N AD - Department of Urology, Hospital Garcia de Horta, Lisbon, Portugal. FAU - Ozturk, Hakan AU - Ozturk H AD - Department of Urology, Medicalpark Izmir Hospital, Izmir, Turkey. FAU - Gonzalez-Enguita, Carmen AU - Gonzalez-Enguita C AD - Department of Urology, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. FAU - Monzo, Juan AU - Monzo J AD - Department of Urology, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. FAU - Lopes, Tome AU - Lopes T AD - Department of Urology, Hospital de Santa Maria, Lisbon, Portugal. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AD - Department of Urology, Hospital Universitario La Paz, Madrid, Spain. FAU - Servan, Patricia Parra AU - Servan PP AD - Department of Urology, Hospital de Merida, Badajoz, Spain. FAU - De La Cruz, Santiago Moreno Perez AU - De La Cruz SMP AD - Department of Urology, Hospital Don Benito-Villanueva, Badajoz, Spain. FAU - Perez, Mario Pual Sanchez AU - Perez MPS AD - Department of Urology, Hospital Universitario de Badajoz, Badajoz, Spain. FAU - Maximo, Valdemar AU - Maximo V AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. AD - Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Soares, Paula AU - Soares P AD - i3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal. AD - Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. AD - U-Monitor Lda, Porto, Portugal. AD - Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal. LA - eng PT - Journal Article DEP - 20191218 PL - Switzerland TA - Front Genet JT - Frontiers in genetics JID - 101560621 PMC - PMC6930177 OTO - NOTNLM OT - FGFR3 mutation OT - TERT promoter mutation OT - Uromonitor(R) OT - non-muscle invasive bladder cancer OT - urinary test EDAT- 2020/01/11 06:00 MHDA- 2020/01/11 06:01 PMCR- 2019/12/18 CRDT- 2020/01/11 06:00 PHST- 2019/06/03 00:00 [received] PHST- 2019/11/08 00:00 [accepted] PHST- 2020/01/11 06:00 [entrez] PHST- 2020/01/11 06:00 [pubmed] PHST- 2020/01/11 06:01 [medline] PHST- 2019/12/18 00:00 [pmc-release] AID - 10.3389/fgene.2019.01237 [doi] PST - epublish SO - Front Genet. 2019 Dec 18;10:1237. doi: 10.3389/fgene.2019.01237. eCollection 2019. PMID- 31917174 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20260307 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 2 DP - 2020 Apr TI - Disparities in Stage at Diagnosis in an Equal-access Integrated Delivery System: A Retrospective Cohort Study of 7244 Patients With Bladder Cancer. PG - e91-e102 LID - S1558-7673(19)30271-X [pii] LID - 10.1016/j.clgc.2019.09.002 [doi] AB - BACKGROUND: Disparities in bladder cancer survival by race/ethnicity and gender are likely related to differences in diagnosis. We assessed disparities in stage at diagnosis and potential contributing factors within a large, integrated delivery system. PATIENTS AND METHODS: We conducted a retrospective cohort study of 7244 patients with bladder cancer age >/= 21 years diagnosed from January 2001 to June 2015 within Kaiser Permanente Southern California. Bivariate analyses compared stage at diagnosis - as well as comorbidities, health plan membership length, and health care utilization prior to diagnosis - by race/ethnicity, gender, and age. Multivariable generalized linear mixed models with urologist as a random effect were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for diagnosis of muscle-invasive bladder cancer (MIBC) versus non-muscle-invasive bladder cancer. RESULTS: In multivariable analyses, stage at diagnosis varied significantly by race/ethnicity (P < .001). Non-Hispanic black patients had significantly higher odds of being diagnosed with MIBC than non-Hispanic white patients (OR, 1.33; 95% CI, 1.05-1.67), whereas Asian patients had significantly lower odds (OR, 0.67; 95% CI, 0.49-0.91). Women were significantly more likely to be diagnosed with MIBC than men (OR, 1.40; 95% CI, 1.22-1.61). Non-Hispanic black women had the highest proportion (39%) of MIBC diagnoses. Among Hispanic and Asian patients, a greater proportion of diagnoses occurred at younger ages. CONCLUSIONS: Health care coverage within an equal-access system did not eliminate disparities in stage at diagnosis by race/ethnicity or gender. Studies are needed to identify etiologic factors and aspects of care delivery (eg, patient-physician interactions) that may affect the diagnostic process to inform efforts to improve health equity. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Danforth, Kim N AU - Danforth KN AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. Electronic address: danfortk@gmail.com. FAU - Luong, Tiffany Q AU - Luong TQ AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. FAU - Yi, David K AU - Yi DK AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. FAU - Yamamoto, Ayae AU - Yamamoto A AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA; Department of Quality and Risk Management, Kaiser Foundation Hospital and Health Plan, Pasadena, CA. FAU - Kawatkar, Aniket A AU - Kawatkar AA AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. FAU - Kim, Philip H AU - Kim PH AD - Department of Urology, Southern California Permanente Medical Group, San Diego, CA. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Southern California Permanente Medical Group, Downey, CA. FAU - Sidell, Margo A AU - Sidell MA AD - Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. FAU - Williams, Stephen G AU - Williams SG AD - Department of Urology, Southern California Permanente Medical Group, Riverside, CA. LA - eng GR - R21 CA185931/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20190912 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM CIN - J Urol. 2021 Nov;206(5):1326-1328. doi: 10.1097/JU.0000000000002156. PMID: 34392695 MH - Black or African American/statistics & numerical data MH - Age Factors MH - Aged MH - Aged, 80 and over MH - California/epidemiology MH - Delivery of Health Care, Integrated/statistics & numerical data MH - Female MH - *Health Status Disparities MH - Hispanic or Latino/statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Retrospective Studies MH - Sex Factors MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/pathology MH - White People/statistics & numerical data OTO - NOTNLM OT - Age OT - Gender OT - Health status disparities OT - Race/ethnicity OT - Urinary bladder neoplasms EDAT- 2020/01/10 06:00 MHDA- 2021/01/30 06:00 CRDT- 2020/01/10 06:00 PHST- 2019/04/27 00:00 [received] PHST- 2019/09/01 00:00 [revised] PHST- 2019/09/05 00:00 [accepted] PHST- 2020/01/10 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2020/01/10 06:00 [entrez] AID - S1558-7673(19)30271-X [pii] AID - 10.1016/j.clgc.2019.09.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Apr;18(2):e91-e102. doi: 10.1016/j.clgc.2019.09.002. Epub 2019 Sep 12. PMID- 31912907 OWN - NLM STAT- MEDLINE DCOM- 20200612 LR - 20240903 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 1 IP - 1 DP - 2020 Jan 8 TI - Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. PG - CD011935 LID - 10.1002/14651858.CD011935.pub2 [doi] LID - CD011935 AB - BACKGROUND: People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain. OBJECTIVES: To assess the effects of BCG intravesical therapy compared to MMC intravesical therapy for treating intermediate- and high-risk Ta and T1 bladder cancer in adults. SEARCH METHODS: We performed a systematic literature search in multiple databases (CENTRAL, MEDLINE, Embase, Web of Science, Scopus, LILACS), as well as in two clinical trial registries. We searched reference lists of relevant publications and abstract proceedings. We applied no language restrictions. The latest search was conducted in September 2019. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared intravesical BCG with intravesical MMC therapy for non-muscle invasive urothelial bladder cancer. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the literature, extracted data, assessed risk of bias and rated the quality of evidence according to GRADE per outcome. In the meta-analyses, we used the random-effects model. MAIN RESULTS: We identified 12 RCTs comparing BCG versus MMC in participants with intermediate- and high-risk non-muscle invasive bladder tumours (published from 1995 to 2013). In total, 2932 participants were randomised. Time to death from any cause: BCG may make little or no difference on time to death from any cause compared to MMC (hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.79 to 1.20; participants = 1132, studies = 5; 567 participants in the BCG arm and 565 in the MMC arm; low-certainty evidence). This corresponds to 6 fewer deaths (40 fewer to 36 more) per 1000 participants treated with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Serious adverse effects: 12/577 participants treated with BCG experienced serious non-fatal adverse effects compared to 4/447 participants in the MMC group. The pooled risk ratio (RR) is 2.31 (95% CI 0.82 to 6.52; participants = 1024, studies = 5; low-certainty evidence). Therefore, BCG may increase the risk for serious adverse effects compared to MMC. This corresponds to nine more serious adverse effects (one fewer to 37 more) with BCG. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Time to recurrence: BCG may reduce the time to recurrence compared to MMC (HR 0.88, 95% CI 0.71 to 1.09; participants = 2616, studies = 11, 1273 participants in the BCG arm and 1343 in the MMC arm; low-certainty evidence). This corresponds to 41 fewer recurrences (104 fewer to 29 more) with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations, imprecision and inconsistency. Time to progression: BCG may make little or no difference on time to progression compared to MMC (HR 0.96, 95% CI 0.73 to 1.26; participants = 1622, studies = 6; 804 participants in the BCG arm and 818 in the MMC arm; low-certainty evidence). This corresponds to four fewer progressions (29 fewer to 27 more) with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Quality of life: we found very limited data for this outcomes and were unable to estimate an effect size. AUTHORS' CONCLUSIONS: Based on our findings, BCG may reduce the risk of recurrence over time although the Confidence Intervals include the possibility of no difference. It may have no effect on either the risk of progression or risk of death from any cause over time. BCG may cause more serious adverse events although the Confidence Intervals once again include the possibility of no difference. We were unable to determine the impact on quality of life. The certainty of the evidence was consistently low, due to concerns that include possible selection bias, performance bias, given the lack of blinding in these studies, and imprecision. CI - Copyright (c) 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Schmidt, Stefanie AU - Schmidt S AD - UroEvidence@Deutsche Gesellschaft fur Urologie, Martin-Buber-Str. 10, Berlin, Germany, 14163. FAU - Kunath, Frank AU - Kunath F AD - UroEvidence@Deutsche Gesellschaft fur Urologie, Martin-Buber-Str. 10, Berlin, Germany, 14163. AD - University Hospital Erlangen, Department of Urology, Krankenhausstrasse 12, Erlangen, Germany, 91054. FAU - Coles, Bernadette AU - Coles B AD - Cardiff University Library Services, Velindre NHS Trust, Velindre Cancer Centre, Whitchurch, Cardiff, UK, CF14 2TL. FAU - Draeger, Desiree Louise AU - Draeger DL AD - UroEvidence@Deutsche Gesellschaft fur Urologie, Martin-Buber-Str. 10, Berlin, Germany, 14163. AD - University of Rostock, Department of Urology, Ernst-Heydemann-Strasse 7, Rostock, Mecklenburg-Vorpommern, Germany, 18057. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - UroEvidence@Deutsche Gesellschaft fur Urologie, Martin-Buber-Str. 10, Berlin, Germany, 14163. AD - University of Muenster Medical Center, Department of Urology, Albert-Schweitzer Campus 1, GB A1, Muenster, NRW, Germany, 48149. FAU - Dersch, Rick AU - Dersch R AD - Medical Center - University of Freiburg, Department of Neurology and Neurophysiology, Berliner Allee 29, Freiburg, Germany, 79110. FAU - Kilian, Samuel AU - Kilian S AD - University of Heidelberg, Institute of Medical Biometry and Informatics, Heidelberg, Germany. FAU - Jensen, Katrin AU - Jensen K AD - University of Heidelberg, Institute of Medical Biometry and Informatics, Heidelberg, Germany. FAU - Dahm, Philipp AU - Dahm P AD - Minneapolis VA Health Care System, Urology Section, One Veterans Drive, Mail Code 112D, Minneapolis, Minnesota, USA, 55417. AD - University of Minnesota, Department of Urology, 420 Delaware Street SE, MMC 394, Minneapolis, Minnesota, USA, 55455. FAU - Meerpohl, Joerg J AU - Meerpohl JJ AD - Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Institute for Evidence in Medicine, Breisacher Str. 153, Freiburg, Germany, D-79110. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20200108 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM UOF - doi: 10.1002/14651858.CD011935 MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/administration & dosage/*therapeutic use MH - BCG Vaccine MH - Carcinoma, Transitional Cell/*drug therapy MH - Humans MH - Mitomycin/administration & dosage/*therapeutic use MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy PMC - PMC6956215 COIS- SS: none. FK: none. BC: none. DD: none. LMK: none. RD: received lecture fees by Roche and travel grants by Biogen. SK: employed by the Institute of Medical Biometry and Informatics, University Heidelberg, which receives support by the German Society for Urology (Deutsche Gesellschaft fur Urologie, DGU) for conducting urology-related systematic reviews. KJ: employed by the Institute of Medical Biometry and Informatics, University Heidelberg, which receives support by the German Society for Urology (Deutsche Gesellschaft fur Urologie, DGU) for conducting urology-related systematic reviews. PD: none. JJM: none. EDAT- 2020/01/09 06:00 MHDA- 2020/06/13 06:00 PMCR- 2021/01/08 CRDT- 2020/01/09 06:00 PHST- 2020/01/09 06:00 [entrez] PHST- 2020/01/09 06:00 [pubmed] PHST- 2020/06/13 06:00 [medline] PHST- 2021/01/08 00:00 [pmc-release] AID - CD011935.pub2 [pii] AID - 10.1002/14651858.CD011935.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2020 Jan 8;1(1):CD011935. doi: 10.1002/14651858.CD011935.pub2. PMID- 31911121 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 3 DP - 2020 Jun TI - Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. PG - 230-235 LID - S1558-7673(19)30352-0 [pii] LID - 10.1016/j.clgc.2019.11.001 [doi] AB - INTRODUCTION: Several studies have shown that abnormal urine levels of cytokeratins 8 and 18 are associated with bladder cancer. However, the clinical benefit of the UBC (urinary bladder cancer) Rapid assay has remained unclear. PATIENTS AND METHODS: We performed the UBC Rapid assay and voided cytology in 336 patients-297 in surveillance for non-muscle-invasive bladder cancer and 39 with newly diagnosed bladder cancer. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated by contingency. We also controlled for the patients with positive UBC Rapid findings but negative cystoscopy findings to prove the former's ability to provide an anticipatory diagnosis. RESULTS: We diagnosed 27 recurrences (9.8%). Overall, the sensitivity of the UBC Rapid assay was better for the higher risk groups and after adding the cytology findings. The only independent predictor of a positive UBC Rapid assay was the tumor size. Of the 81 patients with positive UBC Rapid findings without positive cystoscopy findings, 8 (10%) had developed a recurrence within the first year. Avoiding cystoscopy for the patients with UBC Rapid negative results could avoid 184 cystoscopies (66%) but would result in missing 7 of 13 high-risk recurrences. CONCLUSIONS: The performance of the UBC Rapid assay improved with increasing tumor size. Limiting cystoscopies to patients with UBC Rapid positive results could result in a reduction in surveillance cystoscopies but could result in missing high-risk recurrences. Finally, the UBC Rapid assay was not useful for anticipatory diagnoses. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Agreda Castaneda, Fernando AU - Agreda Castaneda F AD - Department of Urology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: fagreda.germanstrias@gencat.cat. FAU - Raventos Busquets, Carles Xavier AU - Raventos Busquets CX AD - Department of Urology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Morote Robles, Juan AU - Morote Robles J AD - Department of Urology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20191204 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Cystoscopy/*methods MH - Cytodiagnosis/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Prospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/surgery MH - Urologic Surgical Procedures, Male/*methods MH - Watchful Waiting/*methods OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Proteomics OT - Surveillance OT - Urinary marker EDAT- 2020/01/09 06:00 MHDA- 2021/06/16 06:00 CRDT- 2020/01/09 06:00 PHST- 2019/06/21 00:00 [received] PHST- 2019/11/01 00:00 [revised] PHST- 2019/11/27 00:00 [accepted] PHST- 2020/01/09 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2020/01/09 06:00 [entrez] AID - S1558-7673(19)30352-0 [pii] AID - 10.1016/j.clgc.2019.11.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Jun;18(3):230-235. doi: 10.1016/j.clgc.2019.11.001. Epub 2019 Dec 4. PMID- 31911120 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 3 DP - 2020 Jun TI - Perioperative Outcomes of Open Retrograde Extraperitoneal Versus Intracorporeal Robot-assisted Radical Cystoprostatectomy in Men: A Dual-center Comparative Study. PG - e315-e323 LID - S1558-7673(19)30379-9 [pii] LID - 10.1016/j.clgc.2019.12.006 [doi] AB - INTRODUCTION: We compared retrograde extraperitoneal open radical cystoprostatectomy (REORC) and robot-assisted radical cystoprostatectomy with intracorporeal diversion (iRARC) and have reported the early perioperative outcomes. PATIENTS AND METHODS: REORC and iRARC were each performed at a different tertiary high-volume center in 2 countries. Men aged >/= 18 years with precystectomy clinical stage T1-T3 disease were included. Patients with previous major pelvic and/or intra-abdominal surgery, those who had undergone previous pelvic and/or abdominal irradiation, women, and patients with clinical stage T4 disease were excluded. All cases were managed according to a standardized enhanced recovery after surgery protocol, and all the patients had undergone ileal conduit urinary diversion. Bowel recovery was one of the main endpoints; thus, the intervals to passing flatus, tolerating oral feeding, and bowel opening were determined. The operative time, estimated blood loss, intraoperative complications, length of hospital stay, postcystectomy tumor type, stage, margin status, lymph node yield, and 30- and 90-day complications were analyzed. RESULTS: We performed a retrospective analysis of prospectively collected data from October 2016 to December 2018 of 99 patients, 50 of whom had undergone REORC and 49 iRARC. The demographic data and preoperative parameters were comparable between the 2 groups. REORC resulted in a significantly shorter mean operative time (P < .001), significantly greater mean estimated blood loss (P < .001), and greater percentage of patients requiring blood transfusion (98% vs. 12.24%). No significant differences in the length of stay were observed (P = .412). The rate of prolonged postoperative ileus was 16% and 18.4% in the REORC and iRARC groups, respectively (P = .3). Differences in the interval to passing flatus, tolerating solid oral intake, and bowel opening were not statistically significant between the 2 groups (P = .423, P = .770, and P = .700, respectively). No statistically significant difference was observed in the postcystectomy pathologic outcomes and overall and major complications rates at 30 and 90 days. CONCLUSION: REORC resulted in quicker bowel recovery and a shorter length of stay compared with conventional open procedures, with advantages comparable to those realized with iRARC. Thus, REORC can be adopted as the preferred open approach at institutions without surgical robots available. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Refaai, Khaled AU - Refaai K AD - Department of Urology, Alexandria University, Alexandria, Egypt. Electronic address: Javacup16@gmail.com. FAU - Sharafeldin, Mohamed A AU - Sharafeldin MA AD - Department of Urology, Alexandria University, Alexandria, Egypt. FAU - Elabbady, Ahmed AU - Elabbady A AD - Department of Urology, Alexandria University, Alexandria, Egypt. FAU - Sameh, Wael AU - Sameh W AD - Department of Urology, Alexandria University, Alexandria, Egypt. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Department of Urology, Guy's Hospital, London, United Kingdom. FAU - Nair, Rajesh AU - Nair R AD - Department of Urology, Guy's Hospital, London, United Kingdom. FAU - Dasgupta, Prokar AU - Dasgupta P AD - Department of Urology, Guy's Hospital, London, United Kingdom. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Department of Urology, Guy's Hospital, London, United Kingdom. FAU - Mohamed, Elsayedamr AU - Mohamed E AD - Department of Bioinformatics and Medical Statistics, Medical Research Institute, Alexandria University, Alexandria, Egypt. LA - eng PT - Comparative Study PT - Journal Article DEP - 20191214 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy/*mortality MH - Follow-Up Studies MH - Humans MH - Laparoscopy/*mortality MH - Lymph Node Excision/*mortality MH - Male MH - Middle Aged MH - *Perioperative Care MH - Prognosis MH - Prospective Studies MH - Prostatectomy/*mortality MH - Retrospective Studies MH - Robotic Surgical Procedures/*mortality MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Extraperitoneal cystectomy OT - Intracorporeal diversion OT - Retrograde cystoprostatectomy OT - Robot-assisted cystectomy EDAT- 2020/01/09 06:00 MHDA- 2021/06/16 06:00 CRDT- 2020/01/09 06:00 PHST- 2019/09/24 00:00 [received] PHST- 2019/12/08 00:00 [revised] PHST- 2019/12/09 00:00 [accepted] PHST- 2020/01/09 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2020/01/09 06:00 [entrez] AID - S1558-7673(19)30379-9 [pii] AID - 10.1016/j.clgc.2019.12.006 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Jun;18(3):e315-e323. doi: 10.1016/j.clgc.2019.12.006. Epub 2019 Dec 14. PMID- 31905033 OWN - NLM STAT- MEDLINE DCOM- 20210126 LR - 20210126 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 54 IP - 1 DP - 2020 Feb TI - The value of tumour weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer. PG - 40-45 LID - 10.1080/21681805.2019.1708968 [doi] AB - Objective: To further assess the influence of the weight after TURBT as a predictive factor for recurrence and progression in NMIBC.Materials and methods: A cohort of patients with a first episode of NMIBC between 1999 and 2016 was analysed retrospectively. We studied the correlation between the tumour's size and weight, the time-dependent ROC curves for the optimal weight value for the prediction of recurrence and progression and their association with the risk of recurrence and progression at one and five years.Results: We analysed 470 patients who met inclusion criteria. Median (IQR) follow-up time was four years (2.2-6.7), 227 (48.3%) patients had a recurrence and 46 (9.8%) progressed. Median (IQR) weight after resection was 2 g (0.8-6) and its correlation with size was 0.56. The optimal value for the prediction of recurrence was 4 g. The RFS at one and five years with a weight <4 g was 77.7% and 53.5%, respectively, compared to 57.8% and 34.7% with higher weight (p < .001). PFS at one and five years was 98% and 92.7% for a weight <4 g compared to 91.4% and 83.1% for tumours >4 g, respectively (p = .02). On multivariate analysis, a higher weight was associated with an increased risk of recurrence: HR [95%:CI] = 1.52[1.05-1.86], and progression: HR[95%:CI] = 1.87[1.01-3.47] (p < .05).Conclusion: The weight of the specimen obtained after TURBT is a predictive factor of both recurrence and progression in NMIBC that may be more accurate than tumour size and easily and objectively measured. An increase of 52% and 87% in the risk of recurrence and progression, respectively, was found in tumours weighing more than 4 g. FAU - Fernandez-Conejo, Guillermo AU - Fernandez-Conejo G AUID- ORCID: 0000-0002-7317-9107 AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Guijarro, Ana AU - Guijarro A AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Castro, Alejandro AU - Castro A AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Perez-Fernandez, Elia AU - Perez-Fernandez E AD - Unit of Research, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Llorente, Carlos AU - Llorente C AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. LA - eng PT - Journal Article DEP - 20200106 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Cystoscopy MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Prognosis MH - Proportional Hazards Models MH - *Tumor Burden MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Weights and measures OT - disease progression OT - recurrence OT - urinary bladder neoplasms EDAT- 2020/01/07 06:00 MHDA- 2021/01/27 06:00 CRDT- 2020/01/07 06:00 PHST- 2020/01/07 06:00 [pubmed] PHST- 2021/01/27 06:00 [medline] PHST- 2020/01/07 06:00 [entrez] AID - 10.1080/21681805.2019.1708968 [doi] PST - ppublish SO - Scand J Urol. 2020 Feb;54(1):40-45. doi: 10.1080/21681805.2019.1708968. Epub 2020 Jan 6. PMID- 31901243 OWN - NLM STAT- MEDLINE DCOM- 20200722 LR - 20200722 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 18 IP - 1 DP - 2020 Jan 4 TI - Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. PG - 4 LID - 10.1186/s12957-019-1776-4 [doi] LID - 4 AB - BACKGROUND: The purpose of this meta-analysis is to compare the safety and efficacy of en bloc transurethral resection of bladder tumor (EBRT) versus conventional transurethral resection of bladder tumor (CTURBT). METHODS: We performed a meta-analysis of relevant articles through November 2019 using PubMed, Embase, and Cochrane Central Register to compare the safety and efficacy of EBRT versus CTURBT. The main endpoint included the operation time (OT), hospitalization time (HT), catheterization time (AT), perioperative period complications, bladder detrusor muscle found in the specimen, the residual tumor on the base, the ratio of the same site recurrence, and 12/24/36-month recurrence rate. Cochrane Collaboration's Revman software, version 5.3, was used for statistical analysis. RESULTS: A total of 19 studies with 2651 patients were included, 1369 underwent EBRT and 1282 underwent CTURBT. Patients treated with EBRT had a significantly lower AT, HT, obturator nerve reflex, bladder perforation, bladder irritation, postoperative complications, and 24-month recurrence rate than those who underwent CTURBT. While no significant difference was found in terms of OT, the ratio of bladder detrusor muscle found in the specimen, the residual tumor on the base, 12-month recurrence rate, 36-month recurrence rate, and the ratio of the same site recurrence. In mitomycin subgroup, EBRT was superior to CTURBT in terms of 12/24-month recurrence rate. Similarly, in the prospective subgroup and retrospective subgroup, EBRT had a lower 24-month recurrence rate than CTURBT. However, no significant difference was found in the low, intermediate, and high-risk group in the light of 12-36-month recurrence rate. CONCLUSIONS: Based on the included 19 articles, EBRT had a significantly lower AT, HT, intraoperative and postoperative complications, and 24-month recurrence rate than those treated with CTURBT. Well-designed randomized controlled trials were needed to reevaluate these outcomes. TRIAL REGISTRATION: This meta-analysis was reported in agreement with the PRISMA statement and was registered on PROSPERO 2019 CRD42019121673. FAU - Zhang, Dong AU - Zhang D AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. FAU - Yao, Lifeng AU - Yao L AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. FAU - Yu, Sui AU - Yu S AD - Department of Urology, Medical School of Ningbo University, Zhejiang, China. FAU - Cheng, Yue AU - Cheng Y AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. FAU - Jiang, Junhui AU - Jiang J AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. FAU - Ma, Qi AU - Ma Q AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. FAU - Yan, Zejun AU - Yan Z AD - Department of Urology & Nephrology, Ningbo First Hospital, The affiliated Hospital of Zhejiang University, 59, Liuting Street, Ningbo, Zhejiang, China. 380291047@qq.com. LA - eng GR - 2019334160/Medical and Health Science and Technology Project of Zhejiang Province/ PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20200104 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Humans MH - Neoplasm Recurrence, Local/pathology/prevention & control MH - Postoperative Complications/etiology MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Surgical Procedures/adverse effects/methods PMC - PMC6942380 OTO - NOTNLM OT - Bladder tumor OT - Complication OT - Conventional transurethral resection of bladder tumor OT - En bloc transurethral resection OT - Meta-analysis COIS- The authors declare that they have no competing interests. EDAT- 2020/01/07 06:00 MHDA- 2020/07/23 06:00 PMCR- 2020/01/04 CRDT- 2020/01/06 06:00 PHST- 2019/10/08 00:00 [received] PHST- 2019/12/23 00:00 [accepted] PHST- 2020/01/06 06:00 [entrez] PHST- 2020/01/07 06:00 [pubmed] PHST- 2020/07/23 06:00 [medline] PHST- 2020/01/04 00:00 [pmc-release] AID - 10.1186/s12957-019-1776-4 [pii] AID - 1776 [pii] AID - 10.1186/s12957-019-1776-4 [doi] PST - epublish SO - World J Surg Oncol. 2020 Jan 4;18(1):4. doi: 10.1186/s12957-019-1776-4. PMID- 31900581 OWN - NLM STAT- MEDLINE DCOM- 20210526 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 10 DP - 2020 Oct TI - Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. PG - 2537-2545 LID - 10.1007/s00345-019-03065-2 [doi] AB - PURPOSE: Programmed cell death-1 ligand-1 (PD-L1) expression has been associated with prognostic implications in urologic malignancies. We aimed to investigate prognostic significance of pre- and post-treatment PD-L1 expression in patients treated with BCG for high-grade non-muscle-invasive bladder cancer (NMIBC). METHODS: We reviewed a total of 141 high-grade NMIBC cases treated with transurethral resection + >/= 6 BCG instillations between 2004 and 2017. PD-L1 immunohistochemistry (IHC) scoring was done on 0-3 scale, and cut-off for positive and high-level PD-L1 expression was set to >/= 1% and >/= 5% staining of tumor-infiltrating immune cells (IC), respectively. Clinicopathologic characteristics and oncologic outcomes [recurrence-free (RFS) and progression-free survival (PFS)] were compared, stratified by PD-L1 positivity. The prognostic role of PD-L1 was assessed using Kaplan-Meier, and univariate and multivariate Cox regression analyses. RESULTS: Pre-treatment, 46.2% and 6.8% of high-grade NMIBC demonstrated positive and high-level PD-L1 expression, respectively. Positive PD-L1 expression was associated with submucosal invasion and refractory-tumor recurrence. PD-L1 expression was not associated with RFS or PFS in regression analysis. Post-treatment, 55.1% and 11.6% of recurrent tumors demonstrated positive and high-level PD-L1 expression, respectively. Down-regulation of PD-L1 expression was noted in patients with refractory recurrence (p = 0.012). CONCLUSION: Pre-treatment PD-L1 expression was associated with unfavorable pathological features in primary high-grade NMIBC and its expression level after BCG immunotherapy was significantly decreased in patients with refractory recurrence. PD-L1 expression did not have prognostic value for PFS or RFS; therefore, further research is necessary to identify novel biomarkers for prediction of disease outcomes in high-grade NMIBC. FAU - Aydin, Ahmet Murat AU - Aydin AM AUID- ORCID: 0000-0002-6047-8431 AD - Department of Urology, Hacettepe University, Ankara, Turkey. ahmetmurataydin@gmail.com. AD - Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA. ahmetmurataydin@gmail.com. FAU - Baydar, Dilek E AU - Baydar DE AD - Department of Pathology, Koc University, Istanbul, Turkey. FAU - Hazir, Berk AU - Hazir B AD - Department of Urology, Hacettepe University, Ankara, Turkey. FAU - Babaoglu, Berrin AU - Babaoglu B AD - Department of Pathology, Hacettepe University, Ankara, Turkey. FAU - Bilen, Cenk Y AU - Bilen CY AD - Department of Urology, Hacettepe University, Ankara, Turkey. LA - eng GR - H.U. Scientific Research Projects Coordination Unit, TTU-2017- 15644/Hacettepe Universitesi (TR)/ PT - Journal Article DEP - 20200103 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (CD274 protein, human) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - B7-H1 Antigen/*biosynthesis MH - BCG Vaccine/*therapeutic use MH - Disease-Free Survival MH - Female MH - Humans MH - Immunotherapy/methods MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/*metabolism/pathology/surgery OTO - NOTNLM OT - Biomarkers OT - Calmette-Guerin bacillus OT - Disease progression OT - Prognosis OT - Programmed cell death-1 ligand-1 OT - Urinary bladder cancer EDAT- 2020/01/05 06:00 MHDA- 2021/05/27 06:00 CRDT- 2020/01/05 06:00 PHST- 2019/09/05 00:00 [received] PHST- 2019/12/21 00:00 [accepted] PHST- 2020/01/05 06:00 [pubmed] PHST- 2021/05/27 06:00 [medline] PHST- 2020/01/05 06:00 [entrez] AID - 10.1007/s00345-019-03065-2 [pii] AID - 10.1007/s00345-019-03065-2 [doi] PST - ppublish SO - World J Urol. 2020 Oct;38(10):2537-2545. doi: 10.1007/s00345-019-03065-2. Epub 2020 Jan 3. PMID- 31897687 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 146 IP - 2 DP - 2020 Feb TI - Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging. PG - 305-313 LID - 10.1007/s00432-019-03113-9 [doi] AB - INTRODUCTION: Prostate specific membrane antigen (PSMA) has become a target for radionuclide imaging and therapy. Previous studies have shown that the expression of PSMA is not specific to prostate tissue. In this study we examine the expression of PSMA in urothelial cell carcinoma (UCC). METHODS: Immunhistochemical PSMA-staining was performed in 89 UCC samples. PSMA expression in tumor tissue, adjacent healthy tissue and blood vessels was examined. We furthermore analyzed PSMA-mRNA expression in nine human UCC cell lines. We correlated our findings with clinical data regarding recurrence and progression of UCC. RESULTS: UCC tissue showed a significantly higher PSMA expression compared to healthy urothelial tissue (p < 0.001). Non muscle invasive bladder cancer revealed significantly higher PSMA expression compared to muscle invasive bladder cancer (p < 0.05). PSMA expression significantly differed between various T-stages (p < 0.05) and tumor differentiation (p < 0.001). In four human UCC cell lines PSMA-mRNA was detectable. Those patients who suffered recurrence showed a higher rate of PSMA expression but no correlation to recurrence-free survival was evident. Progression of disease correlated significantly with a higher PSMA expression (p = 0.036). CONCLUSIONS: Both UCC tissue and healthy urothelial tissue express PSMA, with significantly higher levels in UCC. We confirmed these findings in human UCC cell lines. In this small first cohort expression of PSMA correlates significant with progression of disease but not with recurrence and recurrence-free survival. These first results make PSMA a promising target for future diagnosis and therapy of UCC. FAU - Schreiber, Henner AU - Schreiber H AUID- ORCID: 0000-0002-3006-8087 AD - Department of Urology and Pediatric Urology, University Hospital Marburg, Marburg, Germany. Henner.Schreiber@med.uni-marburg.de. FAU - Hanze, Jorg AU - Hanze J AD - Department of Urology and Pediatric Urology, University Hospital Marburg, Marburg, Germany. FAU - Nimphius, Wilhelm AU - Nimphius W AD - Department of Pathology, University Hospital Marburg, Marburg, Germany. FAU - Verburg, Frederik Anton AU - Verburg FA AD - Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany. FAU - Luster, Markus AU - Luster M AD - Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany. FAU - Hofmann, Rainer AU - Hofmann R AD - Department of Urology and Pediatric Urology, University Hospital Marburg, Marburg, Germany. FAU - Hegele, Axel AU - Hegele A AD - Department of Urology and Pediatric Urology, University Hospital Marburg, Marburg, Germany. LA - eng PT - Journal Article DEP - 20200102 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - EC 3.4.21.- (KLK3 protein, human) RN - EC 3.4.21.- (Kallikreins) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Aged MH - Female MH - Humans MH - Immunohistochemistry MH - Kallikreins/*biosynthesis MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prostate-Specific Antigen/*biosynthesis MH - Prostatic Neoplasms/metabolism/pathology MH - Survival Analysis MH - Urinary Bladder Neoplasms/*metabolism/*pathology PMC - PMC11804395 OTO - NOTNLM OT - Prostate specific membrane antigen OT - Tumor marker OT - Urothelial cell carcinoma COIS- The authors declare no potential conflicts of interest. EDAT- 2020/01/04 06:00 MHDA- 2020/02/19 06:00 PMCR- 2020/01/02 CRDT- 2020/01/04 06:00 PHST- 2019/10/21 00:00 [received] PHST- 2019/12/13 00:00 [accepted] PHST- 2020/01/04 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2020/01/04 06:00 [entrez] PHST- 2020/01/02 00:00 [pmc-release] AID - 10.1007/s00432-019-03113-9 [pii] AID - 3113 [pii] AID - 10.1007/s00432-019-03113-9 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2020 Feb;146(2):305-313. doi: 10.1007/s00432-019-03113-9. Epub 2020 Jan 2. PMID- 31897161 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 19 IP - 1 DP - 2020 Jan TI - A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. PG - 476-486 LID - 10.3892/ol.2019.11123 [doi] AB - Screening for genes or markers relevant to bladder cancer (BC) tumorigenesis and progression is of vital clinical significance. The present study used reverse-transcription quantitative PCR reaction assays to examine the expression of mRNA encoding Rho GTPase-activating protein 9 (ARHGAP9) in BC tissue samples and to determine whether ARHGAP9 is an independent prognostic biomarker for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). The results revealed that the downregulation of ARHGAP9 expression in the tissue of patients with NMIBC or MIBC was significantly associated with a poor prognosis. In patients with NMIBC, a high expression of ARHGAP9 was significantly associated with prolonged recurrence-free survival, whereas in MIBC patients, it was significantly associated with an increased progression-free and cancer-specific survival. The risk of cancer-specific death was 2.923 times higher (95% confidence interval, 1.192-7.163) when ARHGAP9 levels were decreased. In conclusion, lower expressions of ARHGAP9 correlated with BC prognosis, indicating that it may be a useful marker for guiding treatment application. CI - Copyright: (c) Piao et al. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Yan, Chunri AU - Yan C AD - Department of Preventative Medicine, School of Medicine, Yanbian University, Yanji, Jilin 133000, P.R. China. FAU - Kim, Ye-Hwan AU - Kim YH AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Xu, Yanjie AU - Xu Y AD - Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Seo, Sung Phil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Lee, Jong-Young AU - Lee JY AD - Department of Business Data Convergence, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. AD - Oneomics Institute, Seoul 04158, Republic of Korea. FAU - Kim, Isaac Y AU - Kim IY AD - Section of Urologic Oncology and Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ 732-235, USA. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food Science and Technology, Chung-Ang University, Ansung, Gyeonggi-do 456-756, Republic of Korea. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan 614-052, Republic of Korea. FAU - Cha, Eun-Jong AU - Cha EJ AD - Department of Biomedical Engineering, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. LA - eng PT - Journal Article DEP - 20191119 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6924059 OTO - NOTNLM OT - Rho GTPase-activating protein 9 OT - muscle invasive bladder cancer OT - non-muscle invasive bladder cancer OT - progression OT - recurrence EDAT- 2020/01/04 06:00 MHDA- 2020/01/04 06:01 PMCR- 2019/11/19 CRDT- 2020/01/04 06:00 PHST- 2019/06/27 00:00 [received] PHST- 2019/10/08 00:00 [accepted] PHST- 2020/01/04 06:00 [entrez] PHST- 2020/01/04 06:00 [pubmed] PHST- 2020/01/04 06:01 [medline] PHST- 2019/11/19 00:00 [pmc-release] AID - OL-0-0-11123 [pii] AID - 10.3892/ol.2019.11123 [doi] PST - ppublish SO - Oncol Lett. 2020 Jan;19(1):476-486. doi: 10.3892/ol.2019.11123. Epub 2019 Nov 19. PMID- 31894276 OWN - NLM STAT- MEDLINE DCOM- 20200821 LR - 20240725 IS - 1791-2431 (Electronic) IS - 1021-335X (Print) IS - 1021-335X (Linking) VI - 43 IP - 2 DP - 2020 Feb TI - Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer. PG - 379-394 LID - 10.3892/or.2019.7429 [doi] AB - There are no reliable criteria to assess risk of progression of non‑muscle invasive bladder cancer to muscle invasive bladder cancer. The aim of the present study was to identify potential markers based on gene expression profiling to improve predictive power of disease progression and prognosis in patients with bladder cancer. In the present study, we screened seventy‑three differentially expressed genes by analyzing bladder cancer samples with or without progression. Forty‑seven prognosis‑related genes were screened, 13 of which were identified to build a progression‑associated gene signature using the LASSO regression method. Based on this 13‑mRNA signature, patients were divided into high‑ and low‑risk groups, with different prognostic outcomes. The gene signature was an independent prognostic factor for overall survival. Receiver operating characteristic analysis suggested that the signature performed well in the validation cohort and its predictive power outperformed other several published signatures. CTHRC1, MMP11, AEBP1, SNCAIP, COL1A1 and S100A8 were identified as hub genes and their expression levels were detected using reverse transcriptase‑quantitative polymerase chain reaction. The expression of CTHRC1 was elevated in aggressive bladder cancer compared with non‑invasive type, which suggests CTHRC1 may be a valuable biomarker for prediction of prognosis and progression of bladder cancer. Collectively, this 13‑mRNA signature may be useful in predicting disease progression and prognosis, thereby contributing to individualized management of patients with bladder cancer. FAU - Yin, Hubin AU - Yin H AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China. FAU - Zhang, Chen AU - Zhang C AD - Department of Obstetrics and 4The Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China. FAU - Gou, Xin AU - Gou X AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China. FAU - He, Weiyang AU - He W AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China. FAU - Gan, Daoju AU - Gan D AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China. LA - eng PT - Journal Article DEP - 20191212 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*genetics MH - Cell Line, Tumor MH - Disease Progression MH - Female MH - Gene Expression Profiling/*methods MH - Gene Expression Regulation, Neoplastic MH - *Gene Regulatory Networks MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Prognosis MH - ROC Curve MH - Survival Analysis MH - Urinary Bladder Neoplasms/genetics/*mortality PMC - PMC6967157 OTO - NOTNLM OT - bladder cancer OT - mRNA signature OT - progression OT - prognosis OT - gene set enrichment analysis OT - nomogram EDAT- 2020/01/03 06:00 MHDA- 2020/08/22 06:00 PMCR- 2019/12/12 CRDT- 2020/01/03 06:00 PHST- 2019/06/05 00:00 [received] PHST- 2019/11/08 00:00 [accepted] PHST- 2020/01/03 06:00 [pubmed] PHST- 2020/08/22 06:00 [medline] PHST- 2020/01/03 06:00 [entrez] PHST- 2019/12/12 00:00 [pmc-release] AID - or-43-02-0379 [pii] AID - 10.3892/or.2019.7429 [doi] PST - ppublish SO - Oncol Rep. 2020 Feb;43(2):379-394. doi: 10.3892/or.2019.7429. Epub 2019 Dec 12. PMID- 31894237 OWN - NLM STAT- MEDLINE DCOM- 20200626 LR - 20200626 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 50 IP - 4 DP - 2020 Apr 7 TI - Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer. PG - 456-464 LID - 10.1093/jjco/hyz186 [doi] AB - BACKGROUND: Cadherin-11 (CDH11) is a type II cadherin and reported to function as an oncogene in various cancers. Our present study aims to investigate the role of CDH11 in bladder cancer (BCA). METHODS: Bioinformatics analysis was performed in four independent microarray data including 56 non-muscle-invasive bladder cancer (NMIBC) and 132 muscle-invasive bladder cancer (MIBC) tissues from Gene Expression Omnibus to screen out differentially expressed genes. Next, we detected CDH11 expression in BCA specimens and cell lines by qPCR and western blotting assays. Immunohistochemical analyses were performed in 209 paraffin-embedded BCA samples and 30 adjacent normal bladder tissues. RESULTS: Bioinformatics analysis revealed that CDH11 had a higher expression level in MIBC tissues than in NMIBC, which was consistent with our clinical BCA specimens and cell lines at both mRNA and protein levels. Immunohistochemical analysis demonstrated that over-expression of CDH11 was closely related to the histological grade, pT status, tumour size and poor outcomes of BCA patients. What's more, CDH11 (area under curve (AUC) = 0.673 and 0.735) had a better predictive value than E-cadherin (AUC = 0.629 and 0.629) and a similar discrimination with the European Organization for Research and Treatment of Cancer (EORTC) score system (AUC = 0.719 and 0.667) in evaluating potential recurrence and progression of NMIBC. Moreover, combination of CDH11 and EORTC score system was the best predictive model in predicting recurrence of NMIBC (AUC = 0.779) among the three models. CONCLUSIONS: CDH11 was a reliable therapeutic target in BCA and a useful index to predict the possibilities of recurrence and progression in NMIBC patients. CI - (c) The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. FAU - Chen, Ming-Kun AU - Chen MK AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Chen, Zi-Jian AU - Chen ZJ AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Xiao, Kang-Hua AU - Xiao KH AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Qin, Zi-Ke AU - Qin ZK AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Ye, Yun-Lin AU - Ye YL AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Wen, Wei-Jie AU - Wen WJ AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Bian, Jun AU - Bian J AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Xue, Kang-Yi AU - Xue KY AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Zhou, Qi-Zhao AU - Zhou QZ AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Guo, Wen-Bing AU - Guo WB AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Zhou, Jun-Hao AU - Zhou JH AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Xia, Ming AU - Xia M AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. FAU - Li, Xin AU - Li X AD - Department of Cancer Research institute, Southern Medical University, Guangzhou, China. FAU - Liu, Cun-Dong AU - Liu CD AD - Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Cadherins) RN - 156621-71-5 (osteoblast cadherin) SB - IM MH - Aged MH - Cadherins/*metabolism MH - Cell Line, Tumor MH - Disease Progression MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/genetics/*metabolism MH - Predictive Value of Tests MH - Prognosis MH - Up-Regulation/genetics MH - Urinary Bladder Neoplasms/genetics/*pathology OTO - NOTNLM OT - CDH11 OT - E-cadherin OT - EORTC score system OT - bladder cancer OT - prognosis EDAT- 2020/01/03 06:00 MHDA- 2020/06/27 06:00 CRDT- 2020/01/03 06:00 PHST- 2019/06/11 00:00 [received] PHST- 2019/11/02 00:00 [revised] PHST- 2019/11/14 00:00 [accepted] PHST- 2020/01/03 06:00 [pubmed] PHST- 2020/06/27 06:00 [medline] PHST- 2020/01/03 06:00 [entrez] AID - 5688862 [pii] AID - 10.1093/jjco/hyz186 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2020 Apr 7;50(4):456-464. doi: 10.1093/jjco/hyz186. PMID- 34095407 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210609 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 6 IP - 1 DP - 2020 TI - Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. PG - 9-23 LID - 10.3233/blc-190249 [doi] AB - BACKGROUND: A broad, comprehensive review of studies exploring associations between lifestyle factors and non-muscle invasive bladder cancer (NMIBC) outcomes is warranted to consolidate recommendations and identify gaps in research. OBJECTIVE: To summarize the literature on associations between lifestyle factors and clinical outcomes among patients with NMIBC. METHODS: PubMed was systematically queried for articles published through March 2019 regarding lifestyle factors and recurrence, progression, cancer-specific mortality, and all-cause mortality among patients with NMIBC. RESULTS: Notwithstanding many ambiguities, there is good-quality evidence suggesting a benefit of smoking avoidance/cessation, healthy body mass index (BMI), and type II diabetes mellitus prevention and treatment. Lactobacillus casei probiotic supplementation may reduce recurrence. There have been individual studies suggesting a benefit for uncooked broccoli and supplemental vitamin E as well as avoidance of supplemental vitamin B9, areca nut chewing, and a "Western diet" pattern high in fried foods and red meat. Additional studies do not suggest associations between NMIBC outcomes and use of fibrin clot inhibitors; insulin and other oral hypoglycemics; statins; supplemental selenium, vitamin A, vitamin C, and vitamin B6; fluid intake and intake of specific beverages (e.g., alcohol, coffee, green tea, cola); various dietary patterns (e.g., Tex-Mex, high fruit and vegetable, low-fat); and occupational and chemical exposures. CONCLUSIONS: Despite a myriad of publications on lifestyle factors and NMIBC, a need remains for research on unexplored associations (e.g., physical activity) and further studies that can elucidate causal effects. This would inform future implementation strategies for healthy lifestyle change in NMIBC patients. FAU - Zuniga, Kyle B AU - Zuniga KB AD - Department of Urology, University of California, San Francisco, CA, USA. AD - Osher Center for Integrative Medicine, University of California, San Francisco, CA, USA. AD - College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA. FAU - Graff, Rebecca E AU - Graff RE AD - Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. FAU - Feiger, David B AU - Feiger DB AD - Department of Urology, University of California, San Francisco, CA, USA. AD - School of Medicine, Duke University Medical Center, Durham, NC, USA. AD - Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Meng, Maxwell V AU - Meng MV AD - Department of Urology, University of California, San Francisco, CA, USA. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California, San Francisco, CA, USA. FAU - Kenfield, Stacey A AU - Kenfield SA AD - Department of Urology, University of California, San Francisco, CA, USA. LA - eng GR - T32 AT003997/AT/NCCIH NIH HHS/United States PT - Journal Article DEP - 20200328 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC8174672 MID - NIHMS1583231 OTO - NOTNLM OT - Urinary bladder neoplasms OT - body mass index OT - diabetes mellitus OT - diet OT - dietary supplements OT - lifestyle OT - non-invasive OT - prognosis OT - recurrence OT - smoking COIS- CONFLICT OF INTEREST SPP is on the advisory board for BMS; consultant for Photocure. SAK is on the advisory board and is a consultant for Mojo Enterprises Inc. The other authors have no conflicts of interest to disclose. EDAT- 2020/01/01 00:00 MHDA- 2020/01/01 00:01 PMCR- 2021/06/03 CRDT- 2021/06/07 06:07 PHST- 2021/06/07 06:07 [entrez] PHST- 2020/01/01 00:00 [pubmed] PHST- 2020/01/01 00:01 [medline] PHST- 2021/06/03 00:00 [pmc-release] AID - 10.3233/blc-190249 [doi] PST - ppublish SO - Bladder Cancer. 2020;6(1):9-23. doi: 10.3233/blc-190249. Epub 2020 Mar 28. PMID- 31883941 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 4 DP - 2020 Aug TI - Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. PG - 268-273.e2 LID - S1558-7673(19)30356-8 [pii] LID - 10.1016/j.clgc.2019.11.005 [doi] AB - BACKGROUND: Tetramodal bladder-preservation therapy includes maximal transurethral resection (TUR), induction chemoradiotherapy (CRT), and consolidative partial cystectomy with pelvic lymph node dissection. Tetramodal bladder-preservation therapy theoretically provides surgical consolidation of chemotherapy- and radioresistant cells. However, its efficacy in providing optimal cancer control for patients with histologic variants of urothelial carcinoma (VUCs) is currently unknown. We compared the oncologic outcomes between patients with muscle-invasive bladder cancer (MIBC) and pure urothelial carcinoma (PUC) and those with MIBC and VUCs after selective tetramodal bladder-preservation therapy. PATIENTS AND METHODS: We prospectively enrolled 154 patients. After maximal TUR and induction CRT, patients with a clinical complete response were offered consolidative partial cystectomy to achieve bladder preservation, with radical cystectomy recommended for the others. The VUCs identified in the maximal TUR samples were categorized according to the 2004 World Health Organization classification. The primary endpoint was cancer-specific survival. The secondary endpoints included the clinical and pathologic response rates to induction CRT and MIBC recurrence-free survival. RESULTS: A VUC was identified in 37 patients (24%). The most frequent variants involved glandular differentiation (n = 13), squamous differentiation (n = 11), and micropapillary (n = 8). No difference was found in the clinical complete response rate to CRT between PUC and VUCs (P = .81). On an intention-to-treat basis, the 5-year cancer-specific survival rates for those with PUC (n = 116) and VUC (n = 37) were 82% and 81% (P = .86), respectively. CONCLUSION: Tetramodal bladder-preservation therapy incorporating partial cystectomy could provide favorable locoregional control and survival for patients with VUC. Thus, patients with MIBC need not be excluded from the bladder-preservation approach because of the presence of a variant histologic type. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Kijima, Toshiki AU - Kijima T AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. Electronic address: toshiki.uro@tmd.ac.jp. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Uehara, Sho AU - Uehara S AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Matsuoka, Yoh AU - Matsuoka Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Kihara, Kazunori AU - Kihara K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20191204 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Node Excision/*mortality MH - Male MH - Middle Aged MH - Organ Sparing Treatments/*methods MH - Prognosis MH - Prospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*classification/*mortality/pathology/surgery OTO - NOTNLM OT - Chemoradiotherapy OT - Histologic variants OT - Partial cystectomy OT - Pure urothelial carcinoma OT - Tetramodal therapy EDAT- 2019/12/31 06:00 MHDA- 2021/06/16 06:00 CRDT- 2019/12/30 06:00 PHST- 2019/09/04 00:00 [received] PHST- 2019/11/21 00:00 [revised] PHST- 2019/11/27 00:00 [accepted] PHST- 2019/12/31 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2019/12/30 06:00 [entrez] AID - S1558-7673(19)30356-8 [pii] AID - 10.1016/j.clgc.2019.11.005 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Aug;18(4):268-273.e2. doi: 10.1016/j.clgc.2019.11.005. Epub 2019 Dec 4. PMID- 31868559 OWN - NLM STAT- MEDLINE DCOM- 20210217 LR - 20210217 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 87 IP - 3 DP - 2020 Aug TI - Spotlight on gender-specific disparities in bladder cancer. PG - 103-114 LID - 10.1177/0391560319887327 [doi] AB - Men are at a higher risk of developing bladder cancer, but women present with more advanced disease and have more unfavourable outcomes. Although epidemiologic and genetical studies have underlined the multifactorial aetiology and gender-related differences of bladder cancer, there is lack of evidence-based recommendation for gender-specific management of bladder cancer. We summarize the evidence and most recent findings on gender-specific differences in bladder cancer incidence, diagnosis, treatment and outcome, spotlighting the gender disparities in genetic and hormonal risk factors, pelvic anatomy, diagnostic setting and surgical choices. We reviewed the literature published on PubMed between 1981 and 2018. Males have a threefold to fourfold higher risk of bladder cancer as compared to females; however, women have higher stage-for-stage mortality, being diagnosed with more advanced disease, mostly due to a delay in haematuria evaluation. Numerous studies indicate an increased risk of disease recurrence or progression in women with non-muscle-invasive bladder cancer treated with trans-urethral resection, with or without intravesical chemotherapy or immunotherapy, compared to males. In particular, recent molecular evidence show that there is an excess of female Ta mutant tumours. At the time of radical cystectomy, women have a significantly longer length of hospital stay, operative time, higher blood loss and higher 90-day mortality and perioperative complication rate. Moreover, females are less likely to receive a continent diversion. Future research should guarantee greater inclusion of women in trials and focus on improving the effectiveness of therapies in women, perhaps exploring different therapeutic approaches in men and women. Specific data on functional and oncological outcomes can be analysed to define predictive factors able to guide the surgeon in decisions based on evidence. It is urgently needed to limit gender-related discrepancies in early diagnosis and treatment of bladder cancer. Public awareness and bladder cancer female patients' consciousness on gender inequalities must be similarly uprisen. FAU - Mancini, Mariangela AU - Mancini M AD - Urological Clinic, Department of Surgical, Oncological and Gastroenterological Sciences and School of Medicine and Surgery, University of Padova, Padova, Italy. FAU - Righetto, Marialaura AU - Righetto M AUID- ORCID: 0000-0003-2307-4195 AD - Urological Clinic, Department of Surgical, Oncological and Gastroenterological Sciences and School of Medicine and Surgery, University of Padova, Padova, Italy. FAU - Baggio, Giovannella AU - Baggio G AD - Department of Medicine (DIMED) and School of Medicine and Surgery, University of Padova, Padova, Italy. LA - eng PT - Comparative Study PT - Journal Article PT - Review DEP - 20191223 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Female MH - Humans MH - Incidence MH - Male MH - Prognosis MH - Risk Factors MH - Sex Characteristics MH - Sex Distribution MH - Sex Factors MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/therapy OTO - NOTNLM OT - Female OT - bladder cancer OT - cystectomy OT - diagnosis OT - gender OT - inequalities OT - male OT - neobladder OT - treatment EDAT- 2019/12/24 06:00 MHDA- 2021/02/18 06:00 CRDT- 2019/12/24 06:00 PHST- 2019/12/24 06:00 [pubmed] PHST- 2021/02/18 06:00 [medline] PHST- 2019/12/24 06:00 [entrez] AID - 10.1177/0391560319887327 [doi] PST - ppublish SO - Urologia. 2020 Aug;87(3):103-114. doi: 10.1177/0391560319887327. Epub 2019 Dec 23. PMID- 31867271 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer. PG - 1315 LID - 10.3389/fonc.2019.01315 [doi] LID - 1315 AB - Background: Currently, the diagnosis of non-organ-confined bladder cancer (NOCBCa) has a very poor prognosis. For patients with NOCBCa, treatments such as radical cystectomy (RC) and systemic chemotherapy have shown survival benefits. However, the relative survival benefits of trimodal therapy (TMT) are unclear. Methods: Patients diagnosed with NOCBCa (cT4bN0M0, cTxN1-3M0, or TxNxM1) were identified in the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). Patients were grouped based on their definitive treatment for bladder cancer (RC or TMT with maximal transurethral resection, chemotherapy, or radiotherapy). All-cause mortality (ACM) and bladder cancer-specific mortality (BCSM) were assessed by Cox proportional hazard regression and competitive risk models. Results: A total of 2,988 patients met the inclusion criteria and were treated with RC (83.5%) or TMT (16.5%). Patients who underwent TMT had higher 5-year ACM (91.3%) and BCSM (88.8%) results compared to patients who underwent RC (82.6 and 75.0%, respectively) (P < 0.001). Adjusted hazard rate (AHR) analysis showed that TMT was associated with higher ACM (AHR: 1.33, 95% CI: 1.15-1.54, P < 0.001) and higher BCSM (AHR: 1.32, 95% CI: 1.13-1.54, P = 0.001). Subgroup analysis revealed not statistically significant between RC and TMT among patients aged >/=80 years (P > 0.05). Conclusions: Compared with TMT, RC is associated with a significant reduction in ACM and BCSM. However, the risks and survival benefits of RC should be weighed, especially in older patients, and our results further suggest that there may be no difference in the prognosis of RC and TMT in patients >/=80 years of age. These results are preliminary and emphasize the need for randomized controlled trials to compare TMT and RC. CI - Copyright (c) 2019 Guo, Jie, Zhang, Zhang, Wang, Zhang, Mao, Wu, Wang, Zhang, Yan, Wang and Yao. FAU - Guo, Yadong AU - Guo Y AD - Shanghai Clinical Medical College, Anhui Medical University, Hefei, China. AD - Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Jie, Xiaoliang AU - Jie X AD - Shanghai Clinical Medical College, Anhui Medical University, Hefei, China. AD - Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Zhang, Aihong AU - Zhang A AD - Department of Medical Statistics, Tongji University School of Medicine, Shanghai, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Wang, Ruiliang AU - Wang R AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Zhang, Junfeng AU - Zhang J AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Mao, Shiyu AU - Mao S AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Wu, Yuan AU - Wu Y AD - Shanghai Clinical Medical College, Anhui Medical University, Hefei, China. AD - Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Wang, Longsheng AU - Wang L AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Zhang, Ziwei AU - Zhang Z AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Yan, Yang AU - Yan Y AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Wang, Ping AU - Wang P AD - Shanghai Clinical Medical College, Anhui Medical University, Hefei, China. AD - Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. FAU - Yao, Xudong AU - Yao X AD - Shanghai Clinical Medical College, Anhui Medical University, Hefei, China. AD - Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. AD - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. LA - eng PT - Journal Article DEP - 20191206 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6909817 OTO - NOTNLM OT - SEER data OT - non-organ-confined bladder cancer OT - prognosis OT - radical cystectomy OT - trimodal therapy EDAT- 2019/12/24 06:00 MHDA- 2019/12/24 06:01 PMCR- 2019/01/01 CRDT- 2019/12/24 06:00 PHST- 2019/04/20 00:00 [received] PHST- 2019/11/12 00:00 [accepted] PHST- 2019/12/24 06:00 [entrez] PHST- 2019/12/24 06:00 [pubmed] PHST- 2019/12/24 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.01315 [doi] PST - epublish SO - Front Oncol. 2019 Dec 6;9:1315. doi: 10.3389/fonc.2019.01315. eCollection 2019. PMID- 31865807 OWN - NLM STAT- MEDLINE DCOM- 20210118 LR - 20210118 IS - 1940-2465 (Electronic) IS - 1066-8969 (Linking) VI - 28 IP - 4 DP - 2020 Jun TI - Perivascular Epithelioid Cell Tumor of the Urinary Bladder: A Systematic Review. PG - 393-400 LID - 10.1177/1066896919895810 [doi] AB - Perivascular epithelioid cell tumor (PEComa) of the urinary bladder is a rare neoplasm showing distinct melanocytic and smooth muscle differentiation. We aimed to review the clinicopathologic features of bladder PEComa using all the available cases in the literature, along with 2 new cases from our database. The patients included 15 females and 15 males with a mean age of 39.2 +/- 15.3 years. Painless hematuria was the most common clinical presentation. The tumors were usually well circumscribed with a mean tumor size of 4.4 +/- 2.7 cm. Bladder PEComas demonstrated nests, trabeculae, or sheets of epithelioid cells with intermixed spindled cells and numerous thin-walled vessels. Immunohistochemical studies showed that the tumors were positive for HMB45 (27/27), cathepsin (4/4), SMA (20/22), and caldesmon (3/3) and were negative for pan cytokeratin (0/18) and EMA (0/4). Molecular studies revealed that PEComa was associated with the TFE3 (n = 3) and EWSR1 (n = 1) gene rearrangements. Treatment included partial cystectomy (n = 18), transurethral resection (n = 8), and radical cystectomy (n = 4). Twenty patients had no evidence of disease during a mean follow-up time of 19.4 +/- 17.2 months. Two patients had recurrence, and 1 patient died of metastatic disease. In conclusion, bladder PEComas demonstrate distinct morphologic and immunohistochemical features. Although most tumors follow a benign course, a small subset may develop metastasis and cause death. FAU - Hamza, Ameer AU - Hamza A AUID- ORCID: 0000-0001-6158-4861 AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles C AU - Guo CC AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20191222 PL - United States TA - Int J Surg Pathol JT - International journal of surgical pathology JID - 9314927 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*analysis/genetics/metabolism MH - Cystectomy MH - Gene Rearrangement MH - Hematuria/*etiology MH - Humans MH - Immunohistochemistry MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Perivascular Epithelioid Cell Neoplasms/complications/*diagnosis/surgery MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/complications/*diagnosis/genetics/surgery OTO - NOTNLM OT - HMB45 OT - TFE3 gene OT - perivascular epithelioid cell neoplasm OT - urinary bladder EDAT- 2019/12/24 06:00 MHDA- 2021/01/20 06:00 CRDT- 2019/12/24 06:00 PHST- 2019/12/24 06:00 [pubmed] PHST- 2021/01/20 06:00 [medline] PHST- 2019/12/24 06:00 [entrez] AID - 10.1177/1066896919895810 [doi] PST - ppublish SO - Int J Surg Pathol. 2020 Jun;28(4):393-400. doi: 10.1177/1066896919895810. Epub 2019 Dec 22. PMID- 31864368 OWN - NLM STAT- MEDLINE DCOM- 20200529 LR - 20231112 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 17 IP - 1 DP - 2019 Dec 21 TI - Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes. PG - 225 LID - 10.1186/s12957-019-1759-5 [doi] LID - 225 AB - BACKGROUND: Pelvic lymphadenectomy (PLND) is an integral part of curative surgery for high-risk non-muscle invasive and muscle-invasive bladder cancer. The therapeutic value of extended PLND is controversial. METHODS: We conducted a comprehensive online search in PubMed, EMBASE, and the Cochrane Library databases for relevant literature directly comparing extended PLND (e-PLND) with non-extended PLND (ne-PLND) from database inception to June 2019. We performed the meta-analysis to evaluate the impact of PLND templates on recurrence-free survival (RFS), disease-specific survival (DSS), overall survival (OS), rates of postoperative major complications, and mortality within 90 days of surgery. RESULTS: A total of 10 studies involving 3979 patients undergoing either e-PLND or ne-PLND were included. The results showed that e-PLND was significantly associated with better RFS (HR 0.74, 95% CI 0.62-0.90, p = 0.002) and DSS (HR 0.66, 95% CI 0.55-0.79, p < 0.001). However, no correlation was found between e-PLND template and a better OS (HR 0.93, 95% CI 0.55-1.58, p = 0.79). Postoperative major complications were similar between e-PLND group and ne-PLND group, as was mortality within 90 days of surgery. CONCLUSION: e-PLND template is correlated with favorable RFS and DSS outcomes for patients with bladder cancer. e-PLND did not have more postoperative major complications than did ne-PLND. FAU - Wang, Yu-Chen AU - Wang YC AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. FAU - Wu, Jie AU - Wu J AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. FAU - Dai, Bo AU - Dai B AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Shen, Yi-Jun AU - Shen YJ AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Ma, Chun-Guang AU - Ma CG AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Ye, Ding-Wei AU - Ye DW AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. dwyeli@163.com. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. dwyeli@163.com. FAU - Zhu, Yi-Ping AU - Zhu YP AUID- ORCID: 0000-0001-8015-420X AD - Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai, 200032, People's Republic of China. fudanzhuyiping@163.com. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. fudanzhuyiping@163.com. LA - eng GR - 81772706/National Natural Science Foundation of China/ PT - Comparative Study PT - Journal Article PT - Meta-Analysis DEP - 20191221 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Cystectomy/methods/*mortality MH - Humans MH - Lymph Node Excision/methods/*mortality MH - Lymph Nodes/surgery MH - Lymphatic Metastasis MH - Pelvis/pathology MH - Postoperative Complications/etiology MH - Prognosis MH - Randomized Controlled Trials as Topic MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery PMC - PMC6925870 COIS- The authors declare that they have no competing interests. EDAT- 2019/12/23 06:00 MHDA- 2020/05/30 06:00 PMCR- 2019/12/21 CRDT- 2019/12/23 06:00 PHST- 2019/08/14 00:00 [received] PHST- 2019/11/25 00:00 [accepted] PHST- 2019/12/23 06:00 [entrez] PHST- 2019/12/23 06:00 [pubmed] PHST- 2020/05/30 06:00 [medline] PHST- 2019/12/21 00:00 [pmc-release] AID - 10.1186/s12957-019-1759-5 [pii] AID - 1759 [pii] AID - 10.1186/s12957-019-1759-5 [doi] PST - epublish SO - World J Surg Oncol. 2019 Dec 21;17(1):225. doi: 10.1186/s12957-019-1759-5. PMID- 31843623 OWN - NLM STAT- MEDLINE DCOM- 20200312 LR - 20200312 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 137 DP - 2020 Mar TI - DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence. PG - 91-96 LID - S0090-4295(19)31098-2 [pii] LID - 10.1016/j.urology.2019.12.002 [doi] AB - OBJECTIVE: To examine whether photodynamic diagnosis (PDD) in addition to flexible cystoscopy in the outpatient clinic can reduce risk of tumor recurrence in patients with previous nonmuscle invasive bladder cancer. PDD is an optical technique that enhances the visibility of pathologic tissue and helps guidance tumor resection. METHODS: From February 2016 to December 2017, 699 patients from 3 urologic departments in Denmark were enrolled in a randomized controlled trial. Four months after transurethral resection of bladder tumor patients were randomized 1:1 to either an intervention group (hexaminolevulinate was instilled in the bladder before flexible cystoscopy with PDD video cystoscope) or a control group (white light flexible cystoscope), only. Primary endpoint was tumor recurrence within 8 months from the randomization. Secondary outcomes were numbers of procedures in general anesthesia, time to the first recurrence, differences in tumor size, risk of tumor progression, and identification of carcinoma in situ. RESULTS: A total of 351 patients were allocated to the intervention group (flexible PDD), and 348 to the control group (flexible white light). Throughout the following 8 months after randomization, only 117 patients in the intervention group had at least 1 tumor recurrence compared to 143 patients in the control group (P = .049). Odds ratio of 0.67 (P = .02, 95% CI: 0.48-0.95) correlates with a tumor reduction of 33% in favor of the intervention group. CONCLUSION: Use of PDD in a routine surveillance cystoscopy first time after transurethral resection of bladder tumor for nonmuscle invasive bladder cancer reduces subsequent risk of tumor recurrence compared to WL cystoscopy alone. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Drejer, Ditte AU - Drejer D AD - Department of Urology, Regional Hospital of West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: Dittedrejer@dadlnet.dk. FAU - Moltke, Anne-Louise AU - Moltke AL AD - Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark. FAU - Nielsen, Anna Munk AU - Nielsen AM AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Lam, Gitte W AU - Lam GW AD - Department of Urology, Herlev and Gentofte, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Regional Hospital of West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20191214 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Aged MH - Aminolevulinic Acid/*analogs & derivatives/pharmacology MH - *Carcinoma in Situ/pathology/surgery MH - *Cystoscopy/instrumentation/methods MH - Female MH - Humans MH - Image Enhancement/methods MH - Male MH - *Neoplasm Recurrence, Local/diagnosis/pathology MH - Neoplasm Staging MH - Outcome Assessment, Health Care MH - Patient Selection MH - Photosensitizing Agents/pharmacology MH - Reproducibility of Results MH - Urinary Bladder/*diagnostic imaging MH - *Urinary Bladder Neoplasms/pathology/surgery EDAT- 2019/12/18 06:00 MHDA- 2020/03/13 06:00 CRDT- 2019/12/18 06:00 PHST- 2019/08/23 00:00 [received] PHST- 2019/11/21 00:00 [revised] PHST- 2019/12/03 00:00 [accepted] PHST- 2019/12/18 06:00 [pubmed] PHST- 2020/03/13 06:00 [medline] PHST- 2019/12/18 06:00 [entrez] AID - S0090-4295(19)31098-2 [pii] AID - 10.1016/j.urology.2019.12.002 [doi] PST - ppublish SO - Urology. 2020 Mar;137:91-96. doi: 10.1016/j.urology.2019.12.002. Epub 2019 Dec 14. PMID- 31830927 OWN - NLM STAT- MEDLINE DCOM- 20200529 LR - 20200529 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Dec 12 TI - Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. PG - 1207 LID - 10.1186/s12885-019-6364-z [doi] LID - 1207 AB - BACKGROUND: We aimed to estimate the stage-specific impact of lymph node dissection (LND) on survival for upper urinary tract urothelial carcinoma (UTUC) patients treated with nephroureterectomy (NU). METHODS: Overall, 7278 UTUC patients undergoing NU within the SEER database from 2004 to 2015 were identified. Kaplan-Meier plots illustrated overall survival (OS) and cancer-specific survival (CSS) rates according to LND status. Multivariable Cox regression analyses assessed the effect of LND on OS and CSS rates stratified by pathological tumor stage. RESULTS: LND was performed in 26.9% of patients, and in 18.6, 23.3, 31.2 and 45.9% for pT1, pT2, pT3 and pT4 patients, respectively (P < 0.001). In multivariable Cox regression analyses, LND was associated with a higher OS or CSS in UTUC patients with pT3 and pT4 disease (all P < 0.05), but failed to achieve independent predictor status in patients with pT1 and pT2 disease (all P > 0.05). LND with 1 to 3 regional lymph nodes removed was prone to a higher OS or CSS only in pT4 compared to no LND (both P < 0.01). LND with 4 or more regional lymph nodes removed predisposed to a higher OS or CSS in pT3 or pT4 (all P < 0.05). CONCLUSIONS: The beneficial effect of LND especially LND with 4 or more regional lymph nodes removed on survival was evident in pT3/4 patients. LND can be considered for pT3 and pT4, for pT1/2 remains to be seen, both of which will be verified by further prospective studies. FAU - Zhai, Ting-Shuai AU - Zhai TS AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. FAU - Jin, Liang AU - Jin L AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. FAU - Zhou, Zhen AU - Zhou Z AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. AD - Nanjing Medical University, Nanjing, 210000, China. FAU - Liu, Xiang AU - Liu X AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. AD - Department of Urology, Shanghai Putuo District People's Hospital of Tongji University, School of Medicine, Shanghai, 200333, China. FAU - Liu, Huan AU - Liu H AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. FAU - Chen, Wei AU - Chen W AD - Department of Urology, Shawan People's Hospital, Shawan, Xinjiang, 832100, China. FAU - Lu, Jing-Yi AU - Lu JY AD - Department of Urology, Karamay Central Hospital, Karamay, Xinjiang, 834000, China. FAU - Yao, Xu-Dong AU - Yao XD AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. yaoxudong67@sina.com. FAU - Feng, Li-Ming AU - Feng LM AD - Department of Urology, Shawan People's Hospital, Shawan, Xinjiang, 832100, China. 2357538246@qq.com. FAU - Ye, Lin AU - Ye L AD - Department of Urology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China. ericyelin@163.com. AD - Department of Urology, Karamay Central Hospital, Karamay, Xinjiang, 834000, China. ericyelin@163.com. LA - eng GR - No. 81672549/National Natural Science Foundation of China/ GR - 81972409/National Natural Science Foundation of China/ GR - No. 15ZR1433000/Natural Science Foundation of Shanghai/ GR - No. JK2017-5/Karamay Municipal Science and Technology Foundation/ PT - Journal Article DEP - 20191212 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - Datasets as Topic MH - Female MH - Humans MH - Lymph Node Excision/methods/*mortality MH - Lymph Nodes/pathology/surgery MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Nephroureterectomy/methods/*mortality MH - SEER Program MH - Survival Rate MH - United States/epidemiology MH - Ureteral Neoplasms/mortality/pathology/surgery MH - Urologic Neoplasms/*mortality/pathology/*surgery MH - Young Adult PMC - PMC6907152 OTO - NOTNLM OT - Lymph node dissection OT - Neoplasm staging OT - SEER program OT - Survival analysis OT - Upper urinary tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2019/12/14 06:00 MHDA- 2020/05/30 06:00 PMCR- 2019/12/12 CRDT- 2019/12/14 06:00 PHST- 2019/06/03 00:00 [received] PHST- 2019/11/15 00:00 [accepted] PHST- 2019/12/14 06:00 [entrez] PHST- 2019/12/14 06:00 [pubmed] PHST- 2020/05/30 06:00 [medline] PHST- 2019/12/12 00:00 [pmc-release] AID - 10.1186/s12885-019-6364-z [pii] AID - 6364 [pii] AID - 10.1186/s12885-019-6364-z [doi] PST - epublish SO - BMC Cancer. 2019 Dec 12;19(1):1207. doi: 10.1186/s12885-019-6364-z. PMID- 31824850 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240722 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. PG - 1270 LID - 10.3389/fonc.2019.01270 [doi] LID - 1270 AB - Immunosurveillance, which describes the immunologically mediated elimination of transformed cells, has been widely accepted in the context of bladder cancer for many decades with the successful use of Bacillus-Calmette Guerin for superficial bladder cancer since the 1970s. With the emergence of checkpoint inhibitor blockade in the treatment of urothelial cancers, there has been a resurgent interest in the immunology of bladder cancer. The theory of cancer immunoediting proposes that the immune system has both pro-tumorigenic and anti-tumor effects, the balance between the two determining the progression of an individual tumor. However, whilst there is evidence for the action of various immune cell populations in bladder cancer, a cohesive picture of the immune response to bladder cancer and its driving forces are still lacking. Additionally, little is still known about the normal immune landscape of the bladder. Future progress in bladder cancer therapeutic approaches will require a strong foundation in understanding the immunology of this disease. This review considers the evidence for the role of the main immune cell populations, both innate and adaptive, in the immune response to bladder cancer. Recent research and overarching themes in the immune response to bladder cancer are explored. The minimal evidence regarding the normal immune landscape of the human bladder is also summarized to contextualize downstream immune responses. Of specific interest are the innate and myeloid populations, some of which are resident in the human bladder and which have significant effects on downstream adaptive tumor immunity. We discuss factors which restrain the efficacy of populations known to have anti-tumor activity such as cytotoxic T cells, including the constraints on checkpoint blockade. Additionally, the effects on the immune response of tumor intrinsic factors such as the genomic subtype of bladder cancer and the effect of common therapies such as chemotherapy and intravesical Bacillus Calmette-Guerin are considered. A significant theme is the polarization of immune responses within the tumor by a heavily immunosuppressive tumor microenvironment which affects the phenotype of multiple innate and adaptive populations. Throughout, clinical implications are discussed with suggestions for future research directions and therapeutic targeting. CI - Copyright (c) 2019 Joseph and Enting. FAU - Joseph, Magdalene AU - Joseph M AD - Hayday Laboratory, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom. FAU - Enting, Deborah AU - Enting D AD - Department of Uro-Oncology, Guy's Hospital, Guy's St Thomas NHS Foundation Trust, London, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20191120 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6879653 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - genomic subtypes OT - immunosurveillance OT - tumor microenvironment EDAT- 2019/12/12 06:00 MHDA- 2019/12/12 06:01 PMCR- 2019/01/01 CRDT- 2019/12/12 06:00 PHST- 2019/08/10 00:00 [received] PHST- 2019/11/04 00:00 [accepted] PHST- 2019/12/12 06:00 [entrez] PHST- 2019/12/12 06:00 [pubmed] PHST- 2019/12/12 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.01270 [doi] PST - epublish SO - Front Oncol. 2019 Nov 20;9:1270. doi: 10.3389/fonc.2019.01270. eCollection 2019. PMID- 31821066 OWN - NLM STAT- MEDLINE DCOM- 20200416 LR - 20260301 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 203 IP - 5 DP - 2020 May TI - Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. PG - 902-909 LID - 10.1097/JU.0000000000000688 [doi] AB - PURPOSE: Rescue intravesical therapies for patients with bacillus Calmette-Guerin failure nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel therapy has shown safety and efficacy in 2 retrospective, single institution cohorts. This doublet has since been adopted as an intravesical salvage option at multiple institutions. We report the results of a multi-institutional evaluation of gemcitabine and docetaxel. MATERIALS AND METHODS: Each institution retrospectively reviewed all records of patients treated with intravesical gemcitabine and docetaxel for nonmuscle invasive bladder cancer between June 2009 and May 2018. Only patients with recurrent nonmuscle invasive bladder cancer and a history of bacillus Calmette-Guerin treatment were included in the analysis. If patients were disease-free after induction, maintenance was instituted at the treating physician's discretion. Posttreatment surveillance followed American Urological Association guidelines. Survival analysis was performed using the Kaplan-Meier method and risk factors for treatment failure were assessed with Cox regression models. RESULTS: Overall 276 patients (median age 73 years, median followup 22.9 months) received treatment. Nine patients were unable to tolerate a full induction course. One and 2-year recurrence-free survival rates were 60% and 46%, and high grade recurrence-free survival rates were 65% and 52%, respectively. Ten patients (3.6%) had disease progression on transurethral resection. Forty-three patients (15.6%) went on to cystectomy (median 11.3 months from induction), of whom 11 (4.0%) had progression to muscle invasion. Analysis identified no patient, disease or prior treatment related factors associated with gemcitabine and docetaxel failure. CONCLUSIONS: Intravesical gemcitabine and docetaxel therapy is well tolerated and effective, providing a durable response in patients with recurrent nonmuscle invasive bladder cancer after bacillus Calmette-Guerin therapy. Further prospective study is warranted. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Texas Southwestern, Dallas, Texas. FAU - Thomas, Lewis J AU - Thomas LJ AD - Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio. FAU - Brooks, Nathan AU - Brooks N AD - MD Anderson Cancer Center, Houston, Texas. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. FAU - Vitale, Andrew AU - Vitale A AD - Department of Urology, University of Iowa, Iowa City, Iowa. FAU - Crump, Trafford AU - Crump T AD - Department of Urology, University of Calgary, Calgary, Alberta, Canada. FAU - Rao, Mounica Y AU - Rao MY AD - University of Arizona School of Medicine, Phoenix, Arizona. FAU - Daniels, Marcus J AU - Daniels MJ AD - Department of Urology, Johns Hopkins University, Baltimore, Maryland. FAU - Wang, Jonathan AU - Wang J AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Nagaraju, Supriya AU - Nagaraju S AD - MD Anderson Cancer Center, Houston, Texas. FAU - DeWolf, William C AU - DeWolf WC AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Lamm, Donald L AU - Lamm DL AD - University of Arizona School of Medicine, Phoenix, Arizona. AD - BCG Oncology, Phoenix, Arizona. FAU - Kates, Max AU - Kates M AD - Department of Urology, Johns Hopkins University, Baltimore, Maryland. FAU - Hyndman, M Eric AU - Hyndman ME AD - Department of Urology, University of Calgary, Calgary, Alberta, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - MD Anderson Cancer Center, Houston, Texas. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, Johns Hopkins University, Baltimore, Maryland. FAU - Nepple, Kenneth G AU - Nepple KG AD - Department of Urology, University of Iowa, Iowa City, Iowa. AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, Iowa. AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20191210 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Antineoplastic Agents) RN - 0 (Immunosuppressive Agents) RN - 0W860991D6 (Deoxycytidine) RN - 15H5577CQD (Docetaxel) RN - 0 (Gemcitabine) SB - IM CIN - J Urol. 2020 May;203(5):908-909. doi: 10.1097/JU.0000000000000688.01. PMID: 31986067 CIN - Eur Urol. 2020 Sep;78(3):468. doi: 10.1016/j.eururo.2020.04.020. PMID: 32376135 CIN - Aktuelle Urol. 2020 Sep;51(5):406-410. doi: 10.1055/a-1168-0536. PMID: 32846448 MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Biopsy MH - Canada/epidemiology MH - Cystoscopy MH - Deoxycytidine/administration & dosage/*analogs & derivatives MH - Disease-Free Survival MH - Docetaxel/*administration & dosage MH - Dose-Response Relationship, Drug MH - Drug Therapy, Combination MH - Female MH - Follow-Up Studies MH - Humans MH - Immunosuppressive Agents/administration & dosage MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Survival Rate/trends MH - Time Factors MH - Treatment Outcome MH - United States/epidemiology MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/mortality MH - Gemcitabine OTO - NOTNLM OT - administration OT - docetaxel OT - gemcitabine OT - intravesical OT - salvage therapy OT - urinary bladder neoplasms EDAT- 2019/12/11 06:00 MHDA- 2020/04/17 06:00 CRDT- 2019/12/11 06:00 PHST- 2019/12/11 06:00 [pubmed] PHST- 2020/04/17 06:00 [medline] PHST- 2019/12/11 06:00 [entrez] AID - 10.1097/JU.0000000000000688 [doi] PST - ppublish SO - J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. PMID- 31813714 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20201015 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 30 IP - 1 DP - 2020 Jan TI - Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: Retrospective study in a French peripheral hospital. PG - 26-34 LID - S1166-7087(19)30611-6 [pii] LID - 10.1016/j.purol.2019.11.003 [doi] AB - OBJECTIVES: To assess whether the initial treatment of non-muscle invasive bladder cancer (NMIBC) was performed according to the guidelines, and to determine the reasons why initial treatment was not provided in nonadherence cases. MATERIALS AND METHODS: We retrospectively reviewed all patients with NMIBC who underwent their first transurethral resection of bladder tumor (TURBT) at a peripheral hospital, between 2007 and 2016. The treatment offered to the patient was compared to the European Association of Urology guidelines according to risk stratification. For each patient who did not receive the treatment according to the guidelines, one of the following reasons was identified: poor patient compliance, poor patient general health status, urologist's decision, lack of resources. RESULTS: One hundred fifty-nine patients were included with a mean age of 72.2 years at the time of NMIBC diagnosis. The low-risk patients were strictly treated according to the guidelines. Among the intermediate-risk patients, 14% received mitomycin C. Among the high-risk patients, 39% received intravesical Bacillus Calmette-Guerin. In the nonadherence cases (61%), the reasons were related to the patient in 44% of cases (poor compliance, 21%; poor patient general health status, 23%), urologist's decision in 54% of cases, and lack of resources in 2% of cases. Thirty-seven percent of the high-risk patients underwent re-resection. CONCLUSIONS: Overall, adherence to NMIBC guidelines was low in all treatment types (intravesical therapy, re-resection, or cystectomy for very high-risk patients), but this finding was similar to that in previous studies. Reasons were mainly related to the urologist's decision or to the patient condition (poor compliance or poor general health status). LEVEL OF EVIDENCE: 3. CI - Copyright (c) 2019 Elsevier Masson SAS. All rights reserved. FAU - Jeglinschi, S AU - Jeglinschi S AD - Service d'urologie, CHU Nice, 06000 Nice, France; Service d'urologie, CHU Reims, 51100 Reims, France. Electronic address: csj360@gmail.com. FAU - Schirmann, A AU - Schirmann A AD - Service d'urologie, CHU Reims, 51100 Reims, France. FAU - Durand, M AU - Durand M AD - Service d'urologie, CHU Nice, 06000 Nice, France. FAU - Sanchez, S AU - Sanchez S AD - Department d'information medicale, centre hospitalier, 10000 Troyes, France. FAU - Larre, S AU - Larre S AD - Service d'urologie, CHU Reims, 51100 Reims, France. FAU - Leon, P AU - Leon P AD - Service d'urologie, CHU Reims, 51100 Reims, France; Service d'urologie, clinique Pasteur, 17200 Royan, France. LA - eng PT - Journal Article DEP - 20191206 PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Aged MH - Antibiotics, Antineoplastic/administration & dosage MH - BCG Vaccine/administration & dosage MH - Female MH - France MH - Guideline Adherence/*statistics & numerical data MH - Humans MH - Male MH - Mitomycin/administration & dosage MH - Patient Compliance MH - *Practice Guidelines as Topic MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*therapy MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Adhesion aux recommandations OT - BCG therapy OT - BCG therapie OT - Clinical practice guidelines OT - Cystectomie OT - Instillations intra-vesicales OT - Intravesical therapy OT - Non-muscle invasive bladder cancer OT - Referentiels de traitement OT - Treatment adherence OT - Tumeur de vessie non infiltrante OT - cystectomy EDAT- 2019/12/10 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/12/10 06:00 PHST- 2019/06/07 00:00 [received] PHST- 2019/09/10 00:00 [revised] PHST- 2019/11/07 00:00 [accepted] PHST- 2019/12/10 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/12/10 06:00 [entrez] AID - S1166-7087(19)30611-6 [pii] AID - 10.1016/j.purol.2019.11.003 [doi] PST - ppublish SO - Prog Urol. 2020 Jan;30(1):26-34. doi: 10.1016/j.purol.2019.11.003. Epub 2019 Dec 6. PMID- 31803932 OWN - NLM STAT- MEDLINE DCOM- 20210326 LR - 20250516 IS - 1699-5848 (Electronic) IS - 0213-3911 (Linking) VI - 35 IP - 5 DP - 2020 May TI - Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. PG - 423-432 LID - 10.14670/HH-18-189 [doi] AB - In order to evaluate the potential prognostic/predictive role of androgen receptor (AR) expression in non-muscle-invasive bladder cancer (NMIBC), and whether it may represent a therapeutic target, we conducted a systematic search of the literature using 'androgen receptor or AR', 'testosterone', 'bladder cancer' and 'non-muscle invasive bladder cancer or NMIBC' as keywords. Eleven studies met the inclusion/exclusion criteria. No significant association was found between AR status and patients' gender (p=0.232), tumor size (p=0.975), tumor stage (p=0.237), tumor grade (p=0.444), tumor multicentricity (p=0.397), concomitant CIS (p=0.316) and progression of disease (p=0.397). On the other hand, relative lack of AR expression was significantly correlated to recurrent disease (p=0.001). Evidence for a direct correlation between AR expression and recurrence-free survival of patients with NMIBC indicate ARs as potential markers of BC behavior; moreover, the finding of a role of androgen blockade therapy in improving survival highlights the potential clinical application of this pathway, which deserves to be further explored. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University Hospital, Foggia, Italy. fradolce@hotmail.com. AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Calo, Beppe AU - Calo B AD - Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. FAU - Russo, Davide AU - Russo D AD - Department of Pathology, University Hospital, Foggia, Italy. FAU - Menin, Andrea AU - Menin A AD - Department of Pathology, San Bortolo Hospital, Vicenza, Italy. FAU - Pastore, Antonio Luigi AU - Pastore AL AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Sapienza University of Rome, Latina, Italy. FAU - Greco, Francesco AU - Greco F AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Urology, Humanitas Gavazzeni, Bergamo, Italy. FAU - Bozzini, Giorgio AU - Bozzini G AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Urology, ASST Valle Olona, Busto A. (VA), Italy. FAU - Galfano, Antonio AU - Galfano A AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Pini, Giovannalberto AU - Pini G AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Urology, San Raffaele Turro Hospital, San Raffaele University, Milan, Italy. FAU - Porreca, Angelo AU - Porreca A AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Urology Unit, Policlinico of Abano, Abano Terme, Italy. FAU - Mugavero, Filippo AU - Mugavero F AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Urology Unit, Ospedale Vittorio Emanuele, Catania, Italy. FAU - Falsaperla, Mario AU - Falsaperla M AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Urology Unit, Ospedale Vittorio Emanuele, Catania, Italy. FAU - Ceruti, Carlo AU - Ceruti C AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Urology Clinic, Citta della Salute e della Scienza, University of Turin, Turin, Italy. FAU - Cindolo, Luca AU - Cindolo L AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Urology, ASL02 Abruzzo, Chieti, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Urology Unit, ASST-Spedali Civili, Brescia, Italy. FAU - Minervini, Andrea AU - Minervini A AD - AGILE Group (Italian Group for Advanced Laparoscopic and Robotic Urologic Surgery), Italy. AD - Department of Oncologic, Minimally-Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florence, Italy. LA - eng GR - -/-/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20191205 PL - Spain TA - Histol Histopathol JT - Histology and histopathology JID - 8609357 RN - 0 (AR protein, human) RN - 0 (Androgens) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Androgen) SB - IM MH - Androgens/metabolism MH - Biomarkers, Tumor/*metabolism MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Neoplasm Recurrence, Local MH - Prognosis MH - Receptors, Androgen/*metabolism MH - Risk Factors MH - *Urinary Bladder Neoplasms/metabolism/pathology EDAT- 2019/12/06 06:00 MHDA- 2021/03/27 06:00 CRDT- 2019/12/06 06:00 PHST- 2019/12/06 06:00 [pubmed] PHST- 2021/03/27 06:00 [medline] PHST- 2019/12/06 06:00 [entrez] AID - HH-18-189 [pii] AID - 10.14670/HH-18-189 [doi] PST - ppublish SO - Histol Histopathol. 2020 May;35(5):423-432. doi: 10.14670/HH-18-189. Epub 2019 Dec 5. PMID- 31787543 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 1 DP - 2020 Feb TI - Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer. PG - 11-19.e1 LID - S1558-7673(19)30329-5 [pii] LID - 10.1016/j.clgc.2019.10.025 [doi] AB - PURPOSE: To assess the ability of preoperative plasma fibrinogen and D-dimer as biomarkers to predict survival outcomes in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A total of 206 NMIBC patients receiving transurethral resection of bladder tumor (TURBT) were assessed in our retrospective study. The cutoff values of fibrinogen and D-dimer were determined using receiver operating characteristic curve analysis. Cox regression analyses were adopted to assess the influence of these two parameters on recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: The cutoff values of fibrinogen and D-dimer were 3.56 g/L and 0.48 mug/mL, respectively. Kaplan-Meier analysis demonstrated that high fibrinogen and D-dimer levels were significantly related to poor RFS (all P < .001) and PFS (all P < .001). Moreover, patients with elevated fibrinogen levels tended to have high tumor grade (P = .033), advanced pathologic T stage (P < .001), and multiple tumor lesions (P = .019). Significant associations of high D-dimer levels with advanced pathologic T stage (P = .026), large tumor size (P = .012), and multiple tumor lesions (P = .006) were found. In addition, multivariate analysis revealed that plasma fibrinogen and D-dimer were all independent predictive factors for RFS (P = .029 and .001, respectively) and PFS (P = .023 and .003, respectively). CONCLUSION: High levels of preoperative plasma fibrinogen and D-dimer may indicate advanced clinicopathologic features and worse prognosis, suggesting that these two coagulation parameters could be used as prognostic biomarkers for NMIBC patients. CI - Copyright (c) 2019 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Li, Xing AU - Li X AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. FAU - Shu, Kunpeng AU - Shu K AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Henan University, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. FAU - Zhou, Jun AU - Zhou J AD - Department of Urology, Henan Provincial People's Hospital of Henan University, Zhengzhou, Henan, China. FAU - Yu, Qian AU - Yu Q AD - Department of Urology, Henan Provincial People's Hospital of Henan University, Zhengzhou, Henan, China. FAU - Cui, Shaowei AU - Cui S AD - Department of Urology, Henan Provincial People's Hospital of Henan University, Zhengzhou, Henan, China. FAU - Liu, Jianjun AU - Liu J AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Henan University, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. FAU - Zhou, Ruijin AU - Zhou R AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Henan University, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. FAU - Ding, Degang AU - Ding D AD - Department of Urology, Henan Provincial People's Hospital, People's Hospital of Henan University, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: 13503848199@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191106 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) RN - 0 (Fibrin Fibrinogen Degradation Products) RN - 0 (fibrin fragment D) RN - 9001-32-5 (Fibrinogen) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*blood MH - *Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Fibrin Fibrinogen Degradation Products/*analysis MH - Fibrinogen/*analysis MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/pathology MH - Neoplasm Staging MH - Preoperative Period MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/blood/mortality/pathology/*surgery MH - Young Adult OTO - NOTNLM OT - Bladder urothelial carcinoma OT - Coagulation parameters OT - Predictive factors OT - Prognosis OT - TURBT EDAT- 2019/12/04 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/12/03 06:00 PHST- 2019/07/08 00:00 [received] PHST- 2019/10/28 00:00 [accepted] PHST- 2019/12/04 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/12/03 06:00 [entrez] AID - S1558-7673(19)30329-5 [pii] AID - 10.1016/j.clgc.2019.10.025 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Feb;18(1):11-19.e1. doi: 10.1016/j.clgc.2019.10.025. Epub 2019 Nov 6. PMID- 31787542 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 1 DP - 2020 Feb TI - Sex Differences in Urothelial Bladder Cancer Survival. PG - 26-34.e6 LID - S1558-7673(19)30324-6 [pii] LID - 10.1016/j.clgc.2019.10.020 [doi] AB - BACKGROUND: While urinary bladder cancer is consistently more common in men worldwide, women have poorer prognosis. The aim of this study was to outline sex differences in prognostic factors and clinical management and to explore whether these can explain the poorer urinary bladder cancer outcome in women. PATIENTS AND METHODS: We performed a population-based cohort study including all patients diagnosed with urothelial bladder cancer between 1997 and 2014 at age 18 to 89 who had data recorded in the Swedish Urinary Bladder Cancer Register (n = 36,344). Female-to-male odds ratios for clinical management parameters were estimated by logistic regression. To quantify sex differences in bladder cancer-specific survival, we estimated empirical survival proportions and mortality rates as well as applied flexible parametric models to estimate female-to-male hazard ratios and survival proportions over follow-up. Adjusted models included age, year, World Health Organization grade, stage, marital status, education, health care region, birth country, and comorbidity. RESULTS: Except for an adverse stage distribution in women, we found no evidence of unequal clinical management. Among those diagnosed with bladder cancer, women had a higher bladder cancer mortality (adjusted hazard ratio, 1.15; 95% confidence interval, 1.08-1.23) driven by muscle-invasive tumors (adjusted hazard ratio, 1.24; 95% confidence interval, 1.14-1.34). The female survival disadvantage was confined to the first 2 years after diagnosis. CONCLUSION: The excess bladder cancer mortality in women is limited to those diagnosed with muscle-invasive tumors and cannot be explained by the examined clinicopathologic factors. Further investigations of sex differences in therapeutic procedures and outcomes, including complications, of muscle-invasive bladder cancer, must be performed. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Radkiewicz, Cecilia AU - Radkiewicz C AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: cecilia.radkiewicz@ki.se. FAU - Edgren, Gustaf AU - Edgren G AD - Clinical Epidemiology Division T2, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Johansson, Anna Louise Viktoria AU - Johansson ALV AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Clinical and Experimental Medicine, Division of Clinical Sciences, Linkoping University, Linkoping, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Biobank Research, Umea University, Umea, Sweden. FAU - Akre, Olof AU - Akre O AD - Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. FAU - Lambe, Mats AU - Lambe M AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - Dickman, Paul William AU - Dickman PW AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191106 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Carcinoma, Transitional Cell/*mortality/pathology/therapy MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Registries/statistics & numerical data MH - *Sex Factors MH - Sweden/epidemiology MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*mortality/pathology/therapy MH - Young Adult OTO - NOTNLM OT - Registries OT - Sex factors OT - Survival analysis OT - Sweden/epidemiology OT - Urinary bladder neoplasms/mortality EDAT- 2019/12/04 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/12/03 06:00 PHST- 2019/08/26 00:00 [received] PHST- 2019/10/11 00:00 [revised] PHST- 2019/10/28 00:00 [accepted] PHST- 2019/12/04 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/12/03 06:00 [entrez] AID - S1558-7673(19)30324-6 [pii] AID - 10.1016/j.clgc.2019.10.020 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Feb;18(1):26-34.e6. doi: 10.1016/j.clgc.2019.10.020. Epub 2019 Nov 6. PMID- 31786120 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 1 DP - 2020 Feb TI - Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. PG - 20-25.e2 LID - S1558-7673(19)30325-8 [pii] LID - 10.1016/j.clgc.2019.10.021 [doi] AB - BACKGROUND: The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guerin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic centers. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and Cox proportional hazards regression analyses were used to compare recurrence-free (RFS) and progression-free survival (PFS) of patients in the 2 treatment groups. In addition, we performed exploratory analyses of treatment effect according to the receipt of adequate BCG treatment, high-risk disease, age, gender, smoking status, pathologic stage, and pathologic grade. RESULTS: A total of 321 (48.6%) patients were treated with BCG-Tice and 339 (51.4%) with BCG-Moreau. IPTW-adjusted Cox proportional hazard regression analysis did not show a difference in RFS (hazard ratio, 0.88; 95% confidence interval, 0.56-1.38; P = .58) or PFS (hazard ratio, 0.55; 95% confidence interval, 0.25-1.21, P = .14) between BCG-Tice and BCG-Moreau. On subgroup analyses, we could not identify an association of BCG strain with outcomes. CONCLUSIONS: There was no difference in RFS and PFS between BCG-Tice and BCG-Moreau strains in the adjuvant treatment of NMIBC. However, we confirmed the importance of maintenance therapy for achieving a sustainable response in patients with intermediate- and high-risk NMIBC. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Molinette Hospital, Turin, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The 2 University of Jordan, Amman, Jordan. FAU - Pones, Mario AU - Pones M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienza di Torino, Molinette Hospital, Turin, Italy. FAU - Machado, Andre T AU - Machado AT AD - Department of Urology, University of Sao Paulo Medical School and Institute of Cancer, Sao Paulo, Brazil. FAU - Waksman, Ricardo AU - Waksman R AD - Department of Urology, University of Sao Paulo Medical School and Institute of Cancer, Sao Paulo, Brazil. FAU - Enikeev, Dmitry V AU - Enikeev DV AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Glybochko, Petr V AU - Glybochko PV AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Adonias, Sanarelly Pires AU - Adonias SP AD - Department of Urology, University of Sao Paulo Medical School and Institute of Cancer, Sao Paulo, Brazil. FAU - Nahas, William Carlos AU - Nahas WC AD - Department of Urology, University of Sao Paulo Medical School and Institute of Cancer, Sao Paulo, Brazil. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: shahrokh.shariat@meduniwien.ac.at. FAU - Chade, Daher C AU - Chade DC AD - Department of Urology, University of Sao Paulo Medical School and Institute of Cancer, Sao Paulo, Brazil. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20191106 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Chemotherapy, Adjuvant/methods/statistics & numerical data MH - *Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Drug Administration Schedule MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Progression-Free Survival MH - Proportional Hazards Models MH - Retrospective Studies MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/mortality/pathology/surgery/*therapy OTO - NOTNLM OT - BCG OT - Progression OT - Recurrence OT - Response OT - Strain EDAT- 2019/12/02 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/12/02 06:00 PHST- 2019/08/25 00:00 [received] PHST- 2019/10/23 00:00 [revised] PHST- 2019/10/28 00:00 [accepted] PHST- 2019/12/02 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/12/02 06:00 [entrez] AID - S1558-7673(19)30325-8 [pii] AID - 10.1016/j.clgc.2019.10.021 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Feb;18(1):20-25.e2. doi: 10.1016/j.clgc.2019.10.021. Epub 2019 Nov 6. PMID- 31781979 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20200219 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 20 IP - 12 DP - 2019 Nov 28 TI - High-grade T1 Urothelial Carcinoma: Where Do We Stand? PG - 79 LID - 10.1007/s11934-019-0945-x [doi] AB - PURPOSE OF REVIEW: Bladder cancer is a deadly and common malignancy, with 24% of new cases presenting as T1 disease. High-grade T1 in particular represents a difficult entity to treat due to its clinical variability and known risks of recurrence, progression, and cancer-specific mortality. The differences in guidelines from major urologic organizations underscore this variability, and the past year has seen another BCG shortage, further complicating management. Advances have been made in the molecular and genomic characterization of high-grade T1, and new clinical trials are available to investigate alternative therapies. In this review, we summarize the variations in guidelines, alternatives to BCG, emerging molecular and genomic discoveries, and recent clinical trials. RECENT FINDINGS: Adherence to guidelines for non-muscle-invasive bladder cancer in the community among practicing urologists remains low, in part due to the variations in available guidelines. In the era of a BCG shortage, decreased dosing schedules and alternative intravesical options are increasingly being used. New biomarkers are being discovered to better risk-stratify patients, with future therapies aimed at targeting aggressive disease. HGT1 urothelial carcinoma remains a highly variable and aggressive disease, but we are making significant progress in better characterizing the clinical and molecular factors that influence recurrence and progression, to better guide management. FAU - Yip, Wesley AU - Yip W AD - USC Institute of Urology/Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA. FAU - Ashrafi, Akbar AU - Ashrafi A AD - USC Institute of Urology/Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC Institute of Urology/Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA. daneshma@med.usc.edu. LA - eng PT - Journal Article PT - Review DEP - 20191128 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage/supply & distribution MH - Biomarkers/metabolism MH - Carcinoma, Transitional Cell/genetics/metabolism/pathology/*therapy MH - Clinical Trials as Topic MH - Guideline Adherence MH - Humans MH - Practice Guidelines as Topic MH - Urinary Bladder Neoplasms/genetics/metabolism/pathology/*therapy OTO - NOTNLM OT - BCG OT - Bladder cancer OT - High-grade T1 EDAT- 2019/11/30 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/11/30 06:00 PHST- 2019/11/30 06:00 [entrez] PHST- 2019/11/30 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] AID - 10.1007/s11934-019-0945-x [pii] AID - 10.1007/s11934-019-0945-x [doi] PST - epublish SO - Curr Urol Rep. 2019 Nov 28;20(12):79. doi: 10.1007/s11934-019-0945-x. PMID- 31777254 OWN - NLM STAT- MEDLINE DCOM- 20200313 LR - 20200313 IS - 0028-2685 (Print) IS - 0028-2685 (Linking) VI - 67 IP - 1 DP - 2020 Jan TI - Identification of urinary hsa_circ _0137439 as potential biomarker and tumor regulator of bladder cancer. PG - 137-146 LID - 181214N970 [pii] LID - 10.4149/neo_2018_181214N970 [doi] AB - Cell-free circular RNAs (circRNAs) stably and abundantly exist in body fluids. In this study we aimed to investigate the potential of urinary cell-free circRNAs as a novel class of noninvasive disease biomarkers for diagnosis of bladder cancer. Differentially expressed circRNAs from 10 normal and 10 bladder cancer urine samples were firstly detected by microarray. Hsa_circ_0137439 was then screened and validated in 30 normal and 116 bladder cancer samples. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of hsa_circ_0137439. The Kaplan-Meier method was used to evaluate the significance of hsa_circ_0137439 in the prognosis of bladder cancer. We found that hsa_circ_0137439 was significantly upregulated in bladder cancer samples. Moreover, increased expression of hsa_circ_0137439 was correlated with higher tumor stage, higher tumor grade, higher lymph node status, and history of muscle-invasive bladder cancer (MIBC). Also, urinary cell-free hsa_circ_0137439 could not only differentiate bladder cancer from normal controls but also distinguish MIBC from non-muscle-invasive bladder cancer (NMIBC). Additionally, hsa_circ_0137439 in urine supernatant could serve as an independent prognostic predicator of recurrence-free survival and overall survival for patients with bladder cancer. Cell assays showed that hsa_circ_0137439 knockdown contributed to the inhibition of cell proliferation and migration via hsa_circ_0137439/miR-142-5p/ MTDH axis. In conclusion, urinary cell-free hsa_circ_0137439 could be a promising biomarker for tumor diagnosis and prognostic assessment of bladder cancer patients. FAU - Song, Z AU - Song Z AD - Department of Urology, First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China. FAU - Zhang, Q AU - Zhang Q AD - Department of Urology, Taizhou First People's Hospital, Taizhou, China. FAU - Zhu, J AU - Zhu J AD - Department of Urology, Taizhou First People's Hospital, Taizhou, China. FAU - Yin, G AU - Yin G AD - Department of Urology, Taizhou First People's Hospital, Taizhou, China. FAU - Lin, L AU - Lin L AD - Department of Urology, Taizhou First People's Hospital, Taizhou, China. FAU - Liang, C AU - Liang C AD - Department of Urology, First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China. LA - eng PT - Journal Article DEP - 20191118 PL - Slovakia TA - Neoplasma JT - Neoplasma JID - 0377266 RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Adhesion Molecules) RN - 0 (MTDH protein, human) RN - 0 (Membrane Proteins) RN - 0 (RNA, Circular) RN - 0 (RNA-Binding Proteins) SB - IM MH - Biomarkers, Tumor/*urine MH - Cell Adhesion Molecules MH - Cell Proliferation MH - Humans MH - Membrane Proteins MH - Prognosis MH - RNA, Circular/*urine MH - RNA-Binding Proteins MH - Urinary Bladder Neoplasms/*diagnosis EDAT- 2019/11/30 06:00 MHDA- 2020/03/14 06:00 CRDT- 2019/11/29 06:00 PHST- 2018/12/14 00:00 [received] PHST- 2019/08/14 00:00 [accepted] PHST- 2019/11/30 06:00 [pubmed] PHST- 2020/03/14 06:00 [medline] PHST- 2019/11/29 06:00 [entrez] AID - 181214N970 [pii] AID - 10.4149/neo_2018_181214N970 [doi] PST - ppublish SO - Neoplasma. 2020 Jan;67(1):137-146. doi: 10.4149/neo_2018_181214N970. Epub 2019 Nov 18. PMID- 31772653 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 10 IP - 25 DP - 2019 TI - p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer. PG - 6207-6216 LID - 10.7150/jca.37335 [doi] AB - Purpose: To determine whether p53, PCDH17, Beclin-1 expression is associated with clinicopathological characteristics of bladder cancer. Materials and Methods: 75 patients with non-muscle-invasive and muscle-invasive bladder cancer were included. Immunohistochemical staining for p53, PCDH17 and Beclin-1 were carried out on the same paraffin-embedded blocks serial sections of these patients who underwent surgery between 2010 and 2015. In addition, p53 gene mutations in these tumors were screened by DNA sequencing. Results: Forty-nine (66.7%) of 75 tumors had p53 gene mutations detected by DNA sequencing method. Of these tumors, 43 (86.0%) exhibited p53 high expression. Furthermore, p53 mutation and low expression of PCDH17 were significantly associated with muscle-invasive bladder cancer. Beclin-1 was also strongly associated with T stage. The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. In addition, patients with p53 high-expression or p53 mutation, PCDH17 low-expression and Beclin-1 low-expression significantly had a poor prognosis. Conclusions: Use of a DNA sequencing method to detect p53 gene mutations was consistent with an immunohistochemical method to detect p53 alterations. In conjunction with levels of p53/PCDH17/Beclin-1, p53 and PCDH17 were independently associated with prognosis; Beclin-1 only had a tendency towards overall survival. p53/PCDH17/Beclin-1 phenotype seems to play a more important role than p53 expression in bladder cancer outcome. It is also identified that p53/PCDH17, p53/Beclin-1 or PCDH17/Beclin-1 all have a cooperative and synergistic effect, which may provide us the potential biomarker for bladder cancer patients. CI - (c) The author(s). FAU - Chen, Liuxi AU - Chen L AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Liu, Ying AU - Liu Y AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Zhang, Qi AU - Zhang Q AD - Department of Urology and Institute of Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. FAU - Zhang, Mingming AU - Zhang M AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Han, Xuemeng AU - Han X AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Li, Qiujie AU - Li Q AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Xie, Tian AU - Xie T AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. AD - Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province and Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Wu, Qibiao AU - Wu Q AD - State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China. FAU - Sui, Xinbing AU - Sui X AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. AD - Holistic Integrative Pharmacy Institutes and Comprehensive Cancer Diagnosis and Treatment Center, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. AD - Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province and Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China. LA - eng PT - Journal Article DEP - 20191015 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC6856748 OTO - NOTNLM OT - Beclin-1 OT - Urinary bladder neoplasms OT - p53 OT - protocadherin 17 COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2019/11/28 06:00 MHDA- 2019/11/28 06:01 PMCR- 2019/01/01 CRDT- 2019/11/28 06:00 PHST- 2019/06/05 00:00 [received] PHST- 2019/09/04 00:00 [accepted] PHST- 2019/11/28 06:00 [entrez] PHST- 2019/11/28 06:00 [pubmed] PHST- 2019/11/28 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - jcav10p6207 [pii] AID - 10.7150/jca.37335 [doi] PST - epublish SO - J Cancer. 2019 Oct 15;10(25):6207-6216. doi: 10.7150/jca.37335. eCollection 2019. PMID- 31762799 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 10 IP - 24 DP - 2019 TI - Establishing the prediction models for recurrence and progression of T1G3 bladder urothelial carcinoma. PG - 5891-5902 LID - 10.7150/jca.35866 [doi] AB - We aim to determine clinical recurrence and progression risk factors of T1G3 bladder cancer (BCa), and to establish recurrence and progression prediction models. 5-year follow-up records of 106 T1G3 BCa patients from January 2012 to December 2016 were analyzed for recurrence and progression. Two-sample T-test, Chi-square test, Mann-Whitney test, Kaplan-Meier curves, Cox univariate and multivariate analyses were performed to determine the independent risk factors. Effective prognostic nomograms were established to provide individualized prediction, and the calibration curves were founded to evaluate the agreements of the predicted probability with the actual observed probability. Receiver operating characteristic (ROC) curves were generated for the recurrence and progression prediction models. The stability of prediction models was validated with an external cohort included 61 T1G3 BCa patients. Of the 106 T1G3 BCa patients, 77 were males (72.6%) and 29 were females (27.4%), with median age 70 years. Within 5 years, recurrence was identified in 67 cases (63.2%), and progression was identified in 31 cases (29.2%). The results showed that large size of tumor, multifocal tumors, recrudescent tumor, non-BCG perfusion therapy were the independent risk factors for recurrence, and large size of tumor, multifocal tumors, recrudescent tumor, concomitant carcinoma in situ (CIS) were the independent risk factors for progression. However, no evidence shown that tumor location or operative method was independent risk factors for recurrence and progression. Based on the results of Cox regression analyses, the independent risk factors were used to establish the prediction nomograms to calculate the recurrence and progression probability of each T1G3 BCa patient. Calibration curves, ROC curves and external validation displayed that the nomograms had great value of prediction. CI - (c) The author(s). FAU - Chen, Song AU - Chen S AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Hubei Province, Wuhan, 430071 China. FAU - Lu, Mengxin AU - Lu M AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Hubei Province, Wuhan, 430071 China. FAU - Peng, Tianchen AU - Peng T AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Medical Research Institute, Wuhan University, Wuhan, 430071, China. FAU - Wang, Yejinpeng AU - Wang Y AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Medical Research Institute, Wuhan University, Wuhan, 430071, China. FAU - Liu, Xuefeng AU - Liu X AD - Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington DC, USA. FAU - Xiao, Yu AU - Xiao Y AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Hubei Province, Wuhan, 430071 China. AD - Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. FAU - Wang, Xinghuan AU - Wang X AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Wuhan University, Wuhan, 430071, China. AD - Human Genetics Resource Preservation Center of Hubei Province, Wuhan, 430071 China. AD - Medical Research Institute, Wuhan University, Wuhan, 430071, China. LA - eng PT - Journal Article DEP - 20191011 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC6856570 OTO - NOTNLM OT - Prediction models OT - T1G3 OT - bladder urothelial carcinoma OT - progression OT - recurrence COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2019/11/26 06:00 MHDA- 2019/11/26 06:01 PMCR- 2019/01/01 CRDT- 2019/11/26 06:00 PHST- 2019/04/19 00:00 [received] PHST- 2019/08/26 00:00 [accepted] PHST- 2019/11/26 06:00 [entrez] PHST- 2019/11/26 06:00 [pubmed] PHST- 2019/11/26 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - jcav10p5891 [pii] AID - 10.7150/jca.35866 [doi] PST - epublish SO - J Cancer. 2019 Oct 11;10(24):5891-5902. doi: 10.7150/jca.35866. eCollection 2019. PMID- 31760524 OWN - NLM STAT- MEDLINE DCOM- 20200717 LR - 20200717 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 25 IP - 4 DP - 2020 Apr TI - The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. PG - 698-704 LID - 10.1007/s10147-019-01581-0 [doi] AB - PURPOSE: To evaluate the impact of routine second TUR on the long-term outcome of patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer (NMIBC) MATERIAL AND METHODS: A total of 210 patients (mean age 62.1 years, 89.5% were males) with stage pT1 NMIBC who underwent first TUR were prospectively randomized into two groups including second TUR (n = 105) and no second TUR (n = 105) groups. Data on recurrence, disease progression, 7-year and 10-year recurrence-free survival (RFS), progression-free survival (PFS) and overall survival (OS) were recorded. RESULTS: The median follow-up time was 119 months (IQR 65-168). Per-protocol (PP) analysis revealed that compared to patients without second TUR, patients with second TUR had significantly higher 5-year, 7-year and 10-year rates for RFS (59.4%, 57.9% and 54.8% vs. 36.3%, 31.7% and 26.8%, respectively, p < 0.001) and PFS (93.3%, 91.9% and 90.4% vs. 74.0%, 71.4% and 68.5%, respectively, p < 0.001). According to PP and intention-to-treat (ITT) analyses, the 10-year OS rate was significantly higher in patients with second TUR (59.1 vs. 40.8%, p = 0.004). Multivariate analysis revealed that undergoing second TUR (OR 1.661, 95% CI 1.156-2.385, p = 0.006) was an independent determinant of prolonged OS. CONCLUSIONS: In conclusion, these findings indicate the prognostic value of second TUR in stage pT1 NMIBC patients, not only for RFS and PFS advantages but also for the long-term OS advantage. Therefore, second TUR should be routinely performed in all stage pT1 NMIBC patients with life expectancy of at least 10 years, given the positive contribution to all oncological outcomes. FAU - Eroglu, Askin AU - Eroglu A AUID- ORCID: 0000-0003-2404-6209 AD - Baskent University Zubeyde Hanim Hospital, Izmir, Turkey. askineroglu@gmail.com. FAU - Ekin, Rahmi Gokhan AU - Ekin RG AD - Urla State Hospital, Izmir, Turkey. FAU - Koc, Gokhan AU - Koc G AD - Tepecik Training and Research Hospital, Izmir, Turkey. FAU - Divrik, Rauf Taner AU - Divrik RT AD - Ege Sehir Hospital, Izmir, Turkey. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20191123 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Postoperative Complications/etiology MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Survival Rate MH - Urethra/surgery MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Long-term prognosis OT - Overall survival OT - Second TUR OT - Stage pT1 EDAT- 2019/11/25 06:00 MHDA- 2020/07/18 06:00 CRDT- 2019/11/25 06:00 PHST- 2019/09/19 00:00 [received] PHST- 2019/11/17 00:00 [accepted] PHST- 2019/11/25 06:00 [pubmed] PHST- 2020/07/18 06:00 [medline] PHST- 2019/11/25 06:00 [entrez] AID - 10.1007/s10147-019-01581-0 [pii] AID - 10.1007/s10147-019-01581-0 [doi] PST - ppublish SO - Int J Clin Oncol. 2020 Apr;25(4):698-704. doi: 10.1007/s10147-019-01581-0. Epub 2019 Nov 23. PMID- 31757300 OWN - NLM STAT- MEDLINE DCOM- 20191128 LR - 20200108 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 47 IP - 1 DP - 2020 Feb TI - Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guerin? Predictors and Nomograms. PG - 5-13 LID - S0094-0143(19)30081-3 [pii] LID - 10.1016/j.ucl.2019.09.003 [doi] AB - The best predictors of response to intravesical immunotherapy are tumor grade and stage, tumor recurrence pattern, nomograms, panels of urinary cytokines, and fluorescent in situ hybridization patterns of urine cytology examinations. Future investigations on predictors of Bacillus Calmette-Guerin efficacy are needed to better select those patients who will really benefit from a conservative treatment. Hardly any of the proposed nomograms were designed to precisely predict the outcome of Bacillus Calmette-Guerin immunotherapy. A new nomogram for NMIBC recurrence and progression based on all non-muscle-invasive bladder cancer subgroups would include factors already proven in cancer prognosis and prediction. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Faba, Oscar Rodriguez AU - Faba OR AD - Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain. FAU - Pisano, Francesca AU - Pisano F AD - Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wroclaw, Poland. FAU - Breda, Alberto AU - Breda A AD - Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain. Electronic address: jpalou@fundacio-puigvert.es. LA - eng PT - Journal Article PT - Review PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage MH - Disease Progression MH - Humans MH - Immunotherapy/*methods MH - Neoplasm Invasiveness MH - Nomograms MH - Salvage Therapy/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Nomograms OT - Non-muscle invasive OT - Predictors OT - Recurrence EDAT- 2019/11/24 06:00 MHDA- 2019/11/30 06:00 CRDT- 2019/11/24 06:00 PHST- 2019/11/24 06:00 [entrez] PHST- 2019/11/24 06:00 [pubmed] PHST- 2019/11/30 06:00 [medline] AID - S0094-0143(19)30081-3 [pii] AID - 10.1016/j.ucl.2019.09.003 [doi] PST - ppublish SO - Urol Clin North Am. 2020 Feb;47(1):5-13. doi: 10.1016/j.ucl.2019.09.003. PMID- 31757298 OWN - NLM STAT- MEDLINE DCOM- 20191128 LR - 20200108 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 47 IP - 1 DP - 2020 Feb TI - Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. PG - 35-46 LID - S0094-0143(19)30084-9 [pii] LID - 10.1016/j.ucl.2019.09.006 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guerin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer. CI - Published by Elsevier Inc. FAU - Cooley, Lauren Folgosa AU - Cooley LF AD - Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA. FAU - McLaughlin, Kimberly A AU - McLaughlin KA AD - Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA; Department of Biochemistry, Northwestern University, Feinberg School of Medicine, Polsky Urologic Cancer Institute, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA; Department of Biochemistry, Northwestern University, Feinberg School of Medicine, Polsky Urologic Cancer Institute, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. Electronic address: joshua.meeks@northwestern.edu. LA - eng PT - Journal Article PT - Review PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (DNA, Neoplasm) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage MH - Biomarkers, Tumor/*genetics/metabolism MH - DNA Mutational Analysis MH - DNA, Neoplasm/*genetics MH - Disease Progression MH - Genomics/*methods MH - Humans MH - Immunotherapy/*methods MH - *Mutation MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/drug therapy/*genetics/pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Genomics OT - Immunotherapy OT - Mutation EDAT- 2019/11/24 06:00 MHDA- 2019/11/30 06:00 CRDT- 2019/11/24 06:00 PHST- 2019/11/24 06:00 [entrez] PHST- 2019/11/24 06:00 [pubmed] PHST- 2019/11/30 06:00 [medline] AID - S0094-0143(19)30084-9 [pii] AID - 10.1016/j.ucl.2019.09.006 [doi] PST - ppublish SO - Urol Clin North Am. 2020 Feb;47(1):35-46. doi: 10.1016/j.ucl.2019.09.006. PMID- 31757297 OWN - NLM STAT- MEDLINE DCOM- 20191128 LR - 20200108 IS - 1558-318X (Electronic) IS - 0094-0143 (Linking) VI - 47 IP - 1 DP - 2020 Feb TI - Predictors of Response to Intravesical Therapy. PG - 23-33 LID - S0094-0143(19)30083-7 [pii] LID - 10.1016/j.ucl.2019.09.005 [doi] AB - Despite the 40-year reign of bacillus Calmette-Guerin (BCG) as the most effective immunotherapy in urologic cancers, a lack of clinical tools to predict treatment response has hampered progress in the field. Acting as an immunostimulatory agent against a multitude of phenotypically diverse non-muscle-invasive bladder cancers, response to BCG likely depends on both tumor characteristics as well as host factors. With a deeper understanding of the tumor biology as well as the mechanism of action underpinning immunotherapy, newer and more effective clinical tools are being constructed to improve patient selection. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Li, Roger AU - Li R AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article PT - Review PL - United States TA - Urol Clin North Am JT - The Urologic clinics of North America JID - 0423221 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - BCG Vaccine/*administration & dosage MH - Humans MH - Immunotherapy/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - BCG OT - BCG-unresponsive disease OT - Bladder cancer OT - Immunotherapy OT - Intravesical therapy EDAT- 2019/11/24 06:00 MHDA- 2019/11/30 06:00 CRDT- 2019/11/24 06:00 PHST- 2019/11/24 06:00 [entrez] PHST- 2019/11/24 06:00 [pubmed] PHST- 2019/11/30 06:00 [medline] AID - S0094-0143(19)30083-7 [pii] AID - 10.1016/j.ucl.2019.09.005 [doi] PST - ppublish SO - Urol Clin North Am. 2020 Feb;47(1):23-33. doi: 10.1016/j.ucl.2019.09.005. PMID- 31754921 OWN - NLM STAT- MEDLINE DCOM- 20210406 LR - 20261010 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 26 IP - 3 DP - 2020 Jul TI - Comparative Application of Different Substaging Techniques for Non-Muscle Invasive Urothelial Carcinoma. PG - 1823-1831 LID - 10.1007/s12253-019-00767-1 [doi] AB - To evaluate the diagnostic performance and clinical significance of 4 systems of substaging cases with non-muscle invasive urothelial bladder carcinoma. In addition 4 cutoff measures were evaluated for prediction of muscularis-mucosa invasion. Four substaging systems were applied to 57 NMIBC cases to assess which of these reported methods correlates best with recurrence and progression. On univariate regression analysis patients having tumor size more than 3 cm, solid tumor architecture, high grade, substage B, substage T1e, substage ROL 2 and Tumor depth more than 1 mm were associated with higher recurrence. On multivariate analysis all the four substaging systems, tumor size, grade and tumor type had significant prognostic value for recurrence. Regarding progression only the metric substaging method was associated with tumor progression (p = 0.04). However, on univariate and multivariate regression analysis none of the substaging systems showed prognostic significance and only solid tumor architecture and CIS had significant prognostic value for tumor progression. The ROC curve analysis showed that 1 mm depth of invasion had the best accuracy for detection of muscularis-mucosa invasion (80.2%). Using 1 mm cutoff in measuring the depth and 0.5 mm for the diameter of infiltration may provide clinically relevant information to guide a more personalized therapy for NMIBC. Inclusion of both measures in addition to other histopathologic variables may aid in the development of a scoring system. FAU - Eldin, Mohamed Emad AU - Eldin ME AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Makboul, Rania AU - Makboul R AD - Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Behnsawy, Hosny M AU - Behnsawy HM AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Abdelkawi, Islam F AU - Abdelkawi IF AUID- ORCID: 0000-0002-6386-3909 AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. islamfaa@yahoo.com. FAU - Moeen, Ahmed M AU - Moeen AM AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Faddan, Amr Abou AU - Faddan AA AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Gadelmoula, Mohamed AU - Gadelmoula M AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Shahat, Ahmed A AU - Shahat AA AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Abdel-Aziz, Mohamed Atef AU - Abdel-Aziz MA AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. FAU - Hafez, Moemen M AU - Hafez MM AD - Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Hameed, D A AU - Hameed DA AD - Urology and Nephrology Hospital, Assiut University, Asyut, Egypt. LA - eng PT - Comparative Study PT - Journal Article DEP - 20191121 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging/*methods MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Non-muscle invasive OT - Substaging OT - Urinary bladder OT - Urothelial carcinoma EDAT- 2019/11/23 06:00 MHDA- 2021/04/07 06:00 CRDT- 2019/11/23 06:00 PHST- 2019/06/26 00:00 [received] PHST- 2019/10/14 00:00 [accepted] PHST- 2019/11/23 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2019/11/23 06:00 [entrez] AID - 10.1007/s12253-019-00767-1 [pii] AID - 10.1007/s12253-019-00767-1 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Jul;26(3):1823-1831. doi: 10.1007/s12253-019-00767-1. Epub 2019 Nov 21. PMID- 31744700 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 2 DP - 2020 Apr TI - Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. PG - e62-e70 LID - S1558-7673(19)30309-X [pii] LID - 10.1016/j.clgc.2019.10.005 [doi] AB - BACKGROUND: Tumor location in bladder neck has reported to be a prognostic factor for non-muscle-invasive bladder cancer (NMIBC). We investigated the impact of bladder neck involvement (BNI) on recurrence in NMIBC using time-dependent covariate analysis. PATIENTS AND METHODS: We enrolled 585 Japanese patients who underwent transurethral resection for bladder tumors at a single center from 2000 to 2016 and were pathologically diagnosed with Ta and T1 NMIBC. Each patient at each recurrence was assigned to a separate time-dependent stratum with its own baseline hazard function according to the Prentice-Williams-Peterson gap time model for analyzing recurrent events. RESULTS: Over a median follow-up period of 41.3 months (interquartile range, 18.0-82.3 months), 253 (43.2%) patients experienced a total of 475 recurrences. Among the 1001 total transurethral resection procedures, BNI was observed in 122 (12.2%) cases. The 3-year cumulative recurrence rates of patients with and without BNI were 62.5% and 46.3%, respectively. Multivariable analysis revealed that number of tumors >/= 4 (sub-hazard ratio [SHR], 1.48; P = .004), intravesical bacillus Calmette-Guerin therapy (SHR, 0.44; P < .001), and BNI (SHR, 1.59; P = .004) were all independent predictors of recurrence. Assigning 1 point for each of these 3 predictive factors, the resulting scores enabled us to classify patients into 3 prognostic groups that were clearly stratified according to recurrence. CONCLUSIONS: Our time-dependent covariate analysis shows that BNI is a significant risk factor for recurrence in NMIBC. Our prognostic model incorporating BNI is an easy means of estimating recurrence risk and determining optimal management for individual patients. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Waseda, Yuma AU - Waseda Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Kobayashi, Shuichiro AU - Kobayashi S AD - Department of Urology, Tama-Nambu Chiiki Hospital, Tokyo, Japan. FAU - Kanda, Eiichiro AU - Kanda E AD - Department of Medical Science, Kawasaki Medical School, Okayama, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Matsuoka, Yoh AU - Matsuoka Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. Electronic address: y-fujii.uro@tmd.ac.jp. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20191016 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Chemotherapy, Adjuvant/methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*epidemiology/pathology/prevention & control MH - Prognosis MH - Proportional Hazards Models MH - Prospective Studies MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*therapy OTO - NOTNLM OT - Bladder cancer OT - Bladder neck OT - Non-muscle invasive OT - Recurrent events OT - Risk factor EDAT- 2019/11/21 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/11/21 06:00 PHST- 2019/05/03 00:00 [received] PHST- 2019/09/24 00:00 [revised] PHST- 2019/10/06 00:00 [accepted] PHST- 2019/11/21 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/11/21 06:00 [entrez] AID - S1558-7673(19)30309-X [pii] AID - 10.1016/j.clgc.2019.10.005 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Apr;18(2):e62-e70. doi: 10.1016/j.clgc.2019.10.005. Epub 2019 Oct 16. PMID- 31740332 OWN - NLM STAT- MEDLINE DCOM- 20210506 LR - 20210506 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 5 DP - 2020 May TI - Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. PG - 449-458 LID - S1078-1439(19)30419-3 [pii] LID - 10.1016/j.urolonc.2019.10.013 [doi] AB - OBJECTIVES: Micropapillary urothelial carcinoma of the urinary bladder (MPUC) is a rare variant of urothelial carcinoma which has aggressive clinical characteristics. The objective is to investigate the molecular subtypes of MPUC and the impact to the clinical outcome and determine whether MPUC represents a variant of adenocarcinoma. MATERIALS AND METHODS: We evaluated surrogate immunohistochemical markers of luminal, basal, and p53-like subtypes and correlated with prognosis and the expression of markers related to bladder adenocarcinoma and glandular differentiation in 56 cases of MPUC (10 cases of transurethral resection and 46 cases of radical cystectomy). Biomarker expression in co-existing conventional urothelial carcinoma was also analyzed. Cox regression analysis was performed to study the impact of molecular subtype on the clinical outcome. RESULTS: Thirty-four cases (61%) met criteria for the luminal subtype. Twenty-two cases (39%) displayed a p53-like subtype. In contrast, 40/56 (71%) cases of coexisting conventional urothelial carcinoma were classified as luminal subtype and 16/56 (29%) cases were designated as p53-like subtype. There was no significant survival difference between luminal subtype and p53-like subtype. CDX2, villin, and cadherin 17 were negative in all cases. MUC1 was strongly and diffusely expressed in the stroma-facing surface of MPUC tumor cells in all the cases. CONCLUSIONS: Our findings suggest that MPUC possesses characteristics of luminal and p53-like subtypes, and does not harbor phenotypic features of the basal subtype. There is no significant difference in the prognosis between luminal and p53-like subtype MPUC. MPUC is not a variant of adenocarcinoma and does not represent a form of glandular differentiation, in contrast to other organ sites. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Yang, Yu AU - Yang Y AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Williamson, Sean R AU - Williamson SR AD - Department of Pathology and Laboratory Medicine and Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI; Department of Pathology and Laboratory Medicine, Wayne State University School of Medicine, Detroit, MI. FAU - Koch, Michael O AU - Koch MO AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Huang, Kun AU - Huang K AD - Department of Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Barboza, Marcelo P AU - Barboza MP AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Zhang, Shaobo AU - Zhang S AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Wang, Mingsheng AU - Wang M AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Idrees, Muhammad T AU - Idrees MT AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Grignon, David J AU - Grignon DJ AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Eble, John N AU - Eble JN AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Baldridge, Lee Ann AU - Baldridge LA AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: liang_cheng@yahoo.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20191115 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Adenocarcinoma/chemistry/*classification MH - Aged MH - Aged, 80 and over MH - Algorithms MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Papillary/chemistry/*classification/mortality/surgery MH - Carcinoma, Transitional Cell/chemistry/*classification/mortality/surgery MH - Female MH - Humans MH - Immunophenotyping MH - Male MH - Middle Aged MH - Prognosis MH - Survival Rate MH - Tumor Suppressor Protein p53/*analysis MH - Urinary Bladder Neoplasms/chemistry/*classification/mortality/surgery OTO - NOTNLM OT - Basal/luminal subtype OT - Micropapillary variant OT - Molecular classification OT - Molecular genetics OT - Urinary bladder EDAT- 2019/11/20 06:00 MHDA- 2021/05/07 06:00 CRDT- 2019/11/20 06:00 PHST- 2019/08/14 00:00 [received] PHST- 2019/10/15 00:00 [revised] PHST- 2019/10/23 00:00 [accepted] PHST- 2019/11/20 06:00 [pubmed] PHST- 2021/05/07 06:00 [medline] PHST- 2019/11/20 06:00 [entrez] AID - S1078-1439(19)30419-3 [pii] AID - 10.1016/j.urolonc.2019.10.013 [doi] PST - ppublish SO - Urol Oncol. 2020 May;38(5):449-458. doi: 10.1016/j.urolonc.2019.10.013. Epub 2019 Nov 15. PMID- 31735557 OWN - NLM STAT- MEDLINE DCOM- 20200430 LR - 20210110 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 50 DP - 2019 Dec TI - Identification of an immunotherapy-responsive molecular subtype of bladder cancer. PG - 238-245 LID - S2352-3964(19)30733-9 [pii] LID - 10.1016/j.ebiom.2019.10.058 [doi] AB - BACKGROUND: Although various molecular subtypes of bladder cancer (BC) have been investigated, most of these studies have focused on muscle-invasive BC (MIBC). A few studies have investigated non-muscle-invasive BC (NMIBC) or NMIBC and MIBC together, but none has classified progressive NMIBC or immune checkpoint inhibitor (ICI)-based therapeutic responses in early-stage BC patients. METHODS: A total of 1,934 samples from seven patient cohorts were used. We performed unsupervised hierarchical clustering to stratify patients into distinct subgroups and constructed a classifier by applying SAM/PAM algorithms. We then investigated the association between molecular subtypes and immunotherapy responsiveness using various statistical methods. FINDINGS: We explored large-scale genomic datasets encompassing NMIBC and MIBC, redefining four distinct molecular subtypes, including a subgroup containing progressive NMIBC and MIBC with poor prognosis that would benefit from ICI treatment. This subgroup showed poor progression-free survival with the distinct features of high mutation load, activated cell cycle, and inhibited TGFbeta signalling. Importantly, we verified that BC patients with this subtype were significantly responsive to an anti-PD-L1 agent in the IMvigor210 cohort. INTERPRETATION: Our results reveal an immunotherapeutic option for ICI treatment of highly progressive NMIBC and MIBC with poor prognosis. FUNDING: This research was supported by the National Research Foundation of Korea grant funded by the Korean government, a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea, and a grant from the KRIBB Research Initiative Program. CI - Copyright (c) 2019 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Song, Bic-Na AU - Song BN AD - Genome Editing Research Centre, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea; Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Personalized Genomic Medicine Research Centre, KRIBB, Daejeon, Korea. FAU - Mun, Jeong-Yeon AU - Mun JY AD - Department of Biological Science, Dong-A University, Busan, Korea. FAU - Choi, Young-Deuk AU - Choi YD AD - Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biological Science, Dong-A University, Busan, Korea. Electronic address: shleem@dau.ac.kr. FAU - Chu, In-Sun AU - Chu IS AD - Genome Editing Research Centre, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea; Department of Bioinformatics, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, Korea. Electronic address: chu@kribb.re.kr. LA - eng PT - Journal Article DEP - 20191115 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biomarkers, Tumor) SB - IM MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use MH - Biomarkers, Tumor MH - Cluster Analysis MH - Cohort Studies MH - Databases, Genetic MH - Disease Progression MH - Disease Susceptibility MH - Female MH - Gene Expression Profiling MH - Genomics/methods MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mutation MH - Neoplasm Staging MH - Prognosis MH - Unsupervised Machine Learning MH - Urinary Bladder Neoplasms/diagnosis/*genetics/*immunology/therapy PMC - PMC6921227 OTO - NOTNLM OT - Bladder cancer OT - Disease progression OT - Genomic signature OT - Immunotherapy OT - Subtype COIS- The authors declare that they have no competing interests. EDAT- 2019/11/19 06:00 MHDA- 2020/05/01 06:00 PMCR- 2019/11/15 CRDT- 2019/11/19 06:00 PHST- 2019/08/07 00:00 [received] PHST- 2019/10/31 00:00 [revised] PHST- 2019/10/31 00:00 [accepted] PHST- 2019/11/19 06:00 [pubmed] PHST- 2020/05/01 06:00 [medline] PHST- 2019/11/19 06:00 [entrez] PHST- 2019/11/15 00:00 [pmc-release] AID - S2352-3964(19)30733-9 [pii] AID - 10.1016/j.ebiom.2019.10.058 [doi] PST - ppublish SO - EBioMedicine. 2019 Dec;50:238-245. doi: 10.1016/j.ebiom.2019.10.058. Epub 2019 Nov 15. PMID- 31734230 OWN - NLM STAT- MEDLINE DCOM- 20200504 LR - 20200505 IS - 1525-2191 (Electronic) IS - 0002-9440 (Linking) VI - 190 IP - 2 DP - 2020 Feb TI - Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. PG - 323-332 LID - S0002-9440(19)30801-6 [pii] LID - 10.1016/j.ajpath.2019.10.004 [doi] AB - Bacillus Calmette-Guerin instillation after removal of the tumor is the first line of treatment for urothelial carcinoma in situ (CIS), the precursor lesion of most muscle-invasive bladder cancers. Bacillus Calmette-Guerin therapy fails in >50% of cases, and second-line radical cystectomy is associated with overtreatment and drastic lifestyle consequences. Given the need for alternative bladder-preserving therapies, we identified genomic alterations (GAs) in urothelial CIS having the potential to predict response to targeted therapies. Laser-capture microdissection was applied to isolate 30 samples (25 CIS and 5 muscle controls) from 26 fresh-frozen cystectomy specimens. Targeted next-generation sequencing of 31 genes was performed. The panel comprised genes frequently affected in muscle-invasive bladder cancer of nonpapillary origin, focusing on potentially actionable GAs described to predict response to approved targeted therapies or drugs that are in registered clinical trials. Of CIS patients, 92% harbored at least one potentially actionable GA, which was identified in TP53/cell cycle pathway-related genes (eg, TP53 and MDM2) in 72%, genes encoding chromatin-modifying proteins (eg, ARID1A and KDM6A) in 68%, DNA damage repair genes (eg, BRCA2 and ATM) in 60%, and phosphatidylinositol 3-kinase/mitogen-activated protein kinase pathway genes (eg, ERBB2 and FGFR1) in 36% of the cases. These data might help guide the selection of targeted therapies to be investigated in future clinical CIS trials, and they may provide a basis for future mechanistic studies of urothelial CIS pathogenesis. CI - Copyright (c) 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. FAU - Garczyk, Stefan AU - Garczyk S AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. Electronic address: sgarczyk@ukaachen.de. FAU - Ortiz-Bruchle, Nadina AU - Ortiz-Bruchle N AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Schneider, Ursula AU - Schneider U AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Lurje, Isabella AU - Lurje I AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Guricova, Karolina AU - Guricova K AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Gaisa, Nadine T AU - Gaisa NT AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Lorsy, Eva AU - Lorsy E AD - Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany. FAU - Lindemann-Docter, Katharina AU - Lindemann-Docter K AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Heidenreich, Axel AU - Heidenreich A AD - Department of Urology, University Hospital Cologne, Cologne, Germany; Department of Urology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. FAU - Knuchel, Ruth AU - Knuchel R AD - Institute of Pathology, University Hospital Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen, Aachen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191115 PL - United States TA - Am J Pathol JT - The American journal of pathology JID - 0370502 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Carcinoma in Situ/*genetics/pathology/surgery MH - Case-Control Studies MH - Cystectomy/*methods MH - Female MH - Follow-Up Studies MH - Gene Expression Regulation, Neoplastic MH - High-Throughput Nucleotide Sequencing/*methods MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder/*metabolism/pathology/surgery MH - Urinary Bladder Neoplasms/*genetics/pathology/surgery EDAT- 2019/11/18 06:00 MHDA- 2020/05/06 06:00 CRDT- 2019/11/18 06:00 PHST- 2019/06/28 00:00 [received] PHST- 2019/09/30 00:00 [revised] PHST- 2019/10/08 00:00 [accepted] PHST- 2019/11/18 06:00 [pubmed] PHST- 2020/05/06 06:00 [medline] PHST- 2019/11/18 06:00 [entrez] AID - S0002-9440(19)30801-6 [pii] AID - 10.1016/j.ajpath.2019.10.004 [doi] PST - ppublish SO - Am J Pathol. 2020 Feb;190(2):323-332. doi: 10.1016/j.ajpath.2019.10.004. Epub 2019 Nov 15. PMID- 31732739 OWN - NLM STAT- MEDLINE DCOM- 20200422 LR - 20200422 IS - 1943-7722 (Electronic) IS - 0002-9173 (Linking) VI - 153 IP - 2 DP - 2020 Jan 2 TI - Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer. PG - 274-284 LID - 10.1093/ajcp/aqz165 [doi] AB - OBJECTIVES: Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system. METHODS: Seventy-five bladder cancer cases (including 57 NMIUCs) were classified according to the quantitatively assessed degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier, and C-statistics analyses were performed. RESULTS: UFS proved to be an independent prognostic factor of progression-free survival (PFS) and time to progression (TTP). NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive cancer (TTP; 95% confidence interval, 5.841-198.5; P < .001) in comparison with UFS I to II cases. The addition of UFS to conventional risk scores increased the C-index for PFS and TTP. CONCLUSIONS: UFS can indicate an increased risk for progression into muscle-invasive disease in patients with NMIUC and improves prognostic accuracy of the current clinical risk assessment systems. CI - (c) American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Kocsmar, Ildiko AU - Kocsmar I AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Pajor, Gabor AU - Pajor G AD - Department of Pathology, University of Pecs, Pecs, Hungary. FAU - Gyongyosi, Benedek AU - Gyongyosi B AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Szekely, Eszter AU - Szekely E AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Varga, Marton AU - Varga M AD - Department of Pathology, Peterfy Sandor Municipal Hospital and Trauma Center, Budapest, Hungary. FAU - Kocsmar, Eva AU - Kocsmar E AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Kenessey, Istvan AU - Kenessey I AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Beothe, Tamas AU - Beothe T AD - Department of Urology, Faculty of Medicine, University of Pecs, Pecs, Hungary. AD - Department of Urology, Peterfy Sandor Municipal Hospital and Trauma Center, Budapest, Hungary. FAU - Sule, Norbert AU - Sule N AD - Department of Pathology & Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY. FAU - Majoros, Attila AU - Majoros A AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Szendroi, Attila AU - Szendroi A AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Kiss, Andras AU - Kiss A AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. FAU - Riesz, Peter AU - Riesz P AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Lotz, Gabor AU - Lotz G AD - 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Am J Clin Pathol JT - American journal of clinical pathology JID - 0370470 SB - IM MH - Disease Progression MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Prognosis MH - Urinary Bladder Neoplasms/diagnosis/*genetics/mortality OTO - NOTNLM OT - FISH OT - Molecular diagnosis OT - Prognosis OT - Urinary bladder cancer OT - Urinary cytology OT - UroVysion EDAT- 2019/11/17 06:00 MHDA- 2020/04/23 06:00 CRDT- 2019/11/17 06:00 PHST- 2019/11/17 06:00 [pubmed] PHST- 2020/04/23 06:00 [medline] PHST- 2019/11/17 06:00 [entrez] AID - 5626496 [pii] AID - 10.1093/ajcp/aqz165 [doi] PST - ppublish SO - Am J Clin Pathol. 2020 Jan 2;153(2):274-284. doi: 10.1093/ajcp/aqz165. PMID- 31718471 OWN - NLM STAT- MEDLINE DCOM- 20201208 LR - 20201214 IS - 2474-0896 (Electronic) IS - 0967-4845 (Linking) VI - 77 IP - 2 DP - 2020 Apr TI - Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis. PG - 69-75 LID - 10.1080/09674845.2019.1692761 [doi] AB - Background: Therapy that targets cancer stem cells has the potential to eradicate cancer and prevent tumour recurrence. Therefore, we hypothesized the combined prognostic significance of stem cell markers CD44 (prevalent in basal layer of urothelial carcinoma) and Nanog (embryonic stem cell transcription factor) in bladder cancer.Material and Methods: CD44 and Nanog expression were determined by immunohistochemistry in 112 bladder cancer cases of which 79 were non-muscle invasive and 33 muscle invasive.Results: A significant correlation was found between CD44 and Nanog expression (r = 0.41, p < 0.001). The bladder cancer patients with high CD44 and Nanog expression had poor recurrence-free survival and poor overall survival (all p < 0.01). Multivariate Cox regression analysis identified lymph node positivity (hazard ratio; HR 3.81, 95% confidence interval; CI 1.66-8.75), CD44 (HR/95%CI 7.03 [3.04-16.22]) and Nanog (HR/95%CI 2.89 [1.23-6.77]) as independent prognostic biomarkers for recurrence-free survival, whilst a combined index of CD44 and Nanog expression (high expression group; HR/95%CI 25.45 [6.71-96.50] for recurrence-free survival) and lymph node positivity (HR/95%CI 3.68 [1.63-8.33] for recurrence-free survival) were independent prognostic biomarkers for recurrence-free survival and overall survival (all p < 0.001).Conclusions: A combined index of CD44 and Nanog expression is a promising prognostic predictor of recurrence-free survival and overall survival in bladder cancer. It may help identification of patients who will benefit from intensive treatment. FAU - Siddiqui, Z AU - Siddiqui Z AUID- ORCID: 0000-0003-4384-197X AD - Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow. FAU - Srivastava, A N AU - Srivastava AN AUID- ORCID: 0000-0001-9633-9903 AD - Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow. FAU - Sankhwar, S N AU - Sankhwar SN AD - Department of Urology, King George's Medical University, Lucknow. FAU - Dalela, D AU - Dalela D AD - Department of Urology, King George's Medical University, Lucknow. FAU - Singh, V AU - Singh V AD - Department of Urology, King George's Medical University, Lucknow. FAU - Zaidi, N AU - Zaidi N AD - Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow. FAU - Fatima, N AU - Fatima N AD - Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow. FAU - Bano, I AU - Bano I AD - Research Metabolic Unit, Era's Lucknow Medical College & Hospital, Era University, Lucknow, India. FAU - Anjum, S AU - Anjum S AD - Research Metabolic Unit, Era's Lucknow Medical College & Hospital, Era University, Lucknow, India. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20191220 PL - Switzerland TA - Br J Biomed Sci JT - British journal of biomedical science JID - 9309208 RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (NANOG protein, human) RN - 0 (Nanog Homeobox Protein) SB - IM MH - Aged MH - Biomarkers, Tumor/metabolism MH - Female MH - Humans MH - Hyaluronan Receptors/*metabolism MH - India/epidemiology MH - Male MH - Middle Aged MH - Nanog Homeobox Protein/*metabolism MH - Neoplasm Recurrence, Local/*metabolism MH - Neoplastic Stem Cells/*metabolism MH - Prognosis MH - Urinary Bladder Neoplasms/diagnosis/*metabolism/mortality OTO - NOTNLM OT - CD44 OT - Nanog OT - bladder cancer OT - cancer stem cell OT - prognosis OT - recurrence EDAT- 2019/11/14 06:00 MHDA- 2020/12/15 06:00 CRDT- 2019/11/14 06:00 PHST- 2019/11/14 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2019/11/14 06:00 [entrez] AID - 10.1080/09674845.2019.1692761 [pii] AID - 10.1080/09674845.2019.1692761 [doi] PST - ppublish SO - Br J Biomed Sci. 2020 Apr;77(2):69-75. doi: 10.1080/09674845.2019.1692761. Epub 2019 Dec 20. PMID- 31712383 OWN - NLM STAT- MEDLINE DCOM- 20201117 LR - 20211215 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 26 IP - 4 DP - 2020 Feb 15 TI - Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. PG - 882-891 LID - 10.1158/1078-0432.CCR-19-1920 [doi] AB - PURPOSE: To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG). EXPERIMENTAL DESIGN: Patients with NMIBC treated with intravesical BCG (2008-2015) were identified, and a tissue microarray was constructed using paired pre- and post-BCG bladder samples. Among patients undergoing BCG, cystoscopic evaluation began 3 months after initiating BCG treatment to determine therapeutic response. IHC was performed for CD8, CD4, FoxP3, PD-L1 (SP-142 and 22C3), and PD-1. A full slide review of PD-L1(+) staining tumors was performed to characterize PD-L1 and CD8 colocalization. RNA-seq was performed on cored tumors from available specimens. We compared immune cell populations between BCG responders and nonresponders, and between pretreatment and postreatment tumor samples. Baseline PD-L1 staining in the BCG naive population was then validated in a separate cohort. RESULTS: The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders. No differences in CD4, CD8, or FoxP3 expression were identified between responders and nonresponders. Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01). PD-L1(+) cells in BCG nonresponders colocalized with CD8(+) T cells. In addition, BCG therapy did not increase PD-L1 gene expression (RNA-seq) or protein levels (IHC). The number of pretreatment CD4(+) T cells was very low among PD-L1(+) nonresponders (12%) and high among PD-L1(-) nonresponders (50%, P < 0.01). In a separate cohort of 57 patients with NMIBC undergoing BCG, baseline PD-L1 (22C3) staining was similar (26%). CONCLUSIONS: One mechanism of BCG failure may be adaptive immune resistance. Baseline tumor PD-L1 expression predicts an unfavorable response to BCG and if validated, could be used to guide therapeutic decisions. CI - (c)2019 American Association for Cancer Research. FAU - Kates, Max AU - Kates M AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. Mkates@jhmi.edu. FAU - Matoso, Andres AU - Matoso A AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Choi, Woonyoung AU - Choi W AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Baras, Alexander S AU - Baras AS AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Daniels, Marcus J AU - Daniels MJ AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Lombardo, Kara AU - Lombardo K AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Brant, Aaron AU - Brant A AUID- ORCID: 0000-0001-8523-409X AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Mikkilineni, Nina AU - Mikkilineni N AD - Columbia University Medical Center, New York, New York. FAU - McConkey, David J AU - McConkey DJ AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Kamat, Ashish M AU - Kamat AM AD - MD Anderson Cancer Center, Houston, Texas. FAU - Svatek, Robert S AU - Svatek RS AD - University of Texas Health Science Center, San Antonio, Texas. FAU - Porten, Sima P AU - Porten SP AD - University of California San Francisco, San Francisco, California. FAU - Meeks, Joshua J AU - Meeks JJ AD - Northwestern University School of Medicine, Chicago, Illinois. FAU - Lerner, Seth P AU - Lerner SP AD - Baylor University School of Medicine, Houston, Texas. FAU - Dinney, Colin P AU - Dinney CP AUID- ORCID: 0000-0002-8969-711X AD - Columbia University Medical Center, New York, New York. FAU - Black, Peter C AU - Black PC AUID- ORCID: 0000-0002-2919-7068 AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. FAU - McKiernan, James M AU - McKiernan JM AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. FAU - Anderson, Chris AU - Anderson C AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. FAU - Drake, Charles G AU - Drake CG AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191111 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Cancer Vaccines) SB - IM CIN - Nat Rev Urol. 2020 Jan;17(1):8. doi: 10.1038/s41585-019-0267-2. PMID: 31792432 CIN - J Urol. 2021 Oct;206(4):1061-1062. doi: 10.1097/JU.0000000000001957. PMID: 34293912 MH - Adaptive Immunity/*immunology MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage/immunology MH - Biomarkers, Tumor/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Cancer Vaccines/administration & dosage/immunology MH - Cohort Studies MH - Drug Resistance, Neoplasm MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Prognosis MH - Urinary Bladder Neoplasms/*immunology/pathology/*therapy EDAT- 2019/11/13 06:00 MHDA- 2020/11/18 06:00 CRDT- 2019/11/13 06:00 PHST- 2019/06/14 00:00 [received] PHST- 2019/09/03 00:00 [revised] PHST- 2019/11/06 00:00 [accepted] PHST- 2019/11/13 06:00 [pubmed] PHST- 2020/11/18 06:00 [medline] PHST- 2019/11/13 06:00 [entrez] AID - 1078-0432.CCR-19-1920 [pii] AID - 10.1158/1078-0432.CCR-19-1920 [doi] PST - ppublish SO - Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11. PMID- 31711836 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20250723 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 2 DP - 2020 Feb TI - External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. PG - 39.e21-39.e27 LID - S1078-1439(19)30404-1 [pii] LID - 10.1016/j.urolonc.2019.10.003 [doi] AB - OBJECTIVES: To externally validate the European Organization for the Research and Treatment of Cancer (EORTC) risk calculator and National Comprehensive Cancer Network (NCCN) guidelines in a contemporary population of U.S. non-muscle-invasive bladder cancer (NMIBC) patients treated in a community-based setting and compare our findings to those from another U.S. health system. MATERIALS AND METHODS: We identified 1,491 NMIBC patients with a median follow-up of 2.1 years (recurrence) and 4.1 years (progression). We calculated NCCN risk groupings and EORTC prognostic index for recurrence and progression. We followed Royston and Altman's guidelines for the external validation of prognostic calculators. RESULTS: For predicting recurrence using the EORTC framework, Harrell's C (a measure of discrimination) was smaller in our sample (0.66) than in the European Association of Urology sample (0.61), whereas for progression, Harrell's C was larger in our sample (0.78 vs. 0.75). The EORTC calculator overestimated progression risk in the highest stratum for our sample; calibration and discrimination were adequate for all groups except the highest risk group. For NCCN risk groupings, Harrell's C was 0.54 for recurrence and 0.62 for progression, suggesting poor to fair discrimination in our sample. The NCCN framework had slightly better performance for predicting progression vs. recurrence. CONCLUSIONS: Existing NMIBC risk-stratification frameworks have acceptable accuracy to predict outcomes. However, further innovation in NMIBC care will require predictive tools with more granularity to reflect the differential risks of subgroups of NMIBC recurrence, prior treatment histories, and other prognostic variables. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Leo, Michael C AU - Leo MC AD - Center for Health Research-Kaiser Permanente Northwest, Portland, OR. Electronic address: Michael.C.Leo@kpchr.org. FAU - McMullen, Carmit K AU - McMullen CK AD - Center for Health Research-Kaiser Permanente Northwest, Portland, OR. FAU - O'Keeffe-Rosetti, Maureen AU - O'Keeffe-Rosetti M AD - Center for Health Research-Kaiser Permanente Northwest, Portland, OR. FAU - Weinmann, Sheila AU - Weinmann S AD - Center for Health Research-Kaiser Permanente Northwest, Portland, OR. FAU - Garg, Tullika AU - Garg T AD - Departments of Urology, Epidemiology and Health Services Research-Geisinger, Danville, PA. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Center for Health Research-Kaiser Permanente Northwest, Portland, OR; Departments of Urology, Epidemiology and Health Policy and Management-University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. LA - eng GR - R21 CA191610/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20191109 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Prognosis MH - Public Health/*standards MH - Reproducibility of Results MH - Risk Assessment MH - Risk Factors MH - United States MH - Urinary Bladder Neoplasms/*epidemiology OTO - NOTNLM OT - Practice guidelines as topic OT - Risk assessment OT - Urinary bladder neoplasms EDAT- 2019/11/13 06:00 MHDA- 2021/04/15 06:00 CRDT- 2019/11/13 06:00 PHST- 2019/04/30 00:00 [received] PHST- 2019/09/18 00:00 [revised] PHST- 2019/10/02 00:00 [accepted] PHST- 2019/11/13 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2019/11/13 06:00 [entrez] AID - S1078-1439(19)30404-1 [pii] AID - 10.1016/j.urolonc.2019.10.003 [doi] PST - ppublish SO - Urol Oncol. 2020 Feb;38(2):39.e21-39.e27. doi: 10.1016/j.urolonc.2019.10.003. Epub 2019 Nov 9. PMID- 31704141 OWN - NLM STAT- MEDLINE DCOM- 20210506 LR - 20210506 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 5 DP - 2020 May TI - Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? PG - 440-448 LID - S1078-1439(19)30401-6 [pii] LID - 10.1016/j.urolonc.2019.10.002 [doi] AB - BACKGROUND: Papillary urothelial neoplasm of low malignant potential (PUN-LMP) was introduced as a noninvasive, noncancerous lesion and a separate grade category in 1998. Subsequently, PUN-LMP was reconfirmed by World Health Organization (WHO) 2004 and WHO 2016 classifications for urothelial bladder tumors. OBJECTIVES: To analyze the proportion of PUN-LMP diagnosis over time and to determine its prognostic value compared to Ta-LG (low-grade) and Ta-HG (high-grade) carcinomas. To assess the intraobserver variability of an experienced uropathologist assigning (WHO) 2004/2016 grades at 2 time points. MATERIALS AND METHODS: Individual patient data of 3,311 primary Ta bladder tumors from 17 hospitals in Europe and Canada were available. Transurethral resection of the tumor was performed between 1990 and 2018. Time to recurrence and progression were analyzed with cumulative incidence functions, log-rank tests and multivariable Cox-regression stratified by institution. Intraobserver variability was assessed by examining the same 314 transurethral resection of the tumorslides twice, in 2004 and again in 2018. RESULTS: PUN-LMP represented 3.8% (127/3,311) of Ta tumors. The same pathologist found 71/314 (22.6%) PUN-LMPs in 2004 and only 20/314 (6.4%) in 2018. Overall, the proportion of PUN-LMP diagnosis substantially decreased over time from 31.3% (1990-2000) to 3.2% (2000-2010) and to 1.1% (2010-2018). We found no difference in time to recurrence between the three WHO 2004/2016 Ta-grade categories (log-rank, P = 0.381), nor for LG vs. PUN-LMP (log-rank, P = 0.238). Time to progression was different for all grade categories (log-rank, P < 0.001), but not between LG and PUN-LMP (log-rank, P = 0.096). Multivariable analyses on recurrence and progression showed similar results for all 3 grade categories and for LG vs. PUN-LMP. CONCLUSIONS: The proportion of PUN-LMP has decreased to very low levels in the last decade. Contrary to its reconfirmation in the WHO 2016 classification, our results do not support the continued use of PUN-LMP as a separate grade category in Ta tumors because of the similar prognosis for PUN-LMP and Ta-LG carcinomas. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Hentschel, Anouk E AU - Hentschel AE AD - Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: basvanrhijn@hotmail.com. FAU - Brundl, Johannes AU - Brundl J AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - Pathology, Tenon Hospital, AP-HP, UPMC Paris VI, Sorbonne University, Paris, France. FAU - Plass, Karin AU - Plass K AD - EAU Guidelines Office Board, European Association of Urology, Arnhem, the Netherlands. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Henriquez, Jose D Subiela AU - Henriquez JDS AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - de la Pena, Enrique AU - de la Pena E AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Alemany, Isabel AU - Alemany I AD - Pathology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Turturica, Diana AU - Turturica D AD - Urology Clinic, Citta' della Salute e della Scienza, University of Studies of Torino, Torino, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain; Urology Clinic, Citta' della Salute e della Scienza, University of Studies of Torino, Torino, Italy. FAU - Soria, Francesco AU - Soria F AD - Urology Clinic, Citta' della Salute e della Scienza, University of Studies of Torino, Torino, Italy. FAU - Capoun, Otakar AU - Capoun O AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bauerova, Lenka AU - Bauerova L AD - Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Pesl, Michael AU - Pesl M AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Bruins, H Max AU - Bruins HM AD - Urology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Runneboom, Willemien AU - Runneboom W AD - Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Herdegen, Sonja AU - Herdegen S AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Urology,Teaching Hospital Motol, Prague, Czech Republic. FAU - Scavarda-Lamberti, Andrea AU - Scavarda-Lamberti A AD - Pathology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Calatrava, Ana AU - Calatrava A AD - Pathology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Rubio-Briones, Jose AU - Rubio-Briones J AD - Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Seles, Maximilian AU - Seles M AD - Urology, Medical University of Graz, Graz, Austria. FAU - Mannweiler, Sebastian AU - Mannweiler S AD - Pathology, Medical University of Graz, Graz, Austria. FAU - Bosschieter, Judith AU - Bosschieter J AD - Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. FAU - Kusuma, Venkata R M AU - Kusuma VRM AD - Urology, Royal Surrey County Hospital-NHS Foundation Trust, Guildford, Surrey, United Kingdom. FAU - Ashabere, David AU - Ashabere D AD - Urology, Royal Surrey County Hospital-NHS Foundation Trust, Guildford, Surrey, United Kingdom. FAU - Huebner, Nicolai AU - Huebner N AD - Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Cotte, Juliette AU - Cotte J AD - Urology, Pitie Salpetriere Hospital, AP-HP, GRC n 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Mertens, Laura S AU - Mertens LS AD - Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Cohen, Daniel AU - Cohen D AD - Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, United Kingdom. FAU - Lunelli, Luca AU - Lunelli L AD - Urology, Tenon Hospital, AP-HP, UPMC Paris VI, Sorbonne University, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - Urology, Tenon Hospital, AP-HP, UPMC Paris VI, Sorbonne University, Paris, France. FAU - Sheikh, Soha El AU - Sheikh SE AD - Pathology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, United Kingdom. FAU - Volanis, Dimitrios AU - Volanis D AD - Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, United Kingdom. FAU - Cote, Jean-Francois AU - Cote JF AD - Pathology, Pitie Salpetriere Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Urology, Pitie Salpetriere Hospital, AP-HP, GRC n 5, ONCOTYPE-URO, Sorbonne University, Paris, France. FAU - Haitel, Andrea AU - Haitel A AD - Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Urology,Teaching Hospital Motol, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Urology, Royal Surrey County Hospital-NHS Foundation Trust, Guildford, Surrey, United Kingdom. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. FAU - Zigeuner, Richard AU - Zigeuner R AD - Urology, Medical University of Graz, Graz, Austria. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain. FAU - Hacek, Jaromir AU - Hacek J AD - Pathology, Teaching Hospital Motol, Prague, Czech Republic. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Burger, Maximilian AU - Burger M AD - Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Evert, Matthias AU - Evert M AD - Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Hulsbergen-van de Kaa, Christina A AU - Hulsbergen-van de Kaa CA AD - Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Urology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Soukup, Viktor AU - Soukup V AD - Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. FAU - Molinaro, Luca AU - Molinaro L AD - Pathology, Citta' della Salute e della Scienza, University of Studies of Torino, Torino, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Urology Clinic, Citta' della Salute e della Scienza, University of Studies of Torino, Torino, Italy. FAU - Llorente, Carlos AU - Llorente C AD - Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Algaba, Ferran AU - Algaba F AD - Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - N'Dow, James AU - N'Dow J AD - EAU Guidelines Office Board, European Association of Urology, Arnhem, the Netherlands. FAU - Babjuk, Marko AU - Babjuk M AD - Urology,Teaching Hospital Motol, Prague, Czech Republic; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EAU Guidelines Office Board, European Association of Urology, Arnhem, the Netherlands. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20191105 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Canada MH - Carcinoma, Papillary/*pathology MH - Carcinoma, Transitional Cell/*pathology MH - Europe MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Observer Variation MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Bladder OT - Cancer OT - Carcinomas OT - Grade OT - Nonmuscle-invasive OT - Urothelial OT - WHO EDAT- 2019/11/11 06:00 MHDA- 2021/05/07 06:00 CRDT- 2019/11/10 06:00 PHST- 2019/08/01 00:00 [received] PHST- 2019/09/23 00:00 [revised] PHST- 2019/10/02 00:00 [accepted] PHST- 2019/11/11 06:00 [pubmed] PHST- 2021/05/07 06:00 [medline] PHST- 2019/11/10 06:00 [entrez] AID - S1078-1439(19)30401-6 [pii] AID - 10.1016/j.urolonc.2019.10.002 [doi] PST - ppublish SO - Urol Oncol. 2020 May;38(5):440-448. doi: 10.1016/j.urolonc.2019.10.002. Epub 2019 Nov 5. PMID- 31702551 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 14 IP - 4 DP - 2020 Apr TI - Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. PG - 122-129 LID - 10.5489/cuaj.5945 [doi] AB - INTRODUCTION: Although radical cystectomy is considered the standard of care for muscle-invasive bladder cancer (MIBC), recent data has suggested comparable survival outcomes for bladder-sparing trimodality therapy (TMT). We conducted a retrospective, single-institution analysis of MIBC patients to evaluate the efficacy of TMT as an alternative, curative approach to surgical intervention. METHODS: We conducted a retrospective analysis of MIBC patients assessed by a multidisciplinary team at the Juravinski Cancer Centre from 2010-2016. Patients underwent transurethral resection of bladder tumor (TURBT) followed by radiotherapy with or without concurrent chemotherapy. Patients could receive neoadjuvant treatment. Clinical data and response rates were summarized, and overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. RESULTS: Our analytic cohort included 115 patients, of whom 53 underwent TMT and 62 underwent radiotherapy alone following TURBT. Median age at diagnosis was 79 years and median followup was 21 months. Complete response rates in those receiving TMT and radiation without chemotherapy were 84.4% and 66.7%, respectively. For TMT patients, three-year OS and DFS were 68.5% and 49.6%, respectively. Patients who received TMT had reduction in risk of mortality (hazard ratio [HR] 0.49; p=0.026) and disease recurrence (HR 0.55; p=0.017) compared to those who had radiation without chemotherapy. Overall, four patients had grade 3 or higher late toxicity. CONCLUSIONS: In this single-institution analysis, TMT appears to be a safe and effective approach in the short-term management of MIBC in appropriately selected patients. Extended followup and analysis are necessary to validate these results. FAU - Nguyen, Eric K AU - Nguyen EK AD - Division of Radiation Oncology, McMaster University, Hamilton, ON, Canada. FAU - Yu, Hang AU - Yu H AD - Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. FAU - Pond, Gregory AU - Pond G AD - Escarpment Cancer Research Institute, McMaster University, Hamilton, ON, Canada. FAU - Shayegan, Bobby AU - Shayegan B AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Pinthus, Jehonathan H AU - Pinthus JH AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Kapoor, Anil AU - Kapoor A AD - Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada. FAU - Mukherjee, Som D AU - Mukherjee SD AD - Division of Medical Oncology, McMaster University, Hamilton, ON, Canada. FAU - Neville, Alan AU - Neville A AD - Division of Medical Oncology, McMaster University, Hamilton, ON, Canada. FAU - Lalani, Aly-Khan A AU - Lalani AA AD - Division of Medical Oncology, McMaster University, Hamilton, ON, Canada. FAU - Hotte, Sebastien J AU - Hotte SJ AD - Division of Medical Oncology, McMaster University, Hamilton, ON, Canada. FAU - Corbett, Thomas B AU - Corbett TB AD - Division of Radiation Oncology, McMaster University, Hamilton, ON, Canada. FAU - Dayes, Ian S AU - Dayes IS AD - Division of Radiation Oncology, McMaster University, Hamilton, ON, Canada. FAU - Lukka, Himanshu R AU - Lukka HR AD - Division of Radiation Oncology, McMaster University, Hamilton, ON, Canada. LA - eng PT - Journal Article DEP - 20191105 PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC7124184 COIS- Competing interests: Dr. Pond has received honoraria from Takeda. Dr. Pinthus has been an advisory board member and speakers' bureau member for and received honoraria from Ferring. Dr. Kapoor has been an advisory board member for BMS, Eisai, Ipsen, Novartis, Pfizer, and Roche; and a speakers' bureau member for Novartis. Dr. Mukherjee has been a speakers' bureau member for AstraZeneca; has received honoraria from Amgen, AstraZeneca, Merck, Novartis, and Roche; and has participated in clinical trials supported by AstraZeneca and Roche. Dr. Lalani has received honoraria for ad hoc consultation or advisory board meetings from BMS, Eisai, Ipsen, Merck, Pfizer, Rocher and TerSera; and has participated in clinical trials (unrelated to this work) supported by Merck. Dr. Dayes has been an advisory board member for Abbvie and Astellas; and has participated in clinical trials supported by Bayer. Dr. Lukka has been a speakers' bureau member for and received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, and TerSera; has investments in Vertex Pharma; and has participated in clinical trials supported by Sanofi. The remaining authors report no competing personal or financial interests related to this work. EDAT- 2019/11/09 06:00 MHDA- 2019/11/09 06:01 PMCR- 2020/04/01 CRDT- 2019/11/09 06:00 PHST- 2019/11/09 06:00 [pubmed] PHST- 2019/11/09 06:01 [medline] PHST- 2019/11/09 06:00 [entrez] PHST- 2020/04/01 00:00 [pmc-release] AID - cuaj.5945 [pii] AID - cuaj-4-122 [pii] AID - 10.5489/cuaj.5945 [doi] PST - ppublish SO - Can Urol Assoc J. 2020 Apr;14(4):122-129. doi: 10.5489/cuaj.5945. Epub 2019 Nov 5. PMID- 31699526 OWN - NLM STAT- MEDLINE DCOM- 20210318 LR - 20210318 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 77 IP - 1 DP - 2020 Jan TI - Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. PG - 101-109 LID - S0302-2838(19)30757-2 [pii] LID - 10.1016/j.eururo.2019.09.029 [doi] AB - BACKGROUND: Vesical Imaging Reporting and Data System (VI-RADS) score is adopted to provide preoperative bladder cancer (BCa) staging. Repeated transurethral resection of bladder tumor (Re-TURBT) is recommended in most of high-risk non-muscle-invasive bladder cancers (HR-NMIBCs) due to possibility of persistent/understaged disease after initial TURBT. No diagnostic tools able to improve patient's stratification for such recommendation exist. OBJECTIVE: To (1) prospectively validate VI-RADS for discriminating between NMIBC and muscle-invasive bladder cancer (MIBC) at TURBT, and (2) evaluate the accuracy of VI-RADS for identifying HR-NMIBC patients who could avoid Re-TURBT and detecting those at higher risk for understaging after TURBT. DESIGN, SETTING, AND PARTICIPANTS: Patients with BCa suspicion were offered multiparametric magnetic resonance imaging (mpMRI) before TURBT. According to VI-RADS, a cutoff of >/=3 to define MIBC was assumed. TURBT reports were compared with preoperative VI-RADS scores to assess accuracy of mpMRI for discriminating between NMIBC and MIBC. HR-NMIBC Re-TURBT reports were compared with preoperatively recorded VI-RADS scores to assess mpMRI accuracy in predicting Re-TURBT outcomes. INTERVENTION: Multiparametric MRI of the bladder before TURBT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values were calculated for mpMRI performance in patients undergoing TURBT and for HR-NMIBC patients candidate for Re-TURBT. Performance of mpMRI was assessed by receiver operating characteristic curve analysis. K statistics was used to estimate inter- and intrareader variability. RESULTS AND LIMITATIONS: A total of 231 patients were enrolled. Multiparametric MRI showed sensitivity, specificity, PPV, and NPV for discriminating NMIBC from MIBC at initial TURBT of 91.9% (95% confidence interval [CI]: 82.2-97.3), 91.1% (95% CI: 85.8-94.9), 77.5% (95% CI: 65.8-86.7), and 97.1% (95% CI: 93.3-99.1), respectively. The area under the curve (AUC) was 0.94 (95% CI: 0.91-0.97). Among HR-NMIBC patients (n=114), mpMRI before TURBT showed sensitivity, specificity, PPV, and NPV of 85% (95% CI: 62.1-96.8), 93.6% (95% CI: 86.6-97.6), 74.5% (95% CI: 52.4-90.1), and 96.6% (95% CI: 90.5-99.3) respectively, to identify patients with MIBC at Re-TURBT. The AUC was 0.93 (95% CI: 0.87-0.97). CONCLUSIONS: VI-RADS is accurate for discriminating between NMIBC and MIBC. Within HR-NMIBC cases, VI-RADS could, in future, improve the selection of patients who are candidate for Re-TURBT. PATIENT SUMMARY: We investigated the accuracy of Vesical Imaging Reporting and Data System (VI-RADS) score to asses bladder cancer staging before transurethral resection of bladder tumors, and we explored the performance of VI-RADS score as a future preoperative predictive tool for the selection of high-risk non-muscle-invasive bladder cancer patients who are candidate for undergoing early repeated transurethral resection of the primary tumor site. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Maternal-Child and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Barchetti, Giovanni AU - Barchetti G AD - Department of Radiological, Oncological and Anatomopathological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Maternal-Child and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Pecoraro, Martina AU - Pecoraro M AD - Department of Radiological, Oncological and Anatomopathological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Salvo, Vincenzo AU - Salvo V AD - Department of Radiological, Oncological and Anatomopathological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Simone, Giuseppe AU - Simone G AD - Department of Urology, "Regina Elena" National Cancer Institute, IRCCS, Rome, Italy. FAU - Sciarra, Alessandro AU - Sciarra A AD - Department of Maternal-Child and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Leonardo, Costantino AU - Leonardo C AD - Department of Maternal-Child and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Gallucci, Michele AU - Gallucci M AD - Department of Maternal-Child and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Catalano, Carlo AU - Catalano C AD - Department of Radiological, Oncological and Anatomopathological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Panebianco, Valeria AU - Panebianco V AD - Department of Radiological, Oncological and Anatomopathological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, Rome, Italy. Electronic address: valeria.panebianco@uniroma1.it. LA - eng PT - Journal Article PT - Validation Study DEP - 20191105 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2020 Apr;77(4):e93. doi: 10.1016/j.eururo.2020.01.017. PMID: 31980311 CIN - Eur Urol. 2020 Apr;77(4):e94-e95. doi: 10.1016/j.eururo.2020.01.020. PMID: 32005552 MH - Aged MH - Cystectomy/*methods MH - Diagnosis, Differential MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prospective Studies MH - Reoperation MH - Research Design/*standards MH - Risk Assessment MH - Urethra MH - Urinary Bladder Neoplasms/*diagnostic imaging/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - High-risk non-muscle-invasive bladder cancer OT - Multiparametric magnetic resonance imaging OT - Muscle-invasive bladder cancer OT - Repeated transurethral resection of bladder tumor OT - Transurethral resection of bladder tumor EDAT- 2019/11/09 06:00 MHDA- 2021/03/19 06:00 CRDT- 2019/11/09 06:00 PHST- 2019/07/02 00:00 [received] PHST- 2019/09/24 00:00 [accepted] PHST- 2019/11/09 06:00 [pubmed] PHST- 2021/03/19 06:00 [medline] PHST- 2019/11/09 06:00 [entrez] AID - S0302-2838(19)30757-2 [pii] AID - 10.1016/j.eururo.2019.09.029 [doi] PST - ppublish SO - Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5. PMID- 31693454 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20221207 IS - 1945-0257 (Electronic) IS - 1945-0257 (Linking) VI - 23 IP - 11 DP - 2019 Nov TI - Prognostic Significance of Murine Double Minute 2 Expression in Tumor Cells in Upper Tract Urothelial Carcinoma: An Analysis of 341 Cases in a Large Chinese Center. PG - 797-806 LID - 10.1089/gtmb.2019.0126 [doi] AB - Aims: The prognostic significance of murine double minute 2 (MDM2) expression remains unknown in patients with upper tract urothelial carcinoma (UTUC). This study was designed to evaluate MDM2 expression and its association with clinicopathological characteristics and tumor outcomes in UTUC patients. Materials and Methods: Expression levels of MDM2 and p53 were determined by immunohistochemistry in a cohort of 341 UTUC patients. Associations of MDM2 and p53 expression levels with clinicopathological characteristics, disease-free survival (DFS), cancer-specific survival (CSS), and intravesical recurrence-free survival (IVRFS) were analyzed. Results: Nuclear expression of MDM2 and p53 were detected in the tumor cells of 129 (37.8%) and 203 (59.5%) patients, respectively. Decreased p53 expression was associated with positive MDM2 staining in tumor cells (p = 0.002). MDM2 expression was correlated with the exposure to aristolochic acids (p = 0.020), better preoperative renal function (p = 0.016), ureter location (p = 0.002), higher pathological T stage (p = 0.006), high tumor grade (p < 0.001), presence of glandular differentiation (p = 0.036), and sarcoma differentiation (p = 0.020). Kaplan-Meier analysis showed that positive MDM2 staining was associated with shorter CSS (p < 0.001), DFS (p < 0.001), and IVRFS (p = 0.020); MDM2+/p53- was associated with shorter CSS (p < 0.001) and DFS (p < 0.001), but not IVRFS (p = 0.145); while CSS, DFS, and IVRFS did not differ significantly between the p53+ and p53- patients (p = 0.307, 0.089, and 0.198, respectively). Multivariate analyses revealed that MDM2 expression in tumor cells independently predicted shorter CSS (p < 0.001; hazard ratio [HR] = 2.600; 95% confidence interval [CI]: 1.625-4.161) and DFS (p < 0.001; HR = 1.863; 95% CI: 1.314-2.641), excepting IVRFS (p = 0.092; HR = 1.590; 95% CI: 0.928-2.726). Conclusions: UTUC patients with elevated MDM2 expression may exhibit more aggressive biological features of the tumor and tend to have shorter CSS and DFS. FAU - Bao, Zhengqing AU - Bao Z AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - He, Shiming AU - He S AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Guan, Bao AU - Guan B AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Yang, Xinyu AU - Yang X AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - He, Qun AU - He Q AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, Peking University, Beijing, China. AD - National Urological Cancer Centre, Beijing, China. AD - Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. LA - eng PT - Journal Article PL - United States TA - Genet Test Mol Biomarkers JT - Genetic testing and molecular biomarkers JID - 101494210 RN - EC 2.3.2.27 (MDM2 protein, human) RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Animals MH - Asian People/genetics MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Proto-Oncogene Proteins c-mdm2/*genetics/metabolism MH - Retrospective Studies MH - Transcriptome/genetics MH - Ureter/metabolism/physiopathology MH - Urologic Neoplasms/*genetics/metabolism OTO - NOTNLM OT - cancer-specific survival OT - disease-free survival OT - intravesical recurrence-free survival OT - murine double minute 2 OT - p53 OT - targeted therapy OT - upper tract urothelial carcinoma EDAT- 2019/11/07 06:00 MHDA- 2020/03/18 06:00 CRDT- 2019/11/07 06:00 PHST- 2019/11/07 06:00 [entrez] PHST- 2019/11/07 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] AID - 10.1089/gtmb.2019.0126 [doi] PST - ppublish SO - Genet Test Mol Biomarkers. 2019 Nov;23(11):797-806. doi: 10.1089/gtmb.2019.0126. PMID- 31692890 OWN - NLM STAT- MEDLINE DCOM- 20200326 LR - 20200326 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 60 IP - 6 DP - 2019 Nov TI - Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. PG - 432-442 LID - 10.4111/icu.2019.60.6.432 [doi] AB - PURPOSE: This study aimed to identify prognostic factors for outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: We retrospectively reviewed 184 nonmetastatic cases of UTUC after radical nephroureterectomy, bladder cuffing, and/or partial cystectomy (2004-2016). Bladder recurrence-free survival (BRFS), disease progression-free survival (DPFS), and cancer-specific survival (CSS) were estimated. The prognostic values of clinicopathologic parameters were evaluated by using Cox logistic regression analysis. RESULTS: The median BRFS, DPFS, and CSS values were 19.0 months, 38.5 months, and 67.0 months, respectively. We identified cases of bladder recurrence (64 cases, 34.8%), disease progression (54 cases, 29.3%), and cancer-specific death (23 cases, 12.5%). BRFS was independently associated with lymphovascular invasion (hazard ratio [HR], 0.421); DPFS was associated with intravesical instillation (HR, 0.290), active smoking (HR, 0.367), synchronous bladder lesions (HR, 2.355), and pT2 (HR, 5.199) and pT3 and pT4 (HR, 13.281) stages; and CSS was associated with alkaline phosphatase levels (HR, 0.966). Among 123 cases without previous bladder cancer, DPFS was associated with intravesical instillation (HR, 0.264), multifocal ureteral tumors (HR, 4.823), and pT3 and pT4 stages (HR, 10.899), whereas CSS was associated with pTis (HR, 32.071). CONCLUSIONS: Patients with the factors we identified should receive adjuvant intravesical/systemic chemotherapy and intensive surveillance. CI - (c) The Korean Urological Association, 2019. FAU - Kim, Sung Han AU - Kim SH AUID- ORCID: 0000-0002-1689-5203 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Song, Mi Kyung AU - Song MK AUID- ORCID: 0000-0003-3799-0426 AD - Biometrics Research Branch, Division of Cancer Epidemiology and Prevention, Research Institute and Hospital of National Cancer Center, Goyang, Korea. FAU - Joung, Jae Young AU - Joung JY AUID- ORCID: 0000-0003-2954-1663 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Chung, Jinsoo AU - Chung J AUID- ORCID: 0000-0003-2251-5331 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Lee, Kang Hyun AU - Lee KH AUID- ORCID: 0000-0003-0041-2243 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AUID- ORCID: 0000-0003-2601-1093 AD - Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191011 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kidney Neoplasms/*mortality/pathology/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - *Nephrectomy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Ureter/*surgery MH - Ureteral Neoplasms/*mortality/pathology/*surgery MH - Young Adult PMC - PMC6821986 OTO - NOTNLM OT - Nephroureterectomy OT - Prognosis OT - Risk factors OT - Survival OT - Ureteral neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2019/11/07 06:00 MHDA- 2020/03/27 06:00 PMCR- 2019/11/01 CRDT- 2019/11/07 06:00 PHST- 2019/04/09 00:00 [received] PHST- 2019/06/30 00:00 [accepted] PHST- 2019/11/07 06:00 [entrez] PHST- 2019/11/07 06:00 [pubmed] PHST- 2020/03/27 06:00 [medline] PHST- 2019/11/01 00:00 [pmc-release] AID - 10.4111/icu.2019.60.6.432 [doi] PST - ppublish SO - Investig Clin Urol. 2019 Nov;60(6):432-442. doi: 10.4111/icu.2019.60.6.432. Epub 2019 Oct 11. PMID- 31689813 OWN - NLM STAT- MEDLINE DCOM- 20191114 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 44 DP - 2019 Nov TI - Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases. PG - e17725 LID - 10.1097/MD.0000000000017725 [doi] LID - e17725 AB - Bladder cancer (BC) is a common malignancy associated with high morbidity and mortality, however, accurate and convenient risk assessment tools applicable to BC patients are currently lacking. Previous studies using nomograms to evaluate bladder cancer (BC) survival have been based on small samples. Using a large dataset, this study aimed to construct more precise clinical nomograms to effectively predict bladder cancer survival.Data on patients with pathologically-confirmed bladder cancer were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Additional BC patient data for an external validation cohort were extracted from the Cancer Genome Atlas (TCGA) database. Clinical parameters that constituted potential risk factors were reviewed and analyzed using univariate and multivariate Cox proportional hazards regression. A nomogram was constructed with parameters that significantly correlated with the overall survival (OS). Prognostic performance of a nomogram was assessed using the concordance index (c-index), area under the receiver operating characteristic curve (AUC), and a calibration curve. The model was then tested with data from an internal and external validation cohort. Patients' survival was analyzed and compared with the Kaplan-Meier (KM) method.Multivariate Cox regression showed that age, sex, race, stage_T1, stage_T2a, stage_T2b, stage_T3a, stage_Ta, stage_Tis, stage_N, stage_M were independent predictors of BC survival. A nomogram was constructed based on these factors. The c-index of the nomogram was 0.7916 (95% confidence interval CI, 0.79-0.80). The calibration curve showed excellent agreement between the predicted and observed values. The c-index for the internal validation cohort was 0.7917 (95% CI 0.79-0.80), which was higher than for the training cohort, suggesting robustness of the model. For the training cohort, the AUC for the 3- and the 5-year survival was 0.82 and 0.813, respectively. The c-index for the TNM-based model was superior to that for the AJCC-TNM classification.The models presented in this study might be suitable for clinical use, supporting clinicians in their individualized assessment of expected survival in BC patients. They might also be used as a layered tool for clinical research. FAU - Zhang, Ye AU - Zhang Y AD - Department of Urology, the First affiliated hospital of Medical College Shantou University, 57 Changping Road, Shantou, Guangdong, China. FAU - Hong, Ying-Kai AU - Hong YK FAU - Zhuang, Dong-Wu AU - Zhuang DW FAU - He, Xue-Jun AU - He XJ FAU - Lin, Ming-En AU - Lin ME LA - eng PT - Journal Article PT - Validation Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Aged MH - Aged, 80 and over MH - Area Under Curve MH - Databases, Factual MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Nomograms MH - Prognosis MH - Proportional Hazards Models MH - ROC Curve MH - Regression Analysis MH - Reproducibility of Results MH - Risk Assessment MH - Risk Factors MH - SEER Program MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology PMC - PMC6946294 COIS- The authors report no conflicts of interest EDAT- 2019/11/07 06:00 MHDA- 2019/11/15 06:00 PMCR- 2019/11/01 CRDT- 2019/11/07 06:00 PHST- 2019/11/07 06:00 [entrez] PHST- 2019/11/07 06:00 [pubmed] PHST- 2019/11/15 06:00 [medline] PHST- 2019/11/01 00:00 [pmc-release] AID - 00005792-201911010-00073 [pii] AID - MD-D-19-05227 [pii] AID - 10.1097/MD.0000000000017725 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Nov;98(44):e17725. doi: 10.1097/MD.0000000000017725. PMID- 31685109 OWN - NLM STAT- MEDLINE DCOM- 20201014 LR - 20201014 IS - 1558-349X (Electronic) IS - 1546-1440 (Linking) VI - 16 IP - 11S DP - 2019 Nov TI - ACR Appropriateness Criteria(R) Post-Treatment Surveillance of Bladder Cancer. PG - S417-S427 LID - S1546-1440(19)30616-7 [pii] LID - 10.1016/j.jacr.2019.05.026 [doi] AB - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: (1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; (2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and (3) muscle invasive bladder cancer. This article is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. CI - Copyright (c) 2019 American College of Radiology. Published by Elsevier Inc. All rights reserved. CN - Expert Panel on Urologic Imaging FAU - Allen, Brian C AU - Allen BC AD - Panel Vice-Chair, Duke University Medical Center, Durham, North Carolina. Electronic address: brian.allen@duke.edu. FAU - Oto, Aytekin AU - Oto A AD - Panel Chair, University of Chicago, Chicago, Illinois. FAU - Akin, Oguz AU - Akin O AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Alexander, Lauren F AU - Alexander LF AD - Mayo Clinic, Jacksonville, Florida. FAU - Chong, Jaron AU - Chong J AD - McGill University, Montreal, Quebec, Canada. FAU - Froemming, Adam T AU - Froemming AT AD - Mayo Clinic, Rochester, Minnesota. FAU - Fulgham, Pat F AU - Fulgham PF AD - Urology Clinics of North Texas, Dallas, Texas, American Urological Association. FAU - Lloyd, Shane AU - Lloyd S AD - Huntsman Cancer Hospital, Salt Lake City, Utah. FAU - Maranchie, Jodi K AU - Maranchie JK AD - UPMC, Pittsburgh, Pennsylvania, American Urological Association. FAU - Mody, Rekha N AU - Mody RN AD - Cleveland Clinic, Cleveland, Ohio. FAU - Patel, Bhavik N AU - Patel BN AD - Stanford University Medical Center, Stanford, California. FAU - Schieda, Nicola AU - Schieda N AD - Ottawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada. FAU - Turkbey, Ismail B AU - Turkbey IB AD - National Institutes of Health, Bethesda, Maryland. FAU - Vapiwala, Neha AU - Vapiwala N AD - University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Venkatesan, Aradhana M AU - Venkatesan AM AD - The University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Wang, Carolyn L AU - Wang CL AD - University of Washington, Seattle Cancer Care Alliance, Seattle, Washington. FAU - Yoo, Don C AU - Yoo DC AD - Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, Rhode Island. FAU - Lockhart, Mark E AU - Lockhart ME AD - Specialty Chair, University of Alabama at Birmingham, Birmingham, Alabama. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Coll Radiol JT - Journal of the American College of Radiology : JACR JID - 101190326 SB - IM MH - Carcinoma, Transitional Cell/*diagnostic imaging/pathology/surgery MH - Cystectomy/methods MH - Cystography/methods MH - Cystoscopy/methods MH - Diagnostic Imaging/*methods MH - Evidence-Based Medicine MH - Female MH - Humans MH - Magnetic Resonance Imaging/methods MH - Male MH - Monitoring, Physiologic MH - Neoplasm Grading MH - Neoplasm Invasiveness/pathology MH - *Practice Guidelines as Topic MH - Prognosis MH - Quality Control MH - Radiology/standards MH - Sensitivity and Specificity MH - Societies, Medical/standards MH - Tomography, X-Ray Computed/methods MH - United States MH - Urinary Bladder Neoplasms/*diagnostic imaging/pathology/surgery OTO - NOTNLM OT - AUC OT - Appropriate Use Criteria OT - Appropriateness Criteria OT - Bladder cancer OT - Muscle invasive bladder cancer OT - Nonmuscle invasive bladder cancer OT - Surveillance OT - Transitional cell carcinoma OT - Urothelial cancer EDAT- 2019/11/07 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/11/06 06:00 PHST- 2019/05/16 00:00 [received] PHST- 2019/05/16 00:00 [accepted] PHST- 2019/11/06 06:00 [entrez] PHST- 2019/11/07 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] AID - S1546-1440(19)30616-7 [pii] AID - 10.1016/j.jacr.2019.05.026 [doi] PST - ppublish SO - J Am Coll Radiol. 2019 Nov;16(11S):S417-S427. doi: 10.1016/j.jacr.2019.05.026. PMID- 31683460 OWN - NLM STAT- MEDLINE DCOM- 20200608 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 27 IP - 1 DP - 2020 TI - Evaluating prognostic utility of preoperative Neutrophil to Lymphocyte Ratio and hsa-let-7g/c up-regulation in patients with urinary bladder cancer. PG - 63-73 LID - 10.3233/CBM-190483 [doi] AB - BACKGROUND: Stratification and risk-evaluation of bladder cancer (BCa) patients are far-reached issues, especially for those with non muscle invasive disease. Thus, setting-up biomarkers, especially after resection of the primary tumor, is crucial. Specifically, Neutrophil to lymphocyte ratio NLR and let-7 deregulation which have been preliminarily but not consistently described to be associated to unfavorable prognosis. OBJECTIVE: To explore the clinical value of pre-treatment Neutrophil to Lymphocyte Ratio (NLR), let-7c and let-7g's deregulation. METHODS: Data were extracted from ninety BCa samples. Pre-treatment NLR was estimated as the absolute neutrophil count divided by the absolute lymphocyte count. Expression patterns of let-7c and let-7g were assessed by qRT-PCR. Correlation with clinical characteristics was performed by descriptive statistics. RESULTS: Both let-7 miRs were upregulated. Interestingly, let-7g was associated to pathological stage (p= 0.001) and tumor multiplicity (p= 0.003). NLR was associated to histological grade (p= 0.005) and clinical stage (p= 0.006). They were both associated to more aggressive phenotype and their worth as potential stratification biomarkers was confirmed by ROC curve. CONCLUSIONS: Our data demonstrated the potential clinical value of all markers, especially pretreatment NLR and let-7g. Further studies are recommended to confirm their utility in improving the clinical decision-making regarding treatment and follow-up scheduling. FAU - Boubaker, Nouha Setti AU - Boubaker NS AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Gurtner, Aymone AU - Gurtner A AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Trabelsi, Nesrine AU - Trabelsi N AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. FAU - Manni, Isabella AU - Manni I AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Said, Rahma AU - Said R AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. FAU - Ayed, Haroun AU - Ayed H AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Ksentini, Meriem AU - Ksentini M AD - Pathology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Karray, Omar AU - Karray O AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Saadi, Ahmed AU - Saadi A AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Essid, Mohamed Ali AU - Essid MA AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Blel, Ahlem AU - Blel A AD - Pathology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AD - Pathology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Chebil, Mohamed AU - Chebil M AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Piaggio, Giulia AU - Piaggio G AD - UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. FAU - Ouerhani, Slah AU - Ouerhani S AD - Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (mirnlet7 microRNA, human) SB - IM MH - Aged MH - Biomarkers, Tumor/*blood/genetics MH - Blood Cell Count MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Lymphocytes/pathology MH - Male MH - MicroRNAs/*blood/genetics MH - Neutrophils/pathology MH - Preoperative Period MH - *Prognosis MH - Urinary Bladder Neoplasms/*blood/genetics/pathology PMC - PMC12662266 OTO - NOTNLM OT - NLR OT - Urinary bladder OT - biomarkers OT - let-7 OT - neoplasms OT - stratification COIS- The authors declare there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2019/11/07 06:00 MHDA- 2020/06/09 06:00 PMCR- 2019/12/30 CRDT- 2019/11/06 06:00 PHST- 2019/11/07 06:00 [pubmed] PHST- 2020/06/09 06:00 [medline] PHST- 2019/11/06 06:00 [entrez] PHST- 2019/12/30 00:00 [pmc-release] AID - CBM190483 [pii] AID - 10.3233/CBM-190483 [doi] PST - ppublish SO - Cancer Biomark. 2020;27(1):63-73. doi: 10.3233/CBM-190483. PMID- 31681611 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank. PG - 1082 LID - 10.3389/fonc.2019.01082 [doi] LID - 1082 AB - Introduction: Multiple studies have reported genetic associations with prognostic outcomes of urinary bladder cancer. However, the lack of replication of these associations prohibits establishing further evidence-based research directions. Moreover, there is a lack of independent bladder cancer patient samples that contain prognostic measures, making genetic replication analyses even more challenging. Materials and Methods: We have identified 1,534 eligible patients and used data on Hospital Episode Statistics in the UK Biobank to model variables of otherwise non-collected events on bladder cancer recurrence and progression. Data on survival was extracted from the Death Registry. We have used SNPTEST software to replicate previously reported genetic associations with bladder cancer recurrence (N = 69), progression (N = 23), survival (N = 53), and age at the time of diagnosis (N = 20). Results: Using our algorithm, we have identified 618 recurrence and 58 UBC progression events. In total, there were 209 deaths (106 UBC-specific). In replication analyses, eight SNPs have reached nominal statistical significance (p < 0.05). Rs2042329 (CWC27) for UBC recurrence; rs804256, rs4639, and rs804276 (in/close to NEIL2) for NMIBC recurrence; rs2293347 (EGFR) for UBC OS; rs3756712 (PDCD6) for NMIBC OS; rs2344673 (RGS5) for MIBC OS, and rs2297518 (NOS2) for UBC progression. However, none have remained significant after adjustments for multiple comparisons. Discussion: External replication in genetic epidemiology is an essential step to identify credible findings. In our study, we identify potential genetic targets of higher interest for UBC prognosis. In addition, we propose an algorithm for identifying UBC recurrence and progression using routinely-collected data on patient interventions. CI - Copyright (c) 2019 Lipunova, Wesselius, Cheng, van Schooten, Cazier, Bryan and Zeegers. FAU - Lipunova, Nadezda AU - Lipunova N AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. AD - Department of Complex Genetics, Maastricht University, Maastricht, Netherlands. AD - Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom. FAU - Wesselius, Anke AU - Wesselius A AD - Department of Complex Genetics, Maastricht University, Maastricht, Netherlands. FAU - Cheng, Kar K AU - Cheng KK AD - Institute for Applied Health Research, University of Birmingham, Birmingham, United Kingdom. FAU - van Schooten, Frederik J AU - van Schooten FJ AD - Department of Pharmacology and Toxicology, Maastricht University, Maastricht, Netherlands. FAU - Cazier, Jean-Baptiste AU - Cazier JB AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. AD - Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. AD - Department of Complex Genetics, Maastricht University, Maastricht, Netherlands. LA - eng GR - MC_PC_17228/MRC_/Medical Research Council/United Kingdom GR - MC_QA137853/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20191018 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6813571 OTO - NOTNLM OT - SNP OT - UK Biobank OT - bladder cancer OT - prognosis OT - replication EDAT- 2019/11/05 06:00 MHDA- 2019/11/05 06:01 PMCR- 2019/01/01 CRDT- 2019/11/05 06:00 PHST- 2019/07/31 00:00 [received] PHST- 2019/10/01 00:00 [accepted] PHST- 2019/11/05 06:00 [entrez] PHST- 2019/11/05 06:00 [pubmed] PHST- 2019/11/05 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.01082 [doi] PST - epublish SO - Front Oncol. 2019 Oct 18;9:1082. doi: 10.3389/fonc.2019.01082. eCollection 2019. PMID- 31668714 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20260924 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 3 IP - 2 DP - 2020 Apr TI - A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. PG - 239-249 LID - S2588-9311(19)30151-8 [pii] LID - 10.1016/j.euo.2019.09.008 [doi] AB - CONTEXT: The complexity of bladder cancer diagnosis and staging results in delays in definitive treatment of muscle-invasive bladder cancer by radical cystectomy. OBJECTIVE: This systematic review and meta-analyses aim to assess the impact of delays in radical cystectomy. EVIDENCE ACQUISITION: A systematic review was conducted by searching Medline and Ovid Gateway using protocol-driven search terms in August 2019, with no time limit on the studies included. The identified studies were assessed according to strict criteria and using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist and Risk of Bias in Non-randomised Studies-of Interventions (ROBINS-I) tool. Meta-analyses were conducted based on the type of delay. Random-effect models were used whereby the presence of a delay was the exposure variable and overall survival was the outcome of interest, for which pooled hazard ratios were calculated. EVIDENCE SYNTHESIS: Nineteen studies were eligible for inclusion (17 532 patients), of which 10 were included in the meta-analyses. A longer delay between bladder cancer diagnosis and radical cystectomy resulted in a pooled hazard ratio of 1.34 (95% confidence interval [CI]: 1.18-1.53) for overall death. For a delay between transurethral resection and cystectomy, we found a pooled hazard ratio of 1.18 (95% CI: 0.99-1.41) for overall death. A pooled hazard ratio of 1.04 (95% CI: 0.93-1.16) was calculated for a longer delay between neoadjuvant chemotherapy and radical cystectomy. CONCLUSIONS: A delay in radical cystectomy after diagnosis was found to have a significantly detrimental effect on overall survival for bladder cancer patients. However, there was huge heterogeneity in how a delay was defined. PATIENT SUMMARY: In this review, we investigated the effect of a delay in radical treatment on survival. This review highlights the importance of scheduling radical cystectomies in a timely manner whilst monitoring factors such as comorbidities and scheduling, in order to treat patients requiring radical cystectomy without delay. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Russell, Beth AU - Russell B AD - Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. Electronic address: beth.russell@kcl.ac.uk. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden; Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Malde, Sachin AU - Malde S AD - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Kumar, Pardeep AU - Kumar P AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Van Hemelrijck, Mieke AU - Van Hemelrijck M AD - Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20191023 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM CIN - Eur Urol Oncol. 2020 Apr;3(2):250-251. doi: 10.1016/j.euo.2020.01.004. PMID: 32037303 MH - Humans MH - *Cystectomy/methods MH - Survival Analysis MH - *Urinary Bladder Neoplasms/mortality/surgery MH - Observational Studies as Topic OTO - NOTNLM OT - Bladder cancer OT - Delay OT - Radical cystectomy OT - Survival EDAT- 2019/11/02 06:00 MHDA- 2020/12/15 06:00 CRDT- 2019/11/01 06:00 PHST- 2019/07/16 00:00 [received] PHST- 2019/09/05 00:00 [revised] PHST- 2019/09/27 00:00 [accepted] PHST- 2019/11/02 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2019/11/01 06:00 [entrez] AID - S2588-9311(19)30151-8 [pii] AID - 10.1016/j.euo.2019.09.008 [doi] PST - ppublish SO - Eur Urol Oncol. 2020 Apr;3(2):239-249. doi: 10.1016/j.euo.2019.09.008. Epub 2019 Oct 23. PMID- 31657881 OWN - NLM STAT- MEDLINE DCOM- 20210510 LR - 20210510 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 24 IP - 1 DP - 2020 Jan TI - An EMT-related gene signature for the prognosis of human bladder cancer. PG - 605-617 LID - 10.1111/jcmm.14767 [doi] AB - The transition from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial-mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT-related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease-free survival (DFS) than those with low risk scores. The EMT-related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT-related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT-related gene signature that has tumour-promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA. CI - (c) 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Cao, Rui AU - Cao R AUID- ORCID: 0000-0001-7757-7615 AD - Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. FAU - Yuan, Lushun AU - Yuan L AD - Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands. FAU - Ma, Bo AU - Ma B AD - Department of Stomatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. FAU - Wang, Gang AU - Wang G AD - Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Qiu, Wei AU - Qiu W AD - Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. FAU - Tian, Ye AU - Tian Y AUID- ORCID: 0000-0003-1290-2223 AD - Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191028 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*genetics MH - *Epithelial-Mesenchymal Transition MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - *Nomograms MH - Prognosis MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/genetics/*pathology/therapy PMC - PMC6933372 OTO - NOTNLM OT - Cox OT - EMT OT - GEO OT - LASSO OT - TCGA OT - bladder cancer OT - signature COIS- The authors declare that they have no competing interests. EDAT- 2019/10/29 06:00 MHDA- 2021/05/11 06:00 PMCR- 2020/01/01 CRDT- 2019/10/29 06:00 PHST- 2019/06/27 00:00 [received] PHST- 2019/09/06 00:00 [revised] PHST- 2019/09/23 00:00 [accepted] PHST- 2019/10/29 06:00 [pubmed] PHST- 2021/05/11 06:00 [medline] PHST- 2019/10/29 06:00 [entrez] PHST- 2020/01/01 00:00 [pmc-release] AID - JCMM14767 [pii] AID - 10.1111/jcmm.14767 [doi] PST - ppublish SO - J Cell Mol Med. 2020 Jan;24(1):605-617. doi: 10.1111/jcmm.14767. Epub 2019 Oct 28. PMID- 31654221 OWN - NLM STAT- MEDLINE DCOM- 20210408 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 8 DP - 2020 Aug TI - Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma. PG - 1969-1975 LID - 10.1007/s00345-019-02985-3 [doi] AB - PURPOSE: To develop and validate a prognostic nomogram for patients with intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for non-metastatic upper tract urothelial carcinoma (UTUC). METHODS: The clinical data of 468 patients registered in the surveillance, epidemiology and end results database between 2010 and 2015 were retrospectively analyzed. Multivariate analysis using the Cox proportional hazard model was used to determine independent prognostic factors for the development of a nomogram to predict the 1-, 3-, and 5-year probability of individual cancer-specific survival (CSS). Moreover, the nomogram was internally validated using receiver operating characteristic curves and calibration plots. RESULTS: Age at IVR > 80 years, UTUC stage >/= T3, bladder cancer (BC) stage T1, and muscle-invasive BC (stage >/= T2) were identified as independent risk factors for CSS in patients with IVR after RNU, whereas a time interval of > 24 months between UTUC and BC was an independent protective factor. The 1-, 3-, and 5-year predictive accuracies of our nomogram were 0.74, 0.70, and 0.71, respectively. Additionally, 1-, 3-, and 5-year calibration curves demonstrated perfect agreement between the nomogram-predicted and the actual CSS. CONCLUSIONS: This study developed and internally validated the first nomogram to date to predict individual prognosis in patients with IVR after RUN for UTUC. This nomogram can be used for patient counseling and for designing clinical trials. FAU - Hou, Guangdong AU - Hou G AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Zheng, Yu AU - Zheng Y AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Lai, Dong AU - Lai D AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Wang, Fuli AU - Wang F AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Li, Xi'an AU - Li X AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Yan, Fei AU - Yan F AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Tian, Jingyang AU - Tian J AD - Department of Otorhinolaryngology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China. FAU - Zhang, Geng AU - Zhang G AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Meng, Ping AU - Meng P AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Wei, Di AU - Wei D AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Zhu, Zheng AU - Zhu Z AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Yuan, Jiarui AU - Yuan J AD - St. George's University School of Medicine, West Indies, Grenada. FAU - Hui, Qiang AU - Hui Q AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. FAU - Yuan, Jianlin AU - Yuan J AD - Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. jianliny@fmmu.edu.cn. LA - eng GR - 2014JM4184/the Natural Science Foundation Program of Shaanxi Province/ GR - 2017JM8128/the Natural Science Foundation Program of Shaanxi Province/ PT - Journal Article PT - Validation Study DEP - 20191025 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/*surgery MH - Male MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasms, Second Primary/*epidemiology MH - *Nephroureterectomy/methods MH - *Nomograms MH - Prognosis MH - Retrospective Studies MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder Neoplasms/*epidemiology OTO - NOTNLM OT - Intravesical recurrence OT - Nomogram OT - Prognosis OT - Upper tract urothelial carcinoma EDAT- 2019/10/28 06:00 MHDA- 2021/04/10 06:00 CRDT- 2019/10/27 06:00 PHST- 2019/05/25 00:00 [received] PHST- 2019/10/13 00:00 [accepted] PHST- 2019/10/28 06:00 [pubmed] PHST- 2021/04/10 06:00 [medline] PHST- 2019/10/27 06:00 [entrez] AID - 10.1007/s00345-019-02985-3 [pii] AID - 10.1007/s00345-019-02985-3 [doi] PST - ppublish SO - World J Urol. 2020 Aug;38(8):1969-1975. doi: 10.1007/s00345-019-02985-3. Epub 2019 Oct 25. PMID- 31646822 OWN - NLM STAT- MEDLINE DCOM- 20200304 LR - 20201226 IS - 2241-6293 (Electronic) IS - 1107-0625 (Linking) VI - 24 IP - 4 DP - 2019 Jul-Aug TI - Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter? PG - 1659-1665 AB - PURPOSE: To evaluate patients, diagnosed with non-muscle invasive bladder cancer, according to patient specific parameters including hemoglobin level, estimated glomerular filtration rate (eGFR), body mass index (BMI) and cigarette smoking and to identify if any of these parameters matters in terms of recurrence prediction. METHODS: 231 patients who have undergone transurethral resection of the bladder (TURB) between January 2015 and January 2018 and diagnosed with non-muscle invasive bladder cancer (NMIBC) were included. Patient demographic characteristics including age, sex, BMI and cigarette smoking were assessed. Hemoglobin, creatinine and eGFR values were recorded. Follow-up was performed according to the European Association of Urology (EAU) guidelines' recommendations. Recurrence and progression during follow-up were recorded. RESULTS: 231 patients were included in the study. Median patient BMI, Hb levels, and eGFR values were 26.51 kg/m2 (IQR 5.48), 14,2 g/dL (IQR 2.50), and 83.25 ml/min/1.73m2 (IQR 27.83), respectively. Among all patients, 105 (45%) were ex-smokers and 78 (33%) were current smokers, 41 had anemia (17.7%), 37 (16%) patients were obese; 104 (45%) had mildly impaired renal function and 34 (14.7%) had impaired renal function. During follow-up, 67 (29%) patients had disease recurrence and 21 (9.1%) had disease progression (9.1%). Univariate and multivariate analyses revealed significant relationship between recurrence and obesity, impaired renal function and cigarette smoking. CONCLUSIONS: Recurrence is a commonly encountered unfortunate consequence of NMIBC, and obesity, renal failure, history of smoking and anemia seem to increase the rate of recurrence among bladder cancer patients. FAU - Ucpinar, Burak AU - Ucpinar B AD - Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey. FAU - Erbin, Akif AU - Erbin A FAU - Ayranci, Ali AU - Ayranci A FAU - Caglar, Ufuk AU - Caglar U FAU - Alis, Deniz AU - Alis D FAU - Basal, Seref AU - Basal S FAU - Sarilar, Omer AU - Sarilar O FAU - Akbulut, Mehmet Fatih AU - Akbulut MF LA - eng PT - Journal Article PL - Cyprus TA - J BUON JT - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JID - 100883428 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/pathology/surgery MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*epidemiology/pathology/surgery MH - Neoplasm Staging MH - Risk Factors MH - Smoking/adverse effects MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*epidemiology/pathology/surgery EDAT- 2019/10/28 06:00 MHDA- 2020/03/05 06:00 CRDT- 2019/10/25 06:00 PHST- 2019/10/25 06:00 [entrez] PHST- 2019/10/28 06:00 [pubmed] PHST- 2020/03/05 06:00 [medline] PST - ppublish SO - J BUON. 2019 Jul-Aug;24(4):1659-1665. PMID- 31646091 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210112 IS - 2162-4011 (Print) IS - 2162-402X (Electronic) IS - 2162-4011 (Linking) VI - 8 IP - 11 DP - 2019 TI - Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. PG - e1644108 LID - 10.1080/2162402X.2019.1644108 [doi] LID - e1644108 AB - In patients with muscle invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) prior to radical cystectomy has improved survival but there is an urgent unmet need to identify prognostic and predictive biomarkers to stratify patients who will benefit from treatment. This study aimed to examine the composition of tumor-infiltrating immune cells in MIBC, with particular reference to the clinical outcome and the potential modifying effect of NAC. To this end, the expression of CD8(+) and FoxP3(+) T cells, CD20(+) B cells, PD-1(+) and PD-L1(+) immune cells and PD-L1(+) tumor cells was evaluated by immunohistochemistry on tissue microarrays with paired transurethral resection (TURB) specimens, cystectomy specimens and lymph node metastases from 145 patients, 65 of whom had received NAC. Kaplan-Meier and Cox regression analyses were applied to assess the impact of investigated cell subsets on time to recurrence (TTR). In cystectomy specimens, high infiltration of the investigated immune cell populations, but not PD-L1(+) tumor cells, were independently associated with a prolonged TTR, whereas in TURB specimens, this association was only seen for CD8(+) lymphocytes. An additive beneficial prognostic effect of NAC was seen for the majority of the cell subsets but there was no significant interaction between any immune marker and NAC in relation to TTR. Furthermore, no differences in cell densities prior to NAC treatment were observed between complete and non-complete responders, or pre- and posttreatment in non-complete responders. In conclusion, immune cell infiltration provides important prognostic information in both pre- and postsurgical samples of MIBC, independently of NAC. CI - (c) 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. FAU - Wahlin, Sara AU - Wahlin S AUID- ORCID: 0000-0002-7744-4975 AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund Sweden. FAU - Nodin, Bjorn AU - Nodin B AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund Sweden. FAU - Leandersson, Karin AU - Leandersson K AD - Cancer Immunology, Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Boman, Karolina AU - Boman K AUID- ORCID: 0000-0002-6204-9681 AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund Sweden. FAU - Jirstrom, Karin AU - Jirstrom K AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190803 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 PMC - PMC6791444 OTO - NOTNLM OT - Bladder cancer OT - immunotherapy OT - neoadjuvant chemotherapy OT - prognosis OT - tumor microenvironment EDAT- 2019/10/28 06:00 MHDA- 2019/10/28 06:01 PMCR- 2019/08/03 CRDT- 2019/10/25 06:00 PHST- 2019/05/15 00:00 [received] PHST- 2019/07/10 00:00 [revised] PHST- 2019/07/12 00:00 [accepted] PHST- 2019/10/25 06:00 [entrez] PHST- 2019/10/28 06:00 [pubmed] PHST- 2019/10/28 06:01 [medline] PHST- 2019/08/03 00:00 [pmc-release] AID - 1644108 [pii] AID - 10.1080/2162402X.2019.1644108 [doi] PST - epublish SO - Oncoimmunology. 2019 Aug 3;8(11):e1644108. doi: 10.1080/2162402X.2019.1644108. eCollection 2019. PMID- 31643022 OWN - NLM STAT- MEDLINE DCOM- 20210406 LR - 20261010 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 26 IP - 3 DP - 2020 Jul TI - Development and Validation of a Model for Predicting Intravesical Recurrence in Organ-confined Upper Urinary Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy: a Retrospective Study in One Center with Long-term Follow-up. PG - 1741-1748 LID - 10.1007/s12253-019-00748-4 [doi] AB - Although radical nephroureterectomy is the standard treatment method for upper urinary tract urothelial carcinoma, it is associated with a high risk of intravesical recurrence. There are no models for predicting IVR after RNU in patients with organ-confined UTUC. Therefore, we developed and validated a model for postoperative prediction of IVR after RNU. The development cohort consisted of 416 patients who underwent RNU with bladder cuff excision at our center between 1 January 2007 and 31 December 2015. Patient clinicopathologic data were recorded. Multivariate Cox proportional hazard ratio regression was used to build a predictive model with regression coefficients, backward step-wise selection was applied, and the likelihood ratio test with Akaike's information criterion was used as the stopping rule. An independent cohort consisting of 152 consecutive patients from 1 January 2016 and 31 December 2017 was used for validation. The performance of this predictive model was assessed with respect to discrimination, calibration, and clinical usefulness. The predictors in this model included tumor stage, tumor diameter, tumor location, and tumor grade. In the validation cohort, the model showed good discrimination, with a concordance index of 0.689 (95% CI, 0.629 to 0.748) and good calibration. Decision curve analysis demonstrated that the model was also clinically useful. This study presents a good model that may facilitate individualized postoperative prediction of IVR after RNU in patients with organ-confined UTUC, and thus, may help improve postoperative strategies and facilitate treatment outcomes. FAU - Zhang, Xuanyu AU - Zhang X AD - Department of Urology, ShengJing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China. FAU - Bu, Renge AU - Bu R AD - Department of Urology, ShengJing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China. FAU - Liu, Zeqi AU - Liu Z AD - Department of Urology, ShengJing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China. FAU - Wu, Bin AU - Wu B AD - Department of Urology, ShengJing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China. FAU - Bai, Song AU - Bai S AD - Department of Urology, ShengJing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China. baisongcmu@163.com. LA - eng GR - MC05/Shengjing Hospital Science and Technology Program/ PT - Journal Article PT - Validation Study DEP - 20191023 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 SB - IM MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Humans MH - Neoplasm Recurrence, Local/*epidemiology MH - Nephroureterectomy/methods MH - Retrospective Studies MH - Urologic Neoplasms/*pathology/surgery OTO - NOTNLM OT - Intravesical recurrence OT - Radical nephroureterectomy OT - Retrospective study OT - Upper urinary tract urothelial carcinoma EDAT- 2019/10/24 06:00 MHDA- 2021/04/07 06:00 CRDT- 2019/10/24 06:00 PHST- 2019/05/28 00:00 [received] PHST- 2019/09/03 00:00 [accepted] PHST- 2019/10/24 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2019/10/24 06:00 [entrez] AID - 10.1007/s12253-019-00748-4 [pii] AID - 10.1007/s12253-019-00748-4 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Jul;26(3):1741-1748. doi: 10.1007/s12253-019-00748-4. Epub 2019 Oct 23. PMID- 31635939 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 2 DP - 2020 Apr TI - Preoperative Pyuria Predicts for Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract After Radical Nephroureterectomy Without a History of Bladder Cancer. PG - e167-e173 LID - S1558-7673(19)30286-1 [pii] LID - 10.1016/j.clgc.2019.09.017 [doi] AB - BACKGROUND: We assessed preoperative pyuria as a significant predictor of intravesical recurrence (IVR) in patients with upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). PATIENTS AND METHODS: We evaluated the data from 268 patients with UTUC without a history of bladder cancer who had undergone RNU from 2006 to 2016 at 4 academic institutions. The associations between the clinical variables and the presence of pyuria were evaluated by univariate analysis. IVR was assessed using the Kaplan-Meier method and Cox regression analysis. RESULTS: The median postoperative follow-up of patients with IVR-free survival was 29.1 months (interquartile range, 15.4-55.3 months). The rate of IVR was significantly greater in the patients with than in those without pyuria (P = .025). Multivariate analysis showed that preoperative pyuria (hazard ratio [HR], 1.70; P = .007), a ureteral tumor site (HR, 1.64; P = .012), and positive surgical margins (HR, 2.70; P = .013) were associated with a significantly increased risk of IVR. A postoperative risk stratification model using these factors showed significant differences among the 3 subgroups of patients with low, intermediate, and high risk. The 5-year IVR-free survival rates for the patients with low, intermediate, and high risk were 69.1%, 51.8%, and 18.8%, respectively (P = .004). CONCLUSION: Preoperative pyuria, a ureteral tumor site, and positive surgical margins were associated with a significantly increased risk of IVR. Although external validation is required, the presence of preoperative pyuria could be a significant predictor of IVR in patients with UTUC after RNU. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Sato, Goro AU - Sato G AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan. FAU - Yoshida, Takashi AU - Yoshida T AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan; Department of Urology and Andrology, Kansai Medical University, Kori Hospital, Osaka, Japan. Electronic address: yoshidtk@takii.kmu.ac.jp. FAU - Yanishi, Masaaki AU - Yanishi M AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan. FAU - Murota, Takashi AU - Murota T AD - Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan. FAU - Kawa, Gen AU - Kawa G AD - Department of Urology, Saiseikai Noe Hospital, Osaka, Japan. FAU - Kinoshita, Hidefumi AU - Kinoshita H AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan. FAU - Matsuda, Tadashi AU - Matsuda T AD - Department of Urology and Andrology, Kansai Medical University Hospital, Osaka, Japan. LA - eng PT - Journal Article DEP - 20190927 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/secondary/surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney/pathology/surgery MH - Kidney Neoplasms/mortality/pathology/*surgery/urine MH - Male MH - Margins of Excision MH - *Nephroureterectomy MH - Preoperative Period MH - Proportional Hazards Models MH - Pyuria/*epidemiology MH - Regression Analysis MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Survival Rate MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/mortality/pathology/*surgery/urine MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*epidemiology/secondary/surgery/urine OTO - NOTNLM OT - Intravesical recurrence OT - Preoperative pyuria OT - Prognostic marker OT - Upper urinary tract OT - Urothelial carcinoma EDAT- 2019/10/23 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/10/23 06:00 PHST- 2019/06/28 00:00 [received] PHST- 2019/08/21 00:00 [revised] PHST- 2019/09/10 00:00 [accepted] PHST- 2019/10/23 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/10/23 06:00 [entrez] AID - S1558-7673(19)30286-1 [pii] AID - 10.1016/j.clgc.2019.09.017 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Apr;18(2):e167-e173. doi: 10.1016/j.clgc.2019.09.017. Epub 2019 Sep 27. PMID- 31632462 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220410 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 11 DP - 2019 Jan-Dec TI - Oct-4: a prognostic biomarker of urinary bladder cancer in North India. PG - 1756287219875576 LID - 10.1177/1756287219875576 [doi] LID - 1756287219875576 AB - BACKGROUND: The objective of this study was to evaluate Octamer-binding transcription factor 4 (Oct-4), neutrophil to lymphocyte ratio (NLR) and body mass index (BMI) as independent prognostic biomarkers for prediction of urinary bladder cancer (UBC) outcomes. With the advancement in prognostic biomarker discovery, tumor recurrence is difficult to accurately predict in UBC. UBC is costly to treat due to the requirement of frequent invasive follow-up sessions. Therefore, it is of utmost importance to evaluate good prognostic biomarkers for UBC surveillance. METHODS: We studied 39 UBC tissue samples. Oct-4 protein expression was evaluated semiquantitatively by immunohistochemistry (IHC). Complete blood count data and body weight as well as the height of the patients were retrieved and recorded before the date of the first transurethral resection of bladder tumor (TURBT). The follow-up period was 48 months for recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). RESULTS: Oct-4 expression profile was found to be significantly associated with gender (p = 0.028), tumor grade (p = 0.038), tumor stage (p = 0.003), lymph node status (p = 0.029), recurrence (p = 0.004), progression (p = 0.011), and treatment modality (p = 0.016). Tumor grade and progression were found significant with NLR values (tumor grade, p = 0.006; progression, p = 0.038) and BMI (tumor grade, p = 0.036; progression, p = 0.014). Moreover, BMI was also significantly associated with UBC recurrence (p = 0.014). Kaplan-Meier survival analysis showed poor prognosis with both high Oct-4 expression (RFS, p = 0.001; PFS, p = 0.004; OS, p = 0.014) and high NLR values (RFS, p = 0.049; PFS, p = 0.004; OS, p = 0.005). Patients with high BMI too had poor RFS (p = 0.025) and poor PFS (p = 0.032). Furthermore, multivariate Cox regression analysis, indicated Oct-4 as an independent prognostic biomarker for RFS (HR = 0.240, 95% CI, 0.072-0.804, p = 0.021). CONCLUSIONS: We conclude that the expression profile of Oct-4 will be beneficial in prediction of UBC recurrence, and could have profound implications on the development of new therapeutic targets for UBC treatment. CI - (c) The Author(s), 2019. FAU - Siddiqui, Zainab AU - Siddiqui Z AD - Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India; Department of Biotechnology, Dr. A. P. J. Abdul Kalam Technical University, Lucknow, India. FAU - Srivastava, Anand N AU - Srivastava AN AUID- ORCID: 0000-0001-9633-9903 AD - Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow-226003, Uttar Pradesh, India. FAU - Sankhwar, Satya N AU - Sankhwar SN AD - Department of Urology, King George's Medical University, Lucknow, India. FAU - Zaidi, Noorin AU - Zaidi N AD - Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India. FAU - Fatima, Naseem AU - Fatima N AD - Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India. FAU - Singh, Shivangi AU - Singh S AD - Research Metabolic Unit, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India. FAU - Yusuf, Mohd AU - Yusuf M AD - Department of Pathology, King George's Medical University, Lucknow, India. LA - eng PT - Journal Article DEP - 20190929 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC6769204 OTO - NOTNLM OT - Oct-4 OT - body mass index OT - cancer stem cells OT - lymphocytes OT - neutrophils OT - tumor progression OT - tumor recurrence OT - urinary bladder cancer COIS- Conflict of interest statement: The authors declare that there is no conflict of interest. EDAT- 2019/10/22 06:00 MHDA- 2019/10/22 06:01 PMCR- 2019/09/29 CRDT- 2019/10/22 06:00 PHST- 2019/04/09 00:00 [received] PHST- 2019/08/19 00:00 [accepted] PHST- 2019/10/22 06:00 [entrez] PHST- 2019/10/22 06:00 [pubmed] PHST- 2019/10/22 06:01 [medline] PHST- 2019/09/29 00:00 [pmc-release] AID - 10.1177_1756287219875576 [pii] AID - 10.1177/1756287219875576 [doi] PST - epublish SO - Ther Adv Urol. 2019 Sep 29;11:1756287219875576. doi: 10.1177/1756287219875576. eCollection 2019 Jan-Dec. PMID- 31630978 OWN - NLM STAT- MEDLINE DCOM- 20210129 LR - 20210129 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 18 IP - 2 DP - 2020 Apr TI - Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non-muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis. PG - e55-e61 LID - S1558-7673(19)30274-5 [pii] LID - 10.1016/j.clgc.2019.09.005 [doi] AB - BACKGROUND: The purpose of this study was to investigate whether adding single immediate postoperative intravesical instillation of doxorubicin (SID) to transurethral resection of bladder tumor (TURBT) significantly reduced the risk of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively analyzed the records of 720 patients diagnosed with primary NMIBC between 2002 through 2018 at the Kameda Medical Center. The primary outcome measure was time to recurrence. Time to progression was also compared. The cohort of SID and the cohort of TURBT alone were matched one-to-one by propensity scores. Matching was done by patient age, gender, and factors of the European Organization of Research and Treatment of Cancer recurrence risk table. The associations of adding SID and clinical outcomes were assessed with uni- and multivariate competing-risk regression models. RESULTS: After matching, a total of 364 patients, including 182 receiving SID and 182 receiving TURBT alone, were analyzed. No statistically significant differences existed among the measured baseline characteristics in propensity score-matched cohorts. In the multivariate analysis, there was a significantly longer time to recurrence in patients receiving SID (subdistribution hazard ratio, 0.68; 95% confidence interval, 0.49-0.95; P = .024) in propensity score-matched cohorts. There was no significant difference in time to progression (subdistribution hazard ratio, 0.61; 95% confidence interval, 0.11-3.49; P = .58) in univariate analysis. CONCLUSIONS: Our results demonstrated that SID significantly reduced the recurrence risk of primary NMIBC. Doxorubicin could be an inexpensive alternative to other evidenced-based chemotherapeutic agents for single immediate intravesical chemotherapy. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Fukuokaya, Wataru AU - Fukuokaya W AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. Electronic address: wfukuokaya@gmail.com. FAU - Kimura, Takahiro AU - Kimura T AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Miki, Jun AU - Miki J AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. FAU - Watanabe, Hisaki AU - Watanabe H AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Bo, Fan AU - Bo F AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Okada, Daigo AU - Okada D AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Aikawa, Koichi AU - Aikawa K AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Ochi, Atsuhiko AU - Ochi A AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Suzuki, Koichiro AU - Suzuki K AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Shiga, Naoki AU - Shiga N AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Abe, Hirokazu AU - Abe H AD - Department of Urology, Kameda Medical Center, Kamogawa City, Chiba, Japan. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20190927 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage MH - Chemotherapy, Adjuvant/methods MH - *Cystectomy MH - Disease Progression MH - Doxorubicin/*administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Propensity Score MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Time-to-Treatment MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/epidemiology/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Doxorubicin OT - Intravesical chemotherapy OT - Propensity score EDAT- 2019/10/22 06:00 MHDA- 2021/01/30 06:00 CRDT- 2019/10/22 06:00 PHST- 2019/07/04 00:00 [received] PHST- 2019/08/26 00:00 [revised] PHST- 2019/09/10 00:00 [accepted] PHST- 2019/10/22 06:00 [pubmed] PHST- 2021/01/30 06:00 [medline] PHST- 2019/10/22 06:00 [entrez] AID - S1558-7673(19)30274-5 [pii] AID - 10.1016/j.clgc.2019.09.005 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2020 Apr;18(2):e55-e61. doi: 10.1016/j.clgc.2019.09.005. Epub 2019 Sep 27. PMID- 31624709 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2220-6124 (Print) IS - 2220-6124 (Electronic) IS - 2220-6124 (Linking) VI - 8 IP - 5 DP - 2019 Sep 26 TI - WNT/beta-catenin signaling in urothelial carcinoma of bladder. PG - 83-94 LID - 10.5527/wjn.v8.i5.83 [doi] AB - Urothelial carcinoma of bladder is the second most prevalent genitourinary disease. It is a highly heterogeneous disease as it represents a spectrum of neoplasms, including non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC) and metastatic lesions. Genome-wide approaches and candidate gene analysis suggest that malignant transformation of the bladder is multifactorial and a multitude of genes are involved in the development of MIBC or NMIBC phenotypes. Wnt signaling is being examined to control and maintain balance between stemness and differentiation in adult stem cell niches. Owing to its participation in urothelial development and maintenance of adult urothelial tissue homeostasis, the components of Wnt signaling are reported as an important diagnostic and prognostic markers as well as novel therapeutic targets. Mutations/epigenetic alterations in the key molecules of Wnt/beta-catenin canonical pathway have been linked with tumorigenesis, development of drug resistance and enhanced survival. Present review extends our understanding on the functions of key regulatory molecules of canonical Wnt/beta-catenin pathway in urothelial tumorigenesis by inducing cancer stem cell phenotype (UCSCs). UCSCs may be responsible for tumor heterogeneity, high recurrence rates and complex biological behavior of bladder cancer. Therefore, understanding the role of UCSCs and the regulatory mechanisms that are responsible for high relapse rates and metastasis could help to develop pathway inhibitors and augment current therapies. Potential implications in the treatment of urothelial carcinoma of bladder by targeting this pathway primarily in UCSCs as well as in bulk tumor population that are responsible for high relapse rates and metastasis may facilitate potential therapeutic avenues and better prognosis. CI - (c)The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Garg, Minal AU - Garg M AD - Department of Biochemistry, University of Lucknow, Lucknow 226007, India minal14@yahoo.com. FAU - Maurya, Niharika AU - Maurya N AD - Department of Biochemistry, University of Lucknow, Lucknow 226007, India. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Nephrol JT - World journal of nephrology JID - 101610229 PMC - PMC6794554 OTO - NOTNLM OT - Chemoresistance OT - Therapeutic approaches OT - Urothelial cancer stem cells OT - Urothelial carcinoma of bladder OT - Wnt/beta-catenin COIS- Conflict-of-interest statement: Authors declare no conflict of interest. EDAT- 2019/10/19 06:00 MHDA- 2019/10/19 06:01 PMCR- 2019/09/26 CRDT- 2019/10/19 06:00 PHST- 2019/04/26 00:00 [received] PHST- 2019/08/14 00:00 [revised] PHST- 2019/09/13 00:00 [accepted] PHST- 2019/10/19 06:00 [entrez] PHST- 2019/10/19 06:00 [pubmed] PHST- 2019/10/19 06:01 [medline] PHST- 2019/09/26 00:00 [pmc-release] AID - 10.5527/wjn.v8.i5.83 [doi] PST - ppublish SO - World J Nephrol. 2019 Sep 26;8(5):83-94. doi: 10.5527/wjn.v8.i5.83. PMID- 31622214 OWN - NLM STAT- MEDLINE DCOM- 20210610 LR - 20210610 IS - 1874-4702 (Electronic) IS - 1874-4672 (Linking) VI - 13 IP - 2 DP - 2020 TI - Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis. PG - 150-172 LID - 10.2174/1874467212666191016124935 [doi] AB - BACKGROUND: Bladder cancer accounts for almost 54% of urinary system cancer and is the second most frequent cause of death in genitourinary malignancies after prostate cancer. About 70% of bladder tumors are non-muscle-invasive, and the rest are muscle-invasive. Recurrence of the tumor is the common feature of bladder cancer. Chemotherapy is a conventional treatment for MIBC, but it cannot improve the survival rate of these patients sufficiently. Therefore, researchers must develop new therapies. Antibody-based therapy is one of the most important strategies for the treatment of solid tumors. Selecting a suitable target is the most critical step for this strategy. OBJECTIVE: The aim of this study is to detect therapeutic cell surface antigen targets in bladder cancer using data obtained by proteomic studies. METHODS: Isobaric tag for relative and absolute quantitation (iTRAQ) analysis had identified 131 overexpressed proteins in baldder cancer tissue and reverse-phase proteomic array (RPPA) analysis had been done for 343 tumor tissues and 208 antibodies. All identified proteins from two studies (131+208 proteins) were collected and duplicates were removed (331 unique proteins). Gene ontology study was performed using gene ontology (GO) and protein analysis through evolutionary relationships (PANTHER) databases. The Human Protein Atlas database was used to search the protein class and subcellular location of membrane proteins obtained from the PANTHER analysis. RESULTS: Membrane proteins that could be suitable therapeutic targets for bladder cancer were selected. These included: Epidermal growth factor receptor (EGFR), Her2, Kinase insert domain receptor (KDR), Heat shock protein 60 (HSP60), HSP90, Transferrin receptor (TFRC), Activin A Receptor Like Type 1 (ACVRL1), and cadherin 2 (CDH2). Monoclonal antibodies against these proteins or their inhibitors were used for the treatment of different cancers in preclinical and clinical trials. CONCLUSION: These monoclonal antibodies and inhibitor molecules and also their combination can be used for the treatment of bladder cancer. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Bahrami, Samira AU - Bahrami S AD - Biotechnology Department, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. AD - Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Kazemi, Bahram AU - Kazemi B AD - Biotechnology Department, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. AD - Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Zali, Hakimeh AU - Zali H AD - Medical Nanotechnology and Tissue Engineering Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. FAU - Basiri, Abbas AU - Basiri A AD - Department of Urology, Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Bandehpour, Mojgan AU - Bandehpour M AD - Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hedayati, Mehdi AU - Hedayati M AD - Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Sahebkar, Amirhossein AU - Sahebkar A AD - Halal Research Center of IRI, FDA, Tehran, Iran. AD - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. LA - eng PT - Journal Article PL - Netherlands TA - Curr Mol Pharmacol JT - Current molecular pharmacology JID - 101467997 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) SB - IM MH - Antineoplastic Agents/pharmacology MH - Biomarkers, Tumor/metabolism MH - Cell Membrane/metabolism MH - Clinical Trials as Topic MH - *Data Analysis MH - Humans MH - *Molecular Targeted Therapy MH - Neoplasm Proteins/*metabolism MH - *Proteomics MH - Urinary Bladder Neoplasms/*drug therapy/*metabolism OTO - NOTNLM OT - Bladder cancer OT - DNA OT - monoclonal antibodies OT - proteomics OT - targeted therapy. EDAT- 2019/10/18 06:00 MHDA- 2021/06/11 06:00 CRDT- 2019/10/18 06:00 PHST- 2019/04/04 00:00 [received] PHST- 2019/08/26 00:00 [revised] PHST- 2019/08/30 00:00 [accepted] PHST- 2019/10/18 06:00 [pubmed] PHST- 2021/06/11 06:00 [medline] PHST- 2019/10/18 06:00 [entrez] AID - CMP-EPUB-101531 [pii] AID - 10.2174/1874467212666191016124935 [doi] PST - ppublish SO - Curr Mol Pharmacol. 2020;13(2):150-172. doi: 10.2174/1874467212666191016124935. PMID- 31621380 OWN - NLM STAT- MEDLINE DCOM- 20200708 LR - 20200708 IS - 1752-0371 (Electronic) IS - 1752-0363 (Linking) VI - 13 IP - 18 DP - 2019 Dec TI - Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection. PG - 1543-1555 LID - 10.2217/bmm-2019-0398 [doi] AB - Aim: To investigate and validate predictive value of combination of pretreatment monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR) for disease free survival (DFS) and overall survival (OS) in nonmuscle invasive bladder cancer after transurethral resection. Materials & methods: Total 358 patients enrolled were assigned into three (MLR-NLR 0, 1 and 2) groups per the cut-off values of MLR and NLR. Results: Kaplan-Meier curves showed MLR, NLR and their combination were statistically associated with DFS (p < 0.001) and OS (p < 0.001). Univariate and multivariate COX regression analyses revealed that combination of MLR with NLR was an independent prognostic predictor for both DFS (HR: 3.080; 95% CI: 1.870-5.074; p < 0.001 for MLR-NLR 2 vs MLR-NLR 0) and OS (HR: 2.815; 95% CI: 1.778-4.456; p < 0.001 for MLR-NLR 2 vs MLR-NLR 0). Calibration plots and decision curve analysis exhibited combination of MLR and NLR had good calibration accuracy with potential clinical usefulness. Conclusion: Combined MLR and NLR is a prognostic predictive biomarker in nonmuscle invasive bladder cancer after transurethral resection. FAU - Wang, Qinghai AU - Wang Q AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Huang, Tao AU - Huang T AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Ji, Jianlei AU - Ji J AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Wang, Hongyang AU - Wang H AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Guo, Chen AU - Guo C AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Sun, Xiaoxia AU - Sun X AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Zheng, Kewen AU - Zheng K AD - Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, The First Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang 325000, PR China. FAU - Dong, Zhen AU - Dong Z AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. FAU - Cao, Yanwei AU - Cao Y AD - Department of Kidney Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, PR China. LA - eng PT - Journal Article DEP - 20191017 PL - England TA - Biomark Med JT - Biomarkers in medicine JID - 101312535 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Leukocyte Count MH - Lymphocytes/*cytology MH - Male MH - Middle Aged MH - Monocytes/*cytology MH - Neutrophils/*cytology MH - Prognosis MH - Urinary Bladder Neoplasms/*blood/diagnosis/mortality/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - disease free survival OT - monocyte-to-lymphocyte ratio OT - neutrophil-to-lymphocyte ratio OT - nonmuscle invasive bladder cancer OT - overall survival EDAT- 2019/10/18 06:00 MHDA- 2020/07/09 06:00 CRDT- 2019/10/18 06:00 PHST- 2019/10/18 06:00 [pubmed] PHST- 2020/07/09 06:00 [medline] PHST- 2019/10/18 06:00 [entrez] AID - 10.2217/bmm-2019-0398 [doi] PST - ppublish SO - Biomark Med. 2019 Dec;13(18):1543-1555. doi: 10.2217/bmm-2019-0398. Epub 2019 Oct 17. PMID- 31619424 OWN - NLM STAT- MEDLINE DCOM- 20200922 LR - 20200922 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 9 IP - 10 DP - 2019 Oct 16 TI - The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. PG - e030396 LID - 10.1136/bmjopen-2019-030396 [doi] LID - e030396 AB - INTRODUCTION: Patients with non-muscle-invasive bladder cancer (NMIBC) have a good survival but are at high risk for tumour recurrence and disease progression. It is important to identify lifestyle habits that may reduce the risk of recurrence and progression and improve health-related quality of life (HRQOL). This paper describes the rationale and design of the UroLife study. The main aim of this study is to evaluate whether lifestyle habits are related to prognosis and HRQOL in patients with NMIBC. METHODS AND ANALYSIS: The UroLife study is a multicentre prospective cohort study among more than 1100 newly diagnosed patients with NMIBC recruited from 22 hospitals in the Netherlands. At 6 weeks and 3, 15 and 51 months after diagnosis, participants fill out a general questionnaire, and questionnaires about their lifestyle habits and HRQOL. At 3, 15 and 51 months after diagnosis, information about fluid intake and micturition is collected with a 4-day diary. At 3 and 15 months after diagnosis, patients donate blood samples for DNA extraction and (dietary) biomarker analysis. Tumour samples are collected from all patients with T1 disease to assess molecular subtypes. Information about disease characteristics and therapy for the primary tumour and subsequent recurrences is collected from the medical records by the Netherlands Cancer Registry. Statistical analyses will be adjusted for age, gender, tumour characteristics and other known confounders. ETHICS AND DISSEMINATION: The study protocol has been approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494). Patients who agree to participate in the study provide written informed consent. The findings from our study will be disseminated through peer-reviewed scientific journals and presentations at (inter)national scientific meetings. Patients will be informed about the progress and results of this study through biannual newsletters and through the website of the study and of the bladder cancer patient association. CI - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - de Goeij, Liesbeth AU - de Goeij L AUID- ORCID: 0000-0001-6787-0404 AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - Westhoff, Ellen AU - Westhoff E AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. FAU - Aben, Katja Kh AU - Aben KK AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. AD - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Kampman, Ellen AU - Kampman E AD - Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands. FAU - Kiemeney, Lambertus Alm AU - Kiemeney LA AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud university medical center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AUID- ORCID: 0000-0002-8178-2125 AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands Alina.Vrieling@radboudumc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191016 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 36-88-4 (Carotenoids) RN - R0ZB2556P8 (Tocopherols) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Carotenoids/blood MH - Disease Progression MH - *Healthy Lifestyle MH - Humans MH - Middle Aged MH - Multicenter Studies as Topic MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Netherlands MH - Prognosis MH - Prospective Studies MH - *Quality of Life MH - Research Design MH - Surveys and Questionnaires MH - Tocopherols/blood MH - Urinary Bladder Neoplasms/genetics/*pathology/therapy MH - Young Adult PMC - PMC6797314 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - cohort OT - diet OT - lifestyle OT - prognosis OT - quality of life OT - recurrence OT - study protocol COIS- Competing interests: None declared. EDAT- 2019/10/18 06:00 MHDA- 2020/09/23 06:00 PMCR- 2019/10/16 CRDT- 2019/10/18 06:00 PHST- 2019/10/18 06:00 [entrez] PHST- 2019/10/18 06:00 [pubmed] PHST- 2020/09/23 06:00 [medline] PHST- 2019/10/16 00:00 [pmc-release] AID - bmjopen-2019-030396 [pii] AID - 10.1136/bmjopen-2019-030396 [doi] PST - epublish SO - BMJ Open. 2019 Oct 16;9(10):e030396. doi: 10.1136/bmjopen-2019-030396. PMID- 31615011 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 11 IP - 10 DP - 2019 Oct 14 TI - MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer. LID - 10.3390/cancers11101551 [doi] LID - 1551 AB - Bladder cancer (BC) is still characterized by a very high death rate in patients with this disease. One of the reasons for this is the lack of adequate markers which could help determine the biological potential of the tumor to develop into its invasive stage. It has been found that some microRNAs (miRNAs) correlate with disease progression. The purpose of this study was to identify which miRNAs can accurately predict the presence of BC and can differentiate low grade (LG) tumors from high grade (HG) tumors. The study included 55 patients with diagnosed bladder cancer and 30 persons belonging to the control group. The expression of seven selected miRNAs was estimated with the real-time PCR technique according to miR-103-5p (for the normalization of the results). Receiver operating characteristics (ROC) curves and the area under the curve (AUC) were used to evaluate the feasibility of using selected markers as biomarkers for detecting BC and discriminating non-muscle invasive BC (NMIBC) from muscle invasive BC (MIBC). For HG tumors, the relevant classifiers are miR-205-5p and miR-20a-5p, whereas miR-205-5p and miR-182-5p are for LG (AUC = 0.964 and AUC = 0.992, respectively). NMIBC patients with LG disease are characterized by significantly higher miR-130b-3p expression values compared to patients in HG tumors. FAU - Borkowska, Edyta Marta AU - Borkowska EM AUID- ORCID: 0000-0001-9447-0684 AD - Medical University of Lodz, Chair of Laboratory and Clinical Genetics Department of Clinical Genetics, 251 Pomorska Street, 92-213 Lodz, Poland. edyta.borkowska@umed.lodz.pl. FAU - Konecki, Tomasz AU - Konecki T AD - Medical University of Lodz, 1st Clinic of Urology, 113 Zeromski Street, 90-549 Lodz, Poland. Tomasz.konecki@umed.lodz.pl. FAU - Pietrusinski, Michal AU - Pietrusinski M AUID- ORCID: 0000-0002-9419-6221 AD - Medical University of Lodz, Chair of Laboratory and Clinical Genetics Department of Clinical Genetics, 251 Pomorska Street, 92-213 Lodz, Poland. Michal.pietrusinski@umed.lodz.pl. FAU - Borowiec, Maciej AU - Borowiec M AD - Medical University of Lodz, Chair of Laboratory and Clinical Genetics Department of Clinical Genetics, 251 Pomorska Street, 92-213 Lodz, Poland. maciej.borowiec@umed.lodz.pl. FAU - Jablonowski, Zbigniew AU - Jablonowski Z AD - Medical University of Lodz, 1st Clinic of Urology, 113 Zeromski Street, 90-549 Lodz, Poland. zbigniew.jablonowski@umed.lodz.pl. LA - eng PT - Journal Article DEP - 20191014 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC6826751 OTO - NOTNLM OT - Bladder cancer OT - genetic marker OT - microRNA OT - progression COIS- The authors declare no conflict of interest. EDAT- 2019/10/17 06:00 MHDA- 2019/10/17 06:01 PMCR- 2019/10/14 CRDT- 2019/10/17 06:00 PHST- 2019/09/21 00:00 [received] PHST- 2019/10/09 00:00 [revised] PHST- 2019/10/09 00:00 [accepted] PHST- 2019/10/17 06:00 [entrez] PHST- 2019/10/17 06:00 [pubmed] PHST- 2019/10/17 06:01 [medline] PHST- 2019/10/14 00:00 [pmc-release] AID - cancers11101551 [pii] AID - cancers-11-01551 [pii] AID - 10.3390/cancers11101551 [doi] PST - epublish SO - Cancers (Basel). 2019 Oct 14;11(10):1551. doi: 10.3390/cancers11101551. PMID- 31609466 OWN - NLM STAT- MEDLINE DCOM- 20200629 LR - 20200629 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 146 IP - 9 DP - 2020 May 1 TI - Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. PG - 2636-2647 LID - 10.1002/ijc.32737 [doi] AB - Molecular changes occurring during invasion and clinical progression of cancer are difficult to study longitudinally in patient-derived material. A unique feature of urothelial bladder cancer (UBC) is that patients frequently develop multiple nonmuscle invasive tumors, some of which may eventually progress to invade the muscle of the bladder wall. Here, we use a cohort of 73 patients that experienced a total of 357 UBC diagnoses to study the stability or change in detected molecular alterations during cancer progression. The tumors were subtyped by gene expression profiling and analyzed for hotspot mutations in FGFR3, PIK3CA and TERT, the most frequent early driver mutations in this tumor type. TP53 alterations, frequent in advanced UBC, were inferred from p53 staining pattern, and potential genomic alterations were inferred by gene expression patterns at regions harboring frequent copy number alterations. We show that early driver mutations were largely preserved in UBC recurrences. Changes in FGFR3, PIK3CA or TERT mutation status were not linked to changes in molecular subtype and aggressive behavior. Instead, changes into a more aggressive molecular subtype seem to be associated with p53 alterations. We analyze changes in gene expression from primary tumors, to recurrences and progression tumors, and identify two modes of progression: Patients for whom progression is preceded by or coincides with a radical subtype shift, and patients who progress without any systematic molecular changes. For the latter group of patients, progression may be either stochastic or depending on factors already present at primary tumor initiation. CI - (c) 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Sjodahl, Gottfrid AU - Sjodahl G AUID- ORCID: 0000-0002-7869-0473 AD - Department of Translational Medicine, Division of Urological Research, Lund University, Lund, Sweden. AD - Department of Urology, Skane University Hospital, Skane, Sweden. FAU - Eriksson, Pontus AU - Eriksson P AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Patschan, Oliver AU - Patschan O AD - Department of Translational Medicine, Division of Urological Research, Lund University, Lund, Sweden. AD - Department of Urology, Skane University Hospital, Skane, Sweden. FAU - Marzouka, Nour-Al-Dain AU - Marzouka NA AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Jakobsson, Lovisa AU - Jakobsson L AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Bernardo, Carina AU - Bernardo C AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Lovgren, Kristina AU - Lovgren K AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Chebil, Gunilla AU - Chebil G AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. FAU - Zwarthoff, Ellen AU - Zwarthoff E AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Translational Medicine, Division of Urological Research, Lund University, Lund, Sweden. AD - Department of Urology, Skane University Hospital, Skane, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191114 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell/*genetics/secondary MH - DNA Copy Number Variations MH - Disease Progression MH - Follow-Up Studies MH - *Gene Expression Profiling MH - Genomics MH - Humans MH - Longitudinal Studies MH - Lymphatic Metastasis MH - *Mutation MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Prognosis MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC7079000 OTO - NOTNLM OT - bladder cancer OT - molecular subtypes OT - mutation OT - progression OT - urothelial carcinoma EDAT- 2019/10/15 06:00 MHDA- 2020/07/01 06:00 PMCR- 2020/03/18 CRDT- 2019/10/15 06:00 PHST- 2019/05/02 00:00 [received] PHST- 2019/08/22 00:00 [revised] PHST- 2019/09/13 00:00 [accepted] PHST- 2019/10/15 06:00 [pubmed] PHST- 2020/07/01 06:00 [medline] PHST- 2019/10/15 06:00 [entrez] PHST- 2020/03/18 00:00 [pmc-release] AID - IJC32737 [pii] AID - 10.1002/ijc.32737 [doi] PST - ppublish SO - Int J Cancer. 2020 May 1;146(9):2636-2647. doi: 10.1002/ijc.32737. Epub 2019 Nov 14. PMID- 31609178 OWN - NLM STAT- MEDLINE DCOM- 20200323 LR - 20200323 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 203 IP - 3 DP - 2020 Mar TI - Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. PG - 505-511 LID - 10.1097/JU.0000000000000593 [doi] AB - PURPOSE: We applied nonmuscle invasive bladder cancer AUA (American Urological Association)/SUO (Society of Urologic Oncology) guidelines for risk stratification and analyzed predictors of recurrence and progression. MATERIALS AND METHODS: We retrospectively reviewed the records of 398 patients with nonmuscle invasive bladder cancer treated between 2001 and 2017. Descriptive statistics were used to compare AUA/SUO risk groups. Predictors of recurrence and progression were determined by multivariable regression. Kaplan-Meier analysis was done, a Cox proportional hazards regression model was created and time dependent AUCs were calculated to determine progression-free and recurrence-free survival by risk group. RESULTS: Median followup was 37 months (95% CI 35-42). Of the patients 92% underwent bacillus Calmette-Guerin induction and 46% received at least 1 course of maintenance treatment. Of the patients 11.5% were at low, 32.5% were at intermediate and 55.8% were at high risk. In patients at low, intermediate and high risk the 5-year progression-free survival rate was 93%, 74% and 54%, and the 5-year recurrence-free survival rate was 43%, 33% and 23%, respectively. Kaplan-Meier analysis was done to stratify high grade Ta 3 cm or less tumor recurrence-free and progression-free survival in the intermediate vs the high risk group. Relative to low risk, classification as intermediate and as high risk was an independent predictor of progression (HR 9.7, 95% CI 2.23-42.0, p <0.01, and HR 36, 95% CI 8.16-159, p <0.001, respectively). Recurrence was more likely in patients at high risk than in those at low risk (HR 2.03, 95% CI 1.11-3.71, p=0.022). For recurrence and progression the 1-year AUC was 0.60 (95% CI 0.546-0.656) and 0.68 (95% CI 0.622-0.732), respectively. CONCLUSIONS: The AUA/SUO nonmuscle invasive bladder cancer risk classification system appropriately stratifies patients based on the likelihood of recurrence and progression. It should be used at diagnosis to counsel patients and guide therapy. FAU - Ritch, Chad R AU - Ritch CR AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, Miami, Florida. FAU - Velasquez, Maria C AU - Velasquez MC AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Kwon, Deukwoo AU - Kwon D AD - Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida. FAU - Becerra, Maria F AU - Becerra MF AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Soodana-Prakash, Nachiketh AU - Soodana-Prakash N AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Atluri, Venkatasai S AU - Atluri VS AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Almengo, Katherine AU - Almengo K AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Alameddine, Mahmoud AU - Alameddine M AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Kineish, Omer AU - Kineish O AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. FAU - Kava, Bruce R AU - Kava BR AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, Miami, Florida. FAU - Punnen, Sanoj AU - Punnen S AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, Miami, Florida. FAU - Parekh, Dipen J AU - Parekh DJ AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, Miami, Florida. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Department of Urology, University of Miami Miller School of Medicine, Miami, Florida. AD - Sylvester Comprehensive Cancer Center, Miami, Florida. LA - eng PT - Journal Article PT - Validation Study DEP - 20191014 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2020 Mar;203(3):511. doi: 10.1097/JU.0000000000000593.01. PMID: 31854259 MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Assessment/*methods MH - Risk Factors MH - Urinary Bladder Neoplasms/*pathology/therapy OTO - NOTNLM OT - classification OT - local OT - neoplasm recurrence OT - progression-free survival OT - risk OT - urinary bladder neoplasms EDAT- 2019/10/15 06:00 MHDA- 2020/03/24 06:00 CRDT- 2019/10/15 06:00 PHST- 2019/10/15 06:00 [pubmed] PHST- 2020/03/24 06:00 [medline] PHST- 2019/10/15 06:00 [entrez] AID - 10.1097/JU.0000000000000593 [doi] PST - ppublish SO - J Urol. 2020 Mar;203(3):505-511. doi: 10.1097/JU.0000000000000593. Epub 2019 Oct 14. PMID- 31607136 OWN - NLM STAT- MEDLINE DCOM- 20191202 LR - 20191202 IS - 0028-2685 (Print) IS - 0028-2685 (Linking) VI - 66 IP - 6 DP - 2019 Nov TI - The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma. PG - 1019-1023 LID - 190124N74 [pii] LID - 10.4149/neo_2019_190124N74 [doi] AB - Aim of the study is to define the diagnostic accuracy of selected urinary protein biomarkers in the non-invasive detection of primary and recurrent urothelial carcinoma of the urinary bladder. The urinary levels of calprotectin, CD147, APOA4 and protein deglycase DJ-1 were examined in 255 individuals, including 60 controls with non-malignant urological disease, 61 patients with a history of urinary bladder cancer with negative cytology and negative cystoscopy and 134 patients with urinary bladder cancer. Urinary concentrations of biomarkers were determined by Enzyme-Linked Immunosorbent Assay (ELISA). During the follow-up of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared to the group of 61 patients with a history of NMIBC but with no evidence of disease. Urinary concentrations of the evaluated markers did not reveal any significant difference between these groups. During the primary diagnosis, a group of 90 patients with primary bladder cancer and 60 subjects with benign disease were compared. Urinary levels of CD147 were not significantly higher in patients with tumors. The greatest diagnostic accuracy was observed in APOA4 (sensitivity 55.6, specificity 83.3, AUC 0.75), and lesser in calprotectin (sensitivity 39.4, specificity 87.7, AUC 0.66) and in DJ-1 (sensitivity 61.1, specificity 66.7, AUC 0.64), respectively. Apolipoprotein A4 may be used potentially as a supplemental urinary marker in the diagnosis of primary bladder cancer. FAU - Soukup, V AU - Soukup V AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Capoun, O AU - Capoun O AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Pesl, M AU - Pesl M AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Vavrova, L AU - Vavrova L AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Sobotka, R AU - Sobotka R AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Levova, K AU - Levova K AD - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Hanus, T AU - Hanus T AD - Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Zima, T AU - Zima T AD - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. FAU - Kalousova, M AU - Kalousova M AD - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article DEP - 20191008 PL - Slovakia TA - Neoplasma JT - Neoplasma JID - 0377266 RN - 0 (Apolipoproteins A) RN - 0 (BSG protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Leukocyte L1 Antigen Complex) RN - 0 (apolipoprotein A-IV) RN - 136894-56-9 (Basigin) RN - EC 3.1.2.- (PARK7 protein, human) RN - EC 3.1.2.- (Protein Deglycase DJ-1) SB - IM MH - Apolipoproteins A/*urine MH - Basigin/*urine MH - Biomarkers, Tumor/urine MH - Humans MH - Leukocyte L1 Antigen Complex/*urine MH - Neoplasm Recurrence, Local MH - Protein Deglycase DJ-1/*urine MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnosis/urine EDAT- 2019/10/15 06:00 MHDA- 2019/12/04 06:00 CRDT- 2019/10/15 06:00 PHST- 2019/01/24 00:00 [received] PHST- 2019/05/22 00:00 [accepted] PHST- 2019/10/15 06:00 [pubmed] PHST- 2019/12/04 06:00 [medline] PHST- 2019/10/15 06:00 [entrez] AID - 190124N74 [pii] AID - 10.4149/neo_2019_190124N74 [doi] PST - ppublish SO - Neoplasma. 2019 Nov;66(6):1019-1023. doi: 10.4149/neo_2019_190124N74. Epub 2019 Oct 8. PMID- 31602215 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1792-0981 (Print) IS - 1792-1015 (Electronic) IS - 1792-0981 (Linking) VI - 18 IP - 5 DP - 2019 Nov TI - Application of nomograms in the prediction of overall survival and cancer-specific survival in patients with T1 high-grade bladder cancer. PG - 3405-3414 LID - 10.3892/etm.2019.7979 [doi] AB - To predict survival outcomes for individual patients with clinical T1 high-grade (T1HG) bladder cancer (BC), data from the Surveillance Epidemiology and End Results (SEER) database were analyzed in the present study. The data of 6,980 cases of T1HG BC between 2004 and 2014 were obtained from the SEER database. Uni- and multivariate Cox analyses were performed to identify significant prognostic factors. Subsequently, prognostic nomograms for predicting 3- and 5-year overall survival (OS) and cancer-specific survival (CSS) rates were constructed based on the SEER database. Clinical information from the SEER database was divided into internal and external groups and used to validate the nomograms. In addition, calibration plot diagrams and concordance indices (C-indices) were used to verify the predictive performance of the nomogram. A total of 6,980 patients were randomly allocated to the training cohort (n=4,886) or the validation cohort (n=2094). Univariate and multivariate Cox analyses indicated that age, ethnicity, tumor size, marital status, radiation and surgical status were independent prognostic factors. These characteristics were used to establish nomograms. The C-indices for OS and CSS rate predictions for the training cohort were 0.707 (95% CI, 0.693-0.721) and 0.700 (95% CI, 0.679-0.721), respectively. Internal and external calibration plot diagrams exhibited an excellent consistency between actual survival rates and nomogram predictions, particularly for 3- and 5-year OS and CSS. The significant prognostic factors in patients with T1HG BC were age, ethnicity, marital status, tumor size, status of surgery and use of radiation. In the present study, a nomogram was developed that may serve as an effective and convenient evaluation tool to help surgeons perform individualized survival evaluations and mortality risk determination for patients with T1HG BC. CI - Copyright: (c) Tang et al. FAU - Tang, Fucai AU - Tang F AD - Department of Urology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518033, P.R. China. AD - Department of Urology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China. FAU - He, Zhaohui AU - He Z AD - Department of Urology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518033, P.R. China. FAU - Lu, Zechao AU - Lu Z AD - The First Clinical College of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China. FAU - Wu, Weijia AU - Wu W AD - Department of Urology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518033, P.R. China. FAU - Chen, Yiwen AU - Chen Y AD - Deparement of Urology, Longgang District Central Hospital, Shenzhen, Guangdong 518100, P.R. China. FAU - Wei, Genggeng AU - Wei G AD - Department of Urology, Hongkong University-Shenzhen Hospital, Shenzhen, Guangdong 518053, P.R. China. FAU - Liu, Yangzhou AU - Liu Y AD - Department of Urology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China. LA - eng PT - Journal Article DEP - 20190906 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC6777327 OTO - NOTNLM OT - Surveillance Epidemiology and End Results database OT - cancer-specific survival OT - clinical T1 high-grade bladder cancer OT - nomogram OT - overall survival EDAT- 2019/10/12 06:00 MHDA- 2019/10/12 06:01 PMCR- 2019/09/06 CRDT- 2019/10/12 06:00 PHST- 2019/01/22 00:00 [received] PHST- 2019/08/06 00:00 [accepted] PHST- 2019/10/12 06:00 [entrez] PHST- 2019/10/12 06:00 [pubmed] PHST- 2019/10/12 06:01 [medline] PHST- 2019/09/06 00:00 [pmc-release] AID - ETM-0-0-7979 [pii] AID - 10.3892/etm.2019.7979 [doi] PST - ppublish SO - Exp Ther Med. 2019 Nov;18(5):3405-3414. doi: 10.3892/etm.2019.7979. Epub 2019 Sep 6. PMID- 31600114 OWN - NLM STAT- MEDLINE DCOM- 20191230 LR - 20211124 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 203 IP - 1 DP - 2020 Jan TI - Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. PG - 57-61 LID - 10.1097/JU.0000000000000445 [doi] AB - PURPOSE: We sought to determine the trend of neoadjuvant chemotherapy use for nonmetastatic muscle invasive urothelial bladder cancer and whether it is associated with adverse perioperative morbidity after robot-assisted radical cystectomy. MATERIALS AND METHODS: We retrospectively reviewed the IRCC (International Robotic Cystectomy Consortium) database between 2006 and 2017. After excluding patients with nonmuscle invasive bladder cancer the patients were divided into 2 groups, including those who did vs did not receive neoadjuvant chemotherapy. Data were reviewed for demographics, preoperative, operative and 90-day perioperative outcomes. We used the Cochran-Armitage trend test to assess trends of neoadjuvant chemotherapy associations with high grade and overall complications with time. Multivariate stepwise regression analyses were done to determine whether neoadjuvant chemotherapy was associated with prolonged operative time, 90-day postoperative complications, readmissions, reoperations and mortality after robot-assisted radical cystectomy. RESULTS: A total of 298 patients (26%) received neoadjuvant chemotherapy. These patients were younger (age 67 vs 69 years, p=0.01) and more frequently had an ASA (American Society of Anesthesiologists) score of 3 or greater (62% vs 55%, p=0.02) and pathological T3 stage or greater disease (28% vs 22%, p=0.04). The use of neoadjuvant chemotherapy increased significantly from 10% in 2006 to 2007 to 42% in 2016 to 2017 (p <0.01). On multivariate analysis neoadjuvant chemotherapy was not significantly associated with prolonged operative time, hospital stay, 90-day postoperative complications, reoperation or mortality. Neoadjuvant chemotherapy was associated with 90-day readmissions after robot-assisted radical cystectomy (OR 5.90, 95% CI 3.30-10.90, p <0.01). CONCLUSIONS: Neoadjuvant chemotherapy utilization has significantly increased in the last decade. It was not associated with perioperative surgical morbidity after robot-assisted radical cystectomy. FAU - Aldhaam, Naif A AU - Aldhaam NA AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Elsayed, Ahmed S AU - Elsayed AS AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Jing, Zhe AU - Jing Z AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Richstone, Lee AU - Richstone L AD - Arthur Smith Institute for Urology, New Hyde Park, New York. FAU - Wagner, Andrew A AU - Wagner AA AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Rha, Koon Ho AU - Rha KH AD - Yonsei Medical Health Care System, Seoul, South Korea. FAU - Yuh, Bertram AU - Yuh B AD - City of Hope National Cancer Center, Duarte, California. FAU - Palou, Juan AU - Palou J AD - Fundacio Puigvert, Barcelona, Spain. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Guy's Hospital, London, United Kingdom. FAU - Menon, Mani AU - Menon M AD - Henry Ford Health System, Detroit, Michigan. FAU - Roupret, Morgan AU - Roupret M AD - Hopital Pitie-Salpetriere, Paris, France. FAU - Balbay, Derya AU - Balbay D AD - Koc University Hospital, Istanbul, Turkey. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Karolinska Institute, Solna, Sweden. FAU - Wiklund, Peter AU - Wiklund P AD - Karolinska Institute, Solna, Sweden. FAU - Gaboardi, Franco AU - Gaboardi F AD - Luigi Sacco (San Raffaele), Milan, Italy. FAU - Maatman, Thomas J AU - Maatman TJ AD - Metro Health Hospital, Wyoming, Michigan. FAU - Mottrie, Alexandre AU - Mottrie A AD - Orsi Academy/Onze-Lieve-Vrouwziekenhuis, Aalst, Flanders. FAU - Wijburg, Carl AU - Wijburg C AD - Rijnstate Hospital, Arnhem, The Netherlands. FAU - Stockle, Michael AU - Stockle M AD - Universitatsklinikum des Saarlandes, Homburg, Germany. FAU - Hemal, Ashok AU - Hemal A AD - Wake Forest Medical Center, Winston-Salem, North Carolina. FAU - Kim, Eric AU - Kim E AD - Washington University, St. Louis, Missouri. FAU - Kaouk, Jihad AU - Kaouk J AD - Cleveland Clinic, Cleveland, Ohio. FAU - Hussein, Ahmed A AU - Hussein AA AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York. FAU - Guru, Khurshid A AU - Guru KA AD - Roswell Park Comprehensive Cancer Center, Buffalo, New York. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190717 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Antineoplastic Agents) SB - IM EIN - J Urol. 2020 Mar;203(3):626. doi: 10.1097/JU.0000000000000753. PMID: 34818082 MH - Aged MH - Antineoplastic Agents/therapeutic use MH - *Chemotherapy, Adjuvant MH - *Cystectomy MH - Humans MH - Male MH - *Neoadjuvant Therapy MH - Operative Time MH - Patient Readmission/statistics & numerical data MH - Postoperative Complications MH - Reoperation/statistics & numerical data MH - Retrospective Studies MH - *Robotic Surgical Procedures MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery OTO - NOTNLM OT - cystectomy OT - morbidity OT - mortality OT - robotic surgical procedures OT - urinary bladder EDAT- 2019/10/11 06:00 MHDA- 2019/12/31 06:00 CRDT- 2019/10/11 06:00 PHST- 2019/10/11 06:00 [pubmed] PHST- 2019/12/31 06:00 [medline] PHST- 2019/10/11 06:00 [entrez] AID - 10.1097/JU.0000000000000445 [doi] PST - ppublish SO - J Urol. 2020 Jan;203(1):57-61. doi: 10.1097/JU.0000000000000445. Epub 2019 Jul 17. PMID- 31597600 OWN - NLM STAT- MEDLINE DCOM- 20200828 LR - 20200828 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. PG - 900-906 LID - S1078-1439(19)30360-6 [pii] LID - 10.1016/j.urolonc.2019.09.009 [doi] AB - OBJECTIVES: Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder. The prognostic value of high aurora kinase B (AURKB) expression in local bladder cancer is not well defined, and whether the prognostic value of either AURKA or AURKB is affected by the use of chemotherapy is unknown. We sought to characterize the impact of high AURKA and AURKB expression on clinical outcome in patients with muscle-invasive bladder cancer (MIBC) who received neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: Immunohistochemistry for AURKA and AURKB was performed on pretreatment diagnostic transurethral resection of bladder tumor (TURBT) and matched cystectomy specimens in 50 subjects with MIBC who received NAC. Receiver operator characteristic curves (ROC) were calculated to assess the impact of AURKA and AURKB expression on pathologic response rate. Kaplan-Meier techniques and Cox proportional hazards models were used to assess the association with relapse-free survival (RFS) and overall survival (OS). RESULTS: Twenty-two of 50 [44%] patients had residual muscle-invasive (ypT2-4) urothelial carcinoma after NAC. Neither baseline tumor expression of AURKA (ROC = 0.57, P = 0.46) nor AURKB (ROC = 0.56, P = 0.87) predicted for ypT2-4 status. However, baseline expression of AURKA above the 75th percentile for this cohort was associated with an inferior RFS, (HR = 3.88, P = 0.008) and OS, (HR = 6.10, P < 0.001). Similar trends for worse survival outcomes were also observed for high AURKB levels (RFS, [HR = 2.2, P = 0.13] and OS, (HR = 2.25, P = 0.09). CONCLUSIONS: High baseline tumor AURKA and AURKB expression identified MIBC patients with inferior RFS and OS despite the use of NAC and may identify patients who should be prioritized for clinical trial enrollment rather than standard cisplatin-based chemotherapy. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Burgess, Earle F AU - Burgess EF AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. Electronic address: earle.burgess@atriumhealth.org. FAU - Livasy, Chad AU - Livasy C AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Trufan, Sally AU - Trufan S AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Hartman, Aaron AU - Hartman A AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Guerreri, Renato AU - Guerreri R AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Naso, Caroline AU - Naso C AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Clark, Peter E AU - Clark PE AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Grigg, Claud AU - Grigg C AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Symanowski, James AU - Symanowski J AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. FAU - Raghavan, Derek AU - Raghavan D AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191006 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.11.1 (AURKA protein, human) RN - EC 2.7.11.1 (AURKB protein, human) RN - EC 2.7.11.1 (Aurora Kinase A) RN - EC 2.7.11.1 (Aurora Kinase B) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Aurora Kinase A/*metabolism MH - Aurora Kinase B/*metabolism MH - Biomarkers, Tumor/*metabolism MH - Cisplatin/therapeutic use MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/methods MH - Neoplasm Recurrence, Local MH - Prognosis MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Aurora kinase OT - Bladder cancer OT - Chemotherapy OT - Urothelial carcinoma EDAT- 2019/10/11 06:00 MHDA- 2020/08/29 06:00 CRDT- 2019/10/11 06:00 PHST- 2019/03/15 00:00 [received] PHST- 2019/08/31 00:00 [revised] PHST- 2019/09/07 00:00 [accepted] PHST- 2019/10/11 06:00 [pubmed] PHST- 2020/08/29 06:00 [medline] PHST- 2019/10/11 06:00 [entrez] AID - S1078-1439(19)30360-6 [pii] AID - 10.1016/j.urolonc.2019.09.009 [doi] PST - ppublish SO - Urol Oncol. 2019 Dec;37(12):900-906. doi: 10.1016/j.urolonc.2019.09.009. Epub 2019 Oct 6. PMID- 31595333 OWN - NLM STAT- MEDLINE DCOM- 20191122 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 12 DP - 2019 Dec TI - DeltaNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. PG - 3075-3087 LID - 10.1007/s00432-019-03028-5 [doi] AB - PURPOSE: Bladder cancer represents a major cause of malignancy-related morbidity and the most expensive per-patient-to-treat cancer, due to the lifelong surveillance of the patients. Accurate disease prognosis is essential in establishing personalized treatment decisions; yet optimum tools for precise risk stratification remain a competing task. In the present study, we have performed the complete evaluation of TP63 clinical significance in improving disease prognosis. METHODS: The levels of DeltaNp63 and TAp63 transcripts of TP63 were quantified in 342 bladder tissue specimens of our screening cohort (n = 182). Hedegaard et al. (Cancer Cell 30:27-42. doi:10.1016/j.ccell.2016.05.004, 2016) (n = 476) and TCGA provisional (n = 413) were used as validation cohorts for NMIBC and MIBC, respectively. Survival analysis was performed using recurrence and progression for NMIBC or mortality for MIBC as endpoint events. Bootstrap analysis was performed for internal validation, while decision curve analysis was used for the evaluation of the clinical net benefit on disease prognosis. RESULTS: DeltaNp63 was significantly expressed in bladder tissues, and was found to be over-expressed in bladder tumors. Interestingly, reduced DeltaNp63 levels were correlated with muscle-invasive disease, high-grade tumors and high-EORTC-risk NMIBC patients. Moreover, DeltaNp63 loss was independently associated with higher risk for NMIBC relapse (HR = 2.730; p = 0.007) and progression (HR = 7.757; p = 0.016). Hedegaard et al. and TCGA validation cohorts confirmed our findings. Finally, multivariate models combining DeltaNup63 loss with established prognostic markers led to a superior clinical benefit for NMIBC prognosis and risk stratification. CONCLUSIONS: DeltaNup63 loss is associated with adverse outcome of NMIBC resulting in superior prediction of NMIBC early relapse and progression. FAU - Papadimitriou, Maria-Alexandra AU - Papadimitriou MA AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Panepistimiopolis, 157 01, Athens, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Panepistimiopolis, 157 01, Athens, Greece. FAU - Levis, Panagiotis K AU - Levis PK AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Agiou Thoma 17, 11527, Athens, Greece. FAU - Tokas, Theodoros AU - Tokas T AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Agiou Thoma 17, 11527, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Agiou Thoma 17, 11527, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Panepistimiopolis, 157 01, Athens, Greece. ascorilas@biol.uoa.gr. LA - eng PT - Journal Article DEP - 20191008 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Amino Acid Transport Systems, Neutral) RN - 0 (Biomarkers, Tumor) RN - 0 (SLC16A10 protein, human) RN - 0 (TP63 protein, human) RN - 0 (Transcription Factors) RN - 0 (Tumor Suppressor Proteins) SB - IM MH - Aged MH - Amino Acid Transport Systems, Neutral/*metabolism MH - Biomarkers, Tumor/metabolism MH - Chronic Disease MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*metabolism/pathology MH - Prognosis MH - Recurrence MH - Transcription Factors/*metabolism MH - Tumor Suppressor Proteins/*metabolism MH - Urinary Bladder Neoplasms/*metabolism/pathology PMC - PMC11810263 OTO - NOTNLM OT - Bladder tumors OT - TAp63 OT - TP63 OT - Urothelial carcinoma OT - p53 family OT - p63 COIS- The authors declare no conflict of interest. EDAT- 2019/10/09 06:00 MHDA- 2019/11/23 06:00 PMCR- 2019/10/08 CRDT- 2019/10/10 06:00 PHST- 2019/06/08 00:00 [received] PHST- 2019/09/16 00:00 [accepted] PHST- 2019/10/09 06:00 [pubmed] PHST- 2019/11/23 06:00 [medline] PHST- 2019/10/10 06:00 [entrez] PHST- 2019/10/08 00:00 [pmc-release] AID - 10.1007/s00432-019-03028-5 [pii] AID - 3028 [pii] AID - 10.1007/s00432-019-03028-5 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Dec;145(12):3075-3087. doi: 10.1007/s00432-019-03028-5. Epub 2019 Oct 8. PMID- 31594737 OWN - NLM STAT- MEDLINE DCOM- 20200629 LR - 20200629 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 6 DP - 2019 Dec TI - Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? PG - e1122-e1128 LID - S1558-7673(19)30244-7 [pii] LID - 10.1016/j.clgc.2019.07.016 [doi] AB - PURPOSE: To assess whether receipt of 5-alpha reductase inhibitors (5-ARIs) influences the findings on surgical pathology at the time of radical cystectomy (RC) and subsequent clinical outcomes. 5-ARIs may slow the progression of non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We retrospectively reviewed all patients who underwent RC at our institution between 2009 and 2017. Men were included who had urothelial cancer in the RC specimen. Patients with nonurothelial pathology or who had no cancer in the specimen were excluded. Odds ratios for pathologic features and hazard ratios for survival were adjusted for baseline patient characteristics and disease stage. RESULTS: Our study cohort included 338 men; 48 patients (14%) were receiving dutasteride or finasteride at time of RC, 58 (17%) metformin, and 195 (58%) statins. Among patients receiving 5-ARIs, there was a lower proportion of positive margins (P = .08) and lymphovascular invasion (P = .05). This was statistically significant when patients with urothelial carcinoma variants were excluded. Multivariable logistic regression analysis demonstrated that 5-ARI receipt was associated with a lower odds ratio (OR) for the presence of lymphovascular invasion (OR = 0.49; 95% confidence interval, 0.24-1.00; P = .049) and positive surgical margins (OR = 0.30; 95% confidence interval, 0.09-1.07; P = .063). Further, 5-ARI receipt was associated with better overall survival, with an adjusted hazard ratio of 0.40 (95% confidence interval, 0.19-0.83; P = .015). No similar tendencies were observed with metformin or statins. CONCLUSION: 5-ARIs may exert a protective biologic effect on the invasive properties of high-grade urothelial carcinoma. Further research is needed to understand the therapeutic implications. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - McMartin, Catherine AU - McMartin C AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. FAU - Lacombe, Louis AU - Lacombe L AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. FAU - Fradet, Vincent AU - Fradet V AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. FAU - Fradet, Yves AU - Fradet Y AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. FAU - Lodde, Michele AU - Lodde M AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. FAU - Toren, Paul AU - Toren P AD - Faculty of Medicine, Department of Surgery, Universite Laval, Centre Hospitalier Universitaire (CHU) de Quebec Research Centre, Oncology Division, Quebec, Canada. Electronic address: paul.toren@crchudequebec.ulaval.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190805 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (5-alpha Reductase Inhibitors) RN - 57GNO57U7G (Finasteride) RN - O0J6XJN02I (Dutasteride) SB - IM MH - 5-alpha Reductase Inhibitors/*therapeutic use MH - Aged MH - Carcinoma, Transitional Cell/*therapy MH - Cystectomy/*methods MH - Dutasteride/therapeutic use MH - Finasteride/therapeutic use MH - Humans MH - Logistic Models MH - Male MH - Margins of Excision MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*therapy OTO - NOTNLM OT - Bladder cancer OT - Dutasteride OT - Finasteride OT - Statins OT - Urothelial carcinoma EDAT- 2019/10/09 06:00 MHDA- 2020/07/01 06:00 CRDT- 2019/10/10 06:00 PHST- 2019/04/12 00:00 [received] PHST- 2019/07/16 00:00 [revised] PHST- 2019/07/28 00:00 [accepted] PHST- 2019/10/09 06:00 [pubmed] PHST- 2020/07/01 06:00 [medline] PHST- 2019/10/10 06:00 [entrez] AID - S1558-7673(19)30244-7 [pii] AID - 10.1016/j.clgc.2019.07.016 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Dec;17(6):e1122-e1128. doi: 10.1016/j.clgc.2019.07.016. Epub 2019 Aug 5. PMID- 31594736 OWN - NLM STAT- MEDLINE DCOM- 20200629 LR - 20200629 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 6 DP - 2019 Dec TI - Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial. PG - e1108-e1115 LID - S1558-7673(19)30247-2 [pii] LID - 10.1016/j.clgc.2019.07.019 [doi] AB - INTRODUCTION: The objective of this study was to determine the efficiency of 1-year maintenance intravesical chemotherapy (MIC) in reducing bladder recurrence (BR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma compared with single intravesical instillation (SIC). PATIENTS AND METHODS: Between January 2015 and May 2017, patients who underwent RNU were randomized to receive SIC (epirubicin 50 mg) or MIC (once weekly for 6 weeks plus once monthly for 1 year). The primary outcome was the rate of histologically proven BR. The secondary outcomes included chemotherapy-related toxicities and disease-specific survival (DSS). Thirty-five patients in each arm were required to achieve a power of 80%. RESULTS: A total of 38 (SIC) and 36 (MIC) patients were analyzed. In SIC, BR developed in 5 (13.2%) over a median follow-up of 3 months (range, 3-6 months) compared with 9 (25%) patients over 12 months (range, 3-28 months) in MIC (P = .08). The 6- and 12-month BR-free survivals were the same (86.8%) in SIC versus 88.9% and 83.3% in MIC, respectively (P = .2). Lymphovascular invasion was significantly associated with BR (P = .04). Post-RNU intravesical chemotherapy regimens did not alter DSS. Blood transfusion and advanced tumor stage were independent predictors for DSS. No significant medication toxicity was reported. CONCLUSIONS: Following RNU, MIC did not change the natural course of BR beyond a single instillation apart from potentially delaying its occurrence. Lymphovascular invasion and blood transfusion were associated with worse BR and DSS outcomes, respectively. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Harraz, Ahmed M AU - Harraz AM AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. Electronic address: Ahmed.harraz@hotmail.com. FAU - El-Shabrawy, Magdy AU - El-Shabrawy M AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Nahas, Ahmed R AU - El-Nahas AR AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Kappany, Hamdy AU - El-Kappany H AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Osman, Yasser AU - Osman Y AD - Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20190805 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antibiotics, Antineoplastic) RN - 3Z8479ZZ5X (Epirubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage/adverse effects MH - Carcinoma, Transitional Cell/*prevention & control/surgery MH - Drug Administration Schedule MH - Epirubicin/*administration & dosage/adverse effects MH - Female MH - Humans MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control/surgery MH - Nephroureterectomy MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*prevention & control/surgery OTO - NOTNLM OT - BLadder Recurrence OT - Maintenance therapy OT - Nephroureterectomy OT - Urothelial carcinoma EDAT- 2019/10/09 06:00 MHDA- 2020/07/01 06:00 CRDT- 2019/10/10 06:00 PHST- 2019/04/24 00:00 [received] PHST- 2019/07/25 00:00 [revised] PHST- 2019/07/28 00:00 [accepted] PHST- 2019/10/09 06:00 [pubmed] PHST- 2020/07/01 06:00 [medline] PHST- 2019/10/10 06:00 [entrez] AID - S1558-7673(19)30247-2 [pii] AID - 10.1016/j.clgc.2019.07.019 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Dec;17(6):e1108-e1115. doi: 10.1016/j.clgc.2019.07.019. Epub 2019 Aug 5. PMID- 31586544 OWN - NLM STAT- MEDLINE DCOM- 20210414 LR - 20211109 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 2 DP - 2020 Feb TI - Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors. PG - 40.e9-40.e15 LID - S1078-1439(19)30358-8 [pii] LID - 10.1016/j.urolonc.2019.09.007 [doi] AB - BACKGROUND: The peak incidence of bladder cancer (BCa) occurs at 85 years but data on treatment and outcome are sparse in this age group. We aimed to compare the outcomes of high-grade nonmuscle invasive BCa (HG NMIBC) and muscle invasive BCa (MIBC) treated with standard therapies vs. palliative management in patients >85 years. METHODS: Retrospective multicenter study of 317 patients >85 years who underwent transurethral resection (TURB) for de novo BCa between 2014 and 2016. Standard management consisted in following EAU-guidelines and palliative in monitoring patients without applying oncological treatments after TURB. Low-grade tumors were not compared because all of them were considered to have followed a standard management. RESULTS: Median age was 87 years (85-97). ASA-score was as follows: II, 34.7%; III, 52.1%; IV, 13.2%. Pathological examination showed: 86 Low-grade NMIBC (27.1%), 156 HG NMIBC (49.2%), and 75 MIBC (23.7%). Median follow-up of the series was 21 months (3-61) and median overall survival (OS) 29 (24-33). Among HG NMIBC, 77 patients (49.4%) received standard treatments (BCG, restaging TURB) and 79 (50.6%) palliative management. Among MIBC, 24 (32%) received standard management (cystectomy, radiotherapy, chemotherapy) and 51 (68%) palliative. Applying standard management in HG NMIBC was an independent prognostic factor of OS (44 months vs. 24, HR 1.95; P = 0.013) and decreased the emergency visit rate (33% vs. 43%). In MIBC, the type of management was not a related to OS (P = 0.439) and did not decrease the emergency visit rate (33% vs. 33%). ASA and Charlson-score were not predictors of OS in HG NMIBC (P = 0.368, P = 0.386) and MIBC (P = 0.511, P = 0.665). CONCLUSIONS: Chronological age should not be a contraindication for applying standard therapies in NMIBC. In MIBC the survival is low regardless of the type of management. The lack of correlation between OS and ASA or Charlson-score raises the necessity of a geriatric assessment for selecting the best treatment strategy. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Carrion, Albert AU - Carrion A AD - Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: acarrionpuig@gmail.com. FAU - Huguet, Jorge AU - Huguet J AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Ribal, Maria Jose AU - Ribal MJ AD - Department of Urology, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain. FAU - Dominguez, Arturo AU - Dominguez A AD - Department of Urology, Hospital Parc Tauli, Autonomous University of Barcelona, Barcelona, Spain. FAU - Bonet, Xavier AU - Bonet X AD - Department of Urology, Hospital Bellvitge, University of Barcelona, Barcelona, Spain. FAU - Servian, Pol AU - Servian P AD - Department of Urology, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain. FAU - Mayordomo, Olga AU - Mayordomo O AD - Department of Urology, Fundacio Puigvert, Autonomous University of Barcelona, Barcelona, Spain. FAU - Ajami, Tarek AU - Ajami T AD - Department of Urology, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain. FAU - Picola, Natalia AU - Picola N AD - Department of Urology, Hospital Bellvitge, University of Barcelona, Barcelona, Spain. FAU - Freixa, Roger AU - Freixa R AD - Department of Urology, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain. FAU - Diaz, Fernando AU - Diaz F AD - Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain. FAU - Lozano, Fernando AU - Lozano F AD - Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain. FAU - Raventos, Carles AU - Raventos C AD - Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain. FAU - Morote, Juan AU - Morote J AD - Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20191002 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - J Urol. 2021 Mar;205(3):906-909. doi: 10.1097/JU.0000000000001542. PMID: 33356457 MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Male MH - Palliative Care/*methods MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*therapy OTO - NOTNLM OT - Bladder cancer OT - Elderly OT - Octogenarians OT - Palliative management OT - Transurethral resection of the bladder EDAT- 2019/10/07 06:00 MHDA- 2021/04/15 06:00 CRDT- 2019/10/07 06:00 PHST- 2019/05/10 00:00 [received] PHST- 2019/08/14 00:00 [revised] PHST- 2019/09/04 00:00 [accepted] PHST- 2019/10/07 06:00 [pubmed] PHST- 2021/04/15 06:00 [medline] PHST- 2019/10/07 06:00 [entrez] AID - S1078-1439(19)30358-8 [pii] AID - 10.1016/j.urolonc.2019.09.007 [doi] PST - ppublish SO - Urol Oncol. 2020 Feb;38(2):40.e9-40.e15. doi: 10.1016/j.urolonc.2019.09.007. Epub 2019 Oct 2. PMID- 31584195 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20260127 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 146 IP - 2 DP - 2020 Jan 15 TI - A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. PG - 449-460 LID - 10.1002/ijc.32719 [doi] AB - Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC(50) < 1 nM. Furthermore, our data showed that exposures as short as approximately 3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF-anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer. CI - (c) 2019 UICC. FAU - Jack, Sherwin AU - Jack S AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. FAU - Madhivanan, Kayalvizhi AU - Madhivanan K AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. FAU - Ramadesikan, Swetha AU - Ramadesikan S AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. FAU - Subramanian, Sneha AU - Subramanian S AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. FAU - Edwards, Daniel F 2nd AU - Edwards DF 2nd AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. FAU - Elzey, Bennett D AU - Elzey BD AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Comparative Pathobiology, Purdue University, West Lafayette, IN. AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Dhawan, Deepika AU - Dhawan D AD - Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN. FAU - McCluskey, Andrew AU - McCluskey A AD - Department of Microbiology, Harvard Medical School, Boston, MA. FAU - Kischuk, Erin M AU - Kischuk EM AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Comparative Pathobiology, Purdue University, West Lafayette, IN. FAU - Loftis, Alexander R AU - Loftis AR AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. FAU - Truex, Nicholas AU - Truex N AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. FAU - Santos, Michael AU - Santos M AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. FAU - Lu, Mike AU - Lu M AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. FAU - Rabideau, Amy AU - Rabideau A AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. FAU - Pentelute, Bradley AU - Pentelute B AD - Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA. AD - Koch Institute MIT, Cambridge, MA. AD - Broad Institute of Harvard and MIT, Cambridge, MA. AD - Center for Environmental Health Sciences MIT, Cambridge, MA. FAU - Collier, John AU - Collier J AD - Department of Microbiology, Harvard Medical School, Boston, MA. FAU - Kaimakliotis, Hristos AU - Kaimakliotis H AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Koch, Michael AU - Koch M AD - Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Ratliff, Timothy L AU - Ratliff TL AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Comparative Pathobiology, Purdue University, West Lafayette, IN. FAU - Knapp, Deborah W AU - Knapp DW AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN. FAU - Aguilar, Ruben C AU - Aguilar RC AUID- ORCID: 0000-0001-5623-0073 AD - Purdue University Center for Cancer Research, West Lafayette, IN. AD - Department of Biological Sciences, Purdue University, West Lafayette, IN. LA - eng GR - R21 CA151961/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20191101 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Antigens, Bacterial) RN - 0 (Antineoplastic Agents) RN - 0 (Bacterial Toxins) RN - 62229-50-9 (Epidermal Growth Factor) RN - 0 (Immunotoxins) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (anthrax toxin) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Administration, Intravesical MH - Animals MH - Antigens, Bacterial/*administration & dosage/adverse effects MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - Apoptosis/drug effects MH - Bacterial Toxins/*administration & dosage/adverse effects MH - Cell Line, Tumor MH - Dogs MH - Drug Screening Assays, Antitumor MH - Epidermal Growth Factor/*administration & dosage/adverse effects MH - Female MH - Humans MH - Immunotoxins/*administration & dosage/adverse effects MH - Male MH - Mice MH - Primary Cell Culture MH - Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/veterinary PMC - PMC10303116 MID - NIHMS1910436 OTO - NOTNLM OT - EGF OT - EGFR OT - anthrax toxin OT - bladder cancer OT - therapy COIS- Conflict of interest: The authors declare no potential conflicts of interest. EDAT- 2019/10/05 06:00 MHDA- 2020/02/20 06:00 PMCR- 2023/06/28 CRDT- 2019/10/05 06:00 PHST- 2019/05/10 00:00 [received] PHST- 2019/08/10 00:00 [revised] PHST- 2019/09/11 00:00 [accepted] PHST- 2019/10/05 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/10/05 06:00 [entrez] PHST- 2023/06/28 00:00 [pmc-release] AID - 10.1002/ijc.32719 [doi] PST - ppublish SO - Int J Cancer. 2020 Jan 15;146(2):449-460. doi: 10.1002/ijc.32719. Epub 2019 Nov 1. PMID- 31573328 OWN - NLM STAT- MEDLINE DCOM- 20191127 LR - 20220411 IS - 1748-880X (Electronic) IS - 0007-1285 (Print) IS - 0007-1285 (Linking) VI - 92 IP - 1104 DP - 2019 Dec TI - Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. PG - 20190401 LID - 10.1259/bjr.20190401 [doi] LID - 20190401 AB - OBJECTIVE: To evaluate role of multiparametric MRI (mp-MRI) in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score. METHODS AND MATERIALS: 50 patients diagnosed as cancer bladder were enrolled in this study, mp-MRI including conventional (T(1) weighted imaging and high resolution T(2) weighted imaging) and functional sequences (diffusion-weighted imaging and dynamic contrast enhanced-MRI) were done, all data were regrouped to evaluate the accuracy of each separate sequence and mp-MRI in distinguishing non-muscle invasive from muscle-invasive tumors, with VI-RADS score application and comparison with pathological findings, then interobserver agreement for detection of muscle invasion according to mp-MRI and VI-RADS scoring system findings was calculated. RESULTS: Diagnostic accuracy of mp-MRI in differentiation between muscle invasive and non-muscle invasive bladder cancer was (84%) with highest sensitivity (78%), very good agreement between mp-MRI and histopathological data (k = 0.87), and highest area under curve (AUC) reaching 0.83, dynamic contrast enhanced-MRI sequence showed the highest accuracy in muscle invasion detection by (88%), with highest AUC 0.83. Diagnostic accuracy of VI-RADS score in detection of muscle invasion was 84%, with specificity and negative predictive value of 88% and AUC was 0.83. Interobserver agreement was strong as regard diagnostic performance of mp-MRI and VI-RADS scoring for detection of muscle invasion reaching (K = 0.82, p < 0.001) and (K = 0.87, p < 0.001) respectively. CONCLUSION: mp-MRI is considered as comprehensive and effective tool for determination of muscle invasion in cases of urinary bladder cancer. Also VI-RADS scoring system can accurately differentiate between invasive and non-invasive bladder cancer. ADVANCES IN KNOWLEDGE: The VI-RADS system was recently suggested for the uniform evaluation of muscle invasion in cancer bladder by mp-MRI. In this paper, we applied this system to 50 cases to evaluate its ease and compared the results with the histopathological findings for evaluation of its accuracy. FAU - Makboul, Marwa AU - Makboul M AD - Lecturer of radio diagnosis, Radio diagnosis department, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Farghaly, Shimaa AU - Farghaly S AD - Lecturer of radio diagnosis, Radio diagnosis department, Faculty of Medicine, Assiut University, Assiut, Egypt. FAU - Abdelkawi, Islam F AU - Abdelkawi IF AD - Urology Department, Faculty of Medicine, Assiut University, Assiut, Egypt. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20191008 PL - England TA - Br J Radiol JT - The British journal of radiology JID - 0373125 RN - 0 (Contrast Media) SB - IM CIN - Br J Radiol. 2020 May 1;93(1109):20200025. doi: 10.1259/bjr.20200025. PMID: 32160006 MH - Adult MH - Aged MH - Area Under Curve MH - Carcinoma, Transitional Cell/*diagnostic imaging/pathology MH - Contrast Media MH - Diagnosis, Differential MH - Female MH - Humans MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Muscle, Smooth/diagnostic imaging/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Observer Variation MH - ROC Curve MH - Sensitivity and Specificity MH - Urinary Bladder/*diagnostic imaging/pathology MH - Urinary Bladder Neoplasms/*diagnostic imaging/pathology PMC - PMC6913364 EDAT- 2019/10/02 06:00 MHDA- 2019/11/28 06:00 PMCR- 2020/12/01 CRDT- 2019/10/02 06:00 PHST- 2019/10/02 06:00 [pubmed] PHST- 2019/11/28 06:00 [medline] PHST- 2019/10/02 06:00 [entrez] PHST- 2020/12/01 00:00 [pmc-release] AID - 10.1259/bjr.20190401 [doi] PST - ppublish SO - Br J Radiol. 2019 Dec;92(1104):20190401. doi: 10.1259/bjr.20190401. Epub 2019 Oct 8. PMID- 31569597 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 8 IP - 10 DP - 2019 Sep 27 TI - Association between Bladder Outlet Obstruction and Bladder Cancer in Patients with Aging Male. LID - 10.3390/jcm8101550 [doi] LID - 1550 AB - The associations between the treatment outcomes of benign prostatic hyperplasia/benign prostatic obstruction and lifelong health status, including urologic cancer incidence as well as geriatric adverse events (AEs), are unknown. This retrospective cohort study analyzed claims data collected during the period of 1997-2012 from Taiwan's Longitudinal Health Insurance Database 2000. Patients who received transurethral resection of the prostate (TURP) were prioritized, and the remaining patients who were prescribed alpha-blockers were, subsequently, identified. Patients in the TURP and medication-only groups were further divided into two groups, according to the presence or absence of AEs during the first six-month follow-up. Outcomes of primary interest were all-cause mortality, occurrence of prostate cancer, transurethral resection of the bladder tumor, and radical cystectomy for bladder cancer. Compared with patients in the AE-free TURP group, those in the TURP with AEs had a higher risk of lifelong bladder cancer (subdistribution hazard ratio: 2.3, 95% confidence interval (CI): 1.56-3.39), whereas the risk of prostate cancer was comparable between the two groups (SHR: 1.2, 95% CI: 0.83-1.74). In the medication cohorts, patients undergoing alpha-blocker treatment who had AEs had a higher risk of all-cause mortality (hazard ratio: 1.63, 95% CI: 1.49-1.78) and a higher risk of lifelong bladder cancer (SHR: 2.72, 95% CI: 1.99-3.71) when compared with those without AE. Our study reveals that unfavorable treatment outcomes of benign prostate hyperplasia, whether caused by medication or surgical treatment, are associated with a higher incidence of bladder cancer. Unfavorable outcomes of surgical treatment are associated with higher risk of geriatric AEs, and unfavorable outcomes of medication treatment are associated with a higher risk of all-cause mortality. FAU - Lin, Yu-Hsiang AU - Lin YH AUID- ORCID: 0000-0001-9923-5747 AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. linyh@cgmh.org.tw. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. linyh@cgmh.org.tw. AD - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. linyh@cgmh.org.tw. FAU - Hou, Chen-Pang AU - Hou CP AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. glucose1979@gmail.com. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. glucose1979@gmail.com. AD - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. glucose1979@gmail.com. FAU - Juang, Horng-Heng AU - Juang HH AUID- ORCID: 0000-0002-8524-8253 AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. hhj143@mail.cgu.edu.tw. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. hhj143@mail.cgu.edu.tw. AD - Department of Anatomy, School of Medicine, Chang Gung University, Kwei-shan, Tao-Yuan 333, Taoyuan, Taiwan, China. hhj143@mail.cgu.edu.tw. FAU - Chang, Phei-Lang AU - Chang PL AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. henryc@cgmh.org.tw. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. henryc@cgmh.org.tw. FAU - Chen, Tien-Hsing AU - Chen TH AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. skyheart0826@gmail.com. AD - Department of Cardiology, Chang Gung Memorial Hospital at Keelung, Biostatiscal consultation center of Chang Gung Memorial hospital, Community Medicine Research Center, Keelung, Keelung 204, Taiwan, China. skyheart0826@gmail.com. FAU - Chen, Chien-Lun AU - Chen CL AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. FAU - Tsui, Ke-Hung AU - Tsui KH AUID- ORCID: 0000-0001-9814-0914 AD - Department of Urology, Chang Gung Memorial Hospital at linkou, Taoyuan 333, Taiwan, China. khtsui@yahoo.com. AD - School of Medicine, Chang Gung University, Taoyuan 333, Taiwan, China. khtsui@yahoo.com. LA - eng GR - CRPG3A1061/Chang Gung Memorial Hospital, Linkou/ PT - Journal Article DEP - 20190927 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC6832159 OTO - NOTNLM OT - benign prostate hyperplasia OT - bladder outlet obstruction OT - diabetes mellitus OT - lower urinary tract symptoms OT - prostatectomy OT - urinary tract infection COIS- The authors declare that they have no competing interests. EDAT- 2019/10/02 06:00 MHDA- 2019/10/02 06:01 PMCR- 2019/09/27 CRDT- 2019/10/02 06:00 PHST- 2019/08/14 00:00 [received] PHST- 2019/09/02 00:00 [revised] PHST- 2019/09/23 00:00 [accepted] PHST- 2019/10/02 06:00 [entrez] PHST- 2019/10/02 06:00 [pubmed] PHST- 2019/10/02 06:01 [medline] PHST- 2019/09/27 00:00 [pmc-release] AID - jcm8101550 [pii] AID - jcm-08-01550 [pii] AID - 10.3390/jcm8101550 [doi] PST - epublish SO - J Clin Med. 2019 Sep 27;8(10):1550. doi: 10.3390/jcm8101550. PMID- 31566930 OWN - NLM STAT- MEDLINE DCOM- 20200629 LR - 20210110 IS - 2324-9269 (Electronic) IS - 2324-9269 (Linking) VI - 7 IP - 11 DP - 2019 Nov TI - Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer. PG - e982 LID - 10.1002/mgg3.982 [doi] LID - e982 AB - BACKGROUND: The dreadful prognosis of nonmuscle invasive bladder cancer mainly results from the delay in recognition of individuals with a high risk of progression. Thus, the emphasis of this work lies in developing valuable biomarkers that is conducive to accurately predicting the progression of NMIBC. METHODS: Microarray data from GSE32894 including 209 NMIBC samples were performed by weighted gene coexpression network analysis (WGCNA), which could find modules of highly correlated genes and relate modules to external sample traits. Besides, we constructed a protein-protein interaction to facilitate screening the hub gene. At last, we used RNA-seq and microarray data and clinical information from ArrayExpress (E-MTAB-4321) and GSE13507 to select and validate the candidate gene. RESULTS: In current paper, blue module of 13 gene coexpression clusters we identified was selected as the key modules. Seven genes namely: CDCA8, CENPF, MCM6, MELK, PRC1, STIL, and TPX2 have been identified as candidate genes. Notably, among them, only elevated CENPF in NIMBC tissue was closely associated with low progression-free survival (PFS) and overall survival (OS) rate in three datasets and had a large area under receiver operating characteristic (ROC) curve. Finally, CENPF was identified as an effective biomarker in NMIBC. CONCLUSION: Therefore, our findings submit a new progressive and prognostic molecular marker and therapeutic target for NMIBC. Moreover, these genes that deserve to be further researched may improve the comprehension about the occurrence and development of superficial bladder cancer. CI - (c) 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. FAU - Shi, Jiawei AU - Shi J AUID- ORCID: 0000-0002-1031-3276 AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Pu AU - Zhang P AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Lilong AU - Liu L AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Min, Xiaobo AU - Min X AD - Department of Hepatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xiao, Yajun AU - Xiao Y AUID- ORCID: 0000-0003-0795-8273 AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20190930 PL - United States TA - Mol Genet Genomic Med JT - Molecular genetics & genomic medicine JID - 101603758 RN - 0 (Biomarkers, Tumor) RN - 0 (Chromosomal Proteins, Non-Histone) RN - 0 (Microfilament Proteins) RN - 0 (centromere protein F) SB - IM MH - Biomarkers, Tumor/*genetics MH - Chromosomal Proteins, Non-Histone/*genetics MH - Datasets as Topic MH - Disease Progression MH - *Gene Regulatory Networks MH - Microarray Analysis MH - Microfilament Proteins/*genetics MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/diagnosis/*genetics PMC - PMC6825849 OTO - NOTNLM OT - CENPF OT - biomarkers OT - nonmuscle invasive bladder cancer (NMIBC) OT - progression OT - weighted gene coexpression network analysis (WGCNA) COIS- The authors declare no conflict of interest. EDAT- 2019/10/01 06:00 MHDA- 2020/07/01 06:00 PMCR- 2019/09/30 CRDT- 2019/10/01 06:00 PHST- 2019/03/01 00:00 [received] PHST- 2019/07/23 00:00 [revised] PHST- 2019/08/29 00:00 [accepted] PHST- 2019/10/01 06:00 [pubmed] PHST- 2020/07/01 06:00 [medline] PHST- 2019/10/01 06:00 [entrez] PHST- 2019/09/30 00:00 [pmc-release] AID - MGG3982 [pii] AID - 10.1002/mgg3.982 [doi] PST - ppublish SO - Mol Genet Genomic Med. 2019 Nov;7(11):e982. doi: 10.1002/mgg3.982. Epub 2019 Sep 30. PMID- 31555691 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220410 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 7 IP - 16 DP - 2019 Aug TI - Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma. PG - 377 LID - 10.21037/atm.2019.07.31 [doi] LID - 377 AB - BACKGROUND: The prognostic role of squamous differentiation in upper urinary tract urothelial carcinoma (UTUC) is still unclear. This article describes the impact of squamous differentiation on prognosis and intravesical recurrence of patients with primary UTUC treated with radical nephroureterectomy (RNU). METHODS: Totally, we retrieved (I) 669 histologically confirmed UTUC patients without histologic variants; (II) 101 UTUC patients with squamous differentiation in our institution, dating from April 2003 to April 2016. The clinical pathological characteristics and survival outcomes were compared between these two cohorts. RESULTS: In our study, 13% UTUC patients were detected with squamous differentiation. The mean age of all the patients examined was 66, of whom 70% were males. Squamous differentiation significantly associated with tumor stage, tumor grade and lymphovascular invasion. The Kaplan-Meier and Cox regression analyses showed that presence of squamous differentiation was correlated with shorter cancer specific survival of UTUC patients. The 5-year cancer specific survival rates were 47% for squamous differentiation-present patients and 63% for squamous differentiation-absent patients. UTUC patients with squamous differentiation showed a higher frequency of high-grade disease in advanced stage (pT2/pT3/pT4), while the discrepancy was not shown in early stage (pTa/pT1). Intravesical recurrence was observed in 27% patients. We found that intravesical recurrence had little impact on the cancer specific survival of squamous differentiation-present patients, yet it tended to decrease cancer specific survival among squamous differentiation-absent patients. CONCLUSIONS: The presence of squamous differentiation in UTUC patients was a vital prognostic factor for cancer specific survival and correlated with intravesical recurrence after receiving RNU. FAU - Yu, Jianpeng AU - Yu J AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China. FAU - Li, Gang AU - Li G AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China. FAU - Wang, Aixiang AU - Wang A AD - Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Luo, Qiang AU - Luo Q AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China. FAU - Liu, Zihao AU - Liu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China. FAU - Niu, Yuanjie AU - Niu Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China. FAU - Mei, Yanhui AU - Mei Y AD - Department of Urology, Binzhou Medical University Hospital, Binzhou 256603, China. LA - eng PT - Journal Article PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC6736827 OTO - NOTNLM OT - Squamous differentiation OT - intravesical recurrence OT - prognosis OT - radical nephroureterectomy (RNU) OT - upper urinary tract urothelial carcinoma (UTUC) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2019/09/27 06:00 MHDA- 2019/09/27 06:01 PMCR- 2019/08/01 CRDT- 2019/09/27 06:00 PHST- 2019/09/27 06:00 [entrez] PHST- 2019/09/27 06:00 [pubmed] PHST- 2019/09/27 06:01 [medline] PHST- 2019/08/01 00:00 [pmc-release] AID - atm-07-16-377 [pii] AID - 10.21037/atm.2019.07.31 [doi] PST - ppublish SO - Ann Transl Med. 2019 Aug;7(16):377. doi: 10.21037/atm.2019.07.31. PMID- 31552489 OWN - NLM STAT- MEDLINE DCOM- 20191125 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 11 DP - 2019 Nov TI - MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer. PG - 2725-2736 LID - 10.1007/s00432-019-03035-6 [doi] AB - PURPOSE: The identification of biomarkers characterizing the invasive potential of bladder cancer could enhance the clinical management of individual patients and therefore improve prognosis. The aim of this study was to define a miRNA panel in tumor tissues as well as in urinary extracellular vesicles (EVs) for discriminating muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC). METHODS: miRNA expression was analyzed in 24 formalin-fixed, paraffin-embedded (FFPE) tumor samples by microarray analysis and was further validated by qRT-PCR in 56 FFPE tumor samples as well as in 37 urinary EV samples. RESULTS: Microarray analysis revealed 63 miRNAs that were significantly differentially expressed (P < 0.05) between tissues from MIBC and NMIBC tumors. Five selected miRNAs (miR-146b-5p, miR-155-5p, miR-138-5p, miR-144-5p, and miR-200a-3p) were validated by qRT-PCR. The expression of all except miR-144-5p was significantly associated with high tumor grade. In urinary EVs, a different expression was verified for miR-146b-5p (P = 0.004) and miR-155-5p (P = 0.036), which exhibited significantly higher expression in urinary EVs from patients with MIBC. CONCLUSIONS: miRNAs are promising biomarkers for the identification of invasive bladder carcinomas. Tissue samples as well as urinary EVs may serve as sources for miRNA analysis. This method, in addition to histopathology, could provide a new diagnostic tool and facilitate individual therapeutic decisions to select patients for early cystectomy. FAU - Baumgart, Sophie AU - Baumgart S AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. FAU - Meschkat, Pascal AU - Meschkat P AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. FAU - Edelmann, Philipp AU - Edelmann P AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. FAU - Heinzelmann, Joana AU - Heinzelmann J AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. AD - Department of Ophthalmology, Martin-Luther University Halle-Wittenberg, University Hospital Halle (Saale), Halle (Saale), Germany. FAU - Pryalukhin, Alexey AU - Pryalukhin A AD - Institute of Pathology, Saarland University, Homburg, Germany. FAU - Bohle, Rainer AU - Bohle R AD - Institute of Pathology, Saarland University, Homburg, Germany. FAU - Heinzelbecker, Julia AU - Heinzelbecker J AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. FAU - Stockle, Michael AU - Stockle M AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. FAU - Junker, Kerstin AU - Junker K AUID- ORCID: 0000-0002-0873-8128 AD - Department of Urology and Pediatric Urology, Saarland University, Kirrberger Str 100, 66424, Homburg, Germany. kerstin.junker@uks.eu. LA - eng PT - Journal Article DEP - 20190924 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics/*urine MH - Extracellular Vesicles/*genetics MH - Female MH - Follow-Up Studies MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - MicroRNAs/*genetics/*urine MH - Middle Aged MH - Muscle Neoplasms/*diagnosis/genetics/urine MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/genetics/urine PMC - PMC11810427 OTO - NOTNLM OT - Bladder cancer OT - Extracellular vesicle OT - Muscle-invasive bladder cancer OT - Urine OT - microRNA COIS- The authors declare that they have no conflict of interest. EDAT- 2019/09/26 06:00 MHDA- 2019/11/26 06:00 PMCR- 2019/09/24 CRDT- 2019/09/26 06:00 PHST- 2019/07/18 00:00 [received] PHST- 2019/09/19 00:00 [accepted] PHST- 2019/09/26 06:00 [pubmed] PHST- 2019/11/26 06:00 [medline] PHST- 2019/09/26 06:00 [entrez] PHST- 2019/09/24 00:00 [pmc-release] AID - 10.1007/s00432-019-03035-6 [pii] AID - 3035 [pii] AID - 10.1007/s00432-019-03035-6 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Nov;145(11):2725-2736. doi: 10.1007/s00432-019-03035-6. Epub 2019 Sep 24. PMID- 31551051 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 2046-0236 (Electronic) IS - 0147-8885 (Linking) VI - 43 IP - 1 DP - 2020 Mar TI - Reduced expression of GATA3 predicts progression in non-muscle invasive urothelial carcinoma of the urinary bladder. PG - 21-28 LID - 10.1080/01478885.2019.1667126 [doi] AB - Urothelial carcinoma (UC) of the urinary bladder is the ninth most common cancer worldwide. The majority of these patients present with non-muscle invasive bladder cancer (NMIBC). GATA3 has recently emerged as one of the diagnostically helpful immunohistochemical markers for UC. The published literature, however, lacks comprehensive studies on the impact of GATA3 expression on the prognosis of UC patients. This study evaluated and statistically analyzed the immunohistochemical expressions of GATA3 and Ki67 in 50 Egyptian patients with NMIBC and correlated the markers' expressions with clinicopathological variables and patients' outcome. Ten control cases were included. The expressions of GATA3 and Ki67 were significantly downregulated and upregulated respectively in UC cases compared to the control group. GATA3 down-expression was significantly associated with high grade tumors and tumor progression with 72% prediction accuracy. Higher proliferative activity was significantly correlated with high grade, non-papillary growth pattern, and lamina propria invasion. The predictive performance of GATA3 and Ki67 in predicting malignancy and tumor grade was good. We concluded that GATA3 downregulation and increased proliferative activity might be implicated in UC tumorigenesis, loss of differentiation, and aggressiveness. Reduced GATA3 expression could predict progression in NMIBC with an accuracy of 72% and thus it constitutes a potentially promising novel prognostic marker in patients with urothelial carcinoma. FAU - Kamel, Nahla Abdelfattah AU - Kamel NA AD - Faculty of Medicine, University of Alexandria, Alexandria, Egypt. FAU - Abdelzaher, Eman AU - Abdelzaher E AUID- ORCID: 0000-0002-4291-3065 AD - Faculty of Medicine, University of Alexandria, Alexandria, Egypt. FAU - Elgebaly, Omar AU - Elgebaly O AUID- ORCID: 0000-0002-7119-7803 AD - Faculty of Medicine, University of Alexandria, Alexandria, Egypt. FAU - Ibrahim, Shery Abdullah AU - Ibrahim SA AD - Ras-Altin General Hospital, Ministry of Health Hospitals, Alexandria, Egypt. LA - eng PT - Journal Article DEP - 20190924 PL - England TA - J Histotechnol JT - Journal of histotechnology JID - 8003807 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/analysis MH - Carcinoma, Transitional Cell/metabolism MH - Disease Progression MH - GATA3 Transcription Factor/*metabolism MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Middle Aged MH - Prognosis MH - Urinary Bladder/*metabolism/physiology MH - Urologic Neoplasms/diagnosis/*metabolism/pathology MH - Urothelium/*metabolism/pathology OTO - NOTNLM OT - GATA3 OT - Ki67 OT - Non-muscle invasive bladder cancer OT - ROC curve OT - Urothelial Carcinoma OT - prognostic markers OT - tumor progression EDAT- 2019/09/26 06:00 MHDA- 2021/06/16 06:00 CRDT- 2019/09/26 06:00 PHST- 2019/09/26 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2019/09/26 06:00 [entrez] AID - 10.1080/01478885.2019.1667126 [doi] PST - ppublish SO - J Histotechnol. 2020 Mar;43(1):21-28. doi: 10.1080/01478885.2019.1667126. Epub 2019 Sep 24. PMID- 31549936 OWN - NLM STAT- MEDLINE DCOM- 20200122 LR - 20200122 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 203 IP - 2 DP - 2020 Feb TI - The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guerin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. PG - 283-291 LID - 10.1097/JU.0000000000000566 [doi] AB - PURPOSE: The objective of this study was to assess the value of fluorescence in situ hybridization to predict early recurrence in patients with nonmuscle invasive bladder cancer at intermediate and high risk treated with bacillus Calmette-Guerin. MATERIALS AND METHODS: We performed a systematic review using MEDLINE(R), Embase(R) and the Cochrane Library. Individual patient data from prospective observational studies of fluorescence in situ hybridization in patients treated with bacillus Calmette-Guerin were included. A 2-stage individual patient data meta-analysis was done to assess the value of fluorescence in situ hybridization to predict tumor recurrence after bacillus Calmette-Guerin induction therapy. RESULTS: From a total of 4 studies we obtained individual data on 422 patients, of whom 408 with a median followup of 18.8 months were included in the final analysis. When fluorescence in situ hybridization was positive, the recurrence HR was 1.20 (95% CI 0.81-1.79) before bacillus Calmette-Guerin (time 0), 2.23 (95% CI 1.31-3.62) at 6 weeks (time 1), 3.70 (95% CI 2.34-5.83) at 3 months (time 2) and 23.44 (95% CI 5.26-104.49) at 6 months (time 3). CONCLUSIONS: A positive fluorescence in situ hybridization test after bacillus Calmette-Guerin correlated with higher risk of recurrent tumor. Fluorescence in situ hybridization could aid urologists in risk stratifying and counseling patients. Based on the HR and the narrowest CI the preferred timing of fluorescence in situ hybridization is 3 months after transurethral resection of bladder tumor. This is also in time for patients in whom induction therapy fails to enter clinical trials or change the treatment strategy. FAU - Liem, Esmee I M L AU - Liem EIML AD - Department of Urology, Amsterdam University Medical Center, University of Amsterdam, The Netherlands. FAU - Oddens, Jorg R AU - Oddens JR AD - Department of Urology, Amsterdam University Medical Center, University of Amsterdam, The Netherlands. FAU - Vernooij, Robin W M AU - Vernooij RWM AD - Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. FAU - Li, Roger AU - Li R AD - Department of Urology, MD Anderson Cancer Center, San Antonio, Texas. FAU - Kamat, Ashish AU - Kamat A AD - Department of Urology, MD Anderson Cancer Center, San Antonio, Texas. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, MD Anderson Cancer Center, San Antonio, Texas. FAU - Mengual, Lourdes AU - Mengual L AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. FAU - Izquierdo, Laura AU - Izquierdo L AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. FAU - Savic, Spasenija AU - Savic S AD - Institute of Pathology, University Hospital, Basel, Switzerland. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, University Hospital, Basel, Switzerland. FAU - Bubendorf, Lukas AU - Bubendorf L AD - Institute of Pathology, University Hospital, Basel, Switzerland. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - de Reijke, Theo M AU - de Reijke TM AD - Department of Urology, Amsterdam University Medical Center, University of Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20190924 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2020 Feb;203(2):290-291. doi: 10.1097/01.JU.0000615060.91630.ec. PMID: 31738121 MH - Adjuvants, Immunologic/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Chemotherapy, Adjuvant MH - Humans MH - *In Situ Hybridization, Fluorescence MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Predictive Value of Tests MH - Risk Assessment MH - Urinary Bladder Neoplasms/*drug therapy/*pathology OTO - NOTNLM OT - Mycobacterium bovis OT - fluorescence OT - in situ hybridization OT - local OT - neoplasm recurrence OT - risk OT - urinary bladder neoplasms EDAT- 2019/09/25 06:00 MHDA- 2020/01/23 06:00 CRDT- 2019/09/25 06:00 PHST- 2019/09/25 06:00 [pubmed] PHST- 2020/01/23 06:00 [medline] PHST- 2019/09/25 06:00 [entrez] AID - 10.1097/JU.0000000000000566 [doi] PST - ppublish SO - J Urol. 2020 Feb;203(2):283-291. doi: 10.1097/JU.0000000000000566. Epub 2019 Sep 24. PMID- 31547991 OWN - NLM STAT- MEDLINE DCOM- 20200622 LR - 20200622 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 519 IP - 4 DP - 2019 Nov 19 TI - MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D. PG - 747-753 LID - S0006-291X(19)31750-4 [pii] LID - 10.1016/j.bbrc.2019.09.029 [doi] AB - To uncover the biological function of miRNA-217 in the progression of bladder cancer and the underlying mechanism. Potential miRNAs binding KMT2D were predicted through online bioinformatics. Their expression levels in bladder cancer tissues and adjacent ones were determined. Through Pearson correlation analysis and survival analysis, the most potential miRNA candidate (miRNA-217) that targets and regulates KMT2D in bladder cancer was selected. Subsequently, expression levels of miRNA-217 and KMT2D in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) were detected. MiRNA-217 level in bladder cancer cell lines was determined as well. The interaction between KMT2D and miRNA-217 was verified by dual-luciferase reporter gene assay. Finally, regulatory effect of miRNA-217 on viability and migration in T24 and UMUC-3 cells were investigated. Five potential candidates that were upstream genes binding KMT2D were searched by bioinformatics. Among them, miRNA-217 was remarkably upregulated in bladder cancer tissues and closely linked to poor prognosis of affected patients. Moreover, dual-luciferase reporter gene assay verified the interaction between miRNA-217 and KMT2D. MiRNA-217 was able to downregulate mRNA and protein levels of KMT2D. Furthermore, knockdown of miRNA-217 attenuated viability and migration in bladder cancer cells. MiRNA-217 accelerates proliferative and migratory abilities in bladder cancer via inhibiting the level of tumor suppressor KMT2D, thereafter leading to the poor prognosis in bladder cancer patients. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Hou, Guoliang AU - Hou G AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, China; Department of Urology, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China. FAU - Xu, Wenfeng AU - Xu W AD - Department of Urology, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China. FAU - Jin, Yabin AU - Jin Y AD - Clinical Research Institute, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China. FAU - Wu, Jialing AU - Wu J AD - Clinical Research Institute, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China. FAU - Pan, Yingming AU - Pan Y AD - Clinical Research Institute, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China. FAU - Zhou, Fangjian AU - Zhou F AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, China. Electronic address: kytlhsh@163.com. LA - eng PT - Journal Article DEP - 20190920 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (DNA-Binding Proteins) RN - 0 (KMT2D protein, human) RN - 0 (MicroRNAs) RN - 0 (Neoplasm Proteins) SB - IM MH - Cell Movement/genetics MH - Cell Proliferation/genetics MH - Computational Biology MH - DNA-Binding Proteins/*antagonists & inhibitors/*genetics MH - Humans MH - MicroRNAs/*genetics MH - Neoplasm Proteins/*antagonists & inhibitors/*genetics MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology OTO - NOTNLM OT - Bladder cancer OT - KMT2D OT - MiRNA-217 OT - Migration OT - Proliferation EDAT- 2019/09/25 06:00 MHDA- 2020/06/23 06:00 CRDT- 2019/09/25 06:00 PHST- 2019/08/27 00:00 [received] PHST- 2019/09/09 00:00 [revised] PHST- 2019/09/09 00:00 [accepted] PHST- 2019/09/25 06:00 [pubmed] PHST- 2020/06/23 06:00 [medline] PHST- 2019/09/25 06:00 [entrez] AID - S0006-291X(19)31750-4 [pii] AID - 10.1016/j.bbrc.2019.09.029 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2019 Nov 19;519(4):747-753. doi: 10.1016/j.bbrc.2019.09.029. Epub 2019 Sep 20. PMID- 31545404 OWN - NLM STAT- MEDLINE DCOM- 20200727 LR - 20221207 IS - 1791-244X (Electronic) IS - 1107-3756 (Print) IS - 1107-3756 (Linking) VI - 44 IP - 5 DP - 2019 Nov TI - Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine. PG - 1952-1962 LID - 10.3892/ijmm.2019.4347 [doi] AB - Bladder cancer (BCa) is a common urinary tract malignancy with frequent recurrences after initial resection. Submucosal injection of gemcitabine prior to transurethral resection of bladder tumor (TURBT) may prevent recurrence of urothelial cancer. However, the underlying mechanism remains unknown. In the present study, ultra‑performance liquid chromatography Q‑Exactive mass spectrometry was used to profile tissue metabolites from 12 BCa patients. The 48 samples included pre‑ and post‑gemcitabine treatment BCa tissues, as well as adjacent normal tissues. Principal component analysis (PCA) revealed that the metabolic profiles of pre‑gemcitabine BCa tissues differed significantly from those of pre‑gemcitabine normal tissues. A total of 34 significantly altered metabolites were further analyzed. Pathway analysis using MetaboAnalyst identified three metabolic pathways closely associated with BCa, including glutathione, purine and thiamine metabolism, while glutathione metabolism was also identified by the enrichment analysis using MetaboAnalyst. In search of the possible targets of gemcitabine, metabolite profiles were compared between the pre‑gemcitabine normal and post‑gemcitabine BCa tissues. Among the 34 metabolites associated with BCa, the levels of bilirubin and retinal recovered in BCa tissues treated with gemcitabine. When comparing normal bladder tissues with and without gemcitabine treatment, among the 34 metabolites associated with BCa, it was observed that histamine change may be associated with the prevention of relapse, whereas thiamine change may be involved in possible side effects. Therefore, by employing a hypothesis‑free tissue‑based metabolomics study, the present study investigated the metabolic signatures of BCa and found that bilirubin and retinal may be involved in the mechanism underlying the biomolecular action of submucosal injection of gemcitabine in urothelial BCa. FAU - Yang, Chao AU - Yang C AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Sun, Xian AU - Sun X AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Wang, Hengbing AU - Wang H AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Lu, Ting AU - Lu T AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Wu, Keqing AU - Wu K AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Guan, Yusheng AU - Guan Y AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Tang, Jing AU - Tang J AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Liang, Jian AU - Liang J AD - Center of Reproduction and Genetic, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Sun, Rongli AU - Sun R AD - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu 210009, P.R. China. FAU - Guo, Zhongying AU - Guo Z AD - Department of Pathology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Zheng, Sinian AU - Zheng S AD - Department of Urology, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, Zhejiang 315040, P.R. China. FAU - Wu, Xiaoli AU - Wu X AD - Department of Pharmacy, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Jiang, Hesong AU - Jiang H AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Jiang, Xi AU - Jiang X AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Zhong, Bing AU - Zhong B AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Niu, Xiaobing AU - Niu X AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Sun, Suan AU - Sun S AD - Department of Pathology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. FAU - Wang, Xinru AU - Wang X AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Chen, Minjian AU - Chen M AD - State Key Laboratory of Reproductive Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. FAU - Fu, Guangbo AU - Fu G AD - Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. LA - eng PT - Journal Article DEP - 20190923 PL - Greece TA - Int J Mol Med JT - International journal of molecular medicine JID - 9810955 RN - 0 (Biomarkers, Tumor) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Transitional Cell/drug therapy/metabolism MH - Deoxycytidine/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Male MH - Metabolic Networks and Pathways/drug effects MH - Metabolome/*drug effects MH - Metabolomics/methods MH - Middle Aged MH - Neoplasm Recurrence, Local/metabolism MH - Principal Component Analysis/methods MH - Urinary Bladder/drug effects/metabolism MH - Urinary Bladder Neoplasms/*drug therapy/*metabolism MH - Gemcitabine PMC - PMC6777689 EDAT- 2019/09/24 06:00 MHDA- 2020/07/28 06:00 PMCR- 2019/09/23 CRDT- 2019/09/24 06:00 PHST- 2019/04/18 00:00 [received] PHST- 2019/09/06 00:00 [accepted] PHST- 2019/09/24 06:00 [pubmed] PHST- 2020/07/28 06:00 [medline] PHST- 2019/09/24 06:00 [entrez] PHST- 2019/09/23 00:00 [pmc-release] AID - ijmm-44-05-1952 [pii] AID - 10.3892/ijmm.2019.4347 [doi] PST - ppublish SO - Int J Mol Med. 2019 Nov;44(5):1952-1962. doi: 10.3892/ijmm.2019.4347. Epub 2019 Sep 23. PMID- 31526650 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20210429 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 3 DP - 2020 Mar TI - Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? PG - 77.e1-77.e7 LID - S1078-1439(19)30328-X [pii] LID - 10.1016/j.urolonc.2019.08.010 [doi] AB - PURPOSE: To evaluate the predictive factors of pT0 at repeated transurethral resection of the bladder (re-TURB) in pT1 high-grade (HG) nonmuscle invasive bladder cancer in order to explore the possibility to avoid it in well-selected patients. METHODS: This multicenter retrospective study included patients with pT1HG nonmuscle invasive bladder cancer from 4 different centers who underwent a complete TURB. Re-TURB was defined as a second resection which involved the site of the first TURB performed within 2-6 weeks from the previous resection. A multivariable logistic-regression model was performed to evaluate the predictors of pT0 at re-TURB. A nomogram was built to calculate the probability of obtaining a negative histology at re-TURB. The performance of the nomogram and its net benefit were tested with the decision curve analysis. RESULTS: Overall, 321 patients were included in the study. On multivariable logistic regression, detrusor muscle in the specimen (HR 1.99, P = 0.02), concomitant carcinoma in situ (HR 0.29, P = 0.005) and resection performed with en-bloc technique (HR 7.71, P = 0.01) were independent predictors of pT0 at re-TURB. Decision curve analysis showed a net benefit for the nomogram for each probability over 0.35 compared to the strategy to perform a re-TURB in all pT1HG tumors. CONCLUSIONS: The presence of detrusor muscle in TURB specimen, the absence of concomitant carcinoma in situ and the en-bloc resection were able to predict a negative histology at re-TURB, opening the door to the possibility to avoid it in an extremely well-selected cohort of patients. External validations and prospective studies are urgently needed. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Soria, Francesco AU - Soria F AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. Electronic address: francesco.soria@unito.it. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Giordano, Andrea AU - Giordano A AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Mazzoli, Simone AU - Mazzoli S AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Pizzuto, Giuseppe AU - Pizzuto G AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Altieri, Vincenzo AU - Altieri V AD - Department of Urology, University of Salerno, Salerno, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190914 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Neoplasm, Residual MH - *Patient Selection MH - Predictive Value of Tests MH - Retreatment/statistics & numerical data MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Nomogram OT - Predictive factors OT - Re-TURB OT - Second look TURB OT - T1HG bladder cancer EDAT- 2019/09/19 06:00 MHDA- 2021/04/30 06:00 CRDT- 2019/09/19 06:00 PHST- 2019/06/10 00:00 [received] PHST- 2019/07/31 00:00 [revised] PHST- 2019/08/19 00:00 [accepted] PHST- 2019/09/19 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2019/09/19 06:00 [entrez] AID - S1078-1439(19)30328-X [pii] AID - 10.1016/j.urolonc.2019.08.010 [doi] PST - ppublish SO - Urol Oncol. 2020 Mar;38(3):77.e1-77.e7. doi: 10.1016/j.urolonc.2019.08.010. Epub 2019 Sep 14. PMID- 31522458 OWN - NLM STAT- MEDLINE DCOM- 20200921 LR - 20200921 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 26 IP - 12 DP - 2019 Dec TI - Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. PG - 1106-1112 LID - 10.1111/iju.14103 [doi] AB - OBJECTIVE: To examine the impact of post-void residual urine volume on the risk of postoperative recurrence of intravesical carcinoma in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. METHODS: We retrospectively reviewed the data of 81 patients who were admitted to Chiba University Graduate School of Medicine Hospital and underwent nephroureterectomy for upper urinary tract urothelial carcinoma without bladder carcinoma. We assessed the predictive factors for intravesical recurrence after nephroureterectomy in all patients. Next, we compared patients with and without a residual urine volume using propensity score-matching analysis. The presence of a residual urine volume was defined as >/=30 mL. RESULTS: The median follow-up period among all patients was 48 months. The presence of pyuria and a residual urine volume were associated with bladder recurrence in the multivariate analysis. A total of 19 patients each were selected after matching, and we confirmed a significant difference between the presence and absence of a residual urine volume (P = 0.0291). The 2-year postoperative recurrence-free rate of patients with and without a residual urine volume was 32% and 82%, respectively. CONCLUSIONS: This is the first study to evaluate the post-void residual urine volume and intravesical recurrence rate after nephroureterectomy for upper urinary tract urothelial carcinoma. The presence of residual urine might be a risk factor for postoperative recurrence of intravesical carcinoma. CI - (c) 2019 The Japanese Urological Association. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Sakamoto, Shinichi AU - Sakamoto S AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Nakamura, Kazuyoshi AU - Nakamura K AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Imamura, Yusuke AU - Imamura Y AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Yamamoto, Satoshi AU - Yamamoto S AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Komiya, Akira AU - Komiya A AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. LA - eng PT - Journal Article DEP - 20190914 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2019 Dec;26(12):1112-1113. doi: 10.1111/iju.14113. PMID: 31522463 MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/*surgery MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/mortality/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - *Nephroureterectomy MH - Postoperative Period MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Ureteral Neoplasms/mortality/*surgery MH - Urinary Bladder/*diagnostic imaging/physiopathology MH - Urination/physiology OTO - NOTNLM OT - intravesical recurrence OT - nephroureterectomy OT - residual urine volume OT - risk factor OT - upper urinary tract urothelial carcinoma EDAT- 2019/09/16 06:00 MHDA- 2020/09/22 06:00 CRDT- 2019/09/16 06:00 PHST- 2019/05/11 00:00 [received] PHST- 2019/08/11 00:00 [accepted] PHST- 2019/09/16 06:00 [pubmed] PHST- 2020/09/22 06:00 [medline] PHST- 2019/09/16 06:00 [entrez] AID - 10.1111/iju.14103 [doi] PST - ppublish SO - Int J Urol. 2019 Dec;26(12):1106-1112. doi: 10.1111/iju.14103. Epub 2019 Sep 14. PMID- 31522016 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20200317 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 76 DP - 2019 Nov TI - A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting. PG - 105880 LID - S1567-5769(19)31535-8 [pii] LID - 10.1016/j.intimp.2019.105880 [doi] AB - Tumor-associated macrophages (TAMs) which are often referred to as immunosuppressive cells (M2 macrophage), constitute a subset of tumor microenvironment cells and affect tumor progression in solid tumors. Recently, these cells have gained remarkable importance as therapeutic candidates for solid tumors. In bladder cancer, major studies have focused on evaluating TAMs in response to Bacillus Calmette-Guerin (BCG) therapy. M2 macrophages may directly impact the BCG-induced immune responses against tumor in bladder cancer. They are the main inhibitors of the tumor microenvironment that promotes growth and metastasis of the tumor. However, the clinical significance of M2 macrophages in bladder cancer is controversial. In this review, we will discuss the clinical significance of M2 macrophages in prognosis of bladder cancer as well as worth of their potential targeting in bladder cancer treatment. In the following, we will introduce important factors resulting in M2 macrophage promotion and also experimental therapeutic agents that may cause the inhibition of bladder cancer tumor growth. CI - Copyright (c) 2019 Elsevier B.V. All rights reserved. FAU - Sharifi, Laleh AU - Sharifi L AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Nowroozi, Mohammad Reza AU - Nowroozi MR AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Amini, Erfan AU - Amini E AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Arami, Masoumeh Kourosh AU - Arami MK AD - Department of Basic Sciences, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. FAU - Ayati, Mohsen AU - Ayati M AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mohsenzadegan, Monireh AU - Mohsenzadegan M AD - Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Electronic address: monirehmohsenzadegan@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20190912 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 SB - IM MH - Animals MH - Carcinogenesis/immunology MH - Humans MH - Macrophages/*immunology MH - Tumor Microenvironment/immunology MH - Urinary Bladder Neoplasms/*immunology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - M1 macrophage OT - M2 macrophage OT - Tumor microenvironment OT - Tumor-associated macrophages EDAT- 2019/09/16 06:00 MHDA- 2020/03/18 06:00 CRDT- 2019/09/16 06:00 PHST- 2019/07/14 00:00 [received] PHST- 2019/08/16 00:00 [revised] PHST- 2019/09/03 00:00 [accepted] PHST- 2019/09/16 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] PHST- 2019/09/16 06:00 [entrez] AID - S1567-5769(19)31535-8 [pii] AID - 10.1016/j.intimp.2019.105880 [doi] PST - ppublish SO - Int Immunopharmacol. 2019 Nov;76:105880. doi: 10.1016/j.intimp.2019.105880. Epub 2019 Sep 12. PMID- 31516565 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 18 IP - 4 DP - 2019 Oct TI - PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. PG - 3471-3480 LID - 10.3892/ol.2019.10706 [doi] AB - Promoter mutations of pleckstrin homology domain-containing S1 (PLEKHS1) are frequent in several cancer types. To evaluate the DNA mutations, the mRNA expression and prognostic value of PLEKHS1 was evaluated in bladder cancer. We investigated DNA mutations and mRNA expression of PLEKHS1 in a first series of 154 bladder tumors [71 non-muscle-invasive bladder cancer (NMIBC) and 83 muscle-invasive bladder cancers (MIBC)] from patients who underwent transurethral bladder resection or radical cystectomy between 2001 and 2006, and 20 normal bladder samples. Results were then validated in a second series of 181 bladder tumors (91 NMIBC and 90 MIBC). All patients have signed an informed consent form. DNA mutations were analysed by high-resolution melt analysis and sanger sequencing. The mRNA expression was measured by real-time reverse-transcriptase quantitative PCR. The results of the molecular analysis were compared with survival data. PLEKHS1 mutations occurred in 25.0 and 32.2% of NMIBC and MIBC, respectively in the first series. These results were confirmed in the second series (33.0 and 37.8% of NMIBC and MIBC, respectively). In MIBC, DNA mutations were significantly more frequent with the basal than non-basal phenotype (61.5 vs. 27.1%; P=0.0025). The PLEKHS1 mRNA level was increased in 22.5 and 27.7% of NMIBC and MIBC tumors but was not associated with DNA mutations. In NMIBC, PLEKHS1 mRNA overexpression was significantly associated with progression to muscle-invasive disease (P=0.0069) and remained an independent prognostic factor on multivariate analysis (P=0.034). DNA mutations of PLEKHS1 occurred in one-third of bladder tumors and was frequent in the basal MIBC phenotype. PLEKHS1 mRNA overexpression may be an independent prognostic factor of progression-free survival in NMIBC. FAU - Pignot, Geraldine AU - Pignot G AD - Unit of Oncological Surgery 2, Paoli-Calmettes Institute, Marseille F-13009, France. FAU - Le Goux, Constance AU - Le Goux C AD - Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F-75005, France. FAU - Vacher, Sophie AU - Vacher S AD - Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F-75005, France. FAU - Schnitzler, Anne AU - Schnitzler A AD - Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F-75005, France. FAU - Radvanyi, Francois AU - Radvanyi F AD - Molecular Oncology Team, Institut Curie, UMR 144-CNRS, Paris F-75005, France. FAU - Allory, Yves AU - Allory Y AD - Pathology Department, Institut Curie, Paris F-75005, France. FAU - Lallemand, Francois AU - Lallemand F AD - Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F-75005, France. FAU - Delongchamps, Nicolas Barry AU - Delongchamps NB AD - Urology Department, Cochin Hospital, Paris Descartes University, Paris F-75014, France. FAU - Zerbib, Marc AU - Zerbib M AD - Urology Department, Cochin Hospital, Paris Descartes University, Paris F-75014, France. FAU - Terris, Benoit AU - Terris B AD - Pathology Department, Cochin Hospital, Paris Descartes University, Paris F-75014, France. FAU - Damotte, Diane AU - Damotte D AD - Pathology Department, Cochin Hospital, Paris Descartes University, Paris F-75014, France. AD - Cancer and Anti-tumor Immunity, INSERM U1138, Cordeliers Research Center, Paris F-75006, France. FAU - Bieche, Ivan AU - Bieche I AD - Pharmacogenomics Unit, Genetics Department, Institut Curie, Paris F-75005, France. AD - Inserm U1016, Cochin Institute, Paris Descartes University, Paris F-75006, France. LA - eng PT - Journal Article DEP - 20190802 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6733015 OTO - NOTNLM OT - DNA mutations OT - bladder cancer OT - molecular marker OT - prognosis OT - reverse transcription-PCR EDAT- 2019/09/14 06:00 MHDA- 2019/09/14 06:01 PMCR- 2019/08/02 CRDT- 2019/09/14 06:00 PHST- 2019/02/28 00:00 [received] PHST- 2019/06/03 00:00 [accepted] PHST- 2019/09/14 06:00 [entrez] PHST- 2019/09/14 06:00 [pubmed] PHST- 2019/09/14 06:01 [medline] PHST- 2019/08/02 00:00 [pmc-release] AID - OL-0-0-10706 [pii] AID - 10.3892/ol.2019.10706 [doi] PST - ppublish SO - Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2. PMID- 31506803 OWN - NLM STAT- MEDLINE DCOM- 20210401 LR - 20261010 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 26 IP - 3 DP - 2020 Jul TI - Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). PG - 1625-1632 LID - 10.1007/s12253-019-00745-7 [doi] AB - Downregulation of checkpoint protein kinase 2 (CHEK2), which is involved in DNA repair, is associated with poorer outcome in various tumors. Little is known about the role of CHEK2 in urothelial carcinoma of the bladder (UCB). In the present study, we investigated the prognostic impact of CHEK2 protein expression in stage pT1 UCB. This retrospective, single-center analysis was carried out in a cohort of patients initially diagnosed with a pT1 UCB between 2007 and 2015. Immunohistochemical (IHC) staining of CHEK2 was performed. CHEK2 expression was correlated with recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS) using Kaplan-Meier analysis and multivariable Cox regression analysis. The analysis included 126 patients (86% male, median age 71 years). Loss of immunohistochemical protein expression of CHEK2 (<10%) was associated with significantly worse PFS (p = 0.041). Likewise, CHEK2 loss identified a subgroup of patients with worse PFS in the high-risk groups with concomitant CIS (p = 0.044), multifocal tumors (p < 0.001) and tumor grading G3 according to WHO1973 (p = 0.009). Multivariable Cox regression analysis revealed both loss of CHEK2 expression (HR: 4.18, 95%-CI: 1.35-12.93; p = 0.013) and multifocal tumors (HR: 4.53, 95%-CI:1.29-15.92; p = 0.018) as the only predictive factors for progression. Loss of IHC expression of CHEK2 in pT1 UCB is an independent predictor for progression to muscle-invasive disease and is also associated with worse PFS. This could help to identify high-risk patients who would benefit from early cystectomy. FAU - Spachmann, Philipp J AU - Spachmann PJ AUID- ORCID: 0000-0003-0183-2952 AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. philipp.spachmann@ukr.de. FAU - Azzolina, Vanessa AU - Azzolina V AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Weber, Florian AU - Weber F AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Evert, Matthias AU - Evert M AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20190910 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.1.11 (Checkpoint Kinase 2) RN - EC 2.7.11.1 (CHEK2 protein, human) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Transitional Cell/*pathology MH - Checkpoint Kinase 2/*metabolism MH - Cohort Studies MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - CHEK2 OT - NMIBC OT - Non-muscle-invasive bladder cancer OT - Progression OT - Smoking status EDAT- 2019/09/12 06:00 MHDA- 2021/04/02 06:00 CRDT- 2019/09/12 06:00 PHST- 2019/06/19 00:00 [received] PHST- 2019/09/03 00:00 [accepted] PHST- 2019/09/12 06:00 [pubmed] PHST- 2021/04/02 06:00 [medline] PHST- 2019/09/12 06:00 [entrez] AID - 10.1007/s12253-019-00745-7 [pii] AID - 10.1007/s12253-019-00745-7 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Jul;26(3):1625-1632. doi: 10.1007/s12253-019-00745-7. Epub 2019 Sep 10. PMID- 31500772 OWN - NLM STAT- MEDLINE DCOM- 20200210 LR - 20200210 IS - 1879-3320 (Electronic) IS - 0960-7404 (Linking) VI - 30 DP - 2019 Sep TI - Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far? PG - 109-116 LID - S0960-7404(19)30139-2 [pii] LID - 10.1016/j.suronc.2019.06.008 [doi] AB - PURPOSE: To determine whether the extent or number of lymph nodes (LNs) is important in muscle-invasive bladder cancer and high-risk non-muscle-invasive bladder cancer patients' oncologic outcomes. METHODS: A total of 448 patients who underwent radical cystectomy with lymphadenectomy of standard, extended, and super-extended template were included. Exclusion criteria were neoadjuvant chemotherapy and limited lymphadenectomy. Disease-free survival (DFS) including local recurrence and distant metastasis, cancer-specific survival (CSS), and overall survival (OS) were estimated using the Kaplan-Meier method. Cox hazard regression was applied to analyze risk factors. RESULTS: Standard (n = 124), extended (n = 216), and super-extended group (n = 108) did not show significant differences in the estimated 5-year DFS, CSS and OS rates. On multivariate analysis, the number of removed LNs was a significant factor for distant metastasis-free (hazard ratio [HR] 0.981, p = 0.0222), CSS (HR 0.980, p = 0.0021) and OS (HR 0.984, p = 0.0032). However, the template was not significant in distant metastasis-free survival, CSS and OS. On Kaplan-Meier curve, the number of removed LN showed significant differences in DFS, CSS, and OS. In the subgroup of positive LNs, number of removed LNs was associated with favorable DFS (HR = 0.969, p = 0.0115), CSS (HR = 0.967, p = 0.0068) and OS (HR = 0.971, p = 0.0028). CONCLUSION: The number of removed LNs was a more important factor for CSS and OS than the extent of lymphadenectomy. Meticulous and extended LN dissection can be helpful in controlling recurrence, and its survival benefit might be maximized in cases with positive LN. Meanwhile, the survival benefit of super-extended lymphadenectomy was limited for this patient population. CI - Copyright (c) 2019 Elsevier Ltd. All rights reserved. FAU - Choi, Se Young AU - Choi SY AD - Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, 06973, South Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. Electronic address: cskim@amc.seoul.kr. LA - eng PT - Journal Article DEP - 20190628 PL - Netherlands TA - Surg Oncol JT - Surgical oncology JID - 9208188 SB - IM MH - Adenocarcinoma/*mortality/pathology/surgery MH - Aged MH - Carcinoma, Squamous Cell/*mortality/pathology/surgery MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Node Excision/*mortality MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/surgery OTO - NOTNLM OT - Lymph node dissection OT - Super-extended OT - Template EDAT- 2019/09/11 06:00 MHDA- 2020/02/11 06:00 CRDT- 2019/09/11 06:00 PHST- 2019/03/20 00:00 [received] PHST- 2019/05/31 00:00 [revised] PHST- 2019/06/27 00:00 [accepted] PHST- 2019/09/11 06:00 [entrez] PHST- 2019/09/11 06:00 [pubmed] PHST- 2020/02/11 06:00 [medline] AID - S0960-7404(19)30139-2 [pii] AID - 10.1016/j.suronc.2019.06.008 [doi] PST - ppublish SO - Surg Oncol. 2019 Sep;30:109-116. doi: 10.1016/j.suronc.2019.06.008. Epub 2019 Jun 28. PMID- 31496500 OWN - NLM STAT- MEDLINE DCOM- 20200228 LR - 20240720 IS - 1552-5775 (Electronic) IS - 1552-5767 (Print) IS - 1552-5767 (Linking) VI - 23 DP - 2019 TI - Clinical Use Cases for a Tool to Assess Risk in Superficial Bladder Cancer. LID - 10.7812/TPP/18.276 [doi] LID - 18-276 AB - BACKGROUND: Among the approximately 53,000 patients newly diagnosed with early-stage (superficial) bladder cancer each year, there is substantial variability in the progression to muscle-invasive disease. Enhancing risk stratification and risk-stratified surveillance could minimize risks and harms to patients, as well as unnecessary costs to health systems. OBJECTIVES: As a preliminary step in developing and validating a risk assessment tool for superficial bladder cancer in a population-based clinical cohort, we interviewed urologists who might use such a tool to assess need, determine potential use cases, and identify key features to include. METHODS: Using an opportunistic and purposeful sampling design, we invited 13 urologists from a variety of practice settings and with a wide range of clinical experience to take part in qualitative interviews; 9 (5 urologic oncologists and 4 general urologists) participated. RESULTS: All urologists reported using some form of risk stratification to determine surveillance schedules for patients with bladder cancer. The following use cases were endorsed by 4 or more interviewees: 1) provide evidence to guide clinical management in specific situations, 2) generate patient-facing communication aids, 3) improve documentation about recurrence/progression risk, and 4) create scheduling and callback supports to improve the quality of follow-up care. CONCLUSION: Our findings demonstrated several potential clinical-use cases for a risk calculator and clinical decision-support tool for patients with superficial bladder cancer. Clinicians stressed the potential utility of such a tool to improve patient communication, scheduling, and tracking in general urology practice. FAU - McMullen, Carmit K AU - McMullen CK AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - Rosetti, Maureen O'Keeffe AU - Rosetti MO AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - Weinmann, Sheila AU - Weinmann S AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - Leo, Michael C AU - Leo MC AD - Center for Health Research, Kaiser Permanente Northwest, Portland, OR. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill School of Medicine. LA - eng GR - R21 CA191610/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20190819 PL - United States TA - Perm J JT - The Permanente journal JID - 9800474 SB - IM MH - Humans MH - Interviews as Topic MH - Practice Patterns, Physicians' MH - Risk Assessment/methods MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/etiology/pathology MH - Urologists PMC - PMC6730961 COIS- Disclosure Statement The author(s) have no conflict of interest to report. EDAT- 2019/09/10 06:00 MHDA- 2020/02/29 06:00 PMCR- 2019/01/01 CRDT- 2019/09/10 06:00 PHST- 2019/09/10 06:00 [entrez] PHST- 2019/09/10 06:00 [pubmed] PHST- 2020/02/29 06:00 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 18.276 [pii] AID - 18-276 [pii] AID - 10.7812/TPP/18.276 [doi] PST - ppublish SO - Perm J. 2019;23:18-276. doi: 10.7812/TPP/18.276. Epub 2019 Aug 19. PMID- 31493109 OWN - NLM STAT- MEDLINE DCOM- 20210225 LR - 20210410 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 38 IP - 6 DP - 2020 Jun TI - Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. PG - 1437-1449 LID - 10.1007/s00345-019-02936-y [doi] AB - PURPOSE: To evaluate the prognostic value of substaging on oncological outcomes in patients with T (or pT1) urothelial carcinoma of the bladder. METHODS: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on March 2019 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. The pooled disease recurrence (DR) and disease progression (DP) rate in T1(or pT1) patients were calculated using a fixed or random effects model. RESULTS: Overall 36 studies published between 1994 and 2018 including a total of 6781 bladder cancer patients with T1(or pT1) stage were selected for the systematic review and meta-analysis. Twenty-nine studies reported significant association between tumor infiltration depth or muscularis mucosa (MM) invasion and oncological outcomes. Totally 12 studies were included in the meta-analysis. MM invasion (T1a/b/c [or pT1a/b/c] or T1a/b [or pT1a/b] substaging system) was associated with DR (pooled HR: 1.23, 95%CI: 1.01-1.49) and DP (pooled HR: 2.61, 95%CI: 1.61-4.23). Tumor infiltration depth (T1 m/e [or pT1 m/e] substaging system) was also associated with DR (pooled HR: 1.49, 95%CI: 1.11-2.00) and DP (pooled HR: 3.29, 95%CI: 2.39-4.51). CONCLUSIONS: T1(or pT1) substaging in patients with bladder cancer is of prognostic value as it is associated with oncologic outcomes. Inclusion of this factors into the clinical decision-making process of this heterogeneous tumor may improve outcomes, while avoiding over- and under-treatment for T1(or pT1) bladder cancer. FAU - Kardoust Parizi, Mehdi AU - Kardoust Parizi M AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Glybochko, Petr V AU - Glybochko PV AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Seebacher, Veronika AU - Seebacher V AD - Department for Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria. FAU - Janisch, Florian AU - Janisch F AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Chlosta, Piotr L AU - Chlosta PL AD - Department of Urology, Jagiellonian University, Medical College, Cracow, Poland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. sfshariat@gmail.com. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. sfshariat@gmail.com. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. sfshariat@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20190906 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Carcinoma, Transitional Cell/epidemiology/*pathology MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/epidemiology/*pathology PMC - PMC7245585 OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Progression OT - Staging OT - Substage OT - T1 OT - Urothelial carcinoma OT - pT1 COIS- The authors declare that they have no conflict of interest. EDAT- 2019/09/08 06:00 MHDA- 2021/02/26 06:00 PMCR- 2019/09/06 CRDT- 2019/09/08 06:00 PHST- 2019/05/17 00:00 [received] PHST- 2019/08/28 00:00 [accepted] PHST- 2019/09/08 06:00 [pubmed] PHST- 2021/02/26 06:00 [medline] PHST- 2019/09/08 06:00 [entrez] PHST- 2019/09/06 00:00 [pmc-release] AID - 10.1007/s00345-019-02936-y [pii] AID - 2936 [pii] AID - 10.1007/s00345-019-02936-y [doi] PST - ppublish SO - World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. PMID- 31486884 OWN - NLM STAT- MEDLINE DCOM- 20210225 LR - 20261010 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 6 DP - 2020 Jun TI - Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). PG - 1517-1524 LID - 10.1007/s00345-019-02896-3 [doi] AB - OBJECTIVE: To assess PD-L1 expression in tumor (TC) and tumor infiltrating immune cells (IC) as a predictive factor of BCG therapy failure in high-risk NMIBC. MATERIALS AND METHODS: Patients treated with complete resection followed by bladder BCG instillation for high-risk NMIBC were included. Early recurrence (ER) was defined as tumor recurrence after BCG induction course. The association between ER and immuno-histochemistry PD-L1 (E1L3N clone) expression by tumors cells (TC) and tumor infiltrating immune cells (IC) was investigated using an exact Fisher test variant. RESULTS: A total of 186 patients were included, of whom 38 (20.4%) were ER, 35 (18.8%) were positive for TC PD-L1 expression and 60 (32.3%) were positive for IC PD-L1. ER was not significantly (p = 0.97) more frequent in the TC PD-L1 >/= 1% group (n = 7, 20.0%) than in the TC PD-L1-negative group (n = 31, 20.5%). Patients with IC PD-L1 negative had ER in 15 (19.2%) cases and patients with IC PD-L1 >/= 1% had ER in 23 (21.3%) cases. PD-L1-positive expression for IC (threshold > 1%) was correlated with immune infiltrate density (95.2% dense immune infiltrate vs 47.2% low immune infiltrate, p < 0.05), with increased expression of PD-L1 by IC after BCG therapy (p = 0.006). CONCLUSION: No association was observed between immuno-histochemistry PD-L1 positivity and ER after BCG therapy. Nevertheless, the relationship between immune infiltrate and PD-L1 positivity confirmed the interest of assessing the immune infiltrate density to define tumor's profile. FAU - Delcourt, Clara AU - Delcourt C AD - Department of Urology, Charles Nicolle Rouen University Hospital, 1 rue de Germont, 76031, Rouen Cedex, France. FAU - Gemival, Pierre AU - Gemival P AD - Department of Pathology, Rouen University Hospital, Rouen, France. FAU - Nouhaud, Francois Xavier AU - Nouhaud FX AD - Department of Urology, Charles Nicolle Rouen University Hospital, 1 rue de Germont, 76031, Rouen Cedex, France. FAU - Gobet, Francoise AU - Gobet F AD - Department of Pathology, Rouen University Hospital, Rouen, France. FAU - Gillibert, Andre AU - Gillibert A AD - Department of Biostatistics, Rouen University Hospital, Rouen, France. FAU - Ferlicot, Sophie AU - Ferlicot S AD - Department of Pathology, Kremlin Bicetre Hospital, Paris, France. FAU - Sabourin, Jean Christophe AU - Sabourin JC AD - Department of Pathology, Rouen University Hospital, Rouen, France. FAU - Irani, Jacques AU - Irani J AD - Department of Urology, Kremlin Bicetre Hospital, Paris, France. FAU - Pfister, Christian AU - Pfister C AUID- ORCID: 0000-0002-5920-4468 AD - Department of Urology, Charles Nicolle Rouen University Hospital, 1 rue de Germont, 76031, Rouen Cedex, France. Christian.Pfister@chu-rouen.fr. AD - Clinical Investigation Center, Inserm 6204, Onco-Urology, Rouen, France. Christian.Pfister@chu-rouen.fr. LA - eng PT - Journal Article DEP - 20190905 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (CD274 protein, human) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Aged, 80 and over MH - B7-H1 Antigen/analysis/*biosynthesis MH - BCG Vaccine/*therapeutic use MH - Cohort Studies MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Retrospective Studies MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/chemistry/*drug therapy/*metabolism/pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - PD-L1 EDAT- 2019/09/06 06:00 MHDA- 2021/02/26 06:00 CRDT- 2019/09/06 06:00 PHST- 2019/04/10 00:00 [received] PHST- 2019/07/28 00:00 [accepted] PHST- 2019/09/06 06:00 [pubmed] PHST- 2021/02/26 06:00 [medline] PHST- 2019/09/06 06:00 [entrez] AID - 10.1007/s00345-019-02896-3 [pii] AID - 10.1007/s00345-019-02896-3 [doi] PST - ppublish SO - World J Urol. 2020 Jun;38(6):1517-1524. doi: 10.1007/s00345-019-02896-3. Epub 2019 Sep 5. PMID- 31481299 OWN - NLM STAT- MEDLINE DCOM- 20200828 LR - 20200828 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - Bladder cancer survival: Women only fare worse in the first two years after diagnosis. PG - 853-861 LID - S1078-1439(19)30319-9 [pii] LID - 10.1016/j.urolonc.2019.08.001 [doi] AB - OBJECTIVES: It has consistently been shown that women who are diagnosed with bladder cancer have lower survival than men, but the exact mechanism remains unknown. Most studies assumed that the sex-specific mortality ratio is constant over time, possibly resulting in inaccurate estimates in various periods of follow-up. This study aimed to investigate the sex-specific excess mortality in bladder cancer patients and its variation over follow-up time. METHODS: Observational cohort study. Using data from the population-based Netherlands Cancer Registry, we studied 24,169 patients diagnosed between 2003 and 2014 with histologically confirmed >/=T1 bladder cancer with follow-up until January 2018. We used flexible parametric relative survival models to estimate excess mortality as a function of time for each sex and to explore the effect of covariates on these functions. RESULTS: Female patients (24%) had worse clinical tumor, node, and metastasis-stage at diagnosis and more often a nonurothelial tumor histology. The excess mortality ratio of sex was not constant over time; in the first two years after diagnosis excess mortality rates for women were higher than for men, but lower thereafter; this applied to both nonmuscle-invasive and muscle-invasive bladder cancer subgroups. Baseline differences in age, tumor, node, and metastasis-stage and histology accounted for only part of the excess mortality gap. CONCLUSIONS: The assumption of proportional hazards over time leads to underestimation of the excess mortality ratio for women in the first two years and overestimation thereafter, when excess mortality is comparable for women and men. Clinicians should incorporate the initial sex-specific poorer outcome in their considerations regarding prognosis and treatment options for female patients, e.g., more invasive treatment and neo-adjuvant treatment. These findings also point towards a mechanism of micrometastatic disease, warranting assessment of sex-specific efficacy in randomized controlled trials on treatments in this patient population. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Richters, A AU - Richters A AD - Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands. Electronic address: a.richters@iknl.nl. FAU - Dickman, P W AU - Dickman PW AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden. FAU - Witjes, J A AU - Witjes JA AD - Department of Urology, Radboud university medical center, Nijmegen, the Netherlands. FAU - Boormans, J L AU - Boormans JL AD - Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. FAU - Kiemeney, L A L M AU - Kiemeney LALM AD - Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands. FAU - Aben, K K H AU - Aben KKH AD - Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands; Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands. LA - eng PT - Journal Article PT - Observational Study DEP - 20190831 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Child MH - Child, Preschool MH - Cohort Studies MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Netherlands/epidemiology MH - Prognosis MH - Registries/statistics & numerical data MH - Risk Factors MH - Sex Factors MH - Survival Rate MH - Time Factors MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*mortality/pathology/therapy MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Gender differences OT - Prognosis OT - Sex differences OT - Survival EDAT- 2019/09/05 06:00 MHDA- 2020/08/29 06:00 CRDT- 2019/09/05 06:00 PHST- 2019/04/05 00:00 [received] PHST- 2019/07/23 00:00 [revised] PHST- 2019/08/04 00:00 [accepted] PHST- 2019/09/05 06:00 [pubmed] PHST- 2020/08/29 06:00 [medline] PHST- 2019/09/05 06:00 [entrez] AID - S1078-1439(19)30319-9 [pii] AID - 10.1016/j.urolonc.2019.08.001 [doi] PST - ppublish SO - Urol Oncol. 2019 Dec;37(12):853-861. doi: 10.1016/j.urolonc.2019.08.001. Epub 2019 Aug 31. PMID- 31461726 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20210902 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 103 IP - 3 DP - 2019 TI - Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study. PG - 285-290 LID - 10.1159/000502663 [doi] AB - BACKGROUND: Topical therapy of nonmuscle-invasive bladder cancer (NMIBC) is based on immunotherapy with Bacillus Calmette-Guerin and chemotherapy administered by passive instillation, but an active drug administration achieves a better concentration of the drugs in the bladder. AIM: This study aimed to investigate the effectiveness of electromotive drug administration (EMDA) of mitomycin C (EMDA/MMC) in intermediate- and high-risk NMIBC patients 6 months after the end of induction treatment. MATERIALS AND METHODS: Sixty-five patients diagnosed with histologically confirmed NMIBC, with a complete transurethral resection of all visible tumors underwent EMDA/MMC. Primary endpoint was the proportion of responders at 3 or 6 months. RESULTS: Data on follow-up were available for 62 subjects at 3 months and 45 at 6 months. EMDA was effective in intermediate- and high-risk patients: because of the small number of cases no conclusions can be drawn on the efficacy in the low-risk group. No difference in the response to treatment between intermediate- (83.3%) and high-risk (84%) patients could be seen. CONCLUSIONS: EMDA/MMC is a useful technique for an effective and safe treatment of primary and recurrent NMIBC, and a valuable therapeutic option in intermediate- and high-risk NMIBC patients. CI - (c) 2019 S. Karger AG, Basel. FAU - Carando, Roberto AU - Carando R AD - Clinica Luganese Moncucco, Lugano, Switzerland, roberto.carando@bluewin.ch. AD - Clinica S. Anna, Swiss Medical Group, Sorengo, Switzerland, roberto.carando@bluewin.ch. AD - Clinica Santa Chiara, Locarno, Switzerland, roberto.carando@bluewin.ch. AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland, roberto.carando@bluewin.ch. FAU - Zazzara, Michele AU - Zazzara M AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. FAU - Cotrufo, Simone AU - Cotrufo S AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. FAU - Ludovico, Giuseppe M AU - Ludovico GM AD - Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190828 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM EIN - Urol Int. 2021;105(11-12):1128. doi: 10.1159/000519186. PMID: 34474416 MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage MH - *Electrochemotherapy MH - Female MH - Humans MH - Male MH - Mitomycin/*administration & dosage MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*prevention & control OTO - NOTNLM OT - Bladder cancer OT - Electromotive drug administration OT - Mitomycin OT - Retrospective study OT - Topical treatment EDAT- 2019/08/29 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/08/29 06:00 PHST- 2019/05/16 00:00 [received] PHST- 2019/08/12 00:00 [accepted] PHST- 2019/08/29 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/08/29 06:00 [entrez] AID - 000502663 [pii] AID - 10.1159/000502663 [doi] PST - ppublish SO - Urol Int. 2019;103(3):285-290. doi: 10.1159/000502663. Epub 2019 Aug 28. PMID- 31452420 OWN - NLM STAT- MEDLINE DCOM- 20200131 LR - 20200131 IS - 1464-5157 (Electronic) IS - 0265-6736 (Linking) VI - 36 IP - 1 DP - 2019 TI - Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial. PG - 868-875 LID - 10.1080/02656736.2019.1646929 [doi] AB - Objective: To compare the efficacy and safety of a novel thermochemotherapy scheme and the instillation of pirarubicin (THP) without hyperthermia in patients with intermediate- and high-risk nonmuscle-invasive bladder cancer (NMIBC). Materials and methods: Between June 2012 and December 2016, 300 patients with urothelial carcinoma of the bladder undergoing intravesical adjuvant therapy with THP after transurethral resection of bladder tumors (TURBT) were enrolled in the study. These patients were divided into the CTHC group (thermochemotherapy composed of three consecutive sessions in which only the second hyperthermia was combined with THP, followed by intravesical instillation with THP without using hyperthermia) and the THP group (instillation of THP without hyperthermia). Cystoscopy and urinary cytology were repeated every 3 months. The primary endpoint was 24-month recurrence-free survival (RFS). Secondary endpoints included 24-month progression-free survival (PFS) and adverse event (AE) rates. Results: Baseline characteristics of the CTHC (n = 76) and THP (n = 85) groups were well-balanced. The 24-month RFS was 82.9% in the CTHC group and 63.5% in the THP group (log-rank p = .008). A significantly higher percentage of patients in the CTHC group achieved PFS than in the THP group (97.4% versus 87.1%; log-rank p = .011). There was no significant difference in AEs between the two groups (p > .05). Based on Cox proportional hazards models, CTHC was the only factor that contributed independently to improved RFS (hazard ratio, 0.422; 95% confidence interval, 0.214-0.835; p = .013). Conclusion: The CTHC scheme is a safe and effective adjuvant treatment option after TURBT for patients with intermediate- and high-risk NMIBC. FAU - Zhou, Jun AU - Zhou J AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. FAU - Li, Linlin AU - Li L AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. FAU - Li, Xing AU - Li X AD - Department of Urology, Zhengzhou University People's Hospital , Zhengzhou , P.R. China. FAU - Yu, Qian AU - Yu Q AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. FAU - Cui, Shaowei AU - Cui S AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. FAU - Shu, Kunpeng AU - Shu K AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. FAU - Liu, Jianjun AU - Liu J AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. FAU - Liu, Jie AU - Liu J AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. FAU - Ding, Degang AU - Ding D AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Zhengzhou University People's Hospital , Zhengzhou , P.R. China. FAU - Du, Tao AU - Du T AD - Department of Urology, Henan University People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Henan Provincial People's Hospital , Zhengzhou , P.R. China. AD - Department of Urology, Zhengzhou University People's Hospital , Zhengzhou , P.R. China. LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Int J Hyperthermia JT - International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group JID - 8508395 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*therapeutic use MH - Combined Modality Therapy MH - Doxorubicin/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - *Hyperthermia, Induced MH - Male MH - Middle Aged MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*therapy MH - Urologic Surgical Procedures OTO - NOTNLM OT - Nonmuscle-invasive bladder cancer (NMIBC) OT - hyperthermia OT - intravesical chemotherapy OT - pirarubicin (THP) OT - thermochemotherapy EDAT- 2019/08/28 06:00 MHDA- 2020/02/01 06:00 CRDT- 2019/08/28 06:00 PHST- 2019/08/28 06:00 [entrez] PHST- 2019/08/28 06:00 [pubmed] PHST- 2020/02/01 06:00 [medline] AID - 10.1080/02656736.2019.1646929 [doi] PST - ppublish SO - Int J Hyperthermia. 2019;36(1):868-875. doi: 10.1080/02656736.2019.1646929. PMID- 31448424 OWN - NLM STAT- MEDLINE DCOM- 20191209 LR - 20200108 IS - 1365-3083 (Electronic) IS - 0300-9475 (Linking) VI - 90 IP - 6 DP - 2019 Dec TI - Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. PG - e12818 LID - 10.1111/sji.12818 [doi] AB - Bladder cancer is one of the leading causes of death worldwide. The main immune mechanisms which lead to bladder cancer development or treatment outcomes have yet to be elucidated. Toll-like receptors (TLRs) play key roles against cancer. TLRs are expressed both on immune cells and on tumour cells and drive immune responses in progression as well as treatment of cancer. Identification of signalling pathways via TLRs could revolutionize further improvement of therapeutic strategies against cancers in the future. According to the recent studies, TLRs agonists are effective immunostimulants and have important role in induction of immune responses with immunotherapeutic potential against several diseases including cancer. They play an important role in the bladder urothelium as a part of immune defence against uropathogens. On the other hand, decreased TLRs expression was found in bladder tumours, particularly in non-muscle-invasive ones. Bacillus Calmette-Guerin (BCG) (agonist of TLR2 and TLR4) is approved by US FDA for immunotherapy of bladder cancer. Despite high efficiency, immunotherapy with BCG may cause toxicity and adverse effects. Nowadays, in vitro and in vivo studies have been conducted to find alternative options for non-responder patients. Studies on TLR agonists for bladder cancer treatment have shown promising results. In this review, we discuss recent data about mechanisms played by TLRs in bladder cancer developments as well as therapeutic application of TLR agonists in cancer treatment. CI - (c) 2019 The Scandinavian Foundation for Immunology. FAU - Ohadian Moghadam, Solmaz AU - Ohadian Moghadam S AUID- ORCID: 0000-0001-9745-7063 AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Nowroozi, Mohammad Reza AU - Nowroozi MR AD - Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20191003 PL - England TA - Scand J Immunol JT - Scandinavian journal of immunology JID - 0323767 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biomarkers, Tumor) RN - 0 (Ligands) RN - 0 (Toll-Like Receptors) SB - IM MH - Animals MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use MH - Biomarkers, Tumor MH - Disease Progression MH - Disease Susceptibility MH - Humans MH - Immunogenetic Phenomena MH - Immunotherapy/methods MH - Ligands MH - Molecular Targeted Therapy MH - Neoplasm Grading MH - Neoplasm Staging MH - Polymorphism, Genetic MH - Signal Transduction MH - Toll-Like Receptors/agonists/genetics/*metabolism MH - Urinary Bladder Neoplasms/*etiology/*metabolism/pathology/therapy OTO - NOTNLM OT - TLR agonists OT - Toll-like receptor OT - bladder cancer OT - immunotherapy EDAT- 2019/08/27 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/08/27 06:00 PHST- 2019/04/11 00:00 [received] PHST- 2019/08/16 00:00 [revised] PHST- 2019/08/20 00:00 [accepted] PHST- 2019/08/27 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/08/27 06:00 [entrez] AID - 10.1111/sji.12818 [doi] PST - ppublish SO - Scand J Immunol. 2019 Dec;90(6):e12818. doi: 10.1111/sji.12818. Epub 2019 Oct 3. PMID- 31443960 OWN - NLM STAT- MEDLINE DCOM- 20201030 LR - 20220410 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 76 IP - 5 DP - 2019 Nov TI - European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. PG - 639-657 LID - S0302-2838(19)30660-8 [pii] LID - 10.1016/j.eururo.2019.08.016 [doi] AB - CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). OBJECTIVE: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of <5, one immediate chemotherapy instillation is recommended. Patients with intermediate-risk tumours should receive 1 yr of full-dose bacillus Calmette-Guerin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-unresponsive tumours. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC. The recommendations are based on the current literature (until the end of 2018), with emphasis on high-level data from randomised clinical trials and meta-analyses. Stratification of patients into low-, intermediate-, and high-risk groups is essential for deciding appropriate use of adjuvant intravesical chemotherapy or bacillus Calmette-Guerin (BCG) instillations. Surgical removal of the bladder should be considered in case of BCG-unresponsive tumours or in NMIBCs with the highest risk of progression. CI - Copyright (c) 2019. Published by Elsevier B.V. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: Marek.Babjuk@fnmotol.cz. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Hopital Tenon, Assistance Publique-Hopitaux de Paris, UPMC Paris VI, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Urology, Royal Surrey County Hospital, Guildford, Surrey, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Urology Department, Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Sylvester, Richard AU - Sylvester R AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Department of Urology, Royal Free London NHS Foundation Trust, London, UK. FAU - Escrig, Jose Luis Dominguez AU - Escrig JLD AD - Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Department of Urology, University of Rennes, Rennes, France. FAU - Seisen, Thomas AU - Seisen T AD - Urology Department, Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Paris, France. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article PT - Review DEP - 20190820 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Europe MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Patient Care Management/methods/standards MH - Practice Guidelines as Topic/*standards MH - Societies, Medical MH - *Urinary Bladder Neoplasms/pathology/therapy MH - *Urology/methods/trends OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bacillus Calmette-Guerin unresponsive OT - Bladder cancer OT - Cystoscopy OT - Diagnosis OT - European association of urology OT - Follow-up OT - Guidelines OT - Intravesical chemotherapy OT - Prognosis OT - Radical cystectomy OT - Transurethral resection OT - Urothelial carcinoma EDAT- 2019/08/25 06:00 MHDA- 2020/10/31 06:00 CRDT- 2019/08/25 06:00 PHST- 2019/07/27 00:00 [received] PHST- 2019/08/08 00:00 [accepted] PHST- 2019/08/25 06:00 [pubmed] PHST- 2020/10/31 06:00 [medline] PHST- 2019/08/25 06:00 [entrez] AID - S0302-2838(19)30660-8 [pii] AID - 10.1016/j.eururo.2019.08.016 [doi] PST - ppublish SO - Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20. PMID- 31440088 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 11 DP - 2019 TI - Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells. PG - 6995-7006 LID - 10.2147/CMAR.S208984 [doi] AB - Background: Transforming growth factor-beta-induced (TGFBI) is an exocrine protein, which has been found to be able to promote the development of nasopharyngeal carcinoma, glioma, pancreatic cancer, and other tumors. However, there is currently no report concerning the relationship between TGFBI and invasive progression of bladder cancer (BCa). Methods: IHC staining, qRT-PCR and Western blot were used to analyze TGFBI and EMT markers levels. In vivo tumorigenesis was performed by xenograft tumor model. Results: In this study, we found that both mRNA and protein levels of TGFBI were significantly up-regulated in muscle invasive bladder cancer (MIBC) tissues compared with non-muscle-invasive bladder cancer (NMIBC) tissues. The high expression level of TGFBI was positively correlated with high histological grade and advanced clinical stage, and BCa patients with high TGFBI levels exhibited poor prognoses. We further confirmed that high expression level of TGFBI can promote proliferation, invasive progression, and epithelial-to-mesenchymal transition (EMT) of BCa cells in vitro, as well as promote tumor growth and EMT in vivo, while silencing of TGFBI inhibited these malignant phenotypes. TGFBI was involved in the up-regulation of EMT by inducing the expression level of Slug, Vimentin, Snail, MMP2, and MMP9 genes, while it down-regulated the expression level of E-cadherin. Moreover, Western blot analysis was carried out to demonstrate that BCa cell lines stably transfected with expression of TGFBI, a secreted protein. Furthermore, conditional medium containing TGFBI protein also resulted in enhanced EMT and malignant phenotype of BCa cells. Conclusion: Our results indicate that high expression level of TGFBI promotes EMT, proliferation, and invasive progression of BCa cells, and TGFBI is a potential therapeutic target and prognostic marker for BCa. FAU - Zou, Jun AU - Zou J AD - Department of Emergency Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Huang, Ruiyan AU - Huang R AD - Department of Ultrasonography and Electrocardiograms, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China. FAU - Li, Huajun AU - Li H AD - Department of Emergency Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Wang, Bin AU - Wang B AD - Department of Urology, Affiliated Cancer Hospital & Institue of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Chen, Yanfei AU - Chen Y AD - Department of Urology, Affiliated Cancer Hospital & Institue of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Chen, Shuwei AU - Chen S AD - The Third Clinical College of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Ou, Kaifu AU - Ou K AD - The Third Clinical College of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. FAU - Wang, Xutao AU - Wang X AD - The Third Clinical College of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China. LA - eng PT - Journal Article DEP - 20190725 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6664251 OTO - NOTNLM OT - EMT OT - TGFBI OT - bladder cancer OT - invasive progression OT - secreted protein OT - tumor markers COIS- The authors declare that they have no competing interests in this work. EDAT- 2019/08/24 06:00 MHDA- 2019/08/24 06:01 PMCR- 2019/07/25 CRDT- 2019/08/24 06:00 PHST- 2019/03/16 00:00 [received] PHST- 2019/07/05 00:00 [accepted] PHST- 2019/08/24 06:00 [entrez] PHST- 2019/08/24 06:00 [pubmed] PHST- 2019/08/24 06:01 [medline] PHST- 2019/07/25 00:00 [pmc-release] AID - 208984 [pii] AID - 10.2147/CMAR.S208984 [doi] PST - epublish SO - Cancer Manag Res. 2019 Jul 25;11:6995-7006. doi: 10.2147/CMAR.S208984. eCollection 2019. PMID- 31438567 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240720 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 11 IP - 9 DP - 2019 Aug 21 TI - Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. LID - 10.3390/cancers11091219 [doi] LID - 1219 AB - Urothelial bladder cancer (UBC) are classified into luminal and basal subtypes showing distinct molecular features and clinical behaviour. Recent in silico data have proposed the activation on the Signal Transducer and Activator of Transcription 3 (STAT3) as relevant transcription factor in UBC. To answer this question, we have combined the retrospective analysis of clinical samples, functional assays on cell lines, interrogation of public UBC datasets and a murine model of basal-type UBC. Immunohistochemistry on a retrospective UBC cohort uncovered that STAT3 Y705 phosphorylation (pSTAT3) is significantly increased in infiltrating basal-type UBC compared to luminal UBC. In vitro, STAT3 silencing in UBC cell lines significantly reduced tumor cell viability and invasion. Gene expression profile of UBC cell lines combined with the analysis of the Cancer Genome Atlas (TCGA) and GSE32894 UBC datasets showed that increased expression of a set of STAT3 targets predicts basal-type, propensity to local progression and worse prognosis. MYC and FOSL1 represent relevant STAT3 downstream targets, as validated by their co-localization in pSTAT3+ UBC cancer cells. These findings were largely reproduced in the BBN-induced murine model of basal-type UBC. Of note, FOSL1 protein resulted strongly expressed in the non-papillary UBC pathway and FOSL1-regulated transcripts were significantly enriched in the transition from NMIBC to MIBC, as indicated by the interrogation of the GSE32894 dataset. The blockade of the STAT3 pathway might represent a novel treatment option for these neoplasms. Monitoring pSTAT3 and the downstream targets, particularly FOSL1, could provide meaningful levels of UBC stratification. FAU - Gatta, Luisa Benerini AU - Gatta LB AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Melocchi, Laura AU - Melocchi L AD - Department of Pathology, Fondazione Poliambulanza, 25100 Brescia, Italy. FAU - Bugatti, Mattia AU - Bugatti M AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Missale, Francesco AU - Missale F AD - Department of Otorhinolaryngology, Head and Neck Surgery-IRCCS Ospedale Policlinico San Martino, University of Genoa, 16121 Genoa, Italy. FAU - Lonardi, Silvia AU - Lonardi S AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Zanetti, Benedetta AU - Zanetti B AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Cristinelli, Luca AU - Cristinelli L AD - Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Belotti, Sandra AU - Belotti S AD - Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Ronca, Roberto AU - Ronca R AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. FAU - Grillo, Elisabetta AU - Grillo E AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. FAU - Licini, Sara AU - Licini S AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Bresciani, Debora AU - Bresciani D AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Tardanico, Regina AU - Tardanico R AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. FAU - Chan, Szeman Ruby AU - Chan SR AD - Janssen Research and Development, Spring House, Horsham, PA 19044, USA. FAU - Giurisato, Emanuele AU - Giurisato E AD - Department of Biotechnology Chemistry & Pharmacy, University of Siena, 53100 Siena, Italy. AD - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK. FAU - Calza, Stefano AU - Calza S AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. FAU - Vermi, William AU - Vermi W AD - Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25100 Brescia, Italy. william.vermi@unibs.it. AD - ASST Spedali Civili di Brescia, 25100 Brescia, Italy. william.vermi@unibs.it. AD - Department of Pathology and Immunology, Washington University School of Medicine, St Louis, St. Louis, MO 63130, USA. william.vermi@unibs.it. LA - eng PT - Journal Article DEP - 20190821 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC6770563 OTO - NOTNLM OT - FOSL1 OT - JAK OT - MYC OT - STAT3 OT - basal-type OT - bladder cancer COIS- The authors declare no competing financial interests. EDAT- 2019/08/24 06:00 MHDA- 2019/08/24 06:01 PMCR- 2019/08/21 CRDT- 2019/08/24 06:00 PHST- 2019/07/19 00:00 [received] PHST- 2019/08/09 00:00 [accepted] PHST- 2019/08/24 06:00 [entrez] PHST- 2019/08/24 06:00 [pubmed] PHST- 2019/08/24 06:01 [medline] PHST- 2019/08/21 00:00 [pmc-release] AID - cancers11091219 [pii] AID - cancers-11-01219 [pii] AID - 10.3390/cancers11091219 [doi] PST - epublish SO - Cancers (Basel). 2019 Aug 21;11(9):1219. doi: 10.3390/cancers11091219. PMID- 31432709 OWN - NLM STAT- MEDLINE DCOM- 20200826 LR - 20260127 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 33 IP - 11 DP - 2019 Nov TI - Long-Term Prospective Outcomes of Patients with Non-Muscle Invasive Bladder Cancer After Holmium Laser Ablation. PG - 938-945 LID - 10.1089/end.2019.0253 [doi] AB - Objectives: To evaluate the long-term tumor recurrence, progression, and cancer-specific mortality (CSM) of patients after holmium laser ablation of non-muscle invasive bladder cancer (NMIBC) under topical anesthesia. To identify variables that help to predict risk of tumor recurrence, progression, and CSM. Materials and Methods: A prospective study of 251 consecutive patients with 399 recurrent NMIBC who underwent outpatient Holmium yttrium aluminium garnet laser ablation under topical anesthesia was carried out between September 2006 and September 2018. All patients underwent primary transurethral resection of bladder tumor to obtain histology. All patients completed a patient satisfaction questionnaire and visual analogue scale (VAS) for procedure-related pain. Results: All 251 patients were analyzed with an average age of 75.2 years and follow-up of 69.8 months. The majority of patients had multiple comorbidities with an American Society of Anesthesiologists of 3 or 4. The proportion of tumor grade 1, 2, and 3 disease and tumor stage Ta and T1 was 43.4%, 41.5%, 15.1%, 78.5%, and 21.5%, respectively. Overall, 57.8% of patients had at least one tumor recurrence with an average time of 16.3 months. Risk factors were tumor grade, number of tumors at time of first laser ablation, and tumor stage. Overall, 19.1% of patients demonstrated tumor progression with an average time of 51 months. Only 5.6% of patients had progression to muscle invasive bladder cancer, and the CSM rate was 5.2% with an average time to death of 71.2 months. Risk factors for CSM were tumor grade, stage, and the patient's age. The average VAS for pain was 0.6 out of 10, with all patients willing to have the procedure repeated if required. Conclusion: Laser ablation of NMIBC is a safe, effective, and well-tolerated long-term option for patients, particular in those who have moderate-to-severe co-morbidities. The long-term cancer outcomes are best for younger patients with primary low-grade and low-stage disease. FAU - Darrad, Maitrey AU - Darrad M AD - Department of Urology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Jah, Syed AU - Jah S AD - Department of Urology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Ahmed, Zeba AU - Ahmed Z AD - Department of Urology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Syed, Haider AU - Syed H AD - Department of Urology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. LA - eng PT - Journal Article PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 RN - W1XX32SQN1 (Holmium) SB - IM CIN - J Urol. 2021 Jun;205(6):1821-1823. doi: 10.1097/JU.0000000000001721. PMID: 33827232 MH - Aged MH - Anesthesia, Local MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystoscopy/*methods MH - Disease Progression MH - Female MH - Holmium MH - Humans MH - Laser Therapy/*methods MH - Lasers, Solid-State/*therapeutic use MH - Male MH - Muscle, Smooth/*pathology MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasm Staging MH - Procedural Pain/prevention & control MH - Patient Satisfaction MH - Progression-Free Survival MH - Prospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Surgical Procedures/methods OTO - NOTNLM OT - laser ablation OT - long-term outcomes OT - non-muscle invasive bladder cancer EDAT- 2019/08/23 06:00 MHDA- 2020/08/28 06:00 CRDT- 2019/08/22 06:00 PHST- 2019/08/23 06:00 [pubmed] PHST- 2020/08/28 06:00 [medline] PHST- 2019/08/22 06:00 [entrez] AID - 10.1089/end.2019.0253 [doi] PST - ppublish SO - J Endourol. 2019 Nov;33(11):938-945. doi: 10.1089/end.2019.0253. PMID- 31427158 OWN - NLM STAT- MEDLINE DCOM- 20200828 LR - 20200828 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - Incidence and risk factors for peritoneal carcinomatosis following open radical cystectomy. PG - 886-892 LID - S1078-1439(19)30246-7 [pii] LID - 10.1016/j.urolonc.2019.06.017 [doi] AB - OBJECTIVE: To characterize the frequency and risk factors of peritoneal carcinomatosis (PC) in patients undergoing open radical cystectomy (RC). METHODS: We identified 3,285 patients with urothelial carcinoma treated with RC for curative intent between 1980 and 2016. At last follow-up, 72.1% (2,370/3,285) of patients had died, with a median follow-up of 8.6 years (Interquartile Range, (IQR) 3.7, 14.1). PC was defined as any recurrence involving the omentum, small bowel, and mesentery. Overall-specific survival (OSS) and cancer-specific survival (CSS) was evaluated using Kaplan-Meier methodology and log-rank test. Risk factors for mortality and recurrence were performed using Cox proportional hazards regression models. RESULTS: One hundred and twenty nine (3.9%) patients were diagnosed with PC, while a total of 1,148 (34.9%) patients experienced recurrence at other sites. Median time to PC vs. other-site recurrence was 1.3 (IQR 1.3, 2.3) and 0.9 (IQR 0.5, 2.1) years, respectively (P= 0.04). Only increasing pathologic stage on multivariable analysis was associated with developing PC (pT1 HR 2.51, 95CI 1.14-5.55, P= 0.02; pT2 OR 2.82, 95CI 1.47-5.43, P= 0.002; pT3+ 2.40, 95CI 1.31-4.42, P= 0.005) over other recurrence patterns. Nodal status and tumor margin status were not associated. Patients with PC experienced worse OSS and CSS than other types of recurrence (P< 0.001). CONCLUSION: PC was identified in almost 4% of patients undergoing open RC. PC is a rare occurrence after RC and primarily impacts patients with locally advanced disease. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Yang, David Y AU - Yang DY AD - Mayo Clinic, Department of Urology, Rochester, MN. FAU - Frank, Igor AU - Frank I AD - Mayo Clinic, Department of Urology, Rochester, MN. FAU - Avant, Ross A AU - Avant RA AD - Mayo Clinic, Department of Urology, Rochester, MN. FAU - Miller, Adam R AU - Miller AR AD - Mayo Clinic, Department of Urology, Rochester, MN. FAU - Thapa, Prabin AU - Thapa P AD - Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Mayo Clinic, Department of Urology, Rochester, MN. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Mayo Clinic, Department of Urology, Rochester, MN. Electronic address: Tollefson.Matthew@Mayo.edu. LA - eng PT - Journal Article DEP - 20190817 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/secondary/surgery MH - *Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Peritoneal Neoplasms/*epidemiology/secondary MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Open Cystectomy OT - Outcomes OT - Peritoneal Carcinomatosis OT - Recurrence OT - Urothelial Carcinoma EDAT- 2019/08/21 06:00 MHDA- 2020/08/29 06:00 CRDT- 2019/08/21 06:00 PHST- 2019/04/06 00:00 [received] PHST- 2019/05/30 00:00 [revised] PHST- 2019/06/21 00:00 [accepted] PHST- 2019/08/21 06:00 [pubmed] PHST- 2020/08/29 06:00 [medline] PHST- 2019/08/21 06:00 [entrez] AID - S1078-1439(19)30246-7 [pii] AID - 10.1016/j.urolonc.2019.06.017 [doi] PST - ppublish SO - Urol Oncol. 2019 Dec;37(12):886-892. doi: 10.1016/j.urolonc.2019.06.017. Epub 2019 Aug 17. PMID- 31421144 OWN - NLM STAT- MEDLINE DCOM- 20200115 LR - 20200115 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 133 DP - 2019 Nov TI - Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer. PG - 157-163 LID - S0090-4295(19)30721-6 [pii] LID - 10.1016/j.urology.2019.07.034 [doi] AB - OBJECTIVE: To determine if the timing of radical cystectomy for variant histology of urothelial carcinoma has an impact on survival. Variant histology has been associated with aberrant behavior compared to pure urothelial carcinoma, however the timing of surgery for these patients has not been studied. MATERIALS AND METHODS: We identified 363 patients with cT2-T4N0M0 urothelial carcinoma who underwent radical cystectomy without perioperative intravesical and/or systemic therapy from 2003 to 2014. Clinicopathologic data were compared between pure urothelial carcinoma and variant histology. The time from diagnosis to radical cystectomy was analyzed as a continuous variable and dichotomized at 4-, 8-, and 12-weeks to determine impact on oncologic outcomes. RESULTS: Patients with variant histology, when compared to those with pure urothelial carcinoma, were more likely to present with extravesical disease (P <.01), be upstaged (P <.01), have lymphovascular invasion (P <.01) and have lymph node metastasis at radical cystectomy (P = .02). The median days to radical cystectomy did not differ between pure urothelial and variant histology. On multivariable analysis controlling for age, comorbidities, tumor stage, lymph node status, lymphovascular invasion, and surgical margins, every month in delay was associated with a worse overall survival for variants (HR = 1.36, P = .003). At an 8-week delay or longer, those with variant histology had a statistically worse survival (P = .03). CONCLUSION: For patients with variant histology, delays in surgery were associated with an increased risk of death. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Lin-Brande, Michael AU - Lin-Brande M AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Pearce, Shane M AU - Pearce SM AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Ashrafi, Akbar N AU - Ashrafi AN AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Nazemi, Azadeh AU - Nazemi A AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Burg, Madeleine L AU - Burg ML AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Ghodoussipour, Saum AU - Ghodoussipour S AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Miranda, Gus AU - Miranda G AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Schuckman, Anne AU - Schuckman A AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address: daneshma@med.usc.edu. LA - eng PT - Journal Article DEP - 20190814 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2019 Nov;133:161-162. doi: 10.1016/j.urology.2019.07.035. PMID: 31706415 MH - Aged MH - Carcinoma, Transitional Cell/mortality/*pathology/*surgery MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Survival Rate MH - *Time-to-Treatment/statistics & numerical data MH - Urinary Bladder Neoplasms/mortality/*pathology/*surgery EDAT- 2019/08/20 06:00 MHDA- 2020/01/16 06:00 CRDT- 2019/08/18 06:00 PHST- 2019/04/26 00:00 [received] PHST- 2019/06/17 00:00 [revised] PHST- 2019/07/11 00:00 [accepted] PHST- 2019/08/20 06:00 [pubmed] PHST- 2020/01/16 06:00 [medline] PHST- 2019/08/18 06:00 [entrez] AID - S0090-4295(19)30721-6 [pii] AID - 10.1016/j.urology.2019.07.034 [doi] PST - ppublish SO - Urology. 2019 Nov;133:157-163. doi: 10.1016/j.urology.2019.07.034. Epub 2019 Aug 14. PMID- 31413912 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210112 IS - 2162-4011 (Print) IS - 2162-402X (Electronic) IS - 2162-4011 (Linking) VI - 8 IP - 8 DP - 2019 TI - Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. PG - 1602460 LID - 10.1080/2162402X.2019.1602460 [doi] LID - 1602460 AB - Intravesical Bacille Calmette-Guerin (BCG) remains the most effective treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), unfortunately there is no validated biomarker to predict clinical outcome. Here we tried to explore the possibility that a combination of the density of peritumoral infiltrating cells (Th1, Th2 and PD-L1) and the composition of peripheral immune cells (neutrophil and lymphocyte counts) could generate a more reliable prognostic biomarker. Twenty-two patients with high-risk NMIBC treated with BCG (10 BCG nonresponders and 12 BCG responders) were selected. BCG responders had significantly lower level of peritumoral T-bet(+) cells with an associated higher GATA-3(+)/T-bet(+) ratio (p = 0.04, p = 0.02, respectively). Furthermore, the immune polarization in tissue (GATA-3(+)/T-bet(+) ratio) adjusted for the systemic inflammation (neutrophil-to-lymphocyte ratio) showed a significantly higher association with the BCG response (p = 0.004). A survival analysis demonstrated prolonged recurrence-free survival (RFS) in patients with a lower T-bet(+)/Lymphocyte ratio and higher GTR/NLR (p = 0.01). No association was observed between peritumoral PD-L1(+) expression and the BCG response. In conclusion, alterations in overall immune function, both local and systemic, may influence the therapeutic response to BCG, therefore a combined analysis of tumoral (Th2/Th1 ratio) and peripheral (NLR) immune composition prior to treatment may be a promising approach to predict the BCG response in high-risk NMIBC patients. FAU - Martinez, Roberto AU - Martinez R AD - Urology Department, Hospital Universitario Germans Trias i Pujol, IGTP, UAB, Badalona, Spain. FAU - Tapia, Gustavo AU - Tapia G AD - Pathology Department, Hospital Universitario Germans Trias i Pujol, IGTP, UAB, Badalona, Spain. FAU - De Muga, Silvia AU - De Muga S AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. FAU - Hernandez, Alba AU - Hernandez A AD - Pathology Department, Hospital Universitario Germans Trias i Pujol, IGTP, UAB, Badalona, Spain. FAU - Cao, Maria Gonzalez AU - Cao MG AD - Dr. Rosell Oncology Institute, Quiron Dexeus University Hospital, Barcelona, Spain. FAU - Teixido, Cristina AU - Teixido C AD - Pangaea Biotech, Quiron Dexeus University Hospital, Barcelona, Spain. AD - Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Urrea, Victor AU - Urrea V AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. FAU - Garcia, Elisabet AU - Garcia E AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. FAU - Pedreno-Lopez, Sonia AU - Pedreno-Lopez S AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. FAU - Ibarz, Luis AU - Ibarz L AD - Urology Department, Hospital Universitario Germans Trias i Pujol, IGTP, UAB, Badalona, Spain. FAU - Blanco, Julia AU - Blanco J AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. AD - AIDS and Related Illnesses, Centre for Health and Social Care Research (CESS), Faculty of Medicine, University of Vic - Central University of Catalonia (UVic - UCC), Vic, Barcelona, Spain. FAU - Clotet, Bonaventura AU - Clotet B AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. AD - AIDS and Related Illnesses, Centre for Health and Social Care Research (CESS), Faculty of Medicine, University of Vic - Central University of Catalonia (UVic - UCC), Vic, Barcelona, Spain. FAU - Cabrera, Cecilia AU - Cabrera C AD - IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP) UAB, Badalona, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190413 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 PMC - PMC6682363 OTO - NOTNLM OT - BCG immunotherapy OT - GATA-3 OT - NLR OT - NMIBC OT - T-bet OT - biomarker EDAT- 2019/08/16 06:00 MHDA- 2019/08/16 06:01 PMCR- 2020/04/13 CRDT- 2019/08/16 06:00 PHST- 2018/11/29 00:00 [received] PHST- 2019/01/17 00:00 [revised] PHST- 2019/03/29 00:00 [accepted] PHST- 2019/08/16 06:00 [entrez] PHST- 2019/08/16 06:00 [pubmed] PHST- 2019/08/16 06:01 [medline] PHST- 2020/04/13 00:00 [pmc-release] AID - 1602460 [pii] AID - 10.1080/2162402X.2019.1602460 [doi] PST - epublish SO - Oncoimmunology. 2019 Apr 13;8(8):1602460. doi: 10.1080/2162402X.2019.1602460. eCollection 2019. PMID- 31412916 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20200225 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 14 IP - 1 DP - 2019 Aug 14 TI - Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. PG - 90 LID - 10.1186/s13000-019-0868-3 [doi] LID - 90 AB - BACKGROUND: European treatment guidelines for pTa and pT1 urinary bladder urothelial carcinoma depend highly on stage and WHO-grade. Both the WHO73 and the WHO04 grading systems show some intra- and interobserver variability. The current pilot study investigates which histopathological features are especially sensitive for this undesired lack of reproducibility and the influence on prognostic value. METHODS: Thirty-eight cases of primary non-muscle invasive urothelial carcinomas, including thirteen cases with stage progression, were reviewed by three pathologists. Thirteen microscopic features were extracted from pathology textbooks and evaluated separately. Reproducibility was measured using Gwet's agreement coefficients. Prognostic ability regarding progression was estimated by the area under curve (AUC) of the receiver operating characteristics (ROC) function. RESULTS: The best reproducible features (Gwet's agreement coefficient above 0.60) were papillary architecture, nuclear polarity, cellular maturation, nuclear enlargement and giant nuclei. Nucleoli was the strongest prognostic feature, and the only feature with an AUC above 0.70 for both grading systems, but reproducibility was not among the strongest. Nuclear polarity also had prognostic value with an AUC of 0.70 and 0.67 for the WHO73 and WHO04, respectively. The other features did not have significant prognostic value. CONCLUSIONS: The reproducibility of the histopathological features of the different WHO grading systems varied considerably. Of all the features evaluated, only nuclear polarity was both prognostic and significantly reproducible. Further validation studies are needed on these features to improve grading of urothelial carcinomas. FAU - Kvikstad, Vebjorn AU - Kvikstad V AUID- ORCID: 0000-0003-2980-8217 AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. vebjorn.kvikstad@sus.no. AD - Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway. vebjorn.kvikstad@sus.no. FAU - Mangrud, Ok Malfrid AU - Mangrud OM AD - Department of Pathology, Innlandet Hospital, Lillehammer, Norway. FAU - Gudlaugsson, Einar AU - Gudlaugsson E AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. FAU - Dalen, Ingvild AU - Dalen I AD - Department of Research, Stavanger University Hospital, Stavanger, Norway. FAU - Espeland, Hans AU - Espeland H AD - Department of Urology, Stavanger University Hospital, Stavanger, Norway. FAU - Baak, Jan P A AU - Baak JPA AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Medical practice Dr. med. Jan Baak AS, Tananger, Norway. AD - Department of TCM, Faculty of Sports and Health Sciences, Technical University Munich, Munich, Germany. FAU - Janssen, Emiel A M AU - Janssen EAM AD - Department of Pathology, Stavanger University Hospital, Stavanger, Norway. AD - Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway. LA - eng PT - Journal Article DEP - 20190814 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading/standards MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Recurrence, Local/diagnosis/*pathology MH - Prognosis MH - Reproducibility of Results MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology MH - World Health Organization PMC - PMC6694469 OTO - NOTNLM OT - Grading OT - Papillary urothelial carcinoma OT - Prognosis OT - Reproducibility COIS- The authors declare that they have no competing interests. EDAT- 2019/08/16 06:00 MHDA- 2020/02/19 06:00 PMCR- 2019/08/14 CRDT- 2019/08/16 06:00 PHST- 2019/03/25 00:00 [received] PHST- 2019/08/09 00:00 [accepted] PHST- 2019/08/16 06:00 [entrez] PHST- 2019/08/16 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2019/08/14 00:00 [pmc-release] AID - 10.1186/s13000-019-0868-3 [pii] AID - 868 [pii] AID - 10.1186/s13000-019-0868-3 [doi] PST - epublish SO - Diagn Pathol. 2019 Aug 14;14(1):90. doi: 10.1186/s13000-019-0868-3. PMID- 31412742 OWN - NLM STAT- MEDLINE DCOM- 20191024 LR - 20191024 IS - 1744-7658 (Electronic) IS - 1354-3784 (Linking) VI - 28 IP - 9 DP - 2019 Sep TI - Current advances in BCG-unresponsive non-muscle invasive bladder cancer. PG - 757-770 LID - 10.1080/13543784.2019.1655730 [doi] AB - Introduction: The current first line therapy for high grade (HG) non-muscle invasive bladder cancer (NMIBC) is intravesical Bacillus Calmette-Guerin (BCG). Patients who recur or progress despite BCG are recommended to undergo radical cystectomy or participate in clinical trials. There is an urgent need for alternative therapies in the BCG-unresponsive NMIBC realm. Areas covered: We queried clinicaltrials.gov and pubmed.gov for current and recently completed early clinical trials pertaining to investigational agents used for the treatment of BCG-unresponsive NMIBC. These included intravesical chemotherapy, immunotherapy, vaccines, gene therapy, viruses, and agents used with novel drug delivery methods. In this article, we discuss the treatment guidelines for non-muscle invasive bladder cancer and therapeutic approaches under investigation in clinical trials. Expert opinion: The FDA is currently allowing single-arm studies as a pathway for approval in BCG-refractory patients with CIS. Although many agents are currently undergoing testing, none have been approved since Valrubicin. Hopefully, we will identify therapies sufficiently effective and durable to achieve FDA approval. Other considerations in this realm include the use of biomarkers in NMIBC to identify patients who will most likely respond to specific interventions. In addition, as systemic agents such as checkpoint inhibitors, are studied further, a multidisciplinary approach may be needed to treat this subset of patients. FAU - Tse, Jennifer AU - Tse J AD - Department of Urology, University of Texas Southwestern Medical Center , Dallas , TX , USA. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center , Dallas , TX , USA. FAU - Ghandour, Rashed AU - Ghandour R AD - Department of Urology, University of Texas Southwestern Medical Center , Dallas , TX , USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center , Dallas , TX , USA. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center , Dallas , TX , USA. LA - eng PT - Journal Article PT - Review DEP - 20190815 PL - England TA - Expert Opin Investig Drugs JT - Expert opinion on investigational drugs JID - 9434197 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Drugs, Investigational) SB - IM MH - Animals MH - Antineoplastic Agents/administration & dosage/*pharmacology MH - BCG Vaccine/administration & dosage MH - Biomarkers, Tumor/metabolism MH - Cystectomy/methods MH - Drug Delivery Systems MH - Drugs, Investigational/administration & dosage/*pharmacology MH - Humans MH - Immunotherapy/methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG-refractory OT - BCG-unresponsive OT - clinical trials OT - non-muscle invasive bladder cancer EDAT- 2019/08/16 06:00 MHDA- 2019/10/28 06:00 CRDT- 2019/08/16 06:00 PHST- 2019/08/16 06:00 [pubmed] PHST- 2019/10/28 06:00 [medline] PHST- 2019/08/16 06:00 [entrez] AID - 10.1080/13543784.2019.1655730 [doi] PST - ppublish SO - Expert Opin Investig Drugs. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15. PMID- 31411976 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20211122 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 4 IP - 2 DP - 2021 Apr TI - Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers. PG - 246-255 LID - S2588-9311(19)30058-6 [pii] LID - 10.1016/j.euo.2019.04.009 [doi] AB - BACKGROUND: Bladder cancer (BC) is highly immunogenic. Bacillus Calmette-Guerin (BCG) immunotherapy offers the best results in non-muscle-invasive BC (NMIBC). Natural killer cells (NKcs) play decisive roles in BCG-mediated immune response and in general cancer immune-surveillance. OBJECTIVE: To analyze killer-cell immunoglobulin-like receptors (KIRs), their human leukocyte antigen class-I (HLA-I) ligands, and the expression of DNAX Accessory Molecule-1 (DNAM-1/CD226) on peripheral blood (PB) NKcs, to identify useful predictive biomarkers in BC. DESIGN, SETTING, AND PARTICIPANTS: KIR/HLA-ligand genotypes were compared between 132 BC, 201 other solid cancers, 164 plasma cell disorders, and 615 healthy Caucasoid controls. CD226 expression was evaluated by flow cytometry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: KIR/HLA-I interactions and CD226 expression on NKcs (CD226(high) or CD226(low)) were compared across study groups, cancer stages, treatments, and progression-free and overall survival of patients, using chi-square, analysis of variance/post hoc, Kaplan-Meier/log-rank, and regression analyses. RESULTS AND LIMITATIONS: Three immunological risk groups were identified: low risk (KIR2DL1(-)L2(+)L3(-)/C1C1(-) and KIR2DL1(+)L2(+)L3(+)/C1C1(+)), intermediate risk (rest), and high risk (KIR2DL5(+)/HLA-C*16(+) and KIR2DL1(+)L2(+)L3(-)), which displayed different 10-yr progression-free rates (83.3%, 48.6%, and 0%, respectively; p<0.001) and survival rates (83.3%, 54.3%, and 6.2%, respectively; p<0.001) for muscle-invasive T2/T4, and 10-yr progression-free rates (100%, 81.6%, and 50%, respectively; p<0.05) for NMIBC-T1 treated with BCG. Immunological risk stratification had an independent prognostic value to just histological staging for survival (hazard ratio=2.93, p<0.00001, Harrell C-statistic=0.779). CD226 expression on PB NKcs improved immunological stratification in intermediate-risk T1-T4 BC patients, with survival rates of 94.1% and 66.7% for CD226(high) and CD226(low) (p<0.05), respectively. CONCLUSIONS: Immunological risk stratification will complement BC histopathology to improve risk stratification and guide the selection of personalized treatments. Understanding of the molecular mechanisms of NKc tumor immune surveillance will enable the development of future NKc-based therapies. PATIENT SUMMARY: This work describes a peripheral blood test that aids in our understanding of the immune defense mechanisms against bladder cancer, is useful for classifying patient risk, and will guide personalized treatments. CI - Copyright (c) 2019. Published by Elsevier B.V. FAU - Guillamon, Concepcion F AU - Guillamon CF AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Gimeno, Lourdes AU - Gimeno L AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Server, Gerardo AU - Server G AD - Urology, HCUVA-IMIB, Murcia, Spain. FAU - Martinez-Sanchez, Maria V AU - Martinez-Sanchez MV AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Escudero, Jose F AU - Escudero JF AD - Urology, HCUVA-IMIB, Murcia, Spain. FAU - Lopez-Cubillana, Pedro AU - Lopez-Cubillana P AD - Urology, HCUVA-IMIB, Murcia, Spain. FAU - Cabezas-Herrera, Juan AU - Cabezas-Herrera J AD - Molecular Therapy and Biomarkers Research Group, Clinical Analysis Service, HCUVA-IMIB, Murcia, Spain. FAU - Campillo, Jose A AU - Campillo JA AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Abellan, Daniel J AU - Abellan DJ AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Martinez-Garcia, Jeronimo AU - Martinez-Garcia J AD - Urology, HCUVA-IMIB, Murcia, Spain. FAU - Martinez-Escribano, Jorge AU - Martinez-Escribano J AD - Dermatology Services, HCUVA-IMIB, Murcia, Spain. FAU - Ferri, Belen AU - Ferri B AD - Pathology Services, HCUVA-IMIB, Murcia, Spain. FAU - Lopez-Alvarez, Maria R AU - Lopez-Alvarez MR AD - Centre for Preventive Medicine, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, UK. FAU - Moreno-Alarcon, Cristobal AU - Moreno-Alarcon C AD - Urology, HCUVA-IMIB, Murcia, Spain. FAU - Moya-Quiles, Maria R AU - Moya-Quiles MR AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Muro, Manuel AU - Muro M AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. FAU - Minguela, Alfredo AU - Minguela A AD - Immunology Service, Hospital Clinico Universitario Virgen de la Arrixaca (HCUVA) Instituto Murciano de Investigacion Biosanitaria (IMIB), Murcia, Spain. Electronic address: alfredo.minguela@carm.es. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190514 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Biomarkers) SB - IM MH - Biomarkers MH - Humans MH - Killer Cells, Natural MH - Prognosis MH - Risk Assessment MH - *Urinary Bladder Neoplasms/diagnosis/genetics/therapy OTO - NOTNLM OT - Activating and inhibitory natural killer cell receptors OT - Bladder cancer OT - DNAX Accessory Molecule-1/CD226 OT - Human leukocyte antigen OT - Killer-cell immunoglobulin-like receptor OT - Natural killer cell EDAT- 2019/08/15 06:00 MHDA- 2021/11/23 06:00 CRDT- 2019/08/15 06:00 PHST- 2019/01/28 00:00 [received] PHST- 2019/03/13 00:00 [revised] PHST- 2019/04/17 00:00 [accepted] PHST- 2019/08/15 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2019/08/15 06:00 [entrez] AID - S2588-9311(19)30058-6 [pii] AID - 10.1016/j.euo.2019.04.009 [doi] PST - ppublish SO - Eur Urol Oncol. 2021 Apr;4(2):246-255. doi: 10.1016/j.euo.2019.04.009. Epub 2019 May 14. PMID- 31407969 OWN - NLM STAT- MEDLINE DCOM- 20200310 LR - 20200310 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 293 IP - 1 DP - 2019 Oct TI - Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer. PG - 144-150 LID - 10.1148/radiol.2019190032 [doi] AB - Background Delayed fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT is used to diagnose bladder cancer. However, it remains difficult to determine whether a lesion with abnormal (18)F FDG uptake is tumor residue or recurrence or if it is an inflammatory reaction in patients with bladder cancer after oncologic treatment. Purpose To determine the diagnostic performance of delayed (18)F FDG PET/CT in the differentiation of residual tumors from postoperative inflammatory reactions in patients with bladder cancer after initial transurethral resection of bladder tumor (TURBT). Materials and Methods A retrospective clinical study between January 2015 and April 2018 was performed in 79 patients with bladder cancer who had undergone (18)F FDG PET/CT within 1 month after initial TURBT. After PET/CT, all patients underwent a second surgery within 2 weeks to confirm the histologic nature of the suspicious lesion and to remove residual tumors. Uni- and multivariable analysis were used to identify predictive factors for residual bladder tumors. Results A total of 79 patients (61 men, 18 women; mean age, 63 years +/- 11 [standard deviation]) were enrolled in this study. A total of 98 lesions was studied, 64 (65.3%) of which were residual tumors after initial TURBT. When compared with inflammatory reactions, residual tumors had higher mean standardized uptake value (SUV(mean)) (mean, 5.8 +/- 2.0 vs 9.3 +/- 5.4; P < .001), higher maximum standardized uptake value (SUV(max)) (mean, 15.5 +/- 9.8 vs 22.2 +/- 13.6, P = .01), and greater lesion thickness (mean, 9.6 mm +/- 4.1 vs 17.9 mm +/- 11.1, P < .001) at (18)F FDG PET/CT. SUV(mean) (odds ratio [OR], 1.2; 95% confidence interval [CI]: 1.0, 1.5; P = .049) and lesion thickness (OR, 1.2; 95% CI: 1.0, 1.3; P = .006 or OR, 1.2; 95% CI: 1.1, 1.3; P = .001) were identified as independent predictors for residual tumors with multivariable logistic regression analysis. On the basis of the threshold values of SUV(mean) and lesion thickness, we revealed a prediction rate of 37.5% (17 of 47), 85.4% (26 of 29), and 98.3% (21 of 22) for residual tumors in low-, moderate-, and high-risk subgroups, respectively. Conclusion Use of fluorine 18 fluorodeoxyglucose PET/CT to differentiate lesions after transurethral resection of bladder tumor indicates that higher mean standardized uptake values and greater lesion thickness are predictive factors for residual tumors in patients with bladder cancer after oncologic treatment. Published under a CC BY 4.0 license. FAU - Yan, Hui AU - Yan H AUID- ORCID: 0000-0002-2033-3502 AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Zhou, Xiang AU - Zhou X AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Wang, Xiaoyan AU - Wang X AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Li, Rui AU - Li R AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Shi, Yiping AU - Shi Y AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Xia, Qian AU - Xia Q AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Wan, Liangrong AU - Wan L AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Huang, Gang AU - Huang G AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). FAU - Liu, Jianjun AU - Liu J AUID- ORCID: 0000-0003-0238-0310 AD - From the Departments of Nuclear Medicine (H.Y., X.Z., R.L., Y.S., Q.X., L.W., G.H., J.L.) and Ultrasound (X.W.), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Pudong District, Shanghai 200127, China; and Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China (G.H.). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190813 PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM CIN - J Urol. 2020 Apr;203(4):643-644. doi: 10.1097/JU.0000000000000718. PMID: 31909670 MH - Adult MH - Aged MH - Aged, 80 and over MH - Diagnosis, Differential MH - Female MH - *Fluorodeoxyglucose F18 MH - Humans MH - Male MH - Middle Aged MH - Neoplasm, Residual MH - Positron Emission Tomography Computed Tomography/*methods MH - *Radiopharmaceuticals MH - Time MH - Urinary Bladder/diagnostic imaging/surgery MH - Urinary Bladder Neoplasms/*diagnostic imaging/*surgery EDAT- 2019/08/14 06:00 MHDA- 2020/03/11 06:00 CRDT- 2019/08/14 06:00 PHST- 2019/08/14 06:00 [pubmed] PHST- 2020/03/11 06:00 [medline] PHST- 2019/08/14 06:00 [entrez] AID - 10.1148/radiol.2019190032 [doi] PST - ppublish SO - Radiology. 2019 Oct;293(1):144-150. doi: 10.1148/radiol.2019190032. Epub 2019 Aug 13. PMID- 31402280 OWN - NLM STAT- MEDLINE DCOM- 20200515 LR - 20200515 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 5 DP - 2019 Oct TI - Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice. PG - e1003-e1010 LID - S1558-7673(19)30178-8 [pii] LID - 10.1016/j.clgc.2019.05.028 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk. The aim of the present study was to report the efficacy and toxicity of IPIOC, particularly in intermediate-risk NMIBC patients, in the real-world setting. PATIENTS AND METHODS: We retrospectively analyzed 363 consecutive patients with primary NMIBC who underwent radical TUR at Kyoto University Hospital between 2007 and 2016. RESULTS: In low-risk patients, recurrence-free survival (RFS) was significantly better for IPIOC than non-IPIOC (2-year RFS: 89.3% vs. 59.4%; P = .001). In intermediate-risk patients, IPIOC was associated with significantly longer RFS compared with non-IPIOC (2-year RFS: 85.5% vs. 58.2%; P = .011). IPIOC and bacillus Calmette-Guerin (BCG) were independent predictors for post-TUR recurrence (non-IPIOC vs. IPIOC: hazard ratio [HR], 2.33; 95% confidence interval [CI], 1.14-4.88; P = .02; non-BCG vs. BCG: HR, 2.22; P = .045, 95% CI, 1.02-5.30). In the high-risk group, only BCG was an independent prognostic factor of recurrence in a multivariate Cox proportional hazards model (HR, 2.55; P = .006, 95% CI, 1.32-4.87). There were no significant differences between the BCG-only group and the IPIOC with BCG group in Grade 3 or more local (16 patients [21%] vs. 21 patients [24%]; P = .61) or systemic (3 patients [4%] vs. 6 patients [7%]; P = .40) toxicity rates. CONCLUSION: Our study showed the efficacy of IPIOC for the prevention of intravesical recurrence in primary intermediate-risk NMIBC patients regardless of BCG therapy. CI - Copyright (c) 2019. Published by Elsevier Inc. FAU - Murakami, Kaoru AU - Murakami K AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Hamada, Akihiro AU - Hamada A AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Teramoto, Yuki AU - Teramoto Y AD - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. FAU - Matsumoto, Keiyu AU - Matsumoto K AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kita, Yuki AU - Kita Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Yamasaki, Toshinari AU - Yamasaki T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Inoue, Takahiro AU - Inoue T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Ogawa, Osamu AU - Ogawa O AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: osamuogawa1219@gmail.com. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190530 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Drug Administration Schedule MH - Drug Therapy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Nephrectomy/*methods MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*therapy OTO - NOTNLM OT - BCG OT - Epirubicin OT - Intravesical recurrence OT - Prevention OT - Transurethral resection EDAT- 2019/08/14 06:00 MHDA- 2020/05/16 06:00 CRDT- 2019/08/13 06:00 PHST- 2019/04/07 00:00 [received] PHST- 2019/05/20 00:00 [revised] PHST- 2019/05/26 00:00 [accepted] PHST- 2019/08/14 06:00 [pubmed] PHST- 2020/05/16 06:00 [medline] PHST- 2019/08/13 06:00 [entrez] AID - S1558-7673(19)30178-8 [pii] AID - 10.1016/j.clgc.2019.05.028 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Oct;17(5):e1003-e1010. doi: 10.1016/j.clgc.2019.05.028. Epub 2019 May 30. PMID- 31395480 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 3 IP - 6 DP - 2020 Dec TI - A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma. PG - 756-763 LID - S2588-9311(19)30102-6 [pii] LID - 10.1016/j.euo.2019.06.021 [doi] AB - BACKGROUND: The current guideline lacks evidence for creating individualized surveillance strategies for upper tract urothelial carcinoma (UTUC) patients after radical nephroureterectomy (RNU). OBJECTIVE: To create a novel risk model and to simulate individualized surveillance duration that dynamically illustrates the changing risk relationship of UTUC-related death and non-UTUC death, considering the impact of cigarette smoking. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study comprised 714 pTa-T4N0M0 UTUC patients, with a median follow-up duration of 65mo. There were 279 (39.1%) nonsmokers, 260 (36.4%) current smokers, and 175 (24.5%) ex-smokers. INTERVENTION: All patients underwent RNU. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The risks of UTUC death and non-UTUC death over time were estimated using parametric models for time to failure with Weibull distributions. Age-specific, stage-specific, and smoking status-specific surveillance durations were simulated based upon Weibull estimates. RESULTS AND LIMITATIONS: The hazard rate (HR) of non-UTUC death gradually increased over time in all age groups regardless of the smoking status, whereas that of UTUC-related death decreased markedly according to the pathological T (pT) stage and was affected by the smoking status. Among current smokers, the baseline HR of UTUC-related death in pT3/4 was higher than that of pT /=80yr of with pT3N0M0, the risk of non-UTUC death was greater than that of UTUC-related death 1yr after RNU in nonsmokers, but 7yr for heavy smokers. CONCLUSIONS: Our result revealed that smokers bear a long-term risk burden of UTUC-related death more than the risk of non-UTUC death. For UTUC smokers, longer-term surveillance duration is recommended even in elderly stage. PATIENT SUMMARY: In the present study, we evaluated the risk transition of upper tract urothelial carcinoma (UTUC)-related death and non-cancer-related death over time. We found that smoking weighed a huge impact upon UTUC-related death compared with death from other cause, and therefore, we created a more individualized surveillance duration model. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Abe, Takayuki AU - Abe T AD - Department of Preventive Medicine and Public Health, Biostatistics Unit at the Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan. FAU - Hagiwara, Masayuki AU - Hagiwara M AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Anno, Tadatsugu AU - Anno T AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Umeda, Kota AU - Umeda K AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Baba, Yuto AU - Baba Y AD - Department of Urology, International University of Health and Welfare Mita Hospital, Tokyo, Japan. FAU - Sanjo, Tansei AU - Sanjo T AD - Department of Urology, Isehara Kyodo Hospital, Kanagawa, Japan. FAU - Shojo, Kazunori AU - Shojo K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Mikami, Shuji AU - Mikami S AD - Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20190806 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Cancer Survivors/statistics & numerical data MH - Carcinoma, Transitional Cell/diagnosis/epidemiology/*therapy MH - Cigarette Smoking/epidemiology MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*epidemiology/prevention & control MH - Neoplasm Staging MH - *Nephroureterectomy MH - Practice Guidelines as Topic MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Survivorship MH - Treatment Outcome MH - Urologic Neoplasms/diagnosis/epidemiology/*therapy MH - Watchful Waiting/*standards OTO - NOTNLM OT - Intravesical recurrence OT - Radical nephroureterectomy OT - Surveillance OT - Survival OT - Upper tract urothelial carcinoma OT - Weibull model EDAT- 2019/08/10 06:00 MHDA- 2021/06/29 06:00 CRDT- 2019/08/10 06:00 PHST- 2019/04/02 00:00 [received] PHST- 2019/06/19 00:00 [revised] PHST- 2019/06/27 00:00 [accepted] PHST- 2019/08/10 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2019/08/10 06:00 [entrez] AID - S2588-9311(19)30102-6 [pii] AID - 10.1016/j.euo.2019.06.021 [doi] PST - ppublish SO - Eur Urol Oncol. 2020 Dec;3(6):756-763. doi: 10.1016/j.euo.2019.06.021. Epub 2019 Aug 6. PMID- 31393349 OWN - NLM STAT- MEDLINE DCOM- 20190903 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 32 DP - 2019 Aug TI - Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery. PG - e16451 LID - 10.1097/MD.0000000000016451 [doi] LID - e16451 AB - Early diagnose of bladder cancer could lead to good prognosis and high 5-year-survival rate. Among bladder cancer, about 75% patients with were nonmuscle-invasive bladder cancer (NMIBC). Patients were painful and easily get infected during bladder cancer diagnosis, which mainly depends on invasive cystoscopy and low-sensitivity urine exfoliation cytology. Meanwhile, relapse after surgery was also becoming the major problem for patients. Exploring noninvasive, high-sensitivity, and painless method is very important and meaningful for NMIBC treatment.Firstly, we found potential related gene mutation sites for NMIBC by searching COSMIC database and related study. Urinary sediment cells of patients both in normal group (patients with benign) and NMIMC group were collected before and after operation for potential gene mutation site detecting. Meanwhile, the urinary sediment cells of relapse patients and good prognosis people in NMIBC group after surgery were also collected for further Gene mutation detection and NMIBC relapse after surgery prediction.Fourteen genes (152 mutation sites) were selected between 95 NMIBC patients and 67 control patients, which were FGFR3, TP53, PIK3CA, and others. Compared with control group, mutation ratio of above 14 genes was higher in NMIBC group. NMIBC diagnose model was established by 5 times cross-validation and had a good effects, which included the all mutation site in FGFR3, TP53, PIK3CA, ARID1A, STAG2, and KTM2D. On the contrary, the relapse rate was 30.5% among 95 patients for about 1.5-year follow-up time. Compared with control group, smoking rate and tumor grade were higher in relapse group. Meanwhile, mutation rate of FGFR3, TP53, PIK3CA, ERBB3, and TSC1 in relapse group were higher than that in normal group. According to the mutation sites of FGFR3, TP53, PIK3CA, and ERBB3 and the combination of urinary sediment cells genetic mutation and relapse status, a predicted model for NMIBC relapse was also established, which had 90% accuracy.The diagnosed NMIBC model (based on FGFR3, TP53, PIK3CA, ARID1A, STAG2, and KTM2D gene mutation) and predicted relapse model (based on FGFR3, TP53, PIK3CA, and ERBB3 gene mutation) possess high accuracy and would be applied in early diagnose and early predicting relapse of patients. FAU - Zhu, Feng AU - Zhu F AD - Fifth Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou City. FAU - Zhang, Yan AU - Zhang Y AD - Department of Neurophysiology, Basic Medical College, Xinxiang Medical College, Xinxiang City. FAU - Shi, Lei AU - Shi L AD - Fifth Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou City. FAU - Wu, Chun-Lei AU - Wu CL AD - Department of Urology, First Affiliated Hospital of Xinxiang Medical College, Weihui City. FAU - Chen, Shuai-Qi AU - Chen SQ AD - Department of Urology, First Affiliated Hospital of Xinxiang Medical College, Weihui City. FAU - Zheng, Hang AU - Zheng H AD - Department of Urology, Third Affiliated Hospital of Xinxiang Medical College, Xinxiang City, Henan Province, China. FAU - Song, Dong-Kui AU - Song DK AD - Fifth Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou City. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Biomarkers, Tumor) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor MH - Class I Phosphatidylinositol 3-Kinases/*genetics MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mutation MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/genetics/pathology MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Tumor Suppressor Protein p53/*genetics MH - Urinary Bladder Neoplasms/*genetics/*pathology PMC - PMC6709296 EDAT- 2019/08/09 06:00 MHDA- 2019/09/04 06:00 PMCR- 2019/08/09 CRDT- 2019/08/09 06:00 PHST- 2019/08/09 06:00 [entrez] PHST- 2019/08/09 06:00 [pubmed] PHST- 2019/09/04 06:00 [medline] PHST- 2019/08/09 00:00 [pmc-release] AID - 00005792-201908090-00009 [pii] AID - MD-D-19-00405 [pii] AID - 10.1097/MD.0000000000016451 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Aug;98(32):e16451. doi: 10.1097/MD.0000000000016451. PMID- 31377833 OWN - NLM STAT- MEDLINE DCOM- 20201026 LR - 20201026 IS - 2366-0058 (Electronic) VI - 44 IP - 12 DP - 2019 Dec TI - Preoperative imaging for locoregional staging of bladder cancer. PG - 3843-3857 LID - 10.1007/s00261-019-02168-z [doi] AB - Bladder cancer is the ninth most common cancer, expected to lead to an estimated 17,670 deaths in the United States in 2019. Clinical management and prognosis of bladder cancer mainly depend on the extent of locoregional disease, particularly whether bladder muscle is involved. Therefore, bladder cancer is often divided into superficial, non-muscle-invasive bladder cancer and muscle-invasive bladder cancer; the latter often prompts consideration for cystectomy. While precise staging prior to cystectomy is crucial, the optimal preoperative imaging modality used to stage the disease remains controversial. Transurethral resection of bladder tumor (TURBT) followed by computed tomography (CT) urography is the current recommended approach for staging bladder cancer but suffers from a high rate of understaging. We review the recent literature and compare different imaging modalities for assessing the presence of muscle invasion and lymph node involvement prior to cystectomy and highlight the advantages of each modality. FAU - Mirmomen, S Mojdeh AU - Mirmomen SM AD - Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA. FAU - Shinagare, Atul B AU - Shinagare AB AD - Dana-Farber Cancer Institute, Boston, MA, USA. AD - Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. FAU - Williams, Kristin E AU - Williams KE AD - Dana-Farber Cancer Institute, Boston, MA, USA. AD - Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. FAU - Silverman, Stuart G AU - Silverman SG AD - Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. FAU - Malayeri, Ashkan A AU - Malayeri AA AD - Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA. ashkan.malayeri@nih.gov. AD - Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. ashkan.malayeri@nih.gov. LA - eng PT - Journal Article PT - Review PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Cystectomy MH - Cystoscopy MH - Humans MH - Lymphatic Metastasis/diagnostic imaging/pathology MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Neoplasm Staging MH - *Preoperative Period MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology/surgery OTO - NOTNLM OT - Bladder cancer staging OT - Computed tomography OT - Magnetic resonance imaging OT - Positron emission tomography OT - Preoperative imaging modality EDAT- 2019/08/05 06:00 MHDA- 2020/10/27 06:00 CRDT- 2019/08/05 06:00 PHST- 2019/08/05 06:00 [pubmed] PHST- 2020/10/27 06:00 [medline] PHST- 2019/08/05 06:00 [entrez] AID - 10.1007/s00261-019-02168-z [pii] AID - 10.1007/s00261-019-02168-z [doi] PST - ppublish SO - Abdom Radiol (NY). 2019 Dec;44(12):3843-3857. doi: 10.1007/s00261-019-02168-z. PMID- 31374003 OWN - NLM STAT- MEDLINE DCOM- 20190813 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 31 DP - 2019 Aug TI - The impact of age on intravesical instillation of Bacille Calmette-Guerin treatment in patients with high-grade T1 bladder cancer. PG - e16223 LID - 10.1097/MD.0000000000016223 [doi] LID - e16223 AB - Intravesical instillation of Bacille Calmette-Guerin (BCG) is the standard adjuvant treatment for high-risk non muscle invasive bladder cancer (NMIBC). Since its mechanism of action is supposed to be linked to the immune system efficiency and senescence could negatively affect this efficiency, BCG efficacy in the elderly has been questioned. This study aimed to assess the impact of age on BCG efficacy and safety in patients with high-grade T1 bladder cancer (BC).Among 123 patients with high-grade T1 BCG scheduled for BCG treatment, 82 were <75 year-old (group A) and 41 were >/=75 year-old (group B). Follow-up: urine cytology and cystoscopy every 3 months for the first 2 years, every 6 months for the third year, and then yearly. Tumor recurrence was defined as pathological evidence of disease at the bladder biopsy; tumor progression was defined as pathological shift to muscle invasive disease at the bladder biopsy or the imaging techniques showing recurrent BC and distant metastasis likely related to it.The median follow-up was 65 months (range 11-152). Recurrence occurred in 35 patients, 19 (23.2%) in the group A and 16 (39%) in the group B. Progression occurred in 18 patients, 12 (14.6%) in the group A and 6 (14.6%) in the group B. Recurrence free rate was similar in both groups up to 2 years. The 5 years progression rate was almost the same in both groups A and B (85.9% vs 84.7%), whereas the 5 years cancer-specific survival (CSS) was 92.6% in the group A and 85.4% in the group B. Of the 18 patients with progression, 11 underwent cystectomy; 12 patients died because of their BC. Kaplan-Meier plots pointed out no difference in recurrence-free, progression-free, and CSS between the 2 groups. Adverse events were similar in the 2 groups. Only 4 (3.3%) patients, 2 (2.4%) in the group A and 2 (4.8%) in the group B, experienced mild adverse reactions compatible with treatment.Elderly patients with high-grade T1 BC are not poorer candidates to BCG treatment, as they had similar benefit and adverse reactions than those aging >/=75 years. FAU - Calo, B AU - Calo B AD - Department of Urology and Renal Transplantation. FAU - Sanguedolce, F AU - Sanguedolce F AD - Department of Pathology. FAU - Fortunato, F AU - Fortunato F AD - Department of Epidemiology. FAU - Stallone, G AU - Stallone G AD - Department of Nephrology, University of Foggia, Italy. FAU - d'Altilia, N AU - d'Altilia N AD - Department of Urology and Renal Transplantation. FAU - Chirico, M AU - Chirico M AD - Department of Urology and Renal Transplantation. FAU - Falagario, U AU - Falagario U AD - Department of Urology and Renal Transplantation. FAU - Mancini, Vito AU - Mancini V AD - Department of Urology and Renal Transplantation. FAU - Carrieri, G AU - Carrieri G AD - Department of Urology and Renal Transplantation. FAU - Cormio, L AU - Cormio L AD - Department of Urology and Renal Transplantation. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Administration, Intravesical MH - *Age Factors MH - Aged MH - Chi-Square Distribution MH - Female MH - Humans MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - Prospective Studies MH - Statistics, Nonparametric MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery MH - Urologic Surgical Procedures/*instrumentation/methods PMC - PMC6708772 COIS- The authors report no conflicts of interest EDAT- 2019/08/03 06:00 MHDA- 2019/08/14 06:00 PMCR- 2019/08/02 CRDT- 2019/08/03 06:00 PHST- 2019/08/03 06:00 [entrez] PHST- 2019/08/03 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2019/08/02 00:00 [pmc-release] AID - 00005792-201908020-00001 [pii] AID - MD-D-18-07113 [pii] AID - 10.1097/MD.0000000000016223 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Aug;98(31):e16223. doi: 10.1097/MD.0000000000016223. PMID- 31370109 OWN - NLM STAT- MEDLINE DCOM- 20200904 LR - 20200904 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 26 IP - 11 DP - 2019 Nov TI - Predictive biomarkers for drug response in bladder cancer. PG - 1044-1053 LID - 10.1111/iju.14082 [doi] AB - Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug limits treatment options and impairs improvement of patient survival. For example, approximately half of patients do not respond to cisplatin-based combination chemotherapy, although it is the standard of care for muscle-invasive and metastatic bladder cancer. The development of robust predictive biomarkers is expected to improve outcomes by enabling clinicians to use chemotherapy only in the patients who will benefit from it. Recent advances in the molecular characterization of bladder cancer showed that the basal subtype of bladder cancer and tumors with inactivating mutations in DNA damage repair genes were associated with greater benefit from cisplatin-based chemotherapy. The present review summarizes current efforts to develop predictive biomarkers for drug response in bladder cancer, focusing on those that predict the response to cisplatin-based chemotherapy for advanced bladder cancer. We also review the current situation with regard to the identification of predictive biomarkers for response to intravesical therapy, immune checkpoint inhibitors and molecularly-targeted drugs. We also discuss the future applications of new technologies, including liquid biopsies and patient-derived organoids that will also serve as resources for the identification of biomarkers in bladder cancer. CI - (c) 2019 The Japanese Urological Association. FAU - Yoshida, Takahiro AU - Yoshida T AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. FAU - Kates, Max AU - Kates M AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. AD - The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland, USA. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. AD - The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. AD - The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland, USA. LA - eng PT - Journal Article PT - Review DEP - 20190801 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) RN - EC 2.7.10.1 (Discoidin Domain Receptors) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers/*urine MH - Cisplatin/*therapeutic use MH - Discoidin Domain Receptors/genetics MH - Humans MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - cisplatin OT - drug response OT - neoadjuvant chemotherapy OT - predictive biomarker OT - urothelial cancer EDAT- 2019/08/02 06:00 MHDA- 2020/09/05 06:00 CRDT- 2019/08/02 06:00 PHST- 2019/05/12 00:00 [received] PHST- 2019/07/07 00:00 [accepted] PHST- 2019/08/02 06:00 [pubmed] PHST- 2020/09/05 06:00 [medline] PHST- 2019/08/02 06:00 [entrez] AID - 10.1111/iju.14082 [doi] PST - ppublish SO - Int J Urol. 2019 Nov;26(11):1044-1053. doi: 10.1111/iju.14082. Epub 2019 Aug 1. PMID- 31368913 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 43 IP - 11 DP - 2019 Nov TI - Condyloma Acuminatum of Urinary Bladder: Relation to Squamous Cell Carcinoma. PG - 1547-1553 LID - 10.1097/PAS.0000000000001339 [doi] AB - Condyloma acuminatum rarely occurs in the urinary bladder and is considered to be a risk factor for squamous cell carcinoma, although there are only a few publications with limited cases. We studied 51 cases of condyloma acuminatum of the urinary bladder from transurethral resections of the urinary bladder of 38 patients from the consult files of one of the authors. Transurethral resections of the urinary bladder were obtained from 25 males with a median age of 73 years (range: 41 to 87 y) and 13 females with a median age of 68 years (range: 30 to 86 y). The follow-up period ranged from 15 months to 20 years (median: 6 y). Bladder lesions were accompanied by urethral lesions in 4 men. Eight patients (8/38; 21.0%) had a history of immunosuppression. Seven patients (7/8; 87.5%) from this group had multiple and/or recurrent condylomas. One patient (1/38; 2.6%) with renal transplantation had 10 separate bladder condylomas over time. One patient (1/38; 2.6%) had extensive anogenital condylomas and anal intraepithelial neoplasia grade 3. One patient (1/8; 12.5%) with renal transplantation presented with a solitary condyloma with synchronous squamous cell carcinoma in situ. Three female patients (3/38; 7.9%) had a history of premalignant vagina/cervix lesions. In total, 17 patients (17/38; 44.7%) had squamous cell carcinoma of the bladder, either invasive or in situ. In all cases, the squamous cell carcinoma (either in situ or invasive) was diagnosed either concurrent with the diagnosis of bladder condyloma or within 1 year of the condyloma diagnosis). In total, 9 of 38 (23.7%) patients had invasive squamous cell carcinoma with or without in situ squamous cell carcinoma. Eight of 38 (21.0%) patients had squamous cell carcinoma in situ only (without a definitive invasive component-in 3 cases invasive squamous cell carcinoma could not be excluded with certainty). In total, 19 patients (19/38; 50%) were positive for either low-risk human papillomavirus (LR-HPV) or high-risk human papillomavirus (HR-HPV) or both (3 were positive for both LR-HPV and HR-HPV, 12 patients for only LR-HPV, and 4 for only HR-HPV). Of the 19 patients that were negative for both LR-HPV and HR-HPV, 9 of 19 (47.4%) patients had associated squamous cell carcinoma. Of the 12 patients with only LR-HPV, 4 (33.3%) had associated squamous cell carcinoma (either invasive or in situ). Of the 7 patients with HR-HPV (with or without LR-HPV), 4 (57.1%) has associated squamous cell carcinoma. In summary, condyloma acuminatum of the urinary bladder shows a strong association with squamous cell carcinoma of the bladder, regardless of the condyloma's HPV in situ hybridization results. Immunosuppression is associated with condylomas of the bladder. It is important to distinguish bladder condylomas from papillary urothelial carcinoma, given their different risks for panurothelial disease and risk of squamous cell carcinoma. Recognition of bladder condylomas histologically is often challenging given their rarity, and that they can be negative for both LR-HPV and HR-HPV. The lack of a history of other anogenital human papillomavirus-related lesions further increases the difficulty in establishing the correct diagnosis. FAU - Samarska, Iryna V AU - Samarska IV AD - Departments of Pathology. AD - Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Epstein, Jonathan I AU - Epstein JI AD - Departments of Pathology. AD - Urology. AD - Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD. LA - eng PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Squamous Cell/diagnosis/etiology/*pathology MH - Condylomata Acuminata/diagnosis/etiology/*pathology MH - Diagnosis, Differential MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Precancerous Conditions/diagnosis/etiology/*pathology MH - Risk Factors MH - Urinary Bladder Diseases/diagnosis/etiology/*pathology MH - Urinary Bladder Neoplasms/diagnosis/etiology/pathology EDAT- 2019/08/02 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/08/02 06:00 PHST- 2019/08/02 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/08/02 06:00 [entrez] AID - 10.1097/PAS.0000000000001339 [doi] PST - ppublish SO - Am J Surg Pathol. 2019 Nov;43(11):1547-1553. doi: 10.1097/PAS.0000000000001339. PMID- 31368912 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 43 IP - 12 DP - 2019 Dec TI - Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases. PG - 1638-1643 LID - 10.1097/PAS.0000000000001318 [doi] AB - Although there are 5 well-described morphologic patterns of (nonglandular) urothelial carcinoma in situ (CIS), we have encountered a novel pattern of flat urothelial carcinoma with plasmacytoid features characterized by a triad of morphologic findings including abnormal architecture with cellular rounding, enlarged nuclei with eccentric nuclear localization, and dense globular eosinophilic cytoplasm. A total of 23 cases of plasmacytoid CIS (mean age: 74.1 y, range: 58 to 91 y) were collected and reviewed. We excluded cases in which the diagnostic biopsy had any of the following findings admixed in the same tissue biopsy sample as the plasmacytoid CIS: traditional patterns of CIS, noninvasive glandular CIS, papillary urothelial carcinoma, or invasive carcinoma. Immunostains for CK20, CD44, p53, and e-cadherin were performed on available blocks. History of prior urothelial neoplasia, prior treatment, and clinical follow-up were obtained from medical records and pathology re-review. Immunohistochemical analysis of plasmacytoid CIS showed diffuse/strong CK20 reactivity in 96% of cases (23/24), an abnormal p53 reactivity pattern (either overexpression or "null phenotype") in 37% of cases (7/19), absence of CD44 reactivity in the neoplastic cells in 63% of cases (15/24), and retained membranous e-cadherin expression in 100% of cases (18/18). Clinical follow-up (average follow-up time: 37.7 mo, range: 7 to 115 mo) showed recurrence/new occurrence in 52% of cases (12/23), including all 4 of the 23 patients who initially presented with de novo plasmacytoid CIS (ie, no prior or concomitant urothelial neoplasia). The histologic features, the immunophenotype, the association with other forms of urothelial neoplasia, and the risk of recurrence and progression in de novo lesions support that plasmacytoid CIS represents a novel pattern of flat urothelial carcinoma. These histologic features may be more subtle than in other more typical patterns of CIS and should be carefully distinguished from therapy-related/reactive changes. FAU - Sangoi, Ankur R AU - Sangoi AR AD - El Camino Hospital, Mountain View, CA. FAU - Falzarano, Sara M AU - Falzarano SM AD - University of Florida, Gainesville, FL. FAU - Nicolas, Marlo AU - Nicolas M AD - Cleveland Clinic, Robert Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH. FAU - McKenney, Jesse K AU - McKenney JK AD - Cleveland Clinic, Robert Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH. LA - eng PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Carcinoma in Situ/chemistry/*pathology/therapy MH - Disease Progression MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Phenotype MH - Plasma Cells/chemistry/*pathology MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/chemistry/*pathology/therapy MH - Urothelium/chemistry/*pathology EDAT- 2019/08/02 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/08/02 06:00 PHST- 2019/08/02 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/08/02 06:00 [entrez] AID - 10.1097/PAS.0000000000001318 [doi] PST - ppublish SO - Am J Surg Pathol. 2019 Dec;43(12):1638-1643. doi: 10.1097/PAS.0000000000001318. PMID- 31368905 OWN - NLM STAT- MEDLINE DCOM- 20200320 LR - 20200320 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 42 IP - 9 DP - 2019 Sep TI - The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy. PG - 705-710 LID - 10.1097/COC.0000000000000582 [doi] AB - OBJECTIVES: Higher facility surgical volume predicts for improved outcomes in patients with muscle-invasive bladder cancer (MIBC) who undergo radical cystectomy. We investigated the association between facility radiotherapy (RT) case volume and overall survival (OS) for patients with MIBC who received bladder-preserving RT, and the relationship with adherence to National Comprehensive Cancer Network (NCCN) guidelines for bladder preservation. METHODS: The National Cancer Database was used to identify patients diagnosed with nonmetastatic MIBC from 2004 to 2015 and received RT at the reporting center. Facility case volume was defined as the total MIBC patients treated with RT during the period. Facilities were stratified into high-volume facility (HVF) or low-volume facility at the 80th percentile of RT case volume. OS was assessed using Kaplan-Meier analysis. Rates of compliance with NCCN guidelines regarding the use of transurethral resection of the bladder tumor before RT, planned use of concurrent chemotherapy, and total RT dose were compared. Cox proportional hazard model was used to evaluate predictors of OS. RESULTS: There were 7562 patients included. No differences in age, Charlson-Deyo score, T stage, or node-positive rates were observed between groups. HVFs exhibited greater compliance with NCCN guidelines for bladder preservation (P<0.0001). Treatment at an HVF was associated with the improved OS for all patients (P=0.001) and for the subset of patients receiving NCCN-recommended RT doses (P=0.0081). Volume was an independent predictor of OS (P=0.002). CONCLUSIONS: Treatment at an HVF is associated with improved OS and greater guideline-concordant management among patients with MIBC. FAU - D'Rummo, Kevin A AU - D'Rummo KA AD - Department of Radiation Oncology, The University of Kansas School of Medicine, Kansas City, KS. FAU - TenNapel, Mindi J AU - TenNapel MJ FAU - Shen, Xinglei AU - Shen X LA - eng PT - Journal Article PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Aged MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - *Guideline Adherence MH - Hospitals, High-Volume/*statistics & numerical data MH - Humans MH - Male MH - Muscle Neoplasms/*mortality/pathology/radiotherapy/surgery MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/*mortality MH - Radiotherapy, Adjuvant/*mortality MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*mortality/pathology/radiotherapy/surgery EDAT- 2019/08/02 06:00 MHDA- 2020/03/21 06:00 CRDT- 2019/08/02 06:00 PHST- 2019/08/02 06:00 [pubmed] PHST- 2020/03/21 06:00 [medline] PHST- 2019/08/02 06:00 [entrez] AID - 10.1097/COC.0000000000000582 [doi] PST - ppublish SO - Am J Clin Oncol. 2019 Sep;42(9):705-710. doi: 10.1097/COC.0000000000000582. PMID- 31366524 OWN - NLM STAT- MEDLINE DCOM- 20190807 LR - 20190807 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 39 IP - 8 DP - 2019 Aug TI - Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer. PG - 4325-4328 LID - 10.21873/anticanres.13598 [doi] AB - BACKGROUND/AIM: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. RESULTS: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed up-staging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). CONCLUSION: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR. CI - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Akitake, Masakazu AU - Akitake M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yamaguchi, Akito AU - Yamaguchi A AD - Division of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan shiota@uro.med.kyushu-u.ac.jp. FAU - Imada, Kenjiro AU - Imada K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tatsugami, Katsunori AU - Tatsugami K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Division of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Naito, Seiji AU - Naito S AD - Division of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM CIN - J Urol. 2020 Apr;203(4):661. doi: 10.1097/JU.0000000000000729.02. PMID: 31928466 MH - Adult MH - Aged MH - Carcinoma in Situ/*diagnosis/pathology/surgery MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscles/pathology MH - Neoplasm Invasiveness/genetics/pathology MH - Neoplasm Recurrence, Local/*diagnosis/pathology/surgery MH - Neoplasm Staging MH - Neoplasm, Residual/diagnosis/pathology/*surgery MH - Risk Factors MH - Treatment Outcome MH - Urethra/pathology/surgery MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/pathology/*surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - Carcinoma-in situ OT - non-muscle-invasive bladder cancer OT - residual cancer OT - second transurethral resection OT - up-staging EDAT- 2019/08/02 06:00 MHDA- 2019/08/08 06:00 CRDT- 2019/08/02 06:00 PHST- 2019/06/05 00:00 [received] PHST- 2019/06/24 00:00 [revised] PHST- 2019/06/25 00:00 [accepted] PHST- 2019/08/02 06:00 [entrez] PHST- 2019/08/02 06:00 [pubmed] PHST- 2019/08/08 06:00 [medline] AID - 39/8/4325 [pii] AID - 10.21873/anticanres.13598 [doi] PST - ppublish SO - Anticancer Res. 2019 Aug;39(8):4325-4328. doi: 10.21873/anticanres.13598. PMID- 31364733 OWN - NLM STAT- MEDLINE DCOM- 20191022 LR - 20191022 IS - 1791-2431 (Electronic) IS - 1021-335X (Linking) VI - 42 IP - 4 DP - 2019 Oct TI - Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals. PG - 1609-1620 LID - 10.3892/or.2019.7247 [doi] AB - MicroRNAs (miRNAs/miRs) act as markers for various cancers, including bladder cancer (BC). Plasma miRNAs are potential biomarkers for the noninvasive diagnosis and long‑term surveillance of BC. The aim of the present study was to identify diagnostically reliable miRNAs in the plasma and examine their potential monitoring capacity. miRNAs were measured by reverse transcription‑quantitative polymerase chain reaction. The study was performed as a discovery phase, which included plasma samples from each of the 10 patients with and without BC prior to transurethral resection (TURB). The results were validated in a second phase, involving 36 patients with plasma samples collected before the second TURB or radical cystectomy (RC), and after RC. During the discovery step, three elevated miRNAs (miR‑15b‑5p, miR‑590‑5p, miR‑29b‑3p) and two decreased miRNAs (miR‑10b‑5p, miR‑144‑5p) were selected as potential miRNA candidates for further validation. miR‑15b‑5p and miR‑590‑5p were finally confirmed to discriminate between cancer cases and controls; however, for disease monitoring of BC, both miRNAs were not suitable as a decline in the miRNA levels was not observed in some patients after tumor removal. Our results suggested that circulating miR‑15b‑5p and miR‑590‑5p have useful diagnostic potential for BC, but are rather unsuitable as monitoring markers for disease. The reasons of this apparent contradictory observation may be due to the aspect of biological variation of circulating miRNAs and serial measurements could be unreliable. FAU - Tolle, Angelika AU - Tolle A AD - Department of Urology, Charite‑Universitatsmedizin Berlin, D‑10117 Berlin, Germany. FAU - Buckendahl, Laura AU - Buckendahl L AD - Department of Urology, Charite‑Universitatsmedizin Berlin, D‑10117 Berlin, Germany. FAU - Jung, Klaus AU - Jung K AD - Department of Urology, Charite‑Universitatsmedizin Berlin, D‑10117 Berlin, Germany. LA - eng PT - Journal Article DEP - 20190724 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN15 microRNA, human) RN - 0 (MIRN590 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*blood/genetics MH - Case-Control Studies MH - Female MH - Healthy Volunteers MH - Humans MH - Male MH - MicroRNAs/*blood/genetics MH - Middle Aged MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/*blood/diagnosis/*genetics EDAT- 2019/08/01 06:00 MHDA- 2019/10/23 06:00 CRDT- 2019/08/01 06:00 PHST- 2019/02/12 00:00 [received] PHST- 2019/06/05 00:00 [accepted] PHST- 2019/08/01 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] PHST- 2019/08/01 06:00 [entrez] AID - 10.3892/or.2019.7247 [doi] PST - ppublish SO - Oncol Rep. 2019 Oct;42(4):1609-1620. doi: 10.3892/or.2019.7247. Epub 2019 Jul 24. PMID- 31346958 OWN - NLM STAT- MEDLINE DCOM- 20210326 LR - 20210326 IS - 1532-2807 (Electronic) IS - 1219-4956 (Print) IS - 1219-4956 (Linking) VI - 26 IP - 2 DP - 2020 Apr TI - Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer. PG - 1211-1219 LID - 10.1007/s12253-019-00678-1 [doi] AB - The aim of the study was to determine the prognostic value of expression levels of biomarkers selected on the basis of the literature: p53, Ki-67, survivin, beta-catenin, E-cadherin and N-cadherin in patients with non-muscle invasive bladder cancer. Immunohistochemistry was performed on sections of primary papillary carcinoma of the bladder removed during transurethral resection of the tumor in 134 patients. The expression of beta-catenin and E-cadherin was found in all analyzed cases and N-cadherin expression was demonstrated in 3.73% of the tissues examined. The expression of the p53 protein was confirmed in 96.27% of tissues examined. The expression of the Ki-67 protein was demonstrated in all analyzed cases. Survivin expression was found in 95.52% of the study group. Multivariate analysis confirmed the relationship between the recurrence-free survival (RFS) and the intensity of the nuclear reaction for p53 (HR 1417, 95% CI 1.001-2.007, p = 0.049) and survivin (HR 1.451; 95% CI 1.078-1.955; p = 0.014), the expression level of the Ki-67 protein expressed by the TS index (HR 1.146, 95% CI 1.116-1.823, p = 0.005) and the use of adjuvant BCG therapy (HR 0.218, 95% CI 0.097-0.489, p = 0.0002). The evaluation of Ki-67 expression and the intensity of nuclear staining for survivin and p53 may provide additional information that will allow more accurate stratification of the risk of NMIBC recurrence after TURBT. FAU - Stec, Rafal AU - Stec R AD - Oncology Department, Medical University of Warsaw, 19/25 Stepinska St., 00-739, Warsaw, Poland. FAU - Cierniak, Szczepan AU - Cierniak S AD - Patomorphology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Lubas, Arkadiusz AU - Lubas A AD - Internal Diseases, Nephrology and Dialysis Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Brzoskowska, Urszula AU - Brzoskowska U AD - Patomorphology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Syrylo, Tomasz AU - Syrylo T AD - General, Functional and Oncological Urology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Zielinski, Henryk AU - Zielinski H AD - General, Functional and Oncological Urology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. FAU - Semeniuk-Wojtas, Aleksandra AU - Semeniuk-Wojtas A AUID- ORCID: 0000-0001-9421-6694 AD - Oncology Department, Military Institute of Medicine, 128 Szaserow St., 04-141, Warsaw, Poland. osemeniuk@wp.pl. LA - eng PT - Journal Article DEP - 20190619 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (BIRC5 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - 0 (Survivin) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Papillary/mortality/*pathology MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Ki-67 Antigen/analysis MH - Male MH - Prognosis MH - Survivin MH - Tumor Suppressor Protein p53/analysis MH - Urinary Bladder Neoplasms/mortality/*pathology PMC - PMC7242236 OTO - NOTNLM OT - Bladder cancer OT - Ki-67 OT - NMIBC OT - Survivin OT - p53 COIS- The authors declare no conflicts of interest. EDAT- 2019/07/28 06:00 MHDA- 2021/03/27 06:00 PMCR- 2019/06/19 CRDT- 2019/07/27 06:00 PHST- 2019/01/21 00:00 [received] PHST- 2019/05/29 00:00 [accepted] PHST- 2019/07/28 06:00 [pubmed] PHST- 2021/03/27 06:00 [medline] PHST- 2019/07/27 06:00 [entrez] PHST- 2019/06/19 00:00 [pmc-release] AID - 10.1007/s12253-019-00678-1 [pii] AID - 678 [pii] AID - 10.1007/s12253-019-00678-1 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Apr;26(2):1211-1219. doi: 10.1007/s12253-019-00678-1. Epub 2019 Jun 19. PMID- 31340801 OWN - NLM STAT- MEDLINE DCOM- 20200115 LR - 20221207 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 19 IP - 1 DP - 2019 Jul 24 TI - RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy. PG - 69 LID - 10.1186/s12894-019-0497-x [doi] LID - 69 AB - BACKGROUND: The expression level of ribonucleotide reductase subunit M1 (RRM1) is closely related to the effect of gemcitabine-based therapy in advanced bladder cancer. However, the value of RRM1 expression in predicting progression-free survival in non-muscle-invasive bladder cancer (NMIBC) patients treated with intravesical gemcitabine chemotherapy has not been elucidated. METHODS: This study randomly assigned 162 patients to either the RRM1-known group or the unknown group. We collected cancer tissues from 81 patients to evaluate the mRNA expression of RRM1 by using liquid chip technology. All patients were diagnosed and then treated with intravesical gemcitabine monotherapy immediately after transurethral resection of the bladder tumour (TURBT). RESULTS: RRM1 expression was high in 21% (17/81) of patients. The RRM1 mRNA level was not correlated with sex, age, weight, performance status, or CUA/EAU risk (p > 0.05). Progression-free survival (PFS) was significantly longer for patients with low RRM1 expression than for patients with high and unknown RRM1 expression (p = 0.009). Additionally, the 1- and 2-year relapse rates also differed according to RRM1 expression level. The 1-year relapse rates for RRM1-low, RRM1-high and RRM1-unknown patients were 0, 17.7 and 6.2% (p = 0.009), while the 2-year relapse rates for these groups were 3.1, 29.4, and 11.1% (p = 0.005), respectively. CONCLUSIONS: This preliminary study showed that low RRM1 expression was associated with longer progression-free survival and lower 1-year/2-year relapse rates in NMIBC patients treated with intravesical gemcitabine monotherapy, despite the need for further verification with large sample sizes and considering more mixed factors and biases. FAU - Yang, Zhenxing AU - Yang Z AD - Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China. FAU - Fu, Bingqiang AU - Fu B AD - SurExam Bio-Tech Co, Guangzhou, 510663, Guangdong, China. FAU - Zhou, Luqiang AU - Zhou L AD - Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China. FAU - Xu, Jie AU - Xu J AD - Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China. FAU - Hao, Ping AU - Hao P AD - Department of Oncology, Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China. FAU - Fang, Zhenqiang AU - Fang Z AD - Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, 400037, China. fangzhenqiang123@126.com. LA - eng GR - 81772702/National Natural Science Foundation of China-Yunnan Joint Fund/ GR - 2014YLC28/Clinical research project key projects of Second Affiliated Hospital, Third Military Medical University/ PT - Journal Article DEP - 20190724 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Biomarkers, Tumor) RN - 0W860991D6 (Deoxycytidine) RN - EC 1.17.4.1 (RRM1 protein, human) RN - EC 1.17.4.1 (Ribonucleoside Diphosphate Reductase) RN - 0 (Gemcitabine) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antimetabolites, Antineoplastic/*administration & dosage MH - Biomarkers, Tumor/*biosynthesis MH - Deoxycytidine/administration & dosage/*analogs & derivatives MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/diagnosis MH - Predictive Value of Tests MH - Random Allocation MH - Retrospective Studies MH - Ribonucleoside Diphosphate Reductase/*biosynthesis MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/*metabolism MH - Gemcitabine PMC - PMC6657136 OTO - NOTNLM OT - Gemcitabine OT - Non-muscle-invasive bladder cancer OT - RRM1 COIS- The authors declare that they have no competing interests. EDAT- 2019/07/26 06:00 MHDA- 2020/01/16 06:00 PMCR- 2019/07/24 CRDT- 2019/07/26 06:00 PHST- 2019/01/15 00:00 [received] PHST- 2019/07/08 00:00 [accepted] PHST- 2019/07/26 06:00 [entrez] PHST- 2019/07/26 06:00 [pubmed] PHST- 2020/01/16 06:00 [medline] PHST- 2019/07/24 00:00 [pmc-release] AID - 10.1186/s12894-019-0497-x [pii] AID - 497 [pii] AID - 10.1186/s12894-019-0497-x [doi] PST - epublish SO - BMC Urol. 2019 Jul 24;19(1):69. doi: 10.1186/s12894-019-0497-x. PMID- 31331003 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 8 IP - 7 DP - 2019 Jul 19 TI - Intravesical Chemotherapy after Radical Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis. LID - 10.3390/jcm8071059 [doi] LID - 1059 AB - The aim of this study was to determine the prophylactic effect of intravesical chemotherapy. Furthermore, it aimed to compare the efficacy of regimens on the prevention of bladder recurrence, after nephroureterectomy, for upper tract urothelial carcinoma by systematic review and network meta-analysis. A comprehensive literature search was conducted to search for studies published before 22 December 2016 using PubMed, Embase, and Scopus. All studies comparing nephroureterectomy alone with prophylactic intravesical chemotherapy after nephroureterectomy were included. The primary outcome was intravesical recurrence-free survival rate. In addition, we conducted indirect comparisons among regimens using network meta-analysis, as well as three randomized controlled trials (RCTs) on multicenter setting, and one large retrospective study with a total of 532 patients were analyzed. The pooled hazard ratio (HR) of bladder recurrence was 0.54 (95% CI: 0.38-0.76) in intravesical instillation patients. On network meta-analysis, pirarubicin was ranked the most effective regimen, while maintenance therapy of mitomycin C (MMC) with Ara-C and induction therapy of MMC were ranked as the second and third most effective regimens, respectively. Our study demonstrates that intravesical chemotherapy can prevent bladder recurrence in patients with upper tract urothelial carcinoma after nephroureterectomy. It also suggests that a single instillation of pirarubicin is the most efficacious intravesical regimen. FAU - Yoo, Sang Hyun AU - Yoo SH AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea,. FAU - Jeong, Chang Wook AU - Jeong CW AUID- ORCID: 0000-0002-2200-5019 AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea,. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea,. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea,. FAU - Choo, Min Soo AU - Choo MS AUID- ORCID: 0000-0002-7852-5822 AD - Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, Korea. kuuro70@snu.ac.kr. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul 03080, Korea,. snuhuro@gmail.com. LA - eng GR - 2016R1A2B4011623/National Research Foundation of Korea (NRF) grant/ PT - Journal Article PT - Review DEP - 20190719 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC6678753 OTO - NOTNLM OT - bladder cancer OT - intravesical chemotherapy OT - meta-analysis OT - nephroureterectomy OT - upper tract urothelial carcinoma COIS- The authors declare that they have no competing interests. EDAT- 2019/07/25 06:00 MHDA- 2019/07/25 06:01 PMCR- 2019/07/19 CRDT- 2019/07/24 06:00 PHST- 2019/05/15 00:00 [received] PHST- 2019/07/06 00:00 [revised] PHST- 2019/07/16 00:00 [accepted] PHST- 2019/07/24 06:00 [entrez] PHST- 2019/07/25 06:00 [pubmed] PHST- 2019/07/25 06:01 [medline] PHST- 2019/07/19 00:00 [pmc-release] AID - jcm8071059 [pii] AID - jcm-08-01059 [pii] AID - 10.3390/jcm8071059 [doi] PST - epublish SO - J Clin Med. 2019 Jul 19;8(7):1059. doi: 10.3390/jcm8071059. PMID- 31327502 OWN - NLM STAT- MEDLINE DCOM- 20200610 LR - 20200610 IS - 1532-2157 (Electronic) IS - 0748-7983 (Linking) VI - 45 IP - 10 DP - 2019 Oct TI - Radical cystectomy for pT1 urothelial carcinoma of bladder not amenable to TURBT: Long-term results. PG - 1993-1999 LID - S0748-7983(19)30576-1 [pii] LID - 10.1016/j.ejso.2019.07.018 [doi] AB - PURPOSE: This study sought to identify factors associated with survival of pT1 urothelial carcinoma of bladder (UCB) after radical cystectomy (RC). METHODS: This study consists of 114 pT1 UCB [primary 83, recurrent 31, none were amenable to transurethral resection (TUR)] treated by radical cystectomy. Survival analysis using Cox regression tests were performed to identify factors associated with survival of pT1 UCB after RC. RESULTS: Pelvic lymph node (LN) status, age and lymphovascular invasion (LVI) are associated with survival of pT1 UCB after RC; recurrent pT1 UCB of high grade origin (HGO) tends to have poorer CSS than primary pT1 UCB or recurrent pT1 UCB of low grade origin (LGO) (5-year and 10-year CSS rates was 75% and 73% for primary cases; 77% and 77% for recurrent pT1 UCB of LGO; and 56% and 37% for recurrent pT1 UCB of HGO, p = 0.078). CONCLUSIONS: LN status, age and LVI were significantly associated with survival of pT1 UCB after RC. Recurrent pT1 UCB of HGO should be managed with radical cystectomy in a timely fashion given that these cases tend to have poorer CSS than primary pT1 UCB after RC, even if they did not progress to muscle-invasive bladder cancer (MIBC). CI - Copyright (c) 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. FAU - Ma, Baojie AU - Ma B AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Li, Yu AU - Li Y AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Han, Saisai AU - Han S AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Jiang, Xingkang AU - Jiang X AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Zhao, Yang AU - Zhao Y AD - Department of Radiology, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Guo, Jianing AU - Guo J AD - Department of Urologic Pathology, Tianjin Urologic Institute, Tianjin, China. FAU - Quan, Changyi AU - Quan C AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. FAU - Niu, Yuanjie AU - Niu Y AD - Department of Urologic Surgery, Tianjin Medical University Second Hospital, Tianjin, China. Electronic address: niuyuanjieejso@126.com. LA - eng PT - Journal Article DEP - 20190716 PL - England TA - Eur J Surg Oncol JT - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JID - 8504356 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/secondary/*surgery MH - China/epidemiology MH - Cystectomy/*methods MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Node Excision MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - *Neoplasm Staging MH - Postoperative Period MH - Prognosis MH - Retrospective Studies MH - Survival Rate/trends MH - Time Factors MH - Urinary Bladder Neoplasms/diagnosis/mortality/*surgery OTO - NOTNLM OT - Lymphovascular invasion OT - Non-muscle-invasive bladder cancer OT - Outcome OT - Radical cystectomy EDAT- 2019/07/23 06:00 MHDA- 2020/06/11 06:00 CRDT- 2019/07/23 06:00 PHST- 2019/04/25 00:00 [received] PHST- 2019/06/20 00:00 [revised] PHST- 2019/07/15 00:00 [accepted] PHST- 2019/07/23 06:00 [pubmed] PHST- 2020/06/11 06:00 [medline] PHST- 2019/07/23 06:00 [entrez] AID - S0748-7983(19)30576-1 [pii] AID - 10.1016/j.ejso.2019.07.018 [doi] PST - ppublish SO - Eur J Surg Oncol. 2019 Oct;45(10):1993-1999. doi: 10.1016/j.ejso.2019.07.018. Epub 2019 Jul 16. PMID- 31326327 OWN - NLM STAT- MEDLINE DCOM- 20200622 LR - 20250516 IS - 1873-4898 (Electronic) IS - 1477-5131 (Linking) VI - 15 IP - 4 DP - 2019 Aug TI - Urothelial cell carcinoma of the bladder in pediatric patients: a systematic review and data analysis of the world literature. PG - 309-314 LID - S1477-5131(19)30199-8 [pii] LID - 10.1016/j.jpurol.2019.06.013 [doi] AB - BACKGROUND: Urothelial cell carcinoma (UCC) of the bladder is exceedingly rare in pediatric patients. Limited data are available to guide management in this population. METHODS: The authors systematically searched MEDLINE, Cochrane Library, and Google Scholar (through February 2019) for case reports and series to summarize data regarding presentation, evaluation, management, and follow-up for patients /=TaN0M0 disease (OR: 6.2, 95% CI: 2.5-15.6); and larger tumors at diagnosis (OR: 1.7, 95% CI: 1.2-2.4) had significantly greater adjusted odds of recurrence or death after initial treatment. CONCLUSION: Based on pooled results, disease recurrence or death occurred in 10.7% of pediatric patients and within 9 months for most and within 32 months for all patients. This may suggest that low-grade and stage UCC of the bladder in pediatric patients can be systematically monitored for at least 3 years. However, prospective evaluation of this clinical strategy is warranted. CI - Copyright (c) 2019 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. FAU - Rezaee, M E AU - Rezaee ME AD - Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA. Electronic address: Michael.E.Rezaee@hitchcock.org. FAU - Dunaway, C M AU - Dunaway CM AD - Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH, 03755, USA. FAU - Baker, M L AU - Baker ML AD - Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA. FAU - Penna, F J AU - Penna FJ AD - Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA; Pediatric Urology, Children's Hospital at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA. FAU - Chavez, D R AU - Chavez DR AD - Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA; Pediatric Urology, Children's Hospital at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20190622 PL - England TA - J Pediatr Urol JT - Journal of pediatric urology JID - 101233150 SB - IM MH - Carcinoma, Transitional Cell/diagnosis/epidemiology/*therapy MH - Child MH - Combined Modality Therapy MH - *Disease Management MH - Disease Progression MH - Global Health MH - Humans MH - Incidence MH - Risk Factors MH - Survival Rate/trends MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/diagnosis/epidemiology/*therapy OTO - NOTNLM OT - Management OT - Pediatric OT - Surveillance OT - Transurethral resection OT - Urothelial cell carcinoma EDAT- 2019/07/22 06:00 MHDA- 2020/06/23 06:00 CRDT- 2019/07/22 06:00 PHST- 2019/04/08 00:00 [received] PHST- 2019/06/15 00:00 [accepted] PHST- 2019/07/22 06:00 [pubmed] PHST- 2020/06/23 06:00 [medline] PHST- 2019/07/22 06:00 [entrez] AID - S1477-5131(19)30199-8 [pii] AID - 10.1016/j.jpurol.2019.06.013 [doi] PST - ppublish SO - J Pediatr Urol. 2019 Aug;15(4):309-314. doi: 10.1016/j.jpurol.2019.06.013. Epub 2019 Jun 22. PMID- 31326313 OWN - NLM STAT- MEDLINE DCOM- 20200911 LR - 20220716 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 37 IP - 9 DP - 2019 Sep TI - Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. PG - 572.e1-572.e11 LID - S1078-1439(19)30249-2 [pii] LID - 10.1016/j.urolonc.2019.06.020 [doi] AB - BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive urothelial carcinoma of the bladder confers only a modest survival advantage. Patients with pathologic progression on NAC have poor outcomes related to a delay in definitive surgical management. OBJECTIVE: To characterize the value of epithelial-mesenchymal transition (EMT) effectors and other novel biomarkers to predict response to NAC. METHODS: A tissue microarray was constructed from patients with clinical stage T2 urothelial carcinoma of the bladder using transurethral resection (TUR) specimens (N = 69) and case-matched post-NAC cystectomy specimens (N = 51). Patients were stratified based on pathologic response to NAC and cancer-specific survival. Biomarker expression in TUR specimens was correlated with pathologic response to NAC and clinical outcomes. Phenotypic changes in expression induced by cisplatin-based NAC were characterized in primary TUR and post-NAC cystectomy and lymph node metastasis specimens. RESULTS: Increased expression of mesenchymal markers and actin-cytoskeleton regulators, as well as low apoptosis index, in TUR specimens was associated with pathologic progression on cisplatin-based NAC. Overexpression of N-cadherin and decreased apoptosis was predictive of disease-specific mortality. NAC decreased cofilin phosphorylation and induced a mesenchymal-epithelial transition phenotype. CONCLUSIONS: The epithelial-mesenchymal transition phenotype and actin-cytoskeleton remodeling are associated with pathologic progression on NAC. Chemotherapy induced an mesenchymal-epithelial transition phenotype and decreased cofilin phosphorylation, providing new insights into therapeutic resistance mechanisms. Primary tumors with high apoptosis rates exhibited favorable response to NAC and lower mortality rates, indicating that these tumors may be sensitized to therapy. Further validation will establish these novel signatures as predictors of therapeutic response. CI - Published by Elsevier Inc. FAU - Hensley, Patrick J AU - Hensley PJ AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY; Department of Pathology, University of Kentucky College of Medicine, Lexington, KY. Electronic address: patrick.hensley@uky.edu. FAU - Kyprianou, Natasha AU - Kyprianou N AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY; Department of Pathology, University of Kentucky College of Medicine, Lexington, KY; Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, KY. FAU - Purdom, Matthew S AU - Purdom MS AD - Department of Pathology, University of Kentucky College of Medicine, Lexington, KY. FAU - He, Daheng AU - He D AD - Department of Cancer Biostatistics, University of Kentucky College of Medicine, Lexington, KY. FAU - DiCarlo, Vincent AU - DiCarlo V AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY. FAU - Wang, Chi AU - Wang C AD - Department of Cancer Biostatistics, University of Kentucky College of Medicine, Lexington, KY. FAU - James, Andrew C AU - James AC AD - Department of Urology, University of Kentucky College of Medicine, Lexington, KY. LA - eng GR - P30 CA177558/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20190717 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Chemotherapy, Adjuvant/*methods MH - Cisplatin/pharmacology/*therapeutic use MH - Epithelial-Mesenchymal Transition MH - Female MH - Humans MH - Immunohistochemistry/*methods MH - Male MH - Middle Aged MH - Phenotype MH - Prospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC9186422 MID - NIHMS1809771 OTO - NOTNLM OT - Biomarker OT - Cisplatin OT - Epithelial-mesenchymal transition OT - Neoadjuvant chemotherapy OT - Pathologic response OT - Urothelial carcinoma COIS- Conflict of interest The authors report no competing interest to declare. EDAT- 2019/07/22 06:00 MHDA- 2020/09/12 06:00 PMCR- 2022/06/10 CRDT- 2019/07/22 06:00 PHST- 2019/01/12 00:00 [received] PHST- 2019/03/18 00:00 [revised] PHST- 2019/06/21 00:00 [accepted] PHST- 2019/07/22 06:00 [pubmed] PHST- 2020/09/12 06:00 [medline] PHST- 2019/07/22 06:00 [entrez] PHST- 2022/06/10 00:00 [pmc-release] AID - S1078-1439(19)30249-2 [pii] AID - 10.1016/j.urolonc.2019.06.020 [doi] PST - ppublish SO - Urol Oncol. 2019 Sep;37(9):572.e1-572.e11. doi: 10.1016/j.urolonc.2019.06.020. Epub 2019 Jul 17. PMID- 31324162 OWN - NLM STAT- MEDLINE DCOM- 20191231 LR - 20200225 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Jul 19 TI - Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. PG - 716 LID - 10.1186/s12885-019-5924-6 [doi] LID - 716 AB - BACKGROUND: Assessing the prognostic significance of specific clinicopathological features plays an important role in surgical management after radical cystectomy. This study investigated the association between ten clinicopathological characteristics and cancer-specific survival (CSS) in patients with bladder cancer. METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a literature search was conducted through the PubMed, EMBASE and Web of Science databases using appropriate search terms from the dates of inception until November 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the CSS. Fixed- or random-effects models were constructed according to existence of heterogeneity. RESULTS: Thirty-three articles met the eligibility criteria for this systematic review, which included 19,702 patients. The overall results revealed that CSS was associated with advanced age (old vs. young: pooled HR = 1.01; 95% CI:1.00-1.01; P < 0.001), higher tumor grade (3 vs. 1/2: pooled HR = 1.29; 95% CI:1.15-1.45; P < 0.001), higher pathological stage (3/4 vs. 1/2: pooled HR = 1.60; 95% CI:1.37-1.86; P < 0.001), lymph node metastasis (positive vs. negative: pooled HR = 1.51; 95% CI:1.37-1.67; P < 0.001), lymphovascular invasion (positive vs. negative: pooled HR = 1.36; 95% CI:1.28-1.45; P < 0.001), and soft tissue surgical margin (positive vs. negative: pooled HR = 1.42; 95% CI:1.30-1.56; P < 0.001). However, gender (male vs. female: pooled HR = 0.98; 95% CI: 0.96-1.01; P = 0.278), carcinoma in situ (positive vs. negative: pooled HR = 0.98; 95% CI: 0.88-1.10; P = 0.753), histology (transitional cell cancer vs variant: pooled HR = 0.90; 95% CI: 0.79-1.02; P = 0.089) and adjuvant chemotherapy (yes vs. no: pooled HR = 1.16; 95% CI: 1.00-1.34; P = 0.054) did not affect CSS after radical resection of bladder cancer. CONCLUSIONS: Our results revealed that several clinicopathological characteristics can predict CSS risk after radical cystectomy. Prospective studies are needed to further confirm the predictive value of these variables for the prognosis of bladder cancer patients after radical cystectomy. FAU - Zhang, Lijin AU - Zhang L AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. stzlj913729553@163.com. FAU - Wu, Bin AU - Wu B AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. FAU - Zha, Zhenlei AU - Zha Z AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. FAU - Qu, Wei AU - Qu W AD - Department of Pharmacy, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. FAU - Zhao, Hu AU - Zhao H AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. FAU - Yuan, Jun AU - Yuan J AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20190719 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Chemotherapy, Adjuvant MH - *Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Lymphatic Metastasis MH - Male MH - Margins of Excision MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Young Adult PMC - PMC6642549 OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Meta-analysis OT - Radical cystectomy COIS- We declare that there are no potential competing interests in this research. EDAT- 2019/07/22 06:00 MHDA- 2020/01/01 06:00 PMCR- 2019/07/19 CRDT- 2019/07/21 06:00 PHST- 2019/01/16 00:00 [received] PHST- 2019/07/11 00:00 [accepted] PHST- 2019/07/21 06:00 [entrez] PHST- 2019/07/22 06:00 [pubmed] PHST- 2020/01/01 06:00 [medline] PHST- 2019/07/19 00:00 [pmc-release] AID - 10.1186/s12885-019-5924-6 [pii] AID - 5924 [pii] AID - 10.1186/s12885-019-5924-6 [doi] PST - epublish SO - BMC Cancer. 2019 Jul 19;19(1):716. doi: 10.1186/s12885-019-5924-6. PMID- 31320823 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220411 IS - 0513-5710 (Print) IS - 1346-8049 (Electronic) IS - 0513-5710 (Linking) VI - 62 IP - 2 DP - 2019 Jun TI - Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer. PG - 191-197 LID - 10.33160/yam.2019.06.003 [doi] AB - BACKGROUND: To evaluate the efficacy of Bacilli Calmette-Guerin (BCG) induction instillation therapy after second transurethral resection (TUR) in stage Ta T1 high-grade bladder cancer. METHODS: We performed a retrospective analysis of 49 consecutive new onset Ta T1 high-grade bladder cancer patients treated with second TUR at our affiliated institutions. Residual cancer rate, intravesical recurrence-free survival (RFS), and risk factors related to RFS were evaluated by univariate and multivariate Cox proportional hazard model analyses. RESULTS: Thirty-one patients received BCG therapy after the second TUR (BCG group), and 18 patients were treated with second TUR alone (no BCG group). There were statistically significant differences in the RFS rates between the two groups, (P = 0.037). BCG therapy was the only factor predictive of intravesical recurrence after second TUR in both univariate and multivariate analyses. After the second TUR, BCG therapy significantly decreased intravesical recurrence in the patients with residual tumors (P = 0.014). However, there was no significant difference in intravesical recurrence in the patients with no residual tumors between the two groups (P = 0.359). CONCLUSION: BCG therapy after second TUR significantly decreased intravesical recurrence of residual tumors found at the second TUR. FAU - Kimura, Yusuke AU - Kimura Y AD - Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. FAU - Honda, Masashi AU - Honda M AD - Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. FAU - Morizane, Shuichi AU - Morizane S AD - Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. FAU - Hikita, Katsuya AU - Hikita K AD - Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. FAU - Isoyama, Tadahiro AU - Isoyama T AD - Torrori Prefectual Central Hospital, Tottori 680-0901, Japan. FAU - Ono, Koji AU - Ono K AD - Japanese Red Cross Tottori Hospital, Tottori 680-8517, Japan. FAU - Koumi, Tsutomu AU - Koumi T AD - Japanese Red Cross Matsue Hospital, Matsue 690-8506, Japan. FAU - Takahashi, Chihiro AU - Takahashi C AD - Yonago Medical Center, Yonago 683-0006, Japan. FAU - Takenaka, Atsushi AU - Takenaka A AD - Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. LA - eng PT - Journal Article DEP - 20190620 PL - Japan TA - Yonago Acta Med JT - Yonago acta medica JID - 0414002 PMC - PMC6584257 OTO - NOTNLM OT - bacilli calmette-guerin therapy OT - bladder cancer OT - second transurethral resection COIS- The authors declare no conflict of interest. EDAT- 2019/07/20 06:00 MHDA- 2019/07/20 06:01 PMCR- 2019/06/20 CRDT- 2019/07/20 06:00 PHST- 2019/01/31 00:00 [received] PHST- 2019/05/08 00:00 [accepted] PHST- 2019/07/20 06:00 [entrez] PHST- 2019/07/20 06:00 [pubmed] PHST- 2019/07/20 06:01 [medline] PHST- 2019/06/20 00:00 [pmc-release] AID - 2019.06.003 [pii] AID - 10.33160/yam.2019.06.003 [doi] PST - epublish SO - Yonago Acta Med. 2019 Jun 20;62(2):191-197. doi: 10.33160/yam.2019.06.003. eCollection 2019 Jun. PMID- 31316092 OWN - NLM STAT- MEDLINE DCOM- 20201026 LR - 20221207 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 Jul 17 TI - Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. PG - 10362 LID - 10.1038/s41598-019-46652-4 [doi] LID - 10362 AB - Non-muscle invasive bladder cancer (NMIBC) represents a crucial problem for the national health care systems due to its high rates of recurrence and the consequent need of frequent follow-ups. Here, gene expression analyses in patients diagnosed as NMIBC were performed to determine those molecular pathways involved in tumor initiation, finding that both MYC and E2F are up regulated and helps to tumor initiation and progression. Our results also support an important involvement of alternative splicing events, modifying key pathways to favour bladder tumor evolution. Finally, since MDM2 showed differential exon usage, mutations in TP53 and its protein expression have been also studied in the same patients. Our data support that recurrence is epigenetically mediated and favoured by an increase protein expression of TP53, which appears more frequently mutated in advanced stages and grades, being associated to a worse prognosis. Therefore, TP53 mutational status could be used as a potential biomarker in the first stages of NMIBC to predict recurrence and prognosis. FAU - Duenas, Marta AU - Duenas M AD - Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain. AD - Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain. AD - CIBERONC, Biomedical Research Networking Centers, Madrid, Spain. FAU - Perez-Figueroa, Andres AU - Perez-Figueroa A AUID- ORCID: 0000-0002-7722-3697 AD - Phylogenomics Lab. Department of Biochemistry, Genetics an Immunology & Biomedical Research Center (CINBIO), University of Vigo, 36310, Vigo, Spain. FAU - Oliveira, Carla AU - Oliveira C AD - Expression Regulation in Cancer Lab, Universidade do Porto, i3s & IPATIMUP. Rua Alfredo Allen, 208, 4200-135, Porto, Portugal. FAU - Suarez-Cabrera, Cristian AU - Suarez-Cabrera C AD - Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain. AD - Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain. AD - CIBERONC, Biomedical Research Networking Centers, Madrid, Spain. FAU - Sousa, Abel AU - Sousa A AD - Expression Regulation in Cancer Lab, Universidade do Porto, i3s & IPATIMUP. Rua Alfredo Allen, 208, 4200-135, Porto, Portugal. FAU - Oliveira, Patricia AU - Oliveira P AD - Expression Regulation in Cancer Lab, Universidade do Porto, i3s & IPATIMUP. Rua Alfredo Allen, 208, 4200-135, Porto, Portugal. FAU - Villacampa, Felipe AU - Villacampa F AD - Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain. AD - CIBERONC, Biomedical Research Networking Centers, Madrid, Spain. AD - Urology Department, Clinica Universidad de Navarra, Madrid, Spain. FAU - Paramio, Jesus M AU - Paramio JM AUID- ORCID: 0000-0001-7520-3177 AD - Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain. jesusm.paramio@ciemat.es. AD - Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain. jesusm.paramio@ciemat.es. AD - CIBERONC, Biomedical Research Networking Centers, Madrid, Spain. jesusm.paramio@ciemat.es. FAU - Martinez-Fernandez, Monica AU - Martinez-Fernandez M AD - Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain. monicamartinezfernandez@gmail.com. AD - Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain. monicamartinezfernandez@gmail.com. AD - CIBERONC, Biomedical Research Networking Centers, Madrid, Spain. monicamartinezfernandez@gmail.com. AD - Genomes and Disease Lab. Center for Molecular Medicine and Chronic Diseases Research (CIMUS), Universidade de Santiago de Compostela (USC), Avda de Barcelona, 31, 15706, Santiago de Compostela, Spain. monicamartinezfernandez@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190717 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (E2F Transcription Factors) RN - 0 (MYC protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (Proto-Oncogene Proteins c-myc) RN - EC 2.3.2.27 (MDM2 protein, human) RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) SB - IM MH - *Alternative Splicing MH - Carcinoma, Transitional Cell/*genetics/pathology MH - Disease-Free Survival MH - E2F Transcription Factors/genetics MH - Exons/genetics MH - *Gene Expression Regulation, Neoplastic MH - Gene Ontology MH - Genes, myc MH - *Genes, p53 MH - Humans MH - Kaplan-Meier Estimate MH - Mutation, Missense MH - Neoplasm Invasiveness MH - Neoplasm Proteins/biosynthesis/genetics MH - Papilloma/*genetics/pathology MH - Prognosis MH - Proto-Oncogene Proteins c-mdm2/genetics MH - Proto-Oncogene Proteins c-myc/genetics MH - Recurrence MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/*genetics/pathology MH - Exome Sequencing PMC - PMC6637137 COIS- The authors declare no competing interests. EDAT- 2019/07/19 06:00 MHDA- 2020/10/27 06:00 PMCR- 2019/07/17 CRDT- 2019/07/19 06:00 PHST- 2019/02/22 00:00 [received] PHST- 2019/06/28 00:00 [accepted] PHST- 2019/07/19 06:00 [entrez] PHST- 2019/07/19 06:00 [pubmed] PHST- 2020/10/27 06:00 [medline] PHST- 2019/07/17 00:00 [pmc-release] AID - 10.1038/s41598-019-46652-4 [pii] AID - 46652 [pii] AID - 10.1038/s41598-019-46652-4 [doi] PST - epublish SO - Sci Rep. 2019 Jul 17;9(1):10362. doi: 10.1038/s41598-019-46652-4. PMID- 31313043 OWN - NLM STAT- MEDLINE DCOM- 20200212 LR - 20200212 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 26 IP - 11 DP - 2019 Oct TI - Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching. PG - 3774-3781 LID - 10.1245/s10434-019-07623-1 [doi] AB - BACKGROUND: This study aimed to investigate the long-term oncologic outcomes of laparoscopic radical nephroureterectomy (LRNU) and open radical nephroureterectomy (ORNU) for patients with clinical and pathologic T3N0M0 upper tract urothelial carcinoma (UTUC). METHODS: Among 375 UTUC patients who underwent radical nephroureterectomy, this study identified 144 pT3N0M0 patients as cohort 1 after propensity score (PS) matching. Among 399 UTUC patients, the study identified 110 cT3N0M0 patients as cohort 2 after PS matching. Oncologic outcomes such as intravesical recurrence-free survival (IVRFS) and cancer-specific survival (CSS) were assessed by multivariate Cox's regression analysis. RESULTS: Cohort 1 of pT3N0M0 UTUC had 3-year CSS and IVRFS rates of 67.9 and 52.7%, respectively, in the LRNU group, which were significantly lower than in the ORNU group (81.4%, p = 0.039 and 71.6%, p = 0.046). The multivariate Cox's regression analysis identified the type of surgical approach (LRNU vs. ORNU) as one of the independent prognostic factors for CSS (hazard rate [HR], 1.88, p = 0.043) and IVRFS (HR, 1.75, p = 0.049). Cohort 2 of cT3N0M0 UTUC had 3-year CSS and IVRFS rates of 48.5 and 41.4%, respectively, in the LRNU group, which were significantly lower than in the ORNU group (65.8%, p = 0.049 and 67.2%, p = 0.047), and the type of surgical approach (LRNU vs. ORNU) remained as one of the independent prognostic factors for CSS and IVRFS. CONCLUSIONS: Based on clinical and pathologic T3N0M0 UTUC populations after PS adjustments, LRNU resulted in poorer CSS and IVRFS than ORNU. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Abe, Takayuki AU - Abe T AD - Department of Preventive Medicine and Public Health, Biostatistics Unit at the Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan. FAU - Hagiwara, Masayuki AU - Hagiwara M AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Anno, Tadanori AU - Anno T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. AD - Department of Urology, Saitama City Hospital, Saitama, Japan. AD - Department of Urology, Saitama Medical Hospital, Saitama, Japan. FAU - Umeda, Kota AU - Umeda K AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Baba, Yuto AU - Baba Y AD - Department of Urology, International University of Health and Welfare Mita Hospital, Tokyo, Japan. FAU - Sanjo, Tansei AU - Sanjo T AD - Department of Urology, Isehara Kyodo Hospital, Kanagawa, Japan. FAU - Shojo, Kazunori AU - Shojo K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190716 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2019 Dec;26(Suppl 3):815-816. doi: 10.1245/s10434-019-07996-3. PMID: 31659633 MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Follow-Up Studies MH - Humans MH - Laparoscopy/*mortality MH - Male MH - Middle Aged MH - Nephroureterectomy/*mortality MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urologic Neoplasms/pathology/*surgery EDAT- 2019/07/18 06:00 MHDA- 2020/02/13 06:00 CRDT- 2019/07/18 06:00 PHST- 2019/02/21 00:00 [received] PHST- 2019/07/18 06:00 [pubmed] PHST- 2020/02/13 06:00 [medline] PHST- 2019/07/18 06:00 [entrez] AID - 10.1245/s10434-019-07623-1 [pii] AID - 10.1245/s10434-019-07623-1 [doi] PST - ppublish SO - Ann Surg Oncol. 2019 Oct;26(11):3774-3781. doi: 10.1245/s10434-019-07623-1. Epub 2019 Jul 16. PMID- 31307949 OWN - NLM STAT- MEDLINE DCOM- 20201119 LR - 20220410 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 5 IP - 5 DP - 2019 Sep TI - Current Disease Management of Primary Urethral Carcinoma. PG - 722-734 LID - S2405-4569(19)30172-5 [pii] LID - 10.1016/j.euf.2019.07.001 [doi] AB - CONTEXT: Primary urethral cancer (PUC) is a rare cancer entity. Owing to the low incidence of this malignancy, the main body of literature consists mainly of case reports, making evidence-based management recommendations difficult. OBJECTIVE: To review reported disease management strategies of PUC and their impact on oncological outcomes. EVIDENCE ACQUISITION: A systematic research was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement using Medline, Scopus, and Web of Science, to find studies of the past 10yr including >/=20 patients, and investigating treatment strategies and their impact on outcomes of the three most frequent histologies: urothelial carcinoma, adenocarcinoma, and squamous cell carcinoma. EVIDENCE SYNTHESIS: In localized PUC, penis-sparing surgery can be performed in males, while in females, complete urethrectomy with surrounding tissue is advised to minimize recurrence due to positive margins. Radiotherapy (RT) has worse survival and recurrence rates, as well as more adverse effects, than surgery, limiting its use in genital-preserving therapy. Locally advanced PUC should be treated with multimodal therapy, as monotherapies result in inferior recurrence and survival rates. Extent of surgery is still undecided, favoring radical cyst(oprostat)ectomy with total urethrectomy (RCU). Lymph node involvement is a predictor of survival, highlighting the role of lymph node dissection for disease control and staging. RT can improve survival in combination with surgery and/or chemotherapy (CHT). Neoadjuvant platinum-based CHT can improve overall and recurrence-free survival. At recurrence, salvage therapy with surgery and/or CHT can improve survival. Superficial urothelial carcinoma of the prostatic urethra can be treated with transurethral resection. Stromal invasion often features concomitant bladder cancer with a poor prognosis and requires RCU with or without systemic preoperative CHT. CONCLUSIONS: PUC is a rare malignancy with an often poor natural course, requiring a stage- and gender-specific risk-based treatment strategy. The role of systematic perioperative CHT and the extent of surgery are becoming more important. PATIENT SUMMARY: In this review, we looked at the treatment options for primary urethral cancer. We found that while an organ-confined disease can be managed with local resection, growth beyond the organ border makes a combination of different treatment modalities, such as surgery and systematic chemotherapy, necessary to improve outcomes. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Janisch, Florian AU - Janisch F AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Iwata, Takehiro AU - Iwata T AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology and Andrology, Karl Landsteiner Institute, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Systematic Review DEP - 20190713 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Adenocarcinoma/*diagnosis/*therapy MH - Carcinoma, Squamous Cell/*diagnosis/*therapy MH - Carcinoma, Transitional Cell/*diagnosis/*therapy MH - Decision Trees MH - Female MH - Humans MH - Male MH - Urethral Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - Disease management OT - Primary urethral carcinoma OT - Prognosis OT - Therapy OT - Treatment EDAT- 2019/07/17 06:00 MHDA- 2020/11/20 06:00 CRDT- 2019/07/17 06:00 PHST- 2019/03/21 00:00 [received] PHST- 2019/06/06 00:00 [revised] PHST- 2019/07/02 00:00 [accepted] PHST- 2019/07/17 06:00 [pubmed] PHST- 2020/11/20 06:00 [medline] PHST- 2019/07/17 06:00 [entrez] AID - S2405-4569(19)30172-5 [pii] AID - 10.1016/j.euf.2019.07.001 [doi] PST - ppublish SO - Eur Urol Focus. 2019 Sep;5(5):722-734. doi: 10.1016/j.euf.2019.07.001. Epub 2019 Jul 13. PMID- 31305463 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 28 DP - 2019 Jul TI - Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients. PG - e16426 LID - 10.1097/MD.0000000000016426 [doi] LID - e16426 AB - The aim of this study was to determine clinical recrudescent risk factors of 477 patients with newly discovered nonmuscle-invasive bladder cancer (NMIBC) (Ta-T1) in our hospital, and based on these factors, to establish a recurrence risk prediction model of each NMIBC patient.This study included 477 patients with newly discovered NMIBC (Ta-T1) from January 2012 to December 2016; all patients were treated surgically by transurethral resection of bladder tumor (TURBT). The outcomes of patients were with or without recurrence within 2 years. The nomograms were based on Cox regression analyses, and the calibration curves were founded to evaluate the agreements of the predicted probability with the actual observed probability.Of the 477 patients with NMIBC, 392 were males (82.2%) and 85 were females (17.8%), with median age 64 years. Recurrence was identified in 327 cases (68.6%). The results showed that old age, female sex, smoking history, large size of tumor, multifocal tumors, high grade, and high stage are risk factors for NMIBC recurrence, whereas no significant association was seen between tumor location and recurrence in our study. Based on the results of Cox regression analyses, several independent risk factors, including smoking history, tumor size, multifocal, immediate infusion therapy, T stage, and tumor grade, were used to establish a nomogram to calculate the recurrence probability of each NMIBC patient, and the calibration curve displayed that this nomogram had a great value of prediction.Old age, female sex, smoking history, large size of tumor, multifocal tumors, high grade, and high stage are risk factors for NMIBC recurrence, whereas immediate infusion therapy is a protective factor. And a nomogram was established as a prediction model to calculate the recurrence probability of NMIBC patients. FAU - Lu, Mengxin AU - Lu M AD - Department of Urology. FAU - Chen, Song AU - Chen S AD - Department of Urology. FAU - Zhou, Qiang AU - Zhou Q AD - Department of Urology. FAU - Wang, Lu AU - Wang L AD - Department of Urology. FAU - Peng, Tianchen AU - Peng T AD - Department of Urology. FAU - Wang, Gang AU - Wang G AD - Department of Biological Repositories, Zhongnan Hospital of Wuhan University. AD - Human Genetics Resource Preservation Center of Hubei Province, Wuhan, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R MH - Aged MH - Aged, 80 and over MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/epidemiology MH - Nomograms MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/therapy PMC - PMC6641864 COIS- The authors report no conflicts of interest. EDAT- 2019/07/16 06:00 MHDA- 2019/07/30 06:00 PMCR- 2019/07/12 CRDT- 2019/07/16 06:00 PHST- 2019/07/16 06:00 [entrez] PHST- 2019/07/16 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2019/07/12 00:00 [pmc-release] AID - 00005792-201907120-00076 [pii] AID - MD-D-19-00535 [pii] AID - 10.1097/MD.0000000000016426 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Jul;98(28):e16426. doi: 10.1097/MD.0000000000016426. PMID- 31302753 OWN - NLM STAT- MEDLINE DCOM- 20201228 LR - 20260127 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 38 IP - 3 DP - 2020 Mar TI - Microlocalization and clinical significance of stabilin-1(+) macrophages in treatment-naive patients with urothelial carcinoma of the bladder. PG - 709-716 LID - 10.1007/s00345-019-02853-0 [doi] AB - PURPOSE: Emerging evidence has shown that macrophages (Mphis) at different tumor sites have diverse clinical attributes. Stabilin-1 is a multi-functional scavenger marker for specialized tumor-associated Mphis. This study investigates the relationship between the density and microlocalization of stabilin-1(+) Mphis within tumors and the clinical outcomes of patients with urothelial carcinoma of the bladder (UCB). METHODS: In this retrospective study, 283 UCB patients who received radical cystectomy or transurethral resection were examined. Immunohistochemistry and immunofluorescence analyses were used to colocalize the expression of stabilin-1 with other markers for Mphis (CD14, CD68, CD163, and CD206). Kaplan-Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: In UCB tissues, stabilin-1 was primarily expressed on Mphis, as evident from triple immunofluorescence staining for stabilin-1 and Mphi markers. Stabilin-1(+) Mphis were often more prominent in stromal regions rather than intratumoral regions in UCB tissues (P < 0.0001). After dichotomization at the median cell density for stabilin-1(+) Mphis, only intratumoral stabilin-1(+) Mphi density was a predictor of poor OS (P < 0.001) and RFS (P = 0.026). Moreover, intratumoral stabilin-1(+) Mphi density was positively associated with tumor stage (P < 0.01) and histological grade (P < 0.01), and emerged as an independent prognostic factor for OS (HR 2.371; P < 0.0001), but not for RFS (HR 1.491; P = 0.061). CONCLUSIONS: Our findings indicate that intratumoral stabilin-1(+) Mphis could potentially be used as a pro-tumoral prognostic marker for UCB patients. FAU - Wang, Bo AU - Wang B AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Huang, Hao AU - Huang H AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. FAU - Yang, Meihua AU - Yang M AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. FAU - Yang, Wenjuan AU - Yang W AD - Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, People's Republic of China. FAU - Liu, Zhuowei AU - Liu Z AD - Department of Urology, Cancer Center, Sun Yat-sen (Zhongshan) University, Guangzhou, People's Republic of China. FAU - Hou, Weibin AU - Hou W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. FAU - Zeng, Hong AU - Zeng H AD - Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, People's Republic of China. FAU - He, Zhihua AU - He Z AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. tianxinl@sina.com. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. tianxinl@sina.com. FAU - Huang, Jian AU - Huang J AUID- ORCID: 0000-0001-7315-4252 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, 510120, People's Republic of China. urolhj@sina.com. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. urolhj@sina.com. LA - eng GR - 81402106/National Natural Science Foundation of China/ GR - 81825016/National Natural Science Foundation of China/ GR - 201604020177/Science and Technology Program of Guangzhou/ GR - 201604020156/Science and Technology Program of Guangzhou/ GR - 2015A030310122/National Natural Science Foundation of Guangdong/ GR - 201806010024/Pearl River Nova Program of Guangzhou/ GR - 16ykjc18/Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University/ GR - none/Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to Bo Wang; Yat-Sen Scholarship for Young Scientist/ GR - KLB09001/Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University/ GR - 013-163/Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology/ PT - Journal Article DEP - 20190713 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, Myelomonocytic) RN - 0 (Cell Adhesion Molecules, Neuronal) RN - 0 (Lectins, C-Type) RN - 0 (Lipopolysaccharide Receptors) RN - 0 (Mannose Receptor) RN - 0 (Mannose-Binding Lectins) RN - 0 (Receptors, Cell Surface) RN - 0 (Receptors, Lymphocyte Homing) RN - 0 (CD163 Antigen) RN - 0 (CD68 antigen, human) RN - 0 (CD68 Molecule) RN - 0 (STAB1 protein, human) SB - IM MH - Aged MH - Antigens, CD/metabolism MH - Antigens, Differentiation, Myelomonocytic/metabolism MH - Carcinoma, Transitional Cell/metabolism/*pathology MH - Cell Adhesion Molecules, Neuronal/metabolism MH - Disease-Free Survival MH - Female MH - Humans MH - Lectins, C-Type/metabolism MH - Lipopolysaccharide Receptors/metabolism MH - Male MH - Mannose Receptor MH - Mannose-Binding Lectins/metabolism MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Receptors, Cell Surface/metabolism MH - Receptors, Lymphocyte Homing/metabolism MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Tumor Microenvironment MH - Tumor-Associated Macrophages/cytology/metabolism/*pathology MH - Urinary Bladder Neoplasms/metabolism/*pathology MH - CD163 Antigen MH - CD68 Molecule PMC - PMC7064462 OTO - NOTNLM OT - Microlocalization OT - Stabilin-1 OT - Tumor-associated macrophages OT - Urothelial carcinoma of the bladder COIS- The authors declare that they have no conflict of interest. EDAT- 2019/07/16 06:00 MHDA- 2020/12/29 06:00 PMCR- 2019/07/13 CRDT- 2019/07/15 06:00 PHST- 2018/09/28 00:00 [received] PHST- 2019/06/12 00:00 [accepted] PHST- 2019/07/16 06:00 [pubmed] PHST- 2020/12/29 06:00 [medline] PHST- 2019/07/15 06:00 [entrez] PHST- 2019/07/13 00:00 [pmc-release] AID - 10.1007/s00345-019-02853-0 [pii] AID - 2853 [pii] AID - 10.1007/s00345-019-02853-0 [doi] PST - ppublish SO - World J Urol. 2020 Mar;38(3):709-716. doi: 10.1007/s00345-019-02853-0. Epub 2019 Jul 13. PMID- 31300876 OWN - NLM STAT- MEDLINE DCOM- 20190903 LR - 20200225 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 475 IP - 3 DP - 2019 Sep TI - Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. PG - 349-356 LID - 10.1007/s00428-019-02618-5 [doi] AB - The Cancer Genome Atlas project introduced genomic taxonomy of basal and luminal molecular subtypes in muscle invasive bladder cancer. Fewer studies have addressed the molecular classification in non-muscle invasive bladder cancer (NMIBC). Our aim is to assess the applicability of the proposed phenotypic classification for NMIBC. Three TMAs were constructed from 193 TURBT specimens of 60 bladder cancer patients treated at one of the authors' institutions (1998-2008). Follow-up data on recurrence, grade, or stage progression was obtained. Immunohistochemistry was performed using an automated Ventana System for markers indicative of luminal (GATA3, CK20, ER, Uroplakin II, and HER2/neu) and basal (CK5/6 and CD44) phenotype. Marker expression was evaluated by 3 urologic pathologists. Using unadjusted logistic regression, we found significant association between tumor recurrence at next biopsy and CD44 expression (OR = 2.51, P = 0.03), tumor recurrence at any subsequent biopsy and ER expression (OR = 0.24, P = 0.04), and tumor grade progression at any subsequent biopsy and HER2/neu expression (OR = 0.24, P = 0.04). After adjusting for pathologic stage, we found a significant association between CK5/6 expression and tumor stage progression at either next or any subsequent biopsy (OR = 0.94, P = 0.006; and OR = 0.97, P = 0.02, respectively). Our findings suggest that individual immunohistochemical markers may be of value as prognostic factors in NMIBC. FAU - Rodriguez Pena, Maria Del Carmen AU - Rodriguez Pena MDC AD - Department of Pathology, The University of Alabama at Birmingham, WP Building, Suite P230, 619 19th Street South, Birmingham, AL, 35249-7331, USA. FAU - Chaux, Alcides AU - Chaux A AD - Department of Scientific Research, School of Postgraduate Studies, Norte University, Asuncion, Paraguay. FAU - Eich, Marie-Lisa AU - Eich ML AD - Department of Pathology, The University of Alabama at Birmingham, WP Building, Suite P230, 619 19th Street South, Birmingham, AL, 35249-7331, USA. FAU - Tregnago, Aline C AU - Tregnago AC AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA. FAU - Taheri, Diana AU - Taheri D AD - Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Borhan, Walaa AU - Borhan W AD - Department of Pathology, College of Medicine, Taibah University, Madinah, Saudi Arabia. FAU - Sharma, Rajni AU - Sharma R AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA. FAU - Rezaei, M Katayoon AU - Rezaei MK AD - Department of Pathology, George Washington University, Washington, DC, 20037, USA. FAU - Netto, George J AU - Netto GJ AUID- ORCID: 0000-0003-3915-9134 AD - Department of Pathology, The University of Alabama at Birmingham, WP Building, Suite P230, 619 19th Street South, Birmingham, AL, 35249-7331, USA. gnetto@uabmc.edu. AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA. gnetto@uabmc.edu. LA - eng PT - Journal Article DEP - 20190712 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (Keratin-5) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma in Situ/pathology MH - Carcinoma, Transitional Cell/pathology MH - Female MH - GATA3 Transcription Factor/metabolism MH - Humans MH - Hyaluronan Receptors/metabolism MH - Immunohistochemistry/methods MH - Keratin-5/metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Urinary Bladder/metabolism MH - Urinary Bladder Neoplasms/*classification/*pathology MH - Urothelium/pathology OTO - NOTNLM OT - Basal OT - Immunohistochemistry OT - Luminal OT - Molecular classification OT - Non-muscle invasive bladder cancer OT - Urothelial carcinoma EDAT- 2019/07/14 06:00 MHDA- 2019/09/04 06:00 CRDT- 2019/07/14 06:00 PHST- 2019/02/18 00:00 [received] PHST- 2019/06/27 00:00 [accepted] PHST- 2019/06/04 00:00 [revised] PHST- 2019/07/14 06:00 [pubmed] PHST- 2019/09/04 06:00 [medline] PHST- 2019/07/14 06:00 [entrez] AID - 10.1007/s00428-019-02618-5 [pii] AID - 10.1007/s00428-019-02618-5 [doi] PST - ppublish SO - Virchows Arch. 2019 Sep;475(3):349-356. doi: 10.1007/s00428-019-02618-5. Epub 2019 Jul 12. PMID- 31297119 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20240718 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 10 DP - 2019 TI - In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment. PG - 1460 LID - 10.3389/fimmu.2019.01460 [doi] LID - 1460 AB - The live attenuated mycobacterial strain BCG, in use as vaccine against tuberculosis, is considered the gold standard for primary therapy of carcinoma in situ of the bladder. Despite its limitations, to date it has not been surpassed by any other treatment. Our group has developed a recombinant BCG strain expressing the detoxified S1 pertussis toxin (rBCG-S1PT) that proved more effective than wild type BCG (WT-BCG) in increasing survival time in an experimental mouse model of bladder cancer, due to the well-known adjuvant properties of pertussis toxin. Here, we investigated the capacity of rBCG-S1PT to stimulate human immune responses, in comparison to WT-BCG, using an in vitro stimulation assay based on human whole blood cells that allows for a comprehensive evaluation of leukocyte activation. Blood leukocytes stimulated with rBCG-S1PT produced increased levels of IL-6, IL-8, and IL-10 as compared to WT-BCG, but comparable levels of IL-1beta, IL-2, IFN-gamma, and TNF-alpha. Stimulation of blood cells with the recombinant BCG strain also enhanced the expression of CD25 and CD69 on human CD4(+) T cells. PBMC stimulated with rBCG-S1PT induced higher cytotoxicity to MB49 bladder cancer cells than WT-BCG-stimulated PBMC. These results suggest that the rBCG-S1PT strain is able to activate an immune response in human leukocytes that is higher than that induced by WT-BCG for parameters linked to better prognosis in bladder cancer (regulation of immune and early inflammatory responses), while fully comparable to WT-BCG for classical inflammatory parameters. This establishes rBCG-S1PT as a new highly effective candidate as immunotherapeutic agent against bladder cancer. FAU - Rodriguez, Dunia AU - Rodriguez D AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. FAU - Goulart, Cibelly AU - Goulart C AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. FAU - Pagliarone, Ana C AU - Pagliarone AC AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. FAU - Silva, Eliane P AU - Silva EP AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. AD - Programa de Pos-Graduacao Interunidades em Biotecnologia USP-I.Butantan-IPT, Sao Paulo, Brazil. FAU - Cunegundes, Priscila S AU - Cunegundes PS AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. AD - Programa de Pos-Graduacao Interunidades em Biotecnologia USP-I.Butantan-IPT, Sao Paulo, Brazil. FAU - Nascimento, Ivan P AU - Nascimento IP AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. FAU - Borra, Ricardo C AU - Borra RC AD - Laboratorio de Imunologia Aplicada, Departamento de Genetica e Evolucao, Universidade Federal de Sao Carlos, Sao Carlos, Brazil. FAU - Dias, Waldely O AU - Dias WO AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. FAU - Tagliabue, Aldo AU - Tagliabue A AD - Institute of Genetic and Biomedical Research, National Research Council, Cagliari, Italy. FAU - Boraschi, Diana AU - Boraschi D AD - Institute of Protein Biochemistry, National Research Council, Naples, Italy. FAU - Leite, Luciana C C AU - Leite LCC AD - Laboratorio de Desenvolvimento de Vacinas, Instituto Butantan, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190626 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Cytokines) RN - EC 2.4.2.31 (Pertussis Toxin) SB - IM CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S461-S462. doi: 10.21037/tau.2019.10.08. PMID: 32042616 CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S517-S520. doi: 10.21037/tau.2019.12.23. PMID: 32042636 MH - Adult MH - Aged MH - Animals MH - CD4-Positive T-Lymphocytes/*immunology/pathology MH - Cell Line, Tumor MH - Cytokines/immunology MH - Female MH - Humans MH - *Immunity, Cellular MH - Male MH - Mice MH - Microorganisms, Genetically-Modified/genetics/*immunology MH - Middle Aged MH - Mycobacterium bovis/genetics/*immunology MH - Pertussis Toxin/genetics/immunology MH - Urinary Bladder Neoplasms/immunology/pathology/*therapy PMC - PMC6607967 OTO - NOTNLM OT - CD4 T cells OT - adjuvant OT - bladder cancer OT - cytokines OT - human immune cells OT - immunotherapy OT - recombinant BCG EDAT- 2019/07/13 06:00 MHDA- 2020/10/21 06:00 PMCR- 2019/01/01 CRDT- 2019/07/13 06:00 PHST- 2018/11/23 00:00 [received] PHST- 2019/06/10 00:00 [accepted] PHST- 2019/07/13 06:00 [entrez] PHST- 2019/07/13 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2019.01460 [doi] PST - epublish SO - Front Immunol. 2019 Jun 26;10:1460. doi: 10.3389/fimmu.2019.01460. eCollection 2019. PMID- 31294791 OWN - NLM STAT- MEDLINE DCOM- 20210416 LR - 20210416 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) VI - 185 IP - 1-2 DP - 2020 Feb 12 TI - The Management of Newly-Diagnosed Non-muscle Invasive Bladder Cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration. PG - 276-281 LID - 10.1093/milmed/usz166 [doi] AB - INTRODUCTION: Over 1,500 bladder cancers were diagnosed among US Veterans in 2010, the majority of which were non-muscle invasive bladder cancer (NMIBC). Little is known about NMIBC treatment within the Veterans Health Administration. The objective of the study was to assess the quality of care for Veterans with newly-diagnosed NMIBC within Veterans Integrated Service Network (VISN) 02. MATERIALS AND METHODS: We used ICD-9 and ICD-10 codes to identify patients with newly-diagnosed bladder cancer from 1/2016-8/2017. We risk-stratified the patients into low, intermediate, and high-risk based on the 2016 American Urological Association Guidelines on NMIBC. Our primary objectives were percentages of transurethral resection of bladder tumors (TURBTs) with detrusor, repeat TURBT in high-risk and T1 disease, high-risk NMIBC treated with induction intravesical therapy (IVT), and responders treated with maintenance IVT. We performed logistic regression for association between distance to diagnosing hospital and receipt of induction IVT in high-risk patients. RESULTS: There were 121 newly-diagnosed NMIBC patients; 16% low-risk, 28% intermediate-risk, and 56% high-risk. Detrusor was present in 80% of all initial TURBTs and 84% of high-risk patients. Repeat TURBT was performed in 56% of high-risk NMIBC and 60% of T1. Induction IVT was given to 66% of high-risk patients and maintenance IVT was given to 59% of responders. On multivariate logistic regression, distance to medical center was not associated with receipt of induction IVT (OR = 0.99, 95% CI [0.97,1.01], p = 0.52). CONCLUSIONS: We observed high rates of sampling of detrusor in the first TURBT specimen, utilization of repeat TURBT, and administration of induction and maintenance intravesical BCG for high-risk patients among a regional cohort of US Veterans with NMIBC. While not a comparative study, our findings suggest high quality NMIBC care in VA VISN 02. CI - (c) Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Caputo, Joseph M AU - Caputo JM AD - Department of Urology, NewYork-Presbyterian/Columbia University Medical Center, 161 Fort Washington Avenue 11th Floor, New York, NY 10032. AD - James J. Peters Veterans Affairs Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468. FAU - Moran, George AU - Moran G AD - Department of Urology, NewYork-Presbyterian/Columbia University Medical Center, 161 Fort Washington Avenue 11th Floor, New York, NY 10032. FAU - Muller, Benjamin AU - Muller B AD - Department of Urology, NewYork-Presbyterian/Columbia University Medical Center, 161 Fort Washington Avenue 11th Floor, New York, NY 10032. FAU - Keller, Alison T AU - Keller AT AD - James J. Peters Veterans Affairs Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468. FAU - Li, Gen AU - Li G AD - Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th St, New York, NY 10032. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, NewYork-Presbyterian/Columbia University Medical Center, 161 Fort Washington Avenue 11th Floor, New York, NY 10032. AD - James J. Peters Veterans Affairs Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468. LA - eng PT - Journal Article PL - England TA - Mil Med JT - Military medicine JID - 2984771R SB - IM MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Urinary Bladder Neoplasms/diagnosis/therapy MH - *Veterans MH - Veterans Health OTO - NOTNLM OT - Compliance OT - Guidelines OT - Non-muscle invasive bladder cancer OT - Quality indicators OT - Veterans Health Administration EDAT- 2019/07/12 06:00 MHDA- 2021/04/17 06:00 CRDT- 2019/07/12 06:00 PHST- 2019/03/12 00:00 [received] PHST- 2019/06/04 00:00 [revised] PHST- 2019/06/12 00:00 [accepted] PHST- 2019/07/12 06:00 [pubmed] PHST- 2021/04/17 06:00 [medline] PHST- 2019/07/12 06:00 [entrez] AID - 5531171 [pii] AID - 10.1093/milmed/usz166 [doi] PST - ppublish SO - Mil Med. 2020 Feb 12;185(1-2):276-281. doi: 10.1093/milmed/usz166. PMID- 31293967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Comprehensive Gene Expression Analysis in NMIBC Using RNA-seq Reveals New Therapy Strategies. PG - 523 LID - 10.3389/fonc.2019.00523 [doi] LID - 523 AB - Non-muscle invasive bladder cancer (NMIBC) patients often have fewer treatment options, and suffer the progression of disease due to mechanisms that are not clear, as well as due to its diversity. This study was designed to explore the molecular mechanism of bladder cancer through an RNA-seq. In addition to conventional analyses, we also simplified the network through modularization using the WGCNA algorithm, with the help of the topological overlapping matrix and hierarchical cluster tree, which are based on the PPI network of STRING. Furthermore, the hub genes were confirmed through survival analyses in the independent cohorts (n = 431). Among them, 15 genes were significantly associated with poor prognosis. Finally, we validated the results at mRNA and protein level using qRT-PCR, IHC and western blotting. Taken together, our research is important for the prediction, as well as the prospective clinical development of drug targets and biomarkers. FAU - Chen, Xiaoliang AU - Chen X AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Jiang, Fuquan AU - Jiang F AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Jia, Chunshu AU - Jia C AD - Centre for Reproductive Medicine, Centre for Prenatal Diagnosis, First Hospital of Jilin University, Changchun, China. FAU - Liu, Ming AU - Liu M AD - Central People's Hospital of Siping City, Siping, China. FAU - Nan, Yonghao AU - Nan Y AD - Department of Urology, the Frist Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Qu, Licheng AU - Qu L AD - Centre for Reproductive Medicine, Centre for Prenatal Diagnosis, First Hospital of Jilin University, Changchun, China. FAU - Kong, Qingkuo AU - Kong Q AD - Centre for Reproductive Medicine, Centre for Prenatal Diagnosis, First Hospital of Jilin University, Changchun, China. FAU - Hou, Fangfang AU - Hou F AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Luo, Wenshan AU - Luo W AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Na, Wanli AU - Na W AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Jin, Xuefei AU - Jin X AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. FAU - Tan, Jiufeng AU - Tan J AD - Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China. LA - eng PT - Journal Article DEP - 20190625 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6604748 OTO - NOTNLM OT - NMIBC OT - PPI OT - WGCNA OT - biomarker OT - modularization EDAT- 2019/07/12 06:00 MHDA- 2019/07/12 06:01 PMCR- 2019/01/01 CRDT- 2019/07/12 06:00 PHST- 2019/04/02 00:00 [received] PHST- 2019/05/30 00:00 [accepted] PHST- 2019/07/12 06:00 [entrez] PHST- 2019/07/12 06:00 [pubmed] PHST- 2019/07/12 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.00523 [doi] PST - epublish SO - Front Oncol. 2019 Jun 25;9:523. doi: 10.3389/fonc.2019.00523. eCollection 2019. PMID- 31292267 OWN - NLM STAT- MEDLINE DCOM- 20200901 LR - 20201214 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 24 IP - 12 DP - 2019 Dec TI - Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). PG - e1341-e1350 LID - 10.1634/theoncologist.2018-0280 [doi] AB - BACKGROUND: The aim of this study was to evaluate the efficacy and safety of chemoradiotherapy (RCT) combined with regional deep hyperthermia (RHT) of high-risk bladder cancer after transurethral resection of bladder tumor (TUR-BT). MATERIALS AND METHODS: Between 1982 and 2016, 369 patients with pTa, pTis, pT1, and pT2 cN0-1 cM0 bladder cancer were treated with a multimodal treatment after TUR-BT. All patients received radiotherapy (RT) of the bladder and regional lymph nodes. RCT was administered to 215 patients, RCT + RHT was administered to 79 patients, and RT was used in 75 patients. Treatment response was evaluated 4-6 weeks after treatment with TUR-BT. RESULTS: Complete response (CR) overall was 83% (290/351), and in treatment groups was RT 68% (45/66), RCT 86% (178/208), and RCT + RHT 87% (67/77). CR was significantly improved by concurrent RCT compared with RT (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.05-5.12; p = .037), less influenced by hyperthermia (OR, 2.56; 95% CI, 0.88-8.00; p = .092). Overall survival (OS) after RCT was superior to RT (hazard ratio [HR], 0.7; 95% CI, 0.50-0.99; p = .045). Five-year OS from unadjusted Kaplan-Meier estimates was RCT 64% versus RT 45%. Additional RHT increased 5-year OS to 87% (HR, 0.32; 95% CI, 0.18-0.58; p = .0001). RCT + RHT compared with RCT showed a significantly better bladder-preservation rate (HR, 0.13; 95% CI, 0.03-0.56; p = .006). Median follow-up was 71 months. The median number of RHT sessions was five. CONCLUSION: The multimodal treatment consisted of a maximal TUR-BT followed by RT; concomitant platinum-based chemotherapy combined with RHT in patients with high-grade bladder cancer improves local control, bladder-preservation rate, and OS. It offers a promising alternative to surgical therapies like radical cystectomy. IMPLICATIONS FOR PRACTICE: Radical cystectomy with appropriate lymph node dissection has long represented the standard of care for muscle-invasive bladder cancer in medically fit patients, despite many centers reporting excellent long-term results for bladder preserving strategies. This retrospective analysis compares different therapeutic modalities in bladder-preservation therapy. The results of this study show that multimodal treatment consisting of maximal transurethral resection of bladder tumor followed by radiotherapy, concomitant platinum-based chemotherapy combined with regional deep hyperthermia in patients with Ta, Tis, T1-2 bladder carcinomas improves local control, bladder-preservation rate, and survival. More importantly, these findings offer a promising alternative to surgical therapies like radical cystectomy. The authors hope that, in the future, closer collaboration between urologists and radiotherapists will further improve treatments and therapies for the benefit of patients. CI - (c) 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. FAU - Merten, Ricarda AU - Merten R AD - Department of Radiation Oncology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany ricarda.merten@uk-erlangen.de. FAU - Ott, Oliver AU - Ott O AUID- ORCID: 0000-0001-5806-6158 AD - Department of Radiation Oncology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Haderlein, Marlen AU - Haderlein M AUID- ORCID: 0000-0002-7986-2169 AD - Department of Radiation Oncology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Bertz, Simone AU - Bertz S AUID- ORCID: 0000-0003-0458-7075 AD - Institute of Pathology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AUID- ORCID: 0000-0002-4860-4626 AD - Institute of Pathology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Wullich, Bernd AU - Wullich B AUID- ORCID: 0000-0002-0665-6604 AD - Department of Urology and Pediatric Urology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology and Pediatric Urology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Kuhn, Reinhard AU - Kuhn R AD - Department of Urology, Martha Maria Medical Center, Nuremberg, Germany. FAU - Rodel, Claus Michael AU - Rodel CM AUID- ORCID: 0000-0001-7409-7093 AD - Department of Radiotherapy and Oncology, Universitatsklinikum Frankfurt, Frankfurt, Germany. FAU - Weiss, Christian AU - Weiss C AD - Department of Radiation Oncology, Klinikum Darmstadt GmbH, Darmstadt, Germany. FAU - Gall, Christine AU - Gall C AUID- ORCID: 0000-0002-7727-796X AD - Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Uter, Wolfgang AU - Uter W AUID- ORCID: 0000-0002-4498-3710 AD - Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany. FAU - Fietkau, Rainer AU - Fietkau R AUID- ORCID: 0000-0001-8295-7145 AD - Department of Radiation Oncology, Universitatsklinikum Erlangen Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20190710 PL - England TA - Oncologist JT - The oncologist JID - 9607837 SB - IM CIN - Strahlenther Onkol. 2020 Jun;196(6):576-578. doi: 10.1007/s00066-020-01608-w. PMID: 32342117 MH - Adult MH - Aged MH - Aged, 80 and over MH - Chemoradiotherapy MH - Combined Modality Therapy MH - Female MH - Humans MH - Hyperthermia, Induced/*methods MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Organ Preservation/*methods MH - Randomized Controlled Trials as Topic MH - Retrospective Studies MH - Urinary Bladder Neoplasms/pathology/radiotherapy/*therapy PMC - PMC6975936 OTO - NOTNLM OT - Bladder cancer OT - Bladder preservation OT - Chemoradiotherapy OT - Hyperthermia OT - Radiotherapy COIS- Disclosures of potential conflicts of interest may be found at the end of this article. EDAT- 2019/07/12 06:00 MHDA- 2020/09/02 06:00 PMCR- 2019/07/10 CRDT- 2019/07/12 06:00 PHST- 2018/05/09 00:00 [received] PHST- 2019/02/11 00:00 [accepted] PHST- 2019/07/12 06:00 [pubmed] PHST- 2020/09/02 06:00 [medline] PHST- 2019/07/12 06:00 [entrez] PHST- 2019/07/10 00:00 [pmc-release] AID - theoncologist.2018-0280 [pii] AID - ONCO12952 [pii] AID - 10.1634/theoncologist.2018-0280 [doi] PST - ppublish SO - Oncologist. 2019 Dec;24(12):e1341-e1350. doi: 10.1634/theoncologist.2018-0280. Epub 2019 Jul 10. PMID- 31291718 OWN - NLM STAT- MEDLINE DCOM- 20200908 LR - 20220412 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 52 IP - 1 DP - 2020 Jan TI - Identification of Significant Prognostic Tissue Markers Associated with Survival in Upper Urinary Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy: A Retrospective Immunohistochemical Analysis Using Tissue Microarray. PG - 128-138 LID - 10.4143/crt.2019.119 [doi] AB - PURPOSE: The purpose of this study was to identify prognostic tissue markers for several survival outcomes after radical nephroureterectomy among patients with upper urinary tract urothelial carcinoma using tissue microarray and immunohistochemistry. MATERIALS AND METHODS: Retrospectively, data of 162 non-metastatic patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy between 2004 and 2016 were reviewed to determine intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS). The expression of 27 tissue markers on a tissue microarray of radical nephroureterectomy samples and prognostic values of clinicopathological parameters were evaluated using immunohistochemistry and Cox proportional hazard models after adjusting for significant prognostic clinicopathological variables. The expression of all tissue markers was categorized into a binary group with continuous H-scores (0-300). RESULTS: Median follow-up was 53.4 months (range, 3.6 to 176.5 months); and, 58 (35.8%), 48 (29.6%), and 19 (11.7%) bladder recurrence, disease progression, and all cause death, respectively, were identified. After adjusting for significant clinicopathological factors including intravesical instillation for bladder recurrence-free survival, pathologic T category and intravesical instillation for disease progression-free survival , and pathologic T category for OS (p < 0.05), IVRFS was associated with epithelial cadherin (hazard ratio [HR], 0.49), epidermal growth factor receptor/erythroblastosis oncogene B (c-erb) (HR, 2.59), and retinoblastoma protein loss (HR, 1.85); DFS was associated with cyclin D1 (HR, 2.16) and high-molecular-weight cytokeratin (HR, 0.42); OS was associated with E-cadherin (HR, 0.34) and programmed cell death 1 ligand (HR, 13.42) (p < 0.05). CONCLUSION: Several significant tissue markers were associated with survival outcomes in upper urinary tract urothelial carcinoma patients treated with radical nephroureterectomy. FAU - Kim, Sung Han AU - Kim SH AD - Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea. FAU - Park, Weon Seo AU - Park WS AD - Department of Pathology, Hospital of National Cancer Center, Goyang, Korea. FAU - Park, Boram AU - Park B AD - Biostatistics Collaboration Unit, Research Institute of National Cancer Center, Goyang, Korea. FAU - Chung, Jinsoo AU - Chung J AD - Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea. FAU - Joung, Jae Young AU - Joung JY AD - Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea. FAU - Lee, Kang Hyun AU - Lee KH AD - Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea. LA - eng GR - 1613231/National Cancer Center/Republic of Korea GR - 1810242-1/National Cancer Center/Republic of Korea PT - Journal Article DEP - 20190619 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - 0 (Biomarkers) SB - IM MH - Aged MH - *Biomarkers MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Nephroureterectomy/adverse effects/methods MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Tissue Array Analysis MH - Treatment Outcome MH - Urologic Neoplasms/*diagnosis/mortality/*surgery PMC - PMC6962485 OTO - NOTNLM OT - Microarray OT - Nephroureterectomy OT - Prognosis OT - Risk factor OT - Tissue marker COIS- Conflict of interest relevant to this article was not reported. EDAT- 2019/07/12 06:00 MHDA- 2020/09/09 06:00 PMCR- 2020/01/01 CRDT- 2019/07/12 06:00 PHST- 2019/03/01 00:00 [received] PHST- 2019/06/17 00:00 [accepted] PHST- 2019/07/12 06:00 [pubmed] PHST- 2020/09/09 06:00 [medline] PHST- 2019/07/12 06:00 [entrez] PHST- 2020/01/01 00:00 [pmc-release] AID - crt.2019.119 [pii] AID - crt-2019-119 [pii] AID - 10.4143/crt.2019.119 [doi] PST - ppublish SO - Cancer Res Treat. 2020 Jan;52(1):128-138. doi: 10.4143/crt.2019.119. Epub 2019 Jun 19. PMID- 31286493 OWN - NLM STAT- MEDLINE DCOM- 20200206 LR - 20200206 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 146 IP - 1 DP - 2020 Jan 1 TI - Proteome-based classification of Nonmuscle Invasive Bladder Cancer. PG - 281-294 LID - 10.1002/ijc.32556 [doi] AB - DNA/RNA-based classification of bladder cancer (BC) supports the existence of multiple molecular subtypes, while investigations at the protein level are scarce. Here, we aimed to investigate if Nonmuscle Invasive Bladder Cancer (NMIBC) can be stratified to biologically meaningful groups based on the proteome. Tissue specimens from 117 patients at primary diagnosis (98 with NMIBC and 19 with MIBC), were processed for high-resolution proteomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proteomics output was subjected to unsupervised consensus clustering, principal component analysis (PCA) and investigation of subtype-specific features, pathways, and gene sets. NMIBC patients were optimally stratified to three NMIBC proteomic subtypes (NPS), differing in size, clinicopathologic and molecular backgrounds: NPS1 (mostly high stage/grade/risk samples) was the smallest in size (17/98) and overexpressed proteins reflective of an immune/inflammatory phenotype, involved in cell proliferation, unfolded protein response and DNA damage response, whereas NPS2 (mixed stage/grade/risk composition) presented with an infiltrated/mesenchymal profile. NPS3 was rich in luminal/differentiation markers, in line with its pathological composition (mostly low stage/grade/risk samples). PCA revealed a close proximity of NPS1 and conversely, remoteness of NPS3 to the proteome of MIBC. Proteins distinguishing these two extreme subtypes were also found to consistently differ at the mRNA levels between high and low-risk subtypes of the UROMOL and LUND cohorts. Collectively, our study identifies three proteomic NMIBC subtypes and following a cross-omics validation in two independent cohorts, shortlists molecular features meriting further investigation for their biomarker or potentially therapeutic value. CI - (c) 2019 UICC. FAU - Stroggilos, Rafael AU - Stroggilos R AUID- ORCID: 0000-0003-4068-9167 AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. FAU - Mokou, Marika AU - Mokou M AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. FAU - Latosinska, Agnieszka AU - Latosinska A AD - Mosaiques Diagnostics GmbH, Hannover, Germany. FAU - Makridakis, Manousos AU - Makridakis M AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. FAU - Lygirou, Vasiliki AU - Lygirou V AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. FAU - Mavrogeorgis, Emmanouil AU - Mavrogeorgis E AD - Department of Biotechnology, Agricultural University of Athens, Athens, Greece. FAU - Drekolias, Dimitrios AU - Drekolias D AD - Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Frantzi, Maria AU - Frantzi M AD - Mosaiques Diagnostics GmbH, Hannover, Germany. FAU - Mullen, William AU - Mullen W AD - British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. FAU - Fragkoulis, Charalampos AU - Fragkoulis C AD - Department of Urology, General Hospital of Athens 'Georgios Gennimatas', Athens, Greece. FAU - Stasinopoulos, Konstantinos AU - Stasinopoulos K AD - Department of Urology, General Hospital of Athens 'Georgios Gennimatas', Athens, Greece. FAU - Papadopoulos, Georgios AU - Papadopoulos G AD - Department of Urology, General Hospital of Athens 'Georgios Gennimatas', Athens, Greece. FAU - Stathouros, Georgios AU - Stathouros G AD - Department of Urology, General Hospital of Athens 'Georgios Gennimatas', Athens, Greece. FAU - Lazaris, Andreas C AU - Lazaris AC AD - Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Makrythanasis, Periklis AU - Makrythanasis P AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. AD - Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland. FAU - Ntoumas, Konstantinos AU - Ntoumas K AD - Department of Urology, General Hospital of Athens 'Georgios Gennimatas', Athens, Greece. FAU - Mischak, Harald AU - Mischak H AD - Mosaiques Diagnostics GmbH, Hannover, Germany. AD - British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. FAU - Zoidakis, Jerome AU - Zoidakis J AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. FAU - Vlahou, Antonia AU - Vlahou A AD - Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190726 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Biomarkers, Tumor) RN - 0 (Proteome) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Biomarkers, Tumor/metabolism MH - Chromatography, Liquid/methods MH - Disease Progression MH - Female MH - Humans MH - Inflammation/metabolism/pathology MH - Kaplan-Meier Estimate MH - Male MH - Phenotype MH - Prognosis MH - Proteome/*metabolism MH - Proteomics/methods MH - RNA, Messenger/metabolism MH - Tandem Mass Spectrometry/methods MH - Urinary Bladder Neoplasms/*metabolism/pathology OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - classification OT - proteomics OT - subtype EDAT- 2019/07/10 06:00 MHDA- 2020/02/07 06:00 CRDT- 2019/07/10 06:00 PHST- 2019/02/15 00:00 [received] PHST- 2019/06/17 00:00 [accepted] PHST- 2019/07/10 06:00 [pubmed] PHST- 2020/02/07 06:00 [medline] PHST- 2019/07/10 06:00 [entrez] AID - 10.1002/ijc.32556 [doi] PST - ppublish SO - Int J Cancer. 2020 Jan 1;146(1):281-294. doi: 10.1002/ijc.32556. Epub 2019 Jul 26. PMID- 31285945 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240718 IS - 2156-6976 (Print) IS - 2156-6976 (Electronic) IS - 2156-6976 (Linking) VI - 9 IP - 6 DP - 2019 TI - Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer. PG - 1104-1117 AB - The "gold standard" diagnostic procedure for bladder cancer is cystoscopy, a technique that can be invasive, expensive, and a possible cause of urinary tract infection. Unlike techniques such as histology, PCR, and staining, assays for protein biomarkers lend themselves well to the creation of efficient point-of-care tests, which are easy to use and yield fast results. A couple of urine-based tests have been approved by the U.S. FDA, but these tests suffer from low sensitivity. Hence, there is clearly a need for more reliable non-invasive biomarkers of bladder cancer. Urinary biomarkers are particularly attractive due to the direct contact of the urine with the urothelial tumor and the ease of sample collection. With these considerations, this review aims to provide a comprehensive listing of the most promising protein biomarkers of bladder cancer in urine. Biomarkers are organized by their potential role in detection, surveillance, or monitoring of treatment response. The purpose of this review is to assess progress towards the goal of identifying ideal urinary proteins for use in each of the above three biomarker applications in bladder cancer. FAU - Chakraborty, Ashish AU - Chakraborty A AD - Department of Biomedical Engineering, University of Houston Houston, TX, USA. FAU - Dasari, Shobha AU - Dasari S AD - Department of Biomedical Engineering, University of Houston Houston, TX, USA. FAU - Long, Wang AU - Long W AD - Department of Urology, Xiangya Hospital, Central South University Changsha 410008, Hunan, China. FAU - Mohan, Chandra AU - Mohan C AD - Department of Biomedical Engineering, University of Houston Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20190601 PL - United States TA - Am J Cancer Res JT - American journal of cancer research JID - 101549944 PMC - PMC6610049 OTO - NOTNLM OT - NMIBC OT - NMP22 test OT - Point-of-care tests OT - proteomics OT - tumor recurrence COIS- None. EDAT- 2019/07/10 06:00 MHDA- 2019/07/10 06:01 PMCR- 2019/06/01 CRDT- 2019/07/10 06:00 PHST- 2019/05/21 00:00 [received] PHST- 2019/05/29 00:00 [accepted] PHST- 2019/07/10 06:00 [entrez] PHST- 2019/07/10 06:00 [pubmed] PHST- 2019/07/10 06:01 [medline] PHST- 2019/06/01 00:00 [pmc-release] PST - epublish SO - Am J Cancer Res. 2019 Jun 1;9(6):1104-1117. eCollection 2019. PMID- 31277774 OWN - NLM STAT- MEDLINE DCOM- 20200529 LR - 20200529 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 2 IP - 4 DP - 2019 Jul TI - Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer. PG - 381-389 LID - S2588-9311(18)30139-1 [pii] LID - 10.1016/j.euo.2018.08.020 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) causes a considerable health burden due to the high recurrence and progression rates. Past studies have identified multiple candidate loci associated with NMIBC prognosis, albeit lacking validation. Moreover, scarce reports exist on genetic susceptibility to independent prognostic predictors of NMIBC, such as stage or grade. OBJECTIVE: To investigate genetic associations with NMIBC tumour and patient characteristics at the time of diagnosis. DESIGN, SETTING, AND PARTICIPANTS: A sample of 653 NMIBC cases comes from the Bladder Cancer Prognosis Programme. Replication of the significant findings was conducted in the Nijmegen Bladder Cancer Study cohort (N=1470). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A genome-wide association study (GWAS) was carried out for outcomes of tumour size (as a continuous variable in centimetres), stage (Tis and T1 vs Ta), grade (G3 vs G2 and G1), and age (as continuous [years] and dichotomous [70.2 yr as a cut-off] variables). RESULTS AND LIMITATIONS: Significant (p<5E-08) associations (N=61) with tumour size, stage, grade, and age were identified in the GWAS discovery stage. None of the variants were independently significantly associated in the replication cohort. A meta-analysis of both cohorts suggests that rs180940944 (13q13.3 locus, NBEA) was associated with tumour size as a continuous variable (ss=0.9cm, p=2.92E-09). However, other single nucleotide polymorphisms in this region did not show evidence of association in the meta-analysis. CONCLUSIONS: Our study suggests that rs180940944 (NBEA) is associated with an increased NMIBC tumour size at the time of diagnosis. Given study limitations, further replication is essential to validate the finding. PATIENT SUMMARY: The current study reports on a genome-wide association study on non-muscle-invasive bladder cancer tumour and patient characteristics. We suggest that NBEA gene might be associated with increased tumour size at the time of diagnosis. The result must be replicated to establish validity. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Lipunova, Nadezda AU - Lipunova N AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Complex Genetics, Maastricht University, The Netherlands; Centre for Computational Biology, University of Birmingham, UK. Electronic address: nxl689@student.bham.ac.uk. FAU - Wesselius, Anke AU - Wesselius A AD - Department of Complex Genetics, Maastricht University, The Netherlands. FAU - Cheng, Kar K AU - Cheng KK AD - Institute for Applied Health Research, University of Birmingham, UK. FAU - van Schooten, Frederik-Jan AU - van Schooten FJ AD - Department of Pharmacology and Toxicology, Maastricht University, The Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Cazier, Jean-Baptiste AU - Cazier JB AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, UK. FAU - Galesloot, Tessel E AU - Galesloot TE AD - Radboud University Medical Center, Radboud Institute for Health Sciences, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Radboud University Medical Center, Radboud Institute for Health Sciences, The Netherlands. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Complex Genetics, Maastricht University, The Netherlands. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20180915 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Carrier Proteins) RN - 0 (NBEA protein, human) RN - 0 (Nerve Tissue Proteins) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Carrier Proteins/*genetics MH - Female MH - Genome-Wide Association Study MH - Genotype MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Nerve Tissue Proteins/*genetics MH - Polymorphism, Single Nucleotide MH - Tumor Burden MH - Urinary Bladder Neoplasms/diagnosis/*genetics/*pathology OTO - NOTNLM OT - Age OT - Genome-wide association study OT - Grade OT - Non-muscle-invasive bladder cancer OT - Size OT - Stage EDAT- 2019/07/07 06:00 MHDA- 2020/05/30 06:00 CRDT- 2019/07/07 06:00 PHST- 2018/06/25 00:00 [received] PHST- 2018/08/16 00:00 [revised] PHST- 2018/08/23 00:00 [accepted] PHST- 2019/07/07 06:00 [entrez] PHST- 2019/07/07 06:00 [pubmed] PHST- 2020/05/30 06:00 [medline] AID - S2588-9311(18)30139-1 [pii] AID - 10.1016/j.euo.2018.08.020 [doi] PST - ppublish SO - Eur Urol Oncol. 2019 Jul;2(4):381-389. doi: 10.1016/j.euo.2018.08.020. Epub 2018 Sep 15. PMID- 31277459 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 11 IP - 7 DP - 2019 Jul 4 TI - BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine. LID - 10.3390/cancers11070940 [doi] LID - 940 AB - Background: Intra-vesical instillation of Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, is an effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% of patients free of relapse after three years. Because non-responder patients usually have a bad prognosis, the early identification of treatment failure is crucial. We hypothesized that, if an effective immune response was taking place in the bladder, soluble factors would be released to the urine many days after BCG instillations. Methods: An extensive panel of cytokines and chemokines released into the urine seven days after every BCG instillation was screened in a cohort of NMIBC patients over three years. Results: The determinations of the urinary concentrations of cytokines, chemokines, and creatinine showed that increasing concentrations of C-X-C motif chemokine 10 (CXCL10) also known as interferon-inducible protein 10 (IP10) could be detected during the six-week induction cycle of BCG-treated patients released into the urine by CD14(+) cells. In vitro, CXCL10 facilitated the recruitment of effector immune cells after the BCG-mediated upregulation of CXCR3 in both T- and natural killer (NK)-cells. Conclusions: The high concentrations of chemokine detected one week after the encounter with mycobacteria suggest that the CXCL10 axis might be related to the intensity of the immune anti-tumor response. FAU - Ashiru, Omodele AU - Ashiru O AD - Division of Bacteriology, Medicines and Healthcare products Regulatory Agency-National Institute for Biological Standards and Control (MHRA-NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. FAU - Esteso, Gloria AU - Esteso G AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. AD - Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain. FAU - Garcia-Cuesta, Eva M AU - Garcia-Cuesta EM AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. FAU - Castellano, Eva AU - Castellano E AUID- ORCID: 0000-0003-0858-914X AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. AD - Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain. FAU - Samba, Celia AU - Samba C AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. FAU - Escudero-Lopez, Eva AU - Escudero-Lopez E AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. FAU - Lopez-Cobo, Sheila AU - Lopez-Cobo S AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. FAU - Alvarez-Maestro, Mario AU - Alvarez-Maestro M AUID- ORCID: 0000-0003-0705-7643 AD - Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain. AD - Urology Unit, Infanta Sofia Hospital, 28703 Madrid, Spain. AD - Servicio de Urologia, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain. FAU - Linares, Ana AU - Linares A AD - Urology Unit, Infanta Sofia Hospital, 28703 Madrid, Spain. FAU - Ho, Mei M AU - Ho MM AD - Division of Bacteriology, Medicines and Healthcare products Regulatory Agency-National Institute for Biological Standards and Control (MHRA-NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. FAU - Leibar, Asier AU - Leibar A AD - Urology Unit, Infanta Sofia Hospital, 28703 Madrid, Spain. FAU - Martinez-Pineiro, Luis AU - Martinez-Pineiro L AD - Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain. AD - Urology Unit, Infanta Sofia Hospital, 28703 Madrid, Spain. AD - Servicio de Urologia, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain. FAU - Vales-Gomez, Mar AU - Vales-Gomez M AUID- ORCID: 0000-0001-7424-3206 AD - Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council, 28049 Madrid, Spain. mvales@cnb.csic.es. LA - eng GR - S2010/BMD-2326/Consejeria de Educacion, Juventud y Deporte, Comunidad de Madrid/ GR - SAF2015-69169-R, RTC-2017-6379-1 (MINECO/FEDER/Ministerio de Economia, Industria y Competitividad, Gobierno de Espana/ PT - Journal Article DEP - 20190704 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC6678801 OTO - NOTNLM OT - BCG OT - NMIBC OT - biomarker OT - chemokines OT - cytokines COIS- The authors declare no conflict of interest. EDAT- 2019/07/07 06:00 MHDA- 2019/07/07 06:01 PMCR- 2019/07/04 CRDT- 2019/07/07 06:00 PHST- 2019/06/07 00:00 [received] PHST- 2019/06/26 00:00 [revised] PHST- 2019/06/28 00:00 [accepted] PHST- 2019/07/07 06:00 [entrez] PHST- 2019/07/07 06:00 [pubmed] PHST- 2019/07/07 06:01 [medline] PHST- 2019/07/04 00:00 [pmc-release] AID - cancers11070940 [pii] AID - cancers-11-00940 [pii] AID - 10.3390/cancers11070940 [doi] PST - epublish SO - Cancers (Basel). 2019 Jul 4;11(7):940. doi: 10.3390/cancers11070940. PMID- 31277094 OWN - NLM STAT- MEDLINE DCOM- 20190715 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 27 DP - 2019 Jul TI - IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype. PG - e16009 LID - 10.1097/MD.0000000000016009 [doi] LID - e16009 AB - Bladder cancer is one of the most common malignancies of urinary tract. The current study aimed to investigate the role of insulin-like growth factor II messenger RNA binding protein 3 (IMP3) expression in the prognostic evaluation of non-muscle- invasive urothelial carcinoma of the bladder.Immunohistochemistry (IHC) was carried out to examine IMP3 protein expression in specimens from 183 cases of non-muscle-invasive urothelial carcinoma, 20 cases of muscle-invasive urothelial carcinoma and 20 benign tissues adjacent to cancer tissue.The expression of IMP3 was not detected in the adjacent benign tissues. The expression intensity of IMP3 in muscle-invasive samples was significantly higher than that in non-muscle-invasive urothelial carcinoma specimens (P = .008). IMP3 expression was significantly related with advanced tumor stage (P < .001), advanced tumor grade (P = .004), and tumor recurrence (P < .001) in non-muscle-invasive urothelial carcinomas. Kaplan-Meier analysis showed that IMP3-positive patients had much lower disease-free (P < .001), progression-free (P = .002) and metastasis-free (P = .019) survival rates compared with those with IMP3-negative tumors. By multivariable Cox analysis, we also found that IMP3 expression in non-muscle- invasive urothelial carcinomas proved to be an independent unfavorable prognostic factor of disease-free survival (HR: 2.52; 95% CI, 1.39-4.56; P = .002), progression- free survival (HR: 5.19; 95% CI, 1.54-17.46; P = .008) and metastasis-free survival (HR: 4.87; 95% CI, 1.08-22.02; P = .040).Our results demonstrate that the expression of IMP3 in non-muscle- invasive bladder cancer can serve as an independent predictor that will help recognize the subgroup of patients with a high ability to relapse, progress, and metastasize and who might get the maximum benefit from an early and more aggressive treatment strategy. FAU - Yang, Feiya AU - Yang F AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. FAU - Zhou, Qiang AU - Zhou Q AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan. AD - Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing. FAU - Meng, Lingquan AU - Meng L AD - Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing. AD - Department of Urology, Qianfoshan Hospital, Shandong University, Jinan, PR China. FAU - Xing, Nianzeng AU - Xing N AD - Department of Urology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. AD - Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Biomarkers, Tumor) RN - 0 (IGF2BP3 protein, human) RN - 0 (RNA-Binding Proteins) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Carcinoma, Transitional Cell/*genetics/mortality/pathology MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/genetics/pathology MH - Proportional Hazards Models MH - RNA-Binding Proteins/*genetics/metabolism MH - Urinary Bladder Neoplasms/*genetics/mortality/pathology MH - Urothelium/pathology PMC - PMC6635297 COIS- The authors declare that they have no competing interests. And the abstract of this paper has been presented as poster in "COLD SPRING HARBOR ASIA CONFERENCES", however, it also has no conflict of interest regarding the publication of this paper. EDAT- 2019/07/07 06:00 MHDA- 2019/07/16 06:00 PMCR- 2019/07/05 CRDT- 2019/07/07 06:00 PHST- 2019/07/07 06:00 [entrez] PHST- 2019/07/07 06:00 [pubmed] PHST- 2019/07/16 06:00 [medline] PHST- 2019/07/05 00:00 [pmc-release] AID - 00005792-201907050-00009 [pii] AID - MD-D-19-00579 [pii] AID - 10.1097/MD.0000000000016009 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Jul;98(27):e16009. doi: 10.1097/MD.0000000000016009. PMID- 31272800 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20210518 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 43 IP - 9 DP - 2019 Nov TI - The 1973 WHO and 2004 WHO grading systems are not equal in prediction of survival among stage T1 bladder cancer patients. PG - 467-473 LID - S0210-4806(19)30100-7 [pii] LID - 10.1016/j.acuro.2019.03.011 [doi] AB - INTRODUCTION AND OBJECTIVES: The aim of this study was to analyse prognostic impact of tumour histological grade on survival differences between primary G2 and G3 WHO1973 stage T1 tumours which were graded as HG according to WHO2004 grading system. MATERIALS AND METHODS: Data from 481 patients with primary T1HG bladder cancer who were treated between 1986 and 2016 in 2university centres were retrospectively reviewed. Log-rank test and Cox regression analysis was performed to compare the groups. RESULTS: 95 (19,8%) tumours were classified as G2 and 386 (80,2%) were G3. Median follow-up was 68 months. The recurrence was observed in 228 (47,5%), and progression in 109 patients (22,7%). Radical cystectomy was performed in 114 pts (23,7%) and there were 64 (13,3%) cancer specific deaths. Recurrence-free rates at 5-years follow-up for G2, G3 and all patients were 68,7%, 51,2% and 56,3% and progression-free rates were 89,3%, 73,2% and 78,1% respectively. For total observation period patients with G3 tumours presented also worse recurrence-free, and progression-free survival levels than patients with G2 tumours. In multivariate analysis, after adjustment for clinical features, the risk of recurrence and progression for G3 tumours was 1,65 and 2,42 fold higher than for G2 tumours. CONCLUSIONS: It was shown that G3 T1 tumours are characterized by worse recurrence free and progression free survivals when compared to G2 cancers. CI - Copyright (c) 2019 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Krajewski, W AU - Krajewski W AD - Departamento de Oncologia y Urologia Oncologica, Universidad Medica de Breslavia, Breslavia, Polonia. FAU - Rodriguez-Faba, O AU - Rodriguez-Faba O AD - Departamento de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. Electronic address: ORODRIGUEZ@fundacio-puigvert.es. FAU - Breda, A AU - Breda A AD - Departamento de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Pisano, F AU - Pisano F AD - Departamento de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Poletajew, S AU - Poletajew S AD - Departamento de Oncologia y Urologia Funcional, Universidad Medica de Varsovia, Varsovia, Polonia. FAU - Tukiendorf, A AU - Tukiendorf A AD - Departamento de Medicina Social, Universidad Medica de Breslavia, Breslavia, Polonia. FAU - Algaba, F AU - Algaba F AD - Departamento de Patologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Zdrojowy, R AU - Zdrojowy R AD - Departamento de Oncologia y Urologia Oncologica, Universidad Medica de Breslavia, Breslavia, Polonia. FAU - Kolodziej, A AU - Kolodziej A AD - Departamento de Oncologia y Urologia Oncologica, Universidad Medica de Breslavia, Breslavia, Polonia. FAU - Palou, J AU - Palou J AD - Departamento de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. LA - eng LA - spa PT - Comparative Study PT - Journal Article PT - Multicenter Study TT - Los sistemas de clasificacion de la OMS de 1973 y 2004 difieren en la prediccion de supervivencia entre los pacientes con cancer de vejiga en estadio T1. DEP - 20190702 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading/methods MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery MH - World Health Organization OTO - NOTNLM OT - Bladder cancer OT - Cancer de vejiga OT - Grade OT - Grado OT - Progresion OT - Progression OT - Recurrence OT - Recurrencia EDAT- 2019/07/06 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/07/06 06:00 PHST- 2019/02/13 00:00 [received] PHST- 2019/03/04 00:00 [revised] PHST- 2019/03/19 00:00 [accepted] PHST- 2019/07/06 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/07/06 06:00 [entrez] AID - S0210-4806(19)30100-7 [pii] AID - 10.1016/j.acuro.2019.03.011 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2019 Nov;43(9):467-473. doi: 10.1016/j.acuro.2019.03.011. Epub 2019 Jul 2. PMID- 31261883 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 11 IP - 7 DP - 2019 Jun 29 TI - Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer. LID - 10.3390/cancers11070914 [doi] LID - 914 AB - Patients with non-muscle invasive bladder cancer (NMIBC) undergo lifelong monitoring based on repeated cystoscopy and urinary cytology due to the high recurrence rate of this tumor. Nevertheless, these techniques have some drawbacks, namely, low accuracy in detection of low-grade tumors, omission of pre-neoplastic lesions and carcinomas in situ (CIS), invasiveness, and high costs. This work aims to identify a urinary metabolomic signature of recurrence by proton Nuclear Magnetic Resonance ((1)H NMR) spectroscopy for the follow-up of NMIBC patients. To do this, changes in the urinary metabolome before and after transurethral resection (TUR) of tumors are analyzed and a Partial Least Square Discriminant Analysis (PLS-DA) model is developed. The usefulness of this discriminant model for the detection of tumor recurrences is assessed using a cohort of patients undergoing monitoring. The trajectories of the metabolomic profile in the follow-up period provide a negative predictive value of 92.7% in the sample classification. Pathway analyses show taurine, alanine, aspartate, glutamate, and phenylalanine perturbed metabolism associated with NMIBC. These results highlight the potential of (1)H NMR metabolomics to detect bladder cancer (BC) recurrences through a non-invasive approach. FAU - Loras, Alba AU - Loras A AUID- ORCID: 0000-0003-1426-1765 AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe, 46026 Valencia, Spain. FAU - Martinez-Bisbal, M Carmen AU - Martinez-Bisbal MC AUID- ORCID: 0000-0002-8526-4413 AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe, 46026 Valencia, Spain. mamarbis@upvnet.upv.es. AD - Instituto Interuniversitario de Investigacion de Reconocimiento Molecular y Desarrollo Tecnologico, Universitat Politecnica de Valencia, Universitat de Valencia, 46022 Valencia, Spain. mamarbis@upvnet.upv.es. AD - CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain. mamarbis@upvnet.upv.es. AD - Departamento de Quimica Fisica, Facultad de Quimicas, Universitat de Valencia, 46100 Burjassot, Spain. mamarbis@upvnet.upv.es. FAU - Quintas, Guillermo AU - Quintas G AD - Analytical Unit, Instituto de Investigacion Sanitaria La Fe, 46026 Valencia, Spain. gquintas@leitat.org. AD - Health & Biomedicine, Leitat Technological Center, 08225 Terrassa, Spain. gquintas@leitat.org. FAU - Gil, Salvador AU - Gil S AUID- ORCID: 0000-0002-2818-1320 AD - Instituto Interuniversitario de Investigacion de Reconocimiento Molecular y Desarrollo Tecnologico, Universitat Politecnica de Valencia, Universitat de Valencia, 46022 Valencia, Spain. AD - CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain. AD - Departamento de Quimica Organica, Facultad de Quimicas, Universitat de Valencia, 46100 Burjassot, Spain. FAU - Martinez-Manez, Ramon AU - Martinez-Manez R AUID- ORCID: 0000-0001-5873-9674 AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe, 46026 Valencia, Spain. AD - Instituto Interuniversitario de Investigacion de Reconocimiento Molecular y Desarrollo Tecnologico, Universitat Politecnica de Valencia, Universitat de Valencia, 46022 Valencia, Spain. AD - CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain. AD - Departamento de Quimica, Universitat Politecnica de Valencia, 46022 Valencia, Spain. AD - Unidad Mixta UPV-CIPF de Investigacion en Mecanismos de Enfermedades y Nanomedicina, Universitat Politecnica de Valencia, Centro de Investigacion Principe Felipe, 46012 Valencia, Spain. FAU - Ruiz-Cerda, Jose Luis AU - Ruiz-Cerda JL AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe, 46026 Valencia, Spain. AD - Servicio de Urologia, Hospital Universitario y Politecnico La Fe, 46026 Valencia, Spain. AD - Departamento de Cirugia, Facultad de Medicina y Odontologia, Universitat de Valencia, 46010 Valencia, Spain. LA - eng GR - MAT2015-64139-C4-1-R/Ministerio de Economia y Competitividad/ GR - MAT2015-64139-C4-2-R/Ministerio de Economia y Competitividad/ GR - RTI2018-100910-B-C41/Ministerio de Economia y Competitividad/ GR - RTI2018-100910-B-C43 (MCUI/AEI/FEDER, UE)/Ministerio de Economia y Competitividad/ GR - RETICRD12/0036/0009/Instituto de Salud Carlos III/ GR - CTQ2016-79561-P/Instituto de Salud Carlos III/ GR - PROMETEO II/2014/047/Conselleria d'Educacio, Investigacio, Cultura i Esport/ GR - PROMETEO 2018/024/Conselleria d'Educacio, Investigacio, Cultura i Esport/ PT - Journal Article DEP - 20190629 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC6678457 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - metabolic pathways OT - metabolite OT - metabolomics OT - nuclear magnetic resonance OT - recurrence prediction COIS- The authors declare no conflict of interest. EDAT- 2019/07/03 06:00 MHDA- 2019/07/03 06:01 PMCR- 2019/06/29 CRDT- 2019/07/03 06:00 PHST- 2019/05/27 00:00 [received] PHST- 2019/06/19 00:00 [revised] PHST- 2019/06/27 00:00 [accepted] PHST- 2019/07/03 06:00 [entrez] PHST- 2019/07/03 06:00 [pubmed] PHST- 2019/07/03 06:01 [medline] PHST- 2019/06/29 00:00 [pmc-release] AID - cancers11070914 [pii] AID - cancers-11-00914 [pii] AID - 10.3390/cancers11070914 [doi] PST - epublish SO - Cancers (Basel). 2019 Jun 29;11(7):914. doi: 10.3390/cancers11070914. PMID- 31255543 OWN - NLM STAT- MEDLINE DCOM- 20200915 LR - 20200915 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. PG - 774-783 LID - S1078-1439(19)30219-4 [pii] LID - 10.1016/j.urolonc.2019.05.019 [doi] AB - OBJECTIVES: To assess the role of the urokinase plasminogen activator (uPA) system as a prognostic biomarker in patients with nonmuscle invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB) with or without adjuvant intravesical therapy. MATERIAL AND METHODS: We stained TURB tissue from 827 NMIBC patients with uPA, its receptor (uPAR) and its inhibitor (PAI-1). The status of these markers was categorized as normal vs. overexpressed using the cutoffs of 30% for uPA, 50% for uPAR, and 30% for PAI-1. Multivariable Cox regression analyses were performed to evaluate the prognostic value of these markers. RESULTS: uPA was overexpressed in 37.7% of patients, uPAR in 44.7% and PAI-1 in 44.6%. Overexpression of these markers was associated with high tumor grade. Within a median follow-up was 60 months (interquartile range: 22-109), uPA (hazard ratio [HR]: 1.40; P = 0.006), uPAR (HR: 1.70; P < 0.001), PAI-1 (HR: 1.35; P = 0.014), and the combination of all 3 markers (HR: 3.38; P < 0.001) were associated with recurrence-free survival (RFS); uPA (HR: 1.68; P = 0.035) and the combination of all 3 markers (HR: 8.79; P = 0.005) were associated with progression-free survival (PFS). The addition of the uPA system to a base model improved the discrimination by 1.3% for RFS and 2.1% for PFS. In subgroup analyses, uPA (HR: 2.19; P = 0.018) was associated with PFS in T1G3 patients and its addition to a base model improved the discrimination by 2.5%. uPA (HR: 1.44; P = 0.019), uPAR (HR: 1.54; P = 0.006), PAI-1 (HR: 1.46; P = 0.013) and the combination of all 3 markers (HR: 3.48; P < 0.001) were associated with RFS in TaG1-2 patients and their addition to a base model improved the discrimination by 2.1%. CONCLUSION: uPA, uPAR, and PAI-1 are overexpressed in one-third to half of patients with NMIBC. Their overexpression is an independent prognosticator of RFS and PFS which improved the predictive accuracy of current clinicopathological characteristics. Biomarkers that capture the biological and clinical behavior of individual tumors may help personalize clinical decision-making in patients with NMIBC. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Iwata, Takehiro AU - Iwata T AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Janisch, Florian AU - Janisch F AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Parizi, Mehdi Kardoust AU - Parizi MK AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Teheran, Iran. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Rink, Micheal AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Sorbonne Universite, Paris, France. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Seebacher, Veronica AU - Seebacher V AD - Department for Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. FAU - Enikeev, Dmitry AU - Enikeev D AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Rapoport, Leonid M AU - Rapoport LM AD - Department of Urology, Weill Cornell Medical College, New York, NY. FAU - Nasu, Yasutomo AU - Nasu Y AD - Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190627 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator) SB - IM MH - Aged MH - Female MH - Humans MH - Immunohistochemistry/*methods MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*genetics MH - Urokinase-Type Plasminogen Activator/*metabolism OTO - NOTNLM OT - Nonmuscle invasive bladder cancer OT - Progression OT - Recurrence OT - Urokinase plasminogen activator EDAT- 2019/07/01 06:00 MHDA- 2020/09/17 06:00 CRDT- 2019/07/01 06:00 PHST- 2019/02/04 00:00 [received] PHST- 2019/05/12 00:00 [revised] PHST- 2019/05/29 00:00 [accepted] PHST- 2019/07/01 06:00 [pubmed] PHST- 2020/09/17 06:00 [medline] PHST- 2019/07/01 06:00 [entrez] AID - S1078-1439(19)30219-4 [pii] AID - 10.1016/j.urolonc.2019.05.019 [doi] PST - ppublish SO - Urol Oncol. 2019 Oct;37(10):774-783. doi: 10.1016/j.urolonc.2019.05.019. Epub 2019 Jun 27. PMID- 31255541 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 1 DP - 2020 Jan TI - Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. PG - 5.e9-5.e16 LID - S1078-1439(19)30218-2 [pii] LID - 10.1016/j.urolonc.2019.05.018 [doi] AB - PURPOSE: According to the 2016 American Urological Association (AUA) guidelines for nonmuscle invasive bladder cancer (NMIBC), clinicians should offer a 2nd intravesical induction course of Bacillus Calmette-Guerin (BCG) to patients with persistent or recurrent Ta or CIS disease after a 1st BCG induction course. However, evidence for a 2nd course is limited, and some patients forego a 2nd induction of BCG in favor of a clinical trial or alternate intravesical therapy. We sought to investigate contemporary oncologic outcomes of a 2nd induction course of BCG in a multi-institutional cohort. MATERIALS AND METHODS: Three hundred fifty-three patients who received full induction BCG for NMIBC since 2001 at 2 institutions were identified. Patients were categorized as receiving primary 6-week induction therapy or subsequent 2nd 6-week induction therapy for patients who recurred or persisted. The baseline differences in demographic and tumor characteristics were compared between the 2 groups, and Kaplan-Meier curves were constructed to assess high-grade recurrence free survival (HgRFS) among both groups. Univariable logistic regression was used to determine factors associated with recurrence after 2nd course BCG RESULTS: A total of 353 patients received 1st induction BCG (BCG1) and 116 patients received a 2nd induction course (BCG2). Maintenance therapy was given to 117 (33.1%) patients after BCG1 and 43 (37.1%) patients after BCG2. Both cohorts were similar in demographics including age, sex, and race. Pathologic stage before treatment differed as BCG1 patients were more likely to have T1 (40.8% vs. 25%) and less likely to have CIS (13.9% vs. 33.6%) (P < 0.001). Complete response (CR) 3 months after BCG1 was observed in 276 patients (78.2%) and 104 patients (89.7%) after BCG2. Responses remained durable, with 36-month CR of 54.7% in BCG1 and 65.6% in BCG2. Progression to MIBC was identified in 1.4% of BCG1 patients vs. 3.4% in BCG2 patients (P = 0.17). Pathologic stage before BCG2 does not predict progression to MIBC (P = 0.21) after BCG2. The time interval between the 1st and 2nd induction of BCG was not significantly associated with response to 2nd induction BCG (P = 0.47). Maintenance therapy after BCG2 was associated with decreased recurrence after 2nd induction course of BCG. CONCLUSION: A 2nd course of BCG is efficacious with a durable HgRFS, validating the recommendations of the 2016 AUA guidelines. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Daniels, Marcus J AU - Daniels MJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: mdanie56@jhmi.edu. FAU - Barry, Emily AU - Barry E AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY. FAU - Schoenberg, Mark AU - Schoenberg M AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY. FAU - Lamm, Donald L AU - Lamm DL AD - BCG Oncology, Phoenix, AZ. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Sankin, Alex AU - Sankin A AD - Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY. FAU - Kates, Max AU - Kates M AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. LA - eng PT - Journal Article DEP - 20190627 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/pharmacology/*therapeutic use MH - Aged MH - BCG Vaccine/pharmacology/*therapeutic use MH - Female MH - Humans MH - Male MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - BCG OT - Guidelines OT - Oncology OT - Outcomes EDAT- 2019/07/01 06:00 MHDA- 2021/04/28 06:00 CRDT- 2019/07/01 06:00 PHST- 2019/04/19 00:00 [received] PHST- 2019/05/20 00:00 [revised] PHST- 2019/05/29 00:00 [accepted] PHST- 2019/07/01 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2019/07/01 06:00 [entrez] AID - S1078-1439(19)30218-2 [pii] AID - 10.1016/j.urolonc.2019.05.018 [doi] PST - ppublish SO - Urol Oncol. 2020 Jan;38(1):5.e9-5.e16. doi: 10.1016/j.urolonc.2019.05.018. Epub 2019 Jun 27. PMID- 31252002 OWN - NLM STAT- MEDLINE DCOM- 20200115 LR - 20231020 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 132 DP - 2019 Oct TI - Compliance With American Urological Association Guidelines for Nonmuscle Invasive Bladder Cancer Remains Poor: Assessing Factors Associated With Noncompliance and Survival in a Rural State. PG - 150-155 LID - S0090-4295(19)30562-X [pii] LID - 10.1016/j.urology.2019.06.021 [doi] AB - OBJECTIVE: To identify factors associated with nonmuscle invasive bladder cancer (NMIBC) American Urological Association (AUA) guideline compliance in a rural state, to evaluate compliance rates over time, and to assess the impact of patient and provider rurality on delivery of NMIBC care. METHODS: We identified 847 Iowans in Surveillance, Epidemiology, and End Results-Medicare from 1992 to 2009 with high-grade NMIBC who survived 2 years and were not treated with cystectomy or radiation during this period. Compliance with AUA guidelines was assessed over time and compared to patient demographic, tumor, and treatment institution variables. Impact of rurality was analyzed using Surveillance, Epidemiology, and End Results ZIP code data travel distance of patient to nearest urologist practice location. RESULTS: Overall compliance with AUA guidelines was low (<1%), and did not markedly improve over the study period. In the multivariable model, only care at an academic medical center (OR 11.68, 95% CI 7.07-19.29) and tumor stage (Tis; OR 3.24, 95% CI 1.86-5.63) increased the odds of compliance. Patients living closer (<10 miles) to their urologists underwent more cystoscopies than patients living further (>30 miles) but distance did not affect compliance with other measures. Compliance was not associated with cancer-specific survival. CONCLUSION: Compliance with post-Transurethral Resection of Bladder Tumor (TURBT) NMIBC treatment guidelines has improved but remains suboptimal in our rural state, and is highly associated with treatment at an academic cancer center for reasons that could not be fully explained with these data. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Tobert, Conrad M AU - Tobert CM AD - University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA. FAU - Nepple, Kenneth G AU - Nepple KG AD - University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA; University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. FAU - McDowell, Bradley D AU - McDowell BD AD - University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. FAU - Charlton, Mary E AU - Charlton ME AD - University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. FAU - Mott, Sarah L AU - Mott SL AD - University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. FAU - Gruca, Thomas S AU - Gruca TS AD - University of Iowa, Tippie College of Business, Iowa City, IA. FAU - Quast, Laura AU - Quast L AD - University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA. FAU - Erickson, Bradley A AU - Erickson BA AD - University of Iowa Hospitals and Clinics, Department of Urology, Iowa City, IA. Electronic address: brad-erickson@uiowa.edu. LA - eng GR - P30 CA086862/CA/NCI NIH HHS/United States GR - T35 HL007485/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20190625 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Guideline Adherence/*statistics & numerical data MH - Humans MH - Iowa/epidemiology MH - Male MH - Neoplasm Invasiveness MH - Practice Guidelines as Topic MH - Retrospective Studies MH - Rural Health MH - Societies, Medical MH - Survival Rate MH - United States MH - Urinary Bladder Neoplasms/*mortality/pathology/*therapy MH - Urology PMC - PMC6916249 MID - NIHMS1060356 EDAT- 2019/06/30 06:00 MHDA- 2020/01/16 06:00 PMCR- 2019/12/17 CRDT- 2019/06/29 06:00 PHST- 2019/03/26 00:00 [received] PHST- 2019/05/31 00:00 [revised] PHST- 2019/06/17 00:00 [accepted] PHST- 2019/06/30 06:00 [pubmed] PHST- 2020/01/16 06:00 [medline] PHST- 2019/06/29 06:00 [entrez] PHST- 2019/12/17 00:00 [pmc-release] AID - S0090-4295(19)30562-X [pii] AID - 10.1016/j.urology.2019.06.021 [doi] PST - ppublish SO - Urology. 2019 Oct;132:150-155. doi: 10.1016/j.urology.2019.06.021. Epub 2019 Jun 25. PMID- 31240474 OWN - NLM STAT- MEDLINE DCOM- 20191112 LR - 20261011 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 475 IP - 4 DP - 2019 Oct TI - Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. PG - 445-455 LID - 10.1007/s00428-019-02593-x [doi] AB - Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Each subtype may react differently to current chemotherapy or immunotherapy. Likewise, the technology required for comprehensive molecular analysis is expensive and not yet applicable for routine clinical diagnostics. Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6-) and basal (CK5/6+, CK20-), is sufficient to identify the molecular subtypes of bladder cancer. This would represent a molecular grade that could be used in daily practice. Molecular classification is done using immunohistochemistry to assess luminal-basal phenotype based on tissular expression of CK20 and CK5/6 as surrogate for luminal or basal subtypes, respectively. A series of 147 non-muscle-invasive bladder carcinoma cases was selected, and the tumors were divided into four subgroups based on the presence of CK20 and/or CK5/6, that is, null (CK20-, CK5/6-), mixed (CK20+, CK5/6+), basal (CK20-, CK5/6+), and luminal (CK20+, CK5/6-) categories. Survival analysis was estimated using the Kaplan-Meier method and the log-rank test. Hazard ratios were calculated by Cox multivariate analysis. The molecular grade included cases with null (n = 89), mixed (n = 6), basal (n = 20), and luminal (n = 32) phenotypes with differences in recurrence-free, progression-free and cancer-specific survival associated with molecular-grade categories in patients with low- or high-grade Ta, or high-grade T1 tumors. The multivariate analysis identified the luminal phenotype as a predictor of more aggressive neoplasms. Our findings provide a rationale to investigate luminal and basal subtypes of bladder cancer using two gene expression signatures as surrogate markers and show that non-muscle-invasive bladder carcinoma can be stratified into biologically and clinically different subgroups by using an immunohistochemical classifier. FAU - Rebola, Jorge AU - Rebola J AD - Urology Unit, Champalimaud Clinical Center, Lisbon, Portugal. AD - National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal. FAU - Aguiar, Pedro AU - Aguiar P AD - Public Health Research Center, National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal. FAU - Blanca, Ana AU - Blanca A AD - Maimonides Biomedical Research Institute of Cordoba, Cordoba, Spain. FAU - Montironi, Rodolfo AU - Montironi R AD - Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy. FAU - Cheng, Liang AU - Cheng L AD - Departments of Pathology and Laboratory Medicine and Urology, Indiana University, School of Medicine, Indianapolis, IN, USA. FAU - Henriques, Vanessa AU - Henriques V AD - Anatomic Pathology Service, Champalimaud Clinical Center, Lisbon, Portugal. FAU - Lobato-Faria, Paula AU - Lobato-Faria P AD - Public Health Research Center, National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AUID- ORCID: 0000-0003-3161-8164 AD - Department of Surgery and Pathology, Faculty of Medicine, Avda. Menendez Pidal S/N, 14004, Cordoba, Spain. em1lobea@uco.es. AD - Champalimaud Clinical Center, Lisbon, Portugal. em1lobea@uco.es. LA - eng GR - PI17/01981/Ministerio de Salud y Proteccion Social/ PT - Journal Article DEP - 20190625 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) RN - 0 (KRT20 protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (Keratin-6) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/*classification/mortality/*pathology MH - Female MH - Humans MH - Keratin-20/analysis/biosynthesis MH - Keratin-5/analysis/biosynthesis MH - Keratin-6/analysis/biosynthesis MH - Male MH - Middle Aged MH - Neoplasm Grading/methods MH - Phenotype MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*classification/mortality/*pathology OTO - NOTNLM OT - Basal OT - Bladder cancer OT - Luminal OT - Molecular grade OT - Prognosis OT - Survival EDAT- 2019/06/27 06:00 MHDA- 2019/11/13 06:00 CRDT- 2019/06/27 06:00 PHST- 2019/02/06 00:00 [received] PHST- 2019/06/03 00:00 [accepted] PHST- 2019/05/14 00:00 [revised] PHST- 2019/06/27 06:00 [pubmed] PHST- 2019/11/13 06:00 [medline] PHST- 2019/06/27 06:00 [entrez] AID - 10.1007/s00428-019-02593-x [pii] AID - 10.1007/s00428-019-02593-x [doi] PST - ppublish SO - Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25. PMID- 31237445 OWN - NLM STAT- MEDLINE DCOM- 20200214 LR - 20200214 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 15 IP - 20 DP - 2019 Jul TI - Management of distal ureter and bladder cuff at the time of nephroureterectomy: surgical techniques and predictors of outcome. PG - 2385-2393 LID - 10.2217/fon-2019-0064 [doi] AB - Open radical nephroureterectomy (NU) with removal of the ureter and bladder cuff is the 'gold standard' in the treatment of high-grade urothelial cancers of the upper urinary tract. A salient issue is the management of the distal ureter and bladder cuff at time of surgery. Which technique confers superior oncologic benefit is of particular interest since this disease process is notoriously plagued with high intravesical recurrence rates. Although open radical NU is the 'gold standard', the maturation of minimally invasive surgery formidably challenges approaches considered 'gold standard'. We thus sought to critically review the literature comparing perioperative and oncologic outcomes in the approaches used to manage the distal ureter and bladder cuff in patients undergoing radical NU. FAU - Attalla, Kyrollis AU - Attalla K AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Patnaik, Shyam AU - Patnaik S AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Vellos, Ted AU - Vellos T AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Mehrazin, Reza AU - Mehrazin R AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. LA - eng PT - Journal Article PT - Review DEP - 20190625 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 SB - IM MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Neoplasm Recurrence, Local/pathology/*prevention & control MH - Nephroureterectomy/*methods MH - Prognosis MH - Treatment Outcome MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/pathology/*surgery MH - Urinary Bladder/pathology/surgery OTO - NOTNLM OT - distal ureter and bladder cuff OT - radical nephroureterectomy OT - upper tract urothelial carcinoma EDAT- 2019/06/27 06:00 MHDA- 2020/02/15 06:00 CRDT- 2019/06/26 06:00 PHST- 2019/06/27 06:00 [pubmed] PHST- 2020/02/15 06:00 [medline] PHST- 2019/06/26 06:00 [entrez] AID - 10.2217/fon-2019-0064 [doi] PST - ppublish SO - Future Oncol. 2019 Jul;15(20):2385-2393. doi: 10.2217/fon-2019-0064. Epub 2019 Jun 25. PMID- 31237444 OWN - NLM STAT- MEDLINE DCOM- 20191218 LR - 20191218 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 15 IP - 19 DP - 2019 Jul TI - Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma. PG - 2267-2275 LID - 10.2217/fon-2018-0861 [doi] AB - Aim: To assess mortality from bladder cancer following a diagnosis of nonmuscle-invasive bladder cancer. Materials & methods: This is a SEER registry-based study. The risk of death from bladder cancer was compared with that of the general population. Cox proportional model was performed to calculate the hazard ratio (HR) for death according to baseline characteristics. Results: The bladder cancer-specific mortality at 20 years was 11%; and it was higher for black patients compared with white patients (adjusted HR: 1.711 [95% CI: 1.564-1.872]; p < 0.0001); additionally, it was higher for patients older than 70 years old compared with younger patients (adjusted HR: 2.005 [95% CI: 1.916-2.099]; p < 0 .0001). The risk of bladder cancer mortality increased after diagnosis of a recurrent bladder cancer (both nonmuscle-invasive and muscle-invasive; adjusted HR: 6.97 [95% CI: 6.56-7.40]; p < 0 .0001). Conclusion: Important predictors for death from bladder cancer following a diagnosis of nonmuscle-invasive bladder cancer include older age at diagnosis and black race. FAU - Abdel-Rahman, Omar AU - Abdel-Rahman O AUID- ORCID: 0000-0002-5117-2502 AD - Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11351, Egypt. AD - Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary T2N4N2, Alberta, Canada. LA - eng PT - Journal Article DEP - 20190625 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/diagnosis/*mortality/pathology/surgery MH - Cystectomy/adverse effects MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/diagnosis/*mortality/pathology/surgery MH - Proportional Hazards Models MH - SEER Program MH - Urinary Bladder Neoplasms/diagnosis/*mortality/pathology/surgery OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - mortality OT - nonmuscle-invasive bladder cancer OT - urothelial carcinoma EDAT- 2019/06/27 06:00 MHDA- 2019/12/19 06:00 CRDT- 2019/06/26 06:00 PHST- 2019/06/27 06:00 [pubmed] PHST- 2019/12/19 06:00 [medline] PHST- 2019/06/26 06:00 [entrez] AID - 10.2217/fon-2018-0861 [doi] PST - ppublish SO - Future Oncol. 2019 Jul;15(19):2267-2275. doi: 10.2217/fon-2018-0861. Epub 2019 Jun 25. PMID- 31231851 OWN - NLM STAT- MEDLINE DCOM- 20190725 LR - 20190725 IS - 1600-0463 (Electronic) IS - 0903-4641 (Linking) VI - 127 IP - 8 DP - 2019 Aug TI - Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. PG - 545-553 LID - 10.1111/apm.12973 [doi] AB - microRNA alterations are involved in bladder cancer tumorigenesis. The aim of the current study was to evaluate the potential role of miR-100 and miR-138 as prognostic biomarkers in Ta/T1 non-muscle-invasive bladder cancer (NMIBC). We assessed a quantitative RT-PCR analysis of miR-100 and miR-138 in 50 bladder tumor samples (stage Ta/T1) and four healthy adjacent tissues. Western blot analysis was used to measure protein expression of FGFR3 and cyclin D3 in order to know whether these targets can be regulated by miR-100 and miR-138, respectively. The statistical analysis included non-parametric tests (Mann-Whitney U and Kruskal-Wallis) and univariate survival analysis by Kaplan-Meier method and the log-rank test. Low expression of miR-138 characterized recurrent tumors (p = 0.043), and higher expression levels were associated with longer recurrence-free survival (p = 0.012). However, low miR-100 expression correlated with longer progression-free survival (marginal significance; p = 0.053) and cancer-specific overall survival (p = 0.006). Additionally, higher levels of miR-100 were associated with negative FGFR3 protein expression (p = 0.032) and higher levels of miR-138 were associated with positive cyclin D3 protein expression (p = 0.037). Our results support miR-138 and miR-100 as prognostic biomarkers in patients with NMIBC. CI - (c) 2019 APMIS. Published by John Wiley & Sons Ltd. FAU - Blanca, Ana AU - Blanca A AD - Urology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. FAU - Sanchez-Gonzalez, Alvaro AU - Sanchez-Gonzalez A AD - Urology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. FAU - Requena, Maria J AU - Requena MJ AD - Urology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. FAU - Carrasco-Valiente, Julia AU - Carrasco-Valiente J AD - Urology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. FAU - Gomez-Gomez, Enrique AU - Gomez-Gomez E AD - Urology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. FAU - Cheng, Liang AU - Cheng L AD - Departments of Pathology and Laboratory Medicine, and Urology, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Cimadamore, Alessia AU - Cimadamore A AD - Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Montironi, Rodolfo AU - Montironi R AD - Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Pathology and Surgery, Cordoba University Medical School, Cordoba, Spain. LA - eng GR - PI17/Instituto de Salud Carlos III/ GR - 01981/Instituto de Salud Carlos III/ GR - European Regional Development Fund/ GR - European Social Fund/ PT - Journal Article PL - Denmark TA - APMIS JT - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica JID - 8803400 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN100 microRNA, human) RN - 0 (MIRN138 microRNA, human) RN - 0 (MicroRNAs) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Case-Control Studies MH - Female MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Prognosis MH - Real-Time Polymerase Chain Reaction MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/pathology OTO - NOTNLM OT - bladder cancer OT - microRNA expression OT - prognostic biomarkers OT - stage Ta/T1 EDAT- 2019/06/25 06:00 MHDA- 2019/07/26 06:00 CRDT- 2019/06/25 06:00 PHST- 2018/11/26 00:00 [received] PHST- 2019/06/11 00:00 [accepted] PHST- 2019/06/25 06:00 [pubmed] PHST- 2019/07/26 06:00 [medline] PHST- 2019/06/25 06:00 [entrez] AID - 10.1111/apm.12973 [doi] PST - ppublish SO - APMIS. 2019 Aug;127(8):545-553. doi: 10.1111/apm.12973. PMID- 31227894 OWN - NLM STAT- MEDLINE DCOM- 20190808 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 8 DP - 2019 Aug TI - Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy. PG - 2131-2140 LID - 10.1007/s00432-019-02956-6 [doi] AB - PURPOSE: This study aimed at determining the relationship between classification according to the papillary tumor pattern of carcinoma in situ (CIS) of the bladder and prognosis, as this has not yet been well established. METHODS: This study comprised a consecutive cohort of 254 patients (primary CIS: 66 patients, stage Ta-CIS: 52 patients, and stage T1-CIS: 136 patients) with CIS-associated bladder cancer. We classified CIS according to the pathological pattern of papillary tumors and analyzed prognostic factors, including CIS classification, for progression. We evaluated progression using two endpoints: infiltrative tumors detected at stage T1 or higher or at stage T2 or higher. Bacillus Calmette-Guerin (BCG) immunotherapy response was defined as no recurrence within 6 months. RESULTS: Both the BCG immunotherapy response and CIS classification were significant prognostic factors for both the endpoints. Patients with CIS-associated stage Ta urinary bladder cancer had better prognosis for both the endpoints than those with stage T1 cancer or those with primary CIS. BCG immunotherapy response (p < 0.001) and age (p = 0.007) were also significant prognostic factors for the progression of stage T2 or higher infiltrative tumors. The prognosis of patients with recurrent primary CIS (12/26, 46.2%) and T1-CIS (25/45, 55.6%) was poor for progression; distant metastasis occurred in approximately 40% of these patients. CONCLUSIONS: Clinicians should consider radical surgery for poor prognosis in patients with recurrent CIS-associated T1 cancer or primary CIS. The CIS classification according to the tumor pattern reflects the prognosis. FAU - Kim, Sung Jin AU - Kim SJ AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Bangdong-gil 38, Sacheon-myeon, Gangneung-si, Gangwon-do, Republic of Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Song, Cheryn AU - Song C AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. FAU - Hong, Jun Hyuk AU - Hong JH AUID- ORCID: 0000-0003-2705-0481 AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. jhhong@amc.seoul.kr. LA - eng PT - Journal Article DEP - 20190621 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*diagnosis/*drug therapy/pathology MH - Carcinoma, Papillary/*diagnosis/*drug therapy/pathology MH - Carcinoma, Transitional Cell/diagnosis/drug therapy/pathology MH - Disease Progression MH - Female MH - Humans MH - Immunotherapy/methods MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/*drug therapy/pathology PMC - PMC11810277 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Carcinoma in situ OT - Classification OT - Neoplasms OT - Urinary bladder COIS- The authors declare that they have no competing interests. EDAT- 2019/06/23 06:00 MHDA- 2019/08/09 06:00 PMCR- 2019/06/21 CRDT- 2019/06/23 06:00 PHST- 2019/03/22 00:00 [received] PHST- 2019/06/17 00:00 [accepted] PHST- 2019/06/23 06:00 [pubmed] PHST- 2019/08/09 06:00 [medline] PHST- 2019/06/23 06:00 [entrez] PHST- 2019/06/21 00:00 [pmc-release] AID - 10.1007/s00432-019-02956-6 [pii] AID - 2956 [pii] AID - 10.1007/s00432-019-02956-6 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Aug;145(8):2131-2140. doi: 10.1007/s00432-019-02956-6. Epub 2019 Jun 21. PMID- 31216733 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 2079-9721 (Print) IS - 2079-9721 (Electronic) IS - 2079-9721 (Linking) VI - 7 IP - 2 DP - 2019 Jun 18 TI - Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guerin. LID - 10.3390/diseases7020044 [doi] LID - 44 AB - BACKGROUND: The aim of this study is to evaluate the clinical impact of intravesical Bacillus Calmette-Guerin (BCG)-induced changes in blood/urinary immune markers. METHODS: Time-course changes in blood/urinary clinical parameters and mRNA expression of 13 genes in urine sediment taken eight times during the treatment course of intravesical BCG (before, every 2 weeks for 8 weeks, and after) in 24 patients with non-muscle invasive bladder cancer. The genes examined include cellular markers of four immune checkpoint proteins (PD-L1, PD-L2, PD-1, and CTLA-4), immunosuppressive cells (regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells), pan-T lymphocytes, B lymphocytes, and neutrophils. RESULTS: Significant transient increase in gene expression was observed for PD-L1, PD-1, FOXP3, and CD204 at 6-8 doses of BCG. The patients were stratified into two groups depending on the number of genes with increased mRNA expression. Fourteen (58%) had 0-1 genes upregulated, while 10 (42%) had 2-4 genes with increased expression. No patient in the 0-1 group experienced recurrence, while 70% of patients in the 2-4 group experienced recurrence (p value = 0.037, hazard ratio = 5.93). CONCLUSIONS: Our findings suggested that increases in more than one of PD-L1, PD-1, FOXP3, and CD204, expression in the urine sediments was associated with resistance to BCG treatment. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. makitomiyake@yahoo.co.jp. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. horimaus@gmail.com. FAU - Ohnishi, Sayuri AU - Ohnishi S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sayuri3@naramed-u.ac.jp. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. tintherye@gmail.com. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kota1006ida@yahoo.co.jp. FAU - Ohnishi, Kenta AU - Ohnishi K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kenzmedico0912@yahoo.co.jp. FAU - Morizawa, Yosuke AU - Morizawa Y AUID- ORCID: 0000-0001-7142-5901 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. tigers.yosuke@gmail.com. FAU - Gotoh, Daisuke AU - Gotoh D AUID- ORCID: 0000-0002-6056-3820 AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. dgotou@gmail.com. FAU - Itami, Yoshitaka AU - Itami Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. y.itami.324@gmail.com. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. nakaiyasusiuro@live.jp. FAU - Inoue, Takeshi AU - Inoue T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. you1513tt@yahoo.co.jp. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sanai@naramed-u.ac.jp. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. torimoto@naramed-u.ac.jp. FAU - Aoki, Katsuya AU - Aoki K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. aokik@naramed-u.ac.jp. FAU - Fujii, Tomomi AU - Fujii T AUID- ORCID: 0000-0002-7207-4127 AD - Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. fujiit@naramed-u.ac.jp. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sendo@naramed-u.ac.jp. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kiyokun@naramed-u.ac.jp. LA - eng GR - 16K20159/JSPS KAKENHI/ GR - 26861290/JSPS KAKENHI/ GR - Fiscal Years 2015-2016/Nara Medical University Grant-in-Aid for Collaborative Research Projects/ PT - Journal Article DEP - 20190618 PL - Switzerland TA - Diseases JT - Diseases (Basel, Switzerland) JID - 101636232 PMC - PMC6630414 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - intravesical recurrence OT - myeloid-derived suppressor cell OT - non-muscle invasive bladder cancer OT - regulatory T cell OT - tumor-associated macrophage COIS- The authors disclose no potential conflicts of interest EDAT- 2019/06/21 06:00 MHDA- 2019/06/21 06:01 PMCR- 2019/06/18 CRDT- 2019/06/21 06:00 PHST- 2019/04/19 00:00 [received] PHST- 2019/06/08 00:00 [revised] PHST- 2019/06/17 00:00 [accepted] PHST- 2019/06/21 06:00 [entrez] PHST- 2019/06/21 06:00 [pubmed] PHST- 2019/06/21 06:01 [medline] PHST- 2019/06/18 00:00 [pmc-release] AID - diseases7020044 [pii] AID - diseases-07-00044 [pii] AID - 10.3390/diseases7020044 [doi] PST - epublish SO - Diseases. 2019 Jun 18;7(2):44. doi: 10.3390/diseases7020044. PMID- 31214962 OWN - NLM STAT- MEDLINE DCOM- 20200212 LR - 20220125 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 46 IP - 5 DP - 2019 Oct TI - The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer. PG - 4743-4750 LID - 10.1007/s11033-019-04920-6 [doi] AB - There is a major need for the identification of biomarkers, which are able to guide personalized therapy for bladder cancer, in particular after resection of the primary tumor. Specifically, miR-9 upregulation has been preliminarily associated with a more aggressive phenotype of bladder cancer, namely muscle-invasive bladder cancer (MIBC) or high-grade non-muscle-invasive bladder cancer (HG NMIBC). In order to explore the potential utility of miR-9 as a biomarker in bladder cancer, we have investigated its expression pattern in a sample of Tunisian patients who have undergone primary resection. This is a retrospective study performed on BCa samples from 90 patients (44 specimens of HG NMIBC, 23 specimens of LG NMIBC, and 23 specimens of MIBC). Ten samples from the non-tumoral zone of cystectomy specimens were used as controls. For each specimen, we measured miR-9 expression and correlated it with the clinical characteristics of the patients. Overall, miR-9 was overexpressed in MIBC compared to NMIBC specimens (median fold change [FC]: - 8.89 vs 1.41, p = 0.001). Similarly, miR-9 expression was significantly different in LG NMIBC, HG NMIBC and MIBC subgroups (median FC: 0.68, 2.14 and 8.89, respectively; p = 0.001). ROC analysis showed that miR-9 expression pattern could be used as potential biomarker for distinguishing NMIBC subgroups: indeed miR-9 expression is relatively low in LG NMIBC and high in HG NMIBC. The thresholds are estimated at 0.063 and 21.597, respectively. Moreover, miR-9 was associated with a higher risk of progression. This study suggests the clinical value of miR-9 as a prognostic factor in bladder cancer after tumor resection. Should the prognostic ability of miR-9 be confirmed in larger studies, also on different ethnic groups, it would be useful to investigate whether urine sampling-which is easier to perform, less invasive and less costly-can provide the same results as analysis on surgical specimens. FAU - Setti Boubaker, Nouha AU - Setti Boubaker N AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), National Institute of Applied Sciences and Technology of Tunis (INSAT), The University of Carthage, Tunis, Tunisia. AD - Department of Research, Advanced Diagnostics and Technological Innovation, UOSD SAFU Unit-Translational Research Area, IRCCS, Regina Elena National Cancer Institute, Rome, Italy. FAU - Cicchillitti, Lucia AU - Cicchillitti L AD - Department of Experimental Clinical Oncology Unit, IRCCS, Regina Elena National Cancer Institute, Rome, Italy. FAU - Said, Rahma AU - Said R AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), National Institute of Applied Sciences and Technology of Tunis (INSAT), The University of Carthage, Tunis, Tunisia. FAU - Gurtner, Aymone AU - Gurtner A AUID- ORCID: 0000-0002-7661-9059 AD - Department of Research, Advanced Diagnostics and Technological Innovation, UOSD SAFU Unit-Translational Research Area, IRCCS, Regina Elena National Cancer Institute, Rome, Italy. FAU - Ayed, Haroun AU - Ayed H AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Blel, Ahlem AU - Blel A AUID- ORCID: 0000-0001-6702-3889 AD - Pathology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Karray, Omar AU - Karray O AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Essid, Mohamed Ali AU - Essid MA AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Gharbi, Maroua AU - Gharbi M AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Bouzouita, Abderrazek AU - Bouzouita A AUID- ORCID: 0000-0001-9644-0745 AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Rammeh Rommeni, Soumaya AU - Rammeh Rommeni S AUID- ORCID: 0000-0003-0366-4630 AD - Pathology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Chebil, Mohamed AU - Chebil M AUID- ORCID: 0000-0001-8387-7593 AD - Urology Department, Charles Nicolle Hospital, Tunis, Tunisia. FAU - Piaggio, Giulia AU - Piaggio G AUID- ORCID: 0000-0003-2114-1892 AD - Department of Research, Advanced Diagnostics and Technological Innovation, UOSD SAFU Unit-Translational Research Area, IRCCS, Regina Elena National Cancer Institute, Rome, Italy. giulia.piaggio@ifo.gov.it. FAU - Ouerhani, Slah AU - Ouerhani S AUID- ORCID: 0000-0002-3651-4690 AD - Laboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), National Institute of Applied Sciences and Technology of Tunis (INSAT), The University of Carthage, Tunis, Tunisia. slah_mekni@yahoo.fr. LA - eng PT - Journal Article DEP - 20190618 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN92 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Aged, 80 and over MH - *Biomarkers, Tumor MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Tunisia/epidemiology MH - Urinary Bladder Neoplasms/*diagnosis/*genetics/mortality OTO - NOTNLM OT - Biomarkers OT - Epigenetic variation OT - Neoplasms OT - Prognosis OT - Urinary bladder OT - miRN EDAT- 2019/06/20 06:00 MHDA- 2020/02/13 06:00 CRDT- 2019/06/20 06:00 PHST- 2019/02/08 00:00 [received] PHST- 2019/06/14 00:00 [accepted] PHST- 2019/06/20 06:00 [pubmed] PHST- 2020/02/13 06:00 [medline] PHST- 2019/06/20 06:00 [entrez] AID - 10.1007/s11033-019-04920-6 [pii] AID - 10.1007/s11033-019-04920-6 [doi] PST - ppublish SO - Mol Biol Rep. 2019 Oct;46(5):4743-4750. doi: 10.1007/s11033-019-04920-6. Epub 2019 Jun 18. PMID- 31213917 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 11 DP - 2019 TI - Predictors of postoperative complications after robot-assisted radical cystectomy with extracorporeal urinary diversion. PG - 5055-5063 LID - 10.2147/CMAR.S199432 [doi] AB - Purpose: Robot-assisted radical cystectomy (RARC) is known to have less postoperative morbidity and complications than open radical cystectomy. However, various complications not yet have been reported after RARC. In this study, we aimed to identify the predictors of complications following RARC. Patients and methods: From August 2008 to November 2017, we retrospectively reviewed 126 patients who underwent RARC with extracorporeal urinary diversion. Overall perioperative complications were examined, and factors that may affect complications were analyzed using a logistic regression model. Complications were classified according to the Clavien-Dindo system. Results: Overall postoperative complications occurred in 78 (61.9%) of 126 patients. Whereas the rate of minor complications was 58.0% (grade I=15.9% (n=20), grade II=42.1% (n=53)), the rate of major complications was very low (grade IIIa=1.6% (n=2), grade IIIb =2.4% (n=3)). No fatal complications more than grade IV were developed. Notably, transfusions (27.0%), urinary tract infection (15.9%), anastomosis site leakage (14.3%), and ileus (10.3%) were the most common complications after RARC. In the multivariate regression model, previous intravesical instillation (odds ration [OR]=3.374), preoperative hemoglobin (OR=0.751), and estimated blood loss (EBL) (OR=3.949) were identified as the predictors of postoperative complications. Conclusion: In sum, our data showed the rates of major complications were comparable after RARC with extracorporeal urinary diversion compared as reported in previous studies and lower major than minor complications following RARC. Moreover, we identified the independent predictors of postoperative complications, such as preoperative hemoglobin, intravesical instillation, and EBL. FAU - Lee, Chung Un AU - Lee CU AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kim, Tae Jin AU - Kim TJ AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Na, Jun Phil AU - Na JP AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Lee, Hyun Moo AU - Lee HM AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20190531 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6549423 OTO - NOTNLM OT - bladder cancer OT - complications OT - cystectomy OT - predictor OT - robotic surgery COIS- The authors report no conflicts of interest in this work. EDAT- 2019/06/20 06:00 MHDA- 2019/06/20 06:01 PMCR- 2019/05/31 CRDT- 2019/06/20 06:00 PHST- 2018/12/24 00:00 [received] PHST- 2019/03/26 00:00 [accepted] PHST- 2019/06/20 06:00 [entrez] PHST- 2019/06/20 06:00 [pubmed] PHST- 2019/06/20 06:01 [medline] PHST- 2019/05/31 00:00 [pmc-release] AID - 199432 [pii] AID - 10.2147/CMAR.S199432 [doi] PST - epublish SO - Cancer Manag Res. 2019 May 31;11:5055-5063. doi: 10.2147/CMAR.S199432. eCollection 2019. PMID- 31200845 OWN - NLM STAT- MEDLINE DCOM- 20200602 LR - 20200602 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 2 IP - 3 DP - 2019 May TI - Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. PG - 304-310 LID - S2588-9311(18)30137-8 [pii] LID - 10.1016/j.euo.2018.08.018 [doi] AB - BACKGROUND: While urothelial carcinoma of the bladder is often considered a multifocal disease, the location of the dominant tumor may be prognostic. OBJECTIVE: To determine the association between intravesical tumor location and both adverse pathological outcomes as well as overall survival. DESIGN, SETTINGS, AND PARTICIPANTS: Patients in the National Cancer Database (2010-2015) with nonmetastatic urothelial carcinoma of the bladder who underwent primary treatment with radical cystectomy (RC; n=3464) or chemoradiotherapy (CRT; n=699). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regressions assessed the prognostic ability of tumor location to predict adverse pathology at RC (nodal metastases [pN+] or advanced stage [pT3-4]). Cox regressions were used to determine the effect of tumor location on overall survival in patients treated with RC or CRT. RESULTS AND LIMITATIONS: Following RC, 822 (24%) patients were pN+ and 1551 (55%) were pT3-4. Trigonal tumors were most likely to have adverse pathology (31% pN+ and 59% pT3-4), while anterior wall tumors were the least (19% pN+ and 50% pT3-4). Relative to the anterior wall, trigone (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.12-2.43, p=0.012) and bladder neck (OR 1.79, 95% CI 1.11-2.90, p=0.018) tumors were associated with increased odds of pN+ and dome (OR 1.56, 95% CI 1.08-2.24, p=0.017) with pT3-4. In those patients treated with primary CRT, trigone involvement was associated with worse survival (HR 1.58, 95% CI 1.17-2.13, p=0.003). Limitations included unmeasured variables and a relatively few number of patients with certain tumor locations. CONCLUSIONS: Trigone and bladder neck tumors are associated with increased odds of nodal involvement, and dome with a higher tumor stage at RC. Patients with trigone involvement may have worse overall survival following CRT. PATIENT SUMMARY: Location of the tumor within the bladder may be associated with worse cancer staging at the time of the surgery and worse survival following chemoradiotherapy. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Weiner, Adam B AU - Weiner AB AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Desai, Anuj S AU - Desai AS AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: Joshua.meeks@northwestern.edu. LA - eng GR - I01 BX003692/BX/BLRD VA/United States PT - Journal Article DEP - 20180914 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*pathology/*therapy MH - Chemoradiotherapy MH - Cohort Studies MH - Cystectomy MH - Female MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Odds Ratio MH - Survival Analysis MH - United States/epidemiology MH - Urinary Bladder/*pathology/radiation effects/surgery MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - Cystectomy OT - Epidemiology OT - Survival OT - Therapeutics OT - USA OT - Urinary bladder neoplasms EDAT- 2019/06/16 06:00 MHDA- 2020/06/03 06:00 CRDT- 2019/06/16 06:00 PHST- 2018/06/03 00:00 [received] PHST- 2018/08/06 00:00 [revised] PHST- 2018/08/21 00:00 [accepted] PHST- 2019/06/16 06:00 [entrez] PHST- 2019/06/16 06:00 [pubmed] PHST- 2020/06/03 06:00 [medline] AID - S2588-9311(18)30137-8 [pii] AID - 10.1016/j.euo.2018.08.018 [doi] PST - ppublish SO - Eur Urol Oncol. 2019 May;2(3):304-310. doi: 10.1016/j.euo.2018.08.018. Epub 2018 Sep 14. PMID- 31200843 OWN - NLM STAT- MEDLINE DCOM- 20200602 LR - 20250723 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 2 IP - 3 DP - 2019 May TI - Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. PG - 286-293 LID - S2588-9311(18)30132-9 [pii] LID - 10.1016/j.euo.2018.08.013 [doi] AB - BACKGROUND: Tumors that recur after bacillus Calmette-Guerin (BCG) therapy are considered to be of very high risk, and patients are often recommended to undergo radical cystectomy (RC). However, the nuances associated with the grade of tumor recurrence after BCG treatment are not well understood. OBJECTIVE: To characterize the pattern of bladder cancer progression and cancer-specific survival (CSS) in patients with recurrences dichotomized by low grade (LG) versus high grade (HG) after intravesical BCG treatment, and to assess the safety of continued bladder-sparing therapy in these patients. DESIGN, SETTING, AND PARTICIPANTS: We performed an Institutional Review Board-approved review of our bladder cancer database. Overall, 146 non-muscle-invasive bladder cancer (NMIBC) patients were found to have NMIBC recurrence while on BCG therapy; this recurrence was LG in 38 and HG in 108. Baseline clinicopathologic characteristics including age, gender, primary tumor grade, stage, size, multiplicity, and concurrent carcinoma in situ were also evaluated. The primary endpoint was progression-free survival (PFS), with progression defined as the development of muscle-invasive bladder cancer (MIBC)/distant metastasis. In addition, recurrence-free survival (RFS), HG RFS, cystectomy-free survival (CFS), and CSS were also compared. Multivariable analysis was performed using the Cox regression model. All tests were two sided, and p<0.05 was considered statistically significant. INTERVENTION: Further intravesical therapy versus salvage RC. RESULTS AND LIMITATIONS: Overall, estimated 5-yr PFS was 72.4% (95% confidence interval [CI] 60.4-81.3%). As dichotomized by grade of recurrent tumor, PFS was greater for patients with LG recurrences (85.6%, 95% CI 60.8-95.2%) than for those with HG recurrence (67.9%, 95% CI 54.1-78.4%; p=0.010). Furthermore, patients whose initial recurrence on BCG therapy was LG had improved subsequent RFS (median 62 vs 34mo, p=0.007), HG RFS (median 112 vs 36mo, p<0.001), and CFS (estimated 5-yr CFS 80.8% vs 49.8%, p<0.001) compared with those who had HG initial recurrence. On univariate and multivariate analyses, grade of tumor recurrence after BCG was an independent predictor of time to progression to MIBC/distant metastasis (hazard ratio 3.60, 95% CI 1.18-10.94, p=0.024). CONCLUSIONS: Grade of tumor recurrence after intravesical BCG is an important predictor of bladder cancer progression to MIBC/metastatic urothelial carcinoma. While, patients with LG recurrences have less than half the progression events compared with those with HG recurrences, their estimated 5-yr progression rate is still 14.4%. Hence all patients should be carefully counseled on bladder-sparing therapy. This also has implications for clinical trial design. PATIENT SUMMARY: If bladder cancer recurs after bacillus Calmette-Guerin treatment, there are many factors that determine the further clinical outcome. Although low-grade recurrent tumors confer a less aggressive course, disease progression can still occur, and hence continued vigilance is important. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Li, Roger AU - Li R AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Metcalfe, Michael J AU - Metcalfe MJ AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tabayoyong, William B AU - Tabayoyong WB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras Gonzalez, Graciela M AU - Nogueras Gonzalez GM AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180910 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - Neoplasm Grading MH - *Neoplasm Recurrence, Local MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Intravesical therapy OT - Tumor grade EDAT- 2019/06/16 06:00 MHDA- 2020/06/03 06:00 CRDT- 2019/06/16 06:00 PHST- 2018/06/29 00:00 [received] PHST- 2018/08/04 00:00 [revised] PHST- 2018/08/16 00:00 [accepted] PHST- 2019/06/16 06:00 [entrez] PHST- 2019/06/16 06:00 [pubmed] PHST- 2020/06/03 06:00 [medline] AID - S2588-9311(18)30132-9 [pii] AID - 10.1016/j.euo.2018.08.013 [doi] PST - ppublish SO - Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10. PMID- 31197260 OWN - NLM STAT- MEDLINE DCOM- 20200203 LR - 20261012 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 16 IP - 9 DP - 2019 Sep TI - Organ preservation in bladder cancer: an opportunity for truly personalized treatment. PG - 511-522 LID - 10.1038/s41585-019-0199-x [doi] AB - Radical treatment of many solid tumours has moved from surgery to multimodal organ preservation strategies combining systemic and local treatments. Trimodality bladder-preserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour followed by radiotherapy and concurrent radiosensitizing treatment, thereby sparing the urinary bladder. From the patient's perspective, the choice of maintaining quality of life without a negative effect on the chances of cure and long-term survival is attractive. In muscle-invasive bladder cancer (MIBC), the evidence shows comparable clinical outcomes between patients undergoing radical cystectomy and TMT. Despite this evidence, many patients continue to be offered radical surgery as the standard-of-care treatment. Improvements in radiotherapy techniques with adaptive radiotherapy and advances in imaging translate to increases in the accuracy of treatment delivery and reductions in long-term toxicities. With the advent of novel biomarkers promising improved prediction of treatment response, stratification of patients for different treatments on the basis of tumour biology could soon be a reality. The future of oncological treatment lies in personalized medicine with the combination of technological and biological advances leading to truly bespoke management for patients with MIBC. FAU - Song, Yee Pei AU - Song YP AUID- ORCID: 0000-0002-4459-1215 AD - Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. yeepei.song@christie.nhs.uk. AD - Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK. yeepei.song@christie.nhs.uk. FAU - McWilliam, Alan AU - McWilliam A AD - Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. AD - Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK. FAU - Hoskin, Peter J AU - Hoskin PJ AD - Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. AD - Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. FAU - Choudhury, Ananya AU - Choudhury A AD - Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. AD - Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20190613 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 RN - 0 (Biomarkers) SB - IM MH - Algorithms MH - Biomarkers/analysis MH - Humans MH - Organ Sparing Treatments/*methods MH - *Precision Medicine MH - Predictive Value of Tests MH - Urinary Bladder Neoplasms/diagnosis/diagnostic imaging/*therapy EDAT- 2019/06/15 06:00 MHDA- 2020/02/06 06:00 CRDT- 2019/06/15 06:00 PHST- 2019/05/09 00:00 [accepted] PHST- 2019/06/15 06:00 [pubmed] PHST- 2020/02/06 06:00 [medline] PHST- 2019/06/15 06:00 [entrez] AID - 10.1038/s41585-019-0199-x [pii] AID - 10.1038/s41585-019-0199-x [doi] PST - ppublish SO - Nat Rev Urol. 2019 Sep;16(9):511-522. doi: 10.1038/s41585-019-0199-x. Epub 2019 Jun 13. PMID- 31190987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 11 DP - 2019 TI - Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. PG - 4171-4184 LID - 10.2147/CMAR.S176937 [doi] AB - Objective: Our objective was to conduct a meta-analysis to investigate the clinicopathological features and prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with urothelial carcinoma (UC). Materials and methods: Twenty-seven studies with 4,032 patients were included in the meta-analysis. Pooled ORs and 95% CIs were used to examine the associations between clinical factors and PD-L1 expression. HRs and 95% CIs were extracted from eligible studies. Heterogeneity was evaluated using the chi-squared-based Q test and I(2) statistic. Results: Expression of PD-L1 on tumor cells (TCs) was associated with muscle-invasive disease (OR=3.67, 95% CI: 2.53-5.33), and inversely associated with the history of intravesical bacilli Calmette-Guerin therapy (OR=0.39, 95% CI: 0.18-0.82) in bladder cancer patients. PD-L1 expression on TCs was associated with worse overall survival (HR=2.06, 95% CI: 1.38-3.06) in patients with organ-confined bladder cancer. PD-L1 expression in patients with UC was significantly related to better objective response rate after PD-1/PD-L1 antibody treatment. Conclusions: Expression of PD-L1 on TCs was associated with muscle-invasive disease in patients with bladder cancer. Patients with PD-L1-positive UC had a significantly better response to PD-1/PD-L1 targeted treatment. FAU - Ding, Xiangli AU - Ding X AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. FAU - Chen, Qiaochao AU - Chen Q AD - Department of Geriatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Yang, Zhao AU - Yang Z AD - Department of Biomedical Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Li, Jun AU - Li J AD - Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. FAU - Zhan, Hui AU - Zhan H AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. FAU - Lu, Nihong AU - Lu N AD - Department of Respiration, The Third People's Hospital of Kunming, Kunming, Yunnan, People's Republic of China. FAU - Chen, Min AU - Chen M AD - Department of Cardiology, The First People's Hospital of Kunming, Kunming, Yunnan, People's Republic of China. FAU - Yang, Yanlong AU - Yang Y AD - Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, Yunnan, People's Republic of China. FAU - Wang, Jiansong AU - Wang J AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. FAU - Yang, Delin AU - Yang D AD - Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. LA - eng PT - Journal Article DEP - 20190508 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6512637 OTO - NOTNLM OT - immunotherapy OT - meta-analysis OT - prognosis OT - programmed cell death ligand 1 OT - urothelial carcinoma COIS- The authors report no conflicts of interest in this work. EDAT- 2019/06/14 06:00 MHDA- 2019/06/14 06:01 PMCR- 2019/05/08 CRDT- 2019/06/14 06:00 PHST- 2018/06/12 00:00 [received] PHST- 2019/03/07 00:00 [accepted] PHST- 2019/06/14 06:00 [entrez] PHST- 2019/06/14 06:00 [pubmed] PHST- 2019/06/14 06:01 [medline] PHST- 2019/05/08 00:00 [pmc-release] AID - 176937 [pii] AID - 10.2147/CMAR.S176937 [doi] PST - epublish SO - Cancer Manag Res. 2019 May 8;11:4171-4184. doi: 10.2147/CMAR.S176937. eCollection 2019. PMID- 31188732 OWN - NLM STAT- MEDLINE DCOM- 20191209 LR - 20191217 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 202 IP - 4 DP - 2019 Oct TI - American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model? PG - 682-688 LID - 10.1097/JU.0000000000000389 [doi] AB - PURPOSE: We evaluated the AUA (American Urological Association)/SUO (Society of Urologic Oncology) nonmuscle invasive bladder cancer risk model to predict nonmuscle invasive bladder cancer recurrence and progression prior to death. MATERIALS AND METHODS: We performed a retrospective analysis using electronic medical records and cancer registry data of patients with nonmuscle invasive bladder cancer in a multicenter United States patient population. We evaluated recurrence-free and progression-free survival according to the AUA/SUO nonmuscle invasive bladder cancer risk model. We then assessed discriminative performance with the c-index and compared the cumulative incidence of recurrence, progression and death across 4 age groups. RESULTS: We identified 1,297 patients with nonmuscle invasive bladder cancer. Median followup in the cohort was 3.2 years. The c-index of the AUA/SUO recurrence model was 0.62 and for progression it was higher at 0.77. Patients younger than 60 years had a 40% greater probability of recurrent nonmuscle invasive bladder cancer vs death while patients 84 years old or older had a 12% greater probability of death prior to recurrence at 5 years. This study was limited by its retrospective design. CONCLUSIONS: The AUA/SUO nonmuscle invasive bladder cancer risk model provides predictive performance of recurrence and progression similar to that of previous similar risk models, such as the models of the European Organization for Research and Treatment of Cancer, the Club Urologico Espanol de Tratamiento Oncologico and the National Comprehensive Cancer Network(R). This work illustrates the need to consider age in predictive tools for clinicians who treat patients with nonmuscle invasive bladder cancer. FAU - Ravvaz, Kourosh AU - Ravvaz K AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin. FAU - Weissert, John A AU - Weissert JA AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin. FAU - Downs, Tracy M AU - Downs TM AD - Department of Urology, School of Medicine and Public Health and Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin. LA - eng PT - Journal Article PT - Validation Study DEP - 20190906 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2019 Oct;202(4):688. doi: 10.1097/01.JU.0000577668.06655.a5. PMID: 31766089 MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/pathology MH - Prognosis MH - Progression-Free Survival MH - Registries/statistics & numerical data MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - United States/epidemiology MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*mortality/pathology OTO - NOTNLM OT - bladder neoplasms OT - decision support techniques OT - local OT - medical OT - neoplasm recurrence OT - risk OT - societies EDAT- 2019/06/13 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/06/13 06:00 PHST- 2019/06/13 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/06/13 06:00 [entrez] AID - 10.1097/JU.0000000000000389 [doi] PST - ppublish SO - J Urol. 2019 Oct;202(4):682-688. doi: 10.1097/JU.0000000000000389. Epub 2019 Sep 6. PMID- 31188729 OWN - NLM STAT- MEDLINE DCOM- 20191206 LR - 20200122 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 202 IP - 5 DP - 2019 Nov TI - Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. PG - 927-935 LID - 10.1097/JU.0000000000000386 [doi] AB - PURPOSE: Radical cystectomy is the gold standard for nonmetastatic muscle invasive bladder cancer and for refractory nonmuscle invasive disease. Compared to open radical cystectomy, robot-assisted radical cystectomy has been shown to provide comparable early oncologic outcomes and improved perioperative outcomes. However, there is a paucity of data on long-term oncologic outcomes and concerns about a higher incidence of local recurrence after robot-assisted radical cystectomy. We report 10-year oncologic outcomes following robot-assisted radical cystectomy using a multinational database. MATERIALS AND METHODS: We retrospectively reviewed the prospective International Robotic Cystectomy Consortium database. Consecutive patients who underwent robot-assisted radical cystectomy 10 years ago or earlier were included in analysis. Data were reviewed for demographics, and perioperative, pathological and oncologic outcomes. Kaplan-Meier curves were used to depict recurrence-free, disease specific and overall survival. Multivariate stepwise Cox regression models were applied to identify variables associated with recurrence-free, disease specific and overall survival. RESULTS: We identified 446 patients with a median age of 67 years (IQR 59-76). Of the patients 10% received neoadjuvant chemotherapy, 51% experienced any complication, 23% had high grade complications and 4% died within 3 months of robot-assisted radical cystectomy. Disease was pT3 or greater in 43% of patients and pN+ in 24% while a positive soft tissue surgical margin was observed in 7%. At a median followup of 5 years (IQR 2-10, maximum 14) local and distant recurrence had developed in 15% and 29% of patients, respectively. Ten-year recurrence-free, disease specific and overall survival rates were 59%, 65% and 35%, respectively. Patients with pT3 or greater and pN+ disease showed worse recurrence-free, disease specific and overall survival. CONCLUSIONS: Long-term oncologic outcomes, and recurrence rates and patterns after robot-assisted radical cystectomy seem comparable to those in open series. Advanced disease stage and positive surgical margins remain the main determinants of survival after radical cystectomy. FAU - Hussein, Ahmed A AU - Hussein AA AD - Roswell Park Comprehensive Cancer Center, New York, New York. FAU - Elsayed, Ahmed S AU - Elsayed AS AD - Roswell Park Comprehensive Cancer Center, New York, New York. FAU - Aldhaam, Naif A AU - Aldhaam NA AD - Roswell Park Comprehensive Cancer Center, New York, New York. FAU - Jing, Zhe AU - Jing Z AD - Roswell Park Comprehensive Cancer Center, New York, New York. FAU - Osei, Jennifer AU - Osei J AD - Roswell Park Comprehensive Cancer Center, New York, New York. FAU - Kaouk, Jihad AU - Kaouk J AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Redorta, Juan Palou AU - Redorta JP AD - Fundacio Puigvert, Barcelona, Spain. FAU - Menon, Mani AU - Menon M AD - Henry Ford Health System, Detroit, Michigan. FAU - Peabody, James AU - Peabody J AD - Henry Ford Health System, Detroit, Michigan. FAU - Dasgupta, Prokar AU - Dasgupta P AD - Guy's Hospital and King's College London School of Medicine, London, United Kingdom. FAU - Khan, Mohammed Shamim AU - Khan MS AD - Guy's Hospital and King's College London School of Medicine, London, United Kingdom. FAU - Mottrie, Alexandre AU - Mottrie A AD - Onze-Lieve-Vrouw Ziekenhuis, Aalast, Belgium. FAU - Stockle, Michael AU - Stockle M AD - University of the Saarland, Homburg Saar, Germany. FAU - Hemal, Ashok AU - Hemal A AD - Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. FAU - Richstone, Lee AU - Richstone L AD - Arthur Smith Institute for Urology, New York, New York. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Karolinska Institute, Stockholm, Sweden. FAU - Wiklund, Peter AU - Wiklund P AD - Karolinska Institute, Stockholm, Sweden. FAU - Schanne, Francis AU - Schanne F AD - Urological Surgical Associates of Delaware, Wilmington, Delaware. FAU - Kim, Eric AU - Kim E AD - Washington University School of Medicine, St. Louis, Missouri. FAU - Ho Rha, Koon AU - Ho Rha K AD - Yonsei Medical Health System, Seoul, South Korea. FAU - Guru, Khurshid A AU - Guru KA AD - Roswell Park Comprehensive Cancer Center, New York, New York. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20191009 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2019 Nov;202(5):935. doi: 10.1097/01.JU.0000578536.34232.c9. PMID: 31343943 CIN - J Urol. 2019 Nov;202(5):934-935. doi: 10.1097/01.JU.0000578532.32446.3d. PMID: 31343944 CIN - J Urol. 2020 Mar;203(3):624. doi: 10.1097/JU.0000000000000631. PMID: 31682537 CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S502-S504. doi: 10.21037/tau.2019.08.19. PMID: 32042631 CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S521-S523. doi: 10.21037/tau.2019.12.05. PMID: 32042637 MH - Aged MH - Cystectomy/*methods MH - Disease-Free Survival MH - Europe/epidemiology MH - Female MH - Follow-Up Studies MH - *Forecasting MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Risk Factors MH - Robotic Surgical Procedures/*methods MH - Survival Rate/trends MH - United States/epidemiology MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - cystectomy OT - mortality OT - recurrence OT - robotic surgical procedures OT - urinary bladder neoplasms EDAT- 2019/06/13 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/06/13 06:00 PHST- 2019/06/13 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/06/13 06:00 [entrez] AID - 10.1097/JU.0000000000000386 [doi] PST - ppublish SO - J Urol. 2019 Nov;202(5):927-935. doi: 10.1097/JU.0000000000000386. Epub 2019 Oct 9. PMID- 31182759 OWN - NLM STAT- MEDLINE DCOM- 20201014 LR - 20240717 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 Jun 10 TI - Detection of novel biomarkers for early detection of Non-Muscle-Invasive Bladder Cancer using Competing Endogenous RNA network analysis. PG - 8434 LID - 10.1038/s41598-019-44944-3 [doi] LID - 8434 AB - Bladder Cancer (BC) is one of the most common cancers in the world. Recent studies show that non-coding RNAs such as lncRNAs and circRNAs play critical roles in the progression of this cancer, but their regulatory relationships and functions are still largely unknown. As a new regulatory process within the cell, the coding and non-coding RNAs compete with each other to sponge their target miRNAs. This mechanism is described as "the competing endogenous RNA (ceRNA) hypothesis" which provides a new perspective to understand the regulation of gene expression in health and diseases such as cancer. In this study, to investigate the role of non-coding RNAs in BC, a new approach was used to reconstruct the ceRNA network for Non-Muscle Invasive Bladder Cancer (NMIBC) based on the expression data of coding and non-coding genes. Analysis of ceRNA networks in the early stage of BC led to the detection of an important module containing the lncRNA MEG3 as the central gene. The results show that the lncRNAs CARMN, FENDRR and ADAMTS9-AS2 may regulate MEG3 in NMIBC through sponging some important miRNAs such as miR-143-3p, miR-106a-5p and miR-34a-3p. Also, the lncRNA AC007608.2 is shown to be a potential BC related lncRNA for the first time based on ceRNA stage-specific network analysis. Furthermore, hub and altered genes in stage-specific and between stage networks led to the detection of hsa_circ_0017586 and hsa_circ_0001741 as novel potential circRNAs related to NMIBC. Finally, the hub genes in the networks were shown to be valuable candidates as biomarkers for the early stage diagnosis of BC. FAU - Kouhsar, Morteza AU - Kouhsar M AUID- ORCID: 0000-0001-6092-3016 AD - Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. FAU - Azimzadeh Jamalkandi, Sadegh AU - Azimzadeh Jamalkandi S AUID- ORCID: 0000-0003-3403-3700 AD - Chemical Injury Research Center, Systems Biology and Poisonings Institute, Tehran, Iran. FAU - Moeini, Ali AU - Moeini A AD - Faculty of Engineering Sciences, College of Engineering, University of Tehran, Tehran, Iran. FAU - Masoudi-Nejad, Ali AU - Masoudi-Nejad A AD - Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. amasoudin@ut.ac.ir. LA - eng PT - Journal Article DEP - 20190610 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) SB - IM MH - Biomarkers, Tumor/*genetics MH - *Early Detection of Cancer MH - Gene Expression Regulation, Neoplastic MH - *Gene Regulatory Networks MH - Genes, Neoplasm MH - Humans MH - RNA, Messenger/genetics/metabolism MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/*genetics PMC - PMC6557814 COIS- The authors declare no competing interests. EDAT- 2019/06/12 06:00 MHDA- 2020/10/21 06:00 PMCR- 2019/06/10 CRDT- 2019/06/12 06:00 PHST- 2019/03/19 00:00 [received] PHST- 2019/05/28 00:00 [accepted] PHST- 2019/06/12 06:00 [entrez] PHST- 2019/06/12 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/06/10 00:00 [pmc-release] AID - 10.1038/s41598-019-44944-3 [pii] AID - 44944 [pii] AID - 10.1038/s41598-019-44944-3 [doi] PST - epublish SO - Sci Rep. 2019 Jun 10;9(1):8434. doi: 10.1038/s41598-019-44944-3. PMID- 31177305 OWN - NLM STAT- MEDLINE DCOM- 20210128 LR - 20210128 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 38 IP - 4 DP - 2020 Apr TI - Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. PG - 1001-1007 LID - 10.1007/s00345-019-02841-4 [doi] AB - PURPOSE: To investigate the symptoms and delays in the clinical pathway of bladder cancer (BC). METHODS: This is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations are studied in pTa bladder cancer with high risk for recurrence. The data of presenting symptoms and critical time points were prospectively collected, and the effect of factors on delays was analyzed. RESULTS: At the time of analysis, 245 patients were randomized. Analysis included 131 patients with primary bladder cancer and their complete data. Sixty-nine percent had smoking history and 67% presented with macroscopic hematuria. Median patient delay (from symptoms to health-care contact) was 7 days. The median general practice delay (from health-care contact to urology referral) was 8 days. Median time from urology referral to cystoscopy was 23 days and from cystoscopy to TUR-BT 21 days. Total time used in the clinical pathway (from symptom to TUR-BT) was 78 days. Current and former smokers had non-significantly shorter patient-related and general practice delays compared to never smokers. TUR-BT delay was significantly shorter in patients with malignant cytology (16 days) compared to patients with benign cytology (21 days, p = 0.03). CONCLUSIONS: Patient-derived delay was short and most of the delay occurred in the referral centers. The majority had macroscopic hematuria as the initial symptom. Surprisingly, current and past smokers were more prone to contact the health-care system compared to never smokers. FAU - Sell, Ville AU - Sell V AUID- ORCID: 0000-0003-0899-5981 AD - Department of Urology, Turku University Hospital, Turku, Finland. ville.sell@gmail.com. FAU - Ettala, Otto AU - Ettala O AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Montoya Perez, Ileana AU - Montoya Perez I AD - Department of Future Technology, University of Turku, Turku, Finland. FAU - Jarvinen, Riikka AU - Jarvinen R AD - Department of Urology, Helsinki University Hospital, Helsinki, Finland. FAU - Pekkarinen, Tarmo AU - Pekkarinen T AD - Department of Urology, Tampere University Hospital, Tampere, Finland. FAU - Vaarala, Markku AU - Vaarala M AD - Department of Urology, Oulu University Hospital, Oulu, Finland. FAU - Seppanen, Marjo AU - Seppanen M AD - Department of Surgery, Satakunta Central Hospital, Pori, Finland. FAU - Liukkonen, Tapani AU - Liukkonen T AD - Department of Surgery, Mikkeli Central Hospital, Mikkeli, Finland. FAU - Marttila, Timo AU - Marttila T AD - Department of Surgery, Seinajoki Central Hospital, Seinajoki, Finland. FAU - Aaltomaa, Sirpa AU - Aaltomaa S AD - Department of Urology, Kuopio University Hospital, Kuopio, Finland. FAU - Kaasinen, Eero AU - Kaasinen E AD - Department of Surgery, Hospital of Hyvinkaa, Hyvinkaa, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20190608 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - *Delayed Diagnosis MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Prospective Studies MH - *Risk Assessment MH - Symptom Assessment MH - Urinary Bladder Neoplasms/*diagnosis/*epidemiology PMC - PMC7154016 OTO - NOTNLM OT - Bladder cancer OT - Diagnosis OT - Diagnostic delay OT - Hematuria OT - Symptoms COIS- The authors declare that they have no conflict of interest. EDAT- 2019/06/10 06:00 MHDA- 2021/01/29 06:00 PMCR- 2019/06/08 CRDT- 2019/06/10 06:00 PHST- 2019/04/02 00:00 [received] PHST- 2019/06/03 00:00 [accepted] PHST- 2019/06/10 06:00 [pubmed] PHST- 2021/01/29 06:00 [medline] PHST- 2019/06/10 06:00 [entrez] PHST- 2019/06/08 00:00 [pmc-release] AID - 10.1007/s00345-019-02841-4 [pii] AID - 2841 [pii] AID - 10.1007/s00345-019-02841-4 [doi] PST - ppublish SO - World J Urol. 2020 Apr;38(4):1001-1007. doi: 10.1007/s00345-019-02841-4. Epub 2019 Jun 8. PMID- 31164632 OWN - NLM STAT- MEDLINE DCOM- 20200706 LR - 20250425 IS - 2041-4889 (Electronic) VI - 10 IP - 6 DP - 2019 Jun 4 TI - The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression. PG - 437 LID - 10.1038/s41419-019-1669-z [doi] LID - 437 AB - The prognosis of bladder cancer (BCa) depends on several key factors including anatomical site, tumor grade, and stage. In general, muscle-invasive bladder cancer (MIBC) is associated with higher incidence of distant metastasis compared with Non-muscle-invasive bladder cancer (NMIBC). Treatment outcome of the patients with metastatic BCa has been very poor with ~15% of overall survival rate. Thus, it is apparently important to understand the underlying biology for metastatic progression of BCa. Although epithelial-mesenchymal transition (EMT) has long been implicated in BCa metastasis and treatment resistance, the underlying mechanism is not fully understood. In this study, we have identified that the expression of interferon induced protein with tetratricopeptide repeats 5 (IFIT5) is positively correlated with pathological characteristics, and predicts a poor prognosis of BCa patients. Since the function of IFIT5 in BCa has not yet been characterized, we demonstrate that IFIT5 can induce EMT, promote cell migration and invasion, and increase the expression of ICAM1 in BCa via down-regulation of mature miR-99a. Moreover, ICAM1 is shown as a direct target of miR-99a. Overall, we conclude that IFIT5 is a new oncogene in BCa. FAU - Huang, Jun AU - Huang J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, P.R. China. FAU - Lo, U-Ging AU - Lo UG AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Wu, Shiqi AU - Wu S AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. FAU - Wang, Bin AU - Wang B AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. FAU - Pong, Rey-Chen AU - Pong RC AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Lai, Chih-Ho AU - Lai CH AD - Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Lin, Ho AU - Lin H AUID- ORCID: 0000-0001-7849-9137 AD - Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan. FAU - He, Dalin AU - He D AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. FAU - Hsieh, Jer-Tsong AU - Hsieh JT AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. jt.hsieh@utsouthwestern.edu. AD - Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan. jt.hsieh@utsouthwestern.edu. FAU - Wu, Kaijie AU - Wu K AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China. kaijie_wu@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190604 PL - England TA - Cell Death Dis JT - Cell death & disease JID - 101524092 RN - 0 (ICAM1 protein, human) RN - 0 (IFIT5 protein, human) RN - 0 (MIRN99 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Neoplasm Proteins) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) SB - IM EIN - Cell Death Dis. 2025 Apr 25;16(1):339. doi: 10.1038/s41419-025-07632-x. PMID: 40280954 MH - Animals MH - Cell Line, Tumor MH - Cell Movement MH - Cell Proliferation/*genetics MH - Disease Progression MH - Epithelial-Mesenchymal Transition/*genetics MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Intercellular Adhesion Molecule-1/genetics/metabolism MH - Male MH - Mice MH - Mice, Nude MH - MicroRNAs/genetics/metabolism MH - Neoplasm Metastasis MH - Neoplasm Proteins/genetics/*metabolism MH - Prognosis MH - Transplantation, Heterologous MH - Urinary Bladder Neoplasms/genetics/*metabolism/pathology PMC - PMC6547745 COIS- The authors declare that they have no conflict of interest. EDAT- 2019/06/06 06:00 MHDA- 2020/07/07 06:00 PMCR- 2019/06/04 CRDT- 2019/06/06 06:00 PHST- 2019/01/13 00:00 [received] PHST- 2019/05/15 00:00 [accepted] PHST- 2019/04/25 00:00 [revised] PHST- 2019/06/06 06:00 [entrez] PHST- 2019/06/06 06:00 [pubmed] PHST- 2020/07/07 06:00 [medline] PHST- 2019/06/04 00:00 [pmc-release] AID - 10.1038/s41419-019-1669-z [pii] AID - 1669 [pii] AID - 10.1038/s41419-019-1669-z [doi] PST - epublish SO - Cell Death Dis. 2019 Jun 4;10(6):437. doi: 10.1038/s41419-019-1669-z. PMID- 31164444 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20190729 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 72 IP - 8 DP - 2019 Aug TI - Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. PG - 550-553 LID - 10.1136/jclinpath-2019-205742 [doi] AB - AIMS: To describe a large tertiary care academic centre's experience with patients who achieve a complete pathological response (ie, ypT0N0) following neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with emphasis on morphological features present in the RC and clinical outcome. METHODS: 41 patients with ypT0N0 disease following transurethral resection of bladder tumour (TURBT), NAC and RC with available clinical follow-up information were analysed. Slides from all RCs were reviewed to confirm pathological stage and assess for morphological parameters (eg, foreign body giant cell reaction, dystrophic calcification, scar and fat necrosis). RESULTS: With median follow-up of 32.8 months, the recurrence-free survival at 1 and 5 years was 97.4% and 93.5%, while the overall survival at 3 and 5 years was 94.2% and 88.6%, respectively. No patients died of urothelial carcinoma. Stage assigned at TURBT was 1 pTa (2%), 1 pT1 (2%), 38 pT2 (93%) and 1 pT3a (2%). 17 TURBTs demonstrated variant histology, with the majority of these being squamous (65%). The most common morphological features present at RC were scar (100%), foreign body giant cell reaction (80%), chronic inflammation within lamina propria (68%) and dystrophic calcifications (39%). Other morphological features were less common or absent. CONCLUSION: ypT0N0 disease at RC portends an excellent prognosis, regardless of stage or variant histology in the TURBT; scar, foreign body giant cell reaction, chronic inflammation and dystrophic calcifications are often present. CI - (c) Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Magers, Martin J AU - Magers MJ AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Barboza, Marcelo P AU - Barboza MP AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Bandali, Elhaam AU - Bandali E AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Adra, Nabil AU - Adra N AD - Divisoin of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Koch, Michael O AU - Koch MO AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Cheng, Liang AU - Cheng L AUID- ORCID: 0000-0001-6049-5293 AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA liang_cheng@yahoo.com. AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA. LA - eng PT - Journal Article DEP - 20190604 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 MH - Aged MH - Carcinoma/mortality/secondary/*therapy MH - Chemotherapy, Adjuvant MH - *Cystectomy/adverse effects/mortality MH - Databases, Factual MH - Disease Progression MH - Female MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - *Neoadjuvant Therapy/adverse effects/mortality MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Progression-Free Survival MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Urothelium/*pathology OTO - NOTNLM OT - bladder OT - histopathology OT - neoadjuvant chemotherapy OT - prognosis OT - staging OT - urothelial carcinoma COIS- Competing interests: None declared. EDAT- 2019/06/06 06:00 MHDA- 2019/07/30 06:00 CRDT- 2019/06/06 06:00 PHST- 2019/01/25 00:00 [received] PHST- 2019/05/09 00:00 [revised] PHST- 2019/05/18 00:00 [accepted] PHST- 2019/06/06 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2019/06/06 06:00 [entrez] AID - jclinpath-2019-205742 [pii] AID - 10.1136/jclinpath-2019-205742 [doi] PST - ppublish SO - J Clin Pathol. 2019 Aug;72(8):550-553. doi: 10.1136/jclinpath-2019-205742. Epub 2019 Jun 4. PMID- 31164309 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20210518 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 43 IP - 9 DP - 2019 Nov TI - Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. PG - 503-508 LID - S0210-4806(19)30073-7 [pii] LID - 10.1016/j.acuro.2018.12.004 [doi] AB - OBJECTIVES: Aim of this study is to evaluate the correlation between European Organization for Research and Treatment of Cancer (EORTC) risk score and neutrophil-lymphocyte ratio (NLR) in patients with non-muscle invasive bladder cancer and the relationship between NLR and risk groups. METHODS: We retrospectively reviewed data of 212 patients with non-muscle invasive bladder cancer were included in the study. The tumors were graded according to the 1973 World Health Organization grading system and the tumor node metastasis (TNM) 2012 staging system. Patients were categorized low, intermediate and high risk for recurrence and progression, according to European Association of Urology guidelines. Serum values for the NLR were measured on the day before the operation to ascertain the baseline value for neutrophil and lymphocyte counts and statistically analyzed. RESULTS: Of the 212 patients, 193 were male and 19 were female. Mean age was 66.7. Mean NLR score was 3.04+/-2.11. T1 tumors, G3 tumors, multiple tumors and>3cm tumors seen mostly in patients with NLR>2.41. Low, intermediate and high risk groups compared and NLR rates were significantly higher in high risk group patients (P<.001). When the correlation between NLR and EORTC recurrence and progression scores was evaluated, it was observed that as NLR value increased, recurrence (r=0.252, P<.001) and progression (r=0.145, P=.034) scores increased significantly. CONCLUSIONS: This study demonstrated the association of high NLR value with T1 tumor, high grade, multiple tumor,>3cm tumor and EORTC high risk group in non-muscle invasive bladder cancer patients. There was also a positive correlation between NLR and EORTC recurrence and progression scores. CI - Copyright (c) 2019 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Aydin, M AU - Aydin M AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. Electronic address: mustafaydin28@gmail.com. FAU - Bitkin, A AU - Bitkin A AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. FAU - Kadihasanoglu, M AU - Kadihasanoglu M AD - Department of Urology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turquia. FAU - Irkilata, L AU - Irkilata L AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. FAU - Akgunes, E AU - Akgunes E AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. FAU - Keles, M AU - Keles M AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. FAU - Atilla, M K AU - Atilla MK AD - Department of Urology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turquia. LA - eng LA - spa PT - Journal Article TT - Correlacion entre el indice neutrofilo/linfocito y las puntuaciones de riesgo en el cancer de vejiga no musculo-invasivo. DEP - 20190601 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Correlation of Data MH - Disease Progression MH - Female MH - Humans MH - Leukocyte Count MH - *Lymphocytes MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - *Neutrophils MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*blood/pathology/surgery MH - Young Adult OTO - NOTNLM OT - Bladder cancer risk score OT - Cancer de vejiga no musculo-invasivo OT - Neutrophil-lymphocyte ratio OT - Non-muscle invasive bladder cancer OT - Puntuacion de riesgo de cancer de vejiga OT - Indice neutrofilo/linfocito EDAT- 2019/06/06 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/06/06 06:00 PHST- 2018/09/18 00:00 [received] PHST- 2018/11/10 00:00 [revised] PHST- 2018/12/02 00:00 [accepted] PHST- 2019/06/06 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/06/06 06:00 [entrez] AID - S0210-4806(19)30073-7 [pii] AID - 10.1016/j.acuro.2018.12.004 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2019 Nov;43(9):503-508. doi: 10.1016/j.acuro.2018.12.004. Epub 2019 Jun 1. PMID- 31160192 OWN - NLM STAT- MEDLINE DCOM- 20200416 LR - 20200416 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 4 DP - 2019 Aug TI - Moreau Strain Bacillus Calmette-Guerin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study. PG - e779-e783 LID - S1558-7673(19)30129-6 [pii] LID - 10.1016/j.clgc.2019.04.003 [doi] AB - PURPOSE: To evaluate recurrence, progression, and cancer-specific mortality of high-grade T1 non-muscle-invasive bladder cancer by assessing receipt of a low dose of the underexplored bacillus Calmette-Guerin (BCG) Moreau strain in a retrospective observational cohort study. PATIENTS AND METHODS: From January 2006 to December 2015, a total of 219 consecutive patients with high-grade T1 non-muscle-invasive bladder cancer received half-dose (40 mg; n = 109) or standard-dose (80 mg; n = 110) BCG Moreau strain after transurethral resection of the bladder. BCG therapy was initiated 2 or 3 weeks after transurethral resection of the bladder using the following protocol: 6 weekly doses, 12 monthly, 4 once every 3 months, and 2 once every 6 months, with a total of 24 doses. RESULTS: Comparing the half-dose and standard-dose treatment groups, in a median follow-up of 74.6 months, recurrence (n = 51, 46.8% vs. n = 60, 54.5%, P = .28), progression (n = 18, 16.5% vs. n = 16, 14.5%, P = .69), and disease-specific mortality (n = 9, 8.3% vs. n = 5, 4.5%, P = .26) were not significantly different on Kaplan-Meier curves and log-rank test, respectively. Charlson comorbidity index was an independent predictor of death from disease (hazard ratio = 1.341; 95% confidence interval, 1.033-1.740; P = .0274); no predictor of recurrence or progression was identified. Treatment intolerance occurred in 1 (0.9%) versus 6 (5.4%) patients (P = .12), respectively. No hospital admission or systemic BCG toxicity was reported. CONCLUSION: To our knowledge, this is the largest low-dose Moreau BCG strain study in high-grade T1 scenario. A half dose of BCG Moreau strain might be safe and effective in terms of tumor control, progression, or cancer-specific mortality with a low complication rate, which is central to the worldwide scenario of BCG shortage, and can help regulatory agencies approve efficient daughter BCG strains. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Carneiro, Bruno D B AU - Carneiro BDB AD - UroScience, Pontifical University of Campinas and University of Campinas, Campinas, Sao Paulo, Brazil. FAU - Sanches, Brunno C F AU - Sanches BCF AD - UroScience, Pontifical University of Campinas and University of Campinas, Campinas, Sao Paulo, Brazil. FAU - Andrade, Danilo L AU - Andrade DL AD - UroScience, Pontifical University of Campinas and University of Campinas, Campinas, Sao Paulo, Brazil. FAU - Voris, Brunno R I AU - Voris BRI AD - UroScience, Pontifical University of Campinas and University of Campinas, Campinas, Sao Paulo, Brazil. FAU - Reis, Leonardo O AU - Reis LO AD - UroScience, Pontifical University of Campinas and University of Campinas, Campinas, Sao Paulo, Brazil. Electronic address: reisleo.l@gmail.com. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20190416 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*administration & dosage/therapeutic use MH - Chemotherapy, Adjuvant MH - Cystectomy/*methods MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Daughter strains OT - Progression OT - Recurrence OT - Survival OT - Urothelial carcinoma EDAT- 2019/06/05 06:00 MHDA- 2020/04/17 06:00 CRDT- 2019/06/05 06:00 PHST- 2019/02/13 00:00 [received] PHST- 2019/03/28 00:00 [revised] PHST- 2019/04/09 00:00 [accepted] PHST- 2019/06/05 06:00 [pubmed] PHST- 2020/04/17 06:00 [medline] PHST- 2019/06/05 06:00 [entrez] AID - S1558-7673(19)30129-6 [pii] AID - 10.1016/j.clgc.2019.04.003 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Aug;17(4):e779-e783. doi: 10.1016/j.clgc.2019.04.003. Epub 2019 Apr 16. PMID- 31158085 OWN - NLM STAT- MEDLINE DCOM- 20191021 LR - 20191022 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 1 IP - 5 DP - 2018 Oct TI - Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project. PG - 437-442 LID - S2588-9311(18)30066-X [pii] LID - 10.1016/j.euo.2018.05.006 [doi] AB - BACKGROUND: It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study started in February 2008, and currently still active, at a tertiary university hospital, including patients with pathologically confirmed NMIBC who experienced recurrence during follow-up. INTERVENTION: AS monitoring consisted of cytology and in-office flexible cystoscopy every 3 mo for the first year, and every 6 mo thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was pathological results for patients who failed to remain on AS. The secondary outcome was an update of clinical results from our previous series. Data were complemented by descriptive statistical analysis and univariable and multivariable proportional hazards Cox regression. RESULTS AND LIMITATIONS: Overall, 167 patients were included. Of 181 AS events, 61 (33.7%) were deemed to require treatment because of positive cytology (n=10), gross haematuria (n=11), and increases in the tumour number (n=15), or size (n=17), or both (n=8). The median time on AS was 12 mo (interquartile range 4-26). Pathological specimens from AS failures did not show any malignancy in 20 cases. Histopathology identified urothelial hyperplasia and oedema, submucosal vascular ectasia, mucosal erosion, polypoid cystitis, von Brunn nest hyperplasia, and squamous metaplasia. The time from first transurethral resection to AS start was inversely associated with recurrence-free survival (hazard ratio 0.97, 95% confidence interval 0.96-1.00; p=0.024). The study lacks statistical subanalyses focusing on patients with failure and negative neoplastic pathological outcomes. CONCLUSIONS: AS might be a reasonable strategy in patients presenting with small LG pTa/pT1a recurrent bladder tumours. Approximately 30% of patients deemed to have AS failure did not harbour any neoplastic lesion, strengthening the role of AS. PATIENT SUMMARY: Patients with small low-grade pTa/pT1a recurrent papillary bladder tumours could benefit from an active surveillance protocol with no significant risk of pathological progression to muscle-invasive cancer. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. Electronic address: massimo.lazzeri@humanitas.it. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Buffi, Nicolo Maria AU - Buffi NM AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Elefante, Grazia Maria AU - Elefante GM AD - Department of Pathology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Morenghi, Emanuela AU - Morenghi E AD - Department of Biomedical Science, Humanitas University, Rozzano, Italy; Department of Biostatistics, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Forni, Giovanni AU - Forni G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Cardone, Pasquale AU - Cardone P AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Lista, Giuliana AU - Lista G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Maffei, Davide AU - Maffei D AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20180605 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*diagnosis/epidemiology/*pathology/therapy MH - Cohort Studies MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Italy/epidemiology MH - Lost to Follow-Up MH - Male MH - Middle Aged MH - *Patient Compliance/statistics & numerical data MH - Prognosis MH - Prospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/*pathology/therapy MH - *Watchful Waiting/statistics & numerical data OTO - NOTNLM OT - Active surveillance OT - Non-muscle-invasive bladder cancer OT - Pathological examination OT - Treatment EDAT- 2019/06/04 06:00 MHDA- 2019/10/23 06:00 CRDT- 2019/06/04 06:00 PHST- 2018/03/27 00:00 [received] PHST- 2018/05/01 00:00 [revised] PHST- 2018/05/10 00:00 [accepted] PHST- 2019/06/04 06:00 [entrez] PHST- 2019/06/04 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] AID - S2588-9311(18)30066-X [pii] AID - 10.1016/j.euo.2018.05.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2018 Oct;1(5):437-442. doi: 10.1016/j.euo.2018.05.006. Epub 2018 Jun 5. PMID- 31158079 OWN - NLM STAT- MEDLINE DCOM- 20191021 LR - 20191022 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 1 IP - 5 DP - 2018 Oct TI - Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. PG - 403-410 LID - S2588-9311(18)30088-9 [pii] LID - 10.1016/j.euo.2018.06.006 [doi] AB - BACKGROUND: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). OBJECTIVE: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non-muscle-invasive urothelial BC (NIMBC). DESIGN, SETTING, AND PARTICIPANTS: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo. INTERVENTION: TURBT with intravesical chemotherapy or immunotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regression analysis was performed to identify factors predictive of recurrence, progression, cancer-specific mortality, and overall mortality. A systemic inflammatory marker (SIM) score was calculated based on cutoffs for NLR, PLR, and LMR. RESULTS AND LIMITATIONS: The 48-mo recurrence-free survival was 80.8%, 47.35%, 20.67%, and 17.06% for patients with an SIM score of 0, 1, 2, and 3, respectively (p<0.01, log-rank test) while the corresponding 48-mo progression free-survival was 92.0%, 75.67%, 72.85%, and 63.1% (p<0.01, log-rank test). SIM scores of 1, 2, and 3 were associated with recurrence (hazard ratio [HR] 3.73, 7.06, and 7.88) and progression (HR 3.15, 4.41, and 5.83). Limitations include the lack of external validation and comparison to other clinical risk models. CONCLUSIONS: Patients with high-grade T1 stage NMIBC with high SIM scores have worse oncologic outcomes in terms of recurrence and progression. Further studies should be conducted to stratify patients according to SIM scores to identify individuals who might benefit from early cystectomy. PATIENT SUMMARY: In this study, we defined a risk score (the SIM score) based on the measurement of routine systemic inflammatory markers. This score can identify patients with high-grade bladder cancer not invading the muscular layer who are more likely to suffer from tumor recurrence and progression. Therefore, the score could be used to select patients who might benefit from early bladder removal. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Russo, Giorgio I AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. Electronic address: giorgioivan1987@gmail.com. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology, Milan, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Farhan, Abdal Rahman Abu AU - Farhan ARA AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Di Stasi, Savino M AU - Di Stasi SM AD - Department of Surgery and Experimental Medicine, University Tor Vergata, Rome, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Hospital, Milan, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Urology, University of Palermo, Palermo, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Scafuro, Chiara AU - Scafuro C AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale IRCCS, Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Cioffi, Antonio AU - Cioffi A AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. FAU - Almeida, Gilberto L AU - Almeida GL AD - Department of Urology, University of Vale do Itajai, Itajai, Brazil. FAU - Bove, Pierluigi AU - Bove P AD - Department of Urology, Humanitas Hospital, Milan, Italy. FAU - Lima, Estevao AU - Lima E AD - Department of CUF Urology and Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Ucciero, Giuseppe AU - Ucciero G AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Matei, Deliu Victor AU - Matei DV AD - Division of Urology, European Institute of Oncology, Milan, Italy; Department of Urology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. FAU - Verze, Paolo AU - Verze P AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Surgery and Experimental Medicine, University Tor Vergata, Rome, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, University of Palermo, Palermo, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Morgia, Giuseppe AU - Morgia G AD - Department of Urology, University of Catania, Catania, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20180713 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/*blood MH - Blood Platelets/pathology MH - Carcinoma, Transitional Cell/*blood/*diagnosis/pathology/surgery MH - Cystectomy/methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Inflammation/*blood MH - Lymphocyte Count MH - Lymphocytes/pathology MH - Male MH - Monocytes/pathology MH - Neutrophils/pathology MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/*blood/*diagnosis/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Lymphocyte/monocyte ratio OT - Neutrophil/lymphocyte ratio OT - Platelet/lymphocyte ratio OT - Prognosis EDAT- 2019/06/04 06:00 MHDA- 2019/10/23 06:00 CRDT- 2019/06/04 06:00 PHST- 2018/01/05 00:00 [received] PHST- 2018/06/02 00:00 [revised] PHST- 2018/06/12 00:00 [accepted] PHST- 2019/06/04 06:00 [entrez] PHST- 2019/06/04 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] AID - S2588-9311(18)30088-9 [pii] AID - 10.1016/j.euo.2018.06.006 [doi] PST - ppublish SO - Eur Urol Oncol. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13. PMID- 31155372 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20210518 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 43 IP - 8 DP - 2019 Oct TI - Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder. PG - 445-451 LID - S0210-4806(19)30066-X [pii] LID - 10.1016/j.acuro.2019.02.006 [doi] AB - INTRODUCTION AND OBJECTIVES: Various studies tried to validate Club Urologico Espanol de Tratamiento Oncologico (CUETO) tables, yet, none of this papers focused on the high and very high risk bladder cancers. The aim of the study was to externally validate the CUETO model for predicting disease recurrence and progression in group of T1G3 tumors treated with BCG immunotherapy. PATIENTS OR MATERIALS AND METHODS: Data from 414 patients with primary T1G3 bladder cancer were analysed. To evaluate the model discrimination, Cox proportional hazard regression models were created and concordance indexes were calculated. RESULTS: The median follow-up was 68 months. The recurrence was observed in 212 (51.2%) and 64 patients (15.5%) experienced the recurrence more than once during the study follow-up. Progression of the cancer was observed in 106 patients (25.6%). Radical cystectomy was performed in 115 patients (27.8%) and there were 64 (15.5%) cancer specific deaths. For recurrence and progression probability, the concordance index of the CUETO models was 0.633 and 0.697 respectively. CUETO tables underestimated significantly the risk of recurrence and marginally the risk of progression in the first year of observation. For 5 years of observation, the trend for the recurrence was much less clear. On the contrary, there was slight overestimation in the risk of progression. The study is limited by retrospective nature. CONCLUSIONS: It was shown that the CUETO risk tables exhibit a fair discrimination for both disease recurrence and progression in T1G3 patients treated with BCG. CUETO scoring model underestimates the risk of tumor recurrence, but predicts well risk of progression. CI - Copyright (c) 2019 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Krajewski, W AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Polonia. FAU - Rodriguez-Faba, O AU - Rodriguez-Faba O AD - Servicio de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. Electronic address: ORODRIGUEZ@fundacio-puigvert.es. FAU - Breda, A AU - Breda A AD - Servicio de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Pisano, F AU - Pisano F AD - Servicio de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Poletajew, S AU - Poletajew S AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Polonia. FAU - Tukiendorf, A AU - Tukiendorf A AD - Social Medicine Department, Wroclaw Medical University, Wroclaw, Polonia. FAU - Zdrojowy, R AU - Zdrojowy R AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Polonia. FAU - Kolodziej, A AU - Kolodziej A AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Polonia. FAU - Palou, J AU - Palou J AD - Servicio de Urologia, Fundacion Puigvert, Universidad Autonoma de Barcelona, Barcelona, Espana. LA - eng LA - spa PT - Journal Article PT - Validation Study TT - Validacion de las tablas del grupo CUETO para predecir la recurrencia y progresion del carcinoma urotelial de vejiga T1G3. DEP - 20190530 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/epidemiology/pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Models, Statistical MH - Neoplasm Recurrence, Local/epidemiology MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/epidemiology/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bacilo Calmette-Guerin OT - Bladder cancer OT - Cancer de vejiga OT - Evaluacion de riesgos OT - Progresion OT - Progression OT - Recidiva OT - Recurrence OT - Risk assessment OT - Validacion OT - Validation EDAT- 2019/06/04 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/06/04 06:00 PHST- 2018/11/17 00:00 [received] PHST- 2019/01/23 00:00 [revised] PHST- 2019/02/13 00:00 [accepted] PHST- 2019/06/04 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/06/04 06:00 [entrez] AID - S0210-4806(19)30066-X [pii] AID - 10.1016/j.acuro.2019.02.006 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2019 Oct;43(8):445-451. doi: 10.1016/j.acuro.2019.02.006. Epub 2019 May 30. PMID- 31154670 OWN - NLM STAT- MEDLINE DCOM- 20200518 LR - 20200518 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 127 IP - 7 DP - 2019 Jul TI - Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer. PG - 465-469 LID - 10.1002/cncy.22152 [doi] AB - BACKGROUND: The objective of this study was to evaluate the diagnostic accuracy of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer (NMIBC) and to compare it with the accuracy of urinary cytology, cystoscopy, and/or histology. METHODS: In total, 243 patients were enrolled in the current study. Patients were evaluated by voided urine cytology, by the Bladder EpiCheck test, and by white-light cystoscopy. RESULTS: Overall sensitivity was 33.3% for cytology, 62.3% for Bladder EpiCheck, and 66.7% for the 2 tests combined. The sensitivity of cytology increased from 7.7% in low-grade (LG) tumors to 66.6% in high-grade (HG) tumors; whereas, for the Bladder EpiCheck test, the sensitivity was 46.1% in LG tumors and 83.3% in HG tumors. Combined cytology and Bladder EpiCheck testing yielded an overall sensitivity of 56.4% for LG tumors and 90% for HG tumors. Overall specificity was 98.6% for cytology, 86.3% for Bladder EpiCheck, and 85.6% for the 2 tests combined. The positive predictive value was 92% for cytology and 68.2% for Bladder EpiCheck. For the 2 tests combined, it was 68.6%. The negative predictive value was similar for the 2 tests: 75.8% for cytology, 82.9% for Bladder EpiCheck, and 84.5% for the 2 tests combined. CONCLUSIONS: The sensitivity of the Bladder EpiCheck test was significantly higher than that of cytology. The test performed very well in terms of specificity but could not reach the high value of cytology. The positive predictive value was higher for Bladder EpiCheck, whereas the negative predictive value was approximately the same for both tests. CI - (c) 2019 American Cancer Society. FAU - Trenti, Emanuela AU - Trenti E AUID- ORCID: 0000-0003-3034-531X AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy. FAU - D'Elia, Carolina AU - D'Elia C AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Mian, Christine AU - Mian C AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Schwienbacher, Christine AU - Schwienbacher C AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Hanspeter, Esther AU - Hanspeter E AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Pycha, Alexander AU - Pycha A AD - Department of Urology, Lucerne Canton Hospital, Lucerne, Switzerland. FAU - Kafka, Mona AU - Kafka M AD - Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Degener, Stephan AU - Degener S AD - Department of Urology, Helios-Klinikum Wuppertal, Witten Herdecke University, Wuppertal, Germany. FAU - Danuser, Hansjorg AU - Danuser H AD - Department of Urology, Lucerne Canton Hospital, Lucerne, Switzerland. FAU - Roth, Stephan AU - Roth S AD - Department of Urology, Helios-Klinikum Wuppertal, Witten Herdecke University, Wuppertal, Germany. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy. AD - Medical School, Sigmund Freud Private University, Vienna, Austria. LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article DEP - 20190602 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics/urine MH - Cystoscopy MH - DNA Methylation MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Urinary Bladder/diagnostic imaging/*pathology MH - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology/urine MH - Urine/chemistry/*cytology OTO - NOTNLM OT - bladder cancer OT - cytology OT - follow-up OT - non-muscle-invasive OT - urinary marker EDAT- 2019/06/04 06:00 MHDA- 2020/05/19 06:00 CRDT- 2019/06/03 06:00 PHST- 2019/03/24 00:00 [received] PHST- 2019/04/28 00:00 [revised] PHST- 2019/05/06 00:00 [accepted] PHST- 2019/06/04 06:00 [pubmed] PHST- 2020/05/19 06:00 [medline] PHST- 2019/06/03 06:00 [entrez] AID - 10.1002/cncy.22152 [doi] PST - ppublish SO - Cancer Cytopathol. 2019 Jul;127(7):465-469. doi: 10.1002/cncy.22152. Epub 2019 Jun 2. PMID- 31154583 OWN - NLM STAT- MEDLINE DCOM- 20200110 LR - 20200225 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 51 IP - 7 DP - 2019 Jul TI - Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. PG - 1089-1099 LID - 10.1007/s11255-019-02183-5 [doi] AB - Bacillus Calmette-Guerin (BCG) instillations are considered as a gold standard of therapy in high- and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Unfortunately, up to 40% of patients might experience treatment failure and even 15% of patients initially diagnosed with NMIBC will progress to muscle-invasive disease. Since patients, who fail to respond to BCG, are at particular risk of progression, immediate radical cystectomy (RC) is currently recommended to provide cancer control. However, immunotherapy in NMIBC management still evolves. Immune checkpoint inhibitors emerge as new immunotherapeutics, which in the future might be combined with BCG and may serve as an alternative to radical cystectomy in patients, who failed to respond to BCG alone or are at particular a priori risk of BCG failure, especially if RC is not a safe option. Therefore, there is an urgent need to identify NMIBC patients that will not benefit from BCG therapy and demand radical cystectomy. In the following review, we attempt to focus on several clinical and molecular factors and demonstrate the efforts directed to unravel their significance in BCG-failure risk assessment. FAU - Slusarczyk, Aleksander AU - Slusarczyk A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Zapala, Piotr AU - Zapala P AUID- ORCID: 0000-0002-0569-4203 AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. zapala.piotrek@gmail.com. FAU - Zapala, Lukasz AU - Zapala L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Piecha, Tomasz AU - Piecha T AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20190601 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/*pharmacology MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - Risk Assessment MH - Treatment Failure MH - *Urinary Bladder Neoplasms/pathology/therapy OTO - NOTNLM OT - BCG failure OT - BCG response OT - BCG-refractory bladder cancer OT - High-risk non-muscle-invasive bladder cancer EDAT- 2019/06/04 06:00 MHDA- 2020/01/11 06:00 CRDT- 2019/06/03 06:00 PHST- 2019/03/21 00:00 [received] PHST- 2019/05/26 00:00 [accepted] PHST- 2019/06/04 06:00 [pubmed] PHST- 2020/01/11 06:00 [medline] PHST- 2019/06/03 06:00 [entrez] AID - 10.1007/s11255-019-02183-5 [pii] AID - 10.1007/s11255-019-02183-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2019 Jul;51(7):1089-1099. doi: 10.1007/s11255-019-02183-5. Epub 2019 Jun 1. PMID- 31153747 OWN - NLM STAT- MEDLINE DCOM- 20200721 LR - 20200721 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 8 DP - 2019 Aug TI - Prognostic performance of the 1973 and 2004 WHO grading classification in upper tract urothelial carcinoma. PG - 529.e19-529.e25 LID - S1078-1439(19)30014-6 [pii] LID - 10.1016/j.urolonc.2019.01.013 [doi] AB - BACKGROUND: Grading of upper tract urothelial carcinoma (UTUC) is routinely used in clinical practice; however, reports concerning prognostic performance of different grading systems are contradictory. We aim to assess the clinical reliability of the 1973 and 2004 World Health Organization (WHO) grading classification systems in UTUC. PATIENTS AND METHODS: We retrospectively evaluated 458 consecutive patients with UTUC from 2008 to 2013. The postoperative tumor grades were evaluated by a single uropathologist using the 1973 and 2004 WHO grade classification systems. The Kaplan-Meier method was used to estimate cancer-specific survival (CSS) and overall survival (OS). Univariate and multivariate analyses were used to test the association between clinical variables and the CSS and OS rates. RESULTS: There were 133 (29.0%) low-grade patients and 325 (71.0%) high-grade patients. The 3-year CSS rates were 87.0% and 76.0% for G2 and G3 disease and 89.0% and 80.0% for low- and high-grade disease according to the 2004 system, respectively. For all UTUC patients, there were significant differences in the CSS and OS rates between G2 and G3 cases, as well as between the low- and high-grade groups. The CSS and OS rates were significantly different between the G2 and G3 cases for the overall high-grade population (CSS: P = 0.003; OS: P = 0.009), while no significant difference emerged between low- and high-grade tumors in G2 UTUC patients (CSS: P = 0.717; OS: P = 0.280). In the subgroup of high-grade non-muscle-invasive tumors, the 1973 WHO grading system was an independent predictor of CSS (P = 0.045). CONCLUSIONS: The results support the hypothesis that the 1973 WHO system is superior to the 2004 system for predicting clinical outcomes in patients with non-muscle-invasive UTUC. CI - Copyright (c) 2019. Published by Elsevier Inc. FAU - Guan, Bao AU - Guan B AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Tang, Shiying AU - Tang S AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhan, Yonghao AU - Zhan Y AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Li, Yifan AU - Li Y AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Peng, Ding AU - Peng D AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Gong, Yanqing AU - Gong Y AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - He, Shiming AU - He S AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Yang, Kunlin AU - Yang K AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Liu, Libo AU - Liu L AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China; Department of Pathology, Peking University First Hospital, Xicheng, Beijing, China. FAU - He, Qun AU - He Q AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China; Department of Pathology, Peking University First Hospital, Xicheng, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: pineneedle@sina.com. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Xicheng, Beijing, China; Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: zhoulqmail@sina.com. LA - eng PT - Historical Article PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190530 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Female MH - History, 20th Century MH - History, 21st Century MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Prognosis MH - Urologic Neoplasms/*classification/pathology OTO - NOTNLM OT - 1973 World Health Organization OT - 2004 World Health Organization OT - Grading OT - Upper tract urothelial carcinoma EDAT- 2019/06/04 06:00 MHDA- 2020/07/22 06:00 CRDT- 2019/06/03 06:00 PHST- 2018/10/11 00:00 [received] PHST- 2019/01/03 00:00 [revised] PHST- 2019/01/13 00:00 [accepted] PHST- 2019/06/04 06:00 [pubmed] PHST- 2020/07/22 06:00 [medline] PHST- 2019/06/03 06:00 [entrez] AID - S1078-1439(19)30014-6 [pii] AID - 10.1016/j.urolonc.2019.01.013 [doi] PST - ppublish SO - Urol Oncol. 2019 Aug;37(8):529.e19-529.e25. doi: 10.1016/j.urolonc.2019.01.013. Epub 2019 May 30. PMID- 31149909 OWN - NLM STAT- MEDLINE DCOM- 20200123 LR - 20200123 IS - 1533-4031 (Electronic) IS - 1072-4109 (Linking) VI - 26 IP - 5 DP - 2019 Sep TI - Urothelial Carcinoma In Situ (CIS): New Insights. PG - 313-319 LID - 10.1097/PAP.0000000000000239 [doi] AB - Urothelial carcinoma in situ (CIS) is a high-grade noninvasive malignancy with a high tendency of progression. Although it is typically grouped with other nonmuscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity. Urothelial CIS is histologically characterized by replacement of the urothelium by cells which fulfill the morphologic criteria of malignancy including nuclear pleomorphism, hyperchromasia, prominent nucleoli, and increased numbers of normal and abnormal mitoses. Urothelial CIS may be categorized as primary when it is not associated with any past or present urothelial carcinoma. It is termed as secondary when there is concomitant or previous urothelial carcinoma in the patient. In recent years detailed molecular studies have provided valuable data for intrinsic molecular subclassification of urothelial carcinoma into 2 broad categories namely luminal and basal types with significant implications for prognosis and therapy. Similar studies on urothelial CIS are limited but have provided crucial insight into the molecular basis of CIS. These studies have revealed that urothelial CIS may also be divided into luminal and basal subtypes, but luminal subtype is much more common. It has also been shown that in many cases, luminal type of urothelial CIS may undergo a class switch to basal type during progression to an invasive carcinoma. Additional studies may be required to confirm and further elaborate these findings. FAU - Akhtar, Mohammed AU - Akhtar M AD - Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar. FAU - Al-Bozom, Issam A AU - Al-Bozom IA FAU - Ben Gashir, Mohamed AU - Ben Gashir M FAU - Taha, Noheir M AU - Taha NM FAU - Rashid, Sameera AU - Rashid S FAU - Al-Nabet, Ajayeb D M H AU - Al-Nabet ADMH LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Anat Pathol JT - Advances in anatomic pathology JID - 9435676 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/analysis MH - Carcinoma in Situ/diagnosis/*pathology MH - Carcinoma, Transitional Cell/diagnosis/*pathology MH - Humans MH - Prognosis MH - Urinary Bladder Neoplasms/diagnosis/*pathology MH - Urologic Neoplasms/diagnosis/*pathology EDAT- 2019/06/01 06:00 MHDA- 2020/01/24 06:00 CRDT- 2019/06/01 06:00 PHST- 2019/06/01 06:00 [pubmed] PHST- 2020/01/24 06:00 [medline] PHST- 2019/06/01 06:00 [entrez] AID - 10.1097/PAP.0000000000000239 [doi] PST - ppublish SO - Adv Anat Pathol. 2019 Sep;26(5):313-319. doi: 10.1097/PAP.0000000000000239. PMID- 31145947 OWN - NLM STAT- MEDLINE DCOM- 20200116 LR - 20200901 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 131 DP - 2019 Sep TI - Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-Muscle-invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors. PG - 112-119 LID - S0090-4295(19)30448-0 [pii] LID - 10.1016/j.urology.2019.04.036 [doi] AB - OBJECTIVE: To understand cystoscopic surveillance practices among patients with low-risk non-muscle-invasive bladder cancer (NMIBC) within the Department of Veterans Affairs (VA). METHODS: Using a validated natural language processing algorithm, we included patients newly diagnosed with low-risk (ie low-grade Ta) NMIBC from 2005 to 2011 in the VA. Patients were followed until cancer recurrence, death, last contact, or 2 years after diagnosis. Based on guidelines, surveillance overuse was defined as >1 cystoscopy if followed <1 year, >2 cystoscopies if followed 1 to <2 years, or >3 cystoscopies if followed for 2 years. We identified patient, provider, and facility factors associated with overuse using multilevel logistic regression. RESULTS: Overuse occurred in 75% of patients (852/1135) - with an excess of 1846 more cystoscopies performed than recommended. Adjusting for 14 factors, overuse was associated with patient race (odds ratio [OR] 0.49, 95% confidence interval [CI]: 0.28, 0.85 unlisted race vs White), having 2 comorbidities (OR 1.60, 95% CI: 1.00, 2.55 vs no comorbidities), and earlier year of diagnosis (OR 2.50, 95% CI: 1.29, 4.83 for 2005 vs 2011, and OR 2.03, 95% CI: 1.11, 3.69 for 2006 vs 2011). On sensitivity analyses assuming all patients were diagnosed with multifocal or large low-grade tumors (ie, intermediate-risk), overuse would have still occurred in 45% of patients. CONCLUSION: Overuse of cystoscopy among patients with low-risk NMIBC was common, raising concerns about bladder cancer surveillance cost and quality. However, few factors were associated with overuse. Further qualitative research is needed to identify other determinants of overuse not readily captured in administrative data. CI - Published by Elsevier Inc. FAU - Han, David S AU - Han DS AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH. FAU - Lynch, Kristine E AU - Lynch KE AD - VA Salt Lake City Health Care System and the Division of Epidemiology, University of Utah, Salt Lake City, UT. FAU - Chang, Ji Won AU - Chang JW AD - VA Salt Lake City Health Care System and the Division of Epidemiology, University of Utah, Salt Lake City, UT. FAU - Sirovich, Brenda AU - Sirovich B AD - The White River Junction VA Medical Center, White River Junction, VT. FAU - Robertson, Douglas J AU - Robertson DJ AD - The White River Junction VA Medical Center, White River Junction, VT. FAU - Swanton, Amanda R AU - Swanton AR AD - Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH. FAU - Seigne, John D AU - Seigne JD AD - Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. FAU - Goodney, Philip P AU - Goodney PP AD - The White River Junction VA Medical Center, White River Junction, VT. FAU - Schroeck, Florian R AU - Schroeck FR AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, NH; The White River Junction VA Medical Center, White River Junction, VT; Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: florian.r.schroeck@dartmouth.edu. LA - eng GR - I01 HX001880/HX/HSRD VA/United States PT - Journal Article DEP - 20190528 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2019 Sep;131:118-119. doi: 10.1016/j.urology.2019.04.038. PMID: 31451152 MH - Aged MH - Cohort Studies MH - Cystoscopy/*statistics & numerical data MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Procedures and Techniques Utilization/*statistics & numerical data MH - Retrospective Studies MH - Risk Assessment MH - United States MH - Urinary Bladder Neoplasms/epidemiology/*pathology MH - Watchful Waiting PMC - PMC6711796 MID - NIHMS1036077 COIS- Declarations of interest: JDS, 100 common stock of Johnson and Johnson. All additional coauthors, no conflict of interest. EDAT- 2019/05/31 06:00 MHDA- 2020/01/17 06:00 PMCR- 2020/09/01 CRDT- 2019/05/31 06:00 PHST- 2018/12/14 00:00 [received] PHST- 2019/03/05 00:00 [revised] PHST- 2019/04/06 00:00 [accepted] PHST- 2019/05/31 06:00 [pubmed] PHST- 2020/01/17 06:00 [medline] PHST- 2019/05/31 06:00 [entrez] PHST- 2020/09/01 00:00 [pmc-release] AID - S0090-4295(19)30448-0 [pii] AID - 10.1016/j.urology.2019.04.036 [doi] PST - ppublish SO - Urology. 2019 Sep;131:112-119. doi: 10.1016/j.urology.2019.04.036. Epub 2019 May 28. PMID- 31144582 OWN - NLM STAT- MEDLINE DCOM- 20200825 LR - 20200825 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 53 IP - 4 DP - 2019 Aug TI - Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe). PG - 200-205 LID - 10.1080/21681805.2019.1621377 [doi] AB - Purpose: To investigate the management of TaG3 tumours of the urinary bladder using nationwide population-based data in relation to the prevailing guidelines, patients' characteristics, and outcome.Materials and methods: The Bladder Cancer Data Base Sweden (BladderBaSe), including data from the Swedish National Register for Urinary Bladder Cancer (SNRUBC), was used to study all patients with TaG3 bladder cancer diagnosed from 2008 to 2014. Patients were divided into the following management groups: (1) transurethral resection (TUR) only, (2) TUR and intravesical instillation therapy (IVIT), (3) TUR and second-look resection (SLR), and (4) TUR with both SLR and IVIT. Patient and tumour characteristics and outcome were studied.Results: There were 831 patients (83% males) with a median age of 74 years. SLR was performed more often on younger patients, on men, and less often in the Western and Uppsala/Orebro Healthcare regions. IVIT was performed more often with younger patients, with men, in the Western Healthcare region, and less often in the Uppsala/Orebro Healthcare region. Death from bladder cancer occurred in 6% of cases within a median of 29 months (0-84 months) and was lower in the TUR/IVIT and TUR/SLR/IVIT groups compared to the other two groups.Conclusion: In the present study, there was, according to the prevailing treatment guidelines, an under-treatment with SLR for older patients, women, and in some healthcare regions and, similarly, there was an under-treatment with IVIT for older patients. Cancer-specific survival and relative survival were lower in the TUR only group compared to the TUR/IVIT and TUR/SLR/IVIT groups. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, Orebro University Hospital, Orebro, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Rosell, Johan AU - Rosell J AD - Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University Hospital, Umea, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Department of Biobank Research, Umea University, Umea, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - School of Medicine, King's College London, London, UK. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. LA - eng PT - Journal Article DEP - 20190530 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Age Factors MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/mortality/pathology/*therapy MH - Combined Modality Therapy MH - Cystectomy/statistics & numerical data MH - Cystoscopy/*statistics & numerical data MH - Databases, Factual MH - Female MH - Geography MH - Guideline Adherence MH - Humans MH - Kaplan-Meier Estimate MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Staging MH - Practice Guidelines as Topic MH - Proportional Hazards Models MH - Radiotherapy/statistics & numerical data MH - Second-Look Surgery/*statistics & numerical data MH - Sweden MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - TaG3 OT - intravesical instillation treatment OT - population-based OT - second-look resection EDAT- 2019/05/31 06:00 MHDA- 2020/08/26 06:00 CRDT- 2019/05/31 06:00 PHST- 2019/05/31 06:00 [pubmed] PHST- 2020/08/26 06:00 [medline] PHST- 2019/05/31 06:00 [entrez] AID - 10.1080/21681805.2019.1621377 [doi] PST - ppublish SO - Scand J Urol. 2019 Aug;53(4):200-205. doi: 10.1080/21681805.2019.1621377. Epub 2019 May 30. PMID- 31144485 OWN - NLM STAT- MEDLINE DCOM- 20191203 LR - 20191203 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 71 IP - 4 DP - 2019 Aug TI - Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS. PG - 406-412 LID - 10.23736/S0393-2249.19.03254-5 [doi] AB - BACKGROUND: The aim of this study was to identify the predictive factors for progression defined as any event that shifted the management of the disease from a bladder sparing approach, by comparing patients with pure versus non-pure carcinoma in situ (CIS) of the bladder. METHODS: A retrospective analysis was carried out in consecutive patients affected by newly-diagnosed pure CIS and non-pure CIS (excluding cases with concomitant muscle invasive cancer). All patients were enrolled a in our institution from 1998 to 2010. Data was prospectively collected. Main end point was progression-free survival. RESULTS: Overall, 149 patients with CIS were identified for the analysis. A total of 98 patients had pure CIS (66%). Median follow-up was 103 months (range: 40-206 months). Progression occurred in 29 patients (19%). A total of 30 patients died during the follow-up (20%). In 13 cases (9%), the death was cancer specific. Progression-free survival estimate was 181 months (95% CI: 169-193 months) and 154 months (95% CI: 133-176 months) respectively for pure and non-pure CIS population (P=0.03). Among examined variables (age, gender, symptoms, smoking habit, ASA score, number of bacillus Calmette-Guerin [BCG] instillations), multivariate analysis disclosed that only CIS type was an independent predictor of progression (P=0.03) with a relative risk of 0.37 in favor of pure CIS. CONCLUSIONS: Pure and non-pure CIS are efficiently treated by BCG therapy combined with trans-urethral resection and/or radical cystectomy, with relatively low rate of progression. CIS type was the only significant predictor of progression. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy - alberto.saita@humanitas.it. FAU - Naselli, Angelo AU - Naselli A AD - Unit of Urology, San Giuseppe Hospital, MultiMedica, Milan, Italy. FAU - Guarneri, Andrea AU - Guarneri A AD - University Unit of Urology, San Giuseppe Hospital, MultiMedica, Milan, Italy. FAU - Buffi, Nicolo M AU - Buffi NM AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Fasulo, Vittorio AU - Fasulo V AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Mondellini, Giulio M AU - Mondellini GM AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Domanico, Luigi AU - Domanico L AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Peschechera, Roberto AU - Peschechera R AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Benetti, Alessio AU - Benetti A AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Zandegiacomo, Silvia AU - Zandegiacomo S AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Lista, Giuliana AU - Lista G AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Pasini, Luisa AU - Pasini L AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. AD - Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20190528 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Carcinoma in Situ/mortality/*pathology MH - Combined Modality Therapy MH - Cystectomy MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/mortality/*pathology MH - Urologic Surgical Procedures EDAT- 2019/05/31 06:00 MHDA- 2019/12/04 06:00 CRDT- 2019/05/31 06:00 PHST- 2019/05/31 06:00 [pubmed] PHST- 2019/12/04 06:00 [medline] PHST- 2019/05/31 06:00 [entrez] AID - S0393-2249.19.03254-5 [pii] AID - 10.23736/S0393-2249.19.03254-5 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2019 Aug;71(4):406-412. doi: 10.23736/S0393-2249.19.03254-5. Epub 2019 May 28. PMID- 31129781 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20200225 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 51 IP - 8 DP - 2019 Aug TI - Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience. PG - 1335-1342 LID - 10.1007/s11255-019-02172-8 [doi] AB - PURPOSE: In recent years, second-look transurethral resection of bladder tumors (TURBT) has been recommended for patients with stage T1 bladder cancer after the initial TURBT for restaging and deciding the subsequent treatment. However, we believe that second-look TURBT has therapeutic benefits, such as low incidence of recurrence and progression. Therefore, we compare the differences in long-term outcome between patients who did and did not accept second-look TURBT for stage T1 bladder cancer. METHODS: We assessed 504 patients diagnosed with urothelial carcinoma who underwent initial TURBT between January 2012 and December 2016 at a single medical center; of these patients, 177 were diagnosed with T1 bladder cancer during the initial TURBT, and we excluded no muscle from the specimen in the initial TURBT. The patients were categorized into groups 1 and 2 based on the acceptance of second-look TURBT, which was performed within 4-14 weeks after the initial TURBT. Group 1 underwent second-look TURBT, but group 2 did not. Both groups were followed-up for recurrence-free survival (RFS) and progression-free survival (PFS), and the risk factors for recurrence and progression were analyzed. RESULTS: In total, 93 (52.5%) patients in group 1 underwent second-look TURBT, and 84 (47.5%) in group 2 did not. The 2-year RFS rates were 74.6% and 60.0% and the PFS rates were 91.2% and 87.5% in groups 1 and 2, respectively. CONCLUSION: This study demonstrated higher recurrence-free and progression-free survival rates for patients who underwent second-look TURBT. This result emphasizes the importance of second-look TURBT in stage T1 bladder cancer not only for restaging but also for therapeutic benefit. FAU - Tseng, Wen-Hsin AU - Tseng WH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Liu, Chien-Liang AU - Liu CL AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. wyeun523@gmail.com. AD - Division of Uro-Oncology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. wyeun523@gmail.com. FAU - Huang, Steven K AU - Huang SK AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Liao, Alex Chien-Hwa AU - Liao AC AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Kuo, Jinn-Rung AU - Kuo JR AD - Division of Neurosurgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Hun, Shun-Hsing AU - Hun SH AD - Division of Urology, Department of Surgery, Chi Mei Hospital, Chiali, Tainan, Taiwan. FAU - Chen, Chun-Hao AU - Chen CH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Su, Chia-Cheng AU - Su CC AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Wang, Jhih-Cheng AU - Wang JC AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Lee, Kau-Han AU - Lee KH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Shen, Kun-Hung AU - Shen KH AD - Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. FAU - Li, Chien-Feng AU - Li CF AD - Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan. LA - eng PT - Journal Article DEP - 20190525 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Reoperation MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Second-look TURBT OT - T1 bladder cancer OT - Therapeutic benefit OT - Transurethral resection of bladder tumors EDAT- 2019/05/28 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/05/27 06:00 PHST- 2019/02/09 00:00 [received] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/05/28 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/05/27 06:00 [entrez] AID - 10.1007/s11255-019-02172-8 [pii] AID - 10.1007/s11255-019-02172-8 [doi] PST - ppublish SO - Int Urol Nephrol. 2019 Aug;51(8):1335-1342. doi: 10.1007/s11255-019-02172-8. Epub 2019 May 25. PMID- 31127897 OWN - NLM STAT- MEDLINE DCOM- 20191206 LR - 20191218 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 20 IP - 5 DP - 2019 May 25 TI - Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guerin Therapy. PG - 1389-1392 AB - Objective: Bacillus Calmette-Guerin (BCG) intravesical therapy is currently established using a low dose because of the high incidence of side-effects. Moreover, shortening the dwell time of BCG is conducted in some facilities owing to the complications associated with a long dwell time after injection. The method of BCG administration varies in each facility and even with each doctor. We evaluated whether the dwell-time and dose differences in patients who underwent intravesical BCG therapy is related to completion rates, adverse effects, and nonrecurrence rates. Methods: From November 2006 to April 2016, a total of 173 patients who received intravesical BCG therapy after transurethral resection of bladder tumor or transurethral biopsy were evaluated retrospectively. We allocated them into 4 groups based on the dose (40 or 80 mg BCG) and the dwell time (1 or 2 hours). Completion rate, side effects, and nonrecurrence rates were evaluated. Results: No significant improvement in the completion rate or reduction in side-effects was observed in any of the regimens. Although nonrecurrence rates for the 1-hour dwell time tended to be lower than the 2-hour dwell time, the difference was not significant. Conclusion: Our study suggests that reducing the BCG dose or shortening the dwell time does not reduce adverse effects or affect the nonrecurrence rate. CI - Creative Commons Attribution License FAU - Nagai, Takashi AU - Nagai T AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Okamura, Takehiko AU - Okamura T AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Tanaka, Yutaro AU - Tanaka Y AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Japan FAU - Moritoki, Yoshinobu AU - Moritoki Y AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Kobayashi, Daichi AU - Kobayashi D AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Kobayashi, Takahiro AU - Kobayashi T AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Akita, Hidetoshi AU - Akita H AD - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan. Email: hiko2546@sf.commufa.jp FAU - Yasui, Takahiro AU - Yasui T AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Japan LA - eng PT - Journal Article DEP - 20190525 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*administration & dosage MH - Dose-Response Relationship, Drug MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology/*prevention & control MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Urinary Bladder Neoplasms/pathology/*prevention & control PMC - PMC6857891 OTO - NOTNLM OT - *BCG OT - *dwell-time difference OT - *dose difference EDAT- 2019/05/28 06:00 MHDA- 2019/12/18 06:00 PMCR- 2019/03/01 CRDT- 2019/05/26 06:00 PHST- 2019/05/26 06:00 [entrez] PHST- 2019/05/28 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/03/01 00:00 [pmc-release] AID - APJCP-20-1389 [pii] AID - 10.31557/APJCP.2019.20.5.1389 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2019 May 25;20(5):1389-1392. doi: 10.31557/APJCP.2019.20.5.1389. PMID- 31126772 OWN - NLM STAT- MEDLINE DCOM- 20200416 LR - 20200416 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 4 DP - 2019 Aug TI - Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. PG - e751-e758 LID - S1558-7673(19)30134-X [pii] LID - 10.1016/j.clgc.2019.04.008 [doi] AB - BACKGROUND: The aim of the study was to investigate the feasibility of Epidermal Growth Factor Receptor (EGFR) measurement in bladder washings of patients affected by non-muscle-invasive bladder cancer (NMIBC) and its prognostic role in identifying risk subgroups and predicting disease recurrence and progression. PATIENTS AND METHODS: Patients with NMIBC treated with transurethral resection of bladder tumor (TURBT) from 2012 to 2015 were enrolled. Samples of bladder washings were collected and stored at -80 degrees C until RNA extraction. The cDNA obtained from RNA was used to perform a gene expression analysis by a real time polymerase chain reaction. RESULTS: An adequate cellular pellet was obtained in 50 (86.2%) of 58 patients and in 18 (85.7%) of 21 controls. Patients had a median 2.5-, a 1.6- and a 2.8-fold EGFR expression compared with controls before, during, and after adjuvant treatment, respectively. Patients at higher risk had a significantly higher EGFR expression compared with patients at low and intermediate risk when EGFR was measured during (P = .04) and after (P = .001) adjuvant therapy. At a median follow-up of 35.5 months (interquartile range, 19.0-54.8 months), in the high-risk group, patients with overexpression had a significantly lower recurrence-free survival (27.9% vs. 58%), progression-free survival (75.9% vs. 90.2%), and cancer-specific survival (77.7% vs. 93.3%). At multivariable analysis, EGFR overexpression was an additional independent prognostic factor to the European Organisation for Research and Treatment of Cancer scoring system of disease recurrence (hazard ratio, 1.98; 95% confidence interval, 1.32-2.97) and progression (hazard ratio, 1.84; 95% confidence interval, 1.27-2.65). CONCLUSIONS: EGFR overexpression might represent an additional parameter to the current clinical tools for an individualized risk stratification. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Scalici Gesolfo, Cristina AU - Scalici Gesolfo C AD - Section of Urology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Cangemi, Antonina AU - Cangemi A AD - Section of Medical Oncology, Department of Surgical, Oncological, and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Allegro, Rosalinda AU - Allegro R AD - Department of Statistics, University of Palermo, Palermo, Italy. FAU - Sforza, Simone AU - Sforza S AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Cocci, Andrea AU - Cocci A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Tellini, Riccardo AU - Tellini R AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Masieri, Lorenzo AU - Masieri L AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Russo, Antonio AU - Russo A AD - Section of Medical Oncology, Department of Surgical, Oncological, and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Carini, Marco AU - Carini M AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Minervini, Andrea AU - Minervini A AD - Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Section of Urology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. Electronic address: vincenzo.serretta@unipa.it. LA - eng PT - Journal Article DEP - 20190426 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Administration, Intravesical MH - Aged MH - Chemotherapy, Adjuvant/*methods MH - Cystectomy/*methods MH - Disease Progression MH - ErbB Receptors/genetics MH - Feasibility Studies MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Prognosis MH - Treatment Outcome MH - *Up-Regulation MH - Urinary Bladder Neoplasms/genetics/*therapy OTO - NOTNLM OT - Biomarker OT - Bladder washing OT - Epidermal Growth Factor Receptor (EGFR) OT - Molecular classification OT - Non-Muscle Invasive Bladder Cancer (NMIBC) EDAT- 2019/05/28 06:00 MHDA- 2020/04/17 06:00 CRDT- 2019/05/26 06:00 PHST- 2019/01/24 00:00 [received] PHST- 2019/04/01 00:00 [revised] PHST- 2019/04/09 00:00 [accepted] PHST- 2019/05/28 06:00 [pubmed] PHST- 2020/04/17 06:00 [medline] PHST- 2019/05/26 06:00 [entrez] AID - S1558-7673(19)30134-X [pii] AID - 10.1016/j.clgc.2019.04.008 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Aug;17(4):e751-e758. doi: 10.1016/j.clgc.2019.04.008. Epub 2019 Apr 26. PMID- 31123852 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20260127 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 37 IP - 11 DP - 2019 Nov TI - Consultation on UTUC, Stockholm 2018: aspects of treatment. PG - 2279-2287 LID - 10.1007/s00345-019-02811-w [doi] AB - PURPOSE: To provide an overview of treatment modalities for management of upper tract urothelial carcinoma (UTUC). METHODS: In accordance with the standards for a scoping review, data presentation and discussion at the Consultation on UTUC in Stockholm, 6-7 September 2018, consensus was reached on the latest and most important treatment recommendations for UTUC. Using Pubmed, Web of Science, and Embase, publications were selected based on quality, clinical relevance, and level of evidence. RESULTS: Kidney-sparing surgery should be attempted for low-grade UTUC. Radical nephroureterectomy with bladder cuff excision is first option for high-grade disease. Post-operative bladder instillation of chemotherapy should be offered after RNU to reduce intravesical recurrence rate. Identification of tumor grade and stage is crucial when selecting treatment. Ureteroscopic management of low-grade and non-invasive UTUC achieves disease-free survival similar to that offered by radical nephroureterectomy but seems to be a risk factor for intravesical recurrence. Lymphadenectomy appears important for high-risk disease, although the therapeutic benefit needs further validation. There is little evidence supporting use of Bacillus Calmette-Guerin (BCG) and mitomycin C as monotherapy and adjuvant treatment in UTUC. A randomized clinical trial has indicated that platin-based chemotherapy for invasive UTUC improves disease-free survival, suggesting that adjuvant chemotherapy should be considered standard care for >/= T2 N0-3M0 disease. CONCLUSIONS: Risk stratification assessment is feasible and mandatory in UTUC. Identification of tumor grade and stage is essential for optimal treatment selection. Kidney-sparing surgery should be offered in low-risk disease, whereas radical nephroureterectomy and adjuvant chemotherapy should be considered in high-risk disease. FAU - Jung, Helene AU - Jung H AD - Department of Urology, Urological Research Center, Lillebaelt Hospital, University of Southern Denmark, Vejle, Denmark. FAU - Giusti, Guido AU - Giusti G AD - Department of Urology, IRCCS San Raffaele Hospital, Ville Turro Division, Milan, Italy. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Herrmann, Thomas AU - Herrmann T AD - Department of Urology, Kantonsspital Frauenfeld, Frauenfeld, Switzerland. FAU - Jones, Robert AU - Jones R AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK. FAU - Straub, Michael AU - Straub M AD - Department of Urology, University Hospital Klinikum rechts der Isar, Technical University Munich, Munich, Germany. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Osther, Palle Jorn Sloth AU - Osther PJS AD - Department of Urology, Urological Research Center, Lillebaelt Hospital, University of Southern Denmark, Vejle, Denmark. FAU - Brehmer, Marianne AU - Brehmer M AUID- ORCID: 0000-0001-9232-363X AD - Division of Urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Solna, Sweden. marianne.brehmer@ki.se. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20190523 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) SB - IM MH - Antineoplastic Agents/therapeutic use MH - Carcinoma, Transitional Cell/*therapy MH - Humans MH - Kidney Neoplasms/*therapy MH - Nephrectomy/methods MH - Sweden MH - Ureter/surgery MH - Ureteral Neoplasms/*therapy PMC - PMC6825640 OTO - NOTNLM OT - Adjuvant treatment OT - BCG instillation OT - Chemotherapy OT - Kidney-sparing surgery OT - Lymph node dissection OT - Mitomycin C OT - Radical nephroureterectomy OT - Upper urinary tract OT - Urothelial cancer EDAT- 2019/05/28 06:00 MHDA- 2020/03/18 06:00 PMCR- 2019/05/23 CRDT- 2019/05/25 06:00 PHST- 2018/12/19 00:00 [received] PHST- 2019/05/17 00:00 [accepted] PHST- 2019/05/28 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] PHST- 2019/05/25 06:00 [entrez] PHST- 2019/05/23 00:00 [pmc-release] AID - 10.1007/s00345-019-02811-w [pii] AID - 2811 [pii] AID - 10.1007/s00345-019-02811-w [doi] PST - ppublish SO - World J Urol. 2019 Nov;37(11):2279-2287. doi: 10.1007/s00345-019-02811-w. Epub 2019 May 23. PMID- 31123405 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 12 DP - 2019 TI - Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer. PG - 3441-3457 LID - 10.2147/OTT.S194568 [doi] AB - Purpose: Bladder cancer (BCa) is generally considered one of the most prevalent deadly diseases worldwide. Patients suffering from muscle-invasive bladder cancer (MIBC) possess dismal prognoses, while those with non-muscle-invasive bladder cancer (NMIBC) generally have a favorable outcome after local treatment. However, some NMIBCs relapse and progress to MIBC, with an unclarified mechanism. Hence, insight into the genetic drivers of BCa progression has tremendous potential benefits for precision therapeutics, risk stratification, and molecular diagnosis. Methods: In this study, three cohorts profile datasets (GSE13507, GSE32584, and GSE89) consisting of NMIBC and MIBC samples were integrated to address the differently expressed genes (DEGs). Subsequently, the protein-protein interaction (PPI) network and pathway enrichment analysis of DGEs were performed. Results: Six collagen members (COL1A1, COL1A2, COL5A2, COL6A1, COL6A2, and COL6A3) were up-regulated and gathered in the ECM-receptor interaction signal pathway identified by KEGG pathway analysis and GSEA. Evidence derived from the Oncomine and TCGA databases indicated that the 6 collagen genes promote the progression of BCa and are negatively associated with patient prognosis. Moreover, taking COL1A1 as a further research object, the results showed that COL1A1 was up-regulated in MIBC and its knockdown significantly inhibited the proliferation, migration, and invasion of 5637 and T24 cells by inhibiting epithelial-mesenchymal transition (EMT) process and the TGF-beta signaling pathway. Conclusion: With integrated bioinformatic analysis and cell experiments, we showed that 6 collagen family members are high progression risk factors and that they can be used as independent effective diagnostic and prognostic biomarkers for BCa. FAU - Zhu, Huier AU - Zhu H AD - Department of Emergency Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, People's Republic of China. FAU - Chen, Hui AU - Chen H AD - Department of Pathology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, People's Republic of China. FAU - Wang, Jizhong AU - Wang J AD - Biomedicine Research Center, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, People's Republic of China. FAU - Zhou, Ling AU - Zhou L AD - Special Clinic Center, Zhongshan People's Hospital of Guangdong Province, Zhongshan, 528403, People's Republic of China. FAU - Liu, Shaoyan AU - Liu S AD - Department of Pathology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, People's Republic of China. LA - eng PT - Journal Article DEP - 20190507 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC6511250 OTO - NOTNLM OT - bladder cancer OT - diagnostic marker OT - genomic analysis OT - invasion OT - prognostic markers COIS- The authors declare no conflicts of interest in this work. EDAT- 2019/05/28 06:00 MHDA- 2019/05/28 06:01 PMCR- 2019/05/07 CRDT- 2019/05/25 06:00 PHST- 2018/11/14 00:00 [received] PHST- 2019/03/12 00:00 [accepted] PHST- 2019/05/25 06:00 [entrez] PHST- 2019/05/28 06:00 [pubmed] PHST- 2019/05/28 06:01 [medline] PHST- 2019/05/07 00:00 [pmc-release] AID - 194568 [pii] AID - 10.2147/OTT.S194568 [doi] PST - epublish SO - Onco Targets Ther. 2019 May 7;12:3441-3457. doi: 10.2147/OTT.S194568. eCollection 2019. PMID- 31122840 OWN - NLM STAT- MEDLINE DCOM- 20191210 LR - 20250530 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 44 DP - 2019 Jun TI - Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. PG - 431-438 LID - S2352-3964(19)30305-6 [pii] LID - 10.1016/j.ebiom.2019.05.004 [doi] AB - BACKGROUND: Recurrent mutations in the promoter of the telomerase reverse transcriptase (TERT) gene (C228T and C250T) detected in tumours and cells shed into urine of urothelial cancer (UC) patients are putative biomarkers for UC detection and monitoring. However, the possibility of detecting these mutations in cell-free circulating DNA (cfDNA) in blood and urine, or DNA from urinary exfoliated cells (cellDNA) with a single-gene sensitive assay has never been tested in a case-control setting. METHODS: We developed a single-plex assay (UroMuTERT) for the detection of low-abundance TERT promoter mutations. We tested 93 primary and recurrent UC cases and 94 controls recruited in France (blood, urine samples and tumours for the cases), and 50 primary UC cases and 50 controls recruited in Portugal (urinary exfoliated cell samples). We compared our assay with urine cytology. FINDINGS: In the French series, C228T or C250T were detected in urinary cfDNA or cellDNA in 81 cases (87.1%; 95% CI 78.6-93.2), and five controls (Specificity 94.7%; 95%CI 88.0-98.3), with 98.6% (95% CI 92.5-99.96) concordance in matched tumours. Detection rate in plasma cfDNA among cases was 7.1%. The UroMuTERT sensitivity was (i) highest for urinary cfDNA and cellDNA combined, (ii) consistent across primary and recurrent cases, tumour stages and grades, (iii) higher for low-risk non-muscle invasive UC (86.1%) than urine cytology (23.0%) (P < 0.0001) and (iv) 93.9% when combined with cytology. In the Portuguese series - the sensitivity and specificity for detection of UC with urinary cellDNA was 68.0% (95% CI 53.3-80.5) and 98.0% (95% CI 89.3-100.0). INTERPRETATION: TERT promoter mutations detected by the UroMuTERT assay in urinary DNA (cfDNA or cellDNA) show excellent sensitivity and specificity for the detection of UC, significantly outperforming that of urine cytology notably for detection of low-grade early stages UC. FUND: French Cancer League; French Foster Research in Molecular Biology and European Commission FP7 Marie Curie COFUND. CI - Copyright (c) 2019. Published by Elsevier B.V. FAU - Avogbe, Patrice Hodonou AU - Avogbe PH AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Manel, Arnaud AU - Manel A AD - Protestant Clinic of Lyon, Urology department, Lyon, France. FAU - Vian, Emmanuel AU - Vian E AD - Protestant Clinic of Lyon, Urology department, Lyon, France. FAU - Durand, Geoffroy AU - Durand G AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Forey, Nathalie AU - Forey N AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Voegele, Catherine AU - Voegele C AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Zvereva, Maria AU - Zvereva M AD - International Agency for Research on Cancer (IARC), Lyon, France; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russia. FAU - Hosen, Md Ismail AU - Hosen MI AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Meziani, Sonia AU - Meziani S AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - De Tilly, Berengere AU - De Tilly B AD - Protestant Clinic of Lyon, Urology department, Lyon, France. FAU - Polo, Gilles AU - Polo G AD - Protestant Clinic of Lyon, Urology department, Lyon, France. FAU - Lole, Olesia AU - Lole O AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Francois, Pauline AU - Francois P AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Delhomme, Tiffany Myriam AU - Delhomme TM AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Carreira, Christine AU - Carreira C AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Monteiro-Reis, Sara AU - Monteiro-Reis S AD - Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal. FAU - Henrique, Rui AU - Henrique R AD - Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal; Portuguese Oncology Institute of Porto (IPOP), Department of Pathology, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal. FAU - Abedi-Ardekani, Behnoush AU - Abedi-Ardekani B AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Byrnes, Graham AU - Byrnes G AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Foll, Matthieu AU - Foll M AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Weiderpass, Elisabete AU - Weiderpass E AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - McKay, James AU - McKay J AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Jeronimo, Carmen AU - Jeronimo C AD - Portuguese Oncology Institute of Porto, Research Center (CI-IPOP), Porto, Portugal; Portuguese Oncology Institute of Porto (IPOP), Department of Pathology, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal. FAU - Scelo, Ghislaine AU - Scelo G AD - International Agency for Research on Cancer (IARC), Lyon, France. FAU - Le Calvez-Kelm, Florence AU - Le Calvez-Kelm F AD - International Agency for Research on Cancer (IARC), Lyon, France. Electronic address: lecalvezf@iarc.fr. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article DEP - 20190520 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Biomarkers, Tumor) RN - 0 (Circulating Tumor DNA) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Algorithms MH - *Biomarkers, Tumor MH - Case-Control Studies MH - Circulating Tumor DNA MH - DNA Mutational Analysis MH - Disease Management MH - Female MH - Humans MH - Liquid Biopsy MH - Male MH - Middle Aged MH - *Mutation MH - *Promoter Regions, Genetic MH - Sensitivity and Specificity MH - Telomerase/*genetics MH - Tomography, X-Ray Computed MH - Urologic Neoplasms/diagnosis/*genetics PMC - PMC6603852 OTO - NOTNLM OT - Blood OT - Cell DNA OT - Cell-free DNA OT - TERT mutations OT - Urine OT - Urothelial cancer detection EDAT- 2019/05/28 06:00 MHDA- 2019/12/18 06:00 PMCR- 2019/05/20 CRDT- 2019/05/25 06:00 PHST- 2019/04/18 00:00 [received] PHST- 2019/05/02 00:00 [revised] PHST- 2019/05/02 00:00 [accepted] PHST- 2019/05/28 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/05/25 06:00 [entrez] PHST- 2019/05/20 00:00 [pmc-release] AID - S2352-3964(19)30305-6 [pii] AID - 10.1016/j.ebiom.2019.05.004 [doi] PST - ppublish SO - EBioMedicine. 2019 Jun;44:431-438. doi: 10.1016/j.ebiom.2019.05.004. Epub 2019 May 20. PMID- 31120373 OWN - NLM STAT- MEDLINE DCOM- 20191206 LR - 20191217 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 202 IP - 5 DP - 2019 Nov TI - Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. PG - 920-926 LID - 10.1097/JU.0000000000000355 [doi] AB - PURPOSE: Single center studies have shown that positive UroVysion(R) fluorescence in situ hybridization results were associated with recurrence of nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. Our goal was to validate these findings. MATERIALS AND METHODS: We performed a prospective, multicenter diagnostic trial to determine whether the fluorescence in situ hybridization test could predict recurrence or progression in patients with primary high grade nonmuscle invasive bladder cancer who were scheduled to receive bacillus Calmette-Guerin. Fluorescence in situ hybridization testing was performed prior to the first bacillus Calmette-Guerin instillation, prior to the sixth instillation and at 3-month cystoscopy. The performance of fluorescence in situ hybridization was evaluated. RESULTS: A total of 150 patients were enrolled in analysis, including 68 with Ta disease, 41 with T1 disease, 26 with carcinoma in situ alone and 15 with papillary carcinoma plus carcinoma in situ. At 9 months of followup there were 46 events, including 37 recurrences and 9 progressions. For events with positive fluorescence in situ hybridization findings the HR was 2.59 (95% CI 1.42-4.73) for the baseline test, 1.94 (95% CI 1.04-3.59) for the 6-week test and 3.22 (95% CI 1.65-6.27) at 3 months. Patients with positive results at baseline, 6 weeks and 3 months had events 55% of the time and patients with negative results at each time point had no event 76% of the time. CONCLUSIONS: The study validated that a positive UroVysion fluorescence in situ hybridization test was associated with a 3.3-fold increased risk of recurrence. The test may be useful to risk stratify patients entering clinical trials in whom induction therapy fails. However, using the test to change management decisions is limited due to the discordance between results and outcomes as well as the variance of tests results with time. FAU - Lotan, Yair AU - Lotan Y AD - Departments of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Inman, Brant A AU - Inman BA AD - Division of Urology, Duke University Medical Center, Durham, North Carolina. FAU - Davis, Leah Gerber AU - Davis LG AD - Division of Urology, Duke University Medical Center, Durham, North Carolina. AD - Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina. FAU - Kassouf, Wassim AU - Kassouf W AD - McGill University Health Center, Montreal, Quebec, Canada. FAU - Messing, Edward AU - Messing E AD - University of Rochester, Rochester, New York. FAU - Daneshmand, Siamak AU - Daneshmand S AD - University of Southern California, Los Angeles, California. FAU - Canter, Daniel AU - Canter D AD - Ochsner Medical Center, New Orleans, Louisiana. FAU - Marble, H Tony AU - Marble HT AD - Abbott Molecular Inc., Des Plaines, Illinois. FAU - Joseph, Ajith M AU - Joseph AM AD - Abbott Molecular Inc., Des Plaines, Illinois. FAU - Jewell, Susan AU - Jewell S AD - Abbott Molecular Inc., Des Plaines, Illinois. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Mayo Clinic, Rochester, Minnesota. LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20191009 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2020 Mar;203(3):625. doi: 10.1097/JU.0000000000000624. PMID: 31647387 MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Carcinoma in Situ/drug therapy/*pathology MH - Cystoscopy MH - Disease Progression MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Incidence MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis/epidemiology MH - Neoplasm Staging/*methods MH - Prospective Studies MH - Survival Rate/trends MH - United States/epidemiology MH - Urinary Bladder Neoplasms/drug therapy/*pathology OTO - NOTNLM OT - BCG vaccine OT - carcinoma in situ OT - fluorescence OT - in situ hybridization OT - local OT - neoplasm recurrence OT - urinary bladder neoplasms EDAT- 2019/05/24 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/05/24 06:00 PHST- 2019/05/24 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/05/24 06:00 [entrez] AID - 10.1097/JU.0000000000000355 [doi] PST - ppublish SO - J Urol. 2019 Nov;202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9. PMID- 31118765 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 11 DP - 2019 TI - S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway. PG - 2449-2456 LID - 10.2147/CMAR.S196450 [doi] AB - Objective: To fully investigate the effect of S100 proteins on the chemoresistance of nonmuscle invasive bladder cancer (NMIBC). Materials and methods: The mitomycin C-resistant bladder cancer cell line M-RT4 was established and liquid chromatography-tandem mass spectrometry was performed for proteomics analysis. RT-PCR and Western blot were then performed to confirm the findings. To investigate the mechanisms, S100A16 was knocked down by siRNA. Then, the sensitivity of M-RT4 to mitomycin C was analyzed by a cell counting kit-8 (CCK8) assay, and the molecular expression including epithelial-mesenchymal transition (EMT)-related and apoptosis-related markers were also examined by Western blot. Based on the cancer genome atlas (TCGA) data, the prognostic value of S100A16 was also investigated. Results: There were six S100 proteins with differential expression, among which S100A16 was confirmed to be the only upregulated protein in M-RT4 cells. The expression of S100A16 was regulated by the EMT-related transcription factor Snail. Knockdown of S100A16 suppressed the AKT/Bcl-2 pathway to promote apoptosis, greatly sensitizing M-RT4 cells to mitomycin C. The expression of S100A16 was negatively correlated with the overall survival of bladder cancer patients. Conclusion: S100A16 contributes to the chemoresistance of NMIBC by promoting the AKT/Bcl-2-mediated anti-apoptosis effect and could be a potential prognostic marker and therapeutic target for NMIBC patients. FAU - Wang, Chanjuan AU - Wang C AD - Department of Laboratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China. FAU - Zhu, Xi AU - Zhu X AD - Department of Urology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China. FAU - Li, Aiwei AU - Li A AD - Department of Laboratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China. FAU - Yang, Shuo AU - Yang S AD - Department of Laboratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China. FAU - Qiao, Rui AU - Qiao R AD - Department of Laboratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China. FAU - Zhang, Jie AU - Zhang J AD - Department of Laboratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20190327 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6498975 OTO - NOTNLM OT - S100A16 OT - Snail OT - apoptosis OT - chemoresistance OT - nonmuscle invasive bladder cancer COIS- Miss Chanjuan Wang reports non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work; Dr Xi Zhu reports grants from National Nature Science Foundation of China, Administration of Hospitals Clinical Medicine Development of Special Funding Support, Beijing Municipal Administration of Hospitals' Youth programme, during the conduct of the study; non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work; Miss Aiwei Li reports non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work; Dr Shuo Yang reports non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work; Dr Rui Qiao reports non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work; Dr Jie Zhang reports non-financial support from CapitalBio Co., Ltd (Beijing, China), outside the submitted work. The authors report no other conflicts of interest in this work. EDAT- 2019/05/24 06:00 MHDA- 2019/05/24 06:01 PMCR- 2019/03/27 CRDT- 2019/05/24 06:00 PHST- 2018/11/29 00:00 [received] PHST- 2019/02/27 00:00 [accepted] PHST- 2019/05/24 06:00 [entrez] PHST- 2019/05/24 06:00 [pubmed] PHST- 2019/05/24 06:01 [medline] PHST- 2019/03/27 00:00 [pmc-release] AID - 196450 [pii] AID - 10.2147/CMAR.S196450 [doi] PST - epublish SO - Cancer Manag Res. 2019 Mar 27;11:2449-2456. doi: 10.2147/CMAR.S196450. eCollection 2019. PMID- 31114949 OWN - NLM STAT- MEDLINE DCOM- 20201228 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 3 DP - 2020 Mar TI - En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study. PG - 703-708 LID - 10.1007/s00345-019-02805-8 [doi] AB - PURPOSE: To investigate the role of en bloc re-resection (EBRS) in patients who had undergone previous en bloc resection for high-risk non-muscle-invasive bladder cancer (NMIBC). METHODS: An international, multicenter, observational retrospective analysis of prospectively collected data. Patients with a high-risk NMIBC who had previously undergone en bloc resection were scheduled for EBRS of the resected area after 40 days. The primary outcome was the presence of residual tumor or recurrence-free survival. RESULTS: Overall, 78 patients underwent EBRS. Only five (6.41%) residual cancers were found: one patient had a pTa G3 (1.28%) cancer and four (5.13%) had a pTis. The detrusor muscle was preserved in all samples. Only one patient had a positive margin on EBRS. No procedure called for a conversion to traditional re-TURBT. No patient experienced bladder perforation or other intra-operative complications. The recurrence rate at the first follow-up cystoscopy (RRFF-C at 3 months) was 3.85% (three patients). The median follow-up period was 30.8 months (range 6.9-76.0 months). In univariate analysis, the only predictor of recurrence was grade. Overall we observed 11 recurrences. Only one tumor progressed to T2 MIBC. CONCLUSIONS: The low rates of residual tumor, recurrence, and progression seem to raise doubts about the efficacy of EBRS in patients who have previously undergone en bloc resection. EBRS appears to be a feasible and safe procedure with a low rate of complications. However, further data will be needed before EBRS can be used in clinical trials or recommended as a treatment modality. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. FAU - Paciotti, Marco AU - Paciotti M AUID- ORCID: 0000-0002-8456-6495 AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. marco.paciotti@humanitas.it. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, via Manzoni 56, Rozzano, 20089, Milan, Italy. FAU - Morenghi, Emanuela AU - Morenghi E AD - Department of Biomedical Science, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy. FAU - Oswald, David AU - Oswald D AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Colleselli, Daniela AU - Colleselli D AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Mitterberger, Michael AU - Mitterberger M AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Kunit, Thomas AU - Kunit T AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Hager, Martina AU - Hager M AD - Department of Pathology, Paracelsus Medical University, Salzburg, Austria. FAU - Herrmann, Thomas R W AU - Herrmann TRW AD - Department of Urology, Kantonspital Frauenfeld, Spital Thurgau AG, Frauenfeld, Switzerland. FAU - Lusuardi, Lukas AU - Lusuardi L AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20190521 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystoscopy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplasm, Residual MH - *Reoperation MH - Retrospective Studies MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - En bloc re-resection OT - En bloc resection OT - NMIBC OT - Outcome EDAT- 2019/05/23 06:00 MHDA- 2020/12/29 06:00 CRDT- 2019/05/23 06:00 PHST- 2019/01/15 00:00 [received] PHST- 2019/05/07 00:00 [accepted] PHST- 2019/05/23 06:00 [pubmed] PHST- 2020/12/29 06:00 [medline] PHST- 2019/05/23 06:00 [entrez] AID - 10.1007/s00345-019-02805-8 [pii] AID - 10.1007/s00345-019-02805-8 [doi] PST - ppublish SO - World J Urol. 2020 Mar;38(3):703-708. doi: 10.1007/s00345-019-02805-8. Epub 2019 May 21. PMID- 31114765 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 11 DP - 2019 TI - Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis. PG - 97-104 LID - 10.2147/RRU.S199512 [doi] AB - Background: Matriptase, which is a Type II transmembrane serine protease, has the potential to activate several growth factors, including pro-hepatocyte growth factor (HGF). A G protein-coupled transmembrane cell-surface receptor and a protease-activated receptor 2 (PAR-2) are also required for activation by matriptase. Activation of PAR-2 has been reported to induce the progression of various cancers. In a previous study, we evaluated the correlation between upregulation of MET phosphorylation with high matriptase expression and worse prognosis in patients with muscle invasive bladder cancer; however, expression of PAR-2, matriptase and MET in non-muscle invasive bladder cancer (NMIBC) has not been evaluated. Materials and methods: We retrospectively analyzed the expression of PAR-2, matriptase and MET using 55 paraffin-embedded specimens obtained from patients with NMIBC by immunohistochemistry. Results: MET was significantly expressed in high-grade urothelial carcinoma (UC) and pathological T1 cancers. High expression of PAR-2 was significantly associated with a worse recurrence rate in NMIBC. In subgroup analysis, the expression of PAR-2 was also correlated with high recurrence rate in low-grade UC. In addition, expression of matriptase tended to correlate with worse recurrence rate in high-grade UC. Conclusion: Increased expression of PAR-2 was significantly correlated with worse recurrence rate in patients with NMIBC. In addition, expression of matriptase also indicated a tendency toward recurrence in high-grade UC, suggesting an important role of matriptase-induced PAR-2 activation in NMIBC. FAU - Nakahara, Kozue AU - Nakahara K AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Yamasaki, Koji AU - Yamasaki K AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Nagai, Takahiro AU - Nagai T AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Fujii, Masato AU - Fujii M AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Akioka, Takahiro AU - Akioka T AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Takamori, Hiroki AU - Takamori H AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Terada, Naoki AU - Terada N AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Mukai, Shoichiro AU - Mukai S AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Sato, Yuichiro AU - Sato Y AD - Section of Diagnostic Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Kamoto, Toshiyuki AU - Kamoto T AD - Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. LA - eng PT - Journal Article DEP - 20190411 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC6489562 OTO - NOTNLM OT - MET OT - NMIBC OT - PAR-2 OT - matriptase COIS- The authors report no conflicts of interest in this work. EDAT- 2019/05/23 06:00 MHDA- 2019/05/23 06:01 PMCR- 2019/04/11 CRDT- 2019/05/23 06:00 PHST- 2018/12/25 00:00 [received] PHST- 2019/02/04 00:00 [accepted] PHST- 2019/05/23 06:00 [entrez] PHST- 2019/05/23 06:00 [pubmed] PHST- 2019/05/23 06:01 [medline] PHST- 2019/04/11 00:00 [pmc-release] AID - 199512 [pii] AID - 10.2147/RRU.S199512 [doi] PST - epublish SO - Res Rep Urol. 2019 Apr 11;11:97-104. doi: 10.2147/RRU.S199512. eCollection 2019. PMID- 31111956 OWN - NLM STAT- MEDLINE DCOM- 20190910 LR - 20260622 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 5 IP - 5 DP - 2019 May 14 TI - Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy. PG - CD013336 LID - 10.1002/14651858.CD013336 [doi] LID - CD013336 AB - BACKGROUND: In the treatment of urothelial carcinoma of the bladder, we are currently uncertain of the benefits and harms of standard pelvic lymph node dissection (PLND) compared to extended PLND. OBJECTIVES: To assess the effects of extended versus standard PLND in patients undergoing cystectomy to treat muscle-invasive (cT2 and cT3) and treatment-refractory, non-muscle-invasive (cT1 with or without carcinoma in situ) urothelial carcinoma of the bladder. SEARCH METHODS: We performed a comprehensive literature search using multiple databases (PubMed, Embase, Cochrane Controlled Trials, Web of Science, and LILACS), trial registries, and conference proceedings published up to April 29, 2019, with no restrictions on the language or status of publication. SELECTION CRITERIA: We included randomized controlled trials in which participants underwent radical cystectomy (RC) for muscle-invasive or therapy-refractory non-muscle-invasive urothelial carcinoma of the bladder with either an extended PLND with a superior extent reaching as far cranially as the inferior mesenteric vein, or a standard PLND with a superior extent of the bifurcation of the internal and external iliac artery, with otherwise the same anatomical boundaries. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the included studies and extracted data from them for the primary outcomes: time to death from any cause, time to death from bladder cancer and Clavien-Dindo classification of surgical complications grade III-V, and the secondary outcomes: time to recurrence, Clavien-Dindo I-II complications and disease-specific quality of life.We performed statistical analyses using a random-effects model and rated the certainty of evidence according to the GRADE approach. MAIN RESULTS: The search identified one multicenter trial based in Germany that enrolled 401 participants with histologically confirmed T1 grade 3 or muscle-invasive urothelial carcinoma. The median age was 67 years (range: 59 to 74) and the majority of participants were male (78.3%). No participant received neoadjuvant chemotherapy; a small subset received adjuvant chemotherapy (14.5%).Primary outcomesOur results indicate that extended PLND may reduce the risk of death from any cause over time as compared to standard PLND, but the confidence interval includes the possibility of no effect (hazard ratio [HR]: 0.78, 95% confidence interval [CI]: 0.57 to 1.07, 401 participants, low-certainty evidence). After five years of follow-up, this may result in 83 fewer deaths (95% CI: 174 fewer to 24 more overall deaths) per 1000 participants: 420 deaths for extended PLND compared to 503 deaths per 1000 for standard PLND. We downgraded the certainty of evidence by two levels due to study limitations and imprecision.Our results indicate that extended PLND may reduce the risk of death from bladder cancer over time as compared to standard PLND but, again, the confidence interval includes the possibility of no effect (HR: 0.70, 95% CI: 0.45 to 1.07, participants = 401, low-certainty evidence). After five years of follow-up, this corresponds to 91 fewer deaths per 1000 participants (95% CI: 176 fewer to 19 more bladder cancer deaths): 264 deaths for extended PLND compared to 355 deaths per 1000 for standard PLND. We downgraded the certainty of evidence by two levels due to study limitations and imprecision.Based on follow-up of up to 30 days, we are uncertain whether extended PLND leads to more grade III-V complications as compared to standard PLND, because of study limitations and imprecision (risk ratio [RR]: 1.13, 95% CI: 0.84 to 1.52, participants = 401, very low-certainty evidence).Secondary outcomesWe are uncertain whether extended PLND reduces the risk of recurrence over time as compared to standard PLND, because of study limitations and imprecision (HR: 0.84, 95% CI: 0.58 to 1.22, participants = 401, very low-certainty evidence).Based on follow-up of up to 30 days, we are uncertain whether extended PLND leads to similar grade I-II complications as compared to standard PLND because of study limitations and imprecision (RR: 0.94, 95% CI: 0.74 to 1.19, participants = 401, very low-certainty evidence).We found no trials that reported on disease-specific quality of life. AUTHORS' CONCLUSIONS: Results from a single trial indicate that extended PLND in patients undergoing radical cystectomy for invasive urothelial carcinoma of the bladder may reduce death from any cause and death from bladder cancer over time; however, the results include the possibility of no effect. We are uncertain whether the risk of serious complications up to 30 days may be increased. We are also uncertain as to whether the risk of recurrence over time or the risk of minor complications up to 30 days changes. We were unable to conduct any of the preplanned subgroup analyses, in particular, analyses based on extended lymph node dissection templates, clinical tumor stage, and use of neoadjuvant chemotherapy that may be important effect modifiers. Important additional data is expected from a larger, ongoing trial that will also consider the role of neoadjuvant chemotherapy. Inclusion of this trial in the meta-analysis may help address the issue of imprecision which was a common reason for downgrading the certainty of the evidence. FAU - Hwang, Eu Chang AU - Hwang EC AD - Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South. FAU - Sathianathen, Niranjan J AU - Sathianathen NJ FAU - Imamura, Mari AU - Imamura M FAU - Kuntz, Gretchen M AU - Kuntz GM FAU - Risk, Michael C AU - Risk MC FAU - Dahm, Philipp AU - Dahm P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20190514 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM CIN - J Urol. 2020 Oct;204(4):876-877. doi: 10.1097/JU.0000000000001219.01. PMID: 32716224 UIN - Cochrane Database Syst Rev. 2026 Apr 23;4:CD013336. doi: 10.1002/14651858.CD013336.pub2. PMID: 42023708 MH - Aged MH - Carcinoma, Transitional Cell/*surgery MH - *Cystectomy/methods MH - Female MH - Humans MH - *Lymph Node Excision MH - Male MH - Middle Aged MH - Postoperative Complications MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery PMC - PMC6528183 COIS- ECH: none known. NS: Niranjan J Sathianathen was a previous recipient of a Royal Australasian College of Surgeons (RACS) scholarship awarded for the undertaking of a separate, non-related project that was completed in March 2018. GK: none known. MI: none known. MR: none known. PD: serves as Co-ordinating Editor of Cochrane Urology. However, he was not involved in the editorial processing or decision-making for this review. The editorial process was conducted in collaboration with the Fast-Track Service, which is independent of Cochrane Urology, and the review was signed off by members of Cochrane's Editorial and Methods Department. EDAT- 2019/05/22 06:00 MHDA- 2019/09/11 06:00 PMCR- 2020/05/14 CRDT- 2019/05/22 06:00 PHST- 2019/05/22 06:00 [pubmed] PHST- 2019/09/11 06:00 [medline] PHST- 2019/05/22 06:00 [entrez] PHST- 2020/05/14 00:00 [pmc-release] AID - CD013336 [pii] AID - 10.1002/14651858.CD013336 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2019 May 14;5(5):CD013336. doi: 10.1002/14651858.CD013336. PMID- 31103602 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20220325 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 1 DP - 2021 Jan TI - Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer. PG - 142-147 LID - S2405-4569(19)30141-5 [pii] LID - 10.1016/j.euf.2019.04.021 [doi] AB - BACKGROUND: The challenge of managing non-muscle-invasive bladder cancer (NMIBC) is its high recurrence rate. Clinical investigations have begun to explore the role of androgen suppression as an adjunct to bladder cancer (BC) treatment. OBJECTIVE: To examine the effect of androgen suppression therapy (AST) on recurrence and progression rate of risk-stratified NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Male patients with NMIBC were identified retrospectively from a US institutional database between 2001 and 2017. AST included 5alpha-reductase inhibitor, gonadotropin-releasing hormone agonist, and antiandrogen. Patients who were exposed to AST prior to documented recurrence/progression were included in the treatment arm. BC was risk stratified to investigate the differential response to AST. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Hazard ratios (HRs) for NMIBC recurrence and progression were estimated using Cox proportional hazards multivariate regression models with stepwise method. Recurrence-free survival (RFS) and progression-free survival (PFS) were compared between groups with and without AST. RESULTS AND LIMITATIONS: We identified a total of 274 males with a median follow-up period of 3.1 yr (interquartile range [IQR] 1.5-5.2). Thirty-six patients were exposed to AST with a median duration of 1.7 yr (IQR 0.7-2.6). AST was associated with a lower risk of recurrence (HR 0.53, 95% confidence interval 0.30-0.88) as well as improved RFS (p = 0.014). However, no significant reduction of progression or improvement of PFS (p = 0.23) was found with AST. After risk stratification, all five patients who progressed in the AST cohort had high-risk disease on initial transurethral resection (TUR), whereas no patients with low/intermediate-risk disease progressed on AST. Limitations of the study include nonstandardized initiation of AST in relation to initial TUR, lack of androgen level quantification, and small sample size in the treatment arm. CONCLUSIONS: In this retrospective, single-institution study, AST was associated with a lower risk of recurrence in NMIBC. No significant association between AST and progression was found. Further investigation is warranted to define the role of AST as an adjunctive therapy for NMIBC. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is a highly recurrent disease that often requires patients to undergo repeated surgical treatments. This single-institution report suggests that medical suppression of androgen may be a potential preventive therapy to reduce recurrence in certain patients. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Wu, Shuo-Chieh AU - Wu SC AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Kwon, Deukwoo AU - Kwon D AD - Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Jue, Joshua S AU - Jue JS AD - Department of Urology, Lenox Hill Hospital, Northwell Health, New York, NY, USA. FAU - Chen, Felix V AU - Chen FV AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Velasquez Escobar, Maria C AU - Velasquez Escobar MC AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Punnen, Sanoj AU - Punnen S AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Parekh, Dipen J AU - Parekh DJ AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Ritch, Chad R AU - Ritch CR AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: m.gonzalgo@miami.edu. LA - eng PT - Journal Article DEP - 20190515 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Androgen Antagonists) RN - 0 (Androgens) RN - 0 (GNRHR protein, human) RN - 0 (Receptors, LHRH) RN - EC 1.3.1.22 (Cholestenone 5 alpha-Reductase) SB - IM MH - Aged MH - Aged, 80 and over MH - Androgen Antagonists/*therapeutic use MH - Androgens MH - Cholestenone 5 alpha-Reductase/*therapeutic use MH - Humans MH - Male MH - Middle Aged MH - *Neoplasm Recurrence, Local/drug therapy/epidemiology/pathology MH - Receptors, LHRH MH - Retrospective Studies MH - United States/epidemiology MH - Urinary Bladder Neoplasms/*drug therapy/epidemiology/pathology OTO - NOTNLM OT - Androgen antagonist OT - Bladder cancer OT - Non-muscle invasive OT - Prevention and control OT - Progression OT - Recurrence OT - Risk stratification EDAT- 2019/05/20 06:00 MHDA- 2022/03/26 06:00 CRDT- 2019/05/20 06:00 PHST- 2019/02/18 00:00 [received] PHST- 2019/04/21 00:00 [revised] PHST- 2019/04/30 00:00 [accepted] PHST- 2019/05/20 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] PHST- 2019/05/20 06:00 [entrez] AID - S2405-4569(19)30141-5 [pii] AID - 10.1016/j.euf.2019.04.021 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Jan;7(1):142-147. doi: 10.1016/j.euf.2019.04.021. Epub 2019 May 15. PMID- 31102534 OWN - NLM STAT- MEDLINE DCOM- 20190910 LR - 20231227 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 5 IP - 5 DP - 2019 May 18 TI - Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. PG - CD013160 LID - 10.1002/14651858.CD013160.pub2 [doi] LID - CD013160 AB - BACKGROUND: Single-dose, postoperative intravesical chemotherapy reduces the risk of bladder cancer recurrence after transurethral resection of bladder tumours. However, there is limited evidence whether single-dose intravesical chemotherapy is similarly effective at preventing bladder cancer recurrence after nephroureterectomy. OBJECTIVES: To assess the effects of single-dose intravesical chemotherapy instillation after nephroureterectomy for upper tract urothelial carcinoma. SEARCH METHODS: We performed a comprehensive literature search using multiple databases (MEDLINE, Cochrane Library, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to April 15 2019, with no restrictions on language or status of publication. SELECTION CRITERIA: We included randomised controlled trials in which participants either received or did not receive single-dose intravesical chemotherapy instillation after nephroureterectomy. DATA COLLECTION AND ANALYSIS: Two review authors screened and independently assessed studies and extracted data from included studies. We performed statistical analyses using a random-effects model. We rated the certainty of evidence according to the GRADE approach. MAIN RESULTS: The search identified two studies (a multicenter study from Japan and the United Kingdom) with 361 participants.Primary outcomesOur results indicate that single-dose intravesical chemotherapy instillation may reduce the risk of bladder cancer recurrence over time compared to no instillation (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.32 to 0.82, low-certainty evidence). After 12 months follow-up, this would result in 127 fewer bladder cancer recurrences (95% CI: 182 to 44 fewer bladder cancer recurrences) per 1000 participants. We downgraded the certainty of evidence by two levels due to study limitations and imprecision.We found no trials that reported on the outcomes of time to death from upper tract urothelial carcinoma. The effect of single-dose intravesical chemotherapy instillation on serious adverse events is uncertain (risk ratio [RR]: not estimable, 95% CI: not estimable, there were no events, very low-certainty evidence). We downgraded the certainty of evidence by one level due to study limitations and by two levels due to imprecision.Secondary outcomesWe found no trials that reported on the outcomes of time to death from any cause and participants' disease-specific quality of life. The effect of single-dose intravesical chemotherapy instillation on minor adverse events is uncertain (risk ratio [RR]: not estimable, 95% CI: not estimable, there were no events, very low-certainty evidence). We downgraded the certainty of evidence by one level due to study limitations and by two levels due to imprecision. AUTHORS' CONCLUSIONS: For patients who have undergone nephroureterectomy for upper tract urothelial carcinoma, single-dose intravesical chemotherapy instillation may reduce bladder cancer recurrence after nephroureterectomy. However, we are uncertain as to the risk of serious (and minor) adverse events. We found no evidence for the outcome of time to death from upper tract urothelial carcinoma. We were unable to conduct any of the preplanned subgroup analyses, particularly those based on operative approach, pathologic stage, and method of bladder cuff excision. FAU - Hwang, Eu Chang AU - Hwang EC AD - Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South. FAU - Sathianathen, Niranjan J AU - Sathianathen NJ FAU - Jung, Jae Hung AU - Jung JH FAU - Kim, Myung Ha AU - Kim MH FAU - Dahm, Philipp AU - Dahm P FAU - Risk, Michael C AU - Risk MC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20190518 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antineoplastic Agents) SB - IM UOF - doi: 10.1002/14651858.CD013160 MH - *Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/therapeutic use MH - Carcinoma/*drug therapy MH - Humans MH - Nephroureterectomy MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Ureteral Neoplasms/*drug therapy PMC - PMC6525634 COIS- ECH: none known. NS: none known. JHJ: none known. MHK: none known. PD: serves as Co-ordinating Editor of Cochrane Urology. However, he was not involved in the editorial processing or decision-making for this review. Other editors of Cochrane Urology managed the editorial process, including final sign-off for this review through the Cancer Network. MR: none known. EDAT- 2019/05/19 06:00 MHDA- 2019/09/11 06:00 PMCR- 2020/05/18 CRDT- 2019/05/19 06:00 PHST- 2019/05/19 06:00 [pubmed] PHST- 2019/09/11 06:00 [medline] PHST- 2019/05/19 06:00 [entrez] PHST- 2020/05/18 00:00 [pmc-release] AID - CD013160.pub2 [pii] AID - 10.1002/14651858.CD013160.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2019 May 18;5(5):CD013160. doi: 10.1002/14651858.CD013160.pub2. PMID- 31100252 OWN - NLM STAT- MEDLINE DCOM- 20191021 LR - 20191022 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 1 IP - 4 DP - 2018 Sep TI - Performance of the Bladder EpiCheck Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. PG - 307-313 LID - S2588-9311(18)30096-8 [pii] LID - 10.1016/j.euo.2018.06.011 [doi] AB - BACKGROUND: The highly frequent strategy of surveillance for non-muscle-invasive bladder cancer (NMIBC) involves cystoscopy and cytology. Urine assays currently available have not shown performance sufficient to replace the current gold standard for follow-up, which would require a very high negative predictive value (NPV), especially for high-grade tumors. Bladder EpiCheck (BE) is a novel urine assay that uses 15 proprietary DNA methylation biomarkers to assess the presence of bladder cancer. OBJECTIVE: To assess the performance of BE for NMIBC recurrence. DESIGN, SETTING, AND PARTICIPANTS: This was a blinded, single-arm, prospective multicenter study. The inclusion criteria were age >/=22 yr, urothelial carcinoma (UC) being monitored cystoscopically at 3-mo intervals, all UC resected within 12 mo, able to produce 10ml of urine, and able to consent. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The BE test characteristics were calculated and compared to cytology and cystoscopy results confirmed by pathology. RESULTS AND LIMITATIONS: Out of 440 patients recruited, 353 were eligible for the performance analysis. Overall sensitivity, specificity, NPV, and positive predictive value were 68.2%, 88.0%, 95.1%, and 44.8%, respectively. Excluding low-grade (LG) Ta recurrences, the sensitivity was 91.7% and NPV was 99.3%. The area under receiver operating characteristic (ROC) curves with and without LG Ta lesions was 0.82 and 0.94, respectively. CONCLUSIONS: In follow-up of NMIBC patients, the BE test showed an overall high NPV of 95.1%, and 99.3% when excluding LG Ta recurrences. With high specificity of 88.0%, the test could be incorporated in NMIBC follow-up since high-grade recurrences would be instantly detected with high confidence. Thus, the current burden of repeat cystoscopies and cytology tests could be reduced. PATIENT SUMMARY: The Bladder EpiCheck urine test has a clinically relevant and high negative predictive value. Its use in clinical routine could reduce the number of follow-up cystoscopies, and thus associated patient and financial burdens. CI - Copyright (c) 2018 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. Electronic address: fred.witjes@radboudumc.nl. FAU - Morote, Juan AU - Morote J AD - Department of Urology, Hospital Universitari Vall d'Hebron Hospital, Barcelona, Spain. FAU - Cornel, Erik B AU - Cornel EB AD - Department of Urology, ZGT Medical Center, Hengelo, The Netherlands. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Wurzburg, Germany. FAU - van Valenberg, F Johannes P AU - van Valenberg FJP AD - Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. FAU - Lozano, Fernando AU - Lozano F AD - Department of Urology, Hospital Universitari Vall d'Hebron Hospital, Barcelona, Spain. FAU - Sternberg, Itay A AU - Sternberg IA AD - Department of Urology, Meir Medical Center, Kfar Saba, Israel. FAU - Willemsen, Ellen AU - Willemsen E AD - Department of Urology, ZGT Medical Center, Hengelo, The Netherlands. FAU - Hegemann, Miriam L AU - Hegemann ML AD - Department of Urology, Sindelfingen-Boblingen Hospital, Sindelfingen, Germany. FAU - Paitan, Yossi AU - Paitan Y AD - Clinical Microbiology Laboratory, Meir Medical Center, Kfar Saba, Israel. FAU - Leibovitch, Ilan AU - Leibovitch I AD - Department of Urology, Meir Medical Center, Kfar Saba, Israel. LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20180717 PL - Netherlands TA - Eur Urol Oncol JT - European urology oncology JID - 101724904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis/*urine MH - Carcinoma, Squamous Cell/*diagnosis/genetics/pathology/urine MH - *DNA Methylation MH - Female MH - Humans MH - Male MH - Middle Aged MH - Monitoring, Physiologic/*methods MH - Predictive Value of Tests MH - Sensitivity and Specificity MH - Urinalysis/*methods/standards MH - Urinary Bladder/*metabolism/pathology MH - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology/urine MH - Watchful Waiting/methods OTO - NOTNLM OT - Detection OT - Follow up OT - Negative predictive value OT - Non-muscle-invasive bladder cancer OT - Surveillance OT - Urinary biomarker EDAT- 2019/05/18 06:00 MHDA- 2019/10/23 06:00 CRDT- 2019/05/18 06:00 PHST- 2018/04/30 00:00 [received] PHST- 2018/05/08 00:00 [revised] PHST- 2018/06/22 00:00 [accepted] PHST- 2019/05/18 06:00 [entrez] PHST- 2019/05/18 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] AID - S2588-9311(18)30096-8 [pii] AID - 10.1016/j.euo.2018.06.011 [doi] PST - ppublish SO - Eur Urol Oncol. 2018 Sep;1(4):307-313. doi: 10.1016/j.euo.2018.06.011. Epub 2018 Jul 17. PMID- 31100185 OWN - NLM STAT- MEDLINE DCOM- 20200313 LR - 20200313 IS - 1432-2277 (Electronic) IS - 0934-0874 (Linking) VI - 32 IP - 10 DP - 2019 Oct TI - Significance of atypical urinary cytology in the evaluation of patients with end-stage renal disease for kidney transplantation - a retrospective study. PG - 1085-1094 LID - 10.1111/tri.13464 [doi] AB - To determine what percentage of renal transplant candidates have atypical urinary cytology, what proportion have urothelial carcinoma and whether cystoscopy is necessary with atypical cytology. All end-stage renal disease (ESRD) patients (703) presenting for renal transplantation at our institution were retrospectively reviewed. Individuals producing sufficient urine were screened with urine cytology and those with atypical cytology or risk factors for bladder cancer underwent cystoscopy. Four hundred and thirty patients had available urinary cytology and, of these, 151 (35%) had atypical cytology. Of patients with atypical cytology, three were identified to have urothelial carcinoma. However, three additional patients with urothelial carcinoma did not present with atypical cytology. In total, 6 of 703 (0.85%) patients had bladder cancer. All were treated with transurethral resection and eventually underwent renal transplant. One patient has had disease progression post-transplant to distant metastases. This is the largest study to date evaluating the incidence of urothelial carcinoma in ESRD patients presenting for transplant workup. We found the incidence of bladder cancer to be higher than in the general Canadian population, however, most lesions were low grade. We found atypical cytology in transplant candidates to be a poor predictor for these low-grade lesions and do not recommend routine cystoscopy for atypical cytology. CI - (c) 2019 Steunstichting ESOT. FAU - Law, Jeffrey AU - Law J AUID- ORCID: 0000-0001-7396-5178 AD - Department of Surgery (Urology), Western University, London, ON, Canada. FAU - Ali, Omar AU - Ali O AD - Department of Surgery (Urology), Western University, London, ON, Canada. FAU - Dobrin, Andrei AU - Dobrin A AD - Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Brar, Harmenjit AU - Brar H AD - Department of Surgery (Urology), Western University, London, ON, Canada. FAU - Luke, Patrick P AU - Luke PP AUID- ORCID: 0000-0002-9089-6933 AD - Department of Surgery (Urology), Western University, London, ON, Canada. AD - Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Sener, Alp AU - Sener A AD - Department of Surgery (Urology), Western University, London, ON, Canada. AD - Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. AD - Department of Microbiology and Immunology, Western University, London, ON, Canada. LA - eng PT - Journal Article DEP - 20190531 PL - Switzerland TA - Transpl Int JT - Transplant international : official journal of the European Society for Organ Transplantation JID - 8908516 SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Incidence MH - Kidney Failure, Chronic/*complications/epidemiology/surgery/urine MH - Kidney Transplantation MH - Male MH - Middle Aged MH - Ontario/epidemiology MH - Retrospective Studies MH - Urine/*cytology MH - Urologic Neoplasms/*complications/epidemiology OTO - NOTNLM OT - atypical cytology OT - renal transplantation OT - urothelial carcinoma EDAT- 2019/05/18 06:00 MHDA- 2020/03/14 06:00 CRDT- 2019/05/18 06:00 PHST- 2018/10/14 00:00 [received] PHST- 2019/01/03 00:00 [revised] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/05/18 06:00 [pubmed] PHST- 2020/03/14 06:00 [medline] PHST- 2019/05/18 06:00 [entrez] AID - 10.1111/tri.13464 [doi] PST - ppublish SO - Transpl Int. 2019 Oct;32(10):1085-1094. doi: 10.1111/tri.13464. Epub 2019 May 31. PMID- 31097388 OWN - NLM STAT- MEDLINE DCOM- 20200416 LR - 20200416 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 4 DP - 2019 Aug TI - Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. PG - e784-e792 LID - S1558-7673(19)30140-5 [pii] LID - 10.1016/j.clgc.2019.04.014 [doi] AB - Complete transurethral resection of bladder tumor (TURBT) is the initial procedure of choice for non-muscle-invasive bladder cancer, but its quality is far from optimal in clinical practice. We evaluated the existing body of evidence substantiating current quality control indicators (QCIs) for TURBT. A literature search was performed using PubMed and Embase, and selected articles were reviewed according to their level of evidence. Disease recurrence and progression were used as the primary end points. No hard evidence supports complete resection as a QCI, but rationally, it is the most important indicator for TURBT. A repeat resection is an important QCI in high-risk disease patients, but evidence suggests that it may not be necessary when detrusor muscle is present in the initial resection specimen. The presence of detrusor muscle in the resection specimen is a validated QCI for TURBT. Adjuvant intravesical instillation is a scientifically proven QCI. Bladder perforation is a controversial QCI in the existing literature. No evidence indicates the ideal time frame for the initial TURBT; thus, initial therapy in the first 6 weeks after diagnosis is not a good QCI. Three of the 6 proposed QCIs for TURBT are supported by evidence. Our literature analysis indicated the use of complete resection, repeat resection, the presence of detrusor muscle, and intravesical instillation are QCIs to minimize recurrence and progression, and increase beneficial outcomes. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Akand, Murat AU - Akand M AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium; Department or Urology, Selcuk University, School of Medicine, Konya, Turkey. Electronic address: drmuratakand@yahoo.com. FAU - Muilwijk, Tim AU - Muilwijk T AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Raskin, Yannic AU - Raskin Y AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium. FAU - De Vrieze, Maxime AU - De Vrieze M AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Van Der Aa, Frank AU - Van Der Aa F AD - Department or Urology, University Hospitals Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Review DEP - 20190419 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/therapeutic use MH - Cystectomy/methods MH - Disease Progression MH - Drug Therapy MH - Humans MH - Immunotherapy MH - Prognosis MH - Quality Control MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/*drug therapy/*surgery OTO - NOTNLM OT - Progression OT - Quality indicator OT - Quality parameter OT - Recurrence OT - TURBT EDAT- 2019/05/18 06:00 MHDA- 2020/04/17 06:00 CRDT- 2019/05/18 06:00 PHST- 2019/02/27 00:00 [received] PHST- 2019/04/08 00:00 [revised] PHST- 2019/04/11 00:00 [accepted] PHST- 2019/05/18 06:00 [pubmed] PHST- 2020/04/17 06:00 [medline] PHST- 2019/05/18 06:00 [entrez] AID - S1558-7673(19)30140-5 [pii] AID - 10.1016/j.clgc.2019.04.014 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Aug;17(4):e784-e792. doi: 10.1016/j.clgc.2019.04.014. Epub 2019 Apr 19. PMID- 31097210 OWN - NLM STAT- MEDLINE DCOM- 20201015 LR - 20210518 IS - 2173-5786 (Electronic) IS - 2173-5786 (Linking) VI - 43 IP - 8 DP - 2019 Oct TI - Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review. PG - 404-413 LID - S0210-4806(19)30041-5 [pii] LID - 10.1016/j.acuro.2019.03.001 [doi] AB - BACKGROUND: The surveillance of non-muscle-invasive bladder cancer (NMIBC) is usually performed by cystoscopy and cytology. Until today, no effective urinary biomarker has been used to reduce the morbidity and cost associated with these procedures. OBJECTIVE: To describe the performance of urinary biomarkers in the surveillance of NMIBC. EVIDENCE ACQUISITION: on August 1, 2018, a bibliographic search was carried out in Pubmed, Embase and Cochrane Library, limited to the last 10 years, with the terms: bladder cancer, recurrence, detection and urine marker.973 registers were obtained, and 27 publications were selected following the PRISMA recommendations. EVIDENCE SYNTHESIS: The negative predictive values (NPV) of several assays could reduce the number of cystoscopies in NMIBC surveillance. Six transcription-factor trials had an NPV rate greater than 90%, and one of them can be performed at the control point. Six transcription-factors evaluations describe anticipated diagnosis between 68% and 83% of their "false positives". Two transcription factors and one protein assays proved reduction between 23% and 35% of surveillance cystoscopies. Nowadays, cell-based assays are restricted to reflex test after doubtful cytologies. CONCLUSION: There are few studies analysing the improvement of the NMIBC surveillance protocols. Several transcription factor assays are more precise and allow anticipatory diagnosis. Currently, there are no comparative studies between alternative surveillance protocols and classic ones. CI - Copyright (c) 2019 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Agreda Castaneda, F AU - Agreda Castaneda F AD - Hospital Universitario Germans Trias i Pujol, Barcelona, Espana. Electronic address: fernandoagredac@hotmail.com. FAU - Raventos Busquets, C X AU - Raventos Busquets CX AD - Hospital Universitario Vall d'Hebron, Barcelona, Espana; Universitat Autonoma de Barcelona, Barcelona, Espana. FAU - Morote Robles, J AU - Morote Robles J AD - Hospital Universitario Vall d'Hebron, Barcelona, Espana; Universitat Autonoma de Barcelona, Barcelona, Espana. LA - eng LA - spa PT - Journal Article PT - Review TT - Marcadores urinarios en la vigilancia del tumor vesical no musculo infiltrante. Revision de la literatura. DEP - 20190513 PL - Spain TA - Actas Urol Esp (Engl Ed) JT - Actas urologicas espanolas JID - 101771154 RN - 0 (Biomarkers, Tumor) RN - 0 (Transcription Factors) SB - IM MH - Biomarkers, Tumor/*urine MH - Humans MH - Neoplasm Invasiveness MH - Population Surveillance MH - Transcription Factors/urine MH - Urinary Bladder Neoplasms/pathology/*urine OTO - NOTNLM OT - Biomarcador OT - Biomarker OT - Bladder cancer OT - Cancer vesical OT - Orina OT - Surveillance OT - Urine OT - Vigilancia EDAT- 2019/05/18 06:00 MHDA- 2020/10/21 06:00 CRDT- 2019/05/18 06:00 PHST- 2019/01/16 00:00 [received] PHST- 2019/02/13 00:00 [revised] PHST- 2019/03/04 00:00 [accepted] PHST- 2019/05/18 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2019/05/18 06:00 [entrez] AID - S0210-4806(19)30041-5 [pii] AID - 10.1016/j.acuro.2019.03.001 [doi] PST - ppublish SO - Actas Urol Esp (Engl Ed). 2019 Oct;43(8):404-413. doi: 10.1016/j.acuro.2019.03.001. Epub 2019 May 13. PMID- 31088707 OWN - NLM STAT- MEDLINE DCOM- 20200327 LR - 20200327 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 3 DP - 2019 Jun TI - Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer. PG - e704-e711 LID - S1558-7673(19)30012-6 [pii] LID - 10.1016/j.clgc.2019.04.001 [doi] AB - BACKGROUND: Disease monitoring in non-muscle-invasive bladder cancer (NMIBC) patients is crucial for early identification of disease recurrence and progression. High IQGAP3/BMP4 and IQGAP3/FAM107A ratios in urinary cell-free DNA (ucfDNA) are a diagnostic biomarker for bladder cancer. We aimed to investigate whether the levels of these biomarkers in ucfDNA can be used to monitor disease recurrence or progression in patients with NMIBC. PATIENTS AND METHODS: A total of 103 patients with NMIBC (pTa-pT1) were enrolled. The IQGAP3/BMP4 and IQGAP3/FAM107A ratios in ucfDNA were measured by real-time PCR, and the results were compared with clinical outcome by Kaplan-Meier curves and Cox regression analyses. RESULTS: Overall, 55 patients (53.4%) experienced recurrence and 29 (28.2%) experienced disease progression during a median follow-up of 42.7 months (range, 6.1-172.2 months). Kaplan-Meier analysis revealed that NMIBC patients with a high IQGAP3/BMP4 ratio had worse recurrence-free survival and progression-free survival (PFS) (P = .001 and < .001, respectively), and those with a high IQGAP3/FAM107A ratio had worse PFS (P = .006). Multivariate Cox regression analysis revealed that the IQGAP3/BMP4 ratio was independently associated with recurrence-free survival (hazard ratio, 2.462; P = .003) and PFS (hazard ratio = 3.871; P = .004), whereas the IQGAP3/FAM107A ratio was not an independent factor for PFS (P = .079). CONCLUSION: The IQGAP3/BMP4 ratio in ucfDNA might be a valuable novel biomarker for predicting disease recurrence and progression in patients with NMIBC. CI - Copyright (c) 2019. Published by Elsevier Inc. FAU - Xu, Yanjie AU - Xu Y AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea; Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Kim, Ye-Hwan AU - Kim YH AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Seo, Sung Pil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Lee, Jong-Young AU - Lee JY AD - Department of Business Data Convergence, Chungbuk National University, Cheongju, Korea; Theragen Etex Bio Institute, Suwon, Korea. FAU - Ryu, Dong Hee AU - Ryu DH AD - Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Choi, Jae-Woon AU - Choi JW AD - Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Kim, Isaac Y AU - Kim IY AD - Section of Urologic Oncology and Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food Science and Technology, Chung-Ang University, Ansung, Korea. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan, Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. Electronic address: wjkim@chungbuk.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190409 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BMP4 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Bone Morphogenetic Protein 4) RN - 0 (Cell-Free Nucleic Acids) RN - 0 (FAM107A protein, human) RN - 0 (GTPase-Activating Proteins) RN - 0 (IQGAP3 protein, human) RN - 0 (Nuclear Proteins) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/urine MH - Bone Morphogenetic Protein 4/*genetics/urine MH - Cell-Free Nucleic Acids/*urine MH - Disease Progression MH - Female MH - GTPase-Activating Proteins/*genetics/urine MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Genes, Tumor Suppressor MH - Humans MH - Male MH - Middle Aged MH - Nuclear Proteins/*genetics/urine MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality/urine OTO - NOTNLM OT - Biomarker OT - NMIBC OT - Prognosis OT - Urinary cell-free DNA EDAT- 2019/05/16 06:00 MHDA- 2020/03/28 06:00 CRDT- 2019/05/16 06:00 PHST- 2019/01/07 00:00 [received] PHST- 2019/04/01 00:00 [revised] PHST- 2019/04/02 00:00 [accepted] PHST- 2019/05/16 06:00 [pubmed] PHST- 2020/03/28 06:00 [medline] PHST- 2019/05/16 06:00 [entrez] AID - S1558-7673(19)30012-6 [pii] AID - 10.1016/j.clgc.2019.04.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Jun;17(3):e704-e711. doi: 10.1016/j.clgc.2019.04.001. Epub 2019 Apr 9. PMID- 31084565 OWN - NLM STAT- MEDLINE DCOM- 20200220 LR - 20200220 IS - 2578-5478 (Electronic) IS - 2578-5478 (Linking) VI - 37 IP - 5 DP - 2019 May TI - Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Nonmuscle-Invasive Bladder Cancer Treated with GreenLight Laser Vaporization. PG - 312-317 LID - 10.1089/photob.2018.4592 [doi] AB - Objective: An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poor outcomes in many types of malignancies, including bladder cancer. However, the prognostic value of NLR in patients with nonmuscle-invasive bladder cancer (NMIBC) treated with GreenLight photoselective vaporization of bladder tumor (PVBT) has not been well studied. In this study, we aimed to explore the association between NLR and survival outcomes in patients with NMIBC who underwent PVBT. Materials and methods: We retrospectively investigated 463 patients with NMIBC who underwent PVBT in Tianjin Union Medical center from January 2012 to January 2017. The patients were divided into two groups based on the NLR value (NLR >/=2.5 and NLR <2.5). Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were determined using Kaplan-Meier analysis and the log-rank test. Results: Among 463 patients, age, tumor size, tumor focality, tumor grade, or tumor stage in the two groups did not differ significantly. The median follow-up was 40 months (range, 15-60). Thirty-eight patients (8.2%) died of any cause; 24 (5.2%) patients died of bladder cancer. In addition, 88 (19.0%) patients experienced disease recurrence. Elevated NLR was significantly associated with poor OS (chi(2) = 7.457, p = 0.002), CSS (chi(2) = 6.242, p = 0.012), and RFS (chi(2) = 5.372, p = 0.020) in patients with NMIBC who underwent PVBT. Conclusions: Elevated preoperative NLR was significantly associated with poor OS, CSS, and RFS, and it could be considered as an effective and convenient prognostic biomarker for patients with NMIBC who were treated with PVBT. FAU - Luo, Fei AU - Luo F AD - 1 Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Ma, Chunlei AU - Ma C AD - 2 Department of Urology, Tianjin Fourth Central Hospital, Tianjin, China. FAU - Wu, Jianhui AU - Wu J AD - 3 Department of Urology, Tianjin First Central Hospital, Tianjin, China. FAU - Li, Jian AU - Li J AD - 1 Department of Urology, Tianjin Union Medical Center, Tianjin, China. LA - eng PT - Journal Article DEP - 20190411 PL - United States TA - Photobiomodul Photomed Laser Surg JT - Photobiomodulation, photomedicine, and laser surgery JID - 101734781 SB - IM MH - Aged MH - Female MH - Humans MH - *Laser Therapy MH - *Lymphocyte Count MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Neutrophils MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*blood/mortality/*therapy OTO - NOTNLM OT - lymphocyte OT - neutrophil OT - neutrophil-to-lymphocyte ratio OT - nonmuscle-invasive bladder cancer OT - prognosis EDAT- 2019/05/16 06:00 MHDA- 2020/02/23 06:00 CRDT- 2019/05/16 06:00 PHST- 2019/05/16 06:00 [entrez] PHST- 2019/05/16 06:00 [pubmed] PHST- 2020/02/23 06:00 [medline] AID - 10.1089/photob.2018.4592 [doi] PST - ppublish SO - Photobiomodul Photomed Laser Surg. 2019 May;37(5):312-317. doi: 10.1089/photob.2018.4592. Epub 2019 Apr 11. PMID- 31081431 OWN - NLM STAT- MEDLINE DCOM- 20200109 LR - 20221207 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 53 IP - 2-3 DP - 2019 Apr-Jun TI - Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy. PG - 123-128 LID - 10.1080/21681805.2019.1613445 [doi] AB - Background: The value of preoperative chemotherapy to prostatic stromal invasive urothelial bladder cancer remains uncertain. This study presented the pathological response and oncological outcomes of male patients with cT4a urothelial bladder cancer managed with preoperative chemotherapy followed by radical cystectomy. Materials and methods: Data were collected retrospectively from male patients with cT4a urothelial bladder cancer, who underwent radical cystectomy with or without preoperative chemotherapy. Patient characteristics and pathological response were compared. The Kaplan-Meier method and multivariable Cox regression were used to analyze recurrence-free survival and overall survival. Results: From 1989 to 2016, 90 male patients with primary cT4a urothelial bladder cancer underwent radical cystectomy at the institution, 55 (61%) did not have preoperative chemotherapy and 35 (39%) had preoperative chemotherapy. The preoperative chemotherapy group had more lymphovascular invasion on primary transurethral resection of bladder tumor (31.4% vs 18.2%, p = .2) and more clinically positive nodal disease (31.4% vs 10.9%, p = .09). At radical cystectomy, the preoperative chemotherapy group had more tumor down staging (60% vs 29.1%, p = .005), less lymphovascular invasion (40% vs 54.5%, p = .05) and less positive nodal disease (25.7% vs 45.5%, p = .006). Hydronephrosis, lymphovascular invasion and age >70 were associated with worse recurrence-free survival and overall survival (p < .05). Tumor down-staging was associated with improved recurrence-free survival and overall survival (p = .003, p = .03, respectively). Preoperative chemotherapy alone was not associated with improved oncologic outcomes. Conclusions: Preoperative chemotherapy is associated with cT4a bladder cancer down-staging, decreased lymphovascular invasion and decreased positive nodal disease. Preoperative chemotherapy provides survival benefit to those who achieved pathological response. FAU - Chen, Jian AU - Chen J AD - a Catherine & Joseph Aresty Department of Urology , University of Southern California Institute of Urology , Los Angeles , CA , USA. FAU - Miranda, Gus AU - Miranda G AD - a Catherine & Joseph Aresty Department of Urology , University of Southern California Institute of Urology , Los Angeles , CA , USA. FAU - Cai, Jie AU - Cai J AD - a Catherine & Joseph Aresty Department of Urology , University of Southern California Institute of Urology , Los Angeles , CA , USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - a Catherine & Joseph Aresty Department of Urology , University of Southern California Institute of Urology , Los Angeles , CA , USA. FAU - Djaladat, Hooman AU - Djaladat H AD - a Catherine & Joseph Aresty Department of Urology , University of Southern California Institute of Urology , Los Angeles , CA , USA. LA - eng PT - Journal Article DEP - 20190513 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0W860991D6 (Deoxycytidine) RN - 5V9KLZ54CY (Vinblastine) RN - 80168379AG (Doxorubicin) RN - Q20Q21Q62J (Cisplatin) RN - YL5FZ2Y5U1 (Methotrexate) RN - 0 (Gemcitabine) RN - M-VAC protocol SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma, Transitional Cell/*therapy MH - Case-Control Studies MH - Cisplatin/administration & dosage/therapeutic use MH - *Cystectomy MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease-Free Survival MH - Doxorubicin/therapeutic use MH - Humans MH - Induction Chemotherapy MH - Kaplan-Meier Estimate MH - Lymph Node Excision MH - Lymph Nodes/pathology MH - Male MH - Methotrexate/therapeutic use MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Pelvis MH - Proportional Hazards Models MH - Prostate/*pathology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*therapy MH - Vinblastine/therapeutic use MH - Gemcitabine OTO - NOTNLM OT - Cystectomy OT - induction chemotherapy OT - neoadjuvant chemotherapy OT - preoperative therapy OT - recurrence OT - survival OT - urinary bladder neoplasms EDAT- 2019/05/14 06:00 MHDA- 2020/01/10 06:00 CRDT- 2019/05/14 06:00 PHST- 2019/05/14 06:00 [pubmed] PHST- 2020/01/10 06:00 [medline] PHST- 2019/05/14 06:00 [entrez] AID - 10.1080/21681805.2019.1613445 [doi] PST - ppublish SO - Scand J Urol. 2019 Apr-Jun;53(2-3):123-128. doi: 10.1080/21681805.2019.1613445. Epub 2019 May 13. PMID- 31081198 OWN - NLM STAT- MEDLINE DCOM- 20200810 LR - 20200810 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 26 IP - 8 DP - 2019 Aug TI - Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. PG - 791-796 LID - 10.1111/iju.14014 [doi] AB - OBJECTIVES: To examine the effectiveness of intravesical irrigation with physiological saline solution or distilled water for the prevention of bladder recurrence in patients undergoing laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. METHODS: This retrospective study involved 109 upper urinary tract urothelial carcinoma patients who underwent laparoscopic nephroureterectomy, and were evaluated at Chiba University Hospital and Yokohama Rosai Hospital between 2001 and 2018. We investigated the outcomes and analyzed various clinical factors including with or without intravesical irrigation related to bladder carcinoma recurrence after surgery. Physiological saline solution or distilled water was used for irrigation, which was carried out only during surgery. RESULTS: The median follow-up period after surgery was 26.1 months. Bladder recurrence was confirmed within 2 years for 45 of the 109 patients in the present study. Irrigation was carried out for 48 cases (distilled water, 26 patients; physiological saline solution, 22 patients). Tumor grade (G1-2 vs G3; P = 0.05) and intravesical irrigation (yes vs no; P = 0.0058) were related to bladder recurrence on univariate analyses. On multivariate analyses, intravesical irrigation was the independent factor involved in the prevention of bladder recurrence (P = 0.0051). Comparison between the irrigation and non-irrigation groups showed that bladder recurrence rates were significantly lower in the irrigation group (irrigation group vs non-irrigation group: 25.0% vs 52.5%, P = 0.0066). There was no significant difference in the recurrence rate between the two solutions used for irrigation. CONCLUSIONS: Intravesical irrigation during surgery of upper urinary tract urothelial carcinoma might decrease postoperative bladder recurrence rates. CI - (c) 2019 The Japanese Urological Association. FAU - Yamamoto, Satoshi AU - Yamamoto S AD - Department of Urology, Chiba University Hospital, Chiba, Japan. FAU - Sakamoto, Shinichi AU - Sakamoto S AD - Department of Urology, Chiba University Hospital, Chiba, Japan. FAU - Imamura, Yusuke AU - Imamura Y AD - Department of Urology, Chiba University Hospital, Chiba, Japan. FAU - Sazuka, Tomokazu AU - Sazuka T AD - Department of Urology, Chiba University Hospital, Chiba, Japan. FAU - Nakamura, Kazuyoshi AU - Nakamura K AD - Department of Urology, Chiba University Hospital, Chiba, Japan. FAU - Inoue, Toshihito AU - Inoue T AD - Department of Urology, Yokohama Rosai Hospital, Yokohama, Japan. FAU - Chiba, Kazuto AU - Chiba K AD - Department of Urology, Yokohama Rosai Hospital, Yokohama, Japan. FAU - Miyazaki, Kanetaka AU - Miyazaki K AD - Department of Urology, Yokohama Rosai Hospital, Yokohama, Japan. FAU - Inoue, Atsushi AU - Inoue A AD - Department of Urology, Yokohama Rosai Hospital, Yokohama, Japan. FAU - Nagata, Maki AU - Nagata M AD - Department of Urology, Yokohama Rosai Hospital, Yokohama, Japan. FAU - Ichikawa, Tomohiko AU - Ichikawa T AD - Department of Urology, Chiba University Hospital, Chiba, Japan. LA - eng PT - Comparative Study PT - Journal Article DEP - 20190512 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Saline Solution) RN - 059QF0KO0R (Water) SB - IM MH - Administration, Intravesical MH - Aged MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/*prevention & control MH - Neoplasm Seeding MH - Nephroureterectomy/*methods MH - Retrospective Studies MH - Saline Solution/*administration & dosage MH - Therapeutic Irrigation/methods MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder MH - Water/administration & dosage OTO - NOTNLM OT - bladder cancer OT - irrigation OT - laparoscopic OT - nephroureterectomy OT - recurrence EDAT- 2019/05/14 06:00 MHDA- 2020/08/11 06:00 CRDT- 2019/05/14 06:00 PHST- 2018/12/15 00:00 [received] PHST- 2019/03/27 00:00 [accepted] PHST- 2019/05/14 06:00 [pubmed] PHST- 2020/08/11 06:00 [medline] PHST- 2019/05/14 06:00 [entrez] AID - 10.1111/iju.14014 [doi] PST - ppublish SO - Int J Urol. 2019 Aug;26(8):791-796. doi: 10.1111/iju.14014. Epub 2019 May 12. PMID- 31076356 OWN - NLM STAT- MEDLINE DCOM- 20200911 LR - 20200911 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 9 DP - 2019 Sep TI - Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients. PG - 573.e1-573.e8 LID - S1078-1439(19)30149-8 [pii] LID - 10.1016/j.urolonc.2019.04.016 [doi] AB - BACKGROUND: A healthy lifestyle may reduce the risk of non-muscle-invasive bladder cancer (NMIBC) recurrence. The objective of this study was to obtain insight in whether NMIBC patients are aware of possible risk factors for (bladder) cancer, adhere to lifestyle recommendations for cancer prevention, received lifestyle advice from their physician, and what their attitudes are towards physicians giving lifestyle advice. METHODS: Patients with newly diagnosed NMIBC between 2014 and 2017 participating in the UroLife cohort study completed questionnaires at 6 weeks and 3 months after diagnosis about awareness of (bladder) cancer risk factors, adherence to lifestyle recommendations, reception of lifestyle advice, and attitudes towards physicians giving lifestyle advice. RESULTS: A total of 969 NMIBC patients were included (response rate 46%). Most patients (89%) were aware that smoking is a risk factor for cancer, and knowledge of other risk factors for cancer varied between 29% (low fruit and vegetable consumption) and 67% (overweight). Adherence to cancer prevention recommendations varied between 34% (body weight) and 85% (smoking). Of the smokers, 70% reported they were advised to quit, and 36% quit smoking in the three months before or after diagnosis. Only 21% of all patients indicated they received other lifestyle advice. More than 80% of patients had a positive attitude towards receiving lifestyle advice from their physician. CONCLUSIONS: These findings show that awareness of (bladder) cancer risk factors and adherence to cancer prevention lifestyle recommendations among NMIBC patients is low and that physicians' information provision should be improved. CI - Copyright (c) 2019 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Westhoff, Ellen AU - Westhoff E AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FAU - Kampman, Ellen AU - Kampman E AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands. FAU - Aben, Katja K AU - Aben KK AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. FAU - Hendriks, Inge G AU - Hendriks IG AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FAU - Witjes, Johannes Alfred AU - Witjes JA AD - Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Department of Urology, Nijmegen, the Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. Electronic address: Alina.Vrieling@radboudumc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190508 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Awareness/*physiology MH - Female MH - Humans MH - *Life Style MH - Male MH - Middle Aged MH - Prospective Studies MH - Surveys and Questionnaires MH - Urinary Bladder Neoplasms/*psychology MH - Young Adult OTO - NOTNLM OT - Advice OT - Attitude OT - Awareness OT - Lifestyle recommendations OT - Non-muscle-invasive bladder cancer EDAT- 2019/05/12 06:00 MHDA- 2020/09/12 06:00 CRDT- 2019/05/12 06:00 PHST- 2018/12/10 00:00 [received] PHST- 2019/03/19 00:00 [revised] PHST- 2019/04/16 00:00 [accepted] PHST- 2019/05/12 06:00 [pubmed] PHST- 2020/09/12 06:00 [medline] PHST- 2019/05/12 06:00 [entrez] AID - S1078-1439(19)30149-8 [pii] AID - 10.1016/j.urolonc.2019.04.016 [doi] PST - ppublish SO - Urol Oncol. 2019 Sep;37(9):573.e1-573.e8. doi: 10.1016/j.urolonc.2019.04.016. Epub 2019 May 8. PMID- 31056435 OWN - NLM STAT- MEDLINE DCOM- 20200915 LR - 20200915 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. PG - 791-799 LID - S1078-1439(19)30143-7 [pii] LID - 10.1016/j.urolonc.2019.04.010 [doi] AB - OBJECTIVES: To investigate the preoperative prognostic value of molecular subtypes in relation to clinical information, histopathological findings, and molecular markers for patients with bladder cancer treated with radical cystectomy. PATIENTS AND METHODS: After standard preoperative staging, a population-based cohort of 519 patients underwent radical cystectomy between 2006 and 2011. Following pathological review of all transurethral resection of bladder tumor specimens, tissue microarrays were constructed, and RNA was extracted from formalin-fixed tissue blocks. Immunohistochemistry (IHC) was performed using markers suggested to be relevant for prognosis (ZEB2, CCND1, CD3, CD68, CDH3, HER3, KRT14, CDKN2A(p16), TP63, FGFR3, EPCAM, GATA3, FOXA1, ERBB2, and EGFR). IHC- and gene-expression-based molecular classification was also conducted. Univariate and multivariate Cox proportional hazards regression were used for survival analyses. RESULTS: Clinical T3 stage (Hazard Ratio [HR] 1.6, Confidence Interval [CI] 1.1-2.3), hydronephrosis (HR 1.7, CI 1.2-2.3), lymphovascular invasion (LVI) (HR 2.6, CI 1.9-3.6), extensive necrosis (HR 1.6, CI 1.1-2.5), and CD68/CD3-ratio >1 (HR 1.3, CI 1.1-1.5) in the transurethral resection of bladder tumor specimen was associated with worse cancer-specific survival (CSS) and progression-free survival (data not shown). In multivariate analysis, higher clinical T stage (HR 1.3, CI 1.1-1.7; P = 0.007) and presence of LVI (HR 2.4, CI 1.7-3.5; P = 1.8 x 10(-)(6)) were associated with worse CSS, whereas only LVI was associated with progression-free survival. Molecular subtypes (assessed by Lund taxonomy and the Consensus molecular subtypes of muscle-invasive bladder cancer) and published single IHC markers were not associated with survival. CONCLUSIONS: In the present large population-based cystectomy series, LVI and clinical stage were independently associated with CSS. However, molecular subtypes determined by global gene expression showed no such association with CSS according to either the Consensus molecular subtypes of muscle-invasive bladder cancer or Lund taxonomy. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Kollberg, Petter AU - Kollberg P AD - Department of Urology, Skane University Hospital, Malmo, Sweden; Department of Translational Medicine, Lund University, Malmo, Sweden. Electronic address: petter.kollberg@skane.se. FAU - Chebil, Gunilla AU - Chebil G AD - Unilabs Pathology Department, Helsingborg, Sweden. FAU - Eriksson, Pontus AU - Eriksson P AD - Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - Department of Urology, Skane University Hospital, Malmo, Sweden; Department of Translational Medicine, Lund University, Malmo, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190502 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Urinary Bladder Neoplasms/mortality/pathology OTO - NOTNLM OT - Bladder cancer OT - Molecular subtypes OT - Radical cystectomy OT - Survival EDAT- 2019/05/06 06:00 MHDA- 2020/09/17 06:00 CRDT- 2019/05/07 06:00 PHST- 2019/01/05 00:00 [received] PHST- 2019/04/08 00:00 [revised] PHST- 2019/04/09 00:00 [accepted] PHST- 2019/05/06 06:00 [pubmed] PHST- 2020/09/17 06:00 [medline] PHST- 2019/05/07 06:00 [entrez] AID - S1078-1439(19)30143-7 [pii] AID - 10.1016/j.urolonc.2019.04.010 [doi] PST - ppublish SO - Urol Oncol. 2019 Oct;37(10):791-799. doi: 10.1016/j.urolonc.2019.04.010. Epub 2019 May 2. PMID- 31046476 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1744-7682 (Electronic) IS - 1471-2598 (Linking) VI - 19 IP - 7 DP - 2019 Jul TI - Immunotherapy in non-metastatic urothelial cancer: back to the 'future'. PG - 685-695 LID - 10.1080/14712598.2019.1604673 [doi] AB - INTRODUCTION: Successful results of immuno-oncological drugs in metastatic urothelial cancer have triggered the interest of researchers to test them in the non-metastatic setting. Conventional treatment modalities in that space are limited, sometimes toxic and with no improvement seen for the last 20 years and beyond. For patients failing intravesical BCG and mitomycin C in non-muscle invasive bladder cancer, no effective therapeutic alternatives exist besides cystectomy. In the neoadjuvant setting, cisplatin-based chemotherapy provides limited benefit in terms of disease recurrence and metastases, at the expense of toxic effects. The good news is that preliminary studies are showing great promise with the use of immunotherapy in the local and loco-regional disease. Larger studies are now on the way to confirm the exciting potential benefits of immunotherapy in this direction. AREAS COVERED: This review presents an overview of developments happening on the introduction of immunotherapy in non-metastatic urothelial cancer treatment. EXPERT OPINION: Immunotherapy in the non-metastatic disease setting in urothelial cancer is evolving. Early results tend to anticipate a predominant role in coming times. Large comparative trials are in progress to gather robust practice-changing evidence to bring a paradigm shift in the treatment landscape. FAU - Darling, H S AU - Darling HS AUID- ORCID: 0000-0001-7557-0292 AD - a Medical Oncology & Hemato-oncology , Artemis Hospital , Gurugram , India. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - b Medicine, University Hospital del Mar , Barcelona , Spain. LA - eng PT - Journal Article PT - Review DEP - 20190502 PL - England TA - Expert Opin Biol Ther JT - Expert opinion on biological therapy JID - 101125414 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents, Immunological) RN - DPT0O3T46P (pembrolizumab) RN - QEN1X95CIX (tremelimumab) SB - IM MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Antineoplastic Agents, Immunological/*therapeutic use MH - Chemoradiotherapy MH - Humans MH - *Immunotherapy MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/drug therapy/pathology/*therapy OTO - NOTNLM OT - Adjuvant OT - MIBC OT - NMIBC OT - biomarkers OT - bladder cancer OT - immunotherapy OT - neoadjuvant OT - radical cystectomy OT - urothelial cancer EDAT- 2019/05/03 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/05/04 06:00 PHST- 2019/05/03 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/05/04 06:00 [entrez] AID - 10.1080/14712598.2019.1604673 [doi] PST - ppublish SO - Expert Opin Biol Ther. 2019 Jul;19(7):685-695. doi: 10.1080/14712598.2019.1604673. Epub 2019 May 2. PMID- 31038858 OWN - NLM STAT- MEDLINE DCOM- 20191031 LR - 20221024 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 45 IP - 5 DP - 2019 Sep-Oct TI - Non-functional paraganglioma of urinary bladder managed by transurethral resection. PG - 910-915 LID - 10.1590/S1677-5538.IBJU.2018.0604 [doi] AB - PURPOSE: As a rare bladder tumor, paraganglioma of the urinary bladder (PUB) is frequently misdiagnosed as bladder cancer, particularly for the non-functional type. To date, transurethral resection remains a controversial treatment for non-functional PUB. This study aimed to identify the clinical features, pathological characteristics, prognosis, and safe/effective treatment of non-functional PUB using transurethral resection of the bladder tumor (TURBT). MATERIALS AND METHODS: The clinical records, radiological data, pathological characteristics and follow-up times were retrospectively reviewed in 10 patients with clinically and pathologically proven non-functional PUB in our hospital from January 2008 to November 2016. All patients underwent TURBT treatment. RESULTS: The incidence of non-functional PUB in patients with bladder cancer was 0.17%. The mean age at diagnosis was 44.5 +/- 13.6 years (range, 29-70 years), and the patient population had a female: male ratio of 3: 2. No patients had excess catecholamine (CA) whilst four patients had painless hematuria. All neoplasms were completely resected via TURBT. The majority of samples were positive for immunohistochemical markers including chromogranin A (CgA) and Synaptophysin (Syn), but were negative for cytokeratins (CKs). Only a single recurrence was observed from the mean follow-up period of 36.4 +/- 24.8 months. CONCLUSION: Complete TURBT is a safe and effi cient treatment that serves both diagnostic and therapeutic purposes. Histopathological and immunohistochemistry examinations are mandatory for diagnostic confi rmation. Long-term follow-up is recommended for patients with non-functional PUB. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Zhang, Baochao AU - Zhang B AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Fu, Zhenrui AU - Fu Z AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liu, Liwei AU - Liu L AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Qiao, Baomin AU - Qiao B AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. FAU - Liu, Chunyu AU - Liu C AD - Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - 0 (Chromogranin A) RN - 0 (Synaptophysin) SB - IM MH - Adult MH - Aged MH - Chromogranin A/analysis MH - Cystoscopy/methods MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Paraganglioma/pathology/*surgery MH - Reproducibility of Results MH - Retrospective Studies MH - Synaptophysin/analysis MH - Treatment Outcome MH - Urethra/surgery MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC6844347 OTO - NOTNLM OT - Paraganglioma OT - Transurethral Resection of Prostate OT - Urinary Bladder COIS- None declared. EDAT- 2019/05/01 06:00 MHDA- 2019/11/02 06:00 PMCR- 2019/01/29 CRDT- 2019/05/01 06:00 PHST- 2018/08/28 00:00 [received] PHST- 2019/01/30 00:00 [accepted] PHST- 2019/05/01 06:00 [pubmed] PHST- 2019/11/02 06:00 [medline] PHST- 2019/05/01 06:00 [entrez] PHST- 2019/01/29 00:00 [pmc-release] AID - IBJU20180604 [pii] AID - S1677-5538.IBJU.2018.0604 [pii] AID - 10.1590/S1677-5538.IBJU.2018.0604 [doi] PST - ppublish SO - Int Braz J Urol. 2019 Sep-Oct;45(5):910-915. doi: 10.1590/S1677-5538.IBJU.2018.0604. PMID- 31030273 OWN - NLM STAT- MEDLINE DCOM- 20190627 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 7 DP - 2019 Jul TI - Individual patient risk of progression of urinary bladder papillary tumors estimated from biomarkers at initial transurethral resection of bladder tumor. PG - 1709-1718 LID - 10.1007/s00432-019-02923-1 [doi] AB - OBJECTIVE: To determine if individual, instead of group, patient progression risk could be predicted using p53, Ki67 and CK20 biomarker percentage values at initial transurethral resection of bladder tumor specimens. METHODS: This was an observational study where biomarkers were measured with no knowledge of tumor outcome. Initial bladder tumor specimens were classified as non-invasive and invasive to sub-epithelium (pT1). Percentages of stained biomarker cells were tested as progression predictors from non-invasive to pT1 and pT1 to pT2. Progression probability was correlated with biomarker percentages resulting in a regression equation. RESULTS: We studied 112 patients (median age = 67, range 37-91, males 83/112 (73%), with median follow-up of 39 months (range 1.7-140). Mean biomarker values were higher in stage pT1 than in non-invasive (all p < 0.001). Cut-off points separating progression from non-progression groups in stage pT1 were higher than in non-invasive for all biomarkers. Correlation R values for progression probability vs. biomarker percentages varied from 0.7 to 0.9 (all p < 0.001), regression slopes from 0.1 to 0.8 and intercepts from 11 to 35. A novel individual progression probability was calculated as the product of biomarker percentage of stained cells and slope, plus the prevalence-adjusted intercept. CONCLUSIONS: Identification of individual risk of progression in patients with non-muscle-invasive bladder tumors was possible using p53- and Ki67-derived progression probability using a regression equation. Combining biomarker-derived progression probability to tumor stage pT1 improves progression to pT2 predictive accuracy. FAU - Chirife, Ana Maria AU - Chirife AM AUID- ORCID: 0000-0003-4022-6322 AD - Pathology Service, Hospital Aleman, Pueyrredon 1640, 1118, Buenos Aires, Argentina. amchirife@gmail.com. FAU - Villasante, Nicolas AU - Villasante N AD - Urology Service, Hospital Aleman, Buenos Aires, Argentina. FAU - Rojas Bilbao, Erica AU - Rojas Bilbao E AD - Pathology Service, Hospital Aleman, Pueyrredon 1640, 1118, Buenos Aires, Argentina. FAU - Casas, Gabriel AU - Casas G AD - Pathology Service, Hospital Aleman, Pueyrredon 1640, 1118, Buenos Aires, Argentina. LA - eng PT - Journal Article PT - Observational Study DEP - 20190427 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (KRT20 protein, human) RN - 0 (Keratin-20) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/*metabolism/pathology/surgery MH - Disease Progression MH - Female MH - Humans MH - Keratin-20/metabolism MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Predictive Value of Tests MH - Tumor Suppressor Protein p53/metabolism MH - Urinary Bladder Neoplasms/*metabolism/pathology/surgery PMC - PMC11810434 OTO - NOTNLM OT - Biomarkers OT - Bladder tumors OT - Individual prediction of progression COIS- Authors reported no conflicts of interest. EDAT- 2019/04/29 06:00 MHDA- 2019/06/30 06:00 PMCR- 2019/04/27 CRDT- 2019/04/29 06:00 PHST- 2019/02/19 00:00 [received] PHST- 2019/04/20 00:00 [accepted] PHST- 2019/04/29 06:00 [pubmed] PHST- 2019/06/30 06:00 [medline] PHST- 2019/04/29 06:00 [entrez] PHST- 2019/04/27 00:00 [pmc-release] AID - 10.1007/s00432-019-02923-1 [pii] AID - 2923 [pii] AID - 10.1007/s00432-019-02923-1 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Jul;145(7):1709-1718. doi: 10.1007/s00432-019-02923-1. Epub 2019 Apr 27. PMID- 31030231 OWN - NLM STAT- MEDLINE DCOM- 20200527 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 2 DP - 2020 Feb TI - The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy. PG - 397-406 LID - 10.1007/s00345-019-02780-0 [doi] AB - PURPOSE: To investigate whether hexaminolevulinate-based (HAL) bladder tumor resection (TURBT) impacts on outcomes of patients with primary non-muscle-invasive bladder cancer (NMIBC) who were eventually treated with radical cystectomy (RC). METHODS: A total of 131 consecutive patients exhibiting NMIBC at primary diagnosis were retrospectively investigated whether they had undergone any HAL-guided TURBT prior to RC. Uni- and multivariable analyses were used to evaluate the impact of HAL-TURBT on cancer-specific (CSS) and overall survival (OS). The median follow-up was 38 months (IQR 13-56). RESULTS: Of the 131 patients, 69 (52.7%) were managed with HAL- and 62 (47.3%) with white light (WL)-TURBT only prior to RC. HAL-TURBT was associated with a higher number of TURBTs prior to RC (p = 0.002) and administration of intravesical chemotherapy (p = 0.043). A trend towards a higher rate of tumor-associated immune cell infiltrates in RC specimens (p = 0.07) and a lower utilization rate of post-operative systemic chemotherapy (p = 0.10) was noted for patients who were treated with HAL-TURBT. The 5-year CSS/OS was 90.9%/74.5% for the HAL-group and 73.8%/55.8% for the WL-group (p = 0.042/0.038). In multivariable analysis, lymph node tumor involvement (p = 0.007), positive surgical margins (p = 0.001) and performance of WL-TURBT only (p = 0.040) were independent predictors for cancer-specific death. CONCLUSIONS: The present data suggest that the resection of NMIBC under HAL exerts a beneficial impact on outcomes of patients who will need to undergo RC during their course of disease. This finding may be due to improved risk stratification as the resection under HAL may allow more patients to be treated timely and adequately. FAU - Renninger, Markus AU - Renninger M AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. FAU - Fahmy, Omar AU - Fahmy O AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. AD - Department of Urology, University Putra Malaysia (UPM), Selangor, Malaysia. FAU - Schubert, Tina AU - Schubert T AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Julius-Maximillians University, Oberduerrbacher Strasse 6, 97080, Wurzburg, Germany. FAU - Schmid, Manuel Alexander AU - Schmid MA AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. FAU - Hassan, Fahmy AU - Hassan F AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Julius-Maximillians University, Oberduerrbacher Strasse 6, 97080, Wurzburg, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital of Tubingen, Eberhard-Karls University, Tubingen, Germany. georgios.gakis@gmail.com. AD - Department of Urology and Pediatric Urology, University Hospital of Wurzburg, Julius-Maximillians University, Oberduerrbacher Strasse 6, 97080, Wurzburg, Germany. georgios.gakis@gmail.com. LA - eng PT - Journal Article PT - Observational Study DEP - 20190427 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Administration, Intravesical MH - Aged MH - Aminolevulinic Acid/administration & dosage/*analogs & derivatives MH - Antineoplastic Agents/administration & dosage MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Photochemotherapy/*methods MH - Photosensitizing Agents/*administration & dosage MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder/drug effects/pathology/*surgery MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Fluorescence OT - Hexaminolevulinate OT - Non-muscle invasive OT - Radical cystectomy OT - Survival EDAT- 2019/04/29 06:00 MHDA- 2020/05/28 06:00 CRDT- 2019/04/29 06:00 PHST- 2019/02/13 00:00 [received] PHST- 2019/04/20 00:00 [accepted] PHST- 2019/04/29 06:00 [pubmed] PHST- 2020/05/28 06:00 [medline] PHST- 2019/04/29 06:00 [entrez] AID - 10.1007/s00345-019-02780-0 [pii] AID - 10.1007/s00345-019-02780-0 [doi] PST - ppublish SO - World J Urol. 2020 Feb;38(2):397-406. doi: 10.1007/s00345-019-02780-0. Epub 2019 Apr 27. PMID- 31030230 OWN - NLM STAT- MEDLINE DCOM- 20201204 LR - 20210201 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 38 IP - 2 DP - 2020 Feb TI - Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor. PG - 389-395 LID - 10.1007/s00345-019-02782-y [doi] AB - PURPOSE: To evaluate the clinical significance of invasive urothelial carcinoma that is ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor (TURBT). METHODS: All consecutive in-house TURBTs with invasive urothelial carcinoma from 1999 to 2017 that underwent radical cystectomy (RC) were grouped as follows: invasion of the lamina propria (INLP; n = 102; 24%), invasion of muscularis propria (INMP; n = 296; 69%) and ambiguous for muscularis propria invasion (AMP; n = 30; 7%). AMP was defined as extensive invasive carcinoma displaying thin muscle bundles where it is difficult to determine with certainty if those muscle bundles represent muscularis mucosae or muscularis propria (detrusor). Cases with any amount of small cell carcinoma or prior therapy were excluded. RESULTS: The average age was 66 years in INLP, 67 years in INMP, and 65 years in AMP. RC showed invasive carcinoma stage pT2 or above in 50/102 (49%) of INLP vs. 255/296 (86%) of INMP (P T alteration being the most common in all groups. FGFR3 and PIK3CA mutations were more frequent in low-grade noninvasive papillary carcinomas compared with high-grade noninvasive papillary carcinomas and carcinomas in situ (p < 0.0001), while the opposite was true for TP53 (p < 0.0001). Significantly higher rates of TP53 and CDKN2A mutation rates (p = 0.005 and 0.035, respectively) were encountered in muscle-invasive bladder tumors compared with those of pT1 stage. The overwhelming majority of all investigated tumors showed at least one mutation among UroSEEK assay genes, confirming the comprehensive coverage of the panel and supporting its potential utility as a noninvasive urine-based assay. FAU - Eich, Marie-Lisa AU - Eich ML AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Rodriguez Pena, Maria Del Carmen AU - Rodriguez Pena MDC AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Springer, Simeon U AU - Springer SU AD - Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, MD, USA. AD - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Taheri, Diana AU - Taheri D AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. AD - Department of Pathology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Tregnago, Aline C AU - Tregnago AC AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. FAU - Salles, Daniela C AU - Salles DC AD - Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. FAU - Bezerra, Stephania Martins AU - Bezerra SM AD - Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil. AD - Department of Pathology, Rede D'OR-Sao Luiz, Sao Paulo, Brazil. FAU - Cunha, Isabela W AU - Cunha IW AUID- ORCID: 0000-0002-2029-5139 AD - Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University, Osaka, Japan. FAU - Ertoy, Dilek AU - Ertoy D AD - Department of Pathology, Hacettepe University, Ankara, Turkey. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, Johns Hopkins University, Baltimore, MD, USA. FAU - Tomasetti, Cristian AU - Tomasetti C AD - Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. AD - Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Baltimore, MD, USA. FAU - Papadopoulos, Nickolas AU - Papadopoulos N AD - Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, MD, USA. AD - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Kinzler, Ken W AU - Kinzler KW AD - Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, MD, USA. AD - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Vogelstein, Bert AU - Vogelstein B AD - Howard Hughes Medical Institute, Ludwig Cancer for Cancer Genetics and Therapeutics, Baltimore, MD, USA. AD - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Netto, George J AU - Netto GJ AUID- ORCID: 0000-0003-3915-9134 AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA. gnetto@uabmc.edu. LA - eng GR - P30 CA006973/CA/NCI NIH HHS/United States GR - P30 CA077598/CA/NCI NIH HHS/United States GR - R01 ES019564/ES/NIEHS NIH HHS/United States GR - T32 GM007309/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20190425 PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S493-S496. doi: 10.21037/tau.2019.08.27. PMID: 32042629 CIN - Transl Androl Urol. 2019 Dec;8(Suppl 5):S546-S549. doi: 10.21037/tau.2019.12.41. PMID: 32042643 MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Carcinoma, Transitional Cell/*genetics/pathology MH - DNA Mutational Analysis MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Mutation MH - Mutation Rate MH - *Promoter Regions, Genetic MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC6872189 MID - NIHMS1525315 COIS- Disclosure/Conflict of Interest Nickolas Papadopoulos, Ken W Kinzler, Bert Vogelstein: Founder of Personal Genome Diagnostics and PapGene and advise Sysmex-Inostics. Kinzler and Vogelstein also advise Eisai. Vogelstein is also an advisor to Camden Partners. These companies and others have licensed technologies from Johns Hopkins that are related to the work described in this paper. These licenses are associated with equity or royalty payments to Papadopoulos, Kinzler, Netto, and Vogelstein. Additional patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of these arrangements are managed by the university in accordance with its conflict of interest policies. The other authors declare that no competing interests exist. EDAT- 2019/04/28 06:00 MHDA- 2020/06/26 06:00 PMCR- 2019/11/22 CRDT- 2019/04/28 06:00 PHST- 2019/01/29 00:00 [received] PHST- 2019/03/23 00:00 [accepted] PHST- 2019/03/22 00:00 [revised] PHST- 2019/04/28 06:00 [pubmed] PHST- 2020/06/26 06:00 [medline] PHST- 2019/04/28 06:00 [entrez] PHST- 2019/11/22 00:00 [pmc-release] AID - S0893-3952(22)01007-9 [pii] AID - 10.1038/s41379-019-0276-y [doi] PST - ppublish SO - Mod Pathol. 2019 Oct;32(10):1544-1550. doi: 10.1038/s41379-019-0276-y. Epub 2019 Apr 25. PMID- 31026471 OWN - NLM STAT- MEDLINE DCOM- 20200526 LR - 20200526 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 89 DP - 2019 Jul TI - Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. PG - 24-32 LID - S0046-8177(19)30068-1 [pii] LID - 10.1016/j.humpath.2019.04.003 [doi] AB - Immunotherapy has gained significance in a variety of tumor types including advanced urothelial carcinoma. Noninvasive urothelial lesions have been treated with intravesical Bacillus-Calmette-Guerin (BCG) for decades. Given treatment failure in a subset of these tumors, ongoing clinical trials investigating the role of checkpoint inhibitors are actively pursued in this group of patients. The present study aims to delineate PD-L1, CD8, and FOXP3 expression in tumor microenvironment in non-muscle-invasive urothelial carcinoma samples obtained via sequential biopsies and to assess its potential role in predicting disease outcome. Cases with >1% and> 5% PD-L1 expression in tumor cells showed lower relative risk (RR) to recur at any subsequent biopsy compared with those with lower PD-L1 expression (RRs, 0.83 [P = .009] and 0.81 [P = .03], respectively). Cases with higher expression of FOXP3 in peritumoral lymphocytes were at lower risk for tumor grade progression at any biopsy (RR, 0.2; P = .02). Tumors with FOXP3/CD8 expression ratio of >1 in intratumoral lymphocytes had lower risk of grade progression (RR, 0.28; P = .04). Although higher number of FOXP3-, CD8-, and PD-L1-positive lymphocytes were encountered after BCG treatment, the findings did not reach statistical significance. In patients without BCG treatment, PD-L1 expression in tumor cells and peritumoral lymphocytes varied across serial biopsies, suggesting the need for additional approaches to assess eligibility for immunotherapy in non-muscle-invasive urothelial carcinoma patients. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Eich, Marie-Lisa AU - Eich ML AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA. FAU - Chaux, Alcides AU - Chaux A AD - Department of Scientific Research, School of Postgraduate Studies, Norte University, 1614 Asuncion, Paraguay. FAU - Guner, Gunes AU - Guner G AD - Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Taheri, Diana AU - Taheri D AD - Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Mendoza Rodriguez, Maria Angelica AU - Mendoza Rodriguez MA AD - Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Rodriguez Pena, Maria Del Carmen AU - Rodriguez Pena MDC AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA. FAU - Baras, Alexander S AU - Baras AS AD - Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Hahn, Noah M AU - Hahn NM AD - Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Drake, Charles AU - Drake C AD - Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Sharma, Rajni AU - Sharma R AD - Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21231, USA. FAU - Rezaei, Katayoon AU - Rezaei K AD - Department of Pathology, George Washington University, Washington, DC 20037, USA. FAU - Netto, George J AU - Netto GJ AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA. Electronic address: gnetto@uabmc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190424 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) RN - 0 (FOXP3 protein, human) RN - 0 (Forkhead Transcription Factors) SB - IM MH - Aged MH - Aged, 80 and over MH - B7-H1 Antigen/immunology MH - Biomarkers, Tumor/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Carcinoma, Transitional Cell/*immunology/pathology MH - Female MH - Forkhead Transcription Factors/immunology MH - Humans MH - Lymphocytes, Tumor-Infiltrating/immunology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Tumor Microenvironment/*immunology MH - Urinary Bladder Neoplasms/*immunology/pathology OTO - NOTNLM OT - Bladder OT - CD8 OT - FOXP3 OT - Ki-67 OT - Non-invasive urothelial carcinoma OT - PD-L1 EDAT- 2019/04/27 06:00 MHDA- 2020/05/27 06:00 CRDT- 2019/04/27 06:00 PHST- 2019/03/11 00:00 [received] PHST- 2019/04/09 00:00 [revised] PHST- 2019/04/14 00:00 [accepted] PHST- 2019/04/27 06:00 [pubmed] PHST- 2020/05/27 06:00 [medline] PHST- 2019/04/27 06:00 [entrez] AID - S0046-8177(19)30068-1 [pii] AID - 10.1016/j.humpath.2019.04.003 [doi] PST - ppublish SO - Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24. PMID- 31012814 OWN - NLM STAT- MEDLINE DCOM- 20200127 LR - 20200127 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 291 IP - 3 DP - 2019 Jun TI - Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. PG - 668-674 LID - 10.1148/radiol.2019182506 [doi] AB - Background The Vesical Imaging-Reporting and Data System (VI-RADS) scoring system was created in 2018 to standardize imaging and reporting of bladder cancer staging with multiparametric MRI. The system provides a five-point VI-RADS score, which suggests the likelihood of detrusor muscle invasion. Muscle-invasive disease carries a worse prognosis and requires radical surgery. Purpose To determine the performance of the VI-RADS score in detecting muscle-invasive bladder cancer in a cohort of patients undergoing multiparametric MRI before surgery. Materials and Methods In this retrospective study, a total of 340 patients with bladder cancer were identified from a database of consecutive patients undergoing multiparametric MRI from November 2011 to August 2018. The tumor with the largest burden was selected in those patients with multifocal tumors. Bladder tumors were retrospectively categorized according to the VI-RADS five-point scoring system by two readers, independently and in consensus, who were blinded to histologic findings. The VI-RADS score was compared with postoperative pathology for each tumor, and the performance of VI-RADS for determining detrusor muscle invasion was analyzed by using the Cochran-Armitage test. Results Among the 340 patients, there were 296 men and 44 women; the median age was 64.0 years (interquartile range [IQR], 57.0-87.0 years). Of 340 tumors, 255 (75.0%) were verified as non-muscle-invasive and 85 (25.0%) as muscle-invasive bladder cancer. Both the VI-RADS score and its components were associated with muscle-invasive condition (P < .001). The area under the receiver operating characteristic curve for VI-RADS for muscle invasion was 0.94 (95% confidence interval [CI]: 0.90, 0.98). The sensitivity and specificity of a VI-RADS score of 3 or greater were 87.1% (95% CI: 78%, 93%) and 96.5% (95% CI: 93%, 98%), respectively. Conclusion The Vesical Imaging-Reporting and Data System score effectively defines the likelihood of detrusor muscle invasion in bladder cancer and should be considered for evaluation of tumors prior to surgery. (c) RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Margolis and Hu in this issue. FAU - Wang, Huanjun AU - Wang H AUID- ORCID: 0000-0001-9089-7736 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Luo, Cheng AU - Luo C AUID- ORCID: 0000-0001-9641-9903 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Zhang, Fan AU - Zhang F AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Guan, Jian AU - Guan J AUID- ORCID: 0000-0002-7209-0346 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Li, Shurong AU - Li S AUID- ORCID: 0000-0001-7180-9462 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Yao, Haohua AU - Yao H AUID- ORCID: 0000-0003-0970-1295 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Chen, Junxing AU - Chen J AUID- ORCID: 0000-0002-7264-5110 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Luo, Junhang AU - Luo J AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Chen, Lingwu AU - Chen L AUID- ORCID: 0000-0001-6356-5648 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). FAU - Guo, Yan AU - Guo Y AUID- ORCID: 0000-0002-0267-7328 AD - From the Departments of Radiology (H.W., J.G., S.L., Y.G.) and Urology (C.L., H.Y., J.C., J.L., L.C.), The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China; and Department of Radiology, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China (F.Z.). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20190423 PL - United States TA - Radiology JT - Radiology JID - 0401260 SB - IM CIN - Radiology. 2019 Jun;291(3):675-676. doi: 10.1148/radiol.2019190648. PMID: 31013187 MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Image Interpretation, Computer-Assisted/*methods MH - Male MH - Middle Aged MH - Multiparametric Magnetic Resonance Imaging/*methods MH - Retrospective Studies MH - Urinary Bladder/diagnostic imaging MH - Urinary Bladder Neoplasms/*diagnostic imaging EDAT- 2019/04/24 06:00 MHDA- 2020/01/28 06:00 CRDT- 2019/04/24 06:00 PHST- 2019/04/24 06:00 [pubmed] PHST- 2020/01/28 06:00 [medline] PHST- 2019/04/24 06:00 [entrez] AID - 10.1148/radiol.2019182506 [doi] PST - ppublish SO - Radiology. 2019 Jun;291(3):668-674. doi: 10.1148/radiol.2019182506. Epub 2019 Apr 23. PMID- 31005491 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20220328 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 7 IP - 1 DP - 2021 Jan TI - Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guerin Connaught Strain for Bladder Cancer Patients. PG - 111-116 LID - S2405-4569(19)30109-9 [pii] LID - 10.1016/j.euf.2019.04.002 [doi] AB - BACKGROUND: Between 2013 and 2016, global production of bacillus Calmette-Guerin (BCG) was dramatically reduced due to the collapse of the factory producing BCG Connaught. OBJECTIVE: To evaluate the clinical and economic impact of BCG shortage on a cohort of non-muscle-invasive bladder cancer (NMIBC) patients treated during the period of restricted supply. DESIGN, SETTING AND PARTICIPANTS: This retrospective, before and after, cost-consequence study included patients with intermediate- and high-risk NMIBC. Those resected between November 2011 and September 2013 (control group) were compared with those resected between October 2013 and December 2016 (study group). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the rate of tumor recurrence from 30 d after transurethral resection to the end of follow-up at 24 mo; the secondary endpoints included the average cost of primary treatment, average cost of treatment of recurrence, and excess cost due to BCG shortage per patient. RESULTS AND LIMITATIONS: A total of 402 patients were included: 191 in the control group and 211 in the study group. The rate of recurrence at 24 mo was significantly higher in the study group than in the control group (46.9% vs 16.2%; relative risk: 0.7, 95% confidence interval [0.60; 0.82]; p < 0.001). The increased cost due to the decrease in BCG production was estimated to be euro783 per patient with a new diagnosis of NMIBC during the period of restricted supply. This is a retrospective analysis at the level of our unit. A more precise evaluation would require a study of a larger cohort of patients. CONCLUSIONS: The shortage of BCG between October 2013 and December 2016 had a significant medical and economic impact; there was an increased rate of bladder cancer recurrence, and the total cost of care for intermediate- and high-risk NMIBC was higher. PATIENT SUMMARY: In this report, we analyzed the medical and economic impact of bacillus Calmette-Guerin (BCG) shortage that occurred between 2013 and 2016. We found a significant increase of bladder cancer recurrence and progression, and an increase in the number of patients who had to be treated by cystectomy. BCG shortage also had a significant impact on the total cost. Since there are no alternatives to BCG for high-risk non-muscle-invasive bladder cancer patients, BCG production has to be maintained by any means. CI - Copyright (c) 2019. Published by Elsevier B.V. FAU - Ourfali, Said AU - Ourfali S AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Hopital Edouard Herriot, Hospices Civils de Lyon et Universite Claude Bernard, Lyon, France. FAU - Ohannessian, Robin AU - Ohannessian R AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Univ. Lyon, Universite Claude Bernard Lyon 1, Lyon, France. FAU - Fassi-Fehri, Hakim AU - Fassi-Fehri H AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Hopital Edouard Herriot, Hospices Civils de Lyon et Universite Claude Bernard, Lyon, France. FAU - Pages, Alfreda AU - Pages A AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Hopital Edouard Herriot, Hospices Civils de Lyon et Universite Claude Bernard, Lyon, France. FAU - Badet, Lionel AU - Badet L AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Hopital Edouard Herriot, Hospices Civils de Lyon et Universite Claude Bernard, Lyon, France. FAU - Colombel, Marc AU - Colombel M AD - Service d'Urologie et Chirurgie de la Transplantation, Hopital Edouard Herriot, Universite Lyon Claude Bernard, Lyon, France; Hopital Edouard Herriot, Hospices Civils de Lyon et Universite Claude Bernard, Lyon, France. Electronic address: marc.colombel@chu-lyon.fr. LA - eng PT - Journal Article DEP - 20190418 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*supply & distribution/*therapeutic use MH - BCG Vaccine/administration & dosage/*economics/*supply & distribution MH - Humans MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Cost consequence OT - Prognosis OT - Shortage EDAT- 2019/04/22 06:00 MHDA- 2022/03/29 06:00 CRDT- 2019/04/22 06:00 PHST- 2019/01/21 00:00 [received] PHST- 2019/03/10 00:00 [revised] PHST- 2019/04/04 00:00 [accepted] PHST- 2019/04/22 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] PHST- 2019/04/22 06:00 [entrez] AID - S2405-4569(19)30109-9 [pii] AID - 10.1016/j.euf.2019.04.002 [doi] PST - ppublish SO - Eur Urol Focus. 2021 Jan;7(1):111-116. doi: 10.1016/j.euf.2019.04.002. Epub 2019 Apr 18. PMID- 31000756 OWN - NLM STAT- MEDLINE DCOM- 20201009 LR - 20210109 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 Apr 18 TI - Transperitoneal radical nephroureterectomy is associated with worse disease progression than retroperitoneal radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. PG - 6294 LID - 10.1038/s41598-019-42739-0 [doi] LID - 6294 AB - This study aimed to compare the oncologic outcomes between retroperitoneal radical nephroureterectomy (rRNU) and transperitoneal radical nephroureterectomy (tRNU) for the treatment of patients with upper urinary tract urothelial carcinoma (UTUC). Medical records of 743 eligible patients who underwent rRNU or tRNU between 1995 and 2015 were reviewed retrospectively. Progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were compared according to the surgical approach using the Kaplan-Meier method. Predictors of PFS, CSS, and OS were analyzed with a multivariable Cox regression model. Overall, 620 (83.4%) and 123 (16.6%) patients were treated with rRNU and tRNU, respectively. Five-year CSS and OS rates were equivalent between rRNU and tRNU groups, but 5-year PFS was lower in the tRNU group than the rRNU group (P = 0.005). When patients were stratified by pathological T stage, PFS was significantly different between the two groups in favor of the rRNU group for both organ-confined disease (pTis/pTa/pT1/T2) (P = 0.022) and locally advanced disease (pT3/pT4) (P = 0.039). However, no significant differences in CSS or OS was observed when comparing the two surgical types in patients with organ-confined disease (P = 0.336 and P = 0.851) or patients with locally advanced disease (P = 0.499 and P = 0.278). tRNU was a significant predictor of PFS (hazard ratio = 1.54; P = 0.023), but not CSS or OS. Our findings indicate that the rRNU approach resulted in better PFS than the tRNU approach in patients with UTUC. FAU - Kim, Tae Heon AU - Kim TH AUID- ORCID: 0000-0002-7819-4912 AD - Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. FAU - Suh, Yoon Seok AU - Suh YS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Lee, Hyun Moo AU - Lee HM AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Choi, Han Yong AU - Choi HY AD - Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. hyunhwan.sung@samsung.com. LA - eng PT - Journal Article DEP - 20190418 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/physiopathology/*surgery MH - Female MH - Humans MH - Laparoscopy/methods MH - Male MH - Middle Aged MH - Nephroureterectomy/*adverse effects MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Survival Rate MH - Urinary Tract/pathology/surgery MH - Urologic Neoplasms/physiopathology/*surgery MH - Urothelium/physiopathology/*surgery PMC - PMC6472422 COIS- The authors declare no competing interests. EDAT- 2019/04/20 06:00 MHDA- 2020/10/10 06:00 PMCR- 2019/04/18 CRDT- 2019/04/20 06:00 PHST- 2018/11/23 00:00 [received] PHST- 2019/04/08 00:00 [accepted] PHST- 2019/04/20 06:00 [entrez] PHST- 2019/04/20 06:00 [pubmed] PHST- 2020/10/10 06:00 [medline] PHST- 2019/04/18 00:00 [pmc-release] AID - 10.1038/s41598-019-42739-0 [pii] AID - 42739 [pii] AID - 10.1038/s41598-019-42739-0 [doi] PST - epublish SO - Sci Rep. 2019 Apr 18;9(1):6294. doi: 10.1038/s41598-019-42739-0. PMID- 30999948 OWN - NLM STAT- MEDLINE DCOM- 20190820 LR - 20240716 IS - 2523-3548 (Electronic) IS - 2523-3548 (Linking) VI - 39 IP - 1 DP - 2019 Apr 18 TI - An improved ileal conduit surgery for bladder cancer with fewer complications. PG - 19 LID - 10.1186/s40880-019-0366-8 [doi] LID - 19 AB - BACKGROUND: Radical cystectomy and urinary diversion remains the standard surgical treatment for patients with muscle-invasive or high-risk or recurrent non-muscle-invasive bladder cancer. Although this approach prolongs patient survival remarkably, there are postoperative complications associated with urinary diversion. This study aimed to assess the efficacy of modified ileal conduit surgery for reducing early and late stoma- and ureteroileal anastomosis-related complications, as compared with conventional ileal conduit urinary diversion. METHODS: We retrospectively evaluated the clinical data of bladder cancer patients treated with radical cystectomy and ileal conduit urinary diversion at Sun Yat-sen University Cancer Center between January 1, 2000 and June 30, 2016. Ileal conduit was created by the conventional or a modified technique. The clinicopathologic features of the conventional and the modified ileal conduit groups were compared using the t test and the Chi square test. Multivariable logistic regression analysis and multivariable Cox regression analysis were performed to determine the odds of developing stoma- and ureteroileal anastomosis-related complications in the two groups. RESULTS: 145 and 100 patients underwent the modified and conventional ileal conduit surgery, respectively. The two groups were comparable with regard to clinicopathologic features. The rate of stoma-related complications was significantly lower in the modified ileal conduit group than in the conventional ileal conduit group (0.7% vs. 17.0%, P < 0.001). No late stoma-related complications were seen in the modified ileal conduit group, but were seen in 13 (13.0%) patients in the conventional ileal conduit group. The rate of ureteroileal anastomosis-related complications was significantly lower in the modified ileal conduit group than in the conventional ileal conduit group (4.8% vs. 15.0%, P = 0.001). In multivariable analyses, the modified ileal conduit group was significantly less likely to develop stoma- (odds ratio [OR] = 0.024, 95% confidence interval [CI] 0.003-0.235; P = 0.001) or ureteroileal anastomosis-related complications (OR = 0.141, 95% CI 0.042-0.476; P = 0.002) than the conventional ileal conduit group. CONCLUSIONS: Our modified surgical technique for ileal conduit urinary diversion may be effective for reducing early and late complications related to the stoma and the ureteroileal anastomosis. Prospective randomized clinical trials are needed to confirm our results. FAU - Li, Zhiyong AU - Li Z AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Liu, Zhuowei AU - Liu Z AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Yao, Kai AU - Yao K AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Qin, Zike AU - Qin Z AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Han, Hui AU - Han H AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Li, Yonghong AU - Li Y AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Dong, Pei AU - Dong P AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Ye, Yunlin AU - Ye Y AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Wang, Yanjun AU - Wang Y AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Wu, Zhiming AU - Wu Z AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. FAU - Zhang, Zhiling AU - Zhang Z AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. zhangzhl@sysucc.org.cn. FAU - Zhou, Fangjian AU - Zhou F AD - Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China. zhoufj@sysucc.org.cn. LA - eng PT - Journal Article DEP - 20190418 PL - United States TA - Cancer Commun (Lond) JT - Cancer communications (London, England) JID - 101723675 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anastomosis, Surgical/*adverse effects MH - Female MH - Humans MH - Male MH - Middle Aged MH - Surgical Stomas/*adverse effects MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/*surgery MH - *Urinary Diversion MH - Young Adult PMC - PMC6471754 OTO - NOTNLM OT - Bladder cancer OT - Complication OT - Cystectomy OT - Ileal conduit OT - Surgical technique OT - Urinary diversion COIS- The authors declare that they have no competing interests. EDAT- 2019/04/20 06:00 MHDA- 2019/08/21 06:00 PMCR- 2019/04/18 CRDT- 2019/04/20 06:00 PHST- 2018/05/30 00:00 [received] PHST- 2019/04/08 00:00 [accepted] PHST- 2019/04/20 06:00 [entrez] PHST- 2019/04/20 06:00 [pubmed] PHST- 2019/08/21 06:00 [medline] PHST- 2019/04/18 00:00 [pmc-release] AID - 10.1186/s40880-019-0366-8 [pii] AID - 366 [pii] AID - 10.1186/s40880-019-0366-8 [doi] PST - epublish SO - Cancer Commun (Lond). 2019 Apr 18;39(1):19. doi: 10.1186/s40880-019-0366-8. PMID- 30993426 OWN - NLM STAT- MEDLINE DCOM- 20201111 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 1 DP - 2020 Jan TI - Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guerin after transurethral resection of the bladder tumor. PG - 143-150 LID - 10.1007/s00345-019-02754-2 [doi] AB - BACKGROUND: Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG. METHODS: We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model. RESULTS: A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09-1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12-1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01-1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1-1.68); p = 0.005]. The limitations of a retrospective study are applicable. CONCLUSION: Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted. FAU - Ferro, M AU - Ferro M AUID- ORCID: 0000-0002-9250-7858 AD - Division of Urology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. matteo.ferro@ieo.it. FAU - Di Lorenzo, G AU - Di Lorenzo G AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. AD - Department of Medicine, Universita degli Studi del Molise, Campobasso, Italy. FAU - Vartolomei, M D AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Bruzzese, D AU - Bruzzese D AD - Department of Public Health, Federico II University of Naples, Naples, Italy. FAU - Cantiello, F AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Lucarelli, G AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Musi, G AU - Musi G AD - Division of Urology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. FAU - Di Stasi, S AU - Di Stasi S AD - Department of Experimental Medicine and Surgery, Tor Vegata University, Rome, Italy. FAU - Hurle, R AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Guazzoni, G AU - Guazzoni G AD - Department of Biomedical Science, Humanitas University, Milan, Rozzano, Italy. FAU - Busetto, G M AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Gabriele, A AU - Gabriele A AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Del Giudice, F AU - Del Giudice F AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Damiano, R AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Perri, F AU - Perri F AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Perdona, S AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Verze, P AU - Verze P AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Borghesi, M AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Schiavina, R AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Almeida, G L AU - Almeida GL AD - Departamento de Urologia, University of Vale do Itajai, Itajai, Brazil. FAU - Bove, P AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. FAU - Lima, E AU - Lima E AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Autorino, R AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Crisan, N AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy "Iuliu Hateganu,", Cluj-Napoca, Romania. FAU - Farhan, A R Abu AU - Farhan ARA AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Battaglia, M AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Russo, G I AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Ieluzzi, Vincenzo AU - Ieluzzi V AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. FAU - Morgia, G AU - Morgia G AD - Department of Urology, University of Catania, Catania, Italy. FAU - De Placido, P AU - De Placido P AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. FAU - Terracciano, D AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Cimmino, A AU - Cimmino A AD - Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Naples, Italy. FAU - Scafuri, L AU - Scafuri L AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. FAU - Mirone, V AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - De Cobelli, O AU - De Cobelli O AD - Division of Urology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. FAU - Shariat, S AU - Shariat S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Sonpavde, Guru AU - Sonpavde G AD - Dana-Farber Cancer Institute, GU Oncology Division, Harvard Medical School, Boston, MA, USA. FAU - Buonerba, C AU - Buonerba C AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. AD - Zoo-prophylactic Institute of Southern Italy, Portici, Italy. LA - eng PT - Journal Article DEP - 20190416 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*administration & dosage MH - Basophils/*pathology MH - Cystectomy/*methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Leukocyte Count MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis MH - Neoplasm Staging/*methods MH - Neutrophils/*pathology MH - Retrospective Studies MH - Time Factors MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG OT - Basophils OT - Bladder cancer EDAT- 2019/04/18 06:00 MHDA- 2020/11/12 06:00 CRDT- 2019/04/18 06:00 PHST- 2019/01/09 00:00 [received] PHST- 2019/04/01 00:00 [accepted] PHST- 2019/04/18 06:00 [pubmed] PHST- 2020/11/12 06:00 [medline] PHST- 2019/04/18 06:00 [entrez] AID - 10.1007/s00345-019-02754-2 [pii] AID - 10.1007/s00345-019-02754-2 [doi] PST - ppublish SO - World J Urol. 2020 Jan;38(1):143-150. doi: 10.1007/s00345-019-02754-2. Epub 2019 Apr 16. PMID- 30987527 OWN - NLM STAT- MEDLINE DCOM- 20200110 LR - 20200225 IS - 1533-0338 (Electronic) IS - 1533-0346 (Print) IS - 1533-0338 (Linking) VI - 18 DP - 2019 Jan 1 TI - A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study. PG - 1533033819844483 LID - 10.1177/1533033819844483 [doi] LID - 1533033819844483 AB - Prophylactic intravesical chemotherapy can decrease bladder cancer recurrence rate after nephroureterectomy for upper tract urothelial carcinoma. We aimed to compare the effect of different prophylactic intravesical chemotherapy regimens in bladder recurrence-free survival. From 2000 to 2016, a total of 270 patients treated with radical nephroureterectomy at both institutions were enrolled. Patients were divided into 3 groups: multiple-instillation group, single-instillation group, and no-instillation group. Univariable and multivariable analyses with Cox regression methods were performed to calculate hazard ratios for bladder recurrence using clinicopathologic data, including our different instillation strategies. Sixty-three (23.3%) of 270 patients had subsequent intravesical recurrence. Significantly fewer patients in both the instillation groups had a recurrence compared to in the no-instillation group (13.1% vs 25.4% vs 41.5%, P = .001). Furthermore, there was a significant difference between both the instillation groups ( P = .016). In different subsets of patients with upper tract urothelial carcinoma, intravesical chemotherapy, either multiple or single instillation, was a protective factor of bladder recurrence in pT2-4 ( P = .002) and high grade ( P < .0001). Importantly, Kaplan-Meier curves of bladder recurrence-free survival rate were increased observably in multiple-instillation group compared to that in single-instillation group ( P = .053 in pT2-4 subgroup; P = .048 in high-grade subgroup, respectively). On multivariable analysis, intravesical chemotherapy ( P < .001), especially multiple instillations (hazard ratio 0.230; 95% confidence interval 0.110-0.479), was identified an independent predictor of bladder recurrence-free survival. In conclusion, prophylactic intravesical chemotherapy effectively prevents bladder recurrence after nephroureterectomy, especially with multiple instillations, in patients with invasive upper tract urothelial carcinoma or at high-grade status. FAU - Huang, Yong AU - Huang Y AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. AD - 2 The Department of Emergency, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Cen, Junjie AU - Cen J AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Liu, Zhuowei AU - Liu Z AD - 3 Department of Urology, Cancer Centre, Sun Yat-sen University, Guangzhou, China. FAU - Wei, Jinhuan AU - Wei J AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Chen, Zhenhua AU - Chen Z AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Feng, Zihao AU - Feng Z AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Lu, Jun AU - Lu J AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Fang, Yong AU - Fang Y AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Zhou, Fangjian AU - Zhou F AD - 3 Department of Urology, Cancer Centre, Sun Yat-sen University, Guangzhou, China. FAU - Luo, Junhang AU - Luo J AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Mo, Chengqiang AU - Mo C AUID- ORCID: 0000-0001-9423-5107 AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Chen, Wei AU - Chen W AUID- ORCID: 0000-0002-2042-6952 AD - 1 The Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. LA - eng PT - Clinical Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Technol Cancer Res Treat JT - Technology in cancer research & treatment JID - 101140941 RN - 50SG953SK6 (Mitomycin) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Combined Modality Therapy MH - Cystoscopy MH - Disease-Free Survival MH - Doxorubicin/administration & dosage/analogs & derivatives MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - Neoplasm Recurrence, Local/*drug therapy/pathology/*surgery MH - Nephroureterectomy MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery MH - Urothelium/drug effects/pathology PMC - PMC6469286 OTO - NOTNLM OT - intravesical chemotherapy OT - neoplasm recurrence OT - nephroureterectomy OT - urinary bladder OT - urothelium COIS- Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2019/04/17 06:00 MHDA- 2020/01/11 06:00 PMCR- 2019/04/15 CRDT- 2019/04/17 06:00 PHST- 2019/04/17 06:00 [entrez] PHST- 2019/04/17 06:00 [pubmed] PHST- 2020/01/11 06:00 [medline] PHST- 2019/04/15 00:00 [pmc-release] AID - 10.1177_1533033819844483 [pii] AID - 10.1177/1533033819844483 [doi] PST - ppublish SO - Technol Cancer Res Treat. 2019 Jan 1;18:1533033819844483. doi: 10.1177/1533033819844483. PMID- 30986485 OWN - NLM STAT- MEDLINE DCOM- 20200115 LR - 20220409 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 130 DP - 2019 Aug TI - Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. PG - 93-98 LID - S0090-4295(19)30344-9 [pii] LID - 10.1016/j.urology.2019.04.006 [doi] AB - OBJETIVES: To assess if "tumor budding" (TB) behaves as a poor prognostic factor in muscle-invasive bladder carcinoma (MIBC). TB is the presence of tumor cells isolated or in small groups of fewer than 5 cells located at the tumor invasion front. MATERIAL AND METHODS: Retrospective study of 106 patients with MIBC who underwent radical cystectomy. A cytokeratin AE1/AE3 immunostaining was applied to identify and quantify TB by the "hot-spot" method. The variables evaluated were: age, gender, Tumour, Node, Metastasis Classification (TNM) stage, associated Carcinoma in situ, differentiation degree, tumor size, tumor location, lymphatic, venous or perineural invasion, p53, Ki67, molecular subtype (basal/luminal) and chemotherapy. Main variables were overall and cancer-specific survival. RESULTS: The mean follow-up time was 47 +/- 46.45 months. The mean TB count was 32.3 +/- 25.9 "buds." The ROC curve established 14 "buds" as the cut-off point: the median survival rate for the "low-grade TB" group (14 "buds") was 18.5 months (P= .003). In the multivariate analysis, independent predictive variables regarding mortality were: age, TB, and TNM stage. Patients with more than 14 "buds" had 2.27 times more risk of mortality, 95%CI:1.19-4.34, P = .013. In addition, the risk of mortality rises progressively as the number of "buds" increases, at a rate of 2% per "bud." CONCLUSION: According to our results, TB becomes an independent predictor factor for cancer-specific mortality in MIBC, with a cut-off point of 14 "buds." CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Lorenzo Soriano, Laura AU - Lorenzo Soriano L AD - Department of Urology, Hospital University La Fe, Valencia, Spain. Electronic address: laurals_8@hotmail.com. FAU - Ordaz Jurado, Guzman AU - Ordaz Jurado G AD - Department of Urology, Hospital University La Fe, Valencia, Spain. FAU - Pontones Moreno, Jose Luis AU - Pontones Moreno JL AD - Department of Urology, Hospital University La Fe, Valencia, Spain. FAU - Villarroya Castillo, Sara AU - Villarroya Castillo S AD - Department of Urology, Hospital University La Fe, Valencia, Spain. FAU - Hernandez Giron, Soraya AU - Hernandez Giron S AD - Department of Pathology, Hospital University La Fe, Valencia, Spain. FAU - Saez Moreno, Ivan AU - Saez Moreno I AD - Department of Urology, Hospital University La Fe, Valencia, Spain. FAU - Ramos Soler, David AU - Ramos Soler D AD - Department of Pathology, Hospital University La Fe, Valencia, Spain. LA - eng PT - Journal Article DEP - 20190412 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology/surgery EDAT- 2019/04/16 06:00 MHDA- 2020/01/16 06:00 CRDT- 2019/04/16 06:00 PHST- 2019/02/19 00:00 [received] PHST- 2019/03/20 00:00 [revised] PHST- 2019/04/04 00:00 [accepted] PHST- 2019/04/16 06:00 [pubmed] PHST- 2020/01/16 06:00 [medline] PHST- 2019/04/16 06:00 [entrez] AID - S0090-4295(19)30344-9 [pii] AID - 10.1016/j.urology.2019.04.006 [doi] PST - ppublish SO - Urology. 2019 Aug;130:93-98. doi: 10.1016/j.urology.2019.04.006. Epub 2019 Apr 12. PMID- 30976574 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240715 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 1 DP - 2019 Feb TI - Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. PG - 101-107 LID - 10.21037/tau.2018.09.06 [doi] AB - Bladder cancer (BC) is a common disease in both sexes and majority of cases present as non-muscle invasive BC (NMIBC). The percentage of NMIBC progressing to muscle invasive BC (MIBC) varies between 25% and 75% and currently there are no reliable molecular markers that may predict the outcome of high-risk (HR) NMIBC. Transurethral resection of the bladder tumour (TURBT) with intravesical bacillus Calmette-Guerin (BCG) or immediate radical cystectomy (RC) are the current gold standard treatment options. The European Association of Urology (EAU) guidelines recommend immediate or delayed RC for HR- and a subgroup of "highest-risk" NMIBC. These cases include pT1, carcinoma in-situ (CIS), multifocal disease, histological variants such as micropapillary and sarcomatoid, and patients who have contraindications to, or have failed with BCG. The comparative risks between maintenance BCG (mBCG) and immediate RC are unclear. However, RC may give patients the best oncological outcome. FAU - Pang, Karl H AU - Pang KH AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Noon, Aidan P AU - Noon AP AD - Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6414338 OTO - NOTNLM OT - Immediate radical cystectomy OT - bladder cancer OT - non-muscle invasive bladder cancer (NMIBC) OT - primary cystectomy COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2019/04/13 06:00 MHDA- 2019/04/13 06:01 PMCR- 2019/02/01 CRDT- 2019/04/13 06:00 PHST- 2019/04/13 06:00 [entrez] PHST- 2019/04/13 06:00 [pubmed] PHST- 2019/04/13 06:01 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - tau-08-01-101 [pii] AID - 10.21037/tau.2018.09.06 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Feb;8(1):101-107. doi: 10.21037/tau.2018.09.06. PMID- 30976570 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 1 DP - 2019 Feb TI - The current role of circulating biomarkers in non-muscle invasive bladder cancer. PG - 61-75 LID - 10.21037/tau.2018.11.05 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) is characterized by its high rate of disease recurrence and relevant disease progression rates. Up to today clinical models are insufficiently predicting outcomes for reliable patient counseling and treatment decision-making. This particularly is a serious problem in patients with high-risk NMIBC who are at high risk for failure of local treatment and thus candidates for early radical cystectomy or even systemic (neoadjuvant) chemotherapy. Next to its clinical variability, bladder cancer is genetically a highly heterogeneous disease. There is an essential need of biomarkers for improving clinical staging, real-time monitoring of disease with or without active treatment, as well as improved outcome prognostication. Liquid biopsies of circulating biomarkers in the blood and urine are promising non-invasive diagnostics that hold the potential facilitating these needs. In this review we report the latest data and evidence on cell-free circulating tumor desoxyribonucleic acid (ctDNA) and circulating tumor cells (CTC) in NMIBC. We summarize their current status in clinical diagnostics, discuss limitations and address future needs. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Schwarzenbach, Heidi AU - Schwarzenbach H AD - Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Riethdorf, Sabine AU - Riethdorf S AD - Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6414344 OTO - NOTNLM OT - Urothelial carcinoma OT - circulating cell free DNA OT - circulating tumor cells (CTC) OT - circulating tumor desoxyribonucleic acid (ctDNA) OT - non-muscle invasive bladder cancer (NMIBC) COIS- Conflicts of Interest: Dr. M Rink received honoraria by IPSEN. The other authors have no conflicts of interest to declare. EDAT- 2019/04/13 06:00 MHDA- 2019/04/13 06:01 PMCR- 2019/02/01 CRDT- 2019/04/13 06:00 PHST- 2019/04/13 06:00 [entrez] PHST- 2019/04/13 06:00 [pubmed] PHST- 2019/04/13 06:01 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - tau-08-01-61 [pii] AID - 10.21037/tau.2018.11.05 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Feb;8(1):61-75. doi: 10.21037/tau.2018.11.05. PMID- 30976568 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 1 DP - 2019 Feb TI - The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. PG - 46-53 LID - 10.21037/tau.2018.10.19 [doi] AB - The second look transurethral resection of the bladder (TURB) represents a fundamental step in the treatment of papillary non-muscle invasive bladder cancer (NMIBC); it is therefore recommended by all guidelines. However, not all the literature agrees on its staging value and its ability to improve oncological outcomes of patients. Therefore, the purpose of this review is to evaluate the strengths and weaknesses of second look TURB, trying to depict its evolving role in the management of high grade NMIBC. Using Medline, a non-systematic review was performed including articles between January 2000 and June 2018. English language original articles, reviews and editorials were selected based on their clinical relevance. To date, TURB seems to be largely inadequate in retrieving a correct diagnosis and in removing all tumor tissue. Second look TURB maximizes staging accuracy, allows to clear residual cancer and yields prognostic advantages allowing key information to identify possible candidates for immediate radical cystectomy for very high risk T1HG tumors. Moreover, it seems to have a therapeutic benefit by improving recurrence- and progression-free survivals. However, few recent large studies showed that these advantages seem to be limited to patients without detrusor muscle present at first resection. Similarly, the presence of residual disease and the risk of upstaging are related to the presence of detrusor muscle in specimen. It could well be that in the future the presence of detrusor muscle would be a quality criteria to avoid an unnecessary second look TURB as shown by recent studies using the en-bloc resection technique. Finally, it has to be underlined that this is a surgical procedure not free of risks and complications and with a non-negligible impact on patients' quality of life, waiting lists and healthcare costs. Therefore, future studies trying to identify the criteria that may better allow which patients to select for a second look TURB while avoiding an unnecessary intervention with possible risks and associated cost are needed to allow a personalized approach to even this one size fits all strategy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6414350 OTO - NOTNLM OT - Re-TUR OT - T1HG non-muscle invasive bladder cancer OT - second look transurethral resection of the bladder (second look TURB) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2019/04/13 06:00 MHDA- 2019/04/13 06:01 PMCR- 2019/02/01 CRDT- 2019/04/13 06:00 PHST- 2019/04/13 06:00 [entrez] PHST- 2019/04/13 06:00 [pubmed] PHST- 2019/04/13 06:01 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - tau-08-01-46 [pii] AID - 10.21037/tau.2018.10.19 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Feb;8(1):46-53. doi: 10.21037/tau.2018.10.19. PMID- 30976567 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 1 DP - 2019 Feb TI - Prediction tools in non-muscle invasive bladder cancer. PG - 39-45 LID - 10.21037/tau.2019.01.15 [doi] AB - Non-muscle invasive bladder cancer (BCa) is the second most common genitourinary malignancy, burdened by high rates of recurrence and progression. Urologist are encouraged to stratify patients on the bases of recurrence and progression risks in order to define the best therapeutic approach and follow-up scheme. For these reasons, the aim of the present non-systematic review was to assess the literature on prediction tools in non-muscle invasive BCa. Currently, the most widely used tools remain the European Organization for Research and Treatment of Cancer (EORTC) and the Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk tables, which are based on clinicopathologic features. Recent external validations, therefore, reported their low accuracy, probably related to the lack of the role of re-transurethral resection (TURBT), early instillations, chemotherapy and complete BCG schedules in the studies included to asses these scores. More recently several immunological, biochemical and genetics biomarkers have been tested by themselves and in combination with clinicopathologic features, and many of them resulted related with risk of recurrence and progression. Future perspectives will presumably include the update of EORTC and CUETO scores with newest guidelines' recommendations and their integration with biomarkers. FAU - Zamboni, Stefania AU - Zamboni S AD - Klinik fur Urologie, Luzerner Kantonsspital, Spitalstrasse 2, Lucerne, Switzerland. AD - Department of Urology, Spedali Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Italy. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, Spitalstrasse 2, Lucerne, Switzerland. FAU - Simeone, Claudio AU - Simeone C AD - Department of Urology, Spedali Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Department of Urology, Spedali Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Klinik fur Urologie, Luzerner Kantonsspital, Spitalstrasse 2, Lucerne, Switzerland. FAU - Baumeister, Philipp AU - Baumeister P AD - Klinik fur Urologie, Luzerner Kantonsspital, Spitalstrasse 2, Lucerne, Switzerland. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology Bichat Hospital, Paris Descartes University, Paris, France. FAU - Hakenberg, Oliver W AU - Hakenberg OW AD - Department of Urology, University Medical Center Rostock, Rostock, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University Medical Center Rostock, Rostock, Germany. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6414347 OTO - NOTNLM OT - Bladder cancer (BCa) OT - NMIBC OT - non-muscle invasive OT - progression OT - recurrence OT - tools COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2019/04/13 06:00 MHDA- 2019/04/13 06:01 PMCR- 2019/02/01 CRDT- 2019/04/13 06:00 PHST- 2019/04/13 06:00 [entrez] PHST- 2019/04/13 06:00 [pubmed] PHST- 2019/04/13 06:01 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - tau-08-01-39 [pii] AID - 10.21037/tau.2019.01.15 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Feb;8(1):39-45. doi: 10.21037/tau.2019.01.15. PMID- 30976563 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 8 IP - 1 DP - 2019 Feb TI - Review on gender differences in non-muscle invasive bladder cancer. PG - 12-20 LID - 10.21037/tau.2018.11.06 [doi] AB - Differences in the epidemiology, diagnosis and outcomes according to gender in patients diagnosed with non-muscle invasive bladder cancer (NMIBC) has been widely reported. In this article we present gender-specific differences in NMIBC in terms of epidemiology, risk factors, first clinical presentation, management and clinical outcomes based on systematically review evidence of existing literature. A literature search of English-language publications that included an analysis of the association of gender differences in patients with NMIBC was performed using PubMed. Sixty-four studies were selected for analysis with consensus of all authors. The incidence and mortality for urothelial bladder cancer (UBC) are higher in men, whereas cancer specific mortality to incidence ratio is significantly lower for men than for women. This phenomenon could be partially explained by differences in exposure to bladder cancer carcinogens. However female gender is associated with higher stage at presentation. Thirteen studies with a total of 11,069 patients diagnosed with NMIBC were included for analysis according to outcomes. In studies that found statistically significant differences in outcomes between sexes, female gender was reported as risk factor for disease recurrence, progression or cancer specific mortality. None of included studies found worse outcomes in men when compared to women with NMIBC. Results of our review suggest that female gender in patients diagnosed with NMIBC is associated-though inconsistently-with higher stage at presentation and poorer outcomes. Numerous factors may influence gender gap in incidence rate, clinical management and reported outcomes. Consensus on comparable data collection in routine practice and prospective trials including clinical outcomes are required to identify gender-specific differences in patients diagnosed with NMIBC. FAU - Bilski, Konrad AU - Bilski K AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, Warsaw, Poland. FAU - Zapala, Lukasz AU - Zapala L AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, Warsaw, Poland. FAU - Skrzypczyk, Michal A AU - Skrzypczyk MA AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, Warsaw, Poland. FAU - Oszczudlowski, Maciej AU - Oszczudlowski M AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, Warsaw, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, Warsaw, Poland. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC6414341 OTO - NOTNLM OT - Bladder cancer OT - gender OT - non-muscle invasive bladder cancer (NMIBC) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2019/04/13 06:00 MHDA- 2019/04/13 06:01 PMCR- 2019/02/01 CRDT- 2019/04/13 06:00 PHST- 2019/04/13 06:00 [entrez] PHST- 2019/04/13 06:00 [pubmed] PHST- 2019/04/13 06:01 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - tau-08-01-12 [pii] AID - 10.21037/tau.2018.11.06 [doi] PST - ppublish SO - Transl Androl Urol. 2019 Feb;8(1):12-20. doi: 10.21037/tau.2018.11.06. PMID- 30971548 OWN - NLM STAT- MEDLINE DCOM- 20190802 LR - 20220408 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 62 IP - 2 DP - 2019 Apr-Jun TI - Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. PG - 244-250 LID - 10.4103/IJPM.IJPM_228_18 [doi] AB - AIMS: This study aims to explore the utility of GATA binding protein 3, a zinc finger transcription factor, expression in genitourinary carcinoma, especially urothelial carcinoma. SETTINGS AND DESIGN: It is a prospective study where 74 consecutive cases of urothelial carcinoma along with 10 cases each of prostatic adenocarcinoma (PC) and conventional clear cell renal cell carcinoma were included between August 2016 and January 2017. METHODS AND MATERIALS: All the cases were histopathologically evaluated and immunohistochemically stained for GATA binding protein 3. Only nuclear positivity was considered as positive. Immunoreactivity score for GATA expression was calculated based on the staining intensity as well as percentage. STATISTICAL ANALYSIS USED: The statistical analysis was done using Statistical Package for Social Sciences Version 15.0 statistical analysis software. P value of <0.05 was considered statistically significance. RESULTS: GATA3 expressions were seen in 77% of the cases of urothelial carcinoma, whereas none of the clear cell renal cell carcinoma and prostatic adenocarcinoma cases was GATA3 positive. GATA3 expression significantly correlated with histological grade and muscle invasion with a weaker or negative expression in high-grade muscle invasive tumor as compared to low-grade and noninvasive neoplasm. Significantly weaker expression of GATA3 was found in cases with severe nuclear pleomorphism, mitosis >10/10 hpf, presence of necrosis, and tumor-infiltrating lymphocytes. No significant change in the status of GATA3 expression was seen in follow-up cases between initial Transurethral resection of bladder tumor (TURBT) and post-recurrence TURBT or radical cystectomy specimens. CONCLUSIONS: GATA3 as a sensitive and specific marker for urothelial carcinoma can be effectively used to exclude other genitourinary malignancies, PC, and renal cell carcinoma, at metastatic site. This marker can also be effectively used in predicting the probable grade and invasion in biopsy material with poor morphological characteristics, thereby helping in appropriate management in such cases. FAU - Agarwal, Harshita AU - Agarwal H AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Babu, Suresh AU - Babu S AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Rana, Chanchal AU - Rana C AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Kumar, Madhu AU - Kumar M AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Singhai, Atin AU - Singhai A AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Shankhwar, Shiv Narayan AU - Shankhwar SN AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Singh, Vishwajeet AU - Singh V AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. FAU - Sinha, Rahul Janak AU - Sinha RJ AD - Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Biopsy MH - Carcinoma, Renal Cell/diagnosis/genetics MH - Diagnosis, Differential MH - GATA3 Transcription Factor/*genetics MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Prospective Studies MH - Prostatic Neoplasms/diagnosis/genetics MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/genetics MH - Urothelium/*pathology MH - Young Adult OTO - NOTNLM OT - Carcinoma OT - GATA-3 OT - expression OT - genitourinary OT - urothelial COIS- None EDAT- 2019/04/12 06:00 MHDA- 2019/08/03 06:00 CRDT- 2019/04/12 06:00 PHST- 2019/04/12 06:00 [entrez] PHST- 2019/04/12 06:00 [pubmed] PHST- 2019/08/03 06:00 [medline] AID - IndianJPatholMicrobiol_2019_62_2_244_255808 [pii] AID - 10.4103/IJPM.IJPM_228_18 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2019 Apr-Jun;62(2):244-250. doi: 10.4103/IJPM.IJPM_228_18. PMID- 30961575 OWN - NLM STAT- MEDLINE DCOM- 20190813 LR - 20231006 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Apr 8 TI - Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. PG - 331 LID - 10.1186/s12885-019-5512-9 [doi] LID - 331 AB - BACKGROUND: Non-muscular invasive bladder cancer (NMIBC) has a high risk of recurrence. As androgen receptor (AR) reportedly affects bladder cancer, we assessed the correlation between NMIBC recurrence and tumor AR expression in Japanese patients. METHODS: We retrospectively reviewed 53 specimens of non-metastatic NMIBC, with recurrence-free survival (RFS) as the primary endpoint. We used real-time quantitative polymerase chain reaction to quantify AR mRNA expression. Kaplan-Meier product-limit estimators were used to assess RFS distribution, log-rank tests to analyze differences in RFS between high- and low-risk groups; and multivariate analyses of AR mRNA expression and other clinicopathological factors to predict independent factors for RFS. RESULTS: The high AR mRNA-expressing group (n = 43) tended to have a longer median RFS (not reached) than did the low-AR group (n = 10; 9.04 months; P = 0.112). Multivariate analysis showed female sex (hazard ratio [HR]: 7.360, 95% CI: 1.649-32.856, P = 0.009), tumor size >/=3 cm (HR: 23.697, 95% CI: 4.383-128.117, P < 0.001) and low AR mRNA expression (HR: 0.202, 95% CI: 0.048-0.841, P = 0.028) to be independent predictors of shorter RFS. CONCLUSION: Our study showed that low AR mRNA expression level is an independent risk factor for RFS in Japanese patients with NMIBC. Further studies are necessary but AR expression might be a new indicator of recurrence of NMIBC. FAU - Yasui, Masato AU - Yasui M AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. FAU - Izumi, Koji AU - Izumi K AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. FAU - Yao, Masahiro AU - Yao M AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Ishiguro, Yukari AU - Ishiguro Y AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. FAU - Ishiguro, Hitoshi AU - Ishiguro H AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. AD - Photocatalyst Group, Special Research Laboratory, Kanagawa Academy of Science and Technology, Kawasaki, Japan. FAU - Uemura, Hiroji AU - Uemura H AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. FAU - Miyoshi, Yasuhide AU - Miyoshi Y AUID- ORCID: 0000-0001-8857-9798 AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan. miyoyasu@med.yokohamac-cu.ac.jp. LA - eng PT - Journal Article DEP - 20190408 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (AR protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Androgen) MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/*metabolism MH - Cystectomy/methods MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Japan MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Prognosis MH - RNA, Messenger/isolation & purification/*metabolism MH - Real-Time Polymerase Chain Reaction MH - Receptors, Androgen/genetics/*metabolism MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/genetics/mortality/*pathology/surgery PMC - PMC6454612 OTO - NOTNLM OT - Androgen receptor OT - Bladder cancer OT - Non-muscular invasive OT - RT-qPCR OT - Recurrence COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: IRB approval for Yokohama City University. Informed consent was obtained in the form of opt-out on the web-site. Those who rejected were excluded. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/04/10 06:00 MHDA- 2019/08/14 06:00 PMCR- 2019/04/08 CRDT- 2019/04/10 06:00 PHST- 2017/11/24 00:00 [received] PHST- 2019/03/25 00:00 [accepted] PHST- 2019/04/10 06:00 [entrez] PHST- 2019/04/10 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2019/04/08 00:00 [pmc-release] AID - 10.1186/s12885-019-5512-9 [pii] AID - 5512 [pii] AID - 10.1186/s12885-019-5512-9 [doi] PST - epublish SO - BMC Cancer. 2019 Apr 8;19(1):331. doi: 10.1186/s12885-019-5512-9. PMID- 30951871 OWN - NLM STAT- MEDLINE DCOM- 20190723 LR - 20190723 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 65 DP - 2019 May TI - Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study. PG - 88-93 LID - S1743-9191(19)30081-0 [pii] LID - 10.1016/j.ijsu.2019.03.022 [doi] AB - PURPOSE: To retrospectively evaluate the prognostic value of preoperative plasma fibrinogen to predict oncological outcome and intravesical recurrence in upper urinary tract urothelial carcinoma. METHODS: This retrospective study comprised 130 patients with non-metastatic upper urinary tract urothelial carcinoma who underwent surgery between June 2009 and June 2017 at a single center. Patients were categorized base on an optimal value of preoperative plasma fibrinogen. Progression-free and cancer-specific survival were assessed using Kaplan-Meier method. The associations between plasma fibrinogen and clinical outcomes were assessed with univariate and Multivariate analysis. RESULTS: Elevated plasma fibrinogen was associated with advance tumor stage, high tumor grade and tumor size. No significant association was found between plasma fibrinogen and intravesical recurrence. Multivariate analysis revealed that plasma fibrinogen >/=3.602 g/L was an independent prognostic indicator for progression-free survival (HR = 2.18; 95% CI: 1.17-4.06; p = 0.01) and cancer-specific survival (HR = 2.2; 95% CI: 1.13-4.28; p = 0.02), as well as pathological T stage and tumor grade. CONCLUSIONS: Elevated preoperative plasma fibrinogen is an independent unfavorable prognostic factor for oncological outcomes in patients with upper urinary tract urothelial carcinoma. However, there is no association between preoperative plasma fibrinogen and intravesical recurrence. As an effective and easily accessible biomarker, this parameter can be applied in pre-intervention risk stratification of upper urinary tract urothelial carcinoma. CI - Copyright (c) 2019 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. FAU - Liu, Rongzong AU - Liu R AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Zhou, Xuejian AU - Zhou X AD - Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, China. FAU - Zou, Lujia AU - Zou L AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Chen, Qi AU - Chen Q AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Hu, Yun AU - Hu Y AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Hu, Jimeng AU - Hu J AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Wu, Xiaobo AU - Wu X AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Jiang, Haowen AU - Jiang H AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: oncouro_jhw@126.com. LA - eng PT - Journal Article DEP - 20190402 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 RN - 0 (Biomarkers, Tumor) RN - 9001-32-5 (Fibrinogen) MH - Adult MH - Aged MH - Biomarkers, Tumor/blood MH - Blood Coagulation Tests MH - Female MH - Fibrinogen/*metabolism MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*blood MH - Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - Urologic Neoplasms/*blood/*pathology/surgery MH - Urothelium OTO - NOTNLM OT - Intravesical recurrence OT - Plasma fibrinogen OT - Prognosis OT - Upper urinary tract urothelial carcinoma EDAT- 2019/04/06 06:00 MHDA- 2019/07/25 06:00 CRDT- 2019/04/06 06:00 PHST- 2018/12/06 00:00 [received] PHST- 2019/01/24 00:00 [revised] PHST- 2019/03/24 00:00 [accepted] PHST- 2019/04/06 06:00 [pubmed] PHST- 2019/07/25 06:00 [medline] PHST- 2019/04/06 06:00 [entrez] AID - S1743-9191(19)30081-0 [pii] AID - 10.1016/j.ijsu.2019.03.022 [doi] PST - ppublish SO - Int J Surg. 2019 May;65:88-93. doi: 10.1016/j.ijsu.2019.03.022. Epub 2019 Apr 2. PMID- 30950568 OWN - NLM STAT- MEDLINE DCOM- 20200518 LR - 20200518 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 124 IP - 3 DP - 2019 Sep TI - Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide population-based study. PG - 449-456 LID - 10.1111/bju.14767 [doi] AB - OBJECTIVE: To investigate the association between hospital volume and overall survival (OS), cancer-specific survival (CSS), and quality of care of patients with bladder cancer who undergo radical cystectomy (RC), defined as the use of extended lymphadenectomy (eLND), continent reconstruction, neoadjuvant chemotherapy (NAC), and treatment delay of <3 months. PATIENTS AND METHODS: We used the Bladder Cancer Data Base Sweden (BladderBaSe) to study survival and indicators of perioperative quality of care in all 3172 patients who underwent RC for primary invasive bladder cancer stage T1-T3 in Sweden between 1997 and 2014. The period-specific mean annual hospital volume (PSMAV) during the 3 years preceding surgery was applied as an exposure and analysed using univariate and multivariate mixed models, adjusting for tumour and nodal stage, age, gender, comorbidity, educational level, and NAC. PSMAV was either categorised in tertiles, dichotomised (at >/=25 RCs annually), or used as a continuous variable for every increase of 10 RCs annually. RESULTS: PSMAV in the highest tertile (>/=25 RCs annually) was associated with improved OS (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.75-1.0), whereas the corresponding HR for CSS was 0.87 (95% CI 0.73-1.04). With PSMAV as a continuous variable, OS was improved for every increase of 10 RCs annually (HR 0.95, 95% CI 0.90-0.99). Moreover, higher PSMAV was associated with increased use of eLND, continent reconstruction and NAC, but also more frequently with a treatment delay of >3 months after diagnosis. CONCLUSIONS: The current study supports centralisation of RC for bladder cancer, but also underpins the need for monitoring treatment delays associated with referral. CI - (c) 2019 The Authors BJU International (c) 2019 BJU International Published by John Wiley & Sons Ltd. FAU - Liedberg, Fredrik AU - Liedberg F AUID- ORCID: 0000-0001-8193-0370 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Hagberg, Oskar AU - Hagberg O AD - Regional Cancer Centre South, Lund, Sweden. FAU - Aljabery, Firas AU - Aljabery F AUID- ORCID: 0000-0002-8072-3625 AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AUID- ORCID: 0000-0001-8012-2742 AD - Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden. FAU - Jancke, Georg AU - Jancke G AD - Department of Urology, Skane University Hospital, Malmo, Sweden. AD - Institution of Translational Medicine, Lund University, Malmo, Sweden. FAU - Jerlstrom, Tomas AU - Jerlstrom T AD - Department of Urology, School of Health and Medical Sciences, Orebro University, Orebro, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AUID- ORCID: 0000-0001-8572-9957 AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Strock, Viveka AU - Strock V AD - Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Haggstrom, Christel AU - Haggstrom C AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - Department of Biobank Research, Umea University, Umea, Sweden. FAU - Holmberg, Lars AU - Holmberg L AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. AD - School of Medicine, King's College London, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190422 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Cohort Studies MH - *Cystectomy/mortality/statistics & numerical data MH - Female MH - Hospitals/*statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Quality of Health Care/*statistics & numerical data MH - Sweden MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/mortality/surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - hospital volume OT - quality of care OT - radical cystectomy OT - survival EDAT- 2019/04/06 06:00 MHDA- 2020/05/19 06:00 CRDT- 2019/04/06 06:00 PHST- 2019/04/06 06:00 [pubmed] PHST- 2020/05/19 06:00 [medline] PHST- 2019/04/06 06:00 [entrez] AID - 10.1111/bju.14767 [doi] PST - ppublish SO - BJU Int. 2019 Sep;124(3):449-456. doi: 10.1111/bju.14767. Epub 2019 Apr 22. PMID- 30950446 OWN - NLM STAT- MEDLINE DCOM- 20190802 LR - 20190802 IS - 1998-4774 (Electronic) IS - 0019-509X (Linking) VI - 56 IP - 1 DP - 2019 Jan-Mar TI - Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. PG - 54-58 LID - 10.4103/ijc.IJC_351_18 [doi] AB - BACKGROUND: Bladder cancer (BCa) is the ninth most common cancer accounting for 3.9% of all cancer cases as per the Indian Cancer Registry data. There is a scarcity of data on urinary Bca from India. AIM: The aim of this study was to know demographic background, stage distribution, utilization of various treatment modalities, and oncological outcome in Indian patients presenting with bladder cancer to a tertiary care cancer center in Mumbai. METHODOLOGY: We performed a retrospective audit of all patients registered as urinary BCa in our hospital from January 1, 2013 to December 31, 2013. Electronic medical records of these patients were checked for most of the information gathered. RESULTS: Median age of patients at presentation was 59 years with a range of 18-88 years. There were 84% male and 16% female patients. Forty seven percent of patients had nonmuscle invasive bladder cancer (NMIBC), 36% had muscle invasive bladder cancer and locally advanced disease, and 17% had metastatic disease. Eight patients were treated with trimodality bladder preservation protocol. Recurrence was seen in 38 (22.6%) patients with NMIBC. Out of them. 44.7% and 55.3% were in low- and high-grade tumors, respectively. Overall survival and disease-free survival estimated for 3 years were 63% and 57%, respectively. CONCLUSION: Bladder cancer has a varied spectrum of presentation. Bladder cancer patients presenting to our hospital generally have a higher stage and grade of disease compared with that in the west. FAU - Prakash, Gagan AU - Prakash G AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Pal, Mahendra AU - Pal M AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Odaiyappan, K AU - Odaiyappan K AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Shinde, Rajesh AU - Shinde R AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Mishra, Jeeban AU - Mishra J AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Jalde, Devendra AU - Jalde D AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Rajkumar, Barath AU - Rajkumar B AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Prabhash, Kumar AU - Prabhash K AD - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Joshi, Amit AU - Joshi A AD - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Noronha, Vanita AU - Noronha V AD - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Murthy, Vedang AU - Murthy V AD - Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Krishnatry, Rahul AU - Krishnatry R AD - Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Desai, Sangeeta AU - Desai S AD - Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Menon, Santosh AU - Menon S AD - Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Sable, Nilesh AU - Sable N AD - Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Popat, Palak AU - Popat P AD - Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Rangarajan, Venkatesh AU - Rangarajan V AD - Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Agrawal, Archi AU - Agrawal A AD - Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India. FAU - Bakshi, Ganesh AU - Bakshi G AD - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India. LA - eng PT - Journal Article PL - India TA - Indian J Cancer JT - Indian journal of cancer JID - 0112040 MH - Adult MH - Aged MH - Aged, 80 and over MH - *Cancer Care Facilities MH - Combined Modality Therapy MH - *Demography MH - Female MH - Follow-Up Studies MH - Humans MH - India MH - Male MH - Middle Aged MH - Muscle Neoplasms/*pathology/therapy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - *Tertiary Care Centers MH - Time Factors MH - Urinary Bladder Neoplasms/*pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - muscle invasive bladder cancer OT - nonmuscle invasive bladder cancer OT - survival COIS- There are no conflicts of interest. EDAT- 2019/04/06 06:00 MHDA- 2019/08/03 06:00 CRDT- 2019/04/06 06:00 PHST- 2019/04/06 06:00 [entrez] PHST- 2019/04/06 06:00 [pubmed] PHST- 2019/08/03 06:00 [medline] AID - IndianJournalofCancer_2019_56_1_54_255481 [pii] AID - 10.4103/ijc.IJC_351_18 [doi] PST - ppublish SO - Indian J Cancer. 2019 Jan-Mar;56(1):54-58. doi: 10.4103/ijc.IJC_351_18. PMID- 30949449 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Gender Is a Significant Prognostic Factor for Upper Tract Urothelial Carcinoma: A Large Hospital-Based Cancer Registry Study in an Endemic Area. PG - 157 LID - 10.3389/fonc.2019.00157 [doi] LID - 157 AB - Introduction: Our hospital is a tertiary medical center located in southern Taiwan, which is an endemic area for upper tract urothelial carcinoma (UTUC) cases. Using a large registry-based surgical database, we examined our cohort of patients with UTUC, and evaluated the treatment outcome and gender-specific differences in this population. Methods: A total of 506 patients with localized UTUC undergoing nephroureterectomy from 2004 to 2013 were enrolled. The patient, tumor, and treatment-related characteristics were prospectively recorded by the registry. Overall (OS) and cancer-specific (CSS) survival outcomes were evaluated as well. Gender differences as related to clinical and pathological factors were examined by chi-square testing. Univariate and multivariate Cox regression analyses were applied. Results: There were more female patients (57.9%) in this population. The median follow-up was 6.9 years for living patients. The actuarial 5-year OS and CSS rates were 69.4 and 84.9%, respectively. Being female, aged <70 years, and early T-stage were statistically significantly associated with better OS and CSS by multivariate analyses. The 5-year CSS rates for females vs. males were 89.6 and 78.5%, respectively (P < 0.005). A subgroup analysis suggested that better survival outcomes for females only existed in the stage 0a/0is/I (non-muscle-invasive), but not in the advanced stage. Conclusions: In an endemic area, females were more likely diagnosed with UTUC, but had significantly improved OS and CSS compared to their male counterparts, which were mostly driven by the non-muscle-invasive cases. Future research should focus on better understanding the epidemiologic risk-factor profile and pathophysiologic differences based on gender. FAU - Huang, Chun-Chieh AU - Huang CC AD - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Su, Yu-Li AU - Su YL AD - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Luo, Hao-Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yen-Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Sio, Terence T AU - Sio TT AD - Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, AZ, United States. FAU - Hsu, Hsuan-Chih AU - Hsu HC AD - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lai, Chia-Hsuan AU - Lai CH AD - Department of Radiation Oncology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan. LA - eng PT - Journal Article DEP - 20190321 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6437032 OTO - NOTNLM OT - gender OT - nephroureterectomy OT - renal pelvis OT - upper urinary tract OT - ureter OT - urothelial carcinoma EDAT- 2019/04/06 06:00 MHDA- 2019/04/06 06:01 PMCR- 2019/01/01 CRDT- 2019/04/06 06:00 PHST- 2018/11/26 00:00 [received] PHST- 2019/02/25 00:00 [accepted] PHST- 2019/04/06 06:00 [entrez] PHST- 2019/04/06 06:00 [pubmed] PHST- 2019/04/06 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.00157 [doi] PST - epublish SO - Front Oncol. 2019 Mar 21;9:157. doi: 10.3389/fonc.2019.00157. eCollection 2019. PMID- 30944969 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20260127 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 37 IP - 11 DP - 2019 Nov TI - Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. PG - 2289-2296 LID - 10.1007/s00345-019-02739-1 [doi] AB - PURPOSE: To summarize current knowledge on upper urinary tract carcinoma (UTUC) regarding risk stratification, long-term results, and follow-up. METHODS: A scoping review approach was applied to search literature in Pubmed, Web of Science, and Embase. Consensus was reached through discussions at Consultation on UTUC, September 2018, Stockholm. RESULTS: To optimize oncological outcome considering both cancer-specific survival (CSS) and overall survival (OS), it is essential to identify pre- and postoperative prognostic factors. In low-risk UTUC, kidney-sparing surgery (KSS) and radical nephroureterectomy (RNU) offer equivalent CSS, whereas RNU may result in poorer OS due to nephron loss. For more aggressive tumours, undergrading can lead to insufficient treatment. The strongest prognostic factors are tumour stage and grade. Determining grade is best achieved by ureterorenoscopy (URS) with focal samples, biopsy and cytology. Staging is more difficult but can be indirectly achieved by multiphase computed tomography urography (CTU) or tumour grade determined by cytology and histopathology. Patients treated with KSS should be monitored closely with regular follow-ups (URS and CTU). CONCLUSION: KSS should be offered in low-risk UTUC when feasible, whereas RNU is the treatment of choice in organ-confined high-risk UTUC. Intravesical recurrence (IVR) is common after RNU, but a single postoperative dose of mitomycin instillation decreases IVR. Endourological management has high local and bladder recurrence rates; however, its effect on CSS or overall survival OS is unclear. RNU is associated with significant risk of chronic kidney disease. Careful selection of patients and risk stratification are mandatory, and patients should be followed according to strict protocols. FAU - Hasan, Mudhar N AU - Hasan MN AD - Division of Urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, 75013, Paris, France. FAU - Keeley, Francis AU - Keeley F AD - Bristol Urological Institute, Southmead Hospital, Bristol, England, UK. FAU - Cracco, Cecilia AU - Cracco C AD - Department of Urology, Cottolengo Hospital of Torino, Torino, Italy. FAU - Jones, Robert AU - Jones R AD - Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. FAU - Straub, Michael AU - Straub M AD - Department of Urology, University Hospital Klinikum Rechts Der Isar, Technical University Munich, Munich, Germany. FAU - Traxer, Olivier AU - Traxer O AD - Sorbonne Universite, Hopital Tenon, Paris, France. FAU - Osther, Palle Jorn Sloth AU - Osther PJS AD - Department of Urology, Lillebaelt Hospital, University of Southern Denmark, Vejle, Denmark. FAU - Brehmer, Marianne AU - Brehmer M AUID- ORCID: 0000-0001-9232-363X AD - Division of Urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. marianne.brehmer@ki.se. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20190403 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Carcinoma, Transitional Cell/*diagnosis MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/*diagnosis MH - *Risk Assessment MH - Sweden MH - Time Factors MH - Ureteral Neoplasms/*diagnosis PMC - PMC6825637 OTO - NOTNLM OT - Follow-up OT - KSS OT - Prognosis OT - RNU OT - Renal pelvis OT - Risk stratification OT - Treatment OT - UTUC OT - Upper tract OT - Ureter OT - Urothelial carcinoma COIS- Mudhar Hasan: no conflict of interest. Morgan Roupret: advisory board for Ipsen, Roche, Astra Zeneca, Janssen, GSK, and Arquer. Francis X Keeley: no conflict of interest. Olivier Traxer: consultant for Coloplast, Boston Scientific, Olympus, Rocamed, EMS, and IPG Medical. Michael Straub: consultant for Richard Wolf Endoscopes, Coloplast-Porges, and Ambu. Palle Jorn Sloth Osther: no conflict of interest. Cecilia Cracco: tutor for courses for Boston Scientific. Robert Jones: consultant and speaker for Roche, Bristol Myers Squibb, and MSD. Marianne Brehmer: no conflict of interest. EDAT- 2019/04/05 06:00 MHDA- 2020/03/18 06:00 PMCR- 2019/04/03 CRDT- 2019/04/05 06:00 PHST- 2018/12/30 00:00 [received] PHST- 2019/03/23 00:00 [accepted] PHST- 2019/04/05 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] PHST- 2019/04/05 06:00 [entrez] PHST- 2019/04/03 00:00 [pmc-release] AID - 10.1007/s00345-019-02739-1 [pii] AID - 2739 [pii] AID - 10.1007/s00345-019-02739-1 [doi] PST - ppublish SO - World J Urol. 2019 Nov;37(11):2289-2296. doi: 10.1007/s00345-019-02739-1. Epub 2019 Apr 3. PMID- 30944184 OWN - NLM STAT- MEDLINE DCOM- 20200511 LR - 20200511 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 24 IP - 5 DP - 2019 May TI - Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. PG - 612-616 LID - 10.1634/theoncologist.2018-0784 [doi] AB - BACKGROUND: Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis. High-grade T1 (HGT1) bladder cancer is the highest-risk subtype of NMIBC, with an almost 40% rate of recurrence and 20% of progression at 5 years. Nomograms predicting risk of recurrence, progression, and cancer-specific survival (CSS) are not available specifically within HGT1 bladder cancer, and the identification of robust prognostic biomarkers to better guide therapeutic strategies in this subgroup of patients is of paramount importance. Strategies to identify putative biomarkers in liquid biopsies from blood and urine collected from patients with bladder cancer have been intensively studied in the last few years. SUBJECTS, MATERIALS, AND METHODS: We here report the final analysis of a single-center prospective study aimed to investigate the impact of circulating tumor cells (CTCs) on CSS and overall survival (OS) in 102 patients with HGT1 bladder cancer, in a median follow-up of 63 months. RESULTS: We here demonstrate that the presence of even a single CTC is predictive of shorter CSS and OS, as compared with the standard predictive variables. Points of attention in this multivariable analysis are the long-term follow-up and the adequate number of outcome events. CONCLUSION: The accurate risk stratification provided by CTCs might be essential for determining the best surveillance strategy for patients after diagnosis. A closer follow-up, an early radical surgery, or even a systemic treatment might be recommended in patients with super-high-risk non-muscle-invasive bladder cancer. IMPLICATIONS FOR PRACTICE: Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer who require closer monitoring for local recurrence and/or progression of disease. This super-high-risk subgroup of patients might also require more aggressive treatment interventions, which should be evaluated in large prospective cohorts. CI - (c) AlphaMed Press 2019. FAU - Nicolazzo, Chiara AU - Nicolazzo C AD - Dipartimento Medicina Molecolare, Sapienza Universita di Roma, Rome, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Dipartimento Scienze Ginecologico-Ostetriche e Scienze Urologiche, Sapienza Universita di Roma, Rome, Italy. FAU - Gradilone, Angela AU - Gradilone A AD - Dipartimento Medicina Molecolare, Sapienza Universita di Roma, Rome, Italy. FAU - Sperduti, Isabella AU - Sperduti I AD - IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Dipartimento Scienze Ginecologico-Ostetriche e Scienze Urologiche, Sapienza Universita di Roma, Rome, Italy. FAU - Loreni, Flavia AU - Loreni F AD - Dipartimento Medicina Molecolare, Sapienza Universita di Roma, Rome, Italy. FAU - Cortesi, Enrico AU - Cortesi E AD - Dipartimento Scienze Radiologiche, Oncologiche e Patologiche, Sapienza Universita di Roma, Rome, Italy. FAU - de Berardinis, Ettore AU - de Berardinis E AD - Dipartimento Scienze Ginecologico-Ostetriche e Scienze Urologiche, Sapienza Universita di Roma, Rome, Italy. FAU - Gazzaniga, Paola AU - Gazzaniga P AD - Dipartimento Medicina Molecolare, Sapienza Universita di Roma, Rome, Italy. FAU - Raimondi, Cristina AU - Raimondi C AD - Dipartimento Scienze Radiologiche, Oncologiche e Patologiche, Sapienza Universita di Roma, Rome, Italy cristina.raimondi@uniroma1.it. LA - eng PT - Journal Article DEP - 20190403 PL - England TA - Oncologist JT - The oncologist JID - 9607837 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplastic Cells, Circulating/*metabolism/pathology MH - Prospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC6516110 OTO - NOTNLM OT - Cancer-specific survival OT - Circulating tumor cells OT - Non-muscle-invasive bladder cancer OT - Overall survival OT - Risk variables COIS- Disclosures of potential conflicts of interest may be found at the end of this article. EDAT- 2019/04/05 06:00 MHDA- 2020/05/12 06:00 PMCR- 2019/05/01 CRDT- 2019/04/05 06:00 PHST- 2018/11/15 00:00 [received] PHST- 2019/01/31 00:00 [accepted] PHST- 2019/04/05 06:00 [pubmed] PHST- 2020/05/12 06:00 [medline] PHST- 2019/04/05 06:00 [entrez] PHST- 2019/05/01 00:00 [pmc-release] AID - theoncologist.2018-0784 [pii] AID - ONCO12907 [pii] AID - 10.1634/theoncologist.2018-0784 [doi] PST - ppublish SO - Oncologist. 2019 May;24(5):612-616. doi: 10.1634/theoncologist.2018-0784. Epub 2019 Apr 3. PMID- 30926888 OWN - NLM STAT- MEDLINE DCOM- 20201009 LR - 20210109 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 Mar 29 TI - Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis. PG - 5323 LID - 10.1038/s41598-019-41844-4 [doi] LID - 5323 AB - To evaluate the effect of glandular differentiation (GD) on tumor recurrence and progression of pT1 bladder urothelial carcinoma (UC). We performed a retrospective analysis of 82 bladder urothelial carcinoma with glandular differentiation (UCGD) patients which was pathologically diagnosed as pT1, 166 patients of pT1 UC of bladder without histologic variants served as controls. Patients of UCGD were more likely to have higher recurrence (P = 0.002) rate and higher progression rate (P < 0.001). Moreover, UCGD and a poor 5 -year overall survival (OS) (P = 0.02) while there was no difference in cancer-specific survival (CSS) (P = 0.062) between two groups. According to univariate analysis, largest tumor size (HR 1.502, CI 1.158-1.861, P = 0.029), UCGD (HR 1.787, CI 1.298-2.552, P = 0.001), lymphovascular invasion (LVI) (HR 1.226, CI 1.013-1.945, P = 0.039). UCGD (HR 1.367, CI 1.115-1.853, P = 0.038) and LVI (HR 1.416, CI 1.120-2.254, P = 0.013) were prognostic factors associated with disease recurrence and progression, respectively. Additionally, Additionally, UCGD significantly influence disease recurrence (HR 1.871, CI 1.338-2.589, P < 0.001) and progression (HR 1.462, CI 1.138-2.393, p = 0.007). Similarly, LVI significantly influence disease recurrence (HR 1.356, CI 1.053-2.174, P = 0.042) and progression (HR 1.348, CI 1.052-1.944, p = 0.022) in multivariate analysis. UCGD is significantly associated with higher recurrence and progression rate in patients with newly diagnosed pT1. Recurrent cases should be performed radical cystectomy (RC) earlier. FAU - Zhao, Guobin AU - Zhao G AD - Department of Urology, The First Affiliated Hospital of Hebei North University, Zhangjiakou City, Hebei Province, 07500, China. 797980@sina.com. FAU - Wang, Chao AU - Wang C AD - Department of Urology, Fifth Central Hospital of Tianjin, Tianjin, 300450, China. FAU - Tang, Yuhong AU - Tang Y AD - College of Laboratory Medicine, Hebei North University, Zhangjiakou City, Hebei Province, 07500, China. FAU - Liu, Xin AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Hebei North University, Zhangjiakou City, Hebei Province, 07500, China. FAU - Liu, Zihao AU - Liu Z AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Li, Gang AU - Li G AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Mei, Yanhui AU - Mei Y AD - Department of Urology, Binzhou Medical University Hospital, Binzhou, 256603, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190329 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Carcinoma, Transitional Cell/*mortality/*pathology MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/*mortality/*pathology PMC - PMC6441090 COIS- The authors declare no competing interests. EDAT- 2019/03/31 06:00 MHDA- 2020/10/10 06:00 PMCR- 2019/03/29 CRDT- 2019/03/31 06:00 PHST- 2017/11/14 00:00 [received] PHST- 2019/03/19 00:00 [accepted] PHST- 2019/03/31 06:00 [entrez] PHST- 2019/03/31 06:00 [pubmed] PHST- 2020/10/10 06:00 [medline] PHST- 2019/03/29 00:00 [pmc-release] AID - 10.1038/s41598-019-41844-4 [pii] AID - 41844 [pii] AID - 10.1038/s41598-019-41844-4 [doi] PST - epublish SO - Sci Rep. 2019 Mar 29;9(1):5323. doi: 10.1038/s41598-019-41844-4. PMID- 30919100 OWN - NLM STAT- MEDLINE DCOM- 20201111 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 38 IP - 1 DP - 2020 Jan TI - Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis. PG - 129-142 LID - 10.1007/s00345-019-02738-2 [doi] AB - BACKGROUND: Numerous recent studies have shown that concomitant carcinoma in situ (CIS) can be closely associated with the prognosis of patients with bladder cancer (BCa). However, the prognostic value of CIS in BCa is still not conclusive. Hence, we performed a systematic review and meta-analysis to explore the association between CIS and clinicopathological features and the prognostic value for BCa following radical cystectomy. METHODS: We performed this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were systematically collected from PubMed, EMBASE, and Web of Science, with an expiration date of August 2018. Hazard ratios and 95% confidence intervals (CIs) were pooled to assess the intensity of association. All data were analyzed by Stata 12.0. Moreover, heterogeneity and publication bias were determined, and sensitivity analysis was performed to examine whether the findings of the meta-analysis were robust. RESULTS: A total of 18,845 patients from 24 studies were included in the analysis. Our results indicated that CIS has no significant correlation with cancer-specific mortality (CSM) (pooled HR = 0.97, 95% CI 0.93-1.00, p = 0.059), overall mortality (OM) (pooled HR = 0.93, 95% CI 0.85-1.01, p = 0.076), overall survival (OS) (pooled HR = 1.04, 95% CI 0.96-1.12, p = 0.386), cancer-specific survival (CSS) (pooled HR = 1.06, 95% CI 0.97-1.16, p = 0.186), recurrence-free survival (RFS) (HR = 1.05, 95% CI 0.99-1.11, p = 0.098) or recurrence (pooled HR = 1.04, 95% CI 0.98-1.11, p = 0.212) in BCa patients. In addition, CIS was not correlated with gender (male vs. female, OR = 1.00, 95% CI 0.74-1.34, p = 0.978), pathological stage (III/IV vs. I/II: OR = 0.74, 95% CI 0.50-1.10, p = 0.132), tumor grade (1/2 vs. 3: OR = 3.38, 95% CI 0.73-15.65, p = 0.119), soft tissue surgical margin (STSM) (+ vs. - : OR = 1.20, 95% CI 0.97-1.48, p = 0.093) or lymphovascular invasion (LVI) (+ vs. - : OR = 0.92, 95% CI 0.62-1.38, p = 0.702),but was closely related to adjuvant chemotherapy (ACT) (yes vs. no, OR = 1.17, 95% CI 1.03-1.32, p = 0.019). Furthermore, these findings were demonstrated to be reliable by our sensitivity and subgroup analysis. CONCLUSIONS: The prognostic value of CIS in BCa remains inconclusive in patients submitted to RC. Our data indicated that CIS may have no significant correlation with the prognosis and clinicopathological parameters of BCa patients, and also may not be applied to risk stratification or individualized therapy in BCa patients. Further research should be conducted to confirm our findings. FAU - Zhang, Lijin AU - Zhang L AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. stzlj913729553@163.com. FAU - Wu, Bin AU - Wu B AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. FAU - Zha, Zhenlei AU - Zha Z AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. FAU - Zhao, Hu AU - Zhao H AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. FAU - Yuan, Jun AU - Yuan J AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. FAU - Jiang, Yuefang AU - Jiang Y AD - Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, 163 Shoushan Road, Jiang-Yin, 214400, Jiangsu Province, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20190327 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Carcinoma in Situ/*diagnosis/surgery MH - Cystectomy/*methods MH - Humans MH - Margins of Excision MH - *Neoplasm Grading MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/surgery OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Meta-analysis OT - Prognosis OT - Radical cystectomy EDAT- 2019/03/29 06:00 MHDA- 2020/11/12 06:00 CRDT- 2019/03/29 06:00 PHST- 2018/11/21 00:00 [received] PHST- 2019/03/21 00:00 [accepted] PHST- 2019/03/29 06:00 [pubmed] PHST- 2020/11/12 06:00 [medline] PHST- 2019/03/29 06:00 [entrez] AID - 10.1007/s00345-019-02738-2 [pii] AID - 10.1007/s00345-019-02738-2 [doi] PST - ppublish SO - World J Urol. 2020 Jan;38(1):129-142. doi: 10.1007/s00345-019-02738-2. Epub 2019 Mar 27. PMID- 30915527 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20200402 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - The risk factors of urinary tract infection after transurethral resection of bladder tumors. PG - 2715-2719 LID - 10.1007/s00345-019-02737-3 [doi] AB - PURPOSE: Few studies mention the necessity of antimicrobial prophylaxis (AMP) for transurethral resection of bladder tumor (TURBT) and the risk factors for postoperative urinary tract infections (UTIs) after TURBT. To evaluate the necessity of AMP and to detect the risk of UTIs, we examined the perioperative clinical factors. METHODS: 687 patients who underwent TURBT between 2006 and 2017 at Hiroshima Prefectural Hospital were examined retrospectively. We defined the postoperative UTIs as febrile UTIs (>/= 38 degrees C). The AMP for the TURBT that we used was mostly cephalosporin generation 1. The association between the perioperative clinical/pathological factors and postoperative UTIs was assessed by logistic regression retrospectively. RESULTS: 21 patients (3.1%) suffered from postoperative UTIs, and almost all of them were successfully treated with the immediate administration of antibiotics. Univariate analysis showed that past pelvic radiotherapy (p = 0.024, odds ratio (OR) 6.00), tumor size (>/= 2cm) (p = 0.008, OR 3.38), age (>/= 75 years) (p = 0.036, OR 2.65), preoperative hospital stay (>/= 5 days) (p = 0.017, OR 3.76), asymptomatic pyuria (p = 0.038, OR 2.54) and bacteriuria (p = 0.044, OR 2.97) were all associated with postoperative UTIs. CONCLUSIONS: We demonstrated that AMP was effective for patients who underwent TURBT, and history of pelvic radiotherapy, high age, preoperative hospital stay and a certain tumor size were the risk factors as well as pyuria and bacteriuria of postoperative UTIs. FAU - Kohada, Yuki AU - Kohada Y AUID- ORCID: 0000-0002-6510-7461 AD - Department of Urology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minamiku, Hiroshima, 734-8530, Japan. y.kohada.1213@gmail.com. FAU - Goriki, Akihiro AU - Goriki A AD - Department of Urology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minamiku, Hiroshima, 734-8530, Japan. FAU - Yukihiro, Kazuma AU - Yukihiro K AD - Department of Urology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minamiku, Hiroshima, 734-8530, Japan. FAU - Ohara, Shinya AU - Ohara S AD - Department of Urology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minamiku, Hiroshima, 734-8530, Japan. FAU - Kajiwara, Mitsuru AU - Kajiwara M AD - Department of Urology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minamiku, Hiroshima, 734-8530, Japan. LA - eng PT - Journal Article DEP - 20190326 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - *Antibiotic Prophylaxis MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Postoperative Complications/*epidemiology/*prevention & control MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Urethra MH - Urinary Bladder Neoplasms/*surgery MH - Urinary Tract Infections/*epidemiology/*prevention & control OTO - NOTNLM OT - Antimicrobial prophylaxis OT - Surgical site infection OT - Transurethral resection of bladder tumors OT - Urinary tract infections EDAT- 2019/03/28 06:00 MHDA- 2020/04/03 06:00 CRDT- 2019/03/28 06:00 PHST- 2018/12/05 00:00 [received] PHST- 2019/03/20 00:00 [accepted] PHST- 2019/03/28 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/03/28 06:00 [entrez] AID - 10.1007/s00345-019-02737-3 [pii] AID - 10.1007/s00345-019-02737-3 [doi] PST - ppublish SO - World J Urol. 2019 Dec;37(12):2715-2719. doi: 10.1007/s00345-019-02737-3. Epub 2019 Mar 26. PMID- 30911812 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20261011 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. PG - 2699-2705 LID - 10.1007/s00345-019-02681-2 [doi] AB - PURPOSE: Routine second transurethral resection (TUR) for non-muscle-invasive bladder cancer (NMIBC) is common practice in Germany. Applicability of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in NMIBC patients is still controversial. Aim of the study was to assess the performance of EORTC and CUETO predictive models in NMIBC patients treated with second TUR. METHODS: 479 NMIBC patients with routine second TUR were analyzed retrospectively between 2003 and 2011, and investigated with clinical and pathological variables in regard to tumor recurrence and progression. Furthermore, recurrencefree survival (RFS) and progression-free survival (PFS) were evaluated according to EORTC and CUETO, and the discrimination of the models assessed. RESULTS: With a median follow-up of 60 months, prior recurrence rate, grade, and second TUR pathology were independent prognostic factors for the risk of disease recurrence and progression. The concordance index of the EORTC and the CUETO model was 0.563 and 0.516 for recurrence and 0.681 and 0.702 for progression, respectively. The positive pathology after second TUR was significantly associated with risk of disease recurrence and progression. EORTC and CUETO risk models estimated progression better than recurrence, especially with higherscore groups. CONCLUSIONS: Improved predictive tools should be developed for optimal treatment selection. FAU - Zhang, Guoxian AU - Zhang G AUID- ORCID: 0000-0002-3479-3470 AD - Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. xianguozh@hotmail.com. FAU - Steinbach, Daniel AU - Steinbach D AD - Department of Urology, Friedrich Schiller University, Jena, Germany. FAU - Grimm, Marc-Oliver AU - Grimm MO AD - Department of Urology, Friedrich Schiller University, Jena, Germany. FAU - Horstmann, Marcus AU - Horstmann M AD - Department of Urology, Friedrich Schiller University, Jena, Germany. AD - Department of Urology, Malteser Krankenhaus St. Josefshospital, Krefeld, Germany. LA - eng PT - Journal Article DEP - 20190325 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Europe MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Models, Statistical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology/*surgery MH - Organizations MH - Prognosis MH - Reoperation MH - Retrospective Studies MH - *Risk Assessment MH - Spain MH - Urinary Bladder Neoplasms/*epidemiology/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - CUETO OT - EORTC OT - Progression OT - Recurrence OT - Second TUR EDAT- 2019/03/27 06:00 MHDA- 2020/04/03 06:00 CRDT- 2019/03/27 06:00 PHST- 2018/12/06 00:00 [received] PHST- 2019/02/09 00:00 [accepted] PHST- 2019/03/27 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/03/27 06:00 [entrez] AID - 10.1007/s00345-019-02681-2 [pii] AID - 10.1007/s00345-019-02681-2 [doi] PST - ppublish SO - World J Urol. 2019 Dec;37(12):2699-2705. doi: 10.1007/s00345-019-02681-2. Epub 2019 Mar 25. PMID- 30911811 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20200402 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. PG - 2707-2714 LID - 10.1007/s00345-019-02734-6 [doi] AB - PURPOSE: To evaluate the role of a complete transurethral resection of bladder tumors (c-TURBT) on oncological outcomes after radical cystectomy (RC) and its relationship with adverse pathological features. METHODS: We retrospectively analyzed data of 727 patients treated with RC and bilateral pelvic lymph node dissection at three tertiary referral centers. Possible c-TURBT was reported by the treating surgeon. Multivariable Cox regression analyses were used to assess the relationship of c-TURBT and survival outcomes after surgery in 1:1 propensity score-matched cohort adjusted for age and gender. Moreover, multivariable logistic regression (MVA) was built to predict the relationship between c-TURBT and pT3-T4 stages at RC, lymph node invasion (LNI) and positive soft tissue surgical margin (STSM). RESULTS: A total of 433 (60%) patients received a c-TURBT. 3.0% of patients with a c-TURBT achieved a pT0-pTa-pTis status vs. 2.0% of patients with incomplete TURBT. At multivariable Cox regression analyses, c-TURBT was not associated with survival outcomes. At MVA, incompleteness of TURBT was significantly associated with a pT3-T4 stage [odds ratio (OR) 8.04, 95% confidence interval (CI) 2.33-27.67, p = 0.001]. No significant association was found between c-TURBT, LNI and STSM. CONCLUSION: We found a low rate of achievement of pT0 stage at RC. An incomplete TURBT before RC represented a predictor of pT3-T4 stages, but no effect of a c-TURBT was shown on survival outcomes. Given the current inadequacy of clinical staging strategies with more than 50% of extravesical disease being under-staged, our results could improve patients selection for NAC, driving the decision-making in doubtful cases. FAU - Zamboni, Stefania AU - Zamboni S AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. stefania.zamboni@libero.it. AD - Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. stefania.zamboni@libero.it. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy. FAU - Antonelli, Alessandro AU - Antonelli A AD - Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Simeone, Claudio AU - Simeone C AD - Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Belotti, Sandra AU - Belotti S AD - Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Cristinelli, Luca AU - Cristinelli L AD - Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Baumeister, Philipp AU - Baumeister P AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. LA - eng PT - Journal Article DEP - 20190325 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Incomplete OT - Radical cystectomy OT - TURBT OT - Transurethral resection EDAT- 2019/03/27 06:00 MHDA- 2020/04/03 06:00 CRDT- 2019/03/27 06:00 PHST- 2018/11/28 00:00 [received] PHST- 2019/03/15 00:00 [accepted] PHST- 2019/03/27 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/03/27 06:00 [entrez] AID - 10.1007/s00345-019-02734-6 [pii] AID - 10.1007/s00345-019-02734-6 [doi] PST - ppublish SO - World J Urol. 2019 Dec;37(12):2707-2714. doi: 10.1007/s00345-019-02734-6. Epub 2019 Mar 25. PMID- 30910393 OWN - NLM STAT- MEDLINE DCOM- 20210520 LR - 20210520 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 6 IP - 4 DP - 2020 Jul 15 TI - Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes. PG - 674-682 LID - S2405-4569(19)30087-2 [pii] LID - 10.1016/j.euf.2019.03.012 [doi] AB - CONTEXT: Carcinoma in situ (CIS) of the bladder is defined as a high-grade flat lesion confined to the mucosa. Intravesical treatment with bacillus Calmette-Guerin (BCG) is commonly used to reduce the risk of recurrence and progression; however, CIS of the bladder exhibits a heterogeneous clinical behavior and a significant proportion of patients do not show a primary response. OBJECTIVE: To evaluate the available evidence concerning diagnosis, treatment strategies, follow-up, prognosis, and oncological outcomes in patients with CIS of the bladder. EVIDENCE ACQUISITION: A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search was conducted using the databases PubMed/MEDLINE and Embase. We included randomized controlled trials, systematic reviews, meta-analyses, and observational studies. Outcomes of interest were: (1) diagnostic strategies, (2) first- and second-line treatments, (3) follow-up strategies, and (4) prognosis and oncological outcomes. EVIDENCE SYNTHESIS: Overall 62 articles met the inclusion criteria. Most articles concerned retrospective studies and presented mixed data with other non-muscle-invasive bladder cancer categories. The evidence shows that new optical imaging modalities significantly increase the detection rate of CIS. BCG immunotherapy remains the first-line therapy in patients with CIS of the bladder; however, after treatment, adequate follow-up is necessary. Clinicopathological factors remain the main indicators of response to BCG, recurrence, and progression. CONCLUSIONS: New optical imaging modalities are superior to white light cystoscopy in the detection of CIS of the bladder. There are no robust data that justify consideration of other agents as an alternative to BCG immunotherapy. Despite efforts to identify relevant biomarkers, clinicopathological factors remain the most important prognostic factors. PATIENT SUMMARY: New optical techniques have improved the detection of carcinoma in situ (CIS) of the bladder. Bladder preservation using bacillus Calmette-Guerin immunotherapy remains the cornerstone of the treatment of CIS of the bladder. CI - Copyright (c) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Subiela, Jose Daniel AU - Subiela JD AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Rodriguez Faba, Oscar AU - Rodriguez Faba O AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: orodriguez@fundacio-puigvert.es. FAU - Guerrero Ramos, Felix AU - Guerrero Ramos F AD - Oncology Urology Unit, Department of Urology, University Hospital 12 de Octubre, Madrid, Spain. FAU - Vila Reyes, Helena AU - Vila Reyes H AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Pisano, Francesca AU - Pisano F AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Breda, Alberto AU - Breda A AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Oncology Urology Unit, Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Systematic Review DEP - 20190323 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Carcinoma in Situ/*diagnosis/*therapy MH - Humans MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - Bladder cancer OT - Carcinoma in situ OT - Non-muscle-invasive bladder cancer EDAT- 2019/03/27 06:00 MHDA- 2021/05/21 06:00 CRDT- 2019/03/27 06:00 PHST- 2019/02/01 00:00 [received] PHST- 2019/03/04 00:00 [revised] PHST- 2019/03/12 00:00 [accepted] PHST- 2019/03/27 06:00 [pubmed] PHST- 2021/05/21 06:00 [medline] PHST- 2019/03/27 06:00 [entrez] AID - S2405-4569(19)30087-2 [pii] AID - 10.1016/j.euf.2019.03.012 [doi] PST - ppublish SO - Eur Urol Focus. 2020 Jul 15;6(4):674-682. doi: 10.1016/j.euf.2019.03.012. Epub 2019 Mar 23. PMID- 30907072 OWN - NLM STAT- MEDLINE DCOM- 20200511 LR - 20210109 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 8 IP - 4 DP - 2019 Apr TI - Hope and challenge: Precision medicine in bladder cancer. PG - 1806-1816 LID - 10.1002/cam4.1979 [doi] AB - Bladder cancer (BC) is a complex disease and could be classified into nonmuscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC) subtypes according to the distinct genetic background and clinical prognosis. Until now, the golden standard and confirmed diagnosis of BC is cystoscopy and the major problems of BC are the high rate of recurrence and high costs in the clinic. Recent molecular and genetic studies have provided perspectives on the novel biomarkers and potential therapeutic targets of BC. In this article, we provided an overview of the traditional diagnostic approaches of BC, and introduced some new imaging, endoscopic, and immunological diagnostic technology in the accurate diagnosis of BC. Meanwhile, the minimally invasive precision treatment technique, immunotherapy, chemotherapy, gene therapy, and targeted therapy of BC were also included. Here, we will overview the diagnosis and therapy methods of BC used in clinical practice, focusing on their specificity, efficiency, and safety. On the basis of the discussion of the benefits of precision medicine in BC, we will also discuss the challenges and limitations facing the non-invasive methods of diagnosis and precision therapy of BC. The molecularly targeted and immunotherapeutic approaches, and gene therapy methods to BC treatment improved the prognosis and overall survival of BC patients. CI - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Su, Hongwei AU - Su H AD - Department of Urology, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China. FAU - Jiang, Haitao AU - Jiang H AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, China. FAU - Tao, Tao AU - Tao T AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - Department of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, China. FAU - Kang, Xing AU - Kang X AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Zhang, Xu AU - Zhang X AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Kang, Danyue AU - Kang D AD - Michigan State University, East Lansing, Michigan. FAU - Li, Shucheng AU - Li S AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Li, Chengxi AU - Li C AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Wang, Haifeng AU - Wang H AD - Department of Urology, The Second Affliated Hospital of Kunming Medical University, Kunming, China. FAU - Yang, Zhao AU - Yang Z AD - College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. FAU - Zhang, Jinku AU - Zhang J AD - Department of pathology, First Central Hospital of Baoding, Baoding, Hebei, China. FAU - Li, Chong AU - Li C AUID- ORCID: 0000-0003-4654-4479 AD - Department of Urology, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China. AD - Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - Department of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, China. AD - Beijing Jianlan Institute of Medicine, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20190324 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/urine MH - Chemotherapy, Adjuvant/methods MH - Cystoscopy MH - Genetic Therapy/methods MH - Humans MH - Immunotherapy/methods MH - Minimally Invasive Surgical Procedures/methods MH - Molecular Targeted Therapy/methods MH - Precision Medicine/*methods MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/*therapy PMC - PMC6488142 OTO - NOTNLM OT - bladder cancer OT - gene therapy OT - immunotherapy OT - precision medicine COIS- None declared. EDAT- 2019/03/25 06:00 MHDA- 2020/05/12 06:00 PMCR- 2019/03/24 CRDT- 2019/03/26 06:00 PHST- 2018/11/06 00:00 [received] PHST- 2018/12/20 00:00 [revised] PHST- 2019/01/01 00:00 [accepted] PHST- 2019/03/25 06:00 [pubmed] PHST- 2020/05/12 06:00 [medline] PHST- 2019/03/26 06:00 [entrez] PHST- 2019/03/24 00:00 [pmc-release] AID - CAM41979 [pii] AID - 10.1002/cam4.1979 [doi] PST - ppublish SO - Cancer Med. 2019 Apr;8(4):1806-1816. doi: 10.1002/cam4.1979. Epub 2019 Mar 24. PMID- 30903352 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20250530 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - Patients choose certainty over burden in bladder cancer surveillance. PG - 2747-2753 LID - 10.1007/s00345-019-02728-4 [doi] AB - BACKGROUND: Due to the high risk of recurrence of non-muscle invasive bladder cancer, all patients undergo regular cystoscopic surveillance for early detection. As cystoscopy is invasive, costly and increases the burden of the disease considerably, there is significant ongoing research and development into non-invasive urinary biomarker substitutes. This study aims to assess the level of sensitivity required before patients accept a new urinary biomarker. METHODS: We studied the preferences for a hypothetical diagnostic urinary biomarker and compared this to usual care (cystoscopy) at different levels of sensitivity among 437 patients with bladder cancer (354 men and 83 women) from the UK Bladder Cancer Prognosis Programme. A standard gamble approach was used to estimate the minimally acceptable sensitivity (MAS) of the new biomarker. Additionally, non-parametric statistical analyses were performed to investigate the association between surveillance preference and various patient characteristics. RESULTS: Almost half of patients (183, 43%) would not replace cystoscopy with a urinary biomarker unless it was 100% sensitive. The median MAS was 99.9999%, and nearly 85% of patients demanded a sensitivity of at least 99% before preferring a urinary biomarker test over cystoscopy. These results were consistent across all patient characteristics and demographic categories. CONCLUSIONS: Our results indicate that patients demand urinary biomarkers as sensitive as cystoscopy before they would be willing to forego cystoscopy for bladder cancer surveillance. FAU - van Osch, Frits H M AU - van Osch FHM AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. f.vanosch@maastrichtuniversity.nl. AD - Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. f.vanosch@maastrichtuniversity.nl. FAU - Nekeman, Duncan AU - Nekeman D AD - Department of Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, University of Birmingham, Birmingham, UK. FAU - Aaronson, Neil K AU - Aaronson NK AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Billingham, Lucinda J AU - Billingham LJ AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Cheng, K K AU - Cheng KK AD - Department of Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, University of Birmingham, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Complex Genetics, Nutrition and Metabolism in Translational Research (NUTRIM), Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. LA - eng GR - 25354/CRUK_/Cancer Research UK/United Kingdom PT - Comparative Study PT - Journal Article DEP - 20190323 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Cohort Studies MH - Cost of Illness MH - *Cystoscopy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology/*urine MH - *Patient Preference MH - Population Surveillance MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*pathology/*urine PMC - PMC6867982 OTO - NOTNLM OT - Non-invasive biomarkers OT - Non-muscle-invasive bladder cancer OT - Sensitivity and specificity OT - Standard gamble COIS- The authors declare no potential conflicts of interest. All participants in this study provided written informed consent. EDAT- 2019/03/25 06:00 MHDA- 2020/04/03 06:00 PMCR- 2019/03/23 CRDT- 2019/03/24 06:00 PHST- 2019/01/02 00:00 [received] PHST- 2019/03/11 00:00 [accepted] PHST- 2019/03/25 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/03/24 06:00 [entrez] PHST- 2019/03/23 00:00 [pmc-release] AID - 10.1007/s00345-019-02728-4 [pii] AID - 2728 [pii] AID - 10.1007/s00345-019-02728-4 [doi] PST - ppublish SO - World J Urol. 2019 Dec;37(12):2747-2753. doi: 10.1007/s00345-019-02728-4. Epub 2019 Mar 23. PMID- 30901172 OWN - NLM STAT- MEDLINE DCOM- 20190923 LR - 20191207 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 45 IP - 4 DP - 2019 Jul-Aug TI - Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. PG - 686-694 LID - 10.1590/S1677-5538.IBJU.2018.0530 [doi] AB - PURPOSE: The present study aimed to determine whether sarcopenia after radical cystectomy (RC) could predict overall survival (OS) in patients with urothelial bladder cancer (UBC). MATERIALS AND METHODS: The lumbar skeletal muscle index (SMI) of 80 patients was measured before and 1 year after RC. The prognostic signifi cance of sarcopenia and SMI decrease after RC were evaluated using Kaplan-Meier analysis and a multivariable Cox regression model. RESULTS: Of 80 patients, 26 (32.5%) experienced sarcopenia before RC, whereas 40 (50.0%) experienced sarcopenia after RC. The median SMI change was -2.2 cm2/m2. Patients with sarcopenia after RC had a higher pathological T stage and tumor grade than patients without sarcopenia. Furthermore, the overall mortality rate was signifi - cantly higher in patients with sarcopenia than in those without sarcopenia 1 year after RC. The median follow-up time was 46.2 months, during which 22 patients died. Kaplan-Meier estimates showed a signifi cant difference in OS rates based on sarcopenia (P=0.012) and SMI decrease (P=0.025). Multivariable Cox regression analysis showed that SMI decrease (>/=2.2 cm2/m2) was an independent predictor of OS (hazard ratio: 2.68, confi dence interval: 1.007-7.719, P = 0.048). CONCLUSIONS: The decrease in SMI after surgery might be a negative prognostic factor for OS in patients who underwent RC to treat UBC. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. FAU - Kim, Sang Won AU - Kim SW AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. FAU - Kwon, Tae Gyun AU - Kwon TG AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. FAU - Chung, Sung Kwang AU - Chung SK AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. FAU - Yoo, Eun Sang AU - Yoo ES AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Body Mass Index MH - Carcinoma in Situ/complications/mortality/*surgery MH - Cystectomy/*adverse effects/methods/mortality MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Multivariate Analysis MH - Muscle, Skeletal/physiopathology MH - Proportional Hazards Models MH - Retrospective Studies MH - Sarcopenia/*etiology/physiopathology MH - Time Factors MH - Urinary Bladder Neoplasms/complications/mortality/physiopathology/*surgery PMC - PMC6837591 OTO - NOTNLM OT - Sarcopenia OT - Survival OT - Urinary Bladder Neoplasms COIS- None declared. EDAT- 2019/03/23 06:00 MHDA- 2019/09/24 06:00 PMCR- 2019/09/02 CRDT- 2019/03/23 06:00 PHST- 2018/07/16 00:00 [received] PHST- 2018/12/14 00:00 [accepted] PHST- 2019/03/23 06:00 [pubmed] PHST- 2019/09/24 06:00 [medline] PHST- 2019/03/23 06:00 [entrez] PHST- 2019/09/02 00:00 [pmc-release] AID - IBJU20180530 [pii] AID - S1677-5538.IBJU.2018.0530 [pii] AID - 10.1590/S1677-5538.IBJU.2018.0530 [doi] PST - ppublish SO - Int Braz J Urol. 2019 Jul-Aug;45(4):686-694. doi: 10.1590/S1677-5538.IBJU.2018.0530. PMID- 30900154 OWN - NLM STAT- MEDLINE DCOM- 20190612 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 6 DP - 2019 Jun TI - Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. PG - 1625-1633 LID - 10.1007/s00432-019-02900-8 [doi] AB - OBJECTIVE: To evaluate the efficacy and safety of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IC) in non-muscle invasive bladder cancer (NMIBC) and identify the risk factors for recurrence and progression. METHODS: This is a retrospective cohort study of NMIBC patients in south China. Ninety-nine patients underwent IAC combined with transurethral resection of bladder tumor (TURBT) and IC, and 50 patients underwent TURBT plus IC without IAC. The 5-year outcomes of the two groups were compared. Cox regression was used to evaluate risk factors. Kaplan-Meier curves were used to assess the significant differences of recurrence-free survival and progression-free survival. RESULTS: At 5 years, IAC significantly reduced the recurrence of high-grade NMIBC, 54.5% (18/33) in the non-IAC group vs 30.5% (18/59) in the IAC group (p = 0.028). IAC significantly reduced the recurrence of high-risk NMIBC, 56.3% (18/32) in the non-IAC group vs 26.1% (18/69) in the IAC group (p = 0.007). IAC significantly reduced the recurrence of intermediate-risk NMIBC, 44.4% (8/18) in the non-IAC group vs 22.2% (6/27) in the IAC group (p = 0.030). Tumors numbering from 2 to 7 had the highest recurrence rate (18.1%, 27/149). In this aspect, there was a significantly lower recurrence rate in the IAC group (30.8%, 12/30) than in the non-IAC group (68.2%, 15/22) (p = 0.007). No significant difference was found in the progression rate between the two groups. Only two cases (2/99, 2.0%) in the IAC group showed progression. The results of univariate and multivariate analyses suggested that the number of tumors, grade and risk level were risk factors for recurrence. No difference was found with respect to gender, age, tumor diameter, and T category. In the Kaplan-Meier plot, recurrence-free survival was significantly associated with treatment strategies (p < 0.01). Recurrence-free survival was shorter in the non-IAC group (12.73 +/- 7.56 months) than in the IAC group (17.88 +/- 12.26 months). CONCLUSIONS: Combined IAC is a promising procedure to prevent recurrence and may be useful to suppress progression in NMIBC patients. The independent risk factors for the recurrence of NMIBC were multifocal tumors, grade and risk level. Intra-arterial chemotherapy is an effective and safe procedure and may be a promising choice in areas where BCG is not available or for patients who are intolerant to BCG. FAU - Lian, Fan AU - Lian F AUID- ORCID: 0000-0002-0415-0415 AD - Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Chen, Wenchuan AU - Chen W AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Liu, Yiming AU - Liu Y AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Shen, Long AU - Shen L AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Fan, Wenzhe AU - Fan W AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Cui, Wei AU - Cui W AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Zhao, Yue AU - Zhao Y AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Li, Jiaping AU - Li J AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. FAU - Wang, Yu AU - Wang Y AD - Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China. wangyu2@mail.sysu.edu.cn. LA - eng GR - 81102270/National Natural Science Foundation of China/ GR - 2016A030313217/Natural Science Foundation of Guangdong Province/ GR - 2016A030313206/Natural Science Foundation of Guangdong Province/ PT - Journal Article DEP - 20190321 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Antibiotics, Antineoplastic) RN - 3Z8479ZZ5X (Epirubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/administration & dosage MH - Chemotherapy, Adjuvant MH - Cystectomy/methods MH - Epirubicin/*administration & dosage MH - Female MH - Humans MH - Infusions, Intra-Arterial MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/prevention & control MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery PMC - PMC11810414 OTO - NOTNLM OT - Intra-arterial chemotherapy OT - Non-muscle invasive bladder cancer OT - Progression OT - Recurrence COIS- The authors declare that they have no conflicts of interest. EDAT- 2019/03/23 06:00 MHDA- 2019/06/14 06:00 PMCR- 2019/03/21 CRDT- 2019/03/23 06:00 PHST- 2018/12/28 00:00 [received] PHST- 2019/03/18 00:00 [accepted] PHST- 2019/03/23 06:00 [pubmed] PHST- 2019/06/14 06:00 [medline] PHST- 2019/03/23 06:00 [entrez] PHST- 2019/03/21 00:00 [pmc-release] AID - 10.1007/s00432-019-02900-8 [pii] AID - 2900 [pii] AID - 10.1007/s00432-019-02900-8 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Jun;145(6):1625-1633. doi: 10.1007/s00432-019-02900-8. Epub 2019 Mar 21. PMID- 30888973 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20200219 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 29 IP - 3 DP - 2019 May TI - The interaction of gender and smoking on bladder cancer risks. PG - 249-255 LID - 10.1097/MOU.0000000000000602 [doi] AB - PURPOSE OF REVIEW: Although smoking and gender are well-established bladder cancer (BCa) risk factors, a significant interaction with other risk factors could help in the identification of patterns for early detection and prevention strategies. RECENT FINDINGS: Smoking appears to be more strongly associated with BCa risk in women than in men, which could be related to differences in metabolism, smoking behavior, exposure patterns, and DNA repair mechanisms. BMI is associated with a higher risk of BCa with negligible difference between genders. The risk for BCa is increased in postmenopausal women, specifically in women with earlier menopausal age (<45 years). Other potential risk factors such as alcohol, arsenic exposure, and particulate matter inhalation seem to affect the genders differently.Female smokers experience a higher risk of disease recurrence after bacillus Calmette-Guerin therapy than their male counterparts. Lastly, smoking appears to negatively affect the outcome of radiotherapy in women, but not that of men. SUMMARY: Several lines of evidence point to an interaction between smoking and gender, whereas their impact on other potential risk factors remains to be elucidated. Identifying such differential effects could allow for gender-specific prevention, early detection, and treatment strategies. FAU - Janisch, Florian AU - Janisch F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Medical University of Hamburg, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, New York, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - EAU Research Foundation, Arnhem, The Netherlands. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Schernhammer, Eva AU - Schernhammer E AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard Medical School. AD - Channing Division of Network Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. AD - Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Department of Urology, Medical University of Hamburg, Hamburg, Germany. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - Early Detection of Cancer MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/etiology/prevention & control MH - Risk Factors MH - Sex Factors MH - Smoking/*adverse effects MH - Urinary Bladder Neoplasms/diagnosis/*etiology/prevention & control/therapy EDAT- 2019/03/20 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/03/20 06:00 PHST- 2019/03/20 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/03/20 06:00 [entrez] AID - 10.1097/MOU.0000000000000602 [doi] PST - ppublish SO - Curr Opin Urol. 2019 May;29(3):249-255. doi: 10.1097/MOU.0000000000000602. PMID- 30888482 OWN - NLM STAT- MEDLINE DCOM- 20190905 LR - 20210109 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 29 IP - 7 DP - 2019 Jul TI - Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. PG - 3881-3888 LID - 10.1007/s00330-019-06119-6 [doi] AB - OBJECTIVE: To evaluate the significance of the presence or absence of an "inchworm sign" on DWI for the recurrence and progression of T1 bladder cancer. MATERIALS AND METHODS: We retrospectively analyzed 91 patients with pT1 urothelial carcinoma who underwent DWI prior to transurethral resection between 2007 and 2016. DWI of the dominant tumors was scrutinized for inchworm signs at b = 1000 s/mm(2). The association of the presence of the inchworm sign with progression and recurrence was analyzed; progression was defined as recurrence to stage T2 or higher and/or N+, and/or M1. RESULTS: An inchworm sign was seen in 65 cases (71%), while it was absent in 26 cases. Among the 65, 25 (38%) had confirmed tumor recurrence, while in the remaining 26, 14 (54%) had confirmed recurrence (median time post TURB = 7.9 and 10.1 months for each). At the time of recurrence, the tumor had progressed in one (2%) inchworm-sign-positive and seven (27%) inchworm-sign-negative cases. The progression rate of inchworm-sign-negative cases was significantly higher than that of inchworm-sign-positive cases (hazard ratio = 17.2, p = 0.0017), whereas there was no significant difference in the recurrence rate between two groups. The absence of an inchworm sign and histological grade 3 were independent risk factors for progression (p < 0.001 and 0.010, respectively). CONCLUSIONS: The absence of an inchworm sign on DWI was a significant prognostic factor for progression of T1 bladder cancer. Morphological evaluation of DWI signals may therefore be a useful adjunct to preoperative assessment of biological aggressiveness. KEY POINTS: * An inchworm sign is a simple diagnostic criterion that characterizes only the shape of the tumor signal on DWI, and potentially serves as an imaging biomarker to predict clinical aggressiveness. * The absence of an inchworm sign on DWI is a significant indicator of progression of T1 bladder cancer. FAU - Yajima, Shugo AU - Yajima S AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. s-yoshida.uro@tmd.ac.jp. FAU - Takahara, Taro AU - Takahara T AD - Department of Biomedical Engineering, Tokai University School of Engineering, Isehara, Japan. FAU - Arita, Yuki AU - Arita Y AD - Department of Radiology, Advanced Imaging Center, Yaesu Clinic, Tokyo, Japan. FAU - Tanaka, Hiroshi AU - Tanaka H AD - Department of Radiology, Ochanomizu Surugadai Clinic, Tokyo, Japan. FAU - Waseda, Yuma AU - Waseda Y AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Matsuoka, Yoh AU - Matsuoka Y AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Kihara, Kazunori AU - Kihara K AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan. LA - eng PT - Journal Article DEP - 20190319 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging/*methods MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/diagnostic imaging/mortality/*pathology MH - Urothelium/*pathology OTO - NOTNLM OT - Biomarkers OT - Diffusion magnetic resonance imaging OT - Magnetic resonance imaging OT - Prognosis OT - Urinary bladder neoplasms EDAT- 2019/03/20 06:00 MHDA- 2019/09/07 06:00 CRDT- 2019/03/20 06:00 PHST- 2018/10/28 00:00 [received] PHST- 2019/02/19 00:00 [accepted] PHST- 2019/02/13 00:00 [revised] PHST- 2019/03/20 06:00 [pubmed] PHST- 2019/09/07 06:00 [medline] PHST- 2019/03/20 06:00 [entrez] AID - 10.1007/s00330-019-06119-6 [pii] AID - 10.1007/s00330-019-06119-6 [doi] PST - ppublish SO - Eur Radiol. 2019 Jul;29(7):3881-3888. doi: 10.1007/s00330-019-06119-6. Epub 2019 Mar 19. PMID- 30882164 OWN - NLM STAT- MEDLINE DCOM- 20200804 LR - 20201005 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 16 IP - 6 DP - 2019 Dec 24 TI - The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers. PG - 558-562 LID - 10.22037/uj.v0i0.4519 [doi] AB - PURPOSE: To identify clinically useful predictors for the recurrence of papillary urothelial neoplasm of low malignant potential (PUNLMP), we reviewed the clinical information of patients who were diagnosed and treated in multiple tertiary-care academic facilities. MATERIALS AND METHODS: Between February 2007 and April 2015, 95 patients diagnosed with PUNLMP after transurethral resection of bladder (TURB) were included in this study. Age, gender, body mass index, smoking history, the presence or absence of previous history of urothelial neoplasm, the presence or absence of gross hematuria, cytological results at the time of diagnosis, tumor diameter, and multiplicity of tumor were estimated as variablesfor analysis. Cox regression tests were used for identifying predictive factors for recurrence of PUNLMP. RESULTS: Sixty-nine cases of PUNLMP were de novo primary bladder PUNLMPs without known urothelial lesions in the urinary tract, and 26 PUNLMPs were identified on surveillance biopsies of patients with a previous history of urothelial neoplasm. During the follow-up period, recurrences developed in 13 patients (13.7%). Recurrence rates were 4.2% and 9.5% at 12 and 24 months, respectively. On univariate and multivariate Cox regression analyses, previous history of urothelial neoplasm [95% confidence interval (CI): 0.057-0.604, hazard ratio (HR) = 0.185, P = .005] and multiplicity of tumors [95% CI = 0.064-0.584, HR = 0.193, P = .004] were identified as independent predictors for recurrence-free survival of patients with PUNLMP. CONCLUSION: Tumor multiplicity and previous history of urothelial neoplasm are independent prognostic factors forprediction of recurrence of PUNLMP. More careful and closer follow-up should be recommended for PULNMPpatients with tumor multiplicity or a previous history of urothelial neoplasm. FAU - Kim, Ki Hong AU - Kim KH AD - Department of Urology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan. Koreaurokim@schmc.ac.kr. FAU - Lee, Seung Hwan AU - Lee SH AD - Department of Urology, Shinchon Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. FAU - Kim, Sun Il AU - Kim SI AD - Department of Urology, Ajou University School of Medicine, Suwon, Korea. FAU - Chung, Byung Ha AU - Chung BH AD - Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. FAU - Koo, Kyo Chul AU - Koo KC AD - Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. FAU - Cho, Jin Seon AU - Cho JS AD - Department of Urology, Hallym University College of Medicine, Chuncheon, Korea. FAU - Bang, Woo Jin AU - Bang WJ AD - Department of Urology, Hallym University College of Medicine, Chuncheon, Korea. FAU - Park, Jong Yeon AU - Park JY AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. FAU - Hong, Sung Joon AU - Hong SJ AD - Department of Urology, Shinchon Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20191224 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 SB - IM MH - Academic Medical Centers/*statistics & numerical data MH - Aged MH - Carcinoma, Transitional Cell/*diagnosis/surgery MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis MH - Neoplasm Staging/*methods MH - Predictive Value of Tests MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/surgery MH - Urothelium/*pathology EDAT- 2019/03/19 06:00 MHDA- 2020/08/05 06:00 CRDT- 2019/03/19 06:00 PHST- 2019/03/19 06:00 [pubmed] PHST- 2020/08/05 06:00 [medline] PHST- 2019/03/19 06:00 [entrez] AID - 4519 [pii] AID - 10.22037/uj.v0i0.4519 [doi] PST - epublish SO - Urol J. 2019 Dec 24;16(6):558-562. doi: 10.22037/uj.v0i0.4519. PMID- 30881921 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 9 DP - 2019 TI - Combination of Intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis. PG - 121 LID - 10.3389/fonc.2019.00121 [doi] LID - 121 AB - Background: About 75% of newly diagnosed bladder cancer cases suffer from non-muscle invasive bladder cancer (NMIBC), which used to recur and progress despite transurethral resection of bladder tumor (TURBT). This meta-analysis was conducted to examine if combined application of intravesical bacille Calmette-Guerin (BCG) with chemotherapy is associated with better prognosis. Methods: Systematic searches of randomized controlled trials (RCTs) concerning NMIBC were performed in PubMed, EMbase, CENTRAL, CNKI, WanFang, VIP, CBM databases, and some specialized websites. Two researchers independently implemented study selection, quality assessment and data extraction. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for treatment effects on recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS) were directly extracted, if available, or estimated using relevant data from included studies. Side effects, such as fever, gastrointestinal reaction, cystitis, irritative bladder symptoms and hematuria, were also extracted as outcome measurements, and associated relative risks (RRs) were calculated to assess treatment safety. RevMan 5.3 software was used to perform statistical analyses. Results: Thirteen RCTs containing 1,754 patients with NMIBC were included in this meta-analysis. Compared with BCG alone, the combination therapy significantly improved RFS (HR = 0.53, 95% CI: 0.43-0.66, P < 0.01), OS (HR = 0.66, 95%CI: 0.50-0.86, P = 0.002), and DSS (HR = 0.48, 95%CI: 0.29-0.80, P = 0.005). While PFS showed no obvious difference between combination therapy and BCG alone (HR = 0.65, 95%CI: 0.25-1.68, P = 0.38). The rate of fever (RR = 0.50, 95%CI: 0.27-0.91, P = 0.02), irritative bladder symptoms (RR = 0.69, 95%CI: 0.52-0.90, P = 0.007) and hematuria (RR = 0.50, 95%CI: 0.28-0.89, P = 0.02) were significantly decreased in patients treated with combination therapy compared to those with BCG alone. There were no statistically significant differences between combination therapy and BCG alone in toxicity (RR = 0.69, 95%CI: 0.34-1.40, P = 0.30), gastrointestinal reaction (RR = 2.54, 95%CI: 0.61-10.60, P = 0.20) or cystitis (RR = 0.67, 95%CI: 0.29-1.54, P = 0.34). Conclusions: Combined application of intravesical BCG and chemotherapy appears to be an effective treatment for patients with intermediate- to high-risk NMIBC, but not for those with tumor in situ alone or recurrent bladder cancer. FAU - Huang, Di AU - Huang D AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Jin, Ying-Hui AU - Jin YH AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Weng, Hong AU - Weng H AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Huang, Qiao AU - Huang Q AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Zeng, Xian-Tao AU - Zeng XT AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Wang, Xing-Huan AU - Wang XH AD - Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20190301 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6405446 OTO - NOTNLM OT - bacille Calmette-Guerin OT - chemotherapy OT - meta-analysis OT - non-muscle invasive bladder cancer OT - prognosis EDAT- 2019/03/19 06:00 MHDA- 2019/03/19 06:01 PMCR- 2019/01/01 CRDT- 2019/03/19 06:00 PHST- 2018/12/04 00:00 [received] PHST- 2019/02/11 00:00 [accepted] PHST- 2019/03/19 06:00 [entrez] PHST- 2019/03/19 06:00 [pubmed] PHST- 2019/03/19 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2019.00121 [doi] PST - epublish SO - Front Oncol. 2019 Mar 1;9:121. doi: 10.3389/fonc.2019.00121. eCollection 2019. PMID- 30865491 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 143 IP - 12 DP - 2019 Dec TI - Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections. PG - 1562-1567 LID - 10.5858/arpa.2018-0139-RS [doi] AB - Plasmacytoid urothelial carcinoma (PUC) is a variant of infiltrating urothelial carcinoma that is characterized by tumor cells that have striking morphologic resemblance to and immunohistochemical overlap with plasma cells, and that harbors CDH1 mutation. Plasmacytoid urothelial carcinoma can be widely infiltrative and may permeate the urinary bladder in a linitis plastica-like manner and spread along the fascial planes and into the peritoneum. Compared with conventional urothelial carcinoma, PUCs have a greater chance for higher-stage disease, surgical margin positivity, and metastasis at presentation that translate into its poorer outcome. Upstaging of lamina propria-invasive (pT1) tumors diagnosed at transurethral resections is common. Because of its unfavorable behavior, a more aggressive management approach is being recommended for PUC, including consideration for upfront cystectomy in pT1 tumors. Thus, accurate distinction should be made especially on the initial transurethral resection specimens because of the therapeutic and prognostic implications. Awareness of PUC's unique clinical presentation, morphology, and immunohistochemical profile is important to avoid a potential misdiagnosis from its mimics. FAU - Sood, Sadhika AU - Sood S AD - From Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Mangalore, Karnataka, India (Ms Sood); and the Departments of Pathology and Surgery (Urology), University of Chicago Medical Center, Chicago, Illinois (Dr Paner). At the time of acceptance, Ms Sood was currently a rotating medical student in the Department of Pathology, University of Chicago Medical Center. FAU - Paner, Gladell P AU - Paner GP AD - From Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Mangalore, Karnataka, India (Ms Sood); and the Departments of Pathology and Surgery (Urology), University of Chicago Medical Center, Chicago, Illinois (Dr Paner). At the time of acceptance, Ms Sood was currently a rotating medical student in the Department of Pathology, University of Chicago Medical Center. LA - eng PT - Journal Article DEP - 20190313 PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Urinary Bladder Neoplasms/*pathology EDAT- 2019/03/14 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/03/14 06:00 PHST- 2019/03/14 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/03/14 06:00 [entrez] AID - 10.5858/arpa.2018-0139-RS [doi] PST - ppublish SO - Arch Pathol Lab Med. 2019 Dec;143(12):1562-1567. doi: 10.5858/arpa.2018-0139-RS. Epub 2019 Mar 13. PMID- 30863057 OWN - NLM STAT- MEDLINE DCOM- 20190422 LR - 20220408 IS - 1178-2013 (Electronic) IS - 1176-9114 (Print) IS - 1176-9114 (Linking) VI - 14 DP - 2019 TI - Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer. PG - 1241-1254 LID - 10.2147/IJN.S189688 [doi] AB - BACKGROUND: Traditional intravesical instillation treatment in bladder cancer has limited efficacy, which results in a high frequency of recurrence. PURPOSE: The aim of this study was to report on an epirubicin (EPI)-loaded magnetic multi-walled carbon nanotube (mMWCNTs-EPI) system for intravesical instillation in place of the current formulation. METHODS: The mMWCNTs-EPI system was formulated with carboxylated MWCNTs, Fe(3)O(4) magnetic nanoparticles, and EPI. Features and antitumor activity of the system were investigated. RESULTS: Under the effect of external magnets, the mMWCNTs-EPI system showed sustained release and prolonged retention behavior and better antitumor activity than free EPI. The mMWCNTs-EPI system had higher efficiency in enhancing cytotoxicity and inhibiting proliferation in vitro and in vivo than free EPI. Our studies also revealed the atoxic nature of mMWCNTs. CONCLUSION: These findings suggested that mMWCNTs are effective intravesical instillation agents with great potential for clinical application. FAU - Suo, Ning AU - Suo N AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Wang, Muwen AU - Wang M AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Jin, Yang AU - Jin Y AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Ding, Jun AU - Ding J AD - Department of Mechanical Engineering, University of Maryland, Baltimore County, Baltimore, MD, 21250, USA. FAU - Gao, Xueping AU - Gao X AD - School of Material Science and Engineering, Shandong University, Jinan 250100, China. FAU - Sun, Xiaoliang AU - Sun X AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Zhang, Haiyang AU - Zhang H AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Cui, Meng AU - Cui M AD - Department of Urology, Shandong Provincial Maternity and Childcare Hospital, Jinan 250014, China. FAU - Zheng, Jilu AU - Zheng J AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Li, Nianlu AU - Li N AD - School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China. FAU - Jin, Xunbo AU - Jin X AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. FAU - Jiang, Shaobo AU - Jiang S AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China, jxb@sdu.edu.cn; jiangshaobo@sdu.edu.cn. LA - eng PT - Journal Article DEP - 20190215 PL - New Zealand TA - Int J Nanomedicine JT - International journal of nanomedicine JID - 101263847 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Delayed-Action Preparations) RN - 0 (Ki-67 Antigen) RN - 0 (Nanotubes, Carbon) RN - 3Z8479ZZ5X (Epirubicin) SB - IM MH - Administration, Intravesical MH - Animals MH - Antibiotics, Antineoplastic/pharmacology/therapeutic use MH - Apoptosis/drug effects MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Delayed-Action Preparations MH - Epirubicin/*administration & dosage/pharmacology/*therapeutic use MH - Female MH - Humans MH - Ki-67 Antigen/metabolism MH - *Magnetics MH - Male MH - Nanotubes, Carbon/*chemistry/toxicity/ultrastructure MH - Rats MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC6391142 OTO - NOTNLM OT - carbon nanotubes OT - epirubicin OT - intravesical drug delivery OT - intravesical instillation COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2019/03/14 06:00 MHDA- 2019/04/23 06:00 PMCR- 2019/02/15 CRDT- 2019/03/14 06:00 PHST- 2019/03/14 06:00 [entrez] PHST- 2019/03/14 06:00 [pubmed] PHST- 2019/04/23 06:00 [medline] PHST- 2019/02/15 00:00 [pmc-release] AID - ijn-14-1241 [pii] AID - 10.2147/IJN.S189688 [doi] PST - epublish SO - Int J Nanomedicine. 2019 Feb 15;14:1241-1254. doi: 10.2147/IJN.S189688. eCollection 2019. PMID- 30860885 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230306 IS - 1546-3141 (Electronic) IS - 0361-803X (Linking) VI - 212 IP - 5 DP - 2019 May TI - Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. PG - 1060-1069 LID - 10.2214/AJR.18.20718 [doi] AB - OBJECTIVE. The purpose of this study was to determine whether quantitative T2-weighted imaging and apparent diffusion coefficient (ADC) texture features of bladder cancer and extravesical fat are predictive of muscle invasive bladder cancer (category >/= T2) and extravesical (category >/= T3) disease after transurethral resection of a bladder tumor (TURBT). MATERIALS AND METHODS. In this retrospective study, 36 patients (27 men, nine women; mean age, 71 years) were identified who underwent post-TURBT MRI followed by cystectomy without intervening treatment from August 2011 through October 2016. Texture features of bladder cancer and extravesical fat adjacent to the tumor on T2-weighted and ADC images were extracted and compared between category /= T3 and category T1 versus >/= T2 tumors by means of Kruskal-Wallis or Mann-Whitney U test. Multivariate logistic regression analysis was performed, and ROC curves were calculated. RESULTS. Twenty-six of the 36 (72%) tumors were >/= T2, and 53% (19/36) were >/= T3. In multivariate analysis, bladder cancer entropy on T2-weighted images (p = 0.006; odds ratio [OR], 4.56; 95% CI, 1.49-20.41; AUC, 0.85) and ADC maps (p = 0.019; OR, 2.24; 95% CI, 1.13-5.31; AUC, 0.80) and extravesical fat entropy on T2-weighted images (p = 0.005; OR, 17.50; 95% CI, 3.01-200.80; AUC, 0.84) and ADC maps (p = 0.002; OR, 6.54; 95% CI, 1.90-32.40; AUC, 0.82) remained greater for >/= T3 than for /= T2 compared with category T1 tumors. CONCLUSION. Greater entropy of primary bladder cancers and extravesicular fat was observed in category >/= T3 than in category /= T2 than in category T1 tumors. MRI texture analysis can help with local bladder cancer staging in patients who have undergone TURBT and may serve as a biomarker for higher local category bladder cancers. FAU - Lim, Christopher S AU - Lim CS AD - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. AD - Present address: Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. FAU - Tirumani, Sree AU - Tirumani S AD - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. AD - Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215. FAU - van der Pol, Christian B AU - van der Pol CB AD - Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada. FAU - Alessandrino, Francesco AU - Alessandrino F AD - Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215. FAU - Sonpavde, Guru P AU - Sonpavde GP AD - Department of Oncology, Dana-Farber Cancer Institute, Boston, MA. FAU - Silverman, Stuart G AU - Silverman SG AD - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Shinagare, Atul B AU - Shinagare AB AD - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. AD - Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215. LA - eng PT - Journal Article DEP - 20190312 PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 SB - IM OTO - NOTNLM OT - bladder cancer OT - extravesical extension OT - multiparametric MRI OT - muscle-invasive bladder cancer OT - texture analysis OT - urothelial carcinoma EDAT- 2019/03/13 06:00 MHDA- 2019/03/13 06:01 CRDT- 2019/03/13 06:00 PHST- 2019/03/13 06:00 [pubmed] PHST- 2019/03/13 06:01 [medline] PHST- 2019/03/13 06:00 [entrez] AID - 10.2214/AJR.18.20718 [doi] PST - ppublish SO - AJR Am J Roentgenol. 2019 May;212(5):1060-1069. doi: 10.2214/AJR.18.20718. Epub 2019 Mar 12. PMID- 30858894 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220408 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 11 DP - 2019 Jan-Dec TI - A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer. PG - 1756287219833056 LID - 10.1177/1756287219833056 [doi] LID - 1756287219833056 AB - BACKGROUND: Adjuvant intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is considered as the first-line agent in patients with high-risk nonmuscle invasive bladder cancer (NMIBC) after surgery. There are no data in India where there is a high prevalence of tubercle bacillus and inherent immunity against Bacillus sp. The present study aims to evaluate the outcomes of intravesical BCG in the Indian population. METHODS: A retrospective study of 101 patients who underwent intravesical BCG for high-risk NMIBC between January 2006 and December 2015 was carried out in a single centre. We compared the recurrence-free rate and progression rate of patients who received induction alone and induction with maintenance BCG therapy. The safety profile of intravesical BCG therapy was also assessed in the study. RESULTS: After a median follow up of 2 years, the disease-free survival (DFS) rates of the induction group and maintenance group were 82% and 88% respectively (p = 0.233). There was no difference in progression-free survival (PFS) rates at 2 years in those who receive maintenance BCG (95%) and those with induction BCG (94.7%; p = 0.721). A total of 69.36% of our patients had local adverse events. CONCLUSION: Our results suggest that maintenance therapy does not enhance the therapeutic effects of BCG in patients who respond favourably to 6 weeks of induction. Additional prospective studies are warranted in those countries where tuberculosis exposure is prevalent. FAU - Joshua, Julie Mariam AU - Joshua JM AUID- ORCID: 0000-0003-2100-3190 AD - Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, India. FAU - Vijayan, Meenu AU - Vijayan M AD - Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, India meenuvijayan@aims.amrita.edu. FAU - Pooleri, Ginil Kumar AU - Pooleri GK AD - Amrita Institute of Medical Sciences and Research Centre, AIMS-Ponekkara, 682041 Kochi, Kerala, India. LA - eng PT - Journal Article DEP - 20190305 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC6402057 OTO - NOTNLM OT - effectiveness OT - high-risk NMIBC OT - intravesical BCG OT - prognostic factors OT - progression OT - recurrence OT - safety COIS- Conflict of interest statement: The authors declare that there is no conflict of interest. EDAT- 2019/03/13 06:00 MHDA- 2019/03/13 06:01 PMCR- 2019/03/05 CRDT- 2019/03/13 06:00 PHST- 2018/07/23 00:00 [received] PHST- 2018/12/11 00:00 [accepted] PHST- 2019/03/13 06:00 [entrez] PHST- 2019/03/13 06:00 [pubmed] PHST- 2019/03/13 06:01 [medline] PHST- 2019/03/05 00:00 [pmc-release] AID - 10.1177_1756287219833056 [pii] AID - 10.1177/1756287219833056 [doi] PST - epublish SO - Ther Adv Urol. 2019 Mar 5;11:1756287219833056. doi: 10.1177/1756287219833056. eCollection 2019 Jan-Dec. PMID- 30855378 OWN - NLM STAT- MEDLINE DCOM- 20200309 LR - 20200309 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 29 IP - 3 DP - 2019 May TI - The impact of gender on oncologic outcomes of bladder cancer. PG - 279-285 LID - 10.1097/MOU.0000000000000606 [doi] AB - PURPOSE OF REVIEW: The purpose of this article is to review the current literature on the impact of gender on oncologic outcomes of bladder cancer (BCa). RECENT FINDINGS: Women are more likely to experience disease recurrence, progression, and/or death across all disease states. Furthermore, women are less likely to respond to intravesical therapy for nonmuscle invasive BCa. These disparities are explained by several hypotheses such as differential exposure to environmental carcinogens, hormonal factors, and/or disease management. Additionally, it has been shown that women suffer from delays in diagnosis because of inefficiencies in healthcare delivery. On genomic analyses, women were found to be more likely to harbor basal subtypes of BCa compared with men. SUMMARY: A steadily growing body of evidence reveals that women present with more advanced BCa and have stage-for-stage worse outcome compared with men. The underlying mechanisms for this gender difference are multifactorial. Further studies are needed to elucidate the molecular underpinning of this gender-gap and subsequently explore potential novel gender-specific management strategies. FAU - Mun, Dong-Ho AU - Mun DH AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology Jikei University School of Medicine Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York, New York. AD - Department of Urology, Southwestern Medical Center, University of Texas, Dallas, Texas, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Special Surgery, Division of Urology, The University of Jordan, Amman, Jordan. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Administration, Intravesical MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/etiology MH - Prognosis MH - Sex Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/genetics/mortality/pathology/*therapy EDAT- 2019/03/12 06:00 MHDA- 2020/03/10 06:00 CRDT- 2019/03/12 06:00 PHST- 2019/03/12 06:00 [pubmed] PHST- 2020/03/10 06:00 [medline] PHST- 2019/03/12 06:00 [entrez] AID - 10.1097/MOU.0000000000000606 [doi] PST - ppublish SO - Curr Opin Urol. 2019 May;29(3):279-285. doi: 10.1097/MOU.0000000000000606. PMID- 30854907 OWN - NLM STAT- MEDLINE DCOM- 20191223 LR - 20191223 IS - 1940-2465 (Electronic) IS - 1066-8969 (Linking) VI - 27 IP - 5 DP - 2019 Aug TI - Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients. PG - 483-491 LID - 10.1177/1066896919830509 [doi] AB - Urothelial cancer is a heterogeneous disease with different molecular pathways that produce distinct molecular subtypes with specific characteristics and patient survival outcomes that require different therapeutic methods. Urothelial tumors in young patients appear to have distinct genetic features compared with their counterparts in older patients. Using a Lund subtype-specific immunohistochemistry panel, we performed molecular subtype profiling of an urothelial carcinoma case series (n = 49) in patients younger than 45 years of age. We demonstrate that the urothelial carcinoma in young patients tends to be of molecular urothelial-like A subtype (80%) and is associated with favorable, recurrent-free survival (P = .022). In the urothelial-like cluster, we identified a portion of patients (10%) with high-grade non-muscle-invasive cancers (so-called urothelial-like D type) that showed significantly higher levels of squamous differentiation and p16, E2F3, and ki67 expression in addition to aberrant expression of Ck20 and a trend toward lower recurrent-free survival (P = .057). Segregation of the cohort according to the decade of occurrence revealed that all tumors (n = 8) of patients younger than 30 years were clearly classified as urothelial-like A subtype. Statistically more aggressive molecular subtypes, such as urothelial-like D and basal/squamous-like (6%) subtypes, were identified in patients older than 30 years of age. Genomically unstable (2%) and mesenchymal-like (2%) subtypes were classified in the 40- to 44-year age group only. These data suggest that more aggressive molecular subtypes of bladder carcinoma appear and become more frequent with age. Further investigations are needed to validate this hypothesis. FAU - Shelekhova, Ksenya V AU - Shelekhova KV AUID- ORCID: 0000-0002-2113-0053 AD - 1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia. AD - 2 Saint-Petersburg Medico-Social Institute, Saint Petersburg, Russia. FAU - Krykow, Kirill A AU - Krykow KA AD - 1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia. FAU - Mescherjakov, Igor A AU - Mescherjakov IA AD - 1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia. FAU - Mitin, Nikolay P AU - Mitin NP AD - 1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia. LA - eng PT - Journal Article DEP - 20190311 PL - United States TA - Int J Surg Pathol JT - International journal of surgical pathology JID - 9314927 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Age Factors MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/mortality/*pathology MH - Urothelium/*pathology MH - Young Adult OTO - NOTNLM OT - bladder cancer OT - immunohistochemistry OT - molecular subtyping OT - young patients EDAT- 2019/03/12 06:00 MHDA- 2019/12/24 06:00 CRDT- 2019/03/12 06:00 PHST- 2019/03/12 06:00 [pubmed] PHST- 2019/12/24 06:00 [medline] PHST- 2019/03/12 06:00 [entrez] AID - 10.1177/1066896919830509 [doi] PST - ppublish SO - Int J Surg Pathol. 2019 Aug;27(5):483-491. doi: 10.1177/1066896919830509. Epub 2019 Mar 11. PMID- 30852032 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20210805 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 12 DP - 2020 Dec TI - New horizons in bladder cancer research. PG - 867-885 LID - S1078-1439(18)30508-8 [pii] LID - 10.1016/j.urolonc.2018.12.014 [doi] AB - The 16th Meeting of the International Bladder Cancer Network (IBCN) took place from October 11 to 13, 2018 in Rotterdam, the Netherlands. As in the previous year, muscle-invasive bladder cancer (MIBC) was the main topic of the congress based upon the rapid evolution in this field over the last several years. This year s meeting was dominated by presentations focusing on genomic subtyping in MIBC and identification of novel therapeutic targets. These topics were complemented by submissions on immunotherapy, a variety of clinical topics, and biomarker research. Based upon the presentations, it may be concluded that the IBCN increasingly serves as an interdisciplinary forum not only for the presentation of work-in-progress covering all facets of bladder cancer research, but also for catalyzing the discussion of discrepant research findings in an effort to find consensus. The 16th Meeting of the IBCN took place from October 11 to 13th, 2018 in Rotterdam, the Netherlands, hosted by Ellen Zwarthoff and Joost Boormans. Approximately 120 participants gathered for another fully packed program displaying recent achievements in basic and clinical research covering the entire spectrum of bladder cancer. This year's meeting was dominated by presentations focusing on genomic subtyping and identification of novel therapeutic targets. These topics were complemented by submissions on immunotherapy, clinical topics, and biomarker research. Keynote lectures were delivered by G. Robertson (Canada) on MIBC genomics and the organizational challenges of the PanCancerAtlas project. Comprehensive information was provided on the Cancer Genome Atlas (TCGA) project including the structure of the consortium and the development and validation of molecular classification of MIBC. Results from the project suggest that regulons (groups of genes controlled by a common regulator) appear to be correlated with prognosis and may replace gene expression analysis in the future. M. Thelen (Switzerland) discussed the role of chemokines in cancer metastasization reporting on his research on the atypical chemokine receptor 3. The inaugural IBCN lecture was presented by M. Ingersoll (France) discussing gender disparities in development of adaptive immunity following Bacillus Calmette-Guerin therapy. In addition to the traditional "Industry meets IBCN" sessions, a format for discussion between industry representatives, researchers, and physicians in break-out groups, new formats were introduced-in the Oxford style of debate, P.J. Goebell (Germany) and W. Stadler (USA) delivered animated discussion on the appropriateness of urologists administering systemic immune checkpoint inhibitors. There was consensus that practice may differ between different health systems and countries, and educational/training background. In a second interesting discussion, D. McConkey (USA) and H. Al-Ahmadie (USA) debated if traditional histology will be replaced by molecular classification of bladder tumors. It was concluded that molecular classification offers valuable additional information but cannot yet replace traditional histology. Furthermore, the growing evidence of tumor heterogeneity in bladder cancer was discussed in a separate topic session. L. Dyrskjot discussed genomic and transcriptomic heterogeneity and their impact on clinical decision making. G. Sjodahl presented data on heterogeneity of molecular subtypes within the primary tumor and between the primary tumor and metastases, that is surprisingly limited. Y. Allory discussed spatial and temporal heterogeneity of bladder cancers particularly focusing on the basal-like phenotype. Due to the continued increase in the number of participants and abstract submissions, a poster session was implemented at this year s meeting for the first time. Posters were briefly presented in the forum. Two travel awards were presented to H. Yamashita (USA) for his submission on peroxisome proliferator-activated receptor gamma-mediated repression of transcription factor activating protein 2 alfa expression identifying a transcriptional circuit in basal-squamous bladder cancer in a cell line model. S.B. Williams (USA) received his award for his registry-based analysis of outcome and costs in patients with localized MIBC undergoing either bladder sparing trimodal therapy or radical cystectomy. The latter was found to generate improved survival outcomes at lower costs as compared with trimodal therapy. The best presentation awards were presented to A. Kamoun (France) who discussed a consensus molecular classification for MIBC. The international demand for a consensus classification, already raised at previous meetings, has resonated with important players in this field. A potential consensus comprising 6 classes was proposed based upon a thorough analysis of the existing classifications. As an extension of the IBCN meeting a consensus conference on genomic classification of MIBC was held that included all major groups in this field. M. Garige (USA) received his award for a detailed examination of inhibitors of metabolic processes in bladder cancer cells before and after therapy. A take home message of the meeting was that the IBCN increasingly serves as an interdisciplinary forum not for the presentation of work-in-progress covering all facets of bladder cancer research, but also for catalyzing the discussion of discrepant research findings in an effort to find consensus. Exemplified may this also be by the fact that the efforts to unify the subclassification of MIBC had its nidus on the preceding meetings of the IBCN on this topic and brought together the various disciplines which ultimately were able to finalize their consensus work in a last concluding meeting directly following the IBCN. Thus, the IBCN meetings and the close cooperation of IBCN with its official journal, Urological Oncology, continue to provide a unique platform for exchange, discussing and intensifying multidimensional collaborations, thus finally satisfying the increasing need for answers regarding the management of bladder cancer patients. The 17th meeting of the IBCN will take place in Aarhus, Denmark, October 3 to 5, 2019. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Boormans, Joost L AU - Boormans JL AD - Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Goebell, Peter J AU - Goebell PJ AD - Department of Urology, Friedrich-Alexander University, Erlangen, Germany. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Nawroth, Roman AU - Nawroth R AD - Department of Urology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, University Hospital Bern, Switzerland. FAU - Williams, Stephen B AU - Williams SB AD - Division of Urology, The University of Texas Medical Branch, Galveston, TX. FAU - Schmitz-Drager, Bernd J AU - Schmitz-Drager BJ AD - Department of Urology, Friedrich-Alexander University, Erlangen, Germany; MVZ Urologie 24, Nuremberg, Germany. Electronic address: bsd@euromed.de. LA - eng PT - Journal Article PT - Review DEP - 20190307 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Biomedical Research MH - Humans MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - Basic research OT - Bladder cancer OT - Clinical trials OT - International Bladder Cancer Network (IBCN) OT - Molecular classifier OT - Tumor models EDAT- 2019/03/11 06:00 MHDA- 2021/08/06 06:00 CRDT- 2019/03/11 06:00 PHST- 2018/12/11 00:00 [received] PHST- 2018/12/14 00:00 [accepted] PHST- 2019/03/11 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2019/03/11 06:00 [entrez] AID - S1078-1439(18)30508-8 [pii] AID - 10.1016/j.urolonc.2018.12.014 [doi] PST - ppublish SO - Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7. PMID- 30850856 OWN - NLM STAT- MEDLINE DCOM- 20200402 LR - 20200402 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 12 DP - 2019 Dec TI - Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. PG - 2683-2689 LID - 10.1007/s00345-019-02673-2 [doi] AB - PURPOSE: Non-muscle-invasive bladder cancer involving the prostatic urethra is associated with pathologic upstaging and shorter survival. We investigated the survival impact of prostatic urethral involvement in non-muscle-invasive patients who are not upstaged at cystectomy. METHODS: From 2000 to 2016, 177 male patients underwent cystectomy for high-risk non-muscle-invasive bladder cancer and remained pT1, pTis, or pTa, and N0 on final pathology; 63 (35.6%) patients had prostatic urethral involvement and 114 (64.4%) did not. Prostatic involvement was non-invasive (Ta or Tis) in 56 (88.9%) patients and superficially invasive (T1) in 7 (11.1%) patients. No patient had stromal invasion. Log-rank and Cox regression analyses were used to evaluate survival. RESULTS: Compared to patients without prostatic urethral involvement, patients with involvement were more likely to have received intravesical therapy (84.6% vs. 64.4%, p < 0.01), have multifocal tumor (90.8% vs. 51.7%, p < 0.01), and have positive urethral margins (7.7% vs. 0%, p < 0.01) and ureteral margins (18.5% vs. 5.1%, p < 0.01). Log-rank comparison showed inferior recurrence-free, cancer-specific, and overall survival in patients with prostatic involvement (p = 0.01, p = 0.03, p < 0.01). Patients with prostatic urethral involvement were more likely to experience recurrence in the urinary tract (p < 0.01). On Cox regression, prostatic urethral involvement was an independent predictor of overall mortality (HR = 2.08, p < 0.01). CONCLUSIONS: Prostatic urethral involvement is associated with inferior survival in patients who undergo cystectomy for non-muscle-invasive bladder cancer and remain pT1, pTis, or pTa on final pathology. Prostatic urethral involvement is thus an adverse pathologic feature independent of its association with upstaging. FAU - Brant, Aaron AU - Brant A AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. aab9038@nyp.org. AD - James Buchanan Brady Foundation Department of Urology, Weill Cornell Medical College, 525 East 68th Street, Starr Pavilion, 9th Floor, New York, NY, 10065, USA. aab9038@nyp.org. FAU - Daniels, Marcus AU - Daniels M AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. FAU - Chappidi, Meera R AU - Chappidi MR AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. FAU - Joice, Gregory A AU - Joice GA AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. FAU - Sopko, Nikolai A AU - Sopko NA AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. FAU - Matoso, Andres AU - Matoso A AD - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. FAU - Kates, Max AU - Kates M AD - James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287, USA. LA - eng PT - Journal Article DEP - 20190308 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Prostate MH - Retrospective Studies MH - Survival Rate MH - Urethral Neoplasms/*pathology MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Non-muscle-invasive OT - Prostatic urethra OT - Radical cystectomy EDAT- 2019/03/10 06:00 MHDA- 2020/04/03 06:00 CRDT- 2019/03/10 06:00 PHST- 2018/11/23 00:00 [received] PHST- 2019/02/05 00:00 [accepted] PHST- 2019/03/10 06:00 [pubmed] PHST- 2020/04/03 06:00 [medline] PHST- 2019/03/10 06:00 [entrez] AID - 10.1007/s00345-019-02673-2 [pii] AID - 10.1007/s00345-019-02673-2 [doi] PST - ppublish SO - World J Urol. 2019 Dec;37(12):2683-2689. doi: 10.1007/s00345-019-02673-2. Epub 2019 Mar 8. PMID- 30847751 OWN - NLM STAT- MEDLINE DCOM- 20190805 LR - 20190805 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 26 IP - 5 DP - 2019 May TI - Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion. PG - 1569-1576 LID - 10.1245/s10434-019-07276-0 [doi] AB - BACKGROUND: Two procedures widely performed to treat locally advanced colorectal cancer adherent to the urinary bladder are total cystectomy (as part of pelvic exenteration) and partial cystectomy; however, little is known about outcomes following partial cystectomy. METHODS: A retrospective database of patients with colorectal cancer involving the urinary bladder who underwent R0 or R1 resection at our institution from 2001 to 2015 was constructed. The histological extent of bladder invasion and long-term outcomes were examined. RESULTS: Of the 89 consecutive patients, 49 underwent partial cystectomy and all had negative margins of the bladder. Tumor invasion to the urinary bladder was confirmed histologically in 19 of 49 patients (coincidence rate of diagnosis, 39%): invasion only to the bladder serosa (n = 3), invasion to the bladder muscle (n = 4), and invasion beyond the bladder muscle without (n = 1) and with (n = 11) exposure to the bladder lumen. The 5-year recurrence-free and overall survival rates were 63.2% and 70.2% in the partial cystectomy group, and 66.2% and 72.7% in the total cystectomy group (p = 0.567 and 0.648), respectively. Except for the remnant bladder, recurrence sites were very similar to sites observed in patients who underwent total cystectomy. Intravesical recurrence occurred in four patients 3-13 months after the initial surgery, all of whom showed bladder lumen exposure to the tumor. CONCLUSIONS: With regard to long-term outcomes and low diagnostic concordance rates of clinical and pathological bladder invasion, partial cystectomy seems a generally acceptable treatment option. However, when the bladder lumen is exposed to a colorectal tumor, surgeons should be cognizant of possible intravesical recurrence and act accordingly. FAU - Yoshida, Takefumi AU - Yoshida T AD - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. yoshida_takefumi@med.kurume-u.ac.jp. FAU - Shida, Dai AU - Shida D AD - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Taniguchi, Hirokazu AU - Taniguchi H AD - Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. FAU - Tsukamoto, Shunsuke AU - Tsukamoto S AD - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Kanemitsu, Yukihide AU - Kanemitsu Y AD - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. LA - eng PT - Comparative Study PT - Journal Article DEP - 20190307 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 CIN - Ann Surg Oncol. 2019 Dec;26(Suppl 3):686-687. doi: 10.1245/s10434-019-07716-x. PMID: 31399818 MH - Adult MH - Aged MH - Aged, 80 and over MH - Colorectal Neoplasms/*mortality/pathology/surgery MH - Cystectomy/*mortality/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*mortality/pathology/surgery MH - *Postoperative Complications MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/surgery MH - Young Adult EDAT- 2019/03/09 06:00 MHDA- 2019/08/06 06:00 CRDT- 2019/03/09 06:00 PHST- 2018/10/08 00:00 [received] PHST- 2019/03/09 06:00 [pubmed] PHST- 2019/08/06 06:00 [medline] PHST- 2019/03/09 06:00 [entrez] AID - 10.1245/s10434-019-07276-0 [pii] AID - 10.1245/s10434-019-07276-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2019 May;26(5):1569-1576. doi: 10.1245/s10434-019-07276-0. Epub 2019 Mar 7. PMID- 30844807 OWN - NLM STAT- MEDLINE DCOM- 20191210 LR - 20191217 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 102 IP - 3 DP - 2019 TI - Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. PG - 277-283 LID - 10.1159/000496802 [doi] AB - OBJECTIVES: To analyze outcomes of patients > 85 years with de novo bladder cancer (BCa). To compare outcomes of high grade (HG) non-muscle invasive BCa (NMIBC) treated with standard therapies versus palliative management. METHODS: Retrospective revision of 65 patients > 85 years who underwent transurethral resection of the bladder (TURB) for de novo BCa. According to functional status each patient was offered a standard or palliative management after TURB. RESULTS: Median age was 87.3 years (85.2-95.4) and 51 were men (78.5%). Twenty-eight (43%) were American Society of Anesthesiologists (ASA) II and 37 ASA III-IV (57%). Pathological examination: 29 pTx-pTa (44.6%), 28 pT1 (43.1%) and 8 pT2 (12.3%). Twenty were low grade (30.8%) and 45 HG (69.2%). Among 37 HG NMIBC patients, 43% followed standard therapies (BCG or re-staging TURB + BCG), and 57% a palliative management (no oncological treatments). With a median follow-up of 20 months (3-108), 2 (12.5%) died in standard group compared to 11 (52.4%) in palliative. In univariate analysis, age (p = 0.024), stage (p = 0.009), and standard management (p = 0.019) were related to overall survival (OS). In multivariate, standard management was an independent prognostic factor of OS (hazard ratio 0.164, 95% CI 0.036-0.744, p = 0.048). CONCLUSIONS: Advanced age should not be a contraindication for standard therapies in BCa. A geriatric assessment could identify patients who may benefit from adjuvant therapies after TURB. CI - (c) 2019 S. Karger AG, Basel. FAU - Carrion, Albert AU - Carrion A AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain, acarrionpuig@gmail.com. FAU - Diaz, Fernando AU - Diaz F AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Raventos, Carles AU - Raventos C AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Lozano, Fernando AU - Lozano F AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Pinero, Adria AU - Pinero A AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Morote, Juan AU - Morote J AD - Department of Urology, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Comparative Study PT - Journal Article DEP - 20190307 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Administration, Intravesical MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Palliative Care/*methods MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*pathology/*therapy MH - Urologic Surgical Procedures OTO - NOTNLM OT - Bacillus calmette-guerin OT - Bladder cancer OT - Complication OT - Intravesical instillation OT - Transurethral resection EDAT- 2019/03/08 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/03/08 06:00 PHST- 2018/10/15 00:00 [received] PHST- 2019/01/09 00:00 [accepted] PHST- 2019/03/08 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/03/08 06:00 [entrez] AID - 000496802 [pii] AID - 10.1159/000496802 [doi] PST - ppublish SO - Urol Int. 2019;102(3):277-283. doi: 10.1159/000496802. Epub 2019 Mar 7. PMID- 30837209 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 3 DP - 2019 Jun TI - Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. PG - e488-e493 LID - S1558-7673(19)30036-9 [pii] LID - 10.1016/j.clgc.2019.01.009 [doi] AB - INTRODUCTION: Definitive, curatively intended therapy for muscle-invasive bladder cancer can be associated with significant morbidity and adverse effects on quality of life, leaving patients reluctant to opt for these interventions. We sought to provide perspective to patients and clinicians exploring therapy options. MATERIALS AND METHODS: We examined stage-by-stage overall survival of definitive therapy (DT) (either radical cystectomy in conjunction with neoadjuvant chemotherapy or trimodal therapy) versus non-DT (including palliative transurethral resection, chemotherapy and radiation treatment) among 42,144 patients within the National Cancer Database (2004-2012). RESULTS: The median overall survival stratified by receipt of DT versus non-DT was 45.3 versus 16.4 months, 26.7 versus 9.6 months, and 21.2 versus 7.5 months in American Joint Committee on Cancer stages II, III, and IV, respectively. In multivariable Cox regression analysis, DT conferred a significant survival benefit in all stages, most pronounced in American Joint Committee on Cancer stage IV (hazard ratio, 0.46; 95% confidence interval, 0.43-0.49; P < .001). CONCLUSION: Despite potentially significant morbidity and adverse effects on quality of life, DT is associated with a sizable survival benefit. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Gild, Philipp AU - Gild P AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Nguyen, David-Dan AU - Nguyen DD AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Faculty of Medicine, McGill University, Montreal, Quebec, Canada. FAU - Fletcher, Sean A AU - Fletcher SA AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Cole, Alexander P AU - Cole AP AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Lipsitz, Stuart R AU - Lipsitz SR AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Kibel, Adam S AU - Kibel AS AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Preston, Mark A AU - Preston MA AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: qtrinh@bwh.harvard.edu. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190129 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Combined Modality Therapy MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Muscle Neoplasms/*mortality/pathology/therapy MH - Neoadjuvant Therapy/*mortality MH - Neoplasm Staging MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/therapy OTO - NOTNLM OT - Comparative effectiveness OT - Cystectomy OT - Drug therapy OT - Radiotherapy OT - Urinary bladder neoplasms EDAT- 2019/03/07 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/03/07 06:00 PHST- 2019/01/08 00:00 [received] PHST- 2019/01/19 00:00 [accepted] PHST- 2019/03/07 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/03/07 06:00 [entrez] AID - S1558-7673(19)30036-9 [pii] AID - 10.1016/j.clgc.2019.01.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Jun;17(3):e488-e493. doi: 10.1016/j.clgc.2019.01.009. Epub 2019 Jan 29. PMID- 30834632 OWN - NLM STAT- MEDLINE DCOM- 20200715 LR - 20200715 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 26 IP - 4 DP - 2019 Apr TI - Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size. PG - 481-486 LID - 10.1111/iju.13913 [doi] AB - OBJECTIVE: To validate the significance of the entity of "very-low-risk" bladder cancer by analyzing the clinical outcomes of low-risk bladder cancer when further stratified by tumor size. METHODS: We accessed our prospectively maintained, single-institution, electronic bladder cancer registry to extract the clinicopathological data of patients who were diagnosed with primary, solitary, Ta, low-grade tumors that were <3 cm. Patients were divided into two prognostic groups based on tumor size (1.0 cm). The survival data of the two groups were compared for recurrence, progression and mortality. RESULTS: A total of 165 patients were followed up for a median period of 79 months (interquartile range 47-118 months). A total of 45% (75/165) of the study cohort had tumors that were 1.0 cm was significantly associated with shorter time to recurrence (HR 2.54, 95% CI 1.35-4.77, P = 0.004). Tumor size was not significantly associated with any differences in time to overall progression, muscle-invasive progression or overall mortality (P = 0.108, P = 0.362 and P = 0.225, respectively, log-rank test). CONCLUSIONS: Low-risk bladder cancer can be further stratified based on tumor size. Larger tumors (>1.0 cm) are significantly associated with shorter time to recurrence compared with smaller tumors ( 0.05). No difference in protein expression was observed regarding the risk of recurrence, OS, or cancer-specific mortality (p > 0.05). Stratification of patients based on the IRS into three groups (poor, moderate, and intensive reaction) failed to identify a prognostic marker among the tested proteins (p > 0.05). CONCLUSIONS: Expression of E-cadherin, beta-catenin, and EMA cannot reliably predict survival in patients with high-risk NMIBC. Further searches are needed to identify tissue markers of progression and recurrence in NMIBC. FAU - Poletajew, Slawomir AU - Poletajew S AD - Department of Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Fus, Lukasz AU - Fus L AD - Department of Pathology, Medical University of Warsaw, Warsaw, Poland. FAU - Ilczuk, Tomasz AU - Ilczuk T AD - Department of Pathology, Medical University of Warsaw, Warsaw, Poland. FAU - Wojcieszak, Piotr AU - Wojcieszak P AD - Department of Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Sekowska, Malgorzata AU - Sekowska M AD - Department of Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Wasiutynski, Aleksander AU - Wasiutynski A AD - Department of Pathology, Medical University of Warsaw, Warsaw, Poland. FAU - Gornicka, Barbara AU - Gornicka B AD - Department of Pathology, Medical University of Warsaw, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of Urology, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20181231 PL - Poland TA - Cent Eur J Immunol JT - Central-European journal of immunology JID - 9702239 PMC - PMC6384421 OTO - NOTNLM OT - bladder cancer OT - disease progression OT - immunohistochemistry OT - recurrence OT - survival COIS- The authors declare no conflict of interest. EDAT- 2019/02/26 06:00 MHDA- 2019/02/26 06:01 PMCR- 2018/01/01 CRDT- 2019/02/26 06:00 PHST- 2018/01/14 00:00 [received] PHST- 2018/04/23 00:00 [accepted] PHST- 2019/02/26 06:00 [entrez] PHST- 2019/02/26 06:00 [pubmed] PHST- 2019/02/26 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - 79509 [pii] AID - 10.5114/ceji.2018.79509 [doi] PST - ppublish SO - Cent Eur J Immunol. 2018;43(4):421-427. doi: 10.5114/ceji.2018.79509. Epub 2018 Dec 31. PMID- 30799130 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20200413 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 3 DP - 2019 Jun TI - Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. PG - e461-e471 LID - S1558-7673(19)30018-7 [pii] LID - 10.1016/j.clgc.2019.01.007 [doi] AB - INTRODUCTION: Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guerin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database (NCDB) to identify demographic and clinical determinants of guideline-based treatment (GBT) and RC. PATIENTS AND METHODS: We identified 47,694 patients in the NCDB with cT1 bladder cancer diagnosed in 2004-2013. Those who did not receive any treatment or underwent primary chemotherapy were excluded. Mixed effects logistic regression adjusted for facility-level variation was used to identify factors associated with receipt of GBT. RESULTS: The median age of the cohort was 72 years (interquartile range, 63-79). Of the patients, 22.4% were female, 5.1% were African American, and 2.7% had variant histology. Nearly one-third of patients received GBT: 11,453 (24%) were initially treated with BCG and 3320 (7%) were initially treated with RC. Recent year of diagnosis (odds ratio [OR], 1.67; 95% confidence interval [CI], 1.52-1.85; P < .001), treatment at an academic center (OR, 2.42; 95% CI, 2.27-2.59; P < .001), and private insurance status (OR, 1.41; 95% CI, 1.19-1.66; P < .001) were associated with increased odds of GBT. Of patients who received GBT, variant histology (OR, 5.89; 95% CI, 4.65-7.47; P < .001), and recent year of diagnosis (OR, 1.89; 95% CI, 1.50-2.39; P < .001) were associated with greater odds of RC. CONCLUSION: There is low treatment-guideline compliance for patients with cT1 disease. However, there appears to be a temporal trend toward increased use of GBT. Efforts should be made to understand why many cT1 bladder cancer patients do not receive GBT. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Balakrishnan, Ashwin S AU - Balakrishnan AS AD - Department of Urology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. FAU - Washington, Samuel L 3rd AU - Washington SL 3rd AD - Department of Urology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. FAU - Meng, Maxwell V AU - Meng MV AD - Department of Urology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Sima.porten@ucsf.edu. LA - eng PT - Journal Article DEP - 20190119 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Guideline Adherence/*statistics & numerical data MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*prevention & control MH - Practice Guidelines as Topic/*standards MH - Prognosis MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - Guideline adherence OT - Management OT - Non-muscle-invasive OT - Quality of health care EDAT- 2019/02/26 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/02/26 06:00 PHST- 2018/11/13 00:00 [received] PHST- 2019/01/10 00:00 [revised] PHST- 2019/01/10 00:00 [accepted] PHST- 2019/02/26 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/02/26 06:00 [entrez] AID - S1558-7673(19)30018-7 [pii] AID - 10.1016/j.clgc.2019.01.007 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Jun;17(3):e461-e471. doi: 10.1016/j.clgc.2019.01.007. Epub 2019 Jan 19. PMID- 30786690 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20190522 IS - 1233-9687 (Print) IS - 1233-9687 (Linking) VI - 69 IP - 4 DP - 2018 TI - HIF-1alpha expression is inversely associated with tumor stage, grade and microvessel density in urothelial bladder carcinoma. PG - 395-404 LID - 34935 [pii] LID - 10.5114/pjp.2018.81699 [doi] AB - Urothelial bladder carcinoma (UBC) is the most common urinary tract malignancy. The most important histopathological factors affecting prognosis are cancer stage and grade. Studies show that microvessel density (MVD) reflecting angiogenesis is also associated with clinicopathological features and affects the outcome in UBC. One of the most important regulators of angiogenesis is hypoxia inducible factor 1 (HIF-1). Previous reports describing expression of the HIF-1alpha subunit in UBC showed unclear and inconsistent results. Our study attempted do evaluate the association between HIF-1alpha expression and tumor stage, grade, lymph nodes status and MVD in UBC. We performed immunohistochemical staining in 99 UBC cases, including 38 non-muscle invasive (NMIBC) and 61 muscle invasive tumors (MIBC). We observed inverse relationships between HIF-1alpha immunoreactivity score (IRS) and tumor stage, grade and MVD. Significantly lower HIF-1alpha IRS values were observed in MIBC and high grade cancers. We found a significant negative correlation between HIF-1alpha IRS and MVD. These results suggest that HIF-1alpha pathway is not involved in UBC growth and progression, and that angiogenesis in high grade MIBC is not regulated by HIF-1. Our findings contradict previous reports regarding HIF-1alpha, MVD and UBC which shows the necessity of additional molecular studies in this field. FAU - Fus, Lukasz P AU - Fus LP FAU - Pihowicz, Pawel AU - Pihowicz P FAU - Koperski, Lukasz AU - Koperski L FAU - Marczewska, Janina M AU - Marczewska JM FAU - Gornicka, Barbara AU - Gornicka B LA - eng PT - Journal Article PL - Poland TA - Pol J Pathol JT - Polish journal of pathology : official journal of the Polish Society of Pathologists JID - 9437432 RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) SB - IM MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics MH - Microvessels/pathology MH - Neovascularization, Pathologic/*pathology MH - Urinary Bladder Neoplasms/*genetics OTO - NOTNLM OT - hypoxia-inducible factor 1 OT - microvessel density OT - urothelial bladder cancer OT - angiogenesis EDAT- 2019/02/23 06:00 MHDA- 2019/05/23 06:00 CRDT- 2019/02/22 06:00 PHST- 2019/02/22 06:00 [entrez] PHST- 2019/02/23 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] AID - 34935 [pii] AID - 10.5114/pjp.2018.81699 [doi] PST - ppublish SO - Pol J Pathol. 2018;69(4):395-404. doi: 10.5114/pjp.2018.81699. PMID- 30785915 OWN - NLM STAT- MEDLINE DCOM- 20191029 LR - 20260226 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 14 IP - 2 DP - 2019 TI - Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients. PG - e0210976 LID - 10.1371/journal.pone.0210976 [doi] LID - e0210976 AB - Currently in patients with bladder cancer, various clinical evaluations (imaging, operative findings at transurethral resection and radical cystectomy, pathology) are collectively used to determine disease status and prognosis, and recommend neoadjuvant, definitive and adjuvant treatments. We analyze the predictive power of these measurements in forecasting two key long-term outcomes following radical cystectomy, i.e., cancer recurrence and survival. Information theory and machine learning algorithms are employed to create predictive models using a large prospective, continuously collected, temporally resolved, primary bladder cancer dataset comprised of 3503 patients (1971-2016). Patient recurrence and survival one, three, and five years after cystectomy can be predicted with greater than 70% sensitivity and specificity. Such predictions may inform patient monitoring schedules and post-cystectomy treatments. The machine learning models provide a benchmark for predicting oncologic outcomes in patients undergoing radical cystectomy and highlight opportunities for improving care using optimal preoperative and operative data collection. FAU - Hasnain, Zaki AU - Hasnain Z AD - Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. FAU - Mason, Jeremy AU - Mason J AD - Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. FAU - Gill, Karanvir AU - Gill K AD - Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. FAU - Miranda, Gus AU - Miranda G AUID- ORCID: 0000-0001-6110-9024 AD - USC Institute of Urology, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA, United States of America. FAU - Gill, Inderbir S AU - Gill IS AD - USC Institute of Urology, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA, United States of America. FAU - Kuhn, Peter AU - Kuhn P AUID- ORCID: 0000-0003-2629-4505 AD - Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. AD - Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. AD - USC Institute of Urology, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA, United States of America. AD - Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. AD - Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA, United States of America. FAU - Newton, Paul K AU - Newton PK AD - Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. AD - Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA, United States of America. AD - Department of Mathematics, University of Southern California, University Park Campus, Los Angeles, CA, United States of America. LA - eng GR - HHSN261201500003C/CA/NCI NIH HHS/United States GR - HHSN261201500003I/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20190220 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Aged, 80 and over MH - *Cystectomy MH - *Databases, Factual MH - Disease-Free Survival MH - Female MH - Humans MH - *Machine Learning MH - Male MH - Middle Aged MH - *Models, Biological MH - Survival Rate MH - *Urinary Bladder Neoplasms/mortality/surgery PMC - PMC6382101 COIS- The authors have declared that no competing interests exist. EDAT- 2019/02/21 06:00 MHDA- 2019/10/30 06:00 PMCR- 2019/02/20 CRDT- 2019/02/21 06:00 PHST- 2018/07/27 00:00 [received] PHST- 2019/01/04 00:00 [accepted] PHST- 2019/02/21 06:00 [entrez] PHST- 2019/02/21 06:00 [pubmed] PHST- 2019/10/30 06:00 [medline] PHST- 2019/02/20 00:00 [pmc-release] AID - PONE-D-18-22319 [pii] AID - 10.1371/journal.pone.0210976 [doi] PST - epublish SO - PLoS One. 2019 Feb 20;14(2):e0210976. doi: 10.1371/journal.pone.0210976. eCollection 2019. PMID- 30785697 OWN - NLM STAT- MEDLINE DCOM- 20190726 LR - 20200225 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 45 IP - 2 DP - 2019 Mar-Apr TI - Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? PG - 315-324 LID - 10.1590/S1677-5538.IBJU.2018.0249 [doi] AB - OBJECTIVES: To evaluate the neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for response of high risk non muscle invasive bladder cancer (HRNMIBC) treated with BCG therapy. MATERIALS AND METHODS: Between March 2010 and February 2014 in a tertiary center 100 consecutive patients with newly diagnosed HRNMIBC were retrospectively analyzed. Patients were divided according to NLR value: 46 patients with NLR value less than 3 (NLR < 3 group), and 54 patients with NLR value more than 3 (NLR >/= 3 group). At the end of follow-up 52 patients were high grade disease free (BCG-responder group) and 48 patients underwent radical cystectomy for high grade recurrence or progression to muscle invasive disease (BCG non-responder group). The average follow-up was 60 months. INTERVENTION: analysis and correlation of preoperative NLR value with response to BCG in terms of recurrence and progression. RESULTS: The optimal cut-off for NLR was >/= 3 according to the receiver operating characteristics analysis (AUC 0.760, 95% CI, 0.669-0.850). Mean NLR value was 3.65 +/- 1.16 in BCG non-responder group and 2.61 +/- 0.77 in BCG responder group (p = 0.01). NLR correlated with recurrence (r = 0.55, p = 0.01) and progression risk scores (r = 0.49, p = 0.01). In multivariate analysis, NLR (p = 0.02) and EORTC recurrence risk groups (p = 0.01) were associated to the primary endpoint. The log-rank test showed statistically significant difference between NLR < 3 and NLR >/= 3 curves (p < 0.05). CONCLUSIONS: NLR value preoperatively evaluated could be a useful tool to predict BCG response of HRNMIBC. These results could lead to the development of prospective studies to assess the real prognostic value of NLR in HRNMIBC. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Racioppi, Marco AU - Racioppi M AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. FAU - Ragonese, Mauro AU - Ragonese M AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. FAU - Palermo, Giuseppe AU - Palermo G AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. FAU - Sacco, Emilio AU - Sacco E AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. FAU - Bassi, Pier Francesco AU - Bassi PF AD - Department of Urology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Universita Cattolica del Sacro Cuore di Roma. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/blood MH - Carcinoma, Transitional Cell/*drug therapy/pathology/surgery MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Lymphocyte Count MH - Lymphocytes/*pathology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/surgery MH - Neoplasm Staging MH - Neutrophils/*pathology MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery PMC - PMC6541147 OTO - NOTNLM OT - Lymphocytes OT - Neutrophils OT - Urinary Bladder Neoplasms COIS- None declared. EDAT- 2019/02/21 06:00 MHDA- 2019/07/28 06:00 PMCR- 2019/04/01 CRDT- 2019/02/21 06:00 PHST- 2018/04/04 00:00 [received] PHST- 2018/09/29 00:00 [accepted] PHST- 2019/02/21 06:00 [pubmed] PHST- 2019/07/28 06:00 [medline] PHST- 2019/02/21 06:00 [entrez] PHST- 2019/04/01 00:00 [pmc-release] AID - IBJU20180249 [pii] AID - S1677-5538.IBJU.2018.0249 [pii] AID - 10.1590/S1677-5538.IBJU.2018.0249 [doi] PST - ppublish SO - Int Braz J Urol. 2019 Mar-Apr;45(2):315-324. doi: 10.1590/S1677-5538.IBJU.2018.0249. PMID- 30769831 OWN - NLM STAT- MEDLINE DCOM- 20190604 LR - 20200225 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 20 IP - 4 DP - 2019 Feb 14 TI - Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. LID - 10.3390/ijms20040821 [doi] LID - 821 AB - Diagnostic methods currently used for bladder cancer are cystoscopy and urine cytology. Cystoscopy is an invasive tool and has low sensitivity for carcinoma in situ. Urine cytology is non-invasive, is a low-cost method, and has a high specificity but low sensitivity for low-grade urothelial tumors. Despite the search for urinary biomarkers for the early and non-invasive detection of bladder cancer, no biomarkers are used at the present in daily clinical practice. Extracellular vesicles (EVs) have been recently studied as a promising source of biomarkers because of their role in intercellular communication and tumor progression. In this review, we give an overview of Food and Drug Administration (FDA)-approved urine tests to detect bladder cancer and why their use is not widespread in clinical practice. We also include non-FDA approved urinary biomarkers in this review. We describe the role of EVs in bladder cancer and their possible role as biomarkers for the diagnosis and follow-up of bladder cancer patients. We review recently discovered EV-derived biomarkers for the diagnosis of bladder cancer. FAU - Oeyen, Eline AU - Oeyen E AD - Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium. eline.oeyen@vito.be. AD - Centre for Proteomics (CFP), University of Antwerp, 2020 Antwerp, Belgium. eline.oeyen@vito.be. FAU - Hoekx, Lucien AU - Hoekx L AD - Urology Department, Antwerp University Hospital (UZA), 2650 Edegem, Belgium. lucien.hoekx@uantwerpen.be. FAU - De Wachter, Stefan AU - De Wachter S AUID- ORCID: 0000-0002-6183-9251 AD - Urology Department, Antwerp University Hospital (UZA), 2650 Edegem, Belgium. stefan.dewachter@uantwerpen.be. FAU - Baldewijns, Marcella AU - Baldewijns M AD - Pathological Anatomy Department, Antwerp University Hospital (UZA), 2650 Edegem, Belgium. marcella.baldewijns@uzleuven.be. FAU - Ameye, Filip AU - Ameye F AD - Urology Department, General Hospital Maria Middelares Ghent, 9000 Ghent, Belgium. Filip.Ameye@AZMMSJ.BE. FAU - Mertens, Inge AU - Mertens I AUID- ORCID: 0000-0002-4888-3485 AD - Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium. Inge.Mertens@vito.be. AD - Centre for Proteomics (CFP), University of Antwerp, 2020 Antwerp, Belgium. Inge.Mertens@vito.be. LA - eng PT - Journal Article PT - Review DEP - 20190214 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/genetics/*urine MH - Cystoscopy MH - Cytodiagnosis/trends MH - Extracellular Vesicles/*genetics MH - Humans MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/genetics/pathology/*urine PMC - PMC6412916 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - extracellular vesicles OT - urine COIS- The authors declare no conflict of interest. The funders had no role in the writing of the manuscript. EDAT- 2019/02/17 06:00 MHDA- 2019/06/05 06:00 PMCR- 2019/02/01 CRDT- 2019/02/17 06:00 PHST- 2019/01/21 00:00 [received] PHST- 2019/02/04 00:00 [revised] PHST- 2019/02/08 00:00 [accepted] PHST- 2019/02/17 06:00 [entrez] PHST- 2019/02/17 06:00 [pubmed] PHST- 2019/06/05 06:00 [medline] PHST- 2019/02/01 00:00 [pmc-release] AID - ijms20040821 [pii] AID - ijms-20-00821 [pii] AID - 10.3390/ijms20040821 [doi] PST - epublish SO - Int J Mol Sci. 2019 Feb 14;20(4):821. doi: 10.3390/ijms20040821. PMID- 30764592 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20240730 IS - 1303-6165 (Electronic) IS - 1300-0144 (Print) IS - 1300-0144 (Linking) VI - 49 IP - 1 DP - 2019 Feb 11 TI - 8-armed octopus: Evaluation of clinicopathologic prognostic factors of urothelial carcinoma of the upper urinary system. PG - 153-161 LID - 10.3906/sag-1805-51 [doi] AB - BACKGROUND/AIM: This study was designed to determine the characteristic features of upper urinary system urothelial carcinomas (UUSUCs) and to evaluate the clinicopathological parameters associated with prognosis. MATERIALS AND METHODS: A total of 74 cases of UUSUC were included, from three different centers. Demographic data and histopathological features such as tumor localization, concomitant tumor in the urinary system, distant metastasis with overall survival and disease-free survival obtained from the hospital records were evaluated retrospectively. Histopathologic prognostic features such as grade, perineural invasion, lymphovascular invasion, tumor necrosis, and surgical margin status were also evaluated. RESULTS: Seventy cases (94.6%) underwent open nephroureterectomy whereas 4 cases (5.4%) had laparoscopic nefroureterectomy. Thirty-eight (51.4%) cases were located in the pelvis, 7 (9.5%) in the ureter, 29 (39.2%) both in the pelvis and ureter. Fifty-six (75.7%) cases were alive; however, 18 (24.3%) patients were found to be dead. pTa, pT1, pT2, pT3, and pT4 tumors were reported in 16 (21.6%), 13 (17.6%), 4 (5.4%), 28 (37.8%), and 13 (17.6%) patients, respectively. Histopathologically, 17 cases (23%) were low-grade, 57 cases (77%) were high-grade. Statistically significant correlation was observed between overall survival and lymph node metastasis, distant metastasis, tumor necrosis, and differentiation by univariate analysis. Only distant metastasis was statistically associated with overall survival by multivariate analysis. We found no significant relationship between disease-free survival and all parameters. CONCLUSION: Differentiation and necrosis of tumor, lymph node involvement, and presence of distant metastasis is associated with the overall survival of urothelial carcinoma of the upper urinary system. FAU - Ekmekci, Sumeyye AU - Ekmekci S AUID- ORCID: 0000-0003-1607-500X FAU - Kucuk, Ulku AU - Kucuk U AUID- ORCID: 0000-0003-2916-0123 FAU - Dere, Yelda AU - Dere Y AUID- ORCID: 0000-0003-0238-2236 FAU - Cakir, Ebru AU - Cakir E AUID- ORCID: 0000-0001-7959-3491 FAU - Sayar, Hatice Ceren AU - Sayar HC AUID- ORCID: 0000-0002-9590-4699 FAU - Ergani, Batuhan AU - Ergani B AUID- ORCID: 0000-0002-4667-855X FAU - Cakmak, Ozgur AU - Cakmak O AUID- ORCID: 0000-0002-4618-9465 FAU - Bozkurt, Ozan AU - Bozkurt O AUID- ORCID: 0000-0002-7662-0092 FAU - Yorukoglu, Kutsal AU - Yorukoglu K AUID- ORCID: 0000-0002-4099-0905 LA - eng PT - Journal Article DEP - 20190211 PL - Turkey TA - Turk J Med Sci JT - Turkish journal of medical sciences JID - 9441758 SB - IM MH - *Carcinoma, Transitional Cell/diagnosis/mortality/pathology/physiopathology MH - Correlation of Data MH - Female MH - Humans MH - *Kidney Neoplasms/diagnosis/mortality/pathology/physiopathology MH - Lymphatic Metastasis/*diagnosis MH - Male MH - Margins of Excision MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Nephroureterectomy/adverse effects/methods/statistics & numerical data MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Turkey/epidemiology MH - *Ureteral Neoplasms/diagnosis/mortality/pathology/physiopathology MH - Urothelium/pathology PMC - PMC7350879 OTO - NOTNLM OT - *Prognostic factors OT - *upper tract urothelial carcinomas OT - *upper urinary tract OT - *urothelial carcinomas COIS- CONFLICT OF INTEREST: none declared EDAT- 2019/02/16 06:00 MHDA- 2019/03/15 06:00 PMCR- 2019/02/11 CRDT- 2019/02/16 06:00 PHST- 2019/02/16 06:00 [entrez] PHST- 2019/02/16 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2019/02/11 00:00 [pmc-release] AID - 10.3906/sag-1805-51 [doi] PST - epublish SO - Turk J Med Sci. 2019 Feb 11;49(1):153-161. doi: 10.3906/sag-1805-51. PMID- 30763230 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221110 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 13 IP - 9 DP - 2019 Sep TI - Are there differences between de novo and secondary upper tract urothelial carcinoma tumours? PG - E292-E299 LID - 10.5489/cuaj.5595 [doi] AB - INTRODUCTION: Upper tract urothelial carcinoma (UTUC) accounts for <5% of all urothelial cancers. We aimed to ascertain the clinical differences between UTUC tumours presenting de novo (DnUTUC) and those presenting secondary (SUTUC) following a bladder cancer diagnosis. METHODS: Our institutional database was queried for all UTUC patients who were surgically treated with radical nephroureterectomy or ureterectomy between 2003 and 2017. Bladder recurrence and cancer-specific mortality were compared. To reduce the possible bias due to confounding variables obtained from a simple comparison of outcomes, DnUTUC patients were matched (for age, gender, tumour location, type of surgery, grade, TNM staging, presence of carcinoma in situ, and lymphovascular invasion) with propensity score to SUTUC patients. Bladder recurrence and cancer-specific mortality were assessed with Cox proportional hazards model. RESULTS: A total of 117 UTUC patients were identified: 80 with DnUTUC (68.4%) and 37 with SUTUC (31.6%). A greater proportion of males with SUTUC was demonstrated (89.2% vs. 68.8; p=0.02). In both groups, 67.5% of patients had high-grade disease, but SUTUC demonstrated a higher carcinoma in situ rate (43.2% vs. 25%; p=0.047). Univariate analysis demonstrated that the five-year bladder recurrence rate was trending to be higher in SUTUC (65.3% vs. 20.5%; p=0.099). In the Cox model, however, it was associated with increased bladder recurrence (hazard ratio [HR] 3.69; 95% confidence interval [CI] 1.68-8.09; p=0.001). Although univariate analysis demonstrated that SUTUC patients were more likely to die of their disease (30.6% vs. 9%; p=0.009), the multivariable Cox model did not demonstrate this association. The limitations of this study include its retrospective, single-centre design and relatively small cohort of patients. CONCLUSIONS: In this hypothesis-generating study, some evidence suggests that further research is needed to delineate differences between SUTUC and DnUTUC. FAU - Goldberg, Hanan AU - Goldberg H AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Cheung, Douglas C AU - Cheung DC AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Chandrasekar, Thenappan AU - Chandrasekar T AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Klaassen, Zachary AU - Klaassen Z AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Sayyid, Rashid AU - Sayyid R AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Evans, Andrew AU - Evans A AD - Pathology Department, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Masoomian, Mehdi AU - Masoomian M AD - Pathology Department, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Bapat, Bharati AU - Bapat B AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, and Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada. FAU - van der Kwast, Theodorus AU - van der Kwast T AD - Pathology Department, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Hamilton, Robert J AU - Hamilton RJ AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Zlotta, Alexandre AU - Zlotta A AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. FAU - Fleshner, Neil AU - Fleshner N AD - Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and the University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 CIN - J Urol. 2020 Feb;203(2):249-250. doi: 10.1097/01.JU.0000614728.51095.46. PMID: 31710533 PMC - PMC6754256 COIS- Competing interests: The authors report no competing personal or financial interests related to this work. EDAT- 2019/02/15 06:00 MHDA- 2019/02/15 06:01 PMCR- 2019/09/01 CRDT- 2019/02/15 06:00 PHST- 2019/02/15 06:00 [entrez] PHST- 2019/02/15 06:00 [pubmed] PHST- 2019/02/15 06:01 [medline] PHST- 2019/09/01 00:00 [pmc-release] AID - cuaj.5595 [pii] AID - cuaj-9-e292 [pii] AID - 10.5489/cuaj.5595 [doi] PST - ppublish SO - Can Urol Assoc J. 2019 Sep;13(9):E292-E299. doi: 10.5489/cuaj.5595. PMID- 30762807 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20241121 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 7 DP - 2019 Feb TI - Surveillance of non-muscle invasive bladder cancer using fluorescence in situ hybridization: Protocol for a systematic review and meta-analysis. PG - e14573 LID - 10.1097/MD.0000000000014573 [doi] LID - e14573 AB - BACKGROUND: To evaluate the diagnostic effectiveness and predictive value of fluorescence in situ hybridization (FISH) in the surveillance of non-muscle invasive bladder cancer (NMIBC). METHODS: PubMed/Medline, EMBASE, Web of Science, Ovid, Web of Knowledge, and Cochrane Library will be searched for studies related to the topic. The identification, inclusion, and exclusion flowcharts will be conducted according to preferred reporting items for systematic reviews and meta-analysis guidelines. The identified reports will be critically appraised according to the Newcastle-Ottawa scale, quality assessment of diagnostic accuracy studies-2 and standards for reporting of diagnostic accuracy 2015. Forest plots will be generated to display hazard ratios, sensitivities, and specificities. Pooled estimates with their 95% confidence intervals will be calculated using the bivariate model, the hierarchical summary receiver operating characteristic model and a fixed- or random-effects model. RESULTS: This study will provide evidence and data to form a comprehensive understanding of the value of FISH in the surveillance of NMIBC. CONCLUSION: The diagnostic efficacy of FISH will be affected by post-therapy factors. However, FISH still could facilitate the surveillance of NMIBC owing to its non-invasive feature. This study will improve the clinical decision-making and enlighten the future research of NMIBC. FAU - Lin, Tianhai AU - Lin T AD - Department of Urology, Institute of Urology. AD - Key Laboratory of Transplant Engineering and Immunology, West China Hospital. FAU - Jin, Hongyu AU - Jin H AD - West China School of Medicine, Sichuan University, Chengdu, Sichuan, China. FAU - Gong, Lina AU - Gong L AD - Department of Urology, Institute of Urology. FAU - Yu, Ruichao AU - Yu R AD - Department of Pathophysiology and Molecular Pharmacology, Joslin Diabetes Center. FAU - Sun, Sheng AU - Sun S AD - Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. FAU - Yang, Lu AU - Yang L AD - Department of Urology, Institute of Urology. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, Institute of Urology. FAU - Han, Ping AU - Han P AD - Department of Urology, Institute of Urology. FAU - Cheng, Jingqiu AU - Cheng J AD - Key Laboratory of Transplant Engineering and Immunology, West China Hospital. FAU - Liu, Liangren AU - Liu L AD - Department of Urology, Institute of Urology. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, Institute of Urology. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Disease Progression MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Research Design MH - Survival Analysis MH - Urinary Bladder Neoplasms/*pathology MH - Meta-Analysis as Topic MH - Systematic Reviews as Topic PMC - PMC6408111 COIS- The authors have no conflicts of interest to disclose. EDAT- 2019/02/15 06:00 MHDA- 2019/03/15 06:00 PMCR- 2019/02/15 CRDT- 2019/02/15 06:00 PHST- 2019/02/15 06:00 [entrez] PHST- 2019/02/15 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2019/02/15 00:00 [pmc-release] AID - 00005792-201902150-00084 [pii] AID - MD-D-18-09919 [pii] AID - 10.1097/MD.0000000000014573 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Feb;98(7):e14573. doi: 10.1097/MD.0000000000014573. PMID- 30755233 OWN - NLM STAT- MEDLINE DCOM- 20190319 LR - 20200225 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 17 IP - 1 DP - 2019 Feb 12 TI - The role of oncostatin M receptor gene polymorphisms in bladder cancer. PG - 30 LID - 10.1186/s12957-018-1555-7 [doi] LID - 30 AB - BACKGROUND: Oncostatin M receptor (OSMR) represents a part of the interleukin-six (IL6) cytokine group that was discovered recently to be closely associated with cell's growth and differentiation, inflammation, and enhancement of metastatic capacity. A comprehensive study suggests a close relationship between OSMR and papillary thyroid cancer, colorectal cancer, breast cancer, and other tumors. However, the relationship between OSMR and bladder cancer has yet to be determined. METHODS: Three hundred six patients (including 142 patients with muscle-invasive bladder cancer and 164 patients with non-muscle-invasive bladder cancer) as well as 459 normal controls were included in this study. Two tag SNPs of OSMR, rs2278329, and rs2292016 were genotyped by TaqMan(R) SNP Genotyping Assay method and then the associations with bladder cancer were analyzed, as well as risk factors and prognosis. RESULTS: Patients with bladder cancer and controls did not differ significantly in terms of genotype frequencies and allele frequency distribution of rs2278329 (P = 0.77, OR = 0.97) and rs2292016 (P = 0.39, OR = 1.20) respectively. For rs2278329, no differences were found in terms of risk factors in stratified analyses. However, rs2292016 was associated with recurrence and tumor grade. GT/TT was found to increase the risk of relapse compared to the patients without allele T (GG genotype) (P = 0.016, OR = 1.878, 95% CI = 1.12-3.14) with the T allele of rs2292016 being a risk factor for recurrence (P = 0.032, OR = 0.67, 95% CI = 0.47-0.97). Besides, patients with GT genotype often present with high-grade bladder cancer (P = 0.003, OR = 2.33, 95% CI = 1.32-4.17). Multiple Cox regression analysis showed that rs2278329 and rs2292016 were related to the recurrence-free survival and overall survival in non muscle invasive bladder cancer (NMIBC) patients. For rs2278329, GA genotype could affect recurrence-free survival (P = 0.01, OR = 2.16, 95% CI = 1.17-3.98). For rs2292016, TT/GT genotype had a lower risk of death compared with GG homozygote genotype, and T was a protective factor for overall survival in bladder cancer (P = 0.029, OR = 0.22, 95% CI = 0.06-0.86). CONCLUSIONS: OSMR genotype frequencies were found to be associated with higher recurrence in bladder cancer, and it may serve as a biomarker candidate gene to predict prognosis of this disease. Further validation of OSMR as biomarker is required. FAU - Deng, Shi AU - Deng S AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37# Guoxuexiang Street, Chengdu, 610041, People's Republic of China. FAU - He, Sheng Yin AU - He SY AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37# Guoxuexiang Street, Chengdu, 610041, People's Republic of China. FAU - Zhao, Pan AU - Zhao P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37# Guoxuexiang Street, Chengdu, 610041, People's Republic of China. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37# Guoxuexiang Street, Chengdu, 610041, People's Republic of China. zhangpenghuaxi@163.com. LA - eng PT - Journal Article DEP - 20190212 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 RN - 0 (Biomarkers, Tumor) RN - 0 (OSMR protein, human) RN - 0 (Oncostatin M Receptor beta Subunit) SB - IM MH - Aged MH - Biomarkers, Tumor/*genetics MH - China/epidemiology MH - Disease-Free Survival MH - Female MH - Gene Frequency MH - *Genetic Predisposition to Disease MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*genetics/mortality/pathology MH - Oncostatin M Receptor beta Subunit/*genetics MH - Polymorphism, Single Nucleotide MH - Prognosis MH - Survival Analysis MH - Urinary Bladder MH - Urinary Bladder Neoplasms/*genetics/mortality/pathology PMC - PMC6371456 OTO - NOTNLM OT - Bladder cancer OT - Cancer risk OT - Oncostatin M receptor OT - Polymorphisms COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was performed in compliance with the principles of good clinical practice outlined in the Declaration of Helsinki and federal guidelines, and approval from the West China Hospital Ethics Committee was acquired. Informed consent was obtained from each participant in the study. CONSENT FOR PUBLICATION: Consent for publication was obtained from every individual whose data are included in this manuscript. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/02/14 06:00 MHDA- 2019/03/20 06:00 PMCR- 2019/02/12 CRDT- 2019/02/14 06:00 PHST- 2018/09/05 00:00 [received] PHST- 2018/12/27 00:00 [accepted] PHST- 2019/02/14 06:00 [entrez] PHST- 2019/02/14 06:00 [pubmed] PHST- 2019/03/20 06:00 [medline] PHST- 2019/02/12 00:00 [pmc-release] AID - 10.1186/s12957-018-1555-7 [pii] AID - 1555 [pii] AID - 10.1186/s12957-018-1555-7 [doi] PST - epublish SO - World J Surg Oncol. 2019 Feb 12;17(1):30. doi: 10.1186/s12957-018-1555-7. PMID- 30728859 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 11 DP - 2019 Jan-Dec TI - A review of avelumab in locally advanced and metastatic bladder cancer. PG - 1756287218823485 LID - 10.1177/1756287218823485 [doi] LID - 1756287218823485 AB - Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Guerin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer. FAU - Rao, Arpit AU - Rao A AD - University of Minnesota Medical School, MMC480, 425 Delaware St. SE, Minneapolis, MN 55455, USA. FAU - Patel, Manish R AU - Patel MR AUID- ORCID: 0000-0003-2752-945X AD - University of Minnesota, Minneapolis, MN, USA. LA - eng PT - Journal Article PT - Review DEP - 20190130 PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC6354303 OTO - NOTNLM OT - PD-L1 OT - avelumab OT - immune checkpoint OT - urothelial cancer COIS- Conflict of interest statement: The authors declare that there is no conflict of interest. EDAT- 2019/02/08 06:00 MHDA- 2019/02/08 06:01 PMCR- 2019/01/30 CRDT- 2019/02/08 06:00 PHST- 2018/08/20 00:00 [received] PHST- 2018/12/03 00:00 [accepted] PHST- 2019/02/08 06:00 [entrez] PHST- 2019/02/08 06:00 [pubmed] PHST- 2019/02/08 06:01 [medline] PHST- 2019/01/30 00:00 [pmc-release] AID - 10.1177_1756287218823485 [pii] AID - 10.1177/1756287218823485 [doi] PST - epublish SO - Ther Adv Urol. 2019 Jan 30;11:1756287218823485. doi: 10.1177/1756287218823485. eCollection 2019 Jan-Dec. PMID- 30719704 OWN - NLM STAT- MEDLINE DCOM- 20200413 LR - 20240210 IS - 1096-9896 (Electronic) IS - 0022-3417 (Linking) VI - 248 IP - 2 DP - 2019 Jun TI - Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. PG - 230-242 LID - 10.1002/path.5250 [doi] AB - We present an evolutionary analysis of the relative time of genetic events underlying tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using multiregional whole-exome sequencing. We timed bladder cancer drivers, mutational signatures, ploidy and copy number alterations, provided evidence for kataegis and correlated alterations with tumour areas and histological phenotypes. We found that: (1) heterogeneous tumour areas/phenotypes had distinct driver mutations, (2) papillary-invasive tumours divided early into two parallel evolving branches and (3) parallel evolution of subclonal driver mutations occurred. APOBEC mutational signatures were found to be very early events, active in carcinoma in situ, and often remained a dominant source of mutations throughout tumour evolution. Genetic progression from carcinoma in situ followed driver mutations in NA13/FAT1, ZBTB7B or EP300/USP28/KMT2D. Our results point towards a more diverse mutational trajectory of bladder tumorigenesis and underpin the importance of timing of mutational processes and clonal architecture in bladder cancer as important aspects for successful prognostication and therapy. Copyright (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. CI - Copyright (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. FAU - Heide, Timon AU - Heide T AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Maurer, Angela AU - Maurer A AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Eipel, Monika AU - Eipel M AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Knoll, Katrin AU - Knoll K AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Geelvink, Mirja AU - Geelvink M AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Veeck, Juergen AU - Veeck J AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - Knuechel, Ruth AU - Knuechel R AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. FAU - van Essen, Julius AU - van Essen J AD - Department of Urology, University Hospital RWTH Aachen University, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology University Erlangen-Nuernberg, Erlangen, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology University Erlangen-Nuernberg, Erlangen, Germany. FAU - Altmueller, Janine AU - Altmueller J AD - Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany. AD - Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. FAU - Graham, Trevor A AU - Graham TA AUID- ORCID: 0000-0001-9582-1597 AD - Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. FAU - Gaisa, Nadine T AU - Gaisa NT AUID- ORCID: 0000-0002-4762-3964 AD - Institute of Pathology RWTH Aachen University, Aachen, Germany. LA - eng GR - 19771/CRUK_/Cancer Research UK/United Kingdom GR - A19771/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190318 PL - England TA - J Pathol JT - The Journal of pathology JID - 0204634 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Carcinoma/drug therapy/*genetics/pathology/surgery MH - Carcinoma in Situ/drug therapy/*genetics/pathology/surgery MH - Cystectomy MH - DNA Copy Number Variations MH - Disease Progression MH - Female MH - Gene Dosage MH - *Genetic Heterogeneity MH - Genetic Predisposition to Disease MH - Humans MH - Male MH - Middle Aged MH - Molecular Targeted Therapy MH - Mutation MH - Neoplasm Invasiveness MH - Phenotype MH - Ploidies MH - Precision Medicine MH - Time Factors MH - *Transcriptome MH - Urinary Bladder Neoplasms/drug therapy/*genetics/pathology/surgery MH - *Exome Sequencing OTO - NOTNLM OT - bladder cancer OT - kataegis OT - phylogenetic analysis OT - tumour evolution OT - tumour heterogeneity OT - tumour phenotype EDAT- 2019/02/06 06:00 MHDA- 2020/04/14 06:00 CRDT- 2019/02/06 06:00 PHST- 2018/04/14 00:00 [received] PHST- 2019/01/27 00:00 [revised] PHST- 2019/01/30 00:00 [accepted] PHST- 2019/02/06 06:00 [pubmed] PHST- 2020/04/14 06:00 [medline] PHST- 2019/02/06 06:00 [entrez] AID - 10.1002/path.5250 [doi] PST - ppublish SO - J Pathol. 2019 Jun;248(2):230-242. doi: 10.1002/path.5250. Epub 2019 Mar 18. PMID- 30719635 OWN - NLM STAT- MEDLINE DCOM- 20190708 LR - 20200225 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 26 IP - 4 DP - 2019 Apr TI - Probe-Based Confocal Laser Endomicroscopy During Transurethral Resection of Bladder Tumors Improves the Diagnostic Accuracy and Therapeutic Efficacy. PG - 1158-1165 LID - 10.1245/s10434-019-07200-6 [doi] AB - PURPOSE: This study was designed to assess the diagnostic accuracy and therapeutic efficacy of probe-based confocal laser endomicroscopy (pCLE), which provides real-time, in vivo histological information during transurethral resection of bladder tumors. METHODS: We performed a prospective study between August 2013 and August 2014. pCLE was performed on a total of 119 lesions in 75 patients. We analyzed the diagnostic accuracy of pCLE by comparing the confocal image reports with the pathology reports of surgical specimen. Confocal images were interpreted by a single urologist blinded to the pathology reports. The therapeutic efficacy was analyzed by comparing the outcomes in pCLE and non-pCLE groups. RESULTS: In a total of 119 lesions, 23 were benign and 96 were malignant. The detection accuracy for malignant lesions with pCLE was determined with a sensitivity and a positive predictive value (PPV) of 91.7% and 93.6%, respectively. For high-grade versus low-grade bladder cancer, sensitivity and PPV of pCLE were 94.5% and 89.7%, respectively. Distinguishing carcinoma in situ from inflammatory lesions also was accurate with sensitivity, specificity, and PPV of 71.4%, 81.3%, and 83.3%, respectively. The Kaplan-Meier curves revealed that the recurrence-free survival rate was significantly higher in the pCLE group than in the non-pCLE group (p = 0.031). CONCLUSIONS: Probe-based confocal laser endomicroscopy is a promising method to provide the surgeon during the transurethral resection of a bladder tumor with real-time tumor histology, regardless of the tumor's gross appearance. Furthermore, it also may improve the therapeutic efficacy with longer recurrence-free periods. FAU - Lee, Jongsoo AU - Lee J AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Jeh, Seong Uk AU - Jeh SU AD - Department of Urology, Gyeong-Sang National University College of Medicine, Jinju, Korea. FAU - Koh, Dong Hoon AU - Koh DH AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Chung, Doo Yong AU - Chung DY AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Kim, Min Seok AU - Kim MS AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Goh, Hyeok Jun AU - Goh HJ AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Lee, Joo Yong AU - Lee JY AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. FAU - Choi, Young Deuk AU - Choi YD AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. youngd74@yuhs.ac. LA - eng GR - 6-2014-0033/Yonsei University College of Medicine/ PT - Journal Article DEP - 20190204 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Adult MH - Aged MH - Endoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Microscopy, Confocal/instrumentation/*methods MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology/surgery MH - Urologic Surgical Procedures/*methods PMC - PMC6399171 EDAT- 2019/02/06 06:00 MHDA- 2019/07/10 06:00 PMCR- 2019/02/04 CRDT- 2019/02/06 06:00 PHST- 2018/10/05 00:00 [received] PHST- 2019/02/06 06:00 [pubmed] PHST- 2019/07/10 06:00 [medline] PHST- 2019/02/06 06:00 [entrez] PHST- 2019/02/04 00:00 [pmc-release] AID - 10.1245/s10434-019-07200-6 [pii] AID - 7200 [pii] AID - 10.1245/s10434-019-07200-6 [doi] PST - ppublish SO - Ann Surg Oncol. 2019 Apr;26(4):1158-1165. doi: 10.1245/s10434-019-07200-6. Epub 2019 Feb 4. PMID- 30712313 OWN - NLM STAT- MEDLINE DCOM- 20200210 LR - 20200210 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 124 IP - 1 DP - 2019 Jul TI - Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study. PG - 116-123 LID - 10.1111/bju.14697 [doi] AB - OBJECTIVES: To compare overall (OS), cancer-specific (CSS), recurrence-free survival (RFS) and postoperative renal function amongst patients with upper tract urothelial carcinoma (UTUC) of the distal (lower lumbar and pelvic) ureter, electively treated with segmental resection and termino-terminal anastomosis (TT) vs bladder cuff removal and ureteric re-implantation (RR). PATIENTS AND METHODS: A multicentre retrospective study, including 84 patients diagnosed with UTUC of the distal ureter and treated with TT or RR, is presented. The primary endpoint was to compare TT and RR in terms of OS, CSS and RFS. As a secondary outcome, we compared the postoperative creatinine values as an index of renal function in the two groups. RESULTS: Of 521 patients with UTUC, 65 (77.4%) and 19 (22.6%) patients underwent RR and TT, respectively. Pre- and postoperative characteristics were not statistically different between the two groups. The median follow-up period was 22.7 months. Patients treated with TT and those treated with RR did not have significantly different 5-year OS, CSS or RFS (73.7% vs 92.3%, P = 0.052; 94.7% vs 95.4%, P = 0.970: and 63.2% vs 53.9%, P = 0.489, respectively). No difference in postoperative creatinine variation emerged in association with the surgical technique (P = 0.411). CONCLUSION: Patients treated with TT or RR for UTUC showed comparable OS, CSS, RFS and postoperative renal function. Our data suggest that bladder cuff removal is not imperative in the treatment of distal ureteric UTUC, and TT can be a safe solution in selected cases. CI - (c) 2019 The Authors BJU International (c) 2019 BJU International Published by John Wiley & Sons Ltd. FAU - Abrate, Alberto AU - Abrate A AUID- ORCID: 0000-0003-4100-3104 AD - Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Sessa, Francesco AU - Sessa F AD - Department of Minimally-Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy. FAU - Sebastianelli, Arcangelo AU - Sebastianelli A AD - Department of Minimally-Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy. FAU - Preto, Mirko AU - Preto M AD - Division of Urology, Department of Surgical Science, AOU Citta della Salute e della Scienza di Torino - Presidio Molinette, University of Turin, Turin, Italy. FAU - Olivero, Alberto AU - Olivero A AD - Department of Urology, IRCCS AOU San Martino, University of Genoa, Genoa, Italy. FAU - Varca, Virginia AU - Varca V AD - Department of Urology, ASST Rhodense, G. Salvini Hospital, Garbagnate Milanese, Milan, Italy. FAU - Benelli, Andrea AU - Benelli A AD - Department of Urology, ASST Rhodense, G. Salvini Hospital, Garbagnate Milanese, Milan, Italy. FAU - Campi, Riccardo AU - Campi R AUID- ORCID: 0000-0001-5237-0888 AD - Department of Minimally-Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy. FAU - Sessa, Maurizio AU - Sessa M AD - Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Naples, Italy. AD - Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. FAU - Pavone, Carlo AU - Pavone C AD - Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Vella, Marco AU - Vella M AD - Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. FAU - Brunocilla, Eugenio AU - Brunocilla E AD - Department of Urology, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. FAU - Serni, Sergio AU - Serni S AD - Department of Minimally-Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy. FAU - Trombetta, Carlo AU - Trombetta C AD - Department of Urology, University of Trieste, Trieste, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, IRCCS AOU San Martino, University of Genoa, Genoa, Italy. FAU - Gregori, Andrea AU - Gregori A AD - Department of Urology, ASST Rhodense, G. Salvini Hospital, Garbagnate Milanese, Milan, Italy. FAU - Lissiani, Andrea AU - Lissiani A AD - Department of Urology, University of Trieste, Trieste, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Science, AOU Citta della Salute e della Scienza di Torino - Presidio Molinette, University of Turin, Turin, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. FAU - Gacci, Mauro AU - Gacci M AUID- ORCID: 0000-0001-7877-221X AD - Department of Minimally-Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy. FAU - Simonato, Alchiede AU - Simonato A AUID- ORCID: 0000-0001-9513-4869 AD - Section of Urology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20190225 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) RN - AYI8EX34EU (Creatinine) SB - IM MH - Anastomosis, Surgical MH - Biomarkers, Tumor/metabolism MH - Carcinoma in Situ/*surgery MH - Creatinine/metabolism MH - Disease-Free Survival MH - Female MH - Humans MH - Italy/epidemiology MH - Male MH - Middle Aged MH - Replantation/*methods MH - Retrospective Studies MH - Treatment Outcome MH - Ureter/*surgery MH - Ureteral Neoplasms/mortality/*surgery MH - Urinary Bladder/*surgery OTO - NOTNLM OT - #utuc OT - renal function OT - segmental ureterectomy OT - survival OT - termino-terminal ureteroureterostomy OT - upper tract urothelial carcinoma OT - ureteric re-implantation EDAT- 2019/02/04 06:00 MHDA- 2020/02/11 06:00 CRDT- 2019/02/04 06:00 PHST- 2019/02/04 06:00 [pubmed] PHST- 2020/02/11 06:00 [medline] PHST- 2019/02/04 06:00 [entrez] AID - 10.1111/bju.14697 [doi] PST - ppublish SO - BJU Int. 2019 Jul;124(1):116-123. doi: 10.1111/bju.14697. Epub 2019 Feb 25. PMID- 30706249 OWN - NLM STAT- MEDLINE DCOM- 20190812 LR - 20221207 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 51 IP - 3 DP - 2019 Mar TI - Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. PG - 435-441 LID - 10.1007/s11255-019-02087-4 [doi] AB - PURPOSE: To assess the impact of carcinoma in situ (CIS) on oncologic outcomes in patients who underwent radical cystectomy, with a focus on those who received neoadjuvant chemotherapy (NAC) including patients with down-staging to /=1.5), dNLR (<1.2 vs. >/=1.2), and PLR values (171< vs. >/=171). Patients with NLR >/= 1.5 and dNLR >/= 1.2 were associated with poor prognosis in terms of overall survival and cause-specific survival. However, no serum SIR marker was associated with prognosis in recurrence-free survival or progression-free survival. Cox multivariate analysis revealed that age, NLR, dNLR, hemoglobin, and pathologic T stage were significant factors predicting overall survival. Age, NLR, and pathologic T stage were significant factors predicting cancer-specific survival, NLR and tumor number were the most important predictors of bladder preserving survival. NLR before treatment was correlated with both oncological outcomes and survival outcome in NMIBC patients undergoing initial intravesical BCG treatment after TURB. Increased NLR reflects a poor prognosis of these outcomes. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Inje University Sanggye Paik Hospital, Seoul, South Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, South Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, South Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, South Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, South Korea. LA - eng PT - Journal Article DEP - 20190117 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6344445 OTO - NOTNLM OT - BCG OT - bladder cancer OT - neutrophil-to-lymphocyte ratio OT - non-muscle invasive bladder cancer OT - systemic inflammatory response EDAT- 2019/02/02 06:00 MHDA- 2019/02/02 06:01 PMCR- 2018/01/01 CRDT- 2019/02/02 06:00 PHST- 2018/09/14 00:00 [received] PHST- 2018/12/06 00:00 [accepted] PHST- 2019/02/02 06:00 [entrez] PHST- 2019/02/02 06:00 [pubmed] PHST- 2019/02/02 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2018.00642 [doi] PST - epublish SO - Front Oncol. 2019 Jan 17;8:642. doi: 10.3389/fonc.2018.00642. eCollection 2018. PMID- 30700445 OWN - NLM STAT- MEDLINE DCOM- 20200603 LR - 20200603 IS - 1538-7755 (Electronic) IS - 1055-9965 (Print) IS - 1055-9965 (Linking) VI - 28 IP - 4 DP - 2019 Apr TI - MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis. PG - 782-788 LID - 10.1158/1055-9965.EPI-18-0884 [doi] AB - BACKGROUND: The high rate of non-muscle-invasive bladder cancer recurrence is a major challenge in patient management. miRNAs functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers because they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle-invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype. METHODS: We utilized patients diagnosed with primary non-muscle-invasive bladder cancer in three independent cohorts for a biomarker discovery/validation approach. Baseline tumor tissue from patients with the clinically challenging, non-muscle-invasive primary low stage (Ta), high grade, and T1 tumors (tumors extending into the lamina propria) comprised the discovery cohort (n = 38). We isolated the tumor tissue RNA and assessed a panel of approximately 800 miRNAs. RESULTS: miR-26b-5p was the top-ranking prognostic tumor tissue miRNA, with a time-to-recurrence HR 0.043 for levels above versus below median, (P (adj) = 0.0003). miR-26b-5p was related to a dose-response reduction in tumor recurrence, and levels above the median were also associated with reduced time-to-progression (P (adj) = 0.02). We used two independent longitudinal cohorts that included both low-grade and high-grade Ta and T1 tumors for validation and found a consistent relationship between miR-26b-5p and recurrence and progression. CONCLUSIONS: Our results suggest that miR-26b-5p levels may be prognostic for non-muscle-invasive bladder cancer recurrence, and can feasibly be assessed in baseline tumor tissue from a wide variety of clinical settings. IMPACT: Early identification of those non-muscle-invasive bladder tumor patients with refractory phenotypes would enable individualized treatment and surveillance. CI - (c)2019 American Association for Cancer Research. FAU - Andrew, Angeline S AU - Andrew AS AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. Angeline.Andrew@dartmouth.edu. FAU - Karagas, Margaret R AU - Karagas MR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. FAU - Schroeck, Florian R AU - Schroeck FR AUID- ORCID: 0000-0002-1860-2611 AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth and White River Junction VA Medical Center, White River Junction, Vermont. FAU - Marsit, Carmen J AU - Marsit CJ AD - Department of Environmental Health and Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. FAU - Schned, Alan R AU - Schned AR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. FAU - Pettus, Jason R AU - Pettus JR AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. FAU - Armstrong, David A AU - Armstrong DA AUID- ORCID: 0000-0003-1748-2520 AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. FAU - Seigne, John D AU - Seigne JD AD - Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. LA - eng GR - K07 CA102327/CA/NCI NIH HHS/United States GR - P30 CA023108/CA/NCI NIH HHS/United States GR - P42 ES007373/ES/NIEHS NIH HHS/United States GR - R21 CA182659/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. DEP - 20190130 PL - United States TA - Cancer Epidemiol Biomarkers Prev JT - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JID - 9200608 RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Prognosis MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC6473178 MID - NIHMS1520010 COIS- Conflicts of interest: The authors declare no potential conflicts of interest. EDAT- 2019/02/01 06:00 MHDA- 2020/06/04 06:00 PMCR- 2019/10/01 CRDT- 2019/02/01 06:00 PHST- 2018/08/08 00:00 [received] PHST- 2018/11/20 00:00 [revised] PHST- 2019/01/23 00:00 [accepted] PHST- 2019/02/01 06:00 [pubmed] PHST- 2020/06/04 06:00 [medline] PHST- 2019/02/01 06:00 [entrez] PHST- 2019/10/01 00:00 [pmc-release] AID - 1055-9965.EPI-18-0884 [pii] AID - 10.1158/1055-9965.EPI-18-0884 [doi] PST - ppublish SO - Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):782-788. doi: 10.1158/1055-9965.EPI-18-0884. Epub 2019 Jan 30. PMID- 30696606 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20190528 IS - 1532-2777 (Electronic) IS - 0306-9877 (Linking) VI - 123 DP - 2019 Feb TI - Can immunization with Bacillus Calmette-Guerin (BCG) protect against Alzheimer's disease? PG - 95-97 LID - S0306-9877(18)31215-5 [pii] LID - 10.1016/j.mehy.2019.01.007 [doi] AB - Alzheimer's disease (AD) is a neurodegenerative disorder which is the most prevalent cause of dementia in the western world. Currently, it is the most expensive disease in America, costing more than heart diseases and cancer and as the world population is getting older it is expected to become the most expensive medical disorder in the world. AD is characterized by three core pathologies: accumulation of amyloid beta (Abeta) plaques, neurofibrillary tangles (NFT) and sustained inflammation. It is now believed that inflammation provides the link between Abeta and NFT. The immune system is therefore, a major player in the pathogenesis of AD. Here we propose that Bacillus Calmette-Guerin (BCG) could affect the incidence of AD. Bacillus Calmette-Guerin (BCG) is a live attenuated Mycobacterium bovis preparation first developed as a vaccine against M. tuberculosis. It has been shown to be moderately effective in preventing tuberculosis, while noted to induce modifications in inflammatory response and to regulate the immune system. Intra-vesical administration of BCG is used successfully in the past four decades to prevent recurrence of non-muscle invasive bladder cancer. In this manuscript we investigate the hypothesis that exposure to BCG decreases the prevalence of AD in elderly population and that this occurs through modulation of the immune system. Our hypothesis is based on several lines of evidence: lower prevalence of AD in countries with high BCG coverage, ability of BCG to ameliorate several conditions involving the immune system like type 1 diabetes mellitus and multiple sclerosis, animal models of AD in which BCG shows therapeutic potential and a plausible molecular mechanism which may be the basis for this hypothesis. Namely, elevated systemic levels of IL-2 (as found when BCG is given intra-vesically) that amplify Treg cells that inhibit AD associated inflammation, decreased plaque formation and restore cognitive function. To test this hypothesis one may study cognition in the large available "natural adult population" exposed to high dose of BCG through the bladder. Bladder cancer survivors not given BCG can serve as control group. This population can be used without adding any medical intervention. CI - Copyright (c) 2019 Elsevier Ltd. All rights reserved. FAU - Gofrit, Ofer N AU - Gofrit ON AD - Department of Urology, Jerusalem, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. Electronic address: roferg@hadassah.org.il. FAU - Bercovier, Herve AU - Bercovier H AD - Department of Microbiology and Molecular Genetics, Hebrew University-Hadassah Faculty of Medicine, Jerusalem, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. FAU - Klein, Benjamin Y AU - Klein BY AD - Department of Microbiology and Molecular Genetics, Hebrew University-Hadassah Faculty of Medicine, Jerusalem, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. FAU - Cohen, Irun R AU - Cohen IR AD - Department of Immunology, Weizmann Institute, Rehovot Israel, Rehovot, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. FAU - Ben-Hur, Tamir AU - Ben-Hur T AD - Department of Immunology, Weizmann Institute, Rehovot Israel, Rehovot, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. FAU - Greenblatt, Charles L AU - Greenblatt CL AD - Department of Microbiology and Molecular Genetics, Hebrew University-Hadassah Faculty of Medicine, Jerusalem, Israel; Department of Neurology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. LA - eng PT - Journal Article DEP - 20190111 PL - United States TA - Med Hypotheses JT - Medical hypotheses JID - 7505668 RN - 0 (Amyloid beta-Peptides) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - Alzheimer Disease/*prevention & control MH - Amyloid beta-Peptides/metabolism MH - BCG Vaccine/*therapeutic use MH - Diabetes Mellitus, Type 1/metabolism/therapy MH - Humans MH - Immunization MH - Incidence MH - Inflammation MH - Middle Aged MH - Models, Biological MH - Multiple Sclerosis/metabolism/therapy MH - Mycobacterium bovis MH - Neurofibrillary Tangles MH - Prevalence MH - Risk Factors MH - Urinary Bladder Neoplasms/metabolism/therapy MH - Vaccination EDAT- 2019/01/31 06:00 MHDA- 2019/05/29 06:00 CRDT- 2019/01/31 06:00 PHST- 2018/11/22 00:00 [received] PHST- 2018/12/24 00:00 [revised] PHST- 2019/01/10 00:00 [accepted] PHST- 2019/01/31 06:00 [entrez] PHST- 2019/01/31 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] AID - S0306-9877(18)31215-5 [pii] AID - 10.1016/j.mehy.2019.01.007 [doi] PST - ppublish SO - Med Hypotheses. 2019 Feb;123:95-97. doi: 10.1016/j.mehy.2019.01.007. Epub 2019 Jan 11. PMID- 30694935 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20190816 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 201 IP - 5 DP - 2019 May TI - Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution. PG - 909-915 LID - 10.1097/JU.0000000000000034 [doi] AB - PURPOSE: We investigated the influence of positive pre-cystectomy biopsies of the prostatic urethra in males and the bladder neck in females on urethral recurrence, cancer specific and overall survival, and functional outcomes after orthotopic bladder substitution. MATERIALS AND METHODS: We retrospectively analyzed the records of 803 consecutive patients, including 703 males and 100 females, who underwent orthotopic bladder substitution as well as pre-cystectomy biopsy of the prostatic urethra in males and the bladder neck in females, at our institution between April 1986 and December 2017. RESULTS: Pre-cystectomy biopsies were negative in 755 of the 803 patients (94%) (group 1) and positive in 48 (6%) (group 2). Biopsies in group 2 revealed carcinoma in situ in 35 of the 48 cases (73%), pTaG1/G2 in 5 (10%) and pTaG3/pT1G3 in 8 (17%). Median followup was 64 months (IQR 21-128). At a median followup of 56 months (IQR 18-127) urethral recurrence developed in 45 of the 803 patients (5.6%), including 30 of the 755 (4%) in group 1 and 15 of the 48 (31.3%) in group 2 (p <0.001). Only 10 of the 45 patients (22%) with urethral recurrence required salvage urethrectomy while locally conservative treatment was successful in 27 (60%). Of the remaining 8 patients 6 of 45 (13%) underwent synchronous palliative chemotherapy and 2 of 45 (4%) refused treatment. Multivariate regression analysis revealed a higher risk of urethral recurrence if patients had positive pre-cystectomy biopsies (group 2 HR 6.49, 95% CI 3.33-12.62, p <0.001) or received neoadjuvant or adjuvant chemotherapy (HR 3.05, 95% CI 1.66-5.59, p <0.001). Cancer specific and overall survival as well as functional outcomes were similar in the 2 groups. CONCLUSIONS: Positive pre-cystectomy biopsies prior to orthotopic bladder substitution increased the urethral recurrence rate but did not lower cancer specific or overall survival. Most urethral recurrences were managed successfully by local treatment. Orthotopic bladder substitution is an option in highly selected patients with positive, noninvasive pre-cystectomy biopsies, provided that they undergo regular followup including urethral cytology. FAU - Roth, Beat AU - Roth B AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Furrer, Marc Alain AU - Furrer MA AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Giannakis, Ioannis AU - Giannakis I AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy , Tirgu Mures , Romania. FAU - Boxler, Silvan AU - Boxler S AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Wuethrich, Patrick Y AU - Wuethrich PY AD - Department of Anaesthesiology and Pain Medicine, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Burkhard, Fiona C AU - Burkhard FC AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. FAU - Kiss, Bernhard AU - Kiss B AD - Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland. LA - eng PT - Journal Article PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2019 May;201(5):914-915. doi: 10.1097/01.JU.0000554432.22579.4a. PMID: 30822199 CIN - J Urol. 2019 May;201(5):914. doi: 10.1097/01.JU.0000554431.22579.91. PMID: 30822201 MH - Biopsy/statistics & numerical data MH - Cystectomy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*epidemiology/pathology/prevention & control MH - *Patient Selection MH - Prostate/pathology MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urethra/pathology MH - Urethral Neoplasms/*epidemiology/pathology/prevention & control MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery MH - *Urinary Reservoirs, Continent OTO - NOTNLM OT - biopsy OT - cystectomy OT - prostate OT - urethra OT - urinary bladder neoplasms EDAT- 2019/01/30 06:00 MHDA- 2019/06/07 06:00 CRDT- 2019/01/30 06:00 PHST- 2019/01/30 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2019/01/30 06:00 [entrez] AID - 10.1097/JU.0000000000000034 [doi] PST - ppublish SO - J Urol. 2019 May;201(5):909-915. doi: 10.1097/JU.0000000000000034. PMID- 30684846 OWN - NLM STAT- MEDLINE DCOM- 20191030 LR - 20260127 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 39 DP - 2019 Apr TI - Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. PG - 42-52 LID - S1092-9134(18)30367-8 [pii] LID - 10.1016/j.anndiagpath.2019.01.002 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guerin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p < 0.001, p < 0.0001 respectively). Positive Her2/neu was noted in 18.3% (11/60) of the cases, and its expression was significantly associated with the tumor size, histologic grade, and tumor stage (p = 0.001, p = 0.002, p = 0.011 respectively). High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each). Analysis of follow-up period revealed that NMIBC with high FASN, positive Her2/neu, and high E2F1 expression exhibited a potent relation with tumor progression, shorter RFS, and poor PFS. Conclusions: High FASN, Her2/neu, and E2F1 are considered as adverse prognostic factors of tumor recurrence and progression in NMIBC and these patients should be followed carefully. Therefore, we suggest that FASN, Her2/neu, and E2F1 should be considered and evaluated during the selection of the appropriate management strategy for NMIBC patients. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Abdelrahman, Aziza E AU - Abdelrahman AE AD - Pathology Department, Faculty of Medicine, Zagazig University, Egypt. Electronic address: Azaelsayed@gmail.com. FAU - Rashed, Hayam E AU - Rashed HE AD - Pathology Department, Faculty of Medicine, Zagazig University, Egypt. FAU - Elkady, Ehab AU - Elkady E AD - Urology Department, Faculty of Medicine, Zagazig University, Egypt. FAU - Elsebai, Eman A AU - Elsebai EA AD - Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Egypt. FAU - El-Azony, Ahmed AU - El-Azony A AD - Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Egypt. FAU - Matar, Ihab AU - Matar I AD - Surgical Oncology Department, Al-Ahrar Zagazig Teaching Hospital, Egypt. LA - eng PT - Journal Article DEP - 20190117 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (E2F1 Transcription Factor) RN - EC 2.3.1.85 (Fatty Acid Synthase, Type I) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (E2F1 protein, human) RN - EC 2.3.1.85 (FASN protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - BCG Vaccine/pharmacology/*therapeutic use MH - Biomarkers, Tumor/*metabolism MH - Chemotherapy, Adjuvant MH - Disease Progression MH - E2F1 Transcription Factor/*metabolism MH - Fatty Acid Synthase, Type I/*metabolism MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Prospective Studies MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/metabolism/*therapy MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - E2F1 OT - FASN OT - Her2/neu OT - Immunohistochemistry OT - Non-muscle-invasive bladder cancer OT - Prognostic markers EDAT- 2019/01/27 06:00 MHDA- 2019/10/31 06:00 CRDT- 2019/01/27 06:00 PHST- 2018/11/24 00:00 [received] PHST- 2018/12/25 00:00 [revised] PHST- 2019/01/15 00:00 [accepted] PHST- 2019/01/27 06:00 [pubmed] PHST- 2019/10/31 06:00 [medline] PHST- 2019/01/27 06:00 [entrez] AID - S1092-9134(18)30367-8 [pii] AID - 10.1016/j.anndiagpath.2019.01.002 [doi] PST - ppublish SO - Ann Diagn Pathol. 2019 Apr;39:42-52. doi: 10.1016/j.anndiagpath.2019.01.002. Epub 2019 Jan 17. PMID- 30675249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240607 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 17 IP - 2 DP - 2019 Feb TI - Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer. PG - 1865-1876 LID - 10.3892/ol.2018.9762 [doi] AB - Abnormal spindle-like microcephaly-associated (ASPM) protein is essential for mitotic spindle function during cell replication. The present study aimed to evaluate the hypothesis that ASPM serves a critical role in cancer invasiveness and may act as a prognostic biomarker in bladder cancer. In total, 6 independent worldwide bladder cancer microarray mRNA expression datasets (n=1,355) with clinical and follow-up annotations were collected from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Reverse transcription-quantitative polymerase chain reaction analysis revealed that ASPM mRNA expression was higher in bladder cancer tissue compared with adjacent normal bladder mucosae in 10 paired human tissue samples (P=0.004). ASPM overexpression in human bladder cancer samples was consistent with the mRNA expression datasets from GEO and TCGA. Bioinformatics analysis indicated that ASPM mRNA expression was significantly associated with grade and tumor node metastasis (TNM) stage in bladder cancer, based on pooled GEO and TCGA datasets (P<0.05). Stratification analysis indicated that the clinical significance of ASPM was particularly pronounced in low-grade or papillary subtypes of bladder cancer. Individual Cox and pooled Kaplan-Meier analyses suggested that ASPM expression was significantly directly correlated with poor overall (OS) and progression-free survival (PFS) in bladder cancer. Multivariate and stratification analyses demonstrated that the prognostic significance of ASPM was evident in low-grade or papillary bladder cancers, yet not in high-grade or non-papillary subgroups. Increased expression of ASPM was associated with poor OS in muscle-invasive bladder cancer and with poor PFS in non-muscle-invasive bladder cancer (P<0.05). Bioinformatics analysis identified the top 11 ASPM-related genes on STRING-DB.org. The expression of the majority of these genes was associated with poor outcomes of bladder cancer with statistical significance. Gene set enrichment analysis indicated that the high expression of ASPM could enrich gene signatures involved in mitosis, differentiation and metastasis in bladder cancer. Further analysis of TCGA datasets indicated that increased ASPM expression was significantly associated with higher Gleason score, T stage, N stage and poor clinical outcome in prostate cancer. It was also significantly associated with late TNM stage and poor PFS in renal cell carcinoma. In summary, ASPM may serve as a novel prognostic biomarker for low-grade or papillary bladder cancer. FAU - Xu, Zhenglin AU - Xu Z AD - Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China. AD - Department of Urologic Surgery, Affiliated Dongyang People's Hospital of Wenzhou Medical University, Dongyang, Zhejiang 322100, P.R. China. FAU - Zhang, Qi AU - Zhang Q AD - Department of Bioinformatics and Statistics, Hangzhou Hope Biotechnology, Inc., Hangzhou, Zhejiang 310015, P.R. China. FAU - Luh, Frank AU - Luh F AD - Sino-American Cancer Foundation, California Cancer Institute, Temple City, CA 91780, USA. AD - Tumor Biomarker Development, California Cancer Institute, Temple City, CA 91780, USA. FAU - Jin, Baiye AU - Jin B AD - Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China. FAU - Liu, Xiyong AU - Liu X AD - Sino-American Cancer Foundation, California Cancer Institute, Temple City, CA 91780, USA. AD - Tumor Biomarker Development, California Cancer Institute, Temple City, CA 91780, USA. LA - eng PT - Journal Article DEP - 20181126 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6341836 OTO - NOTNLM OT - abnormal spindle-like microcephaly-associated protein OT - bladder cancer OT - cancer survival OT - gene set enrichment analysis OT - prognostic biomarker EDAT- 2019/01/25 06:00 MHDA- 2019/01/25 06:01 PMCR- 2018/11/26 CRDT- 2019/01/25 06:00 PHST- 2018/04/06 00:00 [received] PHST- 2018/10/31 00:00 [accepted] PHST- 2019/01/25 06:00 [entrez] PHST- 2019/01/25 06:00 [pubmed] PHST- 2019/01/25 06:01 [medline] PHST- 2018/11/26 00:00 [pmc-release] AID - OL-0-0-9762 [pii] AID - 10.3892/ol.2018.9762 [doi] PST - ppublish SO - Oncol Lett. 2019 Feb;17(2):1865-1876. doi: 10.3892/ol.2018.9762. Epub 2018 Nov 26. PMID- 30671639 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20261011 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology. PG - 2051-2058 LID - 10.1007/s00345-018-02624-3 [doi] AB - PURPOSE: Urine cytology remains an essential diagnostic tool in the surveillance of patients with non-muscle invasive bladder cancer (NMIBC). The correlation of urine cytology with biopsy specimens to determine its accuracy following induction intravesical therapy has not been investigated. METHODS: A retrospective review was performed of patients who underwent intravesical therapy for biopsy-proven non-muscle invasive disease between 2013 and 2016 at our institution. All patients uniformly underwent cytology and systematic bladder biopsies in the operating room within 12 weeks following intravesical therapy. The accuracy of urinary cytology in predicting high-grade disease recurrence following intravesical therapy was confirmed by correlating cytology results to post-treatment systematic biopsies, regardless of endoscopic findings. Only patients with complete information regarding urine cytology and pathologic biopsy results, both pre- and post-intravesical therapy, were included. RESULTS: 90 cytology samples following intravesical therapy were analyzed from 76 patients who met inclusion criteria. 72 (80.0%) and 18 (20.0%) of the samples were collected from patients initially treated for high- and low-grade disease, respectively. Fifty-six (62.2%) specimens were obtained from patients following induction of bacillus Calmette-Guerin (BCG) therapy; the remainder were from patients treated with intravesical gemcitabine/docetaxel, mitomycin, or BCG/interferon. For patients treated with BCG, cytology was positive for high-grade disease in 8/15 patients with high-grade pathology on follow-up biopsy, thus demonstrating a sensitivity of 53% (95% CI 27-79%), specificity of 95% (95% CI 84-99%), positive predictive value of 80% (95% CI 44-98%), and negative predictive value of 85% (95% CI 71-94%). If cytologic interpretation was broadened to include high-grade and "suspicious for high-grade" findings, sensitivity increased to 67% (95% CI 38-88%) and specificity decreased to 88% (95% CI 74-96%). CONCLUSIONS: While urinary cytology maintains a high specificity following intravesical therapy, it demonstrates a low sensitivity for potentially aggressive high-grade urothelial carcinoma. Further evaluation of more effective, clinic-based enhanced cystoscopy techniques and biomarkers is warranted to better identify patients at risk for disease recurrence following BCG therapy. FAU - Gupta, Mohit AU - Gupta M AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. mgupta16@jhmi.edu. FAU - Milbar, Niv AU - Milbar N AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. FAU - Tema, Giorgia AU - Tema G AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. FAU - Pederzoli, Filippo AU - Pederzoli F AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. FAU - Chappidi, Meera AU - Chappidi M AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. FAU - Kates, Max AU - Kates M AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. FAU - VandenBussche, Christopher J AU - VandenBussche CJ AD - Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 224, Baltimore, MD, 21287, USA. LA - eng PT - Journal Article DEP - 20190123 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Reproducibility of Results MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Urine/*cytology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Urinary bladder neoplasms OT - Urine cytology OT - Urothelial carcinoma EDAT- 2019/01/24 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/01/24 06:00 PHST- 2018/08/20 00:00 [received] PHST- 2018/12/31 00:00 [accepted] PHST- 2019/01/24 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/01/24 06:00 [entrez] AID - 10.1007/s00345-018-02624-3 [pii] AID - 10.1007/s00345-018-02624-3 [doi] PST - ppublish SO - World J Urol. 2019 Oct;37(10):2051-2058. doi: 10.1007/s00345-018-02624-3. Epub 2019 Jan 23. PMID- 30656539 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20200225 IS - 1573-7225 (Electronic) IS - 0957-5243 (Print) IS - 0957-5243 (Linking) VI - 30 IP - 2 DP - 2019 Feb TI - The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer. PG - 187-193 LID - 10.1007/s10552-019-1130-8 [doi] AB - PURPOSE: Bladder cancer is one of the top five cancers diagnosed in the U.S. with a high recurrence rate, and also one of the most expensive cancers to treat over the life-course. However, there are few observational, prospective studies of bladder cancer survivors. METHODS: The Bladder Cancer Epidemiology, Wellness, and Lifestyle Study (Be-Well Study) is a National Cancer Institute-funded, multi-center prospective cohort study of non-muscle-invasive bladder cancer (NMIBC) patients (Stage Ta, T1, Tis) enrolled from the Kaiser Permanente Northern California (KPNC) and Southern California (KPSC) health care systems, with genotyping and biomarker assays performed at Roswell Park Comprehensive Cancer Center. The goal is to investigate diet and lifestyle factors in recurrence and progression of NMIBC, with genetic profiles considered, and to build a resource for future NMIBC studies. RESULTS: Recruitment began in February 2015. As of 30 June 2018, 1,281 patients completed the baseline interview (774 KPNC, 511 KPSC) with a recruitment rate of 54%, of whom 77% were male and 23% female, and 80% White, 6% Black, 8% Hispanic, 5% Asian, and 2% other race/ethnicity. Most patients were diagnosed with Ta (69%) or T1 (27%) tumors. Urine and blood specimens were collected from 67% and 73% of consented patients at baseline, respectively. To date, 599 and 261 patients have completed the 12- and 24-month follow-up questionnaires, respectively, with additional urine and saliva collection. CONCLUSIONS: The Be-Well Study will be able to answer novel questions related to diet, other lifestyle, and genetic factors and their relationship to recurrence and progression among early-stage bladder cancer patients. FAU - Kwan, Marilyn L AU - Kwan ML AUID- ORCID: 0000-0001-8863-3950 AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. Marilyn.L.Kwan@kp.org. FAU - Kushi, Lawrence H AU - Kushi LH AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. FAU - Danforth, Kim N AU - Danforth KN AD - Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles Avenue, Pasadena, CA, 91101, USA. FAU - Roh, Janise M AU - Roh JM AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. FAU - Ergas, Isaac J AU - Ergas IJ AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. FAU - Lee, Valerie S AU - Lee VS AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. FAU - Cannavale, Kimberly L AU - Cannavale KL AD - Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles Avenue, Pasadena, CA, 91101, USA. FAU - Harrison, Teresa N AU - Harrison TN AD - Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles Avenue, Pasadena, CA, 91101, USA. FAU - Contreras, Richard AU - Contreras R AD - Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles Avenue, Pasadena, CA, 91101, USA. FAU - Loo, Ronald K AU - Loo RK AD - Department of Urology, Kaiser Permanente Downey Medical Center, 9333 Imperial Hwy, Downey, CA, 90242, USA. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, 280 W MacArthur Blvd, Oakland, CA, 94611, USA. FAU - Quesenberry, Charles P AU - Quesenberry CP AD - Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. FAU - Tritchler, David AU - Tritchler D AD - Department of Biostatistics, The State University of New York at Buffalo, 718 Kimball Tower, Buffalo, NY, 14214, USA. FAU - Ghai, Nirupa R AU - Ghai NR AD - Department of Surgical Quality and Outcomes, Kaiser Foundation Health Plan, 393 E. Walnut Street, Pasadena, CA, 91188, USA. FAU - Quinn, Virginia P AU - Quinn VP AD - Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles Avenue, Pasadena, CA, 91101, USA. FAU - Ambrosone, Christine B AU - Ambrosone CB AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA. FAU - Zhang, Yuesheng AU - Zhang Y AD - Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA. FAU - Tang, Li AU - Tang L AD - Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA. LA - eng GR - K07 CA148888/CA/NCI NIH HHS/United States GR - R01 CA172855/CA/NCI NIH HHS/United States GR - R01CA172855/National Cancer Institute/ PT - Journal Article PT - Multicenter Study DEP - 20190117 PL - Netherlands TA - Cancer Causes Control JT - Cancer causes & control : CCC JID - 9100846 SB - IM MH - Aged MH - Aged, 80 and over MH - California/epidemiology MH - Cancer Survivors MH - Diet MH - Disease Progression MH - Female MH - Humans MH - Life Style MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/genetics/prevention & control MH - Prospective Studies MH - Urinary Bladder Neoplasms/*epidemiology/genetics PMC - PMC6422041 MID - NIHMS1518996 OTO - NOTNLM OT - Lifestyle and genetic factors OT - Non-muscle-invasive bladder cancer OT - Prospective cohort study OT - Recurrence OT - Urothelial carcinoma COIS- Conflict of Interest Disclosure Statement: The authors declare no potential conflicts of interest. EDAT- 2019/01/19 06:00 MHDA- 2019/04/04 06:00 PMCR- 2020/02/01 CRDT- 2019/01/19 06:00 PHST- 2018/11/03 00:00 [received] PHST- 2019/01/09 00:00 [accepted] PHST- 2019/01/19 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2019/01/19 06:00 [entrez] PHST- 2020/02/01 00:00 [pmc-release] AID - 10.1007/s10552-019-1130-8 [pii] AID - 10.1007/s10552-019-1130-8 [doi] PST - ppublish SO - Cancer Causes Control. 2019 Feb;30(2):187-193. doi: 10.1007/s10552-019-1130-8. Epub 2019 Jan 17. PMID- 30655790 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 17 IP - 1 DP - 2019 Jan TI - Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract. PG - 482-487 LID - 10.3892/ol.2018.9510 [doi] AB - The transcription factor forkhead box O1 (FOXO1) can be inactivated via its phosphorylation, resulting in suppression of apoptosis. Using immunohistochemistry, the expression of a phosphorylated form of FOXO1 was assessed in upper urinary tract urothelial carcinoma (UUTUC) specimens. Overall, phospho-FOXO1 (p-FOXO1) was immunoreactive in all 99 UUTUC specimens [12 (12.1%) weak (1+), 46 (46.5%) moderate (2+) and 41 (41.4%) strong (3+)], which was significantly (P=0.018) increased, compared with benign urothelium specimens [77/82 (93.9%): 18 (22.0%) 1+, 41 (50.0%) 2+ and 18 (22.0%) 3+]. Muscle invasion (P=0.031) and lymphovascular invasion (P=0.025) were observed more frequently in p-FOXO1(2+/3+) tumor samples compared with p-FOXO1(1+) tumor samples. No statistically significant associations between p-FOXO1 expression and tumor grade or presence of concurrent carcinoma in situ, hydronephrosis or lymph node metastasis were observed. Furthermore, the levels of p-FOXO1 and estrogen receptor-beta expression were significantly (P<0.05) correlated in UUTUC samples [correlation coefficient (CC)=0.244], particularly in tumor samples from male patients (CC=0.330). Additionally, patients with p-FOXO1(3+) tumors had a significantly increased risk of cancer-specific mortality (P=0.043), compared with those with p-FOXO1(1+/2+) tumors. Multivariate analysis further demonstrated a notable, albeit not significant, association between p-FOXO1 expression and cancer-specific survival (hazard ratio=2.204; P=0.053). These findings indicate that FOXO1 is inactivated in UUTUC specimens and p-FOXO1 overexpression may serve as a predictor of poor patient outcomes. FAU - Ide, Hiroki AU - Ide H AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. FAU - Jiang, Guiyang AU - Jiang G AD - Department of Pathology and Laboratory Medicine and James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Mizushima, Taichi AU - Mizushima T AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. AD - Department of Pathology and Laboratory Medicine and James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. FAU - Inoue, Satoshi AU - Inoue S AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. AD - Department of Pathology and Laboratory Medicine and James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Yamaguchi, Seiji AU - Yamaguchi S AD - Department of Urology, Osaka General Medical Center, Osaka 558-8558, Japan. FAU - Fushimi, Hiroaki AU - Fushimi H AD - Department of Pathology, Osaka General Medical Center, Osaka 558-8558, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. AD - Department of Pathology and Laboratory Medicine and James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. AD - Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA. LA - eng PT - Journal Article DEP - 20180926 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6313206 OTO - NOTNLM OT - forkhead box O1 OT - immunohistochemistry OT - prognosis OT - steroid hormone receptors OT - upper urinary tract urothelial carcinoma EDAT- 2019/01/19 06:00 MHDA- 2019/01/19 06:01 PMCR- 2018/09/26 CRDT- 2019/01/19 06:00 PHST- 2018/05/17 00:00 [received] PHST- 2018/08/23 00:00 [accepted] PHST- 2019/01/19 06:00 [entrez] PHST- 2019/01/19 06:00 [pubmed] PHST- 2019/01/19 06:01 [medline] PHST- 2018/09/26 00:00 [pmc-release] AID - OL-0-0-9510 [pii] AID - 10.3892/ol.2018.9510 [doi] PST - ppublish SO - Oncol Lett. 2019 Jan;17(1):482-487. doi: 10.3892/ol.2018.9510. Epub 2018 Sep 26. PMID- 30654296 OWN - NLM STAT- MEDLINE DCOM- 20200508 LR - 20200508 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 108 DP - 2019 Feb TI - Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. PG - 111-119 LID - S0959-8049(18)31556-9 [pii] LID - 10.1016/j.ejca.2018.12.010 [doi] AB - INTRODUCTION: Assessment of tumour-infiltrating lymphocytes (TILs) can provide important prognostic information in various cancers and may be of value in predicting response to immunotherapy. The objective of the present study was to investigate the association of stromal lymphocytic infiltration with clinicopathological parameters and their correlation with outcomes in patients with high-grade pT1 non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We retrospectively analysed clinical data and formalin-fixed paraffin-embedded (FFPE) tissues of 147 patients with primary high-grade pT1 NMIBC who underwent transurethral resection of the bladder. The stromal TIL density was scored as percentage of the stromal area infiltrated by mononuclear inflammatory cells over the total intratumoural stromal area. The main end-point was correlation with cancer-specific survival (CSS). RESULTS: Median follow-up was 8.2 years (6.1-9.5). Induction Bacillus Calmette-Guerin therapy was undergone by 126 patients (86%). Stromal TILs were high (>/=10%) in 82 tumours (56%) and were positively associated with the tumour invasion depth (p = 0.01) and cancers with variant histology (p = 0.01). For the CSS analysis, high (>/=10%) versus. low (<10%) stromal TIL hazard ratio (95% confidence interval) was 1.70 (0.7-3.9, p = 0.2). CONCLUSIONS: A higher density of stromal TILs was associated with the tumour invasion depth in pT1 NMIBC. The level of TILs was not associated with survival outcomes. These data suggest that tumour aggressiveness is associated with an increased adaptive immune response in pT1 NMIBC. Characterisation of T-cell subtypes along with B-cells may be critical to enhance our knowledge of the host immune response in patients with high-risk NMIBC. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - Rouanne, Mathieu AU - Rouanne M AD - INSERM Unit U1015, Laboratoire de Recherche Translationnelle en Immunotherapie, Gustave Roussy, Villejuif, France; Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France. Electronic address: mathieu.rouanne@gustaveroussy.fr. FAU - Betari, Reem AU - Betari R AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France. FAU - Radulescu, Camelia AU - Radulescu C AD - Department of Pathology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France. FAU - Goubar, Aicha AU - Goubar A AD - Department of Biostatistics, INSERM Unit U981, Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France. FAU - Signolle, Nicolas AU - Signolle N AD - Department of Experimental Pathology, INSERM Unit U981, Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France; Institut Curie, CNRS, UMR144, Paris, France. FAU - Marabelle, Aurelien AU - Marabelle A AD - INSERM Unit U1015, Laboratoire de Recherche Translationnelle en Immunotherapie, Gustave Roussy, Villejuif, France; Drug Development Department (DITEP), Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France. FAU - Adam, Julien AU - Adam J AD - Department of Biostatistics, INSERM Unit U981, Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France; Department of Pathology, Gustave Roussy, Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France. FAU - Lebret, Thierry AU - Lebret T AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190114 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Transl Androl Urol. 2019 Jul;8(Suppl 3):S291-S292. doi: 10.21037/tau.2019.04.02. PMID: 31392149 CIN - Transl Androl Urol. 2019 Jul;8(Suppl 3):S335-S336. doi: 10.21037/tau.2019.05.06. PMID: 31392162 MH - Adaptive Immunity/immunology MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/immunology/mortality/*pathology/therapy MH - Cystoscopy MH - Female MH - Humans MH - Lymphocytes, Tumor-Infiltrating/immunology/*pathology MH - Male MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/immunology/mortality/*pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - T1G3 OT - Tumour lymphocyte infiltration EDAT- 2019/01/18 06:00 MHDA- 2020/05/10 06:00 CRDT- 2019/01/18 06:00 PHST- 2018/10/03 00:00 [received] PHST- 2018/11/23 00:00 [revised] PHST- 2018/12/05 00:00 [accepted] PHST- 2019/01/18 06:00 [pubmed] PHST- 2020/05/10 06:00 [medline] PHST- 2019/01/18 06:00 [entrez] AID - S0959-8049(18)31556-9 [pii] AID - 10.1016/j.ejca.2018.12.010 [doi] PST - ppublish SO - Eur J Cancer. 2019 Feb;108:111-119. doi: 10.1016/j.ejca.2018.12.010. Epub 2019 Jan 14. PMID- 30654104 OWN - NLM STAT- MEDLINE DCOM- 20190521 LR - 20191210 IS - 1879-1220 (Electronic) IS - 0960-0760 (Linking) VI - 188 DP - 2019 Apr TI - Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. PG - 134-140 LID - S0960-0760(18)30620-4 [pii] LID - 10.1016/j.jsbmb.2019.01.002 [doi] AB - The development of some cancers is associated with vitamin D deficiency. We suggest that reduced conversion of 25-hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and the resulting modification of tissue specific immune responses may be key. Non-muscle-invasive bladder cancer is highly immunoresponsive and stimulation of an inflammatory response by intravesical bacillus Calmette-Guerin (BCG) treatment prevents recurrence. To assess the relationship between serum 25(OH)D and bladder cancer risk we conducted a systematic review. To test our hypothesis, the synthesis of 1,25(OH)(2)D by human bladder epithelial cell lines (T24/83 and RT4) was examined. Studies were identified from Medline, Web of Science, Embase and Cochrane library (limited to English language, humans and 1990-2018). After removal of duplicates, title and abstract review 6 full papers were appraised. Low vitamin D levels were associated with bladder cancer risk in 5/6 of the studies. Both cell lines express the vitamin D receptor, 25-hydroxyvitamin D 1alpha-hydroxylase (1alpha-OHase) and 24-hydroxylase (24-OHase) mRNA, which was induced by 1,25(OH)(2)D. 24-OHase mRNA was also increased by 25(OH)D indicating 1alpha-OHase activity. Both cell types expressed TLR1,2,4 and the TLR partners MyD88 and CD14mRNA. Cathelicidin mRNA was undetectable in both cell lines but was induced by 1,25(OH)(2)D and 25(OH)D in RT4 cells. The systematic review demonstrated that bladder cancer risk correlates with serum 25(OH)D levels. In addition, we have shown that transitional epithelial cells express functional vitamin D signaling and can synthesize sufficient 1,25(OH)(2)D to stimulate a local immune response. We suggest that in order to maintain optimal immune surveillance within the bladder adequate levels of serum 25(OH)D are required for direct synthesis of 1,25(OH)(2)D by bladder epithelial cells. CI - Copyright (c) 2019 Elsevier Ltd. All rights reserved. FAU - Dunn, Janet A AU - Dunn JA AD - Warwick Medical School, The University of Warwick, Coventry, CV4 7AL, UK. FAU - Jefferson, Kieran AU - Jefferson K AD - Department of Urology, University Hospitals of Coventry and Warwickshire NHS Trust, CV2 2DX, UK. FAU - MacDonald, Donald AU - MacDonald D AD - Department of Urology, University Hospitals of Coventry and Warwickshire NHS Trust, CV2 2DX, UK. FAU - Iqbal, Gulnaz AU - Iqbal G AD - Warwick Medical School, The University of Warwick, Coventry, CV4 7AL, UK. FAU - Bland, Rosemary AU - Bland R AD - Warwick Medical School, The University of Warwick, Coventry, CV4 7AL, UK. Electronic address: R.bland@warwick.ac.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20190114 PL - England TA - J Steroid Biochem Mol Biol JT - The Journal of steroid biochemistry and molecular biology JID - 9015483 RN - 0 (Receptors, Calcitriol) RN - 1406-16-2 (Vitamin D) RN - A288AR3C9H (25-hydroxyvitamin D) RN - EC 1.14.15.18 (25-Hydroxyvitamin D3 1-alpha-Hydroxylase) SB - IM MH - 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism MH - Cell Line, Tumor MH - Humans MH - Receptors, Calcitriol/metabolism MH - Risk Factors MH - Signal Transduction MH - Urinary Bladder Neoplasms/*blood/etiology/metabolism MH - Vitamin D/*analogs & derivatives/blood/metabolism MH - Vitamin D Deficiency/*blood/complications/metabolism OTO - NOTNLM OT - 1,25(OH)(2)D OT - 1alpha-hydroxylase OT - Bladder cancer OT - Cathelicidin OT - Vitamin D EDAT- 2019/01/18 06:00 MHDA- 2019/05/22 06:00 CRDT- 2019/01/18 06:00 PHST- 2018/10/01 00:00 [received] PHST- 2018/12/22 00:00 [revised] PHST- 2019/01/12 00:00 [accepted] PHST- 2019/01/18 06:00 [pubmed] PHST- 2019/05/22 06:00 [medline] PHST- 2019/01/18 06:00 [entrez] AID - S0960-0760(18)30620-4 [pii] AID - 10.1016/j.jsbmb.2019.01.002 [doi] PST - ppublish SO - J Steroid Biochem Mol Biol. 2019 Apr;188:134-140. doi: 10.1016/j.jsbmb.2019.01.002. Epub 2019 Jan 14. PMID- 30653818 OWN - NLM STAT- MEDLINE DCOM- 20200210 LR - 20200210 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 123 IP - 6 DP - 2019 Jun TI - Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. PG - 959-967 LID - 10.1111/bju.14673 [doi] AB - OBJECTIVES: To investigate prospectively the clinical utility and influence on decision-making of Bladder EpiCheck, a non-invasive urine test, in the surveillance of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Urine samples from 440 patients undergoing surveillance for NMIBC were prospectively collected at five centres and evaluated using the Bladder EpiCheck test (NCT02647112). A multivariable nomogram and decision-curve analysis (DCA) were used to evaluate the impact of Bladder EpiCheck on decision-making when used in routine clinical practice. The test was designed to exclude recurrent disease. RESULTS: Data from 357 patients were available for analysis. The test had a specificity of 88% (95% confidence interval [CI] 84-91), a negative predictive value (NPV) of 94.4% (95% CI 91-97) for the detection of any cancer and an NPV of 99.3% for the detection of high-grade cancer. In multivariable analysis, positive Bladder EpiCheck results were independently associated with any and high-grade disease recurrence (odds ratio [OR] 18.1, 95% CI 8.7-40.2; P < 0.001 and OR 78.3, 95% CI 19.2-547; P < 0.001). The addition of Bladder EpiCheck to standard variables improved its predictive ability for any and high-grade disease recurrence by a difference of 16% and 22%, respectively (area under the curve 85.9% and 96.1% for any and high-grade cancer, respectively). DCA showed an improvement in the net benefit relative to cystoscopy over a large threshold of probability, resulting in a significant reduction in unnecessary investigations. These results were similar in subgroups assessing the impact of specific clinical features. CONCLUSIONS: Bladder EpiCheck is a robust high-performing diagnostic test in patients with NMIBC undergoing surveillance that can potentially reduce the number of unnecessary investigations. CI - (c) 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International. FAU - D'Andrea, David AU - D'Andrea D AUID- ORCID: 0000-0003-1625-1077 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University of Turin, Turin, Italy. FAU - Zehetmayer, Sonja AU - Zehetmayer S AD - Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Korn, Stephan AU - Korn S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. LA - eng PT - Evaluation Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20190205 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Clinical Decision-Making/methods MH - DNA Methylation/*physiology MH - Decision Support Techniques MH - Female MH - Humans MH - Male MH - Nomograms MH - Prospective Studies MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnosis/urine MH - Watchful Waiting PMC - PMC6850401 OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - non-muscle-invasive OT - prediction OT - surveillance OT - urinary biomarker COIS- Dr D'Andrea reports personal fees from Nucleix (Rehovot, Israel), during the conduct of the study. Drs Korn, Soria and Zehetmayer have nothing to disclose. Dr Witjes reports personal fees from Nucleix during the conduct of the study. Dr Gust reports personal fees and other fees from serving on the Advisory Boards for Cepheid, Roche, MSD and Ferring and as a Speaker for Astellas, Astra Zeneca, BMS, Ipsen, MSD and Roche, and meeting/travel expenses from Allergan, Astellas, Astra Zeneca, Bayer, BMS, Janssen, MSD, Novartis, Pfizer, Pierre Fabre and Roche outside the submitted work. Dr Shariat reports personal fees from Nucleix (Rehovot, Israel), during the conduct of the study, other from Method to determine prognosis after therapy for prostate cancer (granted 9 June 2002), other from Method to determine prognosis after therapy for bladder cancer (granted 19 June 2003), other from Prognostic methods for patients with prostatic disease (granted 5 August 2004), other from Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma (granted 20 July 2010), and other from Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi and Wolff, outside the submitted work. EDAT- 2019/01/18 06:00 MHDA- 2020/02/11 06:00 PMCR- 2019/11/12 CRDT- 2019/01/18 06:00 PHST- 2019/01/18 06:00 [pubmed] PHST- 2020/02/11 06:00 [medline] PHST- 2019/01/18 06:00 [entrez] PHST- 2019/11/12 00:00 [pmc-release] AID - BJU14673 [pii] AID - 10.1111/bju.14673 [doi] PST - ppublish SO - BJU Int. 2019 Jun;123(6):959-967. doi: 10.1111/bju.14673. Epub 2019 Feb 5. PMID- 30653591 OWN - NLM STAT- MEDLINE DCOM- 20190925 LR - 20200309 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 14 IP - 1 DP - 2019 TI - A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16). PG - e0209998 LID - 10.1371/journal.pone.0209998 [doi] LID - e0209998 AB - BACKGROUND: Although radical cystectomy is a standard treatment in muscle-invasive bladder cancer, bladder preservation therapy including transurethral resection of bladder tumor, radiotherapy, and concurrent chemotherapy has been widely adopted, recently. This retrospective analysis was performed to evaluate the survival rates and prognostic factors related to treatment outcomes following bladder-preserving therapy including radiotherapy (RT) in bladder cancer with a curative intent. MATERIALS AND METHODS: We conducted a multi-institutional retrospective study of 152 patients with stage II-IV bladder cancer treated with curative RT between 2000 and 2010. There were 72 patients in stage II, 49 in stage III, and 31 in stage IV. Ninety-seven patients were treated with concurrent chemoradiotherapy and fifty-five with RT alone. Radiation was delivered to the pelvis (median 63 Gy), mainly with cisplatin. The median follow-up time was 35.5 months. RESULTS: Sixty-nine patients (45.4%) showed a complete response to RT. The 5-year overall survival (OS) rate was 45.8%, the 5-year cause-specific survival (CSS) rate was 48.9%, and the 5-year disease-free survival (DFS) rate was 20.8%. Univariate analysis revealed significant differences in the following factors according to the survival rates: patient age, initial hemoglobin level, clinical T stage, clinical N stage, clinical stage group, tumor response to RT, hydronephrosis, and concurrent chemotherapy. Multivariate analysis also revealed a significant difference in patient age (p = 0.003 in OS, p<0.017 in CSS) and tumor response to RT (p = 0.002 in OS, p<0.001 in CSS). Concurrent chemotherapy was significantly different in the DFS rates (p = 0.046). CONCLUSIONS: The survival rates reported herein are comparable to those from other studies, and tumor response and concurrent chemoradiotherapy were significant prognostic factors for better survival rates. Further randomized studies are needed to elucidate the impact of RT in bladder cancer. FAU - Byun, Sang Jun AU - Byun SJ AUID- ORCID: 0000-0002-6115-2804 AD - Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. FAU - Park, Won AU - Park W AD - Department of radiation oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Cho, Kwan Ho AU - Cho KH AD - The Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. FAU - Cho, Jaeho AU - Cho J AD - Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Chang, Ah Ram AU - Chang AR AD - Department of Radiation Oncology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea. FAU - Kang, Ki Mun AU - Kang KM AD - Department of Radiation Oncology, Gyeongsang National University Hospital, Jinju, Republic of Korea. FAU - Kim, Jin Ho AU - Kim JH AUID- ORCID: 0000-0002-7918-1072 AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Jin Hee AU - Kim JH AD - Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20190117 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Chemoradiotherapy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder/pathology/radiation effects MH - Urinary Bladder Neoplasms/diagnosis/epidemiology/radiotherapy/*therapy PMC - PMC6336268 COIS- The authors have declared that no competing interests exist. EDAT- 2019/01/18 06:00 MHDA- 2019/09/26 06:00 PMCR- 2019/01/17 CRDT- 2019/01/18 06:00 PHST- 2018/06/10 00:00 [received] PHST- 2018/12/15 00:00 [accepted] PHST- 2019/01/18 06:00 [entrez] PHST- 2019/01/18 06:00 [pubmed] PHST- 2019/09/26 06:00 [medline] PHST- 2019/01/17 00:00 [pmc-release] AID - PONE-D-18-17416 [pii] AID - 10.1371/journal.pone.0209998 [doi] PST - epublish SO - PLoS One. 2019 Jan 17;14(1):e0209998. doi: 10.1371/journal.pone.0209998. eCollection 2019. PMID- 30643456 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220331 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 11 DP - 2019 TI - Sex-related differences in urothelial cell carcinoma of the bladder in Germany. PG - 309-316 LID - 10.2147/CMAR.S181532 [doi] AB - BACKGROUND: Urothelial cell carcinoma (UCC), also called transitional cell cancer, occurs significantly more often in males than in females. Essential for the prognosis of recovery is depth of infiltration (muscle-invasive or non-muscle invasive) and tumor-differentiation at initial diagnosis. The current study aimed to explore sex-related differences after initial diagnosis of UCC in Germany. METHODS: We identified patients who underwent transurethral resection of the bladder tumor (TUR-BT). Data were retrospectively analyzed, including TNM classification, histopathological grading, risk group according to the European Association of Urology (EAU), use of photody-namic diagnosis (PDD), and early intravesical chemotherapy (IVC). RESULTS: A total of 539 male and 190 female patients with UCC underwent TUR-BT. Approximately 75% were non-muscle invasive bladder cancer (NMIBC). Females evidenced significantly higher rates of muscle-invasive bladder cancer (MIBC; P=0.04). Carcinoma in situ (CIS) was significantly more common among males (P=0.01). Recurrence and progression rates showed no significant sex differences - only in the small subgroup of EAU low-risk NMIBC females, we found a significantly higher progression rate (P=0.03). In a Cox proportional hazards model, we found for MIBC, an HR for progression of 6.5 (95% CI, 1.29-33.2; P=0.02) after a median follow-up of 56 months. Use of PDD or IVC showed no significant differences in recurrence and progression between females and males. CONCLUSION: Females were significantly more likely to suffer from MIBC at the time of first diagnosis. In NMIBC, males showed a significantly higher prevalence of CIS and EAU low-risk NMIBC females showed significantly higher rates of progression. Sex was not associated with recurrence rates in NMIBC. PDD and IVC were equally effective in both sexes. Based on the collected data we suggest to further investigate possible sex differences in UCC with therapeutical impact. Additional prospective multicenter studies are needed to evaluate both sex-related long-term disease courses and effectiveness of therapies. FAU - Scheller, Thomas AU - Scheller T AD - Philipps University Hospital, Department of Urology, Marburg, Germany, Hegele@med.uni-marburg.de. FAU - Hofmann, Rainer AU - Hofmann R AD - Philipps University Hospital, Department of Urology, Marburg, Germany, Hegele@med.uni-marburg.de. FAU - Hegele, Axel AU - Hegele A AD - Philipps University Hospital, Department of Urology, Marburg, Germany, Hegele@med.uni-marburg.de. LA - eng PT - Journal Article DEP - 20181228 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6314054 OTO - NOTNLM OT - NMIBC OT - TCC OT - UCB OT - UCC OT - bladder cancer OT - gender OT - sex OT - urothelial cancer COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2019/01/16 06:00 MHDA- 2019/01/16 06:01 PMCR- 2018/12/28 CRDT- 2019/01/16 06:00 PHST- 2019/01/16 06:00 [entrez] PHST- 2019/01/16 06:00 [pubmed] PHST- 2019/01/16 06:01 [medline] PHST- 2018/12/28 00:00 [pmc-release] AID - cmar-11-309 [pii] AID - 10.2147/CMAR.S181532 [doi] PST - epublish SO - Cancer Manag Res. 2018 Dec 28;11:309-316. doi: 10.2147/CMAR.S181532. eCollection 2019. PMID- 30630748 OWN - NLM STAT- MEDLINE DCOM- 20200623 LR - 20200623 IS - 1879-4076 (Electronic) IS - 1879-4068 (Linking) VI - 10 IP - 2 DP - 2019 Mar TI - Radical radiotherapy in older patients with muscle invasive bladder cancer. PG - 292-297 LID - S1879-4068(18)30302-3 [pii] LID - 10.1016/j.jgo.2018.10.015 [doi] AB - BACKGROUND: Muscle invasive bladder cancer (MIBC) is prevalent in the older patients, who are a vulnerable population with multiple co-morbidities and at increased risk of complications. Radical cystectomy is often not suitable, hence radical radiotherapy (RT) is an alternative option. We reviewed the outcomes of older patients treated with RT with or without concurrent chemotherapy (CRT) at our institution. METHODS: We retrospectively reviewed patients aged 65 years and above treated with radical RT for MIBC at our institution between March 2002 to January 2017. Data was collected from institutional medical records and RT databases. The primary outcome was 2- and 5-year overall survival (OS), recurrence free survival (RFS), and toxicities. Univariate cox proportional hazard regression models were performed to identify independent factors with significant impact on survival. RESULTS: We identified 45 patients (34 males, 11 females) with a median age of 77 years (range 65-95). All patients received maximal transurethral resection of the bladder tumour prior to RT. Median dose of total RT was 64 Gy (range 50-69.8 Gy). Twenty one patients (47%) received CRT. Planned treatment was completed in 42 (93.3%) patients. Median follow-up was 31 months (range 1-147 months). The 2- and 5-year OS was 64% and 44%, respectively. The 2- and 5-year RFS was 68% and 49%, respectively. Median RFS was 34 months (range 8-121 months). Median OS was 56 months (range 18-100 months). Univariate analysis showed that performance status (0-1 vs. 2-3; HR 2.7, 95% CI 1.07-6.8, p = 0.035) and International Society of Geriatric Oncology (SIOG) group (2; HR 3.23, 95% CI 1.12-8.64, p = 0.019) were significantly associated with increased hazard for death. One patient (2%) had grade 3 cystitis. CONCLUSION: Radical RT is well tolerated in older patients with MIBC. We report outcomes similar to published data. Older patients should be considered for curative treatment despite their age. However, careful selection is warranted as frail patients (PS >/=2; SIOG >2) may benefit less. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - Wujanto, Caryn AU - Wujanto C AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. FAU - Tey, Jeremy AU - Tey J AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. Electronic address: jeremy_tey@nuhs.edu.sg. FAU - Chia, David AU - Chia D AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. FAU - Ho, Francis AU - Ho F AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. FAU - Ooi, Kiat Huat AU - Ooi KH AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. FAU - Wong, Alvin S AU - Wong AS AD - Department of Haematology Oncology, National University Cancer Institute, Singapore. FAU - Soon, Yu Yang AU - Soon YY AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. FAU - Lim, Keith AU - Lim K AD - Department of Radiation Oncology, National University Cancer Institute, Singapore. LA - eng PT - Journal Article DEP - 20190108 PL - Netherlands TA - J Geriatr Oncol JT - Journal of geriatric oncology JID - 101534770 RN - 0 (Antineoplastic Agents) SB - IM MH - Activities of Daily Living MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/therapeutic use MH - Carcinoma, Transitional Cell/epidemiology/pathology/physiopathology/*therapy MH - Chemoradiotherapy, Adjuvant/*methods MH - Cystitis/epidemiology MH - *Cystoscopy MH - Diarrhea/epidemiology MH - Disease-Free Survival MH - Female MH - Frailty/epidemiology MH - Humans MH - Lower Urinary Tract Symptoms/epidemiology MH - Male MH - Muscle, Smooth/*pathology MH - Nausea/epidemiology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Patient Selection MH - Proportional Hazards Models MH - Radiation Injuries/epidemiology MH - Radiodermatitis/epidemiology MH - Radiotherapy, Adjuvant/*methods MH - Retrospective Studies MH - Severity of Illness Index MH - Survival Rate MH - Urinary Bladder Neoplasms/epidemiology/pathology/physiopathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Chemoradiotherapy OT - Elderly OT - Muscle invasive OT - Radiotherapy EDAT- 2019/01/12 06:00 MHDA- 2020/06/24 06:00 CRDT- 2019/01/12 06:00 PHST- 2018/07/29 00:00 [received] PHST- 2018/09/19 00:00 [revised] PHST- 2018/10/22 00:00 [accepted] PHST- 2019/01/12 06:00 [pubmed] PHST- 2020/06/24 06:00 [medline] PHST- 2019/01/12 06:00 [entrez] AID - S1879-4068(18)30302-3 [pii] AID - 10.1016/j.jgo.2018.10.015 [doi] PST - ppublish SO - J Geriatr Oncol. 2019 Mar;10(2):292-297. doi: 10.1016/j.jgo.2018.10.015. Epub 2019 Jan 8. PMID- 30630734 OWN - NLM STAT- MEDLINE DCOM- 20200127 LR - 20200127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 4 DP - 2019 Apr TI - The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer. PG - 291.e1-291.e7 LID - S1078-1439(18)30552-0 [pii] LID - 10.1016/j.urolonc.2018.12.026 [doi] AB - OBJECTIVE: The production of antibody, also referred immunoglobulin, is the principal functions of B cells. Gamma globulin fraction determined by serum protein electrophoresis is composed almost entirely of immunoglobulin. This study aimed to investigate the association between gamma globulin level and oncological outcomes in patients with nonmuscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A total of 274 patients with NMIBC who underwent transurethral surgery between 2000 and 2015 were identified. One hundred forty-four patients (52.6%) had received adjuvant intravesical bacillus Calmette-Guerin. Gamma globulin fraction (%) was determined by serum protein electrophoresis, and gamma globulin level (mg/dl) was calculated by multiplying the total protein level (mg/dl) by the gamma globulin fraction (%). The association between gamma globulin levels and oncological outcomes was statistically evaluated. RESULTS: During a median follow-up period of 39 months, 99 (36.1%) patients experienced at least 1 tumor recurrence and 16 (5.8%) patients had disease progression. The median (interquartile range) gamma globulin level was 1.2 (1.0-1.3) mg/dl. Recurrence-free survival rate of patients with gamma globulin levels of >/=1.4 mg/dl was significant lower than that of patients with gamma globulin levels of <1.4 mg/dl (P < 0.01). There was no significant difference in progression-free survival between the 2 groups (P = 0.17). Multivariate analysis revealed that gamma globulin level of >/=1.4 mg/dl is significantly associated with higher recurrence rate (hazard ratio = 1.83, P < 0.01). CONCLUSION: Gamma globulin level is significantly associated with tumor recurrence. Our results suggest that B cell immunity may be involved in tumor recurrence in patients with NMIBC. CI - Copyright (c) 2019. Published by Elsevier Inc. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: ashandjesus@gmail.com. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20190108 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (gamma-Globulins) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Urinary Bladder Neoplasms/*genetics/*metabolism/pathology MH - gamma-Globulins/*metabolism OTO - NOTNLM OT - B lymphocyte OT - Bladder cancer OT - Gamma globulin OT - Humoral immunity OT - Immune-oncology OT - Immunoglobulin EDAT- 2019/01/12 06:00 MHDA- 2020/01/28 06:00 CRDT- 2019/01/12 06:00 PHST- 2018/09/11 00:00 [received] PHST- 2018/12/05 00:00 [revised] PHST- 2018/12/28 00:00 [accepted] PHST- 2019/01/12 06:00 [pubmed] PHST- 2020/01/28 06:00 [medline] PHST- 2019/01/12 06:00 [entrez] AID - S1078-1439(18)30552-0 [pii] AID - 10.1016/j.urolonc.2018.12.026 [doi] PST - ppublish SO - Urol Oncol. 2019 Apr;37(4):291.e1-291.e7. doi: 10.1016/j.urolonc.2018.12.026. Epub 2019 Jan 8. PMID- 30623554 OWN - NLM STAT- MEDLINE DCOM- 20200210 LR - 20200210 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 IP - 6 DP - 2019 Jun TI - Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. PG - 1011-1019 LID - 10.1111/bju.14612 [doi] AB - OBJECTIVE: To investigate the association between smoking status and pathological response to cisplatin-based neoadjuvant chemotherapy (NAC) and survival outcomes in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy (RC). PATIENTS AND METHODS: We reviewed 201 patients treated with NAC and RC for cT2-cT4N0M0 BC between 01/1999 and 01/2015. Smoking status was categorised as: 'never', 'former', and 'current' smoker. Pathological response to NAC was defined as: complete (ypT0N0), partial (ypTis/Ta/T1, N0), and no response (ypT2-4 or ypN+). Clinicopathological characteristics were analysed according to smoking status. Logistic regression analyses tested the association between smoking status and pathological response to NAC. Cox regression analyses tested risk factors associated with recurrence, overall (OM) and cancer-specific mortality (CSM). RESULTS: Overall, there were 58 (28.9%) never smokers, 87 (43.3%) former smokers, and 56 (27.9%) current smokers. No response to NAC was more frequently noted in current smokers (73.2%; P = 0.007). Former smoker (odds ratio [OR] 2.28; P = 0.024) and current smoker statuses (OR 4.52; P < 0.001) were significantly associated with no response to NAC, after adjusting for age, gender, Charlson Comorbidity Index, and clinical stage. Similarly, current smoking status (hazard ratio [HR] 2.14; P = 0.03) and extravesical pathological tumour stage (HR 3.31; P < 0.001) were independently associated with an increased risk of recurrence after RC. CONCLUSION: Cigarette smoking was significantly associated with adverse pathological response to cisplatin-based NAC in patients with MIBC treated with RC. Current smokers were at significantly higher risk of disease recurrence as compared to former and never smokers. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons. FAU - Boeri, Luca AU - Boeri L AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. AD - Department of Urology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Soligo, Matteo AU - Soligo M AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Thompson, Robert H AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Tollefson, Matthew AU - Tollefson M AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Quevedo, Fernando J AU - Quevedo FJ AD - Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. FAU - Cheville, John C AU - Cheville JC AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. FAU - Karnes, Robert Jeffrey AU - Karnes RJ AUID- ORCID: 0000-0003-2339-5925 AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. LA - eng PT - Journal Article DEP - 20190108 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - Q20Q21Q62J (Cisplatin) SB - IM CIN - J Urol. 2020 Nov;204(5):1095-1096. doi: 10.1097/JU.0000000000001260.02. PMID: 32821004 MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma in Situ/pathology/*therapy MH - Chemotherapy, Adjuvant MH - Cigarette Smoking/*adverse effects MH - Cisplatin/administration & dosage MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle Neoplasms/pathology/therapy MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*etiology/pathology MH - Neoplasm Staging MH - Prospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - #Bladder Cancer OT - #blcsm OT - #uroonc OT - bladder cancer OT - cigarette smoking OT - cisplatin OT - disease recurrence OT - neoadjuvant chemotherapy OT - pathologic response EDAT- 2019/01/10 06:00 MHDA- 2020/02/11 06:00 CRDT- 2019/01/10 06:00 PHST- 2019/01/10 06:00 [pubmed] PHST- 2020/02/11 06:00 [medline] PHST- 2019/01/10 06:00 [entrez] AID - 10.1111/bju.14612 [doi] PST - ppublish SO - BJU Int. 2019 Jun;123(6):1011-1019. doi: 10.1111/bju.14612. Epub 2019 Jan 8. PMID- 30615894 OWN - NLM STAT- MEDLINE DCOM- 20190611 LR - 20190613 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 126 DP - 2019 Apr TI - The Urinary Microbiome: Implications in Bladder Cancer Pathogenesis and Therapeutics. PG - 10-15 LID - S0090-4295(19)30006-8 [pii] LID - 10.1016/j.urology.2018.12.034 [doi] AB - Recent investigation has proven that the bladder is not sterile. However, the implications of this finding in the pathophysiology and management of urothelial cell carcinoma have not been fully described. In this review, we summarize the literature relating to the urinary and gastrointestinal microbiomes in the context of urothelial cell carcinoma. The bladder microbiome may relate to urothelial cell carcinoma pathogenesis/progression, act as a noninvasive and modifiable urinary biomarker and have implications in treatment using immunotherapy agents such as intravesical bacillus Calmette-Guerin. Investigators should continue to optimize techniques to characterize this intriguing new area of human health. CI - Copyright (c) 2019 Elsevier Inc. All rights reserved. FAU - Bajic, Petar AU - Bajic P AD - Department of Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL. Electronic address: pbajicmd@gmail.com. FAU - Wolfe, Alan J AU - Wolfe AJ AD - Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL. FAU - Gupta, Gopal N AU - Gupta GN AD - Department of Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Departments of Surgery and Radiology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL. LA - eng PT - Journal Article PT - Review DEP - 20190104 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/*microbiology/*therapy MH - Humans MH - Immunotherapy MH - *Microbiota MH - Urinary Bladder Neoplasms/*microbiology/*therapy EDAT- 2019/01/08 06:00 MHDA- 2019/06/14 06:00 CRDT- 2019/01/08 06:00 PHST- 2018/11/08 00:00 [received] PHST- 2018/12/20 00:00 [revised] PHST- 2018/12/29 00:00 [accepted] PHST- 2019/01/08 06:00 [pubmed] PHST- 2019/06/14 06:00 [medline] PHST- 2019/01/08 06:00 [entrez] AID - S0090-4295(19)30006-8 [pii] AID - 10.1016/j.urology.2018.12.034 [doi] PST - ppublish SO - Urology. 2019 Apr;126:10-15. doi: 10.1016/j.urology.2018.12.034. Epub 2019 Jan 4. PMID- 30612154 OWN - NLM STAT- MEDLINE DCOM- 20191212 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 6 DP - 2019 Jun TI - Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors. PG - 1075-1084 LID - 10.1007/s00345-019-02628-7 [doi] AB - PURPOSE: We performed a meta-analysis to confirm the efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection for the treatment of non-muscle invasive bladder cancer. METHODS: Randomized controlled trials of continuous saline bladder irrigation compared with intravesical chemotherapy were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were evaluated and statistically analyzed using RevMan version 5.3.0. RESULTS: Four studies including 861 participants which compared continuous saline bladder irrigation with intravesical chemotherapy were considered. One-year recurrence-free survival [odds ratio (OR) = 0.76, 95% CI = 0.55-1.05, p = 0.09]; 2-year recurrence-free survival (OR = 0.94, 95% CI = 0.71-1.25, p = 0.68); the median period to first recurrence (OR = - 1.01, 95% CI = - 2.96 to 0.94, p = 0.31); the number of tumor progression (OR = 0.80, 95% CI = 0.54-1.17, p = 0.25); and the number of recurrence during follow-up (OR = 1.12, 95% CI = 0.84-1.50, p = 0.43) suggested that two methods of postoperative perfusion had no significant differences. In terms of safety, including macrohematuria, frequency of urination and bladder irritation symptoms, continuous saline bladder irrigation showed better tolerance than intravesical chemotherapy. CONCLUSION: Continuous saline bladder irrigation seems to provide a better balance between prevention of recurrence and local toxicities than intravesical chemotherapy after transurethral resection of bladder tumors. FAU - Zhou, Zhongbao AU - Zhou Z AD - Binzhou Medical University, Yantai, Shandong, China. AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. FAU - Zhao, Shikai AU - Zhao S AD - Department of Andrology, The Liaocheng People's Hospital, Liaocheng, Shandong, China. FAU - Lu, Youyi AU - Lu Y AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. FAU - Wu, Jitao AU - Wu J AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. FAU - Li, Yongwei AU - Li Y AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. FAU - Gao, Zhenli AU - Gao Z AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. FAU - Yang, Diandong AU - Yang D AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. 3098516949@qq.com. FAU - Cui, Yuanshan AU - Cui Y AD - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, 264000, Shandong, China. m15275525316@163.com. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis DEP - 20190105 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 0 (Saline Solution) SB - IM CIN - World J Urol. 2020 Feb;38(2):513. doi: 10.1007/s00345-019-02645-6. PMID: 30707303 MH - Administration, Intravesical MH - Antineoplastic Agents/administration & dosage MH - Combined Modality Therapy MH - Cystectomy/methods MH - Humans MH - Randomized Controlled Trials as Topic MH - Saline Solution/*administration & dosage/adverse effects MH - Therapeutic Irrigation/adverse effects/methods MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/drug therapy/surgery/*therapy OTO - NOTNLM OT - Continuous saline bladder irrigation OT - Meta-analysis OT - Non-muscle invasive bladder cancer OT - Randomized controlled trials OT - Transurethral resection of bladder tumors EDAT- 2019/01/07 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/01/07 06:00 PHST- 2018/10/08 00:00 [received] PHST- 2019/01/02 00:00 [accepted] PHST- 2019/01/07 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/01/07 06:00 [entrez] AID - 10.1007/s00345-019-02628-7 [pii] AID - 10.1007/s00345-019-02628-7 [doi] PST - ppublish SO - World J Urol. 2019 Jun;37(6):1075-1084. doi: 10.1007/s00345-019-02628-7. Epub 2019 Jan 5. PMID- 30610817 OWN - NLM STAT- MEDLINE DCOM- 20190830 LR - 20190830 IS - 1107-0625 (Print) IS - 1107-0625 (Linking) VI - 23 IP - 6 DP - 2018 Nov-Dec TI - HMGB1 expression in urothelial carcinoma of the bladder. PG - 1882-1886 AB - PURPOSE: HMGB1, the most important member of the high mobility group box protein family, is a nuclear protein with different functions in the cell; it has a role in cancer progression, angiogenesis, invasion, and metastasis development. We studied the expression of HMGB1 and whether it is a prognostic factor in urothelial carcinoma of bladder (UCB) or not. METHODS: The study included 90 cases that were histopathologically diagnosed with UCB in the tissue samples obtained by transurethral resection (TUR). HMGB1 expression was investigated by immunohistochemistry. RESULTS: A total of 90 patients, 80 (88.9%) male and 10 (11.1%) female, were enrolled in the study. The histopathological diagnosis was infiltrating urothelial carcinoma (IUC) in 63 (70.0%) and non-invasive papillary urothelial carcinoma (NIPUC) in 27 (30.0%). When the NIPUC cases were grouped according to grade, 24 (88.9%) of the cases were low grade and 3 (11.1%) were high grade. HMGB1 expression was found positive in 51 (56.7%) and negative in 39 (43.3%) of the patients. HMGB1 expression was significantly higher in IUCs (p=0.046). CONCLUSION: The results of our study demonstrate that HMGB1 overexpression has a significant role in UCB progression and it corroborates the idea that it might be an important prognostic factor. FAU - Suren, Dinc AU - Suren D AD - Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya. FAU - Yildirim, Hulya Tosun AU - Yildirim HT FAU - Atalay, Irem AU - Atalay I FAU - Sayiner, Alper AU - Sayiner A FAU - Yildirim, Mustafa AU - Yildirim M FAU - Alikanoglu, Arsenal Sezgin AU - Alikanoglu AS FAU - Sezer, Cem AU - Sezer C LA - eng PT - Journal Article PL - Cyprus TA - J BUON JT - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JID - 100883428 RN - 0 (Biomarkers, Tumor) RN - 0 (HMGB1 Protein) RN - 0 (HMGB1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/metabolism/*pathology MH - Carcinoma, Transitional Cell/metabolism/*pathology MH - Disease Progression MH - Female MH - Follow-Up Studies MH - HMGB1 Protein/*metabolism MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Urinary Bladder Neoplasms/metabolism/*pathology EDAT- 2019/01/06 06:00 MHDA- 2019/08/31 06:00 CRDT- 2019/01/06 06:00 PHST- 2019/01/06 06:00 [entrez] PHST- 2019/01/06 06:00 [pubmed] PHST- 2019/08/31 06:00 [medline] PST - ppublish SO - J BUON. 2018 Nov-Dec;23(6):1882-1886. PMID- 36157135 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 5 IP - 2 DP - 2019 TI - CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. PG - 159-169 LID - 10.3233/blc-180206 [doi] AB - BACKGROUND: Major interest lies in the evaluation of immune infiltrate in bladder cancer. CD8+ cytotoxic lymphocytes are key effectors of adaptive immune response. OBJECTIVES: The aims of the study were to set up a standardized methodology for CD8+ lymphocytes estimation in NMIBC and investigate how intra-tumoral heterogeneity influences CD8+ immune infiltrate. METHODS: We considered 995 NMIBC included in the Spanish Bladder Cancer (SBC)/EPICURO Study. Duplicate 0.6mm TMA spots and paired full sections (FS) for 50 selected cases were double stained with anti-pan cytokeratin antibody and anti-CD8 antibody. Slides were digitalized and CD8+ cells were automatically counted after tissue recognition (tumor vs stroma). Spatial heterogeneity was assessed and a resampling strategy was applied to estimate the proper number of 0.6mm TMA spots providing an adequate CD8+ cell estimate. Association between CD8+ count and expression of urothelial differentiation markers was estimated. Cox regression models were performed to assess association between CD8+ cell count and risk of recurrence and progression. RESULTS: Microscopic examination of full sections showed spatial heterogeneity for CD8+ infiltrates. Simulation analyses demonstrated that 5 TMA regions provided a correct sampling of tumor and stromal compartments in Ta while 2 and 6 TMA regions were necessary in T1, respectively. CD8+ cells infiltration was associated with stage, regardless of the histological compartment analyzed (median CD8+ /mm(2) were 25/mm(2) and 129/mm(2) in tumor and stroma respectively in Ta and 111/mm(2) and 344/mm(2) in T1; p-value = 0.006). CD8+ infiltration in tumor compartment was significantly associated with low FGFR3 expression. CD8+/mm(2) count in the tumor compartment was not associated with prognosis. CONCLUSION: Differences identified between Ta and T1 tumours supported the hypothesis that rigorous efforts should be placed in proper study design. These results provide a new framework to investigate microenvironment complexity in bladder cancer. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - IMRB, INSERMU955 team 7, Translational research in uro-genital carcinogenesis, Creteil, France. AD - Department of Urology, Paris Diderot University, AP-HP, Saint Louis Hospital, Paris, France. AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Maille, Pascale AU - Maille P AD - IMRB, INSERMU955 team 7, Translational research in uro-genital carcinogenesis, Creteil, France. AD - Department of Pathological, Institut Curie, Saint Cloud, France. FAU - Pineda, Silvia AU - Pineda S AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Soyeux, Pascale AU - Soyeux P AD - IMRB, INSERMU955 team 7, Translational research in uro-genital carcinogenesis, Creteil, France. FAU - Sagrera, Ana AU - Sagrera A AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Departament de Ciencies experimentals i de la salut, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Rava, Marta AU - Rava M AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - de Maturana, Evangelina Lopez AU - de Maturana EL AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Marquez, Mirari AU - Marquez M AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Tardon, Adonina AU - Tardon A AD - Preventive Medicine and Public Health, University of Oviedo, Oviedo, Spain. AD - Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), Madrid, Spain. FAU - Carrato, Alfredo AU - Carrato A AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. AD - Department of Oncology, Hospital Ramon y Cajal, Madrid, Spain. FAU - Kogevinas, Manolis AU - Kogevinas M AD - Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), Madrid, Spain. AD - IMIM-Institut de Recerca Hospital del Mar; Centre de Recerca en Epidemiologia Ambiental (CREAL), Barcelona, Spain. AD - National School of Public Health, Athens, Greece. FAU - de la Taille, Alexandre AU - de la Taille A AD - IMRB, INSERMU955 team 7, Translational research in uro-genital carcinogenesis, Creteil, France. AD - Department of Urology, AP-HP, CHU Henri Mondor, Creteil, France. FAU - Hartmann, Arndt AU - Hartmann A AD - Department of Pathology, Universitatsklinikum, Erlangen, Germany. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. FAU - Real, Paco AU - Real P AD - Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. AD - Departament de Ciencies experimentals i de la salut, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Allory, Yves AU - Allory Y AD - IMRB, INSERMU955 team 7, Translational research in uro-genital carcinogenesis, Creteil, France. AD - Department of Pathological, Institut Curie, Saint Cloud, France. LA - eng GR - N02 CP011015/CP/NCI NIH HHS/United States PT - Journal Article DEP - 20190816 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC9503287 MID - NIHMS1698441 OTO - NOTNLM OT - CD8 OT - Urothelial carcinoma OT - methodology OT - prognosis COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to report. EDAT- 2019/01/01 00:00 MHDA- 2019/01/01 00:01 PMCR- 2022/09/23 CRDT- 2022/09/26 17:03 PHST- 2022/09/26 17:03 [entrez] PHST- 2019/01/01 00:00 [pubmed] PHST- 2019/01/01 00:01 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - 10.3233/blc-180206 [doi] PST - ppublish SO - Bladder Cancer. 2019;5(2):159-169. doi: 10.3233/blc-180206. Epub 2019 Aug 16. PMID- 32239093 OWN - NLM STAT- MEDLINE DCOM- 20200731 LR - 20200731 IS - 2066-8279 (Electronic) IS - 1220-0522 (Linking) VI - 60 IP - 4 DP - 2019 TI - Histopathological predictive factors for the overall survival rate in patients with urothelial carcinoma of the bladder treated by radical cystectomy: a Romanian cohort study. PG - 1183-1190 AB - INTRODUCTION: Urothelial carcinoma (UC) variants are considered as having a more aggressive behavior and a more advanced stage at presentation than conventional UC. However, the evidence supporting the role of UC variants on overall survival (OS) is conflicting. We aimed to assess the impact of demographic factors (age at surgery, gender) and tumor characteristics [conventional∕variant UC, associated carcinoma in situ (CIS), associated papillary component, Tumor, Node, Metastasis (TNM) staging, positive surgical margins] on OS in a series of patients treated for UC in our Department. PATIENTS, MATERIALS AND METHODS: We performed a retrospective, cohort study and included 69 UC patients treated by radical cystectomy (RC) in our Department over an eight-year period, with complete follow-up information. Associations of UC variants as well as demographic and morphological factors with OS were assessed using univariable and multivariable Cox analysis. RESULTS: Our data showed that UC variants were statistically significantly associated with the presence of distant metastases (p=0.036) and positive surgical margins (p=0.009), but had no influence on OS (p=0.504). Further on, we demonstrated that age at surgery (p=0.045), tumor stage (p=0.012), lymph node involvement (p=0.009), and presence of positive surgical margins (p=0.002) had a statistically significant influence on OS both by univariable and multivariable Cox analysis. CONCLUSIONS: Age, tumor stage and lymph node involvement, as well as positive surgical margins represent prognostic factors in RC patients. UC variants were more likely to be associated to metastases and positive surgical margins but had no influence on OS. FAU - Nechifor-Boila, Ioan Alin AU - Nechifor-Boila IA AD - Department of Urology, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania; calinchibelean@yahoo.com. FAU - Chibelean, Bogdan Calin AU - Chibelean BC FAU - Loghin, Andrada AU - Loghin A FAU - Nechifor-Boila, Adela Corina AU - Nechifor-Boila AC FAU - Voidazan, Toader Septimiu AU - Voidazan TS FAU - Radulescu, Maria Flavia AU - Radulescu MF FAU - Borda, Angela AU - Borda A LA - eng PT - Journal Article PL - Romania TA - Rom J Morphol Embryol JT - Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie JID - 9112454 SB - IM MH - Adult MH - Aged MH - Cohort Studies MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Romania MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery EDAT- 2019/01/01 00:00 MHDA- 2020/08/01 06:00 CRDT- 2020/04/03 06:00 PHST- 2020/04/03 06:00 [entrez] PHST- 2019/01/01 00:00 [pubmed] PHST- 2020/08/01 06:00 [medline] AID - 60041911831190 [pii] PST - ppublish SO - Rom J Morphol Embryol. 2019;60(4):1183-1190. PMID- 30593515 OWN - NLM STAT- MEDLINE DCOM- 20200529 LR - 20221207 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 25 IP - 8 DP - 2019 Apr 15 TI - Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. PG - 2458-2470 LID - 10.1158/1078-0432.CCR-18-3147 [doi] AB - PURPOSE: The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets. EXPERIMENTAL DESIGN: Using targeted exome sequencing (n = 237 genes), we analyzed the mutation spectra of 82 low-grade nonmuscle-invasive bladder cancers (LG-NMIBC), 126 high-grade (HG) NMIBC, 199 muscle-invasive bladder cancers (MIBC), 10 LG-upper tract urothelial cancers (LG-UTUC), and 55 HG-UTUC. RESULTS: FGFR3 and KDM6A mutations were significantly more common in LG-NMIBC (72% and 44%, respectively) versus other bladder subtypes. FGFR3 alterations were also enriched in LG-UTUC versus HG-UTUC tumors (80% vs. 16%). In contrast, TP53 and RB1 mutations were significantly more frequent in all 3 HG urothelial carcinoma subtypes than in LG-NIMBC (45%-58% vs. 4%; 9%-22% vs. 0; respectively). Among LG-NMIBC tumors, KDM6A mutations were more common in women than in men (71% vs. 38%). HG-NMIBC and MIBC had higher tumor mutational burden (TMB) than LG-NMIBC (P = 0.001 and P < 0.01, respectively). DNA-damage repair (DDR) alterations were associated with a higher TMB in HG-NMIBC and MIBC tumors, and these two tumor types were also enriched for an APOBEC mutational signature compared with LG-NMIBC and HG-UTUC. Alterations in FGFR3, PIK3CA, and EP300 correlated with worse overall survival in HG-UTUC and occurred concurrently. CONCLUSIONS: Our analysis suggests that a fraction of MIBCs likely arise from precursor lesions other than LG-NMIBC. KDM6A mutations are twice as common in women with LG-NIMBC than those in men. DDR gene mutations and APOBEC mutagenesis drive mutations in HG-NMIBC and MIBC. UTUC has a distinct mutation profile from bladder cancer. CI - (c)2018 American Association for Cancer Research. FAU - Nassar, Amin H AU - Nassar AH AUID- ORCID: 0000-0002-8084-9105 AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Umeton, Renato AU - Umeton R AD - Department of Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Massachusetts Institute of Technology, Cambridge, Massachusetts. FAU - Kim, Jaegil AU - Kim J AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. FAU - Lundgren, Kevin AU - Lundgren K AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Harshman, Lauren AU - Harshman L AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Van Allen, Eliezer M AU - Van Allen EM AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. AD - The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. FAU - Preston, Mark AU - Preston M AD - Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Dong, Fei AU - Dong F AD - Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain. FAU - Mouw, Kent W AU - Mouw KW AD - Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Choueiri, Toni K AU - Choueiri TK AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Sonpavde, Guru AU - Sonpavde G AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Kwiatkowski, David J AU - Kwiatkowski DJ AUID- ORCID: 0000-0002-5668-5219 AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dk@rics.bwh.harvard.edu. AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. LA - eng PT - Journal Article DEP - 20181228 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Biomarkers, Tumor MH - DNA Copy Number Variations MH - DNA Mutational Analysis MH - Disease Progression MH - Female MH - Gene Expression Profiling MH - Genomics/methods MH - Humans MH - Male MH - Middle Aged MH - *Mutation MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Urologic Neoplasms/*genetics/mortality/*pathology MH - Exome Sequencing EDAT- 2018/12/30 06:00 MHDA- 2020/05/30 06:00 CRDT- 2018/12/30 06:00 PHST- 2018/09/25 00:00 [received] PHST- 2018/11/17 00:00 [revised] PHST- 2018/12/21 00:00 [accepted] PHST- 2018/12/30 06:00 [pubmed] PHST- 2020/05/30 06:00 [medline] PHST- 2018/12/30 06:00 [entrez] AID - 1078-0432.CCR-18-3147 [pii] AID - 10.1158/1078-0432.CCR-18-3147 [doi] PST - ppublish SO - Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. doi: 10.1158/1078-0432.CCR-18-3147. Epub 2018 Dec 28. PMID- 30593457 OWN - NLM STAT- MEDLINE DCOM- 20200806 LR - 20200806 IS - 1538-7755 (Electronic) IS - 1055-9965 (Linking) VI - 28 IP - 6 DP - 2019 Jun TI - Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer. PG - 1036-1044 LID - 10.1158/1055-9965.EPI-18-0893 [doi] AB - BACKGROUND: Despite extensive research to identify biomarkers of response in patients with non-muscle-invasive bladder cancer (NMIBC), there is no biomarker to date that can serve this purpose. Herein, we report how we leveraged serial urine samples to query a panel of cytokines at varying time points in an attempt to identify predictive biomarkers of response in NMIBC. METHODS: Serial urine samples were collected from 50 patients with intermediate- or high-risk NMIBC enrolled in a phase II study, evaluating intravesical BCG +/- intradermal HS-410 therapy. Samples were collected at baseline, week 7, week 13, week 28, and at end of treatment. A total of 105 cytokines were analyzed in each sample. To predict outcome of time-to-event (recurrence or progression), univariate and multivariable Cox analyses were performed. RESULTS: Fifteen patients developed recurrence and 4 patients progressed during the follow-up period. Among clinicopathologic variables, ever-smoker versus nonsmoker status was associated with an improved response rate (HR 0.38; 95% confidence interval (CI), 0.14-0.99; P = 0.04). In the most clinically relevant model, the percent change (for 100 units) of IL18-binding protein-a (HR 1.995; 95% CI, 1.16-3.44; P = 0.01), IL23 (HR 1.12; 95% CI, 1.01-1.23; P = 0.03), IL8 (HR 0.27; 95% CI, 0.07-1.08; P = 0.06), and IFNgamma-induced protein-10 (HR 0.95; 95% CI, 0.91-0.99; P = 0.04) at week 13 from baseline best predicted time to event. CONCLUSIONS: Urinary cytokines provided additional value to clinicopathologic features to predict response to immune-modulating agents in patients with NMIBC. IMPACT: This study serves as a hypothesis-generating report for future studies to evaluate the role of urine cytokines as a predictive biomarker of response to immune treatments. CI - (c)2018 American Association for Cancer Research. FAU - Salmasi, Amirali AU - Salmasi A AUID- ORCID: 0000-0002-3884-6322 AD - Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, California. AD - Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, California. FAU - Elashoff, David A AU - Elashoff DA AD - Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California. FAU - Guo, Rong AU - Guo R AD - Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California. FAU - Upfill-Brown, Alexander AU - Upfill-Brown A AD - Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, California. FAU - Rosser, Charles J AU - Rosser CJ AD - Clinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, Hawaii. FAU - Rose, Jason M AU - Rose JM AD - Heat Biologics, Durham, North Carolina. FAU - Giffin, Louise C AU - Giffin LC AD - Heat Biologics, Durham, North Carolina. FAU - Gonzalez, Louis E AU - Gonzalez LE AD - Heat Biologics, Durham, North Carolina. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, California. AD - Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, California. LA - eng PT - Journal Article DEP - 20181228 PL - United States TA - Cancer Epidemiol Biomarkers Prev JT - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JID - 9200608 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Cancer Vaccines) RN - 0 (Cytokines) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage MH - BCG Vaccine/*administration & dosage MH - Biomarkers, Tumor/urine MH - Cancer Vaccines/*administration & dosage MH - Clinical Trials, Phase II as Topic MH - Cytokines/*urine MH - Drug Synergism MH - Female MH - Follow-Up Studies MH - Humans MH - Injections, Intradermal MH - Male MH - Models, Statistical MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/immunology/pathology/*therapy/*urine MH - Predictive Value of Tests MH - Prognosis MH - Randomized Controlled Trials as Topic MH - Survival Rate MH - Urinary Bladder Neoplasms/immunology/pathology/*therapy/*urine EDAT- 2018/12/30 06:00 MHDA- 2020/08/07 06:00 CRDT- 2018/12/30 06:00 PHST- 2018/08/16 00:00 [received] PHST- 2018/10/18 00:00 [revised] PHST- 2018/12/19 00:00 [accepted] PHST- 2018/12/30 06:00 [pubmed] PHST- 2020/08/07 06:00 [medline] PHST- 2018/12/30 06:00 [entrez] AID - 1055-9965.EPI-18-0893 [pii] AID - 10.1158/1055-9965.EPI-18-0893 [doi] PST - ppublish SO - Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1036-1044. doi: 10.1158/1055-9965.EPI-18-0893. Epub 2018 Dec 28. PMID- 30589047 OWN - NLM STAT- MEDLINE DCOM- 20190218 LR - 20220330 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 14 IP - 7 DP - 2018 TI - Transurethral endoscopic submucosal en bloc dissection for nonmuscle invasive bladder cancer: A comparison study of HybridKnife-assisted versus conventional dissection technique. PG - 1606-1612 LID - 10.4103/jcrt.JCRT_786_17 [doi] AB - SUBJECTS: The aim of this study is to compare the efficacy and safety of en bloc bladder tumor-endoscopic submucosal dissection (BT-ESD) and conventional transurethral resection of BT (TURBT) in nonmuscle invasive bladder cancer (NMIBC) patients. METHODS: A retrospective cohort study was carried out in Shaanxi Provincial People's Hospital. A total of 193 eligible NMIBC (Ta/T1) patients were enrolled in this study (95 cases in BT-ESD group and 98 cases in TURBT group), between November 2013 and January 2017. The operation time, blood loss, postoperative bladder irrigation time, catheter indwelling time, hospital stay time, and complications were compared. Data were presented as median (range). Chi-squared or rank-sum test, two-way ANOVA, and Mantel-Cox (Log-Rank) test were performed using statistical software. A threshold of P < 0.05 was defined as statistically significant. RESULTS: The average operation time in the BT-ESD group was longer than that of in the TURBT group (40.0 [5.0, 100.0] min vs. 19.5 [3.0, 55.5] min); however, no significant longer operating time (P < 0.05) were observed in the smaller tumor (0 cm-3 cm). The postoperative bladder irrigation time, catheter indwelling time, and hospital stay in BT-ESD group were significantly shorter than that of in TURBT group (9.0 [5.0, 18.0] h, 2.5 [1.0, 4.0] d and 3.5 [2.0, 5.0] d for BT-ESD; 18.0 [12.0, 48.0] h, 3.5 [2.0, 7.0] d, and 4.5 [3.0, 8.0] d for TURBT). In addition, the BT-ESD group showed the decreased overall incidence of complications (2.1% vs. 9.2%). The univariate and multivariate analyses indicated an association between surgical option and tumor recurrence (hazard ratio = 5.624, odds ratio = 95% confidence interval = 1.582-19.991), Kaplan-Meir analysis showed significant difference in recurrence-free survival (RFS) (94.7% for ESD group vs. 78.4% for TURBT group) at 33 months. CONCLUSIONS: The application of the HybridKnife lead to a decrease in complications and RFS rate, which was a more safe and effective approach for NMIBC than conventional TURBT. FAU - Cheng, Yong-Yi AU - Cheng YY AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Sun, Yi AU - Sun Y AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Li, Jing AU - Li J AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Liang, Liang AU - Liang L AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Zou, Tie-Jun AU - Zou TJ AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Qu, Wei-Xing AU - Qu WX AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Jiang, Ya-Zhuo AU - Jiang YZ AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Ren, Wei AU - Ren W AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Du, Chun AU - Du C AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Du, Shuang-Kuan AU - Du SK AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. FAU - Zhao, Wen-Cai AU - Zhao WC AD - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Child MH - Child, Preschool MH - Combined Modality Therapy MH - *Endoscopic Mucosal Resection/methods MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multimodal Imaging/methods MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Recurrence MH - Tumor Burden MH - Urinary Bladder Neoplasms/*diagnostic imaging/mortality/*pathology MH - Young Adult OTO - NOTNLM OT - En bloc dissection OT - HybridKnife OT - endoscopic submucosal dissection OT - nonmuscle invasive bladder cancer OT - transurethral resection of bladder tumor COIS- None EDAT- 2018/12/28 06:00 MHDA- 2019/02/20 06:00 CRDT- 2018/12/28 06:00 PHST- 2018/12/28 06:00 [entrez] PHST- 2018/12/28 06:00 [pubmed] PHST- 2019/02/20 06:00 [medline] AID - JCanResTher_2018_14_7_1606_247729 [pii] AID - 10.4103/jcrt.JCRT_786_17 [doi] PST - ppublish SO - J Cancer Res Ther. 2018;14(7):1606-1612. doi: 10.4103/jcrt.JCRT_786_17. PMID- 30588104 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 1179-1322 (Print) IS - 1179-1322 (Electronic) IS - 1179-1322 (Linking) VI - 10 DP - 2018 TI - Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma. PG - 6997-7011 LID - 10.2147/CMAR.S185392 [doi] AB - OBJECTIVES: The aim of this study was to investigate the prognostic effect of amplified in AIB1 and EIF5A2 expression on postoperative intravesical recurrence for upper urinary tract urothelial carcinoma (UTUC) and improve postoperative risk stratification and prediction of intravesical chemotherapy benefit. MATERIALS AND METHODS: We evaluated immunohistochemical expression of AIB1 and EIF5A2 in 109 UTUC patients to determine the predictive significance in intravesical recurrence. A prognostic model was developed based on univariate and multivariate analyses. RESULTS: Intravesical recurrence occurred in 18 out of the 109 (16.5%) patients during the follow-up period. Significant associations of high expression of AIB1 and EIF5A2 with shortened bladder recurrence interval (median: 24 months vs 46 months, P=0.021; 28 months vs 39 months, P=0.002) were demonstrated. In different subsets of UTUC patients, high expression of AIB1 was a prognostic indicator in high grade (P=0.006) and pT2-4 (P=0.007), and high expression of EIF5A2 for high grade (P=0.014), pT2-4 (P=0.002) and pN0 (P=0.009). Moreover, in multivariate analysis, AIB1 and EIF5A2 expression (P=0.034 and 0.022, respectively) together with pN stage (P=0.009) provided significant independent predictors for intravesical recurrence after surgery for UTUC. Surgical approach with radical nephroureterectomy (RNU) was an informative factor toward good oncologic outcomes for intravesical recurrence (P=0.056). Based on a prognostic model with these factors, patients with UTUC were classified into the low-risk group and the high-risk group. In a subset analysis, the patients in the high-risk group were found to have a favorable response to intravesical chemotherapy (P=0.047). A nomogram based on the multivariate analysis was developed to predict intravesical recurrence accurately and guide postoperative intravesical instillations. The concordance index (c-index) of this model was 0.806. CONCLUSION: High expression of AIB1 and EIF5A2 were independent predictors for intravesical recurrence after RNU and might be able to predict which patients benefit from postoperative intravesical chemotherapy. FAU - Huang, Yong AU - Huang Y AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. AD - Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. FAU - Wei, Jinhuan AU - Wei J AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Fang, Yong AU - Fang Y AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Chen, Zhenhua AU - Chen Z AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Cen, Junjie AU - Cen J AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Feng, Zihao AU - Feng Z AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Lu, Jun AU - Lu J AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Liang, Yanping AU - Liang Y AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Luo, Junhang AU - Luo J AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. FAU - Chen, Wei AU - Chen W AD - Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China, chenwei3sysu@163.com. LA - eng PT - Journal Article DEP - 20181214 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC6298448 OTO - NOTNLM OT - AIB1 OT - EIF5A2 OT - intravesical recurrence OT - nomogram OT - prognosis OT - upper tract urothelial carcinoma COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/12/28 06:00 MHDA- 2018/12/28 06:01 PMCR- 2018/12/14 CRDT- 2018/12/28 06:00 PHST- 2018/12/28 06:00 [entrez] PHST- 2018/12/28 06:00 [pubmed] PHST- 2018/12/28 06:01 [medline] PHST- 2018/12/14 00:00 [pmc-release] AID - cmar-10-6997 [pii] AID - 10.2147/CMAR.S185392 [doi] PST - epublish SO - Cancer Manag Res. 2018 Dec 14;10:6997-7011. doi: 10.2147/CMAR.S185392. eCollection 2018. PMID- 30584034 OWN - NLM STAT- MEDLINE DCOM- 20190903 LR - 20190903 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 2 DP - 2019 Feb TI - Mental health implications in bladder cancer patients: A review. PG - 97-107 LID - S1078-1439(18)30498-8 [pii] LID - 10.1016/j.urolonc.2018.12.006 [doi] AB - Although the majority of bladder cancer literature has been dedicated to optimizing oncological outcomes and focuses on physical prognostic criteria such as nutritional and performance status, emerging data has suggested that both pre- and post-treatment mental health may play as important a role in patient outcomes as physical health. In this review, we summarize the literature regarding the prognostic implications of mental illness on bladder cancer patients and review how both the diagnosis and treatment of bladder cancer can affect mental health across various disease states. Literature review via a modified, nonsystematic analysis was performed from 2000 to 2018 in PubMed, Web of Science, EMBASE, SCOPUS, and OVID. Search terms included "bladder cancer," "non-muscle-invasive bladder cancer," "muscle-invasive bladder cancer," "mental health," "psychological distress," "depression," and "suicide." Articles were limited to English-language, peer-reviewed, original research. A total of 87 publications were reviewed that met our initial inclusion criteria, and 19 relevant publications were incorporated in our review. Eleven studies were prospective and 8 were retrospective. Two articles included non-muscle-invasive bladder cancer patients, 11 included muscle-invasive bladder cancer patients, and 6 incorporated bladder cancer patients across all disease stages. Mental health issues, such as depression and anxiety, often coexist with a diagnosis of bladder cancer with a worse prognosis associated with greater psychological burden. Bladder cancer patients also have an increased risk of suicide especially in older, unmarried, male patients with more advanced disease states. Poor mental health can impact treatment outcomes such as postsurgical complication rates as well as survival-related outcomes similar to physical health. While awareness of the importance of mental health in bladder cancer patients is growing, further studies are needed to assess the role of interventions such as cognitive behavioral therapy or pharmacotherapy in order to optimize treatment. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Pham, Hannah AU - Pham H AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. FAU - Torres, Harrison AU - Torres H AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. FAU - Sharma, Pranav AU - Sharma P AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. Electronic address: pranav.sharma@ttuhsc.edu. LA - eng PT - Journal Article PT - Review DEP - 20181221 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Humans MH - Incidence MH - Mental Disorders/*physiopathology/psychology MH - *Mental Health MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*epidemiology/psychology/therapy OTO - NOTNLM OT - Bladder cancer OT - Depression OT - Mental health OT - Suicide OT - Urothelial carcinoma EDAT- 2018/12/26 06:00 MHDA- 2019/09/04 06:00 CRDT- 2018/12/26 06:00 PHST- 2018/09/11 00:00 [received] PHST- 2018/11/09 00:00 [revised] PHST- 2018/12/05 00:00 [accepted] PHST- 2018/12/26 06:00 [pubmed] PHST- 2019/09/04 06:00 [medline] PHST- 2018/12/26 06:00 [entrez] AID - S1078-1439(18)30498-8 [pii] AID - 10.1016/j.urolonc.2018.12.006 [doi] PST - ppublish SO - Urol Oncol. 2019 Feb;37(2):97-107. doi: 10.1016/j.urolonc.2018.12.006. Epub 2018 Dec 21. PMID- 30583038 OWN - NLM STAT- MEDLINE DCOM- 20191031 LR - 20260127 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 104 IP - 1 DP - 2019 May 1 TI - MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. PG - 197-206 LID - S0360-3016(18)34194-4 [pii] LID - 10.1016/j.ijrobp.2018.12.028 [doi] AB - PURPOSE: Trimodality therapy with maximal transurethral resection of bladder tumor and definitive chemoradiation reserving cystectomy for salvage of local recurrence is an accepted treatment alternative to upfront cystectomy for selected patients with muscle-invasive bladder cancer. There is a need for molecular biomarkers to predict which patients will respond to bladder preservation therapy. METHODS AND MATERIALS: We sought to identify biomarkers with the ability to predict response to chemoradiation and survival after selective bladder preservation therapy in a cohort of 40 patients using a microRNA profiling approach. In vitro experiments were performed using transitional cell carcinoma lines CRL1749, HTB5, and HTB4. RESULTS: We identified a panel of microRNAs associated with overall survival in our bladder preservation cohort and in the TCGA cohort. We also identified several microRNAs, including miR-23a and miR-27a, microRNAs of the miR-23a cluster, to be suggestively associated with complete response to chemoradiation therapy. The microRNAs were significantly associated with overall survival in The Cancer Genome Atlas cohort. In vitro studies suggest that the functional roles of miR-23a and miR-27a involve targeting the SFRP1 protein, a negative regulator of the Wnt signaling pathway. The upregulation of beta-catenin in the Wnt signaling pathway mediated proliferation, migration, invasion, and sensitivity to radiation and cisplatin treatment in bladder cancer cells. CONCLUSIONS: Our results indicate that miR-23a and miR-27a act as oncomirs, and once independently validated, they may help appropriately triage selected bladder cancer patients to individualize treatment. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Meng, Wei AU - Meng W AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Efstathiou, Jason AU - Efstathiou J AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Singh, Rajbir AU - Singh R AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - McElroy, Joseph AU - McElroy J AD - Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Volinia, Stefano AU - Volinia S AD - Universita degli Studi di Ferrara, Ferrara, Italy. FAU - Cui, Ri AU - Cui R AD - School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. FAU - Ibrahim, Ahmed AU - Ibrahim A AD - Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden; Division of Pharmaceutical Industries, National Research Centre, Dokki, Egypt. FAU - Johnson, Benjamin AU - Johnson B AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Gupta, Nirmala AU - Gupta N AD - Case Western Reserve University, Cleveland, Ohio. FAU - Mehta, Satvam AU - Mehta S AD - The Ohio State University, Columbus, Ohio. FAU - Wang, Huabao AU - Wang H AD - The Genomics Shared Resource, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Miller, Eric AU - Miller E AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Nguyen, Phuong AU - Nguyen P AD - Department of Radiation Oncology, Ohio Valley Medical Center, Wheeling, West Virginia. FAU - Fleming, Jessica AU - Fleming J AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Wu, Chin-Lee AU - Wu CL AD - Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Haque, S Jaharul AU - Haque SJ AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. FAU - Shipley, William AU - Shipley W AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Chakravarti, Arnab AU - Chakravarti A AD - Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: chakravarti.7@osu.edu. LA - eng GR - R01 CA108633/CA/NCI NIH HHS/United States GR - R01 CA169368/CA/NCI NIH HHS/United States GR - RC2 CA148190/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20181221 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Membrane Proteins) RN - 0 (MicroRNAs) RN - 0 (MIRN23a microRNA, human) RN - 0 (MIRN27 microRNA, human) RN - 0 (SFRP1 protein, human) RN - 0 (Secreted Frizzled-Related Proteins) SB - IM MH - Aged MH - Antineoplastic Agents/therapeutic use MH - Biomarkers, Tumor/analysis/metabolism MH - Carcinoma, Transitional Cell/*genetics/mortality/*therapy MH - Cell Movement MH - Cell Proliferation MH - *Chemoradiotherapy MH - DNA Methylation MH - Epithelial-Mesenchymal Transition MH - Humans MH - Intercellular Signaling Peptides and Proteins/metabolism MH - Membrane Proteins/metabolism MH - MicroRNAs/*analysis/metabolism MH - Middle Aged MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/*methods MH - Regression Analysis MH - Retrospective Studies MH - Triage MH - Up-Regulation MH - Urinary Bladder Neoplasms/*genetics/mortality/*therapy MH - Secreted Frizzled-Related Proteins EDAT- 2018/12/26 06:00 MHDA- 2019/11/02 06:00 CRDT- 2018/12/25 06:00 PHST- 2018/09/07 00:00 [received] PHST- 2018/11/28 00:00 [revised] PHST- 2018/12/16 00:00 [accepted] PHST- 2018/12/26 06:00 [pubmed] PHST- 2019/11/02 06:00 [medline] PHST- 2018/12/25 06:00 [entrez] AID - S0360-3016(18)34194-4 [pii] AID - 10.1016/j.ijrobp.2018.12.028 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):197-206. doi: 10.1016/j.ijrobp.2018.12.028. Epub 2018 Dec 21. PMID- 30580906 OWN - NLM STAT- MEDLINE DCOM- 20200214 LR - 20200214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 3 DP - 2019 Mar TI - Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. PG - 179.e19-179.e28 LID - S1078-1439(18)30451-4 [pii] LID - 10.1016/j.urolonc.2018.11.005 [doi] AB - PURPOSE: To investigate the prognostic value of preoperative modified Glasgow Prognostic Score (mGPS) in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of bladder with or without intravesical therapy. MATERIAL AND METHODS: We retrospectively reviewed our medical records to identify 1,096 consecutive patients with NMIBC treated with transurethral resection of bladder. The mGPS of each patient was calculated on the basis of preoperative serum C-reactive protein and albumin. Univariable and multivariable Cox regression analyses were performed to investigate the association of mGPS with recurrence-free survival (RFS) and progression-free survival (PFS). RESULTS: The mGPS of 0, 1, and 2 was observed in 764 (69.7%), 299 (27.3%), and 33 (3.0%) patients, respectively. On univariable analysis, mGPS 2 was associated with worse RFS (Hazard Ratio [HR]: 1.60, 95%; CI: 1.01-2.54). However, on multivariable analyses, which adjusted for the effects of established clinicopathologic features, mGPS 2 did not maintain its independent association with RFS (HR: 1.41, 95% CI: 0.88-2.26). On multivariable analysis, mGPS 1 and 2 were both independently associated with worse PFS compared to mGPS 0 (HR: 2.06, 95% CI: 1.37-3.12 and HR: 3.31, 95% CI: 1.40-7.87, respectively). The inclusion of mGPS improved the discrimination of a standard prognostic model for PFS from 71.6% to 73.8%. In subgroup analyses, mGPS 1 was associated with PFS (HR 2.09, 95% CI: 1.24-3.52) on multivariable analysis in patients with the European Association of Urology high-risk group. Additionally, in patients treated with bacillus Calmette-Guerin, mGPS 2 was associated with disease PFS (HR10.1, 95% CI: 2.61-38.8). CONCLUSIONS: The mGPS independently predicts PFS in patients with NMIBC. Inclusion of mGPS in prognostic models might help identify patients who are more likely to fail standard therapy and experience disease progression and, therefore, may benefit from intensified therapy such as radical cystectomy or inclusion in clinical trials of novel immunotherapeutics. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - D' Andrea, David AU - D' Andrea D AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University hospital, The University of Jordan, Amman, Jordan. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Iwata, Takehiro AU - Iwata T AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20181221 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 9007-41-4 (C-Reactive Protein) RN - ZIF514RVZR (Serum Albumin, Human) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Agents/administration & dosage MH - Biomarkers, Tumor/*blood MH - C-Reactive Protein/analysis MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - *Models, Biological MH - Neoplasm Recurrence, Local/blood/*diagnosis MH - *Patient Selection MH - Predictive Value of Tests MH - Preoperative Period MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Retrospective Studies MH - Serum Albumin, Human/analysis MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/blood/*mortality/therapy OTO - NOTNLM OT - Bladder cancer OT - Modified Glasgow prognostic score OT - Non-muscle-invasive OT - Outcomes OT - Progression EDAT- 2018/12/26 06:00 MHDA- 2020/02/15 06:00 CRDT- 2018/12/25 06:00 PHST- 2018/08/06 00:00 [received] PHST- 2018/10/30 00:00 [revised] PHST- 2018/11/04 00:00 [accepted] PHST- 2018/12/26 06:00 [pubmed] PHST- 2020/02/15 06:00 [medline] PHST- 2018/12/25 06:00 [entrez] AID - S1078-1439(18)30451-4 [pii] AID - 10.1016/j.urolonc.2018.11.005 [doi] PST - ppublish SO - Urol Oncol. 2019 Mar;37(3):179.e19-179.e28. doi: 10.1016/j.urolonc.2018.11.005. Epub 2018 Dec 21. PMID- 30578161 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20200317 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 6 DP - 2019 Jun TI - Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. PG - 372-379 LID - S1078-1439(18)30447-2 [pii] LID - 10.1016/j.urolonc.2018.11.001 [doi] AB - PURPOSE: To assess the prognostic importance of sarcopenia in survival in patients with high-risk urothelial carcinoma of the bladder (UCB) who were unfit for radical cystectomy or systemic chemotherapy and were, therefore, treated with radiotherapy only. METHODS: We evaluated 94 patients treated with transurethral resection of the bladder and radiotherapy for UCB. Sarcopenia, identified from pretreatment computed tomography scans, was defined as a skeletal muscle index of <39 cm(2)/m(2) for women and <55 cm(2)/m(2) for men. Body mass index -adjusted definition of sarcopenia was used to evaluate for sarcopenic obesity. Univariate models were used to assess the association between body composition and nutritional parameters with survival outcomes. RESULTS: Overall, 68 patients were eligible for the final analysis, and 49 (72%) patients were sarcopenic. After body mass index adjustment of the definition of sarcopenia, its prevalence changed to 53.8% in women and 52.7% in men. Median age was 82 (interquartile range [IQR] 75-86) years, with a median, age-adjusted comorbidity index of 7.5 (IQR 6-10). The median time of follow-up was 12.5 (IQR 5.1-23.5) months. There were 42 (61.7%) patients who died of any cause and 19 (45.2%) who died because of UCB during the study period. Of all the body composition and nutritional parameters investigated, sarcopenic obesity was associated with cancer-specific survival (hazard ratio 5.0, 95% confidence interval 1.4-16.7, P = 0.01) and a low prognostic nutritional index was associated with overall survival (hazard ratio 0.46, 95% confidence interval 0.2-0.9, P = 0.02). CONCLUSION: In patients who are too high risk for the standard treatment of UCB, sarcopenia is highly prevalent, but not prognostic of survival. Nevertheless, sarcopenic obesity and the prognostic nutritional index might act as prognostic markers for patients with UCB undergoing radiotherapy. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Stangl-Kremser, Judith AU - Stangl-Kremser J AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Vartolomei, Mihai AU - Vartolomei M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Goldner, Gregor AU - Goldner G AD - Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria. FAU - Baltzer, Pascal AU - Baltzer P AD - Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Centre, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Tamandl, Dietmar AU - Tamandl D AD - Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. Electronic address: dietmar.tamandl@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20181218 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - *Body Composition MH - Carcinoma, Transitional Cell/*complications/*mortality/radiotherapy MH - Female MH - Humans MH - Male MH - *Nutrition Assessment MH - Prognosis MH - Retrospective Studies MH - Sarcopenia/*complications MH - Survival Rate MH - Urinary Bladder Neoplasms/*complications/*mortality/radiotherapy OTO - NOTNLM OT - Body composition OT - Nutrition OT - Radiotherapy OT - Sarcopenia OT - Survival OT - Urothelial bladder cancer EDAT- 2018/12/24 06:00 MHDA- 2020/03/18 06:00 CRDT- 2018/12/23 06:00 PHST- 2018/07/06 00:00 [received] PHST- 2018/10/31 00:00 [revised] PHST- 2018/11/04 00:00 [accepted] PHST- 2018/12/24 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] PHST- 2018/12/23 06:00 [entrez] AID - S1078-1439(18)30447-2 [pii] AID - 10.1016/j.urolonc.2018.11.001 [doi] PST - ppublish SO - Urol Oncol. 2019 Jun;37(6):372-379. doi: 10.1016/j.urolonc.2018.11.001. Epub 2018 Dec 18. PMID- 30567074 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 2210-2612 (Print) IS - 2210-2612 (Electronic) IS - 2210-2612 (Linking) VI - 53 DP - 2018 TI - Bladder cavernous hemangioma after pelvic radiotherapy in a female patient: A case report and literature review. PG - 479-482 LID - S2210-2612(18)30552-2 [pii] LID - 10.1016/j.ijscr.2018.11.044 [doi] AB - INTRODUCTION: Hemangiomas are benign tumor formations of capillaries and blood vessels which are commonly found in various organs. However they are extremely rare in urinary bladder accounting for only 0.6% of all urinary bladder tumors. The differentiating of these benign tumors from malignant neoplasms are important since they have extremely different prognostic features as well as therapeutic strategies. Here we reported a female patient diagnosed with bladder cavernous hemangioma (BCH) after recent pelvic radiotherapy for the cervical cancer and reviewed relevant literatures. CASE PRESENTATION: We reported a case of 49 years old female patient with persistent painless hematuria for 12 days. Computed tomography revealed a small lesion on the superior wall of the urinary bladder with acute clot retention. Cystoscopy confirmed a solid papillary pedunculated mass with a measuring of 1.0 x 0.5 cm located on the superior posterior wall and surrounded by distended vessels. Transurethral resection of the mass was then performed and the pathological report indicated a cavernous hemangioma of the urinary bladder. In a one and half year follow-up, no tumor recurrence or bleeding was found. CONCLUSIONS: The cavernous hemangioma in urinary bladder is rare and cystoscopic is a gold standard for diagnosis. Treatment options are vary for individuals and pathologic findings are vital for differentiating it from malignant potential tumors. A history of cancer related radiation therapy seems to be a risk factor for BCH. CI - Copyright (c) 2018. Published by Elsevier Ltd. FAU - Hu, Xinming AU - Hu X AD - Department of Urology, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, PR China. FAU - Deng, Kangli AU - Deng K AD - Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, PR China. Electronic address: dengkangli10@163.com. LA - eng PT - Journal Article DEP - 20181124 PL - United States TA - Int J Surg Case Rep JT - International journal of surgery case reports JID - 101529872 PMC - PMC6277215 OTO - NOTNLM OT - Bladder carvenous hemangioma OT - Case report OT - Hematuria OT - Radiotherapy OT - Transurethral resection EDAT- 2018/12/21 06:00 MHDA- 2018/12/21 06:01 PMCR- 2018/11/24 CRDT- 2018/12/21 06:00 PHST- 2018/11/06 00:00 [received] PHST- 2018/11/15 00:00 [accepted] PHST- 2018/12/21 06:00 [entrez] PHST- 2018/12/21 06:00 [pubmed] PHST- 2018/12/21 06:01 [medline] PHST- 2018/11/24 00:00 [pmc-release] AID - S2210-2612(18)30552-2 [pii] AID - 10.1016/j.ijscr.2018.11.044 [doi] PST - ppublish SO - Int J Surg Case Rep. 2018;53:479-482. doi: 10.1016/j.ijscr.2018.11.044. Epub 2018 Nov 24. PMID- 30559065 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20210715 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 6 IP - 6 DP - 2020 Nov 15 TI - Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. PG - 1226-1232 LID - S2405-4569(18)30382-1 [pii] LID - 10.1016/j.euf.2018.12.002 [doi] AB - BACKGROUND: Urothelial carcinoma arising in a bladder diverticulum (UCBD) is uncommon, and data on treatment and outcome are sparse. OBJECTIVE: To analyze clinicopathological characteristics of UCBD and to compare outcome after radical cystectomy (RC) and partial cystectomy (PC). DESIGN, SETTING, AND PARTICIPANTS: Data of 115 UCBD patients treated with RC (n=81) or PC (n=34) between 2000 and 2016 were collected from 11 institutional databases and were analyzed retrospectively. Median follow-up was 5.0yr (95% confidence interval [CI]: 4.0-6.2). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Upstaging of tumor stage at diagnostic transurethral resection (TUR) to the RC/PC specimen was investigated. Overall survival (OS) and metastasis-free survival (MFS) after RC and PC were analyzed using Kaplan-Meier estimates, and compared using the log-rank test. Intravesical recurrences after PC were reported. A multivariable Cox proportional-hazard model was used to identify factors associated with OS. RESULTS AND LIMITATIONS: There were no statistically significant differences in clinicopathological characteristics between RC and PC groups. Fifty-five percent of patients with cTa/is/1 at diagnostic TUR had >/=pT2 tumors at RC/PC. Five-year OS and MFS were, respectively, 62% and 66% for RC and 66% and 55% for PC (p=0.9 and p=0.6). Intravesical tumor recurrence was seen in six of 34 (18%) PC patients. In multivariable analysis, positive surgical margins and extravesical disease (>/=pT2) were associated with worse OS, whereas treatment modality was not (RC: reference; PC: hazard ratio 0.94, [95% CI: 0.47-1.90], p=0.9). CONCLUSIONS: Upstaging of UCBD was frequent, indicating an inaccuracy in clinical staging. We found no differences in OS or MFS between PC and RC groups; therefore, PC may represent a feasible surgical alternative to RC in selected UCBD patients. PATIENT SUMMARY: In this report, we looked at the treatment of urothelial carcinoma arising in a bladder diverticulum (UCBD). We found that bladder-sparing treatment by partial cystectomy may be an alternative to radical cystectomy in carefully selected UCBD patients. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Voskuilen, Charlotte S AU - Voskuilen CS AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: c.voskuilen@nki.nl. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, University Hospital Bern, Bern, Switzerland. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Noon, Aidan P AU - Noon AP AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University Medical Center Rostock, Rostock, Germany. FAU - Lavolle, Alexandre AU - Lavolle A AD - Department of Urology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Young, Matthew J AU - Young MJ AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Marks, Phillip AU - Marks P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Saba, Karim AU - Saba K AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Fransen van de Putte, Elisabeth E AU - Fransen van de Putte EE AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Ablat, Jason AU - Ablat J AD - Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada. FAU - Sosnowski, Roman AU - Sosnowski R AD - Department of Uro-oncology, Institute of Oncology, Warsaw, Poland. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Kumar, Pardeep AU - Kumar P AD - Department of Urology, Royal Marsden Hospital NHS Trust, London, UK. FAU - Jallad, Samer AU - Jallad S AD - Department of Urology, Royal Marsden Hospital NHS Trust, London, UK. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Cochin Hospital, Paris Descartes University, Paris, France. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. CN - Young Academic Urologists' Working Group on Urothelial Carcinoma of the European Association of Urology LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20181214 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - Bladder Diverticulum SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*complications/*surgery MH - Cystectomy/*methods MH - Diverticulum/*complications/*surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder/*abnormalities/surgery MH - Urinary Bladder Neoplasms/*complications/*surgery OTO - NOTNLM OT - Bladder cancer OT - Bladder diverticulum OT - Partial cystectomy OT - Radical cystectomy OT - Urothelial carcinoma EDAT- 2018/12/19 06:00 MHDA- 2021/07/16 06:00 CRDT- 2018/12/19 06:00 PHST- 2018/10/12 00:00 [received] PHST- 2018/11/27 00:00 [revised] PHST- 2018/12/04 00:00 [accepted] PHST- 2018/12/19 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2018/12/19 06:00 [entrez] AID - S2405-4569(18)30382-1 [pii] AID - 10.1016/j.euf.2018.12.002 [doi] PST - ppublish SO - Eur Urol Focus. 2020 Nov 15;6(6):1226-1232. doi: 10.1016/j.euf.2018.12.002. Epub 2018 Dec 14. PMID- 30553613 OWN - NLM STAT- MEDLINE DCOM- 20190812 LR - 20190812 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 75 IP - 4 DP - 2019 Apr TI - Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. PG - 649-658 LID - S0302-2838(18)30956-4 [pii] LID - 10.1016/j.eururo.2018.11.052 [doi] AB - CONTEXT: The optimal treatment of urothelial bladder cancer (UBC) with micropapillary (MP) variant histology is not clear. OBJECTIVE: To review the current literature on disease characteristics and treatment outcomes of MP UBC. EVIDENCE ACQUISITION: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. The primary end points were recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). EVIDENCE SYNTHESIS: We identified 758 reports comprising a total of 3154 patients, of which 28 and 15 articles were selected for qualitative and quantitative analysis, respectively. In patients with T1 MP UBC, the 5-yr CSS rates for early radical cystectomy (RC) ranged from 81% to 100%, while they were between 60% and 85% for transurethral resection of the bladder and Bacillus Calmette-Guerin (BCG). In studies reporting on neoadjuvant chemotherapy (NAC), the rates of complete pathological response (ypT0) ranged from 11% to 55%. Nevertheless, the use of NAC did not improve RFS (hazard ratio [HR] 1.23, 95% confidence interval [CI] 0.52-2.93, p=0.6), CSS (HR 0.9, 95% CI 0.48-1.7, p=0.8), or OS (HR 1.35, 95% CI 0.98-1.86, p=0.1). Fifty-three percent (95% CI 43-63%) of patients who underwent RC alone had locally advanced disease (>/=pT3), and 43% (95% CI 33-52%) were harbouring lymph node metastases. MP component at RC was not significantly associated with worse RFS (HR 1.25, 95% CI 0.88-1.78, p=0.2), CSS (HR 0.96, 95% CI 0.57-1.6, p=0.9), or OS (HR 1.20, 95% CI 0.88-1.62, p=0.3) when adjusted for pathological features. CONCLUSIONS: While MP UBC is associated with clinicopathological features of advanced disease, it is not associated with worse survival outcomes in patients undergoing RC. NAC results in pathological downstaging in a significant number of patients. Nevertheless, this does not translate into better survival outcomes. The optimal treatment of patients with cT1 remains controversial. PATIENT SUMMARY: Our results suggest that micropapillary urothelial bladder cancer does not necessarily mandate different treatment algorithms. Nevertheless, each case should be discussed individually considering other clinicopathological factors. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Schernhammer, Eva AU - Schernhammer E AD - Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Hassler, Melanie R AU - Hassler MR AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Preston, Mark A AU - Preston MA AD - Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Quebec, Canada. FAU - Remzi, Mesut AU - Remzi M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20181213 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 MH - Carcinoma, Papillary/mortality/pathology/*therapy MH - Disease Progression MH - Humans MH - Neoplasm Staging MH - Progression-Free Survival MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Urothelium/*pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin therapy OT - Bladder cancer OT - Bladder sparing OT - Immediate cystectomy OT - Micropapillary OT - Prognosis OT - Transurethral resection OT - Urothelial carcinoma OT - Variant histology EDAT- 2018/12/17 06:00 MHDA- 2019/08/14 06:00 CRDT- 2018/12/17 06:00 PHST- 2018/09/18 00:00 [received] PHST- 2018/11/28 00:00 [accepted] PHST- 2018/12/17 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2018/12/17 06:00 [entrez] AID - S0302-2838(18)30956-4 [pii] AID - 10.1016/j.eururo.2018.11.052 [doi] PST - ppublish SO - Eur Urol. 2019 Apr;75(4):649-658. doi: 10.1016/j.eururo.2018.11.052. Epub 2018 Dec 13. PMID- 30553612 OWN - NLM STAT- MEDLINE DCOM- 20191209 LR - 20191217 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 75 IP - 5 DP - 2019 May TI - Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. PG - 853-860 LID - S0302-2838(18)30959-X [pii] LID - 10.1016/j.eururo.2018.11.055 [doi] AB - BACKGROUND: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC. OBJECTIVE: To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. DESIGN, SETTING, AND PARTICIPANTS: Voided precystoscopy urine samples were prospectively collected at 22 sites. Xpert, cytology, and UroVysion were performed. If cystoscopy was suspicious for BC, a histologic examination was performed. Additionally, technical validation was performed and specificity was determined in patients without a history or clinical evidence of BC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Test characteristics were calculated based on cystoscopy and histology results, and compared between Xpert, cytology, and UroVysion. RESULTS AND LIMITATIONS: Of the eligible patients, 239 with a history of BC had results for all assays. The mean age was 71 yr; 190 patients were male, 53 never smoked, and 64% had previous intravesical immunotherapy (35%) or chemotherapy (29%). Forty-three cases of recurrences occurred. Xpert had overall SN of 74% (95% confidence interval [CI]: 60-85) and 83% (95% CI: 64-93) for high-grade (HG) tumors. The NPV was 93% (95% CI: 89-96) overall and 98% (95% CI: 94-99) for HG tumors. Specificity was 80% (95% CI: 73-85). Xpert SN and NPV were superior to those of cytology and UroVysion. Specificity in non-BC individuals (n=508) was 95% (95% CI: 93-97). CONCLUSIONS: Xpert has an improved NPV compared with UroVysion and cytology in patients under follow-up for BC. It represents a promising tool for excluding BC in these patients, reducing the need for cystoscopy. PATIENT SUMMARY: Xpert is an easy-to-perform urine test with good performance compared with standard urine tests. It should help optimize the follow-up of recurrent bladder cancer patients. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Valenberg, F Johannes P van AU - Valenberg FJPV AD - Radboudumc, Nijmegen, The Netherlands. Electronic address: hans.vanvalenberg@radboudumc.nl. FAU - Hiar, Andrew M AU - Hiar AM AD - Cepheid, Sunnyvale, CA, USA. FAU - Wallace, Ellen AU - Wallace E AD - Cepheid, Sunnyvale, CA, USA. FAU - Bridge, Julia A AU - Bridge JA AD - UNMC, Omaha, NE, USA. FAU - Mayne, Donna J AU - Mayne DJ AD - Sacred Heart Hospital, Pensacola, FL, USA. FAU - Beqaj, Safedin AU - Beqaj S AD - Pathology, Inc., Torrance, CA, USA. FAU - Sexton, Wade J AU - Sexton WJ AD - Moffitt Cancer Center, Tampa, FL, USA. FAU - Lotan, Yair AU - Lotan Y AD - UT Southwestern Medical Center, Dallas, TX, USA. FAU - Weizer, Alon Z AU - Weizer AZ AD - University of Michigan Hospital, Ann Arbor, MI, USA. FAU - Jansz, Godfrey K AU - Jansz GK AD - Urology Office of G. Kenneth Jansz, Burlington, Ontario, Canada. FAU - Stenzl, Arnulf AU - Stenzl A AD - University Medical Clinic of Tuebingen, Tuebingen, Germany. FAU - Danella, John F AU - Danella JF AD - Geisinger Health System, Danville, PA, USA. FAU - Shepard, Barry AU - Shepard B AD - Urological Surgeons of Long Island, PLLC, Garden City, NY, USA. FAU - Cline, Kevin J AU - Cline KJ AD - Regional Urology, Shreveport, LA, USA. FAU - Williams, Michael B AU - Williams MB AD - Urology of Virginia, Virginia Beach, VA, USA. FAU - Montgomery, Scott AU - Montgomery S AD - Kansas City Urology Care, Overland Park, KS, USA. FAU - David, Richard D AU - David RD AD - Skyline Urology, Torrance, CA, USA. FAU - Harris, Richard AU - Harris R AD - UroPartners, Melrose Park, IL, USA. FAU - Klein, Eric W AU - Klein EW AD - Idaho Urologic Institute, Meridian, ID, USA. FAU - Bradford, Timothy J AU - Bradford TJ AD - Virginia Urology, Richmond, VA, USA. FAU - Wolk, Fred N AU - Wolk FN AD - Skyline Urology, Sherman Oaks, CA, USA. FAU - Westenfelder, Karl R AU - Westenfelder KR AD - Five Valleys Urology, Missoula, MT, USA. FAU - Trainer, Andrew F AU - Trainer AF AD - Adult and Pediatric Urology, Omaha, NE, USA. FAU - Richardson, Timothy A AU - Richardson TA AD - Wichita Urology Group, Wichita, KS, USA. FAU - Egerdie, Russell B AU - Egerdie RB AD - Urology Office of R. Blaire Egerdie, Kitchener, Ontario, Canada. FAU - Goldfarb, Bernard AU - Goldfarb B AD - North Bay, Ontario, Canada. FAU - Zadra, Joseph A AU - Zadra JA AD - Barrie, Ontario, Canada. FAU - Ge, Sijian AU - Ge S AD - Cepheid, Sunnyvale, CA, USA. FAU - Zhao, Suling AU - Zhao S AD - Cepheid, Sunnyvale, CA, USA. FAU - Simon, Iris M AU - Simon IM AD - Cepheid, Sunnyvale, CA, USA. FAU - Campbell, Scott A AU - Campbell SA AD - Cepheid, Sunnyvale, CA, USA. FAU - Rhees, Brian AU - Rhees B AD - Cepheid, Sunnyvale, CA, USA. FAU - Bates, Michael P AU - Bates MP AD - Cepheid, Sunnyvale, CA, USA. FAU - Higuchi, Russell G AU - Higuchi RG AD - Cepheid, Sunnyvale, CA, USA. FAU - Witjes, J Alfred AU - Witjes JA AD - Radboudumc, Nijmegen, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20181212 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (ANXA10 protein, human) RN - 0 (Annexins) RN - 0 (IGF2 protein, human) RN - 0 (RNA, Messenger) RN - 0 (UPK1B protein, human) RN - 0 (Uroplakin Ib) RN - 67763-97-7 (Insulin-Like Growth Factor II) RN - 9015-71-8 (Corticotropin-Releasing Hormone) RN - EC 2.7.10.2 (ABL1 protein, human) RN - EC 2.7.10.2 (Proto-Oncogene Proteins c-abl) SB - IM CIN - Eur Urol. 2019 Jun;75(6):e175-e176. doi: 10.1016/j.eururo.2019.02.016. PMID: 30803730 CIN - Eur Urol. 2019 Oct;76(4):e111-e112. doi: 10.1016/j.eururo.2019.05.003. PMID: 31085019 MH - Adult MH - Aged MH - Aged, 80 and over MH - Annexins/genetics MH - Biopsy MH - Corticotropin-Releasing Hormone/genetics MH - Cystoscopy MH - Female MH - Humans MH - Insulin-Like Growth Factor II/genetics MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/genetics/*urine MH - Population Surveillance/*methods MH - Predictive Value of Tests MH - Prospective Studies MH - Proto-Oncogene Proteins c-abl/genetics MH - RNA, Messenger/*urine MH - Urinalysis MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/genetics/*urine MH - Uroplakin Ib/genetics MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Cystoscopy OT - Diagnostic test OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Sensitivity OT - Specificity OT - Urine test OT - mRNA EDAT- 2018/12/17 06:00 MHDA- 2019/12/18 06:00 CRDT- 2018/12/17 06:00 PHST- 2018/06/25 00:00 [received] PHST- 2018/11/30 00:00 [accepted] PHST- 2018/12/17 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/12/17 06:00 [entrez] AID - S0302-2838(18)30959-X [pii] AID - 10.1016/j.eururo.2018.11.055 [doi] PST - ppublish SO - Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12. PMID- 30550547 OWN - NLM STAT- MEDLINE DCOM- 20190513 LR - 20200309 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 12 DP - 2018 TI - Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder. PG - e0209101 LID - 10.1371/journal.pone.0209101 [doi] LID - e0209101 AB - INTRODUCTION: Bladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-muscle invasive disease and systemic cisplatin for muscle-invasive or metastatic disease. Hyperthermia, heating a tumor to 40-44 degrees C, enhances the efficacy of these chemotherapeutics by various modes of action, one of which is inhibition of DNA repair via homologous recombination. Here, we explore whether ex vivo assays on freshly obtained bladder tumors can be applied to predict the response towards hyperthermia. MATERIAL AND METHODS: The cytochrome C release assay (apoptosis) and the RAD51 focus formation assay (DNA repair) were first established in the bladder cancer cell lines RT112 and T24 as measurements for hyperthermia efficiency, and subsequently tested in freshly obtained bladder tumors (n = 59). RESULTS: Hyperthermia significantly increased the fraction of apoptotic cells after cisplatin or MMC treatment in both RT112 and T24 cells and in most of the bladder tumors (8/10). The RAD51 focus formation assay detected both morphological and numerical changes of RAD51 foci upon hyperthermia in the RT112 and T24 cell lines. In 64% of 37 analyzed primary bladder tumor samples, hyperthermia induced similar morphological changes in RAD51 foci. CONCLUSION: The cytochrome C assay and the RAD51 focus formation assay are both feasible on freshly obtained bladder tumors, and could serve to predict the efficacy of hyperthermia together with cytotoxic agents, such as MMC or cisplatin. FAU - van den Tempel, Nathalie AU - van den Tempel N AD - Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Naipal, Kishan A T AU - Naipal KAT AD - Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Raams, Anja AU - Raams A AD - Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - van Gent, Dik C AU - van Gent DC AD - Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. AD - Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Franckena, Martine AU - Franckena M AD - Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Kanaar, Roland AU - Kanaar R AUID- ORCID: 0000-0001-9364-8727 AD - Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. AD - Department of Molecular Genetics, Oncode Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181214 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 50SG953SK6 (Mitomycin) RN - 9007-43-6 (Cytochromes c) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Cell Line, Tumor MH - Cisplatin/therapeutic use MH - Cytochromes c/metabolism MH - Humans MH - *Hyperthermia, Induced MH - Mitomycin/therapeutic use MH - Urinary Bladder Neoplasms/*drug therapy/metabolism/pathology PMC - PMC6294360 COIS- The authors have declared that no competing interests exist. EDAT- 2018/12/15 06:00 MHDA- 2019/05/14 06:00 PMCR- 2018/12/14 CRDT- 2018/12/15 06:00 PHST- 2018/08/13 00:00 [received] PHST- 2018/11/28 00:00 [accepted] PHST- 2018/12/15 06:00 [entrez] PHST- 2018/12/15 06:00 [pubmed] PHST- 2019/05/14 06:00 [medline] PHST- 2018/12/14 00:00 [pmc-release] AID - PONE-D-18-23807 [pii] AID - 10.1371/journal.pone.0209101 [doi] PST - epublish SO - PLoS One. 2018 Dec 14;13(12):e0209101. doi: 10.1371/journal.pone.0209101. eCollection 2018. PMID- 30548363 OWN - NLM STAT- MEDLINE DCOM- 20190211 LR - 20210109 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) VI - 110 IP - 2 DP - 2019 Feb TI - Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. PG - 489-498 LID - 10.1111/cas.13887 [doi] AB - Drugs blocking programmed death ligand-1 (PD-L1) have shown unprecedented activity in metastatic and unresectable bladder cancer. The purpose of the present study was to investigate the expression, clinical significance and association of PD-L1 with tumor-infiltrating lymphocytes (TIL) in resectable urothelial cell carcinoma of the bladder (UCB). In this retrospective study, 248 UCB patients who received radical cystectomy or transurethral resection were examined. Immunohistochemistry was used to evaluate PD-L1 expression and stromal CD8(+) TIL, Th1 orientation T cell (T-bet(+) ) and PD-1(+) TIL densities within the intratumoral regions and associated stromal regions. Of the 248 specimens, 23% showed PD-L1 expression in tumor cells and 55% in tumor-infiltrating immune cells. CD8(+) TIL, T-bet(+) TIL and PD-1(+) TIL were distributed throughout the tumor tissues and were more frequently distributed in stromal regions than in intratumoral regions. PD-L1(+) tumor cells and PD-L1(+) immune cells were positively associated with aggressive clinical features (all P < .05). Both PD-L1(+) tumor cells and PD-L1(+) immune cells were associated with poorer recurrence-free and overall survival (all P < .05). Multivariate analysis showed that PD-L1(+) immune cells were an independent prognostic factor for overall (P = .001) and recurrence-free survival (P = .024). Notably, high stromal CD8(+) TIL and PD-1(+) TIL density were associated with poorer overall survival (P = .031 and P = .001, respectively). In the stroma, CD8(+) TIL density has strong positive association with PD-L1(+) immune cells and PD-1(+) TIL density (all P < .0001). These results suggested that an exhausted immune state occurred in the tumor stroma in UCB. Further clinical development of immune-checkpoint inhibitors may be effective for resectable patients with UCB. CI - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. FAU - Wang, Bo AU - Wang B AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Pan, Wenwei AU - Pan W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Yang, Meihua AU - Yang M AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Yang, Wenjuan AU - Yang W AD - Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - He, Wang AU - He W AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Chen, Xu AU - Chen X AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Bi, Junming AU - Bi J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Jiang, Ning AU - Jiang N AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Lin, Tianxin AU - Lin T AUID- ORCID: 0000-0003-0044-8035 AD - Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. LA - eng GR - Yat-Sen Scholarship for Young Scientist to Bo Wang/ GR - Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to Bo Wang/ GR - J2014 01/Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital/ GR - J2016- 106/Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital/ GR - 2015A030310122/National Natural Science Foundation of Guangdong/ GR - 2015A030311011/National Natural Science Foundation of Guangdong/ GR - S2013020012671/National Natural Science Foundation of Guangdong/ GR - 201604020156/Science and Technology Program of Guangzhou/ GR - 201604020177/Science and Technology Program of Guangzhou/ GR - 201806010024/Science and Technology Program of Guangzhou/ GR - 15ykjc16d/Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University/ GR - 16ykjc18/Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University/ GR - 013-163/Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology/ GR - KLB09001/Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University/ GR - 2017B020227007/Guangdong Science and Technology Development Fund/ GR - 81402106/National Natural Science Foundation of China/ GR - 81472381/National Natural Science Foundation of China/ GR - 81472384/National Natural Science Foundation of China/ GR - 81572514/National Natural Science Foundation of China/ GR - 81702523/National Natural Science Foundation of China/ GR - 81740119/National Natural Science Foundation of China/ GR - 81772719/National Natural Science Foundation of China/ GR - 81772728/National Natural Science Foundation of China/ GR - 81825016/National Natural Science Foundation of China/ PT - Journal Article DEP - 20181212 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) SB - IM MH - B7-H1 Antigen/*immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Carcinoma/*immunology MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Kaplan-Meier Estimate MH - Lymphocytes, Tumor-Infiltrating/*immunology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/immunology MH - Retrospective Studies MH - Urinary Bladder/*immunology MH - Urinary Bladder Neoplasms/*immunology PMC - PMC6361576 OTO - NOTNLM OT - CD8 OT - programmed death 1 OT - programmed death ligand-1 OT - tumor-infiltrating lymphocyte OT - urothelial cell carcinoma of the bladder EDAT- 2018/12/15 06:00 MHDA- 2019/02/12 06:00 PMCR- 2019/02/01 CRDT- 2018/12/15 06:00 PHST- 2018/07/11 00:00 [received] PHST- 2018/11/14 00:00 [revised] PHST- 2018/11/18 00:00 [accepted] PHST- 2018/12/15 06:00 [pubmed] PHST- 2019/02/12 06:00 [medline] PHST- 2018/12/15 06:00 [entrez] PHST- 2019/02/01 00:00 [pmc-release] AID - CAS13887 [pii] AID - 10.1111/cas.13887 [doi] PST - ppublish SO - Cancer Sci. 2019 Feb;110(2):489-498. doi: 10.1111/cas.13887. Epub 2018 Dec 12. PMID- 30548115 OWN - NLM STAT- MEDLINE DCOM- 20191217 LR - 20191217 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 IP - 4 DP - 2019 Apr TI - Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. PG - 618-623 LID - 10.1111/bju.14647 [doi] AB - OBJECTIVES: To assess the location of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), to determine the main predictive factors for IVR in the bladder-cuff area (BCA), and to assess the effect of BCA recurrence (BCAR) on prognosis. PATIENTS AND METHODS: This was a multicentre, retrospective study using the French collaborative database on UTUC, which includes data for all patients treated in 24 referral uro-oncology centres across the country. All patients who underwent RNU with bladder-cuff excision and who developed IVR between 1995 and 2010 were selected. Patients were divided into two groups: Group A: BCAR; and Group B: recurrence elsewhere in the bladder. The Kaplan-Meier method was used to estimate the probability of BCAR-free survival. Groups were compared using the log-rank test. Independent risk factors for BCAR were identified using a Cox proportional hazard regression model, with univariate and multivariate analyses. RESULTS: Overall, 163 patients were included in the final analysis: Group A, 87 patients (53.4%) and Group B, 76 (46.6%). The clinicopathological characteristics were similar in the groups. The median (interquartile range [IQR]) follow-up was 36 (31.7-40.39) months. The median (IQR) time to IVR was 10.0 (8.6-13.39) months [Group A: 11.0 (8.8-13.2) months vs Group B: 10.0 (8.5-11.5) months; P = 0.35]. The probability of BCAR at 1, 2, and 3 years was 45.5% (95% confidence interval [CI] 40.1-50.9), 17.9% (95% CI 13.7-22.1), and 10.8% (95% CI 7.4-14.2) respectively, whereas the probability of recurrence elsewhere in the bladder was 42.1% (95% CI 36.4-47.8), 14.7% (95% CI 10.6-18.8), and 4.4% (95% CI 1.9-6.9), respectively (P = 0.35). Pathological tumour stage (>/=pT3) was significantly related to the risk of BCAR (P = 0.03). CONCLUSION: There were more BCARs after RNU in advanced UTUC. However, no preferred site for recurrence was detected. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Belhadj, Yassine AU - Belhadj Y AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Grande, Pietro AU - Grande P AUID- ORCID: 0000-0002-6887-5589 AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Gobert, Aurelien AU - Gobert A AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Gomez, Florie D AU - Gomez FD AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20190106 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/diagnostic imaging/*pathology/surgery MH - Female MH - Humans MH - *Laparoscopy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology MH - *Nephroureterectomy MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Ureteral Neoplasms/diagnostic imaging/*pathology/surgery MH - *Ureteroscopy OTO - NOTNLM OT - #uroonc OT - #utuc OT - intravesical recurrence OT - radical nephroureterectomy OT - risk factors OT - upper tract urothelial carcinoma EDAT- 2018/12/15 06:00 MHDA- 2019/12/18 06:00 CRDT- 2018/12/15 06:00 PHST- 2018/12/15 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/12/15 06:00 [entrez] AID - 10.1111/bju.14647 [doi] PST - ppublish SO - BJU Int. 2019 Apr;123(4):618-623. doi: 10.1111/bju.14647. Epub 2019 Jan 6. PMID- 30542702 OWN - NLM STAT- MEDLINE DCOM- 20190111 LR - 20190111 IS - 1791-2431 (Electronic) IS - 1021-335X (Linking) VI - 40 IP - 6 DP - 2018 Dec TI - IL‑23 concentration‑dependently regulates T24 cell proliferation, migration and invasion and is associated with prognosis in patients with bladder cancer. PG - 3685-3693 LID - 10.3892/or.2018.6775 [doi] AB - Interleukin‑23 (IL‑23, also known as IL23A), is an important proinflammatory cytokine whose role in the development and progression of tumors remains controversial. The present study on IL‑23 focused on its impact on the tumor microenvironment. Existing studies on its direct role on tumor cells are limited. Previously, we reported that the expression level of IL‑23 in human bladder urothelial carcinoma was significantly higher than that in adjacent tissues as determined by immunohistochemistry. In this study, we further validated the results of immunohistochemistry using the Oncomine database and we found that IL23A expression in non‑muscle invasive bladder urothelial carcinoma (NMIBC) was significantly higher than that in muscle invasive bladder urothelial carcinoma (MIBC). Expression of IL23A was negatively correlated with the clinical stage of bladder urothelial carcinoma and had a positive correlation with prognosis. In vitro experiments revealed that different concentrations of IL‑23 had different effects on T24 cells. A low concentration of 20 ng/ml IL‑23 promoted T24 cell proliferation, migration, invasion and EMT transformation, while a high concentration of 40 ng/ml IL‑23 inhibited these functions. These results indicated that IL‑23 plays a dual role in the progression of bladder cancer. Low concentrations of IL‑23 promote bladder tumor progression, while high concentrations of IL‑23 have the opposite effect. FAU - Wang, Peng AU - Wang P AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Zhang, Yao AU - Zhang Y AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Zhang, Jun AU - Zhang J AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Jiang, Jun AU - Jiang J AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Jin, Fengshuo AU - Jin F AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Sun, Zhongyi AU - Sun Z AD - Department of Urology, Daping Hospital, Institute of Surgery Research, The Third Military Medical University, Chongqing 400042, P.R. China. LA - eng PT - Journal Article DEP - 20181008 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (IL23A protein, human) RN - 0 (Interleukin-23 Subunit p19) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Cell Line, Tumor MH - *Cell Proliferation MH - Datasets as Topic MH - Disease Progression MH - Female MH - Humans MH - Interleukin-23 Subunit p19/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Prognosis MH - Survival Analysis MH - Urinary Bladder/cytology/pathology MH - Urinary Bladder Neoplasms/mortality/*pathology MH - Urothelium/cytology/pathology EDAT- 2018/12/14 06:00 MHDA- 2019/01/12 06:00 CRDT- 2018/12/14 06:00 PHST- 2018/01/18 00:00 [received] PHST- 2018/09/03 00:00 [accepted] PHST- 2018/12/14 06:00 [pubmed] PHST- 2019/01/12 06:00 [medline] PHST- 2018/12/14 06:00 [entrez] AID - 10.3892/or.2018.6775 [doi] PST - ppublish SO - Oncol Rep. 2018 Dec;40(6):3685-3693. doi: 10.3892/or.2018.6775. Epub 2018 Oct 8. PMID- 30542396 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 1792-0981 (Print) IS - 1792-1015 (Electronic) IS - 1792-0981 (Linking) VI - 16 IP - 6 DP - 2018 Dec TI - Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancer. PG - 4463-4470 LID - 10.3892/etm.2018.6787 [doi] AB - Androgen signal has been recently suggested to be associated with the progression of bladder cancer. Steroid sulfatase (STS) is a steroid sulfate activation enzyme, considered to be one of the key enzymes in the androgen signaling pathway. However, the role of STS in bladder cancer has not been elucidated. The purpose of the present study was to determine the clinical and functional significance of STS in bladder cancer. Immunohistochemical analysis of surgical specimens obtained by radical cystectomy (n=114) demonstrated that overexpression of STS was associated with the invasion of bladder cancer, as evidenced by the incidence of STS-positive cancers (11.5 and 37.1% in non-muscle invasive and muscle invasive bladder cancers, respectively; P=0.003). STS-positive cancer demonstrated shorter recurrence-free survival and cancer-specific survival (P=0.0027 and 0.0030, respectively). Furthermore, knockdown of STS significantly reduced cell migration and invasion capacities of bladder cancer cells (P<0.001 and P=0.005, respectively), accompanied by the upregulation of E-cadherin and downregulation of vimentin. In summary, the present study demonstrated that STS promotes the invasion capability of bladder cancer via regulation of the epithelial-mesenchymal transition, and may be a useful marker for predicting the progression of bladder cancers. FAU - Shimizu, Yasuomi AU - Shimizu Y AD - Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Tamada, Satoshi AU - Tamada S AD - Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Kato, Minoru AU - Kato M AD - Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Takeyama, Yuji AU - Takeyama Y AD - Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Fujioka, Masaki AU - Fujioka M AD - Department of Pathology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Kakehashi, Anna AU - Kakehashi A AD - Department of Pathology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Nakatani, Tatsuya AU - Nakatani T AD - Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Wanibuchi, Hideki AU - Wanibuchi H AD - Department of Pathology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. FAU - Gi, Min AU - Gi M AD - Department of Pathology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. LA - eng PT - Journal Article DEP - 20180921 PL - Greece TA - Exp Ther Med JT - Experimental and therapeutic medicine JID - 101531947 PMC - PMC6257456 OTO - NOTNLM OT - bladder cancer OT - cancer-specific survival OT - epithelial-mesenchymal transition OT - recurrence-free survival OT - steroid sulfatase EDAT- 2018/12/14 06:00 MHDA- 2018/12/14 06:01 PMCR- 2018/09/21 CRDT- 2018/12/14 06:00 PHST- 2018/03/13 00:00 [received] PHST- 2018/08/17 00:00 [accepted] PHST- 2018/12/14 06:00 [entrez] PHST- 2018/12/14 06:00 [pubmed] PHST- 2018/12/14 06:01 [medline] PHST- 2018/09/21 00:00 [pmc-release] AID - ETM-0-0-6787 [pii] AID - 10.3892/etm.2018.6787 [doi] PST - ppublish SO - Exp Ther Med. 2018 Dec;16(6):4463-4470. doi: 10.3892/etm.2018.6787. Epub 2018 Sep 21. PMID- 30522445 OWN - NLM STAT- MEDLINE DCOM- 20190325 LR - 20231004 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 18 IP - 1 DP - 2018 Dec 6 TI - ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. PG - 1224 LID - 10.1186/s12885-018-5134-7 [doi] LID - 1224 AB - BACKGROUND: In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the "gold" standard therapy, up to 50% of patients relapse, needing radical cystectomy. Hence, alternative therapeutic strategies have been developed. The aim of the study was to evaluate a first-line salvage treatment with EMDA(R)-MMC in patients with HGNMIBC unresponsive to BCG. METHODS: We carried out a prospective, single-center, single-arm Phase II study in order to evaluate the efficacy (in terms of recurrence and progression) and the safety of the EMDA(R)-MMC treatment in 26 (21 male, 5 female) consecutive patients with "BCG refractory" HGNMIBC on a 3 years follow-up. EMDA(R)-MMC treatment consisted of 40 mg of MMC diluted in 100 ml of sterile water retained in the bladder for 30 min with 20 mA pulsed electric current. EMDA(R)-MMC regimen consisted of an induction course of 6 weekly instillations followed by a maintenance course of 6 monthly instillations. Follow-up was performed with systematic mapping biopsies of the bladder (with sampling in the prostatic urethra for men), voiding and washing urinary cytology, radiological study of the upper urinary tract. We performed Survival Kaplan-Meier curves and Log-rank test in order to analyze high grade disease-free survival. RESULTS: At the end of follow-up, 16 patients (61.5%) preserved their native bladder; 10 patients (38.4%) underwent radical cystectomy, in 6 patients (23.1%) for recurrent HGNMIBC and in 4 patients (15.4%) for progression to muscle-invasive disease. At the end of follow-up, stratifying patients based on TNM classification (TaG3, T1G3, Cis, TaT1G3 + Cis), disease-free rates were 75, 71.4, 50 and 25%, respectively; survival curves showed statistically significant differences (p value < 0.05). Regarding toxicity, we reported severe adverse systemic event of hypersensitivity to the MMC in 3 patients (11.5%), and local side effects in 6 patients (26.1%). CONCLUSIONS: In the field of alternative strategies to radical cystectomy, the EMDA(R)-MMC could be considered safe and effective in high-risk NMIBC unresponsive to BCG, as a "bladder sparing" therapy in selected patients. Multicenter studies with a larger number of patients and a longer follow-up might confirm our preliminary results. TRIAL REGISTRATION: EudraCT2017-002585-43. 17 June 2017 (retrospectively registered). FAU - Racioppi, Marco AU - Racioppi M AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. FAU - Di Gianfrancesco, Luca AU - Di Gianfrancesco L AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. FAU - Ragonese, Mauro AU - Ragonese M AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. FAU - Palermo, Giuseppe AU - Palermo G AUID- ORCID: 0000-0002-0564-7415 AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. gpalerm@libero.it. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. gpalerm@libero.it. FAU - Sacco, Emilio AU - Sacco E AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. FAU - Bassi, Pier Francesco AU - Bassi PF AD - Department of Urology, Fondazione Policlinico Universitario "A. Gemelli" IRCSS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168, Rome, Italy. LA - eng PT - Clinical Trial, Phase II PT - Journal Article DEP - 20181206 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - *Infusion Pumps/trends MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - *Mycobacterium bovis MH - Neoplasm Invasiveness/pathology/prevention & control MH - Prospective Studies MH - Risk Factors MH - Salvage Therapy/*methods/trends MH - Time Factors MH - Treatment Failure MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy PMC - PMC6282335 OTO - NOTNLM OT - BCG failure OT - Device-assisted therapy OT - EMDA OT - High risk non muscle-invasive bladder cancer OT - Mitomycin C OT - Salvage therapy OT - Sparing bladder COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved by the local ethics committee (Fondazione Policlinico "A. Gemelli" IRCSS, Rome, Italy - Universita Cattolica del Sacro Cuore, Rome, Italy). The study involved human participants with their consent; the informed consent was written. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/12/14 06:00 MHDA- 2019/03/26 06:00 PMCR- 2018/12/06 CRDT- 2018/12/08 06:00 PHST- 2018/04/03 00:00 [received] PHST- 2018/11/26 00:00 [accepted] PHST- 2018/12/08 06:00 [entrez] PHST- 2018/12/14 06:00 [pubmed] PHST- 2019/03/26 06:00 [medline] PHST- 2018/12/06 00:00 [pmc-release] AID - 10.1186/s12885-018-5134-7 [pii] AID - 5134 [pii] AID - 10.1186/s12885-018-5134-7 [doi] PST - epublish SO - BMC Cancer. 2018 Dec 6;18(1):1224. doi: 10.1186/s12885-018-5134-7. PMID- 30539751 OWN - NLM STAT- MEDLINE DCOM- 20190131 LR - 20190131 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 12 DP - 2018 Dec TI - The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer. PG - 530.e7-530.e18 LID - S1078-1439(18)30194-7 [pii] LID - 10.1016/j.urolonc.2018.05.025 [doi] AB - PURPOSE: We investigated the effects of alterations in the biological markers p14, p53, p21, and p16 in relation to tumour cell proliferation, T-category, N- category, lymphovascular invasion, and the ability to predict prognosis in patients with muscle-invasive bladder cancer (MIBC) treated with cystectomy and, if applicable, chemotherapy. MATERIALS AND METHODS: We prospectively studied patients with urinary bladder cancer pathological stage pT1 to pT4 treated with cystectomy, pelvic lymph node dissection and postoperative chemotherapy. Tissue microarrays from paraffin-embedded cystectomy tumour samples were examined for expression of immunostaining of p14, p53, p21, p16 and Ki-67 in relation to other clinical and pathological factors as well as cancer-specific survival. RESULTS: The median age of the 110 patients was 70 years (range 51-87 years), and 85 (77%) were male. Pathological staging was pT1 to pT2 (organ-confined) in 28 (25%) patients and pT3 to pT4 (non-organ-confined) in 82 (75%) patients. Lymph node metastases were found in 47 patients (43%). P14 expression was more common in tumours with higher T-stages (P = 0.05). The expression of p14 in p53 negative tumours was associated with a significantly shorter survival time (P=0.003). Independently of p53 expression, p14 expression was associated with an impaired response to chemotherapy (P=0.001). The expression of p21 in p53 negative tumours was associated with significantly decrease levels of tumour cell proliferation detected as Ki-67 expression (P=0.03). CONCLUSIONS: The simultaneous expression of the senescence markers involved in the p53-pathway shows a more relevant correlation to the pathological outcome of MIBC than each protein separately. P14 expression in tumours with non-altered (p53-) tumours is associated with poor prognosis. P14 expression is associated with impaired response to chemotherapy. P21 expression is related to decreased tumour cell proliferation. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Urology, and Department of Clinical and Experimental Medicine, Medical Faculty, Linkoping University, SE 581 85, Linkoping, Sweden. Electronic address: firas.abdulsattar.aljabery@regionostergotland.se. FAU - Shabo, Ivan AU - Shabo I AD - Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery (MMK), Karolinska Institutet, SE 171 77, Stockholm, Sweden. Department of Breast, Endocrine and Sarcoma Surgery, Karolinska University Hospital, SE 171 76, Stockholm, Sweden. FAU - Gimm, Oliver AU - Gimm O AD - Department of Surgery and Department of Clinical and Experimental Medicine, Medical Faculty, Linkoping University, SE 581 85, Linkoping, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Urology, and Department of Clinical and Experimental Medicine, Medical Faculty, Linkoping University, SE 581 85, Linkoping, Sweden. FAU - Olsson, Hans AU - Olsson H AD - Department of Pathology and Department of Clinical and Experimental Medicine, Medical Faculty, Linkoping University, SE 581 85, Linkoping, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181024 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (CDK2AP2 protein, human) RN - 0 (CDKN1A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 0 (Oncogene Proteins) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Biomarkers, Tumor/*metabolism MH - Combined Modality Therapy MH - Cyclin-Dependent Kinase Inhibitor p21/*metabolism MH - Female MH - Follow-Up Studies MH - Genes, Tumor Suppressor MH - Humans MH - Male MH - Middle Aged MH - Muscle Neoplasms/drug therapy/metabolism/*mortality/pathology MH - Neoplasm Invasiveness MH - Oncogene Proteins/*metabolism MH - Postoperative Period MH - Prognosis MH - Prospective Studies MH - Survival Rate MH - Tumor Suppressor Protein p53/*metabolism MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*mortality/pathology OTO - NOTNLM OT - Ki-67 OT - p14 OT - p16 OT - p21 OT - p53 OT - urinary bladder cancer EDAT- 2018/12/13 06:00 MHDA- 2019/02/01 06:00 CRDT- 2018/12/13 06:00 PHST- 2018/03/18 00:00 [received] PHST- 2018/05/23 00:00 [revised] PHST- 2018/05/29 00:00 [accepted] PHST- 2018/12/13 06:00 [entrez] PHST- 2018/12/13 06:00 [pubmed] PHST- 2019/02/01 06:00 [medline] AID - S1078-1439(18)30194-7 [pii] AID - 10.1016/j.urolonc.2018.05.025 [doi] PST - ppublish SO - Urol Oncol. 2018 Dec;36(12):530.e7-530.e18. doi: 10.1016/j.urolonc.2018.05.025. Epub 2018 Oct 24. PMID- 30539282 OWN - NLM STAT- MEDLINE DCOM- 20190228 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 145 IP - 2 DP - 2019 Feb TI - Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer. PG - 487-494 LID - 10.1007/s00432-018-2811-5 [doi] AB - OBJECTIVE: Comparing intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone in the treatment of T1-staged Grade 3 (T1G3) bladder cancer after transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: From January 2007 to December 2012, 203 patients diagnosed with NMIBC were randomly assigned into either intra-arterial chemotherapy combined with intravesical chemotherapy group (Group A, n = 68) or intravesical chemotherapy alone group (Group B, n = 135) after TURBT. Four cycles of intra-arterial chemotherapy were administered after initial TURBT with 1-month interval between each. Intravesical chemotherapy was administered in both groups including an immediate 50 mg epirubicin instillation after TURBT and weekly maintenance for 8 weeks, and then followed by monthly maintenance for 1 year. The primary endpoint was recurrence-free survival. RESULTS: Out of 203 patients, 53 were in Group A and 98 in Group B, and they were evaluated for recurrence and progression rate where recurrence rate was 35.8% (19/53) in group A and 41.8% (41/98) in group B with a significant difference (P < 0.05) and progression rate was 20.7% (11/53) in group A and 23.5% (23/98) in group B with a significant difference (P < 0.05). Univariate and multivariate logistic regression analysis suggested that intra-arterial chemotherapy could be an independent risk factors related to both overall survival and time to first recurrence. CONCLUSIONS: Intra-arterial chemotherapy combined with intravesical chemotherapy could reduce the risk of recurrence and progression compared to intravesical chemotherapy alone in T1G3 bladder cancer. FAU - Huang, Bin AU - Huang B AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Wang, Hua AU - Wang H AD - Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, No.600 Tan He Road, Guangzhou, 510080, China. FAU - Lin, Hao AU - Lin H AD - Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China. linh26@mail2.sysu.edu.cn. FAU - Yao, Zhijun AU - Yao Z AD - Department of Urology, The Central Hospital of Hengyang, Hengyang, 421001, China. FAU - Zheng, Jiabo AU - Zheng J AD - Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. FAU - Fan, Wenzhe AU - Fan W AD - Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. FAU - Qiu, Shaopeng AU - Qiu S AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. AD - Department of Urology, Hui Ya hospital of The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510000, China. FAU - Chen, Lingwu AU - Chen L AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. chenlingwu@hotmail.com. FAU - Chen, Junxing AU - Chen J AUID- ORCID: 0000-0002-7264-5110 AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. cjxsysums@163.com. LA - eng GR - 81402116/Young Scientists Fund/ GR - 2017A030313847/Natural Science Foundation of Guangdong Province/ GR - 2014A020212116/Guangdong Science and Technology Department/ PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20181211 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 3Z8479ZZ5X (Epirubicin) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage MH - Epirubicin/administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - Injections, Intra-Arterial MH - Male MH - Middle Aged MH - Muscle Neoplasms/*drug therapy/pathology/surgery MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy/pathology/surgery MH - Neoplasm Staging MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery PMC - PMC11810394 OTO - NOTNLM OT - Bladder cancer OT - Intra-arterial chemotherapy OT - Intravesical chemotherapy OT - T1G3 OT - Transurethral resection of bladder tumor COIS- The authors declare that they have no conflicts of interest. EDAT- 2018/12/13 06:00 MHDA- 2019/03/01 06:00 PMCR- 2018/12/11 CRDT- 2018/12/13 06:00 PHST- 2018/09/15 00:00 [received] PHST- 2018/12/01 00:00 [accepted] PHST- 2018/12/13 06:00 [pubmed] PHST- 2019/03/01 06:00 [medline] PHST- 2018/12/13 06:00 [entrez] PHST- 2018/12/11 00:00 [pmc-release] AID - 10.1007/s00432-018-2811-5 [pii] AID - 2811 [pii] AID - 10.1007/s00432-018-2811-5 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Feb;145(2):487-494. doi: 10.1007/s00432-018-2811-5. Epub 2018 Dec 11. PMID- 30535715 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20200225 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 9 DP - 2019 Sep TI - Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. PG - 1867-1877 LID - 10.1007/s00345-018-2581-3 [doi] AB - PURPOSE: To develop and validate novel nomograms to predict recurrence and progression after transurethral resection of bladder tumor (TURBT) in Korean patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: We retrospectively analyzed the clinical data on 970 newly diagnosed NMIBC patients after TURBT between 2000 and 2013 in a single institution. We used multivariate Cox proportional hazard models to identify the significant predictors of recurrence and progression, which resulted in the construction of the nomograms predicting the 5-year probability of recurrence and progression. We internally validated the nomograms using the area under the receiver-operating characteristics' curves and calibration plots. In addition, the clinical usefulness of each nomogram was assessed and compared with that of the European Organization of Research and Treatment of Cancer (EORTC)-scoring system using decision curve analysis (DCA). RESULTS: The significant factors related to recurrence were gross hematuria at diagnosis, previous or concomitant upper urinary tract urothelial carcinoma (UTUC), pT1 tumor, high tumor grade, multiple tumors, and intravesical therapy. The significant predictors of progression were previous or concomitant UTUC, pT1 tumor, high tumor grade, carcinoma in situ, and lymphovascular invasion. The 5-year predictive accuracy of each nomogram was 65% for recurrence and 70% for progression, respectively. Compared with the EORTC-scoring system, the nomograms were generally well calibrated. On DCA, each nomogram presented better net benefit gains than did the EORTC-scoring system across a wide range of threshold probabilities. CONCLUSIONS: Our novel nomograms are not completely accurate, but they show a reasonable level of discriminative ability, adequate calibration, and meaningful net benefit gain for the prediction of recurrence and progression after TURBT in Korean NMIBC patients. Additional external validation will be required to generalize the nomograms which we developed. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. kuuro70@snu.ac.kr. LA - eng GR - 2018R1C1B5086339/National Research Foundation of Korea/ PT - Comparative Study PT - Journal Article PT - Validation Study DEP - 20181210 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - *Nomograms MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/*epidemiology/pathology/*surgery OTO - NOTNLM OT - Disease progression OT - Nomograms OT - Recurrence OT - Urinary bladder neoplasms EDAT- 2018/12/12 06:00 MHDA- 2020/02/19 06:00 CRDT- 2018/12/12 06:00 PHST- 2018/07/19 00:00 [received] PHST- 2018/11/26 00:00 [accepted] PHST- 2018/12/12 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2018/12/12 06:00 [entrez] AID - 10.1007/s00345-018-2581-3 [pii] AID - 10.1007/s00345-018-2581-3 [doi] PST - ppublish SO - World J Urol. 2019 Sep;37(9):1867-1877. doi: 10.1007/s00345-018-2581-3. Epub 2018 Dec 10. PMID- 30535583 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20220801 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. PG - 2017-2029 LID - 10.1007/s00345-018-2591-1 [doi] AB - INTRODUCTION: Intravesical therapy has been an important aspect of the management of non-muscle invasive bladder cancer (NMIBC) for 40 years. Bacillus Calmette-Guerin (BCG) is considered standard of care for intermediate and high-grade non-invasive disease, yet understanding the nuances of subsequent intravesical therapy is important for any provider managing bladder cancer. Herein, we review the literature and describe optimal use of intravesical therapies for NMIBC. METHODS: A comprehensive search of the medical literature was performed and highlighted in this review of intravesical therapy for NMIBC. RESULTS: Post-resection intravesical Mitomycin C therapy for low-risk disease remains an important component of care, and gemcitabine now has level-one evidence demonstrating efficacy in this setting but is not yet a guideline recommendation. BCG intravesical therapy remains the most effective therapy preventing recurrence and progression of intermediate and high-risk NMIBC. Adequately characterizing BCG-failure is critical in determining the next step in management which includes radical cystectomy, additional intravesical immunotherapy, chemotherapy with intravesical gemcitabine +/- docetaxel and clinical trials. CONCLUSIONS: Intravesical therapy remains the mainstay of treatment for NMIBC and bladder preservation. Intravesical induction BCG followed by maintenance therapy remains standard of care for intermediate and high-risk patients. Detailing the timing and characteristics of recurrence after intravesical therapy is crucial in determining subsequent treatment recommendations. Current clinical trials focus on systemic immunotherapy and enhancing the intravesical immune response by augmenting the delivery mechanism. FAU - Peyton, Charles C AU - Peyton CC AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Chipollini, Juan AU - Chipollini J AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Azizi, Mounsif AU - Azizi M AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Gilbert, Scott M AU - Gilbert SM AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Spiess, Phillippe E AU - Spiess PE AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. philippe.spiess@moffitt.org. LA - eng PT - Journal Article PT - Review DEP - 20181207 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Algorithms MH - Antineoplastic Agents/*administration & dosage MH - BCG Vaccine/administration & dosage MH - Drug Therapy, Combination MH - Humans MH - Neoplasm Invasiveness MH - Practice Guidelines as Topic MH - Risk Assessment MH - Treatment Failure MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - BCG failure OT - Intravesical therapy OT - Non-muscle invasive bladder cancer EDAT- 2018/12/12 06:00 MHDA- 2020/02/20 06:00 CRDT- 2018/12/12 06:00 PHST- 2018/08/16 00:00 [received] PHST- 2018/11/28 00:00 [accepted] PHST- 2018/12/12 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2018/12/12 06:00 [entrez] AID - 10.1007/s00345-018-2591-1 [pii] AID - 10.1007/s00345-018-2591-1 [doi] PST - ppublish SO - World J Urol. 2019 Oct;37(10):2017-2029. doi: 10.1007/s00345-018-2591-1. Epub 2018 Dec 7. PMID- 30534816 OWN - NLM STAT- MEDLINE DCOM- 20181231 LR - 20181231 IS - 2066-8279 (Electronic) IS - 1220-0522 (Linking) VI - 59 IP - 3 DP - 2018 TI - Bipolar en bloc tumor resection versus standard monopolar TURBT - which is the best way to go in non-invasive bladder cancer? PG - 773-780 AB - The aim of the study was to observe similarities and differences regarding surgical safety and prognosis between en bloc bipolar resection and monopolar transurethral resection of bladder tumors (TURBTs) in medium size papillary non-muscle invasive bladder tumors (NMIBTs). A total of 90 patients with papillary bladder tumors presenting a diameter between 1 and 3 cm were equally divided and alternatively assigned for en bloc bipolar ablation (the study group) and conventional TURBT (the control group). During one year, every three months, the follow-up was performed and the protocol included urinary cytology and cystoscopy. Similar mean patients' age and tumor diameter were determined in both groups. In the study group, it was noticed an important reduced rate of obturator nerve reflex adverse event that caused bladder wall perforation. In addition, comparing the results between the two groups, the following aspects were observed in the study arm: decreased mean operation time (13.4 versus 19.7 minutes), hemoglobin level drop (0.28 versus 0.76 g∕dL), catheterization period (1.9 versus 2.8 days) and hospital stay (2.3 versus 3.1 days). A total of 41 and respectively 40 patients completed the 12 months follow-up protocol. After one year, the en bloc group presented a significantly lower recurrence rate, superior surgical safety, decreased perioperative morbidity and faster recovery. Therefore, the en bloc surgery approach presented a better oncological prognosis due to the reduced heterotopic NMIBT recurrences up to one year. FAU - Balan, Georgiana Xenia AU - Balan GX AD - Department of Nephrology and Dialysis, "St. John" Emergency Clinical Hospital, Clinical Department No. 3, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; niculaeandrei@yahoo.com. FAU - Geavlete, Petrisor Aurelian AU - Geavlete PA FAU - Georgescu, Dragos Adrian AU - Georgescu DA FAU - Ene, Cosmin Victor AU - Ene CV FAU - Bulai, Catalin Andrei AU - Bulai CA FAU - Paunescu, Maria Alexandra AU - Paunescu MA FAU - Niculae, Andrei AU - Niculae A FAU - Peride, Ileana AU - Peride I FAU - Lascar, Ioan AU - Lascar I FAU - Neagu, Tiberiu Paul AU - Neagu TP FAU - Geavlete, Bogdan Florin AU - Geavlete BF LA - eng PT - Comparative Study PT - Journal Article PL - Romania TA - Rom J Morphol Embryol JT - Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie JID - 9112454 SB - IM MH - Aged MH - Follow-Up Studies MH - Humans MH - Middle Aged MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Urologic Surgical Procedures/*methods MH - Urothelium/pathology EDAT- 2018/12/12 06:00 MHDA- 2019/01/01 06:00 CRDT- 2018/12/12 06:00 PHST- 2018/12/12 06:00 [entrez] PHST- 2018/12/12 06:00 [pubmed] PHST- 2019/01/01 06:00 [medline] AID - 590318773780 [pii] PST - ppublish SO - Rom J Morphol Embryol. 2018;59(3):773-780. PMID- 30534436 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 16 IP - 4 DP - 2018 Dec TI - Positive ureteric margins at radical cystectomy: Can it be predicted at initial transurethral resection of bladder tumour? PG - 386-390 LID - 10.1016/j.aju.2018.06.004 [doi] AB - OBJECTIVE: To identify primary tumour-related factors at transurethral resection of bladder tumour (TURBT) that may predict positive distal ureteric margins (PUM) at the time of radical cystectomy (RC). PATIENTS AND METHODS: A retrospective, cohort study was conducted using our institution's data from June 2007 to June 2016. Patients who underwent TURBT followed by RC for non-metastatic urothelial carcinoma (UC) of the bladder were identified. In all, 211 patients underwent RC for UC during the study period. The patients were divided into two groups: Group-I (n = 17) with PUM and Group-II (n = 194) with negative ureteric margins. Univariate and multivariate analyses were performed to determine the predictors of PUM. RESULTS: On univariate analysis, multifocality, tumours involving the ureteric orifice, trigonal tumours, presence of carcinoma in situ (CIS), and lymphovascular invasion at TURBT, were significantly more common in Group-I. On multivariate analysis, tumour involvement in the ureteric orifice(s) and presence of associated CIS significantly predicted PUM. CONCLUSIONS: Primary tumour-related factors on initial TURBT that predicted PUM (at RC) were involvement of the ureteric orifice(s) and presence of associated CIS. These results may help to select patients who can be selectively offered intraoperative frozen section analysis. FAU - Singh, Onkar AU - Singh O AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Nirmal, Thampi John AU - Nirmal TJ AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Mukha, Rajiv Paul AU - Mukha RP AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Mahasampath, Gowri AU - Mahasampath G AD - Department of Biostatistics, Christian Medical College, Vellore, Tamilnadu, India. FAU - Chandrasingh, J AU - Chandrasingh J AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Devasia, Antony AU - Devasia A AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Kumar, Santosh AU - Kumar S AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. FAU - Kekre, Nitin Sudhakar AU - Kekre NS AD - Department of Urology, Christian Medical College and Hospital, Vellore, Tamilnadu, India. LA - eng PT - Journal Article DEP - 20180714 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC6277264 OTO - NOTNLM OT - Bladder cancer OT - CIS, carcinoma in situ OT - Distal ureteric margin OT - IFSA, intraoperative frozen section analysis OT - LVI, lymphovascular invasion OT - OR, odds ratio OT - PUM, positive distal ureteric margins OT - Radical cystectomy OT - Surgical margin OT - TURBT, transurethral resection of bladder tumour OT - Treatment OT - UC, urothelial carcinoma OT - UT, upper tract EDAT- 2018/12/12 06:00 MHDA- 2018/12/12 06:01 PMCR- 2018/07/14 CRDT- 2018/12/12 06:00 PHST- 2018/04/02 00:00 [received] PHST- 2018/06/02 00:00 [revised] PHST- 2018/06/23 00:00 [accepted] PHST- 2018/12/12 06:00 [entrez] PHST- 2018/12/12 06:00 [pubmed] PHST- 2018/12/12 06:01 [medline] PHST- 2018/07/14 00:00 [pmc-release] AID - S2090-598X(18)30063-9 [pii] AID - 10.1016/j.aju.2018.06.004 [doi] PST - epublish SO - Arab J Urol. 2018 Jul 14;16(4):386-390. doi: 10.1016/j.aju.2018.06.004. eCollection 2018 Dec. PMID- 30526804 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221110 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 13 IP - 8 DP - 2019 Aug TI - The oncological outcomes of small cell carcinoma of the bladder. PG - 260-265 LID - 10.5489/cuaj.5579 [doi] AB - INTRODUCTION: Small cell carcinoma of the bladder (SmCC) is a rare and aggressive genitourinary malignancy. The paucity of clinical trials and outcome data provide no standard treatment guidelines. Accordingly, patient prognosis is poor. Our goal was to present the first comprehensive in-depth analysis of SmCC in a tertiary Canadian centre. METHODS: We retrospectively reviewed all patients diagnosed with primary SmCC at the London Regional Cancer Program between January 1990 and 2016. The primary outcome was overall survival (OS). We examined a number of secondary outcomes and baseline characteristics. RESULTS: We identified 15 men and six women (median age 72 years) with a SmCC diagnosis (median followup 11.33 months). Median Charlson Comorbidity Index score was 7 (interquartile range [IQR] 5-10) and 15 patients had a smoking history. Most common presentation was gross hematuria (18 patients, 86%), and pT2 stage at transurethral resection of the bladder tumour (TURBT) (n= 7/21, 33%), although five patients had cT4 (24%). Pure SmCC was found in nine individuals (43%), whereas 12 had mixed differentiation (57%). From initial staging, 15 patients had extravesical disease (71%), 10 had positive pelvic lymphadenopathy (48%), and distant metastases occurred in six (29%). In our series, five individuals (24%) underwent cystectomy, 18 (86%) received radiation, and 14 (67%) received adjuvant chemotherapy. The median OS was 15 months (two-year OS was 19%). CONCLUSIONS: SmCC is a rare and aggressive form of bladder cancer. Despite multimodal therapy, prognosis remains guarded, with little improvement seen over the study's 25-year duration. An understanding of study limitations is warranted in interpretation of results. FAU - Williams, Harley A AU - Williams HA AD - Department of Medical Biophysics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. FAU - Punjani, Nahid AU - Punjani N AD - Department of Surgery, Division of Urology, University of Western Ontario, London, ON, Canada. FAU - Khan, Obaidullah AU - Khan O AD - Department of Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. FAU - Power, Nicholas E AU - Power NE AD - Department of Surgery, Division of Urology, University of Western Ontario, London, ON, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC6737728 COIS- Competing interests: The authors report no competing personal or financial interests related to this work. EDAT- 2018/12/12 06:00 MHDA- 2018/12/12 06:01 PMCR- 2019/08/01 CRDT- 2018/12/12 06:00 PHST- 2018/12/12 06:00 [entrez] PHST- 2018/12/12 06:00 [pubmed] PHST- 2018/12/12 06:01 [medline] PHST- 2019/08/01 00:00 [pmc-release] AID - cuaj.5579 [pii] AID - cuaj-8-260 [pii] AID - 10.5489/cuaj.5579 [doi] PST - ppublish SO - Can Urol Assoc J. 2019 Aug;13(8):260-265. doi: 10.5489/cuaj.5579. PMID- 30526555 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20190403 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 18 IP - 1 DP - 2018 Dec 10 TI - Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. PG - 1239 LID - 10.1186/s12885-018-5137-4 [doi] LID - 1239 AB - BACKGROUND: Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease. The aim of this study was to analyse the expression of A-FABP (adipocyte-fatty acid binding protein) and to evaluate its prognostic value in bladder cancer with a long term clinical follow-up. METHODS: A-FABP expression was investigated by immunohistochemistry in 236 tumours (114 pTa, 61 pT1, 61 pT2-4). Immunostaining was classified as negative (absent or weak immunostaining and moderate or strong staining on 10% of cells). Event-free survival (EFS) and overall survival (OS) were determined with a 87.3 months median follow-up in the overall cohort. Recurrence-free survival (RFS) and progression-free survival (PFS) were established in NMIBC. RESULTS: Loss of A-FABP was associated with higher mean age, high stage/grade, and the presence of metastatic lymph nodes. It was correlated with shorter median EFS (17.5 vs 62.5 months; p = 0.001) and mean OS (76.7 vs 154.2 months; p = 0.009) and with higher risk of progression in the pTa/pT1 subgroup (HR, 0.36; 95% CI, 0.13-0.96; p = 0.041) and importantly in the pTa tumours (HR, 0.34; 95% CI, 0.10-0.97; p = 0.045). CONCLUSION: These results demonstrated that loss of A-FABP expression following a long follow-up was predictive of pTa and pTa/pT1 progression. Immunohistochemistry on diagnostic biopsy is easy to use and could be of value to help clinicians to propose appropriate treatment for these tumours. FAU - Mathis, Christel AU - Mathis C AD - Department of Pathology, University Hospital of Besancon, F-25000, Besancon, France. FAU - Lascombe, Isabelle AU - Lascombe I AD - University Bourgogne Franche-Comte, EA3181, LabEx LipSTIC ANR-11-LABX-0021, F-25030, Besancon, France. FAU - Monnien, Franck AU - Monnien F AD - Department of Pathology, University Hospital of Besancon, F-25000, Besancon, France. FAU - Bittard, Hugues AU - Bittard H AD - University Bourgogne Franche-Comte, EA3181, LabEx LipSTIC ANR-11-LABX-0021, F-25030, Besancon, France. AD - Department of Urology, University Hospital of Besancon, F-25000, Besancon, France. FAU - Kleinclauss, Francois AU - Kleinclauss F AD - Department of Urology, University Hospital of Besancon, F-25000, Besancon, France. FAU - Bedgedjian, Isabelle AU - Bedgedjian I AD - Department of Pathology, University Hospital of Besancon, F-25000, Besancon, France. FAU - Fauconnet, Sylvie AU - Fauconnet S AD - University Bourgogne Franche-Comte, EA3181, LabEx LipSTIC ANR-11-LABX-0021, F-25030, Besancon, France. sylvie.fauconnet@univ-fcomte.fr. AD - Department of Urology, University Hospital of Besancon, F-25000, Besancon, France. sylvie.fauconnet@univ-fcomte.fr. FAU - Valmary-Degano, Severine AU - Valmary-Degano S AD - Department of Pathology, University Hospital of Besancon, F-25000, Besancon, France. svalmarydegano@chu-grenoble.fr. AD - University Bourgogne Franche-Comte, EA3181, LabEx LipSTIC ANR-11-LABX-0021, F-25030, Besancon, France. svalmarydegano@chu-grenoble.fr. LA - eng PT - Journal Article DEP - 20181210 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (FABP4 protein, human) RN - 0 (Fatty Acid-Binding Proteins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/metabolism/mortality/*pathology MH - Disease Progression MH - Down-Regulation MH - Fatty Acid-Binding Proteins/*biosynthesis MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Urinary Bladder Neoplasms/metabolism/mortality/*pathology PMC - PMC6288864 OTO - NOTNLM OT - A-FABP OT - Adipocyte-fatty acid binding protein OT - Bladder cancer OT - FABP4 OT - Prognostic marker COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Ethical approval for this project was obtained from the CPP - Est II, the ethics committee of our institution. All procedures performed in this study involving human participants were thus in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients gave written consent to participation in the study. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/12/12 06:00 MHDA- 2019/04/04 06:00 PMCR- 2018/12/10 CRDT- 2018/12/12 06:00 PHST- 2018/07/20 00:00 [received] PHST- 2018/11/26 00:00 [accepted] PHST- 2018/12/12 06:00 [entrez] PHST- 2018/12/12 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2018/12/10 00:00 [pmc-release] AID - 10.1186/s12885-018-5137-4 [pii] AID - 5137 [pii] AID - 10.1186/s12885-018-5137-4 [doi] PST - epublish SO - BMC Cancer. 2018 Dec 10;18(1):1239. doi: 10.1186/s12885-018-5137-4. PMID- 30515595 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC). PG - 2031-2040 LID - 10.1007/s00345-018-2592-0 [doi] AB - PURPOSE: BCG is the gold standard in management of high-risk non-muscle invasive bladder cancer (HRNMIBC). However, in patients who fail BCG, there are few effective intrasvesical options. This review aims to explore standard and emerging therapies in HRNMIBC. METHODS: A non-systematic literature review was performed using Medline and PubMed. Literature focused on HRNMIBC and BCG failure studies, with particular attention to Phase II and III clinical trials. RESULTS: The only FDA approved therapy for BCG failure patients in Valrubicin. Patients with HRNMIBC and BCG failure patients are at increased risk for progression and death from bladder cancer. There are a variety of clinical trials exploring different therapeutic approaches such as immunotherapy, vaccines, radiotherapy, and gene therapy. These trials are showing some promise in the early reporting phase. CONCLUSION: Despite limited intravesical treatment options in BCG failure patients, there are several promising therapies currently being developed and several with promising early results. FAU - Werntz, Ryan P AU - Werntz RP AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA. ryan.werntz@uchospitals.edu. FAU - Adamic, Brittany AU - Adamic B AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA. LA - eng PT - Journal Article PT - Review DEP - 20181204 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Antineoplastic Agents/therapeutic use MH - BCG Vaccine/therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Risk Assessment MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG failure OT - Immunotherapy OT - Non-muscle invasive bladder cancer OT - Vaccines EDAT- 2018/12/06 06:00 MHDA- 2020/02/20 06:00 CRDT- 2018/12/06 06:00 PHST- 2018/08/07 00:00 [received] PHST- 2018/11/28 00:00 [accepted] PHST- 2018/12/06 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2018/12/06 06:00 [entrez] AID - 10.1007/s00345-018-2592-0 [pii] AID - 10.1007/s00345-018-2592-0 [doi] PST - ppublish SO - World J Urol. 2019 Oct;37(10):2031-2040. doi: 10.1007/s00345-018-2592-0. Epub 2018 Dec 4. PMID- 30496283 OWN - NLM STAT- MEDLINE DCOM- 20190506 LR - 20200309 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 11 DP - 2018 TI - Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer? PG - e0208267 LID - 10.1371/journal.pone.0208267 [doi] LID - e0208267 AB - We evaluated the effect of intravesical Bacillus Calmette-Guerin (BCG) and BCG maintenance therapy on the prognosis of patients with T0 after repeat transurethral resection of bladder mass (TURBT). This retrospective analysis involved 427 patients who underwent repeat TURBT within 6 weeks after initial TURBT from 2007 to 2016. Repeat TURBT was performed in patients with high-risk criteria. Patients who achieved T0 after repeat TURBT did or did not receive intravesical BCG therapy. Patients were divided into three groups: non-BCG, BCG induction, and BCG maintenance groups. The study included 106 patients who achieved T0 after repeat TURBT. The median follow-up was 63 months. There were no significant differences in T stage among the three groups. High grade ratio (p = 0.001) and concomitant CIS ratio (p = 0.037) were significantly higher in the BCG maintenance than in the other two groups. The recurrence rates in the non-BCG, BCG induction, and BCG maintenance groups were 46.2%, 28.3%, and 19.2%, respectively (p = 0.043). Recurrence-free survival was significantly higher in the BCG maintenance group than in the BCG induction group (p = 0.032). Progression-free survival was also higher in the BCG maintenance group than in the BCG induction group, but the difference was not significant (p = 0.056). Multivariate Cox regression analysis showed that only intravesical BCG maintenance therapy was significantly associated with recurrence (hazard ratio 0.016, p = 0.016). In high risk NMIBC patients, intravesical BCG maintenance treatment is required even at T0 after repeat TURBT. Intravesical BCG maintenance therapy of patients with T0 after TURBT reduces recurrence. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Inje University Sanggye Paik Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AUID- ORCID: 0000-0002-1987-2111 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng SI - figshare/10.6084/m9.figshare.6845012 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181129 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology/*prevention & control MH - Neoplasm Recurrence, Local/pathology/prevention & control MH - Progression-Free Survival MH - Retrospective Studies MH - Urinary Bladder Neoplasms/complications/pathology/surgery/*therapy PMC - PMC6264801 COIS- The authors have declared that no competing interests exist. EDAT- 2018/11/30 06:00 MHDA- 2019/05/07 06:00 PMCR- 2018/11/29 CRDT- 2018/11/30 06:00 PHST- 2018/07/25 00:00 [received] PHST- 2018/11/14 00:00 [accepted] PHST- 2018/11/30 06:00 [entrez] PHST- 2018/11/30 06:00 [pubmed] PHST- 2019/05/07 06:00 [medline] PHST- 2018/11/29 00:00 [pmc-release] AID - PONE-D-18-21880 [pii] AID - 10.1371/journal.pone.0208267 [doi] PST - epublish SO - PLoS One. 2018 Nov 29;13(11):e0208267. doi: 10.1371/journal.pone.0208267. eCollection 2018. PMID- 30472983 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221110 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 13 IP - 7 DP - 2019 Jul TI - Segmental ureterectomy can be performed safely in patients with urothelial carcinoma of distal ureter. PG - E202-E209 LID - 10.5489/cuaj.5555 [doi] AB - INTRODUCTION: We aimed to compare oncological outcomes by surgery type (segmental ureterectomy [SU] vs. radical nephroureterectomy [RNU]) in a large cohort of patients with upper tract urothelial carcinoma (UTUC) of the distal ureter. METHODS: We performed a retrospective analysis of 219 patients with UTUC of the distal ureter among 931 patients with UTUC who underwent SU and RNU. Clinicopathological outcomes were evaluated. Cancer-specific survival (CSS), overall survival (OS), local recurrence-free survival (RFS), intravesical recurrence-free survival (IVRFS), contralateral recurrence-free survival, and distal metastasis-free survival were assessed by the Kaplan-Meier method and Cox regression, estimating hazard ratios (HR) and 95% confidence intervals (CIs). RESULTS: A total of 179 (81.7%) patients underwent RNU and 40 (18.3%) underwent SU: 85 males (47.5%) with RNU and 17 (42.5%) with SU (p=0.568). The median age with RNU and SU was 71 years (range 31-86) and 70 years (range 46-90), respectively (p=0.499). The T stage of the two groups did not differ (p=0.122), nor did mean tumour length (3.35+/-2.62 vs. 3.25+/-2.14; p=0.953), grade (p=0.075), tumour necrosis (p=0.634), or followup time (months) (58.1+/-8.1 vs. 63.7+/-3.4; p=0.462). The two groups did not differ in CSS (p=0.358) or OS (p=0.206), and surgery type did not predict CSS (HR 0.862; 95% CI 0.469-1.585; p=0.633) or OS (HR 0.764; 95% CI 0.419-1.392; p=0.379). Local RFS was higher with RNU than SU (96.2% vs. 86.0%; p=0.02), but the groups did not differ in IVRFS (p=0.661), contralateral RFS (p=0.183), or distant metastasis-free survival (p=0.078). On multivariate analysis, SU was associated with local RFS (HR 5.069; 95% CI 1.029-24.968; p=0.046) and distant metastasis-free survival (HR 6.497; 95% CI 1.196-35.283; p=0.03). Local RFS was lower with SU than RNU for patients with pT3-4 stage (p=0.006). CONCLUSIONS: Long-term oncological outcomes were equivalent with SU and RNU in patients with UTUC of the distal ureter. SU affected local recurrence survival, especially with advanced tumour stage, and distant metastasis survival. FAU - Jia, Zhuo AU - Jia Z AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Gong, Yan-Qing AU - Gong YQ AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Zhang, Cui-Jian AU - Zhang CJ AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Bao, Zheng-Qing AU - Bao ZQ AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Li, Xue-Song AU - Li XS AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Hao, Han AU - Hao H AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Xiong, Geng-Yan AU - Xiong GY AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - He, Zhi-Song AU - He ZS AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. FAU - Zhou, Li-Qun AU - Zhou LQ AD - Department of Urology, Peking University First Hospital, Institute of Urology and National Urological Cancer Center, Peking University, Peking University, Beijing, China. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC6667327 COIS- Competing interests: The authors report no competing personal or financial interests related to this work. EDAT- 2018/11/27 06:00 MHDA- 2018/11/27 06:01 PMCR- 2019/07/01 CRDT- 2018/11/27 06:00 PHST- 2018/11/27 06:00 [entrez] PHST- 2018/11/27 06:00 [pubmed] PHST- 2018/11/27 06:01 [medline] PHST- 2019/07/01 00:00 [pmc-release] AID - cuaj.5555 [pii] AID - cuaj-7-202 [pii] AID - 10.5489/cuaj.5555 [doi] PST - ppublish SO - Can Urol Assoc J. 2019 Jul;13(7):E202-E209. doi: 10.5489/cuaj.5555. PMID- 30471370 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20240714 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 125 DP - 2019 Mar TI - Factors That Influence Selectionof Urinary Diversion Among Bladder Cancer Patients in 3 Community-based Integrated Health Care Systems. PG - 222-229 LID - S0090-4295(18)31217-2 [pii] LID - 10.1016/j.urology.2018.09.037 [doi] AB - OBJECTIVE: To assess the relative contributions of patient and surgeon factors for predicting selection of ileal conduit (IC), neobladder (NB), or continent pouch (CP) urinary diversions (UD) for patients diagnosed with muscle-invasive/high-risk nonmuscle invasive bladder cancer. This information is needed to enhance research comparing cancer survivors' outcomes across different surgical treatment options. METHODS: Bladder cancer patients' age >/=21 years with cystectomy/UD performed from January 2010 to June 2015 in 3 Kaiser Permanente regions were included. All patient and surgeon data were obtained from electronic health records. A mixed effects logistic regression model was used treating surgeon as a random effect and region as a fixed effect. RESULTS: Of 991 eligible patients, 794 (80%) received IC. One hundred sixty-nine surgeons performed the surgeries and accounted for a sizeable proportion of the variability in patient receipt of UD (intraclass correlation coefficient = 0.26). The multilevel model with only patient factors showed good fit (area under the curve = 0.93, Hosmer-Lemeshow test P = .44), and older age, female sex, estimated glomerular filtration rate <45, 4+ comorbidity index score, and stage III/IV tumors were associated with higher odds of receiving an IC vs neobladder/continent pouch. However, including surgeon factors (annual cystectomy volume, specialty training, clinical tenure) had no association (P = .29). CONCLUSION: In this community setting, patient factors were major predictors of UD received. Surgeons also played a substantial role, yet clinical training and experience were not major predictors. Surgeon factors such as beliefs about UD options and outcomes should be explored. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Kwan, Marilyn L AU - Kwan ML AD - Kaiser Permanente Division of Research, Oakland, CA. Electronic address: Marilyn.L.Kwan@kp.org. FAU - Leo, Michael C AU - Leo MC AD - Kaiser Permanente Center for Health Research, Portland, OR. FAU - Danforth, Kim N AU - Danforth KN AD - Kaiser Permanente Department of Research & Evaluation, Pasadena, CA. FAU - Weinmann, Sheila AU - Weinmann S AD - Kaiser Permanente Center for Health Research, Portland, OR. FAU - Lee, Valerie S AU - Lee VS AD - Kaiser Permanente Division of Research, Oakland, CA. FAU - Munneke, Julie R AU - Munneke JR AD - Kaiser Permanente Division of Research, Oakland, CA. FAU - Bulkley, Joanna E AU - Bulkley JE AD - Kaiser Permanente Center for Health Research, Portland, OR. FAU - Rosetti, Maureen O'Keeffe AU - Rosetti MO AD - Kaiser Permanente Center for Health Research, Portland, OR. FAU - Yi, David K AU - Yi DK AD - Kaiser Permanente Department of Research & Evaluation, Pasadena, CA. FAU - Banegas, Matthew P AU - Banegas MP AD - Kaiser Permanente Center for Health Research, Portland, OR. FAU - Wagner, Matthew D AU - Wagner MD AD - Department of Urology, Kaiser Permanente Sunnyside Medical Center, Clackamas, OR. FAU - Williams, Stephen G AU - Williams SG AD - Department of Urology, Kaiser Permanente Riverside Medical Center, Riverside, CA. FAU - Aaronson, David S AU - Aaronson DS AD - Department of Urology, Kaiser Permanente Oakland Medical Center, Oakland, CA. FAU - Grant, Marcia AU - Grant M AD - City of Hope Hospital, Duarte, CA. FAU - Krouse, Robert S AU - Krouse RS AD - University of Pennsylvania School of Medicine, University & Woodland Aves., Philadelphia, PA. FAU - Gilbert, Scott M AU - Gilbert SM AD - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. FAU - McMullen, Carmit K AU - McMullen CK AD - Kaiser Permanente Center for Health Research, Portland, OR. LA - eng GR - R01 CA164128/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural DEP - 20181122 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2019 Mar;125:228-229. doi: 10.1016/j.urology.2018.11.022. PMID: 30798970 MH - Aged MH - Community Health Services MH - *Cystectomy MH - Delivery of Health Care, Integrated MH - Female MH - Forecasting MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Patient Selection MH - Postoperative Complications/epidemiology MH - Urinary Bladder Neoplasms/pathology/*surgery MH - *Urinary Diversion/methods/statistics & numerical data PMC - PMC6389399 MID - NIHMS1514151 COIS- Declarations of Interest: None Conflict of Interest: The authors declare that they have no conflict of interest. EDAT- 2018/11/25 06:00 MHDA- 2019/06/07 06:00 PMCR- 2020/03/01 CRDT- 2018/11/25 06:00 PHST- 2018/09/26 00:00 [received] PHST- 2018/10/06 00:00 [revised] PHST- 2018/11/15 00:00 [accepted] PHST- 2018/11/25 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2018/11/25 06:00 [entrez] PHST- 2020/03/01 00:00 [pmc-release] AID - S0090-4295(18)31217-2 [pii] AID - 10.1016/j.urology.2018.09.037 [doi] PST - ppublish SO - Urology. 2019 Mar;125:222-229. doi: 10.1016/j.urology.2018.09.037. Epub 2018 Nov 22. PMID- 30471107 OWN - NLM STAT- MEDLINE DCOM- 20200316 LR - 20200316 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 234 IP - 4 DP - 2019 Apr TI - Cancer stem cells as a therapeutic target in bladder cancer. PG - 3197-3206 LID - 10.1002/jcp.26916 [doi] AB - Bladder cancer is one of the most prevalent genitourinary cancers responsible for about 150,000 deaths per year worldwide. Currently, several treatments, such as endoscopic and open surgery, appended by local or systemic immunotherapy, chemotherapy, and radiotherapy are used to treat this malignancy. However, the differences in treatment outcome among patients suffering from bladder cancer are considered as one of the important challenges. In recent years, cancer stem cells, representing a population of undifferentiated cells with stem-cell like properties, have been eyed as a major culprit for the high recurrence rate in superficial papillary bladder cancer. Cancer stem cells have been reported to be resistant to conventional treatments, such as chemotherapy, radiation, and immunotherapy, which induce selective pressure on tumoral populations resulting in selection and growth of the resistant cells. Therefore, targeting the therapeutic aspects of cancer stem cells in bladder cancer may be promising. In this study, we briefly discuss the biology of bladder cancer and then address the possible relationship between molecular biology of bladder cancer and cancer stem cells. Subsequently, the mechanisms of resistance applied by cancer stem cells against the conventional therapeutic tools, especially chemotherapy, are discussed. Moreover, by emphasizing the biomarkers described for cancer stem cells in bladder cancer, we have provided, described, and proposed targets on cancer stem cells for therapeutic interventions and, finally, reviewed some immunotargeting strategies against bladder cancer stem cells. CI - (c) 2018 Wiley Periodicals, Inc. FAU - Aghaalikhani, Nazi AU - Aghaalikhani N AUID- ORCID: 0000-0001-6997-4362 AD - Department of Clinical Biochemistry and Laboratory Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Drug Applied Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Rashtchizadeh, Nadereh AU - Rashtchizadeh N AD - Department of Clinical Biochemistry and Laboratory Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Drug Applied Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Shadpour, Pejman AU - Shadpour P AD - Hasheminejad Kidney Centre (HKC), Hospital Management Research Centre (HMRC), University of Medical Sciences (IUMS), Tehran, Iran. FAU - Allameh, Abdolamir AU - Allameh A AD - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Mahmoodi, Marzieh AU - Mahmoodi M AD - Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran. LA - eng PT - Journal Article PT - Review DEP - 20181123 PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) SB - IM MH - Animals MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers, Tumor/metabolism MH - Drug Resistance, Neoplasm MH - Humans MH - Molecular Targeted Therapy MH - Neoplastic Stem Cells/*drug effects/metabolism/pathology/radiation effects MH - Radiation Tolerance MH - Signal Transduction MH - Urinary Bladder Neoplasms/*drug therapy/metabolism/pathology/radiotherapy OTO - NOTNLM OT - cancer stem cells OT - drug resistance OT - immunotherapy OT - transitional cell carcinoma OT - urinary bladder neoplasms EDAT- 2018/11/25 06:00 MHDA- 2020/03/17 06:00 CRDT- 2018/11/25 06:00 PHST- 2018/02/10 00:00 [received] PHST- 2018/06/13 00:00 [accepted] PHST- 2018/11/25 06:00 [pubmed] PHST- 2020/03/17 06:00 [medline] PHST- 2018/11/25 06:00 [entrez] AID - 10.1002/jcp.26916 [doi] PST - ppublish SO - J Cell Physiol. 2019 Apr;234(4):3197-3206. doi: 10.1002/jcp.26916. Epub 2018 Nov 23. PMID- 30471076 OWN - NLM STAT- MEDLINE DCOM- 20200305 LR - 20201005 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 16 IP - 5 DP - 2019 Oct 21 TI - Does Mantoux Test Result Predicts BCG Immunotherapy Efficiency and Severe Toxicity in Non-Muscle Invasive Bladder Cancer. PG - 458-462 LID - 10.22037/uj.v0i0.4542 [doi] AB - PURPOSE: To evaluate on a large group of patients whether Mantoux tuberculin skin test (TST) result is associated with BCG immunotherapy effectiveness and whether it can predict occurrence of moderate to severe toxicity. MATERIALS AND METHODS: We analysed group of 823 patients with intermediate and high risk NMIBCs who were treated with BCG. The study included 412 patients with the history TST and 411 without TST. A standard dose of Statens Serum Institute tuberculin RT23 was used. The reaction was read 48-72 hours later by evaluating the diameter of palpable induration. The size of the induration was considered positive when the measurement was greater than or equal to 6 mm and excessively positive when bigger than 26 mm. Whole BCG immunotherapy schedule consisted of 27 instillations. RESULTS: The patients were followed for median 61 months. The 5-year recurrence and progression free survival (RFS, PFS) did not differ between the groups in both total study population and in tumour subgroup analysis. TST result in both total study population and in subgroups was not statistically associated with RFS, PFS and cancer specific survival.The moderate-to-severe toxicity was observed in 181(44%) TST patients, and in 196(47%) patients without TST. Incidence of toxicity was not statistically different and also not statistically associated with TST result in any of the tumour subgroups of TST group. CONCLUSION: This study shows, that TST does not have value in prediction of bladder cancer recurrence, progres-sion nor cancer specific survival. Also it doesn't have a value in predicting therapy toxicity. FAU - Krajewski, Wojciech AU - Krajewski W AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. wk@softstar.pl. FAU - Zdrojowy, Romuald AU - Zdrojowy R AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Grzegolka, Jedrzej AU - Grzegolka J AD - Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland. FAU - Krajewski, Piotr AU - Krajewski P AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Wrobel, Michal AU - Wrobel M AD - Department of Urology and Oncologic Urology, Lowersilesian Specialistic Hospital, Wroclaw, Poland. FAU - Luczak, Mateusz AU - Luczak M AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. FAU - Kolodziej, Anna AU - Kolodziej A AD - Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20191021 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/adverse effects/*therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/adverse effects/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Retrospective Studies MH - Severity of Illness Index MH - Treatment Outcome MH - *Tuberculin Test MH - Urinary Bladder Neoplasms/*drug therapy/pathology EDAT- 2018/11/25 06:00 MHDA- 2020/03/07 06:00 CRDT- 2018/11/25 06:00 PHST- 2018/11/25 06:00 [pubmed] PHST- 2020/03/07 06:00 [medline] PHST- 2018/11/25 06:00 [entrez] AID - 4542 [pii] AID - 10.22037/uj.v0i0.4542 [doi] PST - epublish SO - Urol J. 2019 Oct 21;16(5):458-462. doi: 10.22037/uj.v0i0.4542. PMID- 30470647 OWN - NLM STAT- MEDLINE DCOM- 20210520 LR - 20210520 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 6 IP - 3 DP - 2020 May 15 TI - Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. PG - 479-489 LID - S2405-4569(18)30337-7 [pii] LID - 10.1016/j.euf.2018.11.005 [doi] AB - CONTEXT: This review focuses on the most widely used risk stratification and prediction tools for non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To assess the clinical use and relevance of risk stratification and prediction tools to enhance clinical decision making and counselling of patients with NMIBC. EVIDENCE ACQUISITION: The most frequent, currently used risk stratification tools and prognostic models for NMIBC patients were identified by the members of the European Association of Urology (EAU) Guidelines Panel on NMIBC. EVIDENCE SYNTHESIS: The 2006 European Organization for Research and Treatment of Cancer (EORTC) risk tables are the most widely used and validated tools for risk stratification and prognosis prediction in NMIBC patients. The EAU risk categories constitute a simple alternative to the EORTC risk tables and can be used for comparable risk stratification. In the subgroup of NMIBC patients treated with a short maintenance schedule of bacillus Calmette-Guerin (BCG), the Club Urologico Espanol de Tratamiento Oncologico (CUETO) scoring model is more accurate than the EORTC risk tables. Both the EORTC risk tables and the CUETO scoring model overestimate the recurrence and progression risks in patients treated according to current guidelines. The new concept of conditional recurrence and progression estimates is very promising during follow-up but should be validated. CONCLUSIONS: Risk stratification and prognostic models enable outcome comparisons and standardisation of treatment and follow-up. At present, none of the available risk stratification and prognostic models reflects current standards of treatment. The EORTC risk tables and CUETO scoring model should be updated with previously unavailable data and recalculated. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is a heterogeneous disease. A risk-based therapeutic approach is recommended. We present available risk stratification and prediction tools and the degree of their validation with the aim to increase their use in everyday clinical practice. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Electronic address: viktor.soukup@seznam.cz. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Department of Urology, Royal Free London NHS Foundation Trust, London, UK. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion de Alcorcon, Madrid, Spain. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology and Paediatric Urology, Julius-Maximilians-University Wurzburg, Wurzburg, Germany. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Hopital Tenon, Assistance Publique Hopitaux de Paris, Institut Universitaire de Cancerologie GRC5, Sorbonne University, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Urology, University of Turin, Turin, Italy. FAU - Lam, Thomas AU - Lam T AD - Academic Urology Unit, University of Aberdeen, Scotland, UK. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Hopital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Institut Universitaire de Cancerologie GRC5, Sorbonne University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Sylvester, Richard AU - Sylvester R AD - EAU Guidelines Office Board, European Association of Urology, Arnhem, The Netherlands. FAU - Yuan, Yuhong AU - Yuan Y AD - Department of Medicine, Health Science Centre, McMaster University, Hamilton, Ontario, Canada. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medizinische Universitat Graz, Graz, Austria. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Motol University Hospital and Second Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article PT - Review DEP - 20181122 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Europe MH - Humans MH - Models, Statistical MH - Neoplasm Invasiveness MH - Practice Guidelines as Topic MH - Prognosis MH - Risk Assessment/*methods MH - Societies, Medical MH - Urinary Bladder Neoplasms/*epidemiology/pathology MH - Urology OTO - NOTNLM OT - Bladder cancer OT - Prognosis OT - Progression OT - Recurrence OT - Risk OT - Risk stratification OT - Scoring model OT - Scoring system EDAT- 2018/11/25 06:00 MHDA- 2021/05/21 06:00 CRDT- 2018/11/25 06:00 PHST- 2018/10/01 00:00 [received] PHST- 2018/10/28 00:00 [revised] PHST- 2018/11/10 00:00 [accepted] PHST- 2018/11/25 06:00 [pubmed] PHST- 2021/05/21 06:00 [medline] PHST- 2018/11/25 06:00 [entrez] AID - S2405-4569(18)30337-7 [pii] AID - 10.1016/j.euf.2018.11.005 [doi] PST - ppublish SO - Eur Urol Focus. 2020 May 15;6(3):479-489. doi: 10.1016/j.euf.2018.11.005. Epub 2018 Nov 22. PMID- 30470611 OWN - NLM STAT- MEDLINE DCOM- 20190305 LR - 20200908 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 37 IP - 1 DP - 2019 Jan TI - Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. PG - 1-11 LID - S1078-1439(18)30349-1 [pii] LID - 10.1016/j.urolonc.2018.09.008 [doi] AB - INTRODUCTION AND OBJECTIVES: We previously reported that elevated precystectomy serum levels of epithelial tumor markers predict worse oncological outcome in patients with invasive bladder cancer (BC). Herein, we evaluated the effect of neoadjuvant chemotherapy (NAC) on elevated tumor marker levels and their association with oncological outcomes. METHODS: Under IRB approval, serum levels of Carbohydrate Antigen 125 (CA-125), Carbohydrate Antigen 19-9 (CA 19-9) and Carcinoembryonic Antigen (CEA) were prospectively measured in 480 patients with invasive BC from August 2011 through December 2016. In the subgroup undergoing NAC, markers were measured prior to the first and after the last cycle of chemotherapy (prior to cystectomy). RESULTS: Three hundred and thirty-seven patients were eligible for the study, with a median age was 71 years (range 34-93) and 81% (272) male. Elevated precystectomy level of any tumor markers (31% of patients) was independently associated with worse recurrence-free survival (hazard ratio [HR] = 2.81; P < 0.001) and overall survival (HR = 3.97; P < 0.001). One hundred and twenty-five (37%) patients underwent NAC, of whom 59 had a complete tumor marker profile and 30 (51%) had an elevated pre-NAC tumor marker. Following completion of chemotherapy, 10/30 (33%) patients normalized their tumor markers, while 20/30 (67%) had one or more persistently elevated markers. There was no difference in clinical or pathological stage between groups (P = 0.54 and P = 0.09, respectively). Further analysis showed a significantly lower rate and longer median time to recurrence/progression in the responder group (50% in responders vs. 90% in nonresponders at a median time of 22 vs. 4.8 months, respectively; P = 0.015). There was also significant difference in mortality rates and median overall survival between the study groups (30% in responders vs. 70% in nonresponders at a median time of 27.3 vs. 11.6 months respectively; P = 0.037). Two of the three patients that died in the normalized tumor marker group had tumor marker relapse at recurrence prior to their death. CONCLUSIONS: To our knowledge, this is the first study showing tumor marker response to NAC. Patients with persistently elevated markers following NAC have a very poor prognosis following cystectomy, which may help identifying chemotherapy-resistant tumors. A larger, controlled study with longer follow up is needed to determine their role in predicting survival. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - Bazargani, Soroush T AU - Bazargani ST AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Clifford, Thomas G AU - Clifford TG AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Djaladat, Hooman AU - Djaladat H AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Schuckman, Anne K AU - Schuckman AK AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Wayne, Kevin AU - Wayne K AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Miranda, Gus AU - Miranda G AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Cai, Jie AU - Cai J AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. FAU - Sadeghi, Sarmad AU - Sadeghi S AD - Department of Clinical Medicine, Section of Genitourinary (Gu) Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. FAU - Dorff, Tanya AU - Dorff T AD - Department of Clinical Medicine, Section of Genitourinary (Gu) Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. FAU - Quinn, David I AU - Quinn DI AD - Department of Clinical Medicine, Section of Genitourinary (Gu) Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA. Electronic address: siadaneshmand@yahoo.com. LA - eng GR - P30 CA014089/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20181120 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - Prognosis MH - Prospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC7474471 MID - NIHMS1623357 OTO - NOTNLM OT - BC, bladder cancer OT - Bladder cancer OT - CA 125, carbohydrate antigen 125 OT - CA 19-9, carbohydrate antigen 19-9 OT - CAMs, cellular adhesion molecules OT - CEA, carcinoembryonic antigen OT - NAC, neoadjuvant chemotherapy OT - Neoadjuvant chemotherapy OT - Oncological outcomes OT - Prognosis OT - RC, radical cystectomy OT - TM, tumor markers OT - TURBT, transurethral resection of bladder tumor OT - Tumor markers OT - UBC, urothelial bladder cancer COIS- Conflict of interest: None EDAT- 2018/11/25 06:00 MHDA- 2019/03/06 06:00 PMCR- 2020/09/05 CRDT- 2018/11/25 06:00 PHST- 2017/04/11 00:00 [received] PHST- 2018/06/16 00:00 [revised] PHST- 2018/09/12 00:00 [accepted] PHST- 2018/11/25 06:00 [pubmed] PHST- 2019/03/06 06:00 [medline] PHST- 2018/11/25 06:00 [entrez] PHST- 2020/09/05 00:00 [pmc-release] AID - S1078-1439(18)30349-1 [pii] AID - 10.1016/j.urolonc.2018.09.008 [doi] PST - ppublish SO - Urol Oncol. 2019 Jan;37(1):1-11. doi: 10.1016/j.urolonc.2018.09.008. Epub 2018 Nov 20. PMID- 30467945 OWN - NLM STAT- MEDLINE DCOM- 20200629 LR - 20210109 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 23 IP - 2 DP - 2019 Feb TI - Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. PG - 1396-1405 LID - 10.1111/jcmm.14042 [doi] AB - Exosomes are small membrane vesicles released by many cells. These vesicles can mediate cellular communications by transmitting active molecules including long non-coding RNAs (lncRNAs). In this study, our aim was to identify a panel of lncRNAs in serum exosomes for the diagnosis and recurrence prediction of bladder cancer (BC). The expressions of 11 candidate lncRNAs in exosome were investigated in training set (n = 200) and an independent validation set (n = 320) via quantitative real-time PCR. A three-lncRNA panel (PCAT-1, UBC1 and SNHG16) was finally identified by multivariate logistic regression model to provide high diagnostic accuracy for BC with an area under the receiver-operating characteristic curve (AUC) of 0.857 and 0.826 in training set and validation set, respectively, which was significantly higher than that of urine cytology. The corresponding AUCs of this panel for patients with Ta, T1 and T2-T4 were 0.760, 0.827 and 0.878, respectively. In addition, Kaplan-Meier analysis showed that non-muscle-invasive BC (NMIBC) patients with high UBC1 expression had significantly lower recurrence-free survival (P = 0.01). Multivariate Cox analysis demonstrated that UBC1 was independently associated with tumour recurrence of NMIBC (P = 0.018). Our study suggested that lncRNAs in serum exosomes may serve as considerable diagnostic and prognostic biomarkers of BC. CI - (c) 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Zhang, Shujun AU - Zhang S AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. AD - Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China. FAU - Wang, Lishui AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Jiang, Xiumei AU - Jiang X AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Zhan, Yao AU - Zhan Y AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Li, Juan AU - Li J AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Yan, Keqiang AU - Yan K AD - Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Duan, Weili AU - Duan W AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Zhao, Yinghui AU - Zhao Y AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Yunshan AU - Wang Y AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Shi, Yuliang AU - Shi Y AD - School of Software, Shandong University, Jinan, Shandong, China. FAU - Wang, Chuanxin AU - Wang C AUID- ORCID: 0000-0002-3796-6293 AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. AD - Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181123 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) RN - 0 (SNHG16 lncRNA, human) RN - 0 (long non-coding RNA PCAT1, human) SB - IM MH - Biomarkers, Tumor/*genetics MH - Case-Control Studies MH - Exosomes/*genetics MH - Female MH - Follow-Up Studies MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/blood/*diagnosis/genetics/surgery MH - Prognosis MH - RNA, Long Noncoding/*genetics MH - ROC Curve MH - Urinary Bladder Neoplasms/blood/*diagnosis/genetics/surgery PMC - PMC6349164 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - diagnosis OT - long non-coding RNA OT - recurrence OT - serum exosomes EDAT- 2018/11/24 06:00 MHDA- 2020/07/01 06:00 PMCR- 2019/02/01 CRDT- 2018/11/24 06:00 PHST- 2018/09/30 00:00 [received] PHST- 2018/10/29 00:00 [accepted] PHST- 2018/11/24 06:00 [pubmed] PHST- 2020/07/01 06:00 [medline] PHST- 2018/11/24 06:00 [entrez] PHST- 2019/02/01 00:00 [pmc-release] AID - JCMM14042 [pii] AID - 10.1111/jcmm.14042 [doi] PST - ppublish SO - J Cell Mol Med. 2019 Feb;23(2):1396-1405. doi: 10.1111/jcmm.14042. Epub 2018 Nov 23. PMID- 30467596 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Diagnostic biomarkers in non-muscle invasive bladder cancer. PG - 2009-2016 LID - 10.1007/s00345-018-2567-1 [doi] AB - Successful treatment of non-muscle invasive bladder cancer (NMIBC) relies heavily on our ability to accurately detect disease typically in the presence of hematuria as well as to detect the early recurrent tumors in patients with a history of NMIBC. Unfortunately, the current biomarker landscape for NMIBC is a work in progress. Cystoscopy continues to be the gold standard, but can still miss 10% of tumors. Therefore, physicians frequently use additional tools to aid in the diagnosis of bladder cancer, such as urinary cytology. The urinary cytology is a good option for high-grade disease; however, it is limited by low sensitivity in detecting low-grade disease, as well as variable interpretation among cytopathologists. Thus, the limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. In this non-systematic review, we discuss the performance, potential advantages or disadvantages of these tests, and the future direction of biomarkers in NMIBC. FAU - Faiena, Izak AU - Faiena I AD - Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA. FAU - Rosser, Charles J AU - Rosser CJ AD - Clinical and Translational Research Program, University of Hawaii Cancer Center, 701 Ilalo Street Suite 353, Honolulu, HI, 96813, USA. AD - Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, HI, 96822, USA. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA. FAU - Furuya, Hideki AU - Furuya H AUID- ORCID: 0000-0002-9536-8662 AD - Clinical and Translational Research Program, University of Hawaii Cancer Center, 701 Ilalo Street Suite 353, Honolulu, HI, 96813, USA. hfuruya@hawaii.edu. AD - Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, HI, 96822, USA. hfuruya@hawaii.edu. LA - eng PT - Journal Article PT - Review DEP - 20181122 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM CIN - World J Urol. 2019 Sep;37(9):1985-1986. doi: 10.1007/s00345-018-2611-1. PMID: 30600353 MH - Biomarkers, Tumor/analysis MH - Humans MH - Neoplasm Invasiveness MH - Urinary Bladder Neoplasms/blood/*diagnosis/pathology/urine OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Diagnosis OT - Urine EDAT- 2018/11/24 06:00 MHDA- 2020/02/20 06:00 CRDT- 2018/11/24 06:00 PHST- 2018/07/18 00:00 [received] PHST- 2018/11/12 00:00 [accepted] PHST- 2018/11/24 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2018/11/24 06:00 [entrez] AID - 10.1007/s00345-018-2567-1 [pii] AID - 10.1007/s00345-018-2567-1 [doi] PST - ppublish SO - World J Urol. 2019 Oct;37(10):2009-2016. doi: 10.1007/s00345-018-2567-1. Epub 2018 Nov 22. PMID- 30463072 OWN - NLM STAT- MEDLINE DCOM- 20191210 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 102 IP - 3 DP - 2019 TI - Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review. PG - 249-261 LID - 10.1159/000494359 [doi] AB - Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: "BC," "bladder carcinoma," "bladder neoplasm," "human epidermal growth factor 2," "HER2," "HER-2," "c-erbB-2," "c-erbB2," "erbB-2," "erbB2," "neu," "marker," "biomarker," and "prognosis". Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs' efficacy in well-designed clinical trials. CI - (c) 2018 S. Karger AG, Basel. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University of Foggia, Foggia, Italy. FAU - Russo, Davide AU - Russo D AD - Department of Pathology, University of Foggia, Foggia, Italy. FAU - Mancini, Vito AU - Mancini V AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy, mancini.uro@gmail.com. FAU - Selvaggio, Oscar AU - Selvaggio O AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Calo, Beppe AU - Calo B AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20181121 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Biomarkers, Tumor/metabolism MH - Disease-Free Survival MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Neoplasm Recurrence, Local MH - Prognosis MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/*metabolism/*therapy OTO - NOTNLM OT - Bladder cancer OT - Human epidermal growth factor receptor 2 OT - Non-muscle invasive bladder cancer OT - Prognosis OT - Therapeutic target EDAT- 2018/11/22 06:00 MHDA- 2019/12/18 06:00 CRDT- 2018/11/22 06:00 PHST- 2018/07/02 00:00 [received] PHST- 2018/10/05 00:00 [accepted] PHST- 2018/11/22 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/11/22 06:00 [entrez] AID - 000494359 [pii] AID - 10.1159/000494359 [doi] PST - ppublish SO - Urol Int. 2019;102(3):249-261. doi: 10.1159/000494359. Epub 2018 Nov 21. PMID- 30453959 OWN - NLM STAT- MEDLINE DCOM- 20190529 LR - 20240922 IS - 1755-8794 (Electronic) IS - 1755-8794 (Linking) VI - 11 IP - Suppl 5 DP - 2018 Nov 20 TI - Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature. PG - 106 LID - 10.1186/s12920-018-0413-3 [doi] LID - 106 AB - BACKGROUND: Non-small cell lung cancer (NSCLC) represents more than about 80% of the lung cancer. The early stages of NSCLC can be treated with complete resection with a good prognosis. However, most cases are detected at late stage of the disease. The average survival rate of the patients with invasive lung cancer is only about 4%. Adenocarcinoma in situ (AIS) is an intermediate subtype of lung adenocarcinoma that exhibits early stage growth patterns but can develop into invasion. METHODS: In this study, we used RNA-seq data from normal, AIS, and invasive lung cancer tissues to identify a gene module that represents the distinguishing characteristics of AIS as AIS-specific genes. Two differential expression analysis algorithms were employed to identify the AIS-specific genes. Then, the subset of the best performed AIS-specific genes for the early lung cancer prediction were selected by random forest. Finally, the performances of the early lung cancer prediction were assessed using random forest, support vector machine (SVM) and artificial neural networks (ANNs) on four independent early lung cancer datasets including one tumor-educated blood platelets (TEPs) dataset. RESULTS: Based on the differential expression analysis, 107 AIS-specific genes that consisted of 93 protein-coding genes and 14 long non-coding RNAs (lncRNAs) were identified. The significant functions associated with these genes include angiogenesis and ECM-receptor interaction, which are highly related to cancer development and contribute to the smoking-free lung cancers. Moreover, 12 of the AIS-specific lncRNAs are involved in lung cancer progression by potentially regulating the ECM-receptor interaction pathway. The feature selection by random forest identified 20 of the AIS-specific genes as early stage lung cancer signatures using the dataset obtained from The Cancer Genome Atlas (TCGA) lung adenocarcinoma samples. Of the 20 signatures, two were lncRNAs, BLACAT1 and CTD-2527I21.15 which have been reported to be associated with bladder cancer, colorectal cancer and breast cancer. In blind classification for three independent tissue sample datasets, these signature genes consistently yielded about 98% accuracy for distinguishing early stage lung cancer from normal cases. However, the prediction accuracy for the blood platelets samples was only 64.35% (sensitivity 78.1%, specificity 50.59%, and AUROC 0.747). CONCLUSIONS: The comparison of AIS with normal and invasive tumor revealed diseases-specific genes and offered new insights into the mechanism underlying AIS progression into an invasive tumor. These genes can also serve as the signatures for early diagnosis of lung cancer with high accuracy. The expression profile of gene signatures identified from tissue cancer samples yielded remarkable early cancer prediction for tissues samples, however, relatively lower accuracy for boold platelets samples. FAU - Li, Dan AU - Li D AD - Key Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, College of Computer Science & Technology, Jilin University, Changchun, 130012, China. AD - MidSouth Bioinformatics Center and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and Univ. of Arkansas Medical Sciences, 2801 S. Univ. Ave, Little Rock, AR, 72204, USA. FAU - Yang, William AU - Yang W AD - Department of Computer Science, Carnegie Mellon University School of Computer Science, 5000 Forbes Ave, Pittsburgh, PA, 15213, USA. FAU - Zhang, Yifan AU - Zhang Y AD - MidSouth Bioinformatics Center and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and Univ. of Arkansas Medical Sciences, 2801 S. Univ. Ave, Little Rock, AR, 72204, USA. FAU - Yang, Jack Y AU - Yang JY AD - MidSouth Bioinformatics Center and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and Univ. of Arkansas Medical Sciences, 2801 S. Univ. Ave, Little Rock, AR, 72204, USA. FAU - Guan, Renchu AU - Guan R AD - Key Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, College of Computer Science & Technology, Jilin University, Changchun, 130012, China. AD - MidSouth Bioinformatics Center and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and Univ. of Arkansas Medical Sciences, 2801 S. Univ. Ave, Little Rock, AR, 72204, USA. FAU - Xu, Dong AU - Xu D AD - Key Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, College of Computer Science & Technology, Jilin University, Changchun, 130012, China. AD - Department of Electrical Engineering and Computer Science, Informatics Institute, and Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO, 65211, USA. FAU - Yang, Mary Qu AU - Yang MQ AD - MidSouth Bioinformatics Center and Joint Bioinformatics Ph.D. Program of University of Arkansas at Little Rock and Univ. of Arkansas Medical Sciences, 2801 S. Univ. Ave, Little Rock, AR, 72204, USA. mqyang@ualr.edu. LA - eng GR - HHSF223201510172C/FD/FDA HHS/United States GR - P20 GM103429/GM/NIGMS NIH HHS/United States GR - R15 GM114739/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20181120 PL - England TA - BMC Med Genomics JT - BMC medical genomics JID - 101319628 RN - 0 (RNA, Long Noncoding) SB - IM MH - Adenocarcinoma in Situ/genetics/*pathology MH - Area Under Curve MH - Databases, Genetic MH - Disease Progression MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Lung Neoplasms/genetics/*pathology MH - Machine Learning MH - Neoplasm Staging MH - Open Reading Frames/genetics MH - RNA, Long Noncoding/genetics MH - ROC Curve MH - Transcriptome PMC - PMC6245590 OTO - NOTNLM OT - *AIS OT - *Adenocarcinoma in situ OT - *Early diagnosis OT - *Invasive OT - *Lung cancer OT - *lncRNAs COIS- COMPETING INTEREST: The authors declare that they have no competing interests. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: Not applicable. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/11/21 06:00 MHDA- 2019/05/30 06:00 PMCR- 2018/11/20 CRDT- 2018/11/21 06:00 PHST- 2018/11/21 06:00 [entrez] PHST- 2018/11/21 06:00 [pubmed] PHST- 2019/05/30 06:00 [medline] PHST- 2018/11/20 00:00 [pmc-release] AID - 10.1186/s12920-018-0413-3 [pii] AID - 413 [pii] AID - 10.1186/s12920-018-0413-3 [doi] PST - epublish SO - BMC Med Genomics. 2018 Nov 20;11(Suppl 5):106. doi: 10.1186/s12920-018-0413-3. PMID- 30446799 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20210109 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 10 DP - 2019 Oct TI - Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. PG - 2059-2065 LID - 10.1007/s00345-018-2550-x [doi] AB - INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) is a biologically heterogeneous disease and is one of the most expensive malignancies to treat on a per patient basis. In part, this high cost is attributed to the need for long-term surveillance. We sought to perform an economic analysis of surveillance strategies to elucidate cumulative costs for the management of NMIBC. METHODS: A Markov model was constructed to determine the average 5-year costs for the surveillance of patients with NMIBC. Patients were stratified into low, intermediate, and high-risk groups based on the EORTC risk calculator to determine recurrence and progression rates according to each category. The index patient was a compliant 65-year-old male. A total of four health states were utilized in the Markov model: no evidence of disease, recurrence, progression and cystectomy, and death. RESULTS: Cumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC. The primary driver of cost was progression to muscle-invasive disease requiring definitive therapy, contributing to 81% and 92% of overall cost for intermediate- and high-risk disease. Although low-risk tumors have a high likelihood of 5-year recurrence, the overall cost contribution of recurrence was 8%, whereas disease progression accounted for 71%. CONCLUSION: Although protracted surveillance cystoscopy contributes to the expenditures associated with NMIBC, progression increases the overall cost of care across all three patient risk groups and most notably for intermediate- and high-risk disease patients. FAU - Mossanen, Matthew AU - Mossanen M AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. mmossanen@bwh.harvard.edu. AD - Dana-Farber Cancer Institute, Boston, MA, USA. mmossanen@bwh.harvard.edu. FAU - Wang, Ye AU - Wang Y AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA. FAU - Szymaniak, Julie AU - Szymaniak J AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. FAU - Tan, Wei Shen AU - Tan WS AD - University College of London, London, England, UK. FAU - Huynh, Melissa J AU - Huynh MJ AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Preston, Mark A AU - Preston MA AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Sonpavde, Guru AU - Sonpavde G AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Kibel, Adam S AU - Kibel AS AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Chang, Steven L AU - Chang SL AD - Division of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. AD - Dana-Farber Cancer Institute, Boston, MA, USA. AD - Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20181116 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - *Health Care Costs MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Risk Assessment MH - Urinary Bladder Neoplasms/classification/*economics/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Costs OT - Markov model OT - Non-muscle invasive OT - Surveillance EDAT- 2018/11/18 06:00 MHDA- 2020/02/20 06:00 CRDT- 2018/11/18 06:00 PHST- 2018/09/03 00:00 [received] PHST- 2018/10/29 00:00 [accepted] PHST- 2018/11/18 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2018/11/18 06:00 [entrez] AID - 10.1007/s00345-018-2550-x [pii] AID - 10.1007/s00345-018-2550-x [doi] PST - ppublish SO - World J Urol. 2019 Oct;37(10):2059-2065. doi: 10.1007/s00345-018-2550-x. Epub 2018 Nov 16. PMID- 30446453 OWN - NLM STAT- MEDLINE DCOM- 20190903 LR - 20190903 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 2 DP - 2019 Feb TI - Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). PG - 158-165 LID - S1078-1439(18)30386-7 [pii] LID - 10.1016/j.urolonc.2018.10.005 [doi] AB - OBJECTIVES: To investigate the expression of several immunohistochemical (IHC) markers and their predictive ability for the recurrence-free and progression-free survival of papillary urothelial bladder cancer (UBC) pTa/pT1 G2 (WHO 1973) compared to classical anatomo-clinical variables using a multidimensional analysis. MATERIALS AND METHODS: A population-based cohort of 213 primary stage UBC (pTa/pT1) G2 (WHO 1973) was evaluated by classic anatomopathological variables and characterized by immunohistochemistry (23 IHC markers, representative of different oncogenic pathways). The most important variables as a predictor of recurrence-free and progression-free survival were selected using multidimensional statistical models, such as random survival forests and least absolute shrinkage and selection operator (. Recurrence and progression-free survival of the previously selected variables were also calculated. RESULTS: Mean follow-up was 58 +/- 33.5 months. Recurrence and progression rates were 54.5% (n = 116) and 17,4% (n = 37), respectively. The most influential variables in the low recurrence-free survival were in order: number of resected tumors, high expression of Ki67 (>10%), Cyclin D1 (>10%), and low cytoplasmic staining of p16INK4a. Regarding low progression-free survival, the most important variables were Ki67 (>15%), multicentric tumor arrangement and Survivin nuclear expression (>20%). Kaplan-Meier and cox-regression model analyses showed that the variables selected by multidimensional models were able to discriminate the clinical outcome. CONCLUSIONS: Ki67 index is the most useful IHC marker, since it can improve the prediction of both recurrence and progression-free survival in papillary UBC pTa/pT1 G2 (WHO 1973). There are other markers, whose utility is specific to recurrence-free survival, such as Cyclin D1 and p16INK4a or in progression-free survival, such as Survivin. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - March-Villalba, Jose Antonio AU - March-Villalba JA AD - Department of Urology, University Clinic Hospital of Valencia, Universitat de Valencia, Valencia, Spain. Electronic address: joseantoniomarch@gmail.com. FAU - Ramos-Soler, David AU - Ramos-Soler D AD - Department of Pathology, Universitat de Valencia, Valencia, Spain. FAU - Soriano-Sarrio, Pilar AU - Soriano-Sarrio P AD - Department of Pathology, Universitat de Valencia, Valencia, Spain. FAU - Hervas-Marin, David AU - Hervas-Marin D AD - Biostatistic Department, IIS La Fe, Valencia, Spain. FAU - Martinez-Garcia, Laura AU - Martinez-Garcia L AD - Department of Pathology, Universitat de Valencia, Valencia, Spain. FAU - Martinez-Jabaloyas, Jose Maria AU - Martinez-Jabaloyas JM AD - Department of Urology, University Clinic Hospital of Valencia. Surgery Department, Universitat de Valencia, Valencia, Spain. LA - eng PT - Journal Article DEP - 20181113 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BIRC5 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (CCND1 protein, human) RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Ki-67 Antigen) RN - 0 (Survivin) RN - 136601-57-5 (Cyclin D1) SB - IM MH - Aged MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Papillary/metabolism/*pathology/surgery MH - Cohort Studies MH - Cyclin D1/*metabolism MH - Cyclin-Dependent Kinase Inhibitor p16/*metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Ki-67 Antigen/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/metabolism/*pathology/surgery MH - Neoplasm Staging MH - Predictive Value of Tests MH - Survival Rate MH - Survivin/*metabolism MH - Urinary Bladder Neoplasms/metabolism/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Clinical outcome OT - Immunohistochemistry OT - Multidimensional analysis OT - Stage Ta/T1 EDAT- 2018/11/18 06:00 MHDA- 2019/09/04 06:00 CRDT- 2018/11/18 06:00 PHST- 2018/03/22 00:00 [received] PHST- 2018/08/11 00:00 [revised] PHST- 2018/10/01 00:00 [accepted] PHST- 2018/11/18 06:00 [pubmed] PHST- 2019/09/04 06:00 [medline] PHST- 2018/11/18 06:00 [entrez] AID - S1078-1439(18)30386-7 [pii] AID - 10.1016/j.urolonc.2018.10.005 [doi] PST - ppublish SO - Urol Oncol. 2019 Feb;37(2):158-165. doi: 10.1016/j.urolonc.2018.10.005. Epub 2018 Nov 13. PMID- 30446444 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220622 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 40 IP - 7 DP - 2022 Jul TI - Mutational landscape of non-muscle-invasive bladder cancer. PG - 295-303 LID - S1078-1439(18)30398-3 [pii] LID - 10.1016/j.urolonc.2018.10.015 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) includes stage Ta and stage T1 tumors and carcinoma in situ (CIS). Grading of Ta tumors subdivides these lesions into papillary urothelial neoplasms of low malignant potential and low- and high-grade noninvasive papillary urothelial carcinoma. CIS is by definition high-grade and the majority of stage T1 tumors are of high-grade. This pathologic heterogeneity is associated with divergent clinical outcome, with significantly worse prognosis for patients with T1 tumors or CIS. A wealth of molecular information has accumulated on NMIBC including mutational data that ranges from the whole chromosome level to next generation sequence data at nucleotide level. This has not only identified key genes that are mutated in NMIBC, but also provides insight into the processes that shape their mutational landscape. Although molecular analyses cannot yet provide definitive personal prognostic information, many differences between these entities promise improved disease management in the future. Most information is available for Ta and T1 samples and this is the focus of this review. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Hurst, Carolyn D AU - Hurst CD AD - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom. FAU - Knowles, Margaret A AU - Knowles MA AD - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom. Electronic address: m.a.knowles@leeds.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20181113 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - *Carcinoma in Situ/pathology MH - *Carcinoma, Transitional Cell/pathology MH - Humans MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Prognosis MH - *Urinary Bladder Neoplasms/pathology OTO - NOTNLM OT - Bladder OT - Genomics OT - Mutation OT - Non-muscle-invasive OT - Stage T1 OT - Stage Ta EDAT- 2018/11/18 06:00 MHDA- 2022/06/15 06:00 CRDT- 2018/11/18 06:00 PHST- 2017/11/23 00:00 [received] PHST- 2018/09/11 00:00 [revised] PHST- 2018/10/10 00:00 [accepted] PHST- 2018/11/18 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2018/11/18 06:00 [entrez] AID - S1078-1439(18)30398-3 [pii] AID - 10.1016/j.urolonc.2018.10.015 [doi] PST - ppublish SO - Urol Oncol. 2022 Jul;40(7):295-303. doi: 10.1016/j.urolonc.2018.10.015. Epub 2018 Nov 13. PMID- 30446443 OWN - NLM STAT- MEDLINE DCOM- 20200214 LR - 20200214 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 37 IP - 3 DP - 2019 Mar TI - Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. PG - 184.e1-184.e7 LID - S1078-1439(18)30397-1 [pii] LID - 10.1016/j.urolonc.2018.10.014 [doi] AB - OBJECTIVES: Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease characterized by a high primary tumor recurrence rate. Current prognostic systems used for predicting recurrence in individual patients have limitations and do not consider the biological background of this tumor type. Our study aimed to find microRNAs (miRNAs) associated with NMIBC recurrence. METHODS: Seventy-eight NMIBC patients were prospectively enrolled and divided into exploratory and validation cohorts. Out of these patients, 32 developed recurrence within 18 months after surgery, while 46 did not show any sign of recurrence after 30 months. Expression profiles of 2,578 miRNAs were obtained using Affymetrix miRNA microarrays and candidate miRNAs validated using the individual quantitative reverse-transcription polymerase chain reaction (qRT-PCR). RESULTS: The expression profiling revealed a set of 137 miRNAs differentially expressed between NMIBC patients with and without recurrence (P < 0.05). In the validation phase, miR-34a-3p had a significantly higher expression in tumors of NMIBC patients without recurrence (P = 0.0155). Decreased expression of miR-34a-3p was associated with significantly shorter recurrence-free survival (P = 0.009). Cox regression analysis confirmed that miR-34a-3p is an independent biomarker associated with a lower risk of recurrence (hazard ratio (HR) = 0.3184, 95% confidence interval = 0.003-0.681, P = 0.0258). Combination of miR-34a-3p and European Organization for Research and Treatment of Cancer risk score into one predictive model enabled to predict individual risk of recurrence with high statistical significance and analytical performance (P < 0.0001; area under curve = 0.8368; sensitivity 83%, and specificity 75%). CONCLUSIONS: Our data suggest that miR-34a-3p is an independent biomarker of NMIBC recurrence and a promising candidate for further independent validations as an additional factor to improve predictive value of European Organization for Research and Treatment of Cancer nomogram. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Juracek, Jaroslav AU - Juracek J AD - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Stanik, Michal AU - Stanik M AD - Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: stanik@mou.cz. FAU - Vesela, Petra AU - Vesela P AD - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Radova, Lenka AU - Radova L AD - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Dolezel, Jan AU - Dolezel J AD - Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. FAU - Svoboda, Marek AU - Svoboda M AD - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. FAU - Slaby, Ondrej AU - Slaby O AD - Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: on.slaby@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20181113 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN34 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Cystectomy/methods MH - Cystoscopy/methods MH - Disease-Free Survival MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - MicroRNAs/*metabolism MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/genetics/prevention & control MH - *Nomograms MH - Oligonucleotide Array Sequence Analysis MH - Predictive Value of Tests MH - Prognosis MH - Prospective Studies MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*genetics/mortality/surgery OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Recurrence OT - miR-34-3p OT - microRNA EDAT- 2018/11/18 06:00 MHDA- 2020/02/15 06:00 CRDT- 2018/11/18 06:00 PHST- 2018/06/25 00:00 [received] PHST- 2018/10/08 00:00 [revised] PHST- 2018/10/10 00:00 [accepted] PHST- 2018/11/18 06:00 [pubmed] PHST- 2020/02/15 06:00 [medline] PHST- 2018/11/18 06:00 [entrez] AID - S1078-1439(18)30397-1 [pii] AID - 10.1016/j.urolonc.2018.10.014 [doi] PST - ppublish SO - Urol Oncol. 2019 Mar;37(3):184.e1-184.e7. doi: 10.1016/j.urolonc.2018.10.014. Epub 2018 Nov 13. PMID- 30426560 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 1097-4644 (Electronic) IS - 0730-2312 (Linking) VI - 120 IP - 5 DP - 2019 May TI - A novel messenger RNA and long noncoding RNA signature associated with the progression of nonmuscle invasive bladder cancer. PG - 8101-8109 LID - 10.1002/jcb.28089 [doi] AB - AIM: To explore the molecular mechanism of nonmuscle invasive bladder cancer (NMIBC), matched normal, and cancer tissues of 10 NMIBC were examined for RNA sequencing. METHODS: We profiled the messenger RNA (mRNA) and long noncoding RNA (lncRNA) expression of patients with NMIBC. Differentially expressed mRNAs and lncRNAs were screened between cancer and normal tissues and validated by quantitative polymerase chain reaction (qPCR), and lncRNA-mRNA-miRNA interaction network was constructed. RESULTS: A total of 91 upregulated and 190 downregulated genes and 34 upregulated and 58 downregulated lncRNAs were screened from the sequencing result. The differentially expressed mRNAs were enriched in focal adhesion, rap1 signaling pathway, Hippo signaling pathway, PI3K-Akt signaling pathway, extracellular matrix (ECM)-receptor interaction, Ras signaling pathway, and mitogen-activated protein kinases signaling pathway, of which some pathways were involved in the cancer development. In the RNA sequencing, KIT and laminin subunitgamma gamma3 (LAMC3) were significantly downregulated in the NMIBC group compared with the normal group. The results of quantitative reverse transcription PCR showed that the expression of LAMC3 and KIT were significantly decreased in the NMIBC group compared with the normal group. The lncRNA-mRNA-miRNA interaction network was constructed by Cytoscape software to further investigate the interaction correlations. The results implied that KIT and LAMC3 might regulate the lncRNAs (such as ENST00000445707, ENST00000501122, ENST00000505254, ENST00000528986, ENST00000557661, ENST00000602964, ENST00000614517, ENST00000620864, and ENST00000623414) by the miRNAs (such as hsa-let-7f-2-3p, hsa-miR-125a-3p, hsa-miR-134-3p, hsa-miR-191-5p, hsa-miR-210-5p, hsa-miR-30a-5p, hsa-miR-30d-5p, hsa-miR-30e-5p, hsa-miR-92a-2-5p, and hsa-miR-95-3p), and finally played a role in the development of NMIBC cancer. CONCLUSION: Altogether, our study preliminarily indicated that KIT and LAMC3 might play a crucial role in the development of NMIBC cancer via a complex mRNA-lncRNA-miRNA regulatory network. CI - (c) 2018 Wiley Periodicals, Inc. FAU - He, Yu-Hui AU - He YH AD - China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Deng, Yi-Sen AU - Deng YS AD - China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Peng, Pan-Xin AU - Peng PX AD - China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Wang, Ning AU - Wang N AD - College of Psychology, North China University of Science and Technology, Tangshan, China. FAU - Wang, Jian-Feng AU - Wang JF AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Ding, Zhen-Shan AU - Ding ZS AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Chen, Xing AU - Chen X AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Zhou, Xiao-Feng AU - Zhou XF AUID- ORCID: 0000-0002-0513-9234 AD - China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. LA - eng GR - 2014DFE30010/International S&T Cooperation Program of China/ PT - Journal Article DEP - 20181113 PL - United States TA - J Cell Biochem JT - Journal of cellular biochemistry JID - 8205768 SB - IM OTO - NOTNLM OT - KIT OT - LAMC3 OT - RNA sequencing OT - long noncoding RNAs OT - nonmuscle invasive bladder cancer EDAT- 2018/11/15 06:00 MHDA- 2018/11/15 06:01 CRDT- 2018/11/15 06:00 PHST- 2018/10/10 00:00 [received] PHST- 2018/10/29 00:00 [accepted] PHST- 2018/11/15 06:00 [pubmed] PHST- 2018/11/15 06:01 [medline] PHST- 2018/11/15 06:00 [entrez] AID - 10.1002/jcb.28089 [doi] PST - ppublish SO - J Cell Biochem. 2019 May;120(5):8101-8109. doi: 10.1002/jcb.28089. Epub 2018 Nov 13. PMID- 30420974 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220331 IS - 2588-9311 (Electronic) IS - 2588-9311 (Linking) VI - 1 IP - 1 DP - 2018 May TI - Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. PG - 54-60 LID - 10.1016/j.euo.2018.02.007 [doi] AB - BACKGROUND: Accelerated (also termed dose-dense, DD) chemotherapy regimens such as accelerated methotrexate, vinblastine, doxorubicin, and cisplatin have shown better efficacy and tolerability in the metastatic setting, and shortened the time to surgery in the neoadjuvant setting compared to standard-schedule regimens. We hypothesized that a DD schedule of gemcitabine and cisplatin (GC) would shorten the time to surgery and yield similar pathologic complete response rates (pT0) in patients with muscle-invasive bladder cancer (MIBC) compared with historical controls with standard GC. OBJECTIVE: To determine the safety and efficacy of neoadjuvant DDGC in MIBC. DESIGN SETTING AND PARTICIPANTS: Patients with cT2-4a, N0-1, M0 MIBC were eligible and received three 14-d cycles of DDGC with pegfilgrastim support followed by radical cystectomy with lymph node dissection. The primary end point was the pT0 rate. Molecular subtypes were assigned and correlated with survival. RESULTS AND LIMITATIONS: Thirty-one patients were evaluable for toxicity and response, of whom 58% had baseline clinical stage >T2N0M0; the median age was 69 yr. Ten patients (32%, 95% confidence interval [CI] 16-49%) achieved ypT0N0 status at cystectomy. Another four patients (13%, 95% CI 1-25%) were downstaged to non-muscle-invasive (/=5years and 15 had overall survival of >/=5 years. Of them, 4 patients survived >/=10 years. Older age (p=0.015) and presence of necrosis(p=0.05) were the only clinico-pathological parameters predictive of tumour recurrence. CONCLUSIONS: A relatively higher number females and high number of ureteric tumours were noted compared to similar studies from Asia. FAU - Jayarajah, U AU - Jayarajah U AD - Department of Urology, National Hospital of Colombo, Sri Lanka. umeshe.jaya@gmail.com FAU - Fernando, M H AU - Fernando MH FAU - Herath, K B AU - Herath KB FAU - Kuruppu, S N AU - Kuruppu SN FAU - Wickramanayaka, U L AU - Wickramanayaka UL FAU - Fernando, I U AU - Fernando IU FAU - de Silva, V C AU - de Silva VC FAU - Goonewardena, S A S AU - Goonewardena SAS LA - eng PT - Journal Article PL - Sri Lanka TA - Ceylon Med J JT - The Ceylon medical journal JID - 1264702 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/*pathology/surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Sri Lanka MH - Survival Rate MH - Tertiary Health Care MH - Treatment Outcome MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/mortality/*pathology/surgery MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery MH - Urinary Tract/pathology/surgery EDAT- 2018/11/13 06:00 MHDA- 2019/04/06 06:00 CRDT- 2018/11/13 06:00 PHST- 2018/11/13 06:00 [entrez] PHST- 2018/11/13 06:00 [pubmed] PHST- 2019/04/06 06:00 [medline] AID - 10.4038/cmj.v63i3.8717 [doi] PST - ppublish SO - Ceylon Med J. 2018 Sep 30;63(3):129-132. doi: 10.4038/cmj.v63i3.8717. PMID- 30395172 OWN - NLM STAT- MEDLINE DCOM- 20191107 LR - 20191107 IS - 1460-2180 (Electronic) IS - 0143-3334 (Linking) VI - 40 IP - 1 DP - 2019 Mar 12 TI - Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. PG - 84-92 LID - 10.1093/carcin/bgy154 [doi] AB - CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types. We evaluated the potential of CD73 as a biomarker in predicting the outcome of bladder carcinoma. CD73 expression in tumor and stromal cells was analyzed using immunohistochemistry in 270 bladder cancer (BC) patients [166 non-muscle-invasive BC (NMIBC) and 104 muscle-invasive BC (MIBC) tumors]. The correlations of CD73 with clinical and pathological characteristics were evaluated with Pearson's and Fischer's tests. The Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the association between CD73 expression and outcome. CD73 expression showed substantial variation in basal and suprabasal layers of the cancerous epithelium, stromal fibroblasts, endothelial cells and lymphocytes in different tumor specimens. In log-rank analyses, CD73 expression in cancer cells associated with better survival both in NMIBC and MIBC, whereas CD73 positivity in stromal fibroblasts associated with impaired survival in NMIBC. In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome. We conclude that in contrast to many other cancer types, high CD73 expression in BC predicts favorable prognosis. CI - (c) The Author(s) 2018. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Koivisto, Maarit K AU - Koivisto MK AD - MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland. FAU - Tervahartiala, Minna AU - Tervahartiala M AD - MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland. FAU - Kenessey, Istvan AU - Kenessey I AD - MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland. FAU - Jalkanen, Sirpa AU - Jalkanen S AD - MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Salmi, Marko AU - Salmi M AD - MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Carcinogenesis JT - Carcinogenesis JID - 8008055 RN - 0 (GPI-Linked Proteins) RN - EC 3.1.3.5 (5'-Nucleotidase) RN - EC 3.1.3.5 (NT5E protein, human) SB - IM MH - 5'-Nucleotidase/*analysis MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - GPI-Linked Proteins/analysis MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/chemistry/*mortality EDAT- 2018/11/06 06:00 MHDA- 2019/11/08 06:00 CRDT- 2018/11/06 06:00 PHST- 2018/03/28 00:00 [received] PHST- 2018/10/04 00:00 [revised] PHST- 2018/11/01 00:00 [accepted] PHST- 2018/11/06 06:00 [pubmed] PHST- 2019/11/08 06:00 [medline] PHST- 2018/11/06 06:00 [entrez] AID - 5160033 [pii] AID - 10.1093/carcin/bgy154 [doi] PST - ppublish SO - Carcinogenesis. 2019 Mar 12;40(1):84-92. doi: 10.1093/carcin/bgy154. PMID- 30392939 OWN - NLM STAT- MEDLINE DCOM- 20190807 LR - 20190807 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 17 IP - 1 DP - 2019 Feb TI - Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. PG - e12-e18 LID - S1558-7673(18)30479-8 [pii] LID - 10.1016/j.clgc.2018.10.003 [doi] AB - BACKGROUND: Bladder cancer is commonly diagnosed in patients ineligible for radical cystectomy or chemoradiotherapy (chemo-RT) with cisplatin or fluorouracil with mitomycin. We assessed tolerability, efficacy, and toxicity of hypofractionated radiotherapy with capecitabine in this challenging population. PATIENTS AND METHODS: Patients with high-grade urothelial bladder cancer ineligible for radical cystectomy or high-intensity chemo-RT underwent maximal transurethral resection of bladder tumor followed by capecitabine (median, 825 mg/m(2) per day 2 times a day) and radiation (median, 55 Gy in 2.2 Gy per fraction). Patients underwent surveillance cystoscopy and imaging, and were evaluated for toxicity, freedom from local failure and freedom from distant metastasis, progression-free survival, and overall survival. RESULTS: Eleven patients (median age, 80 years) with localized disease (n = 7), locally advanced disease (n = 3), or local-only recurrence after cystectomy (n = 1) were treated. Four patients (35%) had an Eastern Cooperative Oncology Group performance status of 2; median Charlson comorbidity index was 5. There was 1 acute grade 3 genitourinary event (9%), 6 acute grade 3 hematologic events (55%) of lymphopenia, and no acute grade 4 or higher events or hospitalizations. Ten patients (91%) completed radiotherapy, while 4 patients (36%) temporarily discontinued capecitabine. The complete response rate in the bladder was 64%. Two patients (18%) experienced late grade 1/2 genitourinary toxicities, and 1 (9%) experienced a transient late grade 4 genitourinary toxicity. With a median follow-up of 16.6 months, overall survival, progression-free survival, freedom from local failure, and freedom from distant metastasis at 1 year were 82%, 55%, 100%, and 55%, respectively, and at 2 years were 61%, 41%, 80%, and 55%, respectively. CONCLUSION: Hypofractionated chemo-RT was well tolerated and was associated with a high rate of local control in this comorbid population, thus providing a treatment option for select bladder cancer patients. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Leng, Jim AU - Leng J AD - University of Chicago Pritzker School of Medicine, Chicago, IL. FAU - Akthar, Adil S AU - Akthar AS AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. FAU - Szmulewitz, Russell Z AU - Szmulewitz RZ AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - O'Donnell, Peter H AU - O'Donnell PH AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - Sweis, Randy F AU - Sweis RF AD - Department of Medicine, University of Chicago, Chicago, IL. FAU - Pitroda, Sean P AU - Pitroda SP AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. FAU - Smith, Norm AU - Smith N AD - Department of Surgery, University of Chicago, Chicago, IL. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Surgery, University of Chicago, Chicago, IL. FAU - Liauw, Stanley L AU - Liauw SL AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL. Electronic address: sliauw@radonc.uchicago.edu. LA - eng PT - Journal Article DEP - 20181012 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antimetabolites, Antineoplastic) RN - 6804DJ8Z9U (Capecitabine) MH - Aged MH - Aged, 80 and over MH - Antimetabolites, Antineoplastic/*therapeutic use MH - Capecitabine/*therapeutic use MH - Chemoradiotherapy/*mortality MH - Female MH - Follow-Up Studies MH - Hospitalization/*statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Patient Safety MH - Prognosis MH - *Radiation Dose Hypofractionation MH - Remission Induction MH - Retrospective Studies MH - Survival Rate MH - Urologic Neoplasms/pathology/*therapy OTO - NOTNLM OT - *Bladder cancer OT - *Bladder preservation OT - *Chemoradiation OT - *Muscle invasive EDAT- 2018/11/06 06:00 MHDA- 2019/08/08 06:00 CRDT- 2018/11/06 06:00 PHST- 2018/06/26 00:00 [received] PHST- 2018/09/26 00:00 [revised] PHST- 2018/10/04 00:00 [accepted] PHST- 2018/11/06 06:00 [pubmed] PHST- 2019/08/08 06:00 [medline] PHST- 2018/11/06 06:00 [entrez] AID - S1558-7673(18)30479-8 [pii] AID - 10.1016/j.clgc.2018.10.003 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2019 Feb;17(1):e12-e18. doi: 10.1016/j.clgc.2018.10.003. Epub 2018 Oct 12. PMID- 30387836 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20221207 IS - 1791-2423 (Electronic) IS - 1019-6439 (Linking) VI - 54 IP - 1 DP - 2019 Jan TI - Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. PG - 167-176 LID - 10.3892/ijo.2018.4619 [doi] AB - Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6%, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN+). A total of 102 patients with advanced LN+ bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8% (59/102) of patients in total, and in 78.8% (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4% (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6% (vs. 33.6% in N2-3; P=0.0003), 61.5% (vs. 37.9% in T4; P=0.0485) and 75.1% (vs. 35.5% in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN+ disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Takahara, Kiyoshi AU - Takahara K AD - Department of Urology, Fujita Health University, School of Medicine, Toyoake, Aichi 470-1192, Japan. FAU - Ibuki, Naokazu AU - Ibuki N AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Nomi, Hayahito AU - Nomi H AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Uehara, Hirofumi AU - Uehara H AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Minami, Koichiro AU - Minami K AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Yamamoto, Kazuhiro AU - Yamamoto K AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. FAU - Narumi, Yoshifumi AU - Narumi Y AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan. LA - eng PT - Journal Article DEP - 20181102 PL - Greece TA - Int J Oncol JT - International journal of oncology JID - 9306042 RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/therapeutic use MH - Balloon Occlusion MH - Chemoradiotherapy MH - Cisplatin/*administration & dosage/therapeutic use MH - Deoxycytidine/administration & dosage/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Infusions, Intra-Arterial MH - Lymphatic Metastasis/*radiotherapy MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Pelvis/radiation effects MH - Remission Induction MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy MH - Gemcitabine OTO - NOTNLM OT - balloon-occluded arterial infusion OT - tetramodal therapy OT - Azuma regimen OT - bladder cancer OT - lymph node metastasis OT - pelvic irradiation EDAT- 2018/11/06 06:00 MHDA- 2019/03/15 06:00 CRDT- 2018/11/03 06:00 PHST- 2018/04/25 00:00 [received] PHST- 2018/08/10 00:00 [accepted] PHST- 2018/11/06 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2018/11/03 06:00 [entrez] AID - 10.3892/ijo.2018.4619 [doi] PST - ppublish SO - Int J Oncol. 2019 Jan;54(1):167-176. doi: 10.3892/ijo.2018.4619. Epub 2018 Nov 2. PMID- 30384365 OWN - NLM STAT- MEDLINE DCOM- 20190329 LR - 20190329 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 102 IP - 1 DP - 2019 TI - Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer. PG - 77-82 LID - 10.1159/000493577 [doi] AB - BACKGROUND: Cancer/testis antigens (CTA) are expressed in urothelial bladder cancer (UBC). Their therapeutical and prognostic relevance remains unclear. We studied the correlation of MAGEA3 and CTAG1B with histopathological factors in UBC and their prognostic value. METHODS: Retrospective analysis of 93 patients who underwent treatment for UBC was conducted. Besides clinical and histopathological parameters, the expression of MAGEA3 and CTAG1B was assessed by immunohistochemistry. RESULTS: Median follow-up was 75 months. Fifteen per cent of patients showed strong positive reaction to MAGEA3 staining. These tumours were statistically and significantly more often correlated with unfavourable World Health Organization (WHO) grading (G1: 0%, G2: 10.3%, G3: 23.4%, p = 0.048; low grade 0%, high grade 18.4%, p = 0.046 respectively). Correlation of CTAG1B with WHO grading was impressive with strong expression in no G1, 31.1% of G2 and 51.1% of G3 tumours (low grade 0%, high grade 43.4%, p = 0.001, respectively). Concomitant carcinoma in situ (Cis) was associated with strong CTAG1B expression (54.2% in concomitant Cis vs. 29% without concomitant Cis, p = 0.026). Kaplan-Meier analysis revealed statistically and significantly worse 5 years progression-free survival (PFS) associated with a strong expression of MAGEA3 (59 vs. 84%, p = 0.032). CONCLUSIONS: Strong CTA expression was correlated with unfavourable histopathological features. A strong expression of MAGEA3 was statistically and significantly associated with worse PFS across all stages of UBC. CI - (c) 2018 S. Karger AG, Basel. FAU - Lausenmeyer, Eva Maria AU - Lausenmeyer EM AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany, elausenmeyer@caritasstjosef.de. FAU - Braun, Klara AU - Braun K AD - Institute of Pathology, Leopoldina Hospital, Schweinfurt, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany. FAU - Voelker, Hans-Ullrich AU - Voelker HU AD - Institute of Pathology, Leopoldina Hospital, Schweinfurt, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Centre, Regensburg University, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20181101 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antigens, Neoplasm) RN - 0 (CTAG1B protein, human) RN - 0 (MAGEA3 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Neoplasm Proteins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, Neoplasm/*metabolism MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Male MH - Membrane Proteins/*metabolism MH - Middle Aged MH - Neoplasm Proteins/*metabolism MH - Prognosis MH - Regression Analysis MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*metabolism MH - Urothelium/*pathology OTO - NOTNLM OT - CTAG1B OT - Bladder OT - Cancer OT - Cancertestis antigens OT - MAGEA3 OT - NY-ESO1 OT - Prognostic factors EDAT- 2018/11/02 06:00 MHDA- 2019/03/30 06:00 CRDT- 2018/11/02 06:00 PHST- 2018/07/02 00:00 [received] PHST- 2018/09/07 00:00 [accepted] PHST- 2018/11/02 06:00 [pubmed] PHST- 2019/03/30 06:00 [medline] PHST- 2018/11/02 06:00 [entrez] AID - 000493577 [pii] AID - 10.1159/000493577 [doi] PST - ppublish SO - Urol Int. 2019;102(1):77-82. doi: 10.1159/000493577. Epub 2018 Nov 1. PMID- 30382527 OWN - NLM STAT- MEDLINE DCOM- 20210113 LR - 20211204 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 26 IP - 1 DP - 2020 Jan TI - Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder. PG - 411-418 LID - 10.1007/s12253-018-0524-3 [doi] AB - The substantial difference between normal cells and cancer cells in terms of their energy metabolism in mitochondria provides an interesting basis for the development of novel therapeutic agents targeting energy machinery of tumour cells. TOMM34 is one of the Tom (translocase of the outer membrane of mitochondria) family that was found to be overexpressed in colorectal, hepatocellular, lung and early invasive breast carcinomas. The expression profile of mitochondrial translocases in bladder cancer compared to normal urinary bladder tissues has not been investigated yet. Therefore, the aim of the current study is to investigate the expression pattern of TOMM34 in bladder cancer tissues and explore its correlation with the clinico-pathological parameters of those cases. Sixty patients who underwent either transurethral resection or radical cystectomy for bladder cancer were included in this study with revision of all their clinicopathological data and tumor slides. Ten histologically normal urothelial biopsies were also included. Immunohistochemical staining for TOMM34 was done and semi-quantitatively scored using the modified H-score. All relations were analysed using established statistical methodologies. TOMM34 overexpression was significantly associated with high tumour stage, muscle invasion and high grade. Significant positive association was observed between TOMM34 expression and poor outcome in terms of shorter disease-specific survival. This study suggests TOMM34 as a biomarker of progression and poor prognosis in urothelial cell carcinoma patients. Furthermore, we suggest a role played by mitochondrial machinery in urothelial cell carcinoma progression, which is a potential target for the newly-discovered vaccine therapy for urothelial cell carcinoma. FAU - Ahmed, Mohamed A H AU - Ahmed MAH AD - Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. AD - East Sussex Health Care Trust, Eastbourne District General Hospital, Eastbourne, UK. FAU - Ali, Mohamed Hassan AU - Ali MH AD - Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. FAU - Abbas, Hashem Hafez AU - Abbas HH AD - Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. FAU - Elatrash, Gamal Ali AU - Elatrash GA AD - Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. FAU - Foda, Abd AlRahman Mohammad AU - Foda AAM AUID- ORCID: 0000-0002-6858-9822 AD - Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt. abdofoda@mans.edu.eg. LA - eng PT - Journal Article DEP - 20181031 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Biomarkers, Tumor) RN - 0 (Mitochondrial Membrane Transport Proteins) RN - 0 (Mitochondrial Precursor Protein Import Complex Proteins) RN - 0 (TOMM34 protein, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitochondrial Membrane Transport Proteins/*biosynthesis MH - Mitochondrial Precursor Protein Import Complex Proteins MH - Prognosis MH - Urinary Bladder Neoplasms/mortality/*pathology OTO - NOTNLM OT - Markers OT - Mitochondrial OT - TOMM34 OT - Urothelial EDAT- 2018/11/02 06:00 MHDA- 2021/01/14 06:00 CRDT- 2018/11/02 06:00 PHST- 2018/09/18 00:00 [received] PHST- 2018/10/25 00:00 [accepted] PHST- 2018/11/02 06:00 [pubmed] PHST- 2021/01/14 06:00 [medline] PHST- 2018/11/02 06:00 [entrez] AID - 10.1007/s12253-018-0524-3 [pii] AID - 10.1007/s12253-018-0524-3 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Jan;26(1):411-418. doi: 10.1007/s12253-018-0524-3. Epub 2018 Oct 31. PMID- 30374124 OWN - NLM STAT- MEDLINE DCOM- 20190828 LR - 20200309 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 119 IP - 12 DP - 2018 Dec TI - Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. PG - 1477-1486 LID - 10.1038/s41416-018-0320-6 [doi] AB - BACKGROUND: Bladder cancer (BlCa) heterogeneity and the lack of personalised prognosis lead to patients' highly variable treatment outcomes. Here, we have analysed the utility of the GAS5 tumour-suppressor lncRNA in improving BlCa prognosis. METHODS: GAS5 was quantified in a screening cohort of 176 patients. Hedegaard et al. (2016) (n = 476) and TCGA provisional (n = 413) were used as validation cohorts. Survival analysis was performed using recurrence and progression for NMIBC, or death for MIBC. Internal validation was performed by bootstrap analysis, and decision curve analysis was used to evaluate the clinical benefit on disease prognosis. RESULTS: GAS5 levels were significantly downregulated in BlCa and associated with invasive high-grade tumours, and high EORTC-risk NMIBC patients. GAS5 loss was strongly and independently correlated with higher risk for NMIBC early relapse (HR = 2.680, p = 0.011) and progression (HR = 6.362, p = 0.035). Hedegaard et al. and TCGA validation cohorts' analysis clearly confirmed the association of GAS5 loss with NMIBC worse prognosis. Finally, multivariate models incorporating GAS5 with disease established markers resulted in higher clinical benefit for NMIBC prognosis. CONCLUSIONS: GAS5 loss is associated with adverse outcome of NMIBC and results in improved positive prediction of NMIBC patients at higher risk for short-term relapse and progression, supporting personalised prognosis and treatment decisions. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Athens, Greece. FAU - Tsilimantou, Anastasia AU - Tsilimantou A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Athens, Greece. FAU - Levis, Panagiotis K AU - Levis PK AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Athens, Greece. FAU - Tokas, Theodoros AU - Tokas T AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Athens, Greece. FAU - Sideris, Diamantis C AU - Sideris DC AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Athens, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodostrian University of Athens, Athens, Greece. FAU - Ardavanis, Alexandros AU - Ardavanis A AD - First Medical Oncology Clinic, "Saint Savvas" Anticancer Hospital, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodostrian University of Athens, Athens, Greece. ascorilas@biol.uoa.gr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181030 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (Biomarkers, Tumor) RN - 0 (GAS5 long non-coding RNA, human) RN - 0 (RNA, Long Noncoding) SB - IM MH - Aged MH - Biomarkers, Tumor/*analysis MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*genetics MH - Prognosis MH - RNA, Long Noncoding/*analysis MH - Urinary Bladder Neoplasms/*genetics/mortality PMC - PMC6288135 COIS- The authors declare no competing interests. EDAT- 2018/10/31 06:00 MHDA- 2019/08/29 06:00 PMCR- 2019/10/30 CRDT- 2018/10/31 06:00 PHST- 2018/08/28 00:00 [received] PHST- 2018/10/10 00:00 [accepted] PHST- 2018/10/10 00:00 [revised] PHST- 2018/10/31 06:00 [pubmed] PHST- 2019/08/29 06:00 [medline] PHST- 2018/10/31 06:00 [entrez] PHST- 2019/10/30 00:00 [pmc-release] AID - 10.1038/s41416-018-0320-6 [pii] AID - 320 [pii] AID - 10.1038/s41416-018-0320-6 [doi] PST - ppublish SO - Br J Cancer. 2018 Dec;119(12):1477-1486. doi: 10.1038/s41416-018-0320-6. Epub 2018 Oct 30. PMID- 30367268 OWN - NLM STAT- MEDLINE DCOM- 20181220 LR - 20181220 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 19 IP - 12 DP - 2018 Oct 26 TI - Management of High-grade T1 Urothelial Carcinoma. PG - 103 LID - 10.1007/s11934-018-0850-8 [doi] AB - PURPOSE OF REVIEW: The optimal management of high-grade T1 (HGT1) urothelial carcinoma (UC) is complex given its high rate of recurrence, progression, and cancer-specific mortality as well as its clinical variability. Our current treatment paradigm has been supplemented by recent data describing the expanding options for salvage intravesical therapy, bladder preservation, and the promising role of molecular epidemiology. In the current review, we attempt to summarize and critically analyze these studies. RECENT FINDINGS: Evidence describing new intravesical therapies has demonstrated an adequate safety profile and some efficacy in BCG-unresponsive patients who desire bladder preservation. However, response rates are still poor in this high-risk patient population, and it is important to keep these data in perspective when counseling patients. Concomitantly, the continued molecular characterization of non-muscle-invasive bladder cancer may suggest potential therapeutic targets as well as predictors of treatment response in the future. The integration of new intravesical therapies and molecular data into the current treatment paradigm for HGT1 urothelial carcinoma will be critical to improving oncologic outcomes in this particularly high-risk population. FAU - Reisz, Peter A AU - Reisz PA AD - Department of Urology, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN, 37232, USA. peter.a.reisz@vanderbilt.edu. FAU - Laviana, Aaron A AU - Laviana AA AD - Department of Urology, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN, 37232, USA. FAU - Chang, Sam S AU - Chang SS AD - Department of Urology, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN, 37232, USA. LA - eng PT - Journal Article PT - Review DEP - 20181026 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Antineoplastic Agents/therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Cystectomy MH - Humans MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Prognosis MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG OT - Genomics OT - Intravesical therapy OT - Non-muscle-invasive bladder cancer OT - Risk stratification OT - T1 urothelial carcinoma EDAT- 2018/10/28 06:00 MHDA- 2018/12/21 06:00 CRDT- 2018/10/28 06:00 PHST- 2018/10/28 06:00 [entrez] PHST- 2018/10/28 06:00 [pubmed] PHST- 2018/12/21 06:00 [medline] AID - 10.1007/s11934-018-0850-8 [pii] AID - 10.1007/s11934-018-0850-8 [doi] PST - epublish SO - Curr Urol Rep. 2018 Oct 26;19(12):103. doi: 10.1007/s11934-018-0850-8. PMID- 30366045 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20190606 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 125 DP - 2019 Mar TI - The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement. PG - 131-137 LID - S0090-4295(18)31115-4 [pii] LID - 10.1016/j.urology.2018.10.027 [doi] AB - OBJECTIVES: To characterize the perioperative morbidity of transurethral resection of bladder tumor (TURBT) in order to identify important determinants of both quality and cost in the delivery bladder cancer care. METHODS: We identified 24,100 patients aged 18-89 years who underwent TURBT from 2010 to 2015 in the National Surgical Quality Improvement Program database. Multivariable logistic regression was performed to evaluate the associations of patient features and tumor size (<2 cm, 2-5 cm, or >5 cm) with 30-day perioperative outcomes. RESULTS: Thirty-day postoperative complications occurred in 5.1% of patients, perioperative blood transfusion in 1.5% of patients, hospital readmission in 3.7% of patients, reoperation in 1.5% of patients, and mortality in 0.8% of patients. The most common reasons for readmission were bleeding (29%) and infectious (21%) complications. Although several patient features were associated with increased perioperative morbidity on multivariable analysis, including congestive heart failure, renal failure, higher American Society of Anesthesiology class, and dependent functional status, only larger tumor size was independently associated with increased risks of all perioperative endpoints. CONCLUSION: Perioperative morbidity following TURBT is substantial and represents an important target for quality improvement. Extent of resection, patient functional status, and specific comorbidities are independently associated with increased risks of perioperative morbidity and mortality. These results have implications for patient counseling, perioperative management, and quality improvement programs. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Pereira, Jorge Francisco AU - Pereira JF AD - Columbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, FL. FAU - Pareek, Gyan AU - Pareek G AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI; Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI. FAU - Mueller-Leonhard, Catrina AU - Mueller-Leonhard C AD - Lifespan Oncology Clinical Research, The Miriam Hospital, Providence, RI. FAU - Zhang, Zheng AU - Zhang Z AD - Department of Biostatistics, Brown University, Providence, RI. FAU - Amin, Ali AU - Amin A AD - Department of Pathology and Laboratory Medicine, The Miriam Hospital, Providence, RI. FAU - Mega, Anthony AU - Mega A AD - Department of Hematology/Oncology, The Miriam Hospital, Providence, RI. FAU - Tucci, Christopher AU - Tucci C AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI; Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI. FAU - Golijanin, Dragan AU - Golijanin D AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI; Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI. FAU - Gershman, Boris AU - Gershman B AD - Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI; Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI. Electronic address: Boris.Gershman@lifespan.org. LA - eng PT - Journal Article DEP - 20181023 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy/*adverse effects/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Morbidity MH - Postoperative Complications/*epidemiology/*etiology MH - *Quality Improvement MH - Urinary Bladder Neoplasms/*surgery MH - Young Adult OTO - NOTNLM OT - AKI OT - ASA OT - American Society of Anesthesiology OT - CHF OT - CI OT - COPD OT - CPT OT - HTN OT - IQR OT - LOS OT - NMIBC OT - NSQIP OT - National Surgical Quality Improvement Program OT - OR OT - RF OT - TURBT OT - UTI OT - acute kidney injury OT - chronic obstructive pulmonary disease OT - confidence interval OT - congestive heart failure OT - current procedural erminology OT - hypertension OT - interquartile range OT - length of stay OT - non-muscle-invasive bladder cancer OT - odds ratio OT - renal failure OT - transurethral resection of bladder tumor OT - urinary tract infection EDAT- 2018/10/27 06:00 MHDA- 2019/06/07 06:00 CRDT- 2018/10/27 06:00 PHST- 2018/09/06 00:00 [received] PHST- 2018/10/07 00:00 [revised] PHST- 2018/10/12 00:00 [accepted] PHST- 2018/10/27 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2018/10/27 06:00 [entrez] AID - S0090-4295(18)31115-4 [pii] AID - 10.1016/j.urology.2018.10.027 [doi] PST - ppublish SO - Urology. 2019 Mar;125:131-137. doi: 10.1016/j.urology.2018.10.027. Epub 2018 Oct 23. PMID- 30359714 OWN - NLM STAT- MEDLINE DCOM- 20190514 LR - 20210414 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 124 DP - 2019 Feb TI - Reduced Recurrence of Low-grade Papillary Bladder Tumors Associated With Asymptomatic Bacteriuria. PG - 179-182 LID - S0090-4295(18)31109-9 [pii] LID - 10.1016/j.urology.2018.10.023 [doi] AB - OBJECTIVE: To determine tumor recurrence rate of low-grade, papillary, and non-muscle-invasive (TaLG) bladder tumors in patients who have asymptomatic bacteriuria (ABU). Microbes in the urine trigger immune responses like intravesical Bacillus Calmette-Guerin, suggesting that common bacteria may also exert an antitumor effect. METHODS: We investigated recurrence rates in 387 patients with low-grade, papillary noninvasive bladder tumors TaLG, with or without ABU. They were followed every 6 months for 36 months, and did not receive antibiotics or intravesical chemotherapy. Recurrent tumors were treated generally by outpatient fulguration. Before cystoscopy, patients submitted a voided urine sample for culture, stratified as no growth, <10(4), >10(4), or >10(5) CFU/mL single organism. Any degree of bacteria on culture was classified as ABU. We also measured absolute neutrophil counts (ANC) and the presence of pyuria, as surrogate indicators of local immune response. RESULTS: Of the 387 cases, 200 (52%) had ABU, including 102 (27%) with >10(4) CFU/mL bacteriuria. With absolute 3-year follow-up, 75% of patients with ABU survived tumor-free compared to 40% of 187 uninfected patients (P = .001). Sixty percent of patients with negative cultures recurred vs 25%, 14%, and 29% of patients with <10(4), >10(4), or >10(5) CFU/mL. (P = .001). Mean number of recurrent tumors in colonized patients was 4.2 vs 8.4 in uninfected patients (P = .009). ANC averaged 6.3 K/mcL in bacteriuric vs 4.1 K/mcL in uninfected patients (P = .01). CONCLUSION: Patients with papillary TaLG tumors and chronic ABU had fewer recurrences, fewer numbers of recurrent tumors, and longer tumor-free survival times than similarly staged uninfected patients. Bladder-resident bacteria may reduce bladder tumor recurrences through local immune mechanisms. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Herr, Harry AU - Herr H AD - Urology Service, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: herrh@mskcc.org. FAU - Donat, Machele AU - Donat M AD - Urology Service, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY. LA - eng PT - Journal Article DEP - 20181023 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - J Urol. 2019 Nov;202(5):849. doi: 10.1097/JU.0000000000000485. PMID: 31385735 MH - Adult MH - Aged MH - Aged, 80 and over MH - *Asymptomatic Infections MH - Bacteriuria/*complications MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*complications/*epidemiology/immunology/pathology MH - Young Adult EDAT- 2018/10/26 06:00 MHDA- 2019/05/15 06:00 CRDT- 2018/10/26 06:00 PHST- 2018/08/17 00:00 [received] PHST- 2018/09/28 00:00 [revised] PHST- 2018/10/09 00:00 [accepted] PHST- 2018/10/26 06:00 [pubmed] PHST- 2019/05/15 06:00 [medline] PHST- 2018/10/26 06:00 [entrez] AID - S0090-4295(18)31109-9 [pii] AID - 10.1016/j.urology.2018.10.023 [doi] PST - ppublish SO - Urology. 2019 Feb;124:179-182. doi: 10.1016/j.urology.2018.10.023. Epub 2018 Oct 23. PMID- 30359638 OWN - NLM STAT- MEDLINE DCOM- 20191115 LR - 20191115 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 84 DP - 2019 Feb TI - Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system. PG - 275-282 LID - S0046-8177(18)30395-2 [pii] LID - 10.1016/j.humpath.2018.10.008 [doi] AB - Measures of mitotic activity predict behavior of noninvasive papillary urothelial carcinoma of the urinary bladder, but it is unclear what role these should have in tumor grading. In this article, we compare measures of mitotic activity to contemporary tumor grading, specifically in their association with recurrence of noninvasive papillary urothelial carcinoma. The study uses a retrospective cohort of 199 tumors from 124 patients. Mitotic activity was treated as a categorical variable (mitotic-inert, mitotic-low, or mitotic-high). Evaluating only first-occurrence tumors, recurrence was more frequent in mitotic-high (hazard ratio [HR], 8.8; P < .0001, Cox model) and mitotic-low tumors (HR, 3.7; P = .017) compared with mitotic-inert tumors, when controlling for treatment with intravesical bacillus Calmette-Guerin, age, and sex. Recurrence was likewise more frequent in high-grade tumors (HR, 3.1; P = .00019, Cox model) compared with low-grade tumors, controlling for these factors. However, mitotic group, but not tumor grade, was significantly associated with recurrence in a multivariate Cox model including mitotic group, tumor grade, and treatment status (HR, 6.5 [P = .0025] for mitotic-high versus reference; HR, 3.7 [P = .018] for mitotic-low versus reference). Frailty models including both first-occurrence and recurrent tumors showed similar results. Isolating the analysis to first occurrence, low-grade tumors, recurrence was more frequent in mitotic-high (HR, 6.8; P = .0044, Cox model) and mitotic-low (HR, 3.4; P = .027) tumors compared with mitotic-inert tumors. The findings indicate that mitotic activity is associated with behavior of noninvasive papillary urothelial carcinoma and may be valuable as an adjunct to the contemporary grading system. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Zaleski, Michael AU - Zaleski M AD - Department of Pathology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Gogoj, Augustyna AU - Gogoj A AD - Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. FAU - Walter, Vonn AU - Walter V AD - Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; Department of Biochemistry, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. FAU - Raman, Jay D AU - Raman JD AD - Department of Surgery, Division of Urology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Kaag, Matthew AU - Kaag M AD - Department of Surgery, Division of Urology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Merrill, Suzanne B AU - Merrill SB AD - Department of Surgery, Division of Urology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Drabick, Joseph AU - Drabick J AD - Division of Hematology-Oncology, Department of Medicine, Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Joshi, Monika AU - Joshi M AD - Division of Hematology-Oncology, Department of Medicine, Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Holder, Sheldon AU - Holder S AD - Division of Hematology-Oncology, Department of Medicine, Penn State Cancer Institute, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - DeGraff, David J AU - DeGraff DJ AD - Department of Pathology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA; Department of Surgery, Division of Urology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. FAU - Warrick, Joshua I AU - Warrick JI AD - Department of Pathology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA; Department of Surgery, Division of Urology, Milton S. Hershey Medical Center, Hershey, PA 17033, USA. Electronic address: jwarrick@pennstatehealth.psu.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20181022 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Papillary/*pathology MH - Carcinoma, Transitional Cell/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitosis MH - Neoplasm Grading/*methods MH - Neoplasm Recurrence, Local/*pathology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Bladder cancer OT - Cell cycle OT - Mitotic activity OT - Mitotic figures OT - Mitotic index OT - Noninvasive papillary urothelial cell carcinoma OT - Tumor grading EDAT- 2018/10/26 06:00 MHDA- 2019/11/16 06:00 CRDT- 2018/10/26 06:00 PHST- 2018/08/26 00:00 [received] PHST- 2018/10/01 00:00 [revised] PHST- 2018/10/11 00:00 [accepted] PHST- 2018/10/26 06:00 [pubmed] PHST- 2019/11/16 06:00 [medline] PHST- 2018/10/26 06:00 [entrez] AID - S0046-8177(18)30395-2 [pii] AID - 10.1016/j.humpath.2018.10.008 [doi] PST - ppublish SO - Hum Pathol. 2019 Feb;84:275-282. doi: 10.1016/j.humpath.2018.10.008. Epub 2018 Oct 22. PMID- 30357541 OWN - NLM STAT- MEDLINE DCOM- 20190128 LR - 20261012 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 19 IP - 12 DP - 2018 Oct 24 TI - Current Clinical Trials in Non-muscle Invasive Bladder Cancer. PG - 101 LID - 10.1007/s11934-018-0852-6 [doi] AB - PURPOSE OF REVIEW: As our molecular understanding of bladder cancer continues to advance, more and more novel agents are entering clinical trials across the spectrum of bladder cancer stages. The clinical trial activity for non-muscle invasive bladder cancer (NMIBC) has been boosted further by the evolution of specific disease states that set more uniform inclusion criteria for clinical trial design. Here, we aimed to review the current clinical trials landscape in non-muscle invasive bladder cancer with respect to these disease states. RECENT FINDINGS: Most active clinical trials focus on high-risk NMIBC in either the BCG-naive or BCG-unresponsive setting. Strict criteria to define the disease state and a clear pathway to drug registration have encouraged trials for patients with BCG-unresponsive NMIBC. The most promising potential breakthroughs for BCG-naive patients include alternative BCG strains, immune-priming with intradermal BCG vaccination, and systemic immune checkpoint blockade. The latter therapy is also being actively investigated in multiple trials in BCG-unresponsive NMIBC, along with novel viral agents such as INSTILADRIN (nadofaragene firadenovec) and targeted agents such as oportuzumab monatox. After many years of relative stagnation, multiple new therapies currently under investigation in well-designed clinical trials appear poised for routine clinical implementation in the near future. These therapies should dramatically improve the outcome of patients with NMIBC. We can look forward to the challenges of biomarker-driven drug selection, optimal drug sequencing, and rational combination therapies. FAU - Nykopp, Timo K AU - Nykopp TK AD - Department of Surgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V6N 2W6, Canada. FAU - Batista da Costa, Jose AU - Batista da Costa J AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V6N 2W6, Canada. FAU - Mannas, Miles AU - Mannas M AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V6N 2W6, Canada. FAU - Black, Peter C AU - Black PC AD - Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Level 6, 2775 Laurel St, Vancouver, BC, V6N 2W6, Canada. pblack@mail.ubc.ca. LA - eng PT - Journal Article PT - Review DEP - 20181024 PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 RN - 0 (ALT-803) RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents) RN - 0 (Antineoplastic Agents, Hormonal) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Aziridines) RN - 0 (BCG Vaccine) RN - 0 (Indolequinones) RN - 0 (Polysaccharides, Bacterial) RN - 0 (Proteins) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Ty21a typhoid vaccine) RN - 0 (Typhoid-Paratyphoid Vaccines) RN - 094ZI81Y45 (Tamoxifen) RN - 28X28X9OKV (durvalumab) RN - 50SG953SK6 (Mitomycin) RN - DPT0O3T46P (pembrolizumab) RN - H464ZO600O (apaziquone) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Antineoplastic Agents/therapeutic use MH - Antineoplastic Agents, Hormonal/therapeutic use MH - Antineoplastic Agents, Immunological/*therapeutic use MH - Aziridines/therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Chemotherapy, Adjuvant MH - Clinical Trials as Topic MH - Combined Modality Therapy MH - Humans MH - Indolequinones/therapeutic use MH - Injections, Intradermal MH - Mitomycin/therapeutic use MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Polysaccharides, Bacterial/therapeutic use MH - Proteins/therapeutic use MH - Recombinant Fusion Proteins MH - Tamoxifen/therapeutic use MH - Typhoid-Paratyphoid Vaccines/therapeutic use MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Urologic Surgical Procedures OTO - NOTNLM OT - BCG-naive OT - BCG-unresponsive OT - Clinical trial OT - Non-muscle invasive bladder cancer EDAT- 2018/10/26 06:00 MHDA- 2019/01/29 06:00 CRDT- 2018/10/26 06:00 PHST- 2018/10/26 06:00 [entrez] PHST- 2018/10/26 06:00 [pubmed] PHST- 2019/01/29 06:00 [medline] AID - 10.1007/s11934-018-0852-6 [pii] AID - 10.1007/s11934-018-0852-6 [doi] PST - epublish SO - Curr Urol Rep. 2018 Oct 24;19(12):101. doi: 10.1007/s11934-018-0852-6. PMID- 30355587 OWN - NLM STAT- MEDLINE DCOM- 20190125 LR - 20190125 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 72 IP - 2 DP - 2019 Feb TI - Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. PG - 140-144 LID - 10.1136/jclinpath-2018-205393 [doi] AB - AIMS: Cystoscopy and urine cytology represent the gold standard for monitoring superficial bladder cancer (BC). Xpert BC Monitor is a new urinary marker based on the evaluation of five target mRNAs overexpressed in patients with bladder cancer. The aim of our study was to evaluate the diagnostic accuracy of Xpert BC Monitor in follow-up of patients with non-muscle invasive bladder cancer (NMIBC). METHODS: 230 patients were included in this prospective study. Xpert BC Monitor cut-off was set to 0.5. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of cytology, Xpert BC Monitor and their combination were calculated and compared with cystoscopy/histology. RESULTS: 52/230 patients showed a NMIBC recurrence, 45 low grade (LG) and 7 high grade (HG). Overall sensitivity was 11.5% for cytology, 46.2% for Xpert BC Monitor and 48.1% for the two tests combined. Sensitivity of cytology increased from 4.4% in LG to 57.1% in HG tumours whereas for the Xpert BC Monitor it was 40% in LG and 85.7% in HG tumours. Combined cytology and Xpert BC Monitor yielded an overall sensitivity of 42% for LG and 85.7% for HG. Overall specificity was 97.2% for cytology, 77% for Xpert BC Monitor and 75.8% for the two tests. CONCLUSIONS: Sensitivity for the Xpert BC Monitor Test was significantly higher than for cytology. The test performed very well in terms of specificity but could not reach the value of cytology, while PPV and NPV performed approximately the same for both tests. CI - (c) Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. FAU - D Elia, Carolina AU - D Elia C AUID- ORCID: 0000-0002-8227-9978 AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy karolinedelia@gmail.com. FAU - Pycha, Alexander AU - Pycha A AD - Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Folchini, Decio M AU - Folchini DM AD - Department of Urology, Riga Stradins University Hospital, Riga, Latvia. FAU - Mian, Christine AU - Mian C AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Hanspeter, Esther AU - Hanspeter E AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Schwienbacher, Christine AU - Schwienbacher C AD - Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy. FAU - Vjaters, Egils AU - Vjaters E AD - Department of Urology, Riga Stradins University Hospital, Riga, Latvia. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy. AD - Sigmund Freud Private University, Medical School, Vienna, Austria. FAU - Trenti, Emanuela AU - Trenti E AD - Department of Urology, Central Hospital of Bolzano, Bolzano, Italy. LA - eng PT - Journal Article DEP - 20181024 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Area Under Curve MH - Biomarkers, Tumor/*urine MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/urine MH - Predictive Value of Tests MH - ROC Curve MH - Urinary Bladder Neoplasms/*diagnosis/*urine OTO - NOTNLM OT - bladder cancer OT - cytology OT - follow up OT - non muscle invasive OT - urinary marker COIS- Competing interests: None declared. EDAT- 2018/10/26 06:00 MHDA- 2019/01/27 06:00 CRDT- 2018/10/26 06:00 PHST- 2018/07/17 00:00 [received] PHST- 2018/09/27 00:00 [revised] PHST- 2018/10/01 00:00 [accepted] PHST- 2018/10/26 06:00 [pubmed] PHST- 2019/01/27 06:00 [medline] PHST- 2018/10/26 06:00 [entrez] AID - jclinpath-2018-205393 [pii] AID - 10.1136/jclinpath-2018-205393 [doi] PST - ppublish SO - J Clin Pathol. 2019 Feb;72(2):140-144. doi: 10.1136/jclinpath-2018-205393. Epub 2018 Oct 24. PMID- 30355350 OWN - NLM STAT- MEDLINE DCOM- 20190201 LR - 20240922 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 18 IP - 1 DP - 2018 Oct 24 TI - Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C. PG - 93 LID - 10.1186/s12894-018-0408-6 [doi] LID - 93 AB - BACKGROUND: Intravesical Mitomycin-C (MMC) following transurethral resection of bladder tumor (TURBT), while efficacious, is associated with side effects and poor utilization. Continuous saline bladder irrigation (CSBI) has been examined as an alternative. In this study we sought to compare the rates of recurrence and/or progression in patients with NMIBC who were treated with either MMC or CSBI after TURBT. METHODS: We retrospectively reviewed records of patients with NMIBC at our institution in 2012-2015. Perioperative use of MMC (40 mg in 20 mL), CSBI (two hours), or neither were recorded. Primary outcome was time to recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed. RESULTS: 205 patients met inclusion criteria. Forty-five (22.0%) patients received CSBI, 71 (34.6%) received MMC, and 89 (43.4%) received no perioperative therapy. On survival analysis, MMC was associated with improved DFS compared with CSBI (p = 0.001) and no treatment (p = 0.0009). On multivariable analysis, high risk disease was associated with increased risk of recurrence or progression (HR 2.77, 95% CI: 1.28-6.01), whereas adjuvant therapy (HR 0.35, 95% CI: 0.20-0.59) and MMC (HR 0.43, 95% CI: 0.25-0.75) were associated with decreased risk. CONCLUSIONS: Postoperative MMC was associated with improved DFS compared with CSBI and no treatment. The DFS benefit seen with CSBI in other studies may be limited to patients receiving prolonged irrigation. New intravesical agents being evaluated may consider saline as a control given our data demonstrating that short-term CSBI is not superior to TURBT alone. FAU - Lenis, Andrew T AU - Lenis AT AUID- ORCID: 0000-0001-9413-7793 AD - David Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Asanad, Kian AU - Asanad K AD - David Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA. FAU - Blaibel, Maher AU - Blaibel M AD - Riverside School of Medicine, University of California, Riverside, California, USA. FAU - Donin, Nicholas M AU - Donin NM AD - David Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Chamie, Karim AU - Chamie K AD - David Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA. kchamie@mednet.ucla.edu. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. kchamie@mednet.ucla.edu. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. kchamie@mednet.ucla.edu. LA - eng GR - L30 CA154326/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20181024 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Saline Solution) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/*therapeutic use MH - Combined Modality Therapy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*therapeutic use MH - Neoplasm Recurrence, Local/prevention & control MH - Proportional Hazards Models MH - Retrospective Studies MH - Saline Solution/*therapeutic use MH - Survival Analysis MH - Therapeutic Irrigation MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/drug therapy/*surgery PMC - PMC6201555 OTO - NOTNLM OT - Bladder cancer OT - Mitomycin-C OT - Outcome assessment OT - Recurrence OT - Therapeutic irrigation COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Institutional Review Board #14-000648. CONSENT FOR PUBLICATION: Not required given the retrospective nature of this study. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/10/26 06:00 MHDA- 2019/02/02 06:00 PMCR- 2018/10/24 CRDT- 2018/10/26 06:00 PHST- 2017/10/18 00:00 [received] PHST- 2018/10/17 00:00 [accepted] PHST- 2018/10/26 06:00 [entrez] PHST- 2018/10/26 06:00 [pubmed] PHST- 2019/02/02 06:00 [medline] PHST- 2018/10/24 00:00 [pmc-release] AID - 10.1186/s12894-018-0408-6 [pii] AID - 408 [pii] AID - 10.1186/s12894-018-0408-6 [doi] PST - epublish SO - BMC Urol. 2018 Oct 24;18(1):93. doi: 10.1186/s12894-018-0408-6. PMID- 30352453 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20220409 IS - 1438-8820 (Electronic) IS - 0001-7868 (Linking) VI - 50 IP - 3 DP - 2019 Jul TI - Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. PG - 292-297 LID - 10.1055/a-0750-5595 [doi] AB - ZIEL: Diese Studie erfolgte zum Vergleich der Wirksamkeit einer intravesikalen Instillation von Mitomycin C (MMC) zur Pravention eines nicht muskelinvasiven Ta- oder T1-High-Risk-Harnblasenkarzinoms (NMIBC) unter Verwendung verschiedener Schemata. MATERIAL UND METHODEN: Diese retrospektive Kohortenstudie wurde bei 152 Patienten durchgefuhrt, die zwischen April 2009 und September 2016 mit einer intravesikalen MMC-Injektion behandelt wurden. Der mittlere Nachbeobachtungszeitraum lag bei 32,67 Monaten. Alle Patienten unterzogen sich einer vollstandigen transurethralen Resektion des Blasentumors (TURBT), an die sich innerhalb von 24 Stunden eine postoperative Instillation von MMC anschloss. Die Patienten wurden in 4 Behandlungsgruppen unterteilt: Bei Gruppe 1 erfolgte die Nachbeobachtung ohne MMC-Erhaltungsdosis; Gruppe 2 erhielt in den ersten 8 Wochen einmal pro Woche eine MMC-Instillation; Gruppe 3 erhielt in den ersten 8 Wochen einmal pro Woche und in den darauffolgenden 6 Monaten einmal pro Monat eine MMC-Instillation; Gruppe 4 erhielt in den ersten 8 Wochen einmal pro Woche und in den darauffolgenden 12 Monaten einmal pro Monat eine MMC-Instillation. ERGEBNISSE: Die allgemeine Rezidivrate lag bei 27,6 %. Gruppe 1 zeigte eine signifikant hohe (p < 0,05) Rezidivrate von 50 %, wahrend sich bei den Rezidivraten der ubrigen 3 Schemata kein Unterschied fand (Gruppe 2: 15 %; Gruppe 3: 24,1 %; Gruppe 4: 27,2 %). Daruber hinaus zeigte sich zwischen diesen Patientengruppen kein statistischer Unterschied bei den Rezidivraten von Ta- oder T1-Tumoren sowie niedrig- oder hochgradigen Tumoren. SCHLUSSFOLGERUNG: Unser Vergleich der verschiedenen Schemata einer intravesikalen MMC-Instillation ergab bei einer einzigen MMC-Instillation nach TURBT eine signifikant hohere Rezidivrate als bei Patienten, die nach 8 Wochen, 6 Monaten und 12 Monaten eine Erhaltungsdosis erhielten. Zeitlich fanden sich beim MMC-Erhaltungsschema keine signifikanten Unterschiede zwischen der 8. Woche und dem 12. Monat. Daraus folgern wir, dass bei T1- oder Ta-High-Risk-NMIBC nach TURBT einmalig eine MMC-Instillation mit anschliessender Erhaltungstherapie mit einmal wochentlicher Verabreichung uber 8 Wochen durchgefuhrt werden kann. CI - (c) Georg Thieme Verlag KG Stuttgart . New York. FAU - Chen, Hong-Ray AU - Chen HR AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Kao, Chien-Chang AU - Kao CC AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Tsao, Chih-Wei AU - Tsao CW AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Tang, Shou-Hung AU - Tang SH AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - En, Meng AU - En M AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Cha, Tai-Lung AU - Cha TL AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Sun, Guang-Huan AU - Sun GH AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Wu, Seng-Tang AU - Wu ST AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. FAU - Yu, Dah-Shyong AU - Yu DS AD - Tri-Service General Hospital, Urology, National Defense Medical Center Taiwan, Taipei, Taiwan. LA - eng PT - Comparative Study PT - Journal Article TT - Vergleich verschiedener Behandlungsschemata einer intravesikalen Instillation von Mitomycin C bei Patienten mit oberflachlichem High-Risk-Harnblasenkarzinom. DEP - 20181023 PL - Germany TA - Aktuelle Urol JT - Aktuelle Urologie JID - 0421406 RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Chemotherapy, Adjuvant MH - Cohort Studies MH - Combined Modality Therapy MH - Drug Administration Schedule MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - Neoplasm Recurrence, Local/prevention & control MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Factors MH - Taiwan MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery MH - Young Adult COIS- None EDAT- 2018/10/24 06:00 MHDA- 2020/02/19 06:00 CRDT- 2018/10/24 06:00 PHST- 2018/10/24 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2018/10/24 06:00 [entrez] AID - 10.1055/a-0750-5595 [doi] PST - ppublish SO - Aktuelle Urol. 2019 Jul;50(3):292-297. doi: 10.1055/a-0750-5595. Epub 2018 Oct 23. PMID- 30350309 OWN - NLM STAT- MEDLINE DCOM- 20190521 LR - 20200225 IS - 1097-0215 (Electronic) IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 144 IP - 7 DP - 2019 Apr 1 TI - Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. PG - 1676-1684 LID - 10.1002/ijc.31935 [doi] AB - In urothelial bladder cancer (UBC), risk stratification remains an important unmet need. Limitless self-renewal, governed by TERT expression and telomerase activation, is crucial for cancer progression. Thus, telomerase activation through the interplay of mutations (TERTp(Mut) ) and epigenetic alterations in the TERT promoter may provide further insight into UBC behavior. Here, we investigated the combined effect of TERTp(Mut) and the TERT Hypermethylated Oncological Region (THOR) status on telomerase activation and patient outcome in a UBC international cohort (n = 237). We verified that TERTp(Mut) were frequent (76.8%) and present in all stages and grades of UBC. Hypermethylation of THOR was associated with higher TERT expression and higher-risk disease in nonmuscle invasive bladder cancers (NMIBC). TERTp(Mut) alone predicted disease recurrence (HR: 3.18, 95%CI 1.84 to 5.51, p < 0.0001) but not progression in NMIBC. Combined THOR(high) /TERTp(Mut) increased the risk of disease recurrence (HR 5.12, p < 0.0001) and progression (HR 3.92, p = 0.025). Increased THOR hypermethylation doubled the risk of stage progression of both TERTp(wt) and TERTp(Mut) NMIBC. These results highlight that both mechanisms are common and coexist in bladder cancer and while TERTp(Mut) is an early event in bladder carcinogenesis THOR hypermethylation is a dynamic process that contributes to disease progression. While the absence of alterations comprises an extremely indolent phenotype, the combined genetic and epigenetic alterations of TERT bring additional prognostic value in NMIBC and provide a novel insight into telomere biology in cancer. CI - (c) 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Leao, Ricardo AU - Leao R AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. AD - Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Department of Urology, Coimbra University Hospital, Coimbra, Portugal. FAU - Lee, Donghyun AU - Lee D AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Figueiredo, Arnaldo AU - Figueiredo A AD - Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Department of Urology, Coimbra University Hospital, Coimbra, Portugal. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Wild, Peter AU - Wild P AD - Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Komosa, Martin AU - Komosa M AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Lau, Irene AU - Lau I AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Mistry, Mathew AU - Mistry M AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Nunes, Nuno Miguel AU - Nunes NM AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Price, Aryeh J AU - Price AJ AD - Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA. FAU - Zhang, Cindy AU - Zhang C AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Lipman, Tatiana AU - Lipman T AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Valtcheva, Nadejda AU - Valtcheva N AD - Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Oehl, Kathrin AU - Oehl K AD - Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Coelho, Hugo AU - Coelho H AD - Department of Urology, Coimbra University Hospital, Coimbra, Portugal. FAU - Sayyid, Rashid AU - Sayyid R AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Gomes, Ana Melo AU - Gomes AM AD - Department of Pathology, Coimbra University Hospital, Coimbra, Portugal. FAU - Prado E Castro, Ligia AU - Prado E Castro L AD - Department of Pathology, Coimbra University Hospital, Coimbra, Portugal. FAU - Sweet, Joan AU - Sweet J AD - Department of Pathology, University Health Network, Toronto, ON, Canada. FAU - Vinagre, Joao AU - Vinagre J AD - Institute for Research and Innovation in Health, (I3S), Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal. FAU - Apolonio, Joana AU - Apolonio J AD - Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. AD - Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal. AD - Algarve Biomedical Center, Faro, Portugal. FAU - Stephens, Derek AU - Stephens D AD - Biostatistics, Design and Analysis, The Hospital for Sick Children, Toronto, ON, Canada. FAU - Faleiro, Ines AU - Faleiro I AD - Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. AD - Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal. AD - Algarve Biomedical Center, Faro, Portugal. FAU - Fadaak, Kamel AU - Fadaak K AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia. FAU - Richard, Patrick O AU - Richard PO AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, Faculty of Medicine, CHUS, University of Sherbrooke, Sherbrooke, QC, Canada. FAU - Kulkarni, Girish AU - Kulkarni G AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Hamilton, Robert J AU - Hamilton RJ AD - Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Castelo-Branco, Pedro AU - Castelo-Branco P AD - Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. AD - Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal. AD - Algarve Biomedical Center, Faro, Portugal. FAU - Tabori, Uri AU - Tabori U AUID- ORCID: 0000-0002-5019-2683 AD - Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. LA - eng GR - MOP 137899/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181230 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - *DNA Methylation MH - Disease Progression MH - Epigenesis, Genetic MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - *Mutation MH - Prognosis MH - Promoter Regions, Genetic MH - Sequence Analysis, RNA MH - Telomerase/*genetics MH - Up-Regulation MH - Urinary Bladder Neoplasms/*genetics PMC - PMC6519346 OTO - NOTNLM OT - TERT promoter methylation OT - TERT promoter mutations OT - progression OT - recurrence OT - telomerase OT - urothelial bladder cancer EDAT- 2018/10/24 06:00 MHDA- 2019/05/22 06:00 PMCR- 2019/05/15 CRDT- 2018/10/24 06:00 PHST- 2018/05/04 00:00 [received] PHST- 2018/09/13 00:00 [revised] PHST- 2018/09/26 00:00 [accepted] PHST- 2018/10/24 06:00 [pubmed] PHST- 2019/05/22 06:00 [medline] PHST- 2018/10/24 06:00 [entrez] PHST- 2019/05/15 00:00 [pmc-release] AID - IJC31935 [pii] AID - 10.1002/ijc.31935 [doi] PST - ppublish SO - Int J Cancer. 2019 Apr 1;144(7):1676-1684. doi: 10.1002/ijc.31935. Epub 2018 Dec 30. PMID- 30348146 OWN - NLM STAT- MEDLINE DCOM- 20190201 LR - 20190201 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 18 IP - 1 DP - 2018 Oct 22 TI - Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. PG - 90 LID - 10.1186/s12894-018-0404-x [doi] LID - 90 AB - BACKGROUND: This study aims to prospectively evaluate the ability of Neutrophil-to-Lymphocyte ratio (NLR) to forecast recurrence in patients with non-muscle invasive bladder cancer (NMIBC). This is a continuation of our two previous retrospective studies that indicated the NLR > 2.5 criterion as a predictor of recurrence in patients with NMIBC. METHODS: Since December 2013, all patients admitted to our department for TUR-BT and agreed to participate, had a blood drawn for cell count and differential 24 h prior to surgery. Patients with pathological NMIBC were followed prospectively for disease recurrence. The end-point of the follow up was either a cancer recurrence or the termination of the study. Univariate and multivariate Cox regressions were performed to assess the NLR > 2.5 predictive capability for recurrence, versus and in conjunction to the pathologically based EORTC score, among additional statistical analyses. RESULTS: The study cohort included 96 men and 17 women with a median age of 72 years. Sixty-four patients (56.6%) have had a recurrence during the study occurring at the median time of 9 months (IQR 6, 13), while the median follow-up time for patients without recurrence was 18 months (IQR 10, 29). Univariate Cox regressions for recurrence demonstrated significance for NLR > 2.5 for the whole cohort (p = 0.011, HR 2.015, CI 1.175-3.454) and for the BCG sub-group (p = 0.023, HR 3.7, CI 1.2-11.9), while the EORTC score demonstrated significance for the 'No Treatment' subgroup (p = 0.024, HR 1.278, CI 1.03-1.58). When analyzed together as a multivariate Cox model, the NLR > 2.5 and EORTC score retained their significance for the aforementioned groups, while also improving the EORTC score significance for the whole cohort. CONCLUSION: NLR > 2.5 was found to be a significant predictor of disease recurrence and demonstrated high hazard ratio and worse recurrence-free survival in patients with NMIBC, especially in those treated with BCG. Additionally, our data demonstrated statistical evidence that NLR > 2.5 might have an improving effect on the EORTC score's prediction when analyzed together. FAU - Getzler, Itamar AU - Getzler I AUID- ORCID: 0000-0001-6453-1423 AD - Department of Urology, Bnai Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Golomb 47, 31048, Haifa, Israel. itamargetzler@gmail.com. FAU - Bahouth, Zaher AU - Bahouth Z AD - Department of Urology, Bnai Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Golomb 47, 31048, Haifa, Israel. FAU - Nativ, Ofer AU - Nativ O AD - Department of Urology, Bnai Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Golomb 47, 31048, Haifa, Israel. FAU - Rubinstein, Jacob AU - Rubinstein J AD - Department of Mathematics, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Halachmi, Sarel AU - Halachmi S AD - Department of Urology, Bnai Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Golomb 47, 31048, Haifa, Israel. LA - eng PT - Journal Article DEP - 20181022 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Leukocyte Count MH - *Lymphocytes MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - *Neutrophils MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Prospective Studies MH - Urinary Bladder Neoplasms/*immunology/pathology/surgery PMC - PMC6198354 OTO - NOTNLM OT - Bladder cancer OT - NLR OT - NMIBC, urothelial carcinoma OT - Neutrophil-lymphocyte ratio OT - Recurrence COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The Study approved by the Bnai Zion Medical center Helsinki committee and the ministry of Health of Israel, Registry Number: 0049-10-BNZ. Participants received a comprehensive explanation and a written consent was obtained for participation in the study. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/10/24 06:00 MHDA- 2019/02/02 06:00 PMCR- 2018/10/22 CRDT- 2018/10/24 06:00 PHST- 2018/02/03 00:00 [received] PHST- 2018/10/08 00:00 [accepted] PHST- 2018/10/24 06:00 [entrez] PHST- 2018/10/24 06:00 [pubmed] PHST- 2019/02/02 06:00 [medline] PHST- 2018/10/22 00:00 [pmc-release] AID - 10.1186/s12894-018-0404-x [pii] AID - 404 [pii] AID - 10.1186/s12894-018-0404-x [doi] PST - epublish SO - BMC Urol. 2018 Oct 22;18(1):90. doi: 10.1186/s12894-018-0404-x. PMID- 30337782 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220321 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 34 IP - 4 DP - 2018 Oct-Dec TI - Utility of restage transurethral resection of bladder tumor. PG - 273-277 LID - 10.4103/iju.IJU_218_17 [doi] AB - INTRODUCTION: Transurethral resection of bladder tumor (TURBT) aims at complete resection of all the visible tumors. Existing guidelines recommend restage TURBT in all patients with T1 and high-grade tumors, to avoid under-staging. However, restage TURBT may not be plausible/feasible at all the times. This study was performed with an aim to better define the utility of restage TURBT in a tertiary care hospital of India. METHODS: Patients with high grade/T1 tumors at the first TURBT were prospectively enrolled. Their demographic profile, previous cystoscopic findings, and histological reports were recorded. The primary objective was to assess the tumor detection and stage up-migration rates at restage TURBT. The secondary objectives was to identify factors predicting presence of tumor at restage TURBT. Patients were followed up to detect recurrence and progression for a minimum of 3 months. RESULTS: Of 128 prospective patients' enrolled, 29 patients were lost to follow-up and 11 patients did not undergo restage. A total of eighty-eight patients underwent restage TURBT of which twenty-eight patients (31.8%) had tumor at their second TURBT with five of these patients being upstaged to T2. The risk of having a tumor at restage was significantly higher in patients with solid tumors (56.2% vs. 26.4%, P = 0.02, 95% confidence interval: 0.035-0.024) but was independent of the tumor size (P = 0.472), number of growths (P = 0.267), grade of tumor (P = 0.441), presence or absence of muscle at the initial TURBT (P = 0.371) and place of initial TURBT (P = 0.289). There was a significant difference in the recurrence and progression rates in patients who had tumor at restage as compared to those who did not (recurrence; 33.3% and 23.8%, P = 0.022, respectively vs. progression; 11.1% and 3.7% respectively, P = 0.07; mean follow-up = 10.8 months). CONCLUSIONS: We conclude that restage TURBT is necessary in patients with solid looking tumors and the presence of tumor at restage confers a higher risk of recurrence and progression. FAU - Manoharan, Vignesh AU - Manoharan V AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Mavuduru, Ravimohan Suryanarayan AU - Mavuduru RS AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Kumar, Santosh AU - Kumar S AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Kakkar, Nandita AU - Kakkar N AD - Department of Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Devana, Sudheer Kumar AU - Devana SK AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Bora, Girdhar Singh AU - Bora GS AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Singh, Shrawan Kumar AU - Singh SK AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Mandal, Arup Kumar AU - Mandal AK AD - Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. LA - eng PT - Journal Article PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC6174718 COIS- Conflicts of interest: There are no conflicts of interest. EDAT- 2018/10/20 06:00 MHDA- 2018/10/20 06:01 PMCR- 2018/10/01 CRDT- 2018/10/20 06:00 PHST- 2018/10/20 06:00 [entrez] PHST- 2018/10/20 06:00 [pubmed] PHST- 2018/10/20 06:01 [medline] PHST- 2018/10/01 00:00 [pmc-release] AID - IJU-34-273 [pii] AID - 10.4103/iju.IJU_218_17 [doi] PST - ppublish SO - Indian J Urol. 2018 Oct-Dec;34(4):273-277. doi: 10.4103/iju.IJU_218_17. PMID- 30337218 OWN - NLM STAT- MEDLINE DCOM- 20190131 LR - 20191201 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 36 IP - 12 DP - 2018 Dec TI - Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guerin immunotherapy. PG - 531.e9-531.e17 LID - S1078-1439(18)30348-X [pii] LID - 10.1016/j.urolonc.2018.09.007 [doi] AB - OBJECTIVES: High-grade nonmuscle-invasive urothelial tumors of the bladder that fail intravesical Bacillus Calmette-Guerin (BCG) immunotherapy are at the highest risk of progression. Initial evidence links heat shock protein expression levels and outcome of bladder cancer after BCG treatment. We aimed to determine the association between HSP60, 70, and 90 expression levels and long-term outcomes of T1 high-grade (T1HG) urothelial bladder tumors treated with BCG immunotherapy. MATERIALS AND METHODS: Data of 54 consecutive patients with primary T1HG bladder tumors who underwent transurethral resection between 2002 and 2008 and received at least an induction course of BCG were reviewed. Immunohistochemical staining for heat shock protein (HSP)60, 70, and 90 were performed on resected specimens. Study outcomes included disease recurrence and progression. The association between HSP expression levels and outcomes were evaluated with univariable and multivariable Cox proportional hazards models. RESULTS: During a median follow-up of 9.6 years, 25 patients had a disease recurrence and 14 patients a disease progression. Estimated 5-year recurrence and progression-free survival were 59% and 81%, respectively. On multivariable analyses, HSP60 staining >65% was associated with a higher risk for progression (hazard ratio [HR] = 3.96, 95% confidence interval [CI] 1.35-11.58, P = 0.012), and HSP70 staining >5% was associated with a decreased risk for progression (HR = 0.33, 95% CI 0.11-0.98, P = 0.045), and recurrence (HR = 0.29, 95% CI 0.13-0.65, P = 0.003). HSP90 expression was not associated with disease recurrence or progression. Five patients had both a HSP60 staining >65% and a HSP70 staining /=3 lymphoceles were more frequently reported in the extended LND group within 90d after surgery. Inclusion of T1G3 tumors may have contributed to the negative study result. CONCLUSIONS: Extended LND failed to show a significant advantage over limited LND in RFS, CSS, and OS. A larger trial is required to determine whether extended compared with limited LND leads to a small, but clinically relevant, survival difference (ClinicalTrials.gov NCT01215071). PATIENT SUMMARY: In this study, we investigated the outcome in bladder cancer patients undergoing cystectomy based on the anatomic extent of lymph node resection. We found that extended removal of lymph nodes did not reduce the rate of tumor recurrence in the expected range. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Gschwend, Jurgen E AU - Gschwend JE AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. Electronic address: juergen.gschwend@tum.de. FAU - Heck, Matthias M AU - Heck MM AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. FAU - Lehmann, Jan AU - Lehmann J AD - AUO Study Group, Germany. FAU - Rubben, Herbert AU - Rubben H AD - Department of Urology, University of Essen, Germany. FAU - Albers, Peter AU - Albers P AD - Department of Urology, Heinrich Heine University, Dusseldorf, Germany. FAU - Wolff, Johannes M AU - Wolff JM AD - Department of Urology, Paracelsus Hospital Golzheim Dusseldorf, Dusseldorf, Germany. FAU - Frohneberg, Detlef AU - Frohneberg D AD - Department of Urology, Hospital of Karlsruhe, Germany. FAU - de Geeter, Patrick AU - de Geeter P AD - Department of Urology, Hospital of Kassel, Germany. FAU - Heidenreich, Axel AU - Heidenreich A AD - Department of Urology, University of Cologne, Cologne, Germany. FAU - Kalble, Tilman AU - Kalble T AD - Department of Urology, Hospital of Fulda, Germany. FAU - Stockle, Michael AU - Stockle M AD - Department of Urology, Saarland University Medical Center, Homburg, Germany. FAU - Schnoller, Thomas AU - Schnoller T AD - Department of Urology, Ulm University, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard Karls University, Tubingen, Germany. FAU - Muller, Markus AU - Muller M AD - Department of Urology, Hospital Ludwigshafen, Germany. FAU - Truss, Michael AU - Truss M AD - Department of Urology, Hospital Dortmund, Germany. FAU - Roth, Stephan AU - Roth S AD - Department of Urology, Helios Hospital, Wuppertal, Germany. FAU - Liehr, Uwe-Bernd AU - Liehr UB AD - Department of Urology, Otto von Guericke University, Magdeburg, Germany. FAU - Leissner, Joachim AU - Leissner J AD - Department of Urology, Hospital Holweide, Cologne, Germany. FAU - Bregenzer, Thomas AU - Bregenzer T AD - AUO Study Group, Germany. FAU - Retz, Margitta AU - Retz M AD - Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. LA - eng SI - ClinicalTrials.gov/NCT01215071 PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20181015 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 CIN - Nat Rev Urol. 2019 Jan;16(1):3-4. doi: 10.1038/s41585-018-0126-6. PMID: 30510274 CIN - Eur Urol. 2019 Apr;75(4):612-614. doi: 10.1016/j.eururo.2018.12.028. PMID: 30616946 CIN - Eur Urol. 2019 Jul;76(1):126. doi: 10.1016/j.eururo.2019.02.034. PMID: 30878302 CIN - Eur Urol. 2019 Sep;76(3):408-409. doi: 10.1016/j.eururo.2019.03.042. PMID: 30987842 CIN - Eur Urol. 2019 Aug;76(2):e35-e36. doi: 10.1016/j.eururo.2019.04.031. PMID: 31054784 CIN - Eur Urol. 2019 Aug;76(2):e37. doi: 10.1016/j.eururo.2019.04.032. PMID: 31056229 CIN - J Urol. 2019 Aug;202(2):208-209. doi: 10.1097/JU.0000000000000332. PMID: 31067165 CIN - Transl Androl Urol. 2019 Mar;8(Suppl 1):S104-S105. doi: 10.21037/tau.2018.12.11. PMID: 31143681 CIN - Transl Androl Urol. 2019 Mar;8(Suppl 1):S112-S115. doi: 10.21037/tau.2018.12.09. PMID: 31143684 CIN - Aktuelle Urol. 2019 Aug;50(4):334-336. doi: 10.1055/a-0926-0654. PMID: 31398748 CIN - Transl Cancer Res. 2019 Mar;8(Suppl 2):S180-S182. doi: 10.21037/tcr.2019.01.11. PMID: 35117094 MH - Aged MH - Chemotherapy, Adjuvant MH - Cystectomy/adverse effects/*methods/mortality MH - Disease Progression MH - Female MH - Germany MH - Humans MH - Lymph Node Excision/adverse effects/*methods/mortality MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Progression-Free Survival MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Cystectomy OT - Lymph node dissection OT - Overall survival OT - Recurrence-free survival EDAT- 2018/10/20 06:00 MHDA- 2019/08/14 06:00 CRDT- 2018/10/20 06:00 PHST- 2018/07/26 00:00 [received] PHST- 2018/09/26 00:00 [accepted] PHST- 2018/10/20 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2018/10/20 06:00 [entrez] AID - S0302-2838(18)30737-1 [pii] AID - 10.1016/j.eururo.2018.09.047 [doi] PST - ppublish SO - Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15. PMID- 30334959 OWN - NLM STAT- MEDLINE DCOM- 20181031 LR - 20260127 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 42 DP - 2018 Oct TI - Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection. PG - e12740 LID - 10.1097/MD.0000000000012740 [doi] LID - e12740 AB - PURPOSE: The objective of this study was to evaluate the efficacy, defined by the 3-year tumor recurrence-free survival rate, of intravesical chemotherapy using pirarubicin (THP) in patients with low or intermediate-risk nonmuscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Between October 2010 and January 2015, 206 patients were enrolled, and finally 113 were randomized to receive either a single immediate postoperative intravesical instillation of THP (30 mg) (Group A), or 8 additional weekly intravesical instillations of THP (30 mg) after a single postoperative instillation (Group B). The patients were examined by performing cystoscopy and urine cytology every 3 months after transurethral resection to determine bladder tumor recurrence. The primary endpoint was 3-year-recurrence-free survival rate. RESULTS: All 113 patients were bacillus Calmette-Guerin (BCG)-naive. The 3-year recurrence free survival rate was 63.7% for Group A and 85.3% for Group B (log-rank test, P = .0070). In patients with intermediate recurrence risk, the 3-year recurrence-free survival rate was 63.4% in Group A and 86.1% in Group B (log-rank test, P = .0036). Cox regression analysis revealed that only additional instillation of THP was a significant independent factor for recurrence-free rate in patients with intermediate risk. No patient with progression was noted during this period. Frequent adverse effects (AEs) were frequent urination and micturition pain, and no severe AEs (Grade 3 or more) occurred. CONCLUSION: Additional instillation of THP (30 mg) weekly for 8 weeks reduced the risk of tumor recurrence without severe AEs in BCG-naive NMIBC patients with intermediate risk. FAU - Naya, Yoshio AU - Naya Y AD - Department of Urology, Meiji University of Integrative Medicine, Nantan. AD - Department Urology, Nagahama City Kohoku Hospital, Nagahama. FAU - Mikami, Kazuya AU - Mikami K AD - Department of Urology, Kyoto First Red-Cross Hospital. FAU - Takaha, Natsuki AU - Takaha N AD - Department of Urology, Meiji University of Integrative Medicine, Nantan. FAU - Inoue, Yuuta AU - Inoue Y AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto. FAU - Fujihara, Atsuko AU - Fujihara A AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto. FAU - Kanazawa, Motohiro AU - Kanazawa M AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto. FAU - Nakanishi, Hiroyuki AU - Nakanishi H AD - Department of Urology, Kyoto Chubu Medical Center, Nantan. FAU - Miyashita, Hiroaki AU - Miyashita H AD - Department of Urology, Omihachiman Community Medical Center, Omihachiman, Japan. FAU - Ukimura, Osamu AU - Ukimura O AD - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Agents/*administration & dosage MH - Chemotherapy, Adjuvant/methods MH - Disease-Free Survival MH - Doxorubicin/administration & dosage/*analogs & derivatives MH - Drug Administration Schedule MH - Female MH - Humans MH - Japan MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/etiology MH - Postoperative Period MH - Prospective Studies MH - Regression Analysis MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/*therapy MH - Urologic Surgical Procedures/*methods PMC - PMC6211924 COIS- The authors have no conflicts of interest to disclose. EDAT- 2018/10/20 06:00 MHDA- 2018/11/01 06:00 PMCR- 2018/10/19 CRDT- 2018/10/19 06:00 PHST- 2018/10/19 06:00 [entrez] PHST- 2018/10/20 06:00 [pubmed] PHST- 2018/11/01 06:00 [medline] PHST- 2018/10/19 00:00 [pmc-release] AID - 00005792-201810190-00022 [pii] AID - MD-D-18-03143 [pii] AID - 10.1097/MD.0000000000012740 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Oct;97(42):e12740. doi: 10.1097/MD.0000000000012740. PMID- 30325609 OWN - NLM STAT- MEDLINE DCOM- 20190726 LR - 20200225 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 45 IP - 2 DP - 2019 Mar-Apr TI - Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder. PG - 306-314 LID - 10.1590/S1677-5538.IBJU.2018.0068 [doi] AB - PURPOSE: Non - muscle - invasive bladder cancer (NMIBC) can recur despite transurethral resection (TURBT) and adjuvant intravesical therapy. Tobacco products excreted in the urine are hypothesized to cause tumor - promoting effects on urothelial cells through direct contact. We determined if moderate or severe lower urinary tract symptoms (LUTS) (defined as International Prostate Symptom Score [IPSS] >/= 8) was associated with increased tumor recurrence. MATERIALS AND METHODS: We retrospectively identified 70 consecutive men initially diagnosed with NMIBC at our institution from 2010 - 2016. Means were compared with independent T - test and proportions with chi - square analysis. Multivariate logistic regression was performed to determine independent predictors of recurrence. RESULTS: The majority of patients had Ta disease (58.6%) followed by T1 (28.6%) and Tis (12.9%). Forty - one (58.6%) patients had moderate or severe LUTS upon presentation within 30 days of initial TURBT with mean IPSS of 13.2 vs. 5.2 in the control group (p < 0.01). Biopsy - proven tumor recurrence occurred in 24 (34.3%) patients at mean follow-up of 31.7 months. Mean time to recurrence was 14.6 months. Moderate or severe LUTS was an independent predictor of tumor recurrence (odds ratio [OR]: 19.1, 95% confidence interval [CI]: 2.86 - 127; p = 0.002). Voiding or storage symptoms based on the IPSS did not independently correlate with tumor recurrence (p = 0.08 and p = 0.31, respectively) although total mean IPSS score did (OR: 1.26, 95% CI: 1.07 - 1.47, p = 0.005). CONCLUSIONS: The presence of moderate or severe LUTS may be an important prognostic factor in NMIBC. Patients with significant urinary symptoms could be monitored more aggressively due to higher recurrence risk. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Lunney, Austin AU - Lunney A AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Haynes, Allan AU - Haynes A AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Sharma, Pranav AU - Sharma P AD - Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 MH - Aged MH - Biopsy MH - Disease Progression MH - Follow-Up Studies MH - Humans MH - Lower Urinary Tract Symptoms/*etiology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology MH - Prostatic Hyperplasia/*complications MH - Quality of Life MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology PMC - PMC6541143 OTO - NOTNLM OT - Carcinoma, Transitional Cell OT - Lower Urinary Tract Symptoms OT - Urinary Bladder Neoplasms COIS- None declared. EDAT- 2018/10/17 06:00 MHDA- 2019/07/28 06:00 PMCR- 2019/04/01 CRDT- 2018/10/17 06:00 PHST- 2018/01/30 00:00 [received] PHST- 2018/08/05 00:00 [accepted] PHST- 2018/10/17 06:00 [pubmed] PHST- 2019/07/28 06:00 [medline] PHST- 2018/10/17 06:00 [entrez] PHST- 2019/04/01 00:00 [pmc-release] AID - IBJU20180068 [pii] AID - S1677-5538.IBJU.2018.0068 [pii] AID - 10.1590/S1677-5538.IBJU.2018.0068 [doi] PST - ppublish SO - Int Braz J Urol. 2019 Mar-Apr;45(2):306-314. doi: 10.1590/S1677-5538.IBJU.2018.0068. PMID- 30323201 OWN - NLM STAT- MEDLINE DCOM- 20191114 LR - 20261010 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 16 IP - 1 DP - 2019 Jan TI - T1 bladder cancer: current considerations for diagnosis and management. PG - 23-34 LID - 10.1038/s41585-018-0105-y [doi] AB - Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing many of the genetic features of muscle-invasive bladder cancers, are classified as non-muscle-invasive or 'superficial' tumours. Yet, patients with T1 bladder cancer have an overall mortality of 33% and a cancer-specific mortality of 14% at three years after diagnosis, suggesting that these patients have a high risk of progression and, accordingly, require meticulous surgery, endoscopic surveillance and clinical decision-making. We hypothesize that the variability in the outcomes of patients with T1 bladder cancer is a result of both tumour heterogeneity and pathological staging, as well as inconsistencies in risk stratification, endoscopic resection and schedules of delivery of BCG. Owing to limitations in clinical staging, patients with T1 bladder cancer are at risk of both undertreatment with persistent use of BCG despite recurrence, and overtreatment with early cystectomy. Understanding the molecular features of T1 bladder cancers and how they respond to BCG therapy could improve biomarkers for risk stratification to align therapy with biological risk. FAU - Jordan, Brian AU - Jordan B AUID- ORCID: 0000-0002-2339-1724 AD - Department of Urology, Northwestern University, Chicago, IL, USA. FAU - Meeks, Joshua J AU - Meeks JJ AD - Department of Urology, Northwestern University, Chicago, IL, USA. joshua.meeks@northwestern.edu. LA - eng GR - I01 BX003692/BX/BLRD VA/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Algorithms MH - BCG Vaccine/therapeutic use MH - Cystectomy MH - Humans MH - Neoplasm Grading MH - Neoplasm Staging MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy EDAT- 2018/10/17 06:00 MHDA- 2019/11/15 06:00 CRDT- 2018/10/17 06:00 PHST- 2018/10/17 06:00 [pubmed] PHST- 2019/11/15 06:00 [medline] PHST- 2018/10/17 06:00 [entrez] AID - 10.1038/s41585-018-0105-y [pii] AID - 10.1038/s41585-018-0105-y [doi] PST - ppublish SO - Nat Rev Urol. 2019 Jan;16(1):23-34. doi: 10.1038/s41585-018-0105-y. PMID- 30322230 OWN - NLM STAT- MEDLINE DCOM- 20191217 LR - 20200225 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 51 IP - 3 DP - 2019 Jul TI - Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis. PG - 963-972 LID - 10.4143/crt.2018.465 [doi] AB - PURPOSE: The purpose of this study was to compare oncologic outcomes between open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU) in patients with upper tract urothelial carcinoma. MATERIALS AND METHODS: The medical records of consecutive ONU and LNU cases from five tertiary institutions were retrospectively analyzed between 2000 and 2012. The propensity-score matching methodology was used to compare the two surgical approaches in terms of age, body mass index, American Society of Anesthesiologists score, tumor location, grade, pathologic T and N categories, the presence of lymphovascular invasion, and follow-up duration. The Kaplan-Meier with log-rank tests and clustered Cox regression were used to compare the estimated rates of survival for each surgical approach and to investigate the effect of the surgical approach on each prognostic outcome. RESULTS: Six hundred thirty-eight propensity-score matching pairs (n=1,276) were compared; LNU was significantly better than ONU in all types of survival, including intravesical recurrencefree survival (IVRFS), disease-free survival, overall survival (OS), and cancer-specific survival (CSS) (p < 0.05). The 3-year OS and CSS rates were significantly higher with LNU than with ONU (p < 0.05). Compared with ONU, LNU had significantly better 3-year OS and CSS rates (82.9% and 86.2% vs. 78.3% and 81.8%); there were no differences at 5 years. In subgroup analysis of the early-staged group, advanced-stage group, lymph node-positive group, and lymph node-negative group, the two approaches did not significantly affect prognostic outcomes, except LNU improved the IVRFS in the lymph node-negative or no history of previous bladder cancer group. CONCLUSION: LNU had a significantly better prognostic outcome than ONU after propensity-score matching. FAU - Kim, Sung Han AU - Kim SH AD - Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. FAU - Song, Mi Kyung AU - Song MK AD - Biometrics Research Branch, Research Institute, National Cancer Center, Goyang, Korea. FAU - Kim, Jung Kwon AU - Kim JK AD - Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. LA - eng GR - NCC-2016-0040/National Cancer Center/Republic of Korea PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20181012 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Body Mass Index MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Laparoscopy/*methods MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Nephroureterectomy/*methods MH - Prognosis MH - Propensity Score MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Ureteral Neoplasms/pathology/*surgery PMC - PMC6639211 OTO - NOTNLM OT - Laparoscopy OT - Nephroureterectomy OT - Prognosis OT - Survival OT - Urothelial carcinoma COIS- Conflict of interest relevant to this article was not reported. EDAT- 2018/10/17 06:00 MHDA- 2019/12/18 06:00 PMCR- 2019/07/01 CRDT- 2018/10/17 06:00 PHST- 2018/08/17 00:00 [received] PHST- 2018/10/08 00:00 [accepted] PHST- 2018/10/17 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/10/17 06:00 [entrez] PHST- 2019/07/01 00:00 [pmc-release] AID - crt.2018.465 [pii] AID - crt-2018-465 [pii] AID - 10.4143/crt.2018.465 [doi] PST - ppublish SO - Cancer Res Treat. 2019 Jul;51(3):963-972. doi: 10.4143/crt.2018.465. Epub 2018 Oct 12. PMID- 30315887 OWN - NLM STAT- MEDLINE DCOM- 20190515 LR - 20190515 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 123 DP - 2019 Jan TI - MicroRNA Expression Profiles in Upper Tract Urothelial Carcinoma Differentiate Tumor Grade, Stage, and Survival: Implications for Clinical Decision-Making. PG - 93-100 LID - S0090-4295(18)31086-0 [pii] LID - 10.1016/j.urology.2018.10.004 [doi] AB - OBJECTIVE: To evaluate microRNA (miRNA) biomarkers for upper tract urothelial carcinoma (UTUC) to improve risk stratification. METHODS: miRNA was isolated from 157 radical nephroureterectomy specimens from 2 institutions. The relative expression of miRNA was examined for high grade vs low grade tumors as well as muscle invasive vs nonmuscle invasive tumors. Recurrence free survival (RFS) and overall survival (OS) were also stratified using relative expression of specific miRNA. RESULTS: The optimized model to identify high grade UTUC included miR-29b-2-5p, miR-18a-5p, miR-223-3p, and miR-199a-5p, generating a sensitivity of 83%, specificity of 85%, and generated a receiver operating characteristic (ROC) curve with area-under-the-curve of 0.86. Similarly, the model classifier for predicting >/=pT2 disease incorporated miR-10b-5p, miR-26a-5p-5p, miR-31-5p, and miR-146b-5p, producing a sensitivity of 64%, specificity of 96%, and area-under-the-curve of 0.90. RFS was best reflected by a combination of miR-10a-5p, miR-30c-5p, and miR-10b-5p, while OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p. CONCLUSION: High-grade vs low-grade as well as muscle invasive vs nonmuscle invasive UTUC can be reliable distinguished with unique miRNA signatures. Furthermore, differential expression of UTUC miRNA produces robust classifiers for predicting RFS and OS that may help identify patients who would most benefit from adjuvant therapies. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Browne, Brendan M AU - Browne BM AD - Department of Urology, Lahey Hospital and Medical Center, Burlington, MA. Electronic address: brendan.m.browne@lahey.org. FAU - Stensland, Kristian D AU - Stensland KD AD - Department of Urology, Lahey Hospital and Medical Center, Burlington, MA. FAU - Patel, Chintan K AU - Patel CK AD - Department of Urology, Lahey Hospital and Medical Center, Burlington, MA. FAU - Sullivan, Travis AU - Sullivan T AD - Department of Translational Research-Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA. FAU - Burks, Eric J AU - Burks EJ AD - Department of Pathology, Lahey Hospital and Medical Center, Burlington, MA. FAU - Canes, David AU - Canes D AD - Department of Urology, Lahey Hospital and Medical Center, Burlington, MA. FAU - Raman, Jay D AU - Raman JD AD - Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Warrick, Joshua AU - Warrick J AD - Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Reiger-Christ, Kimberly M AU - Reiger-Christ KM AD - Department of Translational Research-Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA. LA - eng PT - Journal Article DEP - 20181010 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*genetics/mortality/pathology MH - *Clinical Decision-Making MH - Female MH - Humans MH - Kidney Neoplasms/*genetics/mortality/pathology MH - Male MH - MicroRNAs/*biosynthesis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Survival Rate MH - Ureteral Neoplasms/*genetics/mortality/pathology EDAT- 2018/10/14 06:00 MHDA- 2019/05/16 06:00 CRDT- 2018/10/14 06:00 PHST- 2018/06/27 00:00 [received] PHST- 2018/08/05 00:00 [revised] PHST- 2018/10/02 00:00 [accepted] PHST- 2018/10/14 06:00 [pubmed] PHST- 2019/05/16 06:00 [medline] PHST- 2018/10/14 06:00 [entrez] AID - S0090-4295(18)31086-0 [pii] AID - 10.1016/j.urology.2018.10.004 [doi] PST - ppublish SO - Urology. 2019 Jan;123:93-100. doi: 10.1016/j.urology.2018.10.004. Epub 2018 Oct 10. PMID- 30303142 OWN - NLM STAT- MEDLINE DCOM- 20190205 LR - 20220321 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 61 IP - 4 DP - 2018 Oct-Dec TI - Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance. PG - 526-531 LID - 10.4103/IJPM.IJPM_588_17 [doi] AB - BACKGROUND: Transurethral resection of tumor is the main treatment of non-muscle-invasive urothelial carcinoma, but it is associated with high rate of recurrence and/or progression and this arouses the need for adjuvant therapy. Topoisomerase II (Top II), KI-67, and P53 are proliferation and cell cycle regulation markers that may predict tumor response to therapy. AIM: This study aimed to assess Top II, KI-67, and P53 expression and their effect on clinical outcome and response to therapy of non-muscle-invasive urothelial carcinoma. MATERIALS AND METHODS: Fifty cases of non-muscle invasive urothelial carcinoma were collected; Top II, KI-67, and P53 expression was evaluated. Patients received treatment then tumor recurrence was correlated with the expression of previous markers. RESULTS: There was a significant association between high Top II score, P53, and KI-67 and high tumor grade (P = 0.0001, 0.001, and 0.0001), submucosal infiltration (P = 0.0001 and 0.01), and recurrence (P = 0.01, 0.001, and 0.001). CONCLUSION: Top II, P53, and KI-67 may predict tumor response to therapy and the clinical outcome in non-muscle-invasive urothelial carcinoma. FAU - Elkady, Noha AU - Elkady N AD - Department of Pathology, Faculty of Medicine, Menoufia University, Shibin El-Kom, Egypt. FAU - Sultan, Mohamed AU - Sultan M AD - Department of Urology, Faculty of Medicine, Menoufia University, Shibin El-Kom, Egypt. FAU - Elkhouly, Enas AU - Elkhouly E AD - Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin El-Kom, Egypt. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Ki-67 Antigen) RN - 0 (Tumor Suppressor Protein p53) RN - EC 5.99.1.3 (DNA Topoisomerases, Type II) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*pathology/therapy MH - DNA Topoisomerases, Type II/*analysis MH - Female MH - Humans MH - Ki-67 Antigen/*analysis MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Tumor Suppressor Protein p53/*analysis MH - Urinary Bladder Neoplasms/*pathology/therapy OTO - NOTNLM OT - KI-67 OT - P53 OT - non-muscle-invasive urothelial carcinoma OT - recurrence OT - topoisomerase II COIS- There is no conflict of interest EDAT- 2018/10/12 06:00 MHDA- 2019/02/06 06:00 CRDT- 2018/10/11 06:00 PHST- 2018/10/11 06:00 [entrez] PHST- 2018/10/12 06:00 [pubmed] PHST- 2019/02/06 06:00 [medline] AID - IndianJPatholMicrobiol_2018_61_4_526_242996 [pii] AID - 10.4103/IJPM.IJPM_588_17 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2018 Oct-Dec;61(4):526-531. doi: 10.4103/IJPM.IJPM_588_17. PMID- 30297221 OWN - NLM STAT- MEDLINE DCOM- 20210520 LR - 20210520 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 6 IP - 2 DP - 2020 Mar 15 TI - The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. PG - 292-297 LID - S2405-4569(18)30292-X [pii] LID - 10.1016/j.euf.2018.09.019 [doi] AB - BACKGROUND: Lymphovascular invasion (LVI) in muscle-invasive bladder cancer is associated with a poor prognosis when identified from radical cystectomy (RC) specimens. However, LVI is not clearly emphasized in any risk models to guide clinical decision-making. The impact of LVI on the risk of lymph node (LN) metastasis after a transurethral resection of bladder tumor (TURBT) specimen is less understood. OBJECTIVE: The goal was to describe the impact of LVI and the risk of LN metastasis at each clinical stage of urothelial carcinoma of the bladder (UC). DESIGN, SETTING, AND PARTICIPANTS: The National Cancer Database was queried for patients with bladder cancer who underwent RC with LN dissection from 2004 to 2014. Patients with non-bladder primary, non-UC histology, clinical metastatic disease, and having received chemotherapy/radiation were excluded. Pathologic LN positive rates at RC were determined. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was pathologic upstaging at RC and pathologic node positivity. Secondary outcomes included determining overall survival (OS). All hypotheses testing were two-sided and a p value of <0.05 was considered statistically significant. All statistical analyses were performed using Stata version 13.1. RESULTS AND LIMITATIONS: A total of 3007 patients with UC underwent RC with pelvic LN dissection. In patients with LVI, the risk of LN metastasis was significantly higher at each clinical stage as was the rate of pathologic upstaging. Patients with LVI on TURBT had worse OS stage for stage in pure UC (p<0.001). Limitations include that there was no central pathologic review and the number of TURBTs per patient was not known. CONCLUSIONS: Patients with UC with LVI had worse OS and are at higher risk for LN-positive disease and pathologic upstaging at surgery than patients without LVI. PATIENT SUMMARY: In this report we examined the impact of lymphovascular invasion (LVI) at transurethral resection of bladder tumor on pathologic upstaging and lymph node metastasis at radical cystectomy using the National Cancer Database. We identified LVI as being prognostic at each stage of urothelial carcinoma. CI - Published by Elsevier B.V. FAU - Werntz, Ryan P AU - Werntz RP AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. Electronic address: rywerntz@gmail.com. FAU - Smith, Zachary L AU - Smith ZL AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. FAU - Packiam, Vignesh T AU - Packiam VT AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. FAU - Smith, Norm AU - Smith N AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. FAU - Steinberg, Gary D AU - Steinberg GD AD - Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20181005 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology/*surgery MH - *Cystectomy/methods MH - Humans MH - Lymphatic Metastasis/*pathology MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Risk Assessment MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Vascular Neoplasms/*pathology OTO - NOTNLM OT - Lymphovascular invasion OT - Radical cystectomy OT - TURBT EDAT- 2018/10/10 06:00 MHDA- 2021/05/21 06:00 CRDT- 2018/10/10 06:00 PHST- 2018/07/23 00:00 [received] PHST- 2018/08/25 00:00 [revised] PHST- 2018/09/27 00:00 [accepted] PHST- 2018/10/10 06:00 [pubmed] PHST- 2021/05/21 06:00 [medline] PHST- 2018/10/10 06:00 [entrez] AID - S2405-4569(18)30292-X [pii] AID - 10.1016/j.euf.2018.09.019 [doi] PST - ppublish SO - Eur Urol Focus. 2020 Mar 15;6(2):292-297. doi: 10.1016/j.euf.2018.09.019. Epub 2018 Oct 5. PMID- 30290956 OWN - NLM STAT- MEDLINE DCOM- 20190619 LR - 20221207 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 75 IP - 2 DP - 2019 Feb TI - Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. PG - 231-239 LID - S0302-2838(18)30652-3 [pii] LID - 10.1016/j.eururo.2018.09.002 [doi] AB - BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC). It is unknown whether this treatment strategy is appropriate for patients who progress to MIBC after treatment for prior noninvasive disease (secondary MIBC). OBJECTIVE: To determine whether clinical and genomic differences exist between primary and secondary MIBC treated with NAC and RC. DESIGN, SETTING, AND PARTICIPANTS: Clinicopathologic outcomes were compared between 245 patients with clinical T2-4aN0M0-stage primary MIBC and 43 with secondary MIBC treated with NAC and RC at Memorial Sloan Kettering Cancer Center (MSKCC) from 2001 to 2015. Genomic differences were assessed in a retrospective cohort of 385 prechemotherapy specimens sequenced by whole-exome or targeted exon capture by the Cancer Genome Atlas or at MSKCC. Findings were confirmed in an independent validation cohort of 94 MIBC patients undergoing prospective targeted exon sequencing at MSKCC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response rates, recurrence-free survival (RFS), bladder cancer-specific survival (CSS), and overall survival (OS) were measured. Differences in somatic genomic alteration rates were compared using Fisher's exact test and the Benjamini-Hochberg false discovery rate method. RESULTS AND LIMITATIONS: Patients with secondary MIBC had lower pathologic response rates following NAC than those with primary MIBC (univariable: 26% vs 45%, multivariable: odds ratio=0.4 [95% confidence interval=0.18-0.84] p=0.02) and significantly worse RFS, CSS, and OS. Patients with secondary MIBC treated with NAC had worse CSS compared with cystectomy alone (p=0.002). In a separate genomic analysis, we detected significantly more likely deleterious somatic ERCC2 missense mutations in primary MIBC tumors in both the discovery (10.9% [36/330] vs 1.8% [1/55], p=0.04) and the validation (15.7% [12/70] vs 0% [0/24], p=0.03) cohort. CONCLUSIONS: Patients with secondary MIBC treated with NAC had worse clinical outcomes than similarly treated patients with primary MIBC. ERCC2 mutations predicted to result in increased cisplatin sensitivity were enriched in primary versus secondary MIBC. Prospective validation is still needed, but given the lack of clinical benefit with cisplatin-based NAC in patients with secondary MIBC, upfront RC or enrollment in clinical trials should be considered. PATIENT SUMMARY: A retrospective cohort study of patients with "primary" and "secondary" muscle-invasive bladder cancer (MIBC) treated with chemotherapy before surgical removal of the bladder identified lower response rates and shorter survival in patients with secondary MIBC. Tumor genetic sequencing of separate discovery and validation cohorts revealed that chemotherapy-sensitizing DNA damage repair gene mutations occur predominantly in primary MIBC tumors and may underlie the greater sensitivity of primary MIBC to chemotherapy. Prospective validation is still needed, but patients with secondary MIBC may derive greater benefit from upfront surgery or enrollment in clinical trials rather than from standard chemotherapy. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Pietzak, Eugene J AU - Pietzak EJ AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: pietzake@MSKCC.org. FAU - Zabor, Emily C AU - Zabor EC AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Armenia, Joshua AU - Armenia J AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Hu, Wenhuo AU - Hu W AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Zehir, Ahmet AU - Zehir A AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Funt, Samuel AU - Funt S AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Audenet, Francois AU - Audenet F AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Barron, David AU - Barron D AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Maamouri, Noelia AU - Maamouri N AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Li, Qiang AU - Li Q AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Teo, Min Yuen AU - Teo MY AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Arcila, Maria E AU - Arcila ME AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Berger, Michael F AU - Berger MF AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Schultz, Nikolaus AU - Schultz N AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Dalbagni, Guido AU - Dalbagni G AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Herr, Harry W AU - Herr HW AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bajorin, Dean F AU - Bajorin DF AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Solit, David B AU - Solit DB AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Iyer, Gopa AU - Iyer G AD - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States GR - K12 CA184746/CA/NCI NIH HHS/United States GR - UL1 TR002384/TR/NCATS NIH HHS/United States GR - R01 CA182587/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20181002 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) RN - EC 3.6.4.12 (Xeroderma Pigmentosum Group D Protein) RN - EC 5.99.- (ERCC2 protein, human) RN - Q20Q21Q62J (Cisplatin) SB - IM CIN - Eur Urol. 2019 Feb;75(2):240-241. doi: 10.1016/j.eururo.2018.09.043. PMID: 30366635 CIN - Eur Urol. 2019 Apr;75(4):694. doi: 10.1016/j.eururo.2018.12.019. PMID: 30661731 CIN - J Urol. 2019 Jul;202(1):30. doi: 10.1097/01.JU.0000557728.16853.8f. PMID: 30925134 CIN - Transl Androl Urol. 2019 Jul;8(Suppl 3):S236-S239. doi: 10.21037/tau.2019.01.10. PMID: 31392132 CIN - Transl Cancer Res. 2019 Mar;8(Suppl 2):S176-S179. doi: 10.21037/tcr.2019.01.05. PMID: 35117093 MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Biomarkers, Tumor/*genetics MH - Carcinoma/*drug therapy/genetics/mortality/pathology MH - Chemotherapy, Adjuvant MH - Cisplatin/*administration & dosage/adverse effects MH - Cystectomy MH - Female MH - Genetic Predisposition to Disease MH - Genomics/*methods MH - Humans MH - Male MH - Middle Aged MH - Mutation MH - *Neoadjuvant Therapy/adverse effects MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Phenotype MH - Predictive Value of Tests MH - Progression-Free Survival MH - Prospective Studies MH - Reproducibility of Results MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/genetics/mortality/pathology MH - Exome Sequencing MH - Xeroderma Pigmentosum Group D Protein/genetics PMC - PMC6339572 MID - NIHMS1508722 OTO - NOTNLM OT - Bladder cancer OT - ERCC2 OT - Muscle-invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Non-muscle-invasive bladder cancer OT - Radical cystectomy COIS- Financial disclosures: Eugene J. Pietzak certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Pietzak: Scientific Advisory Board: Merck. Berger: Consultant: Roche; Research Support: Illumina. Funt: Research Support: Genentech, AstraZeneca; Stock ownership: Kite Pharma, Urogen Pharma, Allogene Therapeutics, Kronos Bio. Bajorin: Honoraria from the speaker's bureau of Merck; Consultant/advisory board: Merck, Pfizer, Bristol-Myers Squibb, Urogen, Genentech, Eli Lilly. Rosenberg: Stock and Other Ownership Interests: Merck, Illumina; Honoraria: UpToDate, Bristol-Myers Squibb, AstraZeneca, Medscape, Vindico, Peerview, Chugai Pharma; Consulting or Advisory Role: Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Seattle Genetic, Bayer, Inovio Pharmaceuticals, BioClin Therapeutics, QED Therapeutic, Adicet Bio, Sensei Biotherapeutics; Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity; Research Funding: Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genentech/Roche, Incyte, Seattle Genetics, Bayer; Travel, Accommodations, Expenses: Genentech/Roche, Bristol-Myers Squibb. Bochner: Chair of data safety monitoring committee: Genentech; Course Instructor: Olympus. Al-Ahmadie: Consultant: Bristol-Myers-Squibb, AstraZeneca, EMD Serono. Solit: Consultant for Pfizer, Loxo Oncology and Illumina. Iyer: Consultant: Bayer EDAT- 2018/10/07 06:00 MHDA- 2019/06/20 06:00 PMCR- 2020/02/01 CRDT- 2018/10/07 06:00 PHST- 2018/05/19 00:00 [received] PHST- 2018/09/01 00:00 [accepted] PHST- 2018/10/07 06:00 [pubmed] PHST- 2019/06/20 06:00 [medline] PHST- 2018/10/07 06:00 [entrez] PHST- 2020/02/01 00:00 [pmc-release] AID - S0302-2838(18)30652-3 [pii] AID - 10.1016/j.eururo.2018.09.002 [doi] PST - ppublish SO - Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2. PMID- 30289971 OWN - NLM STAT- MEDLINE DCOM- 20190912 LR - 20240904 IS - 1097-0142 (Electronic) IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 124 IP - 23 DP - 2018 Dec 1 TI - Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions. PG - 4477-4485 LID - 10.1002/cncr.31705 [doi] AB - BACKGROUND: Multiple chronic conditions (MCC) are common among older patients with cancer; however, the exclusion of these patients from clinical trials has resulted in scarce knowledge concerning outcomes, resulting in variations in treatment. Superficial bladder cancer (SBC) disproportionately affects older adults, yet to the authors' knowledge few studies to date have examined whether treatment improves long-term survival. In the current study, the authors evaluated the association between treatment of SBC and 10-year mortality in medically complex older adults. METHODS: The authors identified 1800 older (aged >/=60 years) patients with SBC (American Joint Committee on Cancer stage /=2 baseline chronic conditions). Propensity score analysis using stabilized inverse probability of treatment weights was used to compare 10-year mortality in the 2 treatment groups with adjustment for covariates. RESULTS: Overall, 1485 patients (82.5%) and 315 patients (17.5%) received treatment and observation, respectively. In unweighted multivariable analysis, treatment was associated with a 30% reduction in death (adjusted hazard ratio [HR], 0.70; 95% confidence interval [95% CI], 0.58-0.85 [P<.01]) and MCC with a 72% increase in death (adjusted HR, 1.72; 95% CI, 1.44-2.05 [P<.01]). Weighted analysis with adjustment (doubly robust) also demonstrated a survival benefit for treatment (adjusted HR, 0.66; 95% CI, 0.52-0.84 [P<.01]). CONCLUSIONS: The results of the current study demonstrated a clinically meaningful association between cancer treatment and survival benefit in older, medically complex patients with SBC, even after adjustment for medical complexity. These data provide a foundation for future work aimed at personalizing the treatment guidance of older patients with cancer with MCC. CI - (c) 2018 American Cancer Society. FAU - Garg, Tullika AU - Garg T AUID- ORCID: 0000-0003-2679-7460 AD - Department of Urology, Geisinger, Danville, Pennsylvania. AD - Department of Epidemiology and Health Services Research, Geisinger, Danville, Pennsylvania. FAU - Young, Amanda J AU - Young AJ AD - Biostatistics Core, Geisinger, Danville, Pennsylvania. AD - Biomedical and Translational Informatics Institute, Geisinger, Danville, Pennsylvania. FAU - O'Keeffe-Rosetti, Maureen AU - O'Keeffe-Rosetti M AD - Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. FAU - McMullen, Carmit K AU - McMullen CK AD - Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. AD - Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. AD - Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Kirchner, H Lester AU - Kirchner HL AD - Biostatistics Core, Geisinger, Danville, Pennsylvania. AD - Biomedical and Translational Informatics Institute, Geisinger, Danville, Pennsylvania. FAU - Murphy, Terrence E AU - Murphy TE AD - Section of Geriatrics, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. LA - eng GR - R24 AG045050/AG/NIA NIH HHS/United States GR - P30AG21342/Yale Claude D. Pepper Older Americans Independence Center/International GR - R24AG045050/AG/NIA NIH HHS/United States GR - P30AG021342/Yale Claude D. Pepper Older Americans Independence Center/International GR - R24AG045050/Health Care Systems Research Network (HCSRN)-Older Americans Independence Center (OAICs) AGING Initiative/International GR - R21 CA191610/CA/NCI NIH HHS/United States GR - P30AG21342/AG/NIA NIH HHS/United States GR - P30 AG021342/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20181005 PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Antineoplastic Agents) SB - IM CIN - Cancer. 2019 Feb 15;125(4):652. doi: 10.1002/cncr.31888. PMID: 30516824 CIN - Cancer. 2019 Feb 15;125(4):652-653. doi: 10.1002/cncr.31894. PMID: 30516841 CIN - J Urol. 2020 Aug;204(2):384-385. doi: 10.1097/JU.0000000000001114.01. PMID: 32396439 MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage/therapeutic use MH - Comorbidity MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiple Chronic Conditions/*epidemiology MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*therapy MH - Urologic Surgical Procedures/*methods PMC - PMC9455691 MID - NIHMS1825175 OTO - NOTNLM OT - bladder cancer OT - geriatric oncology OT - geriatrics OT - multiple chronic conditions COIS- CONFLICT OF INTEREST DISCLOSURES Tullika Garg, Amanda J. Young, and Terrence E. Murphy report grant support from the National Institute on Aging for work performed as part of the current study. Matthew E. Nielsen has acted as a paid consultant for the High Value Care Task Force for the American College of Physicians; received grants from the Agency for Healthcare Research and Quality, the National Institutes of Health, and the Patient-Centered Outcomes Research Institute; and acted as a paid member of the medical advisory board for Grand Rounds for work performed outside of the current study. EDAT- 2018/10/06 06:00 MHDA- 2019/09/13 06:00 PMCR- 2022/09/08 CRDT- 2018/10/06 06:00 PHST- 2018/04/24 00:00 [received] PHST- 2018/06/11 00:00 [revised] PHST- 2018/07/09 00:00 [accepted] PHST- 2018/10/06 06:00 [pubmed] PHST- 2019/09/13 06:00 [medline] PHST- 2018/10/06 06:00 [entrez] PHST- 2022/09/08 00:00 [pmc-release] AID - 10.1002/cncr.31705 [doi] PST - ppublish SO - Cancer. 2018 Dec 1;124(23):4477-4485. doi: 10.1002/cncr.31705. Epub 2018 Oct 5. PMID- 30288389 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220321 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 10 DP - 2018 TI - Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy. PG - 103-111 LID - 10.2147/RRU.S166497 [doi] AB - BACKGROUND: The clinical use of macrophage colony-stimulating factor, granulocyte colony-stimulating factor (G-CSF), and granulocyte macrophage colony-stimulating factor (GM-CSF) has improved the safety of cytotoxic chemotherapy. However, the overexpression of these CSFs in cancers has been reported to be associated with a poor prognosis in various malignancies. We evaluated the potential of CSF expression as a predictor of clinical outcome in patients with muscle-invasive bladder cancer (MIBC). METHODS: Consecutive patients (n=58) with MIBC who underwent radical cystectomy (RC) were included in this retrospective study. Treatment-naive tumor specimens obtained by initial transurethral resection of bladder tumors prior to RC were immunostained with antibodies against macrophage colony-stimulating factor, G-CSF, and GM-CSF. We compared the clinicopathological variables and survival between these groups. Baseline levels of CSFs in the serum and voided urine were quantified using an enzyme-linked immunosorbent assay and compared with the expression of CSFs in the tumor lesions. RESULTS: Low expression of GM-CSF in the tumor cells was significantly correlated with a pathological T4 category (vs T2-3; P=0.02). In univariate survival analysis, high G-CSF and low GM-CSF expression in the tumor lesion were associated with poor outcomes. Furthermore, Cox proportional regression analysis revealed that high G-CSF and low GM-CSF expression in the tumor were independent predictors of shorter recurrence-free survival, cancer-specific survival, and overall survival. The levels of CSFs in voided urine were associated with the expression of CSFs in the tumor lesions. CONCLUSION: GM-CSF and G-CSF expression in the tumor lesions obtained by initial transurethral resection are independent predictors of poor outcome in MIBC after RC. Levels of G-CSF and GM-CSF in urine before treatment could be useful in prognostication. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. FAU - Fujii, Tomomi AU - Fujii T AD - Department of Diagnostic Pathology, Nara Medical University, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Nara, Japan, kiyokun@naramed-u.ac.jp. LA - eng PT - Journal Article DEP - 20180921 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC6159788 OTO - NOTNLM OT - G-CSF OT - GM-CSF OT - M-CSF OT - colony-stimulating factor OT - muscle-invasive bladder cancer OT - radical cystectomy COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/10/06 06:00 MHDA- 2018/10/06 06:01 PMCR- 2018/09/21 CRDT- 2018/10/06 06:00 PHST- 2018/10/06 06:00 [entrez] PHST- 2018/10/06 06:00 [pubmed] PHST- 2018/10/06 06:01 [medline] PHST- 2018/09/21 00:00 [pmc-release] AID - rru-10-103 [pii] AID - 10.2147/RRU.S166497 [doi] PST - epublish SO - Res Rep Urol. 2018 Sep 21;10:103-111. doi: 10.2147/RRU.S166497. eCollection 2018. PMID- 30286596 OWN - NLM STAT- MEDLINE DCOM- 20190128 LR - 20190128 IS - 2233-4521 (Electronic) IS - 1975-8375 (Print) IS - 1975-8375 (Linking) VI - 51 IP - 5 DP - 2018 Sep TI - Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States. PG - 242-247 LID - 10.3961/jpmph.18.092 [doi] AB - OBJECTIVES: To examine survivorship disparities in demographic factors and risk status for non-muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. METHODS: We used the US National Cancer Institute's Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan-Meier (K-M) and Cox proportional hazard methods for survival analysis. RESULTS: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. CONCLUSIONS: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients. FAU - Seo, Munseok AU - Seo M AD - School of Biomedical Informatics, University of Texas Health Science Center, Houston, TX, USA. FAU - Langabeer Ii, James R AU - Langabeer Ii JR AD - School of Public Health, University of Texas Health Science Center, Houston, TX, USA. LA - eng PT - Journal Article DEP - 20180823 PL - Korea (South) TA - J Prev Med Public Health JT - Journal of preventive medicine and public health = Yebang Uihakhoe chi JID - 101242972 SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Risk Factors MH - SEER Program MH - Sex Factors MH - *Socioeconomic Factors MH - Survival Analysis MH - Tumor Burden MH - United States/epidemiology MH - Urinary Bladder Neoplasms/ethnology/*mortality/pathology PMC - PMC6182276 OTO - NOTNLM OT - Aged OT - Survival analysis OT - Urinary bladder neoplasms OT - Risk COIS- CONFLICT OF INTEREST The authors have no conflicts of interest associated with the material presented in this paper. EDAT- 2018/10/06 06:00 MHDA- 2019/01/29 06:00 PMCR- 2018/09/01 CRDT- 2018/10/06 06:00 PHST- 2018/04/18 00:00 [received] PHST- 2018/08/10 00:00 [accepted] PHST- 2018/10/06 06:00 [entrez] PHST- 2018/10/06 06:00 [pubmed] PHST- 2019/01/29 06:00 [medline] PHST- 2018/09/01 00:00 [pmc-release] AID - jpmph.18.092 [pii] AID - jpmph-51-5-242 [pii] AID - 10.3961/jpmph.18.092 [doi] PST - ppublish SO - J Prev Med Public Health. 2018 Sep;51(5):242-247. doi: 10.3961/jpmph.18.092. Epub 2018 Aug 23. PMID- 30286252 OWN - NLM STAT- MEDLINE DCOM- 20190508 LR - 20190508 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 74 IP - 3 DP - 2019 Feb TI - Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma. PG - 483-493 LID - 10.1111/his.13763 [doi] AB - AIMS: Immunohistochemical (IHC) staining for cytokeratin (CK) 5/6, CD44 and CK20 has been significantly associated with the prognosis of urinary bladder urothelial carcinoma, and probably reflects its molecular characteristics. We aimed to investigate the IHC-based subgroups and their prognostic effects on non-muscle-invasive papillary upper tract urothelial carcinoma (UTUC). METHODS AND RESULTS: IHC staining for CK5/6, CK20 and CD44 was analysed in 211 patients with non-muscle-invasive papillary UTUC. Staining was classified as showing a negative, positive or normal pattern. We found that CK5/6-negative, CD44-negative and CK20-positive tumours were distinctly high-risk subgroups that were associated with high grade (CK5/6-negative, P < 0.001; CD44-negative, P < 0.001; CK20-positive, P = 0.017) and frequent intravesical recurrence (CK5/6-negative, P = 0.002). Using survival analysis with Kaplan-Meier and log-rank tests, we found that these IHC subgroups were correlated with poor progression-free (CK5/6-negative, P = 0.001; CD44-negative, P = 0.009; CK20-positive, P = 0.031) and cancer-specific (CK5/6-negative, P = 0.009) survival. Furthermore, CK5/6 negativity was an independent prognostic factor for shorter progression-free (P = 0.009) and cancer-specific (P = 0.045) survival. CK5/6 improved Harrell's C-indices for progression-free (0.68-0.77, P = 0.029) and cancer-specific (0.59-0.77, P < 0.001) survival. When markers were combined, luminal-like subtypes showed poor prognoses. CONCLUSIONS: We demonstrated that IHC staining for CK5/6, CD44 and CK20 was significantly associated with the clinicopathological characteristics and prognoses of patients with non-muscle-invasive papillary UTUC. The IHC subgroups may be correlated with the molecular characteristics of non-muscle-invasive papillary UTUC. CI - (c) 2018 John Wiley & Sons Ltd. FAU - Jung, Minsun AU - Jung M AUID- ORCID: 0000-0002-8701-4282 AD - Department of Pathology, Medical Research Centre, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Bohyun AU - Kim B AD - Department of Pathology, Medical Research Centre, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Moon, Kyung Chul AU - Moon KC AUID- ORCID: 0000-0002-1969-8360 AD - Department of Pathology, Medical Research Centre, Seoul National University College of Medicine, Seoul, Republic of Korea. AD - Kidney Research Institute, Medical Research Centre, Seoul National University College of Medicine, Seoul, Republic of Korea. LA - eng GR - 2016R1D1A1A02937001/National Research Foundation of Korea (NRF)/ PT - Journal Article DEP - 20181202 PL - England TA - Histopathology JT - Histopathology JID - 7704136 RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (KRT20 protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (Keratin-6) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Papillary/mortality/*pathology MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Female MH - Humans MH - Hyaluronan Receptors/analysis/biosynthesis MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Keratin-20/analysis/biosynthesis MH - Keratin-5/analysis/biosynthesis MH - Keratin-6/analysis/biosynthesis MH - Male MH - Middle Aged MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Urologic Neoplasms/mortality/*pathology OTO - NOTNLM OT - CD44 OT - carcinoma OT - cytokeratin 20 OT - cytokeratin 5/6 OT - immunohistochemistry OT - papillary OT - prognosis OT - transitional cell OT - upper tract urothelial carcinoma EDAT- 2018/10/05 06:00 MHDA- 2019/05/09 06:00 CRDT- 2018/10/05 06:00 PHST- 2018/06/26 00:00 [received] PHST- 2018/09/29 00:00 [accepted] PHST- 2018/10/05 06:00 [pubmed] PHST- 2019/05/09 06:00 [medline] PHST- 2018/10/05 06:00 [entrez] AID - 10.1111/his.13763 [doi] PST - ppublish SO - Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2. PMID- 30285788 OWN - NLM STAT- MEDLINE DCOM- 20181127 LR - 20230928 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 16 IP - 1 DP - 2018 Oct 2 TI - Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. PG - 197 LID - 10.1186/s12957-018-1497-0 [doi] LID - 197 AB - BACKGROUND: High-grade non-muscle-invasive bladder cancer is superficial; nonetheless, it is an aggressive cancer. Proper management strategy selection following transurethral resection between bladder preservation (BP) and radical cystectomy (RC) could result in delayed or excessive treatment. Hence, selecting the optimal treatment modality remains controversial to date. METHODS: We searched MEDLINE, The Cochrane Library, EMBASE, China National Knowledge Infrastructure, and Wanfang database through 12 April 2018. Quality and publication bias were assessed using the Newcastle-Ottawa Scale and Begg's/Egger's test. We collected 2-year, 5-year, 10-year, and 15-year survival rate and hazard ratio (HR) for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). Using the Review Manager 5.2 software, we used the odds ratio (OR) of specific years and HR for meta-analysis. Subgroup analysis was performed by the original tumor state, radical cystectomy timing, bladder preservation modality, and age. RESULTS: In total, 11 cohorts with 1735 patients were selected for the meta-analysis. All OR of OS supported BP as a better treatment option; however, all OR of PFS had no significant differences. As for CSS, only the 15-year OR reflected a statistical significance preferring RC. Subgroup analysis showed that BP is more appropriate for patients older than 65 and G3 tumor. Limited data demonstrated that late RC (> 3 months) is more effective compared to early RC (< 3 months) and intravesical Bacillus Calmette-Guerin was not statistically different from that of RC. The mixed BP modalities were significantly better compared to RC in OS and worse in CSS, with both having a very low evidence strength. CONCLUSIONS: BP is a superior treatment modality compare to RC, especially for older patients and T1G3 or lower grade tumors. However, the superior BP modality was unclear. Conversely, RC could be a better option for younger patients. More specifically, late RC may be more beneficial but had a very-low-level of evidence. Quality of life should be considered equal to survival outcome; hence, post-treatment follow-up needs to be performed. Prospective randomized studies should be performed to overcome the limitations of this meta-analysis study. REGISTRATION: Registration ID is CRD42018093491 . FAU - Shen, Pei-Lin AU - Shen PL AD - Department of Urology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Jinping District, Shantou, Guangdong, China. AD - Shantou University Medical College, No. 22, Xinling Road, Jinping District, Shantou, Guangdong, China. FAU - Lin, Ming-En AU - Lin ME AD - Department of Urology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Jinping District, Shantou, Guangdong, China. FAU - Hong, Ying-Kai AU - Hong YK AD - Department of Urology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Jinping District, Shantou, Guangdong, China. FAU - He, Xue-Jun AU - He XJ AUID- ORCID: 0000-0003-4052-6827 AD - Department of Urology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Jinping District, Shantou, Guangdong, China. sdfyurology@126.com. LA - eng GR - A2018103/Guangdong Medical Research foundation/ GR - 2017026/Shantou Science and Technology Fund/ GR - No. 2015A030310078/Guangdong Natural Science Fund Project/ PT - Comparative Study PT - Journal Article PT - Meta-Analysis DEP - 20181002 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Cystectomy/*methods MH - Humans MH - Organ Sparing Treatments/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery PMC - PMC6169022 OTO - NOTNLM OT - Bladder preservation OT - High-grade non-muscle-invasive bladder cancer OT - Meta-analysis OT - Radical cystectomy COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/10/05 06:00 MHDA- 2018/11/28 06:00 PMCR- 2018/10/02 CRDT- 2018/10/05 06:00 PHST- 2018/07/13 00:00 [received] PHST- 2018/09/20 00:00 [accepted] PHST- 2018/10/05 06:00 [entrez] PHST- 2018/10/05 06:00 [pubmed] PHST- 2018/11/28 06:00 [medline] PHST- 2018/10/02 00:00 [pmc-release] AID - 10.1186/s12957-018-1497-0 [pii] AID - 1497 [pii] AID - 10.1186/s12957-018-1497-0 [doi] PST - epublish SO - World J Surg Oncol. 2018 Oct 2;16(1):197. doi: 10.1186/s12957-018-1497-0. PMID- 30281356 OWN - NLM STAT- MEDLINE DCOM- 20190918 LR - 20190918 IS - 0966-0461 (Print) IS - 0966-0461 (Linking) VI - 27 IP - 18 DP - 2018 Oct 4 TI - Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer. PG - S8-S20 LID - 10.12968/bjon.2018.27.18.S8 [doi] AB - This is Part 2 of an article on bladder cancer: an overview of disease and its management. Part 1 provided an overview of non-muscle-invasive bladder cancer, how the disease presents, is diagnosed and subsequently treated ( Anderson, 2018 ). Part 2 provides an overview of muscle-invasive and metastatic bladder cancer and outlines treatment options currently available to manage the relevant stages of the disease. The management of muscle-invasive cancers comprise surgical intervention with transurethral resections, cystectomy (removal of the bladder), and systemic chemotherapy and radiotherapy (multi-modality treatment). For locally advanced and metastatic disease, systemic chemotherapy and radiotherapy are offered, but only as a palliative measure. The intent of treatments for muscle-invasive disease is curative. For metastatic disease, the intent is disease control, extending life, managing symptoms and improving quality-of-life outcomes. This article will include the treatments for the relevant stage of muscle-invasive and metastatic bladder cancer and highlight the respective risks and benefits. The risk factors for bladder cancer, such as smoking, and risks associated with relevant treatments are discussed. The role of the multidisciplinary team is underlined in the management of bladder cancer, specifically the role of the uro-oncology cancer nurse specialist in the provision of reassurance and support to patients. FAU - Anderson, Beverley AU - Anderson B AD - Macmillan Uro-oncology Clinical Nurse Specialist, Epsom and St Helier University Hospitals NHS Trust. LA - eng PT - Journal Article PL - England TA - Br J Nurs JT - British journal of nursing (Mark Allen Publishing) JID - 9212059 MH - Humans MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Risk Factors MH - Urinary Bladder Neoplasms/*diagnosis/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Muscle-invasive and metastatic bladder cancer OT - Radical cystectomy OT - Radiotherapy OT - Risk factors OT - Transurethral resection OT - Uro-oncology clinical nurse specialist EDAT- 2018/10/04 06:00 MHDA- 2019/09/19 06:00 CRDT- 2018/10/04 06:00 PHST- 2018/10/04 06:00 [entrez] PHST- 2018/10/04 06:00 [pubmed] PHST- 2019/09/19 06:00 [medline] AID - 10.12968/bjon.2018.27.18.S8 [doi] PST - ppublish SO - Br J Nurs. 2018 Oct 4;27(18):S8-S20. doi: 10.12968/bjon.2018.27.18.S8. PMID- 30279015 OWN - NLM STAT- MEDLINE DCOM- 20190812 LR - 20250530 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 75 IP - 4 DP - 2019 Apr TI - BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). PG - 593-601 LID - S0302-2838(18)30683-3 [pii] LID - 10.1016/j.eururo.2018.09.020 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment. DESIGN, SETTING, AND PARTICIPANTS: BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III, randomised controlled trial. Patients aged >/=18 yr with intermediate- or high-risk NMIBC were accrued across 51 UK centres between 1 November 2007 and 23 July 2012. INTERVENTION: Patients were randomised (1:1) to celecoxib 200mg twice daily or placebo for 2 yr. Patients with intermediate-risk NMIBC were recommended to receive six weekly mitomycin C instillations; high-risk NMIBC cases received six weekly bacillus Calmette-Guerin and maintenance therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was time to disease recurrence. Analysis was by intention to treat. RESULTS AND LIMITATIONS: A total of 472 patients were randomised (236:236). With median follow-up of 44 mo (interquartile range: 36-57), 3-yr recurrence-free rate (95% confidence interval) was as follows: celecoxib 68% (61-74%) versus placebo 64% (57-70%; hazard ratio [HR] 0.82 [0.60-1.12], p=0.2). There was no difference in high-risk (HR 0.77 [0.52-1.15], p=0.2) or intermediate-risk (HR 0.90 [0.55-1.48], p=0.7) NMIBC. Subgroup analysis suggested that time to recurrence was longer in pT1 NMIBC patients treated with celecoxib compared with those receiving placebo (HR 0.53 [0.30-0.94], interaction test p=0.04). The 3-yr progression rates in high-risk patients were low: 10% (6.5-17%) and 9.7% (6.0-15%) in celecoxib and placebo arms, respectively. Incidence of serious cardiovascular events was higher in celecoxib (5.2%) than in placebo (1.7%) group (difference +3.4% [-0.3% to 7.2%], p=0.07). CONCLUSIONS: BOXIT did not show that celecoxib reduces the risk of recurrence in intermediate- or high-risk NMIBC, although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib. PATIENT SUMMARY: Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kelly, John D AU - Kelly JD AD - University College London, London, UK. Electronic address: j.d.kelly@ucl.ac.uk. FAU - Tan, Wei Shen AU - Tan WS AD - University College London, London, UK. FAU - Porta, Nuria AU - Porta N AD - The Institute of Cancer Research, London, UK. FAU - Mostafid, Hugh AU - Mostafid H AD - Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. FAU - Huddart, Robert AU - Huddart R AD - The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. FAU - Protheroe, Andrew AU - Protheroe A AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Bogle, Richard AU - Bogle R AD - Epsom and St Helier University Hospitals NHS Trust, Carshalton, UK. FAU - Blazeby, Jane AU - Blazeby J AD - University of Bristol, Bristol, UK. FAU - Palmer, Alison AU - Palmer A AD - Royal Free London NHS Foundation Trust, London, UK. FAU - Cresswell, Jo AU - Cresswell J AD - South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK. FAU - Johnson, Mark AU - Johnson M AD - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Brough, Richard AU - Brough R AD - Stockport NHS Foundation Trust, Stockport, UK. FAU - Madaan, Sanjeev AU - Madaan S AD - Dartford and Gravesham NHS Trust, Dartford, UK. FAU - Andrews, Stephen AU - Andrews S AD - Dorset County Hospital NHS Foundation Trust, Dorchester, UK. FAU - Cruickshank, Clare AU - Cruickshank C AD - The Institute of Cancer Research, London, UK. FAU - Burnett, Stephanie AU - Burnett S AD - The Institute of Cancer Research, London, UK. FAU - Maynard, Lauren AU - Maynard L AD - The Institute of Cancer Research, London, UK. FAU - Hall, Emma AU - Hall E AD - The Institute of Cancer Research, London, UK. CN - BOXIT Investigators LA - eng SI - ISRCTN/ISRCTN84681538 GR - 25351/CRUK_/Cancer Research UK/United Kingdom GR - 5669/CRUK_/Cancer Research UK/United Kingdom GR - CRUK/07/004/CRUK_/Cancer Research UK/United Kingdom PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20180929 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 50SG953SK6 (Mitomycin) RN - JCX84Q7J1L (Celecoxib) CIN - Eur Urol. 2019 Apr;75(4):602-603. doi: 10.1016/j.eururo.2018.10.008. PMID: 30337058 MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - BCG Vaccine/*administration & dosage/adverse effects MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Cardiovascular Diseases/chemically induced MH - Celecoxib/*administration & dosage/adverse effects MH - Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects MH - Disease Progression MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage/adverse effects MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Quality of Life MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - United Kingdom MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Bladder cancer OT - Cardiovascular events OT - Chemoprevention OT - Cyclo-oxygenase 2 inhibitor OT - Randomised trial EDAT- 2018/10/04 06:00 MHDA- 2019/08/14 06:00 CRDT- 2018/10/04 06:00 PHST- 2018/05/31 00:00 [received] PHST- 2018/09/11 00:00 [accepted] PHST- 2018/10/04 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2018/10/04 06:00 [entrez] AID - S0302-2838(18)30683-3 [pii] AID - 10.1016/j.eururo.2018.09.020 [doi] PST - ppublish SO - Eur Urol. 2019 Apr;75(4):593-601. doi: 10.1016/j.eururo.2018.09.020. Epub 2018 Sep 29. PMID- 30275804 OWN - NLM STAT- MEDLINE DCOM- 20190311 LR - 20220321 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 33 IP - 40 DP - 2018 Oct 1 TI - Clinicopathological Characteristics of Urinary Bladder Tumors in Korean Patients 20 Years or Younger. PG - e242 LID - 10.3346/jkms.2018.33.e242 [doi] LID - e242 AB - BACKGROUND: To investigate the clinicopathological characteristics of urinary bladder tumors, a rare malignancy, in patients 20 years or younger. METHODS: Using a retrospective chart review among patients who received bladder surgery at 2 institutions between July 1996 and January 2013, we analyzed the clinicopathological characteristics of urinary bladder tumors in 21 pediatric patients (male:female = 4.25:1.00; mean age, 12.1 years). RESULTS: Pathology revealed 9 urothelial tumors, 6 rhabdomyosarcomas, 1 low-grade leiomyosarcoma, 1 large cell neuroendocrine carcinoma, 1 inflammatory myofibroblastic tumor, and 3 cases of chronic inflammation without tumors (including 1 xanthogranulomatous inflammation). Urothelial tumors (mean patient age, 16.0 years) were benign or low-grade; and only transurethral resection of the bladder tumor was necessary for treatment. Patients with rhabdomyosarcomas (mean age, 5 years) underwent radiotherapy (if unresectable) or transurethral resection of the bladder tumor (if resectable), after chemotherapy. Of these patients, 2 underwent radical cystectomy, with the remaining patients not receiving a cystectomy. With the exception of one patient, all patients are currently alive and recurrence-free. CONCLUSION: Urothelial tumors were the most commonly found pediatric bladder tumor, with embryonal rhabdomyosarcoma being the second most common. Urothelial tumors are common in relatively older age. Since urothelial tumors in children typically have a good prognosis and rarely recur, transurethral resection of the bladder tumor is the treatment of choice. Rhabdomyosarcomas are common in younger patients. Since rhabdomyosarcoma is generally chemosensitive, chemotherapy and radiotherapy are the treatment of choice for bladder preservation in these patients. FAU - Kim, Seong Cheol AU - Kim SC AUID- ORCID: 0000-0003-0228-0037 AD - Department of Urology, Inje University, Haeundae Paik Hospital, Busan, Korea. FAU - Park, Sejun AU - Park S AUID- ORCID: 0000-0002-7647-4355 AD - Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. FAU - Song, Sang Hoon AU - Song SH AUID- ORCID: 0000-0003-4888-483X AD - Department of Urology, Asan Medical Center, University of Ulsan Collage of Medicine, Seoul, Korea. FAU - Kim, Kun Suk AU - Kim KS AUID- ORCID: 0000-0001-8982-6922 AD - Department of Urology, Asan Medical Center, University of Ulsan Collage of Medicine, Seoul, Korea. FAU - Park, Sungchan AU - Park S AUID- ORCID: 0000-0002-2337-983X AD - Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. LA - eng PT - Journal Article DEP - 20180813 PL - Korea (South) TA - J Korean Med Sci JT - Journal of Korean medical science JID - 8703518 SB - IM MH - Carcinoma, Transitional Cell MH - Child MH - Child, Preschool MH - Cystectomy MH - Female MH - Humans MH - Infant MH - Male MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Urinary Bladder Neoplasms MH - Young Adult PMC - PMC6159107 OTO - NOTNLM OT - Cystectomy OT - Pathology OT - Pediatric Patients OT - Surgery OT - Urinary Bladder Tumor COIS- Disclosure: The authors have no potential conflicts of interest to disclose. EDAT- 2018/10/03 06:00 MHDA- 2019/03/12 06:00 PMCR- 2018/10/01 CRDT- 2018/10/03 06:00 PHST- 2018/04/19 00:00 [received] PHST- 2018/06/20 00:00 [accepted] PHST- 2018/10/03 06:00 [entrez] PHST- 2018/10/03 06:00 [pubmed] PHST- 2019/03/12 06:00 [medline] PHST- 2018/10/01 00:00 [pmc-release] AID - 10.3346/jkms.2018.33.e242 [doi] PST - epublish SO - J Korean Med Sci. 2018 Aug 13;33(40):e242. doi: 10.3346/jkms.2018.33.e242. eCollection 2018 Oct 1. PMID- 30274699 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20250530 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 75 IP - 1 DP - 2019 Jan TI - Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. PG - 63-71 LID - S0302-2838(18)30655-9 [pii] LID - 10.1016/j.eururo.2018.09.005 [doi] AB - BACKGROUND: There is no effective intravesical second-line therapy for non-muscle-invasive bladder cancer (NMIBC) when bacillus Calmette-Guerin (BCG) fails. OBJECTIVE: To compare disease-free survival time (DFS) between radiofrequency-induced thermo-chemotherapy effect (RITE) and institutional standard second-line therapy (control) in NMIBC patients with recurrence following induction/maintenance BCG. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, phase III randomised controlled trial accrued across 14 centres between May 2010 and July 2013 (HYMN [ClinicalTrials.gov: NCT01094964]). INTERVENTION: Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42+/-2 degrees C) or control following stratification for carcinoma in situ (CIS) status (present/absent), therapy history (failure of previous induction/maintenance BCG), and treatment centre. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome measures were DFS and complete response (CR) at 3 mo for the CIS at randomisation subgroup. Analysis was based on intention-to-treat. RESULTS AND LIMITATIONS: A total of 104 patients were randomised (48 RITE: 56 control). Median follow-up for the 31 patients without a DFS event was 36 mo. There was no significant difference in DFS between treatment arms (hazard ratio [HR] 1.33, 95% confidence interval [CI] 0.84-2.10, p=0.23) or in 3-mo CR rate in CIS patients (n=71; RITE: 30% vs control: 47%, p=0.15). There was no significant difference in DFS between treatment arms in non-CIS patients (n=33; RITE: 53% vs control: 24% at 24 mo, HR 0.50, 95% CI 0.22-1.17, p=0.11). DFS was significantly lower in RITE than in control in CIS with/without papillary patients (n=71; HR 2.06, 95% CI 1.17-3.62, p=0.01; treatment-subgroup interaction p=0.007). Disease progression was observed in four patients in each treatment arm. Adverse events and health-related quality of life between treatment arms were comparable. CONCLUSIONS: DFS was similar between RITE and control. RITE may be a second-line therapy for non-CIS recurrence following BCG failure; however, confirmatory trials are needed. RITE patients with CIS with/without papillary had lower DFS than control. HYMN highlights the importance of the control arm when evaluating novel therapies. PATIENT SUMMARY: This study did not show a difference in bladder cancer outcomes between microwave-heated chemotherapy and standard of care treatment. Papillary bladder lesions may benefit from microwave-heated chemotherapy treatment; however, more research is needed. Both treatments are similarly well tolerated. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tan, Wei Shen AU - Tan WS AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital, London, UK. FAU - Panchal, Anesh AU - Panchal A AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Buckley, Laura AU - Buckley L AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Devall, Adam J AU - Devall AJ AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Loubiere, Laurence S AU - Loubiere LS AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Pope, Ann M AU - Pope AM AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Feneley, Mark R AU - Feneley MR AD - Department of Urology, University College London Hospital, London, UK. FAU - Cresswell, Jo AU - Cresswell J AD - Department of Urology, James Cook University Hospital, Middlesbrough, UK. FAU - Issa, Rami AU - Issa R AD - Department of Urology, St George's Hospital, London, UK. FAU - Mostafid, Hugh AU - Mostafid H AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - Madaan, Sanjeev AU - Madaan S AD - Department of Urology, Darent Valley Hospital, Dartford, UK. FAU - Bhatt, Rupesh AU - Bhatt R AD - Department of Urology, Queen Elizabeth Hospital, Birmingham, UK. FAU - McGrath, John AU - McGrath J AD - Department of Urology, Royal Devon and Exeter Hospital, Exeter, UK. FAU - Sangar, Vijay AU - Sangar V AD - Department of Urology, Withington Hospital, Manchester, UK. FAU - Griffiths, T R Leyshon AU - Griffiths TRL AD - Department of Urology, Leicester General Hospital, Leicester, UK. FAU - Page, Toby AU - Page T AD - Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK. FAU - Hodgson, Dominic AU - Hodgson D AD - Department of Urology, Queen Alexandra Hospital, Portsmouth, UK. FAU - Datta, Shibendra N AU - Datta SN AD - Department of Urology, University Hospital of Wales, Cardiff, UK. FAU - Billingham, Lucinda J AU - Billingham LJ AD - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK. FAU - Kelly, John D AU - Kelly JD AD - Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital, London, UK. Electronic address: j.d.kelly@ucl.ac.uk. LA - eng SI - ClinicalTrials.gov/NCT01094964 GR - 10008/CRUK_/Cancer Research UK/United Kingdom GR - CRUK/09/012/CRUK_/Cancer Research UK/United Kingdom PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20180928 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Eur Urol. 2019 Jan;75(1):72-73. doi: 10.1016/j.eururo.2018.09.039. PMID: 30293903 CIN - Eur Urol. 2019 May;75(5):879-880. doi: 10.1016/j.eururo.2019.01.030. PMID: 30712968 CIN - J Urol. 2020 Mar;203(3):461-462. doi: 10.1097/JU.0000000000000676. PMID: 31793827 MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/pathology/therapy MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mitomycin/*therapeutic use MH - Neoplasm Recurrence, Local/*therapy MH - *Radiofrequency Therapy MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - BCG failure OT - Bladder cancer OT - Chemotherapy OT - Device-assisted therapy OT - Hyperthermia OT - Mitomycin-C OT - Radiofrequency OT - Randomised controlled trial OT - Thermotherapy EDAT- 2018/10/03 06:00 MHDA- 2019/06/07 06:00 CRDT- 2018/10/03 06:00 PHST- 2018/05/10 00:00 [received] PHST- 2018/09/04 00:00 [accepted] PHST- 2018/10/03 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2018/10/03 06:00 [entrez] AID - S0302-2838(18)30655-9 [pii] AID - 10.1016/j.eururo.2018.09.005 [doi] PST - ppublish SO - Eur Urol. 2019 Jan;75(1):63-71. doi: 10.1016/j.eururo.2018.09.005. Epub 2018 Sep 28. PMID- 30271788 OWN - NLM STAT- MEDLINE DCOM- 20190107 LR - 20220321 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2018 DP - 2018 TI - Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group. PG - 9432606 LID - 10.1155/2018/9432606 [doi] LID - 9432606 AB - OBJECTIVE: Although transurethral resection of bladder tumor (TURBT) is a standard treatment and determines staging for nonmuscle invasive bladder cancer, many deficiencies persist. There is a risk of upstaging and residual cancer when repeat TURBT is performed. Authors compared the results of repeat TURBT by institution performing the initial TURBT. METHODS: We retrospectively reviewed the medical records of 289 patients who underwent repeat TURBT within 2-6 weeks after initial TURBT between 1998 and 2013. The patients were divided into the referred group and the nonreferred group by institution performing the initial TURBT. And we analyzed the intergroup differences in residual tumor and upstaging rate and the factors significantly correlated with residual tumor. RESULTS: The mean age was 69.6 +/- 11.1 years and the mean follow-up was 49.7 (range: 0-191) months. The referred group included 69 patients, while the nonreferred group included 220 patients. The referred group included 57 (82.6%) patients with residual tumor after repeat TURBT. Overall upstaging occurred in 15 (21.7%), and upstaging to T2 occurred in 11 (15.9%) of the initial Ta and T1 patients. In the nonreferred group, there were 123 (55.9%) patients with residual tumor. Overall upstaging occurred in 10 (4.5%) and upstaging to T2 occurred in 7 (3.2%) patients. CONCLUSIONS: Gross hematuria, grade, and tumor quantity and size were significantly associated with residual cancer on multivariate analysis. In the referred group, repeat TURBT and restaging are necessary. FAU - Yuk, Hyeong Dong AU - Yuk HD AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Jung Kwon AU - Kim JK AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Ku, Ja Hyeon AU - Ku JH AUID- ORCID: 0000-0002-0391-2342 AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20180906 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 SB - IM MH - Aged MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm, Residual MH - *Referral and Consultation MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery MH - *Urologic Surgical Procedures PMC - PMC6146742 EDAT- 2018/10/03 06:00 MHDA- 2019/01/08 06:00 PMCR- 2018/09/06 CRDT- 2018/10/02 06:00 PHST- 2018/04/08 00:00 [received] PHST- 2018/08/06 00:00 [revised] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/10/02 06:00 [entrez] PHST- 2018/10/03 06:00 [pubmed] PHST- 2019/01/08 06:00 [medline] PHST- 2018/09/06 00:00 [pmc-release] AID - 10.1155/2018/9432606 [doi] PST - epublish SO - Biomed Res Int. 2018 Sep 6;2018:9432606. doi: 10.1155/2018/9432606. eCollection 2018. PMID- 32721083 OWN - NLM STAT- MEDLINE DCOM- 20210913 LR - 20210913 IS - 2573-8348 (Electronic) IS - 2573-8348 (Linking) VI - 1 IP - 3 DP - 2018 Oct TI - Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients. PG - e1130 LID - 10.1002/cnr2.1130 [doi] LID - e1130 AB - BACKGROUND: Molecular alteration of FGFR3 gene is the most common genetic event currently known in bladder cancer. Notably, FGFR3 mutation has emerged as a promising molecular biomarker for recurrence, prognosis, and therapeutic target in bladder cancer. AIM: The present study explored the frequency and distribution pattern of FGFR3 mutation in 100 Indian bladder cancer patients. METHODS AND RESULTS: Exons 7, 10, and 15 were subjected to nested PCR followed by bidirectional sequencing of the PCR products. Overall, FGFR3 gene mutations were identified in 19 bladder cancer patients (19%, 19 of 100). Most of the mutations were noted in exon 7 (15%), followed by exon 10 (4%). All mutations detected were missense in nature affecting amino acids at codons 248, 249, and 373. The S249C mutations were the most recurrent mutation seen in exon 7, while Y373C was commonly observed in exon 10. In contrast to exons 7 and 10, no mutations were seen in exon 15 in this study. Females and older age patients tend to show increased frequency of FGFR3 mutations. Furthermore, FGFR3 mutations were more common in low pathological stage (6/20 pTa and 13/71 pT1) and low-grade tumors (13/46). This predominance in low-grade tumors were significantly high in comparison to high-grade tumor (P = .04). Likewise, FGFR3 mutations were significantly higher in well-differentiated tumors (32.6%, 14/43) in comparison to moderately differentiated tumors (11.3%, 5/44), and poorly differentiated tumor (0%, 0/13) (P = .007). No other association of FGFR3 with tumor size, necrosis, and variant histology was noted. CONCLUSIONS: The current study highlights the spectrum of FGFR3 mutation in Indian patients, and the data presented here are similar to those reported from across the globe. CI - (c) 2018 Wiley Periodicals, Inc. FAU - Ahmad, Firoz AU - Ahmad F AD - Research and Development, SRL Ltd, Mumbai, India. FAU - Mahal, Vishal AU - Mahal V AD - Research and Development, SRL Ltd, Mumbai, India. FAU - Verma, Geeta AU - Verma G AD - Histopathology Division, SRL Ltd, Mumbai, India. FAU - Bhatia, Simi AU - Bhatia S AD - Histopathology Division, SRL Ltd, Mumbai, India. FAU - Das, Bibhu Ranjan AU - Das BR AUID- ORCID: 0000-0001-5660-117X AD - Research and Development, SRL Ltd, Mumbai, India. LA - eng PT - Journal Article DEP - 20180917 PL - United States TA - Cancer Rep (Hoboken) JT - Cancer reports (Hoboken, N.J.) JID - 101747728 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - DNA Mutational Analysis/statistics & numerical data MH - Exons/genetics MH - Female MH - Humans MH - India/epidemiology MH - Male MH - Middle Aged MH - Mutation, Missense MH - Neoplasm Grading MH - Prognosis MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Risk Factors MH - Sex Factors MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/diagnosis/*genetics/pathology MH - Young Adult PMC - PMC7941566 OTO - NOTNLM OT - FGFR3 mutation OT - India OT - bladder cancer OT - novel mutation OT - sequencing COIS- The authors have stated explicitly that there are no conflicts of interest in connection with this article. EDAT- 2018/10/01 00:00 MHDA- 2018/10/01 00:01 PMCR- 2018/09/17 CRDT- 2020/07/29 06:00 PHST- 2018/02/07 00:00 [received] PHST- 2018/06/30 00:00 [revised] PHST- 2018/07/03 00:00 [accepted] PHST- 2020/07/29 06:00 [entrez] PHST- 2018/10/01 00:00 [pubmed] PHST- 2018/10/01 00:01 [medline] PHST- 2018/09/17 00:00 [pmc-release] AID - CNR21130 [pii] AID - 10.1002/cnr2.1130 [doi] PST - ppublish SO - Cancer Rep (Hoboken). 2018 Oct;1(3):e1130. doi: 10.1002/cnr2.1130. Epub 2018 Sep 17. PMID- 30269149 OWN - NLM STAT- MEDLINE DCOM- 20190329 LR - 20190329 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 102 IP - 1 DP - 2019 TI - Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial. PG - 69-76 LID - 10.1159/000493159 [doi] AB - PURPOSE: To compare the effect of intravesical interleukin-2 (IL-2) instillations with and without a marker lesion on time to recurrence (TTR) in non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: A prospective randomized, controlled trial was conducted. Patients with multiple non-muscle-invasive tumours were randomized for a complete or incomplete transurethral resection (TURBT), followed by 3 IL-2 instillations. The primary end point was TTR. RESULTS: These are the results of an interim analysis, which was performed due to slow accrual after which the study was closed prematurely. Twenty-eight patients were randomized of which 17 were eligible on an intention-to-treat basis. Median TTR or last follow-up was 3 months (interquartile range [IQR] 3-10 months) for the complete and 4 months (IQR 3-8 months) for the incomplete TURBT group. The TTR between the 2 groups did not differ significantly (log-rank, p = 0.54). -Conclusions: These data do not support the hypothesis that a marker lesion enhances the therapeutic effect of IL-2 instillations in patients with NMIBC. CI - (c) 2018 The Author(s) Published by S. Karger AG, Basel. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. FAU - Hentschel, Anouk AU - Hentschel A AD - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. FAU - Lissenberg-Witte, Birgit I AU - Lissenberg-Witte BI AD - Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands. FAU - den Otter, Wim AU - den Otter W AD - Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, VU University Medical Center, Amsterdam, The NetherlandsRJA.vanMoorselaar@vumc.nl. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20180928 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Biomarkers, Tumor) RN - 0 (Interleukin-2) SB - IM MH - Administration, Intravesical MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Cystoscopy MH - Female MH - Humans MH - Interleukin-2/*pharmacology MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy MH - Netherlands MH - Prospective Studies MH - Quality of Life MH - Surveys and Questionnaires MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/metabolism/*surgery OTO - NOTNLM OT - Instillation OT - Immunotherapy OT - Interleukin-2 OT - Marker tumour OT - Urinary bladder neoplasms EDAT- 2018/10/01 06:00 MHDA- 2019/03/30 06:00 CRDT- 2018/10/01 06:00 PHST- 2018/05/16 00:00 [received] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/10/01 06:00 [pubmed] PHST- 2019/03/30 06:00 [medline] PHST- 2018/10/01 06:00 [entrez] AID - 000493159 [pii] AID - 10.1159/000493159 [doi] PST - ppublish SO - Urol Int. 2019;102(1):69-76. doi: 10.1159/000493159. Epub 2018 Sep 28. PMID- 30267200 OWN - NLM STAT- MEDLINE DCOM- 20190919 LR - 20220408 IS - 1776-260X (Electronic) IS - 1776-2596 (Linking) VI - 13 IP - 5 DP - 2018 Oct TI - Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. PG - 599-609 LID - 10.1007/s11523-018-0595-9 [doi] AB - BACKGROUND: The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE: We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor cells [MDSC]; cytotoxic T lymphocytes [CTL]) following ICI therapy and investigated whether these changes correlated with outcomes in patients with metastatic urothelial carcinoma (mUC). PATIENTS AND METHODS: Serial peripheral blood samples were collected from ICI-treated mUC patients. Flow cytometry was used to quantify PD1/PDL1 expression on MDSC (CD33(+)HLADR(-)) and CTL (CD8(+)CD4(-)) from peripheral blood mononuclear cells. MDSC were grouped into monocytic (M)-MDSC (CD14(+)CD15(-)), polymorphonuclear (PMN)-MDSC (CD14(-)CD15(+)), and immature (I)-MDSC (CD14(-)CD15(-)). Mixed-model regression and Wilcoxon signed-rank or rank-sum tests were performed to assess post-ICI changes in immune biomarker expression and identify correlations between PD1/PDL1 expression and objective response to ICI. RESULTS: Of 41 ICI-treated patients, 26 received anti-PDL1 (23 atezolizumab/3 avelumab) and 15 received anti-PD1 (pembrolizumab) therapy. Based on available data, 27.5% had prior intravesical Bacillus Calmette-Guerin therapy, 42% had prior neoadjuvant chemotherapy, and 70% had prior cystectomy or nephroureterectomy. Successive doses of anti-PDL1 correlated with decreased percentage of PDL1(+) (%PDL1(+)) M-MDSC, while doses of anti-PD1 correlated with decreased %PD1(+) M- and I-MDSC. Although pre-treatment %PD1(+) CTL did not predict response, a greater %PD1(+) CTL within 9 weeks after ICI initiation correlated with objective response. CONCLUSIONS: Treatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC. FAU - Tzeng, Alice AU - Tzeng A AD - Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA. FAU - Diaz-Montero, C Marcela AU - Diaz-Montero CM AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Rayman, Patricia A AU - Rayman PA AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kim, Jin S AU - Kim JS AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Pavicic, Paul G Jr AU - Pavicic PG Jr AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Finke, James H AU - Finke JH AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Barata, Pedro C AU - Barata PC AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Lamenza, Marcelo AU - Lamenza M AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Devonshire, Sarah AU - Devonshire S AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Schach, Kim AU - Schach K AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Emamekhoo, Hamid AU - Emamekhoo H AD - Division of Hematology and Medical Oncology, University of Wisconsin, Madison, WI, USA. FAU - Ernstoff, Marc S AU - Ernstoff MS AD - Roswell Park Cancer Institute, Buffalo, NY, USA. FAU - Hoimes, Christopher J AU - Hoimes CJ AD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. FAU - Rini, Brian I AU - Rini BI AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Garcia, Jorge A AU - Garcia JA AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Gilligan, Timothy D AU - Gilligan TD AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Ornstein, Moshe C AU - Ornstein MC AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. ornstem@ccf.org. FAU - Grivas, Petros AU - Grivas P AUID- ORCID: 0000-0003-3965-3394 AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. pgrivas@uw.edu. AD - Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA. pgrivas@uw.edu. LA - eng PT - Journal Article PL - France TA - Target Oncol JT - Targeted oncology JID - 101270595 SB - IM MH - Female MH - Humans MH - Male MH - Neoplasm Metastasis MH - Progression-Free Survival MH - Urologic Neoplasms/*drug therapy/pathology EDAT- 2018/09/30 06:00 MHDA- 2019/09/20 06:00 CRDT- 2018/09/30 06:00 PHST- 2018/09/30 06:00 [pubmed] PHST- 2019/09/20 06:00 [medline] PHST- 2018/09/30 06:00 [entrez] AID - 10.1007/s11523-018-0595-9 [pii] AID - 10.1007/s11523-018-0595-9 [doi] PST - ppublish SO - Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9. PMID- 30266376 OWN - NLM STAT- MEDLINE DCOM- 20190514 LR - 20190514 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 124 DP - 2019 Feb TI - Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer. PG - 183-190 LID - S0090-4295(18)30966-X [pii] LID - 10.1016/j.urology.2018.07.058 [doi] AB - OBJECTIVE: To report long-term results on survival, toxicity, and patterns of failure of 3 different organ-sparing strategies for patients with muscle invasive bladder cancer. MATERIALS AND METHODS: This is a monoinstitutional prospective analysis of 3 consecutive bladder-sparing protocols combining maximal transurethral resection of bladder tumor (mTURBT), radiotherapy (RT), and cisplatin-based chemotherapy. Protocol 1 consisted of neoadjuvant methotrexate-cisplatin-vinblastine followed by endoscopic re-evaluation and consolidative RT 60 Gy in complete responders. Protocol 2 involved altered-fractionation RT 64.8 Gy and concurrent weekly cisplatin with re-evaluation after 40.8 Gy. Protocol 3 consisted of RT 64.8 Gy with concomitant weekly cisplatin. Nonresponders underwent radical cystectomy. Probabilities for overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS) were calculated using Kaplan-Meier product limited estimates. A Cox regression multivariate analysis was performed to detect potential risk factors for OS, CSS, and MFS. RESULTS: The 10-year bladder preservation rate was 79%. The 10-year OS, CSS, and MFS rates were 43.2%, 76.3% and 79.2%, respectively. There was no statistically significant difference in OS between the different treatment protocols. On multivariate analysis, mTURBT of the bladder and the complete response after induction therapy were independent correlates of improved OS and of MFS. The development of invasive bladder recurrence was independently associated with worse CSS and MFS. CONCLUSION: Ten-year results indicate that bladder-sparing treatment is a successful approach for muscle invasive bladder cancer in selected patients. The mTURBT of the bladder tumor and complete response after induction therapy remain the most relevant predictive factors. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Buchser, David AU - Buchser D AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. Electronic address: david.buechsergarcia@osakidetza.eus. FAU - Zapatero, Almudena AU - Zapatero A AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Rogado, Jacobo AU - Rogado J AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Talaya, Marisol AU - Talaya M AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Martin de Vidales, Carmen AU - Martin de Vidales C AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Arellano, Ramon AU - Arellano R AD - Department of Urology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Bocardo, Gloria AU - Bocardo G AD - Department of Urology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Cruz Conde, Alfonso AU - Cruz Conde A AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Perez, Leopoldo AU - Perez L AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Murillo, Maria T AU - Murillo MT AD - Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain. LA - eng PT - Comparative Study PT - Journal Article DEP - 20180925 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2019 Feb;124:189-190. doi: 10.1016/j.urology.2018.07.060. PMID: 30784711 MH - Adult MH - Aged MH - Clinical Protocols MH - Combined Modality Therapy MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/*methods MH - Prospective Studies MH - Survival Rate MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy EDAT- 2018/09/30 06:00 MHDA- 2019/05/15 06:00 CRDT- 2018/09/30 06:00 PHST- 2018/05/02 00:00 [received] PHST- 2018/07/15 00:00 [revised] PHST- 2018/07/25 00:00 [accepted] PHST- 2018/09/30 06:00 [pubmed] PHST- 2019/05/15 06:00 [medline] PHST- 2018/09/30 06:00 [entrez] AID - S0090-4295(18)30966-X [pii] AID - 10.1016/j.urology.2018.07.058 [doi] PST - ppublish SO - Urology. 2019 Feb;124:183-190. doi: 10.1016/j.urology.2018.07.058. Epub 2018 Sep 25. PMID- 30261082 OWN - NLM STAT- MEDLINE DCOM- 20190304 LR - 20191210 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 9 DP - 2018 TI - Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens. PG - e0204745 LID - 10.1371/journal.pone.0204745 [doi] LID - e0204745 AB - Patients with a history of non-muscle-invasive bladder cancer sometimes have recurrence of tumors after transurethral resection of bladder tumor treatment. To find factors related to the recurrence of non-muscle-invasive bladder cancer, we examined tissue specimens taken at transurethral resection of bladder tumor as an initial treatment. We revealed the association between prognosis of non-muscle-invasive bladder cancer and infiltration of Foxp3+ T cells that suppress anti-tumor immunity in 115 primary non-muscle-invasive bladder cancer patients retrospectively identified and followed for at least 3 months after primary transurethral resection. In immunohistological staining, we counted the number of cells positive for CD3 and positive for CD3 and Foxp3 together and calculated the percentage of Foxp3+ T cells among the CD3+ T cells. The recurrence-free survival rate was calculated by the Kaplan-Meier method, and a Cox regression analysis of recurrence factors was performed. The median (interquartile range) percentage of Foxp3+ T cells in all cases was 17.1% (11.9, 11.4-23.3%). Compared by risk stratification, it was 11.4% (10.4, 7.8-18.2%) in the low-risk group (n = 32), 16.8% (12.6, 11.6-24.2%) in the intermediate-risk group (n = 45), and 22.0% (9.7, 16.4-26.1%) in the high-risk group (n = 38). The Kaplan-Meier survival analysis indicated that the Foxp3+ T cell high group (>/= 17.1%) had a worse RFS rate than did the low group (< 17.1%) (P = 0.006). In multivariate analysis, the percentage of Foxp3+ T cells was an independent risk factor for intravesical recurrence (hazard ratio 2.25). Thus, peritumoral Foxp3+ T cell infiltration was correlated to risk stratification and recurrence-free survival. Therefore, the percentage of Foxp3+ T cells in tumor specimens may predict a risk for intravesical recurrence. FAU - Murai, Ryosuke AU - Murai R AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Itoh, Yasushi AU - Itoh Y AUID- ORCID: 0000-0001-7462-2193 AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Kageyama, Susumu AU - Kageyama S AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Nakayama, Misako AU - Nakayama M AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Ishigaki, Hirohito AU - Ishigaki H AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Teramoto, Kazuo AU - Teramoto K AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Narita, Mitsuhiro AU - Narita M AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Yoshida, Tetsuya AU - Yoshida T AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Tomita, Keiji AU - Tomita K AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Kobayashi, Ken-Ichi AU - Kobayashi KI AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Wada, Akinori AU - Wada A AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Nagasawa, Masayuki AU - Nagasawa M AUID- ORCID: 0000-0003-1299-6354 AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Kubota, Shigehisa AU - Kubota S AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Ogasawara, Kazumasa AU - Ogasawara K AD - Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan. FAU - Kawauchi, Akihiro AU - Kawauchi A AD - Department of Urology, Shiga University of Medical Science, Otsu, Shiga, Japan. LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180927 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - *Neoplasm Recurrence, Local/immunology/mortality/pathology/surgery MH - Predictive Value of Tests MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - *T-Lymphocytes, Regulatory/immunology/pathology MH - *Urinary Bladder Neoplasms/immunology/mortality/pathology/surgery PMC - PMC6160186 COIS- The authors have declared that no competing interest exists. EDAT- 2018/09/28 06:00 MHDA- 2019/03/05 06:00 PMCR- 2018/09/27 CRDT- 2018/09/28 06:00 PHST- 2018/01/12 00:00 [received] PHST- 2018/09/13 00:00 [accepted] PHST- 2018/09/28 06:00 [entrez] PHST- 2018/09/28 06:00 [pubmed] PHST- 2019/03/05 06:00 [medline] PHST- 2018/09/27 00:00 [pmc-release] AID - PONE-D-18-01274 [pii] AID - 10.1371/journal.pone.0204745 [doi] PST - epublish SO - PLoS One. 2018 Sep 27;13(9):e0204745. doi: 10.1371/journal.pone.0204745. eCollection 2018. PMID- 30258198 OWN - NLM STAT- MEDLINE DCOM- 20191125 LR - 20240426 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 8 IP - 1 DP - 2018 Sep 26 TI - CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. PG - 14383 LID - 10.1038/s41598-018-32569-x [doi] LID - 14383 AB - Deletions of the cell cycle control gene CDKN2A are described as progression markers of non-muscle invasive bladder cancer and to be associated with fibroblast growth factor 3 (FGFR3) mutations. The prognostic role of CDKN2A RNA expression in muscle invasive bladder cancer (MIBC) is under discussion. In 80 MIBC patients (m/f 60/20) who underwent radical cystectomy the expression of CDKN2A and FGFR3 was examined with qRT-PCR (test cohort). The MDA cohort (n = 57) and the TCGA cohort (n = 365) served for validation. The expression of drug target genes and TCGA molecular subtypes was correlated with CDKN2A expression. In the test cohort CDKN2A(high) patients (n = 8; 10.0%) had a significantly shorter recurrence-free (p = 0.018) and disease-specific (p = 0.006) survival compared to the rest of the cohort. A similar stratification was seen in the validation cohorts (CDKN2A(high): n = 7, 12.3%, p = 0.001; n = 46, 12.6%, p = 0.011). In the TCGA cohort these patients had a comparably low expression of drug target genes. The expression of CDKN2A significantly differed among TGCA molecular subtypes. 71.7% of CDKN2A(high) were TCGA basal squamous tumours but also show divergent molecular features compared to this group. In summary CDKN2A RNA expression-based risk stratification of MIBC allows the identification of a CDKN2A(high) poor prognosis group with low expression of drug target genes. FAU - Worst, Thomas S AU - Worst TS AD - Department of Urology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. thomas.worst@medma.uni-heidelberg.de. FAU - Weis, Cleo-Aron AU - Weis CA AD - Institute of Pathology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Landshuter Strasse 65, 93053, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, University of Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Werthmannstrasse 1, 50935, Cologne, Germany. AD - Institute of Pathology at the St Elisabeth Hospital Koln-Hohenlind, Werthmannstrasse 1, 50935, Cologne, Germany. FAU - Erben, Philipp AU - Erben P AUID- ORCID: 0000-0002-8279-7636 AD - Department of Urology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180926 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Cyclin-Dependent Kinase Inhibitor p16/*genetics MH - Female MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - Muscle Neoplasms/diagnosis/genetics/pathology/*secondary MH - Neoplasm Invasiveness/diagnosis/*genetics/pathology MH - Prognosis MH - RNA, Messenger/genetics MH - Transcriptome MH - Urinary Bladder Neoplasms/diagnosis/*genetics/*pathology PMC - PMC6158275 COIS- The authors declare no competing interests. EDAT- 2018/09/28 06:00 MHDA- 2019/11/26 06:00 PMCR- 2018/09/26 CRDT- 2018/09/28 06:00 PHST- 2017/11/15 00:00 [received] PHST- 2018/09/10 00:00 [accepted] PHST- 2018/09/28 06:00 [entrez] PHST- 2018/09/28 06:00 [pubmed] PHST- 2019/11/26 06:00 [medline] PHST- 2018/09/26 00:00 [pmc-release] AID - 10.1038/s41598-018-32569-x [pii] AID - 32569 [pii] AID - 10.1038/s41598-018-32569-x [doi] PST - epublish SO - Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x. PMID- 30252978 OWN - NLM STAT- MEDLINE DCOM- 20200813 LR - 20260301 IS - 1522-2586 (Electronic) IS - 1053-1807 (Linking) VI - 49 IP - 5 DP - 2019 May TI - Quantitative Identification of Nonmuscle-Invasive and Muscle-Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis. PG - 1489-1498 LID - 10.1002/jmri.26327 [doi] AB - BACKGROUND: Preoperative discrimination between nonmuscle-invasive bladder carcinomas (NMIBC) and the muscle-invasive ones (MIBC) is very crucial in the management of patients with bladder cancer (BC). PURPOSE: To evaluate the discriminative performance of multiparametric MRI radiomics features for precise differentiation of NMIBC from MIBC, preoperatively. STUDY TYPE: Retrospective, radiomics. POPULATION: Fifty-four patients with postoperative pathologically proven BC lesions (24 in NMIBC and 30 in MIBC groups) were included. FIELD STRENGTH/SEQUENCE: 3.0T MRI/T(2) -weighted (T(2) W) and multi-b-value diffusion-weighted (DW) sequences. ASSESSMENT: A total of 1104 radiomics features were extracted from carcinomatous regions of interest on T(2) W and DW images, and the apparent diffusion coefficient maps. Support vector machine with recursive feature elimination (SVM-RFE) and synthetic minority oversampling technique (SMOTE) were used to construct an optimal discriminative model, and its performance was evaluated and compared with that of using visual diagnoses by experts. STATISTICAL TESTS: Chi-square test and Student's t-test were applied on clinical characteristics to analyze the significant differences between patient groups. RESULTS: Of the 1104 features, an optimal subset involving 19 features was selected from T(2) W and DW sequences, which outperformed the other two subsets selected from T(2) W or DW sequence in muscle invasion discrimination. The best performance for the differentiation task was achieved by the SVM-RFE+SMOTE classifier, with averaged sensitivity, specificity, accuracy, and area under the curve of receiver operating characteristic of 92.60%, 100%, 96.30%, and 0.9857, respectively, which outperformed the diagnostic accuracy by experts. DATA CONCLUSION: The proposed radiomics approach has potential for the accurate differentiation of muscle invasion in BC, preoperatively. The optimal feature subset selected from multiparametric MR images demonstrated better performance in identifying muscle invasiveness when compared with that from T(2) W sequence or DW sequence only. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1489-1498. CI - (c) 2018 International Society for Magnetic Resonance in Medicine. FAU - Xu, Xiaopan AU - Xu X AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Zhang, Xi AU - Zhang X AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Tian, Qiang AU - Tian Q AD - Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Wang, Huanjun AU - Wang H AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China. FAU - Cui, Long-Biao AU - Cui LB AD - Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, PR China. AD - School of Medical Psychology, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Li, Shurong AU - Li S AD - Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou, Guangdong, PR China. FAU - Tang, Xing AU - Tang X AD - Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Li, Baojuan AU - Li B AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Dolz, Jose AU - Dolz J AD - LIVIA Laboratory, Ecole de technologie superieure (ETS), Montreal, QC, Canada. FAU - Ayed, Ismail Ben AU - Ayed IB AD - LIVIA Laboratory, Ecole de technologie superieure (ETS), Montreal, QC, Canada. FAU - Liang, Zhengrong AU - Liang Z AD - Department of Radiology, School of Computer Science and Biomedical Engineering, State University of New York, Stony Brook, New York, USA. FAU - Yuan, Jing AU - Yuan J AD - Mathematics and Statistics School Xidian University, Xi'an, Shaanxi, PR China. FAU - Du, Peng AU - Du P AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Lu, Hongbing AU - Lu H AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. FAU - Liu, Yang AU - Liu Y AD - School of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, PR China. LA - eng GR - R01 CA206171/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180925 PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Diffusion Magnetic Resonance Imaging MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Multiparametric Magnetic Resonance Imaging MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Sensitivity and Specificity MH - Support Vector Machine MH - Urinary Bladder Neoplasms/*diagnostic imaging/pathology OTO - NOTNLM OT - bladder cancer OT - multiparametric MRI OT - muscle invasion prediction OT - support vector machine-based recursive feature elimination (SVM-RFE) OT - synthetic minority oversampling technique (SMOTE) OT - visual assessment EDAT- 2018/09/27 06:00 MHDA- 2020/08/14 06:00 CRDT- 2018/09/26 06:00 PHST- 2018/06/07 00:00 [received] PHST- 2018/08/17 00:00 [revised] PHST- 2018/08/20 00:00 [accepted] PHST- 2018/09/27 06:00 [pubmed] PHST- 2020/08/14 06:00 [medline] PHST- 2018/09/26 06:00 [entrez] AID - 10.1002/jmri.26327 [doi] PST - ppublish SO - J Magn Reson Imaging. 2019 May;49(5):1489-1498. doi: 10.1002/jmri.26327. Epub 2018 Sep 25. PMID- 30251745 OWN - NLM STAT- MEDLINE DCOM- 20200114 LR - 20201005 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 16 IP - 2 DP - 2019 May 5 TI - Second Transurethral Resection of Bladder Tumor: Is it Necessary in All T1 and/or High-Grade Tumors? PG - 152-156 LID - 10.22037/uj.v0i0.4670 [doi] AB - PURPOSE: To evaluate the role of second transurethral resection of bladder tumor (TURBT) in patients with T1 and/or high-grade bladder tumor regarding tumor size, multiplicity, and presence or absence of muscle in specimens of initial resection. MATERIALS AND METHODS: A total of 107 patients with either primary T1 or high-grade urothelial bladder cancer underwent second TURBT within 6 weeks after initial surgery and prior to starting intravesical immunotherapy. We assessed the incidence of residual disease and upstaging in second TURBT. RESULTS: Upstaging was noted in 11 (10.3%) patients and residual tumor was evident in 29 (27%) patients. Disease upstaging had a statistically significant association with tumor size, multifocality, and absence of muscle at initial resection in univariate analysis. Presence of residual tumor in second resection also showed significant association with tumor size and absence of muscle at initial resection but not multifocality. Multivariate logistic regression analysis revealed that absence of muscle at initial resection independently predicts disease upstaging during second TURBT (OR = 8.123, 95% CI: 1.478-44.632). Furthermore, both tumor size (OR = 13.573, 95% CI: 3.104-59.359) and absence of muscle (OR = 21.214, 95% CI: 6.062-74.244) were independent predictors of residual disease in second TURBT. CONCLUSION: We showed that second TURBT in a subset of patients with single, small T1 and/or high-grade tumor who underwent complete initial resection might be of limited value. FAU - Ayati, Mohsen AU - Ayati M AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Drayati_mohsen@yahoo.com. FAU - Amini, Erfan AU - Amini E AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Shahrokhi Damavand, Reza AU - Shahrokhi Damavand R AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Nowroozi, Mohammad Reza AU - Nowroozi MR AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Soleimani, Mohammad AU - Soleimani M AD - Department of Urology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Ranjbar, Ehsan AU - Ranjbar E AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Nowroozi, Ali AU - Nowroozi A AD - Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20190505 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology/*surgery MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Neoplasm, Residual/epidemiology MH - Reoperation MH - Retrospective Studies MH - Urethra MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Young Adult EDAT- 2018/09/27 06:00 MHDA- 2020/01/15 06:00 CRDT- 2018/09/26 06:00 PHST- 2018/09/27 06:00 [pubmed] PHST- 2020/01/15 06:00 [medline] PHST- 2018/09/26 06:00 [entrez] AID - 4670 [pii] AID - 10.22037/uj.v0i0.4670 [doi] PST - epublish SO - Urol J. 2019 May 5;16(2):152-156. doi: 10.22037/uj.v0i0.4670. PMID- 30248959 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 10 IP - 10 DP - 2018 Sep 21 TI - NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells. LID - 10.3390/cancers10100347 [doi] LID - 347 AB - The nucleus accumbens-associated protein 1 (NACC1) is a transcription factor constitutively expressed in the urothelium, where it regulates cell growth, senescence, autophagy, and epithelial-mesenchymal transition. microRNA (miRNA) constitutes a class of small non-coding RNAs which are involved in cell proliferation, differentiation, and progression of tumors. miRNAs and their target molecules are utilized for molecular diagnosis of urothelial carcinoma. NACC1 is one of several putative target molecules of miR-331-3p, and is associated with cell proliferation in cancers such as prostate and cervical cancer. Functional experiments involving miR-331-3p and its target molecule NACC1 were conducted using the urothelial carcinoma (UC) cell lines, T24, UMUC6, and KU7. Furthermore, quantitative reverse transcription polymerase chain reaction and immunostaining were performed to evaluate the expression of NACC1 in UC derived from transurethral resection of bladder tumor (TUR-Bt) specimens. The methane thiosulfonate (MTS) assay revealed that cell proliferation was significantly reduced after transient transfection of miR-331-3p precursor and/or NACC1 siRNA in UC cells. Cell senescence via cell cycle arrest at the G1 phase was induced by NACC1 inhibition. On the other hand, suppression of NACC1 induced cell migration and invasion abilities. Immunohistochemical analysis of TUR-Bt specimens revealed that over 70% of UC cells presented strongly positive results for NACC1. In contrast, normal urothelial cells were weakly positive for NACC1. It was also found that NACC1 expression was lower in invasive UC cells than in non-invasive UC cells. Loss of NACC1 induced vessel invasion in invasive UC tissues. The present results indicate that NACC1 regulated by miR-331-3p contributes to cell proliferation, and is involved in cell migration and invasion. This suggests that NACC1 can serve as a potential target molecule for the prediction and prognosis of UC, and can contribute to effective treatment strategies. FAU - Morita, Kohei AU - Morita K AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. moritak@naramed-u.ac.jp. FAU - Fujii, Tomomi AU - Fujii T AUID- ORCID: 0000-0002-7207-4127 AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. fujiit@naramed-u.ac.jp. FAU - Itami, Hiroe AU - Itami H AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. hritami@naramed-u.ac.jp. FAU - Uchiyama, Tomoko AU - Uchiyama T AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. uchiyama0403@naramed-u.ac.jp. FAU - Nakai, Tokiko AU - Nakai T AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. tokiko@naramed-u.ac.jp. FAU - Hatakeyama, Kinta AU - Hatakeyama K AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. kpathol@naramed-u.ac.jp. FAU - Sugimoto, Aya AU - Sugimoto A AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. ayaasano1018@yahoo.co.jp. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University School of Medicine, Nara 634-8521, Japan. makitomiyake@naramed-u.ac.jp. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University School of Medicine, Nara 634-8521, Japan. nakaiyasusiuro@live.jp. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University School of Medicine, Nara 634-8521, Japan. sendo@naramed-u.ac.jp. FAU - Shimada, Keiji AU - Shimada K AD - Department of Diagnostic Pathology, Nara City Hospital, Nara 634-8521, Japan. k-shimada@nara-jadecom.jp. FAU - Yamazaki, Masaharu AU - Yamazaki M AD - Department of Central Clinical Laboratory, Nara Medical University Hospital, Nara 634-8521, Japan. masayama@naramed-u.ac.jp. FAU - Fujimoto, Kiyohide AU - Fujimoto K AUID- ORCID: 0000-0003-1507-2464 AD - Department of Urology, Nara Medical University School of Medicine, Nara 634-8521, Japan. kiyokun@naramed-u.ac.jp. FAU - Ohbayashi, Chiho AU - Ohbayashi C AD - Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan. ohbayashi@naramed-u.ac.jp. LA - eng PT - Journal Article DEP - 20180921 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC6210667 OTO - NOTNLM OT - NACC1 OT - cell cycle arrest OT - miR-331-3p OT - migration and invasion OT - urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2018/09/27 06:00 MHDA- 2018/09/27 06:01 PMCR- 2018/09/21 CRDT- 2018/09/26 06:00 PHST- 2018/08/19 00:00 [received] PHST- 2018/09/12 00:00 [revised] PHST- 2018/09/20 00:00 [accepted] PHST- 2018/09/26 06:00 [entrez] PHST- 2018/09/27 06:00 [pubmed] PHST- 2018/09/27 06:01 [medline] PHST- 2018/09/21 00:00 [pmc-release] AID - cancers10100347 [pii] AID - cancers-10-00347 [pii] AID - 10.3390/cancers10100347 [doi] PST - epublish SO - Cancers (Basel). 2018 Sep 21;10(10):347. doi: 10.3390/cancers10100347. PMID- 30248235 OWN - NLM STAT- MEDLINE DCOM- 20191217 LR - 20191217 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 IP - 4 DP - 2019 Apr TI - Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. PG - 646-650 LID - 10.1111/bju.14557 [doi] AB - OBJECTIVES: To evaluate the impact of an eight-item surgical checklist (SC) on the recurrence-free survival (RFS) of patients with non-muscle-invasive bladder cancer (NMIBC) undergoing transurethral resection of bladder tumour (TURBT). PATIENTS AND METHODS: A group of urologists at two tertiary referral centres, with expertise in bladder cancer, identified eight critical items that should be performed in every high-quality TURBT. An eight-item SC was prospectively implemented into clinical practice and the operative reports of TURBTs performed before and after implementation were reviewed. Results from both institutions were combined to estimate the impact of introducing the SC on oncological outcomes. Multivariable logistic and Cox hazards regression analyses were performed to evaluate the impact of the SC on the presence of detrusor muscle in the TURBT specimen and on RFS, respectively. RESULTS: The operative reports of 266 TURBTs performed after the SC implementation were reviewed and compared to those of 281 TURBTs performed prior to the SC introduction. The SC was independently associated with a significant improvement in RFS (P = 0.02). However, the introduction of the SC was not significantly associated with the presence of detrusor muscle in the surgical specimen (P = 0.4). CONCLUSION: The use of an eight-item SC during TURBT in clinical practice increases the quality of operative reports thereby potentially improving individualised risk-stratification and care resulting in lower disease recurrence rates. Therefore, the introduction of a SC can be recommended to enhance oncological outcomes by improving surgical standardisation and operative reporting. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Suarez-Ibarrola, Rodrigo AU - Suarez-Ibarrola R AUID- ORCID: 0000-0002-3361-9358 AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, University of the Studies of Turin, AOU Citta della Salute e della Scienza di Torino Presidio Molinette, Turin, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AUID- ORCID: 0000-0002-6603-6319 AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Preto, Mirko AU - Preto M AUID- ORCID: 0000-0002-8144-6498 AD - Division of Urology, University of the Studies of Turin, AOU Citta della Salute e della Scienza di Torino Presidio Molinette, Turin, Italy. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, University of the Studies of Turin, AOU Citta della Salute e della Scienza di Torino Presidio Molinette, Turin, Italy. LA - eng PT - Journal Article DEP - 20181023 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - Transl Androl Urol. 2019 Mar;8(Suppl 1):S85-S87. doi: 10.21037/tau.2019.01.06. PMID: 31143675 MH - Aged MH - Checklist MH - Disease-Free Survival MH - Female MH - Health Care Surveys MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Recurrence, Local/*pathology MH - Practice Guidelines as Topic MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery MH - *Urologic Surgical Procedures MH - Urologists/statistics & numerical data OTO - NOTNLM OT - NMIBC OT - bladder cancer OT - recurrence-free survival OT - surgical checklist OT - transurethral resection of bladder tumour EDAT- 2018/09/25 06:00 MHDA- 2019/12/18 06:00 CRDT- 2018/09/25 06:00 PHST- 2018/09/25 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/09/25 06:00 [entrez] AID - 10.1111/bju.14557 [doi] PST - ppublish SO - BJU Int. 2019 Apr;123(4):646-650. doi: 10.1111/bju.14557. Epub 2018 Oct 23. PMID- 30245975 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 8 DP - 2018 TI - Urinary Markers in Bladder Cancer: An Update. PG - 362 LID - 10.3389/fonc.2018.00362 [doi] LID - 362 AB - Bladder cancer (BC) is ones of the most common cancer worldwide. It is classified in muscle invasive (MIBC) and muscle non-invasive (NMIBC) BC. NMIBCs frequently recur and progress to MIBCs with a reduced survival rate and frequent distant metastasis. BC detection require unpleasant and expensive cystoscopy and biopsy, which are often accompanied by several adverse effects. Thus, there is an urgent need to develop novel diagnostic methods for initial detection and surveillance in both MIBCs and NMIBCs. Multiple urine-based tests approved by FDA for BC detection and surveillance are commercially available. However, at present, sensitivity, specificity and diagnostic accuracy of these urine-based assays are still suboptimal and, in the attend to improve them, novel molecular markers as well as multiple-assays must to be translated in clinic. Now there are growing evidence toward the use of minimally invasive "liquid biopsy" to identify biomarkers in urologic malignancy. DNA- and RNA-based markers in body fluids such as blood and urine are promising potential markers in diagnostic, prognostic, predictive and monitoring urological malignancies. Thus, circulating cell-free DNA, DNA methylation and mutations, circulating tumor cells, miRNA, IncRNA and mRNAs, cell-free proteins and peptides, and exosomes have been assessed in urine specimens. However, proteomic and genomic data must to be validated in well-designed multicenter clinical studies, before to be employed in clinic oncology. FAU - Santoni, Giorgio AU - Santoni G AD - Immunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy. FAU - Morelli, Maria B AU - Morelli MB AD - Immunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy. AD - Immunopathology Laboratory, School of Biosciences, Biotechnology and Veterinary Medicine, University of Camerino, Camerino, Italy. FAU - Amantini, Consuelo AU - Amantini C AD - Immunopathology Laboratory, School of Biosciences, Biotechnology and Veterinary Medicine, University of Camerino, Camerino, Italy. FAU - Battelli, Nicola AU - Battelli N AD - Oncology Unit, Macerata Hospital, Macerata, Italy. LA - eng PT - Journal Article PT - Review DEP - 20180907 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC6137202 OTO - NOTNLM OT - bladder cancer OT - exosomes OT - liquid biopsy OT - microRNA OT - urinary biomarkers EDAT- 2018/09/25 06:00 MHDA- 2018/09/25 06:01 PMCR- 2018/01/01 CRDT- 2018/09/25 06:00 PHST- 2018/06/29 00:00 [received] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/09/25 06:00 [entrez] PHST- 2018/09/25 06:00 [pubmed] PHST- 2018/09/25 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2018.00362 [doi] PST - epublish SO - Front Oncol. 2018 Sep 7;8:362. doi: 10.3389/fonc.2018.00362. eCollection 2018. PMID- 30237859 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220322 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 69 DP - 2018 Sep 4 TI - Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8(+) T cells. PG - 33160-33169 LID - 10.18632/oncotarget.26036 [doi] AB - BACKGROUND AND OBJECTIVE: Recurrence of non-muscle invasive bladder cancer (NMIBC) after initial management occurs in 60-70% of patients. Predictive criteria for recurrence remain only clinical and pathological. The aim of this study was to investigate the prognostic significance of the proportion of checkpoint HLA-G's receptor ILT2-expressing peripheral CD8(+) T cells. RESULTS: The proportion of CD4(+)ILT2(+)and CD8(+)ILT2(+) T cells was not increased in NMIBC compared to controls. However, a strong association was found between recurrence and CD8(+)ILT2(+) T cell population levels (p = 0.0006). Two-year recurrence-free survival was 83% in patients with less than 18% CD8(+)ILT2(+) T cells, 39% in the intermediary group, and 12% in patients with more than 46% CD8(+)ILT2(+) T cells. Multivariate analyses demonstrated that the proportion of CD8(+)ILT2(+) T cells was an independent predictive factor for recurrence. Adding CD8(+)ILT2(+) T cells population level to clinical variables increased the predictive accuracy of the model by 4.5%. MATERIALS AND METHODS: All patients treated for NMIBC between 2012 and 2014 were included prospectively. Blood samples, tumor and clinico-pathological characteristics were collected. HLA-G expression was measured using IHC, and CD8(+)ILT2(+) T cell levels using flow cytometry. Association between HLA-G and CD8(+)ILT2(+) T cell population levels with NMIBC risk of recurrence was investigated using Cox regression analyses. Prediction was measured using the concordance index statistic. CONCLUSIONS: We demonstrated a strong association between the proportion of circulating CD8(+)ILT2(+) T cells and NMIBC risk of recurrence. Gain in prediction was substantial. If externally validated, such immunological marker could be integrated to predict NMIBC recurrence. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - LeMaoult, Joel AU - LeMaoult J AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - University Paris Diderot, Sorbonne Paris Cite, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France. FAU - Goujon, Annabelle AU - Goujon A AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - Riviere, Adrien AU - Riviere A AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - Rivero-Juarez, Antonio AU - Rivero-Juarez A AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - Infectious Diseases Unit, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Hospital Universitario Reina Sofia, Universidad de Cordoba, Cordoba, Spain. FAU - Djouadou, Malika AU - Djouadou M AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - de Gouvello, Amory AU - de Gouvello A AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - Dumont, Clement AU - Dumont C AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Medical Oncology, Paris, France. FAU - Wu, Ching-Lien AU - Wu CL AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - University Paris Diderot, Sorbonne Paris Cite, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France. FAU - Culine, Stephane AU - Culine S AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Medical Oncology, Paris, France. FAU - Verine, Jerome AU - Verine J AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Pathology, Paris, France. FAU - Rouas-Freiss, Nathalie AU - Rouas-Freiss N AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - University Paris Diderot, Sorbonne Paris Cite, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France. FAU - Hennequin, Christophe AU - Hennequin C AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Radiotherapy, Paris, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - AP-HP, Saint-Louis Hospital, Department of Urology, Paris, France. FAU - Carosella, Edgardo D AU - Carosella ED AD - CEA, DRF-Francois Jacob Institute, Research Division in Hematology and Immunology (SRHI), Saint-Louis Hospital, Paris, France. AD - University Paris Diderot, Sorbonne Paris Cite, UMR E_5 Institut Universitaire d'Hematologie, Saint-Louis Hospital, Paris, France. LA - eng PT - Journal Article DEP - 20180904 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC6145700 OTO - NOTNLM OT - HLA-G OT - ILT2 OT - bladder OT - cancer OT - immune checkpoint COIS- CONFLICTS OF INTEREST None. EDAT- 2018/09/22 06:00 MHDA- 2018/09/22 06:01 PMCR- 2018/09/04 CRDT- 2018/09/22 06:00 PHST- 2018/01/20 00:00 [received] PHST- 2018/08/03 00:00 [accepted] PHST- 2018/09/22 06:00 [entrez] PHST- 2018/09/22 06:00 [pubmed] PHST- 2018/09/22 06:01 [medline] PHST- 2018/09/04 00:00 [pmc-release] AID - 26036 [pii] AID - 10.18632/oncotarget.26036 [doi] PST - epublish SO - Oncotarget. 2018 Sep 4;9(69):33160-33169. doi: 10.18632/oncotarget.26036. eCollection 2018 Sep 4. PMID- 30236855 OWN - NLM STAT- MEDLINE DCOM- 20190118 LR - 20210316 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 11 DP - 2018 Nov TI - Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. PG - 498.e1-498.e7 LID - S1078-1439(18)30299-0 [pii] LID - 10.1016/j.urolonc.2018.08.004 [doi] AB - OBJECTIVES: To demonstrate patterns of uptake and impact on recurrence of intravesical chemotherapy (IC) immediately following transurethral resection of bladder tumor (TURBT) for low-grade non-muscle-invasive bladder cancer (NMIBC) at a population level. METHODS: Incident cases of low-grade (LG) Ta or T1 NMIBC from 2005 to 2012 were identified from the California Cancer Registry. We determined rates of IC utilization following TURBT. Multivariable logistic regression models were utilized to assess predictors of IC utilization. Multivariable Cox proportional hazards regression was used to assess the association of IC utilization with recurrence-free survival, bladder cancer-specific survival, and overall survival. RESULTS: Ten thousand thirty-one patients with LG NMIBC diagnosed in California between 2005 and 2012. The overall rate of IC utilization was 5.1%, and increased from 1.7% (2005-2006) to 9.6% (2011-2012). More recent year of diagnosis (Odds ratio 1.74, confidence interval 1.60-1.90 for 2-year increments) was associated with an increased likelihood of undergoing immediate postoperative IC. The cumulative incidence of recurrence at 24 months for patients who received IC was 25.2% compared to 30.2% among those who did not receive IC. Use of IC was significantly associated with improved recurrence-free survival (Hazards ratio 0.82, confidence interval 0.70-0.97). CONCLUSION: Utilization of IC for LG NMIBC remains dismally low, with less than 10% of patients receiving this standard of care. Low utilization is associated with increased rates of recurrence. We demonstrate a major shortcoming in quality of care with potential widespread impact on outcomes and cost of care. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Yap, Stanley A AU - Yap SA AD - Department of Urology, University of California Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA; Division of Urology, Department of Surgery, VA Northern California Health Care System, Sacramento, CA. Electronic address: syap@ucdavis.edu. FAU - Brunson, Ann AU - Brunson A AD - Division of Hematology Oncology, Center for Oncology and Hematology Outcomes Research and Training (COHORT), UC Davis School of Medicine, Sacramento, CA. FAU - Pugashetti, Neil AU - Pugashetti N AD - Department of Urology, University of California Davis, Sacramento, CA. FAU - Cress, Rosemary D AU - Cress RD AD - University of California Davis Comprehensive Cancer Center, Sacramento, CA; Department of Public Health Sciences, School of Medicine, University of California Davis, Davis, CA; Public Health Institute, Cancer Registry of Greater California, Sacramento, CA. FAU - Keegan, Theresa H M AU - Keegan THM AD - Division of Hematology Oncology, Center for Oncology and Hematology Outcomes Research and Training (COHORT), UC Davis School of Medicine, Sacramento, CA. FAU - deVere White, Ralph AU - deVere White R AD - Department of Urology, University of California Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA. FAU - Wun, Ted AU - Wun T AD - University of California Davis Comprehensive Cancer Center, Sacramento, CA; Division of Hematology Oncology, Center for Oncology and Hematology Outcomes Research and Training (COHORT), UC Davis School of Medicine, Sacramento, CA. LA - eng PT - Journal Article DEP - 20180917 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Antineoplastic Agents/*administration & dosage MH - California MH - Carcinoma, Transitional Cell/*drug therapy MH - Chemotherapy, Adjuvant/methods MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/*prevention & control MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Proportional Hazards Models MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - bladder cancer OT - intravesical chemotherapy OT - non-muscle-invasive EDAT- 2018/09/22 06:00 MHDA- 2019/01/19 06:00 CRDT- 2018/09/22 06:00 PHST- 2018/01/07 00:00 [received] PHST- 2018/07/22 00:00 [revised] PHST- 2018/08/04 00:00 [accepted] PHST- 2018/09/22 06:00 [pubmed] PHST- 2019/01/19 06:00 [medline] PHST- 2018/09/22 06:00 [entrez] AID - S1078-1439(18)30299-0 [pii] AID - 10.1016/j.urolonc.2018.08.004 [doi] PST - ppublish SO - Urol Oncol. 2018 Nov;36(11):498.e1-498.e7. doi: 10.1016/j.urolonc.2018.08.004. Epub 2018 Sep 17. PMID- 30236545 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20190522 IS - 1532-8198 (Electronic) IS - 1092-9134 (Linking) VI - 37 DP - 2018 Dec TI - Assessment of transurethral resection of the bladder specimens with pT1 high-grade urothelial carcinoma for the predictor features of muscularis propria invasion on radical cystectomy specimens. PG - 25-29 LID - S1092-9134(18)30224-7 [pii] LID - 10.1016/j.anndiagpath.2018.09.003 [doi] FAU - Kir, Gozde Gozde AU - Kir GG AD - Pathology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Patoloji Laboratuari, 34720 Kadikoy, Istanbul, Turkey. Electronic address: gozkir@yahoo.com. FAU - Girgin, Rabia Burcin Burcin AU - Girgin RBB AD - Pathology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Patoloji Laboratuari, 34720 Kadikoy, Istanbul, Turkey. FAU - Soylemez Soylemez, Tuce Tuce AU - Soylemez Soylemez TT AD - Pathology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Patoloji Laboratuari, 34720 Kadikoy, Istanbul, Turkey. FAU - Melemez, Mukaddes Kubra Kubra AU - Melemez MKK AD - Istanbul Medeniyet University School of Medicine, Dr. Erkin Caddesi. Goztepe Egt. Ve Aras. Hastanesi Patoloji Laboratuari, 34720 Kadikoy, Istanbul, Turkey. FAU - Topal, Cumhur Selcuk Selcuk AU - Topal CSS AD - Pathology Department, Umraniye Training and Research Hospital, Elmalikent Mahallesi, Adem Yavuz Cad. No:1, 34764 Umraniye, Istanbul, Turkey. FAU - Turan, Turgay AU - Turan T AD - Urology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Uroloji Klinigi, 34720 Kadikoy, Istanbul, Turkey. FAU - Caskurlu Caskurlu, Turhan AU - Caskurlu Caskurlu T AD - Urology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Uroloji Klinigi, 34720 Kadikoy, Istanbul, Turkey. FAU - Yildirim, Asif Asif AU - Yildirim AA AD - Urology Department, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dr. Erkin Caddesi, Goztepe Egt. Ve Aras. Hastanesi Uroloji Klinigi, 34720 Kadikoy, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20180910 PL - United States TA - Ann Diagn Pathol JT - Annals of diagnostic pathology JID - 9800503 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness/*diagnosis/pathology MH - Neoplasm Staging MH - Turkey MH - Urinary Bladder/pathology/*surgery EDAT- 2018/09/22 06:00 MHDA- 2019/05/23 06:00 CRDT- 2018/09/22 06:00 PHST- 2018/07/11 00:00 [received] PHST- 2018/09/07 00:00 [revised] PHST- 2018/09/08 00:00 [accepted] PHST- 2018/09/22 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] PHST- 2018/09/22 06:00 [entrez] AID - S1092-9134(18)30224-7 [pii] AID - 10.1016/j.anndiagpath.2018.09.003 [doi] PST - ppublish SO - Ann Diagn Pathol. 2018 Dec;37:25-29. doi: 10.1016/j.anndiagpath.2018.09.003. Epub 2018 Sep 10. PMID- 30235462 OWN - NLM STAT- MEDLINE DCOM- 20190415 LR - 20190415 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 101 IP - 3 DP - 2018 TI - Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation. PG - 285-292 LID - 10.1159/000493369 [doi] AB - INTRODUCTION: To mirror guideline-adherence for pT1 bladder cancer treatment in Northern Germany. MATERIALS AND METHODS: Overall, 111 patients with pT1 diagnosis were treated at 4 institutions. Guideline-adherence was defined as repeat resection, instillation, and quarterly cystoscopy. Patient characteristics and pathological parameters were assessed. We summarized patients using descriptive analyses and evaluated guideline-adherence within selected subgroups. We created a multivariable model to identify predictors of guideline-adherence. RESULTS: Median age was 75 years (range 39-94 years), multifocal tumors were found in 44.1%, early instillation was performed in 33.3%, and repeat resection was performed in 77.5%. Of 62.2% who underwent instillation, 59.4% received BCG, while 40.6% received Mitomycin C or other agents. Cystoscopic follow-up was performed in 81.8%. Guideline-adherence was met in 56.8%. Patients aged below the median met adherence metrics more often compared to those above the median (66.7 vs. 46.3%; p = 0.030). Men more frequently met adherence metrics compared to women (62.1 vs. 37.5%; p = 0.038). More patients with multifocal tumors met all 3 adherence metrics (69.4 vs. 48.0%; p = 0.050), as compared to those with unifocal lesions. In multivariable analyses, age-adjusted comorbidity (OR 0.75; 95% CI 0.59-0.94; p = 0.011) and multifocality (OR 2.62; 95% CI 1.09-6.27; p = 0.031) were predictors of guideline-adherence. CONCLUSIONS: We found non-adherence in more than one-third of patients and disparities among patients of different age and according to tumor focality. Larger samples and prospective studies are needed to delineate and eradicate treatment disadvantages in these high-risk patients. CI - (c) 2018 S. Karger AG, Basel. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Gild, Philipp AU - Gild P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Marks, Phillip AU - Marks P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Roschinski, Julia AU - Roschinski J AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Doh, Ousman AU - Doh O AD - Department of Urology, Regio Medical Center Elmshorn, Elmshorn, Germany. FAU - Hoppner, Wolfgang AU - Hoppner W AD - Department of Urology, Itzehoe Medical Center, Itzehoe, Germany. FAU - Wagner, Walter AU - Wagner W AD - Department of Urology, Bundeswehr Medical Center Hamburg, Hamburg, Germany. FAU - Isbarn, Hendrik AU - Isbarn H AD - Department of Urology, Regio Medical Center Elmshorn, Elmshorn, Germany. AD - Martini Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Buscheck, Franziska AU - Buscheck F AD - Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Sauter, Guido AU - Sauter G AD - Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Dahlem, Roland AU - Dahlem R AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20180920 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystoscopy/methods MH - Female MH - *Guideline Adherence MH - Humans MH - Male MH - Medical Oncology/methods/*standards MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/pathology MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - BCG Vaccine OT - Drug OT - Guideline adherence OT - Instillation OT - Quality of health care OT - Urinary bladder neoplasms EDAT- 2018/09/21 06:00 MHDA- 2019/04/16 06:00 CRDT- 2018/09/21 06:00 PHST- 2018/07/25 00:00 [received] PHST- 2018/08/28 00:00 [accepted] PHST- 2018/09/21 06:00 [pubmed] PHST- 2019/04/16 06:00 [medline] PHST- 2018/09/21 06:00 [entrez] AID - 000493369 [pii] AID - 10.1159/000493369 [doi] PST - ppublish SO - Urol Int. 2018;101(3):285-292. doi: 10.1159/000493369. Epub 2018 Sep 20. PMID- 30232708 OWN - NLM STAT- MEDLINE DCOM- 20190926 LR - 20240825 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 35 IP - 11 DP - 2018 Nov TI - Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). PG - 2054-2068 LID - 10.1007/s12325-018-0789-7 [doi] AB - INTRODUCTION: There is an urgent need to identify patients with bladder cancer (BC) who are at high risk of recurrence or progression. Calgranulin A is a strong marker for muscle-invasive or advanced BC and recent studies have shown its potential for identifying patients at risk even in non-muscle-invasive bladder cancer (NMIBC). The present study examines risks of recurrence and progression dependent on immunostaining with calgranulin A in NMIBC. METHODS: Calgranulin A protein expression was evaluated through the immunohistochemistry of 158 randomly selected, transurethrally resected BC specimens of separate patients (pTa 89, pT1 69) using tissue microarrays. Kaplan-Meier survival analysis and Cox regression were performed to determine whether calgranulin A expression is associated with recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS). RESULTS: Calgranulin A expression is significantly different between pTa and pT1 tumors (p = 0.000, Mann-Whitney U test) and between tumor grades (p = 0.015, Kruskal-Wallis test). Kaplan-Meier estimates produced significant results for low and high calgranulin A expression concerning RFS [5y-RFS 70.4 +/- 4.0% vs. 35.9 +/- 12.5%, median RFS not reached (NR) vs. 12.0 +/- 4.4 month, p = 0.029, log-rank test], PFS (5y-PFS 90.3 +/- 2.7% vs. 51.5 +/- 14.0%, median PFS NR in both groups, p = 0.000, log-rank test), and CSS (5y-CSS 92.9 +/- 2.6% vs. 70.7 +/- 12.4%, median CSS NR in both groups, p = 0.005, log-rank test). Calgranulin A remained an independent factor for RFS (p = 0.024, HR 2.43) and PFS (p = 0.002, HR 5.92) according to the multivariate Cox regression model. CONCLUSIONS: Calgranulin A expression in NMIBC, detected through immunohistochemistry, is a promising marker for the identification of NMIBC patients at high risk of recurrence and progression. FAU - Nicklas, Andre P AU - Nicklas AP AD - Department of Urology and Andrology, Tirol Kliniken Landeskrankenhaus Hall, Hall in Tirol, Austria. andre.nicklas@tirol-kliniken.at. AD - Department of Urology and Urologic Oncology, Hannover University Medical School, Hannover, Germany. andre.nicklas@tirol-kliniken.at. FAU - Kramer, Mario W AU - Kramer MW AD - Department of Urology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany. FAU - Serth, Jurgen AU - Serth J AD - Department of Urology and Urologic Oncology, Hannover University Medical School, Hannover, Germany. FAU - Hennenlotter, Jorg AU - Hennenlotter J AD - Department of Urology, Eberhard-Karls-University, Tubingen, Germany. FAU - Hupe, Marie C AU - Hupe MC AD - Department of Urology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany. FAU - Reimer, Daniel U AU - Reimer DU AD - Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls-University, Tubingen, Germany. FAU - Merseburger, Axel S AU - Merseburger AS AD - Department of Urology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany. FAU - Kuczyk, Markus A AU - Kuczyk MA AD - Department of Urology and Urologic Oncology, Hannover University Medical School, Hannover, Germany. FAU - von Klot, Christoph-Alexander J AU - von Klot CJ AD - Department of Urology and Urologic Oncology, Hannover University Medical School, Hannover, Germany. LA - eng SI - figshare/10.6084/m9.figshare.7047752 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180919 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - 0 (Biomarkers, Tumor) RN - 0 (Calcium-Binding Proteins) RN - 0 (Calgranulin A) MH - Aged MH - Biomarkers, Tumor/analysis/metabolism MH - Calcium-Binding Proteins/analysis/metabolism MH - *Calgranulin A/analysis/metabolism MH - Disease Progression MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness/*diagnosis MH - Neoplasm Recurrence, Local/*diagnosis MH - Prognosis MH - Reproducibility of Results MH - Retrospective Studies MH - Risk Assessment/*methods MH - *Urinary Bladder Neoplasms/diagnosis/metabolism/pathology PMC - PMC6224005 OTO - NOTNLM OT - Bladder cancer OT - Calgranulin A OT - Cancer-specific survival OT - Immunohistochemistry OT - NMIBC OT - Oncology OT - Progression OT - Recurrence OT - S100A8 OT - Tissue microarray COIS- Andre Philippe Nicklas, Mario Wolfgang Kramer, Jurgen Serth, Jorg Hennenlotter, Marie Christine Hupe, Daniel Uwe Reimer, Arnulf Stenzl, Axel Stewart Merseburger, Markus Antonius Kuczyk, and Christoph-Alexander Joachim von Klot declare that they have nothing to disclose. EDAT- 2018/09/21 06:00 MHDA- 2019/09/27 06:00 PMCR- 2018/09/19 CRDT- 2018/09/21 06:00 PHST- 2018/06/25 00:00 [received] PHST- 2018/09/21 06:00 [pubmed] PHST- 2019/09/27 06:00 [medline] PHST- 2018/09/21 06:00 [entrez] PHST- 2018/09/19 00:00 [pmc-release] AID - 10.1007/s12325-018-0789-7 [pii] AID - 789 [pii] AID - 10.1007/s12325-018-0789-7 [doi] PST - ppublish SO - Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19. PMID- 30226613 OWN - NLM STAT- MEDLINE DCOM- 20181226 LR - 20240331 IS - 1791-2431 (Electronic) IS - 1021-335X (Print) IS - 1021-335X (Linking) VI - 40 IP - 5 DP - 2018 Nov TI - UCA1 overexpression is associated with less aggressive subtypes of bladder cancer. PG - 2497-2506 LID - 10.3892/or.2018.6697 [doi] AB - Non‑coding RNAs (ncRNAs) have been shown to serve important roles in carcinogenesis via complex mechanisms, including transcriptional and post‑transcriptional regulation, and chromatin interactions. Urothelial carcinoma‑associated 1 (UCA1), a long ncRNA, was recently shown to have tumorigenic properties in urothelial bladder cancer (UBC), as demonstrated by enhanced proliferation, migration, invasion and therapy resistance of UBC cell lines in vitro. These in vitro findings suggested that UCA1 is associated with aggressive tumor behavior and could have prognostic implications in UBC. The aims of the present study were to therefore to investigate the statistical associations between UCA1 RNA expression and UBC pathological features, patient prognosis and p53 and Ki‑67 expression. Chromogenic in situ hybridization and immunohistochemistry were performed on UBC tissue microarrays to characterize UCA1 RNA, and p53 and Ki‑67 expression in 208 UBC cases, including 145 non‑muscle‑invasive and 63 muscle‑invasive cases. UCA1 was observed in the tumor cells of 166/208 (80%) UBC cases tested. No expression was noted in normal stromal and endothelium cells. Patients with UBC that overexpressed UCA1 (35%) had a significantly higher survival rate (P=0.006) compared with that in patients with UBC that did not overexpress UCA1. This prognostic factor was independent of tumor morphology, concomitant carcinoma in situ, tumor grade and tumor stage. In addition, the absence of UCA1 overexpression was significantly associated with a high Ki‑67 proliferative index (P=0.008) and a p53 'mutated' immunoprofile (strong nuclear expression or complete absence of staining; P=0.003). In conclusion, the present results identified UCA1 as potentially being a novel independent prognostic marker in UBC that was associated with a better patient prognosis and that could serve a pivotal role in bladder cancer carcinogenesis. FAU - Lebrun, Laetitia AU - Lebrun L AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. FAU - Milowich, Dina AU - Milowich D AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. FAU - Le Mercier, Marie AU - Le Mercier M AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. FAU - Allard, Justine AU - Allard J AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. FAU - Van Eycke, Yves-Remy AU - Van Eycke YR AD - DIAPath‑Center for Microscopy and Molecular Imaging, ULB, B-6041 Gosselies, Belgium. FAU - Roumeguere, Thierry AU - Roumeguere T AD - Department of Urology, Erasme University Hospital, ULB, B‑1070 Brussels, Belgium. FAU - Decaestecker, Christine AU - Decaestecker C AD - DIAPath‑Center for Microscopy and Molecular Imaging, ULB, B-6041 Gosselies, Belgium. FAU - Salmon, Isabelle AU - Salmon I AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. FAU - Rorive, Sandrine AU - Rorive S AD - Department of Pathology, Erasme University Hospital, Universite Libre de Bruxelles (ULB), B‑1070 Brussels, Belgium. LA - eng PT - Journal Article DEP - 20180910 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) RN - 0 (UCA1 RNA, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Apoptosis/genetics MH - Biomarkers, Tumor/*genetics MH - Carcinogenesis/*genetics MH - Cell Line, Tumor MH - Cell Proliferation/genetics MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - RNA, Long Noncoding/*genetics MH - Urinary Bladder Neoplasms/classification/*genetics/pathology PMC - PMC6151879 EDAT- 2018/09/19 06:00 MHDA- 2018/12/27 06:00 PMCR- 2018/09/10 CRDT- 2018/09/19 06:00 PHST- 2018/03/29 00:00 [received] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/09/19 06:00 [pubmed] PHST- 2018/12/27 06:00 [medline] PHST- 2018/09/19 06:00 [entrez] PHST- 2018/09/10 00:00 [pmc-release] AID - or-40-05-2497 [pii] AID - 10.3892/or.2018.6697 [doi] PST - ppublish SO - Oncol Rep. 2018 Nov;40(5):2497-2506. doi: 10.3892/or.2018.6697. Epub 2018 Sep 10. PMID- 30219710 OWN - NLM STAT- MEDLINE DCOM- 20210520 LR - 20210520 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 6 IP - 2 DP - 2020 Mar 15 TI - Intramuscular Immunization Induces Antigen-specific Antibodies in Urine. PG - 280-283 LID - S2405-4569(18)30257-8 [pii] LID - 10.1016/j.euf.2018.09.003 [doi] AB - Towards the development of vaccines against urinary tract infections (UTI), we determined the ability of intramuscular (i.m.) immunization to result in antigen-specific antibodies in urine. As a model antigen/vaccine, levels of total and vaccine-specific antibodies were determined in urine as a spin-out study of a phase 1 trial. Non-muscle-invasive bladder cancer (NMIBC) patients at different risks of progression, undergoing intravesical bacillus Calmette-Guerin (BCG) immunotherapy or not, received an adjuvanted recombinant protein vaccine that resulted in high titers of vaccine-specific serum immunoglobulin G (IgG) in all patients, regardless of the risk group. Vaccine-specific IgG and immunoglobulin A (IgA) were detected in urine of half of the patients at low risk of progression NMIBC and in all the intermediary/high- (int/high) risk patients. Vaccine-specific IgG titers were correlated to total urinary IgG levels, the latter being higher in the int/high-risk patients. In contrast, vaccine-specific IgA did not correlate to urinary IgA levels. Furthermore, vaccine-specific antibodies were transiently increased by intravesical BCG instillations. Altogether, our data show that a standard i.m. immunization can effectively induce antigen-specific antibodies in urine, which, upon selection of optimal vaccine targets, may provide protection against UTI. Vaccine-specific IgG titers were dependent on conditions affecting total urinary IgG levels, while production of vaccine-specific IgA in situ might independently contribute to protection against infections in the bladder. PATIENT SUMMARY: Towards the development of vaccines able to protect against urinary tract infections, we examined the potential of the intramuscular vaccination using a model antigen. We found two types of specific antibodies in the urine, which together may locally contribute to protection against infections, thus supporting the use of such a standard immunization route. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Derre, Laurent AU - Derre L AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: laurent.derre@chuv.ch. FAU - Lucca, Ilaria AU - Lucca I AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Cesson, Valerie AU - Cesson V AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Valerio, Massimo AU - Valerio M AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Cerantola, Yannick AU - Cerantola Y AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Burruni, Rodolfo AU - Burruni R AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Fritschi, Urs AU - Fritschi U AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Gharbi, Dalila AU - Gharbi D AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Bobst, Martine AU - Bobst M AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Legris, Anne-Sophie AU - Legris AS AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Dartiguenave, Florence AU - Dartiguenave F AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Jichlinski, Patrice AU - Jichlinski P AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Nardelli-Haefliger, Denise AU - Nardelli-Haefliger D AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180913 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antigens, Neoplasm) RN - 0 (BCG Vaccine) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (MAGEA3 protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (Vaccines, Synthetic) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Antigens, Neoplasm/*administration & dosage/*immunology MH - BCG Vaccine/therapeutic use MH - Humans MH - Immunization/*methods MH - Immunoglobulin A/*urine MH - Immunoglobulin G/*urine MH - Injections, Intramuscular MH - Neoplasm Proteins/*administration & dosage/*immunology MH - Urinary Bladder Neoplasms/drug therapy MH - Urinary Tract Infections/prevention & control MH - Vaccines, Synthetic/*administration & dosage/*immunology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Urinary antibody responses OT - Urinary tract infection OT - Vaccination EDAT- 2018/09/17 06:00 MHDA- 2021/05/21 06:00 CRDT- 2018/09/17 06:00 PHST- 2018/08/17 00:00 [received] PHST- 2018/09/05 00:00 [accepted] PHST- 2018/09/17 06:00 [pubmed] PHST- 2021/05/21 06:00 [medline] PHST- 2018/09/17 06:00 [entrez] AID - S2405-4569(18)30257-8 [pii] AID - 10.1016/j.euf.2018.09.003 [doi] PST - ppublish SO - Eur Urol Focus. 2020 Mar 15;6(2):280-283. doi: 10.1016/j.euf.2018.09.003. Epub 2018 Sep 13. PMID- 30214686 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220322 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 67 DP - 2018 Aug 28 TI - Bladder cancer detection by urinary extracellular vesicle mRNA analysis. PG - 32810-32821 LID - 10.18632/oncotarget.25998 [doi] AB - OBJECTIVE: Urinary extracellular vesicles (EV) could be promising biomarkers for urological diseases. In this retrospective feasibility study, we conducted biomarker screening for early stage bladder cancer using EV mRNA analysis. METHODS: Biomarker candidates were identified through RNA-seq analysis of urinary EV from patients with non-muscle invasive bladder cancer (N=3), advanced urothelial cancer (N=3), no residual tumor after TURBT (N=2), and healthy and disease controls (N=4). Diagnostic performance was evaluated by RT-qPCR in a larger patient group including bladder cancer (N=173), renal pelvis and ureter cancer (N=33), no residual tumor and non-cancer disease control (N=36). RESULTS: Urinary EV SLC2A1, GPRC5A and KRT17 were overexpressed in pT1 and higher stage bladder cancer by 20.6-fold, 18.2-fold and 29.5-fold, respectively. These genes allowed detection of non-muscle invasive bladder cancer (AUC: 0.56 to 0.64 for pTa, 0.62 to 0.80 for pTis, and 0.82 to 0.86 for pT1) as well as pT2 and higher muscle invasive bladder cancer (AUC: 0.72 to 0.90). Subgroup analysis indicated that these markers could be useful for the detection of cytology-negative/-suspicious and recurrent bladder cancers. CONCLUSION: Three urinary EV mRNA were discovered to be elevated in bladder cancer. Urinary EV mRNA are promising biomarkers of urothelial cancer and worth further investigation. FAU - Murakami, Taku AU - Murakami T AD - Hitachi Chemical Co. America, Ltd., Irvine, CA, USA. FAU - Yamamoto, Cindy M AU - Yamamoto CM AD - Hitachi Chemical Co. America, Ltd., Irvine, CA, USA. FAU - Akino, Tomoshige AU - Akino T AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Tanaka, Hiroshi AU - Tanaka H AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Fukuzawa, Nobuyuki AU - Fukuzawa N AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Suzuki, Hidetaka AU - Suzuki H AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Osawa, Takahiro AU - Osawa T AD - Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Tsuji, Takahiro AU - Tsuji T AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Seki, Toshimori AU - Seki T AD - Sapporo City General Hospital, Sapporo, Japan. FAU - Harada, Hiroshi AU - Harada H AD - Sapporo City General Hospital, Sapporo, Japan. LA - eng PT - Journal Article DEP - 20180828 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC6132352 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - exosome OT - extracellular vesicles OT - mRNA COIS- CONFLICTS OF INTEREST The authors of this manuscript have conflicts of interest to disclose as follows. TM and CY are employees of Hitachi Chemical Co. America, Ltd. (HCA). TM, CY, and HM have filed patents and patent applications related with this study. The study was funded by Hitachi Chemical Co. America, Ltd. EDAT- 2018/09/15 06:00 MHDA- 2018/09/15 06:01 PMCR- 2018/08/28 CRDT- 2018/09/15 06:00 PHST- 2018/05/03 00:00 [received] PHST- 2018/08/04 00:00 [accepted] PHST- 2018/09/15 06:00 [entrez] PHST- 2018/09/15 06:00 [pubmed] PHST- 2018/09/15 06:01 [medline] PHST- 2018/08/28 00:00 [pmc-release] AID - 25998 [pii] AID - 10.18632/oncotarget.25998 [doi] PST - epublish SO - Oncotarget. 2018 Aug 28;9(67):32810-32821. doi: 10.18632/oncotarget.25998. eCollection 2018 Aug 28. PMID- 30213523 OWN - NLM STAT- MEDLINE DCOM- 20190722 LR - 20190722 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 75 IP - 3 DP - 2019 Mar TI - Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. PG - 423-432 LID - S0302-2838(18)30619-5 [pii] LID - 10.1016/j.eururo.2018.08.027 [doi] AB - BACKGROUND: Previous molecular subtyping for bladder carcinoma (BLCA) involved <450 samples, with diverse classifications. OBJECTIVE: To identify molecular subtypes by curating a large BLCA dataset. DESIGN, SETTING, AND PARTICIPANTS: Gene expression publicly available were combined and reanalyzed. The dataset contained 2411 unique tumors encompassing non-muscle-invasive (NMIBC) and muscle-invasive BLCA (MIBC). Subtypes were reproduced on The Cancer Genome Atlas, UROMOL, and IMvigor210. INTERVENTION: Subtypes were assigned by gene expression. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier analyses were performed for subtype-clinical outcome correlations; Chi-square/Fisher exact tests were used for subtype-clinicopathological parameters associations. RESULTS AND LIMITATIONS: We identified six molecular subtypes with different overall survival (OS) and molecular features. Subtype Neural-like (median OS, 87 mo) is prevalent in MIBC and characterized by high WNT/beta-catenin signaling. HER2-like (107.7 mo) is distributed evenly across NMIBC and MIBC, with higher ERBB2 amplification and signaling. Papillary-like (>135 mo), an NMIBC subtype enriched in urothelial differentiation genes, shows a high frequency of actionable FGFR3 mutations, amplifications, and FGFR3-TACC3 fusion. Luminal-like (91.7 mo), predominantly NMIBC, has higher MAPK signaling and more KRAS and KMT2C/D mutations than other subtypes. Mesenchymal-like (MES; 86.6 mo) and Squamous-cell carcinoma-like (SCC; 20.6 mo) are predominant in MIBC. MES is high in AXL signaling, whereas SCC has elevated PD1, CTLA4 signaling, and macrophage M2 infiltration. About 20% of NMIBCs show MIBC subtype traits and a lower 5-yr OS rate than Papillary-like NMIBC (81% vs 96%). The main limitations of our study are the incomplete clinical annotation, and the analyses were based on transcriptome subset due to comparisons across gene expression quantification technologies. CONCLUSIONS: BLCA can be stratified into six molecular subtypes. NMIBC, with a high risk of progression, displays the molecular features of MIBC. PATIENT SUMMARY: Biomarkers are urgently needed to guide patient treatment selection and avoid unnecessary toxicities in those who fail to respond. We believe molecular subtyping is a promising way to tailor disease management for those who will benefit most. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tan, Tuan Zea AU - Tan TZ AD - Cancer Science Institute of Singapore, National University of Singapore, Center for Translational Medicine, Singapore. Electronic address: csittz@nus.edu.sg. FAU - Rouanne, Mathieu AU - Rouanne M AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, Suresnes, France; INSERM Unit 1015, Laboratoire de Recherche Translationnelle en Immunologie (LRTI), Gustave Roussy, Universite Paris-Saclay, Villejuif, France. FAU - Tan, Kien Thiam AU - Tan KT AD - ACT Genomics Co., Ltd., Taipei city, Taiwan. FAU - Huang, Ruby Yun-Ju AU - Huang RY AD - Cancer Science Institute of Singapore, National University of Singapore, Center for Translational Medicine, Singapore; Department of Obstetrics and Gynecology, National University Health System, Singapore; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. FAU - Thiery, Jean-Paul AU - Thiery JP AD - Biochemistry Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Guangzhou Institute of Biomedicine and Health, Chinese Academy of Science, Guangzhou, People's Republic of China; CNRS Emeritus CNRS UMR 7057 Matter and Complex Systems, University Paris Denis Diderot, Paris, France; INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Medecine - University Paris-Sud, Universite Paris-Saclay, Villejuif, France. Electronic address: bchtjp@nus.edu.sg. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20180910 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Eur Urol. 2019 Mar;75(3):433-434. doi: 10.1016/j.eururo.2018.09.006. PMID: 30237022 CIN - Eur Urol. 2019 Apr;75(4):e106-e107. doi: 10.1016/j.eururo.2018.11.049. PMID: 30522915 CIN - Eur Urol. 2019 Apr;75(4):e108-e109. doi: 10.1016/j.eururo.2018.11.048. PMID: 30527788 MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Carcinoma/classification/*genetics/mortality/pathology MH - Databases, Genetic MH - Disease Progression MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Genetic Predisposition to Disease MH - Humans MH - Male MH - Middle Aged MH - Phenotype MH - Prognosis MH - Risk Assessment MH - Risk Factors MH - *Transcriptome MH - Urinary Bladder Neoplasms/classification/*genetics/mortality/pathology MH - Urothelium/*chemistry/pathology MH - Young Adult OTO - NOTNLM OT - Bladder carcinoma OT - Microarray gene expression OT - Molecular subtypes EDAT- 2018/09/15 06:00 MHDA- 2019/07/23 06:00 CRDT- 2018/09/15 06:00 PHST- 2018/04/11 00:00 [received] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/09/15 06:00 [pubmed] PHST- 2019/07/23 06:00 [medline] PHST- 2018/09/15 06:00 [entrez] AID - S0302-2838(18)30619-5 [pii] AID - 10.1016/j.eururo.2018.08.027 [doi] PST - ppublish SO - Eur Urol. 2019 Mar;75(3):423-432. doi: 10.1016/j.eururo.2018.08.027. Epub 2018 Sep 10. PMID- 30212968 OWN - NLM STAT- MEDLINE DCOM- 20180924 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 37 DP - 2018 Sep TI - Prognostic impact of preoperative anemia on upper tract urothelial carcinoma. PG - e12300 LID - 10.1097/MD.0000000000012300 [doi] LID - e12300 AB - The aim of this study was to investigate the effect of preoperative anemia on the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).A total of 620 patients with UTUC were retrospectively analyzed. Anemia was decided by preoperatively measured hemoglobin values based on the World Health Organization (WHO) classification. Kaplan-Meier method and Cox proportional hazards regression models were used to analyze the relationship between anemia and survival outcomes. The meta-analysis part was performed according to PRISMA guidelines.The median follow-up was 51 (range: 1-168) months. A total of 246 patients had preoperative anemia in our cohort. Anemia was found to be related to high-grade (P < .001), sessile architecture (P = .001), advanced T stage (P < .001), lymphovascular invasion (LVI) (P = .006), and worse chronic kidney disease (CKD) stage (P = .012). Kaplan-Meier curves revealed that patients with preoperative anemia had worse overall survival (OS), cancer-specific survival (CSS), and disease recurrence-free survival (RFS) (all P < .001). Multivariable Cox analyses found that anemia was an independent predictor of CSS [hazard ratio (HR) 1.719, 95% confidence interval (95% CI): 1.285-2.300], RFS (HR 1.427, 95% CI: 1.114-1.829) and OS (HR 1.756, 95% CI: 1.353-2.279). Among patients without end-stage renal disease (ESRD, n = 614), the anemia was also proved to be associated with worse outcomes in multivariable Cox analysis (OS, HR 1.759, 95% CI: 1.353-2.287; CSS, HR 1.726, 95% CI: 1.289-2.311, and RFS, HR 1.431, 95% CI: 1.117-1.837). Seven studies were included in the meta-analysis, and the pooled results showed that anemia was also related to worse CSS (HR 2.05, 95% CI: 1.73-2.44), RFS (HR 1.57, 95% CI: 1.30-1.90), and OS (HR 1.53, 95% CI: 1.10-2.13), but not related to intravesical recurrence (HR 1.17, 95% CI: 0.75-1.82).Preoperative anemia was proved to be significantly associated with worse oncologic outcomes in patients with UTUC following RNU. FAU - Tan, Ping AU - Tan P AD - Department of Urology, Institute of Urology Department of Emergency Department of Liver Surgery, Liver Transplantation Division Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Xie, Nan AU - Xie N FAU - Liao, Haotian AU - Liao H FAU - Zou, Liqun AU - Zou L FAU - Xu, Huan AU - Xu H FAU - Yang, Lu AU - Yang L FAU - Liu, Liangren AU - Liu L FAU - Wei, Qiang AU - Wei Q LA - eng PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Aged MH - Anemia/complications/*mortality/surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/complications/*mortality/surgery MH - Male MH - Middle Aged MH - Nephroureterectomy/*mortality MH - Preoperative Period MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Ureteral Neoplasms/complications/*mortality/surgery PMC - PMC6155943 COIS- The authors declare that they have no conflict of interest. EDAT- 2018/09/15 06:00 MHDA- 2018/09/25 06:00 PMCR- 2018/09/14 CRDT- 2018/09/15 06:00 PHST- 2018/09/15 06:00 [entrez] PHST- 2018/09/15 06:00 [pubmed] PHST- 2018/09/25 06:00 [medline] PHST- 2018/09/14 00:00 [pmc-release] AID - 00005792-201809140-00045 [pii] AID - MD-D-18-02341 [pii] AID - 10.1097/MD.0000000000012300 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Sep;97(37):e12300. doi: 10.1097/MD.0000000000012300. PMID- 30210644 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 9 IP - 17 DP - 2018 TI - Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. PG - 3208-3215 LID - 10.7150/jca.24506 [doi] AB - Background: Current standard methods used to detect and monitor bladder cancer (BC) are invasive or have low sensitivity. We have previously reported in an international European study four non-invasive tests for BC diagnosis based on the gene expression patterns of urine. Objective: to validate the tests in an independent Asian cohort. Design, setting and participants: Prospective blinded study in which consecutive voided urine samples from BC patients and controls (n=520) were collected in the Fudan University Shanghai Cancer Center from 2014-2016. Gene expression values were quantified using TaqMan Arrays. The same cut-off as previously reported for discrimination between tumours and controls was used in this validation study. Results and limitations: Finally, a total of 257 tumour and 132 control urine samples were analysed. We found a high accuracy for the four gene classifiers in this independent Asian set, the classifiers composed of 5 and 10 genes achieved the best sensitivity (80.54% and 81.32%, respectively) maintaining a high specificity (91.67% and 85.61%, respectively). Sensitivity of 5-gene (GS_D5) and 10-gene (GS_D10) expression classifiers in recurrent BC cases (78 and 79%, respectively) is comparable to that of primary BC cases (82%). Cytology and NMP22 identified 67% and 40%, respectively, of tumours that have been diagnosed with our tests. In addition, influence of each studied gene was analyzed and showed similar gene rank between Chinese and Caucasian population. Conclusions: Our study proves that our non-invasive diagnostic BC tests can be reproduced in independent cohorts and in an external laboratory. All the four gene classifiers have shown equal or superior performance to the current gold standard in the present and previously reported validation studies. Consequently, they may be taken for consideration as molecular tests applicable to clinical practice in the management of BC. Patient summary: Our gene classifiers achieve sensitivities up to 90% in HR NMIBC and MIBC patients, while this achievement is comparatively lower in LR NMIBC ones. FAU - Han, Chengtao AU - Han C AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. FAU - Mengual, Lourdes AU - Mengual L AD - Department and Laboratory of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi iSunyer, Universitat de Barcelona, Barcelona, Spain. FAU - Kang, Bin AU - Kang B AD - Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Cancer Institute,Fudan University Shanghai Cancer Center, Shanghai, P.R. China. AD - bioMerieux (Shanghai) Company Limited, Shanghai, P.R. China. FAU - Lozano, Juan Jose AU - Lozano JJ AD - CIBERehd. Plataforma de Bioinformatica. IDIBAPS. FAU - Yang, Xiaoqun AU - Yang X AD - Department of Pathology, Rui Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, P.R. China. FAU - Zhang, Cuizhu AU - Zhang C AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Department and Laboratory of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi iSunyer, Universitat de Barcelona, Barcelona, Spain. FAU - Liang, Ji AU - Liang J AD - Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Cancer Institute,Fudan University Shanghai Cancer Center, Shanghai, P.R. China. AD - bioMerieux (Shanghai) Company Limited, Shanghai, P.R. China. FAU - Ye, Dingwei AU - Ye D AD - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. LA - eng PT - Journal Article DEP - 20180806 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC6134826 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Chinese OT - Gene classifiers OT - Gene expression OT - Non-invasive COIS- Competing Interests: Lourdes Mengual, Juan Jose Lozano, and Antonio Alcaraz are inventors of patents WO 2008/113870 and WO 2014/118334 applied by Fina Biotech S.L. All other authors declared no conflicts of interest. EDAT- 2018/09/14 06:00 MHDA- 2018/09/14 06:01 PMCR- 2018/01/01 CRDT- 2018/09/14 06:00 PHST- 2017/12/22 00:00 [received] PHST- 2018/04/15 00:00 [accepted] PHST- 2018/09/14 06:00 [entrez] PHST- 2018/09/14 06:00 [pubmed] PHST- 2018/09/14 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - jcav09p3208 [pii] AID - 10.7150/jca.24506 [doi] PST - epublish SO - J Cancer. 2018 Aug 6;9(17):3208-3215. doi: 10.7150/jca.24506. eCollection 2018. PMID- 30203936 OWN - NLM STAT- MEDLINE DCOM- 20190315 LR - 20190315 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 70 IP - 6 DP - 2018 Dec TI - The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection. PG - 594-597 LID - 10.23736/S0393-2249.18.03175-2 [doi] AB - BACKGROUND: Histology is one of the most important factors determining the prognosis of bladder cancers and rare variants are generally associated with decreased disease specific survival compared to pure transitional cell carcinomas. We believe that rare bladder cancer variants are likely underdiagnosed in the absence of a dedicated uro-pathologist in many centers. The objective of this study is to evaluate the contribution of a dedicated uro-pathologist on the identification of rare bladder cancer variants. METHODS: We retrospectively analyzed the clinical and histological records of all patients which underwent a radical cystectomy and lymph node dissection between January 2000 and September 2015. The sample was divided in two groups: Group A, consists of patients who underwent radical cystectomy in the absence of a dedicated uro-pathologist at our institution, whereas the Group B consists of patients who underwent surgery when a dedicated uro-pathology service was available. We then evaluated the impact of a dedicated uro-pathologist on rare variants detection. RESULTS: One hundred thirty-seven out of 551 (24.9%) of patients who underwent RC had at least one rare variant. In Group A 38/238 (16%) of patients showed a rare variant, while 99/313 (31.6%; P<0.001) in group B. Furthermore, the diagnosis of sarcomatoid variant was statistically significantly less common in group A (P=0.0026). The concordance between final radical cystectomy histology and previous transurethral resection of bladder tumor (TURBT) histology was poor in both groups (overall 50.4%). CONCLUSIONS: The presence of a dedicated urological anatomical pathologist is of paramount importance and significantly increases the detection rate of non-transitional cell carcinoma bladder cancer types, but it does not increase the concordance rate between histological diagnoses in TURBT and radical cystectomy specimens. FAU - Mantica, Guglielmo AU - Mantica G AD - Department of Urology, Policlinico San Martino Hospital, University of Genoa, Genoa, Italy - guglielmo.mantica@gmail.com. AD - Department of Urology, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa - guglielmo.mantica@gmail.com. FAU - Simonato, Alchiede AU - Simonato A AD - Department of Urology, University of Palermo, Palermo, Italy. FAU - Du Plessis, Danelo E AU - Du Plessis DE AD - Department of Urology, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa. FAU - Maffezzini, Massimo AU - Maffezzini M AD - Department of Urology, Policlinico San Martino Hospital, University of Genoa, Genoa, Italy. FAU - De Rose, Aldo F AU - De Rose AF AD - Department of Urology, Policlinico San Martino Hospital, University of Genoa, Genoa, Italy. FAU - van der Merwe, Andre AU - van der Merwe A AD - Department of Urology, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, Policlinico San Martino Hospital, University of Genoa, Genoa, Italy. LA - eng PT - Journal Article DEP - 20180910 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*diagnosis/pathology/surgery MH - Cystectomy MH - Female MH - Humans MH - Incidence MH - Lymph Node Excision MH - Male MH - Middle Aged MH - *Pathologists MH - Professional Role MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/pathology EDAT- 2018/09/12 06:00 MHDA- 2019/03/16 06:00 CRDT- 2018/09/12 06:00 PHST- 2018/09/12 06:00 [pubmed] PHST- 2019/03/16 06:00 [medline] PHST- 2018/09/12 06:00 [entrez] AID - S0393-2249.18.03175-2 [pii] AID - 10.23736/S0393-2249.18.03175-2 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2018 Dec;70(6):594-597. doi: 10.23736/S0393-2249.18.03175-2. Epub 2018 Sep 10. PMID- 30200146 OWN - NLM STAT- MEDLINE DCOM- 20181001 LR - 20250623 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 36 DP - 2018 Sep TI - The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: A diagnostic meta-analysis and systematic review. PG - e12227 LID - 10.1097/MD.0000000000012227 [doi] LID - e12227 AB - BACKGROUND: The aim of the study was to systematically review the relevant studies to assess the role of fluorescence in situ hybridization (FISH) test for predicting patient response to Bacillus Calmette-Guerin (BCG) therapy after transurethral resection of bladder tumor (TURBT). METHODS: We searched PubMed, Embase, and the Cochrane Library from inception to July 5, 2018, and used Quality Assessment Tool for Diagnosis Accuracy Studies (QUADAS-2) to assess the quality. We pooled sensitivity, specificity, and area under curve (AUC) of baseline and post-BCG FISH test for predicting tumor recurrence. Hazard ratio (HR) with 95% confidence intervals (95% CIs) and a Fagan nomogram were applied to assess predictive accuracy of post-BCG FISH test. RESULTS: A total of 6 studies with 442 participants for post-BCG test and 404 participants for baseline BCG test were included. The pooled analysis for post-BCG FISH test revealed the sensitivity of 0.54 (95% CI 0.38-0.69), specificity of 0.84 (95% CI: 0.72-0.91), and area under the curve (AUC) of 0.78 (95% CI: 0.74-0.81) for predicting tumor recurrence. Patients with positive post-BCG FISH test were more likely to recur during follow-up (HR 3.95, 95% CI 2.72-5.72). The Fagan nomogram revealed the "post-test" probability of tumor recurrence increased by 29% for patients with positive post-BCG FISH test. The baseline FISH test had a pooled sensitivity of 0.70 (95% CI 0.55-0.81), specificity of 0.41 (95% CI: 0.26-0.58), and AUC of 0.60 (95% CI: 0.56-0.64) for predicting recurrence. CONCLUSION: The post-BCG FISH test can predict BCG failure with high specificity and patients with positive post-BCG FISH test were more likely to recur. However, the relatively low sensitivity of post-BCG FISH test and unsatisfactory performance of baseline FISH test may limit their mono-use. FAU - Bao, Yige AU - Bao Y AD - Department of Urology, Institute of Urology West China School of Clinical Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P.R. China. FAU - Tu, Xiang AU - Tu X FAU - Chang, Tiancong AU - Chang T FAU - Qiu, Shi AU - Qiu S FAU - Yang, Lu AU - Yang L FAU - Geng, Jiwen AU - Geng J FAU - Quan, Liuliu AU - Quan L FAU - Wei, Qiang AU - Wei Q LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (BCG Vaccine) RN - 0 (Cancer Vaccines) SB - IM MH - BCG Vaccine/*therapeutic use MH - Cancer Vaccines/*therapeutic use MH - Humans MH - *In Situ Hybridization, Fluorescence MH - Prognosis MH - Urinary Bladder Neoplasms/*pathology/surgery/*therapy PMC - PMC6133599 COIS- The authors of this work have nothing to disclose and the authors report no conflicts of interest. EDAT- 2018/09/12 06:00 MHDA- 2018/10/03 06:00 PMCR- 2018/09/07 CRDT- 2018/09/12 06:00 PHST- 2018/09/12 06:00 [entrez] PHST- 2018/09/12 06:00 [pubmed] PHST- 2018/10/03 06:00 [medline] PHST- 2018/09/07 00:00 [pmc-release] AID - 00005792-201809070-00088 [pii] AID - MD-D-18-03272 [pii] AID - 10.1097/MD.0000000000012227 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Sep;97(36):e12227. doi: 10.1097/MD.0000000000012227. PMID- 30200080 OWN - NLM STAT- MEDLINE DCOM- 20180917 LR - 20260127 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 36 DP - 2018 Sep TI - EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification. PG - e12006 LID - 10.1097/MD.0000000000012006 [doi] LID - e12006 AB - BACKGROUND: Patients with non-muscle-invasive bladder cancer (NMIBC) need accurate estimations of the risk of recurrence and progression. Physicians can offer individualized therapy after identifying high-risk tumors. In our study, we compared the applicability of European Organization for Research and Treatment of Cancer (EORTC) risk tables and American Urological Association (AUA) risk stratification in Chinese patients with NMIBC. METHODS: We retrospectively studied 301 patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) between October 2000 and July 2009 at Huashan Hospital of Fudan University and analyzed their parameters. The recurrence and progression rates at 1 and 5 years postoperatively were calculated along with 95% confidence intervals. We compared them with results obtained from the EORTC risk tables and AUA risk stratification. P values <.05 were considered statistically significant. RESULTS: The median patient age was 67 years (21-92 years) and the median follow-up duration was 46 months (2-151 months). We used EORTC risk tables to classify patients into 3 groups, depending on whether they suffered recurrence or progression after TURBT. Kaplan-Meier curves showed significant differences among the 3 recurrence-free survival (RFS) levels (P < .0001, log-rank test) and among the 3 progression-free survival (PFS) levels (P < .0001, log-rank test). AUA risk stratification showed the same results. Both classifications were suitable to predict recurrence and progression in Chinese patients. However, for high-risk patients in both series, Kaplan-Meier curves showed significant differences between RFS levels (P < .0001, log-rank test) and between PFS levels (P < .0001, log-rank test). EORTC risk tables were stricter and AUA was more sensitive in assigning patients to a high-risk group. CONCLUSION: EORTC risk tables are better than AUA risk stratification for predicting recurrence and progression in Chinese patients with NMIBC, especially among high-risk patients. FAU - Wang, Hui AU - Wang H AD - Department of Urology Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Ding, Weihong AU - Ding W FAU - Jiang, Guangliang AU - Jiang G FAU - Gou, Yuancheng AU - Gou Y FAU - Sun, Chuanyu AU - Sun C FAU - Chen, Zhongqing AU - Chen Z FAU - Xu, Ke AU - Xu K FAU - Xia, Guowei AU - Xia G LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - China MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery MH - Young Adult PMC - PMC6133586 COIS- The authors have no conflicts of interest to disclose. EDAT- 2018/09/12 06:00 MHDA- 2018/09/18 06:00 PMCR- 2018/09/07 CRDT- 2018/09/12 06:00 PHST- 2018/09/12 06:00 [entrez] PHST- 2018/09/12 06:00 [pubmed] PHST- 2018/09/18 06:00 [medline] PHST- 2018/09/07 00:00 [pmc-release] AID - 00005792-201809070-00022 [pii] AID - MD-D-17-05843 [pii] AID - 10.1097/MD.0000000000012006 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Sep;97(36):e12006. doi: 10.1097/MD.0000000000012006. PMID- 30191393 OWN - NLM STAT- MEDLINE DCOM- 20191212 LR - 20191217 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 5 DP - 2019 May TI - Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study. PG - 823-829 LID - 10.1007/s00345-018-2437-x [doi] AB - PURPOSE: To assess the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IVC) in T1G3 bladder cancer (Bca) after transurethral resection of bladder tumor (TURBT). METHODS: Our study retrospectively reviewed 200 patients with T1G3 BCa who had all undergone TURBT. The patients' medical records were divided into two groups, one group only had IVC with pirarubicin after surgery, and the other group had IAC (cisplatin and epirubicin) combined with IVC after surgery. The patients were monitored regularly by urine cytology and cystoscopy. Survival and recurrence curves were calculated using the Kaplan-Meier method. Tumor recurrence, progression and tumor-specific death rate were compared with Chi-square test. A multivariate analysis was carried out to find out potential confounders. RESULTS: A total of 200 medical record was analyzed, 131 patients received IVC, 69 IAC + IVC treatment, tumor-specific death rate between the combined IAC and IVC compared to IVC alone was 7.25 and 17.6%, respectively (p < 0.05); the tumor recurrence rate between the two groups was 31.8% (22/69) and 44.3%, respectively (58/131) (p < 0.05), and tumor recurred later in the IAC + IVC group (p < 0.05), tumor progression rate was 18.8% (13/69) and 28.2% (37/131), respectively, with p < 0.05. Overall survival was longer in IAC + IVC group (p < 0.05). Using the multivariable regression model, IAC was significantly related to disease recurrence (p < 0.05) and overall survival (p < 0.05). CONCLUSION: T1G3 BCa post-TURBT surgery patients who underwent IAC combined with IVC had a longer overall survival and increased time interval to first recurrence, lower tumor recurrence rate, progression rate and tumor-specific death rate than compared with those who only underwent IVC alone. FAU - Huang, Bin AU - Huang B AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Zheng, Jiabo AU - Zheng J AD - Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. FAU - Yao, Zhijun AU - Yao Z AD - Department of Urology, The Central Hospital of Hengyang, Hengyang, 421001, China. FAU - Fan, Wenzhe AU - Fan W AD - Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. FAU - Qiu, Shaopeng AU - Qiu S AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. FAU - Chen, Lingwu AU - Chen L AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. chenlingwu@hotmail.com. FAU - Chen, Junxing AU - Chen J AD - Department of Urology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou, 510080, China. junxingchen@hotmail.com. LA - eng GR - 81402116/The National Natural Science Foundation of China/ GR - 2014A020212116/Science and Technology Planning Project of Guangdong Province/ GR - 2017A030313847/Natural Science Foundation of Guangdong Province/ PT - Comparative Study PT - Journal Article DEP - 20180906 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 3Z8479ZZ5X (Epirubicin) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage MH - *Cystoscopy MH - Doxorubicin/*analogs & derivatives/therapeutic use MH - Epirubicin/administration & dosage MH - Female MH - Humans MH - Injections, Intra-Arterial MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Organ Sparing Treatments MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Bladder cancer OT - Intra-arterial chemotherapy OT - Intravesical chemotherapy OT - T1G3 EDAT- 2018/09/08 06:00 MHDA- 2019/12/18 06:00 CRDT- 2018/09/08 06:00 PHST- 2018/04/12 00:00 [received] PHST- 2018/08/06 00:00 [accepted] PHST- 2018/09/08 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2018/09/08 06:00 [entrez] AID - 10.1007/s00345-018-2437-x [pii] AID - 10.1007/s00345-018-2437-x [doi] PST - ppublish SO - World J Urol. 2019 May;37(5):823-829. doi: 10.1007/s00345-018-2437-x. Epub 2018 Sep 6. PMID- 30190111 OWN - NLM STAT- MEDLINE DCOM- 20190412 LR - 20210116 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 4 DP - 2018 Jul TI - Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. PG - 512-521 LID - S2405-4569(18)30238-4 [pii] LID - 10.1016/j.euf.2018.08.019 [doi] AB - CONTEXT: Current guidelines remain ill-defined regarding the optimal intravesical chemotherapy type and regimen for the treatment of non-muscle-invasive bladder cancer (NMIBC). Although maintenance therapy is a standard part of bacillus Calmette-Guerin (BCG) therapy, its role in the context of chemotherapy remains debatable. OBJECTIVE: We reviewed the literature regarding the utilization of intravesical maintenance chemotherapy in the treatment of NMIBC to determine its impact on recurrence, progression, and survival. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2018 reporting on the utilization of maintenance intravesical chemotherapy. Only randomized controlled trials (RCTs) that included a comparison between an induction regimen and an induction plus maintenance regimen were included. EVIDENCE SYNTHESIS: Sixteen RCTs were included in the final analysis. The most commonly studied intravesical chemotherapy agents used in maintenance regimens were epirubicin, doxorubicin, and mitomycin C. Several maintenance schedules were utilized, some as short as 3mo and others as long as 3 yr, while the most common maintenance regimen utilized was monthly instillation for 1 yr. Of the 16 trials, 13 reported no significant improvement in recurrence for patients receiving maintenance compared with no maintenance, and none of the trials demonstrated a significant impact on progression or survival. CONCLUSIONS: Intermediate length maintenance regimens lasting 7-12mo were the most common maintenance regimens utilized. There was considerable heterogeneity between trial design and duration of follow-up, making direct comparisons for recurrence, progression, and survival outcomes between trials challenging. Although maintenance intravesical chemotherapy is suggested as a treatment option for patients with NMIBC by some guidelines, the majority of evidence suggested that it provided no significant advantage over induction therapy alone with respect to recurrence, progression, or survival. PATIENT SUMMARY: In this review, we reviewed prior clinical trials to determine whether prolonged intravesical chemotherapy ("maintenance therapy") improved the rates of recurrence, progression, and survival. Where differences were found in favor of maintenance therapy, there was no statistical significance demonstrated, possibly due to the underpowered nature of the study design. While there was no consensus on an optimal agent or maintenance schedule, we found no evidence to suggest that maintenance therapy would improve recurrence, progression, or survival. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Tabayoyong, William B AU - Tabayoyong WB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, The University of Iowa, Iowa City, IA, USA. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University Medical Center, New York, NY, USA. FAU - Ray-Zack, Mohamed D AU - Ray-Zack MD AD - Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - Brausi, Maurizio AU - Brausi M AD - Department of Urology, Azienda Unita Sanitaria Locale Modena, Modena, Italy. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, The University of British Columbia, Vancouver, Canada. FAU - Williams, Stephen B AU - Williams SB AD - Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. Electronic address: stbwilli@utmb.edu. LA - eng GR - KL2 TR001441/TR/NCATS NIH HHS/United States GR - TL1 TR001440/TR/NCATS NIH HHS/United States GR - UL1 TR001439/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Systematic Review DEP - 20180903 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*pharmacology MH - Humans MH - Maintenance Chemotherapy/*methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control MH - Prognosis MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/drug therapy/pathology PMC - PMC7810510 MID - NIHMS1659797 OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Intravesical OT - Maintenance COIS- Conflict of Interest: None. EDAT- 2018/09/08 06:00 MHDA- 2019/04/13 06:00 PMCR- 2021/01/15 CRDT- 2018/09/08 06:00 PHST- 2018/07/11 00:00 [received] PHST- 2018/08/02 00:00 [revised] PHST- 2018/08/23 00:00 [accepted] PHST- 2018/09/08 06:00 [pubmed] PHST- 2019/04/13 06:00 [medline] PHST- 2018/09/08 06:00 [entrez] PHST- 2021/01/15 00:00 [pmc-release] AID - S2405-4569(18)30238-4 [pii] AID - 10.1016/j.euf.2018.08.019 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3. PMID- 30188332 OWN - NLM STAT- MEDLINE DCOM- 20190805 LR - 20190805 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 28 IP - 6 DP - 2018 Nov TI - Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice? PG - 584-590 LID - 10.1097/MOU.0000000000000546 [doi] AB - PURPOSE OF REVIEW: To summarize recent findings on tissue biomarkers for nonmuscle-invasive bladder cancer (NMIBC) with an emphasis on their prognostic and predictive role. RECENT FINDINGS: Accurate risk stratification is essential and the major driver in patient counseling regarding surveillance and decision making relative to therapeutic strategies. In NMIBC, there is an unmet need for improving the accuracy of current prognostic and predictive models, which rely only on clinicopathologic features and do not reflect the biological heterogeneity of the cancer in each individual. Studies continuously shed novel light on some processes involved in cancerogenesis, host response and interactions in the tumor's own microenvironment, which may be considered as potential biomarkers and targets for future directed therapies. SUMMARY: Biomarkers are necessary to transform bladder cancer management and usher in the age of personalized medicine. The clinical use is, however, still limited because of heterogeneity in study design, staining methods and an overall lacking adherence to a structured biomarker testing process. FAU - Bruchbacher, Andreas AU - Bruchbacher A AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Hassler, Melanie AU - Hassler M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Institute of Andrology and Urology, Karl Landsteiner University, Krems an der Donau, Austria. AD - Department of Urology, University of Texas Southwestern Medical Centre, Dallas, Texas, USA. AD - Department of Urology, Weill Cornell Medical College, New York, USA. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) MH - Administration, Intravesical MH - Antineoplastic Agents/administration & dosage MH - Biomarkers, Tumor/*analysis/standards MH - Carcinogenesis/pathology MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Guideline Adherence MH - Humans MH - Neoplasm Invasiveness/pathology MH - Practice Guidelines as Topic MH - Predictive Value of Tests MH - Prognosis MH - Risk Assessment/methods/standards MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/pathology/therapy EDAT- 2018/09/07 06:00 MHDA- 2019/08/06 06:00 CRDT- 2018/09/07 06:00 PHST- 2018/09/07 06:00 [pubmed] PHST- 2019/08/06 06:00 [medline] PHST- 2018/09/07 06:00 [entrez] AID - 10.1097/MOU.0000000000000546 [doi] PST - ppublish SO - Curr Opin Urol. 2018 Nov;28(6):584-590. doi: 10.1097/MOU.0000000000000546. PMID- 30182073 OWN - NLM STAT- MEDLINE DCOM- 20190628 LR - 20221207 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 59 IP - 5 DP - 2018 Sep TI - Immune checkpoint inhibitors for urothelial carcinoma. PG - 285-296 LID - 10.4111/icu.2018.59.5.285 [doi] AB - Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most common histological type of cancer. Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC (mUC) and the preferred treatment option in the perioperative (neoadjuvant and/or adjuvant) setting of muscle invasive bladder cancer (MIBC). In addition, intravesical bacillus Calmette-Guerin immunotherapy or chemotherapy is applied as the adjuvant therapeutic option in non-muscle invasive bladder cancer (NMIBC) after transurethral resection, to prevent recurrence and progression. In recent years, with an increased understanding of cancer immunobiology, systemic immunotherapies targeting immune checkpoint inhibition has been explored and clinically used in the area of UC. The programmed cell death 1 receptor (PD-1) and its ligand (PD-L1) are important negative regulators of immune activity, preventing the destruction of normal tissues and autoimmunity. To date, five immune checkpoint inhibitors blocking PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved by the United States Food and Drug Administration (US-FDA) for first- or second-line use in mUC, based on durable therapeutic response and manageable safety profiles observed in relevant clinical trials. In addition, the clinical use of several immune checkpoint inhibitors is currently being tested for MIBC and NMIBC. In this article, we review the current and ongoing clinical trials, regarding immune checkpoint inhibitors, being conducted in various clinical settings of UC, including mUC, MIBC, and NMIBC. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, Korea. FAU - Seo, Ho Kyung AU - Seo HK AUID- ORCID: 0000-0003-2601-1093 AD - Department of Urology, Center for Prostate Cancer, Hospital and Biomarker Branch, Research Institute, National Cancer Center, Goyang, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20180831 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biomarkers, Tumor) RN - 0W860991D6 (Deoxycytidine) RN - 28X28X9OKV (durvalumab) RN - 31YO63LBSN (Nivolumab) RN - 52CMI0WC3Y (atezolizumab) RN - BG3F62OND5 (Carboplatin) RN - DPT0O3T46P (pembrolizumab) RN - KXG2PJ551I (avelumab) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Antineoplastic Agents, Immunological/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Biomarkers, Tumor/blood MH - Carboplatin/administration & dosage MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Cisplatin/administration & dosage MH - Clinical Trials as Topic MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Humans MH - Neoplasm Invasiveness MH - Nivolumab/therapeutic use MH - Ureteral Neoplasms/*drug therapy/pathology MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Gemcitabine PMC - PMC6121021 OTO - NOTNLM OT - Immunotherapy OT - PD-1 inhibitor OT - PD-L1 inhibitor OT - Urinary bladder neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2018/09/06 06:00 MHDA- 2019/06/30 06:00 PMCR- 2018/09/01 CRDT- 2018/09/06 06:00 PHST- 2018/06/15 00:00 [received] PHST- 2018/08/05 00:00 [accepted] PHST- 2018/09/06 06:00 [entrez] PHST- 2018/09/06 06:00 [pubmed] PHST- 2019/06/30 06:00 [medline] PHST- 2018/09/01 00:00 [pmc-release] AID - 10.4111/icu.2018.59.5.285 [doi] PST - ppublish SO - Investig Clin Urol. 2018 Sep;59(5):285-296. doi: 10.4111/icu.2018.59.5.285. Epub 2018 Aug 31. PMID- 30179882 OWN - NLM STAT- MEDLINE DCOM- 20190415 LR - 20190415 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 101 IP - 3 DP - 2018 TI - Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-Guerin: A Retrospective Study. PG - 269-276 LID - 10.1159/000492121 [doi] AB - INTRODUCTION: Primary carcinoma in situ (P-CIS) of the bladder is rare and its clinical behavior and predictive features have not been well described. The purpose of this study was to evaluate the effects of various factors including angiotensin-2 converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) on recurrence-free survival (RFS)-related prognosis in patients with P-CIS. MATERIALS AND METHODS: In our medical center, 5,945 patients were diagnosed with bladder cancer from January 1999 to January 2014. Of these, 64 patients were diagnosed with CIS and were treated with at least 6 cycles of Bacillus Calmette-Guerin (BCG). We accessed variables including patient age, sex, initial presenting symptoms, smoking history, P-CIS descriptions, urine cytology, and medication history related to hypertension. RESULTS AND CONCLUSIONS: We evaluated the use of anti-hypertensive medications (ACEIs/ARBs, p = 0.028), the symptom of non-gross hematuria (p = 0.028), and older age (p = 0.015) as significant factors related to RFS. Older age was also a significant factor for influencing the RFS rate. We found that the use of anti-hypertensive medications (ACEIs/ARBs) improves RFS in patients with P-CIS after BCG therapy. The prognosis was poor when there was no gross hematuria and if patients were at older ages at the time of diagnosis of P-CIS. CI - (c) 2018 S. Karger AG, Basel. FAU - Kim, Sung Jin AU - Kim SJ AD - Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. FAU - Nam, Wook AU - Nam W AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Song, Cheryn AU - Song C AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20180904 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antihypertensive Agents) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Antihypertensive Agents/therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*diagnosis/*drug therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis/*drug therapy OTO - NOTNLM OT - Prognostic factor OT - Bacillus Calmette-Guerin OT - Carcinoma in situ OT - Disease-free OT - Hypertension OT - Renin-angiotensin system OT - Survival OT - Urinary bladder neoplasm EDAT- 2018/09/05 06:00 MHDA- 2019/04/16 06:00 CRDT- 2018/09/05 06:00 PHST- 2018/06/12 00:00 [received] PHST- 2018/07/11 00:00 [accepted] PHST- 2018/09/05 06:00 [pubmed] PHST- 2019/04/16 06:00 [medline] PHST- 2018/09/05 06:00 [entrez] AID - 000492121 [pii] AID - 10.1159/000492121 [doi] PST - ppublish SO - Urol Int. 2018;101(3):269-276. doi: 10.1159/000492121. Epub 2018 Sep 4. PMID- 30176832 OWN - NLM STAT- MEDLINE DCOM- 20181031 LR - 20251218 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 18 IP - 1 DP - 2018 Sep 3 TI - Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study. PG - 861 LID - 10.1186/s12885-018-4779-6 [doi] LID - 861 AB - BACKGROUND: Despite the fact that the cost-effectiveness of robot-assisted radical cystectomy (RARC) is not yet proven, and open radical (ORC) cystectomy is recommended as the standard of care in patients with high-risk non-muscle-invasive and muscle-invasive bladder cancer, the use of RARC is still increasing. The objective of the current ongoing comparative effectiveness trial therefore is to study the (cost-)effectiveness of RARC compared to ORC, both in terms of objective (complication rates, oncological outcomes) and patient-reported (health-related quality of life) outcome measures. METHODS: This study is designed as a non-randomized, multicentre comparative effectiveness trial. Centres with an annual caseload of > 20 radical cystectomies can include patients after informed consent has been given. Centres that perform RARC must have passed the (initial) learning curve of 40 cases. A total of 338 (2 x 169) patients will be enrolled from 23 participating centres (12 ORC, 10 RARC and 1 LRC). Follow-up visits will be scheduled at 1, 3, 6 and 12 months. During each follow-up visit, clinical data and health-related quality of life questionnaires will be administered. Costs will be studied using a monthly resource usage questionnaire. Impact on complications and quality of life will be calculated as the average difference between the groups with 95% confidence intervals, adjusted for potential baseline differences by means of propensity score matching. DISCUSSION: This study aims to contribute to the development of evidence-based guidelines regarding the most cost-effective surgical technique for radical cystectomy. TRIAL REGISTRATION: Nederlands Trial Register/Dutch Trial Registry, trial identifying number: NTR5362. Registered on 14 August 2015. ( http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5362 ). FAU - Wijburg, C J AU - Wijburg CJ AUID- ORCID: 0000-0002-0627-5377 AD - Department of Urology, Rijnstate Hospital, Wagnerlaan 55, 6815, AD, Arnhem, The Netherlands. Cwijburg@rijnstate.nl. FAU - Michels, C T J AU - Michels CTJ AD - Department of Urology, Rijnstate Hospital, Wagnerlaan 55, 6815, AD, Arnhem, The Netherlands. FAU - Oddens, J R AU - Oddens JR AD - Department of Urology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Grutters, J P C AU - Grutters JPC AD - Departments of Operating Rooms and Health Evidence, Radboud university medical center, Geert Grooteplein Noord 21, 6500, HB, Nijmegen, The Netherlands. FAU - Witjes, J A AU - Witjes JA AD - Department of Urology, Radboud university medical center, Geert Grooteplein Noord 21, 6500, HB, Nijmegen, The Netherlands. FAU - Rovers, M M AU - Rovers MM AD - Departments of Operating Rooms and Health Evidence, Radboud university medical center, Geert Grooteplein Noord 21, 6500, HB, Nijmegen, The Netherlands. LA - eng GR - 843002602/ZonMw/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20180903 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Aged MH - Cystectomy/*adverse effects MH - Female MH - Humans MH - Laparoscopy/adverse effects MH - Male MH - Middle Aged MH - Postoperative Complications/pathology MH - Quality of Life MH - Risk Factors MH - Robotic Surgical Procedures/*adverse effects MH - Treatment Outcome MH - Urinary Bladder Neoplasms/epidemiology/pathology/*surgery MH - Non-Randomized Controlled Trials as Topic PMC - PMC6122745 OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Cost-effectiveness OT - Quality of life OT - Radical cystectomy OT - Robot-assisted COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study protocol, amendments, informed consent form and patient information brochure have been reviewed and approved by the sponsor (ZonMw, The Netherlands Organization for Health Research and Development) and the accredited medical ethics committee (Commission for Research in Human Subjects, in Dutch: Commissie Mensgebonden Onderzoek (CMO), region Arnhem - Nijmegen, the Netherlands). Since the enforcement of the Centrale Commissie Mensgebonden Onderzoek (CCMO) External Review Directive in 2012, local medical ethical committees of local participating centers are no longer involved in reviewing the study protocol of multicenter research in the Netherlands and ethical approval obtained, covers all participating centers. The Medical Research Ethics Committee (MREC) "CMO Regio Arnhem-Nijmegen" determined that the RACE study does not fall under the scope of the Medical Research Involving Human Subjects Act (WMO). There will be no extra burden for the patients participating in this study, as the study does not include additional actions compared to regular care except for the questionnaires. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: Carl Wijburg is a freelance proctor (cystectomy and prostatectomy) with a per day fee from Intuitive Surgical. Charlotte Michels has no competing interests. Jorg Oddens has no competing interests. Janneke Grutters has no competing interests. Fred Witjes has no competing interests. Maroeska Rovers has no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/09/05 06:00 MHDA- 2018/11/01 06:00 PMCR- 2018/09/03 CRDT- 2018/09/05 06:00 PHST- 2018/05/22 00:00 [received] PHST- 2018/08/23 00:00 [accepted] PHST- 2018/09/05 06:00 [entrez] PHST- 2018/09/05 06:00 [pubmed] PHST- 2018/11/01 06:00 [medline] PHST- 2018/09/03 00:00 [pmc-release] AID - 10.1186/s12885-018-4779-6 [pii] AID - 4779 [pii] AID - 10.1186/s12885-018-4779-6 [doi] PST - epublish SO - BMC Cancer. 2018 Sep 3;18(1):861. doi: 10.1186/s12885-018-4779-6. PMID- 30172757 OWN - NLM STAT- MEDLINE DCOM- 20190412 LR - 20190412 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 4 DP - 2018 Jul TI - Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. PG - 472-480 LID - S2405-4569(18)30229-3 [pii] LID - 10.1016/j.euf.2018.08.010 [doi] FAU - Campi, Riccardo AU - Campi R AD - Department of Urology, University of Florence, Careggi Hospital, Florence, Italy; Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, F-75013 Paris, France. FAU - Seisen, Thomas AU - Seisen T AD - Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, F-75013 Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, F-75013 Paris, France. Electronic address: mroupret@gmail.com. LA - eng PT - Journal Article DEP - 20180830 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Antineoplastic Agents/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Cystectomy/methods MH - Cystoscopy/*methods MH - Diffusion of Innovation MH - Early Medical Intervention/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis/prevention & control MH - Prognosis MH - Research Design MH - *Urinary Bladder Neoplasms/drug therapy/pathology EDAT- 2018/09/03 06:00 MHDA- 2019/04/13 06:00 CRDT- 2018/09/03 06:00 PHST- 2018/06/04 00:00 [received] PHST- 2018/08/05 00:00 [revised] PHST- 2018/08/16 00:00 [accepted] PHST- 2018/09/03 06:00 [pubmed] PHST- 2019/04/13 06:00 [medline] PHST- 2018/09/03 06:00 [entrez] AID - S2405-4569(18)30229-3 [pii] AID - 10.1016/j.euf.2018.08.010 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jul;4(4):472-480. doi: 10.1016/j.euf.2018.08.010. Epub 2018 Aug 30. PMID- 30171454 OWN - NLM STAT- MEDLINE DCOM- 20190221 LR - 20201006 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 36 IP - 11 DP - 2018 Nov TI - Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. PG - 1775-1781 LID - 10.1007/s00345-018-2450-0 [doi] AB - PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1.79, p = 0.001 and HR = 1.53, p = 0.02, respectively). Patients with tumors > 3 cm, multiple tumors or CIS had earlier T3/T4 or N + cystectomies. In patients who progressed, the timing of cystectomy did not affect the risk of T3/T4 or N + disease at RC. Patients with T3/T4 or N + disease at RC had a shorter disease-specific survival (HR = 4.38, p < 0.001), as did patients with CIS at cystectomy (HR = 2.39, p < 0.001). Patients who progressed prior to cystectomy had a shorter disease-specific survival than patients for whom progression was only detected at cystectomy (HR = 0.58, p = 0.024) CONCLUSIONS: Patients treated with RC before experiencing progression to muscle-invasive disease harbor better oncological and survival outcomes compared to those who progressed before RC and to those upstaged at surgery. Tumor size and concomitant CIS at diagnosis are the main predictors of surgical treatment while tumor size, CIS and tumor multiplicity are associated with extravesical disease at surgery. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Pisano, Francesca AU - Pisano F AD - Citta della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy. francescapisano85@gmail.com. AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. francescapisano85@gmail.com. FAU - Gontero, Paolo AU - Gontero P AD - Citta della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy. FAU - Palou, J AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. FAU - Joniau, S AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Louvain, Belgium. FAU - Serretta, V AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Larre, S AU - Larre S AD - Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK. FAU - Di Stasi, S AU - Di Stasi S AD - Policlinico Tor Vergata-University of Rome, Rome, Italy. FAU - van Rhijn, B AU - van Rhijn B AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Witjes, J A AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Grotenhuis, A AU - Grotenhuis A AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Colombo, R AU - Colombo R AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Briganti, A AU - Briganti A AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Babjuk, M AU - Babjuk M AD - Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic. FAU - Soukup, V AU - Soukup V AD - Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic. FAU - Malmstrom, P U AU - Malmstrom PU AD - Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden. FAU - Irani, J AU - Irani J AD - Department of Urology, CHU de Bicetre, 78, rue du General Leclerc, 94270, Le Kremlin-Bicetre, France. FAU - Malats, N AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Baniel, J AU - Baniel J AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Mano, R AU - Mano R AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Cai, T AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - Cha, E AU - Cha E AD - Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA. FAU - Ardelt, P AU - Ardelt P AD - Facharzt fur Urologie, Abteilung fur Urologie, Chirurgische Universitats klinik, Freiburg, Germany. FAU - Varkarakis, J AU - Varkarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Bartoletti, R AU - Bartoletti R AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Dalbagni, G AU - Dalbagni G AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Shariat, S F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Xylinas, E AU - Xylinas E AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Karnes, R J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Sylvester, R AU - Sylvester R AD - Formerly Department of Biostatistics, EORTC Headquarters, Brussels, Belgium. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20180831 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) SB - IM CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S692-S695. doi: 10.21037/tau.2018.11.07. PMID: 30687597 MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/drug therapy/mortality/pathology/*surgery MH - Cohort Studies MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/mortality/*pathology/therapy MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery PMC - PMC7534829 MID - NIHMS1620896 OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Extravesical disease OT - High risk OT - Outcomes OT - T1G3 COIS- Conflict of interest None EDAT- 2018/09/02 06:00 MHDA- 2019/02/23 06:00 PMCR- 2020/10/05 CRDT- 2018/09/02 06:00 PHST- 2018/03/01 00:00 [received] PHST- 2018/08/13 00:00 [accepted] PHST- 2018/09/02 06:00 [pubmed] PHST- 2019/02/23 06:00 [medline] PHST- 2018/09/02 06:00 [entrez] PHST- 2020/10/05 00:00 [pmc-release] AID - 10.1007/s00345-018-2450-0 [pii] AID - 10.1007/s00345-018-2450-0 [doi] PST - ppublish SO - World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31. PMID- 30168123 OWN - NLM STAT- MEDLINE DCOM- 20190618 LR - 20190618 IS - 0927-3042 (Print) IS - 0927-3042 (Linking) VI - 175 DP - 2018 TI - The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. PG - 193-214 LID - 10.1007/978-3-319-93339-9_9 [doi] AB - Non-muscle-invasive bladder cancer accounts for the majority of incident bladder cancers but is a heterogeneous disease with variation in clinical presentation, course, and outcomes. Risk stratification techniques have attempted to identify those at highest risk of cancer recurrence and progression to help personalize and individualize treatment options. Radical cystectomy during the optimal window of curability could improve cancer outcomes; however, identifying the disease and patient characteristics as well as the correct timing to intervene remains difficult. We review the natural history of non-muscle-invasive bladder cancer, discuss different risk-stratification techniques and how they can help identify those most likely to benefit from radical treatment, and examine the evidence supporting the benefit of timely cystectomy. FAU - Lee, Daniel J AU - Lee DJ AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Chang, Sam S AU - Chang SS AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. sam.chang@Vanderbilt.Edu. LA - eng PT - Journal Article PT - Review PL - United States TA - Cancer Treat Res JT - Cancer treatment and research JID - 8008541 SB - IM MH - *Cystectomy MH - Humans MH - Neoplasm Staging MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Early cystectomy OT - High-risk bladder cancer OT - Micropapillary bladder cancer OT - Non-muscle-invasive bladder cancer OT - Timely cystectomy EDAT- 2018/09/01 06:00 MHDA- 2019/06/19 06:00 CRDT- 2018/09/01 06:00 PHST- 2018/09/01 06:00 [entrez] PHST- 2018/09/01 06:00 [pubmed] PHST- 2019/06/19 06:00 [medline] AID - 10.1007/978-3-319-93339-9_9 [doi] PST - ppublish SO - Cancer Treat Res. 2018;175:193-214. doi: 10.1007/978-3-319-93339-9_9. PMID- 30154342 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20231103 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 9 DP - 2018 Aug 28 TI - Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers. LID - 10.3390/ijms19092548 [doi] LID - 2548 AB - Prognostic/therapeutic stratification of papillary urothelial cancers is solely based upon histology, despite activated FGFR3-signaling was found to be associated with low grade tumors and favorable outcome. However, there are FGFR3-overexpressing tumors showing high proliferation-a paradox of coexisting favorable and adverse features. Therefore, our study aimed to decipher the relevance of FGFR3-overexpression/proliferation for histopathological grading and risk stratification. N = 142 (n = 82 pTa, n = 42 pT1, n = 18 pT2-4) morphologically G1(-)G3 tumors were analyzed for immunohistochemical expression of FGFR3 and Ki67. Mutation analysis of FGFR3 and TP53 and FISH for FGFR3 amplification and rearrangement was performed. SPSS 23.0 was used for statistical analysis. Overall FGFR3(high)/Ki67(high) status (n = 58) resulted in a reduced ∆mean progression-free survival (PFS) (p < 0.01) of 63.92 months, and shorter progression-free survival (p < 0.01; mean PFS: 55.89 months) in pTa tumors (n = 50). FGFR3(mut)/TP53(mut) double mutations led to a reduced ∆mean PFS (p < 0.01) of 80.30 months in all tumors, and FGFR3(mut)/TP53(mut) pTa tumors presented a dramatically reduced PFS (p < 0.001; mean PFS: 5.00 months). Our results identified FGFR3(high)/Ki67(high) papillary pTa tumors as a subgroup with poor prognosis and encourage histological grading as high grade tumors. Tumor grading should possibly be augmented by immunohistochemical stainings and suitable clinical surveillance by endoscopy should be performed. FAU - Geelvink, Mirja AU - Geelvink M AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. mirja.geelvink@rwth-aachen.de. FAU - Babmorad, Armin AU - Babmorad A AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. armin.babmorad@rwth-aachen.de. FAU - Maurer, Angela AU - Maurer A AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. amaurer@ukaachen.de. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), 91054 Erlangen, Germany. Robert.Stoehr@uk-erlangen.de. FAU - Grimm, Tobias AU - Grimm T AUID- ORCID: 0000-0002-6782-6638 AD - Department of Urology, Ludwig Maximilian University Munich, 81377 Munich, Germany. Tobias_Grimm@med.uni-muenchen.de. FAU - Bach, Christian AU - Bach C AD - Department of Urology, RWTH Aachen University, 52074 Aachen, Germany. chbach@ukaachen.de. FAU - Knuechel, Ruth AU - Knuechel R AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. rknuechel-clarke@ukaachen.de. FAU - Rose, Michael AU - Rose M AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. mrose@ukaachen.de. FAU - Gaisa, Nadine T AU - Gaisa NT AD - Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany. ngaisa@ukaachen.de. LA - eng PT - Journal Article DEP - 20180828 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Carcinoma, Papillary/*diagnosis/genetics/*metabolism/mortality MH - Female MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/genetics/*metabolism MH - Male MH - Middle Aged MH - Mutation MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Receptor, Fibroblast Growth Factor, Type 3/genetics/*metabolism MH - Signal Transduction MH - Tumor Suppressor Protein p53/genetics/metabolism MH - Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality PMC - PMC6163244 OTO - NOTNLM OT - FGFR3 OT - Ki67 OT - TP53 OT - bladder cancer OT - prognosis COIS- The authors declare that they have no conflict of interest. EDAT- 2018/08/30 06:00 MHDA- 2018/12/12 06:00 PMCR- 2018/09/01 CRDT- 2018/08/30 06:00 PHST- 2018/07/30 00:00 [received] PHST- 2018/08/19 00:00 [revised] PHST- 2018/08/24 00:00 [accepted] PHST- 2018/08/30 06:00 [entrez] PHST- 2018/08/30 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/09/01 00:00 [pmc-release] AID - ijms19092548 [pii] AID - ijms-19-02548 [pii] AID - 10.3390/ijms19092548 [doi] PST - epublish SO - Int J Mol Sci. 2018 Aug 28;19(9):2548. doi: 10.3390/ijms19092548. PMID- 30148753 OWN - NLM STAT- MEDLINE DCOM- 20190805 LR - 20190805 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 28 IP - 6 DP - 2018 Nov TI - A risk-stratified approach to the management of high-grade T1 bladder cancer. PG - 563-569 LID - 10.1097/MOU.0000000000000548 [doi] AB - PURPOSE OF REVIEW: A bladder-preserving approach for high-grade nonmuscle invasive bladder cancer that has invaded the lamina propria (T1HG) may result in increased recurrence, progression, and even death from bladder cancer in some patients. Initial radical cystectomy does have increased cancer-specific survival (CSS), but represents significant overtreatment for many patients. An evidence-based, risk-stratified approach is required to select patients for immediate radical cystectomy in order to improve CSS. RECENT FINDINGS: A restaging transurethral resection aids in optimal staging and treatment of T1HG. Intravesical Bacillus Calmette-Guerin induction followed by 3 years of maintenance is the standard adjuvant management. However, when very high-risk (hydronephrosis, abnormal bimanual examination, variant histology, lymphovascular invasion, or residual disease on re-resection, and Bacillus Calmette-Guerin failure or early recurrence) or multiple high-risk factors (concomitant CIS, size >3 cm, multifocality, unfavorable tumor location, extensive lamina propria invasion, and elderly) are present, the risk of progression often outweighs the risk associated with radical cystectomy. In these cases, an immediate radical cystectomy likely provides an improved opportunity for cure compared to a bladder-preserving strategy. SUMMARY: In order to increase the CSS of patients diagnosed with T1HG bladder cancer, an aggressive approach may benefit those with increased risk of progression. FAU - Mannas, Miles P AU - Mannas MP AD - Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Lee, Taeweon AU - Lee T FAU - Nykopp, Timo K AU - Nykopp TK FAU - Batista da Costa, Jose AU - Batista da Costa J FAU - Black, Peter C AU - Black PC LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Cystectomy/methods MH - Disease Progression MH - Evidence-Based Medicine/*methods MH - Humans MH - Neoplasm Recurrence, Local/pathology/*therapy MH - Neoplasm Staging MH - Organ Sparing Treatments/methods MH - *Patient Selection MH - Risk Assessment MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy EDAT- 2018/08/28 06:00 MHDA- 2019/08/06 06:00 CRDT- 2018/08/28 06:00 PHST- 2018/08/28 06:00 [pubmed] PHST- 2019/08/06 06:00 [medline] PHST- 2018/08/28 06:00 [entrez] AID - 10.1097/MOU.0000000000000548 [doi] PST - ppublish SO - Curr Opin Urol. 2018 Nov;28(6):563-569. doi: 10.1097/MOU.0000000000000548. PMID- 30142792 OWN - NLM STAT- MEDLINE DCOM- 20180904 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 34 DP - 2018 Aug TI - CDCA8 expression and its clinical relevance in patients with bladder cancer. PG - e11899 LID - 10.1097/MD.0000000000011899 [doi] LID - e11899 AB - Cell division cycle associated 8 (CDCA8) overexpression is detected in various malignant tumors and closely associated with tumor growth. However, the correlations of CDCA8 expression with clinicopathological factors and prognosis of bladder cancer (BC) remain unclear. The purpose of this study was to identify the expression of CDCA8 and its clinical relevance in BC patients.GEO datasets were employed to obtain CDCA8 expression data and its clinical information in BC samples. Real-time PCR (RT-PCR) was performed to detect the expression of CDCA8 in BC and the adjacent normal tissues. Nonpaired t test was used to statistically analyze the difference between the 2 groups. Cox univariable and multivariable analyses of overall survival (OS) and cancer specific survival (CSS) among BC patients were performed. Biological processes or signaling pathways that might mediate the activity of CDCA8 in BC were analyzed.CDCA8 levels were significantly higher in BC (8.870 +/- 0.08281 vs 7.472 +/- 0.07035, P < .0001). CDCA8 expression was significantly associated with tumor progression (P = .001), T stage (P < .0001), N stage (P = .013), and grade (P < .0001). Higher expression of CDCA8 predicted poor cancer-specific survival (P < .0001, HR = 0.2752, 95% CI:0.1364-0.5554) and overall survival (P < .0001, HR = 0.4270, 95% CI: 0.2630-0.6930) in patients with BC. Cox univariable and multivariable analyses showed that intravesical therapy, N stage and progression were the independent influence factors of overall survival among bladder cancer patients, CDCA8 expression, tumor grade and progression were the independent influence factors of cancer specific survival among bladder cancer patients. The results of GSEA indicated that CDCA8-regulated gene sets associated with spermatogenesis, G2M checkpoint, E2F targets, Myc targets, mTORC1 signaling, mitotic spindle angiogenesis, PI3K/AKT/mTOR signaling, cholesterol homeostasis and glycolysis. Finally, RT-PCR results confirmed that CDCA8 expression was upregulated in BC (P = .0039).CDCA8 is overexpressed in BC and its high levels are correlated with poor clinicopathological features of BC patients. Therefore, CDCA8 may act as a novel prognostic marker and therapeutical target in the diagnosis and treatment of patients with BC. FAU - Bi, Yaqiong AU - Bi Y AD - Department of Biological Repositories Department of Urology Laboratory of Precision Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Chen, Song AU - Chen S FAU - Jiang, Jiazhi AU - Jiang J FAU - Yao, Jie AU - Yao J FAU - Wang, Gang AU - Wang G FAU - Zhou, Qiang AU - Zhou Q FAU - Li, Sheng AU - Li S LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (CDCA8 protein, human) RN - 0 (Cell Cycle Proteins) SB - IM MH - Cell Cycle Proteins/*genetics MH - Female MH - Gene Expression Profiling MH - Gene Regulatory Networks MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Survival Analysis MH - *Up-Regulation MH - Urinary Bladder Neoplasms/*genetics/*pathology PMC - PMC6112995 COIS- The authors have no conflicts of interest to disclose. EDAT- 2018/08/26 06:00 MHDA- 2018/09/05 06:00 PMCR- 2018/08/24 CRDT- 2018/08/26 06:00 PHST- 2018/08/26 06:00 [entrez] PHST- 2018/08/26 06:00 [pubmed] PHST- 2018/09/05 06:00 [medline] PHST- 2018/08/24 00:00 [pmc-release] AID - 00005792-201808240-00044 [pii] AID - MD-D-18-02664 [pii] AID - 10.1097/MD.0000000000011899 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Aug;97(34):e11899. doi: 10.1097/MD.0000000000011899. PMID- 30140466 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240330 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 16 IP - 3 DP - 2018 Sep TI - Robot-assisted radical cystectomy with intracorporeal urinary diversion - The new 'gold standard'? Evidence from a systematic review. PG - 307-313 LID - 10.1016/j.aju.2018.01.006 [doi] AB - OBJECTIVE: To investigate whether a totally intracorporeally radical cystectomy (RC) can be considered the new 'gold standard' in bladder cancer, as open RC (ORC) is the current 'gold standard' for surgical treatment of muscle-invasive and high-grade non-muscle-invasive bladder cancer. However, robot-assisted radical cystectomy (RARC) is becoming the preferred surgical approach in many centres as it seems to maintain the oncological control of open surgery whilst offering improved perioperative benefits. MATERIALS AND METHODS: A review of the literature was conducted using the Pubmed/MEDLINE, ISI Web of Knowledge and Cochrane Databases to identify studies that included both ORC and RARC with intracorporeal and extracorporeal urinary diversion (UD) published up to July 2017. RESULTS: Evidence from four single-centre randomised controlled trials and now the multicentre Randomized Trial of Open versus Robotic Cystectomy (RAZOR) trial demonstrate the oncological equivalence of RARC to ORC. The only convincing evidence for the superiority of RARC is in the area of blood loss and transfusion rates. However, the UD procedure in these trials was performed extracorporeally and, to realise the full benefits of RARC, a totally intracorporeal approach is needed. Intracorporeal UDs (ICUDs) have been shown to be technically feasible by a few expert centres and have demonstrated some improved short-term perioperative outcomes compared to extracorporeal UDs. CONCLUSIONS: Although initial outcomes appear promising, RARC with ICUD is far from gaining 'gold standard' status. Further studies are needed to confirm that outcomes are reproducible widely. Furthermore, the benefits of a totally intracorporeal approach must be confirmed in randomised controlled trials. FAU - Lobo, Niyati AU - Lobo N AD - Department of Urology, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. FAU - Thurairaja, Ramesh AU - Thurairaja R AD - Department of Urology, Guy's Hospital, London, UK. FAU - Nair, Rajesh AU - Nair R AD - Department of Urology, Guy's Hospital, London, UK. FAU - Dasgupta, Prokar AU - Dasgupta P AD - Department of Urology, Guy's Hospital, London, UK. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Department of Urology, Guy's Hospital, London, UK. LA - eng PT - Journal Article PT - Review DEP - 20180411 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC6104669 OTO - NOTNLM OT - (EC)(IC)UD, (extracorporeal) (intracorporeal)urinary diversion OT - (N)MIBC, (non-) muscle-invasive bladder cancer OT - (O)(RA)RC, (open) (robot-assisted)radical cystectomy OT - Bladder cancer OT - EORTC, European Organisation for the Research and Treatment of Cancer OT - Extracorporeal urinary diversion OT - HR, hazard ratio OT - HRQOL, health-related quality of life OT - Intracorporeal urinary diversion OT - LOS, length of stay OT - RAZOR, Randomized Trial of Open versus Robotic Cystectomy OT - RCT, randomised controlled trial OT - Radical cystectomy OT - Robotics EDAT- 2018/08/25 06:00 MHDA- 2018/08/25 06:01 PMCR- 2018/04/11 CRDT- 2018/08/25 06:00 PHST- 2017/09/29 00:00 [received] PHST- 2018/01/30 00:00 [accepted] PHST- 2018/08/25 06:00 [entrez] PHST- 2018/08/25 06:00 [pubmed] PHST- 2018/08/25 06:01 [medline] PHST- 2018/04/11 00:00 [pmc-release] AID - S2090-598X(18)30030-5 [pii] AID - 10.1016/j.aju.2018.01.006 [doi] PST - epublish SO - Arab J Urol. 2018 Apr 11;16(3):307-313. doi: 10.1016/j.aju.2018.01.006. eCollection 2018 Sep. PMID- 30139660 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 10 DP - 2018 Oct TI - Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme. PG - 472.e1-472.e9 LID - S1078-1439(18)30263-1 [pii] LID - 10.1016/j.urolonc.2018.07.008 [doi] AB - BACKGROUND: In nonmuscle invasive bladder cancer patients, prediction of pTa and pT1 bladder cancer recurrence and progression must be established. Micropapillary structures have been defined as small clusters of invasive cancer cells having features of the epithelial-mesenchymal transition. Since the stromal microenvironment helps to induce the epithelial-mesenchymal transition, interactions between cancer cells and stroma should be closely examined to predict the tumorigenic phenotype of human bladder cancer cells. MATERIALS AND METHODS: To investigate differences in the responsiveness of cancer cells to stroma, we combined 3 established human bladder cancer cell lines (high-grade T24 and UM-UC-3 cells, and low-grade papillary RT4 cells) with fetal rat mesenchyme. RESULTS: Among 3 bladder cancer cell lines, the expression profiles of p63 isoforms were distinct, i.e., p63gamma in T24 cells, p63beta in UM-UC-3 cells, and p63alpha in RT4 cells. Tumors formed by T24 cells combined with fetal mesenchyme formed micropapillary-like structures, whereas those formed by T24 cells alone did not. T24 cells combined with fetal mesenchyme showed poor differentiation, e.g., innumerable chromatic atypia in the nuclei, higher levels of chromatic condensation, and increased nucleoli. In contrast, both UM-UC-3 and RT4 cells combined with fetal mesenchyme did not form micropapillary-like structures. Ki-67 and p63 labeling indices were significantly elevated by combining fetal mesenchyme with T24 cells but not with the others. CONCLUSIONS: By mixing cancer cells with fetal mesenchyme, our data demonstrated that formation of micropapillary-like structures may predict the tumorigenic phenotype of invasive bladder cancer cells. Taken together, distinct expression profiles of p63 isoforms may predict poor outcomes in invasive bladder cancer. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Miki, Manabu AU - Miki M AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Ishii, Kenichiro AU - Ishii K AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan; Department of Oncologic Pathology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Sasaki, Takeshi AU - Sasaki T AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Kato, Manabu AU - Kato M AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Kajiwara, Shinya AU - Kajiwara S AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Kanda, Hideki AU - Kanda H AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Arima, Kiminobu AU - Arima K AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Hirokawa, Yoshifumi AU - Hirokawa Y AD - Department of Oncologic Pathology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Watanabe, Masatoshi AU - Watanabe M AD - Department of Oncologic Pathology, Mie University Graduate School of Medicine, Mie, Japan. FAU - Sugimura, Yoshiki AU - Sugimura Y AD - Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan. Electronic address: sugimura@clin.medic.mie-u.ac.jp. LA - eng PT - Journal Article DEP - 20180820 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (CKAP4 protein, human) RN - 0 (Membrane Proteins) SB - IM MH - Animals MH - *Carcinogenesis/metabolism/pathology MH - Carcinoma, Transitional Cell/*pathology MH - Coculture Techniques MH - Epithelial-Mesenchymal Transition/*physiology MH - Fetus MH - Humans MH - Membrane Proteins/metabolism MH - *Mesoderm MH - Phenotype MH - Rats MH - Rats, Sprague-Dawley MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Fetal mesenchyme OT - Invasive bladder cancer OT - Micropapillary-like structures OT - Responsiveness of cancer cells to stroma OT - p63 isoforms EDAT- 2018/08/25 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/08/25 06:00 PHST- 2018/04/24 00:00 [received] PHST- 2018/07/10 00:00 [revised] PHST- 2018/07/14 00:00 [accepted] PHST- 2018/08/25 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/08/25 06:00 [entrez] AID - S1078-1439(18)30263-1 [pii] AID - 10.1016/j.urolonc.2018.07.008 [doi] PST - ppublish SO - Urol Oncol. 2018 Oct;36(10):472.e1-472.e9. doi: 10.1016/j.urolonc.2018.07.008. Epub 2018 Aug 20. PMID- 30138427 OWN - NLM STAT- MEDLINE DCOM- 20190208 LR - 20201209 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 8 DP - 2018 TI - ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response? PG - e0202965 LID - 10.1371/journal.pone.0202965 [doi] LID - e0202965 AB - Bladder cancer therapy relies on aggressive treatments highlighting the need for new, targeted therapies with reduced side effects. SWI/SNF complexes are mutated in ~20% across human cancers and dependency of SWI/SNF-deficient tumors on EZH2 has been uncovered recently. To systematically dissect the frequency of genetic alterations in SWI/SNF complexes potentially contributing to their inactivation, mutations and copy number variations in 25 SWI/SNF subunit genes were analyzed making use of publicly available sequencing data for 408 muscle-invasive bladder carcinoma samples. ARID1A truncating mutations were identified as the by far most common alterations of SWI/SNF complexes in urothelial bladder cancer. As current ARID1A protein expression data in bladder cancer are inconsistent and incomplete we examined if the frequency of truncating ARID1A mutations translates into a similar frequency of cases showing ARID1A protein loss. We applied a validated ARID1A antibody conducting a comprehensive immunohistochemistry-based expression analysis in urothelial bladder cancer (n = 362) including carcinoma in situ (CIS) cases. While observing increased median ARID1A protein levels in all carcinoma subgroups compared to normal urothelial controls (n = 21), the percentage of cases showing ARID1A protein loss was positively correlated with increasing stage and grade culminating in a rate of 14.1% in muscle-invasive disease. ARID1A-depletion did neither increase EZH2 protein or trimethylated H3K27 levels in vitro nor did ARID1A expression correlate with EZH2 or H3K27me3 amounts in human bladder carcinomas. Importantly, ARID1A-deficiency was neither associated with enhanced sensitivity towards inhibition of EZH2 enzymatic activity nor depletion of EZH2 protein. In summary, ARID1A truncating mutations, potentially translating into ARID1A protein loss in a subset of high-grade bladder cancers, are the most common SWI/SNF genetic alterations in bladder cancer. Our data do not support ARID1A-deficiency as predictive biomarker for EZH2-inhibitor treatment response in bladder cancer underlining the need for future bladder cancer-specific, drug screens for successfull discovery of ARID1A-deficiency-based targeted drugs. FAU - Garczyk, Stefan AU - Garczyk S AUID- ORCID: 0000-0001-5447-3207 AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Schneider, Ursula AU - Schneider U AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Lurje, Isabella AU - Lurje I AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Becker, Katharina AU - Becker K AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Vogeli, Thomas A AU - Vogeli TA AD - Department of Urology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Gaisa, Nadine T AU - Gaisa NT AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. FAU - Knuchel, Ruth AU - Knuchel R AD - Uropathology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180823 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (ARID1A protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (DNA-Binding Proteins) RN - 0 (Nuclear Proteins) RN - 0 (Transcription Factors) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) SB - IM MH - Biomarkers, Tumor/metabolism MH - Carcinoma/drug therapy/genetics/*metabolism MH - DNA Copy Number Variations MH - DNA Mutational Analysis MH - DNA-Binding Proteins MH - Enhancer of Zeste Homolog 2 Protein/*antagonists & inhibitors MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Nuclear Proteins/*deficiency/genetics MH - Signal Transduction MH - Transcription Factors/*deficiency/genetics MH - Urinary Bladder Neoplasms/drug therapy/genetics/*metabolism MH - Urothelium/metabolism/*pathology PMC - PMC6107234 COIS- The authors have declared that no competing interests exist. EDAT- 2018/08/24 06:00 MHDA- 2019/02/09 06:00 PMCR- 2018/08/23 CRDT- 2018/08/24 06:00 PHST- 2018/05/07 00:00 [received] PHST- 2018/08/13 00:00 [accepted] PHST- 2018/08/24 06:00 [entrez] PHST- 2018/08/24 06:00 [pubmed] PHST- 2019/02/09 06:00 [medline] PHST- 2018/08/23 00:00 [pmc-release] AID - PONE-D-18-13715 [pii] AID - 10.1371/journal.pone.0202965 [doi] PST - epublish SO - PLoS One. 2018 Aug 23;13(8):e0202965. doi: 10.1371/journal.pone.0202965. eCollection 2018. PMID- 30138123 OWN - NLM STAT- MEDLINE DCOM- 20190805 LR - 20190805 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 28 IP - 6 DP - 2018 Nov TI - Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology. PG - 598-603 LID - 10.1097/MOU.0000000000000543 [doi] AB - PURPOSE OF REVIEW: Despite that nearly 75% of bladder cancer patients are diagnosed with nonmuscle-invasive disease, our understanding of the biological landscape in bladder cancer is primarily within the context of muscle-invasive bladder cancer. More recent studies addressing the genomic changes and immunology of nonmuscle-invasive bladder cancer (NMIBC) have helped to extend our understanding of this prevalent disease. RECENT FINDINGS: Genomic studies reveal that NMIBC possesses complexity that can be defined by specific gene expression signatures and has helped to define subsets within this disease. These subsets possess different risk profiles that may impact treatment decisions. In addition, the baseline or posttreatment immunological response to the growing tumor may help to inform whether a specific NMIBC subset is likely to progress. SUMMARY: Findings from studies addressing the molecular landscape of NMIBC may help to establish parameters for stratifying patient risk within this disease as well as establish novel or targeted treatment strategies. Inclusion of information about the immune response within tumors will likely contribute to defining the relative risk and treatment strategy for these patients. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Aarhus, Denmark. FAU - Ingersoll, Molly A AU - Ingersoll MA AD - Department of Immunology, Institut Pasteur. AD - INSERM U1223, Paris, France. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor/*genetics/immunology MH - Cystectomy/methods/standards MH - Disease Progression MH - Gene Expression Profiling/methods/standards MH - Genomics/methods/standards MH - Humans MH - Immunotherapy/methods/standards MH - Neoplasm Invasiveness/genetics/immunology/pathology MH - Precision Medicine/*methods/standards MH - Risk Assessment/methods/standards MH - Tissue Array Analysis MH - Treatment Outcome MH - Tumor Microenvironment/genetics/immunology MH - Urinary Bladder/immunology/pathology MH - Urinary Bladder Neoplasms/*genetics/immunology/pathology/therapy EDAT- 2018/08/24 06:00 MHDA- 2019/08/06 06:00 CRDT- 2018/08/24 06:00 PHST- 2018/08/24 06:00 [pubmed] PHST- 2019/08/06 06:00 [medline] PHST- 2018/08/24 06:00 [entrez] AID - 10.1097/MOU.0000000000000543 [doi] PST - ppublish SO - Curr Opin Urol. 2018 Nov;28(6):598-603. doi: 10.1097/MOU.0000000000000543. PMID- 30128829 OWN - NLM STAT- MEDLINE DCOM- 20191023 LR - 20191023 IS - 1534-6269 (Electronic) IS - 1523-3790 (Linking) VI - 20 IP - 10 DP - 2018 Aug 20 TI - Molecular Subtypes of Bladder Cancer. PG - 77 LID - 10.1007/s11912-018-0727-5 [doi] AB - PURPOSE OF REVIEW: Recent whole genome characterizations of primary human bladder cancers revealed that they can be grouped into "intrinsic" basal and luminal molecular subtypes. Here, we provide an overview of the subtypes and discuss their biological and clinical properties. RECENT FINDINGS: Basal cancers are characterized by advanced stage and metastatic disease at presentation. They tend to be enriched with squamous and small cell/neuroendocrine features and inactivating mutations and deletions of TP53 and RB1. Basal cancers can be divided into "epithelial" and "mesenchymal" (also known as "claudin low") subsets, and a portion of the latter form a "neuroendocrine/neuronal" subset that is associated with particularly poor survival. Luminal cancers are often enriched with papillary histopathological features and activating mutations in FGFR3, and they can also be divided into additional subsets based on differential stromal cell infiltration, relative genomic instability, and high- versus low-level expression of carcinoma in situ (CIS) gene expression signatures. Importantly, the bladder cancer molecular subtypes display differential sensitivities to neoadjuvant chemotherapy and immune checkpoint blockade, and preliminary data also suggest that they respond differently to radiation with or without hypoxia modulation. Ongoing studies are investigating the relevance of the molecular subtypes to the bladder cancer histopathological variants and to upper tract urothelial cancer. The bladder cancer molecular subtypes were associated with different prognoses and responses to conventional and targeted therapies in retrospective studies. If validated in prospective studies, molecular subtyping will be integrated into bladder cancer clinical management. FAU - McConkey, David J AU - McConkey DJ AD - Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Marburg 149, 600 North Wolfe Street, Baltimore, MD, 21287, USA. djmcconkey@jhmi.edu. FAU - Choi, Woonyoung AU - Choi W AD - Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Marburg 149, 600 North Wolfe Street, Baltimore, MD, 21287, USA. LA - eng PT - Journal Article PT - Review DEP - 20180820 PL - United States TA - Curr Oncol Rep JT - Current oncology reports JID - 100888967 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*genetics MH - Humans MH - *Mutation MH - Prognosis MH - Urinary Bladder Neoplasms/*classification/genetics/*pathology OTO - NOTNLM OT - Basal OT - Genomically unstable OT - Immune checkpoint blockade OT - Infiltrated OT - Luminal OT - Neoadjuvant chemotherapy OT - Neuroendocrine OT - Urothelial OT - Variant histology EDAT- 2018/08/22 06:00 MHDA- 2019/10/24 06:00 CRDT- 2018/08/22 06:00 PHST- 2018/08/22 06:00 [entrez] PHST- 2018/08/22 06:00 [pubmed] PHST- 2019/10/24 06:00 [medline] AID - 10.1007/s11912-018-0727-5 [pii] AID - 10.1007/s11912-018-0727-5 [doi] PST - epublish SO - Curr Oncol Rep. 2018 Aug 20;20(10):77. doi: 10.1007/s11912-018-0727-5. PMID- 30128027 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 16 IP - 3 DP - 2018 Sep TI - Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder. PG - 4049-4056 LID - 10.3892/ol.2018.9068 [doi] AB - In Japanese patients with non-muscle-invasive urothelial carcinoma of the bladder, the impact of body mass index (BMI) on recurrence following transurethral resection of bladder tumor (TURBT) is unclear. The present study retrospectively examined data collected from 50 patients diagnosed with primary urothelial carcinoma of the bladder (pTa, pTis, and pT1) who had previously undergone TURBT surgery. Two BMI cut-off points for predicting disease recurrence were evaluated: i) A threshold generated through receiver operating characteristic (ROC) curve analysis; ii) the World Health Organization BMI index (24 kg/m(2)) for overweight status in Japanese populations. Univariate and multivariate analyses were applied to assess individual variables (BMI included) and the effect they had on recurrence-free survival (RFS). Median RFS and BMI values of 19.72 months (range, 3.13-72.13 months) and 23.37 kg/m2 (range, 14.72-36.84 kg/m2), respectively, were recorded. In multivariate analyses, higher continuous BMI was significantly associated with shorter RFS (P=0.019). Based on a ROC-generated BMI cut-off point (23.4 kg/m2), patients were ranked with either a high (>/=23.4 kg/m2) or low (<23.4 kg/m2) BMI status. Multivariate analysis indicated that BMI values >23.4 kg/m2 were significantly associated with shorter RFS (P=0.028). Intravesical Bacillus Calmette-Guerin treatment and history of upper-tract urothelial carcinoma were also independently associated (P=0.044 and P=0.010, respectively). However, BMI values >24 kg/m2 (customary cut-off point) had no significant impact on RFS (P=0.066). Thus, a higher BMI status was revealed to be independently predictive of shorter RFS in Japanese patients undergoing TURBT for urothelial carcinoma of the bladder. A greater number of samples are required in order to determine optimal BMI cut-off points in Japanese patients and to investigate whether weight reduction intervention may improve prognosis. FAU - Yonekura, Satoru AU - Yonekura S AD - Department of Pathology, Tochigi Medical Center Shimotsuga, Tochigi 329-4498, Japan. FAU - Terauchi, Fumihito AU - Terauchi F AD - Department of Urology, Tochigi Medical Center Shimotsuga, Tochigi 329-4498, Japan. FAU - Hoshi, Kenji AU - Hoshi K AD - Department of Pathology, Tochigi Medical Center Shimotsuga, Tochigi 329-4498, Japan. FAU - Yamaguchi, Takehiko AU - Yamaguchi T AD - Department of Pathology, Dokkyo Medical University, Koshigaya Hospital, Koshigaya, Saitama 343-8555, Japan. FAU - Kawai, Shigeo AU - Kawai S AD - Department of Pathology, Tochigi Medical Center Shimotsuga, Tochigi 329-4498, Japan. LA - eng PT - Journal Article DEP - 20180704 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC6096269 OTO - NOTNLM OT - bladder OT - body mass index OT - epidemiology OT - recurrence OT - urothelial carcinoma EDAT- 2018/08/22 06:00 MHDA- 2018/08/22 06:01 PMCR- 2018/07/04 CRDT- 2018/08/22 06:00 PHST- 2017/07/14 00:00 [received] PHST- 2018/06/28 00:00 [accepted] PHST- 2018/08/22 06:00 [entrez] PHST- 2018/08/22 06:00 [pubmed] PHST- 2018/08/22 06:01 [medline] PHST- 2018/07/04 00:00 [pmc-release] AID - OL-0-0-9068 [pii] AID - 10.3892/ol.2018.9068 [doi] PST - ppublish SO - Oncol Lett. 2018 Sep;16(3):4049-4056. doi: 10.3892/ol.2018.9068. Epub 2018 Jul 4. PMID- 30125887 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1421-9794 (Electronic) IS - 0009-3157 (Linking) VI - 63 IP - 4 DP - 2018 TI - NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP. PG - 191-197 LID - 10.1159/000489402 [doi] AB - OBJECTIVES: To analyze the correlation between pharmacogenomic biomarkers and the efficacy of pirarubicin (THP, also named 4'-O-tetrahydropyranyl-adriamycin) and to explore potential associations of individual genetic backgrounds with the clinical outcomes of non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: Between July 2003 and June 2011, a total of 91 patients were treated with transurethral resection (TUR) of the bladder tumor and were histopathologically confirmed to have NMIBC. Patients received an immediate instillation and maintenance therapy with THP. All patients underwent follow-up for recurrence. We genotyped 13 single nucleotide polymorphisms (SNPs) from blood and saliva DNA samples of all patients. RESULTS: The associations of patients' genotypes with tumor recurrence risks were analyzed by survival analysis. A total of 16 (17.6%) of the 91 patients with NMIBC had tumor recurrences with a median follow-up of 17 months (range, 2-83 months). We confirmed the effect of the European Organization for Research and Treatment of Cancer (EORTC) risk score for predicting tumor recurrence (p = 0.002, log-rank test). We adjusted for the EORTC score and found that 2 SNPs, NOS3 895G>T (rs1799983) (p = 0.02, HR = 4.32, 95% CI, 1.30-14.39, GT+TT vs. GG) and CBR3 730G>A (rs1056892) (p = 0.04, HR = 2.57, 95% CI, 1.07-6.18, GA+AA vs. GG), were significantly associated with a higher recurrence risk after TUR and instillations of THP in NMIBC patients. CONCLUSIONS: Our results suggest that NOS3 895G>T and CBR3 730G>A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. The effects of those 2 SNPs are independent of the EORTC scores. Further studies with larger sample sizes and longer follow-ups are needed to confirm our results. CI - (c) 2018 S. Karger AG, Basel. FAU - Zhou, Qidong AU - Zhou Q AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Ding, Weihong AU - Ding W AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Weng, Yingjie AU - Weng Y AD - Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China. FAU - Ding, Guanxiong AU - Ding G AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Xia, Guowei AU - Xia G AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Xu, Jianfeng AU - Xu J AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, Chinajxu8088@gmail.com. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, Chinajxu8088@gmail.com. AD - Fudan-VARI Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, Chinajxu8088@gmail.com. AD - Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USAjxu8088@gmail.com. AD - Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USAjxu8088@gmail.com. FAU - Xu, Ke AU - Xu K AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Ding, Qiang AU - Ding Q AD - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. LA - eng PT - Journal Article DEP - 20180817 PL - Switzerland TA - Chemotherapy JT - Chemotherapy JID - 0144731 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) RN - EC 1.1.- (Alcohol Oxidoreductases) RN - EC 1.1.1.184 (CBR3 protein, human) RN - EC 1.14.13.39 (NOS3 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type III) SB - IM MH - Administration, Intravesical MH - Aged MH - Alcohol Oxidoreductases/*genetics MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers, Tumor/genetics/metabolism MH - Doxorubicin/*analogs & derivatives/therapeutic use MH - Female MH - Genotype MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Nitric Oxide Synthase Type III/*genetics MH - Polymorphism, Single Nucleotide MH - Risk Factors MH - Saliva/metabolism MH - Urinary Bladder Neoplasms/*drug therapy/genetics/mortality OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - Pharmacogenomics OT - Recurrence OT - Single nucleotide polymorphisms OT - THP EDAT- 2018/08/21 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/08/21 06:00 PHST- 2018/01/22 00:00 [received] PHST- 2018/04/18 00:00 [accepted] PHST- 2018/08/21 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/08/21 06:00 [entrez] AID - 000489402 [pii] AID - 10.1159/000489402 [doi] PST - ppublish SO - Chemotherapy. 2018;63(4):191-197. doi: 10.1159/000489402. Epub 2018 Aug 17. PMID- 30125520 OWN - NLM STAT- MEDLINE DCOM- 20190613 LR - 20190613 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 25 IP - 4 DP - 2018 Aug TI - Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer. PG - 9407-9412 AB - INTRODUCTION: To evaluate the effect of urine pH on tumor recurrence rates in patients undergoing surveillance after initial diagnosis of non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: All patients diagnosed with NMIBC at a tertiary referral center from January 2004 to March 2015 were reviewed. Our primary outcome was time to first recurrence after transurethral resection of bladder tumor (TURBT). Patients were analyzed according to the average urine pH of all urinalysis data over the surveillance period from TURBT to first recurrence. Kaplan-Meier survival analysis was used to determine differences in median time to recurrence. Cox proportional hazards regression was used to assess independent predictors of cancer recurrence. RESULTS: A total of 252 patients were included, of which 155 patients had average pH 6 (median pH 6.8), p < 0.001. There was no significant difference in median time to recurrence between low/acidic pH ( 6) groups (28 months versus 17 months, respectively, p = 0.3444). Similarly, urine pH did not affect the risk of recurrence in a subgroup analysis stratified by smoking status. On multivariable Cox regression analysis, there was no association between average pH and recurrence among high grade tumors (HR = 1.33, 95% CI = 0.76 to 2.34, p = 0.3186), or low grade tumors (HR = 1.013, 95% CI = 1.01 to 1.58, p = 0.96). CONCLUSIONS: There was no association between urine pH and risk of tumor recurrence, regardless of smoking status. These findings suggest that modification of urine pH is unlikely to decrease the frequency of tumor recurrence in patients with NMIBC. FAU - Stone, Benjamin V AU - Stone BV AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Ayangbesan, Abimbola AU - Ayangbesan A FAU - Taylor, Benjamin L AU - Taylor BL FAU - Golombos, David M AU - Golombos DM FAU - Lewicki, Patrick AU - Lewicki P FAU - Al Hussein Al Awamlh, Bashir AU - Al Hussein Al Awamlh B FAU - O'Malley, Padraic AU - O'Malley P FAU - Kaplan, Steven A AU - Kaplan SA FAU - Scherr, Douglas S AU - Scherr DS FAU - Chughtai, Bilal AU - Chughtai B LA - eng PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM CIN - Can J Urol. 2018 Aug;25(4):9413. PMID: 30125521 MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Humans MH - Hydrogen-Ion Concentration MH - Kaplan-Meier Estimate MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*urine MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Time Factors MH - Urinary Bladder Neoplasms/*pathology/*urine MH - Urine/*chemistry EDAT- 2018/08/21 06:00 MHDA- 2019/06/14 06:00 CRDT- 2018/08/21 06:00 PHST- 2018/08/21 06:00 [entrez] PHST- 2018/08/21 06:00 [pubmed] PHST- 2019/06/14 06:00 [medline] PST - ppublish SO - Can J Urol. 2018 Aug;25(4):9407-9412. PMID- 30120861 OWN - NLM STAT- MEDLINE DCOM- 20190820 LR - 20190820 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 IP - 1 DP - 2019 Jan TI - FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. PG - 187-196 LID - 10.1111/bju.14525 [doi] AB - OBJECTIVE: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ-preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by single-step quantitative RT-PCR using RNA-specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal-Wallis tests, Kaplan-Meier estimates of recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS) and Cox regression analysis. RESULTS: Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (rho: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (rho: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan-Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13-2.34], L-R chi-squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C. CONCLUSION: High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Breyer, Johannes AU - Breyer J AUID- ORCID: 0000-0003-0674-4150 AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. AD - Institute of Pathology, St Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany. FAU - Rinaldetti, Sebastien AU - Rinaldetti S AD - Department of Haematology and Oncology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany. FAU - Worst, Thomas S AU - Worst TS AD - Department of Urology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Paediatric Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180909 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (FOXM1 protein, human) RN - 0 (Forkhead Box Protein M1) RN - 0 (KRT20 protein, human) RN - 0 (Keratin-20) RN - 0 (Ki-67 Antigen) RN - 0 (MKI67 protein, human) RN - 0 (RNA, Messenger) RN - 50SG953SK6 (Mitomycin) MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/therapeutic use MH - Disease-Free Survival MH - Female MH - Forkhead Box Protein M1/*genetics MH - Humans MH - Kaplan-Meier Estimate MH - Keratin-20/genetics MH - Ki-67 Antigen/genetics MH - Male MH - Middle Aged MH - Mitomycin/therapeutic use MH - Neoplasm Staging MH - Neoplasms, Multiple Primary/*genetics MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - RNA, Messenger/metabolism MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology OTO - NOTNLM OT - FOXM1 OT - instillation therapy OT - non-muscle-invasive bladder cancer OT - pT1 OT - prognosis EDAT- 2018/08/19 06:00 MHDA- 2019/08/21 06:00 CRDT- 2018/08/19 06:00 PHST- 2018/08/19 06:00 [pubmed] PHST- 2019/08/21 06:00 [medline] PHST- 2018/08/19 06:00 [entrez] AID - 10.1111/bju.14525 [doi] PST - ppublish SO - BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9. PMID- 30120763 OWN - NLM STAT- MEDLINE DCOM- 20190708 LR - 20201005 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 16 IP - 1 DP - 2019 Feb 21 TI - A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients. PG - 37-43 LID - 10.22037/uj.v0i0.4091 [doi] AB - PURPOSE: To compare the prediction accuracy of the European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urology Association for Oncological Treatment (CUETO) risk tables in all non-muscle invasive bladder cancer patients. MATERIAL AND METHODS: Recurrence and progression-free survival of all patients were assessed according to the EORTC and the CUETO risk tables for each patient and the concordance index was used to indicate discriminative ability. Statistical analyses were performed, at 1 and 5 years, to the whole group and separately to those treated or not treated with bacillus Calmette-Guerin (BCG) . RESULTS: The study included 400 patients. One-year BCG maintenance therapy was applied to 181 patients (45.3%). The recurrence rate was higher than in CUETO, and similar to EORTC. The EORTC was determined to provide better discrimination than CUETO in the whole patient group and in those treated or not treated with BCG. The concordance indices for these groups were 0.777, 0.705; 0.773, 0.669; and 0.823, 0.758, respectively . The progression rate was similar in this study to the rate defined in both risk tables. The discrimination power was similarin EORTC and CUETO for all the groups. The concordance indices were 0.801, 0.881; 0.915, 0.930; and 0.832, 0.806, respectively. CONCLUSION: The EORTC has more power than CUETO to discriminate each recurrence risk group and both risk tables can successfully discriminate progression risk groups in all patients. FAU - Dalkilic, Ayhan AU - Dalkilic A AD - Department of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. ayhan_dalkilic@yahoo.com. FAU - Bayar, Goksel AU - Bayar G AD - Department of Urology, Idil State Hospital , Sirnak, Turkey. FAU - Kilinc, Muhammet Fatih AU - Kilinc MF AD - Department of Urology, Ankara Training and Research Hospital, Ankara, Turkey. LA - eng PT - Comparative Study PT - Journal Article DEP - 20190221 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (BCG Vaccine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/*pathology MH - Disease Progression MH - Female MH - Humans MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Muscle, Smooth MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Progression-Free Survival MH - Retrospective Studies MH - Risk Assessment/methods MH - Urinary Bladder Neoplasms/*drug therapy/*pathology MH - Young Adult EDAT- 2018/08/19 06:00 MHDA- 2019/07/10 06:00 CRDT- 2018/08/19 06:00 PHST- 2018/08/19 06:00 [pubmed] PHST- 2019/07/10 06:00 [medline] PHST- 2018/08/19 06:00 [entrez] AID - 4091 [pii] AID - 10.22037/uj.v0i0.4091 [doi] PST - epublish SO - Urol J. 2019 Feb 21;16(1):37-43. doi: 10.22037/uj.v0i0.4091. PMID- 30120103 OWN - NLM STAT- MEDLINE DCOM- 20190828 LR - 20190828 IS - 2326-6074 (Electronic) IS - 2326-6066 (Linking) VI - 6 IP - 10 DP - 2018 Oct TI - Baseline Cytokine Profiles of Tuberculin-Specific CD4(+) T Cells in Non-Muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy. PG - 1212-1219 LID - 10.1158/2326-6066.CIR-18-0046 [doi] AB - Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy preserves the bladder after resection of high-risk non-muscle-invasive bladder cancer (NMIBC). About 30% of patients experience treatment failure, which cannot be predicted a priori and carries a high risk of disease progression. We examined the in vitro tuberculin responsiveness of CD4(+) T cells before BCG immunotherapy in 42 patients with high-risk NMIBC. The frequencies and functionalities of cytokine-expressing CD4(+) T cells immediately before and after BCG immunotherapy induction were assessed by flow cytometry after overnight tuberculin stimulation. Tuberculin-induced secreted mediators were measured by electrochemiluminescence. We correlated the results with recurrence-free patient survival 6 months after induction. A tuberculin-induced, secreted, IL2 concentration > 250 pg/mL was the best predictor of recurrence-free survival, providing 79% sensitivity, 86% specificity (AUC = 0.852, P = 0.000), and overall correct classification in 78.6% of cases. In 50% of patients later experiencing recurrence, but not in any of the recurrence-free survivors, IL2 secretion was < 120 pg/mL. Other parameters predicting recurrence-free survival included secreted IFNgamma (AUC = 0.796, P = 0.002) and the frequencies of TNF-producing (TNF(+)) CD4(+) T cells (AUC = 0.745, P = 0.010). "Polyfunctional" CD4(+) T cells (IFNgamma(+)/IL2(+)/TNF(+)) were significantly associated with recurrence-free survival (AUC = 0.801, P = 0.002). Thus, the amount of IL2 secretion from CD4(+) T cells after overnight in vitro incubation with tuberculin predicted the outcome of BCG immunotherapy. As many as half of potential BCG failures could be identified before induction therapy is begun, enabling better choices regarding treatment. Cancer Immunol Res; 6(10); 1212-9. (c)2018 AACR. CI - (c)2018 American Association for Cancer Research. FAU - Jallad, Samer AU - Jallad S AD - Department of Urology, Imperial College Healthcare NHS Trust, London, United Kingdom. AD - Department of Urology, Brighton and Sussex University Hospital Trust (BSUH), Brighton, United Kingdom. FAU - Thomas, Philip AU - Thomas P AD - Department of Urology, Brighton and Sussex University Hospital Trust (BSUH), Brighton, United Kingdom. FAU - Newport, Melanie J AU - Newport MJ AD - Department of Global Health and Infectious Diseases, Brighton and Sussex Medical School, Brighton, United Kingdom. FAU - Kern, Florian AU - Kern F AD - Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom. f.kern@bsms.ac.uk. LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180817 PL - United States TA - Cancer Immunol Res JT - Cancer immunology research JID - 101614637 RN - 0 (BCG Vaccine) RN - 0 (Cytokines) RN - 0 (Tuberculin) SB - IM MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - CD4-Positive T-Lymphocytes/*immunology MH - Cytokines/*immunology/urine MH - Female MH - Humans MH - *Immunotherapy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Treatment Outcome MH - Tuberculin/*immunology MH - Urinary Bladder Neoplasms/immunology/*therapy/urine EDAT- 2018/08/19 06:00 MHDA- 2019/08/29 06:00 CRDT- 2018/08/19 06:00 PHST- 2018/02/01 00:00 [received] PHST- 2018/06/08 00:00 [revised] PHST- 2018/08/08 00:00 [accepted] PHST- 2018/08/19 06:00 [pubmed] PHST- 2019/08/29 06:00 [medline] PHST- 2018/08/19 06:00 [entrez] AID - 2326-6066.CIR-18-0046 [pii] AID - 10.1158/2326-6066.CIR-18-0046 [doi] PST - ppublish SO - Cancer Immunol Res. 2018 Oct;6(10):1212-1219. doi: 10.1158/2326-6066.CIR-18-0046. Epub 2018 Aug 17. PMID- 30117014 OWN - NLM STAT- MEDLINE DCOM- 20190125 LR - 20190125 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 50 IP - 10 DP - 2018 Oct TI - Are there any metastases to the chest in non-muscle-invasive bladder cancer patients on follow-up computed tomography? PG - 1771-1778 LID - 10.1007/s11255-018-1952-4 [doi] AB - PURPOSE: The purpose of the study was to retrospectively determine whether there are metastases to the chest in patients with primary non-muscle-invasive urothelial carcinoma in the bladder on the follow-up computed tomography (CT). METHODS: We analyzed 328 patients with follow-up chest CT for urothelial carcinoma of the bladder diagnosed between January 2004 and September 2013. We divided patients into four groups: Ta (n = 74), T1 (n = 78), carcinoma in situ (CIS, n = 25), and >/= T2 (n = 151). We used the chest CT to determine whether there were positive findings of metastasis. Univariate and multivariate analyses were achieved using categories of T stage, histological grade, multifocal lesions, and recurrence. RESULTS: On univariate analysis, there were significant differences on T stage (p < 0.001) and histological grade (p = 0.001), and there was no significant difference on multifocal lesions (p = 0.11) and recurrence (p = 0.34). Positive findings of metastases were observed in 1.4% (1/74) of the Ta patients, 0% (0/78) of the T1 patients, 8.0% (2/25) of the patients with carcinoma in situ (CIS), and 27.2% (41/151) of the >/= T2 patients (p < 0.001). On multivariate analysis, T staging was independent variable for positive findings of metastasis (Odds ratio; 2.84, 95% Confidence Interval; 1.65-4.89). In contrast, histological grade, multifocal lesions, and recurrence were not independent variables. CONCLUSIONS: T stage would affect to metastasis to the chest. It might be appropriate to omit chest CT in patients with Ta or T1 without upstaging in the course of follow-up. We may suggest that the follow-up chest CT in patients with CIS. FAU - Juri, Hiroshi AU - Juri H AUID- ORCID: 0000-0002-8976-6007 AD - Department of Radiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. rad103@osaka-med.ac.jp. FAU - Koyama, Mitsuhiro AU - Koyama M AD - Department of Radiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. FAU - Narumi, Yoshifumi AU - Narumi Y AD - Department of Radiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. LA - eng PT - Journal Article DEP - 20180816 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Bone Neoplasms/diagnostic imaging/*secondary MH - Carcinoma in Situ/diagnostic imaging/*pathology MH - Carcinoma, Transitional Cell/diagnostic imaging/*secondary MH - Humans MH - Lung Neoplasms/diagnostic imaging/*secondary MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Factors MH - Thorax/diagnostic imaging MH - Tomography, X-Ray Computed MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Bladder cancer OT - CT OT - Chest OT - Follow-up OT - Metastasis EDAT- 2018/08/18 06:00 MHDA- 2019/01/27 06:00 CRDT- 2018/08/18 06:00 PHST- 2018/06/03 00:00 [received] PHST- 2018/08/07 00:00 [accepted] PHST- 2018/08/18 06:00 [pubmed] PHST- 2019/01/27 06:00 [medline] PHST- 2018/08/18 06:00 [entrez] AID - 10.1007/s11255-018-1952-4 [pii] AID - 10.1007/s11255-018-1952-4 [doi] PST - ppublish SO - Int Urol Nephrol. 2018 Oct;50(10):1771-1778. doi: 10.1007/s11255-018-1952-4. Epub 2018 Aug 16. PMID- 30114689 OWN - NLM STAT- MEDLINE DCOM- 20180910 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 48 IP - 6 DP - 2018 TI - Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer. PG - 2364-2373 LID - 10.1159/000492652 [doi] AB - BACKGROUND/AIMS: This study aimed to validate the value of urothelial stem cell (USC) markers DeltaNp63, integrin beta4, CD47, and CD44v6 in predicting the prognosis of non-muscle invasive bladder cancer (NMIBC) located in different anatomic regions of bladder. METHODS: The study reviewed the clinicopathologic data of 169 patients with NMIBC. Using real-time PCR and immunohistochemistry, the expression of DeltaNp63, integrin beta4, CD47, and CD44v6 in archived specimens of patients with NMIBC were validated. Kaplan-Meier analysis and Cox proportional hazards model were used to assess the prognostic impact of USC markers for recurrent-free survival (RFS). RESULTS: The Real-time PCR data showed that the expression of USC markers were higher in tumors located in the trigone and posterior wall than that in other regions of bladder (P< 0.05). Statistical analysis showed that high expression of DeltaNp63 was correlated with tumor stage (P=0.023) and tumor size (P=0.001), that high expression of integrin beta4 was correlated with tumor stage (P=0.026), tumor grade (P=0.005) and tumor size (P=0.003), and that high integrin beta4, CD47, and CD44v6 expression were significantly associated with tumor recurrence (P=0.032, P=0.010, and P=0.043, respectively). Moreover, high expression of DeltaNp63 and integrin beta4 was correlated with poor RFS in patients with tumors located in the trigone (P=0.025 and P=0.023, respectively). High expression of integrin beta4, CD47, and CD44v6 was correlated with poor RFS in patients with tumors in the posterior wall (P=0.017, P=0.033 and P=0.047, respectively). High expression of integrin beta4 and CD47 was correlated with poor RFS in patients with tumors in the trigone/posterior wall area (P=0.002 and P=0.005, respectively). CONCLUSION: Our results suggest that USC markers are linked with poor prognosis of NMIBC patients, especially in patients with tumors in the trigone and posterior wall. CI - (c) 2018 The Author(s). Published by S. Karger AG, Basel. FAU - Wang, Longwang AU - Wang L AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. FAU - Zhao, Jun AU - Zhao J AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Yang, Chenlu AU - Yang C AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Womem and Children Hospital of Guangdong Province, Guangzhou, China. FAU - Kuang, Renrui AU - Kuang R AD - Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. FAU - Kazobinka, Gallina AU - Kazobinka G AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Pang, Zili AU - Pang Z AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hou, Teng AU - Hou T AD - Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20180816 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (CD47 Antigen) RN - 0 (Hyaluronan Receptors) RN - 0 (Integrin beta4) RN - 0 (TP63 protein, human) RN - 0 (Transcription Factors) RN - 0 (Tumor Suppressor Proteins) SB - IM MH - Biomarkers, Tumor/genetics/*metabolism MH - CD47 Antigen/genetics/metabolism MH - Disease-Free Survival MH - Female MH - Humans MH - Hyaluronan Receptors/genetics/metabolism MH - Immunohistochemistry MH - Integrin beta4/genetics/metabolism MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Transcription Factors/genetics/metabolism MH - Tumor Suppressor Proteins/genetics/metabolism MH - Urinary Bladder Neoplasms/metabolism/mortality/*pathology OTO - NOTNLM OT - NMIBC OT - Posterior wall OT - RFS OT - Stem cell marker OT - Trigone EDAT- 2018/08/17 06:00 MHDA- 2018/09/11 06:00 CRDT- 2018/08/17 06:00 PHST- 2018/02/04 00:00 [received] PHST- 2018/08/06 00:00 [accepted] PHST- 2018/08/17 06:00 [pubmed] PHST- 2018/09/11 06:00 [medline] PHST- 2018/08/17 06:00 [entrez] AID - 000492652 [pii] AID - 10.1159/000492652 [doi] PST - ppublish SO - Cell Physiol Biochem. 2018;48(6):2364-2373. doi: 10.1159/000492652. Epub 2018 Aug 16. PMID- 30112441 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 4 IP - 3 DP - 2018 Jul 30 TI - Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study. PG - 303-310 LID - 10.3233/BLC-180172 [doi] AB - OBJECTIVES: To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence. STUDY DESIGN: Prospective cohort study. METHODS: 716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals of developing recurrent bladder cancer in relation to the intake of total fluid, total alcohol, and individual beverages. RESULTS: During 2,025 person-years of follow-up, 238 (33%) of the included 716 NMIBC patients developed one or more recurrences of bladder cancer. Total fluid intake before diagnosis was not associated with a first recurrence of bladder cancer when comparing the highest and lowest intake group (HR = 0.98, 95% C.I. 0.70-1.38, p = 0.91). Comparable results were obtained for total fluid intake pre-diagnosis and the risk of developing multiple recurrences of bladder cancer (HR = 1.01, 95% C.I. 0.87-1.19, p = 0.85). A total of 379 of the 716 patients reported on usual fluid intake within 1 year of diagnosis. No significant associations between total fluid intake 1 year after diagnosis and a first recurrence of bladder cancer were found when comparing the highest and lowest intake group (HR = 0.91; 95% C.I. 0.60-1.37, p = 0.65) or with multiple recurrences of bladder cancer (HR = 1.06; 95% C.I. 0.89-1.26, p = 0.54). In addition, total alcohol intake and individual beverages were not associated with bladder cancer recurrence. CONCLUSIONS: The results indicate that an individual's fluid intake from beverages is unlikely to have an important role in bladder cancer recurrence. FAU - Jochems, Sylvia H J AU - Jochems SHJ AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. FAU - van Osch, Frits H M AU - van Osch FHM AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. FAU - Reulen, Raoul C AU - Reulen RC AD - Department of Public Health, Epidemiology and Biostatistics, institute of Applied Health Research, University of Birmingham, UK. FAU - van Hensbergen, Mitch AU - van Hensbergen M AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. FAU - Nekeman, Duncan AU - Nekeman D AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Pirrie, Sarah J AU - Pirrie SJ AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Wesselius, Anke AU - Wesselius A AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. FAU - van Schooten, Frederik J AU - van Schooten FJ AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Wallace, D Michael A AU - Wallace DMA AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Cheng, K K AU - Cheng KK AD - Department of Public Health, Epidemiology and Biostatistics, institute of Applied Health Research, University of Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands. LA - eng PT - Journal Article DEP - 20180730 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 EIN - Bladder Cancer. 2020 Sep 21;6(3):401. doi: 10.3233/BLC-200006. PMID: 33283032 PMC - PMC6087451 OTO - NOTNLM OT - Fluid intake OT - bladder cancer OT - recurrence EDAT- 2018/08/17 06:00 MHDA- 2018/08/17 06:01 PMCR- 2018/08/11 CRDT- 2018/08/17 06:00 PHST- 2018/08/17 06:00 [entrez] PHST- 2018/08/17 06:00 [pubmed] PHST- 2018/08/17 06:01 [medline] PHST- 2018/08/11 00:00 [pmc-release] AID - BLC180172 [pii] AID - 10.3233/BLC-180172 [doi] PST - epublish SO - Bladder Cancer. 2018 Jul 30;4(3):303-310. doi: 10.3233/BLC-180172. PMID- 30109483 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20210421 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 1 DP - 2019 Jan TI - ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. PG - 51-60 LID - 10.1007/s00345-018-2438-9 [doi] AB - PURPOSE: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC). METHODS: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma in situ [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC. RESULTS: Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies. CONCLUSION: NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk stratification are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC. FAU - Monteiro, Leonardo L AU - Monteiro LL AD - Division of Urology, McGill University Health Center-Glen Site, 1001 Decarie Blvd, Montreal, QC, H3A 3J1, Canada. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Agarwal, Piyush K AU - Agarwal PK AD - Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Columbia University, New York, USA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, USA. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Chang, Sam S AU - Chang SS AD - Ingram Cancer Center, Vanderbilt University, Tennessee, USA. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Columbia University, New York, USA. FAU - Dinney, Colin AU - Dinney C AD - Department of Urology, MD Anderson Cancer Center, Houston, USA. FAU - Godoy, Guilherme AU - Godoy G AD - Scott Department of Urology, Baylor College of Medicine, Houston, USA. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Department of Urology, Western General Hospital, University of Edinburgh, Edinburgh, UK. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - University of Iowa, Iowa City, USA. FAU - Rentsch, Cyrill A AU - Rentsch CA AD - Department of Urology, University of Basel, Basel, Switzerland. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, Stanford University School of Medicine, Stanford, USA. FAU - Solsona, Eduardo AU - Solsona E AD - Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, Division of Urologic Oncology, The University of Texas Health San Antonio, San Antonio, USA. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - van Valenberg, F Johannes P AU - van Valenberg FJP AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University Health Center-Glen Site, 1001 Decarie Blvd, Montreal, QC, H3A 3J1, Canada. wassim.kassouf@muhc.mcgill.ca. LA - eng PT - Journal Article PT - Review DEP - 20180814 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Carcinoma in Situ/pathology/*therapy MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Cystectomy MH - Cystoscopy MH - Disease Progression MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Prognosis MH - Prostate/pathology MH - Urethra/pathology MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Diagnosis OT - Guidelines OT - ICUD OT - Non-muscle invasive bladder cancer OT - Staging OT - Surveillance OT - Transurethral resection of bladder tumor OT - Treatment EDAT- 2018/08/16 06:00 MHDA- 2019/05/23 06:00 CRDT- 2018/08/16 06:00 PHST- 2018/06/05 00:00 [received] PHST- 2018/08/06 00:00 [accepted] PHST- 2018/08/16 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] PHST- 2018/08/16 06:00 [entrez] AID - 10.1007/s00345-018-2438-9 [pii] AID - 10.1007/s00345-018-2438-9 [doi] PST - ppublish SO - World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. PMID- 30109022 OWN - NLM STAT- MEDLINE DCOM- 20190715 LR - 20190715 IS - 2046-1402 (Electronic) IS - 2046-1402 (Linking) VI - 7 DP - 2018 TI - Advances in risk stratification of bladder cancer to guide personalized medicine. LID - F1000 Faculty Rev-1137 [pii] LID - 10.12688/f1000research.14903.1 [doi] AB - Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor's mutational profile. FAU - Matulay, Justin T AU - Matulay JT AUID- ORCID: 0000-0002-2467-5710 AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20180725 PL - England TA - F1000Res JT - F1000Research JID - 101594320 SB - IM MH - Humans MH - Precision Medicine/*methods MH - Risk Assessment MH - *Urinary Bladder Neoplasms/pathology/therapy PMC - PMC6069735 OTO - NOTNLM OT - Bladder cancer OT - bladder cancer genetics OT - personalized medicine OT - risk stratification OT - urothelial carcinoma COIS- Competing interests: AMK is a consultant to TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, and Astra Zeneca and has received research funding from FKD, Merck, Telesta, and Adolo. JTM has no competing interests to declare.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed. EDAT- 2018/08/16 06:00 MHDA- 2019/07/16 06:00 PMCR- 2018/07/25 CRDT- 2018/08/16 06:00 PHST- 2018/07/18 00:00 [accepted] PHST- 2018/08/16 06:00 [entrez] PHST- 2018/08/16 06:00 [pubmed] PHST- 2019/07/16 06:00 [medline] PHST- 2018/07/25 00:00 [pmc-release] AID - F1000 Faculty Rev-1137 [pii] AID - 10.12688/f1000research.14903.1 [doi] PST - epublish SO - F1000Res. 2018 Jul 25;7:F1000 Faculty Rev-1137. doi: 10.12688/f1000research.14903.1. eCollection 2018. PMID- 30107897 OWN - NLM STAT- MEDLINE DCOM- 20200713 LR - 20200713 IS - 1535-6345 (Electronic) IS - 0147-0272 (Linking) VI - 43 IP - 3 DP - 2019 Jun TI - Involved-field irradiation for elderly bladder cancer patients. PG - 195-204 LID - S0147-0272(18)30188-0 [pii] LID - 10.1016/j.currproblcancer.2018.07.009 [doi] AB - OBJECTIVES: Considering that adjuvant radiation therapy is one of the most common treatment methods and the influence of the clinical target volume to treatment-related toxicity, this study aimed to observe the differences in treatment failures about involved-field irradiation (IFI) without lymph node areas versus elective nodal irradiation (ENI) with lymph node areas in elderly patients with bladder cancer. MATERIAL AND METHODS: Ninety-two elderly bladder cancer patients were analyzed from January 2010 to December 2014 in one institution. The primary inclusion criteria were previous after transurethral resection of bladder tumor or partial cystectomy with adjuvant radiotherapy, and the radiation techniques included IFI or ENI. The study required that elderly patients did not received radiotherapy before treatment. We observed treatment-related toxicity and tumor failures, evaluated local progression-free survival, estimated the 3-year overall survival, and analyzed prognostic factors, after IFI and ENI in elderly bladder cancer patients. The outcomes were determined by chi square tests, Kaplan-Meier method and Cox multiple factors analysis. RESULTS: In the experimental group, 42 patients (45.65%) received IFI, and a matched group of 50 patients (54.35%) received ENI. With a median follow-up of 31.47 months (range 4.00-86.00 months), the Kaplan-Meier analysis with a log-rank test demonstrated a statistical difference between the IFI group and the ENI group in acute toxicity (45.23% vs 72.00%, P = 0.008). However, there were no statistical differences in the 3-year overall survival rate (45.20% vs 48.00%, P = 0.860) or the duration of local progression-free survival (24.98 vs 34.30, P =0.729). CONCLUSIONS: IFI is feasible in elderly bladder cancer patients, as shown by a decrease in acute toxicity and no increase in local failure. We need a large number of clinical trials and data to further confirm these results. CI - Copyright (c) 2018. Published by Elsevier Inc. FAU - Li, Hongwei AU - Li H AD - Department of Oncology, School of Medicine, Qingdao University, Qingdao, P.R. of China; Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Chen, Wei AU - Chen W AD - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Ma, Jinbo AU - Ma J AD - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Zang, Rukun AU - Zang R AD - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - You, Dong AU - You D AD - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Liu, Sujing AU - Liu S AD - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Li, Cunqi AU - Li C AD - Department of Oncology, School of Medicine, Qingdao University, Qingdao, P.R. of China; Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. FAU - Song, Yipeng AU - Song Y AD - Department of Oncology, School of Medicine, Qingdao University, Qingdao, P.R. of China; Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. of China. Electronic address: syp1972@sina.com. LA - eng PT - Journal Article DEP - 20180804 PL - United States TA - Curr Probl Cancer JT - Current problems in cancer JID - 7702986 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Squamous Cell/pathology/*therapy MH - Chemoradiotherapy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Lymphatic Irradiation/*mortality MH - Male MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - clinical target volume OT - involved-field irradiation OT - radiotherapy EDAT- 2018/08/16 06:00 MHDA- 2020/07/14 06:00 CRDT- 2018/08/16 06:00 PHST- 2018/06/24 00:00 [received] PHST- 2018/07/13 00:00 [accepted] PHST- 2018/08/16 06:00 [pubmed] PHST- 2020/07/14 06:00 [medline] PHST- 2018/08/16 06:00 [entrez] AID - S0147-0272(18)30188-0 [pii] AID - 10.1016/j.currproblcancer.2018.07.009 [doi] PST - ppublish SO - Curr Probl Cancer. 2019 Jun;43(3):195-204. doi: 10.1016/j.currproblcancer.2018.07.009. Epub 2018 Aug 4. PMID- 30098938 OWN - NLM STAT- MEDLINE DCOM- 20190412 LR - 20190412 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 4 DP - 2018 Jul TI - Predicting Response to Intravesical Therapy in Non-muscle-invasive Bladder Cancer. PG - 494-502 LID - S2405-4569(18)30216-5 [pii] LID - 10.1016/j.euf.2018.07.032 [doi] AB - CONTEXT: The ability to predict response to intravesical therapy (IVT) following transurethral resection in non-muscle-invasive bladder cancer holds important prognostic information. However, few predictive tools are available to guide urologists. OBJECTIVE: We reviewed the most recent studies investigating the predictors of response to IVT. EVIDENCE ACQUISITION: A literature search was conducted using PubMed database from January 1, 2013 to April 1, 2018 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria. For our search strategy, we used the combination of the MeSH terms of "Administration, Intravesical" and "Urinary Bladder Neoplasms" with any of the following words: "Biomarkers," "Predictive Value of Tests," "response," "recurrence," and "progression." We limited our search to the English language. EVIDENCE SYNTHESIS: Risk stratification models utilizing clinicopathological features are the most cost-effective and widely used tools currently available to predict response to IVT. Additionally, urinary fluorescence in situ hybridization testing and urinary cytokine-based nomograms (Cytokine Panel for Response to Intravesical Therapy) may enhance predictive ability. Protein-based biomarkers have been associated with predicting recurrence. Several gene-based biomarkers quantifying mutations in DNA damage repair genes may have predictive ability. However, genomic data are relatively new and lack validation. CONCLUSIONS: Clinicopathological criteria remain the most widely utilized tool for predicting IVT response. Further research to validate protein- and genomic-based biomarkers are needed before adoption in clinical practice. PATIENT SUMMARY: We reviewed contemporary studies that investigated how to predict response to medication instilled in the bladder (intravesical therapy) for bladder cancer. We found that most predictive tools use clinical data, such as tumor stage and grade, to determine the outcome. Newer biological (gene, protein, cytokines) marker tests are being studied. We concluded that the combination of clinical data with levels of certain experimental markers (fluorescence in situ hybridization test or urinary cytokines) may improve predictive ability. Genetic testing methods may also yield additional predictive markers in the future, but this needs more validation. CI - Copyright (c) 2018. Published by Elsevier B.V. FAU - Alameddine, Mahmoud AU - Alameddine M AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Kineish, Omer AU - Kineish O AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Ritch, Chad AU - Ritch C AD - Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: critch@miami.edu. LA - eng PT - Journal Article PT - Review DEP - 20180808 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/pharmacology MH - Administration, Intravesical MH - BCG Vaccine/*pharmacology MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis/*prevention & control MH - Predictive Value of Tests MH - Prognosis MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Intravesical therapy OT - Predicting response EDAT- 2018/08/14 06:00 MHDA- 2019/04/13 06:00 CRDT- 2018/08/13 06:00 PHST- 2018/06/03 00:00 [received] PHST- 2018/07/11 00:00 [revised] PHST- 2018/07/20 00:00 [accepted] PHST- 2018/08/14 06:00 [pubmed] PHST- 2019/04/13 06:00 [medline] PHST- 2018/08/13 06:00 [entrez] AID - S2405-4569(18)30216-5 [pii] AID - 10.1016/j.euf.2018.07.032 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jul;4(4):494-502. doi: 10.1016/j.euf.2018.07.032. Epub 2018 Aug 8. PMID- 30089981 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 10 IP - 3 DP - 2018 Jul-Sep TI - Characterization and outcomes of local treatment for primary bladder lymphoma: A population-based cohort analysis. PG - 249-253 LID - 10.4103/UA.UA_106_17 [doi] AB - INTRODUCTION: Primary bladder lymphoma (PBL) is rare, representing 0.2% of extranodal lymphoma and less than 1% of all tumors originating in the bladder. Since the initial description of the disease, low-grade mucosa-associated lymphoid tissue (MALT) lymphoma has been reported as the most common subtype while high-grade disease was thought to represent only 20% of the reported cases. MATERIALS AND METHODS: One hundred and ninety five patients with PBL from the Surveillance, Epidemiology, and End Results (SEER) registry from 1998-2010 were reviewed. Tumors were classified as high or low grade based on histologic subtype of lymphoma based on revised European-American Lymphoma classification system. Socio-demographic and clinical variables were reported, as well as survival outcome analyses using the Kaplan-Meier method and log-rank test. Cox proportional hazard analysis was used to generate hazard ratios for risk factors associated with mortality. RESULTS: Eighty-three patients (42.6%) with low-grade and 112 patients (57.4%) with high-grade bladder lymphoma were studied. There were no differences between the low and high-grade groups for socio-demographic or clinical variables. Median overall survival or patients with low-grade disease was 38 months versus 15 months for patients with high-grade disease (p< 0.001). Analysis demonstrated worse survival outcomes for patients with high-grade disease compared to low-grade disease (p< 0.001). On multivariable analysis, increasing age and high-grade disease were associated with worse disease specific mortality (p< 0.001). CONCLUSION: Patient with high-grade primary bladder lymphoma had worse survival outcomes compared to those with low-grade disease. While transurethral resection provides tissue for diagnosis, immunotherapy/chemotherapy remains the mainstay of treatment for bladder lymphoma. Consolidation chemotherapy has been recommended in young patients not achieving complete remission with immunotherapy/chemotherapy. FAU - Sellman, David P AU - Sellman DP AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Simpson, W Greg AU - Simpson WG AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Klaassen, Zachary AU - Klaassen Z AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Jen, Rita P AU - Jen RP AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - DiBianco, John M AU - DiBianco JM AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Reinstatler, Lael AU - Reinstatler L AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Li, Qiang AU - Li Q AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Madi, Rabii AU - Madi R AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. FAU - Terris, Martha K AU - Terris MK AD - Department of Surgery, Section of Urology, Medical College of Georgia - Augusta University, Augusta, Georgia, USA. LA - eng PT - Journal Article PL - India TA - Urol Ann JT - Urology annals JID - 101510823 PMC - PMC6060605 OTO - NOTNLM OT - Bladder cancer OT - SEER OT - lymphoma OT - outcomes COIS- There are no conflicts of interest. EDAT- 2018/08/10 06:00 MHDA- 2018/08/10 06:01 PMCR- 2018/07/01 CRDT- 2018/08/10 06:00 PHST- 2018/08/10 06:00 [entrez] PHST- 2018/08/10 06:00 [pubmed] PHST- 2018/08/10 06:01 [medline] PHST- 2018/07/01 00:00 [pmc-release] AID - UA-10-249 [pii] AID - 10.4103/UA.UA_106_17 [doi] PST - ppublish SO - Urol Ann. 2018 Jul-Sep;10(3):249-253. doi: 10.4103/UA.UA_106_17. PMID- 30077559 OWN - NLM STAT- MEDLINE DCOM- 20190218 LR - 20231031 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 201 IP - 1 DP - 2019 Jan TI - Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. PG - 46-53 LID - 10.1016/j.juro.2018.05.162 [doi] AB - PURPOSE: We investigated the prognostic impact of concomitant carcinoma in situ in radical cystectomy specimens. MATERIALS AND METHODS: We performed a systematic review and meta-analysis using MEDLINE(R), Scopus(R), Web of Science and The Cochrane Library to identify eligible studies published until October 2017. Studies were eligible for analysis if they compared patients with concomitant carcinoma in situ in radical cystectomy specimens for bladder cancer to patients without concomitant carcinoma in situ to determine its value to prognosticate overall mortality, recurrence-free survival, cancer specific mortality and ureteral involvement using multivariable analysis. The protocol for this systematic review was registered in PROSPERO (Prospective Register of Systematic Reviews, CRD42018086539) and is available in full on the University of York website. RESULTS: Overall 23 studies published between 2006 and 2017 including a total of 20,647 patients were selected for the systematic review and meta-analysis. Concomitant carcinoma in situ was reported in 39.4% of radical cystectomy specimens. In studies analyzing all patients the presence of concomitant carcinoma in situ was not associated with overall mortality (pooled HR 0.92, 0.77-1.10), recurrence-free survival (pooled HR 1.06, 0.99-1.13) or cancer specific mortality (pooled HR 1.00, 0.93-1.07). It was associated with ureteral involvement (pooled OR 4.51, 2.59-7.84). On subanalysis of studies restricted to patients with organ confined bladder cancer at radical cystectomy concomitant carcinoma in situ was associated with worse recurrence-free survival (pooled HR 1.57, 1.12-2.21) and cancer specific mortality (pooled HR 1.51, 1.001-2.280). CONCLUSIONS: Concomitant carcinoma in situ is significantly associated with ureteral involvement in patients treated with radical cystectomy. In patients with organ confined disease concomitant carcinoma in situ in the radical cystectomy specimen is a prognosticator of recurrence-free survival and cancer specific mortality. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Careggi Hospital, University of Florence, Florence, Italy. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Stangl-Kremser, Judith AU - Stangl-Kremser J AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Egawa, Shin AU - Egawa S AD - Departments of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Weill Cornell Medical College, New York, New York. AD - University of Texas Southwestern Medical Center, Dallas, Texas. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2019 Jan;201(1):54. doi: 10.1097/01.ju.0000550122.69979.70. PMID: 30577388 CIN - J Urol. 2019 Jan;201(1):54-55. doi: 10.1097/01.ju.0000550123.08098.ad. PMID: 30577389 MH - Carcinoma in Situ/diagnosis/epidemiology/*pathology/surgery MH - *Cystectomy MH - Disease-Free Survival MH - Humans MH - Neoplasm Recurrence, Local/*diagnosis/epidemiology/pathology MH - Prognosis MH - Survival Analysis MH - Treatment Outcome MH - Ureteral Neoplasms/*diagnosis/epidemiology/pathology/secondary MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery EDAT- 2018/08/06 06:00 MHDA- 2019/02/20 06:00 CRDT- 2018/08/06 06:00 PHST- 2018/08/06 06:00 [pubmed] PHST- 2019/02/20 06:00 [medline] PHST- 2018/08/06 06:00 [entrez] AID - S0022-5347(18)43637-3 [pii] AID - 10.1016/j.juro.2018.05.162 [doi] PST - ppublish SO - J Urol. 2019 Jan;201(1):46-53. doi: 10.1016/j.juro.2018.05.162. PMID- 30077463 OWN - NLM STAT- MEDLINE DCOM- 20190624 LR - 20220408 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 6 DP - 2018 Dec TI - Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. PG - 445-452 LID - S1558-7673(18)30183-6 [pii] LID - 10.1016/j.clgc.2018.07.003 [doi] AB - INTRODUCTION: The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: The study period was from January 2002 through December 2012. A total of 1046 patients with primary T1 HG/G3 who had NMIBC on re-transurethral bladder resection (TURB) who received adjuvant intravesical bacillus Calmette-Guerin therapy with maintenance from 13 academic institutions were included. Endpoints were time to disease, and recurrence-free (RFS), progression-free (PFS), overall (OS), and cancer-specific survival (CSS). RESULTS: A total of 512 (48.9%) of patients had NLR >/= 3 prior to TURB. High pretreatment NLR was associated with female gender and residual T1HG/G3 on re-TURB. The 5-year RFS estimates were 9.4% (95% confidence interval [CI], 6.8%-12.4%) in patients with NLR >/= 3 compared with 58.8% (95% CI, 54%-63.2%) in patients with NLR < 3; the 5-year PFS estimates were 57.1% (95% CI, 51.5%-62.2%) versus 79.2% (95% CI, 74.7%-83%; P < .0001); the 10-year OS estimates were 63.6% (95% CI, 55%-71%) versus 66.5% (95% CI, 56.8%-74.5%; P = .03); the 10-year CSS estimates were 77.4% (95% CI, 68.4%-84.2%) versus 84.3% (95% CI, 76.6%-89.7%; P = .004). NLR was independently associated with disease recurrence (hazard ratio [HR], 3.34; 95% CI, 2.82-3.95; P < .001), progression (HR, 2.18; 95% CI, 1.71-2.78; P < .001) and CSS (HR, 1.65; 95% CI, 1.02-2.66; P = .03). The addition of NLR to a multivariable model that included established features increased its discrimination for predicting of RFS (+6.9%), PFS (+1.8%), and CSS (+1.7%). CONCLUSIONS: Pretreatment NLR >/= 3 was a strong predictor for RFS, PFS, and CSS in patients with primary T1 HG/G3 NMIBC. It could help in the decision-making regarding intensity of therapy and follow-up. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology, Milan, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Di Stasi, Savino AU - Di Stasi S AD - Department of Experimental Medicine and Surgery, Tor Vegata University, Rome, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy; Humanitas University, Department of Biomedical Science, Rozzano (Milan), Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale" IRCCS, Naples, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - La Rocca, Roberto AU - La Rocca R AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Brunocilla, Eugenio AU - Brunocilla E AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Almeida, Gilberto L AU - Almeida GL AD - Departamento de Urologia, University of Vale do Itajai, Itajai, Brasil. FAU - Bove, Pierluigi AU - Bove P AD - Division of Urology, Department of Experimental Medicine and Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. FAU - Lima, Estevao AU - Lima E AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Grimaldi, Giovanni AU - Grimaldi G AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy "Iuliu Hateganu," Cluj-Napoca, Romania. FAU - Abu Farhan, Abdal Rahman AU - Abu Farhan AR AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Morgia, Giuseppe AU - Morgia G AD - Department of Urology, University of Catania, Catania, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy; Universita degli Studi di Milano, Milan, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20180706 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Lymphocyte Count MH - *Lymphocytes MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/pathology/prevention & control MH - *Neutrophils MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/blood/*mortality/pathology/therapy OTO - NOTNLM OT - High risk OT - High-grade OT - NLR OT - Progression OT - Recurrence EDAT- 2018/08/06 06:00 MHDA- 2019/06/25 06:00 CRDT- 2018/08/06 06:00 PHST- 2018/03/09 00:00 [received] PHST- 2018/06/15 00:00 [revised] PHST- 2018/07/03 00:00 [accepted] PHST- 2018/08/06 06:00 [pubmed] PHST- 2019/06/25 06:00 [medline] PHST- 2018/08/06 06:00 [entrez] AID - S1558-7673(18)30183-6 [pii] AID - 10.1016/j.clgc.2018.07.003 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6. PMID- 30075815 OWN - NLM STAT- MEDLINE DCOM- 20190715 LR - 20211119 IS - 1868-7083 (Electronic) IS - 1868-7075 (Print) IS - 1868-7075 (Linking) VI - 10 IP - 1 DP - 2018 Aug 3 TI - Increased CD4(+) T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. PG - 102 LID - 10.1186/s13148-018-0536-6 [doi] LID - 102 AB - BACKGROUND: Urinary bladder cancer is a common malignancy worldwide. Environmental factors and chronic inflammation are correlated with the disease risk. Diagnosis is performed by transurethral resection of the bladder, and patients with muscle invasive disease preferably proceed to radical cystectomy, with or without neoadjuvant chemotherapy. The anti-tumour immune responses, known to be initiated in the tumour and draining lymph nodes, may play a major role in future treatment strategies. Thus, increasing the knowledge of tumour-associated immunological processes is important. Activated CD4(+) T cells differentiate into four main separate lineages: Th1, Th2, Th17 and Treg, and they are recognized by their effector molecules IFN-gamma, IL-13, IL-17A, and the transcription factor Foxp3, respectively. We have previously demonstrated signature CpG sites predictive for lineage commitment of these four major CD4(+) T cell lineages. Here, we investigate the lineage commitment specifically in tumour, lymph nodes and blood and relate them to the disease stage and response to neoadjuvant chemotherapy. RESULTS: Blood, tumour and regional lymph nodes were obtained from patients at time of transurethral resection of the bladder and at radical cystectomy. Tumour-infiltrating CD4(+) lymphocytes were significantly hypomethylated in all four investigated lineage loci compared to CD4(+) lymphocytes in lymph nodes and blood (lymph nodes vs tumour-infiltrating lymphocytes: IFNG -4229 bp p < 0.0001, IL13 -11 bp p < 0.05, IL17A -122 bp p < 0.01 and FOXP3 -77 bp p > 0.05). Examination of individual lymph nodes displayed different methylation signatures, suggesting possible correlation with future survival. More advanced post-cystectomy tumour stages correlated significantly with increased methylation at the IFNG -4229 bp locus. Patients with complete response to neoadjuvant chemotherapy displayed significant hypomethylation in CD4(+) T cells for all four investigated loci, most prominently in IFNG p < 0.0001. Neoadjuvant chemotherapy seemed to result in a relocation of Th1-committed CD4(+) T cells from blood, presumably to the tumour, indicated by shifts in the methylation patterns, whereas no such shifts were seen for lineages corresponding to IL13, IL17A and FOXP3. CONCLUSION: Increased lineage commitment in CD4(+) T cells, as determined by demethylation in predictive CpG sites, is associated with lower post-cystectomy tumour stage, complete response to neoadjuvant chemotherapy and overall better outcome, suggesting epigenetic profiling of CD4(+) T cell lineages as a useful readout for clinical staging. FAU - Ahlen Bergman, Emma AU - Ahlen Bergman E AUID- ORCID: 0000-0002-6957-7129 AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. emma.ahlen.bergman@ki.se. FAU - Hartana, Ciputra Adijaya AU - Hartana CA AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Johansson, Markus AU - Johansson M AD - Department of Urology, Sundsvall Hospital, Sundsvall, Sweden. AD - Department of surgical and perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Linton, Ludvig B AU - Linton LB AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Berglund, Sofia AU - Berglund S AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Hyllienmark, Martin AU - Hyllienmark M AD - TLA Targeted Immunotherapies AB, Stockholm, Sweden. FAU - Lundgren, Christian AU - Lundgren C AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Holmstrom, Benny AU - Holmstrom B AD - Department of Urology, Akademiska University Hospital, Uppsala, Sweden. FAU - Palmqvist, Karin AU - Palmqvist K AD - Department of surgical and perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. AD - Department of Surgery, Urology Section, Ostersund County Hospital, Ostersund, Sweden. FAU - Hansson, Johan AU - Hansson J AD - Centre for Research and Development, Faculty of Medicine, Uppsala University, County Council of Gavleborg, Uppsala, Sweden. FAU - Alamdari, Farhood AU - Alamdari F AD - Department of Urology, Vastmanland Hospital, Vasteras, Sweden. FAU - Huge, Ylva AU - Huge Y AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Clinical and Experimental Medicine, Division of Urology, Linkoping University, Linkoping, Sweden. FAU - Riklund, Katrine AU - Riklund K AD - Department of Radiation Sciences, Diagnostic Radiology, Umea University, Umea, Sweden. FAU - Winerdal, Malin E AU - Winerdal ME AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Krantz, David AU - Krantz D AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Zirakzadeh, A Ali AU - Zirakzadeh AA AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. AD - Department of surgical and perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. FAU - Marits, Per AU - Marits P AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Sjoholm, Louise K AU - Sjoholm LK AD - Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. FAU - Sherif, Amir AU - Sherif A AD - Department of surgical and perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden. AD - Department of Radiation Sciences, Diagnostic Radiology, Umea University, Umea, Sweden. FAU - Winqvist, Ola AU - Winqvist O AD - Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180803 PL - Germany TA - Clin Epigenetics JT - Clinical epigenetics JID - 101516977 RN - 0 (FOXP3 protein, human) RN - 0 (Forkhead Transcription Factors) RN - 0 (IFNG protein, human) RN - 0 (IL13 protein, human) RN - 0 (IL17A protein, human) RN - 0 (Interleukin-13) RN - 0 (Interleukin-17) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Aged MH - Aged, 80 and over MH - CD4-Positive T-Lymphocytes/*cytology/immunology MH - Cell Differentiation MH - Cell Lineage MH - Cells, Cultured MH - CpG Islands MH - Cystectomy MH - *DNA Methylation MH - Drug Therapy MH - Epigenesis, Genetic MH - Female MH - Forkhead Transcription Factors/genetics MH - Humans MH - Interferon-gamma/genetics MH - Interleukin-13/genetics MH - Interleukin-17/genetics MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Prognosis MH - Sequence Analysis, DNA/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/genetics/immunology/*pathology/*surgery PMC - PMC6076404 OTO - NOTNLM OT - CD4-positive T lymphocytes OT - DNA methylation OT - Urinary bladder neoplasms COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved by the local ethical committee (original dnr: 2007/71-31 with latest amendment 2017/190-32, both EPN-Stockholm). COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/08/05 06:00 MHDA- 2019/07/16 06:00 PMCR- 2018/08/03 CRDT- 2018/08/05 06:00 PHST- 2018/03/01 00:00 [received] PHST- 2018/07/24 00:00 [accepted] PHST- 2018/08/05 06:00 [entrez] PHST- 2018/08/05 06:00 [pubmed] PHST- 2019/07/16 06:00 [medline] PHST- 2018/08/03 00:00 [pmc-release] AID - 10.1186/s13148-018-0536-6 [pii] AID - 536 [pii] AID - 10.1186/s13148-018-0536-6 [doi] PST - epublish SO - Clin Epigenetics. 2018 Aug 3;10(1):102. doi: 10.1186/s13148-018-0536-6. PMID- 30072631 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 6 IP - 3 DP - 2018 Aug 2 TI - Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. LID - 10.3390/biomedicines6030085 [doi] LID - 85 AB - The rapid development of the cancer stem cells (CSC) field, together with powerful genome-wide screening techniques, have provided the basis for the development of future alternative and reliable therapies aimed at targeting tumor-initiating cell populations. Urothelial bladder cancer stem cells (BCSCs) that were identified for the first time in 2009 are heterogenous and originate from multiple cell types; including urothelial stem cells and differentiated cell types-basal, intermediate stratum and umbrella cells Some studies hypothesize that BCSCs do not necessarily arise from normal stem cells but might derive from differentiated progenies following mutational insults and acquisition of tumorigenic properties. Conversely, there is data that normal bladder tissues can generate CSCs through mutations. Prognostic risk stratification by identification of predictive markers is of major importance in the management of urothelial cell carcinoma (UCC) patients. Several stem cell markers have been linked to recurrence or progression. The CD44v8-10 to standard CD44-ratio (total ratio of all CD44 alternative splicing isoforms) in urothelial cancer has been shown to be closely associated with tumor progression and aggressiveness. ALDH1, has also been reported to be associated with BCSCs and a worse prognosis in a large number of studies. UCC include low-grade and high-grade non-muscle invasive bladder cancer (NMIBC) and high-grade muscle invasive bladder cancer (MIBC). Important genetic defects characterize the distinct pathways in each one of the stages and probably grades. As an example, amplification of chromosome 6p22 is one of the most frequent changes seen in MIBC and might act as an early event in tumor progression. Interestingly, among NMIBC there is a much higher rate of amplification in high-grade NMIBC compared to low grade NMIBC. CDKAL1, E2F3 and SOX4 are highly expressed in patients with the chromosomal 6p22 amplification aside from other six well known genes (ID4, MBOAT1, LINC00340, PRL, and HDGFL1). Based on that, SOX4, E2F3 or 6q22.3 amplifications might represent potential targets in this tumor type. Focusing more in SOX4, it seems to exert its critical regulatory functions upstream of the Snail, Zeb, and Twist family of transcriptional inducers of EMT (epithelial(-)mesenchymal transition), but without directly affecting their expression as seen in several cell lines of the Cancer Cell Line Encyclopedia (CCLE) project. SOX4 gene expression correlates with advanced cancer stages and poor survival rate in bladder cancer, supporting a potential role as a regulator of the bladder CSC properties. SOX4 might serve as a biomarker of the aggressive phenotype, also underlying progression from NMIBC to MIBC. The amplicon in chromosome 6 contains SOX4 and E2F3 and is frequently found amplified in bladder cancer. These genes/amplicons might be a potential target for therapy. As an existing hypothesis is that chromatin deregulation through enhancers or super-enhancers might be the underlying mechanism responsible of this deregulation, a potential way to target these transcription factors could be through epigenetic modifiers. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Department of Medical Oncology, Hospital del Mar, IMIM (PSMAR-Hospital del Mar Research Institute), 08003 Barcelona, Spain. jbellmunt@imim.cat. AD - Harvard Medical School, Boston, MA 02115, USA. jbellmunt@imim.cat. LA - eng PT - Journal Article PT - Review DEP - 20180802 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC6164884 OTO - NOTNLM OT - E2F3 OT - EMT OT - SOX-4 OT - bladder cancer OT - bladder cancer stem cells OT - non-muscle invasive bladder cancer COIS- The authors declare no conflicts of interest. EDAT- 2018/08/04 06:00 MHDA- 2018/08/04 06:01 PMCR- 2018/08/02 CRDT- 2018/08/04 06:00 PHST- 2018/06/06 00:00 [received] PHST- 2018/07/25 00:00 [revised] PHST- 2018/07/26 00:00 [accepted] PHST- 2018/08/04 06:00 [entrez] PHST- 2018/08/04 06:00 [pubmed] PHST- 2018/08/04 06:01 [medline] PHST- 2018/08/02 00:00 [pmc-release] AID - biomedicines6030085 [pii] AID - biomedicines-06-00085 [pii] AID - 10.3390/biomedicines6030085 [doi] PST - epublish SO - Biomedicines. 2018 Aug 2;6(3):85. doi: 10.3390/biomedicines6030085. PMID- 30064935 OWN - NLM STAT- MEDLINE DCOM- 20181105 LR - 20181105 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 9 DP - 2018 Sep TI - An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. PG - 400.e7-400.e14 LID - S1078-1439(18)30195-9 [pii] LID - 10.1016/j.urolonc.2018.05.026 [doi] AB - BACKGROUND: In a recent meta-analysis, subgroups of patients were defined that may not benefit from a single, immediate instillation with chemotherapy. This led to a change in the European Association of Urology bladder cancer guidelines. In a previous paper, our group confirmed the efficacy of an immediate instillation of mitomycin C (MMC). However, prognostic groups in that study differ from those in the meta-analysis. Therefore, we performed a reanalysis using contemporary risk groups. OBJECTIVES: To validate whether specific subgroups of patients with non-muscle-invasive bladder cancer (NMIBC) benefit from an immediate instillation with MMC. PATIENTS AND METHODS: All 2,243 NMIBC patients enrolled in our randomized controlled trial between 1998 and 2003 were analyzed. Treatment effect was investigated for all subgroups, including subgroups that did not benefit from an immediate instillation according to the meta-analysis. Time to recurrence was assessed using Kaplan-Meier curves and multivariable Cox regression. Differences in treatment effect between subgroups was tested using the variable treatment by covariate interactions in a Cox regression model. RESULTS: The difference in time to recurrence was statistically significant in favor of an immediate instillation with MMC (P < 0.001) which corresponds to a 25% risk reduction (hazard ratio: 0.75, 95% confidence interval, 0.64-0.88, P < 0.001). Treatment effect of an immediate instillation with MMC did not differ significantly between any of the subgroups. CONCLUSIONS: In contrast to the recommendations in the European Association of Urology guidelines, we could not identify any subgroup of patients with NMIBC who do not benefit from an immediate instillation with MMC after transurethral resection. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: j.bosschieter@vumc.nl. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: j.nieuwenhuijzen@vumc.nl. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: a.vis@vumc.nl. FAU - van Ginkel, Tessa AU - van Ginkel T AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: teslatessa@hotmail.com. FAU - Lissenberg-Witte, Birgit I AU - Lissenberg-Witte BI AD - Department of Epidemiology and Biostatistics, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: b.lissenberg@vumc.nl. FAU - Beckers, Goedele M A AU - Beckers GMA AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: gma.beckers@vumc.nl. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, VU university Medical Center, Amsterdam, the Netherlands. Electronic address: rja.vanmoorselaar@vumc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180729 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S706-S709. doi: 10.21037/tau.2018.10.07. PMID: 30687601 CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S729-S731. doi: 10.21037/tau.2018.09.07. PMID: 30687609 MH - Aged MH - Antibiotics, Antineoplastic/pharmacology/*therapeutic use MH - Female MH - Humans MH - Middle Aged MH - Mitomycin/pharmacology/*therapeutic use MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Bladder cancer OT - Bladder neoplasms: mitomycin C OT - Intravesical chemotherapy OT - Non-muscle-invasive urothelial carcinoma EDAT- 2018/08/02 06:00 MHDA- 2018/11/06 06:00 CRDT- 2018/08/02 06:00 PHST- 2018/03/13 00:00 [received] PHST- 2018/05/22 00:00 [revised] PHST- 2018/05/29 00:00 [accepted] PHST- 2018/08/02 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2018/08/02 06:00 [entrez] AID - S1078-1439(18)30195-9 [pii] AID - 10.1016/j.urolonc.2018.05.026 [doi] PST - ppublish SO - Urol Oncol. 2018 Sep;36(9):400.e7-400.e14. doi: 10.1016/j.urolonc.2018.05.026. Epub 2018 Jul 29. PMID- 30061076 OWN - NLM STAT- MEDLINE DCOM- 20190412 LR - 20190412 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 4 DP - 2018 Jul TI - Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? PG - 525-528 LID - S2405-4569(18)30189-5 [pii] LID - 10.1016/j.euf.2018.07.023 [doi] AB - An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3cm, and single recurrent papillary tumours recurring >1yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy-guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. PATIENT SUMMARY: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria. Electronic address: marek.babjuk@fnmotol.cz. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Hopital Tenon, AP-HP, Sorbonne University, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, San Giovanni Battista Hospital, Citta della Salute e della Scienza, University of Turin, Turin, Italy. FAU - Mostafid, Hugh A AU - Mostafid HA AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Hopital La Pitie-Salpetriere, AP-HP, Sorbonne University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA. FAU - Sylvester, Richard AU - Sylvester R AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Department of Surgery and Cancer, Imperial College London, London, UK; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK. FAU - Dominguez-Escrig, Jose L AU - Dominguez-Escrig JL AD - Servicio de Urologia, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Service d'Urologie, CHU de Rennes, Rennes, France. FAU - Seisen, Thomas AU - Seisen T AD - Department of Urology, Hopital La Pitie-Salpetriere, AP-HP, Sorbonne University, Paris, France. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. CN - European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer LA - eng PT - Journal Article PT - Practice Guideline DEP - 20180727 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage MH - Cystectomy/adverse effects/methods MH - Cystoscopy/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control MH - Postoperative Care/*methods MH - Risk Adjustment MH - *Urinary Bladder Neoplasms/drug therapy/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Indication OT - Non-muscle-invasive OT - Single postoperative instillation of chemotherapy EDAT- 2018/08/01 06:00 MHDA- 2019/04/13 06:00 CRDT- 2018/08/01 06:00 PHST- 2018/06/10 00:00 [received] PHST- 2018/07/08 00:00 [revised] PHST- 2018/07/13 00:00 [accepted] PHST- 2018/08/01 06:00 [pubmed] PHST- 2019/04/13 06:00 [medline] PHST- 2018/08/01 06:00 [entrez] AID - S2405-4569(18)30189-5 [pii] AID - 10.1016/j.euf.2018.07.023 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jul;4(4):525-528. doi: 10.1016/j.euf.2018.07.023. Epub 2018 Jul 27. PMID- 30061034 OWN - NLM STAT- MEDLINE DCOM- 20190624 LR - 20190624 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 6 DP - 2018 Dec TI - Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. PG - e1123-e1132 LID - S1558-7673(18)30415-4 [pii] LID - 10.1016/j.clgc.2018.07.002 [doi] AB - BACKGROUND: Serum cholinesterase (ChE) has been reported to be a prognostic factor in several cancers, but its relationship with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) has not yet been well-studied. MATERIALS AND METHODS: We retrospectively assessed 1117 patients with NMIBC undergoing transurethral resection of the bladder. Cox regression analyses were performed to elucidate the association between preoperative ChE and oncologic outcomes such as recurrence-free survival (RFS) and progression-free survival. RESULTS: The median preoperative ChE level was 5.51 kU/L (interquartile range, 4.95-7.01), and the optimal cut-off value of ChE obtained from receiver operator characteristic analysis was 5.55 kU/L. The 5-year RFS in patients with low and normal ChE levels were 41.1% and 70.0%, respectively (P < .001). The 5-year progression-free survival in patients with low and normal ChE levels were 93.2% and 91.4%, respectively (P = .053). On multivariable analysis, ChE was significantly associated with shorter RFS (P < .001). ChE as a continuous variable and low ChE levels improved the C-index for prediction of disease recurrence by 4.0% and 2.7% to 72.4% and 71.1%, respectively. In patients stratified into the European Association of Urology high-risk category, serum ChE was also a strong predictor of disease recurrence (hazard ratio, 4.14; 95% confidence interval, 2.90-5.89). Moreover, in the European Association of Urology high-risk patients treated with bacillus Calmette-Guerin immunotherapy, serum ChE was still strongly correlated with worse RFS (hazard ratio, 5.46; 95% confidence interval, 2.91-10.2). CONCLUSIONS: Decreased ChE is associated with shorter RFS in patients with NMIBC undergoing transurethral resection of the bladder. Preoperative ChE could improve patients' risk stratification and selection for adjuvant therapy. The mechanisms underlying this association needs further elucidation to design potential targets for intervention. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Vartolomei, Mihai D AU - Vartolomei MD AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Moschini, Marco AU - Moschini M AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland; Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: Kilian.gust@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20180706 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - EC 3.1.1.8 (Cholinesterases) SB - IM MH - Aged MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor/*blood MH - Chemotherapy, Adjuvant/methods MH - Cholinesterases/*blood MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/blood/*diagnosis MH - Predictive Value of Tests MH - Preoperative Period MH - Prognosis MH - Progression-Free Survival MH - ROC Curve MH - Retrospective Studies MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/blood/diagnosis/*mortality/pathology OTO - NOTNLM OT - Biomarker OT - Butyrylcholinesterase OT - NMIBC OT - Progression OT - Recurrence EDAT- 2018/08/01 06:00 MHDA- 2019/06/25 06:00 CRDT- 2018/08/01 06:00 PHST- 2018/05/18 00:00 [received] PHST- 2018/07/02 00:00 [revised] PHST- 2018/07/03 00:00 [accepted] PHST- 2018/08/01 06:00 [pubmed] PHST- 2019/06/25 06:00 [medline] PHST- 2018/08/01 06:00 [entrez] AID - S1558-7673(18)30415-4 [pii] AID - 10.1016/j.clgc.2018.07.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Dec;16(6):e1123-e1132. doi: 10.1016/j.clgc.2018.07.002. Epub 2018 Jul 6. PMID- 30042310 OWN - NLM STAT- MEDLINE DCOM- 20190327 LR - 20190327 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 15 IP - 8 DP - 2018 Jul 24 TI - Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer. LID - 10.3390/ijerph15081563 [doi] LID - 1563 AB - Introduction: Additional or better markers are needed to guide the clinical monitoring of patients with non-muscle-invasive bladder cancer (NMIBC). Aim: To investigate the influence of occupational exposures and genetic polymorphisms on recurrence and progression of NMIBC. Methods: The study includes 160 NMIBC patients. We collected on questionnaire information on demographic variables, lifetime smoking history, lifetime history of occupational exposure to aromatic amines and polycyclic aromatic hydrocarbons. Genetic polymorphism (glutathione S-transferase M1; T1; P1 (GSTM1; GSTT1; GSTP1); N-acetyltransferase 1; 2 (NAT1; NAT2); cytochrome P450 1B1 (CYP1B1); sulfotransferase 1A1 (SULT1A1); myeloperoxidase (MPO); catechol-O-methyltransferase (COMT); manganese superoxide dismutase (MnSOD); NAD(P)H:quinone oxidoreductase (NQO1); X-ray repair cross-complementing group 1; 3 (XRCC1; XRCC3) and xeroderma pigmentosum complementation group (XPD)) was assessed in peripheral blood lymphocytes. DNA adducts were evaluated by 32P-postlabeling. Predictors of recurrence (histological confirmation of a newly found bladder tumor) and progression (transition of tumor from low-grade to high-grade and/or increase in TNM stage) were identified by multivariate Cox proportional hazard regression with stepwise backward selection of independent variables. Hazard ratios (HR) with 95% confidence interval (95%CI) and two-tail probability of error (p-value) were estimated. Results: The risk of BC progression decreased with the homozygous genotype "ValVal" of both COMT and MnSOD (HR = 0.195; 95%CI = 0.060 to 0.623; p = 0.006). The results on BC recurrence were of borderline significance. No occupational exposure influenced recurrence or progression. Conclusion: Our results are supported by experimental evidence of a plausible mechanism between cause (ValVal genotype of both MnSOD and COMT) and effect (decreased progression of tumor in NMIBC patients). The genetic polymorphisms associated with better prognosis may be used in clinic to guide selection of treatment for patients initially diagnosed with NMIBC. However, external validation studies are required. FAU - Carta, Angela AU - Carta A AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, Brescia 25123, Italy. angela.carta@unibs.it. AD - University Research Center "Integrated Models for Prevention and Protection in Environmental and Occupational Health", University of Brescia, Brescia 25123, Italy. angela.carta@unibs.it. FAU - Pavanello, Sofia AU - Pavanello S AD - Department of Cardiac, Thoracic, and Vascular Sciences, Unit of Occupational Medicine, University of Padova, Padova 35128, Italy. sofia.pavanello@unipd.it. FAU - Mastrangelo, Giuseppe AU - Mastrangelo G AD - Department of Cardiac, Thoracic, and Vascular Sciences, Unit of Occupational Medicine, University of Padova, Padova 35128, Italy. giuseppe.mastrangelo@unipd.it. FAU - Fedeli, Ugo AU - Fedeli U AUID- ORCID: 0000-0002-9939-3398 AD - Epidemiological Department of the Veneto Region, Padova 35131, Italy. ugo.fedeli@azero.veneto.it. FAU - Arici, Cecilia AU - Arici C AUID- ORCID: 0000-0003-1493-590X AD - University Research Center "Integrated Models for Prevention and Protection in Environmental and Occupational Health", University of Brescia, Brescia 25123, Italy. cecilia.arici@univr.it. AD - Department of Diagnostics and Public Health, Section of Occupational Health, University of Verona, Verona 37134, Italy. cecilia.arici@univr.it. FAU - Porru, Stefano AU - Porru S AD - University Research Center "Integrated Models for Prevention and Protection in Environmental and Occupational Health", University of Brescia, Brescia 25123, Italy. stefano.porru@univr.it. AD - Department of Diagnostics and Public Health, Section of Occupational Health, University of Verona, Verona 37134, Italy. stefano.porru@univr.it. LA - eng PT - Journal Article DEP - 20180724 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (Air Pollutants) RN - 0 (Amines) RN - 0 (Polycyclic Aromatic Hydrocarbons) SB - IM MH - Adult MH - Aged MH - Air Pollutants/adverse effects/analysis MH - Amines/adverse effects MH - Disease Progression MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/*genetics MH - Occupational Diseases/*chemically induced/*epidemiology/genetics MH - Occupational Exposure/*adverse effects/statistics & numerical data MH - Polycyclic Aromatic Hydrocarbons/adverse effects MH - *Polymorphism, Genetic MH - Risk Factors MH - Urinary Bladder Neoplasms/chemically induced/*epidemiology/*genetics PMC - PMC6121504 OTO - NOTNLM OT - COMT OT - MnSOD OT - bladder cancer OT - genetic polymorphisms OT - non-muscle-invasive bladder cancer OT - occupational exposures OT - progression OT - recurrence COIS- The authors declare no conflict of interest. EDAT- 2018/07/26 06:00 MHDA- 2019/03/28 06:00 PMCR- 2018/08/01 CRDT- 2018/07/26 06:00 PHST- 2018/06/21 00:00 [received] PHST- 2018/07/10 00:00 [revised] PHST- 2018/07/20 00:00 [accepted] PHST- 2018/07/26 06:00 [entrez] PHST- 2018/07/26 06:00 [pubmed] PHST- 2019/03/28 06:00 [medline] PHST- 2018/08/01 00:00 [pmc-release] AID - ijerph15081563 [pii] AID - ijerph-15-01563 [pii] AID - 10.3390/ijerph15081563 [doi] PST - epublish SO - Int J Environ Res Public Health. 2018 Jul 24;15(8):1563. doi: 10.3390/ijerph15081563. PMID- 30040854 OWN - NLM STAT- MEDLINE DCOM- 20190117 LR - 20230928 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 7 DP - 2018 TI - Behavior of blood plasma glycan features in bladder cancer. PG - e0201208 LID - 10.1371/journal.pone.0201208 [doi] LID - e0201208 AB - Despite systemic therapy and cystectomy, bladder cancer is characterized by a high recurrence rate. Serum glycomics represents a promising source of prognostic markers for monitoring patients. Our approach, which we refer to as "glycan node analysis", constitutes the first example of molecularly "bottom-up" glycomics. It is based on a global glycan methylation analysis procedure that is applied to whole blood plasma/serum. The approach detects and quantifies partially methylated alditol acetates arising from unique glycan features such as alpha2-6 sialylation, beta1-4 branching, and core fucosylation that have been pooled together from across all intact glycans within a sample into a single GC-MS chromatographic peak. We applied this method to 122 plasma samples from former and current bladder cancer patients (n = 72 former cancer patients with currently no evidence of disease (NED); n = 38 non-muscle invasive bladder cancer (NMIBC) patients; and n = 12 muscle invasive bladder cancer (MIBC) patients) along with plasma from 30 certifiably healthy living kidney donors. Markers for alpha2-6 sialylation, beta1-4 branching, beta1-6 branching, and outer-arm fucosylation were able to separate current and former (NED) cases from certifiably healthy controls (ROC curve c-statistics ~ 0.80); but NED, NMIBC, and MIBC were not distinguished from one another. Based on the unexpectedly high levels of these glycan nodes in the NED patients, we hypothesized that recurrence of this disease could be predicted by some of the elevated glycan features. Indeed, alpha2-6 sialylation and beta1-6 branching were able to predict recurrence from the NED state using a Cox proportional hazards regression model adjusted for age, gender, and time from cancer. The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation. FAU - Ferdosi, Shadi AU - Ferdosi S AD - School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America. AD - Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute at Arizona State University, Tempe, AZ, United States of America. FAU - Ho, Thai H AU - Ho TH AUID- ORCID: 0000-0003-0023-2939 AD - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United States of America. FAU - Castle, Erik P AU - Castle EP AD - Department of Urology, Mayo Clinic, Phoenix, AZ, United States of America. FAU - Stanton, Melissa L AU - Stanton ML AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, United States of America. FAU - Borges, Chad R AU - Borges CR AUID- ORCID: 0000-0002-8122-3438 AD - School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America. AD - Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute at Arizona State University, Tempe, AZ, United States of America. LA - eng GR - R33 CA191110/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20180724 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Biomarkers, Tumor) RN - 0 (Polysaccharides) SB - IM MH - Age Factors MH - Aged MH - Biomarkers, Tumor/blood MH - Humans MH - Kidney Transplantation MH - Middle Aged MH - Neoplasm Invasiveness/diagnosis MH - Polysaccharides/*blood MH - Prognosis MH - ROC Curve MH - Urinary Bladder Neoplasms/*blood PMC - PMC6057681 COIS- The authors have declared that no competing interests exist. EDAT- 2018/07/25 06:00 MHDA- 2019/01/18 06:00 PMCR- 2018/07/24 CRDT- 2018/07/25 06:00 PHST- 2018/04/18 00:00 [received] PHST- 2018/07/10 00:00 [accepted] PHST- 2018/07/25 06:00 [entrez] PHST- 2018/07/25 06:00 [pubmed] PHST- 2019/01/18 06:00 [medline] PHST- 2018/07/24 00:00 [pmc-release] AID - PONE-D-18-11743 [pii] AID - 10.1371/journal.pone.0201208 [doi] PST - epublish SO - PLoS One. 2018 Jul 24;13(7):e0201208. doi: 10.1371/journal.pone.0201208. eCollection 2018. PMID- 30017900 OWN - NLM STAT- MEDLINE DCOM- 20190412 LR - 20210421 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 4 DP - 2018 Jul TI - Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer. PG - 503-505 LID - S2405-4569(18)30171-8 [pii] LID - 10.1016/j.euf.2018.07.005 [doi] AB - Bacillus Calmette-Guerin (BCG) replaced early intravesical chemotherapeutic agents as the standard of care for non-muscle-invasive bladder cancer (NMIBC) with its US Food and Drug Administration approval in 1990. Multiple studies have proven the superiority of BCG to surgery alone, and to older single-agent intravesical chemotherapy regimens. However, new multiagent intravesical chemotherapy regimens have been developed and tested in recent years. Such regimens offer the possibility of better efficacy and/or tolerability compared to BCG. However, high-quality data comparing such regimens to BCG remain scant. We briefly review the literature regarding combination intravesical chemotherapy for NMIBC. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Thomas, Lewis J AU - Thomas LJ AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. Electronic address: michael-odonnell@uiowa.edu. LA - eng PT - Journal Article PT - Review DEP - 20180714 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/pharmacology MH - Administration, Intravesical MH - Antineoplastic Agents/*pharmacology MH - BCG Vaccine/*pharmacology MH - Drug Therapy, Combination/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis/*prevention & control MH - Predictive Value of Tests MH - Prognosis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy/pathology OTO - NOTNLM OT - Chemotherapy OT - Combination therapy OT - Intravesical therapy OT - Non-muscle-invasive bladder cancer EDAT- 2018/07/19 06:00 MHDA- 2019/04/13 06:00 CRDT- 2018/07/19 06:00 PHST- 2018/05/13 00:00 [received] PHST- 2018/06/27 00:00 [revised] PHST- 2018/07/06 00:00 [accepted] PHST- 2018/07/19 06:00 [pubmed] PHST- 2019/04/13 06:00 [medline] PHST- 2018/07/19 06:00 [entrez] AID - S2405-4569(18)30171-8 [pii] AID - 10.1016/j.euf.2018.07.005 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jul;4(4):503-505. doi: 10.1016/j.euf.2018.07.005. Epub 2018 Jul 14. PMID- 30017405 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20210103 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 74 IP - 5 DP - 2018 Nov TI - Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. PG - 597-608 LID - S0302-2838(18)30449-4 [pii] LID - 10.1016/j.eururo.2018.06.024 [doi] AB - CONTEXT: High-grade T1 (T1HG) bladder cancer (BCa) has a very high likelihood of disease recurrence and progression to muscle invasion. Radical cystectomy is considered the best chance at cure, albeit with a high risk of morbidity, and is overtreatment for some patients. Treatment with bacillus Calmette-Guerin (BCG) allows bladder preservation but may risk disease progression. OBJECTIVE: To systematically review the current literature on the management of T1HG BCa and provide updated treatment recommendations. EVIDENCE ACQUISITION: Medline, EMBASE, and Epub Ahead of Print databases were searched in November 2017 to identify observational cohort studies and controlled trials, between 1946 and 2017, associated with diagnosis, treatment, and prognosis of T1HG BCa. EVIDENCE SYNTHESIS: Clinical understaging and/or persistence of disease is not uncommon at initial transurethral resection (TUR); thus, a second re-TUR is recommended for cases with T1HG BCa. Patients electing a bladder preservation approach should undergo induction BCG therapy followed by a maintenance schedule, while patients with several high-risk features should consider immediate cystectomy and those with BCG-refractory or BCG-unresponsive disease should be considered for early cystectomy. Current phase I/II clinical trials for T1HG patients may offer future bladder preservation therapy approaches. CONCLUSIONS: T1HG tumours are heterogeneous in nature and challenging to treat. Bladder preservation with BCG induction and maintenance, or radical cystectomy is the current standard treatment modality of choice for these tumours. Promising therapies for BCG-unresponsive disease are currently under investigation. PATIENT SUMMARY: Patients with high-grade T1 bladder cancer are at a high risk of tumour recurrence and progression, requiring more aggressive treatment such as bladder removal. Bladder preservation therapies are available (and new therapies are being tested in clinical trials); however, patients should be aware that currently bladder removal is considered the best opportunity for cancer cure. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Klaassen, Zachary AU - Klaassen Z AD - Division of Urology, Department of Surgery, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, Department of Surgery, McGill University Health Center, Montreal, QC, Canada. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Urology, University of Turin, Turin, Italy. FAU - Villavicencio, Humberto AU - Villavicencio H AD - Department of Urology, Fundacio Puigvert, Autonoma University of Barcelona, Barcelona, Spain. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Bladder Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Department of Surgery, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: girish.kulkarni@uhn.ca. LA - eng PT - Journal Article PT - Systematic Review DEP - 20180713 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2018 Nov;74(5):609-610. doi: 10.1016/j.eururo.2018.08.016. PMID: 30174196 MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - BCG Vaccine/*administration & dosage/adverse effects MH - Carcinoma/mortality/secondary/*therapy MH - Chemotherapy, Adjuvant MH - Clinical Decision-Making MH - *Cystectomy/adverse effects/mortality/standards MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Practice Guidelines as Topic MH - Progression-Free Survival MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Urothelium/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Cystectomy OT - Repeat transurethral resection OT - T1 OT - Treatment OT - high-grade T1 EDAT- 2018/07/19 06:00 MHDA- 2019/05/29 06:00 CRDT- 2018/07/19 06:00 PHST- 2018/04/17 00:00 [received] PHST- 2018/06/20 00:00 [accepted] PHST- 2018/07/19 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] PHST- 2018/07/19 06:00 [entrez] AID - S0302-2838(18)30449-4 [pii] AID - 10.1016/j.eururo.2018.06.024 [doi] PST - ppublish SO - Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13. PMID- 30014707 OWN - NLM STAT- MEDLINE DCOM- 20191016 LR - 20191016 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 32 IP - 9 DP - 2018 Sep 12 TI - Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. PG - 806-811 LID - 10.1089/end.2018.0442 [doi] AB - INTRODUCTION: Staging of upper tract urothelial carcinoma (UTUC) remains a dilemma due to imaging and biopsy limitations leading to understaging. We seek to determine the accuracy of endoluminal ultrasound (ELUS) for clinical staging of UTUC. MATERIALS AND METHODS: Patients evaluated for UTUC underwent retrograde pyelography, ureteroscopy, and ELUS. ELUS was performed using mechanical radial scanning at 20 MHz in B-mode with a 5F probe. Cine clips were evaluated by 2 radiologists blinded to ureteroscopic and pathology findings. Results were compared to pathology from nephroureterectomy. Inclusion criteria were patients who underwent nephroureterectomy without pretreatment or managed endoscopically for cTa-1 disease and were without recurrence for >1 year. RESULTS: From 2008 to 2013, 53 patients underwent ELUS without complication. Twenty-seven patients met inclusion criteria with conclusive ELUS imaging. ELUS accurately identified 16 of 21 patients with non-muscle invasive (MI) disease (18 pTa, 2 pT1, 1 CIS) and 1 of 6 patients with at least MI disease (2 pT2, 4 pT3). For MI disease, the positive predictive value (PPV), negative predictive value, and accuracy was 76.2%, 16.7%, and 63%, respectively, while for non-organ confined (OC) disease results were 0%, 81.8%, and 66.7%, respectively. CONCLUSIONS: With current technique and instrumentation, ELUS may prove useful in select cases to confirm findings of non-MI and OC disease. However, it has insufficient PPV for stage pT2-3 disease. Further studies and better instrumentation are needed before incorporation into clinical practice. FAU - Farnum, Jeffrey A AU - Farnum JA AD - 1 Department of Urology, University of Texas MD Anderson Cancer Center , Houston, Texas. FAU - Vikram, Raghunandan AU - Vikram R AD - 2 Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center , Houston, Texas. FAU - Rao, Arvind AU - Rao A AD - 3 Department of Biostatistics, University of Texas MD Anderson Cancer Center , Houston, Texas. FAU - Bedi, Deepak AU - Bedi D AD - 2 Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center , Houston, Texas. FAU - Dinney, Colin P AU - Dinney CP AD - 1 Department of Urology, University of Texas MD Anderson Cancer Center , Houston, Texas. FAU - Matin, Surena F AU - Matin SF AD - 1 Department of Urology, University of Texas MD Anderson Cancer Center , Houston, Texas. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180821 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*diagnostic imaging MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging/*methods MH - Ultrasonography/*methods MH - Ureteroscopy/methods MH - Urologic Neoplasms/*diagnostic imaging OTO - NOTNLM OT - endoluminal ultrasound OT - renal pelvic cancer OT - staging OT - ultrasound OT - ureteral cancer OT - urothelial carcinoma EDAT- 2018/07/18 06:00 MHDA- 2019/10/17 06:00 CRDT- 2018/07/18 06:00 PHST- 2018/07/18 06:00 [pubmed] PHST- 2019/10/17 06:00 [medline] PHST- 2018/07/18 06:00 [entrez] AID - 10.1089/end.2018.0442 [doi] PST - ppublish SO - J Endourol. 2018 Sep 12;32(9):806-811. doi: 10.1089/end.2018.0442. Epub 2018 Aug 21. PMID- 30012566 OWN - NLM STAT- MEDLINE DCOM- 20191118 LR - 20191118 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 24 IP - 21 DP - 2018 Nov 1 TI - The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer. PG - 5422-5432 LID - 10.1158/1078-0432.CCR-17-3850 [doi] AB - Purpose: Non-muscle-invasive bladder cancer (NMIBC) is a malignant disease characterized by high heterogeneity, which corresponds to dysregulated gene expression and alternative splicing (AS) profiles. Bioinformatics analyses of splicing factors potentially linked to bladder cancer progression identified the heterogeneous nuclear ribonucleoprotein I (i.e., PTBP1) as candidate. This study aimed at investigating whether PTBP1 expression associates with clinical outcome in patients with NMIBC.Experimental Design: A cohort of 152 patients presenting with primary NMIBC (pTa-pT1) was enrolled. Primary NMIBCs were assessed for PTBP1 expression by IHC, and the results were correlated with clinical data using Kaplan-Meier curves and Cox regression analyses. Cell proliferation and survival assays were performed to assess the function of PTBP1. Furthermore, the impact of PTBP1 on the AS pattern of specific bladder cancer-related genes was investigated in cancer cell lines and in patients' specimens.Results: Public datasets querying highlighted a positive correlation between PTBP1 expression and NMIBC progression, which was then confirmed by IHC analysis. High PTBP1 expression was associated with worse clinical outcome in terms of incidence of tumor relapse and survival in patients with NMIBC. Interestingly, downregulation of PTBP1 in bladder cancer cell lines affected prosurvival features. Accordingly, PTBP1 modulated AS of bladder cancer-related genes in cell lines and patient's specimens.Conclusions: PTBP1 expression correlates with disease progression, poor prognosis, and worse survival in patients with NMIBC. Downregulation of PTBP1 expression affects prosurvival features of bladder cancer cells and modulates AS of genes with relevance for bladder cancer, suggesting its role as an outcome-predictor in this disease. Clin Cancer Res; 24(21); 5422-32. (c)2018 AACR. CI - (c)2018 American Association for Cancer Research. FAU - Bielli, Pamela AU - Bielli P AD - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. AD - Fondazione Santa Lucia IRCCS, Rome, Italy. FAU - Panzeri, Valentina AU - Panzeri V AUID- ORCID: 0000-0002-8930-7222 AD - Fondazione Santa Lucia IRCCS, Rome, Italy. AD - Department of Science Medical/Chirurgic and Translational Medicine, University of Rome "Sapienza", Rome, Italy. AD - Institute of Human Anatomy and Cell Biology, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Lattanzio, Rossano AU - Lattanzio R AD - Department of Medical, Oral & Biotechnological Sciences, G. d'Annunzio University, Chieti, Italy. AD - Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. d'Annunzio University, Chieti, Italy. FAU - Mutascio, Simona AU - Mutascio S AD - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. AD - Fondazione Santa Lucia IRCCS, Rome, Italy. FAU - Pieraccioli, Marco AU - Pieraccioli M AD - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. AD - Fondazione Santa Lucia IRCCS, Rome, Italy. FAU - Volpe, Elisabetta AU - Volpe E AD - Fondazione Santa Lucia IRCCS, Rome, Italy. FAU - Pagliarulo, Vincenzo AU - Pagliarulo V AD - Department of Emergency and Organ Transplantation, University Aldo Moro, Bari, Italy. FAU - Piantelli, Mauro AU - Piantelli M AD - Department of Medical, Oral & Biotechnological Sciences, G. d'Annunzio University, Chieti, Italy. FAU - Giannantoni, Antonella AU - Giannantoni A AD - Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy. FAU - Di Stasi, Savino M AU - Di Stasi SM AUID- ORCID: 0000-0001-8426-1571 AD - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. claudio.sette@unicatt.it sdistas@tin.it. FAU - Sette, Claudio AU - Sette C AD - Fondazione Santa Lucia IRCCS, Rome, Italy. claudio.sette@unicatt.it sdistas@tin.it. AD - Institute of Human Anatomy and Cell Biology, Universita Cattolica del Sacro Cuore, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180716 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) RN - 0 (Heterogeneous-Nuclear Ribonucleoproteins) RN - 0 (Hyaluronan Receptors) RN - 0 (PTBP1 protein, human) RN - 139076-35-0 (Polypyrimidine Tract-Binding Protein) SB - IM CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S715-S717. doi: 10.21037/tau.2018.10.09. PMID: 30687604 MH - Biomarkers, Tumor MH - Cell Line, Tumor MH - Female MH - Gene Expression Regulation, Neoplastic MH - Heterogeneous-Nuclear Ribonucleoproteins/genetics/*metabolism MH - Humans MH - Hyaluronan Receptors/metabolism MH - Immunohistochemistry MH - Informatics/methods MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Oncogenes MH - Polypyrimidine Tract-Binding Protein/genetics/*metabolism MH - Prognosis MH - *RNA Splicing MH - Urinary Bladder Neoplasms/*genetics/*metabolism/mortality/pathology EDAT- 2018/07/18 06:00 MHDA- 2019/11/19 06:00 CRDT- 2018/07/18 06:00 PHST- 2017/12/29 00:00 [received] PHST- 2018/05/02 00:00 [revised] PHST- 2018/07/10 00:00 [accepted] PHST- 2018/07/18 06:00 [pubmed] PHST- 2019/11/19 06:00 [medline] PHST- 2018/07/18 06:00 [entrez] AID - 1078-0432.CCR-17-3850 [pii] AID - 10.1158/1078-0432.CCR-17-3850 [doi] PST - ppublish SO - Clin Cancer Res. 2018 Nov 1;24(21):5422-5432. doi: 10.1158/1078-0432.CCR-17-3850. Epub 2018 Jul 16. PMID- 30001845 OWN - NLM STAT- MEDLINE DCOM- 20190701 LR - 20190701 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 5 DP - 2018 Oct TI - FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients. PG - 360-364 LID - S1558-7673(18)30344-6 [pii] LID - 10.1016/j.clgc.2018.05.008 [doi] AB - PURPOSE: To determine the accuracy of (18)F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) scans in assessing the response to neoadjuvant chemotherapy (NAC) in patients with bladder cancer scheduled to undergo radical cystectomy (RC). PATIENTS AND METHODS: All patients treated at our center for muscle-invasive bladder cancer (MIBC) were counseled and offered NAC before RC. FDG-PET/CT scans were performed before the initiation of chemotherapy and after completion of the regimen. Patients with disease with complete response to NAC were those who had (pT0) or residual carcinoma-in-situ (pTis) on final pathology. Those who were downstaged from MIBC to non-MIBC were considered to have a chemosensitive tumor. We used percentage reduction in standardized maximum uptake value (SUV(max)) from PET/CT scans as our measure to correlate with the final pathology after cystectomy. RESULTS: Thirty-seven patients with MIBC who underwent NAC followed by RC were included in the final analysis. FDG-PET/CT had 75% sensitivity (89.66% specificity) in identifying those with complete pathologic response with a 100% change in SUV(max), and 83% sensitivity (94% specificity) for the detection of chemosensitive tumors. CONCLUSION: FDG-PET/CT can help determine the response of primary tumor to NAC in patients with MIBC and thus can more accurately predict the prognosis of the patients, or potentially the appropriate time for cystectomy. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Soubra, Ayman AU - Soubra A AD - Department of Urology, University of Minnesota, Minneapolis, MN. Electronic address: asoubra@umn.edu. FAU - Gencturk, Mehmet AU - Gencturk M AD - Department of Radiology, University of Minnesota, Minneapolis, MN. FAU - Froelich, Jerry AU - Froelich J AD - Department of Radiology, University of Minnesota, Minneapolis, MN. FAU - Balaji, Priya AU - Balaji P AD - Department of Urology, University of Minnesota, Minneapolis, MN. FAU - Gupta, Shilpa AU - Gupta S AD - Department of Internal Medicine, University of Minnesota, Minneapolis, MN. FAU - Jha, Gautam AU - Jha G AD - Department of Internal Medicine, University of Minnesota, Minneapolis, MN. FAU - Konety, Badrinath R AU - Konety BR AD - Department of Urology, University of Minnesota, Minneapolis, MN. LA - eng PT - Journal Article DEP - 20180531 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Adult MH - Aged MH - Chemotherapy, Adjuvant/*methods MH - Female MH - Fluorodeoxyglucose F18/*administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Positron Emission Tomography Computed Tomography/methods MH - Prognosis MH - Sensitivity and Specificity MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnostic imaging/*drug therapy OTO - NOTNLM OT - Clinical response OT - Pathologic stage OT - Urinary bladder neoplasms OT - Urothelial carcinoma EDAT- 2018/07/14 06:00 MHDA- 2019/07/02 06:00 CRDT- 2018/07/14 06:00 PHST- 2018/01/09 00:00 [received] PHST- 2018/05/03 00:00 [revised] PHST- 2018/05/07 00:00 [accepted] PHST- 2018/07/14 06:00 [pubmed] PHST- 2019/07/02 06:00 [medline] PHST- 2018/07/14 06:00 [entrez] AID - S1558-7673(18)30344-6 [pii] AID - 10.1016/j.clgc.2018.05.008 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Oct;16(5):360-364. doi: 10.1016/j.clgc.2018.05.008. Epub 2018 May 31. PMID- 29999205 OWN - NLM STAT- MEDLINE DCOM- 20190604 LR - 20190604 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 25 IP - 8 DP - 2018 Aug TI - Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study. PG - 723-729 LID - 10.1111/iju.13718 [doi] AB - OBJECTIVE: To confirm the reproducibility of the effectiveness and safety in photodynamic diagnosis of non-muscle-invasive bladder cancer using 5-aminolevulinic acid in a prospective multicenter non-randomized phase III trial. METHODS: A total of 61 patients with primary or recurrent non-muscle-invasive bladder cancer were prospectively enrolled from five hospitals between May 2015 and March 2016. 5-Aminolevulinic acid (20 mg/kg) was orally administered 3 h before transurethral resection of bladder tumors using white light or fluorescent light. Of 60 evaluable patients, 511 specimens were obtained from tumor-suspicious lesions and normal-looking mucosa. The primary end-point was sensitivity. The secondary end-points were specificity, positive and negative predictive values, and safety. RESULTS: The sensitivity of the fluorescent light source (79.6%) was significantly higher (P < 0.001) than that of the white light source (54.1%). In total, 25.4% (46/181) of tumor specimens were diagnosed as positive with only the fluorescent light source. In nine (15%) of 60 patients, the risk classification and recommended treatment after transurethral resection of bladder tumors were changed depending on the additional types of tumor diagnosed by the fluorescent light source. The specificity of the fluorescent light versus white light source was 80.6% versus 95.5%. No grade 4-5 adverse event was noted. Hypotension and urticaria were severe adverse events whose relationship to oral 5-aminolevulinic acid could not be excluded. CONCLUSIONS: These findings confirm the diagnostic efficacy and safety of photodynamic diagnosis with 20 mg/kg of oral 5-aminolevulinic acid, and show that transurethral resection of bladder tumors with a fluorescent light source using oral 5-aminolevulinic acid is well tolerated. CI - (c) 2018 The Japanese Urological Association. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Inoue, Keiji AU - Inoue K AD - Department of Urology, Kochi Medical School, Nankoku, Kochi, Japan. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AD - Department of Surgical Pathology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan. FAU - Shimamoto, Tsutomu AU - Shimamoto T AD - Department of Urology, Kochi Medical School, Nankoku, Kochi, Japan. FAU - Shuin, Taro AU - Shuin T AD - Department of Urology, Kochi Medical School, Nankoku, Kochi, Japan. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of UroOncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. FAU - Furuse, Hiroshi AU - Furuse H AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Ozono, Seiichiro AU - Ozono S AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study DEP - 20180712 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Administration, Oral MH - Aged MH - Aged, 80 and over MH - Aminolevulinic Acid/*administration & dosage/adverse effects MH - Carcinoma in Situ/*diagnosis/*pathology/surgery MH - Cystoscopy/methods MH - Female MH - Fluorescence MH - Humans MH - Japan MH - Male MH - Middle Aged MH - Photosensitizing Agents/*administration & dosage/adverse effects MH - Prospective Studies MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnosis/*pathology/surgery OTO - NOTNLM OT - 5-aminolevurlinic acid OT - non-muscle-invasive bladder cancer OT - oral intake OT - photodynamic diagnosis OT - transurethral resection EDAT- 2018/07/13 06:00 MHDA- 2019/06/05 06:00 CRDT- 2018/07/13 06:00 PHST- 2018/01/31 00:00 [received] PHST- 2018/05/07 00:00 [accepted] PHST- 2018/07/13 06:00 [pubmed] PHST- 2019/06/05 06:00 [medline] PHST- 2018/07/13 06:00 [entrez] AID - 10.1111/iju.13718 [doi] PST - ppublish SO - Int J Urol. 2018 Aug;25(8):723-729. doi: 10.1111/iju.13718. Epub 2018 Jul 12. PMID- 29992381 OWN - NLM STAT- MEDLINE DCOM- 20190807 LR - 20220408 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 3 DP - 2019 Mar TI - An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. PG - 507-514 LID - 10.1007/s00345-018-2397-1 [doi] AB - PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guerin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.89%) were negative. During follow-up, 678 (64.82%) suffered recurrence, and 303 (30%) progression, 150 (14.34%) died of all causes, and 77 (7.36%) died of bladder cancer. At multivariate analysis, tumor size (hazard ratio [HR]:1.3; p = 0.001), and multifocality (HR:1.24; p = 0.004) were significantly associated with recurrence (c-index for the model:55.98). Overweight (HR: 4; p < 0.001) and obesity (HR:5.33 p < 0.001) were significantly associated with an increased risk of recurrence. Addition of the BMI to a model that included standard clinicopathological factors increased the C-index by 9.9. For progression, we found that tumor size (HR:1.63; p < 0.001), multifocality (HR:1.31; p = 0.01) and concomitant CIS (HR: 2.07; p < 0.001) were significant prognostic factors at multivariate analysis (C-index 63.8). Overweight (HR: 2.52; p < 0.001) and obesity (HR: 2.521 p < 0.001) were significantly associated with an increased risk of progression. Addition of the BMI to a model that included standard clinicopathological factors increased the C-index by 1.9. CONCLUSIONS: The BMI could have a relevant role in the clinical management of T1G3 NMIBC, if associated with bladder cancer recurrence and progression. In particular, this anthropometric factor should be taken into account at initial diagnosis and in therapeutic strategy decision making. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. matteo.ferro@ieo.it. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology, Milan, Italy. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Urology, University of Catania, Catania, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Farhan, Abdal Rahman Abu AU - Farhan ARA AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy. FAU - Cimmino, Amelia AU - Cimmino A AD - Institute of Genetics and Biophysics "A. Buzzati Traverso", National Research Council (CNR), Naples, Italy. FAU - Di Stasi, Savino AU - Di Stasi S AD - Urology Unit, Policlinico Tor Vergata, University of Rome, Rome, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas, Clinical and Research Hospital, Milan, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Division of Urology, University of Palermo, Palermo, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Cioffi, Antonio AU - Cioffi A AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Cozzi, Gabriele AU - Cozzi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Almeida, Gilberto L AU - Almeida GL AD - Department of Urology, University of Vale do Itajai, Itajai, Brazil. FAU - Bove, Pierluigi AU - Bove P AD - Department of Experimental Medicine and Surgery, Urology Unit, Azienda Policlinico Tor Vergata, Rome, Italy. FAU - Lima, Estevao AU - Lima E AD - Department of CUF Urology and Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal. FAU - Grimaldi, Giovanni AU - Grimaldi G AD - Department of CUF Urology and Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal. FAU - Matei, Deliu Victor AU - Matei DV AD - Division of Urology, European Institute of Oncology, Milan, Italy. AD - Department of Urology, University of Medicine and Pharmacy, "Iuliu Hatieganu", Cluj-Napoca, Romania. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy, "Iuliu Hatieganu", Cluj-Napoca, Romania. FAU - Muto, Matteo AU - Muto M AD - Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Naples, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas, Clinical and Research Hospital, Milan, Italy. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Morgia, Giuseppe AU - Morgia G AD - Department of Urology, University of Catania, Catania, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy. AD - Universita degli Studi di Milano, Milan, Italy. FAU - Shariat, Shahrokh AU - Shariat S AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AUID- ORCID: 0000-0001-7807-1229 AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. LA - eng PT - Journal Article DEP - 20180710 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S702-S705. doi: 10.21037/tau.2018.10.17. PMID: 30687600 CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S710-S711. doi: 10.21037/tau.2018.10.11. PMID: 30687602 MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Body Mass Index MH - Carcinoma, Transitional Cell/*drug therapy/mortality/pathology MH - Chemotherapy, Adjuvant MH - Comorbidity MH - *Cystectomy MH - Cystoscopy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mortality MH - Multivariate Analysis MH - Neoplasm Staging MH - Obesity/*epidemiology MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Tumor Burden MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology OTO - NOTNLM OT - Bladder cancer OT - Body mass index OT - Obesity OT - Prognosis EDAT- 2018/07/12 06:00 MHDA- 2019/08/08 06:00 CRDT- 2018/07/12 06:00 PHST- 2018/03/17 00:00 [received] PHST- 2018/06/28 00:00 [accepted] PHST- 2018/07/12 06:00 [pubmed] PHST- 2019/08/08 06:00 [medline] PHST- 2018/07/12 06:00 [entrez] AID - 10.1007/s00345-018-2397-1 [pii] AID - 10.1007/s00345-018-2397-1 [doi] PST - ppublish SO - World J Urol. 2019 Mar;37(3):507-514. doi: 10.1007/s00345-018-2397-1. Epub 2018 Jul 10. PMID- 29986730 OWN - NLM STAT- MEDLINE DCOM- 20190508 LR - 20190508 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 16 IP - 1 DP - 2018 Jul 9 TI - The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence. PG - 135 LID - 10.1186/s12957-018-1411-9 [doi] LID - 135 AB - BACKGROUND: To clarify if diagnostic ureteroscopy (URS) before radical nephroureterectomy for patients with upper tract urothelial carcinoma (UTUC) will increase the risk of intravesical recurrence. METHODS: From retrospective review of cohort at our institution, 502 patients with UTUC who underwent radical nephroureterectomy with bladder cuff excision were enrolled from 1990 to 2013. Cox proportional hazards model was used to analyze the overall survival (OS), disease-free survival (DFS), metastasis-free survival (MFS), and intravesical recurrence-free survival (IVRFS). The log-rank test was used for comparing survival curves. All potential risk factors were included in the multivariate Cox proportional hazards model to recognize independent predictors. From NHI database, we included patients of UTUC without bladder cancer history using population-based database in Taiwan from 1996 to 2013. In total, 3079 URS and 2634 non-URS patients with UTUC were identified. Univariate and multivariate Cox proportional hazards regressions were performed to measure the risk of IVRFS and all-cause mortality. RESULTS: From our database, the comparison of clinicopathological characteristics in UTUC patients between with URS biopsy group (URS+) (n = 206, 41%) and without URS biopsy group (URS-) (n = 296, 59%) was insignificantly different excluding surgical method. URS biopsy is not associated with worse OS (p = 0.720), DFS (p = 0.294), MFS (p = 0.808), and IVRFS (p = 0.560) by multivariate analysis. Only bladder cancer history is an independent significant factor to predict IVR (p < 0.001). The same result from NHI database, URS before radical surgery will not increase the risk of IVRFS [adjusted HR 1.136, 95% CI 1.00-1.30; P = 0.059] and OS [adjusted HR 0.919, 95% CI 0.82-1.04; P = 0.164]. CONCLUSIONS: Preoperative URS manipulation is not associated with higher risk of IVRFS even in patients without bladder cancer history. Diagnostic URS is feasible to compensate the insufficient information of image in patients with UTUC. FAU - Lee, Hsiang-Ying AU - Lee HY AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Yeh, Hsin-Chih AU - Yeh HC AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. FAU - He, Jiun-Shiuan AU - He JS AD - Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Huang, Chun-Nung AU - Huang CN AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. FAU - Ke, Hung-Lung AU - Ke HL AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. AD - Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan. FAU - Li, Chien-Feng AU - Li CF AD - Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan. AD - Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan. AD - National Cancer Research Institute, National Health Research Institutes, Tainan, Taiwan. AD - Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Internal Medicine and Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. ashum1009@gmail.com. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. ashum1009@gmail.com. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. ashum1009@gmail.com. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. ashum1009@gmail.com. LA - eng PT - Journal Article DEP - 20180709 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Aged MH - Carcinoma, Transitional Cell MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Nephrectomy MH - *Nephroureterectomy MH - Prognosis MH - Retrospective Studies MH - Taiwan MH - Ureter MH - *Ureteral Neoplasms/diagnosis/surgery MH - *Ureteroscopy PMC - PMC6038188 OTO - NOTNLM OT - Diagnostic ureteroscopy OT - Intravesical recurrence OT - Upper urinary tract urothelial carcinoma COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/07/11 06:00 MHDA- 2019/05/09 06:00 PMCR- 2018/07/09 CRDT- 2018/07/11 06:00 PHST- 2018/01/22 00:00 [received] PHST- 2018/06/07 00:00 [accepted] PHST- 2018/07/11 06:00 [entrez] PHST- 2018/07/11 06:00 [pubmed] PHST- 2019/05/09 06:00 [medline] PHST- 2018/07/09 00:00 [pmc-release] AID - 10.1186/s12957-018-1411-9 [pii] AID - 1411 [pii] AID - 10.1186/s12957-018-1411-9 [doi] PST - epublish SO - World J Surg Oncol. 2018 Jul 9;16(1):135. doi: 10.1186/s12957-018-1411-9. PMID- 29983794 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1857-9655 (Print) IS - 1857-9655 (Electronic) IS - 1857-9655 (Linking) VI - 6 IP - 6 DP - 2018 Jun 20 TI - Upregulation of Twist2 in Non-Muscle Invasive Urothelial Carcinoma of the Bladder Correlate with Response to Treatment and Progression. PG - 1017-1022 LID - 10.3889/oamjms.2018.165 [doi] AB - BACKGROUND: Twist2 is a transcription factor and an epithelial-to-mesenchymal transition that plays an important role in cell polarity, cell adhesion, and has a role in tumour invasion and metastases. AIM: In this study, we examined the expression of Twist2 in non-muscle invasive bladder carcinoma (NMIBC) and correlated the expression with response to treatment and tumour progression. METHODS: Data of 305 patients with NMIBC of Ta, T1 were retrieved from hospitals archives. Twist2 expression was examined in tissue samples by immunohistochemistry at initial diagnosis and final follow-up, normal control was 10 normal urothelium, 10 patients with muscle-invasive bladder cancer (MIBC) were a positive control. Treatment of NMIBC was implemented according to the European Association of Urology guidelines on NMIBC. The descriptive statistical analysis included means, standard deviation, p-value; Univariate and multivariate Cox regression analyses. RESULTS: Twist2 expression score was identified as negative, low (1-15%); medium (15-40%); and high (40-100%). Patients who had low or low medium scores at the initial diagnosis had a good response and a favourable prognosis. Expression of a high score of Twist2 in patients having high-grade T1 tumours showed non-responsiveness to repeated courses of intravesical bacillus Calmette Guerin (BCG) therapy and was upstaged to MIBC. CONCLUSION: Twist2 expression in tissue samples of NMIBC would indicate the tumour response to therapy, upgrading and upstaging in the follow up after intravesical BCG therapy. FAU - Wishahi, Mohamed AU - Wishahi M AD - Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Khalil, Heba AU - Khalil H AD - Pathology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Badawy, Mohamed H AU - Badawy MH AD - Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Elkholy, Amr AU - Elkholy A AD - Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Eseily, Khaled AU - Eseily K AD - Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Anis, Shady AU - Anis S AD - Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. FAU - Eldahshan, Samir AU - Eldahshan S AD - Urology Department, Theodor Bilharz Research Institute, Cairo, Egypt. FAU - Kamel, Noura AU - Kamel N AD - Pathology Departments, National Research Centre, Cairo, Egypt. FAU - Romeih, Mahmoud AU - Romeih M AD - Biochemistry Department, Theodor Bilharz Research Institute, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20180605 PL - North Macedonia TA - Open Access Maced J Med Sci JT - Open access Macedonian journal of medical sciences JID - 101662294 PMC - PMC6026420 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Epithelial-mesenchymal transition OT - NMIBC OT - Twist2 EDAT- 2018/07/10 06:00 MHDA- 2018/07/10 06:01 PMCR- 2018/06/05 CRDT- 2018/07/10 06:00 PHST- 2018/01/04 00:00 [received] PHST- 2018/05/15 00:00 [revised] PHST- 2018/05/19 00:00 [accepted] PHST- 2018/07/10 06:00 [entrez] PHST- 2018/07/10 06:00 [pubmed] PHST- 2018/07/10 06:01 [medline] PHST- 2018/06/05 00:00 [pmc-release] AID - OAMJMS-6-1017 [pii] AID - 10.3889/oamjms.2018.165 [doi] PST - epublish SO - Open Access Maced J Med Sci. 2018 Jun 5;6(6):1017-1022. doi: 10.3889/oamjms.2018.165. eCollection 2018 Jun 20. PMID- 29975950 OWN - NLM STAT- MEDLINE DCOM- 20190110 LR - 20220408 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 101 IP - 1 DP - 2018 TI - High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. PG - 7-15 LID - 10.1159/000490765 [doi] AB - INTRODUCTION: The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC). PATIENTS AND METHODS: The study period was from January 2002 to -December 2012. A total of 1,046 patients with primary T1 HG/G3 and who had non-muscle invasive BC (NMIBC) on re-TUR followed by adjuvant intravesical Bacillus Calmette-Guerin (BCG) therapy with maintenance were included. Endpoints were time to disease recurrence, progression, and overall and cancer-specific death. RESULTS: A total of 257 (24.6%) patients had residual T1 HG/G3 tumors. The presence of concomitant carcinoma in situ, multiple and large tumors (> 3 cm) at first TUR were associated with residual T1 HG/G3. Five-year recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) were 17% (CI 11.8-23); 58.2% (CI 50.7-65); 73.7% (CI 66.3-79.7); and 84.5% (CI 77.8-89.3), respectively, in patients with residual T1 HG/G3, compared to 36.7% (CI 32.8-40.6); 71.4% (CI 67.3-75.2); 89.8% (CI 86.6-92.3); and 95.7% (CI 93.4-97.3), respectively, in patients with NMIBC other than T1 HG/G3 or T0 tumors. Residual T1 HG/G3 was independently associated with RFS, PFS, OS, and CSS in multivariable analyses. CONCLUSIONS: Residual T1 HG/G3 tumor at re-TUR confers worse prognosis in patients with primary T1 HG/G3 treated with maintenance BCG. Patients with residual T1 HG/G3 for primary T1 HG/G3 are very likely to fail BCG therapy alone. CI - (c) 2018 S. Karger AG, Basel. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Division of Urology, European Institute of Oncology, Milan, Italy. AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Cantiello, Francesco AU - Cantiello F AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Di Stasi, Savino M AU - Di Stasi SM AD - Department of Experimental Medicine and Surgery, Tor Vegata University, Rome, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Humanitas University, Department of Biomedical Science, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Humanitas University, Department of Biomedical Science, Milan, Italy. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Urology, Sapienza University of Rome, Rome, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Perdona, Sisto AU - Perdona S AD - Uro-Gynecological Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"-IRCCS, Naples, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, University of Bologna, Bologna, Italy. FAU - Almeida, Gilberto L AU - Almeida GL AD - Departamento de Urologia, University of Vale do Itajai, Itajai, Brazil. FAU - Bove, Pierluigi AU - Bove P AD - UOC of Urology Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy. FAU - Lima, Estevao AU - Lima E AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Grimaldi, Giovanni AU - Grimaldi G AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Autorino, Riccardo AU - Autorino R AD - Division of Urology, Virginia Commonwealth University, Richmond, Virginia, USA. FAU - Crisan, Nicolae AU - Crisan N AD - Department of Urology, University of Medicine and Pharmacy "Iuliu Hateganu", Cluj-Napoca, Romania. FAU - Abu Farhan, Abdal Rahman AU - Abu Farhan AR AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Verze, Paolo AU - Verze P AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Battaglia, Michele AU - Battaglia M AD - Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Department of Surgery, Urology Section, University of Catania, Catania, Italy. FAU - Morgia, Giuseppe AU - Morgia G AD - Department of Surgery, Urology Section, University of Catania, Catania, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy. AD - Universita degli Studi di Milano, Via Festa del Perdono 7, Milan, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. AD - Department of Urology, Weill Cornell Medical College, New York, New York, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20180704 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology MH - Cystectomy/methods MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology MH - Prognosis MH - Progression-Free Survival MH - Recurrence MH - Regression Analysis MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Bladder cancer OT - High risk OT - High-grade OT - Second look resection OT - Transurethral resection of bladder tumor EDAT- 2018/07/06 06:00 MHDA- 2019/01/11 06:00 CRDT- 2018/07/06 06:00 PHST- 2018/04/17 00:00 [received] PHST- 2018/06/11 00:00 [accepted] PHST- 2018/07/06 06:00 [pubmed] PHST- 2019/01/11 06:00 [medline] PHST- 2018/07/06 06:00 [entrez] AID - 000490765 [pii] AID - 10.1159/000490765 [doi] PST - ppublish SO - Urol Int. 2018;101(1):7-15. doi: 10.1159/000490765. Epub 2018 Jul 4. PMID- 29974604 OWN - NLM STAT- MEDLINE DCOM- 20191021 LR - 20191022 IS - 1445-2197 (Electronic) IS - 1445-1433 (Linking) VI - 88 IP - 10 DP - 2018 Oct TI - Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer. PG - 1033-1036 LID - 10.1111/ans.14709 [doi] AB - BACKGROUND: This study was conducted to evaluate the efficacy and necessity of repeat transurethral resection (re-TUR) treatment for selected patients with muscle-invasive bladder cancer and to investigate the possibility of bladder sparing. METHODS: The study included 61 selected patients with invasive bladder cancer who were treated by re-TUR and in whom biopsies of the muscle layer of the tumour bed were negative. Re-TUR was performed within 4-6 weeks of the initial resection. Pirarubicin instillation was scheduled for the bladder-preserving group. The prognosis was compared with that of patients in our previous research, which included 93 selected patients with invasive bladder cancer who were treated by radical TUR. In that research, we found that the overall survival and disease-specific survival rates were 59.1 and 65.2%, respectively. The clinical stage of tumour influenced the survival rates. RESULTS: Of the 61 patients who underwent re-TUR, 31 never had disease relapse, 19 had disease recurrence and 11 had disease progression. The clinical stage of the tumour influenced the overall survival and disease-specific survival. The 5-year overall survival rate was 70% and disease-specific survival rate was 74%, respectively. Compared with the TUR group, both the overall survival and disease-specific survival rates of the re-TUR group both increased significantly (P < 0.05). CONCLUSIONS: Re-TUR combined with pirarubicin instillation is a suitable bladder-preserving treatment for selected patients with muscle-invasive bladder cancer, based on good overall survival and disease-specific survival rates demonstrated in this research. The clinical stage of tumour has a major influence on the survival rates. CI - (c) 2018 Royal Australasian College of Surgeons. FAU - Li, Zhuo AU - Li Z AD - Department of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Li, Yuanwei AU - Li Y AUID- ORCID: 0000-0001-7817-4586 AD - Department of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Chen, Jia AU - Chen J AD - Department of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, China. LA - eng PT - Comparative Study PT - Journal Article DEP - 20180705 PL - Australia TA - ANZ J Surg JT - ANZ journal of surgery JID - 101086634 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/therapeutic use MH - Carcinoma, Transitional Cell/pathology MH - Combined Modality Therapy MH - Cystectomy/methods MH - Disease-Free Survival MH - Doxorubicin/administration & dosage/analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Natural Orifice Endoscopic Surgery/*methods MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments/methods MH - Prognosis MH - Survival Rate MH - Urethra/*surgery MH - Urinary Bladder Neoplasms/mortality/*pathology/*surgery OTO - NOTNLM OT - bladder transitional cell carcinoma OT - radical transurethral resection OT - repeat radical transurethral resection EDAT- 2018/07/06 06:00 MHDA- 2019/10/23 06:00 CRDT- 2018/07/06 06:00 PHST- 2017/09/12 00:00 [received] PHST- 2018/04/05 00:00 [revised] PHST- 2018/04/26 00:00 [accepted] PHST- 2018/07/06 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] PHST- 2018/07/06 06:00 [entrez] AID - 10.1111/ans.14709 [doi] PST - ppublish SO - ANZ J Surg. 2018 Oct;88(10):1033-1036. doi: 10.1111/ans.14709. Epub 2018 Jul 5. PMID- 29971622 OWN - NLM STAT- MEDLINE DCOM- 20190109 LR - 20190109 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 23 IP - 6 DP - 2018 Dec TI - Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan. PG - 1140-1147 LID - 10.1007/s10147-018-1311-6 [doi] AB - BACKGROUND: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). METHODS: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. RESULTS: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2-64.8%) sensitivity and 72.4% (68.3-76.8%). Urine cytology had 4.5% (0.0-10.7%) sensitivity and 99.8% (99.3-100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. CONCLUSIONS: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence. FAU - Kojima, Takahiro AU - Kojima T AUID- ORCID: 0000-0003-4150-9631 AD - Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan. AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan. nishiuro@md.tsukuba.ac.jp. AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. nishiuro@md.tsukuba.ac.jp. FAU - Ozono, Seiichiro AU - Ozono S AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. FAU - Hinotsu, Shiro AU - Hinotsu S AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Center for Innovative Clinical Medicine, Okayama University, Okayama, Japan. FAU - Keino, Naoto AU - Keino N AD - Tsukuba Clinical Research and Development Organization (T-CReDO), University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Yamaguchi, Akito AU - Yamaguchi A AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Division of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Sakai, Hideki AU - Sakai H AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Nagasaki University, Nagasaki, Japan. FAU - Enomoto, Yutaka AU - Enomoto Y AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Mitsui Memorial Hospital, Tokyo, Japan. FAU - Horie, Shigeo AU - Horie S AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Juntendo University, Tokyo, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Yamaguchi University, Yamaguchi, Japan. FAU - Okamura, Takehiko AU - Okamura T AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan. FAU - Kanimoto, Yusuke AU - Kanimoto Y AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Chutoen General Medical Center, Shizuoka, Japan. FAU - Oya, Mototsugu AU - Oya M AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Keio University, Tokyo, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Urology, Osaka University, Osaka, Japan. FAU - Naito, Seiji AU - Naito S AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Division of Urology, Harasanshin Hospital, Fukuoka, Japan. FAU - Akaza, Hideyuki AU - Akaza H AD - UroVysion Clinical Evaluation Group, Tokyo, Japan. AD - Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20180703 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Adult MH - Aged MH - *Cytodiagnosis MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Japan MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology/surgery MH - Prospective Studies MH - Urinary Bladder Neoplasms/*pathology/surgery MH - Urine/*cytology OTO - NOTNLM OT - Bladder cancer OT - Cytology OT - Fluorescence in situ hybridization OT - Sensitivity OT - Specificity OT - UroVysion EDAT- 2018/07/05 06:00 MHDA- 2019/01/10 06:00 CRDT- 2018/07/05 06:00 PHST- 2018/03/23 00:00 [received] PHST- 2018/06/24 00:00 [accepted] PHST- 2018/07/05 06:00 [pubmed] PHST- 2019/01/10 06:00 [medline] PHST- 2018/07/05 06:00 [entrez] AID - 10.1007/s10147-018-1311-6 [pii] AID - 10.1007/s10147-018-1311-6 [doi] PST - ppublish SO - Int J Clin Oncol. 2018 Dec;23(6):1140-1147. doi: 10.1007/s10147-018-1311-6. Epub 2018 Jul 3. PMID- 29970242 OWN - NLM STAT- MEDLINE DCOM- 20190826 LR - 20191210 IS - 1365-229X (Electronic) IS - 0009-9260 (Linking) VI - 73 IP - 10 DP - 2018 Oct TI - Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer. PG - 881-885 LID - S0009-9260(18)30215-0 [pii] LID - 10.1016/j.crad.2018.05.022 [doi] AB - AIM: To assess the ability of apparent diffusion coefficient (ADC) measurements obtained by MRI to predict disease-specific survival (DSS) in patients with bladder cancer and compare it with established clinico-pathological prognostic factors. MATERIAL AND METHODS: The ethical review board approved this cross-sectional study. Patients with suspected bladder cancer receiving diagnostic 3 T diffusion-weighted imaging (DWI) of the bladder before transurethral resection of the bladder (TUR-B) or radical cystectomy were evaluated prospectively. Two independent radiologists measured ADC values in bladder cancer lesions in regions of interest. Associations between ADC values and pathological features with DSS were tested statistically. A combined model was established using artificial neuronal network (ANN) methodology. RESULTS: A total of 51 patients (median age 69 years, range 41-89 years) were included. Three patients were lost to follow-up, leaving 48 patients for survival analysis. Seven patients died during the 795 months studied. ADC showed significant potential to predict DSS (p<0.05). Except for grading, all pathological features as assessed by TUR-B could predict DSS (p<0.05, respectively). The combined ANN classifier showed the highest accuracy to predict DSS (0.889, 95% confidence interval: 0.732-1, p=0.001) compared to all single parameters. ADC was the second important predictor of the ANN. CONCLUSIONS: ADC measurements obtained by unenhanced MRI predicts DSS in bladder cancer patients. A combined classifier including ADC and clinico-pathological information showed high accuracy to identify patients at high risk for disease-related death. CI - Copyright (c) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. FAU - Sevcenco, S AU - Sevcenco S AD - Department of Urology and Andrology, Donauspital, Vienna, Austria. FAU - Maj-Hes, A B AU - Maj-Hes AB AD - Department of Urology, Medical University of Vienna, Austria. FAU - Hruby, S AU - Hruby S AD - Department of Oncology, Kaiser-Franz-Joseph Hospital, Austria; Department of Urology, Landeskrankenhaus Salzburg, Paracelsus Medical University, Salzburg, Austria. FAU - Ponhold, L AU - Ponhold L AD - Department of Radiology, University Hospital of Sankt-Polten, Austria. FAU - Heinz-Peer, G AU - Heinz-Peer G AD - Department of Radiology, University Hospital of Sankt-Polten, Austria. FAU - Rauchenwald, M AU - Rauchenwald M AD - Department of Urology and Andrology, Donauspital, Vienna, Austria. FAU - Marszalek, M AU - Marszalek M AD - Department of Urology and Andrology, Donauspital, Vienna, Austria. FAU - Klingler, H C AU - Klingler HC AD - Department of Urology, Wilhelminenspital Vienna, Austria. FAU - Polanec, S AU - Polanec S AD - Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Austria. FAU - Baltzer, P A T AU - Baltzer PAT AD - Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Austria. Electronic address: patbaltzer@gmail.com. LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article DEP - 20180630 PL - England TA - Clin Radiol JT - Clinical radiology JID - 1306016 MH - Adult MH - Aged MH - Aged, 80 and over MH - Diffusion Magnetic Resonance Imaging MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Muscle Neoplasms/mortality/*pathology MH - Neoplasm Invasiveness MH - Prognosis MH - ROC Curve MH - Urinary Bladder Neoplasms/mortality/*pathology EDAT- 2018/07/05 06:00 MHDA- 2019/08/27 06:00 CRDT- 2018/07/05 06:00 PHST- 2017/09/13 00:00 [received] PHST- 2018/05/15 00:00 [accepted] PHST- 2018/07/05 06:00 [pubmed] PHST- 2019/08/27 06:00 [medline] PHST- 2018/07/05 06:00 [entrez] AID - S0009-9260(18)30215-0 [pii] AID - 10.1016/j.crad.2018.05.022 [doi] PST - ppublish SO - Clin Radiol. 2018 Oct;73(10):881-885. doi: 10.1016/j.crad.2018.05.022. Epub 2018 Jun 30. PMID- 29968999 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20220330 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 70 IP - 5 DP - 2018 Oct TI - Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guerin: experience of a single center. PG - 501-508 LID - 10.23736/S0393-2249.18.03042-4 [doi] AB - BACKGROUND: To assess the outcomes of patients with high-grade (HG) pT1 bladder cancer (BC) treated with intravesical BCG therapy. METHODS: The study population consisted of 185 patients with HG pT1 BC treated between 1998 and 2010. We aimed to determine recurrence-free (RFS) and progression-free survival (PFS), as well as the predictors of RFS and PFS. RESULTS: Overall, 143 (77.3%) patients were males. Median age was 72 years (IQR: 66-78). Tumor size was >/=3 cm in 100 (54.1%) individuals. Most patients had single tumors (125; 67.6%). Primary, progressive and recurrent patterns of presentation were observed in 146 (78.9%), 21 (11.4%), and 18 (9.7%) cases, respectively. After 2nd-look TURB, 127 (68.6%) patients had no residual disease, 44 (23.8%) had Ta/CIS, and 14 (7.6%) had T1 HG BC. Twenty-two (11.9%) patients experience early recurrence after BCG. Of these, 12 patients (54.5%) were diagnosed with Ta/CIS, while 10 (45.5%) were diagnosed with HG pT1 BC. The median follow-up was 93 months (IQR: 63-147). Ten-year RFS and PFS rates were 69.6 and 79.2%. In multivariable Cox regression models, female gender (HR=2.41; P=0.001), progressive (HR=2.03; P=0.030) and recurrent (HR=3.87; P<0.001) pattern of presentation emerged as independent predictors of RFS, while age >/=70 years (HR=2.13; P=0.027), presence of multiple tumors (HR=2.06; P=0.019), and early recurrence (HR=3.88; P<0.001) emerged as independent predictors of PFS. CONCLUSIONS: Intravesical BCG appears to be an effective treatment for HG pT1 BC. Caution should be used in patients aged >/=70 years, with multiple tumors or experiencing early recurrence. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Buffi, Nicolo AU - Buffi N AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Lista, Giuliana AU - Lista G AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Cardone, Pasquale AU - Cardone P AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Forni, Giovanni AU - Forni G AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Maffei, Davide AU - Maffei D AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Peschechera, Roberto AU - Peschechera R AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Zandegiacomo, Silvia AU - Zandegiacomo S AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Pasini, Luisa AU - Pasini L AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Benetti, Alessio AU - Benetti A AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy - giovanni.lughezzani@humanitas.it. LA - eng PT - Journal Article DEP - 20180703 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Neoplasm Recurrence, Local MH - Progression-Free Survival MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy EDAT- 2018/07/04 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/07/04 06:00 PHST- 2018/07/04 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/07/04 06:00 [entrez] AID - S0393-2249.18.03042-4 [pii] AID - 10.23736/S0393-2249.18.03042-4 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2018 Oct;70(5):501-508. doi: 10.23736/S0393-2249.18.03042-4. Epub 2018 Jul 3. PMID- 37312295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230614 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 5 IP - 4 DP - 2018 Jul TI - The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup. PG - 305-310 LID - 10.1016/j.urpr.2017.07.001 [doi] AB - INTRODUCTION: Radical cystectomy with neoadjuvant chemotherapy is the standard of care for patients with localized muscle invasive urothelial carcinoma of the bladder. One of the strongest predictors of survival in these patients is pathological response to initial treatment. Our objective was to determine whether we could stratify the need for radical cystectomy based on pathological response to neoadjuvant chemotherapy. METHODS: We present a cohort of patients with muscle invasive urothelial carcinoma of the bladder to whom surveillance and bladder preservation were offered if complete response was achieved following neoadjuvant chemotherapy. Descriptive statistics and survival analysis were performed to assess overall, cancer specific and metastasis-free survival. Patients were stratified based on pathological response to neoadjuvant chemotherapy. RESULTS: A total of 60 patients were included in the cohort, of whom 32 (55%) had absence of residual disease on post-neoadjuvant chemotherapy transurethral resection and 27 (45%) had persistent disease. Of patients undergoing surveillance 52% maintained the bladder without evidence of recurrence. By comparison, of those with recurrence only 20% preserved the bladder and were without evidence of disease. CONCLUSIONS: Long-term followup shows a subset of patients achieving good outcomes while preserving the bladder. However, we also observed an inability to reliably identify this subset of patients given current clinical and pathological markers. Until we are able to achieve that goal, the safest oncologic approach remains neoadjuvant chemotherapy followed by radical cystectomy. FAU - Yap, Stanley A AU - Yap SA AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b AD - University of California Davis Comprehensive Cancer Center, Sacramento, California. ES-UID: S2352077917301437-154cf45850506536fbe0995132c96d5e AD - Division of Urology, Department of Surgery, VA Northern California Health Care System, Sacramento, California. ES-UID: S2352077917301437-0b5a5da67837701ce44da608a5a776ef FAU - Pugashetti, Neil AU - Pugashetti N AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b FAU - Chandrasekar, Thenappan AU - Chandrasekar T AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b FAU - Dall'Era, Marc A AU - Dall'Era MA AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b AD - University of California Davis Comprehensive Cancer Center, Sacramento, California. ES-UID: S2352077917301437-154cf45850506536fbe0995132c96d5e FAU - Evans, Christopher P AU - Evans CP AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b AD - University of California Davis Comprehensive Cancer Center, Sacramento, California. ES-UID: S2352077917301437-154cf45850506536fbe0995132c96d5e FAU - Lara, Primo N AU - Lara PN AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b AD - Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-9ad89607dfdec7f3c96056a0210630ca AD - University of California Davis Comprehensive Cancer Center, Sacramento, California. ES-UID: S2352077917301437-154cf45850506536fbe0995132c96d5e FAU - deVere White, Ralph W AU - deVere White RW AD - Department of Urology, University of California, Davis, Sacramento, California. ES-UID: S2352077917301437-5e31d5659056e793c2e247dc905ca12b AD - University of California Davis Comprehensive Cancer Center, Sacramento, California. ES-UID: S2352077917301437-154cf45850506536fbe0995132c96d5e LA - eng PT - Journal Article DEP - 20170721 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - drug therapy OT - neoadjuvant therapy OT - survival OT - urinary bladder neoplasms EDAT- 2018/07/01 00:00 MHDA- 2018/07/01 00:01 CRDT- 2023/06/14 01:00 PHST- 2018/07/01 00:01 [medline] PHST- 2018/07/01 00:00 [pubmed] PHST- 2023/06/14 01:00 [entrez] AID - 10.1016/j.urpr.2017.07.001 [doi] PST - ppublish SO - Urol Pract. 2018 Jul;5(4):305-310. doi: 10.1016/j.urpr.2017.07.001. Epub 2017 Jul 21. PMID- 29960059 OWN - NLM STAT- MEDLINE DCOM- 20190527 LR - 20190527 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 102 IP - 5 DP - 2018 Dec 1 TI - Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy. PG - 1408-1416 LID - S0360-3016(18)31021-6 [pii] LID - 10.1016/j.ijrobp.2018.06.030 [doi] AB - PURPOSE: A bladder-sparing strategy is a useful option for patients with muscle-invasive bladder cancer (MIBC), in which the response to chemoradiation therapy (CRT) is primarily important in achieving favorable oncologic outcomes. Our objective is to evaluate the impact of immunohistochemistry (IHC)-based subtyping in MIBC on prediction of CRT response. METHODS AND MATERIALS: Treatment protocol consisted of induction CRT followed by partial or radical cystectomy as consolidative surgery; 118 eligible patients with nonmetastatic MIBC were retrospectively analyzed. Of these patients, 92 eventually underwent partial or radical cystectomy after CRT. We applied the IHC-based subtyping model developed by Lund University, which classifies patients into urobasal (Uro), genomically unstable (GU), and squamous cell cancer-like (SCCL) subtypes. GU and SCCL cancers are supposed to be highly aggressive and to have worse prognoses than Uro. Correlations of subtypes with CRT response were analyzed clinically in all patients and pathologically in 92 cystectomized patients. The impact of each subtype on cancer-specific mortality (CSM) was also analyzed. RESULTS: Of all patients, 26 (22%), 61 (52%), and 31 (26%) were classified into Uro, GU, and SCCL subtypes, respectively. Clinical complete response (CR) was achieved in 42% of patients overall after CRT, with a significantly higher proportion in GU patients (52%) and SCCL patients (45%) than in Uro patients (15%; P < .001 and P = .01, respectively). On multivariate analysis, the GU/SCCL subtype was a significant predictor of clinical CR, as was absence of hydronephrosis or concomitant carcinoma in situ. Analyses for pathologic CR in the cystectomized patients revealed analogous findings. Five-year CSM of Uro, GU, and SCCL patients was 16%, 23%, and 28% overall, respectively, and 19%, 22%, and 23% in cystectomized patients, respectively, with no significant difference among the subtypes. CR status after CRT was significantly and independently correlated with low CSM in both clinical and pathologic evaluations. CONCLUSIONS: GU and SCCL cancers showed significantly more favorable CRT response than did Uro cancers. IHC-based subtyping may improve clinical decisions about the indication of CRT for MIBC patients. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Tanaka, Hajime AU - Tanaka H AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: s-yoshida.uro@tmd.ac.jp. FAU - Koga, Fumitaka AU - Koga F AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. FAU - Toda, Kazuma AU - Toda K AD - Department of Radiation Oncology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yoshimura, Ryoichi AU - Yoshimura R AD - Department of Radiation Oncology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Nakajima, Yutaka AU - Nakajima Y AD - Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Sugawara, Emiko AU - Sugawara E AD - Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Akashi, Takumi AU - Akashi T AD - Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Waseda, Yuma AU - Waseda Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Inoue, Masaharu AU - Inoue M AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Kijima, Toshiki AU - Kijima T AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yokoyama, Minato AU - Yokoyama M AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Matsuoka, Yoh AU - Matsuoka Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Kihara, Kazunori AU - Kihara K AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20180628 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 SB - IM CIN - Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1417-1419. doi: 10.1016/j.ijrobp.2018.07.2020. PMID: 30103024 MH - Aged MH - Aged, 80 and over MH - *Chemoradiotherapy MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/metabolism/*pathology/*therapy EDAT- 2018/07/01 06:00 MHDA- 2019/05/28 06:00 CRDT- 2018/07/01 06:00 PHST- 2018/02/22 00:00 [received] PHST- 2018/05/25 00:00 [revised] PHST- 2018/06/14 00:00 [accepted] PHST- 2018/07/01 06:00 [pubmed] PHST- 2019/05/28 06:00 [medline] PHST- 2018/07/01 06:00 [entrez] AID - S0360-3016(18)31021-6 [pii] AID - 10.1016/j.ijrobp.2018.06.030 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1408-1416. doi: 10.1016/j.ijrobp.2018.06.030. Epub 2018 Jun 28. PMID- 29959824 OWN - NLM STAT- MEDLINE DCOM- 20190927 LR - 20190927 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 123 IP - 2 DP - 2019 Feb TI - Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guerin (BCG) treatment. PG - 246-251 LID - 10.1111/bju.14470 [doi] AB - OBJECTIVES: To investigate the need to biopsy erythematous lesions of the bladder after bacille Calmette-Guerin (BCG) treatment as well as the diagnostic value of voided urine cytology in the detection of recurrence. MATERIALS AND METHODS: Data on 206 consecutive patients with non-muscle-invasive bladder cancer treated with one or more BCG instillations in the period 2009-2015 at Satakunta Central Hospital and Turku University Hospital were reviewed. Biopsy histology was pooled according to lesion cystoscopy appearance regarding growth pattern and presence of erythema. Voided urine cytology grading before resection was reviewed. We correlated the cystoscopy findings with histology and calculated the sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) for voided urine cytology. RESULTS: In total, 159 patients with a median follow-up of 35 months were included in the study. Altogether, 367 biopsies were analysed. In the case of papillary or flat tumours, 76% of biopsies showed malignant histology and the diagnostic value of cytology was very limited (sensitivity 33%, specificity 84%). Erythematous lesions constituted 57% of all biopsy targets, with the majority being either chronic non-specific inflammation or granulomatous inflammation; 10% of erythematous lesions were malignant at pathological examination. In contrast to papillary and flat tumours, cytology proved to be more accurate in the case of erythematous lesions with a sensitivity, specificity, PPV and NPV of 59%, 76%, 23% and 94%, respectively. CONCLUSION: Bladder lesions after BCG instillations pose a challenge during follow-up and the appropriate management strategy is not clear. Lesions should not be overlooked as being BCG-induced irritation because they may harbour significant malignancies. The presence of papillary or flat tumour always warrants a biopsy or resection. In the case of erythematous lesions, our results suggest that biopsy may be avoided if voided urine cytology is negative. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Nurminen, Pertti AU - Nurminen P AUID- ORCID: 0000-0001-9364-9754 AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Ettala, Otto AU - Ettala O AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Seppanen, Marjo AU - Seppanen M AD - Department of Surgery, Satakunta Central Hospital, Pori, Finland. FAU - Taimen, Pekka AU - Taimen P AD - Pathology, Institute of Biomedicine, University of Turku and Turku University Hospital, Turku, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Kaipia, Antti AU - Kaipia A AD - Department of Urology, Tampere University Hospital, Tampere, Finland. LA - eng PT - Journal Article DEP - 20180812 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2020 May;203(5):879. doi: 10.1097/JU.0000000000000778. PMID: 32073952 MH - Adjuvants, Immunologic/*adverse effects MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*adverse effects MH - Biopsy MH - Cystoscopy MH - Female MH - Granuloma/chemically induced/*diagnostic imaging/pathology MH - Humans MH - Inflammation/chemically induced/*diagnostic imaging/pathology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnostic imaging/*pathology MH - Predictive Value of Tests MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/*pathology MH - Urine/*cytology OTO - NOTNLM OT - BCG vaccine OT - erythema OT - urinary bladder neoplasms OT - urine cytology EDAT- 2018/07/01 06:00 MHDA- 2019/09/29 06:00 CRDT- 2018/07/01 06:00 PHST- 2018/07/01 06:00 [pubmed] PHST- 2019/09/29 06:00 [medline] PHST- 2018/07/01 06:00 [entrez] AID - 10.1111/bju.14470 [doi] PST - ppublish SO - BJU Int. 2019 Feb;123(2):246-251. doi: 10.1111/bju.14470. Epub 2018 Aug 12. PMID- 29959570 OWN - NLM STAT- MEDLINE DCOM- 20180806 LR - 20211204 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 144 IP - 9 DP - 2018 Sep TI - FOXM1 predicts disease progression in non-muscle invasive bladder cancer. PG - 1701-1709 LID - 10.1007/s00432-018-2694-5 [doi] AB - PURPOSE: The proto-oncogene forkhead box M1 (FOXM1) is associated with poor survival in many cancers. The impact of FOXM1 expression on progression-free survival (PFS) of non-muscle invasive bladder cancer (NMIBC) has not yet been investigated. The differential expression of FOXM1 between the different molecular NMIBC subtypes has further been assessed. METHODS: Transcript levels of FOXM1 and MKI67 were determined in 460 NMIBC patients (UROMOL cohort) by RNA-Seq and validated in silico by the Chungbuk and Lund cohort (n = 277). FOXM1 and MKI67 cutoffs were identified by the minimal p value method. Variables were evaluated by multivariable Cox regression analyses in order to identify independent predictors. RESULTS: FOXM1 is an independent predictor for PFS superior to current histological, clinical and molecular staging methods. Patients with high FOXM1 expression have a 6- to 8-fold higher risk of progression in multivariable analysis (p < 0.03). Highest transcript levels were found in the Class 2 and genomically unstable molecular NMIBC subtype (p < 0.03). The proto-oncogene further positively correlated with tumor grade and stage. NMIBCs with high FOXM1 expression showed a PFS advantage when treated with intravesical BCG instillation. CONCLUSION: FOXM1 is a highly prognostic marker for disease progression of NMIBC superior to current histological, clinical and molecular staging methods and MKI67. It is mainly expressed in the Class 2 and genomically unstable molecular bladder cancer subtypes. Its role in drug resistance development makes FOXM1 valuable biomarker for NMIBC risk stratification. FAU - Rinaldetti, Sebastien AU - Rinaldetti S AUID- ORCID: 0000-0003-1053-3831 AD - Department of Hematology and Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. sebastienrinal@hotmail.com. AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. sebastienrinal@hotmail.com. FAU - Wirtz, Ralph AU - Wirtz R AD - Stratifyer Molecular Pathology, Werthmannstrasse 1, 50935, Cologne, Germany. FAU - Worst, Thomas Stefan AU - Worst TS AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Landshuter Str. 65, Regensburg, Germany. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. LA - eng PT - Journal Article DEP - 20180629 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (FOXM1 protein, human) RN - 0 (Forkhead Box Protein M1) RN - 0 (Ki-67 Antigen) RN - 0 (MAS1 protein, human) RN - 0 (Proto-Oncogene Mas) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Forkhead Box Protein M1/*genetics MH - Gene Expression Profiling MH - Humans MH - Ki-67 Antigen/genetics MH - Middle Aged MH - Neoplasm Recurrence, Local/genetics/pathology MH - Neoplasm Staging/methods MH - Prognosis MH - Proto-Oncogene Mas MH - Urinary Bladder Neoplasms/*genetics/*pathology MH - Young Adult PMC - PMC6096766 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - FOXM1 OT - MKI67 OT - Molecular subtypes OT - Progression-free survival COIS- All authors declare to have no COIs. EDAT- 2018/07/01 06:00 MHDA- 2018/08/07 06:00 PMCR- 2018/06/29 CRDT- 2018/07/01 06:00 PHST- 2018/05/31 00:00 [received] PHST- 2018/06/19 00:00 [accepted] PHST- 2018/07/01 06:00 [pubmed] PHST- 2018/08/07 06:00 [medline] PHST- 2018/07/01 06:00 [entrez] PHST- 2018/06/29 00:00 [pmc-release] AID - 10.1007/s00432-018-2694-5 [pii] AID - 2694 [pii] AID - 10.1007/s00432-018-2694-5 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29. PMID- 29955780 OWN - NLM STAT- MEDLINE DCOM- 20191007 LR - 20200306 IS - 2168-6262 (Electronic) IS - 2168-6254 (Print) IS - 2168-6254 (Linking) VI - 153 IP - 10 DP - 2018 Oct 1 TI - Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. PG - 881-889 LID - 10.1001/jamasurg.2018.1680 [doi] AB - IMPORTANCE: Radical cystectomy is the guidelines-recommended treatment of muscle-invasive bladder cancer, but a resurgence of trimodal therapy has occurred. Limited comparative data are available on outcomes and costs attributable to these 2 treatments. OBJECTIVE: To compare the survival outcomes and costs between trimodal therapy and radical cystectomy in older adults with muscle-invasive bladder cancer. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from the Surveillance, Epidemiology, and End Results-Medicare linked database. A total of 3200 older adults (aged >/=66 years) with clinical stage T2 to T4a bladder cancer diagnosed from January 1, 2002, to December 31, 2011, and with claims data available through December 31, 2013, were included in the analysis. Patients who received radical cystectomy underwent either only surgery or surgery in combination with radiotherapy or chemotherapy. Patients who received trimodal therapy underwent transurethral resection of the bladder followed by radiotherapy and chemotherapy. Propensity score matching by sociodemographic and clinical characteristics was used. Data analysis was performed from August 1, 2017, to March 11, 2018. MAIN OUTCOMES AND MEASURES: Overall survival and cancer-specific survival were evaluated using the Cox proportional hazards regression model and the Fine and Gray competing risk model. All Medicare health care costs for inpatient, outpatient, and physician services within 30, 90, and 180 days of treatment were compared. The total amount spent nationwide was estimated, using 180-day medical costs between treatments, by the total number of new cases of muscle-invasive bladder cancer in the United States in 2011. RESULTS: Of the 3200 patients who met the inclusion criteria, 2048 (64.0%) were men and 1152 (36.0%) were women, with a mean (SD) age of 75.8 (6.0) years. After propensity score matching, 687 patients (21.5%) underwent trimodal therapy and 687 patients (21.5%) underwent radical cystectomy. Patients who underwent trimodal therapy had significantly decreased overall survival (hazard ratio [HR], 1.49; 95% CI, 1.31-1.69) and cancer-specific survival (HR, 1.55; 95% CI, 1.32-1.83). No differences in costs at 30 days were observed between trimodal therapy ($15 233 in 2002 vs $18 743 in 2011) and radical cystectomy ($17 990 in 2002 vs $21 738 in 2011). However, median total costs were significantly higher with trimodal therapy than with radical cystectomy at 90 days ($80 174 vs $69 181; median difference, $8964; Hodges-Lehmann 95% CI, $3848-$14 079) and at 180 days ($179 891 vs $107 017; median difference, $63 771; Hodges-Lehmann 95% CI, $55 512-$72 029). Extrapolating these figures to the total US population revealed $335 million in excess spending for trimodal therapy compared with the less costly radical cystectomy ($492 million) for patients who received a muscle-invasive bladder cancer diagnosis in 2011. CONCLUSIONS AND RELEVANCE: Trimodal therapy was associated with significantly decreased overall survival and cancer-specific survival as well as $335 million in excess spending in 2011. These findings have important health policy implications regarding the appropriate use of high value-based care among older adults with invasive bladder cancer who are candidates for either radical cystectomy or trimodal therapy. FAU - Williams, Stephen B AU - Williams SB AD - Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Shan, Yong AU - Shan Y AD - Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Jazzar, Usama AU - Jazzar U AD - Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Mehta, Hemalkumar B AU - Mehta HB AD - Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Baillargeon, Jacques G AU - Baillargeon JG AD - Sealy Center on Aging, Division of Epidemiology, Department of Medicine, The University of Texas Medical Branch, Galveston. FAU - Huo, Jinhai AU - Huo J AD - Department of Health Services Research, Management and Policy, University of Florida, Gainesville. FAU - Senagore, Anthony J AU - Senagore AJ AD - Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Orihuela, Eduardo AU - Orihuela E AD - Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Tyler, Douglas S AU - Tyler DS AD - Department of Surgery, The University of Texas Medical Branch, Galveston. FAU - Swanson, Todd A AU - Swanson TA AD - Department of Radiation Oncology, The University of Texas Medical Branch, Galveston. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - JAMA Surg JT - JAMA surgery JID - 101589553 SB - IM CIN - JAMA Surg. 2018 Oct 1;153(10):889-890. doi: 10.1001/jamasurg.2018.1674. PMID: 29955758 CIN - JAMA Surg. 2019 Feb 1;154(2):186. doi: 10.1001/jamasurg.2018.4372. PMID: 30476959 CIN - JAMA Surg. 2019 Feb 1;154(2):185-186. doi: 10.1001/jamasurg.2018.4371. PMID: 30477005 CIN - JAMA Surg. 2019 Feb 1;154(2):184-185. doi: 10.1001/jamasurg.2018.4370. PMID: 30477011 CIN - J Urol. 2019 May;201(5):837. doi: 10.1097/01.JU.0000553996.66966.57. PMID: 30747883 MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemoradiotherapy/methods MH - Combined Modality Therapy MH - Cystectomy/*methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Muscle Neoplasms/*pathology/therapy MH - Neoplasm Invasiveness MH - Retrospective Studies MH - SEER Program MH - Treatment Outcome MH - United States MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy PMC - PMC6584312 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2018/06/30 06:00 MHDA- 2019/10/08 06:00 PMCR- 2019/06/27 CRDT- 2018/06/30 06:00 PHST- 2018/06/30 06:00 [pubmed] PHST- 2019/10/08 06:00 [medline] PHST- 2018/06/30 06:00 [entrez] PHST- 2019/06/27 00:00 [pmc-release] AID - 2685879 [pii] AID - soi180031 [pii] AID - 10.1001/jamasurg.2018.1680 [doi] PST - ppublish SO - JAMA Surg. 2018 Oct 1;153(10):881-889. doi: 10.1001/jamasurg.2018.1680. PMID- 29954776 OWN - NLM STAT- MEDLINE DCOM- 20191108 LR - 20260127 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 24 IP - 17 DP - 2018 Sep 1 TI - STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. PG - 4145-4153 LID - 10.1158/1078-0432.CCR-17-3244 [doi] AB - Purpose: Most bladder cancers are early-stage tumors known as papillary non-muscle-invasive bladder cancer (NMIBC). After resection, up to 70% of NMIBCs recur locally, and up to 20% of these recurrences progress to muscle invasion. There is an unmet need for additional biomarkers for stratifying tumors based on their risk of recurrence and progression. We previously identified STAG2 as among the most commonly mutated genes in NMIBC and provided initial evidence in a pilot cohort that STAG2-mutant tumors recurred less frequently than STAG2 wild-type tumors. Here, we report a STAG2 biomarker validation study using two independent cohorts of clinically annotated papillary NMIBC tumors from the United States and Europe.Experimental Design: The value of STAG2 immunostaining for prediction of recurrence was initially evaluated in a cohort of 82 patients with papillary NMIBC ("Georgetown cohort"). Next, the value of STAG2 immunostaining for prediction of progression to muscle invasion was evaluated in a progressor-enriched cohort of 253 patients with papillary NMIBC ("Aarhus cohort").Results: In the Georgetown cohort, 52% of NMIBC tumors with intact STAG2 expression recurred, whereas 25% of STAG2-deficient tumors recurred (P = 0.02). Multivariable analysis identified intact STAG2 expression as an independent predictor of recurrence (HR = 2.4; P = 0.05). In the progressor-enriched Aarhus cohort, 38% of tumors with intact STAG2 expression progressed within 5 years, versus 16% of STAG2-deficient tumors (P < 0.01). Multivariable analysis identified intact STAG2 expression as an independent predictor of progression (HR = 1.86; P = 0.05).Conclusions: STAG2 IHC is a simple, binary, new assay for risk stratification in papillary NMIBC. Clin Cancer Res; 24(17); 4145-53. (c)2018 AACR. CI - (c)2018 American Association for Cancer Research. FAU - Lelo, Alana AU - Lelo A AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. AD - Tumor Biology Training Program, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. FAU - Prip, Frederik AU - Prip F AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Harris, Brent T AU - Harris BT AD - Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. AD - Histopathology and Tissue Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. FAU - Solomon, David AU - Solomon D AD - Department of Pathology, University of California San Francisco School of Medicine, San Francisco, California. FAU - Berry, Deborah L AU - Berry DL AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. AD - Histopathology and Tissue Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. FAU - Chaldekas, Krysta AU - Chaldekas K AD - Histopathology and Tissue Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. FAU - Kumar, Anagha AU - Kumar A AD - Department of Biostatistics, MedStar Health Research Institute, Washington, District of Columbia. FAU - Simko, Jeffry AU - Simko J AD - Department of Pathology, University of California San Francisco School of Medicine, San Francisco, California. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Bhattacharyya, Pritish AU - Bhattacharyya P AD - Department of Pathology, Hackensack University Medical Center, Hackensack, New Jersey. FAU - Mannion, Ciaran AU - Mannion C AD - Department of Pathology, Hackensack University Medical Center, Hackensack, New Jersey. FAU - Kim, Jung-Sik AU - Kim JS AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. FAU - Philips, George AU - Philips G AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. AD - MedStar Washington Hospital Center, Washington, District of Columbia. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Waldman, Todd AU - Waldman T AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia. waldmant@georgetown.edu. LA - eng GR - R01 CA169345/CA/NCI NIH HHS/United States GR - UL1 TR001409/TR/NCATS NIH HHS/United States GR - TL1 TR001431/TR/NCATS NIH HHS/United States GR - P30 CA051008/CA/NCI NIH HHS/United States GR - DP5 OD021403/OD/NIH HHS/United States GR - T32 CA009686/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180628 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Antigens, Nuclear) RN - 0 (Cell Cycle Proteins) RN - 0 (STAG2 protein, human) RN - 0 (Cohesins) SB - IM CIN - J Urol. 2020 Oct;204(4):877. doi: 10.1097/JU.0000000000001219.02. PMID: 32716235 MH - Aged MH - Antigens, Nuclear/*genetics MH - Cell Cycle Proteins MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Male MH - Middle Aged MH - Muscles/metabolism/pathology MH - Neoplasm Invasiveness/*genetics/pathology MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Neoplasm Staging MH - Urinary Bladder Neoplasms/*genetics/pathology MH - Cohesins PMC - PMC6125225 MID - NIHMS971927 COIS- Conflict of Interest: The authors declare no potential conflicts of interest. EDAT- 2018/06/30 06:00 MHDA- 2019/11/09 06:00 PMCR- 2019/09/01 CRDT- 2018/06/30 06:00 PHST- 2017/11/02 00:00 [received] PHST- 2018/04/27 00:00 [revised] PHST- 2018/05/23 00:00 [accepted] PHST- 2018/06/30 06:00 [pubmed] PHST- 2019/11/09 06:00 [medline] PHST- 2018/06/30 06:00 [entrez] PHST- 2019/09/01 00:00 [pmc-release] AID - 1078-0432.CCR-17-3244 [pii] AID - 10.1158/1078-0432.CCR-17-3244 [doi] PST - ppublish SO - Clin Cancer Res. 2018 Sep 1;24(17):4145-4153. doi: 10.1158/1078-0432.CCR-17-3244. Epub 2018 Jun 28. PMID- 29948423 OWN - NLM STAT- MEDLINE DCOM- 20190211 LR - 20190215 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 25 IP - 9 DP - 2018 Sep TI - Robotic-Assisted Surgery for Upper Tract Urothelial Carcinoma: A Comparative Survival Analysis. PG - 2550-2562 LID - 10.1245/s10434-018-6557-8 [doi] AB - BACKGROUND: We performed a comparative survival analysis of patients undergoing robotic-assisted versus laparoscopic or open surgery for upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: Patients diagnosed with non-metastatic UTUC undergoing removal of the kidney and/or ureter were identified using Medicare-linked Surveillance, Epidemiology, and End Results Program data (2004-2013). Patients aged 65-85 years were categorized based on surgical approach (open, laparoscopic, or robotic-assisted). Kaplan-Meier methods were used to determine survival (overall and cancer-specific) and intravesical recurrence rates, the former using a propensity score-weighted model. Independent predictors of survival were determined using multivariable Cox proportional hazards regression analysis. RESULTS: We identified a total of 3801 patients meeting the final inclusion criteria: open (n = 1862), laparoscopic (n = 1624), and robotic (n = 315). Robotic surgery was associated with the shortest length of hospital stay (p < 0.001) but highest in-hospital charges (p < 0.001), with no difference in readmission rates (p = 0.964). No difference was found in overall or cancer-specific survival in the robotic cohort when compared with open or laparoscopic surgery. In addition, no difference in the rate of intravesical recurrence was noted in robotic-assisted laparoscopy compared with the other groups. The sole predictor of improved survival was extent of lymphadenectomy, which was highest in the robotic cohort. CONCLUSIONS: Using a large, population-based cancer database, there was no survival difference when a robotic-assisted approach was utilized in patients undergoing surgery for UTUC. These findings are important with the increased use of robotic surgery in the management of UTUC. FAU - Clements, Matthew B AU - Clements MB AD - Department of Urology, University of Virginia, Charlottesville, VA, USA. FAU - Krupski, Tracey L AU - Krupski TL AD - Department of Urology, University of Virginia, Charlottesville, VA, USA. FAU - Culp, Stephen H AU - Culp SH AD - Department of Urology, University of Virginia, Charlottesville, VA, USA. Shc5e@virginia.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20180614 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2018 Sep;25(9):2496-2497. doi: 10.1245/s10434-018-6568-5. PMID: 29946998 MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/secondary/*surgery MH - Female MH - Hospital Charges MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/pathology/*surgery MH - *Laparoscopy/economics MH - Length of Stay MH - Lymphatic Metastasis MH - Male MH - Patient Readmission MH - Proportional Hazards Models MH - *Robotic Surgical Procedures/economics MH - SEER Program MH - Survival Rate MH - Ureteral Neoplasms/pathology/*surgery MH - Urinary Bladder Neoplasms/*secondary EDAT- 2018/06/28 06:00 MHDA- 2019/02/12 06:00 CRDT- 2018/06/28 06:00 PHST- 2017/12/03 00:00 [received] PHST- 2018/06/28 06:00 [pubmed] PHST- 2019/02/12 06:00 [medline] PHST- 2018/06/28 06:00 [entrez] AID - 10.1245/s10434-018-6557-8 [pii] AID - 10.1245/s10434-018-6557-8 [doi] PST - ppublish SO - Ann Surg Oncol. 2018 Sep;25(9):2550-2562. doi: 10.1245/s10434-018-6557-8. Epub 2018 Jun 14. PMID- 29931526 OWN - NLM STAT- MEDLINE DCOM- 20190503 LR - 20240405 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 36 IP - 12 DP - 2018 Dec TI - An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. PG - 1981-1995 LID - 10.1007/s00345-018-2380-x [doi] AB - OBJECTIVES: With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette-Guerin (BCG) therapy. METHODS AND MATERIALS: A medline/pubmed(c) literature search was performed. The performance of commercially available and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and response to BCG therapy. RESULTS: The performance requirements for biomarkers are variable according to the clinical scenario. The clinical role of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased drug development strategy. CONCLUSIONS: Current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be needed to establish their clinical relevance and value. FAU - Soria, Francesco AU - Soria F AUID- ORCID: 0000-0001-8443-8453 AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Droller, Michael J AU - Droller MJ AD - Department of Urology, The Mount Sinai Medical Center, New York, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Hopital Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris Sorbonne Universite, Paris, France. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA. shahrokh.shariat@meduniwien.ac.at. AD - Department of Urology, Weill Cornell Medical College, New York, USA. shahrokh.shariat@meduniwien.ac.at. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Review DEP - 20180621 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM CIN - World J Urol. 2019 Sep;37(9):1985-1986. doi: 10.1007/s00345-018-2611-1. PMID: 30600353 MH - Aftercare/*methods MH - BCG Vaccine/administration & dosage MH - Biomarkers, Tumor/*urine MH - Humans MH - Neoplasm Recurrence, Local/diagnosis/*urine MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/drug therapy/*urine PMC - PMC6280823 OTO - NOTNLM OT - Follow-up OT - Non-muscle invasive bladder cancer OT - Recurrence OT - Surveillance OT - Test OT - Urinary biomarker COIS- CONFLICT OF INTEREST: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is an advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Wolff. He is the speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff. ETHICAL STANDARDS: This study was conducted according to the Declaration of Helsinki. EDAT- 2018/06/23 06:00 MHDA- 2019/05/06 06:00 PMCR- 2018/06/21 CRDT- 2018/06/23 06:00 PHST- 2018/04/11 00:00 [received] PHST- 2018/06/15 00:00 [accepted] PHST- 2018/06/23 06:00 [pubmed] PHST- 2019/05/06 06:00 [medline] PHST- 2018/06/23 06:00 [entrez] PHST- 2018/06/21 00:00 [pmc-release] AID - 10.1007/s00345-018-2380-x [pii] AID - 2380 [pii] AID - 10.1007/s00345-018-2380-x [doi] PST - ppublish SO - World J Urol. 2018 Dec;36(12):1981-1995. doi: 10.1007/s00345-018-2380-x. Epub 2018 Jun 21. PMID- 29912804 OWN - NLM STAT- MEDLINE DCOM- 20191121 LR - 20200306 IS - 1537-453X (Electronic) IS - 0277-3732 (Print) IS - 0277-3732 (Linking) VI - 42 IP - 1 DP - 2019 Jan TI - Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. PG - 36-41 LID - 10.1097/COC.0000000000000471 [doi] AB - PURPOSE: Radical cystectomy currently remains the standard of care for muscle-invasive bladder cancer. However, surgery can be associated with considerable morbidity and mortality, including the removal of the bladder. An alternative strategy is to preserve the bladder through concurrent chemoradiation following a maximal transurethral resection of the tumor. National protocols using a bladder-preservation approach have demonstrated disease-specific outcomes comparable to radical cystectomy in selected patients, but these results have not been replicated in previously reported population-based series. Here, we describe an outcomes analysis of patients with muscle-invasive bladder cancer treated with either radical surgery or bladder-preserving chemoradiation (BPCRT) for those patients meeting BPCRT criterion using the National Cancer Database (NCDB). MATERIALS AND METHODS: Using the NCDB, patients with American Joint Commission on Cancer clinical T2-3, N0, M0 urothelial carcinoma diagnosed between 2004 and 2013 were included for analysis. Only patients treated with definitive intent with either radical cystectomy or concurrent chemotherapy and radiation after a maximal transurethral tumor resection were included. Propensity-score matching was used. RESULTS: Among 8454 eligible patients, 7276 (86%) underwent radical cystectomy, and 1178 (14%) underwent BPCRT. Patients undergoing BPCRT were significantly older (median age, 77 vs. 68 y; P<0.001) and had higher Charlson-Deyo comorbidity scores (P=0.002). Using propensity-matched analysis, 1002 patients remained in each cohort, and there was no significant difference in survival found between the 2 cohorts (median overall survival, 2.7 vs. 3.0 y [P=0.20]; 4-year overall survival, 39.1% and 42.6% [P=0.15], for BPCRT and surgery, respectively). In addition, the hazard ratio (HR) of surgery versus BPCRT decreased over time, with an initial HR of 1.27 favoring BPCRT which decreased by a factor of 0.85 per year. CONCLUSIONS: From 2004 to 2013, approximately 14% of patients from the NCDB who potentially met bladder-preservation criteria underwent the procedure. Our propensity-matched analysis is the only report of its kind to demonstrate similar survival outcomes with bladder preservation when patients are properly selected. This study is also the first to demonstrate a dynamic HR between radical surgery and BPCRT over time. FAU - Zhong, Jim AU - Zhong J AD - Departments of Radiation Oncology. AD - Winship Cancer Institute, Emory University, Atlanta. FAU - Switchenko, Jeffrey AU - Switchenko J AD - Winship Cancer Institute, Emory University, Atlanta. AD - Biostatistics & Bioinformatics. FAU - Jegadeesh, Naresh K AU - Jegadeesh NK AD - Departments of Radiation Oncology. AD - Winship Cancer Institute, Emory University, Atlanta. FAU - Cassidy, Richard J AU - Cassidy RJ AD - Departments of Radiation Oncology. AD - Winship Cancer Institute, Emory University, Atlanta. FAU - Gillespie, Theresa W AU - Gillespie TW AD - Winship Cancer Institute, Emory University, Atlanta. AD - Surgery. FAU - Master, Viraj AU - Master V AD - Winship Cancer Institute, Emory University, Atlanta. AD - Departments of Urology. FAU - Nieh, Peter AU - Nieh P AD - Winship Cancer Institute, Emory University, Atlanta. AD - Departments of Urology. FAU - Alemozaffar, Mehrdad AU - Alemozaffar M AD - Winship Cancer Institute, Emory University, Atlanta. AD - Departments of Urology. FAU - Kucuk, Omer AU - Kucuk O AD - Winship Cancer Institute, Emory University, Atlanta. AD - Hematology and Oncology. FAU - Carthon, Bradley AU - Carthon B AD - Winship Cancer Institute, Emory University, Atlanta. AD - Hematology and Oncology. FAU - Filson, Christopher P AU - Filson CP AD - Winship Cancer Institute, Emory University, Atlanta. AD - Departments of Urology. AD - Atlanta Veterans Affairs Medical Center, Decatur, GA. FAU - Bilen, Mehmet A AU - Bilen MA AD - Winship Cancer Institute, Emory University, Atlanta. AD - Hematology and Oncology. FAU - Jani, Ashesh B AU - Jani AB AD - Departments of Radiation Oncology. AD - Winship Cancer Institute, Emory University, Atlanta. LA - eng GR - P30 CA138292/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Aged MH - Chemoradiotherapy/*methods MH - Comorbidity MH - Cystectomy MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Organ Sparing Treatments MH - Treatment Outcome MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery/therapy PMC - PMC6295350 MID - NIHMS968680 COIS- Conflicts of Interest: None EDAT- 2018/06/19 06:00 MHDA- 2019/11/22 06:00 PMCR- 2020/01/01 CRDT- 2018/06/19 06:00 PHST- 2018/06/19 06:00 [pubmed] PHST- 2019/11/22 06:00 [medline] PHST- 2018/06/19 06:00 [entrez] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.1097/COC.0000000000000471 [doi] PST - ppublish SO - Am J Clin Oncol. 2019 Jan;42(1):36-41. doi: 10.1097/COC.0000000000000471. PMID- 29907864 OWN - NLM STAT- MEDLINE DCOM- 20191011 LR - 20220408 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 8 IP - 1 DP - 2018 Jun 15 TI - Bladder cancer recurrence surveillance by urine metabolomics analysis. PG - 9172 LID - 10.1038/s41598-018-27538-3 [doi] LID - 9172 AB - Non Muscle Invasive Bladder Cancer (NMIBC) is among the most frequent malignant cancers worldwide. NMIBC is treated by transurethral resection of the bladder tumor (TURBT) and intravesical therapies, and has the highest recurrence rate among solid tumors. It requires a lifelong patient monitoring based on repeated cystoscopy and urinary cytology, both having drawbacks that include lack of sensitivity and specificity, invasiveness and care costs. We conducted an investigative clinical study to examine changes in the urinary metabolome of NMBIC patients before and after TURBT, as well during the subsequent surveillance period. Adjusting by prior probability of recurrence per risk, discriminant analysis of UPLC-MS metabolic profiles, displayed negative predictive values for low, low-intermediate, high-intermediate and high risk patient groups of 96.5%, 94.0%, 92.9% and 76.1% respectively. Detailed analysis of the metabolome revealed several candidate metabolites and perturbed phenylalanine, arginine, proline and tryptophan metabolisms as putative biomarkers. A pilot retrospective analysis of longitudinal trajectories of a BC metabolic biomarkers during post TURBT surveillance was carried out and the results give strong support for the clinical use of metabolomic profiling in assessing NMIBC recurrence. FAU - Loras, A AU - Loras A AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia - IIS Hospital La Fe, Valencia, Spain. FAU - Trassierra, M AU - Trassierra M AD - Servicio de Urologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Sanjuan-Herraez, D AU - Sanjuan-Herraez D AD - Health & Biomedicine, Leitat Technological Center, Barcelona, Spain. FAU - Martinez-Bisbal, M C AU - Martinez-Bisbal MC AUID- ORCID: 0000-0002-8526-4413 AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia - IIS Hospital La Fe, Valencia, Spain. AD - Instituto Interuniversitario de Investigacion de Reconocimiento Molecular y Desarrollo Tecnologico, Universitat Politecnica de Valencia, Universitat de Valencia, Valencia, Spain. FAU - Castell, J V AU - Castell JV AD - Departamento de Bioquimica y Biologia Molecular, Universidad de Valencia, Valencia, Spain. AD - Unidad de Hepatologia Experimental, CIBERehd, IIS Hospital La Fe, Valencia, Spain. FAU - Quintas, G AU - Quintas G AD - Health & Biomedicine, Leitat Technological Center, Barcelona, Spain. gquintas@leitat.org. AD - Analytical Unit, IIS Hospital La Fe, Valencia, Spain. gquintas@leitat.org. FAU - Ruiz-Cerda, J L AU - Ruiz-Cerda JL AD - Unidad Mixta de Investigacion en Nanomedicina y Sensores, Universitat Politecnica de Valencia - IIS Hospital La Fe, Valencia, Spain. AD - Servicio de Urologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20180615 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Female MH - Humans MH - Male MH - *Metabolome MH - *Metabolomics MH - Middle Aged MH - *Urinary Bladder Neoplasms/diagnosis/urine PMC - PMC6004013 COIS- The authors declare no competing interests. EDAT- 2018/06/17 06:00 MHDA- 2019/10/12 06:00 PMCR- 2018/06/15 CRDT- 2018/06/17 06:00 PHST- 2018/01/29 00:00 [received] PHST- 2018/05/31 00:00 [accepted] PHST- 2018/06/17 06:00 [entrez] PHST- 2018/06/17 06:00 [pubmed] PHST- 2019/10/12 06:00 [medline] PHST- 2018/06/15 00:00 [pmc-release] AID - 10.1038/s41598-018-27538-3 [pii] AID - 27538 [pii] AID - 10.1038/s41598-018-27538-3 [doi] PST - epublish SO - Sci Rep. 2018 Jun 15;8(1):9172. doi: 10.1038/s41598-018-27538-3. PMID- 29905887 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20200225 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 37 IP - 1 DP - 2019 Jan TI - Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer. PG - 155-163 LID - 10.1007/s00345-018-2375-7 [doi] AB - PURPOSE: To analyse if BCG treatment leads to long-term reduction of recurrence, progression, and cancer-specific mortality (CSM) in patients with high-risk NMIBC. MATERIALS AND METHODS: 140 patients with high-risk NMIBC were drawn from a population-based cohort of 538 patients with newly diagnosed bladder cancer in the Stockholm County between 1995 and 1996. Data were collected prospectively, and a final follow-up for recurrence, progression, and CSM was performed after 15 years. Patients that received BCG were compared with patients who did not receive BCG. Survival analysis was done with Kaplan-Meier estimates and Mantel-Cox log-rank test. Multivariable Cox proportional regression with stepwise selection was performed to verify the statistical significance of clinicopathological factors of prognostic importance. Results were displayed in Hazard ratios and a p < 0.05 was considered to be statistically significant. RESULTS: With a median follow-up of 100 months (2-182), 76 patients recurred; 50 progressed to muscle invasion; and 92 died of whom 38 died from bladder cancer. After 15-year follow-up, there was a statistically significant reduction in rate for recurrence (HR 0.40, p < 0.0001) and progression (HR 0.52, p = 0.038), but not for CSM, in patients that received BCG compared to those who did not. CONCLUSIONS: In this group, BCG in high-risk NMIBC patients reduced the long-term risk of recurrence and progression. The effect on CSM is yet to be clarified. FAU - Thiel, Tomas AU - Thiel T AUID- ORCID: 0000-0001-8182-3129 AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. tomas.thiel@ki.se. AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. tomas.thiel@ki.se. AD - , Norra Kungsvagen 11b, 18131, Lidingo, Sweden. tomas.thiel@ki.se. FAU - Ryk, Charlotta AU - Ryk C AD - Department of Clintec, Karolinska Institutet, Stockholm, Sweden. FAU - Renstrom-Koskela, Lotta AU - Renstrom-Koskela L AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Steineck, Gunnar AU - Steineck G AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. FAU - Schumacher, Martin C AU - Schumacher MC AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - Wiklund, N Peter AU - Wiklund NP AD - Department of Urology, Karolinska University Hospital, Stockholm, Sweden. AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. FAU - de Verdier, Petra J AU - de Verdier PJ AD - Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, 141 86, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20180615 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S720-S722. doi: 10.21037/tau.2018.10.03. PMID: 30687606 MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/mortality/pathology MH - Cause of Death MH - Cystoscopy MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Multivariate Analysis MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasm Staging MH - Proportional Hazards Models MH - Retrospective Studies MH - Survival Analysis MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology PMC - PMC6510863 OTO - NOTNLM OT - BCG OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence OT - Survival COIS- CONFLICT OF INTEREST: There were no potential conflicts of interests among the authors of this article. HUMAN PARTICIPANTS: Research involving human participants was supervised and approved by the Regional Ethics board of the Stockholm County. INFORMED CONSENT: All the participants in this study gave informed consent. EDAT- 2018/06/16 06:00 MHDA- 2019/05/23 06:00 PMCR- 2018/06/15 CRDT- 2018/06/16 06:00 PHST- 2018/02/21 00:00 [received] PHST- 2018/06/09 00:00 [accepted] PHST- 2018/06/16 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] PHST- 2018/06/16 06:00 [entrez] PHST- 2018/06/15 00:00 [pmc-release] AID - 10.1007/s00345-018-2375-7 [pii] AID - 2375 [pii] AID - 10.1007/s00345-018-2375-7 [doi] PST - ppublish SO - World J Urol. 2019 Jan;37(1):155-163. doi: 10.1007/s00345-018-2375-7. Epub 2018 Jun 15. PMID- 29887693 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 0975-7651 (Print) IS - 0976-6952 (Electronic) IS - 0975-7651 (Linking) VI - 9 IP - 2 DP - 2018 Jun TI - Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression. PG - 157-161 LID - 10.1007/s13193-018-0728-8 [doi] AB - Nearly half of newly diagnosed cases of bladder cancer are low grade, noninvasive, and papillary tumors. The standard treatment for non-muscle-invasive bladder cancer (NMIBC) has been transurethral resection of the bladder tumor (TUR-BT) with or without adjuvant intravesical instillation (IVI) of chemotherapy or Bacillus Calmette-Guerin (BCG) therapy. NMIBC is known to be associated with high rates of recurrence and risk of progression. In this study, we have retrospectively analyzed the clinical outcome of initially diagnosed multiple low-grade Ta tumors, with a special focus on tumor recurrence and worsening progression (WP) pattern. We retrospectively reviewed 42 patients with primary, multiple, low-grade Ta bladder cancer. We defined WP as confirmed high-grade Ta, all T1 or Tis/concomitant CIS of bladder recurrence, upper urinary tract recurrence (UTR), or progression to equal to or more than T2. The associations between clinico-pathological factors and tumor recurrence as well as WP pattern were analyzed. Tumor recurrence and WP occurred in 23 (54.76%) and 8 (19.04%) patients during follow-up (median follow-up: 57.38 months), respectively. WP to high grade/stage was seen in 8 patients. Multivariate analysis demonstrated that use of tobacco (p < 0.0001) and absence of IVI (p < 0.0001) were significant risk factors for tumor recurrence. The 5-year recurrence-free survival rate for non-tobacco users (74.0%) was significantly higher than that for tobacco users (42.5%, p = 0.0001), and also higher for patients receiving intravesical instillation (84.2 vs. 30.0% without IVI, p = 0.0001). Recurrence is common in patients with low-grade, Ta bladder cancer, especially in the setting of multiplicity. Recurrences occurred in 54.76% of patients and WP occurred in 19.04% of patients. Use of tobacco and non-use of IVI were strongly associated with high recurrence rate. FAU - Nerli, R B AU - Nerli RB AD - Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Belagavi, India. AD - KLES Kidney Foundation, KLES Dr. Prabhakar Kore Hospital & MRC, Belagavi, India. FAU - Ghagane, Shridhar C AU - Ghagane SC AD - Department of Urology, KLES Kidney Foundation, KLES Dr. Prabhakar Kore Hospital & MRC, Belagavi, India. FAU - Shankar, K AU - Shankar K AD - Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Belagavi, India. FAU - Sanikop, Adarsh C AU - Sanikop AC AD - Department of Pathology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Belagavi, India. FAU - Hiremath, Murigendra B AU - Hiremath MB AD - 5Department of Biotechnology and Microbiology, Karnatak University, Dharwad, India. GRID: grid.444416.7 FAU - Dixit, Neeraj S AU - Dixit NS AD - Department of Urology, KLES Kidney Foundation, KLES Dr. Prabhakar Kore Hospital & MRC, Belagavi, India. FAU - Magadum, Laxman AU - Magadum L AD - Department of Urology, KLES Kidney Foundation, KLES Dr. Prabhakar Kore Hospital & MRC, Belagavi, India. LA - eng PT - Journal Article DEP - 20180129 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC5984851 OTO - NOTNLM OT - Bladder cancer OT - Intravesical instillation OT - Low grade OT - Multiple OT - Progression OT - Recurrence EDAT- 2018/06/12 06:00 MHDA- 2018/06/12 06:01 PMCR- 2019/06/01 CRDT- 2018/06/12 06:00 PHST- 2017/05/22 00:00 [received] PHST- 2018/01/18 00:00 [accepted] PHST- 2018/06/12 06:00 [entrez] PHST- 2018/06/12 06:00 [pubmed] PHST- 2018/06/12 06:01 [medline] PHST- 2019/06/01 00:00 [pmc-release] AID - 728 [pii] AID - 10.1007/s13193-018-0728-8 [doi] PST - ppublish SO - Indian J Surg Oncol. 2018 Jun;9(2):157-161. doi: 10.1007/s13193-018-0728-8. Epub 2018 Jan 29. PMID- 29884516 OWN - NLM STAT- MEDLINE DCOM- 20190701 LR - 20190701 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 5 DP - 2018 Oct TI - Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors. PG - e985-e992 LID - S1558-7673(18)30196-4 [pii] LID - 10.1016/j.clgc.2018.05.002 [doi] AB - BACKGROUND: Histologic grade is an important prognosticator in patients with non-muscle-invasive bladder cancer (NMIBC). Currently, 2 classifications for grade are widely used; the World Health Organization (WHO) 1973 and the WHO 2004. We compare inter-observer variability of both classifications and investigate which histologic criteria cause this variability. Furthermore, the prognostic value of both classifications was assessed. PATIENTS AND METHODS: Three pathologists reviewed 328 bladder tissue samples of 232 patients with NMIBC in a blinded manner. WHO 1973 grade, WHO 2004 grade, histologic criteria of both classifications, and T-category were evaluated. Reproducibility was analyzed using the weighted Fleiss kappa, association between criteria scores and grade with the chi(2) test, and time-to-recurrence and time-to-progression with the log-rank test and Cox regression. RESULTS: Reproducibility of both classifications was poor. The WHO 2004 showed better reproducibility (kappa = 0.35; 95% confidence interval (CI), 0.29-0.42) compared with the WHO 1973 as a 3-tiered (kappa = 0.24; 95% CI, 0.19-0.28), but not as a 2-tiered (G1 + G2 vs. G3) classification (kappa = 0.36; 95% CI, 0.29-0.42). Reproducibility of individual criteria was poor (kappa range, -0.05 to 0.25). All criteria were associated with grade (P < .05). After a median follow-up of 60 months, 33 of 232 and 112 of 232 patients developed progression and recurrence, respectively. In 1 out of the 3 pathologists, progression was predicted by both the WHO 1973 grade and the WHO 2004 grade in multivariable analysis. Recurrence was not predicted by grade (multivariable). CONCLUSIONS: Reproducibility of the WHO 2004 and WHO 1973 classification for grade are poor. Scoring of individual criteria is poorly reproducible, suggesting that descriptions of these criteria for grade are not specific. The prognostic value of both the WHO 1973 and the WHO 2004 differ per pathologist. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU University Medical Center, Amsterdam, the Netherlands. Electronic address: j.bosschieter@vumc.nl. FAU - Hentschel, Anouk AU - Hentschel A AD - Department of Urology, VU University Medical Center, Amsterdam, the Netherlands. FAU - Savci-Heijink, C Dilara AU - Savci-Heijink CD AD - Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands. FAU - Patrick van der Voorn, J AU - Patrick van der Voorn J AD - Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands. FAU - Rozendaal, Lawrence AU - Rozendaal L AD - Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU University Medical Center, Amsterdam, the Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - Lissenberg-Witte, Birgit I AU - Lissenberg-Witte BI AD - Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands. FAU - Fransen van de Putte, Elisabeth E AU - Fransen van de Putte EE AD - Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, VU University Medical Center, Amsterdam, the Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU University Medical Center, Amsterdam, the Netherlands. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20180511 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Cystoscopy MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading/*classification MH - Observer Variation MH - Prognosis MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/*pathology MH - World Health Organization OTO - NOTNLM OT - Inter-observer variability OT - Neoplasm grading OT - Observer variation OT - Prognosticator OT - Urinary bladder neoplasm EDAT- 2018/06/10 06:00 MHDA- 2019/07/02 06:00 CRDT- 2018/06/10 06:00 PHST- 2018/03/16 00:00 [received] PHST- 2018/05/05 00:00 [revised] PHST- 2018/05/05 00:00 [accepted] PHST- 2018/06/10 06:00 [pubmed] PHST- 2019/07/02 06:00 [medline] PHST- 2018/06/10 06:00 [entrez] AID - S1558-7673(18)30196-4 [pii] AID - 10.1016/j.clgc.2018.05.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Oct;16(5):e985-e992. doi: 10.1016/j.clgc.2018.05.002. Epub 2018 May 11. PMID- 29884342 OWN - NLM STAT- MEDLINE DCOM- 20181105 LR - 20250623 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 9 DP - 2018 Sep TI - Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. PG - 389-399 LID - S1078-1439(18)30166-2 [pii] LID - 10.1016/j.urolonc.2018.05.014 [doi] AB - OBJECTIVE: The aim of this study was to summarize and analyze the current evidence regarding the prognostic and predictive value of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients undergoing transurethral resection of bladder tumors (TURBT) for non-muscle-invasive bladder cancer (NMIBC). MATERIAL AND METHODS: A systematic search of Web of Science, Medline/PubMed, Google Scholar, and Cochrane library was performed on the 1(st) of March, 2018. Studies were deemed eligible if they compared NMIBC patients with high vs. low NLR before TURBT to determine its value for prognosticating disease recurrence and progression using multivariable analysis. We performed a formal meta-analysis for both recurrence-free (RFS) and progression-free survival (PFS). RESULTS: Six studies encompassing 2,298 patients (477 [20.7%] females) assessed the prognostic value of NLR in NMIBC patients treated with TURBT. NLR predicted worse RFS (pooled HR = 1.78; 95% CI: 1.32-2.4, P<0.001) and PFS (pooled HR = 2.14; 95% CI: 1.59-2.87, P<0.001). In 4 studies encompassing 599 patients, high pretreatment NLR was associated with decreased RFS (pooled HR = 2.31; 95% CI: 1.27-4.22, P = 0.006) and in 3 of them high pretreatment NLR was associated with decreased PFS (pooled HR = 2.54; 95% CI: 1.36-4.71, P = 0.003) in high-risk NMIBC patients treated with BCG. CONCLUSION: In this meta-analysis, peripheral blood levels of NLR were associated with an increased risk of disease recurrence and progression in patients who underwent TURBT for NMIBC. Furthermore, NLR was an independent predictor of disease recurrence and progression in NMIBC treated with BCG patients. NLR could be used to improve clinical decision-making regarding treatment and follow-up scheduling. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Porav-Hodade, Daniel AU - Porav-Hodade D AD - Department of Urology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology,University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20180606 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Female MH - Humans MH - Lymphocytes/*metabolism MH - Male MH - Middle Aged MH - Neutrophils/*metabolism MH - Prognosis MH - Urinary Bladder Neoplasms/*blood/pathology OTO - NOTNLM OT - Biomarker OT - Neutrophil-to-lymphocyte ratio OT - Non-muscle invasive bladder cancer OT - Progression OT - Recurrence EDAT- 2018/06/10 06:00 MHDA- 2018/11/06 06:00 CRDT- 2018/06/10 06:00 PHST- 2018/04/10 00:00 [received] PHST- 2018/05/11 00:00 [revised] PHST- 2018/05/12 00:00 [accepted] PHST- 2018/06/10 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2018/06/10 06:00 [entrez] AID - S1078-1439(18)30166-2 [pii] AID - 10.1016/j.urolonc.2018.05.014 [doi] PST - ppublish SO - Urol Oncol. 2018 Sep;36(9):389-399. doi: 10.1016/j.urolonc.2018.05.014. Epub 2018 Jun 6. PMID- 29883941 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 105 DP - 2018 Sep TI - Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer. PG - 461-469 LID - S0753-3322(18)32433-8 [pii] LID - 10.1016/j.biopha.2018.05.122 [doi] AB - BACKGROUND: Bladder cancer, the ninth-most-common malignancy worldwide with an estimated 356,000 new cases and 145,000 deaths annually, has a propensity to relapse, requiring lifelong monitoring after diagnosis. 75% patients diagnosed with BC are non-muscle invasive BC and over 50% of them experience recurrences within 6-12 years of initial diagnosis. miRNA are small, noncoding RNA and shown to be oncogenes or anti-oncogenes in bladder cancer, contributing to numerous BC cell processes, including cell proliferation, differentiation, migration and apoptosis. METHODS: RT-qPCR were performed to detect the expression of miR-187-5p in tissues and cell lines, After which, clinicopathological variables and the prognostic value of altered miR-187-5p expression in BC was analyzed with the 48 formalin-fixed paraffin-embedded BC samples. Moreover, Cell functional assays (wound healing assay, CCK-8 assay, transwell assay and flow cytometry assay) were performed to explore the relationship between miR-187-5p expression and cell proliferation, migration, invasion and apoptosis in BC. RESULTS: Up-regulation of miR-187-5p was observed in BC tissues and BC cell lines. Cox proportional hazard regression analysis demonstrated that the patients with low expression of miR-187-5p experience lower risks of recurrence in the univariate and multivariate analysis. The Kaplan-Meier recurrence-free curves suggested that the patients with low expression of miR-187-5p experience lower risks of recurrence. Up-regulation of miR-187-5p promotes cell proliferation and mobility and inhibits the apoptosis of 5637 and UM-UC-3 cell, while down-regulation of miR-187-5p reverses these effects. CONCLUSIONS: The results of our study demonstrated that oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer. CI - Copyright (c) 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Li, Zuwei AU - Li Z AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Shantou University Medical College, Shantou, Guangdong 515041, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Lin, Canbin AU - Lin C AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Shantou University Medical College, Shantou, Guangdong 515041, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Zhao, Liwen AU - Zhao L AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Zhou, Liang AU - Zhou L AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Pan, Xiang AU - Pan X AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Quan, Jing AU - Quan J AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Peng, Xiqi AU - Peng X AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Shantou University Medical College, Shantou, Guangdong 515041, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Li, Weiqing AU - Li W AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Shantou University Medical College, Shantou, Guangdong 515041, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Li, Hang AU - Li H AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China. FAU - Xu, Jinling AU - Xu J AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Xu, Weijie AU - Xu W AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Guan, Xin AU - Guan X AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. FAU - Chen, Yun AU - Chen Y AD - Department of Ultrasound, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China. Electronic address: cyun126@126.com. FAU - Lai, Yongqing AU - Lai Y AD - Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China. Electronic address: yqlord@163.com. LA - eng PT - Journal Article DEP - 20180605 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (MIRN187 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Aged, 80 and over MH - Apoptosis/*genetics MH - Cell Line, Tumor MH - Cell Movement/*genetics MH - Cell Proliferation/genetics MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - MicroRNAs/genetics/*metabolism MH - Middle Aged MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Proportional Hazards Models MH - Reproducibility of Results MH - Risk Factors MH - Transfection MH - Up-Regulation/genetics MH - Urinary Bladder Neoplasms/*genetics/*pathology MH - Wound Healing OTO - NOTNLM OT - Bladder cancer OT - Key words OT - Recurrence OT - Urothelial carcinoma OT - miR-187-5p OT - microRNAs EDAT- 2018/06/09 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/06/09 06:00 PHST- 2018/04/11 00:00 [received] PHST- 2018/05/21 00:00 [revised] PHST- 2018/05/23 00:00 [accepted] PHST- 2018/06/09 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/06/09 06:00 [entrez] AID - S0753-3322(18)32433-8 [pii] AID - 10.1016/j.biopha.2018.05.122 [doi] PST - ppublish SO - Biomed Pharmacother. 2018 Sep;105:461-469. doi: 10.1016/j.biopha.2018.05.122. Epub 2018 Jun 5. PMID- 29882105 OWN - NLM STAT- MEDLINE DCOM- 20190607 LR - 20200306 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 37 IP - 1 DP - 2019 Jan TI - Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. PG - 165-172 LID - 10.1007/s00345-018-2361-0 [doi] AB - BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the detection of carcinoma in situ (CIS) at the time of initial transurethral resection of bladder tumor (TURBT) has an oncological impact on the response to NAC prior to radical cystectomy. PATIENTS AND METHODS: Patients were identified retrospectively from 19 centers who received at least three cycles of NAC or induction chemotherapy for cT2-T4aN0-3M0 urothelial carcinoma of the bladder followed by radical cystectomy between 2000 and 2013. The primary and secondary outcomes were pathological response and overall survival, respectively. Multivariable analysis was performed to determine the independent predictive value of CIS on these outcomes. RESULTS: Of 1213 patients included in the analysis, 21.8% had concomitant CIS. Baseline clinical and pathologic characteristics of the 'CIS' versus 'no-CIS' groups were similar. The pathological response did not differ between the two arms when response was defined as pT0N0 (17.9% with CIS vs 21.9% without CIS; p = 0.16) which may indicate that patients with CIS may be less sensitive to NAC or /= 0.5mm), and according to invasion of the muscularis mucosae (MM) (T1a-invasion above or into MM/T1b). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable analyses for progression-free (PFS) and cancer-specific survival (CSS) were performed including substage, size, multiplicity, carcinoma in situ, sex, age, WHO-grade 1973, and WHO-grade 2004 as variables. RESULTS: Median follow-up was 5.9 years (interquartile range: 3.3-9.0). Progression to T2BC was observed in 148 (25%) patients and 94 (16%) died of BC. The MM was not present at the invasion front in 135 (22%) of tumors. Slides were substaged as follows: 213 T1m and 388 T1e and 281 T1a and 320 T1b. On multivariable analysis, T1m/e substage and WHO 1973 grade were the strongest prognosticators for PFS (hazard ratio [HR] = 3.8 and HR = 1.8) and CSS (HR = 2.7 and HR = 2.6), respectively. Other prognostic factors for CSS were age (HR = 1.03), and tumor size (HR = 1.8). Substage according to MM-invasion was not significant. Our study was limited by its retrospective design and that standard re-TUR was not performed if TUR was macroscopically complete and muscularis propria was present in resected specimens. CONCLUSIONS: Metric substaging of T1BC was possible in all cases of 601 T1BC patients and it was a strong independent prognosticator of both PFS and CSS. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Fransen van de Putte, Elisabeth E AU - Fransen van de Putte EE AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - Bertz, Simone AU - Bertz S AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Manach, Quentin AU - Manach Q AD - Academic Department of Urology, Pitie-Salpetriere Hospital, Assistance-Publique Hopitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Hopital Tenon, HUEP, UPMC Paris VI, Paris, France. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - Jewett, Michael A S AU - Jewett MAS AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - Stoehr, Robert AU - Stoehr R AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - van Leenders, Geert J L H AU - van Leenders GJLH AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada; Department of Urology, Mount Sinai Hospital, University of Toronto, Toronto, Canada. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Academic Department of Urology, Pitie-Salpetriere Hospital, Assistance-Publique Hopitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; Department of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; Department of Urology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Electronic address: basvanrhijn@hotmail.com. LA - eng PT - Journal Article DEP - 20180605 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Mucous Membrane/*physiopathology MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/*physiopathology OTO - NOTNLM OT - Bladder cancer OT - Grade OT - Prognosis OT - Stage OT - T1 OT - Urothelial, Substage OT - WHO EDAT- 2018/06/09 06:00 MHDA- 2018/10/26 06:00 CRDT- 2018/06/09 06:00 PHST- 2018/03/03 00:00 [received] PHST- 2018/05/05 00:00 [revised] PHST- 2018/05/08 00:00 [accepted] PHST- 2018/06/09 06:00 [pubmed] PHST- 2018/10/26 06:00 [medline] PHST- 2018/06/09 06:00 [entrez] AID - S1078-1439(18)30159-5 [pii] AID - 10.1016/j.urolonc.2018.05.007 [doi] PST - ppublish SO - Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5. PMID- 29879397 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20220716 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 200 IP - 5 DP - 2018 Nov TI - Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. PG - 996-1004 LID - S0022-5347(18)43313-7 [pii] LID - 10.1016/j.juro.2018.06.001 [doi] AB - PURPOSE: We investigated the characteristics and outcomes of patients with muscle invasive bladder cancer treated with transurethral resection plus chemotherapy alone in a large observational cohort reflecting the continuum of practice settings in the United States. MATERIALS AND METHODS: In the National Cancer Database from 2004 to 2015 we identified 1,538 patients treated with transurethral resection plus multi-agent chemotherapy as definitive treatment of cT2-T4aN0M0 urothelial carcinoma of the bladder. For comparison purposes we included in study 17,866 patients treated with radical cystectomy with or without perioperative chemotherapy. Baseline characteristics were compared between the 2 groups by multivariable logistic regression. Treatment outcomes were assessed using Kaplan-Meier analysis and a Cox regression model. RESULTS: On multivariate analysis several variables, including patient demography (older age, African American race, prior malignancy and lack of insurance), tumor characteristics (higher cT stage) and facility type (nonacademic facilities and lower radical cystectomy volume) were associated with a higher probability of transurethral resection plus chemotherapy for muscle invasive bladder cancer compared to the standard of care. Two and 5-year survival rates in all patients treated with transurethral resection plus chemotherapy were 49.0% and 32.9%, and in patients with cT2 disease the rates were 52.6% and 36.2%, respectively. CONCLUSIONS: This large population level cohort of unselected patients shows that long-term survival can be achieved in a subset of patients treated with transurethral resection plus chemotherapy alone for muscle invasive bladder cancer. However, the best candidates for this approach remain to be defined. Ongoing clinical trials are now being launched to evaluate the ability of biomarkers to accurately select patients who could be treated with this bladder sparing strategy. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Audenet, Francois AU - Audenet F AD - Department of Urology, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Waingankar, Nikhil AU - Waingankar N AD - Department of Urology, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Ferket, Bart S AU - Ferket BS AD - Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Niglio, Scot A AU - Niglio SA AD - Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Marqueen, Kathryn E AU - Marqueen KE AD - Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Galsky, Matthew D AU - Galsky MD AD - Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: matthew.galsky@mssm.edu. LA - eng PT - Journal Article PT - Observational Study DEP - 20180604 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Nov;200(5):1003-1004. doi: 10.1016/j.juro.2018.06.072. PMID: 30030970 CIN - J Urol. 2018 Nov;200(5):1003. doi: 10.1016/j.juro.2018.06.071. PMID: 30030973 CIN - J Urol. 2018 Nov;200(5):1004. doi: 10.1016/j.juro.2018.06.073. PMID: 30030974 CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S723-S726. doi: 10.21037/tau.2018.10.01. PMID: 30687607 MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma, Transitional Cell/mortality/*pathology/*therapy MH - Chemotherapy, Adjuvant MH - Cohort Studies MH - Cystectomy/*methods MH - Databases, Factual MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Minimally Invasive Surgical Procedures/methods MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - cystectomy OT - drug therapy OT - neoplasm invasiveness OT - organ preservation OT - urinary bladder neoplasms EDAT- 2018/06/08 06:00 MHDA- 2019/05/29 06:00 CRDT- 2018/06/08 06:00 PHST- 2018/05/28 00:00 [accepted] PHST- 2018/06/08 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] PHST- 2018/06/08 06:00 [entrez] AID - S0022-5347(18)43313-7 [pii] AID - 10.1016/j.juro.2018.06.001 [doi] PST - ppublish SO - J Urol. 2018 Nov;200(5):996-1004. doi: 10.1016/j.juro.2018.06.001. Epub 2018 Jun 4. PMID- 29872646 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 10 DP - 2018 TI - High frequency of bladder cancer after nephroureterectomy: justification for adjuvant intravesical treatment? PG - 33-38 LID - 10.2147/RRU.S164166 [doi] AB - BACKGROUND: Bladder recurrence after nephroureterectomy (NU) is common. However, there is no acceptable policy of adjuvant intravesical treatment after NU. OBJECTIVE: To assess the rate of bladder recurrence following NU and to identify the high-risk subgroups that may become candidates for adjuvant intravesical therapy after NU. PATIENTS AND METHODS: Ninety-one patients (mean age 66.4 years) underwent NU. High-grade (HG) tumors were found in 63 patients and low-grade (LG) tumors in 28. Median follow-up was 72 months. The risk of bladder recurrence was assessed by uni- and multivariate analyses of patient and tumor characteristics. RESULTS: Bladder recurrence developed in 38 patients (41.8%) after a median period of 11 months. Among these, 25 patients with HG upper tract urothelial carcinoma (39.7%) and 13 patients with LG upper tract urothelial carcinoma (46.4%) developed recurrence. HG bladder recurrence developed in 24 patients (63.2%) and LG recurrence developed in 14 patients (36.8%). Stages pTa, pT1, pT2, or higher bladder recurrence developed in 26 (68.4%), 7 (18.4%), and 4 patients (10.5%), respectively, and pure pTis developed in 1 patient. On uni- and multivariate analyses, the risk of bladder recurrence was independent of any clinicopathologic characteristics. CONCLUSION: High rate and short time interval of bladder recurrence after NU were found, with no specific subgroup of patients with increased risk. These findings support prescribing adjuvant intravesical therapy to all patients after NU. FAU - Mekayten, Matan AU - Mekayten M AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Yutkin, Vladimir AU - Yutkin V AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Duvdevani, Mordechai AU - Duvdevani M AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Pode, Dov AU - Pode D AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Hidas, Guy AU - Hidas G AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Landau, Ezekiel H AU - Landau EH AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Youssef, Fadi AU - Youssef F AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Gofrit, Ofer N AU - Gofrit ON AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. LA - eng PT - Journal Article DEP - 20180525 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC5973432 OTO - NOTNLM OT - bladder recurrence OT - nephroureterectomy OT - urothelial upper tract tumors COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/06/07 06:00 MHDA- 2018/06/07 06:01 PMCR- 2018/05/25 CRDT- 2018/06/07 06:00 PHST- 2018/06/07 06:00 [entrez] PHST- 2018/06/07 06:00 [pubmed] PHST- 2018/06/07 06:01 [medline] PHST- 2018/05/25 00:00 [pmc-release] AID - rru-10-033 [pii] AID - 10.2147/RRU.S164166 [doi] PST - epublish SO - Res Rep Urol. 2018 May 25;10:33-38. doi: 10.2147/RRU.S164166. eCollection 2018. PMID- 29871812 OWN - NLM STAT- MEDLINE DCOM- 20190923 LR - 20221207 IS - 1879-0887 (Electronic) IS - 0167-8140 (Linking) VI - 129 IP - 3 DP - 2018 Dec TI - Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. PG - 499-506 LID - S0167-8140(18)30281-0 [pii] LID - 10.1016/j.radonc.2018.05.022 [doi] AB - INTRODUCTION: There is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial. MATERIALS AND METHODS: Data were retrospectively analysed for patients who received GemX from two oncology centres in the UK. Elderly was defined as aged >/=75 at the start of GemX. Following transurethral resection of bladder tumour, patients received neo-adjuvant platinum-based chemotherapy followed by radiotherapy concurrently with weekly gemcitabine. A separate, age-specific analysis was performed in the BCON cohort. Overall survival (OS), disease specific survival (DSS) and local progression free survival (LPFS) were evaluated using Kaplan-Meier methodology and Cox proportional hazards regression. RESULTS: Out of 167 patients who received GemX, 61 were elderly (36.5%) with a median age of 78 years. Elderly patients had worse performance status (p = 0.020) and co-morbidities (p = 0.030). A similar proportion of patients received planned dose radiotherapy in both groups (p = 0.260), although fewer elderly patients received all four cycles of concurrent chemotherapy (p = 0.017) due to toxicity. For OS, age had some prognostic power; HR 1.04 (95% CI 1.00-1.08; p = 0.068). Overall survival and LPFS in elderly patients were comparable between CON and GemX (HR 1.13, 95% CI 0.69-1.85; p = 0.616 and HR 0.85, 95% CI 0.41-1.74; p = 0.659 respectively). DISCUSSION: Radiosensitisation is safe and effective and should be considered for fit elderly patients with MIBC. CI - Crown Copyright (c) 2018. Published by Elsevier B.V. All rights reserved. FAU - Christodoulou, Marianna AU - Christodoulou M AD - Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdom. FAU - Reeves, Kimberley J AU - Reeves KJ AD - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, United Kingdom. FAU - Hodgson, Clare AU - Hodgson C AD - Clinical Outcomes Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom. FAU - Zeniou, Anthi AU - Zeniou A AD - Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, United Kingdom. FAU - Slevin, Finbar AU - Slevin F AD - Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, United Kingdom. FAU - Kennedy, Jason AU - Kennedy J AD - Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdom. FAU - Hoskin, Peter J AU - Hoskin PJ AD - Centre for Cancer Treatment, Mount Vernon Hospital, Middlesex, United Kingdom. FAU - Henry, Ann AU - Henry A AD - Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, United Kingdom; The University of Leeds, United Kingdom. FAU - Choudhury, Ananya AU - Choudhury A AD - Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdom; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, United Kingdom. Electronic address: Ananya.Choudhury@christie.nhs.uk. LA - eng GR - Cancer Research UK/United Kingdom PT - Clinical Trial, Phase III PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180602 PL - Ireland TA - Radiother Oncol JT - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JID - 8407192 RN - 0 (Radiation-Sensitizing Agents) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM CIN - J Urol. 2019 Jun;201(6):1034. doi: 10.1097/01.JU.0000554634.73867.12. PMID: 30864906 MH - Aged MH - Aged, 80 and over MH - Deoxycytidine/*analogs & derivatives/therapeutic use MH - Female MH - Humans MH - Male MH - Radiation-Sensitizing Agents/*therapeutic use MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/*radiotherapy MH - Gemcitabine OTO - NOTNLM OT - Elderly OT - Muscle invasive bladder cancer OT - Radiosensitisation OT - Radiotherapy EDAT- 2018/06/07 06:00 MHDA- 2019/09/24 06:00 CRDT- 2018/06/07 06:00 PHST- 2017/05/10 00:00 [received] PHST- 2018/05/15 00:00 [revised] PHST- 2018/05/19 00:00 [accepted] PHST- 2018/06/07 06:00 [pubmed] PHST- 2019/09/24 06:00 [medline] PHST- 2018/06/07 06:00 [entrez] AID - S0167-8140(18)30281-0 [pii] AID - 10.1016/j.radonc.2018.05.022 [doi] PST - ppublish SO - Radiother Oncol. 2018 Dec;129(3):499-506. doi: 10.1016/j.radonc.2018.05.022. Epub 2018 Jun 2. PMID- 29865039 OWN - NLM STAT- MEDLINE DCOM- 20181018 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 22 IP - 3 DP - 2018 TI - High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer. PG - 543-549 LID - 10.3233/CBM-181202 [doi] AB - BACKGROUND: Spindle and kinetochore-associated protein 1 (SKA1) is a component of SKA, which is essential for proper chromosome segregation. Recently, SKA1 was found to be over-expressed in several types of human cancers. However, reports on the relationship between SKA1 expression and the prognosis of bladder cancer, in particular, are lacking. OBJECTIVES: To clarify the clinical significance of SKA1 as a prognostic biomarker for early recurrence and progression of patients with non-muscle invasive bladder cancer (NMIBC). METHODS: The differential expression levels of SKA1 of 148 NMIBC tissues were determined by immunohistochemical staining. Quantitative real-time PCR and western blot analysis were further performed to confirm the immunohistochemistry results. Recurrence and progression free interval were assessed by Kaplan-Meier method and differences between groups calculated by log-rank statistics. The prognostic value of SKA1 for early recurrence and progression was analyzed by multivariate Cox proportional hazard regression models. RESULTS: SKA1 expression was significantly different in various NMIBC tissues. Kaplan-Meier analysis revealed that patients with high SKA1 expression showed high early recurrence (p< 0.001) and progression (p< 0.05) rates. Although univariate Cox regression analysis revealed that several other factors had an impact on recurrence and progression, upon multivariate analysis, high SKA1expression was the only independent predictor for early recurrence (hazards ratio [HR], 0.246; 95% confidence interval [CI], 0.131-0.461; p= 0.000) and progression (HR, 0.194; 95% CI, 0.052-0.715; p= 0.014). CONCLUSIONS: High SKA1 expression is associated with early recurrence and progression in patients with NMIBC, indicating SKA1 may serve as a promising prognostic biomarker for this disease. FAU - Jiang, Sixiong AU - Jiang S AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Tian, Feng AU - Tian F AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Cheng, Wen AU - Cheng W AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China. FAU - Wang, Longxin AU - Wang L AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China. FAU - Wang, Ying AU - Wang Y AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. FAU - Sun, Weibing AU - Sun W AD - Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (Chromosomal Proteins, Non-Histone) RN - 0 (SKA1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Chromosomal Proteins, Non-Histone/*genetics/metabolism MH - Disease Progression MH - Female MH - *Gene Expression MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Recurrence MH - Urinary Bladder Neoplasms/*genetics/metabolism/*pathology PMC - PMC13078469 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - SKA1 OT - biomarker OT - progression OT - recurrence EDAT- 2018/06/06 06:00 MHDA- 2018/10/20 06:00 PMCR- 2018/06/19 CRDT- 2018/06/06 06:00 PHST- 2018/06/06 06:00 [pubmed] PHST- 2018/10/20 06:00 [medline] PHST- 2018/06/06 06:00 [entrez] PHST- 2018/06/19 00:00 [pmc-release] AID - CBM181202 [pii] AID - 10.3233/CBM-181202 [doi] PST - ppublish SO - Cancer Biomark. 2018;22(3):543-549. doi: 10.3233/CBM-181202. PMID- 29863576 OWN - NLM STAT- MEDLINE DCOM- 20200313 LR - 20200313 IS - 1538-9804 (Electronic) IS - 0162-220X (Linking) VI - 42 IP - 3 DP - 2019 May/Jun TI - Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review. PG - E21-E33 LID - 10.1097/NCC.0000000000000606 [doi] AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) represents approximately 75% of newly diagnosed patients with bladder cancer. Non-muscle-invasive bladder cancer survivors have unique chronic burdens including frequent recurrences, repeated surveillance cystoscopies and treatments, and the highest lifetime medical cost per person among all cancers. OBJECTIVE: The purpose of this study was to summarize studies assessing quality of life (QOL) in NMIBC survivors. METHODS: The literature from January 2005 to March 2017 found in PubMed, CINAHL, and PsycINFO databases was reviewed systematically. Inclusion criteria were as follows: (1) research about NMIBC survivors, (2) outcomes included QOL, (3) original research article published in peer-reviewed journals, and (4) published in English. RESULTS: A total of 15 studies were included: 14 quantitative studies and 1 mixed-methods study. Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function. CONCLUSION: Despite a good prognosis, NMIBC and its treatment have a significant impact on QOL in survivors. The findings showed large burdens in NMIBC survivors and suggest that further research is needed to better understand potential opportunities to improve QOL in this population. IMPLICATIONS FOR PRACTICE: Oncology nurses are in the critical position for assessing symptoms and concerns. Oncology nurses should pay special attention to NMIBC survivors who have unique symptoms and burden with the aim of improving survivors' QOL. FAU - Jung, Ahrang AU - Jung A AD - Author Affiliations: School of Nursing (Drs Jung, Crandell, Palmer, Bryant, and Mayer), School of Medicine (Dr Nielsen), and Lineberger Comprehensive Cancer Center (Drs Nielsen, Bryant, and Mayer), The University of North Carolina at Chapel Hill; and School of Nursing, Duke University, Durham, North Carolina (Dr Smith). FAU - Nielsen, Matthew E AU - Nielsen ME FAU - Crandell, Jamie L AU - Crandell JL FAU - Palmer, Mary H AU - Palmer MH FAU - Bryant, Ashley Leak AU - Bryant AL FAU - Smith, Sophia K AU - Smith SK FAU - Mayer, Deborah K AU - Mayer DK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - United States TA - Cancer Nurs JT - Cancer nursing JID - 7805358 SB - IM MH - *Cancer Survivors MH - Humans MH - *Quality of Life MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*therapy EDAT- 2018/06/05 06:00 MHDA- 2020/03/14 06:00 CRDT- 2018/06/05 06:00 PHST- 2018/06/05 06:00 [pubmed] PHST- 2020/03/14 06:00 [medline] PHST- 2018/06/05 06:00 [entrez] AID - 10.1097/NCC.0000000000000606 [doi] PST - ppublish SO - Cancer Nurs. 2019 May/Jun;42(3):E21-E33. doi: 10.1097/NCC.0000000000000606. PMID- 29862474 OWN - NLM STAT- MEDLINE DCOM- 20191219 LR - 20210109 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 25 IP - 3 DP - 2019 Jul TI - Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder. PG - 987-994 LID - 10.1007/s12253-018-0431-7 [doi] AB - The aim of this study is to investigate the role of androgen receptor (AR) expression on clinicopathologic characteristics, first recurrence free survival (RFS), progression free survival (PFS) and multiple recurrences in non-muscle invasive bladder cancer (NMIBC). AR expression in 40 paraffin-embedded specimens of primarily diagnosed NMIBC after transurethral resection was examined by immunohistochemistry using a monoclonal AR antibody. Associations between AR expression and clinicopathologic features and prognosis were statistically assessed. Multivariate Cox proportional hazards model was applied for evaluating predictive factors on RFS and PFS. For multiple recurrences, we used the Andersen-Gill model. AR was positive in 20/40 (50%) cases. Twenty-three patients (57.5%) had no recurrence, 10 (25.0%) had one recurrence, and 7 (17.5%) experienced more than one recurrence. AR expression and clinicopathologic features were not significantly correlated (P >0.05). Univariate analyses showed that AR expression was significantly associated with RFS and PFS (P <0.05). Via multivariate analyses, positive AR expression was significantly associated with lower risk of first recurrence (hazard ratio (HR) = 0.265; 95% confidence interval (95% CI) = 0.084-0.829; P = 0.022). Multivariate analysis of PFS was not feasible in our cohort. Using the multivariate Andersen-Gill model, positive AR expression in the primary tumor was an independent factor predicting lower risk of multiple recurrences (HR = 0.387, 95% CI = 0.161-0.927, P = 0.033). Androgen receptor expression is associated with first and multiple recurrences in NMIBC. FAU - Yonekura, Satoru AU - Yonekura S AUID- ORCID: 0000-0003-4047-3016 AD - Department of Pathology, Tochigi Medical Center Shimotsuga Hospital, 420-1 Ohira-machi Kawatsure, Tochigi, Tochigi, 329-4498, Japan. yonechian@gmail.com. FAU - Terauchi, Fumihito AU - Terauchi F AD - Department of Urology, Tochigi Medical Center Shimotsuga Hospital, 420-1 Ohira-machi Kawatsure, Tochigi, Tochigi, 329-4498, Japan. FAU - Hoshi, Kenji AU - Hoshi K AD - Department of Pathology, Tochigi Medical Center Shimotsuga Hospital, 420-1 Ohira-machi Kawatsure, Tochigi, Tochigi, 329-4498, Japan. FAU - Yamaguchi, Takehiko AU - Yamaguchi T AD - Department of Pathology, Koshigaya Hospital, Dokkyo Medical University, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan. FAU - Kawai, Shigeo AU - Kawai S AD - Department of Pathology, Tochigi Medical Center Shimotsuga Hospital, 420-1 Ohira-machi Kawatsure, Tochigi, Tochigi, 329-4498, Japan. LA - eng PT - Journal Article DEP - 20180603 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (AR protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Androgen) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*metabolism MH - Prognosis MH - Receptors, Androgen/*metabolism MH - Retrospective Studies MH - Urinary Bladder/*metabolism MH - Urinary Bladder Neoplasms/*metabolism OTO - NOTNLM OT - Androgen receptor OT - Bladder cancer OT - Immunohistochemistry OT - Recurrence EDAT- 2018/06/05 06:00 MHDA- 2019/12/20 06:00 CRDT- 2018/06/05 06:00 PHST- 2017/11/13 00:00 [received] PHST- 2018/05/29 00:00 [accepted] PHST- 2018/06/05 06:00 [pubmed] PHST- 2019/12/20 06:00 [medline] PHST- 2018/06/05 06:00 [entrez] AID - 10.1007/s12253-018-0431-7 [pii] AID - 10.1007/s12253-018-0431-7 [doi] PST - ppublish SO - Pathol Oncol Res. 2019 Jul;25(3):987-994. doi: 10.1007/s12253-018-0431-7. Epub 2018 Jun 3. PMID- 29861872 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 38 DP - 2018 May 18 TI - Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis. PG - 25294-25303 LID - 10.18632/oncotarget.25334 [doi] AB - BACKGROUND: Tumor associated macrophages (TAMs) have multifaceted roles in the development of many tumor types. However, the prognostic value of TAMs in bladder cancer is still not conclusive. EXPERIMENTAL DESIGN: This review evaluated the prognostic value of TAMs density in bladder cancer by reviewing published literatures and integrating the results via a meta-analysis. A systematic search was conducted in PubMed, Embase and Chinese National Knowledge Infrastructure (CNKI), WanFang, and Web of Science databases for relevant studies. Overall survival (OS), relapse free survival (RFS), disease specific survival (DSS), and progression free survival (PFS) were assessed in bladder cancer patients. RESULTS: The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) indicated that TAMs identified with CD68 alone have no significant correlation with OS (HR = 1.01, 95% CI = 1.00-1.02), RFS (HR = 0.99, 95% CI = 0.91-1.06), or PFS (HR = 1.19, 95% CI = 0.70-1.68) in bladder cancer patients. Subgroup analyses involved with Bacillus Calmette Guerin (BCG) treatment or sample locations either showed that CD68(+) TAMs presented no prognostic value with regard to OS in bladder cancer patients. However, TAMs detected by CD163 are significantly correlated with poor RFS in bladder cancer patients (HR = 1.54, 95% CI = 1.16-1.92). CONCLUSIONS: Our data indicated that TAMs identified only with CD68 have no significant correlation with the prognosis and clinicopathological parameters of bladder cancer patients. However, TAMs detected with CD163 could serve as a prognostic marker for bladder cancer patients. These findings invite further research on the role of TAM subsets in bladder cancer patients. FAU - Wu, Shui-Qing AU - Wu SQ AD - Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Hunan Province, People's Republic of China. AD - MRC Centre for Reproductive Health, EH16 4TJ, Edinburgh, United Kingdom. FAU - Xu, Ran AU - Xu R AD - Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Hunan Province, People's Republic of China. FAU - Li, Xue-Feng AU - Li XF AD - MRC Centre for Reproductive Health, EH16 4TJ, Edinburgh, United Kingdom. FAU - Zhao, Xiao-Kun AU - Zhao XK AD - Department of Urology, The Second Xiangya Hospital, Central South University, 410011, Hunan Province, People's Republic of China. FAU - Qian, Bin-Zhi AU - Qian BZ AD - MRC Centre for Reproductive Health, EH16 4TJ, Edinburgh, United Kingdom. AD - Edinburgh Cancer Research UK Centre Queen's Medical Research Institute, EH16 4TJ, Edinburgh, United Kingdom. LA - eng GR - MR/N022556/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20180518 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5982745 OTO - NOTNLM OT - bladder cancer OT - meta-analysis OT - system review OT - tumor associated macrophages COIS- CONFLICTS OF INTEREST The authors declared no conflicts of interest. EDAT- 2018/06/05 06:00 MHDA- 2018/06/05 06:01 PMCR- 2018/05/18 CRDT- 2018/06/05 06:00 PHST- 2017/08/15 00:00 [received] PHST- 2018/04/06 00:00 [accepted] PHST- 2018/06/05 06:00 [entrez] PHST- 2018/06/05 06:00 [pubmed] PHST- 2018/06/05 06:01 [medline] PHST- 2018/05/18 00:00 [pmc-release] AID - 25334 [pii] AID - 10.18632/oncotarget.25334 [doi] PST - epublish SO - Oncotarget. 2018 May 18;9(38):25294-25303. doi: 10.18632/oncotarget.25334. eCollection 2018 May 18. PMID- 29861867 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 38 DP - 2018 May 18 TI - Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. PG - 25244-25253 LID - 10.18632/oncotarget.25397 [doi] AB - OBJECTIVES: To investigate whether elevated urinary HAI-1, EpCAM and EGFR are independent prognostic biomarkers within non-muscle-invasive bladder cancer (NMIBC) patients, and have utility for risk stratification to facilitate treatment decisions. RESULTS: After accounting for EAU risk group in NMIBC patients, the risk of BC-specific death was 2.14 times higher (95% CI: 1.08 to 4.24) if HAI-1 was elevated and 2.04 times higher (95% CI: 1.02 to 4.07) if EpCAM was elevated. The majority of events occurred in the high-risk NMIBC group and this is where the biggest difference is seen in the survival curves when plotted for EAU risk groups separately. In MIBC patients, being elevated for any of the three biomarkers was significantly associated with BC-specific mortality after accounting for other risk factors, HR = 4.30 (95% CI: 1.85 to 10.03). PATIENTS AND METHODS: Urinary levels of HAI-1, EpCAM and EGFR were measured by ELISA in 683 and 175 patients with newly-diagnosed NMIBC and MIBC, respectively, recruited to the Bladder Cancer Prognosis Programme. Associations between biomarkers and progression, BC-specific mortality and all-cause mortality were evaluated using univariable and multivariable Cox regression models, adjusted for European Association of Urology (EAU) NMIBC risk groups. The upper 25% of values for each biomarker within NMIBC patients were considered as elevated. Exploratory analyses in urine from MIBC patients were also undertaken. CONCLUSION: Urinary HAI-1 and EpCAM are prognostic biomarkers for NMIBC patients. These biomarkers have potential to guide treatment decisions for high-risk NMIBC patients. Further analyses are required to define the roles of HAI-1, EpCAM and EGFR in MIBC patients. FAU - Snell, Kym I E AU - Snell KIE AD - Centre for Prognosis Research, Research Institute for Primary Care and Health Science, Keele University, Newcastle-under-Lyme, ST5 5BG, UK. FAU - Ward, Douglas G AU - Ward DG AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. FAU - Gordon, Naheema S AU - Gordon NS AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. FAU - Goldsmith, James C AU - Goldsmith JC AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. FAU - Sutton, Andrew J AU - Sutton AJ AD - Leeds Institute of Health Sciences, University of Leeds and The Diagnostic Evidence Cooperative, Leeds LS2 9JT, UK. FAU - Patel, Prashant AU - Patel P AD - Institute of Cancer and Genomic Sciences, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - NUTRIM School for Nutrition and Translational Research in Metabolism and CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht 6200 MD, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. LA - eng PT - Journal Article DEP - 20180518 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5982738 OTO - NOTNLM OT - EGFR OT - EpCAM OT - HAI-1 OT - bladder cancer OT - prognosis COIS- CONFLICTS OF INTEREST RT Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. ND James has contributed to advisory boards for Merck USA and Pierre Fabre. EDAT- 2018/06/05 06:00 MHDA- 2018/06/05 06:01 PMCR- 2018/05/18 CRDT- 2018/06/05 06:00 PHST- 2018/02/16 00:00 [received] PHST- 2018/04/28 00:00 [accepted] PHST- 2018/06/05 06:00 [entrez] PHST- 2018/06/05 06:00 [pubmed] PHST- 2018/06/05 06:01 [medline] PHST- 2018/05/18 00:00 [pmc-release] AID - 25397 [pii] AID - 10.18632/oncotarget.25397 [doi] PST - epublish SO - Oncotarget. 2018 May 18;9(38):25244-25253. doi: 10.18632/oncotarget.25397. eCollection 2018 May 18. PMID- 29860605 OWN - NLM STAT- MEDLINE DCOM- 20190221 LR - 20240403 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 36 IP - 11 DP - 2018 Nov TI - Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. PG - 1741-1748 LID - 10.1007/s00345-018-2359-7 [doi] AB - PURPOSE: To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non-muscle invasive bladder cancer (NMIBC). METHODS: We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregulatory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. RESULTS: A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before and after initiation of BCG. However, the proportion of CD8(+) T cells before BCG was significantly higher in responders. CONCLUSION: The immune phenotype of PBMC from patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease or the initiation of BCG. Peripheral CD8(+) T cells could play a role in response to BCG. FAU - Audenet, Francois AU - Audenet F AUID- ORCID: 0000-0001-5722-2075 AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Farkas, Adam M AU - Farkas AM AD - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Anastos, Harry AU - Anastos H AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Galsky, Matthew D AU - Galsky MD AD - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Bhardwaj, Nina AU - Bhardwaj N AD - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. john.sfakianos@mountsinai.org. LA - eng GR - R01 CA201189/CA/NCI NIH HHS/United States GR - T32 AI007605/AI/NIAID NIH HHS/United States GR - T32 AI007647/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20180602 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/mortality/*pathology/*therapy MH - Chi-Square Distribution MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Immunotherapy/*methods MH - Leukocytes, Mononuclear/*immunology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Phenotype MH - Prospective Studies MH - Statistics, Nonparametric MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy PMC - PMC6207464 MID - NIHMS972534 OTO - NOTNLM OT - BCG OT - Immune checkpoints OT - Immune phenotype OT - Non-muscle invasive bladder cancer OT - Peripheral blood mononuclear cells OT - Predictive factors EDAT- 2018/06/04 06:00 MHDA- 2019/02/23 06:00 PMCR- 2019/11/01 CRDT- 2018/06/04 06:00 PHST- 2018/03/02 00:00 [received] PHST- 2018/05/26 00:00 [accepted] PHST- 2018/06/04 06:00 [pubmed] PHST- 2019/02/23 06:00 [medline] PHST- 2018/06/04 06:00 [entrez] PHST- 2019/11/01 00:00 [pmc-release] AID - 10.1007/s00345-018-2359-7 [pii] AID - 10.1007/s00345-018-2359-7 [doi] PST - ppublish SO - World J Urol. 2018 Nov;36(11):1741-1748. doi: 10.1007/s00345-018-2359-7. Epub 2018 Jun 2. PMID- 29859728 OWN - NLM STAT- MEDLINE DCOM- 20181024 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 8 DP - 2018 Aug TI - Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. PG - 361.e1-361.e6 LID - S1078-1439(18)30135-2 [pii] LID - 10.1016/j.urolonc.2018.04.013 [doi] AB - INTRODUCTION: Blue light cystoscopy (BLC) using hexaminolevulinate (HAL/Cysview/Hexvix) has been previously shown to improve detection of non-muscle-invasive bladder cancer (NMIBC). Herein, we evaluated the detection of malignant lesions in a heterogenous group of patients in the real world setting and documented the change in risk category due to upstaging or upgrading. METHODS: Prospective enrollment during April 2014 to December 2016 of consecutive adult patients with suspected or known non-muscle-invasive bladder cancer based on prior cystoscopy or imaging, undergoing transurethral resection of bladder tumor at 9 different referral medical centers. HAL was instilled in the bladder for 1 to 3 hours before evacuation and inspection. Sensitivity and specificity of BLC, white light cystoscopy (WLC), and the combination of both BLC and WLC for detection of any malignancy was reported on final pathology. Number of patients with a change in American Urological Association (AUA) risk category based on BLC findings leading to a possible change in management and adverse events were recorded. RESULTS: Overall, 1,632 separate samples from bladder resection or biopsy were identified from 641 BLC procedures on 533 patients: 85 (16%) underwent repeat BLC (range: 2-5). Sensitivity of WLC, BLC, and the combination for diagnosis of any malignant lesion was 76%, 91%, and 98.5%, respectively. Addition of BLC to standard WLC increased detection rate by 12% for any papillary lesion and 43% for carcinoma in-situ. Within the WLC negative group, an additional 206 lesions in 133 (25%) patients were detected exclusively with BLC. In multifocal disease, BLC resulted in AUA risk-group migration occurred in 33 (6%) patients and a change in recommended management in 74 (14%). False-positive rate was 25% for WLC and 30% for BLC. One mild dermatologic hypersensitivity reaction (0.2%). CONCLUSIONS: BLC increases detection rates of carcinoma in-situ and papillary lesions over WLC alone and can change management in 14% of cases. Repeat use of HAL for BLC is safe. CI - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address: daneshma@med.usc.edu. FAU - Bazargani, Soroush T AU - Bazargani ST AD - Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - The James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - University of Kansas, Kansas City, KS. FAU - Willard, Brian AU - Willard B AD - Carolina Urology Partners, Lexington, SC. FAU - Taylor, Jennifer M AU - Taylor JM AD - Michael E. DeBakey VAMC, BCM, Houston, TX. FAU - Liao, Joseph C AU - Liao JC AD - VA Palo Alto Health Care System, Palo Alto, CA. FAU - Pohar, Kamal AU - Pohar K AD - Ohio State University, Columbus, OH. FAU - Tierney, James AU - Tierney J AD - Charleston Area Medical Center, Charleston, WV, USA. FAU - Konety, Badrinath AU - Konety B AD - University of Minnesota, Minneapolis, MN. CN - Blue Light Cystoscopy with Cysview Registry Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20180530 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Nat Rev Urol. 2018 Aug;15(8):468. doi: 10.1038/s41585-018-0037-6. PMID: 29875389 MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystoscopy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - United States MH - Urinary Bladder Neoplasms/*diagnostic imaging/pathology MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Blue light cystoscopy OT - Diagnosis OT - Photodynamic EDAT- 2018/06/04 06:00 MHDA- 2018/10/26 06:00 CRDT- 2018/06/04 06:00 PHST- 2017/12/18 00:00 [received] PHST- 2018/04/16 00:00 [revised] PHST- 2018/04/23 00:00 [accepted] PHST- 2018/06/04 06:00 [pubmed] PHST- 2018/10/26 06:00 [medline] PHST- 2018/06/04 06:00 [entrez] AID - S1078-1439(18)30135-2 [pii] AID - 10.1016/j.urolonc.2018.04.013 [doi] PST - ppublish SO - Urol Oncol. 2018 Aug;36(8):361.e1-361.e6. doi: 10.1016/j.urolonc.2018.04.013. Epub 2018 May 30. PMID- 29857476 OWN - NLM STAT- MEDLINE DCOM- 20181002 LR - 20190816 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 6 DP - 2018 May 31 TI - Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder. LID - 10.3390/ijms19061622 [doi] LID - 1622 AB - Bladder cancer still requires improvements in diagnosis and prognosis, because many of the cases will recur and/or metastasize with bad outcomes. Despite ongoing research on bladder biomarkers, the clinicopathological impact and diagnostic function of miRNA maturation regulators Drosha and Argonaute proteins AGO1 and AGO2 in urothelial bladder carcinoma remain unclear. Therefore, we conducted immunohistochemical investigations of a tissue microarray composed of 112 urothelial bladder carcinomas from therapy-naive patients who underwent radical cystectomy or transurethral resection and compared the staining signal with adjacent normal bladder tissue. The correlations of protein expression of Drosha, AGO1 and AGO2 with sex, age, tumor stage, histological grading and overall survival were evaluated in order to identify their diagnostic and prognostic potential in urothelial cancer. Our results show an upregulation of AGO1, AGO2 and Drosha in non-muscle-invasive bladder carcinomas, while there was increased protein expression of only AGO2 in muscle-invasive bladder carcinomas. Moreover, we were able to differentiate between non-muscle-invasive and muscle-invasive bladder carcinoma according to AGO1 and Drosha expression. Finally, despite Drosha being a discriminating factor that can predict the probability of overall survival in the Kaplan(-)Meier analysis, AGO1 turned out to be independent of all clinicopathological parameters according to Cox regression. In conclusion, we assumed that the miRNA processing factors have clinical relevance as potential diagnostic and prognostic tools for bladder cancer. FAU - Rabien, Anja AU - Rabien A AD - Department of Urology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. anja.rabien@charite.de. AD - Berlin Institute for Urologic Research, 10117 Berlin, Germany. anja.rabien@charite.de. FAU - Ratert, Nadine AU - Ratert N AD - Department of Urology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. n.ratert@gmx.de. AD - Berlin Institute for Urologic Research, 10117 Berlin, Germany. n.ratert@gmx.de. FAU - Hogner, Anica AU - Hogner A AD - Institute of Pathology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. anica.hoegner@charite.de. FAU - Erbersdobler, Andreas AU - Erbersdobler A AD - Institute of Pathology, University Medicine Rostock, 18055 Rostock, Germany. andreas.erbersdobler@med.uni-rostock.de. FAU - Jung, Klaus AU - Jung K AD - Department of Urology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. klaus.jung@charite.de. AD - Berlin Institute for Urologic Research, 10117 Berlin, Germany. klaus.jung@charite.de. FAU - Ecke, Thorsten H AU - Ecke TH AUID- ORCID: 0000-0002-0787-2763 AD - Department of Urology, HELIOS Hospital Bad Saarow, 15526 Bad Saarow, Germany. thorsten.ecke@helios-kliniken.de. FAU - Kilic, Ergin AU - Kilic E AD - Institute of Pathology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. e.kilic@pathologie-leverkusen.de. AD - Institute of Pathology, Hospital Leverkusen, 51375 Leverkusen, Germany. e.kilic@pathologie-leverkusen.de. LA - eng PT - Journal Article DEP - 20180531 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (AGO1 protein, human) RN - 0 (AGO2 protein, human) RN - 0 (Argonaute Proteins) RN - 0 (Biomarkers, Tumor) RN - 0 (Eukaryotic Initiation Factors) RN - 0 (MicroRNAs) RN - EC 3.1.26.3 (DROSHA protein, human) RN - EC 3.1.26.3 (Ribonuclease III) SB - IM MH - Aged MH - Aged, 80 and over MH - Argonaute Proteins/*metabolism MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/*diagnosis/*metabolism/mortality MH - Eukaryotic Initiation Factors/*metabolism MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - MicroRNAs/genetics MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Ribonuclease III/*metabolism MH - Urinary Bladder Neoplasms/*diagnosis/*metabolism/mortality PMC - PMC6032056 OTO - NOTNLM OT - AGO1 OT - AGO2 OT - Drosha OT - biomarkers OT - bladder cancer OT - immunohistochemistry COIS- The authors declare no conflict of interest. EDAT- 2018/06/03 06:00 MHDA- 2018/10/03 06:00 PMCR- 2018/06/01 CRDT- 2018/06/03 06:00 PHST- 2018/05/16 00:00 [received] PHST- 2018/05/24 00:00 [revised] PHST- 2018/05/30 00:00 [accepted] PHST- 2018/06/03 06:00 [entrez] PHST- 2018/06/03 06:00 [pubmed] PHST- 2018/10/03 06:00 [medline] PHST- 2018/06/01 00:00 [pmc-release] AID - ijms19061622 [pii] AID - ijms-19-01622 [pii] AID - 10.3390/ijms19061622 [doi] PST - epublish SO - Int J Mol Sci. 2018 May 31;19(6):1622. doi: 10.3390/ijms19061622. PMID- 29857079 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20190606 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 200 IP - 5 DP - 2018 Nov TI - The Association of Aspirin Use with Survival Following Radical Cystectomy. PG - 1014-1021 LID - S0022-5347(18)43297-1 [pii] LID - 10.1016/j.juro.2018.05.119 [doi] AB - PURPOSE: Aspirin may have antineoplastic properties through the inhibition of inflammatory cytokines that regulate cell proliferation, angiogenesis and apoptosis. In patients with nonmuscle invasive bladder cancer aspirin use has been linked to a reduced risk of recurrence. We evaluated the association of aspirin with survival following radical cystectomy. MATERIALS AND METHODS: A total of 1,061 patients underwent radical cystectomy at our institution between 2007 and 2016, of whom 461 (43%) were aspirin users at the time of surgery. Survival estimates were assessed by the Kaplan-Meier method. The Cox proportional hazards model was applied to evaluate associations between patient features and survival. RESULTS: Median followup after radical cystectomy among survivors was 4.2 years (IQR 2-6.2). During this time 442 patients died, including 331 of bladder cancer. Aspirin users were significantly older, more likely to have a history of cardiovascular disease and diabetes, and more likely to use metformin or statin (each p <0.05). Nevertheless, we found that patients who ingested a daily aspirin had significantly higher 5-year cancer specific survival (68% vs 60%, p = 0.02) and overall survival (59% vs 52%, p = 0.03) compared to nonusers. Moreover, after multivariable adjustment aspirin use remained independently associated with lower cancer specific mortality (HR 0.64, 95% CI 0.45-0.89, p = 0.01) as well as all cause mortality (HR 0.70, 95% CI 0.53-0.93, p = 0.02) but not with distant metastasis (p >0.05). CONCLUSIONS: Daily aspirin use was associated with significantly improved survival outcomes following radical cystectomy. Further research is warranted to evaluate the potential underlying biological mechanisms and investigate causality. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Lyon, Timothy D AU - Lyon TD AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Shah, Paras H AU - Shah PH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tarrell, Robert AU - Tarrell R AD - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. FAU - Cheville, John C AU - Cheville JC AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Thompson, R Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, Minnesota. Electronic address: Boorjian.stephen@mayo.edu. LA - eng PT - Journal Article DEP - 20180530 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - R16CO5Y76E (Aspirin) SB - IM MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage MH - Aspirin/*administration & dosage MH - *Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Retrospective Studies MH - Time Factors MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/*mortality/surgery OTO - NOTNLM OT - aspirin OT - bladder neoplasms OT - cystectomy OT - cytokines OT - mortality EDAT- 2018/06/02 06:00 MHDA- 2019/06/07 06:00 CRDT- 2018/06/02 06:00 PHST- 2018/05/21 00:00 [accepted] PHST- 2018/06/02 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2018/06/02 06:00 [entrez] AID - S0022-5347(18)43297-1 [pii] AID - 10.1016/j.juro.2018.05.119 [doi] PST - ppublish SO - J Urol. 2018 Nov;200(5):1014-1021. doi: 10.1016/j.juro.2018.05.119. Epub 2018 May 30. PMID- 29857077 OWN - NLM STAT- MEDLINE DCOM- 20190514 LR - 20190514 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 200 IP - 4 DP - 2018 Oct TI - The Role of Vitamin D Receptor Polymorphisms in Predicting the Response to Therapy for Nonmuscle Invasive Bladder Carcinoma. PG - 737-742 LID - S0022-5347(18)43298-3 [pii] LID - 10.1016/j.juro.2018.05.120 [doi] AB - PURPOSE: Clinical and pathological predictors of bladder carcinoma recurrence and progression are relatively well defined. However, there is a paucity of genetic data specifically on the association of single nucleotide polymorphisms in specific genes for predicting recurrence and progression following immunotherapy. The VDR gene was found to regulate the immunomodulatory effects of vitamin D and it enhances the innate immunity system. We evaluated 3 VDR single nucleotide polymorphisms and their predictive role on the response to immunotherapy. MATERIALS AND METHODS: Patients with bladder cancer at intermediate-high risk who underwent post-transurethral resection intravesical bacillus Calmette-Guerin in Singapore and Hong Kong from 1995 to 2014 were recruited for analysis. We evaluated 3 VDR single nucleotide polymorphisms using polymerase chain reaction. Kaplan-Meier survival curves and relationships with outcomes were analyzed by multivariable Cox regression. RESULTS: A total of 338 predominantly Chinese patients were included in study. Individuals carrying the VDR genotype Bsm A/G were significantly associated with lower time to recurrence after bacillus Calmette-Guerin therapy (p <0.001). On multivariable analysis the HR of recurrence in patients with the Bsm A allele was 3.95 times that in patients without the allele (p = 0.037). Patients with the VDR GATC subhaplotype were 3.05 times more likely than patients with other subhaplotypes to experience recurrences (p = 0.003). Study limitations include the small sample size and the lack of information on previous bacillus Calmette-Guerin vaccine exposure and on vitamin D levels. CONCLUSIONS: Our findings in this study suggest that various VDR single nucleotide polymorphisms are associated with recurrences after bacillus Calmette-Guerin immunotherapy. Further functional studies should be performed to elucidate the significance of the VDR gene in the management of bladder cancer and the potential therapy implications. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Wang, Ziting AU - Wang Z AD - Department of Urology, National University Hospital, Singapore. Electronic address: ziting_wang@nuhs.edu.sg. FAU - Lim, Yew K AU - Lim YK AD - Department of Surgery, National University of Singapore, Singapore. FAU - Lim, Henry C C AU - Lim HCC AD - Department of Urology, National University Hospital, Singapore. FAU - Chan, Yiong H AU - Chan YH AD - Department of Biostatistics, Saw Swee Hock School of Public Health, National University of Singapore, Singapore. FAU - Ngiam, Nerice AU - Ngiam N AD - Department of Urology, National University Hospital, Singapore. FAU - Raman Nee Mani, Lata AU - Raman Nee Mani L AD - Department of Urology, National University Hospital, Singapore. FAU - Esuvaranathan, Kesavan AU - Esuvaranathan K AD - Department of Urology, National University Hospital, Singapore. FAU - Ng, Chi-Fai AU - Ng CF AD - Division of Urology, Department of Surgery, Chinese University of Hong Kong, Hong Kong. FAU - Teoh, Jeremy AU - Teoh J AD - Division of Urology, Department of Surgery, Chinese University of Hong Kong, Hong Kong. FAU - Chan, Eddie AU - Chan E AD - Division of Urology, Department of Surgery, Chinese University of Hong Kong, Hong Kong. FAU - Mahendran, Ratha AU - Mahendran R AD - Department of Surgery, National University of Singapore, Singapore. FAU - Chiong, Edmund AU - Chiong E AD - Department of Urology, National University Hospital, Singapore. LA - eng PT - Journal Article DEP - 20180530 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Receptors, Calcitriol) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Humans MH - Longitudinal Studies MH - Middle Aged MH - Neoplasm Invasiveness MH - *Polymorphism, Single Nucleotide MH - Prognosis MH - Prospective Studies MH - Receptors, Calcitriol/*genetics MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology OTO - NOTNLM OT - BCG vaccine OT - calcitriol OT - carcinoma OT - polymorphism OT - receptors OT - single nucleotide OT - urinary bladder neoplasms EDAT- 2018/06/02 06:00 MHDA- 2019/05/15 06:00 CRDT- 2018/06/02 06:00 PHST- 2018/05/22 00:00 [accepted] PHST- 2018/06/02 06:00 [pubmed] PHST- 2019/05/15 06:00 [medline] PHST- 2018/06/02 06:00 [entrez] AID - S0022-5347(18)43298-3 [pii] AID - 10.1016/j.juro.2018.05.120 [doi] PST - ppublish SO - J Urol. 2018 Oct;200(4):737-742. doi: 10.1016/j.juro.2018.05.120. Epub 2018 May 30. PMID- 29855698 OWN - NLM STAT- MEDLINE DCOM- 20190221 LR - 20190221 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 36 IP - 11 DP - 2018 Nov TI - Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. PG - 1727-1740 LID - 10.1007/s00345-018-2332-5 [doi] AB - PURPOSE: Over the past 3 decades, no major treatment breakthrough has been reported for advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five immune checkpoint inhibitors in the management of advanced bladder cancer represent new therapeutic opportunities. This review examines the available data of the clinical trials leading to the approval of ICIs in the management of metastatic bladder cancer and the ongoing trials in advanced and localized settings. METHODS: A literature search was performed on PubMed and ClinicalTrials.gov combining the MeSH terms: 'urothelial carcinoma' OR 'bladder cancer', and 'immunotherapy' OR 'CTLA-4' OR 'PD-1' OR 'PD-L1' OR 'atezolizumab' OR 'nivolumab' OR 'ipilimumab' OR 'pembrolizumab' OR 'avelumab' OR 'durvalumab' OR 'tremelimumab'. Prospectives studies evaluating anti-PD(L)1 and anti-CTLA-4 monoclonal antibodies were included. RESULTS: Evidence-data related to early phase and phase III trials evaluating the 5 ICIs in the advanced urothelial carcinoma are detailed in this review. Anti-tumour activity of the 5 ICIs supporting the FDA approval in the second-line setting are reported. The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Ongoing trials in earlier disease-states including non-muscle-invasive and muscle-invasive bladder cancer are discussed. CONCLUSIONS: Blocking the PD-1 negative immune receptor or its ligand, PD-L1, results in unprecedented rates of anti-tumour activity in patients with metastatic urothelial cancer. However, a large majority of patients do not respond to anti-PD(L)1 drugs monotherapy. Investigations exploring the potential value of predictive biomarkers, optimal combination and sequences are ongoing to improve such treatment strategies. FAU - Rouanne, Mathieu AU - Rouanne M AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France. rouanne.mathieu@gmail.com. AD - INSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. rouanne.mathieu@gmail.com. FAU - Roumiguie, Mathieu AU - Roumiguie M AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, Institut Universitaire du Cancer, Oncopole, Toulouse, France. FAU - Houede, Nadine AU - Houede N AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Medical Oncology, CHU de Nimes, Nimes, France. AD - INSERM U1194, Montpellier Cancer Research Institute, Universite de Montpellier, Montpellier, France. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, Hopital Saint-Louis, Universite Paris-Diderot, Paris, France. FAU - Colin, Pierre AU - Colin P AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, Hopital prive de la Louviere, Lille, France. FAU - Pignot, Geraldine AU - Pignot G AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, Institut Paoli-Calmettes, Marseille, France. FAU - Larre, Stephane AU - Larre S AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, CHU de Reims, Reims, France. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, CHU Bichat, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. AD - Department of Urology, Hopital La Pitie-Salpetriere, AP-HP, GRC n degrees 5, ONCOTYPE-URO, Paris, France. FAU - Neuzillet, Yann AU - Neuzillet Y AD - Department of Urology, Hopital Foch, Universite Versailles-Saint-Quentin-en-Yvelines, Universite Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France. AD - Comite de Cancerologie de l'Association Francaise d'Urologie (ccAFU), Bladder Cancer Group, Maison de l'Urologie, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20180601 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers) RN - 0 (CTLA-4 Antigen) RN - 0 (CTLA4 protein, human) RN - 0 (Immunologic Factors) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Biomarkers/metabolism MH - CTLA-4 Antigen/*drug effects/metabolism MH - Carcinoma, Transitional Cell/mortality/pathology/*therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Immunologic Factors/*therapeutic use MH - Immunotherapy/*methods MH - Male MH - Molecular Targeted Therapy MH - Prognosis MH - Programmed Cell Death 1 Receptor/*drug effects/metabolism MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - CTLA-4 OT - Immune checkpoint inhibitors OT - Immunotherapy OT - PD-1 OT - PD-L1 OT - Urothelial cancer EDAT- 2018/06/02 06:00 MHDA- 2019/02/23 06:00 CRDT- 2018/06/02 06:00 PHST- 2018/03/02 00:00 [received] PHST- 2018/05/08 00:00 [accepted] PHST- 2018/06/02 06:00 [pubmed] PHST- 2019/02/23 06:00 [medline] PHST- 2018/06/02 06:00 [entrez] AID - 10.1007/s00345-018-2332-5 [pii] AID - 10.1007/s00345-018-2332-5 [doi] PST - ppublish SO - World J Urol. 2018 Nov;36(11):1727-1740. doi: 10.1007/s00345-018-2332-5. Epub 2018 Jun 1. PMID- 29851270 OWN - NLM STAT- MEDLINE DCOM- 20181102 LR - 20181102 IS - 1744-9987 (Electronic) IS - 1744-9979 (Linking) VI - 22 IP - 3 DP - 2018 Jun TI - Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses. PG - 266-277 LID - 10.1111/1744-9987.12694 [doi] AB - The prognosis of metastatic or relapsed renal cell carcinoma (RCC) or bladder cancer (BC) remains poor despite the introduction of immune checkpoint blockade agents. We aimed to investigate the safety and the feasibility of a vaccination with WT1 peptide-loaded dendritic cells (DCs) and OK-432 adjuvant combined with molecular targeted therapy or conventional chemotherapy. Five eligible patients with metastatic or relapsed RCC and five eligible patients with BC were enrolled. No severe adverse events related to a vaccination were observed. Seven patients with RCC or non-muscle invasive BC had durable stable disease and three other patients had disease progression after DC vaccination. DC vaccination augmented WT1 specific immunity and the reduction of regulatory T cells which might be related to clinical outcome. These results indicate that DC-based immunotherapy combined with a molecular targeted therapy or a conventional chemotherapy is safe and feasible for patients in advanced stage of RCC or BC. CI - (c) 2018 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy. FAU - Ogasawara, Masahiro AU - Ogasawara M AD - Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan. AD - Institute for Artificial Organs, Transplantation and Gene Therapy, Sapporo Hokuyu Hospital, Sapporo, Japan. FAU - Miyashita, Mamiko AU - Miyashita M AD - Institute for Artificial Organs, Transplantation and Gene Therapy, Sapporo Hokuyu Hospital, Sapporo, Japan. FAU - Ota, Shuichi AU - Ota S AD - Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan. LA - eng PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Comparative Study PT - Journal Article DEP - 20180530 PL - Australia TA - Ther Apher Dial JT - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JID - 101181252 RN - 0 (Antineoplastic Agents) RN - 0 (Cancer Vaccines) RN - 0 (WT1 Proteins) RN - 39325-01-4 (Picibanil) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Cancer Vaccines/*administration & dosage/adverse effects/immunology MH - Carcinoma, Renal Cell/immunology/*therapy MH - Dendritic Cells/immunology MH - Disease Progression MH - Female MH - Humans MH - Kidney Neoplasms/immunology/*therapy MH - Male MH - Middle Aged MH - Molecular Targeted Therapy MH - Neoplasm Metastasis MH - Neoplasm Recurrence, Local MH - Picibanil/administration & dosage/immunology MH - Treatment Outcome MH - Urinary Bladder Neoplasms/immunology/*therapy MH - WT1 Proteins/administration & dosage/immunology OTO - NOTNLM OT - Bladder cancer OT - Dendritic cell vaccination OT - Immunotherapy OT - Renal cell carcinoma OT - WT1 EDAT- 2018/06/01 06:00 MHDA- 2018/11/06 06:00 CRDT- 2018/06/01 06:00 PHST- 2018/01/15 00:00 [received] PHST- 2018/02/13 00:00 [accepted] PHST- 2018/06/01 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2018/06/01 06:00 [entrez] AID - 10.1111/1744-9987.12694 [doi] PST - ppublish SO - Ther Apher Dial. 2018 Jun;22(3):266-277. doi: 10.1111/1744-9987.12694. Epub 2018 May 30. PMID- 29846846 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20260906 IS - 1573-7225 (Electronic) IS - 0957-5243 (Print) IS - 0957-5243 (Linking) VI - 29 IP - 7 DP - 2018 Jul TI - The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. PG - 675-683 LID - 10.1007/s10552-018-1046-8 [doi] AB - BACKGROUND: Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial treatment and bladder cancer recurrence has been investigated less frequently and not prospectively yet. METHODS: 722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1, and CIS) from the prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the UK between 2005 and 2011, provided complete data on smoking behavior before and up to 5 years after diagnosis. The impact of smoking behavior on NMIBC recurrence was explored by multivariable Cox regression models investigating time-to-first NMIBC recurrence. RESULTS: Over a median follow-up period of 4.21 years, 403 pathologically confirmed NMIBC recurrences occurred in 210 patients. Only 25 current smokers at diagnosis quit smoking (14%) during follow-up and smoking cessation after diagnosis did not decrease risk of recurrence compared to continuing smokers (p = 0.352). CONCLUSIONS: Although quitting smoking after diagnosis might reduce the risk of recurrence based on retrospective evidence, this is not confirmed in this prospective study because the number of NMIBC patients quitting smoking before their first recurrence was too low. Nevertheless, this indicates an important role for urologists and other health care professionals in promoting smoking cessation in NMIBC. FAU - van Osch, Frits H M AU - van Osch FHM AUID- ORCID: 0000-0003-4329-2560 AD - Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. f.vanosch@maastrichtuniversity.nl. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. f.vanosch@maastrichtuniversity.nl. FAU - Jochems, Sylvia H J AU - Jochems SHJ AD - Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Reulen, Raoul C AU - Reulen RC AD - Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK. FAU - Pirrie, Sarah J AU - Pirrie SJ AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Nekeman, Duncan AU - Nekeman D AD - Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Wesselius, Anke AU - Wesselius A AD - Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Wallace, D Michael A AU - Wallace DMA AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Cheng, K K AU - Cheng KK AD - Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK. FAU - van Schooten, Frederik J AU - van Schooten FJ AD - Department of Pharmacology and Toxicology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands. AD - Chairgroup of Complex Genetics and Epidemiology, Care and Public Health Research Institute (CAPRHI), Maastricht University, Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20180530 PL - Netherlands TA - Cancer Causes Control JT - Cancer causes & control : CCC JID - 9100846 MH - Aged MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prognosis MH - Proportional Hazards Models MH - Prospective Studies MH - Risk Factors MH - Smoking/*adverse effects MH - Smoking Cessation/*methods MH - Urinary Bladder Neoplasms/*etiology PMC - PMC5999150 OTO - NOTNLM OT - Bladder cancer OT - Epidemiology OT - Prognosis OT - Recurrence OT - Smoking OT - Smoking cessation EDAT- 2018/05/31 06:00 MHDA- 2019/07/30 06:00 PMCR- 2018/05/30 CRDT- 2018/05/31 06:00 PHST- 2018/04/06 00:00 [received] PHST- 2018/05/28 00:00 [accepted] PHST- 2018/05/31 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2018/05/31 06:00 [entrez] PHST- 2018/05/30 00:00 [pmc-release] AID - 10.1007/s10552-018-1046-8 [pii] AID - 1046 [pii] AID - 10.1007/s10552-018-1046-8 [doi] PST - ppublish SO - Cancer Causes Control. 2018 Jul;29(7):675-683. doi: 10.1007/s10552-018-1046-8. Epub 2018 May 30. PMID- 29844825 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 15 IP - 6 DP - 2018 Jun TI - Bacillus Calmette-Guerin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival. PG - 9231-9241 LID - 10.3892/ol.2018.8462 [doi] AB - Bacillus Calmette-Guerin (BCG) immunotherapy is the standard therapy for non-muscle invasive bladder cancer. The aim of the present study was to identify genes that are induced in response to BCG immunotherapy, as these may be potential biomarkers for the response to clinical therapy. To model clinical therapy, human bladder cancer cell lines were incubated with BCG (live or lyophilized BCG Connaught) for 2 h. RNA was extracted and evaluated by Representational Differential Analysis (RDA) and oligo arrays. Gene expression was confirmed by reverse transcription polymerase chain reaction on fresh cell lines with differential abilities to internalize BCG. The effect of 2 major BCG soluble proteins, antigen 85B (Ag85B) and Mycobacterium protein tyrosine phosphatase A (MptpA) and BCG Tice((R)) on gene expression was also determined. GAPDH and beta-actin, which are normally used as control genes, were upregulated by BCG. Therefore, the ribosomal RNA gene ribosomal protein S27a was used to normalize gene expression. The genes likely to be induced by BCG internalization and soluble factors were: GSTT2, MGST2, CCL20, TNFalpha, CCNE1 and IL10RB. Those induced by BCG membrane interactions and/or soluble factors were: MGST1, CXCL6, IL12A, CSF2, IL1beta and TOLLIP. MptpA decreased GSTT2 expression, and Ag85B increased TNFalpha expression. The two BCG strains significantly increased GSTT2, TNFalpha and TOLLIP levels in MGH cells. However, in J82 cells there was a BCG strain-dependent difference in TNFalpha expression. An important outcome of the present study was the determination that neither GAPDH nor beta-actin were suitable control genes for the analysis of BCG-induced gene expression. BCG Connaught and Tice((R)) induced similar expression levels of genes in bladder cancer cell lines. BCG soluble proteins modulated gene expression and therefore may affect therapeutic outcomes. The genes identified may be novel biomarkers of the response to BCG therapy. FAU - Rahmat, Juwita N AU - Rahmat JN AD - Department of Surgery, Yong Loo Lin, School of Medicine, National University of Singapore, Singapore 119228, Republic of Singapore. FAU - Esuvaranathan, Kesavan AU - Esuvaranathan K AD - Department of Surgery, Yong Loo Lin, School of Medicine, National University of Singapore, Singapore 119228, Republic of Singapore. AD - National University Hospital, National University Health System, Singapore 119228, Republic of Singapore. FAU - Mahendran, Ratha AU - Mahendran R AD - Department of Surgery, Yong Loo Lin, School of Medicine, National University of Singapore, Singapore 119228, Republic of Singapore. LA - eng PT - Journal Article DEP - 20180411 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5958814 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - bladder cancer OT - cell lines OT - gene expression EDAT- 2018/05/31 06:00 MHDA- 2018/05/31 06:01 PMCR- 2018/04/11 CRDT- 2018/05/31 06:00 PHST- 2016/06/14 00:00 [received] PHST- 2018/03/09 00:00 [accepted] PHST- 2018/05/31 06:00 [entrez] PHST- 2018/05/31 06:00 [pubmed] PHST- 2018/05/31 06:01 [medline] PHST- 2018/04/11 00:00 [pmc-release] AID - OL-0-0-8462 [pii] AID - 10.3892/ol.2018.8462 [doi] PST - ppublish SO - Oncol Lett. 2018 Jun;15(6):9231-9241. doi: 10.3892/ol.2018.8462. Epub 2018 Apr 11. PMID- 29807387 OWN - NLM STAT- MEDLINE DCOM- 20190820 LR - 20200728 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 123 IP - 1 DP - 2019 Jan TI - A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. PG - 11-21 LID - 10.1111/bju.14417 [doi] AB - The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2941 patients with /=90 years treated at participating centres. Patients entered either as de novo or as recurrent cancer. The study period ranged from 01.01.2006 to 31.12.2016. RESULTS: A total of 123 patients with a mean (range) age of 91 (90-99) years were recruited. The American Society of Anesthesiologists Physical Status Classification (ASA-score) distribution was as follows: II, 38%; III, 50%; IV, 12%; and the male to female ratio 2.4:1. The median (range) follow-up was 8 (1-132) months. In all, 60% of patients had a de novo cancer diagnosis. Histological findings revealed: pTa 39% (n = 48), pT1 28.5% (n = 35), and >/=pT2 33% (n = 40). Overall, 67.5% patients had no recurrence, 25.2% one and 7.5% two or more. pTa tumours (n = 48) recurred in 20 patients (42%), pT1 tumours (n = 35) in 12 (34%), and >/=pT2 tumours (n = 40) in six (15%). The median overall survival (OS) was 30.0 months for patients with pTa tumours, 14.0 months for pT1 tumours, and 6.0 months for >/=pT2 tumours. The overall mortality rate of patients with pTa tumours was 40%, with pT1 tumours at 60%, and >/=pT2 tumours 75%. The ASA-score also had a strong influence on median OS after stratification by ASA-score (II, 30 months; III, 12 months; IV, 4 months). CONCLUSIONS: In nonagenarians with bladder tumours, pTa/pT1/>/=pT2 stages are almost evenly distributed and two-thirds of patients had no recurrence after transurethral resection of the bladder. The mean OS was 1.3 years, and 6 months for >/=pT2 tumours. Further case-series of patients in this specific age-group are required to identify the best management of this increasing proportion of patients with bladder tumours. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Eredics, Klaus AU - Eredics K AUID- ORCID: 0000-0002-3676-5262 AD - Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria. FAU - Bretterbauer, Katharina M AU - Bretterbauer KM AD - Department of Urology, Landesklinikum Mistelbach, Mistelbach, Austria. FAU - Comploj, Evi AU - Comploj E AD - Department of Urology, Hospital of Bolzano/Bozen, Bozen, Italy. AD - Department of Research, College of Health Care Professions Claudiana, Bozen, Italy. FAU - Friedl, Alexander AU - Friedl A AD - Department of Urology, Barmherzige Schwestern Krankenhaus, Vienna, Austria. FAU - Gschliesser, Tanja AU - Gschliesser T AD - Department of Urology, Krankenhaus Wiener Neustadt, Wiener Neustadt, Austria. FAU - Lenart, Sebastian AU - Lenart S AD - Department of Urology, Krankenhaus der Barmherzigen Bruder, Vienna, Austria. AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Seklehner, Stephan AU - Seklehner S AD - Department of Urology, Landesklinikum Baden-Modling, Baden, Austria. AD - Department of Urology, Paracelsus Medical University, Salzburg, Austria. FAU - Wimpissinger, Florian AU - Wimpissinger F AD - Department of Urology, Rudolfstiftung Hospital, Vienna, Austria. FAU - Madersbacher, Stephan AU - Madersbacher S AD - Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria. AD - Department of Urology, Sigmund Freud Private University, Vienna, Austria. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20180726 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged, 80 and over MH - Cystectomy/*mortality MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/mortality/*pathology MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery OTO - NOTNLM OT - #BLCSM OT - #BladderCancer OT - elderly OT - geriatric OT - nonagenarians OT - outcome OT - treatment EDAT- 2018/05/29 06:00 MHDA- 2019/07/17 06:00 CRDT- 2018/05/28 06:00 PHST- 2018/05/29 06:00 [pubmed] PHST- 2019/07/17 06:00 [medline] PHST- 2018/05/28 06:00 [entrez] AID - 10.1111/bju.14419 [doi] PST - ppublish SO - BJU Int. 2018 Dec;122(6):1010-1015. doi: 10.1111/bju.14419. Epub 2018 Jul 26. PMID- 29803657 OWN - NLM STAT- MEDLINE DCOM- 20181107 LR - 20181107 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 214 IP - 8 DP - 2018 Aug TI - The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. PG - 1074-1080 LID - S0344-0338(18)30352-2 [pii] LID - 10.1016/j.prp.2018.05.010 [doi] AB - Tumor-infiltrating neutrophils (TINs) and lymphocytes (TILs) are found to play essential roles in many tumors and associate with the prognosis of patients. But, the prognostic values of TINs, TILs and NLR (neutrophils-lymphocytes ratio) in bladder cancer (BC) are still undefined. The object of our study was to systematically interrogate the associations of these immune cells with clinical outcomes of BC patients. In our study, a total of 102 patients pathologically diagnosed with BC were included. CD66b(+) and CD8(+) antibodies were used to mark neutrophils and CD8(+) lymphocytes by immunohistochemistry. The results found that TINs and NLR were significantly associated with pathological T-stages of tumors (P < 0.01), but TILs were not. And TINs were also related to pathological tumor grades (P = 0.012). Regarding the prognostic values, TINs was related to the high risk of recurrence in non-muscle invasive BC (NMIBC) patients. Elevated TINs and NLR were associated with poor overall survivals of BC patients, whereas higher TILs were related to longer survivals (P < 0.01). Multivariate analysis showed that both of TINs (HR 2.427, 1.024-5.752, P = 0.044) and NLR (HR 3.529, 1.147-10.864, P = 0.028) were independent unfavorable prognosis markers. In conclusion, Tumor infiltrating immune cells, including TINs, TILs and NLR were important markers in predicting the prognosis of bladder cancer patients. TINs and NLR were more likely to be negative predictors, but TILs were favorable in patients with BC. CI - Copyright (c) 2018 Elsevier GmbH. All rights reserved. FAU - Liu, Kangkang AU - Liu K AD - Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin 300211, PR China. FAU - Zhao, Kun AU - Zhao K AD - Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin 300211, PR China. FAU - Wang, Lining AU - Wang L AD - Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin 300211, PR China. FAU - Sun, Erlin AU - Sun E AD - Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin 300211, PR China. Electronic address: drelsun@163.com. LA - eng PT - Journal Article DEP - 20180520 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/immunology/mortality/*pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocytes, Tumor-Infiltrating/immunology/*pathology MH - Male MH - Middle Aged MH - Neutrophils/*immunology MH - Prognosis MH - Tumor Microenvironment/*immunology MH - Urinary Bladder Neoplasms/immunology/mortality/*pathology OTO - NOTNLM OT - Bladder cancer OT - Neutrophil/lymphocyte rates OT - Prognosis OT - Tumor-infiltrating lymphocytes OT - Tumor-infiltrating neutrophils EDAT- 2018/05/29 06:00 MHDA- 2018/11/08 06:00 CRDT- 2018/05/28 06:00 PHST- 2018/03/28 00:00 [received] PHST- 2018/04/26 00:00 [revised] PHST- 2018/05/15 00:00 [accepted] PHST- 2018/05/29 06:00 [pubmed] PHST- 2018/11/08 06:00 [medline] PHST- 2018/05/28 06:00 [entrez] AID - S0344-0338(18)30352-2 [pii] AID - 10.1016/j.prp.2018.05.010 [doi] PST - ppublish SO - Pathol Res Pract. 2018 Aug;214(8):1074-1080. doi: 10.1016/j.prp.2018.05.010. Epub 2018 May 20. PMID- 29801011 OWN - NLM STAT- MEDLINE DCOM- 20180607 LR - 20250529 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 319 IP - 18 DP - 2018 May 8 TI - Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. PG - 1880-1888 LID - 10.1001/jama.2018.4657 [doi] AB - IMPORTANCE: Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE: To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS: Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBT were enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patients were monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-up was August 14, 2016. INTERVENTIONS: Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES: The primary outcome was time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS: Among 406 randomized eligible patients (median age, 66 years; 84.7% men), 383 completed the trial. In the intention-to-treat analysis, 67 of 201 patients (4-year estimate, 35%) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47%) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95% CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34%) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54%) in the saline group had cancer recurrence (hazard ratio, 0.53; 95% CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE: Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00445601. FAU - Messing, Edward M AU - Messing EM AD - University of Rochester, Rochester, New York. FAU - Tangen, Catherine M AU - Tangen CM AD - SWOG Statistical Center, Seattle, Washington. AD - Fred Hutchinson Cancer Research Center, Seattle, Washington. FAU - Lerner, Seth P AU - Lerner SP AD - Baylor College of Medicine, Houston, Texas. FAU - Sahasrabudhe, Deepak M AU - Sahasrabudhe DM AD - University of Rochester, Rochester, New York. FAU - Koppie, Theresa M AU - Koppie TM AD - Oregon Health & Science University, Portland. FAU - Wood, David P Jr AU - Wood DP Jr AD - Beaumont Health, Royal Oak, Michigan. FAU - Mack, Philip C AU - Mack PC AD - University of California Davis, Sacramento. FAU - Svatek, Robert S AU - Svatek RS AD - University of Texas-San Antonio, San Antonio. FAU - Evans, Christopher P AU - Evans CP AD - University of California Davis, Sacramento. FAU - Hafez, Khaled S AU - Hafez KS AD - University of Michigan, Ann Arbor. FAU - Culkin, Daniel J AU - Culkin DJ AD - University of Oklahoma, Oklahoma City. FAU - Brand, Timothy C AU - Brand TC AD - Madigan Army Medical Center, Tacoma, Washington. FAU - Karsh, Lawrence I AU - Karsh LI AD - Urology Center of Colorado, Denver. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - University of Kansas Cancer Center, Kansas City. FAU - Wilson, Shandra S AU - Wilson SS AD - University of Colorado, Aurora. FAU - Wu, Guan AU - Wu G AD - University of Rochester, Rochester, New York. FAU - Plets, Melissa AU - Plets M AD - SWOG Statistical Center, Seattle, Washington. AD - Fred Hutchinson Cancer Research Center, Seattle, Washington. FAU - Vogelzang, Nicholas J AU - Vogelzang NJ AD - Comprehensive Cancer Centers of Nevada, Las Vegas. FAU - Thompson, Ian M Jr AU - Thompson IM Jr AD - CHRISTUS Santa Rosa Medical Center, San Antonio, Texas. LA - eng SI - ClinicalTrials.gov/NCT00445601 GR - U10 CA180834/CA/NCI NIH HHS/United States GR - UG1 CA233329/CA/NCI NIH HHS/United States GR - U10 CA180801/CA/NCI NIH HHS/United States GR - U10 CA046113/CA/NCI NIH HHS/United States GR - U10 CA180818/CA/NCI NIH HHS/United States GR - U10 CA058416/CA/NCI NIH HHS/United States GR - UG1 CA233340/CA/NCI NIH HHS/United States GR - P20 CA233374/CA/NCI NIH HHS/United States GR - U10 CA022433/CA/NCI NIH HHS/United States GR - P30 CA093373/CA/NCI NIH HHS/United States GR - N01 CA004919/CA/NCI NIH HHS/United States GR - UG1 CA233178/CA/NCI NIH HHS/United States GR - U10 CA037981/CA/NCI NIH HHS/United States GR - U10 CA128567/CA/NCI NIH HHS/United States GR - U10 CA180858/CA/NCI NIH HHS/United States GR - U10 CA180846/CA/NCI NIH HHS/United States GR - U10 CA068183/CA/NCI NIH HHS/United States GR - UG1 CA189854/CA/NCI NIH HHS/United States GR - U10 CA046282/CA/NCI NIH HHS/United States GR - U10 CA180888/CA/NCI NIH HHS/United States GR - U10 CA180819/CA/NCI NIH HHS/United States GR - UG1 CA189953/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PL - United States TA - JAMA JT - JAMA JID - 7501160 RN - 0 (Antimetabolites, Antineoplastic) RN - 0W860991D6 (Deoxycytidine) RN - 451W47IQ8X (Sodium Chloride) RN - 0 (Gemcitabine) SB - IM CIN - JAMA. 2018 May 8;319(18):1864-1865. doi: 10.1001/jama.2018.4656. PMID: 29800998 CIN - Nat Rev Urol. 2018 Aug;15(8):466. doi: 10.1038/s41585-018-0033-x. PMID: 29849109 CIN - Eur Urol. 2019 Feb;75(2):341-342. doi: 10.1016/j.eururo.2018.10.035. PMID: 30391080 CIN - J Urol. 2019 Mar;201(3):442. doi: 10.1097/01.JU.0000553700.73423.cb. PMID: 30759672 MH - Administration, Intravesical MH - Aged MH - Antimetabolites, Antineoplastic/*administration & dosage/adverse effects MH - Carcinoma, Papillary/*drug therapy/pathology MH - Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives MH - Double-Blind Method MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/*prevention & control MH - Sodium Chloride/*administration & dosage MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Urothelium MH - Gemcitabine PMC - PMC6583489 COIS- Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Lerner reports receipt of personal fees for advisory board membership from BioCancell, Incyte, Nucleix, and UroGen and for consultancy from Vaxiion and clinical trial grants from UroGen, Endo, FKD, Viventia, JBL, and Roche/Genentech. Dr Koppie reports receipt of personal fees from Convergent Genomics. Dr Karsh reports receipt of personal fees for consulting and/or speaking and/or research funding to his institution from Astellas, Bayer, Janssen, Sanofi, Spectrum, Precision Biopsy, 3D Biopsy, Augmenix, Dendreon, Pfizer, Abbvie, Myriad Genetics, AstraZeneca, Vaxiion, and Arivan Research. No other disclosures were reported. EDAT- 2018/05/26 06:00 MHDA- 2018/06/08 06:00 PMCR- 2018/11/08 CRDT- 2018/05/26 06:00 PHST- 2018/05/26 06:00 [entrez] PHST- 2018/05/26 06:00 [pubmed] PHST- 2018/06/08 06:00 [medline] PHST- 2018/11/08 00:00 [pmc-release] AID - 2680547 [pii] AID - joi180038 [pii] AID - 10.1001/jama.2018.4657 [doi] PST - ppublish SO - JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657. PMID- 29799404 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 44 IP - 5 DP - 2018 Sep TI - Assessment of the quality of life and sexual functions of patients followed-up for non-muscle invasive bladder cancer: preliminary results of the prospective-descriptive study. PG - 393-398 LID - 10.5152/tud.2018.30040 [doi] AB - OBJECTIVE: The aim of this study is to evaluate sexual functions and quality life of patients who are followed-up for non-muscle invasive bladder cancer (NMIBC). MATERIAL AND METHODS: Between March 2015-June 2016, 50 patients underwent cystoscopy for NMIBC. At the end of the 1(st) year follow-up patients were assessed for sexual functions using 5-item version of the International Sexual Function Index (IIEF-5) for male and the Female Sexual Function Index(FSFI) for female; for quality of life (QoL) by the European Organisation for Research and Treatment of Cancer-Non-Muscle Invasiv Bladder Cancer Quality of Life Questionnaire (EORTC QLQ-NMIBC24) and for emotional status by Beck depression inventory. RESULTS: There were 44 male and 6 female patients with the mean age of 57.6+/-11.5 years. Twenty patients received intravesical treatment after transurethral resection of bladder tumour. The mean Beck (10.7+/-9.5) IIEF-5 (15.6+/-5.9), FSFI (19.2+/-10.9), and the EORTC-QLQ NMBIC 24 (38.2+/-7.7) scores of the patients were determined as indicated. Among the patients, 42 (84%) of them were not feeling bad about their bladder tumors and 37 (74%) were not worrying about their daily lives. Moreover, 12 (24%) patients were not interested with sexuality, while 27 (54%) of them did not feel comfortable about sexual sincerity. Interestingly, 27 patients receiving intravesical treatment were concerned that the treatment they received for prevention of recurrence and progression of bladder tumor infect their partners during sexual intercourse. CONCLUSION: NMIBC affects patients' sexual functions and QoL negatively. Therefore during the follow-up of these patients, it is important to inform these patients accurately about their treatments to be applied and predicted complications in the follow up period. FAU - Bolat, Deniz AU - Bolat D AUID- ORCID: 0000-0001-7338-8737 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Celik, Serdar AU - Celik S AUID- ORCID: 0000-0003-0939-9989 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Aydin, Mehmet Erhan AU - Aydin ME AUID- ORCID: 0000-0002-3567-9987 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Aydogdu, Ozgu AU - Aydogdu O AUID- ORCID: 0000-0003-3210-4616 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Gunlusoy, Bulent AU - Gunlusoy B AUID- ORCID: 0000-0002-2406-7457 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Degirmenci, Tansu AU - Degirmenci T AUID- ORCID: 0000-0001-7747-3613 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. FAU - Dincel, Cetin AU - Dincel C AUID- ORCID: 0000-0001-9099-6195 AD - Clinic of Urology, Bozyaka Training and Research Hospital, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20170912 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC6134978 COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2018/05/26 06:00 MHDA- 2018/05/26 06:01 PMCR- 2018/09/01 CRDT- 2018/05/26 06:00 PHST- 2018/03/09 00:00 [received] PHST- 2017/12/28 00:00 [accepted] PHST- 2018/05/26 06:00 [pubmed] PHST- 2018/05/26 06:01 [medline] PHST- 2018/05/26 06:00 [entrez] PHST- 2018/09/01 00:00 [pmc-release] AID - tud.2018.30040 [pii] AID - tju-44-5-393 [pii] AID - 10.5152/tud.2018.30040 [doi] PST - ppublish SO - Turk J Urol. 2018 Sep;44(5):393-398. doi: 10.5152/tud.2018.30040. Epub 2017 Sep 12. PMID- 29796171 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 33 DP - 2018 May 1 TI - Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma. PG - 23047-23057 LID - 10.18632/oncotarget.25198 [doi] AB - OBJECTIVES: To develop a surveillance protocol with improved cost-effectiveness after radical nephroureterectomy (RNU), as the cost-effectiveness of oncological surveillance after RNU remains unclear. RESULTS: Of 426 patients, 109 (26%) and 113 (27%) experienced visceral and intravesical recurrences, respectively. The pathology-based protocol found significant differences in recurrence-free survival in the visceral recurrence but not in the intravesical recurrence. The medical costs per visceral recurrence detected were high, especially in normal-risk ( 1.19 g/L (high Apo A-I group). OS and CSS were estimated by Kaplan-Meier analysis and the log-rank test was used to compare differences between groups. Univariate and multivariate Cox regression analyses were plotted to assess the prognostic value of Apo A-I in NMIBC patients. In addition, subgroup analyses were performed according to the risk classification of the International Bladder Cancer Group. RESULTS: In the overall population, patients in the high Apo A-I group had greater 5-year OS and 5-year CSS rates as compared to those in the low Apo A-I group. Kaplan-Meier survival analysis revealed that higher albumin, Apo A-I, and hemoglobin levels were associated with greater OS and CSS while elevated neutrophil-lymphocyte ratio was associated with worse OS and CSS in the overall and high-risk population rather than low- and intermediate-risk population. Furthermore, Apo A-I was shown to be an independent predictor in the overall population (for OS, hazard ratio [HR], 0.364, 95% confidence interval [CI], 0.221-0.598, p < 0.001; for CSS, HR, 0.328, 95% CI, 0.185-0.583, p < 0.001) and high-risk patients (for OS, HR, 0.232, 95% CI 0.121-0.443, p < 0.001; for CSS, HR, 0.269, 95% CI, 0.133-0.541, p < 0.001). CONCLUSION: These results suggest that Apo A-I level could potentially serve as a useful prognostic indicator for therapeutic decision making in NMIBC patients. FAU - Shang, Zhenhua AU - Shang Z AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Wang, Jukun AU - Wang J AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Wang, Xu AU - Wang X AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Yan, Hao AU - Yan H AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Cui, Bo AU - Cui B AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Jia, Chunsong AU - Jia C AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Cui, Xin AU - Cui X AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Li, Jin AU - Li J AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. FAU - Ou, Tongwen AU - Ou T AD - Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20180514 PL - New Zealand TA - Cancer Manag Res JT - Cancer management and research JID - 101512700 PMC - PMC5958942 OTO - NOTNLM OT - NMIBC OT - TURBT OT - apolipoprotein A-I OT - cancer-specific survival OT - overall survival OT - prognosis COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/05/26 06:00 MHDA- 2018/05/26 06:01 PMCR- 2018/05/14 CRDT- 2018/05/26 06:00 PHST- 2018/05/26 06:00 [entrez] PHST- 2018/05/26 06:00 [pubmed] PHST- 2018/05/26 06:01 [medline] PHST- 2018/05/14 00:00 [pmc-release] AID - cmar-10-1177 [pii] AID - 10.2147/CMAR.S165213 [doi] PST - epublish SO - Cancer Manag Res. 2018 May 14;10:1177-1190. doi: 10.2147/CMAR.S165213. eCollection 2018. PMID- 29792974 OWN - NLM STAT- MEDLINE DCOM- 20190104 LR - 20260127 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 118 DP - 2018 Aug TI - Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer. PG - 107-113 LID - S0090-4295(18)30473-4 [pii] LID - 10.1016/j.urology.2018.04.039 [doi] AB - OBJECTIVE: To assess patient adherence to intravesical instillation therapy for nonmuscle invasive urothelial carcinoma outside of clinical trials. MATERIALS AND METHODS: We reviewed the records of patients from 2000 to 2013 who received intravesical therapy for nonmuscle invasive urothelial carcinoma. Patients with evidence of tumor recurrence or progression were excluded. We performed univariable and multivariable regression analyses to predict adherence to intravesical therapy. RESULTS: A total of 729 patients started 861 induction cycles, 63% with bacillus Calmette-Guerin (BCG) and 37% with mitomycin C (MMC). The rate of completion of 6 weeks induction therapy with BCG and MMC was similar (86% and 87%, respectively). Within the BCG cohort, 161 (35%) patients commenced the Southwest Oncology Group (SWOG) maintenance protocol after induction and 16 (10%) completed all 21 treatments. A monthly protocol for BCG was started by 87 patients (19%) and 48 (55%) completed all 9 treatments. MMC therapy was started in 270 patients, 97 of whom (36%) commenced monthly maintenance treatment, and 46 (47%) completed treatments. Median number of instillations was 7 for patients undergoing monthly maintenance therapy (MMC or BCG) and 9 for patients allocated to 3 years BCG. On multivariable analysis, recurrence after prior treatment of urothelial carcinoma was predictive of patients' adherence to treatment. CONCLUSION: Compliance with intravesical therapy is low in clinical practice, notably for longer treatment schedules. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Tapiero, Shlomi AU - Tapiero S AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: shlomitapi@gmail.com. FAU - Helfand, Alexander AU - Helfand A AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Kedar, Daniel AU - Kedar D AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Yossepowitch, Ofer AU - Yossepowitch O AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Nadu, Andrei AU - Nadu A AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Baniel, Jack AU - Baniel J AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Lifshitz, David AU - Lifshitz D AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Margel, David AU - Margel D AD - Division of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20180521 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Urology. 2018 Aug;118:111-112. doi: 10.1016/j.urology.2018.04.041. PMID: 29886039 MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage MH - BCG Vaccine/*administration & dosage MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Female MH - Humans MH - Male MH - Mitomycin/*administration & dosage MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - *Drug Monitoring EDAT- 2018/05/25 06:00 MHDA- 2019/01/05 06:00 CRDT- 2018/05/25 06:00 PHST- 2018/01/06 00:00 [received] PHST- 2018/03/29 00:00 [revised] PHST- 2018/04/02 00:00 [accepted] PHST- 2018/05/25 06:00 [pubmed] PHST- 2019/01/05 06:00 [medline] PHST- 2018/05/25 06:00 [entrez] AID - S0090-4295(18)30473-4 [pii] AID - 10.1016/j.urology.2018.04.039 [doi] PST - ppublish SO - Urology. 2018 Aug;118:107-113. doi: 10.1016/j.urology.2018.04.039. Epub 2018 May 21. PMID- 29787740 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20201009 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 200 IP - 5 DP - 2018 Nov TI - Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study. PG - 1005-1013 LID - S0022-5347(18)43234-X [pii] LID - 10.1016/j.juro.2018.05.078 [doi] AB - PURPOSE: We report the outcomes in patients with muscle invasive bladder cancer from 2 institutions who experienced a clinically complete response to neoadjuvant platinum based chemotherapy and elected active surveillance. It was unknown whether conservative treatment could be safely implemented in these patients. MATERIALS AND METHODS: We retrospectively reviewed the records of patients with muscle invasive bladder cancer at our institutions who elected surveillance following a clinically complete response to transurethral resection of bladder tumors and neoadjuvant chemotherapy from 2001 to 2017. A clinically complete response was defined as absent tumor on post-chemotherapy transurethral resection of bladder tumor, negative cytology and normal cross-sectional imaging. RESULTS: In the 148 patients followed a median of 55 months (range 5 to 145) the 5-year disease specific, overall, cystectomy-free and recurrence-free survival rates were 90%, 86%, 76% and 64%, respectively. Of the patients 71 (48%) experienced recurrence in the bladder, including 16 (11%) with muscle invasive disease and 55 (37%) with noninvasive disease. Salvage radical cystectomy prevented cancer specific death in 9 of 12 patients (75%) who underwent cystectomy after muscle invasive relapse and in 13 of 14 (93%) after noninvasive relapse. CONCLUSIONS: We observed high rates of overall and disease specific survival with bladder preservation in patients who achieved a clinically complete response to neoadjuvant chemotherapy. These outcomes support the safety of active surveillance in carefully selected, closely monitored patients with muscle invasive bladder cancer. Future studies should aim to improve patient selection by identifying biomarkers predicting invasive relapse and developing novel imaging methods of early detection. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Mazza, Patrick AU - Mazza P AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - Moran, George W AU - Moran GW AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - Li, Gen AU - Li G AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York. FAU - Robins, Dennis J AU - Robins DJ AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - Matulay, Justin T AU - Matulay JT AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - Herr, Harry W AU - Herr HW AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Decastro, Guarionex J AU - Decastro GJ AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - McKiernan, James M AU - McKiernan JM AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. FAU - Anderson, Christopher B AU - Anderson CB AD - Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. Electronic address: cba2125@cumc.columbia.edu. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20180519 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Nov;200(5):1011-1012. doi: 10.1016/j.juro.2018.05.157. PMID: 30063891 CIN - J Urol. 2018 Nov;200(5):1012. doi: 10.1016/j.juro.2018.05.158. PMID: 30063894 CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S741-S743. doi: 10.21037/tau.2018.08.18. PMID: 30687613 CIN - Eur Urol. 2019 Jul;76(1):127-129. doi: 10.1016/j.eururo.2019.03.001. PMID: 30879794 MH - Aged MH - Cohort Studies MH - Conservative Treatment/*methods MH - Cystectomy/methods/statistics & numerical data MH - Databases, Factual MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods/mortality MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/epidemiology/*pathology MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*mortality/pathology PMC - PMC7543664 MID - NIHMS1625087 OTO - NOTNLM OT - carcinoma OT - cystectomy OT - drug therapy OT - neoplasm invasiveness OT - urinary bladder neoplasms EDAT- 2018/05/23 06:00 MHDA- 2019/05/29 06:00 PMCR- 2020/10/08 CRDT- 2018/05/23 06:00 PHST- 2018/04/26 00:00 [accepted] PHST- 2018/05/23 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] PHST- 2018/05/23 06:00 [entrez] PHST- 2020/10/08 00:00 [pmc-release] AID - S0022-5347(18)43234-X [pii] AID - 10.1016/j.juro.2018.05.078 [doi] PST - ppublish SO - J Urol. 2018 Nov;200(5):1005-1013. doi: 10.1016/j.juro.2018.05.078. Epub 2018 May 19. PMID- 29787373 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221110 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 12 IP - 9 DP - 2018 Sep TI - Gynecological organ involvement at robot-assisted radical cystectomy in females: Is anterior exenteration necessary? PG - E398-E402 LID - 10.5489/cuaj.5086 [doi] AB - INTRODUCTION: We aimed to investigate patient and disease variables associated with gynecological organ invasion in females with bladder cancer at the time of robot-assisted radical cystectomy (RARC). METHODS: We conducted a retrospective review of female patients who underwent robot-assisted anterior pelvic exenteration (RAAE) between 2005 and 2016. Patients were divided into two groups: those with gynecological organ involvement at RAAE and those without. Data were reviewed for perioperative and pathological outcomes. Kaplan-Meier method was used to depict survival outcomes. Multivariable stepwise regression analysis was performed to identify predictors of gynecological organ involvement. RESULTS: A total of 118 female patients were identified; 17 (14%) showed evidence of gynecological organ invasion at RAAE. Patients with gynecological organ invasion had more lymphovascular invasion at transurethral resection of bladder tumour (TURBT) (82% vs. 46%; p=0.006), trigonal tumours at TURBT (59% vs. 18%; p=0.001), multifocal disease (65% vs. 33%; p=0.01), pN+ (71% vs. 22%; p<0.001), positive surgical margins (24% vs. 4%; p=0.02), and they less commonly demonstrated pure urothelial carcinoma at TURBT (18% vs. 66%; p<0.001). On multivariate analysis, significant predictors of gynecological organ invasion were pN positive disease (odds ratio [OR] 6.48; 95% confidence interval [CI] 1.64-25.51; p=0.008), trigonal tumour location (OR 5.72; 95% CI 1.39-23.61; p=0.02), and presence of variant histology (OR18.52; 95% CI 3.32-103.4; p=0.001). CONCLUSIONS: Patients with trigonal tumours, variant histology, and nodal involvement are more likely to have gynecological organs invasion at RAAE. This information may help improve counselling of patients and better identify candidates for gynecological organ-sparing cystectomy. FAU - Whittum, Michelle AU - Whittum M AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Hussein, Ahmed Aly AU - Hussein AA AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Ahmed, Youssef E AU - Ahmed YE AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Khan, Hijab AU - Khan H AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Krasowski, Collin AU - Krasowski C AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Huben, Neil B AU - Huben NB AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - May, Paul R AU - May PR AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Terakawa, Tomoaki AU - Terakawa T AD - Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Li, Qiang AU - Li Q AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. FAU - Guru, Khurshid A AU - Guru KA AD - Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R25 CA181003/CA/NCI NIH HHS/United States PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC6143501 COIS- Competing interests: The authors report no competing personal or financial interests. EDAT- 2018/05/23 06:00 MHDA- 2018/05/23 06:01 PMCR- 2018/09/01 CRDT- 2018/05/23 06:00 PHST- 2018/05/23 06:00 [entrez] PHST- 2018/05/23 06:00 [pubmed] PHST- 2018/05/23 06:01 [medline] PHST- 2018/09/01 00:00 [pmc-release] AID - cuaj.5086 [pii] AID - cuaj-9-e398 [pii] AID - 10.5489/cuaj.5086 [doi] PST - ppublish SO - Can Urol Assoc J. 2018 Sep;12(9):E398-E402. doi: 10.5489/cuaj.5086. PMID- 29778322 OWN - NLM STAT- MEDLINE DCOM- 20190701 LR - 20190701 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 5 DP - 2018 Oct TI - History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy. PG - e969-e976 LID - S1558-7673(18)30303-3 [pii] LID - 10.1016/j.clgc.2018.04.004 [doi] AB - PURPOSE: To investigate whether a history of non-muscle-invasive bladder cancer (NMIBC) plays a prognostic role in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy in the era when neoadjuvant chemotherapy was established as standard therapy for MIBC. PATIENTS AND METHODS: A total of 282 patients who were diagnosed with cT2-T4aN0M0 bladder cancer treated with open radical cystectomy at our institutions were included. Initially diagnosed MIBC without a history of NMIBC was defined as primary MIBC group (n = 231), and MIBC that progressed from NMIBC was defined as progressive MIBC (n = 51). RESULTS: The rate of cT3/4a tumors was significantly higher in the primary MIBC group than in the progressive MIBC group (P = .004). Five-year recurrence-free survival and cancer-specific survival (CSS) rates for the primary MIBC group versus progressive MIBC group were 68.2% versus 55.9% (P = .039) and 76.1% versus 61.6% (P = .005), respectively. Progressive MIBC (hazard ratio, 2.170; P = .008) was independently associated with cancer death. In the primary MIBC group, the 5-year CSS rate in patients treated with neoadjuvant chemotherapy was 85.4%, which was significantly higher than that in patients without (71.5%, P = .023). In the progressive MIBC group, no significant differences were observed in CSS between patients treated with and without neoadjuvant chemotherapy. CONCLUSION: MIBC that progressed from NMIBC had a significantly worse clinical outcome than MIBC without a history of NMIBC and may not respond as well to neoadjuvant chemotherapy. These results are informative, even for NMIBC patients treated with conservative intravesical therapy. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Kayama, Emina AU - Kayama E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Fukumoto, Keishiro AU - Fukumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Shirotake, Suguru AU - Shirotake S AD - Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Miyazaki, Yasumasa AU - Miyazaki Y AD - Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan. FAU - Hakozaki, Kyohei AU - Hakozaki K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kaneko, Gou AU - Kaneko G AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Yoshimine, Shunsuke AU - Yoshimine S AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Takahiro, Maeda AU - Takahiro M AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Kanai, Kunimitsu AU - Kanai K AD - Department of Urology, National Hospital Organization, Saitama National Hospital, Saitama, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Nakajima, Yosuke AU - Nakajima Y AD - Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan. FAU - Hara, Satoshi AU - Hara S AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Monma, Tetsuo AU - Monma T AD - Department of Urology, National Hospital Organization, Saitama National Hospital, Saitama, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20180428 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Intravesical therapy OT - Neoadjuvant chemotherapy OT - Primary OT - Progression OT - Recurrence EDAT- 2018/05/21 06:00 MHDA- 2019/07/02 06:00 CRDT- 2018/05/21 06:00 PHST- 2017/11/16 00:00 [received] PHST- 2018/03/21 00:00 [revised] PHST- 2018/04/20 00:00 [accepted] PHST- 2018/05/21 06:00 [pubmed] PHST- 2019/07/02 06:00 [medline] PHST- 2018/05/21 06:00 [entrez] AID - S1558-7673(18)30303-3 [pii] AID - 10.1016/j.clgc.2018.04.004 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28. PMID- 29776013 OWN - NLM STAT- MEDLINE DCOM- 20190219 LR - 20190320 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 73 IP - 5 DP - 2018 Nov TI - Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy. PG - 732-740 LID - 10.1111/his.13654 [doi] AB - AIMS: We undertook a systematic evaluation of the prognostic value of numerous histological factors in 165 radical cystectomies (RCs) of patients with invasive urothelial carcinoma (UC) who underwent surgery after neoadjuvant chemotherapy (NAC). METHODS AND RESULTS: Tumour regression grade (TRG) and therapy-related stromal and epithelial changes were also recorded. Locally advanced disease (>/=pT2 and/or pN+) was present in 64% of patients, 22% had no evidence of residual carcinoma (pT0 + pN0), and 28% had no evidence of residual muscle-invasive carcinoma (20% staining present. Clinicopathologic characteristics and oncologic outcomes (recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS)) were compared, stratified by EZH2 positivity. The prognostic role of EZH2 was assessed using Kaplan-Meier, univariate (UVA), and multivariate (MVA) Cox regression analyses. Significance was defined for P<0.05. RESULTS: A total of 376 patients were included for analysis, with median follow-up 36.0 months. Overall, 78 (20.7%) were EZH2-positive. EZH2 expression was more often associated with ureteral location, lymphovascular invasion, sessile architecture, necrosis, and concomitant carcinoma in situ. On UVA, increased EZH2 expression was a significant predictor for inferior RFS (HR 1.63, P = 0.033), CSS (HR 2.03, P = 0.003), and OS (HR 2.11, P<0.001). On MVA EZH2 remained a significant predictor of worse CSS (HR 1.99 [95% CI: 1.21-3.27], P = 0.007) and OS (HR 1.54 [95% CI: 1.06-2.24], P = 0.024), while significance was lost for RFS. CONCLUSION: Increased EZH2 expression is associated with adverse pathologic features and inferior oncologic outcomes in patients with high-grade UTUC. The role of EZH2 biology in UTUC pathogenesis remains to be further elucidated. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Aydin, Ahmet M AU - Aydin AM AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Hacettepe University, Ankara, Turkey. FAU - Panwar, Vandana AU - Panwar V AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Woldu, Solomon L AU - Woldu SL AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Freifeld, Yuval AU - Freifeld Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Wood, Christopher G AU - Wood CG AD - Department of Urology, MD Anderson Cancer Center, Houston, TX. FAU - Karam, Jose A AU - Karam JA AD - Department of Urology, MD Anderson Cancer Center, Houston, TX. FAU - Weizer, Alon Z AU - Weizer AZ AD - Department of Urology, University of Michigan Cancer Center, Ann Arbor, MI. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Remzi, Mesut AU - Remzi M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Rioux-Leclercq, Nathalie AU - Rioux-Leclercq N AD - Department of Pathology, Centre Hospitalier Universitaire de Rennes, Rennes, France. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Medical University Vienna, Vienna, Austria. FAU - Roscigno, Marco AU - Roscigno M AD - Department of Urology, Ospedali Riuniti of Bergamo, Bergamo, Italy. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, University of Ulm, Ulm, Germany. FAU - Bensalah, Karim AU - Bensalah K AD - Department of Urology, Centre Hospitalier Universitaire de Rennes, Rennes, France. FAU - Sagalowsky, Arthur I AU - Sagalowsky AI AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Kapur, Payal AU - Kapur P AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: vitaly.margulis@utsouthwestern.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20180507 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/metabolism/*pathology/surgery MH - Cohort Studies MH - Enhancer of Zeste Homolog 2 Protein/*metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/metabolism/*pathology/surgery MH - Nephroureterectomy/*mortality MH - Survival Rate MH - Urologic Neoplasms/metabolism/*pathology/surgery OTO - NOTNLM OT - Enhancer of zeste homolog 2 OT - Outcomes OT - Prognostic biomarker OT - Upper tract urothelial carcinoma EDAT- 2018/05/12 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/05/12 06:00 PHST- 2018/02/10 00:00 [received] PHST- 2018/04/07 00:00 [revised] PHST- 2018/04/09 00:00 [accepted] PHST- 2018/05/12 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/05/12 06:00 [entrez] AID - S1078-1439(18)30126-1 [pii] AID - 10.1016/j.urolonc.2018.04.004 [doi] PST - ppublish SO - Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7. PMID- 29742009 OWN - NLM STAT- MEDLINE DCOM- 20190812 LR - 20230915 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 36 IP - 19 DP - 2018 Jul 1 TI - Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. PG - 1949-1956 LID - 10.1200/JCO.2017.75.0158 [doi] AB - Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neoadjuvant regimen remains undefined. We assessed the efficacy and tolerability of six cycles of neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC. Patients and Methods In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m(2) on day 1 and cisplatin 35 mg/m(2) on days 1 and 2) every 2 weeks for 6 cycles followed by RC. The primary end point was pathologic downstaging to non-muscle-invasive disease (< pT2N0). Patients who did not undergo RC were deemed nonresponders. Pretreatment tumors underwent next-generation sequencing to identify predictors of chemosensitivity. Results Forty-nine patients were enrolled from three institutions. The primary end point was met, with 57% of 46 evaluable patients downstaged to < pT2N0. Pathologic response correlated with improved recurrence-free survival and overall survival. Nineteen patients (39%) required toxicity-related dose modifications. Sixty-seven percent of patients completed all six planned cycles. No patient failed to undergo RC as a result of chemotherapy-associated toxicities. The most frequent treatment-related toxicity was anemia (12%; grade 3). The presence of a presumed deleterious DNA damage response (DDR) gene alteration was associated with chemosensitivity (positive predictive value for < pT2N0 [89%]). No patient with a deleterious DDR gene alteration has experienced recurrence at a median follow-up of 2 years. Conclusion Six cycles of ddGC is an active, well-tolerated neoadjuvant regimen for the treatment of patients with MIBC. The presence of a putative deleterious DDR gene alteration in pretreatment tumor tissue strongly predicted for chemosensitivity, durable response, and superior long-term survival. FAU - Iyer, Gopa AU - Iyer G AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Balar, Arjun V AU - Balar AV AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Milowsky, Matthew I AU - Milowsky MI AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Bochner, Bernard H AU - Bochner BH AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Dalbagni, Guido AU - Dalbagni G AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Donat, S Machele AU - Donat SM AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Herr, Harry W AU - Herr HW AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Huang, William C AU - Huang WC AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Taneja, Samir S AU - Taneja SS AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Woods, Michael AU - Woods M AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Al-Ahmadie, Hikmat AU - Al-Ahmadie H AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Arcila, Maria E AU - Arcila ME AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Riches, Jamie C AU - Riches JC AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Meier, Andreas AU - Meier A AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Bourque, Caitlin AU - Bourque C AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Shady, Maha AU - Shady M AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Won, Helen AU - Won H AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Rose, Tracy L AU - Rose TL AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Kim, William Y AU - Kim WY AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Kania, Brooke E AU - Kania BE AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Boyd, Mariel E AU - Boyd ME AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Cipolla, Catharine K AU - Cipolla CK AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Regazzi, Ashley M AU - Regazzi AM AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Delbeau, Daniela AU - Delbeau D AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - McCoy, Asia S AU - McCoy AS AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Vargas, Hebert Alberto AU - Vargas HA AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Berger, Michael F AU - Berger MF AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Solit, David B AU - Solit DB AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Rosenberg, Jonathan E AU - Rosenberg JE AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Bajorin, Dean F AU - Bajorin DF AD - Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC. LA - eng SI - ClinicalTrials.gov/NCT01589094 GR - K12 CA120780/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P50 CA221745/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180509 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0W860991D6 (Deoxycytidine) RN - 3A58010674 (pegfilgrastim) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - PVI5M0M1GW (Filgrastim) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) CIN - Eur Urol. 2019 Dec;76(6):870-871. doi: 10.1016/j.eururo.2019.07.019. PMID: 31351667 CIN - J Urol. 2020 Apr;203(4):659-660. doi: 10.1097/JU.0000000000000729. PMID: 31928467 MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage/adverse effects MH - Cystectomy MH - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives MH - Disease-Free Survival MH - Female MH - Filgrastim/administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnostic imaging/pathology MH - Neoplasm Staging MH - Polyethylene Glycols/administration & dosage MH - Prospective Studies MH - Urinary Bladder Neoplasms/diagnostic imaging/*drug therapy/pathology/surgery MH - Gemcitabine PMC - PMC6049398 EDAT- 2018/05/10 06:00 MHDA- 2019/08/14 06:00 PMCR- 2019/07/01 CRDT- 2018/05/10 06:00 PHST- 2018/05/10 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2018/05/10 06:00 [entrez] PHST- 2019/07/01 00:00 [pmc-release] AID - 750158 [pii] AID - 10.1200/JCO.2017.75.0158 [doi] PST - ppublish SO - J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9. PMID- 29737959 OWN - NLM STAT- MEDLINE DCOM- 20190819 LR - 20220409 IS - 2038-2529 (Electronic) IS - 0300-8916 (Linking) VI - 104 IP - 6 DP - 2018 Dec TI - Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma. PG - 451-458 LID - 10.5301/tj.5000705 [doi] AB - PURPOSE: The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). METHODS: We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS. RESULTS: In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016). CONCLUSIONS: Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis. FAU - Wu, Yu-Peng AU - Wu YP AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Lin, Yun-Zhi AU - Lin YZ AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Lin, Min-Yi AU - Lin MY AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Lin, Ting-Ting AU - Lin TT AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Chen, Shao-Hao AU - Chen SH AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Wei, Yong AU - Wei Y AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Zheng, Qing-Shui AU - Zheng QS AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Xue, Xue-Yi AU - Xue XY AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. FAU - Xu, Ning AU - Xu N AD - Departments of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou - PR China. LA - eng PT - Journal Article DEP - 20180508 PL - United States TA - Tumori JT - Tumori JID - 0111356 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*mortality/*pathology MH - Nephrectomy/methods MH - Proportional Hazards Models MH - Risk Factors MH - Survival Rate MH - Ureteral Neoplasms/*mortality/*pathology MH - Urinary Bladder Neoplasms/*mortality/*pathology MH - Young Adult OTO - NOTNLM OT - Bladder cancer recurrence survival OT - Nephroureterectomy OT - SEER OT - Segmental ureterectomy OT - Upper-tract urothelial carcinoma EDAT- 2018/05/09 06:00 MHDA- 2019/08/20 06:00 CRDT- 2018/05/09 06:00 PHST- 2018/05/09 06:00 [pubmed] PHST- 2019/08/20 06:00 [medline] PHST- 2018/05/09 06:00 [entrez] AID - 10.5301/tj.5000705 [doi] PST - ppublish SO - Tumori. 2018 Dec;104(6):451-458. doi: 10.5301/tj.5000705. Epub 2018 May 8. PMID- 29737231 OWN - NLM STAT- MEDLINE DCOM- 20190118 LR - 20190118 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 18 IP - 7 DP - 2018 Jul TI - Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. PG - 695-703 LID - 10.1080/14737140.2018.1474104 [doi] AB - The recurrence rate of non-muscle-invasive bladder cancer (NMIBC) is up to 60% within the first year of therapy. Accurate risk stratification is necessary for patient counselling, follow-up scheduling and individualized therapeutic decision making. Current prognostic models rely on clinicopathologic features, but their discrimination remains limited when in external cohorts. Despite intense efforts regarding the value of biomarkers in prognosticating outcomes in NMIBC, clinical utility remains suboptimal. It is clear that a single biomarker is not enough for the prediction of disease recurrence. Therefore, panels of non-redundant biomarkers have been created and integrated in clinical prognostic model further research relying on high throughput technologies is required. Areas covered: We performed a systematic research of the English-language literature on tissue biomarkers for prediction of NMIBC outcomes up to December 2017. Expert commentary: Despite the essential milestones achieved in our knowledge and understanding of the molecular biology underlying NMIBC, no biomarker has been implemented together with clinical feature in clinical practice. Integration of such biomarkers into predictive and prognostic model could, however, improve our accuracy, thereby paving the way for personalized medicine in the management of NMIBC. FAU - D'Andrea, David AU - D'Andrea D AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Hassler, Melanie R AU - Hassler MR AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. AD - b Division of Urology, Department of Special Surgery , Jordan University Hospital, The University of Jordan , Amman , Jordan. FAU - Soria, Francesco AU - Soria F AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Ertl, Iris E AU - Ertl IE AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Ilijazi, Dafina AU - Ilijazi D AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Mari, Andrea AU - Mari A AD - c Department of Urology , University of Florence, Careggi Hospital , Florence , Italy. FAU - Foerster, Beat AU - Foerster B AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. FAU - Egger, Gerda AU - Egger G AD - d Department of Pathology , Medical University of Vienna , Vienna , Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - a Department of Urology , Medical University of Vienna , Vienna , Austria. AD - e Institute of Andrology and Urology , Karl Landsteiner University , Krems an der Donau , Austria. AD - f Department of Urology , University of Texas Southwestern Medical Centre , Dallas , TX , USA. AD - g Department of Urology , Weill Cornell Medical College , New York , NY , USA. LA - eng PT - Journal Article PT - Review DEP - 20180509 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Biomarkers, Tumor) SB - IM MH - Animals MH - Biomarkers, Tumor/*metabolism MH - Disease Progression MH - High-Throughput Screening Assays/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Precision Medicine/*methods MH - Predictive Value of Tests MH - Prognosis MH - Urinary Bladder Neoplasms/*pathology/therapy OTO - NOTNLM OT - Non-muscle-invasive OT - biomarker OT - bladder cancer OT - outcomes OT - prediction EDAT- 2018/05/09 06:00 MHDA- 2019/01/19 06:00 CRDT- 2018/05/09 06:00 PHST- 2018/05/09 06:00 [pubmed] PHST- 2019/01/19 06:00 [medline] PHST- 2018/05/09 06:00 [entrez] AID - 10.1080/14737140.2018.1474104 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2018 Jul;18(7):695-703. doi: 10.1080/14737140.2018.1474104. Epub 2018 May 9. PMID- 29733795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 44 IP - 3 DP - 2018 May TI - Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: A review of 305 patients. PG - 213-220 LID - 10.5152/tud.2018.19677 [doi] AB - OBJECTIVE: Bladder cancer recurrence after management of upper tract urothelial carcinoma (UTUC) is a common disease. Although the incidence and risk factors for the development of noninvasive bladder tumor have been reported in many series, rare studies have reported on muscle invasive bladder cancer (MIBC) and its urethral recurrence. We aimed to report the incidence, risk factors and survival rate for the development of MIBC and urethral tumors after surgical management of UTUC. MATERIAL AND METHODS: We retrospectively reviewed patients who were surgically treated for UTUC from 1983 to 2013. The tumor was categorized according to the 1997 TNM staging and the 3-tiered WHO grading systems. The primary endpoint of this study was the occurrence of any post-treatment MIBC and its urethral recurrences. We studied the possible risk factors that may contribute to the development of such pathology as well as the prognosis of this pathology. RESULTS: A total of 297 patients were eligible for analysis. Intravesical tumor recurrence was observed in 139 (46.8%) patients and radical cystectomy was warranted for 36 patients (MIBC or multicentric bladder recurrence). Twenty-seven patients were fit for surgery with ileal loop conduit was the urinary diversion for the majority, and others received radiotherapy. Ureteral tumor was the only statistically significant risk factor (p=0.001) and the incidence increased as the ureteral tumors became more distal (p=0.01). Occurrence of invasive or multicenteric bladder recurrence was a predictor for local, urethral recurrence and distant metastasis (p=0.016, 0.0001 and 0.01 respectively). Seven patients had urethral urothelial carcinoma; 5 were diagnosed at the time of cystectomy and 2 were discovered later (1 and 3 years after cystectomy). CONCLUSION: MIBC is a relatively uncommon (6%) post UTUC, and ureteral tumors, especially distal in location, are the independent risk factor. Extended surveillance for those patients is needed. Urethral cancer recurrence is rare (2%); most cases are localized in the posterior urethra, they are noninvasive, and may develop even after cystectomy. FAU - Elawdy, Mohamed Mohamed AU - Elawdy MM AD - Department of Urology, Sohar Hospital, Ministry of Health, Sultanate of Oman, Sohar, Oman. FAU - Osman, Yasser AU - Osman Y AD - Department of Urology, Mansoura University, Urology and Nephrology Center, Mansoura, Egypt. FAU - Taha, Diaa Eldin AU - Taha DE AD - Department of Urology, Kafr El Sheikh University Faculty of Medicine, Kafr El Sheikh, Egypt. FAU - El-Halwagy, Samer AU - El-Halwagy S AD - Department of Urology, Sohar Hospital, Ministry of Health, Sultanate of Oman, Sohar, Oman. LA - eng PT - Journal Article DEP - 20180306 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC5937641 COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2018/05/08 06:00 MHDA- 2018/05/08 06:01 PMCR- 2018/05/01 CRDT- 2018/05/08 06:00 PHST- 2017/09/05 00:00 [received] PHST- 2017/12/04 00:00 [accepted] PHST- 2018/05/08 06:00 [entrez] PHST- 2018/05/08 06:00 [pubmed] PHST- 2018/05/08 06:01 [medline] PHST- 2018/05/01 00:00 [pmc-release] AID - tud.2018.19677 [pii] AID - tju-44-3-213 [pii] AID - 10.5152/tud.2018.19677 [doi] PST - ppublish SO - Turk J Urol. 2018 May;44(3):213-220. doi: 10.5152/tud.2018.19677. Epub 2018 Mar 6. PMID- 29733363 OWN - NLM STAT- MEDLINE DCOM- 20180727 LR - 20220318 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 48 IP - 7 DP - 2018 Jul 1 TI - Bacillus Calmette-Guerin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study. PG - 661-666 LID - 10.1093/jjco/hyy066 [doi] AB - OBJECTIVES: To clarify the efficacy of intravesical Bacillus Calmette-Guerin (BCG) instillation for non-muscle invasive bladder (NMIBC) cancer with variant histology, especially glandular differentiation or squamous differentiation. MATERIALS AND METHODS: From May 1991 through June 2016, 53 patients were diagnosed retrospectively as having NMIBC with variant histology. Among these patients, 47 NMIBC patients with squamous differentiation or glandular differentiation were analyzed for this study. The median follow-up interval from diagnosis of NMIBC with variant histology was 28.9 months (1.5-168.8). RESULTS: Of these patients, 38 (80.9%) and 9 (19.1%) were diagnosed as having glandular differentiation and squamous differentiation, respectively. Radical cystectomy was conducted for six (12.8%) immediately after the diagnosis of NMIBC with variant histology. Of the 41 patients with bladder preservation, 20 (48.8%), 3 (7.3%), 3 (7.3%) and 15 (36.6%) underwent BCG, THP, MMC and no additional treatment, respectively. There were significant differences between BCG and other treatments or no additional treatment for recurrence (P = 0.034), progression (P = 0.004) and cancer-specific survival (P = 0.014). CONCLUSION: Overall, our results show that intravesical BCG instillation for variant histology in NMIBC leads to a better prognosis with regard to progression and cause-specific survival than other intravesical treatments or no additional treatment. BCG treatment may also have a clinical benefit for variant histology in non-muscle invasive bladder cancer patients. FAU - Yorozuya, Wakako AU - Yorozuya W AD - Department of Urology, Sapporo Medical University School of Medicine. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Sapporo Medical University School of Medicine. FAU - Shindo, Tetsuya AU - Shindo T AD - Department of Urology, Sapporo Medical University School of Medicine. FAU - Kyoda, Yuki AU - Kyoda Y AD - Department of Urology, NTT East Japan Sapporo Hospital. FAU - Itoh, Naoki AU - Itoh N AD - Department of Urology, NTT East Japan Sapporo Hospital. FAU - Sugita, Shintaro AU - Sugita S AD - Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Hasegawa, Tadashi AU - Hasegawa T AD - Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine. LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/pharmacology/*therapeutic use MH - Carcinoma, Squamous Cell/*drug therapy/*pathology MH - *Cell Differentiation/drug effects MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/pathology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/*pathology EDAT- 2018/05/08 06:00 MHDA- 2018/07/28 06:00 CRDT- 2018/05/08 06:00 PHST- 2018/02/22 00:00 [received] PHST- 2018/04/17 00:00 [accepted] PHST- 2018/05/08 06:00 [pubmed] PHST- 2018/07/28 06:00 [medline] PHST- 2018/05/08 06:00 [entrez] AID - 4992852 [pii] AID - 10.1093/jjco/hyy066 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2018 Jul 1;48(7):661-666. doi: 10.1093/jjco/hyy066. PMID- 29732157 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240324 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 8 IP - 6 DP - 2018 Jun TI - A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases. PG - 785-790 LID - 10.3892/mco.2018.1602 [doi] AB - The aim of the present study was to evaluate the prognostic impact of size and number of tumors in primary low-grade (LG) Ta bladder urothelial carcinoma (UC), and thus allow accurate risk stratification of low-risk non-muscle invasive bladder cancer (NMIBC). This study was a retrospective analysis of 245 patients with primary LG Ta UC of the urinary bladder who were treated with transurethral resection. Differences in intravesical recurrence-free survival (RFS) according to various cutoff values of tumor size and tumor number were calculated using Cox proportional hazards model. Median maximum size of tumor was 1.4 cm, and 153 patients (62.4%) had solitary tumors. Forty-nine patients experienced intravesical recurrence during a median 34 months of follow-up. Patients with solitary tumors had significantly longer RFS times compared with those with >/=8 tumors (P=0.003). Patients with larger tumors had significantly shorter RFS times for each cutoff value (P=0.01 for 1.0 cm, P<0.0001 for 1.5 and 2.0 cm, P=0.006 for 3.0 cm). On multivariate analysis, each cutoff value of tumor size was found to be a predictor of RFS; among them, the cutoff of 1.5 cm showed the strongest association (hazard ratio, 4.12; 95% confidence interval, 2.11-8.81; P<0.001). If we consider only lower risk NMIBC patients, such as primary LG Ta, the appropriate cutoff value of tumor size to predict intravesical recurrence might be 1.5 cm, but not 3.0 cm generally adopted in various guidelines. These findings suggest the need for rational risk assessment with consideration of the diversity of patients with NMIBC. FAU - Akitake, Masakazu AU - Akitake M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Kiyoshima, Keijiro AU - Kiyoshima K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Department of Urology, Harasanshin Hospital, Fukuoka 812-0033, Japan. FAU - Shiga, Kenichiro AU - Shiga K AD - Department of Urology, Harasanshin Hospital, Fukuoka 812-0033, Japan. FAU - Koga, Hirofumi AU - Koga H AD - Department of Urology, Harasanshin Hospital, Fukuoka 812-0033, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Tatsugami, Katsunori AU - Tatsugami K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. FAU - Yamaguchi, Akito AU - Yamaguchi A AD - Department of Urology, Harasanshin Hospital, Fukuoka 812-0033, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Harasanshin Hospital, Fukuoka 812-0033, Japan. LA - eng PT - Journal Article DEP - 20180402 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC5921295 OTO - NOTNLM OT - bladder cancer OT - low-grade urothelial carcinoma OT - risk classification OT - tumor size EDAT- 2018/05/08 06:00 MHDA- 2018/05/08 06:01 PMCR- 2018/04/02 CRDT- 2018/05/08 06:00 PHST- 2018/01/08 00:00 [received] PHST- 2018/03/30 00:00 [accepted] PHST- 2018/05/08 06:00 [entrez] PHST- 2018/05/08 06:00 [pubmed] PHST- 2018/05/08 06:01 [medline] PHST- 2018/04/02 00:00 [pmc-release] AID - MCO-0-0-1602 [pii] AID - 10.3892/mco.2018.1602 [doi] PST - ppublish SO - Mol Clin Oncol. 2018 Jun;8(6):785-790. doi: 10.3892/mco.2018.1602. Epub 2018 Apr 2. PMID- 29727914 OWN - NLM STAT- MEDLINE DCOM- 20190531 LR - 20190531 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 122 IP - 5 DP - 2018 Nov TI - Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis. PG - 808-813 LID - 10.1111/bju.14370 [doi] AB - OBJECTIVES: To perform a systematic evaluation of whether germline DNA repair gene mutations in bladder cancer (BCa) are associated with increased risk of BCa and aggressive disease. MATERIALS AND METHODS: Germline DNA from 98 patients with BCa was analysed for 54 DNA repair genes using a customized targeted sequencing panel. Population control data were obtained from the public databases the Exome Aggregation Consortium database and the Genome Aggregation Database. Mutation pathogenicity was annotated based on American College of Medical Genetics criteria, mutation frequencies in the general population and the ClinVar database. Mutation frequencies were compared based on case-control and case-case designs for disease risks, disease aggressiveness and outcomes. RESULTS: The frequency of pathogenic/likely pathogenic germline DNA repair gene mutations was 10.2% among patients with BCa. Within the subset of patients with carcinoma invading the bladder muscle, the frequency was 15.8%, ~2.4-fold higher than in patients with non-muscle invasive BCa (6.67%). The mutation frequency among patients with early-onset disease (at age <45 years) was ~3-fold higher than among those diagnosed after age 45 years (28.57% vs 8.79%). Mutation carriers had a significantly higher frequency of unfavourable clinical outcomes (disease recurrence or progression to metastatic BCa) than non-carriers (50.0% vs 13.64%; P = 0.013). CONCLUSION: Pathogenic and likely pathogenic mutations in DNA repair genes were associated with unfavourable prognosis of BCa. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Na, Rong AU - Na R AUID- ORCID: 0000-0001-7470-5108 AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Wu, Yishuo AU - Wu Y AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. FAU - Jiang, Guangliang AU - Jiang G AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Yu, Hongjie AU - Yu H AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. FAU - Lin, Xiaoling AU - Lin X AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Wang, Meilin AU - Wang M AD - State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China. FAU - Conran, Carly A AU - Conran CA AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. FAU - Fantus, Richard J AU - Fantus RJ AUID- ORCID: 0000-0002-7529-511X AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. AD - Division of Urology, Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA. FAU - Zhang, Ning AU - Zhang N AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Liu, Shenghua AU - Liu S AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Helfand, Brian T AU - Helfand BT AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. FAU - Zheng, Siqun L AU - Zheng SL AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. FAU - Isaacs, William B AU - Isaacs WB AD - Department of Urology, James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. AD - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. FAU - Ding, Qiang AU - Ding Q AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Shen, Zhoujun AU - Shen Z AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Xu, Jianfeng AU - Xu J AUID- ORCID: 0000-0002-1343-8752 AD - Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. AD - Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180604 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - DNA Repair/*genetics MH - Female MH - *Genetic Predisposition to Disease/epidemiology/genetics MH - Germ-Line Mutation/*genetics MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/genetics OTO - NOTNLM OT - DNA repair genes OT - bladder cancer OT - germline OT - mutation EDAT- 2018/05/05 06:00 MHDA- 2019/06/01 06:00 CRDT- 2018/05/05 06:00 PHST- 2018/05/05 06:00 [pubmed] PHST- 2019/06/01 06:00 [medline] PHST- 2018/05/05 06:00 [entrez] AID - 10.1111/bju.14370 [doi] PST - ppublish SO - BJU Int. 2018 Nov;122(5):808-813. doi: 10.1111/bju.14370. Epub 2018 Jun 4. PMID- 29725532 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 8 IP - 5 DP - 2018 May TI - Clinical significance of random bladder biopsy in primary T1 bladder cancer. PG - 665-670 LID - 10.3892/mco.2018.1587 [doi] AB - The clinical significance of random bladder biopsies in primary non-muscle-invasive bladder cancer is unclear. The present study investigated the significance of positive random bladder biopsies in primary T1 NMIBC. The present study retrospectively reviewed the records of 71 patients with primary pT1N0M0 bladder cancer who underwent transurethral resection of the bladder tumor (TURBT) and concomitant random bladder biopsy. A total of 12 patients who received cystectomy immediately following the TURBT were excluded, and the remaining 59 patients were included in the analysis. Random bladder biopsy was defined as a cold-cup biopsy of pre-specified normal-looking areas in the bladder. The association of clinicopathological factors, including random biopsy results, with intravesical recurrence were assessed by univariate and multivariate Cox proportional hazards analyses. Of the 59 patients, 15 (25%) demonstrated carcinoma in situ (CIS) lesions on random bladder biopsy: Five (33%) in biopsy specimens alone and the remaining 10 (67%) in biopsy and TUR specimens. Positive random biopsy was associated with preoperative positive urine cytology (P=0.011) and small size of the main tumor (P=0.008). Multivariate analysis demonstrated positive random biopsy as the sole independent poor prognostic factor for intravesical recurrence (hazard ratio: 4.69, P=0.014). The five patients who had CIS detected in biopsy specimens alone had worse, although non-significantly worse, recurrence-free survival compared with those with CIS detected in biopsy and TUR specimens (P=0.100). In conclusion, positive bladder random biopsy, equivalent to the presence of CIS, was an independent predictor of recurrence in primary T1 bladder cancer. Given that one-third of CIS lesions could not have been detected without biopsy, random bladder biopsy should be considered for patients with T1 tumors. FAU - Otsuka, Masafumi AU - Otsuka M AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Maekawa, Shigekatsu AU - Maekawa S AD - Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Miyakawa, Jimpei AU - Miyakawa J AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Matsumoto, Akihiko AU - Matsumoto A AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Miyazaki, Hideyo AU - Miyazaki H AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Fujimura, Tetsuya AU - Fujimura T AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Igawa, Yasuhiko AU - Igawa Y AD - Department of Continence Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. FAU - Homma, Yukio AU - Homma Y AD - Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. LA - eng PT - Journal Article DEP - 20180308 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC5920156 OTO - NOTNLM OT - bladder cancer OT - carcinoma in situ OT - non-muscle-invasive bladder cancer OT - random bladder biopsy OT - recurrence EDAT- 2018/05/05 06:00 MHDA- 2018/05/05 06:01 PMCR- 2018/03/08 CRDT- 2018/05/05 06:00 PHST- 2017/11/07 00:00 [received] PHST- 2018/02/27 00:00 [accepted] PHST- 2018/05/05 06:00 [entrez] PHST- 2018/05/05 06:00 [pubmed] PHST- 2018/05/05 06:01 [medline] PHST- 2018/03/08 00:00 [pmc-release] AID - MCO-0-0-1587 [pii] AID - 10.3892/mco.2018.1587 [doi] PST - ppublish SO - Mol Clin Oncol. 2018 May;8(5):665-670. doi: 10.3892/mco.2018.1587. Epub 2018 Mar 8. PMID- 29721611 OWN - NLM STAT- MEDLINE DCOM- 20190318 LR - 20220408 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 36 IP - 10 DP - 2018 Oct TI - Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. PG - 1621-1627 LID - 10.1007/s00345-018-2299-2 [doi] AB - PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model. RESULTS: During a median follow-up of 5.2 years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P < 0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P < 0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen. CONCLUSIONS: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease. FAU - Palou, J AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. FAU - Pisano, F AU - Pisano F AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. francescapisano85@gmail.com. AD - Dept of Urology, Ospedale "Citta della Salute e della Scienza-Molinette", Corso Bramante 88, 10126, Turin, Italy. francescapisano85@gmail.com. FAU - Sylvester, R AU - Sylvester R AD - Department of Biostatistics, EORTC Headquarters, Brussels, Belgium. FAU - Joniau, S AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Louvain, Belgium. FAU - Serretta, V AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Larre, S AU - Larre S AD - Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK. FAU - Di Stasi, S AU - Di Stasi S AD - Policlinico Tor Vergata-University of Rome, Rome, Italy. FAU - van Rhijn, B AU - van Rhijn B AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Witjes, A J AU - Witjes AJ AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Grotenhuis, A AU - Grotenhuis A AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Colombo, R AU - Colombo R AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Briganti, A AU - Briganti A AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Babjuk, M AU - Babjuk M AD - Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic. FAU - Soukup, V AU - Soukup V AD - Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic. FAU - Malmstrom, P U AU - Malmstrom PU AD - Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden. FAU - Irani, J AU - Irani J AD - Department of Urology, Centre Hospitalier Universitaire La Miletrie, University of Poitiers, Poitiers, France. FAU - Malats, N AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Baniel, J AU - Baniel J AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Mano, R AU - Mano R AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Cai, T AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - Cha, E K AU - Cha EK AD - Department of Urology, Weill Medical College of Cornell University, New York, NY, USA. FAU - Ardelt, P AU - Ardelt P AD - Facharzt fur Urologie, Abteilung fur Urologie, Chirurgische Universitats klinik, Freiburg, Germany. FAU - Varkarakis, J AU - Varkarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Bartoletti, R AU - Bartoletti R AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Dalbagni, G AU - Dalbagni G AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Shariat, S F AU - Shariat SF AD - Medical University of Vienna, Vienna, Austria. FAU - Xylinas, E AU - Xylinas E AD - Department of Urology, Cochin Hospital, Paris, France. FAU - Karnes, R J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Gontero, P AU - Gontero P AD - Dept of Urology, Ospedale "Citta della Salute e della Scienza-Molinette", Corso Bramante 88, 10126, Turin, Italy. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20180502 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*therapeutic use MH - Cause of Death MH - Cystectomy/*methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Recurrence, Local/mortality MH - Neoplasm Staging MH - Proportional Hazards Models MH - Reoperation MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/mortality/pathology/therapy PMC - PMC8177015 MID - NIHMS1685833 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - Progression OT - Re-transurethral resection of the bladder OT - Recurrence COIS- Conflict of interest None. EDAT- 2018/05/04 06:00 MHDA- 2019/03/19 06:00 PMCR- 2021/06/04 CRDT- 2018/05/04 06:00 PHST- 2018/02/20 00:00 [received] PHST- 2018/04/13 00:00 [accepted] PHST- 2018/05/04 06:00 [pubmed] PHST- 2019/03/19 06:00 [medline] PHST- 2018/05/04 06:00 [entrez] PHST- 2021/06/04 00:00 [pmc-release] AID - 10.1007/s00345-018-2299-2 [pii] AID - 10.1007/s00345-018-2299-2 [doi] PST - ppublish SO - World J Urol. 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2. PMID- 29719631 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 26 DP - 2018 Apr 6 TI - Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor. PG - 18627-18636 LID - 10.18632/oncotarget.23896 [doi] AB - OBJECTIVE: To investigate the prognostic role of hematological biomarkers, especially hemoglobin-platelet ratio (HPR) in the oncological outcomes in stage 1 and grade 3 (T1G3) bladder cancer. MATERIALS AND METHODS: We identified 457 T1G3 bladder cancer patients who underwent transurethral resection of the bladder (TURB) between 2009 and 2014. Based on hematological parameters (hemoglobin-platelet ratio (HPR), hemoglobin, and platelet counts), recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) and cancer-specific survival (CSS) were analyzed by using Kaplan-Meier analysis. Multivariate Cox regression model was adopted to identify the predictors of oncological outcomes. RESULTS: Kaplan-Meier survival analysis showed that low HPR (< 0.615), low hemoglobin (< 125g/l) and elevated platelet counts (> 240 x 10(3)/mul) were correlated with poor OS. Low HPR, but not low hemoglobin and high platelet counts, is associated with worse PFS. Low HPR and low hemoglobin, but not elevated platelet counts, are associated with worse CSS. However, no significant difference was observed in RFS according to any of these hematological markers. On multivariate analysis, low HPR (HR = 1.27, 95% CI = 0.81-1.75, P = 0.030), low hemoglobin (HR = 1.20, 95% CI = 0.79-1.84, P = 0.028) and elevated platelet counts (HR = 1.07, 95% CI = 0.72-1.32, P = 0.038) were significantly associated with OS. Low hemoglobin (HR = 1.08, 95% CI = 0.68-1.82, P = 0.041) was significantly linked with CSS. Particularly, low HPR was identified as an independent predictor of PFS (HR = 1.16, 95% CI = 0.97-1.49, P = 0.033) and CSS (HR = 1.14, 95% CI = 0.87-1.78, P = 0.029). CONCLUSIONS: Preoperative HPR can be taken into account as a factor predictive of oncological outcomes for T1G3 bladder cancer, particularly disease progression and mortality outcomes. FAU - Tang, Gang AU - Tang G AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Zhen, Yunpeng AU - Zhen Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Xie, Wanqin AU - Xie W AD - Key Laboratory of Genetics and Birth Health of Hunan Province, The Family Planning Research Institute of Hunan Province, Changsha, Hunan 410126, China. FAU - Wang, Yinlei AU - Wang Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Chen, Feiran AU - Chen F AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Qin, Chuan AU - Qin C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Yang, Han AU - Yang H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Du, Zhiyong AU - Du Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Shen, Zhonghua AU - Shen Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Zhang, Bo AU - Zhang B AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Tian, Dawei AU - Tian D AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin 300211, China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. LA - eng PT - Journal Article DEP - 20180103 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5915098 OTO - NOTNLM OT - CSS OT - HPR OT - OS OT - PFS OT - T1G3 bladder cancer COIS- CONFLICTS OF INTEREST None. EDAT- 2018/05/03 06:00 MHDA- 2018/05/03 06:01 PMCR- 2018/04/06 CRDT- 2018/05/03 06:00 PHST- 2016/06/28 00:00 [received] PHST- 2017/11/12 00:00 [accepted] PHST- 2018/05/03 06:00 [entrez] PHST- 2018/05/03 06:00 [pubmed] PHST- 2018/05/03 06:01 [medline] PHST- 2018/04/06 00:00 [pmc-release] AID - 23896 [pii] AID - 10.18632/oncotarget.23896 [doi] PST - epublish SO - Oncotarget. 2018 Jan 3;9(26):18627-18636. doi: 10.18632/oncotarget.23896. eCollection 2018 Apr 6. PMID- 29719336 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 10 IP - 2 DP - 2018 Apr-Jun TI - Study of Proliferating cell nuclear antigen expression and Angiogenesis in Urothelial neoplasms: Correlation with tumor grade and stage. PG - 209-214 LID - 10.4103/UA.UA_167_17 [doi] AB - BACKGROUND: Urinary bladder carcinoma ranks ninth in worldwide cancer incidence. About 74,000 new cases were diagnosed in 2015 alone and 16,000 persons died of the disease. Since histopathology is considered gold standard for diagnosis, it is prudent to look for potential tumor proliferation and predictive markers in such a prevalent malignancy so as to alert surgical and medical oncologists for timely intervention and provide better patient-tailored therapy. AIMS: This study is to analyze the role of potential biomarkers-proliferating cell nuclear antigen (PCNA) and angiogenesis using CD31 in urothelial neoplasms in relation to tumor grade and stage. METHODS: Histopathology slides were prepared from transurethral resection of bladder tumor chips and assessed by three independent observers as per the WHO/International Society of Urologic Pathology criteria 2016. Representative sections were subjected to immunohistochemistry. PCNA labeling index (PCNA LI) and mean vessel density (MVD) were calculated. STATISTICAL ANALYSIS: Tests of analysis were applied as appropriate. A statistical P < 0.05 was considered significant. RESULTS: Forty-nine patients were analyzed. PCNA LI increased with grade and stage. PCNA was significantly higher in noninvasive papillary urothelial carcinoma high grade (NIPUCHG) than in noninvasive papillary urothelial carcinoma low grade (NIPUCLG) and in infiltrating urothelial carcinoma as compared to NIPUCLG. MVD also increased with tumor grade and stage; however, a significant difference was observed only between infiltrating urothelial carcinoma and papillary urothelial neoplasm of low malignant potential. A cutoff value of 73% for PCNA and 49 vessels/high-power field for CD 31 showed 100% accuracy to differentiate between noninvasive papillary urothelial carcinoma high grade and NIPUCLG. No association was observed between tumor recurrence and PCNA or CD31 expression. CONCLUSION: PCNA and CD31 when used together are valuable markers to help classify urothelial neoplasms in limited tumor material. However, larger prospective studies are required for better prognostication. FAU - Agarwal, Poojan AU - Agarwal P AD - Department of Pathology, PGIMER, Dr. RML Hospital, New Delhi, India. FAU - Sen, Achin Kumar AU - Sen AK AD - Department of Pathology, PGIMER, Dr. RML Hospital, New Delhi, India. FAU - Bhardwaj, Minakshi AU - Bhardwaj M AD - Department of Pathology, PGIMER, Dr. RML Hospital, New Delhi, India. FAU - Dinand, Veronique AU - Dinand V AD - Department of Research, Pediatric Hematology Oncology, Sir Ganga Ram Hospital, New Delhi, India. FAU - Ahuja, Arvind AU - Ahuja A AD - Department of Pathology, PGIMER, Dr. RML Hospital, New Delhi, India. FAU - Sood, Rajeev AU - Sood R AD - Department of Urology, PGIMER, Dr. RML Hospital, New Delhi, India. LA - eng PT - Journal Article PL - India TA - Urol Ann JT - Urology annals JID - 101510823 PMC - PMC5907333 OTO - NOTNLM OT - Angiogenesis OT - mean vessel density OT - proliferating cell nuclear antigen OT - urinary bladder OT - urothelial carcinoma COIS- There are no conflicts of interest. EDAT- 2018/05/03 06:00 MHDA- 2018/05/03 06:01 PMCR- 2018/04/01 CRDT- 2018/05/03 06:00 PHST- 2018/05/03 06:00 [entrez] PHST- 2018/05/03 06:00 [pubmed] PHST- 2018/05/03 06:01 [medline] PHST- 2018/04/01 00:00 [pmc-release] AID - UA-10-209 [pii] AID - 10.4103/UA.UA_167_17 [doi] PST - ppublish SO - Urol Ann. 2018 Apr-Jun;10(2):209-214. doi: 10.4103/UA.UA_167_17. PMID- 29717423 OWN - NLM STAT- MEDLINE DCOM- 20190318 LR - 20190318 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 25 IP - 8 DP - 2018 Aug TI - Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guerin Therapy. PG - 2484-2491 LID - 10.1245/s10434-018-6498-2 [doi] AB - BACKGROUND: The programmed cell death-1 (PD-1) pathway has been suggested to play an important role in tumor immune escape. We evaluated changes in PD-1 expression before and after Bacillus Calmette-Guerin (BCG) therapy and its prognostic significance in non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: We examined 78 paired tissue samples of NMIBC in tumors just before BCG therapy and BCG-relapsing tumors, defined as recurrence after achieving disease-free status by initial BCG instillations for 6 months. We counted PD-1-positive cells, and PD-1 expression was defined as high when the number of PD-1-positive cells was more than 18 under x200 magnification. RESULTS: The median number of PD-1-positive cells in tumors just before BCG therapy was 3.5, significantly lower than that in BCG-relapsing tumors (17.0, p < 0.001). High PD-1 expression was observed in 20 tumors just before BCG therapy (25.6%) and 36 BCG-relapsing tumors (46.2%). Fifty-two cases (66.6%) showed an increase in the number of PD-1-positive cells in BCG-relapsing tumors. High PD-1 expression in BCG-relapsing tumors was independently associated with subsequent tumor recurrence (p = 0.011) and stage progression (p = 0.033). The 5-year recurrence-free and progression-free survival rates were 40.7 and 74.1% in patients with high PD-1 expression in BCG-relapsing tumors, significantly lower than those in their counterparts (72.9 and 94.1%, respectively). CONCLUSIONS: PD-1 was induced by BCG therapy, and its expression in BCG-relapsing tumors may be an important indicator for predicting worse clinical outcomes in NMIBC patients treated with BCG therapy. FAU - Fukumoto, Keishiro AU - Fukumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Mikami, Shuji AU - Mikami S AD - Department of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan. FAU - Hayakawa, Nozomi AU - Hayakawa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng GR - 15K20107/Japan Society for the Promotion of Science Grants-in-Aid for Young Scientists (B)/ PT - Journal Article DEP - 20180501 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM CIN - Ann Surg Oncol. 2018 Dec;25(Suppl 3):982-983. doi: 10.1245/s10434-018-6949-9. PMID: 30367304 MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage MH - Biomarkers, Tumor/*metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/metabolism/*pathology MH - Prognosis MH - Programmed Cell Death 1 Receptor/*metabolism MH - Survival Rate MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*pathology EDAT- 2018/05/03 06:00 MHDA- 2019/03/19 06:00 CRDT- 2018/05/03 06:00 PHST- 2017/10/18 00:00 [received] PHST- 2018/05/03 06:00 [pubmed] PHST- 2019/03/19 06:00 [medline] PHST- 2018/05/03 06:00 [entrez] AID - 10.1245/s10434-018-6498-2 [pii] AID - 10.1245/s10434-018-6498-2 [doi] PST - ppublish SO - Ann Surg Oncol. 2018 Aug;25(8):2484-2491. doi: 10.1245/s10434-018-6498-2. Epub 2018 May 1. PMID- 29699809 OWN - NLM STAT- MEDLINE DCOM- 20190808 LR - 20190808 IS - 1873-5487 (Electronic) IS - 0188-4409 (Linking) VI - 49 IP - 2 DP - 2018 Feb TI - Serum Paraoxonase-1 Concentration as a Potential Predictor of Urinary Bladder Cancer Recurrence. A Five Year Follow-Up Study. PG - 119-122 LID - S0188-4409(18)30121-8 [pii] LID - 10.1016/j.arcmed.2018.04.011 [doi] AB - This study provides preliminary information on the usefulness of measuring serum paraoxonase-1 (PON1) concentration and activity (and other inflammatory markers) to predict tumor recurrence in patients with urinary bladder cancer. We studied a total of 39 hospitalized patients in whom the diagnosis of urinary bladder cancer was confirmed by transurethral resection. After five years of follow-up, 29 patients presented with tumor recurrence. As control subjects, we also studied 61 healthy subjects and a further 132 hospitalized patients who had a urinary catheter-related infection due to causes other than cancer. Results showed that urinary bladder patients had lower serum PON1 concentration and activity, and higher chemokine (C-C motif) ligand 2, C-reactive protein, and procalcitonin concentrations than the control individuals. Patients with tumor recurrence had significantly lower serum PON1 concentration than patients without tumor recurrence. The mean area under the curve of the receiver operating characteristics plot for serum PON1 concentration in discriminating patients with and those without tumor recurrence was 0.755 and the best combination of sensitivity and specificity was obtained at PON1 = 100 mg/L (0.72 and 0.80, respectively). Establishing this value as a cut-off, positive predictive value was = 0.91, and negative predictive value was = 0.50. These results suggest that the measurement of serum PON1 concentration may be a high-sensitivity marker of tumor recurrence in urinary bladder cancer patients. CI - Copyright (c) 2018 IMSS. Published by Elsevier Inc. All rights reserved. FAU - Iftimie, Simona AU - Iftimie S AD - Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Garcia-Heredia, Anabel AU - Garcia-Heredia A AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Pujol-Bosch, Francesc AU - Pujol-Bosch F AD - Department of Urology, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Pont-Salvado, Antoni AU - Pont-Salvado A AD - Department of Urology, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Lopez-Azcona, Ana Felisa AU - Lopez-Azcona AF AD - Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Hernandez-Aguilera, Anna AU - Hernandez-Aguilera A AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Cabre, Noemi AU - Cabre N AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Luciano-Mateo, Fedra AU - Luciano-Mateo F AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Fort-Gallifa, Isabel AU - Fort-Gallifa I AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Castro, Antoni AU - Castro A AD - Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. FAU - Camps, Jordi AU - Camps J AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. Electronic address: jcamps@grupsagessa.com. FAU - Joven, Jorge AU - Joven J AD - Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180424 PL - United States TA - Arch Med Res JT - Archives of medical research JID - 9312706 RN - 0 (Biomarkers, Tumor) RN - 0 (Chemokines, C) RN - 0 (Procalcitonin) RN - 0 (XCL2 protein, human) RN - 9007-41-4 (C-Reactive Protein) RN - EC 3.1.8.1 (Aryldialkylphosphatase) RN - EC 3.1.8.1 (PON1 protein, human) MH - Aryldialkylphosphatase/*blood MH - Biomarkers, Tumor/*blood MH - C-Reactive Protein/analysis MH - Chemokines, C/blood MH - Follow-Up Studies MH - Humans MH - Neoplasm Recurrence, Local/*blood/*diagnosis MH - Procalcitonin/blood MH - ROC Curve MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*blood/*diagnosis OTO - NOTNLM OT - Biomarkers OT - Paraoxonase-1 OT - Tumor recurrence OT - Urinary bladder cancer EDAT- 2018/04/28 06:00 MHDA- 2019/08/09 06:00 CRDT- 2018/04/28 06:00 PHST- 2017/10/31 00:00 [received] PHST- 2018/04/13 00:00 [accepted] PHST- 2018/04/28 06:00 [pubmed] PHST- 2019/08/09 06:00 [medline] PHST- 2018/04/28 06:00 [entrez] AID - S0188-4409(18)30121-8 [pii] AID - 10.1016/j.arcmed.2018.04.011 [doi] PST - ppublish SO - Arch Med Res. 2018 Feb;49(2):119-122. doi: 10.1016/j.arcmed.2018.04.011. Epub 2018 Apr 24. PMID- 29695918 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 11 DP - 2018 TI - Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma. PG - 2111-2120 LID - 10.2147/OTT.S155745 [doi] AB - BACKGROUND: High mobility group box 1 (HMGB1), a versatile protein with intranuclear and extracellular functions, plays an important role in a variety of human cancers. However, the clinical/prognostic significance of HMGB1 expression in human bladder urothelial carcinoma (BUC) remains unclear. The aim of this study was to investigate the HMGB1 expression in human BUC with regard to its clinical and prognostic significance. PATIENTS AND METHODS: HMGB1 mRNA and protein expressions in tumor and paired normal bladder tissues were detected in 20 BUC cases by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. HMGB1 protein expression in 165 primary BUC tissues was evaluated by immunohistochemistry (IHC), and its correlations with clinicopathological characteristics and prognosis were also analyzed. Student's t-test, chi(2) test, Kaplan-Meier plots, and Cox proportional hazard regression model were performed to analyze the data. RESULTS: By using qRT-PCR and Western blot, the upregulated expression of HMGB1 mRNA and protein was detected in BUC, compared with paired normal tissue (P<0.05). By using IHC, high HMGB1 expression was examined in 84 of 165 (51.0%) BUC cases. High HMGB1 expression was significantly correlated with poorer differentiation and higher T and N classification (all P<0.05). Univariate analysis showed that high HMGB1 expression was significantly associated with a shortened patients' overall survival (OS) and disease-free survival (DFS; both P<0.001). In different subgroups of BUC patients, HMGB1 expression was a prognostic factor in patients with different histological grades or T classification (all P<0.05), pN- (both P<0.001) for OS and DFS, and pT1/pN- (P<0.05) for OS. HMGB1 expression, as well as pT and pN status, was an independent prognostic factor for both OS (P=0.001, hazard ratio [HR] =2.973, 95% confidence interval [CI] =1.550-5.704) and DFS (P<0.001, HR =3.019, 95% CI =1.902-4.792) in multivariate analysis. CONCLUSION: Overexpression of HMGB1 may be a new independent molecular marker for the poor prognosis of patients with BUC. FAU - Huang, Changkun AU - Huang C AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Huang, Zhichao AU - Huang Z AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Zhao, Xiaokun AU - Zhao X AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Wang, Yinhuai AU - Wang Y AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Zhao, Hongqing AU - Zhao H AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Zhong, Zhaohui AU - Zhong Z AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. FAU - Wang, Lang AU - Wang L AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. LA - eng PT - Journal Article DEP - 20180412 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC5905469 OTO - NOTNLM OT - bladder urothelial carcinoma OT - clinicopathology OT - high mobility group box 1 OT - prognosis COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/04/27 06:00 MHDA- 2018/04/27 06:01 PMCR- 2018/04/12 CRDT- 2018/04/27 06:00 PHST- 2018/04/27 06:00 [entrez] PHST- 2018/04/27 06:00 [pubmed] PHST- 2018/04/27 06:01 [medline] PHST- 2018/04/12 00:00 [pmc-release] AID - ott-11-2111 [pii] AID - 10.2147/OTT.S155745 [doi] PST - epublish SO - Onco Targets Ther. 2018 Apr 12;11:2111-2120. doi: 10.2147/OTT.S155745. eCollection 2018. PMID- 29695915 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 11 DP - 2018 TI - Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis. PG - 2075-2082 LID - 10.2147/OTT.S152999 [doi] AB - BACKGROUND: Pyruvate kinase M2 (PKM2) is a key regulator of the Warburg effect and has critical functions in glycolysis, contributing to the Warburg effect, tumor growth, angiogenesis, cell division, metastasis, and apoptosis. The high expression of PKM2 in various solid tumors renders it a potential biomarker of tumorigenesis and tumor invasion, but the expression and role of PKM2 in bladder cancer have not been studied extensively. PATIENTS AND METHODS: Western blot and immunohistochemistry (IHC) were used to measure the expression of PKM2, and quantitative real-time polymerase chain reaction (PCR) was performed to determine PKM2 mRNA levels. The relationships between PKM2 expression and clinicopathological parameters and prognosis were analyzed using the Kaplan-Meier plots and a Cox proportional hazards regression model. RESULTS: Compared with paired adjacent normal bladder tissues, PKM2 mRNA and protein levels were found to be higher in urothelial carcinoma of the bladder (UCB) samples by real-time PCR and Western blot. By IHC, high expression of PKM2 was seen in 117 of 215 UCBs (54.4%) and in eight of 90 adjacent normal bladder tissues (8.9%). The expression of PKM2 was significantly associated with grade, stage, and lymph node status (P<0.001). In the univariate survival analysis, a significant association between PKM2 expression and shorter patient survival was observed (P<0.001). In different subsets of UCB patients, we found that PKM2 expression was a prognostic factor in patients with G2 (P=0.009), G3 (P<0.001), pTa/pTis (P=0.006), pT1, pT2-4, and pN(-) disease (P<0.001). Importantly, PKM2 expression (P=0.003), with tumor histological grade (P<0.001), pT (P<0.001), and pN status (P=0.005), was a significant independent prognostic parameter in the multivariate analysis. CONCLUSION: PKM2 protein and mRNA are upregulated in UCBs and may serve as molecular markers for a poor prognosis in patients with UCB. FAU - Huang, Changkun AU - Huang C AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China. FAU - Huang, Zhichao AU - Huang Z AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China. FAU - Bai, Peiming AU - Bai P AD - Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, People's Republic of China. FAU - Luo, Guangcheng AU - Luo G AD - Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, People's Republic of China. FAU - Zhao, Xiaokun AU - Zhao X AD - Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China. FAU - Wang, Xinjun AU - Wang X AD - Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, People's Republic of China. LA - eng PT - Journal Article DEP - 20180411 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC5905464 OTO - NOTNLM OT - IHC OT - PKM2 OT - bladder OT - prognosis OT - urothelial carcinoma COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2018/04/27 06:00 MHDA- 2018/04/27 06:01 PMCR- 2018/04/11 CRDT- 2018/04/27 06:00 PHST- 2018/04/27 06:00 [entrez] PHST- 2018/04/27 06:00 [pubmed] PHST- 2018/04/27 06:01 [medline] PHST- 2018/04/11 00:00 [pmc-release] AID - ott-11-2075 [pii] AID - 10.2147/OTT.S152999 [doi] PST - epublish SO - Onco Targets Ther. 2018 Apr 11;11:2075-2082. doi: 10.2147/OTT.S152999. eCollection 2018. PMID- 29690748 OWN - NLM STAT- MEDLINE DCOM- 20190419 LR - 20220408 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 51 IP - 1 DP - 2019 Jan TI - The Comparison of Oncologic Outcomes between Open and Laparoscopic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Korean Multicenter Collaborative Study. PG - 240-251 LID - 10.4143/crt.2017.417 [doi] AB - PURPOSE: We compared oncologic outcomes of patients with upper tract urothelial carcinoma (UTUC) who underwent open nephroureterectomy (ONU) or laparoscopic nephroureterectomy (LNU). MATERIALS AND METHODS: Consecutive cases of ONU and LNU between 2000 and 2012 at five participating institutions were included in this retrospective analysis. Clinical characteristics and pathologic outcomes were compared between the two surgical approaches. The influence of the type of surgical approach on intravesical recurrence-free survival (IVRFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) was analyzed using the Kaplan-Meier method and differences were assessed with the log-rank test. Predictors of IVRFS, PFS, CSS, and OS were also analyzed with a multivariable Cox regression model. RESULTS: A total of 1,521 patients with UTUC were eligible for the present study (ONU, 906; LNU, 615). The estimated 5-year IVRFS (57.8 vs. 51.0%, p=0.010), CSS (80.4 vs. 76.4%, p=0.032), and OS (75.8 vs. 71.4%, p=0.026) rates were significantly different between the two groups in favor of LNU. Moreover, in patients with locally advanced disease (pT3/pT4), the LNU group showed better 5-year IVRFS (62.9 vs. 54.1%, p=0.038), CSS (64.3 vs. 56.9%, p=0.022), and OS (60.4 vs. 53.1%, p=0.018) rates than the ONU group. Multivariable Cox regression analyses showed that type of surgical approach was independently associated with IVRFS, but was not related to PFS, CSS, and OS. CONCLUSION: Our findings indicate that LNU provided better oncologic control of IVRFS, CSS, and OS compared with ONU for the management of patients with UTUC. FAU - Kim, Tae Heon AU - Kim TH AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Seo, Ho Kyung AU - Seo HK AD - Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20180424 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Laparoscopy MH - Male MH - Middle Aged MH - Nephroureterectomy/*methods/mortality MH - Regression Analysis MH - Republic of Korea MH - Retrospective Studies MH - Treatment Outcome MH - Urologic Neoplasms/*surgery PMC - PMC6333991 OTO - NOTNLM OT - Laparoscopy OT - Malignant disease OT - Survival OT - Transitional cell cancer COIS- Conflict of interest relevant to this article was not reported. EDAT- 2018/04/25 06:00 MHDA- 2019/04/20 06:00 PMCR- 2019/01/01 CRDT- 2018/04/26 06:00 PHST- 2017/09/04 00:00 [received] PHST- 2018/04/23 00:00 [accepted] PHST- 2018/04/25 06:00 [pubmed] PHST- 2019/04/20 06:00 [medline] PHST- 2018/04/26 06:00 [entrez] PHST- 2019/01/01 00:00 [pmc-release] AID - crt.2017.417 [pii] AID - crt-2017-417 [pii] AID - 10.4143/crt.2017.417 [doi] PST - ppublish SO - Cancer Res Treat. 2019 Jan;51(1):240-251. doi: 10.4143/crt.2017.417. Epub 2018 Apr 24. PMID- 29685374 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20250623 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. PG - 293-305 LID - S1078-1439(18)30114-5 [pii] LID - 10.1016/j.urolonc.2018.03.018 [doi] AB - PURPOSE: Lymphovascular invasion (LVI) is an important step in bladder cancer cell dissemination. We aimed to perform a systematic review and meta-analysis of the literature to assess the prognostic value of LVI in radical cystectomy (RC) specimens. PATIENTS AND METHODS: A systematic review and meta-analysis of the last 10 years was performed using the MEDLINE, EMBASE, and the Cochrane libraries in July 2017. The analyses were performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. RESULTS: We retrieved 65 studies (including 78,107 patients) evaluating the effect of LVI on oncologic outcomes in patients treated with RC. LVI was reported in 35.4% of patients. LVI was associated with disease recurrence (pooled hazard ratio [HR] = 1.57; 95% CI: 1.45-1.70) and cancer-specific mortality (CSM) (pooled HR = 1.59; 95% CI: 1.48-1.73) in all studies regardless of tumor stage and node status (pT1-4 pN0-2). LVI was associated with recurrence and CSM in patients with node-negative bladder cancer (BC). In patients with node-negative BC, LVI rate increased and was associated with worse oncologic outcome. LVI had a lower but still significant association with disease recurrence and CSM in node-positive BC. CONCLUSIONS: LVI is a strong prognostic factor of worse prognosis in patients treated with RC for bladder cancer. This association is strongest in node-negative BC, but it is also in node-positive BC. LVI should be part of all pathological reporting and could provide additional information for treatment-decision making regarding adjuvant therapy after RC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Florence, Careggi Hospital, Florence, Italy. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University hospital, The University of Jordan, Amman, Jordan. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address: shahrokh.shariat@meduniwien.ac.at. LA - eng PT - Journal Article PT - Systematic Review DEP - 20180421 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Cystectomy/*adverse effects MH - Humans MH - Lymphatic Metastasis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/etiology/*pathology MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Vascular Neoplasms/etiology/*pathology OTO - NOTNLM OT - Bladder cancer OT - Lymph node dissection OT - Lymphovascular invasion OT - Meta-analysis OT - Metastasis OT - Radical cystectomy EDAT- 2018/04/25 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/04/25 06:00 PHST- 2018/01/17 00:00 [received] PHST- 2018/03/06 00:00 [revised] PHST- 2018/03/26 00:00 [accepted] PHST- 2018/04/25 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/04/25 06:00 [entrez] AID - S1078-1439(18)30114-5 [pii] AID - 10.1016/j.urolonc.2018.03.018 [doi] PST - ppublish SO - Urol Oncol. 2018 Jun;36(6):293-305. doi: 10.1016/j.urolonc.2018.03.018. Epub 2018 Apr 21. PMID- 29676355 OWN - NLM STAT- MEDLINE DCOM- 20181001 LR - 20220317 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 61 IP - 2 DP - 2018 Apr-Jun TI - The determination of stage in nonmuscle urothelial carcinoma: Staining pattern of caspase-8. PG - 192-196 LID - 10.4103/IJPM.IJPM_161_17 [doi] AB - CONTEXT: Urothelial carcinoma (UC) is one of the most frequent epithelial tumors worldwide. AIMS: We aimed to investigate the protein expressions of caspase-8, p53, murine double minute 2 (mdm2), and p14(ARF) in nonmuscle UCs and to correlate the findings with clinicopathological characteristics. SETTINGS AND DESIGN: A total of 50 patients who had pTa and pT1 tumors were analyzed. SUBJECTS AND METHODS: The protein expressions of caspase-8, p53, mdm2, and p14(ARF) were analyzed by immunohistochemistry. STATISTICAL ANALYSIS USED: Chi-square test was done using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). RESULTS: Cytoplasmic caspase-8 expression was significantly higher in pT1 UCs while nuclear caspase-8 expression was significantly higher in pTa UCs (P = 0.005 and P = 0.011, respectively). Cytoplasmic caspase-8 expression was also higher in high-grade UCs (P = 0.035). The expression of p53, mdm2, and p14(ARF) was not also related with pathological stage or grade (P > 0.05 for all). The p14(ARF) expression was related with nuclear caspase-8 expression in most of the patients. Complete agreement among nonmuscle UCs for immunohistochemical expression of p14 and nuclear caspase-8 was seen in 41 cases, and the pairwise kappa agreement value was substantial (kappa =0.614). The patients who had recurrence were positive for both p53 and mdm2 or either p53 or mdm2 (P = 0.025). CONCLUSIONS: These results suggested that the staining pattern of caspase-8 might be helpful for determining of the stages in nonmuscle UC. It was also showed that the expression status of p53 and mdm2 were related with the recurrence. FAU - Turk, Nilay Sen AU - Turk NS AD - Department of Pathology, Medical School of Pamukkale University, Denizli, Turkey. FAU - Eskicorapci, Saadettin AU - Eskicorapci S AD - Department of Urology, Medical School of Acibadem University, Istanbul, Turkey. FAU - Aybek, Zafer AU - Aybek Z AD - Department of Urology, Medical School of Pamukkale University, Denizli, Turkey. FAU - Tuncay, Levent AU - Tuncay L AD - Department of Urology, Medical School of Pamukkale University, Denizli, Turkey. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Biomarkers, Tumor) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p14ARF) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.3.2.27 (MDM2 protein, human) RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) RN - EC 3.4.22.- (Caspase 8) SB - IM MH - Biomarkers, Tumor/*analysis MH - Caspase 8/*analysis MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Staging/*methods MH - Neoplasms, Glandular and Epithelial/*diagnosis/pathology MH - Prognosis MH - Proto-Oncogene Proteins c-mdm2/*analysis MH - Tumor Suppressor Protein p14ARF/*analysis MH - Tumor Suppressor Protein p53/*analysis MH - Urothelium/pathology OTO - NOTNLM OT - Caspase-8 OT - murine double minute 2 OT - p14 ARF OT - p53 OT - urothelial carcinoma COIS- There are no conflicts of interest EDAT- 2018/04/21 06:00 MHDA- 2018/10/03 06:00 CRDT- 2018/04/21 06:00 PHST- 2018/04/21 06:00 [entrez] PHST- 2018/04/21 06:00 [pubmed] PHST- 2018/10/03 06:00 [medline] AID - IndianJPatholMicrobiol_2018_61_2_192_230535 [pii] AID - 10.4103/IJPM.IJPM_161_17 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):192-196. doi: 10.4103/IJPM.IJPM_161_17. PMID- 29676191 OWN - NLM STAT- MEDLINE DCOM- 20190201 LR - 20190201 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 52 IP - 3 DP - 2018 Jun TI - Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. PG - 186-193 LID - 10.1080/21681805.2018.1462254 [doi] AB - OBJECTIVE: The aim of this investigation was to study differences between male and female patients with stage T1 urinary bladder cancer (UBC) regarding intravesical instillation therapy, second resection and survival. MATERIALS AND METHODS: This study included all patients with non-metastatic primary T1 UBC reported to the Swedish National Register of Urinary Bladder Cancer (SNRUBC) from 1997 to 2014, excluding those treated with primary cystectomy. Differences between groups were evaluated using chi-squared tests and logistic regression, and survival was investigated using Kaplan-Meier and log-rank tests and Cox proportional hazards analysis. RESULTS: In all, 7681 patients with T1 UBC (77% male, 23% female) were included. Females were older than males at the time of diagnosis (median age at presentation 76 and 74 years, respectively; p < .001). A larger proportion of males than females underwent intravesical instillation therapy (39% vs 33%, p < .001). Relative survival was lower in women aged >/=75 years and women with G3 tumours compared to men. However, women aged >/=75 years who had T1G3 tumours and underwent second resection followed by intravesical instillation therapy showed a relative survival equal to that observed in men. CONCLUSIONS: This population-based study demonstrates that women of all ages with T1 UBC undergo intravesical instillation therapy less frequently than men, and that relative survival is poorer in women aged >/=75 years than in men of the same age when intravesical instillation therapy and second resection are not used. However, these disparities may disappear with treatment according to guidelines. FAU - Sjostrom, Carin AU - Sjostrom C AD - a Section of Urology, Department of Surgery , Capio S:t Goran's Hospital , Stockholm , Sweden. AD - b Department of Molecular Medicine and Surgery , Section of Urology, Karolinska Institute , Stockholm , Sweden. FAU - Thorstenson, Andreas AU - Thorstenson A AD - a Section of Urology, Department of Surgery , Capio S:t Goran's Hospital , Stockholm , Sweden. AD - b Department of Molecular Medicine and Surgery , Section of Urology, Karolinska Institute , Stockholm , Sweden. FAU - Strock, Viveka AU - Strock V AD - c Department of Urology , Sahlgrenska University Hospital , Goteborg , Sweden. FAU - Hosseini-Aliabad, Abolfazl AU - Hosseini-Aliabad A AD - d Department of Urology , Karolinska University Hospital , Stockholm , Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - e Department of Urology , University Hospital and IKE, Linkoping University , Linkoping , Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - f Department of Translational Medicine , Lund University , Malmo , Sweden. AD - g Department of Urology , Skane University Hospital , Malmo , Sweden. FAU - Sherif, Amir AU - Sherif A AD - h Department of Surgical and Perioperative Sciences, Urology and Andrology , Umea University , Umea , Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - i Department of Urology , Akademiska University Hospital , Uppsala , Sweden. FAU - Rosell, Johan AU - Rosell J AD - j Regional Cancer Center South East Sweden and Department of Clinical and Experimental Medicine , Linkoping University , Linkoping , Sweden. FAU - Gardmark, Truls AU - Gardmark T AD - k Section of Urology, Department of Surgery , Danderyd's Hospital , Stockholm , Sweden. AD - l Department of Clinical Sciences Danderyd's Hospital , Karolinska Institute , Stockholm , Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - e Department of Urology , University Hospital and IKE, Linkoping University , Linkoping , Sweden. LA - eng PT - Journal Article DEP - 20180420 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Combined Modality Therapy MH - Female MH - Guideline Adherence MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Neoplasm Staging MH - Practice Guidelines as Topic MH - Proportional Hazards Models MH - Registries MH - Reoperation MH - Sex Factors MH - Survival Rate MH - Sweden MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - female OT - gender OT - intravesical instillation therapy OT - male OT - population-based OT - survival EDAT- 2018/04/21 06:00 MHDA- 2019/02/02 06:00 CRDT- 2018/04/21 06:00 PHST- 2018/04/21 06:00 [pubmed] PHST- 2019/02/02 06:00 [medline] PHST- 2018/04/21 06:00 [entrez] AID - 10.1080/21681805.2018.1462254 [doi] PST - ppublish SO - Scand J Urol. 2018 Jun;52(3):186-193. doi: 10.1080/21681805.2018.1462254. Epub 2018 Apr 20. PMID- 29674052 OWN - NLM STAT- MEDLINE DCOM- 20180924 LR - 20180924 IS - 1873-3573 (Electronic) IS - 0039-9140 (Linking) VI - 184 DP - 2018 Jul 1 TI - Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. PG - 347-355 LID - S0039-9140(18)30271-6 [pii] LID - 10.1016/j.talanta.2018.03.028 [doi] AB - Bladder Cancer (BC) presents one of the highest recurrence rates amongst solid tumours and constitutes the second deadliest disease of the genitourinary track. Non-invasive identification of patients facing disease recurrence and/or progression remains one of the most critical and challenging aspects in disease management. To contribute to this goal, we demonstrate the potential of glycan-affinity glycoproteomics nanoplatforms for urinary biomarkers discovery in bladder cancer. Briefly, magnetic nanoprobes (MNP) coated with three broad-spectrum lectins, namely Concanavalin A (ConA; MNP@ConA), Wheat Germ Agglutinin (WGA; MNP@WGA), and Sambucus nigra (SNA; MNP@SNA), were used to selectively capture glycoproteins from the urine of low-grade and high-grade non-muscle invasive as well as muscle-invasive BC patients. Proteins were identified by nano-LC MALDI-TOF/TOF and data was curated using bioinformatics tools (UniProt, NetOGlyc, NetNGlyc, ClueGO app for Cytoscape and Oncomine) to highlight clinically relevant species. Accordingly, 63 glycoproteins were exclusively identified in cancer samples compared with healthy controls matching in age and gender. Specific glycoprotein sets exclusively found in low-grade non-muscle invasive bladder tumours may aid early diagnosis, while those only found in high-grade non-invasive and muscle-invasive tumours hold potential for accessing progression. Amongst these proteins is bladder cancer stem-cell marker CD44, which has been associated with poor prognosis. Orthogonal validation studies by slot-blotting demonstrated an elevation in urine CD44 levels of high-grade patients, which became more pronounced upon muscle-invasion, in mimicry of the primary tumour. These observations demonstrate the potential of MNP@lectins for identification of clinically relevant glycoproteomics signatures in bladder cancer. Future clinical validation in a larger and well characterized patient subset is required envisaging clinical translation of the results. CI - Copyright (c) 2018 Elsevier B.V. All rights reserved. FAU - Azevedo, Rita AU - Azevedo R AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal. FAU - Soares, Janine AU - Soares J AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Gaiteiro, Cristiana AU - Gaiteiro C AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal. FAU - Peixoto, Andreia AU - Peixoto A AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal. FAU - Lima, Luis AU - Lima L AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal; Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), R. Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal; Porto Comprehensive Cancer Centre(P.ccc), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Ferreira, Dylan AU - Ferreira D AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Relvas-Santos, Marta AU - Relvas-Santos M AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Fernandes, Elisabete AU - Fernandes E AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal. FAU - Tavares, Ana AU - Tavares A AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Cotton, Sofia AU - Cotton S AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal. FAU - Daniel-da-Silva, Ana Luisa AU - Daniel-da-Silva AL AD - CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal. FAU - Santos, Lucio Lara AU - Santos LL AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal. FAU - Vitorino, Rui AU - Vitorino R AD - iBiMED - Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Campus Universitario de Santiago, Agra do Crasto - Edificio 30, 3810-193 Aveiro, Portugal; Research Unit of the Physiology and Cardiothoracic Surgery Department of the Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal. FAU - Amado, Francisco AU - Amado F AD - Mass Spectrometry Centre, Organic Chemistry and Natural Products Unit, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal. FAU - Ferreira, Jose Alexandre AU - Ferreira JA AD - Experimental Pathology and Therapeutics Group, Research Centre, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. Antonio Bernardino de Almeida 62, 4200-162 Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, R. Jorge de Viterbo Ferreira 228, 4050-013 Porto, Portugal; Institute for Research and Innovation in Health (i3S), University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal; Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), R. Julio Amaral de Carvalho 45, 4200-135 Porto, Portugal; International Iberian Nanotechnology Laboratory (INL), Avda. Mestre Jose Veiga, 4715 Braga, Portugal. Electronic address: jose.a.ferreira@ipoporto.min-saude.pt. LA - eng PT - Journal Article DEP - 20180312 PL - Netherlands TA - Talanta JT - Talanta JID - 2984816R RN - 0 (Biomarkers, Tumor) RN - 0 (Glycoproteins) RN - 0 (Magnetite Nanoparticles) RN - 0 (Polysaccharides) RN - 0 (Sialic Acids) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Glycoproteins/*urine MH - Humans MH - Magnetite Nanoparticles/*chemistry MH - Male MH - Middle Aged MH - Polysaccharides/*chemistry MH - Sialic Acids/analysis MH - Urinary Bladder Neoplasms/*urine OTO - NOTNLM OT - Bladder cancer OT - Glycoproteomics OT - Glycosylation OT - Nanoparticles OT - Nanoprobes OT - Urine biomarkers EDAT- 2018/04/21 06:00 MHDA- 2018/09/25 06:00 CRDT- 2018/04/21 06:00 PHST- 2017/12/27 00:00 [received] PHST- 2018/03/07 00:00 [revised] PHST- 2018/03/11 00:00 [accepted] PHST- 2018/04/21 06:00 [entrez] PHST- 2018/04/21 06:00 [pubmed] PHST- 2018/09/25 06:00 [medline] AID - S0039-9140(18)30271-6 [pii] AID - 10.1016/j.talanta.2018.03.028 [doi] PST - ppublish SO - Talanta. 2018 Jul 1;184:347-355. doi: 10.1016/j.talanta.2018.03.028. Epub 2018 Mar 12. PMID- 29673906 OWN - NLM STAT- MEDLINE DCOM- 20190213 LR - 20191210 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 28 IP - 6 DP - 2018 May TI - Interest of next-generation sequencing in BCG-treated high-risk bladder cancer. PG - 344-350 LID - S1166-7087(18)30082-4 [pii] LID - 10.1016/j.purol.2018.03.008 [doi] AB - OBJECTIVES: There are only few predictive factors for response of non-musculo-invasive bladder cancer (NMIBC) to Bacillus Calmette-Guerin (BCG) therapy. Our study analyzed the results of the sequencing of new generation (NGS) targeted on 50 genes of oncological interest obtained on bladder resection parts in high-risk NMIBC patients treated with BCG, to describe this population from a molecular point of view and try to correlate these results in patients who present or not recurrence after BCG. METHODS: We reviewed 63 patients with high grade NMIBC treated between 2014 and 2016 with BCG after endoscopic resection. Each one had NGS analysis. Association tests between mutations detected by NGS and recurrence or progression were realized. RESULTS: The 45 remaining patients were fully analysed. For 73% of cases a mutation has been found, most frequent one's being FGFR3, TP53 and PIK3CA. With a median follow-up of 24 months (4-40), recurrence was present in 15 patients (33.3%), with 10 NMIBC (22.2%) and 5 progressions to muscular-invasive cancer (11.1%). If some mutations were more frequent in different prognostic groups no significant association has been found. No patient presenting CIS had FGFR3 mutation (P<0.0001). CONCLUSION: Next generation sequencing in NMIBC could be a supplementary aid in treatment decision making in the future. In an area where personalized medicine is rapidly growing in importance we need larger studies to define molecular characteristics in tumours to detect genomic associations between clinical phenotypes and recurrence or progression of the disease. LEVEL OF EVIDENCE: 3. CI - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved. FAU - Jungels, C AU - Jungels C AD - Department of urology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - Martinez Chanza, N AU - Martinez Chanza N AD - Department of oncology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - Albisinni, S AU - Albisinni S AD - Department of urology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - Mercier, M AU - Mercier M AD - Department of pathology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - d'Haene, N AU - d'Haene N AD - Department of pathology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - Rorive, S AU - Rorive S AD - Department of pathology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. FAU - Roumeguere, T AU - Roumeguere T AD - Department of urology, Erasme hospital, universite Libre-de-Bruxelles, Brussels, Belgium. Electronic address: Thierry.roumeguere@erasme.ulb.ac.be. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20180417 PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/analysis/genetics MH - Carcinoma, Squamous Cell/*diagnosis/*drug therapy/genetics/pathology MH - DNA Mutational Analysis/methods MH - Disease Progression MH - Female MH - *High-Throughput Nucleotide Sequencing MH - Humans MH - Male MH - Middle Aged MH - Molecular Diagnostic Techniques/*methods MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Predictive Value of Tests MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/*drug therapy/genetics/pathology OTO - NOTNLM OT - BCG OT - Haut risque OT - High risk OT - NMIBC OT - Next generation sequencing OT - Prognostic OT - Pronostic OT - Sequencage de nouvelle generation OT - TVNIM EDAT- 2018/04/21 06:00 MHDA- 2019/02/14 06:00 CRDT- 2018/04/21 06:00 PHST- 2017/12/30 00:00 [received] PHST- 2018/02/18 00:00 [revised] PHST- 2018/03/19 00:00 [accepted] PHST- 2018/04/21 06:00 [pubmed] PHST- 2019/02/14 06:00 [medline] PHST- 2018/04/21 06:00 [entrez] AID - S1166-7087(18)30082-4 [pii] AID - 10.1016/j.purol.2018.03.008 [doi] PST - ppublish SO - Prog Urol. 2018 May;28(6):344-350. doi: 10.1016/j.purol.2018.03.008. Epub 2018 Apr 17. PMID- 29668641 OWN - NLM STAT- MEDLINE DCOM- 20180424 LR - 20260127 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 97 IP - 16 DP - 2018 Apr TI - Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. PG - e0522 LID - 10.1097/MD.0000000000010522 [doi] LID - e0522 AB - To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG).A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0.Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3-78.1) and in G2 patients 59% (CI 49-67.3) (P = .31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette-Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis.Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy. FAU - Balan, Daniel AU - Balan D AD - Department of Cell and Molecular Biology Department of Urology, University of Medicine and Pharmacy, Tirgu Mures, Romania Department of Urology, University of Pecs, Pecs, Hungary Department of Epidemiology, University of Medicine and Pharmacy, Tirgu Mures, Romania Division of Urology, European Institute of Oncology, Milan, Italy Department of Urology, Medical University of Vienna, Vienna, Austria Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari Department of Urology, Sapienza University of Rome, Rome, Italy Department of Histology, University of Medicine and Pharmacy, Tirgu Mures, Romania. FAU - Martha, Orsolya AU - Martha O FAU - Chibelean, Calin Bogdan AU - Chibelean CB FAU - Tataru, Sabin AU - Tataru S FAU - Voidezan, Septimiu AU - Voidezan S FAU - Sin, Anca AU - Sin A FAU - Matei, Victor Deliu AU - Matei VD FAU - Vartolomei, Mihai Dorin AU - Vartolomei MD FAU - Lucarelli, Giuseppe AU - Lucarelli G FAU - Cioffi, Antonio AU - Cioffi A FAU - Del Giudice, Francesco AU - Del Giudice F FAU - De Berardinis, Ettore AU - De Berardinis E FAU - Borda, Angela AU - Borda A FAU - Busetto, Gian Maria AU - Busetto GM FAU - Ferro, Matteo AU - Ferro M FAU - Pytel, Akos AU - Pytel A FAU - Porav-Hodade, Daniel AU - Porav-Hodade D LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - BCG Vaccine/*therapeutic use MH - *Carcinoma, Transitional Cell/mortality/pathology/physiopathology/therapy MH - Combined Modality Therapy MH - *Cystectomy/adverse effects/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis MH - Neoplasm Staging MH - Prognosis MH - Risk Assessment MH - Romania/epidemiology MH - Survival Analysis MH - *Urinary Bladder Neoplasms/mortality/pathology/physiopathology/therapy PMC - PMC5916673 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2018/04/19 06:00 MHDA- 2018/04/25 06:00 PMCR- 2018/04/20 CRDT- 2018/04/19 06:00 PHST- 2018/04/19 06:00 [entrez] PHST- 2018/04/19 06:00 [pubmed] PHST- 2018/04/25 06:00 [medline] PHST- 2018/04/20 00:00 [pmc-release] AID - 00005792-201804200-00067 [pii] AID - MD-D-17-07335 [pii] AID - 10.1097/MD.0000000000010522 [doi] PST - ppublish SO - Medicine (Baltimore). 2018 Apr;97(16):e0522. doi: 10.1097/MD.0000000000010522. PMID- 29667104 OWN - NLM STAT- MEDLINE DCOM- 20190730 LR - 20190730 IS - 1573-7225 (Electronic) IS - 0957-5243 (Print) IS - 0957-5243 (Linking) VI - 29 IP - 6 DP - 2018 Jun TI - Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. PG - 573-579 LID - 10.1007/s10552-018-1029-9 [doi] AB - INTRODUCTION: There is some evidence that greater consumption of fruit and vegetables decreases the risk of bladder cancer. The role of fruit and vegetables in bladder cancer recurrence is still unknown. OBJECTIVE: The role of total fruit and vegetable intake in relation to the risk of developing bladder cancer recurrence in a prospective cohort study. METHODS: 728 patients with non-muscle invasive bladder cancer (NMIBC), who completed self-administrated questionnaires on fruit and vegetable intake at time of diagnosis (over the year before diagnosis) and 1 year after diagnosis, were included. Hazard ratios and 95% confidence intervals were calculated by multivariable Cox regression for developing recurrent bladder cancer in relation to fruit and vegetable intake. RESULTS: During 2,051 person-years of follow-up [mean (SD) follow-up 3.7 (1.5) years], 241 (33.1%) of the included 728 NMIBC patients developed a recurrence of bladder cancer. The sum of total fruit and vegetables before diagnosis was not related to a first bladder cancer recurrence (HR 1.07; 95% CI 0.78-1.47, p = 0.66). No association was found between greater consumption of fruit and vegetables over the year before diagnosis and the risk of developing multiple recurrences of bladder cancer (HR 1.02; 95% CI 0.90-1.15, p = 0.78). Among the remaining 389 NMIBC patients who reported on fruit and vegetable intake 1 year after diagnosis, no association was found between greater consumption of fruit and vegetables and a first recurrence of bladder cancer (HR 0.65; 95% CI 0.42-1.01, p = 0.06) nor with multiple recurrences of bladder cancer (HR 1.00, 95% CI 0.85-1.18, p = 1.00). Similar results were obtained when investigating the association between total intakes of fruit and vegetables separately and bladder cancer recurrence. CONCLUSION: Results from this study did not indicate a protective role for total fruit and vegetables in the development of a recurrence of NMIBC. FAU - Jochems, Sylvia H J AU - Jochems SHJ AUID- ORCID: 0000-0001-7676-1488 AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. s.jochems@maastrichtuniversity.nl. AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. s.jochems@maastrichtuniversity.nl. FAU - van Osch, Frits H M AU - van Osch FHM AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. FAU - Reulen, Raoul C AU - Reulen RC AD - Department of Public Health, Epidemiology and Biostatistics, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - van Hensbergen, Mitch AU - van Hensbergen M AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. FAU - Nekeman, Duncan AU - Nekeman D AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Pirrie, Sarah AU - Pirrie S AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Wesselius, Anke AU - Wesselius A AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. FAU - van Schooten, Frederik-Jan AU - van Schooten FJ AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. FAU - James, Nicholas D AU - James ND AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Wallace, D Michael A AU - Wallace DMA AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Cheng, K K AU - Cheng KK AD - Department of Public Health, Epidemiology and Biostatistics, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20180417 PL - Netherlands TA - Cancer Causes Control JT - Cancer causes & control : CCC JID - 9100846 MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - *Fruit MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Proportional Hazards Models MH - Prospective Studies MH - Surveys and Questionnaires MH - Urinary Bladder Neoplasms/*epidemiology MH - *Vegetables PMC - PMC5938309 OTO - NOTNLM OT - Bladder cancer OT - Fruit OT - Prevention and control OT - Recurrence OT - Vegetables EDAT- 2018/04/19 06:00 MHDA- 2019/07/31 06:00 PMCR- 2018/04/17 CRDT- 2018/04/19 06:00 PHST- 2017/12/11 00:00 [received] PHST- 2018/04/05 00:00 [accepted] PHST- 2018/04/19 06:00 [pubmed] PHST- 2019/07/31 06:00 [medline] PHST- 2018/04/19 06:00 [entrez] PHST- 2018/04/17 00:00 [pmc-release] AID - 10.1007/s10552-018-1029-9 [pii] AID - 1029 [pii] AID - 10.1007/s10552-018-1029-9 [doi] PST - ppublish SO - Cancer Causes Control. 2018 Jun;29(6):573-579. doi: 10.1007/s10552-018-1029-9. Epub 2018 Apr 17. PMID- 29666128 OWN - NLM STAT- MEDLINE DCOM- 20190304 LR - 20220330 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 8 IP - 4 DP - 2018 Apr 17 TI - Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. PG - e019635 LID - 10.1136/bmjopen-2017-019635 [doi] LID - e019635 AB - OBJECTIVES: The aim of this study was to explore the prognostic value of ki67 as a marker in patients with non-muscle invasive bladder cancer (NMIBC) treated with BCG. METHODS: Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library and Embase), and the expiry date was May 2017. The research steps referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. RESULTS: A total of 11 studies that complied with the inclusion criteria were included. The expression of ki67 was not statistically significantly associated with recurrence-free survival (RFS) (HR 1.331; 95% CI 0.980 to 1.809). No significant heterogeneity was found among all included studies (I(2) =36.7%, p=0.148). The expression of ki67 was statistically significantly associated with progression-free survival (PFS) (HR 2.567; 95% CI 1.562 to 4.219), and the overexpression of ki67 was the risk factor for PFS. Significant heterogeneity was noted among all the included studies (I(2) =55.6%, p=0.021). The studies that might cause heterogeneity were excluded using the Galbraith plot, and then the meta-analysis was performed again. The results showed that the expression of ki67 was still associated with PFS (HR 2.922; 95% CI 2.002 to 4.266). CONCLUSIONS: The overexpression of ki67 was the risk factor for PFS, and the relationship between the expression of ki67 and RFS was not statistically significant in patients with NMIBC treated with BCG intravesical immunotherapy. Well-designed, prospective, with a large sample size are still needed to validate the findings. CI - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. FAU - He, Yuhui AU - He Y AD - Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Wang, Ning AU - Wang N AD - College of Psychology, North China University of Science and Technology, Tangshan, Hebei, China. FAU - Zhou, Xiaofeng AU - Zhou X AD - Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Wang, Jianfeng AU - Wang J AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Ding, Zhenshan AU - Ding Z AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Chen, Xing AU - Chen X AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. FAU - Deng, Yisen AU - Deng Y AD - Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China. AD - Department of Urology, China-Japan Friendship Hospital, Beijing, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20180417 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (BCG Vaccine) RN - 0 (Ki-67 Antigen) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/therapeutic use MH - Disease Progression MH - Female MH - Humans MH - *Ki-67 Antigen MH - Male MH - *Neoplasm Invasiveness MH - Prognosis MH - Prospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/drug therapy/pathology PMC - PMC5905754 OTO - NOTNLM OT - Ki67 OT - meta-analysis OT - non-muscular-invasive bladder cancer OT - prognosis COIS- Competing interests: None declared. EDAT- 2018/04/19 06:00 MHDA- 2019/03/05 06:00 PMCR- 2018/04/17 CRDT- 2018/04/19 06:00 PHST- 2018/04/19 06:00 [entrez] PHST- 2018/04/19 06:00 [pubmed] PHST- 2019/03/05 06:00 [medline] PHST- 2018/04/17 00:00 [pmc-release] AID - bmjopen-2017-019635 [pii] AID - 10.1136/bmjopen-2017-019635 [doi] PST - epublish SO - BMJ Open. 2018 Apr 17;8(4):e019635. doi: 10.1136/bmjopen-2017-019635. PMID- 29661592 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 7 DP - 2018 Jul TI - Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. PG - 338.e1-338.e11 LID - S1078-1439(18)30097-8 [pii] LID - 10.1016/j.urolonc.2018.03.015 [doi] AB - PURPOSE: Traditionally, transurethral resection of bladder tumors (TURB) is performed using monopolar technique. Bipolar resection has been postulated to reduce complications. In this study we compare safety and efficacy between monopolar TURB (mTURB) and bipolar TURB (bTURB) for patients with primary non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data were obtained from an international multicenter randomized clinical trial that compared the use of white light cystoscopy with narrow band imaging-assisted TURB using the Olympus system between 2010 and 2014. Main outcomes of interest were operative time, perioperative, and postoperative complications, and 12-month recurrence-free survival. RESULTS: In total, 716 patients were treated for primary NMIBC with mTURB (310 patients) or bTURB (406 patients). The use of white light cystoscopy or narrow band imaging was equally distributed between the 2 resection techniques. Multilevel logistic and linear regression corrected for possible confounders showed no significant difference between mTURB and bTURB for postoperative complications (OR = 1.76, P = 0.180), postoperative bleeding (OR = 1.27, P = 0.722), and the combination of intra + postoperative bleeding (OR = 1.992, P = 0.108). Additionally, no significant difference was found between mTURB and bTURB concerning operative time (1.05min. longer for bTURB, P = 0.536), intraoperative bleeding requiring intervention (OR:1.38, P=0.809), incidence of obturator reflex (OR = 0.93, P = 0.854), and bladder perforation (OR = 3.05, P = 0.195). In total, 185 patients (25.8%) developed a recurrence (mTURB = 88, bTURB = 97). Recurrence-free survival at 12 months in the mTURB and bTURB group was 70% and 74% (P = 0.410), respectively. CONCLUSION: Based on these results, bTURB is as safe and effective as mTURB in treatment of primary NMIBC. bTURB seems to have no evident advantages over mTURB with respect to operation time, perioperative and postoperative complication rates, and recurrence rates at 12 months. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Liem, Esmee I M L AU - Liem EIML AD - Department of Urology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: e.i.liem@amc.uva.nl. FAU - McCormack, Michael AU - McCormack M AD - Department of Urology, Centre Hospitalier de L'Universite de Montreal, Montreal, Canada. FAU - Chan, Eddie S Y AU - Chan ESY AD - Department of Urology, The Chinese University of Hong Kong, HKSAR, Shatin, Hong Kong; Department of Surgery, The Chinese University of Hong Kong, HKSAR, Shatin, Hong Kong. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, Kyoto University, Kyoto, Japan. FAU - Geavlete, Petrisor AU - Geavlete P AD - Department of Urology, Saint John Emergency Clinical Hospital, Bucharest, Romania. FAU - Choi, Young D AU - Choi YD AD - Department of Urology, Yonsei University College of Medicine, Seoul, South Korea. FAU - de Reijke, Theo M AU - de Reijke TM AD - Department of Urology, Academic Medical Center, Amsterdam, The Netherlands. FAU - Farahat, Yasser AU - Farahat Y AD - Department of Urology, Sheikh Khalifa General Hospital, Umm Al Quwain, UAE. FAU - Inman, Brant A AU - Inman BA AD - Division of Urology, Duke University Medical Center, Durham, NC. FAU - de la Rosette, Jean J M C H AU - de la Rosette JJMCH AD - University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. FAU - Naito, Seiji AU - Naito S AD - Department of Urology, Harasanshin Hospital, Fukuoka, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20180413 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Urol Oncol. 2019 Mar;37(3):177-178. doi: 10.1016/j.urolonc.2018.11.014. PMID: 30527341 MH - Aged MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology/*surgery MH - *Postoperative Complications MH - Prognosis MH - Survival Rate MH - Urinary Bladder/pathology/*surgery MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Bipolar OT - Monopolar OT - Non-muscle invasive bladder cancer OT - Transurethral resection bladder tumor (TURB) OT - Urothelial carcinoma EDAT- 2018/04/18 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/04/18 06:00 PHST- 2017/12/18 00:00 [received] PHST- 2018/02/28 00:00 [revised] PHST- 2018/03/19 00:00 [accepted] PHST- 2018/04/18 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/04/18 06:00 [entrez] AID - S1078-1439(18)30097-8 [pii] AID - 10.1016/j.urolonc.2018.03.015 [doi] PST - ppublish SO - Urol Oncol. 2018 Jul;36(7):338.e1-338.e11. doi: 10.1016/j.urolonc.2018.03.015. Epub 2018 Apr 13. PMID- 29657089 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20220531 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 7 DP - 2018 Jul TI - Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. PG - 342.e7-342.e14 LID - S1078-1439(18)30098-X [pii] LID - 10.1016/j.urolonc.2018.03.016 [doi] AB - BACKGROUND: The mechanistic target of rapamycin (mTOR) has been implicated in driving tumor biology in multiple malignancies, including urothelial carcinoma (UC). We investigate how mTOR and phosphorylated mTOR (pmTOR) protein expression correlate with chemoresponsiveness in the tumor and its microenvironment at final pathologic staging after neoadjuvant chemotherapy (NAC). METHODS: A single-institution retrospective analysis was performed on 62 patients with cT2-4Nany UC undergoing NAC followed by radical cystectomy. Diagnostic (transurethral resection specimens, TURBT) and postchemotherapy radical cystectomy specimens were evaluated for mTOR and pmTOR protein expression using immunohistochemistry of the tumor, peritumoral stroma, and normal surrounding stroma. Protein expression levels were compared between clinical and pathologic stage. Whole transcriptome analysis was performed to evaluate mRNA expression relative to mTOR pathway activation. RESULTS: Baseline levels of mTOR and pmTOR within TURBT specimens were not associated with clinical stage and response to chemotherapy overall. Nonresponders with advanced pathologic stage at cystectomy (ypT2-4/ypTanyN+) had significantly elevated mTOR tumor staining (P = 0.006) and a sustained mTOR and pmTOR staining in the peritumoral and surrounding normal stroma (NS). Several genes relevant to mTOR activity were found to be up-regulated in the tumors of nonresponders. Remarkably, complete responders at cystectomy (ypT0) had significant decreases in both mTOR and pmTOR protein expression in the peritumoral and normal stroma (P = 0.01-0.03). CONCLUSIONS: Our results suggest that mTOR pathway activity is increased in tumor and sustained in its microenvironment in patients with adverse pathologic findings at cystectomy. These findings suggest the relevance of targeting this pathway in bladder cancer. CI - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Winters, Brian R AU - Winters BR AD - Department of Urology, University of Washington School of Medicine, Seattle, WA. FAU - Vakar-Lopez, Funda AU - Vakar-Lopez F AD - Department of Pathology, University of Washington School of Medicine, Seattle, WA. FAU - Brown, Lisha AU - Brown L AD - Department of Urology, University of Washington School of Medicine, Seattle, WA. FAU - Montgomery, Bruce AU - Montgomery B AD - Department of Medicine, University of Washington School of Medicine, Seattle, WA. FAU - Seiler, Roland AU - Seiler R AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Urology, University of Bern, Bern, Switzerland. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Dall Era, Marc AU - Dall Era M AD - Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, California. FAU - Davincioni, Elai AU - Davincioni E AD - Department of research and development, GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Douglas, James AU - Douglas J AD - Department of Urology, University Hospital of Southampton, Hampshire, UK. FAU - Gibb, Ewan A AU - Gibb EA AD - Department of research and development, GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - van der Heijden, Michiel S AU - van der Heijden MS AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Hsieh, Andrew C AU - Hsieh AC AD - Department of Medicine, University of Washington School of Medicine, Seattle, WA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Wright, Jonathan L AU - Wright JL AD - Department of Urology, University of Washington School of Medicine, Seattle, WA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Lam, Hung-Ming AU - Lam HM AD - Department of Urology, University of Washington School of Medicine, Seattle, WA; State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau (SAR), China. Electronic address: minglam@uw.edu. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180412 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM EIN - Urol Oncol. 2022 Jul;40(7):352. doi: 10.1016/j.urolonc.2022.05.011. PMID: 35641377 MH - Aged MH - Biomarkers, Tumor/*metabolism MH - Cystectomy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Retrospective Studies MH - Survival Rate MH - TOR Serine-Threonine Kinases/*metabolism MH - Treatment Outcome MH - *Tumor Microenvironment MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Immunohistochemistry OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Tumor microenvironment OT - mTOR EDAT- 2018/04/17 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/04/17 06:00 PHST- 2018/01/16 00:00 [received] PHST- 2018/03/02 00:00 [revised] PHST- 2018/03/19 00:00 [accepted] PHST- 2018/04/17 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/04/17 06:00 [entrez] AID - S1078-1439(18)30098-X [pii] AID - 10.1016/j.urolonc.2018.03.016 [doi] PST - ppublish SO - Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12. PMID- 29654370 OWN - NLM STAT- MEDLINE DCOM- 20180529 LR - 20231105 IS - 1432-2307 (Electronic) IS - 0945-6317 (Print) IS - 0945-6317 (Linking) VI - 472 IP - 5 DP - 2018 May TI - Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. PG - 749-758 LID - 10.1007/s00428-018-2354-9 [doi] AB - The stratification of bladder cancer into luminal and basal tumors has recently been introduced as a novel prognostic system in patient cohorts of muscle-invasive bladder cancer or high-grade papillary carcinomas. Using a representative immunohistochemistry panel, we analyzed luminal and basal marker expression in a large case series (n = 156) of urothelial carcinoma in situ (CIS), a precancerous lesion that frequently progresses to muscle-invasive disease. The majority of CIS cases was characterized by a positivity for luminal markers (aberrant cytokeratin (CK) 20 85% (132/156), GATA3 median Remmele score (score of staining intensity (0-3) multiplied with percentage of positive cells (0-4)): 12, estrogen receptor (ER) beta Remmele score > 2: 88% (138/156), human epidermal growth factor receptor 2 (Her2) Dako score 3+ 32% (50/156), Her2 Dako score 2+ 33% (51/156)), and marginal expression of basal markers (CK5/6+ 2% (3/156), CK14+ 1% (2/156)). To further investigate phenotypic stability during disease progression, we compared 48 pairs of CIS and invasive tumors from the same biopsy. A highly significant loss of luminal marker expression (p < 0.001) was observed in the course of progression whereas an increase of basal marker expression (p < 0.01) was noted in the invasive compartment. Importantly, 91% of CIS cases demonstrated a positivity for at least one of the two predictive markers Her2 and ERbeta, indicating that the analysis of Her2 and ERbeta may help to identify CIS-patient subgroups prone to more efficient targeted treatment strategies. Larger prospective and biomarker-embedded clinical trials are needed to confirm and validate our preliminary findings. FAU - Barth, Isabella AU - Barth I AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Schneider, Ursula AU - Schneider U AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Grimm, Tobias AU - Grimm T AD - Department of Urology, LMU Munich University, Munich, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Karl, Alexander AU - Karl A AD - Department of Urology, LMU Munich University, Munich, Marchioninistrasse 15, 81377, Munich, Germany. FAU - Horst, David AU - Horst D AD - Institute of Pathology, LMU Munich University, Munich, Thalkirchner Str. 36, 80337, Munich, Germany. FAU - Gaisa, Nadine T AU - Gaisa NT AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Knuchel, Ruth AU - Knuchel R AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. rknuechel-clarke@ukaachen.de. FAU - Garczyk, Stefan AU - Garczyk S AD - Institute of Pathology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. LA - eng GR - 06/17/START-Program RWTH Aachen/ PT - Journal Article DEP - 20180413 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma in Situ/classification/*pathology MH - Carcinoma, Transitional Cell/classification/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Phenotype MH - Prospective Studies MH - Urinary Bladder Neoplasms/classification/*pathology PMC - PMC5978840 OTO - NOTNLM OT - Bladder Cancer OT - Carcinoma in situ (CIS) OT - Estrogen receptor Beta (ERbeta) OT - Her2/neu OT - Molecular subtypes OT - Targeted therapy COIS- All patients gave informed consent for retention and anonymous analysis of their tissue for research purposes in accordance with the requirements of the institutional review board of the medical faculty of the RWTH Aachen University (EK 173/06, EK 291/16). CONFLICT OF INTEREST: The authors declare that they have no conflict of interest. EDAT- 2018/04/15 06:00 MHDA- 2018/05/31 06:00 PMCR- 2018/04/13 CRDT- 2018/04/15 06:00 PHST- 2018/01/11 00:00 [received] PHST- 2018/04/02 00:00 [accepted] PHST- 2018/03/13 00:00 [revised] PHST- 2018/04/15 06:00 [pubmed] PHST- 2018/05/31 06:00 [medline] PHST- 2018/04/15 06:00 [entrez] PHST- 2018/04/13 00:00 [pmc-release] AID - 10.1007/s00428-018-2354-9 [pii] AID - 2354 [pii] AID - 10.1007/s00428-018-2354-9 [doi] PST - ppublish SO - Virchows Arch. 2018 May;472(5):749-758. doi: 10.1007/s00428-018-2354-9. Epub 2018 Apr 13. PMID- 29637669 OWN - NLM STAT- MEDLINE DCOM- 20190716 LR - 20190716 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 122 IP - 6 DP - 2018 Dec TI - The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. PG - 978-985 LID - 10.1111/bju.14238 [doi] AB - OBJECTIVES: To compare the prognostic value of the World Health Organization (WHO) 1973 and 2004 classification systems for grade in T1 bladder cancer (T1-BC), as both are currently recommended in international guidelines. PATIENTS AND METHODS: Three uro-pathologists re-revised slides of 601 primary (first diagnosis) T1-BCs, initially managed conservatively (bacille Calmette-Guerin) in four hospitals. Grade was defined according to WHO1973 (Grade 1-3) and WHO2004 (low-grade [LG] and high-grade [HG]). This resulted in a lack of Grade 1 tumours, 188 (31%) Grade 2, and 413 (69%) Grade 3 tumours. There were 47 LG (8%) vs 554 (92%) HG tumours. We determined the prognostic value for progression-free survival (PFS) and cancer-specific survival (CSS) in Cox-regression models and corrected for age, sex, multiplicity, size and concomitant carcinoma in situ. RESULTS: At a median follow-up of 5.9 years, 148 patients showed progression and 94 died from BC. The WHO1973 Grade 3 was negatively associated with PFS (hazard ratio [HR] 2.1) and CSS (HR 3.4), whilst WHO2004 grade was not prognostic. On multivariable analysis, WHO1973 grade was the only prognostic factor for progression (HR 2.0). Grade 3 tumours (HR 3.0), older age (HR 1.03) and tumour size >3 cm (HR 1.8) were all independently associated with worse CSS. CONCLUSION: The WHO1973 classification system for grade has strong prognostic value in T1-BC, compared to the WHO2004 system. Our present results suggest that WHO1973 grade cannot be replaced by the WHO2004 classification in non-muscle-invasive BC guidelines. CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - van de Putte, Elisabeth E Fransen AU - van de Putte EEF AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Bosschieter, Judith AU - Bosschieter J AUID- ORCID: 0000-0002-0718-897X AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - van der Kwast, Theo H AU - van der Kwast TH AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Pathology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. FAU - Bertz, Simone AU - Bertz S AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Manach, Quentin AU - Manach Q AD - Academic Department of Urology, Pitie-Salpetriere Hospital, Assistance-Publique Hopitaux de Paris, Pierre et Marie Curie Medical School, University Paris, Paris, France. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Pitie-Salpetriere Hospital, Assistance-Publique Hopitaux de Paris, Pierre et Marie Curie Medical School, University Paris, Paris, France. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. FAU - Jewett, Michael A S AU - Jewett MAS AD - Department of Surgical Oncology (Urology), Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. FAU - Stoehr, Robert AU - Stoehr R AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - van Leenders, Geert J L H AU - van Leenders GJLH AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. AD - Department of Urology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Academic Department of Urology, Pitie-Salpetriere Hospital, Assistance-Publique Hopitaux de Paris, Pierre et Marie Curie Medical School, University Paris, Paris, France. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Department of Pathology, University of Erlangen, Erlangen, Germany. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Surgical Oncology (Urology), Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. LA - eng PT - Comparative Study PT - Journal Article DEP - 20180427 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) SB - IM CIN - BJU Int. 2018 Dec;122(6):914-915. doi: 10.1111/bju.14465. PMID: 30460787 MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Carcinoma, Transitional Cell/*classification/mortality/pathology MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading/*methods MH - Predictive Value of Tests MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*classification/mortality/pathology MH - World Health Organization OTO - NOTNLM OT - bladder cancer OT - grade OT - prognosis OT - stage OT - urothelial carcinoma EDAT- 2018/04/11 06:00 MHDA- 2019/07/17 06:00 CRDT- 2018/04/12 06:00 PHST- 2018/04/11 06:00 [pubmed] PHST- 2019/07/17 06:00 [medline] PHST- 2018/04/12 06:00 [entrez] AID - 10.1111/bju.14238 [doi] PST - ppublish SO - BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27. PMID- 29606341 OWN - NLM STAT- MEDLINE DCOM- 20181105 LR - 20181105 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 9 DP - 2018 Sep TI - Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. PG - 405-412 LID - S1078-1439(18)30075-9 [pii] LID - 10.1016/j.urolonc.2018.02.018 [doi] AB - BACKGROUND: Myeloid derived suppressor cells (MDSC) are heterogeneous immunosuppressive cells with potential predictive and prognostic roles in cancer. The association between MDSC, clinicopathologic factors, and pathologic response in patients with bladder urothelial carcinoma (UC) was explored. METHODS: Peripheral blood or tissue were collected from patients with UC undergoing definitive surgery. MDSCs levels were measured in peripheral blood mononuclear cells and fresh tumor tissue. MDSCs were identified by flow cytometry and defined as total MDSC (T-MDSC) CD33+/HLADR-. From this population, 3 subsets were identified: polymorphonuclear-MDSC (PMN-MDSC) defined as CD33+/HLADR-/CD15+/CD14-, monocytic-MDSC (M-MDSC) defined as CD33+/HLADR-/CD15-/CD14+, and immature-MDSC (I-MDSC) defined as CD33+/HLADR-/CD15-/CD14-. MDSC populations were presented as % of live nucleated blood cells. Spearman correlations (r) and Wilcoxon rank sum test were used to assess correlations between MDSC populations, clinicopathologic factors, and pathologic complete response (pCR). RESULTS: 85 patients scheduled to undergo cystectomy from February 2015 through Dec 2016 were included. All patients had blood drawn for analysis and 23 patients had residual tumor tissue collected for analysis at the time of surgery. Of these 85, 74 (87%) were men with a median age at diagnosis of 68 (range: 44-87). Pure UC was the most common histology (75%); 28 (35%) patients had prior treatment with intravesical therapy and 36 (42%) were treated with neoadjuvant chemotherapy, primarily gemcitabine plus cisplatin (n = 24). On surgical pathology, 18 (21%) of the patients had pCR, 11 (13%) had positive lymph nodes, and 20 patients (24%) had lymphovascular invasion. Statistically significant associations were found between circulating MDSC levels and pCR rates (P<0.01), absolute neutrophil-lymphocyte ratio (P = 0.008), and histology (P = 0.01). Tumor % M-MDSCs were negatively associated with lymphovascular invasion (P = 0.04). There were no significant correlations between peripheral blood mononuclear cells and tumor MDSC subtypes. CONCLUSIONS: Blood and tissue MDSC levels correlate with several clinicopathologic factors and may predict for pCR. Future studies are needed to highlight the role of MDSC in predicting long-term outcomes and to determine the clinical implications of these findings. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Ornstein, Moshe C AU - Ornstein MC AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Diaz-Montero, Claudia Marcela AU - Diaz-Montero CM AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Rayman, Patricia AU - Rayman P AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Elson, Paul AU - Elson P AD - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. FAU - Haywood, Samuel AU - Haywood S AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Finke, James H AU - Finke JH AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Kim, Jin S AU - Kim JS AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Pavicic, Paul G Jr AU - Pavicic PG Jr AD - Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Lamenza, Marcelo AU - Lamenza M AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Devonshire, Sarah AU - Devonshire S AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Dann, Priscilla AU - Dann P AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Schach, Kim AU - Schach K AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Stephenson, Andrew AU - Stephenson A AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Campbell, Steven AU - Campbell S AD - Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Emamekhoo, Hamid AU - Emamekhoo H AD - Division of Hematology/Oncology, University of Wisconsin, Madison, WI. FAU - Ernstoff, Marc S AU - Ernstoff MS AD - Division of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Hoimes, Christopher J AU - Hoimes CJ AD - Department of Hematology and Oncology, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH. FAU - Gilligan, Timothy D AU - Gilligan TD AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Rini, Brian I AU - Rini BI AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Garcia, Jorge A AU - Garcia JA AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. FAU - Grivas, Petros AU - Grivas P AD - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Department of Medicine, Division of Oncology, University of Washington, Seattle, WA. Electronic address: pgrivas@uw.edu. LA - eng PT - Journal Article PT - Review DEP - 20180330 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cell Differentiation MH - Cystectomy/*methods MH - Female MH - Humans MH - Leukocytes, Mononuclear/*metabolism MH - Male MH - Middle Aged MH - Myeloid Cells/immunology/*metabolism MH - Urologic Neoplasms/*blood/*complications OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - MDSC OT - Myeloid-derived suppressor cells OT - Tumor immunology OT - Urothelial carcinoma EDAT- 2018/04/03 06:00 MHDA- 2018/11/06 06:00 CRDT- 2018/04/03 06:00 PHST- 2017/07/25 00:00 [received] PHST- 2018/01/29 00:00 [revised] PHST- 2018/02/27 00:00 [accepted] PHST- 2018/04/03 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2018/04/03 06:00 [entrez] AID - S1078-1439(18)30075-9 [pii] AID - 10.1016/j.urolonc.2018.02.018 [doi] PST - ppublish SO - Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. PMID- 29605462 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. PG - 310.e15-310.e22 LID - S1078-1439(18)30076-0 [pii] LID - 10.1016/j.urolonc.2018.02.019 [doi] AB - PURPOSE: To explore the function of NORAD in bladder cancer (BC), and to verify whether NORAD could be used as a biomarker to determine preoperative presence of progression and lymph node metastasis. To our knowledge, it is the first study investigating NORAD and its implications in BC. METHODS: BC specimens of 90 patients underwent bladder cystectomy or transurethral resection between January 2012 to December 2016 were tested by fluorescence in situ hybridization. The association between NORAD expression and clinicopathological features and prognosis of the patients was analyzed using Kaplan-Meier survival analysis and Cox regression analysis. Quantitative real-time polymerase chain reaction was performed in 4 BC cell lines and 10 fresh tumor sample together with adjacent tissues. MTT, colony formation assay, and Annexin-V apoptosis detection were performed after knockdown of NORAD using shRNA in TSSCUP cells. Western blot was performed to related proteins extracted from these cells. RESULTS: Fluorescence in situ hybridization indicated that high NORAD expression was associated with more advanced histological grade and clinical stage for patients with BC. Higher NORAD expression resulted in lower overall survival, and was an independent prognostic indicator. Real-time polymerase chain reaction showed that the expression of NORAD in BC tissues was higher than those measured in adjacent normal tissues. MTT and colony formation assay demonstrated that knockdown of NORAD results in lower proliferation in TSSCUP cells, whereas PUM2 expression was upregulated and E2F3 downregulated. CONCLUSIONS: High NORAD expression could serve as an independent prognostic factor for overall survival of patients with transitional BC. NORAD could be considered as a promising candidate for novel biomarker and therapeutic target for human BC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Li, Qiaqia AU - Li Q AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Li, Chao AU - Li C AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Chen, Jinbo AU - Chen J AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Liu, Peihua AU - Liu P AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Cui, Yu AU - Cui Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Zhou, Xinyi AU - Zhou X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Li, Huihuang AU - Li H AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Zu, Xiongbing AU - Zu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. Electronic address: whzuxb@163.com. LA - eng PT - Journal Article DEP - 20180328 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (NORAD long non-coding RNA, human) RN - 0 (RNA, Long Noncoding) SB - IM MH - Apoptosis MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell/genetics/*secondary/surgery MH - Cell Proliferation MH - Cystectomy/*mortality MH - Disease Progression MH - Female MH - Follow-Up Studies MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - RNA, Long Noncoding/*genetics MH - Survival Rate MH - Urinary Bladder Neoplasms/genetics/*pathology/surgery OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - NORAD OT - Prognosis EDAT- 2018/04/02 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/04/02 06:00 PHST- 2017/10/29 00:00 [received] PHST- 2018/02/27 00:00 [revised] PHST- 2018/02/28 00:00 [accepted] PHST- 2018/04/02 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/04/02 06:00 [entrez] AID - S1078-1439(18)30076-0 [pii] AID - 10.1016/j.urolonc.2018.02.019 [doi] PST - ppublish SO - Urol Oncol. 2018 Jun;36(6):310.e15-310.e22. doi: 10.1016/j.urolonc.2018.02.019. Epub 2018 Mar 28. PMID- 29602638 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. PG - 307.e9-307.e14 LID - S1078-1439(18)30078-4 [pii] LID - 10.1016/j.urolonc.2018.03.002 [doi] AB - BACKGROUND: Pelvic lymph node dissection (PLND) has a diagnostic and therapeutic role during radical cystectomy in bladder cancer patients. However, at the time, no prospective data supports the value of extended PLND in improving survival expectances. We sought to describe incidence and location of node metastases in patients treated with extended and superextended PLND. METHODS: We evaluated 653 contemporary patients with clinically nonmetastatic high risk nonmuscle invasive or muscle-invasive bladder cancer treated with radical cystectomy and extended or superextended PLND without neoadjuvant chemotherapy at a single tertiary referral center between 1990 and 2013. Limited PLND is defined as the removal of obturator and internal iliac nodes. Standard included also the external iliac nodes. Extended includes also common and presacral nodes. Finally, superextended PLND includes all the nodes removed along the inferior mesenteric artery. We evaluated incidence of pathologically node metastases. Logistic regression analyses evaluate preoperative and pathologic characteristics to the risk of harboring node metastases in the extended and superextended template. RESULTS: Overall, 191 (29.3%) patients were found with pathologically node confirmed metastases. Of these, 56 (29.3%) patients were found with a single node metastasis, while 135 (70.7%) had multiple node metastases. The vast majority of patients were found with node metastases standard template (n = 172, 26.3%), on the other hand 30 (4.6%) and 21 (3.2%) patients had node metastases in extended and superextended templates, respectively. However, of these only 2 patients were found without concomitant lymph node metastases in the limited or standard templates. On multivariable analyses, cN+ status (odds ratio = 4.40, P<0.001) and cT3-4 vs. cT1-2 (odds ratio = 2.25, P<0.001) were associated with an increased risk of harboring node metastases in the extended or superextended template. CONCLUSIONS: We found that the majority of patients harbored node disease in the limited or standard node dissection pattern. On the other hand, only a minority of patient were found with a disease in extended or superextended template without harboring a concomitant node disease in the limited pattern. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy; Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: marco.moschini87@gmail.com. FAU - Arbelaez, Emilio AU - Arbelaez E AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Cornelius, Julian AU - Cornelius J AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Mattei, Agostino AU - Mattei A AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Dell Oglio, Paolo AU - Dell Oglio P AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Zaffuto, Emanuele AU - Zaffuto E AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Unit of Urology/Division of Oncology; IRCCS Ospedale San Raffaele; URI, Milan, Italy. LA - eng PT - Journal Article DEP - 20180327 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - *Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Nodes/pathology/*surgery MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Pelvic Neoplasms/*secondary/*surgery MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Node metastases OT - PLND OT - Radical cystectomy OT - ePLND EDAT- 2018/04/01 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/04/01 06:00 PHST- 2016/11/08 00:00 [received] PHST- 2018/01/14 00:00 [revised] PHST- 2018/03/08 00:00 [accepted] PHST- 2018/04/01 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/04/01 06:00 [entrez] AID - S1078-1439(18)30078-4 [pii] AID - 10.1016/j.urolonc.2018.03.002 [doi] PST - ppublish SO - Urol Oncol. 2018 Jun;36(6):307.e9-307.e14. doi: 10.1016/j.urolonc.2018.03.002. Epub 2018 Mar 27. PMID- 29599921 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220316 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 19 DP - 2018 Mar 13 TI - A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. PG - 15001-15014 LID - 10.18632/oncotarget.24531 [doi] AB - BACKGROUND: Immunohistochemical PD-L1 assessment is currently used to identify responders towards checkpoint inhibitors although it is limited by inter-observer effects. Here, we conducted a multi-center round robin test to prove the possibility of assessing the PD-L1 status by gene expression to avoid inter-observer effects. PATIENTS AND METHODS: Gene expression of PD-L1 was analyzed in a total of 294 samples (14 cases non-muscle invasive and muscle-invasive bladder cancer; MIBC) in seven centers by a RT-qPCR kit and compared with immunohistochemical scoring of three pathologists (DAKO, 22c3). Both assays were compared towards prognosis prediction in a cohort of 88 patients with MIBC. RESULTS: PD-L1 gene expression revealed very high inter center correlation (centrally extracted RNA: r = 0.68-0.98, p 0.05), while gene methylation status was demonstrated to be an independent prognostic factor. CONCLUSION: Renal pelvic tumors and ureteral tumors exhibited significant differences in clinicopathologic characteristics and epigenetic biomarkers. Gene promoter methylation might be an important mechanism in explaining distinct tumor patterns and behaviors in UTUC. FAU - Fang, Dong AU - Fang D AUID- ORCID: 0000-0001-6746-6559 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - He, Shiming AU - He S AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Cao, Zhenpeng AU - Cao Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. pineneedle@sina.com. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. zhoulqmail@sina.com. LA - eng GR - Z151100004015173/the Clinical Features Reserach of Capital/ GR - BMU20120318/Collaborative Research Foundation of Peking University Health Science Center and National Taiwan University, the College of Medicine/ GR - 7152146/Natural Science Foundation of Beijing/ GR - 2016-1-4077/the Capital Health Research and Development of Special/ GR - BMU2017PY009/Fund for Fostering Young Scholars of Peking University Health Science Center/ PT - Comparative Study PT - Journal Article DEP - 20180327 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers MH - *Biomarkers, Tumor/genetics MH - Cohort Studies MH - *Epigenesis, Genetic/genetics MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/diagnosis/genetics/*pathology MH - Kidney Pelvis/*pathology MH - Male MH - Middle Aged MH - Retrospective Studies MH - Ureteral Neoplasms/diagnosis/genetics/*pathology MH - Urothelium/*pathology PMC - PMC5870733 OTO - NOTNLM OT - Methylation OT - Prognosis OT - Radical nephroureterectomy (RNU) OT - Renal pelvis OT - Upper tract urothelial carcinomas (UTUC) OT - Ureter COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study received the ethics approval by the Ethic Committee of Peking University First Hospital (No. 2016-1253). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients agreed and signed the informed consent to participate into the study, and they agreed that their information (including clinical information, surgical related data, pathological data and surveillance) would be collected for scientific study and by published in professional medical journals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/03/29 06:00 MHDA- 2018/09/27 06:00 PMCR- 2018/03/27 CRDT- 2018/03/29 06:00 PHST- 2017/09/12 00:00 [received] PHST- 2018/03/12 00:00 [accepted] PHST- 2018/03/29 06:00 [entrez] PHST- 2018/03/29 06:00 [pubmed] PHST- 2018/09/27 06:00 [medline] PHST- 2018/03/27 00:00 [pmc-release] AID - 10.1186/s12894-018-0334-7 [pii] AID - 334 [pii] AID - 10.1186/s12894-018-0334-7 [doi] PST - epublish SO - BMC Urol. 2018 Mar 27;18(1):22. doi: 10.1186/s12894-018-0334-7. PMID- 29580697 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome. PG - 307.e1-307.e8 LID - S1078-1439(18)30072-3 [pii] LID - 10.1016/j.urolonc.2018.02.015 [doi] AB - INTRODUCTION: Small cell carcinoma of the bladder (SCCB) is a rare and lethal disease. Previously, we and others have reported a bladder sparing strategy with platinum-etoposide-based chemotherapy followed by radiotherapy of the bladder. Little is known on frequency and treatment of intravesical recurrence following this approach. The objective of this study is to describe the incidence of intravesical recurrences and their management. MATERIALS AND METHODS: Retrospective study including all patients with SCCB treated at a single institution from 1993 until 2016. All patients with limited disease (LD) SCCB who had a bladder sparing approach with sequential chemotherapy and radiotherapy were identified. Intravesical and overall recurrence rate, overall and disease specific survival, salvage treatment options and their results were retrieved. RESULTS: Of the 110 patients with SCCB (82% male) with a mean age of 65 years and a median follow up of 48 months, 89 patients (81%) had LD-SCCB. Of these, 65 were treated with chemotherapy and radiotherapy, with a median overall recurrence free survival of 22 months (CI: 14-30). Of 65 patients, 23 (35%) progressed to distant metastasis without intravesical recurrence after a median of 9 months (CI: 8-11), whereas 14 patients (22%) developed isolated intravesical recurrence at a median of 24 months (CI: 14-34). Local recurrence contained SCCB, urothelial carcinoma, and carcinoma in situ and was treated with various local salvage treatments including TURB, cystectomy, neoadjuvant chemotherapy, and BCG. Following salvage treatment a complete response was seen in 64%. Median overall survival for intravesical vs. systemic recurrence was different, with 28 (CI: 9-47) and 8 (CI: 5-11) months, respectively (P<0.001). CONCLUSION: SCCB is a serious potentially lethal disease. Even in patients with LD-SCCB a high percentage rapidly develops systemic disease. This suggests that systemic therapy is more important than the type of local treatment to control the disease but small sample sizes limit the ability to distinguish between different treatment options in this study. A bladder sparing approach can be a reasonable alternative to major surgery. However, in those surviving long enough isolated intravesical recurrence occurs even after many years. Our results indicate that long term follow up is required because salvage therapy can be successful in the majority of patients. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - van de Kamp, Maaike AU - van de Kamp M AD - Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. Electronic address: maaikevdkamp@hotmail.com. FAU - Meijer, Richard AU - Meijer R AD - Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - Pos, Floris AU - Pos F AD - Department of radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - Kerst, Martijn AU - Kerst M AD - Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - van Werkhoven, Eric AU - van Werkhoven E AD - Department of Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - van Rhijn, Bas AU - van Rhijn B AD - Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - Horenblas, Simon AU - Horenblas S AD - Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. FAU - Bex, Axel AU - Bex A AD - Department of urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20180323 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Small Cell/*mortality/pathology/therapy MH - Combined Modality Therapy MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*mortality MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*mortality/pathology/therapy MH - Organ Sparing Treatments/*mortality MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - *Salvage Therapy MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - Chemoradiation OT - Intravesical recurrence OT - Small cell bladder carcinoma EDAT- 2018/03/28 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/03/28 06:00 PHST- 2017/11/30 00:00 [received] PHST- 2018/02/07 00:00 [revised] PHST- 2018/02/26 00:00 [accepted] PHST- 2018/03/28 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/03/28 06:00 [entrez] AID - S1078-1439(18)30072-3 [pii] AID - 10.1016/j.urolonc.2018.02.015 [doi] PST - ppublish SO - Urol Oncol. 2018 Jun;36(6):307.e1-307.e8. doi: 10.1016/j.urolonc.2018.02.015. Epub 2018 Mar 23. PMID- 29577063 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220316 IS - 2352-0779 (Print) IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 5 IP - 2 DP - 2018 Mar TI - Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guerin Treatment. PG - 132-138 LID - 10.1016/j.urpr.2017.02.012 [doi] AB - INTRODUCTION: Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard adjuvant treatment for patients with high-grade non-muscle-invasive bladder cancer (NMIBC). Despite the association between metabolic syndrome (MetS) and bladder cancer, the association between MetS and BCG failure is unknown. The objective of this study was to characterize disease recurrence following BCG in patients with and without MetS. METHODS: We retrospectively evaluated the records of patients undergoing TURBT at our institution in 2012-2015 for NMIBC and identified those who received adjuvant BCG therapy. MetS was defined as having three of four components: diabetes mellitus, hyperlipidemia, hypertension, or body mass index (BMI)>/=30kg/m(2). The primary outcome was recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed. RESULTS: High grade was present in 83/90 (92.2%) patients. MetS was present in 27/90 (30%) patients. Median follow-up was 20 months. On Kaplan-Meier analysis, patients with MetS had worse DFS compared with patient without MetS. On multivariable analysis, BMI>/=30 kg/m(2) was a significant predictor of recurrence or progression (HR 2.94, 95% CI: 1.43-6.03). Presence of MetS did not significantly affect the type of BCG failure. CONCLUSIONS: The association between MetS and failure to respond to BCG therapy is multifactorial but is in part associated with obesity. Elevated BMI is strongly associated with recurrence or progression. Further studies are warranted to investigate the relationship between increased adiposity and response to BCG, especially as other novel immunotherapeutic agents are likely to enter the NMIBC space. FAU - Lenis, Andrew T AU - Lenis AT AD - David Geffen School of Medicine at the University of California Los Angeles. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Asanad, Kian AU - Asanad K AD - David Geffen School of Medicine at the University of California Los Angeles. FAU - Blaibel, Maher AU - Blaibel M AD - University of California, Riverside School of Medicine, Riverside, California. FAU - Donin, Nicholas M AU - Donin NM AD - David Geffen School of Medicine at the University of California Los Angeles. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Chamie, Karim AU - Chamie K AD - David Geffen School of Medicine at the University of California Los Angeles. AD - Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California. AD - Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. LA - eng GR - F32 CA144461/CA/NCI NIH HHS/United States GR - L30 CA154326/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170302 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 PMC - PMC5861375 MID - NIHMS883979 OTO - NOTNLM OT - Bladder Cancer OT - Calmette-Guerin Bacillus OT - Metabolic Syndrome OT - Outcome Assessment OT - Recurrence EDAT- 2018/03/27 06:00 MHDA- 2018/03/27 06:01 PMCR- 2018/03/21 CRDT- 2018/03/27 06:00 PHST- 2018/03/27 06:00 [entrez] PHST- 2018/03/27 06:00 [pubmed] PHST- 2018/03/27 06:01 [medline] PHST- 2018/03/21 00:00 [pmc-release] AID - 10.1016/j.urpr.2017.02.012 [doi] PST - ppublish SO - Urol Pract. 2018 Mar;5(2):132-138. doi: 10.1016/j.urpr.2017.02.012. Epub 2017 Mar 2. PMID- 29576445 OWN - NLM STAT- MEDLINE DCOM- 20190205 LR - 20190215 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 4 DP - 2018 Aug TI - Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. PG - e879-e892 LID - S1558-7673(18)30118-6 [pii] LID - 10.1016/j.clgc.2018.02.002 [doi] AB - BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy is the standard of care in muscle-invasive bladder cancer. There are limited data regarding chemotherapy tolerability and outcomes for patients with low glomerular filtration rate (GFR) who receive cisplatin-based NAC. PATIENTS AND METHODS: A retrospective analysis of patients who received cisplatin-based NAC at Cleveland Clinic (2005-2016) was undertaken. Patients with pre-NAC GFR < 60 mL/min by either Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) formula were compared to patients with GFR >/= 60 mL/min for NAC tolerability, pathologic complete and partial response (pPR), and the ability to undergo radical cystectomy. RESULTS: Thirty patients with low GFR (34-59 mL/min) and 94 patients with normal GFR (>/= 60 mL/min) were identified. Low GFR patients were older (median, 71 vs. 65 years), but other demographic and transurethral resection of bladder tumor characteristics were comparable. Low GFR patients more frequently had early NAC discontinuation (30% vs. 13%), NAC modifications (delays, dose reduction, or discontinuation, 66% vs. 40%), and cisplatin-based NAC administered in split doses (37% vs. 16%). No differences in NAC tolerability or outcomes were noted among low GFR patients receiving split-dose versus standard regimens. No differences were noted between low and normal GFR patients in NAC cycles (median, 3 for each), cystectomy rates (93% for each), time to cystectomy, and GFR change from baseline to after NAC. Pathologic complete response was higher among normal GFR patients (24% vs. 14%). CONCLUSION: Patients with low GFR had more NAC discontinuations and modifications, but most completed planned NAC cycles. For carefully selected patients with GFR < 60 mL/min, cisplatin-based NAC remains a treatment option. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Koshkin, Vadim S AU - Koshkin VS AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Barata, Pedro C AU - Barata PC AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Rybicki, Lisa A AU - Rybicki LA AD - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. FAU - Zahoor, Haris AU - Zahoor H AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Almassi, Nima AU - Almassi N AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Redden, Alicia M AU - Redden AM AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Fergany, Amr F AU - Fergany AF AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Kaouk, Jihad AU - Kaouk J AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Haber, Georges-Pascal AU - Haber GP AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Stephenson, Andrew J AU - Stephenson AJ AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Ornstein, Moshe C AU - Ornstein MC AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Gilligan, Timothy AU - Gilligan T AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Garcia, Jorge A AU - Garcia JA AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Rini, Brian I AU - Rini BI AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Grivas, Petros AU - Grivas P AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: pgrivas@uw.edu. LA - eng PT - Journal Article DEP - 20180222 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Chemotherapy, Adjuvant MH - Cisplatin/*administration & dosage/adverse effects MH - Cystectomy MH - Female MH - Glomerular Filtration Rate MH - Humans MH - Kidney/*physiopathology MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*adverse effects/methods MH - Retrospective Studies MH - Risk Factors MH - Standard of Care MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/physiopathology/surgery OTO - NOTNLM OT - Glomerular filtration rate OT - Renal insufficiency OT - Split-dose cisplatin OT - Urinary bladder neoplasm OT - Urothelial carcinoma EDAT- 2018/03/27 06:00 MHDA- 2019/02/06 06:00 CRDT- 2018/03/27 06:00 PHST- 2018/01/17 00:00 [received] PHST- 2018/02/06 00:00 [revised] PHST- 2018/02/18 00:00 [accepted] PHST- 2018/03/27 06:00 [pubmed] PHST- 2019/02/06 06:00 [medline] PHST- 2018/03/27 06:00 [entrez] AID - S1558-7673(18)30118-6 [pii] AID - 10.1016/j.clgc.2018.02.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892. doi: 10.1016/j.clgc.2018.02.002. Epub 2018 Feb 22. PMID- 29576423 OWN - NLM STAT- MEDLINE DCOM- 20190722 LR - 20190722 IS - 0740-2570 (Print) IS - 0740-2570 (Linking) VI - 35 IP - 4 DP - 2018 Jul TI - Iatrogenic pathology of the urinary bladder. PG - 218-227 LID - S0740-2570(18)30020-0 [pii] LID - 10.1053/j.semdp.2018.03.001 [doi] AB - Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Pathology and Surgery, Faculty of Medicine, Cordoba E-14004, Spain. Electronic address: em1lobea@uco.es. FAU - Montironi, Rodolfo AU - Montironi R AD - Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, Ancona, Italy. FAU - Raspollini, Maria R AU - Raspollini MR AD - Histopathology and Molecular Diagnostics. University Hospital Careggi, Florence, Italy. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, United States. FAU - Netto, George J AU - Netto GJ AD - Department of Pathology, University at Alabama Birmingham School of Medicine, Birmingham, AL, USA. LA - eng PT - Journal Article PT - Review DEP - 20180314 PL - United States TA - Semin Diagn Pathol JT - Seminars in diagnostic pathology JID - 8502262 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/*analysis MH - Carcinoma in Situ/*pathology/therapy MH - Carcinoma, Transitional Cell/*pathology/therapy MH - Drug-Related Side Effects and Adverse Reactions MH - Humans MH - Iatrogenic Disease MH - Immunohistochemistry MH - Immunotherapy/adverse effects MH - Neoadjuvant Therapy/adverse effects MH - Radiotherapy/adverse effects MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*pathology/therapy MH - Urothelium OTO - NOTNLM OT - Atypia OT - Bladder OT - Chemotherapy OT - Flat lesions OT - Immunotherapy OT - Radiation therapy OT - Urothelium EDAT- 2018/03/27 06:00 MHDA- 2019/07/23 06:00 CRDT- 2018/03/27 06:00 PHST- 2018/03/27 06:00 [pubmed] PHST- 2019/07/23 06:00 [medline] PHST- 2018/03/27 06:00 [entrez] AID - S0740-2570(18)30020-0 [pii] AID - 10.1053/j.semdp.2018.03.001 [doi] PST - ppublish SO - Semin Diagn Pathol. 2018 Jul;35(4):218-227. doi: 10.1053/j.semdp.2018.03.001. Epub 2018 Mar 14. PMID- 29572851 OWN - NLM STAT- MEDLINE DCOM- 20190913 LR - 20230926 IS - 1532-5415 (Electronic) IS - 0002-8614 (Print) IS - 0002-8614 (Linking) VI - 66 IP - 5 DP - 2018 May TI - Mortality and Functional Outcomes After Minor Urological Surgery in Nursing Home Residents: A National Study. PG - 909-915 LID - 10.1111/jgs.15302 [doi] AB - OBJECTIVES: To determine outcomes of minor urological surgery in frail older adults. DESIGN: Retrospective cohort study. SETTING: U.S. nursing homes (NHs). PARTICIPANTS: NH residents aged 65 and older undergoing minor inpatient urological surgery (cystoscopy, bladder biopsy, transurethral resection of bladder tumor, prostate biopsy, transurethral resection of prostate, removal of ureteral obstruction, suprapubic tube placement) in the United States between 2004 and 2012 (N=34,605). MEASUREMENTS: One-year mortality and changes in functional status before and after surgery using the Minimum Data Set Activity of Daily Living (MDS-ADL) summary scale. RESULTS: Overall 1-year mortality was 50%, and on average, residents had a 1.9-point worsening in their MDS-ADL score at 1 year, whereas the most highly functional residents (baseline quartile of MDS-ADL scores (0-12)) had a 4.7-point worsening in their MDS-ADL scores at 1 year. Functional decline in residents 1 year after surgery was associated with decline in function in the 6 months before surgery (adjusted hazard ratio (aH)=2.39, 95% confidence interval (CI)=2.29-2.49), emergency procedures (aHR=1.37, 95% CI=1.31-1.43), older age (>/=85 vs 65-74, aHR=1.17, 95% CI=1.11-1.23), and baseline cognitive impairment (aHR=1.15, 95% CI=1.11-1.20). CONCLUSION: Despite the low complexity of minor urological procedures, NH residents experience high mortality and many demonstrate sustained functional decline up to 1-year postoperatively. CI - (c) 2018, Copyright the Authors Journal compilation (c) 2018, The American Geriatrics Society. FAU - Suskind, Anne M AU - Suskind AM AD - Department of Urology, University of California, San Francisco, San Francisco, California. FAU - Zhao, Shoujun AU - Zhao S AD - Department of Urology, University of California, San Francisco, San Francisco, California. FAU - Walter, Louise C AU - Walter LC AD - Division of Geriatrics, Department of Medicine, University of California, San Francisco, San Francisco, California. AD - Division of Geriatrics, Veterans Affairs Medical Center, San Francisco, California. FAU - Boscardin, W John AU - Boscardin WJ AD - Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. FAU - Finlayson, Emily AU - Finlayson E AD - Department of Surgery, University of California, San Francisco, San Francisco, California. LA - eng GR - K12 DK083021/DK/NIDDK NIH HHS/United States GR - K24 AG041180/AG/NIA NIH HHS/United States GR - R03 AG050872/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180323 PL - United States TA - J Am Geriatr Soc JT - Journal of the American Geriatrics Society JID - 7503062 SB - IM MH - *Activities of Daily Living MH - Aged, 80 and over MH - Female MH - Frail Elderly/*statistics & numerical data MH - Humans MH - Inpatients/statistics & numerical data MH - Male MH - Mortality/*trends MH - *Nursing Homes MH - Retrospective Studies MH - United States MH - Urologic Surgical Procedures/*statistics & numerical data PMC - PMC6009834 MID - NIHMS948387 OTO - NOTNLM OT - Medicare OT - Minimum Data Set (MDS) OT - frail OT - older adults COIS- Conflict of Interest: None. Dr. Suskind is a consultant for Acoustic Wave Cell Therapy, Inc. This is not related to the work presented here in. EDAT- 2018/03/25 06:00 MHDA- 2019/09/14 06:00 PMCR- 2019/05/01 CRDT- 2018/03/25 06:00 PHST- 2018/03/25 06:00 [pubmed] PHST- 2019/09/14 06:00 [medline] PHST- 2018/03/25 06:00 [entrez] PHST- 2019/05/01 00:00 [pmc-release] AID - 10.1111/jgs.15302 [doi] PST - ppublish SO - J Am Geriatr Soc. 2018 May;66(5):909-915. doi: 10.1111/jgs.15302. Epub 2018 Mar 23. PMID- 29571585 OWN - NLM STAT- MEDLINE DCOM- 20190204 LR - 20190215 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 4 DP - 2018 Aug TI - Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. PG - 274-280 LID - S1558-7673(18)30117-4 [pii] LID - 10.1016/j.clgc.2018.02.001 [doi] AB - BACKGROUND: Pathologic T1 high-grade (pT1HG) bladder cancer (BC) is characterized by a high progression rate and constitutes an important clinical challenge; however, there is no consensus on the prediction of progression in pT1HG BC. The purpose of this study was to validate previously published molecular progression risk score (MoPRS) for predicting muscle-invasive disease in pT1HG BC. MATERIALS AND METHODS: The expression of an 8-gene progression-related classifier identified from microarray data was analyzed by real-time PCR, and the MoPRS was calculated in 121 newly recruited patients with pT1HG BC. Progression was defined as muscle invasion or metastasis. RESULTS: Overall, the disease of 28 patients (23.1%) progressed to muscle-invasive BC during the median follow-up of 63.7 (interquartile range, 17.6-96.4) months. The MoPRS was significantly higher in 1973 World Health Organization grade 3 than grade 2 tumors (P = .004). Early development of invasive BC was more prevalent in the highest quartile MoPRS group than in the lowest to 75th percentile MoPRS groups according to Kaplan-Meier analysis. Multivariate Cox regression analysis revealed that the MoPRS was an independent predictor of invasive BC, either as a continuous variable (hazard ratio, 1.624; 95% confidence interval, 1.266-2.082; P < .001) or as a categorical variable (hazard ratio, 3.089; 95% confidence interval, 1.335-7.150; P = .008). CONCLUSION: The MoPRS was an independent prognostic factor for identifying patients at high risk of invasive BC in patients with pT1HG BC. This scale may help identify patients who could benefit from more aggressive therapeutic intervention such as early cystectomy. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Seo, Sung Pil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Byun, Young Joon AU - Byun YJ AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Piao, Xuan-Mei AU - Piao XM AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Ye-Hwan AU - Kim YH AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - School of Food Science and Technology, Chung-Ang University, Anseong, South Korea. FAU - Choi, Yung-Hyun AU - Choi YH AD - Department of Biochemistry, Dongeui University College of Oriental Medicine, Busan, South Korea. FAU - Yun, Seok-Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. Electronic address: sjyun@chungbuk.ac.kr. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University Hospital, Chungbuk National University, Cheongju, South Korea. Electronic address: wjkim@chungbuk.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180223 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Disease Progression MH - Female MH - Gene Expression Profiling/*methods MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Oligonucleotide Array Sequence Analysis/*methods MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*genetics/*pathology OTO - NOTNLM OT - Disease progression OT - Gene expression signatures OT - Real-time polymerase chain reaction OT - Risk assessment OT - Urinary bladder neoplasms EDAT- 2018/03/25 06:00 MHDA- 2019/02/05 06:00 CRDT- 2018/03/25 06:00 PHST- 2017/10/19 00:00 [received] PHST- 2018/02/05 00:00 [revised] PHST- 2018/02/16 00:00 [accepted] PHST- 2018/03/25 06:00 [pubmed] PHST- 2019/02/05 06:00 [medline] PHST- 2018/03/25 06:00 [entrez] AID - S1558-7673(18)30117-4 [pii] AID - 10.1016/j.clgc.2018.02.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Aug;16(4):274-280. doi: 10.1016/j.clgc.2018.02.001. Epub 2018 Feb 23. PMID- 29570711 OWN - NLM STAT- MEDLINE DCOM- 20180622 LR - 20240917 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 13 IP - 3 DP - 2018 TI - Smoking intensity and bladder cancer aggressiveness at diagnosis. PG - e0194039 LID - 10.1371/journal.pone.0194039 [doi] LID - e0194039 AB - OBJECTIVE: To explore the relation between cigarette smoking intensity and bladder cancer aggressiveness at first diagnosis. METHODS: Patients diagnosed with urinary bladder cancer (BC) between 1995-2011 under the age of 75 years were retrospectively identified from the Netherlands Cancer Registry and invited for a study on genetic and lifestyle risk factors for BC. Information on patients' self-reported smoking history was retrieved by means of a postal questionnaire. Tumors were stratified regarding the risk of progression defined by tumor stage and grade. Multinomial logistic regression was used to analyze the relation between smoking intensity and aggressiveness of the tumor. RESULTS: The UBC study population comprised 323 (17.4%) never smokers, 870 (46.8%) former cigarette smokers, and 630 (33.9%) current cigarette smokers. A higher smoking amount was a risk factor of getting high-risk non-muscle invasive bladder cancer (NMIBC) compared with low-risk NMIBC in ever and former cigarette smokers (OR: 1.02 per cigarette smoked, 95% CI: 1.00-1.03 and OR: 1.03, 95% CI: 1.01-1.05, respectively). A statistically significant dose-response increase in the risk of a more aggressive cancer type (high-risk NMIBC and MIBC) was observed with increasing smoking duration among former smokers (p for trend 0.035 and 0.008, respectively). No significant association of the evaluated smoking intensity variables was observed in current smokers. A longer time of smoking cessation correlated with a lower odds of a more aggressive cancer. CONCLUSION: We observed a weak increase in the risk of a more aggressive tumor type with increasing smoking intensity in former smokers, but this association was absent in current smokers. This conflicting result may suggest that there is no strong relation between smoking intensity and bladder cancer aggressiveness. Analyses of prospective studies with longitudinal smoking assessment may provide a more definitive answer to the research question. FAU - Barbosa, Andre L A AU - Barbosa ALA AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. AD - Federal University of Bahia, Salvador, Brazil. FAU - Vermeulen, Sita H H M AU - Vermeulen SHHM AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - Aben, Katja K AU - Aben KK AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. AD - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AUID- ORCID: 0000-0002-2368-1326 AD - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. AD - Department of Urology, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20180323 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cigarette Smoking/adverse effects MH - Disease Progression MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies MH - Risk Factors MH - *Smoking/adverse effects MH - *Urinary Bladder/pathology MH - *Urinary Bladder Neoplasms/pathology PMC - PMC5865728 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2018/03/24 06:00 MHDA- 2018/06/23 06:00 PMCR- 2018/03/23 CRDT- 2018/03/24 06:00 PHST- 2017/10/02 00:00 [received] PHST- 2018/02/25 00:00 [accepted] PHST- 2018/03/24 06:00 [entrez] PHST- 2018/03/24 06:00 [pubmed] PHST- 2018/06/23 06:00 [medline] PHST- 2018/03/23 00:00 [pmc-release] AID - PONE-D-17-35543 [pii] AID - 10.1371/journal.pone.0194039 [doi] PST - epublish SO - PLoS One. 2018 Mar 23;13(3):e0194039. doi: 10.1371/journal.pone.0194039. eCollection 2018. PMID- 29551583 OWN - NLM STAT- MEDLINE DCOM- 20190205 LR - 20190215 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 4 DP - 2018 Aug TI - Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. PG - e751-e760 LID - S1558-7673(18)30073-9 [pii] LID - 10.1016/j.clgc.2018.01.014 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) accounts for approximately 5% of all urothelial cancers. Because of similarities in morphology and histology between UTUC and urothelial carcinoma of the bladder, most treatment guidelines used for UTUC are extrapolated from the urothelial bladder carcinoma setting. With the emergence of new treatment modalities, such as immunotherapy, UTUC-specific prognostic and predictive models are needed. PATIENTS AND METHODS: A retrospective study of 454 UTUC patients who received surgery at Cleveland Clinic (1995-2014) was conducted. Univariable and multivariable analysis (MVA) was used to identify independent predictors of progression-free survival (PFS) and overall survival (OS). RESULTS: Two hundred eighty-six patients with invasive UTUC were identified with pT1, pT2, pT3, and pT4 in 93 (33%), 51 (18%), 126 (44%), and 16 (6%), respectively. Most patients (76%) had laparoscopic nephroureterectomy, 14% had positive invasive surgical margins, and 22% had multifocal tumors. All patients had urothelial carcinoma as primary histology, 93 of 183 (51%) with available follow-up data had disease recurrence. Estimated median PFS was 17.2 months (95% confidence interval [CI], 13.1-39.3). In MVA, pT stage (P = .0005), positive margins (P = .04), and age older than 70 years (P = .002) independently correlated with PFS. Overall, 101 patients (37%) of 272 patients with available data died with estimated median OS of 64.5 months (95% CI, 39.3-107.4); median follow-up was 39.5 (range, 0.3-186) months in patients alive and recurrence-free at last follow-up. In MVA, lymphovascular invasion (P = .005), tumor size (P = .0005), age (P = .005), and pT stage (P = .03) independently predicted OS. Using these factors, 3 prognostic groups for PFS and 2 for OS were identified. CONCLUSION: Clinical-pathological parameters can be prognostic in UTUC and might inform clinical trial design and decision-making. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Emamekhoo, Hamid AU - Emamekhoo H AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Dhillon, Puneet AU - Dhillon P AD - Medicine Institute, Cleveland Clinic, Cleveland, OH. FAU - Gopalakrishnan, Dharmesh AU - Gopalakrishnan D AD - Medicine Institute, Cleveland Clinic, Cleveland, OH. FAU - Elson, Paul AU - Elson P AD - Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. FAU - Stephenson, Andrew AU - Stephenson A AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Magi-Galluzzi, Cristina AU - Magi-Galluzzi C AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH. FAU - McKenney, Jesse AU - McKenney J AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH. FAU - Harper, Holly AU - Harper H AD - Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH. FAU - Haber, Georges-Pascal AU - Haber GP AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Kaouk, Jihad AU - Kaouk J AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Lee, Byron AU - Lee B AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Fergany, Amr AU - Fergany A AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Berglund, Ryan AU - Berglund R AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Gong, Michael AU - Gong M AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Stein, Robert AU - Stein R AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Krishnamurthi, Venkatesh AU - Krishnamurthi V AD - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. FAU - Gilligan, Timothy AU - Gilligan T AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Ornstein, Moshe AU - Ornstein M AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Rini, Brian AU - Rini B AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Garcia, Jorge AU - Garcia J AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Grivas, Petros AU - Grivas P AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: pgrivas@uw.edu. LA - eng PT - Journal Article DEP - 20180206 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Humans MH - Laparoscopy/*methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Nephroureterectomy/*methods MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Treatment Outcome MH - Urologic Neoplasms/*surgery OTO - NOTNLM OT - Biomarkers OT - Prognostication OT - Renal pelvis carcinoma OT - Ureteral carcinoma OT - Urinary tract cancer EDAT- 2018/03/20 06:00 MHDA- 2019/02/06 06:00 CRDT- 2018/03/20 06:00 PHST- 2017/11/22 00:00 [received] PHST- 2018/01/26 00:00 [revised] PHST- 2018/01/27 00:00 [accepted] PHST- 2018/03/20 06:00 [pubmed] PHST- 2019/02/06 06:00 [medline] PHST- 2018/03/20 06:00 [entrez] AID - S1558-7673(18)30073-9 [pii] AID - 10.1016/j.clgc.2018.01.014 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Aug;16(4):e751-e760. doi: 10.1016/j.clgc.2018.01.014. Epub 2018 Feb 6. PMID- 29551582 OWN - NLM STAT- MEDLINE DCOM- 20190205 LR - 20190215 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 4 DP - 2018 Aug TI - Ki-67 as a Prognostic Marker in Upper Urinary Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis. PG - e831-e841 LID - S1558-7673(18)30126-5 [pii] LID - 10.1016/j.clgc.2018.02.010 [doi] AB - BACKGROUND: We systematically evaluated the prognostic significance of Ki-67 on survival outcomes in patients with upper urinary tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). MATERIALS AND METHODS: We searched the Embase, Scopus, and PubMed databases for all articles published up to February 2017 by following the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. The outcomes of interest included intravesical recurrence (IVR)-free survival, disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS). The associations between Ki-67 and the survival outcomes were expressed using a pooled hazard ratio (HR) and a 95% confidence interval (CI). RESULTS: A total of 12 articles, representing 1351 patients with a range from 37 to 475, met the eligibility criteria and were finally selected for this meta-analysis. The overexpression of Ki-67 was significantly associated with worse DFS (HR, 2.74; 95% CI, 1.58-4.74), CSS (HR, 2.26; 95% CI, 1.70-3.01), and OS (HR, 3.71; 95% CI, 1.78-7.75), but not IVR-free survival (HR, 0.77; 95% CI, 0.10-5.82). Interstudy heterogeneity was observed in the analysis of DFS (I(2) = 54%; P = .05) and IVR-free survival (I(2) = 81%; P = .005). The funnel plot test indicated no significant publication bias in the meta-analysis of survival outcomes. CONCLUSION: The results drawn in this meta-analysis suggest that the overexpression of Ki-67 might be a promising prognostic indicator predicting survival outcomes after RNU for UTUC. However, a large, well designed, prospective study is necessary to establish the prognostic value of Ki-67 in UTUC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Ahn, Chihyun AU - Ahn C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Dongguk University Ilsan Medical Center, Goyang, Korea. Electronic address: willybimish@naver.com. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. Electronic address: kuuro70@snu.ac.kr. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20180224 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) SB - IM MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Transitional Cell/metabolism/*surgery MH - Female MH - Humans MH - Ki-67 Antigen/*metabolism MH - Male MH - Nephroureterectomy MH - Prognosis MH - Prospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urologic Neoplasms/metabolism/*surgery OTO - NOTNLM OT - Ki-67 antigen OT - Prognosis OT - Renal pelvis OT - Transitional cell carcinoma OT - Ureter EDAT- 2018/03/20 06:00 MHDA- 2019/02/06 06:00 CRDT- 2018/03/20 06:00 PHST- 2017/12/20 00:00 [received] PHST- 2018/02/05 00:00 [revised] PHST- 2018/02/18 00:00 [accepted] PHST- 2018/03/20 06:00 [pubmed] PHST- 2019/02/06 06:00 [medline] PHST- 2018/03/20 06:00 [entrez] AID - S1558-7673(18)30126-5 [pii] AID - 10.1016/j.clgc.2018.02.010 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Aug;16(4):e831-e841. doi: 10.1016/j.clgc.2018.02.010. Epub 2018 Feb 24. PMID- 29550096 OWN - NLM STAT- MEDLINE DCOM- 20181106 LR - 20181106 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study. PG - 306.e9-306.e15 LID - S1078-1439(18)30065-6 [pii] LID - 10.1016/j.urolonc.2018.02.009 [doi] AB - OBJECTIVES: The aim of this study was to clarify the prognostic indicators for upper tract urothelial carcinoma (UTUC) following intravesical bacillus Calmette-Guerin (BCG) therapy for nonmuscle-invasive bladder cancer (NMIBC). METHODS: Data from 402 patients who received intravesical BCG therapy between January 1990 and November 2011 were collected from 10 institutes. The median follow-up interval from transurethral resection of the bladder tumor (TURBT) followed by BCG treatment was 50.0 months (IQR: 31.8-77.0). Of these patients, 186 (46.3%) had intravesical recurrence during the follow-up period after BCG therapy. RESULTS: Thirty patients (7.5%) were diagnosed with UTUC after BCG therapy. The 10-year recurrence-free survival rates for UTUC (RFS-UTUC) was 87.5%. In univariate and multivariate analyses, the independent predicting factors for UTUC were intravesical recurrence (P = 0.016) and tumor morphology at TURBT before BCG (P = 0.045). The 10-year RFS-UTUC of patients with intravesical recurrence and others, were 80.6% and 95.0%, respectively. The 10-year RFS-UTUC of patients with papillary pedunculated tumors and nonpapillary or nonpedunculated were 96.1% and 84.6%, respectively. CONCLUSIONS: The frequency of UTUC in patients with NMIBC after BCG therapy is not negligible. Two independent predicting factors (intravesical recurrence and nonpapillary nonpedunculated at TURBT before BCG) were identified for UTUC. These results might be useful to predict UTUC after BCG therapy for NMIBC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Nishiyama, Naotaka AU - Nishiyama N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: nishiyan@sapmed.ac.jp. FAU - Hotta, Hiroshi AU - Hotta H AD - Department of Urology, Asahikawa Red Cross Hospital, Asahikawa, Japan. FAU - Takahashi, Atsushi AU - Takahashi A AD - Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan. FAU - Yanase, Masahiro AU - Yanase M AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan. FAU - Itoh, Naoki AU - Itoh N AD - Department of Urology, NTT East Japan Sapporo Hospital, Sapporo, Japan. FAU - Tachiki, Hitoshi AU - Tachiki H AD - Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan. FAU - Miyao, Noriomi AU - Miyao N AD - Department of Urology, Muroran City General Hospital, Muroran, Japan. FAU - Matsukawa, Masanori AU - Matsukawa M AD - Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan. FAU - Kunishima, Yasuharu AU - Kunishima Y AD - Department of Urology, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Japan. FAU - Taguchi, Keisuke AU - Taguchi K AD - Department of Urology, Oji General Hospital, Tomakomai, Japan. FAU - Kitamura, Hiroshi AU - Kitamura H AD - Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama, Toyama, Japan. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180315 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - BCG Vaccine/*therapeutic use MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy/*pathology MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/*pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Nonmuscle-invasive bladder cancer OT - Upper tract urothelial carcinoma EDAT- 2018/03/20 06:00 MHDA- 2018/11/07 06:00 CRDT- 2018/03/19 06:00 PHST- 2017/11/09 00:00 [received] PHST- 2018/01/07 00:00 [revised] PHST- 2018/02/18 00:00 [accepted] PHST- 2018/03/20 06:00 [pubmed] PHST- 2018/11/07 06:00 [medline] PHST- 2018/03/19 06:00 [entrez] AID - S1078-1439(18)30065-6 [pii] AID - 10.1016/j.urolonc.2018.02.009 [doi] PST - ppublish SO - Urol Oncol. 2018 Jun;36(6):306.e9-306.e15. doi: 10.1016/j.urolonc.2018.02.009. Epub 2018 Mar 15. PMID- 29538042 OWN - NLM STAT- MEDLINE DCOM- 20190424 LR - 20190424 IS - 1531-703X (Electronic) IS - 1040-8746 (Linking) VI - 30 IP - 3 DP - 2018 May TI - The evolving genomic landscape in urothelial cancer. PG - 197-202 LID - 10.1097/CCO.0000000000000447 [doi] AB - PURPOSE OF REVIEW: Recent advances in next-generation sequencing have allowed for detailed molecular analysis of urothelial carcinomas, with potentially significant clinical implications for personalized treatment. Our objective in this review is to highlight studies from the past year that have furthered the understanding of urothelial cancer genomics. RECENT FINDINGS: Recent studies by The Cancer Genome Atlas consortium further characterized urothelial carcinomas via molecular subtyping, and a schema was proposed to match each subtype with potential therapeutic implications. Molecular subtyping was also utilized in a separate analysis to determine which tumours benefit from neoadjuvant chemotherapy. Tumour characteristics were also explored pre and postneoadjuvant chemotherapy and a mutational signature associated with postcisplatin treatment was described. We also review a comprehensive analysis of upper tract urinary carcinomas published this past year. SUMMARY: Recent genomic analyses have revealed that the classification of urothelial carcinoma is much more complex than the traditional dichotomy of nonmuscle-invasive and muscle-invasive bladder cancers. Molecular subtyping has provided additional insights into prognoses and treatment options for these patients. Although molecular subtyping is not yet ready for implementation into clinical practice, these latest efforts offer an exciting opportunity to integrate such information into prospective clinical studies that may ultimately lead to improved treatment outcomes. FAU - Kujtan, Lara AU - Kujtan L FAU - Hussain, Arif AU - Hussain A FAU - Subramanian, Janakiraman AU - Subramanian J FAU - Masood, Ashiq AU - Masood A LA - eng GR - I01 BX000545/BX/BLRD VA/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review PL - United States TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 SB - IM MH - Drug Resistance, Neoplasm MH - Genomics/methods MH - Humans MH - Urinary Bladder Neoplasms/drug therapy/*genetics EDAT- 2018/03/15 06:00 MHDA- 2019/04/25 06:00 CRDT- 2018/03/15 06:00 PHST- 2018/03/15 06:00 [pubmed] PHST- 2019/04/25 06:00 [medline] PHST- 2018/03/15 06:00 [entrez] AID - 10.1097/CCO.0000000000000447 [doi] PST - ppublish SO - Curr Opin Oncol. 2018 May;30(3):197-202. doi: 10.1097/CCO.0000000000000447. PMID- 29531584 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1857-9655 (Print) IS - 1857-9655 (Electronic) IS - 1857-9655 (Linking) VI - 6 IP - 2 DP - 2018 Feb 15 TI - Ki-67 Expression as a Predictive Factor of Muscle Invasion in Bladder Cancer. PG - 260-262 LID - 10.3889/oamjms.2018.088 [doi] AB - BACKGROUND: Bladder cancer is the 9th most frequent cancer worldwide. Ki-67 is immunohistochemistry marker that is predictive of cancer cell proliferation. The expression of Ki-67 is associated with poor prognosis in several types of malignancy, yet the value of Ki-67 as the prognostic factor in bladder cancer remains controversial. AIM: This study is aimed to investigate the association between Ki-67 expression with muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). METHODS: This was a case-control study with a retrospective design. The study was conducted at the Department of Pathology, University of Sumatera Utara, Indonesia. Samples were paraffin blocks from patients diagnosed with bladder cancer and agreed to be put in the study. The samples were stained with Immunohistochemistry Staining (IHC), and then we quantitatively counted the number of the Ki-67 stained nucleus on a microscope. RESULTS: A total of 54 samples were obtained in this study. Samples consisted of 27 samples with NMIBC and 27 samples with MIBC. The cut-off point was 20%, we found 17 patients with MIBC and 14 patients with NMIBC presented with biomarker > 20%. Biomarker /=38.04) and low FGFR3 expression (<39.14) were statistically significantly associated with worse progression-free survival (PFS; P = .0194 and P = .0089). Multivariate Cox regression analysis could identify patients with low FGFR3 and high CDKN2A/p16 expression (log rank (LR) chi(2) = 10.69; P = .0048) as well as tumor size >/=3 cm (LR chi(2) = 6.03; P = .0141) as independent predictors for PFS. CONCLUSION: High expression of CDKN2A/p16 and low expression of FGFR3 show a correlation with established prognostic features for non-muscle-invasive bladder cancer and can predict progression of stage pT1 UBC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: johannes.breyer@ukr.de. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Institute of Pathology at the St Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. FAU - Worst, Thomas S AU - Worst TS AD - Department of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology and Pediatric Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Regensburg, Germany. CN - Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180202 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Cyclin-Dependent Kinase Inhibitor p18) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/genetics/*pathology MH - Cyclin-Dependent Kinase Inhibitor p16 MH - Cyclin-Dependent Kinase Inhibitor p18/*genetics MH - Disease Progression MH - *Down-Regulation MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Neoplasm Staging MH - Progression-Free Survival MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Retrospective Studies MH - Tumor Burden MH - *Up-Regulation MH - Urinary Bladder Neoplasms/genetics/*pathology OTO - NOTNLM OT - CDKN2A OT - NMIBC OT - Prognosis OT - mRNA OT - p16 FIR - Breyer, Johannes IR - Breyer J FIR - Wirtz, Ralph M IR - Wirtz RM FIR - Erben, Philipp IR - Erben P FIR - Worst, Thomas S IR - Worst TS FIR - Stoehr, Robert IR - Stoehr R FIR - Eckstein, Markus IR - Eckstein M FIR - Sikic, Danijel IR - Sikic D FIR - Burger, Maximilian IR - Burger M FIR - Hartmann, Arndt IR - Hartmann A FIR - Otto, Wolfgang IR - Otto W EDAT- 2018/03/12 06:00 MHDA- 2019/02/05 06:00 CRDT- 2018/03/12 06:00 PHST- 2017/10/01 00:00 [received] PHST- 2018/01/11 00:00 [revised] PHST- 2018/01/16 00:00 [accepted] PHST- 2018/03/12 06:00 [pubmed] PHST- 2019/02/05 06:00 [medline] PHST- 2018/03/12 06:00 [entrez] AID - S1558-7673(18)30036-3 [pii] AID - 10.1016/j.clgc.2018.01.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2. PMID- 29524970 OWN - NLM STAT- MEDLINE DCOM- 20190405 LR - 20190405 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 25 IP - 1 DP - 2018 Feb TI - Analysis of bladder cancer subtypes in neurogenic bladder tumors. PG - 9161-9167 AB - INTRODUCTION: To establish if the validated tumor biomarkers of luminal and basal bladder cancers in non neuro-urological patients are applicable to a neuro-urological population. MATERIALS AND METHODS: We retrieved bladder cancer samples from neuro-urological patients (n = 20) and non-neurological controls (n = 40). The expression of GATA3 and CK5/6 was analyzed using immunohistochemistry of microarray tissue sections. We also assessed the correlation between previous biomarker expression, gender, age, tumor stage (non-muscle-invasive bladder cancer (NMIBC)/muscle-invasive bladder cancer (MIBC)), squamous-cell differentiation and basal/luminal subtypes using Pearson's correlation coefficient (r). RESULTS: Mean age at diagnosis of bladder cancer in neuro-urological patients was 53.2 years (min 41-max 73). MIBC was found in 13 neuro-urological patients (65%). The luminal subtype was identified in 7 samples (35%, all urothelial differentiation). The basal subtype was found in 13 samples (65%): 12 squamous-cell and 1 sarcomatoid differentiation. GATA3 and CK5/6 were expressed in 6 (30%) neuro-urological patients. A significant positive correlation was found between GATA3 expression and the luminal subtype (p = 0.00001, r = 0.5676). This was not the case with the neuro-urological status (r = -0.307). A poor correlation was found between CK5/6 expression and the neuro-urological status (r = 0.471 and -0.471), squamous-cell differentiation (r = 0.092), tumor stage NMIBC/MIBC (r = -0.118 and 0.118) and basal/luminal subtypes (r = -0.157 and 0.194). CONCLUSION: In summary, the expression of GATA3 and CK5/6 could not differentiate the different subtypes of bladder cancer in neuro-urological patients. This implies that their specific histopathological signature is distinct from non neuro-urological patients. Additional pathways may be involved to explain their urothelial carcinogenesis mechanism. FAU - Manach, Quentin AU - Manach Q AD - Sorbonne Universite, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, F-75013, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O FAU - Roupret, Morgan AU - Roupret M FAU - Game, Xavier AU - Game X FAU - Chartier-Kastler, Emmanuel AU - Chartier-Kastler E FAU - Reus, Christine AU - Reus C FAU - Camparo, Philippe AU - Camparo P FAU - Comperat, Eva AU - Comperat E FAU - Phe, Veronique AU - Phe V LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) SB - IM MH - Adult MH - Aged MH - Biopsy, Needle MH - Carcinoma, Transitional Cell/epidemiology/*genetics/pathology MH - Case-Control Studies MH - Female MH - GATA3 Transcription Factor/*genetics MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Reference Values MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/epidemiology/*genetics/*pathology MH - Urinary Bladder, Neurogenic/epidemiology/*genetics/*pathology EDAT- 2018/03/12 06:00 MHDA- 2019/04/06 06:00 CRDT- 2018/03/12 06:00 PHST- 2018/03/12 06:00 [entrez] PHST- 2018/03/12 06:00 [pubmed] PHST- 2019/04/06 06:00 [medline] PST - ppublish SO - Can J Urol. 2018 Feb;25(1):9161-9167. PMID- 29524168 OWN - NLM STAT- MEDLINE DCOM- 20201211 LR - 20201214 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 26 IP - 1 DP - 2020 Jan TI - Cell Cycle Markers in the Evaluation of Bladder Cancer. PG - 175-181 LID - 10.1007/s12253-018-0389-5 [doi] AB - Bladder cancer (BC) is a heterogeneous neoplasia characterized by a high number of recurrences. Standardized clinical and morphological parameters are not always sufficient to predict individual tumor behavior. The aim of this study was to evaluate the expression of cell cycle regulators proteins as potential adjuvant in prognosis and monitoring of this disease. Block paraffin samples from patients with urothelial bladder carcinoma treated by transurethral resection (TUR) were collected to immunohistochemistry analysis for proteins p16, p21, p27, p53, pRb and Ki-67. Chisquare, logistic regression and Kaplan-Meier curve were used to analyze the prognostic value of these markers. Of the 93 patients included in the study, the main categories of staging observed were T1 (53%) and Ta (29%), and the distribution between tumor grades was 58% of patients with low grade to 42% of patients with high grade. The expressions of p16, p21, p27, p53, pRb and Ki-67 were altered in 31%, 42%, 60%, 91%, 27% and 56% of patients, respectively. The immunohistochemical expression of Ki-67 was associated with tumor histological grade (p = 0.016), and expression of pRb with recurrence-free survival (p = 0.035), but no isolated marker was significant associated with recurrence and progression in multivariate analysis. More than two markers abnormally expressed were associated with presence of recurrence (p = 0.005) and lower recurrence-free surviva (p = 0.004). Our panel marker has important prognostic value for BC, especially when more than two have altered expression predicting good clinical recurrence implication. FAU - da Silva, Jessica Niederauer Leote AU - da Silva JNL AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. FAU - Ranzi, Alana Durayski AU - Ranzi AD AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. FAU - Carvalho, Caroline Trainotti AU - Carvalho CT AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. FAU - Scheide, Tales Vicente AU - Scheide TV AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. FAU - Strey, Yuri Thome Machado AU - Strey YTM AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. FAU - Graziottin, Tulio Meyer AU - Graziottin TM AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. AD - Departament of Urology, Santa Rita Hospital, Hospital system of the Porto Alegre Holy House of Mercy, Porto Alegre, Brazil. FAU - Bica, Claudia Giuliano AU - Bica CG AD - Research Laboratory of Pathology, Health Sciences Federal University of Porto Alegre (UFCSPA), 245 Sarmento Leite, Porto Alegre, RS, 90050-170, Brazil. claudia@ufcspa.edu.br. LA - eng PT - Journal Article DEP - 20180309 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Cycle Proteins) RN - 0 (Ki-67 Antigen) SB - IM MH - Aged MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/*metabolism/mortality/pathology/surgery MH - Cell Cycle Proteins/*metabolism MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*metabolism/mortality/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Cell cycle markers OT - Immunohistochemistry OT - Prognosis EDAT- 2018/03/11 06:00 MHDA- 2020/12/15 06:00 CRDT- 2018/03/11 06:00 PHST- 2016/03/01 00:00 [received] PHST- 2018/02/08 00:00 [accepted] PHST- 2018/03/11 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2018/03/11 06:00 [entrez] AID - 10.1007/s12253-018-0389-5 [pii] AID - 10.1007/s12253-018-0389-5 [doi] PST - ppublish SO - Pathol Oncol Res. 2020 Jan;26(1):175-181. doi: 10.1007/s12253-018-0389-5. Epub 2018 Mar 9. PMID- 29523366 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20190314 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 73 IP - 6 DP - 2018 Jun TI - Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. PG - 925-933 LID - S0302-2838(18)30121-0 [pii] LID - 10.1016/j.eururo.2018.02.014 [doi] AB - CONTEXT: Initial treatment for most bladder cancers (BCs) involves transurethral resection (TUR) or tumours. Often more cancer is found after the initial treatment in around half of patients, requiring a second resection. Repeat transurethral resection (reTUR) is recommended for high-risk, non-muscle-invasive bladder cancer (NMIBC) to remove any residual disease and improve cancer outcomes. OBJECTIVE: To systematically review the practice and therapeutic benefit of an early reTUR for high-risk NMIBC. EVIDENCE ACQUISITION: A systematic review of original articles was performed using PubMed/Medline and Web of Science databases in December 2016 (initial) and October 2017 (final). We searched the references of included papers. EVIDENCE SYNTHESIS: We screened 15 209 manuscripts and selected 31 detailing 8409 persons with high-grade Ta and T1BC for inclusion. Detrusor muscle was found at initial TUR histology in 30-100% of cases. Residual tumour at reTUR was found in 17-67% of patients following Ta and in 20-71% following T1 cancer. Most residual tumours (36-86%) were found at the original resection site. Upstaging occurred in 0-8% (Ta to >/=T1) and 0-32% (T1 to >/=T2) of cases. Conflicting data report the impact of reTUR on subsequent recurrence and cancer-specific mortality. Recurrence for Ta was 16% in the reTUR group versus 58% in the non-reTUR group. For T1, recurrence ranged from 18% to 56%, but no clear trend was identified between reTUR and control. No clear relationship between reTUR and progression was found for Ta, although for T1 rates were higher in the non-reTUR group in series with control populations (5/6 studies). Overall mortality was slightly reduced in the reTUR group in two studies with controls (22-30% vs 26-36% [no reTUR]). CONCLUSIONS: Residual tumour is common after TUR for high-risk NMIBC. The reTUR helps in the diagnosis of this residual cancer and may improve outcomes for cancers initially staged as T1. PATIENT SUMMARY: Some bladder cancers (BCs) are aggressive but confined to the bladder surface. Initial treatment includes endoscopic resection. More cancer is found after the initial treatment in approximately half of patients. In the aggressive but confined group of BC, a second resection, a few weeks after the first, may help find this residual cancer and improve outcomes, although the evidence quality for this is weak. CI - Copyright (c) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Cumberbatch, Marcus G K AU - Cumberbatch MGK AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: m.cumberbatch@nhs.net. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University Health Center, Montreal, Canada. FAU - Jubber, Ibrahim AU - Jubber I AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EAU Guidelines Office, Brussels, Belgium. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20180306 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Humans MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - Neoplasm, Residual MH - *Reoperation MH - Risk Factors MH - Survival Rate MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Bladder OT - Cancer OT - Detrusor OT - Muscle OT - Progression OT - Re-resection OT - Recurrence OT - Upstaging EDAT- 2018/03/11 06:00 MHDA- 2019/03/15 06:00 CRDT- 2018/03/11 06:00 PHST- 2017/11/27 00:00 [received] PHST- 2018/02/13 00:00 [accepted] PHST- 2018/03/11 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2018/03/11 06:00 [entrez] AID - S0302-2838(18)30121-0 [pii] AID - 10.1016/j.eururo.2018.02.014 [doi] PST - ppublish SO - Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6. PMID- 29520448 OWN - NLM STAT- MEDLINE DCOM- 20190329 LR - 20261012 IS - 1534-6277 (Electronic) IS - 1534-6277 (Linking) VI - 19 IP - 3 DP - 2018 Mar 8 TI - Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. PG - 16 LID - 10.1007/s11864-018-0523-3 [doi] AB - Bacillus Calmette-Guerin in urothelial carcinoma, high-dose interleukin-2 in renal cell carcinoma, and sipuleucel-T in prostate cancer serve as enduring examples that the host immune response can be harnessed to promote effective anti-tumor immunity in genitourinary malignancies. Recently, cancer immunotherapy with immune checkpoint inhibitors has transformed the prognostic landscape leading to durable responses in a subset of urothelial carcinoma and renal cell carcinoma patients with traditionally poor prognosis. Despite this success, many patients fail to respond to immune checkpoint inhibitors and progression/relapse remains common. Furthermore, modest clinical activity has been observed with ICIs as a monotherapy in advanced PCa. As such, novel treatment approaches are warranted and improved biomarkers for patient selection and treatment response are desperately needed. Future efforts should focus on exploring synergistic and rational combinations that safely and effectively boost response rates and survival in genitourinary malignancies. Specific areas of interest include (1) evaluating the optimal sequencing, disease burden, and timing of immuno-oncology agents with other anti-cancer therapeutics and (2) validating novel biomarkers of response to immunotherapy to optimize patient selection and to identify individuals most likely to benefit from immunotherapy across the heterogenous spectrum of genitourinary malignancies. FAU - Marciscano, Ariel E AU - Marciscano AE AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240B, Bethesda, MD, 20892, USA. FAU - Madan, Ravi A AU - Madan RA AD - Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240B, Bethesda, MD, 20892, USA. madanr@mail.nih.gov. LA - eng PT - Journal Article PT - Review DEP - 20180308 PL - United States TA - Curr Treat Options Oncol JT - Current treatment options in oncology JID - 100900946 SB - IM MH - Humans MH - Immunity, Innate/drug effects/*immunology MH - Immunotherapy/adverse effects MH - Neoplasm Recurrence, Local/drug therapy/*economics/immunology MH - Tumor Microenvironment/*genetics/immunology MH - Urogenital Neoplasms/*drug therapy/immunology OTO - NOTNLM OT - Bladder cancer OT - Immunotherapy OT - Kidney OT - Prostate cancer OT - Renal cell carcinoma OT - Tumor microenvironment OT - Urothelial carcinoma EDAT- 2018/03/10 06:00 MHDA- 2019/03/30 06:00 CRDT- 2018/03/10 06:00 PHST- 2018/03/10 06:00 [entrez] PHST- 2018/03/10 06:00 [pubmed] PHST- 2019/03/30 06:00 [medline] AID - 10.1007/s11864-018-0523-3 [pii] AID - 10.1007/s11864-018-0523-3 [doi] PST - epublish SO - Curr Treat Options Oncol. 2018 Mar 8;19(3):16. doi: 10.1007/s11864-018-0523-3. PMID- 29519561 OWN - NLM STAT- MEDLINE DCOM- 20181119 LR - 20181119 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 5 DP - 2018 May TI - The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer. PG - 242.e9-242.e14 LID - S1078-1439(18)30042-5 [pii] LID - 10.1016/j.urolonc.2018.02.002 [doi] AB - OBJECTIVE: To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. PATIENTS AND METHODS: Between May 2014 and April 2017, a prospective cohort study was conducted on 105 patients with intermediate or high-risk nonmuscle invasive bladder cancer. Immunohistochemical staining with mouse monoclonal anti-NEDD9 antibody was done. Examination of the slides was done to detect NEDD9 cytoplasmic expression. Intravesical induction bacillus Calmette-Guerin (BCG) instillation therapy was started for all patients 2 to 4 weeks after endoscopy with once weekly instillation for 6 weeks. Intravesical maintenance BCG instillation was then continued every 3 months for at least 1 year. Follow up with cystoscopy every 3 months for 2 years and every 6 months after that. RESULTS: The mean age +/- SD of the patients was 57 +/- 4.5 years. The median follow-up period was 25 (12-36) months. NEDD9 protein was highly expressed in 61 (58.1%) patients, whereas low expression was in 44 (41.9%) patients. Sensitivity and specificity of NEDD9 high expression in predicting recurrence were 83.6% and 64.2%, respectively. Its sensitivity and specificity in predicting progression to muscle invasion or distant metastases were 91.3% and 51.2%, respectively. Its sensitivity and specificity in predicting complete response to BCG therapy were 84.1% and 80.9%. Kaplan-Meier test showed highly significant difference (P<0.0001) in survival without recurrence or progression between patients showing high expression and those showing low expression. CONCLUSION: NEDD9 protein tissue marker could be used as a predictive marker for BCG response in nonmuscle invasive bladder cancer with reasonable sensitivity and specificity. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - El-Babouly, Islam M AU - El-Babouly IM AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Desoky, Esam A E AU - Desoky EAE AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - El Sayed, Diab AU - El Sayed D AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Ali, Maged M AU - Ali MM AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: dr_magood@hotmail.com. FAU - Harb, Ola A AU - Harb OA AD - Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Ragab, Ahmed AU - Ragab A AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Sakr, Ahmed M AU - Sakr AM AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Fawzi, Amr M AU - Fawzi AM AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Salama, Nashaat M AU - Salama NM AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Samaha, Ibrahim I AU - Samaha II AD - Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article DEP - 20180305 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (NEDD9 protein, human) RN - 0 (Phosphoproteins) SB - IM MH - Adaptor Proteins, Signal Transducing/*metabolism MH - Administration, Intravesical MH - Adult MH - Aged MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/*metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/metabolism/*pathology MH - Phosphoproteins/*metabolism MH - Prognosis MH - Prospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*pathology OTO - NOTNLM OT - BCG OT - Bladder cancer OT - NEDD9 OT - Progression OT - Recurrence EDAT- 2018/03/10 06:00 MHDA- 2018/11/20 06:00 CRDT- 2018/03/10 06:00 PHST- 2017/12/02 00:00 [received] PHST- 2018/01/30 00:00 [revised] PHST- 2018/02/05 00:00 [accepted] PHST- 2018/03/10 06:00 [pubmed] PHST- 2018/11/20 06:00 [medline] PHST- 2018/03/10 06:00 [entrez] AID - S1078-1439(18)30042-5 [pii] AID - 10.1016/j.urolonc.2018.02.002 [doi] PST - ppublish SO - Urol Oncol. 2018 May;36(5):242.e9-242.e14. doi: 10.1016/j.urolonc.2018.02.002. Epub 2018 Mar 5. PMID- 29518027 OWN - NLM STAT- MEDLINE DCOM- 20180814 LR - 20211204 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 3 DP - 2018 Mar 8 TI - Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract. LID - 10.3390/ijms19030777 [doi] LID - 777 AB - Using preclinical models, we have recently found that ELK1, a transcriptional factor that activates downstream targets, including c-fos proto-oncogene, induces bladder cancer outgrowth. Here, we immunohistochemically determined the expression status of phospho-ELK1, an activated form of ELK1, in upper urinary tract urothelial carcinoma (UUTUC). Overall, phospho-ELK1 was positive in 47 (47.5%; 37 weak (1+) and 10 moderate (2+)) of 99 UUTUCs, which was significantly (P = 0.002) higher than in benign urothelium (21 (25.3%) of 83; 17 1+ and 4 2+) and was also associated with androgen receptor expression (P = 0.001). Thirteen (35.1%) of 37 non-muscle-invasive versus 34 (54.8%) of 62 muscle-invasive UUTUCs (P = 0.065) were immunoreactive for phospho-ELK1. Lymphovascular invasion was significantly (P = 0.014) more often seen in phospho-ELK1(2+) tumors (80.0%) than in phospho-ELK1(0/1+) tumors (36.0%). There were no statistically significant associations between phospho-ELK1 expression and tumor grade, presence of concurrent carcinoma in situ or hydronephrosis, or pN status. Kaplan-Meier and log-rank tests revealed that patients with phospho-ELK1(2+) tumor had marginally and significantly higher risks of disease progression (P = 0.055) and cancer-specific mortality (P = 0.008), respectively, compared to those with phospho-ELK1(0/1+) tumor. The current results thus support our previous observations in bladder cancer and further suggest that phospho-ELK1 overexpression serves as a predictor of poor prognosis in patients with UUTUC. FAU - Inoue, Satoshi AU - Inoue S AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. inosts411@gmail.com. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. inosts411@gmail.com. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. inosts411@gmail.com. FAU - Ide, Hiroki AU - Ide H AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. h-ide@fc4.so-net.ne.jp. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. fujita@uro.med.osaka-u.ac.jp. FAU - Mizushima, Taichi AU - Mizushima T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. mizu123shima@gmail.com. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. mizu123shima@gmail.com. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. mizu123shima@gmail.com. FAU - Jiang, Guiyang AU - Jiang G AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. guiyang_jiang@urmc.rochester.edu. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. guiyang_jiang@urmc.rochester.edu. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. takashi_tk2001@yahoo.co.jp. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. takashi_tk2001@yahoo.co.jp. FAU - Yamaguchi, Seiji AU - Yamaguchi S AD - Department of Urology, Osaka General Medical Center, Osaka 558-8558, Japan. yamabu1956@gmail.com. FAU - Fushimi, Hiroaki AU - Fushimi H AD - Department of Pathology, Osaka General Medical Center, Osaka 558-8558, Japan. hiroaki-fushimi@gh.opho.jp. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. nono@uro.med.osaka-u.ac.jp. FAU - Miyamoto, Hiroshi AU - Miyamoto H AUID- ORCID: 0000-0001-7610-7769 AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. hiroshi_miyamoto@urmc.rochester.edu. AD - Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA. hiroshi_miyamoto@urmc.rochester.edu. LA - eng PT - Journal Article DEP - 20180308 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers, Tumor) RN - 0 (ELK1 protein, human) RN - 0 (MAS1 protein, human) RN - 0 (Proto-Oncogene Mas) RN - 0 (ets-Domain Protein Elk-1) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/*metabolism MH - Carcinoma/*metabolism/pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Phosphorylation MH - Protein Processing, Post-Translational MH - Proto-Oncogene Mas MH - Urinary Bladder Neoplasms/*metabolism/pathology MH - Urothelium/*metabolism/pathology MH - ets-Domain Protein Elk-1/genetics/*metabolism PMC - PMC5877638 OTO - NOTNLM OT - ELK1 OT - androgen receptor OT - immunohistochemistry OT - prognosis OT - upper urinary tract urothelial carcinoma COIS- The authors declare no conflict of interest. EDAT- 2018/03/09 06:00 MHDA- 2018/08/15 06:00 PMCR- 2018/03/01 CRDT- 2018/03/09 06:00 PHST- 2018/02/20 00:00 [received] PHST- 2018/02/28 00:00 [revised] PHST- 2018/03/06 00:00 [accepted] PHST- 2018/03/09 06:00 [entrez] PHST- 2018/03/09 06:00 [pubmed] PHST- 2018/08/15 06:00 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - ijms19030777 [pii] AID - ijms-19-00777 [pii] AID - 10.3390/ijms19030777 [doi] PST - epublish SO - Int J Mol Sci. 2018 Mar 8;19(3):777. doi: 10.3390/ijms19030777. PMID- 29516641 OWN - NLM STAT- MEDLINE DCOM- 20191023 LR - 20220321 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 22 IP - 5 DP - 2018 May TI - Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. PG - 2838-2845 LID - 10.1111/jcmm.13578 [doi] AB - Cell-free long non-coding RNAs (lncRNAs) are stably present in urine and can serve as non-invasive biomarkers for cancer. We aimed to identify signatures of lncRNAs in urine for diagnosis and prognosis of bladder cancer (BC). Screening of lncRNAs by microarray analysis was performed using urine samples of 10 BC patients and 10 controls. Expressions of candidate lncRNAs were evaluated in the training and validation set including 230 BC patients and 230 controls by quantitative reverse transcription polymerase chain reaction (qRT-PCR). A two-lncRNA panel (uc004cox.4 and GAS5) was constructed and provided high diagnostic accuracy of BC with an area under the curve (AUC) of 0.885 (95% CI, 0.836-0.924). The AUCs of the lncRNA panel for Ta, T1 and T2-T4 were 0.843, 0.867 and 0.923, respectively, significantly higher than those of urine cytology (all P < .05). Kaplan-Meier analysis revealed that higher level of uc004cox.4 was associated with poor recurrence-free survival (RFS) of non-muscle invasive BC (NMIBC) (P = .008). Additionally, Cox regression analysis indicated that uc004cox.4 was an independent prognostic factor for RFS of NMIBC (P = .018). Taken together, our findings indicated that urinary lncRNA signatures possessed potential clinical value for BC diagnosis. Moreover, uc004cox.4 could provide prognostic information for NMIBC. CI - (c) 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. AD - Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China. FAU - Duan, Weili AU - Duan W AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Jiang, Xiumei AU - Jiang X AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Zhao, Li AU - Zhao L AD - Department of Clinical Laboratory, Tai'an Tumour Prevention and Treatment Hospital, Taian, Shandong, China. FAU - Li, Juan AU - Li J AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Rui AU - Wang R AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Yan, Suzhen AU - Yan S AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Xie, Yujiao AU - Xie Y AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Yan, Keqiang AU - Yan K AD - Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Qingliang AU - Wang Q AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China. FAU - Wang, Chuanxin AU - Wang C AUID- ORCID: 0000-0002-3796-6293 AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. AD - Tumor Marker Detection Engineering Laboratory of Shandong Province, Jinan, Shandong, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180308 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/*urine MH - Case-Control Studies MH - Cell-Free System MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*genetics MH - Proportional Hazards Models MH - RNA, Long Noncoding/*genetics/*urine MH - ROC Curve MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/*diagnosis/*genetics/urine PMC - PMC5908122 OTO - NOTNLM OT - bladder cancer OT - diagnosis OT - lncRNA OT - prognosis OT - urine EDAT- 2018/03/09 06:00 MHDA- 2019/10/24 06:00 PMCR- 2018/05/01 CRDT- 2018/03/09 06:00 PHST- 2017/11/28 00:00 [received] PHST- 2018/01/30 00:00 [accepted] PHST- 2018/03/09 06:00 [pubmed] PHST- 2019/10/24 06:00 [medline] PHST- 2018/03/09 06:00 [entrez] PHST- 2018/05/01 00:00 [pmc-release] AID - JCMM13578 [pii] AID - 10.1111/jcmm.13578 [doi] PST - ppublish SO - J Cell Mol Med. 2018 May;22(5):2838-2845. doi: 10.1111/jcmm.13578. Epub 2018 Mar 8. PMID- 29513058 OWN - NLM STAT- MEDLINE DCOM- 20200306 LR - 20200306 IS - 1473-0790 (Electronic) IS - 1368-5538 (Linking) VI - 22 IP - 4 DP - 2019 Dec TI - Evaluation of the relationship between compliance with the follow-up and treatment protocol and health literacy in bladder tumor patients. PG - 266-271 LID - 10.1080/13685538.2018.1447558 [doi] AB - Objective: To investigate the relationship between the compliance of bladder cancer patients with cystoscopic follow-up and the treatment protocol, and their health literacy. Methods: Patients who underwent transurethral resection surgery for bladder tumor were found to have non-muscular invasive bladder carcinoma on pathology examination and then underwent cystoscopic follow-up for 1 year or more were included in the study. Cystoscopic follow-up was recommended to the low- and high-risk groups in terms of progression and recurrence. The patients were evaluated with the Health Literacy Survey-European Union scale. Results: The mean age of the patients was 67.13 +/- 10.77 years. The treatment continuity rate was 80.50% (n = 33) in the adequate health literacy group (n = 41) and significantly higher than the 56.50% (n = 48) rate in the inadequate health literacy group (n = 85) (p = .008). The health literacy results revealed that the health promotion and general index score was higher in the group of patients under the age of 65. Conclusions: Adequate health literacy in bladder cancer patients is associated with better compliance with the treatment protocol. Young patients show better compliance with the follow-up protocol recommended by the physician. Increasing the follow-up protocol compliance of elderly patients with inadequate health literacy is necessary. FAU - Turkoglu, Ali Riza AU - Turkoglu AR AD - Department of Urology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Demirci, Hakan AU - Demirci H AD - Department of Family Medicine, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Coban, Soner AU - Coban S AD - Department of Urology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Guzelsoy, Muhammet AU - Guzelsoy M AD - Department of Urology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Toprak, Erdem AU - Toprak E AD - Department of Urology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Aydos, Mustafa Murat AU - Aydos MM AD - Department of Urology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Ture, Deniz Azkan AU - Ture DA AD - Department of Family Medicine, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. FAU - Ustundag, Yasemin AU - Ustundag Y AD - Department of Clinical Biochemistry, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital , Bursa , Turkey. LA - eng PT - Journal Article DEP - 20180307 PL - England TA - Aging Male JT - The aging male : the official journal of the International Society for the Study of the Aging Male JID - 9808210 SB - IM MH - Aged MH - *Carcinoma/pathology/psychology/surgery MH - Clinical Protocols MH - *Cystectomy/adverse effects/methods/psychology MH - Cystoscopy/methods/statistics & numerical data MH - Disease Progression MH - Europe/epidemiology MH - Follow-Up Studies MH - *Health Literacy/methods/statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/diagnosis/epidemiology/prevention & control MH - Outcome Assessment, Health Care MH - Patient Compliance/*statistics & numerical data MH - Postoperative Period MH - Risk Assessment MH - *Urinary Bladder Neoplasms/pathology/psychology/surgery OTO - NOTNLM OT - Bladder cancer OT - HLS-EU OT - age OT - cystoscopic compliance OT - health literacy EDAT- 2018/03/08 06:00 MHDA- 2020/03/07 06:00 CRDT- 2018/03/08 06:00 PHST- 2018/03/08 06:00 [pubmed] PHST- 2020/03/07 06:00 [medline] PHST- 2018/03/08 06:00 [entrez] AID - 10.1080/13685538.2018.1447558 [doi] PST - ppublish SO - Aging Male. 2019 Dec;22(4):266-271. doi: 10.1080/13685538.2018.1447558. Epub 2018 Mar 7. PMID- 29512924 OWN - NLM STAT- MEDLINE DCOM- 20191023 LR - 20210109 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 22 IP - 5 DP - 2018 May TI - Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer. PG - 2774-2790 LID - 10.1111/jcmm.13571 [doi] AB - Pyruvate kinase M2 (PKM2) regulates the final step of glycolysis levels that are correlated with the sensitivity of anticancer chemotherapeutic drugs. THP is one of the major drugs used in non-muscle-invasive bladder cancer instillation chemotherapy. However, low response ratio of THP (19.7%) treatment to human genitourinary tumours using collagen gel matrix has been observed. This study aims to investigate the effect of down-regulation of PKM2 on THP efficiency. Via inhibitor or siRNA, the effects of reduced PKM2 on the efficiency of THP were determined in 2 human and 1 murine bladder cancer cell lines, using MTT, cologenic and fluorescence approaches. Molecular mechanisms of PKM2 on THP sensitization were explored by probing p-AMPK and p-STAT3 levels via WB. Syngeneic orthotopic bladder tumour model was applied to evaluate this efficiency in vivo, analysed by Kaplan-Meier survival curves, body and bladder weights plus immunohistochemistric tumour biomarkers. PKM2 was overexpressed in bladder cancer cells and tissues, and down-regulation of PKM2 enhanced the sensitivity of THP in vitro. Activation of AMPK is essential for THP to exert anti-bladder cancer activities. On the other hand, down-regulating PKM2 activates AMPK and inhibits STAT3, correlated with THP sensitivity. Compared with THP alone (400 mumol L(-1) , 50 muL), the combination with metformin (60 mmol L(-1) , 50 muL) stopped growth of bladder cancer completely in vivo (combination group VS normal group P = .078). Down-regulating the expression of PKM2 enhances the anticancer efficiency of THP. This study provides a new insight for improving the chemotherapeutic effect of THP. CI - (c) 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Su, Qiongli AU - Su Q AUID- ORCID: 0000-0003-1602-0092 AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. FAU - Tao, Ting AU - Tao T AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. FAU - Tang, Lei AU - Tang L AD - Department of Urology Surgery, 3rd Affiliated Hospital, Changsha, Hunan, China. AD - School of Pharmacy, Central South University, Changsha, Hunan, China. FAU - Deng, Jun AU - Deng J AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. FAU - Darko, Kwame Oteng AU - Darko KO AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. FAU - Zhou, Sichun AU - Zhou S AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. FAU - Peng, Mei AU - Peng M AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. AD - Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - He, Shanping AU - He S AD - Animal Nutrition and Human Health Laboratory, Hunan Normal University, Changsha, Hunan, China. FAU - Zeng, Qing AU - Zeng Q AD - Department of Urology Surgery, 3rd Affiliated Hospital, Changsha, Hunan, China. AD - School of Pharmacy, Central South University, Changsha, Hunan, China. FAU - Chen, Alex F AU - Chen AF AD - Department of Urology Surgery, 3rd Affiliated Hospital, Changsha, Hunan, China. AD - School of Pharmacy, Central South University, Changsha, Hunan, China. FAU - Yang, Xiaoping AU - Yang X AD - Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China. AD - Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), Hunan Normal University, Changsha, Hunan, China. AD - Animal Nutrition and Human Health Laboratory, Hunan Normal University, Changsha, Hunan, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180307 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Antineoplastic Agents) RN - 0 (STAT3 Transcription Factor) RN - 80168379AG (Doxorubicin) RN - 9100L32L2N (Metformin) RN - D58G680W0G (pirarubicin) RN - EC 2.7.4.3 (Adenylate Kinase) SB - IM MH - Adenylate Kinase/metabolism MH - Animals MH - Antineoplastic Agents/pharmacology/*therapeutic use MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - *Down-Regulation/drug effects MH - Doxorubicin/*analogs & derivatives/pharmacology/therapeutic use MH - Drug Synergism MH - Female MH - Gene Expression Regulation, Neoplastic/drug effects MH - Humans MH - Inhibitory Concentration 50 MH - Metformin/pharmacology MH - Mice, Inbred C57BL MH - Phosphorylation/drug effects MH - STAT3 Transcription Factor/metabolism MH - Urinary Bladder Neoplasms/*drug therapy/*enzymology/genetics/pathology PMC - PMC5908113 OTO - NOTNLM OT - THP OT - PKM2 OT - bladder cancer OT - p-AMPK OT - p-STAT3 EDAT- 2018/03/08 06:00 MHDA- 2019/10/24 06:00 PMCR- 2018/05/01 CRDT- 2018/03/08 06:00 PHST- 2017/09/15 00:00 [received] PHST- 2017/12/22 00:00 [accepted] PHST- 2018/03/08 06:00 [pubmed] PHST- 2019/10/24 06:00 [medline] PHST- 2018/03/08 06:00 [entrez] PHST- 2018/05/01 00:00 [pmc-release] AID - JCMM13571 [pii] AID - 10.1111/jcmm.13571 [doi] PST - ppublish SO - J Cell Mol Med. 2018 May;22(5):2774-2790. doi: 10.1111/jcmm.13571. Epub 2018 Mar 7. PMID- 29511580 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220316 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 44 IP - 2 DP - 2018 Mar TI - Predictive role of neutrophil-to-lymphocyte ratio on upstaging of organ-confined invasive urothelial bladder cancer to non-organ-confined disease. PG - 119-124 LID - 10.5152/tud.2017.46038 [doi] AB - OBJECTIVE: The aim of this study is to examine the usefulness of preoperative neutrophile-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratios to predict pathological upstaging of invasive bladder cancer who underwent radical cystectomy. MATERIAL AND METHODS: A total of 126 patients who underwent radical cystectomy at our clinic between January 2006 and March 2015 were retrospectively analysed. One hundred and twelve patients with organ-confined invasive bladder tumors (T2) detected at histopathological examination of transuretral resection material were included in the study. Upstaging was seen at histopathological examination of radical cystectomy specimens of 42 patients. We compared preoperative neutrophile-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio between upstaged and not-upstaged groups. RESULTS: There were no statistically significant correlation between age, time to radical cystectomy, gender, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio ratios and carcinoma in situ in upstaged and non-upstaged groups. Statistical analyses showed that preoperative neutrophile-to-lymphocyte ratio was higher in upstaged patients (p=0.009). In multivariate analysis preoperative neutrophile-to-lymphocyte ratio and positive surgical margin were significantly higher in upstaged group. CONCLUSION: In organ-confined muscle invasive bladder cancer neutrophile-to-lymphocyte ratio seems to be an acceptable parameter to predict locally advanced disease. FAU - Sefik, Ertugrul AU - Sefik E AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Gunlusoy, Bulent AU - Gunlusoy B AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Aydogdu, Ozgu AU - Aydogdu O AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Topcu, Yusuf Kadir AU - Topcu YK AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Ceylan, Yasin AU - Ceylan Y AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Degirmenci, Tansu AU - Degirmenci T AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. FAU - Dincel, Cetin AU - Dincel C AD - Clinic of Urology, Izmir Training and Research Hospital, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20180301 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC5832372 OTO - NOTNLM OT - Bladder cancer OT - neutrophil-to-lymphocyte-ratio OT - upstaging COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2018/03/08 06:00 MHDA- 2018/03/08 06:01 PMCR- 2018/03/01 CRDT- 2018/03/08 06:00 PHST- 2017/03/17 00:00 [received] PHST- 2017/06/20 00:00 [accepted] PHST- 2018/03/08 06:00 [entrez] PHST- 2018/03/08 06:00 [pubmed] PHST- 2018/03/08 06:01 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - tju-44-2-119 [pii] AID - 10.5152/tud.2017.46038 [doi] PST - ppublish SO - Turk J Urol. 2018 Mar;44(2):119-124. doi: 10.5152/tud.2017.46038. Epub 2018 Mar 1. PMID- 29506941 OWN - NLM STAT- MEDLINE DCOM- 20181119 LR - 20181119 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 5 DP - 2018 May TI - Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. PG - 239.e1-239.e7 LID - S1078-1439(18)30040-1 [pii] LID - 10.1016/j.urolonc.2018.01.018 [doi] AB - PURPOSE: To improve current prognostic models for the selection of patients with T1G3 urothelial bladder cancer who are more likely to fail intravesical therapy and progress to muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: We performed a retrospective analysis of 1,289 patients with pT1G3 urothelial bladder cancer who were treated with transurethral resection of the bladder (TURB) and adjuvant intravesical bacillus-Calmette-Guerin (BCG). Random-split sample data and competing-risk regression were used to identify the independent impact of lymphovascular invasion (LVI) and variant histology (VH) on progression to MIBC. We developed a nomogram for predicting patient-specific probability of disease progression at 2 and 5 years after TURB. Decision curve analysis (DCA) was performed to evaluate the clinical benefit associated with the use of our nomogram. RESULTS: In the development cohort, within a median follow-up of 51.6 months (IQR: 19.3-92.5), disease progression occurred in 89 patients (13.8%). A total of 84 (13%) patients were found to have VH and 57 (8.8%) with LVI at TURB. Both factors were independently associated with disease progression on multivariable competing-risk analysis (HR: 4.4; 95% CI: 2.8-6.9; P<0.001 and HR: 3.5; 95% CI: 2.1-5.8; P<0.001, respectively). DCA showed superior net benefits for the nomogram within a threshold probability of progression between 5% and 55%. Limitations are inherent to the retrospective design. CONCLUSIONS: We demonstrated the clinical value of the integration of LVI and VH in a prognostic model for the prediction of MIBC. Indeed, our tool provides superior individualized risk estimation of progression facilitating decision-making regarding early RC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - D Andrea, David AU - D Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Susani, Martin AU - Susani M AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Ristl, Robin AU - Ristl R AD - Institute for Medical Statistic, Center for Medical Statistics, Informatics and Intelligent Systems (CEMSIIS), Medical University of Vienna, Vienna, Austria. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Kimura, Shoji AU - Kimura S AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Canada. FAU - Gust, Killian M AU - Gust KM AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere, Assistance-Publique Hopitaux de Paris and Faculte de Medecine Pierre et Marie Curie, University Paris VI, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology and Andrology, Karl Landsteiner Institute, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Centre, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180303 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Transl Androl Urol. 2018 Aug;7(4):749-751. doi: 10.21037/tau.2018.06.14. PMID: 30211068 CIN - Transl Androl Urol. 2018 Aug;7(4):760-763. doi: 10.21037/tau.2018.06.13. PMID: 30211072 MH - Aged MH - *Clinical Decision-Making MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Muscle Neoplasms/epidemiology/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control MH - Neoplasm Staging MH - *Nomograms MH - Retrospective Studies MH - Risk Assessment MH - Survival Rate MH - Urinary Bladder Neoplasms/*therapy OTO - NOTNLM OT - Lymphovascular invasion OT - Prognosis OT - Progression OT - Urothelial bladder cancer OT - Variant histology EDAT- 2018/03/07 06:00 MHDA- 2018/11/20 06:00 CRDT- 2018/03/07 06:00 PHST- 2017/12/22 00:00 [received] PHST- 2018/01/18 00:00 [revised] PHST- 2018/01/28 00:00 [accepted] PHST- 2018/03/07 06:00 [pubmed] PHST- 2018/11/20 06:00 [medline] PHST- 2018/03/07 06:00 [entrez] AID - S1078-1439(18)30040-1 [pii] AID - 10.1016/j.urolonc.2018.01.018 [doi] PST - ppublish SO - Urol Oncol. 2018 May;36(5):239.e1-239.e7. doi: 10.1016/j.urolonc.2018.01.018. Epub 2018 Mar 3. PMID- 29506940 OWN - NLM STAT- MEDLINE DCOM- 20181119 LR - 20181119 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 5 DP - 2018 May TI - Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. PG - 238.e19-238.e27 LID - S1078-1439(18)30039-5 [pii] LID - 10.1016/j.urolonc.2018.01.017 [doi] AB - OBJECTIVE: To determine conditional recurrence-free survival (RFS) and progression-free survival (PFS) and improve decision-making toward surveillance protocols and scheduling. Furthermore, evaluating the evolution of predictors for disease recurrence over time, because TaG1 non-muscle-invasive bladder cancer harbors a risk of disease recurrence and progression. MATERIAL AND METHODS: The retrospective multicenter design study includes 1,245 TaG1 bladder cancer patients with median follow-up of 62.7 (interquartile range: 34.3-91.1) months. Conditional RFS and PFS estimates were calculated using the Kaplan-Meier method. Multivariable Cox regression model was calculated proportional for the prediction of recurrence and progression (covariables: age, tumor size, multiple tumors, prior recurrence, and immediate postoperative instillation of chemotherapy). RESULTS: After 3 months without event, the conditional RFS and PFS (to >/=pT2) rates for 5 additional years without event were 57.5% and 93.4%, respectively. Given a 1-, 2-, 3-, and 5-year survival, the conditional RFS rates for 5 additional years without event improved by +9.8 (67.3%), +5.2 (72.5%), +6.5 (79.0%), +2.0 (81.0%), and +1.0% (82.0%), respectively. In contrast, the 5-year conditional PFS rates were more or less stable with 94.3% after 1 year to 94.1% after 5 years. Multivariable analyses showed decreasing impact of risk parameters on RFS estimates over time. Based on these findings, we suggest a risk stratification to individualize follow-up for intermediate risk TaG1. Main limitation was the retrospective design. CONCLUSIONS: Conditional-survival analyses demonstrates that the patient risk profile changes over time. RFS rates rise with increasing survival whereas PFS rates were stable. The impact of prognostic features decreases over time. Our findings can be used for patient counseling and planning of personalized follow-up. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - von Landenberg, Nicolas AU - von Landenberg N AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - von Rundstedt, Friedrich C AU - von Rundstedt FC AD - Department of Urology, Jena University Hospital, Friedrich-Schiller- University, Jena, Germany. FAU - Dobruch, Jakub AU - Dobruch J AD - Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Necchi, Andrea AU - Necchi A AD - Department of Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Noon, Aidan AU - Noon A AD - Department of Urology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Decaestecker, Karel P J AU - Decaestecker KPJ AD - Department of Urology, Ghent University Hospital, Ghent, Belgium. FAU - Seiler, Roland AU - Seiler R AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Cochin Hospital, Assistance-Publique Hopitaux de Paris, Paris Descartes University, Paris, France. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: f.roghmann@gmail.com. CN - Young Academic Urologists' Working Group on Urothelial Cancer of the European Association of Urology LA - eng PT - Journal Article PT - Multicenter Study DEP - 20180303 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM CIN - Transl Androl Urol. 2018 Dec;7(6):987-989. doi: 10.21037/tau.2018.07.07. PMID: 30505739 MH - Aged MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*mortality/*pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology OTO - NOTNLM OT - Bladder cancer OT - Conditional analysis OT - Non-muscle invasive OT - Recurrence and progression OT - Urothelial carcinoma EDAT- 2018/03/07 06:00 MHDA- 2018/11/20 06:00 CRDT- 2018/03/07 06:00 PHST- 2017/08/30 00:00 [received] PHST- 2018/01/07 00:00 [revised] PHST- 2018/01/28 00:00 [accepted] PHST- 2018/03/07 06:00 [pubmed] PHST- 2018/11/20 06:00 [medline] PHST- 2018/03/07 06:00 [entrez] AID - S1078-1439(18)30039-5 [pii] AID - 10.1016/j.urolonc.2018.01.017 [doi] PST - ppublish SO - Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3. PMID- 29496649 OWN - NLM STAT- MEDLINE DCOM- 20180910 LR - 20250623 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 52 DP - 2018 Apr TI - Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. PG - 214-220 LID - S1743-9191(18)30580-6 [pii] LID - 10.1016/j.ijsu.2018.02.049 [doi] AB - OBJECTIVE: The aim of the study was to systematically review the relevant studies to evaluate the prognosis of primary and progressive muscle-invasive bladder cancer (MIBC) after radical cystectomy (RC) and provide a clue for the timing of RC in patients with progressive MIBC early at the time of high-risk non-muscle-invasive bladder cancer (NMIBC). MATERIAL AND METHODS: PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched for eligible studies. We extracted hazard ratios (HRs) of overall survival (OS) and cancer-specific survival (CSS) and deaths at 5 and 10 years for each study and performed the meta-analysis using Review Manager 5.3. RESULTS: A total of 11 retrospective studies with 4102 patients were included in the meta-analysis. The pooled analysis suggested a similar CSS (HR: 1.18; 95% CI, 0.74, 1.87; p = 0.50) and OS (HR: 1.15; 95% CI, 0.82, 1.61; p = 0.43) between primary and progressive MIBC patients treated with RC. The results further indicated no significant differences between the two populations in terms of 5-year CSS rate (OR: 1.32; 95% CI, 0.90, 1.95; p = 0.16), 10-year CSS rate (OR: 0.83; 95% CI, 0.37, 1.83; p = 0.64) as well as 5-year OS rate (OR: 1.02; 95% CI, 0.66, 1.56; p = 0.94). Subgroup analysis according to the starting point of follow-up showed similar outcomes. CONCLUSION: The meta-analysis demonstrates comparable CSS and OS in patients with primary and progressive MIBC following RC. Novel risk stratifications and prospective trials are urgently needed to investigate the prognosis after RC of these two groups of patients, which could finally aid clinician decision making and select patients who would actually benefit from early RC. CI - Copyright (c) 2018. Published by Elsevier Ltd. FAU - Chen, Junru AU - Chen J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Zhang, Haoran AU - Zhang H AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Sun, Guangxi AU - Sun G AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Zhang, Xingming AU - Zhang X AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Zhao, Jinge AU - Zhao J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Liu, Jiandong AU - Liu J AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Shen, Pengfei AU - Shen P AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Shi, Ming AU - Shi M AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: Smcm2014@163.com. FAU - Zeng, Hao AU - Zeng H AD - Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: cdhx510@foxmail.com. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20180227 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - *Cystectomy MH - Humans MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Prognosis MH - Proportional Hazards Models MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/*pathology/surgery OTO - NOTNLM OT - Meta-analysis OT - Primary muscle-invasive bladder cancer OT - Prognosis OT - Progressive muscle-invasive bladder cancer OT - Radical cystectomy OT - Systematic review EDAT- 2018/03/03 06:00 MHDA- 2018/09/11 06:00 CRDT- 2018/03/03 06:00 PHST- 2017/12/14 00:00 [received] PHST- 2018/01/23 00:00 [revised] PHST- 2018/02/20 00:00 [accepted] PHST- 2018/03/03 06:00 [pubmed] PHST- 2018/09/11 06:00 [medline] PHST- 2018/03/03 06:00 [entrez] AID - S1743-9191(18)30580-6 [pii] AID - 10.1016/j.ijsu.2018.02.049 [doi] PST - ppublish SO - Int J Surg. 2018 Apr;52:214-220. doi: 10.1016/j.ijsu.2018.02.049. Epub 2018 Feb 27. PMID- 29493186 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20181114 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 44 IP - 3 DP - 2018 May-Jun TI - Nephrogenic adenoma of the bladder: a single institution experience assessing clinical factors. PG - 506-511 LID - 10.1590/S1677-5538.IBJU.2017.0155 [doi] AB - INTRODUCTION: Nephrogenic adenoma (NA) was first described by Davis in 1949 as a "hamartoma" of the bladder. There are many proposed predisposing factors for NA including chronic inflammation, renal transplantation, and bladder cancer. We examined our experience with NA to determine predisposing factors and determine if there was any increased risk for development of subsequent malignancy. MATERIALS AND METHODS: All patients with a pathologic diagnosis of bladder NA from 2001-2013 were included. Patient history, clinical factors including possible predisposing factors for NA, and follow-up were reviewed. RESULTS: Among 60 patients, 68% were males with an average age of 61, an average BMI of 28.7, and 60% had a smoking history. In evaluating pro-inflammatory factors, 26.7% underwent either Bacillus Calmette-Guerin or mitomycin C, 30% had recurrent urinary tract infections, and 25% had a history of catheterization. Recurrence of NA after initial resection occurred only in 14.7% of patients who underwent follow-up cystoscopy. A history of concurrent bladder cancer was seen in 41.7% of patients, but there were no cases of de novo bladder cancer diagnosed after NA. CONCLUSION: To the best of our knowledge, this is the largest series of patients with NA of the bladder. NA occurs in a heterogeneous population of patients, but most often with underlying inflammation. NA occurred concurrent with bladder cancer; however there were no cases of de novo bladder cancer after NA, reassuring that NA is likely a benign reactive condition. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Yi, Yooni AU - Yi Y AD - Deparment of Urology. University of Michigan, Michigan, USA. FAU - Wu, Angela AU - Wu A AD - Deparment of Pathology, University of Michigan, Michigan, USA. FAU - Cameron, Anne P AU - Cameron AP AD - Deparment of Urology. University of Michigan, Michigan, USA. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Adenoma/*etiology/*pathology MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Child MH - Cystoscopy MH - Diagnosis, Differential MH - Female MH - Hematuria MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*etiology/*pathology MH - Young Adult PMC - PMC5996808 OTO - NOTNLM OT - Adenoma OT - Urinary Bladder Neoplasms OT - Urologic Diseases COIS- Conflict of interest: None declared. EDAT- 2018/03/02 06:00 MHDA- 2018/07/25 06:00 PMCR- 2018/05/01 CRDT- 2018/03/02 06:00 PHST- 2017/03/15 00:00 [received] PHST- 2017/11/29 00:00 [accepted] PHST- 2018/03/02 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] PHST- 2018/03/02 06:00 [entrez] PHST- 2018/05/01 00:00 [pmc-release] AID - IBJU20170155 [pii] AID - S1677-5538.IBJU.2017.0155 [pii] AID - 10.1590/S1677-5538.IBJU.2017.0155 [doi] PST - ppublish SO - Int Braz J Urol. 2018 May-Jun;44(3):506-511. doi: 10.1590/S1677-5538.IBJU.2017.0155. PMID- 29485035 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 12 IP - 6 DP - 2018 Jun TI - Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis. PG - 203-210 LID - 10.5489/cuaj.4870 [doi] AB - INTRODUCTION: Non-muscle-invasive bladder cancer (NMIBC) accounts for 75-85% of all urothelial bladder cancers (UBC). Many UBC patients are also afflicted by diabetes mellitus (DM). It has been postulated that several oral hypoglycemic agents could impact disease-specific survival (DSS), but the data are sparse among NMIBC patients. Our primary objective was to evaluate the impact of metformin on DSS and overall survival (OS) in NMIBC patients. METHODS: This is a retrospective, population-based study that used linked administrative databases to identify diabetic patients >/=66 years who were subsequently diagnosed with NMIBC in Ontario between 1992 and 2012. Cumulative use of metformin and other hypoglycemic agent were calculated before and after NMIBC diagnosis. DSS and OS were estimated using multivariable competing risk and Cox proportional hazards models, respectively. RESULTS: A total of 1742 subjects were included in the study. After a median followup of 5.2 years, 1122 (64%) had died, including 247 (15%) deaths as a result of UBC. On multivariable analysis, cumulative duration of metformin use after NMIBC diagnosis did not appear to impact DSS (hazard ratio [HR] 1.1; 95% confidence interval [CI] 0.92-1.2), whereas glyburide use appeared to have a detrimental effect (HR 1.17; 95% CI 1.02-1.3). None of the other hypoglycemic agents had an impact on OS. CONCLUSIONS: In this large, population-based study, we have provided further evidence that metformin use does not significantly impact DSS among diabetic patients diagnosed with NMIBC. However, our findings demonstrate that glyburide use inversely affects DSS. The detrimental effect of glyburide on DSS will require further validation. FAU - Richard, Patrick O AU - Richard PO AD - Division of Urology, Departments of Surgery, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, QC; Canada. FAU - Ahmad, Ardalan E AU - Ahmad AE AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Bashir, Shaheena AU - Bashir S AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Zlotta, Alexandre AU - Zlotta A AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. AD - Division of Urology, Departments of Surgery, Mount Sinai Hospital and the University of Toronto, Toronto, ON; Canada. FAU - Bhindi, Bimal AU - Bhindi B AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Leao, Ricardo AU - Leao R AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Nayan, Madhur AU - Nayan M AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Mohammed, Aza AU - Mohammed A AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON; Canada. AD - Institute for Clinical Evaluative Sciences, Toronto, ON; Canada. LA - eng PT - Journal Article DEP - 20180223 PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC5994977 COIS- Competing interests: Dr. Richard has attended advisory boards for BMS and Sanofi; and has been a speaker for AbbVie, Astellas, and Jasssen. Dr. Zlotta has attended advisory boards for Amgen, Astellas, Ferring, Paladin, and Sanofi; has received educational grants from Pfizer, Red Leaf Medical, and Sanofi; and has participated in clinical trials supported by Sanofi. Dr. Fleshner has been a consultant for Amgen, Astellas, and Janssen; has participated in clinical trials for Amgen, Astellas, Ferring, and Janssen; and has received grant funding from Canadian Cancer Society Research Institute and Prostate Cancer Canada. The remaining authors report no competing personal or financial interests related to this work. EDAT- 2018/02/28 06:00 MHDA- 2018/02/28 06:01 PMCR- 2018/06/01 CRDT- 2018/02/28 06:00 PHST- 2018/02/28 06:00 [pubmed] PHST- 2018/02/28 06:01 [medline] PHST- 2018/02/28 06:00 [entrez] PHST- 2018/06/01 00:00 [pmc-release] AID - cuaj.4870 [pii] AID - cuaj-6-203 [pii] AID - 10.5489/cuaj.4870 [doi] PST - ppublish SO - Can Urol Assoc J. 2018 Jun;12(6):203-210. doi: 10.5489/cuaj.4870. Epub 2018 Feb 23. PMID- 29480994 OWN - NLM STAT- MEDLINE DCOM- 20180822 LR - 20181113 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 19 IP - 2 DP - 2018 Feb 26 TI - Impact of Cyclin D1 and Heterogeneous Nuclear Ribonucleoprotein-K (HnRNP-K) on Urinary Bladder Carcinogenesis. PG - 513-519 AB - Objective: This study aimed to investigate the expression of cyclin D1 and hnRNP-K in relation to the pathological findings in bladder cancer including the type, grade, muscle invasion and bilharzial association. Methods: We studied the immunoexpression; as regard the percentage, intensity and score of both cyclin D1 and hnRNP-K in different bladder lesions including 10 cases of cystitis; 10 cases of carcinoma insitu (CIS), 20 cases of Squamous cell carcinoma (SCC) and 66 cases of urothelial carcinoma (UC). Results: High expression of cyclin D1 was found in UC compared to other groups (p<0.001) and in UC with low grade, non-muscle invasive and papillary tumors compared to their counterparts (p<0.05, <0.01 and <0.05 respectively), however, bilharzial association does not affect cyclin D1 expression. Higher hnRNP-K expression was found in SCC compared to other groups (p <0.001) and in UC with high grade, muscle invasive and non-papillary tumors compared to their counterparts (p<0.001each). Bilharzial-associated UC showed higher expression of hnRNP-K percent (p<0.05) compared to non-bilharzial cases. Conclusion: This study elucidated a possible contribution of cyclin D1 and hnRNP-K expression in the initiation and progression of urinary bladder carcinoma, so, both of them can be used in predicting progression of urinary bladder carcinoma and to differentiate between UC and SCC in high grade tumors. The possible role of both markers in immunotherapy deserves supplementary studies. CI - Creative Commons Attribution License FAU - Aboushousha, Tarek AU - Aboushousha T AD - Pathology Departments,Theodor Bilharz Research Institute, Cairo, Egypt. Email: t.aboushousha@tbri.gov.eg FAU - Hammam, Olfat AU - Hammam O FAU - Helal, Noha AU - Helal N FAU - El Dahshan, Samir AU - El Dahshan S LA - eng PT - Journal Article DEP - 20180226 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Biomarkers, Tumor) RN - 0 (CCND1 protein, human) RN - 0 (Heterogeneous-Nuclear Ribonucleoprotein K) RN - 136601-57-5 (Cyclin D1) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/metabolism MH - Carcinogenesis/*metabolism/*pathology MH - Cyclin D1/*metabolism MH - Disease Progression MH - Female MH - Heterogeneous-Nuclear Ribonucleoprotein K/*metabolism MH - Humans MH - Male MH - Middle Aged MH - Muscles/metabolism/pathology MH - Neoplasm Invasiveness/pathology MH - Urinary Bladder/*metabolism/*pathology MH - Urinary Bladder Neoplasms/metabolism/pathology PMC - PMC5980943 OTO - NOTNLM OT - *Bladder cancer OT - *cystitis OT - *bilharziasis OT - *cyclin D1 OT - *hnRNP-K OT - *immunohistochemistry EDAT- 2018/02/27 06:00 MHDA- 2018/08/23 06:00 PMCR- 2018/03/01 CRDT- 2018/02/27 06:00 PHST- 2018/02/27 06:00 [entrez] PHST- 2018/02/27 06:00 [pubmed] PHST- 2018/08/23 06:00 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - APJCP-19-513 [pii] AID - 10.22034/APJCP.2018.19.2.513 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2018 Feb 26;19(2):513-519. doi: 10.22034/APJCP.2018.19.2.513. PMID- 29480348 OWN - NLM STAT- MEDLINE DCOM- 20180828 LR - 20181113 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 35 IP - 4 DP - 2018 Feb 26 TI - Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. PG - 41 LID - 10.1007/s12032-018-1102-y [doi] AB - The clinical benefits of bacillus Calmette-Guerin (BCG) therapy for the management of upper urinary tract carcinoma in situ (CIS) remain unclear. We aimed to compare the efficacy and safety of BCG therapy for upper urinary tract CIS with those of radical nephroureterectomy (RNU). Of 490 patients with upper urinary tract carcinoma, we retrospectively reviewed the post-treatment course of 58 patients with upper urinary tract CIS who underwent either RNU (RNU group) or BCG therapy (BCG group). Efficacy and safety were compared between the RNU and BCG groups. Inverse probability treatment-weighted (IPTW)-adjusted multivariate Cox regression analysis was performed to identify the influence of BCG therapy on prognosis. The RNU and BCG groups included 20 and 38 patients, respectively. No significant difference was found in patients' background, including age, sex, and performance status, between the groups. The reason underlying the selection of BCG therapy was bilateral CIS of the upper urinary tract (50%), solitary kidney (26%), unwillingness to undergo RNU (13%), and ineligibility for surgery (11%). The cytology became negative in 30 (79%) out of 38 patients after a 6-week course of BCG therapy, and 17 (57%) out of 30 patients remained negative. BCG-related adverse events (AEs) were observed in 92% of patients. The most common AE was cystitis (76%), followed by fever (50%). No significant differences were found in the progression-free, cancer-specific, and overall survivals between the RNU and BCG groups. IPTW-adjusted multivariate analysis revealed that BCG therapy did not worsen the prognosis of these patients. The limitations of our study were its retrospective design and small sample size. In conclusion, BCG therapy for upper urinary tract CIS might be a useful alternative for patient ineligible for RNU under careful observation for AEs. FAU - Horiguchi, Hirotaka AU - Horiguchi H AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. shingoh@hirosaki-u.ac.jp. FAU - Tokui, Noriko AU - Tokui N AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Sato, Tendo AU - Sato T AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Koie, Takuya AU - Koie T AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Narita, Satoshi AU - Narita S AD - Department of Urology, Odate General Hospital, Odate, Japan. FAU - Kawaguchi, Toshiaki AU - Kawaguchi T AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562, Japan. AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng GR - 15H02563/Japan Society for the Promotion of Science/ GR - 15K15579/Japan Society for the Promotion of Science/ GR - 17K11118/Japan Society for the Promotion of Science/ GR - 17K11119/Japan Society for the Promotion of Science/ GR - 17K16768/Japan Society for the Promotion of Science/ GR - 17K16770/Japan Society for the Promotion of Science/ GR - 17K16771/Japan Society for the Promotion of Science/ PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20180226 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (BCG Vaccine) SB - IM MH - Adult MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*drug therapy/*surgery MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Nephroureterectomy/*methods MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Urologic Neoplasms/*drug therapy/*surgery OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Carcinoma in situ OT - Nephroureterectomy OT - Oncological outcome OT - Upper tract urothelial carcinoma EDAT- 2018/02/27 06:00 MHDA- 2018/08/29 06:00 CRDT- 2018/02/27 06:00 PHST- 2018/01/27 00:00 [received] PHST- 2018/02/23 00:00 [accepted] PHST- 2018/02/27 06:00 [entrez] PHST- 2018/02/27 06:00 [pubmed] PHST- 2018/08/29 06:00 [medline] AID - 10.1007/s12032-018-1102-y [pii] AID - 10.1007/s12032-018-1102-y [doi] PST - epublish SO - Med Oncol. 2018 Feb 26;35(4):41. doi: 10.1007/s12032-018-1102-y. PMID- 29473376 OWN - NLM STAT- MEDLINE DCOM- 20190711 LR - 20190711 IS - 1124-3562 (Print) IS - 1124-3562 (Linking) VI - 89 IP - 4 DP - 2017 Dec 31 TI - Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience. PG - 272-276 LID - 10.4081/aiua.2017.4.272 [doi] AB - INTRODUCTION: Understaging after initial transurethral resection is common in patients with high-risk non muscle infiltrating bladder cancer (NMIBC) and can delay accurate diagnosis and definitive treatment. The rate of upstaging from T1 to T2 disease after repeated transurethral resection ranges from 0 to 28%, although the rate of upstaging may be even higher up to 49% when muscularis propria is absent in the first specimen. A restaging classic transurethral resection of bladder tumour (re-cTURBT) is the better predictor of early stage progression. According to some reports, the rate of positivity for tumor in re-cTURBT performed within eight weeks after initial cTURBT was as high as 18-77%, and in about 40% of the patients a change in tumor stage was reported. We aimed to investigate, in high risk group, the presence of residual tumor following white light classical transurethral resection of bladder tumor (WLre-cTURBT) and the different recurrence and progression rate between patients with persistent or negative (pT0) oncological disease after WLre-cTURBT. MATERIALS AND METHODS: A cohort of 285 patients presenting with primitive bladder cancer underwent to WLcTURBT from January 2011 to December 2015; out of them 92 (32.28%) were T1HG. In according to EAU guidelines 2011, after 4-6 weeks all HG bladder cancer patients underwent a WL recTURBT . All patients were submitted to a subsequent followup including cystoscopy every 3 months with multiple biopsies, randomly and in the previous zone of resection; urinary citology on 3 specimens and kidney/bladder ultrasound every 6 months. The average follow-up was 48 months. RESULTS: Following WLre-cTURBT we observed a persistent disease in 18 (15.2%) patients: 14 (77.7%) with a HG-NMIBC and 4 (22.2%) with a high grade (HG) muscle invasive bladder cancer (pT2HG). After follow up of all 92 patients according to the guidelines EAU, we observed recurrence in 36/92 (39.1%) and progression in 14/92 (15.2%). Of 14 NMIBC with persistent disease, 10 patients (71.4%) showed recurrence: 4 patients (40%) were pT1HG with concomitant carcinoma in situ (CIS), 3 patients (30%) multifocal pTaHG, 2 (20%) patients CIS and one patient (10%) a muscle invasive neoplasm (pT2HG). Instead of the group of 48 patients pT0 following WL recTURBT, we observed recurrence in 26 patients (54.1%) and in two patients (4.1%) progressions, who presented after 3 months in association with CIS. The remaining 22 patients (45.9%) with initial pT1HG are still progression free. Multivariate analysis showed that the most important variable of early progression were persistent neoplasm and histopathological findings at WLre-cTURBt (p = 0.01), followed by the Summary No conflict of interest declared. INTRODUCTION Bladder cancer is a common genito-urinary malignancy, with transitional cell carcinoma comprising nearly 90% of all primary bladder tumours. At the first diagnosis 70% to 80% of urothelial tumours are confined to the epithelium, the remainder is characterized by muscle invasion. A significant number of patients with high risk non-muscle invasive bladder tumours (HG-NMIBT) treated with white light classic transurethral resection of bladder tumours (WLcTURBT) and intravesical BCG will progress to invasive disease (1-3). Progression to muscle invasion (pT2) mandates immediate radical cystectomy (4). WLcTURBT is the standard initial therapy for NMIBT, but the high percentage of recurrence after surgery is still an unresolved problem (5). High grade pT1 bladder neoplasm (pT1HG) really represents a therapeutic challenge due to the high risk of progression (about 15-30%) to muscle-invasive disease, usually within 5 years (6). However, no consensus exists regarding the treatment of patients with recurrent bladder tumours that invade the lamina propria (pT1) (7-9). Recent studies suggested that the first cTURBT may be incomplete in a significant number of cases (10). Understaging at the time of the initial transurethral resection is common for patients with high-risk NMIBC and can delay accurate diagnosis and definitive treatment. It is therefore recommended for patients with high-risk disease and in those with large or multiple tumors or when the initial transurethral resection is incomplete, to repeat WLre-cTURBT within 2-6 DOI: 10.4081/aiua.2017.4.272 result of the first cystoscopy (p = 0.002) and presence of CIS (p = 0.02). DISCUSSION: Following WLre-cTURBt in HG-NMIBC patients we identified in 15% of cases a persistent disease with a 4.3% of MIBC. In the high risk persistent bladder neoplasms group we observed recurrent and progression rate higher than in T0 bladder tumours group (Delta = + 17.3% and = Delta + 62.5%, p < 0.05. FAU - Giulianelli, Roberto AU - Giulianelli R AD - CUrA, Nuova Villa Claudia Clinic, Rome. giulianelli0764@gmail.com. FAU - Gentile, Barbara Cristina AU - Gentile BC FAU - Mirabile, Gabriella AU - Mirabile G FAU - Albanesi, Luca AU - Albanesi L FAU - Tariciotti, Paola AU - Tariciotti P FAU - Rizzo, Giorgio AU - Rizzo G FAU - Buscarini, Maurizio AU - Buscarini M FAU - Vermiglio, Mauro AU - Vermiglio M LA - eng PT - Journal Article DEP - 20171231 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cohort Studies MH - Cystoscopy/*methods MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - BCG schedule OT - WLre-cTURBT OT - pCISHG Recurrence and progression rate OT - pT1HG EDAT- 2018/02/24 06:00 MHDA- 2019/07/12 06:00 CRDT- 2018/02/24 06:00 PHST- 2016/11/14 00:00 [received] PHST- 2017/01/11 00:00 [accepted] PHST- 2018/02/24 06:00 [entrez] PHST- 2018/02/24 06:00 [pubmed] PHST- 2019/07/12 06:00 [medline] AID - 10.4081/aiua.2017.4.272 [doi] PST - epublish SO - Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272. PMID- 29473226 OWN - NLM STAT- MEDLINE DCOM- 20190516 LR - 20190516 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 25 IP - 5 DP - 2018 May TI - Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer. PG - 442-449 LID - 10.1111/iju.13532 [doi] AB - OBJECTIVES: To investigate established prognostic factors and relatively new histopathological tumor characteristics including metric substage and lamina propria invasion patterns in a large series of T1 high-grade non-muscle-invasive bladder cancer. METHODS: Between 1989 and 2012, 322 patients with initial stage T1 high-grade bladder cancer underwent transurethral resection, followed by re-transurethral resection and a conservative approach with follow-up regime alone or instillation treatment. Transurethral resection specimens were reassessed by two experienced urological pathologists for tumor grade according to the World Health Organization 1973 classification, metric T1 substage, lamina propria invasion pattern and associated carcinoma in situ. The median follow-up period was 42 months (interquartile range 25-72 months). In addition to Kaplan-Meier analyses, uni- and multivariable Cox regression analyses were used to compare progression-free survival, cancer-specific survival and overall survival for the studied parameters comparing two subcohorts. RESULTS: While in patients after instillation treatment no examined feature was shown as an independent predictor for prognosis, there were predictive histopathological features in multivariable Cox regression analyses in instillation treatment-naive patients: associated carcinoma in situ (hazard ratio 2.278, 95% confidence interval 1.119-4.634, P = 0.023) and World Health Organization 1973 grade 3 (hazard ratio 2.950, 95% confidence interval 1.021-8.536, P = 0.046) for worse progression-free survival, infiltrative lamina propria tumor pattern for worse cancer-specific survival (hazard ratio 2.369, 95% confidence interval 1.034-5.429, P = 0.042) and overall survival (hazard ratio 1.049, 95% confidence interval 1.024-1.075, P = 0.001). CONCLUSIONS: The results of the present T1 high-grade bladder cancer series suggest that lamina propria invasion pattern is a promising parameter to predict the prognosis of T1 high-grade bladder cancer in an instillation treatment-naive subcohort. Prospective multicenter evaluations are warranted. The need for instillation treatment in T1 high-grade bladder cancer is clearly demanded. CI - (c) 2018 The Japanese Urological Association. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. AD - Member of the BRIDGE Consortium, Mannheim, Germany. FAU - van Rhijn, Bas Wg AU - van Rhijn BW AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. AD - Member of the BRIDGE Consortium, Mannheim, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Member of the BRIDGE Consortium, Mannheim, Germany. AD - Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. FAU - Lausenmeyer, Eva M AU - Lausenmeyer EM AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany. AD - Member of the BRIDGE Consortium, Mannheim, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Member of the BRIDGE Consortium, Mannheim, Germany. AD - Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20180222 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Aged MH - Carcinoma in Situ/*diagnosis/mortality/surgery MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mucous Membrane/*pathology MH - Neoplasm Invasiveness/pathology MH - *Neoplasm Staging MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Time Factors MH - Urinary Bladder Neoplasms/*diagnosis/mortality/surgery MH - Urologic Surgical Procedures MH - World Health Organization OTO - NOTNLM OT - instillation treatment OT - prognosis OT - stage T1 high-grade OT - tumor growth pattern OT - urothelial bladder cancer EDAT- 2018/02/24 06:00 MHDA- 2019/05/17 06:00 CRDT- 2018/02/24 06:00 PHST- 2017/05/06 00:00 [received] PHST- 2017/12/22 00:00 [accepted] PHST- 2018/02/24 06:00 [pubmed] PHST- 2019/05/17 06:00 [medline] PHST- 2018/02/24 06:00 [entrez] AID - 10.1111/iju.13532 [doi] PST - ppublish SO - Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. PMID- 29459997 OWN - NLM STAT- MEDLINE DCOM- 20190319 LR - 20221207 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 36 IP - 8 DP - 2018 Aug TI - The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. PG - 1191-1200 LID - 10.1007/s00345-018-2199-5 [doi] AB - PURPOSE: To investigate the effects of intra-arterial chemotherapy on T1 stage bladder cancer (Bca) and evaluate patient outcome with bladder-preserving treatment approaches. MATERIALS AND METHODS: A total of 238 patients with T1 stage Bca were retrospectively analyzed. Among them, 35 patients were categorized into the subgroup of highest-risk T1 stage according to the European Association of Urology guidelines and received immediate radical cystectomy (RC group), whereas 62 were classified as being highest-risk T1 patients but were unwilling to undergo RC and were treated with gemcitabine plus cisplatin intra-arterial chemotherapy (GC group). There were 141 T1 patients who had bladder-preserving surgery with intravesical chemotherapy (IVC group). RESULTS: For patients with T1 stage Bca, the GC group had a higher estimated recurrence-free survival rate (44.4 vs. 13.9%, P = 0.087), progression-free survival rate (75.4 vs. 32.8%, P = 0.006), and cancer-specific survival (CSS) rate (78.7 vs. 67.5%, P = 0.399) when compared with the IVC group, respectively. Using the multivariable regression model, the GC intra-arterial chemotherapy was significantly related to bladder preservation (P = 0.004), lower recurrence (P = 0.012), and less progression (P = 0.004). For patients with the highest-risk T1 stage, GC group did not have a poorer CSS rate in comparison with the RC group (P = 0.383). Moreover, immediate RC did not confer a survival benefit in terms of CSS when compared with those who underwent deferred RC after failing GC intra-arterial chemotherapy (P = 0.283). CONCLUSIONS: Gemcitabine plus cisplatin intra-arterial chemotherapy may be an effective bladder-preserving alternative adjuvant treatment for patients with T1 stage Bca with oncologic benefits, good compliance, and low toxicity. FAU - Liu, Zefu AU - Liu Z AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Ye, Yunlin AU - Ye Y AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Li, Xiangdong AU - Li X AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Guo, Shengjie AU - Guo S AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Jiang, Lijuan AU - Jiang L AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Dong, Pei AU - Dong P AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Li, Yonghong AU - Li Y AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Shi, Yanxia AU - Shi Y AD - Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China. FAU - Fan, Weijun AU - Fan W AD - Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou, China. FAU - Cao, Yun AU - Cao Y AD - Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou, China. FAU - Yao, Kai AU - Yao K AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Qin, Zike AU - Qin Z AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Han, Hui AU - Han H AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. FAU - Zhou, Fangjian AU - Zhou F AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. zhoufj@sysucc.org.cn. FAU - Liu, Zhuowei AU - Liu Z AUID- ORCID: 0000-0002-8159-3033 AD - Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, China. liuzhw@sysucc.org.cn. LA - eng PT - Journal Article DEP - 20180219 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM MH - Aged MH - Antineoplastic Agents/*administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Chemotherapy, Adjuvant MH - China MH - Cisplatin/administration & dosage MH - Cystectomy MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease-Free Survival MH - Female MH - Humans MH - Injections, Intra-Arterial MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Organ Sparing Treatments MH - Progression-Free Survival MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/surgery MH - Gemcitabine OTO - NOTNLM OT - Bladder cancer OT - Bladder preservation OT - Intra-arterial chemotherapy OT - T1 EDAT- 2018/02/21 06:00 MHDA- 2019/03/20 06:00 CRDT- 2018/02/21 06:00 PHST- 2017/10/27 00:00 [received] PHST- 2018/01/19 00:00 [accepted] PHST- 2018/02/21 06:00 [pubmed] PHST- 2019/03/20 06:00 [medline] PHST- 2018/02/21 06:00 [entrez] AID - 10.1007/s00345-018-2199-5 [pii] AID - 10.1007/s00345-018-2199-5 [doi] PST - ppublish SO - World J Urol. 2018 Aug;36(8):1191-1200. doi: 10.1007/s00345-018-2199-5. Epub 2018 Feb 19. PMID- 29453645 OWN - NLM STAT- MEDLINE DCOM- 20181126 LR - 20181126 IS - 1863-4362 (Electronic) IS - 0021-1265 (Linking) VI - 187 IP - 4 DP - 2018 Nov TI - Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer. PG - 1115-1119 LID - 10.1007/s11845-018-1764-7 [doi] AB - BACKGROUND: Bladder cancer (BCa) is the seventh most common cancer among males worldwide. Some reliable markers in blood, urine, and tumor tissue, including clinicopathologic variables, molecular and inflammatory markers, gene polymorphisms, and tumor gene expression profiles are identified for predicting response to BCG immunotherapy in high-risk BCa patients. AIMS: We aimed to determine if FAS and FASL polymorphisms are associated with lack of response to BCG in patients with BCa. METHODS: The study included patients with primary non-muscle invasive BCa that had undergone transurethral resection (TUR). Patient demographics, BCa characteristics, use of BCG immunotherapy, lack of response to BCG (if administered), BCa recurrence, and fatty acid synthetase/fatty acid syntethase ligand (FAS/FASL) polymorphisms were investigated. RESULTS: The study included 127 patients with primary BCa. Mean age of the 107 (84.3%) male and 20 (15.7%) female patients was 59.3 +/- 13.2 years. Among the patients that received BCG immunotherapy, more FAS homozygous patients had BCa recurrence than FAS polymorphism-negative patients (P < 0.001) and more patients with homozygote FASL polymorphisms had BCa recurrence than those with heterozygous FASL polymorphisms and no polymorphism. CONCLUSION: Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated. FAU - Ceylan, Cavit AU - Ceylan C AUID- ORCID: 0000-0002-7825-8808 AD - Yuksek Ihtisas Training and Research Hospital, Clinic of Urology, Health Sciences University, 06230, Ankara, Turkey. FAU - Yahsi, Sedat AU - Yahsi S AD - Yuksek Ihtisas Training and Research Hospital, Clinic of Urology, 06230, Ankara, Turkey. FAU - Dogan, Serkan AU - Dogan S AD - Yuksek Ihtisas Training and Research Hospital, Clinic of Urology, 06230, Ankara, Turkey. FAU - OztUrk, Elife AU - OztUrk E AD - Department of Medical Genetics, Ataturk Training and Research Hospital, 06800, Ankara, Turkey. FAU - Ceylan, Gulay AU - Ceylan G AD - Department of Medical Genetics, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey. gulayceylan23@gmail.com. LA - eng PT - Journal Article DEP - 20180216 PL - Ireland TA - Ir J Med Sci JT - Irish journal of medical science JID - 7806864 RN - 0 (BCG Vaccine) RN - 0 (FASLG protein, human) RN - 0 (Fas Ligand Protein) RN - EC 2.3.1.85 (FASN protein, human) RN - EC 2.3.1.85 (Fatty Acid Synthase, Type I) SB - IM MH - BCG Vaccine/administration & dosage MH - Fas Ligand Protein/*genetics MH - Fatty Acid Synthase, Type I/*genetics MH - Female MH - Genotyping Techniques MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Polymerase Chain Reaction MH - *Polymorphism, Single Nucleotide MH - Urinary Bladder Neoplasms/*genetics/pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - FAS OT - FASL OT - Immunotherapy OT - Intravesical BCG OT - Polymorphism EDAT- 2018/02/18 06:00 MHDA- 2018/11/27 06:00 CRDT- 2018/02/18 06:00 PHST- 2018/01/14 00:00 [received] PHST- 2018/02/01 00:00 [accepted] PHST- 2018/02/18 06:00 [pubmed] PHST- 2018/11/27 06:00 [medline] PHST- 2018/02/18 06:00 [entrez] AID - 10.1007/s11845-018-1764-7 [pii] AID - 10.1007/s11845-018-1764-7 [doi] PST - ppublish SO - Ir J Med Sci. 2018 Nov;187(4):1115-1119. doi: 10.1007/s11845-018-1764-7. Epub 2018 Feb 16. PMID- 29444544 OWN - NLM STAT- MEDLINE DCOM- 20190516 LR - 20260127 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 25 IP - 5 DP - 2018 May TI - Uridine 5'diphospho-glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract. PG - 429-435 LID - 10.1111/iju.13528 [doi] AB - OBJECTIVE: To determine the expression status of uridine 5'diphospho-glucuronosyltransferase 1A, a major phase II drug metabolism enzyme, in upper urinary tract urothelial carcinoma, as well as to assess its prognostic significance. METHODS: We immunohistochemically stained for uridine 5'diphospho-glucuronosyltransferase 1A in tissue microarray consisting of 99 upper urinary tract urothelial carcinoma samples and paired non-neoplastic urothelial tissues. We also assessed the effect of uridine 5'diphospho-glucuronosyltransferase 1A knockdown on urothelial cancer cell growth. RESULTS: Uridine 5'diphospho-glucuronosyltransferase 1A was positive in 92.9% (27.3% weak [1+], 37.4% moderate [2+], 28.3% strong [3+]) of tumors, which was significantly (P < 0.001) lower than in benign urothelial tissues (98.8%; 3.5% 1+, 18.8% 2+, 76.4% 3+). All 37 (100%) non-muscle-invasive versus 55 (88.7%) of 62 muscle-invasive tumors (P = 0.043) were immunoreactive for uridine 5'diphospho-glucuronosyltransferase 1A. The rates of moderate-to-strong uridine 5'diphospho-glucuronosyltransferase 1A expression and its positivity were also strongly associated with the absence of concomitant carcinoma in situ (P = 0.034) and lymphovascular invasion (P = 0.016), respectively. However, there were no statistically significant associations between uridine 5'diphospho-glucuronosyltransferase 1A expression and tumor grade or pN/M status. Uridine 5'diphospho-glucuronosyltransferase 1A loss in M0 tumors was strongly associated with lower progression-free survival (P < 0.001) and cancer-specific survival (P < 0.001) rates. Multivariate analysis further identified a strong correlation of uridine 5'diphospho-glucuronosyltransferase 1A positivity with reduced cancer-specific mortality (hazard ratio 0.28, P = 0.018). Meanwhile, uridine 5'diphospho-glucuronosyltransferase 1A knockdown in urothelial cancer cells resulted in significant increases in their viability and migration. CONCLUSIONS: These results suggest a preventive role of uridine 5'diphospho-glucuronosyltransferase 1A signals in the development and progression of upper urinary tract urothelial carcinoma. Loss of uridine 5'diphospho-glucuronosyltransferase 1A expression might serve as an independent predictor of poor prognosis in patients with upper urinary tract urothelial carcinoma. CI - (c) 2018 The Japanese Urological Association. FAU - Izumi, Koji AU - Izumi K AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. AD - Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Inoue, Satoshi AU - Inoue S AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Ide, Hiroki AU - Ide H AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Mizushima, Taichi AU - Mizushima T AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Jiang, Guiyang AU - Jiang G AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA. FAU - Yamaguchi, Seiji AU - Yamaguchi S AD - Department of Urology, Osaka General Medical Center, Osaka, Japan. FAU - Fushimi, Hiroaki AU - Fushimi H AD - Department of Pathology, Osaka General Medical Center, Osaka, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. AD - James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA. AD - Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. AD - Department of Urology, University of Rochester Medical Center, Rochester, New York, USA. LA - eng PT - Journal Article DEP - 20180214 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (Biomarkers, Tumor) RN - EC 2.4.1.17 (Glucuronosyltransferase) RN - 0 (RNA, Small Interfering) RN - EC 2.4.1.17 (UGT1A1 Enzyme) SB - IM MH - Aged MH - Biomarkers, Tumor/metabolism MH - Carcinoma/*enzymology/pathology MH - Cell Line, Tumor MH - Cell Movement MH - Cell Proliferation MH - Female MH - *Gene Expression Regulation, Enzymologic MH - Glucuronosyltransferase/*metabolism MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Prognosis MH - Proportional Hazards Models MH - RNA, Small Interfering/genetics MH - Urologic Neoplasms/*enzymology/pathology MH - Urothelium/*pathology MH - UGT1A1 Enzyme OTO - NOTNLM OT - immunohistochemistry OT - prognosis OT - upper urinary tract urothelial carcinoma OT - uridine 5'diphospho-glucuronosyltransferase EDAT- 2018/02/15 06:00 MHDA- 2019/05/17 06:00 CRDT- 2018/02/15 06:00 PHST- 2017/05/29 00:00 [received] PHST- 2017/12/25 00:00 [accepted] PHST- 2018/02/15 06:00 [pubmed] PHST- 2019/05/17 06:00 [medline] PHST- 2018/02/15 06:00 [entrez] AID - 10.1111/iju.13528 [doi] PST - ppublish SO - Int J Urol. 2018 May;25(5):429-435. doi: 10.1111/iju.13528. Epub 2018 Feb 14. PMID- 29435873 OWN - NLM STAT- MEDLINE DCOM- 20180917 LR - 20220317 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 23 IP - 4 DP - 2018 Aug TI - Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma. PG - 726-733 LID - 10.1007/s10147-018-1248-9 [doi] AB - BACKGROUND: Oncologic benefits of laparoscopic radical nephroureterectomy (LNU) are unclear. We aimed to evaluate the impact of surgical approach for radical nephroureterectomy on oncologic outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC). METHODS: Of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017, we retrospectively investigated oncological outcomes in 229 with locally advanced UTUC (stages cT3-4 and/or cN+). The surgical approach was classified as open nephroureterectomy (ONU) or LNU, and oncologic outcomes, including intravesical recurrence-free survival (RFS), visceral RFS, cancer-specific survival (CSS), and overall survival (OS), were compared between the groups. The inverse probability of treatment weighting (IPTW)-adjusted Cox-regression analyses was performed to evaluate the impact of LNU on the prognosis. RESULTS: Of the 229 patients, 48 (21%) underwent LNU. There were significant differences in patient backgrounds, including preoperative renal function, lymph-node involvement, lymphovascular invasion, and surgical margins, between the groups. Before the background adjustment, intravesical RFS, visceral RFS, CSS, and OS were significantly inferior in the ONU group than in the LNU group. However, in the IPTW-adjusted Cox-regression analysis, no significant differences were observed in intravesical RFS (hazard ratio [HR], 0.65; P = 0.476), visceral RFS (HR, 0.46; P = 0.109), CSS (HR, 0.48; P = 0.233), and OS (HR, 0.40; P = 0.147). CONCLUSION: Surgical approaches were not independently associated with prognosis in patients with locally advanced UTUC. FAU - Kido, Koichi AU - Kido K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AUID- ORCID: 0000-0002-0026-4079 AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. shingoh@hirosaki-u.ac.jp. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Koie, Takuya AU - Koie T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Iwabuchi, Ikuya AU - Iwabuchi I AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. FAU - Ogasawara, Masaru AU - Ogasawara M AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. FAU - Kawaguchi, Toshiaki AU - Kawaguchi T AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. LA - eng GR - 15H02563/Japan Society for the Promotion of Science/ GR - 15K15579/Japan Society for the Promotion of Science/ GR - 17K11118/Japan Society for the Promotion of Science/ GR - 17K11119/Japan Society for the Promotion of Science/ GR - 17K16768/Japan Society for the Promotion of Science/ GR - 17K16770/Japan Society for the Promotion of Science/ GR - 17K16771/Japan Society for the Promotion of Science/ PT - Journal Article PT - Multicenter Study DEP - 20180212 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Aged MH - Female MH - Humans MH - Laparoscopy/*mortality MH - Male MH - Neoplasm Staging MH - Nephroureterectomy/*mortality MH - Retrospective Studies MH - Treatment Outcome MH - Urologic Neoplasms/pathology/*surgery OTO - NOTNLM OT - Laparoscopic OT - Oncologic outcome OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2018/02/13 06:00 MHDA- 2018/09/18 06:00 CRDT- 2018/02/14 06:00 PHST- 2017/10/21 00:00 [received] PHST- 2018/02/06 00:00 [accepted] PHST- 2018/02/13 06:00 [pubmed] PHST- 2018/09/18 06:00 [medline] PHST- 2018/02/14 06:00 [entrez] AID - 10.1007/s10147-018-1248-9 [pii] AID - 10.1007/s10147-018-1248-9 [doi] PST - ppublish SO - Int J Clin Oncol. 2018 Aug;23(4):726-733. doi: 10.1007/s10147-018-1248-9. Epub 2018 Feb 12. PMID- 29430510 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 4 IP - 1 DP - 2018 Jan 20 TI - Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. PG - 91-112 LID - 10.3233/BLC-170147 [doi] AB - BACKGROUND: Urologists are frequently confronted with questions of urinary bladder cancer (UBC) patients about what they can do to improve their prognosis. Unfortunately, it is largely unknown which lifestyle factors can influence prognosis. OBJECTIVE: To systematically review the available evidence on the association between body mass index (BMI), diet, dietary supplements, and physical activity and UBC prognosis. METHODS: We searched PubMed and Embase up to May 2017. We included thirty-one articles reporting on observational and randomized controlled trials investigating BMI, diet and dietary supplements in relation to recurrence, progression, cancer-specific or all-cause mortality in UBC patients. RESULTS: In non-muscle invasive bladder cancer (NMIBC) patients, both overweight (3 studies, pooled hazard ratio (HR) 1.29, 95% CI 1.05-1.58, I(2) = 0%) as well as obesity (3 studies, pooled HR 1.82, 95% CI 1.12-2.95, I(2) = 79%) were associated with increased risk of recurrence when compared to normal weight. No association of BMI with risk of progression was found. Results for BMI and prognosis in muscle-invasive or in all stages series were inconsistent. Observational studies on diet and randomized controlled trials with dietary supplements showed inconsistent results. No studies on physical activity and UBC prognosis have been published to date. CONCLUSIONS: Evidence for an association of lifestyle factors with UBC prognosis is limited, with some evidence for an association of BMI with risk of recurrence in NMIBC. Well-designed, prospective studies are needed to develop evidence-based guidelines on this topic. FAU - Westhoff, Ellen AU - Westhoff E AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Fleshner, Neil E AU - Fleshner NE AD - Department of Surgery, Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. AD - Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. AD - Karl Landsteiner University, Krems an der Donau, Austria. FAU - Steineck, Gunnar AU - Steineck G AD - Department of Oncology, Division of Clinical Cancer Epidemiology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. AD - Department of Oncology and Pathology, Division of Clinical Cancer Epidemiology, Karolinska Institutet, Stockholm, Sweden. FAU - Kampman, Ellen AU - Kampman E AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Vrieling, Alina AU - Vrieling A AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20180120 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC5798521 OTO - NOTNLM OT - Body mass index OT - diet OT - dietary supplements OT - prognosis OT - urinary bladder cancer EDAT- 2018/02/13 06:00 MHDA- 2018/02/13 06:01 PMCR- 2018/02/05 CRDT- 2018/02/13 06:00 PHST- 2018/02/13 06:00 [entrez] PHST- 2018/02/13 06:00 [pubmed] PHST- 2018/02/13 06:01 [medline] PHST- 2018/02/05 00:00 [pmc-release] AID - BLC170147 [pii] AID - 10.3233/BLC-170147 [doi] PST - epublish SO - Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147. PMID- 29416811 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220314 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 2 DP - 2018 Jan 5 TI - Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients. PG - 2782-2796 LID - 10.18632/oncotarget.23451 [doi] AB - PURPOSE: Patients frequently undergo radical cystectomy and urinary diversion for treatment of bladder cancer. However, they remain at risk of urethral recurrence (UR). Studies have determined various risk factors leading to urethral recurrence. However, no publications have weighed the predictive values of these factors. MATERIALS AND METHODS: Studies published between 1971 and 2016 were retrieved from PubMed, EMBASE and MEDLINE. We used STATA software (Version 12.0) to estimate the pooled risk ratio. RESULTS: Twenty-five publications with 9498 patients were included. Overall, male patients, especially those with concomitant carcinoma in situ, superficial or intravesical bladder cancer, non-orthotopic diversion, prostatic involvement, bladder neck involvement, positive urethral margins or multifocal bladder cancer were at higher risk of urethral recurrence. The overall risks of recurrence, reported as risk ratios, varied widely. Among all 25 studies, 118 (60.2%) cases in 9 studies were diagnosed through routine follow-up. Another 82 (40.8%) patients in 11 studies first reported symptomatic abnormalities. Prognoses were worse for patients with symptomatic recurrence. Urethral cytology was the most common diagnostic method. Treatment after UR was reported for 272 cases in 14 publications, and 190 patients underwent urethrectomy and 52 underwent urethra-sparing treatments. Outcomes after UR were described in 12 studies reporting 180 cases, and 41 patients were alive through the end of follow-up and 65 patients died of bladder cancer. CONCLUSIONS: UR following radical cystectomy for bladder cancer was closely related to risk factors. Precautions, strict follow-up protocols and rational therapies were critical to patients with high risks of urethral recurrences. FAU - Li, Xinyuan AU - Li X AD - Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Wang, Wuwan AU - Wang W AD - Department of Cardiology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Zhu, Gongmin AU - Zhu G AD - Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - He, Weiyang AU - He W AD - Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Gou, Xin AU - Gou X AD - Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article DEP - 20171219 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5788679 OTO - NOTNLM OT - cystectomy OT - recurrence OT - risk factors OT - ureteral neoplasms OT - urinary bladder neoplasms COIS- CONFLICTS OF INTEREST None. EDAT- 2018/02/09 06:00 MHDA- 2018/02/09 06:01 PMCR- 2018/01/05 CRDT- 2018/02/09 06:00 PHST- 2017/05/18 00:00 [received] PHST- 2017/08/26 00:00 [accepted] PHST- 2018/02/09 06:00 [entrez] PHST- 2018/02/09 06:00 [pubmed] PHST- 2018/02/09 06:01 [medline] PHST- 2018/01/05 00:00 [pmc-release] AID - 23451 [pii] AID - 10.18632/oncotarget.23451 [doi] PST - epublish SO - Oncotarget. 2017 Dec 19;9(2):2782-2796. doi: 10.18632/oncotarget.23451. eCollection 2018 Jan 5. PMID- 29416608 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 9 IP - 1 DP - 2018 Jan 2 TI - Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. PG - 217-223 LID - 10.18632/oncotarget.18563 [doi] AB - The role of squamous differentiation in pT1 bladder tumors in the response to intravesical chemotherapy was unknown. We performed a retrospective analysis of 213 pT1 bladder urothelial carcinoma patients with squamous differentiation (group1), the remaining 213 pT1 pure urothelial carcinoma served as controls (group2). All cases were treated with transurethral resection of bladder tumor and subsequent intravesical chemotherapy. Within a five-year period, the tumor recurrence rate was 75.1% (160/213) in group 1 and 64.3% (137/213) in group 2. Tumor grade (HR = 2.926, P = 0.014), number of tumors (HR = 2.130, P = 0.038), tumor size (HR = 2.748, P = 0.031), and squamous differentiation (HR = 3.726, P = 0.019) were found to be important prognostic factors. Subgroup analysis for high grade tumors was performed, finding that group 1 had higher recurrence rate (50.3% vs 36.3%; for group 2). Progression was found in 32.2% (30/160) of group1 and 15.1% (11/137) of group2 (P = 0.011). Our data suggests that squamous differentiation is a predictor of poor response for intravesical chemotherapy, and that early radical cystectomy should be performed for high grade tumors, especially when dealing with recurrent cases. FAU - Li, Gang AU - Li G AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China. FAU - Hu, Jieping AU - Hu J AD - Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China. FAU - Niu, Yuanjie AU - Niu Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China. LA - eng PT - Journal Article DEP - 20170619 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5787459 OTO - NOTNLM OT - bladder cancer OT - intravesical chemotherapy OT - pT1 OT - squamous differentiation OT - urothelial carcinoma COIS- CONFLICTS OF INTEREST The authors declare that they have no competing interests. EDAT- 2018/02/09 06:00 MHDA- 2018/02/09 06:01 PMCR- 2018/01/02 CRDT- 2018/02/09 06:00 PHST- 2016/10/31 00:00 [received] PHST- 2017/06/02 00:00 [accepted] PHST- 2018/02/09 06:00 [entrez] PHST- 2018/02/09 06:00 [pubmed] PHST- 2018/02/09 06:01 [medline] PHST- 2018/01/02 00:00 [pmc-release] AID - 18563 [pii] AID - 10.18632/oncotarget.18563 [doi] PST - epublish SO - Oncotarget. 2017 Jun 19;9(1):217-223. doi: 10.18632/oncotarget.18563. eCollection 2018 Jan 2. PMID- 29410884 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 70 IP - 4 DP - 2017 TI - Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor. PG - 349-355 LID - 10.5173/ceju.2017.1357 [doi] AB - INTRODUCTION: It has been shown that CD47 is an important diagnostic and prognostic marker in many cancer types. However, the relationship between CD47 and bladder tumor stage has not been shown in previous studies. To the best of our knowledge, this is the first study investigating the association of CD47 with stages of bladder cancer. MATERIAL AND METHODS: Surgical specimens of 175 patients were included in the study. The CD47 staining assessment was performed in the following categories; none, focal, moderate and diffuse. The statistics of the study were tested using t-test and analysis of variance. RESULTS: We demonstrated much less CD47 staining extent in Ta tumor pathology compared to T1 and T1+T2+T3+T4 tumor pathology (p = 0.034 and p = 0.016, respectively). We also showed that the average value of CD47 staining extent with CIS+ was significantly higher compared to CIS- among NMIBC (p = 0.0248). However, no significant differences in CD47 staining pattern were observed in the following study groups: high vs. low-grade tumors in non-muscle invasive bladder cancer (NMIBC); MIBC (T2-T4) vs. NMIBC; lymph node involvement (N1-N3) vs. non-lymph node involvement (N0) in MIBC (T2-T4). CONCLUSIONS: Our study demonstrated that CD47 might have a critical role in the progression of Ta to T1 stage. Furthermore, we showed that CD47 is highly expressed in CIS+ NMIBC compared to CIS- NMIBC. Thus, differentiating stages with the help of this new potential marker may help clinicians treat bladder tumors better. Future studies to determine the role of CD47 on pathophysiology, diagnosis and prognosis of bladder tumor are warranted. FAU - Olcucuoglu, Erkan AU - Olcucuoglu E AD - Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Urology, Ankara, Turkey. FAU - Sirin, Mehmet Emin AU - Sirin ME AD - Ahi Evran University, Education and Research Hospital, Department of Urology, Kirsehir, Turkey. FAU - Aydog, Gulden AU - Aydog G AD - Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Pathology, Ankara, Turkey. FAU - Gazel, Eymen AU - Gazel E AD - Konya Education and Research Hospital, Department of Urology, Konya, Turkey. FAU - Tastemur, Sedat AU - Tastemur S AD - Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Urology, Ankara, Turkey. FAU - Odabas, Oner AU - Odabas O AD - Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Urology, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20171016 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC5791396 OTO - NOTNLM OT - CD47 OT - bladder tumor OT - immunohistochemical stain EDAT- 2018/02/08 06:00 MHDA- 2018/02/08 06:01 PMCR- 2017/01/01 CRDT- 2018/02/08 06:00 PHST- 2017/03/29 00:00 [received] PHST- 2017/09/25 00:00 [revised] PHST- 2017/09/26 00:00 [accepted] PHST- 2018/02/08 06:00 [entrez] PHST- 2018/02/08 06:00 [pubmed] PHST- 2018/02/08 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - 1357 [pii] AID - 10.5173/ceju.2017.1357 [doi] PST - ppublish SO - Cent European J Urol. 2017;70(4):349-355. doi: 10.5173/ceju.2017.1357. Epub 2017 Oct 16. PMID- 29405907 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 12 IP - 5 DP - 2018 May TI - Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. PG - E210-E218 LID - 10.5489/cuaj.4922 [doi] AB - INTRODUCTION: Urinary biomarkers are being developed to detect bladder cancer recurrence/progression in patients with non-muscle-invasive bladder cancer (NMIBC). We conducted a questionnaire-based study to determine what diagnostic accuracy and cost would such test(s) need for both patients and urologic oncologists to comfortably forgo surveillance cystoscopy in favour of these tests. METHODS: Surveys were administered to NMIBC patients at followup cystoscopy visit and to physician members of the Society of Urologic Oncology. Participants were questioned about acceptable false-negative (FN) rates and costs for such alternatives, in addition to demographics that could influence chosen error rates and costs. RESULTS: A total of 137 patient and 51 urologic oncologist responses were obtained. Seventy-seven percent of patients were not comfortable with urinary biomarker(s) alternatives to repeat cystoscopy, with a further 14% willing to accept such alternatives only if the FN rate were 0.5% or lower. Seventy-five percent of urologic oncologists were comfortable with an alternative urinary biomarker test(s), with 37% and 33% willing to accept FN rates of 5% and 1%, respectively. Forty-seven percent of patients were not willing to pay out-of-pocket for such tests, while 61% of urologic oncologists felt that a price range of $100-500 would be reasonable. CONCLUSIONS: This is the first survey evaluating patient and urologic oncologist perspectives on acceptable error rates and costs for urinary biomarker alternatives to surveillance cystoscopy for patients with NMIBC. Despite potential responder bias, this study suggests that urinary biomarker(s) will require sensitivity equivalent to that of cystoscopy in order to completely replace it in surveillance of patients with NMIBC. FAU - Sayyid, Rashid K AU - Sayyid RK AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. AD - Augusta University Medical Centre, Augusta, GA, United States. FAU - Sayyid, Abdallah K AU - Sayyid AK AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Klaassen, Zachary AU - Klaassen Z AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Hersey, Karen AU - Hersey K AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Goldberg, Hanan AU - Goldberg H AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Perlis, Nathan AU - Perlis N AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Ahmad, Ardalanejaz AU - Ahmad A AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Leao, Ricardo AU - Leao R AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Chandrasekar, Thenappan AU - Chandrasekar T AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Fadaak, Kamel AU - Fadaak K AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Madi, Rabii AU - Madi R AD - Augusta University Medical Centre, Augusta, GA, United States. FAU - Terris, Martha K AU - Terris MK AD - Augusta University Medical Centre, Augusta, GA, United States. FAU - Finelli, Antonio AU - Finelli A AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Hamilton, Robert J AU - Hamilton RJ AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Fleshner, Neil E AU - Fleshner NE AD - Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20180206 PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC5966932 COIS- Competing interests: Dr. Finelli has attended advisory boards for Amgen, Astellas, and Janssen; and has received honoraria from AbbVie, AstraZeneca, and Ferring. Dr. Hamilton has attended advisory boards for AbbVie, Astellas, Bayer, and Janssen. Dr. Kulkarni has attended advisory boards for Amgen, Astellas, Bayer, Ferring, and Janssen; and has received educational grants from AbbVie and Sanofi. Dr. Zlotta has been an advisor for Ferring, LLC, Sanofi, and 3DBiopsy. Dr. Fleshner has attended advisory boards for AbbVie, Amgen, Astellas, Bayer, Ferring, Janssen, and Sanofi; has received grants from AbbVie, Amgen, Astellas, Bayer, the Canadian Cancer Research Institute, Ferring, Hybridyne Imaging Technologies, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Medivation, Nucleix, Progenics, Sanofi, and Spectracure AB. The remaining authors report no competing personal or financial interests. EDAT- 2018/02/07 06:00 MHDA- 2018/02/07 06:01 PMCR- 2018/05/01 CRDT- 2018/02/07 06:00 PHST- 2018/02/07 06:00 [pubmed] PHST- 2018/02/07 06:01 [medline] PHST- 2018/02/07 06:00 [entrez] PHST- 2018/05/01 00:00 [pmc-release] AID - cuaj.4922 [pii] AID - cuaj-5-e210 [pii] AID - 10.5489/cuaj.4922 [doi] PST - ppublish SO - Can Urol Assoc J. 2018 May;12(5):E210-E218. doi: 10.5489/cuaj.4922. Epub 2018 Feb 6. PMID- 29393701 OWN - NLM STAT- MEDLINE DCOM- 20180323 LR - 20180323 IS - 1532-4192 (Electronic) IS - 0735-7907 (Linking) VI - 36 IP - 2 DP - 2018 Feb 7 TI - Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ. PG - 152-157 LID - 10.1080/07357907.2018.1430815 [doi] AB - There are few data on Bacillus Calmette-Guerin (BCG) therapy for upper urinary tract carcinoma in situ (UUT CIS). We retrospectively evaluated the efficacy and tolerability of BCG therapy for 41 patients [52 renal units(RUs)] with UUT CIS. Of 52 RUs, complete response was achieved in 47 (90%). The 5-year recurrence-, progression-free survival rates were 60.2% and 74.2%, respectively. Adverse events were observed in 31 (76%) patients, but most of them were mild. The scheduled instillations were completed in 31 (74%) of 42 patients. Our results demonstrated that BCG therapy for UUT CIS was satisfactory with high efficacy and tolerability. FAU - Tomisaki, Ikko AU - Tomisaki I AD - a Department of Urology , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan. FAU - Kubo, Tatsuhiko AU - Kubo T AD - b Department of Public Health , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan. FAU - Minato, Akinori AU - Minato A AD - a Department of Urology , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan. FAU - Fujimoto, Naohiro AU - Fujimoto N AD - a Department of Urology , University of Occupational and Environmental Health , 1-1 Iseigaoka Yahatanishi-ku Kitakyushu City Fukuoka , Japan. LA - eng PT - Journal Article DEP - 20180202 PL - England TA - Cancer Invest JT - Cancer investigation JID - 8307154 RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*drug therapy/mortality/pathology MH - Female MH - Humans MH - Male MH - Maximum Tolerated Dose MH - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology OTO - NOTNLM OT - BCG OT - Carcinoma in situ OT - Upper urinary tract OT - Urothelial neoplasm EDAT- 2018/02/03 06:00 MHDA- 2018/03/24 06:00 CRDT- 2018/02/03 06:00 PHST- 2018/02/03 06:00 [pubmed] PHST- 2018/03/24 06:00 [medline] PHST- 2018/02/03 06:00 [entrez] AID - 10.1080/07357907.2018.1430815 [doi] PST - ppublish SO - Cancer Invest. 2018 Feb 7;36(2):152-157. doi: 10.1080/07357907.2018.1430815. Epub 2018 Feb 2. PMID- 29387931 OWN - NLM STAT- MEDLINE DCOM- 20190308 LR - 20190308 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 36 IP - 6 DP - 2018 Jun TI - Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation. PG - 889-895 LID - 10.1007/s00345-018-2196-8 [doi] AB - PURPOSE: Single immediate intravesical instillation of chemotherapy after transurethral resection of bladder tumor (TURBT) has been the gold standard treatment for patients with low- and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Herein, we conducted a multicenter prospective randomized controlled trial in Japan, comparing recurrence-free survival between single and two-time instillation of pirarubicin (THP) for solitary NMIBC. METHODS: Between 2005 and 2009, 257 patients with solitary NMIBC were enrolled and randomized to single instillation of THP (30 mg/50 mL) immediately after TURBT (Group A) or two-time instillation of THP immediately after and 1 day after TURBT (Group B). The primary endpoint was recurrence-free survival. Secondary endpoints included rates of recurrence and adverse effects, including hematuria, micturition pain, difficult urination, pollakiuria, systemic symptoms, and other complications. This study was registered as UMIN C000000266. RESULTS: Of 257 patients, 99 in Group A and 102 in Group B could be evaluated for recurrence. Median follow-up was 71 months. The overall recurrence rate was 39 and 31%, respectively (p = 0.2704). Although the 5-year recurrence-free survival rates were 55.9% and 67.7% in groups A and B, respectively, the difference between groups was not significant (p = 0.2031). No significant differences in adverse effects were observed between groups, except for pollakiuria (7 vs 22%, p = 0.0031). Multivariate analyses did not show that the treatment group was a significant risk factor for bladder cancer recurrence. CONCLUSIONS: Postoperative two-time intravesical instillation of THP was not superior to single immediate instillation for preventing recurrence after complete resection of a solitary NMIBC. FAU - Tanimoto, Ryuta AU - Tanimoto R AD - Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama, Okayama, 700-8558, Japan. tanimo10@gmail.com. FAU - Saika, Takashi AU - Saika T AD - Department of Urology, Hiroshima City Hospital, Hiroshima, Hiroshima, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Ebara, Shin AU - Ebara S AD - Department of Urology, Hiroshima City Hospital, Hiroshima, Hiroshima, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Kobayashi, Yasuyuki AU - Kobayashi Y AD - Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama, Okayama, 700-8558, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Nasu, Ryoji AU - Nasu R AD - Department of Urology, Kochi Health Science Center, Kochi, Kochi, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Yamada, Daisuke AU - Yamada D AD - Department of Urology, Mitoyo General Hospital, Kanonji, Kagawa, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Takamoto, Hitoshi AU - Takamoto H AD - Department of Urology, Kurashiki Medical Center, Kurashiki, Okayama, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Miyaji, Yoshiyuki AU - Miyaji Y AD - Department of Urology, Iwakuni Clinical Center, Iwakuni, Yamaguchi, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Nasu, Yasutomo AU - Nasu Y AD - Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama, Okayama, 700-8558, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Tsushima, Tomoyasu AU - Tsushima T AD - Department of Urology, Okayama Medical Center, Oskayama, Okayama, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. FAU - Kumon, Hiromi AU - Kumon H AD - Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama, Okayama, 700-8558, Japan. AD - Okayama Urological Research Group (OURG), Okayama, Okayama, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20180131 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Analysis of Variance MH - Antineoplastic Agents/*administration & dosage MH - Disease-Free Survival MH - Doxorubicin/administration & dosage/*analogs & derivatives MH - Drug Administration Schedule MH - Female MH - Humans MH - Japan MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Postoperative Care/methods MH - Prospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/epidemiology/pathology/surgery OTO - NOTNLM OT - Intravesical chemotherapy OT - Non muscle invasive bladder cancer OT - Pirarubicin OT - Randomized controlled trial OT - Recurrence free survival EDAT- 2018/02/02 06:00 MHDA- 2019/03/09 06:00 CRDT- 2018/02/02 06:00 PHST- 2017/09/23 00:00 [received] PHST- 2018/01/19 00:00 [accepted] PHST- 2018/02/02 06:00 [pubmed] PHST- 2019/03/09 06:00 [medline] PHST- 2018/02/02 06:00 [entrez] AID - 10.1007/s00345-018-2196-8 [pii] AID - 10.1007/s00345-018-2196-8 [doi] PST - ppublish SO - World J Urol. 2018 Jun;36(6):889-895. doi: 10.1007/s00345-018-2196-8. Epub 2018 Jan 31. PMID- 29367430 OWN - NLM STAT- MEDLINE DCOM- 20190927 LR - 20190927 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 24 IP - 7 DP - 2018 Apr 1 TI - Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. PG - 1586-1593 LID - 10.1158/1078-0432.CCR-17-2719 [doi] AB - Purpose: The European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC) recommend risk stratification based on clinicopathologic parameters. Our aim was to investigate the added value of biomarkers to improve risk stratification of NMIBC.Experimental Design: We prospectively included 1,239 patients in follow-up for NMIBC in six European countries. Fresh-frozen tumor samples were analyzed for GATA2, TBX2, TBX3, and ZIC4 methylation and FGFR3, TERT, PIK3CA, and RAS mutation status. Cox regression analyses identified markers that were significantly associated with progression to muscle-invasive disease. The progression incidence rate (PIR = rate of progression per 100 patient-years) was calculated for subgroups.Results: In our cohort, 276 patients had a low, 273 an intermediate, and 555 a high risk of tumor progression based on the EAU NMIBC guideline. Fifty-seven patients (4.6%) progressed to muscle-invasive disease. The limited number of progressors in this large cohort compared with older studies is likely due to improved treatment in the past two decades. Overall, wild-type FGFR3 and methylation of GATA2 and TBX3 were significantly associated with progression (HR = 0.34, 2.53, and 2.64, respectively). The PIR for EAU high-risk patients was 4.25. On the basis of FGFR3 mutation status and methylation of GATA2, this cohort could be reclassified into a good class (PIR = 0.86, 26.2% of patients), a moderate class (PIR = 4.32, 49.7%), and a poor class (PIR = 7.66, 24.0%).Conclusions: We conclude that the addition of selected biomarkers to the EAU risk stratification increases its accuracy and identifies a subset of NMIBC patients with a very high risk of progression. Clin Cancer Res; 24(7); 1586-93. (c)2018 AACR. CI - (c)2018 American Association for Cancer Research. FAU - van Kessel, Kim E M AU - van Kessel KEM AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - van der Keur, Kirstin A AU - van der Keur KA AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Algaba, Ferran AU - Algaba F AD - Section of Pathology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Welvaart, Naeromy Y C AU - Welvaart NYC AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Beukers, Willemien AU - Beukers W AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Keck, Bastian AU - Keck B AD - Department of Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Maurer, Tobias AU - Maurer T AD - Department of Urology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany. FAU - Simic, Tatjana AU - Simic T AD - Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Horstmann, Marcus AU - Horstmann M AD - Department of Urology, Friedrich-Schiller-University Jena, Jena, Germany. FAU - Grimm, Marc-Oliver AU - Grimm MO AD - Department of Urology, Friedrich-Schiller-University Jena, Jena, Germany. FAU - Hermann, Gregers G AU - Hermann GG AD - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. FAU - Mogensen, Karin AU - Mogensen K AD - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nurnberg, Erlangen, Germany. FAU - Harving, Niels AU - Harving N AD - Department of Urology, Aalborg University Hospital, Aalborg, Denmark. FAU - Petersen, Astrid C AU - Petersen AC AD - Department of Pathology, Aalborg University Hospital, Aalborg, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Junker, Kerstin AU - Junker K AD - Department of Urology, Saarland University, Homburg, Germany. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Real, Francisco X AU - Real FX AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, CIBERONC, Spain. AD - Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, CIBERONC, Spain. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Orntoft, Torben F AU - Orntoft TF AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, the Netherlands. e.zwarthoff@erasmusmc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180124 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Biomarkers, Tumor) RN - 0 (GATA2 Transcription Factor) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM CIN - Nat Rev Urol. 2018 Mar;15(3):138. doi: 10.1038/nrurol.2018.13. PMID: 29405205 CIN - Transl Androl Urol. 2018 Aug;7(4):736-739. doi: 10.21037/tau.2018.07.11. PMID: 30211064 CIN - Transl Androl Urol. 2018 Dec;7(Suppl 6):S753-S755. doi: 10.21037/tau.2018.08.10. PMID: 30687617 MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/*metabolism MH - Disease Progression MH - Europe MH - Female MH - GATA2 Transcription Factor/genetics/metabolism MH - Humans MH - Male MH - Middle Aged MH - Mutation/genetics MH - Neoplasm Invasiveness/genetics/*pathology MH - Prospective Studies MH - Receptor, Fibroblast Growth Factor, Type 3/genetics/metabolism MH - Risk Factors MH - Urinary Bladder Neoplasms/genetics/*metabolism/*pathology MH - Urology/methods MH - Young Adult EDAT- 2018/01/26 06:00 MHDA- 2019/09/29 06:00 CRDT- 2018/01/26 06:00 PHST- 2017/09/18 00:00 [received] PHST- 2017/11/14 00:00 [revised] PHST- 2018/01/08 00:00 [accepted] PHST- 2018/01/26 06:00 [pubmed] PHST- 2019/09/29 06:00 [medline] PHST- 2018/01/26 06:00 [entrez] AID - 1078-0432.CCR-17-2719 [pii] AID - 10.1158/1078-0432.CCR-17-2719 [doi] PST - ppublish SO - Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24. PMID- 29366633 OWN - NLM STAT- MEDLINE DCOM- 20190204 LR - 20220330 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 3 DP - 2018 Jun TI - Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non-Muscle-Invasive Bladder Cancer. PG - e655-e661 LID - S1558-7673(18)30001-6 [pii] LID - 10.1016/j.clgc.2017.12.013 [doi] AB - PURPOSE: To investigate the relationship between albumin-to-globulin ratio (AGR) and oncologic outcomes in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We identified 364 patients with primary NMIBC who underwent transurethral surgery between 2000 and 2015. The association between pretreatment AGR and clinicopathologic variables, including oncologic outcomes, was statistically evaluated. RESULTS: One hundred twenty patients (33.0%) experienced at least one tumor recurrence, and 23 (6.3%) developed muscle-invasive disease. The median (interquartile range) pretreatment AGR was 1.73 (1.53-1.89). The Kaplan-Meier curve revealed that tumor recurrence was strongly predicted in patients with pretreatment AGR < 1.6, and similar results were observed for disease progression (P < .01 and P < .01, respectively). On multivariate analysis, we found that pretreatment AGR < 1.6 is an independent risk factor for tumor recurrence (hazard ratio, 0.53; P < .01). On univariate analysis, pretreatment AGR < 1.6 was also associated with disease progression (hazard ratio, 0.24; P < .01). CONCLUSION: Low pretreatment AGR is an independent risk factor for tumor recurrence and is one risk factor for disease progression in NMIBC patients. This inexpensive and easily accessible biomarker may become useful in selecting patients with NMIBC with higher risk of recurrence and progression. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: ashandjesus@gmail.com. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ide, Hiroki AU - Ide H AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan; Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Nagata, Hirohiko AU - Nagata H AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20180104 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Serum Globulins) RN - ZIF514RVZR (Serum Albumin, Human) SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/blood/*surgery MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - Serum Albumin, Human/*analysis MH - Serum Globulins/*analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/blood/*therapy MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Biomarker OT - Inflammation OT - Progression OT - Recurrence OT - Urothelial carcinoma EDAT- 2018/01/26 06:00 MHDA- 2019/02/05 06:00 CRDT- 2018/01/26 06:00 PHST- 2017/11/22 00:00 [received] PHST- 2017/12/26 00:00 [revised] PHST- 2017/12/29 00:00 [accepted] PHST- 2018/01/26 06:00 [pubmed] PHST- 2019/02/05 06:00 [medline] PHST- 2018/01/26 06:00 [entrez] AID - S1558-7673(18)30001-6 [pii] AID - 10.1016/j.clgc.2017.12.013 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Jun;16(3):e655-e661. doi: 10.1016/j.clgc.2017.12.013. Epub 2018 Jan 4. PMID- 29362915 OWN - NLM STAT- MEDLINE DCOM- 20180321 LR - 20260127 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 144 IP - 4 DP - 2018 Apr TI - Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. PG - 637-644 LID - 10.1007/s00432-018-2593-9 [doi] AB - PURPOSE: The identification of factors predicting the outcome of stage T1 high-grade bladder cancer (BC) is a major clinical issue. METHODS: We performed immunohistochemistry to assess the role of human epidermal growth factor receptor-2 (HER-2) and microsatellite instability (MSI) factors MutL homologue 1 (MLH1) and MutS homologue 2 (MSH2) in predicting recurrence and progression of T1 high-grade BCs having undergone transurethral resection of bladder tumor (TURBT) alone or TURBT + intravesical instillations of bacillus Calmette-Guerin (BCG). RESULTS: HER-2 overexpression was a significant predictor of disease-free survival (DFS) in the overall as well as in the two patients' population; as for progression-free survival (PFS), it was significant in the overall but not in the two patients' population. MLH1 was an independent predictor of PFS only in patients treated with BCG and MSH2 failed to predict DFS and PFS in all populations. Most importantly, the higher the number of altered markers the lowers the DFS and PFS. In multivariate Cox proportional-hazards regression analysis, the number of altered molecular markers and BCG treatment were significant predictors (p = 0.0004 and 0.0283, respectively) of DFS, whereas the number of altered molecular markers was the only significant predictor (p = 0.0054) of PFS. CONCLUSIONS: Altered expression of the proto-oncogene HER-2 and the two molecular markers of genetic instability MLH1 and MSH2 predicted T1 high-grade BC outcome with the higher the number of altered markers the lower the DFS and PFS. These findings provide grounds for further testing them in predicting the outcome of this challenging disease. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Cormio, Antonella AU - Cormio A AD - Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Via E. Orabona 4, 70124, Bari, BA, Italy. FAU - Massenio, Paolo AU - Massenio P AD - Department of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Pedicillo, Maria C AU - Pedicillo MC AD - Department of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Cagiano, Simona AU - Cagiano S AD - Department of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Fortunato, Francesca AU - Fortunato F AD - Department of Epidemiology and Public Health, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Calo, Beppe AU - Calo B AD - Department of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Di Fino, Giuseppe AU - Di Fino G AD - Department of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Bufo, Pantaleo AU - Bufo P AD - Department of Pathology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology, University of Foggia, Viale L. Pinto 1, 71122, Foggia, FG, Italy. luigicormio@libero.it. LA - eng PT - Journal Article DEP - 20180123 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (BCG Vaccine) RN - EC 3.6.1.3 (MutL Protein Homolog 1) RN - EC 3.6.1.3 (MutS Homolog 2 Protein) RN - 0 (Proto-Oncogene Mas) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (MAS1 protein, human) RN - 0 (MLH1 protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 3.6.1.3 (MSH2 protein, human) SB - IM MH - Age Factors MH - Aged MH - BCG Vaccine/therapeutic use MH - Female MH - Humans MH - Male MH - MutL Protein Homolog 1/*biosynthesis/genetics MH - MutS Homolog 2 Protein/*biosynthesis/genetics MH - Neoplasm Grading MH - Prognosis MH - Proto-Oncogene Mas MH - Erb-b2 Receptor Tyrosine Kinases/*biosynthesis/genetics MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*genetics/*metabolism/pathology/therapy PMC - PMC11813396 OTO - NOTNLM OT - HER-2 OT - Immunohistochemistry OT - MLH1 OT - MSH2 OT - Non-muscle-invasive bladder cancer OT - Prognosis COIS- Francesca Sanguedolce declares that she has no conflict of interest. Antonella Cormio declares that she has no conflict of interest. Paolo Massenio declares that he has no conflict of interest. Maria C. Pedicillo declares that she has no conflict of interest. Simona Cagiano declares that she has no conflict of interest. Francesca Fortunato declares that she has no conflict of interest. Beppe Calo declares that he has no conflict of interest. Giuseppe Di Fino declares that he has no conflict of interest. Giuseppe Carrieri declares that he has no conflict of interest. Pantaleo Bufo declares that he has no conflict of interest. Luigi Cormio declares that he has no conflict of interest. EDAT- 2018/01/25 06:00 MHDA- 2018/03/22 06:00 PMCR- 2018/01/23 CRDT- 2018/01/25 06:00 PHST- 2017/09/11 00:00 [received] PHST- 2018/01/19 00:00 [accepted] PHST- 2018/01/25 06:00 [pubmed] PHST- 2018/03/22 06:00 [medline] PHST- 2018/01/25 06:00 [entrez] PHST- 2018/01/23 00:00 [pmc-release] AID - 10.1007/s00432-018-2593-9 [pii] AID - 2593 [pii] AID - 10.1007/s00432-018-2593-9 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2018 Apr;144(4):637-644. doi: 10.1007/s00432-018-2593-9. Epub 2018 Jan 23. PMID- 29359984 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 18 IP - 3 DP - 2018 Mar TI - Current approaches for identifying high-risk non-muscle invasive bladder cancer. PG - 223-235 LID - 10.1080/14737140.2018.1432358 [doi] AB - Management of high risk non-muscle invasive bladder cancer (NMIBC) is challenging. It is vital to detect recurrences early and predict which tumors are likely to progress. Areas covered: This manuscript reviews the current approaches available for detection and surveillance of high risk NMIBCs. A literature review was utilized to evaluate risk factors for recurrence and progression as well as evaluating approaches including pathological aspects of NMIBC, molecular subtyping, methods for tumor visualization, urine cytology, urinary molecular markers, molecular tissue markers as well as the scoring systems and nomograms. Expert commentary: Clinical and pathological factors are still the mainstay of prediction of recurrence and progression. However, genomic information such as molecular subtyping may improve understanding of prognosis. White light cystoscopy is still a dominant approach but enhanced cystoscopy is likely superior for detection of cancer especially carcinoma in situ. Urinary biomarkers are evolving; however, they are not ready to replace cystoscopy and trials are still necessary to determine optimal clinical utility. Prognostic scoring systems and nomograms are available for counseling the patients but there is room to improve predictive accuracy. FAU - Sanli, Oner AU - Sanli O AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. FAU - Lotan, Yair AU - Lotan Y AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. LA - eng PT - Journal Article PT - Review DEP - 20180131 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor MH - Carcinoma in Situ/*diagnosis/pathology MH - Cystoscopy/*methods MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/*diagnosis/pathology OTO - NOTNLM OT - Carcinoma in situ OT - HAL OT - bladder cancer OT - molecular subtypes OT - prognosis OT - progression EDAT- 2018/01/24 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/01/24 06:00 PHST- 2018/01/24 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/01/24 06:00 [entrez] AID - 10.1080/14737140.2018.1432358 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2018 Mar;18(3):223-235. doi: 10.1080/14737140.2018.1432358. Epub 2018 Jan 31. PMID- 29358573 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2157-9024 (Print) IS - 2157-9024 (Electronic) IS - 2157-9024 (Linking) VI - 7 IP - 1 DP - 2018 Jan 23 TI - Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. PG - 2 LID - 10.1038/s41389-017-0013-7 [doi] LID - 2 AB - Urothelial bladder cancer (UBC) is one of the most common lethal cancer worldwide and the 5-year survival rate has not improved significantly with current treatment protocols during the last decade. Intravesical immunotherapy with Bacillus Calmette-Guerin is currently the standard care for non-muscle invasive UBC. Recently, a subset of patients with locally advanced or metastatic UBC have responded to checkpoint blockade immunotherapy against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) or the cytotoxic T-lymphocyte antigen 4 that releases the inhibition of T cells, the remarkable clinical efficacy on UBC has brought total five checkpoint inhibitors approved by the FDA in the last 2 years, and this is revolutionizing treatment of advanced UBC. We discuss the rationale for immunotherapy in bladder cancer, progress with blocking the PD-1/PD-L1 pathway for UBC treatment, and ongoing clinical trials. We highlight the complexity of the interactions between cancer cells and the immune system, the genomic basis for response to checkpoint blockade immunotherapy, and potential biomarkers for predicting immunotherapeutic response. FAU - Cheng, Wen AU - Cheng W AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. Dr_chengwen@126.com. FAU - Fu, Dian AU - Fu D AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. FAU - Xu, Feng AU - Xu F AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. FAU - Zhang, Zhengyu AU - Zhang Z AD - Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. zhangzyph@yahoo.com.cn. LA - eng PT - Journal Article DEP - 20180123 PL - United States TA - Oncogenesis JT - Oncogenesis JID - 101580004 PMC - PMC5833720 COIS- CONFLICT OF INTEREST: The authors declare that they have no competing interests. ETHICAL APPROVAL: This article does not contain any studies with human participants or animals performed by any of the authors. EDAT- 2018/01/24 06:00 MHDA- 2018/01/24 06:01 PMCR- 2018/01/23 CRDT- 2018/01/24 06:00 PHST- 2017/04/26 00:00 [received] PHST- 2017/11/22 00:00 [accepted] PHST- 2018/01/24 06:00 [entrez] PHST- 2018/01/24 06:00 [pubmed] PHST- 2018/01/24 06:01 [medline] PHST- 2018/01/23 00:00 [pmc-release] AID - 10.1038/s41389-017-0013-7 [pii] AID - 13 [pii] AID - 10.1038/s41389-017-0013-7 [doi] PST - epublish SO - Oncogenesis. 2018 Jan 23;7(1):2. doi: 10.1038/s41389-017-0013-7. PMID- 29358570 OWN - NLM STAT- MEDLINE DCOM- 20180813 LR - 20220317 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 24 DP - 2018 Jan 23 TI - Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder. PG - 438-447 AB - BACKGROUND The aim of this study was to investigate the expression of long non-coding RNAs (lncRNA) cancer susceptibility candidate 2a (CASC2a) in patients with urothelial carcinoma of the bladder (UCB) and its predictive value in the recurrence of UCB after radical cystectomy (RC). MATERIAL AND METHODS Tumor and paired adjacent normal tissues were obtained from 112 patients with UCB who underwent RC in our hospital from March 2010 to March 2012. The expression of CASC2a was evaluated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). RESULTS CASC2a was down-regulated in UCB tissues, and was highly negatively correlated with the pT, pN, tumor size, and lymphovascular invasion (LVI). The sensitivities of CASC2a for diagnosing UCB and its recurrence after RC were 89.30% and 81.55%, respectively, and the specificities were 71.43% and 58.21%, respectively. Patients with a high expression of CASC2a had a higher 5-year recurrence-free survival rate than those with low expression of CASC2a. Kaplan-Meier survival analysis demonstrated that the pT, pN, tumor grade, tumor size, concomitant carcinoma in situ (CIS), LVI, soft tissue surgical margin (STSM), and CASC2a expression were related to the recurrence in patients undergoing RC for UCB. Cox proportional hazard model analysis showed that CASC2 expression, pT4, lymph node metastasis, and CIS were independent risk factors. CONCLUSIONS CASC2a was down-regulated in patients with UCB, and was associated with the risk of recurrence among patients undergoing RC, indicating that lncRNAs could act as predictive biomarkers and potential therapeutic targets in bladder cancer, including CASC2a. FAU - Li, Zhen AU - Li Z AD - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China (mainland). FAU - Wang, Kang-Er AU - Wang KE AD - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China (mainland). FAU - Zhou, Xie-Lai AU - Zhou XL AD - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China (mainland). FAU - Zhou, Jin AU - Zhou J AD - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China (mainland). FAU - Ye, Chun-Hua AU - Ye CH AD - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China (mainland). LA - eng PT - Journal Article DEP - 20180123 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) SB - IM MH - Biomarkers, Tumor/*metabolism MH - *Cystectomy MH - Female MH - Gene Expression Regulation, Neoplastic MH - *Genetic Predisposition to Disease MH - Humans MH - Kaplan-Meier Estimate MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Proportional Hazards Models MH - RNA, Long Noncoding/*genetics/metabolism MH - ROC Curve MH - Urinary Bladder Neoplasms/*genetics/pathology/*surgery MH - Urothelium/*pathology PMC - PMC5791421 COIS- Conflicts of interest The authors declare no conflict of interest. EDAT- 2018/01/24 06:00 MHDA- 2018/08/14 06:00 PMCR- 2018/01/23 CRDT- 2018/01/24 06:00 PHST- 2018/01/24 06:00 [entrez] PHST- 2018/01/24 06:00 [pubmed] PHST- 2018/08/14 06:00 [medline] PHST- 2018/01/23 00:00 [pmc-release] AID - 905393 [pii] AID - 10.12659/msm.905393 [doi] PST - epublish SO - Med Sci Monit. 2018 Jan 23;24:438-447. doi: 10.12659/msm.905393. PMID- 29354491 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 6 IP - 6 DP - 2017 Dec TI - Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. PG - 1043-1048 LID - 10.21037/tau.2017.10.04 [doi] AB - Bladder cancer (BC) is a common disease in both sexes and majority of cases present as non-muscle invasive BC (NMIBC). The percentage of NMIBC progressing to muscle invasive BC (MIBC) varies between 25% and 75% and currently there are no reliable biomarkers that may predict the outcome of high-risk (HR) NMIBC. Whilst The Cancer Genome Atlas (TCGA) project has identified genetic alteration in MIBC using next-generation sequencing (NGS), genetic data in HR-NMIBC outcome prediction using this new technology are limited. We reviewed data on NGS performed on DNA and RNA extracted from tissue, plasma and urinary samples obtained from patients with NMIBC. Analysis on different specimens revealed genetic alterations and microRNA alterations in common oncogenic pathways such as gene expression (TERT) and cell proliferation (PTEN, cyclin D). Validation of a 12-gene (CDC25B, KPNA2, BIRC5, COL18A1, MSN, UBE2C, COL4A1, FABP4, MBNL2, SKAP2, COL4A3BP, NEK1) progression score has shown significant association with progression. ARID1A mutations are associated with an increased risk of recurrence after Bacillus Calmette-Guerin (BCG) together with a high DNA damage repair (DDR) gene alterations in HR-NMIBC. Patients with progressive disease seem to have significantly higher levels of both plasma and urinary tumour DNA compared with patients with recurrence. Although experimental data appear promising, well-designed systematic studies are urgently needed to translate applicability to clinical practice. FAU - Pang, Karl H AU - Pang KH AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. AD - Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. FAU - Esperto, Francesco AU - Esperto F AD - Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. FAU - Noon, Aidan P AU - Noon AP AD - Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. CN - EAU Young Academic Urologists-Urothelial Cancer Working party LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC5760392 OTO - NOTNLM OT - Next-generation sequencing (NGS) OT - biomarker OT - non-muscle invasive bladder cancer (NMIBC) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2018/01/23 06:00 MHDA- 2018/01/23 06:01 PMCR- 2017/12/01 CRDT- 2018/01/23 06:00 PHST- 2018/01/23 06:00 [entrez] PHST- 2018/01/23 06:00 [pubmed] PHST- 2018/01/23 06:01 [medline] PHST- 2017/12/01 00:00 [pmc-release] AID - tau-06-06-1043 [pii] AID - 10.21037/tau.2017.10.04 [doi] PST - ppublish SO - Transl Androl Urol. 2017 Dec;6(6):1043-1048. doi: 10.21037/tau.2017.10.04. PMID- 29354488 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 6 IP - 6 DP - 2017 Dec TI - Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. PG - 1018-1026 LID - 10.21037/tau.2017.11.10 [doi] AB - BACKGROUND: The identification of protein biomarkers to guide treatment decisions regarding adjuvant therapies for high-risk non-muscle-invasive bladder cancer (NMIBC) has been of increasing interest. Evidence of the impact of tumor suppressor gene product p53 and cell proliferation marker Ki-67 on oncologic outcomes in bladder cancer patients at highest risk of recurrence and progression is partially contradictory. We sought to mirror contemporary expression patterns of p53 and Ki-67 in a select cohort of patients with pT1 bladder cancer. METHODS: Patients from four Northern German institutions with a primary diagnosis of pT1 bladder cancer between 2009 and 2016 and complete data regarding p53 or Ki-67 expression status were included for final analyses. Baseline patient characteristics (age, gender, age-adjusted Charlson comorbidity index) and tumor characteristics [diagnostic sequence, tumor focality, concomitant carcinoma in situ, 1973 World Health Organization (WHO) grading, lymphovascular invasion, adjuvant instillation therapy] were abstracted by retrospective chart review. Immunohistochemistry for detection of p53 and Ki-67 expression was performed according to standardized protocols. Microscopic analyses were performed by central pathologic review. First, we compared patients with positive vs. negative p53 expression and Ki-67 labeling index [>40% vs. 40%. Mean Ki-67 labeling index was higher in WHO grade 3 vs. grade 2 tumors (45.8 vs. 29.7; P=0.004). At a median follow-up of 51.0 months, 31/91 patients with complete follow-up information (34.1%) suffered from disease recurrence or progression. In univariable Kaplan-Meier analyses, no difference regarding DFS was found in p53 positive vs. negative (P=0.8) or Ki-67 labeling index >40% vs. 40% remained an independent predictor of DFS [hazard ratio (HR), 2.66; 95% confidence interval (CI), 1.02-6.95; P=0.046], after adjusting for p53 expression and lymphovascular invasion. However, p53 status was not associated with our endpoint (P=0.8). CONCLUSIONS: While we found an association of a Ki-67 labeling index >40% and shorter DFS in pT1 bladder cancer patients, this did not hold true for p53 positivity. Future research is needed to identify additional microscopic and molecular risk factors and biomarker panels to improve risk stratification and guide adjuvant therapies in those patients. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Roschinski, Julia AU - Roschinski J AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Gild, Philipp AU - Gild P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Marks, Phillip AU - Marks P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Doh, Ousman AU - Doh O AD - Department of Urology, Regio Medical Center Elmshorn, Elmshorn, Germany. FAU - Isbarn, Hendrik AU - Isbarn H AD - Department of Urology, Regio Medical Center Elmshorn, Elmshorn, Germany. FAU - Hoppner, Wolfgang AU - Hoppner W AD - Department of Urology, Itzehoe Medical Center, Itzehoe, Germany. FAU - Wagner, Walter AU - Wagner W AD - Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Brausi, Maurizio AU - Brausi M AD - Department of Urology, Azienda Unita Sanitaria Locale di Modena, Modena, Italy. FAU - Buscheck, Franziska AU - Buscheck F AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Sauter, Guido AU - Sauter G AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC5760387 OTO - NOTNLM OT - Adjuvants OT - biomarkers OT - disease progression OT - immunologic OT - recurrence OT - survival OT - urinary bladder neoplasms COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2018/01/23 06:00 MHDA- 2018/01/23 06:01 PMCR- 2017/12/01 CRDT- 2018/01/23 06:00 PHST- 2018/01/23 06:00 [entrez] PHST- 2018/01/23 06:00 [pubmed] PHST- 2018/01/23 06:01 [medline] PHST- 2017/12/01 00:00 [pmc-release] AID - tau-06-06-1018 [pii] AID - 10.21037/tau.2017.11.10 [doi] PST - ppublish SO - Transl Androl Urol. 2017 Dec;6(6):1018-1026. doi: 10.21037/tau.2017.11.10. PMID- 29343995 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 1179-299X (Print) IS - 1179-299X (Electronic) IS - 1179-299X (Linking) VI - 10 DP - 2018 TI - HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. PG - 1179299X17751920 LID - 10.1177/1179299X17751920 [doi] LID - 1179299X17751920 AB - BACKGROUND: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. We therefore sought to identify novel DNA methylation markers of HR-NMIBC clinical outcomes that might predict tumour behaviour at initial diagnosis and help guide patient management. PATIENTS AND METHODS: A total of 21 primary initial diagnosis HR-NMIBC tumours were analysed by Illumina HumanMethylation450 BeadChip arrays and subsequently bisulphite Pyrosequencing. In all, 7 had not recurred at 1 year after resection and 14 had recurred and/or progressed despite intra-vesical BCG. A further independent cohort of 32 HR-NMIBC tumours (17 no recurrence and 15 recurrence and/or progression despite BCG) were also assessed by bisulphite Pyrosequencing. RESULTS: Array analyses identified 206 CpG loci that segregated non-recurrent HR-NMIBC tumours from clinically more aggressive recurrence/progression tumours. Hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HR-NMIBC recurrence and/or progression within 1 year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative predictive values. CONCLUSIONS: This is the first genome-wide DNA methylation analysis of a unique HR-NMIBC tumour cohort encompassing known 1-year clinical outcomes. Our analyses identified potential novel epigenetic markers that could help guide individual patient management in this clinically unpredictable disease. FAU - Kitchen, Mark O AU - Kitchen MO AD - Institute for Science and Technology in Medicine, Keele University, London, UK. AD - Urology Department, University Hospitals of North Midlands NHS Trust, Stafford, UK. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Emes, Richard D AU - Emes RD AD - Advanced Data Analysis Centre, University of Nottingham, Nottingham, UK. FAU - Luscombe, Christopher J AU - Luscombe CJ AD - Urology Department, University Hospitals of North Midlands NHS Trust, Stafford, UK. FAU - Cheng, K K AU - Cheng KK AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. AD - Department of Complex Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands. AD - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands. AD - CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - James, Nicholas D AU - James ND AD - Cancer Research Centre, University of Warwick, Coventry, UK. FAU - Gommersall, Lyndon M AU - Gommersall LM AD - Urology Department, University Hospitals of North Midlands NHS Trust, Stafford, UK. FAU - Fryer, Anthony A AU - Fryer AA AD - Institute for Science and Technology in Medicine, Keele University, London, UK. LA - eng PT - Journal Article DEP - 20180108 PL - United States TA - Biomark Cancer JT - Biomarkers in cancer JID - 101533144 PMC - PMC5764140 OTO - NOTNLM OT - HumanMethylation450 BeadChip array OT - epigenetics OT - high-risk non-muscle invasive bladder cancer OT - methylation OT - prognostic biomarker COIS- Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2018/01/19 06:00 MHDA- 2018/01/19 06:01 PMCR- 2018/01/08 CRDT- 2018/01/19 06:00 PHST- 2017/09/03 00:00 [received] PHST- 2017/11/15 00:00 [accepted] PHST- 2018/01/19 06:00 [entrez] PHST- 2018/01/19 06:00 [pubmed] PHST- 2018/01/19 06:01 [medline] PHST- 2018/01/08 00:00 [pmc-release] AID - 10.1177_1179299X17751920 [pii] AID - 10.1177/1179299X17751920 [doi] PST - epublish SO - Biomark Cancer. 2018 Jan 8;10:1179299X17751920. doi: 10.1177/1179299X17751920. eCollection 2018. PMID- 29342465 OWN - NLM STAT- MEDLINE DCOM- 20180927 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 100 IP - 2 DP - 2018 TI - De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study. PG - 185-192 LID - 10.1159/000481917 [doi] AB - BACKGROUND AND OBJECTIVES: Renal transplant recipients (RTRs) have a 2- to 7-fold risk of developing a neoplasm compared to general population. Bladder urothelial neoplasms in this cohort has an incidence of 0.4-2%. Many reports describe a more aggressive behavior. The objective of this study is to describe oncologic characteristics of bladder urothelial neoplasms in RTRs and to evaluate its recurrence, progression, and survival rates. METHODS: A retrospective multicentered study was performed evaluating all de novo bladder urothelial neoplasms cases in RTRs from 1988 to 2014. Descriptive statistical analysis and evaluation of recurrence, progression, and survival rates were performed. RESULTS: A total of 28 de novo bladder transitional cell carcinomas (TCCs) were identified (incidence rate 0.64%). Cancer-specific survival rates were 100, 75, and 70% after 1, 5, and 10 years, respectively. Age at diagnosis superior to 60 years was found to be a statistically significant variable for recurrence risk. Progression rate was 14%. Presence of CIS was significantly associated with progression. All cancer-specific deaths were in the high-risk group and all were progressions from non-muscle invasive to muscle invasive bladder cancer. CONCLUSIONS: Bladder urothelial neoplasms following renal transplant is associated with a trend toward worst prognosis. Early aggressive treatments, such as early radical cystectomy, might be advisable to reduce cancer-specific deaths. CI - (c) 2018 S. Karger AG, Basel. FAU - Palazzetti, Anna AU - Palazzetti A AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Bosio, Andrea AU - Bosio A AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Dalmasso, Ettore AU - Dalmasso E AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Destefanis, Paolo AU - Destefanis P AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Fop, Fabrizio AU - Fop F AD - Department of Nephrology and Dialysis, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Pisano, Francesca AU - Pisano F AD - Department of Nephrology and Dialysis, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Segoloni, Giuseppe AU - Segoloni G AD - Department of Nephrology and Dialysis, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Biancone, Luigi AU - Biancone L AD - Department of Nephrology and Dialysis, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Volpe, Alessandro AU - Volpe A AD - Department of Urology, University of Novara, Maggiore della Carita Hospital, Novara, Italy. FAU - Di Domenico, Antonia AU - Di Domenico A AD - Department of Urology, University of Novara, Maggiore della Carita Hospital, Novara, Italy. FAU - Terrone, Carlo AU - Terrone C AD - Department of Urology, University of Novara, Maggiore della Carita Hospital, Novara, Italy. FAU - Iesari, Samuele AU - Iesari S AD - Department of Nephrology and Dialysis, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy. FAU - Famulari, Antonio AU - Famulari A AD - Department of Nephrology and Dialysis, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy. FAU - Todeschini, Paola AU - Todeschini P AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. AD - Department of Nephrology and Dialysis, University of Bologna, Alma Mater Hospital, Bologna, Italy. FAU - Frea, Bruno AU - Frea B AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, University of Turin, Citta della Salute e della Scienza, Turin, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20180117 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/etiology/mortality/*pathology/therapy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Italy MH - Kaplan-Meier Estimate MH - Kidney Transplantation/*adverse effects/mortality MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - *Transplant Recipients MH - Treatment Outcome MH - Urinary Bladder Neoplasms/etiology/mortality/*pathology/therapy MH - Urothelium/*pathology MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Immunosuppression OT - Kidney OT - Renal transplant OT - Urothelial neoplasm EDAT- 2018/01/18 06:00 MHDA- 2018/09/28 06:00 CRDT- 2018/01/18 06:00 PHST- 2017/05/30 00:00 [received] PHST- 2017/09/28 00:00 [accepted] PHST- 2018/01/18 06:00 [pubmed] PHST- 2018/09/28 06:00 [medline] PHST- 2018/01/18 06:00 [entrez] AID - 000481917 [pii] AID - 10.1159/000481917 [doi] PST - ppublish SO - Urol Int. 2018;100(2):185-192. doi: 10.1159/000481917. Epub 2018 Jan 17. PMID- 29342309 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20240207 IS - 1460-2105 (Electronic) IS - 0027-8874 (Print) IS - 0027-8874 (Linking) VI - 110 IP - 5 DP - 2018 May 1 TI - Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. PG - 448-459 LID - 10.1093/jnci/djx243 [doi] AB - BACKGROUND: Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas. METHODS: Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome. The current study extrapolates this conventional wisdom and combines it with molecular profiling. We developed an 18-gene signature that molecularly defines urothelial cellular differentiation, thus classifying MIBCs and NMIBCs into two subgroups: basal and differentiated. We evaluated the prognostic capability of this "tumor differentiation signature" and three other existing gene signatures including the The Cancer Genome Atlas (TCGA; 2707 genes), MD Anderson Cancer Center (MDA; 2252 genes/2697 probes), and University of North Carolina at Chapel Hill (UNC; 47 genes) using five gene expression data sets derived from MIBC and NMIBC patients. All statistical tests were two-sided. RESULTS: The tumor differentiation signature demonstrated consistency and statistical robustness toward stratifying MIBC patients into different overall survival outcomes (TCGA cohort 1, P = .03; MDA discovery, P = .009; MDA validation, P = .01), while the other signatures were not as consistent. In addition, we analyzed the progression (Ta/T1 progressing to >/=T2) probability of NMIBCs. NMIBC patients with a basal tumor differentiation signature associated with worse progression outcome (P = .008). Gene functional term enrichment and gene set enrichment analyses revealed that genes involved in the biologic process of immune response and inflammatory response are among the most elevated within basal bladder cancers, implicating them as candidates for immune checkpoint therapies. CONCLUSIONS: These results provide definitive evidence that a biology-prioritizing clustering methodology generates meaningful insights into patient stratification and reveals targetable molecular pathways to impact future therapeutic approach. FAU - Mo, Qianxing AU - Mo Q AD - Department of Medicine, University of Texas MD Anderson Cancer Center, Smithville, TX. AD - Dan L. Duncan Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Nikolos, Fotis AU - Nikolos F AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Chen, Fengju AU - Chen F AD - Dan L. Duncan Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Tramel, Zoe AU - Tramel Z AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Lee, Yu-Cheng AU - Lee YC AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Hayashi, Kazukuni AU - Hayashi K AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Xiao, Jing AU - Xiao J AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Shen, Jianjun AU - Shen J AD - Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX. FAU - Chan, Keith Syson AU - Chan KS AD - Department of Molecular and Cellular Biology, University of Texas MD Anderson Cancer Center, Smithville, TX. AD - Stem Cells and Regenerative Medicine (STaR) Center, Center for Drug Discovery, and Scott Department of Urology, Baylor College of Medicine, Houston, TX. LA - eng GR - P30 CA125123/CA/NCI NIH HHS/United States GR - R01 CA175397/CA/NCI NIH HHS/United States GR - T32 GM088129/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 RN - 0 (Biomarkers, Tumor) CIN - J Natl Cancer Inst. 2018 May 1;110(5):439-440. doi: 10.1093/jnci/djx254. PMID: 29342301 EIN - J Natl Cancer Inst. 2019 Nov 1;111(11):1236. doi: 10.1093/jnci/djy191. PMID: 30295800 MH - Biomarkers, Tumor/analysis/*genetics MH - Carcinoma, Transitional Cell/*diagnosis/genetics/mortality/pathology MH - Cell Differentiation/*genetics MH - Cohort Studies MH - Disease Progression MH - Gene Expression Profiling MH - Humans MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Prognosis MH - Sensitivity and Specificity MH - *Transcriptome MH - Urinary Bladder Neoplasms/*diagnosis/genetics/mortality/pathology MH - Urothelium/metabolism/pathology PMC - PMC6279371 EDAT- 2018/01/18 06:00 MHDA- 2019/07/30 06:00 PMCR- 2019/01/12 CRDT- 2018/01/18 06:00 PHST- 2017/04/25 00:00 [received] PHST- 2017/10/20 00:00 [accepted] PHST- 2018/01/18 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2018/01/18 06:00 [entrez] PHST- 2019/01/12 00:00 [pmc-release] AID - 4804352 [pii] AID - djx243 [pii] AID - 10.1093/jnci/djx243 [doi] PST - ppublish SO - J Natl Cancer Inst. 2018 May 1;110(5):448-459. doi: 10.1093/jnci/djx243. PMID- 29336367 OWN - NLM STAT- MEDLINE DCOM- 20180817 LR - 20181113 IS - 2542-5641 (Electronic) IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 131 IP - 2 DP - 2018 Jan 20 TI - Reduction of Tat-interacting Protein 30 Expression Could be a Prognostic Marker in Bladder Urothelial Cancer. PG - 188-193 LID - 10.4103/0366-6999.222325 [doi] AB - BACKGROUND: Tat-interacting protein 30 (TIP30) has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer (BUC) has not been investigated. Therefore, herein, we investigated the expression of TIP30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. METHODS: We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007. TIP30 expression was examined by immunohistochemistry. The relationship between TIP30 expression and tumor stage, histological grade, and survival was analyzed. Differences between groups were evaluated using the t-test or matched-pairs test, and differences in the survival rates were analyzed with the log-rank test. RESULTS: TIP30 protein expression was significantly reduced in BUC tissue (t = -6.91, P < 0.05) compared with normal tissue samples, and in invasive bladder cancer (t = 10.89, P < 0.05) compared with superficial bladder cancer. TIP30 protein expression differed significantly among different differentiated groups classified either according to the World Health Organization (2004, F = 17.48, P < 0.01) or World Health Organization (1973, F = 10.68, P < 0.01). TIP30 protein expression was significantly reduced in high-grade papillary urothelial carcinoma compared with papillary urothelial neoplasm of low malignant potential (P < 0.05) and low-grade papillary urothelial carcinoma (P < 0.05). Meanwhile, TIP30 protein expression was significantly reduced in Grade III BUC, compared with Grade I (P < 0.05) and Grade II (P < 0.05). Patients with low TIP30 expression showed a higher incidence of disease progression than those with high TIP30 expression (t = 2.63, P < 0.05). Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and overall survival (OS) (chi2 = 17.29, P < 0.05). CONCLUSIONS: TIP30 expression was associated with clinical tumor stage in BUC, suggesting that it might play an important role in disease progression. Furthermore, TIP30 might predict postoperative OS. Thus, its evaluation might be useful for predicting prognosis. FAU - Li, Ye-Ping AU - Li YP AD - Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. FAU - Zhu, Jian-Fang AU - Zhu JF AD - Department of Vascular Surgery, The Second Hospital of Shaoxing City, Shaoxing, Zhejiang 312000, China. FAU - Huang, Ka-Te AU - Huang KT AD - Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. FAU - Wang, Rong-Rong AU - Wang RR AD - Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. FAU - Cai, Bing AU - Cai B AD - Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. FAU - Xie, Hui AU - Xie H AD - Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. FAU - Chen, Hong-De AU - Chen HD AD - Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. LA - eng PT - Journal Article PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 RN - 0 (Biomarkers, Tumor) RN - 0 (Transcription Factors) RN - EC 2.3.1.- (Acetyltransferases) RN - EC 2.3.1.48 (HTATIP2 protein, human) SB - IM MH - Acetyltransferases/*analysis MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Prognosis MH - Tissue Array Analysis MH - Transcription Factors/*analysis MH - Urinary Bladder Neoplasms/chemistry/*mortality/pathology PMC - PMC5776849 COIS- There are no conflicts of interest. EDAT- 2018/01/18 06:00 MHDA- 2018/08/18 06:00 PMCR- 2018/01/20 CRDT- 2018/01/17 06:00 PHST- 2018/01/17 06:00 [entrez] PHST- 2018/01/18 06:00 [pubmed] PHST- 2018/08/18 06:00 [medline] PHST- 2018/01/20 00:00 [pmc-release] AID - ChinMedJ_2018_131_2_188_222325 [pii] AID - CMJ-131-188 [pii] AID - 10.4103/0366-6999.222325 [doi] PST - ppublish SO - Chin Med J (Engl). 2018 Jan 20;131(2):188-193. doi: 10.4103/0366-6999.222325. PMID- 29334958 OWN - NLM STAT- MEDLINE DCOM- 20180814 LR - 20181113 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 16 IP - 1 DP - 2018 Jan 15 TI - Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. PG - 6 LID - 10.1186/s12957-018-1310-0 [doi] LID - 6 AB - BACKGROUND: Indications for restaging transurethral resection of the bladder tumor (reTURBT) in patients with non-muscle-invasive bladder cancer (NMIBC) remain controversial. This study was aimed at evaluation of clinical value and safety of reTURBT in different clinical indications. METHODS: This is a retrospective analysis of consecutive 141 patients who underwent TURBT followed by reTURBT in years 2011-2015 in a single department. Pathological results and surgical complications were analyzed in the whole study cohort and stratified by clinical stage (Ta, T1, Tx (no muscle in the specimen)) and grade (low-grade (LG), high-grade (HG)) of bladder cancer diagnosed at primary TURBT. RESULTS: Full data was available for 132 patients. Residual disease was found in 53 patients (40.2%) with highest rate for Ta-HG cases (57.1%) followed by T1-HG (51.4%), Tx-HG (45.2%), T1-LG (32.1%), and Tx-LG (25.8%). In the multivariate analysis, high grade (p = 0.02) was the only independent predictor of residual disease. Upstaging to muscle-invasive bladder cancer was noticed in 9 patients (6.8%). The rate of grade >/= 2 Clavien-Dindo complications (1.5 vs. 5.3%) did not differ significantly between TURBT and reTURBT cases. CONCLUSIONS: ReTURBT is a safe procedure that remains crucial for therapeutic and staging purposes in patients with T1, Tx, or high-grade bladder cancer found in the primary resection. FAU - Zapala, Piotr AU - Zapala P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. FAU - Dybowski, Bartosz AU - Dybowski B AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. slawomir.poletajew@wum.edu.pl. FAU - Bialek, Lukasz AU - Bialek L AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. FAU - Niewczas, Andrzej AU - Niewczas A AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4 Str, 02-005, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20180115 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplasm, Residual/*pathology/*surgery MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*pathology/*surgery MH - Urologic Surgical Procedures/*methods PMC - PMC5769235 OTO - NOTNLM OT - Bladder cancer OT - Cancer staging OT - Urologic surgical procedures COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This retrospective study has been approved by the local review board. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. Individual patient data are not reported within the study. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/01/18 06:00 MHDA- 2018/08/15 06:00 PMCR- 2018/01/15 CRDT- 2018/01/17 06:00 PHST- 2017/07/21 00:00 [received] PHST- 2018/01/08 00:00 [accepted] PHST- 2018/01/17 06:00 [entrez] PHST- 2018/01/18 06:00 [pubmed] PHST- 2018/08/15 06:00 [medline] PHST- 2018/01/15 00:00 [pmc-release] AID - 10.1186/s12957-018-1310-0 [pii] AID - 1310 [pii] AID - 10.1186/s12957-018-1310-0 [doi] PST - epublish SO - World J Surg Oncol. 2018 Jan 15;16(1):6. doi: 10.1186/s12957-018-1310-0. PMID- 29333509 OWN - NLM STAT- MEDLINE DCOM- 20190306 LR - 20190306 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 59 IP - 1 DP - 2018 Jan TI - Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor. PG - 10-17 LID - 10.4111/icu.2018.59.1.10 [doi] AB - PURPOSE: To evaluate the rate of pyuria and bacteriuria after transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We retrospectively evaluated data obtained from 363 patients who underwent TURBT between October 2012 and December 2013 at Seoul National University Hospital. Urinalysis and urine culture were assessed at 3, 6, 12, and 24 months postoperatively. Primary endpoint was the rate of bacteriuria (>/=10(5)/mL in a midstream) and pyuria (white blood cells >/=5/high-power field). RESULTS: We analyzed 306 patients who were eligible for the study. Pyuria was present in 23.5% of patients in the 3rd postoperative month and in 31.7% of patients in the 24th postoperative month. Bacteriuria was present in 1.3% of patients in the 3rd postoperative month and in 2.6% of patients in the 24th postoperative month. Among urothelial carcinoma patients (n=220), 24.1% showed pyuria and 1.8% showed bacteriuria at the 3rd postoperative month. We found that 31.8% showed pyuria and 3.2% showed bacteriuria at the 24th postoperative month. There was no significant difference in the rate of pyuria and bacteriuria between the intravesical treatment group and the no-treatment group. Multivariate analysis demonstrated that pyuria in the 3rd postoperative month (odd ratio [OR], 2.254; p=0.039), tumor multiplicity (OR, 3.331; p=0.001), and the absence of intravesical treatment (OR, 4.927; p=0.001) increases the risk of tumor recurrence. CONCLUSIONS: A significant proportion of patients showed pyuria after TURBT during the follow-up period. Additionally, presence of pyuria in the short-term follow-up period after TURBT constitutes a risk factor for recurrence of bladder cancer. FAU - Kim, Byung Soo AU - Kim BS AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Tae, Bum Sik AU - Tae BS AD - Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AUID- ORCID: 0000-0002-2200-5019 AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng PT - Journal Article DEP - 20171215 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Bacteriuria/etiology MH - Chemotherapy, Adjuvant MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*etiology MH - Postoperative Complications MH - Pyuria/etiology MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/drug therapy/*surgery MH - Urinary Tract Infections/*etiology PMC - PMC5754576 OTO - NOTNLM OT - Pyuria OT - Recurrence OT - Urinary bladder neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2018/01/16 06:00 MHDA- 2019/03/07 06:00 PMCR- 2018/01/01 CRDT- 2018/01/16 06:00 PHST- 2017/08/04 00:00 [received] PHST- 2017/10/10 00:00 [accepted] PHST- 2018/01/16 06:00 [entrez] PHST- 2018/01/16 06:00 [pubmed] PHST- 2019/03/07 06:00 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - 10.4111/icu.2018.59.1.10 [doi] PST - ppublish SO - Investig Clin Urol. 2018 Jan;59(1):10-17. doi: 10.4111/icu.2018.59.1.10. Epub 2017 Dec 15. PMID- 29329444 OWN - NLM STAT- MEDLINE DCOM- 20180507 LR - 20181202 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 48 IP - 3 DP - 2018 Mar 1 TI - Prevention of IVR: a need for investigation. PG - 295-296 LID - 10.1093/jjco/hyx169 [doi] AB - Intravesical recurrence (IVR) after RNU for UTUC is a frequent event, occurring in 20-50% of patients, mostly in the first postoperative year. Several retrospective studies have shown that predictors of IVR include clinical characteristics, surgical features and as well pathological characteristics (previous history of bladder cancer, pathological stage, lymph node involvement, cis, endoscopic distal ureter, etc.) management. Two prospective studies provide level I evidence for the safety and efficacy of intravesical single postoperative chemotherapy for patients treated with radical nephroureterectomy (RNU) for UTUC in order to prevent IVR. However, some questions remain unanswered. Yamashita et al. in the current issue of the journal have shown that early ureteral ligation during RNU decreases the risk of IVR in patients with pelvycalyceal upper tract urothelial carcinoma. This study despite its limitations represent a step towards improved outcomes for our patients with UTUC, the relatively low morbidity of the procedure added to the potential benefit associated with this early ligation make it an easy implementation in daily practice. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Bichat Hospital, APHP, Paris Diderot University. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. CN - Young Academic Urologists of the European Association of Urology Urothelial Carcinoma Group LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM CIN - Jpn J Clin Oncol. 2018 Mar 1;48(3):297. doi: 10.1093/jjco/hyx192. PMID: 29329445 MH - Clinical Trials as Topic MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology/*prevention & control MH - Nephroureterectomy MH - Prospective Studies MH - Risk Factors MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/*pathology/surgery MH - Urinary Bladder Neoplasms/pathology EDAT- 2018/01/13 06:00 MHDA- 2018/05/08 06:00 CRDT- 2018/01/13 06:00 PHST- 2017/10/11 00:00 [received] PHST- 2017/11/01 00:00 [accepted] PHST- 2018/01/13 06:00 [pubmed] PHST- 2018/05/08 06:00 [medline] PHST- 2018/01/13 06:00 [entrez] AID - 4797157 [pii] AID - 10.1093/jjco/hyx169 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2018 Mar 1;48(3):295-296. doi: 10.1093/jjco/hyx169. PMID- 29323062 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20180724 IS - 0974-5130 (Electronic) IS - 0377-4929 (Linking) VI - 60 IP - 4 DP - 2017 Oct-Dec TI - Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder. PG - 505-509 LID - 10.4103/IJPM.IJPM_246_17 [doi] AB - BACKGROUND: Urothelial carcinoma is common urinary malignancy responsible for a significant proportion of cancer morbidity and mortality. We carried out the present study to demonstrate the clinicohistopathological features and to correlate the p53 and Ki-67 immunoexpression with grade and stage of bladder carcinomas. MATERIALS AND METHODS: We investigated 110 cases of bladder tumor. Grading and staging were done according to the WHO-2004 and American Joint Committee on Cancer-TNM staging recommendations. Immunohistochemical staining for p53 and Ki-67 was performed in all the cases, categorized as high and low expression taking 20% positivity as cutoff value. Statistical analysis was done using McNemar's Chi-square test and Fisher's exact test. RESULTS: There were 61 cases of high grade and 49 cases of low grade exhibiting urothelial carcinoma as the most common variant (97.3%). Muscle invasive carcinomas (pT2) noted in 29 cases whereas 23 and 58 cases revealed stage pTa and pT1, respectively. Evaluation of p53 and Ki-67 immunoexpression showed a significant association with histological grade and stage individually and also in combination (P < 0.05). CONCLUSION: Our results corroborate with the opinion that combined use of p53 and Ki-67 immunomarkers may provide additional prognostic information along with histological grading and staging in bladder carcinomas. FAU - Thakur, Brijesh AU - Thakur B AD - Department of Pathology, SGRRIM and HS, Dehradun, Uttarakhand, India. FAU - Kishore, Sanjeev AU - Kishore S AD - Department of Pathology, SGRRIM and HS, Dehradun, Uttarakhand, India. FAU - Dutta, Kanika AU - Dutta K AD - Department of Pathology, SGRRIM and HS, Dehradun, Uttarakhand, India. FAU - Kaushik, Sanjay AU - Kaushik S AD - Department of Pathology, SGRRIM and HS, Dehradun, Uttarakhand, India. FAU - Bhardwaj, Aparna AU - Bhardwaj A AD - Department of Pathology, SGRRIM and HS, Dehradun, Uttarakhand, India. LA - eng PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 0 (Ki-67 Antigen) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM CIN - Hum Vaccin Immunother. 2018 Jul 3;14(7):1543. doi: 10.1080/21645515.2018.1501953. PMID: 30024841 MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma/*diagnosis/*pathology MH - Female MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/*analysis MH - Male MH - Microscopy MH - Middle Aged MH - Neoplasm Grading MH - Prognosis MH - Tumor Suppressor Protein p53/*analysis MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*diagnosis/*pathology MH - Young Adult EDAT- 2018/01/13 06:00 MHDA- 2018/07/25 06:00 CRDT- 2018/01/12 06:00 PHST- 2018/01/12 06:00 [entrez] PHST- 2018/01/13 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] AID - IndianJPatholMicrobiol_2017_60_4_505_222964 [pii] AID - 10.4103/IJPM.IJPM_246_17 [doi] PST - ppublish SO - Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):505-509. doi: 10.4103/IJPM.IJPM_246_17. PMID- 29322799 OWN - NLM STAT- MEDLINE DCOM- 20190625 LR - 20190625 IS - 0028-2685 (Print) IS - 0028-2685 (Linking) VI - 65 IP - 1 DP - 2018 TI - Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer - results of a cross country retrospective study. PG - 147-152 LID - 10.4149/neo_2018_170217N123 [doi] AB - Adjuvant diagnostic and therapeutic procedures are available to reduce the risk of recurrence or progression in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, their indications and efficacy remain a matter of debate. The aim of this study was to analyze therapeutic decisions in patients with primary high-risk NMIBC and to analyze the adherence to clinical guidelines in this field.545 consecutive patients, aged a median of 70.3 years, diagnosed with primary high-risk NMIBC in thirteen urological institutions, were enrolled into this retrospective study. Diagnostic and therapeutic decisions after transurethral resection (TUR) were recorded, and predictive factors were analyzed.Restaging TUR was offered to 260 patients (47.7%), up-front intravesical Bacillus Calmette-Guerin (BCG) therapy to 74 patients (13.6%), immediate radical cystectomy to 38 patients (7.0%), and intravesical chemotherapy with the maintenance therapy to 12 patients (2.2%). No additional procedure was performed in 161 patients (29.5%). The strongest predictive factor for restaging TUR was G3 or high-grade cancer (RR 1.68, p<0.01), for upfront BCG therapy it was carcinoma in situ (RR 3.20, p=0.01), for immediate cystectomy it was stage T1 tumor (RR 3.71, p<0.01), for no additional procedures it was G2 or low-grade cancer (RR 2.18, p<0.01).Clinical management of patients with high-risk NMIBC is suboptimal and not standardized. As this can directly influence patients' survival, urgent improvement of urological care in this field should be considered. FAU - Poletajew, S AU - Poletajew S FAU - Biernacki, R AU - Biernacki R FAU - Buraczynski, P AU - Buraczynski P FAU - Chojnacki, J AU - Chojnacki J FAU - Czarniecki, S AU - Czarniecki S FAU - Gajewska, D AU - Gajewska D FAU - Pohaba, T AU - Pohaba T FAU - Sondka-Migdalska, J AU - Sondka-Migdalska J FAU - Skrzypczyk, M AU - Skrzypczyk M FAU - Suchojad, T AU - Suchojad T FAU - Wojtkowiak, D AU - Wojtkowiak D FAU - Zaforemski, B AU - Zaforemski B FAU - Zapala, L AU - Zapala L FAU - Zemla, A AU - Zemla A FAU - Radziszewski, P AU - Radziszewski P LA - eng PT - Journal Article PL - Slovakia TA - Neoplasma JT - Neoplasma JID - 0377266 SB - IM MH - Aged MH - Humans MH - Neoplasm Recurrence, Local/diagnosis MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/*therapy OTO - NOTNLM OT - bladder cancer OT - clinical decision-making OT - multicenter study survival. EDAT- 2018/01/13 06:00 MHDA- 2019/06/27 06:00 CRDT- 2018/01/12 06:00 PHST- 2018/01/12 06:00 [entrez] PHST- 2018/01/13 06:00 [pubmed] PHST- 2019/06/27 06:00 [medline] AID - 10.4149/neo_2018_170217N123 [doi] PST - ppublish SO - Neoplasma. 2018;65(1):147-152. doi: 10.4149/neo_2018_170217N123. PMID- 29319922 OWN - NLM STAT- MEDLINE DCOM- 20190326 LR - 20190326 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 122 IP - 4 DP - 2018 Oct TI - The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. PG - 571-575 LID - 10.1111/bju.14124 [doi] AB - OBJECTIVE: To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: All patients with NMIBC who were enrolled in a prospective trial between 1998 and 2003, and treated with an early mitomycin C instillation (on the day of TURBT or 1 day later), were selected. Statistical analysis was performed with Kaplan-Meier curves and multivariable Cox regression. RESULTS: Administering an instillation of mitomycin C on the day of TURBT or 1 day later did not show a statistically significant difference in time to recurrence in a univariable model (log-rank P = 0.99). After correcting for the number of scheduled adjuvant instillations, no statistically significant difference could be detected either: hazard ratio 1.05 (95% confidence interval 0.81-1.35, P = 0.74). CONCLUSION: These data do not support the hypothesis that a very early instillation (on the day of TURBT) of mitomycin C decreases the risk of recurrence as compared with an early instillation (1 day after TURBT). CI - (c) 2018 The Authors BJU International (c) 2018 BJU International Published by John Wiley & Sons Ltd. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - van Ginkel, Tessa AU - van Ginkel T AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Lissenberg-Witte, Birgit I AU - Lissenberg-Witte BI AD - Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands. FAU - Beckers, Goedele M A AU - Beckers GMA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20180131 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - BJU Int. 2018 Oct;122(4):525-526. doi: 10.1111/bju.14229. PMID: 30251474 MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/*administration & dosage MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - Muscle, Smooth MH - Neoplasm Recurrence, Local/drug therapy/*prevention & control MH - Prospective Studies MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery MH - Urologic Surgical Procedures OTO - NOTNLM OT - intravesical chemotherapy OT - mitomycin C OT - urinary bladder neoplasms EDAT- 2018/01/11 06:00 MHDA- 2019/03/27 06:00 CRDT- 2018/01/11 06:00 PHST- 2018/01/11 06:00 [pubmed] PHST- 2019/03/27 06:00 [medline] PHST- 2018/01/11 06:00 [entrez] AID - 10.1111/bju.14124 [doi] PST - ppublish SO - BJU Int. 2018 Oct;122(4):571-575. doi: 10.1111/bju.14124. Epub 2018 Jan 31. PMID- 29313114 OWN - NLM STAT- MEDLINE DCOM- 20191118 LR - 20220330 IS - 2366-0058 (Electronic) VI - 43 IP - 9 DP - 2018 Sep TI - Bladder cancer local staging: multiparametric MRI performance following transurethral resection. PG - 2412-2423 LID - 10.1007/s00261-017-1449-0 [doi] AB - PURPOSE: To evaluate the performance of multiparametric MRI (mpMRI) for the local staging of bladder cancer following transurethral resection of bladder tumor. METHODS: This Institutional Review Board-approved, retrospective study identified 45 patients with pathology-proven bladder cancer who underwent transurethral resection followed by mpMRI between August 2011 and October 2016. Two radiologists reviewed each MRI independently and assigned T and N stage. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for the presence of muscle invasion (T2 or higher), peri-vesical invasion (T3 or higher), and regional nodal disease compared to findings at cystectomy as the reference standard. Inter-observer agreement was measured using Cohen's kappa coefficient. RESULTS: Of 45 patients, 13% were stage T2, 27% T3, 16% T4; of 40 patients, 28% had regional nodal disease. Sensitivity, specificity, PPV, NPV, and accuracy of mpMRI for readers 1 and 2, respectively, were muscle invasion, 92% and 88%, 74% and 84%, 81% and 88%, 88% and 84%, 84% and 86%; peri-vesical invasion, 72% and 67%, 92% and 92%, 87% and 86%, 81% and 79%, 83% and 81%; regional nodal disease, 45% and 45%, 93% and 90%, 71% and 63%, 82% and 81%, 80% and 78%. Inter-observer agreement was good using all sequences. CONCLUSIONS: mpMRI was both sensitive and specific in the detection of muscle invasive bladder cancer, and was specific but not sensitive for both peri-vesical invasion and nodal involvement. mpMRI may have a role at locally staging bladder cancer following transurethral resection. FAU - van der Pol, Christian B AU - van der Pol CB AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. FAU - Shinagare, Atul B AU - Shinagare AB AD - Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. ashinagare@partners.org. FAU - Tirumani, Sree Harsha AU - Tirumani SH AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. FAU - Preston, Mark A AU - Preston MA AD - Division of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASBII-3, Boston, MA, 02115, USA. FAU - Vangel, Mark G AU - Vangel MG AD - Massachusetts General Hospital, Harvard Medical School, Radiology/CNY149-Rm 2301, 149 13th St, Charlestown, MA, 02129, USA. FAU - Silverman, Stuart G AU - Silverman SG AD - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. LA - eng PT - Journal Article PL - United States TA - Abdom Radiol (NY) JT - Abdominal radiology (New York) JID - 101674571 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy MH - Female MH - Humans MH - Lymphatic Metastasis/diagnostic imaging/pathology MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*diagnostic imaging/*pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - MRI OT - Multiparametric MRI OT - Staging OT - TURBT EDAT- 2018/01/10 06:00 MHDA- 2019/11/19 06:00 CRDT- 2018/01/10 06:00 PHST- 2018/01/10 06:00 [pubmed] PHST- 2019/11/19 06:00 [medline] PHST- 2018/01/10 06:00 [entrez] AID - 10.1007/s00261-017-1449-0 [pii] AID - 10.1007/s00261-017-1449-0 [doi] PST - ppublish SO - Abdom Radiol (NY). 2018 Sep;43(9):2412-2423. doi: 10.1007/s00261-017-1449-0. PMID- 29307686 OWN - NLM STAT- MEDLINE DCOM- 20190606 LR - 20210105 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 199 IP - 6 DP - 2018 Jun TI - Purified Protein Derivative Skin test prior to bacillus Calmette-Guerin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer. PG - 1446-1451 LID - S0022-5347(18)30006-5 [pii] LID - 10.1016/j.juro.2017.12.057 [doi] AB - PURPOSE: We investigated the clinical impact of the purified protein derivative skin test prior to bacillus Calmette-Guerin therapy in patients with nonmuscle invasive bladder cancer treated with adjuvant bacillus Calmette-Guerin therapy. MATERIALS AND METHODS: A total of 498 patients with nonmuscle invasive bladder cancer treated with adjuvant bacillus Calmette-Guerin were included in study, of whom 320 underwent the purified protein derivative skin test 1 to 2 weeks prior to therapy. Oncologic outcomes and the rate of bacillus Calmette-Guerin related side effects were statistically evaluated. RESULTS: The mean +/- SD 5-year recurrence-free survival rate in patients who did vs did not undergo the purified protein derivative skin test was 66.6% +/- 2.8% and 59.1% +/- 4.1%, respectively, which was significantly different (p = 0.048). No significant difference was observed in the progression-free survival rate between patients who did vs did not undergo the test. Multivariate Cox regression analysis revealed that a history of recurrence (HR 1.59, p = 0.02), multiple tumors (HR 1.95, p <0.01), the bacillus Calmette-Guerin Connaught strain (HR 0.71, p = 0.04), 7 or more bacillus Calmette-Guerin instillations (HR 0.70, p = 0.04) and undergoing the purified protein derivative skin test (HR 0.72, p = 0.04) were independently associated with tumor recurrence. Major bacillus Calmette-Guerin related side effects were noted in 77 of the 320 patients (24.1%) who did vs 27 of the 178 (15.2%) who did not undergo the test, which was significantly different (p = 0.02). CONCLUSIONS: The purified protein derivative skin test prior to bacillus Calmette-Guerin treatment enhances the therapeutic effects of this treatment and potentially results in a higher incidence of major bacillus Calmette-Guerin related side effects. Combination therapy with bacillus Calmette-Guerin using the purified protein derivative skin test may improve the oncologic outcomes of that therapy. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kosaka, Takeo AU - Kosaka T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20180104 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) RN - 0 (Bacterial Proteins) SB - IM CIN - J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.076. PMID: 29545189 CIN - J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.077. PMID: 29545192 MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage/*adverse effects/immunology MH - Bacterial Proteins/immunology/isolation & purification MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Immunotherapy/*adverse effects/methods MH - Incidence MH - Male MH - Middle Aged MH - Mycobacterium bovis/immunology MH - Neoplasm Recurrence, Local/*diagnosis/etiology MH - Prognosis MH - Progression-Free Survival MH - Skin Tests/*adverse effects/methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/immunology/mortality/*therapy OTO - NOTNLM OT - BCG vaccine OT - adjuvants OT - adverse effects OT - immunologic OT - skin tests OT - urinary bladder neoplasms EDAT- 2018/01/09 06:00 MHDA- 2019/06/07 06:00 CRDT- 2018/01/09 06:00 PHST- 2017/12/22 00:00 [accepted] PHST- 2018/01/09 06:00 [pubmed] PHST- 2019/06/07 06:00 [medline] PHST- 2018/01/09 06:00 [entrez] AID - S0022-5347(18)30006-5 [pii] AID - 10.1016/j.juro.2017.12.057 [doi] PST - ppublish SO - J Urol. 2018 Jun;199(6):1446-1451. doi: 10.1016/j.juro.2017.12.057. Epub 2018 Jan 4. PMID- 29297169 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20180724 IS - 0890-9091 (Print) IS - 0890-9091 (Linking) VI - 31 IP - 12 DP - 2017 Dec 15 TI - Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers. PG - 855-62 LID - 460202 [pii] AB - Cystoscopy and urine cytology are the gold-standard tests for detection of recurrent disease during follow-up in patients with a history of non-muscle-invasive bladder cancer (NMIBC). High associated costs, as well as side effects, have driven the desire for inexpensive, noninvasive, accurate, and easy-to-use urine markers to detect bladder cancer recurrence. While many urine markers have been developed, very few have been clinically implemented. In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC. FAU - Zuiverloon, Tahlita C M AU - Zuiverloon TCM FAU - de Jong, Florus C AU - de Jong FC FAU - Theodorescu, Dan AU - Theodorescu D LA - eng PT - Journal Article PT - Review PL - United States TA - Oncology (Williston Park) JT - Oncology (Williston Park, N.Y.) JID - 8712059 RN - 0 (Biomarkers, Tumor) RN - 0 (Nuclear Proteins) RN - 0 (nuclear matrix protein 22) SB - IM MH - Biomarkers, Tumor/*urine MH - *Clinical Decision-Making MH - Cystoscopy MH - Humans MH - Neoplasm Recurrence, Local/diagnosis MH - Nuclear Proteins/urine MH - Standard of Care MH - Urinary Bladder Neoplasms/*diagnosis/urine MH - Urine/*cytology EDAT- 2018/01/04 06:00 MHDA- 2018/07/25 06:00 CRDT- 2018/01/04 06:00 PHST- 2018/01/04 06:00 [entrez] PHST- 2018/01/04 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] AID - 460202 [pii] PST - ppublish SO - Oncology (Williston Park). 2017 Dec 15;31(12):855-62. PMID- 29288007 OWN - NLM STAT- MEDLINE DCOM- 20181105 LR - 20181105 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 4 DP - 2018 Apr TI - Overexpression of semaphorin 3A in patients with urothelial cancer. PG - 161.e1-161.e6 LID - S1078-1439(17)30620-8 [pii] LID - 10.1016/j.urolonc.2017.12.007 [doi] AB - OBJECTIVE: A highly sensitive and specific urine marker for the detection of recurrent urothelial cancer and for screening healthy population or people at risk for urothelial cancer has not been found yet. As urine cytology is not sensitive enough, patients with non-muscle-invasive bladder cancer need lifelong follow-up involving multiple invasive cystoscopies. Our aims of study were to examine the expression of semaphorin 3A in urothelial cancer patients and to evaluate semaphorin 3A as a potential marker for urothelial cancer. MATERIALS AND METHODS: Urine samples were taken from patients with known bladder tumor, hospitalized for transurethral resection of lesions, from patients with history of urothelial cancer admitted for endoscopic follow up, from patients with other nonmalignant urological conditions such as prostatic hyperplasia, stress incontinence, urethral stricture, ureteral and kidney stones, and from healthy volunteers with no history of urothelial malignancy and no urological symptoms. Semaphorin 3A (sema3A) protein level was measured using enzyme-linked immunosorbent assay in every sample and levels were correlated with endoscopic and pathological findings. In addition, we performed immunohistochemically staining with semaphorin 3A of 15 tissue samples (various tumors and normal bladder tissues). RESULTS: A total of 183 urine samples were tested. Out of them, 116 patients (mean age 70.7; 94 males and 22 females) had positive cystoscopy, and 67 (mean age 64.7; 51 males and 16 females) had negative cystoscopy. Higher sema3A values were significantly correlated (P = 0.006) with presence of urothelial cancer, as determined by positive cystoscopy or urethroscopy and pathological biopsy. Sema3A levels also showed positive correlation with the number of tumors. Sema3A levels combined with urine cytology showed much higher sensitivity compared with cytology alone (66% vs. 33%), with smaller reduction of specificity (77% vs. 90%). Immunohistochemical staining showed intense staining in high stage and grade tumors, and almost no staining in normal tissue. CONCLUSIONS: Semaphorin 3A is overexpressed in urothelial cancer patients, as evidenced both in its presence in urine and in bladder tissue. Semaphorin 3A in urine is a promising potential urothelial cancer biomarker either independently or in conjunction with cytology. Further tests are needed to elucidate the sex difference in the expression of Sema3A in the urine of bladder cancer patients. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Vadasz, Zahava AU - Vadasz Z AD - The Department of Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel. FAU - Rubinstein, Jacob AU - Rubinstein J AD - The Department of Mathematic, Technion, Israeli Institute of Technology, Haifa, Israel. FAU - Bejar, Jacob AU - Bejar J AD - The Department of Pathology, Bnai Zion Medical Center, Haifa, Israel. FAU - Sheffer, Hilla AU - Sheffer H AD - The Department of Pathology, Bnai Zion Medical Center, Haifa, Israel. FAU - Halachmi, Sarel AU - Halachmi S AD - The Department of Urology, Bnai Zion Medical Center, Haifa, Israel. Electronic address: sarel.halachmi@b-zion.org.il. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20171227 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) RN - 0 (SEMA3A protein, human) RN - 0 (Semaphorin-3A) SB - IM MH - Aged MH - Biomarkers, Tumor/*metabolism/urine MH - Carcinoma, Transitional Cell/diagnostic imaging/*pathology/surgery MH - Cystectomy/methods MH - Cystoscopy MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Liquid Biopsy/methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Semaphorin-3A/*metabolism/urine MH - Sensitivity and Specificity MH - Urinary Bladder/diagnostic imaging/pathology/surgery MH - Urinary Bladder Neoplasms/diagnostic imaging/*pathology/surgery OTO - NOTNLM OT - Noninvasive detection OT - Overexpression OT - Urine, Semaphoring 3a OT - Urothelial cancer EDAT- 2017/12/31 06:00 MHDA- 2018/11/06 06:00 CRDT- 2017/12/31 06:00 PHST- 2017/08/29 00:00 [received] PHST- 2017/12/09 00:00 [revised] PHST- 2017/12/11 00:00 [accepted] PHST- 2017/12/31 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2017/12/31 06:00 [entrez] AID - S1078-1439(17)30620-8 [pii] AID - 10.1016/j.urolonc.2017.12.007 [doi] PST - ppublish SO - Urol Oncol. 2018 Apr;36(4):161.e1-161.e6. doi: 10.1016/j.urolonc.2017.12.007. Epub 2017 Dec 27. PMID- 29285224 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 62 DP - 2017 Dec 1 TI - Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas. PG - 104946-104959 LID - 10.18632/oncotarget.20737 [doi] AB - Information on biomarkers of urothelial carcinomas (UC) for clinical decision-making is limited. Here, we newly identified and verified CXCL16 as a promising novel biomarker in urine for high grade and muscle invasive UC in a cross-sectional cohort of 308 UC patients, 126 urological hospital controls, and 50 population controls using antibody arrays and ELISA. Median CXCL16 levels in urine was significantly higher in UC patients (273.2 pg/mg creatinine) compared to hospital (148.1 pg/mg) and population controls (85.1 pg/mg) with a particular preference for high grade (460.8 pg/mg), muscle invasive (535.7 pg/mg) and primary UC (327.8 pg/mg) (all p<0.0001). Group differences were confirmed after adjusting or stratifying for potential clinical and individual characteristics, such as leukocyte counts, haematuria, age, gender, and smoking status. In contrast, CXCL16 showed less discriminating power in low grade (244.3 pg/mg), non-muscle invasive (3 vs 5 vs 3 years. The median follow-up duration was 60 months. By multivariate analysis, AA exposure history was significantly associated with cancer specific survival (hazard ratio [HR]: 0.43, p=0.02), intravesical recurrence (IVR) (HR: 2.25, p<0.001) and contralateral UTUC recurrence (HR: 2.71, p=0.001). After adjusted for the effects of standard clinicopathologic characteristics, exposure duration was independent risk factor for subsequent IVR (exposure duration 3 years vs none/possible AA, HR: 3.07, p<0.001), but not for cancer-specific survival (p=0.06). Also, of those patients who had AA exposure, those having exposure within 5 years prior to RNU did not differ from patients having last exposure >5 years ago regarding cancer specific mortality (p=0.67) and IVR (p=0.54). CONCLUSION: AA exposure was associated with worse cancer-specific survival, higher rate of IVR and contralateral UTUC recurrence of UTUC treated with RNU. The association between AA exposure and IVR seems to be time-dependent. Exposure cessation >5 years prior to RNU cannot mitigate the impact of AA on the UTUC prognosis. FAU - Zhong, Wenlong AU - Zhong W AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Ma, Jiajian AU - Ma J AD - Peking University Health Science Center, Beijing. FAU - Shao, Shan AU - Shao S AD - Neuroscience Research Institute, Peking University, Beijing, China. FAU - Lin, Rongcheng AU - Lin R AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital. AD - Institute of Urology, Peking University. AD - National Urological Cancer Center, Beijing. LA - eng PT - Journal Article DEP - 20171205 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC5722008 OTO - NOTNLM OT - aristolochic acid OT - prognosis OT - radical nephroureterectomy OT - survival OT - upper urinary tract OT - urothelial carcinoma COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2017/12/20 06:00 MHDA- 2017/12/20 06:01 PMCR- 2017/12/05 CRDT- 2017/12/20 06:00 PHST- 2017/12/20 06:00 [entrez] PHST- 2017/12/20 06:00 [pubmed] PHST- 2017/12/20 06:01 [medline] PHST- 2017/12/05 00:00 [pmc-release] AID - ott-10-5775 [pii] AID - 10.2147/OTT.S148641 [doi] PST - epublish SO - Onco Targets Ther. 2017 Dec 5;10:5775-5782. doi: 10.2147/OTT.S148641. eCollection 2017. PMID- 29247553 OWN - NLM STAT- MEDLINE DCOM- 20190424 LR - 20190424 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 25 IP - 3 DP - 2018 Mar TI - Prediction models for progression of non-muscle-invasive bladder cancer: A review. PG - 212-218 LID - 10.1111/iju.13509 [doi] AB - An accurate prediction of progression is critically important in the management of non-muscle-invasive bladder cancer. At present, three risk models are widely known for prediction of the risk of tumor recurrence and progression of non-muscle-invasive bladder cancer: the European Organization for Research and Treatment of Cancer, Club Urologico Espanol de Tratamiento Oncologico, and new European Organization for Research and Treatment of Cancer models. Bladder neck involvement has been shown to be one of the significant predictors for progression in non-muscle-invasive bladder cancer, and a new scoring model (Tokyo Medical and Dental University model) consisting of bladder neck involvement, tumor grade, and stage has been developed and externally validated. However, the predictive abilities of these models are still unsatisfactory, and more precise models are necessary for accurate individual prediction of prognosis. Until now, time-fixed analysis has been used for most studies predicting the prognosis and outcome of non-muscle-invasive bladder cancer patients. In order to predict progression more precisely, time-dependent models should be developed using multiple-event analytical techniques, as non-muscle-invasive bladder cancer often progresses to muscle-invasive bladder cancer after multiple recurrences and changes in tumor characteristics over a long natural history. Integration of molecular markers is also a promising approach. A validated model that accurately predicts the risk of progression would help urologists and patients decide whether and when to choose radical cystectomy on an individual basis. CI - (c) 2017 The Japanese Urological Association. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. LA - eng PT - Journal Article PT - Review DEP - 20171216 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2018 Mar;25(3):218-219. doi: 10.1111/iju.13551. PMID: 29569774 MH - Carcinoma, Transitional Cell/*pathology/surgery/therapy MH - Disease Progression MH - Humans MH - Neoplasm Staging MH - Prognosis MH - Risk Assessment MH - Time Factors MH - Urinary Bladder Neoplasms/*pathology/surgery/therapy OTO - NOTNLM OT - bladder neck OT - carcinoma OT - non-muscle invasive OT - prediction OT - progression OT - urinary bladder EDAT- 2017/12/17 06:00 MHDA- 2019/04/25 06:00 CRDT- 2017/12/17 06:00 PHST- 2017/09/05 00:00 [received] PHST- 2017/11/09 00:00 [accepted] PHST- 2017/12/17 06:00 [pubmed] PHST- 2019/04/25 06:00 [medline] PHST- 2017/12/17 06:00 [entrez] AID - 10.1111/iju.13509 [doi] PST - ppublish SO - Int J Urol. 2018 Mar;25(3):212-218. doi: 10.1111/iju.13509. Epub 2017 Dec 16. PMID- 29246006 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220314 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 59 DP - 2017 Nov 21 TI - Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis. PG - 100614-100630 LID - 10.18632/oncotarget.21899 [doi] AB - PURPOSE: This meta-analysis evaluated the prognostic significance of Ki-67 in non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: We selected 39 articles including 5,229 patients from Embase, Scopus, and PubMed searches. The primary outcomes, recurrence-free survival (RFS), progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) were determined using time-to event hazard ratios (HRs) with 95% confidence intervals (CIs). Study heterogeneity was tested by chi-square and I(2) statistics. Heterogeneity sources were identified by subgroup meta-regression analysis. RESULTS: Two studies were prospective; 37 were retrospective. Immunohistochemistry was performed in tissue microarrays or serial sections. A wide range of antibody dilutions and Ki-67 positivity thresholds were used. Study heterogeneity was attributed to analysis results in studies of RFS (p < 0.0001). Meta-regression analysis revealed that region and analysis results accounted for heterogeneity in PFS studies (p = 0.00471, p < 0.0001). High Ki-67 expression was associated with poor RFS (pooled HR, 1.78; 95% CI, 1.48-2.15), poor PFS (pooled HR, 1.28; 95% CI, 1.13-2.15), poor DSS (pooled HR, 2.24; 95% CI, 1.47-2.15), and worse OS (pooled HR, 2.29; 95% CI, 1.24-4.22). CONCLUSIONS: The meta-analysis found that current evidence supports the prognostic value of Ki-67 in NMIBC patients. FAU - Ko, Kyungtae AU - Ko K AD - Department of Urology, Kandong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng PT - Journal Article DEP - 20171013 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5725048 OTO - NOTNLM OT - Ki-67 OT - bladder cancer OT - meta-analysis OT - prognosis OT - urothelial carcinoma COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests. EDAT- 2017/12/17 06:00 MHDA- 2017/12/17 06:01 PMCR- 2017/11/21 CRDT- 2017/12/17 06:00 PHST- 2017/08/13 00:00 [received] PHST- 2017/09/23 00:00 [accepted] PHST- 2017/12/17 06:00 [entrez] PHST- 2017/12/17 06:00 [pubmed] PHST- 2017/12/17 06:01 [medline] PHST- 2017/11/21 00:00 [pmc-release] AID - 21899 [pii] AID - 10.18632/oncotarget.21899 [doi] PST - epublish SO - Oncotarget. 2017 Oct 13;8(59):100614-100630. doi: 10.18632/oncotarget.21899. eCollection 2017 Nov 21. PMID- 29245935 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220314 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 59 DP - 2017 Nov 21 TI - Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. PG - 99707-99721 LID - 10.18632/oncotarget.20686 [doi] AB - BACKGROUND: We previously reported an accurate urine-based bladder cancer (BCa)-associated diagnostic signature that can be used to non-invasively detect BCa. In this study, we investigated whether a component of this signature could risk stratify patients with BCa. METHODS: Utilizing immunohistochemistry, we investigated angiogenin, MMP-2, p53, RB and PAI-1 expression from 939 patients with BCa. The expression levels were scored by assigning a proportion score and an intensity score to yield a total staining score for each protein. The expressions of each protein individually and as an aggregate were then correlated with progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). RESULTS: Differential expressions of these markers were noted in BCa. With multivariate analysis in non-muscle invasive bladder cancer (NMIBC) age, tumor grade portended a worse PFS, while age, tumor grade, nodal status, MMP2, RB and PAI-1 expression portended a worse OS. As for multivariate analysis in muscle invasive bladder cancer (MIBC), age MMP-2 and RB were associated with a worse PFS, while age, nodal status, MMP-2, RB and PAI-1 were associated with a worse OS. Using Kaplan-Meier survival analysis, we noted a significant reduction in OS as more of the five biomarkers were expressed in a tumor. Thus, overall, high expressions of MMP-2, RB and/or PAI-1 in bladder tumors were markers of poor prognosis. CONCLUSION: Individually, MMP-2, RB and PAI-1, as well as in aggregate correlated with poor survival in patients with BCa. Thus, patients whose bladder tumors express these biomarkers may benefit from early radical treatment and/or neoadjuvant or adjuvant therapies. FAU - Chan, Owen T M AU - Chan OTM AD - Clinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. FAU - Furuya, Hideki AU - Furuya H AD - Clinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. FAU - Pagano, Ian AU - Pagano I AD - Cancer Prevention and Control Program Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. FAU - Shimizu, Yoshiko AU - Shimizu Y AD - Clinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. AD - Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, HI, USA. FAU - Hokutan, Kanani AU - Hokutan K AD - Clinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. AD - Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, HI, USA. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Departments of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Segersten, Ulrika AU - Segersten U AD - Departments of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Janku, Filip AU - Janku F AD - Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Rosser, Charles J AU - Rosser CJ AD - Clinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. LA - eng GR - R01 CA198887/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170906 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5725126 OTO - NOTNLM OT - IHC OT - MMP-2 OT - PAI-1 OT - angiogenin OT - bladder cancer COIS- CONFLICTS OF INTEREST All authors declare that they have no competing interests. EDAT- 2017/12/17 06:00 MHDA- 2017/12/17 06:01 PMCR- 2017/11/21 CRDT- 2017/12/17 06:00 PHST- 2017/05/07 00:00 [received] PHST- 2017/07/12 00:00 [accepted] PHST- 2017/12/17 06:00 [entrez] PHST- 2017/12/17 06:00 [pubmed] PHST- 2017/12/17 06:01 [medline] PHST- 2017/11/21 00:00 [pmc-release] AID - 20686 [pii] AID - 10.18632/oncotarget.20686 [doi] PST - epublish SO - Oncotarget. 2017 Sep 6;8(59):99707-99721. doi: 10.18632/oncotarget.20686. eCollection 2017 Nov 21. PMID- 29244843 OWN - NLM STAT- MEDLINE DCOM- 20180105 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 12 DP - 2017 TI - Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. PG - e0189354 LID - 10.1371/journal.pone.0189354 [doi] LID - e0189354 AB - The prognostic value of repeat transurethral resection of bladder tumor (TURBT) in patients with diagnosed high-risk, non-muscle-invasive bladder cancer (NMIBC) was investigated. We retrospectively reviewed the medical records of patients treated from October 2004 to December 2013 at Seoul National University who underwent repeated TURBT within 2-6 weeks after an initial resection. The study enrolled patients who had been diagnosed with NMIBC at both the initial and repeat TURBT; patients with muscle-invasive tumors on repeat TURBT were excluded. We used stepwise multivariate Cox regression models stratified by study to assess the independent effects of the predictive factors and estimated hazard ratios (HRs) from the Cox models. We investigated a total of 198 patients who were diagnosed with high-risk NMIBC. In logistic regression analyses, number of bladder tumors (2-7: OR, 2.319; 82.5 mm was used as threshold for detrusor muscle thickening. Patients underwent to adjuvant local treatment in according to their progression and recurrence risk computed by European Organization Research and Treatment of Cancer (EORTC) Score for NMIBC. Every three months cystoscopy and urinary cytology were used to detect disease recurrence and progression. The main clinic-pathological variables were compared between patients with DWT2.5 mm. RESULTS: One hundred patients (49.8%) with DWT >2.5 mm were significantly older, had larger and more tumors and experienced more prior NMIBC than 101 (50.2%) patients with a DWT2.5 was a predictive risk factors of cancer recurrence and progression, respectively: OR 4.9 (95% CI: 2.5-9.5) P=0.001 and OR 2.21 (95% CI: 1.71-4.73), P=0.001. Enclosing DWT in EORTC risk calculator significantly increased by 3% and 1% recurrence and progression risk assessment, respectively. CONCLUSIONS: Detrusor muscle thickening may have a role in NMIBC course with a higher recurrence rate, however further confirmatory and elucidating studies are required. FAU - Cicione, Antonio AU - Cicione A AD - Department of Urology, Citta di Castello Hospital - ASL Umbria 1, Citta di Castello, Perugia, Italy - acicione@libero.it. FAU - Manno, Stefano AU - Manno S AD - Unit of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Ucciero, Giuseppe AU - Ucciero G AD - Unit of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Unit of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Unit of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Lima, Estevao AU - Lima E AD - Life and Health Sciences Research Institute, University of Minho, Braga, Portugal. FAU - Posti, Alessandro AU - Posti A AD - Department of Urology, Citta di Castello Hospital - ASL Umbria 1, Citta di Castello, Perugia, Italy. FAU - Balloni, Filippo AU - Balloni F AD - Department of Urology, Citta di Castello Hospital - ASL Umbria 1, Citta di Castello, Perugia, Italy. FAU - De Nunzio, Cosimo AU - De Nunzio C AD - Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20171214 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 SB - IM MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Risk Assessment MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*epidemiology/*pathology/surgery MH - Urologic Surgical Procedures EDAT- 2017/12/16 06:00 MHDA- 2018/11/08 06:00 CRDT- 2017/12/16 06:00 PHST- 2017/12/16 06:00 [pubmed] PHST- 2018/11/08 06:00 [medline] PHST- 2017/12/16 06:00 [entrez] AID - S0393-2249.17.02992-7 [pii] AID - 10.23736/S0393-2249.17.02992-7 [doi] PST - ppublish SO - Minerva Urol Nefrol. 2018 Jun;70(3):310-318. doi: 10.23736/S0393-2249.17.02992-7. Epub 2017 Dec 14. PMID- 29240252 OWN - NLM STAT- MEDLINE DCOM- 20190227 LR - 20190227 IS - 1097-4644 (Electronic) IS - 0730-2312 (Linking) VI - 119 IP - 6 DP - 2018 Jun TI - Ganoderma microsporum immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells. PG - 4592-4606 LID - 10.1002/jcb.26616 [doi] AB - Current chemotherapy and immunotherapy treatments followed by transurethral resection for urinary bladder urothelial carcinoma (UC) usually suffer from poor prognosis and high recurrence rate. Design and modification of current formulation with the novel adjuvants are needed. A recombinant protein derived from Ganoderma microsporum named as Ganoderma microsporum immunomodulatory protein (GMIP) was used to treat UC cells. We found GMIP elicits a dose-dependent and time-dependent anti-UC cell proliferation effect, with a half-maximal inhibition concentration (IC(50) ) comparable to mitomycin C (MMC), a commonly used chemotherapy agent. After GMIP treatment, UC cells showed apoptotic phenomenon including cell cycle arrest in the G1 phase, elevated sub-G1 population, mitochondrial membrane potential loss, up-regulated p21 expression, p21 nuclear translocation, caspase activation, and PARP cleavage in a p53-independent but p21-mediated pathways. Unlike lung cancer cells, GMIP treated UC cells showed no autophagic scheme including Beclin-1, an autophagy to apoptosis switch marker, was not cleaved by caspase 3 and slight LC3B-II accumulation. Also, the classic autophagic inhibitor, chloroquine had no effect in GMIP-mediated cell death made us conclude that GMIP induced apoptosis through caspase activation but not autophagy in UC cells. Additionally, GMIP showed synergistic effects with MMC in killing UC cells and thus decreased the concentration of MMC usage to reach the comparable apoptotic effects. Our results delineate novel strategies for treatment of UC by GMIP alone or in combination with MMC application and provide a promising therapeutic cocktail for better treatment of urinary bladder urothelial carcinoma. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Huang, Sheng-Yuan AU - Huang SY AD - Proteomics Laboratory, Department of Medical Research, Cathay General Hospital, Taipei, Taiwan. FAU - Chien, Chih-Cheng AU - Chien CC AD - School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. AD - Department of Anesthesiology, Cathay General Hospital, Taipei, Taiwan. FAU - Hseu, Ruey-Shyang AU - Hseu RS AD - Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan. FAU - Huang, Victoria Ying Jen AU - Huang VYJ AD - Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada. FAU - Chiang, Shang Ying AU - Chiang SY AD - Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada. FAU - Huang, Chi-Jung AU - Huang CJ AD - Clinical Gene Laboratory, Department of Medical Research, Cathay General Hospital, Taipei, Taiwan. AD - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan. FAU - Chen, Shao-Kuan AU - Chen SK AD - School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. AD - Department of Urology, Sijhih Cathay General Hospital, New Taipei City, Taiwan. FAU - Tsai, Ru-Yin AU - Tsai RY AD - College of Nursing and Health Science, Da-Yeh University, Changhua, Taiwan. FAU - Lin, Hsi-Ting AU - Lin HT AD - Department of Surgery, Cathay General Hospital, Taipei, Taiwan. AD - Department of Orthopedics, Cathay General Hospital, Taipei, Taiwan. FAU - Cheng, Yu-Che AU - Cheng YC AUID- ORCID: 0000-0002-5346-3610 AD - Proteomics Laboratory, Department of Medical Research, Cathay General Hospital, Taipei, Taiwan. AD - School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. AD - Department of Biomedical Sciences and Engineering, National Central University, Jhongli, Taiwan. AD - Center for Biocellular Engineering, National Central University, Jhongli, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180227 PL - United States TA - J Cell Biochem JT - Journal of cellular biochemistry JID - 8205768 RN - 0 (Fungal Proteins) RN - 0 (Immunologic Factors) RN - 0 (Neoplasm Proteins) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Apoptosis/*drug effects MH - Cell Line, Tumor MH - Fungal Proteins/*pharmacology MH - Ganoderma/*chemistry MH - Gene Expression Regulation, Neoplastic/drug effects MH - Humans MH - Immunologic Factors/*pharmacology MH - Mitomycin/*pharmacology MH - Neoplasm Proteins/biosynthesis MH - Urinary Bladder Neoplasms/*drug therapy/metabolism/pathology OTO - NOTNLM OT - apoptosis OT - bladder urothelial carcinoma OT - ganoderma microsporum immunomodulatory protein OT - mitomycin C EDAT- 2017/12/15 06:00 MHDA- 2019/02/28 06:00 CRDT- 2017/12/15 06:00 PHST- 2017/08/22 00:00 [received] PHST- 2017/12/07 00:00 [accepted] PHST- 2017/12/15 06:00 [pubmed] PHST- 2019/02/28 06:00 [medline] PHST- 2017/12/15 06:00 [entrez] AID - 10.1002/jcb.26616 [doi] PST - ppublish SO - J Cell Biochem. 2018 Jun;119(6):4592-4606. doi: 10.1002/jcb.26616. Epub 2018 Feb 27. PMID- 29235103 OWN - NLM STAT- MEDLINE DCOM- 20190108 LR - 20190108 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 142 IP - 9 DP - 2018 May 1 TI - Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. PG - 1797-1804 LID - 10.1002/ijc.31214 [doi] AB - The association of dietary factors with urinary bladder cancer prognosis has scarcely been investigated, and results of studies conducted to date are inconsistent. We investigated whether empirically derived dietary patterns are associated with risks of recurrence and progression in non-muscle-invasive bladder cancer (NMIBC) patients. Data from 595 newly diagnosed NMIBC patients from an ongoing prospective cohort study were used to derive dietary patterns using exploratory factor analysis. Factor scores were calculated and then categorized in sex-specific tertiles. Multivariable-adjusted proportional hazards regression models were used to estimate hazard ratios and 95% confidence intervals for the associations between tertiles of adherence to the dietary patterns and risks of recurrence and progression. We identified four dietary patterns: "fruits and vegetables," "Western," "low-fat," and "Tex-Mex." Patients in the highest tertile of adherence to the Western pattern experienced a 1.48 times higher risk of recurrence (95% CI 1.06-2.06) compared to patients in the lowest tertile. No statistically significant associations of a Western diet with risk of progression or of the other dietary patterns with risk of recurrence and progression were found. Overall, we found that adherence to a Western diet was associated with a higher risk of recurrence but further studies are needed to confirm our findings. CI - (c) 2017 UICC. FAU - Westhoff, Ellen AU - Westhoff E AUID- ORCID: 0000-0002-1892-3706 AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. FAU - Wu, Xifeng AU - Wu X AUID- ORCID: 0000-0001-5174-3769 AD - Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX. FAU - Ye, Yuanqing AU - Ye Y AD - Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. FAU - Huang, Maosheng AU - Huang M AD - Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. FAU - Vrieling, Alina AU - Vrieling A AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. FAU - Tu, Huakang AU - Tu H AD - Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20171226 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 SB - IM CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S90-S92. doi: 10.21037/tau.2018.01.11. PMID: 29645018 MH - Aged MH - Diet/*statistics & numerical data MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/pathology MH - Prospective Studies MH - Risk Factors MH - Texas/epidemiology MH - Urinary Bladder Neoplasms/*epidemiology/pathology OTO - NOTNLM OT - diet OT - factor analysis OT - prognosis OT - urinary bladder cancer EDAT- 2017/12/14 06:00 MHDA- 2019/01/09 06:00 CRDT- 2017/12/14 06:00 PHST- 2017/06/22 00:00 [received] PHST- 2017/11/18 00:00 [revised] PHST- 2017/11/22 00:00 [accepted] PHST- 2017/12/14 06:00 [pubmed] PHST- 2019/01/09 06:00 [medline] PHST- 2017/12/14 06:00 [entrez] AID - 10.1002/ijc.31214 [doi] PST - ppublish SO - Int J Cancer. 2018 May 1;142(9):1797-1804. doi: 10.1002/ijc.31214. Epub 2017 Dec 26. PMID- 29224014 OWN - NLM STAT- MEDLINE DCOM- 20180813 LR - 20180813 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 100 IP - 1 DP - 2018 TI - Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Increased the Risk of Intravesical Recurrence. PG - 92-99 LID - 10.1159/000484417 [doi] AB - OBJECTIVE: To assess the impact of diagnostic ureteroscopy (URS) prior to radical nephroureterectomy (RNU) on intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: A systematic literature search of the Medline, Embase, PubMed, and Cochrane library was performed in August 2017. Cumulative analyses of available hazard ratios (HRs) and their 95% CI were conducted using Stata version 12.0. RESULTS: Eleven studies including 4,057 participants were included, with a total of 1,403 patients diagnosed with IVR during the follow-up period. The pooled HRs of eight studies suggested that diagnostic URS prior to RNU significantly increased the IVR risk after RNU (HR 1.53, 95% CI 1.31-1.77; p < 0.001). However, the preoperative diagnostic URS was not associated with cancer-specific survival (HR 0.72; p = 0.11), metastasis-free survival (HR 1.09; p = 0.60) or overall survival (HR 1.12; p = 0.73). No publication bias was observed (Begg, p = 0.90; Egger, p = 0.71). CONCLUSIONS: Regardless, the diagnostic URS prior to RNU might increase the IVR risk in patients with UTUC. As ureteroscopy provides important prognostic and therapeutic value and guides decisions in UTUC, more future studies should be performed to find a novel way to mitigate the potential risk of IVR after RNU, such as chemoprophylaxis after endoscopy. CI - (c) 2017 S. Karger AG, Basel. FAU - Tan, Ping AU - Tan P AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Xie, Nan AU - Xie N AD - Department of Emergency, West China Hospital, Sichuan University, Chengdu, China. FAU - Yang, Lu AU - Yang L AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Liangren AU - Liu L AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Tang, Zhuang AU - Tang Z AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wei, Qiang AU - Wei Q AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, China. AD - Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20171208 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Carcinoma, Transitional Cell/*diagnosis/*etiology/surgery MH - Humans MH - Kidney Neoplasms/*diagnosis/surgery MH - *Neoplasm Seeding MH - Nephroureterectomy MH - *Preoperative Care MH - Risk Assessment MH - Ureteral Neoplasms/*diagnosis/surgery MH - Ureteroscopy/*adverse effects MH - Urinary Bladder Neoplasms/*etiology OTO - NOTNLM OT - Intravesical recurrence OT - Nephroureterectomy OT - Upper urinary tract OT - Ureteroscopy OT - Urothelial carcinoma EDAT- 2017/12/11 06:00 MHDA- 2018/08/14 06:00 CRDT- 2017/12/11 06:00 PHST- 2017/09/12 00:00 [received] PHST- 2017/10/18 00:00 [accepted] PHST- 2017/12/11 06:00 [pubmed] PHST- 2018/08/14 06:00 [medline] PHST- 2017/12/11 06:00 [entrez] AID - 000484417 [pii] AID - 10.1159/000484417 [doi] PST - ppublish SO - Urol Int. 2018;100(1):92-99. doi: 10.1159/000484417. Epub 2017 Dec 8. PMID- 29221642 OWN - NLM STAT- MEDLINE DCOM- 20181024 LR - 20220330 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 3 DP - 2018 Mar TI - Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. PG - 89.e1-89.e5 LID - S1078-1439(17)30595-1 [pii] LID - 10.1016/j.urolonc.2017.11.010 [doi] AB - OBJECTIVES: To evaluate whether age affects the clinical benefit afforded by immediate postoperative intravesical instillation of mitomycin C in a contemporary cohort of patients with NMIBC. PATIENTS AND METHODS: A total of 4,258 patients with NMIBC treated with transurethral resection of the bladder with (n = 2,605, 61%) or without (n = 1,652, 39%) one immediate instillation of mitomycin C from 5 institutions (study period: 2000-2007) were included. No patients received adjuvant instillations. A multivariable Cox proportional hazards regression model adjusting for standard clinical and pathological features tested the potential interaction term between age and administration of mitomycin C with regard to disease recurrence. RESULTS: A total of 2,063 patients experienced disease recurrence with a median follow-up of 48 months for those who did not recur. In multivariable Cox regression analysis, immediate postoperative instillation of mitomycin C (HR: 0.62; 95% CI: 0.56-0.68; P<0.0001) and age (HR: 1.04; 95% CI: 1.00-1.09; P = 0.036) were associated with disease recurrence. We observed only slight decreases in recurrence-free survival with age irrespective of treatment administration of mitomycin C or not. CONCLUSION: We confirmed reduced disease recurrence rates associated with 1 immediate postoperative intravesical instillation of mitomycin C in NMIBC patients. The benefit on recurrence-free survival of a postoperative intravesical instillation was preserved across all ages and therefore age by itself should not be taken into consideration when deciding to use it. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. FAU - Kent, Matthew AU - Kent M AD - Department of Statistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Dabi, Yohann AU - Dabi Y AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rieken, Malte AU - Rieken M AD - Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Al Hussein Al Awamlh, Bashir AU - Al Hussein Al Awamlh B AD - Department of Urology, Weill Cornell Medical College, New York, NY. FAU - Ouzaid, Idir AU - Ouzaid I AD - Department of Urology, Bichat Hospital, APHP, Paris Diderot University, Paris, France. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, General Hospital of Bolzano, Bolzano, Italy. FAU - Comploj, Evi AU - Comploj E AD - Department of Urology, General Hospital of Bolzano, Bolzano, Italy. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Canada. FAU - Holmang, Sten AU - Holmang S AD - Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20171206 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Transl Androl Urol. 2018 Apr;7(2):289-291. doi: 10.21037/tau.2018.03.11. PMID: 29733076 MH - Administration, Intravesical MH - Age Factors MH - Aged MH - Antibiotics, Antineoplastic/*therapeutic use MH - Carcinoma, Transitional Cell/mortality/*therapy MH - Chemotherapy, Adjuvant/methods MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*therapeutic use MH - Neoplasm Recurrence, Local/*epidemiology/prevention & control MH - Patient Selection MH - Postoperative Care/methods MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder/surgery MH - Urinary Bladder Neoplasms/mortality/*therapy OTO - NOTNLM OT - Age OT - Bladder cancer OT - Chemotherapy OT - Elderly OT - Immediate instillation EDAT- 2017/12/10 06:00 MHDA- 2018/10/26 06:00 CRDT- 2017/12/10 06:00 PHST- 2017/04/03 00:00 [received] PHST- 2017/11/06 00:00 [revised] PHST- 2017/11/12 00:00 [accepted] PHST- 2017/12/10 06:00 [pubmed] PHST- 2018/10/26 06:00 [medline] PHST- 2017/12/10 06:00 [entrez] AID - S1078-1439(17)30595-1 [pii] AID - 10.1016/j.urolonc.2017.11.010 [doi] PST - ppublish SO - Urol Oncol. 2018 Mar;36(3):89.e1-89.e5. doi: 10.1016/j.urolonc.2017.11.010. Epub 2017 Dec 6. PMID- 29219283 OWN - NLM STAT- MEDLINE DCOM- 20180524 LR - 20220330 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 44 IP - 2 DP - 2018 Mar-Apr TI - Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder. PG - 267-272 LID - 10.1590/S1677-5538.IBJU.2017.0424 [doi] AB - OBJECTIVE: To evaluate the prognostic value of the depth of lamina propria invasion in patients with T1 bladder cancer and to display comparative differences between the T1a/b and T1e/m substaging systems. PATIENTS AND METHODS: This study included 106 patients with primary stage T1 urothelial bladder tumours who underwent surgery between January 2009 and December 2014. Pathologic specimens were re-evaluated to confirm the diagnosis of T1 and substaging by the same pathologist using two systems: T1a and T1b, and T1m and T1e. Age, tumour size, multiplicity, associated carcinoma in situ, tumour grade, and T1 substaging system were investigated to detect the relation between disease progression and recurrence. RESULTS: The recurrence rate was 52% for T1a (n=42) vs. 76% for T1b (n=20) (p=0.028) and 55% for T1m (n=32) vs. 62% for T1e (n=30), respectively (p=0.446). There was no significant difference between the substaging groups for disease progression: T1a (n=12, 15%) vs. T1b (n=7, 27%), and T1m (n=8, 13.8%) vs. T1e (n=11, 23%) (p>0.05). In the multivariate analysis, tumour size >3 cm (p=0.008), multiplicity (p=0.049), and substaging T1b (p=0.043) were independent predictive factors for tumour recurrence. According to the Kaplan-Meier actuarial method, recurrence-free survival was significantly different in patients with pT1a tumours compared with those with pT1b tumours (p=0.033). CONCLUSIONS: Substaging T1 provides a prediction of disease recurrence. Regarding recurrence, T1a/b substaging can provide better knowledge of disease behaviour because it is predicted as more superior than T1 m/e, and it can help in determining the requirement for early cystectomy. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Turan, Turgay AU - Turan T AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. FAU - Efiloglu, Ozgur AU - Efiloglu O AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. FAU - Gunaydin, Bilal AU - Gunaydin B AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. FAU - Ozkanli, Seyma AU - Ozkanli S AD - Istanbul Medeniyet University, Faculty of Medicine, Department of Pathology, Istanbul, Turkey. FAU - Nikerel, Emrah AU - Nikerel E AD - Yeditepe Universitesi, Genetics and Bioengineering Istanbul, Turkey. FAU - Atis, Gokhan AU - Atis G AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. FAU - Caskurlu, Turhan AU - Caskurlu T AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey. LA - eng PT - Comparative Study PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Mucous Membrane/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - *Neoplasm Staging MH - Prognosis MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology PMC - PMC6050560 OTO - NOTNLM OT - Carcinoma OT - Urinary Bladder OT - Urinary Bladder Neoplasms COIS- Conflict of interest: None declared. EDAT- 2017/12/09 06:00 MHDA- 2018/05/25 06:00 PMCR- 2018/03/01 CRDT- 2017/12/09 06:00 PHST- 2017/07/19 00:00 [received] PHST- 2017/11/23 00:00 [accepted] PHST- 2017/12/09 06:00 [pubmed] PHST- 2018/05/25 06:00 [medline] PHST- 2017/12/09 06:00 [entrez] PHST- 2018/03/01 00:00 [pmc-release] AID - IBJU20170424 [pii] AID - S1677-5538.IBJU.2017.0424 [pii] AID - 10.1590/S1677-5538.IBJU.2017.0424 [doi] PST - ppublish SO - Int Braz J Urol. 2018 Mar-Apr;44(2):267-272. doi: 10.1590/S1677-5538.IBJU.2017.0424. PMID- 29207636 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 53 DP - 2017 Oct 31 TI - Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. PG - 91199-91208 LID - 10.18632/oncotarget.20043 [doi] AB - The mechanisms of bladder cancer progression are unknown, and new treatments and biomarkers are needed. Patient urinary extracellular vesicles (EVs) derive in part from bladder cancer cells and contain a specific protein cargo which may provide information about the disease. We conducted a proteomics study comparing EVs from the muscle-invasive bladder cancer (MIBC) cell line TCCSUP to EVs from normal urothelial line SVHUC. GO term analysis showed that TCCSUP EVs are enriched in proteins associated with the cell membrane, extracellular matrix, and inflammation and angiogenesis signaling pathways. Proteins characteristic of cancer EVs were further screened at the mRNA level in bladder cancer cell lines. In Western blots, three of six proteins examined showed greater than fifteenfold enrichment in patient urinary EVs compared to healthy volunteers (n = 6). Finally, we performed immunohistochemical staining of bladder tissue microarrays for three proteins of interest. One of them, transaldolase (TALDO1), is a nearly ubiquitous enzyme and normally thought to reside in the cytoplasm. To our surprise, nuclei were stained for transaldolase in 94% of MIBC tissue samples (n = 51). While cytoplasmic transaldolase was found in 89-90% of both normal urothelium (n = 79) and non-muscle-invasive samples (n = 71), the rate falls to 39% in MIBC samples (P < 0.001), and negative cytoplasmic staining was correlated with worse cancer-specific survival in MIBC patients (P = 0.008). The differential EV proteomics strategy reported here successfully identified a number of proteins associated with bladder cancer and points the way to future investigation. FAU - Silvers, Christopher R AU - Silvers CR AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Messing, Edward M AU - Messing EM AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Netto, George J AU - Netto GJ AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Lee, Yi-Fen AU - Lee YF AD - Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. AD - Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. LA - eng GR - R01 CA173986/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170808 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5710916 OTO - NOTNLM OT - bladder cancer OT - exosomes OT - extracellular vesicles OT - proteomic OT - transaldolase COIS- CONFLICTS OF INTEREST None. EDAT- 2017/12/07 06:00 MHDA- 2017/12/07 06:01 PMCR- 2017/10/31 CRDT- 2017/12/07 06:00 PHST- 2017/01/10 00:00 [received] PHST- 2017/07/26 00:00 [accepted] PHST- 2017/12/07 06:00 [entrez] PHST- 2017/12/07 06:00 [pubmed] PHST- 2017/12/07 06:01 [medline] PHST- 2017/10/31 00:00 [pmc-release] AID - 20043 [pii] AID - 10.18632/oncotarget.20043 [doi] PST - epublish SO - Oncotarget. 2017 Aug 8;8(53):91199-91208. doi: 10.18632/oncotarget.20043. eCollection 2017 Oct 31. PMID- 29203988 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220408 IS - 0975-7651 (Print) IS - 0976-6952 (Electronic) IS - 0975-7651 (Linking) VI - 8 IP - 4 DP - 2017 Dec TI - Correlation of Transabdominal Ultrasonography and Cystoscopy in Follow-up of Patients with Non-muscle Invasive Bladder Cancer. PG - 548-553 LID - 10.1007/s13193-017-0678-6 [doi] AB - Cystoscopy (CS) is considered to be the gold standard in the follow-up of non-muscle invasive bladder cancer. However, CS is invasive, time-consuming, and expensive. On the other hand, modern sensitive transducers have improved the imaging of urinary tract rendering transabdominal ultrasonography (US) more effective in visualizing intraluminal filling defects in the bladder than it was in the past. Twenty-five follow-up patients of low-risk bladder cancer meeting the inclusion and exclusion criteria were included in study. Ultrasonography of the bladder was performed by a single senior radiologist, and subsequently, these patients were subjected to flexible cystoscopy under local anesthesia. Pain score was calculated for each of the cystoscopies done. Findings of transabdominal ultrasound of the bladder were correlated and compared with those of cystoscopy. Subjects with US and/or CS findings suggestive of recurrence underwent transurethral resection of bladder tumor (TURBT) under general anesthesia and confirmation of the bladder carcinoma was achieved by the histopathological examination. Mean patient age was 60.56 years with range of 29 to 77 years. The sensitivity of modern ultrasonographic techniques was found to be 84.61% with specificity of 91.7% taking flexible cystoscopy as the gold standard for detection of recurrence. The accuracy of US was 88% with positive predictive value of 91.7% and negative predictive value of 84.61%. Technological evolution has improved the accuracy of ultrasonography in diagnosis of bladder carcinoma. It represents a valuable surveillance tool in selected sub group of low risk non-muscle invasive bladder cancer patients. FAU - Puneet, Ahluwalia AU - Puneet A AUID- ORCID: 0000-0003-0937-6023 AD - Department of Surgical Oncology, Max Institute of Cancer Care, Max Smart Superspeciality Hospital, Press Enclave Road, Saket, New Delhi, 110017 India. FAU - Balagopal, Nair AU - Balagopal N AD - Department of Urology, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Kerala 682041 India. GRID: grid.427788.6 FAU - Ginil, Kumar AU - Ginil K AD - Department of Urology, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Kerala 682041 India. GRID: grid.427788.6 FAU - Georgie, Mathew AU - Georgie M AD - Department of Urology, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Kerala 682041 India. GRID: grid.427788.6 FAU - Sanjeevan, K V AU - Sanjeevan KV AD - Department of Urology, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Kerala 682041 India. GRID: grid.427788.6 FAU - Appu, Thomas AU - Appu T AD - Department of Urology, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Kerala 682041 India. GRID: grid.427788.6 LA - eng PT - Journal Article DEP - 20170721 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC5705512 OTO - NOTNLM OT - Cystoscopy OT - Non-muscle invasive bladder cancer OT - Surveillance OT - Ultrasonography COIS- SOURCES OF SUPPORT: Nil. CONFLICT OF INTEREST: The authors declare that they have no conflict of interest. EDAT- 2017/12/06 06:00 MHDA- 2017/12/06 06:01 PMCR- 2018/12/01 CRDT- 2017/12/06 06:00 PHST- 2016/08/05 00:00 [received] PHST- 2017/07/11 00:00 [accepted] PHST- 2017/12/06 06:00 [entrez] PHST- 2017/12/06 06:00 [pubmed] PHST- 2017/12/06 06:01 [medline] PHST- 2018/12/01 00:00 [pmc-release] AID - 678 [pii] AID - 10.1007/s13193-017-0678-6 [doi] PST - ppublish SO - Indian J Surg Oncol. 2017 Dec;8(4):548-553. doi: 10.1007/s13193-017-0678-6. Epub 2017 Jul 21. PMID- 29201501 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 43 IP - 4 DP - 2017 Dec TI - Alternative therapies in patients with non-muscle invasive bladder cancer. PG - 414-424 LID - 10.5152/tud.2017.64624 [doi] AB - Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized. FAU - Sanli, Oner AU - Sanli O AD - Department of Urology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. LA - eng PT - Journal Article PT - Review DEP - 20171201 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 EIN - Turk J Urol. 2018 Jan;44(1):92. doi: 10.5152/tud.2018.0801182. PMID: 29485146 PMC - PMC5687201 OTO - NOTNLM OT - BCG OT - bladder cancer OT - instillation OT - survival COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2017/12/05 06:00 MHDA- 2017/12/05 06:01 PMCR- 2017/12/01 CRDT- 2017/12/05 06:00 PHST- 2017/10/10 00:00 [received] PHST- 2017/10/19 00:00 [accepted] PHST- 2017/12/05 06:00 [entrez] PHST- 2017/12/05 06:00 [pubmed] PHST- 2017/12/05 06:01 [medline] PHST- 2017/12/01 00:00 [pmc-release] AID - tju-43-4-414 [pii] AID - 10.5152/tud.2017.64624 [doi] PST - ppublish SO - Turk J Urol. 2017 Dec;43(4):414-424. doi: 10.5152/tud.2017.64624. Epub 2017 Dec 1. PMID- 29200869 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 10 DP - 2017 TI - Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. PG - 5541-5550 LID - 10.2147/OTT.S146990 [doi] AB - BACKGROUND AND OBJECTIVES: Among the cancers of the urogenital system, bladder cancer is ranked second both in incidence and mortality, and hence, a more accurate estimate of the prognosis for individual patients with non-muscle-invasive bladder cancer (NMIBC) is urgently needed. Prognostic nutritional index (PNI) which is based on serum albumin levels and peripheral lymphocyte count has been confirmed to have prognostic value in various cancers. The aim of this study was to clarify the prognostic value of PNI in patients with NMIBC. METHODS: Data of 329 patients with NMIBC were evaluated retrospectively. Recurrence-free survival (RFS) was assessed using the Kaplan-Meier method, and the equivalences of survival curves were tested by log-rank tests. The univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Discrimination of the nomogram was measured by the concordance index. A p-value of <0.05 was considered statistically significant. RESULTS: In univariate analysis, age, tumor focality, tumor size, tumor grade, pathological T stage and preoperative PNI were significantly associated with RFS. Multivariate analysis identified PNI as an independent predictor of RFS in patients with NMIBC. According to these independent predictors, a nomogram for the prediction of recurrence was developed. CONCLUSION: PNI can be regarded as an independent prognostic factor for predicting RFS in NMIBC. The nomogram could be useful to improve personalized therapy for patients with NMIBC. FAU - Cui, Jianfeng AU - Cui J AD - Department of Urology. FAU - Chen, Shouzhen AU - Chen S AD - Department of Urology. FAU - Bo, Qiyu AU - Bo Q AD - Department of First Operating Room, Qilu Hospital of Shandong University. FAU - Wang, Shiyu AU - Wang S AD - Department of Urology. FAU - Zhang, Ning AU - Zhang N AD - Department of Urology. FAU - Yu, Meng AU - Yu M AD - Department of Urology. FAU - Wang, Wenfu AU - Wang W AD - Department of Urology. FAU - Han, Jie AU - Han J AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute Affiliated to Shandong University, Jinan, People's Republic of China. FAU - Zhu, Yaofeng AU - Zhu Y AD - Department of Urology. FAU - Shi, Benkang AU - Shi B AD - Department of Urology. LA - eng PT - Journal Article DEP - 20171121 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC5702160 OTO - NOTNLM OT - nomogram OT - non-muscle-invasive bladder cancer OT - prognosis OT - prognostic nutritional index OT - recurrence-free survival COIS- Disclosure None of the contributing authors have any conflict of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. EDAT- 2017/12/05 06:00 MHDA- 2017/12/05 06:01 PMCR- 2017/11/21 CRDT- 2017/12/05 06:00 PHST- 2017/12/05 06:00 [entrez] PHST- 2017/12/05 06:00 [pubmed] PHST- 2017/12/05 06:01 [medline] PHST- 2017/11/21 00:00 [pmc-release] AID - ott-10-5541 [pii] AID - 10.2147/OTT.S146990 [doi] PST - epublish SO - Onco Targets Ther. 2017 Nov 21;10:5541-5550. doi: 10.2147/OTT.S146990. eCollection 2017. PMID- 29199023 OWN - NLM STAT- MEDLINE DCOM- 20190204 LR - 20211204 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 16 IP - 2 DP - 2018 Apr TI - The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. PG - e269-e276 LID - S1558-7673(17)30317-8 [pii] LID - 10.1016/j.clgc.2017.10.011 [doi] AB - The phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is a well studied signaling pathway that regulates diverse cellular functions including proliferation, metabolism, and transcription. Aberrant activation of this pathway has been implicated in multiple cancers. Genomic studies have shown that activating mutations in oncogenes as well as inactivating mutations in tumor suppressor genes are present across a variety of malignancies, including urothelial carcinoma. In bladder cancer, up to 40% of tumors exhibit constitutive activation of the PI3K/AKT/mTOR pathway. Current treatments for non-muscle-invasive disease confer a 5-year cancer-specific survival rate as high as 90%. However, patients with muscle-invasive, recurrent, or metastatic disease have a poor prognosis. Although the introduction of immune checkpoint inhibitors is certainly changing the therapeutic landscape and is a great addition to the platinum-based therapy that was the standard of care for the past 3 decades, it is anticipated that a great number of patients would fail to respond or their disease would progress with either chemotherapy or immunotherapy. Therefore, the use of agents that target members of the PI3K/AKT/mTOR pathway represent an attractive, alternative therapeutic strategy for patients with advanced urothelial carcinoma. In this review we describe the pathway, with a focus on the rationale for targeting the PI3K/AKT/mTOR pathway in patients with advanced urothelial carcinoma and considers the challenges that we face from the current clinical trials. Novel agents such as PI3K inhibitors and microRNA inhibitors that target this pathway might lead to durable responses especially when used in combination with chemotherapy or immune checkpoint inhibitors, however, toxicity remains an obstacle. Finally, in this review we discuss the importance of developing biomarkers to help select appropriate patients and identify optimal treatment options. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Liu, Sandy T AU - Liu ST AD - Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. FAU - Hui, Gavin AU - Hui G AD - David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. FAU - Mathis, Colleen AU - Mathis C AD - Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. FAU - Chamie, Karim AU - Chamie K AD - Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. FAU - Pantuck, Allan J AU - Pantuck AJ AD - Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. FAU - Drakaki, Alexandra AU - Drakaki A AD - Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address: adrakaki@mednet.ucla.edu. LA - eng PT - Journal Article PT - Review DEP - 20171103 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Antineoplastic Agents/pharmacology/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/metabolism MH - Clinical Trials as Topic MH - Humans MH - Immunotherapy MH - Phosphatidylinositol 3-Kinase/metabolism MH - Prognosis MH - Protein Kinase Inhibitors/pharmacology/therapeutic use MH - Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction/*drug effects MH - Standard of Care MH - TOR Serine-Threonine Kinases/metabolism MH - Urinary Bladder Neoplasms/*drug therapy/metabolism OTO - NOTNLM OT - Bladder cancer OT - Inhibitors OT - PI3K OT - Targeted therapy OT - mTOR EDAT- 2017/12/05 06:00 MHDA- 2019/02/05 06:00 CRDT- 2017/12/05 06:00 PHST- 2017/05/26 00:00 [received] PHST- 2017/10/13 00:00 [revised] PHST- 2017/10/14 00:00 [accepted] PHST- 2017/12/05 06:00 [pubmed] PHST- 2019/02/05 06:00 [medline] PHST- 2017/12/05 06:00 [entrez] AID - S1558-7673(17)30317-8 [pii] AID - 10.1016/j.clgc.2017.10.011 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. PMID- 29198850 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 113 DP - 2018 Mar TI - Safety and Efficacy of En Bloc Transurethral Resection With 1.9 microm Vela Laser for Treatment of Non-Muscle-invasive Bladder Cancer. PG - 246-250 LID - S0090-4295(17)31231-1 [pii] LID - 10.1016/j.urology.2017.11.030 [doi] AB - OBJECTIVES: To evaluate the safety and efficacy of 1.9 microm Vela laser in treatment of primary non-muscle-invasive bladder cancer. METHODS: The data of the patients with non-muscle-invasive bladder cancer treated by either en bloc transurethral resection with 1.9 microm Vela laser (n = 26) or conventional transurethral resection of bladder tumor (n = 44) were analyzed retrospectively. The preoperative characteristics and intraoperative complications were compared in the 2 groups. RESULTS: Patients who were treated by 1.9 microm Vela laser obtained a higher rate of specimens meeting the requirements of pathologic assessment for tumor staging compared with the patients treated by conventional transurethral resection of bladder tumor. No obturator nerve reflex and bladder perforation occurred during surgery in the 1.9 microm Vela laser group. However, 7 patients in the conventional transurethral resection of bladder tumor group encountered obturator nerve reflex, and 3 of them encountered bladder perforation (P <.05). There were no significant differences between the 2 groups in operative duration and transfusion rate. Patients in the 1.9 microm Vela laser group had shorter postoperative continuous bladder irrigation time than that in the conventional transurethral resection of bladder tumor group. There was no significant difference in the overall recurrence rate between the 2 groups during the follow-up periods. CONCLUSION: En bloc transurethral resection with 1.9 microm Vela laser in the treatment of non-muscle-invasive bladder cancer demonstrates an advantage over conventional transurethral resection of bladder tumor in reducing intraoperative complications, improving the quality of the specimens admitted for pathologic assessment, and shortening the duration of postoperative continuous bladder irrigation. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Xu, Hao AU - Xu H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Ma, Jun AU - Ma J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Chen, Zhong AU - Chen Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: chenzhongtj@126.com. FAU - Yang, Jun AU - Yang J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Yuan, Huixin AU - Yuan H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Wang, Tao AU - Wang T AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Liu, Jihong AU - Liu J AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Yang, Weimin AU - Yang W AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. FAU - Ye, Zhangqun AU - Ye Z AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. LA - eng PT - Comparative Study PT - Journal Article DEP - 20171202 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Adult MH - Aged MH - Blood Loss, Surgical/physiopathology MH - Carcinoma, Transitional Cell/mortality/pathology/surgery MH - Cohort Studies MH - Cystectomy/*methods MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Laser Therapy/*methods MH - Lasers, Solid-State MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Operative Time MH - Patient Safety MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/*pathology/*surgery EDAT- 2017/12/05 06:00 MHDA- 2018/12/12 06:00 CRDT- 2017/12/05 06:00 PHST- 2017/06/21 00:00 [received] PHST- 2017/10/07 00:00 [revised] PHST- 2017/11/18 00:00 [accepted] PHST- 2017/12/05 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2017/12/05 06:00 [entrez] AID - S0090-4295(17)31231-1 [pii] AID - 10.1016/j.urology.2017.11.030 [doi] PST - ppublish SO - Urology. 2018 Mar;113:246-250. doi: 10.1016/j.urology.2017.11.030. Epub 2017 Dec 2. PMID- 29196179 OWN - NLM STAT- MEDLINE DCOM- 20181022 LR - 20250623 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 2 DP - 2018 Feb TI - Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis. PG - 54-59 LID - S1078-1439(17)30592-6 [pii] LID - 10.1016/j.urolonc.2017.11.007 [doi] AB - PURPOSE: Currently, identified factors for urethral recurrence (UR) are based on individual reporting which has displayed controversy. In addition, risk of UR is one of the limiting factors to offer neobladder diversion during radical cystectomy (RC). We aim to systematically evaluate the incidence and risk factors of UR post-RC and its effect on survival. MATERIALS AND METHODS: A systematic online search was conducted according to PRISMA statement for publications reporting on UR after RC. From initial 802 results, 14 articles including 6169 patients were included finally after exclusion of ineligible studies. RESULTS: The incidence rate of UR was 4.4% (1.3%-13.7%). It was significantly lower with neobladder diversion (odds ratio = 0.44, 95% CI: 0.24-0.79, P = 0.006). Muscle invasion (hazard ratio = 1.18, 95% CI: 0.86-1.62, P = 0.31), carcinoma in situ (hazard ratio 0.97, 95% CI: 0.64-1.47, P = 0.88), prostatic stromal involvement (hazard ratio = 2.26, 95% CI: 0.01-627.75, P = 0.78), and prostatic urethral involvement (hazard ratio = 2.04, 95% CI: 0.20-20.80, P = 0.55) have no significant effect on UR. Men displayed tendency toward higher incidence of UR (odds ratio = 2.21, 95% CI: 0.96-5.06, P = 0.06). Absence of recurrence displayed tendency toward better disease specific survival, yet not significant (hazard ratio = 0.84, 95% CI: 0.66-1.08, P = 0.17). These results are limited by the retrospective nature of the included studies. CONCLUSION: Muscle invasion, carcinoma in situ and prostatic stromal or urethral involvement at time of RC have no significant effect on UR. Orthotopic neobladder is associated with a significant lower risk of UR after RC. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Fahmy, Omar AU - Fahmy O AD - Department of Urology, Universiti Putra Malaysia (UPM), Selangor, Malaysia. Electronic address: omarfahmy.ahmed@upm.edu.my. FAU - Khairul-Asri, Mohd Ghani AU - Khairul-Asri MG AD - Department of Urology, Universiti Putra Malaysia (UPM), Selangor, Malaysia. FAU - Schubert, Tina AU - Schubert T AD - Department of Urology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Renninger, Markus AU - Renninger M AD - Department of Urology, Eberhard-Karls University, Tubingen, Germany. FAU - Kubler, Hubert AU - Kubler H AD - Department of Urology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls University, Tubingen, Germany. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital Wurzburg, Wurzburg, Germany. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20171128 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystectomy/*methods MH - Humans MH - Kaplan-Meier Estimate MH - Neoplasm Recurrence, Local MH - Risk Factors MH - Urethra/*pathology MH - Urinary Bladder/pathology/surgery MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Neobladder OT - Radical cystectomy OT - Urethral recurrence OT - Urothelial carcinoma EDAT- 2017/12/03 06:00 MHDA- 2018/10/23 06:00 CRDT- 2017/12/03 06:00 PHST- 2017/08/18 00:00 [received] PHST- 2017/11/05 00:00 [revised] PHST- 2017/11/12 00:00 [accepted] PHST- 2017/12/03 06:00 [pubmed] PHST- 2018/10/23 06:00 [medline] PHST- 2017/12/03 06:00 [entrez] AID - S1078-1439(17)30592-6 [pii] AID - 10.1016/j.urolonc.2017.11.007 [doi] PST - ppublish SO - Urol Oncol. 2018 Feb;36(2):54-59. doi: 10.1016/j.urolonc.2017.11.007. Epub 2017 Nov 28. PMID- 29196070 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20191210 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 113 DP - 2018 Mar TI - Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study. PG - 71-78 LID - S0090-4295(17)31223-2 [pii] LID - 10.1016/j.urology.2017.11.025 [doi] AB - OBJECTIVE: To clarify the clinical utility of urinary DNA methylation for detection of intravesical recurrence of non-muscle invasive BCa (NMIBC), we performed a 2-center prospective study. PATIENTS AND METHODS: A series of 207 self-voided urine samples were prospectively collected from 132 patients with NMIBC who had undergone transurethral resection of BCa. Methylation of miRNA genes (miR-9-3, miR-124-2, miR-124-3, and miR-137) was analyzed using bisulfite pyrosequencing. The primary end point was detection of intravesical recurrence; the secondary end point was prediction of late recurrence. The number of methylated genes (M-score) or quantitative level of methylation were compared with outcomes. RESULTS: Twenty-six urine specimens were collected on the same day intravesical recurrence was detected, and 14 were collected from patients whose recurrences were found during the subsequent follow-up period (0-632 days, mean, 342.2 days). For detection of current recurrence, M-scores achieved 61.5% sensitivity and 74.0% specificity, and the area under the ROC curve was 0.71. Regarding prediction of late recurrence, patients with a high M-score (>/=3) showed worse recurrence-free survival (P <.01). Multivariate analysis revealed that high M-scores were independently associated with current (P = .028) and late recurrence (P = .026). Elevated levels of urinary DNA methylation were also strongly associated with recurrence and radical cystectomy. CONCLUSION: Our data suggest that urinary methylation of miRNA genes may be a useful marker for detecting and predicting BCa recurrence. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Shindo, Tetsuya AU - Shindo T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Shimizu, Takashi AU - Shimizu T AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Nojima, Masanori AU - Nojima M AD - Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan. FAU - Niinuma, Takeshi AU - Niinuma T AD - Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Maruyama, Reo AU - Maruyama R AD - Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kitajima, Hiroshi AU - Kitajima H AD - Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Kai, Masahiro AU - Kai M AD - Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. FAU - Itoh, Naoki AU - Itoh N AD - Department of Urology, NTT East Corporation Sapporo Hospital, Sapporo, Japan. FAU - Suzuki, Hiromu AU - Suzuki H AD - Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: hsuzuki@sapmed.ac.jp. FAU - Masumori, Naoya AU - Masumori N AD - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. LA - eng PT - Evaluation Study PT - Journal Article PT - Multicenter Study DEP - 20171128 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell/*genetics/mortality/surgery MH - Cohort Studies MH - DNA Methylation MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Neoplasm Staging MH - Prognosis MH - Prospective Studies MH - ROC Curve MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*genetics/mortality/surgery EDAT- 2017/12/03 06:00 MHDA- 2018/12/12 06:00 CRDT- 2017/12/03 06:00 PHST- 2017/08/27 00:00 [received] PHST- 2017/11/08 00:00 [revised] PHST- 2017/11/14 00:00 [accepted] PHST- 2017/12/03 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2017/12/03 06:00 [entrez] AID - S0090-4295(17)31223-2 [pii] AID - 10.1016/j.urology.2017.11.025 [doi] PST - ppublish SO - Urology. 2018 Mar;113:71-78. doi: 10.1016/j.urology.2017.11.025. Epub 2017 Nov 28. PMID- 29187447 OWN - NLM STAT- MEDLINE DCOM- 20171219 LR - 20171219 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 12 DP - 2017 Dec TI - Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer. PG - 6705-6714 AB - BACKGROUND/AIM: Bladder cancer (BC) has a high recurrence rate and may progress to being a muscle-invasive lesion, that is potentially associated with a poor prognosis. We identified tumor-associated proteins that were recognized by autoantibodies in sera from patients with high-grade non-muscle-invasive bladder cancer (HG-NMIBC) by proteomic analysis. MATERIALS AND METHODS: The serum levels of these autoantibodies against identified proteins were validated by dot blot analysis with sera from 95 patients with BC and 35 healthy controls. The expression of identified proteins was immunohistochemically analyzed in 115 BC tissues. RESULTS: Autoantibody against protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA) protein was detected in pretreated sera from patients with HG-NMIBC who showed progression. The serum IgG level of anti-PPP1CA autoantibody was significantly correlated with pathological stage, grade, lymphovascular invasion, and prognosis. The immunoreactions for PPP1CA protein in BC was significantly correlated with pathological stage, grade, and lymphovascular invasion. CONCLUSION: PPP1CA is a candidate sero-diagnostic and prognostic marker for patients with BC. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Minami, Sho AU - Minami S AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. FAU - Matsumoto, Kazumasa AU - Matsumoto K AD - Department of Urology, School of Medicine, Kitasato University, Sagamihara, Japan kazumasa@cd5.so-net.ne.jp. FAU - Nagashio, Ryo AU - Nagashio R AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. AD - Department of Molecular Diagnosis, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan. FAU - Hagiuda, Daisuke AU - Hagiuda D AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. FAU - Fukuda, Eriko AU - Fukuda E AD - Functional Proteomics Team, Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan. FAU - Goshima, Naoki AU - Goshima N AD - Functional Proteomics Team, Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan. FAU - Hattori, Manabu AU - Hattori M AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. AD - Department of Clinical Cytology, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan. FAU - Tsuchiya, Benio AU - Tsuchiya B AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. AD - Department of Pathology, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan. FAU - Hachimura, Kazuo AU - Hachimura K AD - Department of Molecular Diagnosis, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan. FAU - Jiang, Shi-Xu AU - Jiang SX AD - Department of Pathology, School of Medicine, Kitasato University, Sagamihara, Japan. FAU - Saegusa, Makoto AU - Saegusa M AD - Department of Pathology, School of Medicine, Kitasato University, Sagamihara, Japan. FAU - Iwamura, Masatsugu AU - Iwamura M AD - Department of Urology, School of Medicine, Kitasato University, Sagamihara, Japan. FAU - Sato, Yuichi AU - Sato Y AD - Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan. AD - Department of Molecular Diagnosis, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Autoantibodies) RN - 0 (Immunoglobulin G) RN - 0 (Proteome) RN - EC 3.1.3.16 (PPP1CA protein, human) RN - EC 3.1.3.16 (Protein Phosphatase 1) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Autoantibodies/blood/*immunology MH - Disease Progression MH - Female MH - Humans MH - Immunoglobulin G/blood/immunology MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Prognosis MH - Protein Phosphatase 1/immunology/metabolism MH - Proteome/*immunology MH - Proteomics/*methods MH - Urinary Bladder Neoplasms/blood/*immunology/metabolism OTO - NOTNLM OT - Bladder cancer OT - PPP1CA OT - autoantibody OT - biomarker OT - serum EDAT- 2017/12/01 06:00 MHDA- 2017/12/20 06:00 CRDT- 2017/12/01 06:00 PHST- 2017/09/05 00:00 [received] PHST- 2017/09/22 00:00 [revised] PHST- 2017/09/27 00:00 [accepted] PHST- 2017/12/01 06:00 [entrez] PHST- 2017/12/01 06:00 [pubmed] PHST- 2017/12/20 06:00 [medline] AID - 37/12/6705 [pii] AID - 10.21873/anticanres.12129 [doi] PST - ppublish SO - Anticancer Res. 2017 Dec;37(12):6705-6714. doi: 10.21873/anticanres.12129. PMID- 29181884 OWN - NLM STAT- MEDLINE DCOM- 20180904 LR - 20260127 IS - 1098-2264 (Electronic) IS - 1045-2257 (Linking) VI - 57 IP - 3 DP - 2018 Mar TI - miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. PG - 150-161 LID - 10.1002/gcc.22516 [doi] AB - Clinical heterogeneity of bladder cancer prognosis requires the identification of bladder tumors' molecular profile to improve the prediction value of the established and clinically used markers. In this study, we have analyzed miR-221/222 cluster expression in bladder tumors and its clinical significance for patients' prognosis and disease outcome. The study included 387 tissue specimens. Following extraction, total RNA was polyadenylated at 3'-end and reversed transcribed. SYBR-Green based qPCR assays were performed for the quantification of miR-221/222 expression. Extensive statistical analysis was completed for the evaluation of miR-221/222 cluster's clinical significance. The expression of miR-221/222 is significantly downregulated in tumors compared to normal urothelium, while ROC curve and logistic regression analysis highlighted cluster's discriminatory ability. However, miR-222 levels were increased in muscle-invasive (T2-T4) compared to superficial tumors (TaT1), and in high compared to low-grade tumors. Kaplan-Meier survival curves and Cox regression analysis revealed the stronger risk of TaT1 patients overexpressing miR-222 for disease short-term relapse and progression following treatment. Moreover, multivariate Cox models highlighted the independent prognostic value of miR-222 overexpression for TaT1 patients' poor prognosis. Finally, the analysis of miR-222 expression improved significantly the positive prediction strength of the clinically used prognostic markers of tumor stage, grade, EORTC risk-stratification and recurrence at the first follow-up cystoscopy for TaT1 patients' outcome, and resulted to higher clinical net benefit following decision curve analysis. In conclusion, the expression of miR-221/222 cluster is deregulated in bladder tumors and miR-222 overexpression results to a superior positive prediction of TaT1 patients' short-term relapse and progression. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Tsikrika, Foteini D AU - Tsikrika FD AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, 157 01, Greece. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, 157 01, Greece. FAU - Levis, Panagiotis K AU - Levis PK AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Agiou Thoma 17, Athens, 115 27, Greece. FAU - Tokas, Theodoros AU - Tokas T AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Agiou Thoma 17, Athens, 115 27, Greece. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - First Department of Urology, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Agiou Thoma 17, Athens, 115 27, Greece. FAU - Scorilas, Andreas AU - Scorilas A AUID- ORCID: 0000-0003-2427-4949 AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, 157 01, Greece. LA - eng PT - Journal Article DEP - 20171215 PL - United States TA - Genes Chromosomes Cancer JT - Genes, chromosomes & cancer JID - 9007329 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (MIR221, human) RN - 0 (MIR222, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Disease Progression MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Male MH - MicroRNAs/biosynthesis/*genetics MH - Neoplasm Recurrence, Local/genetics/pathology MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/*genetics/pathology EDAT- 2017/11/29 06:00 MHDA- 2018/09/05 06:00 CRDT- 2017/11/29 06:00 PHST- 2017/06/08 00:00 [received] PHST- 2017/10/12 00:00 [revised] PHST- 2017/11/24 00:00 [accepted] PHST- 2017/11/29 06:00 [pubmed] PHST- 2018/09/05 06:00 [medline] PHST- 2017/11/29 06:00 [entrez] AID - 10.1002/gcc.22516 [doi] PST - ppublish SO - Genes Chromosomes Cancer. 2018 Mar;57(3):150-161. doi: 10.1002/gcc.22516. Epub 2017 Dec 15. PMID- 29179514 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 51 DP - 2017 Oct 24 TI - Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma. PG - 89228-89235 LID - 10.18632/oncotarget.19159 [doi] AB - Transurethral bladder tumor resection (TURBT) reportedly increases the circulating tumor cell count in patients with urothelial carcinoma of the bladder (UCB). To determine whether diagnostic TURBT leads to poorer progression-free survival (PFS) than diagnostic cystoscopic biopsy, we retrospectively reviewed the records of 96 consecutive primary pathological high-grade, stage T3/T4 UCB patients treated with radical cystectomy (RC) between January 2009 to December 2013. Clinicopathological features were collected from the medical records. PFS was determined from Kaplan-Meier curves, and potential independent prognostic factors for PFS were identified based on multivariable Cox analysis. During the follow-up period (median, 29 months), 43 patients experienced tumor progression (40 received diagnostic TURBT, 56 received cystoscopic biopsy). Patients who received cystoscopic biopsy had better PFS than those who received diagnostic TURBT (p = 0.008). Additionally, diagnostic TURBT was a significant risk factor for tumor metastasis in both univariable (HR: 2.219; 95% CI: 1.207-4.079; p = 0.010) and multivariable (HR: 2.455; 95% CI: 1.278-4.714; p = 0.007) Cox analyses. The present study provides the first evidence that diagnostic TURBT before RC negatively affects PFS in patients with pathological high-grade, stage T3/T4 UCB. FAU - Huang, Haichao AU - Huang H AD - Department of Urology, The First Affiliated Hospital of Xiamen University, Siming District, Xiamen, Fujian 361003, China. FAU - Liu, Zhenhua AU - Liu Z AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing 100034, China. FAU - Li, Xin AU - Li X AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing 100034, China. FAU - Li, Wei AU - Li W AD - Department of Urology, The First Affiliated Hospital of Xiamen University, Siming District, Xiamen, Fujian 361003, China. FAU - Xing, Jinchun AU - Xing J AD - Department of Urology, The First Affiliated Hospital of Xiamen University, Siming District, Xiamen, Fujian 361003, China. FAU - Yu, Wei AU - Yu W AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing 100034, China. FAU - Jin, Jie AU - Jin J AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer Center, Xicheng District, Beijing 100034, China. LA - eng PT - Journal Article DEP - 20170711 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5687684 OTO - NOTNLM OT - bladder OT - cystoscopic biopsy OT - diagnostic TURBT OT - progression-free survival OT - urothelial carcinoma COIS- CONFLICTS OF INTEREST The authors declare that no conflicts of interest exists. EDAT- 2017/11/29 06:00 MHDA- 2017/11/29 06:01 PMCR- 2017/10/24 CRDT- 2017/11/29 06:00 PHST- 2017/03/17 00:00 [received] PHST- 2017/06/28 00:00 [accepted] PHST- 2017/11/29 06:00 [entrez] PHST- 2017/11/29 06:00 [pubmed] PHST- 2017/11/29 06:01 [medline] PHST- 2017/10/24 00:00 [pmc-release] AID - 19159 [pii] AID - 10.18632/oncotarget.19159 [doi] PST - epublish SO - Oncotarget. 2017 Jul 11;8(51):89228-89235. doi: 10.18632/oncotarget.19159. eCollection 2017 Oct 24. PMID- 29179475 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 51 DP - 2017 Oct 24 TI - Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin. PG - 88782-88791 LID - 10.18632/oncotarget.21222 [doi] AB - Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Guerin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients. We used Cox proportional hazards regression analyses to identify SNPs as predictors for recurrence and progression. In the discovery phase, we identified 20 variants that were significantly associated with recurrence outcomes and 15 SNPs significantly associated with progression in patients treated with BCG but not in the transurethral resection (TUR)-only group. In BCG treated patients, rs7089861 was the only SNP significantly associated with risk of progression in both the discovery phase (Hazard Ratio [HR]=3.15, 95% Confidence Interval [CI]: 1.38-7.22, P<0.01) and validation phase (HR=3.84, 95% CI: 1.64-9.0, P=0.002; meta-analysis HR=3.47, 95% CI: 1.92-6.28, P<0.001). Two variants, rs1800686 and rs2071081, had probable association with HRs of the same trend in the discovery and validation groups (meta-analysis P=0.002). These findings supported the notion that genetic variation of inflammation pathway may impact clinical outcome of NMIBC patients treated with BCG immunotherapy. Further validation of these results in order to improve risk stratification to identify patients most likely to benefit from BCG treatment versus upfront radical cystectomy and future development of potential targeted therapies are warranted. SIGNIFICANCE STATEMENT: In a two-stage study, we identified several genetic variants in the inflammation pathway associated with recurrence and progression in early-stage bladder cancer. In particular, variant rs7089861 was validated for progression among patients who underwent BCG immunotherapy. Several other variants showed marginal association with recurrence or progression. These findings suggest that inflammatory pathway genetic variants may influence clinical outcome of bladder cancer patients and help to select patients most appropriate for BCG treatment. FAU - Williams, Stephen B AU - Williams SB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. AD - Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Mmeje, Chinedu AU - Mmeje C AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Ye, Yuanquing AU - Ye Y AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Huang, Maosheng AU - Huang M AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Chang, David W AU - Chang DW AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Wu, Xifeng AU - Wu X AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States GR - U01 CA127615/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170923 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5687645 OTO - NOTNLM OT - BCG OT - bladder cancer OT - clinical outcome OT - inflammation OT - polymorphisms COIS- CONFLICTS OF INTEREST No conflicts of interest were declared by all authors. EDAT- 2017/11/29 06:00 MHDA- 2017/11/29 06:01 PMCR- 2017/10/24 CRDT- 2017/11/29 06:00 PHST- 2016/12/15 00:00 [received] PHST- 2017/08/02 00:00 [accepted] PHST- 2017/11/29 06:00 [entrez] PHST- 2017/11/29 06:00 [pubmed] PHST- 2017/11/29 06:01 [medline] PHST- 2017/10/24 00:00 [pmc-release] AID - 21222 [pii] AID - 10.18632/oncotarget.21222 [doi] PST - epublish SO - Oncotarget. 2017 Sep 23;8(51):88782-88791. doi: 10.18632/oncotarget.21222. eCollection 2017 Oct 24. PMID- 29171098 OWN - NLM STAT- MEDLINE DCOM- 20190429 LR - 20190429 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 25 IP - 2 DP - 2018 Feb TI - Can bladder preservation therapy come to the center stage? PG - 134-140 LID - 10.1111/iju.13495 [doi] AB - Decision-making in urological cancer care requires a multidisciplinary approach for refinement, but its impact on urothelial carcinoma of the bladder has not been fully addressed for the past three decades, except for the latest immunological checkpoint inhibitor approved by the U.S. Food and Drug Administration for metastatic muscle-invasive bladder cancer that is resistant to platinum-based chemotherapy. For the time being, radical cystectomy is the gold standard of curative therapy for muscle-invasive bladder cancer. Trimodal therapy that combines chemotherapy for the purpose of radiation sensitization, external beam radiotherapy and transurethral resection of bladder tumor has emerged as a potential alternative treatment option that preserves the bladder. In lack of randomized studies for bladder preservation therapy compared with surgery, the principles of management of urothelial carcinoma of the bladder have evolved in recent times, with an emphasis on bladder preservation. A number of bladder preservation techniques are available to the surgeon; however, appropriately selected patients with muscle-invasive bladder cancer should be offered the opportunity to discuss various treatment options, including organ-sparing trimodal therapy. The aim of the present study was to compare the primary outcomes of the available treatment methods and identify the sources of variance among studies. A review of various bladder preservation techniques in vogue for the management of urothelial carcinoma of the bladder is discussed. CI - (c) 2017 The Japanese Urological Association. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Ibuki, Naokazu AU - Ibuki N AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Juri, Hiroshi AU - Juri H AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Yamamoto, Kiyohito AU - Yamamoto K AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Yamamoto, Kazuhiro AU - Yamamoto K AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Fujita, Kazutoshi AU - Fujita K AD - Department of Urology, Osaka University, Suita, Osaka, Japan. FAU - Nonomura, Norio AU - Nonomura N AD - Department of Urology, Osaka University, Suita, Osaka, Japan. FAU - Narumi, Yoshifumi AU - Narumi Y AD - Department of Radiology, Osaka Medical College, Takatsuki, Osaka, Japan. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka, Japan. LA - eng PT - Comparative Study PT - Journal Article PT - Review DEP - 20171123 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma, Transitional Cell/diagnostic imaging/pathology/*therapy MH - Chemoradiotherapy, Adjuvant/adverse effects/methods MH - Cystectomy/adverse effects/*methods MH - Cystoscopy/methods MH - Humans MH - Neoadjuvant Therapy/adverse effects/methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/pathology/prevention & control MH - Organ Sparing Treatments/adverse effects/*methods MH - Patient Selection MH - Quality of Life MH - Treatment Outcome MH - Urinary Bladder/diagnostic imaging/pathology/radiation effects/surgery MH - Urinary Bladder Neoplasms/diagnostic imaging/pathology/*therapy OTO - NOTNLM OT - bladder preservation OT - muscle-invasive bladder cancer OT - prognosis EDAT- 2017/11/25 06:00 MHDA- 2019/04/30 06:00 CRDT- 2017/11/25 06:00 PHST- 2017/09/06 00:00 [received] PHST- 2017/10/23 00:00 [accepted] PHST- 2017/11/25 06:00 [pubmed] PHST- 2019/04/30 06:00 [medline] PHST- 2017/11/25 06:00 [entrez] AID - 10.1111/iju.13495 [doi] PST - ppublish SO - Int J Urol. 2018 Feb;25(2):134-140. doi: 10.1111/iju.13495. Epub 2017 Nov 23. PMID- 29164059 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 7 DP - 2017 TI - Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity. PG - 260 LID - 10.3389/fonc.2017.00260 [doi] LID - 260 AB - BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. OBJECTIVES: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. METHODS: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015. The survival cutoff was December 2016. Primary end point was disease-free survival (DFS) and secondary end point was toxicity. After optimal transurethral resection all patients received weekly intravesical BCG or gemcitabine for 6 weeks and maintenance treatment according to their risk. The recurrence was defined as histology proven tumor recurrence (any grade), or appearance of carcinoma in situ. RESULTS: One hundred and three patients were evaluable, 52 treated with BCG and 51 with gemcitabine with a median age of 77 and 78, and were mostly male. Approximately half of each received maintenance therapy. The groups were well balanced, apart from some difference in cancer risk groups. Twenty-one percent in the BCG group and 29% in the gemcitabine group had received prior BCG. Median follow up was 15.0 months. Median DFS was 19.6 months for BCG, whereas median DFS was not reached with gemcitabine. There was a trend toward improved DFS with gemcitabine in multivariate analysis, HR: 0.49 (95% CI: 0.22-1.06, p = 0.07). Adverse events were significantly less frequent with gemcitabine (7 versus 44%, p /= 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021]. CONCLUSION: High mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. AD - Institute of Pathology, St Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Worst, Thomas S AU - Worst TS AD - Department of Urology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. LA - eng GR - 110541/Deutsche Krebshilfe/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20171117 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - B7-H1 Antigen/*genetics/metabolism MH - Biomarkers, Tumor/*genetics/metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - RNA, Messenger/*genetics/metabolism MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/genetics/*mortality/pathology PMC - PMC11028240 OTO - NOTNLM OT - NMIBC OT - PD1 OT - PDL1 OT - Prognosis OT - mRNA COIS- Ralph Markus Wirtz is founder and employee of STRATIFYER Molecular Pathology GmbH. All other authors declare that they have no conflict of interest. EDAT- 2017/11/19 06:00 MHDA- 2018/11/21 06:00 PMCR- 2017/11/17 CRDT- 2017/11/19 06:00 PHST- 2016/12/23 00:00 [received] PHST- 2017/11/11 00:00 [accepted] PHST- 2017/11/19 06:00 [pubmed] PHST- 2018/11/21 06:00 [medline] PHST- 2017/11/19 06:00 [entrez] PHST- 2017/11/17 00:00 [pmc-release] AID - 10.1007/s00262-017-2093-9 [pii] AID - 2093 [pii] AID - 10.1007/s00262-017-2093-9 [doi] PST - ppublish SO - Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17. PMID- 29147616 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210112 IS - 2162-4011 (Print) IS - 2162-402X (Electronic) IS - 2162-4011 (Linking) VI - 6 IP - 11 DP - 2017 TI - mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. PG - e1358330 LID - 10.1080/2162402X.2017.1358330 [doi] LID - e1358330 AB - Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high FOXP3/CD8 ratio and overexpression of OX40L (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes (OX40L, CD8 and TIGIT) was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high FOXP3/CD8 ratio and OX40L overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy. FAU - Le Goux, Constance AU - Le Goux C AD - Department of Genetic, Institut curie, Unite de pharmacogenomique, Service de genetique, Paris, France. FAU - Vacher, Sophie AU - Vacher S AD - Department of Genetic, Institut curie, Unite de pharmacogenomique, Service de genetique, Paris, France. FAU - Pignot, Geraldine AU - Pignot G AD - Department of Urology, Institut Paoli-Calmettes, Service d'Urologie, Marseille, France. FAU - Sibony, Mathilde AU - Sibony M AD - Department of Pathology, Universite Paris Descartes; Hopital Cochin, Service d'Anatomopathologie, Paris, France. FAU - Barry Delongchamps, Nicolas AU - Barry Delongchamps N AD - Department of Urology, Universite Paris Descartes, Hopital Cochin, Service d'Urologie, Paris, France. FAU - Terris, Benoit AU - Terris B AD - Department of Pathology, Universite Paris Descartes; Hopital Cochin, Service d'Anatomopathologie, Paris, France. FAU - Piaggio, Eliane AU - Piaggio E AD - Department of Translational Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Translational Immunotherapy Siric Team, Centre d'Investigation Clinique Biotherapie CICBT , Paris, France. FAU - Zerbib, Marc AU - Zerbib M AD - Department of Urology, Universite Paris Descartes, Hopital Cochin, Service d'Urologie, Paris, France. FAU - Damotte, Diane AU - Damotte D AD - Department of Pathology, Universite Paris Descartes; Hopital Cochin, Service d'Anatomopathologie, Paris, France. AD - Centre de Recherche des Cordeliers, Cancer et Immunite anti tumorale, INSERM U1138, Paris, France. FAU - Bieche, Ivan AU - Bieche I AD - Department of Genetic, Institut curie, Unite de pharmacogenomique, Service de genetique, Paris, France. AD - Universite Paris Descartes, Paris, France. LA - eng PT - Journal Article DEP - 20170814 PL - United States TA - Oncoimmunology JT - Oncoimmunology JID - 101570526 PMC - PMC5674963 OTO - NOTNLM OT - Bladder cancer OT - RT-PCR OT - immune checkpoints OT - immunohistochemistry OT - prognostic factor EDAT- 2017/11/18 06:00 MHDA- 2017/11/18 06:01 PMCR- 2018/08/14 CRDT- 2017/11/18 06:00 PHST- 2017/05/12 00:00 [received] PHST- 2017/07/18 00:00 [accepted] PHST- 2017/11/18 06:00 [entrez] PHST- 2017/11/18 06:00 [pubmed] PHST- 2017/11/18 06:01 [medline] PHST- 2018/08/14 00:00 [pmc-release] AID - 1358330 [pii] AID - 10.1080/2162402X.2017.1358330 [doi] PST - epublish SO - Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017. PMID- 29141603 OWN - NLM STAT- MEDLINE DCOM- 20180626 LR - 20250530 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 17 IP - 1 DP - 2017 Nov 15 TI - DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells. PG - 767 LID - 10.1186/s12885-017-3758-7 [doi] LID - 767 AB - BACKGROUND: Haematuria is a common finding in general practice which requires visual inspection of the bladder by cystoscopy as well as upper tract imaging. In addition, patients with non-muscle invasive bladder cancer (NMIBC) often require surveillance cystoscopy as often as three monthly depending on disease risk. However, cystoscopy is an invasive procedure which is uncomfortable, requires hospital attendance and is associated with a risk of urinary tract infection. We have developed the UroMark assay, which can detect 150 methylation specific alteration specific to bladder cancer using DNA from urinary sediment cells. METHODS: DETECT I and DETECT II are two multi-centre prospective observational studies designed to conduct a robust validation of the UroMark assay. DETECT I will recruit patients having diagnostic investigations for haematuria to determine the negative predictive value of the UroMark to rule out the presence of bladder cancer. DETECT II will recruit patients with new or recurrent bladder cancer to determine the sensitivity of the UroMark in detecting low, intermediate and high grade bladder cancer. NMIBC patients in DETECT II will be followed up with three monthly urine sample collection for 24 months while having surveillance cystoscopy. DETECT II will include a qualitative analysis of semi-structured interviews to explore patients' experience of being diagnosed with bladder cancer and having cystoscopy and a urinary test for bladder cancer surveillance. Results of the UroMark will be compared to cystoscopy findings and histopathological results in patients with bladder cancer. DISCUSSION: A sensitive and specific urinary biomarker will revolutionise the haematuria diagnostic pathway and surveillance strategies for NMIBC patients. None of the six approved US Food and Drug Administration urinary test are recommended as a standalone test. The UroMark assay is based on next generation sequencing technology which interrogates 150 loci and represents a step change compared to other biomarker panels. This enhances the sensitivity of the test and by using a random forest classifier approach, where the UroMark results are derived from a cut off generated from known outcomes of previous samples, addresses many shortcomings of previous assays. TRIAL REGISTRATION: Both trails are registered on clinicaltrials.gov. DETECT I: NCT02676180 (18th December 2015). DETECT II: NCT02781428 (11th May 2016). FAU - Tan, Wei Shen AU - Tan WS AUID- ORCID: 0000-0002-6119-4043 AD - Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK. wei.tan@ucl.ac.uk. AD - Department of Urology, University College London Hospitals, London, UK. wei.tan@ucl.ac.uk. FAU - Feber, Andrew AU - Feber A AD - UCL Cancer Institute, University College London, London, UK. FAU - Dong, Liqin AU - Dong L AD - UCL Cancer Institute, University College London, London, UK. FAU - Sarpong, Rachael AU - Sarpong R AD - Surgical & Interventional Trials Unit, Division of Surgery and Interventional Sciences, Faculty of Medical Sciences, University College London, London, UK. FAU - Rezaee, Sheida AU - Rezaee S AD - UCL Cancer Institute, University College London, London, UK. FAU - Rodney, Simon AU - Rodney S AD - Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK. AD - Department of Urology, University College London Hospitals, London, UK. FAU - Khetrapal, Pramit AU - Khetrapal P AD - Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK. AD - Department of Urology, University College London Hospitals, London, UK. FAU - de Winter, Patricia AU - de Winter P AD - Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK. FAU - Ocampo, Frelyn AU - Ocampo F AD - Department of Urology, University College London Hospitals, London, UK. FAU - Jalil, Rumana AU - Jalil R AD - Surgical & Interventional Trials Unit, Division of Surgery and Interventional Sciences, Faculty of Medical Sciences, University College London, London, UK. FAU - Williams, Norman R AU - Williams NR AD - Surgical & Interventional Trials Unit, Division of Surgery and Interventional Sciences, Faculty of Medical Sciences, University College London, London, UK. FAU - Brew-Graves, Chris AU - Brew-Graves C AD - Surgical & Interventional Trials Unit, Division of Surgery and Interventional Sciences, Faculty of Medical Sciences, University College London, London, UK. FAU - Kelly, John D AU - Kelly JD AD - Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK. AD - Department of Urology, University College London Hospitals, London, UK. LA - eng SI - ClinicalTrials.gov/NCT02781428 SI - ClinicalTrials.gov/NCT02676180 GR - MR/M025411/1/MRC_/Medical Research Council/United Kingdom GR - Kelly MR/M025411/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20171115 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - *Biomarkers, Tumor MH - *Clinical Protocols MH - Female MH - Humans MH - Liquid Biopsy/*methods MH - Male MH - Prospective Studies MH - Urinary Bladder Neoplasms/*diagnosis PMC - PMC5688623 OTO - NOTNLM OT - Bladder cancer OT - Clinical trial OT - Diagnostic OT - Haematuria OT - Methylation OT - Next generation sequencing OT - Surveillance OT - Urinary assay OT - Urinary biomarker OT - Validation COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: DETECT I was approved by NHS Health Research Authority on the 18th May 2016 (IRAS project ID: 179,245, REC reference: 16/NW/0150, clinicaltrials.gov: NCT02676180). DETECT II study protocol received NHS Health Research Authority approval on the 30th August 2016 (IRAS project ID: 203,022, REC reference: 16/LO/1044, clinicaltrials.gov: NCT02781428). Written consent will be obtained from all patients. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/11/17 06:00 MHDA- 2018/06/27 06:00 PMCR- 2017/11/15 CRDT- 2017/11/17 06:00 PHST- 2017/01/08 00:00 [received] PHST- 2017/11/06 00:00 [accepted] PHST- 2017/11/17 06:00 [entrez] PHST- 2017/11/17 06:00 [pubmed] PHST- 2018/06/27 06:00 [medline] PHST- 2017/11/15 00:00 [pmc-release] AID - 10.1186/s12885-017-3758-7 [pii] AID - 3758 [pii] AID - 10.1186/s12885-017-3758-7 [doi] PST - epublish SO - BMC Cancer. 2017 Nov 15;17(1):767. doi: 10.1186/s12885-017-3758-7. PMID- 29137333 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 47 DP - 2017 Oct 10 TI - Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. PG - 83183-83194 LID - 10.18632/oncotarget.20554 [doi] AB - OBJECTIVE: To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy. METHODS: A total of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017 were retrospectively examined. Oncological outcomes, including intravesical recurrence-free, visceral recurrence-free, cancer-specific, and overall survival rates (intravesical RFS, visceral RFS, CSS, and OS, respectively) stratified by preoperative CKD status (CKD vs. non-CKD) were investigated. Cox proportional hazards regression analysis was performed using inverse probability of treatment weighting (IPTW) to evaluate the impact of preoperative CKD on prognosis and a prognostic factor-based risk stratification nomogram was developed. RESULTS: Of the 426 patients, 250 (59%) were diagnosed with CKD before radical nephroureterectomy. Before the background adjustment, intravesical RFS, visceral RFS, CSS, and OS after radical nephroureterectomy were significantly shorter in the CKD group than in the non-CKD group. Background-adjusted IPTW analysis demonstrated that preoperative CKD was significantly associated with poor visceral RFS, CSS, and OS after radical nephroureterectomy. Intravesical RFS was not significantly associated with preoperative CKD. The nomogram for predicting 5-year visceral RFS and CSS probability demonstrated a significant correlation with actual visceral RFS and CSS (c-index = 0.85 and 0.83, respectively). CONCLUSIONS: Upper tract urothelial carcinoma patients with preoperative CKD had a significantly lower survival probability than those without CKD. FAU - Kodama, Hirotake AU - Kodama H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Fujita, Naoki AU - Fujita N AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Iwamura, Hiromichi AU - Iwamura H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Urology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. FAU - Anan, Go AU - Anan G AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Urology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. FAU - Fukushi, Ken AU - Fukushi K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Narita, Takuma AU - Narita T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tanaka, Toshikazu AU - Tanaka T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kubota, Yuka AU - Kubota Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Horiguchi, Hirotaka AU - Horiguchi H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Momota, Masaki AU - Momota M AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Kido, Koichi AU - Kido K AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Matsumoto, Teppei AU - Matsumoto T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Soma, Osamu AU - Soma O AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hamano, Itsuto AU - Hamano I AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yamamoto, Hayato AU - Yamamoto H AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Tobisawa, Yuki AU - Tobisawa Y AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Tohru AU - Yoneyama T AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Yoneyama, Takahiro AU - Yoneyama T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Hashimoto, Yasuhiro AU - Hashimoto Y AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Koie, Takuya AU - Koie T AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. FAU - Ito, Hiroyuki AU - Ito H AD - Department of Urology, Aomori Rosai Hospital, Hachinohe, Japan. FAU - Yoshikawa, Kazuaki AU - Yoshikawa K AD - Department of Urology, Mutsu General Hospital, Mutsu, Japan. FAU - Sasaki, Atsushi AU - Sasaki A AD - Department of Urology, Tsugaru General Hospital, Goshogawara, Japan. FAU - Kawaguchi, Toshiaki AU - Kawaguchi T AD - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan. FAU - Sato, Makoto AU - Sato M AD - Department of Urology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. AD - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. LA - eng PT - Journal Article DEP - 20170824 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5669959 OTO - NOTNLM OT - chronic kidney disease OT - oncological outcome OT - radical nephroureterectomy OT - renal function OT - upper urinary tract urothelial carcinoma COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest. EDAT- 2017/11/16 06:00 MHDA- 2017/11/16 06:01 PMCR- 2017/10/10 CRDT- 2017/11/16 06:00 PHST- 2017/07/19 00:00 [received] PHST- 2017/07/28 00:00 [accepted] PHST- 2017/11/16 06:00 [entrez] PHST- 2017/11/16 06:00 [pubmed] PHST- 2017/11/16 06:01 [medline] PHST- 2017/10/10 00:00 [pmc-release] AID - 20554 [pii] AID - 10.18632/oncotarget.20554 [doi] PST - epublish SO - Oncotarget. 2017 Aug 24;8(47):83183-83194. doi: 10.18632/oncotarget.20554. eCollection 2017 Oct 10. PMID- 29127452 OWN - NLM STAT- MEDLINE DCOM- 20180924 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 36 IP - 2 DP - 2018 Feb TI - Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. PG - 231-240 LID - 10.1007/s00345-017-2116-3 [doi] AB - OBJECTIVES: To evaluate the concordance rate of lymphovascular invasion (LVI) and variant histology (VH) of transurethral resection (TUR) with radical cystectomy (RC) specimens. Furthermore, to evaluate the value of LVI and VH at TUR for predicting non-organ confined (NOC) disease, lymph node metastasis, and survival outcomes. PATIENTS AND METHODS: Two hundred and sixty-eight patients who underwent TUR and subsequent RC were reviewed. Logistic regression analyses were performed to evaluate the association of LVI and VH with NOC and lymph node metastasis at RC. Cox regression analyses were used to estimate recurrence-free survival (RFS) and cancer-specific survival (CSS). RESULTS: LVI and VH were detected in 13.8 and 11.2% of TUR specimens, and in 30.2 and 25.4% of RC specimens, respectively. The concordance rate between LVI and VH at TUR and subsequent RC was 69.8 and 83.6%, respectively. They were both associated with adverse pathological features such as lymph node metastasis and advanced stage. TUR LVI and VH were both independently associated with lymph node metastasis and TUR VH was independently associated with NOC. On univariable Cox regression analyses, TUR LVI was associated with RFS and CSS while TUR VH was only associated with RFS. Only TUR LVI was independently associated with RFS. CONCLUSION: Detection of LVI is missed in a third of TUR specimens while VH seems more accurately identified. TUR LVI and VH are associated with more advanced disease and LVI predicts disease recurrence. Assessment and reporting of LVI and VH on TUR specimen are important for risk stratification and decision-making. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. sfshariat@gmail.com. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. sfshariat@gmail.com. AD - Department of Urology, University of Texas Southwestern Medical Centre, Dallas, TX, USA. sfshariat@gmail.com. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Pozo, Carmen AU - Pozo C AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, University of Rennes, Rennes, France. FAU - Susani, Martin AU - Susani M AD - Department of Pathology, Medical University of Vienna, Vienna, Austria. FAU - Czech, Anna K AU - Czech AK AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Jagiellonian University in Krakow, Krakow, Poland. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Canada. FAU - Seebacher, Veronika AU - Seebacher V AD - Department for Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20171111 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/*pathology/surgery MH - Clinical Decision-Making MH - Cystectomy MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Humans MH - Logistic Models MH - Lymph Nodes/pathology MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Lymphovascular invasion OT - Prediction OT - Prognosis OT - Recurrence OT - Survival OT - Transurethral resection OT - Urothelial tumor OT - Variant histology EDAT- 2017/11/12 06:00 MHDA- 2018/09/25 06:00 CRDT- 2017/11/12 06:00 PHST- 2017/08/16 00:00 [received] PHST- 2017/10/27 00:00 [accepted] PHST- 2017/11/12 06:00 [pubmed] PHST- 2018/09/25 06:00 [medline] PHST- 2017/11/12 06:00 [entrez] AID - 10.1007/s00345-017-2116-3 [pii] AID - 10.1007/s00345-017-2116-3 [doi] PST - ppublish SO - World J Urol. 2018 Feb;36(2):231-240. doi: 10.1007/s00345-017-2116-3. Epub 2017 Nov 11. PMID- 29126568 OWN - NLM STAT- MEDLINE DCOM- 20190124 LR - 20190124 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 41 IP - 10 DP - 2017 Dec TI - Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis. PG - 639-645 LID - S0210-4806(17)30176-6 [pii] LID - 10.1016/j.acuro.2017.05.007 [doi] AB - OBJECTIVES: Bladder cancer (BC) in the transplanted population can represent a challenge owing to the immunosuppressed state of patients and the higher rate of comorbidities. The objective was to analyze the treatment of BC after renal transplant (RT), focusing on the mode of presentation, diagnosis, treatment options and predictive factors for recurrence. MATERIAL AND METHODS: We conducted an observational prospective study with a retrospective analysis of 88 patients with BC after RT at 10 European centers. Clinical and oncologic data were collected, and indications and results of adjuvant treatment reviewed. The Kaplan-Meier method and uni- and multivariate Cox regression analyses were performed. RESULTS: A total of 10,000 RTs were performed. Diagnosis of BC occurred at a median of 73 months after RT. Median follow-up was 126 months. Seventy-one patients (81.6%) had non-muscle invasive bladder cancer, of whom 29 (40.8%) received adjuvant treatment; of these, six (20.6%) received bacillus Calmette-Guerin and 20 (68.9%) mitomycin C. At univariate analysis, patients who received bacillus Calmette-Guerin had a signi fi cantly lower recurrence rate (P=.043). At multivariate analysis, a switch from immunosuppression to mTOR inhibitors signi fi cantly reduced the risk of recurrence (HR 0.24, 95% CI: 0.053-0.997, P=.049) while presence of multiple tumors increased it (HR 6.31, 95% CI: 1.78-22.3, P=.004). Globally, 26 patients (29.88%) underwent cystectomy. No major complications were recorded. Overall mortality (OM) was 32.2% (28 patients); the cancer-specific mortality was 13.8%. CONCLUSIONS: Adjuvant bacillus Calmette-Guerin signi fi cantly reduces the risk of recurrence, as does switch to mTOR inhibitors. Multiple tumors increase the risk. CI - Copyright (c) 2017 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Rodriguez Faba, O AU - Rodriguez Faba O AD - Servicio de Urologia, Fundacio Puigvert, Barcelona, Espana. Electronic address: orodriguez@fundacio-puigvert.es. FAU - Palou, J AU - Palou J AD - Servicio de Urologia, Fundacio Puigvert, Barcelona, Espana. FAU - Vila Reyes, H AU - Vila Reyes H AD - Servicio de Urologia, Fundacio Puigvert, Barcelona, Espana. FAU - Guirado, L AU - Guirado L AD - Servicio de Nefrologia, Fundacio Puigvert, Barcelona, Espana. FAU - Palazzetti, A AU - Palazzetti A AD - Servicio de Urologia, University of Torino, Turin, Italia. FAU - Gontero, P AU - Gontero P AD - Servicio de Urologia, University of Torino, Turin, Italia. FAU - Vigues, F AU - Vigues F AD - Servicio de Urologia, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Espana. FAU - Garcia-Olaverri, J AU - Garcia-Olaverri J AD - Servicio de Urologia, Hospital de Cruces, Barakaldo, Espana. FAU - Fernandez Gomez, J M AU - Fernandez Gomez JM AD - Servicio de Urologia, Hospital Central de Asturias, Universidad de Oviedo, Oviedo, Espana. FAU - Olsburg, J AU - Olsburg J AD - Servicio Urologia, Guy's and St. Thomas' NHS Foundation Trust, Londres, Reino Unido. FAU - Terrone, C AU - Terrone C AD - Servicio Urologia, University of Novara, Novara, Italia. FAU - Figueiredo, A AU - Figueiredo A AD - Servicio Urologia, University of Coimbra, Coimbra, Portugal. FAU - Burgos, J AU - Burgos J AD - Servicio Urologia, Hospital Ramon y Cajal, Madrid, Espana. FAU - Lledo, E AU - Lledo E AD - Servicio Urologia, Hospital Gregorio Maranon, Madrid, Espana. FAU - Breda, A AU - Breda A AD - Servicio de Urologia, Fundacio Puigvert, Barcelona, Espana. LA - eng LA - spa PT - Journal Article PT - Multicenter Study PT - Observational Study TT - Opciones terapeuticas y factores predictivos de recurrencia y mortalidad cancer-especi fi ca en pacientes con tumor vesical despues de trasplante renal: analisis multiinstitucional. DEP - 20171108 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 SB - IM MH - Female MH - Humans MH - *Kidney Transplantation MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*epidemiology/*therapy MH - Postoperative Complications/diagnosis/*mortality/*therapy MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder Neoplasms/diagnosis/*mortality/*therapy OTO - NOTNLM OT - Bladder cancer OT - Inhibidores de mTOR OT - Recurrence OT - Recurrencia OT - Renal transplant OT - Trasplante renal OT - Tumor vesical OT - mTOR inhibitors EDAT- 2017/11/12 06:00 MHDA- 2019/01/25 06:00 CRDT- 2017/11/12 06:00 PHST- 2017/03/07 00:00 [received] PHST- 2017/05/09 00:00 [revised] PHST- 2017/05/10 00:00 [accepted] PHST- 2017/11/12 06:00 [pubmed] PHST- 2019/01/25 06:00 [medline] PHST- 2017/11/12 06:00 [entrez] AID - S0210-4806(17)30176-6 [pii] AID - 10.1016/j.acuro.2017.05.007 [doi] PST - ppublish SO - Actas Urol Esp. 2017 Dec;41(10):639-645. doi: 10.1016/j.acuro.2017.05.007. Epub 2017 Nov 8. PMID- 29126388 OWN - NLM STAT- MEDLINE DCOM- 20180709 LR - 20260127 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 17 IP - 1 DP - 2017 Nov 10 TI - YRNA expression predicts survival in bladder cancer patients. PG - 749 LID - 10.1186/s12885-017-3746-y [doi] LID - 749 AB - BACKGROUND: Non-coding RNAs play an important role in human carcinogenesis. YRNAs (Ro-associated Y), a novel class of non-coding RNAs, have been identified as biomarker in various malignancies, but remain to be studied in urinary bladder cancer (BCA) patients. METHODS: The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival BCA (urothelial carcinoma, n = 88) and normal urothelial bladder (n = 30) tissues using quantitative real-time PCR. Associations with clinicopathological parameters and prognostic role for overall and cancer-specific survival were analysed. RESULTS: All YRNAs were significantly downregulated in BCA tissue. A low expression of RNY1, RNY3 and RNY4 was associated with muscle-invasive BCA, lymph node metastases and advanced grade. Furthermore, expression of RNY1 and RNY3 was predictive for BCA patients' overall (also RNY4) and cancer-specific survival as estimated using Kaplan-Meier and univariate (but not multivariate) Cox regression analyses. RNY1, RNY3 and RNY4 show good discriminative ability between tumor and normal tissue, as well as between muscle-invasive and non-muscle-invasive urothelial carcinoma. CONCLUSIONS: The expression of YRNAs is altered in BCA and associated with poor prognosis. Possible diagnostic role of YRNAs should be investigated in further studies. FAU - Tolkach, Yuri AU - Tolkach Y AD - Institute of Pathology, University Hospital Bonn, Bonn, Germany. FAU - Stahl, Anna Franziska AU - Stahl AF AD - Department of Urology, University Hospital Bonn, Bonn, Germany. FAU - Niehoff, Eva-Maria AU - Niehoff EM AD - Department of Urology, University Hospital Bonn, Bonn, Germany. FAU - Zhao, Chenming AU - Zhao C AD - Department of Urology, University Hospital Bonn, Bonn, Germany. FAU - Kristiansen, Glen AU - Kristiansen G AD - Institute of Pathology, University Hospital Bonn, Bonn, Germany. FAU - Muller, Stefan Cajetan AU - Muller SC AD - Department of Urology, University Hospital Bonn, Bonn, Germany. FAU - Ellinger, Jorg AU - Ellinger J AUID- ORCID: 0000-0002-7526-0857 AD - Department of Urology, University Hospital Bonn, Bonn, Germany. joerg.ellinger@ukbonn.de. LA - eng PT - Journal Article DEP - 20171110 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Autoantigens) RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Small Cytoplasmic) RN - 0 (Ribonucleoproteins) RN - 0 (RO60 protein, human) RN - 0 (SS-A Antigen) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Autoantigens/*genetics MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis/*genetics/pathology MH - Male MH - Middle Aged MH - Prognosis MH - RNA, Small Cytoplasmic/*genetics MH - Ribonucleoproteins/*genetics MH - Urinary Bladder Neoplasms/*genetics/pathology MH - SS-A Antigen PMC - PMC5681827 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Prognosis OT - YRNA COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All patients gave written informed consent for the collection of biomaterials within the framework of the Biobank at the University Hospital Bonn. The study was approved by the Ethikkommission at the Medical Faculty at the University Bonn (approval number 280/12). CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/11/12 06:00 MHDA- 2018/07/10 06:00 PMCR- 2017/11/10 CRDT- 2017/11/12 06:00 PHST- 2017/05/21 00:00 [received] PHST- 2017/10/31 00:00 [accepted] PHST- 2017/11/12 06:00 [entrez] PHST- 2017/11/12 06:00 [pubmed] PHST- 2018/07/10 06:00 [medline] PHST- 2017/11/10 00:00 [pmc-release] AID - 10.1186/s12885-017-3746-y [pii] AID - 3746 [pii] AID - 10.1186/s12885-017-3746-y [doi] PST - epublish SO - BMC Cancer. 2017 Nov 10;17(1):749. doi: 10.1186/s12885-017-3746-y. PMID- 29121502 OWN - NLM STAT- MEDLINE DCOM- 20171120 LR - 20250623 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 61 DP - 2017 Dec TI - The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. PG - 82-93 LID - S0305-7372(17)30160-3 [pii] LID - 10.1016/j.ctrv.2017.10.004 [doi] AB - BACKGROUND: Despite adequate treatment and follow-up, around one fifth of patients with localized bladder cancer will present with disease progression. Adequate prognostic biomarkers are lacking to define patients who are at risk. Mutations in chromatin remodeling genes are more frequently found in bladder cancer than in any other solid tumor. However, the prognostic relevance of epigenetic dysregulation has not been established and may offer an opportunity for biomarker discovery. METHODS: Looking for prognostic epigenetic factors, we performed a comprehensive PubMed search using keywords such as "bladder cancer", "chromatin remodeling", "gene methylation" and "epigenetics". We only included studies reporting on the association of epigenetic markers with prognostic outcomes such as recurrence, progression or survival. RESULTS: Of 1113 results, 87 studies met the inclusion criteria, which represented a total of 85 epigenetic markers with potential prognostic relevance. No prospective studies were identified. Seventy-three percent (64/87) of the studies involved mixed cohorts of muscle invasive and non-muscle invasive bladder cancer. Promoter methylation of genes with putative prognostic value affected cellular processes such as cell cycle, apoptosis, cell-adhesion or migration, as well as critical pathways such as MAP-kinase or Wnt. Alteration of chromatin regulatory elements suggest a prognostic relevance alterations leading to a predominantly silenced chromatin state. CONCLUSIONS: The prognostic impact of epigenetic alterations in bladder cancer is still unclear. Prospective evaluation of methylation marks and chromatin remodeling gene alterations using consistent methods and criteria is warranted. CI - Copyright (c) 2017 Elsevier Ltd. All rights reserved. FAU - Casadevall, David AU - Casadevall D AD - Cancer Research Program, PSMAR-IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader 88, 08003 Barcelona, Spain. Electronic address: dcasadevall@imim.es. FAU - Kilian, Anais Yacine AU - Kilian AY AD - Universitat Pompeu Fabra, Placa de la Merce 10, 08002 Barcelona, Spain. Electronic address: anaisyacine.kilian01@estudiant.upf.edu. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Cancer Research Program, PSMAR-IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader 88, 08003 Barcelona, Spain; Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, USA. Electronic address: jbellmunt@imim.cat. LA - eng PT - Journal Article PT - Systematic Review DEP - 20171106 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/genetics MH - DNA Methylation MH - Epigenesis, Genetic MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*genetics OTO - NOTNLM OT - Chromatin remodeling OT - Methylation OT - Non-coding RNA OT - Prognosis OT - Progression OT - Recurrence OT - Urothelial carcinoma EDAT- 2017/11/10 06:00 MHDA- 2017/11/29 06:00 CRDT- 2017/11/10 06:00 PHST- 2017/07/14 00:00 [received] PHST- 2017/10/14 00:00 [revised] PHST- 2017/10/16 00:00 [accepted] PHST- 2017/11/10 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/11/10 06:00 [entrez] AID - S0305-7372(17)30160-3 [pii] AID - 10.1016/j.ctrv.2017.10.004 [doi] PST - ppublish SO - Cancer Treat Rev. 2017 Dec;61:82-93. doi: 10.1016/j.ctrv.2017.10.004. Epub 2017 Nov 6. PMID- 29118536 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220310 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 9 IP - 4 DP - 2017 Oct-Dec TI - Characteristics of bladder neoplasms in the young population of Saudi Arabia. PG - 343-347 LID - 10.4103/UA.UA_122_17 [doi] AB - CONTEXT: Bladder neoplasms are a well-studied subject in medicine. However, the evidence of bladder neoplasms in children and the young adult population (/=72 years old, (44% vs. 86%; p = 0.02) and among women (63% vs. 88%; p = 0.07). When patients who died were compared to survivors the following distribution of comorbidities was found: diabetes mellitus - 30.0% vs. 11.8%, p = 0.3; history of stroke - 30.0% vs. 2.9%, p = 0.1; thyroid disease - 30.0% vs. 11.8%, p = 0.3. CONCLUSIONS: Majority of patients died because cystectomy was performed too late. History of stroke, diabetes mellitus, and thyroid diseases should be assessed as possible risk factors in larger studies. FAU - Kwiatkowska, Marta AU - Kwiatkowska M AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Dybowski, Bartosz AU - Dybowski B AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Kuczkiewicz-Siemion, Olga AU - Kuczkiewicz-Siemion O AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Osiecki, Rafal AU - Osiecki R AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Smigielska, Kaja AU - Smigielska K AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Gonczar, Stefan AU - Gonczar S AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Poletajew, Slawomir AU - Poletajew S AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Medical University of Warsaw, Department of Urology, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20170808 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC5656372 OTO - NOTNLM OT - bladder cancer OT - cystectomy OT - diabetes mellitus OT - mortality OT - stroke OT - thyroid gland EDAT- 2017/11/07 06:00 MHDA- 2017/11/07 06:01 PMCR- 2017/01/01 CRDT- 2017/11/07 06:00 PHST- 2017/06/11 00:00 [received] PHST- 2017/08/04 00:00 [revised] PHST- 2017/08/04 00:00 [accepted] PHST- 2017/11/07 06:00 [entrez] PHST- 2017/11/07 06:00 [pubmed] PHST- 2017/11/07 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - 1484 [pii] AID - 10.5173/ceju.2017.1484 [doi] PST - ppublish SO - Cent European J Urol. 2017;70(3):238-244. doi: 10.5173/ceju.2017.1484. Epub 2017 Aug 8. PMID- 29102949 OWN - NLM STAT- MEDLINE DCOM- 20180615 LR - 20181113 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 31 IP - 6 DP - 2017 Nov-Dec TI - Effect of Preoperative Bacteriuria and Pyuria on Intravesical Recurrence in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy. PG - 1215-1220 AB - BACKGROUND/AIM: We investigated the effect of bacteriuria and pyuria on intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). PATIENTS AND METHODS: Preoperative bacteriuria and pyuria were defined as urine containing >/=5 bacteria/high-power field (HPF) and >5 white blood cells/HPF, respectively. Their associations with IVR were evaluated in 97 patients with UTUC undergoing RNU. RESULTS: Preoperative bacteriuria [n=15 (15%)] was significantly associated with preoperative pyuria [n=42 (43%), p<0.001]. During follow-up (median of 19 months), 45 (46%) patients developed IVR (median IVR-free survival=38 months). On multivariate analysis, preoperative bacteriuria was an independent predictor for reduced risk of IVR (hazard ratio=0.23, p=0.010). The 2-year IVR-free survival of patients with preoperative bacteriuria and pyuria was significantly longer than that of patients without preoperative bacteriuria (83% vs. 54%, p=0.028) and pyuria (69% vs. 50%, p=0.024), respectively. CONCLUSION: Bacteriuria and pyuria may reduce the risk of IVR in patients with UTUC undergoing RNU. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Fukushima, Hiroshi AU - Fukushima H AD - Department of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan fukuuro@tmd.ac.jp. FAU - Kobayashi, Masaki AU - Kobayashi M AD - Department of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. FAU - Kawano, Keizo AU - Kawano K AD - Department of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. FAU - Morimoto, Shinji AU - Morimoto S AD - Department of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 SB - IM MH - Aged MH - Aged, 80 and over MH - Bacteriuria/complications/microbiology/*pathology MH - Carcinoma, Transitional Cell/complications/microbiology/pathology/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Nephroureterectomy MH - Pyuria/complications/*pathology MH - Risk Factors MH - Urothelium/microbiology/pathology/*surgery PMC - PMC5756655 OTO - NOTNLM OT - Bacteriuria OT - intravesical recurrence OT - pyuria OT - radical nephroureterectomy OT - upper tract urothelial carcinoma EDAT- 2017/11/06 06:00 MHDA- 2018/06/16 06:00 PMCR- 2017/11/03 CRDT- 2017/11/06 06:00 PHST- 2017/07/28 00:00 [received] PHST- 2017/08/11 00:00 [revised] PHST- 2017/08/21 00:00 [accepted] PHST- 2017/11/06 06:00 [entrez] PHST- 2017/11/06 06:00 [pubmed] PHST- 2018/06/16 06:00 [medline] PHST- 2017/11/03 00:00 [pmc-release] AID - 31/6/1215 [pii] AID - 10.21873/invivo.11193 [doi] PST - ppublish SO - In Vivo. 2017 Nov-Dec;31(6):1215-1220. doi: 10.21873/invivo.11193. PMID- 29097085 OWN - NLM STAT- MEDLINE DCOM- 20181022 LR - 20181022 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 36 IP - 2 DP - 2018 Feb TI - Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy. PG - 77.e15-77.e21 LID - S1078-1439(17)30535-5 [pii] LID - 10.1016/j.urolonc.2017.10.005 [doi] AB - OBJECTIVES: To investigate the relationship between purified protein derivative (PPD) skin test reactions before bacillus Calmette-Guerin (BCG) therapy and the clinical outcomes of BCG-naive nonmuscle invasive bladder cancer patients treated with adjuvant BCG therapy. MATERIALS AND METHODS: A total of 288 nonmuscle invasive bladder cancer patients subjected to the PPD skin test before BCG therapy were included. PPD skin test reactions were categorized into 3 groups: positive, slightly positive, and negative. The presence of an induration was positive. If an induration was absent, erythema of 10mm or more and less than 10mm corresponded to slightly positive and negative, respectively. RESULTS: A total of 66 (22.9%), 149 (51.7%), and 73 (25.3%) patients exhibited a positive, slightly positive, and negative to PPD skin test, respectively. The 5-year recurrence-free survival rate of patients with positive PPD skin test reactions was 89.4 +/- 4.1%, which was significantly higher than those of patients with slightly positive (65.5 +/- 4.2%, P = 0.001) and negative reactions (56.4 +/- 6.6%, P<0.001). A multivariate Cox regression analysis revealed that a positive PPD skin test reaction was independently associated with tumor recurrence (hazard ratio of 0.233, P<0.001), but not with stage progression. The incidence of fever persisting for more than 2 days or fever of >/=38 degrees C was significantly higher in patients with a positive PPD skin test reaction (18.2%) than in patients with slightly positive (8.7%) and negative PPD skin test reactions (4.1%). CONCLUSIONS: The PPD skin test reactions before BCG therapy may predict clinical outcomes following BCG therapy and help clinicians counsel patients exhibiting strong therapeutic effects with BCG therapy and potentially major BCG-related side effects. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Niwa, Naoya AU - Niwa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kosaka, Takeo AU - Kosaka T AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20171031 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) SB - IM CIN - Urol Oncol. 2019 Jun;37(6):346-347. doi: 10.1016/j.urolonc.2019.01.024. PMID: 30737157 MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Induction Chemotherapy/methods MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Skin/drug effects/pathology MH - Skin Tests/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Immunotherapy OT - Purified protein derivatives OT - Treatment outcome OT - Urinary bladder neoplasms EDAT- 2017/11/04 06:00 MHDA- 2018/10/23 06:00 CRDT- 2017/11/04 06:00 PHST- 2017/06/12 00:00 [received] PHST- 2017/09/29 00:00 [revised] PHST- 2017/10/06 00:00 [accepted] PHST- 2017/11/04 06:00 [pubmed] PHST- 2018/10/23 06:00 [medline] PHST- 2017/11/04 06:00 [entrez] AID - S1078-1439(17)30535-5 [pii] AID - 10.1016/j.urolonc.2017.10.005 [doi] PST - ppublish SO - Urol Oncol. 2018 Feb;36(2):77.e15-77.e21. doi: 10.1016/j.urolonc.2017.10.005. Epub 2017 Oct 31. PMID- 29094888 OWN - NLM STAT- MEDLINE DCOM- 20171116 LR - 20260127 IS - 1532-0650 (Electronic) IS - 0002-838X (Linking) VI - 96 IP - 8 DP - 2017 Oct 15 TI - Bladder Cancer: Diagnosis and Treatment. PG - 507-514 AB - Bladder cancer is the sixth most prevalent malignancy in the United States and causes more than 16,000 deaths annually. The most common clinical presentation is asymptomatic hematuria, which should prompt evaluation with cystoscopy, renal function testing, and upper urinary tract imaging in adults 35 years and older and in those with irritative voiding symptoms, risk factors for bladder cancer, or gross hematuria at any age. Transurethral resection of the bladder tumor allows for definitive diagnosis, staging, and primary treatment. Non-muscle-invasive disease is treated with transurethral resection, most often followed by intravesical bacille Calmette-Guerin or intravesical chemotherapy. Bladder cancer that invades the muscle layer is typically treated with radical cystectomy and neoadjuvant chemotherapy because of higher rates of progression and recurrence. No major organization recommends screening asymptomatic adults for bladder cancer, and the U.S. Preventive Services Task Force concluded that current evidence is insufficient to assess the balance of benefits and harms of screening. FAU - DeGeorge, Katharine C AU - DeGeorge KC AD - University of Virginia School of Medicine, Charlottesville, VA, USA. FAU - Holt, Harry R AU - Holt HR AD - University of Virginia School of Medicine, Charlottesville, VA, USA. FAU - Hodges, Stephanie C AU - Hodges SC AD - University of Virginia School of Medicine, Charlottesville, VA, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Am Fam Physician JT - American family physician JID - 1272646 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Antineoplastic Agents/administration & dosage MH - BCG Vaccine/administration & dosage MH - Biomarkers, Tumor/blood MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Risk Assessment MH - United States MH - Urinary Bladder Neoplasms/blood/*diagnosis/*therapy EDAT- 2017/11/03 06:00 MHDA- 2017/11/29 06:00 CRDT- 2017/11/03 06:00 PHST- 2017/11/03 06:00 [entrez] PHST- 2017/11/03 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] AID - d13130 [pii] PST - ppublish SO - Am Fam Physician. 2017 Oct 15;96(8):507-514. PMID- 29089252 OWN - NLM STAT- MEDLINE DCOM- 20201022 LR - 20220410 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 5 IP - 4 DP - 2019 Jul TI - Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. PG - 650-657 LID - S2405-4569(17)30241-9 [pii] LID - 10.1016/j.euf.2017.10.004 [doi] AB - BACKGROUND: Guidelines advocate early re-resection for these cancers, although the benefits are unclear and the uniform need is questioned. Here, we compare the outcomes using a large single-center cohort. OBJECTIVES: To compare the outcomes of patients with high-grade non-muscle-invasive bladder cancer (BC) who underwent and who did not undergo re-resection following their initial treatment. DESIGN, SETTING, AND PARTICIPANTS: We identified all eligible patients with a new diagnosis treated between 1994 and 2009 in Sheffield. We annotated these with hospital and registry records. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcomes were disease-specific and overall survival. Secondary outcomes were the findings at re-resection, rates of muscle invasion, and radical treatment. Statistical tests were two tailed and significance defined as p<0.05. RESULTS AND LIMITATIONS: We identified 932 eligible patients, including 229(25%) who underwent re-resection within 12 wk and 234 (25%) within 3-6 mo after diagnosis. Clinicopathological criteria were similar in patients with and without re-resection. Histological findings on re-resection were no residual cancer in 91 (20%) and BC in 138 (30%: 15 low-grade and 85 high-grade non-muscle-invasive cancers, and 38 muscle-invasive cancers). Patients with re-resection were more frequently diagnosed with muscle invasion (126 [27%] vs 49 [11%], chi-square p<0.001) and more commonly underwent radical treatment (127 [27%] vs 35 [8%], p<0.001) than those without re-resection. A total of 207 patients died from BC, including 46 (22%) with and 161 (78%) without re-resection. Patients who underwent re-resection within 3 mo had significantly higher disease-specific (log rank p=0.009) and overall survival (p<0.001) survival compared with those who did not. Differences were present only for patients with pT1 cancer at diagnosis. CONCLUSIONS: Patients undergoing re-resection within 3 mo of diagnosis were more likely to have histologically identified muscle invasion, were more likely to undergo radical treatment, and had a higher survival rate. The differences were greatest in patients with lamina propria invasion, suggesting the potential to avoid in others. Limitations of our work include retrospective design and selection bias. PATIENT SUMMARY: Patients undergoing re-resection after a diagnosis of high-grade non-muscle-invasive bladder cancer had higher disease-specific and overall survival rates due to more accurate diagnosis and appropriate subsequent radical treatment. Re-resection carries greatest benefit to patients with lamina propria invasion at diagnosis. CI - Crown Copyright (c) 2017. Published by Elsevier B.V. All rights reserved. FAU - Gordon, Patrick C AU - Gordon PC AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Thomas, Francis AU - Thomas F AD - Department of Urology, Doncaster Royal Infirmary, Doncaster, UK. FAU - Noon, Aidan P AU - Noon AP AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Rosario, Derek J AU - Rosario DJ AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk. LA - eng PT - Comparative Study PT - Journal Article DEP - 20171028 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Reoperation MH - Retrospective Studies MH - Risk Assessment MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - High-grade non-muscle invasive OT - Re-resection OT - Urothelial cancer EDAT- 2017/11/02 06:00 MHDA- 2020/10/23 06:00 CRDT- 2017/11/02 06:00 PHST- 2017/05/30 00:00 [received] PHST- 2017/09/14 00:00 [revised] PHST- 2017/10/16 00:00 [accepted] PHST- 2017/11/02 06:00 [pubmed] PHST- 2020/10/23 06:00 [medline] PHST- 2017/11/02 06:00 [entrez] AID - S2405-4569(17)30241-9 [pii] AID - 10.1016/j.euf.2017.10.004 [doi] PST - ppublish SO - Eur Urol Focus. 2019 Jul;5(4):650-657. doi: 10.1016/j.euf.2017.10.004. Epub 2017 Oct 28. PMID- 29081034 OWN - NLM STAT- MEDLINE DCOM- 20190228 LR - 20200225 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 25 IP - 1 DP - 2019 Jan TI - Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFkappaB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression. PG - 225-231 LID - 10.1007/s12253-017-0340-1 [doi] AB - To investigate the potential prognostic role of NFkappaB expression in primary high-grade non-muscle-invasive bladder cancer. Patients with primary high-grade non-muscle-invasive bladder cancer who received induction and maintenance BCG therapy were retrospectively included. Recurrence and progression were histologically proven. Intensity and extent of immunochemistry were assessed. The final evaluation of the NFkappaB staining was done by combining intensity and extent as ΄΄product΄΄ and expressing it as ΄΄low NFkappaBeta expression΄΄ or ΄΄high NFkappaB expression΄΄. Epidemiological, pathological, clinical parameters and NFkappaB expression were statistically analyzed for recurrence (REC), progression (PR), recurrence-free survival (RFS) and progression-free survival (PFS). NFkappaB is significantly associated with disease progression (p < 0,001 in univariate analysis and p = 0,001, Odds Ratio = 14,484, 95% Confidence Interval = 3187-65,821 in multivariate analysis), but not with recurrence. The median value of NFkappaB expression as ΄΄product΄΄ is significantly higher for the patients with progression in comparison to patients with recurrence only (p = 0,003) and patients without recurrence or progression (p = 0,001). Patients' age is significantly associated (p = 0,001 in univariate analysis and p = 0,003, Odds Ratio = 1273, 95% Confidence Interval = 1086-1492 in multivariate analysis) with disease recurrence. High NFkappaB expression in primary high-grade non-muscle-invasive bladder cancer, treated with postoperative intravesical BCG immunotherapy, could represent an unfavorable prognostic factor. FAU - Mitrakas, Lampros AU - Mitrakas L AUID- ORCID: 0000-0002-2563-5833 AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. lamprosmit@gmail.com. AD - Klinik fur Urologie und Kinderurologie, Sozialstiftung Bamberg-Klinikum am Bruderwald, Akademisches Lehrkrankenhaus der Friedrich-Alexander-Universitat Erlangen-Nurnberg, Buger Strasse 80, 96049, Bamberg, Germany. lamprosmit@gmail.com. FAU - Gravas, Stavros AU - Gravas S AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Papandreou, Christos AU - Papandreou C AD - Department of Oncology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Koukoulis, Georgios AU - Koukoulis G AD - Department of Pathology and Cytology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Karasavvidou, Foteini AU - Karasavvidou F AD - Department of Pathology and Cytology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Dimakopoulos, Georgios AU - Dimakopoulos G AD - Medical Statistics, Science and Technology Park of Epirus, Ioannina, Greece. FAU - Weingartner, Karl AU - Weingartner K AD - Klinik fur Urologie und Kinderurologie, Sozialstiftung Bamberg-Klinikum am Bruderwald, Akademisches Lehrkrankenhaus der Friedrich-Alexander-Universitat Erlangen-Nurnberg, Buger Strasse 80, 96049, Bamberg, Germany. FAU - Karatzas, Anastasios AU - Karatzas A AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Zachos, Ioannis AU - Zachos I AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. FAU - Tzortzis, Vasilios AU - Tzortzis V AD - Department of Urology, Faculty of Medicine-School of Health Sciences-University of Thessaly, University Hospital of Larissa, Larissa, Greece. LA - eng PT - Journal Article DEP - 20171028 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Biomarkers, Tumor) RN - 0 (NF-kappa B) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Immunotherapy MH - Male MH - Middle Aged MH - NF-kappa B/*metabolism MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/metabolism/*pathology MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*pathology OTO - NOTNLM OT - Bladder cancer OT - High-grade OT - NFkappaBeta OT - Non-muscle-invasive OT - Progression; BCG EDAT- 2017/10/31 06:00 MHDA- 2019/03/01 06:00 CRDT- 2017/10/30 06:00 PHST- 2017/01/06 00:00 [received] PHST- 2017/10/20 00:00 [accepted] PHST- 2017/10/31 06:00 [pubmed] PHST- 2019/03/01 06:00 [medline] PHST- 2017/10/30 06:00 [entrez] AID - 10.1007/s12253-017-0340-1 [pii] AID - 10.1007/s12253-017-0340-1 [doi] PST - ppublish SO - Pathol Oncol Res. 2019 Jan;25(1):225-231. doi: 10.1007/s12253-017-0340-1. Epub 2017 Oct 28. PMID- 29076872 OWN - NLM STAT- MEDLINE DCOM- 20171229 LR - 20210415 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 42 IP - 1 DP - 2018 Jan TI - Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. PG - e1-e10 LID - 10.1097/PAS.0000000000000964 [doi] AB - Urothelial carcinoma of the bladder invasive into lamina propria on biopsy or transurethral resection of bladder tumor, termed "T1" disease, progresses to muscularis propria invasion in a subset of patients. Prior studies have proposed histopathologic metrics to predict progression, although methods vary widely and it is unclear which method is most robust. This poses a challenge since recent World Health Organization and American Joint Commission on Cancer editions encourage some attempt to substratify T1 disease. To address this critical problem, we analyzed T1 specimens to test which T1 quantification method is best to predict progression and to then establish the optimal cut-off. Progression was analyzed for all patients or for patients with definitive muscularis propria only. Multivariate analysis and outcomes modeling controlled for additional histopathologic features. Our results suggest that aggregate linear length of invasive carcinoma (ALLICA) measured by optical micrometer is far superior to other methods (P=3.067x10) and could be applied to 100% of specimens. ALLICA retained significance in multivariate analysis and eliminated contribution of other histopathologic features to progression. The best cut-off for ALLICA using a 30% false-positive threshold was 2.3 mm and using a 10% false-positive threshold at 25 mm, although the latter severely limited patients who could achieve this threshold. After comparison of all proposed methods of T1 quantification, we recommend the adoption of the ALLICA measurement and a cut-off of >/=2.3 mm as the best predictor of progression, acknowledging that additional nonhistopathologic methods may be required to increase broad applicability and further reduce the false-positive threshold. FAU - Leivo, Mariah Z AU - Leivo MZ AD - Departments of Pathology. FAU - Sahoo, Debashis AU - Sahoo D AD - Computer Science and Engineering. FAU - Hamilton, Zachary AU - Hamilton Z AD - Urology, University of California at San Diego, La Jolla, CA. FAU - Mirsadraei, Leili AU - Mirsadraei L AD - Departments of Pathology. FAU - Shabaik, Ahmed AU - Shabaik A AD - Departments of Pathology. FAU - Parsons, John K AU - Parsons JK AD - Urology, University of California at San Diego, La Jolla, CA. FAU - Kader, Andrew K AU - Kader AK AD - Urology, University of California at San Diego, La Jolla, CA. FAU - Derweesh, Ithaar AU - Derweesh I AD - Urology, University of California at San Diego, La Jolla, CA. FAU - Kane, Christopher AU - Kane C AD - Urology, University of California at San Diego, La Jolla, CA. FAU - Hansel, Donna E AU - Hansel DE AD - Departments of Pathology. AD - Urology, University of California at San Diego, La Jolla, CA. LA - eng GR - R00 CA151673/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM CIN - J Urol. 2018 Nov;200(5):942-943. doi: 10.1016/j.juro.2018.08.004. PMID: 30360339 CIN - J Urol. 2019 Feb;201(2):225-226. doi: 10.1097/01.JU.0000553022.59240.43. PMID: 30634335 MH - Adult MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Cystectomy/methods MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Linear Models MH - Male MH - Middle Aged MH - Mucous Membrane/*pathology/surgery MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*pathology/surgery EDAT- 2017/10/28 06:00 MHDA- 2017/12/30 06:00 CRDT- 2017/10/28 06:00 PHST- 2017/10/28 06:00 [pubmed] PHST- 2017/12/30 06:00 [medline] PHST- 2017/10/28 06:00 [entrez] AID - 10.1097/PAS.0000000000000964 [doi] PST - ppublish SO - Am J Surg Pathol. 2018 Jan;42(1):e1-e10. doi: 10.1097/PAS.0000000000000964. PMID- 29071155 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 15 IP - 3 DP - 2017 Sep TI - Risk factors and prognosis of intravesical recurrence after surgical management of upper tract urothelial carcinoma: A 30-year single centre experience. PG - 216-222 LID - 10.1016/j.aju.2017.03.006 [doi] AB - OBJECTIVE: To review the incidence, predictors and prognosis of bladder cancer recurrence after management of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: We retrospectively reviewed patients who were surgically treated for UTUC from 1983 to 2013. The tumours were categorised according to the 1997 Tumour-Node-Metastasis (TNM) staging and the three-tiered World Health Organization grading systems. The primary endpoint was the occurrence of any intravesical recurrence after treatment. We studied the possible risk factors that may contribute to development of intravesical recurrence, as well as the prognosis of the patients who had recurrence. RESULTS: In all, 297 patients were eligible for analysis. Recurrent bladder tumours occurred in 139 patients (46.8%). The mean (range) time to recurrence after surgery was 33 (6-300) months. Neither sex, past history of bladder tumours, concomitant bladder tumour, the side of the tumour, UTUC stage, grade, presence of carcinoma in situ or multicentricity at the time of diagnosis of UTUC, were significant predictors of intravesical tumour recurrence. Ureteric tumour was the only identified risk factor (P = 0.02). Post-treatment bladder recurrence was a significant predictor of later urethral recurrence (P = 0.002). CONCLUSIONS: In our present series, bladder cancer recurrence of urothelial malignancy occurred in nearly half of the patients after surgical management of UTUC. Ureteric tumour was the only identifiable risk factor, thus patients with ureteric tumours may benefit from prophylactic intravesical chemoimmunotherapy. Bladder recurrence does not appear to affect the cancer-specific survival after surgical management of UTUC. FAU - Elawdy, Mohamed Mohamed AU - Elawdy MM AD - Department Urology, Ibri Regional Hospital, Ministry of Health, Al Khdar, Oman. FAU - Osman, Yasser AU - Osman Y AD - Department Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Taha, Diaa Eldin AU - Taha DE AD - Department Urology, Faculty of Medicine, Kafr El Sheikh University, Kafr El Sheikh, Egypt. FAU - Zahran, Mohamed H AU - Zahran MH AD - Department Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - El-Halwagy, Samer AU - El-Halwagy S AD - Department Urology, Sohar Hospital, Ministry of Health, Muscat, Oman. FAU - Garba, Muftah El AU - Garba ME AD - Department Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Harraz, Ahmed M AU - Harraz AM AD - Department Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20170509 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC5651950 OTO - NOTNLM OT - CIS, carcinoma in situ OT - Intravesical recurrence OT - RNU, radical nephroureterectomy OT - Transitional cell carcinoma OT - UTUC, upper tract urothelial carcinoma OT - Ureteric neoplasms OT - Urinary bladder neoplasms OT - Urological neoplasms EDAT- 2017/10/27 06:00 MHDA- 2017/10/27 06:01 PMCR- 2017/05/09 CRDT- 2017/10/27 06:00 PHST- 2017/01/15 00:00 [received] PHST- 2017/03/07 00:00 [revised] PHST- 2017/03/29 00:00 [accepted] PHST- 2017/10/27 06:00 [entrez] PHST- 2017/10/27 06:00 [pubmed] PHST- 2017/10/27 06:01 [medline] PHST- 2017/05/09 00:00 [pmc-release] AID - S2090-598X(17)30042-6 [pii] AID - 10.1016/j.aju.2017.03.006 [doi] PST - epublish SO - Arab J Urol. 2017 May 9;15(3):216-222. doi: 10.1016/j.aju.2017.03.006. eCollection 2017 Sep. PMID- 29064650 OWN - NLM STAT- MEDLINE DCOM- 20180601 LR - 20181113 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 44 IP - 1 DP - 2018 Jan-Feb TI - The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience. PG - 45-52 LID - 10.1590/S1677-5538.IBJU.2016.0347 [doi] AB - INTRODUCTION: Carcinosarcoma of the bladder is a very rare neoplasm. The pathogenesis of carcinosarcomas is not clearly understood and remains a subject of debate. Whilst there is some research conceptualizing the histopathological findings of bladder carcinosarcomas, the demographic features, clinical outcomes, prognosis and treatment options remain unclear. MATERIALS AND METHODS: We analyzed 12 consecutive cases of patients with sarcoma-toid bladder cancer who were treated surgically at a single Urology Department be-tween 1999 and 2015. Radiology, pathology and surgical reports were reviewed to determine the pathological staging at the time of cystectomy. These were directly compared with 230 patients having cystectomies for urothelial cell carcinoma. The sarcomatoid patients, were compared to patients with urothelial cell cancers. The other histological sub types, squamous cell (17), neuroendocrine (9), metastatic (7), mixed (4), adenocarcinoma (3), were not included. RESULTS AND CONCLUSION: Carcinosarcoma of the urinary bladder is often described in the literature as a highly malignant neoplasm that is rapidly lethal. We found that the sarcoma does not offer a worse prognosis than conventional high-grade urothelial car-cinoma. There is no significant difference in grade, stage, positive surgical margin rate, nodal involvement, associated prostate cancer or incidence rates of progression, all cause or disease specific mortality. There was a barely significant difference in carcinoma in-situ. However, carcinosarcomas are three times the volume of urothelial cell tumors which may contribute to its reputation as an aggressive tumour (44cc v 14cc). Sarcomatous elements do not appear, from our small study, to bestow a worse prognosis. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Robinson, Simon Paul AU - Robinson SP AD - Frimley Health Foundation Trust - Urologia, Wexham Street, Slough, United Kingdom, UK. FAU - Farooq, Assad AU - Farooq A AD - Heatherwood and Wexham Park Hospitals NHS Trust, Wexham Park Hospital Wexham Slough, Slough, United Kingdom, UK. FAU - Laniado, Marc AU - Laniado M AD - Department of Urology, Heatherwood and Wexham Park Hospitals NHS Trust - Slough, Berkshire, United Kingdom, UK. FAU - Motiwala, Hanif AU - Motiwala H AD - Department of Urology, Heatherwood and Wexham Park Hospitals NHS Trust - Slough, Berkshire, United Kingdom, UK. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/surgery MH - Carcinosarcoma/mortality/pathology/*surgery MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery PMC - PMC5815531 OTO - NOTNLM OT - Carcinoma OT - Sarcoma OT - Urinary Bladder COIS- Conflict of interest: None declared. EDAT- 2017/10/25 06:00 MHDA- 2018/06/02 06:00 PMCR- 2018/01/01 CRDT- 2017/10/25 06:00 PHST- 2016/06/16 00:00 [received] PHST- 2017/05/25 00:00 [accepted] PHST- 2017/10/25 06:00 [pubmed] PHST- 2018/06/02 06:00 [medline] PHST- 2017/10/25 06:00 [entrez] PHST- 2018/01/01 00:00 [pmc-release] AID - IBJU20160347 [pii] AID - S1677-5538.IBJU.2016.0347 [pii] AID - 10.1590/S1677-5538.IBJU.2016.0347 [doi] PST - ppublish SO - Int Braz J Urol. 2018 Jan-Feb;44(1):45-52. doi: 10.1590/S1677-5538.IBJU.2016.0347. PMID- 29063301 OWN - NLM STAT- MEDLINE DCOM- 20180625 LR - 20181113 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 34 IP - 12 DP - 2017 Oct 23 TI - Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy. PG - 187 LID - 10.1007/s12032-017-1048-5 [doi] AB - Although the clinical utility of a frozen section analysis (FSA) at the time of radical cystectomy (RC) has already been established, its significance and utility in bladder cancer patients receiving neoadjuvant chemotherapy (NAC) have not yet been fully evaluated. We identified 458 patients (937 ureters) who underwent open RC for bladder cancer at our 7 Japanese institutions between 2004 and 2015. Among these patients, 139 (284 ureters) received NAC before RC (NAC group), while 319 (653 ureters) underwent RC alone (non-NAC group). FSA was performed on 356 out of 937 (38.0%) ureters and 179 out of 458 (39.1%) patients. FSA was positive in 30 out of 356 (8.4%) ureters and its sensitivity, specificity, and accuracy were 89.3, 98.5, and 97.8%, respectively. In the NAC group, FSA was performed on 138 out of 284 (48.6%) ureters and 68 out of 139 (48.9%) patients. FSA was positive in 8 out of 138 ureters (5.8%), and its sensitivity, specificity, and accuracy were 77.8, 99.2, and 97.8%, respectively. In the non-NAC group, FSA was performed on 218 out of 653 (33.4%) ureters and 111 out of 319 (34.8%) patients. FSA was positive in 22 out of 218 (10.1%) ureters, and its sensitivity, specificity, and accuracy were 94.7, 98.0, and 97.7%, respectively. No correlation was observed between preoperative clinical factors and FSA positivity in the NAC group; however, in the non-NAC group, the incidence of FSA positivity in the ureters of patients with concomitant CIS in TUR-BT specimens was 8/41 (19.5%), which was significantly higher than that in their counterpart (14/177, 7.9%, p = 0.033). Even in the era of NAC in the management of bladder cancer patients, the performance of FSA does not change and FSA at the time of RC may provide useful diagnostic information. FAU - Hakozaki, Kyohei AU - Hakozaki K AD - Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AUID- ORCID: 0000-0001-7368-4958 AD - Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Fukumoto, Keishiro AU - Fukumoto K AD - Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan. FAU - Shirotake, Suguru AU - Shirotake S AD - Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Miyazaki, Yasumasa AU - Miyazaki Y AD - Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan. FAU - Maeda, Takahiro AU - Maeda T AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Kaneko, Gou AU - Kaneko G AD - Department of Urology, Kawasaki Municipal Hospital, Kanagawa, Japan. FAU - Yoshimine, Shunsuke AU - Yoshimine S AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Saitama City Hospital, Saitama, Japan. FAU - Kanai, Kunimitsu AU - Kanai K AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Oyama, Masafumi AU - Oyama M AD - Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Nakajima, Yosuke AU - Nakajima Y AD - Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan. FAU - Momma, Tetsuo AU - Momma T AD - Department of Urology, National Hospital Organization Saitama National Hospital, Saitama, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan. LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20171023 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Cystectomy MH - Female MH - Frozen Sections MH - Humans MH - Male MH - Margins of Excision MH - Neoadjuvant Therapy MH - Preoperative Period MH - Prognosis MH - Sensitivity and Specificity MH - Treatment Outcome MH - Ureter/*pathology/surgery MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Frozen section analysis OT - Neoadjuvant chemotherapy OT - Radical cystectomy OT - Ureters EDAT- 2017/10/25 06:00 MHDA- 2018/06/26 06:00 CRDT- 2017/10/25 06:00 PHST- 2017/09/18 00:00 [received] PHST- 2017/10/16 00:00 [accepted] PHST- 2017/10/25 06:00 [entrez] PHST- 2017/10/25 06:00 [pubmed] PHST- 2018/06/26 06:00 [medline] AID - 10.1007/s12032-017-1048-5 [pii] AID - 10.1007/s12032-017-1048-5 [doi] PST - epublish SO - Med Oncol. 2017 Oct 23;34(12):187. doi: 10.1007/s12032-017-1048-5. PMID- 29055653 OWN - NLM STAT- MEDLINE DCOM- 20190214 LR - 20220330 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 73 IP - 5 DP - 2018 May TI - Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review. PG - 738-748 LID - S0302-2838(17)30850-3 [pii] LID - 10.1016/j.eururo.2017.10.003 [doi] AB - CONTEXT: Bacillus Calmette-Guerin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors. OBJECTIVE: To review existing data on clinical, pathologic, immune, and molecular markers that allow prediction of BCG response. EVIDENCE ACQUISITION: PubMed and MEDLINE search of English language literature was conducted from its inception to July 2017 using appropriate search terms. Following systematic literature review and analysis of data, consensus voting was used to generate the content of this review. EVIDENCE SYNTHESIS: As seen in the EORTC and CUETO risk nomograms, clinicopathologic features, especially tumor stage and grade, are the most effective predictors of BCG response. Data are less robust with regards to the association of response with age, female sex, recurrent tumors, multiplicity of tumors, and the presence of carcinoma in situ. Single biomarkers, such as tumor p53 and urinary interleukin-2 expression, have had limited success in predicting BCG response, possibly due to the multifaceted nature of the generated immune response. More comprehensive biomarker panels (eg, urinary cytokines), have a more robust correlation with response, as do patterns of urinary cytologic fluorescent in-situ hybridization examination. Gene expression data correlate with disease progression, but studies examining potential associations with BCG response are limited. CONCLUSIONS: Currently, the best predictors of BCG response are clinicopathologic features such as tumor grade and stage. Panels of urinary cytokines, as well as fluorescent in-situ hybridization patterns of cytologic anomalies, appear to be promising biomarkers. The complexity of the immune response to BCG and the heterogeneity of bladder cancer suggest that future studies should amalgamate measures reflecting innate immune response and tumor/stromal gene expression before these can be adopted for clinical use. PATIENT SUMMARY: Bacillus Calmette-Guerin (BCG) immunotherapy is an effective treatment for many patients with nonmuscle invasive bladder cancer. An individual's response to BCG can be predicted by using various features of the cancer. In the future, predictive markers using molecular measures of the tumor type and the immune response to BCG may allow us to precisely know an individual's likely outcome after BCG treatment. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. FAU - Li, Roger AU - Li R AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, Iowa City, IA, USA. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, University Paris Sorbonne, Paris, France. FAU - Catto, James W AU - Catto JW AD - Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Tenon Hospital, AP-HP, University Pierre and Marie Curie, Paris, France. FAU - Ingersoll, Molly A AU - Ingersoll MA AD - Department of Immunology, Institut Pasteur and INSERM U1223, Paris, France. FAU - Witjes, Wim P AU - Witjes WP AD - EAU Research Foundation, EAU Central Office, Arnhem, The Netherlands. FAU - McConkey, David J AU - McConkey DJ AD - The Greenberg Bladder Cancer Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. LA - eng PT - Journal Article PT - Systematic Review DEP - 20171018 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2018 May;73(5):749-750. doi: 10.1016/j.eururo.2017.11.021. PMID: 29199024 MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Biopsy, Needle MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Immunotherapy/*methods MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/mortality/*pathology MH - Predictive Value of Tests MH - Prognosis MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Immunotherapy OT - Personalized therapy OT - Response prediction EDAT- 2017/10/23 06:00 MHDA- 2019/02/15 06:00 CRDT- 2017/10/23 06:00 PHST- 2017/08/19 00:00 [received] PHST- 2017/10/02 00:00 [accepted] PHST- 2017/10/23 06:00 [pubmed] PHST- 2019/02/15 06:00 [medline] PHST- 2017/10/23 06:00 [entrez] AID - S0302-2838(17)30850-3 [pii] AID - 10.1016/j.eururo.2017.10.003 [doi] PST - ppublish SO - Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18. PMID- 29049231 OWN - NLM STAT- MEDLINE DCOM- 20171101 LR - 20210109 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 96 IP - 42 DP - 2017 Oct TI - Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials. PG - e8300 LID - 10.1097/MD.0000000000008300 [doi] LID - e8300 AB - BACKGROUND: Intravesical bacillus Calmette-Guerin (BCG) instillation is widely used as an adjuvant therapy after transurethral resection of bladder tumor (TURBT) in patients with intermediate- and high-risk nonmuscle invasive bladder cancer (NMIBC). However, the effective dose, duration, and strain of BCG have not yet been clearly determined. We aimed to elucidate the relationship between dose, duration, and strain of BCG and clinical outcomes in NMIBC patients treated with TURBT. METHODS: We conducted a literature search in Embase, Scopus, and PubMed databases for all relevant articles published up to October 2016 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. The relative risks of clinical outcomes, including recurrence, progression, cancer-specific mortality, and all-cause mortality according to dose (standard vs low), duration (induction vs maintenance), and strain of BCG were presented as the pooled risk ratio (RR) and 95% confidence interval (CI). RESULTS: Nineteen studies meeting the inclusion criteria were finally selected in this meta-analysis. The risk of recurrence was significantly highly observed in case of low-dose BCG (RR, 1.17; 95% CI 1.06-1.30) and induction BCG (RR, 1.33; 95% CI 1.17-1.50) only group without heterogeneity among the included studies. Although there were no significant differences between dose or duration and other clinical outcomes. On direct comparison in each study comparing BCG strains, the Tice stain showed a relatively high probability of recurrence compared with the Connaught (RR, 1.29; 95% CI 1.01-1.64) and RIVM (RR, 2.04, 95% CI 1.28-3.25) strains. Funnel plot testing revealed no significant publication bias. CONCLUSION: The use of standard dose and maintenance BCG instillation may be effective to reduce recurrence rate after TURBT for NMIBC. Further large scale, well-designed, and prospective studies, with stratification of the patients into risk group at randomization, will be required to determine the optimal guideline of BCG use to improve clinical outcomes in NMIBC. FAU - Quan, Yongjun AU - Quan Y AD - Department of Urology, Seoul National University Hospital, Seoul Department of Urology, Dongguk University Ilsan Medical Center, Goyang, Korea. FAU - Jeong, Chang Wook AU - Jeong CW FAU - Kwak, Cheol AU - Kwak C FAU - Kim, Hyeon Hoe AU - Kim HH FAU - Kim, Hyung Suk AU - Kim HS FAU - Ku, Ja Hyeon AU - Ku JH LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Chemotherapy, Adjuvant MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Humans MH - Neoplasm Recurrence, Local MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*drug therapy/mortality/surgery PMC - PMC5662397 COIS- The authors have no conflicts of interest to disclose. EDAT- 2017/10/20 06:00 MHDA- 2017/11/02 06:00 PMCR- 2017/10/20 CRDT- 2017/10/20 06:00 PHST- 2017/10/20 06:00 [entrez] PHST- 2017/10/20 06:00 [pubmed] PHST- 2017/11/02 06:00 [medline] PHST- 2017/10/20 00:00 [pmc-release] AID - 00005792-201710200-00069 [pii] AID - MD-D-17-04510 [pii] AID - 10.1097/MD.0000000000008300 [doi] PST - ppublish SO - Medicine (Baltimore). 2017 Oct;96(42):e8300. doi: 10.1097/MD.0000000000008300. PMID- 29048388 OWN - NLM STAT- MEDLINE DCOM- 20180530 LR - 20181113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 18 IP - 10 DP - 2017 Oct 19 TI - Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guerin: A Long-Term Follow-Up Study of a Japanese Cohort. LID - 10.3390/ijms18102186 [doi] LID - 2186 AB - The clinical significance of regulatory T cells (Treg) and tumor-associated macrophages (TAM) in the tumor microenvironment of human bladder cancer remains unclear. The aim of this study is to explore their relevance to oncological features in non-muscle invasive bladder cancer (NMIBC). We carried out immunohistochemical analysis of forkhead box P3 (FOXP3, Treg maker), CD204 (TAM marker), and interleukin-6 (IL6) using surgical specimens obtained from 154 NMIBC patients. The Treg and TAM counts surrounding the cancer lesion and IL6-positive cancer cell counts were evaluated against clinicopathological variables. We focused on the ability of the Treg and TAM counts around the cancer lesion to predict outcomes after adjuvant intravesical Bacille Calmette-Guerin (BCG) treatment. High Treg counts were associated with female patients, older age, T1 category, and high tumor grade. TAM count was significantly correlated with Treg count and with IL6-positive cancer cell count. In our analysis of 71 patients treated with BCG, high counts of Treg and TAM were associated with shorter recurrence-free survival, and the former was an independent predictor of recurrence. Poor response to intravesical BCG was associated with Treg and TAM in the tumor microenvironment. Disrupting the immune network can be a supplementary therapeutic approach for NMIBC patients receiving intravesical BCG. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. makitomiyake@naramed-u.ac.jp. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. takuro.birds.nest@gmail.com. AD - Department of Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. takuro.birds.nest@gmail.com. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. dgotou@gmail.com. FAU - Ohnishi, Sayuri AU - Ohnishi S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sayuri3@naramed-u.ac.jp. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. tintherye@gmail.com. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kota1006ida@yahoo.co.jp. FAU - Ohnishi, Kenta AU - Ohnishi K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kenzmedico0912@yahoo.co.jp. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. horimaus@gmail.com. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. tigers.yosuke@gmail.com. FAU - Itami, Yoshitaka AU - Itami Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. y.itami.324@gmail.com. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. nakaiyasusiuro@live.jp. FAU - Inoue, Takeshi AU - Inoue T AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. you1513tt@yahoo.co.jp. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sanai@naramed-u.ac.jp. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. torimoto@nmu-gw.naramed-u.ac.jp. FAU - Aoki, Katsuya AU - Aoki K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. aokik@naramed-u.ac.jp. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, 1501 Higashi kidera-cho, Nara-shi, Nara 630-8305, Japan. k-shimada@nara-jadecom.jp. FAU - Konishi, Noboru AU - Konishi N AD - Department of Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. n-konishi@takai-hp.com. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. sendo@naramed-u.ac.jp. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. kiyokun@naramed-u.ac.jp. LA - eng PT - Journal Article DEP - 20171019 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BCG Vaccine) RN - 0 (FOXP3 protein, human) RN - 0 (Forkhead Transcription Factors) RN - 0 (Interleukin-6) RN - 0 (MSR1 protein, human) RN - 0 (Scavenger Receptors, Class A) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Carcinoma/immunology/pathology/*therapy MH - Female MH - Forkhead Transcription Factors/genetics/metabolism MH - Humans MH - Interleukin-6/genetics/metabolism MH - Macrophages/*immunology MH - Male MH - Middle Aged MH - Scavenger Receptors, Class A/genetics/metabolism MH - T-Lymphocytes, Regulatory/*immunology MH - *Tumor Microenvironment MH - Urinary Bladder Neoplasms/immunology/pathology/*therapy PMC - PMC5666867 OTO - NOTNLM OT - Bacille Calmette-Guerin OT - intravesical recurrence OT - non-muscle invasive bladder cancer OT - progression OT - regulatory T cell OT - tumor-associated macrophage COIS- The authors declare no conflicts of interest. EDAT- 2017/10/20 06:00 MHDA- 2018/05/31 06:00 PMCR- 2017/10/01 CRDT- 2017/10/20 06:00 PHST- 2017/09/23 00:00 [received] PHST- 2017/10/16 00:00 [revised] PHST- 2017/10/17 00:00 [accepted] PHST- 2017/10/20 06:00 [entrez] PHST- 2017/10/20 06:00 [pubmed] PHST- 2018/05/31 06:00 [medline] PHST- 2017/10/01 00:00 [pmc-release] AID - ijms18102186 [pii] AID - ijms-18-02186 [pii] AID - 10.3390/ijms18102186 [doi] PST - epublish SO - Int J Mol Sci. 2017 Oct 19;18(10):2186. doi: 10.3390/ijms18102186. PMID- 29037861 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20190522 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 199 IP - 4 DP - 2018 Apr TI - Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy. PG - 933-939 LID - S0022-5347(17)77724-5 [pii] LID - 10.1016/j.juro.2017.10.019 [doi] AB - PURPOSE: In patients with urothelial carcinoma CIS (carcinoma in situ) generally has a poor prognosis. However, to our knowledge the outcomes of pure/primary CIS and the behavior of CIS concomitant with pTa-pT4 upper tract urothelial carcinoma managed by nephroureterectomy have not been previously specified. We explored the biological and prognostic features of concomitant CIS compared with those of pure/primary CIS. MATERIALS AND METHODS: We queried a multicenter upper tract urothelial carcinoma database. Data from NUOG (Nishinihon Uro-Oncology Group) were analyzed, including patient gender, age, presence of bladder cancer and pT stage. Clinicopathological features were compared between the different subtypes. Cancer specific and overall survival, and the relative excess risk of death were estimated by CIS subtype. RESULTS: We identified 163 patients with CIS in the upper urinary tract, of whom pure/primary CIS was noted in 24.5%. In the concomitant CIS cohort the pathological diagnosis of the nonCIS region was pTa, pT1, pT2, pT3 and pT4 in 4.9%, 22.8%, 25.2%, 44.7% and 1.6% of patients, respectively. The sensitivity of a selective urine cytology test was higher in the pure/primary CIS group than in the concomitant CIS group (60.0% vs 37.4%). At a median followup of 32 months 10-year estimated mean cancer specific survival was 92.4 months (range 83.7 to 101.0) in the overall CIS cohort. Ten-year estimated mean cancer specific survival in patients with pure/primary CIS was significantly longer than in patients with concomitant carcinoma in situ (111.8 months, range 101.0 to 122.6 vs 85.89, range 75.3 to 96.5, log rank p = 0.007). CONCLUSIONS: Patients presenting with concomitant CIS have a worse outcome than those who present with pure/primary CIS, suggesting a need to differentiate these 2 entities in the treatment decision process. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Osaka Medical College, Takatsuki, Japan. Electronic address: tinamoto@osaka-med.ac.jp. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Ibuki, Naokazu AU - Ibuki N AD - Department of Urology, Osaka Medical College, Takatsuki, Japan. FAU - Komura, Kazumasa AU - Komura K AD - Department of Urology, Osaka Medical College, Takatsuki, Japan. FAU - Takahara, Kiyoshi AU - Takahara K AD - Department of Urology, Osaka Medical College, Takatsuki, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Shiina, Hiroaki AU - Shiina H AD - Department of Urology, Shimane University School of Medicine, Izumo, Japan. FAU - Sakano, Shigeru AU - Sakano S AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Kashihara, Japan. FAU - Yasumoto, Hiroaki AU - Yasumoto H AD - Department of Urology, Shimane University School of Medicine, Izumo, Japan. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical College, Takatsuki, Japan. CN - Nishinihon Uro-Oncology Collaborative Group LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20171014 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Apr;199(4):938-939. doi: 10.1016/j.juro.2017.10.064. PMID: 29331547 MH - Aged MH - Aged, 80 and over MH - Carcinoma in Situ/mortality/pathology/*surgery MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney/pathology/surgery MH - Kidney Neoplasms/mortality/pathology/*surgery MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Nephroureterectomy MH - Prognosis MH - Survival Rate MH - Treatment Outcome MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - carcinoma in situ OT - kidney OT - prognosis OT - ureter OT - urothelium EDAT- 2017/10/19 06:00 MHDA- 2019/05/23 06:00 CRDT- 2017/10/18 06:00 PHST- 2017/10/10 00:00 [accepted] PHST- 2017/10/19 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] PHST- 2017/10/18 06:00 [entrez] AID - S0022-5347(17)77724-5 [pii] AID - 10.1016/j.juro.2017.10.019 [doi] PST - ppublish SO - J Urol. 2018 Apr;199(4):933-939. doi: 10.1016/j.juro.2017.10.019. Epub 2017 Oct 14. PMID- 29034222 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2253-2447 (Print) IS - 2253-2447 (Electronic) IS - 2253-2447 (Linking) VI - 9 DP - 2017 TI - Risk factor assessment in high-risk, bacillus Calmette-Guerin-treated, non-muscle-invasive bladder cancer. PG - 195-202 LID - 10.2147/RRU.S143865 [doi] AB - OBJECTIVE: To assess the risk factors associated with recurrence, progression and survival in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with bacillus Calmette-Guerin (BCG) and validate the European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) scores. PATIENTS AND METHODS: We retrospectively analyzed all BCG-treated NMIBC patients from 1998 to 2012. Multiple variables were tested as risk factors for recurrence-free survival and progression-free survival (PFS). Variables included age, sex, grade, stage, tumor size, number of tumors, carcinoma in situ (CIS), recurrence status, BCG strain used, smoking status, use of re-staging transurethral resection and use of single immediate postoperative instillation. We also tested the accuracy of EORTC and CUETO scores in predicting recurrence and progression. RESULTS: Overall, 123 patients were analyzed. Median (interquartile range) follow-up was 49 months. The 5-year overall survival, cancer-specific survival, recurrence-free survival and PFS were 75.0%, 89.3%, 59.4% and 79.2%, respectively. On univariate analysis, multiple tumors (>/=3), concomitant CIS and smoking influenced recurrence. Regarding progression, multiple tumors, concomitant CIS and Connaught strain (vs Tice) negatively influenced PFS on univariate and multivariate analyses were independent prognostic factors. CUETO scores were accurate, with a slight overestimation, while EORTC score was not predictive of recurrence or progression. CONCLUSION: In this study, CIS and tumor multiplicity were unfavorable predictors of recurrence and progression in patients with NMIBC receiving BCG. CUETO model was superior to EORTC risk tables in predicting recurrence and progression in our BCG-treated patient population. Nonetheless, both scores overestimated recurrence and progression rates. Prospective trials are needed to validate our findings. FAU - Holz, Serge AU - Holz S AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Albisinni, Simone AU - Albisinni S AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Gilsoul, Jacques AU - Gilsoul J AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Pirson, Michel AU - Pirson M AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Duthie, Veronique AU - Duthie V AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Quackels, Thierry AU - Quackels T AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Vanden Bossche, Marc AU - Vanden Bossche M AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. FAU - Roumeguere, Thierry AU - Roumeguere T AD - Department of Urology, Erasme Hospital, Universite libre de Bruxelles, Belgium. LA - eng PT - Journal Article DEP - 20170926 PL - England TA - Res Rep Urol JT - Research and reports in urology JID - 101576971 PMC - PMC5628686 OTO - NOTNLM OT - BCG OT - bladder cancer OT - progression OT - recurrence COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2017/10/17 06:00 MHDA- 2017/10/17 06:01 PMCR- 2017/09/26 CRDT- 2017/10/17 06:00 PHST- 2017/10/17 06:00 [entrez] PHST- 2017/10/17 06:00 [pubmed] PHST- 2017/10/17 06:01 [medline] PHST- 2017/09/26 00:00 [pmc-release] AID - rru-9-195 [pii] AID - 10.2147/RRU.S143865 [doi] PST - epublish SO - Res Rep Urol. 2017 Sep 26;9:195-202. doi: 10.2147/RRU.S143865. eCollection 2017. PMID- 29032580 OWN - NLM STAT- MEDLINE DCOM- 20180313 LR - 20220330 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 121 IP - 2 DP - 2018 Feb TI - Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. PG - 184-193 LID - 10.1111/bju.14053 [doi] AB - OBJECTIVES: To investigate whether ureteroscopy (URS) before radical nephroureterectomy (RNU) for upper tract urothelial carcinomas (UTUCs) has an impact on oncological outcomes. PATIENTS AND METHODS: We performed a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described URS performed on patients with UTUC and conducted a standard meta-analysis on survival outcomes. RESULTS: Our meta-analysis included eight eligible studies containing 3975 patients. The results were as follows: cancer-specific survival (CSS; hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.99; P = 0.04), overall survival (OS; HR 0.76, 95% CI 0.48-1.21; P = 0.24), recurrence-free survival (RFS; HR 0.89, 95% CI 0.69-1.14; P = 0.37), metastasis-free survival (MFS; HR 1.06, 95% CI 0.82-1.36; P = 0.66), and intravesical recurrence-free survival (IRFS; HR 1.51, 95% CI 1.29-1.77; P < 0.001). When excluding previous bladder tumour history, the result for IRFS was a HR of 1.81 (95% CI 1.53-2.13; P < 0.001). CONCLUSIONS: This meta-analysis indicated that URS before RNU did not have a negative impact on CSS, OS, RFS, or MFS in patients with UTUC. However, patients were at higher risk of intravesical recurrence after RNU when they had undergone URS before RNU. Further studies are needed to assess the effects of post-URS intravesical chemotherapy on intravesical recurrence. CI - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John Wiley & Sons Ltd. FAU - Guo, Run-Qi AU - Guo RQ AUID- ORCID: 0000-0001-7026-6937 AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Hong, Peng AU - Hong P AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Xiong, Geng-Yan AU - Xiong GY AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Li, Xue-Song AU - Li XS AUID- ORCID: 0000-0002-7030-0856 AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Zhang, Kai AU - Zhang K AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. FAU - Zhou, Li-Qun AU - Zhou LQ AD - Department of Urology, Peking University First Hospital, Beijing, China. AD - Institute of Urology, National Research Centre for Genitourinary Oncology, Beijing, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20171101 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Carcinoma, Transitional Cell/*diagnostic imaging/secondary/surgery MH - Disease-Free Survival MH - Humans MH - Kidney Neoplasms/*diagnostic imaging/pathology/surgery MH - *Neoplasm Recurrence, Local/etiology MH - Nephroureterectomy MH - Preoperative Period MH - Survival Rate MH - Ureteral Neoplasms/*diagnostic imaging/pathology/surgery MH - *Ureteroscopy MH - *Urinary Bladder Neoplasms/etiology OTO - NOTNLM OT - #UTUC OT - recurrence OT - survival OT - upper urinary tract OT - ureteroscopy OT - urothelial carcinoma EDAT- 2017/10/17 06:00 MHDA- 2018/03/14 06:00 CRDT- 2017/10/17 06:00 PHST- 2017/10/17 06:00 [pubmed] PHST- 2018/03/14 06:00 [medline] PHST- 2017/10/17 06:00 [entrez] AID - 10.1111/bju.14053 [doi] PST - ppublish SO - BJU Int. 2018 Feb;121(2):184-193. doi: 10.1111/bju.14053. Epub 2017 Nov 1. PMID- 29021651 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 33 IP - 4 DP - 2017 Oct-Dec TI - MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer. PG - 283-290 LID - 10.4103/iju.IJU_4_17 [doi] AB - INTRODUCTION: High relapse rate of nonmuscle invasive bladder cancer (NMIBC) is a major challenge. Overexpression of microRNA-21 (miR-21) which targets phosphatase and tensin homolog (PTEN), a gene associated with malignancy, has been reported in the bladder tumor tissue compared to normal mucosa by us and others. We have tested whether miR-21 levels in bladder mucosa could predict tumor recurrence. METHODS: In a prospective cohort setting, tumor tissues and normal bladder mucosa (NBM) were taken from BC patients during transurethral resection of bladder tumor. Age- and ethnicity-matched NBM from benign prostate hyperplasia patients was taken as controls. The expression of miR-21 was analyzed using quantitative reverse transcription polymerase chain reaction. Patients were followed for 4 years for tumor reoccurrence. Postoperative recurrence were recorded and calculated by Kaplan-Meier curve. RESULTS: In 31 patients, miR-21 was up-regulated (>4-fold, P = 0.003), and PTEN levels were significantly lower (<7-folds, P = 0.001) in tumor tissue relative to NBM. Moreover, the fold change in miR-21 levels was significantly higher (>3-folds, P = 0.03) in patients showing recurrence compared to those in which tumor did not recur. Further, Kaplan-Meier analysis shows overexpression of miR-21 corresponds to less time to recurrence with higher cumulative hazard. CONCLUSION: We found overexpression of miR-21 in tumor tissue and its association with recurrence, time to recurrence and invasiveness in BC. Quantification of miR-21 along with other pathological parameters could be more objective molecular approach to predict recurrence in NMIBC. FAU - Mitash, Nilay AU - Mitash N AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Agnihotri, Shalini AU - Agnihotri S AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Tiwari, Swasti AU - Tiwari S AD - Department of Molecular Medicine and Biotechnology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Agrawal, Vinita AU - Agrawal V AD - Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Mandhani, Anil AU - Mandhani A AD - Department of Uro-oncology and Minimally Invasive Surgery, Fortis Escorts Kidney and Urology Institute, New Delhi, India. LA - eng PT - Journal Article PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC5635668 COIS- There are no conflicts of interest. EDAT- 2017/10/13 06:00 MHDA- 2017/10/13 06:01 PMCR- 2017/10/01 CRDT- 2017/10/13 06:00 PHST- 2017/10/13 06:00 [entrez] PHST- 2017/10/13 06:00 [pubmed] PHST- 2017/10/13 06:01 [medline] PHST- 2017/10/01 00:00 [pmc-release] AID - IJU-33-283 [pii] AID - 10.4103/iju.IJU_4_17 [doi] PST - ppublish SO - Indian J Urol. 2017 Oct-Dec;33(4):283-290. doi: 10.4103/iju.IJU_4_17. PMID- 28994883 OWN - NLM STAT- MEDLINE DCOM- 20181219 LR - 20181219 IS - 0041-4131 (Print) IS - 0041-4131 (Linking) VI - 94 IP - 12 DP - 2016 Dec TI - Long-term outcome of intravesical bacillus Calmette-Guerin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. PG - 844 AB - INTRODUCTION: Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited. OBJECTIVES: We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression. METHODS: Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively. RESULTS: The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The fi ve-year progression-free survival rate was 87.2%.Several factors, such as age (<60 or >60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identi fi ed in only one patient. During follow-up period, none died of bladder cancer. CONCLUSION: Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn't find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy. FAU - Sallami, Sataa AU - Sallami S FAU - Khouni, Hassen AU - Khouni H FAU - Ben Atta, Mahmoud AU - Ben Atta M FAU - Abou El Makarim, Sana AU - Abou El Makarim S FAU - Zouari, Mohamed Bechir AU - Zouari MB FAU - Ben Rhouma, Sami AU - Ben Rhouma S LA - eng PT - Journal Article PT - Multicenter Study PL - Tunisia TA - Tunis Med JT - La Tunisie medicale JID - 0413766 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - BCG Vaccine/*administration & dosage MH - Carcinoma in Situ/*therapy MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Urinary Bladder Neoplasms/*therapy EDAT- 2017/10/11 06:00 MHDA- 2018/12/20 06:00 CRDT- 2017/10/11 06:00 PHST- 2017/10/11 06:00 [entrez] PHST- 2017/10/11 06:00 [pubmed] PHST- 2018/12/20 06:00 [medline] AID - /article-medicale-tunisie.php?article=3150 [pii] PST - ppublish SO - Tunis Med. 2016 Dec;94(12):844. PMID- 28984720 OWN - NLM STAT- MEDLINE DCOM- 20180727 LR - 20180727 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 28 IP - 1 DP - 2018 Jan TI - Prevention of bladder cancer incidence and recurrence: tobacco use. PG - 80-87 LID - 10.1097/MOU.0000000000000453 [doi] AB - PURPOSE OF REVIEW: To summarize the current knowledge about smoking carcinogenesis in bladder cancer (BCa), individual susceptibility and impact of smoking on incidence and outcomes of nonmuscle invasive BCa (NMIBC) and muscle-invasive BCa (MIBC). To assess the impact of smoking cessation on oncological outcomes. RECENT FINDINGS: Smoking pattern, intensity, and duration are responsible for an increased risk of developing BCa and for worse tumor features at presentation. Tobacco consumption is associated with a higher risk of recurrence in NMIBC and with an impaired intravesical therapy efficacy. To date, the impact of smoking on oncological outcomes after radical surgery remains unclear. SUMMARY: Smoking cessation decreases the risk of BCa and may also allow benefits on treatment outcomes. Nonetheless, the magnitude of the effect remains unclear and prospective series with the specific aim of weighing smoking cessation on outcomes are needed. Because even a 5-min counseling in the urology setting may be sufficient to significantly enhance smoking cessation rates, adequate knowledge of links between tobacco and BCa, from its molecular pathophysiology and its harms to benefits of cessation is paramount for urologists and for everyday clinical practice. FAU - Soria, Francesco AU - Soria F AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Marra, Giancarlo AU - Marra G AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, Charles University in Prague, Prague, Czech Republic. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, Charles University in Prague, Prague, Czech Republic. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Carcinogenesis/chemically induced MH - Disease Progression MH - Humans MH - Incidence MH - Neoplasm Recurrence, Local/epidemiology/etiology/*prevention & control MH - Prospective Studies MH - Risk Factors MH - Smoking/*adverse effects MH - *Smoking Cessation MH - Tobacco Products/toxicity MH - Treatment Outcome MH - Urinary Bladder Neoplasms/epidemiology/etiology/*prevention & control EDAT- 2017/10/07 06:00 MHDA- 2018/07/28 06:00 CRDT- 2017/10/07 06:00 PHST- 2017/10/07 06:00 [pubmed] PHST- 2018/07/28 06:00 [medline] PHST- 2017/10/07 06:00 [entrez] AID - 10.1097/MOU.0000000000000453 [doi] PST - ppublish SO - Curr Opin Urol. 2018 Jan;28(1):80-87. doi: 10.1097/MOU.0000000000000453. PMID- 28982752 OWN - NLM STAT- MEDLINE DCOM- 20180524 LR - 20220408 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 15 IP - 10 DP - 2017 Oct TI - Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. PG - 1277-1284 LID - 10.6004/jnccn.2017.7036 [doi] AB - With the advent of platinum-based chemotherapy, survival rates for metastatic urothelial carcinoma have plateaued, giving way to the modern immunotherapy paradigm. Although immunotherapy as an effective treatment dates back to the live, attenuated bacillus Calmette-Guerin vaccine, the recent impact of immune checkpoint inhibitors targeting programmed death/programmed death-ligand 1 (PD-1/PD-L1) coupled with the promise of both anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies and indoleamine-2, 3-dioxygenase-1 (IDO-1) inhibitors have provided a resurgence. To date, pembrolizumab, a PD-1 inhibitor, has been granted full FDA approval based on its high antitumor activity, tolerability, and efficacy, with notable prolonged durable responses in the second-line setting. Nivolumab (a PD-1 inhibitor) and atezolizumab, durvalumab, and avelumab (PD-L1 inhibitors) have also gained accelerated drug approval in the second-line setting. In addition, atezolizumab and pembrolizumab have been approved for platinum-ineligible patients in the first-line setting. Effective 2-drug combinations reported include nivolumab plus the CTLA-4 antibody ipilimumab and pembrolizumab plus the IDO-1 inhibitor epacadostat. Further expansion of immunotherapy will hinge in part on the ability to define responders versus nonresponders through the use of biomarkers like PD-L1 or mutational load. Clinical trials with immunotherapy for metastatic disease as single agents or in combination are ongoing. This review explores the rise of immunotherapy and presents the current treatments and challenges posed with development of biomarkers, and provides a summary of ongoing phase III clinical trials. CI - Copyright (c) 2017 by the National Comprehensive Cancer Network. FAU - Chism, David D AU - Chism DD AD - From the Division of Hematology and Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. LA - eng PT - Journal Article PT - Review PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) SB - IM MH - Antineoplastic Agents, Immunological/administration & dosage/adverse effects/therapeutic use MH - B7-H1 Antigen/antagonists & inhibitors MH - Biomarkers, Tumor MH - Carcinoma/etiology/pathology/*therapy MH - Clinical Trials as Topic MH - Humans MH - *Immunotherapy/adverse effects/methods MH - Molecular Targeted Therapy MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Treatment Outcome MH - Urinary Bladder Neoplasms/etiology/pathology/*therapy EDAT- 2017/10/07 06:00 MHDA- 2018/05/25 06:00 CRDT- 2017/10/07 06:00 PHST- 2017/07/17 00:00 [received] PHST- 2017/09/11 00:00 [accepted] PHST- 2017/10/07 06:00 [entrez] PHST- 2017/10/07 06:00 [pubmed] PHST- 2018/05/25 06:00 [medline] AID - 15/10/1277 [pii] AID - 10.6004/jnccn.2017.7036 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2017 Oct;15(10):1277-1284. doi: 10.6004/jnccn.2017.7036. PMID- 28982751 OWN - NLM STAT- MEDLINE DCOM- 20180524 LR - 20190203 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 15 IP - 10 DP - 2017 Oct TI - Clinical Significance of Histologic Variants of Bladder Cancer. PG - 1268-1274 LID - 10.6004/jnccn.2017.7027 [doi] AB - Pathologists have identified many "histologic variants" of bladder cancer (BCA): histologic patterns that differ from conventional urothelial carcinoma (transitional cell carcinoma). Several of these are biologically aggressive, and their identification may aid in clinical decision-making. This article reviews several histologic variants and their value in deciding management of cT1 disease and predicting response to neoadjuvant chemotherapy (NAC). Diagnostic issues are also addressed, such as interobserver variability among pathologists. For example, although stage cT1 conventional urothelial carcinoma is usually managed conservatively, cT1 micropapillary carcinoma has high mortality following conservative management, and early cystectomy may reduce mortality. Similarly, plasmacytoid and small cell cancers are remarkably aggressive, and those diagnosed as stage cT1 at transurethral resection are likely understaged; conservative management thus greatly risks undertreatment. As an example of response, NAC dramatically reduces mortality in patients with small cell BCA, and is thus the standard of care, even in stage cT1 disease. Although identification of histologic variants may inform on optimal management, diagnostic issues challenge their incorporation into clinical practice. For example, interobserver reproducibility is only moderate for the diagnosis of micropapillary BCA. Studies have identified specific histologic issues underlying this diagnostic irreproducibility, and ongoing work aims to remedy this issue. In summary, histologic variants are emerging as potentially useful biomarkers in the management of BCA. Although issues remain unresolved, pathologists and treating physicians will benefit from understanding these variants and their prognostic and therapeutic implications. CI - Copyright (c) 2017 by the National Comprehensive Cancer Network. FAU - Warrick, Joshua I AU - Warrick JI AD - From the Departments of Pathology and Surgery, Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania. LA - eng PT - Journal Article PT - Review PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM MH - Clinical Decision-Making MH - Combined Modality Therapy MH - Disease Management MH - Humans MH - Neoplasm Grading MH - Neoplasm Staging MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/*pathology/therapy EDAT- 2017/10/07 06:00 MHDA- 2018/05/25 06:00 CRDT- 2017/10/07 06:00 PHST- 2017/04/26 00:00 [received] PHST- 2017/08/23 00:00 [accepted] PHST- 2017/10/07 06:00 [entrez] PHST- 2017/10/07 06:00 [pubmed] PHST- 2018/05/25 06:00 [medline] AID - 15/10/1268 [pii] AID - 10.6004/jnccn.2017.7027 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2017 Oct;15(10):1268-1274. doi: 10.6004/jnccn.2017.7027. PMID- 28977963 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 37 DP - 2017 Sep 22 TI - Reduced E-cadherin expression is correlated with poor prognosis in patients with bladder cancer: a systematic review and meta-analysis. PG - 62489-62499 LID - 10.18632/oncotarget.19934 [doi] AB - The prognostic significance of E-cadherin expression in bladder cancer (BC) has been elevated for years, but published results remain controversial and inconsistent. We thus performed a systematic review and meta-analysis to determine the association between E-cadherin expression and BC prognosis. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases to identify eligible studies published until March 2017. On the basis of our inclusion and exclusion criteria, a total of 2,089 patients from 19 studies were eligible for final analysis. Our results showed that reduced E-cadherin expression in BC was associated with poor overall survival (hazard ratio [HR] = 2.73, 95% CI: 1.74-4.27, p < 0.001), poor progression-free survival (HR = 6.39, 95% CI: 3.48-11.73, p < 0.001), and poor recurrence-free survival (HR = 2.48, 95% CI: 1.68-3.64, p < 0.001). Moreover, reduced E-cadherin expression was significantly correlated with pathological T stage (T2-4 vs. Ta-1: risk ratio [RR] = 2.14, 95% CI: 1.70-2.71), metastasis (yes vs. no: RR = 1.68, 95% CI: 1.17-2.40), grade (3 vs. 1/2: RR = 1.58, 95% CI: 1.29-1.93), and carcinoma in situ (yes vs. no: RR = 1.68, 95% CI: 1.09-2.58). This meta-analysis suggested that reduced E-cadherin expression was associated with poor prognosis and advanced clinicopathological characteristics and can serve as a useful biomarker for the clinical management of BC. FAU - Xie, Yongpeng AU - Xie Y AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. AD - School of Medicine, Nankai University, Tianjin, People's Republic of China. FAU - Li, Pin AU - Li P AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. AD - School of Medicine, Nankai University, Tianjin, People's Republic of China. FAU - Gao, Yu AU - Gao Y AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Gu, Liangyou AU - Gu L AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Chen, Luyao AU - Chen L AD - Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China. FAU - Fan, Yang AU - Fan Y AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Zhang, Fan AU - Zhang F AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Zhang, Xu AU - Zhang X AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20170804 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 EIN - Oncotarget. 2019 Apr 5;10(27):2657. doi: 10.18632/oncotarget.26865. PMID: 31080556 PMC - PMC5617523 OTO - NOTNLM OT - E-cadherin OT - biomarker OT - bladder cancer OT - immunohistochemistry OT - prognosis COIS- CONFLICTS OF INTEREST No potential conflicts of interest were disclosed. EDAT- 2017/10/06 06:00 MHDA- 2017/10/06 06:01 PMCR- 2017/09/05 CRDT- 2017/10/06 06:00 PHST- 2017/04/21 00:00 [received] PHST- 2017/07/25 00:00 [accepted] PHST- 2017/10/06 06:00 [entrez] PHST- 2017/10/06 06:00 [pubmed] PHST- 2017/10/06 06:01 [medline] PHST- 2017/09/05 00:00 [pmc-release] AID - 19934 [pii] AID - 10.18632/oncotarget.19934 [doi] PST - epublish SO - Oncotarget. 2017 Aug 4;8(37):62489-62499. doi: 10.18632/oncotarget.19934. eCollection 2017 Sep 22. PMID- 28971783 OWN - NLM STAT- MEDLINE DCOM- 20180426 LR - 20180426 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 24 IP - 5 DP - 2017 Oct TI - Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education. PG - 8976-8981 AB - INTRODUCTION: To assess the quality of resident dictations for transurethral resection of bladder tumor (TURBT). One indicator of surgical quality is the completeness of the operative report. Surprisingly, there is a paucity of standardized operative templates for TURBT and little formalized instruction for learners. The quality of TURBT dictations was assessed and areas of improvement were determined after implementation of a 10 item TURBT checklist. MATERIALS AND METHODS: A retrospective review of the last 50 TURBT operative reports dictated by residents was performed. A 'TURBT checklist' was used assessing 10 key factors in documentation. A formal training session regarding TURBT dictations was given with TURBT checklists handed out to each trainee. Fifty TURBT dictations were subsequently analyzed. RESULTS: TURBT dictations improved across the board following checklist implementation. Total number of checklist items dictated increased to 7.0 from 2.6 prior (p < 0.05). When stratified by resident experience, TURBT dictations improved across different resident years (p < 0.05). Junior resident dictations statistically improved in every checklist item (p < 0.05). Senior resident dictations improved in almost every category but only two reached statistical significance. A regression model demonstrated checklist implantation to be a significant predictor of improvement in mean number of checklist items dictated independent of PGY level. CONCLUSIONS: Our study demonstrates that prior to implementation, TURBT operative dictations performed by residents lacked many of the critical components required for a quality TURBT. However, once properly instructed, a relatively simple 'checklist' can be easily implemented and serve as a teaching tool for residents in training to ensure critical procedural elements are documented. FAU - Haddad, Joseph AU - Haddad J AD - Department of Urology, University of Oklahoma, Oklahoma City, Oklahoma, USA. FAU - Anderson, Christopher AU - Anderson C FAU - Heinlen, Jonathan AU - Heinlen J FAU - Stratton, Kelly AU - Stratton K FAU - Mellis, Adamantios AU - Mellis A FAU - Herr, Harry AU - Herr H FAU - Cookson, Michael AU - Cookson M FAU - Patel, Sanjay AU - Patel S LA - eng PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Checklist/*standards MH - Cystectomy/*methods MH - Humans MH - *Internship and Residency MH - *Quality Improvement MH - Research Report/*standards MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*surgery MH - Urology/*education EDAT- 2017/10/04 06:00 MHDA- 2018/04/27 06:00 CRDT- 2017/10/04 06:00 PHST- 2017/10/04 06:00 [entrez] PHST- 2017/10/04 06:00 [pubmed] PHST- 2018/04/27 06:00 [medline] PST - ppublish SO - Can J Urol. 2017 Oct;24(5):8976-8981. PMID- 28969401 OWN - NLM STAT- MEDLINE DCOM- 20190705 LR - 20190705 IS - 1124-3562 (Print) IS - 1124-3562 (Linking) VI - 89 IP - 3 DP - 2017 Oct 3 TI - Narrow band imaging (NBI) cystoscopy and assisted bipolar TURBT: A preliminary experience in a single centre. PG - 232-235 LID - 10.4081/aiua.2017.3.232 [doi] AB - OBJECTIVE: The aim of this study was to compare, in order to increase our ability to detect bladder cancer, the predictive power of narrow band imaging (NBI) versus white light cystoscopy (WL). The secondary objective was to evaluate how the preoperative use of NBI cystoscopy can increase the ability to detect bladder lesions in terms of status, multi-focality and dimensions. MATERIALS AND METHODS: Between June 2010 and April 2012, 797 consecutive patients, 423 male and 374 female, affected by suspected bladder cancer lesions, underwent to WL plus NBI cystoscopy and subsequently to WL Bipolar Gyrus PK (Olympus, Tokyo, Japan) transurethral resection of bladder tumour (WL-TURBT). The average follow-up was 24 (16-38) months. Mean age was 67.7 yrs. (range 46-88). All the patients underwent by same surgeon to WL resection (WL-TURBT) of the previously identified lesions by same surgeon. All the removed tissue was sent separately for histological evaluation after mapping the areas of resection on a topographic sheet. RESULTS: In our study we considered 797 patients that matched our inclusion criteria. Through the use of WL cystoscopy, we identified 603 patients (75.53%) with suspicious lesions, instead, with the use of light NBI, we found 786 patients with suspicious lesions (98.49%).The use of NBI cystoscopy increases by approximately 30% the specific ability to detect lesions not otherwise visible with WL cystoscopy (OR 21.9 and RR 1.30), in particular for patients with lesions size < 3 cm (OR 24.00; RR 1.40), unifocal (OR: 22.28; RR 1.47) and recurrent (OR 58.4; RR 1.34). Pathology demonstrated the presence of cancer in 512 (64.2%) patients, of whom 412 (51.8%) were visible both with WL cystoscopy and NBI cystoscopy. In our experience, only 11 (1.38%) lesions were only positive at WL cystoscopy (negative at NBI cystoscopy) thus 501 (62.8%, OR 10.13; RR 1.21) patients showed bladder oncological lesions positive at NBI cystoscopy. In these patients, the use the NBI Cystoscopy has better highlighted a recurrence (p < 0.005; OR 22.8, RR 1.23; 95% CI-1.13 to 0.24) or a lesion < 3 cm (p < 0.05; OR 11.4 , RR 1.30; 95% CI-0.18 to 0.29) or a unifocal lesion (p < 0.005; OR 10.38, RR 1.34, CI 0.18 to 0.30). CONCLUSIONS: The use of NBI cystoscopy, significantly increases by approximately 30% our predictive power to identify neoplastic lesions, especially unifocal or < 3 cm or recurrent lesions. Following WLTURBT, stage, dimension and focaliity are statistically significant determinants (p < 0.001) of the bladder oncological lesions detected by NBI cystoscopy rather than by WL cystoscopy. FAU - Giulianelli, Roberto AU - Giulianelli R AD - C.Ur.A., Urology Department, Nuova Villa Claudia Clinic, Rome. giulianelli0764@gmail.com. FAU - Gentile, Barbara Cristina AU - Gentile BC FAU - Albanesi, Luca AU - Albanesi L FAU - Tariciotti, Paola AU - Tariciotti P FAU - Mirabile, Gabriella AU - Mirabile G LA - eng PT - Comparative Study PT - Journal Article DEP - 20171003 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - *Narrow Band Imaging MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Predictive Value of Tests MH - Preoperative Care/methods MH - Urinary Bladder Neoplasms/*diagnosis/pathology MH - Urologic Surgical Procedures/*methods EDAT- 2017/10/04 06:00 MHDA- 2019/07/06 06:00 CRDT- 2017/10/04 06:00 PHST- 2017/07/12 00:00 [received] PHST- 2017/08/07 00:00 [accepted] PHST- 2017/08/05 00:00 [revised] PHST- 2017/10/04 06:00 [entrez] PHST- 2017/10/04 06:00 [pubmed] PHST- 2019/07/06 06:00 [medline] AID - 10.4081/aiua.2017.3.232 [doi] PST - epublish SO - Arch Ital Urol Androl. 2017 Oct 3;89(3):232-235. doi: 10.4081/aiua.2017.3.232. PMID- 28967804 OWN - NLM STAT- MEDLINE DCOM- 20180105 LR - 20180105 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 142 IP - 1 DP - 2018 Jan TI - CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. PG - 64-69 LID - 10.5858/arpa.2016-0411-OA [doi] AB - CONTEXT: - Urinary bladder flat carcinoma in situ (CIS) is a worrisome lesion, requiring aggressive surveillance and treatment. Cytokeratin 20 (CK20) and p53 are common immunohistochemical antibodies used to supplement CIS diagnosis in biopsy samples. However, existing data come primarily from unequivocally benign and malignant specimens. OBJECTIVE: - To correlate these markers in specimens with borderline histology with outcomes. DESIGN: - CK20 and p53 immunohistochemistry was analyzed for staining pattern, classified as CIS pattern (both stains yielding strong labeling of the area of concern), discordant (only 1 stain yielding CIS pattern), indeterminate (1 or both stains yielding partial or equivocal labeling), or benign (both stains yielding a benign pattern). RESULTS: - Specimens with equivocal atypia (n = 69) from 65 patients were studied. There were 9 specimens (13%) that had a CIS staining pattern, 18 (26%) were discordant, 31 (45%) were indeterminate, and 11 (16%) were benign. Of the discordant specimens, 13 labeled for CK20 but not p53, whereas 5 showed the opposite. Most specimens (n = 47; 68%) were obtained from patients with a known history of bladder cancer, of which recurrence developed in 27, with an average interval of 37 months (range, 2-216 months). A subset (n = 22; 34%) had no prior history of bladder cancer, from which only 1 patient with CK20-positive/p53-equivocal staining later developed diagnostic carcinoma. CONCLUSIONS: - In our cohort of specimens with equivocal urothelial atypia, very few patients without a prior diagnosis of bladder cancer progressed to diagnostic cancer (1 of 22), suggesting that staining results should be interpreted with caution in de novo atypia. Patients with a known history of bladder cancer had a substantial rate of recurrence, independent of staining pattern. FAU - Arias-Stella, Javier A 3rd AU - Arias-Stella JA 3rd AD - From the Department of Pathology and Laboratory Medicine, Henry Ford Health System and Cancer Institute, Detroit, Michigan (Drs Arias-Stella, Shah, Gupta, and Williamson); and the Department of Pathology, Wayne State University School of Medicine, Detroit (Dr Williamson). Dr Arias-Stella is now with the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Shah, Alpa B AU - Shah AB AD - From the Department of Pathology and Laboratory Medicine, Henry Ford Health System and Cancer Institute, Detroit, Michigan (Drs Arias-Stella, Shah, Gupta, and Williamson); and the Department of Pathology, Wayne State University School of Medicine, Detroit (Dr Williamson). Dr Arias-Stella is now with the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Gupta, Nilesh S AU - Gupta NS AD - From the Department of Pathology and Laboratory Medicine, Henry Ford Health System and Cancer Institute, Detroit, Michigan (Drs Arias-Stella, Shah, Gupta, and Williamson); and the Department of Pathology, Wayne State University School of Medicine, Detroit (Dr Williamson). Dr Arias-Stella is now with the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Williamson, Sean R AU - Williamson SR AD - From the Department of Pathology and Laboratory Medicine, Henry Ford Health System and Cancer Institute, Detroit, Michigan (Drs Arias-Stella, Shah, Gupta, and Williamson); and the Department of Pathology, Wayne State University School of Medicine, Detroit (Dr Williamson). Dr Arias-Stella is now with the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. LA - eng PT - Journal Article DEP - 20171002 PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 RN - 0 (Biomarkers, Tumor) RN - 0 (KRT20 protein, human) RN - 0 (Keratin-20) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma in Situ/*metabolism/*pathology MH - Carcinoma, Transitional Cell/metabolism/pathology MH - Cohort Studies MH - Disease Progression MH - Female MH - Humans MH - Immunohistochemistry MH - Keratin-20/metabolism MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/metabolism/pathology MH - Tumor Suppressor Protein p53/*metabolism MH - Urinary Bladder Neoplasms/*metabolism/*pathology EDAT- 2017/10/03 06:00 MHDA- 2018/01/06 06:00 CRDT- 2017/10/03 06:00 PHST- 2017/10/03 06:00 [pubmed] PHST- 2018/01/06 06:00 [medline] PHST- 2017/10/03 06:00 [entrez] AID - 10.5858/arpa.2016-0411-OA [doi] PST - ppublish SO - Arch Pathol Lab Med. 2018 Jan;142(1):64-69. doi: 10.5858/arpa.2016-0411-OA. Epub 2017 Oct 2. PMID- 28967037 OWN - NLM STAT- MEDLINE DCOM- 20180730 LR - 20260127 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 24 IP - 13 DP - 2017 Dec TI - Loss of Stromal Antigen 2 (STAG2) Expression in Upper Urinary Tract Carcinoma: Differential Prognostic Effect According to the Ki-67 Proliferating Index. PG - 4059-4066 LID - 10.1245/s10434-017-6097-7 [doi] AB - BACKGROUND: Inactivating mutation and consequent expression loss of stromal antigen 2 (STAG2, also known as SA2), a component of the cohesion complex, is one of the most common genetic aberrations in urothelial carcinoma. However, the clinicopathologic or prognostic significance of STAG2 alterations in upper tract urothelial carcinoma (UTUC) is largely unknown. METHODS: This study immunohistochemically examined the expression of STAG2 in 171 patients with UTUC. The correlations of STAG2 loss with clinicopathologic features and patients' prognoses were examined. RESULTS: Loss of STAG2 expression was observed in 28 cases (16%). Loss of STAG2 was significantly correlated with histological low grade, papillary architecture, noninvasive tumors, absence of concomitant carcinoma in situ, and lower Ki-67 expression. Loss of STAG2 alone was not significantly associated with patients' prognoses in either the uni- or multivariate analysis. However, STAG2 loss was significantly associated with worse clinical outcome in UTUC with high Ki-67 proliferation indexes, but not in UTUC with low Ki-67 expression. CONCLUSIONS: Loss of STAG2 was generally associated with less aggressive features in UTUC. However, the STAG2 loss was an ominous sign in the subpopulation with higher Ki-67 proliferation indexes. Examining both STAG2 and Ki-67 status may be useful for identifying aggressive clinical behavior of UTUC. FAU - Miyakawa, Jimpei AU - Miyakawa J AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. tmorikawa-tky@umin.ac.jp. FAU - Miyama, Yu AU - Miyama Y AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Homma, Yukio AU - Homma Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Fukayama, Masashi AU - Fukayama M AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20171002 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Antigens, Nuclear) RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Cycle Proteins) RN - 0 (Ki-67 Antigen) RN - 0 (STAG2 protein, human) RN - 0 (Cohesins) SB - IM MH - Aged MH - Antigens, Nuclear/*metabolism MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/metabolism/*secondary MH - Cell Cycle Proteins MH - Female MH - Follow-Up Studies MH - Humans MH - Ki-67 Antigen/*metabolism MH - Lymphatic Metastasis MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/metabolism/*pathology MH - Prognosis MH - Survival Rate MH - Urologic Neoplasms/metabolism/*pathology MH - Cohesins EDAT- 2017/10/03 06:00 MHDA- 2018/07/31 06:00 CRDT- 2017/10/03 06:00 PHST- 2017/04/05 00:00 [received] PHST- 2017/10/03 06:00 [pubmed] PHST- 2018/07/31 06:00 [medline] PHST- 2017/10/03 06:00 [entrez] AID - 10.1245/s10434-017-6097-7 [pii] AID - 10.1245/s10434-017-6097-7 [doi] PST - ppublish SO - Ann Surg Oncol. 2017 Dec;24(13):4059-4066. doi: 10.1245/s10434-017-6097-7. Epub 2017 Oct 2. PMID- 28964932 OWN - NLM STAT- MEDLINE DCOM- 20180515 LR - 20181202 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) VI - 47 DP - 2017 Nov TI - Predictors of female genital organ involvement in radical cystectomy for urothelial carcinoma of the bladder: A single-center retrospective analysis of 112 female patients. PG - 101-106 LID - S1743-9191(17)31307-9 [pii] LID - 10.1016/j.ijsu.2017.09.059 [doi] AB - OBJECTIVES: To evaluate predictors of organ involvement and oncological outcomes after radical cystectomy with anterior exenteration in female patients. METHODS: Among 1198 patients who underwent radical cystectomy for the bladder tumor between 1990 and 2015, 178 (14.9%) patients were female. They were divided into two groups according to pelvic involvement in pathology. Their medical records and pathology and image findings were reviewed retrospectively. Non-urothelial cell carcinoma and no genital organ pathology were excluded. Multivariate logistic regression was performed to predict factors associated with female organ involvement. RESULTS: Out of 112 eligible female patients with urothelial cell carcinoma, 11 (9.8%) had female genital organ involvement. Female genital organ involvement occurred primarily in the uterus (63.6%) mostly. The 5-year overall survival rates were 67.3% in the non-involvement group and 18.9% in the involvement group. On multivariate analysis Tumor location of trigone or bladder neck at transurethral resection of bladder tumor (TUR-B) (odds ratio [OR] 19.84, 95% confidence interval [CI] 2.89-230.68, p = 0.0056), maximum tumor size at computed tomography (CT) (OR 2.17, 95% CI 1.29-4.34, p = 0.0095), and hydronephrosis at CT (OR 17.61, 95% CI 2.28-296.26, p = 0.0158) were associated with female organ involvement. CONCLUSIONS: Tumor location of trigone or bladder neck at TUR-B, maximum tumor size at CT or hydronephrosis at CT were significant factors to predict female genital organ involvement. Preoperative recognition of female genital organ involvement could increase the decision to perform genital organ-sparing surgeries. CI - Copyright (c) 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. FAU - Choi, Se Young AU - Choi SY AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Yoo, Sangjun AU - Yoo S AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Han, Jae Hyeon AU - Han JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: dalsanyou@amc.seoul.kr. LA - eng PT - Journal Article DEP - 20170928 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Genitalia, Female/*surgery MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Retrospective Studies MH - Tomography, X-Ray Computed MH - Urinary Bladder Neoplasms/diagnostic imaging/mortality/*surgery OTO - NOTNLM OT - Bladder cancer OT - Female OT - Genital organ OT - Radical cystectomy EDAT- 2017/10/02 06:00 MHDA- 2018/05/16 06:00 CRDT- 2017/10/02 06:00 PHST- 2017/05/30 00:00 [received] PHST- 2017/09/16 00:00 [revised] PHST- 2017/09/18 00:00 [accepted] PHST- 2017/10/02 06:00 [pubmed] PHST- 2018/05/16 06:00 [medline] PHST- 2017/10/02 06:00 [entrez] AID - S1743-9191(17)31307-9 [pii] AID - 10.1016/j.ijsu.2017.09.059 [doi] PST - ppublish SO - Int J Surg. 2017 Nov;47:101-106. doi: 10.1016/j.ijsu.2017.09.059. Epub 2017 Sep 28. PMID- 28959653 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220408 IS - 2214-7500 (Print) IS - 2214-7500 (Electronic) IS - 2214-7500 (Linking) VI - 4 DP - 2017 TI - p-Benzoquinone initiates non-invasive urothelial cancer through aberrant tyrosine phosphorylation of EGFR, MAP kinase activation and cell cycle deregulation: Prevention by vitamin C. PG - 296-305 LID - 10.1016/j.toxrep.2017.06.005 [doi] AB - According to WHO classification system, non-invasive urothelial carcinoma represents urothelial carcinoma in situ (CIS) and dysplasia. Dysplastic urothelium often progresses to CIS that further advances to urothelial carcinoma (UC). The strongest risk factor for UC is cigarette smoking. However, the pathogenesis of cigarette smoke (CS)-induced UC is poorly understood. Earlier we had shown that p-benzoquinone (p-BQ), a major toxic quinone derived from p-benzosemiquinone of CS in vivo, is a causative factor for various CS-induced diseases. Here, using a guinea pig model we showed that prolonged treatment with p-BQ led to non-invasive UC, specifically carcinoma in situ (CIS) of the renal pelvis and dysplasia in the ureter and bladder. The mechanisms of carcinogenesis were p-BQ-induced oxidative damage and apoptosis that were later suppressed and followed by activation of epidermal growth factor receptor, aberrant phosphorylation of intracellular tyrosine residues, activation of MAP kinase pathway and persistent growth signaling. This was accompanied by deregulation of cell cycle as shown by marked decrease in the expression of p21(waf1/cip1) and cyclin D1 proteins as well as hyperphosphorylation of pRb. UC has been characterised by histopathology and immunohistochemistry showing aberrant CK20, increased Ki-67, and marked p53 nuclear immunopositivity with uniformly negative labelling of CD44. Oral supplementation of vitamin C (30 mg/kg body weight/day) prevented CIS of the renal pelvis and dysplasia in the ureter and bladder. Since majority of non-invasive UC progresses to invasive cancer with increased risk of mortality, our preclinical study might help to devise effective strategies for early intervention of the disease. FAU - Ganguly, Shinjini AU - Ganguly S AD - Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering & Biotechnology, Calcutta University College of Science, Kolkata 700019, India. FAU - Chandra, Ayan AU - Chandra A AD - Department of Statistics, St. Xavier's College (Autonomous), Kolkata 700016, India. FAU - Chattopadhyay, Dhruba J AU - Chattopadhyay DJ AD - Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering & Biotechnology, Calcutta University College of Science, Kolkata 700019, India. FAU - Chatterjee, Indu B AU - Chatterjee IB AD - Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering & Biotechnology, Calcutta University College of Science, Kolkata 700019, India. LA - eng PT - Journal Article DEP - 20170615 PL - Ireland TA - Toxicol Rep JT - Toxicology reports JID - 101630272 PMC - PMC5615141 OTO - NOTNLM OT - Aberrant EGFR activation OT - Bax, BCL2-associated X protein OT - Bcl-2, B-cell lymphoma 2 OT - CIS, carcinoma in situ OT - CS, cigarette smoke OT - Carcinoma in situ OT - Cell cycle deregulation OT - DNPH, 2 4-dinitrophenylhydrazine OT - Dysplasia OT - EGFR, epidermal growth factor receptor OT - GAPDH, glyceraldehyde 3-phosphate dehydrogenase OT - IARC, International Agency for Research on Cancer OT - MAPK, mitogen activated protein kinase OT - PAHs, polycyclic aromatic hydrocarbons OT - PBS, phosphate buffered saline OT - ROS, reactive oxygen species OT - SDS PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis OT - TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling OT - UC, urothelial carcinoma OT - Vitamin C OT - WHO, World Health Organization OT - p-BQ, p-benzoquinone OT - p-BSQ, p-benzosemiquinone OT - p-Benzoquinone EDAT- 2017/09/30 06:00 MHDA- 2017/09/30 06:01 PMCR- 2017/06/15 CRDT- 2017/09/30 06:00 PHST- 2017/04/05 00:00 [received] PHST- 2017/05/23 00:00 [revised] PHST- 2017/06/13 00:00 [accepted] PHST- 2017/09/30 06:00 [entrez] PHST- 2017/09/30 06:00 [pubmed] PHST- 2017/09/30 06:01 [medline] PHST- 2017/06/15 00:00 [pmc-release] AID - S2214-7500(17)30035-5 [pii] AID - 10.1016/j.toxrep.2017.06.005 [doi] PST - epublish SO - Toxicol Rep. 2017 Jun 15;4:296-305. doi: 10.1016/j.toxrep.2017.06.005. eCollection 2017. PMID- 28947304 OWN - NLM STAT- MEDLINE DCOM- 20180720 LR - 20220331 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 36 IP - 1 DP - 2018 Jan TI - Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. PG - 8.e17-8.e24 LID - S1078-1439(17)30461-1 [pii] LID - 10.1016/j.urolonc.2017.08.027 [doi] AB - PURPOSE: To characterize outcomes of patients with TaT1 urothelial carcinoma of the bladder stratified by the European Association of Urology (EAU) categories and to compare them with European Organization for Research and Treatment of Cancer (EORTC) risk groups to assess the rate and effect of reclassification. PATIENTS AND METHODS: A multi-institutional database of 5,122 patients with TaT1 urothelial carcinoma of the bladder who underwent transurethral resection of the bladder with or without adjuvant therapy at 8 institutions between 1996 and 2007. Multivariable Cox-regression analyses addressed factors associated with disease recurrence and progression. The net reclassification index was used to compare the performance of the EAU categories with the EORTC scoring system. RESULTS: Of 5,122 patients, 632 (12.3%), 2,302 (45.0%), and 2,188 (42.7%) were assigned to the low-, intermediate-, and high-risk EAU category, respectively. Within a median follow-up of 62 months (interquartile range: 27-97), 2,365 (46.2%) and 516 (10.1%) patients experienced disease recurrence and progression, respectively. In multivariable Cox-regression analyses, EAU intermediate- and high-risk categories were associated with a higher risk of disease recurrence (P<0.001) and progression (P<0.001) compared to low-risk patients. Application of the EAU categories reclassified 1,940 (37.9%) patients into a higher risk group for recurrence. Likewise, 602 (11.8%) patients were reclassified to a higher and 278 (5.4%) to a lower risk group for progression. The net reclassification index of the EAU risk stratification was 0.1% (95% CI: -3.1% to 3.2%) for recurrence and 10.1% (95% CI: -8.0% to 12.0%) for progression, respectively. CONCLUSIONS: Compared to EORTC risk stratification, the EAU categories reclassifies 37.9% patients into a higher risk group of recurrence and 11.8% into a higher risk of progression. However, the novel risk stratification assigns most patients to the same treatment as the more complex EORTC tables and can be regarded as an alternative tool for treatment decision-making. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Rieken, Malte AU - Rieken M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Basel, Basel, Switzerland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: sfshariat@gmail.com. FAU - Kluth, Luis AU - Kluth L AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Crivelli, Joseph J AU - Crivelli JJ AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Mari, Andrea AU - Mari A AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. FAU - Ilijazi, Dafina AU - Ilijazi D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, QC, Canada. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. FAU - Gonen, Mithat AU - Gonen M AD - Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology Cochin Hospital, APHP, Paris Descartes University, Paris, France. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20170923 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/pathology MH - Risk Factors MH - Risk-Taking MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*diagnosis/pathology PMC - PMC7675223 MID - NIHMS1623667 OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive OT - Prediction OT - Progression OT - Recurrence OT - Risk stratification EDAT- 2017/09/28 06:00 MHDA- 2018/07/22 06:00 PMCR- 2020/11/19 CRDT- 2017/09/27 06:00 PHST- 2017/04/18 00:00 [received] PHST- 2017/08/12 00:00 [revised] PHST- 2017/08/29 00:00 [accepted] PHST- 2017/09/28 06:00 [pubmed] PHST- 2018/07/22 06:00 [medline] PHST- 2017/09/27 06:00 [entrez] PHST- 2020/11/19 00:00 [pmc-release] AID - S1078-1439(17)30461-1 [pii] AID - 10.1016/j.urolonc.2017.08.027 [doi] PST - ppublish SO - Urol Oncol. 2018 Jan;36(1):8.e17-8.e24. doi: 10.1016/j.urolonc.2017.08.027. Epub 2017 Sep 23. PMID- 28946546 OWN - NLM STAT- MEDLINE DCOM- 20180718 LR - 20180718 IS - 1875-8592 (Electronic) IS - 1574-0153 (Linking) VI - 20 IP - 4 DP - 2017 Dec 6 TI - The relation between Ring Box-1 protein overexpression and tumor grade and stage in bladder urothelial cell carcinoma. PG - 389-394 LID - 10.3233/CBM-170002 [doi] AB - BACKGROUND: Ring Box Protein-1 (RBX-1), a component of SCF E3 ubiquitin ligases, has a crucial role in bladder urothelial cell carcinoma (UCC) carcinogenesis and progression. OBJECTIVES: In the present study, it is aimed to determine the expression of RBX-1 protein in bladder UCC and the association between tumor grade, stage and RBX-1 expression. METHODS: Ninety UCC samples and 20 samples containing foci of normal bladder urothelium were recruited and analyzed immunohistochemically in terms of RBX-1 expression. Immuno-reactivity scoring system (IRS) was used to determine RBX-1 expression levels. RESULTS: RBX-1 overexpression was associated with high tumor grade (p= 0.001) and advanced stage (p= 0.001). pT1 tumors showed higher RBX-1 expression than pTa tumors. pT2 tumors showed not only higher expression than pTa tumors but also higher expression than the total of pTa and pT1 groups combined. There was no statistically significant relation between RBX-1 expression and patient gender (p= 0.116) or age (p= 0.191). CONCLUSIONS: In bladder UCC, RBX-1 overexpression is associated with high tumor grade and advanced stage and represents biological potential of invasiveness and aggressive disease. Results of the present study have to be supported with further studies to reveal clinical and therapeutic implications of RBX-1 overexpression in bladder UCC. FAU - Celik, Zeliha Esin AU - Celik ZE AD - Department of Pathology, Faculty of Medicine, Selcuk University, 42130 Selcuklu, Konya, Turkey. FAU - Kaynar, Mehmet AU - Kaynar M AD - Department of Urology, Faculty of Medicine, Selcuk University, 42130 Selcuklu, Konya, Turkey. FAU - Karabagli, Pinar AU - Karabagli P AD - Department of Pathology, Faculty of Medicine, Selcuk University, 42130 Selcuklu, Konya, Turkey. FAU - Gergerlioglu, Nursadan AU - Gergerlioglu N AD - Department of Pathology, Konya Education and Training Hospital, Konya, Turkey. FAU - Goktas, Serdar AU - Goktas S AD - Department of Urology, Faculty of Medicine, Selcuk University, 42130 Selcuklu, Konya, Turkey. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (Carrier Proteins) RN - 0 (RBX1 protein, human) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/*genetics/*pathology MH - Carrier Proteins/*genetics MH - Female MH - *Gene Expression MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Urinary Bladder Neoplasms/*genetics/*pathology OTO - NOTNLM OT - Ring Box-1 OT - Urothelial cell carcinoma OT - immunohistochemistry OT - invasiveness OT - prognosis EDAT- 2017/09/28 06:00 MHDA- 2018/07/19 06:00 CRDT- 2017/09/27 06:00 PHST- 2017/09/28 06:00 [pubmed] PHST- 2018/07/19 06:00 [medline] PHST- 2017/09/27 06:00 [entrez] AID - CBM170002 [pii] AID - 10.3233/CBM-170002 [doi] PST - ppublish SO - Cancer Biomark. 2017 Dec 6;20(4):389-394. doi: 10.3233/CBM-170002. PMID- 28941000 OWN - NLM STAT- MEDLINE DCOM- 20180321 LR - 20220331 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 121 IP - 1 DP - 2018 Jan TI - Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. PG - 29-37 LID - 10.1111/bju.14019 [doi] AB - OBJECTIVES: To evaluate the diagnostic accuracy of the Xpert Bladder Cancer (BC) Monitor, compared with cystoscopy and cytology in the oncological follow-up of non-muscle-invasive bladder cancer (NMIBC). MATERIAL AND METHODS: A total of 140 patients with a history of NMIBC undergoing routine surveillance at our institution were enrolled prospectively in this study (ISRCTN study registry number 37210907). Urine cytology was evaluated according to the Paris classification system. In addition, urinary specimens were analysed using the Xpert BC Monitor, which measures five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) using real-time PCR. Descriptive analysis, diagnostic accuracy including sensitivity, specificity, positive (PPV) and negative predictive value (NPV), receiver-operating characteristic curve, and area under the curve (AUC) were calculated. RESULTS: The overall sensitivity (0.84) and NPV (0.93) of the Xpert BC Monitor were significantly superior to those of bladder washing cytology (0.33 and 0.76; P < 0.001). Subgroup analyses confirmed the high sensitivity of the Xpert BC Monitor even in low-grade (0.77) and pTa (0.82) disease compared with barbotage cytology (low-grade: 0.13; pTa: 0.21). The overall specificity of the Xpert BC Monitor and barbotage cytology was similar (0.91 vs 0.94; P = 0.41). Combining the Xpert BC Monitor with barbotage cytology (AUC = 0.85) did not enhance diagnostic performance compared with the performance of the Xpert BC Monitor alone (AUC = 0.87). CONCLUSION: In this study, we report for the first time that the Xpert BC Monitor, a new mRNA-based urine test, outperforms cytology with regard to sensitivity and NPV, even in low-grade and pTa tumours, with no reduction of specificity. CI - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John Wiley & Sons Ltd. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. FAU - Fritz, Josef AU - Fritz J AD - Department of Medical Statistics, Informatics and Health Economics, Medical University Innsbruck, Innsbruck, Austria. FAU - Tulchiner, Gennadi AU - Tulchiner G AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. FAU - Klinglmair, Gerald AU - Klinglmair G AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. FAU - Soleiman, Afschin AU - Soleiman A AD - Clinical Pathology and Cytodiagnostics, Tyrolean State Hospitals Ltd, Innsbruck, Austria. FAU - Horninger, Wolfgang AU - Horninger W AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. FAU - Klocker, Helmut AU - Klocker H AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. AD - Urological Laboratory and Division of Experimental Urology, Innsbruck, Austria. FAU - Heidegger, Isabel AU - Heidegger I AD - Department of Urology, Medical University Innsbruck, Innsbruck, Austria. LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article DEP - 20171012 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) SB - IM CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S96-S97. doi: 10.21037/tau.2018.01.04. PMID: 29644171 CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S109-S110. doi: 10.21037/tau.2017.12.18. PMID: 29644175 MH - Adult MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor/*urine MH - Carcinoma, Transitional Cell/*diagnosis/urine MH - Cystoscopy/methods MH - Cytodiagnosis/methods MH - Early Detection of Cancer/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Monitoring, Physiologic/methods MH - Neoplasm Recurrence, Local/diagnosis MH - Predictive Value of Tests MH - Prognosis MH - RNA, Messenger/*analysis MH - ROC Curve MH - Risk Assessment MH - Sensitivity and Specificity MH - Urinalysis/*methods MH - Urinary Bladder Neoplasms/*diagnosis/urine OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - follow-up OT - mRNA-based markers OT - recurrence OT - surveillance OT - urine markers EDAT- 2017/09/25 06:00 MHDA- 2018/03/22 06:00 CRDT- 2017/09/24 06:00 PHST- 2017/09/25 06:00 [pubmed] PHST- 2018/03/22 06:00 [medline] PHST- 2017/09/24 06:00 [entrez] AID - 10.1111/bju.14019 [doi] PST - ppublish SO - BJU Int. 2018 Jan;121(1):29-37. doi: 10.1111/bju.14019. Epub 2017 Oct 12. PMID- 28936147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1658-3639 (Print) IS - 1658-3639 (Linking) VI - 11 IP - 3 DP - 2017 Jul-Sep TI - Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease. PG - 24-28 AB - OBJECTIVE: The prognosis of bladder cancer patients with positive lymph node (LN) disease is affected by both the extent of lymphadenectomy and LN density retrieved during radical cystectomy. This study aimed at assessing the differences in LN metastasis between patients who presented primarily with muscle-invasive transitional cell carcinoma of the bladder "de novo disease" versus "progressive disease." The latter is defined as patients who progressed to muscle-invasive bladder cancer (MIBC) following prior conservative management of a non-muscle-invasive disease. METHODS: Data were prospectively collected from consecutive 41 radical cystectomies that were divided into two groups: Group I included de novo MIBC cases and Group II included progressive MIBC cases. RESULTS: The median age was 60 years (44-75). Thirty-four patients exhibited de novo disease versus 7 patients who presented as progressive MIBC with a median duration of 9 months between the resection of the first non-invasive tumor and the diagnosis of progressive MIBC (range: 6-56 months). The median number of retrieved LNs in both groups was 15 LNs (range: 4-36). Ten patients (24.39%) had positive pathological LN disease; distributed as 9 patients in Group I and 1 patient in Group II. The median LN density of LN-positive patients was 15.73% (6.46 % in Group I, 28.57% in Group II). Five patients had LN density >20%. CONCLUSION: Although non-muscle-invasive urothelial bladder tumor may progress to muscle-invasive disease, it still carries less aggressive course than de novo MIBC based on differences in LN metastasis and density. FAU - Elabbady, Ahmed AU - Elabbady A AD - Department of Urology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Hashad, Mohamed Mohieeldin AU - Hashad MM AD - Department of Urology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Kotb, Ahmed Fouad AU - Kotb AF AD - Department of Urology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Abdullah, Dina Mohamed AU - Abdullah DM AD - Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Beltagy, Ahmad AU - Beltagy A AD - Department of Urology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. LA - eng PT - Journal Article PL - United States TA - Int J Health Sci (Qassim) JT - International journal of health sciences JID - 101528042 PMC - PMC5604267 OTO - NOTNLM OT - Bladder cancer OT - lymph node density OT - non-muscle-invasive bladder tumor OT - progressive muscle-invasive bladder tumor EDAT- 2017/09/25 06:00 MHDA- 2017/09/25 06:01 PMCR- 2017/07/01 CRDT- 2017/09/23 06:00 PHST- 2017/09/23 06:00 [entrez] PHST- 2017/09/25 06:00 [pubmed] PHST- 2017/09/25 06:01 [medline] PHST- 2017/07/01 00:00 [pmc-release] AID - IJHS-11-24 [pii] PST - ppublish SO - Int J Health Sci (Qassim). 2017 Jul-Sep;11(3):24-28. PMID- 28931051 OWN - NLM STAT- MEDLINE DCOM- 20171017 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 9 DP - 2017 TI - Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. PG - e0184841 LID - 10.1371/journal.pone.0184841 [doi] LID - e0184841 AB - The tumour immune microenvironment is considered to influence cancer behaviour and outcome. Using a panel of markers for innate and adaptive immune cells we set out to characterise and understand the bladder tumour microenvironment of 114 patients from a prospective multicentre cohort of newly-diagnosed bladder cancer patients, followed-up for 4.33+/-1.71 years. We found IL-17-positive cells were significantly increased in primary and concomitant carcinoma in situ (CIS), p<0.0001, a highly malignant lesion which is the most significant single risk factor for disease progression. Further characterisation of the tumour immunophenotype identified IL-17+ cells as predominantly mast cells rather than T-cells, in contrast to most other tumour types. Expression of the IL-17-receptor in bladder tumours, and functional effects and gene expression changes induced by IL-17 in bladder tumour cells in vitro suggest a role in tumour behaviour. Finally, we assessed the effects of IL-17 in the context of patient outcome, following intravesical BCG immunotherapy which is the standard of care; higher numbers of IL-17+ cells were associated with improved event-free survival (p = 0.0449, HR 0.2918, 95% CI 0.08762-0.9721) in patients with primary and concomitant CIS (n = 41), we propose a model of IL-17+ Mast cells mechanism of action. Thus, in the context of bladder CIS, IL-17+ mast cells predict favourable outcome following BCG immunotherapy indicative of a novel mechanism of BCG immunotherapy in UBC and could form the basis of a stratified approach to treatment. FAU - Dowell, Alexander C AU - Dowell AC AUID- ORCID: 0000-0002-1909-7047 AD - Institute of Immunology & Immunotherapy, University of Birmingham, Vincent Drive, Birmingham, United Kingdom. FAU - Cobby, Ellen AU - Cobby E AD - Royal Shrewsbury Hospital, Shrewsbury, Shropshire, United Kingdom. FAU - Wen, Kaisheng AU - Wen K AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Devall, Adam J AU - Devall AJ AD - Birmingham Clinical Trials Unit (BCTU), Institute of Applied Health Research, Public Health Building, University of Birmingham, Edgbaston, United Kingdom. FAU - During, Vinnie AU - During V AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Anderson, Jane AU - Anderson J AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - James, Nicholas D AU - James ND AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. FAU - Cheng, Kar K AU - Cheng KK AD - School of Health and Population Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Nutrition and Translational Research in Metabolism (School NUTRIM), and Care and Public Health Research Institute (School CAPHRI), Maastricht University, The Netherlands. AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Taylor, Graham S AU - Taylor GS AD - Institute of Immunology & Immunotherapy, University of Birmingham, Vincent Drive, Birmingham, United Kingdom. LA - eng PT - Journal Article DEP - 20170920 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (BCG Vaccine) RN - 0 (Interleukin-17) SB - IM CIN - Nat Rev Urol. 2017 Nov;14(11):639. doi: 10.1038/nrurol.2017.166. PMID: 28994827 MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/drug therapy/*immunology/metabolism MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Disease Progression MH - Humans MH - *Immunotherapy MH - Interleukin-17/*pharmacology MH - Mast Cells/drug effects/immunology/*metabolism MH - Prospective Studies MH - Tumor Cells, Cultured MH - Tumor Microenvironment/drug effects/*immunology MH - Urinary Bladder Neoplasms/drug therapy/*immunology/metabolism PMC - PMC5607173 COIS- Competing Interests: RT Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. ND James has contributed to advisory boards for Merck USA and Pierre Fabre. This does not alter our adherence to PLOS ONE policies on sharing data and materials. This does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2017/09/21 06:00 MHDA- 2017/10/19 06:00 PMCR- 2017/09/20 CRDT- 2017/09/21 06:00 PHST- 2017/06/28 00:00 [received] PHST- 2017/08/31 00:00 [accepted] PHST- 2017/09/21 06:00 [entrez] PHST- 2017/09/21 06:00 [pubmed] PHST- 2017/10/19 06:00 [medline] PHST- 2017/09/20 00:00 [pmc-release] AID - PONE-D-17-24486 [pii] AID - 10.1371/journal.pone.0184841 [doi] PST - epublish SO - PLoS One. 2017 Sep 20;12(9):e0184841. doi: 10.1371/journal.pone.0184841. eCollection 2017. PMID- 28928878 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 8 IP - 15 DP - 2017 TI - Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC). PG - 2885-2891 LID - 10.7150/jca.20003 [doi] AB - Purpose: To verify if the distinction between papillary urothelial neoplasm of low malignant potential (PUNLMP) and noninvasive low-grade papillary urothelial carcinoma (LGPUC) reflects a different biologic activity. Materials and Methods: We reviewed and analyzed the clinical data from 678 patients who had a diagnosis of PUNLMP (n=53) or noninvasive LGPUC (n=625) after initial TUR-BT for bladder neoplasm between 2000 and 2012. Results: The noninvasive LGPUC group showed a higher frequency of recurrence in comparison with the PUNLMP group (46.7% vs. 30.2%, p=0.022). In contrast, there were no significant differences in progression (15.2% vs. 18.9%, p=0.295) between the two groups. Grade progression was reported in 10 patients (LG: n=5; high grade: n=2; carcinoma in situ: n=3) and stage progression was reported in 2 patients (all: T1) in PUNLMP group. The Kaplan-Meier survival analysis showed significantly decreased 5-year recurrence-free survival (RFS) (50.3% vs. 74.6%, log-rank test, p=0.014) in the noninvasive LGPUC group compared to the PUNLMP group. However, there were no significant differences in progression-free survival (PFS) between the two groups. Multivariate analysis revealed that tumor grades according to 2004 WHO/ISUP classification system (PUNLMP vs. LG) were identified as significant predictors of RFS. However, it was not a significant predictor of both PFS and overall survival. Conclusions: PUNLMP had a substantial number of recurrences (30.2%), although RFS was better than noninvasive LGPUC. In addition, PUNLMP had a similar risk of progression compared with noninvasive LGPUC. Consequently, PUNLMP should be treated in a manner similar to noninvasive LGPUC, and long-term clinical follow-up should be recommended for patients with PUNLMP. FAU - Kim, Jung Kwon AU - Kim JK AD - Department of Urology, Center for Prostate Cancer, Research Institute and Hospital of the National Cancer Center, Goyang, Korea. FAU - Moon, Kyung Chul AU - Moon KC AD - Department of Pathology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyun Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng PT - Journal Article DEP - 20170824 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC5604438 OTO - NOTNLM OT - PUNLMP OT - noninvasive low-grade papillary urothelial carcinoma OT - progression OT - recurrence OT - urothelial carcinoma. COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2017/09/21 06:00 MHDA- 2017/09/21 06:01 PMCR- 2017/01/01 CRDT- 2017/09/21 06:00 PHST- 2017/03/09 00:00 [received] PHST- 2017/06/01 00:00 [accepted] PHST- 2017/09/21 06:00 [entrez] PHST- 2017/09/21 06:00 [pubmed] PHST- 2017/09/21 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - jcav08p2885 [pii] AID - 10.7150/jca.20003 [doi] PST - epublish SO - J Cancer. 2017 Aug 24;8(15):2885-2891. doi: 10.7150/jca.20003. eCollection 2017. PMID- 28927152 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 14 IP - 3 DP - 2017 Sep TI - Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. PG - 3817-3824 LID - 10.3892/ol.2017.6621 [doi] AB - The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P<0.001). Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P<0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression. Stratification by exon site of FGFR3 mutations yielded significant differences in mRNA expression level. None of the patients with BC harboring FGFR3 mutations in exon 9 demonstrated disease progression. The mRNA expression level of the FGFR3 gene may be used to precisely identify subsets of patients with pT1 BC that have a relatively better prognosis. The prognostic influences of FGFR3 mutations may be modulated by the exon site of FGFR3 mutations. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kim, Ye-Hwan AU - Kim YH AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Park, Cheol AU - Park C AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Ryu, Dong Hee AU - Ryu DH AD - Department of Surgery, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Cha, Eun-Jong AU - Cha EJ AD - Department of Biomedical Engineering, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University Medical Center, Daegu 41404, Republic of Korea. FAU - Kim, Tae-Hwan AU - Kim TH AD - Department of Urology, School of Medicine, Kyungpook National University Medical Center, Daegu 41404, Republic of Korea. FAU - Kwon, Tae Gyun AU - Kwon TG AD - Department of Urology, School of Medicine, Kyungpook National University Medical Center, Daegu 41404, Republic of Korea. FAU - Moon, Sung-Kwon AU - Moon SK AD - Department of Food and Biotechnology, Chungang University, Seoul 06974, Republic of Korea. FAU - Choi, Yung Hyun AU - Choi YH AD - Department of Biomaterial Control, Dong-Eui University, Busan 47340, Republic of Korea. FAU - Yun, Seok-Joong AU - Yun SJ AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Chungcheongbuk-do 28644, Republic of Korea. LA - eng PT - Journal Article DEP - 20170720 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5587943 OTO - NOTNLM OT - bladder cancer OT - expression OT - fibroblast growth factor receptor 3 OT - mutation OT - prognosis EDAT- 2017/09/21 06:00 MHDA- 2017/09/21 06:01 PMCR- 2017/07/20 CRDT- 2017/09/21 06:00 PHST- 2016/03/29 00:00 [received] PHST- 2017/04/28 00:00 [accepted] PHST- 2017/09/21 06:00 [entrez] PHST- 2017/09/21 06:00 [pubmed] PHST- 2017/09/21 06:01 [medline] PHST- 2017/07/20 00:00 [pmc-release] AID - OL-0-0-6621 [pii] AID - 10.3892/ol.2017.6621 [doi] PST - ppublish SO - Oncol Lett. 2017 Sep;14(3):3817-3824. doi: 10.3892/ol.2017.6621. Epub 2017 Jul 20. PMID- 28927108 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 14 IP - 3 DP - 2017 Sep TI - Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder. PG - 3522-3528 LID - 10.3892/ol.2017.6581 [doi] AB - The aim of the present study was to investigate the impact of squamous and/or glandular differentiation on the recurrence and progression in patients with nonmuscle invasive urothelial carcinoma of bladder (NMIUCB) following transurethral resection (TURBT). A total of 869 patients with NMIUCB who had been treated with TURBT at The Second Hospital of Tianjin Medical University (Tianjin, China) between January 2006 and January 2011 were retrospectively selected for the present analysis. Associations among squamous and/or glandular differentiation with other clinical and pathological features were assessed by the chi2 test. Recurrence-free survival (RFS) and progression-free survival (PFS) curves were estimated using the Kaplan-Meier method. Univariate and multivariate analyses were performed through a Cox's proportional hazards regression model. Among the 869 patients, 232 (26.7%) patients had squamous and/or glandular differentiation. High grade tumors were more common in patients with squamous and/or glandular differentiation compared with those with pure urothelial carcinoma of bladder (P<0.001). Associations between age (P=0.115), sex (P=0.184), tumor size (P=0.223), tumor multiplicity (P=0.108), pathological tumor stage (P=0.909) and squamous and/or glandular differentiation were not observed to be statistically significant. There was a significant tendency towards higher recurrence rate and shorter RFS time in patients with squamous and/or glandular differentiation. However, no statistically significant differences were observed in progression rate and PFS between the two groups. The multivariate Cox regression analysis, identified squamous and/or glandular differentiation as an independent prognostic predictor of recurrence (hazard ratio =1.46, 95% confidence interval=1.10-1.92, P=0.008). In the present study, the presence of squamous and/or glandular differentiation was associated with a higher recurrence rate and shorter RFS time in patients with NMIUCB. Squamous and/or glandular differentiation is therefore an independent prognostic predictor of recurrence. FAU - Xu, Hao AU - Xu H AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Xie, Linguo AU - Xie L AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Liu, Xiaoteng AU - Liu X AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Shen, Zhonghua AU - Shen Z AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Qiu, Xiaoyu AU - Qiu X AD - College of Management and Economics, Tianjin University, Nankai, Tianjin 300072, P.R. China. FAU - Sha, Nan AU - Sha N AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Xing, Chen AU - Xing C AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. FAU - Wu, Changli AU - Wu C AD - Department of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Hexi, Tianjin 300211, P.R. China. LA - eng PT - Journal Article DEP - 20170715 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5587993 OTO - NOTNLM OT - glandular OT - progression OT - recurrence OT - squamous OT - urothelial carcinoma EDAT- 2017/09/21 06:00 MHDA- 2017/09/21 06:01 PMCR- 2017/07/15 CRDT- 2017/09/21 06:00 PHST- 2015/09/02 00:00 [received] PHST- 2017/03/03 00:00 [accepted] PHST- 2017/09/21 06:00 [entrez] PHST- 2017/09/21 06:00 [pubmed] PHST- 2017/09/21 06:01 [medline] PHST- 2017/07/15 00:00 [pmc-release] AID - OL-0-0-6581 [pii] AID - 10.3892/ol.2017.6581 [doi] PST - ppublish SO - Oncol Lett. 2017 Sep;14(3):3522-3528. doi: 10.3892/ol.2017.6581. Epub 2017 Jul 15. PMID- 28916862 OWN - NLM STAT- MEDLINE DCOM- 20181120 LR - 20240426 IS - 1432-0851 (Electronic) IS - 0340-7004 (Print) IS - 0340-7004 (Linking) VI - 67 IP - 1 DP - 2018 Jan TI - Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat model. PG - 67-77 LID - 10.1007/s00262-017-2063-2 [doi] AB - Intravesical Bacillus Calmette-Guerin (BCG) is the best treatment modality for progression of non-muscle invasive bladder cancer. We aimed to monitor changes at the proteome level to identify putative protein biomarkers associated with the response of urothelial precancerous lesions to intravesical BCG treatment. The rats were divided into three groups (n = 10/group): control, non-treated, and BCG-treated groups. The non-treated and BCG-treated groups received N-methyl-N-nitrosourea intravesically. BCG Tice-strain was instilled into bladder in BCG-treated group. At the endpoint of experiment, all surviving rat bladders were collected and equally divided into two portions vertically from dome to neck. Half of each bladder was assessed immunohistopathologically and the other half was used for 2D-based comparative proteomic analysis. Differentially expressed proteins were validated by Western blot analysis. Precancerous lesions of bladder cancer were more common in non-treated group (77.8%) than in BCG-treated group (50%) and the control group (0%). Greater than twofold changes occurred in the expression of a number of proteins. Among them, Rab-GDIbeta, aldehyde dehydrogenase 2 (ALDH2) and 14-3-3 zeta/delta were important since they were previously reported to be associated with cancer and their expression levels were found to be lower in BCG-treated group in comparison to the non-treated group. ALDH2 and 14-3-3 zeta/delta were also found to be highly expressed in the non-treated group compared to the control group. The down-regulation of these proteins and Rab-GDIbeta was achieved with BCG; this result indicates that they may be used as putative biomarkers for monitoring changes in bladder carcinogenesis in response to BCG immunotherapy. FAU - Teke, Kerem AU - Teke K AUID- ORCID: 0000-0001-9030-4662 AD - Department of Urology, Kocaeli University School of Medicine, Umuttepe Campus, 41380, Kocaeli, Turkey. drtekekerem@gmail.com. FAU - Guzel, Nil AU - Guzel N AD - Department of Molecular Biology, Kocaeli University School of Medicine, Kocaeli, Turkey. FAU - Uslubas, Ali Kemal AU - Uslubas AK AD - Department of Urology, Kocaeli University School of Medicine, Umuttepe Campus, 41380, Kocaeli, Turkey. FAU - Kasap, Murat AU - Kasap M AD - Department of Molecular Biology, Kocaeli University School of Medicine, Kocaeli, Turkey. FAU - Yilmaz, Hasan AU - Yilmaz H AD - Department of Urology, Kocaeli University School of Medicine, Umuttepe Campus, 41380, Kocaeli, Turkey. FAU - Akpinar, Gurler AU - Akpinar G AD - Department of Molecular Biology, Kocaeli University School of Medicine, Kocaeli, Turkey. FAU - Yildiz, Demir Kursat AU - Yildiz DK AD - Department of Pathology, Kocaeli University School of Medicine, Kocaeli, Turkey. FAU - Dillioglugil, Ozdal AU - Dillioglugil O AD - Department of Urology, Kocaeli University School of Medicine, Umuttepe Campus, 41380, Kocaeli, Turkey. LA - eng GR - 2015/035/Kocaeli Universitesi/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170915 PL - Germany TA - Cancer Immunol Immunother JT - Cancer immunology, immunotherapy : CII JID - 8605732 RN - 0 (BCG Vaccine) RN - 0 (Cancer Vaccines) RN - 0 (GDP dissociation inhibitor 1) RN - 0 (Guanine Nucleotide Dissociation Inhibitors) RN - 0 (Proteome) SB - IM MH - Administration, Intravesical MH - Animals MH - BCG Vaccine/*immunology MH - Cancer Vaccines/*immunology MH - Disease Models, Animal MH - Female MH - Guanine Nucleotide Dissociation Inhibitors/genetics/metabolism MH - Humans MH - Immunotherapy/*methods MH - Precancerous Conditions MH - Proteome MH - Rats MH - Rats, Wistar MH - Urologic Neoplasms/immunology/*therapy MH - Urothelium/*metabolism/pathology PMC - PMC11028241 OTO - NOTNLM OT - 14-3-3 Zeta/delta OT - ALDH2 OT - Biomarkers OT - Intravesical BCG OT - Monitoring OT - Rab-GDIbeta COIS- The authors do not have any conflicts of interest to disclose. EDAT- 2017/09/17 06:00 MHDA- 2018/11/21 06:00 PMCR- 2017/09/15 CRDT- 2017/09/17 06:00 PHST- 2017/05/15 00:00 [received] PHST- 2017/09/08 00:00 [accepted] PHST- 2017/09/17 06:00 [pubmed] PHST- 2018/11/21 06:00 [medline] PHST- 2017/09/17 06:00 [entrez] PHST- 2017/09/15 00:00 [pmc-release] AID - 10.1007/s00262-017-2063-2 [pii] AID - 2063 [pii] AID - 10.1007/s00262-017-2063-2 [doi] PST - ppublish SO - Cancer Immunol Immunother. 2018 Jan;67(1):67-77. doi: 10.1007/s00262-017-2063-2. Epub 2017 Sep 15. PMID- 28903527 OWN - NLM STAT- MEDLINE DCOM- 20171130 LR - 20220316 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 47 IP - 9 DP - 2017 Sep 1 TI - Efficacy of early ureteral ligation on prevention of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: a prospective single-arm multicenter clinical trial. PG - 870-875 LID - 10.1093/jjco/hyx085 [doi] AB - OBJECTIVE: The rate of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma is high. Seeding upper urinary tract urothelial carcinoma cells onto the damaged bladder wall is considered to be one of the causes of intravesical recurrence after radical nephroureterectomy. We evaluated the utility of early ureteral ligation in preventing the intravesical recurrence. METHODS: This prospective single-arm clinical trial included patients who underwent radical nephroureterectomy for upper urinary tract urothelial carcinoma in the Tohoku Urological Evidence-Based Medicine Study Group between 2012 and 2013. Early ureteral ligation was defined as ligation of the ureter as quickly as possible after expanding the retroperitoneal space. A historical control was extracted from 454 patients who underwent radical nephroureterectomy in the same group, using propensity score-matched analysis. Intravesical recurrence-free survival rates were analyzed using Kaplan-Meier curves. Factors predicting intravesical recurrence were assessed using multivariate analyses. RESULTS: Seventy-four patients underwent early ureteral ligation. Seventeen (23%) patients had intravesical recurrence with a median follow-up period of 24 months. The 1- and 2-year intravesical recurrence-free survival rates in the early ureteral ligation group were 81% and 76%, and in the control group 75% and 63%, respectively (P = 0.160). In patients with renal pelvic cancer, the 1- and 2-year intravesical recurrence-free survival rates in the early ureteral ligation group were 89% and 86%, but in the control group 74% and 64%, respectively (P = 0.025). However, intravesical recurrence-free survival rates were similar in patients with ureteral cancer. Multivariate analyses of a subset of patients with renal pelvic cancer identified early ureteral ligation as an independent predictor of intravesical recurrence. CONCLUSIONS: Early ureteral ligation decreases the rate of intravesical recurrence after radical nephroureterectomy in patients with renal pelvic cancer. Thus, early ureteral ligation might help in prevention of intravesical recurrence for renal pelvic cancer. CI - (c) The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com FAU - Yamashita, Shinichi AU - Yamashita S AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai. FAU - Ito, Akihiro AU - Ito A AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai. FAU - Mitsuzuka, Koji AU - Mitsuzuka K AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai. FAU - Ioritani, Naomasa AU - Ioritani N AD - Department of Urology, Japan Community Health Care Organization Sendai Hospital, Sendai. FAU - Ishidoya, Shigeto AU - Ishidoya S AD - Department of Urology, Sendai City Hospital, Sendai. FAU - Ikeda, Yoshihiro AU - Ikeda Y AD - Department of Urology, Osaki Citizen Hospital, Osaki. FAU - Numahata, Kenji AU - Numahata K AD - Department of Urology, Yamagata Prefectural Central Hospital, Yamagata. FAU - Orikasa, Kazuhiko AU - Orikasa K AD - Department of Urology, Kesennuma City Hospital, Kesennuma. FAU - Tochigi, Tatsuo AU - Tochigi T AD - Department of Urology, Miyagi Cancer Center, Natori. FAU - Soma, Fumihiko AU - Soma F AD - Department of Urology, Hachinohe City Hospital, Hachinohe. FAU - Namima, Takashige AU - Namima T AD - Department of Urology, Tohoku Rosai Hospital, Sendai, Japan. FAU - Arai, Yoichi AU - Arai Y AD - Department of Urology, Tohoku University Graduate School of Medicine, Sendai. LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kidney/pathology/*surgery MH - Ligation/*methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*prevention & control MH - Nephrectomy/*methods MH - Prospective Studies MH - Retrospective Studies MH - Ureter/pathology/*surgery MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Neoplasms/pathology/*surgery OTO - NOTNLM OT - early ureteral ligation OT - intravesical recurrence OT - radical nephroureterectomy OT - upper urinary tract OT - urothelial carcinoma EDAT- 2017/09/15 06:00 MHDA- 2017/12/01 06:00 CRDT- 2017/09/15 06:00 PHST- 2017/04/02 00:00 [received] PHST- 2017/05/26 00:00 [accepted] PHST- 2017/09/15 06:00 [entrez] PHST- 2017/09/15 06:00 [pubmed] PHST- 2017/12/01 06:00 [medline] AID - 3867593 [pii] AID - 10.1093/jjco/hyx085 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2017 Sep 1;47(9):870-875. doi: 10.1093/jjco/hyx085. PMID- 28898400 OWN - NLM STAT- MEDLINE DCOM- 20171206 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 IP - 9 DP - 2017 Sep 12 TI - Intravesical electromotive drug administration for non-muscle invasive bladder cancer. PG - CD011864 LID - 10.1002/14651858.CD011864.pub2 [doi] LID - CD011864 AB - BACKGROUND: Electromotive drug administration (EMDA) is the use of electrical current to improve the delivery of intravesical agents to reduce the risk of recurrence in people with non-muscle invasive bladder cancer (NMIBC). It is unclear how effective this is in comparison to other forms of intravesical therapy. OBJECTIVES: To assess the effects of intravesical EMDA for the treatment of NMIBC. SEARCH METHODS: We performed a comprehensive search using multiple databases (CENTRAL, MEDLINE, EMBASE), two clinical trial registries and a grey literature repository. We searched reference lists of relevant publications and abstract proceedings. We applied no language restrictions. The last search was February 2017. SELECTION CRITERIA: We searched for randomised studies comparing EMDA of any intravesical agent used to reduce bladder cancer recurrence in conjunction with transurethral resection of bladder tumour (TURBT). DATA COLLECTION AND ANALYSIS: Two review authors independently screened the literature, extracted data, assessed risk of bias and rated quality of evidence (QoE) according to GRADE on a per outcome basis. MAIN RESULTS: We included three trials with 672 participants that described five distinct comparisons. The same principal investigator conducted all three trials. All studies used mitomycin C (MMC) as the chemotherapeutic agent for EMDA. 1. Postoperative MMC-EMDA induction versus postoperative Bacillus Calmette-Guerin (BCG) induction: based on one study with 72 participants with carcinoma in situ (CIS) and concurrent pT1 urothelial carcinoma, we are uncertain (very low QoE) about the effect of MMC-EMDA on time to recurrence (risk ratio (RR) 1.06, 95% confidence interval (CI) 0.64 to 1.76; corresponding to 30 more per 1000 participants, 95% CI 180 fewer to 380 more). There was no disease progression in either treatment arm at three months' follow-up. We are uncertain (very low QoE) about serious adverse events (RR 0.75, 95% CI 0.18 to 3.11). 2. Postoperative MMC-EMDA induction versus MMC-passive diffusion (PD) induction: based on one study with 72 participants with CIS and concurrent pT1 urothelial carcinoma, postoperative MMC-EMDA may (low QoE) reduce disease recurrence (RR 0.65, 95% CI 0.44 to 0.98; corresponding to 147 fewer per 1000 participants, 95% CI 235 fewer to 8 fewer). There was no disease progression in either treatment arm at three months' follow-up. We are uncertain (very low QoE) about the effect of MMC-EMDA on serious adverse events (RR 1.50, 95% CI 0.27 to 8.45). 3. Postoperative MMC-EMDA with sequential BCG induction and maintenance versus postoperative BCG induction and maintenance: based on one study with 212 participants with pT1 urothelial carcinoma of the bladder with or without CIS, postoperative MMC-EMDA with sequential BCG may result (low QoE) in a longer time to recurrence (hazard ratio (HR) 0.51, 95% CI 0.34 to 0.77; corresponding to 181 fewer per 1000 participants, 95% CI 256 fewer to 79 fewer) and time to progression (HR 0.36, 95% CI 0.17 to 0.75; corresponding to 63 fewer per 1000 participants, 95% CI 82 fewer to 24 fewer). We are uncertain (very low QoE) about the effect of MMC-EMDA on serious adverse events (RR 1.02, 95% CI 0.21 to 4.94). 4. Single-dose, preoperative MMC-EMDA versus single-dose, postoperative MMC-PD: based on one study with 236 participants with primary pTa and pT1 urothelial carcinoma, preoperative MMC-EMDA likely (moderate QoE) results in a longer time to recurrence (HR 0.47, 95% CI 0.32 to 0.69; corresponding to 247 fewer per 1000 participants, 95% CI 341 fewer to 130 fewer) for a median follow-up of 86 months. We are uncertain (very low QoE) about the effect of MMC-EMDA on time to progression (HR 0.81, 95% CI 0.00 to 259.93; corresponding to 34 fewer per 1000 participants, 95% CI 193 fewer to 807 more) and serious adverse events (RR 0.79, 95% CI 0.30 to 2.05). 5. Single-dose, preoperative MMC-EMDA versus TURBT alone: based on one study with 233 participants with primary pTa and pT1 urothelial carcinoma, preoperative MMC-EMDA likely (moderate QoE) results in a longer time to recurrence (HR 0.40, 95% CI 0.28 to 0.57; corresponding to 304 fewer per 1000 participants, 95% CI 390 fewer to 198 fewer) for a median follow-up of 86 months. We are uncertain (very low QoE) about the effect of MMC-EMDA on time to progression (HR 0.74, 95% CI 0.00 to 247.93; corresponding to 49 fewer per 1000 participants, 95% CI 207 fewer to 793 more) or serious adverse events (HR 1.74, 95% CI 0.52 to 5.77). AUTHORS' CONCLUSIONS: While the use of EMDA to administer intravesical MMC may result in a delay in time to recurrence in select patient populations, we are uncertain about its impact on serious adverse events in all settings. Common reasons for downgrading the QoE were study limitations and imprecision. A potential role for EMDA-based administration of MMC may lie in settings where more established agents (such as BCG) are not available. In the setting of low or very low QoE for most comparisons, our confidence in the effect estimates is limited and the true effect sizes may be substantially different from those reported here. FAU - Jung, Jae Hung AU - Jung JH AD - Department of Urology, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju, Gangwon, Korea, South, 26426. FAU - Gudeloglu, Ahmet AU - Gudeloglu A FAU - Kiziloz, Halil AU - Kiziloz H FAU - Kuntz, Gretchen M AU - Kuntz GM FAU - Miller, Alea AU - Miller A FAU - Konety, Badrinath R AU - Konety BR FAU - Dahm, Philipp AU - Dahm P LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20170912 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM UOF - doi: 10.1002/14651858.CD011864 MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/*administration & dosage MH - BCG Vaccine/administration & dosage MH - Carcinoma in Situ/*drug therapy/mortality/pathology MH - Carcinoma, Transitional Cell/*drug therapy/mortality/pathology MH - Disease Progression MH - Electrochemotherapy/adverse effects/*methods MH - Humans MH - Mitomycin/*administration & dosage MH - Neoplasm Recurrence, Local MH - Randomized Controlled Trials as Topic MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology PMC - PMC6483767 COIS- JHJ: none known. AG: none known. HK: none known. GMK: none known. AM: none known. BK: none known. PD: none known. EDAT- 2017/09/13 06:00 MHDA- 2017/12/07 06:00 PMCR- 2018/09/12 CRDT- 2017/09/13 06:00 PHST- 2017/09/13 06:00 [pubmed] PHST- 2017/12/07 06:00 [medline] PHST- 2017/09/13 06:00 [entrez] PHST- 2018/09/12 00:00 [pmc-release] AID - CD011864.pub2 [pii] AID - 10.1002/14651858.CD011864.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD011864. doi: 10.1002/14651858.CD011864.pub2. PMID- 28889382 OWN - NLM STAT- MEDLINE DCOM- 20180511 LR - 20220321 IS - 1940-6029 (Electronic) IS - 1064-3745 (Linking) VI - 1655 DP - 2018 TI - Urothelial Carcinoma Stem Cells: Current Concepts, Controversies, and Methods. PG - 121-136 LID - 10.1007/978-1-4939-7234-0_10 [doi] AB - Cancer stem cells are defined as a self-renewing and self-protecting subpopulation of cancer cells able to differentiate into morphologically and functionally diverse cancer cells with a limited lifespan. To purify cancer stem cells, two basic approaches can be applied, the marker-based approach employing various more of less-specific cell surface marker molecules and a marker-free approach largely based on various self-protection mechanisms. Within the context of urothelial carcinoma, both methods could find use. The cell surface markers have been mainly derived from the urothelial basal cell, a probable cell of origin of muscle-invasive urothelial carcinoma, with CD14, CD44, CD90, and 67LR representing successful examples of this strategy. The marker-free approaches involve side population sorting, for which a detailed protocol is provided, as well as the Aldefluor assay, which rely on a specific overexpression of efflux pumps or the detoxification enzyme aldehyde dehydrogenase, respectively, in stem cells. These assays have been applied to both non-muscle-invasive and muscle-invasive bladder cancer samples and cell lines. Urothelial carcinoma stem cells feature a pronounced heterogeneity as to their molecular stemness mechanisms. Several aspects of urothelial cancer stem cell biology could enter translational development rather soon, e.g., a specific CD44(+)-derived gene expression signature able to identify non-muscle-invasive bladder cancer patients with a high risk of progression, or deciphering a mechanism responsible for repopulating activity of urothelial carcinoma stem cells within the context of therapeutic resistance. FAU - Hatina, Jiri AU - Hatina J AD - Faculty of Medicine in Pilsen, Institute of Biology, Charles University in Prague, Plzen, Czech Republic. Jiri.Hatina@lfp.cuni.cz. FAU - Parmar, Hamendra Singh AU - Parmar HS AD - Faculty of Medicine in Pilsen, Institute of Biology, Charles University in Prague, Plzen, Czech Republic. FAU - Kripnerova, Michaela AU - Kripnerova M AD - Faculty of Medicine in Pilsen, Institute of Biology, Charles University in Prague, Plzen, Czech Republic. FAU - Hepburn, Anastasia AU - Hepburn A AD - Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK. FAU - Heer, Rakesh AU - Heer R AD - Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Methods Mol Biol JT - Methods in molecular biology (Clifton, N.J.) JID - 9214969 RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) SB - IM MH - Animals MH - Biomarkers MH - Biomarkers, Tumor MH - Cell Line, Tumor MH - Cell Separation/methods MH - Disease Models, Animal MH - Flow Cytometry MH - Heterografts MH - Humans MH - Immunophenotyping MH - Mice MH - Mice, Transgenic MH - Neoplastic Stem Cells/*metabolism/*pathology MH - Stem Cells/cytology/metabolism MH - Tumor Stem Cell Assay MH - Urologic Neoplasms/*metabolism/*pathology MH - Urothelium/cytology/metabolism OTO - NOTNLM OT - Cancer stem cells OT - Drug resistance OT - Side population OT - Urothelial carcinoma OT - Urothelial carcinoma cells of origin OT - Urothelial carcinoma stem cell markers OT - Urothelial regeneration OT - Urothelium stem cells EDAT- 2017/09/11 06:00 MHDA- 2018/05/12 06:00 CRDT- 2017/09/11 06:00 PHST- 2017/09/11 06:00 [entrez] PHST- 2017/09/11 06:00 [pubmed] PHST- 2018/05/12 06:00 [medline] AID - 10.1007/978-1-4939-7234-0_10 [doi] PST - ppublish SO - Methods Mol Biol. 2018;1655:121-136. doi: 10.1007/978-1-4939-7234-0_10. PMID- 28888813 OWN - NLM STAT- MEDLINE DCOM- 20190515 LR - 20190515 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 6 DP - 2018 Dec TI - Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PG - 924-936 LID - S2405-4569(17)30199-2 [pii] LID - 10.1016/j.euf.2017.08.007 [doi] AB - CONTEXT: The incidence of urothelial carcinoma of the bladder (UCB) is lower in women; however, women tend to present with more advanced disease. To date, there is no quantitative synthesis of studies reporting gender-specific outcomes in non-muscle-invasive UCB. OBJECTIVE: To conduct a meta-analysis evaluating gender-specific differences in recurrence of non-muscle-invasive urinary bladder cancer (NMIBC). EVIDENCE ACQUISITION: An unrestricted systematic literature search of the MEDLINE, EMBASE, and Cochrane libraries was conducted. Studies evaluating the impact of gender on disease recurrence after local treatment of NMIBC using multivariable Cox proportional hazard models were included. Random effect meta-analysis, subgroup analyses, meta-influence, and cumulative meta-analyses were conducted. Publication bias was assessed via a funnel plot and Eggers test. EVIDENCE SYNTHESIS: Of 609 studies screened, 27 comprising 23 754 patients were included. Random effect meta-analyses indicated women at increased risk for UCB recurrence compared with men (hazard ratio [HR]=1.11, 95% confidence interval [CI]: 1.01-1.23, p=0.03). Subgroup analyses yielded estimates between HR=0.99 and HR=1.68. Gender-specific differences in UCB recurrence were most pronounced in studies administering exclusively bacillus Calmette-Guerin (BCG; HR=1.64, 95% CI: 1.13-2.39, p=0.01), especially in a long-term treatment regimen (HR=1.68, 95% CI: 1.32-2.15, p<0.001). Sensitivity analyses confirmed female patients at increased risk for UCB recurrence. CONCLUSIONS: Women are at increased risk for disease recurrence after local treatment of NMIBC compared with male patients. Reduced effectiveness of BCG treatment might underlie this observation. Gender-specific differences were evident across various subgroups and proved robust upon sensitivity analyses. PATIENT SUMMARY: In this report, we combined several studies on gender-specific differences in relapse of superficial bladder cancer. Women were more likely to experience cancer relapse than men. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Uhlig, Annemarie AU - Uhlig A AD - Department of Urology, University Medical Center Goettingen, Goettingen, Germany. Electronic address: annemarie.uhlig@med.uni-goettingen.de. FAU - Strauss, Arne AU - Strauss A AD - Department of Urology, University Medical Center Goettingen, Goettingen, Germany. FAU - Seif Amir Hosseini, Ali AU - Seif Amir Hosseini A AD - Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. FAU - Lotz, Joachim AU - Lotz J AD - Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. FAU - Trojan, Lutz AU - Trojan L AD - Department of Urology, University Medical Center Goettingen, Goettingen, Germany. FAU - Schmid, Marianne AU - Schmid M AD - Department of Urology, University Medical Center Goettingen, Goettingen, Germany. FAU - Uhlig, Johannes AU - Uhlig J AD - Department of Radiology, University Medical Center Goettingen, Goettingen, Germany; Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20170906 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Cystoscopy MH - Female MH - Humans MH - Male MH - Multivariate Analysis MH - Muscle, Smooth/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Proportional Hazards Models MH - Sex Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*therapy MH - *Urologic Surgical Procedures OTO - NOTNLM OT - Bladder cancer OT - Gender differences OT - Local recurrence OT - Meta-analysis OT - Transurethral resection of bladder tumor EDAT- 2017/09/11 06:00 MHDA- 2019/05/16 06:00 CRDT- 2017/09/11 06:00 PHST- 2017/06/03 00:00 [received] PHST- 2017/07/29 00:00 [revised] PHST- 2017/08/11 00:00 [accepted] PHST- 2017/09/11 06:00 [pubmed] PHST- 2019/05/16 06:00 [medline] PHST- 2017/09/11 06:00 [entrez] AID - S2405-4569(17)30199-2 [pii] AID - 10.1016/j.euf.2017.08.007 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Dec;4(6):924-936. doi: 10.1016/j.euf.2017.08.007. Epub 2017 Sep 6. PMID- 28888400 OWN - NLM STAT- MEDLINE DCOM- 20180702 LR - 20220410 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 12 DP - 2017 Dec TI - Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy. PG - 674.e19-674.e24 LID - S1078-1439(17)30411-8 [pii] LID - 10.1016/j.urolonc.2017.08.004 [doi] AB - BACKGROUND: Nowadays, the intravesical Bacillus Calmette-Guerin (BCG) instillation is the method of choice for the postsurgical treatment of high-grade nonmuscle-invasive bladder cancer , to reduce both recurrence rate and risk of progression. BCG is hypothesized to correct the immune system disequilibrium occurring during carcinogenesis, through an immunostimulation with detrimental effects for tumoral cells. Inflammation plays a crucial role in tumor progression. The deregulation of inflammasomes upon carcinogenesis underlines its importance both in physiologic and pathologic human conditions. Nucleotide oligomerization domain-like receptors (NLRs) are key components of this molecular platform and the increase in expression of some members of nucleotide oligomerization domain-like receptors family (NLRP3, NLRP4, NLRP9, and NLR family apoptosis inhibitory protein [NAIP]) in urothelial carcinoma was already demonstrated in our previous work. The first aim of the present work was to estimate whether these inflammasome-related genes show alterations during BCG instillations. The expression levels of NLRP3, NLRP4, NLRP9, and NAIP were assessed in the urine sediments from patients, which underwent surgery for superficial high-grade bladder cancer and further subjected to serial BCG instillations. The eventual association between NLR expression and recurrence was also evaluated. The expression of CK20 mRNA as confirmed marker of bladder cancer was also assayed. METHODS: Urine were sampled from patients harboring high-grade superficial bladder cancer and treated postsurgically with weekly BCG instillations for 6 weeks (induction cycle, I). Urine sediments were processed and resulting RNA was reverse transcribed and used for amplification by real-time PCR. RESULTS: After surgery, CK20 levels decreased significantly whereas NLRP4 and NLRP9 genes showed an increase. NLRP3 and NAIP remained substantially unmodified. CK20 mRNA decreased at the end of the induction cycle. NLRP3 did not show relevant modifications. The expression levels of NLRP4 and NLRP9 decreased significantly after 2 BCG administrations and remained substantially downregulated during the whole induction cycle. CK20 was higher in recurrence cases before BCG administration compared to the recurrence-free group, while no significant difference after BCG therapy was recorded. NLRP4 and NLRP9 were higher in patients with recurrence before BCG administration. CONCLUSIONS: The study underlines the importance of NLRP4 and NLRP9 in urothelial carcinoma and if these preliminary data will be confirmed in larger cohort studies, the assessment of NLRP4 and NLRP9 expression levels could help to predict the BCG failure, playing a relevant role in decision making for early radical surgery. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Poli, Giulia AU - Poli G AD - Department of Experimental Medicine, Section of Terni, University of Perugia, Perugia, Italy. FAU - Cochetti, Giovanni AU - Cochetti G AD - Department of Surgical and Biomedical Sciences, Institute of Urological, Andrological Surgery and Minimally Invasive Techniques, University of Perugia, Perugia, Italy. FAU - Boni, Andrea AU - Boni A AD - Department of Surgical and Biomedical Sciences, Institute of Urological, Andrological Surgery and Minimally Invasive Techniques, University of Perugia, Perugia, Italy. FAU - Egidi, Maria Giulia AU - Egidi MG AD - Department of Surgical and Biomedical Sciences, Institute of Urological, Andrological Surgery and Minimally Invasive Techniques, University of Perugia, Perugia, Italy. Electronic address: mariagiuliaegidi@gmail.com. FAU - Brancorsini, Stefano AU - Brancorsini S AD - Department of Experimental Medicine, Section of Terni, University of Perugia, Perugia, Italy. FAU - Mearini, Ettore AU - Mearini E AD - Department of Surgical and Biomedical Sciences, Institute of Urological, Andrological Surgery and Minimally Invasive Techniques, University of Perugia, Perugia, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170906 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Inflammasomes) RN - 0 (RNA, Messenger) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Disease Progression MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Inflammasomes/*genetics MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/prevention & control MH - Postoperative Period MH - RNA, Messenger/genetics/metabolism/*urine MH - Urinary Bladder Neoplasms/*drug therapy/genetics/urine OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Inflammation OT - Instillation therapy OT - NOD-like receptor family OT - mRNA EDAT- 2017/09/11 06:00 MHDA- 2018/07/03 06:00 CRDT- 2017/09/11 06:00 PHST- 2017/04/28 00:00 [received] PHST- 2017/07/26 00:00 [revised] PHST- 2017/08/04 00:00 [accepted] PHST- 2017/09/11 06:00 [pubmed] PHST- 2018/07/03 06:00 [medline] PHST- 2017/09/11 06:00 [entrez] AID - S1078-1439(17)30411-8 [pii] AID - 10.1016/j.urolonc.2017.08.004 [doi] PST - ppublish SO - Urol Oncol. 2017 Dec;35(12):674.e19-674.e24. doi: 10.1016/j.urolonc.2017.08.004. Epub 2017 Sep 6. PMID- 28887095 OWN - NLM STAT- MEDLINE DCOM- 20180702 LR - 20220408 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 12 DP - 2017 Dec TI - Psychological distress in patients undergoing surgery for urological cancer: A single centre cross-sectional study. PG - 673.e1-673.e7 LID - S1078-1439(17)30413-1 [pii] LID - 10.1016/j.urolonc.2017.08.006 [doi] AB - PURPOSE: Interest in the disease-specific psychological well-being of patients with cancer has increased, and it has been estimated that less than half of all patients with cancer are properly identified and subsequently treated for anxiety or depression. The aim of this study is to evaluate psychological distress in uro-oncological patients undergoing different surgeries: radical cystectomy, radical prostatectomy, radical nephrectomy, or transurethral resection (TUR) before the surgery. MATERIALS AND METHODS: We performed a cross-sectional study in consecutively enrolled patients with bladder, kidney, or prostate cancer, scheduled for surgery. Demographic data, socioeconomic status, education level, and diagnoses were recorded. Patients with a previous diagnosis of depression or anxiety were excluded. We evaluated the level of clinically meaningful depression and anxiety assessed by 2 tools: the Hospital Anxiety and Depression Scale (HADS; score >/=8 presence of anxiety and depression; score >/=11 clinical anxiety and depression) and the State-Trait Anxiety Inventory (STAI). To determine variables related to depression and anxiety among the demographic variables, logistic regression analyses were conducted, with P<0.05 considered as statistically significant. RESULTS: A total of 207 patients were recruited, completed the questionnaires and were included in the study. Patients presented a mean age of 70.8 (+/-10.8) years, 89% were males (n = 184) and 19% of patients presented previous cancer. The majority of patients underwent surgery for bladder tumors (60.4%) and the most common type of surgery was TUR. The most frequent procedures were performed for bladder tumors (60.4%), being TUR the most common type of surgery (52.7%) followed by radical prostatectomy (24.6%). Mean STAI-State score was 19.3 (+/-10.3), and mean STAI-Trait score was 18.4 (+/-11.9) points. Clinical levels of anxiety and depression (HADS >/= 11 points) were found in 19 (9.8%) and 7 (3.6%) cases. And HADS anxiety 8 to 10 points was present in 14.5% (n = 28) and HADS depression 8 to 10 points in 5.7% (n = 11) of the sample, representing presence of psychological distress. Female patients showed a higher level of anxiety and STAI-Trait compared to males. CONCLUSION: The present results show that our patients had lower levels of anxiety and depression than those described in the literature. Sex, tumor type, and surgical approach were significantly related to psychological distress in patients undergoing surgery for urological cancer. Females and patients with kidney tumor and patients undergoing radical nephrectomy presented higher levels of anxiety. Patients with radical cystectomy showed a higher level of STAI-State compared with other surgeries. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Pastore, Antonio Luigi AU - Pastore AL AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Faculty of Pharmacy and Medicine, Urology Unit, Latina, Italy. Electronic address: antopast@hotmail.com. FAU - Mir, Ana AU - Mir A AD - Department of Psychology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Maruccia, Serena AU - Maruccia S AD - Department of Urology, Istituti Clinici Zucchi, Monza, Italy. FAU - Palleschi, Giovanni AU - Palleschi G AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Faculty of Pharmacy and Medicine, Urology Unit, Latina, Italy. FAU - Carbone, Antonio AU - Carbone A AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Faculty of Pharmacy and Medicine, Urology Unit, Latina, Italy. FAU - Lopez, Cristina AU - Lopez C AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Camps, Nuria AU - Camps N AD - Department of Psychology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20170905 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Anxiety/diagnosis/psychology MH - Cross-Sectional Studies MH - Depression/diagnosis/psychology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Psychometrics/methods MH - Risk Factors MH - Stress, Psychological/*psychology MH - Surveys and Questionnaires MH - Urologic Neoplasms/*psychology/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Anxiety OT - Bladder cancer OT - Depressive disorder OT - Kidney cancer OT - Prostate cancer OT - Psychological distress EDAT- 2017/09/10 06:00 MHDA- 2018/07/03 06:00 CRDT- 2017/09/10 06:00 PHST- 2016/12/27 00:00 [received] PHST- 2017/08/06 00:00 [revised] PHST- 2017/08/08 00:00 [accepted] PHST- 2017/09/10 06:00 [pubmed] PHST- 2018/07/03 06:00 [medline] PHST- 2017/09/10 06:00 [entrez] AID - S1078-1439(17)30413-1 [pii] AID - 10.1016/j.urolonc.2017.08.006 [doi] PST - ppublish SO - Urol Oncol. 2017 Dec;35(12):673.e1-673.e7. doi: 10.1016/j.urolonc.2017.08.006. Epub 2017 Sep 5. PMID- 28885656 OWN - NLM STAT- MEDLINE DCOM- 20180209 LR - 20180209 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 84 IP - 4 DP - 2017 Oct 25 TI - Bladder cancer to patients younger than 30 years: a retrospective study and review of the literature. PG - 231-235 LID - 10.5301/uj.5000264 [doi] AB - OBJECTIVES: The aim of this report was to study the specific characteristics of bladder cancer in patients younger than 30 years. MATERIALS AND METHODS: Five patients with a mean age of 24 +/- 2.83 years were included in the study. All patients had painless macroscopic hematuria as the first symptom. Three patients had pTa as a first diagnosis, one had pT1 and one pT2. All the patients had smoking as a risk factor and at least one additional possible risk factor. RESULTS: One patient with pTa had an aggressive course and after multiple recurrences was diagnosed with pT2 and refused to be submitted to radical cystectomy and died from the disease even though he received a multimodality treatment. The other two patients with the pTa diagnosis had no recurrence after the first TUR-BT and the patient with the pT1 diagnosis after one recurrence with a pTa histology is free of recurrence for the last 2 years. The patient diagnosed with pT2 was submitted to a radical cystectomy and an s-pouch diversion with a preservation of the genital system in order to have the ability of a future motherhood with the acceptance of course risks. CONCLUSIONS: Young patients with bladder cancer is a difficult group of patients and show more reluctance to comply to the necessary strict follow-up of the repeated urinary cytology examinations, cystoscopies and CT pyelographies. Herein, we report a retrospective study of five patients younger than 30 years with bladder cancer. FAU - Katafigiotis, Ioannis AU - Katafigiotis I AD - 1 University Urology Clinic, Laiko Hospital, Athens - Greece. FAU - Sfoungaristos, Stavros AU - Sfoungaristos S AD - Hebrew Hadassah University Medical Center, Jerusalem - Israel. FAU - Martini, Alberto AU - Martini A AD - Unit of Urology, Urological Research Institute, Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan - Italy. FAU - Stravodimos, Konstantinos AU - Stravodimos K AD - 1 University Urology Clinic, Laiko Hospital, Athens - Greece. FAU - Anastasiou, Ioannis AU - Anastasiou I AD - 1 University Urology Clinic, Laiko Hospital, Athens - Greece. FAU - Mykoniatis, Ioannis AU - Mykoniatis I AD - 1 Department of Urology, G. Gennimatas Hospital, Aristotle University, Thessaloniki - Greece. FAU - Duvdevani, Mordechai AU - Duvdevani M AD - Hebrew Hadassah University Medical Center, Jerusalem - Israel. FAU - Constantinides, Constantinos AU - Constantinides C AD - 1 University Urology Clinic, Laiko Hospital, Athens - Greece. LA - eng PT - Journal Article PT - Review DEP - 20170905 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Adult MH - Age Factors MH - Female MH - Humans MH - Male MH - Retrospective Studies MH - Risk Factors MH - *Urinary Bladder Neoplasms/diagnosis/urine MH - Young Adult EDAT- 2017/09/09 06:00 MHDA- 2018/02/10 06:00 CRDT- 2017/09/09 06:00 PHST- 2017/07/23 00:00 [accepted] PHST- 2017/09/09 06:00 [pubmed] PHST- 2018/02/10 06:00 [medline] PHST- 2017/09/09 06:00 [entrez] AID - 56F83989-10E7-4ACD-80D9-0FDFA1215A52 [pii] AID - 10.5301/uj.5000264 [doi] PST - ppublish SO - Urologia. 2017 Oct 25;84(4):231-235. doi: 10.5301/uj.5000264. Epub 2017 Sep 5. PMID- 28872778 OWN - NLM STAT- MEDLINE DCOM- 20180313 LR - 20190201 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 121 IP - 2 DP - 2018 Feb TI - Effects of thiazolidinedione in patients with active bladder cancer. PG - 244-251 LID - 10.1111/bju.14009 [doi] AB - OBJECTIVE: To examine the influence of perioperative thiazolidinedione (TZD) on cancer-specific outcomes in patients with diabetes mellitus (DM) undergoing radical cystectomy (RC) for urothelial carcinoma (UC). PATIENTS AND METHODS: A retrospective cohort of 173 patients with DM undergoing RC from 2005 to 2010 was identified. Of those, 53 were on TZD treatment at the time of RC, with 33 patients taking pioglitazone. Baseline clinicopathological characteristics, as well as cancer-specific survival (CSS), recurrence-free survival (RFS), and overall survival (OS) were compared between the patients on and off TZD therapy at the time of RC. In subgroup analysis, outcomes in patients specifically taking pioglitazone at the time of RC were compared to those not on a TZD. RESULTS: Baseline clinicopathological characteristics were similar between patients on and off TZD therapy at the time of RC. Overall, the median CSS rate was not reached in either group (P = 0.7). The estimated 5-year CSS was 67.8% in the non-TZD group and 66.3% in the TZD group. On multivariate analysis incorporating patient age, pathological T-staging, and adjuvant chemotherapy, TZD use was found not to be a significant predictor for CSS (hazard ratio 1.20, 95% confidence interval 0.66-2.17; P = 0.5). Additionally, RFS (P= 0.3) and OS (P = 0.2) were also similar between the two groups without adjusting for other variables. Comparison between patients taking pioglitazone vs patients not taking TZD yielded similar CSS (P = 0.2), RFS (P = 0.5), and OS (P= 0.2). CONCLUSIONS: CSS, as well as RFS and OS after RC were not compromised in patients on TZD therapy at the time of RC. Additional investigation is warranted in patients with non-muscle-invasive bladder cancer and muscle-invasive bladder cancer undergoing bladder-sparing procedures to assess the safety of using TZD in the setting of active UC. CI - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John Wiley & Sons Ltd. FAU - Li, Roger AU - Li R AUID- ORCID: 0000-0003-1274-7200 AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Metcalfe, Michael J AU - Metcalfe MJ AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Ferguson, James E 3rd AU - Ferguson JE 3rd AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Mokkapati, Sharada AU - Mokkapati S AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras Gonzalez, Graciela M AU - Nogueras Gonzalez GM AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Sahai, Sunil K AU - Sahai SK AD - Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20170923 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Hypoglycemic Agents) RN - 0 (Thiazolidinediones) RN - 05V02F2KDG (Rosiglitazone) RN - X4OV71U42S (Pioglitazone) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/complications/secondary/*surgery MH - Cystectomy MH - Diabetes Mellitus/*drug therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Hypoglycemic Agents/*therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Pioglitazone MH - Retrospective Studies MH - Rosiglitazone MH - Survival Rate MH - Thiazolidinediones/*therapeutic use MH - Urinary Bladder Neoplasms/complications/pathology/*surgery PMC - PMC5780258 MID - NIHMS903925 OTO - NOTNLM OT - BCG OT - #BladderCancer OT - PPARgamma agonist OT - thiazolidinedione COIS- Conflict of interest: None EDAT- 2017/09/06 06:00 MHDA- 2018/03/14 06:00 PMCR- 2019/02/01 CRDT- 2017/09/06 06:00 PHST- 2017/09/06 06:00 [pubmed] PHST- 2018/03/14 06:00 [medline] PHST- 2017/09/06 06:00 [entrez] PHST- 2019/02/01 00:00 [pmc-release] AID - 10.1111/bju.14009 [doi] PST - ppublish SO - BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23. PMID- 28870862 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20190403 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 199 IP - 2 DP - 2018 Feb TI - Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. PG - 407-415 LID - S0022-5347(17)77426-5 [pii] LID - 10.1016/j.juro.2017.08.106 [doi] AB - PURPOSE: We describe the incidence, clinicopathological risk factors, management and outcomes of recurrent nonmuscle invasive bladder cancer after a complete response to trimodality therapy of muscle invasive bladder cancer. MATERIALS AND METHODS: We retrospectively reviewed the records of 342 patients with cT2-4aN0M0 muscle invasive bladder cancer and a complete response after trimodality therapy from 1986 to 2013. Using competing risks analyses we examined the association between baseline clinicopathological variables and nonmuscle invasive bladder cancer outcomes. Kaplan-Meier and the generalized Fleming-Harrington test were used to compare disease specific and overall survival. RESULTS: At a median followup of 9 years nonmuscle invasive bladder cancer recurred in 85 patients (25%) who had had a complete response. On Kaplan-Meier analysis baseline carcinoma in situ was associated with recurrent nonmuscle invasive bladder cancer (p = 0.02). However, on multivariate analysis carcinoma in situ and other baseline clinicopathological characteristics did not predict such recurrence. Patients with recurrent nonmuscle invasive bladder cancer had worse 10-year disease specific survival than those without recurrence (72.1% vs 78.4%, p = 0.002), although overall survival was similar (p = 0.66). Of the 39 patients (46%) who received adjuvant intravesical bacillus Calmette-Guerin 29 (74%) completed induction therapy and 19 (49%) reported bacillus Calmette-Guerin toxicity. Three-year recurrence-free and progression-free survival after induction bacillus Calmette-Guerin was 59% and 63%, respectively. CONCLUSIONS: After a complete response to trimodality therapy nonmuscle invasive bladder cancer recurred in 25% of patients, developing in some of them more than a decade after trimodality therapy. No baseline clinicopathological characteristics were associated with such recurrence after a complete response. Patients with nonmuscle invasive bladder cancer recurrence had worse disease specific survival than those without such recurrence but similar overall survival. Adjuvant intravesical bacillus Calmette-Guerin had a reasonable toxicity profile and efficacy in this population. Properly selected patients with recurrent nonmuscle invasive bladder cancer after a complete response may avoid immediate salvage cystectomy. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Sanchez, Alejandro AU - Sanchez A AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Wszolek, Matthew F AU - Wszolek MF AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Niemierko, Andrzej AU - Niemierko A AD - Division of Biostatistics, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Clayman, Rebecca H AU - Clayman RH AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Drumm, Michael AU - Drumm M AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Rodriguez, Dayron AU - Rodriguez D AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Feldman, Adam S AU - Feldman AS AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Dahl, Douglas M AU - Dahl DM AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Heney, Niall M AU - Heney NM AD - Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Shipley, William U AU - Shipley WU AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Zietman, Anthony L AU - Zietman AL AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: jefstathiou@partners.org. LA - eng PT - Journal Article DEP - 20170901 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Feb;199(2):415. doi: 10.1016/j.juro.2017.08.133. PMID: 29131983 CIN - J Urol. 2018 Feb;199(2):414-415. doi: 10.1016/j.juro.2017.08.132. PMID: 29131984 MH - Adult MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/diagnosis/epidemiology/pathology/therapy MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/diagnosis/epidemiology/pathology/therapy OTO - NOTNLM OT - BCG vaccine OT - local OT - mortality OT - neoplasm invasiveness OT - neoplasm recurrence OT - urinary bladder neoplasms EDAT- 2017/09/06 06:00 MHDA- 2019/04/04 06:00 CRDT- 2017/09/06 06:00 PHST- 2017/08/29 00:00 [accepted] PHST- 2017/09/06 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2017/09/06 06:00 [entrez] AID - S0022-5347(17)77426-5 [pii] AID - 10.1016/j.juro.2017.08.106 [doi] PST - ppublish SO - J Urol. 2018 Feb;199(2):407-415. doi: 10.1016/j.juro.2017.08.106. Epub 2017 Sep 1. PMID- 28867446 OWN - NLM STAT- MEDLINE DCOM- 20180806 LR - 20221109 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 73 IP - 1 DP - 2018 Jan TI - European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. PG - 111-122 LID - S0302-2838(17)30665-6 [pii] LID - 10.1016/j.eururo.2017.07.036 [doi] AB - CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Roupret, Morgan AU - Roupret M AD - AP-HP, Hopital La Pitie-Salpetriere, Service d'Urologie, Paris, France; UPMC University Paris 06, GRC5, ONCOTYPE-Uro, Institut Universitaire de Cancerologie, Paris, France. Electronic address: mroupret@gmail.com. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Hopital Tenon, Assistance Publique-Hopitaux de Paris, UPMC Paris VI, Paris, France. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Cowan, Nigel C AU - Cowan NC AD - Department of Radiology, Queen Alexandra Hospital, Portsmouth, UK. FAU - Gontero, Paolo AU - Gontero P AD - Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Studies of Torino, Turin, Italy. FAU - Van Rhijn, Bas W G AU - Van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20170901 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Carcinoma/diagnosis/mortality/*therapy MH - Clinical Decision-Making MH - Consensus MH - Evidence-Based Medicine/*standards MH - Humans MH - Neoplasm Staging MH - Risk Factors MH - Treatment Outcome MH - Urologic Neoplasms/diagnosis/mortality/*therapy MH - Urology/*standards MH - Urothelium/*pathology OTO - NOTNLM OT - Cytology OT - Guidelines OT - Nephroureterectomy OT - Renal pelvis OT - Risk factors OT - Survival OT - Ureter OT - Ureteroscopy OT - Urinary tract cancer OT - Urothelial carcinoma EDAT- 2017/09/05 06:00 MHDA- 2018/08/07 06:00 CRDT- 2017/09/05 06:00 PHST- 2017/07/17 00:00 [received] PHST- 2017/07/26 00:00 [accepted] PHST- 2017/09/05 06:00 [pubmed] PHST- 2018/08/07 06:00 [medline] PHST- 2017/09/05 06:00 [entrez] AID - S0302-2838(17)30665-6 [pii] AID - 10.1016/j.eururo.2017.07.036 [doi] PST - ppublish SO - Eur Urol. 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036. Epub 2017 Sep 1. PMID- 28866819 OWN - NLM STAT- MEDLINE DCOM- 20180618 LR - 20240326 IS - 1559-131X (Electronic) IS - 1357-0560 (Print) IS - 1357-0560 (Linking) VI - 34 IP - 10 DP - 2017 Sep 2 TI - Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. PG - 172 LID - 10.1007/s12032-017-1033-z [doi] LID - 172 AB - A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette-Guerin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion((R)) is a multitarget fluorescence in situ hybridization (FISH) test for bladder cancer detection. The aim of this study was to evaluate whether FISH can be used to early identify recurrence during treatment with BCG. In a multicenter, prospective study, three bladder washouts at different time points during treatment (t (0) = week 0, pre-BCG, t (1) = 6 weeks following TURB, t (2) = 3 months following TURB) were collected for FISH from patients with bladder cancer treated with BCG between 2008 and 2013. Data on bladder cancer recurrence and duration of BCG maintenance therapy were recorded. Thirty-six (31.6%) out of 114 patients developed a recurrence after a median of 6 months (range 2-32). No significant association was found between a positive FISH test at t (0) or t (1) and risk of recurrence (p = 0.79 and p = 0.29). A positive t (2) FISH test was associated with a higher risk of recurrence (p = 0.001). Patients with a positive FISH test 3 months following TURB had a 4.0-4.6 times greater risk of developing a recurrence compared to patients with a negative FISH. Patients with a positive FISH test 3 months following TURB and induction BCG therapy have a higher risk of developing tumor recurrence. FISH can therefore be a useful additional tool for physicians when determining a treatment strategy. FAU - Liem, Esmee I M L AU - Liem EIML AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. e.i.liem@amc.uva.nl. FAU - Baard, Joyce AU - Baard J AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Cauberg, Evelyne C C AU - Cauberg ECC AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Bus, Mieke T J AU - Bus MTJ AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - de Bruin, D Martijn AU - de Bruin DM AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. AD - Department of Biomedical Engineering and Physics, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Laguna Pes, M Pilar AU - Laguna Pes MP AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - de la Rosette, Jean J M C H AU - de la Rosette JJMCH AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - de Reijke, Theo M AU - de Reijke TM AD - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20170902 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (BCG Vaccine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Female MH - Humans MH - Immunotherapy/*methods MH - In Situ Hybridization, Fluorescence/*methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/genetics MH - Prospective Studies MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality/pathology/*therapy PMC - PMC5581817 OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Biomarker OT - Bladder cancer OT - Fluorescence in situ hybridization (FISH) OT - Non-muscle-invasive bladder carcinoma (NMIBC) OT - Recurrence COIS- CONFLICT OF INTEREST: The authors declare no conflicts of interest. HUMAN AND ANIMAL RIGHTS: The medical ethical committee of the Academic Medical Center reviewed the study protocol and concluded that the study did not imply that participants of the study were subjected to procedures or were required to follow rules of behavior according the 'Wet Medisch-wetenschappelijk onderzoek met mensen' (WMO). The WMO is the Medical Research involving Human Beings Act. When the research does not fall under the scope of the WMO, then the protocol does not have to be reviewed by an accredited medical research ethical committee. Therefore, approval of the medical ethical committee was not required. A copy of this decision is available. INFORMED CONSENT: Informed consent was verbally obtained from all participants prior to inclusion. EDAT- 2017/09/04 06:00 MHDA- 2018/06/19 06:00 PMCR- 2017/09/02 CRDT- 2017/09/04 06:00 PHST- 2017/08/04 00:00 [received] PHST- 2017/08/29 00:00 [accepted] PHST- 2017/09/04 06:00 [entrez] PHST- 2017/09/04 06:00 [pubmed] PHST- 2018/06/19 06:00 [medline] PHST- 2017/09/02 00:00 [pmc-release] AID - 10.1007/s12032-017-1033-z [pii] AID - 1033 [pii] AID - 10.1007/s12032-017-1033-z [doi] PST - epublish SO - Med Oncol. 2017 Sep 2;34(10):172. doi: 10.1007/s12032-017-1033-z. PMID- 28848075 OWN - NLM STAT- MEDLINE DCOM- 20171116 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 42 IP - 6 DP - 2017 TI - Gene Expression, DNA Methylation and Prognostic Significance of DNA Repair Genes in Human Bladder Cancer. PG - 2404-2417 LID - 10.1159/000480182 [doi] AB - BACKGROUND/AIMS: This study investigated the gene expression and DNA methylation of selected DNA repair genes (MBD4, TDG, MLH1, MLH3) and DNMT1 in human bladder cancer in the context of pathophysiological and prognostic significance. METHODS: To determine the relationship between the gene expression pattern, global methylation and promoter methylation status, we performed real-time PCR to quantify the mRNA of selected genes in 50 samples of bladder cancer and adjacent non-cancerous tissue. The methylation status was analyzed by methylation-specific polymerase chain reaction (MSP) or digestion of genomic DNA with a methylation-sensitive restriction enzyme and PCR with gene-specific primers (MSRE-PCR). The global DNA methylation level was measured using the antibody-based 5-mC detection method. RESULTS: The relative levels of mRNA for MBD4, MLH3, and MLH1 were decreased in 28% (14/50), 34% (17/50) and 36% (18/50) of tumor samples, respectively. The MBD4 mRNA expression was decreased in 46% of non-muscle invasive tumors (Ta/T1) compared with 11% found in muscle invasive tumors (T2-T4) (P<0.003). Analysis of mRNA expression for TDG did not show any significant differences between Ta/T1 and T2-T4 tumors. The frequency of increased DNMT1 mRNA expression was higher in T2-T4 (52%) comparing to Ta/T1 (16%). The overall methylation rates in tumor tissue were 18% for MBD4, 25% for MLH1 and there was no evidence of MLH3 promoter methylation. High grade tumors had significantly lower levels of global DNA methylation (P=0.04). There was a significant association between shorter survival and increased expression of DNMT1 mRNA (P=0.002), decreased expression of MLH1 mRNA (P=0.032) and the presence of MLH1 promoter methylation (P=0.006). CONCLUSION: This study highlights the importance of DNA repair pathways and provides the first evidence of the role of MBD4 and MLH3 in bladder cancer. In addition, our findings suggest that DNMT1 mRNA and MLH1 mRNA expression, as well as the status of MLH1 promoter methylation, are attractive prognostic markers in this pathology. CI - (c) 2017 The Author(s). Published by S. Karger AG, Basel. FAU - Wojtczyk-Miaskowska, Anita AU - Wojtczyk-Miaskowska A AD - Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland. FAU - Presler, Malgorzata AU - Presler M AD - Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland. FAU - Michajlowski, Jerzy AU - Michajlowski J AD - Department of Urology, Medical University of Gdansk, Gdansk, Poland. FAU - Matuszewski, Marcin AU - Matuszewski M AD - Department of Urology, Medical University of Gdansk, Gdansk, Poland. FAU - Schlichtholz, Beata AU - Schlichtholz B AD - Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland. LA - eng PT - Journal Article DEP - 20170821 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (MLH1 protein, human) RN - 0 (MLH3 protein, human) RN - 0 (RNA, Messenger) RN - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1) RN - EC 2.1.1.37 (DNMT1 protein, human) RN - EC 3.1.- (Endodeoxyribonucleases) RN - EC 3.1.- (MBD4 protein, human) RN - EC 3.6.1.3 (MutL Protein Homolog 1) RN - EC 3.6.1.3 (MutL Proteins) SB - IM MH - Aged MH - Aged, 80 and over MH - DNA (Cytosine-5-)-Methyltransferase 1/genetics/metabolism MH - *DNA Methylation MH - DNA Repair/*genetics MH - Endodeoxyribonucleases/genetics/metabolism MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - MutL Protein Homolog 1/genetics/metabolism MH - MutL Proteins/genetics/metabolism MH - Neoplasm Grading MH - Promoter Regions, Genetic MH - RNA, Messenger/metabolism MH - Real-Time Polymerase Chain Reaction MH - Urinary Bladder Neoplasms/genetics/mortality/*pathology OTO - NOTNLM OT - DNA methylation OT - Dna repair genes OT - Expression OT - Human bladder cancer EDAT- 2017/08/30 06:00 MHDA- 2017/11/29 06:00 CRDT- 2017/08/30 06:00 PHST- 2017/04/06 00:00 [received] PHST- 2017/06/02 00:00 [accepted] PHST- 2017/08/30 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/08/30 06:00 [entrez] AID - 000480182 [pii] AID - 10.1159/000480182 [doi] PST - ppublish SO - Cell Physiol Biochem. 2017;42(6):2404-2417. doi: 10.1159/000480182. Epub 2017 Aug 21. PMID- 28847481 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20190403 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 199 IP - 2 DP - 2018 Feb TI - Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. PG - 401-406 LID - S0022-5347(17)77391-0 [pii] LID - 10.1016/j.juro.2017.08.091 [doi] AB - PURPOSE: We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer. MATERIALS AND METHODS: This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Assessment of failure predictive variables and per year direct hospital resource consumption analysis were secondary outcomes. Descriptive statistical analysis and Cox regression with univariable and multivariable analysis were done. RESULTS: Of 625 patients with nonmuscle invasive bladder cancer 122 with a total of 146 active surveillance events were included in the protocol. Of the events 59 (40.4%) were deemed to require treatment after entering active surveillance. Median time on active surveillance was 11 months (IQR 5-26). Currently 76 patients (62.3%) remain under observation. On univariable analysis only time from the first transurethral resection to the start of active surveillance seemed to be inversely associated with recurrence-free survival (HR 0.99, 95% CI 0.98-1.00, p = 0.027). Multivariable analysis also revealed an association with age at active surveillance start (HR 0.97, 95% CI 0.94-1.00, p = 0.031) and the size of the lesion at the first transurethral resection (HR 1.55, 95% CI 1.06-2.27, p = 0.025). The average specific annual resource consumption savings for each avoided transurethral bladder tumor resection was euro1,378 for each intervention avoided. CONCLUSIONS: Active surveillance might be a reasonable clinical and cost-effective strategy in patients who present with small, low grade pTa/pT1a recurrent papillary bladder tumors. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Lazzeri, Massimo AU - Lazzeri M AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. Electronic address: massimo.lazzeri@humanitas.it. FAU - Vanni, Elena AU - Vanni E AD - Business Operations Office, Humanitas Clinical and Research Center, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Lughezzani, Giovanni AU - Lughezzani G AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Buffi, NicoloMaria AU - Buffi N AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Casale, Paolo AU - Casale P AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Saita, Alberto AU - Saita A AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Morenghi, Emanuela AU - Morenghi E AD - Department of Biostatistics, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. FAU - Forni, Giovanni AU - Forni G AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Cardone, Pasquale AU - Cardone P AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Lista, Giuliana AU - Lista G AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Peschechera, Roberto AU - Peschechera R AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Pasini, Luisa AU - Pasini L AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Zandegiacomo, Silvia AU - Zandegiacomo S AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Benetti, Alessio AU - Benetti A AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Maffei, Davide AU - Maffei D AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy. FAU - Vavassori, Ivano AU - Vavassori I AD - Department of Urology, Ospedale di Treviglio, Bergamo, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy; Business Operations Office, Humanitas Clinical and Research Center, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20170826 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Feb;199(2):406. doi: 10.1016/j.juro.2017.08.126. PMID: 29097189 MH - Aged MH - *Cost-Benefit Analysis MH - Cystectomy/*economics MH - Facilities and Services Utilization/economics/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Italy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis/economics/surgery MH - Neoplasm Staging MH - Prospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/economics/surgery MH - Watchful Waiting/*economics OTO - NOTNLM OT - cost-benefit analysis OT - neoplasm invasiveness OT - risk OT - urinary bladder neoplasms OT - watchful waiting EDAT- 2017/08/30 06:00 MHDA- 2019/04/04 06:00 CRDT- 2017/08/30 06:00 PHST- 2017/08/21 00:00 [accepted] PHST- 2017/08/30 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2017/08/30 06:00 [entrez] AID - S0022-5347(17)77391-0 [pii] AID - 10.1016/j.juro.2017.08.091 [doi] PST - ppublish SO - J Urol. 2018 Feb;199(2):401-406. doi: 10.1016/j.juro.2017.08.091. Epub 2017 Aug 26. PMID- 28844793 OWN - NLM STAT- Publisher LR - 20240227 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) DP - 2017 Aug 1 TI - Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. LID - S1558-7673(17)30208-2 [pii] LID - 10.1016/j.clgc.2017.07.011 [doi] AB - BACKGROUND: Radical cystectomy (RC) represents a treatment option for patients with high-grade non-muscle-invasive bladder cancer (HG-NMIBC); however, perioperative morbidity is not insignificant, particularly in elderly patients. We sought to evaluate the associations of age with utilization and outcomes of RC for HG-NMIBC. PATIENTS AND METHODS: Patients with HG-NMIBC diagnosed between 2004 and 2013 were identified in the National Cancer Database and stratified by age: 80 years. Association between age and treatment with RC was assessed by multivariable logistic regression. Associations between age and overall survival were assessed using the Kaplan-Meier method. A multi-institutional analysis was performed to evaluate the associations of age with perioperative outcomes and survival among patients managed with RC for HG-NMIBC. RESULTS: On multivariable analysis, age was associated with RC utilization, with the lowest usage in patients > 80 years (2.1%; P < .01). Upstaging at RC occurred in 40% of patients with HG-NMIBC, and no association of age with upstaging risk was noted. Significantly inferior overall survival was observed in the patients who were upstaged across age strata (all P < .01). In the multi-institutional cohort, age was not associated with risks of upstaging, receipt of transfusion, 30-/90-day complications, or recurrence-free or cancer-specific survival (all P > .05), whereas upstaging was associated with inferior recurrence-free and cancer-specific survival regardless of age. CONCLUSION: RC for HG-NMIBC is used less frequently in older adults, despite similar risks of pathologic upstaging. As upstaging is associated with inferior survival regardless of age, these data suggest that elderly patients with HG-NMIBC may be at risk for undertreatment. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Parker, William P AU - Parker WP AD - Department of Urology, Mayo Clinic, Rochester, MN; Department of Urology, University of Kansas Medical Center, Kansas City, KS. FAU - Smelser, Woodson AU - Smelser W AD - Department of Urology, University of Kansas Medical Center, Kansas City, KS. FAU - Lee, Eugene K AU - Lee EK AD - Department of Urology, University of Kansas Medical Center, Kansas City, KS. FAU - Habermann, Elizabeth B AU - Habermann EB AD - Department of Health Services Research, Mayo Clinic, Rochester, MN. FAU - Thapa, Prabin AU - Thapa P AD - Department of Health Services Research, Mayo Clinic, Rochester, MN. FAU - Zaid, Harras B AU - Zaid HB AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Griebling, Tomas L AU - Griebling TL AD - Department of Urology, University of Kansas Medical Center, Kansas City, KS; The Landon Center on Aging, University of Kansas Medical Center, Kansas City, KS. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Thompson, R Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Holzbeierlein, Jeffrey M AU - Holzbeierlein JM AD - Department of Urology, University of Kansas Medical Center, Kansas City, KS. FAU - Karnes, R Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Boorjian.Stephen@mayo.edu. LA - eng PT - Journal Article DEP - 20170801 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 OTO - NOTNLM OT - Complications OT - Outcomes OT - Practice patterns OT - Upstaging OT - Utilization EDAT- 2017/08/29 06:00 MHDA- 2017/08/29 06:00 CRDT- 2017/08/29 06:00 PHST- 2017/05/20 00:00 [received] PHST- 2017/06/27 00:00 [revised] PHST- 2017/07/18 00:00 [accepted] PHST- 2017/08/29 06:00 [entrez] PHST- 2017/08/29 06:00 [pubmed] PHST- 2017/08/29 06:00 [medline] AID - S1558-7673(17)30208-2 [pii] AID - 10.1016/j.clgc.2017.07.011 [doi] PST - aheadofprint SO - Clin Genitourin Cancer. 2017 Aug 1:S1558-7673(17)30208-2. doi: 10.1016/j.clgc.2017.07.011. PMID- 28842247 OWN - NLM STAT- MEDLINE DCOM- 20190403 LR - 20220331 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 199 IP - 2 DP - 2018 Feb TI - Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. PG - 416-423 LID - S0022-5347(17)77384-3 [pii] LID - 10.1016/j.juro.2017.08.086 [doi] AB - PURPOSE: Elderly patients with muscle invasive bladder cancer can pose a therapeutic dilemma, given multiple comorbidities which may preclude surgery. In this registry based analysis we investigated treatment patterns and survival outcomes in this group of patients. MATERIALS AND METHODS: We queried the National Cancer Database for muscle invasive (cT2-T4aN0M0) bladder cancer in patients 80 years old or older who were diagnosed from 2004 to 2013. Patients included in study underwent transurethral resection of bladder tumor followed by radical cystectomy, radical cystectomy plus chemotherapy, radiation therapy alone, chemotherapy alone, chemoradiation or no treatment. We performed Kaplan-Meier, log rank and multivariate Cox proportional hazards regression and propensity score matching. RESULTS: A total of 9,270 patients were identified with a median followup of 12.8 months. Median overall survival in patients treated with radical cystectomy alone was 23.2 months (95% CI 19.8-26.6), which was superior to that of chemotherapy alone or radiation therapy alone (p <0.0001). Those treated with chemoradiation had a median overall survival of 27.3 months (95% CI 25.0-29.7), which did not statistically differ from that of radical cystectomy alone (p = 0.39). Surgery plus chemotherapy showed the longest median overall survival of 34.5 months (95% CI 22.2-46.7, vs chemoradiation and radical cystectomy alone p <0.0001). On multivariate analysis and propensity score matching the best overall survival was seen in patients treated with surgery plus chemotherapy and there was no difference in overall survival between chemoradiation and radical cystectomy alone. CONCLUSIONS: In elderly patients with muscle invasive bladder cancer chemoradiation is an alternative definitive treatment strategy with survival equal to that of surgery alone and superior to that of chemotherapy alone or radiation therapy alone. If a patient was able to receive neoadjuvant or adjuvant chemotherapy with surgery, additional survival was observed in this nonrandomized study. CI - Copyright (c) 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Fischer-Valuck, Benjamin W AU - Fischer-Valuck BW AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Rao, Yuan James AU - Rao YJ AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Rudra, Soumon AU - Rudra S AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Przybysz, Daniel AU - Przybysz D AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Germino, Elizabeth AU - Germino E AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Samson, Pamela AU - Samson P AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Baumann, Brian C AU - Baumann BC AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Gay, Hiram AU - Gay H AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. FAU - Michalski, Jeff AU - Michalski J AD - Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: jmichalski@radonc.wustl.edu. LA - eng PT - Journal Article DEP - 20170824 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Feb;199(2):422-423. doi: 10.1016/j.juro.2017.08.129. PMID: 29127777 MH - Age Factors MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/pathology/*therapy MH - Chemoradiotherapy, Adjuvant MH - Cystectomy MH - Databases, Factual MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Registries MH - Retrospective Studies MH - Survival Analysis MH - United States/epidemiology MH - Urinary Bladder Neoplasms/*mortality/pathology/*therapy OTO - NOTNLM OT - aged OT - chemoradiotherapy OT - cystectomy OT - mortality OT - urinary bladder neoplasms EDAT- 2017/08/27 06:00 MHDA- 2019/04/04 06:00 CRDT- 2017/08/27 06:00 PHST- 2017/08/17 00:00 [accepted] PHST- 2017/08/27 06:00 [pubmed] PHST- 2019/04/04 06:00 [medline] PHST- 2017/08/27 06:00 [entrez] AID - S0022-5347(17)77384-3 [pii] AID - 10.1016/j.juro.2017.08.086 [doi] PST - ppublish SO - J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24. PMID- 28837258 OWN - NLM STAT- MEDLINE DCOM- 20171128 LR - 20210109 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) VI - 108 IP - 11 DP - 2017 Nov TI - Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. PG - 2221-2228 LID - 10.1111/cas.13384 [doi] AB - Collagen type 4 alpha 1 (COL4A1) and collagen type 13 alpha 1 (COL13A1) produced by urothelial cancer cells support the vital oncogenic property of tumor invasion. We investigated the diagnostic and prognostic capability of COL4A1 and COL13A1 in voided urine and compared the observed values with those of fragments of cytokeratin-19 (CYFRA21-1), nuclear matrix protein 22 (NMP-22), and voided urine cytology in bladder cancer (BCa). We collected voided urine samples from 154 patients newly diagnosed with BCa, before surgery and from 61 control subjects. Protein levels of COL4A1, COL13A1, CYFRA21-1, and NMP-22 in urine supernatants were measured using enzyme-linked immunosorbent assays. Diagnostic performance and optimal cut-off values were determined by receiver operating characteristic analysis. Urine levels of COL4A1, COL13A1, the combined values of COL4A1 and COL13A1 (COL4A1 + COL13A1), and CYFRA21-1 were significantly elevated in urine from patients with BCa compared to the controls. Among these biomarkers, the optimal cut-off value of COL4A1 + COL13A1 at 1.33 ng/mL resulted in 57.4%, 83.7%, 56.1%, 80.7%, and 91.7% sensitivity for low-grade tumors, high-grade tumors, Ta, T1, and muscle invasive disease, respectively. We evaluated the prognostic value of preoperative urine levels in 130 non-muscle invasive BCa samples after the initial transurethral surgery. A high urinary COL4A1 + COL13A1 was found to be an independent risk factor for intravesical recurrence. Although these data need to be externally validated, urinary COL4A1 and COL13A1 could be a potential diagnostic and prognostic biomarker for BCa. This easy-to-use urinary signature identifies a subgroup of patients with a high probability of recurrence and progression in non-muscle invasive and muscle invasive BCa. CI - (c) 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. FAU - Miyake, Makito AU - Miyake M AUID- ORCID: 0000-0001-9503-7356 AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Nara, Japan. AD - Department of Pathology, Nara Medical University, Nara, Japan. FAU - Onishi, Sayuri AU - Onishi S AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Owari, Takuya AU - Owari T AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Iida, Kota AU - Iida K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Onishi, Kenta AU - Onishi K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Chihara, Yoshitomo AU - Chihara Y AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Aoki, Katsuya AU - Aoki K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara City Hospital, Nara, Japan. FAU - Konishi, Noboru AU - Konishi N AD - Department of Pathology, Nara Medical University, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Nara, Japan. LA - eng PT - Journal Article DEP - 20170915 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 0 (COL14A1 protein, human) RN - 0 (COL4A1 protein, human) RN - 0 (Collagen Type IV) RN - 0 (Glycoproteins) RN - 0 (Keratin-19) RN - 0 (Nuclear Proteins) RN - 0 (antigen CYFRA21.1) RN - 0 (nuclear matrix protein 22) RN - 9007-34-5 (Collagen) SB - IM MH - Aged MH - Antigens, Neoplasm/*urine MH - Biomarkers, Tumor/*urine MH - Collagen/*urine MH - Collagen Type IV/*urine MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Gene Expression Regulation, Neoplastic MH - Glycoproteins/*urine MH - Humans MH - Keratin-19/*urine MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/genetics/pathology MH - Neoplasm Recurrence, Local/pathology/*urine MH - Nuclear Proteins/urine MH - Prognosis MH - Urinary Bladder Neoplasms/pathology/*urine PMC - PMC5665760 OTO - NOTNLM OT - Collagen OT - enzyme-linked immunosorbent assay OT - recurrence OT - urinary bladder neoplasm OT - urine EDAT- 2017/08/25 06:00 MHDA- 2017/11/29 06:00 PMCR- 2017/11/01 CRDT- 2017/08/25 06:00 PHST- 2017/06/21 00:00 [received] PHST- 2017/07/25 00:00 [revised] PHST- 2017/08/21 00:00 [accepted] PHST- 2017/08/25 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/08/25 06:00 [entrez] PHST- 2017/11/01 00:00 [pmc-release] AID - CAS13384 [pii] AID - 10.1111/cas.13384 [doi] PST - ppublish SO - Cancer Sci. 2017 Nov;108(11):2221-2228. doi: 10.1111/cas.13384. Epub 2017 Sep 15. PMID- 28836549 OWN - NLM STAT- MEDLINE DCOM- 20180514 LR - 20181113 IS - 2542-5641 (Electronic) IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 130 IP - 17 DP - 2017 Sep 5 TI - Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma. PG - 2063-2068 LID - 10.4103/0366-6999.213414 [doi] AB - BACKGROUND: The pretreatment neutrophil-to-lymphocyte ratio (NLR) has been reported to be a prognostic factor in various types of carcinomas. The aim of this study was to investigate the prognostic value of pretreatment NLR in a large cohort of Chinese patients with upper tract urothelial carcinoma (UTUC). METHODS: We retrospectively analyzed the medical data of 656 UTUC patients who underwent radical nephroureterectomy (RNU) from 2001 to 2011 at Peking University First Hospital. Receiver operating characteristic (ROC) curve analysis was performed to calculate the optimal cutoff point of pretreatment NLR. Uni- and multi-variate analyses were used to identify the prognostic factors for cancer-specific survival (CSS) and intravesical recurrence-free survival (IVRFS). RESULTS: The optimal cutoff point of pretreatment NLR was 2.40 by ROC curves, by which patients with high NLR (NLR >/=2.40) and low NLR (NLR <2.40) accounted for 314 (47.9%) and 342 (52.1%) patients, respectively. Patients with a high pretreatment NLR tended to have high tumor grades (chi2 = 15.725, P< 0.001), high tumor stages (chi2 = 25.416, P< 0.001), tumor sizes >5 cm (chi2 = 8.213, P= 0.005), ipsilateral hydronephrosis (chi2 = 4.624, P= 0.033), and concomitant carcinoma in situ(CIS) (chi2 = 9.517, P= 0.003). A high pretreatment NLR (hazard ratio [HR] = 1.820, P= 0.001), main tumor diameter >5 cm (HR = 1.789, P= 0.009), lymph node metastasis (HR = 1.863, P= 0.024), and high tumor stage (HR = 1.745, P< 0.001) independently predicted poor CSS after surgery, while only concomitant carcinoma in situ(CIS) (HR = 2.164, P= 0.034), ureteroscopy before surgery (HR = 1.701, P= 0.015), and high tumor grade (HR = 1.645, P= 0.018) were independent predictors of IVRFS after RNU. CONCLUSIONS: The pretreatment NLR was related to some adverse clinicopathological features and was an independent predictor of CSS, although not IVRFS, in Chinese UTUC patients. FAU - Cao, Zhen-Peng AU - Cao ZP AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Guan, Bao AU - Guan B AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Zhao, Guang-Zhi AU - Zhao GZ AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Xiong, Geng-Yan AU - Xiong GY AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Li, Xue-Song AU - Li XS AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. FAU - Zhou, Li-Qun AU - Zhou LQ AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing 100034, China. LA - eng PT - Journal Article PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocytes/*metabolism MH - Male MH - Middle Aged MH - Neutrophils/*metabolism MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Urologic Neoplasms/*immunology/*metabolism PMC - PMC5586174 COIS- There are no conflicts of interest. EDAT- 2017/08/25 06:00 MHDA- 2018/05/15 06:00 PMCR- 2017/09/05 CRDT- 2017/08/25 06:00 PHST- 2017/08/25 06:00 [entrez] PHST- 2017/08/25 06:00 [pubmed] PHST- 2018/05/15 06:00 [medline] PHST- 2017/09/05 00:00 [pmc-release] AID - ChinMedJ_2017_130_17_2063_213414 [pii] AID - CMJ-130-2063 [pii] AID - 10.4103/0366-6999.213414 [doi] PST - ppublish SO - Chin Med J (Engl). 2017 Sep 5;130(17):2063-2068. doi: 10.4103/0366-6999.213414. PMID- 28824945 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 3 IP - 3 DP - 2017 Jul 27 TI - Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer. PG - 173-180 LID - 10.3233/BLC-170103 [doi] AB - OBJECTIVES: To investigate the predictive impact of the proliferation biomarker Ki-67 on the clinical course of patients with initial stage pTa urothelial carcinoma of the bladder (UCB). METHODS: We retrospectively analyzed all patients treated by transurethral resection of bladder tumors (TUR-B) for UCB between 1992-2004 in a single-center. Disease recurrence (>/=pTa UCB) and absent tumor in histopathology, assessed by TUR-B with a non-malignant result for endoscopic suspect bladder lesion displayed endpoints. Immunohistochemical (IHC) analysis of formalin-fixed and paraffin-embedded tissue blocks was performed with an immunostainer using a primary antibody for Ki-67. Semiquantitative evaluation of Ki-67 was performed by three reviewers. Increased proliferation was defined with a cut-off value of >/=50%. Uni- and multivariable binary regression analyses were applied to address prediction of disease recurrence. RESULTS: 215 patients (84% male, median age 69 years at first diagnosis) were evaluable and included to the study. 89 patients stayed disease-free (41%), 126 patients showed recurrence (59%). Recurrence rates of patients with Ki-67 expression <10%, 10-24%, 25-49% and >/=50% were 14.8% vs. 30.8% vs. 63.9% and 80.7%, respectively (p < 0.001). In Kaplan-Meier analysis patients with increased proliferation >/=50% showed a statistically significant worse 10-year recurrence-free survival (19% vs. 57%, p < 0.001). Multivariable regression analysis revealed instillation treatment (p = 0.001) and high proliferation of Ki-67 (p < 0.001) to be independent predictors of recurrence in stage pTa UCB. CONCLUSIONS: High proliferation with Ki-67 expression >/=50% was strongly associated with worse recurrence-free survival in patients with initial stage pTa UCB. Stage pTa UCB patients with increased Ki-67 expression should undergo a strictly follow-up regime comparable to stage pT1 bladder carcinoma, while at least patients with Ki-67 expression <10% might be feasible for more liberate follow-up regime after evaluation of our data in randomized, prospective and multicenter studies. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Shalekenov, Sanzhar AU - Shalekenov S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University of Hamburg, Hamburg, Germany. FAU - van Rhijn, Bastiaan W G AU - van Rhijn BWG AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Brundl, Johannes AU - Brundl J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Lausenmeyer, Eva AU - Lausenmeyer E AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Schafer, Julius AU - Schafer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Giedl, Christian AU - Giedl C AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Evert, Matthias AU - Evert M AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20170727 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC5545917 OTO - NOTNLM OT - Immunohistochemistry OT - Ki-67 OT - recurrence OT - urothelial bladder cancer EDAT- 2017/08/22 06:00 MHDA- 2017/08/22 06:01 PMCR- 2017/08/07 CRDT- 2017/08/22 06:00 PHST- 2017/08/22 06:00 [entrez] PHST- 2017/08/22 06:00 [pubmed] PHST- 2017/08/22 06:01 [medline] PHST- 2017/08/07 00:00 [pmc-release] AID - BLC170103 [pii] AID - 10.3233/BLC-170103 [doi] PST - epublish SO - Bladder Cancer. 2017 Jul 27;3(3):173-180. doi: 10.3233/BLC-170103. PMID- 28824943 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 3 IP - 3 DP - 2017 Jul 27 TI - Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. PG - 161-169 LID - 10.3233/BLC-160086 [doi] AB - OBJECTIVE: Urothelial prostatic involvement (UPI) at the time of radical cystoprostatectomy (RCP) was found associated with worse survival outcomes by several previous reports. Our aim is to evaluate the impact of different levels of UPI on survival outcomes using a large series of male patients treated with RCP. METHODS: Whole step section specimens from 995 male BCa patients were assessed for UPI defined as: no involvement vs. prostatic urethral carcinoma in situ (CIS) vs. lamina propria involvement vs. ductal CIS vs. prostate stromal involvement. Primary end point of the study was predictors of prostatic involvement at RCP and its impact on overall survival after surgery. RESULTS: Prostatic involvement was recorded in 307 (30.9%) patients: 28% with prostatic urethral CIS, 12% with lamina propria involvement, 13% with ductal CIS and 47% with stromal involvement. Median follow-up was 70 months. Patients with stromal involvement had a worse 5-year survival (12%) than those with prostatic urethra CIS (40%), lamina propria involvement (36%), and ductal CIS (35%). Considering predictors of prostatic involvement, multifocal tumor (Odds Ratio [OR]: 6.60, p < 0.001), lymphovascular invasion (OR: 2.61, p < 0.001), lymph node metastases (OR: 2.02, p < 0.001) and CIS (OR: 2.02, p < 0.001) were found associated. Similar predictors were found assessing stromal involvement. CONCLUSIONS: Approximately one third of RCP patients harbor prostatic involvement of urothelial carcinoma. While all UPI are associated with worse overall survival, stromal involvement confers the worst outcome supporting its classification as T4 in the TNM staging. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Italy. FAU - Susani, Martin AU - Susani M AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Korn, Stephan AU - Korn S AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere Academic Hospital, Assistance Publique-Hopitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France. FAU - Seitz, Christian AU - Seitz C AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Gust, Killian AU - Gust K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Haitel, Andrea AU - Haitel A AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Wirth, Gregory AU - Wirth G AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Surgery, Division of Urology, Geneva University Hospital, Geneva, Switzerland. FAU - Robinson, Brian D AU - Robinson BD AD - Department of Pathology, Weill Cornell Medical College, New York, NY, USA. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. FAU - Ozsoy, Mehmet AU - Ozsoy M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Rink, Michael AU - Rink M AD - Division of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article DEP - 20170727 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC5545907 OTO - NOTNLM OT - Bladder cancer OT - incidental OT - prostate cancer invasion OT - radical cystectomy EDAT- 2017/08/22 06:00 MHDA- 2017/08/22 06:01 PMCR- 2017/08/07 CRDT- 2017/08/22 06:00 PHST- 2017/08/22 06:00 [entrez] PHST- 2017/08/22 06:00 [pubmed] PHST- 2017/08/22 06:01 [medline] PHST- 2017/08/07 00:00 [pmc-release] AID - BLC160086 [pii] AID - 10.3233/BLC-160086 [doi] PST - epublish SO - Bladder Cancer. 2017 Jul 27;3(3):161-169. doi: 10.3233/BLC-160086. PMID- 28824318 OWN - NLM STAT- MEDLINE DCOM- 20180504 LR - 20181113 IS - 1449-1907 (Electronic) IS - 1449-1907 (Linking) VI - 14 IP - 9 DP - 2017 TI - Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. PG - 811-819 LID - 10.7150/ijms.19929 [doi] AB - Background: Non-muscle invasive bladder cancer (NMIBC) is associated with high rates of recurrence, resulting in frequent follow-up cystoscopies. We evaluated the use of two point-of-care tests - the nuclear matrix protein 22 (NMP22) and urinary bladder cancer antigen (UBC) Rapid - compared to routine follow-up in patients with a previous history of NMIBC. Methods: 31 patients with cystoscopy-verified active bladder cancer, and 44 follow-up patients without disease as confirmed by cystoscopy were prospectively enrolled. All urine samples were analyzed by voided urine and bladder washing cytology, NMP22 and UBC rapid test (qualitatively and quantitatively). The best cutoff (highest Youden index; >/=6.7 ng/ml) for the quantitative UBC was determined by receiver operating characteristic curves. Results: Voided urine and barbotage cytology resulted in a sensitivity of 25.8% and 32.3%, and a specificity of 100% and 100%, while the NMP22 showed a sensitivity and specificity of 12.9% and 100%, respectively. The qualitative and quantitative UBC Rapid revealed a sensitivity of 61.3% and 64.5%, with a specificity of 77.3% and 81.8%. Barbotage cytology and qualitative UBC test proved to be the best dual combination with the highest overall sensitivity (77.4%). In contrast to barbotage cytology alone, sensitivity increased from 21.4% to 50% for detecting low-grade tumors, and from 43.8% to 100% for high-grade cancers, but reducing specificity from 100% to 77.3%. Conclusion: Compared to urinary cytology, UBC tests alone as well as UBC tests in combination with bladder washing cytology revealed higher sensitivities in detecting low- and high-grade tumors, but at the expense of a lower specificity. Thus, currently cystoscopy cannot be replaced by any of the evaluated methods. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Medical University of Innsbruck, Austria. FAU - Tulchiner, Gennadi AU - Tulchiner G AD - Department of Urology, Medical University of Innsbruck, Austria. FAU - Fritz, Josef AU - Fritz J AD - Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Austria. FAU - Schaefer, Georg AU - Schaefer G AD - Department of Pathology, Division of General Pathology, Medical University of Innsbruck, Austria. FAU - Horninger, Wolfgang AU - Horninger W AD - Department of Urology, Medical University of Innsbruck, Austria. FAU - Heidegger, Isabel AU - Heidegger I AD - Department of Urology, Medical University of Innsbruck, Austria. LA - eng PT - Journal Article DEP - 20170719 PL - Australia TA - Int J Med Sci JT - International journal of medical sciences JID - 101213954 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 0 (Nuclear Proteins) RN - 0 (UBC antigen) RN - 0 (nuclear matrix protein 22) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, Neoplasm/*urine MH - Biomarkers, Tumor/*urine MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology/urine MH - Nuclear Proteins/*urine MH - Prognosis MH - Urinary Bladder Neoplasms/pathology/*urine PMC - PMC5562188 OTO - NOTNLM OT - Bladder Cancer OT - NMP22 OT - UBC OT - biomarkers OT - cytology OT - recurrence OT - surveillance OT - urine markers COIS- Competing interests: The authors declare that there are no conflicts of interest. EDAT- 2017/08/22 06:00 MHDA- 2018/05/05 06:00 PMCR- 2017/01/01 CRDT- 2017/08/22 06:00 PHST- 2017/03/05 00:00 [received] PHST- 2017/05/17 00:00 [accepted] PHST- 2017/08/22 06:00 [entrez] PHST- 2017/08/22 06:00 [pubmed] PHST- 2018/05/05 06:00 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - ijmsv14p0811 [pii] AID - 10.7150/ijms.19929 [doi] PST - epublish SO - Int J Med Sci. 2017 Jul 19;14(9):811-819. doi: 10.7150/ijms.19929. eCollection 2017. PMID- 28815808 OWN - NLM STAT- MEDLINE DCOM- 20190624 LR - 20190624 IS - 1522-2586 (Electronic) IS - 1053-1807 (Linking) VI - 47 IP - 4 DP - 2018 Apr TI - Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation. PG - 1054-1060 LID - 10.1002/jmri.25839 [doi] AB - BACKGROUND: Nonmuscle-invasive bladder cancer (NMIBC, Stage T1 or lower) is treated with transurethral resection (TUR), while muscle-invasive bladder cancer (MIBC, Stage T2 or more) requires neoadjuvant chemotherapy before radical cystectomy. Hence, preoperative differentiation is vital. PURPOSE: To investigate whether intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) can differentiate NMIBC from MIBC and to assess whether there were correlations between IVIM parameters and the Ki-67 labeling index (LI). STUDY TYPE: Retrospective. SUBJECTS: Thirty-six patients diagnosed with bladder cancer confirmed by histopathological findings. FIELD STRENGTH/SEQUENCE: 3.0T magnetic resonance imaging (MRI) DWI with eight b-values ranging from 0 to 1000 s/mm(2) . ASSESSMENT: Molecular diffusion coefficient (D), perfusion-related diffusion coefficient (D*), perfusion fraction (f), and apparent diffusion coefficient (ADC) were calculated by biexponential and monoexponential models fits, respectively. STATISTICAL TESTS: Comparisons were made between the MIBC and NMIBC group, and differences were analyzed by comparing the areas under the receiver-operating characteristic curves (AUCs). The correlations between these parameters and Ki-67 LI were assessed by Spearman's rank correlation analysis. RESULTS: The ADC and D value were significantly lower in patients with MIBC compared to those with NMIBC (P < 0.01). No significant (P > 0.05) differences were observed in D* and f. The AUC of D value (0.894) was significantly (P < 0.05) larger than the ADC value (0.786), with sensitivities and specificities of 95% and 87.5% (D) and 80% and 68.7% (ADC), respectively. In addition, the D and ADC values were significantly correlated with Ki-67 LI (r = -0.785, r = -0.643, respectively; both P < 0.01). DATA CONCLUSION: The D value obtained from IVIM exhibited better performance than conventional DWI for distinguishing NMIBC from MIBC and may serve as a potential imaging biomarker for bladder cancer invasion. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:1054-1060. CI - (c) 2017 International Society for Magnetic Resonance in Medicine. FAU - Wang, Fang AU - Wang F AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. FAU - Wu, Lian-Ming AU - Wu LM AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. FAU - Hua, Xiao-Lan AU - Hua XL AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. FAU - Zhao, Zi-Zhou AU - Zhao ZZ AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. FAU - Chen, Xiao-Xi AU - Chen XX AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. FAU - Xu, Jian-Rong AU - Xu JR AD - Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China. LA - eng PT - Journal Article DEP - 20170817 PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 RN - 0 (PSRC1 protein, human) RN - 0 (Phosphoproteins) SB - IM MH - Adult MH - Aged MH - *Cell Proliferation MH - Diffusion Magnetic Resonance Imaging/*methods MH - Female MH - Humans MH - Image Processing, Computer-Assisted/*methods MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/diagnostic imaging/pathology MH - Phosphoproteins MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Urinary Bladder/diagnostic imaging/pathology MH - Urinary Bladder Neoplasms/*diagnostic imaging/*pathology OTO - NOTNLM OT - bladder cancer OT - diffusion-weighted imaging OT - intravoxel incoherent motion OT - invasiveness EDAT- 2017/08/18 06:00 MHDA- 2019/06/25 06:00 CRDT- 2017/08/18 06:00 PHST- 2017/06/08 00:00 [received] PHST- 2017/07/29 00:00 [accepted] PHST- 2017/08/18 06:00 [pubmed] PHST- 2019/06/25 06:00 [medline] PHST- 2017/08/18 06:00 [entrez] AID - 10.1002/jmri.25839 [doi] PST - ppublish SO - J Magn Reson Imaging. 2018 Apr;47(4):1054-1060. doi: 10.1002/jmri.25839. Epub 2017 Aug 17. PMID- 28811688 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 0970-1915 (Print) IS - 0974-0422 (Electronic) IS - 0970-1915 (Linking) VI - 32 IP - 3 DP - 2017 Jul TI - Genetic Variation in CD166 Gene and Its Association with Bladder Cancer Risk in North Indian Population. PG - 292-300 LID - 10.1007/s12291-016-0606-5 [doi] AB - Adhesion molecules play a key role in cancer progression and tumorigenesis. Genetic polymorphism of adhesion molecules may alter the normal functioning thereby leading to bladder cancer susceptibility. Hence we aimed to evaluate three SNPs of CD166 gene (CD166rs6437585 C/T, CD166rs10511244 C/T, and CD166rs1157 A/G) in bladder cancer patients and normal controls of North Indian population. A total of 270 healthy controls and 240 confirmed bladder cancer patients were recruited for this study. Three SNPs of CD166 gene viz. CD166rs6437585 C/T, CD166rs10511244 C/T, and CD166rs1157 A/G were selected for this study. CD166rs6437585 C/T and CD166rs10511244 C/T were genotyped by Taqman allelic discrimination assay and CD166rs1157 A/G was genotyped by PCR-RFLP. The statistical analysis was done using the SPSS software, version 16.0 (SPSS, Chicago, IL), and p < 0.05 was considered statistically significant. Haplotypic analysis was done by using SNP analyzer version 1.2A. CD166rs6437585 C/T and CD166rs10511244 C/T showed significant association with reduced risk in bladder cancer while CD166rs1157 A/G showed significant high risk along with association at genotypic and allelic levels. Haplotypic analysis showed 1.8-folds risk in CCG combination, whereas CTA and TCG showed significant association with reduced risk. Further stratification on the basis of smoking, tumor grade/stage and BGC therapy revealed no association of these three polymorphic sites of CD166. Our study suggests that CD166rs6437585 C/T and CD166rs10511244 C/T are predictive for the reduced risk of bladder cancer, whereas CD166rs1157 A/G had shown significant association with high risk of bladder cancer in North Indians. This somehow suggests that CD166rs1157 A/G can be used as a marker for risk prediction of bladder cancer. FAU - Verma, Archana AU - Verma A AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh 226014 India. ISNI: 0000 0000 9346 7267. GRID: grid.263138.d FAU - Kapoor, Rakesh AU - Kapoor R AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh 226014 India. ISNI: 0000 0000 9346 7267. GRID: grid.263138.d FAU - Mittal, Rama Devi AU - Mittal RD AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh 226014 India. ISNI: 0000 0000 9346 7267. GRID: grid.263138.d LA - eng PT - Journal Article DEP - 20160826 PL - India TA - Indian J Clin Biochem JT - Indian journal of clinical biochemistry : IJCB JID - 8708303 PMC - PMC5539001 OTO - NOTNLM OT - BCG immunotherapy OT - Bladder cancer OT - CD166 gene (ALCAM) OT - PCR-RFLP COIS- Authors have no conflicts of interest in this work. EDAT- 2017/08/16 06:00 MHDA- 2017/08/16 06:01 PMCR- 2018/07/01 CRDT- 2017/08/17 06:00 PHST- 2016/05/20 00:00 [received] PHST- 2016/08/13 00:00 [accepted] PHST- 2017/08/17 06:00 [entrez] PHST- 2017/08/16 06:00 [pubmed] PHST- 2017/08/16 06:01 [medline] PHST- 2018/07/01 00:00 [pmc-release] AID - 606 [pii] AID - 10.1007/s12291-016-0606-5 [doi] PST - ppublish SO - Indian J Clin Biochem. 2017 Jul;32(3):292-300. doi: 10.1007/s12291-016-0606-5. Epub 2016 Aug 26. PMID- 28803385 OWN - NLM STAT- MEDLINE DCOM- 20180719 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 35 IP - 12 DP - 2017 Dec TI - 'Real-life experience': recurrence rate at 3 years with Hexvix((R)) photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. PG - 1871-1877 LID - 10.1007/s00345-017-2077-6 [doi] AB - PURPOSE: To compare the recurrence rate at 3 years (RR-3y) for non-muscle invasive bladder cancer (NMIBC) between good quality (GQ) PDD-TURBT and GQWL-TURBT where PDD is used in routine practice for all new tumours. METHODS: All new, consecutive, NMIBC that received "good quality" criteria first TURBT across a university hospital service were prospectively recruited to this study over a 4-year period. Data were prospectively collected on all WL-TURBTs performed in 2007/8 and compared with PDD-TURBT from 2009/10. Only resection meeting strict "good quality criteria" were included from each cohort to control for resection quality, then cases were further matched 1:1 based on demographic and pathological criteria. The primary outcome was overall and risk group-specific recurrence rate at 3 years. RESULTS: Of 808 patients recruited, 345 had GQ-TURBT for NMIBC and were included. RR-3y was significantly less for GQ-PDD overall [RR-3y: GQ-PDD: 57/146 (39.0%), GQ-WL: 72/135 (53.3%) OR = 0.56 (0.35-0.90) p = 0.02] and on a 1:1 matched pair basis [RR GQ-PDD: 29/118 (24.6) vs. 59/118 (50.0) OR 0.33 (0.19-0.57) p < 0.001)]. Benefit was most marked in high-risk patients: RR-3y in high-risk patients treated with GQ-PDD was 25/48 (52.1%) vs. 28/35 (80%) for GQ-WL [OR 0.27 (0.10-0.74) p = 0.01]. CONCLUSION: When adopted for all new bladder tumour resections in routine practice, PDD appears to be associated with significantly reduced recurrence rates at 3 years in our "real life" experience, particularly in high-risk patients. FAU - Gallagher, Kevin M AU - Gallagher KM AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Gray, Kayleigh AU - Gray K AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Anderson, Claire H AU - Anderson CH AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Lee, Hannah AU - Lee H AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Stewart, Sarah AU - Stewart S AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Donat, Roland AU - Donat R AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom. param.mariappan@nhs.net. LA - eng PT - Journal Article DEP - 20170812 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM CIN - Aktuelle Urol. 2018 Sep;49(5):383-384. doi: 10.1055/s-0044-100031. PMID: 30184587 MH - Administration, Intravesical MH - Aged MH - Aminolevulinic Acid/administration & dosage/*analogs & derivatives MH - *Cystectomy/adverse effects/methods MH - *Cystoscopy/instrumentation/methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Light MH - Male MH - Neoplasm Invasiveness MH - *Neoplasm Recurrence, Local/epidemiology/pathology MH - Photosensitizing Agents/administration & dosage MH - Prospective Studies MH - Risk Assessment/methods MH - *Surgery, Computer-Assisted/adverse effects/methods MH - *Urinary Bladder Neoplasms/diagnosis/pathology/surgery PMC - PMC5693980 OTO - NOTNLM OT - Bladder cancer OT - Non-muscle invasive bladder cancer (NMIBC) OT - Photodynamic diagnosis (PDD) OT - Transurethral resection of bladder tumour (TURBT) COIS- CONFLICT OF INTEREST: KMG has received conference travel and accommodation contributions from GE Healthcare and IPSEN on one occasion each. PM has been a consultant for GE Healthcare and IPSEN in relation to HEXVIX. All other authors have nothing to disclose. ETHICAL APPROVAL STATEMENT: This study was registered as an audit. All data collection and storage were approved by the Caldicott data guardian. FUNDING: This study was not funded. EDAT- 2017/08/15 06:00 MHDA- 2018/07/20 06:00 PMCR- 2017/08/12 CRDT- 2017/08/14 06:00 PHST- 2017/05/04 00:00 [received] PHST- 2017/07/31 00:00 [accepted] PHST- 2017/08/15 06:00 [pubmed] PHST- 2018/07/20 06:00 [medline] PHST- 2017/08/14 06:00 [entrez] PHST- 2017/08/12 00:00 [pmc-release] AID - 10.1007/s00345-017-2077-6 [pii] AID - 2077 [pii] AID - 10.1007/s00345-017-2077-6 [doi] PST - ppublish SO - World J Urol. 2017 Dec;35(12):1871-1877. doi: 10.1007/s00345-017-2077-6. Epub 2017 Aug 12. PMID- 28802888 OWN - NLM STAT- MEDLINE DCOM- 20180126 LR - 20220330 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 6 DP - 2017 Dec TI - Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis. PG - e1055-e1061 LID - S1558-7673(17)30206-9 [pii] LID - 10.1016/j.clgc.2017.07.009 [doi] AB - INTRODUCTION: The purpose of this study was to identify the prognostic impact of intravesical recurrence (IVR) on oncologic outcomes and the clinicopathologic factors that predict IVR in patients who undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. PATIENTS AND METHODS: Between January 2000 and December 2015, 760 patients with upper tract urothelial carcinoma underwent RNU at 5 institutions in Korea, and patient data were retrospectively collected. Clinicopathologic factors were analyzed for intravesical recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to test the clinicopathologic factors on IVR. RESULTS: Of the 760 patients, 231 (30.3%) patients experienced IVR within 10 months of the median interval between RNU and the first IVR. The overall estimated probabilities of 5-year CSS, intravesical recurrence-free survival, and OS were 84.2%, 63.8%, and 79.2%, respectively. No difference was noted in terms of CSS and OS between the patients who did or did not experience IVR. The multivariate Cox analysis showed an association between IVR and positive hydronephrosis, tumor size, positive preoperative urinary cytology, and ureterorenoscopy before RNU (all P < .05). However, a significantly decreased risk of IVR was associated with female gender, laparoscopic RNU, and receipt of adjuvant systemic chemotherapy (all P < .05). CONCLUSION: The occurrence of IVR following RNU did not affect CSS and OS. Patients with larger tumor size, preoperative hydronephrosis, positive preoperative urinary cytology, and ureterorenoscopy before RNU had a higher risk of IVR following RNU. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Lee, Chan Ho AU - Lee CH AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. FAU - Ku, Ja Yoon AU - Ku JY AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Tae, Bum Sik AU - Tae BS AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. FAU - Choi, Seock Hwan AU - Choi SH AD - Department of Urology, Chilgok Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea. FAU - Kim, Hyun Tae AU - Kim HT AD - Department of Urology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea. FAU - Kim, Tae-Hwan AU - Kim TH AD - Department of Urology, Chilgok Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea. FAU - Kwon, Tae Gyun AU - Kwon TG AD - Department of Urology, Chilgok Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea. FAU - Hwang, Eu Chang AU - Hwang EC AD - Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Jung, Seung Il AU - Jung SI AD - Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Kang, Taek Won AU - Kang TW AD - Department of Urology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Kwon, Dong Deuk AU - Kwon DD AD - Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Ha, Hong Koo AU - Ha HK AD - Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. Electronic address: hongkooha@naver.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170722 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Nephroureterectomy/*methods MH - Regression Analysis MH - Risk Factors MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Bladder cancer development OT - Intravesical recurrence OT - Nephroureterectomy OT - Predictive factors OT - Urothelial cancer EDAT- 2017/08/15 06:00 MHDA- 2018/01/27 06:00 CRDT- 2017/08/14 06:00 PHST- 2017/05/04 00:00 [received] PHST- 2017/07/06 00:00 [revised] PHST- 2017/07/18 00:00 [accepted] PHST- 2017/08/15 06:00 [pubmed] PHST- 2018/01/27 06:00 [medline] PHST- 2017/08/14 06:00 [entrez] AID - S1558-7673(17)30206-9 [pii] AID - 10.1016/j.clgc.2017.07.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Dec;15(6):e1055-e1061. doi: 10.1016/j.clgc.2017.07.009. Epub 2017 Jul 22. PMID- 28801444 OWN - NLM STAT- MEDLINE DCOM- 20180427 LR - 20240612 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 7 IP - 8 DP - 2017 Aug 11 TI - Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. PG - e017913 LID - 10.1136/bmjopen-2017-017913 [doi] LID - e017913 AB - INTRODUCTION: High-risk non-muscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease that can be difficult to predict. While around 25% of cancers progress to invasion and metastases, the remaining majority of tumours remain within the bladder. It is uncertain whether patients with HRNMIBC are better treated with intravesical maintenance BCG (mBCG) immunotherapy or primary radical cystectomy (RC). A definitive randomised controlled trial (RCT) is needed to compare these two different treatments but may be difficult to recruit to and has not been attempted to date. Before undertaking such an RCT, it is important to understand whether such a comparison is possible and how best to achieve it. METHODS AND ANALYSIS: BRAVO is a multi-centre, parallel-group, mixed-methods, individually randomised, controlled, feasibility study for patients with HRNMIBC. Participants will be randomised to receive either mBCG immunotherapy or RC. The primary objective is to assess the feasibility and acceptability of performing the definitive phase III trial via estimation of eligibility and recruitment rates, assessing uptake of allocated treatment and compliance with mBCG, determining quality-of-life questionnaire completion rates and exploring reasons expressed by patients for declining recruitment into the study. We aim to recruit 60 participants from six centres in the UK. Surgical trials with disparate treatment options find recruitment challenging from both the patient and clinician perspective. By building on the experiences of other similar trials through implementing a comprehensive training package aimed at clinicians to address these challenges (qualitative substudy), we hope that we can demonstrate that a phase III trial is feasible. ETHICS AND DISSEMINATION: The study has ethical approval (16/YH/0268). Findings will be made available to patients, clinicians, the funders and the National Health Service through traditional publishing and social media. TRIAL REGISTRATION NUMBER: ISRCTN12509361; Pre results. CI - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. FAU - Oughton, Jamie B AU - Oughton JB AUID- ORCID: 0000-0002-2047-804X AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Poad, Heather AU - Poad H AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Twiddy, Maureen AU - Twiddy M AD - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. FAU - Collinson, Michelle AU - Collinson M AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Hiley, Victoria AU - Hiley V AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Gordon, Kathryn AU - Gordon K AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Johnson, Mark AU - Johnson M AD - Freeman Hospital, Newcastle, UK. FAU - Jain, Sunjay AU - Jain S AD - St James's University Hospital, Leeds, UK. FAU - Noon, Aidan P AU - Noon AP AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Chahal, Rohit AU - Chahal R AD - Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK. FAU - Simms, Matt AU - Simms M AD - Hull and East Yorkshire NHS Trust, Hull, UK. FAU - Dooldeniya, Mohantha AU - Dooldeniya M AD - Mid Yorkshire Hospitals NHS Trus, Wakefield, UK. FAU - Koenig, Phillip AU - Koenig P AD - Airedale NHS Foundation Trust, Keighley, UK. FAU - Goodwin, Louise AU - Goodwin L AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - Brown, Julia M AU - Brown JM AD - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. FAU - Catto, James W F AU - Catto JWF AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. CN - BRAVO study group LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20170811 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) SB - IM CIN - Eur Urol. 2018 Apr;73(4):636. doi: 10.1016/j.eururo.2017.12.007. PMID: 29273406 MH - Adjuvants, Immunologic/administration & dosage/*therapeutic use MH - Administration, Intravesical MH - Adolescent MH - Adult MH - Aged MH - Antineoplastic Agents/administration & dosage/*therapeutic use MH - *Cystectomy MH - Disease Progression MH - Feasibility Studies MH - Female MH - Humans MH - *Immunotherapy MH - Male MH - Middle Aged MH - Research Design MH - Urinary Bladder/drug effects/*pathology/surgery MH - Urinary Bladder Neoplasms/drug therapy/surgery/*therapy PMC - PMC5724134 OTO - NOTNLM OT - BCG OT - RCT OT - feasibility study OT - high-risk non-muscle invasive bladder cancer OT - radical cystectomy OT - surgical trial COIS- Competing interests: None declared. EDAT- 2017/08/13 06:00 MHDA- 2018/04/28 06:00 PMCR- 2017/08/11 CRDT- 2017/08/13 06:00 PHST- 2017/08/13 06:00 [entrez] PHST- 2017/08/13 06:00 [pubmed] PHST- 2018/04/28 06:00 [medline] PHST- 2017/08/11 00:00 [pmc-release] AID - bmjopen-2017-017913 [pii] AID - 10.1136/bmjopen-2017-017913 [doi] PST - epublish SO - BMJ Open. 2017 Aug 11;7(8):e017913. doi: 10.1136/bmjopen-2017-017913. PMID- 28799673 OWN - NLM STAT- MEDLINE DCOM- 20181019 LR - 20201209 IS - 1097-4644 (Electronic) IS - 0730-2312 (Linking) VI - 119 IP - 2 DP - 2018 Feb TI - TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer. PG - 1791-1803 LID - 10.1002/jcb.26340 [doi] AB - The targeting protein for Xenopus kinesin-like protein 2 (TPX2) is associated with the metastasis and prognosis of bladder cancer. p53 is closely related to the progression of bladder cancer. Human glioma pathogenesis-related protein 1 (GLIPR1) is a p53 target gene with antitumor activity. This study aims to explore the interplay between TPX2, p53, and GLIPR1 and its correlation with cell proliferation, invasion, and tumor growth in bladder cancer. Here, Western blot and qRT-PCR analysis revealed that TPX2 at both mRNA and protein levels was up-regulated in bladder carcinoma tissues compared to their paired adjacent normal tissues. Additionally, tissues expressing high TPX2 level exhibited high p53 level and low GLIPR1 level. The expressions of TPX2 and p53 in non-muscle-invasive bladder cancer cells (KK47 and RT4) were lower than those in muscle-invasive bladder cancer cells (T24, 5637, and UM-UC-3), while GLIPR1 showed the converse expression pattern. Further investigation revealed that TPX2 activated the synthesis of p53; and GLIPR1 is up-regulated by wild-type (wt)-p53 but not affected by mutated p53; Additionally, GLIPR1 inhibited TPX2. These data suggested a TPX2-p53-GLIPR1 regulatory circuitry. Meanwhile, TPX2 overexpression promoted while overexpression of GLIPR1 or p53 inhibited bladder cancer growth. Interestingly, in T24 cells with mutated p53, p53 silence suppressed bladder cancer growth. This study identified a novel TPX2-p53-GLIPR1 regulatory circuitry which modulated cell proliferation, migration, invasion, and tumorigenicity of bladder cancer. Our findings provide new insight into underlying mechanisms of tumorigenesis and novel therapeutic options in bladder cancer. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Yan, Liang AU - Yan L AUID- ORCID: 0000-0002-0122-3324 AD - Department of, Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Li, Qi AU - Li Q AD - Department of, Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Yang, Juan AU - Yang J AD - Department of, Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. FAU - Qiao, Baoping AU - Qiao B AD - Department of, Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. LA - eng PT - Journal Article DEP - 20170911 PL - United States TA - J Cell Biochem JT - Journal of cellular biochemistry JID - 8205768 RN - 0 (Cell Cycle Proteins) RN - 0 (GLIPR1 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Microtubule-Associated Proteins) RN - 0 (Neoplasm Proteins) RN - 0 (Nerve Tissue Proteins) RN - 0 (Nuclear Proteins) RN - 0 (TP53 protein, human) RN - 0 (TPX2 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Animals MH - Cell Cycle Proteins/*genetics/metabolism MH - Cell Line, Tumor MH - Cell Movement MH - Cell Proliferation MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Membrane Proteins MH - Mice MH - Microtubule-Associated Proteins/*genetics/metabolism MH - Mutation MH - Neoplasm Proteins/*genetics/metabolism MH - Neoplasm Transplantation MH - Nerve Tissue Proteins/*genetics/metabolism MH - Nuclear Proteins/*genetics/metabolism MH - Prognosis MH - Tumor Suppressor Protein p53/*genetics/metabolism MH - Urinary Bladder Neoplasms/genetics/metabolism/*pathology OTO - NOTNLM OT - GLIPR1 OT - TPX2 OT - apoptosis OT - bladder cancer OT - invasion OT - migration OT - p53 OT - proliferation EDAT- 2017/08/12 06:00 MHDA- 2018/10/20 06:00 CRDT- 2017/08/12 06:00 PHST- 2017/06/11 00:00 [received] PHST- 2017/08/08 00:00 [accepted] PHST- 2017/08/12 06:00 [pubmed] PHST- 2018/10/20 06:00 [medline] PHST- 2017/08/12 06:00 [entrez] AID - 10.1002/jcb.26340 [doi] PST - ppublish SO - J Cell Biochem. 2018 Feb;119(2):1791-1803. doi: 10.1002/jcb.26340. Epub 2017 Sep 11. PMID- 28789622 OWN - NLM STAT- MEDLINE DCOM- 20180423 LR - 20181113 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 17 IP - 1 DP - 2017 Aug 8 TI - Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. PG - 530 LID - 10.1186/s12885-017-3520-1 [doi] LID - 530 AB - BACKGROUND: The independent prognostic role of squamous differentiation in pT1 bladder urothelial carcinoma has not been reported in previous studies. This article describes the impact of squamous differentiation on tumor recurrence and survival, and whether this histologic variant could indeed alter definitive treatment, based on single center-based retrospective data. METHODS: Totally, we retrieved (1)1449 histologically confirmed pT1 bladder urothelial carcinoma patients without histologic variants; (2)227 pT1 bladder urothelial carcinoma patients with squamous differentiation in our institution, from May 2004 to Oct 2015. The total amount of high/low grade urothelial carcinoma patients was 991/685 respectively. Transurethral resection of bladder tumor (TURBT) and intravesical chemotherapy were performed as initial treatments for all the patients. The clinical and pathological characteristics, treatment and survival outcomes were compared between squamous differentiation-positive and squamous differentiation-negative patients. RESULTS: In our study, 14% urothelial carcinoma patients were detected with squamous differentiation. The mean age of all the patients examined was 66.4, of whom 82% were males. The 5-year cancer specific survival rates were 69% for squamous differentiation-positive patients and 91% for squamous differentiation-negative patients (p < 0.001). Recurrence proved to be more common in squamous differentiation-positive patients than in negative patients. In the results of the univariate and multivariate Cox proportional hazard analysis, tumor size, lymphovascular invasion, recurrence and squamous differentiation were confirmed to be the prognostic factors associated with patients' survival. CONCLUSIONS: Squamous differentiation in pT1 bladder urothelial carcinoma is correlated to high risk of recurrence and poor prognosis as an independent prognostic factor. Radical cystectomy is essential for recurred high grade pT1 bladder urothelial carcinoma with squamous differentiation accompanied by lymphovascular invasion. FAU - Li, Gang AU - Li G AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Yu, Jianpeng AU - Yu J AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Song, Hualin AU - Song H AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Zhu, Shimiao AU - Zhu S AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Sun, Libin AU - Sun L AD - Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China. FAU - Shang, Zhiqun AU - Shang Z AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Niu, Yuanjie AU - Niu Y AD - Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China. inkexist@tmu.edu.cn. LA - eng PT - Journal Article DEP - 20170808 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Carcinoma, Squamous Cell/*mortality/*pathology/therapy MH - Carcinoma, Transitional Cell/*mortality/*pathology/therapy MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Proportional Hazards Models MH - Tumor Burden MH - Urinary Bladder Neoplasms/*mortality/*pathology/therapy PMC - PMC5549361 OTO - NOTNLM OT - Bladder cancer OT - Radical cystectomy OT - Recurrence OT - Squamous differentiation OT - Transurethral resection of bladder tumor OT - Urothelial carcinoma COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Our study was approved by an independent ethical committee/institutional review board of the Second Hospital of Tianjin Medical University, Tianjin, China. Written informed consent was obtained from all participants. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/08/10 06:00 MHDA- 2018/04/24 06:00 PMCR- 2017/08/08 CRDT- 2017/08/10 06:00 PHST- 2017/03/06 00:00 [received] PHST- 2017/08/01 00:00 [accepted] PHST- 2017/08/10 06:00 [entrez] PHST- 2017/08/10 06:00 [pubmed] PHST- 2018/04/24 06:00 [medline] PHST- 2017/08/08 00:00 [pmc-release] AID - 10.1186/s12885-017-3520-1 [pii] AID - 3520 [pii] AID - 10.1186/s12885-017-3520-1 [doi] PST - epublish SO - BMC Cancer. 2017 Aug 8;17(1):530. doi: 10.1186/s12885-017-3520-1. PMID- 28781684 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 14 IP - 2 DP - 2017 Aug TI - Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. PG - 2468-2474 LID - 10.3892/ol.2017.6408 [doi] AB - Our previous study reported a clinically applicable prognostic gene classifier for primary non-muscle-invasive bladder cancer (NMIBC). The present study aimed to perform long-term validation of this classifier in the prediction of muscle-invasive disease. Previously published gene expression profiles were used from 176 patients with NMIBC with extended follow-up. Progression was defined as development of muscle invasion or metastasis, and the progression risk score was calculated using the previously developed eight-gene progression classifier. During median follow-up of 72.8 (interquartile range, 37.0-118.7) months, 26 (14.8%) patients progressed to muscle-invasive bladder cancer. The molecular progression risk score was significantly associated with clinicopathological variables, including tumor number, stage, grade and multivariate risk assessment tools (P<0.05 in each case). Multivariate Cox regression analysis revealed that molecular progression risk score was an independent predictor of development of invasive tumor, either as a continuous variable [hazard ratio (HR), 1.489; 95% confidence interval (CI), 1.216-1.823; P<0.001] or as a categorical variable (HR, 5.026; 95% CI, 1.619-15.608; P=0.005). In conclusion, the present results confirmed the clinical utility of the progression-associated gene classifier for prediction of development of muscle invasion in NMIBC. The molecular progression risk score may aid in selecting patients who could benefit from more aggressive therapeutic intervention. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Seo, Sung Pil AU - Seo SP AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Jeong, Pildu AU - Jeong P AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Ha, Yun-Sok AU - Ha YS AD - Department of Urology, School of Medicine, Kyungpook National University Medical Center, Daegu 41404, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Yun, Seok-Joong AU - Yun SJ AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine and Institute for Tumor Research, Cheongju, Chungbuk 28644, Republic of Korea. LA - eng PT - Journal Article DEP - 20170619 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5530216 OTO - NOTNLM OT - bladder cancer OT - gene signature OT - progression OT - risk score EDAT- 2017/08/07 06:00 MHDA- 2017/08/07 06:01 PMCR- 2017/06/19 CRDT- 2017/08/08 06:00 PHST- 2016/10/02 00:00 [received] PHST- 2017/03/21 00:00 [accepted] PHST- 2017/08/08 06:00 [entrez] PHST- 2017/08/07 06:00 [pubmed] PHST- 2017/08/07 06:01 [medline] PHST- 2017/06/19 00:00 [pmc-release] AID - OL-0-0-6408 [pii] AID - 10.3892/ol.2017.6408 [doi] PST - ppublish SO - Oncol Lett. 2017 Aug;14(2):2468-2474. doi: 10.3892/ol.2017.6408. Epub 2017 Jun 19. PMID- 28768702 OWN - NLM STAT- MEDLINE DCOM- 20180202 LR - 20180202 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 71 IP - 2 DP - 2018 Feb TI - Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. PG - 154-160 LID - 10.1136/jclinpath-2017-204562 [doi] AB - AIMS: Inflammation and necrosis have been associated with prognosis in multiple epithelial malignancies. Our objective was to evaluate inflammation and necrosis in a cohort of patients with high-grade urothelial carcinomas of the bladder to determine their association with pathological parameters and their prognostic effect on relapse-free and disease-specific survival. METHODS: A retrospective cohort that underwent radical cystectomy for urothelial carcinomas (n=235) was evaluated for invasive front and central inflammation using the Klintrup-Makinen assessment method. Necrosis was scored using a four-point scale. The relationship of inflammation and necrosis with stage, nodal status, carcinoma in situ, tumour size, margin status and vascular space invasion and the impact on relapse-free and disease-specific survival were calculated using appropriate statistical tests. RESULTS: On multivariate analysis, invasive front inflammation (p=0.003) and necrosis (p=0.000) were independent predictors of relapse-free survival. Both invasive front inflammation (p=0.009) and necrosis (p=0.002) again were independent predictors of disease-specific survival. For pathological features, low invasive front inflammation was associated with lymphovascular space invasion (p=0.008), a positive soft tissue margin (p=0.028) and carcinoma in situ (p=0.042). Necrosis was statistically associated with tumours >3aeuro per thousandcm in size (p=0.013) and carcinoma in situ (p<0.001). CONCLUSIONS: Necrosis and invasive front inflammation are additional histological variables with independent prognostic relevance in high-grade urothelial carcinoma of the bladder. CI - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. FAU - Hodgson, Anjelica AU - Hodgson A AD - Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. FAU - Xu, Bin AU - Xu B AD - Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. FAU - Satkunasivam, Raj AU - Satkunasivam R AD - Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. FAU - Downes, Michelle R AU - Downes MR AD - Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20170802 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*diagnosis/mortality/*pathology/surgery MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Inflammation/*pathology MH - Male MH - Middle Aged MH - Necrosis/*pathology MH - Neoplasm Grading MH - Observer Variation MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*diagnosis/mortality/*pathology/surgery OTO - NOTNLM OT - bladder OT - inflammation OT - necrosis OT - prognosis OT - urothelial COIS- Competing interests: None declared. EDAT- 2017/08/05 06:00 MHDA- 2018/02/03 06:00 CRDT- 2017/08/04 06:00 PHST- 2017/05/09 00:00 [received] PHST- 2017/06/08 00:00 [revised] PHST- 2017/06/13 00:00 [accepted] PHST- 2017/08/05 06:00 [pubmed] PHST- 2018/02/03 06:00 [medline] PHST- 2017/08/04 06:00 [entrez] AID - jclinpath-2017-204562 [pii] AID - 10.1136/jclinpath-2017-204562 [doi] PST - ppublish SO - J Clin Pathol. 2018 Feb;71(2):154-160. doi: 10.1136/jclinpath-2017-204562. Epub 2017 Aug 2. PMID- 28762118 OWN - NLM STAT- MEDLINE DCOM- 20180801 LR - 20181113 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 49 IP - 10 DP - 2017 Oct TI - Laparoscopic and robotic nephroureterectomy: does lymphadenectomy have an impact on the clinical outcome? PG - 1785-1792 LID - 10.1007/s11255-017-1672-1 [doi] AB - PURPOSE: To evaluate the effect of lymphadenectomy (LND) in conjunction with nephroureterectomy on cancer-specific mortality (CSM) and overall survival (OS) for patients with muscle-invasive UTUC. METHODS: A retrospective, multicenter study of patients with UTUC, clinical stage N0M0, who underwent nephroureterectomy between January 2008 and December 2014 was conducted. Outcome measures were OS and CSM. RESULTS: In total, 298 patients underwent robot-assisted or laparoscopic radical nephroureterectomy with a final histological diagnosis of UTUC. LND was performed in 46 (15.4%). One hundred and seventy-two patients (62%) had non-muscle-invasive disease (NMID); 105 patients (38%) had muscle-invasive disease (MID). Median time of follow-up was 43.5 months (95% CI 36.0-47.2). For patients with MID, the 5-year cumulative incidence of all-cause mortality and CSM was 73.5% (95% CI 60.4-86.6) and 52.4% (95% CI 38.9-65.9), respectively (p < 0.0001). There was no significant difference in OS between patients with N1 and patients with N0 disease (p = 0.53). The 5-year OS rates were 30.5% (95% CI 6.6-54.4) and 25.7% (95% CI 10.9-40.5), respectively. This study is limited by its retrospective nature. There may also have been bias in the selection of patients undergoing LND. CONCLUSIONS: Five-year OS and CSM are comparable between patients with N1 and N0 MID. This evidence may support the use of the LND procedure in patients with muscle-invasive UTUC. FAU - Azawi, Nessn H AU - Azawi NH AUID- ORCID: 0000-0001-7519-8654 AD - Department of Urology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. azawinessn@gmail.com. AD - Institute of Clinical Research, University of Southern Denmark, Odense M, Denmark. azawinessn@gmail.com. FAU - Berg, Kasper Drimer AU - Berg KD AD - Department of Urology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. AD - Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. FAU - Thamsborg, Andreas Key Milan AU - Thamsborg AKM AD - Department of Urology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. FAU - Dahl, Claus AU - Dahl C AD - Department of Urology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. FAU - Jepsen, Jan Viberg AU - Jepsen JV AD - Herlev and Gentofte University Hospital, Herlev, Denmark. FAU - Kroman-Andersen, Bjarne AU - Kroman-Andersen B AD - Herlev and Gentofte University Hospital, Herlev, Denmark. FAU - Poulsen, Johan AU - Poulsen J AD - Aalborg University Hospital, Aalborg, Denmark. FAU - Petersen, Helle Handler AU - Petersen HH AD - Aalborg University Hospital, Aalborg, Denmark. FAU - Henning Olsen, L AU - Henning Olsen L AD - Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Aarhus University Hospital, Aarhus, Denmark. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170731 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*mortality/secondary/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/*mortality/pathology/*surgery MH - Laparoscopy MH - *Lymph Node Excision MH - Lymphatic Metastasis MH - Male MH - Neoplasm Invasiveness MH - Nephrectomy/methods MH - Proportional Hazards Models MH - Retrospective Studies MH - Robotic Surgical Procedures MH - Survival Rate MH - Ureteral Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - Cancer-specific survival OT - Lymphadenectomy OT - Nephroureterectomy OT - Overall survival OT - UTUC EDAT- 2017/08/02 06:00 MHDA- 2018/08/02 06:00 CRDT- 2017/08/02 06:00 PHST- 2017/06/04 00:00 [received] PHST- 2017/07/28 00:00 [accepted] PHST- 2017/08/02 06:00 [pubmed] PHST- 2018/08/02 06:00 [medline] PHST- 2017/08/02 06:00 [entrez] AID - 10.1007/s11255-017-1672-1 [pii] AID - 10.1007/s11255-017-1672-1 [doi] PST - ppublish SO - Int Urol Nephrol. 2017 Oct;49(10):1785-1792. doi: 10.1007/s11255-017-1672-1. Epub 2017 Jul 31. PMID- 28753886 OWN - NLM STAT- MEDLINE DCOM- 20190515 LR - 20240610 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 6 DP - 2018 Dec TI - Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. PG - 907-915 LID - S2405-4569(17)30107-4 [pii] LID - 10.1016/j.euf.2017.04.005 [doi] AB - BACKGROUND: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. OBJECTIVE: To identify lipidomic signatures associated with survival and different clinical stages of UCB. DESIGN, SETTING, AND PARTICIPANTS: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n=16), T1 (n=30), T2 (n=43), T3 (n=27), and T4 (n=9); lymphovascular invasion (LVI) positive (n=52) and negative (n=69); and lymph node status N0 (n=28), N1 (n=11), N2 (n=9), N3 (n=3), and Nx (n=75). RESULTS AND LIMITATIONS: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. CONCLUSIONS: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. PATIENT SUMMARY: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Piyarathna, Danthasinghe Waduge Badrajee AU - Piyarathna DWB AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA. FAU - Rajendiran, Thekkelnaycke M AU - Rajendiran TM AD - Department of Pathology, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA; Division of Bioinformatics, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA. FAU - Putluri, Vasanta AU - Putluri V AD - Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Vantaku, Venkatrao AU - Vantaku V AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA. FAU - Soni, Tanu AU - Soni T AD - Division of Bioinformatics, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA. FAU - von Rundstedt, Friedrich-Carl AU - von Rundstedt FC AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Department of Urology, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany. FAU - Donepudi, Sri Ramya AU - Donepudi SR AD - Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Jin, Feng AU - Jin F AD - Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Maity, Suman AU - Maity S AD - Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Ambati, Chandrashekar R AU - Ambati CR AD - Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Dong, Jianrong AU - Dong J AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA. FAU - Godde, Daniel AU - Godde D AD - Department of Pathology, Witten-Herdecke University, Wuppertal, Germany. FAU - Roth, Stephan AU - Roth S AD - Department of Urology Helios Klinikum, Witten-Herdecke University, Wuppertal, Germany. FAU - Storkel, Stephan AU - Storkel S AD - Department of Pathology, Witten-Herdecke University, Wuppertal, Germany. FAU - Degener, Stephan AU - Degener S AD - Department of Urology Helios Klinikum, Witten-Herdecke University, Wuppertal, Germany. FAU - Michailidis, George AU - Michailidis G AD - Department of Statistics, University of Florida, Gainesville, FL, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. FAU - Pennathur, Subramaniam AU - Pennathur S AD - Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor MI 48015. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Coarfa, Cristian AU - Coarfa C AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. FAU - Sreekumar, Arun AU - Sreekumar A AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA. FAU - Putluri, Nagireddy AU - Putluri N AD - Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. Electronic address: putluri@bcm.edu. LA - eng GR - RC1 CA145444/CA/NCI NIH HHS/United States GR - U01 CA167234/CA/NCI NIH HHS/United States GR - T32 HD007495/HD/NICHD NIH HHS/United States GR - R01 CA133458/CA/NCI NIH HHS/United States GR - U54 HD007495/HD/NICHD NIH HHS/United States GR - P30 CA125123/CA/NCI NIH HHS/United States GR - P30 DK056338/DK/NIDDK NIH HHS/United States GR - P30 DK081943/DK/NIDDK NIH HHS/United States GR - U24 DK097153/DK/NIDDK NIH HHS/United States GR - P30 HD007495/HD/NICHD NIH HHS/United States GR - U01 CA111275/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20170420 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 0 (Diglycerides) RN - 0 (Fatty Acids) RN - 0 (Lysophospholipids) RN - 0 (Phosphatidylethanolamines) RN - 0 (Phosphatidylserines) RN - 0 (Phospholipids) RN - 0 (Triglycerides) RN - 0 (lysophosphatidylethanolamine) RN - 107-73-3 (Phosphorylcholine) RN - EC 2.6.- (Nitrogenous Group Transferases) RN - EC 2.7.8.- (phospholipid serine base exchange enzyme) SB - IM EIN - Eur Urol Focus. 2019 Sep;5(5):920. doi: 10.1016/j.euf.2019.08.010. PMID: 31474581 MH - Carcinoma, Transitional Cell/genetics/*metabolism/pathology MH - Case-Control Studies MH - Chromatography, Liquid MH - Computational Biology MH - Diglycerides/metabolism MH - Fatty Acids/*metabolism MH - Female MH - Humans MH - Lipid Metabolism/genetics MH - Lymph Nodes/pathology MH - Lysophospholipids/metabolism MH - Male MH - Mass Spectrometry MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Nitrogenous Group Transferases/genetics/metabolism MH - Phosphatidylethanolamines/metabolism MH - Phosphatidylserines/metabolism MH - Phospholipids/*metabolism MH - Phosphorylcholine/metabolism MH - Principal Component Analysis MH - Triglycerides/*metabolism MH - Urinary Bladder Neoplasms/genetics/*metabolism/pathology PMC - PMC5650548 MID - NIHMS868188 OTO - NOTNLM OT - Lymphovascular invasion OT - Phosphatidylserine synthase OT - Phospholipids OT - Triglycerides EDAT- 2017/07/30 06:00 MHDA- 2019/05/16 06:00 PMCR- 2019/12/01 CRDT- 2017/07/30 06:00 PHST- 2017/03/13 00:00 [received] PHST- 2017/04/07 00:00 [accepted] PHST- 2017/07/30 06:00 [pubmed] PHST- 2019/05/16 06:00 [medline] PHST- 2017/07/30 06:00 [entrez] PHST- 2019/12/01 00:00 [pmc-release] AID - S2405-4569(17)30107-4 [pii] AID - 10.1016/j.euf.2017.04.005 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Dec;4(6):907-915. doi: 10.1016/j.euf.2017.04.005. Epub 2017 Apr 20. PMID- 28753837 OWN - NLM STAT- MEDLINE DCOM- 20190423 LR - 20190423 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 5 DP - 2018 Sep TI - Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. PG - 720-724 LID - S2405-4569(16)30181-X [pii] LID - 10.1016/j.euf.2016.12.005 [doi] AB - BACKGROUND: For patients with bladder cancer (BC) receiving neoadjuvant chemotherapy (NAC), complete pathologic absence of tumor (pT0) at radical cystectomy (RC) is associated with better survival. It is unclear if pT0 status can be attributed to the absence of residual disease (cT0) on transurethral resection of bladder tumor (TURBT) or to the effects of NAC. OBJECTIVE: To determine how often cT0 is associated with pT0 and identify preoperative and postoperative factors associated with survival. DESIGN, SETTING, AND PARTICIPANTS: Between 1995 and 2011, 157 out of 1897 RC patients were identified as stage cT0 after at least two TURBT procedures at a single center. INTERVENTION: RC with or without NAC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Initial TURBT pathology and clinical staging were reviewed. The primary endpoint was pathologic stage at RC. Cox proportional hazards ratios identified factors associated with residual disease at RC, overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS). RESULTS AND LIMITATIONS: Of the cT0 patients, 49.7% (n=78) underwent NAC. pT0 was found in 35.7% (n=56). Residual tumor was found at RC in 63.7% (n=101), of whom 24.8% (n=39) had advanced disease (>/=pT3 or node-positive disease). Positive lymph nodes at RC were found in 12.7% (n=20) of the patients. There was no significant difference in achieving pT0 status between patients with and without NAC. The presence of advanced BC was most predictive of OS. NAC was associated with longer OS and RFS. During median follow-up of 6.3 yr, the 5-yr RFS was 81% for those with non-advanced disease and 46% for advanced BC (p<0.001). The 5-yr OS rate was 77% for non-advanced BC and 46% for invasive BC (p<0.001). Limitations include the retrospective design. CONCLUSIONS: Complete TURBT does not predict pT0 at RC. A notable fraction of patients with cT0 bladders have locally advanced and/or lymph node-positive disease. These findings may be of value when counseling patients on bladder preservation strategies for muscle-invasive BC. PATIENT SUMMARY: Among patients thought to have had the entire tumor in their bladder removed via cystoscopy, a majority have persistent tumors when their bladders were removed. In a sizable proportion, these persistent tumors were even more invasive than initially thought. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kukreja, Janet Baack AU - Kukreja JB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: janet.kukreja@gmail.com. FAU - Porten, Sima AU - Porten S AD - Department of Urology, University of California San Francisco, San Francisco, CA, USA. FAU - Golla, Vishnukamal AU - Golla V AD - Department of Urology, University of California Los Angeles, Los Angeles, CA, USA. FAU - Ho, Philip Levy AU - Ho PL AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Noguera-Gonzalez, Graciela AU - Noguera-Gonzalez G AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P N AU - Dinney CPN AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20170118 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Aged MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/methods MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Neoplasm, Residual/*pathology MH - Postoperative Period MH - Predictive Value of Tests MH - Preoperative Care MH - Retrospective Studies MH - Urinary Bladder/pathology/*surgery MH - Urinary Bladder Neoplasms/drug therapy/mortality/pathology/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Disease-free survival OT - Neoplasm staging OT - Treatment outcome EDAT- 2017/07/30 06:00 MHDA- 2019/04/24 06:00 CRDT- 2017/07/30 06:00 PHST- 2016/10/18 00:00 [received] PHST- 2016/11/30 00:00 [revised] PHST- 2016/12/08 00:00 [accepted] PHST- 2017/07/30 06:00 [pubmed] PHST- 2019/04/24 06:00 [medline] PHST- 2017/07/30 06:00 [entrez] AID - S2405-4569(16)30181-X [pii] AID - 10.1016/j.euf.2016.12.005 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Sep;4(5):720-724. doi: 10.1016/j.euf.2016.12.005. Epub 2017 Jan 18. PMID- 28753816 OWN - NLM STAT- MEDLINE DCOM- 20190124 LR - 20191008 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 3 IP - 6 DP - 2017 Dec TI - Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. PG - 577-583 LID - S2405-4569(17)30155-4 [pii] LID - 10.1016/j.euf.2017.06.004 [doi] AB - BACKGROUND: High-risk non-muscle-invasive bladder cancer (NMIBC) that invades into the lamina propria is frequently understaged and is associated with a risk of lymph node metastasis and death. OBJECTIVE: To identify high-risk features (HRFs) for NMIBC that may identify patients with poorer prognosis who may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We performed a single-center retrospective review of patients who underwent RC for NMIBC with invasion into the lamina propria between 1995 and 2013. HRFs included hydronephrosis, abnormal examination under anesthesia, lymphovascular invasion, or variant histology. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathology at RC, and overall (OS) and disease-specific (DSS) survival were evaluated and analyzed by Fisher's exact test, Student t test, Cox proportional hazards regression analysis, and the Kaplan-Meier method. RESULTS AND LIMITATIONS: We identified 336 patients with a median follow-up of 130 mo. Of these, 159 (47%) had no HRF, 140 (41.5%) had one HRF, and 37 (11%) had >/=2 HRFs. At RC, patients with >/=2 HRFs had a significantly higher rate of pathologic T stage upstaging and lymph node metastasis (p<0.05). Median OS was 139 mo for those with no HRF, 127 mo for those with one HRF, and 56 mo for those with >/=2 HRF (p=0.0057). HRFs are also associated with a decreased DSS (p=0.0009). Patients with >/=2 HRFs (11/37) who received NAC showed improved OS (21% vs 55% 5-yr OS, p=0.0353) and trended toward an improvement in DSS (25% vs 56% 5-yr OS, p=0.0716) compared with RC alone. CONCLUSIONS: The presence of >/=2 HRFs in NMIBC invading the lamina propria is associated with worse pathology at RC and a significant decrease in OS and DSS. NAC appears to provide benefit for these patients. Limitations include retrospective design and limited sample size. PATIENT SUMMARY: The presence of high-risk features in urothelial cancer with invasion into the lamina propria has a worse prognosis that may be mitigated by neoadjuvant chemotherapy. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Metcalfe, Michael J AU - Metcalfe MJ AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Ferguson, James E AU - Ferguson JE AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Li, Roger AU - Li R AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Xiao, Lianchun AU - Xiao L AD - Department of Biostatistics at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Czerniak, Bogdan A AU - Czerniak BA AD - Department of Pathology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Siefker-Radtke, Arlene AU - Siefker-Radtke A AD - Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Pretzsch, Shanna M AU - Pretzsch SM AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Navai, Neema AU - Navai N AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology at Johns Hopkins, Baltimore, Maryland, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Campbell, Mathew AU - Campbell M AD - Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Dinney, Colin AU - Dinney C AD - Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: cdinney@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20170713 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 RN - 5V9KLZ54CY (Vinblastine) RN - 80168379AG (Doxorubicin) RN - Q20Q21Q62J (Cisplatin) RN - YL5FZ2Y5U1 (Methotrexate) RN - M-VAC protocol SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use MH - Chemotherapy, Adjuvant/methods MH - Cisplatin/administration & dosage MH - Cystectomy/methods MH - Disease-Free Survival MH - Doxorubicin/administration & dosage MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Methotrexate/administration & dosage MH - Middle Aged MH - Mucous Membrane MH - Muscle Neoplasms/*drug therapy/pathology/surgery MH - Neoplasm Invasiveness MH - Preoperative Care/methods MH - Risk Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery MH - Vinblastine/administration & dosage PMC - PMC5767145 MID - NIHMS884652 OTO - NOTNLM OT - Cystectomy OT - High-risk features OT - Neoadjuvant chemotherapy OT - Non-muscle-invasive bladder cancer OT - Superficial bladder cancer OT - T1 high-grade bladder cancer OT - Urothelial cancer OT - Variant histology EDAT- 2017/07/30 06:00 MHDA- 2019/01/25 06:00 PMCR- 2018/12/01 CRDT- 2017/07/30 06:00 PHST- 2017/04/06 00:00 [received] PHST- 2017/05/23 00:00 [revised] PHST- 2017/06/07 00:00 [accepted] PHST- 2017/07/30 06:00 [pubmed] PHST- 2019/01/25 06:00 [medline] PHST- 2017/07/30 06:00 [entrez] PHST- 2018/12/01 00:00 [pmc-release] AID - S2405-4569(17)30155-4 [pii] AID - 10.1016/j.euf.2017.06.004 [doi] PST - ppublish SO - Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13. PMID- 28753746 OWN - NLM STAT- MEDLINE DCOM- 20190212 LR - 20190215 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 4 IP - 1 DP - 2018 Jan TI - Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. PG - 87-93 LID - S2405-4569(16)30064-5 [pii] LID - 10.1016/j.euf.2016.06.004 [doi] AB - BACKGROUND: Decision making in T1 high-grade bladder cancer patients remains a challenging issue in urologic practice. OBJECTIVE: To assess the feasibility and potential prognostic role of three different substaging systems in specimens from both primary and second transurethral resection (TUR) of the bladder in T1 high-grade bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS: A total of 250 consecutive, confirmed pure transitional T1 high-grade bladder tumors submitted to second TUR entered the retrospective study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Feasibility of two already clinically tested microstaging systems (anatomy-based T1a/T1b/T1c and micrometric T1m/T1e with 0.5-mm thresholds of invasion) and that of a micrometric substage designed by the authors and based on a 1-mm threshold of invasion (Rete Oncologica Lombarda [ROL] system) was assessed by five independent uropathologists on both first and second TUR specimens. Univariable Cox proportional hazards models were attempted to identify significant independent predictors of recurrence and progression after TUR. Kaplan-Meier curves were plotted to compare different substaging methods analyzing recurrence and progression. RESULTS AND LIMITATIONS: The ROL system proved to be feasible in nearly all cases at both first and second TUR. Median follow-up was 60 mo. The univariate Cox regression analysis documented the ROL substage (ROL2 vs ROL1) to be the only statistically significant predictor of progression (hazard ratio: 2.01; 95% CI, 1.03-3.79; p<0.03). For the first time to our knowledge, the substage was investigated and used to assess T1 tumors found at second TUR, registering a high rate of feasibility. CONCLUSIONS: T1 microstaging using different procedures is feasible on both primary- and second-TUR specimens. A high rate of feasibility may be expected for T1m/T1e and ROL systems. The clinical role of microstaging on second TUR remains to be defined. PATIENT SUMMARY: The Rete Oncologica Lombarda system showed feasible results in T1 high-grade bladder tumors. Our substratification was predictive of progression of disease. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Colombo, Renzo AU - Colombo R AD - Division of Oncology/Urology, Urological Research Institute, IRCCS, Ospedale S. Raffaele, Milan, Italy. FAU - Hurle, Rodolfo AU - Hurle R AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Milan, Italy. FAU - Moschini, Marco AU - Moschini M AD - Division of Oncology/Urology, Urological Research Institute, IRCCS, Ospedale S. Raffaele, Milan, Italy. Electronic address: marco.moschini87@gmail.com. FAU - Freschi, Massimo AU - Freschi M AD - Department of Pathology, Ospedale San Raffaele, Milan, Italy. FAU - Colombo, Piergiuseppe AU - Colombo P AD - Department of Pathology, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Milan, Italy. FAU - Colecchia, Maurizio AU - Colecchia M AD - Uropathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Ferrari, Lucia AU - Ferrari L AD - Department of Pathology, Azienda Ospedaliera Sant'Anna, Como, Italy. FAU - Luciano, Roberta AU - Luciano R AD - Department of Pathology, Ospedale San Raffaele, Milan, Italy. FAU - Conti, Giario AU - Conti G AD - Department of Urology, Azienda Ospedaliera Sant'Anna, Como, Italy. FAU - Magnani, Tiziana AU - Magnani T AD - Prostate Cancer Programme, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Capogrosso, Paolo AU - Capogrosso P AD - Division of Oncology/Urology, Urological Research Institute, IRCCS, Ospedale S. Raffaele, Milan, Italy. FAU - Conti, Andrea AU - Conti A AD - Department of Urology, Azienda Ospedaliera Sant'Anna, Como, Italy. FAU - Pasini, Luisa AU - Pasini L AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Milan, Italy. FAU - Burgio, Giusy AU - Burgio G AD - Division of Oncology/Urology, Urological Research Institute, IRCCS, Ospedale S. Raffaele, Milan, Italy. FAU - Guazzoni, Giorgio AU - Guazzoni G AD - Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Humanitas University, Milan, Italy. FAU - Patriarca, Carlo AU - Patriarca C AD - Department of Pathology, Azienda Ospedaliera Sant'Anna, Como, Italy. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20160615 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Disease Progression MH - Feasibility Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging/methods MH - Predictive Value of Tests MH - Retrospective Studies MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery MH - Urologic Surgical Procedures/*adverse effects/methods OTO - NOTNLM OT - Grade OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence OT - Stage OT - Substaging system EDAT- 2017/07/30 06:00 MHDA- 2019/02/13 06:00 CRDT- 2017/07/30 06:00 PHST- 2016/03/24 00:00 [received] PHST- 2016/05/13 00:00 [revised] PHST- 2016/06/06 00:00 [accepted] PHST- 2017/07/30 06:00 [pubmed] PHST- 2019/02/13 06:00 [medline] PHST- 2017/07/30 06:00 [entrez] AID - S2405-4569(16)30064-5 [pii] AID - 10.1016/j.euf.2016.06.004 [doi] PST - ppublish SO - Eur Urol Focus. 2018 Jan;4(1):87-93. doi: 10.1016/j.euf.2016.06.004. Epub 2016 Jun 15. PMID- 28752351 OWN - NLM STAT- MEDLINE DCOM- 20180416 LR - 20181202 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 22 IP - 5 DP - 2017 Oct TI - The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. PG - 817-825 LID - 10.1007/s10147-017-1171-5 [doi] AB - The aim of this study was to evaluate the evidence regarding the neutrophil-to-lymphocyte ratio (NLR) as a factor predictive of survival in bladder cancer patients. A search of PubMed and Embase for relevant studies between January 1, 1966 and November 10, 2016 was performed with the terms [NLR OR (neutrophil lymphocyte ratio)] AND [(bladder cancer) OR BCa OR NMIBC OR MIBC]. Inclusion required studies published in English containing bladder cancer patients and evaluating NLR as a predictive factor. Endpoints of NLR and survival data were extracted for pooled analysis. The pooled results showed that an elevated NLR was a predictor for poor overall survival (OS) [hazard ratio (HR) = 1.19, 95% confidence interval (CI) 1.07-1.31], cancer-specific survival (CSS) (HR = 1.40, 95% CI 1.17-1.69), recurrence-free survival (RFS) (HR = 1.58, 95% CI 1.24-2.03) and progression-free survival (PFS) (HR = 1.33, 95% CI 1.19-1.49) in patients with bladder cancer. Heterogeneity between studies was observed for OS, CSS and RFS, but not for PFS. Publication bias was detected for all these outcomes. Our results showed that elevated NLR might be valuable as a predictive factor of survival in bladder cancer patients. FAU - Tang, Xingxing AU - Tang X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. FAU - Du, Peng AU - Du P AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. dupeng9000@126.com. FAU - Yang, Yong AU - Yang Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China. LA - eng GR - 7142035/Beijing Municipal Natural Science Foundation/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20170727 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Blood Cell Count MH - Disease-Free Survival MH - Humans MH - *Lymphocyte Count MH - Lymphocytes MH - Neutrophils/*pathology MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/*mortality/*pathology OTO - NOTNLM OT - Bladder cancer OT - Meta-analysis OT - Neutrophil-to-lymphocyte ratio OT - Oncological outcome EDAT- 2017/07/29 06:00 MHDA- 2018/04/17 06:00 CRDT- 2017/07/29 06:00 PHST- 2017/03/30 00:00 [received] PHST- 2017/07/20 00:00 [accepted] PHST- 2017/07/29 06:00 [pubmed] PHST- 2018/04/17 06:00 [medline] PHST- 2017/07/29 06:00 [entrez] AID - 10.1007/s10147-017-1171-5 [pii] AID - 10.1007/s10147-017-1171-5 [doi] PST - ppublish SO - Int J Clin Oncol. 2017 Oct;22(5):817-825. doi: 10.1007/s10147-017-1171-5. Epub 2017 Jul 27. PMID- 28752222 OWN - NLM STAT- MEDLINE DCOM- 20181026 LR - 20190816 IS - 1532-2807 (Electronic) IS - 1219-4956 (Linking) VI - 24 IP - 3 DP - 2018 Jul TI - High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting. PG - 567-574 LID - 10.1007/s12253-017-0279-2 [doi] AB - Differentiation of noninvasive from invasive papillary urothelial carcinoma can be challenging due to inability of proper orientation and thermal damage of transurethrally obtained material. The aim of this study was to analyze the presence and extent of peritumoral retractions in pT1 compared to pTa papillary urothelial carcinoma. Since peritumoral retractions may result from altered expression profiles of extracellular matrix proteins, we additionally analyzed the expression of matrix metalloproteinase 2 (MMP-2) and interleukin 8 (IL-8) in these tumors. The study comprised 50 noninvasive (pTa) and 50 invasive (pT1) cases of transurethrally obtained primary papillary urothelial carcinomas. The invasive nature of nests showing peritumoral retractions was confirmed immunohistochemically using antibody against collagen IV. Staining for MMP-2 and IL-8 was evaluated semiquantitatively using immunohistochemical staining index, calculated by multiplying the percentage of positive cells and staining intensity. Peritumoral retractions were found in 32% of pT1 carcinomas but in none of the pTa carcinomas. All tumors showing peritumoral retraction were high grade tumors. There was no statistically significant correlation between the expression of MMP-2 or IL-8 and the presence of peritumoral retractions or stage of the tumor (pTa vs. pT1). A statistically significant but weak correlation was found between MMP-2 and IL-8 expression (chi2-test, p=0,015). There was no statistically significant correlation between the presence of peritumoral retractions or MMP-2 expression and tumor recurrence and progression. Our study shows that, in doubtful cases, when differentiating between pTa and pT1 stages of papillary urothelial carcinoma, the presence of peritumoral retractions could favor the diagnosis of invasive neoplasm. FAU - Dzombeta, Tihana AU - Dzombeta T AUID- ORCID: 0000-0002-8858-3524 AD - Department of Pathology, School of Medicine, University of Zagreb, Salata 10, 10 000, Zagreb, Croatia. tihana.dzombeta@mef.hr. AD - Department of Pathology, Clinical Hospital Centre Sestre milosrdnice, Vinogradska 29, 10 000, Zagreb, Croatia. tihana.dzombeta@mef.hr. FAU - Kruslin, Bozo AU - Kruslin B AD - Department of Pathology, School of Medicine, University of Zagreb, Salata 10, 10 000, Zagreb, Croatia. AD - Department of Pathology, Clinical Hospital Centre Sestre milosrdnice, Vinogradska 29, 10 000, Zagreb, Croatia. LA - eng PT - Journal Article DEP - 20170727 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Biomarkers, Tumor) RN - 0 (CXCL8 protein, human) RN - 0 (Interleukin-8) RN - EC 3.4.24.24 (MMP2 protein, human) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/metabolism/*pathology/surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Interleukin-8/metabolism MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/metabolism/*pathology/surgery MH - Survival Rate MH - Urinary Bladder Neoplasms/metabolism/*pathology/surgery OTO - NOTNLM OT - Interleukin 8 OT - Matrix metalloproteinase 2 OT - Papillary urothelial carcinoma OT - Peritumoral retraction clefting OT - Urinary bladder EDAT- 2017/07/29 06:00 MHDA- 2018/10/27 06:00 CRDT- 2017/07/29 06:00 PHST- 2016/07/26 00:00 [received] PHST- 2017/07/12 00:00 [accepted] PHST- 2017/07/29 06:00 [pubmed] PHST- 2018/10/27 06:00 [medline] PHST- 2017/07/29 06:00 [entrez] AID - 10.1007/s12253-017-0279-2 [pii] AID - 10.1007/s12253-017-0279-2 [doi] PST - ppublish SO - Pathol Oncol Res. 2018 Jul;24(3):567-574. doi: 10.1007/s12253-017-0279-2. Epub 2017 Jul 27. PMID- 28739768 OWN - NLM STAT- MEDLINE DCOM- 20170803 LR - 20170906 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 8 DP - 2017 Aug TI - Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer. PG - 4659-4663 AB - AIM: To evaluate the correlation between the neutrophil-to-lymphocyte ratio (NLR) and histopathological characteristics of bladder cancer. MATERIALS AND METHODS: A retrospective analysis was performed on a cohort of patients (n=302) who were diagnosed with bladder cancer and underwent transurethral resection of bladder tumor or cystectomy between 2009 and 2016. The pathological outcomes were compared between patients with low NLR and those with high NLR with a cut-off value of 2.5, and a logistic regression analysis was performed to find potential predictors of pathological tumor outcomes. RESULTS: Patients with high-grade disease had significantly higher NLRs compared to those with low-grade disease (median NLR=4.42 vs. 3.42, p<0.001). Univariate analysis suggested that age, neutrophil count and NLR, as a continuous or binary variable, were significantly associated with high-grade disease. Multivariate analysis suggested that age and NLR, as a continuous variable, were predictors of pathologically high-grade disease. CONCLUSION: Preoperative NLR was found to be associated with pathological tumor grading, but was not associated with pathological tumor staging in patients with bladder cancer. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Tang, Xingxing AU - Tang X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China. FAU - Wang, Shuo AU - Wang S AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China. FAU - An, Chao AU - An C AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China. FAU - Du, Peng AU - Du P AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China dupeng9000@126.com. FAU - Yang, Yong AU - Yang Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, P.R. China. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Aged MH - Female MH - Humans MH - *Leukocyte Count MH - *Lymphocytes MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Metastasis MH - Neoplasm Staging MH - *Neutrophils MH - Preoperative Period MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*blood/*pathology/surgery OTO - NOTNLM OT - Neutrophil to lymphocyte ratio OT - bladder cancer OT - pathological outcome EDAT- 2017/07/26 06:00 MHDA- 2017/08/05 06:00 CRDT- 2017/07/26 06:00 PHST- 2017/05/02 00:00 [received] PHST- 2017/06/07 00:00 [revised] PHST- 2017/06/13 00:00 [accepted] PHST- 2017/07/26 06:00 [entrez] PHST- 2017/07/26 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] AID - 37/8/4659 [pii] AID - 10.21873/anticanres.11869 [doi] PST - ppublish SO - Anticancer Res. 2017 Aug;37(8):4659-4663. doi: 10.21873/anticanres.11869. PMID- 28738880 OWN - NLM STAT- MEDLINE DCOM- 20180207 LR - 20260127 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 12 IP - 1 DP - 2017 Jul 24 TI - Level of mitoses in non-muscle invasive papillary urothelial carcinomas (pTa and pT1) at initial bladder biopsy is a simple and powerful predictor of clinical outcome: a multi-center study in South Korea. PG - 54 LID - 10.1186/s13000-017-0639-y [doi] LID - 54 AB - BACKGROUND: Histologic grade is the most important predictor of the clinical outcome of non-muscle invasive (Ta, T1) papillary urothelial carcinoma (NMIPUCa), but its ambiguous criteria diminish its power to predict recurrence/progression for individual patients. We attempted to find an objective and reproducible histologic predictor of NMIPUCa that correlates well with the clinical outcome. METHODS: A total of 296 PUCas were collected from the Departments of Surgical Pathology of 11 institutions in South Korea. The clinical outcome was grouped into no event (NE), recurrence (R), and progression (P) categories. All 25 histological parameters were numerically redefined. The clinical pathology of each case was reviewed individually by 11 pathologists from 11 institutions based on the 2004 WHO criteria and afterwards blindly evaluated by two participants, based on our proposed parameters. Univariate and multivariate logistic regression analyses were performed using the R software package. RESULTS: The level of mitoses was the most reliable parameter for predicting the clinical outcome. We propose a four-tiered grading system based on mitotic count (> 10/10 high-power fields), nuclear pleomorphism (smallest-to-largest ratio of tumor nuclei >20), presence of divergent histology, and capillary proliferation (> 20 capillary lumina per papillary core). CONCLUSIONS: The level of mitoses at the initial bladder biopsy and transurethral resection (TUR) specimen appeared to be an independent predictor of the Ta PUCa outcome. Other parameters include the number of mitoses, nuclear pleomorphism, divergent histology, and capillary proliferation within the fibrovascular core. These findings may improve selection of patients for a therapeutic strategy as compared to previous grading systems. FAU - Kwon, Ji Eun AU - Kwon JE AD - Department of Pathology, Ajou University school of Medicine, Suwon, South Korea. FAU - Cho, Nam Hoon AU - Cho NH AD - Department of Pathology, Yonsei Medical College of Medicine, Seoul, South Korea. FAU - Choi, Yeong-Jin AU - Choi YJ AD - Department of Pathology, Seoul St Mary's Hospital, The Catholic University, Seoul, South Korea. FAU - Lim, So Dug AU - Lim SD AD - Department of Pathology, Konkuk University Medical center, Konkuk University School of Medicine, Seoul, South Korea. FAU - Cho, Yong Mee AU - Cho YM AD - Department of Pathology, Asan Medical Center, Ulsan College of Medicine, Seoul, South Korea. FAU - Jun, Sun Young AU - Jun SY AD - Department of Pathology, Inchun St. Mary's Hospital, The Catholic University, Incheon, South Korea. FAU - Park, Sanghui AU - Park S AD - Department of Pathology, College of Medicine, Ewha Womens University, Seoul, South Korea. FAU - Kim, Young A AU - Kim YA AD - Department of Pathology, SMG-SNU Boramae Medical Center, Seoul, South Korea. FAU - Kim, Sung-Sun AU - Kim SS AD - Departments of Pathology, Chonnam National University Medical school, Gwangju, South Korea. FAU - Choe, Mi Sun AU - Choe MS AD - Department of Pathology, Keimyung University School of Medicine, Daegu, South Korea. FAU - Lee, Jung-Dong AU - Lee JD AD - Office of Biostatistics, Ajou University, School of Medicine, Suwon, South Korea. FAU - Kang, Dae Yong AU - Kang DY AD - Office of Biostatistics, Ajou University, School of Medicine, Suwon, South Korea. FAU - Ro, Jae Y AU - Ro JY AD - Department of Pathology, Houston Methodist Hospital, Weill Medical College of Cornell University, New York, USA. FAU - Kim, Hyun-Jung AU - Kim HJ AD - Department of Pathology, Inje University Sanggye Paik Hospital, 1342, Dongilro, Nowon-gu, Seoul, South Korea. hjkim@paik.ac.kr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170724 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 SB - IM MH - Aged MH - Biopsy MH - Carcinoma, Transitional Cell/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitosis MH - Neoplasm Grading/*methods MH - Prognosis MH - Republic of Korea MH - Urinary Bladder Neoplasms/*pathology PMC - PMC5525253 OTO - NOTNLM OT - Clinical outcome OT - Mitotic level OT - Papillary urothelial carcinoma OT - Predictor COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the hospital's institutional review boards; (SGPAIK2014-10-021)(1), (Ajou Univ. AJIRB-14-692)(2), (Yonsei University Health system, Severance Hospital IRB, 4-2015-1172)(3), (KCMCIRB, KC13SISI0909)(4), (KUH1210051)(5), (AMC IRB2013-107)(6), (Inchun St. Mary's Hospital IRB, OC15ZISE0090)(7), (EUMC 2015-01-021-001)(8), (Boramae Hospital IRB, 20,150,126/26-2015-5/022)(9), (CNUH-2015-011)(10), (DSMC13-216)(11). CONSENT FOR PUBLICATION: Not applicable (no individual person's data are contained in this manuscript). COMPETING INTERESTS: The authors declare that they have no competing interests. EDAT- 2017/07/26 06:00 MHDA- 2018/02/08 06:00 PMCR- 2017/07/24 CRDT- 2017/07/26 06:00 PHST- 2016/12/07 00:00 [received] PHST- 2017/06/28 00:00 [accepted] PHST- 2017/07/26 06:00 [entrez] PHST- 2017/07/26 06:00 [pubmed] PHST- 2018/02/08 06:00 [medline] PHST- 2017/07/24 00:00 [pmc-release] AID - 10.1186/s13000-017-0639-y [pii] AID - 639 [pii] AID - 10.1186/s13000-017-0639-y [doi] PST - epublish SO - Diagn Pathol. 2017 Jul 24;12(1):54. doi: 10.1186/s13000-017-0639-y. PMID- 28736063 OWN - NLM STAT- MEDLINE DCOM- 20180716 LR - 20180716 IS - 1578-8989 (Electronic) IS - 0025-7753 (Linking) VI - 149 IP - 10 DP - 2017 Nov 22 TI - Bladder cancer: Present and future. PG - 449-455 LID - S0025-7753(17)30478-5 [pii] LID - 10.1016/j.medcli.2017.06.009 [doi] AB - Bladder cancer has a high incidence and involves high associated morbidity and mortality. Since its initial clinical suspicion, early diagnostic confirmation and multimodal treatment involve different medical specialties. For this reason, we consider it important to spread the current consensus for its management. Recent advances in immunology and Chemotherapy make it necessary to expose and reflect on future perspectives. CI - Copyright (c) 2017 Elsevier Espana, S.L.U. All rights reserved. FAU - Martinez Rodriguez, Roberto Hugo AU - Martinez Rodriguez RH AD - Servicio de Urologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana. Electronic address: dr.rmartinez@yahoo.es. FAU - Buisan Rueda, Oscar AU - Buisan Rueda O AD - Servicio de Urologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana. FAU - Ibarz, Luis AU - Ibarz L AD - Servicio de Urologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana. LA - eng LA - spa PT - Journal Article PT - Review TT - Tumor vesical: presente y futuro. DEP - 20170721 PL - Spain TA - Med Clin (Barc) JT - Medicina clinica JID - 0376377 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/urine MH - Combined Modality Therapy MH - Early Detection of Cancer/methods MH - Humans MH - Neoplasm Grading MH - Urinary Bladder Neoplasms/*diagnosis/pathology/*therapy/urine OTO - NOTNLM OT - Bacilo Calmette-Guerin OT - Bladder cancer OT - Calmette-Guerin bacillus OT - Cistectomia OT - Cystectomy OT - Haematuria OT - Hematuria OT - Immunotherapy OT - Inmunoterapia OT - Tumor vesical OT - Urotelio OT - Urothelial EDAT- 2017/07/25 06:00 MHDA- 2018/07/17 06:00 CRDT- 2017/07/25 06:00 PHST- 2017/04/26 00:00 [received] PHST- 2017/06/07 00:00 [revised] PHST- 2017/06/08 00:00 [accepted] PHST- 2017/07/25 06:00 [pubmed] PHST- 2018/07/17 06:00 [medline] PHST- 2017/07/25 06:00 [entrez] AID - S0025-7753(17)30478-5 [pii] AID - 10.1016/j.medcli.2017.06.009 [doi] PST - ppublish SO - Med Clin (Barc). 2017 Nov 22;149(10):449-455. doi: 10.1016/j.medcli.2017.06.009. Epub 2017 Jul 21. PMID- 28734027 OWN - NLM STAT- MEDLINE DCOM- 20190415 LR - 20190415 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 24 IP - 8 DP - 2017 Aug TI - Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer. PG - 594-600 LID - 10.1111/iju.13389 [doi] AB - OBJECTIVES: To investigate the relationship between chronic kidney disease and primary non-muscle-invasive bladder cancer. METHODS: Disease outcomes were analyzed in 418 patients treated with transurethral resection for primary non-muscle-invasive bladder cancer, and were correlated to traditional risk factors as well as chronic kidney disease stage according to estimated glomerular filtration rate: >/=60 (G1-2), 45-59 (G3a) or <45 (G3b-5). RESULTS: The median follow-up time was 40.0 months. There were 287 (68.7%), 98 (23.4%), and 33 (7.9%) patients with G1-2, G3a and G3b-5 chronic kidney disease, respectively. T1 tumor was present in 29.6% of G1-2, 43.9% of G3a and 51.4% of G3b-5 chronic kidney disease (P = 0.004). The proportion of histological grade 3 non-muscle-invasive bladder cancer was higher in G3a and G3b-5 than G1-2 (P < 0.001). Higher chronic kidney disease stage was associated with worse recurrence-free (P < 0.001) and progression-free survival (P = 0.017). In multivariable analysis, G3b-5 was found to be an independent predictor for recurrence (hazard ratio 1.87; P = 0.004) and progression (hazard ratio 2.96; P = 0.019). Chronic kidney disease stage was also strongly associated with the European Association of Urology bladder cancer risk groups (P < 0.001), and with shorter time to recurrence and progression in each group. CONCLUSIONS: Chronic kidney disease predicts the clinical outcome of primary non-muscle-invasive bladder cancer. Adding chronic kidney disease to the conventional risk factors might increase the accuracy of risk stratification. CI - (c) 2017 The Japanese Urological Association. FAU - Kobatake, Kohei AU - Kobatake K AD - Department of Urology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Hayashi, Tetsutaro AU - Hayashi T AD - Department of Urology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Black, Peter C AU - Black PC AD - The Vancouver Prostate Center and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Goto, Keisuke AU - Goto K AD - Department of Urology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. AD - Thoracic Oncology and Cancer Biology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii. FAU - Sentani, Kazuhiro AU - Sentani K AD - Department of Molecular Pathology, Graduate School of Biochemical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Kaneko, Mayumi AU - Kaneko M AD - Department of Pathology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. FAU - Yasui, Wataru AU - Yasui W AD - Department of Molecular Pathology, Graduate School of Biochemical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Mita, Koji AU - Mita K AD - Department of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan. FAU - Teishima, Jun AU - Teishima J AD - Department of Urology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Matsubara, Akio AU - Matsubara A AD - Department of Urology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. LA - eng PT - Journal Article DEP - 20170722 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2017 Aug;24(8):600-601. doi: 10.1111/iju.13402. PMID: 28734028 MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Glomerular Filtration Rate/*physiology MH - Humans MH - Kidney/*physiopathology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*mortality/physiopathology MH - Prognosis MH - Progression-Free Survival MH - Proportional Hazards Models MH - Renal Insufficiency, Chronic/*physiopathology MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Urinary Bladder Neoplasms/*mortality/physiopathology OTO - NOTNLM OT - bladder cancer OT - chronic kidney disease OT - non-muscle invasive OT - progression OT - recurrence EDAT- 2017/07/25 06:00 MHDA- 2019/04/16 06:00 CRDT- 2017/07/23 06:00 PHST- 2016/11/14 00:00 [received] PHST- 2017/05/07 00:00 [accepted] PHST- 2017/07/25 06:00 [pubmed] PHST- 2019/04/16 06:00 [medline] PHST- 2017/07/23 06:00 [entrez] AID - 10.1111/iju.13389 [doi] PST - ppublish SO - Int J Urol. 2017 Aug;24(8):594-600. doi: 10.1111/iju.13389. Epub 2017 Jul 22. PMID- 28716562 OWN - NLM STAT- MEDLINE DCOM- 20180612 LR - 20180627 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 11 DP - 2017 Nov TI - Predictive factors for final pathologic ureteral sections on 700 radical cystectomy specimens: Implications for intraoperative frozen section decision-making. PG - 659.e1-659.e6 LID - S1078-1439(17)30337-X [pii] LID - 10.1016/j.urolonc.2017.06.053 [doi] AB - PURPOSE: To identify preoperative predictive factors for final ureteral section invasion after radical cystectomy (RC) and to validate significant factors on an external independent cohort. MATERIAL AND METHODS: We retrospectively reviewed data of all consecutive RC performed for bladder cancer in 2 high-volume institutions. Clinical, pathological, and follow-up data were collected prospectively and reviewed retrospectively. Pathological evaluation was performed by 2 well-trained uropathologists in each center. Logistic regression analyses were performed to identify predictive factors for final ureteral sections involvement. Significant factors in cohort A were validated in cohort B. Receiver operating curve and area under curve were modeled to evaluate predictive accuracy of the markers. RESULTS: A total of 441 RC were performed in center A and 307 RC were performed in center B. Mean follow-ups were 36.2 and 38.1 months, respectively. Invasion of the final ureteral section was observed on 5.5% of patients in cohort A and 4.8% of patients in cohort B. In cohort A, multivariable logistic regression identified preoperative hydronephrosis on computed tomography scan (odds ratio [OR] = 4.9, P = 0.004) and presence of Carcinoma in situ (CIS, OR = 3.9, P = 0.01) as the only factors associated with ureteral sections positivity. In cohort B, hydronephrosis and CIS were both associated with ureteral sections positivity in univariable analysis. In multivariable analysis, only hydronephrosis remained significant (OR = 5.9, P = 0.01). Predictive accuracy of hydronephrosis and CIS combined in 1 variable was 0.72. CONCLUSION: Hydronephrosis and bladder CIS have good accuracy in predicting ureteral sections positivity after RC. In the presence of those factors, ureteral frozen sections should be performed. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Department of Urology and Transplantation, Saint Louis Academic Hospital, Paris Diderot University, Paris, France. Electronic address: amassonlecomte@gmail.com. FAU - Francois, Thomas AU - Francois T AD - Department of Urology and Transplantation, Picardie Jules Verne University, CHU Amiens, Amiens, France. FAU - Vordos, Dimitri AU - Vordos D AD - Department of Urology, Henri Mondor Hospital, Paris Est Creteil University, Creteil, France. FAU - Cordonnier, Carole AU - Cordonnier C AD - Department of Pathology, Picardie Jules Verne University, CHU Amiens, Amiens, France. FAU - Allory, Yves AU - Allory Y AD - Department of Pathology, Henri Mondor Hospital, Paris Est Creteil University, Creteil, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - Department of Urology and Transplantation, Saint Louis Academic Hospital, Paris Diderot University, Paris, France. FAU - de la Taille, Alexandre AU - de la Taille A AD - Department of Urology, Henri Mondor Hospital, Paris Est Creteil University, Creteil, France. FAU - Saint, Fabien AU - Saint F AD - Department of Urology and Transplantation, Picardie Jules Verne University, CHU Amiens, Amiens, France; HeRVI EA 3801, Picardie Jules Verne University, CHU Amiens, Amiens, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170714 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Carcinoma in Situ/*surgery MH - Cystectomy/*methods MH - Decision Making MH - Female MH - Frozen Sections MH - Humans MH - Hydronephrosis/diagnosis MH - Intraoperative Period MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Retrospective Studies MH - Ureter/pathology/*surgery MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Predictive factors OT - Radical cystectomy OT - Ureteral frozen section OT - Urothelial carcinoma EDAT- 2017/07/19 06:00 MHDA- 2018/06/13 06:00 CRDT- 2017/07/19 06:00 PHST- 2017/04/18 00:00 [received] PHST- 2017/06/16 00:00 [revised] PHST- 2017/06/19 00:00 [accepted] PHST- 2017/07/19 06:00 [pubmed] PHST- 2018/06/13 06:00 [medline] PHST- 2017/07/19 06:00 [entrez] AID - S1078-1439(17)30337-X [pii] AID - 10.1016/j.urolonc.2017.06.053 [doi] PST - ppublish SO - Urol Oncol. 2017 Nov;35(11):659.e1-659.e6. doi: 10.1016/j.urolonc.2017.06.053. Epub 2017 Jul 14. PMID- 28705539 OWN - NLM STAT- MEDLINE DCOM- 20190104 LR - 20190104 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 73 IP - 2 DP - 2018 Feb TI - Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. PG - 226-232 LID - S0302-2838(17)30538-9 [pii] LID - 10.1016/j.eururo.2017.06.038 [doi] AB - BACKGROUND: The efficacy of an immediate single chemotherapy instillation after transurethral resection of a bladder tumour (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC) remains a topic of debate. Evidence is even more scarce when an immediate instillation is followed by adjuvant instillations. OBJECTIVE: To compare the effect of a mitomycin C (MMC) instillation within 24h to an instillation 2 wk after TURBT in patients with NMIBC with or without adjuvant instillations. DESIGN, SETTING, AND PARTICIPANTS: Between 1998 and 2003, 2844 NMIBC patients were randomised for immediate versus delayed MMC instillation after TURBT. Patients were categorised in low-risk (LOR), intermediate-risk (IMR), and high-risk (HIR) groups. Total numbers of instillations in these groups were 1, 9, and 15, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary end point was 3-yr recurrence risk for the IMR and HIR groups and 5-yr risk for the LOR group. Secondary outcomes were time to recurrence and incidence of adverse events. Analyses were performed with the log-rank test, Cox-regression, and chi(2) test in SPSS. RESULTS AND LIMITATIONS: A total of 2243 patients were eligible on an intention-to-treat basis. Recurrence risks were 43% and 46% in the LOR group (5-yr follow-up, p=0.11), 20% and 32% in the IMR group (3-yr follow-up, p=0.037), and 28% and 35% in the HIR group (3-yr follow-up, p=0.007), for an immediate and a delayed instillation, respectively. For all patients, the recurrence risk was 27% (95% confidence interval [CI], 24-30) in the immediate and 36% (95% CI, 33-39) in the delayed instillation group (p<0.001) with a 27% reduction in relative recurrence risk (hazard ratio: 0.73, 95% CI, 0.63-0.85, p<0.001). The incidence of adverse events did not differ significantly between treatment groups (immediate instillation 25%, delayed instillation 22%, p=0.08). The risk groups in our study differ slightly from the current guidelines, which is a limitation of our study. CONCLUSIONS: An immediate, single instillation after TURBT reduces the recurrence risk in NMIBC patients, independent of the number of adjuvant installations. PATIENT SUMMARY: A single instillation of chemotherapy after the resection of non-muscle-invasive bladder cancer reduces the recurrence risk, even if patients are treated with an adjuvant schedule of instillations. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - van Ginkel, Tessa AU - van Ginkel T AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Witte, Birgit AU - Witte B AD - Department of Epidemiology and Biostatistics, VU university Medical Center, Amsterdam, The Netherlands. FAU - Newling, Don AU - Newling D AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - Beckers, Goedele M A AU - Beckers GMA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. FAU - van Moorselaar, R Jeroen A AU - van Moorselaar RJA AD - Department of Urology, VU university Medical Center, Amsterdam, The Netherlands. Electronic address: RJA.vanMoorselaar@vumc.nl. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20170710 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Eur Urol. 2018 Feb;73(2):233-235. doi: 10.1016/j.eururo.2017.09.014. PMID: 28967551 CIN - Eur Urol. 2018 Sep;74(3):397-398. doi: 10.1016/j.eururo.2018.03.025. PMID: 29636256 CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S135-S137. doi: 10.21037/tau.2017.09.20. PMID: 29644182 CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S138-S140. doi: 10.21037/tau.2017.09.19. PMID: 29644183 MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/*administration & dosage MH - Chemotherapy, Adjuvant MH - *Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/*administration & dosage MH - Muscle, Smooth MH - Neoplasm Invasiveness MH - Postoperative Period MH - Prospective Studies MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Bladder neoplasms OT - Intravesical chemotherapy OT - Mitomycin C OT - Non-muscle-invasive urothelial carcinoma EDAT- 2017/07/15 06:00 MHDA- 2019/01/05 06:00 CRDT- 2017/07/15 06:00 PHST- 2017/02/21 00:00 [received] PHST- 2017/06/24 00:00 [accepted] PHST- 2017/07/15 06:00 [pubmed] PHST- 2019/01/05 06:00 [medline] PHST- 2017/07/15 06:00 [entrez] AID - S0302-2838(17)30538-9 [pii] AID - 10.1016/j.eururo.2017.06.038 [doi] PST - ppublish SO - Eur Urol. 2018 Feb;73(2):226-232. doi: 10.1016/j.eururo.2017.06.038. Epub 2017 Jul 10. PMID- 28694147 OWN - NLM STAT- MEDLINE DCOM- 20180126 LR - 20180503 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 6 DP - 2017 Dec TI - Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. PG - e1039-e1045 LID - S1558-7673(17)30169-6 [pii] LID - 10.1016/j.clgc.2017.06.003 [doi] AB - PURPOSE: The purpose of this study was to evaluate the predictive and prognostic role of preoperative thrombocytosis (TC) in upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) in a large multi-institutional cohort of patients. METHODS: Records of 2492 patients undergoing RNU for non-metastatic UTUC between 1990 and 2008 were retrospectively analyzed. Preoperative TC was defined as a platelet count > 400 x 10(9)/L, irrespective of gender type. Logistic regression analyses were performed to evaluate its association with pathologic features. Cox proportional hazards regression was used for estimation of recurrence-free survival, cancer-specific survival, and overall survival. RESULTS: Preoperative TC was found in 309 (12.4%) patients and was associated with advanced tumor stage and grade, lymph node metastasis, lymphovascular invasion, tumor architecture, necrosis, and concomitant carcinoma in situ (P-values /= pT2 (P < .001), non-organ-confined (P < .001), and lymph node-positive (P < .001) disease in a preoperative model that adjusted for the effects of age, gender, location, multifocality, and tumor architecture. Within a median follow-up of 45 months, recurrence occurred in 663 (26.6%) patients with 545 (21.9%) dying of UTUC. In univariable Cox proportional hazard regression analysis, TC was significantly associated with recurrence-free survival (hazard ratio [HR], 1.32; P = .015) and overall survival (HR, 1.4; P < .001), but not cancer-specific survival (HR, 1.17; P = .2). In both pre- and postoperative multivariable models, when adjusted for the effects of standard clinicopathologic features, TC did not retain its association with survival outcomes. CONCLUSIONS: Preoperative TC is associated with adverse clinicopathologic features and predicts worse pathology at RNU. Among other serum biomarkers, TC could benefit preoperative risk stratification and help guide treatment decisions. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy. FAU - Gust, Kilian M AU - Gust KM AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere, Assistance-Publique Hopitaux de Paris and Faculte de Medecine Pierre et Marie Curie, University Paris VI, Paris, France. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Canada. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Kluth, Luis AU - Kluth L AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - John, Hubert AU - John H AD - Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address: shahrokh.shariat@meduniwien.ac.at. CN - UTUC Collaboration LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20170619 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Logistic Models MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Nephroureterectomy MH - Preoperative Period MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Thrombocytosis/*epidemiology MH - Treatment Outcome MH - Urologic Neoplasms/*surgery OTO - NOTNLM OT - Cancer of urinary tract OT - Platelet count OT - Prognostic factors OT - Radical nephroureterectomy OT - Urothelium EDAT- 2017/07/12 06:00 MHDA- 2018/01/27 06:00 CRDT- 2017/07/12 06:00 PHST- 2017/02/22 00:00 [received] PHST- 2017/06/09 00:00 [revised] PHST- 2017/06/13 00:00 [accepted] PHST- 2017/07/12 06:00 [pubmed] PHST- 2018/01/27 06:00 [medline] PHST- 2017/07/12 06:00 [entrez] AID - S1558-7673(17)30169-6 [pii] AID - 10.1016/j.clgc.2017.06.003 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Dec;15(6):e1039-e1045. doi: 10.1016/j.clgc.2017.06.003. Epub 2017 Jun 19. PMID- 28693295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 14 IP - 1 DP - 2017 Jul TI - Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression. PG - 1193-1199 LID - 10.3892/ol.2017.6233 [doi] AB - Accumulating evidence has suggested that germline DNA copy number variations (CNVs) affect various disorders, including human malignancies. However, the significance of CNVs in non-muscle invasive bladder cancer (NMIBC) remains unclear. The purpose of the present study was to identify the role of CNVs in NMIBC. Array comparative genomic hybridization (CGH) analysis was performed to search for candidate CNVs associated with NMIBC susceptibility. Quantitative polymerase chain reaction was carried out to evaluate CNVs associated with patient outcome in 189 NMIBC cases. In total, 11 CNVs were associated with NMIBC risk in array CGH analysis. Out of the 189 CNVs examined, family with sequence similarity 81 member A (FAM81A) and proprotein convertase subtilisin/kexin type 6 (PCSK6) CNVs exhibited a significant association with recurrence and disease progression in NMIBC. PCSK6 has been reported to regulate proliferation and tumor progression in breast and prostate malignancies. Notably, patients with pT1 stage had significantly lower PCSK6 relative copy number than those with pTa (P=0.0196). In multivariate analyses, PCSK6 copy number was an independent prognostic factor for progression-free survival (P=0.0456; risk ratio, 2.17; 95% confidence interval, 1.02-4.82). These data suggest that PCSK6 CNV is a potential new tumor marker for estimating disease progression in NMIBC. FAU - Yamamoto, Yoshiaki AU - Yamamoto Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Suehiro, Yutaka AU - Suehiro Y AD - Department of Oncology and Laboratory Medicine, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Suzuki, Atomu AU - Suzuki A AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Nawata, Ryosuke AU - Nawata R AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Kawai, Yoshihisa AU - Kawai Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Inoue, Ryo AU - Inoue R AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Hirata, Hiroshi AU - Hirata H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Yamasaki, Takahiro AU - Yamasaki T AD - Department of Oncology and Laboratory Medicine, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. FAU - Sasaki, Kohsuke AU - Sasaki K AD - Department of Pathology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. AD - Department of Pathology, Shimonoseki Medical Center, Shimonoseki, Yamaguchi 750-0061, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan. LA - eng PT - Journal Article DEP - 20170524 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5494660 OTO - NOTNLM OT - DNA copy number variations OT - FAM81A OT - PCSK6 OT - non-muscle invasive bladder cancer EDAT- 2017/07/12 06:00 MHDA- 2017/07/12 06:01 PMCR- 2017/05/24 CRDT- 2017/07/12 06:00 PHST- 2016/12/28 00:00 [received] PHST- 2017/03/28 00:00 [accepted] PHST- 2017/07/12 06:00 [entrez] PHST- 2017/07/12 06:00 [pubmed] PHST- 2017/07/12 06:01 [medline] PHST- 2017/05/24 00:00 [pmc-release] AID - OL-0-0-6233 [pii] AID - 10.3892/ol.2017.6233 [doi] PST - ppublish SO - Oncol Lett. 2017 Jul;14(1):1193-1199. doi: 10.3892/ol.2017.6233. Epub 2017 May 24. PMID- 28688872 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20180710 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 5 DP - 2017 Oct TI - Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center. PG - e765-e771 LID - S1558-7673(17)30072-1 [pii] LID - 10.1016/j.clgc.2017.03.010 [doi] AB - OBJECTIVE: Paraganglioma of the urinary bladder (PUB) is rare in bladder cancer, and currently, a study examining large number of cases from a single center has not been reported. This study aimed to present the clinical features, treatments, pathological characteristics, and prognosis of PUB. PATIENTS AND METHODS: From January 2006 to June 2016, 22 patients were pathologically diagnosed with PUB in our hospital. Their clinical records, operative notes, pathological reports, and follow-up records were retrospectively reviewed. RESULTS: The incidence of PUB in patients with bladder cancer was 0.92%. The mean age at diagnosis was 49.8 +/- 14.6 years (range, 16-76 years) and the male to female ratio was 1:1. Fourteen cases (63.6%) were functional. The common indicative symptoms included hematuria (36.4%), hypertension (31.8%), micturition syncope (27.3%), headache (18.2%), and palpitation (13.6%). All neoplasms were completely resected via transurethral resection of bladder tumor (TURBT), en bloc transurethral resection with thulium-yag laser, or partial cystectomy. Most PUB samples were positive for immunohistochemical (IHC) staining markers such as chromogranin A (CgA), Synaptophysin (Syn), CD56, and S-100 protein, while negative for IHC markers such as cytokeratins (CKs) and Melan A. According to pathological reports, 72.7% of PUB cases were at stage T2, 18.2% at T3, and 9.1% at T4. Two cases (9.1%) with metastasis were malignant. Two patients (9.1%) were lost during follow-up, and the remaining 20 patients were followed up for a period of 67.8 +/- 38.5 months (range, 6-130 months). Among them, 16 patients (80%) recovered after the surgery, 1 patient (5%) died of natural causes. PUB recurred in 3 patients (15%), and 1 patient among them died of PUB. CONCLUSION: Despite the rarity, PUB should be suspected in patients with unexplained symptoms such as micturition syncope, hematuria, hypertension, headache, or palpitation. Surgery and adjuvant therapies are effective treatments for PUB. Compared with open surgery, laparoscopic partial cystectomy and robot-assisted laparoscopic partial cystectomy are advantageous in the treatment of PUB. Long-term follow-up is recommended for patients with PUB. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Zhai, Hongyun AU - Zhai H AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Ma, Xin AU - Ma X AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Nie, Wenyuan AU - Nie W AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Li, Hongzhao AU - Li H AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Peng, Cheng AU - Peng C AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Li, Xintao AU - Li X AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. FAU - Zhang, Xu AU - Zhang X AD - Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. Electronic address: xzhang@tjh.tjmu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170328 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Biomarkers, Tumor/metabolism MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Paraganglioma/*epidemiology/metabolism/*pathology/surgery MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*epidemiology/metabolism/*pathology/surgery MH - Urologic Surgical Procedures MH - Young Adult OTO - NOTNLM OT - Clinical feature OT - Pathologic characteristic OT - Pheochromocytoma OT - Prognosis OT - Treatment EDAT- 2017/07/10 06:00 MHDA- 2018/05/22 06:00 CRDT- 2017/07/10 06:00 PHST- 2017/03/14 00:00 [received] PHST- 2017/03/18 00:00 [accepted] PHST- 2017/07/10 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/07/10 06:00 [entrez] AID - S1558-7673(17)30072-1 [pii] AID - 10.1016/j.clgc.2017.03.010 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Oct;15(5):e765-e771. doi: 10.1016/j.clgc.2017.03.010. Epub 2017 Mar 28. PMID- 28687411 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20250623 IS - 1873-4898 (Electronic) IS - 1477-5131 (Linking) VI - 13 IP - 5 DP - 2017 Oct TI - Systematic review of bladder cancer outcomes in patients with spina bifida. PG - 456.e1-456.e9 LID - S1477-5131(17)30234-6 [pii] LID - 10.1016/j.jpurol.2017.05.006 [doi] AB - BACKGROUND: In patients with congenital bladder anomalies, bladder augmentation is used as a last resort to reduce intravesical pressure, but concerns about malignant transformation in augmented patients were first raised in the 1980s. The best evidence to date indicates that augmentation does not appear to increase the risk of bladder cancer in spina bifida patients. To date, oncologic outcomes from patients with spina bifida with and without augmentation have only been available in small case reports. OBJECTIVE: To systematically evaluate factors in myelomeningocele patients with bladder cancer, including bladder augmentation, that contribute to overall survival (OS). STUDY DESIGN: A systematic review using PubMed was conducted by cross referencing terms 'myelomeningocele,' 'cystoplasty,' 'bladder cancer' and respective synonyms according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Inclusion criteria were studies with patients with an underlying diagnosis of myelomeningocele and bladder cancer with data on age, stage, and mortality status. Studies were excluded for spinal cord injury, history of tuberculosis or schistosomiasis, or prior ureterosigmoidostomy. RESULTS: Fifty-two patients were identified from 28 studies with a median age at bladder cancer diagnosis of 41 years (range 13-73); 37 (71%) presented with stage III or IV bladder cancer. Overall survival at 1 year and 2 years was 48.5% and 31.5%, respectively. Overall survival was different between those with and without augmentation (P = 0.009) by log-rank analysis. No between-group differences in OS were seen based on age, management with indwelling catheter, diversion with ileal conduit or being on a surveillance program. Only stage remained a significant predictor of OS on multivariate analysis (HR 2.011, 95% CI 1.063-3.804, P = 0.032). Secondary analysis was performed after removing patients with gastric augmentation (n = 8), and no difference in OS was seen between patients with (n = 8) and without augmentation (n = 36, P = 0.112). Of augmented patients, latency to development of bladder cancer was variable (Summary Figure). DISCUSSION: Bladder cancer is a deadly diagnosis in patients with congenital bladder anomalies like spina bifida, and while overall prevalence of the two conditions occurring together is low, bladder cancer will go on to affect 2-4% of spina bifida patients. The present study examined overall survival, and further characterized outcomes in these patients. Presence of a bladder augment did not appear to worsen overall survival. CONCLUSIONS: Patients with myelomeningocele who developed bladder cancer had aggressive disease. Augmentation did not worsen OS, based on cases reported in the literature. Risk of bladder cancer should be discussed with all myelomeningocele patients. CI - Copyright (c) 2017 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. FAU - Rove, K O AU - Rove KO AD - Division of Pediatric Urology, Washington University in St. Louis, MO, USA. Electronic address: rovek@wustl.edu. FAU - Husmann, D A AU - Husmann DA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Wilcox, D T AU - Wilcox DT AD - Department of Pediatric Urology, Children's Hospital Colorado, Aurora, CO, USA. FAU - Vricella, G J AU - Vricella GJ AD - Division of Pediatric Urology, Washington University in St. Louis, St. Louis, MO, USA. FAU - Higuchi, T T AU - Higuchi TT AD - Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20170601 PL - England TA - J Pediatr Urol JT - Journal of pediatric urology JID - 101233150 SB - IM CIN - J Urol. 2021 Jan;205(1):309-312. doi: 10.1097/JU.0000000000001470. PMID: 33185119 MH - Humans MH - Spinal Dysraphism/*complications MH - Urinary Bladder Neoplasms/*epidemiology MH - Urinary Bladder, Neurogenic/pathology/*surgery OTO - NOTNLM OT - Bladder augmentation OT - Bladder cancer OT - Myelomeningocele OT - Spina bifida OT - Systematic review EDAT- 2017/07/09 06:00 MHDA- 2018/07/25 06:00 CRDT- 2017/07/09 06:00 PHST- 2017/03/10 00:00 [received] PHST- 2017/05/06 00:00 [accepted] PHST- 2017/07/09 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] PHST- 2017/07/09 06:00 [entrez] AID - S1477-5131(17)30234-6 [pii] AID - 10.1016/j.jpurol.2017.05.006 [doi] PST - ppublish SO - J Pediatr Urol. 2017 Oct;13(5):456.e1-456.e9. doi: 10.1016/j.jpurol.2017.05.006. Epub 2017 Jun 1. PMID- 28683751 OWN - NLM STAT- MEDLINE DCOM- 20180426 LR - 20181113 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 15 IP - 1 DP - 2017 Jul 6 TI - A novel transurethral resection technique for superficial bladder tumor: retrograde en bloc resection. PG - 125 LID - 10.1186/s12957-017-1192-6 [doi] LID - 125 AB - BACKGROUND: Transurethral resection of bladder tumor (TURBT) is the standard approach to bladder tumors but suffers from several disadvantages. The aim of this study was to evaluate the safety and efficacy of a novel procedure of retrograde en bloc resection of bladder tumor (RERBT) with conventional monopolar resection electrode for the treatment of superficial bladder tumors. METHODS: RERBT and conventional TURBT (C-TURBT) were conducted, respectively, in 40 and 50 patients diagnosed with superficial papillary bladder tumors. In the RERBT group, the tumors were en bloc removed retrogradely under direct vision using a conventional monopolar electrode. Patients' clinicopathological, intraoperative, and postoperative data were compared retrospectively between the RERBT and C-TURBT groups. RESULTS: Of the 90 patients, 40 underwent RERBT and 50 underwent C-TURBT. Both groups were comparable in clinicopathological characteristic. RERBT could be performed as safely and effectively as C-TURBT. There were no significant differences in operative time and surgical complications. The cumulative recurrence rates between groups were similar during up to 18 months follow-up. The detrusor muscle could be identified pathologically in 100% of RERBT tumor specimens and the biopsy of tumor bases, but only in 54 and 70%, respectively, of C-TURBT samples (P < 0.01). CONCLUSIONS: The RERBT technique is feasible and safe for superficial bladder tumors using conventional monopolar resection setting, with the advantages of adequate tumor resection and the ability to collect good quality tumor specimens for pathological diagnosis and staging compared to conventional TURBT. FAU - Zhang, Kai-Yan AU - Zhang KY AD - Department of Urology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. FAU - Xing, Jin-Chun AU - Xing JC AD - Department of Urology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. xmcua2007@sina.com. FAU - Li, Wei AU - Li W AD - Department of Urology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. FAU - Wu, Zhun AU - Wu Z AD - Department of Urology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. FAU - Chen, Bin AU - Chen B AD - Department of Urology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. FAU - Bai, Dong-Yu AU - Bai DY AD - Department of Pathology, Xiamen University Affiliated First Hospital, 55 Zhenhai Road, Siming District, Xiamen, 361003, China. LA - eng PT - Journal Article DEP - 20170706 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Cystectomy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Urologic Surgical Procedures/instrumentation/*methods PMC - PMC5501371 OTO - NOTNLM OT - En-bloc resection OT - Non-muscle-invasive bladder cancer OT - Transurethral resection of bladder tumor COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the Ethics Committee of Xiamen University Affiliated First Hospital. CONSENT FOR PUBLICATION: All patients enrolled in the study signed the consent for publication. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/07/08 06:00 MHDA- 2018/04/27 06:00 PMCR- 2017/07/06 CRDT- 2017/07/08 06:00 PHST- 2017/03/25 00:00 [received] PHST- 2017/06/22 00:00 [accepted] PHST- 2017/07/08 06:00 [entrez] PHST- 2017/07/08 06:00 [pubmed] PHST- 2018/04/27 06:00 [medline] PHST- 2017/07/06 00:00 [pmc-release] AID - 10.1186/s12957-017-1192-6 [pii] AID - 1192 [pii] AID - 10.1186/s12957-017-1192-6 [doi] PST - epublish SO - World J Surg Oncol. 2017 Jul 6;15(1):125. doi: 10.1186/s12957-017-1192-6. PMID- 28683471 OWN - NLM STAT- MEDLINE DCOM- 20170907 LR - 20220330 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 117 IP - 4 DP - 2017 Aug 8 TI - Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. PG - 583-587 LID - 10.1038/bjc.2017.210 [doi] AB - BACKGROUND: Urothelial bladder cancer (UBC) is characterised by a high risk of recurrence. Patient monitoring is currently based on iterative cystoscopy and on urine cytology with low sensitivity in non-muscle-invasive bladder cancer (NMIBC). Telomerase reverse transcriptase (TERT) is frequently reactivated in UBC by promoter mutations. METHODS: We studied whether detection of TERT mutation in urine could be a predictor of UBC recurrence and compared this to cytology/cystoscopy for patient follow-up. A total of 348 patients treated by transurethral bladder resection for UBC were included together with 167 control patients. RESULTS: Overall sensitivity was 80.5% and specificity 89.8%, and was not greatly impacted by inflammation or infection. TERT remaining positive after initial surgery was associated with residual carcinoma in situ. TERT in urine was a reliable and dynamic predictor of recurrence in NMIBC (P<0.0001). In univariate analysis, TERT positive-status after initial surgery increased risk of recurrence by 5.34-fold (P=0.0004). TERT positive-status was still associated with recurrence in the subset of patients with negative cystoscopy (P=0.034). CONCLUSIONS: TERT mutations in urine might be helpful for early detection of recurrence in UBC, especially in NMIBC. FAU - Descotes, Francoise AU - Descotes F AD - Hospices Civils de Lyon, Service de Biochimie Biologie Moleculaire, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. FAU - Kara, Norelyakin AU - Kara N AD - Hospices Civils de Lyon, Service d'Urologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. FAU - Decaussin-Petrucci, Myriam AU - Decaussin-Petrucci M AD - Hospices Civils de Lyon, Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. AD - Universite Lyon 1, Centre de Recherche en Cancerologie de Lyon - INSERM 1052 CNRS 5286, Centre Leon Berard, LYON cedex 08 69373, France. FAU - Piaton, Eric AU - Piaton E AD - Hospices Civils de Lyon, Centre de Pathologie Est, Hopital Femme-Mere-Enfant, Boulevard Pinel, Bron 69677, France. FAU - Geiguer, Florence AU - Geiguer F AD - Hospices Civils de Lyon, Service de Biochimie Biologie Moleculaire, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. FAU - Rodriguez-Lafrasse, Claire AU - Rodriguez-Lafrasse C AD - Hospices Civils de Lyon, Service de Biochimie Biologie Moleculaire, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. FAU - Terrier, Jean E AU - Terrier JE AD - Hospices Civils de Lyon, Service d'Urologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. FAU - Lopez, Jonathan AU - Lopez J AD - Hospices Civils de Lyon, Service de Biochimie Biologie Moleculaire, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. AD - Universite Lyon 1, Centre de Recherche en Cancerologie de Lyon - INSERM 1052 CNRS 5286, Centre Leon Berard, LYON cedex 08 69373, France. FAU - Ruffion, Alain AU - Ruffion A AD - Hospices Civils de Lyon, Service d'Urologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex 69495, France. AD - Universite Lyon 1, Centre de Recherche en Cancerologie de Lyon - INSERM 1052 CNRS 5286, Centre Leon Berard, LYON cedex 08 69373, France. LA - eng PT - Comparative Study PT - Journal Article DEP - 20170706 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/genetics/pathology/surgery/*urine MH - Cystoscopy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mutation MH - Neoplasm Recurrence, Local/genetics/pathology/*urine MH - Neoplasm, Residual MH - Population Surveillance/*methods MH - Predictive Value of Tests MH - Promoter Regions, Genetic MH - Prospective Studies MH - Telomerase/genetics/*urine MH - Urinary Bladder Neoplasms/genetics/pathology/surgery/*urine MH - Urine/cytology PMC - PMC5558690 COIS- All named authors declare that they have no competing interest. They have agreed to the submission and have participated in the study to a sufficient extent to be named as authors. EDAT- 2017/07/07 06:00 MHDA- 2017/09/08 06:00 PMCR- 2018/08/08 CRDT- 2017/07/07 06:00 PHST- 2017/03/13 00:00 [received] PHST- 2017/05/31 00:00 [revised] PHST- 2017/06/08 00:00 [accepted] PHST- 2017/07/07 06:00 [pubmed] PHST- 2017/09/08 06:00 [medline] PHST- 2017/07/07 06:00 [entrez] PHST- 2018/08/08 00:00 [pmc-release] AID - bjc2017210 [pii] AID - 10.1038/bjc.2017.210 [doi] PST - ppublish SO - Br J Cancer. 2017 Aug 8;117(4):583-587. doi: 10.1038/bjc.2017.210. Epub 2017 Jul 6. PMID- 28680010 OWN - NLM STAT- MEDLINE DCOM- 20180518 LR - 20220330 IS - 2185-4610 (Electronic) IS - 0016-2590 (Print) IS - 0016-2590 (Linking) VI - 63 IP - 2 DP - 2017 Aug 9 TI - Apparent diffusion coefficient on magnetic resonance imaging (MRI) in bladder cancer: relations with recurrence/progression risk. PG - 90-99 LID - 10.5387/fms.2017-05 [doi] AB - AIMS: To evaluate the relationship between the apparent diffusion coefficient (ADC) value for bladder cancer and the recurrence/progression risk of post-transurethral resection (TUR). METHODS: Forty-one patients with initial and non-muscle-invasive bladder cancer underwent MRI from 2009 to 2012. Two radiologists measured ADC values. A pathologist calculated the recurrence/progression scores, and risk was classified based on the scores. Pearson's correlation was used to analyze the correlations of ADC value with each score and with each risk group, and the optimal cut-off value was established based on receiver operating characteristic (ROC) curve analysis. Furthermore, the relationship between actual recurrence / progression of cases and ADC values was examined by Unpaird U test. RESULTS: There were significant correlations between ADC value and the recurrence score as well as the progression score (P<0.01, P<0.01, respectively). There were also significant correlations between ADC value and the recurrence risk group as well as progression risk group (P=0.042, P<0.01, respectively). The ADC cut-off value on ROC analysis was 1.365 (sensitivity 100%; specificity 97.4%) for the low and intermediate recurrence risk groups, 1.024 (sensitivity 47.4%; specificity 100%) for the intermediate and high recurrence risk groups, 1.252 (sensitivity 83.3%; specificity 81.3%) for the low and intermediate progression risk groups, and 0.955 (sensitivity 87.5%; specificity 63.2%) between the intermediate and high progression risk groups. The difference between the ADC values of the recurrence and nonrecurrence group in Unpaired t test was significant (P<0.05). CONCLUSION: ADC on MRI in bladder cancer could potentially be useful, non-invasive measurement for estimating the risks of recurrence and progression. FAU - Kikuchi, Ken AU - Kikuchi K AD - Departments of Radiology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Shigihara, Takeshi AU - Shigihara T AD - Departments of Radiology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Hashimoto, Yuko AU - Hashimoto Y AD - Departments of Diagnostic Pathology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Miyajima, Masayuki AU - Miyajima M AD - Departments of Radiology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Haga, Nobuhiro AU - Haga N AD - Departments of Urology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Kojima, Yoshiyuki AU - Kojima Y AD - Departments of Urology, Division of Medicine, Fukushima Medical University, School of Medicine. FAU - Shishido, Fumio AU - Shishido F AD - Departments of Radiology, Division of Medicine, Fukushima Medical University, School of Medicine. LA - eng PT - Journal Article DEP - 20170705 PL - Japan TA - Fukushima J Med Sci JT - Fukushima journal of medical science JID - 0374626 SB - IM MH - Aged MH - Diffusion MH - Disease Progression MH - Female MH - Humans MH - *Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*etiology MH - ROC Curve MH - Urinary Bladder Neoplasms/*diagnostic imaging/surgery PMC - PMC5597528 OTO - NOTNLM OT - apparent diffusion coefficient OT - bladder cancer OT - magnetic resonance imaging OT - recurrence OT - transurethral resection EDAT- 2017/07/07 06:00 MHDA- 2018/05/19 06:00 PMCR- 2017/01/01 CRDT- 2017/07/07 06:00 PHST- 2017/07/07 06:00 [pubmed] PHST- 2018/05/19 06:00 [medline] PHST- 2017/07/07 06:00 [entrez] PHST- 2017/01/01 00:00 [pmc-release] AID - 10.5387/fms.2017-05 [doi] PST - ppublish SO - Fukushima J Med Sci. 2017 Aug 9;63(2):90-99. doi: 10.5387/fms.2017-05. Epub 2017 Jul 5. PMID- 28665070 OWN - NLM STAT- MEDLINE DCOM- 20180404 LR - 20211204 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 32 IP - 8 DP - 2017 Aug TI - Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder. PG - 1327-1336 LID - 10.3346/jkms.2017.32.8.1327 [doi] AB - Microarray analysis was used to investigate the lack of identified mammalian target of rapamycin (mTOR) pathway downstream genes to overcome cross-talk at non-muscle invasive high-grade (HG)-urothelial carcinoma (UC) of the bladder, gene expression patterns, gene ontology, and gene clustering by triple (p70S6K, S6K, and eIF4E) small interfering RNAs (siRNAs) or rapamycin in 5637 and T24 cell lines. We selected mTOR pathway downstream genes that were suppressed by siRNAs more than 2-fold, or were up-regulated or down-regulated by rapamycin more than 2-fold. We validated mTOR downstream genes with immunohistochemistry using a tissue microarray (TMA) of 125 non-muscle invasive HG-UC patients and knockout study to evaluate the synergistic effect with rapamycin. The microarray analysis selected mTOR pathway downstream genes consisting of 4 rapamycin up-regulated genes (FABP4, H19, ANXA10, and UPK3A) and 4 rapamycin down-regulated genes (FOXD3, ATP7A, plexin D1, and ADAMTS5). In the TMA, FABP4, and ATP7A were more expressed at T1 and FOXD3 was at Ta. ANXA10 and ADAMTS5 were more expressed in tumors 70 (p<0.001) led to improved survival; EQD2 >55 Gy showed a trend (p=0.065) for such association. On Cox regression, gender [risk ratio (RR)=2.81; p=0.039], TURBT (RR=4.44; p=0.033) and KPS (RR=3.45; p=0.018) remained significant. CONCLUSION: This study identified independent predictors of survival in patients irradiated for carcinoma of the urinary bladder and contributes to creation of personalised treatment programs. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Rades, Dirk AU - Rades D AD - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany rades.dirk@gmx.net. FAU - Manig, Lisa AU - Manig L AD - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany. FAU - Janssen, Stefan AU - Janssen S AD - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany. FAU - Schild, Steven E AU - Schild SE AD - Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma/*epidemiology/pathology/*radiotherapy MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Karnofsky Performance Status MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder/pathology/radiation effects MH - Urinary Bladder Neoplasms/*epidemiology/pathology/*radiotherapy PMC - PMC5566933 OTO - NOTNLM OT - Carcinoma of the urinary bladder OT - definitive treatment OT - independent predictive factors OT - irradiation OT - overall survival EDAT- 2017/06/28 06:00 MHDA- 2018/03/22 06:00 PMCR- 2017/07/03 CRDT- 2017/06/28 06:00 PHST- 2017/04/03 00:00 [received] PHST- 2017/04/14 00:00 [revised] PHST- 2017/04/19 00:00 [accepted] PHST- 2017/06/28 06:00 [entrez] PHST- 2017/06/28 06:00 [pubmed] PHST- 2018/03/22 06:00 [medline] PHST- 2017/07/03 00:00 [pmc-release] AID - 31/4/741 [pii] AID - 10.21873/invivo.11124 [doi] PST - ppublish SO - In Vivo. 2017 Jul-Aug;31(4):741-744. doi: 10.21873/invivo.11124. PMID- 28650339 OWN - NLM STAT- MEDLINE DCOM- 20171009 LR - 20250530 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 127 IP - 8 DP - 2017 Aug 1 TI - ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. PG - 2916-2929 LID - 89717 [pii] LID - 10.1172/JCI89717 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunotherapy instillation with the bacillus Calmette-Guerin (BCG) vaccine. In a prospective longitudinal study, we took advantage of BCG instillations, which increase local immune infiltration, to characterize immune cell populations in the urine of patients with NMIBC as a surrogate for the bladder tumor microenvironment. We observed an infiltration of neutrophils, T cells, monocytic myeloid-derived suppressor cells (M-MDSCs), and group 2 innate lymphoid cells (ILC2). Notably, patients with a T cell-to-MDSC ratio of less than 1 showed dramatically lower recurrence-free survival than did patients with a ratio of greater than 1. Analysis of early and later time points indicated that this patient dichotomy existed prior to BCG treatment. ILC2 frequency was associated with detectable IL-13 in the urine and correlated with the level of recruited M-MDSCs, which highly expressed IL-13 receptor alpha1. In vitro, ILC2 were increased and potently expressed IL-13 in the presence of BCG or tumor cells. IL-13 induced the preferential recruitment and suppressive function of monocytes. Thus, the T cell-to-MDSC balance, associated with a skewing toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of patients with muscle-invasive cancer. Moreover, these results underline the ILC2/IL-13 axis as a targetable pathway to curtail the M-MDSC compartment and improve bladder cancer treatment. FAU - Chevalier, Mathieu F AU - Chevalier MF AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Trabanelli, Sara AU - Trabanelli S AD - Translational Tumor Immunology, Ludwig Center for Cancer Research at the University of Lausanne, Department of Fundamental Oncology, Epalinges, Switzerland. FAU - Racle, Julien AU - Racle J AD - Computational Cancer Biology, Ludwig Center for Cancer Research at the University of Lausanne, Epalinges, Switzerland. AD - Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. FAU - Salome, Berengere AU - Salome B AD - Translational Tumor Immunology, Ludwig Center for Cancer Research at the University of Lausanne, Department of Fundamental Oncology, Epalinges, Switzerland. FAU - Cesson, Valerie AU - Cesson V AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Gharbi, Dalila AU - Gharbi D AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Bohner, Perrine AU - Bohner P AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Domingos-Pereira, Sonia AU - Domingos-Pereira S AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Dartiguenave, Florence AU - Dartiguenave F AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Fritschi, Anne-Sophie AU - Fritschi AS AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Speiser, Daniel E AU - Speiser DE AD - Department of Oncology and Ludwig Center for Cancer Research, University of Lausanne, Epalinges, Switzerland. FAU - Rentsch, Cyrill A AU - Rentsch CA AD - Department of Urology, University Hospital of Basel, Basel, Switzerland. FAU - Gfeller, David AU - Gfeller D AD - Computational Cancer Biology, Ludwig Center for Cancer Research at the University of Lausanne, Epalinges, Switzerland. AD - Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. FAU - Jichlinski, Patrice AU - Jichlinski P AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Nardelli-Haefliger, Denise AU - Nardelli-Haefliger D AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. FAU - Jandus, Camilla AU - Jandus C AD - Translational Tumor Immunology, Ludwig Center for Cancer Research at the University of Lausanne, Department of Fundamental Oncology, Epalinges, Switzerland. FAU - Derre, Laurent AU - Derre L AD - Urology Research Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. LA - eng GR - 146638/SNSF_/Swiss National Science Foundation/Switzerland PT - Journal Article DEP - 20170626 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (BCG Vaccine) RN - 0 (Interleukin-13) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine MH - Disease-Free Survival MH - Female MH - Humans MH - Immune System MH - Immunotherapy MH - Interleukin-13/metabolism MH - Longitudinal Studies MH - Lymphocytes/cytology MH - Male MH - Middle Aged MH - Monocytes/cytology MH - Neoplasm Recurrence, Local/*immunology/*urine MH - Neutrophils/cytology MH - Prospective Studies MH - T-Lymphocytes/cytology MH - Urinary Bladder Neoplasms/*immunology/therapy/*urine PMC - PMC5531411 COIS- Conflict of interest: The authors have declared that no conflict of interest exists. EDAT- 2017/06/27 06:00 MHDA- 2017/10/11 06:00 PMCR- 2017/11/01 CRDT- 2017/06/27 06:00 PHST- 2016/07/21 00:00 [received] PHST- 2017/05/04 00:00 [accepted] PHST- 2017/06/27 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2017/06/27 06:00 [entrez] PHST- 2017/11/01 00:00 [pmc-release] AID - 89717 [pii] AID - 10.1172/JCI89717 [doi] PST - ppublish SO - J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26. PMID- 28648755 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20220330 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 5 DP - 2017 Oct TI - High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer. PG - 570-576 LID - S1558-7673(17)30125-8 [pii] LID - 10.1016/j.clgc.2017.05.001 [doi] AB - BACKGROUND: Recent studies have demonstrated that the expression of long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes cancer cell proliferation, invasion, and metastasis in many tumor types, but the association between bladder cancer and MALAT1 remains unknown. MATERIALS: The expression of MALAT1 was tested by in situ hybridization (ISH) in 120 bladder cancer specimens. The association between MALAT1 expression and clinicopathological features and prognosis of the patients with bladder cancer was analyzed. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the relationship between the expression of MALAT1 and progression and metastasis of bladder cancer. RESULTS: ISH showed that high MALAT1 expression was associated with advanced histological grade, high tumor stage, and positive lymph nodes. Kaplan-Meier survival analysis and Cox regression analysis indicated that high tumor stage, positive lymph nodes, and high MALAT1 expression were independent prognostic indicators for overall survival (OS) of patients with bladder cancer. qRT-PCR showed that the expression of MALAT1 in bladder cancer tissues was 2.85 times higher than those measured in adjacent normal tissues (P < .001). The expression of MALAT1 was 2.673 +/- 0.254 in non-muscle-invasive bladder cancer and 2.987 +/- 0.381 in muscle-invasive bladder cancer (P = .018). In bladder cancer specimens with positive lymph nodes, MALAT1 expression was 3.167 +/- 0.297 versus 2.896 +/- 0.329 in bladder cancer specimens with negative lymph nodes (P = .020). CONCLUSION: High MALAT1 expression could serve as an independent prognostic factor for OS of patients with bladder cancer and could be considered as a potential therapeutic target of bladder cancer. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Li, Chao AU - Li C AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Cui, Yu AU - Cui Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Liu, Long-Fei AU - Liu LF AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Ren, Wen-Biao AU - Ren WB AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Li, Qia-Qia AU - Li QQ AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Zhou, Xu AU - Zhou X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Li, Yang-Le AU - Li YL AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Li, Yang AU - Li Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. FAU - Bai, Xiang-Yang AU - Bai XY AD - Dliner Bioelectrical LLC, Jiangyin, Wuxi, Jiangsu Province, PR China. FAU - Zu, Xiong-Bing AU - Zu XB AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. Electronic address: whzuxb@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170510 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (MALAT1 long non-coding RNA, human) RN - 0 (RNA, Long Noncoding) SB - IM MH - Adult MH - Disease Progression MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Prognosis MH - RNA, Long Noncoding/*genetics MH - Survival Analysis MH - *Up-Regulation MH - Urinary Bladder Neoplasms/*genetics/*pathology OTO - NOTNLM OT - Biomarker OT - Diagnosis OT - Lymph node metastasis OT - Survival analysis OT - Tumor biology EDAT- 2017/06/27 06:00 MHDA- 2018/05/22 06:00 CRDT- 2017/06/27 06:00 PHST- 2016/08/22 00:00 [received] PHST- 2017/04/24 00:00 [revised] PHST- 2017/05/01 00:00 [accepted] PHST- 2017/06/27 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/06/27 06:00 [entrez] AID - S1558-7673(17)30125-8 [pii] AID - 10.1016/j.clgc.2017.05.001 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Oct;15(5):570-576. doi: 10.1016/j.clgc.2017.05.001. Epub 2017 May 10. PMID- 28637373 OWN - NLM STAT- MEDLINE DCOM- 20170726 LR - 20170726 IS - 1744-7607 (Electronic) IS - 1742-5255 (Linking) VI - 13 IP - 7 DP - 2017 Jul TI - Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. PG - 783-791 LID - 10.1080/17425255.2017.1341490 [doi] AB - Apaziquone (also known as EO9 and Qapzola(TM)) is a prodrug that is activated to DNA damaging species by oxidoreductases (particularly NQO1) and has the ability to kill aerobic and/or hypoxic cancer cells. Areas covered: Whilst its poor pharmacokinetic properties contributed to its failure in phase II clinical trials when administered intravenously, these properties were ideal for loco-regional therapies. Apaziquone demonstrated good anti-cancer activity against non-muscle invasive bladder cancer (NMIBC) when administered intravesically to marker lesions and was well tolerated with no systemic side effects. However, phase III clinical trials did not reach statistical significance for the primary endpoint of 2-year recurrence in apaziquone over placebo although improvements were observed. Post-hoc analysis of the combined study data did indicate a significant benefit for patients treated with apaziquone, especially when the instillation of apaziquone was given 30 min or more after surgery. A further phase III study is ongoing to test the hypotheses generated in the unsuccessful phase III studies conducted to date. Expert opinion: Because of its specific pharmacological properties, Apaziquone is excellently suited for local therapy such as NMIBC. Future studies should include proper biomarkers. FAU - Phillips, R M AU - Phillips RM AD - a Department of Pharmacy , University of Huddersfield , Huddersfield , UK. AD - b Department of Chemical Sciences , University of Huddersfield , UK. FAU - Hendriks, H R AU - Hendriks HR AD - c Hendriks Pharmaceutical Consulting , Purmerend , The Netherlands. FAU - Sweeney, J B AU - Sweeney JB AD - a Department of Pharmacy , University of Huddersfield , Huddersfield , UK. AD - b Department of Chemical Sciences , University of Huddersfield , UK. FAU - Reddy, G AU - Reddy G AD - d Spectrum Pharmaceuticals Inc , Irvine , CA , USA. FAU - Peters, G J AU - Peters GJ AD - e Department of Medical Oncology , VU University Medical Center , Amsterdam , The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20170703 PL - England TA - Expert Opin Drug Metab Toxicol JT - Expert opinion on drug metabolism & toxicology JID - 101228422 RN - 0 (Antineoplastic Agents) RN - 0 (Aziridines) RN - 0 (Indolequinones) RN - H464ZO600O (apaziquone) SB - IM MH - Administration, Intravesical MH - Animals MH - Antineoplastic Agents/*administration & dosage/pharmacokinetics/pharmacology MH - Aziridines/*administration & dosage/pharmacokinetics/pharmacology MH - Humans MH - Indolequinones/*administration & dosage/pharmacokinetics/pharmacology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Apaziquone OT - EO9 OT - NAD(P)H:quinone oxidoreductase 1 (NQO1) OT - QapzolaTM OT - bioreductive prodrug OT - hypoxia activated prodrug OT - non-muscle invasive bladder cancer EDAT- 2017/06/24 06:00 MHDA- 2017/07/27 06:00 CRDT- 2017/06/23 06:00 PHST- 2017/06/24 06:00 [pubmed] PHST- 2017/07/27 06:00 [medline] PHST- 2017/06/23 06:00 [entrez] AID - 10.1080/17425255.2017.1341490 [doi] PST - ppublish SO - Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):783-791. doi: 10.1080/17425255.2017.1341490. Epub 2017 Jul 3. PMID- 28634017 OWN - NLM STAT- MEDLINE DCOM- 20190424 LR - 20190424 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 198 IP - 6 DP - 2017 Dec TI - The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. PG - 1278-1285 LID - S0022-5347(17)74909-9 [pii] LID - 10.1016/j.juro.2017.06.073 [doi] AB - PURPOSE: Since conditional survival analysis provides better estimates of survival time at each followup, we assessed changes in conditional intravesical recurrence-free survival rates after radical nephroureterectomy. We also sought to determine how the impact of well-known risk factors evolves with time, particularly in patients with localized upper tract urothelial carcinoma. MATERIALS AND METHODS: We identified 364 patients with Ta-3N0M0 localized upper tract urothelial carcinoma who underwent open or laparoscopic radical nephroureterectomy at 1 of our 3 institutions. Conditional intravesical recurrence-free and cancer specific survival rates were calculated using the Kaplan-Meier method. The changing impact of parameters on intravesical recurrence with time was assessed by multivariate Cox regression analysis. RESULTS: Intravesical recurrence after radical nephroureterectomy was detected in 176 patients (48.4%) and 93 (25.5%) died of localized upper tract urothelial carcinoma. Five-year intravesical recurrence-free and cancer specific survival rates after surgery were 41.5% and 72.9%, respectively. Based on 1, 2, 3 and 4-year survivorship the 5-year conditional intravesical recurrence-free survival rate increased from 41.5% to 60.5%, 73.4%, 79.5% and 96.7%, respectively. The 5-year conditional cancer specific survival rate also improved from 72.9% to 78.4%, 85.4%, 90.9% and 95.5% at 1, 2, 3 and 4 years, respectively. The effects of well-known predictive factors on estimated conditional survival decreased with time for intravesical recurrence. In contrast, the impact of T2 or lower pathological stage and laparoscopic radical nephroureterectomy sustained statistical power with time. CONCLUSIONS: Conditional survival analysis revealed that the probability of intravesical recurrence-free survival increased with time in patients with localized Ta-3N0M0 upper tract urothelial carcinoma after radical nephroureterectomy. Patients with T2 or lower T stage who undergo laparoscopic radical nephroureterectomy may be recommended for longer followup to detect subsequent intravesical recurrence. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Hagiwara, Masayuki AU - Hagiwara M AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Ando, Toshiyuki AU - Ando T AD - Department of Urology, Isehara Kyodo Hospital, Kanagawa, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Abe, Takayuki AU - Abe T AD - Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan. FAU - Mikami, Shuji AU - Mikami S AD - Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan. FAU - Miyajima, Akira AU - Miyajima A AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Nakagawa, Ken AU - Nakagawa K AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20170617 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/pathology/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Male MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Neoplasms, Second Primary/*epidemiology MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Ureteral Neoplasms/pathology/*surgery MH - Urinary Bladder Neoplasms/*epidemiology OTO - NOTNLM OT - carcinoma OT - kidney OT - local OT - neoplasm recurrence OT - survival analysis OT - ureter EDAT- 2017/06/22 06:00 MHDA- 2019/04/25 06:00 CRDT- 2017/06/22 06:00 PHST- 2017/06/10 00:00 [accepted] PHST- 2017/06/22 06:00 [pubmed] PHST- 2019/04/25 06:00 [medline] PHST- 2017/06/22 06:00 [entrez] AID - S0022-5347(17)74909-9 [pii] AID - 10.1016/j.juro.2017.06.073 [doi] PST - ppublish SO - J Urol. 2017 Dec;198(6):1278-1285. doi: 10.1016/j.juro.2017.06.073. Epub 2017 Jun 17. PMID- 28628910 OWN - NLM STAT- MEDLINE DCOM- 20180725 LR - 20181202 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 99 IP - 4 DP - 2017 TI - The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer. PG - 446-452 LID - 10.1159/000477912 [doi] AB - INTRODUCTION: Open radical cystectomy (ORC) is currently the standard treatment for muscle-invasive bladder cancer (MIBC) without metastasis, while many patients with MIBC are not always appropriate candidates due to multiple comorbidities. To evaluate the bladder-preservation strategy, we compared the results with those obtained by ORC. PATIENTS AND METHODS: We retrospectively analyzed the data of 50 patients with MIBC treated by trimodal chemoradiotherapy with cisplatin (CDDP-radiation [CDDP-R]). Transurethral resection of the bladder tumor (TURBT) was performed before treatment to confirm pathological stage >/=T2. Extensive TURBT was performed after chemoradiotherapy to evaluate the pathological response to treatment. We compared the survival outcomes of our CDDP-R with those of ORC (retrospective cohort, n = 205) by propensity score matching analysis. RESULTS: The 2- and 5-year progression-free survival, bladder-intact survival, cancer-specific survival, and overall survival (OS) rates after treatment were 70.8 and 63.9%, 64.0 and 49.8%, 86.7 and 71.8%, and 84.3 and 64.8%, respectively. The 2- and 5-year OS rates after CDDP-R were 90.5 and 74.3%, respectively, and those after ORC were 71.8 and 59.9%, respectively, indicating a significant survival advantage conferred by CDDP-R over ORC (p < 0.05, HR 0.45, 95% CI 0.21-0.94). CONCLUSIONS: In selected patients, CDDP-R for MIBC may provide comparative oncological outcomes as ORC. CI - (c) 2017 S. Karger AG, Basel. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. FAU - Hara, Takahiko AU - Hara T FAU - Nishijima, Jun AU - Nishijima J FAU - Shimizu, Kosuke AU - Shimizu K FAU - Fujii, Nakanori AU - Fujii N FAU - Kobayashi, Keita AU - Kobayashi K FAU - Kawai, Yoshihisa AU - Kawai Y FAU - Inoue, Ryo AU - Inoue R FAU - Yamamoto, Yoshiaki AU - Yamamoto Y FAU - Matsumoto, Hiroaki AU - Matsumoto H FAU - Matsuyama, Hideyasu AU - Matsuyama H LA - eng PT - Journal Article DEP - 20170621 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antineoplastic Agents) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/adverse effects/*therapeutic use MH - *Chemoradiotherapy/adverse effects/mortality MH - Cisplatin/adverse effects/*therapeutic use MH - Disease Progression MH - Disease-Free Survival MH - *Dose Fractionation, Radiation MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Odds Ratio MH - Organ Sparing Treatments/adverse effects/*methods/mortality MH - Propensity Score MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder preservation OT - Cisplatin OT - Muscle-invasive bladder cancer OT - Radical cystectomy EDAT- 2017/06/20 06:00 MHDA- 2018/07/26 06:00 CRDT- 2017/06/20 06:00 PHST- 2017/02/07 00:00 [received] PHST- 2017/05/31 00:00 [accepted] PHST- 2017/06/20 06:00 [pubmed] PHST- 2018/07/26 06:00 [medline] PHST- 2017/06/20 06:00 [entrez] AID - 000477912 [pii] AID - 10.1159/000477912 [doi] PST - ppublish SO - Urol Int. 2017;99(4):446-452. doi: 10.1159/000477912. Epub 2017 Jun 21. PMID- 28625005 OWN - NLM STAT- MEDLINE DCOM- 20180628 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 11 DP - 2017 Nov TI - Dose dense MVAC prior to radical cystectomy: a real-world experience. PG - 1729-1736 LID - 10.1007/s00345-017-2065-x [doi] AB - PURPOSE: Our primary endpoint was to assess pathological response rate (pT0N0 and 90% of patients completed all scheduled cycles. The observed rates of pT0N0 and /=3) occurred in 8% of the patients. The study is limited by the small sample size and short follow-up time. CONCLUSIONS: RAL BTC implantation is technically feasible and could serve as safe, minimally invasive alternative to open surgery in selected patients. The results of this study should be confirmed in larger studies. PATIENT SUMMARY: Brachytherapy catheter (BTC) implantation is traditionally carried out via open retropubic surgery. We describe robot-assisted laparoscopic BTC implantation as a minimally invasive alternative. Perioperative outcomes are described and confirm the safety and feasibility of this procedure. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Bosschieter, Judith AU - Bosschieter J AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. Electronic address: j.bosschieter@vumc.nl. FAU - Vis, Andre N AU - Vis AN AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - van der Poel, Henk G AU - van der Poel HG AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Moonen, Luc M AU - Moonen LM AD - Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Horenblas, Simon AU - Horenblas S AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Pieters, Bradley R AU - Pieters BR AD - Department of Radiation Oncology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. FAU - Nieuwenhuijzen, Jakko A AU - Nieuwenhuijzen JA AD - Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands. FAU - Hendricksen, Kees AU - Hendricksen K AD - Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PT - Video-Audio Media DEP - 20170612 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - Urachal cancer SB - IM CIN - Transl Androl Urol. 2018 Mar;7(Suppl 1):S114-S117. doi: 10.21037/tau.2017.11.24. PMID: 29644176 MH - Aged MH - Brachytherapy/adverse effects/*instrumentation/mortality MH - Carcinoma/diagnostic imaging/mortality/pathology/*radiotherapy MH - Catheterization/adverse effects/*instrumentation/mortality MH - *Catheters, Indwelling MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Dose Fractionation, Radiation MH - Feasibility Studies MH - Female MH - Humans MH - Laparoscopy/adverse effects/*instrumentation/mortality MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Netherlands MH - Risk Factors MH - Robotic Surgical Procedures/adverse effects/*instrumentation/mortality MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnostic imaging/mortality/pathology/*radiotherapy OTO - NOTNLM OT - Bladder-preserving therapy OT - Brachytherapy OT - Urinary bladder neoplasm OT - robotic surgical procedures EDAT- 2017/06/18 06:00 MHDA- 2019/05/21 06:00 CRDT- 2017/06/17 06:00 PHST- 2017/02/28 00:00 [received] PHST- 2017/05/29 00:00 [accepted] PHST- 2017/06/18 06:00 [pubmed] PHST- 2019/05/21 06:00 [medline] PHST- 2017/06/17 06:00 [entrez] AID - S0302-2838(17)30494-3 [pii] AID - 10.1016/j.eururo.2017.05.054 [doi] PST - ppublish SO - Eur Urol. 2018 Sep;74(3):369-375. doi: 10.1016/j.eururo.2017.05.054. Epub 2017 Jun 12. PMID- 28603003 OWN - NLM STAT- MEDLINE DCOM- 20190424 LR - 20190424 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 198 IP - 6 DP - 2017 Dec TI - Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. PG - 1263-1268 LID - S0022-5347(17)74752-0 [pii] LID - 10.1016/j.juro.2017.06.020 [doi] AB - PURPOSE: Patients with bladder cancer who present with hydronephrosis may require drainage of the affected kidney before receiving further cancer treatment. Drainage can be done by retrograde stenting or percutaneously. However, retrograde stenting carries the risk of tumor cell spillage to the upper urinary tract. The aim of this study was to evaluate whether patients with bladder cancer are at higher risk for upper urinary tract recurrence if retrograde stenting has been performed prior to radical cystectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 1,005 consecutive patients with bladder cancer who underwent radical cystectomy at our department between January 2000 and June 2016. Negative intraoperative ureteral margins were mandatory for study inclusion. Patients received regular followup according to our institutional protocol, including imaging of the upper urinary tract and urine cytology. RESULTS: Preoperative drainage of the upper urinary tract was performed in 114 of the 1,005 patients (11%), including in 53 (46%) by Double-J(R) stenting and in 61 (54%) by percutaneous nephrostomy. Recurrence developed in the upper urinary tract in 31 patients (3%) at a median of 17 months after cystectomy, including 7 of 53 (13%) in the Double-J group, 0% in the nephrostomy group and 24 of 891 (3%) in the no drainage group. Multivariate regression analysis revealed a higher risk of upper urinary tract recurrence if patients underwent Double-J stenting (HR 4.54, 95% CI 1.43-14.38, p = 0.01) and preoperative intravesical instillations (HR 2.94, 95% CI 1.40-6.16, p = 0.004). CONCLUSIONS: Patients who undergo Double-J stenting prior to radical cystectomy are at higher risk for upper urinary tract recurrence. If preoperative upper urinary tract drainage is required, percutaneous drainage might be recommended. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Kiss, Bernhard AU - Kiss B AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. Electronic address: bernhard_kiss@yahoo.com. FAU - Furrer, Marc A AU - Furrer MA AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Wuethrich, Patrick Y AU - Wuethrich PY AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Burkhard, Fiona C AU - Burkhard FC AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Roth, Beat AU - Roth B AD - Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine (PYW), University Hospital of Bern, University of Bern, Bern, Switzerland. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20170608 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2018 Apr;199(4):1069-1070. doi: 10.1016/j.juro.2017.11.119. PMID: 29305838 CIN - Transl Androl Urol. 2017 Dec;6(6):1195-1197. doi: 10.21037/tau.2017.10.08. PMID: 29354511 CIN - Transl Androl Urol. 2017 Dec;6(6):1203-1204. doi: 10.21037/tau.2017.11.26. PMID: 29354513 CIN - Eur Urol. 2018 Sep;74(3):395-396. doi: 10.1016/j.eururo.2018.04.008. PMID: 29685643 CIN - J Urol. 2018 Aug;200(2):457-458. doi: 10.1016/j.juro.2018.02.3095. PMID: 29772193 MH - Carcinoma, Transitional Cell/epidemiology/*secondary/*surgery MH - *Cystectomy MH - Female MH - Humans MH - Kidney Neoplasms/epidemiology/*secondary MH - Male MH - *Neoplasm Seeding MH - Preoperative Care MH - Retrospective Studies MH - Risk Factors MH - *Stents MH - Ureteral Neoplasms/epidemiology/*secondary MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - cystectomy OT - local OT - neoplasm recurrence OT - nephrostomy OT - percutaneous OT - stents OT - urinary bladder neoplasms EDAT- 2017/06/13 06:00 MHDA- 2019/04/25 06:00 CRDT- 2017/06/13 06:00 PHST- 2017/06/01 00:00 [accepted] PHST- 2017/06/13 06:00 [pubmed] PHST- 2019/04/25 06:00 [medline] PHST- 2017/06/13 06:00 [entrez] AID - S0022-5347(17)74752-0 [pii] AID - 10.1016/j.juro.2017.06.020 [doi] PST - ppublish SO - J Urol. 2017 Dec;198(6):1263-1268. doi: 10.1016/j.juro.2017.06.020. Epub 2017 Jun 8. PMID- 28601885 OWN - NLM STAT- MEDLINE DCOM- 20180507 LR - 20250623 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 99 IP - 1 DP - 2017 TI - Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review. PG - 1-5 LID - 10.1159/000477673 [doi] AB - Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU) remains a matter of debate. The aim of this systematic review was to present available evidence on the safety and efficacy of BCG immunotherapy in patients with ABU. A literature search within the Medline and the Embase databases was conducted with the following search terms: adverse events, bacteriuria, BCG, bladder cancer, cystitis, infection, pyuria, side effects and urinary tract infection (UTI). Sixteen relevant original articles were identified, including 6 articles directly presenting the safety or efficacy of BCG therapy in patients with ABU. None of them was a randomized controlled trial. Intravesical BCG instillations in patients with ABU were not associated with the increased risk of symptomatic UTI and did not affect negatively the recurrence- or progression-free survival. Routine urine analysis before BCG instillation created increased cost and potentially unnecessary delays in BCG therapy. ABU does not affect negatively the safety and efficacy of intravesical BCG immunotherapy. There is no evidence to support routine screening and treatment of ABU in patients scheduled for intravesical BCG instillations due to bladder cancer. However, this issue was not addressed adequately and needs further research. CI - (c) 2017 S. Karger AG, Basel. FAU - Poletajew, Slawomir AU - Poletajew S AD - Department of Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Zapala, Piotr AU - Zapala P FAU - Radziszewski, Piotr AU - Radziszewski P LA - eng PT - Journal Article PT - Systematic Review DEP - 20170610 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - Asymptomatic Diseases MH - BCG Vaccine/*administration & dosage/adverse effects MH - Bacteriuria/*complications/diagnosis MH - Humans MH - Immunotherapy/adverse effects/*methods MH - Neoplasm Invasiveness MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/complications/*drug therapy/immunology/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bacteriuria OT - Bladder cancer OT - Intravesical instillation EDAT- 2017/06/12 06:00 MHDA- 2018/05/08 06:00 CRDT- 2017/06/12 06:00 PHST- 2017/03/15 00:00 [received] PHST- 2017/05/22 00:00 [accepted] PHST- 2017/06/12 06:00 [pubmed] PHST- 2018/05/08 06:00 [medline] PHST- 2017/06/12 06:00 [entrez] AID - 000477673 [pii] AID - 10.1159/000477673 [doi] PST - ppublish SO - Urol Int. 2017;99(1):1-5. doi: 10.1159/000477673. Epub 2017 Jun 10. PMID- 28601352 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20260127 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 72 IP - 4 DP - 2017 Oct TI - Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. PG - 641-649 LID - S0302-2838(17)30488-8 [pii] LID - 10.1016/j.eururo.2017.05.048 [doi] AB - BACKGROUND: Upper urinary tract urothelial cancer (UTUC) may have unique etiologic and genomic factors compared to bladder cancer. OBJECTIVE: To characterize the genomic landscape of UTUC and provide insights into its biology using comprehensive integrated genomic analyses. DESIGN, SETTING, AND PARTICIPANTS: We collected 31 untreated snap-frozen UTUC samples from two institutions and carried out whole-exome sequencing (WES) of DNA, RNA sequencing (RNAseq), and protein analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adjusting for batch effects, consensus mutation calls from independent pipelines identified DNA mutations, gene expression clusters using unsupervised consensus hierarchical clustering (UCHC), and protein expression levels that were correlated with relevant clinical variables, The Cancer Genome Atlas, and other published data. RESULTS AND LIMITATIONS: WES identified mutations in FGFR3 (74.1%; 92% low-grade, 60% high-grade), KMT2D (44.4%), PIK3CA (25.9%), and TP53 (22.2%). APOBEC and CpG were the most common mutational signatures. UCHC of RNAseq data segregated samples into four molecular subtypes with the following characteristics. Cluster 1: no PIK3CA mutations, nonsmokers, high-grade /=36.3 versus <21.3% (OR 1.23, 95% CI 1.04-1.44, p = 0.013), Midwest versus West (OR 1.64, 95% CI 1.39-1.94, p < 0.001), and more advanced clinical stage III versus I (OR 29.1, 95% CI 23.9-35.3, p < 0.001) were associated with increased use of radical cystectomy. Overall survival was improved for patients who underwent radical cystectomy compared with those who did not undergo a radical cystectomy (hazard ratio 0.88, 95% CI 0.80-0.97, p = 0.008). CONCLUSION: There is significant underutilization of radical cystectomy in patients across all age groups diagnosed with bladder cancer, especially among older, non-Hispanic black patients. FAU - Williams, Stephen B AU - Williams SB AD - The Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. stbwilli@utmb.edu. FAU - Huo, Jinhai AU - Huo J AD - The Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Kosarek, Christopher D AU - Kosarek CD AD - The Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. FAU - Chamie, Karim AU - Chamie K AD - Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. FAU - Rogers, Selwyn O Jr AU - Rogers SO Jr AD - Department of Surgery, The University of Chicago, Chicago, IL, USA. FAU - Williams, Michele A AU - Williams MA AD - School of Public Health, Washington University, St. Louis, MO, USA. FAU - Giordano, Sharon H AU - Giordano SH AD - The Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Kim, Simon P AU - Kim SP AD - Department of Urology, Case Western Reserve Medical Center, Cleveland, OH, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - KL2 TR001441/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20170505 PL - Netherlands TA - Cancer Causes Control JT - Cancer causes & control : CCC JID - 9100846 SB - IM CIN - J Urol. 2019 Oct;202(4):659. doi: 10.1097/01.JU.0000576988.05549.2c. PMID: 31287354 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - *Cystectomy MH - Ethnicity MH - Female MH - Humans MH - Lymph Node Excision MH - Male MH - Middle Aged MH - Odds Ratio MH - Proportional Hazards Models MH - Racial Groups MH - Regression Analysis MH - Urinary Bladder Neoplasms/*ethnology/mortality/*surgery MH - Young Adult PMC - PMC5497706 MID - NIHMS874238 OTO - NOTNLM OT - Bladder cancer OT - Disparities OT - Lymph node dissection OT - Radical cystectomy OT - Utilization COIS- Conflict of Interest: All authors declare they have no conflict of interest. EDAT- 2017/05/10 06:00 MHDA- 2017/11/29 06:00 PMCR- 2018/07/01 CRDT- 2017/05/07 06:00 PHST- 2016/10/13 00:00 [received] PHST- 2017/04/29 00:00 [accepted] PHST- 2017/05/10 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/05/07 06:00 [entrez] PHST- 2018/07/01 00:00 [pmc-release] AID - 10.1007/s10552-017-0902-2 [pii] AID - 10.1007/s10552-017-0902-2 [doi] PST - ppublish SO - Cancer Causes Control. 2017 Jul;28(7):755-766. doi: 10.1007/s10552-017-0902-2. Epub 2017 May 5. PMID- 28471272 OWN - NLM STAT- MEDLINE DCOM- 20180213 LR - 20250729 IS - 1473-4877 (Electronic) IS - 0300-7995 (Linking) VI - 33 IP - 8 DP - 2017 Aug TI - Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. PG - 1379-1387 LID - 10.1080/03007995.2017.1326889 [doi] AB - OBJECTIVES: To figure out optimal bacillus Calmette-Guerin (BCG) maintenance schedules for non-muscle-invasive bladder cancer (NMIBC) patients by comparing different schedules in a systematic review using conventional and network meta-analysis. MATERIALS AND METHODS: Literature was searched in the databases of Medline, Embase, Cochrane library, Clinicaltrials.gov, Wanfang, CNKI and SinoMed in April 2016 and 9 randomized clinical trials comparing intravesical BCG maintenance therapy with BCG induction-only therapy or comparing different BCG maintenance schedules (induction-only, 1 year, 1.5 year, 2 year, 3 year maintenance) in NMIBC patients were included. Conventional and network meta-analyses within a Bayesian framework were performed to calculate odds ratios of tumor recurrence, progression and side effects (cystitis, hematuria, general malaise and fever). The surface under the cumulative ranking curve (SUCRA) mean ranking was used to obtain schedule hierarchy. RESULTS: Data from 1951 patients showed that longer-term maintenance BCG therapy does not significantly decrease tumor recurrence and progression rate of NMIBC compared to shorter-term maintenance BCG therapy. However, longer-maintenance therapy does not increase side effect incidence compared to induction-only therapy. According to SUCRA results, induction-only therapy has the highest probability of recurrence and progression but least probability of side effects. CONCLUSIONS: Longer BCG maintenance therapy (such as 3 years) is not superior to shorter maintenance therapy (such as 1 year). But maintenance therapy overall is better than induction-only BCG therapy while not increasing side effects. Though further evidence and clinical practice with balanced confounding factors (risk stratification and BCG strain) are wished for, the current study suggests the common use of 1 year intravesical BCG instillation for NMIBC patients. FAU - Huang, Zixiong AU - Huang Z AD - a Department of Urology , Peking University People's Hospital , Beijing , China. FAU - Liu, Huixin AU - Liu H AD - b Department of Clinical Epidemiology , Peking University People's Hospital , Beijing , China. FAU - Wang, Yizeng AU - Wang Y AD - c Department of Vascular Surgery , Peking University People's Hospital , Beijing , China. FAU - Zhang, Chunfang AU - Zhang C AD - b Department of Clinical Epidemiology , Peking University People's Hospital , Beijing , China. FAU - Xu, Tao AU - Xu T AD - a Department of Urology , Peking University People's Hospital , Beijing , China. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20170606 PL - England TA - Curr Med Res Opin JT - Current medical research and opinion JID - 0351014 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Antineoplastic Agents/therapeutic use MH - BCG Vaccine/*administration & dosage MH - Bayes Theorem MH - Disease Progression MH - Humans MH - Immunotherapy/*methods MH - Incidence MH - Neoplasm Recurrence, Local/drug therapy MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Intravesical bacillus Calmette-Guerin OT - efficacy OT - maintenance OT - non-muscle-invasive bladder cancer OT - side effects EDAT- 2017/05/05 06:00 MHDA- 2018/02/14 06:00 CRDT- 2017/05/05 06:00 PHST- 2017/05/05 06:00 [pubmed] PHST- 2018/02/14 06:00 [medline] PHST- 2017/05/05 06:00 [entrez] AID - 10.1080/03007995.2017.1326889 [doi] PST - ppublish SO - Curr Med Res Opin. 2017 Aug;33(8):1379-1387. doi: 10.1080/03007995.2017.1326889. Epub 2017 Jun 6. PMID- 28470753 OWN - NLM STAT- MEDLINE DCOM- 20180510 LR - 20240603 IS - 1365-2559 (Electronic) IS - 0309-0167 (Print) IS - 0309-0167 (Linking) VI - 71 IP - 3 DP - 2017 Sep TI - Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. PG - 406-414 LID - 10.1111/his.13247 [doi] AB - AIMS: Pathological stage pT1 bladder cancers constitute a clinically heterogeneous group. However, current staging guidelines for superficially invasive cancers do not acknowledge the variability in type and extent of lamina propria invasion in papillary urothelial carcinomas (PUCs), and historically proposed substaging systems showed either high interobserver variation or limited value in predicting patient outcomes. The aim of this study was to reappraise pT1 PUC substaging, with the objective of identifying a novel scheme that is reproducible and prognostically meaningful. METHODS AND RESULTS: pT1 PUCs diagnosed during 1999-2015 were retrospectively reviewed and characterized as focal invasion confined to the papillary stalk, focal invasion of the tumour base, or extensive invasion of the tumour base. Cases with concurrent flat carcinoma in situ, angiolymphatic invasion, absent muscularis propria or clinically advanced disease were excluded. We calculated cumulative incidence rates of recurrence, progression and death by tumour subtype, and evaluated differential risks by using log-rank tests and Kaplan-Meier curves stratified by type and extent of invasion. Among 62 patients satisfying the inclusion criteria, 22 of 29 patients with base-extensive invasion progressed, whereas four of 13 with base-focal and none of 20 with stalk-only invasion progressed. There was strong evidence that base-extensive patients had a higher risk of progression and death resulting from bladder cancer than base-focal or stalk-only patients (P < 0.0001). However, tumour subtype was not significantly associated with risk of recurrence (P = 0.21). CONCLUSIONS: We propose an innovative substaging approach for reporting the site and extent of lamina propria invasion in patients with pT1 PUC, allowing patient stratification for risk of progression. CI - (c) 2017 John Wiley & Sons Ltd. FAU - Lawless, Margaret AU - Lawless M AD - Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA. FAU - Gulati, Roman AU - Gulati R AUID- ORCID: 0000-0002-7592-6567 AD - Fred Hutchison Cancer Research Center, Seattle, WA, USA. FAU - Tretiakova, Maria AU - Tretiakova M AUID- ORCID: 0000-0002-0819-9638 AD - Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA. LA - eng GR - P50 CA097186/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170627 PL - England TA - Histopathology JT - Histopathology JID - 7704136 SB - IM CIN - Histopathology. 2018 Jan;72(2):361-362. doi: 10.1111/his.13374. PMID: 28851130 MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Papillary/mortality/*pathology MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Staging/*methods MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/mortality/*pathology PMC - PMC5552491 MID - NIHMS873241 OTO - NOTNLM OT - bladder OT - papillary urothelial carcinoma OT - stalk invasion COIS- Conflicts of interest The authors declare no conflicts of interest. EDAT- 2017/05/05 06:00 MHDA- 2018/05/11 06:00 PMCR- 2018/09/01 CRDT- 2017/05/05 06:00 PHST- 2017/01/24 00:00 [received] PHST- 2017/04/28 00:00 [accepted] PHST- 2017/05/05 06:00 [pubmed] PHST- 2018/05/11 06:00 [medline] PHST- 2017/05/05 06:00 [entrez] PHST- 2018/09/01 00:00 [pmc-release] AID - 10.1111/his.13247 [doi] PST - ppublish SO - Histopathology. 2017 Sep;71(3):406-414. doi: 10.1111/his.13247. Epub 2017 Jun 27. PMID- 28469275 OWN - NLM STAT- MEDLINE DCOM- 20180912 LR - 20220317 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 7 IP - 1 DP - 2017 May 3 TI - Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients. PG - 1380 LID - 10.1038/s41598-017-01532-7 [doi] LID - 1380 AB - To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue rin (BCG) immunotherapy in patients with non-muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study. Tumor recurrence was observed in 171 patients (49.3%); progression to higher pT category or grade was found in 68 patients (15.1%). Multivariate analysis demonstrated that recurrent tumors and the presence of multiple tumors increased the risk of recurrence. However, other factors also appeared to predict recurrence, such as impaired renal function (<60 ml/min), which was associated with recurrence in univariate and multivariate analyses (HR 1.879 p = 0.008). It is worthy of notice that impaired renal function was an independent predictor of tumor recurrence after BCG instillation in multivariate analysis. Therefore, we should consider not only the clinical or pathologic findings of a tumor but also renal function during decision-making for additional therapy. FAU - Tae, Bum Sik AU - Tae BS AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Jung Kwon AU - Kim JK AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. randyku@hanmail.net. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170503 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Female MH - *Glomerular Filtration Rate MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder Neoplasms/*diagnosis/*drug therapy/immunology PMC - PMC5431111 COIS- The authors declare that they have no competing interests. EDAT- 2017/05/05 06:00 MHDA- 2018/09/13 06:00 PMCR- 2017/05/03 CRDT- 2017/05/05 06:00 PHST- 2016/10/19 00:00 [received] PHST- 2017/03/30 00:00 [accepted] PHST- 2017/05/05 06:00 [entrez] PHST- 2017/05/05 06:00 [pubmed] PHST- 2018/09/13 06:00 [medline] PHST- 2017/05/03 00:00 [pmc-release] AID - 10.1038/s41598-017-01532-7 [pii] AID - 1532 [pii] AID - 10.1038/s41598-017-01532-7 [doi] PST - epublish SO - Sci Rep. 2017 May 3;7(1):1380. doi: 10.1038/s41598-017-01532-7. PMID- 28464520 OWN - NLM STAT- MEDLINE DCOM- 20170831 LR - 20180305 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 120 IP - 3 DP - 2017 Sep TI - Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m(2) ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. PG - 387-393 LID - 10.1111/bju.13904 [doi] AB - OBJECTIVE: To evaluate if moderate chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) ] is associated with high rates of non-muscle-invasive bladder cancer (NMIBC) recurrence or progression. PATIENTS AND METHODS: A multi-institutional database identified patients with serum creatinine values prior to first transurethral resection of bladder tumour (TURBT). The CKD-epidemiology collaboration formula calculated patient eGFR. Cox proportional hazards models evaluated associations with recurrence-free (RFS) and progression-free survival (PFS). RESULTS: In all, 727 patients were identified with a median (interquartile range [IQR]) patient age of 69.8 (60.1-77.6) years. Data for eGFR were available for 632 patients. During a median (IQR) follow-up of 3.7 (1.5-6.5) years, 400 (55%) patients had recurrence and 145 (19.9%) patients had progression of tumour stage or grade. Moderate or severe CKD was identified in 183 patients according to eGFR. Multivariable analysis identified an eGFR of <60 mL/min/1.73 m(2) (hazard ratio [HR] 1.5, 95% confidence interval [CI]: 1.2-1.9; P = 0.002) as a predictor of tumour recurrence. The 5-year RFS rate was 46% for patients with an eGFR of >/=60 mL/min/1.73 m(2) and 27% for patients with an eGFR of <60 mL/min/1.73 m(2) (P < 0.001). Multivariable analysis showed that an eGFR of <60 mL/min/1.73 m(2) (HR 3.7, 95% CI: 1.75-7.94; P = 0.001) was associated with progression to muscle-invasive disease. The 5-year PFS rate was 83% for patients with an eGFR of >/=60 mL/min/1.73 m(2) and 71% for patients with an eGFR of <60 mL/min/1.73 m(2) (P = 0.01). CONCLUSION: Moderate CKD at first TURBT is associated with reduced RFS and PFS. Patients with reduced renal function should be considered for increased surveillance. CI - (c) 2017 The Authors BJU International (c) 2017 BJU International Published by John Wiley & Sons Ltd. FAU - Blute, Michael L Jr AU - Blute ML Jr AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Kucherov, Victor AU - Kucherov V AD - Department of Urology, University of Rochester, Rochester, NY, USA. FAU - Rushmer, Timothy J AU - Rushmer TJ AD - University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. FAU - Damodaran, Shivashankar AU - Damodaran S AUID- ORCID: 0000-0001-6392-2553 AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Shi, Fangfang AU - Shi F AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Abel, E Jason AU - Abel EJ AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Jarrard, David F AU - Jarrard DF AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Richards, Kyle A AU - Richards KA AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. FAU - Messing, Edward M AU - Messing EM AD - Department of Urology, University of Rochester, Rochester, NY, USA. FAU - Downs, Tracy M AU - Downs TM AD - Department of Urology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. AD - University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. LA - eng PT - Journal Article DEP - 20170623 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Analysis of Variance MH - Disease Progression MH - Female MH - Glomerular Filtration Rate/*physiology MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/pathology MH - Renal Insufficiency, Chronic/complications/*epidemiology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/complications/*epidemiology/*pathology/surgery OTO - NOTNLM OT - non-muscle-invasive bladder cancer OT - tumour progression OT - tumour recurrence EDAT- 2017/05/04 06:00 MHDA- 2017/09/01 06:00 CRDT- 2017/05/03 06:00 PHST- 2017/05/04 06:00 [pubmed] PHST- 2017/09/01 06:00 [medline] PHST- 2017/05/03 06:00 [entrez] AID - 10.1111/bju.13904 [doi] PST - ppublish SO - BJU Int. 2017 Sep;120(3):387-393. doi: 10.1111/bju.13904. Epub 2017 Jun 23. PMID- 28461983 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 70 IP - 1 DP - 2017 TI - Assessment of the infiltrative character of bladder cancer at the time of transurethral resection: a single center study. PG - 22-26 LID - 10.5173/ceju.2017.768 [doi] AB - INTRODUCTION: Determining the clinical stage of bladder carcinoma before radical cystectomy is characterized by a high inaccuracy rate. The discrepancy in some reports reaches up to 48%. Therefore intraoperative clinical staging of bladder carcinoma is not recommended before radical treatment as it is for prostate cancer. However, the accuracy of clinical assessment of the muscle invasive character of the tumors at the time of transurethral resection has not been studied. In our study we estimate the accuracy of clinical staging during endoscopic treatment. MATERIAL AND METHODS: 332 patients who had undergone transurethral resection of bladder cancer were studied in this retrospective analysis. Data such as age, gender, presence of hydronephrosis, operator, the results of bimanual bladder examination, TURB report and pathologic report, were collected from each patient. Intraoperative prediction of the muscle invasive nature of the tumor was compared with pathological reports. A logistic regression analysis was used to evaluate the influence of particular variables on upstaging and downstaging. RESULTS: Overall accuracy between clinical and histopathology staging was 87.8%. Discrepancy was observed only in 36 patients. Patients with pTa stage were the most numerous group among patients with accurate prediction of the muscle invasiveness character of the tumor. Univariable logistic regression indicated that the presence of a palpable mass in the bimanual examination was a predictor of upstaging, with an OR 11.75 CI95% [2.49-55.32]. CONCLUSIONS: The study indicated the high accuracy between clinical and pathological reports. Intraoperative evaluation of tumor character should be an indispensable part of treatment, which can be useful for planning in advance the further stages of treatment. FAU - Grzegolkowski, Pawel AU - Grzegolkowski P AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Kaczmarek, Krystian AU - Kaczmarek K AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Leminski, Artur AU - Leminski A AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Soczawa, Michal AU - Soczawa M AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Golab, Adam AU - Golab A AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. FAU - Slojewski, Marcin AU - Slojewski M AD - Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland. LA - eng PT - Journal Article DEP - 20161230 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 CIN - Cent European J Urol. 2017;70(1):27-28. doi: 10.5173/ceju.2017.1242. PMID: 28466880 PMC - PMC5407325 OTO - NOTNLM OT - bladder carcinoma OT - cancer staging OT - transurethral resection COIS- The authors declare no conflicts of interest. EDAT- 2017/05/04 06:00 MHDA- 2017/05/04 06:01 PMCR- 2017/01/01 CRDT- 2017/05/03 06:00 PHST- 2016/01/06 00:00 [received] PHST- 2016/02/12 00:00 [revised] PHST- 2016/12/04 00:00 [accepted] PHST- 2017/05/03 06:00 [entrez] PHST- 2017/05/04 06:00 [pubmed] PHST- 2017/05/04 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - 00768 [pii] AID - 10.5173/ceju.2017.768 [doi] PST - ppublish SO - Cent European J Urol. 2017;70(1):22-26. doi: 10.5173/ceju.2017.768. Epub 2016 Dec 30. PMID- 28460449 OWN - NLM STAT- MEDLINE DCOM- 20180305 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 16 DP - 2017 Apr 18 TI - Laparoscopic versus open radical cystectomy for patients with bladder cancer over 75-year-old: a prospective randomized controlled trial. PG - 26565-26572 LID - 10.18632/oncotarget.15717 [doi] AB - The aim of this study was to compare the morbidity, mortality, oncological results and quality of life between laparoscopic radical cystectomy (LRC) and open radical cystectomy (ORC) in the elderly patients over 75 years old. Between January 2012 and January 2015, 60 patients were recruited into this study, who were randomly assigned in a 1:1 ratio to either LRC or ORC group. Baseline patient characteristics, pathological factors, operative and postoperative characteristics, postoperative complications and survival data were retrospectively collected, analyzed and compared between the two groups. Patients in LRC group and ORC group had comparable baseline characteristics and pathological factors (all P > 0.05). LRC group required longer operative time (408.2 +/- 76.9 vs. 311.7 +/- 65.3 min, P = 0.000) and had less EBL (621.6 +/- 100.7 vs. 1088.5 +/- 109.4 ml, P = 0.000) compared with ORC group. The incidence of infection and ileus within 90 days after surgery in ORC group was significantly higher than LRC group(6.9% vs. 28.6%, P = 0.041; 3.4% vs. 25%, P = 0.025). At a median follow-up of 28 months (range 12-48 months), the survival analysis showed that there were no significant differences between the LRC and ORC groups in overall survival (log-rank chi2 = 0.122; P = 0.726), or progress-free survival (log-rank chi2 = 0.153; P = 0.696). In conclusion, this study confirmed that LRC could achieve similar tumor treatment efficacy compared to ORC, with fewer perioperative complications and less blood loss. We suggest that LRC should be considered as the primary intervention for patients aged over 75 years old with muscle invasive bladder cancer or non-muscle invasive bladder cancer with high risk factors. FAU - Yong, Chen AU - Yong C AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Daihui, Chen AU - Daihui C AD - Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Bo, Zhou AU - Bo Z AD - Department of Urology, Department of Urology, Daping Hospital, Third Military Medical University, Chongqing, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers MH - Comorbidity MH - *Cystectomy/adverse effects/methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - *Laparoscopy/adverse effects/methods MH - Male MH - Neoplasm Grading MH - Neoplasm Staging MH - Postoperative Complications MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/mortality/*surgery PMC - PMC5432279 OTO - NOTNLM OT - bladder cancer OT - elderly patients OT - laparoscopic OT - open radical cystectomy COIS- CONFLICTS OF INTEREST None to declare. EDAT- 2017/05/04 06:00 MHDA- 2018/03/06 06:00 PMCR- 2017/04/18 CRDT- 2017/05/03 06:00 PHST- 2016/11/09 00:00 [received] PHST- 2017/02/10 00:00 [accepted] PHST- 2017/05/03 06:00 [entrez] PHST- 2017/05/04 06:00 [pubmed] PHST- 2018/03/06 06:00 [medline] PHST- 2017/04/18 00:00 [pmc-release] AID - 15717 [pii] AID - 10.18632/oncotarget.15717 [doi] PST - ppublish SO - Oncotarget. 2017 Apr 18;8(16):26565-26572. doi: 10.18632/oncotarget.15717. PMID- 28457661 OWN - NLM STAT- MEDLINE DCOM- 20180618 LR - 20250623 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 72 IP - 5 DP - 2017 Nov TI - Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. PG - 801-813 LID - S0302-2838(17)30323-8 [pii] LID - 10.1016/j.eururo.2017.04.015 [doi] AB - CONTEXT: Tumour grade is an important prognostic indicator in non-muscle-invasive bladder cancer (NMIBC). Histopathological classifications are limited by interobserver variability (reproducibility), which may have prognostic implications. European Association of Urology NMIBC guidelines suggest concurrent use of both 1973 and 2004/2016 World Health Organization (WHO) classifications. OBJECTIVE: To compare the prognostic performance and reproducibility of the 1973 and 2004/2016 WHO grading systems for NMIBC. EVIDENCE ACQUISITION: A systematic literature search was undertaken incorporating Medline, Embase, and the Cochrane Library. Studies were critically appraised for risk of bias (QUIPS). For prognosis, the primary outcome was progression to muscle-invasive or metastatic disease. Secondary outcomes were disease recurrence, and overall and cancer-specific survival. For reproducibility, the primary outcome was interobserver variability between pathologists. Secondary outcome was intraobserver variability (repeatability) by the same pathologist. EVIDENCE SYNTHESIS: Of 3593 articles identified, 20 were included in the prognostic review; three were eligible for the reproducibility review. Increasing tumour grade in both classifications was associated with higher disease progression and recurrence rates. Progression rates in grade 1 patients were similar to those in low-grade patients; progression rates in grade 3 patients were higher than those in high-grade patients. Survival data were limited. Reproducibility of the 2004/2016 system was marginally better than that of the 1973 system. Two studies on repeatability showed conflicting results. Most studies had a moderate to high risk of bias. CONCLUSIONS: Current grading classifications in NMIBC are suboptimal. The 1973 system identifies more aggressive tumours. Intra- and interobserver variability was slightly less in the 2004/2016 classification. We could not confirm that the 2004/2016 classification outperforms the 1973 classification in prediction of recurrence and progression. PATIENT SUMMARY: This article summarises the utility of two different grading systems for non-muscle-invasive bladder cancer. Both systems predict progression and recurrence, although pathologists vary in their reporting; suggestions for further improvements are made. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University in Praha, Praha, Czech Republic. Electronic address: viktor.soukup@seznam.cz. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University in Praha, Praha, Czech Republic. Electronic address: otakar.capoun@seznam.cz. FAU - Cohen, Daniel AU - Cohen D AD - Department of Urology, Royal Free London NHS Foundation Trust, London, UK. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion de Alcorcon, Madrid, Spain. FAU - Babjuk, Marek AU - Babjuk M AD - Hospital Motol and Second Faculty of Medicine, Charles University, Department of Urology, Prague, Czech Republic. FAU - Burger, Max AU - Burger M AD - Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Germany. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Hopitaux Universitaires de l'Est-Parisien HUEP, Assistance Publique Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancerologie GRC5, University Paris 6, Paris, France. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Urology, University of Turin, Turin, Italy. FAU - Lam, Thomas AU - Lam T AD - Academic Urology Unit, University of Aberdeen, Scotland, UK; Department of Urology, Aberdeen Royal, 12 Infirmary, Aberdeen, Scotland. FAU - MacLennan, Steven AU - MacLennan S AD - Academic Urology Unit, University of Aberdeen, Scotland, UK. FAU - Mostafid, A Hugh AU - Mostafid AH AD - Department of Urology, Royal Surrey County Hospital, Guildford, UK. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancerologie GRC5, University Paris 6, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Sylvester, Richard AU - Sylvester R AD - EAU Guidelines Office Board, European Association of Urology, The Netherlands. FAU - Yuan, Yuhong AU - Yuan Y AD - Department of Medicine, Health Science Centre, McMaster University, Hamilton, Ontario, Canada. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medizinische Universitat Graz, Graz, Austria. LA - eng PT - Comparative Study PT - Journal Article PT - Systematic Review DEP - 20170428 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM MH - Disease Progression MH - Disease-Free Survival MH - Humans MH - Neoplasm Grading/methods/*standards MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Neoplasm Recurrence, Local MH - Observer Variation MH - Practice Guidelines as Topic/*standards MH - Predictive Value of Tests MH - Reproducibility of Results MH - Treatment Outcome MH - Urinary Bladder Neoplasms/classification/mortality/*pathology/therapy MH - *World Health Organization OTO - NOTNLM OT - 1973 World Health Organization classification OT - 2004/2016 World Health Organization classification OT - Grade OT - Non-muscle-invasive bladder cancer OT - Prognosis OT - Progression OT - Recurrence OT - Repeatability OT - Reproducibility EDAT- 2017/05/02 06:00 MHDA- 2018/06/19 06:00 CRDT- 2017/05/02 06:00 PHST- 2017/03/23 00:00 [received] PHST- 2017/04/12 00:00 [accepted] PHST- 2017/05/02 06:00 [pubmed] PHST- 2018/06/19 06:00 [medline] PHST- 2017/05/02 06:00 [entrez] AID - S0302-2838(17)30323-8 [pii] AID - 10.1016/j.eururo.2017.04.015 [doi] PST - ppublish SO - Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28. PMID- 28457495 OWN - NLM STAT- MEDLINE DCOM- 20190218 LR - 20190219 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 41 IP - 9 DP - 2017 Nov TI - Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: The importance of the strain and maintenance. PG - 590-595 LID - S0210-4806(17)30062-1 [pii] LID - 10.1016/j.acuro.2017.03.003 [doi] AB - BACKGROUND AND OBJECTIVE: Intravesical Bacille Calmette-Guerin (BCG) is essential for preventing the recurrence and progression of superficial bladder tumours. The aim of our study was to compare the efficacy and toxicity of the Connaught and Tice strains, as well as the importance of the maintenance regimen. MATERIAL AND METHODS: We retrospectively reviewed 110 patients with superficial bladder tumours who underwent adjuvant endovesical treatment. The patients were distributed into 3 groups, based on whether the treatment was with the Connaught strain, the Tice strain or both sequentially. We calculated the relapse-free survival rate in each group and compared the patients who completed the maintenance treatments against those who did not. To identify the predictors of relapse, we performed a multivariate analysis. We also assessed the toxicity by analysing the onset of BCGitis, urinary urgency, fever, urinary tract infection and treatment withdrawing due to adverse effects. RESULTS: We found no differences in the efficacy parameters. The patients in the Connaught group completed the maintenance to a lesser extent (38.4 vs. 72% for the Tice group and 76.3% for both groups; P=.010). The patients who completed the maintenance had better relapse-free survival at 60 months (88.5 vs. 74.2%; P=.036), regardless of the strain employed. The multivariate analysis identified a size larger than 3cm, more than 3 implants and not completing the maintenance as risk factors of relapse. The patients with the Connaught strain had higher rates of BCGitis, with no differences in the other events studied. CONCLUSION: Completing the maintenance phase is essential, regardless of the strain employed. The Connaught strain has a greater risk of BCGitis, and a sequential regimen could be useful in certain scenarios. CI - Copyright (c) 2017 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Guerrero-Ramos, F AU - Guerrero-Ramos F AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. Electronic address: felixguerrero@gmail.com. FAU - Lara-Isla, A AU - Lara-Isla A AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. FAU - Justo-Quintas, J AU - Justo-Quintas J AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. FAU - Duarte-Ojeda, J M AU - Duarte-Ojeda JM AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. FAU - de la Rosa-Kehrmann, F AU - de la Rosa-Kehrmann F AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. FAU - Villacampa-Auba, F AU - Villacampa-Auba F AD - Servicio de Urologia, Hospital Universitario 12 de Octubre, Madrid, Espana. LA - eng LA - spa PT - Comparative Study PT - Journal Article TT - Tratamiento adyuvante intravesical en cancer de vejiga no musculo invasivo: importancia de la cepa y el mantenimiento. DEP - 20170428 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Connaught) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*administration & dosage/adverse effects MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*administration & dosage/adverse effects MH - Female MH - Humans MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Bacille Calmette-Guerin OT - Bacilo de Calmette-Guerin OT - Bladder cancer OT - Cancer de vejiga OT - Efficacy OT - Eficacia OT - Toxicidad OT - Toxicity EDAT- 2017/05/02 06:00 MHDA- 2019/02/20 06:00 CRDT- 2017/05/02 06:00 PHST- 2017/01/13 00:00 [received] PHST- 2017/03/24 00:00 [revised] PHST- 2017/03/27 00:00 [accepted] PHST- 2017/05/02 06:00 [pubmed] PHST- 2019/02/20 06:00 [medline] PHST- 2017/05/02 06:00 [entrez] AID - S0210-4806(17)30062-1 [pii] AID - 10.1016/j.acuro.2017.03.003 [doi] PST - ppublish SO - Actas Urol Esp. 2017 Nov;41(9):590-595. doi: 10.1016/j.acuro.2017.03.003. Epub 2017 Apr 28. PMID- 28455741 OWN - NLM STAT- MEDLINE DCOM- 20170914 LR - 20181113 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 470 IP - 6 DP - 2017 Jun TI - Lymphoepithelioma-like carcinoma of the upper urinary tract. PG - 703-709 LID - 10.1007/s00428-017-2117-z [doi] AB - In this report, we summarized the clinicopathologic features of ten cases of lymphoepithelioma-like carcinoma (LELC) of the upper urinary tract (ureter n = 6; renal pelvis n = 4), a rare variant of urothelial cancer characterized by a malignant epithelial component densely infiltrated by lymphoid cells. The initial diagnosis was made on radical nephrectomy in five cases, nephroureterectomy in three cases, and ureterectomy in two others. Four patients had pathologic stage T1 (n = 2) or T2 (n = 2) tumors, and six patients had stage pT3 disease. Microscopically, all tumors contained pure (n = 3) or predominant (n = 7) LELC, which composed 60 to 80% of the entire tumor. Non-LELC tumor component was adenocarcinoma (n = 2), spindle cell carcinoma (n = 1), or high-grade conventional urothelial carcinoma (n = 4). The LELC component was characterized by indistinct cytoplasmic borders and a syncytial growth pattern. Immunohistochemical staining showed LELC to be positive for cytokeratin AE1/AE3, CK7, CK34ssE12 (rare cells), CK5/6 (rare cells), and CK20 (rare cells); rare cells were p40 positive. GATA 3 was positive in all cases in a variable proportion of cells (20-80%). Lymphoid markers showed a polyclonal proliferation of predominant T cells admixed with B cells. In situ hybridization for the HPV genome was negative in all ten cases. Survival analysis showed no differences between LELC and conventional upper urinary tract urothelial carcinoma, pT classification being the only significant prognostic parameter. Morphologic recognition and distinction from other (non-)neoplastic lesions with prominent lymphoid stroma are critical for its clinical management. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A AD - Department of Pathology and Surgery, Unit of Anatomical Pathology, Faculty of Medicine, University of Cordoba, 14004, Cordoba, Spain. em1lobea@uco.es. FAU - Paner, Gladell AU - Paner G AD - Section of Urology, Departments of Pathology and Surgery, University of Chicago, Chicago, IL, USA. FAU - Blanca, Ana AU - Blanca A AD - Biomedical Research Unit, Reina Sofia University Hospital, Cordoba, Spain. FAU - Montironi, Rodolfo AU - Montironi R AD - Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Tsuzuki, Toyonori AU - Tsuzuki T AD - Department of Surgical Pathology, Aichi Medical University, School of Medicine, Yazakokarimata, Nagakute, Japan. FAU - Nagashima, Yoji AU - Nagashima Y AD - Department of Surgical Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan. FAU - Chuang, Shi-Sung AU - Chuang SS AD - Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan. FAU - Win, Khin Than AU - Win KT AD - Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan. FAU - Madruga, Leo AU - Madruga L AD - Pathology Service, Champalimaud Clinical Center, Lisbon, Portugal. FAU - Raspollini, Maria R AU - Raspollini MR AD - Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. LA - eng PT - Journal Article DEP - 20170428 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM CIN - Virchows Arch. 2017 Oct;471(4):559. doi: 10.1007/s00428-017-2188-x. PMID: 28699107 MH - Aged MH - Aged, 80 and over MH - Carcinoma/mortality/*pathology MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/mortality/*pathology MH - Male MH - Middle Aged MH - Ureteral Neoplasms/mortality/*pathology OTO - NOTNLM OT - Lymphoepithelioma OT - Lymphoepithelioma-like OT - Renal pelvis OT - Ureter EDAT- 2017/04/30 06:00 MHDA- 2017/09/15 06:00 CRDT- 2017/04/30 06:00 PHST- 2016/09/21 00:00 [received] PHST- 2017/04/03 00:00 [accepted] PHST- 2017/01/31 00:00 [revised] PHST- 2017/04/30 06:00 [pubmed] PHST- 2017/09/15 06:00 [medline] PHST- 2017/04/30 06:00 [entrez] AID - 10.1007/s00428-017-2117-z [pii] AID - 10.1007/s00428-017-2117-z [doi] PST - ppublish SO - Virchows Arch. 2017 Jun;470(6):703-709. doi: 10.1007/s00428-017-2117-z. Epub 2017 Apr 28. PMID- 28445991 OWN - NLM STAT- MEDLINE DCOM- 20180410 LR - 20260127 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 15 DP - 2017 Apr 11 TI - Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. PG - 25433-25441 LID - 10.18632/oncotarget.15989 [doi] AB - In the present study we tested the role of Human Epidermal Growth Factor Receptor-2 (HER-2) expression, as assayed by immunohistochemistry, in predicting recurrence and progression in 67 patients with T1G3 BC having undergone transurethral resection of bladder tumor (TURBT) alone (33) or TURBT + Bacillus Calmette Guerin (BCG) instillations (34). All patients had a negative restaging TURBT within 4 months after the first TURBT. At median follow-up of 75.7 months, the overall disease-free and progression-free rates were 35.8% and 73.0%, respectively. Univariate Kaplan-Meier survival analysis showed that traditional prognostic factors (sex, tumor number/size/recurrence) failed to predict disease-free and progression free survival (DFS, PFS). BCG treatment was a significant predictor of DFS (p=0.0231) but not of PFS (p=0.6901). HER-2 overexpression was a significant predictor of DFS (p=0.0013) and PFS (p=0.0322) in the overall patients population, but failed to predict PFS when patients were stratified for treatment (BCG: p=0.1290; no BCG: p=0.1696) probably due to the limited number of events. Multivariate Cox proportional-hazards regression analysis confirmed that BCG treatment was a significant predictor of DFS (p=0.012) but not of PFS (p=0.924), whereas HER-2 overexpression was a significant predictor of DFS (p=0.001) and PFS (p=0.041). These findings suggest that HER-2 status performs better than "traditional" prognostic factors as well as of BCG treatment in predicting the outcome of T1G3 BC, thus providing grounds for further testing this marker and possibly incorporating it in a panel of molecular markers that could reliably predict the behavior of this challenging disease. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology, University Hospital of Foggia, Foggia, Italy. FAU - Sanguedolce, Francesca AU - Sanguedolce F AD - Department of Pathology, University Hospital of Foggia, Foggia, Italy. FAU - Cormio, Antonella AU - Cormio A AD - Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, Italy. FAU - Massenio, Paolo AU - Massenio P AD - Department of Urology, University Hospital of Foggia, Foggia, Italy. FAU - Pedicillo, Maria Carmela AU - Pedicillo MC AD - Department of Pathology, University Hospital of Foggia, Foggia, Italy. FAU - Cagiano, Simona AU - Cagiano S AD - Department of Pathology, University Hospital of Foggia, Foggia, Italy. FAU - Calo, Giuseppe AU - Calo G AD - Department of Urology, University Hospital of Foggia, Foggia, Italy. FAU - Pagliarulo, Vincenzo AU - Pagliarulo V AD - Department of Urology, University Hospital of Bari, Bari, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology, University Hospital of Foggia, Foggia, Italy. FAU - Bufo, Pantaleo AU - Bufo P AD - Department of Pathology, University Hospital of Foggia, Foggia, Italy. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (BCG Vaccine) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM CIN - J Urol. 2019 Mar;201(3):441-442. doi: 10.1097/01.JU.0000553699.73423.0a. PMID: 30759671 MH - Aged MH - BCG Vaccine/*therapeutic use MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Erb-b2 Receptor Tyrosine Kinases/*biosynthesis/metabolism MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*metabolism/pathology/*therapy PMC - PMC5421941 OTO - NOTNLM OT - HER-2 OT - immunohistochemistry OT - non-muscle-invasive bladder cancer OT - prognosis COIS- CONFLICTS OF INTEREST The authors disclose no conflict of interest. EDAT- 2017/04/28 06:00 MHDA- 2018/04/11 06:00 PMCR- 2017/04/11 CRDT- 2017/04/28 06:00 PHST- 2016/10/02 00:00 [received] PHST- 2017/02/06 00:00 [accepted] PHST- 2017/04/28 06:00 [entrez] PHST- 2017/04/28 06:00 [pubmed] PHST- 2018/04/11 06:00 [medline] PHST- 2017/04/11 00:00 [pmc-release] AID - 15989 [pii] AID - 10.18632/oncotarget.15989 [doi] PST - ppublish SO - Oncotarget. 2017 Apr 11;8(15):25433-25441. doi: 10.18632/oncotarget.15989. PMID- 28443140 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 11 IP - 1-2 DP - 2017 Jan-Feb TI - Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. PG - 24-30 LID - 10.5489/cuaj.4008 [doi] AB - INTRODUCTION: While radical cystectomy is the gold standard for muscle-invasive bladder cancer (MIBC), in octogenarians cystectomy results in a higher perioperative mortality rate (6.8-11.1%) than in younger patients (2.2%). Trimodality therapy is a bladder-sparing regimen composed of transurethral resection of bladder tumour (TURBT) and chemoradiotherapy, with intent for salvage cystectomy, and has a 62.5-90% initial complete response rate. In this study, we evaluate TURBT and chemoradiotherapy without salvage cystectomy in medically inoperable octogenarian patients. METHODS: We identified a retrospective cohort of patients aged 80-89 years with invasive urothelial carcinoma who received combination chemoradiotherapy between 2008 and June 2014. Outcomes were evaluated by Kaplan-Meier (KM) and Cox regression. RESULTS: In 40 patients, the mean age was 84.5 years (interquartile range [IQR] 83-86). Seventeen patients received hypofractionated, low-dose radiotherapy (LD) (37.5-40 Gy), while 23 received conventionally fractionated radiotherapy (high-dose [HD]) (50-65 Gy). Mean overall survival (OS) was 20.7 months (IQR 12.75-23.25), while mean recurrence-free survival (RFS) was 13.75 months (IQR 3.75-16.5). Patients receiving HD radiotherapy showed improved OS and local RFS (LRFS) without significant differences in Grade 3-4 toxicities. Univariate Cox regression identified hydronephrosis as a predictor of worse OS and local recurrence and HD radiotherapy as a predictor of improved OS and local recurrence rates. Multivariate Cox regression identified hydronephrosis to be a significant predictor of LRFS. CONCLUSIONS: Primary chemoradiotherapy for inoperable patients with MIBC resulted in a three-year OS of 54.9% (comparable to cystectomy) and three-year RFS of 42.3%. Superior outcomes were associated with more aggressive chemoradiotherapy treatment. The results of the local control subanalyses in this study are hypothesis-generating due to the limited patient numbers in the cohort. FAU - McPherson, Victor A AU - McPherson VA AD - Division of Urology. FAU - Rodrigues, George AU - Rodrigues G AD - Division of Radiation Oncology. FAU - Bauman, Glenn AU - Bauman G AD - Division of Radiation Oncology. FAU - Winquist, Eric AU - Winquist E AD - Division of Medical Oncology; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Chin, Joseph AU - Chin J AD - Division of Urology. FAU - Izawa, Jonathan AU - Izawa J AD - Division of Urology. FAU - Potvin, Kylea AU - Potvin K AD - Division of Medical Oncology; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Ernst, Scott AU - Ernst S AD - Division of Medical Oncology; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Venkatesan, Varagur AU - Venkatesan V AD - Division of Radiation Oncology. FAU - Sexton, Tracy AU - Sexton T AD - Division of Radiation Oncology. FAU - Ahmad, Belal AU - Ahmad B AD - Division of Radiation Oncology. FAU - Power, Nicholas AU - Power N AD - Division of Urology. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 CIN - Can Urol Assoc J. 11(1-2):31. CIN - Can Urol Assoc J. 11:e64. PMC - PMC5403684 EDAT- 2017/04/27 06:00 MHDA- 2017/04/27 06:01 PMCR- 2017/01/01 CRDT- 2017/04/27 06:00 PHST- 2017/04/27 06:00 [entrez] PHST- 2017/04/27 06:00 [pubmed] PHST- 2017/04/27 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - cuaj-1-2-24 [pii] AID - 10.5489/cuaj.4008 [doi] PST - ppublish SO - Can Urol Assoc J. 2017 Jan-Feb;11(1-2):24-30. doi: 10.5489/cuaj.4008. PMID- 28438520 OWN - NLM STAT- MEDLINE DCOM- 20170911 LR - 20220409 IS - 1878-1810 (Electronic) IS - 1878-1810 (Linking) VI - 184 DP - 2017 Jun TI - Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. PG - 108-117 LID - S1931-5244(16)30227-4 [pii] LID - 10.1016/j.trsl.2017.03.005 [doi] AB - Several reports over the last 10 years provided evidence that long noncoding RNAs (lncRNAs) are often altered in bladder cancers. lncRNAs are longer than 200 nucleotides and function as important regulators of gene expression, interacting with the major pathways of cell growth, proliferation, differentiation, and survival. A large number of lncRNAs has oncogenic function and is more expressed in tumor compared with normal tissues. Their overexpression may be associated with tumor formation, progression, and metastasis in a variety of tumors including bladder cancer. Although lncRNAs have been shown to have critical regulatory roles in cancer biology, the biological functions and prognostic values in nonmuscle-invasive bladder cancer remain largely unknown. Nevertheless, a growing body of evidence suggests that several lncRNAs expression profiles in bladder malignancies are associated with poor prognosis, and they can be detected in biological fluids, such as urines. Here, we review current progress in the biology and the implication of lncRNAs associated with bladder cancer, and we discuss their potential use as diagnosis and prognosis biomarkers in bladder malignancies with a focus on their role in high-risk nonmuscle-invasive tumors. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Terracciano, Daniela AU - Terracciano D AD - Department of Translational Medical Sciences, University "Federico II", Naples, Italy. Electronic address: daniela.terracciano@unina.it. FAU - Ferro, Matteo AU - Ferro M AD - Division of Urology, European Institute of Oncology, Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Terreri, Sara AU - Terreri S AD - Institute of Genetics and Biophysics "A. Buzzati Traverso", National Research Council (CNR), Naples, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - D'Elia, Carolina AU - D'Elia C AD - Urology Department, Central Hospital of Bolzano, Bolzano, Italy. FAU - Musi, Gennaro AU - Musi G AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Division of Urology, European Institute of Oncology, Milan, Italy. FAU - Mirone, Vincenzo AU - Mirone V AD - Urology Department, University of Naples Federico II, Naples, Italy. FAU - Cimmino, Amelia AU - Cimmino A AD - Institute of Genetics and Biophysics "A. Buzzati Traverso", National Research Council (CNR), Naples, Italy. Electronic address: amelia.cimmino@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20170407 PL - United States TA - Transl Res JT - Translational research : the journal of laboratory and clinical medicine JID - 101280339 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) SB - IM MH - Biomarkers, Tumor/*genetics MH - Gene Expression Regulation, Neoplastic MH - Genes, Tumor Suppressor MH - Humans MH - Oncogenes MH - RNA, Long Noncoding/physiology/*urine MH - Urinary Bladder Neoplasms/*genetics/urine EDAT- 2017/04/26 06:00 MHDA- 2017/09/12 06:00 CRDT- 2017/04/26 06:00 PHST- 2016/09/26 00:00 [received] PHST- 2017/03/22 00:00 [revised] PHST- 2017/03/28 00:00 [accepted] PHST- 2017/04/26 06:00 [pubmed] PHST- 2017/09/12 06:00 [medline] PHST- 2017/04/26 06:00 [entrez] AID - S1931-5244(16)30227-4 [pii] AID - 10.1016/j.trsl.2017.03.005 [doi] PST - ppublish SO - Transl Res. 2017 Jun;184:108-117. doi: 10.1016/j.trsl.2017.03.005. Epub 2017 Apr 7. PMID- 28433642 OWN - NLM STAT- MEDLINE DCOM- 20190415 LR - 20190415 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 198 IP - 4 DP - 2017 Oct TI - Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population. PG - 824-831 LID - S0022-5347(17)54785-0 [pii] LID - 10.1016/j.juro.2017.04.077 [doi] AB - PURPOSE: We assessed the performance of the EORTC (European Organisation for Research and Treatment of Cancer) and CUETO (Club Urologico Espanol de Tratamiento Oncologico) nonmuscle invasive bladder cancer predictive models compared to current United States NCCN Guidelines(R) in an American population. MATERIALS AND METHODS: We retrospectively analyzed the electronic medical records of patients with nonmuscle invasive bladder cancer in a multicenter population in the United States. We evaluated recurrence-free and progression-free survival according to EORTC and CUETO, and assessed discriminative performance with the c-index at 1 and 5 years. We then compared the discrimination of EORTC and CUETO to the discrimination of the 4 nonmuscle invasive bladder cancer treatment groups described in NCCN Guidelines. RESULTS: We identified 1,333 patients with nonmuscle invasive bladder cancer and a median followup of 37 months. At 5 years the recurrence c-index of EORTC and CUETO was 0.59 and 0.56 while for progression it was higher at 0.74 and 0.72, respectively. NCCN Guidelines demonstrated a similar c-index of 0.56 and 0.75, respectively. The discrimination of all 3 risk models decreased in patients who received bacillus Calmette-Guerin. EORTC was better able to identify patients at low risk for recurrence or progression but it overestimated the 5-year risk of progression in patients at high risk. This study was limited by its retrospective design. CONCLUSIONS: Our work illustrates the need for improved predictive tools for clinicians who treat patients with nonmuscle invasive bladder cancer. However, until new tools are developed NCCN Guidelines are a simple option for clinicians who treat patients with nonmuscle invasive bladder cancer. Those guidelines provide predictive power comparable to that of the EORTC and CUETO models. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Ravvaz, Kourosh AU - Ravvaz K AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin. Electronic address: kourosh.ravvaz@aurora.org. FAU - Walz, Marcus E AU - Walz ME AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin. FAU - Weissert, John A AU - Weissert JA AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin. FAU - Downs, Tracy M AU - Downs TM AD - Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison (TMD), Wisconsin. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20170419 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BCG Vaccine) SB - IM CIN - J Urol. 2018 Oct;200(4):706-708. doi: 10.1016/j.juro.2018.06.019. PMID: 29906436 MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/mortality/*pathology/therapy MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Electronic Health Records/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis/epidemiology/prevention & control MH - Practice Guidelines as Topic MH - Predictive Value of Tests MH - Prognosis MH - Progression-Free Survival MH - Retrospective Studies MH - Risk Assessment/*methods/standards MH - United States MH - Urinary Bladder Neoplasms/mortality/*pathology/therapy OTO - NOTNLM OT - BCG vaccine OT - bladder neoplasms OT - mortality OT - practice guidelines as topic OT - risk assessment EDAT- 2017/04/24 06:00 MHDA- 2019/04/16 06:00 CRDT- 2017/04/24 06:00 PHST- 2017/04/12 00:00 [accepted] PHST- 2017/04/24 06:00 [pubmed] PHST- 2019/04/16 06:00 [medline] PHST- 2017/04/24 06:00 [entrez] AID - S0022-5347(17)54785-0 [pii] AID - 10.1016/j.juro.2017.04.077 [doi] PST - ppublish SO - J Urol. 2017 Oct;198(4):824-831. doi: 10.1016/j.juro.2017.04.077. Epub 2017 Apr 19. PMID- 28433471 OWN - NLM STAT- MEDLINE DCOM- 20180509 LR - 20180616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 8 DP - 2017 Aug TI - Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. PG - 528.e1-528.e5 LID - S1078-1439(17)30133-3 [pii] LID - 10.1016/j.urolonc.2017.03.024 [doi] AB - INTRODUCTION: To evaluate incidence of histological variants and grade agreement between transurethral resection (TUR) and radical cystectomy (RC) in patients with bladder cancer. METHODS: A total of 779 patients treated with TUR and subsequently with RC between 1990 and 2013 at a single center were analyzed retrospectively. Variant histology classifications used in our analyses were sarcomatoid, small cell, squamous, or micropapillary. Grade agreement was calculated using the Cohen kappa coefficient. Logistic regression analyses were built to predict adverse pathologic features from histological variants at TUR. RESULTS: Considering TUR, 213 (27.3%) patients were diagnosed with histological variants. Of these, 2.1% (n = 16) were found with sarcomatoid variant, 1.7% (n = 13) with small cell, 7.1% (n = 55) with squamous, 12.5% (n = 97) with micropapillary. Considering RC, 212 (27.2%) patients were diagnosed with histological variants. Poor agreement was found considering micropapillary variant and the presence of a histological variant in general (0.11 and 0.27, respectively). Intermediate agreement was found analyzing the presence of sarcomatoid, small cell, and squamous variants (0.43, 0.61, and 0.61, respectively). Small cell carcinoma at TUR was found associated with an increased risk of harboring positive soft tissue surgical margin (odds ratio = 2.08; CI: 1.27-3.41; P = 0.03). CONCLUSIONS: One out of our patients with bladder cancer was diagnosed with a histological variant either at TUR and RC. We found poor agreement between TUR and RC. Our findings highlight that TUR alone is not sufficient to accurately evaluate the presence of histological variants that may have an effect on treatment and survival outcomes. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy; Department of Urology, Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: marco.moschini87@gmail.com. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Freschi, Massimo AU - Freschi M AD - Department of Pathology, Ospedale San Raffaele, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Foerster, Beat AU - Foerster B AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Dell'Oglio, Paolo AU - Dell'Oglio P AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Zaffuto, Emanuele AU - Zaffuto E AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Department of Urology, Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Salonia, Andrea AU - Salonia A AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Urological Research Institute, Milan, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170419 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adult MH - Aged MH - Carcinoma, Transitional Cell/*diagnosis/pathology/surgery MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Histological variants OT - Radical cystectomy OT - Transurethral resection EDAT- 2017/04/24 06:00 MHDA- 2018/05/10 06:00 CRDT- 2017/04/24 06:00 PHST- 2016/12/23 00:00 [received] PHST- 2017/02/23 00:00 [revised] PHST- 2017/03/21 00:00 [accepted] PHST- 2017/04/24 06:00 [pubmed] PHST- 2018/05/10 06:00 [medline] PHST- 2017/04/24 06:00 [entrez] AID - S1078-1439(17)30133-3 [pii] AID - 10.1016/j.urolonc.2017.03.024 [doi] PST - ppublish SO - Urol Oncol. 2017 Aug;35(8):528.e1-528.e5. doi: 10.1016/j.urolonc.2017.03.024. Epub 2017 Apr 19. PMID- 28427201 OWN - NLM STAT- MEDLINE DCOM- 20180326 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 19 DP - 2017 May 9 TI - Wnt5a / planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker. PG - 31655-31665 LID - 10.18632/oncotarget.15877 [doi] AB - Bladder cancer is the fourth most common cancer in men and the most common malignancy of the urinary tract. Bladder cancers detected at an early stage have a very high five-year survival rate, but when detected after local metastasis the rate is only about 50%. Our group recently reported a positive correlation between the expression of Wnt5a, a member of the Wnt proteins family, and histopathological grade and stage of urothelial carcinoma (UC). The objective of this study was to analyze UC cases reported in Athens, Ohio and investigate the major components of Wnt5a / planar cell polarity (PCP) signaling pathway in UC human tissue samples and UC cell lines.Formalin fixed and paraffin embedded transurethral resection tissues were immunostained for Wnt5a, Ror-2, CTHRC1 and E-cadherin. In addition, in vitro studies using UC cell lines were investigated for Wnt5a/PCP signaling and epithelial mesenchymal transition (EMT) gene expression. The IHC results showed a correlation between the expression of Wnt5a, Ror2 and CTHRC1 with high histological grade of the tumor, while E-cadherin showed an opposite trend of expression. Real time RT-PCR results showed that RNA expression of the Wnt5a/ PCP pathway genes vary in low and high grade UC cell lines and that the high grade cell lines exhibited signs of EMT.These findings support that Wnt5a-Ror2 signaling plays a role in UC, support the potential use of Wnt5a as a prognostic marker and provide evidence that Wnt5a signaling may be used as an effective molecular target for novel therapeutic tools. FAU - Saling, Mark AU - Saling M AD - Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. FAU - Duckett, Jordan K AU - Duckett JK AD - Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. FAU - Ackers, Ian AU - Ackers I AD - Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. FAU - Coschigano, Karen AU - Coschigano K AD - Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. AD - Interdisciplinary Program in Molecular and Cellular Biology, Ohio University, Athens, Ohio, USA. AD - The Diabetes Institute of Ohio University, Athens, Ohio, USA. FAU - Jenkinson, Scott AU - Jenkinson S AD - University Medical Associates, Inc., Pathology, Athens, Ohio, USA. FAU - Malgor, Ramiro AU - Malgor R AD - Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. AD - Interdisciplinary Program in Molecular and Cellular Biology, Ohio University, Athens, Ohio, USA. AD - The Diabetes Institute of Ohio University, Athens, Ohio, USA. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (WNT5A protein, human) RN - 0 (Wnt-5a Protein) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Carcinoma, Transitional Cell/metabolism/mortality/pathology MH - Cell Line, Tumor MH - *Cell Polarity/genetics MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - *Signal Transduction MH - Urinary Bladder Neoplasms/*metabolism/mortality/pathology MH - Wnt-5a Protein/genetics/*metabolism PMC - PMC5458237 OTO - NOTNLM OT - Wnt5a OT - biomarker OT - bladder OT - epithelial mesenchymal transition OT - urothelial carcinoma COIS- CONFLICTS OF INTERESTS There is no financial conflict of interest concerning this study. EDAT- 2017/04/22 06:00 MHDA- 2018/03/27 06:00 PMCR- 2017/05/09 CRDT- 2017/04/22 06:00 PHST- 2016/08/25 00:00 [received] PHST- 2017/02/01 00:00 [accepted] PHST- 2017/04/22 06:00 [pubmed] PHST- 2018/03/27 06:00 [medline] PHST- 2017/04/22 06:00 [entrez] PHST- 2017/05/09 00:00 [pmc-release] AID - 15877 [pii] AID - 10.18632/oncotarget.15877 [doi] PST - ppublish SO - Oncotarget. 2017 May 9;8(19):31655-31665. doi: 10.18632/oncotarget.15877. PMID- 28423532 OWN - NLM STAT- MEDLINE DCOM- 20171010 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 13 DP - 2017 Mar 28 TI - Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. PG - 21871-21883 LID - 10.18632/oncotarget.15669 [doi] AB - Several lymphangiogenic factors, such as vascular endothelial growth factors (VEGFs), have been found to drive the development of lymphatic metastasis in bladder cancer (BCa).Here, we have analyzed the gene expression of lymphangiogenic factors in tissue specimens from 12 non-muscle invasive bladder cancers (NMIBC) and 11 muscle invasive bladder cancers (MIBC), considering tumor and tumor-adjacent normal bladder areas obtained from the same organs. We then compared the results observed in patients with those obtained after treating human primary bladder microvascular endothelial cells (MEC) with either direct stimulation with VEGF-A or VEGF-C or by co-culturing (trans-well assay) MEC with bladder cancer cell lines varying in VEGF-A and VEGF-C production based on tumor grade.The genes of three markers of lymphatic endothelial commitment and development (PDPN, LYVE-1 and SLP-76) were significantly overexpressed in tissues of MIBC patients showing positive lymphovascular invasion (LVI+), lymph node metastasis (Ln+) and tumor progression. Their expression was also significantly enhanced either after direct stimulation of MEC by VEGF-A and VEGF-C or in the trans-well assay with each bladder cancer cell line.SLP-76 showed the highest gene expression. Both VEGF-A and VEGF-C also enhanced the expression of SLP-76 protein in MEC. However, a correlation between increase of SLP-76 gene expression and the ability of MEC to migrate could only be seen after induction by VEGF-C.The significant expression of SLP-76 in LVI+/Ln+ progressive MIBC and its overexpression in MEC after VEGF-A and VEGF-C stimulation suggest the need to develop this regulator of developmental lymphangiogenesis as a diagnostic tool in BCa. FAU - Poyet, Cedric AU - Poyet C AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Thomas, Linto AU - Thomas L AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Benoit, Tobias M AU - Benoit TM AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Delmo, David Aquino AU - Delmo DA AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Luberto, Laura AU - Luberto L AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Banzola, Irina AU - Banzola I AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Gunthart, Michele S AU - Gunthart MS AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Sais, Giovanni AU - Sais G AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Eberli, Daniel AU - Eberli D AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Sulser, Tullio AU - Sulser T AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. FAU - Provenzano, Maurizio AU - Provenzano M AD - Oncology Research Unit, Department of Urology and Division of Surgical Research, University Hospital of Zurich, Switzerland. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Biomarkers, Tumor) RN - 0 (Phosphoproteins) RN - 0 (SLP-76 signal Transducing adaptor proteins) RN - 0 (VEGFA protein, human) RN - 0 (VEGFC protein, human) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (Vascular Endothelial Growth Factor C) SB - IM MH - Adaptor Proteins, Signal Transducing/biosynthesis MH - Adult MH - Aged MH - Biomarkers, Tumor/analysis MH - Blotting, Western MH - Carcinoma, Transitional Cell/metabolism/*pathology MH - Female MH - Flow Cytometry MH - Fluorescent Antibody Technique MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic/physiology MH - Humans MH - Lymphangiogenesis/physiology MH - Lymphatic Metastasis MH - Lymphatic Vessels/metabolism/*pathology MH - Male MH - Middle Aged MH - Phosphoproteins/biosynthesis MH - Polymerase Chain Reaction MH - Transcriptome MH - Urinary Bladder Neoplasms/metabolism/*pathology MH - Vascular Endothelial Growth Factor A/*metabolism MH - Vascular Endothelial Growth Factor C/*metabolism PMC - PMC5400630 OTO - NOTNLM OT - SLP-76 OT - VEGF-A OT - bladder cancer OT - diagnosis OT - lymphangiogenesis COIS- CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest. EDAT- 2017/04/21 06:00 MHDA- 2017/10/11 06:00 PMCR- 2017/03/28 CRDT- 2017/04/21 06:00 PHST- 2016/08/19 00:00 [received] PHST- 2017/01/11 00:00 [accepted] PHST- 2017/04/21 06:00 [entrez] PHST- 2017/04/21 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2017/03/28 00:00 [pmc-release] AID - 15669 [pii] AID - 10.18632/oncotarget.15669 [doi] PST - ppublish SO - Oncotarget. 2017 Mar 28;8(13):21871-21883. doi: 10.18632/oncotarget.15669. PMID- 28421294 OWN - NLM STAT- MEDLINE DCOM- 20170613 LR - 20170613 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 79 IP - 6 DP - 2017 Jun TI - A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer. PG - 1099-1107 LID - 10.1007/s00280-017-3305-x [doi] AB - Objective To compare intra-arterial chemotherapy combined with intravesical chemotherapy with intravesical chemotherapy alone in the treatment of high-risk non-muscle invasive bladder cancer (HRBC) after thulium laser resection of a bladder tumor (TmLRBT). MATERIALS AND METHODS: From January 2009 to December 2013, 283 patients with HRBC were randomly assigned to the combined group (group A, n = 141) or intravesical chemotherapy-alone group (group B, n = 142) after TmLRBT. Intra-arterial chemotherapy was administered after initial TmLRBT, with 3 courses at 4-week intervals. Each course consisted of cisplatin (50 mg/m(2)) and epirubicin (30 mg/m(2)). Intravesical chemotherapy was administered in both groups, including an immediate 50 mg of epirubicin instillation after TmLRBT and weekly maintenance for 8 weeks, followed by monthly maintenance for 1 year. RESULTS: The recurrence rate was 29.1% (41/141) in group A and 42.9% (61/142) in group B, with a significant difference (p = 0.01). The progression rate was 15.6% (22/141) in group A and 25.3% (36/142) in group B, with a significant difference (p = 0.039). Patients with concomitant carcinoma in situ (CIS) also had a lower recurrence rate and progression rate in group A compared to those in group B (p = 0.006 and p = 0.03, respectively). On univariate and multivariate logistic regression analyses, patients with low-grade histology had a higher reccurrence-free rate. Multivariate COX analysis of tumor-related factors suggested that concomitant CIS was the only significant prognostic factor associated with poorer recurrence-free survival and progression-free survival. CONCLUSIONS: Intra-arterial chemotherapy combined with intravesical chemotherapy could reduce the risk of recurrence and progression compared to intravesical chemotherapy alone in HRBC. FAU - Sun, Feng AU - Sun F AD - Shanghai General Hospital, Shanghai, China. FAU - Zhao, Ruizhe AU - Zhao R AD - Shanghai General Hospital, Shanghai, China. FAU - Zhu, Yiyong AU - Zhu Y AD - Shanghai General Hospital, Shanghai, China. FAU - Cui, Di AU - Cui D AD - Shanghai General Hospital, Shanghai, China. FAU - Wang, Xiaohai AU - Wang X AD - Shanghai General Hospital, Shanghai, China. FAU - Han, Bangmin AU - Han B AD - Shanghai General Hospital, Shanghai, China. FAU - Liang, Shengjie AU - Liang S AD - Shanghai General Hospital, Shanghai, China. FAU - Liu, Haitao AU - Liu H AD - Shanghai General Hospital, Shanghai, China. FAU - Sun, Xiaowen AU - Sun X AD - Shanghai General Hospital, Shanghai, China. FAU - Zhao, Fujun AU - Zhao F AD - Shanghai General Hospital, Shanghai, China. FAU - Xu, Dongliang AU - Xu D AD - Shanghai General Hospital, Shanghai, China. urologistdlx@126.com. FAU - Xia, Shujie AU - Xia S AD - Shanghai General Hospital, Shanghai, China. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20170418 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Antineoplastic Agents) RN - 3Z8479ZZ5X (Epirubicin) RN - 8RKC5ATI4P (Thulium) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/administration & dosage MH - Antineoplastic Agents/administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/*therapeutic use MH - Cisplatin/administration & dosage MH - Combined Modality Therapy MH - Cystectomy MH - Disease-Free Survival MH - Epirubicin/administration & dosage MH - Female MH - Humans MH - Injections, Intra-Arterial MH - Laser Therapy/*methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - Prospective Studies MH - Thulium MH - Urinary Bladder Neoplasms/diagnostic imaging/surgery/*therapy OTO - NOTNLM OT - High-risk non-muscle invasive bladder cancer OT - Intra-arterial chemotherapy OT - Intravesical chemotherapy OT - Thulium laser EDAT- 2017/04/20 06:00 MHDA- 2017/06/14 06:00 CRDT- 2017/04/20 06:00 PHST- 2016/12/07 00:00 [received] PHST- 2017/04/11 00:00 [accepted] PHST- 2017/04/20 06:00 [pubmed] PHST- 2017/06/14 06:00 [medline] PHST- 2017/04/20 06:00 [entrez] AID - 10.1007/s00280-017-3305-x [pii] AID - 10.1007/s00280-017-3305-x [doi] PST - ppublish SO - Cancer Chemother Pharmacol. 2017 Jun;79(6):1099-1107. doi: 10.1007/s00280-017-3305-x. Epub 2017 Apr 18. PMID- 28420564 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20180710 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 5 DP - 2017 Oct TI - Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. PG - e755-e764 LID - S1558-7673(17)30069-1 [pii] LID - 10.1016/j.clgc.2017.03.007 [doi] AB - INTRODUCTION: The purpose of this study was to assess the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) as a predictor of clinical outcomes in patients treated with transurethral resection (TURB) for primary non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Data from 918 patients treated with TURB for primary NMIBC were retrospectively collected. NLR was evaluated as binary variable with the cut-point of 3 based on the visual best correlation of the receiver operating curve analyses focusing on disease recurrence. The median follow-up was 62 months. Cox regression analyses were used to evaluate associations with recurrence (RFS) and progression-free survival (PFS). Subgroup analyses were done according to risk groups and receipt of intravesical bacillus Calmette-Guerin therapy. RESULTS: Overall, 293 patients had a NLR >/= 3. High NLR was associated with pathologic T stage and smoking status. The 5-year RFS and PFS for NLR < 3 and NLR >/= 3 were, respectively, 55.5% versus 45.9% (P = .01) and 94.9% versus 89.9% (P = .004). On multivariable analyses, NLR >/= 3 remained significantly associated with RFS and PFS. The addition of NLR increased the discrimination of a multivariable model by 0.6% and 2.3% for RFS and PFS, respectively. Moreover, NLR showed a trend in the association with outcomes in patients treated with intravesical bacillus Calmette-Guerin therapy. CONCLUSIONS: Integration of NLR in a prediction model could be helpful in predicting RFS and PFS in patients with primary NMIBC and identifying those who are likely to fail therapy and may benefit from an early radical cystectomy. Limitations are associated to the retrospective design. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - D'Andrea, David AU - D'Andrea D AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Gust, Kilian AU - Gust K AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Ozsoy, Mehmet AU - Ozsoy M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, University of Turin, Turin, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere Hospital, APHP, University Paris VI, Paris, France. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Karl Landsteiner Univeristy, Krems an der Donau, Austria. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article DEP - 20170327 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Disease Progression MH - Female MH - Humans MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Neutrophils/*cytology MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Survival Analysis MH - Urinary Bladder Neoplasms/blood/*immunology/pathology/*surgery OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Neutrophil-to-lymphocyte ratio OT - Non-muscle invasive OT - Prognostic EDAT- 2017/04/20 06:00 MHDA- 2018/05/22 06:00 CRDT- 2017/04/20 06:00 PHST- 2016/12/30 00:00 [received] PHST- 2017/03/17 00:00 [revised] PHST- 2017/03/18 00:00 [accepted] PHST- 2017/04/20 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/04/20 06:00 [entrez] AID - S1558-7673(17)30069-1 [pii] AID - 10.1016/j.clgc.2017.03.007 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Oct;15(5):e755-e764. doi: 10.1016/j.clgc.2017.03.007. Epub 2017 Mar 27. PMID- 28415801 OWN - NLM STAT- MEDLINE DCOM- 20180322 LR - 20221109 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 21 DP - 2017 May 23 TI - Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. PG - 34442-34452 LID - 10.18632/oncotarget.16284 [doi] AB - For many years, research on the biology underlying bladder cancer focused on protein-coding genes which cover only about 3% of the human genome. Recently, it was discovered that a large part of the human genome is actively transcribed as long non-coding RNAs (lncRNAs). LncRNAs are master regulators of gene expression and several lncRNAs were shown to play a role in bladder cancer development and progression. Here, we analyzed lncRNA expression in muscle-invasive bladder cancer (MIBC) using the MiTranscriptome database of cancer lncRNA expression profiles, and we studied their function in bladder cancer-derived tumor cells. Analysis of the MiTranscriptome lncRNA expression data revealed four MIBC subgroups, which partially overlapped with the four mRNA clusters identified by The Cancer Genome Atlas consortium. Up-regulation of three lncRNAs CAT266, CAT1297, and CAT1647 in bladder cancer, in comparison to normal urothelium, was confirmed in an independent series of normal, non-muscle invasive (NMIBC) and MIBC tissue samples. Furthermore, expression levels of CAT1297 were found to be correlated with disease-free and overall survival in MIBC. Knockdown of CAT266, CAT1297, and CAT1647 decreased cell viability and colony formation, due to the induction of apoptosis. In conclusion, our data show that lncRNAs expression is de-regulated in MIBC and three aberrantly expressed transcripts regulate proliferation and apoptosis. Our data indicate that lncRNAs play an important role in MIBC development and progression and are a treasure chest for the discovery of new biomarkers. FAU - Dudek, Aleksandra M AU - Dudek AM AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. FAU - Boer, Sabrina J AU - Boer SJ AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. FAU - Boon, Nanda AU - Boon N AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A L M AU - Kiemeney LALM AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. AD - Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. FAU - Verhaegh, Gerald W AU - Verhaegh GW AD - Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (RNA, Long Noncoding) SB - IM MH - Cell Line, Tumor MH - Cell Survival MH - Databases, Genetic MH - Disease Progression MH - Female MH - Gene Expression Profiling/*methods MH - Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - Humans MH - Male MH - Prognosis MH - RNA, Long Noncoding/*genetics MH - Survival Analysis MH - Up-Regulation MH - Urinary Bladder Neoplasms/*genetics PMC - PMC5470981 OTO - NOTNLM OT - MiTranscriptome OT - biomarker OT - bladder cancer OT - lncRNA OT - long non-coding RNA COIS- CONFLICT OF INTEREST The authors declare no conflict of interest. EDAT- 2017/04/19 06:00 MHDA- 2018/03/23 06:00 PMCR- 2017/05/23 CRDT- 2017/04/19 06:00 PHST- 2016/12/14 00:00 [received] PHST- 2017/03/08 00:00 [accepted] PHST- 2017/04/19 06:00 [pubmed] PHST- 2018/03/23 06:00 [medline] PHST- 2017/04/19 06:00 [entrez] PHST- 2017/05/23 00:00 [pmc-release] AID - 16284 [pii] AID - 10.18632/oncotarget.16284 [doi] PST - ppublish SO - Oncotarget. 2017 May 23;8(21):34442-34452. doi: 10.18632/oncotarget.16284. PMID- 28410909 OWN - NLM STAT- MEDLINE DCOM- 20180426 LR - 20201230 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 15 IP - 4 DP - 2017 Aug TI - Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. PG - e583-e589 LID - S1558-7673(17)30030-7 [pii] LID - 10.1016/j.clgc.2017.01.014 [doi] AB - INTRODUCTION: We conducted this study to determine if, in appropriately selected elderly patients receiving neoadjuvant chemotherapy (NAC), clinical outcomes including pathologic complete response/downstaging and overall survival were similar to a younger cohort. METHODS: Chart review was performed on patients receiving NAC for urothelial carcinoma of the bladder (UCB) from 2004 to 2013. A total of 116 patients were identified that underwent NAC from 2004 to 2013 for >/= cT2N0M0 UCB. Patients were excluded who received 2 cycles or less of chemotherapy (N = 18; 11 patients in the younger cohort, 7 in the elderly group; P = .74). Data was analyzed, and Kaplan-Meir analysis curves were used for survival and recurrence. RESULTS: Forty-six elderly patients (age >/= 70 years) (67% cisplatin-based regimen) were identified and compared with 70 (93% cisplatin-based regimen) younger patients. The estimated glomerular filtration rate, performance status, preoperative hemoglobin, and body mass index were significantly worse in elderly patients. Dose reduction and pathologic downstaging to non-muscle-invasive disease was not statistically different between older and younger patients Complete pathologic response in older patients (16%) and in the younger cohort (17%) were similar (P = .146). There was no significant difference in follow-up, recurrence, or in median overall survival between patient groups (28 months elderly vs. 35 months younger; P = .78). Age was not an independent predictor of pathologic downstaging, complete response, overall survival, or recurrence-free survival. CONCLUSIONS: NAC in elderly patients (>/= 70 years old) demonstrated equivalent toxicity and oncologic outcomes in our single-institution cohort. Although older patients had significantly poorer performance status and renal function, there were no differences in survival or response to NAC. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Leone, Andrew R AU - Leone AR AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: Andrew.Leone@moffitt.org. FAU - Zargar-Shoshtari, Kamran AU - Zargar-Shoshtari K AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Diorio, Gregory J AU - Diorio GJ AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Sharma, Pranav AU - Sharma P AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Boulware, David AU - Boulware D AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Gilbert, Scott M AU - Gilbert SM AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Powsang, Julio M AU - Powsang JM AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Zhang, Jingsong AU - Zhang J AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Sexton, Wade J AU - Sexton WJ AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. FAU - Poch, Michael A AU - Poch MA AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. LA - eng GR - P30 CA076292/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20170201 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*drug therapy MH - Chemotherapy, Adjuvant/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy PMC - PMC7771283 MID - NIHMS1655130 OTO - NOTNLM OT - Adjuvant chemotherapy OT - Cystectomy OT - Neoadjuvant therapy OT - Survival OT - Urinary bladder neoplasms COIS- Disclosure The authors have stated that they have no conflicts of interest. EDAT- 2017/04/16 06:00 MHDA- 2018/04/27 06:00 PMCR- 2020/12/29 CRDT- 2017/04/16 06:00 PHST- 2016/10/12 00:00 [received] PHST- 2017/01/10 00:00 [revised] PHST- 2017/01/23 00:00 [accepted] PHST- 2017/04/16 06:00 [pubmed] PHST- 2018/04/27 06:00 [medline] PHST- 2017/04/16 06:00 [entrez] PHST- 2020/12/29 00:00 [pmc-release] AID - S1558-7673(17)30030-7 [pii] AID - 10.1016/j.clgc.2017.01.014 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. doi: 10.1016/j.clgc.2017.01.014. Epub 2017 Feb 1. PMID- 28406148 OWN - NLM STAT- MEDLINE DCOM- 20180710 LR - 20220410 IS - 2056-676X (Electronic) IS - 2056-676X (Linking) VI - 3 DP - 2017 Apr 13 TI - Bladder cancer. PG - 17022 LID - 10.1038/nrdp.2017.22 [doi] AB - Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours. The two subtypes have unique pathological features and different molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers of muscle-invasive bladder cancer (MIBC) as well as subtypes of MIBC with distinct characteristics and therapeutic responses. For non-muscle-invasive bladder cancer (NMIBC), intravesical therapies (primarily Bacillus Calmette-Guerin (BCG)) with maintenance are the main treatments to prevent recurrence and progression after initial TURBT; additional therapies are needed for those who do not respond to BCG. For localized MIBC, optimizing care and reducing morbidity following cystectomy are important goals. In metastatic disease, advances in our genetic understanding of bladder cancer and in immunotherapy are being translated into new therapies. FAU - Sanli, Oner AU - Sanli O AD - Department of Urology, UT Southwestern Medical Center at Dallas, Moss Building, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9110, USA. FAU - Dobruch, Jakub AU - Dobruch J AD - Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Knowles, Margaret A AU - Knowles MA AD - Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. FAU - Burger, Maximilian AU - Burger M AD - Klinik fur Urologie, Universitat Regensburg, Regensburg, Germany. FAU - Alemozaffar, Mehrdad AU - Alemozaffar M AD - Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - Nielsen, Matthew E AU - Nielsen ME AD - Department of Urology, University of North Carolina, Chapel Hill, North Carolina, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center at Dallas, Moss Building, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9110, USA. LA - eng PT - Journal Article PT - Review DEP - 20170413 PL - England TA - Nat Rev Dis Primers JT - Nature reviews. Disease primers JID - 101672103 RN - 0 (Biomarkers) RN - 0 (DNA-Binding Proteins) RN - 0 (E2F3 Transcription Factor) RN - 0 (E2F3 protein, human) RN - 0 (RB1 protein, human) RN - 0 (Retinoblastoma Binding Proteins) RN - 0 (TP53TG1 protein, human) RN - 0 (Tuberous Sclerosis Complex 1 Protein) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.3.2.27 (Ubiquitin-Protein Ligases) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Biomarkers/analysis MH - Cystectomy/methods MH - DNA-Binding Proteins/analysis/blood MH - E2F3 Transcription Factor/analysis/blood MH - Humans MH - Neoadjuvant Therapy/methods MH - Occupational Exposure/adverse effects MH - Quality of Life/psychology MH - Receptor, Fibroblast Growth Factor, Type 3/analysis/blood MH - Retinoblastoma Binding Proteins/analysis/blood MH - Risk Factors MH - Smoking/adverse effects MH - Tuberous Sclerosis Complex 1 Protein MH - Tumor Suppressor Proteins/analysis/blood MH - Ubiquitin-Protein Ligases/analysis/blood MH - Urinary Bladder Neoplasms/*complications/*diagnosis EDAT- 2017/04/14 06:00 MHDA- 2018/07/11 06:00 CRDT- 2017/04/14 06:00 PHST- 2017/04/14 06:00 [entrez] PHST- 2017/04/14 06:00 [pubmed] PHST- 2018/07/11 06:00 [medline] AID - nrdp201722 [pii] AID - 10.1038/nrdp.2017.22 [doi] PST - epublish SO - Nat Rev Dis Primers. 2017 Apr 13;3:17022. doi: 10.1038/nrdp.2017.22. PMID- 28398951 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20170418 IS - 1533-4031 (Electronic) IS - 1072-4109 (Linking) VI - 24 IP - 3 DP - 2017 May TI - Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. PG - 113-127 LID - 10.1097/PAP.0000000000000152 [doi] AB - The paradigm of pathologic stage (pT) categorization in bladder cancer remains the depth of invasion into the different histologic layers of the bladder wall. However, the approaches to assigning pT stage category toward an enhanced outcome stratification have been marked by challenges and innovations, due in part to our growing appreciation of the surprisingly perplexing bladder histoanatomy. Upstaging of pT1 tumors after radical cystectomy is substantial and underscores the potential value of pT1 substaging in transurethral resection (TUR) specimens. The 2017 American Joint Committee on Cancer tumor-node-metastasis system recommends pT1 substaging but recognizes the need to optimize the approach. Over the years, the cut-off for microinvasion has been significantly lowered to 0.5 mm and is now a promising scheme for pT1 (micrometric) substaging. Unlike the micrometric approach, histoanatomic substaging using muscularis mucosae (MM) and vascular plexus as landmarks is less feasible in TUR specimens and inconsistent in stratifying the outcome of pT1 tumors. The lamina propria possesses inherent variations in depth, MM, and vascular plexus dispositions that should be factored in future pT1 substaging proposals. Histoanatomic variations among the bladder regions also occur, and studies suggest that trigone and bladder neck cancers may have more adverse outcomes. The muscularis propria (MP), besides being the essential histologic landmark for assigning pT2 stage category, is also considered a surrogate for the adequacy of TUR, furthering the importance of identifying its presence in TUR specimens. MP, however, may be mimicked by hyperplastic or isolated MP-like MM muscle bundles in the lamina propria with overstaging implications, and caution should be exercised in distinguishing these 2 muscle types morphologically and immunohistochemically. Presence of additional superficial MP unique from the detrusor muscle proper may also complicate staging at the trigone and ureter insertion sites. With regard to the depth of MP invasion, large and multicenter studies have reaffirmed the prognostic significance of pT2a/b subcategories. It is revealed that there are at least 3 ways used to demarcate the irregular MP to perivesical soft tissue junction, and use of a common criterion indicates improvement in pT2b/pT3a staging reproducibility. Although studies have shown significantly poorer outcome in pT3b compared with pT3a tumors, this designation has a substantial reliance on the prosector's gross assessment of perivesical soft tissue invasion which if performed incorrectly may lead to staging inaccuracy of pT3 tumors. The 8th edition of the American Joint Committee on Cancer has updated the staging schema for bladder cancers with concomitant prostatic stromal invasion and cancers within bladder diverticula. Because of 2 possible pT designations, prostatic stromal invasion in TUR specimens should not be automatically staged as either pT4a or pT2 (urethral). Recent data support that bladder cancer invading into the seminal vesicle has comparable outcome to pT4b tumors. Interestingly, several studies in pT4a tumors, which are staged based on sex-specific organs, have shown poorer outcome in females than males after radical cystectomy, and while there are possibly several reasons, they may also include anatomic factors. Despite the progress has been made, work remains to be done to inform future bladder cancer pT category definitions and their reproducibility in application and prognostication. FAU - Paner, Gladell P AU - Paner GP AD - *Department of Pathology and Surgery, Section of Urology, University of Chicago, Chicago, IL double daggerDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN daggerSection of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy. FAU - Montironi, Rodolfo AU - Montironi R FAU - Amin, Mahul B AU - Amin MB LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Anat Pathol JT - Advances in anatomic pathology JID - 9435676 RN - Bladder Diverticulum SB - IM CIN - J Urol. 2018 Jan;199(1):25-26. doi: 10.1016/j.juro.2017.09.114. PMID: 29310180 MH - Carcinoma, Transitional Cell/*pathology MH - Diverticulum/diagnosis/*pathology MH - Humans MH - Neoplasm Invasiveness/*pathology MH - *Neoplasm Staging MH - Urinary Bladder/*abnormalities/diagnostic imaging/*pathology MH - Urinary Bladder Neoplasms/diagnosis/*pathology EDAT- 2017/04/12 06:00 MHDA- 2017/04/19 06:00 CRDT- 2017/04/12 06:00 PHST- 2017/04/12 06:00 [entrez] PHST- 2017/04/12 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] AID - 00125480-201705000-00001 [pii] AID - 10.1097/PAP.0000000000000152 [doi] PST - ppublish SO - Adv Anat Pathol. 2017 May;24(3):113-127. doi: 10.1097/PAP.0000000000000152. PMID- 28398113 OWN - NLM STAT- MEDLINE DCOM- 20180430 LR - 20191210 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 51 IP - 4 DP - 2017 Aug TI - Second-look resection for primary stage T1 bladder cancer: a population-based study. PG - 301-307 LID - 10.1080/21681805.2017.1303846 [doi] AB - OBJECTIVE: This study aimed to evaluate the use of second-look resection (SLR) in stage T1 bladder cancer (BC) in a population-based Swedish cohort. MATERIALS AND METHODS: All patients diagnosed with stage T1 BC in 2008-2009 were identified in the Swedish National Registry for Urinary Bladder Cancer. Registry data on TNM stage, grade, primary treatment and pathological reports from the SLR performed within 8 weeks of the primary transurethral resection were validated against patient charts. The endpoint was cancer-specific survival (CSS). RESULTS: In total, 903 patients with a mean age of 74 years (range 28-99 years) were included. SLR was performed in 501 patients (55%), who had the following stages at SLR: 172 (35%) T0, 83 (17%) Ta/Tis, 210 (43%) T1 and 26 (5%) T2-4. The use of SLR varied from 18% to 77% in the six healthcare regions. Multiple adjuvant intravesical instillations were given to 420 patients (47%). SLR was associated with intravesical instillations, age younger than 74 years, discussion at multidisciplinary tumour conference, G3 tumour and treatment at high-volume hospitals. Patients undergoing SLR had a lower risk of dying from BC (hazard ratio 0.62, 95% confidence interval 0.45-0.84, p < .0022). Five-year CSS rates were as follows, in patients with the indicated tumours at SLR (p = .001): 82% in those with T1, 90% in T0, 90% in Ta/Tis and 56% in T2-4. CONCLUSIONS: There are large geographical differences in the use of SLR in stage T1 BC in Sweden, which are presumably related to local treatment traditions. Patients treated with SLR have a high rate of residual tumour but lower age, which suggests that a selection bias affects CSS. FAU - Patschan, Oliver AU - Patschan O AD - a Department of Translational Medicine , Lund University and Department of Urology, Skane University Hospital , Malmo , Sweden. FAU - Holmang, Sten AU - Holmang S AD - b Department of Urology , Sahlgrenska University Hospital , Goteborg , Sweden. FAU - Hosseini, Abolfazl AU - Hosseini A AD - c Department of Urology , Karolinska University Hospital , Stockholm , Sweden. FAU - Jancke, Georg AU - Jancke G AD - a Department of Translational Medicine , Lund University and Department of Urology, Skane University Hospital , Malmo , Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - a Department of Translational Medicine , Lund University and Department of Urology, Skane University Hospital , Malmo , Sweden. FAU - Ljungberg, Borje AU - Ljungberg B AD - d Department of Surgical and Perioperative Sciences, Urology and Andrology , Umea University , Umea , Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - e Department of Urology , Akademiska University Hospital , Uppsala , Sweden. FAU - Rosell, Johan AU - Rosell J AD - f Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine , Linkoping University , Linkoping , Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - g Department of Urology , University Hospital and IKE, Linkoping University , Linkoping , Sweden. LA - eng PT - Journal Article DEP - 20170411 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Administration, Intravesical MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Catchment Area, Health/statistics & numerical data MH - Female MH - Hospitals, High-Volume/statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prospective Studies MH - Registries MH - Second-Look Surgery/*statistics & numerical data MH - Survival Rate MH - Sweden MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - cancer-specific survival OT - population-based OT - second-look resection OT - stage T1 EDAT- 2017/04/12 06:00 MHDA- 2018/05/01 06:00 CRDT- 2017/04/12 06:00 PHST- 2017/04/12 06:00 [pubmed] PHST- 2018/05/01 06:00 [medline] PHST- 2017/04/12 06:00 [entrez] AID - 10.1080/21681805.2017.1303846 [doi] PST - ppublish SO - Scand J Urol. 2017 Aug;51(4):301-307. doi: 10.1080/21681805.2017.1303846. Epub 2017 Apr 11. PMID- 28396613 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1472-6890 (Print) IS - 1472-6890 (Electronic) IS - 1472-6890 (Linking) VI - 17 DP - 2017 TI - Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. PG - 3 LID - 10.1186/s12907-017-0046-z [doi] LID - 3 AB - BACKGROUND: Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters. METHODS: 103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody. RESULTS: HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04). CONCLUSION: HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior. FAU - El Ochi, Mohamed Reda AU - El Ochi MR AUID- ORCID: 0000-0001-7325-4659 AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 AD - Hopital militaire Mohamed V, Hay Riad, BP10000 Rabat, Morocco. FAU - Oukabli, Mohamed AU - Oukabli M AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 FAU - Bouaiti, Elarbi AU - Bouaiti E AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 AD - Laboratory of Biostatistics Clinical Research and Epidemiology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. FAU - Chahdi, Hafsa AU - Chahdi H AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 FAU - Boudhas, Adil AU - Boudhas A AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 FAU - Allaoui, Mohamed AU - Allaoui M AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 FAU - Ameur, Ahmed AU - Ameur A AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 AD - Department of Urology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. FAU - Abbar, Mohamed AU - Abbar M AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 AD - Department of Urology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. FAU - Al Bouzidi, Abderrahmane AU - Al Bouzidi A AD - Department of Pathology, Mohamed V Military Hospital, Hay Riad, Rabat, Morocco. AD - Faculty of Medicine and Pharmacy, Mohammed V University, Hay Riad, Rabat, Morocco. GRID: grid.31143.34 LA - eng PT - Journal Article DEP - 20170404 PL - England TA - BMC Clin Pathol JT - BMC clinical pathology JID - 101088665 PMC - PMC5381084 OTO - NOTNLM OT - Bladder OT - Carcinoma OT - HER2 OT - Urothelial EDAT- 2017/04/12 06:00 MHDA- 2017/04/12 06:01 PMCR- 2017/04/04 CRDT- 2017/04/12 06:00 PHST- 2016/07/14 00:00 [received] PHST- 2017/03/29 00:00 [accepted] PHST- 2017/04/12 06:00 [entrez] PHST- 2017/04/12 06:00 [pubmed] PHST- 2017/04/12 06:01 [medline] PHST- 2017/04/04 00:00 [pmc-release] AID - 46 [pii] AID - 10.1186/s12907-017-0046-z [doi] PST - epublish SO - BMC Clin Pathol. 2017 Apr 4;17:3. doi: 10.1186/s12907-017-0046-z. eCollection 2017. PMID- 28390739 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20221207 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 72 IP - 4 DP - 2017 Oct TI - Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. PG - 544-554 LID - S0302-2838(17)30251-8 [pii] LID - 10.1016/j.eururo.2017.03.030 [doi] AB - BACKGROUND: An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. OBJECTIVE: To investigate the ability of molecular subtypes to predict pathological downstaging and survival after NAC. DESIGN, SETTING, AND PARTICIPANTS: Whole transcriptome profiling was performed on pre-NAC transurethral resection specimens from 343 patients with MIBC. Samples were classified according to four published molecular subtyping methods. We developed a single-sample genomic subtyping classifier (GSC) to predict consensus subtypes (claudin-low, basal, luminal-infiltrated and luminal) with highest clinical impact in the context of NAC. Overall survival (OS) according to subtype was analyzed and compared with OS in 476 non-NAC cases (published datasets). INTERVENTION: Gene expression analysis was used to assign subtypes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Receiver-operating characteristics were used to determine the accuracy of GSC. The effect of GSC on survival was estimated by Cox proportional hazard regression models. RESULTS AND LIMITATIONS: The models generated subtype calls in expected ratios with high concordance across subtyping methods. GSC was able to predict four consensus molecular subtypes with high accuracy (73%), and clinical significance of the predicted consensus subtypes could be validated in independent NAC and non-NAC datasets. Luminal tumors had the best OS with and without NAC. Claudin-low tumors were associated with poor OS irrespective of treatment regimen. Basal tumors showed the most improvement in OS with NAC compared with surgery alone. The main limitations of our study are its retrospective design and comparison across datasets. CONCLUSIONS: Molecular subtyping may have an impact on patient benefit to NAC. If validated in additional studies, our results suggest that patients with basal tumors should be prioritized for NAC. We discovered the first single-sample classifier to subtype MIBC, which may be suitable for integration into routine clinical practice. PATIENT SUMMARY: Different molecular subtypes can be identified in muscle-invasive bladder cancer. Although cisplatin-based neoadjuvant chemotherapy improves patient outcomes, we identified that the benefit is highest in patients with basal tumors. Our newly discovered classifier can identify these molecular subtypes in a single patient and could be integrated into routine clinical practice after further validation. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Seiler, Roland AU - Seiler R AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Urology, University of Bern, Bern, Switzerland. FAU - Ashab, Hussam Al Deen AU - Ashab HAD AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Erho, Nicholas AU - Erho N AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Winters, Brian AU - Winters B AD - Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Douglas, James AU - Douglas J AD - Department of Urology, University Hospital of Southampton, Hampshire, UK. FAU - Van Kessel, Kim E AU - Van Kessel KE AD - Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Fransen van de Putte, Elisabeth E AU - Fransen van de Putte EE AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Sommerlad, Matthew AU - Sommerlad M AD - Department of Urology, University Hospital of Southampton, Hampshire, UK. FAU - Wang, Natalie Q AU - Wang NQ AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Choeurng, Voleak AU - Choeurng V AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Gibb, Ewan A AU - Gibb EA AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Palmer-Aronsten, Beatrix AU - Palmer-Aronsten B AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Lam, Lucia L AU - Lam LL AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Buerki, Christine AU - Buerki C AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Davicioni, Elai AU - Davicioni E AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Sjodahl, Gottfrid AU - Sjodahl G AD - Division of Urological Research, Department of Translational Medicine, Lund University, Malmo, Sweden. FAU - Kardos, Jordan AU - Kardos J AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Hoadley, Katherine A AU - Hoadley KA AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urologic Oncology, Baylor College of Medicine, Houston, Texas, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Choi, Woonyoung AU - Choi W AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Kim, William Y AU - Kim WY AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Kiss, Bernhard AU - Kiss B AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, University of Bern, Bern, Switzerland. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Crabb, Simon J AU - Crabb SJ AD - Department of Medical Oncology, University Hospital of Southampton, Hampshire, UK. FAU - North, Scott AU - North S AD - Cross Cancer Institute, Department of Oncology, University of Alberta Edmonton, Alberta, Canada. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Wright, Jonathan AU - Wright J AD - Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Dall'Era, Marc AU - Dall'Era M AD - UC Davis Comprehensive Cancer Center, Sacramento, California, USA. FAU - van der Heijden, Michiel S AU - van der Heijden MS AD - Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: pblack@mail.ubc.ca. LA - eng GR - P30 CA016086/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170405 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Eur Urol. 2017 Oct;72(4):555-556. doi: 10.1016/j.eururo.2017.04.012. PMID: 28433377 CIN - J Urol. 2020 Aug;204(2):246. doi: 10.1097/JU.0000000000000798.02. PMID: 32459976 CIN - J Urol. 2020 Aug;204(2):245-246. doi: 10.1097/JU.0000000000000798.01. PMID: 32459977 MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor/*genetics MH - Chemotherapy, Adjuvant MH - Female MH - Gene Expression Profiling/methods MH - Genetic Predisposition to Disease MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - *Neoadjuvant Therapy/adverse effects/mortality MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Phenotype MH - Predictive Value of Tests MH - Proportional Hazards Models MH - ROC Curve MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - *Transcriptome MH - Treatment Outcome MH - Urinary Bladder Neoplasms/genetics/mortality/pathology/*therapy MH - Exome Sequencing OTO - NOTNLM OT - Bladder cancer OT - Molecular subtypes OT - Neoadjuvant chemotherapy OT - Response prediction EDAT- 2017/04/10 06:00 MHDA- 2018/05/22 06:00 CRDT- 2017/04/10 06:00 PHST- 2017/01/01 00:00 [received] PHST- 2017/03/21 00:00 [accepted] PHST- 2017/04/10 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/04/10 06:00 [entrez] AID - S0302-2838(17)30251-8 [pii] AID - 10.1016/j.eururo.2017.03.030 [doi] PST - ppublish SO - Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5. PMID- 28389159 OWN - NLM STAT- MEDLINE DCOM- 20180509 LR - 20260127 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 8 DP - 2017 Aug TI - Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer. PG - 532.e1-532.e6 LID - S1078-1439(17)30110-2 [pii] LID - 10.1016/j.urolonc.2017.03.010 [doi] AB - OBJECTIVE: The aim of our study was to try to validate 3 promising predictive biomarkers in a database based on prospective trials comparing bacillus Calmette-Guerin (BCG) with mitomycin-C and a combination of epirubicin and interferon, respectively. BACKGROUND: The most common form of bladder cancer is non-muscle-invasive tumors treated initially with transurethral resection. Unfortunately more than half recur and some also progress. Consequently, an attempt to prevent poor outcome is frequently made by intravesical instillations either by chemo- or immunotherapy. The response to such treatment is unpredictable, which is why markers predicting outcome would be valuable. PATIENTS AND METHODS: Immunohistochemical expression of ezrin, CK20, and Ki-67 was evaluated in a tumor tissue microarray based on 2 nordic multicenter trials comparing treatment with BCG vs. other intravesical adjuvant therapies. Kaplan-Meier analysis, log-rank test, and Cox regression were used to evaluate the effect of the biomarkers on recurrence-, progression-, and treatment failure-free survival. RESULTS: Of the 294 available patients immunoreactivity could be assessed in 285 patients for ezrin (97%), 285 patients for CK20 (97%), and 294 patient׳s for Ki-67 (100%). The 3 biomarkers did not predict time to any of the endpoints. Multifocality was the only predictive factor for time to recurrence (P = 0.029) and progression (P = 0.031). Ezrin was, however, predictive for treatment failure (P = 0.029) in a subgroup (BCG treated in one of the trials). In a multivariate analysis among BCG treated, none of the variables correlated to recurrence and only multifocality correlated to progression. Limitations in our study are the retrospective design and those inherent to immunohistochemistry. CONCLUSIONS: The negative results from this validation study question the ability of the tested biomarkers to predict therapy effect. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: pum@surgsci.uu.se. FAU - Hemdan, Tammer AU - Hemdan T AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. LA - eng PT - Journal Article PT - Validation Study DEP - 20170425 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Cytoskeletal Proteins) RN - 0 (Keratin-20) RN - 0 (Ki-67 Antigen) RN - 0 (Ezrin) RN - 0 (KRT20 protein, human) SB - IM MH - Aged MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/*drug therapy/mortality MH - Cytoskeletal Proteins/analysis MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Keratin-20/analysis MH - Ki-67 Antigen/analysis MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality MH - Ezrin OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Prognosis EDAT- 2017/04/09 06:00 MHDA- 2018/05/10 06:00 CRDT- 2017/04/09 06:00 PHST- 2016/12/13 00:00 [received] PHST- 2017/02/17 00:00 [revised] PHST- 2017/03/06 00:00 [accepted] PHST- 2017/04/09 06:00 [pubmed] PHST- 2018/05/10 06:00 [medline] PHST- 2017/04/09 06:00 [entrez] AID - S1078-1439(17)30110-2 [pii] AID - 10.1016/j.urolonc.2017.03.010 [doi] PST - ppublish SO - Urol Oncol. 2017 Aug;35(8):532.e1-532.e6. doi: 10.1016/j.urolonc.2017.03.010. Epub 2017 Apr 25. PMID- 28388561 OWN - NLM STAT- MEDLINE DCOM- 20180425 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 25 DP - 2017 Jun 20 TI - Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer. PG - 40832-40842 LID - 10.18632/oncotarget.16586 [doi] AB - Urinary microRNAs (miRNAs) are potential biomarkers for the noninvasive diagnosis of bladder cancer (BC). In this study, we aimed to develop a urinary miRNAs panel for diagnosing and predicting recurrence of BC. Genome-wide miRNAs analysis by deep sequencing followed by two phases of quantitative real-time PCR assays were performed on urine supernatant of 276 BC patients and 276 controls. We identified a seven-miRNA panel (miR-7-5p, miR-22-3p, miR-29a-3p, miR-126-5p, miR-200a-3p, miR-375, and miR-423-5p) that provided high diagnostic accuracy of BC with an AUC of 0.923 and 0.916 in training and validation set, respectively. The corresponding AUCs of this panel for Ta, T1 and T2-T4 were 0.864, 0.930 and 0.978, significantly higher than those of urine cytology, which were 0.531, 0.628 and 0.724, respectively (all p < 0.05). Moreover, Kaplan-Meier analysis showed that nonmuscle-invasive BC (NMIBC) patients with high miR-22-3p and low miR-200a-3p level had worse recurrence-free survival (RFS) (p = 0.002 and 0.040, respectively). Multivariate Cox regression analysis revealed that miR-22-3p and miR-200a-3p were independently associated with RFS of NMIBC (p = 0.024 and 0.008, respectively). In conclusion, our results suggested that urinary miRNAs may have considerable clinical value in diagnosis and recurrence prediction of BC. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Jiang, Xiumei AU - Jiang X AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Duan, Weili AU - Duan W AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Rui AU - Wang R AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Lishui AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Zheng, Guixi AU - Zheng G AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Yan, Keqiang AU - Yan K AD - Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Li, Juan AU - Li J AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Zhang, Xin AU - Zhang X AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Pan, Hongwei AU - Pan H AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Chuanxin AU - Wang C AD - Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, Shandong, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (Circulating MicroRNA) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics/*urine MH - Cell-Free System MH - Circulating MicroRNA/*urine MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/urine MH - Prognosis MH - Urinary Bladder Neoplasms/genetics/*urine PMC - PMC5522322 OTO - NOTNLM OT - bladder cancer OT - diagnosis OT - microRNA OT - recurrence OT - urine COIS- CONFLICTS OF INTEREST No potential conflicts of interest were disclosed. EDAT- 2017/04/08 06:00 MHDA- 2018/04/26 06:00 PMCR- 2017/06/20 CRDT- 2017/04/08 06:00 PHST- 2016/10/22 00:00 [received] PHST- 2017/03/14 00:00 [accepted] PHST- 2017/04/08 06:00 [pubmed] PHST- 2018/04/26 06:00 [medline] PHST- 2017/04/08 06:00 [entrez] PHST- 2017/06/20 00:00 [pmc-release] AID - 16586 [pii] AID - 10.18632/oncotarget.16586 [doi] PST - ppublish SO - Oncotarget. 2017 Jun 20;8(25):40832-40842. doi: 10.18632/oncotarget.16586. PMID- 28371465 OWN - NLM STAT- MEDLINE DCOM- 20170913 LR - 20260127 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 125 IP - 7 DP - 2017 Jul TI - p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up. PG - 552-562 LID - 10.1002/cncy.21853 [doi] AB - BACKGROUND: Overexpression of p16(INK4a) has been identified in urothelial malignancies both cytologically and histologically. In addition, p16/Ki-67 dual labeling has been shown to identify high-grade urothelial cancer cells and some progression cases within a 12-month delay. The Paris System for Reporting Urinary Cytology (TPS) was published in late 2015. Its aim is to clarify the criteria for diagnosing or, conversely, excluding high-grade urothelial carcinoma (HGUC). METHODS: Dual labeling was performed on archived ThinPrep-based Papanicolaou slides. A total of 208 samples (negative for high-grade urothelial carcinoma [NHGUC], 59; consistent with low-grade urothelial neoplasia [LGUN], 24; atypical urothelial cells [AUC], 15; and suspicious for or showing HGUC, 110) were analyzed for p16/Ki-67 after reclassification according to TPS. We assessed the oncologic status of the patients with cystoscopy, urinary cytology, histology, and prolonged 36-month follow-up data. RESULTS: The sensitivity of p16/Ki-67 for life-threatening lesions was not different from that of urinary cytology (82.8% vs 83.6%; P = 1). However, among patients with samples classified as NHGUC and AUC, disease-free survival was significantly shorter for dual-labeled cases versus cases with negative dual labeling (P < .0001). The same tendency was observed in patients with histologically proven LGUN (P < .0001). As for specificity in patients with negative cystoscopy and cytology combined, prolonged follow-up showed 90% overall survival at 24 months. CONCLUSIONS: A long-term evaluation of p16/Ki-67 dual labeling may identify HGUC and progression in cases with negative/low-grade urinary cytology results, and there are potential implications for the clinical management of patients after the conservative treatment of non-muscle-invasive urothelial carcinoma. Cancer Cytopathol 2017;125:552-62. (c) 2017 American Cancer Society. CI - (c) 2017 American Cancer Society. FAU - Piaton, Eric AU - Piaton E AD - Centre de Pathologie Est, Hopitaux de Lyon, Hopital Femme-Mere-Enfant, Bron, France. AD - Universite Claude Bernard Lyon 1, Lyon, France. FAU - Advenier, Anne-Sophie AU - Advenier AS AD - Universite Claude Bernard Lyon 1, Lyon, France. AD - Service de Medecine Legale, Lyon, France. FAU - Carre, Christian AU - Carre C AD - Roche Diagnostics France, Meylan, France. FAU - Decaussin-Petrucci, Myriam AU - Decaussin-Petrucci M AD - UMR INSERM U 1052/CNRS 5286, Universite Claude Bernard Lyon, 1, France. AD - Centre de Pathologie Sud, Centre Hospitalier Lyon Sud, Pierre Benite, France. FAU - Mege-Lechevallier, Florence AU - Mege-Lechevallier F AD - Universite Claude Bernard Lyon 1, Lyon, France. AD - Service d'Anatomie et Cytologie Pathologiques, Hopital Edouard Herriot, Lyon, France. FAU - Hutin, Karine AU - Hutin K AD - Centre de Pathologie Est, Hopitaux de Lyon, Hopital Femme-Mere-Enfant, Bron, France. FAU - Nennig, Cindy AU - Nennig C AD - Centre de Pathologie Est, Hopitaux de Lyon, Hopital Femme-Mere-Enfant, Bron, France. FAU - Colombel, Marc AU - Colombel M AD - Universite Claude Bernard Lyon 1, Lyon, France. AD - Service d'Urologie, Hopital Edouard Herriot, Lyon, France. FAU - Ruffion, Alain AU - Ruffion A AD - Universite Claude Bernard Lyon 1, Lyon, France. AD - Service d'Urologie, Centre Hospitalier Lyon Sud, Pierre Benite, France. LA - eng PT - Journal Article DEP - 20170403 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 RN - 0 (Ki-67 Antigen) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*genetics/mortality/pathology MH - Cohort Studies MH - Cystoscopy/methods MH - Cytodiagnosis/methods MH - Disease-Free Survival MH - Female MH - France MH - *Gene Expression Regulation, Neoplastic MH - Genes, p16 MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/*metabolism MH - Male MH - Middle Aged MH - Sampling Studies MH - Sensitivity and Specificity MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality/pathology OTO - NOTNLM OT - Ki-67 OT - bladder OT - disease-free survival OT - p16INK4a OT - prognosis OT - urinary cytology OT - urothelial carcinoma EDAT- 2017/04/04 06:00 MHDA- 2017/09/14 06:00 CRDT- 2017/04/04 06:00 PHST- 2016/11/25 00:00 [received] PHST- 2017/01/04 00:00 [revised] PHST- 2017/01/04 00:00 [accepted] PHST- 2017/04/04 06:00 [pubmed] PHST- 2017/09/14 06:00 [medline] PHST- 2017/04/04 06:00 [entrez] AID - 10.1002/cncy.21853 [doi] PST - ppublish SO - Cancer Cytopathol. 2017 Jul;125(7):552-562. doi: 10.1002/cncy.21853. Epub 2017 Apr 3. PMID- 28367434 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 4 DP - 2017 TI - Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. PG - 30 LID - 10.3389/fmed.2017.00030 [doi] LID - 30 AB - INTRODUCTION: Bladder cancer (BCa) is among the most frequent cancer entities and relevantly contributes to cancer-associated deaths worldwide. The multi-protein Mediator complex is a central regulator of the transcriptional machinery of protein-coding genes and has been described to be altered in several malignancies. MED1, a subunit of the tail module, was described to negatively modulate expression of metastasis-related genes and to be downregulated in melanoma and lung cancer. In contrast, MED1 hyperactivity was described in breast and prostate cancer, likely due its function as a hub for nuclear hormone receptors. So far, only little is known about the function of the Mediator complex in BCa. The aim of this study was therefore to investigate the role of MED1 in BCa as a prognostic biomarker and a biomarker of disease progression. METHODS: The protein expression of MED1 was assessed by immunohistochemistry (IHC) on tissue microarrays from 224 patients: benign urothelium n = 31, non-muscle invasive BCa (pTis, pT1) n = 72, and muscle invasive BCa (pT2-T4) n = 121. Comprehensive clinicopathological information including follow-up were available. Quantification of MED1 protein expression was evaluated by the semiquantitative image analysis program Definiens. RESULTS: MED1 expression significantly decreased during BCa progression from benign urothelium to advanced BCa. Muscle invasion, the crucial step in BCa progression, was associated with low MED1 protein expression. Accordingly, decreased MED1 expression was found in primary BCa samples with positive lymphonodal status and distant metastases. Furthermore, cancer-specific survival was significantly worse in the group of low MED1 expression. CONCLUSION: Our findings show that the downregulation of MED1 is associated with muscle invasion, metastatic spread, and shorter overall survival in BCa. CI - Copyright (c) 2017 Klumper, Syring, Vogel, Schmidt, Muller, Ellinger, Adler, Bragelmann and Perner. FAU - Klumper, Niklas AU - Klumper N AD - Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany. FAU - Syring, Isabella AU - Syring I AD - Clinic for Urology and Pediatric Urology, University Hospital of Bonn, Bonn, Germany. FAU - Vogel, Wenzel AU - Vogel W AD - Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany. FAU - Schmidt, Doris AU - Schmidt D AD - Clinic for Urology and Pediatric Urology, University Hospital of Bonn, Bonn, Germany. FAU - Muller, Stefan C AU - Muller SC AD - Clinic for Urology and Pediatric Urology, University Hospital of Bonn, Bonn, Germany. FAU - Ellinger, Jorg AU - Ellinger J AD - Clinic for Urology and Pediatric Urology, University Hospital of Bonn, Bonn, Germany. FAU - Adler, David AU - Adler D AD - Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany. FAU - Bragelmann, Johannes AU - Bragelmann J AD - Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany. AD - Department of Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany. FAU - Perner, Sven AU - Perner S AD - Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany. LA - eng PT - Journal Article DEP - 20170317 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC5355444 OTO - NOTNLM OT - MED1 OT - bladder cancer OT - immunohistochemistry OT - mediator OT - mediator complex EDAT- 2017/04/04 06:00 MHDA- 2017/04/04 06:01 PMCR- 2017/03/17 CRDT- 2017/04/04 06:00 PHST- 2017/01/15 00:00 [received] PHST- 2017/03/03 00:00 [accepted] PHST- 2017/04/04 06:00 [pubmed] PHST- 2017/04/04 06:01 [medline] PHST- 2017/04/04 06:00 [entrez] PHST- 2017/03/17 00:00 [pmc-release] AID - 10.3389/fmed.2017.00030 [doi] PST - epublish SO - Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017. PMID- 28365159 OWN - NLM STAT- MEDLINE DCOM- 20180508 LR - 20250530 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 72 IP - 3 DP - 2017 Sep TI - Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. PG - 354-365 LID - S0302-2838(17)30175-6 [pii] LID - 10.1016/j.eururo.2017.03.010 [doi] AB - CONTEXT: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties. OBJECTIVE: The availability of comprehensive genomic data from The Cancer Genome Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA alterations with tumor molecular subtype membership. Our overall goal was to determine whether specific DNA mutations and/or copy number variations are enriched in specific molecular subtypes. EVIDENCE: We used the complete TCGA RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them. We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers. EVIDENCE SYNTHESIS: The results confirmed that alterations involving RB1 and NFE2L2 were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were enriched in luminal tumors. CONCLUSIONS: The results further reinforce the conclusion that the molecular subtypes of bladder cancer are distinct disease entities with specific genetic alterations. PATIENT SUMMARY: Our observation showed that some of subtype-enriched mutations and copy number aberrations are clinically actionable, which has direct implications for the clinical management of patients with bladder cancer. CI - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Choi, Woonyoung AU - Choi W AD - Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. FAU - Ochoa, Andrea AU - Ochoa A AD - Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. FAU - McConkey, David J AU - McConkey DJ AD - Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. Electronic address: djmcconkey@jhmi.edu. FAU - Aine, Mattias AU - Aine M AD - Division of Oncology and Pathology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology and Pathology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden. FAU - Kim, William Y AU - Kim WY AD - University of North Carolina, Chapel Hill, North Carolina, USA. FAU - Real, Francisco X AU - Real FX AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain; Departament de Ciencies Experimentalsi de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Kiltie, Anne E AU - Kiltie AE AD - Department of Oncology, University of Oxford, Oxford, UK. FAU - Milsom, Ian AU - Milsom I AD - Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Lerner, Seth P AU - Lerner SP AD - TCGA Analysis Working Group, Baylor College of Medicine, Houston, Texas, USA. LA - eng GR - 23279/CRUK_/Cancer Research UK/United Kingdom GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20170330 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) RN - 0 (NF-E2-Related Factor 2) RN - 0 (NFE2L2 protein, human) RN - 0 (Nuclear Proteins) RN - 0 (RB1 protein, human) RN - 0 (Retinoblastoma Binding Proteins) RN - EC 1.14.11.- (Histone Demethylases) RN - EC 1.14.11.- (KDM6A protein, human) RN - EC 2.3.2.27 (Ubiquitin-Protein Ligases) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM CIN - Eur Urol. 2017 Sep;72(3):366-367. doi: 10.1016/j.eururo.2017.04.006. PMID: 28427785 CIN - Eur Urol. 2018 Apr;73(4):e102-e103. doi: 10.1016/j.eururo.2017.10.032. PMID: 29129400 CIN - Eur Urol. 2018 Apr;73(4):e104-e105. doi: 10.1016/j.eururo.2017.11.003. PMID: 29174465 MH - *Atlases as Topic MH - Biomarkers, Tumor/*genetics MH - DNA Copy Number Variations MH - *Databases, Genetic MH - Gene Dosage MH - Genetic Predisposition to Disease MH - *Genome, Human MH - Histone Demethylases/genetics MH - Humans MH - Mutation MH - NF-E2-Related Factor 2/genetics MH - Nuclear Proteins/genetics MH - Phenotype MH - Receptor, Fibroblast Growth Factor, Type 3/genetics MH - Retinoblastoma Binding Proteins/genetics MH - Ubiquitin-Protein Ligases/genetics MH - Urinary Bladder Neoplasms/classification/*genetics/pathology PMC - PMC5764190 MID - NIHMS859007 OTO - NOTNLM OT - DNA alterations OT - Molecular subtypes OT - Muscle-invasive bladder cancer EDAT- 2017/04/04 06:00 MHDA- 2018/05/09 06:00 PMCR- 2018/09/01 CRDT- 2017/04/03 06:00 PHST- 2016/12/12 00:00 [received] PHST- 2017/03/06 00:00 [accepted] PHST- 2017/04/04 06:00 [pubmed] PHST- 2018/05/09 06:00 [medline] PHST- 2017/04/03 06:00 [entrez] PHST- 2018/09/01 00:00 [pmc-release] AID - S0302-2838(17)30175-6 [pii] AID - 10.1016/j.eururo.2017.03.010 [doi] PST - ppublish SO - Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. PMID- 28362839 OWN - NLM STAT- MEDLINE DCOM- 20170830 LR - 20190208 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 3 DP - 2017 TI - Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies. PG - e0174746 LID - 10.1371/journal.pone.0174746 [doi] LID - e0174746 AB - OBJECTIVE: Emerging preclinical evidence suggests the involvement of sex hormones and their receptor signals in the development and progression of bladder cancer. Meanwhile, previous studies have demonstrated conflicting results on the relationship between the status of sex hormone receptors in urothelial tumors and histopathological characteristics of the tumors or patient outcomes. We therefore conducted this meta-analysis to assess the clinicopathological impact of the expression of androgen receptor (AR) and estrogen receptors (ERs) in bladder cancer. METHODS: A comprehensive literature search in databases (i.e. PubMed, Web of Science, Cochrane) was performed for all immunohistochemical studies stained for AR, ERalpha, and/or ERbeta in surgically resected bladder cancer specimens and analyzed for patient outcomes. We selected eligible studies in accordance with the PRISMA guidelines and analyzed data using R software. RESULTS: A total of 2,049 patients from 13 retrospective studies were included in this meta-analysis. The difference in ERalpha expression between non-tumors and tumors was significant [odds ratio (OR) = 0.412; P<0.001], while those of AR (OR = 3.256; P = 0.336) or ERbeta (OR = 0.580; P = 0.674) were not statistically significant. AR positivity in tumors was strongly correlated with gender (male vs. female: OR = 0.658; P = 0.027) or tumor grade (low-grade vs. high-grade: OR = 0.575; P<0.001). ERbeta positive rates were significantly higher in high-grade (OR = 2.169; P<0.001) and muscle-invasive (OR = 3.104; P<0.001) tumors than in low-grade and non-muscle-invasive tumors, respectively. Survival analysis in patients with non-muscle-invasive bladder cancer revealed associations between AR expression and better recurrence-free survival [hazard ration (HR) = 0.593; P = 0.006) as well as between ERbeta expression and worse recurrence-free (HR = 1.573; P = 0.013) or progression-free (HR = 4.148; P = 0.089) survivals. CONCLUSIONS: These data suggest down-regulation of ERalpha expression in bladder tumors, compared with non-neoplastic urothelial tissues. AR or ERbeta expression was down- or up-regulated, respectively, in high-grade and/or muscle-invasive bladder cancers. Moreover, immunohistochemistry of AR/ERbeta in surgical specimens may serve as prognosticators in patients with non-muscle-invasive bladder tumor. FAU - Ide, Hiroki AU - Ide H AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. AD - The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. FAU - Inoue, Satoshi AU - Inoue S AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. AD - The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States of America. AD - The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States of America. FAU - Miyamoto, Hiroshi AU - Miyamoto H AUID- ORCID: 0000-0001-7610-7769 AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. AD - The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. AD - Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States of America. AD - The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States of America. AD - Department Urology, University of Rochester Medical Center, Rochester, New York, United States of America. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20170331 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Estrogen Receptor alpha) RN - 0 (Estrogen Receptor beta) RN - 0 (Receptors, Androgen) SB - IM MH - Estrogen Receptor alpha/metabolism MH - Estrogen Receptor beta/metabolism MH - Female MH - Humans MH - Immunohistochemistry/*methods MH - Male MH - Prognosis MH - Receptors, Androgen/metabolism MH - Retrospective Studies MH - Software MH - Urinary Bladder Neoplasms/*metabolism/pathology PMC - PMC5375178 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2017/04/01 06:00 MHDA- 2017/08/31 06:00 PMCR- 2017/03/31 CRDT- 2017/04/01 06:00 PHST- 2016/12/28 00:00 [received] PHST- 2017/03/14 00:00 [accepted] PHST- 2017/04/01 06:00 [entrez] PHST- 2017/04/01 06:00 [pubmed] PHST- 2017/08/31 06:00 [medline] PHST- 2017/03/31 00:00 [pmc-release] AID - PONE-D-16-51188 [pii] AID - 10.1371/journal.pone.0174746 [doi] PST - epublish SO - PLoS One. 2017 Mar 31;12(3):e0174746. doi: 10.1371/journal.pone.0174746. eCollection 2017. PMID- 28359179 OWN - NLM STAT- MEDLINE DCOM- 20170529 LR - 20220330 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 17 IP - 5 DP - 2017 May TI - Tackling non-muscle invasive bladder cancer in the clinic. PG - 467-480 LID - 10.1080/14737140.2017.1313119 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC - which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC. FAU - Woldu, Solomon L AU - Woldu SL AD - a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. FAU - Sanli, Oner AU - Sanli O AD - a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. AD - b Department of Urology, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey. FAU - Lotan, Yair AU - Lotan Y AD - a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. LA - eng PT - Journal Article PT - Review DEP - 20170411 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Antineoplastic Agents/administration & dosage MH - BCG Vaccine/administration & dosage MH - Combined Modality Therapy MH - Cystectomy/methods MH - Disease Progression MH - Humans MH - Immunotherapy/methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - *Practice Guidelines as Topic MH - Prognosis MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - BCG OT - Non-muscle invasive bladder cancer OT - chemothermotherapy OT - electromotive drug administration OT - intravesical therapy OT - novel EDAT- 2017/04/01 06:00 MHDA- 2017/05/30 06:00 CRDT- 2017/04/01 06:00 PHST- 2017/04/01 06:00 [pubmed] PHST- 2017/05/30 06:00 [medline] PHST- 2017/04/01 06:00 [entrez] AID - 10.1080/14737140.2017.1313119 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2017 May;17(5):467-480. doi: 10.1080/14737140.2017.1313119. Epub 2017 Apr 11. PMID- 28351206 OWN - NLM STAT- MEDLINE DCOM- 20180501 LR - 20260127 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 51 IP - 2 DP - 2017 Apr TI - Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder. PG - 124-129 LID - 10.1080/21681805.2017.1298156 [doi] AB - OBJECTIVE: The aim of this study was to evaluate the use of intravesical treatment and cancer-specific survival of patients with primary carcinoma in situ (CIS). MATERIALS AND METHODS: Data acquisition was based on the Swedish National Registry of Urinary Bladder Cancer by selecting all patients with primary CIS. The analysis covered gender, age, hospital type and hospital volume. Intravesical treatment and death due to bladder cancer were evaluated by multivariate logistic regression and multivariate Cox analysis, respectively. RESULTS: The study included 1041 patients (median age at diagnosis 72 years) with a median follow-up of 65 months. Intravesical instillation therapy was given to 745 patients (72%), and 138 (13%) died from bladder cancer during the observation period. Male gender [odds ratio (OR) = 1.56, 95% confidence interval (CI) 1.13-2.17] and treatment at county (OR = 1.65, 95% CI 1.17-2.33), university (OR =2.12, 95% CI 1.48-3.03) or high-volume (OR = 1.92, 95% CI 1.34-2.75) hospitals were significantly associated with higher odds of intravesical instillations. The age category >/=80 years had a significantly lower chance of receiving intravesical therapy (OR = 0.44, 95% CI 0.26-0.74) and a significantly higher risk of dying from bladder cancer (hazard ratio = 3.03, 95% CI 1.71-5.35). CONCLUSION: Significantly more frequent use of intravesical treatment of primary CIS was found for males and for patients treated at county, university and high-volume hospitals. Age >/=80 years was significantly related to less intravesical treatment and poorer cancer-specific survival. FAU - Jancke, Georg AU - Jancke G AD - a Department of Urology , Skane University Hospital, Malmo, and Department of Translational Medicine, Lund University , Malmo , Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - a Department of Urology , Skane University Hospital, Malmo, and Department of Translational Medicine, Lund University , Malmo , Sweden. FAU - Aljabery, Firas AU - Aljabery F AD - b Department of Urology , Linkoping University Hospital , Linkoping , Sweden. FAU - Sherif, Amir AU - Sherif A AD - c Department of Urology , Norrland University Hospital , Umea , Sweden. FAU - Strock, Viveka AU - Strock V AD - d Department of Urology , Sahlgrenska University Hospital , Goteborg , Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - e Department of Urology , Uppsala Akademiska Hospital , Uppsala , Sweden. FAU - Hosseini-Aliabad, Abolfazl AU - Hosseini-Aliabad A AD - f Department of Urology , Karolinska University Hospital , Stockholm , Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - b Department of Urology , Linkoping University Hospital , Linkoping , Sweden. LA - eng PT - Journal Article DEP - 20170329 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage MH - BCG Vaccine/*administration & dosage MH - Carcinoma in Situ/*drug therapy MH - Female MH - Follow-Up Studies MH - Hospitals, County/statistics & numerical data MH - Hospitals, High-Volume/statistics & numerical data MH - Hospitals, University/statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - Registries MH - Sex Factors MH - Survival Rate MH - Sweden MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - Cancer-specific survival OT - intravesical treatment OT - primary CIS EDAT- 2017/03/30 06:00 MHDA- 2018/05/02 06:00 CRDT- 2017/03/30 06:00 PHST- 2017/03/30 06:00 [pubmed] PHST- 2018/05/02 06:00 [medline] PHST- 2017/03/30 06:00 [entrez] AID - 10.1080/21681805.2017.1298156 [doi] PST - ppublish SO - Scand J Urol. 2017 Apr;51(2):124-129. doi: 10.1080/21681805.2017.1298156. Epub 2017 Mar 29. PMID- 28344874 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210112 IS - 2162-4011 (Print) IS - 2162-402X (Electronic) IS - 2162-4011 (Linking) VI - 6 IP - 2 DP - 2017 TI - High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. PG - e1265719 LID - 10.1080/2162402X.2016.1265719 [doi] LID - e1265719 AB - Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) can significantly reduce the risk of recurrence and progression. However, BCG therapy may fail in up to a half of treated patients and may also cause toxicities. Biomarkers to predict the effectiveness of BCG therapy are desired to pre-select patients for BCG therapy to maximize efficacy while avoid unnecessary toxicity. Twelve cytokines were measured in 100 blood and 112 urine samples using cytokine antibody array and correlated with recurrence-free survival in overall and BCG-treated NMIBC patients. Of the 12 cytokines, interleukin (IL) -2, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-gamma were measurable in more than 30% of peripheral blood leukocyte (PBL) samples. Only IL-8 in PBL was found to be significantly associated with tumor recurrence, especially in those who receiving BCG therapy (hazard ratio [HR] = 4.24; 95% confidence interval [95%CI] = 1.65-10.88; p = 0.003). The median recurrence-free survival time for BCG-treated patients with high baseline IL-8 levels were much shorter than those with low IL-8 levels (7.9 vs. >78.4 mo, p = 0.004). Furthermore, consistent associations between urinary IL-8 levels and tumor recurrence in patients receiving BCG therapy were observed in 58 pre-BCG and 54 long-term post-BCG-treated urine samples (both p /=35.47 is associated with statistically significant better recurrence-free survival (RFS) (P=.0007), progression-free survival (PFS) (P=.0420), and cancer-specific survival (CSS) (P=.0050). Multivariate Cox regression analysis revealed that high AR1 mRNA expression is an independent prognostic marker for RFS (P=.0029) and CSS (P=.0119). Spearman rank correlation revealed a significant positive association between mRNA expression of AR1 and KRT5 (r(s): 0.3171, P<.0001) as well as a negative association with multifocal tumors (r(s): 0.1478, P<.0109). No association was noted between AR1 expression and tumor grade, concomitant CIS, gender, tumor size, and KRT20 in patients with stage T1 NMIBC. CONCLUSIONS: AR mRNA expression can predict RFS and CSS in patients with stage T1 NMIBC. Further studies are necessary to refine the relevance of AR mRNA expression compared with immunohistochemically detectable AR expression. CI - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Sikic, Danijel AU - Sikic D AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: danijel.sikic@uk-erlangen.de. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: johannes.breyer@ukr.de. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: arndt.hartmann@uk-erlangen.de. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: maximilian.burger@ukr.de. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: philipp.erben@medma.uni-heidelberg.de. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: stefan.denzinger@ukr.de. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: markus.eckstein@uk-erlangen.de. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. Electronic address: robert.stoehr@uk-erlangen.de. FAU - Wach, Sven AU - Wach S AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: sven.wach@uk-erlangen.de. FAU - Wullich, Bernd AU - Wullich B AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: bernd.wullich@uk-erlangen.de. FAU - Keck, Bastian AU - Keck B AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. Electronic address: bastian.keck@uk-erlangen.de. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. Electronic address: ralph.wirtz@STRATIFYER.de. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: wolfgang.otto@ukr.de. LA - eng PT - Journal Article DEP - 20170322 PL - United States TA - Transl Oncol JT - Translational oncology JID - 101472619 PMC - PMC5367846 EDAT- 2017/03/28 06:00 MHDA- 2017/03/28 06:01 PMCR- 2017/03/22 CRDT- 2017/03/26 06:00 PHST- 2016/12/12 00:00 [received] PHST- 2017/01/24 00:00 [revised] PHST- 2017/01/31 00:00 [accepted] PHST- 2017/03/28 06:00 [pubmed] PHST- 2017/03/28 06:01 [medline] PHST- 2017/03/26 06:00 [entrez] PHST- 2017/03/22 00:00 [pmc-release] AID - S1936-5233(16)30279-0 [pii] AID - 10.1016/j.tranon.2017.01.013 [doi] PST - ppublish SO - Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22. PMID- 28339163 OWN - NLM STAT- MEDLINE DCOM- 20170829 LR - 20260127 IS - 1934-6638 (Electronic) IS - 0008-543X (Print) IS - 1934-662X (Linking) VI - 125 IP - 6 DP - 2017 Jun TI - Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin. PG - 416-426 LID - 10.1002/cncy.21847 [doi] AB - BACKGROUND: Biopsies from patients with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Guerin (BCG) treatment. METHODS: Forty-one cytology slides from patients with HR NMIUC treated with intravesical BCG were selected for this study. Histological confirmation was available for all cases. The specimens were subjected to NGS analysis with a customized targeted exome capture assay composed of 341 genes. RESULTS: In this cohort, genomic alterations were successfully identified in all cytology samples. Mutations were detected down to a 2% allele frequency and chromosomal rearrangements including copy number alterations and gene fusions were identified. The most frequently altered genes included telomerase reverse transcriptase (TERT), tumor protein 53 (TP53), Erb-B2 receptor tyrosine kinase 2 (ERBB2), and chromatin remodeling genes such as lysine demethylase 6A (KDM6A) and AT-rich interaction domain 1A (ARID1A). For patients with matched tumor tissue, cytology specimens revealed all mutations detected in tissue as well as additional mutations, and this suggested that urine might more effectively capture the full genetic heterogeneity of disease than an individual cystectomy. Alterations in multiple genes correlated with clinical and histopathological features, including responses to BCG treatment, flat architecture versus papillary architecture, and smoking history. CONCLUSIONS: Urine specimens can replace tissue as a substrate for NGS analysis of HR NMIUC. Several genomic alterations identified in urine specimens might be associated with histological features and clinical characteristics. Cancer Cytopathol 2017;125:416-26. (c) 2017 American Cancer Society. CI - (c) 2017 American Cancer Society. FAU - Scott, Sasinya N AU - Scott SN AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Ostrovnaya, Irina AU - Ostrovnaya I AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Lin, Caroline M AU - Lin CM AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Bouvier, Nancy AU - Bouvier N AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Bochner, Bernard H AU - Bochner BH AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Iyer, Gopakumar AU - Iyer G AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Solit, David AU - Solit D AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Berger, Michael F AU - Berger MF AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. AD - Marie Josee and Henry R. Kravis Center for Molecular Oncology, New York, New York. FAU - Lin, Oscar AU - Lin O AUID- ORCID: 0000-0003-2089-6118 AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170324 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (DNA-Binding Proteins) RN - EC 1.14.11.- (Histone Demethylases) RN - 0 (Nuclear Proteins) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.7.49 (Telomerase) RN - 0 (Transcription Factors) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (ARID1A protein, human) RN - 0 (TP53 protein, human) RN - EC 1.14.11.- (KDM6A protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.7.49 (TERT protein, human) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/drug therapy/*genetics/pathology/urine MH - DNA-Binding Proteins MH - Female MH - High-Throughput Nucleotide Sequencing/*methods MH - Histone Demethylases/genetics MH - Humans MH - Male MH - Middle Aged MH - Mutation MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Nuclear Proteins/genetics MH - Erb-b2 Receptor Tyrosine Kinases/genetics MH - Sequence Analysis, DNA MH - Telomerase/genetics MH - Transcription Factors/genetics MH - Tumor Suppressor Protein p53/genetics MH - Urinary Bladder Neoplasms/drug therapy/*genetics/pathology/urine MH - Urine/*cytology PMC - PMC5477237 MID - NIHMS859907 OTO - NOTNLM OT - bacille Calmette-Guerin (BCG) OT - bladder cancer OT - next-generation sequencing OT - urine cytology EDAT- 2017/03/25 06:00 MHDA- 2017/08/30 06:00 PMCR- 2018/06/01 CRDT- 2017/03/25 06:00 PHST- 2017/01/10 00:00 [received] PHST- 2017/01/25 00:00 [revised] PHST- 2017/01/27 00:00 [accepted] PHST- 2017/03/25 06:00 [pubmed] PHST- 2017/08/30 06:00 [medline] PHST- 2017/03/25 06:00 [entrez] PHST- 2018/06/01 00:00 [pmc-release] AID - 10.1002/cncy.21847 [doi] PST - ppublish SO - Cancer Cytopathol. 2017 Jun;125(6):416-426. doi: 10.1002/cncy.21847. Epub 2017 Mar 24. PMID- 28334788 OWN - NLM STAT- MEDLINE DCOM- 20171030 LR - 20220316 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 47 IP - 6 DP - 2017 Jun 1 TI - Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer. PG - 560-567 LID - 10.1093/jjco/hyx030 [doi] AB - OBJECTIVE: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscle-invasive bladder cancers. We investigated the clinical outcomes among patients with T1 high-grade bladder cancer to identify factors related to cancer recurrence and disease progression. METHODS: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 high-grade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution. Clinicopathological factors were analyzed using univariate and multivariate analyses. RESULTS: The median age and follow-up duration were 72 years and 45.4 months, respectively. Sixty-two patients (41.9%) had recurrence, 28 (18.9%) experienced progression and 13 (8.8%) died of bladder cancer. In the multivariate analysis, divergent differentiation was an independent factor related to recurrence (P = 0.0096, hazard ratio = 2.5), whereas a non-papillary tumor shape, divergent differentiation and presence of a residual tumor at the time of the second transurethral resection were independent factors related to progression (P = 0.0349, hazard ratio = 3.8; P = 0.0074, hazard ratio = 6.8 and P = 0.0449, hazard ratio = 4.1, respectively). There were no independent factors related to cancer-specific mortality. Divergent differentiation was the only independent factor associated with both recurrence and progression. In addition, patients with divergent differentiation had significantly worse recurrence-free survival and progression-free survival rates than did patients without divergent differentiation (log-rank P = 0.0009 and P = 0.0019, respectively). CONCLUSIONS: In this study, the presence of divergent differentiation was related to worse oncological outcomes in patients with T1 high-grade bladder cancer. Patients with divergent differentiation may require stringent follow-up and early cystectomy after recurrence to improve oncological outcomes. CI - (c) The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com FAU - Fujii, Nakanori AU - Fujii N AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Hoshii, Yoshinobu AU - Hoshii Y AD - Department of Diagnostic Pathology, Yamaguchi University Hospital, Ube, Yamaguchi. FAU - Hirata, Hiroshi AU - Hirata H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. AD - Department of Urology, Ube Memorial Hospital, Ube, Yamaguchi, Japan. FAU - Mori, Junichi AU - Mori J AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Shimizu, Kosuke AU - Shimizu K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Kobayashi, Keita AU - Kobayashi K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Kawai, Yoshihisa AU - Kawai Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Inoue, Ryo AU - Inoue R AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Yamamoto, Yoshiaki AU - Yamamoto Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm, Residual/surgery MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*pathology MH - Urothelium/*pathology OTO - NOTNLM OT - T1 OT - divergent differentiation OT - high grade OT - non-muscle-invasive bladder cancer OT - urothelial carcinoma EDAT- 2017/03/24 06:00 MHDA- 2017/10/31 06:00 CRDT- 2017/03/24 06:00 PHST- 2016/10/03 00:00 [received] PHST- 2017/02/12 00:00 [accepted] PHST- 2017/03/24 06:00 [pubmed] PHST- 2017/10/31 06:00 [medline] PHST- 2017/03/24 06:00 [entrez] AID - 3063353 [pii] AID - 10.1093/jjco/hyx030 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2017 Jun 1;47(6):560-567. doi: 10.1093/jjco/hyx030. PMID- 28332983 OWN - NLM STAT- MEDLINE DCOM- 20170710 LR - 20250623 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 97 IP - 5 DP - 2017 Apr 1 TI - Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. PG - 1002-1020 LID - S0360-3016(16)33549-0 [pii] LID - 10.1016/j.ijrobp.2016.11.056 [doi] AB - PURPOSE: To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. METHODS AND MATERIALS: We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments. CONCLUSION: Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Vashistha, Vishal AU - Vashistha V AD - Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. FAU - Wang, Hanzhang AU - Wang H AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. FAU - Mazzone, Andrew AU - Mazzone A AD - Rush Medical College, Rush University Medical Center, Chicago, Illinois. FAU - Liss, Michael A AU - Liss MA AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. FAU - Schleicher, Mary AU - Schleicher M AD - Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. FAU - Kaushik, Dharam AU - Kaushik D AD - Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Electronic address: Kaushik@uthscsa.edu. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20161213 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 SB - IM CIN - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757. doi: 10.1016/j.ijrobp.2017.07.001. PMID: 29280469 CIN - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757-758. doi: 10.1016/j.ijrobp.2017.07.002. PMID: 29280470 CIN - Strahlenther Onkol. 2018 Apr;194(4):358-359. doi: 10.1007/s00066-018-1274-6. PMID: 29396699 MH - Aged MH - Aged, 80 and over MH - Chemoradiotherapy/*mortality/*statistics & numerical data MH - Combined Modality Therapy MH - Cystectomy/*mortality/*statistics & numerical data MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Postoperative Complications/mortality/prevention & control MH - Prevalence MH - Radiation Injuries/mortality/prevention & control MH - Risk Factors MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*mortality/*therapy EDAT- 2017/03/24 06:00 MHDA- 2017/07/14 06:00 CRDT- 2017/03/24 06:00 PHST- 2016/09/30 00:00 [received] PHST- 2016/11/23 00:00 [revised] PHST- 2016/11/29 00:00 [accepted] PHST- 2017/03/24 06:00 [entrez] PHST- 2017/03/24 06:00 [pubmed] PHST- 2017/07/14 06:00 [medline] AID - S0360-3016(16)33549-0 [pii] AID - 10.1016/j.ijrobp.2016.11.056 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1002-1020. doi: 10.1016/j.ijrobp.2016.11.056. Epub 2016 Dec 13. PMID- 28332428 OWN - NLM STAT- MEDLINE DCOM- 20180501 LR - 20180501 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 51 IP - 2 DP - 2017 Apr TI - Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. PG - 130-136 LID - 10.1080/21681805.2017.1295399 [doi] AB - OBJECTIVE: The aim of the present study was to determine the influence of intraoperative and postoperative blood transfusion on cancer-specific outcome. MATERIALS AND METHODS: Follow-up data were collected from 722 patients undergoing radical cystectomy for urothelial carcinoma of the bladder (UCB) between 2004 and 2014. Median follow-up was 26 months (interquartile range 12-61 months). Outcome was analyzed in relation to the amount of intraoperative and postoperative blood transfusion and different tumor stages. The primary endpoint was cancer-specific survival (CSS) after cystectomy. Kaplan-Meier analysis with log-rank test and Cox regression models were used. RESULTS: Intraoperative blood transfusion was given in 36% (263/722) and postoperative blood transfusion in 18% (132/722). In patients with and without intraoperative blood transfusion, 5 year CSS was 48% and 67%, respectively (p < .001). In patients with and without postoperative blood transfusion, 5 year CSS was 48% and 63%, respectively (p < .001). The number of transfused red blood cell (RBC) units [intraoperatively: hazard ratio (HR) = 1.08, 95% confidence interval (CI) 1.01-1.15, p = .023; postoperatively: HR = 1.14, 95% CI 1.07-1.21, p < .001] was an independent prognostic factor for CSS. The dose-dependent negative effect of transfusions was also found in favorable subgroups (pT1 tumor, hemoglobin >/=13 mg/dl, p = .004) and in a high-volume surgeon subgroup (n = 244, p < .001). CONCLUSIONS: Blood transfusions during and after radical cystectomy were independent prognostic factors for CSS in this retrospective study. Therefore, efforts should be made to reduce the necessity of intraoperative and postoperative blood transfusion in cystectomy patients. FAU - Buchner, Alexander AU - Buchner A AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Grimm, Tobias AU - Grimm T AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Schneevoigt, Birte-Swantje AU - Schneevoigt BS AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Wittmann, Georg AU - Wittmann G AD - b Department of Transfusion Medicine , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Kretschmer, Alexander AU - Kretschmer A AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Jokisch, Friedrich AU - Jokisch F AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Grabbert, Markus AU - Grabbert M AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Apfelbeck, Maria AU - Apfelbeck M AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Schulz, Gerald AU - Schulz G AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Gratzke, Christian AU - Gratzke C AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Stief, Christian G AU - Stief CG AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. FAU - Karl, Alexander AU - Karl A AD - a Department of Urology , Ludwig-Maximilians-Universitat Munchen , Munich , Germany. LA - eng PT - Journal Article DEP - 20170323 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - *Blood Transfusion/statistics & numerical data MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - *Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Intraoperative Care MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Postoperative Care MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - blood transfusion OT - cystectomy OT - outcome EDAT- 2017/03/24 06:00 MHDA- 2018/05/02 06:00 CRDT- 2017/03/24 06:00 PHST- 2017/03/24 06:00 [pubmed] PHST- 2018/05/02 06:00 [medline] PHST- 2017/03/24 06:00 [entrez] AID - 10.1080/21681805.2017.1295399 [doi] PST - ppublish SO - Scand J Urol. 2017 Apr;51(2):130-136. doi: 10.1080/21681805.2017.1295399. Epub 2017 Mar 23. PMID- 28325826 OWN - NLM STAT- MEDLINE DCOM- 20180302 LR - 20250529 IS - 1940-6215 (Electronic) IS - 1940-6207 (Print) IS - 1940-6215 (Linking) VI - 10 IP - 5 DP - 2017 May TI - A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. PG - 298-307 LID - 10.1158/1940-6207.CAPR-16-0167 [doi] AB - We performed a phase II pharmacodynamic prevention trial of Polyphenon E [a green tea polyphenol formulation primarily consisting of epigallocatechin gallate (EGCG)] in patients prior to bladder cancer surgery. Patients with a bladder tumor were randomized to receive Polyphenon E containing either 800 or 1,200 mg of EGCG or placebo for 14 to 28 days prior to transurethral resection of bladder tumor or cystectomy. The primary objective was to compare the postintervention EGCG tissue levels in patients receiving Polyphenon E as compared with placebo. Secondary objectives included assessments of tissue expression of PCNA, MMP2, clusterin, VEGF, p27, IGF-1, IGFBP-3; correlation of tissue, plasma, and urine levels of EGCG; and EGCG metabolism by catechol-O-methyltransferase and UDP-glucuronosyltransferase pharmacogenomic mutations. Thirty-one patients (male:female, 26:5; mean age, 67.2 years) were randomized and 29 (94%) completed the study. There was not an observed significant difference (P = 0.12) in EGCG tissue levels between two Polyphenon E dosage groups combined versus placebo. However, a dose-response relationship for EGCG levels was observed in both normal (P = 0.046) and malignant bladder tissue (P = 0.005) across the three study arms. In addition, EGCG levels in plasma (P < 0.001) and urine (P < 0.001) increased and PCNA (P = 0.016) and clusterin (P = 0.008) were downregulated in a dose-dependent fashion. No pharmacogenomic relationship was observed. EGCG levels in plasma, urine, and bladder tissue followed a dose-response relationship, as did modulation of tissue biomarkers of proliferation and apoptosis. Despite the limitations of this pilot study, the observed pharmacodynamics and desirable biologic activity warrant further clinical studies of this agent in bladder cancer prevention. Cancer Prev Res; 10(5); 298-307. (c)2017 AACR. CI - (c)2017 American Association for Cancer Research. FAU - Gee, Jason R AU - Gee JR AD - Institute of Urology, Lahey Hospital and Medical Center, Burlington, Massachusetts. Jason.R.Gee@Lahey.org. FAU - Saltzstein, Daniel R AU - Saltzstein DR AD - Urology San Antonio Research, University of Wisconsin-Madison, Madison, Wisconsin. FAU - Kim, KyungMann AU - Kim K AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. AD - Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin. FAU - Kolesar, Jill AU - Kolesar J AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Huang, Wei AU - Huang W AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Havighurst, Thomas C AU - Havighurst TC AD - Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin. FAU - Wollmer, Barbara W AU - Wollmer BW AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Stublaski, Jeanne AU - Stublaski J AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Downs, Tracy AU - Downs T AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - Mukhtar, Hasan AU - Mukhtar H AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. FAU - House, Margaret G AU - House MG AD - Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD. FAU - Parnes, Howard L AU - Parnes HL AD - Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD. FAU - Bailey, Howard H AU - Bailey HH AD - University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. LA - eng GR - N01 CN035153/CA/NCI NIH HHS/United States GR - P30 CA014520/CA/NCI NIH HHS/United States GR - UL1 TR000427/TR/NCATS NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20170321 PL - United States TA - Cancer Prev Res (Phila) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - 0 (Biomarkers, Tumor) RN - 8R1V1STN48 (Catechin) RN - T432289GYZ (polyphenon E) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/analysis MH - Catechin/administration & dosage/*analogs & derivatives/pharmacokinetics MH - Dose-Response Relationship, Drug MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pilot Projects MH - Tissue Distribution MH - Urinary Bladder/*drug effects MH - *Urinary Bladder Neoplasms PMC - PMC5503683 MID - NIHMS861698 COIS- Disclosure of Potential Conflicts of Interest: No authors had any potential conflicts of interest to disclose. EDAT- 2017/03/23 06:00 MHDA- 2018/03/03 06:00 PMCR- 2018/05/01 CRDT- 2017/03/23 06:00 PHST- 2016/06/22 00:00 [received] PHST- 2016/07/29 00:00 [revised] PHST- 2017/03/13 00:00 [accepted] PHST- 2017/03/23 06:00 [pubmed] PHST- 2018/03/03 06:00 [medline] PHST- 2017/03/23 06:00 [entrez] PHST- 2018/05/01 00:00 [pmc-release] AID - 1940-6207.CAPR-16-0167 [pii] AID - 10.1158/1940-6207.CAPR-16-0167 [doi] PST - ppublish SO - Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21. PMID- 28319171 OWN - NLM STAT- MEDLINE DCOM- 20170829 LR - 20220311 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 3 DP - 2017 TI - A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. PG - e0174039 LID - 10.1371/journal.pone.0174039 [doi] LID - e0174039 AB - BACKGROUND: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy. METHODS: We studied diagnostic transurethral resection of bladder tumors (dTURBT) of 150 MIBC patients (urothelial carcinoma) who were subsequently treated by radical cystectomy and pelvic lymph node dissection. RNA was isolated and the expression level of the 20 genes was determined on a qRT-PCR platform. Normalized Ct values were used to calculate a risk score to predict the presence of node-positive disease. The Cancer Genome Atlas (TCGA) RNA expression data was analyzed to subsequently validate the results. RESULTS: In a univariate regression analysis, none of the 20 genes significantly correlated with node-positive disease. The area under the curve of the risk score calculated by the 20-gene expression signature was 0.54 (95% Confidence Interval: 0.44-0.65) versus 0.67 for the model published by Smith et al. Node-negative patients had a significantly lower tumor grade at TURBT (p = 0.03), a lower pT stage (p<0.01) and less frequent lymphovascular invasion (13% versus 38%, p<0.01) at radical cystectomy than node-positive patients. In addition, in the TCGA data, none of the 20 genes was differentially expressed in node-negative versus node-positive patients. CONCLUSIONS: We conclude that a 20-gene expression signature developed for nodal staging of MIBC at radical cystectomy could not be validated on a qRT-PCR platform in a large cohort of dTURBT specimens. FAU - van Kessel, Kim E M AU - van Kessel KE AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - van de Werken, Harmen J G AU - van de Werken HJ AD - Department of Urology, Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Lurkin, Irene AU - Lurkin I AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Ziel-van der Made, Angelique C J AU - Ziel-van der Made AC AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Validation Study DEP - 20170320 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma/*genetics/metabolism/*pathology/surgery MH - *Cystectomy MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Lymph Node Excision MH - Lymphatic Metastasis/*diagnosis MH - Male MH - Middle Aged MH - Muscle Neoplasms/metabolism/pathology MH - Neoplasm Grading MH - Neoplasm Staging MH - Retrospective Studies MH - *Transcriptome MH - Urinary Bladder Neoplasms/*genetics/metabolism/*pathology/surgery PMC - PMC5358850 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2017/03/21 06:00 MHDA- 2017/08/30 06:00 PMCR- 2017/03/20 CRDT- 2017/03/21 06:00 PHST- 2017/01/27 00:00 [received] PHST- 2017/03/02 00:00 [accepted] PHST- 2017/03/21 06:00 [entrez] PHST- 2017/03/21 06:00 [pubmed] PHST- 2017/08/30 06:00 [medline] PHST- 2017/03/20 00:00 [pmc-release] AID - PONE-D-17-03600 [pii] AID - 10.1371/journal.pone.0174039 [doi] PST - epublish SO - PLoS One. 2017 Mar 20;12(3):e0174039. doi: 10.1371/journal.pone.0174039. eCollection 2017. PMID- 28317587 OWN - NLM STAT- MEDLINE DCOM- 20170817 LR - 20170817 IS - 1879-3320 (Electronic) IS - 0960-7404 (Linking) VI - 26 IP - 1 DP - 2017 Mar TI - Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma. PG - 73-79 LID - S0960-7404(17)30028-2 [pii] LID - 10.1016/j.suronc.2017.01.003 [doi] AB - OBJECTIVE: To evaluate the impact of pneumoperitoneum time on intravesical recurrence (IVR) in upper tract urothelial carcinoma (UTUC) patients who underwent laparoscopic radical nephroureterectomy (LRNU). PATIENTS AND METHODS: We identified 129 UTUC patients who underwent LRNU at our three institutions from 2004 to 2014. We evaluated the association of IVR rate and patient clinico-pathological characteristics including operation time. By retrospectively reviewing all videotapes, we defined pneumoperitoneum time as being from the infusion of pressurized CO2 gas with a pressure of 10-12 mmHg to extirpation of the kidney. RESULTS: During the median follow-up of 31.1 months, 61 (47.3%) had subsequent IVR after LRNU. Multivariate analysis revealed that prolonged pneumoperitoneum time (HR = 1.81, p = 0.025) and presence of lymphovascular invasion (LVI) (HR = 1.53, p = 0.006) were independent risk factors for subsequent IVR. The 3-year and 5-year IVR free survival rates were 43.7% and 21.8% in patients with a prolonged pneumoperitoneum time of >/=150 min, which were significantly lower than those in their counterparts (59.0% and 48.3%, respectively, p = 0.024). The subsequent IVR rates were 27.3% for a pneumoperitoneum time of <90 min, 35.8% for that of 90-150 min, 55.0% for that of 150-210 min, 61.1% for that of 210-270 min, and 85.7% for that of >270 min. CONCLUSIONS: Prolongation of pneumoperitoneum time and presence of LVI might be associated with higher risk of subsequent IVR in UTUC patients who underwent LRNU. CI - Copyright (c) 2017 Elsevier Ltd. All rights reserved. FAU - Shigeta, Keisuke AU - Shigeta K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Hagiwara, Masayuki AU - Hagiwara M AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Ando, Toshiyuki AU - Ando T AD - Department of Urology, Isehara Kyodo Hospital, Kanagawa, Japan. FAU - Mizuno, Ryuichi AU - Mizuno R AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Miyajima, Akira AU - Miyajima A AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Nakagawa, Ken AU - Nakagawa K AD - Department of Urology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20170123 PL - Netherlands TA - Surg Oncol JT - Surgical oncology JID - 9208188 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Immunoenzyme Techniques MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*etiology/pathology MH - Neoplasm Staging MH - Nephrectomy/*adverse effects MH - Pneumoperitoneum/*complications MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Time Factors MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Intravesical recurrence OT - Lymphovascular invasion OT - Pneumoperitoneum time OT - Upper tract urothelial carcinoma EDAT- 2017/03/21 06:00 MHDA- 2017/08/18 06:00 CRDT- 2017/03/21 06:00 PHST- 2016/07/18 00:00 [received] PHST- 2016/10/08 00:00 [revised] PHST- 2017/01/20 00:00 [accepted] PHST- 2017/03/21 06:00 [entrez] PHST- 2017/03/21 06:00 [pubmed] PHST- 2017/08/18 06:00 [medline] AID - S0960-7404(17)30028-2 [pii] AID - 10.1016/j.suronc.2017.01.003 [doi] PST - ppublish SO - Surg Oncol. 2017 Mar;26(1):73-79. doi: 10.1016/j.suronc.2017.01.003. Epub 2017 Jan 23. PMID- 28314306 OWN - NLM STAT- MEDLINE DCOM- 20170411 LR - 20211108 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 3 DP - 2017 Mar TI - Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas. PG - 1375-1380 AB - AIM: To evaluate indoleamine 2,3-dioxygenase (IDO) gene expression in non-muscle-invasive urothelial cell bladder carcinoma (NMIBC). PATIENTS AND METHODS: Seventy-four patients undergoing surgical treatment for NMIBC were enrolled in the study. IDO gene expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: IDO gene expression was detectable significantly more frequently (48/74, 64.86% vs. 5/21, 23.81%, p<0.001) and to significantly higher extents (p=0.01) in cancer tissues than in normal bladder mucosa. IDO gene expression was observed significantly more frequently in large (p=0.02), high-grade (p=0.05) and stage T1 (p=0.03) than in small, low-grade and stage Ta tumors. Expression levels were also significantly higher in large, high-grade and stage T1 tumors (p<0.01, p=0.05 and p=0.03, respectively). A direct positive correlation between IDO gene expression in tumor tissues and tumor size (R=0.24, p=0.04), grade (R=0.23, p=0.05) and stage (R=0.25, p=0.03) was detected. Multivariate analysis suggested a trend (p=0.08) towards longer overall survival in patients bearing tumors that did not express IDO gene. CONCLUSION: These data indicate that IDO gene expression is a feature of aggressive NMIBC, suggesting a potential immunosuppressive role of IDO. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Hudolin, Tvrtko AU - Hudolin T AD - Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia tvrtkohudolin@gmail.com. FAU - Mengus, Chantal AU - Mengus C AD - Department of Surgery, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. AD - Department of Biomedicine, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. FAU - Coulot, Julie AU - Coulot J AD - Department of Surgery, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. AD - Department of Biomedicine, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. FAU - Kastelan, Zeljko AU - Kastelan Z AD - Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia. FAU - El-Saleh, Ahmad AU - El-Saleh A AD - Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia. FAU - Spagnoli, Giulio C AU - Spagnoli GC AD - Department of Surgery, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. AD - Department of Biomedicine, Institute of Surgical Research and Hospital Management, Basel University Hospital, Basel, Switzerland. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (IDO1 protein, human) RN - 0 (Immunosuppressive Agents) RN - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase) SB - IM MH - Aged MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Enzymologic MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics/*metabolism MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Prognosis MH - Real-Time Polymerase Chain Reaction MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*enzymology/genetics/mortality MH - Urothelium/*enzymology/pathology OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - indoleamine 2,3-dioxygenase OT - polymerase chain reaction EDAT- 2017/03/21 06:00 MHDA- 2017/04/12 06:00 CRDT- 2017/03/19 06:00 PHST- 2016/12/22 00:00 [received] PHST- 2017/02/19 00:00 [revised] PHST- 2017/02/21 00:00 [accepted] PHST- 2017/03/19 06:00 [entrez] PHST- 2017/03/21 06:00 [pubmed] PHST- 2017/04/12 06:00 [medline] AID - 37/3/1375 [pii] AID - 10.21873/anticanres.11458 [doi] PST - ppublish SO - Anticancer Res. 2017 Mar;37(3):1375-1380. doi: 10.21873/anticanres.11458. PMID- 28293425 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2050-7771 (Print) IS - 2050-7771 (Electronic) IS - 2050-7771 (Linking) VI - 5 DP - 2017 TI - Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study. PG - 10 LID - 10.1186/s40364-017-0090-y [doi] LID - 10 AB - BACKGROUND: Urothelial bladder cancer (UBC) is a disease that often is discovered when the tumour is non-muscle invasive, i.e. in Ta or T1 stage. Some patients will progress into muscle-invasive disease, a potentially deadly condition. Although there are some prognostic models, the need for prognostic and predictive biomarkers is considerate and urgent. Membranous expression of podocalyxin-like protein 1 (PODXL) and low expression of the RNA-binding motif 3 (RBM3) has previously been shown to be associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer, including UBC. In this study, we sought to validate the prognostic impact of PODXL and RBM3 in an independent cohort of UBC. METHODS: Using tissue microarrays and immunohistochemistry, PODXL and RBM3 expression was evaluated in 272 incident UBC cases from the prospective, population-based cohort study Malmo Diet and Cancer. Kaplan-Meier analysis and Cox proportional hazards modelling were used to evaluate the prognostic impact of these markers on 5-year overall survival (OS). RESULTS: In line with previous studies, both membranous PODXL expression and low RBM3 expression was significantly associated with disadvantageous clinicopathological features. Membranous PODXL expression was significantly associated with a reduced 5-year overall survival in the entire cohort (univariable HR 3.28; 95% CI 1.89-5.69), but this association did not remain significant in multivariable analysis. In T1 tumours, PODXL was significantly associated with reduced survival in univariable analysis (HR = 2.83; 95% CI 1.04-7.72) and borderline significant in multivariable analysis (HR = 2.60; 95% CI 0.91-7.39). Low RBM3 expression was an independent predictor of a reduced survival in the entire cohort (univariable HR 3.19; 95% CI 2.02-5.04, and multivariable HR 1.85; 95% CI 1.11-3.09), and in T1 tumours (univariable HR 2.64; 95% CI 1.11-6.27, and multivariable HR 2.63; 95% CI 1.01-6.84). CONCLUSIONS: A link between membranous PODXL expression and clinically more aggressive tumours was further confirmed, but PODXL expression was not an independent prognostic biomarker in this study. Low RBM3 expression was validated as an independent factor of poor prognosis in UBC, including T1 disease. These findings suggest that these biomarkers could be useful in stratifying patients with non-muscle invasive disease for more aggressive first line treatment. FAU - Boman, Karolina AU - Boman K AUID- ORCID: 0000-0002-6204-9681 AD - Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 FAU - Andersson, Gustav AU - Andersson G AD - Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 FAU - Wennersten, Christoffer AU - Wennersten C AD - Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 FAU - Nodin, Bjorn AU - Nodin B AD - Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 FAU - Ahlgren, Goran AU - Ahlgren G AD - Department of Translational Medicine, Lund University, Malmo, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 AD - Department of Urology, Skane University Hospital, Malmo, Sweden. ISNI: 0000 0004 0623 9987. GRID: grid.412650.4 FAU - Jirstrom, Karin AU - Jirstrom K AD - Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden. ISNI: 0000 0001 0930 2361. GRID: grid.4514.4 LA - eng PT - Journal Article DEP - 20170314 PL - England TA - Biomark Res JT - Biomarker research JID - 101607860 PMC - PMC5348745 OTO - NOTNLM OT - Bladder cancer OT - PODXL OT - Prognosis OT - RBM3 EDAT- 2017/03/16 06:00 MHDA- 2017/03/16 06:01 PMCR- 2017/03/14 CRDT- 2017/03/16 06:00 PHST- 2016/10/27 00:00 [received] PHST- 2017/03/06 00:00 [accepted] PHST- 2017/03/16 06:00 [entrez] PHST- 2017/03/16 06:00 [pubmed] PHST- 2017/03/16 06:01 [medline] PHST- 2017/03/14 00:00 [pmc-release] AID - 90 [pii] AID - 10.1186/s40364-017-0090-y [doi] PST - epublish SO - Biomark Res. 2017 Mar 14;5:10. doi: 10.1186/s40364-017-0090-y. eCollection 2017. PMID- 28291636 OWN - NLM STAT- MEDLINE DCOM- 20180115 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 5 DP - 2017 May TI - Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. PG - 257-263 LID - S1078-1439(17)30016-9 [pii] LID - 10.1016/j.urolonc.2017.01.014 [doi] AB - OBJECTIVES: Immunotherapy for bladder cancer seems to have promising results. Here, we evaluated the association between messenger RNA (mRNA) and protein levels and possible prognostic value of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immune checkpoint pathways during bladder carcinogenesis. METHODS AND MATERIALS: Tumor samples were obtained from 155 patients (84 with muscle-invasive bladder cancer [MIBC], and 71 non-muscle-invasive bladder cancer [NMIBC]) and normal bladder tissue from 15 patients. We evaluated the mRNA expression of 3 genes in the PD-1 pathway (PD-1, PD-L1, and PD-L2) and 4 in the CTLA4 pathway (CTLA4, CD28, CD80, and CD86) in normal and tumoral human bladder samples by quantitative real-time reverse transcription polymerase chain reaction, with immunohistochemistry used to evaluate the protein expression of PD-1 and PD-L1 in tumor and immune cells. Results of molecular analyses were compared with survival analyses. RESULTS: As compared with normal bladder tissue, MIBC tissue showed PD-1, PD-L1, CTLA4, and CD80 overexpression (59.5%, 60.7%, 84.5%, and 92.9%, respectively), whereas overexpression was lower in NMIBC tissue (22.5%, 4.2%, 35.2%, and 46.5%, respectively). The results of reverse transcription polymerase chain reaction analysis were confirmed by immunohistochemistry, with a high correlation between mRNA and protein expression. On multivariate analyses, overexpression of the studied genes was not associated with prognosis in relapse or progression of NMIBC or in recurrence-free and overall survival of MIBC. CONCLUSIONS: The CTLA4 pathway appears to be deregulated along with the PD-1/PD-L1 pathway in bladder carcinogenesis, with good correlation between mRNA and protein expression endorsing the useful role of immune checkpoints, especially for a large subgroup of MIBC. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Le Goux, Constance AU - Le Goux C AD - Unite de Pharmacogenomique, Service de genetique, Institut Curie, Paris, France. FAU - Damotte, Diane AU - Damotte D AD - Service d׳Anatomopathologie, Hopital Cochin, Universite Paris Descartes, Paris, France; Cancer et Immunite anti tumorale, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France. FAU - Vacher, Sophie AU - Vacher S AD - Unite de Pharmacogenomique, Service de genetique, Institut Curie, Paris, France. FAU - Sibony, Mathilde AU - Sibony M AD - Service d׳Anatomopathologie, Hopital Cochin, Universite Paris Descartes, Paris, France. FAU - Delongchamps, Nicolas Barry AU - Delongchamps NB AD - Service d׳Urologie, Hopital Cochin, Universite Paris Descartes, Paris, France. FAU - Schnitzler, Anne AU - Schnitzler A AD - Unite de Pharmacogenomique, Service de genetique, Institut Curie, Paris, France. FAU - Terris, Benoit AU - Terris B AD - Service d׳Anatomopathologie, Hopital Cochin, Universite Paris Descartes, Paris, France. FAU - Zerbib, Marc AU - Zerbib M AD - Service d׳Urologie, Hopital Cochin, Universite Paris Descartes, Paris, France. FAU - Bieche, Ivan AU - Bieche I AD - Unite de Pharmacogenomique, Service de genetique, Institut Curie, Paris, France; Universite Paris Descartes, Paris, France. FAU - Pignot, Geraldine AU - Pignot G AD - Service d׳Urologie, Institut Paoli-Calmettes, Marseille, France. Electronic address: pignotg@ipc.unicancer.fr. LA - eng PT - Journal Article DEP - 20170311 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (B7-1 Antigen) RN - 0 (B7-2 Antigen) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (CD28 Antigens) RN - 0 (CD86 protein, human) RN - 0 (CTLA-4 Antigen) RN - 0 (CTLA4 protein, human) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Ligand 2 Protein) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - B7-1 Antigen/genetics/metabolism MH - B7-2 Antigen/genetics/metabolism MH - B7-H1 Antigen/genetics/metabolism MH - CD28 Antigens/genetics/metabolism MH - CTLA-4 Antigen/genetics/metabolism MH - Carcinoma, Transitional Cell/*genetics/*metabolism/pathology MH - Female MH - Gene Expression MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Programmed Cell Death 1 Ligand 2 Protein/genetics MH - Programmed Cell Death 1 Receptor/genetics/metabolism MH - RNA, Messenger/*metabolism MH - Retrospective Studies MH - Signal Transduction MH - Urinary Bladder/metabolism MH - Urinary Bladder Neoplasms/*genetics/*metabolism/pathology OTO - NOTNLM OT - Bladder cancer OT - CTLA4 OT - Immune checkpoints OT - Immunohistochemistry OT - Molecular marker OT - PD-1 OT - RT-PCR EDAT- 2017/03/16 06:00 MHDA- 2018/01/16 06:00 CRDT- 2017/03/15 06:00 PHST- 2016/09/28 00:00 [received] PHST- 2016/12/30 00:00 [revised] PHST- 2017/01/16 00:00 [accepted] PHST- 2017/03/16 06:00 [pubmed] PHST- 2018/01/16 06:00 [medline] PHST- 2017/03/15 06:00 [entrez] AID - S1078-1439(17)30016-9 [pii] AID - 10.1016/j.urolonc.2017.01.014 [doi] PST - ppublish SO - Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11. PMID- 28286068 OWN - NLM STAT- MEDLINE DCOM- 20190321 LR - 20250729 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 198 IP - 3 DP - 2017 Sep TI - Efficacy of bacillus Calmette-Guerin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. PG - 503-510 LID - S0022-5347(17)39246-7 [pii] LID - 10.1016/j.juro.2017.01.086 [doi] AB - PURPOSE: We sought to determine the efficacy of genetically distinct bacillus Calmette-Guerin strains in preventing disease recurrence in patients with nonmuscle invasive bladder cancer. MATERIALS AND METHODS: We conducted a systematic review and network meta-analysis of trials evaluating bacillus Calmette-Guerin strains against all possible comparators (different bacillus Calmette-Guerin strains, chemotherapy and nonbacillus Calmette-Guerin biological therapies) with intravesical chemotherapy as the common comparator. MEDLINE(R) (http://www.ncbi.nlm.nih.gov/pubmed) served as the primary data source, with the search from inception to October 2016 for clinical trials involving patients with nonmuscle invasive bladder cancer receiving bacillus Calmette-Guerin. Primary outcome measure was bladder cancer recurrence, defined as recurrent bladder tumor of any grade or stage. Random effect network meta-analysis provided estimates for outcomes and is presented as odds ratios. RESULTS: Across all possible comparators (65 trials, 12,246 patients, 9 strains) there were 2,177 recurrences in 5,642 treated patients (38.6%) and 2,316 recurrences in 5,441 comparators (42.6%). With chemotherapy as the common comparator (28 trials, 5,757 patients, 5 strains) Tokyo-172 (OR 0.39, 95% CI 0.16-0.93), Pasteur (OR 0.49, 95% CI 0.28-0.86) and TICE(R) (OR 0.61, 95% CI 0.40-0.93) strains were significantly better than chemotherapy at preventing recurrence. No bacillus Calmette-Guerin strain demonstrated significant superiority when compared to any other strain at preventing recurrence in the network meta-analysis. CONCLUSIONS: Bacillus Calmette-Guerin strains exhibited significant differences in efficacy compared to chemotherapy. However, no definitive conclusions could be reached regarding strain superiority, and head-to-head trials are greatly needed to further understand the importance of strain selection in determining bacillus Calmette-Guerin efficacy. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Boehm, Brock E AU - Boehm BE AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. FAU - Cornell, John E AU - Cornell JE AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. FAU - Wang, Hanzhang AU - Wang H AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. FAU - Mukherjee, Neelam AU - Mukherjee N AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. FAU - Oppenheimer, Jacob S AU - Oppenheimer JS AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. FAU - Svatek, Robert S AU - Svatek RS AD - Department of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. Electronic address: svatek@uthscsa.edu. LA - eng GR - K23 CA178204/CA/NCI NIH HHS/United States PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20170310 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Humans MH - Mycobacterium bovis MH - Urinary Bladder Neoplasms/*drug therapy/pathology PMC - PMC6464123 MID - NIHMS1016246 OTO - NOTNLM OT - BCG vaccine OT - immunotherapy OT - urinary bladder neoplasms COIS- The authors declare no potential conflicts of interest EDAT- 2017/03/14 06:00 MHDA- 2019/03/22 06:00 PMCR- 2019/04/15 CRDT- 2017/03/14 06:00 PHST- 2017/01/05 00:00 [accepted] PHST- 2017/03/14 06:00 [pubmed] PHST- 2019/03/22 06:00 [medline] PHST- 2017/03/14 06:00 [entrez] PHST- 2019/04/15 00:00 [pmc-release] AID - S0022-5347(17)39246-7 [pii] AID - 10.1016/j.juro.2017.01.086 [doi] PST - ppublish SO - J Urol. 2017 Sep;198(3):503-510. doi: 10.1016/j.juro.2017.01.086. Epub 2017 Mar 10. PMID- 28282341 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201127 IS - 1531-703X (Electronic) IS - 1040-8746 (Print) IS - 1040-8746 (Linking) VI - 29 IP - 3 DP - 2017 May TI - New developments in the management of nonmuscle invasive bladder cancer. PG - 179-183 LID - 10.1097/CCO.0000000000000362 [doi] AB - PURPOSE OF REVIEW: In this review, we summarize the core principles in the management of nonmuscle invasive bladder cancer (NMIBC) with an emphasis on new developments that have emerged over the last year. RECENT FINDINGS: NMIBC has a propensity to recur and progress. Risk stratification has facilitated appropriate patient selection for treatment but improved tools, including biomarkers, are still needed. Enhanced cystoscopy with photodynamic imaging and narrow band imaging show promise for diagnosis, risk stratification, and disease monitoring and has been formally recommended this year by the American Urological Association. Attempts at better treatment, especially in refractory high-risk cases, include the addition of intravesical hyperthermia, combination and sequential therapy with existing agents, and the use of novel agents such as mycobacterial cell wall extract. New data are emerging regarding the potential role of early cystectomy in bacillus Calmette-Guerin-refractory NMIBC patients. SUMMARY: NMIBC represents an assortment of disease states and continues to pose management challenges. Continued research is needed to bolster the evidence needed for patients and providers to make data-driven treatment decisions. FAU - Tyson, Mark D AU - Tyson MD AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Lee, Daniel AU - Lee D FAU - Clark, Peter AU - Clark P LA - eng GR - T32 CA106183/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 SB - IM PMC - PMC5665722 MID - NIHMS890460 COIS- Conflict of interest: None. EDAT- 2017/03/11 06:00 MHDA- 2017/03/11 06:01 PMCR- 2018/09/09 CRDT- 2017/03/11 06:00 PHST- 2017/03/11 06:00 [pubmed] PHST- 2017/03/11 06:01 [medline] PHST- 2017/03/11 06:00 [entrez] PHST- 2018/09/09 00:00 [pmc-release] AID - 10.1097/CCO.0000000000000362 [doi] PST - ppublish SO - Curr Opin Oncol. 2017 May;29(3):179-183. doi: 10.1097/CCO.0000000000000362. PMID- 28278504 OWN - NLM STAT- MEDLINE DCOM- 20170621 LR - 20250724 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 41 IP - 4 DP - 2017 TI - Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guerin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis. PG - 1298-1312 LID - 10.1159/000464432 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives with equivalent efficacy If other alternative intravesical agents have equivalent efficacy compared to BCG, then it may be feasible to replace standard BCG with alternative options. METHODS: We searched all relevant evidence in multiple sources and key data was extracted from included studies. Conventional and network meta-analysis were conducted so that pooled odds ratios (ORs) for the event of tumor recurrence and progression can be computed. The relative efficacy of different intravesical instillation procedures was computed by pooled odds ratios and their 95% confidence or creditable intervals. Besides, several key model assumptions were evaluated in our analysis. RESULTS: Three intravesical instillation procedures have the potential for preventing tumor recurrence: standard-dose BCG (BCG_SD), Epirubicin (EPI) and Mitomycin C (MMC) (ORs < 1). Patients with BCG SD also exhibited a decreased risk of tumor recurrence and progression compared to those with EPI. No significant difference in the risk of tumor recurrence or progression was detected between patients treated with BCG_ SD and those with low-dose BCG (BCG_LD). Results of SUCRA indicated that BCG_EPI, BCG_ MMC and BCG SD had higher rankings with respect to tumor recurrence and progression. CONCLUSIONS: BCG SD, EPI and MMC exhibited established efficacy for preventing tumor recurrence in postoperative BC patients. The efficacy of BCG may not be significantly reduced if standard dose was reduced to a lower level. However, there is no consensus suggesting that intravesical BCG with standard dose can be replaced by alternating or sequentially combined intravesical instillation therapies. CI - (c) 2017 The Author(s)Published by S. Karger AG, Basel. FAU - Wu, Cheng AU - Wu C AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. FAU - Zhou, Xunrong AU - Zhou X AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. FAU - Miao, Chunqing AU - Miao C AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. FAU - Zhang, Jianzhong AU - Zhang J AD - Department of Urology, The first affiliated hospital of Nanjing Medical University, Nanjing, China. FAU - Tang, Qingsheng AU - Tang Q AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. FAU - Chang, Xiumei AU - Chang X AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. FAU - Ni, Haodong AU - Ni H AD - Department of Urology, People's Hospital of Dongtai City, Dongtai, China. LA - eng PT - Journal Article PT - Network Meta-Analysis DEP - 20170308 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 3Z8479ZZ5X (Epirubicin) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Female MH - Humans MH - Male MH - *Epirubicin/therapeutic use MH - *Immunotherapy/methods MH - *Mitomycin/therapeutic use MH - *Mycobacterium bovis MH - *Urinary Bladder Neoplasms/immunology/pathology/therapy OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Consistency OT - Epirubicin OT - Gemcitabine OT - Heterogeneity OT - Interferon-Alpha OT - Intravesical instillation therapies OT - Mitomycin C OT - Pairwise/network meta-analysis OT - Tumor progression OT - Tumor recurrence EDAT- 2017/03/10 06:00 MHDA- 2017/06/22 06:00 CRDT- 2017/03/10 06:00 PHST- 2016/08/29 00:00 [received] PHST- 2016/11/16 00:00 [accepted] PHST- 2017/03/10 06:00 [pubmed] PHST- 2017/06/22 06:00 [medline] PHST- 2017/03/10 06:00 [entrez] AID - 000464432 [pii] AID - 10.1159/000464432 [doi] PST - ppublish SO - Cell Physiol Biochem. 2017;41(4):1298-1312. doi: 10.1159/000464432. Epub 2017 Mar 8. PMID- 28275033 OWN - NLM STAT- MEDLINE DCOM- 20171019 LR - 20260127 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 15 IP - 3 DP - 2017 Mar TI - Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy. PG - 327-333 AB - Background: The Deyo adaptation of the Charlson comorbidity index (DaCCI), which relies on 17 comorbid condition groupings, represents one of the most frequently used baseline comorbidity assessment tools in retrospective database studies. However, this index is not specific for patients with bladder cancer (BCa) treated with radical cystectomy (RC). The goal of this study was to develop a short-form of the original DaCCI (DaCCI-SF) that may specifically predict 90-day mortality after RC, with equal or better accuracy. Patients and Methods: Between 2000 and 2009, we identified 7,076 patients in the SEER-Medicare database with stage T1 through T4 nonmetastatic BCa treated with RC. We randomly divided the population into development (n=6,076) and validation (n=1,000) cohorts. Within the development cohort, logistic regression models tested the ability to predict 90-day mortality with various iterations of the DaCCI-SF, wherein <17 original comorbid condition groupings were included after adjusting for age, sex, race, T stage, and N stage. We relied on the Akaike information criterion to identify the most parsimonious and informative set of comorbid condition groupings. Accuracy of the DaCCI and the DaCCI-SF was tested in the external validation cohort. Results: Within the development cohort, the most parsimonious and informative model resulted in the inclusion of 3 of the 17 (17.6%) original comorbid condition groupings: congestive heart failure, cerebrovascular disease, and chronic pulmonary disease. Within the validation cohort, the accuracy was 68.4% for the DaCCI versus 69.7% for the DaCCI-SF. Higher accuracy of the DaCCI-SF was confirmed in subgroup analyses performed according to age (75 years), stage (organ-confined vs non-organ-confined), type of diversion (ileal-conduit vs non-ileal-conduit), and treatment period. Conclusions: DaCCI-SF relies on 17.6% of the original comorbid condition groupings and provides higher accuracy for predicting 90-day mortality after RC compared with the original DaCCI, especially in most contemporary patients. CI - Copyright (c) 2017 by the National Comprehensive Cancer Network. FAU - Dell'Oglio, Paolo AU - Dell'Oglio P AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Tian, Zhe AU - Tian Z AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada AD - Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada FAU - Leyh-Bannurah, Sami-Ramzi AU - Leyh-Bannurah SR AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada AD - Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany FAU - Trudeau, Vincent AU - Trudeau V AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada AD - Department of Urology, University of Montreal Health Center, Montreal, Canada FAU - Larcher, Alessandro AU - Larcher A AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Di Trapani, Ettore AU - Di Trapani E AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Capitanio, Umberto AU - Capitanio U AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Montorsi, Francesco AU - Montorsi F AD - Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy AD - Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy FAU - Saad, Fred AU - Saad F AD - Department of Urology, University of Montreal Health Center, Montreal, Canada FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada AD - Department of Urology, University of Montreal Health Center, Montreal, Canada LA - eng PT - Journal Article PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM CIN - J Urol. 2017 Sep;198(3):474-475. doi: 10.1016/j.juro.2017.06.019. PMID: 28817898 MH - Aged MH - Aged, 80 and over MH - Comorbidity MH - Cystectomy/methods MH - Female MH - Humans MH - Male MH - Mortality MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Population Surveillance MH - SEER Program MH - United States/epidemiology MH - Urinary Bladder Neoplasms/diagnosis/*epidemiology/mortality/surgery EDAT- 2017/03/10 06:00 MHDA- 2017/10/20 06:00 CRDT- 2017/03/10 06:00 PHST- 2016/06/11 00:00 [received] PHST- 2016/11/28 00:00 [accepted] PHST- 2017/03/10 06:00 [entrez] PHST- 2017/03/10 06:00 [pubmed] PHST- 2017/10/20 06:00 [medline] AID - 15/3/327 [pii] AID - 10.6004/jnccn.2017.0032 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2017 Mar;15(3):327-333. doi: 10.6004/jnccn.2017.0032. PMID- 28270951 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240524 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 43 IP - 1 DP - 2017 Mar TI - Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients. PG - 48-54 LID - 10.5152/tud.2016.77603 [doi] AB - OBJECTIVE: To evaluate the consistency of the results of patients who were treated for non-muscle-invasive bladder cancer (NMIBC) in our clinic with the European Organization for Research and Treatment of Cancer (EORTC) risk table. MATERIAL AND METHODS: Data were retrospectively analyzed from 452 patients who had undergone transurethral resection of bladder tumor (TUR-BT) between the years 2002, and 2010 for primary or recurrent NMIBC. Our study had a retrospective design but based on prospective cohort study. Patients were staged according to the 2002 Tumor Node Metastasis (TNM) classification and the 1973 World Health Organization grading system. Recurrence was defined as non-muscle-invasive or muscle-invasive and progression as muscle-invasive tumor determined based on following cystoscopy and TUR-BT results, and confirmed by histopathologic analysis. Patients in the current study were classified into four groups according to the EORTC risk tables. Time to first recurrence and progression was determined for each risk group. RESULTS: Of the 452 patients, 348 were enrolled in this study. The overall mean follow-up period was 55.25 months of all patients. Of 348 patients, 130 (37.4%) and 258 patients (74.1%) had recurrence after treatment at the 1 and 5 year follow-up period, respectively. While 35 (10.1%) and 99 patients (28.4%) progressed to muscle-invasive cancer at the 1 and 5 year follow-up period, respectively. In the multivariate analysis, grade, number, size of the tumor size, and concomitant carcinoma in situ were found to be statistically significant for disease progression and recurrence. CONCLUSION: When EORTC risk tables were comparatively evaluated in our patient population, we can say that EORTC tables predict nearly accurately the clinical course of patients with NMIBC. FAU - Kilinc, Muhammet Fatih AU - Kilinc MF AD - Clinic of Urology, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Bayar, Goksel AU - Bayar G AD - Clinic of Urology, Idil State Hospital, Sirnak, Turkey. FAU - Dalkilic, Ayhan AU - Dalkilic A AD - Clinic of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. FAU - Sonmez, Nurettin Cem AU - Sonmez NC AD - Clinic of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. FAU - Arisan, Serdar AU - Arisan S AD - Clinic of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. FAU - Guney, Soner AU - Guney S AD - Clinic of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20170106 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC5330268 OTO - NOTNLM OT - Disease recurrence OT - EORTC OT - progression OT - urinary bladder neoplasm COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2017/03/09 06:00 MHDA- 2017/03/09 06:01 PMCR- 2017/03/01 CRDT- 2017/03/09 06:00 PHST- 2016/06/21 00:00 [received] PHST- 2016/07/28 00:00 [accepted] PHST- 2017/03/09 06:00 [entrez] PHST- 2017/03/09 06:00 [pubmed] PHST- 2017/03/09 06:01 [medline] PHST- 2017/03/01 00:00 [pmc-release] AID - tju-43-1-48 [pii] AID - 10.5152/tud.2016.77603 [doi] PST - ppublish SO - Turk J Urol. 2017 Mar;43(1):48-54. doi: 10.5152/tud.2016.77603. Epub 2017 Jan 6. PMID- 28270945 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220408 IS - 2149-3235 (Print) IS - 2149-3057 (Electronic) IS - 2149-3235 (Linking) VI - 43 IP - 1 DP - 2017 Mar TI - What is new in non-muscle-invasive bladder cancer in 2016? PG - 9-13 LID - 10.5152/tud.2017.60376 [doi] AB - Approximately 75% of bladder cancers are non-muscle-invasive bladder cancer (NMIBC), and 50% of NMIBC patients who are treated with transurethral resection (TUR) have a recurrence of the disease and 5-25% of these patients progressed to muscle-invasive disease after repeated recurrences. NMIBC patients receive various treatments aimed at reducing disease recurrence and progression. Although the recurrence rate of disease remains above target, thus increasing treatment cost, the true rate of recurrence after the primary surgery is controversial. Recurrences can be categorized as either true recurrence due to aggressive tumor biology and implantation of floating cancer cells or false recurrence such as small, flat, or carcinoma in situ lesions overlooked in the primary procedure. Here we discuss new diagnostic methods and treatment options to improve outcomes and reduce recurrence rates in NMIBC. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas, MD Anderson Cancer Center, Texas, USA. FAU - Bagcioglu, Murat AU - Bagcioglu M AD - Department of Urology, Kafkas University School of Medicine, Kars, Turkey. FAU - Huri, Emre AU - Huri E AD - Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20170301 PL - Turkey TA - Turk J Urol JT - Turkish journal of urology JID - 101643563 PMC - PMC5330275 OTO - NOTNLM OT - Bladder cancer OT - diagnostic assessment OT - intravesical chemotherapy OT - intravesical immunotherapy OT - predictive markers COIS- Conflict of Interest: No conflict of interest was declared by the authors. EDAT- 2017/03/09 06:00 MHDA- 2017/03/09 06:01 PMCR- 2017/03/01 CRDT- 2017/03/09 06:00 PHST- 2017/01/09 00:00 [received] PHST- 2017/01/10 00:00 [accepted] PHST- 2017/03/09 06:00 [entrez] PHST- 2017/03/09 06:00 [pubmed] PHST- 2017/03/09 06:01 [medline] PHST- 2017/03/01 00:00 [pmc-release] AID - tju-43-1-9 [pii] AID - 10.5152/tud.2017.60376 [doi] PST - ppublish SO - Turk J Urol. 2017 Mar;43(1):9-13. doi: 10.5152/tud.2017.60376. Epub 2017 Mar 1. PMID- 28268259 OWN - NLM STAT- MEDLINE DCOM- 20170705 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 3 IP - 3 DP - 2017 Mar 8 TI - Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. PG - CD012112 LID - 10.1002/14651858.CD012112.pub2 [doi] LID - CD012112 AB - BACKGROUND: Despite local therapies, commonly transurethral resection (TUR) followed by adjuvant treatments, non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence and progression. Intravesical Bacillus Calmette-Guerin (BCG) has been shown to reduce recurrence and progression in people with NMIBC following TUR, however many people do not respond to treatment, have recurrence shortly after, or cannot tolerate standard-dose therapy. The potential for synergistic antitumour activity of interferon (IFN)-alpha (alpha) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy. OBJECTIVES: To assess the effects of intravesically administered BCG plus IFN-alpha compared with BCG alone for treating non-muscle-invasive bladder cancer. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2016), MEDLINE (OvidSP) (1946 to 2016), Embase (OvidSP) (1974 to 2016), ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) as well as reference lists of retrieved articles and handsearched abstract proceedings of relevant conferences for the past three years. We applied no language restrictions. The date of last search of all databases was 25 August 2016. SELECTION CRITERIA: We included randomised controlled trials (RCTs) and pseudo-randomised trials assessing intravesically administered BCG plus IFN-alpha versus BCG alone in adults of either gender with histologically confirmed Ta and T1 superficial bladder cancer, with or without carcinoma in situ, treated with TUR. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias of included studies. We used Review Manager 5 for data synthesis and employed the random-effects model for meta-analyses. For prespecified outcomes, where we were unable to derive time-to-event information (e.g. time-to-recurrence), we assessed dichotomous outcomes (e.g. recurrence) instead. We assessed the quality of the evidence for the main comparisons using the GRADE approach. MAIN RESULTS: We included five RCTs involving a total of 1231 participants with NMIBC in this review. Due to poor reporting, the risk of bias in the included studies was often unclear. We assessed the studies under two main comparisons: intravesical BCG plus IFN-alpha versus intravesical BCG alone (four RCTs), and intravesical BCG alternating with IFN-alpha versus intravesical BCG alone (one RCT). Intravesical BCG plus IFN-alpha versus intravesical BCG alone (four RCTs): We observed no clear difference between BCG plus IFN-alpha and BCG alone for recurrence (average risk ratio (RR) 0.76, 95% confidence interval (CI) 0.44 to 1.32; 4 RCTs; 925 participants; very low-quality evidence) or progression (average RR 0.26, 95% CI 0.04 to 1.87; 2 RCTs; 219 participants; low-quality evidence). The included RCTs did not report on the other primary outcome of this review, discontinuation of therapy due to adverse events. Regarding secondary outcomes, we observed no clear difference for disease-specific mortality (RR 0.38, 95% CI 0.05 to 3.05; 1 RCT; 99 participants; very low-quality evidence). Two RCTs reporting contradictory findings for adverse events could not be pooled due to variation in definitions. There were no data from the included RCTs on time-to-death or disease-specific quality of life. Intravesical BCG alternating with IFN-alpha versus intravesical BCG alone (one RCT): We observed shorter time-to-recurrence for participants in the BCG alternating with IFN-alpha group compared with the BCG alone group (hazard ratio (HR) 2.86, 95% CI 1.98 to 4.13; 1 RCT; 205 participants; low-quality evidence), but no clear differences in time-to-progression (HR 2.39, 95% CI 0.92 to 6.21; 1 RCT; 205 participants; low-quality evidence) and discontinuation of therapy due to adverse events (RR 2.97, 95% CI 0.31 to 28.09; 1 RCT; 205 participants; low-quality evidence). Regarding secondary outcomes, there were no clear differences between the BCG alternating with IFN-alpha and BCG alone groups for disease-specific mortality (HR 2.74, 95% CI 0.73 to 10.28; 1 RCT; 205 participants; low-quality evidence), time-to-death (overall survival) (HR 1.00, 95% CI 0.68 to 1.47; 1 RCT; 205 participants; low-quality evidence), or systemic or local adverse events (RR 1.65, 95% CI 0.41 to 6.73; 1 RCT; 205 participants; low-quality evidence). There were no data on disease-specific quality of life. AUTHORS' CONCLUSIONS: We found low- to very low-quality evidence suggesting no clear differences in recurrence or progression with BCG plus IFN-alpha compared with BCG alone for people with NMIBC; there was no information to determine the effect on discontinuation of therapy due to adverse events. Low-quality evidence suggests BCG alternating with IFN-alpha compared with BCG alone may increase time-to-recurrence, however low-quality evidence also suggests no clear differences for time-to-progression or discontinuation of therapy due to adverse events.Additional high-quality, adequately powered trials using standardised instillation regimens and doses of both BCG and IFN-alpha, reporting outcomes in subgroups stratified by patient and tumour characteristics, and on long-term outcomes related not only to recurrence but also to progression, discontinuation due to adverse events, and mortality may help to clarify the ideal treatment strategy and provide a more definitive result. FAU - Shepherd, Andrew Rh AU - Shepherd AR AD - Department of Urology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia, 5000. AD - School of Medicine, The University of Adelaide, Adelaide, Australia. FAU - Shepherd, Emily AU - Shepherd E AD - ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Adelaide, South Australia, Australia, 5006. FAU - Brook, Nicholas R AU - Brook NR AD - Department of Urology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia, 5000. AD - School of Medicine, The University of Adelaide, Adelaide, Australia. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20170308 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Interferon-alpha) SB - IM CIN - Urologe A. 2017 Aug;56(8):1031-1033. doi: 10.1007/s00120-017-0436-y. PMID: 28653093 MH - Adjuvants, Immunologic/*administration & dosage/adverse effects MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - BCG Vaccine MH - Carcinoma in Situ/mortality/pathology/*therapy MH - Combined Modality Therapy/adverse effects/methods MH - Disease Progression MH - Drug Administration Schedule MH - Humans MH - Interferon-alpha/*administration & dosage/adverse effects MH - Neoplasm Recurrence, Local MH - Randomized Controlled Trials as Topic MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - Withholding Treatment/statistics & numerical data PMC - PMC6464648 COIS- ARHS: none known ES: none known NRB: none known EDAT- 2017/03/08 06:00 MHDA- 2017/07/06 06:00 PMCR- 2018/03/08 CRDT- 2017/03/08 06:00 PHST- 2017/03/08 06:00 [pubmed] PHST- 2017/07/06 06:00 [medline] PHST- 2017/03/08 06:00 [entrez] PHST- 2018/03/08 00:00 [pmc-release] AID - CD012112.pub2 [pii] AID - 10.1002/14651858.CD012112.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2017 Mar 8;3(3):CD012112. doi: 10.1002/14651858.CD012112.pub2. PMID- 28263495 OWN - NLM STAT- MEDLINE DCOM- 20190107 LR - 20190107 IS - 1300-0144 (Print) IS - 1300-0144 (Linking) VI - 47 IP - 1 DP - 2017 Feb 27 TI - Neutrophil-to-lymphocyte ratio is elevated in recurringnonmuscle invasive bladder cancer. PG - 234-239 LID - 10.3906/sag-1509-73 [doi] AB - BACKGROUND/AIM: Although it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may predict the progression of nonmuscle invasive bladder cancer (NMIBC), its association with the recurrence of NMIBC has been poorly studied. The aim of this study is to evaluate the association between NLR and disease recurrence in patients with NMIBC. MATERIALS AND METHODS: The medical records of 428 consecutive initially diagnosed NMIBC patients who underwent transurethral resection between January 2010 and July 2014 were retrospectively reviewed. Patients without a preoperative NLR (n = 6), without a minimum of 6 months of follow-up (n = 56), who were lost to follow-up (n = 38), or who had progressive disease during follow-up (n = 42) were excluded. The demographics, tumor characteristics, and NLRs of patients with and without tumor recurrence were compared. RESULTS: Of 286 patients who met the inclusion criteria, 68 (17.43%) had recurrent disease. Tumor size (P = 0.198), tumor type (P = 0.929), and the presence of carcinoma in situ (P = 0.373) were also similar between groups. Patients with recurrent disease had a higher mean NLR (2.62 +/- 0.99 vs. 2.2 +/- 0.96, P = 0.002). CONCLUSION: Our results show that NLR may be used as a predictor of recurrence in patients with NMIBC; however, prospective studies are required to validate these findings. FAU - Yuruk, Emrah AU - Yuruk E AD - Department of Urology, Bagcilar Training & Research Hospital, Istanbul, Turkey. FAU - Saitz, Theodore Robert AU - Saitz TR AD - Department of Urology, Oregon Health & Science University, Portland, OR, USA. FAU - Gonultas, Serkan AU - Gonultas S AD - Department of Urology, Bagcilar Training & Research Hospital, Istanbul, Turkey. FAU - Serefoglu, Ege Can AU - Serefoglu EC AD - Department of Urology, Bagcilar Training & Research Hospital, Istanbul, Turkey. FAU - Muslumanoglu, Ahmet Yaser AU - Muslumanoglu AY AD - Department of Urology, Bagcilar Training & Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20170227 PL - Turkey TA - Turk J Med Sci JT - Turkish journal of medical sciences JID - 9441758 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Lymphocyte Count/*statistics & numerical data MH - Lymphocytes/*cytology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neutrophils/*cytology MH - Retrospective Studies MH - Urinary Bladder Neoplasms/blood/*epidemiology/immunology/*pathology MH - Young Adult EDAT- 2017/03/07 06:00 MHDA- 2019/01/08 06:00 CRDT- 2017/03/07 06:00 PHST- 2015/09/15 00:00 [received] PHST- 2016/06/12 00:00 [accepted] PHST- 2017/03/07 06:00 [entrez] PHST- 2017/03/07 06:00 [pubmed] PHST- 2019/01/08 06:00 [medline] AID - 10.3906/sag-1509-73 [doi] PST - epublish SO - Turk J Med Sci. 2017 Feb 27;47(1):234-239. doi: 10.3906/sag-1509-73. PMID- 28238757 OWN - NLM STAT- MEDLINE DCOM- 20180618 LR - 20260127 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 103 DP - 2017 May TI - Variations in Preoperative Use of Bone Scan Among Medicare Beneficiaries Undergoing Radical Cystectomy. PG - 84-90 LID - S0090-4295(17)30170-X [pii] LID - 10.1016/j.urology.2017.02.028 [doi] AB - OBJECTIVE: To examine factors associated with bone scan use in patients undergoing radical cystectomy and to assess trends in use over time. MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified 5573 patients who underwent radical cystectomy from 2004 to 2011. The primary outcome was completion of a bone scan within 6 months prior to surgery. Demographic, regional, and clinicopathologic predictors of bone scan use were examined using a mixed logit model with health service area as a random effect. RESULTS: Among radical cystectomy patients, 1754 (31%) completed a preoperative bone scan. Urologists ordered most of these studies (69%). The adjusted probability of a patient undergoing a bone scan decreased from 0.40 in 2004 to 0.29 in 2011 (P = .01). Compared with patients in the northeast region, those in the south, central, and west regions were less likely to have a bone scan (P <.001). Compared with those with stage /=66 years diagnosed with NMIBC. Of these, 4,748 individuals (34%) were exposed to statins during follow-up. The median statin exposure after NMIBC diagnosis was 21.4 months (interquartile range: 7.8-45.4). After a median follow-up of 7.1 years (interquartile range: 4.0-11.3) from NMIBC diagnosis, 8,900 (64%) individuals had died. The cumulative use of statins after NMIBC diagnosis did not significantly affect cancer-specific survival (P = 0.10). However, its cumulative use after NMIBC diagnosis was associated with a better overall survival ([0.93; 95% CI: 0.91-0.96], per year of use). CONCLUSIONS: This large population-based study has provided evidence that cumulative statin use was not associated with an improved cancer-specific survival among individuals with NMIBC. However, our findings did demonstrate that statin users had a better overall survival than nonusers. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Richard, Patrick O AU - Richard PO AD - Division of Urology, Departments of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Centre de Recherche du CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada; Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Ahmad, Ardalan E AU - Ahmad AE AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Bashir, Shaheena AU - Bashir S AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Hamilton, Robert J AU - Hamilton RJ AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Nam, Robert K AU - Nam RK AD - Division of Urology, Departments of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. FAU - Leao, Ricardo AU - Leao R AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Jeldres, Claudio AU - Jeldres C AD - Division of Urology, Departments of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Centre de Recherche du CHUS, Universite de Sherbrooke, Sherbrooke, QC, Canada. FAU - Kulkarni, Girish S AU - Kulkarni GS AD - Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: girish.kulkarni@uhn.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170209 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/pharmacology/*therapeutic use MH - Male MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*drug therapy/pathology OTO - NOTNLM OT - Outcome OT - Statins OT - Urinary bladder neoplasms EDAT- 2017/02/14 06:00 MHDA- 2018/03/20 06:00 CRDT- 2017/02/14 06:00 PHST- 2016/11/15 00:00 [received] PHST- 2016/12/13 00:00 [revised] PHST- 2016/12/19 00:00 [accepted] PHST- 2017/02/14 06:00 [pubmed] PHST- 2018/03/20 06:00 [medline] PHST- 2017/02/14 06:00 [entrez] AID - S1078-1439(16)30417-3 [pii] AID - 10.1016/j.urolonc.2016.12.009 [doi] PST - ppublish SO - Urol Oncol. 2017 Jun;35(6):342-348. doi: 10.1016/j.urolonc.2016.12.009. Epub 2017 Feb 9. PMID- 28188046 OWN - NLM STAT- MEDLINE DCOM- 20180426 LR - 20220321 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 4 DP - 2017 Aug TI - The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. PG - e661-e666 LID - S1558-7673(17)30011-3 [pii] LID - 10.1016/j.clgc.2017.01.011 [doi] AB - INTRODUCTION: The purpose of this study was to evaluate the impact of circulating tumor cells (CTCs) as a prognostic marker in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and assess the efficacy and reliability of 2 different CTC isolation methods. MATERIALS AND METHODS: Globally, 155 patients with a pathologically confirmed diagnosis of high-risk NMIBC were included (pT1G3 with or without carcinoma in situ) and underwent transurethral resection of bladder tumor (TURB) after a blood withdrawal for CTC evaluation. A total of 101 patients (Group A) had their samples analyzed with the CellSearch automated system, and 54 (Group B) had their samples analyzed with the CELLection Dynabeads manual system. RESULTS: Patients were followed for 28 months, and during this interval, there were a total of 65 (41.9%) recurrences, 27 (17.4%) disease progressions, and 9 (5.8%) lymph node and/or bone metastasis. In our CTC analysis, there were 20 (19.8%) positive patients in Group A and 24 in Group B (44.4%). In our analysis, we found a strong correlation between CTC presence and time to first recurrence; in Group A, we observed an incidence of recurrence in 75% of CTC-positive patients and in Group B of 83% of CTC-positive patients. The time to progression was also strongly correlated with CTCs: 65% and 29%, respectively, of those patients who progressed in those with CTCs in Group A and B. CONCLUSION: The study demonstrates the potential role of CTCs as a prognostic marker for risk stratification in patients with NMIBC, to predict both recurrence and progression. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Busetto, Gian Maria AU - Busetto GM AD - Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. FAU - Ferro, Matteo AU - Ferro M AD - Department of Urology, European Institute of Oncology (IEO), Milan, Italy. Electronic address: matteo.ferro@ieo.it. FAU - Del Giudice, Francesco AU - Del Giudice F AD - Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. FAU - Antonini, Gabriele AU - Antonini G AD - Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. FAU - Chung, Benjamin I AU - Chung BI AD - Department of Urology, Stanford University Medical Center, Stanford, CA. FAU - Sperduti, Isabella AU - Sperduti I AD - Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy. FAU - Giannarelli, Diana AU - Giannarelli D AD - Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy. FAU - Lucarelli, Giuseppe AU - Lucarelli G AD - Department of Emergency and Organ Transplantation, Urology, Andrology, and Kidney Transplantation Unit, University of Bari, Bari, Italy. FAU - Borghesi, Marco AU - Borghesi M AD - Department of Urology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. FAU - Musi, Gennaro AU - Musi G AD - Department of Urology, European Institute of Oncology (IEO), Milan, Italy. FAU - de Cobelli, Ottavio AU - de Cobelli O AD - Department of Urology, European Institute of Oncology (IEO), Milan, Italy. FAU - De Berardinis, Ettore AU - De Berardinis E AD - Department of Gynecological-Obstetrics Sciences and Urological Sciences, Sapienza Rome University Policlinico Umberto I, Rome, Italy. LA - eng PT - Journal Article DEP - 20170118 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplastic Cells, Circulating/*pathology MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/blood/*pathology/*surgery MH - Urologic Surgical Procedures/*methods OTO - NOTNLM OT - CELLection OT - CellSearch OT - NMIBC OT - Prognosis OT - TURB EDAT- 2017/02/12 06:00 MHDA- 2018/04/27 06:00 CRDT- 2017/02/12 06:00 PHST- 2016/11/15 00:00 [received] PHST- 2017/01/07 00:00 [revised] PHST- 2017/01/10 00:00 [accepted] PHST- 2017/02/12 06:00 [pubmed] PHST- 2018/04/27 06:00 [medline] PHST- 2017/02/12 06:00 [entrez] AID - S1558-7673(17)30011-3 [pii] AID - 10.1016/j.clgc.2017.01.011 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Aug;15(4):e661-e666. doi: 10.1016/j.clgc.2017.01.011. Epub 2017 Jan 18. PMID- 28184446 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20220316 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 47 IP - 5 DP - 2017 May 1 TI - Lymphovascular invasion predicts poor prognosis in high-grade pT1 bladder cancer patients who underwent transurethral resection in one piece. PG - 447-452 LID - 10.1093/jjco/hyx012 [doi] AB - BACKGROUND: Lymphovascular invasion (LVI) in high-grade clinical T1 bladder cancer is usually considered a poor prognostic factor, but it is often difficult to achieve correct staging of T1 bladder cancer and diagnose the presence of LVI because of the inadequacy of conventional transurethral resection specimens. The aims of this study were to evaluate the prognostic value of LVI in patients with correctly staged high-grade pathological T1 (pT1) bladder cancer who initially underwent transurethral resection in one piece (TURBO). METHODS: Eighty-six high-grade pT1 bladder cancer patients who underwent TURBO were enrolled. Risk of tumor understaging was avoided by examining the vertical resection margin of the TURBO specimen. Immunohistochemical staining using D2-40 and CD31 was performed to confirm LVI. We examined the association of LVI with other clinicopathological factors and the impact of LVI on progression-free survival and cancer-specific survival. RESULTS: The median follow-up period was 49 months (range, 6-142). In all patients, the tumors were accurately staged as pT1 at initial TURBO. LVI was detected in 15 patients (17%) and was significantly associated with tumor growth pattern (P = 0.001). Multivariate analysis identified LVI as the only independent predictor for reduced progression-free survival (HR, 4.48; 95% CI, 1.45-13.90; P = 0.009) and cancer-specific survival (HR, 4.35; 95% CI, 1.17-16.24; P = 0.029). CONCLUSIONS: The presence of LVI in TURBO specimens independently predicts poor clinical outcomes in patients with high-grade pT1 bladder cancer. This information may help urologists to counsel their patients when deciding whether to choose a bladder-preserving strategy or radical cystectomy. CI - (c) The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Ukai, Rinzo AU - Ukai R AD - Department of Urology, JR Hiroshima Hospital, Hiroshima. FAU - Hashimoto, Kunihiro AU - Hashimoto K AD - Department of Urology, JR Hiroshima Hospital, Hiroshima. FAU - Nakayama, Hirofumi AU - Nakayama H AD - Department of Pathology and Laboratory Medicine, JR Hiroshima Hospital, Hiroshima. FAU - Iwamoto, Toshiyuki AU - Iwamoto T AD - Department of Pathology, Chuden Hospital, Hiroshima, Japan. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis/*pathology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - disease progression OT - lymphovascular invasion OT - survival OT - urinary bladder neoplasms OT - urothelial carcinoma EDAT- 2017/02/12 06:00 MHDA- 2017/10/17 06:00 CRDT- 2017/02/11 06:00 PHST- 2016/10/23 00:00 [received] PHST- 2017/01/27 00:00 [accepted] PHST- 2017/02/12 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] PHST- 2017/02/11 06:00 [entrez] AID - 2981875 [pii] AID - 10.1093/jjco/hyx012 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2017 May 1;47(5):447-452. doi: 10.1093/jjco/hyx012. PMID- 28182725 OWN - NLM STAT- MEDLINE DCOM- 20170907 LR - 20240714 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 2 DP - 2017 TI - Prognostic implications of preoperative anemia in urothelial carcinoma: A meta-analysis. PG - e0171701 LID - 10.1371/journal.pone.0171701 [doi] LID - e0171701 AB - The prognostic significance of preoperative anemia (PA) has been identified in various malignancies. However, its predictive role in urothelial carcinoma (UC) remains controversial. The aim of this study was to investigate the prognostic value of PA in UC patients. We performed a meta-analysis of the association between PA and survival outcome in UC patients. Electronic databases were searched up to June 30, 2016. Study characteristics and prognostic data were extracted from each included study. Cancer-specific survival (CSS), recurrence-free survival (RFS), and overall survival (OS) were pooled using hazard ratio (HR) with corresponding 95% confidence intervals (CI). Herein, 12 studies comprising 3815 patients were included in the meta-analysis. There were 1593 (41.76%) patients in the PA group and 2222 (58.24%) in the control group. The overall pooled HRs of PA for CSS, RFS, and OS were significant at 2.21, (95% CI: 1.83-2.65, Pheterogeneity = 0.49, I2 = 0%), 1.87 (95% CI: 1.59-2.20, Pheterogeneity = 0.22, I2 = 28%), and 2.04(95% CI: 1.76-2.37, Pheterogeneity = 0.36, I2 = 9%) respectively. Stratified analyses indicated that PA was a predictor of poor prognosis based on ethnicity, sample size, tumor T stage, G grade, lymphovascular invasion (LVI), concomitant carcinoma in situ (CIS), and follow-up values. Our findings show that PA has negative prognostic effects on the survival outcome (CSS, RFS, and OS) in UC patients and can serve as a useful and cost-effective marker to aid prognosis prediction. FAU - Luo, Fei AU - Luo F AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Wang, Ya-Shen AU - Wang YS AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Su, Yan-Hui AU - Su YH AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Zhang, Zhi-Hua AU - Zhang ZH AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Sun, Hong-Hong AU - Sun HH AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. FAU - Li, Jian AU - Li J AD - Department of Urology, Tianjin Union Medical Center, Tianjin, China. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20170209 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Anemia/complications/*diagnosis/mortality MH - Carcinoma, Transitional Cell/complications/*diagnosis/mortality/surgery MH - Female MH - Humans MH - Male MH - Nephrectomy/methods MH - Preoperative Period MH - Prognosis MH - Recurrence MH - Survival Analysis MH - Treatment Outcome MH - Urologic Neoplasms/complications/*diagnosis/mortality/surgery PMC - PMC5300162 COIS- The authors have declared that no competing interests exist. EDAT- 2017/02/10 06:00 MHDA- 2017/09/08 06:00 PMCR- 2017/02/09 CRDT- 2017/02/10 06:00 PHST- 2016/08/15 00:00 [received] PHST- 2017/01/08 00:00 [accepted] PHST- 2017/02/10 06:00 [entrez] PHST- 2017/02/10 06:00 [pubmed] PHST- 2017/09/08 06:00 [medline] PHST- 2017/02/09 00:00 [pmc-release] AID - PONE-D-16-31123 [pii] AID - 10.1371/journal.pone.0171701 [doi] PST - epublish SO - PLoS One. 2017 Feb 9;12(2):e0171701. doi: 10.1371/journal.pone.0171701. eCollection 2017. PMID- 28179340 OWN - NLM STAT- MEDLINE DCOM- 20170306 LR - 20260127 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 2 DP - 2017 Feb TI - Different Gene Expression and Activity Pattern of Antioxidant Enzymes in Bladder Cancer. PG - 841-848 AB - The aim of this study was to evaluate the possible role in and contribution of antioxidant enzymes to bladder cancer (BC) etiology and recurrence after transurethral resection (TUR). We enrolled 40 patients with BC who underwent TUR and 100 sex- and age-matched healthy controls. The analysis was performed at diagnosis and recurrence, taking into account the time of recurrence. Gene expression of catalase (CAT), glutathione peroxidase 1 (GPX1) and manganese superoxide dismutase (SOD2) was determined in peripheral blood leukocytes. The activity of glutathione peroxidase 3 (GPX3) was examined in plasma, and GPX1 and copper-zinc containing superoxide dismutase 1 (SOD1) in erythrocytes. SOD2 and GPX1 expression and GPX1 and SOD1 activity were significantly higher in patients at diagnosis of BC in comparison to controls. In patients who had recurrence earlier than 1 year from TUR, CAT and SOD2 expression was lower (at diagnosis p=0.024 and p=0.434, at recurrence p=0.022 and p=0.010), while the GPX1 and GPX3 activity was higher (at diagnosis p=0.242 and p=0.394, at recurrence p=0.019 and p=0.025) compared to patients with recurrence after 1 year from TUR. This study revealed that the gene expression and activity of the antioxidant enzymes are elevated in blood of patients with BC, although a low expression of CAT might contribute to the recurrence of BC, in early prognosis. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Wieczorek, Edyta AU - Wieczorek E AD - Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine, Lodz, Poland edytaw@imp.lodz.pl. FAU - Jablonowski, Zbigniew AU - Jablonowski Z AD - First Department of Urology, Medical University of Lodz, Lodz, Poland. FAU - Tomasik, Bartlomiej AU - Tomasik B AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. FAU - Gromadzinska, Jolanta AU - Gromadzinska J AD - Department of Biological and Environmental Monitoring, Nofer Institute of Occupational Medicine, Lodz, Poland. FAU - Jablonska, Ewa AU - Jablonska E AD - Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine, Lodz, Poland. FAU - Konecki, Tomasz AU - Konecki T AD - First Department of Urology, Medical University of Lodz, Lodz, Poland. FAU - Fendler, Wojciech AU - Fendler W AD - Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. FAU - Sosnowski, Marek AU - Sosnowski M AD - First Department of Urology, Medical University of Lodz, Lodz, Poland. FAU - Wasowicz, Wojciech AU - Wasowicz W AD - Department of Biological and Environmental Monitoring, Nofer Institute of Occupational Medicine, Lodz, Poland. FAU - Reszka, Edyta AU - Reszka E AD - Department of Toxicology and Carcinogenesis, Nofer Institute of Occupational Medicine, Lodz, Poland. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Antioxidants) RN - EC 1.11.1.6 (Catalase) RN - 0 (Enzymes) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.15.1.1 (Superoxide Dismutase-1) RN - EC 1.11.1.9 (Glutathione Peroxidase GPX1) RN - EC 1.15.1.1 (Superoxide Dismutase 2) RN - 0 (SOD1 protein, human) RN - EC 1.11.1.- (GPX3 protein, human) RN - EC 1.11.1.9 (GPX1 protein, human) SB - IM MH - Aged MH - Analysis of Variance MH - Antioxidants/metabolism MH - Catalase/genetics/metabolism MH - Enzymes/blood/*genetics/metabolism MH - Female MH - Gene Expression Profiling/*methods MH - *Gene Expression Regulation, Enzymologic MH - *Gene Expression Regulation, Neoplastic MH - Glutathione Peroxidase/genetics/metabolism MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Outcome Assessment, Health Care MH - Reverse Transcriptase Polymerase Chain Reaction MH - Spectrophotometry MH - Superoxide Dismutase/genetics/metabolism MH - Superoxide Dismutase-1/genetics/metabolism MH - Time Factors MH - Urinary Bladder Neoplasms/enzymology/*genetics/surgery MH - Glutathione Peroxidase GPX1 MH - Superoxide Dismutase 2 OTO - NOTNLM OT - CAT OT - Urinary bladder OT - activity OT - antioxidant enzymes OT - bladder cancer recurrence OT - gene expression EDAT- 2017/02/10 06:00 MHDA- 2017/03/07 06:00 CRDT- 2017/02/10 06:00 PHST- 2016/11/02 00:00 [received] PHST- 2016/12/18 00:00 [revised] PHST- 2016/12/20 00:00 [accepted] PHST- 2017/02/10 06:00 [entrez] PHST- 2017/02/10 06:00 [pubmed] PHST- 2017/03/07 06:00 [medline] AID - 37/2/841 [pii] AID - 10.21873/anticanres.11387 [doi] PST - ppublish SO - Anticancer Res. 2017 Feb;37(2):841-848. doi: 10.21873/anticanres.11387. PMID- 28178653 OWN - NLM STAT- MEDLINE DCOM- 20170801 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 10 DP - 2017 Mar 7 TI - Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling. PG - 17059-17069 LID - 10.18632/oncotarget.15001 [doi] AB - Derlin-1 has been found to be overexpressed in several human cancers. However, its clinical significance and biological roles in bladder cancer remain unexplored. Here, we found that Derlin-1 was upregulated in 38.6% (58/150) cases of cancer samples. The rate of Derlin-1 overexpression was higher in muscle invasive bladder cancer (MIBC) than non-muscle invasive bladder cancer (NMIBC) (p=0.0079). Derlin-1 was a predicting factor for poor patient prognosis. Derlin-1 depletion inhibited while its overexpression facilitated cell invasion and colony formation. In addition, Derlin-1 overexpression induced cisplatin resistance while its depletion sensitized cancer cells to cisplatin. Further analysis demonstrated that Derlin-1 activated AKT phosphorylation and upregulated Bcl-2 expression. Blockage of AKT signaling by LY294005 abolished the effects of Derlin-1 on Bcl-2 and cisplatin resistance. Immunoprecipitation indicated Derlin-1 interacted with p110alpha subunit of PI3K. In addition, we showed that Derlin-1 depletion downregulated and its overexpression upregulated cell MMP-2/9 expression and ERK phosphorylation. Derlin-1 mediated upregulation of MMP-2/9 could be blocked by ERK inhibitor. In conclusion, our study demonstrated that Derlin-1 is overexpressed in bladder cancer and promotes malignant phenotype through ERK/MMP and PI3K/AKT/Bcl-2 signaling pathway. FAU - Dong, Qianze AU - Dong Q AD - Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China. FAU - Fu, Lin AU - Fu L AD - Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China. FAU - Zhao, Yue AU - Zhao Y AD - Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China. FAU - Tan, Shutao AU - Tan S AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Wang, Enhua AU - Wang E AD - Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Antineoplastic Agents) RN - 0 (DERL1 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - EC 2.7.1.137 (Class Ia Phosphatidylinositol 3-Kinase) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Antineoplastic Agents/pharmacology MH - Blotting, Western MH - Cell Line, Tumor MH - Cisplatin/pharmacology MH - Class Ia Phosphatidylinositol 3-Kinase/*metabolism MH - Drug Resistance, Neoplasm/drug effects/genetics MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - MAP Kinase Signaling System MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Matrix Metalloproteinases/*metabolism MH - Membrane Proteins/genetics/*metabolism MH - Middle Aged MH - Muscles/metabolism/pathology MH - Neoplasm Invasiveness MH - Phosphorylation MH - Prognosis MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Proto-Oncogene Proteins c-bcl-2/metabolism MH - RNA Interference MH - Signal Transduction MH - Urinary Bladder Neoplasms/drug therapy/genetics/*metabolism PMC - PMC5370022 OTO - NOTNLM OT - AKT OT - Derlin-1 OT - ERK OT - bladder cancer OT - prognosis COIS- CONFLICTS OF INTEREST No potential conflicts of interest were disclosed. EDAT- 2017/02/09 06:00 MHDA- 2017/08/02 06:00 PMCR- 2017/03/07 CRDT- 2017/02/09 06:00 PHST- 2016/10/06 00:00 [received] PHST- 2017/01/04 00:00 [accepted] PHST- 2017/02/09 06:00 [pubmed] PHST- 2017/08/02 06:00 [medline] PHST- 2017/02/09 06:00 [entrez] PHST- 2017/03/07 00:00 [pmc-release] AID - 15001 [pii] AID - 10.18632/oncotarget.15001 [doi] PST - ppublish SO - Oncotarget. 2017 Mar 7;8(10):17059-17069. doi: 10.18632/oncotarget.15001. PMID- 28168135 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240324 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 9 IP - 1 DP - 2017 Jan 5 TI - Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study. PG - e957 LID - 10.7759/cureus.957 [doi] LID - e957 AB - Non-muscle-invasive bladder cancer (NMIBC) is categorized into high-risk and low-risk groups. Although, bacillus Calmette-Guerin (BCG) is the recommended adjuvant therapy of high-risk bladder tumor, optimal schedule (induction versus maintenance) of this therapy is a subject of debate. The objective was to evaluate outcomes of induction BCG in high-risk NMIBC patients at Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan and retrospective cohort study conducted in the department of urology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan. Three-year disease-free survival and progression-free survival was the main outcome measure. Data of 68 high-risk (Ta and T1 with G3 or high-grade subtype) bladder cancer patients who underwent transurethral resection followed by six-weekly intravesical BCG instillation was included in the study. Recurrence was described as biopsy-proven bladder cancer; whereas the presence of muscle invasion was considered as progression. Disease-free survival and progression-free survival were defined as time intervals elapsed between the starting date of BCG instillation and recurrence or progression, respectively. Kaplan-Meier curve was employed to estimate the three-year study end-points. Disease-free survival at three years was observed to be 66.2% and progression-free survival at 86.8%. The use of induction BCG alone for high-risk patients of NMIBC is a viable option both in terms of effective disease-free and progression-free survival rates. FAU - Pirzada, Muhammad T AU - Pirzada MT AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Ghauri, Rashid AU - Ghauri R AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Ahmed, Monis J AU - Ahmed MJ AD - Department of Surgery, Mediclinic City Hospital, Dubai, UAE. FAU - Shah, Muhammad F AU - Shah MF AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Nasir, Irfan Ul Islam AU - Nasir IU AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Siddiqui, Jasim AU - Siddiqui J AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Ahmed, Irfan AU - Ahmed I AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. FAU - Mir, Khurram AU - Mir K AD - Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre. LA - eng PT - Journal Article DEP - 20170105 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC5291702 OTO - NOTNLM OT - bacillus calmette-guerin (bcg) OT - non-muscle-invasive bladder cancer (nmibc) OT - progressio OT - recurrence COIS- The authors have declared that no competing interests exist. EDAT- 2017/02/09 06:00 MHDA- 2017/02/09 06:01 PMCR- 2017/01/05 CRDT- 2017/02/08 06:00 PHST- 2017/02/08 06:00 [entrez] PHST- 2017/02/09 06:00 [pubmed] PHST- 2017/02/09 06:01 [medline] PHST- 2017/01/05 00:00 [pmc-release] AID - 10.7759/cureus.957 [doi] PST - epublish SO - Cureus. 2017 Jan 5;9(1):e957. doi: 10.7759/cureus.957. PMID- 28165132 OWN - NLM STAT- MEDLINE DCOM- 20170803 LR - 20171213 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 84 IP - 1 DP - 2017 Feb 3 TI - Nonmuscle-invasive bladder cancer: what's changing and what has changed. PG - 1-8 LID - 10.5301/uro.5000213 [doi] AB - PURPOSE: Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette-Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish 'what changes has already occurred and what is expected in the future' in NMIBC. METHODS: A Medline search was performed to identify the published literature with respect to diagnosis, treatment and future perspectives on NMIBC. Particular emphasis was directed to determinants such as the quality of TUR and the newer modifications, Re-TUR, current status of newer macroscopic and microscopic imaging, role of urinary biomarkers, clinical, histologic and molecular predictors of high-risk disease, administration of intravesical agents, salvage therapy in BCG recurrence and the current best practice guidelines were analyzed. RESULTS AND CONCLUSIONS: Optimal TUR, restaging in select group, incorporation of newer endoscopic imaging and judicious administration of intravesical chemo-immunotherapeutic agents can contribute to better patient care. Although there is a plethora of urinary markers, there is insufficient evidence for their use in isolation. The future probably lies in identification of genetic markers to determine disease recurrence, nonresponders to standard treatment and early institution of alternative/targeted therapy. FAU - Manikandan, Ramanitharan AU - Manikandan R AD - Jawaharlal Institute of Postgraduate Medical Institution and Research, Dhavantri Nagar, Gorimedu, Puducherry - India. FAU - Rodriguez, Oscar AU - Rodriguez O AD - Puigvert Foundation, Universitat Autonoma de Barcelona, Barcelona - Spain. FAU - Parada, Ruben AU - Parada R AD - Puigvert Foundation, Universitat Autonoma de Barcelona, Barcelona - Spain. FAU - Palou Redorta, Joan AU - Palou Redorta J AD - Puigvert Foundation, Universitat Autonoma de Barcelona, Barcelona - Spain. LA - eng PT - Journal Article PT - Review DEP - 20170202 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - Humans MH - Urinary Bladder Neoplasms/*diagnosis/*therapy EDAT- 2017/02/07 06:00 MHDA- 2017/08/05 06:00 CRDT- 2017/02/07 06:00 PHST- 2016/12/09 00:00 [accepted] PHST- 2017/02/07 06:00 [entrez] PHST- 2017/02/07 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] AID - F6C6BE1A-6564-4B07-B3ED-EED740805CEB [pii] AID - 10.5301/uro.5000213 [doi] PST - ppublish SO - Urologia. 2017 Feb 3;84(1):1-8. doi: 10.5301/uro.5000213. Epub 2017 Feb 2. PMID- 28157703 OWN - NLM STAT- MEDLINE DCOM- 20170926 LR - 20191210 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 13 DP - 2017 Mar 28 TI - Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method. PG - 20719-20728 LID - 10.18632/oncotarget.14988 [doi] AB - Bladder cancer (BC) is the second most prevalent malignancy in the urinary system and is associated with significant mortality; thus, there is an urgent need for novel noninvasive diagnostic biomarkers. A urinary pseudotargeted method based on gas chromatography-mass spectrometry was developed and validated for a BC metabolomics study. The method exhibited good repeatability, intraday and interday precision, linearity and metabolome coverage. A total of 76 differential metabolites were defined in the discovery sample set, 58 of which were verified using an independent validation urine set. The verified differential metabolites revealed that energy metabolism, anabolic metabolism and cell redox states were disordered in BC. Based on a binary logistic regression analysis, a four-biomarker panel was defined for the diagnosis of BC. The area under the receiving operator characteristic curve was 0.885 with 88.0% sensitivity and 85.7% specificity in the discovery set and 0.804 with 78.0% sensitivity and 70.3% specificity in the validation set. The combinatorial biomarker panel was also useful for the early diagnosis of BC. This approach can be used to discriminate non-muscle invasive and low-grade BCs from healthy controls with satisfactory sensitivity and specificity. The results show that the developed urinary metabolomics method can be employed to effectively screen noninvasive biomarkers. FAU - Zhou, Yang AU - Zhou Y AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. AD - University of Chinese Academy of Sciences, Beijing 100049, China. FAU - Song, Ruixiang AU - Song R AD - Department of Urology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai 200433, China. FAU - Ma, Chong AU - Ma C AD - Department of Urology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai 200433, China. FAU - Zhou, Lina AU - Zhou L AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. FAU - Liu, Xinyu AU - Liu X AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. AD - University of Chinese Academy of Sciences, Beijing 100049, China. FAU - Yin, Peiyuan AU - Yin P AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai 200433, China. FAU - Sun, Yinghao AU - Sun Y AD - Department of Urology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai 200433, China. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai 200433, China. FAU - Lu, Xin AU - Lu X AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. FAU - Xu, Guowang AU - Xu G AD - Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. LA - eng PT - Journal Article PT - Validation Study PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor/*urine MH - Carcinoma, Transitional Cell/*diagnosis/urine MH - Female MH - Gas Chromatography-Mass Spectrometry/methods MH - Humans MH - Male MH - Metabolomics/*methods MH - Middle Aged MH - ROC Curve MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnosis/urine PMC - PMC5400539 OTO - NOTNLM OT - biomarker OT - bladder cancer OT - gas chromatography-mass spectrometry OT - metabolomics OT - urine COIS- CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest. EDAT- 2017/02/06 06:00 MHDA- 2017/09/28 06:00 PMCR- 2017/03/28 CRDT- 2017/02/04 06:00 PHST- 2016/11/15 00:00 [received] PHST- 2017/01/24 00:00 [accepted] PHST- 2017/02/06 06:00 [pubmed] PHST- 2017/09/28 06:00 [medline] PHST- 2017/02/04 06:00 [entrez] PHST- 2017/03/28 00:00 [pmc-release] AID - 14988 [pii] AID - 10.18632/oncotarget.14988 [doi] PST - ppublish SO - Oncotarget. 2017 Mar 28;8(13):20719-20728. doi: 10.18632/oncotarget.14988. PMID- 28149933 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 3 IP - 1 DP - 2017 Jan 27 TI - Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. PG - 35-44 LID - 10.3233/BLC-160062 [doi] AB - Introduction: Level I evidence supports the use of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer prior to radical cystectomy (RC). On average, 30-40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC. Some centers risk-stratify patients, suggesting that there may be a higher-risk population that would derive the most benefit from NAC. Recently, a risk-stratification model developed at M.D. Anderson Cancer Center (MDACC) specified criteria for clinical staging and patient selection for NAC. We applied this model to our own RC patient cohort and evaluated our own experience with clinical risk stratification and the effect of NAC on post treatment risk categories. Methods: We retrospectively reviewed the charts of consecutive patients who underwent RC at two institutions between 2004 and 2014 and noted whether or not they received NAC. We determined the clinical stage by reviewing the exam under anesthesia, transurethral resection biopsy (TURBT) pathology, and preoperative imaging. Patients with cT2-T4a node-negative disease were included. Those with sarcomatoid features or adenocarcinoma were excluded. Patients were classified as high risk if they had tumor-associated hydronephrosis, clinical stage>/=T3b-T4a disease, variant histology (i.e., micropapillary or small cell), or lymphovascular invasion (LVI), as specified by the MDACC model. Variables were examined for associations with cancer-specific survival (CSS), overall survival (OS), and risk-category reclassification. Results: We identified 166 patients with a median follow-up time of 22.2 months. In all, 117 patients (70.5%) did not receive NAC, 68 (58.1%) of whom we classified as high risk. Among patients not receiving NAC, CSS and OS were significantly decreased in high-risk patients (log-rank test p = 0.01 for both comparisons). The estimated age-adjusted hazard ratios of high-risk classification for cancer-specific and overall death were 3.2 (95% CI: 1.2 to 8.6) and 2.2 (95% CI: 1.1 to 4.4), respectively. On post-RC final pathology, 23 (46.9%) low-risk patients were up-classified to high risk and 17 (25.0%) high-risk patients were down-classified. Complete pathologic responses (pT0) were achieved in 7 (6.0%) patients and partial responses (pT1, pTa, pTis) were achieved in 28 (23.9%) patients. Of the 49 patients who did receive NAC, 43 (87.8%) received cisplatin-based and six (12.2%) received carboplatin-based regimens. Applying the MDACC model, we categorized 41 (83.7%) patients as high risk prior to NAC treatment. On final pathology, 3 (37.5%) low-risk patients were up-classified and 17 (41.5%) high-risk patients were down-classified. Complete pathologic responses (pT0) were seen in 13 (26.5%) patients and partial responses were seen in 10 (20.4%) patients. Although the utilization of NAC was not statistically significantly associated with CSS or OS (log-rank test p > 0.05 for both comparisons), it was associated with a 1.2 times increased odds (95% CI: 0.4 to 2.1) of post-RC reclassification from high to low risk on age-adjusted logistic regression. Conclusions: We found similar results using the clinical risk-stratification model in our cohort and showed that the high-risk category was associated with lower CSS and OS. NAC was associated with a higher probability of risk reclassification from high to low risk. FAU - von Rundstedt, Friedrich-Carl AU - von Rundstedt FC AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Department of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany. FAU - Mata, Douglas A AU - Mata DA AD - Department of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, MA, USA. FAU - Kryvenko, Oleksandr N AU - Kryvenko ON AD - Departments of Pathology and Urology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , FL, USA. FAU - Shah, Anup A AU - Shah AA AD - Department of Urology, University of Pittsburgh Medical Center , PA, USA. FAU - Jhun, Iny AU - Jhun I AD - Department of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, MA, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine , Houston, TX, USA. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20170127 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC5271426 OTO - NOTNLM OT - bladder cancer OT - clinical staging OT - neoadjuvant chemotherapy OT - risk stratification EDAT- 2017/02/06 06:00 MHDA- 2017/02/06 06:01 CRDT- 2017/02/03 06:00 PHST- 2017/02/03 06:00 [entrez] PHST- 2017/02/06 06:00 [pubmed] PHST- 2017/02/06 06:01 [medline] AID - BLC160062 [pii] AID - 10.3233/BLC-160062 [doi] PST - epublish SO - Bladder Cancer. 2017 Jan 27;3(1):35-44. doi: 10.3233/BLC-160062. PMID- 28135623 OWN - NLM STAT- MEDLINE DCOM- 20170314 LR - 20170314 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 54 DP - 2017 Mar TI - Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. PG - 1-9 LID - S0305-7372(17)30002-6 [pii] LID - 10.1016/j.ctrv.2017.01.002 [doi] AB - Cystectomy is the gold standard for treatment of localized muscle-invasive bladder cancer. However, about 50% of patients develop metastases within 2years after cystectomy and subsequently die for the disease. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival in patients with muscle-invasive bladder cancer, and pathological response to neoadjuvant treatment (downstaging to ⩽pT1 at cystectomy) is a strong predictor of better disease-specific survival. Nevertheless, some patients do not benefit from neoadjuvant therapy. The identification of reliable biomarkers that could enable the clinicians to identify patients who will really benefit from neoadjuvant chemotherapy is a major issue. This approach could lead to individualized therapy, in order to optimize the chance of response, avoiding the impact of neoadjuvant treatment on quality of life and the delay of cystectomy in non-responder patients. However, no molecular predictive biomarkers have shown clinical utility. This paper aims to review currently available data about biomarkers predictive of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. CI - Copyright (c) 2017 Elsevier Ltd. All rights reserved. FAU - Buttigliero, Consuelo AU - Buttigliero C AD - Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy. FAU - Tucci, Marcello AU - Tucci M AD - Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy. FAU - Vignani, Francesca AU - Vignani F AD - Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy. FAU - Scagliotti, Giorgio V AU - Scagliotti GV AD - Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy. Electronic address: giorgio.scagliotti@unito.it. FAU - Di Maio, Massimo AU - Di Maio M AD - Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy. LA - eng PT - Journal Article PT - Review DEP - 20170111 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Apoptosis/drug effects/physiology MH - Biomarkers, Tumor/genetics/*metabolism MH - Cell Survival/drug effects/physiology MH - Cisplatin/administration & dosage MH - DNA Repair/drug effects/physiology MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Molecular Targeted Therapy/methods MH - Neoadjuvant Therapy MH - Receptor Protein-Tyrosine Kinases/metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Neoadjuvant chemotherapy OT - Resistance OT - Sensitivity OT - Urothelial carcinoma EDAT- 2017/01/31 06:00 MHDA- 2017/03/16 06:00 CRDT- 2017/01/31 06:00 PHST- 2016/11/07 00:00 [received] PHST- 2017/01/03 00:00 [revised] PHST- 2017/01/04 00:00 [accepted] PHST- 2017/01/31 06:00 [pubmed] PHST- 2017/03/16 06:00 [medline] PHST- 2017/01/31 06:00 [entrez] AID - S0305-7372(17)30002-6 [pii] AID - 10.1016/j.ctrv.2017.01.002 [doi] PST - ppublish SO - Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11. PMID- 28127187 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240521 IS - 0975-7651 (Print) IS - 0976-6952 (Electronic) IS - 0975-7651 (Linking) VI - 8 IP - 1 DP - 2017 Mar TI - Current Concepts in the Management of Muscle Invasive Bladder Cancer. PG - 74-81 LID - 10.1007/s13193-016-0586-1 [doi] AB - Bladder cancer is the ninth most common cancer in the world. Twenty to twenty-five percent of all newly diagnosed bladder cancers are muscle invasive in nature, and further, 20-25% of patients who are diagnosed with high-risk non-muscle invasive disease will eventually progress to muscle invasive disease in due course of time irrespective of adjuvant intravesical therapies. Availability of newer imaging modalities improves appropriate identification of patients with muscle invasive disease. Radical cystectomy remains the mainstay of treatment for management of muscle invasive disease. Availability of neoadjuvant chemotherapy has improved overall survival. Risk stratification systems are now in consideration to identify patients who benefit maximally from neoadjuvant chemotherapy. Urinary diversion is a major cause of morbidity in these patients, and several strategies are being employed to reduce morbidity. In this article, we review available literature on various aspects of management of muscle invasive disease. FAU - Krishna, Suprita R AU - Krishna SR AD - Department of Urology, University of Minnesota, Minneapolis, MN 55455 USA. FAU - Konety, Badrinath R AU - Konety BR AD - Department of Urology, University of Minnesota, Minneapolis, MN 55455 USA. LA - eng PT - Journal Article PT - Review DEP - 20161215 PL - India TA - Indian J Surg Oncol JT - Indian journal of surgical oncology JID - 101532448 PMC - PMC5236024 OTO - NOTNLM OT - Bladder cancer OT - Blue light cystoscopy OT - Cystectomy OT - Muscle invasive bladder cancer OT - Neoadjuvant chemotherapy for bladder cancer OT - PET CT EDAT- 2017/01/28 06:00 MHDA- 2017/01/28 06:01 PMCR- 2018/03/01 CRDT- 2017/01/28 06:00 PHST- 2016/10/17 00:00 [received] PHST- 2016/10/24 00:00 [accepted] PHST- 2017/01/28 06:00 [entrez] PHST- 2017/01/28 06:00 [pubmed] PHST- 2017/01/28 06:01 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - 586 [pii] AID - 10.1007/s13193-016-0586-1 [doi] PST - ppublish SO - Indian J Surg Oncol. 2017 Mar;8(1):74-81. doi: 10.1007/s13193-016-0586-1. Epub 2016 Dec 15. PMID- 28124528 OWN - NLM STAT- MEDLINE DCOM- 20170731 LR - 20191210 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 43 IP - 1 DP - 2017 Jan-Feb TI - Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non muscle invasive bladder cancer? PG - 67-72 LID - 10.1590/S1677-5538.IBJU.2016.0158 [doi] AB - OBJECTIVE: Recent studies have demonstrated the role of systemic inflammation in the development and progression of cancer. In this study, we evaluated whether preoperatively measured neutrophil-to-lymphocyte ratio (NLR) can predict lamina propria invasion in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIAL AND METHODS: We reviewed the medical records of 304 consecutive and newly diagnosed patients with bladder cancer who had been treated with transurethral resection between January 2008 and June 2014. In total, 271 patients were included in the study and the patients were divided into two groups according to the pathological stage (Group 1: Ta, Group 2: T1). NLR was calculated by dividing the absolute neutrophil count (N) by the absolute lymphocyte count (L). RESULTS: In total, 271 patients (27 women and 244 men) were enrolled. Mean age was higher in Group 2 than in Group 1 (67.3+/-10.8 vs. 62.9+/-10.8, p<0.001). Furthermore, the presence of high grade tumors and tumors >/=3cm in size was statistically higher in Group 2 than in Group 1 (70.9% vs. 9.9%, p=0.0001; 71.8% vs. 36%, p=0.0001, respectively). While the mean white blood cell (WBC) and N counts were statistically insignificant (7.63+/-1.87 vs. 7.69+/-1.93, p=0.780; 4.72+/-1.54 vs. 4.46+/-1.38, p=0.140; respectively), L was significantly lower and NLR was significantly higher in Group 2 than in Group 1 (2.07+/-0.75 vs. 2.4+/-0.87, p=0.001; 2.62+/-1.5 vs. 2.19+/-1.62, p=0.029; respectively). CONCLUSION: Our data indicate that high NLR and low L are statistically associated with T1 stage, whereas low L are able to predict lamina propria invasion in patients with NMIBC. These findings suggest that pretreatment measurement of NLR may provide valuable information for the clinical management of patients with NMIBC. Prospective studies are now required to further validate the role of NLR as a risk factor in NMIBC. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Cimen, Haci Ibrahim AU - Cimen HI AD - Department of Urology, Sakarya Training and Research Hospital, Sakarya University, Sakarya, Turkey. FAU - Halis, Fikret AU - Halis F AD - Department of Urology, Sakarya Training and Research Hospital, Sakarya University, Sakarya, Turkey. FAU - Saglam, Hasan Salih AU - Saglam HS AD - Department of Urology, Sakarya Training and Research Hospital, Sakarya University, Sakarya, Turkey. FAU - Gokce, Ahmet AU - Gokce A AD - Department of Urology, Sakarya Training and Research Hospital, Sakarya University, Sakarya, Turkey. LA - eng PT - Evaluation Study PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/blood MH - Disease Progression MH - Female MH - Humans MH - Logistic Models MH - Lymphocyte Count MH - *Lymphocytes MH - Male MH - Medical Records MH - Middle Aged MH - Mucous Membrane/*pathology MH - Neoplasm Grading MH - *Neutrophils MH - Reference Values MH - Reproducibility of Results MH - Retrospective Studies MH - Risk Factors MH - Sensitivity and Specificity MH - Tumor Burden MH - Urinary Bladder Neoplasms/*blood/*pathology PMC - PMC5293385 OTO - NOTNLM OT - Inflammation OT - Neoplasms OT - Urinary Bladder COIS- CONFLICT OF INTEREST None declared. EDAT- 2017/01/27 06:00 MHDA- 2017/08/02 06:00 PMCR- 2017/01/01 CRDT- 2017/01/27 06:00 PHST- 2016/02/03 00:00 [received] PHST- 2016/06/17 00:00 [accepted] PHST- 2017/01/27 06:00 [entrez] PHST- 2017/01/27 06:00 [pubmed] PHST- 2017/08/02 06:00 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - IBJUv43n1a7 [pii] AID - S1677-5538.IBJU.2016.0158 [pii] AID - 10.1590/S1677-5538.IBJU.2016.0158 [doi] PST - ppublish SO - Int Braz J Urol. 2017 Jan-Feb;43(1):67-72. doi: 10.1590/S1677-5538.IBJU.2016.0158. PMID- 28123555 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 13 IP - 1 DP - 2017 Jan TI - Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2. PG - 275-280 LID - 10.3892/ol.2016.5416 [doi] AB - Heme oxygenase 1 (HO-1) is a stress-response protein and its expression is associated with malignant potential and poor prognosis in several types of cancer. The present study investigated the association between HO-1 expression levels and the pathological features, clinical outcomes and other associated factors in patients with non-muscle-invasive bladder cancer (NMIBC). HO-1 expression was evaluated using immunohistochemistry in 147 formalin-fixed tissue specimens. The proliferation index, microvessel density, lymph vessel density and expression of cyclooxygenase (COX)-2 and vascular endothelial growth factor (VEGF)-A, -C, and -D were also investigated. Correlations among variables were analyzed by multivariate analysis. Survival was assessed using Kaplan-Meier survival curves and multivariate statistics. HO-1 expression levels in high-grade and pT1 tumors were significantly higher compared with low-grade and pTa tumors, and were correlated with the proliferation index (P<0.001), lymph vessel density (P=0.021) and COX-2 expression levels (P=0.003). The proliferation index and COX-2 expression levels were also identified as independent contributing factors in multivariate models. Kaplan-Meier survival curves associated HO-1 expression with a poor prognosis in metastasis-free (P=0.047) and cause-specific survival (P=0.017), but not with urinary tract recurrence (P=0.231). Furthermore, HO-1 expression was identified by multivariate analysis to be a significant predictor for cause-specific survival (hazard ratio, 4.08; 95% confidence interval, 1.06-15.66; P=0.004). HO-1 has an important role in the malignant aggressiveness of NMIBC and its expression is associated with cause-specific survival. HO-1-associated activities are regulated by cancer cell proliferation, lymphangiogenesis and COX-2. The results suggest that HO-1 may be a potential therapeutic target and a useful predictive prognostic factor in patients with NMIBC. FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. FAU - Miyata, Yasuyoshi AU - Miyata Y AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. FAU - Mitsunari, Kensuke AU - Mitsunari K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. FAU - Yasuda, Takuji AU - Yasuda T AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. FAU - Ohba, Kojiro AU - Ohba K AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. FAU - Sakai, Hideki AU - Sakai H AD - Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan. LA - eng PT - Journal Article DEP - 20161122 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC5245111 OTO - NOTNLM OT - angiogenesis OT - cell proliferation OT - cyclooxygenase-2 OT - heme oxygenase 1 OT - lymphangiogenesis OT - non-muscle-invasive bladder cancer OT - vascular endothelial growth factor EDAT- 2017/01/27 06:00 MHDA- 2017/01/27 06:01 PMCR- 2016/11/22 CRDT- 2017/01/27 06:00 PHST- 2015/07/27 00:00 [received] PHST- 2016/10/03 00:00 [accepted] PHST- 2017/01/27 06:00 [entrez] PHST- 2017/01/27 06:00 [pubmed] PHST- 2017/01/27 06:01 [medline] PHST- 2016/11/22 00:00 [pmc-release] AID - OL-0-0-5416 [pii] AID - 10.3892/ol.2016.5416 [doi] PST - ppublish SO - Oncol Lett. 2017 Jan;13(1):275-280. doi: 10.3892/ol.2016.5416. Epub 2016 Nov 22. PMID- 28122346 OWN - NLM STAT- MEDLINE DCOM- 20171004 LR - 20220321 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 9 DP - 2017 Feb 28 TI - SETD6 regulates NF-kappaB signaling in urothelial cell survival: Implications for bladder cancer. PG - 15114-15125 LID - 10.18632/oncotarget.14750 [doi] AB - Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-kappaB del/del genotype have an increased risk of recurrence suggesting an important role of NF-kappaB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells. We found and validated high expression of the SET-domain-containing protein methyltransferase, SETD6. SETD6 monomethylates NF-kappaB-p65 at lysine 310. Our results show that primary urothelial cells and normal bladder tissue have nearly undetectable message and protein level of SETD6 that increases in transformed urothelial cells and is further increased in bladder cancer cells and tissues. Overexpression of SETD6 in transformed urothelial cells increased cell survival and colony formation while knockdown in cancer cells decreased both parameters. Luciferase reporter assays showed that SETD6 induced the canonical NF-kappaB signaling pathway. Further, the use of catalytic SETD6 and IkappaBalpha mutant shows that SETD6 positively regulates survival by affecting p65 message, protein level and its function as determined by increased expression of NF-kappaB target genes. Our findings suggest that SETD6 plays an important role in NF-kappaB regulation and may have an important role in NF-kappaB-mediated local inflammatory response following BCG treatment. FAU - Mukherjee, Neelam AU - Mukherjee N AD - Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. FAU - Cardenas, Eduardo AU - Cardenas E AD - Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. FAU - Bedolla, Roble AU - Bedolla R AD - Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. FAU - Ghosh, Rita AU - Ghosh R AD - Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. AD - Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. AD - Department of Molecular Medicine and School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. AD - Department of Cancer Therapy and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. LA - eng GR - R01 CA149516/CA/NCI NIH HHS/United States GR - R03 CA136058/CA/NCI NIH HHS/United States GR - T32 CA148724/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (NF-kappa B) RN - EC 2.1.1.- (Protein Methyltransferases) RN - EC 2.1.1.- (SETD6 protein, human) SB - IM MH - Apoptosis MH - Biomarkers, Tumor/genetics/*metabolism MH - Cell Proliferation MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - NF-kappa B/genetics/*metabolism MH - Protein Methyltransferases/genetics/*metabolism MH - Signal Transduction MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/genetics/metabolism/*pathology PMC - PMC5362471 OTO - NOTNLM OT - NF-kappaB OT - SETD6 OT - bladder cancer OT - methyltransferase OT - signaling COIS- CONFLICTS OF INTEREST None declared. EDAT- 2017/01/26 06:00 MHDA- 2017/10/05 06:00 PMCR- 2017/02/28 CRDT- 2017/01/26 06:00 PHST- 2016/09/01 00:00 [received] PHST- 2017/01/10 00:00 [accepted] PHST- 2017/01/26 06:00 [pubmed] PHST- 2017/10/05 06:00 [medline] PHST- 2017/01/26 06:00 [entrez] PHST- 2017/02/28 00:00 [pmc-release] AID - 14750 [pii] AID - 10.18632/oncotarget.14750 [doi] PST - ppublish SO - Oncotarget. 2017 Feb 28;8(9):15114-15125. doi: 10.18632/oncotarget.14750. PMID- 28095848 OWN - NLM STAT- MEDLINE DCOM- 20170301 LR - 20220408 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 17 IP - 1 DP - 2017 Jan 17 TI - Laparoscopic versus open nephroureterectomy to treat localized and/or locally advanced upper tract urothelial carcinoma: oncological outcomes from a multicenter study. PG - 8 LID - 10.1186/s12893-016-0202-x [doi] LID - 8 AB - BACKGROUND: Many studies have reported the oncological outcomes between open radical nephroureterectomy (ONU) and laparoscopic radical nephroureterectomy (LNU) of upper tract urothelial carcinoma (UTUC). However, few data have focused on the oncological outcomes of LNU in the subgroup of localized and/or locally advanced UTUC (T(1-4)/N(0-X)). The purpose of this study was to compare the oncological outcomes of LNU vs. ONU for the treatment in patients with T(1-4)/N(0-X) UTUC. METHODS: We collected and analyzed the data and clinical outcomes retrospectively for 265 patients who underwent radical nephroureterectomy for T(1-4)/N(0-X) UTUC between April 2000 and April 2013 at two Chinese tertiary hospitals. Survival was estimated using the Kaplan-Meier method. Cox's proportional hazards model was used for univariate and multivariate analysis. RESULTS: The mean patient age was 62.0 years and the median follow-up was 60.0 months. Of the 265 patients, 213 (80.4%) underwent conventional ONU, and 52 (19.6%) patients underwent LNU. The groups differed significantly in their presence of previous hydronephrosis, presence of previous bladder urothelial carcinoma, and management of distal ureter (P < 0.05). The predicted 5-year intravesical recurrence- free survival (RFS) (79% vs. 88%, P = 0.204), overall RFS (47% vs. 59%, P = 0.076), cancer-specific survival (CSS) (63% vs. 70%, P = 0.186), and overall survival (OS) (61% vs. 55%, P = 0.908) rates did not differ between the ONU and LNU groups. Multivariable Cox proportional regression analysis showed that surgical approach was not significantly associated with intravesical RFS (odds ratio [OR] 1.23, 95% confidence interval [CI] 0.46-3.65, P = 0.622), Overall RFS (OR 0.99, 95% CI 0.54-1.83, P = 0.974), CSS (OR 1.38, 95% CI 0.616-3.13, P = 0.444), or OS (OR 1.61, 95% CI 0.81-3.17, P = 0.17). CONCLUSIONS: The results of this retrospective study showed no statistically significant differences in intravesical RFS, overall RFS, CSS, or OS between the laparoscopy and the open groups. Thus, LNU can be an alternative to the open procedure for T(1-4)/N(0-X) UTUC. Further studies, including a multi-institutional, prospective study are required to confirm these findings. FAU - Liu, Jian-Ye AU - Liu JY AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Dai, Ying-Bo AU - Dai YB AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Zhou, Fang-Jian AU - Zhou FJ AD - Department of Urology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. AD - State Key Laboratory of Oncology in South China, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. FAU - Long, Zhi AU - Long Z AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Li, Yong-Hong AU - Li YH AD - Department of Urology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. AD - State Key Laboratory of Oncology in South China, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. FAU - Xie, Dan AU - Xie D AD - Department of Pathology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. AD - State Key Laboratory of Oncology in South China, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, China. FAU - Liu, Bin AU - Liu B AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Tang, Jin AU - Tang J AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Tan, Jing AU - Tan J AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - Yao, Kun AU - Yao K AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. FAU - He, Le-Ye AU - He LY AD - Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. heleye_csu@163.com. AD - Institute of Prostate Disease of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. heleye_csu@163.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20170117 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Female MH - Humans MH - *Laparoscopy/methods MH - Male MH - Middle Aged MH - Multivariate Analysis MH - *Nephrectomy MH - Odds Ratio MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/pathology/*surgery PMC - PMC5240226 OTO - NOTNLM OT - Laparoscopic radical nephroureterectomy OT - Oncological OT - Open radical nephroureterectomy OT - Outcomes OT - Recurrent OT - Survival OT - Upper tract urothelial carcinoma EDAT- 2017/01/18 06:00 MHDA- 2017/03/03 06:00 PMCR- 2017/01/17 CRDT- 2017/01/19 06:00 PHST- 2016/09/02 00:00 [received] PHST- 2016/12/30 00:00 [accepted] PHST- 2017/01/19 06:00 [entrez] PHST- 2017/01/18 06:00 [pubmed] PHST- 2017/03/03 06:00 [medline] PHST- 2017/01/17 00:00 [pmc-release] AID - 10.1186/s12893-016-0202-x [pii] AID - 202 [pii] AID - 10.1186/s12893-016-0202-x [doi] PST - epublish SO - BMC Surg. 2017 Jan 17;17(1):8. doi: 10.1186/s12893-016-0202-x. PMID- 28087474 OWN - NLM STAT- MEDLINE DCOM- 20170424 LR - 20220311 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 62 DP - 2017 Apr TI - FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. PG - 222-231 LID - S0046-8177(17)30011-4 [pii] LID - 10.1016/j.humpath.2016.12.022 [doi] AB - Nuclear FOXOs mediate cell cycle arrest and promote apoptosis. FOXOs and p53 could have similar effects as tumor suppressor genes. In spite of extensive literature, little is known about the role of FOXO1 and its relationship with p53 status in bladder cancer. Expression of FOXO1 and p53 were analyzed by immunohistochemistry in 162 urothelial carcinomas (UC). Decreased FOXO1 expression, p53 overexpression and the combination FOXO1 down-regulation/p53 overexpression were strongly associated with high grade (P=.030; P=.017; P=.004, respectively), high stage (P=.0001; P<.0001; P<.0001, respectively) or both (P=.0004; P<.0001; P<.0001, respectively). In the overall series of cases, p53 overexpression was associated with tumor progression (hazard ratio [HR]=3.18, 95% confidence interval [CI] 1.19-8.48, P=.02), but this association was even stronger if having any alteration in any of the 2 genes was considered (HR=3.51, 95% CI 1.34-9.21, P=.01). Having both FOXO1 down-regulation and p53 overexpression was associated with disease recurrence (HR=2.75, 95% CI 1.06-7.13, P=.03). In the analysis of the different subgroups, having any alteration in any of the 2 genes was associated with progression in low-grade (P=.005) and pTa (P=.006) tumors. Finally, the combined FOXO1 down-regulation/p53 overexpression was associated with disease recurrence specifically in high-grade (P=.04) and in pT1 stage tumors (P=.007). Adding FOXO1 expression to the immunohistochemical analysis of p53 can provide relevant prognostic information on progression and recurrence of bladder cancer. It may be particularly informative on the risk of progression in the more indolent and on the risk of recurrence in the more aggressive tumors. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Lloreta, Josep AU - Lloreta J AD - Department of Pathology, Hospital del Mar, Barcelona 08003, Spain; Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona 08003, Spain. FAU - Font-Tello, Alba AU - Font-Tello A AD - Dana Farber Cancer Institute, Boston, MA 02215, USA. FAU - Juanpere, Nuria AU - Juanpere N AD - Department of Pathology, Hospital del Mar, Barcelona 08003, Spain; Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona 08003, Spain. FAU - Frances, Albert AU - Frances A AD - Department of Urology, Hospital del Mar, Barcelona 08003, Spain. FAU - Lorenzo, Marta AU - Lorenzo M AD - Department of Pathology, Hospital del Mar, Barcelona 08003, Spain. FAU - Nonell, Lara AU - Nonell L AD - Microarray Analysis Service, Hospital del Mar-IMIM Medical Research Institute, Barcelona 08003, Spain. FAU - de Muga, Silvia AU - de Muga S AD - Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona 08003, Spain. FAU - Vazquez, Ivonne AU - Vazquez I AD - Department of Pathology, Hospital del Mar, Barcelona 08003, Spain. FAU - Cecchini, Lluis AU - Cecchini L AD - Department of Urology, Hospital del Mar, Barcelona 08003, Spain. FAU - Hernandez-Llodra, Silvia AU - Hernandez-Llodra S AD - Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona 08003, Spain. Electronic address: silvia.hernandez@upf.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170111 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Biomarkers, Tumor) RN - 0 (FOXO1 protein, human) RN - 0 (Forkhead Box Protein O1) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Biopsy MH - Carcinoma/*chemistry/pathology/therapy MH - Down-Regulation MH - Female MH - Forkhead Box Protein O1/*analysis MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Risk Factors MH - Tissue Array Analysis MH - Treatment Outcome MH - Tumor Suppressor Protein p53/*analysis MH - Up-Regulation MH - Urinary Bladder Neoplasms/*chemistry/pathology/therapy MH - Young Adult OTO - NOTNLM OT - Bladder Cancer OT - FOXO1 OT - Progression OT - Recurrence OT - p53 EDAT- 2017/01/15 06:00 MHDA- 2017/04/25 06:00 CRDT- 2017/01/15 06:00 PHST- 2016/08/11 00:00 [received] PHST- 2016/12/12 00:00 [revised] PHST- 2016/12/19 00:00 [accepted] PHST- 2017/01/15 06:00 [pubmed] PHST- 2017/04/25 06:00 [medline] PHST- 2017/01/15 06:00 [entrez] AID - S0046-8177(17)30011-4 [pii] AID - 10.1016/j.humpath.2016.12.022 [doi] PST - ppublish SO - Hum Pathol. 2017 Apr;62:222-231. doi: 10.1016/j.humpath.2016.12.022. Epub 2017 Jan 11. PMID- 28084860 OWN - NLM STAT- MEDLINE DCOM- 20170718 LR - 20260127 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 51 IP - 1 DP - 2017 Feb TI - Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway. PG - 38-43 LID - 10.1080/21681805.2016.1271354 [doi] AB - OBJECTIVE: Reports from cancer registries often lack clinically relevant information, which would be useful in estimating the prognosis of individual patients with urothelial carcinoma of the urinary bladder (UCB). This article presents estimates of crude probabilities of death due to UCB and the expected loss of lifetime stratified for patient characteristics. MATERIALS AND METHODS: In Norway, 10,332 patients were diagnosed with UCB between 2001 and 2010. The crude probabilities of death due to UCB were estimated, stratified by gender, age and T stage, using flexible parametric survival models. Based on these models, the loss in expectation of lifetime due to UCB was also estimated for the different strata. RESULTS: There is large variation in the estimated crude probabilities of death due to UCB (from 0.03 to 0.76 within 10 years since diagnosis) depending on age, gender and T stage. Furthermore, the expected loss of life expectancy is more than a decade for younger patients with muscle-invasive UCB and between a few months and 5 years for nonmuscle-invasive UCB. CONCLUSIONS: The suggested framework leads to clinically relevant prognostic risk estimates for individual patients diagnosed with UCB and the consequence in terms of loss of lifetime expectation. The published probability tables can be used in clinical praxis for risk communication. FAU - Andreassen, Bettina K AU - Andreassen BK AD - a Department of Research, Cancer Registry of Norway , Institute for Population-Based Research , Oslo , Norway. FAU - Myklebust, Tor A AU - Myklebust TA AD - b Department of Registration, Cancer Registry of Norway , Institute for Population-Based Research , Oslo , Norway. FAU - Haug, Erik S AU - Haug ES AD - c Vestfold Hospital Trust , Tonsberg , Norway. AD - d Institute of Cancer Genetics and Informatics (ICI) , Oslo University Hospital , Oslo , Norway. LA - eng PT - Journal Article DEP - 20170113 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/pathology MH - Cause of Death MH - Female MH - Humans MH - *Life Expectancy MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Norway/epidemiology MH - Prognosis MH - *Registries MH - Sex Factors MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*mortality/pathology OTO - NOTNLM OT - Bladder cancer OT - crude survival OT - epidemiology OT - loss of lifetime expectancy OT - survival OT - urothelial carcinoma of the urinary bladder EDAT- 2017/01/14 06:00 MHDA- 2017/07/19 06:00 CRDT- 2017/01/14 06:00 PHST- 2017/01/14 06:00 [pubmed] PHST- 2017/07/19 06:00 [medline] PHST- 2017/01/14 06:00 [entrez] AID - 10.1080/21681805.2016.1271354 [doi] PST - ppublish SO - Scand J Urol. 2017 Feb;51(1):38-43. doi: 10.1080/21681805.2016.1271354. Epub 2017 Jan 13. PMID- 28082741 OWN - NLM STAT- MEDLINE DCOM- 20180112 LR - 20181113 IS - 2092-6413 (Electronic) IS - 1226-3613 (Print) IS - 1226-3613 (Linking) VI - 49 IP - 1 DP - 2017 Jan 13 TI - Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer. PG - e282 LID - 10.1038/emm.2016.120 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) patients frequently fail to respond to treatment and experience disease progression because of their clinical and biological diversity. In this study, we identify a prognostic molecular signature for predicting the heterogeneity of NMIBC by using an integrative analysis of copy number and gene expression data. We analyzed the copy number and gene expression profiles of 404 patients with bladder cancer obtained from The Cancer Genome Atlas (TCGA) consortium. Of the 14 molecules with significant copy number alterations that were previously reported, 13 were significantly correlated with copy number and expression changes. Prognostic gene sets based on the 13 genes were developed, and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts. The CCNE1 signature was an independent risk factor based on the result of a multivariate analysis (hazard ratio=6.849, 95% confidence interval=1.613-29.092, P=0.009). Finally, gene network and upstream regulator analyses revealed that NMIBC progression is potentially mediated by CCND1-CCNE1-SP1 pathways. The prognostic molecular signature defined by copy number and expression changes of CCNE1 suggests a novel diagnostic tool for predicting the likelihood of NMIBC progression. FAU - Song, Bic-Na AU - Song BN AUID- ORCID: 0000-0001-5133-5511 AD - Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. AD - Department of Bioinformatics, Korea University of Science and Technology, Daejeon, Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Department of Bioinformatics, Korea University of Science and Technology, Daejeon, Korea. AD - Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. FAU - Chu, In-Sun AU - Chu IS AD - Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. AD - Department of Bioinformatics, Korea University of Science and Technology, Daejeon, Korea. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20170113 PL - United States TA - Exp Mol Med JT - Experimental & molecular medicine JID - 9607880 RN - 0 (Cysteine-Rich Protein 61) SB - IM MH - Cohort Studies MH - *Computational Biology/methods MH - Cysteine-Rich Protein 61/*genetics MH - *DNA Copy Number Variations MH - Databases, Nucleic Acid MH - Follow-Up Studies MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Gene Regulatory Networks MH - Humans MH - Neoplasm Invasiveness MH - Prognosis MH - Reproducibility of Results MH - Transcriptome MH - Urinary Bladder Neoplasms/*genetics/*mortality/pathology PMC - PMC5291834 EDAT- 2017/01/14 06:00 MHDA- 2018/01/13 06:00 PMCR- 2017/01/01 CRDT- 2017/01/14 06:00 PHST- 2016/04/12 00:00 [received] PHST- 2016/08/03 00:00 [revised] PHST- 2016/08/04 00:00 [accepted] PHST- 2017/01/14 06:00 [entrez] PHST- 2017/01/14 06:00 [pubmed] PHST- 2018/01/13 06:00 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - emm2016120 [pii] AID - 10.1038/emm.2016.120 [doi] PST - epublish SO - Exp Mol Med. 2017 Jan 13;49(1):e282. doi: 10.1038/emm.2016.120. PMID- 28081860 OWN - NLM STAT- MEDLINE DCOM- 20180305 LR - 20260127 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 71 IP - 6 DP - 2017 Jun TI - Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. PG - 952-960 LID - S0302-2838(16)30924-1 [pii] LID - 10.1016/j.eururo.2016.12.020 [doi] AB - BACKGROUND: Tri-modality therapy (TMT) is a recognized treatment strategy for selected patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: Report long-term outcomes of patients with MIBC treated by TMT. DESIGN, SETTING, AND PARTICIPANTS: Four hundred and seventy-five patients with cT2-T4a MIBC were enrolled on protocols or treated as per protocol at the Massachusetts General Hospital between 1986 and 2013. INTERVENTION: Patients underwent transurethral resection of bladder tumor followed by concurrent radiation and chemotherapy. Patients with less than a complete response (CR) to chemoradiation or with an invasive recurrence were recommended to undergo salvage radical cystectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-specific survival (DSS) and overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS AND LIMITATIONS: Median follow-up for surviving patients was 7.21 yr. Five- and 10-yr DSS rates were 66% and 59%, respectively. Five- and 10-yr OS rates were 57% and 39%, respectively. The risk of salvage cystectomy at 5 yr was 29%. In multivariate analyses, T2 disease (OS hazard ratio [HR]: 0.57, 95% confidence interval [CI]: 0.44-0.75, DSS HR: 0.51, 95% CI: 0.36-0.73), CR to chemoradiation (OS HR: 0.61, 95% CI: 0.46-0.81, DSS HR: 0.49, 95% CI: 0.34-0.71), and presence of tumor-associated carcinoma in situ (OS HR: 1.56, 95% CI: 1.17-2.08, DSS HR: 1.50, 95% CI: 1.03-2.17) were significant predictors for OS and DSS. When evaluating our cohort over treatment eras, rates of CR improved from 66% to 88% and 5-yr DSS improved from 60% to 84% during the eras of 1986-1995 to 2005-2013, while the 5-yr risk of salvage radical cystectomy rate decreased from 42% to 16%. CONCLUSIONS: These data demonstrate high rates of CR and bladder preservation in patients receiving TMT, and confirm DSS rates similar to modern cystectomy series. Contemporary results are particularly encouraging, and therefore TMT should be discussed and offered as a treatment option for selected patients. PATIENT SUMMARY: Tri-modality therapy is an alternative to radical cystectomy for patients with muscle-invasive bladder cancer, and is associated with comparable long-term survival and high rates of bladder preservation. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Giacalone, Nicholas J AU - Giacalone NJ AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; Harvard Radiation Oncology Program, Boston, MA, USA. FAU - Shipley, William U AU - Shipley WU AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Clayman, Rebecca H AU - Clayman RH AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Niemierko, Andrzej AU - Niemierko A AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Drumm, Michael AU - Drumm M AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Heney, Niall M AU - Heney NM AD - Department of Urology, Massachusetts General Hospital, Boston, MA, USA. FAU - Michaelson, Marc D AU - Michaelson MD AD - Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Lee, Richard J AU - Lee RJ AD - Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Saylor, Philip J AU - Saylor PJ AD - Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Wszolek, Matthew F AU - Wszolek MF AD - Department of Urology, Massachusetts General Hospital, Boston, MA, USA. FAU - Feldman, Adam S AU - Feldman AS AD - Department of Urology, Massachusetts General Hospital, Boston, MA, USA. FAU - Dahl, Douglas M AU - Dahl DM AD - Department of Urology, Massachusetts General Hospital, Boston, MA, USA. FAU - Zietman, Anthony L AU - Zietman AL AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. FAU - Efstathiou, Jason A AU - Efstathiou JA AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: jefstathiou@partners.org. LA - eng PT - Journal Article DEP - 20170109 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. PMID: 28642020 CIN - Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. PMID: 28648368 MH - Aged MH - Boston MH - Carcinoma/mortality/pathology/*therapy MH - *Chemoradiotherapy, Adjuvant/adverse effects/mortality MH - *Cystectomy/adverse effects/methods/mortality MH - Disease-Free Survival MH - Hospitals, General MH - Humans MH - Kaplan-Meier Estimate MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments/adverse effects/methods/mortality MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Survivors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Chemotherapy OT - Radiation therapy OT - Tri-modality therapy EDAT- 2017/01/14 06:00 MHDA- 2018/03/06 06:00 CRDT- 2017/01/14 06:00 PHST- 2016/06/03 00:00 [received] PHST- 2016/12/21 00:00 [accepted] PHST- 2017/01/14 06:00 [pubmed] PHST- 2018/03/06 06:00 [medline] PHST- 2017/01/14 06:00 [entrez] AID - S0302-2838(16)30924-1 [pii] AID - 10.1016/j.eururo.2016.12.020 [doi] PST - ppublish SO - Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9. PMID- 28078533 OWN - NLM STAT- MEDLINE DCOM- 20171013 LR - 20181113 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 49 IP - 3 DP - 2017 Mar TI - Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. PG - 425-430 LID - 10.1007/s11255-017-1510-5 [doi] AB - PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients). We classified UUTUCs into three types: renal pelvic, short-length ureteral, and long-length ureteral cancer; the cutoff for categorizing short- versus long-length ureteral cancer was the median tumor length. Univariate and multivariate analyses with Cox regression methods were performed to calculate hazard ratios (HRs) for BC recurrence using nine clinical covariates, including our new pathologic classification. RESULTS: The median follow-up period for the survivors was 60 months (range 1-157 months). Of 99 patients, 36 (36%) had BC recurrence; of these 36 patients, 30 (85%) experienced recurrence within 2 years and 17 (47%) had invasive BC (>/=pT1). Statistical analyses demonstrated that pathologic tumor type was the major significant risk factor for BC recurrence. Long-length (>5 cm) ureteral cancer had the highest risk of BC recurrence compared to other tumor types (multivariate HR 2.1; 95% confidence interval 1.03-4.2). CONCLUSIONS: Our simple classification system based on the tumor's pathologic appearance is useful for predicting BC recurrence. Patients with long-length ureteral cancer have a high risk of BC recurrence. FAU - Yamashita, Ryo AU - Yamashita R AD - Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. r.yamashita@scchr.jp. FAU - Watanabe, Reiko AU - Watanabe R AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Ito, Ichiro AU - Ito I AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. FAU - Shinsaka, Hideo AU - Shinsaka H AD - Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Nakamura, Masafumi AU - Nakamura M AD - Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Matsuzaki, Masato AU - Matsuzaki M AD - Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. FAU - Niwakawa, Masashi AU - Niwakawa M AD - Division of Urology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntougun, Shizuoka, 411-8777, Japan. LA - eng PT - Journal Article DEP - 20170111 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*surgery MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kidney Neoplasms/*pathology/*surgery MH - Kidney Pelvis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*etiology/pathology MH - Nephrectomy MH - Risk Factors MH - Tumor Burden MH - Ureter/surgery MH - Ureteral Neoplasms/*pathology/*surgery MH - Urinary Bladder Neoplasms/*etiology/pathology OTO - NOTNLM OT - Bladder cancer recurrence OT - Nephroureterectomy OT - Tumor classification OT - Upper urinary tract OT - Urothelial carcinoma EDAT- 2017/01/13 06:00 MHDA- 2017/10/14 06:00 CRDT- 2017/01/13 06:00 PHST- 2016/11/27 00:00 [received] PHST- 2017/01/06 00:00 [accepted] PHST- 2017/01/13 06:00 [pubmed] PHST- 2017/10/14 06:00 [medline] PHST- 2017/01/13 06:00 [entrez] AID - 10.1007/s11255-017-1510-5 [pii] AID - 10.1007/s11255-017-1510-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2017 Mar;49(3):425-430. doi: 10.1007/s11255-017-1510-5. Epub 2017 Jan 11. PMID- 28074276 OWN - NLM STAT- MEDLINE DCOM- 20170316 LR - 20181113 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 470 IP - 3 DP - 2017 Mar TI - In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. PG - 267-274 LID - 10.1007/s00428-017-2064-8 [doi] AB - Differential expression of cytokeratins (CK) is a characteristic feature of chemoresistant luminal (KRT20) and chemosensitive intrinsic aggressive basal (KRT5) subtypes in muscle-invasive bladder cancer (MIBC). We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 bladder cancer. In retrospective analysis of clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder, a single-step RT-qPCR was used to measure mRNA expression. Furthermore, immunohistochemical (IHC) staining of CK20, panCK, and MIB1 was performed. Valid measurements were obtained from 231 samples out of a series of 284 patients. Spearman correlation revealed significant associations between mRNA and protein expression of KRT20/CK20 (rho 0.6096, p < 0.0001) and MKI67/MIB1 (rho 0.5467, p < 0.0001). A positive correlation was found between MKI67 and KRT20 expression (rho 0.3492, p < 0.0001), while MKI67 and KRT5 were negatively correlated (rho -0.1693, p = 0.01). High KRT20 expression (>/=40.26) was significantly associated with worse recurrence free survival (RFS) (p = 0.001), progression-free survival (PFS) (p = 0.0003), and cancer specific survival (CSS) (p = 0.0414). The combination of high KRT20 expression and low KRT5 expression (<36.83) was associated with unfavorable RFS (p = 0.0038) and PFS (p = 0.0003) and proved to be the only independent predictor for RFS (p = 0.0055) and PFS (p = 0.0023) in multivariate analysis. KRT20 mRNA determination was superior to CK20 protein estimation with regard to RFS and PFS prediction. KRT20 and KRT5 mRNA quantification can predict recurrence and progression of stage pT1 NMIBC reflecting basal and luminal subtypes of MIBC and is superior to CK20 protein expression determined by IHC. FAU - Breyer, Johannes AU - Breyer J AUID- ORCID: 0000-0003-0674-4150 AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de. FAU - Wirtz, Ralph M AU - Wirtz RM AD - STRATIFYER Molecular Pathology GmbH, Cologne, Germany. AD - Institute of Pathology at the St Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, University Hospital of Mannheim, Mannheim, Germany. FAU - Kriegmair, Maximilian C AU - Kriegmair MC AD - Department of Urology, University Hospital of Mannheim, Mannheim, Germany. FAU - Stoehr, Robert AU - Stoehr R AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Eckstein, Markus AU - Eckstein M AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Eidt, Sebastian AU - Eidt S AD - Institute of Pathology at the St Elisabeth Hospital Koln-Hohenlind, Cologne, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Caritas St. Josef Medical Center Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. CN - BRIDGE Consortium LA - eng PT - Journal Article DEP - 20170110 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) RN - 0 (KRT20 protein, human) RN - 0 (KRT5 protein, human) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Keratin-20/analysis/biosynthesis MH - Keratin-5/analysis/*biosynthesis MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Proportional Hazards Models MH - RNA, Messenger/analysis MH - Retrospective Studies MH - Reverse Transcriptase Polymerase Chain Reaction MH - Urinary Bladder Neoplasms/mortality/*pathology OTO - NOTNLM OT - Cytokeratin OT - KRT20 OT - KRT5 OT - Molecular subtypes OT - NMIBC OT - mRNA EDAT- 2017/01/12 06:00 MHDA- 2017/03/17 06:00 CRDT- 2017/01/12 06:00 PHST- 2016/11/29 00:00 [received] PHST- 2017/01/03 00:00 [accepted] PHST- 2016/12/12 00:00 [revised] PHST- 2017/01/12 06:00 [pubmed] PHST- 2017/03/17 06:00 [medline] PHST- 2017/01/12 06:00 [entrez] AID - 10.1007/s00428-017-2064-8 [pii] AID - 10.1007/s00428-017-2064-8 [doi] PST - ppublish SO - Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10. PMID- 28070508 OWN - NLM STAT- MEDLINE DCOM- 20170214 LR - 20181113 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2016 DP - 2016 TI - The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. PG - 4368943 LID - 10.1155/2016/4368943 [doi] LID - 4368943 AB - Previous studies have reached diverse conclusions about the influence of tumor size on the oncologic outcomes in patients with upper tract urothelial carcinoma (UTUC). In this study, we retrospectively analyzed the records of 687 patients and evaluated how tumor size affected the prognosis of patients with UTUC after surgery. Clinicopathologic characteristics and oncological outcomes were compared according to tumor size (3 cm). During a median follow-up period of 65 months (range 3-144 months), 225 patients (32.8%) died from UTUC and 228 patients (33.2%) experienced intravesical recurrence (IVR). Patients with a larger tumor size tended to have a significantly higher percentage of being male (p = 0.011), tobacco consumption (p = 0.036), lack of preoperative ureteroscopy history (p = 0.003), renal pelvic location (p < 0.001), tumor necrosis (p = 0.003), advanced tumor stage (p < 0.001), higher tumor grade (p = 0.003), and lymph node metastasis (p = 0.018). Univariate analysis revealed that a tumor size >3 cm was significantly associated with worse cancer-specific survival (p = 0.002) and IVR (p = 0.011). However, the influence was not statistically significant after controlling for other factors in the multivariate analysis (hazard ratio [HR] 1.124, p = 0.414 and HR 1.196, p = 0.219). In conclusion, UTUC patients with a larger tumor present aggressive biological characteristics and tend to have a worse prognosis. FAU - Su, Xiaohong AU - Su X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Li, Xuesong AU - Li X AUID- ORCID: 0000-0002-7030-0856 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Xiong, Gengyan AU - Xiong G AUID- ORCID: 0000-0003-1385-5297 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Zhang, Lei AU - Zhang L AUID- ORCID: 0000-0002-3783-7168 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Hao, Han AU - Hao H AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Gong, Yanqing AU - Gong Y AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Zhang, Zheng AU - Zhang Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. FAU - Zhou, Liqun AU - Zhou L AUID- ORCID: 0000-0003-2795-9038 AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. LA - eng PT - Journal Article DEP - 20161214 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Follow-Up Studies MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Nephrectomy/*methods MH - Prognosis MH - Retrospective Studies MH - Surgical Procedures, Operative MH - Treatment Outcome MH - Ureter/*surgery MH - Urinary Bladder Neoplasms/diagnosis/mortality/*surgery MH - Young Adult PMC - PMC5192298 COIS- The authors declare that they have no competing interests. EDAT- 2017/01/11 06:00 MHDA- 2017/02/15 06:00 PMCR- 2016/12/14 CRDT- 2017/01/11 06:00 PHST- 2016/09/20 00:00 [received] PHST- 2016/11/10 00:00 [accepted] PHST- 2017/01/11 06:00 [entrez] PHST- 2017/01/11 06:00 [pubmed] PHST- 2017/02/15 06:00 [medline] PHST- 2016/12/14 00:00 [pmc-release] AID - 10.1155/2016/4368943 [doi] PST - ppublish SO - Biomed Res Int. 2016;2016:4368943. doi: 10.1155/2016/4368943. Epub 2016 Dec 14. PMID- 28069289 OWN - NLM STAT- MEDLINE DCOM- 20180305 LR - 20220321 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 71 IP - 6 DP - 2017 Jun TI - Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. PG - 961-969 LID - S0302-2838(16)30920-4 [pii] LID - 10.1016/j.eururo.2016.12.016 [doi] AB - BACKGROUND: Disease surveillance in patients with bladder cancer is important for early diagnosis of progression and metastasis and for optimised treatment. OBJECTIVE: To develop urine and plasma assays for disease surveillance for patients with FGFR3 and PIK3CA tumour mutations. DESIGN, SETTING, AND PARTICIPANTS: Droplet digital polymerase chain reaction (ddPCR) assays were developed and tumour DNA from two patient cohorts was screened for FGFR3 and PIK3CA hotspot mutations. One cohort included 363 patients with non-muscle-invasive bladder cancer (NMIBC). The other cohort included 468 patients with bladder cancer undergoing radical cystectomy (Cx). Urine supernatants (NMIBC n=216, Cx n=27) and plasma samples (NMIBC n=39, Cx n=27) from patients harbouring mutations were subsequently screened using ddPCR assays. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival, recurrence-free survival, and overall survival were measured. Fisher's exact test, the Wilcoxon rank-sum test and Cox regression analysis were applied. RESULTS AND LIMITATIONS: In total, 36% of the NMIBC patients (129/363) and 11% of the Cx patients (44/403) harboured at least one FGFR3 or PIK3CA mutation. Screening of DNA from serial urine supernatants from the NMIBC cohort revealed that high levels of tumour DNA (tDNA) were associated with later disease progression in NMIBC (p=0.003). Furthermore, high levels of tDNA in plasma samples were associated with recurrence in the Cx cohort (p=0.016). A positive correlation between tDNA levels in urine and plasma was observed (correlation coefficient 0.6). The retrospective study design and low volumes of plasma available for analysis were limitations of the study. CONCLUSIONS: Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer. PATIENT SUMMARY: Urine and plasma from patients with bladder cancer may be monitored for diagnosis of progression and metastasis using mutation assays. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Christensen, Emil AU - Christensen E AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Birkenkamp-Demtroder, Karin AU - Birkenkamp-Demtroder K AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Nordentoft, Iver AU - Nordentoft I AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Hoyer, Soren AU - Hoyer S AD - Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - van der Keur, Kirstin AU - van der Keur K AD - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - van Kessel, Kim AU - van Kessel K AD - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Zwarthoff, Ellen AU - Zwarthoff E AD - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Agerbaek, Mads AU - Agerbaek M AD - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. FAU - Orntoft, Torben Falck AU - Orntoft TF AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: lars@clin.au.dk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170106 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Biomarkers, Tumor) RN - 0 (Circulating Tumor DNA) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM CIN - Transl Androl Urol. 2017 Apr;6(2):331-335. doi: 10.21037/tau.2017.03.08. PMID: 28540249 CIN - Transl Androl Urol. 2017 Jun;6(3):590-592. doi: 10.21037/tau.2017.03.65. PMID: 28725603 MH - Aged MH - Biomarkers, Tumor/blood/*genetics/urine MH - Circulating Tumor DNA/blood/*genetics/urine MH - Class I Phosphatidylinositol 3-Kinases/blood/*genetics/urine MH - Cystectomy MH - DNA Mutational Analysis MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Kaplan-Meier Estimate MH - Liquid Biopsy MH - Male MH - Middle Aged MH - *Mutation MH - Neoplasm Invasiveness MH - Neoplasm Metastasis MH - Neoplasm Recurrence, Local MH - Phenotype MH - Polymerase Chain Reaction MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Receptor, Fibroblast Growth Factor, Type 3/blood/*genetics/urine MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/blood/*genetics/surgery/urine OTO - NOTNLM OT - Biomarker OT - Cell-free DNA OT - Droplet digital polymerase chain reaction OT - FGFR3 OT - Liquid biopsy OT - PIK3CA OT - Personalised analysis EDAT- 2017/01/11 06:00 MHDA- 2018/03/06 06:00 CRDT- 2017/01/11 06:00 PHST- 2016/11/04 00:00 [received] PHST- 2016/12/15 00:00 [accepted] PHST- 2017/01/11 06:00 [pubmed] PHST- 2018/03/06 06:00 [medline] PHST- 2017/01/11 06:00 [entrez] AID - S0302-2838(16)30920-4 [pii] AID - 10.1016/j.eururo.2016.12.016 [doi] PST - ppublish SO - Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6. PMID- 28065502 OWN - NLM STAT- MEDLINE DCOM- 20180319 LR - 20220317 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 6 DP - 2017 Jun TI - Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma. PG - 322-327 LID - S1078-1439(16)30406-9 [pii] LID - 10.1016/j.urolonc.2016.11.018 [doi] AB - OBJECTIVE: To determine trends in neoadjuvant and adjuvant chemotherapy use for upper tract urothelial cancer and assess its effects on survival. MATERIALS AND METHODS: We identified all patients diagnosed with upper tract urothelial cancer who underwent surgical treatment in the SEER-Medicare database from 2002 to 2011. We collected and analyzed patient demographic, clinical, and pathologic characteristics. We strictly defined neoadjuvant and adjuvant chemotherapy and studied patients who met such criteria. Multivariable Cox proportional hazards models identified were used to identify independent predictors of overall and cancer-specific survival. RESULTS: A total of 3,432 patients met inclusion criteria, and their median age was 77 years. Overall, 86.4% of patients underwent surgery alone, 1.8% received neoadjuvant chemotherapy plus surgery, and 11.8% underwent surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy use increased during the study period. Gemcitabine, carboplatin, cisplatin, and paclitaxel were the most commonly used agents. Cancer-specific survival at 5 years was 65.0% (95% CI: 63.2%-66.8%). Cox proportional hazards modeling controlling for sex, race, year of diagnosis, location, and pathologic stage revealed that higher pathologic nodal stage, tumor size>3cm, increased age, and carcinoma in situ predicted for worse survival. CONCLUSION: Age, nodal stage, and tumor size>3cm predict for worse cancer-specific survival. Neoajduvant chemotherapy is underused. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Cohen, Andrew AU - Cohen A AD - Section of Urology, University of Chicago, Chicago, IL. Electronic address: Andrew.Cohen@uchospitals.edu. FAU - Kuchta, Kristine AU - Kuchta K AD - Division of Urology, NorthShore University HealthSystem, Evanston, IL. FAU - Park, Sangtae AU - Park S AD - Division of Urology, NorthShore University HealthSystem, Evanston, IL. LA - eng PT - Journal Article DEP - 20170105 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Chemotherapy, Adjuvant MH - Female MH - Humans MH - Male MH - Neoadjuvant Therapy MH - Survival Analysis MH - Urologic Neoplasms/*drug therapy/pathology/*therapy OTO - NOTNLM OT - Chemotherapy OT - Neoadjuvant OT - Nephroureterectomy OT - SEER-medicare OT - Upper tract transitional cell carcinoma OT - Upper tract urothelial cancer EDAT- 2017/01/10 06:00 MHDA- 2018/03/20 06:00 CRDT- 2017/01/10 06:00 PHST- 2016/09/09 00:00 [received] PHST- 2016/11/12 00:00 [revised] PHST- 2016/11/29 00:00 [accepted] PHST- 2017/01/10 06:00 [pubmed] PHST- 2018/03/20 06:00 [medline] PHST- 2017/01/10 06:00 [entrez] AID - S1078-1439(16)30406-9 [pii] AID - 10.1016/j.urolonc.2016.11.018 [doi] PST - ppublish SO - Urol Oncol. 2017 Jun;35(6):322-327. doi: 10.1016/j.urolonc.2016.11.018. Epub 2017 Jan 5. PMID- 28065394 OWN - NLM STAT- MEDLINE DCOM- 20180115 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 5 DP - 2017 May TI - Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy. PG - 208-214 LID - S1078-1439(16)30402-1 [pii] LID - 10.1016/j.urolonc.2016.11.014 [doi] AB - PURPOSE: Patients with intermediate-risk non-muscle-invasive bladder cancer have traditionally been defined as those not included in the low- or high-risk groups. Therefore, the intermediate-risk group consists of heterogeneous patients. MATERIALS AND METHODS: We reviewed 326 patients diagnosed with intermediate-risk tumors. We subclassified these patients into 3 groups according to their clinical courses. Group A included patients with initial and multiple low-grade tumors (N = 170). Group B consisted of patients with a low-grade tumor that recurred after a low-risk tumor (N = 97), and Group C consisted of patients with a low-grade tumor that recurred after a high-risk tumor (N = 59). RESULTS: The 2-year recurrence-free survival rate was significantly lower in Group C (42%) than in Groups A (69%, P<0.01) and B (70%, P<0.01). Regarding progression-free survival, no significant differences were observed among the groups. In total, 167 patients received adjuvant bacillus Calmette-Guerin (BCG), and 39 received adjuvant chemotherapy instillations. In Groups A and B, there were no significant differences in efficiency against tumor recurrence between BCG and chemotherapy. In Group C, the 5-year recurrence-free survival rate was 65% in patients receiving BCG, which was significantly higher when compared with patients receiving chemotherapy (P = 0.01). Furthermore, Group C included 11 BCG refractory cases, 5 of whom later experienced stage progression during follow-up. CONCLUSION: Our subclassification analysis suggested that intermediate-risk tumors that recurred after a high-risk tumor (Group C) should be treated with adjuvant BCG therapy, owing to the high probability of subsequent recurrence. Furthermore, the definition of intermediate risk may include some BCG refractory cases. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: eiji-k@kb3.so-net.ne.jp. FAU - Yanai, Yoshinori AU - Yanai Y AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Hayakawa, Nozomi AU - Hayakawa N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ito, Yujiro AU - Ito Y AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Maeda, Takahiro AU - Maeda T AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Nagata, Hirohiko AU - Nagata H AD - Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Miyajima, Akira AU - Miyajima A AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20170103 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Chemotherapy, Adjuvant MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy/surgery MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/*classification/*drug therapy/pathology/surgery OTO - NOTNLM OT - BCG OT - Bacillus Calmette-Guerin OT - Intermediate risk OT - Non-muscle-invasive bladder cancer EDAT- 2017/01/10 06:00 MHDA- 2018/01/16 06:00 CRDT- 2017/01/10 06:00 PHST- 2015/08/24 00:00 [received] PHST- 2016/11/11 00:00 [revised] PHST- 2016/11/29 00:00 [accepted] PHST- 2017/01/10 06:00 [pubmed] PHST- 2018/01/16 06:00 [medline] PHST- 2017/01/10 06:00 [entrez] AID - S1078-1439(16)30402-1 [pii] AID - 10.1016/j.urolonc.2016.11.014 [doi] PST - ppublish SO - Urol Oncol. 2017 May;35(5):208-214. doi: 10.1016/j.urolonc.2016.11.014. Epub 2017 Jan 3. PMID- 28060766 OWN - NLM STAT- MEDLINE DCOM- 20180220 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 6 DP - 2017 Feb 7 TI - Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. PG - 10531-10542 LID - 10.18632/oncotarget.14453 [doi] AB - The high rates of tumor recurrence and progression represent a major clinical problem in non-muscle invasive bladder cancer. Previous data showed that EZH2-dependent signaling mediates these processes, whereas the frequent alterations of PIK3CA gene (copy gains and mutations) are predictive of reduced recurrence. Here we show, using clinical samples and bladder cancer cell lines, a functional interaction between EZH2- and PIK3CA-dependent signaling pathways. PIK3CA alterations mediated, on the one hand, the increased expression of two miRNAs, miR-101 and miR-138, which posttranscriptionally downregulate EZH2 expression. On the other hand, PIK3CA alterations facilitate the activation of Akt which phosphorylates EZH2 on Ser21, precluding the trimethylation of histone H3 in K27. Remarkably the increased expression of miR101 or miR138 and the expression of Ser21-phosphorylated EZH2 are good prognostic factors regarding non-muscle invasive bladder cancer recurrence and progression. Collectively, this study provides molecular evidences indicating that the gene expression rewiring occurring in primary bladder tumors, associated with increased EZH2 expression and activity and mediating the increased recurrence and progression risk, are prevented by PIK3CA-dependent signaling. This molecular process may have deep implications in the management of bladder cancer patients and in the design of novel molecularly targeted therapeutic approaches. FAU - Segovia, Cristina AU - Segovia C AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Martinez-Fernandez, Monica AU - Martinez-Fernandez M AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Duenas, Marta AU - Duenas M AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Rubio, Carolina AU - Rubio C AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Lopez-Calderon, Fernando F AU - Lopez-Calderon FF AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Costa, Clotilde AU - Costa C AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Unidad Mixta Roche-CHUS, Hospital Universitario de Santiago de Compostela, Travesia de Choupana, s/n, Santiago de Compostela, A Coruna, Spain. FAU - Saiz-Ladera, Cristina AU - Saiz-Ladera C AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Departamento de Bioquimica y Biologia Molecular I, Facultad de Biologia, Universidad Complutense, Madrid, Spain. FAU - Fernandez-Grajera, Maria AU - Fernandez-Grajera M AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. FAU - Duarte, Jose AU - Duarte J AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Munoz, Huberto Garcia AU - Munoz HG AD - Servicio de Anatomia Patologica, Hospital Universitario 12 de Octubre, Instituto de Investigacion 12 de Octubre i+12, UCM, Av Cordoba s/n, Madrid, Spain. FAU - de la Rosa, Federico AU - de la Rosa F AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Villacampa, Felipe AU - Villacampa F AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Castellano, Daniel AU - Castellano D AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. FAU - Paramio, Jesus M AU - Paramio JM AD - Unidad de Oncologia Molecular, CIEMAT (ed70A), Madrid, Spain. AD - Grupo de Oncologia celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Cancer (CIBER ONC), Spain. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (Histones) RN - 0 (MIRN101 microRNA, human) RN - 0 (MIRN138 microRNA, human) RN - 0 (MicroRNAs) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM MH - Biomarkers, Tumor/*genetics/metabolism MH - Cell Line, Tumor MH - Class I Phosphatidylinositol 3-Kinases/*genetics/metabolism MH - Disease Progression MH - Enhancer of Zeste Homolog 2 Protein/*genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Histones/metabolism MH - Humans MH - Kaplan-Meier Estimate MH - Methylation MH - MicroRNAs/genetics/metabolism MH - *Mutation MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Phosphorylation MH - Proto-Oncogene Proteins c-akt/metabolism MH - *Signal Transduction MH - Time Factors MH - Transcription, Genetic MH - Urinary Bladder Neoplasms/enzymology/*genetics/pathology/therapy PMC - PMC5354678 OTO - NOTNLM OT - Ezh2 OT - PIK3CA OT - bladder cancer OT - genomics OT - recurrence progression COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest EDAT- 2017/01/07 06:00 MHDA- 2018/02/21 06:00 PMCR- 2017/02/07 CRDT- 2017/01/07 06:00 PHST- 2016/07/20 00:00 [received] PHST- 2016/12/12 00:00 [accepted] PHST- 2017/01/07 06:00 [pubmed] PHST- 2018/02/21 06:00 [medline] PHST- 2017/01/07 06:00 [entrez] PHST- 2017/02/07 00:00 [pmc-release] AID - 14453 [pii] AID - 10.18632/oncotarget.14453 [doi] PST - ppublish SO - Oncotarget. 2017 Feb 7;8(6):10531-10542. doi: 10.18632/oncotarget.14453. PMID- 28049011 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20220316 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 197 IP - 6 DP - 2017 Jun TI - FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. PG - 1410-1418 LID - S0022-5347(16)32099-7 [pii] LID - 10.1016/j.juro.2016.12.096 [doi] AB - PURPOSE: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 were investigated as a diagnostic urinary marker combination during followup of patients with primary nonmuscle invasive bladder cancer. MATERIALS AND METHODS: In this international, multicenter, prospective study 977 patients with nonmuscle invasive bladder cancer were included. A total of 2,496 urine samples were collected prior to cystoscopy during regular visits. Sensitivity was estimated to detect concomitant recurrences. Kaplan-Meier curves were used to estimate the development of future recurrences after urinalysis and a negative cystoscopy. RESULTS: Sensitivity of the assay combination for recurrence detection was 57% in patients with primary low grade, nonmuscle invasive bladder cancer. However, sensitivity was 83% for recurrences that were pT1 or muscle invasive bladder cancer. Of the cases 2% progressed to muscle invasive bladder cancer. Sensitivity for recurrence detection in patients with primary high grade disease was 72% and 7% of them had progression to muscle invasive bladder cancer. When no concomitant tumor was found by cystoscopy, positive urine samples were more frequently followed by a recurrence over time compared to a negative urine sample (58% vs 36%, p <0.001). High stage recurrences were identified within 1 year after a positive urine test and a negative cystoscopy. CONCLUSIONS: Recurrences in patients with primary nonmuscle invasive bladder cancer can be detected by a combination of urine assays. This study supports the value of urinalysis as an alternative diagnostic tool in patients presenting with low grade tumors and as a means to identify high stage tumors earlier. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Beukers, Willemien AU - Beukers W AD - Department of Pathology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - van der Keur, Kirstin A AU - van der Keur KA AD - Department of Pathology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Kandimalla, Raju AU - Kandimalla R AD - Department of Pathology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Vergouwe, Yvonne AU - Vergouwe Y AD - Department of Public Health, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Steyerberg, Ewout W AU - Steyerberg EW AD - Department of Public Health, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Boormans, Joost L AU - Boormans JL AD - Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Lorente, Jose A AU - Lorente JA AD - Servei d'Urologia, Hospital del Mar, Barcelona, Spain. FAU - Real, Francisco X AU - Real FX AD - Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain; Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain. FAU - Segersten, Ulrike AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Orntoft, Torben F AU - Orntoft TF AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Malats, Nuria AU - Malats N AD - Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus Medical Centre, Rotterdam, the Netherlands. Electronic address: e.zwarthoff@erasmusmc.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20161231 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers, Tumor) RN - 0 (OTX1 protein, human) RN - 0 (Otx Transcription Factors) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.7.49 (TERT protein, human) RN - EC 2.7.7.49 (Telomerase) SB - IM CIN - Nat Rev Urol. 2017 Apr;14(4):198. doi: 10.1038/nrurol.2017.6. PMID: 28094332 CIN - J Urol. 2017 Jun;197(6):1417. doi: 10.1016/j.juro.2016.12.132. PMID: 28263731 CIN - J Urol. 2017 Jun;197(6):1417. doi: 10.1016/j.juro.2016.12.133. PMID: 28263732 MH - Aged MH - Biomarkers, Tumor/*urine MH - Cystoscopy MH - Feasibility Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*epidemiology/pathology/*urine MH - Otx Transcription Factors/*urine MH - Population Surveillance MH - Predictive Value of Tests MH - Prospective Studies MH - Receptor, Fibroblast Growth Factor, Type 3/*urine MH - Telomerase/*urine MH - Urinary Bladder Neoplasms/pathology/*urine OTO - NOTNLM OT - cystoscopy OT - local OT - neoplasm recurrence OT - neoplasm invasiveness OT - urinalysis OT - urinary bladder neoplasms EDAT- 2017/01/04 06:00 MHDA- 2019/03/15 06:00 CRDT- 2017/01/04 06:00 PHST- 2016/12/25 00:00 [accepted] PHST- 2017/01/04 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2017/01/04 06:00 [entrez] AID - S0022-5347(16)32099-7 [pii] AID - 10.1016/j.juro.2016.12.096 [doi] PST - ppublish SO - J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31. PMID- 28041998 OWN - NLM STAT- MEDLINE DCOM- 20180115 LR - 20210421 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 5 DP - 2017 May TI - Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. PG - 201-207 LID - S1078-1439(16)30404-5 [pii] LID - 10.1016/j.urolonc.2016.11.016 [doi] AB - OBJECTIVES: Adjuvant intravesical Bacillus Calmette-Guerin (BCG) remains the standard-of-care for high-grade non-muscle-invasive bladder cancer (NMIBC). Conflicting reports exist regarding disparate outcomes among BCG strains. We sought to determine whether a difference in recurrence-free survival (RFS) existed between TICE BCG and Connaught BCG strains used with interferon (IFN) for the treatment of NMBIC. MATERIALS AND METHODS: A post hoc analysis of the phase 2 BCG/IFN study, conducted from May 1999 to February 2001. A total of 901 patients had sufficient records for analysis. Enrollment criteria were liberal and included primary and recurrent NMIBC, patients with and without carcinoma in situ, and patients with prior BCG failure. At the beginning, 3 to 8 weeks after transurethral resection or biopsy, patients received induction with 6 weekly intravesical treatments of BCG (TICE or Connaught) with 50 million units of IFN. Surveillance for recurrence began 4 to 6 weeks after induction and quarterly thereafter for 2 years. If no recurrence was identified, patients received maintenance therapy. Separate models were created for BCG naive and failure patients. Multivariable analysis was performed using Cox proportional hazards regression. RESULTS: Overall, 609 patients received TICE BCG and 292 received Connaught BCG with similar baseline characteristics. BCG strain was not associated with worse RFS in both the multivariable BCG naive model (P = 0.28) and BCG failure model (P = 0.53). Duration of disease, tumor focality, tumor size, and BCG failure interval (in the BCG failure model) were associated with worse RFS. CONCLUSION: No significant difference in RFS was observed among patients treated with TICE BCG or Connaught BCG in combination with IFN. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Steinberg, Ryan L AU - Steinberg RL AD - Department of Urology, University of Iowa, 200 Hawkins Dr, 3231 RCP, Iowa City, IA 52242-1089. FAU - Brooks, Nathan A AU - Brooks NA AD - Department of Urology, University of Iowa, 200 Hawkins Dr, 3231 RCP, Iowa City, IA 52242-1089. FAU - Thomas, Lewis J AU - Thomas LJ AD - Department of Urology, University of Iowa, 200 Hawkins Dr, 3231 RCP, Iowa City, IA 52242-1089. FAU - Mott, Sarah L AU - Mott SL AD - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, 200 Hawkins Dr, 3231 RCP, Iowa City, IA 52242-1089; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. Electronic address: michael-odonnell@uiowa.edu. LA - eng PT - Clinical Trial, Phase II PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20161229 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (BCG Connaught) RN - 0 (BCG Vaccine) RN - 0 (Interferon alpha-2) RN - 0 (Interferon-alpha) RN - 0 (Recombinant Proteins) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use MH - BCG Vaccine/administration & dosage MH - Carcinoma in Situ/*drug therapy/pathology/surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Induction Chemotherapy MH - Interferon alpha-2 MH - Interferon-alpha/administration & dosage MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy MH - Recombinant Proteins/administration & dosage MH - Retreatment MH - Time Factors MH - Treatment Failure MH - Tumor Burden MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery OTO - NOTNLM OT - Adjuvant immunologic OT - BCG Connaught OT - BCG vaccine OT - Mycobacterium bovis OT - Urinary bladder neoplasms EDAT- 2017/01/04 06:00 MHDA- 2018/01/16 06:00 CRDT- 2017/01/03 06:00 PHST- 2016/08/22 00:00 [received] PHST- 2016/11/02 00:00 [revised] PHST- 2016/11/29 00:00 [accepted] PHST- 2017/01/04 06:00 [pubmed] PHST- 2018/01/16 06:00 [medline] PHST- 2017/01/03 06:00 [entrez] AID - S1078-1439(16)30404-5 [pii] AID - 10.1016/j.urolonc.2016.11.016 [doi] PST - ppublish SO - Urol Oncol. 2017 May;35(5):201-207. doi: 10.1016/j.urolonc.2016.11.016. Epub 2016 Dec 29. PMID- 28040424 OWN - NLM STAT- MEDLINE DCOM- 20180426 LR - 20250112 IS - 1938-0682 (Electronic) IS - 1558-7673 (Print) IS - 1558-7673 (Linking) VI - 15 IP - 4 DP - 2017 Aug TI - Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. PG - 479-486 LID - S1558-7673(16)30345-7 [pii] LID - 10.1016/j.clgc.2016.11.009 [doi] AB - BACKGROUND: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. MATERIALS AND METHODS: Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were compared. The secondary analyses included tumor response, progression-free survival (PFS), overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only (pTisN0) at cystectomy. RESULTS: A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of the patients. The absence of TURBT CIS was associated with a significantly increased pCR rate (23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, 1.19-13.98; P = .025). Stage pTisN0 disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not significantly affect the PFS or OS outcomes. Post hoc analysis of the pTisN0 patients revealed prolonged median PFS (104.5 vs. 139.9 months; P = .055) and OS (104.5 vs. 152.3 months; P = .091) outcomes similar to those for the pCR patients. CONCLUSION: The absence of CIS on pretreatment TURBT in patients with MIUC undergoing NAC was associated with increased pCR rates, with no observed differences in PFS or OS. Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to those for pCR patients. Further studies aimed at understanding the biology and clinical effect of CIS in MIUC are warranted. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Thomas, Derek E AU - Thomas DE AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Rice, Kevin R AU - Rice KR AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Pereira, Jose A AU - Pereira JA AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Johnston, Paul AU - Johnston P AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Moore, Marietta L AU - Moore ML AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Reed, Angela AU - Reed A AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Cregar, Dylan M AU - Cregar DM AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Franklin, Cindy AU - Franklin C AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Loman, Rhoda L AU - Loman RL AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Koch, Michael O AU - Koch MO AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Bihrle, Richard AU - Bihrle R AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Foster, Richard S AU - Foster RS AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Masterson, Timothy A AU - Masterson TA AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Gardner, Thomas A AU - Gardner TA AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Sundaram, Chandru P AU - Sundaram CP AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Powell, Charles R AU - Powell CR AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Beck, Stephen D W AU - Beck SDW AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. FAU - Grignon, David J AU - Grignon DJ AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Cheng, Liang AU - Cheng L AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN. FAU - Albany, Costantine AU - Albany C AD - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Hahn, Noah M AU - Hahn NM AD - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: nhahn4@jhmi.edu. LA - eng GR - P30 CA006973/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20161130 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) RN - Q20Q21Q62J (Cisplatin) SB - IM CIN - Urol Oncol. 2018 Jul;36(7):345. doi: 10.1016/j.urolonc.2018.05.003. PMID: 29880459 MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma in Situ/*drug therapy/pathology/surgery MH - Carcinoma, Transitional Cell/*drug therapy/pathology/surgery MH - Cisplatin/*therapeutic use MH - Cystectomy MH - Disease-Free Survival MH - Drug Therapy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Odds Ratio MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery PMC - PMC5449261 MID - NIHMS852985 OTO - NOTNLM OT - CIS OT - NAC OT - Pathologic complete response OT - Transurethral resection of bladder tumor OT - UC COIS- Disclosure The authors declare that they have no competing interests. EDAT- 2017/01/04 06:00 MHDA- 2018/04/27 06:00 PMCR- 2017/08/01 CRDT- 2017/01/02 06:00 PHST- 2016/09/28 00:00 [received] PHST- 2016/11/16 00:00 [revised] PHST- 2016/11/20 00:00 [accepted] PHST- 2017/01/04 06:00 [pubmed] PHST- 2018/04/27 06:00 [medline] PHST- 2017/01/02 06:00 [entrez] PHST- 2017/08/01 00:00 [pmc-release] AID - S1558-7673(16)30345-7 [pii] AID - 10.1016/j.clgc.2016.11.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Aug;15(4):479-486. doi: 10.1016/j.clgc.2016.11.009. Epub 2016 Nov 30. PMID- 28040419 OWN - NLM STAT- MEDLINE DCOM- 20180226 LR - 20221207 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 2 DP - 2017 Feb TI - A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience. PG - 38.e9-38.e15 LID - S1078-1439(16)30254-X [pii] LID - 10.1016/j.urolonc.2016.08.017 [doi] AB - BACKGROUND: Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guerin-preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as "T1G3." OBJECTIVE: To evaluate the characteristics and the long-term outcome of GC adjuvant chemotherapy in T1G3 bladder cancer after transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: We retrospectively reviewed 48 patients who were newly diagnosed with T1G3 bladder cancer between January 2009 and December 2012. A total of 48 patients received 4 cycles of GC adjuvant chemotherapy after TURBT. One month after 4 cycles of GC adjuvant chemotherapy, response was evaluated by re-TURBT. Median follow-up was 59.5 (range: 18-70) months, all patients have been observed for more than 3 years. Salvage cystectomy was recommended for patients with persistent disease and for tumor progression after initial complete response. RESULT: Complete response was achieved in 44 (91.7%) patients. Of complete responders, 5 patients experienced recurrence and 5 patients showed progression. The progression rate and disease-specific survival rate were 10.4% and 91.7% at 3 years, respectively. More than 80% of survivors preserved their bladder. Kaplan-Meier curves showed that concomitant carcinoma in situ (CIS) was the only factor that had an influence on progression-free survival (P = 0.022) and disease-specific survival (P = 0.017). Concomitant CIS was the prognostic factor for progression rate and disease-specific survival rate at 3 years (P = 0.008 and P = 0.035). CONCLUSION: GC adjuvant chemotherapy is a safe conservative treatment for T1G3 bladder cancer, but effective is really a phase II study. Patients with T1G3 bladder cancer with concomitant CIS should be treated more aggressively because of the high risk of progression. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Yang, Guo-Liang AU - Yang GL AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Zhang, Lian-Hua AU - Zhang LH AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Liu, Qiang AU - Liu Q AD - Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Wang, Zhao-Liang AU - Wang ZL AD - Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Duan, Xue-Hui AU - Duan XH AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Huang, Yi-Ran AU - Huang YR AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Bo, Juan-Jie AU - Bo JJ AD - Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: bojuanjie@sina.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20161228 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0W860991D6 (Deoxycytidine) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Gemcitabine) SB - IM CIN - Urol Oncol. 2018 Jul;36(7):346-347. doi: 10.1016/j.urolonc.2018.05.012. PMID: 29859729 MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage/adverse effects MH - Constipation/chemically induced MH - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives MH - Diarrhea/chemically induced MH - Disease Progression MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neutropenia/chemically induced MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery MH - Gemcitabine OTO - NOTNLM OT - Adjuvant chemotherapy OT - Bladder cancer OT - Progression EDAT- 2017/01/04 06:00 MHDA- 2018/02/27 06:00 CRDT- 2017/01/02 06:00 PHST- 2016/05/17 00:00 [received] PHST- 2016/08/10 00:00 [revised] PHST- 2016/08/27 00:00 [accepted] PHST- 2017/01/04 06:00 [pubmed] PHST- 2018/02/27 06:00 [medline] PHST- 2017/01/02 06:00 [entrez] AID - S1078-1439(16)30254-X [pii] AID - 10.1016/j.urolonc.2016.08.017 [doi] PST - ppublish SO - Urol Oncol. 2017 Feb;35(2):38.e9-38.e15. doi: 10.1016/j.urolonc.2016.08.017. Epub 2016 Dec 28. PMID- 29556618 OWN - NLM STAT- MEDLINE DCOM- 20180905 LR - 20180905 IS - 2066-8279 (Electronic) IS - 1220-0522 (Linking) VI - 58 IP - 4 DP - 2017 TI - Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. PG - 1279-1283 AB - BACKGROUND: Bladder cancer (BC) currently accounts for 5% of all malignancies and the most common tumor of the urinary tract. Diagnosis of bladder cancer is based on urine cytology and white-light cystoscopy (WLC) performed for patients with suspected bladder mass and/or hematuria. Recent studies suggest that using the fluorescence photodynamic diagnosis (PDD) significantly improves diagnostic sensitivity with a positive influence upon the recurrence rate of bladder cancer. OBJECTIVE: To evaluate the diagnostic efficiency and long-term influence upon the tumor recurrence rate for patients with non-muscle-invasive bladder cancer (NMIBC) undergoing hexaminolevulinate PDD compared to standard WLC. PATIENTS, MATERIALS AND METHODS: Between 2009 and 2011, 113 primary NMIBC patients were enrolled in our prospective study and randomized in two parallel groups: 57 patients in the study group (PDD) and 56 patients in the control group (WLC). All patients had primary Ta/T1 NMIBC with good life expectancy and no significant bladder outlet obstruction [postvoid residual urine volume (PVR) <100 mL]. RESULTS: Fluorescence cystoscopy examination identified 26.3% more tumors than the conventional examination (p=0.034) in the PDD group. Tumor recurrence rate analysis proved a significant reduction by up to 20% after five years of follow-up by using PDD [hazard ratio (HR) 0.566, 95% confidence interval (CI) 0.343-0.936; p=0.0267]. CONCLUSIONS: The use of PDD for patients with NMIBC results in a significant 26% diagnostic sensitivity improvement as well as superior patient prognosis and quality of life following conservative treatment by reducing the tumor recurrence rate with up to 20% after five years of follow-up. FAU - Dragoescu, Petru Octavian AU - Dragoescu PO AD - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Romania; stefania.tudorache@gmail.com. FAU - Tudorache, Stefania AU - Tudorache S FAU - Drocas, Andrei Ioan AU - Drocas AI FAU - Mitroi, George AU - Mitroi G FAU - Panus, Andrei AU - Panus A FAU - Dragoescu, Nicoleta Alice Marilena AU - Dragoescu NAM FAU - Mesina, Cristian AU - Mesina C FAU - Mititelu, Cosmin Daniel AU - Mititelu CD FAU - Stanculescu, Andreea Doriana AU - Stanculescu AD FAU - Mohamed, Guleed AU - Mohamed G FAU - Tomescu, Paul Ioan AU - Tomescu PI LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Romania TA - Rom J Morphol Embryol JT - Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie JID - 9112454 RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Aminolevulinic Acid/*analogs & derivatives/pharmacology/therapeutic use MH - Female MH - Fluorescence MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Photochemotherapy/*methods MH - Prospective Studies MH - Urinary Bladder Neoplasms/pathology/*radiotherapy EDAT- 2017/01/01 00:00 MHDA- 2018/09/06 06:00 CRDT- 2018/03/21 06:00 PHST- 2018/03/21 06:00 [entrez] PHST- 2017/01/01 00:00 [pubmed] PHST- 2018/09/06 06:00 [medline] AID - 58041712791283 [pii] PST - ppublish SO - Rom J Morphol Embryol. 2017;58(4):1279-1283. PMID- 28039452 OWN - NLM STAT- MEDLINE DCOM- 20171002 LR - 20220410 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 8 DP - 2017 Feb 21 TI - Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. PG - 12891-12901 LID - 10.18632/oncotarget.14179 [doi] AB - The prognostic role of systemic inflammatory response (SIR) markers is unclear in patients with non-muscle invasive bladder cancer (NMIBC). Here, we aimed to investigate the prognostic role of various SIR markers in the oncological outcomes in non-muscle invasive bladder cancer (NMIBC) patients at a single institution in Korea. Neutrophil-lymphocyte ratio (NLR), derived-NLR (dNLR), and platelet-lymphocyte ratio (PLR) were examined as SIR markers. We retrospectively collected data of 1,698 NMIBC patients who underwent transurethral resection of the bladder (TURB) between 1990 and 2013. After excluding 147 patients, the study population finally consisted of 1,551 individuals. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analyzed by using Kaplan-Meier estimates. Multivariate Cox regression model was adopted to identify the predictors of oncological outcomes. Notably, elevated NLR (>/=2.0), dNLR (>/=1.5) and PLR (>/=124) were associated with poor OS outcomes. Patients with increased NLR, but not dNLR and PLR, only had poor CSS estimates compared to those with lower NLR. However, no significant differences were found in RFS and PFS according to the SIR status. In the multivariate Cox regression analysis, elevated NLR was identified as a key predictor of OS [hazard ratio (HR)=1.52, 95% confidence interval (CI)=1.19-1.95], in addition to age (HR=1.07, 95% CI=1.05-1.08), hemoglobin (HR=0.83, 95% CI=0.78-0.88), and high grade tumor (HR=1.88, 95% CI=1.45-1.08). With respect to CSS, increased NLR was also identified as an independent predictor (HR=1.12, 95% CI=1.01-1.25). In summary, our results indicate that NLR can be a very reliable SIR marker for predicting the oncological outcomes, particularly mortality outcomes. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor/*blood MH - Carcinoma, Transitional Cell/*immunology/mortality/surgery MH - Cell Count MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocyte Count MH - *Lymphocytes MH - Male MH - Middle Aged MH - *Neutrophils MH - Prognosis MH - Proportional Hazards Models MH - ROC Curve MH - Urinary Bladder Neoplasms/*immunology/mortality/surgery PMC - PMC5355064 OTO - NOTNLM OT - neutrophil-lymphocyte ratio OT - predictors OT - systemic inflammatory response OT - urinary bladder OT - urothelial carcinoma COIS- CONFLICTS OF INTEREST None declared. EDAT- 2017/01/01 06:00 MHDA- 2017/10/03 06:00 PMCR- 2017/02/21 CRDT- 2017/01/01 06:00 PHST- 2016/07/25 00:00 [received] PHST- 2016/11/24 00:00 [accepted] PHST- 2017/01/01 06:00 [pubmed] PHST- 2017/10/03 06:00 [medline] PHST- 2017/01/01 06:00 [entrez] PHST- 2017/02/21 00:00 [pmc-release] AID - 14179 [pii] AID - 10.18632/oncotarget.14179 [doi] PST - ppublish SO - Oncotarget. 2017 Feb 21;8(8):12891-12901. doi: 10.18632/oncotarget.14179. PMID- 28035618 OWN - NLM STAT- MEDLINE DCOM- 20171013 LR - 20181113 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 49 IP - 3 DP - 2017 Mar TI - WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. PG - 431-437 LID - 10.1007/s11255-016-1491-9 [doi] AB - PURPOSE: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC. METHODS: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin. Kaplan-Meier analysis and univariate and multivariate Cox regression analyses regarding progression-free (PFS) and cancer-specific survival (CSS) were performed. RESULTS: Aberrant expression of E-cadherin was recognized in 74% of patients. Kaplan-Meier analysis showed that aberrant E-cadherin expression was associated with worse 10-year PFS (62 vs. 90%, p = 0.045). In univariate analysis, aberrant E-cadherin staining, associated carcinoma in situ, grading 3 after WHO classification 1973 and infiltrative growth pattern at the invasion front were the statistically significant predictive factors for worse PFS, only infiltrative growth pattern for CSS. With regard to progression, grading 3 after WHO classification of 1973 (HR 6.49; CI 1.54-27.28, p = 0.011) and infiltrative tumor invasion pattern (HR 2.06; CI 1.10-3.86, p = 0.024) revealed as independent factors for PFS, and there was a trend also for E-cadherin expression (HR 0.45; CI 0.19-1.06; p = 0.068). Regarding CSS, infiltrative tumor growth pattern (HR 3.79; CI 1.67-8.60, p = 0.001) was the only statistically significantly independent predictive factor in multivariate Cox regression analysis. CONCLUSIONS: Beside invasion growth pattern and WHO grading 1973 that achieved to be independent prognostic factors, there was a trend for the parameter E-cadherin expression to be of predictive value for PFS in stage pT1 hg urothelial bladder carcinoma after organ-sparing approach. Further studies on genetic level are warranted to define the distinct role of EMT in early-invasive UBC. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - Breyer, Johannes AU - Breyer J AUID- ORCID: 0000-0003-0674-4150 AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. Johannes.breyer@ukr.de. FAU - Herdegen, Sonja AU - Herdegen S AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - Eder, Fabian AU - Eder F AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Bertz, Simone AU - Bertz S AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - May, Matthias AU - May M AD - Department of Urology, Hospital St. Elisabeth, Straubing, Germany. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - Lausenmeyer, Eva M AU - Lausenmeyer EM AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - van Rhijn, Bas W G AU - van Rhijn BW AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20161229 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 RN - 0 (Biomarkers, Tumor) RN - 0 (Cadherins) SB - IM MH - Aged MH - Biomarkers, Tumor/analysis MH - Cadherins/*analysis MH - Carcinoma in Situ/*chemistry/*pathology/surgery MH - Carcinoma, Transitional Cell/*chemistry/*pathology/surgery MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Organ Sparing Treatments MH - Predictive Value of Tests MH - Survival Rate MH - Urinary Bladder Neoplasms/*chemistry/*pathology/surgery OTO - NOTNLM OT - E-cadherin OT - Epithelial-mesenchymal transition OT - Immunohistochemistry OT - Stage pT1 bladder cancer OT - WHO grading classifications EDAT- 2016/12/31 06:00 MHDA- 2017/10/14 06:00 CRDT- 2016/12/31 06:00 PHST- 2016/10/11 00:00 [received] PHST- 2016/12/20 00:00 [accepted] PHST- 2016/12/31 06:00 [pubmed] PHST- 2017/10/14 06:00 [medline] PHST- 2016/12/31 06:00 [entrez] AID - 10.1007/s11255-016-1491-9 [pii] AID - 10.1007/s11255-016-1491-9 [doi] PST - ppublish SO - Int Urol Nephrol. 2017 Mar;49(3):431-437. doi: 10.1007/s11255-016-1491-9. Epub 2016 Dec 29. PMID- 28013415 OWN - NLM STAT- MEDLINE DCOM- 20170403 LR - 20181202 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 32 IP - 2 DP - 2017 Feb TI - Prognostic impact of preoperative anemia on non-muscle-invasive bladder carcinoma treated with GreenLight laser vaporization. PG - 397-403 LID - 10.1007/s10103-016-2133-2 [doi] AB - In this study, we aimed to evaluate the impact of preoperative anemia (PA) on oncological outcomes among patients with non-muscle-invasive bladder cancer (NMIBC) treated with GreenLight laser vaporization of bladder tumor (PV-BT). Between January 2010 and December 2015, 407 patients with NMIBC who underwent PV-BT surgery were stratified into normal and anemia groups based on the World Health Organization classification (anemia cutoff value: hemoglobin level, <13.0 m g/dL in men and <12.0 mg/dL in women). The Student's t test and chi-square test were performed to assess the effects of PA on clinical and pathological characteristics of patients with NMIBC. The Kaplan-Meier method was used to investigate the influence of PA on oncological survival outcomes. Before PV-BT, 139 patients (34.2%) were anemic. No significant differences in age, sex, smoking habit, tumor size, focality, grade, and stage were found between the anemia and normal groups. At a median follow-up period of 32.5 months (range, 8-60 months), 74 patients (18.2%) had urothelial recurrence, 30 (7.4%) died from any cause, and 21 (5.2%) died from bladder cancer. In the Kaplan-Meier analysis, preoperative anemia was significantly associated with decreased cancer-specific survival (CSS) and overall survival (OS) of the patients with NMIBC. However, recurrence-free survival (RFS) showed no statistically significant difference between the PA and normal groups. The preoperative anemic patients with NMIBC who underwent PV-BT surgery had worse CSS and OS. PA can be a useful and cost-effective prognostic marker in the clinical practice for NMIBC treatment. FAU - Luo, Fei AU - Luo F AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. FAU - Wang, Ya-Shen AU - Wang YS AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. FAU - Su, Yan-Hui AU - Su YH AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. FAU - Zhang, Zhi-Hua AU - Zhang ZH AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. FAU - Sun, Hong-Hong AU - Sun HH AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. FAU - Li, Jian AU - Li J AD - Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China. lijian_2016tj@163.com. LA - eng PT - Journal Article DEP - 20161224 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 SB - IM MH - Aged MH - Anemia/*complications MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Laser Therapy/*methods MH - Male MH - Middle Aged MH - Muscles/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - *Preoperative Care MH - Prognosis MH - Urinary Bladder Neoplasms/*complications/pathology/*surgery OTO - NOTNLM OT - Anemia OT - Bladder cancer OT - Hemoglobin OT - Laser EDAT- 2016/12/26 06:00 MHDA- 2017/04/04 06:00 CRDT- 2016/12/26 06:00 PHST- 2016/08/11 00:00 [received] PHST- 2016/12/14 00:00 [accepted] PHST- 2016/12/26 06:00 [pubmed] PHST- 2017/04/04 06:00 [medline] PHST- 2016/12/26 06:00 [entrez] AID - 10.1007/s10103-016-2133-2 [pii] AID - 10.1007/s10103-016-2133-2 [doi] PST - ppublish SO - Lasers Med Sci. 2017 Feb;32(2):397-403. doi: 10.1007/s10103-016-2133-2. Epub 2016 Dec 24. PMID- 28010124 OWN - NLM STAT- MEDLINE DCOM- 20180618 LR - 20191210 IS - 1366-5804 (Electronic) IS - 1354-750X (Linking) VI - 22 IP - 7 DP - 2017 Nov TI - Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer. PG - 674-681 LID - 10.1080/1354750X.2016.1276628 [doi] AB - CONTEXT: About 50-70% of patients with non-muscle invasive bladder cancer (NMIBC) experience relapse of disease. OBJECTIVE: To establish a panel of protein biomarkers incorporated in a multiplexed microarray (BCa chip) and a classifier for diagnosing recurrent NMIBC. MATERIALS AND METHODS: Urine samples from 45 patients were tested. Diagnostic performance was evaluated by receiver operating characteristic (ROC) analysis. RESULTS: A multi biomarker panel (ECadh, IL8, MMP9, EN2, VEGF, past recurrences, BCG therapies and stage at diagnosis) was identified yielding an area under the curve of 0.96. DISCUSSION AND CONCLUSION: This biomarker panel represents a potential diagnostic tool for noninvasive diagnosis of recurrent NMIBC. FAU - Gogalic, Selma AU - Gogalic S AD - a Health and Environment Department, Bioresources Unit, AIT Austrian Institute of Technology GmbH , Tulln , Austria. FAU - Sauer, Ursula AU - Sauer U AD - a Health and Environment Department, Bioresources Unit, AIT Austrian Institute of Technology GmbH , Tulln , Austria. FAU - Doppler, Sara AU - Doppler S AD - a Health and Environment Department, Bioresources Unit, AIT Austrian Institute of Technology GmbH , Tulln , Austria. FAU - Heinzel, Andreas AU - Heinzel A AD - b Emergentec Biodevelopment GmbH , Vienna , Austria. FAU - Perco, Paul AU - Perco P AD - b Emergentec Biodevelopment GmbH , Vienna , Austria. FAU - Lukas, Arno AU - Lukas A AD - b Emergentec Biodevelopment GmbH , Vienna , Austria. FAU - Simpson, Guy AU - Simpson G AD - c Department of Oncology, Faculty of Health and Medical Sciences , Leggett Building, University of Surrey , Surrey , UK. FAU - Pandha, Hardev AU - Pandha H AD - c Department of Oncology, Faculty of Health and Medical Sciences , Leggett Building, University of Surrey , Surrey , UK. FAU - Horvath, Andras AU - Horvath A AD - c Department of Oncology, Faculty of Health and Medical Sciences , Leggett Building, University of Surrey , Surrey , UK. FAU - Preininger, Claudia AU - Preininger C AD - a Health and Environment Department, Bioresources Unit, AIT Austrian Institute of Technology GmbH , Tulln , Austria. LA - eng PT - Journal Article PT - Validation Study DEP - 20170119 PL - England TA - Biomarkers JT - Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals JID - 9606000 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/standards/*urine MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis MH - ROC Curve MH - Recurrence MH - Urinary Bladder Neoplasms/*diagnosis/pathology OTO - NOTNLM OT - ECadh OT - EN2 OT - IL8 OT - MMP9 OT - Recurrent bladder cancer OT - VEGF EDAT- 2016/12/25 06:00 MHDA- 2018/06/19 06:00 CRDT- 2016/12/25 06:00 PHST- 2016/12/25 06:00 [pubmed] PHST- 2018/06/19 06:00 [medline] PHST- 2016/12/25 06:00 [entrez] AID - 10.1080/1354750X.2016.1276628 [doi] PST - ppublish SO - Biomarkers. 2017 Nov;22(7):674-681. doi: 10.1080/1354750X.2016.1276628. Epub 2017 Jan 19. PMID- 27992871 OWN - NLM STAT- MEDLINE DCOM- 20171026 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 98 IP - 3 DP - 2017 TI - ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. PG - 282-289 LID - 10.1159/000453670 [doi] AB - Background/Aims/Objectives: It is difficult to identify patients with a non-muscle-invasive bladder cancer (NMIBC) at stage pT1 with concomitant carcinoma in situ (Cis) who will benefit from an early cystectomy. METHODS: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues of patients with NMIBC. Messenger ribonucleic acid (mRNA) expression of progesterone receptor (PGR), estrogen receptor (ESR1), ERBB2, and marker of proliferation Ki-67 (MKI67) was measured by single-step reverse transcription quantitative real-time polymerase chain reaction using RNA-specific TaqMan assays. Relative gene expression was determined by the normalization of 2 reference genes (CALM2, B2M) using the 40 DeltaDeltaCT method and relative gene expression was correlated to the histopathological stage and oncological outcome. RESULTS: Of 302 patients with pT1 NMIBC in the initial transurethral resection of the bladder, 65 had a concomitant Cis. Elevated ERBB2 expression (>40.1) significantly correlated with progress in patients with and without concomitant Cis (p = 0.020 and p = 0.049, respectively). For the subgroup of pT1 with concomitant Cis, elevated ERBB2 expression significantly discriminated between a high-risk group of 55% progression-free survival (PFS) and a low-risk group of 90% PFS after a 5-year follow-up (p = 0.020). Cox-regression analysis revealed ERBB2 expression as the only independent prognostic factor for PFS (p = 0.0037). CONCLUSIONS: High mRNA expression of ERBB2 can identify patients with pT1 NMIBC with concomitant Cis, who have a high risk of progression and might benefit from an early cystectomy. CI - (c) 2016 S. Karger AG, Basel. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, University of Regensburg, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W FAU - Wirtz, Ralph M AU - Wirtz RM FAU - Wullich, Bernd AU - Wullich B FAU - Keck, Bastian AU - Keck B FAU - Erben, Philipp AU - Erben P FAU - Kriegmair, Maximilian C AU - Kriegmair MC FAU - Stoehr, Robert AU - Stoehr R FAU - Eckstein, Markus AU - Eckstein M FAU - Laible, Mark AU - Laible M FAU - Schlombs, Kornelia AU - Schlombs K FAU - Eidt, Sebastian AU - Eidt S FAU - Denzinger, Stefan AU - Denzinger S FAU - Burger, Maximilian AU - Burger M FAU - Hartmann, Arndt AU - Hartmann A CN - BRIDGE Consortium LA - eng PT - Journal Article DEP - 20161217 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Estrogen Receptor alpha) RN - 0 (Ki-67 Antigen) RN - 0 (RNA, Messenger) RN - 0 (RNA, Neoplasm) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (Receptors, Progesterone) RN - 0 (ESR1 protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Aged MH - Carcinoma in Situ/*metabolism/surgery MH - *Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Estrogen Receptor alpha/metabolism MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prognosis MH - Proportional Hazards Models MH - RNA, Messenger/metabolism MH - RNA, Neoplasm/analysis MH - Erb-b2 Receptor Tyrosine Kinases/genetics/*metabolism MH - Receptors, Progesterone/metabolism MH - Retrospective Studies MH - Sensitivity and Specificity MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*metabolism/surgery EDAT- 2016/12/20 06:00 MHDA- 2017/10/27 06:00 CRDT- 2016/12/20 06:00 PHST- 2016/08/15 00:00 [received] PHST- 2016/11/21 00:00 [accepted] PHST- 2016/12/20 06:00 [pubmed] PHST- 2017/10/27 06:00 [medline] PHST- 2016/12/20 06:00 [entrez] AID - 000453670 [pii] AID - 10.1159/000453670 [doi] PST - ppublish SO - Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17. PMID- 27986532 OWN - NLM STAT- MEDLINE DCOM- 20190314 LR - 20190314 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 197 IP - 6 DP - 2017 Jun TI - Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. PG - 1419-1426 LID - S0022-5347(16)31930-9 [pii] LID - 10.1016/j.juro.2016.12.010 [doi] AB - PURPOSE: Urothelial carcinoma is associated with a high rate of recurrence. Guidelines recommend rigorous, regular surveillance programs that are invasive and expensive. This study describes a noninvasive urine test with sufficient sensitivity to rule out recurrent urothelial carcinoma, thereby reducing invasive diagnostic evaluations without compromising patient care. METHODS AND MATERIALS: A total of 1,036 urine samples were prospectively collected from 763 patients undergoing routine surveillance for recurrent urothelial carcinoma of the bladder. The purpose was to develop and validate a test with combined high sensitivity and high negative predictive value. Cxbladder Monitor combines gene expression, clinical and patient data, and it is designed to rule out the presence of recurrent urothelial carcinoma. RESULTS: Cxbladder Monitor showed an internally validated sensitivity of 0.93 with a negative predictive value of 0.97 and a test negative rate of 0.34. Sensitivity was 0.95 for recurrent disease with a high risk of progression (all high grade disease and low grade, stage T1 or greater disease) compared with 0.86 for low grade Ta disease. Subgroup analyses indicated that diagnostic performance was not significantly different in different age groups, or by gender or tumor stage. Sensitivity was not affected by adjuvant bacillus Calmette-Guerin treatment within the last 6 months. False-negative findings were reported in fewer than 1.5% of all samples collected. CONCLUSIONS: The Cxbladder Monitor test offers combined high sensitivity and high negative predictive value to rule out urothelial carcinoma. This test has clinical utility as a confirmatory negative adjunct to cystoscopy, potentially justifying the postponement/avoidance of cystoscopic investigations to monitor recurrence in patients. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Kavalieris, Laimonis AU - Kavalieris L AD - Pacific Edge Ltd., Dunedin, New Zealand. FAU - O'Sullivan, Paul AU - O'Sullivan P AD - Pacific Edge Ltd., Dunedin, New Zealand. FAU - Frampton, Chris AU - Frampton C AD - Department of Medicine, University of Otago, Christchurch, New Zealand. FAU - Guilford, Parry AU - Guilford P AD - Pacific Edge Ltd., Dunedin, New Zealand; Department of Biochemistry, University of Otago, Dunedin, New Zealand. FAU - Darling, David AU - Darling D AD - Pacific Edge Ltd., Dunedin, New Zealand. FAU - Jacobson, Elsie AU - Jacobson E AD - Pacific Edge Ltd., Dunedin, New Zealand. FAU - Suttie, James AU - Suttie J AD - Pacific Edge Ltd., Dunedin, New Zealand. Electronic address: jimmy.suttie@pelnz.com. FAU - Raman, Jay D AU - Raman JD AD - Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Weill Cornell Medical College, Cornell University, New York, New York; Department of Urology Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20161214 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers, Tumor) SB - IM CIN - J Urol. 2017 Jun;197(6):1425-1426. doi: 10.1016/j.juro.2016.12.130. PMID: 28259763 CIN - Aktuelle Urol. 2018 Feb;49(1):18-19. doi: 10.1055/s-0043-115853. PMID: 29390211 MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Carcinoma, Transitional Cell/genetics/*urine MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/genetics/*urine MH - Population Surveillance MH - Predictive Value of Tests MH - Prospective Studies MH - Urinary Bladder Neoplasms/genetics/*urine OTO - NOTNLM OT - biomarkers OT - diagnostic techniques OT - local OT - molecular diagnostic techniques OT - neoplasm recurrence OT - tumor OT - urinary bladder neoplasms OT - urological EDAT- 2016/12/18 06:00 MHDA- 2019/03/15 06:00 CRDT- 2016/12/18 06:00 PHST- 2016/12/06 00:00 [accepted] PHST- 2016/12/18 06:00 [pubmed] PHST- 2019/03/15 06:00 [medline] PHST- 2016/12/18 06:00 [entrez] AID - S0022-5347(16)31930-9 [pii] AID - 10.1016/j.juro.2016.12.010 [doi] PST - ppublish SO - J Urol. 2017 Jun;197(6):1419-1426. doi: 10.1016/j.juro.2016.12.010. Epub 2016 Dec 14. PMID- 27959887 OWN - NLM STAT- MEDLINE DCOM- 20170523 LR - 20220318 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 116 IP - 2 DP - 2017 Jan 17 TI - Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer. PG - 202-210 LID - 10.1038/bjc.2016.411 [doi] AB - BACKGROUND: Bladder cancer (BC) is among the most common malignancies worldwide. The identification of new biomarkers for early BC detection, recurrence/progression is urgently needed. The cytokinesis-block micronucleus assay (CBMN) evaluates chromosome damage in cultured human lymphocytes and micronuclei (MN) provide a convenient and reliable index of both chromosome breakage and loss. METHODS: Chromosomal damage (expressed as frequencies of MN, nucleoplasmic bridges and nuclear buds (NBUD)) was evaluated by CBMN assay in cryopreserved lymphocytes from 158 age/smoking-matched pairs of cases and controls in relation to BC risk, recurrence or progression. Moreover, non-muscle invasive BC (NMIBC) patients were characterised for 783 DNA repair gene polymorphisms for their possible association with the investigated cytogenetic end points. RESULTS: MN and NBUD frequencies were significantly higher in cases than in controls (P=0.001 and P=0.006, respectively), with the associations being stronger in NMIBC. In a logistic regression model, for each increase of one unit in the MN frequency, a 1.12 increased risk of developing NMIBC was observed. In NMIBC cases, 10 polymorphisms were associated with different MN frequencies after genotype stratification. CONCLUSIONS: A model including traditional BC risk factors, MN frequency and the selected polymorphisms differentially distributed in cases and controls improved BC patient identification. Understanding the meaning of systemic chromosomal damage in BC patients with respect to the general population may help to adopt specific prevention strategies and therapeutic intervention. FAU - Pardini, Barbara AU - Pardini B AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. AD - Department of Medical Sciences, University of Turin, Via Santena 19, Turin 10126, Italy. FAU - Viberti, Clara AU - Viberti C AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. AD - Department of Medical Sciences, University of Turin, Via Santena 19, Turin 10126, Italy. FAU - Naccarati, Alessio AU - Naccarati A AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. FAU - Allione, Alessandra AU - Allione A AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. AD - Department of Medical Sciences, University of Turin, Via Santena 19, Turin 10126, Italy. FAU - Oderda, Marco AU - Oderda M AD - Department of Urology, Citta della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy. FAU - Critelli, Rossana AU - Critelli R AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. FAU - Preto, Mirko AU - Preto M AD - Department of Urology, Citta della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy. FAU - Zijno, Andrea AU - Zijno A AD - Department of Environment and Primary prevention, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome 00161, Italy. FAU - Cucchiarale, Giuseppina AU - Cucchiarale G AD - Department of Urology, Clinica Cellini, Via Cellini 5, Turin 10126, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Department of Urology, Citta della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy. FAU - Vineis, Paolo AU - Vineis P AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. AD - Department of Epidemiology and Public Health, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. FAU - Sacerdote, Carlotta AU - Sacerdote C AD - Unit of Cancer Epidemiology, Center for Cancer Prevention (CPO-Piemonte), Via Santena 7, Turin 10126, Italy. FAU - Matullo, Giuseppe AU - Matullo G AD - Human Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy. AD - Department of Medical Sciences, University of Turin, Via Santena 19, Turin 10126, Italy. LA - eng PT - Journal Article DEP - 20161213 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/genetics MH - Case-Control Studies MH - DNA Damage/*genetics MH - Humans MH - Lymphocytes/*metabolism/pathology MH - Male MH - Micronucleus Tests MH - Middle Aged MH - Prognosis MH - Risk Factors MH - Up-Regulation/genetics MH - Urinary Bladder Neoplasms/*diagnosis/*genetics/pathology PMC - PMC5243995 EDAT- 2016/12/14 06:00 MHDA- 2017/05/24 06:00 PMCR- 2018/01/17 CRDT- 2016/12/14 06:00 PHST- 2016/07/19 00:00 [received] PHST- 2016/10/24 00:00 [revised] PHST- 2016/11/09 00:00 [accepted] PHST- 2016/12/14 06:00 [pubmed] PHST- 2017/05/24 06:00 [medline] PHST- 2016/12/14 06:00 [entrez] PHST- 2018/01/17 00:00 [pmc-release] AID - bjc2016411 [pii] AID - 10.1038/bjc.2016.411 [doi] PST - ppublish SO - Br J Cancer. 2017 Jan 17;116(2):202-210. doi: 10.1038/bjc.2016.411. Epub 2016 Dec 13. PMID- 27951584 OWN - NLM STAT- MEDLINE DCOM- 20171026 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 98 IP - 3 DP - 2017 TI - 90-Day Mortality after Radical Cystectomy for Bladder Cancer: Prognostic Factors in a Multicenter Case Series. PG - 255-261 LID - 10.1159/000452135 [doi] AB - OBJECTIVES: To identify preoperative risk factors for 90-day mortality and to validate existing nomograms in a multicenter series of patients undergoing radical cystectomy (RC). MATERIALS AND METHODS: We evaluated 90-day mortality in 475 patients following RC and urinary diversion at 2 Italian institutions and validated Aziz and Isbarn nomogram. Univariable logistic models assessed the predictive ability of operative volume, age at intervention, gender, body mass index, carcinoma in situ at transurethral resection of the bladder, American Society of Anesthesiologist (ASA) score, Charlson Comorbidity Index, clinical stage and pathological stage (TNM). RESULTS: Of the total number of patients, 387 of them (81%) were male. The median age at RC was 71.8. The most frequent ASA score was 2 (53%). Twenty-five deaths occurred within 90 days (5.3%), all among patients who had undergone RC and incontinent urinary diversion. Risk was higher in patients with advanced disease (OR 2.4); moreover, 90-day mortality odd in 70-79-year-old patients was 13 times higher than those of younger patients (<70). Predictive accuracy using Isbarn's and Aziz's nomogram were 67 and 71%, respectively. CONCLUSIONS: Our multicenter study confirmed the moderate predictive value of the Aziz nomogram. Larger studies are needed to improve on existing nomograms with the aim of enhancing preoperative counseling. CI - (c) 2016 S. Karger AG, Basel. FAU - D'Elia, Carolina AU - D'Elia C AD - Department of Urology, Bolzano General Hospital, Bolzano, Italy. FAU - Comploj, Evi AU - Comploj E FAU - Cerruto, Maria Angela AU - Cerruto MA FAU - Trenti, Emanuela AU - Trenti E FAU - Palermo, Salvatore Mario AU - Palermo SM FAU - Melotti, Roberto AU - Melotti R FAU - Artibani, Walter AU - Artibani W FAU - Pycha, Armin AU - Pycha A LA - eng PT - Journal Article PT - Multicenter Study DEP - 20161213 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Age Factors MH - Aged MH - Body Mass Index MH - Cystectomy/*methods MH - Female MH - Humans MH - Italy MH - Male MH - Middle Aged MH - Nomograms MH - Postoperative Complications MH - Prognosis MH - Regression Analysis MH - Reproducibility of Results MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*mortality/*surgery MH - Urinary Diversion EDAT- 2016/12/13 06:00 MHDA- 2017/10/27 06:00 CRDT- 2016/12/13 06:00 PHST- 2016/09/02 00:00 [received] PHST- 2016/09/28 00:00 [accepted] PHST- 2016/12/13 06:00 [pubmed] PHST- 2017/10/27 06:00 [medline] PHST- 2016/12/13 06:00 [entrez] AID - 000452135 [pii] AID - 10.1159/000452135 [doi] PST - ppublish SO - Urol Int. 2017;98(3):255-261. doi: 10.1159/000452135. Epub 2016 Dec 13. PMID- 27932269 OWN - NLM STAT- MEDLINE DCOM- 20180312 LR - 20180616 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 4 DP - 2017 Apr TI - The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. PG - 151.e17-151.e23 LID - S1078-1439(16)30369-6 [pii] LID - 10.1016/j.urolonc.2016.11.003 [doi] AB - INTRODUCTION: To evaluate the incidence of carcinoma in situ (CIS) in patients treated with radical cystectomy (RC) due to bladder cancer and to assess its effect on recurrence and survival rates. METHODS: The study focused on 1,128 consecutive nonmetastatic patients with bladder cancer treated with RC at a single tertiary care referral center from 1994 to 2014. The Kaplan-Meier method was used to compare recurrence, cancer-specific mortality (CSM), and overall mortality-free rates in the overall population and in pT0-pT2 and pT3-pT4 patients after stratifying according to the presence of CIS. Multivariable (MVA) Cox regression analyses tested the effect of the presence of CIS on survival outcomes. MVA competing risk analyses were performed to assess the effect of CIS on urothelial recurrence. RESULTS: The presence of CIS was reported in 277 (24.6%) patients. During a median follow-up of 6 years, 355 recurrences, 377 CSM, and 468 overall mortality were reported. At MVA Cox regression analyses, the presence of concomitant CIS was not associated with any survival effect when the overall population was considered (all P>/=0.3). At MVA Cox regression analyses, there was no effect of CIS on survival outcomes in pT3-pT4 patients (all P>0.2); on the contrary, the presence of CIS was associated with worse CSM in pT0-pT2 patients only (hazard ratio [HR] = 1.82; CI: 1.01-3.29; P = 0.04). At MVA competing risk analyses predicting urothelial recurrence only, the presence of CIS was associated to an increased risk of urothelial recurrence in pT0-pT2 patients (HR = 2.99; CI: 1.05-8.53; P = 0.04), pT3-pT4 patients (HR = 10.29; CI: 1.40-75.75; P = 0.02), and in the overall population (HR = 4.47; CI: 1.81-11.07; P = 0.001). CONCLUSION: An increased risk of developing urothelial recurrence only was recorded in patients diagnosed with CIS at RC. Physicians should consider this aspect ensuring a more severe follow-up schemes in patients who harbored this pathological feature. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy; Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: marco.moschini87@gmail.com. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Abufaraj, Mohammad AU - Abufaraj M AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Croce, Giovanni La AU - Croce G AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. FAU - Mattei, Agostino AU - Mattei A AD - Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Damiano, Rocco AU - Damiano R AD - Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20161205 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Carcinoma in Situ/*pathology MH - Cystectomy/*adverse effects MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Node Excision/*adverse effects MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*epidemiology/surgery MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Cancer-specific survival OT - Carcinoma in situ OT - Radical cystectomy OT - Recurrence OT - pTis EDAT- 2016/12/10 06:00 MHDA- 2018/03/13 06:00 CRDT- 2016/12/10 06:00 PHST- 2016/09/28 00:00 [received] PHST- 2016/10/27 00:00 [revised] PHST- 2016/11/04 00:00 [accepted] PHST- 2016/12/10 06:00 [pubmed] PHST- 2018/03/13 06:00 [medline] PHST- 2016/12/10 06:00 [entrez] AID - S1078-1439(16)30369-6 [pii] AID - 10.1016/j.urolonc.2016.11.003 [doi] PST - ppublish SO - Urol Oncol. 2017 Apr;35(4):151.e17-151.e23. doi: 10.1016/j.urolonc.2016.11.003. Epub 2016 Dec 5. PMID- 27913867 OWN - NLM STAT- MEDLINE DCOM- 20170320 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 143 IP - 4 DP - 2017 Apr TI - Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. PG - 677-685 LID - 10.1007/s00432-016-2310-5 [doi] AB - PURPOSE: Urine fluorescence in situ hybridization (FISH) has become a broadly used marker for noninvasive detection of bladder cancer (BC). However, it has been discussed whether the interpretation algorithm proposed by the manufacturer could be improved. Aim of the present study was to compare alternative evaluation strategies of FISH for detection of BC. METHODS: We included 1048 patients suspicious for BC, who underwent urine FISH examination before cystoscopy (diagnostic cohort). Herefrom, we selected 122 patients (prognostic cohort) with a history of non-muscle-invasive BC who were cystoscopically tumor free and received FISH analysis ahead of a follow-up period of 24 months. FISH results were interpreted by the algorithms of UroVysion, Bubendorf et al. and Zellweger et al. RESULTS: In the diagnostic cohort, 228 patients (21.8%) had BC at time of evaluation; in the prognostic cohort 39 patients (32.0%) experienced tumor recurrence. Alterations in chromosome 3, 7 and 17 correlated with the presence of BC. Relative loss of 9p21 was associated with BC and higher risk for progression. The evaluation strategy proposed by Zellweger et al. showed highest accuracy of all FISH assessments. Performance of evaluation strategies differed in voided urine samples and samples obtained after mechanical manipulation. CONCLUSIONS: The performance of FISH in BC diagnosis strongly depends on the interpretation criteria. Alternative evaluation methods partly show superior diagnostic performance compared to the manufacturer's algorithm. The introduction of specific cutoffs for tetraploid cells improves specificity. Further modifications of the interpretation algorithm of the Urovysion((R)) FISH assay have the potential to positively affect the value of this test in diagnosis and surveillance of BC. FAU - Mischinger, Johannes AU - Mischinger J AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Guttenberg, Lutz Philipp AU - Guttenberg LP AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Hennenlotter, Jorg AU - Hennenlotter J AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Aufderklamm, Stefan AU - Aufderklamm S AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Rausch, Steffen AU - Rausch S AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Neumann, Eva AU - Neumann E AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Bedke, Jens AU - Bedke J AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Kruck, Stefan AU - Kruck S AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Schwentner, Christian AU - Schwentner C AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Department of Urology, University Hospital Tuebingen, Eberhard-Karls University, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. tilman.todenhoefer@med.uni-tuebingen.de. LA - eng PT - Comparative Study PT - Journal Article DEP - 20161202 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Chromosome Aberrations MH - Female MH - Humans MH - *In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Urothelium/*cytology MH - Young Adult PMC - PMC11819138 OTO - NOTNLM OT - Bladder cancer OT - Diagnostic and prognostic value OT - FISH OT - Urine marker OT - Urovysion COIS- The authors declare that they have no conflict of interest. EDAT- 2016/12/04 06:00 MHDA- 2017/03/21 06:00 PMCR- 2016/12/02 CRDT- 2016/12/04 06:00 PHST- 2016/09/21 00:00 [received] PHST- 2016/11/01 00:00 [accepted] PHST- 2016/12/04 06:00 [pubmed] PHST- 2017/03/21 06:00 [medline] PHST- 2016/12/04 06:00 [entrez] PHST- 2016/12/02 00:00 [pmc-release] AID - 10.1007/s00432-016-2310-5 [pii] AID - 2310 [pii] AID - 10.1007/s00432-016-2310-5 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2017 Apr;143(4):677-685. doi: 10.1007/s00432-016-2310-5. Epub 2016 Dec 2. PMID- 27908681 OWN - NLM STAT- MEDLINE DCOM- 20180226 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 3 DP - 2017 Mar TI - Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. PG - 113.e9-113.e14 LID - S1078-1439(16)30362-3 [pii] LID - 10.1016/j.urolonc.2016.10.021 [doi] AB - PURPOSE: To evaluate the effect of preoperative anemia (PA) on oncological outcomes in a multicenter cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB) and adjuvant intravesical therapies. We hypothesize that PA represents a marker of disease aggressiveness and could be used to improve the discrimination of prognostic tools for the prediction of disease recurrence and progression. METHODS: This multicenter retrospective study included 1,117 patients from 4 different centers. The presence of PA was assessed according to the World Health Organization classification as a preoperative hemoglobin level of0.05 each). CONCLUSIONS: The number, size and grade of the tumour strongly correlated with recurrence at check cystoscopy. FAU - Farhan, Muhammad AU - Farhan M AD - Section of Urology, Department of Surgery, The Aga Khan University Karachi, Pakistan. FAU - Nazim, Syed Muhammad AU - Nazim SM AD - Section of Urology, Department of Surgery, The Aga Khan University Karachi, Pakistan. FAU - Ahmed, Jibran AU - Ahmed J AD - Section of Urology, Department of Surgery, The Aga Khan University Karachi, Pakistan. FAU - Ather, Muhammad Hammad AU - Ather MH AD - Section of Urology, Department of Surgery, The Aga Khan University Karachi, Pakistan. LA - eng PT - Journal Article PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cross-Sectional Studies MH - *Cystoscopy MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Neoplasm Recurrence, Local MH - Tertiary Care Centers MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Non-muscle invasive bladder cancer, Recurrence, Check cystoscopy, Predictors. EDAT- 2016/11/30 06:00 MHDA- 2018/08/22 06:00 CRDT- 2016/11/30 06:00 PHST- 2016/11/30 06:00 [entrez] PHST- 2016/11/30 06:00 [pubmed] PHST- 2018/08/22 06:00 [medline] PST - ppublish SO - J Pak Med Assoc. 2016 Oct;66(Suppl 3)(10):S125-S130. PMID- 27894979 OWN - NLM STAT- MEDLINE DCOM- 20180416 LR - 20180416 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 102 DP - 2017 Apr TI - Comparison of White Light, Photodynamic Diagnosis, and Narrow-band Imaging in Detection of Carcinoma In Situ or Flat Dysplasia at Transurethral Resection of the Bladder: the DaBlaCa-8 Study. PG - 138-142 LID - S0090-4295(16)30905-0 [pii] LID - 10.1016/j.urology.2016.11.032 [doi] AB - OBJECTIVE: To compare findings in NBI to findings in WL and PDD in a high-risk patient population. MATERIALS AND METHODS: A total of 171 patients were included in the study from 4 different urology departments in Denmark and Norway. Patients were scheduled for a PDD-guided transurethral tumor resection or cystoscopy-guided biopsy in accordance with Danish guidelines, on the suspicion of primary or concomitant CIS. All patients were examined with WL cystoscopy followed by both NBI and PDD before biopsy. RESULTS: A total of 136 patients were biopsied due to findings with suspicion of CIS in at least 1 modality (482 biopsies with a mean of 3.5 biopsies per patient). Analysis at patient level showed that NBI and PDD had a significantly higher sensitivity regarding identification of CIS and dysplasia compared with WL (NBI: 95.7%, PDD: 95.7% vs WL: 65.2%, P < .05). Specificity was not significantly different between the 3 methods (NBI: 52.0%, PDD: 48.0%, and WL: 56.8%). When analyzed per biopsy, NBI and PDD had a significantly higher sensitivity than WL (NBI: 72.7% and PDD: 78.2% vs WL: 52.7%, P < .05), whereas the positive predictive values were not significantly different (NBI: 23.7%, PDD: 22.2%, and WL: 19.0%). CONCLUSION: NBI was found to be a valid alternative to PDD regarding diagnosis of CIS and flat dysplasia. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Drejer, Ditte AU - Drejer D AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Hospital of West Jutland, Holstebro, Denmark. Electronic address: Dittedrejer@dadlnet.dk. FAU - Beji, Sami AU - Beji S AD - Department of Urology, Herlev Hospital, Herlev, Denmark. FAU - Oezeke, Recep AU - Oezeke R AD - Department of Urology, Oslo University Hospital, Oslo, Norway. FAU - Nielsen, Anna Munk AU - Nielsen AM AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark. FAU - Hoyer, Soren AU - Hoyer S AD - Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Bjerklund Johansen, Truls Erik AU - Bjerklund Johansen TE AD - Department of Urology, Oslo University Hospital, Oslo, Norway. FAU - Lam, Gitte W AU - Lam GW AD - Department of Urology, Herlev Hospital, Herlev, Denmark. FAU - Jensen, Jorgen B AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Hospital of West Jutland, Holstebro, Denmark. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20161125 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma in Situ/*diagnostic imaging/*surgery MH - *Cystectomy/methods MH - *Cystoscopy MH - Female MH - Humans MH - *Light MH - Male MH - Middle Aged MH - *Narrow Band Imaging MH - Prospective Studies MH - Urethra MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*diagnostic imaging/*surgery MH - Young Adult EDAT- 2016/11/30 06:00 MHDA- 2018/04/17 06:00 CRDT- 2016/11/30 06:00 PHST- 2016/10/13 00:00 [received] PHST- 2016/11/15 00:00 [revised] PHST- 2016/11/18 00:00 [accepted] PHST- 2016/11/30 06:00 [pubmed] PHST- 2018/04/17 06:00 [medline] PHST- 2016/11/30 06:00 [entrez] AID - S0090-4295(16)30905-0 [pii] AID - 10.1016/j.urology.2016.11.032 [doi] PST - ppublish SO - Urology. 2017 Apr;102:138-142. doi: 10.1016/j.urology.2016.11.032. Epub 2016 Nov 25. PMID- 27894096 OWN - NLM STAT- MEDLINE DCOM- 20180305 LR - 20210227 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 1 DP - 2017 Jan 3 TI - Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. PG - 722-741 LID - 10.18632/oncotarget.13546 [doi] AB - Proteins involved in tumor cell migration can potentially serve as markers of invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes adhesion, while shedding of its extracellular domain is associated with migration. We hypothesized that shed ALCAM in biofluids could be predictive of progressive disease. ALCAM expression in tumor (n = 198) and shedding in biofluids (n = 120) were measured in two separate VUMC bladder cancer cystectomy cohorts by immunofluorescence and enzyme-linked immunosorbent assay, respectively. The primary outcome measure was accuracy of predicting 3-year overall survival (OS) with shed ALCAM compared to standard clinical indicators alone, assessed by multivariable Cox regression and concordance-indices. Validation was performed by internal bootstrap, a cohort from a second institution (n = 64), and treatment of missing data with multiple-imputation. While ALCAM mRNA expression was unchanged, histological detection of ALCAM decreased with increasing stage (P = 0.004). Importantly, urine ALCAM was elevated 17.0-fold (P < 0.0001) above non-cancer controls, correlated positively with tumor stage (P = 0.018), was an independent predictor of OS after adjusting for age, tumor stage, lymph-node status, and hematuria (HR, 1.46; 95% CI, 1.03-2.06; P = 0.002), and improved prediction of OS by 3.3% (concordance-index, 78.5% vs. 75.2%). Urine ALCAM remained an independent predictor of OS after accounting for treatment with Bacillus Calmette-Guerin, carcinoma in situ, lymph-node dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy (HR, 1.10; 95% CI, 1.02-1.19; P = 0.011). In conclusion, shed ALCAM may be a novel prognostic biomarker in bladder cancer, although prospective validation studies are warranted. These findings demonstrate that markers reporting on cell motility can act as prognostic indicators. FAU - Arnold Egloff, Shanna A AU - Arnold Egloff SA AD - Department of Veterans Affairs, Nashville, TN, USA. AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Du, Liping AU - Du L AD - Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Loomans, Holli A AU - Loomans HA AD - Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Starchenko, Alina AU - Starchenko A AD - Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Su, Pei-Fang AU - Su PF AD - Department of Statistics, National Cheng Kung University, Taiwan. FAU - Ketova, Tatiana AU - Ketova T AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Knoll, Paul B AU - Knoll PB AD - Meharry Medical College, Nashville, TN, USA. FAU - Wang, Jifeng AU - Wang J AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. AD - Department of Urology, The Fifth People's Hospital of Shanghai, Shanghai, China. FAU - Haddad, Ahmed Q AU - Haddad AQ AD - Department of Urology, The University of Louisville, Louisville, KY, USA. AD - Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Fadare, Oluwole AU - Fadare O AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. AD - University of California San Diego, La Jolla, CA, USA. FAU - Cates, Justin M AU - Cates JM AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Shyr, Yu AU - Shyr Y AD - Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. AD - Vanderbilt Ingram-Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Clark, Peter E AU - Clark PE AD - Vanderbilt Ingram-Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. AD - Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Zijlstra, Andries AU - Zijlstra A AD - Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. AD - Vanderbilt Ingram-Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. LA - eng GR - S10 OD017985/OD/NIH HHS/United States GR - UL1 TR000445/TR/NCATS NIH HHS/United States GR - U54 CA163069/CA/NCI NIH HHS/United States GR - P01 CA040035/CA/NCI NIH HHS/United States GR - P30 DK079341/DK/NIDDK NIH HHS/United States GR - UL1 TR001105/TR/NCATS NIH HHS/United States GR - K12 CA090625/CA/NCI NIH HHS/United States GR - IK2 BX002498/BX/BLRD VA/United States GR - R01 CA143081/CA/NCI NIH HHS/United States GR - UL1 RR024982/RR/NCRR NIH HHS/United States GR - R01 CA151489/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Activated-Leukocyte Cell Adhesion Molecule) RN - 0 (Biomarkers, Tumor) SB - IM MH - Activated-Leukocyte Cell Adhesion Molecule/genetics/metabolism/*urine MH - Aged MH - *Biomarkers, Tumor MH - Cohort Studies MH - Computational Biology/methods MH - Cystectomy/methods MH - Databases, Genetic MH - Female MH - Gene Expression MH - Gene Expression Profiling MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/genetics/*mortality/surgery/*urine PMC - PMC5352192 OTO - NOTNLM OT - ALCAM OT - bladder cancer OT - metastasis OT - transitional cell carcinoma OT - urothelial cell carcinoma COIS- CONFLICTS OF INTEREST The authors have no current competing interests to disclose. However, Vanderbilt University Medical Center has filed, but has not yet been awarded, a patent on the use of shed ALCAM as a biomarker for a variety of cancers on behalf of Andries Zijlstra, Shanna Arnold, and Amanda Hansen. EDAT- 2016/11/29 06:00 MHDA- 2018/03/06 06:00 PMCR- 2017/01/03 CRDT- 2016/11/29 06:00 PHST- 2016/07/06 00:00 [received] PHST- 2016/10/19 00:00 [accepted] PHST- 2016/11/29 06:00 [pubmed] PHST- 2018/03/06 06:00 [medline] PHST- 2016/11/29 06:00 [entrez] PHST- 2017/01/03 00:00 [pmc-release] AID - 13546 [pii] AID - 10.18632/oncotarget.13546 [doi] PST - ppublish SO - Oncotarget. 2017 Jan 3;8(1):722-741. doi: 10.18632/oncotarget.13546. PMID- 27887951 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20260127 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 197 IP - 5 DP - 2017 May TI - A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. PG - 1208-1213 LID - S0022-5347(16)31801-8 [pii] LID - 10.1016/j.juro.2016.11.094 [doi] AB - PURPOSE: We evaluated differences in clinicopathological characteristics and oncologic outcomes between patients with upper tract urothelial carcinoma in mainland China and the United States. MATERIALS AND METHODS: We retrospectively compiled clinicopathological and oncologic outcomes data on patients with upper tract urothelial carcinoma treated surgically at tertiary care medical facilities in the United States or China from 1998 to 2015. Baseline demographics, comorbidities and pathological features were evaluated. Oncologic end points, including intravesical recurrence and cancer specific survival, were obtained after excluding patients who received systemic chemotherapy. Multivariable Cox regression was performed to determine predictors of adverse oncologic outcomes for each country. RESULTS: A total of 775 patients with upper tract urothelial carcinoma were identified, including 451 in China and 324 in the United States. Median followup was 42 months. American patients were more frequently male (65% vs 44%) and smokers (79% vs 18%), and had a worse mean ASA(R) (American Society of Anesthesiologists(R)) score (2.7 vs 2.2) and prior bladder cancer (41% vs 4%, all p <0.001). Chinese patients more often had preoperative hydronephrosis (56% vs 40%), high grade pathology (98% vs 77%), muscle invasion (64% vs 38%) and nodal metastases (26% vs 6%, all p <0.001). American patients had worse overall survival on Kaplan-Meier analysis (p = 0.049). However, country of origin did not predict local relapse or cancer specific survival. CONCLUSIONS: Patient and disease characteristics of upper tract urothelial carcinoma differed between the Chinese and American cohorts. Chinese patients appeared relatively healthier at presentation but more often exhibited adverse pathological features. While evaluation and management patterns may account for these variations, the pathological findings may reflect a differential underlying pathogenesis of disease. Additional study is warranted to further characterize these differences. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Su, Xiaohong AU - Su X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Bao, Zhengqing AU - Bao Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Cao, Zhenpeng AU - Cao Z AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Jafri, Syed M AU - Jafri SM AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Hutchinson, Ryan AU - Hutchinson R AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Sagalowsky, Arthur AU - Sagalowsky A AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: vitaly.margulis@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20161122 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/complications/*epidemiology/pathology/surgery MH - China/epidemiology MH - Comorbidity MH - Female MH - Humans MH - Hydronephrosis/*epidemiology/etiology MH - Kidney/pathology/surgery MH - Kidney Neoplasms/complications/*epidemiology/pathology/surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology/pathology MH - Nephrectomy MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - United States/epidemiology MH - Ureter/pathology/surgery MH - Ureteral Neoplasms/complications/*epidemiology/pathology/surgery OTO - NOTNLM OT - China OT - United States OT - carcinoma OT - urinary tract OT - urothelium EDAT- 2016/11/27 06:00 MHDA- 2018/12/12 06:00 CRDT- 2016/11/27 06:00 PHST- 2016/11/17 00:00 [accepted] PHST- 2016/11/27 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2016/11/27 06:00 [entrez] AID - S0022-5347(16)31801-8 [pii] AID - 10.1016/j.juro.2016.11.094 [doi] PST - ppublish SO - J Urol. 2017 May;197(5):1208-1213. doi: 10.1016/j.juro.2016.11.094. Epub 2016 Nov 22. PMID- 27882470 OWN - NLM STAT- MEDLINE DCOM- 20180227 LR - 20180227 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 24 IP - 5 DP - 2017 May TI - Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial. PG - 1428-1434 LID - 10.1245/s10434-016-5700-7 [doi] AB - PURPOSE: Our aim was to investigate the detrusor muscle sampling rate after monopolar versus bipolar transurethral resection of bladder tumor (TURBT). METHODS: This was a single-center, prospective, randomized, phase III trial on monopolar versus bipolar TURBT. Baseline patient characteristics, disease characteristics and perioperative outcomes were compared, with the primary outcome being the detrusor muscle sampling rate in the TURBT specimen. Multivariate logistic regression analyses on detrusor muscle sampling were performed. RESULTS: From May 2012 to December 2015, a total of 160 patients with similar baseline characteristics were randomized to receive monopolar or bipolar TURBT. Fewer patients in the bipolar TURBT group required postoperative irrigation than patients in the monopolar TURBT group (18.7 vs. 43%; p = 0.001). In the whole cohort, no significant difference in the detrusor muscle sampling rates was observed between the bipolar and monopolar TURBT groups (77.3 vs. 63.3%; p = 0.057). In patients with urothelial carcinoma, bipolar TURBT achieved a higher detrusor muscle sampling rate than monopolar TURBT (84.6 vs. 67.7%; p = 0.025). On multivariate analyses, bipolar TURBT (odds ratio [OR] 2.23, 95% confidence interval [CI] 1.03-4.81; p = 0.042) and larger tumor size (OR 1.04, 95% CI 1.01-1.08; p = 0.022) were significantly associated with detrusor muscle sampling in the whole cohort. In addition, bipolar TURBT (OR 2.88, 95% CI 1.10-7.53; p = 0.031), larger tumor size (OR 1.05, 95% CI 1.01-1.10; p = 0.035), and female sex (OR 3.25, 95% CI 1.10-9.59; p = 0.033) were significantly associated with detrusor muscle sampling in patients with urothelial carcinoma. CONCLUSIONS: There was a trend towards a superior detrusor muscle sampling rate after bipolar TURBT. Further studies are needed to determine its implications on disease recurrence and progression. FAU - Teoh, Jeremy Yuen-Chun AU - Teoh JY AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Chan, Eddie Shu-Yin AU - Chan ES AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. eddie@surgery.cuhk.edu.hk. AD - S. H. Ho Urology Centre, Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. eddie@surgery.cuhk.edu.hk. FAU - Yip, Siu-Ying AU - Yip SY AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Tam, Ho-Man AU - Tam HM AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Chiu, Peter Ka-Fung AU - Chiu PK AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Yee, Chi-Hang AU - Yee CH AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Wong, Hon-Ming AU - Wong HM AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Chan, Chi-Kwok AU - Chan CK AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Hou, Simon See-Ming AU - Hou SS AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Ng, Chi-Fai AU - Ng CF AD - Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. AD - S. H. Ho Urology Centre, Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. LA - eng PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20161123 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Electrosurgery/adverse effects/instrumentation/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/*pathology/surgery MH - Prospective Studies MH - Sex Factors MH - Tumor Burden MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/pathology/*surgery EDAT- 2016/11/25 06:00 MHDA- 2018/02/28 06:00 CRDT- 2016/11/25 06:00 PHST- 2016/09/12 00:00 [received] PHST- 2016/11/25 06:00 [pubmed] PHST- 2018/02/28 06:00 [medline] PHST- 2016/11/25 06:00 [entrez] AID - 10.1245/s10434-016-5700-7 [pii] AID - 10.1245/s10434-016-5700-7 [doi] PST - ppublish SO - Ann Surg Oncol. 2017 May;24(5):1428-1434. doi: 10.1245/s10434-016-5700-7. Epub 2016 Nov 23. PMID- 27875859 OWN - NLM STAT- MEDLINE DCOM- 20190405 LR - 20220330 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 24 IP - 2 DP - 2017 Feb TI - Clinical significance of preoperative renal function and gross hematuria for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. PG - 111-116 LID - 10.1111/iju.13256 [doi] AB - OBJECTIVES: To investigate the predictive values of perioperative factors and to develop a nomogram for intravesical recurrence after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. METHODS: A retrospective analysis of 144 patients who underwent radical nephroureterectomy from 1996 to 2014 was carried out. The actuarial probabilities of the intravesical recurrence-free survival rate were calculated using the Kaplan-Meier method. Prognostic indicators for intravesical recurrence were identified using competing-risks regression analyses. RESULTS: Intravesical recurrence occurred in 63 patients during the follow-up period. The intravesical recurrence-free survival rates at 1, 3, and 5 years were 65.7%, 50.6% and 47.1%, respectively. In univariate analysis, the presence of gross hematuria (P = 0.028) and the preoperative serum creatinine level (P = 0.033) were significantly associated with intravesical recurrence. In multivariate analysis, the presence of gross hematuria (subdistribution hazard ratio 2.03, 95% CI 1.145-3.496; P = 0.013) and the preoperative serum creatinine level (subdistribution hazard ratio 3.15, 95% CI 1.161-3.534; P = 0.021) were independent predictors for intravesical recurrence after radical nephroureterectomy. Accordingly, a nomogram based on the model was developed. The concordance index of this model was 0.632. CONCLUSION: The presence of gross hematuria and preoperative serum creatinine levels seem to be independent predictors for intravesical recurrence after radical nephroureterectomy. Our nomogram developed based on these factors might aid in appropriate patient selection for clinical trials of novel therapeutic interventions, including administration of intravesical chemotherapy. CI - (c) 2016 The Japanese Urological Association. FAU - Hashimoto, Takeshi AU - Hashimoto T AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Nakashima, Jun AU - Nakashima J AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. AD - Department of Urology, Sanno Hospital, Tokyo, Japan. AD - Clinical Medicine Research Center, International University of Health and Welfare, Tokyo, Japan. FAU - Kashima, Takeshi AU - Kashima T AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Hirasawa, Yosuke AU - Hirasawa Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Shimodaira, Kenji AU - Shimodaira K AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Gondo, Tatsuo AU - Gondo T AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Nakagami, Yoshihiro AU - Nakagami Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Namiki, Kazunori AU - Namiki K AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Horiguchi, Yutaka AU - Horiguchi Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohno, Yoshio AU - Ohno Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohori, Makoto AU - Ohori M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Tachibana, Masaaki AU - Tachibana M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20161122 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - AYI8EX34EU (Creatinine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/blood/*pathology/surgery/urine MH - Creatinine/*blood MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Hematuria/diagnosis/*epidemiology/urine MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis/epidemiology/prevention & control MH - Nephroureterectomy MH - Nomograms MH - Predictive Value of Tests MH - Preoperative Period MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder/diagnostic imaging/*pathology MH - Urologic Neoplasms/blood/*pathology/surgery/urine OTO - NOTNLM OT - gross hematuria OT - intravesical recurrence OT - radical nephroureterectomy OT - serum creatinine level OT - upper tract urothelial carcinoma EDAT- 2016/11/23 06:00 MHDA- 2019/04/06 06:00 CRDT- 2016/11/23 06:00 PHST- 2016/05/26 00:00 [received] PHST- 2016/10/17 00:00 [accepted] PHST- 2016/11/23 06:00 [pubmed] PHST- 2019/04/06 06:00 [medline] PHST- 2016/11/23 06:00 [entrez] AID - 10.1111/iju.13256 [doi] PST - ppublish SO - Int J Urol. 2017 Feb;24(2):111-116. doi: 10.1111/iju.13256. Epub 2016 Nov 22. PMID- 27870887 OWN - NLM STAT- MEDLINE DCOM- 20170626 LR - 20181202 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 11 DP - 2016 TI - Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy. PG - e0166884 LID - 10.1371/journal.pone.0166884 [doi] LID - e0166884 AB - BACKGROUND: To date, prophylactic intravesical chemotherapy after radical nephroureterectomy is one of the few available treatments that effectively prevent secondary bladder cancer. However, treating all patients with prophylactic intravesical chemotherapy is excessive for patients who are at a low risk or insensitive to the treatment. Thus, to guide individualized clinical treatment, in addition to identifying patients who are at risk of bladder cancer recurrence, it is equally necessary to identify the patients who will benefit the most from prophylactic, postoperative intravesical instillation therapy. METHODS: Epidermal growth factor receptor (EGFR) and Ki-67 expression levels were measured using immunohistochemical staining samples from 320 patients with upper urinary tract urothelial carcinoma (UTUC) from 2004 to 2012. Although no patients received intravesical chemotherapy after RNU before 2008, this method began to be used in 2008 to prevent bladder cancer recurrence. To identify the patients who would most benefit from intravesical chemotherapy, we assessed biological interactions between intravesical chemotherapy and clinicopathological factors or biomarkers. RESULTS: The incidence rates of bladder UTUC recurrence decreased after intravesical chemotherapy, and the decrease was greater in patients with low Ki-67 levels, negative EGFR staining and preoperative positive urine cytology. Biological interactions were observed between intravesical chemotherapy, low-level Ki-67 and EGFR negativity. The multivariate analysis showed that after balancing a variety of factors, intravesical chemotherapy is a protective factor for preventing intravesical recurrence in the negative EGFR, low-level Ki-67 and preoperative positive urine cytology sub-groups but not in their corresponding sub-groups. Additionally, the multivariate analysis revealed that preoperative positive urine cytology and Ki-67 were not but that EGFR positivity was an independent risk factor for recurrence after intravesical chemotherapy. CONCLUSIONS: Patients with low Ki-67 levels, negative EGFR staining and preoperative positive urine cytology appear to be more sensitive to intravesical instillations for bladder recurrence prevention after RNU. FAU - Long, Xingbo AU - Long X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Zu, Xiongbing AU - Zu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Li, Yuan AU - Li Y AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - He, Wei AU - He W AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Hu, Xiheng AU - Hu X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Tong, Shiyu AU - Tong S AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Wang, Zhi AU - Wang Z AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Chen, Minfeng AU - Chen M AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Qi, Lin AU - Qi L AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China. LA - eng PT - Journal Article PT - Observational Study DEP - 20161121 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Administration, Intravesical MH - Aged MH - Antineoplastic Agents/*administration & dosage/therapeutic use MH - Biomarkers, Tumor/metabolism MH - ErbB Receptors/*metabolism MH - Female MH - Humans MH - Incidence MH - Ki-67 Antigen/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/epidemiology/*prevention & control MH - Nephrectomy MH - Precision Medicine MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*surgery PMC - PMC5117727 COIS- The authors have declared that no competing interests exist. EDAT- 2016/11/22 06:00 MHDA- 2017/06/27 06:00 PMCR- 2016/11/21 CRDT- 2016/11/22 06:00 PHST- 2016/06/23 00:00 [received] PHST- 2016/11/04 00:00 [accepted] PHST- 2016/11/22 06:00 [entrez] PHST- 2016/11/22 06:00 [pubmed] PHST- 2017/06/27 06:00 [medline] PHST- 2016/11/21 00:00 [pmc-release] AID - PONE-D-16-24632 [pii] AID - 10.1371/journal.pone.0166884 [doi] PST - epublish SO - PLoS One. 2016 Nov 21;11(11):e0166884. doi: 10.1371/journal.pone.0166884. eCollection 2016. PMID- 27858162 OWN - NLM STAT- MEDLINE DCOM- 20170217 LR - 20250719 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 143 IP - 3 DP - 2017 Mar TI - Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. PG - 521-532 LID - 10.1007/s00432-016-2301-6 [doi] AB - PURPOSE: Despite recent research advantages on the molecular and subcellular background, bladder cancer (BlCa) remains a clinically neglected malignancy. This is strongly reflected by the generic approach of disease diagnosis and management. Additionally, patients' prognosis became a rather demanding task due to the great disease heterogeneity. Here, we aimed to evaluate, for the first time, the clinical value of KLK13 in BlCa. METHODS: A total of 279 bladder specimens (137 tumors, 107 adjacent normal tissues and 35 healthy samples) were included. Total RNA was extracted, reverse transcribed, and KLK13 expression was assessed by quantitative real-time PCR. RESULTS: KLK13 expression is significantly increased in bladder tumors compared to normal adjacent epithelium. However, reduced KLK13 expression is correlated with disease aggressiveness, including higher tumor stage and grade, and high-risk TaT1 tumors according to the EORTC stratification. Moreover, Kaplan-Meier and Cox regression analysis highlighted the prognostic value of the reduced KLK13 expression for the prediction of TaT1 patients' recurrence and shorter disease-free survival following TURBT. Finally, the combination of KLK13 expression with EORTC-risk stratification results to an improved prediction of TaT1 patients' outcome. CONCLUSION: This first clinical study of KLK13 in BlCa reveals its deregulated expression in bladder tumors and highlights KLK13 as a promising marker for improving TaT1 patients' prognosis following treatment. FAU - Tokas, Theodoros AU - Tokas T AD - First Department of Urology, "Laiko" General Hospital, Medical School, University of Athens, Agiou Thoma 17, 11527, Athens, Greece. ttokas@yahoo.com. AD - Department of Urology and Andrology, General Hospital Hall in Tirol, Milser Str. 10, 6060, Hall in Tirol, Austria. ttokas@yahoo.com. FAU - Avgeris, Margaritis AU - Avgeris M AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701, Athens, Greece. FAU - Alamanis, Christos AU - Alamanis C AD - First Department of Urology, "Laiko" General Hospital, Medical School, University of Athens, Agiou Thoma 17, 11527, Athens, Greece. FAU - Scorilas, Andreas AU - Scorilas A AD - Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701, Athens, Greece. FAU - Stravodimos, Konstantinos G AU - Stravodimos KG AD - First Department of Urology, "Laiko" General Hospital, Medical School, University of Athens, Agiou Thoma 17, 11527, Athens, Greece. FAU - Constantinides, Constantinos A AU - Constantinides CA AD - First Department of Urology, "Laiko" General Hospital, Medical School, University of Athens, Agiou Thoma 17, 11527, Athens, Greece. LA - eng PT - Journal Article DEP - 20161117 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) RN - EC 3.4.21.- (KLK13 protein, human) RN - EC 3.4.21.- (Kallikreins) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/biosynthesis/genetics MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kallikreins/*biosynthesis/genetics MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*genetics/pathology MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Neoplasm Staging MH - *Prognosis MH - RNA, Messenger/biosynthesis MH - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology PMC - PMC11819349 OTO - NOTNLM OT - Bladder tumors OT - KLK OT - KLKs OT - Kallikrein 13 OT - Kallikrein-related peptidase 13 OT - Kallikrein-related peptidases COIS- All authors declare that they have no conflict of interest. EDAT- 2016/11/20 06:00 MHDA- 2017/02/18 06:00 PMCR- 2016/11/17 CRDT- 2016/11/19 06:00 PHST- 2016/07/29 00:00 [received] PHST- 2016/11/05 00:00 [accepted] PHST- 2016/11/20 06:00 [pubmed] PHST- 2017/02/18 06:00 [medline] PHST- 2016/11/19 06:00 [entrez] PHST- 2016/11/17 00:00 [pmc-release] AID - 10.1007/s00432-016-2301-6 [pii] AID - 2301 [pii] AID - 10.1007/s00432-016-2301-6 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2017 Mar;143(3):521-532. doi: 10.1007/s00432-016-2301-6. Epub 2016 Nov 17. PMID- 27842318 OWN - NLM STAT- MEDLINE DCOM- 20171026 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 98 IP - 3 DP - 2017 TI - Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed. PG - 312-319 LID - 10.1159/000451004 [doi] AB - OBJECTIVE: To evaluate the efficacies of different chemotherapy regimens in different risk sub-groups for the prevention of bladder recurrence after radical nephroureterectomy (RNU). MATERIALS AND METHODS: Between 2004 and 2012, we recruited 685 patients who underwent RNU for upper tract urothelial carcinoma at 4 Chinese institutions. We assessed whether the type of intravesical chemotherapy regimen affected the bladder recurrence rate in patients with different risk levels after RNU. RESULTS: For all patients, the bladder recurrence rate was lower with intravesical chemotherapy than without, but no significant differences were found between the 2 intravesical chemotherapy regimens (single dose or relatively long-term therapy). We used multivariate analysis to define the risk factors for bladder recurrence and stratified patients into low-, intermediate-, and high-risk sub-groups accordingly. The bladder recurrence rate in the low-risk patients was not significantly different between patients with or without intravesical chemotherapy. However, in the intermediate-risk and high-risk patients, the rate was greater in patients without intravesical chemotherapy than in patients with. Furthermore, the rate was not significantly different between the 2 intravesical chemotherapy regimens in the intermediate-risk patients, while the efficacy of the relatively long-term regimen in high-risk patients remains unclear. CONCLUSIONS: Our study showed that an individualized strategy based on patient risk stratification is needed. CI - (c) 2016 S. Karger AG, Basel. FAU - Long, Xingbo AU - Long X AD - Department of Urology, Xiangya Hospital, Central South University, Changsha, China. FAU - Qi, Lin AU - Qi L FAU - Zu, Xiongbing AU - Zu X FAU - Li, Yuan AU - Li Y FAU - He, Wei AU - He W FAU - Pi, Shuohuang AU - Pi S FAU - Chen, Xiang AU - Chen X FAU - Zhou, Kebing AU - Zhou K FAU - Hu, Xiheng AU - Hu X FAU - Chen, Minfeng AU - Chen M LA - eng PT - Journal Article PT - Multicenter Study DEP - 20161115 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Carcinoma/*surgery MH - Carcinoma, Transitional Cell/pathology/surgery MH - China MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*prevention & control/*surgery MH - Risk MH - Ureter/surgery MH - Ureteral Neoplasms/pathology/surgery MH - Urinary Bladder Neoplasms/*surgery MH - Urologic Neoplasms/*surgery MH - Urologic Surgical Procedures/*methods MH - Urothelium/pathology EDAT- 2016/11/15 06:00 MHDA- 2017/10/27 06:00 CRDT- 2016/11/15 06:00 PHST- 2016/06/02 00:00 [received] PHST- 2016/09/22 00:00 [accepted] PHST- 2016/11/15 06:00 [pubmed] PHST- 2017/10/27 06:00 [medline] PHST- 2016/11/15 06:00 [entrez] AID - 000451004 [pii] AID - 10.1159/000451004 [doi] PST - ppublish SO - Urol Int. 2017;98(3):312-319. doi: 10.1159/000451004. Epub 2016 Nov 15. PMID- 27836246 OWN - NLM STAT- MEDLINE DCOM- 20180112 LR - 20240610 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 34 IP - 12 DP - 2016 Dec TI - Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. PG - 556-565 LID - S1078-1439(16)30313-1 [pii] LID - 10.1016/j.urolonc.2016.10.006 [doi] AB - Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette-Guerin was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and patients with bladder cancer finally have new active immunotherapeutic drugs on the horizon. Anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) therapy has shown impressively durable responses in urothelial bladder cancer (UBC), but the reported response rates warrant improvement. To outline potential strategies to overcome tumor immune resistance, herein, we summarize current models of tumor immunology with a specific focus on bladder cancer. Recognition of tumor-specific antigens through cross-presentation, T-cell priming and activation, and trafficking of immune cells to the tumor microenvironment are some of the critical steps we now understand to be necessary for an effective antitumor immune response. Many of the involved steps are important targets for therapeutic interventions. As new immunotherapies are developed, predictive biomarkers would also be important to select patients most likely to respond and to better understand tumor biology. Several potential biomarkers are reviewed including PD-L1 expression, identification of T-cell-inflamed/non-T-cell-inflamed tumors based on immune gene expression, intrinsic molecular subtyping based on luminal/basal or the cancer genome atlas (TCGA) groups, T-cell receptor sequencing, and somatic mutational density. Even within the past few years, our current knowledge of immune biology has exploded, and we are highly optimistic about the future of UBC therapy that will be available to patients. CI - Copyright A(c) 2016 Elsevier Inc. All rights reserved. FAU - Sweis, Randy F AU - Sweis RF AD - Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. FAU - Galsky, Matthew D AU - Galsky MD AD - Division of Hematology & Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: matthew.galsky@mssm.edu. LA - eng GR - T32 CA009566/CA/NCI NIH HHS/United States GR - T32 GM007019/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Review DEP - 20161109 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antigens, Neoplasm) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (Costimulatory and Inhibitory T-Cell Receptors) RN - 0 (Neoplasm Proteins) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Receptors, Antigen, T-Cell) RN - 52CMI0WC3Y (atezolizumab) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized MH - Antigen-Presenting Cells/immunology MH - Antigens, Neoplasm/*immunology MH - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use MH - B7-H1 Antigen/antagonists & inhibitors/*immunology MH - Carcinoma, Transitional Cell/chemistry/drug therapy/immunology/*therapy MH - Clinical Trials as Topic MH - Costimulatory and Inhibitory T-Cell Receptors/immunology MH - Humans MH - *Immunotherapy MH - Lymphocyte Activation MH - Lymphocytes, Tumor-Infiltrating/immunology MH - *Molecular Targeted Therapy MH - Mutation MH - Neoplasm Proteins/antagonists & inhibitors/immunology MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/*immunology MH - Receptors, Antigen, T-Cell/immunology MH - T-Lymphocytes, Cytotoxic/immunology MH - Therapies, Investigational MH - Tumor Escape/immunology MH - Tumor Microenvironment/immunology MH - Urinary Bladder Neoplasms/chemistry/drug therapy/immunology/*therapy PMC - PMC5709811 MID - NIHMS920288 OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Immune checkpoint therapy OT - Immunology OT - Urothelial cancer COIS- All authors report no conflicts of interest to disclose. EDAT- 2016/11/12 06:00 MHDA- 2018/01/13 06:00 PMCR- 2017/12/01 CRDT- 2016/11/13 06:00 PHST- 2016/05/02 00:00 [received] PHST- 2016/09/21 00:00 [revised] PHST- 2016/10/05 00:00 [accepted] PHST- 2016/11/12 06:00 [pubmed] PHST- 2018/01/13 06:00 [medline] PHST- 2016/11/13 06:00 [entrez] PHST- 2017/12/01 00:00 [pmc-release] AID - S1078-1439(16)30313-1 [pii] AID - 10.1016/j.urolonc.2016.10.006 [doi] PST - ppublish SO - Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. PMID- 27828864 OWN - NLM STAT- MEDLINE DCOM- 20170224 LR - 20210109 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 95 IP - 45 DP - 2016 Nov TI - Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis. PG - e5372 LID - 10.1097/MD.0000000000005372 [doi] LID - e5372 AB - BACKGROUND: The aim of this meta-analysis was to compare the feasibility of en bloc transurethral resection of bladder tumor (ETURBT) versus conventional transurethral resection of bladder tumor (CTURBT). METHODS: Relevant trials were identified in a literature search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and Google Scholar using appropriate search terms. All comparative studies reporting participant demographics, tumor characteristics, study characteristics, and outcome data were included. RESULTS: Seven trials with 886 participants were included, 438 underwent ETURBT and 448 underwent CTURBT. There was no significant difference in operation time between 2 groups (P = 0.38). The hospitalization time (HT) and catheterization time (CT) were shorter in ETURBT group (mean difference[MD] -1.22, 95% confidence interval [CI] -1.63 to -0.80, P < 0.01; MD -0.61, 95% CI -1.11 to -0.11, P < 0.01). There was significant difference in 24-month recurrence rate (24-month RR) (odds ratio [OR] 0.66, 95% CI 0.47-0.92, P = 0.02). The rate of complication with respect to bladder perforation (P = 0.004), bladder irritation (P < 0.01), and obturator nerve reflex (P < 0.01) was lower in ETURBT. The postoperative adjuvant intravesical chemotherapy was evaluated by subgroup analysis, and 24-month RR in CTURBT is higher than that in ETURBT in mitomycin intravesical irrigation group (P = 0.02). CONCLUSION: The first meta-analysis indicates that ETURBT might prove to be preferable alternative to CTURBT management of nonmuscle invasive bladder carcinoma. ETURBT is associated with shorter HT and CT, less complication rate, and lower recurrence-free rate. Moreover, it can provide high-qualified specimen for the pathologic diagnosis. Well designed randomized controlled trials are needed to make results comparable. FAU - Wu, Yu-Peng AU - Wu YP AD - Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. FAU - Lin, Ting-Ting AU - Lin TT FAU - Chen, Shao-Hao AU - Chen SH FAU - Xu, Ning AU - Xu N FAU - Wei, Yong AU - Wei Y FAU - Huang, Jin-Bei AU - Huang JB FAU - Sun, Xiong-Lin AU - Sun XL FAU - Zheng, Qing-Shui AU - Zheng QS FAU - Xue, Xue-Yi AU - Xue XY FAU - Li, Xiao-Dong AU - Li XD LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Cystectomy/*methods MH - Feasibility Studies MH - Humans MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*surgery PMC - PMC5106070 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2016/11/10 06:00 MHDA- 2017/02/25 06:00 PMCR- 2016/11/11 CRDT- 2016/11/10 06:00 PHST- 2016/11/10 06:00 [entrez] PHST- 2016/11/10 06:00 [pubmed] PHST- 2017/02/25 06:00 [medline] PHST- 2016/11/11 00:00 [pmc-release] AID - 00005792-201611080-00026 [pii] AID - 10.1097/MD.0000000000005372 [doi] PST - ppublish SO - Medicine (Baltimore). 2016 Nov;95(45):e5372. doi: 10.1097/MD.0000000000005372. PMID- 27823975 OWN - NLM STAT- MEDLINE DCOM- 20171010 LR - 20250623 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 14 DP - 2017 Apr 4 TI - Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. PG - 23880-23890 LID - 10.18632/oncotarget.13054 [doi] AB - CONTEXT: Compared with white light imaging (WLI) cystoscopy, narrow band imaging (NBI) cystoscopy could increase the visualization and detection of bladder cancer (BC) at the time of transurethral resection (TUR). NBI cystoscopy could increase the detection of BC, but it remains unclear whether narrow band imaging-assisted transurethral resection (NBI-TUR) could reduce the recurrence risk of non-muscle invasive bladder cancer (NMIBC). Several randomized clinical trials (RCTs) have recently tested the efficacy of NBI-TUR for NMIBC. OBJECTIVE: To perform a systematic review and meta-analysis of RCTs and evaluate the efficacy of NBI-TUR for NMIBC compared with white light imaging-assisted transurethral resection (WLI-TUR). The end point was recurrence risk. EVIDENCE ACQUISITION: A systematic review of PubMed, Medline, Ovid, Embase, Cochrane and Web of Science was performed in February 2016 and updated in July 2016. EVIDENCE SYNTHESIS: Overall, six (n = 1084) of 278 trials were included. Three trials performed narrow band imaging-assisted electro-transurethral resection (NBI-ETUR), and two trials performed narrow band imaging-associated bipolar plasma vaporization (NBI-BPV). The last trial performed narrow band imaging-associated holmium laser resection (NBI-HLR). Statistical analysis was performed using Review Manager software (RevMan v.5.3; The Nordic Cochrane Center, Copenhagen, Denmark). The recurrence risk was compared by calculating risk ratios (RRs) with 95% confidence interval (CIs). Risk ratios with 95% CIs were calculated to compare 3-mo, 1-yr, and 2-yr survival rates. NBI-TUR was associated with improvements in the 3-mo recurrence risk (RR: 0.39; 95% CI, 0.26-0.60; p < 0.0001), 1-yr recurrence risk (RR: 0.52; 95% CI, 0.40-0.67; p < 0.00001) and 2-yr recurrence risk (RR: 0.60; 95% CI, 0.42-0.85; p = 0.004) compared with WLI-TUR. CONCLUSIONS: Compared with WLI-TUR, NBI-TUR can reduce the recurrence risk of NMIBC. The results of this review will facilitate the appropriate application of NBI in NMIBC. FAU - Kang, Weiting AU - Kang W AD - Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. AD - School of Medicine, Shandong University, Jinan, Shandong, China. FAU - Cui, Zilian AU - Cui Z AD - Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. AD - School of Medicine, Shandong University, Jinan, Shandong, China. FAU - Chen, Qianqian AU - Chen Q AD - Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. AD - School of Medicine, Shandong University, Jinan, Shandong, China. FAU - Zhang, Dong AU - Zhang D AD - Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. FAU - Zhang, Haiyang AU - Zhang H AD - Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. FAU - Jin, Xunbo AU - Jin X AD - Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 SB - IM MH - Data Collection MH - Humans MH - Neoplasm Recurrence, Local/*prevention & control MH - Risk Factors MH - Urinary Bladder Neoplasms/diagnostic imaging/*surgery PMC - PMC5410352 OTO - NOTNLM OT - narrow band imaging OT - non-muscle invasive bladder cancer OT - recurrence risk OT - resection OT - white light imaging COIS- CONFLICTS OF INTEREST The authors report no declarations of interest. EDAT- 2016/11/09 06:00 MHDA- 2017/10/11 06:00 PMCR- 2017/04/04 CRDT- 2016/11/09 06:00 PHST- 2016/08/27 00:00 [received] PHST- 2016/10/27 00:00 [accepted] PHST- 2016/11/09 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2016/11/09 06:00 [entrez] PHST- 2017/04/04 00:00 [pmc-release] AID - 13054 [pii] AID - 10.18632/oncotarget.13054 [doi] PST - ppublish SO - Oncotarget. 2017 Apr 4;8(14):23880-23890. doi: 10.18632/oncotarget.13054. PMID- 27818773 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2051-4158 (Print) IS - 2051-4166 (Electronic) IS - 2051-4158 (Linking) VI - 9 IP - 6 DP - 2016 Nov TI - Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy. PG - 404-408 AB - PURPOSE: Biopsy of the prostatic urethra is an integral part of clinical staging in patients prior to radical cystoprostatectomy (RC) and urinary diversion. We examined whether preoperative transurethral resection (TUR) biopsy was associated with final apical urethral margin status and hypothesized that a negative biopsy could replace intraoperative frozen section for decision making regarding the feasibility of orthotopic neobladder reconstruction. METHODS: TUR biopsy, frozen section, urethrectomy, and final apical urethral margin pathologic data were extracted from the charts of men who had undergone RC at the Houston Methodist Hospital between 1987 and 2013. TUR biopsies were performed at five and seven o'clock adjacent to the verumontanum. A positive biopsy was defined as the presence of in situ or invasive urothelial carcinoma. Clinical and perioperative variables were analyzed using descriptive and inferential statistics. RESULTS: We reviewed the medical records of 272 men. Preoperative TUR biopsies of the prostatic urethra were negative in 74% (200/272) and positive in 26% (72/272) of men. The overall incidence of apical urethral margin positivity on final pathology was 2.2% (six of 272). Four men underwent primary or secondary urethrectomy. TUR biopsy negative and positive predictive values for apical urethral margin positivity were 99.5% (95% confidence interval (CI): 97.2 to 99.9) and 6.9% (95% CI: 2.3 to 15.5), respectively. CONCLUSIONS: The incidence of a positive apical urethral margin was low in patients undergoing RC. A negative preoperative TUR biopsy of the prostatic urethra was reliably associated with a negative final margin, obviating the need for intraoperative frozen section. Furthermore, a positive biopsy was not reliably associated with final margin status. These data will aid in the counseling of patients regarding the feasibility of neobladder reconstruction. FAU - von Rundstedt, Friedrich-Carl AU - von Rundstedt FC AD - Department of Urology, Helios Medical Center, Witten/Herdecke University, Germany and Scott Department of Urology, Baylor College of Medicine, USA. FAU - Mata, Douglas A AU - Mata DA AD - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, USA. FAU - Shen, Steven AU - Shen S AD - Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Cornell Medical College, USA. FAU - Li, Yi AU - Li Y AD - Scott Department of Urology and Dan L. Duncan Cancer Center, Baylor College of Medicine, USA. FAU - Godoy, Guilherme AU - Godoy G AD - Scott Department of Urology and Dan L. Duncan Cancer Center, Baylor College of Medicine, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology and Dan L. Duncan Cancer Center, Baylor College of Medicine, USA. LA - eng GR - K23 CA160664/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20161102 PL - England TA - J Clin Urol JT - Journal of clinical urology JID - 101619599 PMC - PMC5096792 MID - NIHMS748152 OTO - NOTNLM OT - Cystectomy OT - carcinoma in situ OT - prostate OT - transurethral biopsy OT - urothelial cancer COIS- Conflicting interests The Authors declare that there is no conflict of interest. EDAT- 2016/11/08 06:00 MHDA- 2016/11/08 06:01 PMCR- 2016/11/04 CRDT- 2016/11/08 06:00 PHST- 2016/11/08 06:00 [entrez] PHST- 2016/11/08 06:00 [pubmed] PHST- 2016/11/08 06:01 [medline] PHST- 2016/11/04 00:00 [pmc-release] AID - 10.1177/2051415815617876 [doi] PST - ppublish SO - J Clin Urol. 2016 Nov;9(6):404-408. doi: 10.1177/2051415815617876. Epub 2016 Nov 2. PMID- 27816403 OWN - NLM STAT- MEDLINE DCOM- 20180228 LR - 20220408 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 1 DP - 2017 Jan TI - A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. PG - 14-20 LID - S1078-1439(16)30309-X [pii] LID - 10.1016/j.urolonc.2016.10.004 [doi] AB - PURPOSE: Recent observations have focused attention on the means that human tumors employ to evade host defense systems critical to immune surveillance. The concepts of immunotherapy are familiar to urologists because of the use of bacillus Calmette-Guerin in bladder cancer. Research demonstrating the importance of checkpoint inhibitors in suppressing immune responses against tumors has heightened interest in immunotherapy at a time when there is a need for alternatives to bacillus Calmette-Guerin. We review the literature on the application of immunotherapeutic agents targeting a key checkpoint pathway, programmed death 1 (PD-1) and its ligand (PD-L1), in the field of bladder cancer. MATERIALS AND METHODS: A comprehensive literature review was performed using Medline/Pubmed and Embase. RESULTS: The PD-1/PD-L1 pathway may be manipulated by cancer cells to subvert the immune system. PD-1/PD-L1 blockade has been tested in clinical trials for various malignancies including metastatic urothelial carcinoma, with significant response rates and limited side effects. PD-L1 expression has also been proposed as a prognostic marker for bladder cancer with mixed results. CONCLUSIONS: PD-1 is one of several key receptors mediating immune escape, and agents targeting its ligand PD-L1 have already been successfully applied to patients with metastatic urothelial cancer. More research is needed to standardize criteria for PD-L1 positivity, explore its use as a biomarker, and optimize its use in the treatment for bladder cancer. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Zhou, Tian C AU - Zhou TC AD - Department of Urology, Montefiore Medical Center, Bronx, NY. Electronic address: tianc.zhou@gmail.com. FAU - Sankin, Alexander I AU - Sankin AI AD - Department of Urology, Montefiore Medical Center, Bronx, NY. FAU - Porcelli, Steven A AU - Porcelli SA AD - Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY. FAU - Perlin, David S AU - Perlin DS AD - Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ. FAU - Schoenberg, Mark P AU - Schoenberg MP AD - Department of Urology, Montefiore Medical Center, Bronx, NY. FAU - Zang, Xingxing AU - Zang X AD - Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY. LA - eng PT - Journal Article PT - Review DEP - 20161103 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (B7-H1 Antigen) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (CD274 protein, human) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) RN - 52CMI0WC3Y (atezolizumab) RN - DPT0O3T46P (pembrolizumab) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use MH - B7-H1 Antigen/*antagonists & inhibitors/metabolism MH - BCG Vaccine/therapeutic use MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/*drug therapy/immunology MH - Humans MH - Immunotherapy/*methods MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors MH - Tumor Escape MH - Urinary Bladder Neoplasms/*drug therapy/immunology OTO - NOTNLM OT - BCG failure OT - Biomarker OT - Bladder cancer OT - Immunotherapy OT - PD-1 OT - PD-L1 EDAT- 2016/11/07 06:00 MHDA- 2018/03/01 06:00 CRDT- 2016/11/07 06:00 PHST- 2016/07/27 00:00 [received] PHST- 2016/09/07 00:00 [revised] PHST- 2016/10/04 00:00 [accepted] PHST- 2016/11/07 06:00 [pubmed] PHST- 2018/03/01 06:00 [medline] PHST- 2016/11/07 06:00 [entrez] AID - S1078-1439(16)30309-X [pii] AID - 10.1016/j.urolonc.2016.10.004 [doi] PST - ppublish SO - Urol Oncol. 2017 Jan;35(1):14-20. doi: 10.1016/j.urolonc.2016.10.004. Epub 2016 Nov 3. PMID- 27814472 OWN - NLM STAT- MEDLINE DCOM- 20170731 LR - 20260127 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 69 DP - 2016 Dec TI - Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. PG - 9-18 LID - S0959-8049(16)32452-2 [pii] LID - 10.1016/j.ejca.2016.09.021 [doi] AB - BACKGROUND: In Belgium, bladder cancer (BC) is the fifth most common cancer in men. The per-patient lifetime cost is high. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of BC. We therefore hypothesised that selenium may be suitable for chemoprevention of recurrence of BC. METHOD: The Selenium and Bladder Cancer Trial (SELEBLAT) was an academic phase III placebo-controlled, double-blind, randomised clinical trial designed to determine the effect of selenium on recurrence of non-invasive urothelial carcinoma conducted in 14 Belgian hospitals. Patients were randomly assigned by a computer program to oral selenium yeast 200 mug once a day or placebo for three years, in addition to standard care. All study personnel and participants were blinded to treatment assignment for the duration of the study. All randomised patients were included in the intention to treat (ITT) and safety analyses. Per protocol analyses (PPAs) included all patients in the study three months after start date. RESULTS: Between September 18, 2009 and April 18, 2013, 151 and 141 patients were randomised in the selenium and placebo group. Patients were followed until December 31, 2015. The ITT analysis resulted in 43 (28%; 95% CI, 0.21-0.35) and 45 (32%; 95% CI, 0.24-0.40) recurrences in the selenium and placebo group. The hazard ratio (HR) was 0.85 (95% CI, 0.56-1.29; p = 0.44) while the HR for the PPA resulted in 42 and 39 (28%; 95% CI, 0.20-0.35) recurrences in the selenium and placebo group (HR = 0.96 [95% CI, 0.62-1.48]; p = 0.93). CONCLUSION: Selenium supplementation does not lower the probability of recurrence in BC patients. CI - Copyright A(c) 2016 Elsevier Ltd. All rights reserved. FAU - Goossens, Maria E AU - Goossens ME AD - Department of General Practice, University of Leuven, ACHG-KU Leuven, Kapucijnenvoer 33, Blok J, Bus 7001, 3000, Leuven, Belgium. Electronic address: Mieke.Goossens@kuleuven.be. FAU - Zeegers, Maurice P AU - Zeegers MP AD - University of Maastricht, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands; CAPHRI School for Public Health and Primary Care, University of Maastricht, The Netherlands; School of Cancer Sciences, University of Birmingham, Birmingham, UK. FAU - van Poppel, Hendrik AU - van Poppel H AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Joniau, Steven AU - Joniau S AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Ackaert, Koen AU - Ackaert K AD - Department of Urology, Sint-Elisabethziekenhuis, Turnhout, Belgium. FAU - Ameye, Filip AU - Ameye F AD - Department of Urology, AZ Maria Middelares, Gent, Belgium. FAU - Billiet, Ignace AU - Billiet I AD - Department of Urology, AZ Groeninge, Kortrijk, Belgium. FAU - Braeckman, Johan AU - Braeckman J AD - Department of Urology, UZ Brussel, Brussel, Belgium. FAU - Breugelmans, Alex AU - Breugelmans A AD - Department of Urology, Heilig Hart ziekenhuis, Leuven, Belgium. FAU - Darras, Jochen AU - Darras J AD - Department of Urology, AZ Damiaan, Oostende, Belgium. FAU - Dilen, Kurt AU - Dilen K AD - Department of Urology, Jessa ziekenhuis, Hasselt, Belgium. FAU - Goeman, Lieven AU - Goeman L AD - Department of Urology, Heilig Hartziekenhuis, Roeselaere, Belgium. FAU - Tombal, Bertrand AU - Tombal B AD - Department of Urology, Cliniques universitaires Saint-Luc, Brussel, Belgium. FAU - Van Bruwaene, Siska AU - Van Bruwaene S AD - Department of Urology, AZ Groeninge, Kortrijk, Belgium. FAU - Van Cleyenbreugel, Ben AU - Van Cleyenbreugel B AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Van der Aa, Frank AU - Van der Aa F AD - Department of Urology, UZ Leuven, Leuven, Belgium. FAU - Vekemans, Kris AU - Vekemans K AD - Department of Urology, Jessa ziekenhuis, Hasselt, Belgium. FAU - Buntinx, Frank AU - Buntinx F AD - Department of General Practice, University of Leuven, ACHG-KU Leuven, Kapucijnenvoer 33, Blok J, Bus 7001, 3000, Leuven, Belgium; CAPHRI School for Public Health and Primary Care, University of Maastricht, The Netherlands. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20161029 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (Antioxidants) RN - H6241UJ22B (Selenium) SB - IM MH - Aged MH - Aged, 80 and over MH - Antioxidants/*therapeutic use MH - Belgium MH - Carcinoma in Situ/*drug therapy/pathology MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - Chemoprevention MH - Chemotherapy, Adjuvant MH - Disease-Free Survival MH - Double-Blind Method MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*prevention & control MH - Neoplasm Staging MH - Proportional Hazards Models MH - Selenium/*therapeutic use MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - *Urologic Surgical Procedures OTO - NOTNLM OT - Bladder cancer OT - Chemoprevention OT - Non-invasive urothelial carcinoma OT - Randomised clinical trial OT - Selenium OT - Transitional cell carcinoma OT - Urology EDAT- 2016/11/05 06:00 MHDA- 2017/08/02 06:00 CRDT- 2016/11/05 06:00 PHST- 2016/06/26 00:00 [received] PHST- 2016/09/08 00:00 [revised] PHST- 2016/09/16 00:00 [accepted] PHST- 2016/11/05 06:00 [pubmed] PHST- 2017/08/02 06:00 [medline] PHST- 2016/11/05 06:00 [entrez] AID - S0959-8049(16)32452-2 [pii] AID - 10.1016/j.ejca.2016.09.021 [doi] PST - ppublish SO - Eur J Cancer. 2016 Dec;69:9-18. doi: 10.1016/j.ejca.2016.09.021. Epub 2016 Oct 29. PMID- 27509369 OWN - NLM STAT- MEDLINE DCOM- 20170731 LR - 20221109 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 42 IP - 6 DP - 2016 Nov-Dec TI - Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma is Independently Associated with Intravesical Recurrence after Radical Nephroureterectomy. PG - 1129-1135 LID - 10.1590/S1677-5538.IBJU.2015.0366 [doi] AB - PURPOSE: To determine the effect of diagnostic ureteroscopy on intravesical recurrence in patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterec nottomy (RNU). MATERIALS AND METHODS: We conducted a retrospective analysis of 664 patients who were treated with RNU for UTUC from June 2000 to December 2011, excluding those who had concomitant/prior bladder tumors. Of the 664 patients, 81 underwent di notagnostic ureteroscopy (URS). We analyzed the impact of diagnostic ureteroscopy on intravesical recurrence (IVR) using the Kaplan-Meier method. Univariate and multi notvariate analyses were used to determine the independent risk factors. RESULTS: The median follow-up time was 48 months (interquartile range (IQR): 31- 77 months). Patients who underwent ureteroscopy were more likely to have a small (p<0.01), early-staged (p=0.019), multifocality (p=0.035) and ureteral tumor (p<0.001). IVR occurred in 223 patients during follow-up within a median of 17 months (IQR: 7-33). Patients without preoperative ureteroscopy have a statistically significant better 2-year (79.3%+/-0.02 versus 71.4%+/-0.02, p<0.001) and 5-year intravesical recurrence-free survival rates (64.9%+/-0.05 versus 44.3%+/-0.06, p<0.001) than patients who un notderwent ureteroscopy. In multivariate analysis, the diagnostic ureteroscopy (p=0.006), multiple tumors (p=0.001), tumor size <3cm (p=0.008), low-grade (p=0.022) and pN0 stage tumor (p=0.045) were independent predictors of IVR. CONCLUSIONS: Diagnostic ureteroscopy is independently associated with intravesical re notcurrence after radical nephroureterectomy. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Liu, Pei AU - Liu P AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Su, Xiao-Hong AU - Su XH AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xiong, Geng-Yan AU - Xiong GY AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Li, Xue-Song AU - Li XS AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Zhou, Li-Qun AU - Zhou LQ AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/secondary/surgery MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*pathology MH - Nephrectomy/*methods MH - Ureter/pathology MH - Ureteral Neoplasms/*pathology/surgery MH - Ureteroscopy/*methods MH - Urinary Bladder Neoplasms/*pathology/surgery MH - Urologic Neoplasms/*pathology/surgery PMC - PMC5117968 OTO - NOTNLM OT - Bladder OT - Oncology OT - Ureteroscopy COIS- Conflicts of Interest: None declared. EDAT- 2016/11/05 06:00 MHDA- 2017/08/02 06:00 PMCR- 2016/11/01 CRDT- 2016/08/11 06:00 PHST- 2015/07/09 00:00 [received] PHST- 2016/02/29 00:00 [accepted] PHST- 2016/11/05 06:00 [pubmed] PHST- 2017/08/02 06:00 [medline] PHST- 2016/08/11 06:00 [entrez] PHST- 2016/11/01 00:00 [pmc-release] AID - IBJUaheadofprint6 [pii] AID - S1677-5538.IBJU.2015.0366 [pii] AID - 10.1590/S1677-5538.IBJU.2015.0366 [doi] PST - ppublish SO - Int Braz J Urol. 2016 Nov-Dec;42(6):1129-1135. doi: 10.1590/S1677-5538.IBJU.2015.0366. PMID- 27799511 OWN - NLM STAT- MEDLINE DCOM- 20170928 LR - 20190918 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 14 IP - 11 DP - 2016 Nov TI - High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy. PG - 1403-1411 AB - BACKGROUND: Radical cystectomy (RC) is used to treat select patients with T1 high-grade (T1HG) bladder cancer. However, population-level utilization trends and outcomes for these patients are not well-known. We sought to evaluate treatment patterns and clinicopathologic outcomes of RC for T1HG bladder cancer. PATIENTS AND METHODS: Using the National Cancer Data Base (NCDB) for 1998-2012, we conducted a retrospective cohort study of patients with clinical T1HG bladder cancer. The prevalence of RC used to treat T1HG bladder cancer from 1998-2012 was determined. For years 2010-2012, demographic and cancer-related factors were described and regression analysis was used to examine associations with RC. Oncologic outcomes of RC were described and related to mortality using Cox proportional hazards regression. RESULTS: Treatment of T1HG bladder cancer with RC nearly doubled, from 5.5% during 1998-2000 to 9.9%, during 2010-2012. For 2010-2012, 18,277 patients with T1HG bladder cancer were analyzed. Patients who underwent RC were younger, had fewer comorbidities, and were more often treated at an academic center than those who did not undergo RC. At the time of RC, 41% of patients with T1HG bladder cancer were upstaged (pT2 or greater) and 12.7% had lymph node metastases. The 1- and 3-year survival rates were 0.89 and 0.68, respectively. Extravesical (T3+) disease at RC had the strongest independent hazard (hazard ratio [HR], 2.32; 95% CI, 1.72-3.11) of death other than age of 82 years or older (HR, 3.40; 95% CI, 2.28-5.07). CONCLUSIONS: The use of RC for T1HG bladder cancer has increased in prevalence in recent years but is still not widely used. There are concerning pathologic outcomes in patients with clinical T1HG bladder cancer treated with RC, including high rates of pathologic upstaging and nodal metastases. Future studies are necessary to better risk-stratify patients with T1HG bladder cancer to best select those who will benefit from aggressive therapy with RC. CI - Copyright (c) 2016 by the National Comprehensive Cancer Network. FAU - Matulewicz, Richard S AU - Matulewicz RS AD - From the Department of Urology, Northwestern University Feinberg School of Medicine, and Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois. AD - From the Department of Urology, Northwestern University Feinberg School of Medicine, and Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois. FAU - Frainey, Brendan T AU - Frainey BT AD - From the Department of Urology, Northwestern University Feinberg School of Medicine, and Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois. FAU - Oberlin, Daniel T AU - Oberlin DT AD - From the Department of Urology, Northwestern University Feinberg School of Medicine, and Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois. FAU - Meeks, Joshua J AU - Meeks JJ AD - From the Department of Urology, Northwestern University Feinberg School of Medicine, and Surgical Outcomes and Quality Improvement Center (SOQIC), Northwestern University, Chicago, Illinois. LA - eng GR - I01 BX003692/BX/BLRD VA/United States GR - P30 CA060553/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20161031 PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Risk MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery EDAT- 2016/11/02 06:00 MHDA- 2017/09/29 06:00 CRDT- 2016/11/02 06:00 PHST- 2016/04/08 00:00 [received] PHST- 2016/07/18 00:00 [accepted] PHST- 2016/11/02 06:00 [pubmed] PHST- 2017/09/29 06:00 [medline] PHST- 2016/11/02 06:00 [entrez] AID - 14/11/1403 [pii] AID - 10.6004/jnccn.2016.0150 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2016 Nov;14(11):1403-1411. doi: 10.6004/jnccn.2016.0150. Epub 2016 Oct 31. PMID- 37592583 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230818 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 3 IP - 6 DP - 2016 Nov TI - Guideline Adherence of Immediate Post-Transurethral Resection Intravesical Chemotherapy for Patients with Nonmuscle Invasive Bladder Cancer. PG - 456-461 LID - 10.1016/j.urpr.2015.10.003 [doi] AB - INTRODUCTION: Immediate postoperative instillation of chemotherapy to prevent intravesical recurrence of nonmuscle invasive bladder cancer is supported by level 1 evidence and recommended by contemporary guidelines. However, there have been a few reports on the feasibility and adherence of immediate postoperative chemotherapy instillation after transurethral resection. We retrospectively assessed the adherence rate of this treatment in patients with nonmuscle invasive bladder cancer. METHODS: We identified 438 patients with clinically Ta/T1 bladder cancer who underwent transurethral resection with curative intent between 2008 and 2013. We investigated the implementation of immediate postoperative instillation of chemotherapy. For those who did not receive this treatment we tried to identify the reasons for nonadministration from the clinical record and categorized them into technical, patient or other factors. We further interrogated clinicopathological characteristics associated with nonadministration. RESULTS: Overall 193 of the 438 study patients (44.1%) did not receive immediate postoperative instillation of chemotherapy. The noninstillation rate constantly decreased with time from 58.8% to 28.0% during the study period. Deep resection was the most common reason for nonadministration. There was a statistically significant decreasing time trend for nonadministration. Multivariate analysis revealed that clinical stage T1 tumor, negative cytology and larger tumor size were independently associated with nonadministration. CONCLUSIONS: Guideline adherence improved with time, suggesting that better education and better understanding of the guideline contributed to achieve high adherence. Deep resection was the most common reason for nonadministration, which was associated with clinically infiltrating cancer and larger tumor size. FAU - Matsumoto, Keiyu AU - Matsumoto K AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Negoro, Hiromitsu AU - Negoro H AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Terada, Naoki AU - Terada N AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Yamasaki, Toshinari AU - Yamasaki T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Inoue, Takahiro AU - Inoue T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kamba, Tomomi AU - Kamba T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Ogawa, Osamu AU - Ogawa O AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. LA - eng PT - Journal Article DEP - 20160813 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - drug therapy OT - guideline adherence OT - local OT - neoplasm recurrence OT - physicians' OT - practice patterns OT - urinary bladder neoplasms EDAT- 2016/11/01 00:00 MHDA- 2016/11/01 00:01 CRDT- 2023/08/18 01:09 PHST- 2016/11/01 00:01 [medline] PHST- 2016/11/01 00:00 [pubmed] PHST- 2023/08/18 01:09 [entrez] AID - 10.1016/j.urpr.2015.10.003 [doi] PST - ppublish SO - Urol Pract. 2016 Nov;3(6):456-461. doi: 10.1016/j.urpr.2015.10.003. Epub 2016 Aug 13. PMID- 27797436 OWN - NLM STAT- MEDLINE DCOM- 20170831 LR - 20180305 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 120 IP - 3 DP - 2017 Sep TI - Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study. PG - 329-336 LID - 10.1111/bju.13700 [doi] AB - OBJECTIVES: To investigate the possibility of detecting sentinel lymph nodes (SNs) in patients with urinary bladder cancer (BCa) intra-operatively and whether the histopathological status of the identified SNs reflected that of the lymphatic field. PATIENTS AND METHODS: We studied 103 patients with BCa pathological stage T1-T4 who were treated with cystectomy and pelvic lymph node (LN) dissection during 2005-2011 at the Department of Urology, Linkoping University Hospital. Radioactive tracer Nanocoll 70 MBq and blue dye were injected into the bladder wall around the primary tumour before surgery. SNs were detected ex vivo during the operation with a handheld Geiger probe (Gamma Detection System; Neoprobe Corp., Dublin, OH, USA). All LNs were formalin-fixed, sectioned three times, mounted on slides and stained with haematoxylin and eosin. An experienced uropathologist evaluated the slides. RESULTS: The mean age of the patients was 69 years, and 80 (77%) were male. Pathological staging was T1-12 (12%), T2-20 (19%), T3-48 (47%) and T4-23 (22%). A mean (range) number of 31 (7-68) nodes per patient were examined, totalling 3 253 nodes. LN metastases were found in 41 patients (40%). SNs were detected in 83 of the 103 patients (80%). Sensitivity and specificity for detecting metastatic disease by SN biopsy (SNB) varied between LN stations, with average values of 67% and 90%, respectively. LN metastatic density (LNMD) had a significant prognostic impact; a value of >/=8% was significantly related to shorter survival. Lymphovascular invasion (LVI) occurred in 65% of patients (n = 67) and was significantly associated with shorter cancer-specific survival (P < 0.001). CONCLUSION: We conclude that SNB is not a reliable technique for peri-operative localization of LN metastases during cystectomy for BCa; however, LNMD has a significant prognostic value in BCa and may be useful in the clinical context and in BCa oncological and surgical research. LVI was also found to be a prognostic factor. CI - (c) 2016 The Authors BJU International (c) 2016 BJU International Published by John Wiley & Sons Ltd. FAU - Aljabery, Firas AU - Aljabery F AD - Department of Urology, Region Ostergotland, Linkoping University Hospital, Linkoping, Sweden. AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, sweden. FAU - Shabo, Ivan AU - Shabo I AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, sweden. AD - Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. AD - Department of Breast and Endocrine Surgery, Karolinska University Hospital, Solna Stockholm, Sweden. FAU - Olsson, Hans AU - Olsson H AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, sweden. AD - Department of Pathology, Region Ostergotland, Linkoping University Hospital, Linkoping, Sweden. FAU - Gimm, Oliver AU - Gimm O AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, sweden. AD - Department of Surgery, Region Ostergotland, Linkoping University Hospital, Linkoping, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Urology, Region Ostergotland, Linkoping University Hospital, Linkoping, Sweden. AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20161204 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM CIN - BJU Int. 2017 Sep;120(3):302-303. doi: 10.1111/bju.13745. PMID: 28815981 MH - Aged MH - Cystectomy MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymph Node Excision MH - Lymph Nodes/*pathology/surgery MH - Male MH - Prognosis MH - Prospective Studies MH - *Sentinel Lymph Node Biopsy/methods/mortality/statistics & numerical data MH - *Urinary Bladder Neoplasms/mortality/pathology/surgery OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - cystectomy OT - lymph node metastasis OT - prognostic factors OT - sentinel node EDAT- 2016/11/01 06:00 MHDA- 2017/09/01 06:00 CRDT- 2016/11/01 06:00 PHST- 2016/11/01 06:00 [pubmed] PHST- 2017/09/01 06:00 [medline] PHST- 2016/11/01 06:00 [entrez] AID - 10.1111/bju.13700 [doi] PST - ppublish SO - BJU Int. 2017 Sep;120(3):329-336. doi: 10.1111/bju.13700. Epub 2016 Dec 4. PMID- 27696932 OWN - NLM STAT- MEDLINE DCOM- 20171009 LR - 20180218 IS - 1744-8352 (Electronic) IS - 1473-7159 (Linking) VI - 16 IP - 11 DP - 2016 Nov TI - Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. PG - 1189-1199 AB - The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the '-omic' technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. AD - b Department of Urology , University of Muenster Medical Center , Muenster , Germany. FAU - Woldu, Solomon L AU - Woldu SL AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. AD - c Department of Urology, Comprehensive Cancer Center , Medical University of Vienna , Vienna , Austria. AD - d Department of Urology and Medical Oncology , Weill Medical College of Cornell University , New York , NY , USA. FAU - Lotan, Yair AU - Lotan Y AD - a Department of Urology , UT Southwestern Medical Center , Dallas , TX , USA. LA - eng GR - T32 CA136515/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20161014 PL - England TA - Expert Rev Mol Diagn JT - Expert review of molecular diagnostics JID - 101120777 RN - 0 (Biomarkers, Tumor) SB - IM MH - *Biomarkers, Tumor MH - Carcinoma/*diagnosis/genetics/metabolism/urine MH - Cytological Techniques MH - Disease Management MH - Early Detection of Cancer MH - Epigenomics/methods MH - Gene Expression Profiling/methods MH - Humans MH - In Situ Hybridization, Fluorescence MH - Metabolomics MH - Microsatellite Repeats MH - *Molecular Diagnostic Techniques/methods/standards MH - Neoplasm Recurrence, Local MH - Polymorphism, Single Nucleotide MH - Proteomics/methods MH - Urethral Neoplasms/*diagnosis/genetics/metabolism/urine OTO - NOTNLM OT - Bladder cancer OT - follow-up OT - molecular biomarker OT - non-muscle invasive OT - surveillance OT - transitional cell carcinoma OT - urothelial carcinoma EDAT- 2016/10/30 06:00 MHDA- 2017/10/11 06:00 CRDT- 2016/10/05 06:00 PHST- 2016/10/30 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2016/10/05 06:00 [entrez] AID - 10.1080/14737159.2016.1244006 [doi] PST - ppublish SO - Expert Rev Mol Diagn. 2016 Nov;16(11):1189-1199. doi: 10.1080/14737159.2016.1244006. Epub 2016 Oct 14. PMID- 27788495 OWN - NLM STAT- MEDLINE DCOM- 20180222 LR - 20250630 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 50 DP - 2016 Dec 13 TI - Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis. PG - 82567-82579 LID - 10.18632/oncotarget.12856 [doi] AB - Various intravesical therapies have been introduced into clinical practices for controlling non-muscle invasive bladder cancer (NMIBC). However, evidence with respect to the efficacy and safety of those intravesical therapies is very limited. Hence, we present a network meta-analysis in order to address this limitation in the current literature. The primary outcomes were the risk of tumor recurrence (TR), tumor progression (TP) and disease-specific mortality (DM). Secondary outcomes included the risk of fever, cystitis and haematuria. Conventional pair-wise and network meta-analysis were both performed for each endpoint. The surface under the cumulative ranking curve (SUCRA) was incorporated in our analysis for ranking the corresponding intravesical instillation interventions. In total, 23 randomized clinical trials (RCTs) were finally included in our study after irrelevant papers were screened out. Results of network meta-analysis suggested that Epirubicin (EPI) was less preferable than Bacille Calmette Guerin (BCG), BCG+EPI, BCG+ Isoniazid (INH), BCG+ Mytomicin C (MMC), Gemcitabine (GEM) and MMC with respect to TR. As suggested by the corresponding ranking probabilities and SUCRA, incorporating EPI or MMC into BCG may enhance the efficacy of BCG monotherapy. FAU - Zhuo, Chuanjun AU - Zhuo C AD - Department of Psychological Medicine, Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang, 325005, China. AD - Department of Psychological Medicine, Jining Medical University, Jining, Shandong, 272067, China. AD - Department of Psychological Medicine, Tianjin Anding Hospital, Tianjin, 300222, China. FAU - Li, Xubin AU - Li X AD - Department of Radiotherapy, Tianjin Cancer Institute & Hospital, Tianjin, 30000, China. FAU - Zhuang, Hongqing AU - Zhuang H AD - Department of Radiotherapy, Tianjin Cancer Institute & Hospital, Tianjin, 30000, China. FAU - Tian, Shunli AU - Tian S AD - Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, 300075, China. FAU - Cui, Hailong AU - Cui H AD - Intensive Care Unit, Tianjin Medical University General Hospital, Tianjin, 300075, China. FAU - Jiang, Ronghuan AU - Jiang R AD - Department of Psychological Medicine, Chinese PLA (People's Liberation Army) General Hospital; Chinese PLA (People's Liberation Army) Medical School, Beijing, 100853, China. FAU - Liu, Chuanxin AU - Liu C AD - Department of Psychological Medicine, Jining Medical University, Jining, Shandong, 272067, China. FAU - Tao, Ran AU - Tao R AD - Beijing Shijian Integrated Medicine Science Institute, Beijing, 100700, China. FAU - Lin, Xiaodong AU - Lin X AD - Department of Psychological Medicine, Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang, 325005, China. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Review PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (BCG Vaccine) RN - 0W860991D6 (Deoxycytidine) RN - 3Z8479ZZ5X (Epirubicin) RN - 50SG953SK6 (Mitomycin) RN - V83O1VOZ8L (Isoniazid) RN - 0 (Gemcitabine) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects MH - BCG Vaccine/administration & dosage MH - Bayes Theorem MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Disease Progression MH - Epirubicin/administration & dosage MH - Female MH - Humans MH - Isoniazid/administration & dosage MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Odds Ratio MH - Randomized Controlled Trials as Topic MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology MH - Gemcitabine PMC - PMC5347714 OTO - NOTNLM OT - efficacy and safety OT - intravesical therapy OT - non-muscle invasive bladder cancer OT - tumor progression OT - tumor recurrence COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest. EDAT- 2016/10/28 06:00 MHDA- 2018/02/23 06:00 PMCR- 2016/12/13 CRDT- 2016/10/28 06:00 PHST- 2016/07/22 00:00 [received] PHST- 2016/10/04 00:00 [accepted] PHST- 2016/10/28 06:00 [pubmed] PHST- 2018/02/23 06:00 [medline] PHST- 2016/10/28 06:00 [entrez] PHST- 2016/12/13 00:00 [pmc-release] AID - 12856 [pii] AID - 10.18632/oncotarget.12856 [doi] PST - ppublish SO - Oncotarget. 2016 Dec 13;7(50):82567-82579. doi: 10.18632/oncotarget.12856. PMID- 27787959 OWN - NLM STAT- MEDLINE DCOM- 20170529 LR - 20180102 IS - 1934-6638 (Electronic) IS - 1934-662X (Linking) VI - 125 IP - 2 DP - 2017 Feb TI - Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resection. PG - 114-119 LID - 10.1002/cncy.21785 [doi] AB - BACKGROUND: The current study was conducted to determine the feasibility of cytologically clearing the bladder of tumor cells after transurethral resection of bladder tumor (TURBT) and aggressive serial bladder washing. METHODS: A prospective pilot sample of 20 patients with known bladder masses was enrolled before undergoing TURBT. Preoperative cytology and 4 postoperative cytology specimens were assessed for malignant cells between serial bladder washes. Surgeons assessed tumor grade visually at the time of TURBT. RESULTS: Surgeons were able to differentiate high-grade disease with limited accuracy (75% sensitivity, 92% specificity, 85% negative predictive value, and 86% positive predictive value). For patients with low-grade disease (12 patients), cytology was atypical in 25% of patients immediately before TURBT and was negative after serial washings in all patients. In patients with high-grade disease (8 patients), approximately 75% had cytology consistent with high-grade urothelial carcinoma immediately before TURBT and only 1 patient was cleared cytologically after serial bladder washings. CONCLUSIONS: In patients with high-grade disease, serial bladder washing after TURBT does not appear to clear malignant cells as detected by cytology. This theoretical oncologic risk should be weighed when considering concomitant upper tract procedures such as retrograde pyelography. Future work is needed to quantify risk. Cancer Cytopathol 2017;125:114-119. (c) 2016 American Cancer Society. CI - (c) 2016 American Cancer Society. FAU - Macleod, Liam C AU - Macleod LC AUID- ORCID: 0000-0003-1163-6621 AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. AD - Department of Urology, University of Washington School of Medicine, Seattle, Washington. FAU - Pham, Khanh N AU - Pham KN AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. FAU - Agoff, S Nicholas AU - Agoff SN AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. FAU - Dahl, Kathryn L AU - Dahl KL AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. FAU - Pritchett, Thomas R AU - Pritchett TR AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. FAU - Corman, John M AU - Corman JM AD - Section of Urology, Virginia Mason Medical Center, Seattle, Washington. LA - eng PT - Journal Article DEP - 20161027 PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 SB - IM MH - Aged MH - *Cytodiagnosis MH - Endoscopy/*methods MH - Female MH - Humans MH - Male MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/pathology/surgery MH - Urinary Bladder Neoplasms/diagnosis/pathology/*surgery MH - Urinary Tract/pathology/*surgery MH - Urography OTO - NOTNLM OT - bladder cancer OT - cytology OT - transurethral resection of bladder tumor (TURBT) OT - urothelial cancer EDAT- 2016/10/28 06:00 MHDA- 2017/05/30 06:00 CRDT- 2016/10/28 06:00 PHST- 2016/07/09 00:00 [received] PHST- 2016/09/11 00:00 [revised] PHST- 2016/09/12 00:00 [accepted] PHST- 2016/10/28 06:00 [pubmed] PHST- 2017/05/30 06:00 [medline] PHST- 2016/10/28 06:00 [entrez] AID - 10.1002/cncy.21785 [doi] PST - ppublish SO - Cancer Cytopathol. 2017 Feb;125(2):114-119. doi: 10.1002/cncy.21785. Epub 2016 Oct 27. PMID- 27785917 OWN - NLM STAT- MEDLINE DCOM- 20170830 LR - 20181202 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 31 IP - 3 DP - 2017 Mar TI - Risk of Intravesical Recurrence After Ureteroscopic Biopsy for Upper Tract Urothelial Carcinoma: Does the Location Matter? PG - 259-265 LID - 10.1089/end.2016.0611 [doi] AB - INTRODUCTION: To investigate whether ureteroscopic biopsy (URS-Bx) for upper tract urothelial carcinoma (UTUC) before radical nephroureterectomy affects intravesical recurrence (IVR). PATIENTS AND METHODS: Of the 515 patients receiving radical nephroureterectomy for UTUC between 1998 and 2012, 387 patients were included for the analysis. URS-Bx was performed in 69 patients (17.8%). Patients were stratified according to tumor location, and the impact of URS-Bx on IVR was evaluated after adjusting for other clinicopathologic variables. RESULTS: IVR occurred in 163 patients (42.1%). The postoperative 5-year IVR-free survival was not significantly different according to URS-Bx in the overall patient group (54.0% vs 39.3%, p = 0.056). In patients with renal pelvic tumor, IVR-free probability was lower in patients with URS-Bx than in patients without URS-Bx (39.6% vs 62.2%, p = 0.012), although IVR-free survival in patients with ureteral tumor was equivalent (36.7% vs 45.8%, p = 0.946). In multivariate analysis, previous bladder tumors (hazard ratio [HR], 1.65; p = 0.016) were a significant risk factor for IVR in all patients and ureteral tumor location (HR, 1.35; p = 0.071) was associated with IVR, although statistical significance was not achieved. In patients with renal pelvic tumor, URS-Bx HR, 1.98; p = 0.020 was the only risk factor for IVR. However, URS-Bx was not associated with IVR in patients with ureteral tumor, although previous bladder tumor HR, 1.74; p = 0.028 was a risk factor for IVR. CONCLUSION: URS-Bx is a significant risk factor for IVR in patients with renal pelvic tumor and should be performed after sufficient consideration in these patients if other examinations are uncertain. FAU - Yoo, Sangjun AU - Yoo S AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Song, Cheryn AU - Song C AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea. LA - eng PT - Journal Article DEP - 20161129 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Adult MH - Aged MH - Biopsy/*adverse effects MH - Carcinoma, Transitional Cell/diagnosis/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/diagnosis/*surgery MH - Kidney Pelvis MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*etiology MH - Nephrectomy/*methods MH - Proportional Hazards Models MH - Risk Factors MH - Survival Analysis MH - Urologic Neoplasms/diagnosis/*surgery MH - Urothelium OTO - NOTNLM OT - biopsy OT - carcinoma OT - transitional cell OT - ureteroscopy OT - urinary bladder neoplasms EDAT- 2016/10/28 06:00 MHDA- 2017/08/31 06:00 CRDT- 2016/10/28 06:00 PHST- 2016/10/28 06:00 [pubmed] PHST- 2017/08/31 06:00 [medline] PHST- 2016/10/28 06:00 [entrez] AID - 10.1089/end.2016.0611 [doi] PST - ppublish SO - J Endourol. 2017 Mar;31(3):259-265. doi: 10.1089/end.2016.0611. Epub 2016 Nov 29. PMID- 27785426 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 5 IP - 5 DP - 2016 Oct TI - Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? PG - 692-701 AB - Bladder cancer (BC) is a frequent type of carcinoma with an estimated incidence of approximately 100,000 men and women each year in the European Union (EU) with an associated mortality of 30,000 of these patients. In more than 70% the disease is diagnosed in a non-muscle invasive stage with the chance of minimally invasive, local treatment only, which might be required repetitively due to high rate of recurrence. In contrast, muscle invasive or metastatic stages need multimodal treatment strategies including surgical treatment and chemotherapy (CTX) in neoadjuvant (NAC), adjuvant, or palliative settings. Therapy recommendations and guidelines mainly refer to the most common histological type of BC, pure urothelial carcinoma (UC). However, BC can be classified as urothelial and non-UC. Non-urothelial BC and variants of UC account for up to 25% of all BCs. Further discrimination can be made into epithelial and non-epithelial non-UC. Most of the non-UCs are of epithelial origin (approximately 90%) including squamous-cell carcinoma, adenocarcinoma and small-cell carcinoma. Non-epithelial tumors are rare and include variants as sarcoma, carcinosarcoma, paraganglioma, melanoma and lymphoma. Even though it is unclear whether the prognosis of non-urothelial cancer truly differs from that of UC, there is evidence that additional variant histology might prognosticate an impaired prognosis. Accordingly, aggressive behavior and often advanced stages at primary presentation are frequently observed in non-UC arguing for radical and sometimes different treatment strategies as compared to pure UC. This review aims to summarize the available data for the most common histological variants of non-urothelial BC. FAU - Klaile, Yvonne AU - Klaile Y AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Schlack, Katrin AU - Schlack K AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Boegemann, Martin AU - Boegemann M AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Steinestel, Julie AU - Steinestel J AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Schrader, Andres Jan AU - Schrader AJ AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - Department of Urology, University of Muenster Medical Center, Muenster, Germany; ; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC5071184 OTO - NOTNLM OT - Bladder cancer (BC) OT - management OT - muscle-invasive OT - non-muscle-invasive OT - variant histology COIS- The authors have no conflicts of interest to declare. EDAT- 2016/10/28 06:00 MHDA- 2016/10/28 06:01 PMCR- 2016/10/01 CRDT- 2016/10/28 06:00 PHST- 2016/10/28 06:00 [pubmed] PHST- 2016/10/28 06:01 [medline] PHST- 2016/10/28 06:00 [entrez] PHST- 2016/10/01 00:00 [pmc-release] AID - tau-05-05-692 [pii] AID - 10.21037/tau.2016.06.13 [doi] PST - ppublish SO - Transl Androl Urol. 2016 Oct;5(5):692-701. doi: 10.21037/tau.2016.06.13. PMID- 27785424 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 5 IP - 5 DP - 2016 Oct TI - Female with bladder cancer: what and why is there a difference? PG - 668-682 AB - While men are at a considerable higher risk of developing urothelial carcinoma of the bladder (UCB), women present with more advanced disease stages and seem to experience unfavorable outcomes. Evaluating specific differences in the UCB incidence and outcomes between both genders in the non-muscle invasive, muscle-invasive or locally advanced and metastatic setting, as well as determining the underlying causes of disease, may allow optimizing treatment and improving the quality of urological care among both genders. In this review we summarize the best evidence and most recent findings on gender-specific differences in UCB incidence and outcomes. In addition, we present a comprehensive overview on established and potential reasons for differences in gender-specific UCB outcomes, including disparities in the pelvic anatomy, the diagnostic work-up, the modality and quality of treatment, the exposure to risk factors, the degradation of carcinogens as well as the sex-hormone signaling. FAU - Marks, Phillip AU - Marks P AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Fajkovic, Harun AU - Fajkovic H AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC5071204 OTO - NOTNLM OT - Urothelial carcinoma of the bladder (UCB) OT - chemotherapy OT - gender OT - outcome OT - sex OT - steroid hormones OT - surgery OT - survival OT - therapy OT - urinary bladder neoplasms COIS- SF Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Wolff. He is speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff. R Mathieu-Consultant: Astellas, Ipsen, Janssen; Speaker: Janssen, Sanofi, Novartis, Takeda. The other authors have no conflicts of interest to declare. EDAT- 2016/10/28 06:00 MHDA- 2016/10/28 06:01 PMCR- 2016/10/01 CRDT- 2016/10/28 06:00 PHST- 2016/10/28 06:00 [pubmed] PHST- 2016/10/28 06:01 [medline] PHST- 2016/10/28 06:00 [entrez] PHST- 2016/10/01 00:00 [pmc-release] AID - tau-05-05-668 [pii] AID - 10.21037/tau.2016.03.22 [doi] PST - ppublish SO - Transl Androl Urol. 2016 Oct;5(5):668-682. doi: 10.21037/tau.2016.03.22. PMID- 27785420 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2223-4691 (Print) IS - 2223-4691 (Electronic) IS - 2223-4683 (Linking) VI - 5 IP - 5 DP - 2016 Oct TI - Why are upper tract urothelial carcinoma two different diseases? PG - 636-647 AB - In the last few years growing evidence highlighted the differences between upper tract urothelial carcinoma (UTUC) and urothelial bladder carcinoma (UBC) which cannot be explained solely by their different anatomical location. The aim of this review was to summarize current progress in UTUC research and to underline the differences and similarities between UTUC and UBC by focusing on epidemiology, etiology, staging and risk factors as well as on surgical and medical management. UBC and UTUC sharing common risk factors such as smoking and aromatic amines, while aristolochic acid exposure or familiar Lynch syndrome are rather specific for UTUC. The grading of UBC and UTUC are identical, but inherent from their different anatomical locations, there are some differences between their stage classifications. As an example, in contrast to UBC where a clear recommendation for pT3 subclassification exists, in UTUC current research aims to define an adequate subclassification for pelvic pT3 cases aiming to provide a better risk stratification. The primary treatment for both UBC and UTUC is surgery. Similarly to UBC, UTUC patients at high risk of disease progression are treated by radical surgery. However, because of the inaccurate preoperative or transurethral staging of UTUC, many radical nephroureterectomies are performed unnecessarily. Preoperative prediction of pathological stage or patients' prognosis may reduce this overtreatment by selecting patients for nephron-sparing surgery. To this end, predictive models combining histological and molecular features together with imaging data may be used. The antegrade or retrograde instillation of BCG or mitomycin C, as topical agents is feasible after conservative treatment of UTUC or for the treatment of CIS. However, the prognostic significance of lymph node positivity in UTUC seems to be similar to that of UBC, the therapeutic benefit of lymph node dissection (LND) in UTUC has not been firmly established yet. In addition, the number of lymph nodes to be removed and the sequence of lymphadenectomy also remain to be defined. Systemic neoadjuvant and adjuvant chemotherapies appear to have beneficial effect on UTUC survival, however, this has to be confirmed by large prospective studies. Due to the intensive research of the last few years, our knowledge on UTUC has been largely improved, but many questions remained to be answered. Further research on the molecular background of UTUC holds the potential to identify prognostic or predictive markers which, together with imaging and histologic data, may help to overcome the inaccuracy of ureteroscopic endoscopy and may therefore help to improve therapeutic decision-making. Further, prospective studies should confirm the benefit of LND and adjuvant chemotherapy. Considering the low incidence of UTUC, conduction of such studies is difficult and may only be performed in a multicenter setting. FAU - Szarvas, Tibor AU - Szarvas T AD - Department of Urology, Semmelweis University, Budapest, Hungary; ; Department of Urology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany. FAU - Modos, Orsolya AU - Modos O AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Horvath, Andras AU - Horvath A AD - Department of Urology, Semmelweis University, Budapest, Hungary. FAU - Nyirady, Peter AU - Nyirady P AD - Department of Urology, Semmelweis University, Budapest, Hungary. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Androl Urol JT - Translational andrology and urology JID - 101581119 PMC - PMC5071198 OTO - NOTNLM OT - Upper tract urothelial carcinoma (UTUC) OT - chemotherapy OT - epidemiology OT - predictive tools OT - risk factors OT - staging COIS- The authors have no conflicts of interest to declare. EDAT- 2016/10/28 06:00 MHDA- 2016/10/28 06:01 PMCR- 2016/10/01 CRDT- 2016/10/28 06:00 PHST- 2016/10/28 06:00 [pubmed] PHST- 2016/10/28 06:01 [medline] PHST- 2016/10/28 06:00 [entrez] PHST- 2016/10/01 00:00 [pmc-release] AID - tau-05-05-636 [pii] AID - 10.21037/tau.2016.03.23 [doi] PST - ppublish SO - Transl Androl Urol. 2016 Oct;5(5):636-647. doi: 10.21037/tau.2016.03.23. PMID- 27776977 OWN - NLM STAT- MEDLINE DCOM- 20180112 LR - 20210103 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 12 DP - 2016 Dec TI - Emerging role of checkpoint inhibition in localized bladder cancer. PG - 548-555 LID - S1078-1439(16)30272-1 [pii] LID - 10.1016/j.urolonc.2016.09.004 [doi] AB - OBJECTIVE: Checkpoint inhibitors have rapidly become a standard treatment option for metastatic urothelial carcinoma. A wave of enthusiasm for these drugs has pushed them also into the setting of localized bladder cancer, including both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive disease bladder cancer (MIBC). Here, we aimed to review the emerging role of checkpoint inhibition in localized bladder cancer. METHODS: We reviewed the current treatment landscape for both NMIBC and MIBC and established a significant unmet clinical need for novel therapies. We have compiled the evidence that supports the investigation of checkpoint blockade in localized bladder cancer and have reviewed the corresponding clinical trial׳s landscape. RESULTS: The success of checkpoint inhibitors in metastatic bladder cancer offers the most compelling rationale for testing checkpoint blockade in localized disease. The established benefit of intravesical Bacillus Calmette-Guerin provides precedent for immune therapy in bladder cancer. Immune dysfunction has been described in bladder cancer, and we know that checkpoint molecules are expressed in these tumors. Furthermore, the high neoantigen burden of bladder cancer and results from preclinical studies suggest that checkpoint blockade deserves testing in earlier stage disease. Multiple trials are either planned or underway in almost all bladder cancer disease states. CONCLUSION: Ongoing trials would determine in the next several years whether checkpoint inhibitors can have a similar effect in localized disease as they have had in metastatic bladder cancer. They would also determine if patients with earlier disease would tolerate the toxicity of systemic therapy. The future holds promise for predictive biomarkers to guide individualized use of these agents and for effective combination therapies to overcome resistances. CI - Copyright A(c) 2016 Elsevier Inc. All rights reserved. FAU - Singh, Parminder AU - Singh P AD - Division of Hematology and Oncology , Mayo clinic, Phoenix, AZ. Electronic address: drparminder.singh@me.com. FAU - Black, Peter AU - Black P AD - Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Review DEP - 20161021 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (B7-H1 Antigen) RN - 0 (CD274 protein, human) RN - 0 (CTLA-4 Antigen) RN - 0 (Ipilimumab) RN - 0 (PDCD1 protein, human) RN - 0 (Programmed Cell Death 1 Receptor) RN - 52CMI0WC3Y (atezolizumab) SB - IM MH - Animals MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized MH - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use MH - B7-H1 Antigen/antagonists & inhibitors/immunology MH - CTLA-4 Antigen/antagonists & inhibitors/immunology MH - Carcinoma, Transitional Cell/drug therapy/immunology/surgery/*therapy MH - Clinical Trials as Topic MH - Combined Modality Therapy MH - Cystectomy MH - Humans MH - *Immunotherapy MH - Ipilimumab/therapeutic use MH - *Molecular Targeted Therapy MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology MH - Radiotherapy, Adjuvant MH - T-Lymphocyte Subsets/drug effects/immunology MH - Tumor Escape MH - Urinary Bladder Neoplasms/drug therapy/immunology/surgery/*therapy OTO - NOTNLM OT - Bladder cancer OT - Checkpoint inhibitors OT - Clinical trials OT - Immune therapy OT - Urothelial carcinoma EDAT- 2016/10/26 06:00 MHDA- 2018/01/13 06:00 CRDT- 2016/10/26 06:00 PHST- 2016/06/11 00:00 [received] PHST- 2016/08/27 00:00 [revised] PHST- 2016/09/17 00:00 [accepted] PHST- 2016/10/26 06:00 [pubmed] PHST- 2018/01/13 06:00 [medline] PHST- 2016/10/26 06:00 [entrez] AID - S1078-1439(16)30272-1 [pii] AID - 10.1016/j.urolonc.2016.09.004 [doi] PST - ppublish SO - Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21. PMID- 27614395 OWN - NLM STAT- MEDLINE DCOM- 20170209 LR - 20260127 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 12 DP - 2016 Oct TI - Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia. PG - 98-104 LID - S2352-3964(16)30405-4 [pii] LID - 10.1016/j.ebiom.2016.08.051 [doi] AB - BACKGROUND: Some risk classifications to determine prognosis of patients with non-muscle invasive bladder cancer (NMIBC) have disadvantages in the clinical setting. We investigated whether the EORTC (European Organization for Research and Treatment of Cancer) risk stratification is useful to predict recurrence and progression in Japanese patients with NMIBC. In addition, we developed and validated a novel, and simple risk classification of recurrence. METHODS: The analysis was based on 1085 patients with NMIBC at six hospitals. Excluding recurrent cases, we included 856 patients with initial NMIBC for the analysis. The Kaplan-Meier method with the log-rank test were used to calculate recurrence-free survival (RFS) rate and progression-free survival (PFS) rate according to the EORTC risk classifications. We developed a novel risk classification system for recurrence in NMIBC patients using the independent recurrence prognostic factors based on Cox proportional hazards regression analysis. External validation was done on an external data set of 641 patients from Kyorin University Hospital. FINDINGS: There were no significant differences in RFS and PFS rates between the groups according to EORTC risk classification. We constructed a novel risk model predicting recurrence that classified patients into three groups using four independent prognostic factors to predict tumour recurrence based on Cox proportional hazards regression analysis. According to the novel recurrence risk classification, there was a significant difference in 5-year RFS rate between the low (68.4%), intermediate (45.8%) and high (33.7%) risk groups (P<0.001). INTERPRETATION: As the EORTC risk group stratification may not be applicable to Asian patients with NMIBC, our novel classification model can be a simple and useful prognostic tool to stratify recurrence risk in patients with NMIBC. FUNDING: None. CI - Copyright (c) 2016 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Ieda, Takeshi AU - Ieda T AD - Department of Urology, Juntendo University, Graduate School of Medicine, Japan. FAU - Muto, Satoru AU - Muto S AD - Department of Urology, Teikyo University, School of Medicine, Japan. FAU - Shimizu, Fumitaka AU - Shimizu F AD - Department of Urology, Juntendo Nerima Hospital, Japan. FAU - Taguri, Masataka AU - Taguri M AD - Department of Biostatistics, Yokohama City University, School of Medicine, Japan. FAU - Yanada, Shigeto AU - Yanada S AD - Department of Urology, Juntendo Urayasu Hospital, Japan. FAU - Kitamura, Kousuke AU - Kitamura K AD - Department of Urology, Juntendo University, Graduate School of Medicine, Japan. FAU - Terai, Kazutaka AU - Terai K AD - Department of Urology, Teikyo University, School of Medicine, Japan. FAU - Saito, Keisuke AU - Saito K AD - Department of Urology, Teikyo University, School of Medicine, Japan. FAU - Ogishima, Tatsuya AU - Ogishima T AD - Department of Urology, Tokushukai Hospital, Chiba, Japan. FAU - Nagata, Masayoshi AU - Nagata M AD - Department of Urology, Juntendo University, Graduate School of Medicine, Japan. FAU - Ide, Hisamitsu AU - Ide H AD - Department of Urology, Teikyo University, School of Medicine, Japan. FAU - Okegawa, Takatsugu AU - Okegawa T AD - Department of Urology, Kyorin University School of Medicine. FAU - Wakumoto, Yoshiaki AU - Wakumoto Y AD - Department of Urology, Juntendo University, Graduate School of Medicine, Japan. FAU - Sakamoto, Yoshiro AU - Sakamoto Y AD - Department of Urology, Juntendo Nerima Hospital, Japan. FAU - Tsujimura, Akira AU - Tsujimura A AD - Department of Urology, Juntendo Urayasu Hospital, Japan. FAU - Yamaguchi, Raizo AU - Yamaguchi R AD - Department of Urology, Teikyo University, School of Medicine, Japan. FAU - Nutahara, Kikuo AU - Nutahara K AD - Department of Urology, Kyorin University School of Medicine. FAU - Horie, Shigeo AU - Horie S AD - Department of Urology, Juntendo University, Graduate School of Medicine, Japan. Electronic address: shorie@juntendo.ac.jp. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160902 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 SB - IM MH - Aged MH - Asia/epidemiology MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Reproducibility of Results MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/*epidemiology/mortality/*pathology/therapy PMC - PMC5078579 OTO - NOTNLM OT - Classification OT - Non-muscle invasive bladder cancer OT - Recurrence OT - Risk factor EDAT- 2016/10/26 06:00 MHDA- 2017/02/10 06:00 PMCR- 2016/09/02 CRDT- 2016/09/12 06:00 PHST- 2016/08/02 00:00 [received] PHST- 2016/08/25 00:00 [revised] PHST- 2016/08/31 00:00 [accepted] PHST- 2016/10/26 06:00 [pubmed] PHST- 2017/02/10 06:00 [medline] PHST- 2016/09/12 06:00 [entrez] PHST- 2016/09/02 00:00 [pmc-release] AID - S2352-3964(16)30405-4 [pii] AID - 10.1016/j.ebiom.2016.08.051 [doi] PST - ppublish SO - EBioMedicine. 2016 Oct;12:98-104. doi: 10.1016/j.ebiom.2016.08.051. Epub 2016 Sep 2. PMID- 27599396 OWN - NLM STAT- MEDLINE DCOM- 20170310 LR - 20171116 IS - 1791-2431 (Electronic) IS - 1021-335X (Linking) VI - 36 IP - 5 DP - 2016 Nov TI - Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. PG - 2852-2860 LID - 10.3892/or.2016.5061 [doi] AB - CD44, a major surface receptor for hyaluronic acid, has multiple isoforms and represents a major cancer stem cell marker for various epithelial tumors. CD44 variant 9 (CD44v9) was correlated with recurrence and metastasis in gastric and colon cancer. We examined its role in invasion and as a biomarker for the basal muscle invasive molecular subtype showing worse prognosis, and for tumor progression in high risk (pT1/high grade) non‑muscle invasive bladder cancers (NMIBCs). CD44v9, cytokeratin 5/6 (CK5/6), and cytokeratin 20 (CK20) expression was evaluated by immunohistochemistry in 98 pathologically confirmed specimens (36 muscle and 62 high‑risk non‑muscle) and correlated to clinical outcome. In vitro analysis was performed using two human bladder cancer cell lines (HT1376 and 5637). The CD44v9 high‑expressing group exhibited significantly lower progression‑free and cancer‑specific survival rates in both muscle (P=0.0349 and 0.0382, respectively) and non‑muscle (P=0.0002 and 0.0079) invasive patients. CD44v9 expression was significantly correlated with CK5/6 (P<0.001), colocalizing at the muscle invasion front but distinctly separated from CK20 in non‑muscle invasion. CD44 and CD44v9 siRNA knockdown demonstrated significantly lower Matrigel invasion ability and significantly shorter migration distance (all P<0.01). CD44 and CD44v9 knockdown increased E‑cadherin and decreased N‑cadherin, snail, and slug epithelial‑mesenchymal transition marker protein expression. Thus, higher CD44v9 expression was associated with worse prognosis, likely impacting invasion and migration via the epithelial‑mesenchymal transition. Together, these findings suggest that CD44v9 expression might be a useful predictive biomarker in basal‑type muscle and high-risk NMIBC. FAU - Kobayashi, Keita AU - Kobayashi K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Matsumoto, Hiroaki AU - Matsumoto H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Fujii, Nakanori AU - Fujii N AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Inoue, Ryo AU - Inoue R AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Yamamoto, Yoshiaki AU - Yamamoto Y AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755‑8505, Japan. LA - eng PT - Journal Article DEP - 20160901 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (Biomarkers, Tumor) RN - 0 (Hyaluronan Receptors) RN - 0 (Keratin-20) RN - 0 (Keratin-5) RN - 0 (Protein Isoforms) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*biosynthesis/genetics MH - Epithelial-Mesenchymal Transition/genetics MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Hyaluronan Receptors/*biosynthesis/genetics MH - Keratin-20/biosynthesis/genetics MH - Keratin-5/biosynthesis/genetics MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*genetics/pathology MH - Neoplastic Stem Cells/pathology MH - Prognosis MH - Protein Isoforms/*biosynthesis/genetics MH - Urinary Bladder Neoplasms/*genetics/pathology EDAT- 2016/10/26 06:00 MHDA- 2017/03/11 06:00 CRDT- 2016/09/08 06:00 PHST- 2016/03/08 00:00 [received] PHST- 2016/06/30 00:00 [accepted] PHST- 2016/10/26 06:00 [pubmed] PHST- 2017/03/11 06:00 [medline] PHST- 2016/09/08 06:00 [entrez] AID - 10.3892/or.2016.5061 [doi] PST - ppublish SO - Oncol Rep. 2016 Nov;36(5):2852-2860. doi: 10.3892/or.2016.5061. Epub 2016 Sep 1. PMID- 27221038 OWN - NLM STAT- MEDLINE DCOM- 20180112 LR - 20220317 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 26 DP - 2016 Jun 28 TI - Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer. PG - 39916-39930 LID - 10.18632/oncotarget.9537 [doi] AB - Although Bacillus Calmette-Guerin (BCG) is the most successful immunotherapy for high-risk non-muscle-invasive bladder cancer, approximately 30% of patients are unresponsive to treatment. New biomarkers are important to identify patients who will benefit most from BCG during a worldwide BCG shortage. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded tissue sections of bladder cancer by immunohistochemistry, using monoclonal antibodies to tumor-associated macrophages (TAMs; CD68, CD163), B-lymphocytes (CD20) and T-lymphocyte subsets (CD3, CD4, CD8, GATA3, T-bet, FOXP3 and CD25). Cell densities in the lamina propria without invasion, at the invasive front if present, in the papillary tumor stroma, and in the neoplastic urothelium were calculated. Twenty-nine (72.5%) of 40 patients were classified as BCG responders after a mean follow-up of 35.3 months. A statistically significant association was observed for BCG failure with low density of CD4+ and GATA3+ T-cells, and increased expression of FOXP3+ and CD25+ regulatory T-cells (Tregs) as well as CD68+ and CD163+ TAMs. Survival analysis demonstrated prolonged recurrence-free survival (RFS) in patients with an increased count of CD4+ and GATA3+ T-cells. TAMs, Tregs and T-bet+ T-cells were inversely correlated with RFS. Thus, the tumor microenvironment seems to influence the therapeutic response to BCG, permitting an individualized treatment. FAU - Pichler, Renate AU - Pichler R AD - Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. FAU - Fritz, Josef AU - Fritz J AD - Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, A-6020 Innsbruck, Austria. FAU - Zavadil, Claudia AU - Zavadil C AD - Department of Pathology, Division of General Pathology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. FAU - Schafer, Georg AU - Schafer G AD - Department of Pathology, Division of General Pathology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. FAU - Culig, Zoran AU - Culig Z AD - Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. FAU - Brunner, Andrea AU - Brunner A AD - Department of Pathology, Division of General Pathology, Medical University of Innsbruck, A-6020 Innsbruck, Austria. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Monoclonal/chemistry MH - Antineoplastic Agents/pharmacology MH - BCG Vaccine/*therapeutic use MH - Biomarkers, Tumor/metabolism MH - CD4-Positive T-Lymphocytes/cytology MH - Disease-Free Survival MH - Female MH - Humans MH - Lymphocytes, Tumor-Infiltrating/*cytology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Pilot Projects MH - Proportional Hazards Models MH - Th2 Cells/cytology MH - Tumor Microenvironment MH - Urinary Bladder Neoplasms/immunology/*therapy PMC - PMC5129981 OTO - NOTNLM OT - BCG immunotherapy OT - bladder cancer OT - lymphocytes OT - tumor microenvironment OT - tumor-associated macrophages COIS- The authors have no conflicts of interest. EDAT- 2016/10/26 06:00 MHDA- 2018/01/13 06:00 PMCR- 2016/06/28 CRDT- 2016/05/26 06:00 PHST- 2016/03/22 00:00 [received] PHST- 2016/05/05 00:00 [accepted] PHST- 2016/10/26 06:00 [pubmed] PHST- 2018/01/13 06:00 [medline] PHST- 2016/05/26 06:00 [entrez] PHST- 2016/06/28 00:00 [pmc-release] AID - 9537 [pii] AID - 10.18632/oncotarget.9537 [doi] PST - ppublish SO - Oncotarget. 2016 Jun 28;7(26):39916-39930. doi: 10.18632/oncotarget.9537. PMID- 27473264 OWN - NLM STAT- MEDLINE DCOM- 20170828 LR - 20220331 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 57 DP - 2016 Nov TI - T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIalpha, survivin, and E-cadherin. PG - 78-84 LID - S0046-8177(16)30158-7 [pii] LID - 10.1016/j.humpath.2016.06.022 [doi] AB - High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and /=400) versus low smoking exposure (cigarette index <400). Association with outcomes was examined by multivariable analyses after adjusting for the effects of standard clinicopathologic factors, and the Kaplan-Meier method was used to estimate the effect of smoking status and cumulative smoking exposure on RFS. RESULTS: A total of 168 (34.7 %) patients were never smoker, 121 (25 %) patients were current smokers, and 195 (40.3 %) patients were former smokers. The median follow-up was 25 months. By multivariate analysis, pathological grade (p = 0.013), history of recurrence (p < 0.001), number of tumors (p < 0.001) and size of tumors (p = 0.013) were significantly associated with tumor recurrence; nevertheless, smoking status did not influence tumor recurrence (p = 0.063). Among current and former smokers, cumulative smoking exposure was significantly associated with tumor recurrence (p < 0.001), compared to current smokers, patients with smoking cessation >/=10 years had a lower risk of tumor recurrence [hazard ratio (HR) 0.456, p = 0.007]. CONCLUSIONS: Smoking affects the prognosis of patient with NMIBC, which is still controversial; however, among ever smokers, a high cumulative exposure smoking can significantly increase the risk of tumor recurrence. Quitting smoking might be associated with a lower recurrence rate for patients with NMIBC. FAU - Li, Hao Min AU - Li HM AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Azhati, Baihetiya AU - Azhati B AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Rexiati, Mulati AU - Rexiati M AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Wang, Wen Guang AU - Wang WG AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Li, Xiao Dong AU - Li XD AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Liu, Qiang AU - Liu Q AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. FAU - Wang, Yu-Jie AU - Wang YJ AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Xinjiang, 830054, People's Republic of China. wangyujie62@sina.com. LA - eng PT - Journal Article DEP - 20161020 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*epidemiology/pathology/therapy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Risk Factors MH - Smoking/*epidemiology MH - Smoking Cessation MH - Time Factors MH - Tumor Burden MH - Urinary Bladder Neoplasms/epidemiology/pathology/therapy OTO - NOTNLM OT - Cumulative exposure smoking OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Smoking status OT - Survival EDAT- 2016/10/22 06:00 MHDA- 2017/07/28 06:00 CRDT- 2016/10/22 06:00 PHST- 2016/08/19 00:00 [received] PHST- 2016/10/15 00:00 [accepted] PHST- 2016/10/22 06:00 [pubmed] PHST- 2017/07/28 06:00 [medline] PHST- 2016/10/22 06:00 [entrez] AID - 10.1007/s11255-016-1441-6 [pii] AID - 10.1007/s11255-016-1441-6 [doi] PST - ppublish SO - Int Urol Nephrol. 2017 Jan;49(1):69-76. doi: 10.1007/s11255-016-1441-6. Epub 2016 Oct 20. PMID- 27765612 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20220318 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 2 DP - 2017 Apr TI - Preoperative Albumin Is Predictive of Early Postoperative Morbidity and Mortality in Common Urologic Oncologic Surgeries. PG - e255-e262 LID - S1558-7673(16)30283-X [pii] LID - 10.1016/j.clgc.2016.09.008 [doi] AB - INTRODUCTION: Multiple studies have linked preoperative nutrition status to postoperative outcomes. This relationship has been little studied in urology. We used a standardized, national, risk-adjusted surgical database to evaluate 30-day outcomes of patients undergoing common urologic oncologic procedures as they related to preoperative albumin. METHODS: The American College of Surgeons National Surgical Quality Improvement Program is a risk-adjusted dataset analyzing preoperative risk factors, demographics, and 30-day outcomes. From 2005 through 2012, we identified a total of 17,805 patients who underwent prostatectomy, nephrectomy, partial nephrectomy, cystectomy, or transurethral resection of bladder tumor (TURBT). Hypoalbuminemic patients were compared with those with normal preoperative albumin, and 30-day outcomes were evaluated. Logistic regression analyses were used to estimate odds ratios for mortality and complication rates. RESULTS: Evaluation of the cohort noted significantly increased overall morbidity, serious morbidity, and mortality in the hypoalbuminemic group (P < .01 for all procedures). Hypoalbuminemia was associated with a significantly higher 30-day mortality in major procedures such as cystectomy, and in smaller procedures such as TURBT (P < .01). Hypoalbuminemia was associated with a 6.4% 30-day mortality in the TURBT group compared with 0.6% in those with normal albumin (P < .0001). These findings remained significant after adjustment for other risk factors. CONCLUSIONS: The large sample size, standardized data definitions, and quality control measures of the American College of Surgeons National Surgical Quality Improvement Program database allow for in-depth analysis of subtle but significant differences in outcomes between groups. Serum albumin is a strong predictor of short-term postoperative complications in the urologic oncology patient. CI - Published by Elsevier Inc. FAU - Caras, Ronald J AU - Caras RJ AD - Urology Department, Tripler Army Medical Center, Honolulu, HI. Electronic address: RJCaras@gmail.com. FAU - Lustik, Michael B AU - Lustik MB AD - Department of Clinical Investigation, Tripler Army Medical Center, Honolulu, HI. FAU - Kern, Sean Q AU - Kern SQ AD - Urology Department, Tripler Army Medical Center, Honolulu, HI. FAU - McMann, Leah P AU - McMann LP AD - Urology Department, Tripler Army Medical Center, Honolulu, HI. FAU - Sterbis, Joseph R AU - Sterbis JR AD - Urology Department, Tripler Army Medical Center, Honolulu, HI. LA - eng PT - Journal Article DEP - 20160923 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Serum Albumin) SB - IM MH - Adult MH - Aged MH - Cystectomy/*mortality MH - Female MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Nephrectomy/*mortality MH - Nutritional Status MH - Postoperative Complications/mortality MH - Preoperative Period MH - Prostatectomy/*mortality MH - Quality Improvement MH - Serum Albumin/*metabolism MH - Survival Analysis MH - Urinary Bladder Neoplasms/metabolism/mortality/*surgery MH - Young Adult OTO - NOTNLM OT - ACS-NSQIP OT - Cystectomy OT - Nephrectomy OT - Prostatectomy OT - TURBT EDAT- 2016/10/22 06:00 MHDA- 2017/10/24 06:00 CRDT- 2016/10/22 06:00 PHST- 2016/06/16 00:00 [received] PHST- 2016/09/13 00:00 [revised] PHST- 2016/09/16 00:00 [accepted] PHST- 2016/10/22 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2016/10/22 06:00 [entrez] AID - S1558-7673(16)30283-X [pii] AID - 10.1016/j.clgc.2016.09.008 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Apr;15(2):e255-e262. doi: 10.1016/j.clgc.2016.09.008. Epub 2016 Sep 23. PMID- 27716885 OWN - NLM STAT- MEDLINE DCOM- 20170803 LR - 20171213 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 83 IP - Suppl 2 DP - 2016 Oct 4 TI - Mitomycin C from birth to adulthood. PG - 2-6 LID - 10.5301/uro.5000195 [doi] AB - Mitomycin C (MMC) intravesical therapy for "superficial" papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks. In the following decades, many large randomized studies showed the benefit of intravesical prophylaxis with MMC versus transurethral resection (TUR) alone. Since 2002, the role of adjuvant intravesical chemotherapy and of an early MMC instillation in preventing recurrence compared with TUR alone has been confirmed by large meta-analyses and stated by the European Association of Urology (EAU) guidelines. The need for further intravesical chemotherapy after the early instillation in patients at intermediate-high risk of recurrence has been proved by several trials. Although intravesical Bacillus Calmette-Guerin (BCG) is considered the best choice for high-risk patients and MMC for the low-risk group, both MMC and BCG can be given to prevent recurrence in intermediate-risk patients. However, the higher efficacy of BCG over MMC is evident only if maintenance regimen is administered. Despite its proven efficacy, immediate intravesical MMC is not yet fully entered in common clinical practice and efforts should be made by the urologists to optimize its adoption. FAU - Serretta, Vincenzo AU - Serretta V AD - Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy. FAU - Scalici Gesolfo, Cristina AU - Scalici Gesolfo C AD - Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy. FAU - Alonge, Vincenza AU - Alonge V AD - Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy. FAU - Di Maida, Fabrizio AU - Di Maida F AD - Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy. FAU - Caruana, Giovanni AU - Caruana G AD - Section of Urology, Department of Surgical Oncological and Stomathological Sciences, University of Palermo, Palermo - Italy. LA - eng PT - Journal Article PT - Review DEP - 20161001 PL - United States TA - Urologia JT - Urologia JID - 0417372 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Adult MH - Antibiotics, Antineoplastic/*therapeutic use MH - Child MH - Humans MH - Mitomycin/*therapeutic use MH - Urinary Bladder Neoplasms/drug therapy MH - Young Adult EDAT- 2016/10/22 06:00 MHDA- 2017/08/05 06:00 CRDT- 2016/10/08 06:00 PHST- 2016/08/31 00:00 [accepted] PHST- 2016/10/22 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] PHST- 2016/10/08 06:00 [entrez] AID - 5710A90F-36C7-4BF0-97A7-57EBED430167 [pii] AID - 10.5301/uro.5000195 [doi] PST - ppublish SO - Urologia. 2016 Oct 4;83(Suppl 2):2-6. doi: 10.5301/uro.5000195. Epub 2016 Oct 1. PMID- 27756245 OWN - NLM STAT- MEDLINE DCOM- 20170918 LR - 20191210 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 IP - 1 DP - 2016 Oct 18 TI - A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression. PG - 805 LID - 805 AB - BACKGROUND: Pathological stage and grade have limited ability to predict the outcomes of superficial urothelial bladder carcinoma at initial transurethral resection (TUR). AT-motif binding factor 1 (ATBF1) is a tumor suppressive transcription factor that is normally localized to the nucleus but has been detected in the cytoplasm in several cancers. Here, we examined the diagnostic value of the intracellular localization of ATBF1 as a marker for the identification of high risk urothelial bladder carcinoma. METHODS: Seven anti-ATBF1 antibodies were generated to cover the entire ATBF1 sequence. Four human influenza hemagglutinin-derived amino acid sequence-tagged expression vectors with truncated ATBF1 cDNA were constructed to map the functional domains of nuclear localization signals (NLSs) with the consensus sequence KR[X10-12]K. A total of 117 samples from initial TUR of human bladder carcinomas were analyzed. None of the patients had received chemotherapy or radiotherapy before pathological evaluation. RESULTS: ATBF1 nuclear localization was regulated synergistically by three NLSs on ATBF1. The cytoplasmic fragments of ATBF1 lacked NLSs. Patients were divided into two groups according to positive nuclear staining of ATBF1, and significant differences in overall survival (P = 0.021) and intravesical recurrence-free survival (P = 0.013) were detected between ATBF1+ (n = 110) and ATBF1- (n = 7) cases. Multivariate analysis revealed that ATBF1 staining was an independent prognostic factor for intravesical recurrence-free survival after adjusting for cellular grading and pathological staging (P = 0.008). CONCLUSIONS: Cleavage of ATBF1 leads to the cytoplasmic localization of ATBF1 fragments and downregulates nuclear ATBF1. Alterations in the subcellular localization of ATBF1 due to fragmentation of the protein are related to the malignant character of urothelial carcinoma. Pathological evaluation using anti-ATBF1 antibodies enabled the identification of highly malignant cases that had been overlooked at initial TUR. Nuclear localization of ATBF1 indicates better prognosis of urothelial carcinoma. FAU - Kawaguchi, Makoto AU - Kawaguchi M AD - Division of Diagnostic Pathology, Niigata Rosai Hospital, Japan Organization of Occupational Health and Safety, 1-7-12 Toh-un-cho, Johetsu, Niigata, 942-8502, Japan. AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Hara, Noboru AU - Hara N AD - Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 754 Ichiban-cho, Asahimachi-dohri, Cyuo-ku, Niigata, Niigata, 951-8520, Japan. FAU - Bilim, Vladimir AU - Bilim V AD - Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 754 Ichiban-cho, Asahimachi-dohri, Cyuo-ku, Niigata, Niigata, 951-8520, Japan. FAU - Koike, Hiroshi AU - Koike H AD - Division of Urology, Niigata Rosai Hospital, Japan Organization of Occupational Health and Safety, 1-7-12 Toh-un-cho, Johetsu, Niigata, 942-8502, Japan. FAU - Suzuki, Mituko AU - Suzuki M AD - Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, LG 581, Ghana. AD - Section of Environmental Parasitology, Faculty of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. FAU - Kim, Tae-Sun AU - Kim TS AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Gao, Nan AU - Gao N AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Dong, Yu AU - Dong Y AD - Department of Oncology, Immunology and Surgery, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Zhang, Sheng AU - Zhang S AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 11-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. FAU - Fujinawa, Yuji AU - Fujinawa Y AD - Division of Diagnostic Pathology, Niigata Rosai Hospital, Japan Organization of Occupational Health and Safety, 1-7-12 Toh-un-cho, Johetsu, Niigata, 942-8502, Japan. FAU - Yamamoto, Osamu AU - Yamamoto O AD - Division of Diagnostic Pathology, Niigata Rosai Hospital, Japan Organization of Occupational Health and Safety, 1-7-12 Toh-un-cho, Johetsu, Niigata, 942-8502, Japan. FAU - Ito, Hiromi AU - Ito H AD - Laboratory of Molecular Oncology, Department of Urology, School of Medicine, Yamagata University, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan. FAU - Tomita, Yoshihiko AU - Tomita Y AD - Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 754 Ichiban-cho, Asahimachi-dohri, Cyuo-ku, Niigata, Niigata, 951-8520, Japan. FAU - Naruse, Yuchi AU - Naruse Y AD - Department of Human Science and Fundamental Nursing, School of Nursing, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. FAU - Sakamaki, Akira AU - Sakamaki A AD - Department of Internal Medicine, Ooshima Kurumi Hospital, 48 Kitano, Ooshima, Imizu, Toyama, 939-0271, Japan. FAU - Ishii, Yoko AU - Ishii Y AD - Department of Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. FAU - Tsuneyama, Koichi AU - Tsuneyama K AD - Department of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Graduate School of Medicine, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. FAU - Inoue, Masaaki AU - Inoue M AD - Division of Chest Surgery, Shimonoseki City Hospital, Koyo-cho, Shimonoseki, Yamaguchi, 750-8520, Japan. FAU - Itoh, Johbu AU - Itoh J AD - Education and Research Support Center, School of Medicine, Tokai University, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. FAU - Yasuda, Masanori AU - Yasuda M AD - Department of Diagnostic Pathology, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan. FAU - Sakata, Nobuo AU - Sakata N AD - Department of Biochemistry, Showa Pharmaceutical University, 3-3165 Higashi-tamagawagakuen, Machida, Tokyo, 194-8543, Japan. FAU - Jung, Cha-Gyun AU - Jung CG AD - Department of Neurophysiology and Brain Science, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Kanazawa, Satoshi AU - Kanazawa S AD - Department of Molecular and Cellular Biology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cyo, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Akatsu, Hiroyasu AU - Akatsu H AD - Department of Medicine for Aging in Place and Community-Based Medical Education, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Minato, Hiroshi AU - Minato H AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 11-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. FAU - Nojima, Takayuki AU - Nojima T AD - Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 11-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. FAU - Asai, Kiyofumi AU - Asai K AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. FAU - Miura, Yutaka AU - Miura Y AD - Department of Molecular Neurobiology, Graduate School of Medical Sciences, Nagoya City University, 1-Chome, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. miura-ngi@umin.net. LA - eng PT - Journal Article DEP - 20161018 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (Homeodomain Proteins) RN - 143258-00-8 (ZFHX3 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Animals MH - Biomarkers, Tumor/*metabolism MH - Blotting, Western MH - COS Cells MH - Carcinoma, Transitional Cell/*metabolism/pathology MH - Cell Line, Tumor MH - Cell Nucleus/metabolism MH - Chlorocebus aethiops MH - Cytoplasm/metabolism MH - Disease Progression MH - Female MH - HEK293 Cells MH - Homeodomain Proteins/*metabolism MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Urinary Bladder Neoplasms/*metabolism/pathology PMC - PMC5070376 OTO - NOTNLM OT - ATBF1 OT - nuclear localization signals OT - prognostic marker OT - urothelial bladder carcinoma EDAT- 2016/10/21 06:00 MHDA- 2017/09/19 06:00 PMCR- 2016/10/18 CRDT- 2016/10/21 06:00 PHST- 2015/09/07 00:00 [received] PHST- 2016/10/06 00:00 [accepted] PHST- 2016/10/21 06:00 [pubmed] PHST- 2017/09/19 06:00 [medline] PHST- 2016/10/21 06:00 [entrez] PHST- 2016/10/18 00:00 [pmc-release] AID - 10.1186/s12885-016-2845-5 [pii] AID - 2845 [pii] AID - 10.1186/s12885-016-2845-5 [doi] PST - epublish SO - BMC Cancer. 2016 Oct 18;16(1):805. doi: 10.1186/s12885-016-2845-5. PMID- 27509372 OWN - NLM STAT- MEDLINE DCOM- 20170628 LR - 20191210 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 42 IP - 5 DP - 2016 Sep-Oct TI - External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1. PG - 932-941 LID - 10.1590/S1677-5538.IBJU.2015.0169 [doi] AB - Validate the EORTC risk tables in Brazilian patients with NMIBC. METHODS: 205 patients were analyzed. The 6 parameters analyzed were: histologic grading, pathologic stage, size and number of tumors, previous recurrence rate and concomitant CIS. The time for first recurrence (TFR), risk score and probability of re notcurrence were calculated and compared to the probabilities obtained from EORTC risk tables. C-index was calculated and accuracy of EORTC tables was analyzed. RESULTS: pTa was presented in 91 (44.4%) patients and pT1 in 114 (55.6%). Ninety-seven (47.3%) patients had solitary tumor, and 108 (52.7%) multiple tumors. One hundred and three (50.2%) patients had tumors smaller than 3 cm and 102 (40.8%) had bigger than 3 cm. Concomitant CIS was observed in 21 (10.2%) patients. Low grade was presented in 95 (46.3%) patients, and high grade in 110 (53.7%). Intravesical therapy was utilized in 105 (56.1%) patients. Recurrence was observed in 117 (57.1%) patients and the mean TFR was 14,2 +/- 7,3 months. C-index was 0,72 for 1 year and 0,7 for 5 years. The re notcurrence risk was 28,8% in 1 year and 57,1% in 5 years, independently of the scoring risk. In our population, the EORTC risk tables overestimated the risk of recurrence in 1 year and underestimated in 5 years. CONCLUSION: The validation of the EORTC risk tables in Brazilian patients with NMIBC was satisfactory and should be stimulated to predict recurrence, although these may overestimated the risk of recurrence in 1 year and underestimated in 5 years. CI - Copyright(R) by the International Brazilian Journal of Urology. FAU - Almeida, Gilberto L AU - Almeida GL AD - Universidade do Vale do Itajai, SC, Brasil/Instituto Catarinense de Urologia (INCAU), Itajai, Brasil. AD - Faculdade Evangelica do Parana (FEPAR)/Instituto de Pesquisas Medicas (IPEM), Curitiba, Brasil. FAU - Busato, Wilson F S Jr AU - Busato WF Jr AD - Universidade do Vale do Itajai, SC, Brasil/Instituto Catarinense de Urologia (INCAU), Itajai, Brasil. FAU - Ribas, Carmen Marcondes AU - Ribas CM AD - Faculdade Evangelica do Parana (FEPAR)/Instituto de Pesquisas Medicas (IPEM), Curitiba, Brasil. FAU - Ribas, Jurandir Marcondes Filho AU - Ribas JM Filho AD - Faculdade Evangelica do Parana (FEPAR)/Instituto de Pesquisas Medicas (IPEM), Curitiba, Brasil. FAU - De Cobelli, Ottavio AU - De Cobelli O AD - Universita degli Studi di Milano, Milano, Italia. AD - Dipartimento di Urologia, Istituto Europeo di Oncologia (IEO), Milano, Italia. LA - eng PT - Journal Article PT - Validation Study PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Aged, 80 and over MH - Brazil MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - Predictive Value of Tests MH - Prospective Studies MH - Reproducibility of Results MH - Risk Assessment/*methods MH - Risk Factors MH - Time Factors MH - Urinary Bladder Neoplasms/*pathology/*surgery PMC - PMC5066889 OTO - NOTNLM OT - Carcinoma OT - Transurethral Resection of Prostate OT - Urinary Bladder COIS- Conflicts of Interest: None declared. EDAT- 2016/10/21 06:00 MHDA- 2017/06/29 06:00 PMCR- 2016/09/01 CRDT- 2016/08/11 06:00 PHST- 2015/03/25 00:00 [received] PHST- 2015/10/26 00:00 [accepted] PHST- 2016/10/21 06:00 [pubmed] PHST- 2017/06/29 06:00 [medline] PHST- 2016/08/11 06:00 [entrez] PHST- 2016/09/01 00:00 [pmc-release] AID - IBJUaheadofprint9 [pii] AID - S1677-5538.IBJU.2015.0169 [pii] AID - 10.1590/S1677-5538.IBJU.2015.0169 [doi] PST - ppublish SO - Int Braz J Urol. 2016 Sep-Oct;42(5):932-941. doi: 10.1590/S1677-5538.IBJU.2015.0169. PMID- 27753185 OWN - NLM STAT- MEDLINE DCOM- 20170630 LR - 20200502 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 119 IP - 5 DP - 2017 May TI - Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. PG - 684-691 LID - 10.1111/bju.13689 [doi] AB - OBJECTIVE: To analyse survival in patients with clinically localised, surgically resectable micropapillary bladder cancer (MPBC) undergoing radical cystectomy (RC) with and without neoadjuvant chemotherapy (NAC) and develop risk strata based on outcome data. PATIENTS AND METHODS: A review of our database identified 103 patients with surgically resectable (/=cT2, no hydronephrosis; and highest-risk: cTany with tumour-associated hydronephrosis. The 5-year DSS for the low-, high-, and highest-risk groups were 92%, 51%, and 17%, respectively (P < 0.001). Patients down-staged at RC /=5 cm) were significant and independent factors associated with progression (hazard ratio 3.5, 95% confidence interval 1.1-12; hazard ratio 5.0, 95% confidence interval 1.3-17; P < 0.05 for all). As for toxicity, 26 (18%) patients had grade 3-4 acute hematologic toxicities and 2 (3%) patients had grade 3 late genitourinary toxicity. No patient had to discontinue the treatment due to acute toxicity. CONCLUSIONS: Our bladder-preserving therapy with proton beam therapy was well tolerated and achieved a favorable mortality rate. Tumor multiplicity and tumor size were important risk factors for progression. Our findings indicate that this therapy can be an effective treatment option for selected muscle-invasive bladder cancer patients. CI - (c) The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Takaoka, Ei-Ichiro AU - Takaoka EI AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Miyazaki, Jun AU - Miyazaki J AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Ishikawa, Hitoshi AU - Ishikawa H AD - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Kawai, Koji AU - Kawai K AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Kimura, Tomokazu AU - Kimura T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Ishitsuka, Ryutaro AU - Ishitsuka R AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Kojima, Takahiro AU - Kojima T AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba. FAU - Kanuma, Reiko AU - Kanuma R AD - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Takizawa, Daichi AU - Takizawa D AD - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Okumura, Toshiyuki AU - Okumura T AD - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Sakurai, Hideyuki AU - Sakurai H AD - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba nishiuro@md.tsukuba.ac.jp. LA - eng PT - Journal Article DEP - 20161013 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Disease-Free Survival MH - Female MH - Hematologic Diseases/etiology MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Prognosis MH - Proportional Hazards Models MH - *Proton Therapy/adverse effects MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/radiotherapy/*therapy OTO - NOTNLM OT - muscle-invasive bladder cancer OT - proton beam therapy OT - toxicity OT - trimodal bladder-preserving therapy EDAT- 2016/10/16 06:00 MHDA- 2017/03/30 06:00 CRDT- 2016/10/15 06:00 PHST- 2016/07/20 00:00 [received] PHST- 2016/09/14 00:00 [revised] PHST- 2016/09/15 00:00 [accepted] PHST- 2016/10/16 06:00 [pubmed] PHST- 2017/03/30 06:00 [medline] PHST- 2016/10/15 06:00 [entrez] AID - hyw151 [pii] AID - 10.1093/jjco/hyw151 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2017 Jan;47(1):67-73. doi: 10.1093/jjco/hyw151. Epub 2016 Oct 13. PMID- 27732981 OWN - NLM STAT- MEDLINE DCOM- 20171026 LR - 20221207 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 98 IP - 3 DP - 2017 TI - Validation of the Preoperative Platelet-to-Lymphocyte Ratio as a Prognostic Factor in a European Cohort of Patients with Upper Tract Urothelial Carcinoma. PG - 320-327 LID - 10.1159/000452109 [doi] AB - INTRODUCTION: This study is aimed at investigating the potential prognostic impact of the preoperatively assessed platelet-to-lymphocyte ratio (PLR) in a European cohort of patients with non-metastatic upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: Clinicopathological data from 180 consecutive non-metastatic UTUC patients, operated between 1990 and 2012 at a single tertiary academic center, were evaluated retrospectively. The preoperative PLR was assessed one day before surgery. Patients were categorized using a PLR cut-off value according to receiver-operating curve analysis. Cancer-specific survival (CSS) and overall survival (OS) were assessed using the Kaplan-Meier method. Additionally, multivariate proportional Cox regression models were applied. RESULTS: In multivariate analyses, age at the date of surgery (<65 vs. >/=65 years, hazard ratio (HR) 1.827, 95% CI 1.051-3.175, p = 0.033), pathologic T-stage (pT1 vs. pT2-4, HR 1.873, 95% CI 1.066-3.292, p = 0.029), and pretreatment PLR (<150.0 vs. >/=150.0, HR 1.782, 95% CI 1.041-3.050, p = 0.035) were independent predictors of OS. Regarding CSS, pathologic T-stage (pT1 vs. pT2-4, HR 2.176, 95% CI 1.062-4.460, p = 0.034) and pretreatment PLR (<150.0 vs. >/=150.0, HR 2.026, 95% CI 1.045-3.930, p = 0.037) were considered independent predictors. CONCLUSIONS: In the cohort studied, patients with an elevated (>/=150.0) preoperative PLR had a higher cancer-specific mortality and overall mortality after radical surgery for UTUC, compared with those with a low pretreatment PLR. CI - (c) 2016 S. Karger AG, Basel. FAU - Dalpiaz, Orietta AU - Dalpiaz O AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Krieger, Daniel AU - Krieger D FAU - Ehrlich, Georg C AU - Ehrlich GC FAU - Pohlmann, Kristof AU - Pohlmann K FAU - Stojakovic, Tatjana AU - Stojakovic T FAU - Pummer, Karl AU - Pummer K FAU - Zigeuner, Richard AU - Zigeuner R FAU - Pichler, Martin AU - Pichler M FAU - Hutterer, Georg C AU - Hutterer GC LA - eng PT - Journal Article PT - Validation Study DEP - 20161013 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - Blood Platelets/*cytology MH - Cell Count MH - Europe MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocytes/*cytology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Metastasis MH - Preoperative Period MH - Prognosis MH - Proportional Hazards Models MH - ROC Curve MH - Retrospective Studies MH - Treatment Outcome MH - Urologic Neoplasms/*surgery MH - Urothelium/*pathology MH - White People EDAT- 2016/10/13 06:00 MHDA- 2017/10/27 06:00 CRDT- 2016/10/13 06:00 PHST- 2016/05/24 00:00 [received] PHST- 2016/09/26 00:00 [accepted] PHST- 2016/10/13 06:00 [pubmed] PHST- 2017/10/27 06:00 [medline] PHST- 2016/10/13 06:00 [entrez] AID - 000452109 [pii] AID - 10.1159/000452109 [doi] PST - ppublish SO - Urol Int. 2017;98(3):320-327. doi: 10.1159/000452109. Epub 2016 Oct 13. PMID- 27726892 OWN - NLM STAT- MEDLINE DCOM- 20171214 LR - 20171214 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 41 IP - 3 DP - 2017 Apr TI - Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance. PG - 172-180 LID - S0210-4806(16)30132-2 [pii] LID - 10.1016/j.acuro.2016.09.003 [doi] AB - OBJECTIVE: To determine the differential protein expression of biomarkers FGFR3, PI3K (subunits PI3Kp110alpha, PI3KClassIII, PI3Kp85), AKT, p21Waf1/Cip1 and cyclins D1 and D3 in T1 bladder cancer versus healthy tissue and to study their potential role as early recurrence markers. MATERIAL AND METHOD: This is a prospective study that employed a total of 67 tissue samples (55 cases of T1 bladder tumours that underwent transurethral resection and 12 cases of adjacent healthy mucosa). The protein expression levels were assessed using Western blot, and the means and percentages were compared using Student's t-test and the chi-squared test. The survival analysis was conducted using the Kaplan-Meier method and the log-rank test. RESULTS: Greater protein expression was detected for FGFR3, PI3Kp110alpha, PI3KClassIII, cyclins D1 and D3 and p21Waf1/Cip1 in the tumour tissue than in the healthy mucosa. However, these differences were not significant for PI3Kp85 and AKT. We observed statistically significant correlations between early recurrence and PI3Kp110alpha, PI3KClassIII, PI3Kp85 and AKT (P=.003, P=.045, P=.050 and P=.028, respectively), between the tumour type (primary vs. recurrence) and cyclin D3 (P=.001), between the tumour size and FGFR3 (P=.035) and between multifocality and cyclin D1 (P=.039). The survival analysis selected FGFR3 (P=.024), PI3Kp110alpha (P=.014), PI3KClassIII (P=.042) and AKT (P=.008) as markers of early-recurrence-free survival. CONCLUSIONS: There is an increase in protein expression levels in bladder tumour tissue. The overexpression of FGFR3, PI3Kp110alpha, PI3KClassIII and AKT is associated with increased early-recurrence-free survival for patients with T1 bladder tumours. CI - Copyright (c) 2016 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Blanca Pedregosa, A M AU - Blanca Pedregosa AM AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. FAU - Sanchez-Gonzalez, A AU - Sanchez-Gonzalez A AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. FAU - Carrasco Valiente, J AU - Carrasco Valiente J AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. FAU - Ruiz Garcia, J M AU - Ruiz Garcia JM AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. FAU - Gomez Gomez, E AU - Gomez Gomez E AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. FAU - Lopez Beltran, A AU - Lopez Beltran A AD - Departamento de Especialidades Medico-Quirurgicas, Facultad de Medicina, Universidad de Cordoba, Cordoba, Espana. FAU - Requena Tapia, M J AU - Requena Tapia MJ AD - Instituto Maimonides de Investigacion Biomedica de Cordoba, Servicio de Urologia del Hospital Universitario Reina Sofia, Cordoba, Espana. Electronic address: tapia3434@gmail.com. LA - eng LA - spa PT - Journal Article TT - Expresion de las proteinas FGFR3, PI3K, AKT, p21Waf1/Cip1 y ciclinas D1 y D3 en pacientes con tumores de vejiga T1: implicaciones clinicas y significado pronostico. DEP - 20161007 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 RN - 0 (CCND1 protein, human) RN - 0 (CCND2 protein, human) RN - 0 (CDKN1A protein, human) RN - 0 (Cyclin D2) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 136601-57-5 (Cyclin D1) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.7.11.1 (Oncogene Protein v-akt) SB - IM MH - Aged MH - Aged, 80 and over MH - Cyclin D1/biosynthesis MH - Cyclin D2/biosynthesis MH - Cyclin-Dependent Kinase Inhibitor p21/biosynthesis MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Oncogene Protein v-akt/biosynthesis MH - Phosphatidylinositol 3-Kinases/biosynthesis MH - Prognosis MH - Prospective Studies MH - Receptor, Fibroblast Growth Factor, Type 3/biosynthesis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*metabolism/*mortality/pathology/surgery OTO - NOTNLM OT - Bladder cancer OT - Cancer de vejiga OT - Early recurrence OT - Expresion proteica, Western blot OT - Protein expression OT - Recidiva precoz OT - Western blot EDAT- 2016/10/12 06:00 MHDA- 2017/12/15 06:00 CRDT- 2016/10/12 06:00 PHST- 2016/03/30 00:00 [received] PHST- 2016/09/04 00:00 [revised] PHST- 2016/09/05 00:00 [accepted] PHST- 2016/10/12 06:00 [pubmed] PHST- 2017/12/15 06:00 [medline] PHST- 2016/10/12 06:00 [entrez] AID - S0210-4806(16)30132-2 [pii] AID - 10.1016/j.acuro.2016.09.003 [doi] PST - ppublish SO - Actas Urol Esp. 2017 Apr;41(3):172-180. doi: 10.1016/j.acuro.2016.09.003. Epub 2016 Oct 7. PMID- 27720534 OWN - NLM STAT- MEDLINE DCOM- 20180212 LR - 20250623 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 71 IP - 4 DP - 2017 Apr TI - Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. PG - 545-557 LID - S0302-2838(16)30675-3 [pii] LID - 10.1016/j.eururo.2016.09.035 [doi] AB - CONTEXT: Urothelial carcinoma is considered a pan-urothelial disease. As such, the remnant urothelium in the upper urinary tract and urethra following radical cystectomy (RC) remains at risk for secondary urothelial tumors (SUTs). OBJECTIVE: To describe the incidence, diagnosis, treatment, and outcomes of patients with SUTs after RC. EVIDENCE ACQUISITION: A systematic search was conducted using PubMed database according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2016 reporting on malignant diseases of the urothelium after RC for bladder cancer. The search strategy separated between upper and lower tract urothelial tumors. EVIDENCE SYNTHESIS: Of a total of 1069 studies, 57 were considered for evidence synthesis. SUTs occured in approximately 4-10% of patients after RC. Carcinoma in situ of the bladder, a history of nonmuscle invasive bladder cancer, and tumor involvement of the distal ureter are the strongest risk factors for secondary upper tract tumors. Risk factors for secondary urethral tumors represent urothelial malignancy in the prostatic urethra/prostate and bladder neck (in women), nonorthotopic diversions, and positive findings on permanent sections. The majority of patients (84%) with SUTs, presented with urothelial recurrence without evidence of metastasis. Of those, 84.0% were treated with surgery, 10.5% with systemic chemotherapy and/or radiotherapy, and 5.6% with topical chemotherapy and/or immunotherapy. After a median follow-up of 91 mo (range: 26-155), 65.9% of patients died of disease and 21.5% died of other causes. Detection and treatment of SUTs at an asymptomatic stage can reduce the risks of cancer-specfific and overall mortality by 30%. A limitation of the study is that the available data were retrospective. CONCLUSIONS: SUTs are rare oncological events and most patients have an adverse prognosis despite absence of distant disease at diagnosis. Therefore, surveillance of the remnant urothelium should be implemented for patients with histological features of panurothelial disease as it may improve timely detection and treatment. PATIENT SUMMARY: Secondary tumors of the renal pelvis, ureters, and urethra occur in approximately 4-10% of patients after radical removal of the bladder for bladder cancer. These patients' prognoses are reduced, likely due to delayed diagnosis. Therefore, routine surveillance might be important to detect tumors at an early stage. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, Eberhard-Karls University of Tubingen, Germany. Electronic address: georgios.gakis@med.uni-tuebingen.de. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls University of Tubingen, Germany. FAU - Thalmann, George N AU - Thalmann GN AD - Department of Urology, Inselspital Bern, University of Bern, Switzerland. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, McGill University, Montreal, QC, Canada. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Systematic Review DEP - 20161006 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2017 Apr;71(4):558-559. doi: 10.1016/j.eururo.2016.11.016. PMID: 27887944 MH - Carcinoma, Transitional Cell/epidemiology/*surgery MH - *Cystectomy MH - Humans MH - Kidney Neoplasms/*epidemiology MH - Neoplasms, Second Primary/*epidemiology MH - Ureteral Neoplasms/*epidemiology MH - Urethral Neoplasms/*epidemiology MH - Urinary Bladder Neoplasms/*surgery PMC - PMC5533286 MID - NIHMS884073 OTO - NOTNLM OT - Bladder cancer OT - Radical cystectomy OT - Recurrence OT - Remnant OT - Upper urinary tract OT - Urethra OT - Urothelium COIS- Financial disclosures: Georgios Gakis certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. EDAT- 2016/10/11 06:00 MHDA- 2018/02/13 06:00 PMCR- 2018/04/01 CRDT- 2016/10/11 06:00 PHST- 2016/07/11 00:00 [received] PHST- 2016/09/22 00:00 [accepted] PHST- 2016/10/11 06:00 [pubmed] PHST- 2018/02/13 06:00 [medline] PHST- 2016/10/11 06:00 [entrez] PHST- 2018/04/01 00:00 [pmc-release] AID - S0302-2838(16)30675-3 [pii] AID - 10.1016/j.eururo.2016.09.035 [doi] PST - ppublish SO - Eur Urol. 2017 Apr;71(4):545-557. doi: 10.1016/j.eururo.2016.09.035. Epub 2016 Oct 6. PMID- 27699608 OWN - NLM STAT- MEDLINE DCOM- 20180130 LR - 20220330 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 23 IP - Suppl 5 DP - 2016 Dec TI - Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy. PG - 1048-1054 AB - PURPOSE: To investigate the prognostic significance of sarcopenia on long-term outcomes in patients with bladder cancer after radical cystectomy (RC). METHODS: We retrospectively reviewed 136 patients undergoing RC for urothelial carcinoma at our institution. Prognostic impact of the preoperative clinical, laboratory, and radiologic parameters were evaluated by Cox proportional hazard model analyses, and a nomogram was developed to predict cancer-specific survival (CSS) after RC. RESULTS: The mean follow-up was 46.7 months. Patients with sarcopenia had a significantly shorter CSS than those without sarcopenia. On univariate Cox analysis, clinical T stage, histology of transurethral resection of bladder tumor (TURBT) specimen, pretreatment hemoglobin, pretreatment neutrophil-to-lymphocyte ratio (NLR), pretreatment serum C-reactive protein level, pretreatment serum albumin level, presence of hydronephrosis, and presence of sarcopenia were associated with significantly worse CSS. On multivariate Cox stepwise analysis, sarcopenia (hazard rate [HR] = 2.3, p = 0.015), clinical T stage (cT4: HR = 5.3; p = 0.0096), presence of hydronephrosis (HR = 2.0; p = 0.033), histology of TURBT specimen (HR = 2.2, p = 0.044), and NLR (HR = 1.3; p = 0.0048) were significant independent predictors of an unfavorable prognosis Based on the results of the multivariate analysis, we developed a nomogram to predict 1-, 3-, and 5-year CSS after RC. CONCLUSIONS: Sarcopenia, clinical T stage, presence of hydronephrosis, histology of TURBT specimen, and NLR are novel preoperative prognostic factors even after adjustment for other known preoperative predictors in patients undergoing RC for bladder cancer. FAU - Hirasawa, Yosuke AU - Hirasawa Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. wbqmd473@yahoo.co.jp. FAU - Nakashima, Jun AU - Nakashima J AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. AD - Department of Urology, Sanno Hospital, Tokyo, Japan. AD - Clinical Medicine Research Center, International University of Health and Welfare, Tokyo, Japan. FAU - Yunaiyama, Daisuke AU - Yunaiyama D AD - Department of Radiology, Tokyo Medical University, Tokyo, Japan. FAU - Sugihara, Toru AU - Sugihara T AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Gondo, Tatsuo AU - Gondo T AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Nakagami, Yoshihiro AU - Nakagami Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Horiguchi, Yutaka AU - Horiguchi Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohno, Yoshio AU - Ohno Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Namiki, Kazunori AU - Namiki K AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohori, Makoto AU - Ohori M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Tokuuye, Koichi AU - Tokuuye K AD - Department of Radiology, Tokyo Medical University, Tokyo, Japan. FAU - Tachibana, Masaaki AU - Tachibana M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20161003 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/blood/*complications/pathology/*surgery MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Hydronephrosis/etiology MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Neutrophils MH - Preoperative Period MH - Proportional Hazards Models MH - Retrospective Studies MH - Sarcopenia/*complications MH - Survival Rate MH - Urinary Bladder Neoplasms/blood/*complications/pathology/*surgery EDAT- 2016/10/05 06:00 MHDA- 2018/01/31 06:00 CRDT- 2016/10/05 06:00 PHST- 2016/01/25 00:00 [received] PHST- 2016/10/05 06:00 [pubmed] PHST- 2018/01/31 06:00 [medline] PHST- 2016/10/05 06:00 [entrez] AID - 10.1245/s10434-016-5606-4 [pii] AID - 10.1245/s10434-016-5606-4 [doi] PST - ppublish SO - Ann Surg Oncol. 2016 Dec;23(Suppl 5):1048-1054. doi: 10.1245/s10434-016-5606-4. Epub 2016 Oct 3. PMID- 27696214 OWN - NLM STAT- MEDLINE DCOM- 20170727 LR - 20260127 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 49 IP - 1 DP - 2017 Jan TI - Socioeconomic status is associated with urinary diversion utilization after radical cystectomy for bladder cancer. PG - 77-82 LID - 10.1007/s11255-016-1422-9 [doi] AB - PURPOSE: To assess socioeconomic disparities in urinary diversion utilization in a contemporary American cohort. METHODS: In the National Cancer Database, we identified 4538 patients who underwent cystectomy with urinary diversion for clinical T1-2N0M0 bladder cancer from 2010 to 2013. Multivariable logistic regression was used to identify predictors of urinary diversion type: ileal conduit (IC), continent cutaneous reservoir (CCR), or orthotopic neobladder (ON). Covariates included age, gender, race, income, Charlson score, clinical T stage, hospital cystectomy volume, teaching status, and surgical approach. Subgroup analysis by hospital volume (low, intermediate, or high) and teaching status (academic or non-academic) was performed to ascertain the impact of regionalization on urinary diversion use. RESULTS: The final cohort included 4066 (89.6 %) patients with IC, 292 (6.4 %) with CCR, and 180 (4.0 %) with ON. On multivariable analysis, younger age (p < .01), higher income (p < .01), and high cystectomy volume predicted increased use of CCR and ON. Female gender predicted increased use of CCR versus IC (p < .01), and academic hospital status predicted increased use of ON versus IC (p = .04). On subgroup analysis, after further adjustment for hospital volume and teaching status, higher income remained an independent predictor of ON use. CONCLUSIONS: Despite regionalization of care, higher income patients are more likely to receive complex urinary diversions after radical cystectomy. Other related socioeconomic factors, especially patient education, may influence this practice pattern. FAU - Maurice, Matthew J AU - Maurice MJ AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kim, Simon P AU - Kim SP AD - Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Ave., Office 4565, Mailstop LKS 5046, Cleveland, OH, 44106, USA. FAU - Abouassaly, Robert AU - Abouassaly R AD - Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Ave., Office 4565, Mailstop LKS 5046, Cleveland, OH, 44106, USA. robert.abouassaly@uhhospitals.org. LA - eng PT - Journal Article PT - Observational Study DEP - 20160930 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Academic Medical Centers/statistics & numerical data MH - Age Factors MH - Aged MH - Carcinoma, Transitional Cell/*surgery MH - Cystectomy MH - Educational Status MH - Female MH - Healthcare Disparities MH - Hospitals, High-Volume/statistics & numerical data MH - Humans MH - Income MH - Male MH - Middle Aged MH - Registries MH - Retrospective Studies MH - Sex Factors MH - *Social Class MH - *Surgically-Created Structures MH - United States MH - Urinary Bladder/*surgery MH - Urinary Bladder Neoplasms/*surgery MH - Urinary Diversion/methods/*statistics & numerical data OTO - NOTNLM OT - Income OT - Social class OT - Urinary diversion EDAT- 2016/10/04 06:00 MHDA- 2017/07/28 06:00 CRDT- 2016/10/04 06:00 PHST- 2016/09/05 00:00 [received] PHST- 2016/09/18 00:00 [accepted] PHST- 2016/10/04 06:00 [pubmed] PHST- 2017/07/28 06:00 [medline] PHST- 2016/10/04 06:00 [entrez] AID - 10.1007/s11255-016-1422-9 [pii] AID - 10.1007/s11255-016-1422-9 [doi] PST - ppublish SO - Int Urol Nephrol. 2017 Jan;49(1):77-82. doi: 10.1007/s11255-016-1422-9. Epub 2016 Sep 30. PMID- 29371493 OWN - NLM STAT- MEDLINE DCOM- 20180212 LR - 20260127 IS - 1812-2078 (Electronic) IS - 1812-2027 (Linking) VI - 14 IP - 56 DP - 2016 Oct.-Dec. TI - Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital. PG - 352-356 AB - Background Most of the recent evidences suggest for risk-based management of non muscle invasive bladder cancer (NMIBC) to reduce the risk of recurrence and progression. Objective This study was conducted to assess the recurrence and progression of non muscle invasive bladder cancer in Nepalese patients using European Organization for Research and Treatment of Cancer (EORTC) risk tables and to assess the effectiveness of intravesical therapy to reduce the risk of recurrence. Method A prospective observational single centre study was conducted at Tribhuvan University Teaching Hospital from January 2010- December 2012. Forty six patients with non muscle invasive bladder cancer who underwent transurethral resection of bladder tumor and completed two years follow up were included. According to the European Organization for Research and Treatment of Cancer (EORTC) risk table, the patients were divided into low, intermediate and high risk groups. The patients received postoperative adjuvant therapy and surveillance as per the European Association of Urology guidelines. Result Among the 46 patients, the overall two year recurrence and progression rate was 8 (17%) and 1 (2%) respectively. Out of seven patients in low risk category, none of them developed recurrence or progression of disease. Out of 15 patients in intermediate risk category the one year and two year recurrence rate was 13% and 20% respectively. Out of 24 patients in high risk category the one and two year recurrence rate was 17% and 21% respectively. The risk reduction by use of intravesical Bacillus Calmette Guerin (BCG) for recurrence in high risk category was 58% and 60% in first and second year respectively. In our study, the overall and individual risk group, the one and two year recurrence rate was lower than that predicted by European Organization for Research and Treatment of Cancer risk table. Conclusion Risk-based management of non muscle invasive bladder cancer by using the European Organization for Research and Treatment of Cancer risk table is a useful method of management, though its prediction rates are lower in Nepalese population. FAU - Luitel, B R AU - Luitel BR AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Chalise, P R AU - Chalise PR AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Nathani, S AU - Nathani S AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Gupta, D K AU - Gupta DK AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Subedi, P AU - Subedi P AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Chapagain, S AU - Chapagain S AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Sharma, U K AU - Sharma UK AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Gyawali, P R AU - Gyawali PR AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Shrestha, G K AU - Shrestha GK AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. FAU - Joshi, B R AU - Joshi BR AD - Department of Surgery, Urology Unit, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal. LA - eng PT - Journal Article PT - Observational Study PL - Nepal TA - Kathmandu Univ Med J (KUMJ) JT - Kathmandu University medical journal (KUMJ) JID - 101215359 SB - IM MH - Administration, Intravesical MH - Aged MH - Disease Progression MH - Female MH - Hospitals, Teaching MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Nepal/epidemiology MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Urinary Bladder Neoplasms/*pathology/*surgery EDAT- 2016/10/01 00:00 MHDA- 2018/02/13 06:00 CRDT- 2018/01/27 06:00 PHST- 2018/01/27 06:00 [entrez] PHST- 2016/10/01 00:00 [pubmed] PHST- 2018/02/13 06:00 [medline] PST - ppublish SO - Kathmandu Univ Med J (KUMJ). 2016 Oct.-Dec.;14(56):352-356. PMID- 27690238 OWN - NLM STAT- MEDLINE DCOM- 20170504 LR - 20220409 IS - 1476-5586 (Electronic) IS - 1522-8002 (Print) IS - 1476-5586 (Linking) VI - 18 IP - 10 DP - 2016 Oct TI - CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. PG - 636-646 LID - S1476-5586(16)30031-8 [pii] LID - 10.1016/j.neo.2016.08.002 [doi] AB - Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are reported to be associated with poor prognosis, depending on their pro-tumoral roles. Current knowledge of TAMs and CAFs in the tumor microenvironment of urothelial cancer of the bladder (UCB) is limited. Therefore, we investigated the paracrine effect induced by TAMs and CAFs in the tumor microenvironment of human UCB. For this, we first carried out immunohistochemical analysis for CXCL1, CD204 (TAM marker), alphaSMA (CAF marker), E-cadherin, and MMP2 using 155 UBC tissue samples. Next, CXCL1-overexpressing clones of THP-1-derived TAMs and NIH3T3-derived CAFs were developed by lentiviral vector infection. The immunohistochemical study showed high CXCL1 levels in UCB cells to be associated with enhanced recruitment of TAMs/CAFs, higher metastatic potential, and poor prognosis. Three-dimensional (3D) co-culture of UCB cells and TAMs/CAFs suggested that CXCL1 production in TAMs/CAFs play an important role in cell-to-cell adhesion and interaction among cancer cells and these stromal cells. CXCL1-expressing TAMs/CAFs enhanced tumor growth of subcutaneous UCB tumors in nude mice when injected together. In addition, an experiment using the orthotopic bladder cancer model revealed that CXCL1 production in TAMs/CAFs supported tumor implantation into the murine bladder wall and UCB growth when injected together, which was confirmed by clinical data of patients with bladder cancer. Thus, CXCL1 signaling in the tumor microenvironment is highly responsible for repeated intravesical recurrence, disease progression, and drug resistance through enhanced invasion ability. In conclusion, disrupting CXCL1 signaling to dysregulate this chemokine is a promising therapeutic approach for human UCB. CI - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. Electronic address: makitomiyake@yahoo.co.jp. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan; Department of Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Aoki, Katsuya AU - Aoki K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Konishi, Noboru AU - Konishi N AD - Department of Pathology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Toritsuka, Michihiro AU - Toritsuka M AD - Department of Psychiatry, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Kishimoto, Toshifumi AU - Kishimoto T AD - Department of Psychiatry, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. FAU - Rosser, Charles J AU - Rosser CJ AD - Clinical and Translational Research Program, University of Hawaii Cancer Center, 701 Ilalo St, Rm 327, Honolulu, HI 96813, USA. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara 634-8522, Japan. LA - eng PT - Journal Article DEP - 20160928 PL - United States TA - Neoplasia JT - Neoplasia (New York, N.Y.) JID - 100886622 RN - 0 (Chemokine CXCL1) RN - 0 (Cytokines) SB - IM EIN - Neoplasia. 2017 Mar;19(3):250-251. doi: 10.1016/j.neo.2016.12.012. PMID: 28254152 MH - Animals MH - Cell Adhesion MH - Cell Line MH - Chemokine CXCL1/genetics/*metabolism MH - Cytokines/genetics/metabolism MH - Disease Models, Animal MH - Disease Progression MH - Fibroblasts/*metabolism/pathology MH - Gene Expression MH - Humans MH - Macrophages/*metabolism/pathology MH - Mice MH - Models, Biological MH - Neoplasm Invasiveness MH - Tumor Microenvironment MH - Urinary Bladder Neoplasms/genetics/*metabolism/*pathology/therapy PMC - PMC5043399 EDAT- 2016/10/01 06:00 MHDA- 2017/05/05 06:00 PMCR- 2016/09/28 CRDT- 2016/10/01 06:00 PHST- 2016/04/29 00:00 [received] PHST- 2016/08/05 00:00 [revised] PHST- 2016/08/11 00:00 [accepted] PHST- 2016/10/01 06:00 [pubmed] PHST- 2017/05/05 06:00 [medline] PHST- 2016/10/01 06:00 [entrez] PHST- 2016/09/28 00:00 [pmc-release] AID - S1476-5586(16)30031-8 [pii] AID - 10.1016/j.neo.2016.08.002 [doi] PST - ppublish SO - Neoplasia. 2016 Oct;18(10):636-646. doi: 10.1016/j.neo.2016.08.002. Epub 2016 Sep 28. PMID- 27689332 OWN - NLM STAT- MEDLINE DCOM- 20180226 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 46 DP - 2016 Nov 15 TI - Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival. PG - 75648-75658 LID - 10.18632/oncotarget.12315 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) often has a worse prognosis following its progression to muscle-invasive bladder cancer (MIBC), despite radical cystectomy with pelvic lymph node dissection combined with chemotherapy. Therefore, the discovery of novel biomarkers for predicting the progression of this disease and of therapeutic targets for preventing it is crucial. We performed whole-exome sequencing to analyze superficial tumor tissues (Tsup) and basal tumor tissues (Tbas) from 3 MIBC patients and identified previously unreported copy number variations in IPO11 that warrants further investigation as a molecular target. In addition, we identified a significant association between the absolute copy number and mRNA expression of IPO11 and found that high importin-11 expression was correlated with poor 3-year overall survival (OS), cancer-specific survival (CSS) and cancer-free survival (CFS) compared with low expression in the BCa patients. Importin-11 overexpression was also an independent risk factor for CSS and CFS in the BCa patients. Our study has revealed that IPO11 copy number amplification contributes to its overexpression and that these changes are unfavorable prognostic factors in NMIBC. Thus, IPO11 copy number amplification and importin-11 overexpression are promising biomarkers for predicting the progression and poor prognosis of patients with NMIBC. FAU - Zhao, Junjie AU - Zhao J AD - Department of Urology, Yantai Yuhuangding Hospital, Yantai 264000, China. AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - Xu, Weidong AU - Xu W AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - He, Minghui AU - He M AD - Cancer Research Department, BGI-Shenzhen, Yantian District, Shenzhen, Guangdong 518083, China. FAU - Zhang, Zhensheng AU - Zhang Z AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - Zeng, Shuxiong AU - Zeng S AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - Ma, Chong AU - Ma C AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - Sun, Yinghao AU - Sun Y AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. FAU - Xu, Chuanliang AU - Xu C AD - Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (IPO11 protein, human) RN - 0 (beta Karyopherins) SB - IM MH - Aged MH - Combined Modality Therapy MH - *DNA Copy Number Variations MH - *Gene Expression MH - Humans MH - Male MH - Middle Aged MH - Muscles/pathology MH - Mutation MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/*genetics/*mortality/pathology/therapy MH - *Whole Genome Sequencing MH - beta Karyopherins/*genetics PMC - PMC5342767 OTO - NOTNLM OT - IPO11 OT - bladder cancer OT - prognosis OT - tumor progression OT - whole-exome sequencing COIS- CONFLICTS OF INTEREST The authors declare that there are no competing financial interests. EDAT- 2016/10/01 06:00 MHDA- 2018/02/27 06:00 PMCR- 2016/11/15 CRDT- 2016/10/01 06:00 PHST- 2016/07/10 00:00 [received] PHST- 2016/09/06 00:00 [accepted] PHST- 2016/10/01 06:00 [pubmed] PHST- 2018/02/27 06:00 [medline] PHST- 2016/10/01 06:00 [entrez] PHST- 2016/11/15 00:00 [pmc-release] AID - 12315 [pii] AID - 10.18632/oncotarget.12315 [doi] PST - ppublish SO - Oncotarget. 2016 Nov 15;7(46):75648-75658. doi: 10.18632/oncotarget.12315. PMID- 27683040 OWN - NLM STAT- MEDLINE DCOM- 20180305 LR - 20250418 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 2 DP - 2017 Jan 10 TI - Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis. PG - 3568-3580 LID - 10.18632/oncotarget.12239 [doi] AB - BACKGROUND: Perioperative treatments have been used to improve prognosis in patients with upper tract urothelial carcinoma (UTUC). However, optimal management remains unestablished. METHODS: We searched the Embase, Web of Science and Cochrane databases for studies published before June 20, 2015. All included studies were categorised into three groups on the basis of the outcome reported (overall survival (OS), disease-specific survival (DSS) and recurrence-free survival (RFS)). Relative hazard ratios (HRs) for death were calculated using random-effects Bayesian network meta-analysis methods. We also ranked the three different treatments in terms of three outcomes. RESULTS: A total of 31 trials with 8100 patients were included. Compared with the control, adjuvant chemotherapy (AC) could improve OS, DSS and RFS by 32% (HR 0.68, 95% CI 0.51-0.89), 29% (HR 0.71, 95% CI 0.54-0.89) and 51% (HR 0.49, 95% CI 0.23-0.85), respectively. We noted a marked prolongation of RFS in both intravesical chemotherapy (HR 0.32, 95% CI 0.09-0.69) as well as concurrent radiotherapy and intravesical chemotherapy (HR 0.32, 95% CI 0.03-0.97) than in the control. Neoadjuvant chemotherapy (NAC) showed a significant improvement in DSS relative to the control (HR 0.25, 95% CI 0.06-0.61) and a distinct advantage over AC (HR 0.36, 95% CI 0.08-0.90) or AR (HR 6.89, 95% CI 1.25-18.66). CONCLUSIONS: Our results showed that AC; intravesical chemotherapy; and concurrent radiotherapy and intravesical chemotherapy could improve the prognosis of UTUC patients. NAC was found to be more favourable for UTUC than AC in terms of DSS. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Li, Peng AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Deng, Xiaheng AU - Deng X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Dong, Hongquan AU - Dong H AD - Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cheng, Yidong AU - Cheng Y AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhang, Xiaolei AU - Zhang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yang, Chengdi AU - Yang C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Tang, Jingyuan AU - Tang J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yuan, Wenbo AU - Yuan W AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Xu, Xiaoting AU - Xu X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Tao, Jun AU - Tao J AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Li, Pengchao AU - Li P AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yang, Haiwei AU - Yang H AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Gu, Min AU - Gu M AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Zengjun AU - Wang Z AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article PT - Network Meta-Analysis PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 SB - IM MH - Bayes Theorem MH - Combined Modality Therapy MH - Disease Management MH - Humans MH - *Perioperative Care/methods MH - Survival Analysis MH - Treatment Outcome MH - Urethral Neoplasms/mortality/*pathology/*therapy MH - Urologic Neoplasms/mortality/*pathology/*therapy PMC - PMC5356904 OTO - NOTNLM OT - network meta-analysis OT - perioperative treatment OT - upper tract urothelial carcinoma COIS- CONFLICTS OF INTEREST Authors have nothing to disclose. EDAT- 2016/09/30 06:00 MHDA- 2018/03/06 06:00 PMCR- 2017/01/10 CRDT- 2016/09/30 06:00 PHST- 2015/12/23 00:00 [received] PHST- 2016/09/20 00:00 [accepted] PHST- 2016/09/30 06:00 [pubmed] PHST- 2018/03/06 06:00 [medline] PHST- 2016/09/30 06:00 [entrez] PHST- 2017/01/10 00:00 [pmc-release] AID - 12239 [pii] AID - 10.18632/oncotarget.12239 [doi] PST - ppublish SO - Oncotarget. 2017 Jan 10;8(2):3568-3580. doi: 10.18632/oncotarget.12239. PMID- 27670858 OWN - NLM STAT- MEDLINE DCOM- 20180327 LR - 20260127 IS - 1613-7671 (Electronic) IS - 0043-5325 (Print) IS - 0043-5325 (Linking) VI - 129 IP - 11-12 DP - 2017 Jun TI - Impact of gender on tumor stage and survival of upper urinary tract urothelial cancer : A population-based study. PG - 385-390 LID - 10.1007/s00508-016-1088-4 [doi] AB - BACKGROUND: The aim of this study was to analyze the impact of gender on tumor stage, overall and cancer-specific mortality of upper urinary tract urothelial cancer (UTUC) in a population-based, nationwide analysis. METHODS: All Austrian patients with UTUC diagnosed between 1983 and 2010 were included in this study. Overall mortality was estimated by the Kaplan-Meier method. Cancer-specific (UTUC) mortality was estimated by cumulative incidence with mortality due to other causes as a competing risk. The effect of age was adjusted in a descriptive as well as a statistical inferential way. RESULTS: This study included 2066 patients (men n = 1169, mean age 68.3 +/-11.5 years, women n = 897, 72.6 +/-10.4 years). Tumor stage distribution was as follows: pT1: men n = 411, women n = 268, pT2: men n = 263, women n = 187, pT3: men n = 382, women n = 328 and pT4: men n = 113, women n = 114. The male:female ratio continuously declined from 1.5 for pT1 tumors to 1.4 for pT2 tumors, 1.2 for pT3 tumors and 1.0 for pT4-tumors. In the entire cohort the 5‑year cumulative overall mortality was 57 % for women versus 50 % for men (p = 0.0002). For pT1 (women 33 %, men 31 %) and pT2 stage tumors (women 45 %, men 45 %) the 5‑year overall mortality was comparable between both sexes. In pT3 (women 68 %, men 62 %) and pT4 (women 95 %, men 87 %) tumors women had a higher overall mortality rate. The 5‑year cancer-specific mortality (CSM) of the entire cohort was 12 % for women and 10 % for men (p = 0.067): pT1 women 5 % men 3 %, pT2 women 9 % men 10 %, pT3 women 14 % men 11 % and pT4 women 29 % men 27 %. CONCLUSIONS: In this population-based nationwide analysis, sex differences were notable for UTUC. Women tended to have more advanced tumor stages at diagnosis and a higher overall and cancer-specific mortality in advanced tumor stages. FAU - Mohamad Al-Ali, Badereddin AU - Mohamad Al-Ali B AD - Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria. AD - Department of Urology, Medical University of Graz, Graz, Austria. FAU - Madersbacher, Stephan AU - Madersbacher S AD - Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria. FAU - Zielonke, Nadine AU - Zielonke N AD - Austrian National Cancer Registry, Statistics Austria, Vienna, Austria. FAU - Schauer, Ingrid AU - Schauer I AD - Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria. FAU - Waldhoer, Thomas AU - Waldhoer T AD - Department of Epidemiology, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria. thomas.waldhoer@meduniwien.ac.at. FAU - Haidinger, Gerald AU - Haidinger G AD - Department of Epidemiology, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria. LA - eng PT - Journal Article DEP - 20160926 PL - Austria TA - Wien Klin Wochenschr JT - Wiener klinische Wochenschrift JID - 21620870R SB - IM MH - Age Distribution MH - Austria/epidemiology MH - Carcinoma, Transitional Cell/*mortality/*pathology MH - Cohort Studies MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Neoplasm Staging MH - Prevalence MH - Reproducibility of Results MH - Risk Factors MH - Sensitivity and Specificity MH - Sex Distribution MH - Survival Rate MH - Urologic Neoplasms/*mortality/*pathology PMC - PMC5486730 OTO - NOTNLM OT - Radical nephroureterectomy OT - Sex OT - Tumor stage OT - Upper urinary tract OT - Urothelial carcinoma COIS- B. Mohamad Al-Ali, S. Madersbacher, N. Zielonke, I. Schauer, T. Waldhoer, and G. Haidinger declare that they have no competing interests. EDAT- 2016/09/28 06:00 MHDA- 2018/03/28 06:00 PMCR- 2016/09/26 CRDT- 2016/09/28 06:00 PHST- 2016/04/29 00:00 [received] PHST- 2016/08/24 00:00 [accepted] PHST- 2016/09/28 06:00 [pubmed] PHST- 2018/03/28 06:00 [medline] PHST- 2016/09/28 06:00 [entrez] PHST- 2016/09/26 00:00 [pmc-release] AID - 10.1007/s00508-016-1088-4 [pii] AID - 1088 [pii] AID - 10.1007/s00508-016-1088-4 [doi] PST - ppublish SO - Wien Klin Wochenschr. 2017 Jun;129(11-12):385-390. doi: 10.1007/s00508-016-1088-4. Epub 2016 Sep 26. PMID- 27660385 OWN - NLM STAT- Publisher LR - 20191120 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2016 DP - 2016 TI - Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis. PG - 4591910 LID - 4591910 AB - Purpose. Nonmuscle invasive bladder cancer (BCa) has a high recurrence rate requiring lifelong surveillance. Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of recurrent bladder cancer. However, no single marker can achieve the required accuracy. The purpose of this study was to select a multiparameter panel, comprising urinary biomarkers and clinical parameters, for BCa recurrence diagnosis. Experimental Design. Candidate biomarkers were measured in urine samples of BCa patients with recurrence and BCa patients without recurrence. A multiplatform strategy was used for marker quantification comprising a multiplexed microarray and an automated platform for ELISA analysis. A multivariate statistical analysis combined the results from both platforms with the collected clinical data. Results. The best performing combination of biomarkers and clinical parameters achieved an AUC value of 0.91, showing better performance than individual parameters. This panel comprises six biomarkers (cadherin-1, IL-8, ErbB2, IL-6, EN2, and VEGF-A) and three clinical parameters (number of past recurrences, number of BCG therapies, and stage at time of diagnosis). Conclusions. The multiparameter panel could be a useful noninvasive tool for BCa surveillance and potentially impact the clinical management of this disease. Validation of results in an independent cohort is warranted. FAU - De Paoli, Marine AU - De Paoli M AD - AXO Science SAS, 34 rue du Mail, 69004 Lyon, France. FAU - Gogalic, Selma AU - Gogalic S AD - AIT Austrian Institute of Technology GmbH, Konrad-Lorenz-Strasse 24, 3430 Tulln, Austria. FAU - Sauer, Ursula AU - Sauer U AD - AIT Austrian Institute of Technology GmbH, Konrad-Lorenz-Strasse 24, 3430 Tulln, Austria. FAU - Preininger, Claudia AU - Preininger C AD - AIT Austrian Institute of Technology GmbH, Konrad-Lorenz-Strasse 24, 3430 Tulln, Austria. FAU - Pandha, Hardev AU - Pandha H AD - Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Leggett Building, Surrey GU2 7WG, UK. FAU - Simpson, Guy AU - Simpson G AD - Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Leggett Building, Surrey GU2 7WG, UK. FAU - Horvath, Andras AU - Horvath A AD - Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Leggett Building, Surrey GU2 7WG, UK. FAU - Marquette, Christophe AU - Marquette C AUID- ORCID: 0000-0003-3019-0696 AD - Universite de Lyon, Universite Lyon 1, CNRS, INSA, CPE-Lyon, ICBMS, UMR 5246, No. 43, boulevard du 11 Novembre 1918, 69622 Villeurbanne Cedex, France. LA - eng PT - Journal Article DEP - 20160831 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 PMC - PMC5021863 EDAT- 2016/09/24 06:00 MHDA- 2016/09/24 06:00 PMCR- 2016/08/31 CRDT- 2016/09/24 06:00 PHST- 2016/05/17 00:00 [received] PHST- 2016/07/27 00:00 [accepted] PHST- 2016/09/24 06:00 [entrez] PHST- 2016/09/24 06:00 [pubmed] PHST- 2016/09/24 06:00 [medline] PHST- 2016/08/31 00:00 [pmc-release] AID - 10.1155/2016/4591910 [doi] PST - ppublish SO - Dis Markers. 2016;2016:4591910. doi: 10.1155/2016/4591910. Epub 2016 Aug 31. PMID- 27660257 OWN - NLM STAT- MEDLINE DCOM- 20180130 LR - 20220311 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 23 IP - Suppl 5 DP - 2016 Dec TI - The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking. PG - 1039-1047 AB - PURPOSE: We speculated that a heterogeneous population of non-muscle invasive bladder cancer (NMIBC) patients with a previous history of smoking may be more precisely stratified by a biomarker associated with tumor aggressiveness and then focused on the preoperative neutrophil-to-lymphocyte ratio (pre-NLR), which is a simple index of systemic inflammation. METHODS: Our study population comprised 605 patients initially diagnosed with NMIBC at our 3 institutions between 1995 and 2013. We analyzed the relationships between pre-NLR levels and clinical outcomes in NMIBC. A pre-NLR level of >/=2.2 was defined as elevated according to a calculation by a receiver-operating curve analysis. RESULTS: In overall, a total of 296 patients (48.9 %) had pre-NLR >/= 2.2, and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. Among 344 patients with a previous history of smoking, 184 (53.5 %) had pre-NLR >/= 2.2 and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. The 5-year recurrence-free survival and progression-free survival rates in patients with pre-NLR < 2.2 were 66.3 and 97.5 %, respectively, which were significantly higher than those in their counterparts (31.7 and 90.4 %, p < 0.001). In either subgroup of patients who were current smokers (N = 175) or former smokers (N = 169), the pre-NLR level was the only independent risk factor for tumor recurrence. The pre-NLR level was not associated with tumor recurrence or stage progression in 261 nonsmoking patients. CONCLUSIONS: Pre-NLR levels may be a useful marker for identifying worse clinical outcomes in NMIBC patients, particularly those with a previous history of smoking. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Yuge, Kazuyuki AU - Yuge K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Yanai, Yoshinori AU - Yanai Y AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Miyajima, Akira AU - Miyajima A AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Asakura, Hirotaka AU - Asakura H AD - Department of Urology, Saitama Medical University Hospital, Saitama, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20160922 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/blood MH - *Cigarette Smoking MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*blood/*pathology MH - Neoplasm Staging MH - *Neutrophils MH - Predictive Value of Tests MH - Preoperative Period MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*blood/*pathology/surgery MH - Young Adult EDAT- 2016/09/24 06:00 MHDA- 2018/01/31 06:00 CRDT- 2016/09/24 06:00 PHST- 2016/04/04 00:00 [received] PHST- 2016/09/24 06:00 [pubmed] PHST- 2018/01/31 06:00 [medline] PHST- 2016/09/24 06:00 [entrez] AID - 10.1245/s10434-016-5578-4 [pii] AID - 10.1245/s10434-016-5578-4 [doi] PST - ppublish SO - Ann Surg Oncol. 2016 Dec;23(Suppl 5):1039-1047. doi: 10.1245/s10434-016-5578-4. Epub 2016 Sep 22. PMID- 27655672 OWN - NLM STAT- MEDLINE DCOM- 20180222 LR - 20240524 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 50 DP - 2016 Dec 13 TI - Positive association of collagen type I with non-muscle invasive bladder cancer progression. PG - 82609-82619 LID - 10.18632/oncotarget.12089 [doi] AB - PURPOSE: Non-muscle invasive bladder cancers (NMIBC) are generally curable, while ~15% progresses into muscle-invasive cancer with poor prognosis. While efforts have been made to identify genetic alternations associated with progression, the extracellular matrix (ECM) microenvironment remains largely unexplored. Type I collagen is a major component of the bladder ECM, and can be altered during cancer progression. We set out to explore the association of type I collagen with NMIBC progression. EXPERIMENTAL DESIGN: The associations of COL1A1 and COL1A2 mRNA levels with progression were evaluated in a multi-center cohort of 189 patients with NMIBCs. Type I collagen protein expression and structure were evaluated in an independent single-center cohort of 80 patients with NMIBCs. Immunohistochemical analysis was performed and state-of-the-art multi-photon microscopy was used to evaluate collagen structure via second harmonic generation imaging. Progression to muscle invasion was the primary outcome. Kaplan-Meier method, Cox regression, and Wilcoxon rank-sum were used for statistical analysis. RESULTS: There is a significant association of high COL1A1 and COL1A2 mRNA expression in patients with poor progression-free survival (P=0.0037 and P=0.011, respectively) and overall survival (P=0.024 and P=0.012, respectively). Additionally, immunohistochemistry analysis of type I collagen protein deposition revealed a significant association with progression (P=0.0145); Second-harmonic generation imaging revealed a significant lower collagen fiber curvature ratio in patients with invasive progression (P = 0.0018). CONCLUSIONS: Alterations in the ECM microenvironment, particularly type I collagen, likely contributes to bladder cancer progression. These findings will open avenues to future functional studies to investigate ECM-tumor interaction as a potential therapeutic intervention to treat NMIBCs. FAU - Brooks, Michael AU - Brooks M AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Mo, Qianxing AU - Mo Q AD - Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Krasnow, Ross AU - Krasnow R AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Ho, Philip Levy AU - Ho PL AD - Department of Urology, Baylor College of Medicine, Kelsey-Seybold Clinic, Houston, Texas 77030, USA. FAU - Lee, Yu-Cheng AU - Lee YC AD - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Xiao, Jing AU - Xiao J AD - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Kurtova, Antonina AU - Kurtova A AD - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Lerner, Seth AU - Lerner S AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Godoy, Gui AU - Godoy G AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Jian, Weiguo AU - Jian W AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Castro, Patricia AU - Castro P AD - Department of Pathology and Immunology, and Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Chen, Fengju AU - Chen F AD - Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Rowley, David AU - Rowley D AD - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Ittmann, Michael AU - Ittmann M AD - Department of Pathology and Immunology, and Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. FAU - Chan, Keith Syson AU - Chan KS AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Department of Urology, Baylor College of Medicine, Kelsey-Seybold Clinic, Houston, Texas 77030, USA. AD - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Center for Cell, Gene and Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. AD - Center for Drug Discovery Baylor College of Medicine, Houston, Texas 77030, USA. LA - eng GR - P30 CA125123/CA/NCI NIH HHS/United States GR - R01 CA175397/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (COL1A2 protein, human) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Biomarkers, Tumor/*analysis/genetics MH - Collagen Type I/*analysis/genetics/ultrastructure MH - Collagen Type I, alpha 1 Chain MH - Disease Progression MH - Disease-Free Survival MH - Extracellular Matrix/*chemistry/genetics/ultrastructure MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Oligonucleotide Array Sequence Analysis MH - Proportional Hazards Models MH - RNA, Messenger/genetics MH - Registries MH - Retrospective Studies MH - Second Harmonic Generation Microscopy MH - Texas MH - Time Factors MH - *Tumor Microenvironment MH - Urinary Bladder Neoplasms/*chemistry/genetics/mortality/pathology PMC - PMC5347718 OTO - NOTNLM OT - bladder cancer OT - cancer progression OT - invasion OT - tumor microenvironment OT - type I collagen COIS- CONFLICTS OF INTEREST The authors declare no conflict of interest. EDAT- 2016/09/23 06:00 MHDA- 2018/02/23 06:00 PMCR- 2016/12/13 CRDT- 2016/09/23 06:00 PHST- 2016/06/30 00:00 [received] PHST- 2016/09/02 00:00 [accepted] PHST- 2016/09/23 06:00 [pubmed] PHST- 2018/02/23 06:00 [medline] PHST- 2016/09/23 06:00 [entrez] PHST- 2016/12/13 00:00 [pmc-release] AID - 12089 [pii] AID - 10.18632/oncotarget.12089 [doi] PST - ppublish SO - Oncotarget. 2016 Dec 13;7(50):82609-82619. doi: 10.18632/oncotarget.12089. PMID- 27646875 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20220317 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. PG - 483.e17-483.e24 LID - S1078-1439(16)30065-5 [pii] LID - 10.1016/j.urolonc.2016.05.013 [doi] AB - BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein (CRP) are markers of systemic inflammatory response, which have been associated with the prognosis of multiple malignancies, but their relationships with oncologic outcomes of non-muscle-invasive bladder cancer (NMIBC) have not been well studied yet. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1,117 patients with NMIBC who underwent a transurethral resection of the bladder. Univariable and multivariable competing risk regression models were used to assess the association of preoperative NLR and CRP with disease recurrence and progression to muscle-invasive disease. The median follow-up was 64 months. RESULTS: In total, 360 patients (32.2%) had a high NLR (>/=2.5) and 145 (13.0%) had a high CRP (>/=5mg/l). On multivariable analyses, a high NLR was associated with both disease recurrence (subhazard ratio [SHR] = 1.27, P = 0.013) and progression (SHR = 1.72, P = 0.007), and high CRP was associated with disease progression (SHR = 1.72, P = 0.031). Adding NLR and CRP to the multivariable model predicting disease progression lead to a relevant change in discrimination (+2.0%). In a subgroup analysis of 300 patients treated with bacillus Calmette-Guerin, both high NLR and high CRP were associated with disease progression (SHR = 2.80, P = 0.026 and SHR = 3.51, P = 0.021, respectively), and NLR was associated with disease recurrence (SHR = 1.46, P = 0.046). There was also an increase in the discrimination of the model predicting progression after bacillus Calmette-Guerin following the inclusion of both markers (+2.4%). CONCLUSION: In patients with NMIBC, markers of systemic inflammation response are associated with disease recurrence and progression. The inclusion of such markers in prognostic models does enhance their accuracy. CI - Copyright (c) 2016. Published by Elsevier Inc. FAU - Mbeutcha, Aurelie AU - Mbeutcha A AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, University of Nice Sophia-Antipolis, Hopital Archet 2, Centre Hospitalier Universitaire de Nice, Nice, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: sfshariat@gmail.com. FAU - Rieken, Malte AU - Rieken M AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, University Hospital Basel, Basel, Switzerland. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology Cochin Hospital, APHP, Paris Descartes University, Paris, France. FAU - Seitz, Christian AU - Seitz C AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Lucca, Ilaria AU - Lucca I AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Rennes University Hospital, Rennes, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie- Salpetriere, APHP, University Paris VI, Paris, France. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Universita Vita-Salute, Ospedale S. Raffaele, Milan, Italy. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal, Montreal, Quebec, Canada. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160916 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers) RN - 50SG953SK6 (Mitomycin) RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Aged MH - Antineoplastic Agents/therapeutic use MH - BCG Vaccine/therapeutic use MH - Biomarkers/*blood MH - C-Reactive Protein/analysis MH - Carcinoma, Transitional Cell/*blood/complications/pathology/therapy MH - Combined Modality Therapy MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - Leukocyte Count MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Mitomycin/therapeutic use MH - Models, Biological MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neutrophils MH - Prognosis MH - Recurrence MH - Retrospective Studies MH - Systemic Inflammatory Response Syndrome/*blood/complications MH - Urinary Bladder Neoplasms/*blood/complications/pathology/therapy OTO - NOTNLM OT - BCG OT - Biomarker OT - Guideline OT - Prediction OT - Prognosis OT - Progression OT - Response EDAT- 2016/09/21 06:00 MHDA- 2018/01/18 06:00 CRDT- 2016/09/21 06:00 PHST- 2015/12/23 00:00 [received] PHST- 2016/03/23 00:00 [revised] PHST- 2016/05/12 00:00 [accepted] PHST- 2016/09/21 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/09/21 06:00 [entrez] AID - S1078-1439(16)30065-5 [pii] AID - 10.1016/j.urolonc.2016.05.013 [doi] PST - ppublish SO - Urol Oncol. 2016 Nov;34(11):483.e17-483.e24. doi: 10.1016/j.urolonc.2016.05.013. Epub 2016 Sep 16. PMID- 27639776 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20181113 IS - 1873-2496 (Electronic) IS - 1078-1439 (Print) IS - 1078-1439 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. PG - 484.e19-484.e25 LID - S1078-1439(16)30114-4 [pii] LID - 10.1016/j.urolonc.2016.05.033 [doi] AB - BACKGROUND: Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE: To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomized comparison, BCG Connaught and TICE were compared for time to recurrence, progression, and the duration of cancer specific survival and overall survival. RESULTS AND LIMITATIONS: Information on the BCG strain was available for 2,099 patients: 957 on Connaught and 1,142 on TICE. Overall, 765 (36%) patients received some form of maintenance BCG, 560 (59%) on Connaught and 205 (18%) on TICE. Without maintenance, Connaught was more effective than TICE only for the time to first recurrence (hazard ratio [HR] = 1.48; 95% CI: 1.20-1.82; P<0.001). With maintenance, TICE was more effective than Connaught for the time to first recurrence (HR = 0.66; 95% CI: 0.47-0.93; P = 0.019) with a trend for cancer specific survival (HR = 0.36; 95% CI: 0.14-0.92; P = 0.033). For time to progression and overall survival, Connaught and TICE had a similar efficacy. Compared to no maintenance therapy, maintenance BCG significantly reduced the risk of recurrence, progression and death, both overall, and disease specific, for TICE, but not for Connaught. CONCLUSIONS: We found that BCG Connaught results in a lower recurrence rate as compared with BCG TICE when no maintenance is used. However, the opposite is true when maintenance is given. PATIENT SUMMARY: As there is currently a BCG shortage, information on the efficacy of different BCG strains is important. In this nonrandomized retrospective comparison in over 2,000 patients, we found that BCG Connaught reduces the recurrence rate compared to BCG TICE when no maintenance is used, but the opposite is true when maintenance is given. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, RadboudUMC, Nijmegen, The Netherlands. Electronic address: fred.witjes@radboudumc.nl. FAU - Dalbagni, Guido AU - Dalbagni G AD - Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. FAU - Karnes, Robert J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Shariat, Shahrokh AU - Shariat S AD - Department of Urology, Comprehensive Cancer Center Medical University Vienna, Vienna, Austria. FAU - Joniau, Steven AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Urology, Paolo Giaccone General Hospital, Palermo, Italy. FAU - Larre, Stephane AU - Larre S AD - Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK. FAU - di Stasi, Savino AU - di Stasi S AD - Policlinico Tor Vergata, University of Rome, Rome, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Dipartimento di Urologia, Universita; Vita-Salute, Ospedale S. Raffaele, Milan, Italy. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Motol Hospital, 2nd Faculty of Medicine, Charles, University of Prague, Prague, Czech Republic. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. FAU - Malats, Nuria AU - Malats N AD - Department of Urology, Spanish National Cancer Research Centre-Madrid, Madrid, Spain. FAU - Irani, Jacques AU - Irani J AD - Department of Urology, Centre Hospitalier Universitaire La Miletrie, University of Poitiers, Poitiers, France. FAU - Baniel, Jack AU - Baniel J AD - Institute of Urology, Rabin Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Cai, Tommaso AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - Cha, Eugene AU - Cha E AD - Department of Urology, Weill Medical College of Cornell University, New York, NY; Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. FAU - Ardelt, Peter AU - Ardelt P AD - Facharzt fur Urologie, Abteilung fur Urologie, Chirurgische Universitatsklinik, Freiburg, Germany. FAU - Varkarakis, John AU - Varkarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Bartoletti, Riccardo AU - Bartoletti R AD - Urology Unit, S. Maria Annunziata Hospital, University of Florence, Florence, Italy. FAU - Spahn, Martin AU - Spahn M AD - Department of Urology, University Hospital of Wuerzburg, Wuertzburg, Germany. FAU - Pisano, Francesca AU - Pisano F AD - Department of Surgical Sciences, Molinette Hospital, University of Studies of Turin, Turin, Italy. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Molinette Hospital, University of Studies of Turin, Turin, Italy. FAU - Sylvester, Richard AU - Sylvester R AD - Formerly Department of Biostatistics, EORTC Headquarters, Brussels, Belgium. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20160914 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Connaught) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Drug Evaluation MH - Female MH - Follow-Up Studies MH - Humans MH - *Immunotherapy, Active MH - Kaplan-Meier Estimate MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Proportional Hazards Models MH - Recurrence MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy PMC - PMC5515280 MID - NIHMS878571 OTO - NOTNLM OT - BCG Connaught OT - BCG Tice OT - BCG vaccine OT - Immunotherapy OT - Intravesical drug administration OT - T1G3 OT - bladder cancer OT - high grade OT - progression OT - recurrence EDAT- 2016/09/19 06:00 MHDA- 2018/01/18 06:00 PMCR- 2017/11/01 CRDT- 2016/09/19 06:00 PHST- 2016/01/27 00:00 [received] PHST- 2016/05/25 00:00 [revised] PHST- 2016/05/30 00:00 [accepted] PHST- 2016/09/19 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/09/19 06:00 [entrez] PHST- 2017/11/01 00:00 [pmc-release] AID - S1078-1439(16)30114-4 [pii] AID - 10.1016/j.urolonc.2016.05.033 [doi] PST - ppublish SO - Urol Oncol. 2016 Nov;34(11):484.e19-484.e25. doi: 10.1016/j.urolonc.2016.05.033. Epub 2016 Sep 14. PMID- 27637323 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20191210 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. PG - 485.e7-485.e14 LID - S1078-1439(16)30066-7 [pii] LID - 10.1016/j.urolonc.2016.05.014 [doi] AB - PURPOSE: To assess if a panel of cell-cycle markers could improve the discrimination of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in predicting recurrence and progression of high-grade non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Between January 2007 and January 2012, every patient with high-grade NMIBC treated with transurethral resection of bladder underwent immunohistochemical staining for 5 biomarkers (p21, p27, p53, KI-67, and cyclin E1). We excluded patients who had muscle-insvasive disease, underwent early cystectomy, and those with incomplete follow-up. Kaplan-Meier curves assessed recurrence and progression-free survival. Univariate and multivariate Cox regression analysis assessed the predictive ability of markers after correcting for EORTC or CUETO risk scores. Harrel concordance index assessed for discrimination. RESULTS: There were 131 patients with a median follow-up of 31.1 months. Stage was Ta (50%), T1 (44%), and Tis (8%). For 95 patients this was the primary tumor. Intravesical therapy was used in 76% of cases of which 45% had maintenance. Recurrence-free survival rates at 6, 12, and 24 months were 68.9%, 52.1%, and 33.2%, respectively, whereas progression-free survival rate at 6, 12, and 24 months were 93.8%, 88%, and 84.3%, respectively. No differences in survival based on number of altered markers were noted. Biomarker status was neither a significant predictor of recurrence nor progression. Marker alterations marginally improved discrimination of EORTC and CUETO models, which were confirmed to be mediocre. CONCLUSIONS: Markers were not significant predictors of recurrence nor progression in patients with high-grade NMIBC and their addition to prediction models is of little benefit. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Passoni, Niccolo AU - Passoni N AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. Electronic address: niccolo.passoni@gmail.com. FAU - Gayed, Bishoy AU - Gayed B AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX; Chesapeake Urology, Saint Agnes Hospital, Baltimore, MD. FAU - Kapur, Payal AU - Kapur P AD - Department of Pathology, UT Southwestern Medical Center, Dallas, TX. FAU - Sagalowsky, Arthur I AU - Sagalowsky AI AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX; Department of Urology, Medical University of Vienna, Austria. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, UT Southwestern Medical Center, Dallas, TX. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20160913 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Cycle Proteins) SB - IM MH - Aged MH - Biomarkers MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/*chemistry/pathology/surgery MH - Cell Cycle MH - Cell Cycle Proteins/*analysis MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - *Models, Biological MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/*pathology MH - Prognosis MH - Proportional Hazards Models MH - Risk Assessment MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*chemistry/pathology/surgery OTO - NOTNLM OT - High-risk OT - Markers OT - Non-muscle-invasive bladder cancer OT - Outcomes OT - Risk tables EDAT- 2016/09/18 06:00 MHDA- 2018/01/18 06:00 CRDT- 2016/09/18 06:00 PHST- 2015/01/14 00:00 [received] PHST- 2016/03/24 00:00 [revised] PHST- 2016/05/12 00:00 [accepted] PHST- 2016/09/18 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/09/18 06:00 [entrez] AID - S1078-1439(16)30066-7 [pii] AID - 10.1016/j.urolonc.2016.05.014 [doi] PST - ppublish SO - Urol Oncol. 2016 Nov;34(11):485.e7-485.e14. doi: 10.1016/j.urolonc.2016.05.014. Epub 2016 Sep 13. PMID- 27631180 OWN - NLM STAT- MEDLINE DCOM- 20170303 LR - 20170817 IS - 1735-3947 (Electronic) IS - 1029-2977 (Linking) VI - 19 IP - 9 DP - 2016 Sep TI - Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer. PG - 645-51 AB - BACKGROUND: Abnormal expression of microRNAs (miRNAs) plays an important role in development of several cancer types, including bladder cancer (BCa). However, the relationship between the ratio of miR-181/miR-100 and the prognosis of BCa has not been studied yet. The aim of this study was to evaluate the expression of miR-182, miR-100 and their clinical significance in BCa. METHODS: Upregulation of miR-182 and down-regulation of miR-100 were validated in tissue specimens of 134 BCa cases compared with 148 normal bladder epithelia (NBE) specimens using TaqMan-based real-time reverse transcription quantitative PCR (RT-qPCR). The diagnostic and prognostic evaluation of miR-182, miR-100, and miR-182/miR-100 ratio was also performed. RESULTS: miR-182 was upregulated in BCa and miR-100 was down-regulated in BCa compared with NBE (P < 0.001). The areas under receiver operating characteristic curves (AUCs-ROC) for miR-182 and miR-100 were 0.913 and 0.810, respectively. However, miR-182/miR-100 ratio increased the diagnostic performance, yielding an AUC of 0.981 (97.01% sensitivity and 90.54% specificity). Moreover, miR-182/miR-100 ratio was associated with pT-stage, histological grade, BCa recurrence and carcinoma in situ (P < 0.05 for all). Multivariate Cox regression analysis indicated that miR-182/miR-100 ratio was an independent prognostic factor for overall survival (Hazard ratio: 7.142; 95% CI: 2.106 - 9.891; P < 0.01). Furthermore, Kaplan-Meier curve analysis revealed that high-level of miR-182/miR-100 ratio was significantly correlated with shortened survival time for BCa patients (P < 0.01). CONCLUSION: The miR-182/miR-100 ratio may serve as a novel promising biomarker for diagnosis and survival prediction in BCa. Further studies are needed to elucidate the role of miR-182/miR-100 ratio as a non‑invasive diagnostic tool for BCa. FAU - Chen, Zhanguo AU - Chen Z AD - Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Wu, Lili AU - Wu L AD - Department of Clinical Laboratory, The Dingli Clinical College of Wenzhou Medical University,Wenzhou, China. FAU - Lin, Qi AU - Lin Q AD - School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China. FAU - Shi, Jing AU - Shi J AD - Department of Human Anatomy, The Fenyang College of Shanxi Medical University, Fenyang, China. FAU - Lin, Xiangyang AU - Lin X AD - Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Shi, Liang AU - Shi L AD - Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. LA - eng PT - Journal Article PL - Iran TA - Arch Iran Med JT - Archives of Iranian medicine JID - 100889644 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN100 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Mirn182 microRNA, human) SB - IM MH - Aged MH - Area Under Curve MH - Biomarkers, Tumor/genetics MH - Down-Regulation MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local MH - Proportional Hazards Models MH - ROC Curve MH - Real-Time Polymerase Chain Reaction MH - Urinary Bladder Neoplasms/*diagnosis/genetics/pathology EDAT- 2016/09/16 06:00 MHDA- 2017/03/04 06:00 CRDT- 2016/09/16 06:00 PHST- 2016/09/16 06:00 [entrez] PHST- 2016/09/16 06:00 [pubmed] PHST- 2017/03/04 06:00 [medline] AID - 008 [pii] PST - ppublish SO - Arch Iran Med. 2016 Sep;19(9):645-51. PMID- 27617552 OWN - NLM STAT- MEDLINE DCOM- 20170214 LR - 20170214 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 69 IP - 7 DP - 2016 Sep TI - Failure of Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder cancer: Definition and treatment options. PG - 423-33 AB - Adjuvant intravesical bacillus Calmette- Guerin (BCG) therapy is the standard conservative adjuvant treatment and the most effective regimen for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The term "BCG failure" is generally used to refer to recurrence or progression following BCG therapy, as experienced by many patients. However, the term has been defined inconsistently, and several studies have indicated that patients with a particular pattern of BCG failure have a worse prognosis. There are many different treatment options for patients who experience BCG failure. OBJECTIVE: To summarize the different current definitions of BCG failure and the present treatment options available for patients with high-risk NMIBC who experience BCG failure. EVIDENCE SYNTHESIS: Overall, the failure rate in response to BCG is about 40-50%. Most guidelines recommend that patients failing BCG should be offered radical cystectomy (RC). The significant potential for progression specific to high-risk NMIBC leads some clinicians to argue that immediate RC should be considered the preferred first-line treatment in high-risk patients, bearing in mind that it achieves a long-term survival rate in excess of 90% with ongoing improvements in morbidity. While other salvage intravesical treatments have to be considered oncologically inferior to RC, several therapies are now available if the patient is unfit to undergo RC or if bladder preservation is the objective, and some agents have shown promise in the context of BCG failure. CONCLUSIONS: The definition, prediction, and treatment of BCG failure remain topics of debate. Patients with BCG failure need carefully selected, individualized therapy in experienced hands. Stratification of patients with BCG failure into groups can identify those with a better or worse prognosis. RC should be the selected option if a patient experiences BCG failure, but several promising intravesical salvage options are available for those cases in which the patient is unfit for surgery or bladder preservation is preferred. Currently data are still inadequate to allow formulation of definitive recommendations, and larger and higher quality studies of salvage intravesical therapies are urgently required. FAU - Gual Frau, J AU - Gual Frau J AD - Urology Service. Parc Tauli Sabadell. Hospital de Sabadell. Spain. FAU - Palou, J AU - Palou J AD - Urology Service. Fundacio Puigvert. Barcelona. Spain. FAU - Rodriguez, O AU - Rodriguez O AD - Urology Service. Fundacio Puigvert. Barcelona. Spain. FAU - Parada, R AU - Parada R AD - Urology Service. Fundacio Puigvert. Barcelona. Spain. FAU - Breda, A AU - Breda A AD - Urology Service. Fundacio Puigvert. Barcelona. Spain. FAU - Villavicencio, H AU - Villavicencio H AD - Urology Service. Fundacio Puigvert. Barcelona. Spain. LA - eng PT - Journal Article PT - Review TT - Fracaso del tratamiento con Bacilo de Calmette-Guerin en cancer de vejiga sin invasion muscular: definicion y opciones de tratamiento. PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Humans MH - Neoplasm Invasiveness MH - Treatment Failure MH - Urinary Bladder Neoplasms/*drug therapy/pathology/therapy EDAT- 2016/09/13 06:00 MHDA- 2017/02/15 06:00 CRDT- 2016/09/13 06:00 PHST- 2016/09/13 06:00 [entrez] PHST- 2016/09/13 06:00 [pubmed] PHST- 2017/02/15 06:00 [medline] PST - ppublish SO - Arch Esp Urol. 2016 Sep;69(7):423-33. PMID- 27614622 OWN - NLM STAT- MEDLINE DCOM- 20170223 LR - 20181202 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 22 IP - 1 DP - 2017 Feb TI - The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. PG - 153-158 LID - 10.1007/s10147-016-1040-7 [doi] AB - BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with recurrence and poor prognosis in numerous cancer types. The aim of this study was to evaluate the use of the NLR as a biomarker for intravesical recurrence (IVR) in patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) for the first time. METHODS: We retrospectively analyzed the records of 100 patients with UTUC who had undergone RNU between 1999 and 2015 at our institution. The association between the preoperative NLR and IVR were assessed using multivariate models. RESULTS: Among the 100 patients enrolled in the study, 33 developed IVR during a median follow-up of 34 months. The receiver operating characteristic analysis revealed that the optimum cut-off value for the preoperative NLR was >3.8. A high preoperative NLR (n = 21) was associated with a significantly increased risk of lymph node involvement (p = 0.036) and IVR (p = 0.034) compared with a low preoperative NLR (n = 79). IVR-free survival in patients with a high preoperative NLR was significantly worse than that of patients with a low preoperative NLR (p = 0.018). On multivariate analysis, the preoperative NLR [hazard ratio (HR) 2.49; p = 0.015] and tumor multifocality (HR 2.96; p = 0.024) were independent risk factors predictive of IVR. CONCLUSION: In our study population of patients with UTUC who had undergone RNU the preoperative NLR was associated with a significantly increased risk of IVR, suggesting that the NRL could be a useful biomarker for predicting IVR. FAU - Kishimoto, Nozomu AU - Kishimoto N AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Takao, Tetsuya AU - Takao T AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. takao@gh.opho.jp. FAU - Kuribayashi, Sohei AU - Kuribayashi S AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Yamamichi, Gaku AU - Yamamichi G AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Nakano, Kosuke AU - Nakano K AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Kawamura, Masataka AU - Kawamura M AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Tsutahara, Koichi AU - Tsutahara K AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Tanigawa, Go AU - Tanigawa G AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. FAU - Yamaguchi, Seiji AU - Yamaguchi S AD - Department of Urology, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, Osaka, 558-8558, Japan. LA - eng PT - Journal Article DEP - 20160910 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*blood/secondary/surgery MH - Female MH - Humans MH - Lymphatic Metastasis MH - Lymphocyte Count MH - *Lymphocytes MH - Male MH - Neoplasm Recurrence, Local/*blood MH - Nephrectomy MH - *Neutrophils MH - Preoperative Period MH - Prognosis MH - ROC Curve MH - Retrospective Studies MH - Risk Factors MH - Ureter/surgery MH - Ureteral Neoplasms/*blood/pathology/surgery MH - Urinary Bladder Neoplasms/*blood/secondary OTO - NOTNLM OT - *Intravesical recurrence OT - *Nephroureterectomy OT - *Neutrophil-to-lymphocyte ratio OT - *Upper urinary tract urothelial carcinoma EDAT- 2016/09/12 06:00 MHDA- 2017/02/24 06:00 CRDT- 2016/09/12 06:00 PHST- 2016/06/30 00:00 [received] PHST- 2016/08/30 00:00 [accepted] PHST- 2016/09/12 06:00 [pubmed] PHST- 2017/02/24 06:00 [medline] PHST- 2016/09/12 06:00 [entrez] AID - 10.1007/s10147-016-1040-7 [pii] AID - 10.1007/s10147-016-1040-7 [doi] PST - ppublish SO - Int J Clin Oncol. 2017 Feb;22(1):153-158. doi: 10.1007/s10147-016-1040-7. Epub 2016 Sep 10. PMID- 27604374 OWN - NLM STAT- MEDLINE DCOM- 20171024 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 5 DP - 2017 May TI - Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. PG - 745-752 LID - 10.1007/s00345-016-1927-y [doi] AB - OBJECTIVES: To assess the efficacy of two treatment options for non-muscle-invasive bladder cancer (NMIBC): (1) transurethral resection (TUR) guided by fluorescence cystoscopy (FC) with the use of 5-aminolevulinic acid (5-ALA) and (2) single early instillation of doxorubicin in a single-center open-label prospective randomized study with a 2 x 2 factorial design. PATIENTS AND METHODS: Patients with clinical suspicion of primary or recurrent NMIBC were randomized into four study arms: FC-assisted TUR with 5-ALA and single instillation of doxorubicin, FC-assisted TUR without instillation, TUR in white light (WL) with single instillation of doxorubicin, and WL-TUR only. The study was designed to assess recurrence-free survival in arms with and without any of two interventions. RESULTS: Of 525 patients included, 377 (72 %) were eligible for primary outcome assessment. The median follow-up was 54.8 months. FC statistically significantly decreased the risk of disease recurrence and progression with hazard ratio (HR) 0.56 (95 % CI 0.39-0.80, p = 0.001) and 0.33 (95 % CI 0.12-0.91, p = 0.031), respectively. The HRs for recurrence and progression for single instillation of doxorubicin were 0.76 (95 % CI 0.54-1.07, p = 0.11) and 0.65 (95 % CI 0.28-1.52, p = 0.32), respectively. The overall and cancer-specific survival rates did not differ significantly based on the therapeutic interventions. CONCLUSIONS: In patients with NMIBC, FC-assisted TUR with 5-ALA results in a substantial recurrence and progression risk reduction as compared to WL-TUR. The single early postoperative instillation of doxorubicin did not have a statistically significant impact on recurrence and progression risks. FAU - Rolevich, Alexander I AU - Rolevich AI AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. alexander.rolevich@gmail.com. FAU - Zhegalik, Alexander G AU - Zhegalik AG AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Mokhort, Andrey A AU - Mokhort AA AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Minich, Alexander A AU - Minich AA AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Vasilevich, Vladimir Yu AU - Vasilevich VY AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Polyakov, Sergey L AU - Polyakov SL AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Krasny, Sergey A AU - Krasny SA AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. FAU - Sukonko, Oleg G AU - Sukonko OG AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Lesnoy, Minsk region, Republic of Belarus. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20160907 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Photosensitizing Agents) RN - 80168379AG (Doxorubicin) RN - 88755TAZ87 (Aminolevulinic Acid) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Aminolevulinic Acid MH - Antibiotics, Antineoplastic/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Cystoscopy/*methods MH - Disease-Free Survival MH - Doxorubicin/*therapeutic use MH - Female MH - Fluorescence MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology MH - Photosensitizing Agents MH - Proportional Hazards Models MH - Prospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*therapy OTO - NOTNLM OT - 5-Aminolevulinic acid OT - Fluorescence cystoscopy OT - Non-muscle-invasive bladder cancer OT - Single early instillation of chemotherapeutic drug EDAT- 2016/09/09 06:00 MHDA- 2017/10/25 06:00 CRDT- 2016/09/09 06:00 PHST- 2016/06/22 00:00 [received] PHST- 2016/08/23 00:00 [accepted] PHST- 2016/09/09 06:00 [pubmed] PHST- 2017/10/25 06:00 [medline] PHST- 2016/09/09 06:00 [entrez] AID - 10.1007/s00345-016-1927-y [pii] AID - 10.1007/s00345-016-1927-y [doi] PST - ppublish SO - World J Urol. 2017 May;35(5):745-752. doi: 10.1007/s00345-016-1927-y. Epub 2016 Sep 7. PMID- 27603424 OWN - NLM STAT- MEDLINE DCOM- 20170601 LR - 20170801 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 50 IP - 5 DP - 2016 Oct TI - Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. PG - 360-8 LID - 10.1080/21681805.2016.1210672 [doi] AB - OBJECTIVE: The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS). MATERIALS AND METHODS: Between 1992 and 1997, 321 patients with CIS were randomized from Finland, Norway and Sweden in a prospective multicenter trial into two treatment groups. The alternating therapy comprised six weekly instillations of MMC 40 mg followed by 10 instillations of BCG (Connaught 120 mg) or MMC alternating monthly for 1 year. BCG monotherapy followed the same 6 + 10 schedule. Stratification was done by nationality and CIS category. Primary endpoints were time to first recurrence and time to progression. Secondary endpoints were disease-specific mortality and overall survival. The main statistical methods were the proportional subdistribution hazards model and Cox proportional hazards model with the cumulative incidence and Kaplan-Meier analyses. RESULTS: The median follow-up time was 9.9 years (maximum 19.9 years) in the BCG group and 8.9 years (maximum 20.3 years) in the alternating group. The risk of recurrence was significantly lower in the BCG group than in the alternating group (49 vs 59% at 15 years, respectively; hazard ratio 0.74, 95% confidence interval 0.54-1.00, p = 0.048). There were no significant differences in the other endpoints. Patients who progressed after 2 years were particularly prone to dying from bladder carcinoma. Younger patients performed worse than older ones. CONCLUSIONS: BCG monotherapy including monthly maintenance was effective and better than the alternating therapy. The risk of dying from bladder carcinoma after progression was high. FAU - Kaasinen, Eero AU - Kaasinen E AD - a Department of Surgery , Hyvinkaa Hospital, Hyvinkaa and Helsinki University Hospital , Helsinki , Finland ; FAU - Wijkstrom, Hans AU - Wijkstrom H AD - b Department of Urology , Karolinska University Hospital Huddinge , Stockholm , Sweden ; FAU - Rintala, Erkki AU - Rintala E AD - c Department of Urology , Helsinki University Hospital , Helsinki , Finland ; FAU - Mestad, Oddvar AU - Mestad O AD - d Section for Urology, Surgical Division , University of Stavanger , Stavanger , Norway ; FAU - Jahnson, Staffan AU - Jahnson S AD - e Department of Urology, IKE , University Hospital Linkoping, Linkoping University , Linkoping , Sweden ; FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - f Department of Surgical Sciences , University Hospital Uppsala , Uppsala , Sweden. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20160815 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Scand J Urol. 2016 Oct;50(5):369. doi: 10.1080/21681805.2016.1217559. PMID: 27603425 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Antibiotics, Antineoplastic/*therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/*drug therapy MH - Drug Therapy, Combination MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Mitomycin/*therapeutic use MH - Prospective Studies MH - Time Factors MH - Urinary Bladder Neoplasms/*drug therapy OTO - NOTNLM OT - BCG OT - carcinoma in situ OT - combination therapy OT - immunotherapy OT - instillation therapy OT - long-term efficacy OT - mitomycin C OT - randomized controlled trial OT - urinary bladder EDAT- 2016/09/08 06:00 MHDA- 2017/06/02 06:00 CRDT- 2016/09/08 06:00 PHST- 2016/09/08 06:00 [entrez] PHST- 2016/09/08 06:00 [pubmed] PHST- 2017/06/02 06:00 [medline] AID - 10.1080/21681805.2016.1210672 [doi] PST - ppublish SO - Scand J Urol. 2016 Oct;50(5):360-8. doi: 10.1080/21681805.2016.1210672. Epub 2016 Aug 15. PMID- 27602160 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220419 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 12 IP - 3 DP - 2016 Sep TI - Bladder and vaginal transitional cell carcinoma: A case report. PG - 2181-2183 AB - The involvement of the female genital tract in transitional cell carcinoma (TCC) has not been fully elucidated in women, although involvement is usually associated with a poor prognosis. The vagina, in particular, is considered to be the most commonly affected gynecological organ, with an incidence of 4% of total TCC cases. The pathogenesis of vaginal TCC is challenging to determine, although it is essential for the adequate management of the tumor and to determine the appropriate treatment. The present study reports a case of bladder TCC and metachronous vaginal TCC. The patient had a history of high risk non muscle invasive bladder cancer treated by BCG and presented with a recurrent carcinoma in situ. A novel cycle of BCG was initiated but the patient had a persistent disease and a palpable mass on bimanual examination. Radical anterior pelvectomy and bilateral pelvic and inguinal lymph node dissection was performed revealing the presence of TCC of the bladder neck and the invasion into the anterior vaginal wall. The differences between local vaginal invasion and the metastatic spread from a primary bladder TCC, the occurrence of a second primary vaginal tumor and the direct implantation of TCC via urine that contains transitional cancer cells were reviewed and analyzed. Finally, a management plan was determined. FAU - Aoun, Fouad AU - Aoun F AD - Department of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels 1000, Belgium. FAU - Kourie, Hampig Raphael AU - Kourie HR AD - Department of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels 1000, Belgium. FAU - El Rassy, Elie AU - El Rassy E AD - Department of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels 1000, Belgium. FAU - van Velthoven, Roland AU - van Velthoven R AD - Department of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels 1000, Belgium. LA - eng PT - Journal Article DEP - 20160720 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC4998585 OTO - NOTNLM OT - bladder cancer OT - local invasion OT - metastasis OT - second primary OT - transitional cell carcinoma OT - vaginal cancer EDAT- 2016/09/08 06:00 MHDA- 2016/09/08 06:01 PMCR- 2016/07/20 CRDT- 2016/09/08 06:00 PHST- 2015/01/16 00:00 [received] PHST- 2015/11/20 00:00 [accepted] PHST- 2016/09/08 06:00 [entrez] PHST- 2016/09/08 06:00 [pubmed] PHST- 2016/09/08 06:01 [medline] PHST- 2016/07/20 00:00 [pmc-release] AID - OL-0-0-4894 [pii] AID - 10.3892/ol.2016.4894 [doi] PST - ppublish SO - Oncol Lett. 2016 Sep;12(3):2181-2183. doi: 10.3892/ol.2016.4894. Epub 2016 Jul 20. PMID- 27601277 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 2 DP - 2017 Apr TI - Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder. PG - e187-e197 LID - S1558-7673(16)30224-5 [pii] LID - 10.1016/j.clgc.2016.07.021 [doi] AB - INTRODUCTION: Epithelial-to-mesenchymal transition (EMT) is a dynamic process in the pathogenesis of urinary bladder cancer. Despite significant advancements in its diagnosis and treatment, the outcomes have more or less remained the same. In the present study, the expression of EMT markers was investigated to evaluate its prognostic significance in patients with non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: The present study was undertaken to examine the expression of EMT markers, including E-cadherin, N-cadherin, vimentin, Snail, Twist, Zeb, and Slug, on 28 bladder tumor tissues (15 cases of NMIBC and 13 of MIBC) using reverse transcription-polymerase chain reaction. Immunohistochemical (IHC) staining was performed to check the protein expression and localization of E-cadherin, N-cadherin, vimentin, Snail, and Slug. RESULTS: At the message level, reduced expression of E-cadherin correlated with gender (P = .004), enhanced expression of N-cadherin correlated with stage and age (P = .02, for both), and increased expression of EMT transcription factors correlated significantly with stage, grade, or age. Inverse correlation of reduced levels of E-cadherin were observed with new expression of N-cadherin (P = .001; Mann-Whitney U test) and vimentin (P = .001; Mann-Whitney U test). On IHC, novel expression of vimentin and N-cadherin was associated with enhanced expression of Snail and Slug (P = .005; Wilcoxon signed rank test). CONCLUSION: Molecular validation of the EMT marker profile proved to be a sensitive and an effective prognostic tool for objective and systematic investigation of EMT function in the pathogenesis of urinary bladder cancer. Nevertheless, further studies are required with a greater number of clinical samples. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Singh, Rinni AU - Singh R AD - Department of Biochemistry, Lucknow University, Lucknow, India. FAU - Ansari, Jamal A AU - Ansari JA AD - Department of Food Toxicology, Indian Institute of Toxicology Research, Lucknow, India. FAU - Maurya, Niharika AU - Maurya N AD - Department of Biochemistry, Lucknow University, Lucknow, India. FAU - Mandhani, Anil AU - Mandhani A AD - Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. FAU - Agrawal, Vinita AU - Agrawal V AD - Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. FAU - Garg, Minal AU - Garg M AD - Department of Biochemistry, Lucknow University, Lucknow, India. Electronic address: minal14@yahoo.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160809 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*genetics/*metabolism MH - Carcinoma, Transitional Cell/genetics/metabolism/*pathology MH - Disease Progression MH - *Epithelial-Mesenchymal Transition MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/genetics/metabolism/*pathology OTO - NOTNLM OT - Bladder cancer OT - Epithelial and mesenchymal markers OT - Metastasis OT - Pathologic stage and grade OT - Prognosis EDAT- 2016/09/08 06:00 MHDA- 2017/10/24 06:00 CRDT- 2016/09/08 06:00 PHST- 2016/05/23 00:00 [received] PHST- 2016/07/26 00:00 [revised] PHST- 2016/07/30 00:00 [accepted] PHST- 2016/09/08 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2016/09/08 06:00 [entrez] AID - S1558-7673(16)30224-5 [pii] AID - 10.1016/j.clgc.2016.07.021 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Apr;15(2):e187-e197. doi: 10.1016/j.clgc.2016.07.021. Epub 2016 Aug 9. PMID- 27592529 OWN - NLM STAT- MEDLINE DCOM- 20180228 LR - 20181202 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 1 DP - 2017 Jan TI - Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base. PG - 34.e1-34.e8 LID - S1078-1439(16)30210-1 [pii] LID - 10.1016/j.urolonc.2016.08.002 [doi] AB - PURPOSE: To determine patient and pathologic characteristics as well as outcomes for patients with clinically localized, nonurothelial histology bladder cancer. MATERIALS AND METHODS: Using the National Cancer Data Base, we identified patients between 2000 and 2010 diagnosed with bladder cancer as their only malignancy undergoing definitive surgical management. Patients were characterized as urothelial (n = 13,442), squamous (n = 789), small cell (n = 124), adenocarcinoma (n = 789), or other histology (n = 499). Patient and pathologic characteristics were compared across histologic subtypes. We also evaluated for incidence of T and N upstaging. Survival analysis was performed using the Kaplan-Meier method. Multivariate survival analysis was performed to identify predictors of adverse overall survival. RESULTS: Patients with nonurothelial histology were more likely to be African-American, treated at academic medical centers, and of younger age (all P<0.05). Among those with nonurothelial histology, 55.4% of patients presenting with clinical stage T1 or less had their tumor upstaged during definitive surgical treatment compared to 42.7% of those with urothelial carcinoma. Squamous histology incurred the highest upgrading rate of 61.8%. Five-year survival varied by subtype, with universally decreased survival for those upstaged. Among nonurothelial histology, overall 5-year survival was 32.4% (95% CI: 28.8%-36.2%) vs. 46.0% (95% CI: 42.3%-49.6%) for those upstaged and not upstaged, respectively. Neoadjuvant therapy is used infrequently in this population. CONCLUSION: We present the largest survival analysis of various rare subtypes of bladder cancer to date. Patients with nonurothelial bladder cancer have significantly higher rate of upstaging at cystectomy and with this a worsened overall survival. Aggressive treatment should be strongly considered for nonurothelial cancers when identified. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Cohen, Andrew J AU - Cohen AJ AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL. Electronic address: Andrew.Cohen@uchospitals.edu. FAU - Packiam, Vignesh AU - Packiam V AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL. FAU - Nottingham, Charles AU - Nottingham C AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL. FAU - Steinberg, Gary AU - Steinberg G AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL. FAU - Smith, Norm D AU - Smith ND AD - Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, IL. FAU - Patel, Sanjay AU - Patel S AD - Department of Urology at the University of Oklahoma, Oklahoma City, OK. LA - eng PT - Journal Article DEP - 20160901 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Adenocarcinoma/mortality/pathology/therapy MH - Aged MH - Aged, 80 and over MH - Carcinoma/mortality/*pathology/*therapy MH - Carcinoma, Small Cell/mortality/pathology/therapy MH - Carcinoma, Squamous Cell/mortality/pathology/therapy MH - Carcinoma, Transitional Cell/mortality/pathology/therapy MH - Chemotherapy, Adjuvant/statistics & numerical data MH - Databases, Factual MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/statistics & numerical data MH - Neoplasm Staging MH - Radiotherapy, Adjuvant/statistics & numerical data MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - Adenocarcinoma OT - Bladder cancer OT - Prognosis OT - Small cell OT - Squamous EDAT- 2016/09/07 06:00 MHDA- 2018/03/01 06:00 CRDT- 2016/09/06 06:00 PHST- 2016/05/25 00:00 [received] PHST- 2016/07/22 00:00 [revised] PHST- 2016/08/01 00:00 [accepted] PHST- 2016/09/07 06:00 [pubmed] PHST- 2018/03/01 06:00 [medline] PHST- 2016/09/06 06:00 [entrez] AID - S1078-1439(16)30210-1 [pii] AID - 10.1016/j.urolonc.2016.08.002 [doi] PST - ppublish SO - Urol Oncol. 2017 Jan;35(1):34.e1-34.e8. doi: 10.1016/j.urolonc.2016.08.002. Epub 2016 Sep 1. PMID- 27589904 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 2 DP - 2017 Apr TI - Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. PG - e223-e228 LID - S1558-7673(16)30227-0 [pii] LID - 10.1016/j.clgc.2016.07.024 [doi] AB - INTRODUCTION: We evaluated the effect of the year of surgery on the clinical, pathologic, and oncologic outcomes of patients with bladder cancer (BCa) treated with radical cystectomy (RC) at a single institution. MATERIALS AND METHODS: The present study included 1253 consecutive patients with BCa treated with RC and extended pelvic lymphadenectomy at a single institution from January 1990 to December 2014. Analysis of variance and chi(2) trend tests were used to report the clinical and pathologic characteristics of the cohort over time. Multivariable Cox regression analysis was used to test the relationship between the year of surgery and recurrence, cancer-specific mortality (CSM) and overall mortality (OM). RESULTS: Considering the clinical characteristics, patient age (P = .1) and gender (P = .2) remained steady during the study period. In contrast, the body mass index (P < .005) increased. Also, of the pathologic features, carcinoma in situ detection (P < .001) showed an increasing rate, and pathologic stage T3-T4 (P = .005) showed a decreasing trend. The number of lymph nodes removed increased during the study period (P < .001), resulting in an increased number of positive nodes (P < .001). However, the rate of lymph node invasion (P = .1) remained stable in the overall population. Multivariable Cox regression analyses revealed the year of surgery as a predictor of recurrence (hazard ratio [HR], 0.97), CSM (HR, 0.97), and OM (HR, 0.98), with a slight, but constant, reduction in all survival outcomes (P < .04 for all). CONCLUSION: Changes were recorded considering the patient and tumor characteristics across the previous 25 years. These variations directly reflect the differences in long-term survival expectations we recorded. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: marco.moschini87@gmail.com. FAU - Luzzago, Stefano AU - Luzzago S AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Cazzaniga, Walter AU - Cazzaniga W AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Cucchiara, Vito AU - Cucchiara V AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Bandini, Marco AU - Bandini M AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Salonia, Andrea AU - Salonia A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. LA - eng PT - Journal Article DEP - 20160808 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Logistic Models MH - Lymph Node Excision/methods MH - Lymph Nodes MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Pelvis MH - Survival Rate MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - BMI OT - Bladder cancer OT - Pathological stage OT - Radical cystectomy OT - Stage migration EDAT- 2016/09/04 06:00 MHDA- 2017/10/24 06:00 CRDT- 2016/09/04 06:00 PHST- 2016/06/09 00:00 [received] PHST- 2016/07/18 00:00 [revised] PHST- 2016/07/30 00:00 [accepted] PHST- 2016/09/04 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2016/09/04 06:00 [entrez] AID - S1558-7673(16)30227-0 [pii] AID - 10.1016/j.clgc.2016.07.024 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Apr;15(2):e223-e228. doi: 10.1016/j.clgc.2016.07.024. Epub 2016 Aug 8. PMID- 27586786 OWN - NLM STAT- MEDLINE DCOM- 20171030 LR - 20250103 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 IP - 1 DP - 2016 Sep 1 TI - Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. PG - 704 LID - 10.1186/s12885-016-2748-5 [doi] LID - 704 AB - BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) is a high incidence form of bladder cancer (BCa), where genetic and epigenetic alterations occur frequently. We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients. METHODS: We used allele specific PCR to determine the FGFR3 mutation status for R248C, S249C, G372C, and Y375C. We preselected 18 candidate genes reported in the literature as being hypermethylated in cancer and measured their methylation levels by quantitative multiplex-methylation specific PCR. We selected HS3ST2, SLIT2 and SEPTIN9 as the most discriminative between control and NMIBC patients and we assayed these markers on urine DNA from a diagnostic study consisting of 167 NMIBC and 105 controls and a follow-up study consisting of 158 NMIBC at diagnosis time's and 425 at follow-up time. ROC analysis was performed to evaluate the diagnostic accuracy of each assay alone and in combination. RESULTS: For Diagnosis: Using a logistic regression analysis with a model consisting of the 3 markers' methylation values, FGFR3 status, age and known smoker status at the diagnosis time we obtained sensitivity/specificity of 97.6 %/84.8 % and an optimism-corrected AUC of 0.96. With an estimated BCa prevalence of 12.1 % in a hematuria cohort, this corresponds to a negative predictive value (NPV) of 99.6 %. For Follow-up: Using a logistic regression with FGFR3 mutation and the CMI at two time points (beginning of the follow-up and current time point), we got sensitivity/specificity/NPV of 90.3 %/65.1 %/97.0 % and a corrected AUC of 0.84. We also tested a thresholding algorithm with FGFR3 mutation and the two time points as described above, obtaining sensitivity/specificity/NPV values of, respectively, 94.5 %/75.9 %/98.5 % and an AUC of 0.82. CONCLUSIONS: We showed that combined analysis of FGFR3 mutation and DNA methylation markers on urine can be a useful strategy in diagnosis, surveillance and for risk stratification of patients with NMIBC. These results provide the basis for a highly accurate noninvasive test for population screening and allowing to decrease the frequency of cystoscopy, an important feature for both patient quality of life improvement and care cost reduction. FAU - Roperch, Jean-Pierre AU - Roperch JP AUID- ORCID: 0000-0002-6745-6067 AD - OncoDiag SAS, Agoranov, Paris, France. roperch@oncodiag.fr. FAU - Grandchamp, Bernard AU - Grandchamp B AD - OncoDiag SAS, Agoranov, Paris, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - Departement of Urology, Saint-Louis Hospital, Paris, France. FAU - Mongiat-Artus, Pierre AU - Mongiat-Artus P AD - Departement of Urology, Saint-Louis Hospital, Paris, France. FAU - Ravery, Vincent AU - Ravery V AD - Departement of Urology, Bichat-Claude Bernard Hospital, Paris, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - Departement of Urology, Bichat-Claude Bernard Hospital, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC-05, University Institute of Oncology, University Paris-6, Paris, France. AD - Department of Urology, Pitie Hospital, Paris, France. AD - Department of Urology, Tenon Hospital, Paris, France. FAU - Phe, Veronique AU - Phe V AD - Department of Urology, Pitie Hospital, Paris, France. FAU - Ciofu, Calin AU - Ciofu C AD - Department of Urology, Tenon Hospital, Paris, France. FAU - Tubach, Florence AU - Tubach F AD - INSERM, ECEVE, UMR 1123, CIC-EC 11425, Paris, France. AD - University Paris Diderot, ECEVE, UMR 1123, Sorbonne Paris Cite, Paris, France. AD - Department of Epidemiology and Clinical Research, Bichat-Claude Bernard Hospital, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - GRC-05, University Institute of Oncology, University Paris-6, Paris, France. AD - Department of Urology, Pitie Hospital, Paris, France. AD - Department of Urology, Tenon Hospital, Paris, France. FAU - Incitti, Roberto AU - Incitti R AD - OncoDiag SAS, Agoranov, Paris, France. AD - Computational Bioscience Research Center, KAUST University, Thuwal, Saudi Arabia. LA - eng PT - Journal Article DEP - 20160901 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Nerve Tissue Proteins) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) RN - EC 2.8.2.- (Sulfotransferases) RN - EC 3.6.1.- (Septins) RN - R6FXH13RRC (Slit Homolog 2 Protein) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Algorithms MH - Area Under Curve MH - Biomarkers, Tumor/*genetics/*urine MH - Carcinoma, Transitional Cell/*diagnosis/genetics/urine MH - DNA Methylation/genetics MH - Female MH - Humans MH - Intercellular Signaling Peptides and Proteins/genetics MH - Logistic Models MH - Male MH - Middle Aged MH - Multiplex Polymerase Chain Reaction MH - *Mutation MH - Nerve Tissue Proteins/genetics MH - Promoter Regions, Genetic/genetics MH - ROC Curve MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics MH - Septins/genetics MH - Sulfotransferases/genetics MH - Urinary Bladder Neoplasms/*diagnosis/genetics/urine MH - Slit Homolog 2 Protein PMC - PMC5007990 OTO - NOTNLM OT - Diagnosis OT - Genetic and Epigenetic DNA biomarkers OT - Non-muscle-invasive bladder cancer OT - Surveillance OT - Urine-based assay EDAT- 2016/09/03 06:00 MHDA- 2017/10/31 06:00 PMCR- 2016/09/01 CRDT- 2016/09/03 06:00 PHST- 2016/02/02 00:00 [received] PHST- 2016/08/25 00:00 [accepted] PHST- 2016/09/03 06:00 [entrez] PHST- 2016/09/03 06:00 [pubmed] PHST- 2017/10/31 06:00 [medline] PHST- 2016/09/01 00:00 [pmc-release] AID - 10.1186/s12885-016-2748-5 [pii] AID - 2748 [pii] AID - 10.1186/s12885-016-2748-5 [doi] PST - epublish SO - BMC Cancer. 2016 Sep 1;16(1):704. doi: 10.1186/s12885-016-2748-5. PMID- 27586262 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20170418 IS - 1699-5848 (Electronic) IS - 0213-3911 (Linking) VI - 32 IP - 2 DP - 2017 Feb TI - microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. PG - 107-119 LID - 10.14670/HH-11-814 [doi] AB - Bladder cancer (BC) is generally divided into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). The standard treatment protocol for MIBC patients is radical cystectomy preceded by neoadjuvant chemotherapy (NAC). About one-half of the MIBC patients show a priori resistance to chemotherapy, and are therefore exposed to the risks of disease progression and toxicity from ineffective NAC. The discovery of microRNA (miRNA) regulation in tumorigenesis has provided new directions for the development of a new type of BC biomarkers. In this review, we describe the emerging miRNAs as BC biomarkers for different purposes, including diagnosis, prognosis and therapeutic response. miRNA expression profile changes with alteration of the tissue phenotype. This phenomenon is utilized to predict tumor diagnosis, cancer subclass, disease stage, prognosis and therapeutic response. We classified the miRNAs which are involved in bladder cancer according to malignant potential, chemoresistance, discrimination between normal to cancerous and clinical outcome. Focusing on the major obstacle regarding MIBC patient's NAC response, we summarized the miRNAs that are deregulated and have the potential to identify the patients resistant to NAC, such as miR-34, miR-100, miR-146b and miR-9 and miR-193a-3p. In conclusion, miRNAs expression profile of bladder cancer patient is a promising tool that can serve as biomarker for different aims. Based on this profile we propose upfront radical cystectomy instead of standard NAC to those MIBC patients who are at higher risk for chemoresistance and poor response. FAU - Amir, Sharon AU - Amir S AD - Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Mabjeesh, Nicola J AU - Mabjeesh NJ AD - Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. nicolam@tlvmc.gov.il. LA - eng PT - Journal Article PT - Review DEP - 20160902 PL - Spain TA - Histol Histopathol JT - Histology and histopathology JID - 8609357 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Biomarkers, Tumor/*genetics/metabolism MH - *Disease Management MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - MicroRNAs/*genetics/metabolism MH - Prognosis MH - Urinary Bladder Neoplasms/genetics/metabolism/pathology/*therapy EDAT- 2016/09/03 06:00 MHDA- 2017/04/19 06:00 CRDT- 2016/09/03 06:00 PHST- 2016/09/03 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] PHST- 2016/09/03 06:00 [entrez] AID - HH-11-814 [pii] AID - 10.14670/HH-11-814 [doi] PST - ppublish SO - Histol Histopathol. 2017 Feb;32(2):107-119. doi: 10.14670/HH-11-814. Epub 2016 Sep 2. PMID- 27579290 OWN - PIP STAT- PubMed-not-MEDLINE DCOM- 20160831 LR - 20181113 IS - 1016-1430 (Print) IS - 2251-6840 (Electronic) IS - 1016-1430 (Linking) VI - 30 DP - 2016 TI - Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. PG - 400 AB - BACKGROUND: Flat urothelial lesions comprise a spectrum of morphologic changes ranging from reactive atypia to carcinoma in situ (CIS). Urothelial dysplasia and CIS are associated with the recurrence and progression of urothelial carcinoma. Distinguishing CIS and dysplasia from reactive atypia based on histolopathogical features alone is often difficult. Using different immunohistochemical markers such as Cytokeratin 20 (CK20), CD44, p53, and Ki-67 is recommended for differential diagnosis. The aim of this study was to evaluate the immunohistochemical pattern of these antibodies to differentiate different flat urothelial lesions. METHODS: In this cross- sectional study, three groups of bladder biopsy specimens were evaluated: 20 samples with reactive urothelial lesions, 20 histologically diagnosed as CIS, and 20 morphologically normal samples. Immunohistochemical staining of CK20, p53, CD44 and Ki-67 markers was performed on paraffin-embedded blocks. The groups were compared using chi square test, and the diagnostic value of the markers were evaluated with sensitivity, specificity, positive and negative predictive values. RESULTS: CK20 was full thickness positive in 15 (75%) CIS samples and negative in all samples of the normal and reactive groups (p<0.001); CD44 was positive in 2 (10%) cases of the CIS group and in 17 (85%) of the reactive group; this marker was negative in all the normal samples (p<0.001). P53 was positive in 12 (60%) samples of the CIS group and negative in all samples of the normal and reactive groups (p<0.001). Ki67 was positive in 13 (65%) samples of the CIS group and 1 (5%) sample of the reactive group. This marker was negative in all samples of the normal group (p<0.001). CONCLUSION: The results of this study revealed that CK20, CD44, P53 and Ki67 are useful in distinguishing CIS from reactive and normal samples. However, they should be used in a panel including at least three markers. Correlation with the morphologic features is necessary. FAU - Asgari, Mojgan AU - Asgari M AD - Associate Professor of Pathology, Oncopathology Research Center and Hasheminejad Clinical Research Developing Center (HCRDC), Iran University of Medical Sciences, Tehran, Iran. mojgan_asgari@yahoo.com. FAU - Nabi Maybodi, Mahtab AU - Nabi Maybodi M AD - Pathologist, Iran University of Medical Sciences, Tehran, Iran. mahtab_nabi@yahoo.com. FAU - Abolhasani, Maryam AU - Abolhasani M AD - Assistant Professor of Pathology, Oncopathology Research Center and Hasheminejad Clinical Research Developing Center, Iran University of Medical Sciences, Tehran, Iran. mar.abolhasani@gmail.com. LA - eng PT - Journal Article DEP - 20160718 PL - Iran TA - Med J Islam Repub Iran JT - Medical journal of the Islamic Republic of Iran JID - 8910777 PMC - PMC5004568 OTO - NOTNLM OT - CD44 OT - CK20 OT - P53 and Ki67 OT - Urothelial Carcinoma in Situ OT - Urothelium EDAT- 2016/09/01 06:00 MHDA- 2016/09/01 06:01 PMCR- 2016/07/18 CRDT- 2016/09/01 06:00 PHST- 2015/04/05 00:00 [received] PHST- 2016/01/13 00:00 [accepted] PHST- 2016/09/01 06:00 [entrez] PHST- 2016/09/01 06:00 [pubmed] PHST- 2016/09/01 06:01 [medline] PHST- 2016/07/18 00:00 [pmc-release] PST - epublish SO - Med J Islam Repub Iran. 2016 Jul 18;30:400. eCollection 2016. PMID- 27576438 OWN - NLM STAT- MEDLINE DCOM- 20170419 LR - 20181202 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 46 IP - 12 DP - 2016 Dec TI - Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study. PG - 1148-1155 AB - OBJECTIVE: We investigated chronological changes in the outcomes of patients with upper urinary tract urothelial carcinoma treated in the past two decades, during which there was an important change in treatment paradigm. METHODS: A retrospective review was conducted of 1180 urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy in multicenter collaborative institutions between 1996 and 2015. The patients were divided into four groups according to the year when radical nephroureterectomy was performed, as follows: 1996-2000 (period 1; P1), 2001-05 (P2), 2006-10 (P3) and 2011-15 (P4). Variables including tumor grade, T and N categories, administration of perioperative chemotherapy and treatment outcomes were compared among the four groups. RESULTS: There were 146 (12%), 312 (27%), 459 (39%) and 263 (22%) patients in the P1, P2, P3 and P4 groups, respectively. The proportion of patients harboring pT2/3 and Grade 3 tumors increased gradually from 42% (P1) to 58% (P4) and from 49% (P1) to 65% (P4), respectively. The 5-year disease-free survival rates were 74%, 74%, 73% and 75%, and the 5-year overall survival rates were 74%, 65%, 67% and 72% for the P1, P2, P3, and P4 groups, respectively. Multivariate analysis with adjustment for possible confounding factors revealed no significant differences in disease-specific survival, overall survival or intravesical recurrence-free survival among the four groups. CONCLUSIONS: Despite advances in diagnostic instruments, surgery and systemic chemotherapy, the clinical outcome of urinary tract urothelial carcinoma after radical surgery has not significantly improved over the last two decades, and further research is therefore required. CI - (c) The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Nara. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Kashihara, Nara. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara kiyokun@naramed-u.ac.jp. FAU - Nagao, Kazuhiro AU - Nagao K AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Sakano, Shigeru AU - Sakano S AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Matsuyama, Hideyasu AU - Matsuyama H AD - Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi. FAU - Inamoto, Teruo AU - Inamoto T AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka. FAU - Azuma, Haruhito AU - Azuma H AD - Department of Urology, Osaka Medical College, Takatsuki, Osaka. FAU - Yasumoto, Hiroaki AU - Yasumoto H AD - Department of Urology, Shimane University School of Medicine, Izumo, Shimane, Japan. FAU - Shiina, Hiroaki AU - Shiina H AD - Department of Urology, Shimane University School of Medicine, Izumo, Shimane, Japan. CN - Nishinipon Uro-Oncology Collaborative Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160830 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Adult MH - Aged MH - Carcinoma/mortality/*surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Nephrectomy MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/*surgery OTO - NOTNLM OT - chronological change OT - disease-specific survival OT - intravesical recurrence OT - overall survival OT - upper urinary tract carcinoma OT - urothelial carcinoma EDAT- 2016/09/01 06:00 MHDA- 2017/04/20 06:00 CRDT- 2016/09/01 06:00 PHST- 2016/05/22 00:00 [received] PHST- 2016/08/10 00:00 [revised] PHST- 2016/08/15 00:00 [accepted] PHST- 2016/09/01 06:00 [pubmed] PHST- 2017/04/20 06:00 [medline] PHST- 2016/09/01 06:00 [entrez] AID - hyw128 [pii] AID - 10.1093/jjco/hyw128 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2016 Dec;46(12):1148-1155. doi: 10.1093/jjco/hyw128. Epub 2016 Aug 30. PMID- 27573985 OWN - NLM STAT- MEDLINE DCOM- 20170303 LR - 20211203 IS - 1791-2431 (Electronic) IS - 1021-335X (Linking) VI - 36 IP - 4 DP - 2016 Oct TI - Clinical significance of alpha‑ and beta‑Klotho in urothelial carcinoma of the bladder. PG - 2117-25 LID - 10.3892/or.2016.5053 [doi] AB - Non-muscle invasive bladder cancer (NMIBC) accounts for ~70% of all bladder cancers. One of the serious clinical issues related to the management of NMIBC is that it has significant potential to progress to muscle invasive bladder cancer (MIBC) after initial treatments. alpha‑Klotho (KLalpha), originally identified as an anti‑aging gene, has recently been reported to have antitumor effects in various malignancies. In contrast, beta‑Klotho (KLbeta) has been reported to have protumoral functions. However, the associations between KLalpha/KLbeta and the biological behavior of urothelial carcinoma remain unclear. In the present study, we evaluated the association between clinicopathological background factors of NMIBC and the expression levels of KLalpha or KLbeta. A high expression level of KLbeta, but not KLalpha, was an independent predictive factor of short progression‑free survival for NMIBC. An elevated level of KLbeta correlated with a higher incidence of lymphovascular invasion (LVI). We added in vitro assays using human bladder cancer cell lines to investigate the role of KLbeta. Treatment with exogenous KLbeta protein increased the proliferation, migration, transendothelial migration abilities and anchorage‑independent growth of the cell lines. In addition, the KLbeta concentration in voided urine samples obtained before initial transurethral surgery was quantitated with enzyme‑linked immunosorbent assay (ELISA). The urine KLbeta concentration was found to be higher in patients with bladder cancer than that in healthy volunteers. Our results suggest that KLbeta plays important roles in tumor invasion and progression, and its concentration may be a valuable urine‑based marker for the detection of bladder cancer. FAU - Hori, Shunta AU - Hori S AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Onishi, Sayuri AU - Onishi S AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Morizawa, Yosuke AU - Morizawa Y AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan. LA - eng PT - Journal Article DEP - 20160825 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (Biomarkers, Tumor) RN - 0 (KLB protein, human) RN - 0 (Membrane Proteins) RN - EC 3.2.1.31 (Glucuronidase) RN - EC 3.2.1.31 (Klotho Proteins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Blotting, Western MH - Carcinoma, Transitional Cell/metabolism/mortality/*pathology MH - Cell Movement/physiology MH - Cell Proliferation/physiology MH - Disease Progression MH - Disease-Free Survival MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Glucuronidase/*metabolism MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Klotho Proteins MH - Male MH - Membrane Proteins/*metabolism MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/metabolism/mortality/pathology MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/metabolism/mortality/*pathology EDAT- 2016/08/31 06:00 MHDA- 2017/03/04 06:00 CRDT- 2016/08/31 06:00 PHST- 2016/02/25 00:00 [received] PHST- 2016/04/05 00:00 [accepted] PHST- 2016/08/31 06:00 [entrez] PHST- 2016/08/31 06:00 [pubmed] PHST- 2017/03/04 06:00 [medline] AID - 10.3892/or.2016.5053 [doi] PST - ppublish SO - Oncol Rep. 2016 Oct;36(4):2117-25. doi: 10.3892/or.2016.5053. Epub 2016 Aug 25. PMID- 27564278 OWN - NLM STAT- MEDLINE DCOM- 20170713 LR - 20260127 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 42 IP - 4 DP - 2016 Jul-Aug TI - Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. PG - 685-93 LID - 10.1590/S1677-5538.IBJU.2015.0243 [doi] AB - BACKGROUND: Bladder cancer represents one of the most important clinical challenges in urologic practice. In this context, inflammation has an important role in the development and progression of many malignancies. The objective of the present study was to evaluate the prognostic value of pre-treatment Neutrophil to lymphocyte ratio (NLR) on the risk of recurrence and progression in patients with primary non-muscle invasive bladder cancer. MATERIALS AND METHODS: Data obtained from 178 bladder cancer patients who underwent transurethral resection of bladder tumor (TURB) between July 2008 and December 2014 were evaluated prospectively. NLR was obtained from each patient before TURB and defined as the absolute neutrophil count divided by the absolute lymphocyte count. Cox proportional hazards regression model was performed to calculate disease recurrence and progression including NLR. RESULTS: During the follow-up study (median: 53 months), 14 (23.3%) and 44 (37.9%) (p=0.04) patients respectively with NLR<3 and >/=3experienced recurrence and 2 (3.3%) and 14 (11.9%) experienced progression (p=0.06), respectively. At the multivariate Cox regression analysis, NLR >/=3 was associated with worse disease recurrence (HR: 2.84; p<0.01). No association was found regarding disease progression. The 5-year recurrence free survival was 49% and 62% in patients with NLR>/=3 and <3 (p<0.01). The 5-year progression free survival was 77% and 93% in patients with NLR>/=3 and <3 (p=0.69). CONCLUSION: NLR predicts disease recurrence but not disease progression in NMIBC patients. NLR alterations may depend of tumor inflammatory microenvironment. CI - Copyright(c) by the International Brazilian Journal of Urology. FAU - Favilla, Vincenzo AU - Favilla V AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Castelli, Tommaso AU - Castelli T AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Urzi, Daniele AU - Urzi D AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Reale, Giulio AU - Reale G AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Privitera, Salvatore AU - Privitera S AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Salici, Antonio AU - Salici A AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Russo, Giorgio Ivan AU - Russo GI AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Cimino, Sebastiano AU - Cimino S AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. FAU - Morgia, Giuseppe AU - Morgia G AD - Sezione Urologia, Dipartimento di Chirurgia, Universita di Catania, Italia. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Biomarkers, Tumor/*blood MH - Blood Cell Count MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Italy/epidemiology MH - Leukocyte Count MH - Lymphocyte Count MH - *Lymphocytes MH - Male MH - Neoplasm Invasiveness MH - *Neutrophils MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*blood/mortality/pathology PMC - PMC5006763 OTO - NOTNLM OT - Biomarkers OT - Neutrophils OT - Urinary Bladder Neoplasms COIS- Conflicts of Interest: None declared. EDAT- 2016/08/27 06:00 MHDA- 2017/07/14 06:00 PMCR- 2016/07/01 CRDT- 2016/08/27 06:00 PHST- 2015/05/01 00:00 [received] PHST- 2015/10/26 00:00 [accepted] PHST- 2016/08/27 06:00 [entrez] PHST- 2016/08/27 06:00 [pubmed] PHST- 2017/07/14 06:00 [medline] PHST- 2016/07/01 00:00 [pmc-release] AID - IBJUv42n4a9 [pii] AID - S1677-5538.IBJU.2015.0243 [pii] AID - 10.1590/S1677-5538.IBJU.2015.0243 [doi] PST - ppublish SO - Int Braz J Urol. 2016 Jul-Aug;42(4):685-93. doi: 10.1590/S1677-5538.IBJU.2015.0243. PMID- 27563657 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160826 LR - 20220318 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 4 IP - 14 DP - 2016 Jul TI - Immunobiology and immunotherapy in genitourinary malignancies. PG - 270 LID - 10.21037/atm.2016.06.29 [doi] LID - 270 AB - Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guerin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant prostate cancer (mCRPC), based on a phase III trial showing overall survival (OS) benefit compared to placebo. The immune checkpoint inhibitor nivolumab (anti-PD-1) recently received FDA approval for the management of patients with advanced RCC patients previously treated with anti-angiogenic therapy, based on OS benefit compared to everolimus. Recently, large clinical trials demonstrated meaningful clinical benefit, including durable responses, as well as a good tolerability/safety profile with the use of immune checkpoint inhibitors in advanced RCC and chemotherapy-resistant advanced urothelial carcinoma (UC), while FDA just approved atezolizumab for platinum-treated advanced UC. Numerous interesting trials in different cancers are ongoing. Several combinations of immune checkpoint blockade with chemotherapeutics, vaccines, targeted tyrosine kinase inhibitors & monoclonal antibodies, epigenetic modifiers, anti-angiogenic agents, tumor microenvironment & myeloid cell targeting therapies, metabolic modification strategies, radiation, and others, are being tested in clinical trials. Comprehensive understanding of the factors underlying antitumor immune responses in physiologically relevant animal models and humans will refine further the clinical benefit of immunotherapy. Discovery and validation of appropriate molecular biomarkers via coordinated translational research efforts, rational clinical trial designs with suitable endpoints and well-defined eligibility criteria, prospective registries/databases, careful evaluation of cost-effectiveness and safety/tolerability, adequate funding and open continuous discussions among all stakeholders will support the revolutionary nature of immunotherapy in GU cancers. FAU - Tsiatas, Marinos AU - Tsiatas M AD - Department of Genitourinary Oncology, Athens Medical Center, Maroussi, Greece ; FAU - Grivas, Petros AU - Grivas P AD - Department of Hematology/Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC4971374 OTO - NOTNLM OT - Bladder cancer (BC) OT - immunotherapy OT - prostate cancer OT - renal cancer COIS- Conflicts of Interest: M Tsiatas has received medical advisor fees from Janssen and honoraria from AstraZeneca and GSK; P Grivas has done consulting and participated in unbranded, not-product related, educational program with Genentech, and has done consulting with Bayer and Dendreon. EDAT- 2016/08/27 06:00 MHDA- 2016/08/27 06:01 PMCR- 2016/07/01 CRDT- 2016/08/27 06:00 PHST- 2016/08/27 06:00 [entrez] PHST- 2016/08/27 06:00 [pubmed] PHST- 2016/08/27 06:01 [medline] PHST- 2016/07/01 00:00 [pmc-release] AID - atm-04-14-270 [pii] AID - 10.21037/atm.2016.06.29 [doi] PST - ppublish SO - Ann Transl Med. 2016 Jul;4(14):270. doi: 10.21037/atm.2016.06.29. PMID- 27557492 OWN - NLM STAT- MEDLINE DCOM- 20180223 LR - 20190216 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 40 DP - 2016 Oct 4 TI - Foxp3 enhances HIF-1alpha target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. PG - 65403-65417 LID - 10.18632/oncotarget.11395 [doi] AB - Hypoxia-inducible factor-1alpha (HIF-1alpha) can control a transcriptional factor forkhead box P3 (Foxp3) protein expression in T lymphocyte differentiation through proteasome-mediated degradation. In this study, we unveil a reverse regulatory mechanism contributing to bladder cancer progression; Foxp3 expression attenuates HIF-1alpha degradation. We first demonstrated that Foxp3 expression positively correlates with the metastatic potential in T24 cells and can increase the expression of HIF-1alpha-target genes, such as vascular endothelial growth factor (VEGF) and glucose transporter (GLUT). Foxp3 protein can bind with HIF-1alpha, particularly under hypoxia. In vivo ubiquination assay demonstrated that Foxp3 can decrease HIF-1alpha degradation in a dose-dependent manner. Knocking-down of Foxp3 expression blocks in vivo tumor growth in mice and prolongs mice's survival, which is associated with von Willebrand factor expression. Thirty-three of 145 (22.8 %) bladder tumors exhibit Foxp3 expression. Foxp3 expression is an independent predictor for disease progression in superficial bladder cancer patients (p = 0.032), associated with less number of intratumoral CD8+ lymphocyte. The metaanalysis from 2 published datasets showed Foxp3 expression is positively associated with GLUT-4,-9, and VEGF-A, B-, D expression. This reverse post-translational regulation of HIF-1alpha protein by Foxp3 provides a new potential target for developing new therapeutic strategy for bladder cancer. FAU - Jou, Yeong-Chin AU - Jou YC AD - Department of Urology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan. FAU - Tsai, Yuh-Shyan AU - Tsai YS AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Lin, Chang-Te AU - Lin CT AD - Department of Urology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan. FAU - Tung, Chun-Liang AU - Tung CL AD - Department of Pathology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan. FAU - Shen, Cheng-Huang AU - Shen CH AD - Department of Urology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan. FAU - Tsai, Hsin-Tzu AU - Tsai HT AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Yang, Wen-Horng AU - Yang WH AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chang, Hung-I AU - Chang HI AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chen, Syue-Yi AU - Chen SY AD - Department of Medical Researh, Chia-Yi Christian Hospital, Chia-Yi, Taiwan. FAU - Tzai, Tzong-Shin AU - Tzai TS AD - Department of Urology, School of Medicine, China Medical University, Taichung, Taiwan. AD - Department of Urology, Tainan Municipal An-Nan Hospital, China Medical University, Tainan, Taiwan. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (FOXP3 protein, human) RN - 0 (Forkhead Transcription Factors) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (RNA, Small Interfering) RN - EC 3.4.25.1 (Proteasome Endopeptidase Complex) SB - IM MH - Aged MH - Aged, 80 and over MH - Animals MH - Biomarkers, Tumor/genetics/*metabolism MH - Cell Line, Tumor MH - Cell Movement MH - Female MH - Forkhead Transcription Factors/genetics/*metabolism MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/*metabolism MH - Male MH - Mice MH - Mice, SCID MH - Middle Aged MH - Proteasome Endopeptidase Complex/*metabolism MH - Proteolysis MH - RNA, Small Interfering/genetics MH - Survival Analysis MH - Ubiquitination MH - Up-Regulation MH - Urinary Bladder Neoplasms/genetics/*metabolism/mortality PMC - PMC5323164 OTO - NOTNLM OT - Foxp3 OT - bladder neoplasms OT - glycolysis OT - immunohistochemistry OT - prognosis COIS- CONFLICTS OF INTEREST The authors declare no financial disclosure. EDAT- 2016/08/25 06:00 MHDA- 2018/02/24 06:00 PMCR- 2016/10/04 CRDT- 2016/08/25 06:00 PHST- 2015/12/14 00:00 [received] PHST- 2016/08/08 00:00 [accepted] PHST- 2016/08/25 06:00 [pubmed] PHST- 2018/02/24 06:00 [medline] PHST- 2016/08/25 06:00 [entrez] PHST- 2016/10/04 00:00 [pmc-release] AID - 11395 [pii] AID - 10.18632/oncotarget.11395 [doi] PST - ppublish SO - Oncotarget. 2016 Oct 4;7(40):65403-65417. doi: 10.18632/oncotarget.11395. PMID- 27555684 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160824 LR - 20220317 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 32 IP - 3 DP - 2016 Jul-Sep TI - Grading of complications of transurethral resection of bladder tumor using Clavien-Dindo classification system. PG - 232-7 LID - 10.4103/0970-1591.185104 [doi] AB - INTRODUCTION: Clavien-Dindo classification system is used for grading complications of various oncological, renal, and endourological procedures. We applied this system for grading the severity of perioperative complications in patients undergoing transurethral resection of bladder tumor (TURBT) and identify parameters predicting these complications. MATERIALS AND METHODS: Data of 984 patients who underwent TURBT from 2006 to 2014 were included in this study. All data was retrospectively collected and analyzed for complications occurring within the first postoperative month. All complications were classified according to the five grades of modified CCS (.Clavien classification system). RESULTS: A total of 172 complications were observed in 138 patients. Majority were low grade complications (Grade 1 [77.3%] and Grade 2 [12.7%]). Higher grade complications were rare (Grade 3 [6.4%] and Grade 4 [3.0%]). There was one death (Grade 5 0.6%), with an overall mortality rate of 0.1%. The incidence of complications was significantly greater for age >60 years, baseline serum creatinine >1.4 mg/dl, size of tumor >4 cm, tumor located at dome, resection time >60 min, incomplete resection and if surgery performed by a resident urologist. CONCLUSIONS: Clavien-Dindo classification system can be easily applied to grade the complications of TURBT, and it is easily reproducible. We observed that TURBT was a safe procedure. Majority of complications were Grade 1-2 (90%) and Grade 3-5 were rare (10%). Postoperative bleeding is the most common complication. A greater rate of complications of TURBT was associated with patient age, size of tumor, location of tumor, surgeon experience, resection time, and completion of tumor resection. FAU - Bansal, Ankur AU - Bansal A AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. FAU - Sankhwar, Satyanarayan AU - Sankhwar S AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. FAU - Goel, Apul AU - Goel A AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. FAU - Kumar, Manoj AU - Kumar M AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. FAU - Purkait, Bimalesh AU - Purkait B AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. FAU - Aeron, Ruchir AU - Aeron R AD - Department of Urology, King George Medical College, Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4970397 OTO - NOTNLM OT - Bladder tumor OT - Clavien-Dindo OT - complications OT - transurethral resection EDAT- 2016/08/25 06:00 MHDA- 2016/08/25 06:01 PMCR- 2016/07/01 CRDT- 2016/08/25 06:00 PHST- 2016/08/25 06:00 [entrez] PHST- 2016/08/25 06:00 [pubmed] PHST- 2016/08/25 06:01 [medline] PHST- 2016/07/01 00:00 [pmc-release] AID - IJU-32-232 [pii] AID - 10.4103/0970-1591.185104 [doi] PST - ppublish SO - Indian J Urol. 2016 Jul-Sep;32(3):232-7. doi: 10.4103/0970-1591.185104. PMID- 27554791 OWN - NLM STAT- MEDLINE DCOM- 20180328 LR - 20181202 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 9 DP - 2016 Sep TI - Immune signature of urothelial cancer associated with grade, recurrence, and invasion. PG - 418.e17-26 LID - S1078-1439(16)30047-3 [pii] LID - 10.1016/j.urolonc.2016.04.013 [doi] AB - BACKGROUND: Urothelial carcinoma (UC) is one of most common genitourinary malignancy and the spectrum of disease ranges from in situ lesions to muscle-invasive cancers. The non-muscle-invasive lesions have tendency to recur or progress to muscle-invasive disease. The study of the immune profile may identify immune determinants associated with high-grade, recurrence, and invasion in patients with UC. METHODS: Pathway-focused RT(2) profiler arrays were used to screen patients with UC for dysregulation of candidate genes of Th1-Th2-Th3 and NFkappaB pathways, which were then validated by real-time polymerase chain reaction on tumor samples and correlated with grade, recurrence, and invasion of tumors to identify their role in predicting behavior of the tumor. The cytokines found associated with recurrence were then validated in urine of patients with UC. RESULTS: IFNgamma, IL2, IL4, IL10, IL17, CCL7, CTLA4, and SPP1 of the cytokine pathway and TLR4, TLR3, RELA, NFkappaB1, and MYD88 of the NFkappaB pathway were found differentially expressed in patients with urothelial cancer by array and quantative real-time polymerase chain reaction. Among these, IL10 and SPP1 were found consistently up-regulated in high-grade, invasive, and recurrent cases and up-regulated IL10 and CTLA4 were found associated with a short recurrence-free survival time (P = 0.001 and P = 0.065). Urinary IL10 concentration was significantly higher in both patients with cancer and cystitis compared with healthy controls, but the difference in concentration between patients with cancer and cystitis patients was not statistically significant. However, urinary CTLA4 concentrations were found to be significantly higher in urothelial cancer patients compared with healthy controls and cystitis cases and found to be associated with poor recurrence-free survival. CONCLUSION: The study indicates that high urinary CTLA4 concentration raises the index of suspicion of recurrence in a known case of urothelial cancer and may be used as a surveillance marker. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Agrawal, Usha AU - Agrawal U AD - National Institute of Pathology, Indian Council of Medical Research, New Delhi, India; Symbiosis International University, Lavale, Pune, India. FAU - Kumari, Nitu AU - Kumari N AD - National Institute of Pathology, Indian Council of Medical Research, New Delhi, India; BITS, Pilani, Rajasthan, India. FAU - Mishra, Ashwani K AU - Mishra AK AD - NDDTC and Department of Psychiatry, AIIMS, New Delhi, India. FAU - Vasudeva, Pawan AU - Vasudeva P AD - Deptartment of Urology, VMMC and Safdarjung Hospital, New Delhi, India. FAU - Kumar, Anup AU - Kumar A AD - Deptartment of Urology, VMMC and Safdarjung Hospital, New Delhi, India. FAU - Mohanty, Nayan K AU - Mohanty NK AD - Saket City Hospital, New Delhi, India. FAU - Saxena, Sunita AU - Saxena S AD - National Institute of Pathology, Indian Council of Medical Research, New Delhi, India. Electronic address: sunita_saxena@yahoo.com. LA - eng PT - Journal Article PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers) RN - 0 (Cytokines) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers MH - Carcinoma, Transitional Cell/*diagnosis/*immunology MH - Cytokines/immunology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Signal Transduction MH - Urologic Neoplasms/*diagnosis/*immunology OTO - NOTNLM OT - CTLA4 OT - Cytokines OT - NFkappaB OT - Urothelial cancer EDAT- 2016/08/25 06:00 MHDA- 2018/03/29 06:00 CRDT- 2016/08/25 06:00 PHST- 2015/08/11 00:00 [received] PHST- 2016/04/19 00:00 [revised] PHST- 2016/04/23 00:00 [accepted] PHST- 2016/08/25 06:00 [entrez] PHST- 2016/08/25 06:00 [pubmed] PHST- 2018/03/29 06:00 [medline] AID - S1078-1439(16)30047-3 [pii] AID - 10.1016/j.urolonc.2016.04.013 [doi] PST - ppublish SO - Urol Oncol. 2016 Sep;34(9):418.e17-26. doi: 10.1016/j.urolonc.2016.04.013. PMID- 27551554 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160823 LR - 20200930 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 69 IP - 2 DP - 2016 TI - Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. PG - 170-7 LID - 10.5173/ceju.2016.795 [doi] AB - INTRODUCTION: One of the factors responsible for the risk of recurrence after complete transurethral resection of the bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) is the quality of surgery that may vary between individual surgeons. The aim of the study was to evaluate the impact of the surgeon on recurrence-free survival in patients with NMIBC. MATERIAL AND METHODS: The long-term results of a series of consecutive TURBTs performed by five staff urologists at a single institution were retrospectively analyzed. A total of 949 cases of organ-preserving treatment in 784 patients with NMIBC were included in the analysis. RESULTS: With the median follow-up of 64.3 months (3-124 months), the 5-year recurrence-free survival rates according to the surgeon were 62.9% (95% CI 56.2-69.7%), 53.6% (95% CI 47.4-59.9%), 51.0% (95% CI 39.6-62.4%), 46.2% (95% CI 36.4-56.0%), and 44.2% (95% CI 36.8-51.7%), respectively (p <0.0001). In the multivariate analysis including all potential risk factors, the individual surgeon was associated with a risk of recurrence with a high degree of statistical significance (p = 0.0013). The between-surgeon differences in the recurrence risk were not that pronounced in less extensive tumors. CONCLUSIONS: A surgeon has a significant impact on the risk of recurrence after curative treatment of patients with NMIBC. This effect was observed despite the relatively extensive experience in bladder endoscopic surgery of all of the surgeons and practicing in a setting of one specialized center. These findings should be taken into account while performing and evaluating the results of comparative studies. FAU - Rolevich, Alexander AU - Rolevich A AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. FAU - Minich, Alexander AU - Minich A AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. FAU - Nabebina, Tatiana AU - Nabebina T AD - Department of Pathology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. FAU - Polyakov, Sergey AU - Polyakov S AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. FAU - Krasny, Sergey AU - Krasny S AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. FAU - Sukonko, Oleg AU - Sukonko O AD - Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus. LA - eng PT - Journal Article DEP - 20160419 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC4986305 OTO - NOTNLM OT - non-muscle invasive bladder cancer OT - quality of surgery OT - transurethral resection EDAT- 2016/08/24 06:00 MHDA- 2016/08/24 06:01 PMCR- 2016/01/01 CRDT- 2016/08/24 06:00 PHST- 2016/02/16 00:00 [received] PHST- 2016/03/16 00:00 [revised] PHST- 2016/03/23 00:00 [accepted] PHST- 2016/08/24 06:00 [entrez] PHST- 2016/08/24 06:00 [pubmed] PHST- 2016/08/24 06:01 [medline] PHST- 2016/01/01 00:00 [pmc-release] AID - 00795 [pii] AID - 10.5173/ceju.2016.795 [doi] PST - ppublish SO - Cent European J Urol. 2016;69(2):170-7. doi: 10.5173/ceju.2016.795. Epub 2016 Apr 19. PMID- 27547459 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160822 LR - 20200930 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 14 IP - 3 DP - 2016 Sep TI - Computed tomography virtual cystoscopy for follow-up of patients with superficial bladder tumours in comparison to conventional cystoscopy: An exploratory study. PG - 192-7 LID - 10.1016/j.aju.2016.06.003 [doi] AB - OBJECTIVE: To evaluate and analyse the efficacy of computed tomography (CT) virtual cystoscopy in comparison to conventional cystoscopy for the follow-up of patients with non-muscle-invasive bladder cancer. PATIENTS AND METHODS: The study was done over 3 years, from April 2010 to June 2013, and included 30 patients who all had non-muscle-invasive transitional cell carcinoma (Ta, T1). The patients all underwent complete transurethral resection of the tumour and presented for first follow-up check cystoscopy. The examination was performed using a 16-slice multi-detector (MD) CT scanner. The results were compared for sensitivity and specificity in relation to the site, size, and shape of the tumour. RESULTS: In all, 20 lesions were detected by CT virtual cystoscopy in 18 patients, whilst the remaining 12 were lesion free. Conventional cystoscopy, detected 23 lesions in 19 patients. The sensitivity of the virtual images was 87%; its specificity in identifying lesions was 100%, with a positive predictive value of 100% and negative predictive value of 78.5%. CONCLUSION: CT virtual cystoscopy is a promising technique for detecting bladder tumours and some other bladder lesions. However, the detection rate for recurrent NMIBC does not appear to be adequate to replace conventional cystoscopy. FAU - Elawady, Hossam AU - Elawady H AD - Department of Urology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Mahmoud, Mahmoud A AU - Mahmoud MA AD - Department of Urology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Mostafa, Diaaeldin M A AU - Mostafa DM AD - Department of Urology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Abdelmaksoud, Alaa AU - Abdelmaksoud A AD - Department of Urology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Safa, Mohamed W AU - Safa MW AD - Department of Urology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Elia, Remon Z AU - Elia RZ AD - Department of Radiodiagnosis, Faculty of Medicine, Ain Shams University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20160725 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC4983164 OTO - NOTNLM OT - Conventional cystoscopy OT - MDCT, multi-detector CT OT - NMIBC, non-muscle-invasive bladder cancer OT - NPV, negative predictive value OT - Non-muscle-invasive bladder cancer OT - PPV, positive predictive value OT - TURBT, transurethral resection of bladder tumour OT - Virtual cystoscopy EDAT- 2016/08/23 06:00 MHDA- 2016/08/23 06:01 PMCR- 2016/07/25 CRDT- 2016/08/23 06:00 PHST- 2016/03/30 00:00 [received] PHST- 2016/05/18 00:00 [revised] PHST- 2016/06/08 00:00 [accepted] PHST- 2016/08/23 06:00 [entrez] PHST- 2016/08/23 06:00 [pubmed] PHST- 2016/08/23 06:01 [medline] PHST- 2016/07/25 00:00 [pmc-release] AID - S2090-598X(16)30036-5 [pii] AID - 10.1016/j.aju.2016.06.003 [doi] PST - epublish SO - Arab J Urol. 2016 Jul 25;14(3):192-7. doi: 10.1016/j.aju.2016.06.003. eCollection 2016 Sep. PMID- 27530435 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 15 IP - 2 DP - 2017 Apr TI - Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. PG - e267-e273 LID - S1558-7673(16)30217-8 [pii] LID - 10.1016/j.clgc.2016.07.014 [doi] AB - INTRODUCTION: The aim of this study was to validate the value of preoperative patient characteristics in prognosticating survival after radical cystectomy (RC) to guide treatment decisions regarding neoadjuvant systemic treatment. METHODS: We evaluated a single cohort of 449 consecutive patients treated with RC for bladder cancer. Patients treated with neoadjuvant therapy were excluded from the study cohort (n = 24). Patients were stratified based on preoperative characteristics into 2 risk groups. The high-risk group included patients harboring clinically non-organ-confined disease (>/= cT3), hydroureteronephrosis, lymphovascular invasion, or variant histology (micropapillary, neuroendocrine, sarcomatoid, or plasmacytoid variants on transurethral resection). The low-risk group included patients with cT2 disease without any of the aforementioned features. Survival expectancies after surgery were evaluated using competing risk and Kaplan-Meier analyses. RESULTS: We identified 153 (44.6%) low-risk and 190 (55.4%) high-risk patients. The majority of high-risk patients had only 1 high-risk feature (n = 111; 58.4%); the most common high-risk feature was preoperative hydroureteronephrosis (n = 107; 56.3%). The majority of low-risk patients were upstaged at time of RC (n = 118; 70.6%), whereas a pathologic downstage occurred only in 27 high-risk patients (14.2%). Cancer-specific mortality-free rates at 5 years after RC were 77.4% versus 64.4% for low-risk versus high-risk patients, respectively. CONCLUSIONS: We confirm that preoperative risk features can stratify patients with muscle-invasive bladder cancer into differential risk groups regarding survival. Decision-making regarding neoadjuvant systemic therapy administration is likely to be improved by integrating clinical stage, lymphovascular invasion, variant histology, and hydroureteronephrosis. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Soria, Francesco AU - Soria F AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Torino, Italy. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Wirth, Gregory J AU - Wirth GJ AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Division of Urology, Department of Surgery, Geneva University Hospital, Geneva, Switzerland. FAU - Ozsoy, Mehmet AU - Ozsoy M AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Gust, Killian AU - Gust K AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere Academic Hospital, Assistance Publique-Hopitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France. FAU - Susani, Martin AU - Susani M AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Haitel, Andrea AU - Haitel A AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: sfshariat@gmail.com. LA - eng PT - Journal Article DEP - 20160722 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Chemotherapy, Adjuvant/methods MH - Clinical Decision-Making MH - Cystectomy/*methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Patient Selection MH - Prognosis MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/drug therapy/*pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Muscle invasive bladder cancer OT - Neoadjuvant chemotherapy OT - Preoperative characteristics OT - Radical cystectomy EDAT- 2016/08/18 06:00 MHDA- 2017/10/24 06:00 CRDT- 2016/08/18 06:00 PHST- 2016/06/21 00:00 [received] PHST- 2016/07/14 00:00 [revised] PHST- 2016/07/17 00:00 [accepted] PHST- 2016/08/18 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2016/08/18 06:00 [entrez] AID - S1558-7673(16)30217-8 [pii] AID - 10.1016/j.clgc.2016.07.014 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2017 Apr;15(2):e267-e273. doi: 10.1016/j.clgc.2016.07.014. Epub 2016 Jul 22. PMID- 27519277 OWN - NLM STAT- MEDLINE DCOM- 20180228 LR - 20220321 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 35 IP - 1 DP - 2017 Jan TI - An easily applicable single condition-based mortality index for patients undergoing radical prostatectomy or radical cystectomy. PG - 32.e17-32.e23 LID - S1078-1439(16)30171-5 [pii] LID - 10.1016/j.urolonc.2016.07.008 [doi] AB - PURPOSE: There is no generally accepted instrument to measure comorbidity in patients with cancer. We determined which single comorbid conditions are independently associated with competing mortality after radical prostatectomy or radical cystectomy in order to develop a mortality index. METHODS: The study samples consisted of 2,961 consecutive patients who underwent radical prostatectomy between 1992 and 2007 for clinically localized prostate cancer and 932 consecutive patients who underwent radical cystectomy between 1993 and 2012 for high-risk non-muscle-invasive or muscle-invasive urothelial or undifferentiated bladder cancer. Competing mortality was the study endpoint. Proportional hazard models for the subdistribution of competing risks were used for analysis. RESULTS: Age, angina pectoris, peripheral vascular disease, cerebrovascular disease, chronic lung disease, diabetes mellitus, moderate or severe renal disease, current smoking, and American Society of Anesthesiologists (ASA) physical status class 3 to 4 were independent predictors of competing mortality after radical prostatectomy. After identifying radical cystectomy, age, angina pectoris, chronic lung disease, diabetes mellitus, current smoking, ASA class 3 to 4, and male sex as independent predictors of competing mortality, a combined mortality index using the conditions independently associated with competing mortality in both samples stratified the patients into risk groups with 0% 10-year competing mortality in the lowest and approximately 50% in the highest-risk classes. CONCLUSIONS: This simple and plausible combined mortality index based on age, ASA class, smoking status, and the presence of the conditions such as angina pectoris, chronic lung disease, and diabetes mellitus may be used to predict competing mortality in candidates for radical prostatectomy or radical cystectomy. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Froehner, Michael AU - Froehner M AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. Electronic address: Michael.Froehner@uniklinikum-dresden.de. FAU - Koch, Rainer AU - Koch R AD - Department of Medical Statistics and Biometry, University Hospital Carl Gustav Carus, Dresden, Germany. FAU - Heberling, Ulrike AU - Heberling U AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. FAU - Novotny, Vladimir AU - Novotny V AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. FAU - Hubler, Matthias AU - Hubler M AD - Department of Anesthesiology, University Hospital Carl Gustav Carus, Dresden, Germany. FAU - Wirth, Manfred P AU - Wirth MP AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden, Germany. LA - eng PT - Journal Article DEP - 20160809 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Angina Pectoris/mortality MH - Chronic Disease MH - Comorbidity MH - *Cystectomy/mortality MH - Diabetes Mellitus/mortality MH - Health Status MH - Humans MH - Lung Diseases/mortality MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - *Prostatectomy/mortality MH - Prostatic Neoplasms/*mortality/surgery MH - Risk Assessment/methods MH - Risk Factors MH - Sex Factors MH - Smoking/mortality MH - Urinary Bladder Neoplasms/*mortality/surgery OTO - NOTNLM OT - Bladder cancer OT - Comorbidity OT - Competing risk analysis OT - Mortality OT - Mortality index OT - Proportional hazards model OT - Prostate cancer OT - Radical cystectomy OT - Radical prostatectomy OT - Urologic neoplasms EDAT- 2016/08/16 06:00 MHDA- 2018/03/01 06:00 CRDT- 2016/08/14 06:00 PHST- 2016/03/05 00:00 [received] PHST- 2016/05/31 00:00 [revised] PHST- 2016/07/11 00:00 [accepted] PHST- 2016/08/16 06:00 [pubmed] PHST- 2018/03/01 06:00 [medline] PHST- 2016/08/14 06:00 [entrez] AID - S1078-1439(16)30171-5 [pii] AID - 10.1016/j.urolonc.2016.07.008 [doi] PST - ppublish SO - Urol Oncol. 2017 Jan;35(1):32.e17-32.e23. doi: 10.1016/j.urolonc.2016.07.008. Epub 2016 Aug 9. PMID- 27510392 OWN - NLM STAT- MEDLINE DCOM- 20170713 LR - 20260127 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 31 IP - 9 DP - 2016 Sep TI - Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. PG - 1464-71 LID - 10.3346/jkms.2016.31.9.1464 [doi] AB - The purpose of the present study was to determine the potential relationships of glycemic control and use of metformin with non-muscle invasive bladder cancer characteristics. We reviewed data from 645 patients with non-muscle invasive bladder cancer between January 2004 and May 2015. We analyzed the association of pre and post-operative glycemic control and use of metformin with clinical characteristics of bladder tumors. We also analyzed the association of glycemic control and use of metformin with recurrence-free and progression-free survivals. Diabetes mellitus patients showed decreased recurrence-free survival (hazard ratio 1.42; 95% confidence interval 1.1-1.9; P = 0.021) and progression-free survival (hazard ratio 1.79; 95% confidence interval 1.1-2.8; P = 0.013). Diabetes mellitus patients with a HbA1c >/= 7.0% demonstrated a higher rate of progression (P = 0.026). Kaplan-Meier analysis showed that progression-free survival rate was associated with poor baseline glycemic control (P = 0.026) and post-operative glycemic control (P = 0.025). However, use of metformin had no impact on the recurrence (P = 1.00) and progression (P = 0.282). In conclusion, poor baseline and post-operative glycemic control was related with shorter progression-free survival of patients with non-muscle invasive bladder cancer. Use of metformin had no impact on the recurrence and progression. Therefore, tight glycemic control and close follow-up for bladder tumor may be beneficial in patients with poor glycemic control. FAU - Ahn, Ji Hoon AU - Ahn JH AUID- ORCID: 0000-0002-9658-8501 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Jung, Seung Il AU - Jung SI AUID- ORCID: 0000-0003-4864-8175 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. drjsi@yahoo.co.kr. FAU - Yim, Sang Un AU - Yim SU AUID- ORCID: 0000-0002-6555-9126 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Kim, Sun Woo AU - Kim SW AUID- ORCID: 0000-0001-5243-1564 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Hwang, Eu Chang AU - Hwang EC AUID- ORCID: 0000-0002-2031-124X AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. FAU - Kwon, Dong Deuk AU - Kwon DD AUID- ORCID: 0000-0002-4544-5420 AD - Department of Urology, Chonnam National University Medical School, Gwangju, Korea. LA - eng PT - Journal Article PL - Korea (South) TA - J Korean Med Sci JT - Journal of Korean medical science JID - 8703518 RN - 0 (Glycated Hemoglobin) RN - 9100L32L2N (Metformin) RN - 0 (hemoglobin A1c protein, human) SB - IM MH - Aged MH - Diabetes Mellitus, Type 2/complications/*drug therapy MH - Disease-Free Survival MH - Female MH - Glycated Hemoglobin/analysis MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Metformin/*therapeutic use MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Odds Ratio MH - Proportional Hazards Models MH - Retrospective Studies MH - Urinary Bladder Neoplasms/complications/mortality/*pathology/surgery PMC - PMC4974190 OTO - NOTNLM OT - Bladder Cancer OT - Diabetes Mellitus OT - Metformin OT - Progression OT - Recurrence COIS- DISCLOSURE: The authors have no potential conflicts of interest to disclose. EDAT- 2016/08/12 06:00 MHDA- 2017/07/14 06:00 PMCR- 2016/09/01 CRDT- 2016/08/12 06:00 PHST- 2016/03/15 00:00 [received] PHST- 2016/06/11 00:00 [accepted] PHST- 2016/08/12 06:00 [entrez] PHST- 2016/08/12 06:00 [pubmed] PHST- 2017/07/14 06:00 [medline] PHST- 2016/09/01 00:00 [pmc-release] AID - 31.1464 [pii] AID - 10.3346/jkms.2016.31.9.1464 [doi] PST - ppublish SO - J Korean Med Sci. 2016 Sep;31(9):1464-71. doi: 10.3346/jkms.2016.31.9.1464. PMID- 27506696 OWN - NLM STAT- MEDLINE DCOM- 20190128 LR - 20190128 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 197 IP - 2 DP - 2017 Feb TI - Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor. PG - 308-313 LID - S0022-5347(16)30971-5 [pii] LID - 10.1016/j.juro.2016.08.006 [doi] AB - PURPOSE: We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer. MATERIALS AND METHODS: We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5alpha-reductase inhibitor dutasteride for benign prostatic hyperplasia. RESULTS: We studied 228 men, including 32 with and 196 without androgen suppression therapy. During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively. On multivariate analysis multiple tumors (HR 1.82, p = 0.027), a large tumor (HR 2.13, p = 0.043) and ever smoking (HR 2.45, p = 0.020) as well as the presence of androgen suppression therapy (HR 0.36, p = 0.024) were independent risk factors for intravesical recurrence. Notably, tumor progressed to muscle invasive bladder cancer in 6 men (3.1%) without androgen suppression therapy. No man with androgen suppression therapy progressed to muscle invasive bladder cancer. CONCLUSIONS: Our study suggests the possibility of androgen suppression therapy as prophylaxis for intravesical recurrence of bladder cancer. Further explorations are warranted of the prophylactic effect of androgen suppression therapy on bladder cancer pathogenesis. CI - Copyright (c) 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: shiota@uro.med.kyushu-u.ac.jp. FAU - Kiyoshima, Keijiro AU - Kiyoshima K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Kashiwagi, Eiji AU - Kashiwagi E AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Dejima, Takashi AU - Dejima T AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takahashi, Ryosuke AU - Takahashi R AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tatsugami, Katsunori AU - Tatsugami K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article DEP - 20160806 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (5-alpha Reductase Inhibitors) RN - 0 (Androgen Antagonists) RN - 0 (Antineoplastic Agents) SB - IM CIN - J Urol. 2017 Feb;197(2):313. doi: 10.1016/j.juro.2016.08.134. PMID: 28346984 CIN - J Urol. 2017 Jul;198(1):211-212. doi: 10.1016/j.juro.2017.01.079. PMID: 28365365 MH - 5-alpha Reductase Inhibitors/adverse effects/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Androgen Antagonists/adverse effects/*therapeutic use MH - Antineoplastic Agents/administration & dosage MH - Disease Progression MH - Humans MH - Japan MH - Male MH - Neoplasm Recurrence, Local/drug therapy/*epidemiology/pathology MH - Prostatic Hyperplasia/drug therapy MH - Prostatic Neoplasms/drug therapy MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/drug therapy/*pathology OTO - NOTNLM OT - 5-alpha reductase inhibitors OT - androgen antagonists OT - bladder neoplasms OT - local OT - neoplasm recurrence OT - prevention and control EDAT- 2016/08/11 06:00 MHDA- 2019/01/29 06:00 CRDT- 2016/08/11 06:00 PHST- 2016/08/01 00:00 [accepted] PHST- 2016/08/11 06:00 [pubmed] PHST- 2019/01/29 06:00 [medline] PHST- 2016/08/11 06:00 [entrez] AID - S0022-5347(16)30971-5 [pii] AID - 10.1016/j.juro.2016.08.006 [doi] PST - ppublish SO - J Urol. 2017 Feb;197(2):308-313. doi: 10.1016/j.juro.2016.08.006. Epub 2016 Aug 6. PMID- 27500197 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 2 IP - 3 DP - 2016 Jul 27 TI - Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer. PG - 293-300 AB - Introduction: Although there is evidence that hexaminolevulinate (HAL)-based transurethral bladder tumor resection (TURBT) improves the detection of Ta-T1 non-muscle-invasive bladder cancer (NMIBC) as well as carcinoma in situ there is uncertainty about its beneficial effects on progression. Material and Methods: A systematic literature search was conducted according to the PRISMA statement to identify studies reporting on HAL- vs. white-light (WL-) based TUR-BT in non-muscle invasive bladder cancer between 2000 and 2016. A two-stage selection process was utilized to determine eligible studies. Of a total of 294 studies, 5 (4 randomized and one retrospective) were considered for final analysis. The primary objective was the rate of progression. Results: The median follow-up for patients treated with HAL- and WL-TURBT was 27.6 (1-55.1) and 28.9 (1-53) months, respectively. Of a total of 1301 patients, 644 underwent HAL- and 657 WL-based TURBT. Progression was reported in 44 of 644 patients (6.8%) with HAL- and 70 of 657 patients (10.7%) with WL-TURBT, respectively (median odds ratio: 1.64, 1.10-2.45 for HAL vs. WL; p = 0.01). Data on progression-free survival was reported in a single study with a trend towards improved survival for patients treated with HAL-TURBT (p = 0.05). Conclusions: In this meta-analysis the rate of progression was significantly lower in patients treated with HAL- vs. WL-based TURBT. These results support the initiation of randomized trials on HAL with progression as primary endpoint. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital Tubingen , Tubingen, Germany. FAU - Fahmy, Omar AU - Fahmy O AD - Department of Urology, University Putra Malaysia (UPM) , Selangor, Malaysia. LA - eng PT - Journal Article DEP - 20160727 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC4969683 OTO - NOTNLM OT - Aminolevulinate OT - and transurethral resection OT - bladder cancer OT - fluorescence OT - hexaminolevulinate OT - photodynamic diagnosis OT - progression EDAT- 2016/08/09 06:00 MHDA- 2016/08/09 06:01 CRDT- 2016/08/09 06:00 PHST- 2016/08/09 06:00 [entrez] PHST- 2016/08/09 06:00 [pubmed] PHST- 2016/08/09 06:01 [medline] AID - BLC160060 [pii] AID - 10.3233/BLC-160060 [doi] PST - epublish SO - Bladder Cancer. 2016 Jul 27;2(3):293-300. doi: 10.3233/BLC-160060. PMID- 27479049 OWN - NLM STAT- MEDLINE DCOM- 20171206 LR - 20260726 IS - 1878-5905 (Electronic) IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 104 DP - 2016 Oct TI - Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. PG - 339-51 LID - S0142-9612(16)30363-5 [pii] LID - 10.1016/j.biomaterials.2016.07.026 [doi] AB - The overall prognosis of bladder cancer has not been improved over the last 30 years and therefore, there is a great medical need to develop novel diagnosis and therapy approaches for bladder cancer. We developed a multifunctional nanoporphyrin platform that was coated with a bladder cancer-specific ligand named PLZ4. PLZ4-nanoporphyrin (PNP) integrates photodynamic diagnosis, image-guided photodynamic therapy, photothermal therapy and targeted chemotherapy in a single procedure. PNPs are spherical, relatively small (around 23 nm), and have the ability to preferably emit fluorescence/heat/reactive oxygen species upon illumination with near infrared light. Doxorubicin (DOX) loaded PNPs possess slower drug release and dramatically longer systemic circulation time compared to free DOX. The fluorescence signal of PNPs efficiently and selectively increased in bladder cancer cells but not normal urothelial cells in vitro and in an orthotopic patient derived bladder cancer xenograft (PDX) models, indicating their great potential for photodynamic diagnosis. Photodynamic therapy with PNPs was significantly more potent than 5-aminolevulinic acid, and eliminated orthotopic PDX bladder cancers after intravesical treatment. Image-guided photodynamic and photothermal therapies synergized with targeted chemotherapy of DOX and significantly prolonged overall survival of mice carrying PDXs. In conclusion, this uniquely engineered targeting PNP selectively targeted tumor cells for photodynamic diagnosis, and served as effective triple-modality (photodynamic/photothermal/chemo) therapeutic agents against bladder cancers. This platform can be easily adapted to individualized medicine in a clinical setting and has tremendous potential to improve the management of bladder cancer in the clinic. CI - Copyright (c) 2016 Elsevier Ltd. All rights reserved. FAU - Lin, Tzu-Yin AU - Lin TY AD - Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. Electronic address: tylin@ucdavis.edu. FAU - Li, Yuanpei AU - Li Y AD - Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA. FAU - Liu, Qiangqiang AU - Liu Q AD - Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA. FAU - Chen, Jui-Lin AU - Chen JL AD - Department of Biochemical Science and Technology, National Taiwan University, Taipei 403, Taiwan. FAU - Zhang, Hongyong AU - Zhang H AD - Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. FAU - Lac, Diana AU - Lac D AD - Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA. FAU - Zhang, Hua AU - Zhang H AD - Department of Biomedical Engineering, University of California Davis, Sacramento, CA 95817, USA. FAU - Ferrara, Katherine W AU - Ferrara KW AD - Department of Biomedical Engineering, University of California Davis, Sacramento, CA 95817, USA. FAU - Wachsmann-Hogiu, Sebastian AU - Wachsmann-Hogiu S AD - Department of Pathology and Laboratory Medicine and Center for Biophotonics Science and Technology, University of California Davis, Sacramento, CA 95817, USA. FAU - Li, Tianhong AU - Li T AD - Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA 95655, USA. FAU - Airhart, Susan AU - Airhart S AD - The Jackson Laboratory, Bar Harbor, ME 04609, USA. FAU - deVere White, Ralph AU - deVere White R AD - Department of Urology, University of California Davis, Sacramento, CA 95817, USA. FAU - Lam, Kit S AU - Lam KS AD - Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA. FAU - Pan, Chong-Xian AU - Pan CX AD - Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA 95655, USA; Department of Urology, University of California Davis, Sacramento, CA 95817, USA. Electronic address: cxpan@ucdavis.edu. LA - eng GR - P30 CA093373/CA/NCI NIH HHS/United States GR - I01 BX001784/BX/BLRD VA/United States GR - R01 HD086195/HD/NICHD NIH HHS/United States GR - R01 CA134659/CA/NCI NIH HHS/United States GR - R01 CA112356/CA/NCI NIH HHS/United States GR - R01 CA199668/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20160722 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (PLZ4 peptide) RN - 0 (Peptides, Cyclic) RN - 0 (Photosensitizing Agents) RN - 0 (Porphyrins) RN - 80168379AG (Doxorubicin) SB - IM MH - Animals MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage MH - Cell Line, Tumor MH - Combined Modality Therapy/methods MH - Doxorubicin/administration & dosage MH - Humans MH - Mice MH - Mice, Inbred C57BL MH - Microscopy, Fluorescence/*methods MH - Molecular Targeted Therapy/methods MH - Nanoparticles/*administration & dosage/chemistry MH - Peptides, Cyclic/administration & dosage MH - Photochemotherapy/*methods MH - Photosensitizing Agents/administration & dosage MH - Phototherapy/methods MH - Porphyrins/*administration & dosage MH - Theranostic Nanomedicine/methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*pathology PMC - PMC5412594 MID - NIHMS807226 OTO - NOTNLM OT - Bladder cancer OT - Nanotechnology OT - Photodynamic therapy OT - Photothermal therapy COIS- Potential conflicts of interest : T. Lin, Y.L, K.S.L. and C.P. are the inventors of a pending patent on nanoporphyrin (US patent application US76916-856975/212300). H. Z., K.S.L. and C.P. are the inventors of PLZ4 (US Patent application No.: 13/497,041). K.S.L. and C.P. are co-founder of LP Therapeutics Inc that has licensed the PLZ4 patent from University of California Davis. EDAT- 2016/08/02 06:00 MHDA- 2017/12/07 06:00 PMCR- 2017/10/01 CRDT- 2016/08/02 06:00 PHST- 2016/05/18 00:00 [received] PHST- 2016/07/19 00:00 [revised] PHST- 2016/07/21 00:00 [accepted] PHST- 2016/08/02 06:00 [entrez] PHST- 2016/08/02 06:00 [pubmed] PHST- 2017/12/07 06:00 [medline] PHST- 2017/10/01 00:00 [pmc-release] AID - S0142-9612(16)30363-5 [pii] AID - 10.1016/j.biomaterials.2016.07.026 [doi] PST - ppublish SO - Biomaterials. 2016 Oct;104:339-51. doi: 10.1016/j.biomaterials.2016.07.026. Epub 2016 Jul 22. PMID- 27466500 OWN - NLM STAT- MEDLINE DCOM- 20170126 LR - 20170126 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 36 IP - 8 DP - 2016 Aug TI - Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. PG - 3961-4 AB - BACKGROUND/AIM: Alterations of global histone modification levels have been identified in various tumor entities, including bladder cancer (BCA). Our study was designed to investigate the value of global histone acetylation levels as diagnostic and prognostic biomarker for BCA patients. MATERIALS AND METHODS: A tissue microarray with formalin-fixed paraffin-embedded tissues (271 BCA and 29 normal urothelial samples) was used to determine global histone acetylation levels (histone H3 acetylation (H3Ac); histone H3 lysine 18 acetylation (H3K18Ac); histone H4 acetylation (H4Ac)). RESULTS: Global H3Ac levels were decreased in BCA patients, whereas H3K18Ac and H4Ac levels were similar in both groups. All studied histone acetylation markers were lower in muscle-invasive BCA compared to non-muscle invasive BCA and normal urothelial tissue, thereby indicating a possible prognostic relevance. CONCLUSION: Global histone acetylation levels undergo quantitative alterations during bladder cancer progression and could be helpful to identify patients at risk for early cancer recurrence. CI - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Ellinger, Jorg AU - Ellinger J AD - University Hospital Bonn, Department of Urology, Bonn, Germany joerg.ellinger@ukb.uni-bonn.de. FAU - Schneider, Ann-Christin AU - Schneider AC AD - University Hospital Bonn, Department of Urology, Bonn, Germany. FAU - Bachmann, Anne AU - Bachmann A AD - University Hospital Bonn, Department of Urology, Bonn, Germany. FAU - Kristiansen, Glen AU - Kristiansen G AD - University Hospital Bonn, Institute of Pathology, Bonn, Germany. FAU - Muller, Stefan C AU - Muller SC AD - University Hospital Bonn, Department of Urology, Bonn, Germany. FAU - Rogenhofer, Sebastian AU - Rogenhofer S AD - University Hospital Bonn, Department of Urology, Bonn, Germany. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Biomarkers, Tumor) RN - 0 (Histones) SB - IM MH - Acetylation MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Epigenesis, Genetic/genetics MH - Female MH - Histones/genetics MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*genetics/pathology MH - *Prognosis MH - Protein Processing, Post-Translational MH - Urinary Bladder Neoplasms/*genetics/pathology MH - Urothelium/metabolism OTO - NOTNLM OT - Bladder cancer OT - epigenetics OT - histone acetylation OT - immunohistochemistry EDAT- 2016/07/29 06:00 MHDA- 2017/01/27 06:00 CRDT- 2016/07/29 06:00 PHST- 2016/06/06 00:00 [received] PHST- 2016/06/29 00:00 [accepted] PHST- 2016/07/29 06:00 [entrez] PHST- 2016/07/29 06:00 [pubmed] PHST- 2017/01/27 06:00 [medline] AID - 36/8/3961 [pii] PST - ppublish SO - Anticancer Res. 2016 Aug;36(8):3961-4. PMID- 27461645 OWN - NLM STAT- MEDLINE DCOM- 20170316 LR - 20260127 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 12 IP - 2 DP - 2016 Apr-Jun TI - A clinicoepidemiological study of young age bladder tumors: An eastern Indian scenario. PG - 751-4 LID - 10.4103/0973-1482.154028 [doi] AB - INTRODUCTION: Though, bladder cancer is one of the most common urological malignancies, studies addressing the young age group bladder tumors are rare. Present study was done to determine the clinicoepidemiological aspects of bladder tumor diagnosed in young age patients and to compare these aspects with elderly patients. PATIENTS AND METHODS: Patients with urinary bladder tumor were selectively divided into two groups; young (<40 years) and elderly (>60 years). Groups were compared on various parameters and statistically analyzed using Fisher's exact two-tailed test. RESULTS: Smoking, tea and coffee intake and exposure of dye were found significantly associated with development of bladder tumor. Most of the tumors in young age were small, solitary, and papillomatous. Transitional cell carcinoma (TCC) was the most common histological subtype, though most were of low grade and were non-muscle invasive in comparison to the tumors in elderly group. CONCLUSION: The incidence of bladder cancer is common in younger age group. Active and passive cigarette smoking, tea, coffee intake, and exposure to organic dyes are major risk factor for younger age group bladder tumor in this part of world. TCC is most common histological subtype and most of them are in low grade without muscle invasion. FAU - Singh, Jitendra Pratap AU - Singh JP AD - Department of Urology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India. FAU - Priyadarshi, Vinod AU - Priyadarshi V AD - Department of Urology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India. FAU - Pal, Dilip Kumar AU - Pal DK AD - Department of Urology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 SB - IM MH - Adult MH - Age Factors MH - Aged MH - Combined Modality Therapy MH - Female MH - Humans MH - India/epidemiology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*epidemiology/etiology/therapy MH - Young Adult EDAT- 2016/07/28 06:00 MHDA- 2017/03/17 06:00 CRDT- 2016/07/28 06:00 PHST- 2016/07/28 06:00 [entrez] PHST- 2016/07/28 06:00 [pubmed] PHST- 2017/03/17 06:00 [medline] AID - JCanResTher_2016_12_2_751_154028 [pii] AID - 10.4103/0973-1482.154028 [doi] PST - ppublish SO - J Cancer Res Ther. 2016 Apr-Jun;12(2):751-4. doi: 10.4103/0973-1482.154028. PMID- 27453656 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160725 LR - 20200930 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 8 IP - 3 DP - 2016 Jul-Sep TI - Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. PG - 333-7 LID - 10.4103/0974-7796.184891 [doi] AB - BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG) has been the standard of care for the prevention of nonmuscle invasive bladder cancer (NMIBC) recurrence following resection. Attempts to improve on the result by combining it with other agents have largely failed. This study addresses the result of BCG therapy in our patient population and compares the result with our combination BCG and interferon therapy published earlier. MATERIALS AND METHODS: The medical records of patients diagnosed with NMIBC and treated with transurethral resection and intravesical BCG were reviewed. Univariate analysis was performed on most known prognostic factors. Results were compared to published data on the use of BCG and interferon from the same institution. RESULTS: Thirty-one patients were identified. Median age was 66 (range 33-109), 80.6% were males. Fourteen patients (45%) had 0.05). On multivariable analysis, only Foley placement in the operating room remained associated with higher rates of hematuria-related UR, while preoperative antibiotics, female gender and aspirin therapy remained associated with a lower likelihood of this event. CONCLUSIONS: UR following TURBT is common and typically results from gross hematuria. Patients with postoperative Foley catheterization in the operating room may require additional counseling or supervision before discharge, and should be considered for discharge with a Foley rather than having a prompt voiding trial. FAU - Ghali, Fady AU - Ghali F AD - a Geisel School of Medicine at Dartmouth , Hanover , NH , USA ; FAU - Moses, Rachel A AU - Moses RA AD - b Section of Urology , Dartmouth-Hitchcock Medical Center , Lebanon , NH , USA. FAU - Raffin, Eric AU - Raffin E AD - b Section of Urology , Dartmouth-Hitchcock Medical Center , Lebanon , NH , USA. FAU - Hyams, Elias S AU - Hyams ES AD - a Geisel School of Medicine at Dartmouth , Hanover , NH , USA ; AD - b Section of Urology , Dartmouth-Hitchcock Medical Center , Lebanon , NH , USA. LA - eng PT - Journal Article DEP - 20160720 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Adult MH - Cystectomy/*methods MH - Female MH - Hematuria/epidemiology MH - Humans MH - Male MH - Middle Aged MH - Patient Readmission/*statistics & numerical data MH - Postoperative Complications/*epidemiology MH - Retrospective Studies MH - Risk Factors MH - Urethra MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Bivariate analysis OT - TURBT OT - bladder tumor OT - postoperative complications OT - readmission EDAT- 2016/07/21 06:00 MHDA- 2017/06/02 06:00 CRDT- 2016/07/21 06:00 PHST- 2016/07/21 06:00 [entrez] PHST- 2016/07/21 06:00 [pubmed] PHST- 2017/06/02 06:00 [medline] AID - 10.1080/21681805.2016.1201856 [doi] PST - ppublish SO - Scand J Urol. 2016 Oct;50(5):370-3. doi: 10.1080/21681805.2016.1201856. Epub 2016 Jul 20. PMID- 27431340 OWN - NLM STAT- MEDLINE DCOM- 20180816 LR - 20181113 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 13 IP - 8 DP - 2016 Aug TI - The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. PG - 471-9 LID - 10.1038/nrurol.2016.126 [doi] AB - Outcome prediction in patients with bladder cancer has improved through the development of nomograms and predictive models. However, integration of further characteristics such as lymphovascular invasion (LVI) might increase the accuracy and clinical utility of these instruments. Assessment and reporting of LVI in specimens from transurethral resection of the bladder tumour (TURBT) or biopsy in patients with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) might enable improved staging, prognostication and clinical decision-making. In NMIBC, presence of LVI in TURBT and biopsy samples seems to be associated with understaging and increased risks of disease recurrence and progression. In MIBC, presence of LVI is associated with features of aggressive disease and predicts recurrence and survival. Integration of LVI status into predictive models might aid clinical decision-making regarding intravesical instillation schedules and regimens, early radical cystectomy in patients with high-grade T1 disease and perioperative chemotherapy. However, LVI assessment is hampered by insufficient reproducibility and reliability, lack of routine evaluation and limited concordance between findings in TURBT and radical cystectomy specimens. Standardization of the pathological criteria defining LVI is warranted to improve its reporting in routine clinical practice and its utility as a care-changing prognostic marker. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. AD - Department of Urology, Rennes University Hospital, 2 Rue Henri le Guilloux, 35000 Rennes, France. FAU - Lucca, Ilaria AU - Lucca I AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. AD - Department of Urology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, CH-1010 Lausanne, Switzerland. FAU - Roupret, Morgan AU - Roupret M AD - Academic Department of Urology, Hopital de la Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, 47-83 Boulevard de l'Hopital, Paris, 75013, France. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Vita-Salute San Raffaele University, via Olgettina 60, 20132 Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9110, USA. AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, 525 East 68th Street, Starr 912, New York, New York 10065, USA. LA - eng PT - Journal Article PT - Review DEP - 20160719 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 SB - IM MH - Cystectomy MH - Decision Making MH - Disease Progression MH - Humans MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Metastasis/*pathology MH - Neoplasm Staging/methods MH - Nomograms MH - Prognosis MH - Reproducibility of Results MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology EDAT- 2016/07/20 06:00 MHDA- 2018/08/17 06:00 CRDT- 2016/07/20 06:00 PHST- 2016/07/20 06:00 [entrez] PHST- 2016/07/20 06:00 [pubmed] PHST- 2018/08/17 06:00 [medline] AID - nrurol.2016.126 [pii] AID - 10.1038/nrurol.2016.126 [doi] PST - ppublish SO - Nat Rev Urol. 2016 Aug;13(8):471-9. doi: 10.1038/nrurol.2016.126. Epub 2016 Jul 19. PMID- 27423823 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. PG - 485.e1-485.e6 LID - S1078-1439(16)30125-9 [pii] LID - 10.1016/j.urolonc.2016.06.008 [doi] AB - OBJECTIVE: The development of a ureteroenteric anastomotic (UEA) stricture has been reported in up to 15% of patients undergoing radical cystectomy (RC) with urinary diversion. Although benign strictures are thought to be the result of ischemia, the incidence, risk factors, and outcomes of patients with malignant UEA strictures have not been well described. MATERIAL AND METHODS: We reviewed 2,523 patients treated with RC for bladder cancer from 1980 to 2012 at Mayo Clinic. Patients diagnosed with a UEA stricture following the surgery were identified, and a subset with malignant UEA was then analyzed. Cox proportional hazard regression models were performed to evaluate factors associated with the diagnosis of malignant UEA. Survival was assessed using the Kaplan-Meier method. RESULTS: At a median of 10.5 years of follow-up, 232 (9.2%) patients were diagnosed with UEA stricture, of which 38 (16.4%) had malignant strictures (MS). Median time from RC to the diagnosis of a malignant vs. benign UEA stricture was 32.4 months and 7.2 months, respectively (P = 0.004). Pathologic non-muscle-invasive disease stage at RC was more common among patients diagnosed with a MS compared with patients who did not develop a MS (71.1% vs. 45.9%; P = 0.002). The presence of carcinoma in situ on initial ureteral margin at RC was associated with a significantly increased risk of subsequent diagnosis (hazard ratio = 4.1; P<0.001). Following malignant stricture diagnosis, 2- and 5-year cancer-specific survival was 50% and 30%, respectively, whereas overall survival was 44% and 23%, respectively. CONCLUSIONS: MS are uncommon after RC, and present later than benign strictures. Ureteral margin involvement with carcinoma in situ was associated with a significantly increased risk of MS diagnosis. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Westerman, Mary E AU - Westerman ME AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Parker, William P AU - Parker WP AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Viers, Boyd R AU - Viers BR AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Rivera, Marcelino E AU - Rivera ME AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Karnes, Robert Jeffrey AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Frank, Igor AU - Frank I AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tarrell, Robert AU - Tarrell R AD - Department of Health Sciences Research, Mayo Clinic, Rochester, MN. FAU - Thapa, Prabin AU - Thapa P AD - Department of Health Sciences Research, Mayo Clinic, Rochester, MN. FAU - Thompson, Robert Houston AU - Thompson RH AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Tollefson, Matthew K AU - Tollefson MK AD - Department of Urology, Mayo Clinic, Rochester, MN. FAU - Boorjian, Stephen A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: Boorjian.Stephen@mayo.edu. LA - eng PT - Journal Article DEP - 20160714 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Anastomosis, Surgical MH - Carcinoma in Situ/epidemiology/etiology/surgery MH - Constriction, Pathologic/etiology MH - *Cystectomy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Hematuria/etiology MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Margins of Excision MH - Middle Aged MH - Neoplasm Recurrence, Local/*complications/epidemiology/surgery MH - Postoperative Complications/epidemiology/*etiology/surgery MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Ureteral Obstruction/epidemiology/*etiology/surgery MH - Urinary Bladder Neoplasms/complications/*surgery MH - *Urinary Diversion OTO - NOTNLM OT - Anastomotic stricture OT - Bladder cancer OT - Malignant stricture OT - Upper tract recurrence OT - Urinary diversion EDAT- 2016/07/18 06:00 MHDA- 2018/01/18 06:00 CRDT- 2016/07/18 06:00 PHST- 2015/03/17 00:00 [received] PHST- 2016/06/08 00:00 [revised] PHST- 2016/06/13 00:00 [accepted] PHST- 2016/07/18 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/07/18 06:00 [entrez] AID - S1078-1439(16)30125-9 [pii] AID - 10.1016/j.urolonc.2016.06.008 [doi] PST - ppublish SO - Urol Oncol. 2016 Nov;34(11):485.e1-485.e6. doi: 10.1016/j.urolonc.2016.06.008. Epub 2016 Jul 14. PMID- 27414486 OWN - NLM STAT- MEDLINE DCOM- 20170726 LR - 20220330 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 64 DP - 2016 Sep TI - A five-gene expression signature to predict progression in T1G3 bladder cancer. PG - 127-36 LID - S0959-8049(16)32206-7 [pii] LID - 10.1016/j.ejca.2016.06.003 [doi] AB - OBJECTIVE: The aim of this study was to analyze tumour gene expression profiles of progressive and non-progressive T1G3 bladder cancer (BC) patients to develop a gene expression signature to predict tumour progression. METHODS: Retrospective, multicenter study of 96 T1G3 BC patients without carcinoma in situ (CIS) who underwent a transurethral resection. Formalin-fixed paraffin-embedded tissue samples were collected. Global gene expression patterns were analyzed in 21 selected samples from progressive and non-progressive T1G3 BC patients using Illumina microarrays. Expression levels of 94 genes selected based on microarray data and based on literature were studied by quantitative polymerase chain reaction (qPCR) in an independent series of 75 progressive and non-progressive T1G3 BC patients. Univariate logistic regression was used to identify individual predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination of the model was measured by area under the receiver-operating characteristic curve. Interaction networks between the genes of the model were built by GeneMANIA Cytoscape plugin. RESULTS: A total of 1294 genes were found differentially expressed between progressive and non-progressive patients. Differential expression of 15 genes was validated by qPCR in an additional set of samples. A five-gene expression signature (ANXA10, DAB2, HYAL2, SPOCD1, and MAP4K1) discriminated progressive from non-progressive T1G3 BC patients with a sensitivity of 79% and a specificity of 86% (AUC = 0.83). Direct interactions between the five genes of the model were not found. CONCLUSIONS: Progressive and non-progressive T1G3 bladder tumours have shown different gene expression patterns. To identify T1G3 BC patients with a high risk of progression, a five-gene expression signature has been developed. CI - Copyright (c) 2016 Elsevier Ltd. All rights reserved. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Toine.vanderHeijden@radboudumc.nl. FAU - Mengual, Lourdes AU - Mengual L AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain. Electronic address: lmengual@clinic.ub.es. FAU - Lozano, Juan J AU - Lozano JJ AD - CIBERehd, Plataforma de Bioinformatica, Centro de Investigacion Biomedica en red de Enfermedades Hepaticas y Digestivas, Barcelona, Spain. Electronic address: juanjo.lozano@Ciberehd.org. FAU - Ingelmo-Torres, Mercedes AU - Ingelmo-Torres M AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain. Electronic address: INGELMO@clinic.ub.es. FAU - Ribal, Maria J AU - Ribal MJ AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain. Electronic address: mjribal@clinic.ub.es. FAU - Fernandez, Pedro L AU - Fernandez PL AD - Pathology Department, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain. Electronic address: PLFERNAN@clinic.ub.es. FAU - Oosterwijk, Egbert AU - Oosterwijk E AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Egbert.Oosterwijk@radboudumc.nl. FAU - Schalken, Jack A AU - Schalken JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Jack.Schalken@radboudumc.nl. FAU - Alcaraz, Antonio AU - Alcaraz A AD - Laboratory and Department of Urology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain. Electronic address: ALCARAZ@clinic.ub.es. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Fred.Witjes@radboudumc.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160711 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (ANXA10 protein, human) RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Annexins) RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (Biomarkers, Tumor) RN - 0 (Cell Adhesion Molecules) RN - 0 (DAB2 protein, human) RN - 0 (GPI-Linked Proteins) RN - 0 (Proteoglycans) RN - 0 (RNA, Messenger) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.7.1.11 (hematopoietic progenitor kinase 1) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 3.2.1.25 (Hyal2 protein, human) RN - EC 3.2.1.35 (Hyaluronoglucosaminidase) SB - IM CIN - Eur J Cancer. 2016 Nov;68:196-197. doi: 10.1016/j.ejca.2016.09.017. PMID: 27806880 CIN - Eur J Cancer. 2016 Nov;68:198. doi: 10.1016/j.ejca.2016.09.018. PMID: 27806881 MH - Adaptor Proteins, Signal Transducing/genetics/metabolism MH - Adult MH - Aged MH - Aged, 80 and over MH - Annexins/genetics/metabolism MH - Apoptosis Regulatory Proteins MH - Biomarkers, Tumor/*metabolism MH - Carcinoma in Situ/*genetics/pathology MH - Cell Adhesion Molecules/genetics/metabolism MH - *Disease Progression MH - Female MH - GPI-Linked Proteins/genetics/metabolism MH - Gene Expression Profiling/*methods MH - Humans MH - Hyaluronoglucosaminidase/genetics/metabolism MH - Logistic Models MH - Male MH - Middle Aged MH - Prognosis MH - Protein Serine-Threonine Kinases/genetics/metabolism MH - Proteoglycans/genetics/metabolism MH - RNA, Messenger/analysis MH - Retrospective Studies MH - Tumor Suppressor Proteins/genetics/metabolism MH - Urinary Bladder Neoplasms/*genetics/pathology OTO - NOTNLM OT - Biomarkers OT - Bladder cancer OT - Gene expression signature OT - Prognosis OT - Progressive disease EDAT- 2016/07/15 06:00 MHDA- 2017/07/27 06:00 CRDT- 2016/07/15 06:00 PHST- 2016/05/02 00:00 [received] PHST- 2016/05/31 00:00 [revised] PHST- 2016/06/10 00:00 [accepted] PHST- 2016/07/15 06:00 [entrez] PHST- 2016/07/15 06:00 [pubmed] PHST- 2017/07/27 06:00 [medline] AID - S0959-8049(16)32206-7 [pii] AID - 10.1016/j.ejca.2016.06.003 [doi] PST - ppublish SO - Eur J Cancer. 2016 Sep;64:127-36. doi: 10.1016/j.ejca.2016.06.003. Epub 2016 Jul 11. PMID- 27392930 OWN - NLM STAT- MEDLINE DCOM- 20170222 LR - 20220408 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 469 IP - 3 DP - 2016 Sep TI - Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. PG - 339-44 LID - 10.1007/s00428-016-1986-x [doi] AB - Purpose of this study was to evaluate prognostic impact of rare variants of urothelial bladder cancer (BC) after treatment with combined radiochemotherapy (RCT). To this end tumour tissue of 238 patients with urothelial carcinoma (UC) treated with transurethral resection of the bladder (TUR-B) and RCT with curative intent was collected. Histomorphological analysis included re-evaluation and semi-quantitative assessment of rare UC subtypes. Additionally, human epidermal growth factor receptor 2 (HER2) chromogenic in situ hybridisation (CISH) was performed in tumours with a micropapillary component exceeding 30 %. Long-term follow-up was available for 200 patients (range 3-282 months). Variant UC histology was found in 45 of 238 tumours, most frequently micropapillary UC (N = 17) including cases with a small fraction of tumour with micropapillary morphology. The mere presence of micropapillary morphology did not affect prognosis. In tumours with extensive (>/=30 %) micropapillary morphology (N = 8) Kaplan-Meier analysis revealed significantly worse cancer specific survival (CSS) (P = 0.002) compared to conventional UC (mean survival times 97 months and 229 months, respectively). Univariate Cox regression analysis of cases with >/=30 % micropapillary morphology revealed a hazard ratio of 4.726 (95 % CI 1.629-13.714) for CSS (P = 0.004). CISH revealed HER2 gene amplification in 3/10 tumours with >/=30 % micropapillary component. In conclusion, for BC treated with TUR-B and RCT, the presence of micropapillary morphology in more than 30 % of the tumour is an adverse prognostic factor. Further studies are needed to evaluate a potential benefit of different, especially multimodal treatment strategies for micropapillary UC and also other subtypes of UC. Her2 represents a promising therapeutic target in a subset of micropapillary UC. FAU - Bertz, Simone AU - Bertz S AD - Department of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nurnberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. Simone.Bertz@uk-erlangen.de. FAU - Wach, S AU - Wach S AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Taubert, H AU - Taubert H AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Merten, R AU - Merten R AD - Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. FAU - Krause, F S AU - Krause FS AD - Department of Urology, AKH - General Hospital, Medical Faculty, Johannes Kepler University Linz, Linz, Austria. FAU - Schick, S AU - Schick S AD - Clinical Cancer Registry, Tumor Center of the University Erlangen-Nurnberg, Erlangen, Germany. FAU - Ott, O J AU - Ott OJ AD - Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. FAU - Weigert, E AU - Weigert E AD - Department of Pathology, City Hospital Furth, Furth, Germany. FAU - Dworak, O AU - Dworak O AD - Department of Pathology, City Hospital Furth, Furth, Germany. FAU - Rodel, C AU - Rodel C AD - Department of Radiation Therapy and Oncology, University of Frankfurt am Main, Frankfurt, Germany. FAU - Fietkau, R AU - Fietkau R AD - Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. FAU - Wullich, B AU - Wullich B AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Keck, B AU - Keck B AD - Department of Urology, University Hospital Erlangen, Erlangen, Germany. FAU - Hartmann, A AU - Hartmann A AD - Department of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nurnberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20160708 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Papillary/diagnosis/*pathology/therapy MH - Carcinoma, Transitional Cell/*diagnosis/*pathology MH - *Chemoradiotherapy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Urologic Neoplasms/*diagnosis/*pathology/therapy MH - Urothelium/pathology OTO - NOTNLM OT - HER2 OT - Micropapillary OT - Radiochemotherapy OT - Rare variants OT - Urothelial carcinoma EDAT- 2016/07/10 06:00 MHDA- 2017/02/23 06:00 CRDT- 2016/07/10 06:00 PHST- 2016/01/10 00:00 [received] PHST- 2016/07/03 00:00 [accepted] PHST- 2016/05/27 00:00 [revised] PHST- 2016/07/10 06:00 [entrez] PHST- 2016/07/10 06:00 [pubmed] PHST- 2017/02/23 06:00 [medline] AID - 10.1007/s00428-016-1986-x [pii] AID - 10.1007/s00428-016-1986-x [doi] PST - ppublish SO - Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8. PMID- 27392651 OWN - NLM STAT- MEDLINE DCOM- 20180104 LR - 20260127 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 97 DP - 2016 Nov TI - Preoperative Frailty Is Associated With Discharge to Skilled or Assisted Living Facilities After Urologic Procedures of Varying Complexity. PG - 25-32 LID - S0090-4295(16)30372-7 [pii] LID - 10.1016/j.urology.2016.03.073 [doi] AB - OBJECTIVE: To evaluate the association between frailty and postoperative discharge destination after different types of commonly performed urologic procedures in older patients. MATERIALS AND METHODS: Using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) from 2011 to 2013, we identified commonly performed inpatient urologic procedures among patients aged 65 and older. We then assessed the effect of frailty, measured by the NSQIP Frailty Index (NSQIP-FI), on discharge to a skilled or assisted living facility using logistic regression and assessed the heterogeneity of this effect across procedures using 2-level random effects modeling. RESULTS: Overall, 1144 out of 20,794 (5.5%) urologic cases, representing 19 different procedures, resulted in discharge to a skilled or assisted living facility. Cystectomy and large transurethral resection of bladder tumor had the highest percentage (16.3%). Twenty-five percent of patients undergoing urology procedures were frail (NSQIP-FI 0.18+), including 9.8% of patients discharged to a facility. Even after adjustment for year, age, race, type of anesthesia, smoking status, recent weight loss, and whether or not the procedure was elective, frailty was strongly associated with discharge to a facility (adjusted odds ratio 3.1 [96% confidence interval 2.5, 3.8] for NSQIP-FI 0.18+ compared to NSQIP FI 0). This finding was consistent across most procedures of varying complexity with an overall effect of odds ratio 1.6 (95% confidence interval 1.5, 2.0). CONCLUSION: Increasing frailty is associated with discharge to a skilled or assisted living facility across most inpatient urologic procedures evaluated, regardless of complexity. This information is important for preoperative counseling with patients undergoing urologic surgery. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Suskind, Anne M AU - Suskind AM AD - Department of Urology, University of California, San Francisco, CA. Electronic address: Anne.Suskind@ucsf.edu. FAU - Jin, Chengshi AU - Jin C AD - Division of Geriatrics, University of California, San Francisco, CA. FAU - Cooperberg, Matthew R AU - Cooperberg MR AD - Department of Urology, University of California, San Francisco, CA. FAU - Finlayson, Emily AU - Finlayson E AD - Department of General Surgery, University of California, San Francisco, CA. FAU - Boscardin, W John AU - Boscardin WJ AD - Department of Epidemiology and Biostatistics, University of California, San Francisco, CA. FAU - Sen, Saunak AU - Sen S AD - Department of Preventative Medicine, University of Tennessee Health Science Center. FAU - Walter, Louise C AU - Walter LC AD - Division of Geriatrics, University of California, San Francisco, CA. LA - eng GR - K12 DK083021/DK/NIDDK NIH HHS/United States GR - K24 AG041180/AG/NIA NIH HHS/United States GR - P30 AG044281/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20160705 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM CIN - Urology. 2016 Nov;97:31-32. doi: 10.1016/j.urology.2016.03.074. PMID: 27492668 MH - Aged MH - Aged, 80 and over MH - Assisted Living Facilities/*statistics & numerical data MH - Frailty/*complications MH - Humans MH - Patient Discharge/*statistics & numerical data MH - Skilled Nursing Facilities/*statistics & numerical data MH - United States MH - *Urologic Surgical Procedures PMC - PMC5477056 MID - NIHMS862333 EDAT- 2016/07/10 06:00 MHDA- 2018/01/05 06:00 PMCR- 2017/06/20 CRDT- 2016/07/10 06:00 PHST- 2016/01/18 00:00 [received] PHST- 2016/03/11 00:00 [revised] PHST- 2016/03/29 00:00 [accepted] PHST- 2016/07/10 06:00 [pubmed] PHST- 2018/01/05 06:00 [medline] PHST- 2016/07/10 06:00 [entrez] PHST- 2017/06/20 00:00 [pmc-release] AID - S0090-4295(16)30372-7 [pii] AID - 10.1016/j.urology.2016.03.073 [doi] PST - ppublish SO - Urology. 2016 Nov;97:25-32. doi: 10.1016/j.urology.2016.03.073. Epub 2016 Jul 5. PMID- 27385379 OWN - NLM STAT- MEDLINE DCOM- 20180522 LR - 20240325 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Jul 7 TI - Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence. PG - 29466 LID - 10.1038/srep29466 [doi] LID - 29466 AB - The present study sought to investigate the predictive value of preoperative clinicopathological variables, with a special focus on areca nut chewing, on disease recurrence and progression in patients with non-muscle-invasive bladder cancer (NMIBC). Data from 242 patients diagnosed with NMIBC between 2008 and 2013 were analyzed retrospectively. Fifteen clinicopathological variables were analyzed to evaluate their prognostic value. During a mean observation period of 21 months, disease recurrence occurred in 140 patients (57.9%). On multivariate analysis, heavy-areca nut chewing (HR = 2.18, 95% CI: 1.37-3.47), current smoking (HR = 3.09, 95% CI: 1.99-4.80), moderately impaired estimated glomerular filtration rate (eGFR) (HR = 1.76, 95% CI: 1.09-2.83), severely impaired eGFR (HR = 3.32, 95% CI: 1.70-6.48) and tumor grade (HR = 1.94, 95% CI: 1.36-2.77) were independent factors for recurrence, based on which a risk factor model was developed to stratify patients into high, medium and low risk groups. In conclusion, our study suggests that in addition to quitting smoking, quitting areca nut chewing may also reduce the risk of first recurrence in NMBIC patients, monitoring and preserving their renal function may be beneficial as well. Further prospective studies are needed to verify the prognostic significance of these factors and the risk stratification model in this population. FAU - Cao, Jian AU - Cao J AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. AD - MRC Centre for Reproductive Health, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. FAU - Xu, Ran AU - Xu R AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Zhao, Xiaokun AU - Zhao X AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Zhong, Zhaohui AU - Zhong Z AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Zhang, Lei AU - Zhang L AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Zhu, Xuan AU - Zhu X AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Wu, Shuiqing AU - Wu S AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. FAU - Ai, Kai AU - Ai K AD - Department of Urology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha 410011, Hunan Province, People's Republic of China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160707 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Aged, 80 and over MH - Areca/*adverse effects MH - Disease Progression MH - Female MH - Glomerular Filtration Rate MH - Humans MH - Male MH - Mastication MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/chemically induced/*epidemiology/*pathology MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/chemically induced/*epidemiology/*pathology PMC - PMC4935873 EDAT- 2016/07/08 06:00 MHDA- 2018/05/23 06:00 PMCR- 2016/07/07 CRDT- 2016/07/08 06:00 PHST- 2016/04/07 00:00 [received] PHST- 2016/06/20 00:00 [accepted] PHST- 2016/07/08 06:00 [entrez] PHST- 2016/07/08 06:00 [pubmed] PHST- 2018/05/23 06:00 [medline] PHST- 2016/07/07 00:00 [pmc-release] AID - srep29466 [pii] AID - 10.1038/srep29466 [doi] PST - epublish SO - Sci Rep. 2016 Jul 7;6:29466. doi: 10.1038/srep29466. PMID- 27383043 OWN - NLM STAT- MEDLINE DCOM- 20170613 LR - 20170817 IS - 1365-2559 (Electronic) IS - 0309-0167 (Linking) VI - 69 IP - 6 DP - 2016 Dec TI - Both cancerous miR-21 and stromal miR-21 in urothelial carcinoma are related to tumour progression. PG - 993-999 LID - 10.1111/his.13032 [doi] AB - AIMS: Urothelial carcinoma (UC) is a globally common cancer. miR-21 appears to be important in the tumorigenesis of almost all types of human cancer. However, its precise localization and significance in UC have yet to be clarified. The aim of this study was to examine miR-21 expression in UC and reveal its clinicopathological importance. METHODS AND RESULTS: Tissue arrays of 232 UCs were examined for miR-21 by the use of in-situ hybridization. One hundred and forty-eight transurethral resection specimens and 84 surgically resected specimens were used. After miR-21 positivity had been evaluated separately in tumour cells and the tumour stroma, it was compared with clinicopathological factors and overall survival. miR-21 was strongly expressed in tumour cells in 9% of cases and in the tumour stroma in 6% of cases. Stromal miR-21 positivity was lower than that of cancerous miR-21. Both miR-21s were correlated with each other and related to tumour stage, locus, and histological grade. In addition, strong positivity of miR-21 in cancer and the stroma was significantly related to poorer prognosis among surgically resected cases. In a Cox proportional hazard model, cancerous miR-21 was the only independent prognostic factor except for tumour stage. CONCLUSIONS: miR-21 in both cancer and stromal cells is closely related to tumour progression in UC. miR-21 may be a prognostic marker for cancer progression. CI - (c) 2016 John Wiley & Sons Ltd. FAU - Ohno, Rena AU - Ohno R AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Uozaki, Hiroshi AU - Uozaki H AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Yoshinao AU - Kikuchi Y AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Kumagai, Arisa AU - Kumagai A AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Aso, Tatsuya AU - Aso T AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Watanabe, Masato AU - Watanabe M AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Watabe, Shiori AU - Watabe S AD - Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Muto, Satoru AU - Muto S AD - Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Yamaguchi, Raizo AU - Yamaguchi R AD - Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20160916 PL - England TA - Histopathology JT - Histopathology JID - 7704136 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN21 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Biomarkers, Tumor/genetics MH - Carcinoma, Transitional Cell/genetics/*pathology MH - Disease Progression MH - Female MH - Humans MH - In Situ Hybridization MH - Male MH - MicroRNAs/*biosynthesis MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Stromal Cells/metabolism MH - Tissue Array Analysis MH - Tumor Microenvironment/*physiology MH - Urinary Bladder Neoplasms/genetics/*pathology OTO - NOTNLM OT - in-situ hybridization OT - miR-21 OT - progression OT - survival OT - tumour stroma OT - urothelial carcinoma EDAT- 2016/07/08 06:00 MHDA- 2017/06/14 06:00 CRDT- 2016/07/08 06:00 PHST- 2016/04/17 00:00 [received] PHST- 2016/07/05 00:00 [accepted] PHST- 2016/07/08 06:00 [pubmed] PHST- 2017/06/14 06:00 [medline] PHST- 2016/07/08 06:00 [entrez] AID - 10.1111/his.13032 [doi] PST - ppublish SO - Histopathology. 2016 Dec;69(6):993-999. doi: 10.1111/his.13032. Epub 2016 Sep 16. PMID- 27381893 OWN - NLM STAT- MEDLINE DCOM- 20180104 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 10 DP - 2016 Oct TI - Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. PG - 452-9 LID - S1078-1439(16)30118-1 [pii] LID - 10.1016/j.urolonc.2016.06.001 [doi] AB - RATIONALE: Numerous molecular urine markers for the diagnosis of bladder cancer have been developed and evaluated mostly in case-control settings through the past decades. However, despite all efforts none of them has been included into clinical decision-making and guideline recommendations until today. The aim of this retrospective longitudinal analysis was to investigate if a molecular marker might be able to replace cystoscopy as a primary examination in diagnosis and follow-up of patients with pTa grade 1-2 bladder cancer. MATERIALS AND METHODS: Totally 36 patients (32 men) with pTa grade 1-2 bladder cancer underwent 232 follow-up examinations including urine analysis, cytology, immunocytology (uCyt+), and urethrocystoscopy (UC). Mean age at study entry was 63 years. Patients were observed through a median follow-up interval of 3.8 years. RESULTS: In summary, 47 Transurethral Resection of Bladder Tumors (TURB) procedures were indicated based upon a positive UC (44) or as re-TURB (3) and 33 tumors (plus 1 case of pTa G0) were histopathologically confirmed. Although uCyt+was positive in 12/13 primary tumors (92.3%), sensitivity dropped to 13/20 (65%) in tumor recurrence presumably because of their smaller size. Urine cytology had a sensitivity and a specificity of 30.3% and 94.9%, respectively, but did not improve the sensitivity of uCyt+alone. If UC was based upon a positive uCyt+test, 8/33 tumors (24.2%) would have been overlooked or diagnosed late. In contrast, 173 UCs (74%) would have been saved and 5 presumably unnecessary TURB procedures would not have been indicated. CONCLUSIONS: This longitudinal study suggests a potential of molecular urine tests in replacing cystoscopy in the follow-up of patients with pTa G1-2 bladder cancer. The use of additional markers might further improve sensitivity of urine testing. A prospective randomized study has been initiated to prospectively investigate the performance of a marker panel against UC. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Schmitz-Drager, Claudia AU - Schmitz-Drager C AD - Urologie(24)/Urologie Schon Klinik Nurnberg Furth, Furth, Germany. FAU - Bonberg, Nadine AU - Bonberg N AD - Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany. FAU - Pesch, Beate AU - Pesch B AD - Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Department of Urology, Eberhard-Karls-University of Tubingen, Tubingen, Germany. FAU - Sahin, Sevim AU - Sahin S AD - Urologie(24)/Urologie Schon Klinik Nurnberg Furth, Furth, Germany. FAU - Behrens, Thomas AU - Behrens T AD - Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany; Protein Research Unit Ruhr Within Europe (PURE), Bochum, Germany. FAU - Bruning, Thomas AU - Bruning T AD - Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany. FAU - Schmitz-Drager, Bernd J AU - Schmitz-Drager BJ AD - Urologie(24)/Urologie Schon Klinik Nurnberg Furth, Furth, Germany; Department of Urology, Friedrich-Alexander University, Erlangen, Germany. Electronic address: bernd_sd@yahoo.de. LA - eng PT - Journal Article PT - Review DEP - 20160702 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - *Cystoscopy MH - Cytodiagnosis MH - Female MH - Follow-Up Studies MH - Humans MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*diagnosis/pathology/*urine MH - Predictive Value of Tests MH - Retrospective Studies MH - Tumor Burden MH - Urinalysis MH - Urinary Bladder Neoplasms/*diagnosis/pathology/surgery/*urine MH - Urine/chemistry/cytology OTO - NOTNLM OT - Cystoscopy OT - Disease management OT - Follow-up OT - Immunocytology OT - Non-muscle-invasive bladder cancer OT - TURB OT - Urine cytology OT - Urine markers EDAT- 2016/07/07 06:00 MHDA- 2018/01/05 06:00 CRDT- 2016/07/07 06:00 PHST- 2016/03/01 00:00 [received] PHST- 2016/05/30 00:00 [revised] PHST- 2016/06/01 00:00 [accepted] PHST- 2016/07/07 06:00 [entrez] PHST- 2016/07/07 06:00 [pubmed] PHST- 2018/01/05 06:00 [medline] AID - S1078-1439(16)30118-1 [pii] AID - 10.1016/j.urolonc.2016.06.001 [doi] PST - ppublish SO - Urol Oncol. 2016 Oct;34(10):452-9. doi: 10.1016/j.urolonc.2016.06.001. Epub 2016 Jul 2. PMID- 27381494 OWN - NLM STAT- MEDLINE DCOM- 20170220 LR - 20181202 IS - 1744-8301 (Electronic) IS - 1479-6694 (Print) IS - 1479-6694 (Linking) VI - 12 IP - 19 DP - 2016 Oct TI - A place for precision medicine in bladder cancer: targeting the FGFRs. PG - 2243-63 LID - 10.2217/fon-2016-0042 [doi] AB - Bladder tumors show diverse molecular features and clinical outcome. Muscle-invasive bladder cancer has poor prognosis and novel approaches to systemic therapy are urgently required. Non-muscle-invasive bladder cancer has good prognosis, but high recurrence rate and the requirement for life-long disease monitoring places a major burden on patients and healthcare providers. Studies of tumor tissues from both disease groups have identified frequent alterations of FGFRs, including mutations of FGFR3 and dysregulated expression of FGFR1 and FGFR3 that suggest that these may be valid therapeutic targets. We summarize current understanding of the molecular alterations affecting these receptors in bladder tumors, preclinical studies validating them as therapeutic targets, available FGFR-targeted agents and results from early clinical trials in bladder cancer patients. FAU - di Martino, Erica AU - di Martino E AD - Section of Molecular Oncology, Leeds Institute of Cancer & Pathology, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. FAU - Tomlinson, Darren C AU - Tomlinson DC AD - Astbury Centre for Structural & Molecular Biology, School of Molecular & Cellular Biology, Astbury Building, University of Leeds, Leeds, LS2 9JT, UK. FAU - Williams, Sarah V AU - Williams SV AD - Section of Molecular Oncology, Leeds Institute of Cancer & Pathology, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. FAU - Knowles, Margaret A AU - Knowles MA AD - Section of Molecular Oncology, Leeds Institute of Cancer & Pathology, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. LA - eng PT - Journal Article PT - Review DEP - 20160706 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) RN - 0 (Ligands) RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.10.1 (FGFR1 protein, human) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Animals MH - Antineoplastic Agents/pharmacology/*therapeutic use MH - Biomarkers MH - Drug Evaluation, Preclinical MH - Drug Resistance, Neoplasm MH - ErbB Receptors/*antagonists & inhibitors/chemistry/genetics MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Ligands MH - *Molecular Targeted Therapy MH - Mutation MH - Neoplasm Staging MH - Patient Outcome Assessment MH - Patient Selection MH - *Precision Medicine/methods MH - Prognosis MH - Receptor, Fibroblast Growth Factor, Type 1/genetics/metabolism MH - Receptor, Fibroblast Growth Factor, Type 3/genetics/metabolism MH - Signal Transduction/drug effects MH - Translocation, Genetic MH - Urinary Bladder Neoplasms/*drug therapy/genetics/mortality/pathology PMC - PMC5066128 OTO - NOTNLM OT - FGFR1 OT - FGFR3 OT - FGFRs OT - bladder OT - cancer OT - targeted therapy OT - urothelial COIS- Financial & competing interests disclosure The authors received funding from the following grants; Cancer Research UK: C6228/5437, C6228/5433, C6228/A12512; Worldwide Cancer Research (AICR): AICR 06-034; and Yorkshire Cancer Research: L376PA, L367, L346 and L372. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. EDAT- 2016/07/07 06:00 MHDA- 2017/02/25 06:00 PMCR- 2017/10/01 CRDT- 2016/07/07 06:00 PHST- 2016/07/07 06:00 [entrez] PHST- 2016/07/07 06:00 [pubmed] PHST- 2017/02/25 06:00 [medline] PHST- 2017/10/01 00:00 [pmc-release] AID - 10.2217/fon-2016-0042 [doi] PST - ppublish SO - Future Oncol. 2016 Oct;12(19):2243-63. doi: 10.2217/fon-2016-0042. Epub 2016 Jul 6. PMID- 27377847 OWN - NLM STAT- MEDLINE DCOM- 20170417 LR - 20250529 IS - 2410-8650 (Electronic) IS - 1607-551X (Print) IS - 1607-551X (Linking) VI - 32 IP - 6 DP - 2016 Jun TI - Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? PG - 327-33 LID - S1607-551X(16)30066-3 [pii] LID - 10.1016/j.kjms.2016.05.001 [doi] AB - The aim of our study was to evaluate whether neutrophil-to-lymphocyte ratio (NLR) is a predictor of disease progression and recurrence in patients with primary non-muscle-invasive bladder cancer (NMIBC). This was a prospective study of 86 patients with newly diagnosed NMIBC. The patients were classified by the number of points assigned by the European Organization for Research and Treatment of Cancer risk tables. The correlation between progression score, recurrence score, age, mean platelet volume, red blood cell distribution width and NLR was assessed statistically. The same parameters were compared between the risk groups. A significant difference in NLR and age values was observed between recurrence and progression risk score groups. The relationships between NLR and recurrence and progression risk scores were no longer significant after correcting for the statistical effect of age on scores. Age was significantly different between groups after adjusting for NLR. Our study revealed that NLR and age were associated with patient age and bladder tumor progression and recurrence risk scores. After correcting for age, the significant relationship with NLR was lost, in contrast to some previous studies. We recommend that patient age should be corrected to avoid misleading results in NLR studies. CI - Copyright (c) 2016. Published by Elsevier Taiwan. FAU - Albayrak, Sebahattin AU - Albayrak S AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. FAU - Zengin, Kursad AU - Zengin K AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. FAU - Tanik, Serhat AU - Tanik S AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. Electronic address: tanikserhat@gmail.com. FAU - Atar, Muhittin AU - Atar M AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. FAU - Unal, Serhat Haluk AU - Unal SH AD - Department of Urology, Amasya Serafeddin Sabuncuoglu Education and Research Hospital, Amasya, Turkey. FAU - Imamoglu, M Abdurrahim AU - Imamoglu MA AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. FAU - Gurdal, Mesut AU - Gurdal M AD - Department of Urology, Bozok University, School of Medicine, Yozgat, Turkey. LA - eng PT - Journal Article DEP - 20160602 PL - China (Republic : 1949- ) TA - Kaohsiung J Med Sci JT - The Kaohsiung journal of medical sciences JID - 100960562 SB - IM MH - Aged MH - *Disease Progression MH - Erythrocyte Indices MH - Female MH - Follow-Up Studies MH - Humans MH - Leukocyte Count MH - Linear Models MH - Lymphocytes/*pathology MH - Male MH - Mean Platelet Volume MH - Neoplasm Recurrence, Local/*pathology MH - Neutrophils/*pathology MH - Risk Factors MH - Urinary Bladder Neoplasms/*blood/*pathology PMC - PMC11916276 OTO - NOTNLM OT - Age OT - Bladder cancer OT - Neutrophil-to-lymphocyte ratio OT - Progression OT - Recurrence EDAT- 2016/07/06 06:00 MHDA- 2017/04/18 06:00 PMCR- 2016/06/02 CRDT- 2016/07/06 06:00 PHST- 2016/01/29 00:00 [received] PHST- 2016/03/12 00:00 [revised] PHST- 2016/03/23 00:00 [accepted] PHST- 2016/07/06 06:00 [entrez] PHST- 2016/07/06 06:00 [pubmed] PHST- 2017/04/18 06:00 [medline] PHST- 2016/06/02 00:00 [pmc-release] AID - S1607-551X(16)30066-3 [pii] AID - KJM2327 [pii] AID - 10.1016/j.kjms.2016.05.001 [doi] PST - ppublish SO - Kaohsiung J Med Sci. 2016 Jun;32(6):327-33. doi: 10.1016/j.kjms.2016.05.001. Epub 2016 Jun 2. PMID- 27377810 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - Ulceration in bladder cancer associates with extravesical disease, independent of cell cycle, or hypoxia pathways status: Integrating gross morphology and expression profiles in cystectomies. PG - 484.e9-484.e17 LID - S1078-1439(16)30112-0 [pii] LID - 10.1016/j.urolonc.2016.05.031 [doi] AB - OBJECTIVE: Ulceration is common in bladder tumors, but its prognostic role, although intuitive, is not established. We aim to explore the presence of gross ulceration and its relationship with other morphological and biological features classically associated with extravesical disease, in patients submitted to radical cystectomy. METHODS: Tumor size and morphology were noted on 101 cystectomy patients (2000-2010). Papillary, exophytic, and vegetant tumors were grouped as "papillary" and solid/nodular, ulcerated and infiltrative as "nonpapillary." Ulceration was noted grossly in every case as a binary parameter, regardless of morphology. Immunohistochemistry was performed for hypoxia (hypoxia-inducible factor-1alpha and vascular endothelial growth factor), and cell cycle proteins (pRb, p53, and cyclin D1). RESULTS: Mean age was 66.7 year, male:female ratio was 2:1, 20 patients received bacillus Calmette-Guerin and 10 neoadjuvant chemotherapy. Upstaging rate was 56.4%. Ulcerated lesions presented mostly as nonpapillary and nonorgan confined (nOC), whereas nonulcerated tumors were often papillary and organ confined (OC). Tumor size was smaller in nonpapillary tumors (P = 0.002), but did not associate with altered hypoxia or cell cycle expressions. pRb and cyclin D1 loss and p53 overexpression were more frequent in ulcerated and non-OC tumors as did the phenotype vascular endothelial growth factor-negative/hypoxia-inducible factor-1alpha-low (P<0.001). On a multivariate model, ulceration was an independent predictor of non-OC and extravesical disease. CONCLUSION: Patients with ulcerated tumors were often staged with extravesical disease, independent of other morphologic and biological features known to affect prognosis. Prospective studies are needed to confirm the predictive value of tumor ulceration at cystoscopy, which could improve patient stratification for neoadjuvant chemotherapy. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Schultz, Luciana AU - Schultz L AD - Antonio Prudente Foundation, Sao Paulo, Brazil. FAU - Spagnul, Samuel J T AU - Spagnul SJT AD - Antonio Prudente Foundation, Sao Paulo, Brazil. FAU - Damm, Gilcy R AU - Damm GR AD - Antonio Prudente Foundation, Sao Paulo, Brazil. FAU - da Cunha, Isabela W AU - da Cunha IW AD - Antonio Prudente Foundation, Sao Paulo, Brazil; Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil. FAU - Bezerra, Stephania M AU - Bezerra SM AD - Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil. FAU - da Costa, Walter H AU - da Costa WH AD - Antonio Prudente Foundation, Sao Paulo, Brazil; Urology Division, A.C. Camargo Cancer Center, Sao Paulo, Brazil. Electronic address: waltercosta@hotmail.com. FAU - Guimaraes, Gustavo C AU - Guimaraes GC AD - Antonio Prudente Foundation, Sao Paulo, Brazil; Urology Division, A.C. Camargo Cancer Center, Sao Paulo, Brazil. FAU - Zequi, Stenio deC AU - Zequi SD AD - Antonio Prudente Foundation, Sao Paulo, Brazil; Urology Division, A.C. Camargo Cancer Center, Sao Paulo, Brazil. FAU - Soares, Fernando A AU - Soares FA AD - Antonio Prudente Foundation, Sao Paulo, Brazil; Department of Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160701 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Neoplasm Proteins) RN - 0 (VEGFA protein, human) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Aged MH - Antineoplastic Agents/therapeutic use MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/chemistry/complications/*secondary/therapy MH - Cell Cycle MH - Cell Hypoxia MH - Combined Modality Therapy MH - *Cystectomy MH - Female MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/analysis MH - Lymph Node Excision MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Proteins/analysis MH - Tumor Burden MH - Ulcer/*etiology/pathology MH - Urinary Bladder Neoplasms/chemistry/complications/*pathology/therapy MH - Vascular Endothelial Growth Factor A/analysis OTO - NOTNLM OT - Bladder cancer OT - Cell cycle OT - Hypoxia OT - Morphology OT - Ulceration OT - pappilary EDAT- 2016/07/06 06:00 MHDA- 2018/01/18 06:00 CRDT- 2016/07/06 06:00 PHST- 2016/03/01 00:00 [received] PHST- 2016/05/16 00:00 [revised] PHST- 2016/05/30 00:00 [accepted] PHST- 2016/07/06 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/07/06 06:00 [entrez] AID - S1078-1439(16)30112-0 [pii] AID - 10.1016/j.urolonc.2016.05.031 [doi] PST - ppublish SO - Urol Oncol. 2016 Nov;34(11):484.e9-484.e17. doi: 10.1016/j.urolonc.2016.05.031. Epub 2016 Jul 1. PMID- 27377079 OWN - NLM STAT- MEDLINE DCOM- 20170110 LR - 20170111 IS - 1124-3562 (Print) IS - 1124-3562 (Linking) VI - 88 IP - 2 DP - 2016 Jul 4 TI - Prognostic impact of ReTURB in high grade T1 primary bladder cancer. PG - 81-5 LID - 10.4081/aiua.2016.2.81 [doi] AB - PURPOSE: To evaluate whether pathological outcomes of ReTURB have a prognostic impact on recurrence and progression of primitive T1HG bladder cancer. MATERIAL AND METHODS: Patients affected by primitive T1HG TCC of bladder underwent restaging TURB (ReTURB). Patients with muscle invasive disease at ReTURB underwent radical cystectomy; those with non-muscle invasive residual (NMI-RT) and those with no residual tumour (NRT) received an intravesical BCG therapy. We compared recurrence and progression in NMIRT patients and NRT patients at restaging TURB. Patients were followed every 3-6 months with cystoscopy and urine cytology. RESULTS: 212 patients were enrolled in the study. At ReTURB, residual cancer was detected in 92 of 196 (46.9%) valuable patients: 14.3% of these were upstaged to T2. At follow up of 26.3 +/- 22.8 months, there were differences in recurrence and progression rates between NRT and NMIRT patients: 26.9% and 45.3% (p < 0.001), 10.6% and 23.4% (p 0.03), respectively. Recurrence-free and progression-free survivals were significantly higher in NRT compared to NMIRT patients: 73.1% and 54.7% (p < 0.001), 89.4% and 76.6 (p 0.03), respectively. CONCLUSIONS: ReTURB allows to identify a considerable number of residual and understaged cancer. Patients with NMIRT on ReTURB have worse prognosis than those with NRT in terms of recurrence and progression free survival. These outcomes seem to suggest a prognostic impact of findings on ReTURB that could be a valid tool in management of high grade T1 TCC. FAU - Sanseverino, Roberto AU - Sanseverino R AD - U.O.C. di Urologia, Ospedale Umberto I, ASL Salerno, Nocera Inferiore. giorgio.napodano@gmail.com. FAU - Napodano, Giorgio AU - Napodano G FAU - Campitelli, Antonio AU - Campitelli A FAU - Addesso, Maria AU - Addesso M LA - eng PT - Journal Article DEP - 20160704 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Aged MH - Antineoplastic Agents/administration & dosage MH - BCG Vaccine/*administration & dosage MH - Carcinoma, Transitional Cell/drug therapy/pathology/*surgery MH - Combined Modality Therapy MH - Cystectomy/*methods MH - Cystoscopy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/drug therapy/pathology/*surgery EDAT- 2016/07/06 06:00 MHDA- 2017/01/11 06:00 CRDT- 2016/07/06 06:00 PHST- 2016/01/22 00:00 [received] PHST- 2016/02/11 00:00 [accepted] PHST- 2016/07/06 06:00 [entrez] PHST- 2016/07/06 06:00 [pubmed] PHST- 2017/01/11 06:00 [medline] AID - 10.4081/aiua.2016.2.81 [doi] PST - epublish SO - Arch Ital Urol Androl. 2016 Jul 4;88(2):81-5. doi: 10.4081/aiua.2016.2.81. PMID- 27376130 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 2 IP - 1 DP - 2016 Jan 7 TI - Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. PG - 91-99 AB - PURPOSE: To assess the concordance rate in alterations of molecular markers at the time of transurethral resection (TUR) and subsequent radical cystectomy (RC) among patients with high-grade urothelial carcinoma of the bladder (UCB). METHODS: We prospectively performed immunohistochemical staining p53, p21, p27, Ki-67 and cyclin E1 on TUR and on RC specimens from 102 patients treated with RC and bilateral lymphadenectomy for high-grade UCB. We analyzed the concordance rate of individual markers and of the number of altered markers. Concordant and discordant findings were reported in the overall population and according to clinical stage. RESULTS: Median patient age was 74 years (IQR 67-79) and mostly male (86%). Median time from TUR to RC was 1.5 months (IQR 1.0-2.4). Clinical stage at time of RC was cTa/Tis/T1 in 50% , cT2 in 47% , and cT4 in 1% of patients Nine (9%) patients received neoadjuvant chemotherapy. The concordance of biomarkers between TUR and RC specimens was 92.2% , 77.5% , 80.4% , 77.5% , and 83.3% for cyclin E1, p21, p27, p53 and Ki-67, respectively. The concordance between number of altered biomarkers was 51.0%. CONCLUSIONS: The rate of individual marker alterations at time of TUR closely approximates that found at RC specimens. However, the correlation of number of altered markers is lower. Molecular marker status at TUR could help predict the marker status at RC and may help guide multimodal therapeutic planning. FAU - Passoni, Niccolo M AU - Passoni NM AD - Departments of Urology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Departments of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Medical University of Vienna, Vienna, Austria. FAU - Bagrodia, Aditya AU - Bagrodia A AD - Departments of Urology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Francis, Franto AU - Francis F AD - Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Rachakonda, Varun AU - Rachakonda V AD - Departments of Urology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Weill Cornell Medical College , New York, Presbyterian Hospital, New York, NY, USA. FAU - Kapur, Payal AU - Kapur P AD - Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Sagalowsky, Arthur I AU - Sagalowsky AI AD - Departments of Urology, University of Texas Southwestern Medical Center , Dallas, TX, USA. FAU - Lotan, Yair AU - Lotan Y AD - Departments of Urology, University of Texas Southwestern Medical Center , Dallas, TX, USA. LA - eng PT - Journal Article DEP - 20160107 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC4927883 OTO - NOTNLM OT - Bladder cancer OT - cystectomy OT - molecular markers OT - transurethral resection of bladder tumors EDAT- 2016/07/05 06:00 MHDA- 2016/07/05 06:01 CRDT- 2016/07/05 06:00 PHST- 2016/07/05 06:00 [entrez] PHST- 2016/07/05 06:00 [pubmed] PHST- 2016/07/05 06:01 [medline] AID - BLC150036 [pii] AID - 10.3233/BLC-150036 [doi] PST - epublish SO - Bladder Cancer. 2016 Jan 7;2(1):91-99. doi: 10.3233/BLC-150036. PMID- 27376129 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 2 IP - 1 DP - 2016 Jan 7 TI - Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. PG - 77-89 AB - BACKGROUND: Many studies investigated the prognostic or predictive relevance of single nucleotide polymorphisms (SNPs) in biologically plausible genes in urinary bladder cancer (UBC) patients. Most published SNP associations have never been replicated in independent patient series. OBJECTIVE: To independently replicate all previously reported associations between germline SNPs and disease prognosis or treatment response in UBC. METHODS: A Pubmed search was performed to identify studies published by July 1, 2014 reporting on germline SNP associations with UBC prognosis or treatment response. For the replication series, consisting of 1,284 non-muscle-invasive bladder cancer (NMIBC) and 275 muscle-invasive or metastatic bladder cancer (MIBC) patients recruited through the Netherlands Cancer Registry, detailed clinical data were retrieved from medical charts. Patients were genotyped using a genome-wide SNP array. SNP association with recurrence-free, progression-free, and overall survival (OS) within specific patient and treatment strata was tested using Cox regression analyses. RESULTS: For only six of the 114 evaluated SNPs, the association with either UBC prognosis or treatment response was replicated at the p < 0.05 level: rs1799793 (ERCC2) and rs187238 (IL18) for BCG recurrence; rs6678136 (RGS4) and rs11585883 (RGS5) for NMIBC progression; rs12035879 (RGS5) and rs2075786 (TERT) for MIBC OS. CONCLUSIONS: Non-replicated genetic associations in the literature require cautious interpretation. This single replication does not provide definitive proof of association for the six SNPs, and non-replication of other SNPs may result from population-specific effects or the retrospective patient enrollment. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, The Netherlands. FAU - Dudek, Aleksandra M AU - Dudek AM AD - Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, The Netherlands. FAU - Verhaegh, Gerald W AU - Verhaegh GW AD - Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, The Netherlands. FAU - Aben, Katja K AU - Aben KK AD - Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands. FAU - Witjes, J Alfred AU - Witjes JA AD - Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, The Netherlands. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, The Netherlands. FAU - Vermeulen, Sita H AU - Vermeulen SH AD - Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20160107 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC4927992 OTO - NOTNLM OT - Treatment outcome OT - genetic association studies OT - prognosis OT - reproducibility of results OT - single nucleotide polymorphisms OT - urinary bladder neoplasms EDAT- 2016/07/05 06:00 MHDA- 2016/07/05 06:01 CRDT- 2016/07/05 06:00 PHST- 2016/07/05 06:00 [entrez] PHST- 2016/07/05 06:00 [pubmed] PHST- 2016/07/05 06:01 [medline] AID - BLC150027 [pii] AID - 10.3233/BLC-150027 [doi] PST - epublish SO - Bladder Cancer. 2016 Jan 7;2(1):77-89. doi: 10.3233/BLC-150027. PMID- 27376128 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231105 IS - 2352-3727 (Print) IS - 2352-3735 (Electronic) IS - 2352-3727 (Linking) VI - 2 IP - 1 DP - 2016 Jan 7 TI - BcCluster: A Bladder Cancer Database at the Molecular Level. PG - 65-76 AB - BACKGROUND: Bladder Cancer (BC) has two clearly distinct phenotypes. Non-muscle invasive BC has good prognosis and is treated with tumor resection and intravesical therapy whereas muscle invasive BC has poor prognosis and requires usually systemic cisplatin based chemotherapy either prior to or after radical cystectomy. Neoadjuvant chemotherapy is not often used for patients undergoing cystectomy. High-throughput analytical omics techniques are now available that allow the identification of individual molecular signatures to characterize the invasive phenotype. However, a large amount of data produced by omics experiments is not easily accessible since it is often scattered over many publications or stored in supplementary files. OBJECTIVE: To develop a novel open-source database, BcCluster (http://www.bccluster.org/), dedicated to the comprehensive molecular characterization of muscle invasive bladder carcinoma. MATERIALS: A database was created containing all reported molecular features significant in invasive BC. The query interface was developed in Ruby programming language (version 1.9.3) using the web-framework Rails (version 4.1.5) (http://rubyonrails.org/). RESULTS: BcCluster contains the data from 112 published references, providing 1,559 statistically significant features relative to BC invasion. The database also holds 435 protein-protein interaction data and 92 molecular pathways significant in BC invasion. The database can be used to retrieve binding partners and pathways for any protein of interest. We illustrate this possibility using survivin, a known BC biomarker. CONCLUSIONS: BcCluster is an online database for retrieving molecular signatures relative to BC invasion. This application offers a comprehensive view of BC invasiveness at the molecular level and allows formulation of research hypotheses relevant to this phenotype. FAU - Bhat, Akshay AU - Bhat A AD - Charite-Universitatsmedizin Berlin, Berlin, Germany; Mosaiques diagnostics GmbH, Hannover, Germany. FAU - Mokou, Marika AU - Mokou M AD - Biomedical Research Foundation Academy of Athens , Biotechnology Division, Athens, Greece. FAU - Zoidakis, Jerome AU - Zoidakis J AD - Biomedical Research Foundation Academy of Athens , Biotechnology Division, Athens, Greece. FAU - Jankowski, Vera AU - Jankowski V AD - Institute for Molecular Cardiovascular Research (IMCAR) , Aachen, Germany. FAU - Vlahou, Antonia AU - Vlahou A AD - Biomedical Research Foundation Academy of Athens , Biotechnology Division, Athens, Greece. FAU - Mischak, Harald AU - Mischak H AD - Mosaiques diagnostics GmbH, Hannover, Germany; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. LA - eng PT - Journal Article DEP - 20160107 PL - United States TA - Bladder Cancer JT - Bladder cancer (Amsterdam, Netherlands) JID - 101668567 PMC - PMC4927921 OTO - NOTNLM OT - Bladder cancer OT - bioinformatics OT - biomarker OT - data integration OT - protein interactome OT - relational database management system OT - survivin OT - web application framework EDAT- 2016/07/05 06:00 MHDA- 2016/07/05 06:01 CRDT- 2016/07/05 06:00 PHST- 2016/07/05 06:00 [entrez] PHST- 2016/07/05 06:00 [pubmed] PHST- 2016/07/05 06:01 [medline] AID - BLC150024 [pii] AID - 10.3233/BLC-150024 [doi] PST - epublish SO - Bladder Cancer. 2016 Jan 7;2(1):65-76. doi: 10.3233/BLC-150024. PMID- 27368880 OWN - NLM STAT- MEDLINE DCOM- 20180104 LR - 20220330 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 10 DP - 2016 Oct TI - Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. PG - 460-8 LID - S1078-1439(16)30109-0 [pii] LID - 10.1016/j.urolonc.2016.05.028 [doi] AB - OBJECTIVE: Non-muscle-invasive bladder cancer (NMIBC) comprises a wide spectrum of tumors with different behaviors and prognoses. It follows that the surveillance for these tumors should be adapted according to the risks of recurrence and progression and should be dynamic in design. METHODS AND MATERIALS: Medline search was conducted from 1980 to 2016 using a combination of MeSH and keyword terms. The highest available evidence was reviewed to define different risk groups in NMIBC. The performance of different follow-up tools such as urine cytology, cystoscopy, and upper tract imaging in detecting bladder carcinoma was assessed. Different commercially available urinary markers were investigated to determine whether such markers would contribute to the surveillance of patients with NMIBC. A follow-up scheme based on the early evidence is proposed. RESULTS: A risk-based approach is paramount. Cystoscopy and cytology are recommended to be done at 3 months following transurethral resection of bladder tumor. For low-risk tumors, annual cystoscopy alone is sufficient; no upper tract evaluations or cytology is needed except at diagnosis. High-risk tumors should be followed up with a more intense schedule: cystoscopy every 3 months for 2 years, 6 months for 2 years, and then annually, with cytology at frequent intervals, and imaging for upper tract evaluation at 1 year and then every 2 years. Intermediate-risk tumors should be subclassified as per the International Bladder Cancer Group recommendations and when associated with 3 or more of the following findings (multiple tumors, size>/=3cm, early recurrence<1 year, frequent recurrences>1 per year) then a surveillance strategy similar to that of high risk should be followed. Several urine markers were more sensitive than cytology in the detection of NMIBC; however, these tests are still costly, require specialized laboratories, and do not replace cystoscopy. Until better and cheaper markers are available, their routine use has not been integrated in the follow-up recommendation of current guidelines. CONCLUSIONS: Surveillance of NMIBC should follow a risk-adapted approach, with a combination of cystoscopy, cytology, and upper tract imaging. The aim of this approach is to minimize the therapeutic burden of a disease with high recurrence rates without missing progressing tumors. When designing a diagnostic pathway, first-line diagnostic imaging tests should have high sensitivity to ensure disease positives are included in the test population for further investigation. Second-line investigations should be highly specific, to ensure false-positives are minimized. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Urology, McGill University Health Centre, Montreal, Canada. Electronic address: wassim.kassouf@muhc.mcgill.ca. FAU - Traboulsi, Samer L AU - Traboulsi SL AD - Department of Urology, McGill University Health Centre, Montreal, Canada. FAU - Schmitz-Drager, Bernd AU - Schmitz-Drager B AD - Urologie, Schon Klinik Nurnberg Furth/Urologie, Furth, Germany. FAU - Palou, Joan AU - Palou J AD - Servicio de Urologia, Fundacion Puigvert, Barcelona, Spain. FAU - Witjes, Johannes Alfred AU - Witjes JA AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van Rhijn, Bas W G AU - van Rhijn BW AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Grossman, Herbert Barton AU - Grossman HB AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Kiemeney, Lambertus A AU - Kiemeney LA AD - Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Goebell, Peter J AU - Goebell PJ AD - Department of Urology, University Clinic Erlangen, Erlangen, Germany. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: akamat@mdanderson.org. LA - eng PT - Journal Article PT - Review DEP - 20160629 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/urine MH - *Cystoscopy MH - Cytodiagnosis MH - Disease Progression MH - Humans MH - Kidney Neoplasms/*diagnostic imaging MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis/pathology/urine MH - Practice Guidelines as Topic MH - Risk Factors MH - Time Factors MH - Ureteral Neoplasms/*diagnostic imaging MH - Urinary Bladder Neoplasms/*diagnosis/pathology/urine MH - Urine/chemistry/cytology MH - Urography MH - Watchful Waiting/*standards OTO - NOTNLM OT - Follow-up OT - Prediction OT - Recurrence OT - Risk OT - Surveillance OT - Urine markers EDAT- 2016/07/03 06:00 MHDA- 2018/01/05 06:00 CRDT- 2016/07/03 06:00 PHST- 2016/03/01 00:00 [received] PHST- 2016/05/26 00:00 [revised] PHST- 2016/05/26 00:00 [accepted] PHST- 2016/07/03 06:00 [entrez] PHST- 2016/07/03 06:00 [pubmed] PHST- 2018/01/05 06:00 [medline] AID - S1078-1439(16)30109-0 [pii] AID - 10.1016/j.urolonc.2016.05.028 [doi] PST - ppublish SO - Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29. PMID- 27351322 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20201005 IS - 1735-546X (Electronic) IS - 1735-1308 (Linking) VI - 13 IP - 3 DP - 2016 Jun 28 TI - Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin. PG - 2677-83 AB - PURPOSE: To investigate the role of CD44, cytokeratin 20 (CK20) and survivin for the detection and prognosis of patients with urothelial carcinoma of the bladder. MATERIALS AND METHODS: The study included 82 patients who underwent transurethral resection of bladder tumors between 2009 and 2014. The patient and tumor characteristics with relevance to age, tumor size and focality, grade and stage, recurrence and progression were noted. Patients with carcinoma in situ, those who had at more than 3 sites of lesions and greater than 3 cm tumors were excluded. All cases were ex-smokers. All histological samples stained with hematoxylin and eosin were re-evaluated according to the 2004 World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification system and immunohistochemically stained for CD44, CK20 and survivin. RESULTS: The study group comprised 57 (69.5%) males and 25 (30.5%) females with a mean age of 60 years (range, 26-87 years). All were newly-diagnosed patients with bladder tumors. Immunohistochemical evaluation revealed that there was a statistically significant correlation between the grade and stage of the tumor with CK20 and survivin positivity (P < .05). As the grade and stage increased CD44 immunoreactivity significantly decreased (P = .002, P = .0001, respectively). However, relationship of protein expressions with recurrence and progression remained insignificant (P > .05). CONCLUSION: In cases of bladder urothelial carcinoma positivity for CD44, CK20, and survivin has significant relation with the tumor grade and stage while no significant relationship was determined in terms of recurrence and progression . FAU - Yikilmaz, Taha Numan AU - Yikilmaz TN AD - Department of Urology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Turkey. numanyikilmaz@gmail.com. FAU - Dirim, Ayhan AU - Dirim A AD - Department of Urology, Baskent University, Ankara 06200, Turkey. FAU - Ayva, Ebru Sebnem AU - Ayva ES AD - Department of Pathology, Baskent University, Ankara 06200, Turkey. FAU - Ozdemir, Handan AU - Ozdemir H AD - Department of Pathology, Baskent University, Ankara 06200, Turkey. FAU - Ozkardes, Hakan AU - Ozkardes H AD - Department of Urology, Baskent University, Ankara 06200, Turkey. LA - eng PT - Comparative Study PT - Journal Article DEP - 20160628 PL - Iran TA - Urol J JT - Urology journal JID - 101286676 RN - 0 (BIRC5 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (CD44 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (Inhibitor of Apoptosis Proteins) RN - 0 (Keratin-20) RN - 0 (Survivin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Disease Progression MH - Female MH - Humans MH - Hyaluronan Receptors/*analysis MH - Inhibitor of Apoptosis Proteins/*analysis MH - Keratin-20/*analysis MH - Male MH - Middle Aged MH - Prognosis MH - Survivin MH - Urinary Bladder Neoplasms/*chemistry/pathology EDAT- 2016/06/29 06:00 MHDA- 2017/04/19 06:00 CRDT- 2016/06/29 06:00 PHST- 2015/11/25 00:00 [received] PHST- 2016/02/04 00:00 [accepted] PHST- 2016/05/02 00:00 [revised] PHST- 2016/06/29 06:00 [entrez] PHST- 2016/06/29 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] AID - 3294 [pii] PST - epublish SO - Urol J. 2016 Jun 28;13(3):2677-83. PMID- 27330798 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 5 IP - 1 DP - 2016 Jul TI - Preoperative Glasgow prognostic score as a predictor of primary bladder cancer recurrence. PG - 201-206 AB - The correlation between systemic inflammatory markers and malignancies has been assessed by a number of recent studies. The aim of this study was to prospectively assess preoperative inflammation markers and Glasgow prognostic scores (GPS) in patients who underwent surgery for primary bladder cancer (BC), and evaluate the predictive value of GPS for disease recurrence and progression. A total of 38 patients (mean age, 60.16+/-9.71 years; range, 33-76 years) who were treated in our department between May, 2014 and August, 2015 were enrolled in the present study. Preoperatively, patient information regarding gender, body mass index, serum C-reactive protein (CRP) and albumin levels, GPS and comorbidities, were collected and recorded. Transurethral resection of the bladder was performed, followed by histopathological evaluation of the resected material. The tumor size, stage and grade and the presence of necrosis were determined. According to the international TNM classification, the results of the histopathological analysis were as follows: Ta low- (n=24) and high-grade (n=4); and T1 low- (n=2) and high-grade (n=8). The median follow-up period was 10.1 months (range, 6-12 months). During this period, recurrence was observed in 10 cases and disease progression was detected in 1 patient. Hypoalbuminemia was encountered in 40% of the cases with recurrence, which was significantly higher compared with that in patients without recurrence (7.1%; P=0.031). In patients who had recurrence, a GPS of 1-2 points and tumor necrosis were more frequently detected compared with those without recurrence (60 vs. 7.1%, P=0.002; and 80 vs. 7.1%, P=0.001, respectively). Excluding a cystectomized case with a diagnosis of muscle-invasive BC, disease progression was not detected in any of the cases with recurrence during follow-up. Therefore, we consider that GPS and serum markers of systemic inflammatory response may be used as predictors of recurrence in patients with transitional cell BC. FAU - Yuksel, Ozgur Haki AU - Yuksel OH AD - Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, TR-34752 Istanbul, Turkey. FAU - Akan, Serkan AU - Akan S AD - Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, TR-34752 Istanbul, Turkey. FAU - Urkmez, Ahmet AU - Urkmez A AD - Department of Urology, Haydarpasa Numune Research and Training Hospital, TR-34668 Istanbul, Turkey. FAU - Yildirim, Caglar AU - Yildirim C AD - Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, TR-34752 Istanbul, Turkey. FAU - Sahin, Aytac AU - Sahin A AD - Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, TR-34752 Istanbul, Turkey. FAU - Verit, Ayhan AU - Verit A AD - Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, TR-34752 Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20160511 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC4906850 OTO - NOTNLM OT - Glasgow prognostic score OT - bladder cancer OT - hypoalbuminemia OT - inflammation EDAT- 2016/06/23 06:00 MHDA- 2016/06/23 06:01 PMCR- 2016/05/11 CRDT- 2016/06/23 06:00 PHST- 2016/02/12 00:00 [received] PHST- 2016/04/27 00:00 [accepted] PHST- 2016/06/23 06:00 [entrez] PHST- 2016/06/23 06:00 [pubmed] PHST- 2016/06/23 06:01 [medline] PHST- 2016/05/11 00:00 [pmc-release] AID - MCO-0-0-901 [pii] AID - 10.3892/mco.2016.901 [doi] PST - ppublish SO - Mol Clin Oncol. 2016 Jul;5(1):201-206. doi: 10.3892/mco.2016.901. Epub 2016 May 11. PMID- 27326407 OWN - NLM STAT- MEDLINE DCOM- 20180123 LR - 20181113 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 57 Suppl 1 IP - Suppl 1 DP - 2016 Jun TI - How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy? PG - S44-51 LID - 10.4111/icu.2016.57.S1.S44 [doi] AB - High-grade T1 bladder cancer has a poor prognosis due to a higher incidence of recurrence and progression than other nonmuscle invasive bladder cancer; thus patients with high-grade T1 have to be carefully monitored and managed. If patients are diagnosed with high-grade T1 at initial transurethral resection (TUR), a second TUR is strongly recommended regardless of whether muscle layer is present in the specimen because of the possibility of understating due to incomplete resection. Since high-grade T1 disease shows diverse clinical courses, individual approaches are recommended for treatment. In cases with low risk of progression, cystectomy could represent overtreatment and deteriorate quality of life irreversibly, while, in those with high risk, bacillus Calmette-Guerin (BCG) therapy may worsen survival by delaying definitive therapy. Therefore, a strategy for predicting prognosis based on the risk of progression is needed for managing high-grade T1 disease. Molecular risk classifiers predicting the risk of progression and response to BCG may help identify the optimal management of high-grade T1 disease for each individual. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Medical Genomics Research Center, Research Institute of Bioscience and Biotechnology, Daejeon, Korea.; Korean Bioinformation Center, Research Institute of Bioscience and Biotechnology, Daejeon, Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20160610 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 RN - 0 (BCG Vaccine) SB - IM MH - BCG Vaccine/therapeutic use MH - Cystectomy/methods MH - Disease Progression MH - Humans MH - Neoplasm Grading MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/diagnosis/pathology/*therapy PMC - PMC4910762 OTO - NOTNLM OT - Disease progression OT - Therapeutics OT - Urinary bladder neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2016/06/22 06:00 MHDA- 2018/01/24 06:00 PMCR- 2016/06/01 CRDT- 2016/06/22 06:00 PHST- 2016/04/14 00:00 [received] PHST- 2016/05/06 00:00 [accepted] PHST- 2016/06/22 06:00 [entrez] PHST- 2016/06/22 06:00 [pubmed] PHST- 2018/01/24 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.4111/icu.2016.57.S1.S44 [doi] PST - ppublish SO - Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S44-51. doi: 10.4111/icu.2016.57.S1.S44. Epub 2016 Jun 10. PMID- 27326406 OWN - NLM STAT- MEDLINE DCOM- 20180123 LR - 20181113 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 57 Suppl 1 IP - Suppl 1 DP - 2016 Jun TI - Active surveillance for nonmuscle invasive bladder cancer. PG - S4-S13 LID - 10.4111/icu.2016.57.S1.S4 [doi] AB - Nonmuscle invasive bladder cancer (NMIBC) is known to be a heterogeneous malignancy that requires varying treatment modalities and follow-up schedules. Low-grade Ta papillary tumors are categorized as low-risk NMIBC because of their favorable prognosis. There is an expanding movement that overdiagnosis and overtreatment should be avoided considering the economic impact and the patients' quality of life. It has been over 10 years since the initial assessment of active surveillance for low-risk NMIBC suggested its feasibility and safety. However, urologists are still unfamiliar with this treatment option, which can be ideal in appropriately selected patients. In this review article, we focus on active surveillance for low-risk NMIBC and discuss the evidence and rationale for this treatment option. There are several issues to resolve in order to advocate active surveillance as a standard option in selected patients. A specific follow-up protocol including intervals of cystoscopy, urine cytology, urine markers, and other radiographic examinations need to be optimized and validated. Finally, we integrate the available data into the follow-up strategy and propose a new surveillance protocol for active surveillance of recurrent low-risk bladder cancer. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan. FAU - Hirao, Yoshihiko AU - Hirao Y AD - Department of Urology, Nara Medical University, Kashihara, Nara, Japan.; Department of Urology, Osaka Gyoumeikan Hospital, Konohana-ku, Osaka, Japan. LA - eng PT - Journal Article PT - Review DEP - 20160527 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Animals MH - Disease Models, Animal MH - Evidence-Based Medicine/methods MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/diagnosis MH - Population Surveillance/methods MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/pathology MH - Watchful Waiting/*methods PMC - PMC4910757 OTO - NOTNLM OT - Local neoplasm recurrence OT - Risk assessment OT - Urinary bladder neoplasms OT - Watchful waiting COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2016/06/22 06:00 MHDA- 2018/01/24 06:00 PMCR- 2016/06/01 CRDT- 2016/06/22 06:00 PHST- 2016/03/28 00:00 [received] PHST- 2016/04/22 00:00 [accepted] PHST- 2016/06/22 06:00 [entrez] PHST- 2016/06/22 06:00 [pubmed] PHST- 2018/01/24 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.4111/icu.2016.57.S1.S4 [doi] PST - ppublish SO - Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S4-S13. doi: 10.4111/icu.2016.57.S1.S4. Epub 2016 May 27. PMID- 27326404 OWN - NLM STAT- MEDLINE DCOM- 20180123 LR - 20181113 IS - 2466-054X (Electronic) IS - 2466-0493 (Print) IS - 2466-0493 (Linking) VI - 57 Suppl 1 IP - Suppl 1 DP - 2016 Jun TI - Treatment of bladder cancer in the elderly. PG - S26-35 LID - 10.4111/icu.2016.57.S1.S26 [doi] AB - As the population ages and life expectancy increases in the human population, more individuals will be diagnosed with bladder cancer (BC). The definition of who is elderly is likely to change in the future from the commonly used cut-off of >/=75 years of age. Physiological rather than chronological age is key. BC care in the elderly is likely to become a very common problem in daily practice. Concerns have been raised that senior BC patients are not given treatments that could cure their disease. Clinicians lack quantitative and reliable estimates of competing mortality risks when considering treatments for BC. Majority of patients diagnosed with BC are elderly, making treatment decisions complex with their increasing number of comorbidities. A multidisciplinary approach to these patients may be a way to incorporate discussion from various disciplines regarding treatment options available. Here we review various treatment options for elderly patients with muscle invasive BC and nonmuscle invasive BC. We include differences in treatments from robotic versus open radical cystectomy, various urinary diversion techniques, chemotherapy, radiation therapy and combination treatments. In clinical practice, treatment decisions for elderly patients should be done on a case-by-case basis, tailored to each patient with their specific histories and comorbidities considered. Some healthy elderly patients may be better candidates for extensive curative treatments than their younger counterparts. This implies that these important, life-altering decisions cannot be solely based on age as many other factors can affect patient survival outcomes. FAU - Erlich, Annette AU - Erlich A AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada. FAU - Zlotta, Alexandre R AU - Zlotta AR AD - Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada.; Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Review DEP - 20160527 PL - Korea (South) TA - Investig Clin Urol JT - Investigative and clinical urology JID - 101674989 SB - IM MH - Age Factors MH - Aged MH - Clinical Decision-Making/methods MH - Combined Modality Therapy MH - Comorbidity MH - Cystectomy/methods MH - Humans MH - Life Expectancy MH - Prognosis MH - Robotic Surgical Procedures/methods MH - Urinary Bladder Neoplasms/*therapy PMC - PMC4910758 OTO - NOTNLM OT - Bladder cancer OT - Cystectomy OT - Elderly OT - Geriatric OT - Treatment COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2016/06/22 06:00 MHDA- 2018/01/24 06:00 PMCR- 2016/06/01 CRDT- 2016/06/22 06:00 PHST- 2016/05/03 00:00 [received] PHST- 2016/05/12 00:00 [accepted] PHST- 2016/06/22 06:00 [entrez] PHST- 2016/06/22 06:00 [pubmed] PHST- 2018/01/24 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.4111/icu.2016.57.S1.S26 [doi] PST - ppublish SO - Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S26-35. doi: 10.4111/icu.2016.57.S1.S26. Epub 2016 May 27. PMID- 27324428 OWN - NLM STAT- MEDLINE DCOM- 20180212 LR - 20260127 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 71 IP - 3 DP - 2017 Mar TI - EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. PG - 447-461 LID - S0302-2838(16)30249-4 [pii] LID - 10.1016/j.eururo.2016.05.041 [doi] AB - CONTEXT: The European Association of Urology (EAU) panel on Non-muscle-invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non-muscle-invasive Bladder Cancer. OBJECTIVE: To present the 2016 EAU guidelines on NMIBC. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guerin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines). CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression. CI - Copyright (c) 2016. Published by Elsevier B.V. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. Electronic address: marek.babjuk@lfmotol.cuni.cz. FAU - Bohle, Andreas AU - Bohle A AD - Department of Urology, HELIOS Agnes-Karll-Krankenhaus, Bad Schwartau, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Capoun, Otakar AU - Capoun O AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Cohen, Daniel AU - Cohen D AD - Department of Surgery and Cancer, Imperial College London, UK; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK. FAU - Comperat, Eva M AU - Comperat EM AD - Department of Pathology, Hopital La Pitie-Salpetriere, UPMC, Paris, France. FAU - Hernandez, Virginia AU - Hernandez V AD - Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. FAU - Kaasinen, Eero AU - Kaasinen E AD - Department of Urology, Hyvinkaa Hospital, Hyvinkaa, Finland. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Roupret, Morgan AU - Roupret M AD - AP-HP, Hopital La Pitie-Salpetriere, Service d'Urologie, Paris, France; UPMC University Paris 06, GRC5, ONCOTYPE-Uro, Institut Universitaire de Cancerologie, Paris, France. FAU - van Rhijn, Bas W G AU - van Rhijn BWG AD - Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Sylvester, Richard J AU - Sylvester RJ AD - European Association of Urology Guidelines Office, Brussels, Belgium. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medical University of Graz, Graz, Austria. LA - eng PT - Journal Article DEP - 20160617 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2017 Jun;71(6):e173-e174. doi: 10.1016/j.eururo.2016.11.029. PMID: 27939074 CIN - Eur Urol. 2017 Jun;71(6):e171-e172. doi: 10.1016/j.eururo.2016.11.030. PMID: 27979427 MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage MH - BCG Vaccine/administration & dosage MH - Carcinoma in Situ/pathology/*therapy MH - Carcinoma, Transitional Cell/pathology/*therapy MH - *Cystectomy MH - *Cystoscopy MH - Europe MH - Humans MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Practice Guidelines as Topic MH - Societies, Medical MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/pathology/*therapy MH - Urology OTO - NOTNLM OT - Bacillus Calmette-Guerin (BCG) OT - Bladder cancer OT - Cystectomy OT - Diagnosis OT - European Association of Urology OT - Guidelines OT - Intravesical chemotherapy OT - Prognosis OT - Transurethral resection (TUR) OT - Urothelial carcinoma EDAT- 2016/06/22 06:00 MHDA- 2018/02/13 06:00 CRDT- 2016/06/22 06:00 PHST- 2016/05/23 00:00 [received] PHST- 2016/05/30 00:00 [accepted] PHST- 2016/06/22 06:00 [pubmed] PHST- 2018/02/13 06:00 [medline] PHST- 2016/06/22 06:00 [entrez] AID - S0302-2838(16)30249-4 [pii] AID - 10.1016/j.eururo.2016.05.041 [doi] PST - ppublish SO - Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17. PMID- 27323781 OWN - NLM STAT- MEDLINE DCOM- 20180130 LR - 20250626 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 29 DP - 2016 Jul 19 TI - Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. PG - 45479-45488 LID - 10.18632/oncotarget.9991 [doi] AB - We performed a network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy of several intravesical chemotherapeutic (IVC) agents after transurethral resection of bladder tumor (TURB) in non-muscle invasive bladder cancer patients. The literature search was conducted using the Embase, Scopus and PubMed databases for RCTs, including patients with single or multiple, primary or recurrent stage Ta or T1 urothelial carcinoma of the bladder managed with a single, immediate instillation of IVC after TURB. Thirteen RCTs met the eligibility criteria. Pair-wise meta-analysis (direct comparison) showed that pirarubicin [hazard ratio (HR): 0.31], epirubicin (HR: 0.62), and MMC (HR: 0.40) were the most effective drugs for reducing tumor recurrence. Bayesian network meta-analysis (indirect comparison) revealed that treatment with pirarubicin (HR: 0.31), MMC (HR: 0.44), or epirubicin (HR: 0.60) was associated with prolonged recurrence-free survival. Among the drugs examined, only pirarubicin reduced disease progression compared to controls. These results suggest that a single, immediate administration of IVC with pirarubicin, MMC, or epirubicin is associated with prolonged recurrence-free survival following TURB in non-muscle invasive bladder cancer patients, though only pirarubicin also reduced disease progression. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Antineoplastic Agents) RN - 13909-09-6 (Semustine) RN - 3Z8479ZZ5X (Epirubicin) RN - 80168379AG (Doxorubicin) RN - 8N3DW7272P (Cyclophosphamide) RN - D58G680W0G (pirarubicin) RN - Q41OR9510P (Melphalan) RN - MMC protocol SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage MH - Carcinoma, Transitional Cell/*drug therapy/mortality MH - Cyclophosphamide/administration & dosage MH - Doxorubicin/administration & dosage/analogs & derivatives MH - Epirubicin/administration & dosage MH - Humans MH - Melphalan/administration & dosage MH - Semustine/administration & dosage MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality PMC - PMC5216735 OTO - NOTNLM OT - chemotherapy OT - drug therapy OT - single instillation OT - systematic review OT - urinary bladder neoplasm COIS- The authors declare that no competing interests exist. EDAT- 2016/06/22 06:00 MHDA- 2018/01/31 06:00 PMCR- 2016/07/19 CRDT- 2016/06/22 06:00 PHST- 2016/03/18 00:00 [received] PHST- 2016/05/29 00:00 [accepted] PHST- 2016/06/22 06:00 [pubmed] PHST- 2018/01/31 06:00 [medline] PHST- 2016/06/22 06:00 [entrez] PHST- 2016/07/19 00:00 [pmc-release] AID - 9991 [pii] AID - 10.18632/oncotarget.9991 [doi] PST - ppublish SO - Oncotarget. 2016 Jul 19;7(29):45479-45488. doi: 10.18632/oncotarget.9991. PMID- 27321955 OWN - NLM STAT- MEDLINE DCOM- 20170324 LR - 20220317 IS - 1878-3686 (Electronic) IS - 1535-6108 (Linking) VI - 30 IP - 1 DP - 2016 Jul 11 TI - Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. PG - 27-42 LID - S1535-6108(16)30209-4 [pii] LID - 10.1016/j.ccell.2016.05.004 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into three major classes with basal- and luminal-like characteristics and different clinical outcomes. Large differences in biological processes such as the cell cycle, epithelial-mesenchymal transition, and differentiation were observed. Analysis of transcript variants revealed frequent mutations in genes encoding proteins involved in chromatin organization and cytoskeletal functions. Furthermore, mutations in well-known cancer driver genes (e.g., TP53 and ERBB2) were primarily found in high-risk tumors, together with APOBEC-related mutational signatures. The identification of subclasses in NMIBC may offer better prognostication and treatment selection based on subclass assignment. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Hedegaard, Jakob AU - Hedegaard J AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Lamy, Philippe AU - Lamy P AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Nordentoft, Iver AU - Nordentoft I AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Algaba, Ferran AU - Algaba F AD - Section of Pathology, Fundacio Puigvert, University Autonoma de Barcelona, Barcelona 08025, Spain. FAU - Hoyer, Soren AU - Hoyer S AD - Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark. FAU - Ulhoi, Benedicte Parm AU - Ulhoi BP AD - Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark. FAU - Vang, Soren AU - Vang S AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Reinert, Thomas AU - Reinert T AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Hermann, Gregers G AU - Hermann GG AD - Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark. FAU - Mogensen, Karin AU - Mogensen K AD - Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark. FAU - Thomsen, Mathilde Borg Houlberg AU - Thomsen MBH AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Nielsen, Morten Muhlig AU - Nielsen MM AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Marquez, Mirari AU - Marquez M AD - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden. FAU - Aine, Mattias AU - Aine M AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund 22100, Sweden. FAU - Hoglund, Mattias AU - Hoglund M AD - Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund 22100, Sweden. FAU - Birkenkamp-Demtroder, Karin AU - Birkenkamp-Demtroder K AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Fristrup, Niels AU - Fristrup N AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Borre, Michael AU - Borre M AD - Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany. FAU - Stohr, Robert AU - Stohr R AD - Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany. FAU - Wach, Sven AU - Wach S AD - Department of Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany. FAU - Keck, Bastian AU - Keck B AD - Department of Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nurnberg, Erlangen 91054, Germany. FAU - Seitz, Anna Katharina AU - Seitz AK AD - Department of Urology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich 81675, Germany. FAU - Nawroth, Roman AU - Nawroth R AD - Department of Urology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich 81675, Germany. FAU - Maurer, Tobias AU - Maurer T AD - Department of Urology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich 81675, Germany. FAU - Tulic, Cane AU - Tulic C AD - Faculty of Medicine, Clinic of Urology, Clinical Centre of Serbia, University of Belgrade, 11000 Belgrade, Serbia. FAU - Simic, Tatjana AU - Simic T AD - Faculty of Medicine, Institute of Medical and Clinical Biochemistry, University of Belgrade, 11000 Belgrade, Serbia. FAU - Junker, Kerstin AU - Junker K AD - Department of Urology, Saarland University, Homburg 66421, Germany. FAU - Horstmann, Marcus AU - Horstmann M AD - Department of Urology, Friedrich-Schiller-University Jena, Jena 07737, Germany. FAU - Harving, Niels AU - Harving N AD - Department of Urology, Aalborg University Hospital, Aalborg 9000, Denmark. FAU - Petersen, Astrid Christine AU - Petersen AC AD - Department of Pathology, Aalborg University Hospital, Aalborg 9000, Denmark. FAU - Calle, M Luz AU - Calle ML AD - Systems Biology Department, University of Vic, Vic, Barcelona 08500, Spain. FAU - Steyerberg, Ewout W AU - Steyerberg EW AD - Department of Public Health, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands. FAU - Beukers, Willemien AU - Beukers W AD - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands. FAU - van Kessel, Kim E M AU - van Kessel KEM AD - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands. FAU - Jensen, Jorgen Bjerggaard AU - Jensen JB AD - Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Pedersen, Jakob Skou AU - Pedersen JS AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden. FAU - Malats, Nuria AU - Malats N AD - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. FAU - Real, Francisco X AU - Real FX AD - Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08003, Spain. FAU - Zwarthoff, Ellen C AU - Zwarthoff EC AD - Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands. FAU - Orntoft, Torben Falck AU - Orntoft TF AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. FAU - Dyrskjot, Lars AU - Dyrskjot L AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: lars@clin.au.dk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160616 PL - United States TA - Cancer Cell JT - Cancer cell JID - 101130617 RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Long Noncoding) RN - EC 3.5.4.5 (APOBEC Deaminases) SB - IM CIN - Cancer Cell. 2016 Jul 11;30(1):1-3. doi: 10.1016/j.ccell.2016.06.012. PMID: 27411578 CIN - Eur Urol. 2016 Dec;70(6):1076. doi: 10.1016/j.eururo.2016.08.029. PMID: 27567209 CIN - Urol Oncol. 2017 Sep;35(9):576-577. doi: 10.1016/j.urolonc.2017.07.020. PMID: 28789929 MH - APOBEC Deaminases/genetics MH - Biomarkers, Tumor/*genetics MH - Cluster Analysis MH - Female MH - Gene Expression Profiling/*methods MH - Gene Expression Regulation, Neoplastic MH - Genetic Predisposition to Disease MH - Humans MH - Male MH - *Mutation MH - Neoplasm Staging MH - RNA, Long Noncoding/genetics MH - Sequence Analysis, RNA/*methods MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/*pathology EDAT- 2016/06/21 06:00 MHDA- 2017/03/25 06:00 CRDT- 2016/06/21 06:00 PHST- 2015/11/26 00:00 [received] PHST- 2016/02/18 00:00 [revised] PHST- 2016/05/13 00:00 [accepted] PHST- 2016/06/21 06:00 [entrez] PHST- 2016/06/21 06:00 [pubmed] PHST- 2017/03/25 06:00 [medline] AID - S1535-6108(16)30209-4 [pii] AID - 10.1016/j.ccell.2016.05.004 [doi] PST - ppublish SO - Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16. PMID- 27321168 OWN - NLM STAT- MEDLINE DCOM- 20170814 LR - 20180113 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 53 DP - 2016 Jul TI - Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response. PG - 35-40 LID - S0046-8177(16)00076-9 [pii] LID - 10.1016/j.humpath.2016.02.011 [doi] AB - We evaluated the spectrum of histologic changes associated with neoadjuvant chemotherapy (NAC) and compared them with those resulting from transurethral resection (TUR). Twenty-five patients who received NAC were divided based on both their preoperative clinical/radiographic findings (clinical stage, hydronephrosis, palpable mass) and the cystectomy (RC) findings into NAC respondents (advanced clinical stage and /=pT2and/or >/=pN1). In addition, 14 patients who received TUR alone and had 0.05). Moreover, it also could distinguish MIBC from NMIBC, with AUC of 0.787. For MIBC patients, high expression of cf-EZH2 mRNA associated with advanced stage and was an independent predictor of reduced disease free survival or overall survival. In conclusion, detection of cf-EZH2 mRNA in urine by nqPCR is a sensitive and noninvasive approach and may be used for diagnosis and prognosis prediction of MIBC. CI - (c) 2016 UICC. FAU - Zhang, Xin AU - Zhang X AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Zhang, Yanli AU - Zhang Y AD - Department of Clinical Laboratory, Traffic Hospital of Shandong Province, Jinan, Shandong Province, China. FAU - Liu, Xinfeng AU - Liu X AD - Department of Clinical Laboratory, Traffic Hospital of Shandong Province, Jinan, Shandong Province, China. FAU - Liu, Tong AU - Liu T AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Li, Peilong AU - Li P AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Wang, Chuanxin AU - Wang C AUID- ORCID: 0000-0002-3796-6293 AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160628 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (RNA, Messenger) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) SB - IM MH - Aged MH - Aged, 80 and over MH - Case-Control Studies MH - Enhancer of Zeste Homolog 2 Protein/*genetics MH - Female MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Staging MH - RNA, Messenger/genetics/*urine MH - Real-Time Polymerase Chain Reaction/methods MH - Reproducibility of Results MH - Urinary Bladder Neoplasms/enzymology/genetics/pathology/*urine OTO - NOTNLM OT - EZH2 mRNA OT - bladder cancer OT - cell-free OT - urine EDAT- 2016/06/15 06:00 MHDA- 2017/06/10 06:00 CRDT- 2016/06/15 06:00 PHST- 2016/02/18 00:00 [received] PHST- 2016/05/23 00:00 [revised] PHST- 2016/06/01 00:00 [accepted] PHST- 2016/06/15 06:00 [entrez] PHST- 2016/06/15 06:00 [pubmed] PHST- 2017/06/10 06:00 [medline] AID - 10.1002/ijc.30230 [doi] PST - ppublish SO - Int J Cancer. 2016 Oct 15;139(8):1830-8. doi: 10.1002/ijc.30230. Epub 2016 Jun 28. PMID- 27300339 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20260518 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 2 DP - 2017 Feb TI - Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. PG - 245-250 LID - 10.1007/s00345-016-1877-4 [doi] AB - PURPOSE: Results of a retrospective single-institution study recently suggested improved prognostic outcomes in patients undergoing photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) prior to radical cystectomy (RC). We sought to validate the prognostic influence of PDD-assisted TURBT on survival after RC by relying on a multi-institutional dataset. METHODS: To provide a homogeneous study population, patients with organ metastasis at the time of RC and/or after neoadjuvant chemotherapy were excluded from analysis, which resulted in overall 549 bladder cancer (BC) patients from 18 centers of the Prospective Multicenter Radical Cystectomy Series 2011 (PROMETRICS 2011). To evaluate the influence of PDD conducted during primary or final TURBT on cancer-specific mortality (CSM) and overall mortality (OM) after RC, bootstrap-corrected multivariate Cox proportional-hazards regression models were applied (median follow-up: 25 months; IQR: 19-30). Sensitivity analyses were performed for both patients with pure urothelial carcinoma and patients undergoing one single TURBT only. RESULTS: In 88 (16.0 %) and 100 (18.2 %) patients, PDD was used in primary and final TURBTs, respectively. In 335 (61.0 %) patients, a single TURBT was performed prior to RC; in 194 patients (35.3 %), TURBT had been performed in a different center. CSM and OM rates at 3 years were 32 and 40 %, respectively. Use of PDD during primary or final TURBT was no independent predictor of CSM or OM. These results were internally valid and were confirmed in sensitivity analyses. CONCLUSIONS: PDD utilization during TURBT prior to RC does not independently impact the prognosis of BC patients after RC. FAU - May, Matthias AU - May M AD - Department of Urology, St. Elisabeth-Hospital Straubing, St. Elisabeth-Strasse 23, 94315, Straubing, Germany. matthias.may@klinikum-straubing.de. FAU - Fritsche, Hans-Martin AU - Fritsche HM AD - Department of Urology, Caritas-Hospital St. Josef, University of Regensburg, Regensburg, Germany. FAU - Vetterlein, Malte W AU - Vetterlein MW AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bastian, Patrick J AU - Bastian PJ AD - Department of Urology, Marien-Hospital Dusseldorf, Dusseldorf, Germany. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, Caritas-Hospital St. Josef, University of Regensburg, Regensburg, Germany. FAU - Nuhn, Philipp AU - Nuhn P AD - Department of Urology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Stief, Christian G AU - Stief CG AD - Department of Urology, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Hohenfellner, Markus AU - Hohenfellner M AD - Department of Urology, University of Heidelberg, Heidelberg, Germany. FAU - Wirth, Manfred P AU - Wirth MP AD - Department of Urology, University Hospital 'Carl Gustav Carus', Dresden University of Technology, Dresden, Germany. FAU - Novotny, Vladimir AU - Novotny V AD - Department of Urology, University Hospital 'Carl Gustav Carus', Dresden University of Technology, Dresden, Germany. FAU - Hakenberg, Oliver W AU - Hakenberg OW AD - Department of Urology, University of Rostock, Rostock, Germany. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology, Marien-Hospital Herne, Ruhr-University of Bochum, Herne, Germany. FAU - Gilfrich, Christian AU - Gilfrich C AD - Department of Urology, St. Elisabeth-Hospital Straubing, St. Elisabeth-Strasse 23, 94315, Straubing, Germany. FAU - Bolenz, Christian AU - Bolenz C AD - Department of Urology, University of Ulm, Ulm, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas-Hospital St. Josef, University of Regensburg, Regensburg, Germany. FAU - Brookman-May, Sabine D AU - Brookman-May SD AD - Department of Urology, Ludwig-Maximilians-University Munich, Munich, Germany. CN - PROMETRICS 2011 Research Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160614 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Optical Imaging MH - Prognosis MH - Prospective Studies MH - Surgery, Computer-Assisted MH - Survival Rate MH - Urethra MH - Urinary Bladder Neoplasms/diagnostic imaging/*mortality/*surgery OTO - NOTNLM OT - Cystectomy OT - Hexaminolevulinate OT - Photodynamic diagnosis OT - Prognosis OT - Survival OT - Transurethral resection of bladder tumor OT - Urinary bladder neoplasms FIR - Bartsch, G IR - Bartsch G FIR - Bolenz, C IR - Bolenz C FIR - Buchner, A IR - Buchner A FIR - Chun, F K IR - Chun FK FIR - Dahlem, R IR - Dahlem R FIR - Durschnabel, M IR - Durschnabel M FIR - Ellinger, J IR - Ellinger J FIR - Froehner, M IR - Froehner M FIR - Georgieva, G IR - Georgieva G FIR - Gorduk, M IR - Gorduk M FIR - Grimm, M O IR - Grimm MO FIR - Grimm, T IR - Grimm T FIR - Hadaschik, B IR - Hadaschik B FIR - Haferkamp, A IR - Haferkamp A FIR - Hartmann, F IR - Hartmann F FIR - Herrmann, E IR - Herrmann E FIR - Janetschek, G IR - Janetschek G FIR - Karl, A IR - Karl A FIR - Keck, B IR - Keck B FIR - Kraischits, N IR - Kraischits N FIR - Krausse, A IR - Krausse A FIR - Lusuardi, L IR - Lusuardi L FIR - Martini, T IR - Martini T FIR - Mayr, R IR - Mayr R FIR - Michel, M S IR - Michel MS FIR - Moritz, R IR - Moritz R FIR - Muller, S C IR - Muller SC FIR - Nuhn, P IR - Nuhn P FIR - Pahernik, S IR - Pahernik S FIR - Palisaar, R J IR - Palisaar RJ FIR - Ponholzer, A IR - Ponholzer A FIR - Protzel, C IR - Protzel C FIR - Pycha, A IR - Pycha A FIR - Rink, M IR - Rink M FIR - Roghmann, F IR - Roghmann F FIR - Roigas, J IR - Roigas J FIR - Schmid, M IR - Schmid M FIR - Schramek, P IR - Schramek P FIR - Seitz, C IR - Seitz C FIR - Shariat, S F IR - Shariat SF FIR - Sikic, D IR - Sikic D FIR - Syring, I IR - Syring I FIR - Vallo, S IR - Vallo S FIR - Wagenlehner, F M IR - Wagenlehner FM FIR - Wullich, B IR - Wullich B EDAT- 2016/06/15 06:00 MHDA- 2017/04/19 06:00 CRDT- 2016/06/15 06:00 PHST- 2016/04/30 00:00 [received] PHST- 2016/06/06 00:00 [accepted] PHST- 2016/06/15 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] PHST- 2016/06/15 06:00 [entrez] AID - 10.1007/s00345-016-1877-4 [pii] AID - 10.1007/s00345-016-1877-4 [doi] PST - ppublish SO - World J Urol. 2017 Feb;35(2):245-250. doi: 10.1007/s00345-016-1877-4. Epub 2016 Jun 14. PMID- 27283218 OWN - NLM STAT- MEDLINE DCOM- 20180104 LR - 20180228 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 10 DP - 2016 Oct TI - Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. PG - 432.e1-8 LID - S1078-1439(16)30059-X [pii] LID - 10.1016/j.urolonc.2016.05.008 [doi] AB - PURPOSE: To evaluate the prognostic relevance of different prostatic invasion patterns in pT4a urothelial carcinoma of the bladder (UCB) after radical cystectomy. MATERIALS AND METHODS: Our study comprised a total of 358 men with pT4a UCB. Patients were divided in 2 groups-group A with stromal infiltration of the prostate via the prostatic urethra with additional muscle-invasive UCB (n = 121, 33.8%) and group B with continuous infiltration of the prostate through the entire bladder wall (n = 237, 66.2%). The effect of age, tumor grade, carcinoma in situ, lymphovascular invasion, soft tissue surgical margin, lymph node metastases, administration of adjuvant chemotherapy, and prostatic invasion patterns on cancer-specific mortality (CSM) was evaluated using competing-risk regression analysis. Decision curve analysis was used to evaluate the net benefit of including the variable invasion pattern within our model. RESULTS: The estimated 5-year CSM-rates for group A and B were 50.1% and 66.0%, respectively. In multivariable competing-risk analysis, lymph node metastases (hazard ratio [HR] = 1.73, P<0.001), lymphovascular invasion (HR = 1.62, P = 0.0023), soft tissue surgical margin (HR = 1.49, P = 0.026), absence of adjuvant chemotherapy (HR = 2.11, P<0.001), and tumor infiltration of the prostate by continuous infiltration of the entire bladder wall (HR = 1.37, P = 0.044) were significantly associated with a higher risk for CSM. Decision curve analysis showed a net benefit of our model including the variable invasion pattern. CONCLUSIONS: Continuous infiltration of the prostate through the entire bladder wall showed an adverse effect on CSM. Besides including these patients into clinical trials for an adjuvant therapy, we recommend including prostatic invasion patterns in predictive models in pT4a UCB in men. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Vallo, Stefan AU - Vallo S AD - Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany. Electronic address: stefanvallo@gmx.de. FAU - Gilfrich, Christian AU - Gilfrich C AD - Department of Urology, St. Elisabeth Medical Center Straubing, Straubing, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Volkmer, Bjorn AU - Volkmer B AD - Department of Urology, Kassel Medical Center, Kassel, Germany. FAU - Boehm, Katharina AU - Boehm K AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Chun, Felix K AU - Chun FK AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Roghmann, Florian AU - Roghmann F AD - Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Novotny, Vladimir AU - Novotny V AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden Technical University, Dresden, Germany. FAU - Mani, Jens AU - Mani J AD - Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany. FAU - Brisuda, Antonin AU - Brisuda A AD - Department of Urology, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic. FAU - Mayr, Roman AU - Mayr R AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Urology, General Hospital of Bolzano, Bolzano, Italy. FAU - Stredele, Regina AU - Stredele R AD - Department of Urology, Kassel Medical Center, Kassel, Germany. FAU - Noldus, Joachim AU - Noldus J AD - Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. FAU - Schnabel, Marco AU - Schnabel M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - May, Matthias AU - May M AD - Department of Urology, St. Elisabeth Medical Center Straubing, Straubing, Germany. FAU - Fritsche, Hans-Martin AU - Fritsche HM AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. FAU - Pycha, Armin AU - Pycha A AD - Department of Urology, General Hospital of Bolzano, Bolzano, Italy. FAU - Martini, Thomas AU - Martini T AD - Department of Urology, General Hospital of Bolzano, Bolzano, Italy; Department of Urology, University Hospital Mannheim, Mannheim, Germany. FAU - Wirth, Manfred AU - Wirth M AD - Department of Urology, University Hospital Carl Gustav Carus, Dresden Technical University, Dresden, Germany. FAU - Roigas, Jan AU - Roigas J AD - Department of Urology, Vivantes Medical Center Im Friedrichshain and Am Urban, Berlin, Germany. FAU - Bastian, Patrick J AU - Bastian PJ AD - Department of Urology, Marien Hospital Dusseldorf, Dusseldorf, Germany. FAU - Nuhn, Philipp AU - Nuhn P AD - Department of Urology, University Hospital Mannheim, Mannheim, Germany. FAU - Dahlem, Roland AU - Dahlem R AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Haferkamp, Axel AU - Haferkamp A AD - Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Comparative Study PT - Journal Article DEP - 20160606 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Blood Vessels/pathology MH - Carcinoma, Transitional Cell/mortality/*pathology/secondary/therapy MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Humans MH - Lymphatic Metastasis MH - Lymphatic Vessels/pathology MH - Male MH - Margins of Excision MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prostate/*pathology MH - Risk Factors MH - Survival Rate MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/mortality/*pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - Mortality OT - Outcome OT - Prostatic invasion pattern OT - Radical cystectomy EDAT- 2016/06/11 06:00 MHDA- 2018/01/05 06:00 CRDT- 2016/06/11 06:00 PHST- 2015/11/01 00:00 [received] PHST- 2016/04/27 00:00 [revised] PHST- 2016/05/04 00:00 [accepted] PHST- 2016/06/11 06:00 [entrez] PHST- 2016/06/11 06:00 [pubmed] PHST- 2018/01/05 06:00 [medline] AID - S1078-1439(16)30059-X [pii] AID - 10.1016/j.urolonc.2016.05.008 [doi] PST - ppublish SO - Urol Oncol. 2016 Oct;34(10):432.e1-8. doi: 10.1016/j.urolonc.2016.05.008. Epub 2016 Jun 6. PMID- 27280069 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160609 LR - 20220408 IS - 2167-8359 (Print) IS - 2167-8359 (Electronic) IS - 2167-8359 (Linking) VI - 4 DP - 2016 TI - Long-term oncologic outcomes of laparoscopic nephroureterectomy versus open nephroureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis. PG - e2063 LID - 10.7717/peerj.2063 [doi] LID - e2063 AB - Background. Several factors have been validated as predictors of disease recurrence in upper tract urothelial carcinoma. However, the oncological outcomes between different surgical approaches (open nephroureterectomy versus laparoscopic nephroureterectomy, ONU vs LNU) remain controversial. Therefore, we performed a meta-analysis to evaluate the oncological outcomes associated with different surgical approaches. Methods. We conducted an electronic search of the PubMed, Embase, ISI Web of Knowledge and Cochrane Library electronic databases through November 2015, screened the retrieved references, collected and evaluated the relevant information. We extracted and synthesized the corresponding hazard ratios (HRs) and 95% confidence intervals (95% CI) using Stata 13. Results. Twenty-one observational studies were eligible for inclusion in the meta-analysis. The results of the meta-analysis showed no differences in the intravesical recurrence-free survival (IRFS), unspecified recurrence-free survival (UnRFS) and overall survival (OS) between LNUandONU. However, improvements in the extravesical recurrence free survival (ExRFS) and cancer specific survival (CSS) were observed inLNU. The pooled hazard ratios were 1.05 (95% CI [0.92-1.18]) for IRFS, 0.80 (95% CI [0.64-0.96]) for ExRFS, 1.10 (95% CI [0.93-1.28]) for UnRFS, 0.91 (95% CI [0.66-1.17]) for OS and 0.79 (95% CI [0.68-0.91]) for CSS. Conclusion. Based on current evidence, LNU could provide equivalent prognostic effects for upper tract urothelial carcinoma, and had better oncological control of ExRFS and CSS compared to ONU. However, considering all eligible studies with the intrinsic bias of retrospective study design, the results should be interpreted with caution. Prospective randomized trials are needed to verify these results. FAU - Zhang, Su AU - Zhang S AD - Department of Urology, Lanzhou University Second Hospital , Lan Zhou , China. FAU - Luo, You AU - Luo Y AD - Department of Urology, Lanzhou University Second Hospital , Lan Zhou , China. FAU - Wang, Cheng AU - Wang C AD - Department of Urology, Lanzhou University Second Hospital , Lan Zhou , China. FAU - Fu, Sheng-Jun AU - Fu SJ AD - Department of Urology, Lanzhou University Second Hospital , Lan Zhou , China. FAU - Yang, Li AU - Yang L AD - Department of Urology, Lanzhou University Second Hospital , Lan Zhou , China. LA - eng PT - Journal Article DEP - 20160531 PL - United States TA - PeerJ JT - PeerJ JID - 101603425 PMC - PMC4893337 OTO - NOTNLM OT - Laparoscopic nephroureterectomy OT - Meta-analysis OT - Open nephroureterectomy OT - Upper tract urothelial carcinoma COIS- The authors declare there are no competing interests. EDAT- 2016/06/10 06:00 MHDA- 2016/06/10 06:01 PMCR- 2016/05/31 CRDT- 2016/06/10 06:00 PHST- 2016/02/20 00:00 [received] PHST- 2016/05/01 00:00 [accepted] PHST- 2016/06/10 06:00 [entrez] PHST- 2016/06/10 06:00 [pubmed] PHST- 2016/06/10 06:01 [medline] PHST- 2016/05/31 00:00 [pmc-release] AID - 2063 [pii] AID - 10.7717/peerj.2063 [doi] PST - epublish SO - PeerJ. 2016 May 31;4:e2063. doi: 10.7717/peerj.2063. eCollection 2016. PMID- 27279531 OWN - NLM STAT- MEDLINE DCOM- 20180720 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Jun 9 TI - Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer. PG - 27586 LID - 10.1038/srep27586 [doi] LID - 27586 AB - Lymphovascular invasion (LVI) is the primary and essential step in the systemic dissemination of cancer cells. The aim of our study was to assess the independent prognostic role of LVI for pT1 urothelial carcinoma with squamous differentiation in bladder cancer. We retrospectively analyzed the clinical and pathological information of 206 patients diagnosed pT1 urothelial carcinoma with squamous differentiation. Of the 206 patients, LVI was detected in 57 (27.6%) patients. The 5 year cancer specific survival (CSS) rates were 87.2% in LVI (-) and 52.4% in LVI (+) (p < 0.001). According to univariate analysis, tumor multiplicity, tumor size, recurrence and LVI were the prognostic factors associated with CSS. Additionally, tumor size and LVI significantly influenced the CSS in multivariate analysis. TURBT had shorter median CSS than RC in recurred patients with LVI (+). Our study suggested that LVI is an important predictor for survival of pT1 urothelial carcinoma with squamous differentiation. LVI positive status and tumor size >/=3 cm led to a higher risk of death. RC should be routinely performed in recurred LVI (+) bladder cancer patients of pT1 urothelial carcinoma with squamous differentiation. FAU - Li, Gang AU - Li G AD - Department of Urology, The second hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China. FAU - Song, Hualin AU - Song H AD - Department of Urology, The second hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China. FAU - Wang, Jiaxin AU - Wang J AD - Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. FAU - Bao, Yali AU - Bao Y AD - Department of Pathology, The second Hospital of Tianjin Medical University, Tianjin, 300211, China. FAU - Niu, Yuanjie AU - Niu Y AD - Department of Urology, The second hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160609 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology MH - Cell Differentiation MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis/*diagnosis/*pathology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Proportional Hazards Models MH - Recurrence MH - Retrospective Studies MH - Risk MH - Urinary Bladder Neoplasms/*diagnosis/*pathology MH - Urothelium/*pathology PMC - PMC4899777 EDAT- 2016/06/10 06:00 MHDA- 2018/07/22 06:00 PMCR- 2016/06/09 CRDT- 2016/06/10 06:00 PHST- 2016/02/10 00:00 [received] PHST- 2016/05/20 00:00 [accepted] PHST- 2016/06/10 06:00 [entrez] PHST- 2016/06/10 06:00 [pubmed] PHST- 2018/07/22 06:00 [medline] PHST- 2016/06/09 00:00 [pmc-release] AID - srep27586 [pii] AID - 10.1038/srep27586 [doi] PST - epublish SO - Sci Rep. 2016 Jun 9;6:27586. doi: 10.1038/srep27586. PMID- 27269944 OWN - NLM STAT- MEDLINE DCOM- 20170912 LR - 20220311 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 34 IP - 29 DP - 2016 Oct 10 TI - Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. PG - 3529-3536 LID - 10.1200/JCO.2016.66.7352 [doi] AB - Purpose Evidence from studies of other malignancies has indicated that aggressive local treatment (LT), even in the presence of metastatic disease, is beneficial. Against a backdrop of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentation, we hypothesized that high-intensity LT of primary tumor burden, defined as the receipt of radical cystectomy or >/= 50 Gy of radiation therapy delivered to the bladder, affects overall survival (OS). Patients and Methods We identified 3,753 patients within the National Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versus conservative LT for primary mUCB. Patients who received no LT, transurethral resection of the bladder tumor alone, or < 50 Gy of radiation therapy delivered to the bladder were included in the conservative LT group. Inverse probability of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox regression analyses were used to compare OS of patients who received high-intensity versus conservative LT. Results Overall, 297 (7.91%) and 3,456 (92.09%) patients with mUCB received high-intensity and conservative LT, respectively. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer in the high-intensity LT group than in the conservative LT group (14.92 [interquartile range, 9.82 to 30.72] v 9.95 [interquartile range, 5.29 to 17.08] months, respectively; P < .001). Furthermore, in IPTW-adjusted Cox regression analysis, high-intensity LT was associated with a significant OS benefit (hazard ratio, 0.56; 95% CI, 0.48 to 0.65; P < .001). Conclusion We report an OS benefit for individuals with mUCB treated with high-intensity versus conservative LT. Although the findings are subject to the usual biases related to the observational study design, these preliminary data warrant further consideration in randomized controlled trials, particularly given the poor prognosis associated with mUCB. FAU - Seisen, Thomas AU - Seisen T AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Sun, Maxine AU - Sun M AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Leow, Jeffrey J AU - Leow JJ AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Preston, Mark A AU - Preston MA AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Cole, Alexander P AU - Cole AP AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Gelpi-Hammerschmidt, Francisco AU - Gelpi-Hammerschmidt F AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Hanna, Nawar AU - Hanna N AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Meyer, Christian P AU - Meyer CP AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Kibel, Adam S AU - Kibel AS AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Lipsitz, Stuart R AU - Lipsitz SR AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Nguyen, Paul L AU - Nguyen PL AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Choueiri, Toni K AU - Choueiri TK AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. FAU - Trinh, Quoc-Dien AU - Trinh QD AD - Thomas Seisen, Maxine Sun, Jeffrey J. Leow, Mark A. Preston, Alexander P. Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P. Meyer, Adam S. Kibel, Stuart R. Lipsitz, Paul L. Nguyen, and Quoc-Dien Trinh, Brigham and Women's Hospital; and Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0 (Antineoplastic Agents) SB - IM CIN - Eur Urol. 2016 Nov;70(5):894. doi: 10.1016/j.eururo.2016.07.048. PMID: 27497763 CIN - Eur Urol. 2016 Nov;70(5):893. doi: 10.1016/j.eururo.2016.07.040. PMID: 27498598 CIN - J Urol. 2018 Jun;199(6):1396. doi: 10.1016/j.juro.2018.03.018. PMID: 29783592 MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma, Transitional Cell/secondary/*therapy MH - Chemoradiotherapy/methods MH - *Cystectomy MH - Cytoreduction Surgical Procedures MH - Databases, Factual MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Propensity Score MH - Proportional Hazards Models MH - Radiotherapy Dosage MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*therapy EDAT- 2016/06/09 06:00 MHDA- 2017/09/13 06:00 CRDT- 2016/06/09 06:00 PHST- 2016/06/09 06:00 [pubmed] PHST- 2017/09/13 06:00 [medline] PHST- 2016/06/09 06:00 [entrez] AID - JCO.2016.66.7352 [pii] AID - 10.1200/JCO.2016.66.7352 [doi] PST - ppublish SO - J Clin Oncol. 2016 Oct 10;34(29):3529-3536. doi: 10.1200/JCO.2016.66.7352. PMID- 27268930 OWN - NLM STAT- MEDLINE DCOM- 20190111 LR - 20220311 IS - 0028-2685 (Print) IS - 0028-2685 (Linking) VI - 63 IP - 4 DP - 2016 TI - Stage of bladder cancer in Central Europe - Polish perspective. PG - 642-7 LID - 10.4149/neo_2016_420 [doi] AB - Mortality rate from bladder cancer in Europe is the highest in its Central Region. This study is an attempt to find underlying factors by proper characterisation of large cohort of Polish patients with bladder cancer.This is a multicentre study enrolling 1360 consecutive patients diagnosed with primary urothelial carcinoma of the bladder in years 2012-2013 in Poland. All patients underwent transurethral resection of the bladder tumor. Data on staging and grading of all cancers were collected, as well as several demographic and clinical factors were tested for the association with muscle invasiveness of the cancer.Mean age of the cohort was 69.6 years, male to female ratio was 3:1. Bladder cancer stage Ta, T1 and muscle-invasive (MIBC) was diagnosed in 533 (39.2%), 516 (37.9%) and 296 (21.8%) patients, respectively. Patients with MIBC were older (73 vs. 68 years, p<0.05), had lower body mass index (25.4 vs. 26.5 kg/m2, p<0.05), lower haemoglobin concentration (12.2 vs. 13.4 mg/l, p<0.05), longer history of haematuria (86.2 vs. 74.4 days) and longer time interval from first symptom to diagnosis (118.0 vs. 88.2 days), compared to patients with Ta and T1 tumors.High mortality rate from bladder cancer in Central Europe can result from very high incidence of high-risk T1 tumors and high prevalence of prognostic factors of poor survival. FAU - Poletajew, S AU - Poletajew S FAU - Biernacki, R AU - Biernacki R FAU - Buraczynski, P AU - Buraczynski P FAU - Chojnacki, J AU - Chojnacki J FAU - Czarniecki, S AU - Czarniecki S FAU - Gajewska, D AU - Gajewska D FAU - Pohaba, T AU - Pohaba T FAU - Sondka, J AU - Sondka J FAU - Skrzypczyk, M AU - Skrzypczyk M FAU - Suchojad, T AU - Suchojad T FAU - Wojtkowiak, D AU - Wojtkowiak D FAU - Zaforemski, B AU - Zaforemski B FAU - Zapala, L AU - Zapala L FAU - Zemla, A AU - Zemla A FAU - Radziszewski, P AU - Radziszewski P LA - eng PT - Journal Article PL - Slovakia TA - Neoplasma JT - Neoplasma JID - 0377266 SB - IM MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Neoplasm Invasiveness/pathology MH - *Neoplasm Staging MH - Poland MH - Sex Factors MH - Urinary Bladder Neoplasms/mortality/*pathology OTO - NOTNLM OT - Central Europe. OT - bladder cancer OT - cancer stage OT - diagnosis OT - prognosis EDAT- 2016/06/09 06:00 MHDA- 2019/01/12 06:00 CRDT- 2016/06/09 06:00 PHST- 2016/06/09 06:00 [entrez] PHST- 2016/06/09 06:00 [pubmed] PHST- 2019/01/12 06:00 [medline] AID - 10.4149/neo_2016_420 [doi] PST - ppublish SO - Neoplasma. 2016;63(4):642-7. doi: 10.4149/neo_2016_420. PMID- 27267922 OWN - NLM STAT- MEDLINE DCOM- 20170124 LR - 20260127 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 16 IP - 1 DP - 2016 Jun 7 TI - Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. PG - 24 LID - 10.1186/s12894-016-0142-x [doi] LID - 24 AB - BACKGROUND: Intestinal metaplasia of the bladder is an uncommon glandular proliferation. We examined a large series of intestinal metaplasia for the clinicopathological features and discuss the significance of this lesion. METHODS: All cases of intestinal metaplasia diagnosed in our institution between 1990 and 2014 were retrospectively reviewed. Patients with a history of urothelial carcinoma or concurrent adenocarcinoma were excluded. Patient characteristics, pathological features, and follow-up outcomes were obtained. RESULTS: We identified 89 patients with intestinal metaplasia during this period. Sixty seven were men and 22 were women. Mean age at diagnosis was 57 years (range 23-81). Common presenting complaints included haematuria (73 cases), mucosuria (13 cases), and irritative voiding symptoms (seven cases). The majority of intestinal metaplasias located on or near the trigone (67 cases). Eighty-two patients underwent transurethral resection of their lesions. Partial cystectomy was performed in the remaining seven patients. The mean follow-up of 78 patients was 105 months (range 6-255). One case of bladder adenocarcinoma was indentified 6 months later. The initial histologic findings had revealed intestinal metaplasia with severe dysplasia. Four patients presented recurrence during the follow-up, and this occurred 9, 13, 17 and 24 months after the surgery. CONCLUSIONS: Although intestinal metaplasia can be treated effectively by transurethral resection in most cases, its potential malignancy need to be taken into consideration after the evidence of recurrences and its association with bladder adenocarcinoma. Therefore, it is necessary to perform close surveillance following the surgery, particularly in patients with dysplastic changes. FAU - Xin, Zhixiang AU - Xin Z AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. FAU - Zhao, Chenhui AU - Zhao C AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. FAU - Huang, Tao AU - Huang T AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. FAU - Zhang, Zhaohui AU - Zhang Z AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. FAU - Chu, Chenlong AU - Chu C AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. FAU - Lu, Caifeng AU - Lu C AD - Department of Pathology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, 200020, China. FAU - Wu, Min AU - Wu M AD - Department of Pathology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, 200020, China. FAU - Zhou, Wenlong AU - Zhou W AD - Department of Urology, Rui Jin Hospital Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, No.149, South Chongqing Road, Shanghai, 200020, China. zhouwenlong6063@126.com. LA - eng PT - Journal Article DEP - 20160607 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Adult MH - Age Distribution MH - Aged MH - Aged, 80 and over MH - China/epidemiology MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Metaplasia/pathology MH - Middle Aged MH - Precancerous Conditions/epidemiology/*pathology/*surgery MH - Prevalence MH - Retrospective Studies MH - Risk Factors MH - Sex Distribution MH - Treatment Outcome MH - Urinary Bladder/*pathology/*surgery MH - Urinary Bladder Neoplasms/epidemiology/*pathology/*surgery PMC - PMC4895895 OTO - NOTNLM OT - Bladder neoplasm OT - Cancer risk OT - Intestinal metaplasia OT - Transurethral resection EDAT- 2016/06/09 06:00 MHDA- 2017/01/25 06:00 PMCR- 2016/06/07 CRDT- 2016/06/09 06:00 PHST- 2016/02/13 00:00 [received] PHST- 2016/05/22 00:00 [accepted] PHST- 2016/06/09 06:00 [entrez] PHST- 2016/06/09 06:00 [pubmed] PHST- 2017/01/25 06:00 [medline] PHST- 2016/06/07 00:00 [pmc-release] AID - 10.1186/s12894-016-0142-x [pii] AID - 142 [pii] AID - 10.1186/s12894-016-0142-x [doi] PST - epublish SO - BMC Urol. 2016 Jun 7;16(1):24. doi: 10.1186/s12894-016-0142-x. PMID- 27267320 OWN - NLM STAT- MEDLINE DCOM- 20180806 LR - 20220321 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 196 IP - 4 DP - 2016 Oct TI - lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence. PG - 1270-8 LID - S0022-5347(16)30559-6 [pii] LID - 10.1016/j.juro.2016.05.107 [doi] AB - PURPOSE: While lncRNAs (long noncoding RNAs) have been shown to have critical regulatory roles in cancer biology, the biological functions and prognostic values in nonmuscle invasive bladder cancer remain largely unknown. We identified a lncRNA termed lncRNA-UNMIBC (up-regulated in nonmuscle invasive bladder cancer) and evaluated its prognostic value in patients with primary nonmuscle invasive bladder cancer. MATERIALS AND METHODS: We analyzed the expression of lncRNA-UNMIBC in the tissues of 75 cases of primary nonmuscle invasive bladder cancer and adjacent normal mucosa by quantitative real-time polymerase chain reaction. Data were compared with clinicopathological parameters using the Kaplan-Meier method and multivariate Cox regression analysis. The functions of lncRNA-UNMIBC were assessed by silencing the lncRNA in vitro and in vivo. RNA immunoprecipitation was performed to assay whether lncRNA-UNMIBC could be physically associated with EZH2 (enhancer of zeste homolog 2) and SUZ12 (SUZ12 polycomb repressive complex 2 subunit), which are core components of PRC2 (polycomb repressive complex 2). Chromatin immunoprecipitation was done to examine histone modification status. RESULTS: The expression level of lncRNA-UNMIBC was up-regulated in the tissues of 45 cases of primary nonmuscle invasive bladder cancer compared with normal mucosa. Kaplan-Meier estimates showed that lncRNA-UNMIBC expression was significantly associated with recurrence (log rank test p = 0.0151). We also found that lncRNA-UNMIBC had a key role in G0/G1 arrest. Furthermore, RNA and chromatin immunoprecipitation assays demonstrated that lncRNA-UNMIBC was physically associated with EZH2 and SUZ12, leading to an altered histone H3 lysine 27 methylation status of target genes. CONCLUSIONS: These findings indicate that lncRNA-UNMIBC can facilitate tumor growth and may act as a negative prognostic factor of recurrence. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Zhang, Simin AU - Zhang S AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Zhong, Guangzheng AU - Zhong G AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - He, Wang AU - He W AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Yu, Hao AU - Yu H AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. FAU - Huang, Jian AU - Huang J AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. Electronic address: urolhj@sina.com. FAU - Lin, Tianxin AU - Lin T AD - Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. Electronic address: tianxinl@sina.com. LA - eng PT - Journal Article DEP - 20160605 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (RNA, Long Noncoding) RN - 0 (RNA, Neoplasm) SB - IM MH - Aged MH - Animals MH - Blotting, Western MH - Carcinoma, Transitional Cell/*genetics/metabolism/pathology MH - Cell Line, Tumor MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Mice MH - Mice, Inbred NOD MH - Neoplasm Invasiveness MH - *Neoplasms, Experimental MH - Prognosis MH - RNA, Long Noncoding/biosynthesis/*genetics MH - RNA, Neoplasm/*genetics MH - Real-Time Polymerase Chain Reaction MH - Urinary Bladder Neoplasms/*genetics/metabolism/pathology OTO - NOTNLM OT - RNA, long noncoding OT - biomarkers, tumor OT - neoplasm recurrence, local OT - prognosis OT - urinary bladder neoplasms EDAT- 2016/06/09 06:00 MHDA- 2018/08/07 06:00 CRDT- 2016/06/09 06:00 PHST- 2016/05/20 00:00 [accepted] PHST- 2016/06/09 06:00 [entrez] PHST- 2016/06/09 06:00 [pubmed] PHST- 2018/08/07 06:00 [medline] AID - S0022-5347(16)30559-6 [pii] AID - 10.1016/j.juro.2016.05.107 [doi] PST - ppublish SO - J Urol. 2016 Oct;196(4):1270-8. doi: 10.1016/j.juro.2016.05.107. Epub 2016 Jun 5. PMID- 27262370 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 6 DP - 2016 Dec TI - Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up. PG - e609-e615 LID - S1558-7673(16)30107-0 [pii] LID - 10.1016/j.clgc.2016.04.017 [doi] AB - INTRODUCTION: Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting on the pathologic features in detail, cancer characteristics, and survival. MATERIALS AND METHODS: We retrospectively reviewed the data from patients who had undergone surgery for UTUC from 1983 to 2013. The tumors were staged according to the 1997 TNM classification and the 3-tiered World Health Organization grading system. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. RESULTS: A total of 305 patients were eligible for analysis. The 5-year CSS for grade 1, 2, and 3 was 88%, 84%, and 60%, respectively. The CSS for stage pT1, T2, T3, and T4 was 82%, 70%, 62%, and 0%, respectively. On univariate analysis, tumor stage, tumor grade, positive lymph node status, and micropapillary invasion had adverse effects on survival (P = .006, P = .045, P = .01, and P = .005, respectively). On multivariate analysis, only stage and micropapillary variant maintained significance (P = .01). Multicentricity and tumor location affected CSS in the early follow-up period but did not in the late follow-up period. Neither carcinoma in situ nor adverse pathologic variants affected survival. CONCLUSION: The tumor stage and presence of a micropapillary variant are of paramount prognostic significance for survival in patients with UTUC. The tumor grade and lymph node status are also good predictors. In our series, multifocality and tumor location affected early and mid-term survival with no significant effects on late survival. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Elawdy, Mohamed Mohamed AU - Elawdy MM AD - Department of Urology, Ministry of Health, Ibri, Sultanate of Oman. Electronic address: mmelawdy@gmail.com. FAU - Taha, Diaa E AU - Taha DE AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Elbaset, Mohamed A AU - Elbaset MA AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Abouelkheir, Rasha T AU - Abouelkheir RT AD - Department of Radiology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. FAU - Osman, Yasser AU - Osman Y AD - Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20160505 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Follow-Up Studies MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Survival Analysis MH - Urologic Neoplasms/*pathology/*surgery MH - Urologic Surgical Procedures/methods OTO - NOTNLM OT - Kidney pelvic neoplasms OT - Survival OT - UTUC pathology OT - Ureteral neoplasms OT - Urologic neoplasms EDAT- 2016/06/06 06:00 MHDA- 2017/10/24 06:00 CRDT- 2016/06/06 06:00 PHST- 2016/02/18 00:00 [received] PHST- 2016/04/18 00:00 [revised] PHST- 2016/04/22 00:00 [accepted] PHST- 2016/06/06 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2016/06/06 06:00 [entrez] AID - S1558-7673(16)30107-0 [pii] AID - 10.1016/j.clgc.2016.04.017 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Dec;14(6):e609-e615. doi: 10.1016/j.clgc.2016.04.017. Epub 2016 May 5. PMID- 27259534 OWN - NLM STAT- MEDLINE DCOM- 20171030 LR - 20250529 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 DP - 2016 Jun 3 TI - Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. PG - 351 LID - 10.1186/s12885-016-2361-7 [doi] LID - 351 AB - BACKGROUND: We adapted Bayesian statistical learning strategies to the prognosis field to investigate if genome-wide common SNP improve the prediction ability of clinico-pathological prognosticators and applied it to non-muscle invasive bladder cancer (NMIBC) patients. METHODS: Adapted Bayesian sequential threshold models in combination with LASSO were applied to consider the time-to-event and the censoring nature of data. We studied 822 NMIBC patients followed-up >10 years. The study outcomes were time-to-first-recurrence and time-to-progression. The predictive ability of the models including up to 171,304 SNP and/or 6 clinico-pathological prognosticators was evaluated using AUC-ROC and determination coefficient. RESULTS: Clinico-pathological prognosticators explained a larger proportion of the time-to-first-recurrence (3.1 %) and time-to-progression (5.4 %) phenotypic variances than SNPs (1 and 0.01 %, respectively). Adding SNPs to the clinico-pathological-parameters model slightly improved the prediction of time-to-first-recurrence (up to 4 %). The prediction of time-to-progression using both clinico-pathological prognosticators and SNP did not improve. Heritability (h (2)) of both outcomes was <1 % in NMIBC. CONCLUSIONS: We adapted a Bayesian statistical learning method to deal with a large number of parameters in prognostic studies. Common SNPs showed a limited role in predicting NMIBC outcomes yielding a very low heritability for both outcomes. We report for the first time a heritability estimate for a disease outcome. Our method can be extended to other disease models. FAU - Lopez de Maturana, E AU - Lopez de Maturana E AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. FAU - Picornell, A AU - Picornell A AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. FAU - Masson-Lecomte, A AU - Masson-Lecomte A AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. FAU - Kogevinas, M AU - Kogevinas M AD - Centre for Research in Environmental Epidemiology (CREAL), Parc de Salut Mar, Barcelona, Spain. AD - CIBERESP, Madrid, Spain. FAU - Marquez, M AU - Marquez M AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. FAU - Carrato, A AU - Carrato A AD - Servicio de Oncologia, Hospital Universitario Ramon y Cajal, Madrid, and Servicio de Oncologia, Hospital Universitario de Elche, Elche, Spain. FAU - Tardon, A AU - Tardon A AD - Department of Preventive Medicine Universidad de Oviedo, Oviedo, Spain. AD - CIBERESP, Madrid, Spain. FAU - Lloreta, J AU - Lloreta J AD - Parc de Salut Mar and Departament of Pathology, Hospital del Mar - IMAS, Barcelona, Spain. FAU - Garcia-Closas, M AU - Garcia-Closas M AD - Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. FAU - Silverman, D AU - Silverman D AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, USA. FAU - Rothman, N AU - Rothman N AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, USA. FAU - Chanock, S AU - Chanock S AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, USA. FAU - Real, F X AU - Real FX AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, and Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Goddard, M E AU - Goddard ME AD - Biosciences Research Division, Department of Environment and Primary Industries, Agribio, and Department of Food and Agricultural Systems, University of Melbourne, Melbourne, Australia. FAU - Malats, N AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernandez, Almagro, 3, 28029, Madrid, Spain. nmalats@cnio.es. CN - SBC/EPICURO Study Investigators LA - eng GR - N02 CP011015/CP/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160603 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Area Under Curve MH - *Bayes Theorem MH - Biomarkers, Tumor/analysis MH - Carcinoma, Transitional Cell/genetics/*pathology MH - Disease Progression MH - Genotype MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/genetics/pathology MH - Polymorphism, Single Nucleotide MH - Predictive Value of Tests MH - Prognosis MH - ROC Curve MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/genetics/*pathology PMC - PMC4893282 OTO - NOTNLM OT - AUC-ROC OT - Bayesian LASSO OT - Bayesian regression OT - Bayesian statistical learning method OT - Bladder cancer outcome OT - Determination coefficient OT - Genome-wide common SNP OT - Illumina Infinium HumanHap 1 M array OT - Multimarker models OT - Predictive ability OT - Prognosis OT - Progression OT - Recurrence OT - heritability EDAT- 2016/06/05 06:00 MHDA- 2017/10/31 06:00 PMCR- 2016/06/03 CRDT- 2016/06/05 06:00 PHST- 2015/11/03 00:00 [received] PHST- 2016/05/12 00:00 [accepted] PHST- 2016/06/05 06:00 [entrez] PHST- 2016/06/05 06:00 [pubmed] PHST- 2017/10/31 06:00 [medline] PHST- 2016/06/03 00:00 [pmc-release] AID - 10.1186/s12885-016-2361-7 [pii] AID - 2361 [pii] AID - 10.1186/s12885-016-2361-7 [doi] PST - epublish SO - BMC Cancer. 2016 Jun 3;16:351. doi: 10.1186/s12885-016-2361-7. PMID- 27256177 OWN - NLM STAT- MEDLINE DCOM- 20170308 LR - 20181113 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 42 IP - 2 DP - 2016 Mar-Apr TI - Urothelial neoplasm of the bladder in childhood and adolescence: a rare disease. PG - 242-6 LID - 10.1590/S1677-5538.IBJU.2015.0200 [doi] AB - PURPOSE: Bladder tumors are rare in children and adolescents. For this reason, the diagnosis is sometimes delayed in pediatric patients. We aimed to describe the diagnosis, treatment, and follow-up methods of bladder urothelial neoplasms in children and adolescents. MATERIALS AND METHODS: We carried out a retrospective multicenter study involving patients who were treated between 2008 and 2014. Eleven patients aged younger than 18 years were enrolled in the study. In all the patients, a bladder tumor was diagnosed using ultrasonography and was treated through transurethral resection of the bladder (TURBT). RESULTS: Nine of the 11 patients (82%) were admitted with gross hematuria. The average delay in diagnosis was 3 months (range, 0-16 months) until the ultrasonographic diagnosis was performed from the first episodes of macroscopic hematuria. A single exophytic tumor (1-4cm) was present in each patient. The pathology of all patients was reported as superficial urothelial neoplasm: two with papilloma, one with papillary urothelial neoplasm of low malignant potential (PUNLMP), four with low grade pTa, and four with low grade pT1. No recurrence was observed during regular cystoscopic and ultrasonographic follow-up. CONCLUSIONS: Regardless of the presence of hematuria, bladder tumors in children are usually not considered because urothelial carcinoma in this population is extremely rare, which causes a delay in diagnosis. Fortunately, the disease has a good prognosis and recurrences are infrequent. Cystoscopy may be unnecessary in the follow-up of children with bladder tumors. We believe that ultrasonography is sufficient in follow-up. FAU - Polat, Haci AU - Polat H AD - Adiyaman University, Faculty of Medicine, Department of Urology, Adiyaman, Turkey. FAU - Utangac, Mehmet M AU - Utangac MM AD - Dicle University, Faculty of Medicine, Department of Urology, Diyarbakir, Turkey. FAU - Gulpinar, Murat T AU - Gulpinar MT AD - Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Urology, Canakkale, Turkey. FAU - Cift, Ali AU - Cift A AD - Adiyaman University, Faculty of Medicine, Department of Urology, Adiyaman, Turkey. FAU - Erdogdu, Ibrahim Halil AU - Erdogdu IH AD - Adiyaman University, Faculty of Medicine, Department of Medical Pathology, Adiyaman, Turkey. FAU - Turkcu, Gul AU - Turkcu G AD - Dicle University, Faculty of Medicine, Department of Medical Pathology, Diyarbakir, Turkey. LA - eng PT - Journal Article PT - Multicenter Study PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Adolescent MH - Age Factors MH - Carcinoma, Papillary/*pathology/*surgery MH - Carcinoma, Renal Cell/diagnostic imaging/*pathology/*surgery MH - Child MH - Cystoscopy/methods MH - Delayed Diagnosis MH - Female MH - Follow-Up Studies MH - Hematuria MH - Humans MH - Male MH - Rare Diseases MH - Retrospective Studies MH - Time Factors MH - Treatment Outcome MH - Ultrasonography MH - Urinary Bladder Neoplasms/diagnostic imaging/*pathology/*surgery MH - Urothelium/pathology PMC - PMC4871383 COIS- CONFLICT OF INTEREST None declared. EDAT- 2016/06/04 06:00 MHDA- 2017/03/09 06:00 PMCR- 2016/03/01 CRDT- 2016/06/04 06:00 PHST- 2015/04/08 00:00 [received] PHST- 2015/09/09 00:00 [accepted] PHST- 2016/06/04 06:00 [entrez] PHST- 2016/06/04 06:00 [pubmed] PHST- 2017/03/09 06:00 [medline] PHST- 2016/03/01 00:00 [pmc-release] AID - IBJUv42n2a11 [pii] AID - S1677-5538.IBJU.2015.0200 [pii] AID - 10.1590/S1677-5538.IBJU.2015.0200 [doi] PST - ppublish SO - Int Braz J Urol. 2016 Mar-Apr;42(2):242-6. doi: 10.1590/S1677-5538.IBJU.2015.0200. PMID- 27237781 OWN - NLM STAT- MEDLINE DCOM- 20170921 LR - 20181113 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 94 DP - 2016 Aug TI - Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. PG - 148-53 LID - S0090-4295(16)30240-0 [pii] LID - 10.1016/j.urology.2016.05.039 [doi] AB - OBJECTIVE: To compare the oncologic outcomes of patients with upper tract urothelial carcinoma undergoing nephroureterectomy (NU) with and without prior ureteroscopy (URS). METHODS: We reviewed records of all patients with no prior history of bladder cancer who underwent NU at our institution (n = 201). We compared patients who underwent URS before NU with patients who proceeded directly to NU based on imaging alone. After excluding patients undergoing URS with therapeutic intent, we used multivariable Cox proportional hazards models, adjusting for tumor characteristics with cancer-specific survival (CSS), intravesical recurrence-free survival, metastasis-free survival (MFS), and overall survival (OS) as end points. This study received institutional review board approval. RESULTS: A total of 144 (72%) patients underwent URS before NU, and 57 (28%) patients proceeded directly to NU. The median follow-up time for survivors was 5.4 years from diagnosis. The performance of diagnostic URS before NU was significantly associated with IR (hazard ratio 2.58; 95% CI 1.47, 4.54; P = .001), although it was not associated with CSS, MFS, or OS. The adjusted intravesical recurrence-free survival probability 3 years after diagnosis is 71% and 42% for patients who did not and did receive URS before NU, respectively (adjusted risk difference 30%; 95% CI 13%, 47%). CONCLUSION: We did not find evidence that URS adversely impacts disease progression and survival in patients with upper tract urothelial carcinoma. Although patients are at higher risk for IR after NU when they have undergone prior diagnostic URS, their CSS, MFS, and OS are not significantly affected. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Sankin, Alexander AU - Sankin A AD - Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address: asankin@montefiore.org. FAU - Tin, Amy L AU - Tin AL AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Mano, Roy AU - Mano R AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Chevinsky, Michael AU - Chevinsky M AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Jakubowski, Chris AU - Jakubowski C AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sfakianos, John P AU - Sfakianos JP AD - Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Cha, Eugene K AU - Cha EK AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Yee, Alyssa AU - Yee A AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Friedman, Fara M AU - Friedman FM AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Sjoberg, Daniel D AU - Sjoberg DD AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Ehdaie, Behfar AU - Ehdaie B AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Coleman, Jonathan AU - Coleman J AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - T32 CA082088/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20160526 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*pathology/*surgery MH - Disease Progression MH - Female MH - Humans MH - Kidney Neoplasms/*pathology/*surgery MH - Male MH - Middle Aged MH - *Nephrectomy MH - Preoperative Care MH - Treatment Outcome MH - Ureter/*surgery MH - Ureteral Neoplasms/*pathology/*surgery MH - *Ureteroscopy PMC - PMC5114126 MID - NIHMS828367 COIS- The authors declare that they have no conflict of interest. EDAT- 2016/05/31 06:00 MHDA- 2017/09/22 06:00 PMCR- 2017/08/01 CRDT- 2016/05/31 06:00 PHST- 2016/03/15 00:00 [received] PHST- 2016/05/11 00:00 [revised] PHST- 2016/05/18 00:00 [accepted] PHST- 2016/05/31 06:00 [entrez] PHST- 2016/05/31 06:00 [pubmed] PHST- 2017/09/22 06:00 [medline] PHST- 2017/08/01 00:00 [pmc-release] AID - S0090-4295(16)30240-0 [pii] AID - 10.1016/j.urology.2016.05.039 [doi] PST - ppublish SO - Urology. 2016 Aug;94:148-53. doi: 10.1016/j.urology.2016.05.039. Epub 2016 May 26. PMID- 27237631 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20250103 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 14 IP - 1 DP - 2016 May 30 TI - Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. PG - 144 LID - 10.1186/s12967-016-0891-z [doi] LID - 144 AB - BACKGROUND: The aim of this study was to investigate the clinical significance of three immune cell-related transcription factors, T-bet, GATA-3 and Bcl-6 in bladder cancer in Tunisian patients. METHODS: Expression of T-bet, GATA-3 and Bcl-6 genes was assessed using RT-qPCR in 65 bladder cancers from patients: 32 being diagnosed as low- and medium-grade, 31 as high-grade, 25 as muscle invasive stage and 39 as non-muscle invasive stage. Gene expression was statistically correlated according to the grade, the stage, tobacco consumption, the BCG response and disease severity. RESULTS: T-bet levels in patients with high-grade bladder cancer were significantly elevated compared to patients with low- or medium-grade bladder cancer (p = 0.005). In invasive carcinoma (T2-T4), the T-bet levels were significantly higher than in superficial non-invasive bladder tumors (Tis, Ta, and T1) (p = 0.02). However, T-bet is predictive of the response to BCG. Its expression is high in good responders to BCG (p = 0.02). In contrast, the expression of GATA-3 and Bcl-6 in non-invasive carcinoma (p = 0.008 and p = 0.0003) and in patients with low- and medium-grade cancers (p = 0.001 and p < 0.0001) is significantly higher than in invasive bladder tumors and in patients with high-grade bladder carcinoma, respectively. In addition, heavy smokers, whose tumors express low levels of GATA-3 and Bcl-6, are poor responders to BCG (p = 0.01 and p = 0.03). Finally, better patient survival correlated with GATA-3 (p = 0.04) and Bcl-6 (p = 0.04) but not T-bet expression. CONCLUSIONS: Our results suggest that T-bet expression in bladder tumors could be a positive prognostic indicator of BCG therapy, even if high levels are found in high-grade and stage of the disease. However, GATA-3 and Bcl-6 expression could be considered as predictive factors for good patient survival. FAU - Bahria-Sediki, Islem Ben AU - Bahria-Sediki IB AD - Laboratoire d'Immunologie et Immunotherapie des Cancers (LIIC), EPHE, PSL Research University, 75014, Paris, France. AD - Universite Bourgogne Franche-Comte, EA7269, 21000, Dijon, France. AD - Laboratoire de Genetique, Immunologie et Pathologies Humaines, Faculte de Sciences Tunis, Universite de Tunis El Manar, Tunis, Tunisia. FAU - Yousfi, Nadhir AU - Yousfi N AD - Laboratoire d'Immunologie et Immunotherapie des Cancers (LIIC), EPHE, PSL Research University, 75014, Paris, France. AD - Universite Bourgogne Franche-Comte, EA7269, 21000, Dijon, France. FAU - Paul, Catherine AU - Paul C AD - Laboratoire d'Immunologie et Immunotherapie des Cancers (LIIC), EPHE, PSL Research University, 75014, Paris, France. AD - Universite Bourgogne Franche-Comte, EA7269, 21000, Dijon, France. FAU - Chebil, Mohamed AU - Chebil M AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Cherif, Mohamed AU - Cherif M AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Zermani, Rachida AU - Zermani R AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - El Gaaied, Amel Ben Ammar AU - El Gaaied AB AD - Laboratoire de Genetique, Immunologie et Pathologies Humaines, Faculte de Sciences Tunis, Universite de Tunis El Manar, Tunis, Tunisia. FAU - Bettaieb, Ali AU - Bettaieb A AD - Laboratoire d'Immunologie et Immunotherapie des Cancers (LIIC), EPHE, PSL Research University, 75014, Paris, France. ali.bettaieb@u-bourgogne.fr. AD - Universite Bourgogne Franche-Comte, EA7269, 21000, Dijon, France. ali.bettaieb@u-bourgogne.fr. AD - UFR des Sciences de Sante, 7 boulevard Jeanne d'Arc, BP 87900, 21079, Dijon, France. ali.bettaieb@u-bourgogne.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160530 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (BCL6 protein, human) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Proto-Oncogene Proteins c-bcl-6) RN - 0 (T-Box Domain Proteins) RN - 0 (T-bet Transcription Factor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - GATA3 Transcription Factor/*genetics/metabolism MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Mycobacterium bovis MH - Prognosis MH - Proto-Oncogene Proteins c-bcl-6/*genetics/metabolism MH - Smoking/genetics MH - Substance-Related Disorders/genetics MH - T-Box Domain Proteins/*genetics/metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*genetics/pathology/surgery MH - T-bet Transcription Factor PMC - PMC4885121 OTO - NOTNLM OT - Bcl-6 OT - Bladder carcinomas OT - GATA-3 OT - Prognosis OT - T-bet EDAT- 2016/05/31 06:00 MHDA- 2017/10/17 06:00 PMCR- 2016/05/30 CRDT- 2016/05/31 06:00 PHST- 2016/03/17 00:00 [received] PHST- 2016/05/02 00:00 [accepted] PHST- 2016/05/31 06:00 [entrez] PHST- 2016/05/31 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] PHST- 2016/05/30 00:00 [pmc-release] AID - 10.1186/s12967-016-0891-z [pii] AID - 891 [pii] AID - 10.1186/s12967-016-0891-z [doi] PST - epublish SO - J Transl Med. 2016 May 30;14(1):144. doi: 10.1186/s12967-016-0891-z. PMID- 27233931 OWN - NLM STAT- MEDLINE DCOM- 20170929 LR - 20260127 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 95 DP - 2016 Sep TI - Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data. PG - 115-20 LID - S0090-4295(16)30234-5 [pii] LID - 10.1016/j.urology.2016.05.033 [doi] AB - OBJECTIVE: To determine survival differences among patients receiving endoscopic vs surgical management for upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: Using Surveillance, Epidemiology and End Results-Medicare data, patients diagnosed with nonmuscle-invasive, low-grade UTUC as their first cancer diagnosis between 2004 and 2009 were identified. Receipts of endoscopic and surgical interventions were assessed, and patients were separated into surgical or endoscopic management cohorts. Two-to-one propensity score analysis was performed to control for baseline characteristics between groups. RESULTS: The endoscopic management (n = 151) and matched surgical management (n = 302) groups demonstrated no significant differences in age, gender, race, marital status, Charlson comorbidity index, or year of diagnosis. Endoscopic management was an independent and significant predictor of all-cause and cancer-specific mortality (hazard ratio 1.6 for overall survival [OS], hazard ratio 2.1 for cancer-specific survival [CSS]). Kaplan-Meier estimated survival was significantly lower for endoscopic management, with both OS and CSS curves diverging at approximately 24-36 months. A subset of patients initially receiving endoscopic management went on to receive surgical intervention (80/151 = 53%) at a median of 8.8 months from diagnosis. For these patients, Kaplan-Meier-estimated CSS was not significantly different from those who continued with only endoscopic management, and remained significantly lower than patients who received upfront surgery. CONCLUSION: Although initial survival outcomes (first 24 months) are similar for endoscopic and surgical management of nonmuscle-invasive, low-grade UTUC, both CSS and OS are significantly inferior for the endoscopic management group in the longer term. Furthermore, transition from initial endoscopic management to surgical intervention appears to have limited impact on survival. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Vemana, Goutham AU - Vemana G AD - Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO. FAU - Kim, Eric H AU - Kim EH AD - Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO. FAU - Bhayani, Sam B AU - Bhayani SB AD - Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO. FAU - Vetter, Joel M AU - Vetter JM AD - Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO. FAU - Strope, Seth A AU - Strope SA AD - Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO. Electronic address: stropes@wudosis.wustl.edu. LA - eng GR - R24 HS019455/HS/AHRQ HHS/United States GR - UL1 RR024992/RR/NCRR NIH HHS/United States GR - UL1 TR000448/TR/NCATS NIH HHS/United States GR - K08 DK097302/DK/NIDDK NIH HHS/United States GR - KL2 TR000450/TR/NCATS NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20160524 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/*mortality/*surgery MH - Male MH - Medicare MH - Propensity Score MH - SEER Program MH - Survival Rate MH - United States MH - Ureteral Neoplasms/*mortality/*surgery MH - *Ureteroscopy MH - Urologic Surgical Procedures/methods PMC - PMC5115634 MID - NIHMS797752 COIS- Financial Disclosure: The authors declare that they have no relevant financial interests. EDAT- 2016/05/29 06:00 MHDA- 2017/09/30 06:00 PMCR- 2017/09/01 CRDT- 2016/05/29 06:00 PHST- 2016/02/23 00:00 [received] PHST- 2016/05/04 00:00 [revised] PHST- 2016/05/17 00:00 [accepted] PHST- 2016/05/29 06:00 [entrez] PHST- 2016/05/29 06:00 [pubmed] PHST- 2017/09/30 06:00 [medline] PHST- 2017/09/01 00:00 [pmc-release] AID - S0090-4295(16)30234-5 [pii] AID - 10.1016/j.urology.2016.05.033 [doi] PST - ppublish SO - Urology. 2016 Sep;95:115-20. doi: 10.1016/j.urology.2016.05.033. Epub 2016 May 24. PMID- 27233780 OWN - NLM STAT- MEDLINE DCOM- 20171002 LR - 20231112 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 35 IP - 3 DP - 2017 Mar TI - Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. PG - 355-365 LID - 10.1007/s00345-016-1859-6 [doi] AB - INTRODUCTION: The conservative management of upper tract urothelial carcinoma (UTUC) has historically been offered to patients with imperative indications. The recent International Consultation on Urologic Diseases (ICUD) publication on UTUC stratified treatment allocations based on high- and low-risk groups. This report updates the conservative management of the low-risk group. METHODS: The ICUD for low-risk UTUC working group performed a thorough review of the literature with an assessment of the level of evidence and grade of recommendation for a variety of published studies in this disease space. We update these publications and provide a summary of that original report. RESULTS: There are no prospective randomized controlled studies to support surgical management guidelines. A risk-stratified approach based on clinical, endoscopic, and biopsy assessment allows selection of patients who could benefit from kidney-preserving procedures with oncological outcomes potentially similar to radical nephroureterectomy with bladder cuff excision, with the added benefit of renal function preservation. These treatments are aided by the development of high-definition flexible digital URS, multi-biopsies with the aid of access sheaths and other tools, and promising developments in the use of adjuvant topical therapy. CONCLUSIONS: Recent developments in imaging, minimally invasive techniques, multimodality approaches, and adjuvant topical regimens and bladder cancer prevention raise the hope for improved risk stratification and may greatly improve the endoscopic treatment for low-risk UTUC. FAU - Mandalapu, Rao S AU - Mandalapu RS AD - , Houston, TX, USA. FAU - Remzi, Mesut AU - Remzi M AD - LKH Korneuburg, Korneuburg, Austria. FAU - de Reijke, Theo M AU - de Reijke TM AD - AMC University Hospital, Amsterdam, The Netherlands. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern, Dallas, TX, USA. FAU - Palou, J AU - Palou J AD - Fundacio Puigvert, Barcelona, Spain. FAU - Kapoor, A AU - Kapoor A AD - McMaster University, Hamilton, ON, Canada. FAU - Yossepowitch, Ofer AU - Yossepowitch O AD - Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel. FAU - Coleman, Jonathan AU - Coleman J AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Traxer, Olivier AU - Traxer O AD - Hopital Tenon, Universite Pierre et Marie Curie Paris 6, Paris, France. FAU - Anderson, J Kyle AU - Anderson JK AD - University of Minnesota Medical Center, Minneapolis, MN, USA. FAU - Catto, James AU - Catto J AD - Academic Urology Unit, University of Sheffield, Sheffield, UK. FAU - de la Rosette, Jean AU - de la Rosette J AD - AMC University Hospital, Amsterdam, The Netherlands. FAU - O'Brien, Timothy AU - O'Brien T AD - Guy's and St. Thomas' NHS Foundation Trust, London, UK. FAU - Zlotta, Anthony AU - Zlotta A AD - Mt. Sinai Hospital, Toronto, ON, Canada. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX, 77030, USA. surmatin@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20160527 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Administration, Topical MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma in Situ/diagnostic imaging/pathology/*therapy MH - Carcinoma, Transitional Cell/diagnostic imaging/pathology/*therapy MH - Combined Modality Therapy MH - Cystoscopy MH - Disease-Free Survival MH - Humans MH - Kidney Neoplasms/diagnostic imaging/pathology/*therapy MH - Kidney Pelvis/diagnostic imaging/pathology/*surgery MH - Lymph Node Excision MH - Minimally Invasive Surgical Procedures MH - Nephrectomy MH - Nephrostomy, Percutaneous MH - Organ Sparing Treatments MH - Practice Guidelines as Topic MH - Risk Assessment MH - Societies, Medical MH - Tomography, X-Ray Computed MH - Ureter/surgery MH - Ureteral Neoplasms/diagnostic imaging/pathology/*therapy MH - Ureteroscopy MH - Urologic Surgical Procedures MH - Urology PMC - PMC5554604 MID - NIHMS883505 OTO - NOTNLM OT - Calyces OT - Nephroureterectomy OT - Renal pelvis OT - Upper tract OT - Ureteroscopy OT - Urothelial cancer EDAT- 2016/05/29 06:00 MHDA- 2017/10/03 06:00 PMCR- 2018/03/01 CRDT- 2016/05/29 06:00 PHST- 2016/04/13 00:00 [received] PHST- 2016/05/17 00:00 [accepted] PHST- 2016/05/29 06:00 [pubmed] PHST- 2017/10/03 06:00 [medline] PHST- 2016/05/29 06:00 [entrez] PHST- 2018/03/01 00:00 [pmc-release] AID - 10.1007/s00345-016-1859-6 [pii] AID - 10.1007/s00345-016-1859-6 [doi] PST - ppublish SO - World J Urol. 2017 Mar;35(3):355-365. doi: 10.1007/s00345-016-1859-6. Epub 2016 May 27. PMID- 27221848 OWN - NLM STAT- MEDLINE DCOM- 20170124 LR - 20190606 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 17 IP - 4 DP - 2016 TI - Predictive Effect of Preoperative Anemia on Long-Term Survival Outcomes with Non-Muscle Invasive Bladder Cancer. PG - 1755-8 AB - BACKGROUND: Anemia is the most common hematologic abnormality in bladder cancer (BC) patients. We evaluated the impact of preoperative anemia on oncologic outcomes in BC undergoing transurethral resection of a bladder tumor (TURBT) for the first time diagnosis. MATERIALS AND METHODS: We retrospectively evaluated the data collected from 639 patients who underwent TURBT between January 2006 and September 2014 in our department. Of these patients, 320 qualified for inclusion in the study. The primary efficacy endpoint was the effect of preoperative anemia status on cancer-specific and overall survival. Independent t-test and chi-square analyses were performed to assess the effects of anemia on oncologic outcomes. Survival was estimated by using the Kaplan-Meier test. RESULTS: There were 118 (36.9%) and 202 (63.1%) patients in the anemia (Group-1) and non-anemia groups (Group-2), respectively. The median follow-up duration was 68 months. Anemia was associated with decreased overall survival (<0.001). Comparison between cancer-specific survival of two groups did not show any statistically significant difference (p=0.17). CONCLUSIONS: Preoperative anemia status of BC patients according to World Health Organization classification is associated with decreased overall survival, but not with cancer-specific survival. We think that preoperative hemoglobin levels should be considered in patient counseling and decision-making for additional therapy. FAU - Celik, Orcun AU - Celik O AD - 1Department of Urology, Tepecik Education and Research Hospital, Izmir, Turkey E-mail : drmuratakand@yahoo.com. FAU - Akand, Murat AU - Akand M FAU - Keskin, Mehmet Zeynel AU - Keskin MZ FAU - Ekin, Rahmi Gokhan AU - Ekin RG FAU - Yoldas, Mehmet AU - Yoldas M FAU - Ilbey, Yusuf Ozlem AU - Ilbey YO LA - eng PT - Journal Article PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Anemia/*physiopathology MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*mortality/pathology/surgery MH - Neoplasm Staging MH - Preoperative Care MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/surgery EDAT- 2016/05/26 06:00 MHDA- 2017/01/25 06:00 CRDT- 2016/05/26 06:00 PHST- 2016/05/26 06:00 [entrez] PHST- 2016/05/26 06:00 [pubmed] PHST- 2017/01/25 06:00 [medline] AID - 10.7314/apjcp.2016.17.4.1755 [doi] PST - ppublish SO - Asian Pac J Cancer Prev. 2016;17(4):1755-8. doi: 10.7314/apjcp.2016.17.4.1755. PMID- 27215483 OWN - NLM STAT- MEDLINE DCOM- 20170921 LR - 20170921 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 94 DP - 2016 Aug TI - Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. PG - 314.e1-7 LID - S0090-4295(16)30228-X [pii] LID - 10.1016/j.urology.2016.05.030 [doi] AB - OBJECTIVE: To determine the prognostic significance of Forkhead Box A1 (FOXA1) expression in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). MATERIALS AND METHODS: A retrospective analysis of 566 patients undergoing RNU at seven academic medical centers was performed. Tissue microarrays were subjected to immunohistochemistry using a commercially available polyclonal FOXA1 antibody. Logistic regression determined the association of FOXA1 expression with pathologic features and survival outcomes. RESULTS: Three hundred twenty-two men and 244 women were included. The pathologic distribution of specimens included 53% muscle-invasive or greater (>/=pT2), 74% high-grade, 16% with flat architecture, 13% with necrosis, 21% with lymphovascular invasion, 18% with concomitant carcinoma in situ, and 8% with positive lymph nodes. The median FOXA1 score was 5.0 (range: 0-8). Lower FOXA1 expression was significantly correlated with advanced pathologic stage (>/=pT3) (P = .02), concomitant carcinoma in situ (P = .006), and renal pelvis (vs ureter) location (P < .0001). At a median follow-up of 27.0 months (range: 3-196), 139 patients (25%) experienced disease recurrence and 121 (21%) died from the disease. In a multivariate model, lower FOXA1 expression was independently associated with disease recurrence (hazard ratio [HR]: 1.11, 95% confidence interval [CI]: 1.05-1.62, P = .04), cancer-specific mortality (HR: 1.17, 95% CI: 1.03-1.92, P = .04), and all-cause mortality (HR: 1.08, 95% CI: 1.02-1.18, P = .05). CONCLUSION: Lower FOXA1 expression is associated with adverse pathologic features and inferior survival outcomes for UTUC patients undergoing RNU. These data indicate lower FOXA1 expression may be a marker of aggressive disease in UTUC. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Raman, Jay D AU - Raman JD AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Warrick, Joshua I AU - Warrick JI AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Caruso, Carla AU - Caruso C AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Yang, Zhaohai AU - Yang Z AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Shuman, Lauren AU - Shuman L AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Bruggeman, Richard D AU - Bruggeman RD AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. FAU - Shariat, Shahrokh AU - Shariat S AD - General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Karam, Jose A AU - Karam JA AD - M.D. Anderson Cancer Center, Houston, TX. FAU - Wood, Christopher AU - Wood C AD - M.D. Anderson Cancer Center, Houston, TX. FAU - Weizer, Alon Z AU - Weizer AZ AD - University of Michigan, Ann Arbor, MI. FAU - Remzi, Mesut AU - Remzi M AD - General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Haitel, Andrea AU - Haitel A AD - General Hospital, Medical University of Vienna, Vienna, Austria. FAU - Bensalah, Karim AU - Bensalah K AD - University of Rennes, Rennes, France. FAU - Rioux-Leclerq, Nathalie AU - Rioux-Leclerq N AD - University of Rennes, Rennes, France. FAU - Bolenz, Christian AU - Bolenz C AD - University of Ulm, Ulm, Germany. FAU - Roscigno, Marco AU - Roscigno M AD - AO Papa Giovanni XXIII, Bergamo, Italy. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - UT Southwestern Medical Center, Dallas, TX. FAU - Kapur, Payal AU - Kapur P AD - UT Southwestern Medical Center, Dallas, TX. FAU - Lotan, Yair AU - Lotan Y AD - UT Southwestern Medical Center, Dallas, TX. FAU - Margulis, Vitaly AU - Margulis V AD - UT Southwestern Medical Center, Dallas, TX. FAU - DeGraff, David J AU - DeGraff DJ AD - Penn State Milton S. Hershey Medical Center, Hershey, PA. Electronic address: ddegraff@hmc.psu.edu. LA - eng PT - Journal Article DEP - 20160520 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (FOXA1 protein, human) RN - 0 (Hepatocyte Nuclear Factor 3-alpha) RN - 0 (Transcription Factors) SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*metabolism/mortality/*surgery MH - Female MH - Hepatocyte Nuclear Factor 3-alpha/*biosynthesis MH - Humans MH - Kidney Neoplasms/*metabolism/mortality/*surgery MH - Male MH - Middle Aged MH - *Nephrectomy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Transcription Factors/*biosynthesis MH - Ureter/*surgery MH - Ureteral Neoplasms/*metabolism/mortality/*surgery EDAT- 2016/05/25 06:00 MHDA- 2017/09/22 06:00 CRDT- 2016/05/25 06:00 PHST- 2016/03/11 00:00 [received] PHST- 2016/04/26 00:00 [revised] PHST- 2016/05/14 00:00 [accepted] PHST- 2016/05/25 06:00 [entrez] PHST- 2016/05/25 06:00 [pubmed] PHST- 2017/09/22 06:00 [medline] AID - S0090-4295(16)30228-X [pii] AID - 10.1016/j.urology.2016.05.030 [doi] PST - ppublish SO - Urology. 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030. Epub 2016 May 20. PMID- 27207387 OWN - NLM STAT- MEDLINE DCOM- 20170524 LR - 20260127 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 118 IP - 6 DP - 2016 Dec TI - Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. PG - 935-939 LID - 10.1111/bju.13536 [doi] AB - OBJECTIVE: To report the oncological safety and the risk of progression for patients with non-muscle-invasive bladder cancer (NMIBC) included in an active surveillance (AS) programme after the diagnosis of recurrence. PATIENTS AND METHODS: This is a prospective study enrolling patients with history of pathologically confirmed low grade pTa-pT1a NMIBC and diagnosed with a tumour recurrence. Inclusion criteria consisted of negative urine cytology, presence of 10 years. We selected 1,679 SNPs belonging to 251 inflammatory genes. The association of SNPs with risk-of-recurrence and risk-of-progression was assessed using Cox regression single-marker (SMM) and multimarker methods (MMM) Bayes A and Bayesian LASSO. Discriminative abilities of the models were calculated using the c index and validated with bootstrap cross-validation procedures. RESULTS: While no SNP was found to be associated with risk-of-recurrence using SMM, three SNPs in TNIP1, CD5, and JAK3 showed very strong association with posterior probabilities >90% using MMM. Regarding risk-of-progression, one SNP in CD3G was significantly associated using SMM (HR, 2.69; P = 1.55 x 10(-5)) and two SNPs in MASP1 and AIRE, showed a posterior probability >/=80% with MMM. Validated discriminative abilities of the models without and with the SNPs were 58.4% versus 60.5% and 72.1% versus 72.8% for risk-of-recurrence and risk-of-progression, respectively. CONCLUSIONS: Using innovative analytic approaches, we demonstrated that SNPs in inflammatory-related genes were associated with NMIBC prognosis and that they improve the discriminative ability of prognostic clinical models for NMIBC. IMPACT: This study provides proof of concept for the joint effect of genetic variants in improving the discriminative ability of clinical prognostic models. The approach may be extended to other diseases. Cancer Epidemiol Biomarkers Prev; 25(7); 1144-50. (c)2016 AACR. CI - (c)2016 American Association for Cancer Research. FAU - Masson-Lecomte, Alexandra AU - Masson-Lecomte A AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Urology Department, Henri Mondor Academic Hospital, Paris Est Creteil University, Creteil, France. FAU - Lopez de Maturana, Evangelina AU - Lopez de Maturana E AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Goddard, Michael E AU - Goddard ME AD - Biosciences Research Division, Department of Environment and Primary Industries, Agribio, Bundoora, Victoria, Australia. Department of Food and Agricultural Systems, University of Melbourne, Melbourne, Australia. FAU - Picornell, Antoni AU - Picornell A AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Rava, Marta AU - Rava M AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Gonzalez-Neira, Anna AU - Gonzalez-Neira A AD - Human Genotyping-CEGEN Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Marquez, Mirari AU - Marquez M AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Carrato, Alfredo AU - Carrato A AD - Servicio de Oncologia, Hospital Universitario Ramon y Cajal, Madrid, and Servicio de Oncologia, Hospital Universitario de Elche, Elche, Spain. FAU - Tardon, Adonina AU - Tardon A AD - Department of Preventive Medicine, Universidad de Oviedo, Oviedo, Spain. FAU - Lloreta, Josep AU - Lloreta J AD - Institut Municipal d'Investigacio Medica - Hospital del Mar and Departament de Patologia, Hospital del Mar - IMAS, Barcelona, Spain. FAU - Garcia-Closas, Montserrat AU - Garcia-Closas M AD - Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom. FAU - Silverman, Debra AU - Silverman D AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland. FAU - Rothman, Nathaniel AU - Rothman N AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland. FAU - Kogevinas, Manolis AU - Kogevinas M AD - Centre for Research in Environmental Epidemiology (CREAL) and Institut Municipal d'Investigacio Medica - Hospital del Mar, Barcelona, Spain. FAU - Allory, Yves AU - Allory Y AD - Pathology Department, Henri Mondor Academic Hospital, Paris Est Creteil University, INSERM, Creteil, France. FAU - Chanock, Stephen J AU - Chanock SJ AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland. FAU - Real, Francisco X AU - Real FX AD - Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. nmalats@cnio.es. CN - SBC/EPICURO Study Investigators LA - eng GR - N02 CP011015/CP/NCI NIH HHS/United States GR - Z01 CP010136/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20160506 PL - United States TA - Cancer Epidemiol Biomarkers Prev JT - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JID - 9200608 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Bayes Theorem MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Transitional Cell/*genetics/pathology MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Genetic Predisposition to Disease MH - Genetic Variation MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/genetics MH - Polymorphism, Single Nucleotide MH - Proportional Hazards Models MH - Risk Factors MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC6984594 MID - NIHMS1014808 COIS- Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. EDAT- 2016/05/20 06:00 MHDA- 2018/01/18 06:00 PMCR- 2020/01/27 CRDT- 2016/05/20 06:00 PHST- 2015/09/21 00:00 [received] PHST- 2016/04/22 00:00 [accepted] PHST- 2016/05/20 06:00 [entrez] PHST- 2016/05/20 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2020/01/27 00:00 [pmc-release] AID - 1055-9965.EPI-15-0894 [pii] AID - 10.1158/1055-9965.EPI-15-0894 [doi] PST - ppublish SO - Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1144-50. doi: 10.1158/1055-9965.EPI-15-0894. Epub 2016 May 6. PMID- 27194044 OWN - NLM STAT- MEDLINE DCOM- 20170614 LR - 20181202 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 1 DP - 2017 Jan TI - Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. PG - 105-111 LID - 10.1007/s00345-016-1853-z [doi] AB - PURPOSE: To evaluate whether anti-inflammatory agents affect outcomes in patients receiving intravesical BCG therapy for high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). METHODS: We reviewed the records of 203 patients in a prospective database of HG NMIBC from 2006 to 2012 at a single institution. Patients who had muscle-invasive disease (n = 32), low-grade pathology (n = 4), underwent early cystectomy within 3 months (n = 25), had <3 months of follow-up (n = 11), or did not receive an induction course of intravesical BCG (n = 32) were excluded. Clinicopathologic data were tabulated including demographics, comorbidities, pathologic stage and grades, intravesical therapy, and concomitant use of aspirin, NSAIDs, COX inhibitors, and statins. Multivariate Cox regression analysis explored predictive factors for recurrence, progression (stage progression or progression to cystectomy), cancer-specific survival (CSS), and overall survival (OS). RESULTS: Ninety-nine patients with HG NMIBC who received at least one induction course of intravesical BCG were identified, with median follow-up of 31.4 months. There were 20 (20.2 %) deaths, including 6 (6.1 %) patients with bladder cancer-related mortality. 13 % patients experienced tumor progression and 27 % underwent cystectomy following failure of intravesical therapy. Anti-inflammatory use included statins (65 %), aspirin (63 %), or non-aspirin NSAIDs/COX inhibitors (26 %). Anti-inflammatory use was not significantly predictive of recurrence, progression, or mortality outcomes on Cox regression. CIS stage was associated with higher progression, while age, BMI, and Charlson score were independent predictors of overall mortality. CONCLUSION: Despite speculation of inhibitory effects on BCG immunomodulation there was no evidence that anti-inflammatory agents impacted oncologic outcomes in patients receiving BCG for HG NMIBC. FAU - Singla, Nirmish AU - Singla N AD - Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9110, USA. FAU - Haddad, Ahmed Q AU - Haddad AQ AD - Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9110, USA. FAU - Passoni, Niccolo M AU - Passoni NM AD - Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9110, USA. FAU - Meissner, Matthew AU - Meissner M AD - Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9110, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9110, USA. yair.lotan@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20160518 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (BCG Vaccine) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - R16CO5Y76E (Aspirin) SB - IM CIN - J Urol. 2017 Nov;198(5):978-980. doi: 10.1016/j.juro.2017.08.019. PMID: 29059771 MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Aspirin/therapeutic use MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/mortality/pathology MH - Cause of Death MH - Cyclooxygenase Inhibitors/*therapeutic use MH - Cystectomy/statistics & numerical data MH - Databases, Factual MH - Disease Progression MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use MH - Male MH - Mortality MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Tumor Burden MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*drug therapy/mortality/pathology OTO - NOTNLM OT - Anti-inflammatory agents OT - BCG OT - Intravesical therapy OT - Non-muscle-invasive bladder cancer EDAT- 2016/05/20 06:00 MHDA- 2017/06/15 06:00 CRDT- 2016/05/20 06:00 PHST- 2016/03/13 00:00 [received] PHST- 2016/05/10 00:00 [accepted] PHST- 2016/05/20 06:00 [pubmed] PHST- 2017/06/15 06:00 [medline] PHST- 2016/05/20 06:00 [entrez] AID - 10.1007/s00345-016-1853-z [pii] AID - 10.1007/s00345-016-1853-z [doi] PST - ppublish SO - World J Urol. 2017 Jan;35(1):105-111. doi: 10.1007/s00345-016-1853-z. Epub 2016 May 18. PMID- 27193437 OWN - NLM STAT- MEDLINE DCOM- 20170719 LR - 20260127 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 48 IP - 8 DP - 2016 Aug TI - Upper urinary tract urothelial carcinoma behaviors in patients with end-stage renal disease after kidney transplantation in Taiwan. PG - 1261-1265 LID - 10.1007/s11255-016-1308-x [doi] AB - PURPOSE: To determine upper urinary tract urothelial carcinoma (UT-UC) behavior in patients with end-stage renal disease (ESRD) after kidney transplantation (KT). METHODS: From 2005 to 2012, 117 ESRD patients with localized UT-UC underwent nephroureterectomy at our institution. We divide these patients into two groups according to having had KT or not. Kaplan-Meier survival plot and multivariate analysis were used to evaluate whether kidney transplantation interfered with the UT-UC outcome. RESULTS: The mean age was younger in ESRD with KT group (p = 0.001), but there was no difference in gender, smoking, or previous bladder cancer history between these two groups. The pathological features were more aggressive in ESRD with KT group compared to those without KT in regard to incidence of carcinoma in situ (p = 0.025) and multifocality (p = 0.001). Kidney transplantation did not interfere with the oncological outcome of UT-UC in ESRD patients. There were no differences in oncological outcome. Five-year metastasis-free survival rate was comparable. CONCLUSION: In our sample, for patients with ESRD after kidney transplantation, the postoperative onset of UT-UC was younger and the pathological features were more aggressive. Standard surgical intervention resulted in satisfactory and similar outcome as did ESRD. FAU - Chien, Chia-Shen AU - Chien CS AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan. FAU - Luo, Hao Lun AU - Luo HL AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan. FAU - Ling, Chou Shu AU - Ling CS AD - Department of Health Care Administration, Chang Jung Christian University, Kaohsiung, Taiwan. FAU - Chiang, Po-Hui AU - Chiang PH AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan. FAU - Chen, Yen-Ta AU - Chen YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan. yenta1965@gmail.com. FAU - Cheng, Yuan Tso AU - Cheng YT AD - Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan. ytsocheng@gmail.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20160518 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Cause of Death MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Graft Rejection MH - Graft Survival MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Failure, Chronic/diagnosis/mortality/*surgery MH - Kidney Transplantation/*methods/mortality MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Risk Assessment MH - Taiwan MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/pathology/*surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - End-stage renal disease OT - Kidney transplantation OT - Upper urinary tract urothelial carcinoma EDAT- 2016/05/20 06:00 MHDA- 2017/07/20 06:00 CRDT- 2016/05/20 06:00 PHST- 2016/02/02 00:00 [received] PHST- 2016/04/24 00:00 [accepted] PHST- 2016/05/20 06:00 [entrez] PHST- 2016/05/20 06:00 [pubmed] PHST- 2017/07/20 06:00 [medline] AID - 10.1007/s11255-016-1308-x [pii] AID - 10.1007/s11255-016-1308-x [doi] PST - ppublish SO - Int Urol Nephrol. 2016 Aug;48(8):1261-1265. doi: 10.1007/s11255-016-1308-x. Epub 2016 May 18. PMID- 27189277 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260127 IS - 1976-2437 (Electronic) IS - 0513-5796 (Print) IS - 0513-5796 (Linking) VI - 57 IP - 4 DP - 2016 Jul TI - Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study. PG - 855-64 LID - 10.3349/ymj.2016.57.4.855 [doi] AB - PURPOSE: To identify the prognostic factors related to tumor recurrence and progression in Korean patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data were collected and analyzed for 2412 NMIBC patients from 15 centers who were initially diagnosed after transurethral resection of bladder tumor (TURBT) from January 2006 to December 2010. Using univariable and multivariable Cox proportional hazards models, the prognostic value of each variable was evaluated for the time to first recurrence and progression. RESULTS: With a median follow-up duration of 37 months, 866 patients (35.9%) experienced recurrence, and 137 (5.7%) experienced progression. Patients with recurrence had a median time to the first recurrence of 10 months. Multivariable analysis conducted in all patients revealed that preoperative positive urine cytology (PUC) was independently associated with worse recurrence-free survival [RFS; hazard ratio (HR) 1.56; p<0.001], and progression-free survival (PFS; HR 1.56; p=0.037). In particular, on multivariable analysis conducted for the high-risk group (T1 tumor/high-grade Ta tumor/carcinoma in situ), preoperative PUC was an independent predictor of worse RFS (HR 1.73; p<0.001) and PFS (HR 1.96; p=0.006). On multivariable analysis in patients with T1 high-grade (T1HG) cancer (n=684), better RFS (HR 0.75; p=0.033) and PFS (HR 0.33; p<0.001) were observed in association with the administration of intravesical Bacillus Calmette-Guerin (BCG) induction therapy. CONCLUSION: A preoperative PUC result may adversely affect RFS and PFS, particularly in high-risk NMIBC patients. Of particular note, intravesical BCG induction therapy should be administered as an adjunct to TURBT in order to improve RFS and PFS in patients with T1HG cancer. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Dongguk University Ilsan Medical Center, Goyang, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Se Joong AU - Kim SJ AD - Department of Urology, Ajou University College of Medicine, Suwon, Korea. FAU - Hong, Sung Joon AU - Hong SJ AD - Department of Urology, Yonsei University College of Medicine, Seoul, Korea. FAU - Hong, Sung Hoo AU - Hong SH AD - Department of Urology, The Catholic University College of Medicine, Seoul, Korea. FAU - Kim, Hong Sup AU - Kim HS AD - Department of Urology, Konkuk University College of Medicine, Chungju, Korea. FAU - Kwon, Tae Gyun AU - Kwon TG AD - Department of Urology, Kyungpook National University College of Medicine, Daegu, Korea. FAU - Cho, Jin Seon AU - Cho JS AD - Department of Urology, Hallym University College of Medicine, Chuncheon, Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. FAU - Joo, Kwan Joong AU - Joo KJ AD - Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Korea. FAU - Ahn, Han Jong AU - Ahn HJ AD - Department of Urology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea. FAU - Park, Hong Seok AU - Park HS AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Seong, Do Hwan AU - Seong do H AD - Department of Urology, Inha University College of Medicine, Incheon, Korea. FAU - Kwon, Dong Deuk AU - Kwon DD AD - Department of Urology, Chonnam National University College of Medicine, Gwangju, Korea. FAU - Kim, Hyung Jin AU - Kim HJ AD - Department of Urology, Chonbuk National University College of Medicine, Jeonju, Korea. FAU - Lim, Jae Sung AU - Lim JS AD - Department of Urology, Chungnam National University College of Medicine, Daejeon, Korea. FAU - Lee, Hyung Lae AU - Lee HL AD - Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea. hllee61@hanmail.net. LA - eng PT - Journal Article PT - Multicenter Study PL - Korea (South) TA - Yonsei Med J JT - Yonsei medical journal JID - 0414003 SB - IM MH - Aged MH - Carcinoma in Situ/*mortality/*pathology/therapy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*mortality/*pathology MH - Prognosis MH - Proportional Hazards Models MH - Republic of Korea MH - Retrospective Studies MH - Risk MH - Urinary Bladder Neoplasms/*mortality/*pathology/therapy PMC - PMC4951460 OTO - NOTNLM OT - Urinary bladder neoplasm OT - disease progression OT - prognosis OT - recurrence COIS- The authors have no financial conflicts of interest. EDAT- 2016/05/18 06:00 MHDA- 2016/12/15 06:00 PMCR- 2016/07/01 CRDT- 2016/05/19 06:00 PHST- 2015/09/07 00:00 [received] PHST- 2015/11/13 00:00 [revised] PHST- 2015/11/25 00:00 [accepted] PHST- 2016/05/19 06:00 [entrez] PHST- 2016/05/18 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2016/07/01 00:00 [pmc-release] AID - 57.855 [pii] AID - 10.3349/ymj.2016.57.4.855 [doi] PST - ppublish SO - Yonsei Med J. 2016 Jul;57(4):855-64. doi: 10.3349/ymj.2016.57.4.855. PMID- 27173513 OWN - NLM STAT- MEDLINE DCOM- 20210203 LR - 20210203 IS - 1875-5607 (Electronic) IS - 1389-5575 (Linking) VI - 20 IP - 12 DP - 2020 TI - Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer. PG - 1133-1152 LID - 10.2174/1389557516666160512151202 [doi] AB - Urothelial carcinoma of the bladder (UCB) is a very heterogeneous disease and divided into invasive and non-invasive disease. In non-muscle-invasive bladder cancer (NMIBC), recurrence after transurethral resection or instillation-therapy, and progression to invasive disease are issues of concern. In muscle-invasive bladder cancer (MIBC), systemic recurrence after radical treatment is a pressing problem, as the available therapies in this setting are of limited efficacy. For both entities there are only few clinicopathological prognostic biomarkers to identify subgroups at risk to aid in decision making to whom to offer early radical cystectomy in case of NMIBC or neoadjuvant/adjuvant chemotherapy in case of MIBC to improve outcomes. Despite advances in surgery and intravesical therapy, up to 30% of NMIBC-patients suffer progression to MIBC. After cystectomy around 50% of MIBC patients suffer local or systemic recurrence and subsequently succumb to the disease. Standard features, like pathological staging and grading, are not sufficient to identify patients at risk beyond doubt. Recent advances in molecular diagnostics in combination with standard pathological features could be used to improve risk stratification of patients, guide treatment plans and ultimately improve outcomes. Immunohistochemical (IHC) analysis can detect altered regulatory pathway-products. Until now a plethora of prognostic IHC-biomarkers has been reported on in UCB, but only few have been validated and no biomarker is in routine use or recommended by guidelines. In this review we discuss the prognostic potential of the most promising IHC-biomarkers in NMIBC and MIBC with a focus on prognostication of recurrence and stage progression in NMIBC as well as recurrence-free, cancer-specific and overall survival in MIBC. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Boegemann, Martin AU - Boegemann M AD - Department of Urology, University of Muenster Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany. FAU - Krabbe, Laura-Maria AU - Krabbe LM AD - Department of Urology, University of Muenster Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149 Muenster, Germany. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Mini Rev Med Chem JT - Mini reviews in medicinal chemistry JID - 101094212 RN - 0 (Biomarkers) RN - 0 (Cell Cycle Proteins) SB - IM MH - Apoptosis/genetics MH - Biomarkers/*metabolism MH - Cell Cycle Proteins/metabolism MH - Humans MH - Immunohistochemistry MH - Microvessels/physiology MH - Neoplasm Invasiveness MH - Prognosis MH - Signal Transduction/genetics MH - Urinary Bladder Neoplasms/diagnosis/*pathology OTO - NOTNLM OT - Biomarkers OT - bladder cancer OT - immunohistochemistry OT - muscle-invasive OT - non-muscle-invasive OT - prognostic EDAT- 2016/05/14 06:00 MHDA- 2021/02/04 06:00 CRDT- 2016/05/14 06:00 PHST- 2017/02/09 00:00 [received] PHST- 2017/05/08 00:00 [revised] PHST- 2017/05/09 00:00 [accepted] PHST- 2016/05/14 06:00 [pubmed] PHST- 2021/02/04 06:00 [medline] PHST- 2016/05/14 06:00 [entrez] AID - MRMC-EPUB-75653 [pii] AID - 10.2174/1389557516666160512151202 [doi] PST - ppublish SO - Mini Rev Med Chem. 2020;20(12):1133-1152. doi: 10.2174/1389557516666160512151202. PMID- 27167342 OWN - NLM STAT- MEDLINE DCOM- 20171229 LR - 20220310 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 24 DP - 2016 Jun 14 TI - Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer. PG - 36733-36742 LID - 10.18632/oncotarget.9166 [doi] AB - Noninvasive biomarkers for predicting the risk of muscle-invasive bladder cancer (MIBC) may expedite appropriate therapy and reduce morbidity and cost. Genome-wide miRNA analysis by Miseq sequencing followed by two phases of reverse transcription quantitative real-time PCR (RT-qPCR) assays were performed on serum from 207 MIBC patients, 285 nonmuscle-invasive bladder cancer (NMIBC) patients and 193 controls. A four-miRNA panel (miR-422a-3p, miR-486-3p, miR-103a-3p and miR-27a-3p) was developed for MIBC prediction with an area under the receiver operating characteristic curve (AUC) of 0.894 (95% CI, 0.846-0.931) for training set. Prospective evaluation of the miRNA panel revealed an AUC of 0.880 (95% CI, 0.834 to 0.917) in validation set, which was significantly higher than those of grade and urine cytology (both p < 0.05). Moreover, Kaplan-Meier analysis showed that MIBC patients with low miR-486-3p and miR-103a-3p levels had worse overall survival (p = 0.002 and p = 0.034, respectively). Cox analysis indicated miR-486-3p and miR-103a-3p were independently associated with overall survival of MIBC (p = 0.042 and p = 0.021, respectively). In conclusion, serum miRNA signatures might have considerable clinical values in predicting and providing prognostic information for MIBC. FAU - Jiang, Xiumei AU - Jiang X AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Duan, Weili AU - Duan W AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Rui AU - Wang R AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Yan, Keqiang AU - Yan K AD - Department of Urology, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Li, Juan AU - Li J AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Zheng, Guixi AU - Zheng G AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Zhang, Xin AU - Zhang X AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. FAU - Wang, Chuanxin AU - Wang C AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN103 microRNA, human) RN - 0 (MIRN486 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Aged MH - Biomarkers, Tumor/blood/*genetics MH - Female MH - Gene Expression Profiling/*methods MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - MicroRNAs/blood/*genetics MH - Middle Aged MH - Muscles/pathology MH - Neoplasm Invasiveness MH - Prognosis MH - Prospective Studies MH - Urinary Bladder Neoplasms/blood/*genetics/pathology PMC - PMC5095035 OTO - NOTNLM OT - microRNA OT - muscle-invasive bladder cancer OT - prediction OT - prognosis OT - serum COIS- The authors declare that no potential conflicts of interest were disclosed. EDAT- 2016/05/12 06:00 MHDA- 2017/12/30 06:00 PMCR- 2016/06/14 CRDT- 2016/05/12 06:00 PHST- 2015/09/29 00:00 [received] PHST- 2016/04/16 00:00 [accepted] PHST- 2016/05/12 06:00 [pubmed] PHST- 2017/12/30 06:00 [medline] PHST- 2016/05/12 06:00 [entrez] PHST- 2016/06/14 00:00 [pmc-release] AID - 9166 [pii] AID - 10.18632/oncotarget.9166 [doi] PST - ppublish SO - Oncotarget. 2016 Jun 14;7(24):36733-36742. doi: 10.18632/oncotarget.9166. PMID- 27161431 OWN - NLM STAT- MEDLINE DCOM- 20170215 LR - 20250529 IS - 1877-783X (Electronic) IS - 1877-7821 (Print) IS - 1877-7821 (Linking) VI - 42 DP - 2016 Jun TI - Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system. PG - 154-8 LID - S1877-7821(16)30052-2 [pii] LID - 10.1016/j.canep.2016.04.012 [doi] AB - BACKGROUND: While the incidence of bladder cancer is twice as high among whites than among blacks, mortality is higher among blacks than whites. Unequal access to medical care may be an important factor. Insufficient access to care could delay cancer detection and treatment, which can result in worse survival. The purpose of this study was to evaluate whether survival differed between black and white bladder cancer patients in the Department of Defense (DoD), which provides universal healthcare to all beneficiaries regardless of racial background. METHODS: This study was based on data from the U.S. DoD Automated Central Tumor Registry (ACTUR). White and black patients histologically diagnosed with bladder cancer between 1990 and 2004 were included in the study and followed to the end of 2007. The outcomes were all-cause mortality and recurrence. We assessed the relationship between race and outcomes of interest using Cox proportional hazard ratios (HRs) for all, non-muscle invasive (NMIBC), and muscle invasive (MIBC) bladder cancers, separately. RESULTS: The survival of black and white individuals did not differ statistically. No significant racial differences in survival (HR: 0.96, 95% CI: 0.76-1.22) or recurrence-free survival (HR: 0.94, 95% CI: 0.69-1.30) were observed after adjustment for demographic variables, tumor characteristics, and treatment. Similar findings were observed for NMIBC and MIBC patients, respectively. CONCLUSION: Black patients were more likely to present with MIBC than white patients. However, white and black patients with bladder cancer were not significantly different in overall and recurrence-free survival regardless of muscle invasion. Our study suggests the importance of equal access to healthcare in reducing racial disparities in bladder cancer survival. CI - Copyright (c) 2016 Elsevier Ltd. All rights reserved. FAU - Schinkel, Jill K AU - Schinkel JK AD - John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States. FAU - Shao, Stephanie AU - Shao S AD - John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States; Uniformed Services University of the Health Sciences, Bethesda, MD, United States. FAU - Zahm, Shelia H AU - Zahm SH AD - National Cancer Institute, NIH, Rockville, MD, United States. FAU - McGlynn, Katherine A AU - McGlynn KA AD - National Cancer Institute, NIH, Rockville, MD, United States. FAU - Shriver, Craig D AU - Shriver CD AD - John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States; General Surgery Service, Walter Reed National Military Medical Center, Bethesda, MD, United States; Uniformed Services University of the Health Sciences, Bethesda, MD, United States. FAU - Zhu, Kangmin AU - Zhu K AD - John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, United States; Uniformed Services University of the Health Sciences, Bethesda, MD, United States. Electronic address: kzhu@murthacancercenter.org. LA - eng GR - ZIA CP010158/ImNIH/Intramural NIH HHS/United States PT - Journal Article DEP - 20160506 PL - Netherlands TA - Cancer Epidemiol JT - Cancer epidemiology JID - 101508793 SB - IM MH - Black People MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - United States MH - Urinary Bladder Neoplasms/*ethnology/mortality MH - White People MH - Black or African American PMC - PMC5727912 MID - NIHMS924440 OTO - NOTNLM OT - Bladder cancer OT - Race OT - Survival COIS- Conflicts of interest The authors declare that they have no conflict of interest. EDAT- 2016/05/11 06:00 MHDA- 2017/02/16 06:00 PMCR- 2017/12/13 CRDT- 2016/05/11 06:00 PHST- 2015/12/11 00:00 [received] PHST- 2016/04/06 00:00 [revised] PHST- 2016/04/23 00:00 [accepted] PHST- 2016/05/11 06:00 [entrez] PHST- 2016/05/11 06:00 [pubmed] PHST- 2017/02/16 06:00 [medline] PHST- 2017/12/13 00:00 [pmc-release] AID - S1877-7821(16)30052-2 [pii] AID - 10.1016/j.canep.2016.04.012 [doi] PST - ppublish SO - Cancer Epidemiol. 2016 Jun;42:154-8. doi: 10.1016/j.canep.2016.04.012. Epub 2016 May 6. PMID- 27141183 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160504 LR - 20201001 IS - 0974-7796 (Print) IS - 0974-7834 (Electronic) IS - 0974-7796 (Linking) VI - 8 IP - 2 DP - 2016 Apr-Jun TI - Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. PG - 151-6 LID - 10.4103/0974-7796.163797 [doi] AB - PURPOSE: We determined the prevalence of prostatic malignancy in patients undergoing radical cystoprostatectomy (RC) for urothelial carcinoma (UC) with a history of radiation therapy (XRT) treatment for prostatic adenocarcinoma (PCa). MATERIALS AND METHODS: Fifty-three men who underwent a RC for UC that were previously treated for PCa with XRT were retrospectively identified. Pathology reports were reviewed to assess for residual PCa or prostatic UC at the time of surgery. RESULTS: Thirteen (25%) patients had residual PCa, 16 (30%) had prostatic UC, and 8 (15%) had both. Sixteen (30%) patients had no evidence of prostatic disease. Patients with PCa had median tumor volume of 2.2 cc (interquartile range: 1.2-2.5 cc) and one-third had high-risk features (Gleason score >8 or pT3-T4 disease). Sixteen of 24 patients (67%) with prostatic UC had a stromal invasion, 5 (21%) had a ductal invasion, and 3 (13%) had carcinoma in situ. Tumors at bladder neck or trigone during transurethral resection were predictive of prostatic UC (odds ratio: 4.32, 95% confidence interval: 1.2-15.5, P = 0.025). CONCLUSIONS: Despite prior XRT for PCa, less than one-third of patients had no prostatic disease at the time of RC. Routine prostatic sampling should be considered in these patients especially if considering the orthotopic diversion. FAU - Sharma, Pranav AU - Sharma P AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Zargar-Shoshtari, Kamran AU - Zargar-Shoshtari K AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Sexton, Wade J AU - Sexton WJ AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. FAU - Poch, Michael A AU - Poch MA AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. LA - eng PT - Journal Article PL - India TA - Urol Ann JT - Urology annals JID - 101510823 PMC - PMC4839230 OTO - NOTNLM OT - Pathology OT - prostate cancer OT - radiation OT - radical cystectomy OT - urothelial carcinoma EDAT- 2016/05/04 06:00 MHDA- 2016/05/04 06:01 PMCR- 2016/04/01 CRDT- 2016/05/04 06:00 PHST- 2016/05/04 06:00 [entrez] PHST- 2016/05/04 06:00 [pubmed] PHST- 2016/05/04 06:01 [medline] PHST- 2016/04/01 00:00 [pmc-release] AID - UA-8-151 [pii] AID - 10.4103/0974-7796.163797 [doi] PST - ppublish SO - Urol Ann. 2016 Apr-Jun;8(2):151-6. doi: 10.4103/0974-7796.163797. PMID- 27129876 OWN - NLM STAT- MEDLINE DCOM- 20170109 LR - 20220311 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 14 DP - 2016 Apr 30 TI - p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. PG - 137 LID - 10.1186/s12957-016-0890-9 [doi] LID - 137 AB - BACKGROUND: Published studies have yielded inconsistent results on the relationship between p53 status and the progression of stage T1 non-muscle invasive bladder cancer (NMIBC). Therefore, we performed a meta-analysis to evaluate the prognostic value of p53 in T1 NMIBC. METHODS: We systematically searched for relevant literatures in MEDLINE, EMBASE, and Web of Science. Data were pooled together from individual studies, and meta-analysis was performed. Study quality was assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs) and 95% CI were calculated to estimate the effect sizes. Moreover, subgroup analyses were carried out. RESULTS: A total of 12 studies comprising 712 patients were subjected to the final analysis. p53 overexpression was significantly associated with higher progression rate of T1 NMIBC (RR 2.32, 95% CI 1.59-3.38). Moderate heterogeneity was observed across the studies (I(2) = 39%, P < 0.0001). In a subgroup analysis stratified by stage, p53 overexpression was a predictor of progression in T1 grade 3 NMIBC (RR 2.71, 95% CI 1.31-5.64). In addition, in a subgroup analysis stratified by intravesical therapy, p53 overexpression was a predictor of progression in T1 NMIBC received Bacillus Calmette-Guerin intravesical therapy (RR 3.35, 95% CI 1.89-5.93). Furthermore, after excluding the study that possibly contributed to the heterogeneity by the sensitivity analysis, the association p53 overexpression was significantly correlated with progression of T1 NMIBC (RR 2.74, 95% CI 2.05-3.65) without evidence of heterogeneity (I(2) = 0 %, P < 0.0001). CONCLUSIONS: This meta-analysis suggested that p53 overexpression may be associated with progression of T1 NMIBC patients. Because of the heterogeneity and other limitations, further studies with rigid criteria and large populations are still warranted to confirm our findings. FAU - Du, Jun AU - Du J AD - Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. FAU - Wang, Shu-hua AU - Wang SH AD - Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. FAU - Yang, Qing AU - Yang Q AD - Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. FAU - Chen, Qian-qian AU - Chen QQ AD - Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. FAU - Yao, Xin AU - Yao X AD - Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. yaoxin@tjmuch.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20160430 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Disease Progression MH - Humans MH - Prognosis MH - Risk Factors MH - Tumor Suppressor Protein p53/*metabolism MH - Urinary Bladder Neoplasms/*metabolism/*pathology PMC - PMC4851770 OTO - NOTNLM OT - Meta-analysis OT - Non-muscle invasive bladder cancer OT - Progression OT - Stage T1 OT - p53 EDAT- 2016/05/01 06:00 MHDA- 2017/01/10 06:00 PMCR- 2016/04/30 CRDT- 2016/05/01 06:00 PHST- 2015/12/22 00:00 [received] PHST- 2016/04/21 00:00 [accepted] PHST- 2016/05/01 06:00 [entrez] PHST- 2016/05/01 06:00 [pubmed] PHST- 2017/01/10 06:00 [medline] PHST- 2016/04/30 00:00 [pmc-release] AID - 10.1186/s12957-016-0890-9 [pii] AID - 890 [pii] AID - 10.1186/s12957-016-0890-9 [doi] PST - epublish SO - World J Surg Oncol. 2016 Apr 30;14:137. doi: 10.1186/s12957-016-0890-9. PMID- 27129576 OWN - NLM STAT- MEDLINE DCOM- 20170614 LR - 20181202 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 35 IP - 1 DP - 2017 Jan TI - Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. PG - 113-120 LID - 10.1007/s00345-016-1835-1 [doi] AB - PURPOSE: To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients. METHODS: Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10 % or more cells had decreased expression (<90 %). RESULTS: Decreased E-cadherin expression was observed in 353 patients (52.1 %) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15-57), 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses. CONCLUSION: In UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin's association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy. FAU - Favaretto, Ricardo L AU - Favaretto RL AD - Department of Urology, A. C. Camargo Hospital, Sao Paulo, Brazil. FAU - Bahadori, Atessa AU - Bahadori A AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Mathieu, Romain AU - Mathieu R AD - Department of Urology, A. C. Camargo Hospital, Sao Paulo, Brazil. AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Haitel, Andrea AU - Haitel A AD - Department of Pathology, Medical University Vienna, Vienna, Austria. FAU - Grubmuller, Bernhard AU - Grubmuller B AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Margulis, Vitaly AU - Margulis V AD - Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. FAU - Karam, Jose A AU - Karam JA AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - Roupret, Morgan AU - Roupret M AD - Academic Department of Urology, Faculte de Medecine Pierre et Marie Curie, La Pitie-Salpetriere Hospital, Assistance Publique-Hopitaux de Paris, University Paris 6, Paris, France. FAU - Seitz, Christian AU - Seitz C AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. FAU - Cunha, Isabela W AU - Cunha IW AD - Department of Urology, A. C. Camargo Hospital, Sao Paulo, Brazil. FAU - Zequi, Stenio C AU - Zequi SC AD - Department of Urology, A. C. Camargo Hospital, Sao Paulo, Brazil. FAU - Wood, Christopher G AU - Wood CG AD - Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. FAU - Weizer, Alon Z AU - Weizer AZ AD - Department of Urology, University of Michigan Cancer Center, Ann Arbor, MI, USA. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. FAU - Remzi, Mesut AU - Remzi M AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Rioux-Leclercq, Nathalie AU - Rioux-Leclercq N AD - Department of Pathology, Rennes University Hospital, Rennes, France. FAU - Jacquet-Kammerer, Solene AU - Jacquet-Kammerer S AD - Department of Pathology, Rennes University Hospital, Rennes, France. FAU - Bensalah, Karim AU - Bensalah K AD - Department of Urology, Rennes University Hospital, Rennes, France. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. FAU - Bachmann, Alexander AU - Bachmann A AD - Department of Urology, University Hospital Basel, Basel, Switzerland. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Vita Salute San Raffaele University, Milan, Italy. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. sfshariat@gmail.com. AD - Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. sfshariat@gmail.com. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160429 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antigens, CD) RN - 0 (CDH1 protein, human) RN - 0 (Cadherins) SB - IM MH - Aged MH - Antigens, CD MH - Cadherins/*metabolism MH - Carcinoma in Situ/complications/*metabolism/pathology MH - Carcinoma, Transitional Cell/*metabolism/mortality/pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kidney Neoplasms/*metabolism/mortality/pathology MH - Lymph Nodes/pathology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Staging MH - Neoplasms, Multiple Primary/*metabolism/mortality/pathology MH - Prognosis MH - Retrospective Studies MH - Ureteral Neoplasms/*metabolism/mortality/pathology PMC - PMC5233747 OTO - NOTNLM OT - Carcinoma OT - E-cadherin OT - Prediction OT - Prognosis OT - Recurrence OT - Survival OT - Urothelium COIS- The authors disclose no competing interests. EDAT- 2016/05/01 06:00 MHDA- 2017/06/15 06:00 PMCR- 2016/04/29 CRDT- 2016/05/01 06:00 PHST- 2016/02/10 00:00 [received] PHST- 2016/04/16 00:00 [accepted] PHST- 2016/05/01 06:00 [pubmed] PHST- 2017/06/15 06:00 [medline] PHST- 2016/05/01 06:00 [entrez] PHST- 2016/04/29 00:00 [pmc-release] AID - 10.1007/s00345-016-1835-1 [pii] AID - 1835 [pii] AID - 10.1007/s00345-016-1835-1 [doi] PST - ppublish SO - World J Urol. 2017 Jan;35(1):113-120. doi: 10.1007/s00345-016-1835-1. Epub 2016 Apr 29. PMID- 27127359 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160429 LR - 20200930 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 32 IP - 2 DP - 2016 Apr-Jun TI - Molecular cystoscopy: Micro-RNAs could be a marker for identifying genotypic changes for transitional cell carcinoma of the urinary bladder. PG - 149-53 LID - 10.4103/0970-1591.174775 [doi] AB - INTRODUCTION: Normal-looking mucosa may harbor genetic changes preceding a visible tumor. This study was aimed at exploring the role of the quantitative expression of micro-RNAs (miRNAs) in bladder cancer tissue in comparison with normal mucosa and healthy controls (HCs) as a molecular marker. MATERIALS AND METHODS: Between October 2011 to December 2012, tissue from the bladder tumor of 21 patients (cases tumor, CT), normal mucosa (case control, CC) of the same patients (n-21) and normal bladder mucosa from 10 HCs were obtained. miRNAs of angiogenesis, endothelial mesenchymal transition and apoptosis were quantified using stem-loop RT Taq Man polymerase chain reaction. Statistical analysis was performed using the Chi square and independent sample T tests by using SPSS version 16. RESULTS: The mean age of the patients and controls were 55.41 +/- 11.03 and 52.14 +/- 13.04 years. miR-21, miR-205, miR-126, miR-10b and miR-200a were highly expressed in CT (P < 0.027, <0.048, <0.025, <0.029 and < 0.005) as compared with HC. Expression of miR-21 and miR-129 were both correlated with grade and stage (P = 0.001 and < 0.009, respectively) and the level of expression was different in the same grade of non-muscle invasive tumors. The fold change of miR129, miR205 and miR200a was significantly higher in the normal-looking mucosa of bladder tumor patients than the HC (P < 0.005). CONCLUSION: Expression of miR129, miR205 and miR200a in the normal-looking mucosa of bladder cancer patients was significantly higher than the normal mucosa of a HC. This may help in predicting recurrence and formulating the follow-up strategy. FAU - Mitash, Nilay AU - Mitash N AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Agnihotri, Shalini AU - Agnihotri S AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Mittal, Balraj AU - Mittal B AD - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Tiwari, Swasti AU - Tiwari S AD - Department of Molecular Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. FAU - Mandhani, Anil AU - Mandhani A AD - Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4831505 OTO - NOTNLM OT - Bladder cancer OT - micro-RNA OT - muscle invasive OT - non-muscle invasive EDAT- 2016/04/30 06:00 MHDA- 2016/04/30 06:01 PMCR- 2016/04/01 CRDT- 2016/04/30 06:00 PHST- 2016/04/30 06:00 [entrez] PHST- 2016/04/30 06:00 [pubmed] PHST- 2016/04/30 06:01 [medline] PHST- 2016/04/01 00:00 [pmc-release] AID - IJU-32-149 [pii] AID - 10.4103/0970-1591.174775 [doi] PST - ppublish SO - Indian J Urol. 2016 Apr-Jun;32(2):149-53. doi: 10.4103/0970-1591.174775. PMID- 27123328 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160428 LR - 20201001 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 69 IP - 1 DP - 2016 TI - Clinicopathological prognostic factors for upper tract urothelial carcinoma. PG - 57-62 LID - 10.5173/ceju.2016.713 [doi] AB - INTRODUCTION: The aim of the present study was to evaluate the influence of clinicopathological factors including age, gender, tumor grade, tumor stage, lymphovascular invasion (LVI), tumor necrosis and previous history of non-muscle invasive bladder cancer on outcomes of patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). MATERIAL AND METHODS: A total of 60 patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma at our institute between 2005 to 2012 were included in our study. Univariate and multivariate analysis was performed using the Kaplan-Meier method, log rank statistics, the chi-square test and Cox regression models. RESULTS: The mean length of follow-up time was 33.3 months. There were 27 (45%) patients alive with the disease, whereas 33 (55%) were dead. In 19 cases (31.7%) the tumor grade was low, while in 41 cases (68.3%) it was high. Lymphovascular invasion was observed in 28 (46.7%) cases. Tumor necrosis was registered in 14 patients (23.3%). From the patients with LVI, 3 (9.6%) were alive, whereas from the patients negative for LVI, 75% were alive. Significant relationship was found between gender and grading and between positive LVI and low grading. CONCLUSIONS: Day case Variables such as gender, grading, tumor stage, LVI and tumor necrosis were all demonstrated to be significant independent prognostic factors for the overall survival. On the multivariate analysis only LVI remained statistically significant, which may explain the different clinical course in patients and could be considered as a part of pathological reporting and treatment planning for the future. FAU - Elenkov, Angel Andreev AU - Elenkov AA AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Timev, Alexander AU - Timev A AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Dimitrov, Plamen AU - Dimitrov P AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Vasilev, Vasil AU - Vasilev V AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Krastanov, Alexander AU - Krastanov A AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Georgiev, Marincho AU - Georgiev M AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Yanev, Krasimir AU - Yanev K AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Simeonov, Peter AU - Simeonov P AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. FAU - Panchev, Peter AU - Panchev P AD - Medical University Sofia, Department of Urology, Sofia, Bulgaria. LA - eng PT - Journal Article DEP - 20160226 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC4846726 OTO - NOTNLM OT - lymphovascular invasion OT - tumors prognosis OT - upper urothelial tract EDAT- 2016/04/29 06:00 MHDA- 2016/04/29 06:01 PMCR- 2016/01/01 CRDT- 2016/04/29 06:00 PHST- 2015/10/02 00:00 [received] PHST- 2015/12/06 00:00 [revised] PHST- 2016/02/03 00:00 [accepted] PHST- 2016/04/29 06:00 [entrez] PHST- 2016/04/29 06:00 [pubmed] PHST- 2016/04/29 06:01 [medline] PHST- 2016/01/01 00:00 [pmc-release] AID - 00713 [pii] AID - 10.5173/ceju.2016.713 [doi] PST - ppublish SO - Cent European J Urol. 2016;69(1):57-62. doi: 10.5173/ceju.2016.713. Epub 2016 Feb 26. PMID- 28977980 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 37 DP - 2017 Sep 22 TI - Prognostic value of neutrophil-to-lymphocyte ratio in urothelial carcinoma of the upper urinary tract and bladder: a systematic review and meta-analysis. PG - 62681-62692 LID - 10.18632/oncotarget.17467 [doi] AB - The neutrophil-to-lymphocyte ratio (NLR) is an inflammation marker that has prognostic value for various tumors, but its prognostic value in urothelial carcinoma (UC) remains controversial. This meta-analysis investigated the prognostic value of NLR in UC. A systematic search was performed on PubMed, ISI Web of Science, and Embase for studies focusing on the association between NLR and clinical features or prognosis of UC and published until November 2016. Prognostic outcomes and clinical features were collected and analyzed. A total of 11,538 patients from 32 studies were included in the meta-analysis. Increased pretreatment NLR predicted poor overall survival (hazard ratio [HR] = 1.72, 95% confidence interval [CI] = 1.45-2.05), progression free survival (HR = 1.68, 95% CI = 1.44-1.96), and cancer specific survival (HR = 1.64, 95% CI = 1.39-1.93) in all the patients. The increased pretreatment NLR was correlated with increased lymphovascular invasion (HR = 1.29, 95% CI = 1.17-1.43), high tumor T stage (HR = 1.25, 95% CI = 1.12-1.39), and tumor grade (HR = 1.07, 95% CI = 1.01-1.14) but not with lymph node involvement, carcinoma in situ, multifocality, or positive margin. Our meta-analysis indicated that NLR could predict the prognosis for UC and was associated with UC progression in terms of lymphovascular invasion, tumor T stage, and tumor grade. FAU - Li, Xintao AU - Li X AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Ma, Xin AU - Ma X AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Tang, Lu AU - Tang L AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Wang, Baojun AU - Wang B AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Chen, Luyao AU - Chen L AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Zhang, Fan AU - Zhang F AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Zhang, Xu AU - Zhang X AD - Department of Urology, State Key Laboratory of Kidney Disease, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20160427 PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 PMC - PMC5617540 OTO - NOTNLM OT - inflammation OT - meta-analysis OT - neutrophil-to-lymphocyte ratio OT - prognosis OT - urothelial cancer COIS- CONFLICTS OF INTEREST The authors have nothing to disclose. EDAT- 2016/04/27 00:00 MHDA- 2016/04/27 00:01 PMCR- 2017/09/05 CRDT- 2017/10/06 06:00 PHST- 2016/06/13 00:00 [received] PHST- 2017/02/20 00:00 [accepted] PHST- 2017/10/06 06:00 [entrez] PHST- 2016/04/27 00:00 [pubmed] PHST- 2016/04/27 00:01 [medline] PHST- 2017/09/05 00:00 [pmc-release] AID - 17467 [pii] AID - 10.18632/oncotarget.17467 [doi] PST - epublish SO - Oncotarget. 2016 Apr 27;8(37):62681-62692. doi: 10.18632/oncotarget.17467. eCollection 2017 Sep 22. PMID- 27105761 OWN - NLM STAT- MEDLINE DCOM- 20180806 LR - 20220316 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 196 IP - 4 DP - 2016 Oct TI - Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. PG - 1036-41 LID - S0022-5347(16)30204-X [pii] LID - 10.1016/j.juro.2016.04.061 [doi] AB - PURPOSE: Clinical staging in patients with muscle invasive bladder cancer misses up to 25% of lymph node metastasis. These patients are at high risk for disease recurrence and improved clinical staging is critical to guide management. MATERIALS AND METHODS: Whole transcriptome expression profiles were generated in 199 patients who underwent radical cystectomy and extended pelvic lymph node dissection. The cohort was divided randomly into a discovery set of 133 patients and a validation set of 66. In the discovery set features were identified and modeled in a KNN51 (K-nearest neighbor classifier 51) to predict pathological lymph node metastases. Two previously described bladder cancer gene signatures, including RF15 (15-gene cancer recurrence signature) and LN20 (20-gene lymph node signature), were also modeled in the discovery set for comparison. The AUC and the OR were used to compare the performance of these signatures. RESULTS: In the validation set KNN51 achieved an AUC of 0.82 (range 0.71-0.93) to predict lymph node positive cases. It significantly outperformed RF15 and LN20, which had an AUC of 0.62 (range 0.47-0.76) and 0.46 (range 0.32-0.60), respectively. Only KNN51 showed significant odds of predicting LN metastasis with an OR of 2.65 (range 1.68-4.67) for every 10% increase in score (p <0.001). RF15 and LN20 had a nonsignificant OR of 1.21 (range 0.97-1.54) and 1.39 (range 0.52-3.77), respectively. CONCLUSIONS: The new KNN51 signature was superior to previously described gene signatures for predicting lymph node metastasis. If validated prospectively in transurethral resection of bladder tumor samples, KNN51 could be used to guide patients at high risk to early multimodal therapy. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Seiler, Roland AU - Seiler R AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Lam, Lucia L AU - Lam LL AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Erho, Nicholas AU - Erho N AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Takhar, Mandeep AU - Takhar M AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Mitra, Anirban P AU - Mitra AP AD - Institute of Urology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. FAU - Buerki, Christine AU - Buerki C AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Davicioni, Elai AU - Davicioni E AD - GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. FAU - Skinner, Eila C AU - Skinner EC AD - Department of Urology and Stanford Cancer Institute, Stanford University, Stanford, California. FAU - Daneshmand, Siamak AU - Daneshmand S AD - Institute of Urology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. FAU - Black, Peter C AU - Black PC AD - Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: pblack@mail.ubc.ca. LA - eng PT - Journal Article DEP - 20160419 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Nat Rev Urol. 2016 Jun;13(6):301. doi: 10.1038/nrurol.2016.91. PMID: 27162049 CIN - Eur Urol. 2017 May;71(5):832. doi: 10.1016/j.eururo.2017.01.005. PMID: 28094054 MH - Aged MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/*genetics/metabolism/secondary MH - Disease-Free Survival MH - Female MH - Humans MH - Lymph Node Excision MH - Lymph Nodes/*pathology MH - Lymphatic Metastasis MH - Male MH - *Neoplasm Staging MH - Pelvis MH - Transcriptome/*genetics MH - Urinary Bladder Neoplasms/*genetics/metabolism/pathology OTO - NOTNLM OT - biomarkers, tumor OT - genomics OT - lymph nodes OT - neoplasm metastasis OT - urinary bladder neoplasms EDAT- 2016/04/24 06:00 MHDA- 2018/08/07 06:00 CRDT- 2016/04/24 06:00 PHST- 2016/04/01 00:00 [accepted] PHST- 2016/04/24 06:00 [entrez] PHST- 2016/04/24 06:00 [pubmed] PHST- 2018/08/07 06:00 [medline] AID - S0022-5347(16)30204-X [pii] AID - 10.1016/j.juro.2016.04.061 [doi] PST - ppublish SO - J Urol. 2016 Oct;196(4):1036-41. doi: 10.1016/j.juro.2016.04.061. Epub 2016 Apr 19. PMID- 27101100 OWN - NLM STAT- MEDLINE DCOM- 20171002 LR - 20261011 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 3 DP - 2017 Mar TI - Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. PG - 337-353 LID - 10.1007/s00345-016-1826-2 [doi] AB - BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC. METHODS: A systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival. RESULTS: A total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing. CONCLUSION: Efforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making. FAU - Mbeutcha, Aurelie AU - Mbeutcha A AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University of Nice Sophia-Antipolis, Hopital Pasteur 2, Centre Hospitalier Universitaire de Nice, Nice, France. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Pitie-Salpetriere Hospital, APHP, University Paris VI, Paris, France. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Karakiewicz, Pierre I AU - Karakiewicz PI AD - Department of Urology, University of Montreal Health Center, Montreal, QC, Canada. FAU - Lawrentschuk, Nathan AU - Lawrentschuk N AD - Department of Surgical Oncology, Peter MacCallum Cancer Centre and Department of Surgery/Olivia Newton John Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. FAU - Novara, Giacomo AU - Novara G AD - Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. FAU - Seitz, Christian AU - Seitz C AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. sfshariat@gmail.com. AD - Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. sfshariat@gmail.com. LA - eng PT - Journal Article PT - Systematic Review DEP - 20160421 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Age Factors MH - Biomarkers, Tumor/*metabolism MH - Carcinoma in Situ/epidemiology MH - Carcinoma, Transitional Cell/epidemiology/metabolism/pathology/*therapy MH - Clinical Decision-Making MH - Disease-Free Survival MH - Humans MH - Hydronephrosis/epidemiology MH - Kidney Neoplasms/epidemiology/metabolism/pathology/*therapy MH - Kidney Pelvis/pathology/*surgery MH - Lymph Nodes/pathology MH - Lymphatic Metastasis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplasms, Multiple Primary/epidemiology/metabolism/pathology/*therapy MH - Obesity/epidemiology MH - Prognosis MH - Risk Assessment MH - Smoking/epidemiology MH - Ureteral Neoplasms/epidemiology/metabolism/pathology/*therapy OTO - NOTNLM OT - Biomarkers OT - Disease recurrence OT - Nomograms OT - Predictive tools OT - Prognosis OT - Prognostic factors OT - Risk stratification OT - Survival OT - Upper tract urothelial carcinoma EDAT- 2016/04/22 06:00 MHDA- 2017/10/03 06:00 CRDT- 2016/04/22 06:00 PHST- 2016/01/09 00:00 [received] PHST- 2016/04/04 00:00 [accepted] PHST- 2016/04/22 06:00 [pubmed] PHST- 2017/10/03 06:00 [medline] PHST- 2016/04/22 06:00 [entrez] AID - 10.1007/s00345-016-1826-2 [pii] AID - 10.1007/s00345-016-1826-2 [doi] PST - ppublish SO - World J Urol. 2017 Mar;35(3):337-353. doi: 10.1007/s00345-016-1826-2. Epub 2016 Apr 21. PMID- 27098923 OWN - NLM STAT- MEDLINE DCOM- 20180104 LR - 20180117 IS - 1464-5157 (Electronic) IS - 0265-6736 (Linking) VI - 32 IP - 4 DP - 2016 Jun TI - Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. PG - 434-45 LID - 10.3109/02656736.2016.1155761 [doi] AB - Non-muscle-invasive bladder cancer is a challenging disease, even given its superficial nature. It is prone to multiple recurrences and progression to muscle-invasive cancer. These features of this disease contribute significantly to reduced quality of life as well as creating significant morbidity and even mortality. Randomised trials demonstrate that when hyperthermia is added to conventional mitomycin-C treatment that local control rates and progression-free survival are substantially improved. In this review we consider how hyperthermia can exert such beneficial effects. Some of the mechanisms presented are theoretical, while others are facts. It is hoped that this review will contribute rationale for further examination of mechanisms, because an understanding of such mechanisms may lead to even better chemotherapeutic approaches, as well as potential biomarkers for predicting and monitoring treatment success. FAU - van der Heijden, Antoine G AU - van der Heijden AG AD - a Department of Urology , Radboud University Medical Centre , Nijmegen , the Netherlands ; FAU - Dewhirst, Mark W AU - Dewhirst MW AD - b Radiation Oncology, Duke University , Durham , North Carolina , USA. LA - eng PT - Journal Article PT - Review DEP - 20160420 PL - England TA - Int J Hyperthermia JT - International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group JID - 8508395 RN - 0 (Antineoplastic Agents) SB - IM MH - Animals MH - Antineoplastic Agents/*administration & dosage/pharmacokinetics/therapeutic use MH - Biological Transport MH - Combined Modality Therapy MH - *Drug Resistance, Neoplasm MH - Humans MH - *Hyperthermia, Induced MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*therapy OTO - NOTNLM OT - Drug transport OT - hyperthermia OT - intravesical chemotherapy OT - non-muscle-invasive bladder cancer OT - thermochemotherapy EDAT- 2016/04/22 06:00 MHDA- 2018/01/05 06:00 CRDT- 2016/04/22 06:00 PHST- 2016/04/22 06:00 [entrez] PHST- 2016/04/22 06:00 [pubmed] PHST- 2018/01/05 06:00 [medline] AID - 10.3109/02656736.2016.1155761 [doi] PST - ppublish SO - Int J Hyperthermia. 2016 Jun;32(4):434-45. doi: 10.3109/02656736.2016.1155761. Epub 2016 Apr 20. PMID- 27091807 OWN - NLM STAT- MEDLINE DCOM- 20171227 LR - 20200225 IS - 1569-8041 (Electronic) IS - 0923-7534 (Print) IS - 0923-7534 (Linking) VI - 27 IP - 7 DP - 2016 Jul TI - Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. PG - 1311-6 LID - 10.1093/annonc/mdw170 [doi] AB - BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candidate for personalized bladder cancer treatment, particularly in patients with mutated FGFR3. We addressed tumor heterogeneity in a large multicenter, multi-laboratory study, as this may have significant impact on therapeutic response. PATIENTS AND METHODS: We evaluated possible FGFR3 heterogeneity by the PCR-SNaPshot method in the superficial and deep compartments of tumors obtained by transurethral resection (TUR, n = 61) and in radical cystectomy (RC, n = 614) specimens and corresponding cancer-positive lymph nodes (LN+, n = 201). RESULTS: We found FGFR3 mutations in 13/34 (38%) T1 and 8/27 (30%) >/=T2-TUR samples, with 100% concordance between superficial and deeper parts in T1-TUR samples. Of eight FGFR3 mutant >/=T2-TUR samples, only 4 (50%) displayed the mutation in the deeper part. We found 67/614 (11%) FGFR3 mutations in RC specimens. FGFR3 mutation was associated with pN0 (P < 0.001) at RC. In 10/201 (5%) LN+, an FGFR3 mutation was found, all concordant with the corresponding RC specimen. In the remaining 191 cases, RC and LN+ were both wild type. CONCLUSIONS: FGFR3 mutation status seems promising to guide decision-making on adjuvant anti-FGFR3 therapy as it appeared homogeneous in RC and LN+. Based on the results of TUR, the deep part of the tumor needs to be assessed if neoadjuvant anti-FGFR3 treatment is considered. We conclude that studies on the heterogeneity of actionable molecular targets should precede clinical trials with these drugs in the perioperative setting. CI - (c) The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Pouessel, D AU - Pouessel D AD - Inserm U955, Hopital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Creteil Department of Medical Oncology, Hopital Saint-Louis, AP-HP, Paris, France. FAU - Neuzillet, Y AU - Neuzillet Y AD - Departments of Surgical Oncology (Urology). FAU - Mertens, L S AU - Mertens LS AD - Departments of Surgical Oncology (Urology). FAU - van der Heijden, M S AU - van der Heijden MS AD - Medical Oncology. FAU - de Jong, J AU - de Jong J AD - Pathology. FAU - Sanders, J AU - Sanders J AD - Pathology Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Peters, D AU - Peters D AD - Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Leroy, K AU - Leroy K AD - Tissue Biobank Unit. FAU - Manceau, A AU - Manceau A AD - Tissue Biobank Unit. FAU - Maille, P AU - Maille P AD - Departments of Pathology. FAU - Soyeux, P AU - Soyeux P AD - Inserm U955, Hopital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Creteil. FAU - Moktefi, A AU - Moktefi A AD - Departments of Pathology. FAU - Semprez, F AU - Semprez F AD - Inserm U955, Hopital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Creteil. FAU - Vordos, D AU - Vordos D AD - Urology, Hopital Henri Mondor, APHP, Creteil, France. FAU - de la Taille, A AU - de la Taille A AD - Inserm U955, Hopital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Creteil Urology, Hopital Henri Mondor, APHP, Creteil, France. FAU - Hurst, C D AU - Hurst CD AD - Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK. FAU - Tomlinson, D C AU - Tomlinson DC AD - Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK. FAU - Harnden, P AU - Harnden P AD - Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK. FAU - Bostrom, P J AU - Bostrom PJ AD - Departments of Urology Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto. FAU - Mirtti, T AU - Mirtti T AD - Pathology, University of Turku, Turku, Finland. FAU - Horenblas, S AU - Horenblas S AD - Departments of Surgical Oncology (Urology). FAU - Loriot, Y AU - Loriot Y AD - Department of Cancer Medicine and INSERM U981, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif. FAU - Houede, N AU - Houede N AD - Department of Oncological Medicine, Institut Bergonie, Bordeaux. FAU - Chevreau, C AU - Chevreau C AD - Department of Oncological Medicine, Institut Claudius Regaud, Toulouse. FAU - Beuzeboc, P AU - Beuzeboc P AD - Department of Oncological Medicine, Institut Curie, Paris, France. FAU - Shariat, S F AU - Shariat SF AD - Departments of Urology Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Sagalowsky, A I AU - Sagalowsky AI AD - Departments of Urology. FAU - Ashfaq, R AU - Ashfaq R AD - Pathology, University of Texas, Southwestern Medical Center, Dallas, USA. FAU - Burger, M AU - Burger M AD - Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Jewett, M A S AU - Jewett MA AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto. FAU - Zlotta, A R AU - Zlotta AR AD - Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto Departments of Surgery (Urology). FAU - Broeks, A AU - Broeks A AD - Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Bapat, B AU - Bapat B AD - Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto. FAU - Knowles, M A AU - Knowles MA AD - Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK. FAU - Lotan, Y AU - Lotan Y AD - Departments of Urology. FAU - van der Kwast, T H AU - van der Kwast TH AD - Department of Pathology, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. FAU - Culine, S AU - Culine S AD - Department of Medical Oncology, Hopital Saint-Louis, AP-HP, Paris, France Department of Medical Oncology, Paris 7 University, Paris. FAU - Allory, Y AU - Allory Y AD - Inserm U955, Hopital Henri Mondor, APHP, Team 7 Translational Research of Genito-Urinary Oncogenesis, Creteil Departments of Pathology Department of Pathology, Universite Paris Est, UPEC, Creteil, France. FAU - van Rhijn, B W G AU - van Rhijn BW AD - Departments of Surgical Oncology (Urology) Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, Regensburg, Germany Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto Departments of Surgery (Urology) Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto b.v.rhijn@nki.nl. LA - eng GR - Cancer Research UK/United Kingdom PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20160418 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*genetics MH - Clinical Decision-Making MH - Cystectomy MH - Female MH - Gene Expression Regulation, Neoplastic MH - Genetic Heterogeneity MH - Humans MH - Lymph Nodes/pathology MH - Male MH - Middle Aged MH - Mutation MH - Perioperative Period MH - Receptor, Fibroblast Growth Factor, Type 3/antagonists & inhibitors/*genetics MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/pathology/surgery PMC - PMC6608613 OTO - NOTNLM OT - FGFR3 OT - bladder OT - cancer OT - heterogeneity OT - mutations OT - targeted therapy EDAT- 2016/04/20 06:00 MHDA- 2017/12/28 06:00 PMCR- 2017/07/01 CRDT- 2016/04/20 06:00 PHST- 2016/02/04 00:00 [received] PHST- 2016/04/06 00:00 [accepted] PHST- 2016/04/20 06:00 [entrez] PHST- 2016/04/20 06:00 [pubmed] PHST- 2017/12/28 06:00 [medline] PHST- 2017/07/01 00:00 [pmc-release] AID - S0923-7534(19)35696-0 [pii] AID - mdw170 [pii] AID - 10.1093/annonc/mdw170 [doi] PST - ppublish SO - Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. PMID- 27085823 OWN - NLM STAT- MEDLINE DCOM- 20170112 LR - 20260127 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 23 IP - 2 DP - 2016 Apr TI - Short term complications from transurethral resection of bladder tumor. PG - 8198-203 AB - INTRODUCTION: The diagnosis and subsequent management of bladder cancer often involves transurethral resection of bladder tumor (TURBT). Risks of TURBT include perioperative complications such as bleeding, pain and perforation. We aimed to determine TURBT complication rates and risk factors in a contemporary series. MATERIALS AND METHODS: From 2002 to 2011, 505 patients underwent TURBT either for suspected bladder cancer or during follow up at a single institution. Baseline patient characteristics and complications within 2 weeks of surgery were extracted from the electronic medical record for all TURBTs. Patient and tumor characteristics were evaluated for associations with complication using univariate analysis. A multivariable logistic regression was fit to further examine associations between TURBT related characteristics and complication. RESULTS: A total of 910 TURBTs were performed on 505 patients. Overall complication rate was 8.1%. The most common complications were pain or spasm (3.0%), retention (2.8%), and infection (2.1%), and 0.5% of TURBTs had perforation. Over 85% of complications were Clavien-Dindo grade I or II. Forty-three patients had a complication after their first TURBT, while 25 had complications after subsequent TURBTs. Prior complication and single tumor, but not other patient or tumor-related characteristics, were associated with complication. Only prior complication (p < 0.01) was associated with subsequent complication after TURBT on multivariable analysis. CONCLUSIONS: Complication rate after TURBT is 8.1% and complications are generally not severe in nature. Prior short term complication is likely associated with subsequent complication. Further studies are needed to validate these results and determine patient groups most at risk for intraoperative and post TURBT complications. FAU - Gregg, Justin R AU - Gregg JR AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - McCormick, Benjamin AU - McCormick B FAU - Wang, Li AU - Wang L FAU - Cohen, Paul AU - Cohen P FAU - Sun, Daniel AU - Sun D FAU - Penson, David F AU - Penson DF FAU - Smith, Joseph A AU - Smith JA FAU - Clark, Peter E AU - Clark PE FAU - Cookson, Michael S AU - Cookson MS FAU - Barocas, Daniel A AU - Barocas DA FAU - Resnick, Matthew J AU - Resnick MJ FAU - Moses, Kelvin A AU - Moses KA FAU - Chang, Sam S AU - Chang SS LA - eng GR - UL1TR000445/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Aged MH - Cystectomy/*adverse effects/methods MH - Cystoscopy MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Natural Orifice Endoscopic Surgery/*adverse effects MH - Neoplasm Staging MH - Postoperative Complications/*epidemiology/etiology MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - United States/epidemiology MH - Urethra MH - Urinary Bladder Neoplasms/diagnosis/*surgery EDAT- 2016/04/18 06:00 MHDA- 2017/01/14 06:00 CRDT- 2016/04/18 06:00 PHST- 2016/04/18 06:00 [entrez] PHST- 2016/04/18 06:00 [pubmed] PHST- 2017/01/14 06:00 [medline] PST - ppublish SO - Can J Urol. 2016 Apr;23(2):8198-203. PMID- 27085624 OWN - NLM STAT- MEDLINE DCOM- 20180111 LR - 20181203 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 70 IP - 2 DP - 2016 Aug TI - Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-alpha2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. PG - 341-7 LID - S0302-2838(16)30010-0 [pii] LID - 10.1016/j.eururo.2016.03.034 [doi] AB - BACKGROUND: Patients with non-muscle-invasive bladder cancer (NMIBC) belonging to the intermediate-risk group should be treated with intravesical instillations to prevent recurrence and progression. OBJECTIVE: We compared the outcome of a monthly maintenance bacillus Calmette-Guerin (BCG) regimen with that of epirubicin (EPI) and interferon-alpha2a (IFN) in patients with NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Our prospective randomized multicenter study comprised 229 eligible patients with frequently recurrent TaT1 grade 1-2 or low-grade NMIBC enrolled between 1997 and 2008. INTERVENTIONS: The four-arm study involved a single perioperative instillation of EPI plus five weekly instillations of BCG or EPI/IFN, followed by 11 monthly instillations in the 1-yr BCG or EPI/IFN maintenance arms, further followed by four additional quarterly instillations in the two 2-yr maintenance arms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence, progression, disease-specific survival, and overall mortality were analyzed using the Kaplan-Meier and cumulative incidence analyses plus the Cox and proportional subdistribution hazards models. RESULTS AND LIMITATIONS: The median follow-up time was 7.5 and 7.4 yr in the BCG and EPI/IFN groups, respectively. The probability of recurrence was significantly lower in the BCG group than in the EPI/IFN group. The probability was 39% versus 72% at 7.4 yr, respectively (hazard ratio [HR]: 0.41; 95% confidence interval [CI], 0.28-0.60; p<0.001). There was no significant difference in the probability of progression or in overall survival. However, there was a significant difference in disease-specific mortality in favor of the BCG group (HR: 0.20; 95% CI, 0.04-0.91; p=0.04). CONCLUSIONS: The monthly maintenance BCG regimen showed excellent efficacy and was significantly better in preventing recurrence than a similar regimen of EPI/IFN-alpha2a. PATIENT SUMMARY: A monthly bacillus Calmette-Guerin (BCG) regimen showed excellent efficacy and was significantly better in preventing recurrence than a similar regimen of epirubicin and interferon-alpha2a. TRIAL REGISTRATION: Registration was not considered necessary at this stage of the follow-up because the study was initiated as early as in 1997, before the current requirements concerning study registrations were implemented. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Marttila, Timo AU - Marttila T AD - Department of Urology, Seinajoki Central Hospital, Seinajoki, Finland. Electronic address: timo.marttila@epshp.fi. FAU - Jarvinen, Riikka AU - Jarvinen R AD - Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Liukkonen, Tapani AU - Liukkonen T AD - Department of Surgery, Mikkeli Central Hospital, Mikkeli, Finland. FAU - Rintala, Erkki AU - Rintala E AD - Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Bostrom, Peter AU - Bostrom P AD - Department of Urology, Turku University Hospital, Turku, Finland. FAU - Seppanen, Marjo AU - Seppanen M AD - Department of Surgery, Satakunta Central Hospital, Pori, Finland. FAU - Tammela, Teuvo AU - Tammela T AD - Department of Urology, Tampere University Hospital, Tampere, Finland. FAU - Hellstrom, Pekka AU - Hellstrom P AD - Department of Urology, Oulu University Hospital, Oulu, Finland. FAU - Aaltomaa, Sirpa AU - Aaltomaa S AD - Department of Urology, Kuopio University Hospital, Kuopio, Finland. FAU - Leskinen, Markku AU - Leskinen M AD - Department of Urology, Seinajoki Central Hospital, Seinajoki, Finland. FAU - Raitanen, Mika AU - Raitanen M AD - Department of Urology, Seinajoki Central Hospital, Seinajoki, Finland. FAU - Kaasinen, Eero AU - Kaasinen E AD - Department of Surgery, Hyvinkaa Hospital and Helsinki University Hospital, Hyvinkaa, Finland. CN - FinnBladder Group LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20160413 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 0 (Interferon alpha-2) RN - 0 (Interferon-alpha) RN - 0 (Recombinant Proteins) RN - 3Z8479ZZ5X (Epirubicin) SB - IM CIN - Eur Urol. 2017 Jan;71(1):139-140. doi: 10.1016/j.eururo.2016.10.016. PMID: 27793477 MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Aged MH - Antibiotics, Antineoplastic/administration & dosage MH - BCG Vaccine/*administration & dosage MH - Epirubicin/*administration & dosage MH - Female MH - Humans MH - Interferon alpha-2 MH - Interferon-alpha/*administration & dosage MH - Male MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Recombinant Proteins/administration & dosage MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder/*pathology MH - *Urinary Bladder Neoplasms/drug therapy/mortality/pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Epirubicin OT - Instillation therapy OT - Interferon alpha-2b OT - Mitomycin C OT - Recurrent non-muscle-invasive bladder cancer OT - SWOG EDAT- 2016/04/18 06:00 MHDA- 2018/01/13 06:00 CRDT- 2016/04/18 06:00 PHST- 2016/01/07 00:00 [received] PHST- 2016/03/26 00:00 [accepted] PHST- 2016/04/18 06:00 [entrez] PHST- 2016/04/18 06:00 [pubmed] PHST- 2018/01/13 06:00 [medline] AID - S0302-2838(16)30010-0 [pii] AID - 10.1016/j.eururo.2016.03.034 [doi] PST - ppublish SO - Eur Urol. 2016 Aug;70(2):341-7. doi: 10.1016/j.eururo.2016.03.034. Epub 2016 Apr 13. PMID- 27073547 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 11 IP - 4 DP - 2016 Apr TI - Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review. PG - 2751-2756 AB - The aim of the present meta-analysis was to compare the benefits of Bacillus Calmetter-Guerin (BCG) and mitomycin C in the treatment of patients with superficial bladder cancer. The present meta-analysis analyzed the benefits of BCG and mitomycin C in the treatment of patients with superficial bladder cancer by comparing progression-free survival (PFS) rates in patients treated with either of the drugs following transurethral resection. The Medline, Cochrane and EMBASE databases were searched between January 1966 and August 31, 2014 for studies that investigated the efficacy of the intravesical instillation of chemotherapy in patients with non-muscle invasive bladder cancer who had been treated with transurethral resection. Search terms included: 'Urinary bladder neoplasms', 'superficial bladder cancer' and 'non-muscle invasive bladder cancer'; 'bacillus Calmette-Guerin' or 'BCG'; 'mitomycin C'; and 'intravesical administration'. Sensitivity and data quality analyses were performed. A total of 6 randomized controlled studies were included with 1,289 patients. Complete 5-year PFS data for patients who received intravesical resection and were treated with mitomycin C or BCG was provided for 3 of the 6 studies, which were therefore included in the meta-analysis. The overall analysis revealed a significant benefit of BCG compared with mitomycin C in terms of 5-year PFS rate (odds ratio, 0.53; 95% confidence interval, 0.38-0.75; P<0.001), indicating that BCG was superior to mitomycin C therapy in patients with non-muscle invasive bladder cancer following transurethral resection. FAU - Jiang, Shang-Jun AU - Jiang SJ AD - Department of Urinary Surgery, The People's Hospital of Fuyang, Hangzhou, Zhejiang 311400, P.R. China. FAU - Ye, Li-Yin AU - Ye LY AD - Department of Urinary Surgery, The People's Hospital of Fuyang, Hangzhou, Zhejiang 311400, P.R. China. FAU - Meng, Fan-Hua AU - Meng FH AD - Department of Urinary Surgery, The People's Hospital of Fuyang, Hangzhou, Zhejiang 311400, P.R. China. LA - eng PT - Journal Article DEP - 20160309 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC4812557 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - mitomycin C OT - non-muscle invasive bladder cancer OT - progression-free survival OT - superficial bladder cancer EDAT- 2016/04/14 06:00 MHDA- 2016/04/14 06:01 PMCR- 2016/03/09 CRDT- 2016/04/14 06:00 PHST- 2015/01/27 00:00 [received] PHST- 2016/02/05 00:00 [accepted] PHST- 2016/04/14 06:00 [entrez] PHST- 2016/04/14 06:00 [pubmed] PHST- 2016/04/14 06:01 [medline] PHST- 2016/03/09 00:00 [pmc-release] AID - OL-0-0-4325 [pii] AID - 10.3892/ol.2016.4325 [doi] PST - ppublish SO - Oncol Lett. 2016 Apr;11(4):2751-2756. doi: 10.3892/ol.2016.4325. Epub 2016 Mar 9. PMID- 27072170 OWN - NLM STAT- MEDLINE DCOM- 20160711 LR - 20161020 IS - 1124-3562 (Print) IS - 1124-3562 (Linking) VI - 88 IP - 1 DP - 2016 Mar 31 TI - Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy? PG - 13-6 LID - 10.4081/aiua.2016.1.13 [doi] AB - OBJECTIVE: To evaluate the main factors which influence understaging in patients with T1G3 non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: 109 patients with T1/G3 underwent transurethral resection of bladder tumor (TURBT) and then radical cystectomy (RC) with pelvic lymph nodes dissection. A number of variables were considered when evaluating the detection of understaging. We considered the patients age and gender, as well as the size, number, location and morphology of their tumor. We also considered coexistence of bladder carcinoma in situ (CIS), microscopic vascular invasion and deep lamina propria invasion. The level of experience of the surgeon was also analyzed. RESULTS: in RC samples muscle invasion, that is understaging, was detected in 74 (67.9%) patients, while 35 (32.1%) patients were appropriately staged. In these cohort of patients with high grade tumors, understaging was associated with deep lamina propria and microscopic vascular invasion, multiple tumors, tumor size > 6 cm, tumor location (trigone and dome), presence of residual tumor; age, gender, tumor morphology, CIS associated, and experience of urological surgeon were not associated with clinical understaging. CONCLUSIONS: in our study, evaluating patients with high grade NMIBC at first TURBT, we identified some risk factors that need to be considered and that are able to increase the risk of understaging: deep lamina propria and microscopic vascular invasion, multiple tumors, tumor size > 6 cm, tumor location (trigone and dome), presence of residual tumor. When these risk factors are present, performing an early cystectomy, and not a re-TURBT, could lower the risk of worse pathological finding due to rapid disease progression of the high grade tumors, and can prolong survival. FAU - Minardi, Daniele AU - Minardi D AD - Department of Clinic and Specialistic Sciences, Urology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona. d.minardi@gostec.net. FAU - Milanese, Giulio AU - Milanese G FAU - Parri, Gianni AU - Parri G FAU - Lacetera, Vito AU - Lacetera V FAU - Muzzonigro, Giovanni AU - Muzzonigro G LA - eng PT - Journal Article DEP - 20160331 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Cystectomy/*methods MH - Databases, Factual MH - Disease Progression MH - Female MH - Humans MH - Lymph Node Excision MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Risk Factors MH - Urinary Bladder Neoplasms/*pathology/surgery EDAT- 2016/04/14 06:00 MHDA- 2016/07/12 06:00 CRDT- 2016/04/14 06:00 PHST- 2015/03/07 00:00 [received] PHST- 2015/03/29 00:00 [accepted] PHST- 2016/04/14 06:00 [entrez] PHST- 2016/04/14 06:00 [pubmed] PHST- 2016/07/12 06:00 [medline] AID - 10.4081/aiua.2016.1.13 [doi] PST - epublish SO - Arch Ital Urol Androl. 2016 Mar 31;88(1):13-6. doi: 10.4081/aiua.2016.1.13. PMID- 27070091 OWN - NLM STAT- MEDLINE DCOM- 20171212 LR - 20211204 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 19 DP - 2016 May 10 TI - Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer. PG - 28384-92 LID - 10.18632/oncotarget.8635 [doi] AB - Bladder cancer is a heterogeneous disease with outcome difficult to predict, and novel predictive biomarkers are needed. PCDH7, a member of protocadherins family, functions as tumor suppressor in several human cancers. The human PCDH7 gene is localized in chromosome 4p15, which is often inactivated in human cancers, including bladder cancer. The aim of this study was to investigate the clinical significance of PCDH7 expression in non-muscle invasive bladder cancer (NMIBC). PCDH7 expression was examined using immunohistochemical staining in 199 primary NMIBC tissues and 25 normal bladder epithelial tissues. Then the relationship between PCDH7 expression and clinicopathologic features was evaluated. Kaplan-Meier survival analysis and Cox analysis was used to evaluate the correlation between PCDH7 expression and prognosis. PCDH7 expression in NMIBC tissues was significantly lower than that in normal bladder epithelial tissues (P < 0.001). Low PCDH7 expression correlated with advanced grade (P = 0.021) and larger tumor size (P = 0.044). Moreover, patients with low PCDH7 expression have shorter recurrence-free survival (P < 0.001), progression-free survival (P = 0.007) and overall survival (P = 0.011) than patients with high PCDH7 expression. Low PCDH7 expression is an independent predictor of recurrence-free survival (multivariate Cox analysis: P = 0.007), progression-free survival (multivariate Cox analysis: P = 0.014) and overall survival (multivariate Cox analysis: P = 0.004). The findings indicate that low PCDH7 expression is a potential prognostic biomarker for primary NMIBC. FAU - Lin, Ying-Li AU - Lin YL AD - Department of Urology, Xuzhou Cancer Hospital, Affiliated Xuzhou Hospital of Jiangsu University, Xuzhou, 221000, Jiangsu, China. FAU - Wang, Yan-Ling AU - Wang YL AD - Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, Guangdong, China. FAU - Fu, Xing-Li AU - Fu XL AD - Health Science Center, Jiangsu University, Zhenjiang, 212000, Jiangsu, China. FAU - Li, Wen-Ping AU - Li WP AD - Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, 050051, Hebei, China. FAU - Wang, Yu-Hao AU - Wang YH AD - Department of Clinical Medicine, Nanjing Medical University, Nanjing, 210000, Jiangsu, China. FAU - Ma, Jian-Guo AU - Ma JG AD - Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, 050051, Hebei, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (Cadherins) RN - 0 (PCDH7 protein, human) RN - 0 (Protocadherins) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*analysis MH - Cadherins/analysis/*biosynthesis MH - Carcinoma, Transitional Cell/mortality/*pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Protocadherins MH - Urinary Bladder Neoplasms/mortality/*pathology PMC - PMC5053733 OTO - NOTNLM OT - PCDH7 OT - biomarker OT - bladder cancer OT - prognosis OT - protocadherin7 COIS- The authors had no conflicts of interest to declare in relation to this article. EDAT- 2016/04/14 06:00 MHDA- 2017/12/13 06:00 PMCR- 2016/05/10 CRDT- 2016/04/13 06:00 PHST- 2015/12/04 00:00 [received] PHST- 2016/02/23 00:00 [accepted] PHST- 2016/04/13 06:00 [entrez] PHST- 2016/04/14 06:00 [pubmed] PHST- 2017/12/13 06:00 [medline] PHST- 2016/05/10 00:00 [pmc-release] AID - 8635 [pii] AID - 10.18632/oncotarget.8635 [doi] PST - ppublish SO - Oncotarget. 2016 May 10;7(19):28384-92. doi: 10.18632/oncotarget.8635. PMID- 27069153 OWN - NLM STAT- MEDLINE DCOM- 20160822 LR - 20260127 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 36 IP - 4 DP - 2016 Apr TI - Predictive Value of NRAMP1 and HGPX1 Gene Polymorphism for Maintenance BCG Response in Non-muscle-invasive Bladder Cancer. PG - 1737-43 AB - AIM: To assess the potential predictive value of natural resistance-associated macrophage protein 1 (NRAMP1) and human glutathione peroxidase 1 (hGPX1) polymorphism in non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation, we conducted an original ancillary multicenter study. PATIENTS AND METHODS: We evaluated patients included in the multicenter URO-BCG 4 trial, who received three weekly instillations of one-third dose BCG every 6 months (group I) or two weekly instillations every 3 months (group II) for 3 years. For clinical evaluation we also evaluated tumor recurrence and muscle progression. NRAMP1 and hGPX1 polymorphism analyses were performed on blood DNA. NRAMP1 exon 15 and hGPX1 exon 1c were amplified using Type-it Microsatellite PCR Kit(R) for multiplex polymerase chain reaction. RESULTS: From June 2004 to April 2010, 146 randomized patients were included in this retrospective study. Blood samples were obtained from 107 patients. With 36 months of follow-up, 13.6% of patients had a tumor recurrence and muscle-invasive progression was observed in 4.3% of patients. Concerning NRAMP1 D543N polymorphism, patients with allele A had no tumor recurrence or muscle-invasive progression. No significant difference was observed in gene polymorphism distribution between groups I and II. Moreover, we did not observe any significant association of gene polymorphisms, tumor recurrence or muscle-invasive progression, event time and disease-free survival. CONCLUSION: Our results suggest that no significant difference was found for NRAMP1 and hGPX1 gene polymorphisms associated with recurrence time, muscle invasion frequency and disease-free survival, nevertheless, we observed that the NRAMP1 D543N GG genotype group had a shorter time to tumor recurrence. CI - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Lenormand, Claire AU - Lenormand C AD - Department of Urology, Rouen University Hospital, Rouen, France. FAU - Couteau, Jerome AU - Couteau J AD - BioTechnology Laboratory, Science and Technology University, Le Havre, France. FAU - Nouhaud, Francois-Xavier AU - Nouhaud FX AD - Department of Urology, Rouen University Hospital, Rouen, France. FAU - Maillet, Geraldine AU - Maillet G AD - BioTechnology Laboratory, Science and Technology University, Le Havre, France. FAU - Bou, Jacqueline AU - Bou J AD - Department of Genetics, Rouen University Hospital, Rouen, France. FAU - Gobet, Francoise AU - Gobet F AD - Department of Pathology, Rouen University Hospital, Rouen, France. FAU - Pfister, Christian AU - Pfister C AD - Department of Urology, Rouen University Hospital, Rouen, France Clinical Investigation Center, Inserm 6204, Onco-Urology Group, Rouen, France christian.pfister@chu-rouen.fr. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Cation Transport Proteins) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.11.1.9 (Glutathione Peroxidase GPX1) RN - 0 (Natural Resistance-associated Macrophage Protein 1) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cation Transport Proteins/*genetics MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Glutathione Peroxidase/*genetics MH - Humans MH - Male MH - Middle Aged MH - Muscles/microbiology/*pathology MH - Mycobacterium bovis/*metabolism MH - Neoplasm Recurrence, Local/genetics/microbiology/pathology MH - Polymorphism, Genetic/*genetics MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*genetics/microbiology/pathology MH - Glutathione Peroxidase GPX1 MH - Natural Resistance-associated Macrophage Protein 1 OTO - NOTNLM OT - BGG OT - NRAMP1 OT - bladder cancer OT - hGPX1 OT - polymorphism OT - recurrence EDAT- 2016/04/14 06:00 MHDA- 2016/08/23 06:00 CRDT- 2016/04/13 06:00 PHST- 2015/12/18 00:00 [received] PHST- 2016/01/29 00:00 [accepted] PHST- 2016/04/13 06:00 [entrez] PHST- 2016/04/14 06:00 [pubmed] PHST- 2016/08/23 06:00 [medline] AID - 36/4/1737 [pii] PST - ppublish SO - Anticancer Res. 2016 Apr;36(4):1737-43. PMID- 27045233 OWN - NLM STAT- MEDLINE DCOM- 20170601 LR - 20170601 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 50 IP - 3 DP - 2016 Jun TI - Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. PG - 234-8 LID - 10.3109/21681805.2016.1163616 [doi] AB - OBJECTIVE: Transurethral resection of bladder tumor (TURBT) pathology specimens which lack muscle are associated with clinical upstaging and may necessitate repeat resections, potentially delaying curative treatment. This study evaluated whether resident involvement in TURBT is associated with suboptimal perioperative outcomes. MATERIALS AND METHODS: All TURBTs performed at a Canadian healthcare institution from November 2011 to June 2014 were reviewed. Multivariable logistic regression models assessed associations between intraoperative resident involvement and TURBT muscle presence. Among high-risk patients (high grade, >/= T1 or carcinoma in situ) who underwent cystectomy, time from TURBT to cystectomy was compared between resident and attending urologists with the log-rank test. RESULTS: In total, 463 TURBTs were identified. In multivariable analyses, residents were less likely to obtain muscle in specimens for all TURBTs [adjusted odds ratio (aOR) 0.59, p = 0.03] and the subset of 275 high-risk TURBTs (aOR 0.41, p = 0.006). Among patients who underwent cystectomy, time to cystectomy was delayed by a median of 23 days when residents were involved in the initial high-risk TURBT compared with attending urologists only (p = 0.024). CONCLUSIONS: In this single academic center series, intraoperative resident involvement was associated with a decreased rate of muscle presence in TURBT specimens and a prolonged time to cystectomy. FAU - Bos, Derek AU - Bos D AD - a McMaster University , Hamilton , ON , Canada ; FAU - Allard, Christopher B AU - Allard CB AD - a McMaster University , Hamilton , ON , Canada ; AD - b Massachusetts General Hospital , Boston , MA , USA ; AD - c Brigham and Women's Hospital , Boston , MA , USA. FAU - Dason, Shawn AU - Dason S AD - a McMaster University , Hamilton , ON , Canada ; FAU - Ruzhynsky, Vladimir AU - Ruzhynsky V AD - a McMaster University , Hamilton , ON , Canada ; FAU - Kapoor, Anil AU - Kapoor A AD - a McMaster University , Hamilton , ON , Canada ; FAU - Shayegan, Bobby AU - Shayegan B AD - a McMaster University , Hamilton , ON , Canada ; LA - eng PT - Journal Article DEP - 20160404 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 SB - IM MH - Aged MH - Cohort Studies MH - Cystectomy/*methods MH - *Cystoscopy MH - Female MH - Humans MH - *Internship and Residency MH - Male MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Bladder cancer OT - cystectomy OT - education OT - endoscopy EDAT- 2016/04/06 06:00 MHDA- 2017/06/02 06:00 CRDT- 2016/04/06 06:00 PHST- 2016/04/06 06:00 [entrez] PHST- 2016/04/06 06:00 [pubmed] PHST- 2017/06/02 06:00 [medline] AID - 10.3109/21681805.2016.1163616 [doi] PST - ppublish SO - Scand J Urol. 2016 Jun;50(3):234-8. doi: 10.3109/21681805.2016.1163616. Epub 2016 Apr 4. PMID- 27045034 OWN - NLM STAT- MEDLINE DCOM- 20170427 LR - 20170427 IS - 1940-6215 (Electronic) IS - 1940-6215 (Linking) VI - 9 IP - 6 DP - 2016 Jun TI - Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer. PG - 437-44 LID - 10.1158/1940-6207.CAPR-15-0345 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993-1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P >/= 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P = 0.02), CS (P = 0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (>/=350 pg/mL) had a significantly shorter OS (P = 0.01), CS (P = 0.02), and BCS (P = 0.008). The trend across quintiles of VEGF was significant for BCS (P = 0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR = 2.7; 95% CI, 1.1-6.5), CS (HR = 3.3; 95% CI, 1.1-9.4) and BCS (HR = 8.9; 95% CI,1.3-61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437-44. (c)2016 AACR. CI - (c)2016 American Association for Cancer Research. FAU - Puntoni, Matteo AU - Puntoni M AD - Clinical Trial Unit, Scientific Direction, E.O. Ospedali Galliera, Genoa, Italy. FAU - Petrera, Marilena AU - Petrera M AD - Medical Oncology Unit, E.O. Ospedali Galliera, Genoa, Italy. FAU - Campora, Sara AU - Campora S AD - Medical Oncology Unit, E.O. Ospedali Galliera, Genoa, Italy. FAU - Garrone, Elsa AU - Garrone E AD - Liguria Region Mortality Registry, IRCCS AOU San Martino-IST, Genoa, Italy. FAU - Defferrari, Carlotta AU - Defferrari C AD - Medical Oncology Unit, E.O. Ospedali Galliera, Genoa, Italy. FAU - Torrisi, Rosalba AU - Torrisi R AD - Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy. FAU - Johansson, Harriet AU - Johansson H AD - Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. FAU - Bruno, Silvia AU - Bruno S AD - Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy. FAU - Curotto, Antonio AU - Curotto A AD - University Urology Clinic, IRCCS AOU San Martino-IST, Genoa, Italy. FAU - DeCensi, Andrea AU - DeCensi A AD - Medical Oncology Unit, E.O. Ospedali Galliera, Genoa, Italy. Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK. andrea.decensi@galliera.it. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160404 PL - United States TA - Cancer Prev Res (Phila) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (VEGFA protein, human) RN - 0 (Vascular Endothelial Growth Factor A) RN - 187EJ7QEXL (Fenretinide) SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Biomarkers, Tumor/*blood MH - Carcinoma, Transitional Cell/*drug therapy/mortality MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Fenretinide/*therapeutic use MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Muscle, Skeletal/pathology MH - Prognosis MH - Proportional Hazards Models MH - Registries MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/mortality MH - Vascular Endothelial Growth Factor A/analysis/*blood EDAT- 2016/04/06 06:00 MHDA- 2017/04/28 06:00 CRDT- 2016/04/06 06:00 PHST- 2015/09/17 00:00 [received] PHST- 2016/03/25 00:00 [accepted] PHST- 2016/04/06 06:00 [entrez] PHST- 2016/04/06 06:00 [pubmed] PHST- 2017/04/28 06:00 [medline] AID - 1940-6207.CAPR-15-0345 [pii] AID - 10.1158/1940-6207.CAPR-15-0345 [doi] PST - ppublish SO - Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4. PMID- 27043218 OWN - NLM STAT- MEDLINE DCOM- 20171002 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 35 IP - 3 DP - 2017 Mar TI - Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. PG - 327-335 LID - 10.1007/s00345-016-1819-1 [doi] AB - PURPOSE: To provide a comprehensive overview and update of the joint consultation of the International Consultation on Urological Diseases (ICUD) and Societe Internationale d'Urologie for the treatment of localized high-risk upper tract urothelial carcinoma (UTUC). METHODS: A detailed analysis of the literature was conducted reporting on treatment modalities and outcomes in localized high-risk UTUC. An international, multidisciplinary expert committee evaluated and graded the data according to the Oxford System of Evidence-based Medicine modified by the ICUD. RESULTS: Radical nephroureterectomy (RNU) is the standard of treatment for high-grade or clinically infiltrating UTUC and includes the removal of the entire kidney, ureter and ipsilateral bladder cuff. The distal ureter can be managed either by extravesical or transvesical approach, whereas endoscopically assisted procedures are associated with decreased intravesical recurrence-free survival. Post-operative intravesical chemotherapy decreases the risk of subsequent bladder tumour recurrence. Regional lymph node dissection is of prognostic importance in infiltrative UTUC, but its extent has not been standardized. Renal-sparing surgery is an option for manageable, high-grade tumours of any part of the upper tract, especially of the distal ureter, as an alternative to RNU. Endoscopy-based renal-sparing procedures are associated with a higher risk of recurrence and progression. CONCLUSIONS: A multimodal approach should be considered in localized high-risk UTUC to improve outcomes. RNU is the standard of treatment in high-risk disease. Renal-sparing approaches may be oncologically equivalent alternatives to RNU in well-selected patients, especially in those with distal ureteric tumours. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital Tubingen, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. georgios.gakis@web.de. FAU - Schubert, Tina AU - Schubert T AD - Department of Urology, University Hospital Tubingen, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. FAU - Alemozaffar, Mehrdad AU - Alemozaffar M AD - USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, CA, USA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Bochner, Bernard H AU - Bochner BH AD - Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Boorjian, Steven A AU - Boorjian SA AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, CA, USA. FAU - Huang, William C AU - Huang WC AD - Department of Urology, New York University Langone Medical Center, New York, NY, USA. FAU - Kondo, Tsunenori AU - Kondo T AD - Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. FAU - Konety, Badrinath R AU - Konety BR AD - Department of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. FAU - Laguna, Maria Pilar AU - Laguna MP AD - Department of Urology, AMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Matin, Surena F AU - Matin SF AD - Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. FAU - Siefker-Radtke, Arlene O AU - Siefker-Radtke AO AD - Department of Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital Tubingen, Hoppe-Seyler Street 3, 72076, Tubingen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20160404 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Combined Modality Therapy MH - Disease-Free Survival MH - Humans MH - Kidney Neoplasms/pathology/*therapy MH - Kidney Pelvis/pathology/*surgery MH - Lymph Node Excision MH - Nephrectomy MH - Organ Sparing Treatments MH - Practice Guidelines as Topic MH - Risk Assessment MH - Societies, Medical MH - Ureter/surgery MH - Ureteral Neoplasms/pathology/*therapy MH - Ureteroscopy MH - Urologic Surgical Procedures MH - Urology OTO - NOTNLM OT - Chemotherapy OT - Lymph node dissection OT - Nephroureterectomy OT - Renal-sparing OT - Salvage, upper tract urothelial carcinoma EDAT- 2016/04/05 06:00 MHDA- 2017/10/03 06:00 CRDT- 2016/04/05 06:00 PHST- 2015/12/28 00:00 [received] PHST- 2016/03/23 00:00 [accepted] PHST- 2016/04/05 06:00 [pubmed] PHST- 2017/10/03 06:00 [medline] PHST- 2016/04/05 06:00 [entrez] AID - 10.1007/s00345-016-1819-1 [pii] AID - 10.1007/s00345-016-1819-1 [doi] PST - ppublish SO - World J Urol. 2017 Mar;35(3):327-335. doi: 10.1007/s00345-016-1819-1. Epub 2016 Apr 4. PMID- 27021588 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 5 DP - 2016 Oct TI - Upper Tract Urothelial Carcinomas Accompanied by Previous or Synchronous Nonmuscle-Invasive Bladder Cancer and Preoperative Hydronephrosis Might Have Worse Oncologic Outcomes After Radical Nephroureterectomy. PG - e469-e477 LID - S1558-7673(16)30036-2 [pii] LID - 10.1016/j.clgc.2016.02.008 [doi] AB - BACKGROUND: The purpose of the study was to identify predictors of clinicopathologic features and oncologic outcomes in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy (RNU). PATIENTS AND METHODS: The medical records of 172 patients treated with RNU from January 2001 to September 2014 were retrospectively reviewed. Logistic regression and survival analysis methodology were respectively used to evaluate predictors of clinicopathologic features and oncologic outcomes. RESULTS: Of the enrolled 172 patients, 80 (46.5%) had renal pelvic tumors, 67 (39%) had ureteral tumors, and the remaining 25 (14.5%) patients had multifocal tumors. Compared with patients with renal pelvic tumors, those with ureteral and multifocal tumors were more likely to have previous or synchronous nonmuscle-invasive bladder cancer (NMIBC) and severe hydronephrosis (P = .001 and P < .001, respectively). Logistic regression analysis showed that previous or synchronous NMIBC was significantly associated with worse renal function and high grade (P = .034 and P = .014, respectively), and severe hydronephrosis independently predicted worse renal function and positive lymph node or lymphovascular invasion status (P = .001 and P = .007, respectively). Moreover, severe hydronephrosis was an independent risk factor for overall survival and cancer-specific survival in multivariate analysis (P = .025 and P = .045, respectively). Multifocality and previous or synchronous NMIBC were significantly associated with bladder-recurrence-free survival (P = .023 and P = .001, respectively). CONCLUSION: Upper tract urothelial carcinoma accompanied by previous or synchronous NMIBC and preoperative severe hydronephrosis could have worse oncologic outcomes after RNU. These common accompanied diagnoses could be valuable for guiding preoperative planning and postoperative adjuvant therapy. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Liang, Chengcai AU - Liang C AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Chi, Runmin AU - Chi R AD - Department of Radiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Huang, Liqun AU - Huang L AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Wang, Jinliang AU - Wang J AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Liu, Hailong AU - Liu H AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Xu, Ding AU - Xu D AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Qian, Subo AU - Qian S AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Qian, Xiaoqiang AU - Qian X AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Qi, Jun AU - Qi J AD - Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: urologistqijun@163.com. LA - eng PT - Journal Article DEP - 20160221 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Humans MH - Hydronephrosis/*epidemiology MH - Logistic Models MH - Male MH - Middle Aged MH - Neoplasms, Multiple Primary/epidemiology/surgery MH - Neoplasms, Second Primary/epidemiology MH - Nephrectomy/methods MH - Prognosis MH - Survival Analysis MH - Treatment Outcome MH - Ureter/surgery MH - Urinary Bladder Neoplasms/*epidemiology MH - Urologic Neoplasms/*surgery OTO - NOTNLM OT - Hydronephrosis OT - Oncologic outcome OT - Previous or synchronous non-muscle-invasive bladder cancer OT - Radical nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2016/03/30 06:00 MHDA- 2017/10/17 06:00 CRDT- 2016/03/30 06:00 PHST- 2015/11/27 00:00 [received] PHST- 2016/02/07 00:00 [revised] PHST- 2016/02/14 00:00 [accepted] PHST- 2016/03/30 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] PHST- 2016/03/30 06:00 [entrez] AID - S1558-7673(16)30036-2 [pii] AID - 10.1016/j.clgc.2016.02.008 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Oct;14(5):e469-e477. doi: 10.1016/j.clgc.2016.02.008. Epub 2016 Feb 21. PMID- 27021587 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20260127 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 4 DP - 2016 Aug TI - Prognostic Value of Gene Methylation and Clinical Factors in Non-Muscle-Invasive Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. PG - e371-8 LID - S1558-7673(16)30037-4 [pii] LID - 10.1016/j.clgc.2016.02.009 [doi] AB - INTRODUCTION: To systematically analyze the outcomes and prognostic value of gene methylation and clinical parameters in non-muscle-invasive upper tract urothelial carcinoma (NMIUTUC) after radical nephroureterectomy (RNU). PATIENTS AND METHODS: The methylation status of 10 selected genes and clinical parameters of 192 NMIUTUC patients who received RNU and postoperative intravesical mitomycin were assessed. Univariate and multivariate Cox regression models were performed to evaluate the prognostic factors of cancer-specific mortality and intravesical recurrence. RESULTS: For 192 NMIUTUC patients, 1-, 3-, and 5-year cancer-specific survival (CSS)/bladder recurrence-free survival (BRFS) rates were 98.4%/86.4%, 90.6%/74.6%, and 86.9%/62.4%, respectively. After the multivariate analysis, the methylation of ABCC6 (hazard ratio [HR], 3.46, P = .005), GDF15 (HR, 2.03, P = .002), multiple tumors (HR, 2.11, P = .049), impaired renal function (HR, 3.09, P = .004), and open RNU (HR, 2.14, P = .047) were independently associated with cancer-specific mortality, whereas the methylation of GDF15 (HR, 0.55, P = .022), RASSF1A (HR, 0.31, P = .006), multiple tumors (HR, 2.11, P = .002), and concomitant ipsilateral hydronephrosis (HR, 1.87, P = .022) were independently associated with intravesical recurrence after RNU. The c index of the multivariate model to predict cancer-specific mortality and intravesical recurrence was 0.81 and 0.78, respectively. CONCLUSION: As an early stage disease, NMIUTUC has better postoperative survival and later intravesical recurrence than upper tract urothelial carcinoma; however, the intravesical recurrence rate is not decreased. The nomogram can be used to accurately predict the oncologic outcomes of NMIUTUC patients and can be used to guide clinical decision making. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Xing, Yunchao AU - Xing Y AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Xiong, Gengyan AU - Xiong G AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Fang, Dong AU - Fang D AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Yang, Xinyu AU - Yang X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. FAU - Li, Xuesong AU - Li X AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: pineneedle@sina.com. FAU - Zhou, Liqun AU - Zhou L AD - Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address: zhoulqmail@sina.com. LA - eng PT - Journal Article DEP - 20160226 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Growth Differentiation Factor 15) RN - 0 (ATP-Binding Cassette, Sub-Family C Proteins) RN - 0 (Tumor Suppressor Proteins) RN - 0 (ABCC6 protein, human) RN - 0 (GDF15 protein, human) RN - 0 (RASSF1 protein, human) SB - IM MH - Carcinoma, Transitional Cell/genetics/*surgery MH - *DNA Methylation MH - Female MH - *Gene Regulatory Networks MH - Growth Differentiation Factor 15/genetics MH - Humans MH - Male MH - ATP-Binding Cassette, Sub-Family C Proteins/genetics MH - Multivariate Analysis MH - Nephrectomy/*methods MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Tumor Suppressor Proteins/genetics MH - Urinary Bladder Neoplasms/genetics/*surgery OTO - NOTNLM OT - Gene methylation OT - Nomogram OT - Non-muscle-invasive upper tract urothelial carcinoma OT - Prognostic factor OT - Radical nephroureterectomy EDAT- 2016/03/30 06:00 MHDA- 2017/10/17 06:00 CRDT- 2016/03/30 06:00 PHST- 2015/10/19 00:00 [received] PHST- 2016/01/27 00:00 [revised] PHST- 2016/02/14 00:00 [accepted] PHST- 2016/03/30 06:00 [entrez] PHST- 2016/03/30 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] AID - S1558-7673(16)30037-4 [pii] AID - 10.1016/j.clgc.2016.02.009 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Aug;14(4):e371-8. doi: 10.1016/j.clgc.2016.02.009. Epub 2016 Feb 26. PMID- 27014622 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160325 LR - 20201001 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 6 DP - 2016 TI - The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer. PG - 43 LID - 10.3389/fonc.2016.00043 [doi] LID - 43 AB - BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette-Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. METHODS: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. FINDINGS: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (>/=T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). INTERPRETATION: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC. FAU - Gofrit, Ofer N AU - Gofrit ON AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Yutkin, Vladimir AU - Yutkin V AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Shapiro, Amos AU - Shapiro A AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Pizov, Galina AU - Pizov G AD - Department of Pathology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Zorn, Kevin C AU - Zorn KC AD - Section of Urology, Department of Surgery , Montreal, QC , Canada. FAU - Hidas, Guy AU - Hidas G AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Gielchinsky, Ilan AU - Gielchinsky I AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Duvdevani, Mordechai AU - Duvdevani M AD - Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Landau, Ezekiel H AU - Landau EH AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. FAU - Pode, Dov AU - Pode D AD - Department of Urology, Hadassah Hebrew University Medical Center , Jerusalem , Israel. LA - eng PT - Journal Article DEP - 20160315 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC4791377 OTO - NOTNLM OT - high-grade OT - immunotherapy OT - prognosis OT - urothelial carcinoma OT - variants EDAT- 2016/03/26 06:00 MHDA- 2016/03/26 06:01 PMCR- 2016/01/01 CRDT- 2016/03/26 06:00 PHST- 2015/07/02 00:00 [received] PHST- 2016/02/12 00:00 [accepted] PHST- 2016/03/26 06:00 [entrez] PHST- 2016/03/26 06:00 [pubmed] PHST- 2016/03/26 06:01 [medline] PHST- 2016/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2016.00043 [doi] PST - epublish SO - Front Oncol. 2016 Mar 15;6:43. doi: 10.3389/fonc.2016.00043. eCollection 2016. PMID- 27003158 OWN - NLM STAT- MEDLINE DCOM- 20170214 LR - 20220330 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 468 IP - 6 DP - 2016 Jun TI - Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival. PG - 733-40 LID - 10.1007/s00428-016-1924-y [doi] AB - The purpose of this study is to investigate the clinical relevance of deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP) expression in human urothelial carcinoma (UC). We studied DAB2IP protein expression by immunohistochemistry in 130 UCs (90 of the bladder and 40 of the upper urinary tract) and 79 adjacent normal tissues and assessed its prognostic value in terms of recurrence-free and progression-free survival in superficial bladder UC. Twelve human UC cell lines were examined for DAB2IP messenger RNA (mRNA) and protein expression using quantitative RT-PCR and western blotting. Selected cell lines were used to study the effect of treatment with chromatin-modifying agents (5-aza-2'-deoxycytidine, Trichostatin A, or both) on DAB2IP expression. Of 90 bladder tumors, 50 (56 %) and, of 40 upper tract UC, 11 (28 %) were positive for DAB2IP immunostaining (bladder cancer versus upper tract UC, p = 0.003). In 65 superficial cases of bladder cancer loss of DAB2IP, expression was significantly associated with decreased recurrence-free survival (p = 0.046), but not with progression-free survival. Most human urothelial cancer cell lines consistently express DAB2IP mRNA and protein, without any relation to S-phase kinase protein expression. After treatment with either 5-aza-2'-deoxycytidine or Trichostatin A or both, the low DAB2IP-expressing bladder cancer cell lines BFTC905 and BFTC909 showed increased DAB2IP mRNA expression. DAB2IP protein levels are higher in bladder cancer than in upper tract UC and in superficial bladder cancer. This is associated with longer recurrence-free survival. Epigenetic regulation of DAB2IP protein appears to play an important role in human urothelial carcinoma. FAU - Jou, Yeong-Chin AU - Jou YC AD - Department of Urology, Chia-Yi Christian Hospital, Chiayi, Taiwan. FAU - Tsai, Yuh-Shyan AU - Tsai YS AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan. youh@mail.ncku.edu.tw. FAU - Chen, Syue-Yi AU - Chen SY AD - Department of Medical Research, Chia-Yi Christian Hospital, Chiayi, Taiwan. FAU - Hsieh, Hsiao-Yen AU - Hsieh HY AD - Department of Medical Research, Chia-Yi Christian Hospital, Chiayi, Taiwan. FAU - Tsai, Hsin-Tzu AU - Tsai HT AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan. FAU - Tzai, Tzong-Shin AU - Tzai TS AD - Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan. tts777@mail.ncku.edu.tw. LA - eng PT - Journal Article DEP - 20160322 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (Biomarkers, Tumor) RN - 0 (DAB2IP protein, human) RN - 0 (ras GTPase-Activating Proteins) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/pathology MH - Epigenesis, Genetic/*genetics MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Middle Aged MH - Prognosis MH - Recurrence MH - Urologic Neoplasms/genetics/metabolism/*mortality/pathology MH - Urothelium/pathology MH - ras GTPase-Activating Proteins/*metabolism OTO - NOTNLM OT - Bladder neoplasms OT - DAB2IP OT - Methylation OT - Prognosis EDAT- 2016/03/24 06:00 MHDA- 2017/02/15 06:00 CRDT- 2016/03/23 06:00 PHST- 2015/09/29 00:00 [received] PHST- 2016/03/03 00:00 [accepted] PHST- 2016/01/18 00:00 [revised] PHST- 2016/03/23 06:00 [entrez] PHST- 2016/03/24 06:00 [pubmed] PHST- 2017/02/15 06:00 [medline] AID - 10.1007/s00428-016-1924-y [pii] AID - 10.1007/s00428-016-1924-y [doi] PST - ppublish SO - Virchows Arch. 2016 Jun;468(6):733-40. doi: 10.1007/s00428-016-1924-y. Epub 2016 Mar 22. PMID- 27002765 OWN - NLM STAT- MEDLINE DCOM- 20170118 LR - 20260813 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 16 IP - 4 DP - 2016 Mar 18 TI - MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence. PG - 627-32 LID - 10.3233/CBM-160604 [doi] AB - BACKGROUND: Urinary bladder carcinoma is one of the leading causes of death among men, and its high recurrence rates make it one of the most solid tumors to treat. The silencing of the tumor suppressor gene by hypermethylation of the CpG islands and overexpression of proto-oncogene proteins are the main mechanisms in cancers. Here, we investigate methylation status of O6-methylguanine-DNA-methyltransferase (MGMT), a tumor suppressor gene and expression level of BCL-2 a proto-oncogene protein that is frequently observed in bladder carcinoma and its recurrences. MATERIALS AND METHODS: We analyzed the methylation of MGMT in 80 tissue samples of patients suffering from bladder cancer and 80 urine samples of cancer-free individuals by MS-PCR. Additionally, BCL-2 protein expression level was analyzed on these 80 tissue samples by immunohistochemistry. RESULTS: 45% of patients had MGMT methylation, of which this hypermethylation does not have significant association with an increase in grade, but there was significant association in cases with recurrence tumors and metastasis tumors. Among patients with recurrence tumor, 92.5% patients showed MGMT hypermethylation; 66% of these showed BCL-2 overexpression. CONCLUSION: Our data indicate that MGMT hypermethylation and BCL-2 overexpression may have an intense role in superficial bladder cancer recurrences. FAU - Jahed, Marzieh AU - Jahed M AD - Varamin - Pishva Branch, Islamic Azad University, Varamin, Iran. FAU - Ebadi, Nader AU - Ebadi N AD - Varamin - Pishva Branch, Islamic Azad University, Varamin, Iran. FAU - Mivehchi, Mohamad AU - Mivehchi M AD - Varamin - Pishva Branch, Islamic Azad University, Varamin, Iran. FAU - Majidizadeh, Tayebeh AU - Majidizadeh T AD - Department of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. FAU - Shahshanipour, Majid AU - Shahshanipour M AD - Department of Urology, Hasheminejad Clinical Research Developing Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Asgari, Mojgan AU - Asgari M AD - Department of Pathology, Hasheminejad Clinical Research Developing Center, Iran University of Medical Sciences, Tehran, Iran. AD - Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Ghadakzadeh, Sara AU - Ghadakzadeh S AD - Department of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. FAU - Hosseini, Seyed Ali AU - Hosseini SA AD - Department of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. AD - Department of Laboratory Medicine, Boston Children Hospital/Harvard Medical School, and Claritas Genomics Inc, MA, USA. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (MAS1 protein, human) RN - 0 (Proto-Oncogene Mas) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.1.1.- (DNA Modification Methylases) RN - EC 2.1.1.63 (MGMT protein, human) RN - EC 6.5.1.- (DNA Repair Enzymes) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Case-Control Studies MH - CpG Islands MH - *DNA Methylation MH - DNA Modification Methylases/*genetics MH - DNA Repair Enzymes/*genetics MH - Female MH - *Gene Expression MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Odds Ratio MH - Promoter Regions, Genetic MH - Proto-Oncogene Mas MH - Proto-Oncogene Proteins c-bcl-2/*genetics MH - Tumor Suppressor Proteins/*genetics MH - Urinary Bladder Neoplasms/*genetics/*pathology PMC - PMC13016509 OTO - NOTNLM OT - BCL-2 OT - Bladder cancer OT - MGMT OT - methylation OT - tumor suppressor gene EDAT- 2016/03/24 06:00 MHDA- 2017/01/19 06:00 PMCR- 2016/04/13 CRDT- 2016/03/23 06:00 PHST- 2016/03/23 06:00 [entrez] PHST- 2016/03/24 06:00 [pubmed] PHST- 2017/01/19 06:00 [medline] PHST- 2016/04/13 00:00 [pmc-release] AID - CBM604 [pii] AID - 10.3233/CBM-160604 [doi] PST - ppublish SO - Cancer Biomark. 2016 Mar 18;16(4):627-32. doi: 10.3233/CBM-160604. PMID- 26997439 OWN - NLM STAT- MEDLINE DCOM- 20160801 LR - 20221109 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 50 DP - 2016 Apr TI - MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma. PG - 62-9 LID - S0046-8177(15)00477-3 [pii] LID - 10.1016/j.humpath.2015.11.007 [doi] AB - The melanoma-associated antigen A (MAGE-A) family comprises cancer-testis antigens that represent promising prognostic biomarkers and immunotherapy targets in several cancer types. The aim of this study was to investigate the significance of MAGE-A expression in upper urinary tract urothelial carcinoma in relation to clinicopathological features, lymphocytic infiltration, and clinical outcome. We immunohistochemically examined the expression of MAGE-A in 171 patients with upper urinary tract urothelial carcinoma. High (>/= 50% positive) and low MAGE-A expression levels were observed in 33 (19%) and 49 (29%) cases, respectively. MAGE-A was negative in 89 cases (52%). MAGE-A expression was positively correlated with high histologic grade; concomitant carcinoma in situ; higher Ki-67 proliferation index; and infiltration of CD3-, CD8-, and CD45RO-positive T lymphocytes, but not with CD20-positive B lymphocytes. High MAGE-A expression was significantly associated with shorter metastasis-free survival after nephroureterectomy (log-rank P = .019; multivariate hazard ratio, 1.98; 95% confidence interval, 1.00-3.92). MAGE-A expression in metastatic lymph nodes was highly correlated with its expression in primary lesions. MAGE-A expression was retained in chemotherapy-resistant metachronous metastatic lesions of urothelial carcinoma. MAGE-A may be a promising prognostic biomarker and potential immunotherapeutic target for patients with upper urinary tract urothelial carcinoma. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Makise, Naohiro AU - Makise N AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. Electronic address: tmorikawa-tky@umin.ac.jp. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Ichimura, Takashi AU - Ichimura T AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Matsushita, Hirokazu AU - Matsushita H AD - Department of Immunotherapeutics (Medinet), The University of Tokyo Hospital, Tokyo 113-0033, Japan. FAU - Kakimi, Kazuhiro AU - Kakimi K AD - Department of Immunotherapeutics (Medinet), The University of Tokyo Hospital, Tokyo 113-0033, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Homma, Yukio AU - Homma Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. FAU - Fukayama, Masashi AU - Fukayama M AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151128 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Biomarkers, Tumor) RN - 0 (Melanoma-Specific Antigens) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma/*immunology/mortality/secondary/therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis MH - Lymphocytes, Tumor-Infiltrating MH - Male MH - Melanoma-Specific Antigens/*analysis MH - Middle Aged MH - Neoplasm Grading MH - Time Factors MH - Treatment Outcome MH - *Tumor Microenvironment MH - Urologic Neoplasms/*immunology/mortality/pathology/therapy OTO - NOTNLM OT - Cancer-testis antigen OT - Immunohistochemistry OT - Immunotherapy OT - Survival OT - Urothelial carcinoma EDAT- 2016/03/22 06:00 MHDA- 2016/08/02 06:00 CRDT- 2016/03/22 06:00 PHST- 2015/09/02 00:00 [received] PHST- 2015/11/13 00:00 [revised] PHST- 2015/11/19 00:00 [accepted] PHST- 2016/03/22 06:00 [entrez] PHST- 2016/03/22 06:00 [pubmed] PHST- 2016/08/02 06:00 [medline] AID - S0046-8177(15)00477-3 [pii] AID - 10.1016/j.humpath.2015.11.007 [doi] PST - ppublish SO - Hum Pathol. 2016 Apr;50:62-9. doi: 10.1016/j.humpath.2015.11.007. Epub 2015 Nov 28. PMID- 26995008 OWN - NLM STAT- MEDLINE DCOM- 20170711 LR - 20220310 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 48 IP - 6 DP - 2016 Jun TI - Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. PG - 993-9 LID - 10.1007/s11255-016-1264-5 [doi] AB - PURPOSE: To evaluate the impact of chronic kidney disease (CKD) on oncologic outcomes among non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder cancer. METHODS: We followed up the medical data of 158 newly diagnosed NMIBC patients enrolled in this study for more than 4 years. The ten putative risk factors included patient age, gender, white blood cells, neutrophil to lymphocyte ratio, tumor count, size, grade, stage, CKD (estimated glomerular filtration rate, eGFR < 60) and histological differentiation. RESULTS: Total recurrent bladder and upper urinary tract (UUT) tumors were observed in 51 patients (32 %) and 5 patients (3 %), respectively. Cancer progression to the high pT(>/=pT2) stage was found in 9 patients (6 %). Cancer-specific and overall survival rates were 91 % (144/158 patients) and 78 % (123/158 patients), respectively. In univariate analysis, significant predictive determinants were tumor count, size, grade, stage, CKD and squamous differentiation for bladder tumor recurrence; CKD and squamous differentiation for UUT tumor recurrence; and tumor count, grade, stage and CKD for cancer progression. On the other hand, old age (>70 years), high grade, T1 stage, and CKD were poor prognostic factors for overall survival. In multivariate analysis, CKD was an independent risk factor for bladder/UUT tumor recurrences and the overall survival rate. CONCLUSIONS: NMIBC patients with CKD had worse prognosis and higher tumor recurrence and progression rates than other patients. These patients should be intensively monitored at upper and lower urinary tracts and be aggressively treated for comorbidities of CKD. FAU - Li, Chia-En AU - Li CE AD - Department of Computer Science and Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan. FAU - Chien, Chia-Shen AU - Chien CS AD - Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. AD - Chang Gung University, Kaohsiung, Taiwan. FAU - Chuang, Yao-Chi AU - Chuang YC AD - Chang Gung University, Kaohsiung, Taiwan. AD - Cancer Center, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. FAU - Chang, Ye-In AU - Chang YI AD - Department of Computer Science and Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan. FAU - Tang, Hsiu-Pei AU - Tang HP AD - Department of Computer Science and Engineering, National Sun Yat-sen University, Kaohsiung, Taiwan. FAU - Kang, Chih-Hsiung AU - Kang CH AD - Chang Gung University, Kaohsiung, Taiwan. lice@db.cse.nsysu.edu.tw. AD - Cancer Center, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. lice@db.cse.nsysu.edu.tw. LA - eng PT - Journal Article DEP - 20160319 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*etiology/mortality/pathology MH - Neoplasm Staging MH - Renal Insufficiency, Chronic/*complications/mortality/pathology MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/*etiology/mortality/surgery OTO - NOTNLM OT - Chronic kidney disease OT - Non-muscle-invasive bladder cancer OT - Progression OT - Recurrence OT - Survival OT - Urothelial carcinoma EDAT- 2016/03/21 06:00 MHDA- 2017/07/14 06:00 CRDT- 2016/03/21 06:00 PHST- 2015/12/24 00:00 [received] PHST- 2016/03/09 00:00 [accepted] PHST- 2016/03/21 06:00 [entrez] PHST- 2016/03/21 06:00 [pubmed] PHST- 2017/07/14 06:00 [medline] AID - 10.1007/s11255-016-1264-5 [pii] AID - 10.1007/s11255-016-1264-5 [doi] PST - ppublish SO - Int Urol Nephrol. 2016 Jun;48(6):993-9. doi: 10.1007/s11255-016-1264-5. Epub 2016 Mar 19. PMID- 26990746 OWN - NLM STAT- MEDLINE DCOM- 20180124 LR - 20180314 IS - 1533-4058 (Electronic) IS - 1533-4058 (Linking) VI - 25 IP - 7 DP - 2017 Aug TI - Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. PG - 505-512 LID - 10.1097/PAI.0000000000000334 [doi] AB - BACKGROUND: Immunoreactivity for CD44 and cytokeratin (CK)5 (urothelial stem/basal cell markers) are decreased/negative in the common type of intraurothelial neoplasia including urothelial carcinomas (UC) in situ. Recent studies also reveal that a majority of muscle-invasive UC are basal-like UC with large areas of positive CD44/CK5 immunoreactivity. In addition, approximately 80% of muscle-invasive UC develop de novo as nonpapillary invasive UC. In this study, we investigate the CD44/CK5 immunoreactivity of the flat intraurothelial neoplasia (FIUN) associated with nonpapillary invasive UC. MATERIALS AND METHODS: Consecutive cases of nonpapillary UC were submitted for immunostaining. Immunostaining for CK5/CD44 was scored as high for staining of >25% thickness of urothelium and low for lesser immunoreactivity. RESULTS: In total, 109 consecutive cases were grouped into: in situ UC [carcinoma in situ (CIS)] (n=11), pT1 (n=14), and pT2-4 (n=84) with surface urothelium available for study. Forty-four cases including CIS (n=9), pT1 (n=12), and pT2-4 (n=23) showed FIUN with low/negative CD44/CK5 reactivity; 40 cases showed strong CK20 reactivity. Sixty-two cases including CIS (n=2), pT1 (n=2), and pT2-4 (n=58) showed extensive FIUN exhibiting high CD44/CK5 reactivity; 30 cases showed reactive CK20. FIUN lesions with high CD44/CK5 reactivity scores were associated with mild (urothelial dysplasia) to moderate atypia (CIS) and were rarely preceded by papillary UC. Most invasive UC associated with FIUN with high CD44/CK5 reactivity also exhibited extensive CD44/CK5 reactivity. The remaining 3 cases showed only reactive urothelium. Of interest, 4 cases with FIUN showed negative CD44/CK5/CK20 reactivity. CONCLUSIONS: Existence of CD44/CK5-immunoreactive (or basal-like) FIUN is consistent with the recent distinction of basal and luminal subtypes of UC. This type of FIUN is often associated with UC with progression to high-stage disease not preceded by recurrent papillary UC. FAU - Mai, Kien T AU - Mai KT AD - *Anatomical Pathology, The Ottawa Hospital daggerPathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Busca, Aurelia AU - Busca A FAU - Belanger, Eric C AU - Belanger EC LA - eng PT - Journal Article PL - United States TA - Appl Immunohistochem Mol Morphol JT - Applied immunohistochemistry & molecular morphology : AIMM JID - 100888796 RN - 0 (CD44 protein, human) RN - 0 (Hyaluronan Receptors) RN - 0 (Keratin-5) RN - 0 (Neoplasm Proteins) SB - IM MH - Aged MH - Aged, 80 and over MH - *Carcinoma in Situ/metabolism/pathology MH - Female MH - Humans MH - Hyaluronan Receptors/*metabolism MH - Keratin-5/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Proteins/*metabolism MH - *Urologic Neoplasms/metabolism/pathology MH - *Urothelium/metabolism/pathology EDAT- 2016/03/19 06:00 MHDA- 2018/01/25 06:00 CRDT- 2016/03/19 06:00 PHST- 2016/03/19 06:00 [pubmed] PHST- 2018/01/25 06:00 [medline] PHST- 2016/03/19 06:00 [entrez] AID - 10.1097/PAI.0000000000000334 [doi] PST - ppublish SO - Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):505-512. doi: 10.1097/PAI.0000000000000334. PMID- 26981499 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160316 LR - 20201001 IS - 2251-7006 (Print) IS - 2251-7014 (Electronic) IS - 2251-7006 (Linking) VI - 8 IP - 1 DP - 2016 Jan TI - A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System. PG - e33240 LID - 10.5812/numonthly.33240 [doi] LID - e33240 AB - BACKGROUND: Transitional cell carcinoma of the bladder, the second most common urologic malignancy, is amenable to early diagnosis. This study presents the potential prognostic benefit for a less invasive modification to the standard endoscopic approach. OBJECTIVES: To evaluate the risk index for the progression and recurrence of additional tumors detected with narrow-band imaging (NBI) cystoscopy compared to standard white light imaging (WLI) cystoscopy in non-muscle-invasive bladder cancer (NMIBC), based on the European organization for research and treatment of cancer (EORTC) scoring system. PATIENTS AND METHODS: Patients with NMIBC, who were scheduled for resection between May 2012 and May 2013, were studied and mapped under NBI and WLI cystoscopy by independent surgeons prior to resection. Detection rates and tumor characteristics, including EORTC progression and the recurrence risk index, were compared. RESULTS: Fifty patients, aged 63.86 +/- 10.05 years, were enrolled. The overall detection rate was 98.9% for NBI vs. 89.4% for WLI (P = 0.001), and the false-positive rates were 9.6% and 5.8%, respectively (P = 0.051). Ten tumors were detected by NBI alone, including four grade I tumors, four grade III tumors, and two carcinomas in situ. The tumor progression index was not significantly reduced with NBI compared to WLI (P > 0.05); however, the recurrence index was significantly lower in the NBI group (P < 0.05). CONCLUSIONS: NBI cystoscopy improved the detection rate. Although false positives were more common with NBI, this was not statistically significant. NBI found additional aggressive tumors, which underscores the impact of detection in EORTC recurrence risk scoring. FAU - Shadpour, Pejman AU - Shadpour P AD - Hasheminejad Kidney Center (HKC), Hospital Management Research Center (HMRC), Iran University of Medical Sciences (IUMS), Tehran, IR Iran. FAU - Emami, Maryam AU - Emami M AD - Hasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, IR Iran. FAU - Haghdani, Saeid AU - Haghdani S AD - Hasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, IR Iran. LA - eng PT - Journal Article DEP - 20160109 PL - Netherlands TA - Nephrourol Mon JT - Nephro-urology monthly JID - 101578609 PMC - PMC4779587 OTO - NOTNLM OT - Bladder Cancer OT - Cystoscopy OT - EORTC Score OT - Narrowband Imaging OT - Recurrence OT - Transitional Cell Carcinoma OT - Urothelial Carcinoma EDAT- 2016/03/17 06:00 MHDA- 2016/03/17 06:01 PMCR- 2016/01/01 CRDT- 2016/03/17 06:00 PHST- 2015/09/18 00:00 [received] PHST- 2015/11/16 00:00 [accepted] PHST- 2016/03/17 06:00 [entrez] PHST- 2016/03/17 06:00 [pubmed] PHST- 2016/03/17 06:01 [medline] PHST- 2016/01/01 00:00 [pmc-release] AID - 10.5812/numonthly.33240 [doi] PST - epublish SO - Nephrourol Mon. 2016 Jan 9;8(1):e33240. doi: 10.5812/numonthly.33240. eCollection 2016 Jan. PMID- 26976725 OWN - NLM STAT- MEDLINE DCOM- 20180315 LR - 20181202 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 6 DP - 2016 Jun TI - Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. PG - 258.e1-6 LID - S1078-1439(16)00044-2 [pii] LID - 10.1016/j.urolonc.2016.02.011 [doi] AB - BACKGROUND: Studies evaluating enhancer of zeste homolog 2 (EZH2) expression and oncologic outcomes in bladder cancer have been discrepant. EZH2 expression in noninvasive bladder cancer is not well studied. We thus set out to address the discrepancy in previous reports, and to study expression of EZH2 in noninvasive bladder cancer and its associations, in a large cystectomy cohort. MATERIALS AND METHODS: EZH2 expression was evaluated in tissue microarray material (invasive and noninvasive cancer). Associations between EZH2 expression and oncologic outcomes, tumor stage, and disease type were determined. Receiver operating characteristic analysis was performed for EZH2 expression in the diagnosis of invasive carcinoma and flat carcinoma in situ (CIS) compared to benign urothelium. RESULTS: EZH2 expression was most common in CIS, followed by invasive carcinoma, noninvasive papillary urothelial carcinoma, and benign urothelium, in decreasing order (P<0.05 all comparisons, linear model). The receiver operating characteristic analysis demonstrated an area under the curve of 0.92 for CIS and 0.83 for invasive carcinoma, both compared to benign urothelium. At a cutoff of>/=4, this corresponded to sensitivities of 89% and 73%, and specificities of 82% and 82%, for CIS and invasive carcinoma, respectively. The EZH2 expression was not associated with oncologic outcomes, including recurrence-free survival and death from bladder cancer. The EZH2 expression status (positive or negative) of noninvasive and invasive carcinomas taken from the same bladder correlated (P = 0.05, Fisher exact). CONCLUSION: That EZH2 status of noninvasive and invasive cancer correlated in individual patients suggests that EZH2 may be a marker of lineage. EZH2 may offer diagnostic utility, particularly in flat urothelial CIS vs. benign urothelium. The present study supports that EZH2 expression in bladder cancer is not predictive of oncologic outcome. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Warrick, Joshua I AU - Warrick JI AD - Department of Pathology, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA. Electronic address: jwarrick@hmc.psu.edu. FAU - Raman, Jay D AU - Raman JD AD - Division of Urology, Department of Surgery, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA. FAU - Kaag, Matthew AU - Kaag M AD - Division of Urology, Department of Surgery, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA. FAU - Bruggeman, Trey AU - Bruggeman T AD - Department of Pathology, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA. FAU - Cates, Justin AU - Cates J AD - Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN. FAU - Clark, Peter AU - Clark P AD - Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN. FAU - DeGraff, David J AU - DeGraff DJ AD - Department of Pathology, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA; Division of Urology, Department of Surgery, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA; Department of Biochemistry and Molecular Biology, Penn State University School of Medicine and Milton S. Hershey Medical Center, Hershey, PA. LA - eng PT - Journal Article DEP - 20160311 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma in Situ/diagnosis/metabolism MH - Cystectomy MH - Enhancer of Zeste Homolog 2 Protein/*metabolism MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/diagnosis/*metabolism MH - Urothelium/metabolism MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - EZH2 OT - Papillary urothelial carcinoma OT - Tumor lineage OT - Urothelial carcinoma in situ OT - Urothelium EDAT- 2016/03/16 06:00 MHDA- 2018/03/16 06:00 CRDT- 2016/03/16 06:00 PHST- 2015/10/29 00:00 [received] PHST- 2016/01/20 00:00 [revised] PHST- 2016/02/06 00:00 [accepted] PHST- 2016/03/16 06:00 [entrez] PHST- 2016/03/16 06:00 [pubmed] PHST- 2018/03/16 06:00 [medline] AID - S1078-1439(16)00044-2 [pii] AID - 10.1016/j.urolonc.2016.02.011 [doi] PST - ppublish SO - Urol Oncol. 2016 Jun;34(6):258.e1-6. doi: 10.1016/j.urolonc.2016.02.011. Epub 2016 Mar 11. PMID- 26975197 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260127 IS - 1744-8301 (Electronic) IS - 1479-6694 (Linking) VI - 12 IP - 8 DP - 2016 TI - Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden. PG - 1025-38 LID - 10.2217/fon-2015-0021 [doi] AB - AIM: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden. METHODS: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor. RESULTS: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate- and high-risk groups from year 2. CONCLUSION: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL. FAU - Dansk, Viktor AU - Dansk V AD - HERON Commercialization, PAREXEL, Stockholm, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden. FAU - Blackberg, Mats AU - Blackberg M AD - Department of Urology & Surgery, Helsingborg Hospital, Helsingborg, Sweden. FAU - Malmenas, Maria AU - Malmenas M AD - HERON Commercialization, PAREXEL, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20160315 PL - England TA - Future Oncol JT - Future oncology (London, England) JID - 101256629 RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Aminolevulinic Acid/*analogs & derivatives MH - Costs and Cost Analysis MH - Cystectomy MH - Cystoscopy/economics/*methods MH - Disease Progression MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - *Light MH - Markov Chains MH - Neoplasm Staging MH - Outpatients MH - Population Surveillance MH - Recurrence MH - Sweden/epidemiology MH - Urinary Bladder Neoplasms/*diagnosis/epidemiology/therapy OTO - NOTNLM OT - Sweden OT - bladder cancer OT - budget impact OT - cost-consequences model OT - detection OT - economic evaluation OT - fluorescence cystoscopy OT - fulguration OT - hexaminolevulinate OT - recurrence EDAT- 2016/03/16 06:00 MHDA- 2016/12/15 06:00 CRDT- 2016/03/16 06:00 PHST- 2016/03/16 06:00 [entrez] PHST- 2016/03/16 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.2217/fon-2015-0021 [doi] PST - ppublish SO - Future Oncol. 2016;12(8):1025-38. doi: 10.2217/fon-2015-0021. Epub 2016 Mar 15. PMID- 26971194 OWN - NLM STAT- MEDLINE DCOM- 20161006 LR - 20181113 IS - 1471-2253 (Electronic) IS - 1471-2253 (Linking) VI - 16 DP - 2016 Mar 12 TI - A comparison of regional and general anesthesia effects on 5 year survival and cancer recurrence after transurethral resection of the bladder tumor: a retrospective analysis. PG - 16 LID - 10.1186/s12871-016-0181-6 [doi] LID - 16 AB - BACKGROUND: Recent studies have reported that cancer surgeries involving regional anesthesia have better outcomes than those under general anesthesia. However, the effects of anesthetic technique have not been investigated in patients with bladder cancer. Therefore, this retrospective study was conducted to investigate which anesthetic technique results in a better bladder cancer prognosis. METHODS: Sixty-one of 531 patients underwent transurethral resection of a bladder tumor under general anesthesia from 2001 to 2008 in our hospital. Patients who attended five years of follow-up and who had pathological findings of urothelial carcinoma grades I-II were enrolled. Finally, 24 patients (G group) who underwent general anesthesia and 137 (R group) who underwent regional (spinal or epidural) anesthesia were compared. Five-year survival and recurrence-free time were compared using the chi-square and t-tests, respectively. A logistic regression and partial correlation analysis were performed to evaluate other factors affecting survival. RESULTS: Five-year survival was 87.5% for general anesthesia and 96.3% for regional (P = 0.099). The regression analysis showed that older age contributed to reduced survival (odds ratio = 0.85, P = 0.001). Regional anesthesia showed higher 5-year survival (coefficient = -0.167, P = 0.044) more than general anesthesia through the partial correlation analysis. CONCLUSIONS: Though partial correlation analysis show that five-year survival is higher in patients whose surgery is under regional than general anesthesia, the association was not significant in the chi-square test and logistic regression analysis. Large prospective studies are needed to determine whether the association between regional anesthesia and survival is causative. FAU - Jang, Dale AU - Jang D AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. FAU - Lim, Chae Seong AU - Lim CS AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. limtwo2@gmail.com. FAU - Shin, Yong Sup AU - Shin YS AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. FAU - Ko, Young Kwon AU - Ko YK AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. FAU - Park, Sang Il AU - Park SI AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. FAU - Song, Seong Hyun AU - Song SH AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. FAU - Kim, Bum June AU - Kim BJ AD - Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160312 PL - England TA - BMC Anesthesiol JT - BMC anesthesiology JID - 100968535 SB - IM MH - Aged MH - Aged, 80 and over MH - Anesthesia, Conduction/*mortality/trends MH - Anesthesia, General/*mortality/trends MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*mortality/*surgery MH - Retrospective Studies MH - Survival Rate/trends MH - Time Factors MH - Urethra/*surgery MH - Urinary Bladder Neoplasms/*mortality/*surgery PMC - PMC4789273 EDAT- 2016/03/15 06:00 MHDA- 2016/10/08 06:00 PMCR- 2016/03/12 CRDT- 2016/03/14 06:00 PHST- 2015/04/14 00:00 [received] PHST- 2016/03/04 00:00 [accepted] PHST- 2016/03/14 06:00 [entrez] PHST- 2016/03/15 06:00 [pubmed] PHST- 2016/10/08 06:00 [medline] PHST- 2016/03/12 00:00 [pmc-release] AID - 10.1186/s12871-016-0181-6 [pii] AID - 181 [pii] AID - 10.1186/s12871-016-0181-6 [doi] PST - epublish SO - BMC Anesthesiol. 2016 Mar 12;16:16. doi: 10.1186/s12871-016-0181-6. PMID- 26962244 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200123 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 46 IP - 6 DP - 2016 Jun TI - Predictive value of radiological response rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer. PG - 560-567 LID - hyw025 [pii] LID - 10.1093/jjco/hyw025 [doi] AB - OBJECTIVE: To determine the predictive value of the radiological response rate assessed by serial pelvic computed tomography scans for pathological response to neoadjuvant chemotherapy and clinical outcomes after radical cystectomy in bladder urothelial cancer patients. METHODS: We retrospectively reviewed 59 patients with muscle-invasive bladder cancer who underwent radical cystectomy following neoadjuvant chemotherapy. Pretreatment and post-neoadjuvant chemotherapy computed tomography scans were evaluated by a single radiologist to determine the radiological response rate based on the largest diameter of the primary tumor. Association of the radiological response rate with pathological findings of the radical cystectomy specimen and post-radical cystectomy clinical outcomes were assessed. RESULTS: The pathological complete response rate was 25% (n = 15) and the median (range) radiological response rate was 0.58 (0.00-1.00). The radiological response rate was significantly associated with /=0.57) had significantly better post-radical cystectomy recurrence-free survival (2-year survival 89.7 vs. 48.1%, P = 0.0011), disease-specific survival (2-year survival 93.2 vs. 48.2%, P < 0.0001) and overall survival (2-year survival 90.0 vs. 39.0%, P < 0.0001). Multivariate analyses using the Cox proportional hazard model revealed that the radiological response rate was an independent predictor for favorable pT stage and recurrence-free survival. CONCLUSION: The radiological response rate determined by pretreatment and post-chemotherapy computed tomography scans predicts the pathological outcome and post-radical cystectomy prognosis, which is clinically relevant and useful for patient counselling and decision-making. CI - (c) The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Fukui, Tomohiro AU - Fukui T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto. FAU - Umeoka, Shigeaki AU - Umeoka S AD - Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Inoue, Takahiro AU - Inoue T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto. FAU - Kamba, Tomomi AU - Kamba T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto. FAU - Togashi, Kaori AU - Togashi K AD - Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Ogawa, Osamu AU - Ogawa O AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto ogawao@kuhp.kuoyo-u.ac.jp. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto. LA - eng PT - Journal Article DEP - 20160308 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 OTO - NOTNLM OT - CT scan OT - muscle-invasive bladder cancer OT - radical cystectomy OT - surrogate marker OT - survival EDAT- 2016/03/11 06:00 MHDA- 2016/03/11 06:01 CRDT- 2016/03/11 06:00 PHST- 2016/03/11 06:00 [entrez] PHST- 2016/03/11 06:00 [pubmed] PHST- 2016/03/11 06:01 [medline] AID - hyw025 [pii] AID - 10.1093/jjco/hyw025 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2016 Jun;46(6):560-567. doi: 10.1093/jjco/hyw025. Epub 2016 Mar 8. PMID- 26944862 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20220331 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 DP - 2016 Mar 5 TI - Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. PG - 185 LID - 10.1186/s12885-016-2219-z [doi] LID - 185 AB - BACKGROUND: There is no reliable biomarker for predicting the prognosis of patients who undergo radical cystectomy for bladder cancer. Recent studies have shown that the neutrophil-to-lymphocyte ratio (NLR) could function as a useful prognostic factor in several types of malignancies. This study aimed to assess the usefulness of NLR in bladder cancer. METHODS: A total of 74 patients who underwent radical cystectomy in our institutions from 1999 to 2014 were analyzed. The NLR was calculated using the patients' neutrophil and lymphocyte counts before radical cystectomy. An immunohistochemical analysis was also performed to detect tumor infiltrating neutrophils (CD66b) and lymphocytes (CD8) in bladder cancer specimens. RESULTS: A univariate analysis showed that the patients with a high NLR (>/=2.38; HR = 4.84; p = 0.007), high C-reactive protein level (>0.08; HR = 10.06; p = 0.030), or pathological lymph node metastasis (HR = 4.73; p = 0.030) had a significantly higher risk of cancer-specific mortality. Kaplan-Meier and log-rank tests further revealed that NLR was strongly correlated with overall survival (p = 0.018), but not progression-free survival (p = 0.137). In a multivariate analysis, all of these were found to be independent risk factors (HR = 4.62, 10.8, and 12.35, respectively). The number of CD8-positive lymphocytes was significantly increased in high-grade (p = 0.001) and muscle-invasive (p = 0.012) tumors, in comparison to low-grade and non-muscle-invasive tumors, respectively. CONCLUSIONS: The NLR predicted the prognosis of patients who underwent radical cystectomy and might therefore function as a reliable biomarker in cases of invasive bladder cancer. FAU - Kawahara, Takashi AU - Kawahara T AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. takashi_tk2001@yahoo.co.jp. AD - Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan. takashi_tk2001@yahoo.co.jp. FAU - Furuya, Kazuhiro AU - Furuya K AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. kazuhiro.furuya1981@gmail.com. FAU - Nakamura, Manami AU - Nakamura M AD - Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan. hirojiuemura@icloud.com. FAU - Sakamaki, Kentaro AU - Sakamaki K AD - Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. sakamaki@yokohama-cu.ac.jp. FAU - Osaka, Kimito AU - Osaka K AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. ousaka@yokohama-cu.ac.jp. FAU - Ito, Hiroki AU - Ito H AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. pug_daikichi@yahoo.co.jp. FAU - Ito, Yusuke AU - Ito Y AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. yusukeitou1@gmail.com. FAU - Izumi, Koji AU - Izumi K AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. koji.izumi522@gmail.com. FAU - Ohtake, Shinji AU - Ohtake S AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. sohtake1112@live.jp. FAU - Miyoshi, Yasuhide AU - Miyoshi Y AD - Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan. miyoyasu@yokohama-cu.ac.jp. FAU - Makiyama, Kazuhide AU - Makiyama K AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. makiya@yokohama-cu.ac.jp. FAU - Nakaigawa, Noboru AU - Nakaigawa N AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. nakaigan@yokohama-cu.ac.jp. FAU - Yamanaka, Takeharu AU - Yamanaka T AD - Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. yamanaka@yokohama-cu.ac.jp. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, USA. hmiyamo1@jhmi.edu. FAU - Yao, Masahiro AU - Yao M AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. masayao@yokohama-cu.ac.jp. FAU - Uemura, Hiroji AU - Uemura H AD - Department of Urology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. hu0428@yokohama-cu.ac.jp. AD - Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan. hu0428@yokohama-cu.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160305 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers) SB - IM MH - Aged MH - Biomarkers MH - CD8-Positive T-Lymphocytes/pathology MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - *Leukocyte Count MH - Lymphocyte Count MH - *Lymphocytes MH - Lymphocytes, Tumor-Infiltrating/metabolism/pathology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - *Neutrophils MH - Patient Outcome Assessment MH - Prognosis MH - Urinary Bladder Neoplasms/*blood/diagnosis/*mortality/therapy PMC - PMC4779264 EDAT- 2016/03/06 06:00 MHDA- 2016/12/15 06:00 PMCR- 2016/03/05 CRDT- 2016/03/06 06:00 PHST- 2015/06/27 00:00 [received] PHST- 2016/02/24 00:00 [accepted] PHST- 2016/03/06 06:00 [entrez] PHST- 2016/03/06 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2016/03/05 00:00 [pmc-release] AID - 10.1186/s12885-016-2219-z [pii] AID - 2219 [pii] AID - 10.1186/s12885-016-2219-z [doi] PST - epublish SO - BMC Cancer. 2016 Mar 5;16:185. doi: 10.1186/s12885-016-2219-z. PMID- 26929985 OWN - NLM STAT- MEDLINE DCOM- 20170524 LR - 20220330 IS - 1559-2308 (Electronic) IS - 1559-2294 (Print) IS - 1559-2294 (Linking) VI - 11 IP - 3 DP - 2016 Mar 3 TI - Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. PG - 237-46 LID - 10.1080/15592294.2016.1154246 [doi] AB - High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable disease with greater risks of recurrence and progression relative to their low-intermediate-grade counterparts. The molecular events, including those affecting the epigenome, that characterize this disease entity in the context of tumor development, recurrence, and progression, are incompletely understood. We therefore interrogated genome-wide DNA methylation using HumanMethylation450 BeadChip arrays in 21 primary HG-NMIBC tumors relative to normal bladder controls. Using strict inclusion-exclusion criteria we identified 1,057 hypermethylated CpGs within gene promoter-associated CpG islands, representing 256 genes. We validated the array data by bisulphite pyrosequencing and examined 25 array-identified candidate genes in an independent cohort of 30 HG-NMIBC and 18 low-intermediate-grade NMIBC. These analyses revealed significantly higher methylation frequencies in high-grade tumors relative to low-intermediate-grade tumors for the ATP5G2, IRX1 and VAX2 genes (P<0.05), and similarly significant increases in mean levels of methylation in high-grade tumors for the ATP5G2, VAX2, INSRR, PRDM14, VSX1, TFAP2b, PRRX1, and HIST1H4F genes (P<0.05). Although inappropriate promoter methylation was not invariantly associated with reduced transcript expression, a significant association was apparent for the ARHGEF4, PON3, STAT5a, and VAX2 gene transcripts (P<0.05). Herein, we present the first genome-wide DNA methylation analysis in a unique HG-NMIBC cohort, showing extensive and discrete methylation changes relative to normal bladder and low-intermediate-grade tumors. The genes we identified hold significant potential as targets for novel therapeutic intervention either alone, or in combination, with more conventional therapeutic options in the treatment of this clinically unpredictable disease. FAU - Kitchen, Mark O AU - Kitchen MO AD - a Institute for Science and Technology in Medicine, Keele University , UK. AD - b Urology Department , University Hospitals of North Midlands NHS Trust , UK. FAU - Bryan, Richard T AU - Bryan RT AD - c Institute of Cancer and Genomic Sciences, University of Birmingham , UK. FAU - Emes, Richard D AU - Emes RD AD - d Advanced Data Analysis Center, University of Nottingham , UK. FAU - Glossop, John R AU - Glossop JR AD - a Institute for Science and Technology in Medicine, Keele University , UK. FAU - Luscombe, Christopher AU - Luscombe C AD - b Urology Department , University Hospitals of North Midlands NHS Trust , UK. FAU - Cheng, K K AU - Cheng KK AD - c Institute of Cancer and Genomic Sciences, University of Birmingham , UK. FAU - Zeegers, Maurice P AU - Zeegers MP AD - c Institute of Cancer and Genomic Sciences, University of Birmingham , UK. AD - e Department of Complex Genetics , Maastricht University Medical Center , The Netherlands. AD - f NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center , The Netherlands. AD - g CAPHRI School for Public Health and Primary Care, Maastricht University Medical Center , The Netherlands. FAU - James, Nicholas D AU - James ND AD - h Cancer Research Unit, University of Warwick , UK. FAU - Devall, Adam J AU - Devall AJ AD - c Institute of Cancer and Genomic Sciences, University of Birmingham , UK. FAU - Mein, Charles A AU - Mein CA AD - i The Genome Center, Barts and the London School of Medicine and Dentistry , London , UK. FAU - Gommersall, Lyndon AU - Gommersall L AD - b Urology Department , University Hospitals of North Midlands NHS Trust , UK. FAU - Fryer, Anthony A AU - Fryer AA AD - a Institute for Science and Technology in Medicine, Keele University , UK. FAU - Farrell, William E AU - Farrell WE AD - a Institute for Science and Technology in Medicine, Keele University , UK. LA - eng PT - Journal Article DEP - 20160301 PL - United States TA - Epigenetics JT - Epigenetics JID - 101265293 RN - 0 (ARHGEF4 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Homeodomain Proteins) RN - 0 (Neoplasm Proteins) RN - 0 (Rho Guanine Nucleotide Exchange Factors) RN - 0 (STAT5 Transcription Factor) RN - 0 (STAT5A protein, human) RN - 0 (Tumor Suppressor Proteins) RN - 0 (VAX2 protein, human) RN - EC 3.1.8.1 (Aryldialkylphosphatase) RN - EC 3.1.8.1 (PON3 protein, human) SB - IM MH - Aryldialkylphosphatase/*genetics MH - Biomarkers, Tumor/genetics MH - CpG Islands/genetics MH - DNA Methylation/*genetics MH - Female MH - Genome, Human MH - Genome-Wide Association Study MH - Homeodomain Proteins/*genetics MH - Humans MH - Male MH - Neoplasm Invasiveness/genetics MH - Neoplasm Proteins/genetics MH - Neoplasm Recurrence, Local/genetics/pathology MH - Promoter Regions, Genetic/genetics MH - Rho Guanine Nucleotide Exchange Factors/genetics MH - STAT5 Transcription Factor/*genetics MH - Tumor Suppressor Proteins/*genetics MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC4854556 OTO - NOTNLM OT - Epigenetics OT - HumanMethylation450 BeadChip Array OT - gene expression OT - high-grade non-muscle invasive bladder cancer OT - methylation EDAT- 2016/03/02 06:00 MHDA- 2017/05/26 06:00 PMCR- 2017/03/01 CRDT- 2016/03/02 06:00 PHST- 2016/03/02 06:00 [entrez] PHST- 2016/03/02 06:00 [pubmed] PHST- 2017/05/26 06:00 [medline] PHST- 2017/03/01 00:00 [pmc-release] AID - 1154246 [pii] AID - 10.1080/15592294.2016.1154246 [doi] PST - ppublish SO - Epigenetics. 2016 Mar 3;11(3):237-46. doi: 10.1080/15592294.2016.1154246. Epub 2016 Mar 1. PMID- 26927059 OWN - NLM STAT- MEDLINE DCOM- 20161104 LR - 20260127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 17 IP - 3 DP - 2016 Feb 24 TI - Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma. PG - 271 LID - 10.3390/ijms17030271 [doi] LID - 271 AB - Bladder cancer represents the ninth most widespread malignancy throughout the world. It is characterized by the presence of two different clinical and prognostic subtypes: non-muscle-invasive bladder cancers (NMIBCs) and muscle-invasive bladder cancers (MIBCs). MIBCs have a poor outcome with a common progression to metastasis. Despite improvements in knowledge, treatment has not advanced significantly in recent years, with the absence of new therapeutic targets. Because of the limitations of current therapeutic options, the greater challenge will be to identify biomarkers for clinical application. For this reason, we compared our array comparative genomic hybridization (array-CGH) results with those reported in literature for invasive bladder tumors and, in particular, we focused on the evaluation of copy number alterations (CNAs) present in biopsies and retained in the corresponding cancer stem cell (CSC) subpopulations that should be the main target of therapy. According to our data, CCNE1, MYC, MDM2 and PPARG genes could be interesting therapeutic targets for bladder CSC subpopulations. Surprisingly, HER2 copy number gains are not retained in bladder CSCs, making the gene-targeted therapy less interesting than the others. These results provide precious advice for further study on bladder therapy; however, the clinical importance of these results should be explored. FAU - Conconi, Donatella AU - Conconi D AD - School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. donatella.conconi@unimib.it. FAU - Sala, Elena AU - Sala E AD - Medical Genetics Laboratory, San Gerardo Hospital, 20900 Monza, Italy. elena.sala@hsgerardo.org. FAU - Bovo, Giorgio AU - Bovo G AD - Department of Pathology, San Gerardo Hospital, 20900 Monza, Italy. g.bovo@hsgerardo.org. FAU - Strada, Guido AU - Strada G AD - Urology Division, Bassini Icp Hospital, 20092 Cinisello Balsamo, Italy. guido.strada@icp.mi.it. FAU - Dalpra, Leda AU - Dalpra L AD - School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. leda.dalpra@unimib.it. AD - Medical Genetics Laboratory, San Gerardo Hospital, 20900 Monza, Italy. leda.dalpra@unimib.it. FAU - Lavitrano, Marialuisa AU - Lavitrano M AD - School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. marialuisa.lavitrano@unimib.it. FAU - Bentivegna, Angela AU - Bentivegna A AD - School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy. angela.bentivegna@unimib.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160224 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cyclin E) RN - 0 (Oncogene Proteins) RN - 0 (PPAR gamma) RN - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2) RN - 0 (Proto-Oncogene Proteins c-myc) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - 0 (CCNE1 protein, human) RN - EC 2.3.2.27 (MDM2 protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Carcinoma/drug therapy/*genetics MH - Cyclin E/genetics MH - *DNA Copy Number Variations MH - Humans MH - Molecular Targeted Therapy/methods MH - Oncogene Proteins/genetics MH - PPAR gamma/genetics MH - Proto-Oncogene Proteins c-mdm2/genetics MH - Proto-Oncogene Proteins c-myc/genetics MH - Erb-b2 Receptor Tyrosine Kinases/genetics MH - Urinary Bladder Neoplasms/drug therapy/*genetics PMC - PMC4813135 OTO - NOTNLM OT - bladder cancer OT - cancer stem cells OT - copy number alterations OT - therapeutic targets OT - transitional cell carcinomas EDAT- 2016/03/02 06:00 MHDA- 2016/11/05 06:00 PMCR- 2016/03/01 CRDT- 2016/03/02 06:00 PHST- 2016/01/11 00:00 [received] PHST- 2016/02/17 00:00 [revised] PHST- 2016/02/17 00:00 [accepted] PHST- 2016/03/02 06:00 [entrez] PHST- 2016/03/02 06:00 [pubmed] PHST- 2016/11/05 06:00 [medline] PHST- 2016/03/01 00:00 [pmc-release] AID - ijms17030271 [pii] AID - ijms-17-00271 [pii] AID - 10.3390/ijms17030271 [doi] PST - epublish SO - Int J Mol Sci. 2016 Feb 24;17(3):271. doi: 10.3390/ijms17030271. PMID- 26922518 OWN - NLM STAT- MEDLINE DCOM- 20170810 LR - 20170817 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 40 IP - 6 DP - 2016 Jul-Aug TI - Retrospective study of various conservative treatment options with bacille Calmette-Guerin in bladder urothelial carcinoma T1G3: Maintenance therapy. PG - 370-7 LID - S0210-4806(16)00004-8 [pii] LID - 10.1016/j.acuro.2015.12.009 [doi] AB - OBJECTIVE: To compare various conservative treatment options for high-grade T1 nonmuscle-invasive bladder cancer (NMIBC). Bacille Calmette-Guerin (BCG) is the preferred intravesical treatment for high-grade T1 tumours; however, a number of experts still question the need for maintenance BCG. MATERIAL AND METHODS: We retrospectively analysed data from 1039 patients with primary and recurrent T1G3 NMIBC. All patients underwent complete transurethral resection of the bladder tumour (TURBT), with muscle in the sample and multiple bladder biopsies. The patients were treated with the following: only one initial TURBT (n=108), re-TURBT (n=153), induction with 27mg of BCG (Connaught strain) (n=87), induction with 81mg of BCG (n=489) or induction with 81mg of BCG+maintenance (n=202). The time to first recurrence, progression (to T2 or greater or to metastatic disease) and specific mortality of the disease was assessed using the Kaplan-Meier survival function and were compared using the log-rank test and the Cox multivariate regression model of proportional risks. RESULTS: The mean follow-up was 62+/-39 months. The risk of recurrence was significantly lower for the patients treated with maintenance therapy of 81mg of BCG than in the other treatment groups (P<.001). The risk of tumour progression was also significantly lower for the patients treated with maintenance BCG than for the patients treated only with one TURBT, re-TURBT and with induction therapy with 27mg of BCG (P=.0003). The specific disease mortality was significantly lower with BCG maintenance (9.4%) than with only one TURBT (27.8%; P=.003). CONCLUSIONS: In the case of T1G3 NMIBC, a complete dose of BCG with maintenance is associated with better recurrence results than are other conservative treatment modalities. The results of progression and survival specific to the disease were also better with induction BCG, with or without maintenance. CI - Copyright (c) 2016 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Palou-Redorta, J AU - Palou-Redorta J AD - Servicio de Urologia, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Espana. Electronic address: jpalou@fundacio-puigvert.es. FAU - Solsona, E AU - Solsona E AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Instituto Valenciano de Oncologia, Valencia, Espana. FAU - Angulo, J AU - Angulo J AD - Servicio de Urologia, Hospital Universitario de Getafe, Madrid, Espana. FAU - Fernandez, J M AU - Fernandez JM AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Hospital Central de Asturias, Universidad de Oviedo, Oviedo, Espana. FAU - Madero, R AU - Madero R AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Departamento de Estadistica, Hospital la Paz, Madrid, Espana. FAU - Unda, M AU - Unda M AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Hospital de Basurto, Bilbao, Espana. FAU - Martinez-Pineiro, J A AU - Martinez-Pineiro JA AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Hospital La Paz, Madrid, Espana. FAU - Portillo, J AU - Portillo J AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Hospital Marques de Valdecilla, Santander, Espana. FAU - Chantada, V AU - Chantada V AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Complejo Hospitalario Universitario A Coruna, A Coruna, Espana. FAU - Moyano, J L AU - Moyano JL AD - Club Urologico Espanol de Tratamiento Oncologico (CUETO); Servicio de Urologia, Hospital Universitario Virgen Macarena, Sevilla, Espana. LA - eng LA - spa PT - Comparative Study PT - Journal Article TT - Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guerin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento. DEP - 20160224 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/pathology MH - *Conservative Treatment MH - Female MH - Humans MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*drug therapy/pathology MH - Young Adult OTO - NOTNLM OT - Bacille Calmette-Guerin OT - Bacilo de Calmette-Guerin OT - Maintenance therapy OT - Nonmuscle-invasive bladder tumour OT - Reseccion transuretral de tumor vesical OT - T1G3 carcinoma urotelial OT - T1G3 urothelial carcinoma OT - Transurethral resection of bladder tumour OT - Tratamiento de mantenimiento OT - Tumor vesical no musculo-invasivo EDAT- 2016/02/29 06:00 MHDA- 2017/08/11 06:00 CRDT- 2016/02/29 06:00 PHST- 2015/10/01 00:00 [received] PHST- 2015/12/11 00:00 [revised] PHST- 2015/12/14 00:00 [accepted] PHST- 2016/02/29 06:00 [entrez] PHST- 2016/02/29 06:00 [pubmed] PHST- 2017/08/11 06:00 [medline] AID - S0210-4806(16)00004-8 [pii] AID - 10.1016/j.acuro.2015.12.009 [doi] PST - ppublish SO - Actas Urol Esp. 2016 Jul-Aug;40(6):370-7. doi: 10.1016/j.acuro.2015.12.009. Epub 2016 Feb 24. PMID- 26922408 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20181113 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 70 IP - 5 DP - 2016 Nov TI - Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design. PG - 778-785 LID - S0302-2838(16)00209-8 [pii] LID - 10.1016/j.eururo.2016.02.031 [doi] AB - BACKGROUND: Recurrence with papillary tumor(s) by 3-mo after induction bacillus Calmette-Guerin (BCG) is historically believed to be a poor prognostic indicator in patients with high-risk non-muscle invasive bladder cancer. However, the impact of a clinical Ta (cTa) papillary recurrence at 3 mo after BCG is often debated. OBJECTIVE: To evaluate the prognostic implications of cTa papillary recurrence found 3 mo after induction BCG therapy and to evaluate its significance in clinical trial design. DESIGN, SETTING, AND PARTICIPANTS: We reviewed our database of 917 patients who underwent transurethral resection and induction of BCG from 1995 to 2012. Clinical characteristics were compared between 3-mo recurrence stages. INTERVENTION: Transurethral resection of bladder tumor and intravesical therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Chi-square analysis and Student t test were used to compare clinical characteristics between 3-mo recurrence stages. Kaplan-Meier method was used to determine bladder-preservation time, progression-free survival, and disease-specific survival. RESULTS AND LIMITATIONS: We identified 84 patients who met the study criteria (66 patients with cTa and 18 patients with clinical T1 [cT1]). The median follow-up for the entire cohort was 74 mo. Of the patients with cTa recurrence, 60 continued with bladder-sparing therapy. Patients with a high-grade cTa recurrence who continued bladder-sparing therapy had a 17% incidence of disease progression and a 62% incidence of recurrence within 1 yr. No patients with low-grade cTa recurrence (n=13) developed disease progression or underwent radical cystectomy. Patients with an initial cTa at diagnosis had a higher 5-yr bladder preservation rate than those with an initial cT1 diagnosis (84% vs 61%; p=0.041). Patients with high-grade cTa recurrence and those with cT1 recurrence had similar outcomes with respect to death rates over the entire follow-up period (11% and 15%, respectively), as well as 5-yr progression-free survival (77% vs 83%). Limitations include using a single institution and a retrospective review. CONCLUSIONS: Patients with low-grade cTa papillary recurrence 3 mo after induction of BCG can safely continue with bladder-sparing therapy. Patients with high-grade cTa papillary recurrence at that time have risks of recurrence and progression similar to those of patients with cT1 recurrence. These are important factors to consider during clinical trial design. PATIENT SUMMARY: Low-grade clinical Ta papillary recurrence following induction of bacillus Calmette-Guerin therapy can be safely managed conservatively, although a high-grade clinical Ta recurrence should be treated similar to a clinical T1 recurrence due to its comparable progression rates. CI - Copyright (c) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Mmeje, Chinedu O AU - Mmeje CO AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Guo, Charles C AU - Guo CC AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Navai, Neema AU - Navai N AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160224 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2016 Nov;70(5):786-787. doi: 10.1016/j.eururo.2016.03.055. PMID: 27156128 CIN - J Urol. 2017 Aug;198(2):255. doi: 10.1016/j.juro.2017.04.093. PMID: 29370649 MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Aged MH - *BCG Vaccine/administration & dosage/adverse effects MH - Clinical Trials as Topic MH - Cystectomy/methods/statistics & numerical data MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - *Neoplasm Recurrence, Local/diagnosis/prevention & control MH - Neoplasm Staging MH - Prognosis MH - Research Design MH - Retrospective Studies MH - *Urinary Bladder Neoplasms/diagnosis/pathology/therapy PMC - PMC5115993 MID - NIHMS825293 OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Bladder cancer OT - Clinical outcomes OT - Non-muscle invasive OT - Recurrence EDAT- 2016/02/29 06:00 MHDA- 2018/01/18 06:00 PMCR- 2017/11/01 CRDT- 2016/02/29 06:00 PHST- 2015/12/08 00:00 [received] PHST- 2016/02/04 00:00 [accepted] PHST- 2016/02/29 06:00 [pubmed] PHST- 2018/01/18 06:00 [medline] PHST- 2016/02/29 06:00 [entrez] PHST- 2017/11/01 00:00 [pmc-release] AID - S0302-2838(16)00209-8 [pii] AID - 10.1016/j.eururo.2016.02.031 [doi] PST - ppublish SO - Eur Urol. 2016 Nov;70(5):778-785. doi: 10.1016/j.eururo.2016.02.031. Epub 2016 Feb 24. PMID- 26921394 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20220330 IS - 1538-8514 (Electronic) IS - 1535-7163 (Print) IS - 1535-7163 (Linking) VI - 15 IP - 3 DP - 2016 Mar TI - High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with approximately 240-Fold Higher Drug Concentration in Urine than Serum. PG - 430-8 LID - 10.1158/1535-7163.MCT-15-0714-T [doi] AB - While pharmacoepidemiologic and laboratory studies have supported the hypothesis that the antidiabetic drug metformin may be useful in treating or preventing cancer, there is limited evidence to suggest which specific cancer sites may be particularly sensitive. Sensitivity likely is determined both by features of tumor pathophysiology and by pharmacokinetic factors. We used UPII-mutant Ha-ras transgenic mice that develop hyperplasia and low-grade, papillary urothelial cell carcinoma to determine whether metformin has activity in a model of superficial bladder cancer. Metformin significantly improved survival, reduced urinary tract obstruction, reduced bladder weight (a surrogate for tumor volume), and led to clear activation of AMP alpha kinase and inhibition of mTOR signaling in neoplastic tissue. We investigated the basis of the unusual sensitivity of this model to metformin, and observed that following oral dosing, urothelium is exposed to drug concentrations via the urine that are approximately 240-fold higher than those in the circulation. In addition, we observed that bladder cancer cell lines (RT4, UMUC-3, and J82) with homozygous deletion of either TSC1 or PTEN are more sensitive to metformin than those (TEU2, TCCSUP, and HT1376) with wild-type TSC1 and PTEN genes. Our findings provide a strong rationale for clinical trials of oral metformin in treatment of superficial bladder cancer. CI - (c)2016 American Association for Cancer Research. FAU - Liu, Zhongbo AU - Liu Z AD - Department of Urology, University of California, Irvine, Orange, California. FAU - Yokoyama, Noriko N AU - Yokoyama NN AD - Department of Urology, University of California, Irvine, Orange, California. FAU - Blair, Christopher A AU - Blair CA AD - Department of Urology, University of California, Irvine, Orange, California. FAU - Li, Xuesen AU - Li X AD - Department of Urology, University of California, Irvine, Orange, California. FAU - Avizonis, Daina AU - Avizonis D AD - Metabolomics Core Facility, Goodman Cancer Research Center, McGill University, Montreal, Quebec, Canada. FAU - Wu, Xue-Ru AU - Wu XR AD - Departments of Urology and Pathology, New York University School of Medicine and Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, New York. FAU - Uchio, Edward AU - Uchio E AD - Department of Urology, University of California, Irvine, Orange, California. FAU - Youssef, Ramy AU - Youssef R AD - Department of Urology, University of California, Irvine, Orange, California. FAU - McClelland, Michael AU - McClelland M AD - Department of Pathology and Laboratory Medicine, University of California, Irvine, Orange, California. FAU - Pollak, Michael AU - Pollak M AD - Department of Oncology and Segal Cancer Center, McGill University, Montreal, Quebec, Canada. FAU - Zi, Xiaolin AU - Zi X AD - Department of Urology, University of California, Irvine, Orange, California. Department of Pharmacology, University of California, Irvine, Orange, California. Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California. xzi@uci.edu. LA - eng GR - 5R01CA122558-05/CA/NCI NIH HHS/United States GR - 1R21CA152804-01A1/CA/NCI NIH HHS/United States GR - P01 CA165980/CA/NCI NIH HHS/United States GR - R01 CA122558/CA/NCI NIH HHS/United States GR - UL1 TR001414/TR/NCATS NIH HHS/United States GR - P30 CA062203/CA/NCI NIH HHS/United States GR - R21 CA152804/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160226 PL - United States TA - Mol Cancer Ther JT - Molecular cancer therapeutics JID - 101132535 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) RN - 0 (S-Phase Kinase-Associated Proteins) RN - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27) RN - 9100L32L2N (Metformin) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Animals MH - Antineoplastic Agents/*pharmacokinetics MH - Biomarkers MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - Cyclin-Dependent Kinase Inhibitor p27/metabolism MH - Disease Models, Animal MH - Disease Progression MH - Drug Resistance, Neoplasm/*genetics MH - Female MH - *Genes, ras MH - Homozygote MH - Humans MH - Male MH - Metformin/*pharmacokinetics MH - Mice MH - Mice, Transgenic MH - Mutation MH - Neoplasm Grading MH - S-Phase Kinase-Associated Proteins/metabolism MH - Signal Transduction/drug effects MH - TOR Serine-Threonine Kinases MH - Tumor Burden/drug effects MH - Urinary Bladder Neoplasms/drug therapy/*genetics/metabolism/pathology MH - Xenograft Model Antitumor Assays PMC - PMC4783238 MID - NIHMS751789 COIS- Conflicts of Interest: The authors declared no potential conflicts of interest. EDAT- 2016/02/28 06:00 MHDA- 2016/12/15 06:00 PMCR- 2017/03/01 CRDT- 2016/02/28 06:00 PHST- 2015/08/27 00:00 [received] PHST- 2015/12/16 00:00 [accepted] PHST- 2016/02/28 06:00 [entrez] PHST- 2016/02/28 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2017/03/01 00:00 [pmc-release] AID - 1535-7163.MCT-15-0714-T [pii] AID - 10.1158/1535-7163.MCT-15-0714-T [doi] PST - ppublish SO - Mol Cancer Ther. 2016 Mar;15(3):430-8. doi: 10.1158/1535-7163.MCT-15-0714-T. Epub 2016 Feb 26. PMID- 26920373 OWN - NLM STAT- MEDLINE DCOM- 20161012 LR - 20220409 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 16 DP - 2016 Feb 27 TI - Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer. PG - 8 LID - 10.1186/s12894-016-0126-x [doi] LID - 8 AB - BACKGROUND: The purpose of this study was to assess the efficacy of Bacillus Calmette-Guerin (BCG) therapy after a second transurethral resection (TUR) in new onset high-grade T1 bladder cancer. METHODS: From January 2008 to September 2013, 207 patients with new onset high-grade T1 bladder cancer after an initial TUR were treated at our university and at affiliated hospitals. Residual cancer rate, intravesical recurrence-free survival (RFS), and risk factors for intravesical recurrence were analyzed. RESULTS: Among a total of 207 patients, 42 patients were treated with BCG therapy following a second TUR (group 1), 23 were treated with second TUR alone (group 2), 72 were treated with BCG alone (group 3), and 70 were treated without a second TUR or BCG. The median patients' age was 72.0 years, and the median follow-up period was 33.5 months. The second TUR revealed that 34 patients (52 %) had residual cancer. Between groups 1 and 2 and groups 1 and 3, the differences in RFS were statistically significant (p = 0.002 and 0.045, respectively). In addition, BCG therapy was the most significant factor to predict RFS after the second TUR. Among the 31 patients whose pathology of the second TUR was pT0, only 1 of 12 patients (8 %) in group 1 and 11 of 19 patients (58 %) in group 2 had a recurrence. CONCLUSIONS: BCG instillation following a second TUR decreases intravesical recurrence, even if the pathology of the second TUR is pT0. FAU - Iida, Keitaro AU - Iida K AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. ikeitarou1009@gmail.com. FAU - Naiki, Taku AU - Naiki T AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. rx-nike@hotmail.co.jp. AD - Department of Urology, Daido Hospital, Aichi, Japan. rx-nike@hotmail.co.jp. FAU - Kawai, Noriyasu AU - Kawai N AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. n-kawai@med.nagoya-cu.ac.jp. FAU - Etani, Toshiki AU - Etani T AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. to_etani@yahoo.co.jp. FAU - Ando, Ryosuke AU - Ando R AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. ryo@med.nagoya-cu.ac.jp. FAU - Ikegami, Yosuke AU - Ikegami Y AD - Department of Urology, Nagoya City East Medical Center, Aichi, Japan. urouroyokun@yahoo.co.jp. FAU - Okamura, Takehiko AU - Okamura T AD - Department of Urology, Anjo Kosei Hospital, Aichi, Japan. hiko2546@kosei.anjo.aichi.jp. FAU - Kubota, Hiroki AU - Kubota H AD - Department of Urology, Kainan Hospital, Aichi, Japan. 479659@kainan.jaaikosei.or.jp. FAU - Okada, Atsushi AU - Okada A AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. a-okada@med.nagoya-cu.ac.jp. FAU - Kohri, Kenjiro AU - Kohri K AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. urokk@med.nagoya-cu.ac.jp. FAU - Yasui, Takahiro AU - Yasui T AD - Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan. yasui@med.nagoya-cu.ac.jp. LA - eng PT - Journal Article DEP - 20160227 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Case-Control Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*epidemiology MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder/*surgery MH - Urinary Bladder Neoplasms/pathology/*therapy PMC - PMC4769574 EDAT- 2016/02/28 06:00 MHDA- 2016/10/13 06:00 PMCR- 2016/02/27 CRDT- 2016/02/28 06:00 PHST- 2015/09/30 00:00 [received] PHST- 2016/02/23 00:00 [accepted] PHST- 2016/02/28 06:00 [entrez] PHST- 2016/02/28 06:00 [pubmed] PHST- 2016/10/13 06:00 [medline] PHST- 2016/02/27 00:00 [pmc-release] AID - 10.1186/s12894-016-0126-x [pii] AID - 126 [pii] AID - 10.1186/s12894-016-0126-x [doi] PST - epublish SO - BMC Urol. 2016 Feb 27;16:8. doi: 10.1186/s12894-016-0126-x. PMID- 26914490 OWN - NLM STAT- MEDLINE DCOM- 20170816 LR - 20181202 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 30 IP - 7 DP - 2016 Jul TI - Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. PG - 792-8 LID - 10.1089/end.2016.0050 [doi] AB - OBJECTIVE: To evaluate perioperative morbidity and mortality rate, a 3-year recurrence-free survival, and cancer-specific mortality rate in patients older than 80 years undergoing robot-assisted radical cystectomy (RARC). MATERIALS AND METHODS: We retrospectively collected data of 155 consecutive patients who received RARC for muscle-invasive or high-risk nonmuscle-invasive urothelial carcinoma of the bladder between 2003 and 2014 at a high-volume robotic center. Diversion was performed intra- or extracorporeally according to the surgeon's preferences. Complications were graded according to the Clavien-Dindo system. Logistic regression analyses were used to assess the impact of age on postoperative outcomes. RESULTS: Of 155 consecutive patients, 22 (14.2%) patients were 80 years or older. Octogenarians did not significantly differ from younger patients in ASA score (p = 0.4) and Charlson comorbidity index (p = 0.4). Prevalence of any grade and high-grade complications was similar in both groups (all p >/= 0.6). Older patients had a significantly higher pathologic tumor grade (p = 0.04) and a lower use of pelvic lymphadenectomy (p < 0.001). No perioperative mortality rate was recorded within 90 days from surgery. Elderly patients had a similar risk of 3-year oncologic recurrence after surgery compared with their younger counterparts (odds ratio [OR] 1.63; p = 0.2). Conversely, the risk of cancer-specific mortality rate was significantly higher (OR 2.78; p = 0.02). CONCLUSIONS: Patients 80 years or older undergoing RARC for bladder cancer did not have a higher risk of peri- and postoperative morbidity and mortality rate and had a similar 3-year recurrence-free survival, suggesting that RARC can be safely performed in selected elderly patients by experienced surgeons. FAU - De Groote, Ruben AU - De Groote R AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Gandaglia, Giorgio AU - Gandaglia G AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . AD - 2 O.L.V. Vattikuti Robotic Surgery Institute , Melle, Belgium . AD - 3 Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele , Milan, Italy . FAU - Geurts, Nicolas AU - Geurts N AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Goossens, Marijn AU - Goossens M AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Pauwels, Elisabeth AU - Pauwels E AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - D'Hondt, Frederiek AU - D'Hondt F AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Gratzke, Christian AU - Gratzke C AD - 4 Urologische Klinik und Poliklinik, Klinikum der Universitat Munchen, Ludwig-Maximilians Universitat Munchen , Munich, Germany . FAU - Fossati, Nicola AU - Fossati N AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . AD - 2 O.L.V. Vattikuti Robotic Surgery Institute , Melle, Belgium . AD - 3 Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele , Milan, Italy . FAU - De Naeyer, Geert AU - De Naeyer G AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Schatteman, Peter AU - Schatteman P AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Carpentier, Paul AU - Carpentier P AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . FAU - Novara, Giacomo AU - Novara G AD - 2 O.L.V. Vattikuti Robotic Surgery Institute , Melle, Belgium . AD - 5 Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua , Padua, Italy . FAU - Mottrie, Alexandre AU - Mottrie A AD - 1 Department of Urology, O.L.V. Hospital , Aalst, Belgium . AD - 2 O.L.V. Vattikuti Robotic Surgery Institute , Melle, Belgium . LA - eng PT - Journal Article DEP - 20160606 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Cystectomy/*methods MH - Female MH - Humans MH - Lymph Node Excision MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Odds Ratio MH - Pelvis MH - Postoperative Complications/*epidemiology MH - Proportional Hazards Models MH - Retrospective Studies MH - Robotic Surgical Procedures/*methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery EDAT- 2016/02/26 06:00 MHDA- 2017/08/17 06:00 CRDT- 2016/02/26 06:00 PHST- 2016/02/26 06:00 [entrez] PHST- 2016/02/26 06:00 [pubmed] PHST- 2017/08/17 06:00 [medline] AID - 10.1089/end.2016.0050 [doi] PST - ppublish SO - J Endourol. 2016 Jul;30(7):792-8. doi: 10.1089/end.2016.0050. Epub 2016 Jun 6. PMID- 26906030 OWN - NLM STAT- MEDLINE DCOM- 20170425 LR - 20260127 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 34 IP - 10 DP - 2016 Oct TI - Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. PG - 1405-9 LID - 10.1007/s00345-016-1795-5 [doi] AB - PURPOSE: Urinary cytology (C) and cystoscopy remain the gold standard for the detection and screening of bladder cancer (BC). In this prospective study, we analyzed whether baseline C, ImmunoCyt (I), BTA Stat (B), hemoglobin dipstick (H), and NMP22 BladderChek (N) can predict recurrence and progression. METHODS: Urinary samples from 91 patients with BC were prospectively collected over an 18-month period. Baseline characteristics of the population included patient demographics, various clinicopathological variables and use of intravesical therapy. Progression and recurrence were then assessed after a median follow-up of 48 months (IQR 23.7-59.5). Univariate and multivariate analyses were performed using COX proportional hazards models. RESULTS: On univariate analysis, C (HR 1.36; p = 0.26), I (HR 0.89; p = 0.66), B (HR 0.80; p = 0.42), H (HR 0.75; p = 0.30), and N (HR 0.82; p = 0.48) were not associated with recurrence-free survival (RFS). With regard to progression-free survival (PFS), C was significantly prognostic (HR 2.67; p = 0.017), whereas I, B, H, and N were not. On multivariable analysis, NMP22 was the only marker to be independently associated with RFS (HR 0.41, p < 0.01) and PFS (HR 0.32, p = 0.02). CONCLUSION: Based on the results of this study, baseline C, B, I, and H were not independently prognostic. Prognostic impact of NMP22 requires further validation in a multicenter larger study. FAU - Bell, Michael D AU - Bell MD AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. FAU - Yafi, Faysal A AU - Yafi FA AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. FAU - Brimo, Fadi AU - Brimo F AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. AD - Division of Pathology, McGill University Health Center, Montreal, QC, Canada. FAU - Steinberg, Jordan AU - Steinberg J AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. FAU - Aprikian, Armen G AU - Aprikian AG AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. FAU - Tanguay, Simon AU - Tanguay S AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. FAU - Kassouf, Wassim AU - Kassouf W AD - Department of Surgery (Urology), McGill University, Montreal, QC, Canada. wassim.kassouf@muhc.mcgill.ca. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20160223 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/urine MH - Canada/epidemiology MH - Cystoscopy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/mortality/*urine MH - Prognosis MH - Proportional Hazards Models MH - Prospective Studies MH - Survival Rate/trends MH - Time Factors MH - Urinalysis MH - Urinary Bladder Neoplasms/diagnosis/mortality/*urine OTO - NOTNLM OT - Bladder cancer OT - Progression OT - Recurrence OT - Urinary biomarkers OT - Urinary cytology EDAT- 2016/02/26 06:00 MHDA- 2017/04/26 06:00 CRDT- 2016/02/25 06:00 PHST- 2015/09/20 00:00 [received] PHST- 2016/02/13 00:00 [accepted] PHST- 2016/02/25 06:00 [entrez] PHST- 2016/02/26 06:00 [pubmed] PHST- 2017/04/26 06:00 [medline] AID - 10.1007/s00345-016-1795-5 [pii] AID - 10.1007/s00345-016-1795-5 [doi] PST - ppublish SO - World J Urol. 2016 Oct;34(10):1405-9. doi: 10.1007/s00345-016-1795-5. Epub 2016 Feb 23. PMID- 26901314 OWN - NLM STAT- MEDLINE DCOM- 20160715 LR - 20250529 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 2 DP - 2016 TI - Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PG - e0149756 LID - 10.1371/journal.pone.0149756 [doi] LID - e0149756 AB - BACKGROUND: Highly sensitive and specific urine-based tests to detect either primary or recurrent bladder cancer have proved elusive to date. Our ever increasing knowledge of the genomic aberrations in bladder cancer should enable the development of such tests based on urinary DNA. METHODS: DNA was extracted from urine cell pellets and PCR used to amplify the regions of the TERT promoter and coding regions of FGFR3, PIK3CA, TP53, HRAS, KDM6A and RXRA which are frequently mutated in bladder cancer. The PCR products were barcoded, pooled and paired-end 2 x 250 bp sequencing performed on an Illumina MiSeq. Urinary DNA was analysed from 20 non-cancer controls, 120 primary bladder cancer patients (41 pTa, 40 pT1, 39 pT2+) and 91 bladder cancer patients post-TURBT (89 cancer-free). RESULTS: Despite the small quantities of DNA extracted from some urine cell pellets, 96% of the samples yielded mean read depths >500. Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer. Overall, these previously reported bladder cancer mutations were detected in 86 out of 122 bladder cancer patients (70% sensitivity) and in only 3 out of 109 patients with no detectable bladder cancer (97% specificity). CONCLUSION: This simple, cost-effective approach could be used for the non-invasive surveillance of patients with non-muscle-invasive bladder cancers harbouring these mutations. The method has a low DNA input requirement and can detect low levels of mutant DNA in a large excess of normal DNA. These genes represent a minimal biomarker panel to which extra markers could be added to develop a highly sensitive diagnostic test for bladder cancer. FAU - Ward, Douglas G AU - Ward DG AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Baxter, Laura AU - Baxter L AD - Warwick Systems Biology Centre, University of Warwick, Coventry, CV4 7AL, United Kingdom. FAU - Gordon, Naheema S AU - Gordon NS AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Ott, Sascha AU - Ott S AD - Warwick Systems Biology Centre, University of Warwick, Coventry, CV4 7AL, United Kingdom. FAU - Savage, Richard S AU - Savage RS AD - Warwick Systems Biology Centre, University of Warwick, Coventry, CV4 7AL, United Kingdom. AD - Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United Kingdom. FAU - Beggs, Andrew D AU - Beggs AD AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - James, Jonathan D AU - James JD AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Lickiss, Jennifer AU - Lickiss J AD - West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, B15 2TG, United Kingdom. FAU - Green, Shaun AU - Green S AD - West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, B15 2TG, United Kingdom. FAU - Wallis, Yvonne AU - Wallis Y AD - West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, B15 2TG, United Kingdom. FAU - Wei, Wenbin AU - Wei W AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - James, Nicholas D AU - James ND AD - Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, United Kingdom. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. AD - Department of Complex Genetics, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Cheng, K K AU - Cheng KK AD - School of Health and Population Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Mathews, Glenn M AU - Mathews GM AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Patel, Prashant AU - Patel P AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. FAU - Griffiths, Michael AU - Griffiths M AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. AD - West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, B15 2TG, United Kingdom. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - MR/M009157/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160222 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (DNA, Neoplasm) RN - 0 (Neoplasm Proteins) SB - IM MH - Aged MH - Aged, 80 and over MH - *DNA, Neoplasm/genetics/urine MH - Female MH - High-Throughput Nucleotide Sequencing/*methods MH - Humans MH - Male MH - Multiplex Polymerase Chain Reaction/*methods MH - *Mutation MH - Neoplasm Proteins/*genetics MH - Sensitivity and Specificity MH - *Urinary Bladder Neoplasms/genetics/urine PMC - PMC4762704 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2016/02/24 06:00 MHDA- 2016/07/16 06:00 PMCR- 2016/02/22 CRDT- 2016/02/23 06:00 PHST- 2015/09/21 00:00 [received] PHST- 2016/02/04 00:00 [accepted] PHST- 2016/02/23 06:00 [entrez] PHST- 2016/02/24 06:00 [pubmed] PHST- 2016/07/16 06:00 [medline] PHST- 2016/02/22 00:00 [pmc-release] AID - PONE-D-15-41370 [pii] AID - 10.1371/journal.pone.0149756 [doi] PST - epublish SO - PLoS One. 2016 Feb 22;11(2):e0149756. doi: 10.1371/journal.pone.0149756. eCollection 2016. PMID- 26894268 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20171116 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 96 IP - 2 DP - 2016 TI - Tumor Suppressor in Lung Cancer-1 Is a Prognostic Predictor for the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer. PG - 142-7 LID - 10.1159/000438492 [doi] AB - OBJECTIVE: To investigate the relationship between the expression of tumor suppressor in lung cancer-1 (TSLC1) and clinicopathological characteristics of patients with non-muscle-invasive bladder cancer (NMIBC) and evaluate the prognostic significance of TSLC1. METHODS: TSLC1 expression in 241 specimens of NMIBC was examined by immunohistochemistry. The correlation between TSLC1 expression and clinicopathological characteristics was evaluated using the chi-square test. The prognostic significance of TSLC1 was analyzed by univariate, multivariate analysis and Kaplan-Meier survival curves. RESULTS: The total negative rate of TSLC1 expression was 47.3% in NMIBC. Decreased expression of TSLC1 was correlated with a higher clinical stage, higher pathological grade, the number of tumors, lager tumor size, tumor recurrence and progression. TSLC1 expression was an independent risk factor for predicting tumor recurrence (p = 0.005) and progression (p < 0.001). CONCLUSION: Decreased expression of TSLC1 is correlated with the malignancy of NMIBC tissues and low TSLC1 expression may serve as a predictor for bladder cancer recurrence and progression. CI - (c) 2015 S. Karger AG, Basel. FAU - Chen, Yegang AU - Chen Y AD - Department of Urology, Second Hospital of Tianjin Medical University and Tianjin Institute of Urology, Tianjin, China. FAU - Yang, Yongjiao AU - Yang Y FAU - Liu, Li AU - Liu L FAU - Wang, Shangren AU - Wang S FAU - Song, Hong AU - Song H FAU - Liu, Xiaoqiang AU - Liu X LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150815 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Biomarkers, Tumor) RN - 0 (CADM1 protein, human) RN - 0 (Cell Adhesion Molecule-1) RN - 0 (Cell Adhesion Molecules) RN - 0 (Immunoglobulins) SB - IM MH - Aged MH - Biomarkers, Tumor/*analysis MH - Cell Adhesion Molecule-1 MH - Cell Adhesion Molecules/*analysis MH - Chi-Square Distribution MH - Disease Progression MH - Disease-Free Survival MH - Down-Regulation MH - Female MH - Humans MH - Immunoglobulins/*analysis MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - *Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*chemistry/mortality/pathology/therapy EDAT- 2016/02/20 06:00 MHDA- 2016/12/15 06:00 CRDT- 2016/02/20 06:00 PHST- 2015/04/20 00:00 [received] PHST- 2015/07/09 00:00 [accepted] PHST- 2016/02/20 06:00 [entrez] PHST- 2016/02/20 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 000438492 [pii] AID - 10.1159/000438492 [doi] PST - ppublish SO - Urol Int. 2016;96(2):142-7. doi: 10.1159/000438492. Epub 2015 Aug 15. PMID- 26887985 OWN - NLM STAT- MEDLINE DCOM- 20161223 LR - 20250626 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Feb 18 TI - Prognostic role of urinary collecting system invasion in renal cell carcinoma: a systematic review and meta-analysis. PG - 21325 LID - 10.1038/srep21325 [doi] LID - 21325 AB - The relationship between urinary collecting system invasion (UCSI) and oncological outcomes in renal cell carcinoma (RCC) patients has attracted extensive attention recent years. However, the reports were inconsistent and remain controversial. Thus, we performed a systematic literature search of PubMed, Embase, Web of Science and The Cochrane Library databases to identify relevant studies up to June 2015 and conducted a standard meta-analysis of survival outcomes. 17 studies containing 9012 RCC patients satisfied the inclusion criteria. Pooled HRs for overall survival (OS) and recurrence-free survival (RFS) were 1.45 (95%CI, 1.26-1.66, P < 0.001) and 2.27 (95% CI, 1.54-3.34, P < 0.001), respectively. Further subgroup analysis suggested that UCSI was significant associated with poor cancer-specific survival (CSS) in stage T1-T2 RCC (HR = 2.05, 95%CI: 1.43-2.96, P < 0.001) but not in stage T3-T4 tumors (HR = 1.08, 95%CI: 0.63-1.85, P = 0.771). Current evidence revealed that UCSI has a significant negative impact on OS and RFS in RCC patients and could be used to predict CSS especially in localized RCC. Thus, RCC patients with UCSI should be paid more attention by clinician and pathologist and require close follow up for their poor prognosis. FAU - Chen, Luyao AU - Chen L AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Li, Hongzhao AU - Li H AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Gu, Liangyou AU - Gu L AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Ma, Xin AU - Ma X AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Li, Xintao AU - Li X AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Zhang, Fan AU - Zhang F AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Gao, Yu AU - Gao Y AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Fan, Yang AU - Fan Y AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Zhang, Yu AU - Zhang Y AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. FAU - Xie, Yongpeng AU - Xie Y AD - Medical School, Nankai University, Tianjin, People's Republic of China. FAU - Zhang, Xu AU - Zhang X AD - State Key Laboratory of Kidney Diseases, Department of Urology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20160218 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Carcinoma, Renal Cell/*mortality/pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Kidney Neoplasms/*mortality/pathology MH - Male MH - Neoplasm Invasiveness MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/*secondary PMC - PMC4758053 EDAT- 2016/02/19 06:00 MHDA- 2016/12/24 06:00 PMCR- 2016/02/18 CRDT- 2016/02/19 06:00 PHST- 2015/10/14 00:00 [received] PHST- 2016/01/21 00:00 [accepted] PHST- 2016/02/19 06:00 [entrez] PHST- 2016/02/19 06:00 [pubmed] PHST- 2016/12/24 06:00 [medline] PHST- 2016/02/18 00:00 [pmc-release] AID - srep21325 [pii] AID - 10.1038/srep21325 [doi] PST - epublish SO - Sci Rep. 2016 Feb 18;6:21325. doi: 10.1038/srep21325. PMID- 26885620 OWN - NLM STAT- MEDLINE DCOM- 20171215 LR - 20231105 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 12 DP - 2016 Mar 22 TI - Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. PG - 14153-60 LID - 10.18632/oncotarget.7358 [doi] AB - Our recent retrospective study revealed a significantly reduced risk of bladder cancer (BC) recurrence in men who received androgen deprivation therapy (ADT) for their prostate cancer. However, whether androgen receptor (AR) signals contributed to the preventive effect of ADT remained unclear because ADT could reduce serum estrogens as well. The purpose of this study is to investigate the associations between the expression of AR/estrogen receptors (ERs) and BC recurrence in patients treated with ADT. We immunohistochemically stained 72 BCs and 42 corresponding normal urothelial tissues. AR/ERalpha/ERbeta were positive in 44(61%)/22(31%)/39(54%) tumors and 35(83%)/24(57%)/34(81%) corresponding normal urothelial tissues, respectively. There were no statistically significant correlations between AR/ERalpha/ERbeta expression and clinicopathological features of BC. With a median follow-up of 31.3 months, 12 (43%) of 28 patients with AR-negative tumor versus 11 (23%) of 44 patients with AR-positive tumor experienced BC recurrence. Thus, patients with AR-positive tumor had a significantly lower risk of BC recurrence (P=0.031), compared with those with AR-negative tumor. Meanwhile, the expression of ERalpha/ERbeta in tumors and that of AR/ERalpha/ERbeta in normal urothelial tissues were not significantly correlated with BC recurrence. A multivariate analysis revealed AR positivity in tumors as an independent prognosticator (hazard ratio: 0.27; 95% confidence interval: 0.11-0.67) for BC recurrence. These results indicate that ADT prevents BC recurrence via the AR pathway, but not via the ERalpha/ERbeta pathways. FAU - Izumi, Koji AU - Izumi K AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. AD - Department of Urology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. FAU - Ito, Yusuke AU - Ito Y AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Miyamoto, Hiroshi AU - Miyamoto H AD - Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Miyoshi, Yasuhide AU - Miyoshi Y AD - Department of Urology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Ota, Junichi AU - Ota J AD - Department of Urology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. FAU - Moriyama, Masatoshi AU - Moriyama M AD - Department of Urology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. FAU - Murai, Tetsuo AU - Murai T AD - Department of Urology, International Goodwill Hospital, Yokohama, Japan. FAU - Hayashi, Hiroyuki AU - Hayashi H AD - Department of Pathology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. FAU - Inayama, Yoshiaki AU - Inayama Y AD - Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Ohashi, Kenichi AU - Ohashi K AD - Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Yao, Masahiro AU - Yao M AD - Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Uemura, Hiroji AU - Uemura H AD - Department of Urology, Yokohama City University Medical Center, Yokohama, Japan. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (AR protein, human) RN - 0 (Androgen Antagonists) RN - 0 (Biomarkers, Tumor) RN - 0 (ESR1 protein, human) RN - 0 (Estrogen Receptor alpha) RN - 0 (Receptors, Androgen) SB - IM MH - Aged MH - Aged, 80 and over MH - Androgen Antagonists/*therapeutic use MH - Biomarkers, Tumor/metabolism MH - Disease Progression MH - Estrogen Receptor alpha/metabolism MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/*metabolism/pathology MH - Prognosis MH - Receptors, Androgen/*metabolism MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/drug therapy/*metabolism/pathology MH - Urothelium/drug effects/*metabolism PMC - PMC4924704 OTO - NOTNLM OT - androgen deprivation therapy OT - androgen receptor OT - bladder cancer OT - recurrence COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to disclose. EDAT- 2016/02/18 06:00 MHDA- 2017/12/16 06:00 PMCR- 2016/03/22 CRDT- 2016/02/18 06:00 PHST- 2015/11/04 00:00 [received] PHST- 2016/01/29 00:00 [accepted] PHST- 2016/02/18 06:00 [entrez] PHST- 2016/02/18 06:00 [pubmed] PHST- 2017/12/16 06:00 [medline] PHST- 2016/03/22 00:00 [pmc-release] AID - 7358 [pii] AID - 10.18632/oncotarget.7358 [doi] PST - ppublish SO - Oncotarget. 2016 Mar 22;7(12):14153-60. doi: 10.18632/oncotarget.7358. PMID- 26874973 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20180502 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 4 DP - 2016 Aug TI - Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer. PG - e307-12 LID - S1558-7673(16)30002-7 [pii] LID - 10.1016/j.clgc.2016.01.002 [doi] AB - INTRODUCTION: Pathological staging of bladder cancer (BC) on trans-urethral bladder resection (TURB) specimens is critical for the indication of radical cystectomy (RC). MATERIALS AND METHODS: We aimed to assess the inter-observer variability among dedicated and not dedicated genito-urinary pathologists (GUP) and the predictive value of the amount of muscularis propria (MP) in the TURB specimens to predict accurate staging in RC. We selected 101 patients with at least 1 diagnosis of pT1 high grade BC who underwent RC during the history of disease. All the pathological TURB and RC specimens were reviewed by 3 GUPs, and concordance among them and with the original pathology report (OPR) was made. The presence and the extent of MP was measured in all the TURB specimens and correlated to stage at RC. RESULTS: Excellent (0.90 >/= K >/= 0.74) diagnostic concordance was reached among GUP while only good (0.77 >/= K >/= 0.67) with the OPR on stage and grade in TURBs. We found a general up-stage in the OPR compared with the GUP review. After histological review, 34.4% cases were downstaged to pT1 from pT2 and 10.1% from pT1 to pTa. The presence of MP was associated with a better discrimination of the stage at RC (P = .00065), and a trend towards correlation was found with its extent (area under the curve-receiver operator characteristic = 0.752; best cut-off 3.69 mm). CONCLUSION: The implementation of dedicated GUP can improve diagnostic sensitivity and specificity in BC diagnosis. The amount of MP and perhaps its extent in pT1 TURB speciments can predict more accurate cancer stage at RC. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Giunchi, Francesca AU - Giunchi F AD - Pathology Service, Addarii Institute of Oncology, Bologna, Italy. FAU - Panzacchi, Riccardo AU - Panzacchi R AD - Pathology Service, Addarii Institute of Oncology, Bologna, Italy. FAU - Capizzi, Elisa AU - Capizzi E AD - Pathology Service, Addarii Institute of Oncology, Bologna, Italy. FAU - Schiavina, Riccardo AU - Schiavina R AD - Department of Urology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Bologna, Italy. FAU - Brunocilla, Eugenio AU - Brunocilla E AD - Department of Urology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Bologna, Italy. FAU - Martorana, Giuseppe AU - Martorana G AD - Department of Urology, S.Orsola-Malpighi Teaching Hospital, University of Bologna, Bologna, Italy. FAU - D'Errico, Antonietta AU - D'Errico A AD - Pathology Service, Addarii Institute of Oncology, Bologna, Italy. FAU - Fiorentino, Michelangelo AU - Fiorentino M AD - Pathology Service, Addarii Institute of Oncology, Bologna, Italy. Electronic address: michelangelo.fiorentino@aosp.bo.it. LA - eng PT - Journal Article DEP - 20160122 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/*pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Observer Variation MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - Inter-observer variability OT - Muscolaris propria OT - Radical cystectomy OT - Urothelial cancer OT - pT1 G3 EDAT- 2016/02/15 06:00 MHDA- 2017/10/17 06:00 CRDT- 2016/02/15 06:00 PHST- 2015/08/14 00:00 [received] PHST- 2016/01/05 00:00 [revised] PHST- 2016/01/16 00:00 [accepted] PHST- 2016/02/15 06:00 [entrez] PHST- 2016/02/15 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] AID - S1558-7673(16)30002-7 [pii] AID - 10.1016/j.clgc.2016.01.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Aug;14(4):e307-12. doi: 10.1016/j.clgc.2016.01.002. Epub 2016 Jan 22. PMID- 26870291 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240324 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 11 IP - 1 DP - 2016 Jan TI - Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients. PG - 823-830 AB - A non-invasive marker is required for the diagnosis and follow-up of patients with bladder cancer. The aim of the current study was to evaluate the potential prognostic significance of serum osteoprotegerin (OPG), p53 protein and urine telomerase in patients with bladder cancer. For all patients, serum levels of OPG and p53 protein were determined using enzyme-linked immunosorbent assay (ELISA), and urine telomerase was assessed using a polymerase chain reaction ELISA technique. Patients were assigned into group 1 (cystectomy and adjuvant radiotherapy) or group 2 (transurethral resection and chemoradiotherapy). The results revealed that serum OPG and p53, and urine telomerase levels were significantly higher in bladder cancer patients compared with in healthy individuals (P<0.0001). High serum OPG was associated with significantly lower overall survival and disease-free survival rates (both P=0.001), and was correlated with advanced tumor stages (P<0.0001), high tumor grades (P<0.0001) and the occurrence of disease relapse (P=0.001). Serum p53 and urine telomerase did not demonstrate prognostic significance. These findings indicate that serum OPG level may be used as a diagnostic tool and a prognostic variable for patients with muscle invasive bladder cancer. Future trials are required to elucidate its therapeutic role in such patients. FAU - Bakry, Rania AU - Bakry R AD - Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut 71111, Egypt. FAU - El-Sayed, Mohamed I AU - El-Sayed MI AD - Department of Radiotherapy, South Egypt Cancer Institute, Assiut University, Assiut 71111, Egypt. FAU - Hamza, Hesham M AU - Hamza HM AD - Department of Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut 71111, Egypt. FAU - Hassan, Khaled H AU - Hassan KH AD - Department of Biochemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11566, Egypt. LA - eng PT - Journal Article DEP - 20151117 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC4727083 OTO - NOTNLM OT - biomarkers OT - bladder cancer OT - disease-free survival rate OT - overall survival rate EDAT- 2016/02/13 06:00 MHDA- 2016/02/13 06:01 PMCR- 2015/11/17 CRDT- 2016/02/13 06:00 PHST- 2014/10/28 00:00 [received] PHST- 2015/08/27 00:00 [accepted] PHST- 2016/02/13 06:00 [entrez] PHST- 2016/02/13 06:00 [pubmed] PHST- 2016/02/13 06:01 [medline] PHST- 2015/11/17 00:00 [pmc-release] AID - OL-0-0-3925 [pii] AID - 10.3892/ol.2015.3925 [doi] PST - ppublish SO - Oncol Lett. 2016 Jan;11(1):823-830. doi: 10.3892/ol.2015.3925. Epub 2015 Nov 17. PMID- 26869805 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160212 LR - 20200930 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 9 DP - 2016 TI - Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. PG - 605-11 LID - 10.2147/OTT.S99866 [doi] AB - OBJECTIVE: The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for T1G3 bladder cancer after TURBT surgery. METHODS: We retrospectively reviewed the cases of 457 patients who were newly diagnosed with T1G3 bladder urothelial carcinoma between January 2009 and March 2014. After TURBT, 281 patients received intravesical chemotherapy alone, whereas 176 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. Tumor recurrence and progression were monitored periodically by urine cytology and cystoscopy in follow-up. Recurrence-free survival and progression-free survival of the two chemotherapy strategies following TURBT were analyzed. Univariable and multivariable Cox hazards analyses were performed to predict the prognostic factors for tumor recurrence and progression. RESULTS: The tumor recurrence rate was 36.7% for patients who received intravesical chemotherapy alone after TURBT, compared with 19.9% for patients who received intravenous chemotherapy combined with intravesical chemotherapy after TURBT (P<0.001). The progression rate was 10.6% for patients who underwent intravesical chemotherapy alone and 2.3% for patients who underwent the combined chemotherapies (P=0.003). Kaplan-Meier curves showed significant differences in recurrence-free survival and progression-free survival between the two treatment strategies, with a log-rank P-value of <0.001 and 0.003, respectively. Multivariable analyses revealed that intravenous chemotherapy was the independent prognostic factor for tumor recurrence and progression in the cohort. CONCLUSION: Intravenous chemotherapy combined with intravesical chemotherapy offers a better oncologic outcome than the intravesical chemotherapy alone for patients with T1G3 bladder urothelial carcinoma after TURBT, and it may be considered as a new therapy strategy for T1G3 bladder cancer. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Xie, Linguo AU - Xie L AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Xie, Wanqin AU - Xie W AD - Key Laboratory of Genetics and Birth Health of Hunan Province, The Family Planning Research Institute of Hunan Province, Changsha, People's Republic of China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Xu, Hao AU - Xu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Xing, Chen AU - Xing C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Sha, Nan AU - Sha N AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Shen, Zhonghua AU - Shen Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Qie, Yunkai AU - Qie Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Liu, Xiaoteng AU - Liu X AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Wu, Changli AU - Wu C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, People's Republic of China. LA - eng PT - Journal Article DEP - 20160128 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC4734785 OTO - NOTNLM OT - bladder OT - intravenous chemotherapy OT - progression OT - recurrence EDAT- 2016/02/13 06:00 MHDA- 2016/02/13 06:01 PMCR- 2016/01/28 CRDT- 2016/02/13 06:00 PHST- 2016/02/13 06:00 [entrez] PHST- 2016/02/13 06:00 [pubmed] PHST- 2016/02/13 06:01 [medline] PHST- 2016/01/28 00:00 [pmc-release] AID - ott-9-605 [pii] AID - 10.2147/OTT.S99866 [doi] PST - epublish SO - Onco Targets Ther. 2016 Jan 28;9:605-11. doi: 10.2147/OTT.S99866. eCollection 2016. PMID- 26869491 OWN - NLM STAT- MEDLINE DCOM- 20161226 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Feb 12 TI - Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. PG - 20894 LID - 10.1038/srep20894 [doi] LID - 20894 AB - RNF2 (ring finger protein 2) is frequently overexpressed in several types of human cancer, but the status of RNF2 amplification and expression in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance is unclear. In this study, immunohistochemical analysis and fluorescence in situ hybridization (FISH) were used to examine the expression and amplification of RNF2 in 184 UCB patients after radical cystectomy. Overexpression of RNF2 was observed in 44.0% of UCBs and was found to significantly associate with shortened overall and cancer-specific survival (P < 0.001). In different subsets of UCBs, RNF2 overexpression was also identified as a prognostic indicator in patients with pT1, pT2, pN(-), and/or negative surgical margins (P < 0.05). Importantly, RNF2 overexpression together with pT status and surgical margin status provided significant independent prognostic parameters in multivariate analysis (P < 0.01). FISH results showed amplification of RNF2 in 8/79 (10.1%) of informative UCB cases. Additionally, RNF2 overexpression was significantly associated with RNF2 gene amplification (P = 0.004) and cell proliferation (P = 0.003). These findings suggested that overexpression of RNF2, as examined by immunohistochemical analysis, might serve as a novel prognostic biomarker and potential therapeutic target for UCB patients who undergo radical cystectomy. FAU - Li, Xiang-Dong AU - Li XD AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Chen, Si-Liang AU - Chen SL AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Dong, Pei AU - Dong P AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Chen, Jie-Wei AU - Chen JW AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Wang, Feng-Wei AU - Wang FW AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Guo, Sheng-Jie AU - Guo SJ AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Jiang, Li-Juan AU - Jiang LJ AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Zhou, Fang-Jian AU - Zhou FJ AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Xie, Dan AU - Xie D AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Liu, Zhuo-Wei AU - Liu ZW AD - State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160212 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Ki-67 Antigen) RN - EC 2.3.2.27 (Polycomb Repressive Complex 1) RN - EC 2.3.2.27 (RNF2 protein, human) SB - IM MH - Cell Proliferation MH - Cohort Studies MH - *Cystectomy MH - Female MH - Gene Amplification MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Ki-67 Antigen/metabolism MH - Male MH - Middle Aged MH - Polycomb Repressive Complex 1/genetics/*metabolism MH - Prognosis MH - Proportional Hazards Models MH - Regression Analysis MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/genetics/*metabolism/*surgery MH - Urothelium/*metabolism/pathology/*surgery PMC - PMC4751429 EDAT- 2016/02/13 06:00 MHDA- 2016/12/27 06:00 PMCR- 2016/02/12 CRDT- 2016/02/13 06:00 PHST- 2015/10/23 00:00 [received] PHST- 2016/01/11 00:00 [accepted] PHST- 2016/02/13 06:00 [entrez] PHST- 2016/02/13 06:00 [pubmed] PHST- 2016/12/27 06:00 [medline] PHST- 2016/02/12 00:00 [pmc-release] AID - srep20894 [pii] AID - 10.1038/srep20894 [doi] PST - epublish SO - Sci Rep. 2016 Feb 12;6:20894. doi: 10.1038/srep20894. PMID- 26863611 OWN - NLM STAT- MEDLINE DCOM- 20170410 LR - 20260127 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 97 IP - 1 DP - 2016 TI - Survival after Radical Cystectomy for Bladder Cancer in Relation to Prior Non-Muscle Invasive Disease in Quebec. PG - 49-53 LID - 10.1159/000444093 [doi] AB - INTRODUCTION AND OBJECTIVES: The aim of this study was to assess if there is a difference in survival after radical cystectomy (RC) when examined in relation to prior non-muscle invasive bladder cancer (NMIBC) disease vs. invasive cancer de novo at time of diagnosis. METHODS: We conducted a retrospective study of all patients who underwent RC within Quebec health insurance medical services database during the years (2000-2009). Overall survival (OS) outcome was assessed with Kaplan-Meier curves and hazard ratios (HRs) adjusted for age and gender. RESULTS: A total of 2,671 subjects met the eligibility criteria. Among them, 19.8% had presumed prior NMIBC that further progressed to invasive disease. Median survival after RC for patients with presumed prior NMIBC was 4.3 years as compared to patients with presumed invasive disease de novo 3.7 years (p = 0.007, Wilcoxon test). Patients with presumed NMIBC at the time of diagnosis had a 16% decrease in the risk of mortality after RC, when compared to patients with presumed invasive BC de novo (HR 0.84, 95% CI 0.73-0.96 (p = 0.0166)). CONCLUSION: Our results suggest a slightly better prognosis, regarding OS after RC for patients with presumed NMIBC who progressed to invasive disease, when compared to patients with presumed invasive disease de novo at the time of diagnosis. CI - (c) 2016 S. Karger AG, Basel. FAU - Zakaria, Ahmed S AU - Zakaria AS AD - Department of Surgery, Division of Urology, McGill University, Montreal, Que., Canada. FAU - Santos, Fabiano AU - Santos F FAU - Kassouf, Wassim AU - Kassouf W FAU - Tanguay, Simon AU - Tanguay S FAU - Aprikian, Armen AU - Aprikian A LA - eng PT - Journal Article DEP - 20160211 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Aged MH - *Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasms, Second Primary/*mortality/pathology/*surgery MH - Quebec MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery EDAT- 2016/02/11 06:00 MHDA- 2017/04/11 06:00 CRDT- 2016/02/11 06:00 PHST- 2015/09/07 00:00 [received] PHST- 2016/01/17 00:00 [accepted] PHST- 2016/02/11 06:00 [entrez] PHST- 2016/02/11 06:00 [pubmed] PHST- 2017/04/11 06:00 [medline] AID - 000444093 [pii] AID - 10.1159/000444093 [doi] PST - ppublish SO - Urol Int. 2016;97(1):49-53. doi: 10.1159/000444093. Epub 2016 Feb 11. PMID- 26851042 OWN - NLM STAT- MEDLINE DCOM- 20160712 LR - 20160206 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 36 IP - 2 DP - 2016 Feb TI - Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer. PG - 799-802 AB - AIM: To examine the clinical significance of preoperative urine cytology in patients with low-grade bladder cancer. PATIENTS AND METHODS: We retrospectively investigated the records of 155 patients diagnosed with primary low-grade (Ta) urothelial carcinoma of the bladder between January 2000 and September 2014. RESULTS: Patients with class III or greater cytology had significantly higher-grade (G2) (p=0.01), larger tumors (>/=15 mm, p=0.0009) and significantly shorter recurrence-free survival compared to patients with class II or lower cytology (p<0.0001). However, Cox proportional hazards analysis for recurrence-free survival only identified tumor size (>/=15 mm) (hazard ratio=5.97, 95% confidence interval=2.39-17.29; p<0.0001) as a predictor of poor prognosis, although patients with class III or higher preoperative cytology showed a tendency towards frequent intravesical recurrence (hazard ratio=1.98, 95% confidence interval=0.96-4.2; p=0.063). CONCLUSION: Preoperative urine cytology, in addition to tumor size, might be a useful predictor of intravesical recurrence of bladder cancer. CI - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Kiyoshima, Keijiro AU - Kiyoshima K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Akitake, Masakazu AU - Akitake M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takahashi, Ryosuke AU - Takahashi R AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tatsugami, Katsunori AU - Tatsugami K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan yokoa@uro.med.kyushu-u.ac.jp. FAU - Eto, Masatoshi AU - Eto M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Aged MH - Carcinoma/*pathology/surgery/*urine MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Tumor Burden MH - Urinalysis MH - Urinary Bladder Neoplasms/*pathology/surgery/*urine MH - Urine/*cytology MH - Urothelium/*pathology OTO - NOTNLM OT - Urine cytology OT - bladder cancer OT - low-grade urothelial carcinoma EDAT- 2016/02/07 06:00 MHDA- 2016/07/13 06:00 CRDT- 2016/02/07 06:00 PHST- 2016/02/07 06:00 [entrez] PHST- 2016/02/07 06:00 [pubmed] PHST- 2016/07/13 06:00 [medline] AID - 36/2/799 [pii] PST - ppublish SO - Anticancer Res. 2016 Feb;36(2):799-802. PMID- 26851002 OWN - NLM STAT- MEDLINE DCOM- 20160621 LR - 20191210 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 36 IP - 2 DP - 2016 Feb TI - Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. PG - 495-501 AB - BACKGROUND/AIM: Platinum (Pt)-based neoadjuvant chemotherapy (NAC) is the standard-of-care for muscle-invasive bladder cancer (MIBC). However, the survival benefit with NAC is driven by patients with pathological response at cystectomy. Non-responders are subject to adverse effects of Pt, with delay in definitive treatment. Copper transporter receptor 1 (CTR1) plays an important role in Pt uptake and the level of expression may influence Pt sensitivity. We hypothesized that tumor CTR1 expression correlated with pathological outcome. PATIENTS AND METHODS: We identified matched paraffin-embedded tissues from pre-NAC transurethral bladder tumor resection (TURBT) and post-NAC radical cystectomy (RC) specimens in 47 patients with MIBC who received Pt-based NAC. Tumor and adjacent normal tissues were stained with CTR1 antibody. CTR1 expression was determined through immunohistochemistry by two pathologists blinded to the outcome (0=undetectable; 1+=barely detectable; 2+=moderate; and 3+=intense staining). Pathological response was defined as either down-staging to non-MIBC (pT2 (p = 0.0014) and grade >/=G3 (p = 0.0041), respectively. IHC expression patterns did not show correlation to survival data. PTOV1 RNA expression correlated with features of the luminal UC subtype. CONCLUSIONS: Subcellular distribution seems to be the most important feature of PTOV1 expression in UC. Nuclear localization of PTOV1 along with cytoplasmic decrease in PTOV1 expression was identified as putative surrogate for PTOV1-associated cellular proliferation and dedifferentiation in UC. The functional relevance as well as the potential role of PTOV1 as a biomarker in UC remains to be specified in future studies. FAU - Rausch, Steffen AU - Rausch S AD - Department of Urology, University Hospital, Tubingen, Germany. steffen.rausch@med.uni-tuebingen.de. AD - Department of Urology, Eberhard-Karls-University Tubingen, Hoppe-Seyler-Str. 4-6, 72076, Tubingen, Germany. steffen.rausch@med.uni-tuebingen.de. FAU - Hennenlotter, Jorg AU - Hennenlotter J AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Scharpf, Marcus AU - Scharpf M AD - Department of Pathology, University Hospital, Tubingen, Germany. FAU - Teepe, Katharina AU - Teepe K AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Kuhs, Ursula AU - Kuhs U AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Aufderklamm, Stefan AU - Aufderklamm S AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Bier, Simone AU - Bier S AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Mischinger, Johannes AU - Mischinger J AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Schwentner, Christian AU - Schwentner C AD - Department of Urology, University Hospital, Tubingen, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Department of Urology, University Hospital, Tubingen, Germany. AD - Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160108 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) RN - 0 (PTOV1 protein, human) RN - 0 (Adaptor Proteins, Signal Transducing) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/*metabolism MH - Carcinoma in Situ/genetics/*metabolism/pathology MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - High-Throughput Nucleotide Sequencing MH - Humans MH - Immunoenzyme Techniques MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Proteins/genetics/*metabolism MH - Neoplasm Staging MH - Prognosis MH - Prostatic Neoplasms/genetics/*metabolism/pathology MH - Survival Rate MH - Urologic Neoplasms/genetics/*metabolism/pathology MH - Urothelium/*metabolism/pathology MH - Adaptor Proteins, Signal Transducing PMC - PMC11819414 OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Immunohistochemistry OT - PTOV1 OT - Proliferation COIS- Steffen Rausch, Jorg Hennenlotter, Marcus Scharpf, Katharina Teepe, Ursula Kuhs, Stefan Aufderklamm, Simone Bier, Johannes Mischinger, Georgios Gakis, Arnulf Stenzl, Christian Schwentner, and Tilman Todenhofer declare that they have no conflict of interest. EDAT- 2016/01/10 06:00 MHDA- 2016/08/31 06:00 PMCR- 2016/01/08 CRDT- 2016/01/10 06:00 PHST- 2015/10/22 00:00 [received] PHST- 2015/12/28 00:00 [accepted] PHST- 2016/01/10 06:00 [entrez] PHST- 2016/01/10 06:00 [pubmed] PHST- 2016/08/31 06:00 [medline] PHST- 2016/01/08 00:00 [pmc-release] AID - 10.1007/s00432-015-2107-y [pii] AID - 2107 [pii] AID - 10.1007/s00432-015-2107-y [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2016 May;142(5):937-47. doi: 10.1007/s00432-015-2107-y. Epub 2016 Jan 8. PMID- 26742964 OWN - NLM STAT- MEDLINE DCOM- 20160525 LR - 20260127 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 41 IP - 6 DP - 2015 Nov-Dec TI - Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer. PG - 1080-7 LID - 10.1590/S1677-5538.IBJU.2014.0628 [doi] AB - OBJECTIVE: We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression. MATERIALS AND METHODS: Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2) and 40 healthy control group (Group 1) were included the study. Blood and urinary samples were collected from all patients and HER2/neu levels were measured by ELISA method. Blood and urinary HER2/neu levels and additionally, ratio of urinary HER2/neu levels to urinary creatinine levels were recorded. Demographic data and tumor characteristics were recorded. RESULTS: Mean serum HER2/neu levels were similar between two groups and statistically significant difference wasn't observed. Urinary HER2/neu levels were significantly higher in group 2 than group 1. Ratio of urinary HER2/neu to urinary creatinine was significantly higher in group 2 than group 1, (p=0,021). Serum and urinary HER2/ neu levels were not associated with tumor stage, grade, recurrence and progression while ratio of urinary HER2/neu to urinary creatinin levels were significantly higher in high-grade tumors. HER2/neu, the sensitivity of the test was found to be 20.5%, and the specificity was 97.5%, also for the urinary HER2/neu/urinary creatinine ratio, the sensitivity and specificity of the test were found to be 31.8% and 87.5%, respectively. CONCLUSIONS: Urinary HER2/neu and ratio of urinary creatinine urine were significantly higher in patients with bladder cancer compared to healthy subjects. Large series and controlled studies are needed for use as a tumor marker. FAU - Arikan, Ozgur AU - Arikan O AD - Department of Urology, Nigde Bor State Hospital, Bor Nigde, Istanbul, Turkey. FAU - Yyldyrym, Asyf AU - Yyldyrym A AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Ysbilen, Banu AU - Ysbilen B AD - Department of Biochemistry, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Canakci, Cengiz AU - Canakci C AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Atys, Gokhan AU - Atys G AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Gurbuz, Cenk AU - Gurbuz C AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Erol, Bulent AU - Erol B AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Ysman, Ferruh Kemal AU - Ysman FK AD - Department of Biochemistry, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Ozkanli, Seyma AU - Ozkanli S AD - Department of Pathology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. FAU - Caskurlu, Turhan AU - Caskurlu T AD - Department of Urology, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 RN - 0 (Biomarkers, Tumor) RN - AYI8EX34EU (Creatinine) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor MH - Body Mass Index MH - Carcinoma, Transitional Cell/*pathology MH - Case-Control Studies MH - Creatinine/urine MH - Disease Progression MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/pathology MH - Neoplasm Staging MH - Erb-b2 Receptor Tyrosine Kinases/*blood/*urine MH - Sensitivity and Specificity MH - Tumor Burden MH - Urinary Bladder Neoplasms/*pathology PMC - PMC4756932 COIS- CONFLICT OF INTEREST None declared. EDAT- 2016/01/09 06:00 MHDA- 2016/05/26 06:00 PMCR- 2015/11/01 CRDT- 2016/01/09 06:00 PHST- 2014/12/04 00:00 [received] PHST- 2015/06/09 00:00 [accepted] PHST- 2016/01/09 06:00 [entrez] PHST- 2016/01/09 06:00 [pubmed] PHST- 2016/05/26 06:00 [medline] PHST- 2015/11/01 00:00 [pmc-release] AID - IBJUv41n6a8 [pii] AID - S1677-5538.IBJU.2014.0628 [pii] AID - 10.1590/S1677-5538.IBJU.2014.0628 [doi] PST - ppublish SO - Int Braz J Urol. 2015 Nov-Dec;41(6):1080-7. doi: 10.1590/S1677-5538.IBJU.2014.0628. PMID- 26729098 OWN - NLM STAT- MEDLINE DCOM- 20161025 LR - 20181113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 17 IP - 1 DP - 2015 Dec 29 TI - Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives. LID - 10.3390/ijms17010043 [doi] LID - 43 AB - Bladder cancer (BC), the most common cancer arising from the human urinary tract, consists of two major clinicopathological phenotypes: muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). MIBC frequently metastasizes and is associated with an unfavorable prognosis. A certain proportion of patients with metastatic BC can achieve a remission with systemic chemotherapy; however, the disease relapses in most cases. Evidence suggests that MIBC comprises a small population of cancer stem cells (CSCs), which may be resistant to these treatments and may be able to form new tumors in the bladder or other organs. Therefore, the unambiguous identification of bladder CSCs and the development of targeted therapies are urgently needed. Nevertheless, it remains unclear where bladder CSCs originate and how they are generated. We review recent studies on bladder CSCs, specifically focusing on their proposed origin and the possible therapeutic options based on the CSC theory. FAU - Ohishi, Tomokazu AU - Ohishi T AD - Institute of Microbial Chemistry (BIKAKEN), Numazu, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan. ohishit@bikaken.or.jp. AD - Division of Molecular Biotherapy, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. ohishit@bikaken.or.jp. FAU - Koga, Fumitaka AU - Koga F AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan. f-koga@cick.jp. FAU - Migita, Toshiro AU - Migita T AD - Division of Molecular Biotherapy, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. toshiro.migita@jfcr.or.jp. AD - Department of Urology, Kashiwa Kousei General Hospital, 617 Shikoda, Kashiwa-shi, Chiba 277-8551, Japan. toshiro.migita@jfcr.or.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20151229 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplastic Stem Cells/*pathology MH - Urinary Bladder/*pathology MH - Urinary Bladder Neoplasms/*pathology/therapy PMC - PMC4730288 OTO - NOTNLM OT - bladder cancer OT - cancer stem cell EDAT- 2016/01/06 06:00 MHDA- 2016/10/26 06:00 PMCR- 2016/01/01 CRDT- 2016/01/06 06:00 PHST- 2015/11/06 00:00 [received] PHST- 2015/12/14 00:00 [revised] PHST- 2015/12/24 00:00 [accepted] PHST- 2016/01/06 06:00 [entrez] PHST- 2016/01/06 06:00 [pubmed] PHST- 2016/10/26 06:00 [medline] PHST- 2016/01/01 00:00 [pmc-release] AID - ijms17010043 [pii] AID - ijms-17-00043 [pii] AID - 10.3390/ijms17010043 [doi] PST - epublish SO - Int J Mol Sci. 2015 Dec 29;17(1):43. doi: 10.3390/ijms17010043. PMID- 39363914 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241006 IS - 2213-0896 (Print) IS - 2213-0896 (Electronic) IS - 2213-0896 (Linking) VI - 5 DP - 2016 TI - Predictors of recurrence and patterns of failure among patients treated with nephroureterectomy for upper tract urothelial carcinoma. PG - 39-45 LID - 10.1016/j.ctrc.2015.12.004 [doi] AB - PURPOSE: Recurrence rates following nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) remain high. As such, adjuvant therapy directed at high risk sites may improve long term outcomes. We describe patterns and predictors of UTUC recurrence according to patient, disease and treatment-related factors. METHODS AND MATERIALS: We reviewed the records of 113 patients treated with NU for UTUC at our institution between 2006 and 2013. Time to locoregional (LR), intravesical (IV), distant recurrence and death were described using the Kaplan-Meier method and compared using the log rank statistic. Cox Proportional Hazards analyses were performed to evaluate the adjusted hazard for LR/IV and LR recurrence. RESULTS: Advanced T stage (T3/4) was present in 41 (36%) patients, 10 (9%) were node-positive and 21 (19%) showed evidence of lymphovascular space invasion (LVSI). Median overall survival and time to any recurrence was 54.6 and 20.7 months, respectively. Disease recurrence was observed in 48 (42%) patients. The location of failure was intravesical in 27 (24%), locoregional in 22 (19%) and distant in 20 (18%). Three-year LR/IV and distant failure rates were 38.7% and 22.2%, respectively. Three-year LR failure was 4.6% in pTa-2 vs. 25.8% in T3-T4 disease. Multivariate analysis identified history of prior bladder disease as a significant predictor of LR/IV recurrence. CONCLUSIONS: In this study we demonstrate LR/IV recurrence as the predominant pattern of failure in UTUC patients treated with nephroureterectomy. This systematic description of recurrence patterns and associated factors will guide further investigation of adjuvant therapy to minimize the treatment failures defined herein. FAU - Hughes, Ryan T AU - Hughes RT AD - Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, United States. FAU - Lucas, John T AU - Lucas JT AD - Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, United States. FAU - Krane, Louis Spencer AU - Krane LS AD - Department of Surgical Sciences-Urology, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, United States. FAU - Divers, Jude L AU - Divers JL AD - Department of Anesthesiology, University of Massachusetts Memorial Medical Center, Worchester, MA 01655, United States. FAU - Hemal, Ashok K AU - Hemal AK AD - Department of Surgical Sciences-Urology, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, United States. FAU - Frizzell, Bart A AU - Frizzell BA AD - Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, United States. LA - eng GR - P30 CA012197/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20151221 PL - Netherlands TA - Cancer Treat Commun JT - Cancer treatment communications JID - 101641616 PMC - PMC11449456 MID - NIHMS1980472 OTO - NOTNLM OT - Locoregional control OT - Renal pelvis OT - Transitional cell carcinoma OT - Ureter OT - Urothelial carcinoma COIS- Conflicts of interest None. EDAT- 2016/01/01 00:00 MHDA- 2016/01/01 00:01 PMCR- 2024/10/03 CRDT- 2024/10/04 04:15 PHST- 2016/01/01 00:01 [medline] PHST- 2016/01/01 00:00 [pubmed] PHST- 2024/10/04 04:15 [entrez] PHST- 2024/10/03 00:00 [pmc-release] AID - 10.1016/j.ctrc.2015.12.004 [doi] PST - ppublish SO - Cancer Treat Commun. 2016;5:39-45. doi: 10.1016/j.ctrc.2015.12.004. Epub 2015 Dec 21. PMID- 37596737 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230819 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 3 IP - 1 DP - 2016 Jan TI - Patients with High Grade Bladder Cancer, and Tumor-Free 3 and 6-Month Cystoscopy after bacillus Calmette-Guerin have a Good Prognosis without Further Maintenance bacillus Calmette-Guerin. PG - 50-54 LID - 10.1016/j.urpr.2015.02.002 [doi] AB - INTRODUCTION: The benefit of 3 years of maintenance bacillus Calmette-Guerin has been questioned. The outcome is reported for bacillus Calmette-Guerin treated patients who had negative 3 and 6-month cystoscopy results and were subsequently not treated with maintenance bacillus Calmette-Guerin. METHODS: A retrospective, population based study of patients with high grade nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin was performed. Patients were included in analysis who had tumor-free cystoscopy findings 3 and 6 months after the start of treatment. No patient was treated with maintenance bacillus Calmette-Guerin after the 6-month cystoscopy. The Kaplan-Meier estimated 5-year survival rates were calculated. RESULTS: Three and 6-month cystoscopy revealed no tumor in 196 patients with a median age of 72 years. Of the patients 84% had carcinoma in situ or multiple and/or recurrent high grade tumors. Five-year recurrence-free, progression-free and disease specific survival was 69%, 95% and 98%, respectively. Median followup in 119 patients who were alive at the last contact was 79 months. Recurrence developed in 62 of 196 patients (32%), disease stage progressed to at least T2 in 13 (7%) and 7 (3%) died of bladder cancer. CONCLUSIONS: Patients without maintenance bacillus Calmette-Guerin after tumor-free 3 and 6-month cystoscopy have a low rate of progression and bladder cancer death. An alternative to 1 to 3 years of bacillus Calmette-Guerin maintenance may be no maintenance after the second tumor-free cystoscopy with re-treatment with bacillus Calmette-Guerin in case of recurrence. FAU - Holmang, Sten AU - Holmang S AD - Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden. LA - eng PT - Journal Article DEP - 20151013 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - BCG vaccine OT - carcinoma in situ OT - disease progression OT - mortality OT - urinary bladder neoplasms EDAT- 2016/01/01 00:00 MHDA- 2016/01/01 00:01 CRDT- 2023/08/19 01:01 PHST- 2016/01/01 00:01 [medline] PHST- 2016/01/01 00:00 [pubmed] PHST- 2023/08/19 01:01 [entrez] AID - 10.1016/j.urpr.2015.02.002 [doi] PST - ppublish SO - Urol Pract. 2016 Jan;3(1):50-54. doi: 10.1016/j.urpr.2015.02.002. Epub 2015 Oct 13. PMID- 26715266 OWN - NLM STAT- MEDLINE DCOM- 20170216 LR - 20260127 IS - 1423-0380 (Electronic) IS - 1010-4283 (Linking) VI - 37 IP - 6 DP - 2016 Jun TI - Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer. PG - 8075-82 LID - 10.1007/s13277-015-4698-y [doi] AB - MicroRNA (miRNA) expression profile analysis indicated that miR-205 was upregulated in bladder cancer tissue compared to healthy tissue. The aim of this study is to analyze value of circulating miR-205 for the detection and prognosis evaluation of bladder cancer (BC). Eighty-nine patients with BC and 56 healthy controls (HC) were enrolled in the study. miR-205 expression was determined using TaqMan quantitative real-time polymerase chain reaction assay and further correlated with patients' clinicopathological parameters and follow-up data. The results indicated that plasma miR-205 was upregulated in BC compared with HC (P < 0.001) and in muscle invasive BC (MIBC) compared to nonmuscle invasive BC (NMIBC) (P = 0.016). miR-205 yielded an area under the receiver-operating characteristic curve of 0.950 with 76.4 % sensitivity and 96.4 % specificity in discriminating BC from HC, and 0.668 with 57.1 % sensitivity and 77.0 % specificity in distinguishing MIBC from NMIBC. Plasma miR-205 expression was significantly associated with tumor stage (P < 0.001) and pathological grade (P = 0.048). The results indicated that BC patients with high miR-205 expression experienced shorter disease-free survival and disease-specific survival (P = 0.022 and P = 0.026; P = 0.027 and P = 0.034; respectively), which was not proven by multivariate Cox regression analysis (multi-Cox) (P = 0.0765 and P = 0.279, respectively). Log-rank test showed that NMIBC patients with high miR-205 expression experienced shorter cancer-free survival (P = 0.044). Log-rank test and univariate and multivariate Cox regression analyses did not indicate that high miR-205 expression in NMIBC patients was associated with cancer-specific survival (P = 0.079, P = 0.089, and P = 0.201, respectively). In conclusion, miR-205 may be a promising biomarker for the detection and prognosis evaluation of BC. FAU - Fang, Zhenqiang AU - Fang Z AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. FAU - Dai, Wei AU - Dai W AD - Chongqing Petroleum Hospital, Chongqing, 400037, China. FAU - Wang, Xiangwei AU - Wang X AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. FAU - Chen, Wei AU - Chen W AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. FAU - Shen, Chongxin AU - Shen C AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. FAU - Ye, Gang AU - Ye G AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. FAU - Li, Longkun AU - Li L AD - Department of Urology, Center of Nephrology, The Second Affiliated Hospital of the Third Military Medical University, Chongqing, 400037, China. lilongk@hotmail.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20151229 PL - United States TA - Tumour Biol JT - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine JID - 8409922 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (RNA, Messenger) RN - 0 (MIR205, human) SB - IM MH - Aged MH - Biomarkers, Tumor/*genetics MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - MicroRNAs/*genetics MH - Muscle Neoplasms/*genetics/*pathology MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - RNA, Messenger/genetics MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Survival Rate MH - Urinary Bladder Neoplasms/*genetics/*pathology OTO - NOTNLM OT - Biomarker OT - Bladder cancer OT - Humans OT - Survival analysis OT - miR-205 EDAT- 2015/12/31 06:00 MHDA- 2017/02/17 06:00 CRDT- 2015/12/31 06:00 PHST- 2014/06/08 00:00 [received] PHST- 2014/07/08 00:00 [accepted] PHST- 2015/12/31 06:00 [entrez] PHST- 2015/12/31 06:00 [pubmed] PHST- 2017/02/17 06:00 [medline] AID - 10.1007/s13277-015-4698-y [pii] AID - 10.1007/s13277-015-4698-y [doi] PST - ppublish SO - Tumour Biol. 2016 Jun;37(6):8075-82. doi: 10.1007/s13277-015-4698-y. Epub 2015 Dec 29. PMID- 26714143 OWN - NLM STAT- MEDLINE DCOM- 20171004 LR - 20171004 IS - 1365-2354 (Electronic) IS - 0961-5423 (Linking) VI - 26 IP - 2 DP - 2017 Mar TI - The role of endoscopic bladder tumour assessment in the management of patients subjected to transurethral bladder tumour resection. LID - 10.1111/ecc.12431 [doi] AB - Despite complete resection, non-muscle invasive bladder cancers tend to recur. Therefore, their risk stratification was implemented to select adjuvant therapy. Immediate intravesical chemotherapeutic instillations were shown to decrease the risk of recurrence in those with low-risk disease. The purpose of the study was to determine the role of endoscopic assessment in the management of patients subjected to transurethral resection of the bladder tumour (TURBT). In 262 patients submitted to TURBT due to primary bladder tumour, the size and the number of the lesion(s) were noted and the stage as well as the grade of the tumour(s) were typed. The individual features were then scored according to the European Organisation of Research and Treatment of Cancer 'Bladder Calculator' and the lesions were classified into the low, intermediate and high risk of recurrence group. Clinical evaluation was then compared with pathological report and final triage. Based on the clinical data, 95 (36.25%), 105 (40.07%) and 3 (1.14%) patients were endoscopically assigned to the groups of low, intermediate and high risk of recurrence respectively. After pathological report, correct risk stratification was confirmed in 86 (90.5%), 95 (90.5%) and 3 (100%) patients respectively. Endoscopic assessment of bladder cancers allows to accurately establish the risk of recurrence and may facilitate implementation of adjuvant therapy before histological evaluation. CI - (c) 2015 John Wiley & Sons Ltd. FAU - Skrzypczyk, M A AU - Skrzypczyk MA AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Nyk, L AU - Nyk L AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, European Health Centre in Otwock, Otwock, Poland. FAU - Szostek, P AU - Szostek P AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, European Health Centre in Otwock, Otwock, Poland. FAU - Szemplinski, S AU - Szemplinski S AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. FAU - Borowka, A AU - Borowka A AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, European Health Centre in Otwock, Otwock, Poland. FAU - Dobruch, J AU - Dobruch J AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. AD - Clinical Department of Urology, Centre of Postgraduate Medical Education, European Health Centre in Otwock, Otwock, Poland. LA - eng PT - Journal Article DEP - 20151229 PL - China TA - Eur J Cancer Care (Engl) JT - European journal of cancer care JID - 9301979 MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystoscopy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasms, Multiple Primary/pathology/*surgery MH - Risk Assessment MH - Tumor Burden MH - Urinary Bladder Neoplasms/pathology/*surgery OTO - NOTNLM OT - bladder cancer OT - risk stratification OT - transurethral resection EDAT- 2015/12/30 06:00 MHDA- 2017/10/05 06:00 CRDT- 2015/12/30 06:00 PHST- 2015/11/18 00:00 [accepted] PHST- 2015/12/30 06:00 [pubmed] PHST- 2017/10/05 06:00 [medline] PHST- 2015/12/30 06:00 [entrez] AID - 10.1111/ecc.12431 [doi] PST - ppublish SO - Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12431. Epub 2015 Dec 29. PMID- 26700664 OWN - NLM STAT- MEDLINE DCOM- 20170216 LR - 20261011 IS - 1423-0380 (Electronic) IS - 1010-4283 (Linking) VI - 37 IP - 6 DP - 2016 Jun TI - Akt activation correlates with the tumor aggressiveness in Tunisian patients with bladder cancer. PG - 7873-9 LID - 10.1007/s13277-015-4678-2 [doi] AB - Various studies in western countries found Akt amplification to be a frequent event in human cancers, including bladder, but the correlation with clinicopathological features is controversial. Such studies have not been reported in African populations, including Tunisians. The purpose of this study was to assess expression of the phosphorylated/activated forms of Akt in tumors from Tunisian patients with bladder cancer and to correlate its expression with pathological and clinical parameters of the disease. The study included 72 patients of whom 34 were diagnosed as low- to medium-grade and 35 as high-grade; 30 were muscle stage and 39 non-muscle stage. Primary tumors from these patients, normal adjacent tissues, or bladder cancer cell-lines were analyzed for Ser473 phosphorylated Akt expression by Western blot. Seventy-two percent of primary tumors from patients with bladder cancer had increased levels of p-Akt. The p-Akt levels in patients with high-grade bladder cancer were significantly elevated compared to patients with low- or medium-grade bladder cancer. In invasive carcinoma, the p-Akt level was significantly higher than in superficial non-invasive bladder tumors. Concerning the influence of tobacco on Akt activation, no significant differences of p-Akt expression were found between non-smoker and smoker patients. Altogether, our results suggest that Akt activation can provide useful prognostic information and that tobacco represents a serious risk factor for recurrence in a cohort of Tunisian patients. FAU - Ben Bahria-Sediki, Islem AU - Ben Bahria-Sediki I AD - EPHE, Laboratoire d'Immunologie et Immunotherapie des Cancers, Paris, F-75014, France. AD - EA 7269, Universite de Bourgogne, Dijon, F-21079, Dijon, France. AD - Laboratoire de Genetique, Immunologie et Pathologies Humaines, Faculte de Sciences Tunis, Universite de Tunis El Manar, Tunis, Tunisia. FAU - Sampaio, Carla AU - Sampaio C AD - EPHE, Laboratoire d'Immunologie et Immunotherapie des Cancers, Paris, F-75014, France. AD - EA 7269, Universite de Bourgogne, Dijon, F-21079, Dijon, France. FAU - Chebil, Mohamed AU - Chebil M AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Cherif, Mohamed AU - Cherif M AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Zermani, Rachida AU - Zermani R AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Rammeh, Soumaya AU - Rammeh S AD - Hopital Charles Nicolle de Tunis, Tunis, Tunisia. FAU - Ben Ammar El Gaaied, Amel AU - Ben Ammar El Gaaied A AD - Laboratoire de Genetique, Immunologie et Pathologies Humaines, Faculte de Sciences Tunis, Universite de Tunis El Manar, Tunis, Tunisia. amel.benammarelgaaied@gmail.com. FAU - Bettaieb, Ali AU - Bettaieb A AD - EPHE, Laboratoire d'Immunologie et Immunotherapie des Cancers, Paris, F-75014, France. ali.bettaieb@u-bourgogne.fr. AD - EA 7269, Universite de Bourgogne, Dijon, F-21079, Dijon, France. ali.bettaieb@u-bourgogne.fr. LA - eng PT - Journal Article DEP - 20151223 PL - United States TA - Tumour Biol JT - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine JID - 8409922 RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Black People/ethnology MH - Blotting, Western MH - Cell Line, Tumor MH - Cell Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Phosphorylation MH - Prognosis MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Tunisia/epidemiology MH - Urinary Bladder Neoplasms/ethnology/*metabolism/pathology OTO - NOTNLM OT - Akt OT - Bladder carcinoma OT - Prognosis OT - Tobacco EDAT- 2015/12/25 06:00 MHDA- 2017/02/17 06:00 CRDT- 2015/12/25 06:00 PHST- 2015/11/04 00:00 [received] PHST- 2015/12/16 00:00 [accepted] PHST- 2015/12/25 06:00 [entrez] PHST- 2015/12/25 06:00 [pubmed] PHST- 2017/02/17 06:00 [medline] AID - 10.1007/s13277-015-4678-2 [pii] AID - 10.1007/s13277-015-4678-2 [doi] PST - ppublish SO - Tumour Biol. 2016 Jun;37(6):7873-9. doi: 10.1007/s13277-015-4678-2. Epub 2015 Dec 23. PMID- 26681820 OWN - NLM STAT- MEDLINE DCOM- 20160909 LR - 20220317 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2015 DP - 2015 TI - Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy. PG - 857416 LID - 10.1155/2015/857416 [doi] LID - 857416 AB - High recurrence rate is one representative characteristic of bladder cancer. Intravesical therapy after transurethral resection is often performed in patients with nonmuscle invasive bladder cancer (NMIBC) to prevent recurrence. Bacillus Calmette-Guerin (BCG) and several anticancer/antibiotic agents, such as mitomycin C and epirubicin, are commonly used for this therapy. BCG treatment demonstrates strong anticancer effects. However, it is also characterized by a high frequency of adverse events. On the other hand, although intravesical therapies using other anticancer and antibiotic agents are relatively safe, their anticancer effects are lower than those obtained using BCG. Thus, the appropriate selection of agents for intravesical therapy is important to improve treatment outcomes and maintain the quality of life of patients with NMIBC. In this review, we discuss the predictive value of various histological and molecular markers for recurrence after intravesical therapy in patients with NMIBC. FAU - Miyata, Yasuyoshi AU - Miyata Y AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. FAU - Sakai, Hideki AU - Sakai H AD - Department of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20151123 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Biomarkers, Tumor) SB - IM MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/administration & dosage/*therapeutic use MH - Apoptosis MH - Biomarkers, Tumor/genetics/*metabolism MH - Humans MH - Recurrence MH - Urinary Bladder Neoplasms/drug therapy/metabolism/*pathology PMC - PMC4670878 EDAT- 2015/12/19 06:00 MHDA- 2016/09/10 06:00 PMCR- 2015/11/23 CRDT- 2015/12/19 06:00 PHST- 2015/09/26 00:00 [received] PHST- 2015/11/10 00:00 [accepted] PHST- 2015/12/19 06:00 [entrez] PHST- 2015/12/19 06:00 [pubmed] PHST- 2016/09/10 06:00 [medline] PHST- 2015/11/23 00:00 [pmc-release] AID - 10.1155/2015/857416 [doi] PST - ppublish SO - Dis Markers. 2015;2015:857416. doi: 10.1155/2015/857416. Epub 2015 Nov 23. PMID- 26672516 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151217 LR - 20200930 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 8 DP - 2015 TI - Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer: new data in a Chinese population and an updated meta-analysis. PG - 3679-90 LID - 10.2147/OTT.S95353 [doi] AB - OBJECTIVE: Human murine double minute 2 protein (MDM2) is mainly a negative regulator of p53 tumor suppressor pathway. We aimed to investigate the association between MDM2 SNP309 polymorphism and bladder cancer risk. METHODS: A total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T>G polymorphism was genotyped by polymerase chain reaction-ligase detection reaction method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan-Meier estimates and log-rank test were obtained to analyze the association between the genotype and risk of recrudesce in nonmuscle-invasive bladder cancer patients. A multivariable Cox proportional hazards model was fitted to identify independent prognostic factors. To further investigate the association, we conducted a meta-analysis including six studies. RESULTS: The frequency of the MDM2 SNP309 T>G polymorphism showed no significant difference between cases and controls (all P>0.05). In the stratification analysis, the results showed that G allele carriers were prone to have a significant decrease in risk of low-grade bladder cancer (adjusted odds ratio: 0.613, 95% confidence interval: 0.427-0.881), and G variant was associated with a significantly reduced risk of recurrence in nonmuscle-invasive bladder cancer patients with or without chemotherapy (P<0.05). The results of the meta-analysis showed that G allele and GG genotype of MDM2 SNP309 polymorphism were significantly associated with increased risk of bladder cancer in Caucasians (both P<0.05), and no association was observed in total populations and Asians (P>0.05). CONCLUSION: MDM2 SNP309 T>G polymorphism has no influence on bladder cancer risk in Asians, but this single nucleotide polymorphism may be associated with genetic susceptibility of bladder cancer among Caucasians. FAU - Xie, Linguo AU - Xie L AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Sun, Yan AU - Sun Y AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Tian, Dawei AU - Tian D AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Li, Yujuan AU - Li Y AD - Department of Dermatology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Ding, Na AU - Ding N AD - Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Shen, Zhonghua AU - Shen Z AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Xu, Hao AU - Xu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Nian, Xuewu AU - Nian X AD - Department of Urology, Tianjin Nankai Hospital, Tianjin, People's Republic of China. FAU - Sha, Nan AU - Sha N AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Han, Ruifa AU - Han R AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. FAU - Wu, Changli AU - Wu C AD - Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China ; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, People's Republic of China. LA - eng PT - Journal Article DEP - 20151207 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC4676618 OTO - NOTNLM OT - MDM2 OT - bladder cancer OT - meta-analysis OT - recurrence OT - rs2279744 OT - single nucleotide polymorphism EDAT- 2015/12/18 06:00 MHDA- 2015/12/18 06:01 PMCR- 2015/12/07 CRDT- 2015/12/18 06:00 PHST- 2015/12/18 06:00 [entrez] PHST- 2015/12/18 06:00 [pubmed] PHST- 2015/12/18 06:01 [medline] PHST- 2015/12/07 00:00 [pmc-release] AID - ott-8-3679 [pii] AID - 10.2147/OTT.S95353 [doi] PST - epublish SO - Onco Targets Ther. 2015 Dec 7;8:3679-90. doi: 10.2147/OTT.S95353. eCollection 2015. PMID- 26671037 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20161230 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 23 IP - 5 DP - 2016 May TI - Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients. PG - 1752-9 LID - 10.1245/s10434-015-5016-z [doi] AB - PURPOSE: We investigated whether smoking cessation could have preventative effects against tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). METHODS: Our study population comprised 634 patients with initially diagnosed NMIBC at Keio University Hospital, Saiseikai Central Hospital, and Saitama Medical University Hospital between 1995 and 2012. We analyzed the relationships between tumor recurrence in NMIBC and patient clinicopathological parameters, including smoking status. RESULTS: Overall, 181 patients (28.5 %) were classified as current smokers, 154 (24.3 %) as former smokers, and 299 (47.2 %) as non-smokers. Kaplan-Meier curve analysis revealed that the tumor recurrence rate was significantly lower in the non-smoker group than in the current- and former-smoker groups (p < 0.001 and p < 0.001, respectively). In the 154 former smokers, Kaplan-Meier curve analysis revealed that smoking intensity and duration was not associated with tumor recurrence rate; however, patients with a smoking cessation period of 15 years or more had a significantly lower tumor recurrence rate than their counterparts (p < 0.001). A multivariate analysis identified a smoking cessation period of <15 years (hazard ratio [HR] 2.20; p = 0.003) and T1 tumors (HR 1.99; p = 0.013) as independent risk factors for tumor recurrence in the former-smokers subgroup. CONCLUSIONS: A positive smoking history was identified as one of the independent risk factors for bladder tumor recurrence after transurethral resection of the bladder tumor. Furthermore, refraining from smoking for 15 years or more reduced the risk of tumor recurrence in former smokers with NMIBC regardless of the intensity or duration of smoking. Therefore, smoking cessation may reduce the risk of tumor recurrence in patients with NMIBC. FAU - Ogihara, Koichiro AU - Ogihara K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Kikuchi, Eiji AU - Kikuchi E AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. eiji-k@kb3.so-net.ne.jp. FAU - Yuge, Kazuyuki AU - Yuge K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Ito, Yujiro AU - Ito Y AD - Department of Urology, Saiseikai Central Hospital, Tokyo, Japan. FAU - Tanaka, Nobuyuki AU - Tanaka N AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Kazuhiro AU - Matsumoto K AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Miyajima, Akira AU - Miyajima A AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. FAU - Asakura, Hirotaka AU - Asakura H AD - Department of Urology, Saitama Medical University Hospital, Saitama, Japan. FAU - Oya, Mototsugu AU - Oya M AD - Department of Urology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20151215 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - J Urol. 2017 Nov;198(5):979-980. doi: 10.1016/j.juro.2017.08.021. PMID: 29059772 MH - Adult MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/epidemiology/pathology/*prevention & control MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Smoking/*physiopathology MH - *Smoking Cessation MH - Survival Rate MH - Urinary Bladder Neoplasms/epidemiology/pathology/*surgery MH - Young Adult EDAT- 2015/12/17 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/12/17 06:00 PHST- 2015/08/31 00:00 [received] PHST- 2015/12/17 06:00 [entrez] PHST- 2015/12/17 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 10.1245/s10434-015-5016-z [pii] AID - 10.1245/s10434-015-5016-z [doi] PST - ppublish SO - Ann Surg Oncol. 2016 May;23(5):1752-9. doi: 10.1245/s10434-015-5016-z. Epub 2015 Dec 15. PMID- 26657502 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 3 DP - 2016 Jan 19 TI - Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. PG - 3255-66 LID - 10.18632/oncotarget.6487 [doi] AB - High recurrence rates of non-muscle invasive bladder cancer (NMIBC) in patients require lifelong testing and monitoring. The aim of this study is to develop a simplified RT-qPCR method (RT-qPCR-D) which directly quantifies cell-free miR-155 in urine without RNA extraction, and assess it as a potential tool in NMIBC detection. A pilot study including 60 urine samples was used to investigate the feasibility of RT-qPCR-D in detecting cell-free miR-155. Then, miR-155 levels were quantified in a large independent cohort of urine from 162 NIMBC patients, 76 cystitis patients, and 86 healthy donors using the RT-qPCR-D method. Changes of cell-free miR-155 before and after operation were also analyzed in 32 NIMBC patients. In pilot study, we found a significant linear association between RT-qPCR and RT-qPCR-D in urinary miR-155 detection. Both methods showed cell-free miR-155 were significantly increased in NMIBC patients, and could reflect their expression in tissues. Then, the increased expression of cell-free miR-155 was successfully validated in 162 NIMBC patients when compared with cystitis patients and healthy donors. Moreover, it distinguished NMIBC patients from others with 80.2% sensitivity and 84.6% specificity, which was superior to urine cytology. Cell-free miR-155 correlated with NMIBC stage and grade, and was an independent factor for predicting recurrence and progression to muscle invasion. In addition, cell-free miR-155 was significantly decreased after NMIBC patients underwent transurethral bladder resection. In conclusion, detection of cell-free miR-155 in urine using RT-qPCR-D is a simple and noninvasive approach which may be used for NMIBC diagnosis and prognosis prediction. FAU - Zhang, Xin AU - Zhang X AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. FAU - Zhang, Yanli AU - Zhang Y AD - Department of Clinical Laboratory, Traffic Hospital of Shandong Province, Jinan 250031, China. FAU - Liu, Xinfeng AU - Liu X AD - Department of Clinical Laboratory, Traffic Hospital of Shandong Province, Jinan 250031, China. FAU - Fang, Aiju AU - Fang A AD - Department of Pathology, Traffic Hospital of Shandong Province, Jinan 250031, China. FAU - Wang, Jinfeng AU - Wang J AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. FAU - Wang, Chuanxin AU - Wang C AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan 250012, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN155 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*urine MH - Cystitis/urine MH - Disease Progression MH - Female MH - Humans MH - Male MH - MicroRNAs/genetics/*urine MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology/*urine MH - Pilot Projects MH - Prognosis MH - Real-Time Polymerase Chain Reaction MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/genetics/pathology/*urine PMC - PMC4823104 OTO - NOTNLM OT - biomarker OT - cell-free OT - miR-155 OT - non-muscle invasive bladder cancer OT - urine COIS- CONFLICTS OF INTEREST All the authors had no potential confict of interest to disclose. EDAT- 2015/12/15 06:00 MHDA- 2016/12/15 06:00 PMCR- 2016/01/19 CRDT- 2015/12/15 06:00 PHST- 2015/07/07 00:00 [received] PHST- 2015/11/21 00:00 [accepted] PHST- 2015/12/15 06:00 [entrez] PHST- 2015/12/15 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2016/01/19 00:00 [pmc-release] AID - 6487 [pii] AID - 10.18632/oncotarget.6487 [doi] PST - ppublish SO - Oncotarget. 2016 Jan 19;7(3):3255-66. doi: 10.18632/oncotarget.6487. PMID- 26656345 OWN - NLM STAT- MEDLINE DCOM- 20160420 LR - 20250711 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 94 IP - 49 DP - 2015 Dec TI - Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. PG - e2176 LID - 10.1097/MD.0000000000002176 [doi] LID - e2176 AB - Whether low-dose Bacillus Calmette-Guerin (BCG) treatment can reduce the side effects while maintaining efficacy for patients with nonmuscle invasive bladder cancer (NMIBC) is controversial.To investigate whether low-dose BCG treatment can reduce the side effects while maintaining efficacy for patients with NMIBC when compared with standard-dose BCG treatment.A comprehensive literature search of PubMed, EMBASE, CINAHL, LILACS, and CENTRAL databases was conducted to identify relevant randomized controlled trials (RCT) or quasi-randomized controlled trials (qRCT) that have assessed the efficacy of low- and standard-dose BCG therapy for patients with NMIBC. Systematic review and meta-analysis were performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis Criteria.Six RCTs and 2 qRCTs were eligible for meta-analysis. Low-dose BCG instillation was not inferior to reduce the risk of bladder tumor recurrence (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.00-1.31; P = 0.05), meanwhile no difference was found regarding tumor progression (HR = 1.08; 95%CI, 0.83-1.42; P = 0.57). However, low-dose BCG provided a significantly lower incidence of overall side effects (RR = 0.75; 95%CI, 0.60-0.94; P = 0.01), systemic side effects (RR = 0.57; 95%CI, 0.34-0.97; P = 0.04), severe side effects (RR = 0.52; 95%CI, 0.36-0.74; P = 0.0003), and withdrawal due to BCG toxicity (RR = 0.49; 95%CI, 0.26-0.91; P = 0.02). In contrast, local side effects were comparable between low- and standard-dose arms (RR = 0.89; 95%CI, 0.73-1.08; P = 0.24).Low-dose BCG instillation significantly reduces the incidence of overall side effects, especially severe and systemic symptoms in patients with NMIBC, while the oncological control efficacy of low-dose BCG is not inferior to standard-dose BCG. Further studies with stratification using different risk factors at randomization are required to assess whether the efficacy of low-dose BCG is comparable to standard dose BCG for different risk of patients.PROSPERO registration No CRD42014014871 (http://www.crd.york.ac.uk/prospero/). FAU - Zeng, Shuxiong AU - Zeng S AD - From the Department of Urology(SZ, CM, ZZ, RS, XC, YS, CX); and Department of Geriatrics(XY), Changhai Hospital, Second Military Medical University, Shanghai, P.R. China. FAU - Yu, Xiaowen AU - Yu X FAU - Ma, Chong AU - Ma C FAU - Zhang, Zhensheng AU - Zhang Z FAU - Song, Ruixiang AU - Song R FAU - Chen, Xin AU - Chen X FAU - Sun, Yinghao AU - Sun Y FAU - Xu, Chuanliang AU - Xu C LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/administration & dosage/adverse effects/*therapeutic use MH - BCG Vaccine/administration & dosage/adverse effects/*therapeutic use MH - Disease Progression MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Humans MH - Neoplasm Recurrence, Local MH - Proportional Hazards Models MH - Randomized Controlled Trials as Topic MH - Urinary Bladder Neoplasms/*drug therapy PMC - PMC5008490 EDAT- 2015/12/15 06:00 MHDA- 2016/04/21 06:00 PMCR- 2015/12/11 CRDT- 2015/12/15 06:00 PHST- 2015/12/15 06:00 [entrez] PHST- 2015/12/15 06:00 [pubmed] PHST- 2016/04/21 06:00 [medline] PHST- 2015/12/11 00:00 [pmc-release] AID - 00005792-201512080-00025 [pii] AID - 10.1097/MD.0000000000002176 [doi] PST - ppublish SO - Medicine (Baltimore). 2015 Dec;94(49):e2176. doi: 10.1097/MD.0000000000002176. PMID- 26649138 OWN - NLM STAT- MEDLINE DCOM- 20160908 LR - 20260709 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2016 DP - 2016 TI - The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer. PG - 5710403 LID - 10.1155/2016/5710403 [doi] LID - 5710403 AB - Genome instability and impaired DNA repair are hallmarks of carcinogenesis. The study was aimed at evaluating the DNA damage response in H2O2-treated lymphocytes using the alkaline comet assay in bladder cancer (BC) patients as compared to clinically healthy controls, elderly persons, and individuals with chronic inflammations. Polymorphism in DNA repair genes involved in nucleotide excision repair (NER) and base excision repair (BER) was studied using the PCR-RFLP method in the Belarusian population to elucidate the possible association of their variations with both bladder cancer risk and clinicopathological features of tumors. The increased level of H2O2-induced DNA damage and a higher proportion of individuals sensitive to oxidative stress were found among BC patients as compared to other groups under study. Heterozygosity in the XPD gene (codon 751) increased cancer risk: OR (95% CI) = 1.36 (1.03-1.81), p = 0.031. The frequency of the XPD 312Asn allele was significantly higher in T >/= 2 high grade than in T >/= 2 low grade tumors (p = 0.036); the ERCC6 1097Val/Val genotype was strongly associated with muscle-invasive tumors. Combinations of homozygous wild type alleles occurred with the increased frequency in patients with non-muscle-invasive tumors suggesting that the maintenance of normal DNA repair activity may prevent cancer progression. FAU - Savina, Nataliya V AU - Savina NV AD - Institute of Genetics and Cytology, National Academy of Sciences of Belarus, 27 Akademicheskaya Street, 220072 Minsk, Belarus. FAU - Nikitchenko, Nataliya V AU - Nikitchenko NV AD - Institute of Genetics and Cytology, National Academy of Sciences of Belarus, 27 Akademicheskaya Street, 220072 Minsk, Belarus. FAU - Kuzhir, Tatyana D AU - Kuzhir TD AD - Institute of Genetics and Cytology, National Academy of Sciences of Belarus, 27 Akademicheskaya Street, 220072 Minsk, Belarus. FAU - Rolevich, Alexander I AU - Rolevich AI AD - N.N. Alexandrov National Cancer Centre of Belarus, Lesnoy, 223040 Minsk, Belarus. FAU - Krasny, Sergei A AU - Krasny SA AD - N.N. Alexandrov National Cancer Centre of Belarus, Lesnoy, 223040 Minsk, Belarus. FAU - Goncharova, Roza I AU - Goncharova RI AD - Institute of Genetics and Cytology, National Academy of Sciences of Belarus, 27 Akademicheskaya Street, 220072 Minsk, Belarus. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20151116 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 RN - 0 (Neoplasm Proteins) RN - 0 (Poly-ADP-Ribose Binding Proteins) RN - EC 3.6.4.- (DNA Helicases) RN - EC 3.6.4.12 (ERCC6 protein, human) RN - EC 3.6.4.12 (Xeroderma Pigmentosum Group D Protein) RN - EC 5.99.- (ERCC2 protein, human) RN - EC 6.5.1.- (DNA Repair Enzymes) SB - IM MH - Adult MH - *DNA Damage MH - DNA Helicases/*genetics/metabolism MH - *DNA Repair MH - DNA Repair Enzymes/*genetics/metabolism MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Proteins/*genetics/metabolism MH - Oxidation-Reduction MH - Poly-ADP-Ribose Binding Proteins MH - *Polymorphism, Restriction Fragment Length MH - Urinary Bladder Neoplasms/*genetics/metabolism/pathology MH - Xeroderma Pigmentosum Group D Protein/*genetics/metabolism PMC - PMC4663333 EDAT- 2015/12/10 06:00 MHDA- 2016/09/09 06:00 PMCR- 2015/11/16 CRDT- 2015/12/10 06:00 PHST- 2015/05/18 00:00 [received] PHST- 2015/06/26 00:00 [revised] PHST- 2015/07/21 00:00 [accepted] PHST- 2015/12/10 06:00 [entrez] PHST- 2015/12/10 06:00 [pubmed] PHST- 2016/09/09 06:00 [medline] PHST- 2015/11/16 00:00 [pmc-release] AID - 10.1155/2016/5710403 [doi] PST - ppublish SO - Oxid Med Cell Longev. 2016;2016:5710403. doi: 10.1155/2016/5710403. Epub 2015 Nov 16. PMID- 26645279 OWN - NLM STAT- MEDLINE DCOM- 20161025 LR - 20260127 IS - 1940-6215 (Electronic) IS - 1940-6215 (Linking) VI - 9 IP - 2 DP - 2016 Feb TI - Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. PG - 189-95 LID - 10.1158/1940-6207.CAPR-15-0069 [doi] AB - Cigarette smoking is the most important known risk factor for urinary bladder cancer. Selected arylamines in cigarette smoke are recognized human bladder carcinogens and undergo biotransformation through several detoxification pathways, such as the glutathione S-transferases (GST), and uridine-diphospho-glucuronosyltransferases (UGT) pathways. GSTM1 deletion status and UGT1A1*28 rs8175347 genotypes were assessed in 189 non-muscle-invasive bladder cancers (NMIBC) patients with pTa (77.2%) and pT1 (22.8%) tumors and a mean follow-up of 5.6 years, to investigate whether two common functional polymorphisms in GSTM1 and UGT1A1 genes and smoking history are associated with recurrence-free survival of patients with NMIBC. Most patients were current (48.7%) or previous (35.4%) cigarette smokers and 15.9% never smoked. Tumor recurrence occurred in 65.1% of patients, at a median time of 12.9 months. Upon multivariate analysis, previous and current smokers approximately tripled their risk of recurrences [HR = 2.76; 95% confidence interval (CI), 1.03-7.40 and HR = 2.93; 95% CI, 1.08-7.94, respectively]. When adjusted for age, smoking status, stage, grade, gender, and presence of carcinoma in situ, carriers of GSTM1 (+/- and -/-) and UGT1A1*28/*28 alleles were significantly at risk of NMIBC recurrence (HR = 10.05; 95% CI, 1.35-75.1 and HR = 1.91; 95% CI, 1.01-3.62, respectively). Compared with nonsmokers with UGT1A1*1/*1 and *1/*28 genotypes, previous and current smokers homozygous for the UGT1A1*28 allele demonstrated a risk of recurrence of 4.95 (95% CI, 1.02-24.0) and 5.32 (95% CI, 2.07-13.7), respectively. This study establishes a connection between GSTM1, UGT1A1, and tobacco exposure as prognostic markers of NMIBC recurrence in bladder cancer patients. These findings warrant validation in larger cohorts. CI - (c)2015 American Association for Cancer Research. FAU - Lacombe, Louis AU - Lacombe L AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. louis.lacombe@crchudequebec.ulaval.ca. FAU - Fradet, Vincent AU - Fradet V AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Levesque, Eric AU - Levesque E AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Laval University, Quebec, Canada. Department of Medecine (Hemato-oncology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Pouliot, Frederic AU - Pouliot F AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Larue, Helene AU - Larue H AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Bergeron, Alain AU - Bergeron A AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Hovington, Helene AU - Hovington H AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. FAU - Caron, Andre AU - Caron A AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. FAU - Nguile-Makao, Moliere AU - Nguile-Makao M AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. FAU - Harvey, Mario AU - Harvey M AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Laval University, Quebec, Canada. FAU - Fradet, Yves AU - Fradet Y AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Department of Surgery (Urology), Faculty of Medecine, Laval University, Quebec, Canada. FAU - Guillemette, Chantal AU - Guillemette C AD - Centre Hospitalier Universitaire (CHU) de Quebec Research Center, Laval University, Quebec, Canada. Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Laval University, Quebec, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151208 PL - United States TA - Cancer Prev Res (Phila) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - 0 (Biomarkers, Tumor) RN - EC 2.4.1.17 (Glucuronosyltransferase) RN - EC 2.5.1.18 (Glutathione Transferase) RN - EC 2.4.1.17 (UGT1A1 Enzyme) SB - IM CIN - J Urol. 2017 Jul;198(1):40. doi: 10.1016/j.juro.2017.04.005. PMID: 28618712 MH - Aged MH - Biomarkers, Tumor/genetics MH - Female MH - Follow-Up Studies MH - Gene-Environment Interaction MH - Genetic Predisposition to Disease MH - Genotype MH - Glucuronosyltransferase/*genetics MH - Glutathione Transferase/*genetics MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/etiology/metabolism/*pathology MH - Neoplasm Staging MH - Polymorphism, Genetic/*genetics MH - Prognosis MH - Risk Factors MH - Smoking/*genetics MH - Survival Rate MH - Urinary Bladder Neoplasms/etiology/metabolism/*pathology MH - UGT1A1 Enzyme EDAT- 2015/12/10 06:00 MHDA- 2016/10/26 06:00 CRDT- 2015/12/10 06:00 PHST- 2015/02/19 00:00 [received] PHST- 2015/11/04 00:00 [accepted] PHST- 2015/12/10 06:00 [entrez] PHST- 2015/12/10 06:00 [pubmed] PHST- 2016/10/26 06:00 [medline] AID - 1940-6207.CAPR-15-0069 [pii] AID - 10.1158/1940-6207.CAPR-15-0069 [doi] PST - ppublish SO - Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8. PMID- 26637476 OWN - NLM STAT- MEDLINE DCOM- 20171006 LR - 20180131 IS - 1533-0338 (Electronic) IS - 1533-0338 (Linking) VI - 15 IP - 6 DP - 2016 Dec TI - Expression of Annexin A2 and Its Correlation With Drug Resistance and Recurrence of Bladder Cancer. PG - NP61-NP68 AB - OBJECTIVE: To explore the expressions of annexin A2 in bladder cancer cell lines and bladder cancer tissues, we want to find the relationship among annexin A2, drug resistance, and recurrence of bladder cancer. METHODS: Our laboratory established the PUMC-91 bladder cancer cell line against gradient concentration of Adriamycin (0.3, 0.6, and 1.0 mug/mL), and we also collected 60 cases of surgically resected bladder cancer recurrent tissue samples. The tissues were classified into 2 groups according to the frequency of recurrence (<6 months and >2 years) after initial surgery. The method of immunohistochemistry was used to examine the differences in the expression of annexin A2. RESULTS: There were statistical differences in annexin A2 among normal bladder epithelial cell line SV-HUC-1, PUMC-91, PUMC-91 against 0.3 mug/mL Adriamycin, and PUMC-91 against 1.0 mug/mL Adriamycin (P < .05). The expressions of Annexin A2 were found to be higher than those that recurred at >2 years (P = .002) in the bladder cancer tissues and that recurred at <6 months after initial surgery. It was also associated with invasion depth (stage) of bladder cancer, such as higher expression in T2 (invasive muscular) group than Tis (carcinoma in situ) and T1 (invasive mucosa lamina propria) groups (P = .003 and P = .000, respectively). But, it did not correlate with the differentiation (grade) of cancer cells in bladder cancer tissues (P = .593). CONCLUSION: Annexin A2 can act as a valuable biomarker for predicting the drug resistance and recurrence of bladder cancer. CI - (c) The Author(s) 2015. FAU - Hu, Huihui AU - Hu H AD - Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China. FAU - Zhao, Jin AU - Zhao J AD - Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China. FAU - Zhang, Man AU - Zhang M AD - Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China mzhang99@aliyun.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151204 PL - United States TA - Technol Cancer Res Treat JT - Technology in cancer research & treatment JID - 101140941 RN - 0 (Annexin A2) RN - 80168379AG (Doxorubicin) SB - IM MH - Aged MH - Annexin A2/*genetics MH - Cell Line, Tumor MH - Doxorubicin/therapeutic use MH - Drug Resistance, Neoplasm/*genetics MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*genetics MH - Urinary Bladder Neoplasms/drug therapy/*genetics/*pathology OTO - NOTNLM OT - annexin A2 OT - bladder cancer OT - drug resistance OT - immunohistochemistry OT - recurrence EDAT- 2015/12/08 06:00 MHDA- 2017/10/07 06:00 CRDT- 2015/12/06 06:00 PHST- 2015/05/03 00:00 [received] PHST- 2015/09/10 00:00 [revised] PHST- 2015/10/01 00:00 [accepted] PHST- 2015/12/08 06:00 [pubmed] PHST- 2017/10/07 06:00 [medline] PHST- 2015/12/06 06:00 [entrez] AID - 1533034615617078 [pii] AID - 10.1177/1533034615617078 [doi] PST - ppublish SO - Technol Cancer Res Treat. 2016 Dec;15(6):NP61-NP68. doi: 10.1177/1533034615617078. Epub 2015 Dec 4. PMID- 26634848 OWN - NLM STAT- MEDLINE DCOM- 20170131 LR - 20170131 IS - 1840-2445 (Electronic) IS - 1840-0132 (Linking) VI - 13 IP - 1 DP - 2016 Feb 1 TI - Predicting recurrence of non-muscle-invasive bladder cancer after transurethral resection. PG - 56-61 LID - 10.17392/824-16 [doi] AB - AIM: To determine clinical prognostic factors and their impact on the risk of recurrence of newly discovered non-muscle-invasive bladder cancer. METHODS: The study included 120 patients of both sexes aged 45-80 years with newly discovered non-muscle-invasive bladder cancer. All the patients were treated surgically by transurethral electro resection (TUER). The outcome of patients with and without recurrence was followed at intervals of three months after surgery, the total of two years. For monitoring the probability of early recurrence the criteria of the European Organization for Research and Treatment of Cancer (EORTC) were used. RESULTS: The average age of the patients was 65.9 years, 79 (79.2%) males and 21 (20.8%) females. The total of 67 (55.8%) patients had a recurrence during the period of monitoring. The average time to the first and fourth recurrence was 15.4 and 23.9 months, respectively. Numbers of tumors and a degree of invasion had a significant prognostic impact on the risk of recurrence. The EORTC score was a highly significant predictor of recurrence (OR=1.237; p < 0.001). CONCLUSION: Based on available clinical and pathological prognostic factors and by stratification of patients into three disease risk groups it is possible to predict the possibility of disease. Individual approach and recommendations for the treatment using EORTC risk tables should improve the quality of treatment. CI - Copyright(c) by the Medical Assotiation of Zenica-Doboj Canton. FAU - Ethug, Haris AU - Ethug H AD - Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla; Tuzla, Bosnia and Herzegovina. FAU - Jagodic, Samed AU - Jagodic S AD - Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla; Tuzla, Bosnia and Herzegovina. FAU - Ahmetovic-Ethug, Jasmina AU - Ahmetovic-Ethug J AD - Clinic of Anesthesiology and Reanimation, University Clinical Centre of Tuzla; Tuzla, Bosnia and Herzegovina. FAU - Selimovic, Zijad AU - Selimovic Z AD - Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla; Tuzla, Bosnia and Herzegovina. FAU - Sulejmanovic, Alemdar AU - Sulejmanovic A AD - Department of Urology, Clinic of Surgery, University Clinical Centre of Tuzla; Tuzla, Bosnia and Herzegovina. LA - eng PT - Journal Article PT - Observational Study PL - Bosnia and Herzegovina TA - Med Glas (Zenica) JT - Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina JID - 101250177 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/*pathology MH - Prognosis MH - Prospective Studies MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*pathology/*surgery OTO - NOTNLM OT - immunotherapy OT - probability OT - treatment EDAT- 2015/12/05 06:00 MHDA- 2017/02/01 06:00 CRDT- 2015/12/05 06:00 PHST- 2015/06/29 00:00 [received] PHST- 2015/08/19 00:00 [revised] PHST- 2015/09/30 00:00 [accepted] PHST- 2015/12/05 06:00 [entrez] PHST- 2015/12/05 06:00 [pubmed] PHST- 2017/02/01 06:00 [medline] AID - 10.17392/824-16 [doi] PST - ppublish SO - Med Glas (Zenica). 2016 Feb 1;13(1):56-61. doi: 10.17392/824-16. PMID- 26630130 OWN - NLM STAT- MEDLINE DCOM- 20161103 LR - 20220311 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 30 IP - 3 DP - 2016 Mar TI - The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience. PG - 262-7 LID - 10.1089/end.2015.0248 [doi] AB - INTRODUCTION: The gold standard treatment for upper tract urothelial carcinoma (UTUC) is radical nephroureterectomy (RNU). The role of endoscopic resection is limited to low-risk patients. In this study, we present our 30-year experience in the endoscopic management of UTUC. METHODS: In this retrospective study, we identified 141 patients who underwent percutaneous UTUC resection. Demographic and clinical data were collected, including tumor characteristics, bacillus Calmette-Guerin (BCG) and mitomycin use, tumor recurrence, progression to RNU, and overall survival (OS), and compared in univariate and multivariate analyses. RESULTS: Median follow-up was 66 months. Recurrence occurred in 37% of low-grade patients and 63% of high-grade (HG) patients, with a median time to recurrence of 71.4 vs 36.4 months, respectively. Grade was the only predictor of recurrence (HR 2.12, p = 0.018). The latest time to recurrence occurred after 116 months of surveillance. RNU was avoided by 87% of patients. Age, imperative indications for endoscopy, a history of bladder cancer, and tumor stage and grade were predictors of OS; however, in multivariate analysis, grade and stage lost significance. BCG and mitomycin did not protect against recurrence, progression to RNU, or death over resection alone. CONCLUSION: Percutaneous management of UTUC allows for renal preservation in the majority of patients with resectable disease. Patients with HG tumors are more likely to experience recurrence, but are not at an increased risk of death. Intraluminal BCG and mitomycin continue to have a limited adjuvant role to resection. Recurrence may occur many years following initial resection and therefore prolonged surveillance is advised. FAU - Motamedinia, Piruz AU - Motamedinia P AD - 1 Arthur Smith Institute for Urology, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York. AD - 2 Department of Urology, Yale University, New Haven, Connecticut. FAU - Keheila, Mohamed AU - Keheila M AD - 1 Arthur Smith Institute for Urology, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York. FAU - Leavitt, David A AU - Leavitt DA AD - 1 Arthur Smith Institute for Urology, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York. AD - 3 Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan. FAU - Rastinehad, Ardeshir R AU - Rastinehad AR AD - 4 Icahn School of Medicine at Mt. Sinai, New York, New York. FAU - Okeke, Zeph AU - Okeke Z AD - 1 Arthur Smith Institute for Urology, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York. FAU - Smith, Arthur D AU - Smith AD AD - 1 Arthur Smith Institute for Urology, North Shore-Long Island Jewish Medical Center, New Hyde Park, New York. LA - eng PT - Journal Article DEP - 20151202 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/therapeutic use MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/pathology/*therapy MH - Disease Progression MH - Endoscopy/methods MH - Female MH - Humans MH - Kidney Neoplasms/pathology/*surgery MH - Kidney Pelvis MH - Male MH - Middle Aged MH - Mitomycin/therapeutic use MH - Multivariate Analysis MH - Neoplasm Grading MH - *Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Nephrectomy/*methods MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Ureter/*surgery MH - Ureteral Neoplasms/pathology/*surgery EDAT- 2015/12/03 06:00 MHDA- 2016/11/04 06:00 CRDT- 2015/12/03 06:00 PHST- 2015/12/03 06:00 [entrez] PHST- 2015/12/03 06:00 [pubmed] PHST- 2016/11/04 06:00 [medline] AID - 10.1089/end.2015.0248 [doi] PST - ppublish SO - J Endourol. 2016 Mar;30(3):262-7. doi: 10.1089/end.2015.0248. Epub 2015 Dec 2. PMID- 26623061 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 3 IP - 5 DP - 2015 Sep TI - Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin. PG - 1113-1116 AB - This study was conducted to evaluate the utility of pyuria as a predictive marker of bacillus Calmette-Guerin (BCG) treatment for non-muscle-invasive bladder cancer (NMIBC). A cohort of 243 NMIBC patients treated with BCG through intravesical instillation between 1994 and 2007 at the Tokyo Metropolitan Tama Medical Center were enrolled in this retrospective study. Pyuria was defined as urine containing >/=10 white blood cells per high-power field. A total of 30 of the patients with pyuria (30/37, 81%) and 87 patients of those without pyuria (87/206, 42%) exhibited recurrence following BCG treatment. The 3-year recurrence-free survival rate of patients with and without pyuria following BCG treatment was 20 and 62%, respectively. The multivariate Cox proportional hazards regression model indicated that pyuria was an independent predictor of disease recurrence following BCG treatment. Patients with inflammatory NMIBC exhibited resistance to therapy with intravesical instillation of BCG. FAU - Azuma, Takeshi AU - Azuma T AD - Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo 183-0042, Japan. FAU - Nagase, Yasushi AU - Nagase Y AD - Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo 183-0042, Japan. FAU - Oshi, Masaya AU - Oshi M AD - Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo 183-0042, Japan. LA - eng PT - Journal Article DEP - 20150615 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC4534862 OTO - NOTNLM OT - bacillus Calmette-Guerin OT - bladder cancer OT - predictive factors OT - pyuria OT - recurrence EDAT- 2015/12/02 06:00 MHDA- 2015/12/02 06:01 PMCR- 2015/06/15 CRDT- 2015/12/02 06:00 PHST- 2015/04/04 00:00 [received] PHST- 2015/04/29 00:00 [accepted] PHST- 2015/12/02 06:00 [entrez] PHST- 2015/12/02 06:00 [pubmed] PHST- 2015/12/02 06:01 [medline] PHST- 2015/06/15 00:00 [pmc-release] AID - MCO-0-0-582 [pii] AID - 10.3892/mco.2015.582 [doi] PST - ppublish SO - Mol Clin Oncol. 2015 Sep;3(5):1113-1116. doi: 10.3892/mco.2015.582. Epub 2015 Jun 15. PMID- 26622883 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 10 IP - 4 DP - 2015 Oct TI - Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. PG - 2527-2532 AB - The identification of biomarkers in urine or serum samples from patients with bladder cancer is urgently required for the development of non-invasive methods for the diagnosis of bladder carcinoma and to facilitate follow-up surveillance, to combat the high progression and recurrence rates of this type of cancer. The current study measured the content of matrix metalloproteinase (MMP)-2 and -9, as well as tissue inhibitor of metalloproteinase (TIMP)-1 and -2 in the urine and sera of 41 patients with bladder cancer by ELISA. The association between levels of MMP-2 and -9 and TIMP-1 and -2, and tumor grade and stage were investigated to verify whether these molecules are involved in tumor differentiation. Statistical analysis of the data revealed that urinary TIMP-1 levels were significantly higher in the high grade group compared with those of the low grade samples (P=0.022). The results also revealed a significantly differing distribution of TIMP-1 expression between Ta and T1 stage specimens (P=0.040). The corresponding area under the curves (AUCs) were 0.72, with a sensitivity of 0.70 and specificity of 0.75. In addition, neutrophil gelatinase-associated lipocalin (NGAL) and MMP-9/NGAL complex levels in the sera were measured. All molecules evaluated were detected in the sera of the patients studied. In particular, tumors staged as non-muscle invasive (Ta and T1), demonstrated significantly higher NGAL levels compared with those of muscle invasive (>T1) bladder cancer (32.8 ng/ml vs. 16.2 ng/ml; P=0.029). The discriminatory ability of NGAL expression was confirmed by receiver operating characteristic curve analysis that revealed an AUC of 0.75, a sensitivity of 0.88 and a specificity of 0.67. These data indicated that urinary TIMP-1 and serum NGAL may be useful non-invasive biomarkers to provide clinical information for bladder cancer disease management. Multicenter, prospective studies are required to confirm these preliminary results. FAU - Ricci, Serena AU - Ricci S AD - Department of Translational Medical Science, University of Naples 'Federico II', Naples 80131, Italy. FAU - Bruzzese, Dario AU - Bruzzese D AD - Department of Public Health, University of Naples 'Federico II', Naples 80131, Italy. FAU - DI Carlo, Angelina AU - DI Carlo A AD - Department of Medico-Surgical Sciences and Biotechnologies, 'Sapienza' University of Rome, Latina 04100, Italy. LA - eng PT - Journal Article DEP - 20150803 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC4580016 OTO - NOTNLM OT - bladder carcinoma OT - matrix metalloproteinase-2 OT - matrix metalloproteinase-9 OT - neutrophil gelatinase-associated lipocalin OT - sera OT - tissue inhibitor of metalloproteinase-1 OT - tissue inhibitor of metalloproteinase-2 OT - urine EDAT- 2015/12/02 06:00 MHDA- 2015/12/02 06:01 PMCR- 2015/08/03 CRDT- 2015/12/02 06:00 PHST- 2014/09/24 00:00 [received] PHST- 2015/06/22 00:00 [accepted] PHST- 2015/12/02 06:00 [entrez] PHST- 2015/12/02 06:00 [pubmed] PHST- 2015/12/02 06:01 [medline] PHST- 2015/08/03 00:00 [pmc-release] AID - OL-0-0-3558 [pii] AID - 10.3892/ol.2015.3558 [doi] PST - ppublish SO - Oncol Lett. 2015 Oct;10(4):2527-2532. doi: 10.3892/ol.2015.3558. Epub 2015 Aug 3. PMID- 26622632 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200929 IS - 1792-1074 (Print) IS - 1792-1082 (Electronic) IS - 1792-1074 (Linking) VI - 10 IP - 2 DP - 2015 Aug TI - Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. PG - 1097-1102 AB - The aim of the present study was to compare the benefits of transurethral resection (TUR) under narrow band imaging (NBI-TUR) and TUR under conventional white light imaging (WLI-TUR) for non-muscle invasive bladder cancer (NMIBC). The study cohort consisted of 135 patients with NMIBC who were followed up for >/=1 year after TUR and who received no additional post-operative treatment. In the WLI-TUR group (n=78), systematic intravesical observation under WLI was followed by a multiple site biopsy (MSB), after which lesions detected as positive findings were resected completely under WLI. In the NBI-TUR group (n=57), similar observation under WLI was followed by systematic intravesical observation under NBI. Following MSB under NBI, TUR was performed for all lesions detected as positive findings under NBI. The sensitivity, specificity, positive-predictive value, negative-predictive value (NPV) and accuracy in the NBI-TUR group were calculated using results from the cystoscopical and pathological examinations of MSB samples under WLI and NBI. The tumor recurrence rate was analyzed in the two groups. Background factors did not differ significantly between the two groups, with the exception of the observation period (31.0 vs. 15.0 months; P<0.01). The procedure under NBI exhibited significantly higher sensitivity (95.0 vs. 70.0%; P<0.01) and NPV (97.1 vs. 86.8%; P<0.01) compared with the procedure under WLI. The 1-year recurrence rate in the NBI-TUR group was significantly lower than that in the WLI-TUR group (21.1 vs. 39.7%; P=0.016). In conclusion, the present study indicated that NBI-TUR is more advantageous than conventional WLI-TUR for patients with NMIBC. FAU - Kobatake, Kohei AU - Kobatake K AD - Department of Urology, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan. FAU - Mita, Koji AU - Mita K AD - Department of Urology, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan. FAU - Ohara, Shinya AU - Ohara S AD - Department of Urology, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan. FAU - Kato, Masao AU - Kato M AD - Department of Urology, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan. LA - eng PT - Journal Article DEP - 20150527 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC4509371 OTO - NOTNLM OT - bladder cancer OT - narrow band imaging OT - transurethral resection EDAT- 2015/12/02 06:00 MHDA- 2015/12/02 06:01 PMCR- 2015/05/27 CRDT- 2015/12/02 06:00 PHST- 2014/07/03 00:00 [received] PHST- 2015/04/17 00:00 [accepted] PHST- 2015/12/02 06:00 [entrez] PHST- 2015/12/02 06:00 [pubmed] PHST- 2015/12/02 06:01 [medline] PHST- 2015/05/27 00:00 [pmc-release] AID - OL-0-0-3280 [pii] AID - 10.3892/ol.2015.3280 [doi] PST - ppublish SO - Oncol Lett. 2015 Aug;10(2):1097-1102. doi: 10.3892/ol.2015.3280. Epub 2015 May 27. PMID- 26622316 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151201 LR - 20240521 IS - 1756-2872 (Print) IS - 1756-2880 (Electronic) IS - 1756-2872 (Linking) VI - 7 IP - 6 DP - 2015 Dec TI - Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. PG - 303-11 LID - 10.1177/1756287215599695 [doi] AB - OBJECTIVES: New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC. METHODS: Treatment with celecoxib was administered orally for 12 months and compared with a contemporary series of patients treated with intravesical mitomycin C (MMC), given weekly for 4 weeks and then monthly for 11 months. Primary endpoints were time to first recurrence and adverse events. RESULTS: From 2003 through 2006, 58 patients were treated with celecoxib and compared with 66 patients receiving MMC. After a median follow up of 75 months, 49 patients were disease free, including 23 (34.85%) in the MMC group and 26 (44.8%) in the celecoxib group. Median disease-free interval was 67 months [95% confidence interval (CI) 35.8 to NA] versus 41 months (95% CI 27.1-67.1; log-rank p = 0.25) for patients treated with MMC and celecoxib, respectively. In the multivariate analysis, treatment was not found to be an independent predictor for recurrence [hazard ratio (HR) 0.76, 95% CI 0.47-1.22, p = 0.25). Overall, 45 AEs were recorded in 35/124 patients. There were no differences between the two groups. CONCLUSIONS: Our data support a clinical benefit of celecoxib and encourage future trials in which COX-2 inhibitors may be tested in selected patients with NMIBC. FAU - Pagliarulo, Vincenzo AU - Pagliarulo V AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy. FAU - Ancona, Patrizia AU - Ancona P AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Martines, Ivan AU - Martines I AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Spadavecchia, Rossana AU - Spadavecchia R AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Di Stasi, Savino AU - Di Stasi S AD - Department of Surgery/Urology, Tor Vergata University, Rome, Italy. FAU - Alba, Stefano AU - Alba S AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. FAU - Cormio, Luigi AU - Cormio L AD - Department of Urology and Renal Transplantation, University of Foggia, Italy. FAU - Fanizza, Caterina AU - Fanizza C AD - Department of Clinical Pharmacology and Epidemiology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Italy. FAU - Salerno, Annamaria AU - Salerno A AD - Department of Urology, University Hospital Campus Bio-Medico, Rome, Italy. FAU - Carrieri, Giuseppe AU - Carrieri G AD - Department of Urology and Renal Transplantation, University of Foggia, Italy. FAU - Pagliarulo, Arcangelo AU - Pagliarulo A AD - Urology and Andrology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. LA - eng PT - Journal Article PL - England TA - Ther Adv Urol JT - Therapeutic advances in urology JID - 101487328 PMC - PMC4647141 OTO - NOTNLM OT - bladder cancer OT - celecoxib OT - cyclooxygenase OT - recurrence OT - treatment COIS- Conflict of interest statement: The authors declare no conflicts of interest in preparing this article. EDAT- 2015/12/02 06:00 MHDA- 2015/12/02 06:01 PMCR- 2015/12/01 CRDT- 2015/12/02 06:00 PHST- 2015/12/02 06:00 [entrez] PHST- 2015/12/02 06:00 [pubmed] PHST- 2015/12/02 06:01 [medline] PHST- 2015/12/01 00:00 [pmc-release] AID - 10.1177_1756287215599695 [pii] AID - 10.1177/1756287215599695 [doi] PST - ppublish SO - Ther Adv Urol. 2015 Dec;7(6):303-11. doi: 10.1177/1756287215599695. PMID- 26617883 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20181113 IS - 1936-2625 (Electronic) IS - 1936-2625 (Linking) VI - 8 IP - 9 DP - 2015 TI - High CD4(+) T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. PG - 11510-6 AB - PURPOSE: The aim of this study was to investigate the clinical significance of CD4(+) T cells in non-muscle-invasive bladder cancer (NMIBC) tissues in situ. METHODS: Immunohistochemistry was used to examine the distribution of CD4(+) T cells in 131 NMIBC tissues. Kaplan-Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS). RESULTS: NMIBC patients were divided into two groups based on the median frequency of CD4(+) T cells (median, 1/x400 high resolution). On univariate analysis, CD4(+) T cell density was inversely associated with overall survival (P = 0.01). In those patients with high CD4(+) T density, 5-year OS rates was only 77%, compared with 86% in those with low density, respectively. Although CD4(+) T cell density showed no prognostic significance for RFS (P = 0.36), 5-year RFS rates of patients with high CD4(+) T density (58%) was lower than those of patients with low CD4(+) T density (65%, respectively). By multivariate analysis, tumor infiltrating CD4(+) T cell density emerged as an independent prognostic factor for OS (HR, 2.75; P = 0.004). In addition, no association was found between CD4(+) T cell density and any clinicopathological variables (P > 0.05). CONCLUSION: Our findings suggest that CD4(+) T cells could potentially serve as a poor prognostic marker for patients with NMIBC. FAU - Zhang, Qinglei AU - Zhang Q AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University Jinan, Shandong, China ; Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Hao, Chongli AU - Hao C AD - Department of Oncology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Cheng, Guangzhou AU - Cheng G AD - Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Wang, Lei AU - Wang L AD - Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Wang, Xiang AU - Wang X AD - Department of Urology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Li, Chang AU - Li C AD - Department of Pathology, Tengzhou Central People's Hospital Zaozhuang, Shangdong, China. FAU - Qiu, Juhui AU - Qiu J AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University Jinan, Shandong, China. FAU - Ding, Kejia AU - Ding K AD - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University Jinan, Shandong, China. LA - eng PT - Journal Article DEP - 20150901 PL - United States TA - Int J Clin Exp Pathol JT - International journal of clinical and experimental pathology JID - 101480565 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/immunology MH - CD4-Positive T-Lymphocytes/*immunology MH - Carcinoma, Transitional Cell/*immunology/mortality/pathology MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Lymphocytes, Tumor-Infiltrating/*immunology MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Urinary Bladder Neoplasms/*immunology/mortality/pathology MH - Young Adult PMC - PMC4637699 OTO - NOTNLM OT - CD4 OT - T cells OT - non-muscle-invasive bladder cancers (NMIBC) OT - prognosis EDAT- 2015/12/01 06:00 MHDA- 2016/12/15 06:00 PMCR- 2015/09/01 CRDT- 2015/12/01 06:00 PHST- 2015/07/02 00:00 [received] PHST- 2015/08/25 00:00 [accepted] PHST- 2015/12/01 06:00 [entrez] PHST- 2015/12/01 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2015/09/01 00:00 [pmc-release] PST - epublish SO - Int J Clin Exp Pathol. 2015 Sep 1;8(9):11510-6. eCollection 2015. PMID- 26614845 OWN - NLM STAT- MEDLINE DCOM- 20160912 LR - 20220331 IS - 1840-4812 (Electronic) IS - 1512-8601 (Print) IS - 1512-8601 (Linking) VI - 15 IP - 4 DP - 2015 Aug 19 TI - Prognostic significance of survivin, beta-catenin and p53 expression in urothelial carcinoma. PG - 7-14 LID - 10.17305/bjbms.2015.556 [doi] AB - Survivin, beta-catenin, and p53 are well-known cell-cycle and apoptosis regulators of tumorigenesis. Urothelial carcinomas (UCs) are the most common of the human cancers. Compared to superficial tumors (Ta, CIS, or T1), invasive UCs are important with regard to recurrence, progression, and mortality. Therefore, we examined whether survivin, beta-catenin, and p53 could be used as the biomarkers for the early prediction of the invasiveness of UCs and the overall survival of the patients. We investigated the prognostic expressions of those biomarkers in UC (n=147) and in non-muscle invasive UC (NMI-UC) (n=113), using tissue microarray and immunohistochemistry. Spearman's correlation analysis and multivariate Cox regression analyses were used for statistical interpretation. High expressions of beta-catenin, survivin, and p53 were associated with a high T stage, recurrence, progression, mortality, low recurrence-free survival, low progression-free survival and low overall survival (p <0.01). Similar findings were achieved for recurrence and progression in the NMI-UC group, except for mortality. Moreover, a positive correlation was shown between p53 and beta-catenin and between p53 and survivin (r=0.221, p <0.01; r=0.236, p <0.01, respectively). Survivin, p53, and beta-catenin overexpression, as prognostic markers, might suggest that the UCs are biologically aggressive with the poor prognosis. Thus, dysregulation of those these cell-cycle and apoptosis regulators in bladder carcinoma could be used as a molecular marker to determine the best treatment strategy and could contribute to the development of targeted therapies. FAU - Senol, Serkan AU - Senol S AD - Medeniyet Univercity Goztepe Research and Training Hospital Istanbul TURKEY. drserkansenol@gmail.com. FAU - Yildirim, Asif AU - Yildirim A FAU - Ceyran, Bahar AU - Ceyran B FAU - Uruc, Fatih AU - Uruc F FAU - Zemheri, Ebru AU - Zemheri E FAU - Ozkanli, Seyma AU - Ozkanli S FAU - Akalin, Ibrahim AU - Akalin I FAU - Ulus, Ismail AU - Ulus I FAU - Caskurlu, Turhan AU - Caskurlu T FAU - Aydin, Abdullah AU - Aydin A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150819 PL - Bosnia and Herzegovina TA - Bosn J Basic Med Sci JT - Bosnian journal of basic medical sciences JID - 101200947 RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (BIRC5 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (CTNNB1 protein, human) RN - 0 (Inhibitor of Apoptosis Proteins) RN - 0 (Survivin) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (beta Catenin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Apoptosis Regulatory Proteins/genetics MH - Biomarkers, Tumor/analysis MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Inhibitor of Apoptosis Proteins/*biosynthesis/*genetics MH - Male MH - Microarray Analysis MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Prognosis MH - Survival Analysis MH - Survivin MH - Tumor Suppressor Protein p53/*biosynthesis/*genetics MH - Urinary Bladder Neoplasms/metabolism/mortality MH - Urologic Neoplasms/*metabolism/mortality MH - beta Catenin/*biosynthesis/*genetics PMC - PMC4690447 EDAT- 2015/11/29 06:00 MHDA- 2016/09/13 06:00 PMCR- 2015/09/01 CRDT- 2015/11/29 06:00 PHST- 2015/06/03 00:00 [received] PHST- 2015/07/01 00:00 [accepted] PHST- 2015/06/30 00:00 [revised] PHST- 2015/11/29 06:00 [entrez] PHST- 2015/11/29 06:00 [pubmed] PHST- 2016/09/13 06:00 [medline] PHST- 2015/09/01 00:00 [pmc-release] AID - BJBMS-15-7 [pii] AID - 10.17305/bjbms.2015.556 [doi] PST - epublish SO - Bosn J Basic Med Sci. 2015 Aug 19;15(4):7-14. doi: 10.17305/bjbms.2015.556. PMID- 26612221 OWN - NLM STAT- MEDLINE DCOM- 20160912 LR - 20151127 IS - 1875-9157 (Electronic) IS - 1875-9157 (Linking) VI - 8 IP - 4 DP - 2015 Dec TI - Diagnosis of Bladder Carcinoma: A Clinician's Perspective. PG - 677-85 LID - S1875-9181(15)00088-4 [pii] LID - 10.1016/j.path.2015.07.004 [doi] AB - In 2014, more than 74,000 new cases and 15,000 deaths from bladder cancer were estimated to occur. The most reliable prognostic factors for survival are pathologic stage and histologic grade. Accordingly, a good understanding of the pathologic features of these cancers is essential to guide optimal clinical treatment, which requires a multidisciplinary team of pathologists, urologists, radiation oncologists, and medical oncologists. This review highlights several clinical scenarios in which detailed pathologic evaluation and accurate reporting impact clinical management. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Harshman, Lauren C AU - Harshman LC AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 1230 DANA, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: LaurenC_Harshman@DFCI.HARVARD.EDU. FAU - Preston, Mark A AU - Preston MA AD - Division of Urology, Brigham and Women's Hospital, Harvard Medical School, 45, Francis street, Boston, MA 02115, USA. FAU - Bellmunt, Joaquim AU - Bellmunt J AD - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 1230 DANA, 450 Brookline Ave, Boston, MA 02215, USA. FAU - Beard, Clair AU - Beard C AD - Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Surg Pathol Clin JT - Surgical pathology clinics JID - 101491209 SB - IM MH - Carcinoma, Transitional Cell/diagnosis/pathology/therapy MH - Combined Modality Therapy MH - Humans MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Urinary Bladder Neoplasms/*diagnosis/pathology/therapy OTO - NOTNLM OT - Bladder cancer OT - Histologic variants OT - Nonmetastatic muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer EDAT- 2015/11/28 06:00 MHDA- 2016/09/13 06:00 CRDT- 2015/11/28 06:00 PHST- 2015/11/28 06:00 [entrez] PHST- 2015/11/28 06:00 [pubmed] PHST- 2016/09/13 06:00 [medline] AID - S1875-9181(15)00088-4 [pii] AID - 10.1016/j.path.2015.07.004 [doi] PST - ppublish SO - Surg Pathol Clin. 2015 Dec;8(4):677-85. doi: 10.1016/j.path.2015.07.004. PMID- 26612196 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260127 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 195 IP - 5 DP - 2016 May TI - Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. PG - 1354-1361 LID - S0022-5347(15)05255-6 [pii] LID - 10.1016/j.juro.2015.11.036 [doi] AB - PURPOSE: We compared the oncologic outcomes of radical nephroureterectomy, distal ureterectomy and endoscopic surgery for elective treatment of clinically organ confined upper tract urothelial carcinoma of the distal ureter. MATERIALS AND METHODS: From a multi-institutional collaborative database we identified 304 patients with unifocal, clinically organ confined urothelial carcinoma of the distal ureter and bilateral functional kidneys. Rates of overall, cancer specific, local recurrence-free and intravesical recurrence-free survival according to surgery type were compared using Kaplan-Meier statistics. Univariable and multivariable Cox regression analyses were performed to assess the adjusted outcomes of radical nephroureterectomy, distal ureterectomy and endoscopic surgery. RESULTS: Overall 128 (42.1%), 134 (44.1%) and 42 patients (13.8%) were treated with radical nephroureterectomy, distal ureterectomy and endoscopic surgery, respectively. Although rates of overall, cancer specific and intravesical recurrence-free survival were equivalent among the 3 surgical procedures, 5-year local recurrence-free survival was lower for endoscopic surgery (35.7%) than for nephroureterectomy (95.0%, p <0.001) or ureterectomy (85.5%, p = 0.01) with no significant difference between nephroureterectomy and distal ureterectomy. On multivariable analyses only endoscopic surgery was an independent predictor of decreased local recurrence-free survival compared to nephroureterectomy (HR 1.27, p = 0.001) or distal ureterectomy (HR 1.14, p = 0.01). Distal ureterectomy and endoscopic surgery did not significantly correlate to cancer specific or intravesical recurrence-free survival. However, when adjustment was made for ASA((R)) (American Society of Anesthesiologists((R))) score, distal ureterectomy (HR 0.80, p = 0.01) and endoscopic surgery (HR 0.84, p = 0.02) were independent predictors of increased overall survival, although no significant difference was found between them. CONCLUSIONS: Because of better oncologic outcomes, distal ureterectomy could be considered the elective first line treatment of clinically organ confined urothelial carcinoma of the distal ureter. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Seisen, Thomas AU - Seisen T AD - Academic Department of Urology, University Hospital Pitie Salpetriere, Paris, France; UPMC Universitaire Paris 06, GRC5, ONCOTYPE-Uro and Institut Universitaire de Cancerologie, Paris, France. FAU - Nison, Laurent AU - Nison L AD - Academic Department of Urology, University Hospital Claude Huriez, Lille, France. FAU - Remzi, Mezut AU - Remzi M AD - Academic Department of Urology, Landesklinikum Korneuburg, Korneuburg, Austria. FAU - Klatte, Tobias AU - Klatte T AD - Academic Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria. FAU - Mathieu, Romain AU - Mathieu R AD - Academic Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria. FAU - Lucca, Ilaria AU - Lucca I AD - Academic Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria. FAU - Bozzini, Gregory AU - Bozzini G AD - Academic Department of Urology, University Hospital Claude Huriez, Lille, France. FAU - Capitanio, Umberto AU - Capitanio U AD - Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele University, Milan, Italy. FAU - Novara, Giacomo AU - Novara G AD - Department of Surgery, Oncology and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy. FAU - Cussenot, Olivier AU - Cussenot O AD - Academic Department of Urology, University Hospital Tenon, Assistance Publique-Hopitaux de Paris, Paris, France; UPMC Universitaire Paris 06, GRC5, ONCOTYPE-Uro and Institut Universitaire de Cancerologie, Paris, France. FAU - Comperat, Eva AU - Comperat E AD - Academic Department of Pathology, University Hospital Pitie Salpetriere, Paris, France. FAU - Renard-Penna, Raphaele AU - Renard-Penna R AD - Academic Department of Radiology, University Hospital Pitie Salpetriere, Paris, France. FAU - Peyronnet, Benoit AU - Peyronnet B AD - Academic Department of Urology, University Hospital Pontchaillou, Rennes, France. FAU - Merseburger, Axel S AU - Merseburger AS AD - Academic Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Fritsche, Hans-Martin AU - Fritsche HM AD - Academic Department of Urology, St. Josef Medical Center, University of Regensburg, Germany. FAU - Hora, Milan AU - Hora M AD - Academic Department of Urology, Faculty Hospital Plzen and Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Academic Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria. FAU - Colin, Pierre AU - Colin P AD - Department of Urology, Private Hospital La Louviere, Lille, France. FAU - Roupret, Morgan AU - Roupret M AD - Academic Department of Urology, University Hospital Pitie Salpetriere, Paris, France; UPMC Universitaire Paris 06, GRC5, ONCOTYPE-Uro and Institut Universitaire de Cancerologie, Paris, France. Electronic address: morgan.roupret@psl.aphp.fr. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20151121 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2016 May;195(5):1360-1361. doi: 10.1016/j.juro.2015.11.082. PMID: 26802740 MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Disease-Free Survival MH - Elective Surgical Procedures/*methods MH - Europe/epidemiology MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Laparoscopy/*methods MH - Male MH - Neoplasm Recurrence, Local/epidemiology MH - Nephrectomy/*methods MH - Postoperative Complications/*epidemiology MH - Prognosis MH - Retrospective Studies MH - Survival Rate/trends MH - Time Factors MH - Ureter/*surgery MH - Ureteral Neoplasms/pathology/*surgery OTO - NOTNLM OT - carcinoma OT - kidney OT - mortality OT - ureter OT - urothelium EDAT- 2015/11/28 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/11/28 06:00 PHST- 2015/11/11 00:00 [accepted] PHST- 2015/11/28 06:00 [entrez] PHST- 2015/11/28 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - S0022-5347(15)05255-6 [pii] AID - 10.1016/j.juro.2015.11.036 [doi] PST - ppublish SO - J Urol. 2016 May;195(5):1354-1361. doi: 10.1016/j.juro.2015.11.036. Epub 2015 Nov 21. PMID- 26609439 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151126 LR - 20200929 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 13 IP - 4 DP - 2015 Dec TI - A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Guerin injection in the management of superficial bladder cancer. PG - 233-7 LID - 10.1016/j.aju.2015.07.002 [doi] AB - OBJECTIVES: To determine whether a half-dose of bacille Calmette-Guerin (BCG) can reduce toxicity without affecting its efficacy in the management of non-muscle-invasive bladder cancer. PATIENTS AND METHODS: From January 2012 to January 2014, 80 patients with superficial bladder cancer and in the intermediate-risk group were simply randomised to receive two different doses of BCG, i.e., a full dose of 90 mg (group A) or a half-dose of 45 mg (group B). There were no significant differences in clinical and pathological characteristics between the groups. At completion of the study, 40 patients could be evaluated in each group. RESULTS: All patients were evaluated for a follow-up of 12 months after treatment. There was no significant difference in recurrence rate (15 patients, 38%, in group A and 16, 40%, in group B) in the two groups, and no difference in progression rate of the disease, at eight patients (20%) in each group. There were significant differences between groups A and B in toxicity (grade 1 adverse events, 70% vs. 60%; grade 2, 18% vs. 7.5%, respectively). Grade 3 adverse events were only reported in group A (2.5%). CONCLUSION: The half dose of intravesical BCG instillation can reduce the toxicity and side-effects that are associated with the treatment of superficial bladder cancer, without affecting the efficacy of therapy. FAU - Kandeel, Wael AU - Kandeel W AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Abdelal, Ashraf AU - Abdelal A AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Elmohamady, Basheer N AU - Elmohamady BN AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Sebaey, Ahmed AU - Sebaey A AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Elshaaer, Waleed AU - Elshaaer W AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Elbarky, Ehab AU - Elbarky E AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. FAU - Abdelwahab, Osama AU - Abdelwahab O AD - Urology Department, Benha Faculty of Medicine, Benha University, Egypt. LA - eng PT - Journal Article DEP - 20150807 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC4656796 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - CIS, carcinoma in situ OT - NMIBC, non-muscle-invasive bladder cancer OT - Non-muscle-invasive OT - TCC OT - TURBT, transurethral resection of the bladder tumour EDAT- 2015/11/27 06:00 MHDA- 2015/11/27 06:01 PMCR- 2015/08/07 CRDT- 2015/11/27 06:00 PHST- 2015/04/24 00:00 [received] PHST- 2015/07/06 00:00 [revised] PHST- 2015/07/13 00:00 [accepted] PHST- 2015/11/27 06:00 [entrez] PHST- 2015/11/27 06:00 [pubmed] PHST- 2015/11/27 06:01 [medline] PHST- 2015/08/07 00:00 [pmc-release] AID - S2090-598X(15)00074-1 [pii] AID - 10.1016/j.aju.2015.07.002 [doi] PST - ppublish SO - Arab J Urol. 2015 Dec;13(4):233-7. doi: 10.1016/j.aju.2015.07.002. Epub 2015 Aug 7. PMID- 26604797 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151125 LR - 20200930 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 8 DP - 2015 TI - Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. PG - 3401-6 LID - 10.2147/OTT.S95609 [doi] AB - OBJECTIVE: To evaluate the clinical significance of lymphovascular invasion (LVI) on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. METHODS: This retrospective study was performed with 155 patients with newly diagnosed pT1 urothelial carcinoma of bladder who were treated with transurethral resection of bladder tumor at our institution from January 2006 to January 2010. The presence or absence of LVI was examined by pathologists. Chi-square test was performed to identify the correlations between LVI and other clinical and pathological features. Kaplan-Meier method was used to estimate the recurrence-free survival (RFS) and progression-free survival curves and difference was determined by the log-rank test. Univariate and multivariate analyses were performed to determine the predictive factors through a Cox proportional hazards analysis model. RESULTS: LVI was detected in a total of 34 patients (21.9%). While LVI was associated with high-grade tumors (P<0.001) and intravesical therapy (P=0.009). Correlations with age (P=0.227), sex (P=0.376), tumor size (P=0.969), tumor multiplicity (P=0.196), carcinoma in situ (P=0.321), and smoking (P=0.438) were not statistically significant. There was a statistically significant tendency toward higher recurrence rate and shorter RFS time in LVI-positive patients. However, no statistically significant differences were observed in progression rate between the two groups. Moreover, multivariate Cox proportional hazards analysis revealed that LVI, tumor size, and smoking were independent prognostic predictors of recurrence. The hazard ratios (95% confidence interval) were 2.042 (1.113-3.746, P=0.021), 1.817 (1.014-3.256, P=0.045), and 2.079 (1.172-3.687, P=0.012), respectively. CONCLUSION: The presence of LVI in transurethral resection of bladder tumor specimens is significantly associated with higher recurrence rate and shorter RFS time in patients with newly diagnosed T1 urothelial carcinoma of the bladder. It is an independent prognostic predictor for disease recurrence. Thus, patients with LVI should be followed up closely. FAU - Sha, Nan AU - Sha N AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Xie, Linguo AU - Xie L AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Chen, Tao AU - Chen T AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Xing, Chen AU - Xing C AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Liu, Xiaoteng AU - Liu X AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Shen, Zhonghua AU - Shen Z AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Xu, Hao AU - Xu H AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Wu, Zhouliang AU - Wu Z AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Hu, Hailong AU - Hu H AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. FAU - Wu, Changli AU - Wu C AD - Department of Urology, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. LA - eng PT - Journal Article DEP - 20151118 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC4655960 OTO - NOTNLM OT - TURBT OT - bladder urothelial carcinoma OT - lymphovascular invasion OT - progression OT - recurrence EDAT- 2015/11/26 06:00 MHDA- 2015/11/26 06:01 PMCR- 2015/11/18 CRDT- 2015/11/26 06:00 PHST- 2015/11/26 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/11/26 06:01 [medline] PHST- 2015/11/18 00:00 [pmc-release] AID - ott-8-3401 [pii] AID - 10.2147/OTT.S95609 [doi] PST - epublish SO - Onco Targets Ther. 2015 Nov 18;8:3401-6. doi: 10.2147/OTT.S95609. eCollection 2015. PMID- 26604440 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151125 LR - 20200930 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 31 IP - 4 DP - 2015 Oct-Dec TI - Intravesical chemotherapy in non-muscle-invasive bladder cancer. PG - 297-303 LID - 10.4103/0970-1591.166446 [doi] AB - Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacity for progression. Intravesical instillation therapy has been employed in various clinical settings, which are summarized within this review. Several chemotherapeutic agents have shown clinical efficacy in reducing recurrence rates in the post-transurethral resection of bladder tumor (TURBT) setting, including mitomycin C (MMC), doxorubicin, and epirubicin. Mounting evidence also supports the use of intravesical MMC following nephroureterectomy to reduce later urothelial bladder recurrence. In the adjuvant setting, bacillus Calmette-Guerin (BCG) immunotherapy is an established first-line agent in the management of carcinoma in situ (CIS) and high-grade non muscle invasive urothelial carcinoma (UC). Among high and intermediate-risk patients (based on tumor grade, size, and focality) improvements in disease-free intervals have been seen with adjunctive administration of MMC prior to scheduled BCG dosing. Following failure of first-line intravesical therapy, gemcitabine and valrubicin have demonstrated modest activity, though valrubicin remains the only agent currently Food and Drug Administration (FDA)-approved for the treatment of BCG-refractory CIS. Techniques to optimize intravesical chemotherapy delivery have also been explored including pharmacokinetic methods such as urinary alkalization and voluntary dehydration. Chemohyperthermia and electromotive instillation have been associated with improved freedom from recurrence intervals but may be associated with increased urinary toxicity. Improvements in therapeutic selection may be heralded by novel opportunities for genomic profiling and refinements in clinical risk stratification. FAU - Porten, Sima P AU - Porten SP AD - Department of Urology, University of California, San Francisco, California, USA. FAU - Leapman, Michael S AU - Leapman MS AD - Department of Urology, University of California, San Francisco, California, USA. FAU - Greene, Kirsten L AU - Greene KL AD - Department of Urology, University of California, San Francisco, California, USA. LA - eng PT - Journal Article PT - Review PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4626913 OTO - NOTNLM OT - Intermediate risk OT - intravesical chemotherapy OT - non-muscle-invasive bladder cancer EDAT- 2015/11/26 06:00 MHDA- 2015/11/26 06:01 PMCR- 2015/10/01 CRDT- 2015/11/26 06:00 PHST- 2015/11/26 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/11/26 06:01 [medline] PHST- 2015/10/01 00:00 [pmc-release] AID - IJU-31-297 [pii] AID - 10.4103/0970-1591.166446 [doi] PST - ppublish SO - Indian J Urol. 2015 Oct-Dec;31(4):297-303. doi: 10.4103/0970-1591.166446. PMID- 26604439 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151125 LR - 20200930 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 31 IP - 4 DP - 2015 Oct-Dec TI - Non-muscle invasive bladder cancer risk stratification. PG - 289-96 LID - 10.4103/0970-1591.166445 [doi] AB - INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) comprises about 70% of all newly diagnosed bladder cancer, and includes tumors with stage Ta, T1 and carcinoma in situ (CIS.) Since, NMIBC patients with progression to muscle-invasive disease tend to have worse prognosis than with patients with primary muscle-invasive disease, there is a need to significantly improve risk stratification and earlier definitive treatment for high-risk NMIBC. MATERIALS AND METHODS: A detailed Medline search was performed to identify all publications on the topic of prognostic factors and risk predictions for superficial bladder cancer/NMIBC. The manuscripts were reviewed to identify variables that could predict recurrence and progression. RESULTS: The most important prognostic factor for progression is grade of tumor. T category, tumor size, number of tumors, concurrent CIS, intravesical therapy, response to bacillus Calmette-Guerin at 3- or 6-month follow-up, prior recurrence rate, age, gender, lymphovascular invasion and depth of lamina propria invasion are other important clinical and pathological parameters to predict recurrence and progression in patients with NMIBC. The European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Club UrologicoEspanol de Tratamiento Oncologico (CUETO) risk tables are the two best-established predictive models for recurrence and progression risk calculation, although they tend to overestimate risk and have poor discrimination for prognostic outcomes in external validation. Molecular biomarkers such as Ki-67, FGFR3 and p53 appear to be promising in predicting recurrence and progression but need further validation prior to using them in clinical practice. CONCLUSION: EORTC and CUETO risk tables are the two best-established models to predict recurrence and progression in patients with NMIBC though they tend to overestimate risk and have poor discrimination for prognostic outcomes in external validation. Future research should focus on enhancing the predictive accuracy of risk assessment tools by incorporating additional prognostic factors such as depth of lamina propria invasion and molecular biomarkers after rigorous validation in multi-institutional cohorts. FAU - Isharwal, Sumit AU - Isharwal S AD - Department of Urology, Institute for Prostate and Urologic Cancers, University of Minnesota, Minneapolis, MN, USA. FAU - Konety, Badrinath AU - Konety B AD - Department of Urology, Institute for Prostate and Urologic Cancers, University of Minnesota, Minneapolis, MN, USA. LA - eng PT - Journal Article PT - Review PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4626912 OTO - NOTNLM OT - Non-muscle invasive bladder cancer OT - outcome OT - prediction models OT - progression OT - recurrence OT - risk stratification OT - superficial bladder cancer EDAT- 2015/11/26 06:00 MHDA- 2015/11/26 06:01 PMCR- 2015/10/01 CRDT- 2015/11/26 06:00 PHST- 2015/11/26 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/11/26 06:01 [medline] PHST- 2015/10/01 00:00 [pmc-release] AID - IJU-31-289 [pii] AID - 10.4103/0970-1591.166445 [doi] PST - ppublish SO - Indian J Urol. 2015 Oct-Dec;31(4):289-96. doi: 10.4103/0970-1591.166445. PMID- 26604438 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151125 LR - 20220330 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 31 IP - 4 DP - 2015 Oct-Dec TI - Diagnostics techniques in nonmuscle invasive bladder cancer. PG - 283-8 LID - 10.4103/0970-1591.166449 [doi] AB - INTRODUCTION: Nonmuscle invasive bladder cancer (NMIBC) is the most common presentation of bladder cancer and is often treatable with endoscopic resection and intravesical therapies. Cystoscopy and urine cytology are the gold standard in diagnosis and surveillance but are limited by their sensitivity in some situations. We seek to provide an overview of recent additions to the diagnostic armamentarium for urologists treating this disease. METHODS: Articles were identified through a literature review of articles obtained through PubMed searches including the terms "bladder cancer" and various diagnostic techniques described in the article. RESULTS: A variety of urinary biomarkers are available to assist the diagnosis and management of patients with NMIBC. Many have improved sensitivity over urine cytology, but less specificity. There are certain situations in which this has proved valuable, but as yet these are not part of the standard guidelines for NMIBC. Fluorescence cystoscopy has level 1 evidence demonstrating increased rates of tumor detection and prolonged recurrence-free survival when utilized for transurethral resection. Other technologies seeking to enhance cystoscopy, such as narrow band imaging, confocal laser endomicroscopy, and optical coherence tomography are still under evaluation. CONCLUSIONS: A variety of urine biomarker and adjunctive endoscopic technologies have been developed to assist the management of NMIBC. While some, such as fluorescence cystoscopy, have demonstrated a definite benefit in this disease, others are still finding their place in the diagnosis and treatment of this disease. Future studies should shed light on how these can be incorporated to improve outcomes in NMIBC. FAU - Soubra, Ayman AU - Soubra A AD - Department of Urology, University of Minnesota, Minneapolis, MN, USA. FAU - Risk, Michael C AU - Risk MC AD - Department of Urology, Minneapolis VA Medical Center, Minneapolis, MN, USA. LA - eng PT - Journal Article PT - Review PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4626911 OTO - NOTNLM OT - Biological markers OT - cystoscopy OT - cytology OT - diagnostic techniques OT - urinary bladder neoplasms OT - urological EDAT- 2015/11/26 06:00 MHDA- 2015/11/26 06:01 PMCR- 2015/10/01 CRDT- 2015/11/26 06:00 PHST- 2015/11/26 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/11/26 06:01 [medline] PHST- 2015/10/01 00:00 [pmc-release] AID - IJU-31-283 [pii] AID - 10.4103/0970-1591.166449 [doi] PST - ppublish SO - Indian J Urol. 2015 Oct-Dec;31(4):283-8. doi: 10.4103/0970-1591.166449. PMID- 26604437 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151125 LR - 20200930 IS - 0970-1591 (Print) IS - 1998-3824 (Electronic) IS - 0970-1591 (Linking) VI - 31 IP - 4 DP - 2015 Oct-Dec TI - Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. PG - 273-82 LID - 10.4103/0970-1591.166448 [doi] AB - The search continues for optimal markers that can be utilized to improve bladder cancer detection and to predict disease recurrence. Although no single marker has yet replaced the need to perform cystoscopy and urine cytology, many tests have been evaluated and are being developed. In the future, these promising markers may be incorporated into standard practice to address the challenge of screening in addition to long-term surveillance of patients who have or are at risk for developing bladder cancer. FAU - Darwiche, Fadi AU - Darwiche F AD - Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA. FAU - Parekh, Dipen J AU - Parekh DJ AD - Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA. FAU - Gonzalgo, Mark L AU - Gonzalgo ML AD - Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA. LA - eng PT - Journal Article PT - Review PL - India TA - Indian J Urol JT - Indian journal of urology : IJU : journal of the Urological Society of India JID - 8510441 PMC - PMC4626910 OTO - NOTNLM OT - Biomarkers OT - bladder cancer OT - transitional cell carcinoma OT - urothelial carcinoma EDAT- 2015/11/26 06:00 MHDA- 2015/11/26 06:01 PMCR- 2015/10/01 CRDT- 2015/11/26 06:00 PHST- 2015/11/26 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/11/26 06:01 [medline] PHST- 2015/10/01 00:00 [pmc-release] AID - IJU-31-273 [pii] AID - 10.4103/0970-1591.166448 [doi] PST - ppublish SO - Indian J Urol. 2015 Oct-Dec;31(4):273-82. doi: 10.4103/0970-1591.166448. PMID- 26598081 OWN - NLM STAT- MEDLINE DCOM- 20160315 LR - 20260127 IS - 1980-5322 (Electronic) IS - 1807-5932 (Print) IS - 1807-5932 (Linking) VI - 70 IP - 10 DP - 2015 Oct TI - Association between interleukin-22 genetic polymorphisms and bladder cancer risk. PG - 686-90 LID - 10.6061/clinics/2015(10)05 [doi] AB - OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays. RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer. CONCLUSION: To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding. FAU - Zhao, Tao AU - Zhao T AD - YongChuan Hospital, Department of Urology, Chongqing Medical University, YongChuan, Chongqing, China. FAU - Wu, XiaoHou AU - Wu X AD - The First Affiliated Hospital of Chongqing, Department of Urology, Medical University, Chongqing, China. FAU - Liu, JiaJi AU - Liu J AD - YongChuan Hospital, Department of Urology, Chongqing Medical University, YongChuan, Chongqing, China. LA - eng PT - Journal Article PL - United States TA - Clinics (Sao Paulo) JT - Clinics (Sao Paulo, Brazil) JID - 101244734 RN - 0 (Interleukins) RN - 0 (Interleukin-22) SB - IM MH - Aged MH - Carcinoma, Papillary/*genetics MH - Case-Control Studies MH - Female MH - Gene Frequency MH - Genetic Association Studies MH - Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Interleukins/classification/*genetics MH - Male MH - Middle Aged MH - Polymerase Chain Reaction MH - *Polymorphism, Genetic MH - Prospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*genetics MH - Interleukin-22 PMC - PMC4602377 COIS- No potential conflict of interest was reported. EDAT- 2015/11/26 06:00 MHDA- 2016/03/16 06:00 PMCR- 2015/10/01 CRDT- 2015/11/25 06:00 PHST- 2015/05/29 00:00 [received] PHST- 2015/07/21 00:00 [accepted] PHST- 2015/11/25 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2016/03/16 06:00 [medline] PHST- 2015/10/01 00:00 [pmc-release] AID - S1807-5932(22)01327-8 [pii] AID - cln_70p686 [pii] AID - 10.6061/clinics/2015(10)05 [doi] PST - ppublish SO - Clinics (Sao Paulo). 2015 Oct;70(10):686-90. doi: 10.6061/clinics/2015(10)05. PMID- 26597334 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20181202 IS - 1557-900X (Electronic) IS - 0892-7790 (Linking) VI - 30 IP - 4 DP - 2016 Apr TI - Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality? PG - 400-5 LID - 10.1089/end.2015.0591 [doi] AB - INTRODUCTION: Published series of transurethral resection of bladder tumor (TURBT) show high rates (18%-52%) of procedures resulting in no detrusor muscle (DM) layer being present in the pathologic specimen. This is of clinical importance since DM inclusion in surgical specimens is invariably associated with better oncologic results and is considered a surrogate marker of surgical quality. We sought to assess rates and predictors of DM absence (DM-) at a final pathology report in a series of consecutive TURBTs performed at a single tertiary-referral academic center. MATERIALS AND METHODS: We retrospectively collected data from 437 TURBTs performed over 1 year. Complete endoscopic perioperative data were available for all patients; surgeons were categorized as either staff physicians or residents. Likewise, pathologic data, including tumor grade and stage, and DM status (present vs absent) were recorded. Only procedures with bladder cancer (BCa) at final pathology were included in the analyses. Logistic regression analyses tested potential predictors of DM-. Kaplan-Meier analyses were applied to assess the impact of DM- on postoperative tumor recurrence. RESULTS: Overall, BCa was found in 302 (69.1%) specimens at final pathology; DM- occurred in 29 (9.6%) cases. A comparable rate of DM- was observed for procedures conducted by staff physicians and residents (9% [23/232] vs 12.8% [6/41], respectively; p = 0.6). Flat morphology emerged as the most informative predictor of DM- after adjusting for tumor size, number of lesions, tumor stage and grade, surgeon experience, and resection modality. At Kaplan-Meier analysis, DM- was not associated with worse outcomes in terms of postoperative recurrence-free survival. CONCLUSIONS: Current findings showed a rate of roughly 10% of DM- at TURBT. Flat morphology emerged as the most significant predictor of DM-, whereas surgeon experience was not associated with DM-. FAU - Capogrosso, Paolo AU - Capogrosso P AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Capitanio, Umberto AU - Capitanio U AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Ventimiglia, Eugenio AU - Ventimiglia E AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Boeri, Luca AU - Boeri L AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Briganti, Alberto AU - Briganti A AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Colombo, Renzo AU - Colombo R AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Montorsi, Francesco AU - Montorsi F AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . FAU - Salonia, Andrea AU - Salonia A AD - 1 Universita Vita-Salute San Raffaele , Milan, Italy . AD - 2 Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele , Milan, Italy . LA - eng PT - Journal Article DEP - 20151230 PL - United States TA - J Endourol JT - Journal of endourology JID - 8807503 SB - IM CIN - J Urol. 2017 Oct;198(4):740-741. doi: 10.1016/j.juro.2017.07.002. PMID: 28905783 MH - Carcinoma, Transitional Cell/pathology/*surgery MH - Cystoscopy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Muscle, Smooth/pathology/*surgery MH - Neoplasm Staging MH - Retrospective Studies MH - Tumor Burden MH - Urinary Bladder Neoplasms/pathology/*surgery EDAT- 2015/11/26 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/11/25 06:00 PHST- 2015/11/25 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.1089/end.2015.0591 [doi] PST - ppublish SO - J Endourol. 2016 Apr;30(4):400-5. doi: 10.1089/end.2015.0591. Epub 2015 Dec 30. PMID- 26577765 OWN - NLM STAT- MEDLINE DCOM- 20160707 LR - 20220321 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 13 DP - 2015 Nov 14 TI - Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study. PG - 317 LID - 10.1186/s12957-015-0730-3 [doi] LID - 317 AB - BACKGROUND: RNA-binding motif protein 3 (RBM3), involved in cell survival, has paradoxically been linked to both oncogenesis as well as an increased survival in several cancers, including urothelial carcinoma (UCA). METHODS: The putative prognostic role of RBM3 was studied using cystectomy specimens with 152 invasive UCA with 35 matched metastases, 65 carcinomas in situ (CIS), 22 high-grade papillary UCAs (PAP), and 112 benign urothelium cases. RESULTS: The H-score (HS, staining intensity x % of positive cells) was used for RBM3 immunoexpression. CIS showed the highest HS (mean = 140) followed by benign urothelium (mean = 97). Metastases showed higher HS than primary invasive UCA (P /=T2) is generally associated with poor prognosis, constituting the second most common cause of death among genitourinary tumours. Due to high molecular heterogeneity significant variations in the natural history and disease outcome have been observed. This has also delayed the introduction of personalized therapeutics, making advanced stage bladder cancer almost an orphan disease in terms of treatment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen (STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are cancer-associated events that may hold potential for patient stratification and guided therapy. Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expression of Tn was residual and was not linked to stage or outcome, while STn was statically higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR pathway intermediates showed an equal distribution between non-muscle invasive bladder cancer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discriminating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Furthermore, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/mTOR pathway proteins in STn+ MIBC was independently associated with approximately 6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced bladder tumours mimicking the histological and molecular nature of human tumours were then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the number of invasive lesions and, concomitantly, the expression of STn and also pS6, the downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR pathway evaluation, holds potential to improve the stratification of stage disease. Animal experiments suggest that mTOR pathway inhibition could be a potential therapeutic approach for this specific subtype of MIBC. FAU - Costa, Ceu AU - Costa C AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal. AD - Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal. FAU - Pereira, Sofia AU - Pereira S AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal. AD - Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal. FAU - Lima, Luis AU - Lima L AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - Nucleo de Investigacao e Informacao em Farmacia - Centro de Investigacao em Saude e Ambiente (CISA), School of Allied Health Sciences - Polytechnic Institute of Oporto, Porto, Portugal. AD - Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), Porto, Portugal. FAU - Peixoto, Andreia AU - Peixoto A AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. FAU - Fernandes, Elisabete AU - Fernandes E AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. FAU - Neves, Diogo AU - Neves D AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. FAU - Neves, Manuel AU - Neves M AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. FAU - Gaiteiro, Cristiana AU - Gaiteiro C AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. FAU - Tavares, Ana AU - Tavares A AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - Department of Pathology, Portuguese Institute of Oncology, Porto, Portugal. FAU - Gil da Costa, Rui M AU - Gil da Costa RM AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - Faculty of Engineering, Laboratory for Process, Environment, Biotechnology and Energy Engineering (LEPABE), University of Porto, Porto, Portugal. FAU - Cruz, Ricardo AU - Cruz R AD - Department of Urology, Portuguese Institute of Oncology, Porto, Portugal. FAU - Amaro, Teresina AU - Amaro T AD - Department of Urology, Hospital Pedro Hispano, Matosinhos, Portugal. FAU - Oliveira, Paula A AU - Oliveira PA AD - Department of Veterinary Sciences, CITAB, University of Tras-os-Montes and Alto Douro, Vila Real, Portugal. FAU - Ferreira, Jose Alexandre AU - Ferreira JA AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - Mass Spectrometry Center of the University of Aveiro, Campus de Santiago, Aveiro, Portugal. FAU - Santos, Lucio L AU - Santos LL AD - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. Antonio Bernardino de Almeida, Porto, Portugal. AD - Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal. AD - Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151116 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antigens, Tumor-Associated, Carbohydrate) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (sialosyl-Tn antigen) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (AKT1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Animals MH - Antigens, Tumor-Associated, Carbohydrate/metabolism MH - Female MH - Gene Expression Regulation, Neoplastic MH - Glycosylation MH - Humans MH - Male MH - Mice MH - Mice, Inbred ICR MH - Middle Aged MH - Neoplasm Staging MH - Phosphatidylinositol 3-Kinases/*metabolism MH - Prognosis MH - Proportional Hazards Models MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Retrospective Studies MH - *Signal Transduction MH - TOR Serine-Threonine Kinases/*metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/*metabolism/mortality/*therapy PMC - PMC4646664 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/11/17 06:00 MHDA- 2016/06/24 06:00 PMCR- 2015/11/16 CRDT- 2015/11/17 06:00 PHST- 2015/07/28 00:00 [received] PHST- 2015/10/06 00:00 [accepted] PHST- 2015/11/17 06:00 [entrez] PHST- 2015/11/17 06:00 [pubmed] PHST- 2016/06/24 06:00 [medline] PHST- 2015/11/16 00:00 [pmc-release] AID - PONE-D-15-33076 [pii] AID - 10.1371/journal.pone.0141253 [doi] PST - epublish SO - PLoS One. 2015 Nov 16;10(11):e0141253. doi: 10.1371/journal.pone.0141253. eCollection 2015. PMID- 26568866 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151116 LR - 20220410 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 68 IP - 3 DP - 2015 TI - Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. PG - 278-83 LID - 10.5173/ceju.2015.620 [doi] AB - INTRODUCTION: Long-term outcomes of patients treated for invasive bladder cancer in Poland are poorly documented in the literature. Impact of various clinical parameters on their survival is even less well studied. Radical cystectomy is a major surgery, so the patients' condition can be equally important as cancer stage. The aim of the study was to assess 5-year overall survival (OS) after cystectomy and impact of comorbidity on OS in a single Polish academic centre. MATERIAL AND METHODS: Clinical data of all patients who underwent cystectomy in years 2004-2006 for urothelial cancer were retrospectively reviewed. Survival status was determined at least 5 years after surgery. Pathological variables, comorbidities, surgery delay and complications were evaluated as potential predictors of OS. Kaplan-Meier estimates of the survival function as well as Cox proportional hazards models were utilized. RESULTS: Thirty-day, 1-year and 5-year OS for 63 patients was 98.4%, 58.7% and 31.7%, respectively. None of the investigated parameters were significantly related to five-year OS. However, a composite parameter consisting of stage, diabetes status and postoperative course was found as a significant predictor. Five-year OS in 16 patients with pT1-2 and without diabetes and without post-operative complications was higher than in the remaining 47 patients (56% vs. 23%; P = 0.02). CONCLUSIONS: Five-year OS in our group was lower than in most published international series but concordant with a previous Polish report. Improvement in survival after radical cystectomy may be expected when early diagnosis will be accompanied by optimal care of patients with diabetes mellitus and avoidance of postoperative complications. FAU - Dybowski, Bartosz AU - Dybowski B AD - Department of Urology, Medical University of Warsaw, Poland. FAU - Ossolinski, Krzysztof AU - Ossolinski K AD - Department of Urology, Medical University of Warsaw, Poland. FAU - Ossolinska, Anna AU - Ossolinska A AD - Department of Urology, Medical University of Warsaw, Poland. FAU - Peller, Michal AU - Peller M AD - Department of Urology, Medical University of Warsaw, Poland. FAU - Bres-Niewada, Ewa AU - Bres-Niewada E AD - Department of Urology, Medical University of Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of Urology, Medical University of Warsaw, Poland. LA - eng PT - Journal Article DEP - 20151015 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC4643711 OTO - NOTNLM OT - bladder cancer OT - cystectomy OT - diabetes mellitus OT - lymphadenectomy OT - postoperative complications OT - survival EDAT- 2015/11/17 06:00 MHDA- 2015/11/17 06:01 PMCR- 2015/01/01 CRDT- 2015/11/17 06:00 PHST- 2015/04/14 00:00 [received] PHST- 2015/05/03 00:00 [revised] PHST- 2015/06/01 00:00 [accepted] PHST- 2015/11/17 06:00 [entrez] PHST- 2015/11/17 06:00 [pubmed] PHST- 2015/11/17 06:01 [medline] PHST- 2015/01/01 00:00 [pmc-release] AID - 00620 [pii] AID - 10.5173/ceju.2015.620 [doi] PST - ppublish SO - Cent European J Urol. 2015;68(3):278-83. doi: 10.5173/ceju.2015.620. Epub 2015 Oct 15. PMID- 26556239 OWN - NLM STAT- MEDLINE DCOM- 20160621 LR - 20221109 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 11 DP - 2015 TI - Diagnostic Ureterorenoscopy Is Associated with Increased Intravesical Recurrence following Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. PG - e0139976 LID - 10.1371/journal.pone.0139976 [doi] LID - e0139976 AB - Diagnostic ureterorenoscopy is powerful tool to confirm upper tract urothelial cancer (UTUC). However, URS and associated manipulation may be related to the risk of intravesical recurrence (IVR) following radical nephroureterectomy (RNU). We aimed to investigate whether preoperative ureterorenoscopy would increase IVR after RNU in patients with UTUC. We performed a retrospective analysis of 630 patients who had RNU with bladder cuff excision due to UTUC. Diagnostic URS was performed in 282 patients (44.7%). Patients were divided into two groups according to the URS. Survival analysis and multivariate Cox regression model were performed to address risk factors for the IVR. The interval from URS to RNU was measured. During URS, manipulation such as biopsy and resection was determined. The median age was 64 (IQR 56-72) years with follow-up duration of 34.3 (15.7-64.9) months. Median time from URS to RNU was 16 (0-38) days. The IVR developed in 42.5% (n = 268) patients at 8.2 (4.9-14.7) months. The five-year IVR-free survival rate was 42.6 +/- 8.0% and 63.6 +/- 6.9% in patients with and without preoperative URS, respectively (P < 0.001). In multivariate analysis, previous history of bladder tumour, extravesical excision of distal ureter, multifocal tumour, and URS (HR, 95% CI; 1.558, 1.204-2.016, P = 0.001) were independent predictors for higher IVR. The IVR rate in patients without manipulation during URS was not different to those with manipulation (P = 0.658). The duration from URS to RNU was not associated with IVR (P = 0.799). Diagnostic URS for UTUC increased IVR rate after RNU. However, the lessening of interval from URS to radical surgery or URS without any manipulation could not reduce the IVR rate. FAU - Sung, Hyun Hwan AU - Sung HH AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Hwang Gyun AU - Jeon HG AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Han, Deok Hyun AU - Han DH AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Byong Chang AU - Jeong BC AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Seo, Seong Il AU - Seo SI AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Hyun Moo AU - Lee HM AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Choi, Han-Yong AU - Choi HY AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Seong Soo AU - Jeon SS AD - Department of Urology, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151110 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/diagnosis/pathology/*secondary/surgery MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*etiology MH - *Neoplasm Seeding MH - Nephrectomy/*methods MH - Preoperative Care MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Ureter/pathology/*surgery MH - Ureteral Neoplasms/*pathology/surgery MH - Ureteroscopy/*adverse effects MH - Urinary Bladder Neoplasms/diagnosis/*secondary/surgery PMC - PMC4640521 COIS- Competing Interests: This study was supported by Samsung Medical Center, grant #CRS11115. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. EDAT- 2015/11/12 06:00 MHDA- 2016/06/22 06:00 PMCR- 2015/11/10 CRDT- 2015/11/12 06:00 PHST- 2015/04/16 00:00 [received] PHST- 2015/09/18 00:00 [accepted] PHST- 2015/11/12 06:00 [entrez] PHST- 2015/11/12 06:00 [pubmed] PHST- 2016/06/22 06:00 [medline] PHST- 2015/11/10 00:00 [pmc-release] AID - PONE-D-15-16256 [pii] AID - 10.1371/journal.pone.0139976 [doi] PST - epublish SO - PLoS One. 2015 Nov 10;10(11):e0139976. doi: 10.1371/journal.pone.0139976. eCollection 2015. PMID- 26555711 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20161230 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 96 IP - 1 DP - 2016 TI - The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage? PG - 46-50 LID - 10.1159/000440701 [doi] AB - BACKGROUND: Bacillus Calmette-Guerin (BCG) is the standard of care for adjuvant intravesical instillation therapy for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after complete transurethral resection. Increasing evidence suggests that there are marked differences in outcomes according to BCG substrains. BCG-Moreau was recently introduced to the European market to cover the issue of BCG shortage, but there are little data regarding the oncologic efficacy. METHODS: We retrospectively analyzed 295 consecutive patients, who received adjuvant intravesical instillation therapy with BCG-Moreau for intermediate- and high-risk NMIBC between October 2007 and April 2013 at a single institution. The end points of this study were time to first recurrence and progression to muscle-invasive disease. RESULTS: Median age was 66 years (interquartile range 59-74, mean 65.9 years). According to the EAU risk group, 76 patients presented with intermediate-risk and 219 patients with high-risk NMIBC. The 5-year recurrence-free survival and progression-free survival rate was 64.8% (95% CI 52.8-74.4) and 81.4% (95% CI 65.2-90.2), respectively. CONCLUSIONS: BCG-Moreau is an effective substrain for adjuvant instillation therapies of NMIBC, and outcomes appear to be comparable to series using other substrains. During worldwide shortage of BCG-TICE, Connaught and RIVM, BCG-Moreau may serve as an equally effective alternative. CI - (c) 2015 S. Karger AG, Basel. FAU - Hofbauer, Sebastian L AU - Hofbauer SL AD - Department of Urology, Medical University of Vienna and General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF FAU - Chade, Daher C AU - Chade DC FAU - Sarkis, Alvaro S AU - Sarkis AS FAU - Ribeiro-Filho, Leopoldo A AU - Ribeiro-Filho LA FAU - Nahas, Willian C AU - Nahas WC FAU - Klatte, Tobias AU - Klatte T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151111 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*supply & distribution/*therapeutic use MH - Chemotherapy, Adjuvant MH - Combined Modality Therapy MH - Disease Progression MH - Disease-Free Survival MH - Drug Administration Schedule MH - *Drug Substitution MH - Female MH - Health Services Accessibility MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/*surgery EDAT- 2015/11/12 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/11/12 06:00 PHST- 2015/07/27 00:00 [received] PHST- 2015/08/26 00:00 [accepted] PHST- 2015/11/12 06:00 [entrez] PHST- 2015/11/12 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 000440701 [pii] AID - 10.1159/000440701 [doi] PST - ppublish SO - Urol Int. 2016;96(1):46-50. doi: 10.1159/000440701. Epub 2015 Nov 11. PMID- 26543299 OWN - NLM STAT- MEDLINE DCOM- 20160726 LR - 20181113 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2015 DP - 2015 TI - CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. PG - 785461 LID - 10.1155/2015/785461 [doi] LID - 785461 AB - AIMS: CD73 is a membrane associated 5'-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course. METHODS: Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS). RESULTS: High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors (n = 158) was significantly associated with longer PFS (HR: 0.228; p = 0.047) in univariable Cox regression analysis. CONCLUSION: High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis. FAU - Wettstein, Marian S AU - Wettstein MS AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Buser, Lorenz AU - Buser L AD - Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Roudnicky, Filip AU - Roudnicky F AD - Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland. FAU - Eberli, Daniel AU - Eberli D AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Baumeister, Philipp AU - Baumeister P AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Sulser, Tullio AU - Sulser T AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Wild, Peter AU - Wild P AD - Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20151012 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (Biomarkers, Tumor) RN - EC 3.1.3.5 (5'-Nucleotidase) SB - IM MH - 5'-Nucleotidase/genetics/*metabolism MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics/*metabolism MH - Carcinoma/*metabolism/pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Urinary Bladder Neoplasms/*metabolism/pathology MH - Urothelium/metabolism/pathology PMC - PMC4620269 EDAT- 2015/11/07 06:00 MHDA- 2016/07/28 06:00 PMCR- 2015/10/12 CRDT- 2015/11/07 06:00 PHST- 2015/08/01 00:00 [received] PHST- 2015/09/27 00:00 [accepted] PHST- 2015/11/07 06:00 [entrez] PHST- 2015/11/07 06:00 [pubmed] PHST- 2016/07/28 06:00 [medline] PHST- 2015/10/12 00:00 [pmc-release] AID - 10.1155/2015/785461 [doi] PST - ppublish SO - Dis Markers. 2015;2015:785461. doi: 10.1155/2015/785461. Epub 2015 Oct 12. PMID- 26537069 OWN - NLM STAT- MEDLINE DCOM- 20160107 LR - 20250711 IS - 1107-0625 (Print) IS - 1107-0625 (Linking) VI - 20 IP - 5 DP - 2015 Sep-Oct TI - Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis. PG - 1229-38 AB - PURPOSE: A high incidence of bladder tumor (BT) occurs after radical nephroureterectomy (NU) for primary upper tract urothelial carcinoma (UTUC). Although some studies have shown that prophylactic intravesical chemotherapy could prevent BT recurrence, it has not become standard practice at this stage. The purpose of this study was to evaluate the effect of intravesical instillation chemotherapy in preventing BT recurrence in patients with primary UTUC after nephroureterectomy. METHODS: A comprehensive literature search was performed in July 2014 using the Medline, Embase, and Cochrane Library databases, as well as the China National Knowledge Infrastructure and Wanfang Data. All clinical trials compared the effect of prophylactic intravesical chemotherapy after radical NU for primary UTUC. Analysis was performed using the Stata 12.0 SE software. RESULTS: Eight trials were analyzed with a total of 979 patients including 521 patients receiving intravesical chemotherapy instillation and 458 without instillation. The BT incidence rate was 125 out of 521 patients (24.0%) with intravesical instillation chemotherapy after NU, and 169 out of 458 patients (36.9%) without intravesical chemotherapy after NU. Compared with those who didn't receive instillation, the pooled odds ratio (OR) of BT recurrence was 0.45 (95% confidence interval/CI 0.34-0.61, p<0.0001) in instillation patients. In the sub-analyses, the OR of single instillation was similar to repeated instillations (0.48 and 0.42). The OR of beginning the first instillation within 24 hrs, 48 hrs and 2 weeks was 0.34, 0.48 and 0.46, respectively. CONCLUSIONS: This systematic review demonstrates that prophylactic intravesical instillation chemotherapy can prevent BT recurrence in primary UTUC patients after NU. It also suggests that single instillation may have a similar effect to repeated instillations. The first instillation beginning within 24 hrs seems to show lower BT recurrence than at 48 hrs or 2 weeks. However, given that some limitations exist, well-designed randomized controlled trials are needed to further evaluate these results. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China. FAU - Zhu, Gang AU - Zhu G FAU - Wei, Dong AU - Wei D FAU - Liu, Shengjie AU - Liu S FAU - Walsh, Kilian AU - Walsh K FAU - Li, Ding AU - Li D FAU - Harron, Usman AU - Harron U FAU - Wang, Xiaoming AU - Wang X FAU - Ma, Hong AU - Ma H FAU - Wan, Ben AU - Wan B FAU - Sun, Liang AU - Sun L FAU - Yang, Ze AU - Yang Z FAU - Wang, Jianye AU - Wang J LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - Cyprus TA - J BUON JT - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JID - 100883428 RN - 0 (Antineoplastic Agents) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage MH - Humans MH - Neoplasm Recurrence, Local/*prevention & control MH - *Nephrectomy MH - Randomized Controlled Trials as Topic MH - Ureter/*surgery MH - Urinary Bladder Neoplasms/*prevention & control MH - Urologic Neoplasms/*surgery EDAT- 2015/11/06 06:00 MHDA- 2016/01/08 06:00 CRDT- 2015/11/06 06:00 PHST- 2015/11/06 06:00 [entrez] PHST- 2015/11/06 06:00 [pubmed] PHST- 2016/01/08 06:00 [medline] PST - ppublish SO - J BUON. 2015 Sep-Oct;20(5):1229-38. PMID- 26523878 OWN - NLM STAT- MEDLINE DCOM- 20170104 LR - 20170105 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 195 IP - 4 Pt 1 DP - 2016 Apr TI - Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. PG - 872-9 LID - S0022-5347(15)05162-9 [pii] LID - 10.1016/j.juro.2015.10.139 [doi] AB - PURPOSE: Although cigarette smoking is a well established risk factor for urothelial cancer, its role in urothelial cancer prognosis is still undetermined. In this meta-analysis we quantify the role of lifetime smoking history in bladder cancer recurrence, progression and survival by pooling available data on nonmuscle invasive bladder cancer, muscle invasive bladder cancer and upper tract urothelial carcinoma. MATERIALS AND METHODS: A total of 24 studies, comprising data from 13,114 patients with bladder cancer and 2,259 patients with upper tract urothelial carcinoma, were included in this meta-analysis. Publication bias was addressed through Egger's test, and the heterogeneity among studies was assessed by the I(2) test statistic and subgroup analyses. RESULTS: Current smokers at diagnosis are at increased risk for local recurrence in nonmuscle invasive bladder cancer (HR 1.27, 95% CI 1.09-1.46) and smokers with muscle invasive bladder cancer have an increased risk of dying of bladder cancer (HR 1.23, 95% CI 1.02-1.44). In the upper tract urothelial carcinoma population smokers have an increased risk of recurrence in the operative bed (HR 1.57, 95% CI 1.19-1.95) and of death from upper tract urothelial carcinoma (HR 1.53, 95% CI 1.13-1.92). We did not identify significant heterogeneity among included studies. CONCLUSIONS: The body of evidence is limited due to the absence of prospective studies. However, the results from this meta-analysis unambiguously support the hypothesis that lifetime cigarette smokers are at increased risk for a more malignant type of urothelial carcinoma associated with a worse prognosis. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - van Osch, Frits H M AU - van Osch FH AD - Department of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: f.vanosch@maastrichtuniversity.nl. FAU - Jochems, Sylvia H J AU - Jochems SH AD - Department of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - van Schooten, Frederik J AU - van Schooten FJ AD - Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Bryan, Richard T AU - Bryan RT AD - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. FAU - Zeegers, Maurice P AU - Zeegers MP AD - Department of Complex Genetics, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20151031 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Carcinoma, Transitional Cell/*etiology MH - Disease Progression MH - Humans MH - Kidney Neoplasms/*etiology MH - Smoking/*adverse effects MH - Time Factors MH - Ureteral Neoplasms/*etiology MH - Urinary Bladder Neoplasms/*etiology OTO - NOTNLM OT - carcinoma OT - meta-analysis OT - prognosis OT - smoking OT - transitional cell OT - urinary bladder neoplasms EDAT- 2015/11/03 06:00 MHDA- 2017/01/05 06:00 CRDT- 2015/11/03 06:00 PHST- 2015/10/26 00:00 [accepted] PHST- 2015/11/03 06:00 [entrez] PHST- 2015/11/03 06:00 [pubmed] PHST- 2017/01/05 06:00 [medline] AID - S0022-5347(15)05162-9 [pii] AID - 10.1016/j.juro.2015.10.139 [doi] PST - ppublish SO - J Urol. 2016 Apr;195(4 Pt 1):872-9. doi: 10.1016/j.juro.2015.10.139. Epub 2015 Oct 31. PMID- 26521718 OWN - NLM STAT- MEDLINE DCOM- 20170104 LR - 20260518 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 195 IP - 4 Pt 1 DP - 2016 Apr TI - Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? PG - 886-93 LID - S0022-5347(15)05153-8 [pii] LID - 10.1016/j.juro.2015.10.133 [doi] AB - PURPOSE: We assessed survival dependent on pathological response after neoadjuvant chemotherapy in a large multicenter patient cohort, with a particular focus on the difference between the absence of residual cancer (pT0) and the presence of only nonmuscle invasive residual cancer (pTa, pTis, pT1). MATERIALS AND METHODS: We retrospectively reviewed records of patients with urothelial cancer who received neoadjuvant chemotherapy and underwent radical cystectomy at 19 contributing institutions from 2000 to 2013. Patients with cT2-4aN0M0 and eventual pN0 disease were selected for this analysis. Estimated overall survival was compared between patients with pT0 and pTa/Tis/T1 disease. A multivariable Cox proportional hazards regression model for overall survival was generated to evaluate hazard ratios for variables of interest. RESULTS: Of 1,543 patients treated with neoadjuvant chemotherapy and radical cystectomy during the study period 257 had pT0N0 and 207 had pTa/Tis/T1N0 disease. The Kaplan-Meier mean estimates of overall survival for pT0 and pTa/Tis/T1 cases were 186.7 months (95% CI 145.9-227.6, median 241.1) and 138 months (95% CI 118.2-157.8, median 187.4), respectively (p=0.58). In the Cox proportional hazards regression model for overall survival pTa/Tis/T1N0 status (HR 0.36, 95% CI 0.23-0.67) and pT0N0 status (HR 0.28, 95% CI 0.17-0.47) compared to pT2N0 pathology, positive surgical margin (HR 1.75, 95% CI 1.07-2.86), and receiving a methotrexate, vinblastine, doxorubicin and cisplatin regimen compared to an "other" regimen (HR 0.45, 95% CI 0.27-0.76) were predictors of overall survival. CONCLUSIONS: pTa/Tis/T1N0 and pT0N0 stage on the final cystectomy specimen are strong predictors of survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. We did not discern a statistically significant difference in overall survival when comparing these 2 end points. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Zargar, Homayoun AU - Zargar H AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. FAU - Zargar-Shoshtari, Kamran AU - Zargar-Shoshtari K AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Shah, Jay B AU - Shah JB AD - Department of Urology, MD Anderson Cancer Center, Houston, Texas. FAU - van Rhijn, Bas W AU - van Rhijn BW AD - Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Daneshmand, Siamak AU - Daneshmand S AD - USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. FAU - Black, Peter AU - Black P AD - Vancouver Prostate Centre, Vancouver, British Columbia, Canada. Electronic address: pblack@mail.ubc.ca. CN - Collaborators LA - eng PT - Comparative Study PT - Journal Article DEP - 20151029 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Antineoplastic Agents) SB - IM CIN - J Urol. 2016 Apr;195(4 Pt 1):892. doi: 10.1016/j.juro.2015.10.185. PMID: 26777240 CIN - J Urol. 2016 Apr;195(4 Pt 1):892-3. doi: 10.1016/j.juro.2015.10.186. PMID: 26777241 CIN - J Urol. 2016 Apr;195(4 Pt 1):891-2. doi: 10.1016/j.juro.2015.10.184. PMID: 26777242 MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - *Cystectomy/methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - cystectomy OT - drug therapy OT - neoadjuvant therapy OT - urinary bladder neoplasms FIR - Fairey, Adrian S IR - Fairey AS FIR - Mertens, Laura S IR - Mertens LS FIR - Horenblas, Simon IR - Horenblas S FIR - Dinney, Colin P IR - Dinney CP FIR - Mir, Maria C IR - Mir MC FIR - Ercole, Cesar E IR - Ercole CE FIR - Stephenson, Andrew J IR - Stephenson AJ FIR - Krabbe, Laura-Maria IR - Krabbe LM FIR - Cookson, Michael S IR - Cookson MS FIR - Jacobsen, Niels-Erik IR - Jacobsen NE FIR - Barocas, Daniel A IR - Barocas DA FIR - Griffin, Joshua IR - Griffin J FIR - Holzbeierlein, Jeff M IR - Holzbeierlein JM FIR - Montgomery, Jeffrey S IR - Montgomery JS FIR - Morgan, Todd M IR - Morgan TM FIR - Vasdev, Nikhil IR - Vasdev N FIR - Thorpe, Andrew C IR - Thorpe AC FIR - Aning, Jonathan IR - Aning J FIR - Yu, Evan Y IR - Yu EY FIR - Wright, Jonathan L IR - Wright JL FIR - Xylinas, Evanguelos IR - Xylinas E FIR - Campain, Nicholas J IR - Campain NJ FIR - Pourmalek, Farshad IR - Pourmalek F FIR - McGrath, John S IR - McGrath JS FIR - Kassouf, Wassim IR - Kassouf W FIR - Dall'Era, Marc A IR - Dall'Era MA FIR - Seah, Jo-An IR - Seah JA FIR - Sridhar, Srikala S IR - Sridhar SS FIR - Sharma, Pranav IR - Sharma P FIR - Shariat, Shahrokh F IR - Shariat SF FIR - North, Scott IR - North S FIR - Grivas, Petros IR - Grivas P FIR - Gandhi, Nilay IR - Gandhi N FIR - Bivalacqua, Trinity J IR - Bivalacqua TJ EDAT- 2015/11/03 06:00 MHDA- 2017/01/05 06:00 CRDT- 2015/11/03 06:00 PHST- 2015/10/23 00:00 [accepted] PHST- 2015/11/03 06:00 [entrez] PHST- 2015/11/03 06:00 [pubmed] PHST- 2017/01/05 06:00 [medline] AID - S0022-5347(15)05153-8 [pii] AID - 10.1016/j.juro.2015.10.133 [doi] PST - ppublish SO - J Urol. 2016 Apr;195(4 Pt 1):886-93. doi: 10.1016/j.juro.2015.10.133. Epub 2015 Oct 29. PMID- 26520419 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20151215 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 47 IP - 1 DP - 2016 Jan TI - Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. PG - 20-5 LID - S0046-8177(15)00344-5 [pii] LID - 10.1016/j.humpath.2015.09.007 [doi] AB - To assess the clinicopathological features and prognostic significance of the presence of 5% or less high-grade component in otherwise low-grade noninvasive bladder urothelial carcinoma, referred to as mixed-grade (MG) urothelial carcinoma, we reviewed all archival cases with such diagnosis between 2005 and 2014. Clinicopathological and outcome parameters were compared to those in our previously reported low- and high-grade noninvasive bladder urothelial carcinoma cohorts (LGUC and HGUC, respectively). The study included 31 MG urothelial carcinomas. Mean patient age was 67.6 years, and mean follow-up was 39.7 months. Intravesical treatment was administered in 15 patients (48.4%). Recurrence occurred in 14 cases (45.2%): 10 as LGUC and 4 as HGUC; there was no stage progression. Mean time to progression was 9 months (5-17 months), and there was no death of disease. MG urothelial carcinoma stage progression and dead of disease rates were comparable to that of LGUC. MG urothelial carcinoma stage progression was significantly lower than that of HGUC, P = .002, using Pearson chi(2) test. MG urothelial carcinoma patients with no intravesical treatment had higher incidence rate of grade progression (25%) compared to LGUC patients (7.9%); however, the difference was not statistically significant. MG urothelial carcinoma had a prognosis closer to "pure" LGUC than "pure" HGUC. Untreated MG urothelial carcinoma may have a higher rate of grade progression than LGUC, although more data are needed before this issue can be definitively addressed. Until such data are available, it is reasonable to keep MG urothelial carcinoma as a distinct grade category with potential management implications. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Reis, Leonardo O AU - Reis LO AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD; Urology, Johns Hopkins Medical Institution, Baltimore, MD. FAU - Taheri, Diana AU - Taheri D AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD; Isfahan University of Medical Sciences, Isfahan Kidney Diseases Research Center, Isfahan, Iran. FAU - Chaux, Alcides AU - Chaux A AD - Department of Scientific Research, Norte University, Asuncion, 1614, Paraguay. FAU - Guner, Gunes AU - Guner G AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD. FAU - Mendoza Rodriguez, Maria A AU - Mendoza Rodriguez MA AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD. FAU - Bivalacqua, Trinity J AU - Bivalacqua TJ AD - Urology, Johns Hopkins Medical Institution, Baltimore, MD; Oncology, Johns Hopkins Medical Institution, Baltimore, MD. FAU - Schoenberg, Mark P AU - Schoenberg MP AD - Department of Urology, Montefiore Medical Center, The Albert Einstein College of Medicine, Bronx, NY. FAU - Epstein, Jonathan I AU - Epstein JI AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD; Urology, Johns Hopkins Medical Institution, Baltimore, MD. FAU - Netto, George J AU - Netto GJ AD - Pathology, Johns Hopkins Medical Institution, Baltimore, MD; Urology, Johns Hopkins Medical Institution, Baltimore, MD. Electronic address: gnetto1@jhmi.edu. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150925 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - BCG Vaccine/administration & dosage MH - Carcinoma, Papillary/mortality/*pathology/therapy MH - Chemotherapy, Adjuvant MH - Chi-Square Distribution MH - Cystectomy MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Odds Ratio MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/*pathology/therapy MH - Urothelium/*pathology OTO - NOTNLM OT - High grade OT - Intravesical treatment OT - Low grade OT - Mixed OT - Non-invasive urothelial carcinoma OT - Progression OT - pTa EDAT- 2015/11/02 06:00 MHDA- 2016/04/19 06:00 CRDT- 2015/11/02 06:00 PHST- 2015/06/22 00:00 [received] PHST- 2015/08/20 00:00 [revised] PHST- 2015/09/02 00:00 [accepted] PHST- 2015/11/02 06:00 [entrez] PHST- 2015/11/02 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] AID - S0046-8177(15)00344-5 [pii] AID - 10.1016/j.humpath.2015.09.007 [doi] PST - ppublish SO - Hum Pathol. 2016 Jan;47(1):20-5. doi: 10.1016/j.humpath.2015.09.007. Epub 2015 Sep 25. PMID- 37559287 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230810 IS - 2352-0787 (Electronic) IS - 2352-0779 (Linking) VI - 2 IP - 6 DP - 2015 Nov TI - Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer? PG - 335-342 LID - 10.1016/j.urpr.2015.02.003 [doi] AB - INTRODUCTION: Interest on the impact of variant histology in bladder cancer prognosis is increasing. Although squamous differentiation is the most well characterized, only recently have less common variants gained increased recognition. We assessed whether squamous differentiation conferred a worse prognosis than nonvariant urothelial bladder cancer in a contemporary cohort of patients treated with radical cystectomy given the increased awareness of other less common variants. METHODS: We identified patients with squamous differentiation or nonvariant histology on transurethral resection of bladder tumor and/or cystectomy pathology during a 10-year period. Disease specific and overall survival were evaluated using Kaplan-Meier methodology. Cox regression was used to assess variables associated with mortality. RESULTS: Between 2003 and 2013, 934 patients underwent cystectomy for urothelial bladder cancer. Overall 617 nonvariant and 118 squamous differentiation cases were identified, and the remainder was nonsquamous differentiation variant histology. Overall 75% of patients with squamous differentiation had muscle invasive disease at diagnosis compared with 59% of those with nonvariant histology (p=0.002). Nonorgan confined disease at cystectomy was more common in patients with squamous differentiation (57% vs 44%, p=0.009). Among cases on neoadjuvant chemotherapy 20% (9 of 45) of nonvariant and 13% (1 of 8) of squamous differentiation were pT0N0 (p=0.527). Median followup was 52 months. Adjusted for demographics, pathological stage and chemotherapy, squamous differentiation was not associated with an increased risk of disease specific (HR 1.35, 95% CI 0.90-2.04, p=0.150) or all cause mortality (HR 0.90, 95% CI 0.60-1.25, p=0.515). CONCLUSIONS: In a contemporary cohort of urothelial bladder cancer with recognition and characterization of less commonly described variants, squamous differentiation is not associated with a worse disease specific and all cause mortality when compared to a pure nonvariant cohort. FAU - Yang, David Y AU - Yang DY AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Monn, M Francesca AU - Monn MF AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Kaimakliotis, Hristos Z AU - Kaimakliotis HZ AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Cho, Jane S AU - Cho JS AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Cary, K Clint AU - Cary KC AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Pedrosa, Jose A AU - Pedrosa JA AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Bihrle, Richard AU - Bihrle R AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Koch, Michael O AU - Koch MO AD - Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. LA - eng PT - Journal Article DEP - 20150902 PL - United States TA - Urol Pract JT - Urology practice JID - 101635343 SB - IM OTO - NOTNLM OT - carcinoma OT - cystectomy OT - outcome assessment (health care) OT - pathology OT - surgical OT - transitional cell OT - urinary bladder neoplasms EDAT- 2015/11/01 00:00 MHDA- 2015/11/01 00:01 CRDT- 2023/08/10 01:05 PHST- 2015/11/01 00:01 [medline] PHST- 2015/11/01 00:00 [pubmed] PHST- 2023/08/10 01:05 [entrez] AID - 10.1016/j.urpr.2015.02.003 [doi] PST - ppublish SO - Urol Pract. 2015 Nov;2(6):335-342. doi: 10.1016/j.urpr.2015.02.003. Epub 2015 Sep 2. PMID- 26517683 OWN - NLM STAT- MEDLINE DCOM- 20160927 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 39 DP - 2015 Dec 8 TI - A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. PG - 42258-75 LID - 10.18632/oncotarget.5546 [doi] AB - Bladder cancer (BC) is a highly prevalent disease, ranking fifth in the most common cancers worldwide. Various miRNAs have recently emerged as potential prognostic biomarkers in cancer. The miR-200 family, which repressed the epithelial-to-mesenchymal transition (EMT), is repressed in multiple advanced cancers. However, its expression and function in BC is still poorly understood. Here we show that miR-200 family displays increased expression, probably due to the activation of specific oncogenic signaling pathways, and reduced promoter methylation, in BC compared to normal bladder samples. Furthermore, we show that the expression of these miRNAs is decreased in high grade and stage tumors, and the down-regulation is associated with patient's poor clinical outcome. Our data indicate that the miR-200 family plays distinct roles in Non-Muscle (NMIBC) and Muscle-Invasive BC (MIBC). In MIBC, miR-200 expression post transcriptionally regulates EMT-promoting transcription factors ZEB1 and ZEB2, whereas suppresses BMI1 expression in NMIBC. Interestingly, we show that increased EZH2 and/or BMI1 expression repress the expression of miR-200 family members. Collectively, these findings support a model of BC progression through a coordinated action between the Polycomb Repression Complex (PRC) members repressing the miR-200 expression, which ultimately favors invasive BC development. Since pharmacological inhibition of EZH2 in BC cell lines lead to increased miR-200 expression, our findings may support new therapeutic strategies for BC clinical management. FAU - Martinez-Fernandez, Monica AU - Martinez-Fernandez M AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Duenas, Marta AU - Duenas M AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Feber, Andrew AU - Feber A AD - Medical Genomics, UCL Cancer Institute, University College London, London WC1E 6BT, UK. FAU - Segovia, Cristina AU - Segovia C AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Garcia-Escudero, Ramon AU - Garcia-Escudero R AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Rubio, Carolina AU - Rubio C AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Lopez-Calderon, Fernando F AU - Lopez-Calderon FF AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - Diaz-Garcia, Claudio AU - Diaz-Garcia C AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. FAU - Villacampa, Felipe AU - Villacampa F AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. AD - Uro-oncology Section, Universitary Hospital 12 de Octubre, 28041 Madrid, Spain. FAU - Duarte, Jose AU - Duarte J AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. AD - Uro-oncology Section, Universitary Hospital 12 de Octubre, 28041 Madrid, Spain. FAU - Gomez-Rodriguez, Maria J AU - Gomez-Rodriguez MJ AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. AD - Uro-oncology Section, Universitary Hospital 12 de Octubre, 28041 Madrid, Spain. FAU - Castellano, Daniel AU - Castellano D AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. AD - Uro-oncology Section, Universitary Hospital 12 de Octubre, 28041 Madrid, Spain. FAU - Rodriguez-Peralto, Jose L AU - Rodriguez-Peralto JL AD - Anatomic Pathology Service, Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. FAU - de la Rosa, Federico AU - de la Rosa F AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. AD - Uro-oncology Section, Universitary Hospital 12 de Octubre, 28041 Madrid, Spain. FAU - Beck, Stephan AU - Beck S AD - Medical Genomics, UCL Cancer Institute, University College London, London WC1E 6BT, UK. FAU - Paramio, Jesus M AU - Paramio JM AD - Molecular Oncology Unit, CIEMAT (ed70A), 28040 Madrid, Spain. AD - Universitary Hospital 12 de Octubre, Research Institute 12 de Octubre i+12, 28041 Madrid, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (BMI1 protein, human) RN - 0 (Homeodomain Proteins) RN - 0 (MIRN200 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Polycomb-Group Proteins) RN - 0 (Repressor Proteins) RN - 0 (Transcription Factors) RN - 0 (ZEB1 protein, human) RN - 0 (ZEB2 protein, human) RN - 0 (Zinc Finger E-box Binding Homeobox 2) RN - 0 (Zinc Finger E-box-Binding Homeobox 1) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) RN - EC 2.1.1.43 (Polycomb Repressive Complex 2) RN - EC 2.3.2.27 (Polycomb Repressive Complex 1) SB - IM MH - Aged MH - Aged, 80 and over MH - Blotting, Western MH - Cell Line, Tumor MH - DNA Methylation MH - Enhancer of Zeste Homolog 2 Protein MH - Epithelial-Mesenchymal Transition/genetics MH - Female MH - Gene Expression Profiling/*methods MH - *Gene Expression Regulation, Neoplastic MH - Homeodomain Proteins/genetics/metabolism MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Polycomb Repressive Complex 1/genetics/metabolism MH - Polycomb Repressive Complex 2/genetics/metabolism MH - Polycomb-Group Proteins/*genetics/metabolism MH - Prognosis MH - Repressor Proteins/genetics/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Signal Transduction/genetics MH - Transcription Factors/genetics/metabolism MH - Urinary Bladder Neoplasms/*genetics/metabolism/pathology MH - Zinc Finger E-box Binding Homeobox 2 MH - Zinc Finger E-box-Binding Homeobox 1 PMC - PMC4747223 OTO - NOTNLM OT - Polycomb OT - bladder cancer OT - epigenetics OT - miRNA OT - recurrence COIS- CONFLICTS OF INTEREST No potential conflicts of interest were disclosed. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. EDAT- 2015/10/31 06:00 MHDA- 2016/09/28 06:00 PMCR- 2015/12/08 CRDT- 2015/10/31 06:00 PHST- 2015/05/27 00:00 [received] PHST- 2015/10/04 00:00 [accepted] PHST- 2015/10/31 06:00 [entrez] PHST- 2015/10/31 06:00 [pubmed] PHST- 2016/09/28 06:00 [medline] PHST- 2015/12/08 00:00 [pmc-release] AID - 5546 [pii] AID - 10.18632/oncotarget.5546 [doi] PST - ppublish SO - Oncotarget. 2015 Dec 8;6(39):42258-75. doi: 10.18632/oncotarget.5546. PMID- 26513586 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20220330 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 96 IP - 1 DP - 2016 TI - Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. PG - 51-6 LID - 10.1159/000440889 [doi] AB - OBJECTIVES: To retrospectively evaluate the value of CT for lymph node (LN) staging in bladder cancer. METHODS: Two uroradiologists reviewed CT scans of 231 patients who underwent radical cystectomy and pelvic lymphadenectomy according to a predefined 12-field template. A 5-step model was used to grade the radiological likelihood of a LN to represent malignant spread based on size, configuration and structure as well as regional clustering. Statistical analyses were performed both on patient- and field-based levels. RESULTS: LN metastases were found in 59 of 231 patients (25.5%). On a patient-based level, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were 52.6, 93.6, 73.2, 85.6 and 83.4%, respectively. Using the field-based approach, a total of 1,649 anatomical fields were evaluable, of which 114 fields showed malignancy (6.9%). On a field basis, sensitivity, specificity, PPV, NPV and accuracy were 30.2, 98, 51.5, 94.5 and 93.3%, respectively. Concerning local staging (pT category), the overall accuracy was 78%; overstaging occurred in 6% and understaging in 16%. CONCLUSIONS: In line with prior studies, the sensitivity of CT imaging for the detection of LN metastases was low, while high values for specificity were achieved. This was further underlined by analyzing standardized anatomical fields. Concerning local staging, postoperative changes after TURB-T rarely led to overstaging. CI - (c) 2015 S. Karger AG, Basel. FAU - Horn, Thomas AU - Horn T AD - Department of Urology, Klinikum Rechts der Isar, Technische Universitx00E4;t Mx00FC;nchen, Munich, Germany. FAU - Zahel, Tina AU - Zahel T FAU - Adt, Nathanja AU - Adt N FAU - Schmid, Sebastian C AU - Schmid SC FAU - Heck, Matthias M AU - Heck MM FAU - Thalgott, Mark K AU - Thalgott MK FAU - Hatzichristodoulou, Georgios AU - Hatzichristodoulou G FAU - Haller, Bernhard AU - Haller B FAU - Autenrieth, Michael AU - Autenrieth M FAU - Kubler, Hubert R AU - Kubler HR FAU - Gschwend, Jurgen E AU - Gschwend JE FAU - Holzapfel, Konstantin AU - Holzapfel K FAU - Maurer, Tobias AU - Maurer T LA - eng PT - Journal Article DEP - 20151030 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Cystectomy MH - Data Interpretation, Statistical MH - Diagnostic Errors/prevention & control MH - Humans MH - Lymph Nodes/pathology MH - Lymphatic Metastasis MH - Middle Aged MH - Neoplasm Staging/*methods MH - Observer Variation MH - Predictive Value of Tests MH - Preoperative Period MH - Radiographic Image Interpretation, Computer-Assisted MH - Reproducibility of Results MH - Retrospective Studies MH - *Tomography, X-Ray Computed MH - Urinary Bladder Neoplasms/*diagnostic imaging/*surgery EDAT- 2015/10/30 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/10/30 06:00 PHST- 2015/05/18 00:00 [received] PHST- 2015/09/07 00:00 [accepted] PHST- 2015/10/30 06:00 [entrez] PHST- 2015/10/30 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 000440889 [pii] AID - 10.1159/000440889 [doi] PST - ppublish SO - Urol Int. 2016;96(1):51-6. doi: 10.1159/000440889. Epub 2015 Oct 30. PMID- 26511817 OWN - NLM STAT- MEDLINE DCOM- 20180308 LR - 20181202 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 48 IP - 2 DP - 2016 Apr TI - Conditional Survival and Associated Prognostic Factors in Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Retrospective Study at a Single Institution. PG - 621-31 LID - 10.4143/crt.2015.220 [doi] AB - PURPOSE: The purpose of this study is to evaluate the changes of conditional survival (CS) probabilities and to identify the prognostic parameters that significantly affect CS over time post-surgery in upper tract urothelial carcinoma (UTUC) patients. MATERIALS AND METHODS: A total of 330 patients were examined in the final analysis. Primary end point was conditional cancer-specific survival (CSS), overall survival (OS), and intravesical recurrence-free survival (IVRFS) after surgery. The Kaplan-Meier method was used for calculation of CS. Cox regression hazard ratio model was used to determine the predictors of CS. RESULTS: UTUC patients who had already survived 5 years after radical nephroureterectomy had a more favorable CS probability in all given survivorships compared to those with shorter survival times. Patients with unfavorable pathologic features showed a higher increment of 5-year conditional CSS and OS compared to their counterparts. For 5-year conditional CSS, several factors, including high-grade tumor, lymphovascular invasion, and tumor location showed significant association with risk elevation over time. Only age remained as a predictor of 5-year conditional OS with increased risk in all given survivorships. For 5-year IVRFS, no variables remained as significant predictive factors over time after surgery. CONCLUSION: Our study provides valuable information for practical survival estimation and relevant prognostic factors for patients with UTUC after surgery. FAU - Kang, Minyong AU - Kang M AD - Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University Hospital, Seoul, Korea. LA - eng PT - Journal Article DEP - 20150909 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Carcinoma, Transitional Cell/physiopathology/*surgery MH - Humans MH - Nephrectomy MH - Prognosis MH - Retrospective Studies MH - Urologic Neoplasms/physiopathology/*surgery PMC - PMC4843715 OTO - NOTNLM OT - Conditional variables OT - Survival OT - Transitional cell carcinoma OT - Urinary tract OT - Urologic surgical procedures COIS- Conflict of interest relevant to this article was not reported. EDAT- 2015/10/30 06:00 MHDA- 2018/03/09 06:00 PMCR- 2016/04/01 CRDT- 2015/10/30 06:00 PHST- 2015/06/19 00:00 [received] PHST- 2015/08/21 00:00 [accepted] PHST- 2015/10/30 06:00 [entrez] PHST- 2015/10/30 06:00 [pubmed] PHST- 2018/03/09 06:00 [medline] PHST- 2016/04/01 00:00 [pmc-release] AID - crt.2015.220 [pii] AID - crt-2015-220 [pii] AID - 10.4143/crt.2015.220 [doi] PST - ppublish SO - Cancer Res Treat. 2016 Apr;48(2):621-31. doi: 10.4143/crt.2015.220. Epub 2015 Sep 9. PMID- 26497823 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20220408 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 34 IP - 6 DP - 2016 Jun TI - Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma. PG - 859-69 LID - 10.1007/s00345-015-1712-3 [doi] AB - PURPOSE: To compare survival outcomes between laparoscopic radical nephroureterectomy (LRNU) and open radical nephroureterectomy (ORNU) in upper urinary tract urothelial carcinoma (UTUC) patients. METHODS: We retrospectively analyzed the data of 371 UTUC patients who underwent ORNU (n = 271) or LRNU (n = 100) between 1992 and 2012. The survival outcomes included intravesical recurrence (IVR)-free survival, overall survival (OS), and cancer-specific survival (CSS). The Kaplan-Meier method and log-rank test were used to estimate and compare survival curves between groups. Factors associated with survival outcomes were evaluated using univariable and multivariable Cox proportional hazard models. RESULTS: The three-year IVR-free survival rates were similar between the ORNU and LRNU groups (59.9 and 61.7 %, p = 0.267). However, the LRNU group showed worse five-year OS (59.1 vs. 75.2 %, p = 0.027) and CSS (66.1 vs. 80.2 %, p = 0.015) rates than the ORNU group. In particular, on stratifying the study cohort by pathological stages, significant differences in OS (p = 0.007) and CSS (p = 0.005) between the surgical approaches were observed only in locally advanced disease (pT3/T4). In multivariable analysis, LRNU was an independent predictor of worse OS (p = 0.001) and CSS (p = 0.006) than ORNU. Likewise, in multivariable analysis in patients with pT3/T4 stage, LRNU was significantly associated with worse OS (hazard ratio [HR] 2.59, p = 0.001) and CSS (HR 2.50, p = 0.005). CONCLUSIONS: Our data suggest that in UTUC patients, LRNU, compared to ORNU, is generally associated with unfavorable OS and CSS results. In particular, LRNU should be performed in locally advanced UTUC patients after careful consideration of its impact on patient survival. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University College of Medicine, Seoul, Korea. hhkim@snu.ac.kr. AD - Department of Urology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. hhkim@snu.ac.kr. LA - eng PT - Comparative Study PT - Journal Article DEP - 20151023 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - Female MH - Humans MH - Kidney Neoplasms/*mortality/pathology/*surgery MH - *Laparoscopy MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Nephrectomy/*methods MH - Retrospective Studies MH - Survival Rate MH - Ureter/*surgery MH - Ureteral Neoplasms/*mortality/pathology/*surgery OTO - NOTNLM OT - Laparoscopic OT - Open OT - Radical nephroureterectomy OT - Survival OT - Upper tract urothelial carcinoma EDAT- 2015/10/27 06:00 MHDA- 2017/04/19 06:00 CRDT- 2015/10/27 06:00 PHST- 2015/09/03 00:00 [received] PHST- 2015/10/10 00:00 [accepted] PHST- 2015/10/27 06:00 [entrez] PHST- 2015/10/27 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] AID - 10.1007/s00345-015-1712-3 [pii] AID - 10.1007/s00345-015-1712-3 [doi] PST - ppublish SO - World J Urol. 2016 Jun;34(6):859-69. doi: 10.1007/s00345-015-1712-3. Epub 2015 Oct 23. PMID- 26489616 OWN - NLM STAT- MEDLINE DCOM- 20160915 LR - 20220410 IS - 1993-1352 (Electronic) IS - 1672-0733 (Linking) VI - 35 IP - 5 DP - 2015 Oct TI - Prognostic significance of lymphovascular invasion in bladder cancer after surgical resection: A meta-analysis. PG - 646-655 LID - 10.1007/s11596-015-1484-4 [doi] AB - Bladder cancer remains a commonly diagnosed malignancy worldwide, bringing huge economic burden and high morbidity for patients. Assessment of prognostic significance of lymphovascular invasion (LVI) is a critical issue in the surgical management of bladder cancer after transurethral resection or radical cystectomy. A systematic search of PubMed, Embase and Cochrane Library was performed up to Oct 10, 2014 to identify eligible studies. Outcomes of interest were collected from studies comparing overall survival (OS), cancer specific survival (CSS) and recurrence free survival (RFS) in patients with the LVI. Results of studies were pooled, and combined hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for survival were used as the effect size estimation. Funnel plots were done to show the publication bias, while the forest plots and subgroup analyses were used to limit the heterogeneity. A total of 20 studies (10 663 patients) met the eligibility criteria and were included for this meta-analysis. Our pooled results showed that there were significant differences in OS (pooled HR, 1.71; 95%CI, 1.52-1.92; P<0.00001), CSS (pooled HR, 2.25; 95% CI, 1.80-2.81; P<0.00001) and RFS (pooled HR, 1.91; 95% CI, 1.57-2.32; P<0.00001) between the patients with LVI and the patients without LVI. There were significant heterogeneities observed in the studies concerning the relationship between LVI and CSS, RFS. There was no clear evidence of publication bias. When tumor stage was beyond T3, LVI lost its predictive value for CSS and RFS. For the patients who had negative lymph nodes, LVI was still an adverse predictor. Our pooled results demonstrate that LVI indicates poor prognosis of patients with bladder cancer after surgical procedures, and it can be of particular importance in clinical practice. However, these results need to be further confirmed by more adequately designed prospective studies. FAU - Tian, Yuan-Feng AU - Tian YF AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Zhou, Hui AU - Zhou H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Yu, Gan AU - Yu G AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Wang, Ji AU - Wang J AD - Department of Cell Death and Cancer Genetics, The Hormel Institute, University of Minnesota, Austin, 55912, USA. FAU - Li, Heng AU - Li H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Xia, Ding AU - Xia D AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Xiao, Hai-Bing AU - Xiao HB AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Liu, Ji-Hong AU - Liu JH AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Ye, Zhang-Qun AU - Ye ZQ AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Xu, Hua AU - Xu H AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Zhuang, Qian-Yuan AU - Zhuang QY AD - Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. qyzhuang@tjh.tjmu.edu.cn. AD - Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. qyzhuang@tjh.tjmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't DEP - 20151022 PL - China TA - J Huazhong Univ Sci Technolog Med Sci JT - Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban JID - 101169627 SB - IM MH - Carcinoma, Squamous Cell/*diagnosis/*mortality/pathology/surgery MH - Cystectomy/*mortality MH - Female MH - Humans MH - Lymph Nodes MH - Lymphatic Metastasis MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*diagnosis/*mortality/pathology/surgery MH - Urothelium/pathology/surgery OTO - NOTNLM OT - bladder cancer OT - lymphovascular invasion OT - meta-analysis OT - survival EDAT- 2015/10/23 06:00 MHDA- 2016/09/16 06:00 CRDT- 2015/10/23 06:00 PHST- 2015/04/10 00:00 [received] PHST- 2015/06/15 00:00 [revised] PHST- 2015/10/23 06:00 [entrez] PHST- 2015/10/23 06:00 [pubmed] PHST- 2016/09/16 06:00 [medline] AID - 10.1007/s11596-015-1484-4 [pii] AID - 10.1007/s11596-015-1484-4 [doi] PST - ppublish SO - J Huazhong Univ Sci Technolog Med Sci. 2015 Oct;35(5):646-655. doi: 10.1007/s11596-015-1484-4. Epub 2015 Oct 22. PMID- 26486930 OWN - NLM STAT- MEDLINE DCOM- 20160404 LR - 20181202 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 16 IP - 12 DP - 2015 Dec TI - Expectant Management of Low-Risk Bladder Cancer. PG - 82 LID - 10.1007/s11934-015-0555-1 [doi] AB - Patients with one or more low-grade bladder tumors of the urinary bladder will often develop a subsequent tumor but these so called "recurrences" are almost always of similar grade and rarely invade beyond the basement membrane. Therefore, the clinician should try to minimize the morbidity associated with treating these new tumors. Since many of these patients are elderly or have comorbidities, active surveillance is a very reasonable initial approach if these tumors are very small and appear low-grade. Another alternative is fulguration in the outpatient setting using a flexible cystoscope and electrode. The goal is to try to avoid the hospital and performing a formal transurethral resection. This adds potential morbidity, inconvenience, and cost. FAU - Smith, Zachary L AU - Smith ZL AD - Division of Urologic Oncology, Memorial Hospital, Hollywood, FL, USA. FAU - Soloway, Mark S AU - Soloway MS AD - Division of Urologic Oncology, Memorial Hospital, Hollywood, FL, USA. mssoloway@yahoo.com. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 SB - IM MH - Cost-Benefit Analysis MH - Cystoscopy MH - Electrocoagulation MH - Humans MH - Risk Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/economics/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - Low-risk OT - Management OT - Tumor EDAT- 2015/10/22 06:00 MHDA- 2016/04/05 06:00 CRDT- 2015/10/22 06:00 PHST- 2015/10/22 06:00 [entrez] PHST- 2015/10/22 06:00 [pubmed] PHST- 2016/04/05 06:00 [medline] AID - 10.1007/s11934-015-0555-1 [pii] AID - 10.1007/s11934-015-0555-1 [doi] PST - ppublish SO - Curr Urol Rep. 2015 Dec;16(12):82. doi: 10.1007/s11934-015-0555-1. PMID- 26482391 OWN - NLM STAT- MEDLINE DCOM- 20161019 LR - 20220408 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 2 DP - 2016 Feb TI - Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. PG - 59.e15-22 LID - S1078-1439(15)00444-5 [pii] LID - 10.1016/j.urolonc.2015.09.001 [doi] AB - BACKGROUND: Despite several studies, the adequate management of positive distal ureter margins at the time of radical cystectomy (RC) remains controversial. Particularly, it is not clear whether the achievement of negative distal ureter margins at the intraoperative frozen sections (IFS) affects postoperative cancer-specific mortality (CSM). METHODS: In all, 1,447 consecutive patients treated with RC at a single center between January 1987 and August 2014 were considered. Multivariable (MVA) logistic regression analyses were used to determine predictors of positive IFS. MVA Cox regression analyses were used to test the effect on CSM of intraoperative conversion to negative margins. RESULTS: At IFS, 368 patients (25%) experienced at least 1 positive margin. Of these, a negative conversion of the margin at IFS occurred in 178 (48%) whereas 190 (52%) had a positive final ureteral margin. The mean follow-up was 95 months (median = 102). At MVA, history of carcinoma in situ (odds ratio = 6.40, P<0.001) was predictors of positive margin at IFS. At MVA, ureteral margins that were not converted to negative (hazard ratio = 1.92, P = 0.01) were associated with CSM but only in patients with negative soft tissue margin and without node metastases. CONCLUSIONS: Achieving negative IFS margins may be associated with survival benefit in patients without residual bladder cancer after RC. Patients who recorded a history of carcinoma in situ before RC are at higher risk to incur positive ureteral margin at IFS and should be investigated during RC. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy; Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. Electronic address: marco.moschini87@gmail.com. FAU - Gallina, Andrea AU - Gallina A AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Freschi, Massimo AU - Freschi M AD - Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Luzzago, Stefano AU - Luzzago S AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Fossati, Nicola AU - Fossati N AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Dell'oglio, Paolo AU - Dell'oglio P AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Dipartimento di Discipline Chirurgiche ed Oncologiche, Universita degli Studi di Palermo, Palermo, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Urological Research Institute, Vita-Salute, University, San Raffaele Scientific Institute, Milano, Italy. LA - eng PT - Journal Article DEP - 20151009 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Postoperative Period MH - Retrospective Studies MH - Survival Analysis MH - Ureteral Neoplasms/mortality/*surgery OTO - NOTNLM OT - Bladder cancer OT - Frozen section OT - Margin OT - Radical cystectomy OT - Ureteral margin EDAT- 2015/10/21 06:00 MHDA- 2016/12/30 06:00 CRDT- 2015/10/21 06:00 PHST- 2015/06/24 00:00 [received] PHST- 2015/08/21 00:00 [revised] PHST- 2015/09/01 00:00 [accepted] PHST- 2015/10/21 06:00 [entrez] PHST- 2015/10/21 06:00 [pubmed] PHST- 2016/12/30 06:00 [medline] AID - S1078-1439(15)00444-5 [pii] AID - 10.1016/j.urolonc.2015.09.001 [doi] PST - ppublish SO - Urol Oncol. 2016 Feb;34(2):59.e15-22. doi: 10.1016/j.urolonc.2015.09.001. Epub 2015 Oct 9. PMID- 26481720 OWN - NLM STAT- MEDLINE DCOM- 20170424 LR - 20171213 IS - 1724-6075 (Electronic) IS - 0391-5603 (Linking) VI - 82 Suppl 2 DP - 2015 Oct TI - NBI: results review. PG - S9-11 LID - 10.5301/uro.5000155 [doi] AB - The narrow band imaging (NBI) is a new technology introduced to complement the traditional endoscopy in order to enhance the detection of nonmuscle-invasive bladder cancer and, consequently, to improve the management of the disease. In this review, we considered the most important studies about the use of NBI in the diagnosis and treatment of bladder cancer. Current results demonstrate a greater sensitivity in the diagnosis of bladder cancer and especially a better negative predictive value of cystoscopy enhanced by NBI technology than white light standard cystoscopy. Similarly, improving the performance of endoscopic resection, this new technology would have a positive therapeutic impact in order to decrease residual tumors and relapses. The validation of the results and diffusion of NBI in clinical practice may provide new perspectives in the management of nonmuscle-invasive bladder cancer. FAU - Racioppi, Marco AU - Racioppi M AD - Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome - Italy. FAU - D'Agostino, Daniele AU - D'Agostino D AD - Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome - Italy. FAU - Ragonese, Mauro AU - Ragonese M AD - Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome - Italy. FAU - Gianfrancesco, Luca Di AU - Gianfrancesco LD AD - Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome - Italy. FAU - Bassi, Pier Francesco AU - Bassi PF AD - Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome - Italy. LA - eng PT - Journal Article PT - Review DEP - 20151009 PL - United States TA - Urologia JT - Urologia JID - 0417372 SB - IM MH - *Cystoscopy/methods MH - Evidence-Based Medicine MH - Humans MH - *Narrow Band Imaging/methods MH - Neoplasm Invasiveness MH - Neoplasm, Residual/*diagnosis/diagnostic imaging MH - Predictive Value of Tests MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*diagnosis/diagnostic imaging/therapy EDAT- 2015/10/21 06:00 MHDA- 2017/04/25 06:00 CRDT- 2015/10/21 06:00 PHST- 2015/09/12 00:00 [accepted] PHST- 2015/10/21 06:00 [entrez] PHST- 2015/10/21 06:00 [pubmed] PHST- 2017/04/25 06:00 [medline] AID - 6CB1A6B3-5CCF-4DD7-8956-538BE6364087 [pii] AID - 10.5301/uro.5000155 [doi] PST - ppublish SO - Urologia. 2015 Oct;82 Suppl 2:S9-11. doi: 10.5301/uro.5000155. Epub 2015 Oct 9. PMID- 26469362 OWN - NLM STAT- MEDLINE DCOM- 20170524 LR - 20220408 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 118 IP - 1 DP - 2016 Jul TI - The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. PG - 44-52 LID - 10.1111/bju.13354 [doi] AB - OBJECTIVES: To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). PATIENTS AND METHODS: In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette-Guerin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical outcomes were compared across the four groups. RESULTS: Re-TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re-TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re-TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. CONCLUSIONS: Our retrospective analysis suggests that re-TUR may not be necessary in patients with T1-HG/G3, if muscle is present in the specimen of the primary TUR. CI - (c) 2015 The Authors BJU International (c) 2015 BJU International Published by John Wiley & Sons Ltd. FAU - Gontero, Paolo AU - Gontero P AD - Urology Clinic, Citta della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy. FAU - Sylvester, Richard AU - Sylvester R AD - Formerly Department of Biostatistics, EORTC Headquarters, Brussels, Belgium. FAU - Pisano, Francesca AU - Pisano F AD - Urology Clinic, Citta della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy. FAU - Joniau, Steven AU - Joniau S AD - Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium. FAU - Oderda, Marco AU - Oderda M AD - Urology Clinic, Citta della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy. FAU - Serretta, Vincenzo AU - Serretta V AD - Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy. FAU - Larre, Stephane AU - Larre S AD - Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK. FAU - Di Stasi, Savino AU - Di Stasi S AD - Policlinico Tor Vergata-University of Rome, Rome, Italy. FAU - Van Rhijn, Bas AU - Van Rhijn B AD - Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Witjes, Alfred J AU - Witjes AJ AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Grotenhuis, Anne J AU - Grotenhuis AJ AD - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. FAU - Colombo, Renzo AU - Colombo R AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Dipartimento di Urologia, Universita Vita-Salute. Ospedale S. Raffaele, Milan, Italy. FAU - Babjuk, Marek AU - Babjuk M AD - Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic. FAU - Soukup, Viktor AU - Soukup V AD - Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden. FAU - Irani, Jacques AU - Irani J AD - Department of Urology, Centre Hospitalier Universitaire La Miletrie, University of Poitiers, Poitiers, France. FAU - Malats, Nuria AU - Malats N AD - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. FAU - Baniel, Jack AU - Baniel J AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Mano, Roy AU - Mano R AD - Department of Urology, Rabin Medical Centre, Tel Aviv, Israel. FAU - Cai, Tommaso AU - Cai T AD - Department of Urology, Santa Chiara Hospital, Trento, Italy. FAU - Cha, Eugene K AU - Cha EK AD - Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA. FAU - Ardelt, Peter AU - Ardelt P AD - Facharzt fur Urologie, Abteilung fur Urologie. Chirurgische Universitats klinik, Freiburg, Germany. FAU - Vakarakis, John AU - Vakarakis J AD - Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. FAU - Bartoletti, Riccardo AU - Bartoletti R AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Dalbagni, Guido AU - Dalbagni G AD - Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA. FAU - Xylinas, Evanguelos AU - Xylinas E AD - Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA. FAU - Karnes, Robert J AU - Karnes RJ AD - Department of Urology, Mayo Clinic, Rochester, MN, USA. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20151106 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - BJU Int. 2016 Jul;118(1):9-10. doi: 10.1111/bju.13385. PMID: 27311547 CIN - J Urol. 2018 Feb;199(2):340-342. doi: 10.1016/j.juro.2017.11.022. PMID: 29357559 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - BCG Vaccine/*therapeutic use MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Reoperation MH - Retrospective Studies MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery PMC - PMC5502757 MID - NIHMS860337 OTO - NOTNLM OT - T1G3 OT - bladder cancer OT - high grade OT - progression OT - re-TUR OT - recurrence COIS- Conflicts of Interest: None disclosed. EDAT- 2015/10/16 06:00 MHDA- 2017/05/26 06:00 PMCR- 2017/07/10 CRDT- 2015/10/16 06:00 PHST- 2015/10/16 06:00 [entrez] PHST- 2015/10/16 06:00 [pubmed] PHST- 2017/05/26 06:00 [medline] PHST- 2017/07/10 00:00 [pmc-release] AID - 10.1111/bju.13354 [doi] PST - ppublish SO - BJU Int. 2016 Jul;118(1):44-52. doi: 10.1111/bju.13354. Epub 2015 Nov 6. PMID- 26462931 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 34 IP - 6 DP - 2016 Jun TI - Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. PG - 847-51 LID - 10.1007/s00345-015-1710-5 [doi] AB - PURPOSE: Although the role of second transurethral resection of bladder tumor (TURB) is well established in high-risk non-muscle-invasive bladder cancer, to the best of our knowledge, there is no study regarding the role of a second transurethral resection (TUR) after a complete first TURB in multimodal therapy (MMT). The aim of this study was to evaluate the role of a second TUR on disease-specific survival (DSS) and overall survival (OS) rates in muscle-invasive bladder cancer (MIBC) patients who were treated with MMT. METHODS: We assessed the data of 90 patients (stage T2-4, N0-1, M0 urothelial cancer) who were treated with MMT at our clinic between January 2000 and June 2014. Patients with incomplete initial TURB were excluded. A total of 43 patients had a second TUR before starting radiochemotherapy of MMT (group 1), and 47 patients (group 2) were treated with MMT without having a second TUR. The impact of second TUR on DSS and OS rates was the primary outcome measure of the study. RESULTS: Mean (SD, range) age and mean follow-up of the patients were 65.1 (7.1, 52-81) years and 60.3 (38.3, 6-159) months, respectively. The two groups were similar with regard to sex, age, presence of hydronephrosis, lymph node involvement and stage. The 5-year DSS rate was better in group 1 compared to group 2 (68 vs. 41 %) (p = 0.046). The 5-year OS rates of the patients were 63.7 and 40.1 % in groups 1 and 2, respectively (p = 0.054). Multivariate analysis revealed that second TUR, lymph node involvement, presence of hydronephrosis and tumor stage were independent prognostic factors for DSS. CONCLUSIONS: Second TUR should be performed in patients with MIBC who are going to be treated with bladder-preserving MMT protocols. FAU - Suer, Evren AU - Suer E AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Hamidi, Nurullah AU - Hamidi N AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. dr.nhamidi86@gmail.com. FAU - Gokce, Mehmet Ilker AU - Gokce MI AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Gulpinar, Omer AU - Gulpinar O AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Turkolmez, Kadir AU - Turkolmez K AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Beduk, Yasar AU - Beduk Y AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. FAU - Baltaci, Sumer AU - Baltaci S AD - Department of Urology, Ankara University School of Medicine, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20151013 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth MH - Neoplasm Invasiveness MH - Organ Sparing Treatments MH - Reoperation MH - Retrospective Studies MH - Survival Rate MH - Treatment Outcome MH - Urethra MH - Urinary Bladder Neoplasms/mortality/*surgery OTO - NOTNLM OT - Bladder cancer OT - Bladder preserving OT - Multimodal therapy OT - Second resection EDAT- 2015/10/16 06:00 MHDA- 2017/04/19 06:00 CRDT- 2015/10/15 06:00 PHST- 2015/08/19 00:00 [received] PHST- 2015/10/08 00:00 [accepted] PHST- 2015/10/15 06:00 [entrez] PHST- 2015/10/16 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] AID - 10.1007/s00345-015-1710-5 [pii] AID - 10.1007/s00345-015-1710-5 [doi] PST - ppublish SO - World J Urol. 2016 Jun;34(6):847-51. doi: 10.1007/s00345-015-1710-5. Epub 2015 Oct 13. PMID- 26459040 OWN - NLM STAT- MEDLINE DCOM- 20161005 LR - 20161230 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 1 DP - 2016 Feb TI - Correlation Between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer. PG - e37-41 LID - S1558-7673(15)00181-0 [pii] LID - 10.1016/j.clgc.2015.07.008 [doi] AB - To identify the effects of diagnostic ureteroscopy on intravesical recurrence, 104 patients who had undergone radical nephroureterectomy were analyzed. The number of patients with intravesical recurrence was 34 (32.6%) at a mean of 37 months. Multivariate Cox model analysis revealed that delayed nephroureterectomy after diagnostic ureteroscopy were independent predictive factors for intravesical recurrence. BACKGROUND: The purpose of this study was to evaluate the effects of the timing of diagnostic ureteroscopy (URS) relative to radical nephroureterectomy (RNU) on intravesical recurrence (IVR). PATIENTS AND METHODS: We retrospectively evaluated 104 patients who had undergone RNU for upper tract urothelial cancer (UTUC) at a single tertiary referral center between March 2003 and December 2012. All patients were divided depending on the timing of diagnostic URS: the no URS group (30 patients, no URS), 1-session group (33 patients, diagnostic URS immediately followed by RNU), and 2-session group (41 patients, RNU after diagnostic URS at a median time of 5 days). We analyzed for IVR-free survival using the Kaplan-Meier and Cox proportional regression methods. RESULTS: Of the 104 patients, 34 (32.6%) developed subsequent IVR at a mean interval of 7.2 months. The Kaplan-Meier curve showed that the IVR rate was significantly greater in the 2-session group than in the other groups (P = .004). Univariate analysis indicated no effect on IVR in the 1-session group compared with the no URS group (hazard ratio [HR], 95% confidence interval [CI] 1.58; 0.517-4.833). However, the 2-session group had a significantly greater number of patients with IVR than the no URS group (HR, 3.82; 95% CI 1.438-10.131). Multivariate Cox proportional analysis revealed that the 2-session group was an independent predictor of IVR in UTUC patients (HR, 3.61; 95% CI 1.039-12.557). CONCLUSION: Delay of RNU after diagnostic URS significantly increased the risk of IVR in UTUC patients. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Lee, Jung Keun AU - Lee JK AD - Department of Urology, Seoul National University of Hospital, Seoul, Republic of Korea. FAU - Kim, Ki Bom AU - Kim KB AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Park, Yong Hyun AU - Park YH AD - Department of Urology, Seoul St Mary's Hospital, Seoul, Republic of Korea. FAU - Oh, Jong Jin AU - Oh JJ AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Lee, Sangchul AU - Lee S AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Jeong, Seong Jin AU - Jeong SJ AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Hong, Sung Kyu AU - Hong SK AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Byun, Seok-Soo AU - Byun SS AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. FAU - Lee, Sang Eun AU - Lee SE AD - Department of Urology, Seoul National University Bundang Hospital, Seoul, Republic of Korea. Electronic address: 38jklee@gmail.com. LA - eng PT - Journal Article DEP - 20150806 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/mortality/*pathology MH - Nephrectomy MH - Proportional Hazards Models MH - Retrospective Studies MH - Ureteroscopy MH - Urologic Neoplasms/mortality/*pathology OTO - NOTNLM OT - Diagnosis OT - Intravesical recurrence OT - Nephroureterectomy​ OT - Upper tract urothelial cancer OT - Ureteroscopy EDAT- 2015/10/16 06:00 MHDA- 2016/10/07 06:00 CRDT- 2015/10/14 06:00 PHST- 2015/05/18 00:00 [received] PHST- 2015/07/30 00:00 [accepted] PHST- 2015/10/14 06:00 [entrez] PHST- 2015/10/16 06:00 [pubmed] PHST- 2016/10/07 06:00 [medline] AID - S1558-7673(15)00181-0 [pii] AID - 10.1016/j.clgc.2015.07.008 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Feb;14(1):e37-41. doi: 10.1016/j.clgc.2015.07.008. Epub 2015 Aug 6. PMID- 26459038 OWN - NLM STAT- MEDLINE DCOM- 20160613 LR - 20160208 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 195 IP - 2 DP - 2016 Feb TI - Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. PG - 493-8 LID - S0022-5347(15)04962-9 [pii] LID - 10.1016/j.juro.2015.09.090 [doi] AB - PURPOSE: Due to the high recurrence risk of nonmuscle invasive urothelial carcinoma it is crucial to distinguish patients at high risk from those with indolent disease. In this study we used a machine learning algorithm to identify the genes in patients with nonmuscle invasive urothelial carcinoma at initial presentation that were most predictive of recurrence. We used the genes in a molecular signature to predict recurrence risk within 5 years after transurethral resection of bladder tumor. MATERIALS AND METHODS: Whole genome profiling was performed on 112 frozen nonmuscle invasive urothelial carcinoma specimens obtained at first presentation on Human WG-6 BeadChips (Illumina(R)). A genetic programming algorithm was applied to evolve classifier mathematical models for outcome prediction. Cross-validation based resampling and gene use frequencies were used to identify the most prognostic genes, which were combined into rules used in a voting algorithm to predict the sample target class. Key genes were validated by quantitative polymerase chain reaction. RESULTS: The classifier set included 21 genes that predicted recurrence. Quantitative polymerase chain reaction was done for these genes in a subset of 100 patients. A 5-gene combined rule incorporating a voting algorithm yielded 77% sensitivity and 85% specificity to predict recurrence in the training set, and 69% and 62%, respectively, in the test set. A singular 3-gene rule was constructed that predicted recurrence with 80% sensitivity and 90% specificity in the training set, and 71% and 67%, respectively, in the test set. CONCLUSIONS: Using primary nonmuscle invasive urothelial carcinoma from initial occurrences genetic programming identified transcripts in reproducible fashion, which were predictive of recurrence. These findings could potentially impact nonmuscle invasive urothelial carcinoma management. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Bartsch, Georg Jr AU - Bartsch G Jr AD - University of Southern California, Los Angeles, California; Goethe University Frankfurt, Frankfurt, Germany. FAU - Mitra, Anirban P AU - Mitra AP AD - University of Southern California, Los Angeles, California. FAU - Mitra, Sheetal A AU - Mitra SA AD - University of Southern California, Los Angeles, California. FAU - Almal, Arpit A AU - Almal AA AD - Everist Genomics, Ann Arbor, Michigan. FAU - Steven, Kenneth E AU - Steven KE AD - University of Copenhagen, Copenhagen, Denmark. FAU - Skinner, Donald G AU - Skinner DG AD - University of Southern California, Los Angeles, California. FAU - Fry, David W AU - Fry DW AD - Everist Genomics, Ann Arbor, Michigan. FAU - Lenehan, Peter F AU - Lenehan PF AD - Everist Genomics, Ann Arbor, Michigan. FAU - Worzel, William P AU - Worzel WP AD - Everist Genomics, Ann Arbor, Michigan. FAU - Cote, Richard J AU - Cote RJ AD - University of Miami, Miami, Florida. Electronic address: RCote@med.miami.edu. LA - eng GR - CA132499/CA/NCI NIH HHS/United States GR - CA71921/CA/NCI NIH HHS/United States GR - CA86871/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20151013 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Algorithms MH - *Artificial Intelligence MH - Biopsy MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Female MH - *Gene Expression Profiling MH - Humans MH - Machine Learning MH - Male MH - Neoplasm Invasiveness/*pathology MH - Neoplasm Staging MH - Polymerase Chain Reaction MH - Predictive Value of Tests MH - Prognosis MH - Risk Assessment MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - algorithms OT - genome OT - local OT - neoplasm recurrence OT - software OT - urinary bladder neoplasms EDAT- 2015/10/16 06:00 MHDA- 2016/06/14 06:00 CRDT- 2015/10/14 06:00 PHST- 2015/09/21 00:00 [accepted] PHST- 2015/10/14 06:00 [entrez] PHST- 2015/10/16 06:00 [pubmed] PHST- 2016/06/14 06:00 [medline] AID - S0022-5347(15)04962-9 [pii] AID - 10.1016/j.juro.2015.09.090 [doi] PST - ppublish SO - J Urol. 2016 Feb;195(2):493-8. doi: 10.1016/j.juro.2015.09.090. Epub 2015 Oct 13. PMID- 26457124 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20151012 LR - 20231111 IS - 1868-7075 (Print) IS - 1868-7083 (Electronic) IS - 1868-7075 (Linking) VI - 7 DP - 2015 TI - Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. PG - 109 LID - 10.1186/s13148-015-0141-x [doi] LID - 109 AB - BACKGROUND: Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but their exact role in bladder cancer is still obscure. We have recently found a major role of the Polycomb repression complex in recurrence of non-muscle-invasive bladder cancer. Here, we report the xpression of Polycomb-related lncRNAs:antisense noncoding RNA in the INK4 locus (ANRIL) and HOX antisense intergenic RNA (HOTAIR) in these tumors. FINDINGS: We studied a dataset of non-invasive bladder cancer samples by quantitative reverse transcription PCR (RT-qPCR) and analyzed also invasive bladder cancer samples using TCGA data. Our results showed that, while ANRIL seemed not to have a determining role, an increased HOTAIR expression appeared in recurrent and high-graded tumors associated with poor prognosis. In addition, through genome-wide transcriptome analyses, we observed that HOTAIR-EZH2-complex-regulated genes can efficiently discriminate between non-tumoral, recurrent, and non-recurrent bladder cancer samples. We also observed a significant correlation between EZH2 and HOTAIR expression levels. Using overexpression, knockdown, and pharmacological approaches in bladder cancer cell lines, we also observed that EZH2 regulates HOTAIR expression. CONCLUSIONS: Our findings indicate that HOTAIR expression has prognostic value for bladder cancer progression, recurrence, and survival and suggest that HOTAIR plays active roles in modulating the cancer epigenome, becoming an interesting candidate as a target for cancer diagnosis and therapy. The observed HOTAIR regulation by EZH2 and the possibility of modulating EZH2 activity with specific inhibitors open new possible paths to be explored in bladder cancer therapy. FAU - Martinez-Fernandez, Monica AU - Martinez-Fernandez M AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Feber, Andrew AU - Feber A AD - Medical Genomics, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT UK. FAU - Duenas, Marta AU - Duenas M AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Segovia, Cristina AU - Segovia C AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Rubio, Carolina AU - Rubio C AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Fernandez, Maria AU - Fernandez M AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Villacampa, Felipe AU - Villacampa F AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Duarte, Jose AU - Duarte J AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Lopez-Calderon, Fernando F AU - Lopez-Calderon FF AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Gomez-Rodriguez, Ma Jose AU - Gomez-Rodriguez MJ AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Castellano, Daniel AU - Castellano D AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Rodriguez-Peralto, Jose L AU - Rodriguez-Peralto JL AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain ; Servicio de Anatomia Patologica, Hospital Universitario 12 de Octubre, Instituto de Investigacion 12 de Octubre i+12, UCM, Av Cordoba s/n., 28041 Madrid, Spain. FAU - de la Rosa, Federico AU - de la Rosa F AD - Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. FAU - Beck, Stephan AU - Beck S AD - Medical Genomics, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT UK. FAU - Paramio, Jesus M AU - Paramio JM AD - Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Cordoba s/n., 28041 Madrid, Spain. LA - eng PT - Journal Article DEP - 20151008 PL - Germany TA - Clin Epigenetics JT - Clinical epigenetics JID - 101516977 PMC - PMC4599691 OTO - NOTNLM OT - ANRIL OT - Bladder cancer OT - Epigenetics OT - HOTAIR OT - LncRNA OT - Recurrence EDAT- 2015/10/13 06:00 MHDA- 2015/10/13 06:01 PMCR- 2015/10/08 CRDT- 2015/10/13 06:00 PHST- 2015/04/10 00:00 [received] PHST- 2015/09/26 00:00 [accepted] PHST- 2015/10/13 06:00 [entrez] PHST- 2015/10/13 06:00 [pubmed] PHST- 2015/10/13 06:01 [medline] PHST- 2015/10/08 00:00 [pmc-release] AID - 141 [pii] AID - 10.1186/s13148-015-0141-x [doi] PST - epublish SO - Clin Epigenetics. 2015 Oct 8;7:109. doi: 10.1186/s13148-015-0141-x. eCollection 2015. PMID- 26452033 OWN - NLM STAT- MEDLINE DCOM- 20161026 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 34 DP - 2015 Nov 3 TI - Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. PG - 36185-201 LID - 10.18632/oncotarget.5517 [doi] AB - Striking evidence associates cancer stem cells (CSCs) to the high recurrence rates and poor survival of patients with muscle-invasive bladder cancer (BC). However, the prognostic implication of those cells in risk stratification is not firmly established, mainly due to the functional and phenotypic heterogeneity of CSCs populations, as well as, to the conflicting data regarding their identification based on a single specific marker. This emphasizes the need to exploit putative CSC-related molecular markers with potential prognostic significance in BC patients.This study aimed to isolate and characterize bladder CSCs making use of different functional and molecular approaches. The data obtained provide strong evidence that muscle-invasive BC is enriched with a heterogeneous stem-like population characterized by enhanced chemoresistance and tumor initiating properties, able to recapitulate the heterogeneity of the original tumor. Additionally, a logistic regression analysis identified a 2-gene stem-like signature (SOX2 and ALDH2) that allows a 93% accurate discrimination between non-muscle-invasive and invasive tumors.Our findings suggest that a stemness-related gene signature, combined with a cluster of markers to more narrowly refine the CSC phenotype, could better identify BC patients that would benefit from a more aggressive therapeutic intervention targeting CSCs population. FAU - Ferreira-Teixeira, Margarida AU - Ferreira-Teixeira M AD - Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - CNC.IBILI, University of Coimbra, Coimbra, Portugal. FAU - Parada, Belmiro AU - Parada B AD - Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Urology and Renal Transplantation Department, Coimbra University Hospital Centre (CHUC), Coimbra, Portugal. FAU - Rodrigues-Santos, Paulo AU - Rodrigues-Santos P AD - Immunology and Oncology Laboratory, Center for Neurosciences and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal. AD - Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. FAU - Alves, Vera AU - Alves V AD - Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. FAU - Ramalho, Jose S AU - Ramalho JS AD - CEDOC, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal. FAU - Caramelo, Francisco AU - Caramelo F AD - Laboratory of Biostatistics and Medical Informatics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. FAU - Sousa, Vitor AU - Sousa V AD - Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - Service of Anatomical Pathology, Coimbra University Hospital Centre (CHUC), Coimbra, Portugal. FAU - Reis, Flavio AU - Reis F AD - Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - CNC.IBILI, University of Coimbra, Coimbra, Portugal. AD - Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. FAU - Gomes, Celia M AU - Gomes CM AD - Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. AD - CNC.IBILI, University of Coimbra, Coimbra, Portugal. AD - Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 SB - IM MH - Aged MH - Aged, 80 and over MH - Animals MH - Cell Line, Tumor MH - Female MH - Heterografts MH - Humans MH - Male MH - Mice MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplastic Stem Cells/*metabolism/*pathology MH - Urinary Bladder Neoplasms/*metabolism/*pathology PMC - PMC4742170 OTO - NOTNLM OT - ALDH OT - bladder cancer OT - cancer stem cells OT - chemoresistance OT - stemness markers COIS- CONFLICTS OF INTEREST The authors declared no conflicts of interest. EDAT- 2015/10/10 06:00 MHDA- 2016/10/27 06:00 PMCR- 2015/11/03 CRDT- 2015/10/10 06:00 PHST- 2015/05/22 00:00 [received] PHST- 2015/09/24 00:00 [accepted] PHST- 2015/10/10 06:00 [entrez] PHST- 2015/10/10 06:00 [pubmed] PHST- 2016/10/27 06:00 [medline] PHST- 2015/11/03 00:00 [pmc-release] AID - 5517 [pii] AID - 10.18632/oncotarget.5517 [doi] PST - ppublish SO - Oncotarget. 2015 Nov 3;6(34):36185-201. doi: 10.18632/oncotarget.5517. PMID- 26450700 OWN - NLM STAT- MEDLINE DCOM- 20160229 LR - 20220330 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 45 IP - 12 DP - 2015 Dec TI - Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. PG - 1175-81 LID - 10.1093/jjco/hyv139 [doi] AB - OBJECTIVE: To evaluate the association of molecular markers and conventional clinicopathological factors with bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. METHODS: The expressions of Ki-67 and P53 were measured by immunohistochemical staining prospectively in 115 consecutive patients with primary upper tract urothelial carcinoma from March 2004 to February 2014. The Cox proportional hazards regression model was used to identify independent predictors. The association between Ki-67 expression and clinicopathological variables was assessed by the chi(2) test. RESULTS: Intravesical recurrence occurred in 13 out of 115 (11.3%) patients with a mean follow-up of 54.2 months (range: 7-130). Low-level Ki-67 expression (P = 0.010), older age (>65, P = 0.040) and lower ureter tumour (P = 0.001) were independent predictors of bladder tumour recurrence in Cox regression analysis. Ki-67 expression was elevated with the progression of tumour grade (P = 0.004) but not with stage (P = 0.186). Ki-67 overexpression was also significantly higher in aggressive pathological types (P = 0.008), but only shows an inclination towards poor oncologic outcomes in the cancer-specific survival rate (P = 0.107) and the overall survival rate (P = 0.063). CONCLUSIONS: Low-level Ki-67 expression was an independent predictor for bladder tumour recurrence, while Ki-67 overexpression was associated with adverse clinicopathological parameters and poor prognosis in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. CI - (c) The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Wu, Pengjie AU - Wu P AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing Beijing Institute of Geriatrics, Ministry of Health, Graduate School of Peking Union Medical College, Beijing. FAU - Liu, Shengjie AU - Liu S AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing. FAU - Zhang, Wei AU - Zhang W AD - Department of Pathology, Beijing Hospital of the Ministry of Health, Beijing, China. FAU - Zhang, Yaoguang AU - Zhang Y AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing Beijing Institute of Geriatrics, Ministry of Health, Graduate School of Peking Union Medical College, Beijing. FAU - Zhu, Gang AU - Zhu G AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing Beijing Institute of Geriatrics, Ministry of Health, Graduate School of Peking Union Medical College, Beijing Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China zhugang2000@aliyun.com dongwei63@hotmail.com wangjy@bjhmoh.com.cn. FAU - Wei, Dong AU - Wei D AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing Beijing Institute of Geriatrics, Ministry of Health, Graduate School of Peking Union Medical College, Beijing zhugang2000@aliyun.com dongwei63@hotmail.com wangjy@bjhmoh.com.cn. FAU - Wan, Ben AU - Wan B AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing. FAU - Wang, Jianye AU - Wang J AD - Department of Urology, Beijing Hospital of the Ministry of Health, Beijing Beijing Institute of Geriatrics, Ministry of Health, Graduate School of Peking Union Medical College, Beijing zhugang2000@aliyun.com dongwei63@hotmail.com wangjy@bjhmoh.com.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151008 PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Carcinoma, Transitional Cell/*surgery MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen/*analysis MH - Kidney Neoplasms/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnosis MH - *Nephrectomy MH - Proportional Hazards Models MH - Prospective Studies MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder Neoplasms/chemistry/*diagnosis/pathology OTO - NOTNLM OT - Ki-67 expression OT - bladder tumour OT - nephroureterectomy OT - predictor OT - upper tract urothelial carcinoma EDAT- 2015/10/10 06:00 MHDA- 2016/03/02 06:00 CRDT- 2015/10/10 06:00 PHST- 2015/05/04 00:00 [received] PHST- 2015/08/18 00:00 [accepted] PHST- 2015/10/10 06:00 [entrez] PHST- 2015/10/10 06:00 [pubmed] PHST- 2016/03/02 06:00 [medline] AID - hyv139 [pii] AID - 10.1093/jjco/hyv139 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2015 Dec;45(12):1175-81. doi: 10.1093/jjco/hyv139. Epub 2015 Oct 8. PMID- 26444918 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260128 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 2 DP - 2016 Apr TI - EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice? PG - 176-82 LID - S1558-7673(15)00246-3 [pii] LID - 10.1016/j.clgc.2015.09.005 [doi] AB - PURPOSE: To evaluate the validation of European Organization for Research and Treatment of Cancer (EORTC) risk tables to predict progression in Brazilian patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Two hundred five consecutively and prospectively selected patients with NMIBC who underwent transurethral resection were analyzed during 12 years. Six parameters were analyzed: tumor grade, size, and number, pT stage, previous recurrence rate, and carcinoma-in-situ. Time to progression, risk score, and progression probabilities were calculated and compared to probabilities obtained from the EORTC model. The C index was calculated, and accuracy was analyzed for external validation. RESULTS: A total of 152 patients had complete follow-up data, 36 died, and 17 were lost to follow-up. One hundred thirty-seven patients had primary tumors and 68 had recurrent tumors. Progression to muscle-invasive disease occurred in 42 patients (20.5%). Significant characteristics related to progression were male gender, pT1 stage, lesion size >/= 3 cm, high grade of disease, and no combined intravesical therapy. Mean time to progression was 26.9 months; the 1-year progression rate was 3.4% and the 5-year rate was 19.1%. The C index was 0.86 at 1 year and 0.78 at 5 years. For calibration, 1- and 5-year progression rates were lower than the values predicted by EORTC risk tables, mainly in high-risk groups. Although the EORTC model overestimated the short- and long-term risk of progression, an overlapping of the confidence intervals between both populations was detected. CONCLUSION: The EORTC model successfully stratified progression risks in a Brazilian cohort, although it overestimated progression rates. This scoring system is useful in predicting progression of NMIBC; however, updating new risk markers is essential to improve risk classification and prediction of progression. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Busato Junior, Wilson F S AU - Busato Junior WF AD - University of Vale do Itajai, Itajai, Brazil, Instituto Catarinense de Urologia (INCAU), Itajai, Brazil. FAU - Almeida, Gilberto Laurino AU - Almeida GL AD - University of Vale do Itajai, Itajai, Brazil, Instituto Catarinense de Urologia (INCAU), Itajai, Brazil; Faculdade Evangelica do Parana (FEPAR), Instituto de Pesquisas Medicas (IPEM), Curitiba, Brazil. Electronic address: glalmeida@ibest.com.br. FAU - Ribas, Carmen A P M AU - Ribas CA AD - Faculdade Evangelica do Parana (FEPAR), Instituto de Pesquisas Medicas (IPEM), Curitiba, Brazil. FAU - Ribas Filho, Jurandir M AU - Ribas Filho JM AD - Faculdade Evangelica do Parana (FEPAR), Instituto de Pesquisas Medicas (IPEM), Curitiba, Brazil. FAU - De Cobelli, Ottavio AU - De Cobelli O AD - University of Milan, Milan, Italy; Department of Urology, European Institute of Oncology (IEO), Milan, Italy. LA - eng PT - Journal Article DEP - 20150925 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Brazil MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*epidemiology MH - Proportional Hazards Models MH - Risk Assessment MH - Survival Analysis MH - Urinary Bladder Neoplasms/*pathology OTO - NOTNLM OT - Non-muscle-invasive bladder cancer OT - Prediction OT - Progression OT - Recurrence OT - Validation EDAT- 2015/10/08 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/10/08 06:00 PHST- 2015/05/15 00:00 [received] PHST- 2015/08/19 00:00 [revised] PHST- 2015/09/11 00:00 [accepted] PHST- 2015/10/08 06:00 [entrez] PHST- 2015/10/08 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - S1558-7673(15)00246-3 [pii] AID - 10.1016/j.clgc.2015.09.005 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Apr;14(2):176-82. doi: 10.1016/j.clgc.2015.09.005. Epub 2015 Sep 25. PMID- 26442922 OWN - NLM STAT- MEDLINE DCOM- 20161025 LR - 20161230 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 23 IP - 2 DP - 2016 Feb TI - Acute Kidney Injury After Radical Cystectomy for Bladder Cancer is Associated with Chronic Kidney Disease and Mortality. PG - 686-93 LID - 10.1245/s10434-015-4886-4 [doi] AB - PURPOSE: The aim of this study was to investigate the prevalence of acute kidney injury (AKI) after radical cystectomy, and evaluate its impact on chronic kidney disease (CKD) and mortality. METHODS: The medical records of 866 patients who underwent radical cystectomy for bladder cancer were reviewed. AKI was assessed within 7 days after surgery according to the Acute Kidney Injury Network criteria. The prevalence of AKI after surgery was examined, and the significance of AKI for CKD and mortality was analyzed. RESULTS: Of 866 patients, 269 (31.1 %) developed AKI in the first week after surgery. Of these, 231 (85.9 %) were at stage 1, 32 (11.9 %) at stage 2, and 6 (2.2 %) at stage 3. Of 722 patients with a preoperative Modification of Diet in Renal Disease estimated glomerular filtration rate (eGFR) of >60 ml/min/1.73 m(2), CKD developed in 23.0 % (118/513) of patients in the non-AKI group and 32.5 % (68/209) of patients in the AKI group. Independent factors predicting new-onset CKD were a preoperative eGFR (p < 0.001), age (p = 0.011), urinary tract complication (p < 0.001) and AKI (p = 0.015). In all, 297 patients died (191 in the non-AKI group and 106 in the AKI group). AKI also correlated significantly with overall survival (p = 0.001). CONCLUSIONS: AKI is not only commonly encountered after radical cystectomy but is also associated with higher CKD rates and mortality. There is a critical need for strategies to increase the identification of patients at risk of postoperative AKI, and to improve the management of patients, with an aim toward preventing AKI and improving the treatment of AKI once it occurs. FAU - Kwon, Taekmin AU - Kwon T AD - Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Jeong, In Gab AU - Jeong IG AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Lee, Chunwoo AU - Lee C AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - You, Dalsan AU - You D AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Bumsik AU - Hong B AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Jun Hyuk AU - Hong JH AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Choung-Soo AU - Kim CS AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. cskim@amc.seoul.kr. LA - eng PT - Journal Article DEP - 20151006 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Acute Kidney Injury/epidemiology/*etiology MH - Carcinoma in Situ/pathology/*surgery MH - Cystectomy/*adverse effects/*mortality MH - Female MH - Follow-Up Studies MH - Glomerular Filtration Rate MH - Humans MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - *Postoperative Complications MH - Prognosis MH - Renal Insufficiency, Chronic/epidemiology/etiology/*mortality MH - Retrospective Studies MH - Risk Factors MH - Survival Rate MH - Urinary Bladder Neoplasms/pathology/*surgery EDAT- 2015/10/08 06:00 MHDA- 2016/10/26 06:00 CRDT- 2015/10/08 06:00 PHST- 2015/04/13 00:00 [received] PHST- 2015/10/08 06:00 [entrez] PHST- 2015/10/08 06:00 [pubmed] PHST- 2016/10/26 06:00 [medline] AID - 10.1245/s10434-015-4886-4 [pii] AID - 10.1245/s10434-015-4886-4 [doi] PST - ppublish SO - Ann Surg Oncol. 2016 Feb;23(2):686-93. doi: 10.1245/s10434-015-4886-4. Epub 2015 Oct 6. PMID- 26437330 OWN - NLM STAT- MEDLINE DCOM- 20160922 LR - 20151006 IS - 0004-0614 (Print) IS - 0004-0614 (Linking) VI - 68 IP - 8 DP - 2015 Oct TI - Thermochemotherapy in adjuvant treatment of primary high risk non muscle invasive bladder cancers: Single center results. PG - 666-71 AB - OBJECTIVE: To evaluate the results of Thermochemotherapy in adjuvant treatment of primary high risk non-muscle invasive bladder cancer in our center. METHODS: The study included 26 patients with an age of 51-78 years (mean: 62.4 years). All patients had transurethral tumor resection (TURB) after being diagnosed with a primary bladder tumor and were pathologically diagnosed with non-muscle invasive urothelial carcinoma. Thermochemotherapy (TCT) applications were performed via the Synergo(R) system SB-TS 101. RESULTS: Of the study participants, 13 patients had T1 Grade III, six patients had T1Grade III CIS (+), four patients had Ta Grade III, and three patients Ta Grade II multiple > 5 cm tumor. In all patients, six weeks plus six months protocol were completed. All patients completed the follow-up protocol. With a median follow-up time of 16.4 months (range: 6 - 48 months), recurrent urothelial carcinoma was identified in three patients. With a median follow-up time of 16.4 months, the recurrence-free survival was 88.4% in 26 patients included in the study. CONCLUSIONS: The obtained data suggest that the TCT method can be used effectively and safely in non-muscle invasive bladder cancers of primary high-risk. Prospective randomized studies will shed light on this subject which are BCG vs TCT in primary high risk patients and second course BCG vs TCT in the BCG insufficient patients. FAU - Erturhan, Sakip AU - Erturhan S AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Sen, Haluk AU - Sen H AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Demirbag, Asaf AU - Demirbag A AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Bayrak, Omer AU - Bayrak O AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Yagci, Faruk AU - Yagci F AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Seckiner, Iker AU - Seckiner I AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. FAU - Erbagci, Ahmet AU - Erbagci A AD - University of Gaziantep, School of Medicine, Department of Urology, Gaziantep, Turkey. LA - eng PT - Journal Article PL - Spain TA - Arch Esp Urol JT - Archivos espanoles de urologia JID - 0064757 RN - 0 (Antineoplastic Agents) SB - IM MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Combined Modality Therapy MH - Female MH - Humans MH - *Hyperthermia, Induced MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Risk Factors MH - Urinary Bladder Neoplasms/pathology/*therapy EDAT- 2015/10/06 06:00 MHDA- 2016/09/23 06:00 CRDT- 2015/10/06 06:00 PHST- 2015/10/06 06:00 [entrez] PHST- 2015/10/06 06:00 [pubmed] PHST- 2016/09/23 06:00 [medline] PST - ppublish SO - Arch Esp Urol. 2015 Oct;68(8):666-71. PMID- 26435378 OWN - NLM STAT- MEDLINE DCOM- 20160824 LR - 20220330 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 117 IP - 5 DP - 2016 May TI - Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. PG - 783-6 LID - 10.1111/bju.13345 [doi] AB - OBJECTIVES: To determine whether the severity of haematuria (microscopic or gross) at diagnosis influences the disease stage at presentation in patients diagnosed with bladder cancer. PATIENTS AND METHODS: We conducted a multi-institutional observational cohort study of patients who were newly diagnosed with bladder cancer between August 1999 and May 2012. We reviewed the degree of haematuria, demographic information, clinical and social history, imaging, and pathology. The association of haematuria severity with incident tumour stage and grade was evaluated using logistic regression. RESULTS: Patients diagnosed with bladder cancer presented with gross haematuria (GH; 1 083, 78.3%), microscopic haematuria (MH; 189, 13.7%) or without haematuria (112, 8.1%). High-grade disease was found in 64% and 57.1% of patients presenting with GH and MH, respectively, and severity of haematuria was not associated with higher grade disease. Stage of disease at diagnosis for patients presenting with MH was Ta/carcinoma in situ (CIS) in 68.8%, T1 in 19.6%, and >/=T2 in 11.6%. Stage of disease at diagnosis for patients presenting with GH was Ta/CIS in 55.9%, T1 in 19.6%, and >/=T2 in 17.9%. On multivariate analyses, GH was independently associated with >/=T2 disease at diagnosis (odds ratio 1.69, 95% confidence interval 1.05-2.71, P = 0.03). CONCLUSIONS: Among patients with newly diagnosed bladder cancer, presentation with GH is associated with a more advanced pathological stage. Earlier detection of disease, before development of GH, could influence survival in patients with bladder cancer. Type of haematuria at presentation does not impact grade of disease. CI - (c) 2015 The Authors BJU International (c) 2015 BJU International Published by John Wiley & Sons Ltd. FAU - Ramirez, Daniel AU - Ramirez D AD - Department of Urology, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA. FAU - Gupta, Amit AU - Gupta A AD - University of Iowa Hospitals and Clinics, Iowa City, IA, USA. FAU - Canter, Daniel AU - Canter D AD - Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA. FAU - Harrow, Brian AU - Harrow B AD - Department of Urology, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA. FAU - Dobbs, Ryan W AU - Dobbs RW AD - Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA. FAU - Kucherov, Victor AU - Kucherov V AD - University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. FAU - Mueller, Edward AU - Mueller E AD - UT Health Science Center San Antonio, San Antonio, TX, USA. FAU - Streeper, Necole AU - Streeper N AD - UT Health Science Center San Antonio, San Antonio, TX, USA. FAU - Uhlman, Matthew A AU - Uhlman MA AD - University of Iowa Hospitals and Clinics, Iowa City, IA, USA. FAU - Svatek, Robert S AU - Svatek RS AD - UT Health Science Center San Antonio, San Antonio, TX, USA. FAU - Messing, Edward M AU - Messing EM AD - University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. FAU - Lotan, Yair AU - Lotan Y AD - Department of Urology, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20151029 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Cohort Studies MH - Early Detection of Cancer MH - Female MH - Hematuria/diagnosis/*etiology MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Urinary Bladder Neoplasms/*complications/*pathology OTO - NOTNLM OT - bladder cancer OT - gross haematuria OT - microscopic haematuria EDAT- 2015/10/06 06:00 MHDA- 2016/08/25 06:00 CRDT- 2015/10/06 06:00 PHST- 2015/10/06 06:00 [entrez] PHST- 2015/10/06 06:00 [pubmed] PHST- 2016/08/25 06:00 [medline] AID - 10.1111/bju.13345 [doi] PST - ppublish SO - BJU Int. 2016 May;117(5):783-6. doi: 10.1111/bju.13345. Epub 2015 Oct 29. PMID- 26430961 OWN - NLM STAT- MEDLINE DCOM- 20160920 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 37 DP - 2015 Nov 24 TI - Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer. PG - 40370-84 LID - 10.18632/oncotarget.5458 [doi] AB - The expression and function of caldesmon (CAD) in urothelial bladder carcinoma (BC) have not been reported. Here, we investigated the expression, prognostic value, and potential functional mechanism of CAD in primary non-muscle-invasive bladder cancer (NMIBC). Protein profiling of tissue samples using antibody microarrays showed significantly higher CAD expression in muscle-invasive BC tissues compared with NMIBC tissues. We then validated the CAD expression in BC cells by immunohistochemistry analysis using paraffin-embedded tissue blocks and western blots using BC cell lines. In addition, we examined the expression of CAD variants by reverse transcription-polymerase chain reaction, and confirmed the expression of low-molecular-weight isoforms (L-CAD), specifically encoded by WI-38 L-CAD II (transcript variant 2), in BC cells. Survival analysis in an independent primary NMIBC cohort comprising 132 patients showed that positive CAD expression was significantly associated with poorer prognosis than no CAD expression with regard to recurrence- and progression-free survival (p = 0.001 and 0.014, respectively). Multivariate analyses further indicated that positive CAD expression was an independent predictor of progression-free survival (p = 0.032; HR = 5.983). Data obtained from in vitro silencing and overexpression studies indicated that L-CAD promotes migration and invasiveness of BC cells. Immunofluorescence assays showed dramatic structural changes in the actin cytoskeleton of BC cells after L-CAD overexpression. Our findings collectively suggest that L-CAD overexpression in primary NMIBC is significantly associated with tumor progression and that a possible mechanism for L-CAD's activity is implicated in increased cell motility and invasive characteristics through morphological changes in BC cells. FAU - Lee, Myung-Shin AU - Lee MS AD - Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Lee, Jisu AU - Lee J AD - Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Kim, Joo Heon AU - Kim JH AD - Department of Pathology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Park, Jinsung AU - Park J AD - Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, South Korea. LA - eng SI - GEO/GSE69736 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Calmodulin-Binding Proteins) RN - 0 (Protein Isoforms) SB - IM MH - Blotting, Western MH - Calmodulin-Binding Proteins/*genetics/metabolism MH - Carcinoma, Transitional Cell/*genetics/metabolism/pathology MH - Cell Line MH - Cell Line, Tumor MH - Cell Movement/genetics MH - Disease Progression MH - Female MH - Gene Expression Profiling/methods/statistics & numerical data MH - *Gene Expression Regulation, Neoplastic MH - HeLa Cells MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Microscopy, Confocal MH - Multivariate Analysis MH - Prognosis MH - Proportional Hazards Models MH - Protein Isoforms/genetics/metabolism MH - RNA Interference MH - Reverse Transcriptase Polymerase Chain Reaction MH - Urinary Bladder Neoplasms/*genetics/metabolism/pathology PMC - PMC4741901 OTO - NOTNLM OT - antibody microarray OT - biomarkers OT - bladder cancer OT - caldesmon OT - tumor progression COIS- CONFLICTS OF INTEREST None. EDAT- 2015/10/03 06:00 MHDA- 2016/09/22 06:00 PMCR- 2015/11/24 CRDT- 2015/10/03 06:00 PHST- 2015/06/21 00:00 [received] PHST- 2015/09/15 00:00 [accepted] PHST- 2015/10/03 06:00 [entrez] PHST- 2015/10/03 06:00 [pubmed] PHST- 2016/09/22 06:00 [medline] PHST- 2015/11/24 00:00 [pmc-release] AID - 5458 [pii] AID - 10.18632/oncotarget.5458 [doi] PST - ppublish SO - Oncotarget. 2015 Nov 24;6(37):40370-84. doi: 10.18632/oncotarget.5458. PMID- 26427157 OWN - NLM STAT- MEDLINE DCOM- 20151026 LR - 20191113 IS - 1433-6510 (Print) IS - 1433-6510 (Linking) VI - 61 IP - 8 DP - 2015 TI - MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis. PG - 1101-8 AB - BACKGROUND: Bladder cancer (BCa) is the fifth most common cancer with significant morbidity and mortality. Recently, numerous studies demonstrated that microRNAs (miRNAs) are emerging as diagnostic biomarkers for BCa. However, the findings in these studies are inconsistent. To systematically assess the potential diagnostic value of miRNAs for BCa, a meta-analysis was performed in this study. METHODS: Relevant literature was researched in PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to September 1, 2014. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative LR (NLR), diagnostic odds ratio (DOR), and area under the SROC curve (AUC) value were analyzed by the random-effects model, whose parameters reflected the overall diagnostic performance of miRNAs. RESULTS: Thirty studies from 10 individual publications, including 1019 BCa patients and 690 controls, were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.80 (95% CI: 0.78 - 0.81), 0.74 (95% CI: 0.72 - 0.76), 3.22 (95% CI: 2.68 - 3.87), 0.26 (95% CI: 0.21 - 0.32), 15.20 (95% CI: 10.25 - 22.53) and 0.85, respectively, indicating a moderate diagnostic accuracy for BCa. Moreover, our subgroup analyses showed that analysis of multiple miRNAs (AUC, sensitivity, and specificity of 0.913, 0.86, and 0.80, respectively) yielded a higher diagnostic accuracy than of single miRNAs (AUC, sensitivity, and specificity of 0.84, 0.78, and 0.73, respectively) in BCa diagnosis. In addition, as biomarkers, miRNAs are more suitable for the diagnosis of non-muscle-invasive BCa (NMIBCa) with AUC of 0.84, sensitivity of 0.74, and specificity of 0.77 than muscle-invasive BCa (MIBCa) with AUC of 0.79, sensitivity of 0.73, and specificity of 0.73. CONCLUSIONS: The present meta-analysis suggests that miRNAs are potential novel biomarkers for detection of BCa. However, further validation studies are still needed to confirm our findings. FAU - Chen, Liangyuan AU - Chen L FAU - Cui, Zhaolei AU - Cui Z FAU - Liu, Yaohua AU - Liu Y FAU - Bai, Ye AU - Bai Y FAU - Lan, Fenghua AU - Lan F LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PL - Germany TA - Clin Lab JT - Clinical laboratory JID - 9705611 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Area Under Curve MH - Biomarkers, Tumor/*genetics MH - Chi-Square Distribution MH - Genetic Testing/*methods MH - Humans MH - MicroRNAs/*genetics MH - Odds Ratio MH - Predictive Value of Tests MH - ROC Curve MH - Urinary Bladder Neoplasms/*diagnosis/*genetics EDAT- 2015/10/03 06:00 MHDA- 2015/10/27 06:00 CRDT- 2015/10/03 06:00 PHST- 2015/10/03 06:00 [entrez] PHST- 2015/10/03 06:00 [pubmed] PHST- 2015/10/27 06:00 [medline] AID - 10.7754/clin.lab.2015.150204 [doi] PST - ppublish SO - Clin Lab. 2015;61(8):1101-8. doi: 10.7754/clin.lab.2015.150204. PMID- 26632629 STAT- Publisher PB - Agency for Healthcare Research and Quality (US) CTI - AHRQ Comparative Effectiveness Reviews DP - 2015 Oct BTI - Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer AB - OBJECTIVES: Non-muscle-invasive bladder cancer (NMIBC) frequently recurs and can progress to muscle-invasive disease. This report reviews the current evidence on emerging approaches to diagnosing and treating bladder cancer. DATA SOURCES: Electronic databases (Ovid MEDLINE((R)), January 1990-October 2014, Cochrane Central Register of Controlled Trials through September 2014, Cochrane Database of Systematic Reviews through September 2014, Health Technology Assessment through Third Quarter 2014, National Health Sciences Economic Evaluation Database through Third Quarter 2014, and Database of Abstracts of Reviews of Effects through Third Quarter 2014); reference lists; and clinical trials registries. REVIEW METHODS: Using predefined criteria, we selected studies on diagnostic accuracy of urinary biomarkers versus cystoscopy, and trials of fluorescent cystoscopy, intravesical therapy, and radiation therapy for NMIBC that evaluated bladder cancer recurrence, progression, mortality, or harms. The quality of included studies was assessed, data were extracted, and results were summarized qualitatively and using meta-analysis. RESULTS: Urinary biomarkers were associated with sensitivity for bladder cancer that ranged from 0.57 to 0.82 and specificity from 0.74 to 0.88, for positive likelihood ratios from 2.52 to 5.53 and negative likelihood ratios from 0.21 to 0.48 (strength of evidence [SOE]: moderate for quantitative nuclear matrix protein 22 [NMP22], qualitative bladder tumor antigen [BTA], fluorescence in situ hybridization [FISH], and ImmunoCyt(); low for other biomarkers). Sensitivity increased for higher stage and grade tumors. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (SOE: moderate). Most trials found fluorescent cystoscopy to be associated with decreased risk of subsequent bladder recurrence versus white light cystoscopy, but results were inconsistent, and there was no difference in risk of progression or mortality (SOE: low). Intravesical therapy was more effective than no intravesical therapy for reducing risk of bladder cancer recurrence (for bacillus Calmette-Guerin [BCG], relative risk [RR], 0.56; 95% confidence interval [CI]. 0.43 to 0.71; SOE: moderate; for mitomycin C [MMC], doxorubicin, and epirubicin, RR, 0.66 to 0.72; SOE: moderate). BCG was also associated with decreased risk of bladder cancer progression, but no intravesical agent was associated with decreased risk of all-cause or bladder cancer mortality. Intravesical therapy appeared to be effective across subgroups defined by tumor stage, grade, multiplicity, recurrence status, and size (SOE: low). Evidence was too limited to draw strong conclusions regarding effects of dose or duration of therapy on effectiveness. Compared with no intravesical therapy, BCG was associated with a higher rate of local and systemic adverse events (granulomatous cystitis or irritative symptoms in 27% to 84% of patients, macroscopic hematuria in 21% to 72%, and fever in 27% to 44%) (SOE: low). Compared with MMC, BCG was also associated with an increased risk of local adverse events and fever (SOE: low). One randomized trial found no difference between radiation therapy and no radiation therapy in clinical outcomes in patients with T1G3 cancers. CONCLUSIONS: Urinary biomarkers miss a substantial proportion of patients with bladder cancer, and additional research is needed to clarify advantages of fluorescent cystoscopy over white light cystoscopy. Intravesical therapy reduces risk of bladder cancer recurrence versus no intravesical therapy. BCG is the only intravesical therapy shown to be associated with decreased risk of bladder cancer progression, but it is associated with a high rate of adverse events. More research is needed to define optimal doses and regimens of intravesical therapy. FAU - Chou, Roger AU - Chou R AD - Pacific Northwest Evidence-based Practice Center FAU - Buckley, David AU - Buckley D AD - Pacific Northwest Evidence-based Practice Center FAU - Fu, Rochelle AU - Fu R AD - Pacific Northwest Evidence-based Practice Center FAU - Gore, John L AU - Gore JL AD - Pacific Northwest Evidence-based Practice Center FAU - Gustafson, Katie AU - Gustafson K AD - Pacific Northwest Evidence-based Practice Center FAU - Griffin, Jessica AU - Griffin J AD - Pacific Northwest Evidence-based Practice Center FAU - Grusing, Sara AU - Grusing S AD - Pacific Northwest Evidence-based Practice Center FAU - Selph, Shelley AU - Selph S AD - Pacific Northwest Evidence-based Practice Center LA - eng PT - Review PT - Book PL - Rockville (MD) EDAT- 2015/10/01 00:00 CRDT- 2015/10/01 00:00 AID - NBK330472 [bookaccession] PMID- 26413353 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150928 LR - 20240323 IS - 2090-598X (Print) IS - 2090-5998 (Electronic) IS - 2090-598X (Linking) VI - 13 IP - 3 DP - 2015 Sep TI - The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin. PG - 225-30 LID - 10.1016/j.aju.2015.05.001 [doi] AB - OBJECTIVE: To investigate whether the immunohistochemical expression of p53, p63 and her2/neu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer. PATIENTS AND METHODS: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2/neu immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 36 months in the Urology Department. RESULTS: For tumour grade there was a significant relationship with the overexpression of p53 (P = 0.010), her2 (P = 0.025) and negativity of p63 (P = 0.025). There was no significant relationship between p53 or her2/neu overexpression and tumour stage. However, there was a significant correlation (P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 (P = 0.01), her2/neu (P = 0.025) overexpression and p63 negativity (P = 0.005) and tumour recurrence and progression. CONCLUSION: Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2/neu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies. FAU - Hegazy, Raafat AU - Hegazy R AD - Department of Pathology, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Kamel, Mostafa AU - Kamel M AD - Department of Anatomy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Salem, Emad A AU - Salem EA AD - Department of Anatomy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Salem, Neveen A AU - Salem NA AD - National Research Centre, Cairo, Egypt. FAU - Fawzy, Amr AU - Fawzy A AD - Department of Anatomy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Sakr, Ahmed AU - Sakr A AD - Department of Anatomy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - El-Farargy, Ola AU - El-Farargy O AD - Department of Urology, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Nawar, Nashwa AU - Nawar N AD - Department of Radiotherapy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - El-Atar, Ahmed AU - El-Atar A AD - Department of Radiotherapy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Shahin, Ashraf M S AU - Shahin AM AD - Department of Anatomy, Faculty of medicine, Zagazig University, Cairo, Egypt. FAU - Hegazy, Abdelmonem AU - Hegazy A AD - Department of Medical Oncology, Faculty of medicine, Zagazig University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20150717 PL - United States TA - Arab J Urol JT - Arab journal of urology JID - 101562480 PMC - PMC4563013 OTO - NOTNLM OT - BCG OT - Bladder cancer OT - Cis, carcinoma in situ OT - H&E, haematoxylin and eosin OT - NMI, non-muscle invasive OT - P53, P63, Her2 OT - TURBT, transurethral resection of the bladder tumour EDAT- 2015/09/29 06:00 MHDA- 2015/09/29 06:01 PMCR- 2015/07/17 CRDT- 2015/09/29 06:00 PHST- 2014/11/14 00:00 [received] PHST- 2015/04/17 00:00 [revised] PHST- 2015/05/03 00:00 [accepted] PHST- 2015/09/29 06:00 [entrez] PHST- 2015/09/29 06:00 [pubmed] PHST- 2015/09/29 06:01 [medline] PHST- 2015/07/17 00:00 [pmc-release] AID - S2090-598X(15)00066-2 [pii] AID - 10.1016/j.aju.2015.05.001 [doi] PST - ppublish SO - Arab J Urol. 2015 Sep;13(3):225-30. doi: 10.1016/j.aju.2015.05.001. Epub 2015 Jul 17. PMID- 26411593 OWN - NLM STAT- MEDLINE DCOM- 20161005 LR - 20161230 IS - 1938-0682 (Electronic) IS - 1558-7673 (Linking) VI - 14 IP - 1 DP - 2016 Feb TI - Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. PG - 82-8 LID - S1558-7673(15)00220-7 [pii] LID - 10.1016/j.clgc.2015.08.006 [doi] AB - We assessed 126 patients with cT1-4, N0-2 urothelial carcinoma of the bladder who were treated with neoadjuvant chemotherapy followed by radical cystectomy. Twenty patients (16%) had squamous or glandular histological variation (HV). Significant pathologic downstaging (pT<2, N0) was seen in the HV patients (60% vs. 32%; P [ .02) and this difference remained significant after controlling for other clinical and pathological confounders. BACKGROUND: To assess the pathological response rates and survival outcomes in patients with squamous or glandular histological variation (HV) treated with neoadjuvant chemotherapy (nCT) and radical cystectomy (RC), and compare these with patients with pure urothelial carcinoma of the bladder (PUCB). PATIENTS AND METHODS: We performed a retrospective review of patients with clinical stage T1-4, N0-2 urothelial cancer treated with cisplatin-based nCT and RC in a single institution setting. Patients who received neoadjuvant carboplatin-based regimens were excluded. The primary end point was pathological response. Overall survival (OS) was a secondary end point. Logistic regression and Cox proportional hazard models were used for multivariate analyses. RESULTS: We evaluated 126 patients, including 20 (16%) with HV. Median estimated glomerular filtration rate (79.6 vs. 73.6 mL/min; P = .07) and the rate of complete endoscopic resection (75% vs. 40%; P = .01) were higher in the HV patients. Complete pathological response was similar between the groups (21% PUCB vs. 25% HV; P = .77). However, a significantly higher rate of pathologic downstaging (pT<2, N0 [pDS]) was seen in the HV patients (60% vs. 32%; P = .02). In a logistic regression model to predict pDS, in which clinically relevant confounding variables were included, HV (odds ratio, 4.01; 95% confidence interval, 1.16-13.9) remained an independent predictor of pDS. OS was similar between the 2 groups (HV: 45.7 vs. PUCB: 48.3 months; P = .73). CONCLUSION: When controlling for confounding factors, improved pDS rates were seen in the HV patients although there were no significant differences in the OS stratified according to histology. These results support the continued use of systemic nCT for this subgroup of patients. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Zargar-Shoshtari, Kamran AU - Zargar-Shoshtari K AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Sverrisson, Einar F AU - Sverrisson EF AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Sharma, Pranav AU - Sharma P AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Gupta, Shilpa AU - Gupta S AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Poch, Michael A AU - Poch MA AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Pow-Sang, Julio M AU - Pow-Sang JM AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Spiess, Philippe E AU - Spiess PE AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. FAU - Sexton, Wade J AU - Sexton WJ AD - Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: wade.sexton@moffitt.org. LA - eng PT - Journal Article DEP - 20150829 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/pathology/*therapy MH - Cell Transformation, Neoplastic MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoadjuvant Therapy MH - Neoplasms, Squamous Cell/mortality/pathology/*therapy MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Cystectomy carcinoma OT - Histology OT - Neoadjuvant therapy OT - Transitional Cell OT - Urinary bladder neoplasms EDAT- 2015/09/29 06:00 MHDA- 2016/10/07 06:00 CRDT- 2015/09/29 06:00 PHST- 2015/05/26 00:00 [received] PHST- 2015/08/16 00:00 [revised] PHST- 2015/08/24 00:00 [accepted] PHST- 2015/09/29 06:00 [entrez] PHST- 2015/09/29 06:00 [pubmed] PHST- 2016/10/07 06:00 [medline] AID - S1558-7673(15)00220-7 [pii] AID - 10.1016/j.clgc.2015.08.006 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2016 Feb;14(1):82-8. doi: 10.1016/j.clgc.2015.08.006. Epub 2015 Aug 29. PMID- 26411547 OWN - NLM STAT- MEDLINE DCOM- 20161019 LR - 20221109 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 34 IP - 2 DP - 2016 Feb TI - Lower ureteral lesion is an independent predictor of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. PG - 59.e9-13 LID - S1078-1439(15)00438-X [pii] LID - 10.1016/j.urolonc.2015.08.015 [doi] AB - OBJECTIVE: To elucidate whether the lower ureteral lesion can predict subsequent intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). PATIENTS AND METHODS: We retrospectively reviewed 186 consecutive patients with UTUC who underwent RNU at our institution between 1996 and 2013. Associations of various clinicopathological factors with subsequent IVR were assessed. Lower ureteral lesion was defined as the pathologically confirmed lowest carcinoma component within 5 cm from the lower end of the ureter. The log-rank test and Cox proportional hazards model were used for univariable and multivariable analysis, respectively. RESULTS: Overall, 86 patients (46%) developed IVR during the follow-up, with a median follow-up period of 43 months (interquartile range: 17-79 mo). In all, 53 patients (28%) had lower ureteral lesions, and 34 (64%) of them developed IVR. Univariable analysis demonstrated that lower ureteral lesion was significantly associated with IVR, as well as tumor multifocality, lymphatic invasion, and history of bladder cancer. Multivariable analysis identified the lower ureteral lesion as a sole independent predictor of IVR (P = 0.0304, hazard ratio = 1.74). CONCLUSIONS: Lower ureteral lesion was an independent predictor of IVR in patients with UTUC treated with RNU. Such patients may deserve prophylactic treatment and intensive follow-up. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Otsuka, Masafumi AU - Otsuka M AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: tohru-tky@umin.ac.jp. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Miyazaki, Hideyo AU - Miyazaki H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Fujimura, Tetsuya AU - Fujimura T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Fukuhara, Hiroshi AU - Fukuhara H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Homma, Yukio AU - Homma Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20150926 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Nephrectomy/*methods MH - Retrospective Studies MH - Ureter/*pathology MH - Ureteral Neoplasms/pathology/*surgery OTO - NOTNLM OT - Bladder cancer OT - Intravesical recurrence OT - Lower ureter OT - Nephroureterectomy OT - Upper tract urothelial carcinoma EDAT- 2015/09/29 06:00 MHDA- 2016/12/30 06:00 CRDT- 2015/09/29 06:00 PHST- 2015/06/09 00:00 [received] PHST- 2015/08/11 00:00 [revised] PHST- 2015/08/25 00:00 [accepted] PHST- 2015/09/29 06:00 [entrez] PHST- 2015/09/29 06:00 [pubmed] PHST- 2016/12/30 06:00 [medline] AID - S1078-1439(15)00438-X [pii] AID - 10.1016/j.urolonc.2015.08.015 [doi] PST - ppublish SO - Urol Oncol. 2016 Feb;34(2):59.e9-13. doi: 10.1016/j.urolonc.2015.08.015. Epub 2015 Sep 26. PMID- 26410305 OWN - NLM STAT- MEDLINE DCOM- 20160923 LR - 20260714 IS - 1873-3913 (Electronic) IS - 0898-6568 (Linking) VI - 27 IP - 12 DP - 2015 Dec TI - DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. PG - 2515-23 LID - S0898-6568(15)00276-4 [pii] LID - 10.1016/j.cellsig.2015.09.014 [doi] AB - There is a high frequency of tumor recurrence in non-muscle invasive bladder cancer (NMIBC) after transurethral resection and postoperative intravesical chemotherapy, however, the molecular mechanisms leading to the chemoresistance and tumor re-growth remain largely unknown. In this study, we observed a significant decrease of DAB2IP expression in high-grade and recurrent NMIBC specimens, which was negatively correlated with Twist1 expression and predicted a lower recurrence-free survival of patients. Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. Overall, this study reveals a new promising biomarker modulating the chemoresistance and tumor recurrence of NMIBC after bladder preservation surgery. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Wu, Kaijie AU - Wu K AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Wang, Bin AU - Wang B AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Chen, Yule AU - Chen Y AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Zhou, Jiancheng AU - Zhou J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Huang, Jun AU - Huang J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Hui, Ke AU - Hui K AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Zeng, Jin AU - Zeng J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Zhu, Jianning AU - Zhu J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Zhang, Kai AU - Zhang K AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Li, Lei AU - Li L AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Guo, Peng AU - Guo P AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Wang, Xinyang AU - Wang X AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. FAU - Hsieh, Jer-Tsong AU - Hsieh JT AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas 75390, TX, USA. FAU - He, Dalin AU - He D AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. Electronic address: dalinhe@yahoo.com. FAU - Fan, Jinhai AU - Fan J AD - Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. Electronic address: jinhaif029@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150926 PL - England TA - Cell Signal JT - Cellular signalling JID - 8904683 RN - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1) RN - 0 (Antineoplastic Agents) RN - 0 (DAB2IP protein, human) RN - 0 (Nuclear Proteins) RN - 0 (STAT3 Transcription Factor) RN - 0 (STAT3 protein, human) RN - 0 (TWIST1 protein, human) RN - 0 (Twist-Related Protein 1) RN - 0 (ras GTPase-Activating Proteins) RN - 80168379AG (Doxorubicin) RN - D58G680W0G (pirarubicin) SB - IM EIN - Cell Signal. 2026 Nov;147:112700. doi: 10.1016/j.cellsig.2026.112700. PMID: 42448519 MH - ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism MH - Animals MH - Antineoplastic Agents/*pharmacology/therapeutic use MH - Cell Line, Tumor MH - Cell Survival/drug effects MH - Down-Regulation MH - Doxorubicin/*analogs & derivatives/pharmacology/therapeutic use MH - Drug Resistance, Neoplasm MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Mice, Inbred BALB C MH - Mice, Nude MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*metabolism/mortality/prevention & control MH - Nuclear Proteins/metabolism MH - STAT3 Transcription Factor/metabolism MH - Signal Transduction MH - Twist-Related Protein 1/metabolism MH - Urinary Bladder Neoplasms/drug therapy/*epidemiology/*metabolism/mortality/pathology MH - Urothelium/metabolism/pathology MH - Xenograft Model Antitumor Assays MH - ras GTPase-Activating Proteins/*physiology OTO - NOTNLM OT - Bladder cancer OT - DAB2IP OT - P-glycoprotein OT - Pirarubicin OT - Tumor recurrence OT - Twist1 EDAT- 2015/09/28 06:00 MHDA- 2016/09/24 06:00 CRDT- 2015/09/28 06:00 PHST- 2015/09/16 00:00 [received] PHST- 2015/09/23 00:00 [accepted] PHST- 2015/09/28 06:00 [entrez] PHST- 2015/09/28 06:00 [pubmed] PHST- 2016/09/24 06:00 [medline] AID - S0898-6568(15)00276-4 [pii] AID - 10.1016/j.cellsig.2015.09.014 [doi] PST - ppublish SO - Cell Signal. 2015 Dec;27(12):2515-23. doi: 10.1016/j.cellsig.2015.09.014. Epub 2015 Sep 26. PMID- 26406865 OWN - NLM STAT- MEDLINE DCOM- 20160627 LR - 20260421 IS - 1875-8592 (Electronic) IS - 1574-0153 (Print) IS - 1574-0153 (Linking) VI - 15 IP - 4 DP - 2015 TI - Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer. PG - 357-64 LID - 10.3233/CBM-150472 [doi] AB - BACKGROUND AND OBJECTIVE: To clarify the clinical usefulness and diagnostic accuracy of urine chemokine (C-X-C motif) ligand 1 (CXCL1) as a biomarker for tumor detection and outcome prediction in patients with bladder cancer (BCa). METHODS: We measured urine CXCL1 levels in 175 patients with BCa and 30 healthy controls. The value of urine CXCL1 concentration normalized by urine creatinine (CXCL1/Cre) was analyzed in terms of detecting bladder tumors and predicting intravesical recurrence after transurethral resection (TUR). RESULTS: CXCL1/Cre was significantly higher (3-fold) in BCa patients than in healthy participants and the difference from control samples was greater in patients with advanced BCa. Although the urine cytology test generally lost diagnostic power in patients with low-grade superficial tumors, the sensitivity of CXCL1/Cre was not compromised in this patient population. Patients with higher CXCL1/Cre were significantly more likely to develop intravesical recurrence after TUR and multivariate analysis identified CXCL1/Cre as an independent predictor of post-TUR intravesical recurrence. Importantly, CXCL1/Cre could successfully classify the probabilities of post-TUR recurrence among patients with intermediate-risk according to EORTC risk criteria into two groups equivalent to its high- and low-risk groups. CONCLUSIONS: Urine CXCL1 is a promising, non-invasive molecular marker for tumor detection and outcome prediction in patients with BCa. FAU - Nakashima, Masakazu AU - Nakashima M AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Matsui, Yoshiyuki AU - Matsui Y AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kobayashi, Takashi AU - Kobayashi T AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Saito, Ryoichi AU - Saito R AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Hatahira, Satoko AU - Hatahira S AD - Toray Industries Inc., New Frontiers Research Laboratories, Kanagawa, Japan. FAU - Kawakami, Kazumi AU - Kawakami K AD - Toray Industries Inc., New Frontiers Research Laboratories, Kanagawa, Japan. FAU - Nakamura, Eijiro AU - Nakamura E AD - Laboratory for Malignancy Control Research, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Nishiyama, Hiroyuki AU - Nishiyama H AD - Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Ogawa, Osamu AU - Ogawa O AD - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. LA - eng PT - Journal Article PL - United States TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (CXCL1 protein, human) RN - 0 (Chemokine CXCL1) RN - AYI8EX34EU (Creatinine) SB - IM MH - Adult MH - Aged MH - Biomarkers, Tumor/*urine MH - Chemokine CXCL1/*urine MH - Creatinine/urine MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Prognosis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/surgery/*urine PMC - PMC12965094 OTO - NOTNLM OT - Bladder cancer OT - detection OT - prognostic factor OT - sensitivity and specificity OT - urine biomarker EDAT- 2015/09/26 06:00 MHDA- 2016/06/28 06:00 PMCR- 2015/01/01 CRDT- 2015/09/26 06:00 PHST- 2015/09/26 06:00 [entrez] PHST- 2015/09/26 06:00 [pubmed] PHST- 2016/06/28 06:00 [medline] PHST- 2015/01/01 00:00 [pmc-release] AID - CBM472 [pii] AID - 10.3233/CBM-150472 [doi] PST - ppublish SO - Cancer Biomark. 2015;15(4):357-64. doi: 10.3233/CBM-150472. PMID- 26397029 OWN - NLM STAT- MEDLINE DCOM- 20170119 LR - 20170119 IS - 1557-8550 (Electronic) IS - 1549-5418 (Linking) VI - 33 IP - 10 DP - 2015 Oct TI - Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. PG - 517-23 LID - 10.1089/pho.2015.3913 [doi] AB - BACKGROUND AND OBJECTIVE: Until now, various laser types have been used in the treatment of bladder cancer. The purpose of this study is to evaluate the feasibility and effectiveness of 2 mum continuous-wave (CW) thulium laser in treating primary non-muscle-invasive bladder cancer (NMIBC). METHODS: A comparative (randomized prospective) interventional study was conducted in our center. A total of 400 patients with Ta or T1 bladder cancer were enrolled and randomized to transurethral resection of bladder tumor (TURBT) or laser vaporesection (LVRBT). Patients in the TURBT group received standard transurethral resection with a bipolar electrocautery system, while those in the LVRBT group received transurethral vaporesction with a 2 mum CW thulium laser. All patients received intravesical irrigation with sterile water for at least 12 h immediately after the procedure. The end-points of this study were tumor recurrence and/or progression, or the completion of 36 months of follow-up (10 cystoscopies) with no recurrence. RESULTS: A total of 292 patients were included in our analysis, of whom 143 received TURBT and 149 received LVRBT. During 36 months of follow-up, 129 cases (44.2%) had recurrence: 61 (42.7%) in the TURBT group and 68 (45.6%) in the LVRBT group (p = 0.608). Tumor progression was found in 19 patients (6.5%): 11 in the TURBT (7.7%) and 8 (5.4%) in the LVRBT group (p = 0.421). Median tumor-free survival was 25.2 months (25.46 in the TURBT group vs. 24.9 in the LVRBT group, p = 0.729). Overall recurrence rate was 14.7%, 42.1%, and 62.5% in the low, intermediate low, and intermediate high risk subgroups, respectively. Operation time was significantly lower in the TURBT than in the LVRBT group (28.43 vs. 31.5 min, p = 0.044). CONCLUSIONS: Use of a 2 mum CW thulium laser is feasible and effective in treating primary NMIBC. With a cystoscopic biopsy of the bladder muscle, 2 mum CW thulium laser could retrieve sufficient diagnostic and prognostic specimens. FAU - Zhang, Xin-Ru AU - Zhang XR AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Feng, Chao AU - Feng C AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Zhu, Wei-Dong AU - Zhu WD AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Si, Jie-Min AU - Si JM AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Gu, Bao-Jun AU - Gu BJ AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Guo, Hui AU - Guo H AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Song, Lu-Jie AU - Song LJ AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . FAU - Li, Chao AU - Li C AD - Department of Urology, Shanghai Jiaotong University-Affiliated Shanghai Sixth People's Hospital , ShangHai, PR China . LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20150923 PL - United States TA - Photomed Laser Surg JT - Photomedicine and laser surgery JID - 101222340 RN - 8RKC5ATI4P (Thulium) SB - IM MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Feasibility Studies MH - Female MH - Humans MH - Laser Therapy/*methods/*statistics & numerical data MH - Male MH - Middle Aged MH - Prospective Studies MH - Thulium MH - Urinary Bladder Neoplasms/*mortality/*therapy EDAT- 2015/09/24 06:00 MHDA- 2017/01/20 06:00 CRDT- 2015/09/24 06:00 PHST- 2015/09/24 06:00 [entrez] PHST- 2015/09/24 06:00 [pubmed] PHST- 2017/01/20 06:00 [medline] AID - 10.1089/pho.2015.3913 [doi] PST - ppublish SO - Photomed Laser Surg. 2015 Oct;33(10):517-23. doi: 10.1089/pho.2015.3913. Epub 2015 Sep 23. PMID- 26394624 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20220331 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 34 IP - 5 DP - 2016 May TI - Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. PG - 709-16 LID - 10.1007/s00345-015-1690-5 [doi] AB - PURPOSE: To determine whether the immunohistochemical markers survivin and E-cadherin can predict progress at initially diagnosed Ta bladder cancer. METHODS: We retrospectively searched for every initially diagnosed pTa urothelial bladder carcinoma having been treated at our single-center hospital in Germany from January 1992 up to December 2004. Follow-up was recorded up to June 2010, with recurrence or progress being the endpoints. Immunohistochemical staining and analysis of survivin and E-cadherin of the TURB specimens were performed. Outcome dependency of progression and no progression with immunohistochemical staining was analyzed using uni- and multivariate regression analysis, Kaplan-Meier analysis and uni- and multivariate Cox regression analysis. RESULTS: Overall, 233 patients were included. Forty-two percent of those were tumor free in their follow-up TURBs, 46 % had at least one pTa recurrence and 12 % even showed progress to at least pT1 bladder cancer. Aberrant staining of E-cadherin was found within 71 % of patients with progression in contrast to only 40 % in cases without progression (p = 0.004). Of all progressed patients, 92 % showed overexpression of survivin in their initial pTa specimen compared to 61 % without progression (p = 0.001). Kaplan-Meier analysis revealed aberrant E-cadherin staining to be associated with worse progression-free survival (PFS) (p = 0.005) as well as overexpression of survivin (p = 0.003). In multivariate Cox regression analysis, strong E-cadherin staining was an independent prognosticator for better PFS (p = 0.033) and multifocality (p = 0.046) and tumor size over 3 cm (p = 0.042) were prognosticators for worse PFS. CONCLUSION: Adding the immunohistochemical markers survivin and E-cadherin could help to identify patients at risk of developing a progressive disease in initial stage pTa bladder cancer. FAU - Breyer, Johannes AU - Breyer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. Johannes.Breyer@ukr.de. FAU - Gierth, Michael AU - Gierth M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Shalekenov, Sanzhar AU - Shalekenov S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Aziz, Atiqullah AU - Aziz A AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. AD - Department of Urology, University of Hamburg, Hamburg, Germany. FAU - Schafer, Julius AU - Schafer J AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Denzinger, Stefan AU - Denzinger S AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. FAU - Hofstadter, Ferdinand AU - Hofstadter F AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Giedl, Christian AU - Giedl C AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Otto, Wolfgang AU - Otto W AD - Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. LA - eng PT - Journal Article DEP - 20150922 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Antigens, CD) RN - 0 (BIRC5 protein, human) RN - 0 (CDH1 protein, human) RN - 0 (Cadherins) RN - 0 (Inhibitor of Apoptosis Proteins) RN - 0 (Survivin) SB - IM MH - Aged MH - Aged, 80 and over MH - Antigens, CD MH - Cadherins/*analysis MH - Carcinoma, Transitional Cell/*chemistry/*pathology MH - Disease Progression MH - *Epithelial-Mesenchymal Transition MH - Female MH - Humans MH - Inhibitor of Apoptosis Proteins/*analysis MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Retrospective Studies MH - Survivin MH - Urinary Bladder Neoplasms/*chemistry/*pathology OTO - NOTNLM OT - E-cadherin OT - EMT OT - Immunohistochemistry OT - Non-muscle-invasive bladder cancer OT - Stage pTa bladder cancer OT - Survivin EDAT- 2015/09/24 06:00 MHDA- 2017/04/19 06:00 CRDT- 2015/09/24 06:00 PHST- 2015/07/08 00:00 [received] PHST- 2015/09/14 00:00 [accepted] PHST- 2015/09/24 06:00 [entrez] PHST- 2015/09/24 06:00 [pubmed] PHST- 2017/04/19 06:00 [medline] AID - 10.1007/s00345-015-1690-5 [pii] AID - 10.1007/s00345-015-1690-5 [doi] PST - ppublish SO - World J Urol. 2016 May;34(5):709-16. doi: 10.1007/s00345-015-1690-5. Epub 2015 Sep 22. PMID- 26382667 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260127 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 50 IP - 1 DP - 2016 TI - Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. PG - 14-20 LID - 10.3109/21681805.2015.1085089 [doi] AB - OBJECTIVE: The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. MATERIALS AND METHODS: All patients with newly detected bladder cancer reported to the SNRUBC during 1997-2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. RESULTS: The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997-2001) and 72.5 years in the last subperiod (2007-2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2-T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2-T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2-T4 tumours, or in the whole cohort. CONCLUSIONS: This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time. FAU - Jahnson, Staffan AU - Jahnson S AD - a 1 Department of Urology, IBK, Linkoping University , Linkoping, Sweden. FAU - Hosseini Aliabad, Abolfazl AU - Hosseini Aliabad A AD - b 2 Department of Urology, Karolinska University Hospital , Stockholm, Sweden. FAU - Holmang, Sten AU - Holmang S AD - c 3 Department of Urology, Sahlgrenska University Hospital , Gothenburg, Sweden. FAU - Jancke, Georg AU - Jancke G AD - a 1 Department of Urology, IBK, Linkoping University , Linkoping, Sweden. FAU - Liedberg, Fredrik AU - Liedberg F AD - d 4 Department of Urology, Skane University Hospital , Malmo, Sweden. FAU - Ljungberg, Borje AU - Ljungberg B AD - e 5 Department of Urology, Northern University Hospital , Umea, Sweden. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - f 6 Department of Urology, Uppsala University Hospital , Uppsala, Sweden. FAU - Rosell, Johan AU - Rosell J AD - g 7 Department of Urology, Regional Cancer Center South East , Linkoping, Sweden. LA - eng PT - Journal Article DEP - 20150918 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/*therapeutic use MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Carcinoma, Transitional Cell/mortality/pathology/*therapy MH - *Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Muscle, Smooth/pathology MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - *Registries MH - Survival Rate MH - Sweden MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder cancer OT - population-based OT - survival EDAT- 2015/09/19 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/09/19 06:00 PHST- 2015/09/19 06:00 [entrez] PHST- 2015/09/19 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.3109/21681805.2015.1085089 [doi] PST - ppublish SO - Scand J Urol. 2016;50(1):14-20. doi: 10.3109/21681805.2015.1085089. Epub 2015 Sep 18. PMID- 26372035 OWN - NLM STAT- MEDLINE DCOM- 20160713 LR - 20151002 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 25 IP - 6 DP - 2015 Nov TI - Long-term complications of urinary diversion. PG - 570-7 LID - 10.1097/MOU.0000000000000222 [doi] AB - PURPOSE OF REVIEW: Radical cystectomy and urinary diversion remains the cornerstone in surgical management of patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer. This approach has been associated with remarkable increase in patient survival and more patients are now living for years after surgery who may present with long-term complications. This review describes long-term complications associated with urinary diversion including renal function deterioration, voiding dysfunction, stoma and bowel-related complications, ureteroenteric stricture, metabolic disorders, and infectious complications. RECENT FINDINGS: The overall complication rate reported in recent large studies assessing long-term complications of urinary diversion is as high as 60%. Stoma-related complications followed by urinary tract infections are among the most common complications. Some of these complications may occur years after surgery; therefore, long-term follow-up of patients with urinary diversion is of utmost importance. SUMMARY: Long-term regular follow-up is imperative in patients with urinary diversion as nonfatal complications may occur years after surgery. FAU - Amini, Erfan AU - Amini E AD - aUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran bNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California, USA. FAU - Djaladat, Hooman AU - Djaladat H LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - *Cystectomy MH - Humans MH - Postoperative Complications/*etiology/physiopathology MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder/physiopathology/*surgery MH - Urinary Diversion/*adverse effects EDAT- 2015/09/16 06:00 MHDA- 2016/07/14 06:00 CRDT- 2015/09/16 06:00 PHST- 2015/09/16 06:00 [entrez] PHST- 2015/09/16 06:00 [pubmed] PHST- 2016/07/14 06:00 [medline] AID - 10.1097/MOU.0000000000000222 [doi] PST - ppublish SO - Curr Opin Urol. 2015 Nov;25(6):570-7. doi: 10.1097/MOU.0000000000000222. PMID- 26364695 OWN - NLM STAT- MEDLINE DCOM- 20160510 LR - 20151231 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 86 IP - 6 DP - 2015 Dec TI - The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. PG - 1185-90 LID - S0090-4295(15)00802-X [pii] LID - 10.1016/j.urology.2015.07.036 [doi] AB - OBJECTIVE: To assess the diagnostic and prognostic performance of a noninvasive FGFR3 mutation analysis. After transurethral resection (TUR) of noninvasive bladder transitional cell carcinoma (B-TCC), recurrence occurs in 70% of patients, thus justifying cystoscopic surveillance. MATERIALS AND METHODS: A prospective multicenter study was carried out with a 2-year follow-up of patients with superficial B-TCC. Urine samples were collected before TUR and then before each cystoscopy during follow-up. Screening for the most prevalent FGFR3 mutations was done using urinary cells. The prognostic significance of an FGFR3 mutation at the time of the initial diagnosis was determined. The performance of the test in diagnosing and/or predicting recurrence during follow-up was assessed by calculating sensitivity and specificity. RESULTS: Of 191 patients studied, 74 (39%) had a positive analysis before TUR (FGFR3 mutation group). The presence of an FGFR3 mutation at the time of diagnosis was associated with a shorter time to recurrence (P = .02). During follow-up, 68 patients from the FGFR3 mutation group were evaluated. FGFR3 mutation analysis showed a sensitivity of 0.73 and a specificity of 0.87 when compared with the results of cystoscopy. A positive urine test was predictive of recurrence either at the time of the positive result or later during the 2-year follow-up, with a sensitivity of 0.70 and a specificity of 0.87. CONCLUSION: Among patients with an FGFR3 mutation in the initial tumor, a noninvasive urine test during follow-up can be valuable in diagnosing or predicting subsequent recurrence. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Couffignal, Camille AU - Couffignal C AD - INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cite, Paris, France; AP-HP, Department of Biostatistics, Bichat Hospital, Paris, France. FAU - Desgrandchamps, Francois AU - Desgrandchamps F AD - AP-HP, Department of Urology, Saint Louis Hospital, Paris, France. FAU - Mongiat-Artus, Pierre AU - Mongiat-Artus P AD - AP-HP, Department of Urology, Saint Louis Hospital, Paris, France. FAU - Ravery, Vincent AU - Ravery V AD - AP-HP, Department of Urology, Bichat Hospital, Paris, France. FAU - Ouzaid, Idir AU - Ouzaid I AD - AP-HP, Department of Urology, Bichat Hospital, Paris, France. FAU - Roupret, Morgan AU - Roupret M AD - GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitie Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Pitie Hospital, Paris, France. FAU - Phe, Veronique AU - Phe V AD - AP-HP, Department of Urology, Pitie Hospital, Paris, France. FAU - Ciofu, Calin AU - Ciofu C AD - AP-HP, Department of Urology, Tenon Hospital, Paris, France. FAU - Tubach, Florence AU - Tubach F AD - INSERM, ECEVE, UMR 1123, CIC-EC 11425, Paris, France; ECEVE, UMR 1123, University of Paris Diderot, Sorbonne Paris Cite, Paris, France; AP-HP, Department of Epidemiology and Clinical Research, Bichat Hospital, Paris, France. FAU - Mentre, France AU - Mentre F AD - INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cite, Paris, France; AP-HP, Department of Biostatistics, Bichat Hospital, Paris, France. FAU - Cussenot, Olivier AU - Cussenot O AD - GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitie Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Tenon Hospital, Paris, France. FAU - Grandchamp, Bernard AU - Grandchamp B AD - AP-HP, Department of Genetics, Bichat Hospital, Paris, France. Electronic address: bernard.grandchamp@bch.aphp.fr. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20150911 PL - United States TA - Urology JT - Urology JID - 0366151 RN - EC 2.7.10.1 (FGFR3 protein, human) RN - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) SB - IM CIN - Urology. 2015 Dec;86(6):1190-1. doi: 10.1016/j.urology.2015.07.037. PMID: 26719118 MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/diagnosis/genetics/surgery/*urine MH - Cystoscopy MH - DNA Mutational Analysis MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/diagnosis/genetics/*urine MH - Population Surveillance/*methods MH - Predictive Value of Tests MH - Prognosis MH - Prospective Studies MH - Receptor, Fibroblast Growth Factor, Type 3/*genetics/*urine MH - Time Factors MH - Urinary Bladder Neoplasms/diagnosis/genetics/surgery/*urine EDAT- 2015/09/15 06:00 MHDA- 2016/05/11 06:00 CRDT- 2015/09/15 06:00 PHST- 2015/02/17 00:00 [received] PHST- 2015/06/15 00:00 [revised] PHST- 2015/07/09 00:00 [accepted] PHST- 2015/09/15 06:00 [entrez] PHST- 2015/09/15 06:00 [pubmed] PHST- 2016/05/11 06:00 [medline] AID - S0090-4295(15)00802-X [pii] AID - 10.1016/j.urology.2015.07.036 [doi] PST - ppublish SO - Urology. 2015 Dec;86(6):1185-90. doi: 10.1016/j.urology.2015.07.036. Epub 2015 Sep 11. PMID- 26364452 OWN - NLM STAT- MEDLINE DCOM- 20150928 LR - 20190918 IS - 0042-8450 (Print) IS - 0042-8450 (Linking) VI - 72 IP - 7 DP - 2015 Jul TI - The clinical course of non-muscle invasive bladder cancer after transurethral resection of the tumor with or without subsequent intravesical application of bacillus Calmette-Guerin: The influence of patients gender and age. PG - 596-601 AB - BACGROUND/AIM: The therapy with intravesical instillation of bacillus Calmette-Guerin (BCG) after transurethral resection (TUR) of tumor is the gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The role and importance of BCG intravesical therapy in various shape of tumors, were confirmed by our previous investigation. The aim of this study was to examine whether incidence of recurrence and tumor regression differs depending on sex and age of patients. METHODS: This study included a total of 899 patients suffering from NIMBC, treated at our institution from January 1, 2007 to March 1, 2013. Two groups of patients were formed: patients underwent TUR + BCG therapy (the group I) and the group II with patients in whom TUR was performed as only therapy. These two groups of patients were divided into subgroups of respondents male and female, age 60 years or younger and older than 60 years. Statistical analysis was performed using chi2 test and the Kolmogorov-Smirnov test. RESULTS: This research suggests that if the frequency of recurrence is seen as the only parameter, considering all the subjects, the lowest recurrence rate was determined in the male subjects, aged 60 years and younger who had received BCG after TUR. A high statistical significance was found in the incidence of recurrence in patients younger than 60 years, depending on the response to the therapy, while in those older than 60 years, the difference was at the level of statistical significance. This can be attributed to a certain degree of infravesical obstruction in older men. CONCLUSIONS: Sex and age of patients may have a significant influence on the course and outcome of NMIBC. The disease has the most malignant and most aggressive behavior when present in males older than 60 years. FAU - Milosevic, Radovan AU - Milosevic R FAU - Milovic, Novak AU - Milovic N FAU - Aleksic, Predrag AU - Aleksic P FAU - Lazic, Miodrag AU - Lazic M FAU - Cerovic, Snezana AU - Cerovic S FAU - Prelevic, Rade AU - Prelevic R FAU - Spasic, Aleksandar AU - Spasic A FAU - Simic, Dejan AU - Simic D FAU - Kovacevic, Bozidar AU - Kovacevic B LA - eng PT - Journal Article PL - Serbia TA - Vojnosanit Pregl JT - Vojnosanitetski pregled JID - 21530700R RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Age Factors MH - Aged MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - BCG Vaccine/*administration & dosage/adverse effects MH - Chemotherapy, Adjuvant MH - Chi-Square Distribution MH - Cystectomy/adverse effects/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Remission Induction MH - Risk Assessment MH - Risk Factors MH - Serbia MH - Sex Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*therapy EDAT- 2015/09/15 06:00 MHDA- 2015/09/29 06:00 CRDT- 2015/09/15 06:00 PHST- 2015/09/15 06:00 [entrez] PHST- 2015/09/15 06:00 [pubmed] PHST- 2015/09/29 06:00 [medline] AID - 10.2298/vsp140616003m [doi] PST - ppublish SO - Vojnosanit Pregl. 2015 Jul;72(7):596-601. doi: 10.2298/vsp140616003m. PMID- 26354850 OWN - NLM STAT- MEDLINE DCOM- 20160803 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 5 DP - 2015 Sep 10 TI - GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. PG - 14000 LID - 10.1038/srep14000 [doi] LID - 14000 AB - SNPs may restrict cell detoxification activity and be a potential risk factor for cancer chemosensitivity. We evaluated the predictive value of these polymorphisms on the sensitivity of bladder cancer patients to epirubicin and mitomycin chemotherapy instillation as well as their toxicities. SNPs were analyzed by TaqMan genotyping assays in 130 patients treated with epirubicin and 114 patients treated with mitomycin. Recurrence-free survival (RFS) was estimated by the Kaplan-Meier method, and hazard ratios (HRs) and 95% confidence intervals (CIs) of the HRs were derived from multivariate Cox proportional hazard models. GSTP1 rs1695 and GSTO1 rs4925 were also associated with RFS in the epirubicin group. Patients carrying the GSTP1 AG+GG and GSTO1 AC+AA genotypes had an unfavorable RFS. Patients with the GSTP1 AA and GSTO1 CC genotypes had a reduced risk of recurrence after the instillation of epirubicin. In addition, patients with the GSTP1 rs1695 AA genotype had an increased risk of irritative voiding symptoms; while patients with the GSTO1 rs4925 CC genotype had a decreased risk of hematuria. Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity. FAU - Deng, Xiaheng AU - Deng X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Yang, Xiao AU - Yang X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Cheng, Yidong AU - Cheng Y AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Liu, Xuzhong AU - Liu X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Li, Xiao AU - Li X AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Zhao, Ruizhe AU - Zhao R AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Qin, Chao AU - Qin C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Lu, Qiang AU - Lu Q AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. FAU - Yin, Changjun AU - Yin C AD - Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150910 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 3Z8479ZZ5X (Epirubicin) RN - 50SG953SK6 (Mitomycin) RN - EC 2.5.1.18 (GSTO1 protein, human) RN - EC 2.5.1.18 (Glutathione S-Transferase pi) RN - EC 2.5.1.18 (Glutathione Transferase) SB - IM MH - Administration, Intravesical MH - Aged MH - Alleles MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Epirubicin/administration & dosage MH - Female MH - Genotype MH - Glutathione S-Transferase pi/*genetics MH - Glutathione Transferase/*genetics MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - Neoplasm Grading MH - *Polymorphism, Single Nucleotide MH - Retrospective Studies MH - Treatment Outcome MH - Tumor Burden MH - Urinary Bladder Neoplasms/*drug therapy/*genetics/mortality/pathology PMC - PMC4564850 EDAT- 2015/09/12 06:00 MHDA- 2016/08/04 06:00 PMCR- 2015/09/10 CRDT- 2015/09/11 06:00 PHST- 2015/01/08 00:00 [received] PHST- 2015/07/31 00:00 [accepted] PHST- 2015/09/11 06:00 [entrez] PHST- 2015/09/12 06:00 [pubmed] PHST- 2016/08/04 06:00 [medline] PHST- 2015/09/10 00:00 [pmc-release] AID - srep14000 [pii] AID - 10.1038/srep14000 [doi] PST - epublish SO - Sci Rep. 2015 Sep 10;5:14000. doi: 10.1038/srep14000. PMID- 26343350 OWN - NLM STAT- MEDLINE DCOM- 20160613 LR - 20191210 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 195 IP - 2 DP - 2016 Feb TI - External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. PG - 283-9 LID - S0022-5347(15)04716-3 [pii] LID - 10.1016/j.juro.2015.08.093 [doi] AB - PURPOSE: We externally validated 3 previously published nomograms to predicting recurrence, and cancer specific and overall survival following radical cystectomy and pelvic lymph node dissection for urothelial carcinoma of the bladder. MATERIALS AND METHODS: Two surgeons from a single institution performed a total of 197 consecutive radical cystectomies and pelvic lymph node dissections for bladder cancer from January 2003 to September 2009. A total of 23 patients were excluded from analysis. Examined parameters were those used in the original nomograms, including patient age, gender, pathological T stage, N stage, tumor grade, presence of carcinoma in situ and lymphovascular invasion, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiation therapy. Nomogram predictions were compared to actuarial outcomes and predictive accuracy was quantified using measures of discrimination and calibration. RESULTS: At the time of analysis 34 patients had experienced recurrence, of whom 28 died of disease and 6 were currently alive with disease. Discrimination at 2, 5 and 8 years was 0.776, 0.809 and 0.794 for recurrence, 0.822, 0.840 and 0.849 for cancer specific survival, and 0.812, 0.820 and 0.825, respectively, for overall survival. Calibration plots revealed nomogram overestimation of all 3 end points. CONCLUSIONS: Nomograms for bladder cancer recurrence, cancer specific survival and overall survival following radical cystectomy and pelvic lymph node dissection performed well in our series with accuracy comparable to that in the original series. The use of nomogram predictions should be further explored in clinical trials to assess the impact on patient care in clinical practice. CI - Copyright (c) 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Brooks, Michael AU - Brooks M AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas. FAU - Godoy, Guilherme AU - Godoy G AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas. FAU - Sun, Maxine AU - Sun M AD - University of Montreal Health Center, Montreal, Quebec, Canada; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard School of Medicine, Boston, Massachusetts. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Bladder Cancer Research Consortium; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Weil Medical College Cornell University, New York, New York. FAU - Amiel, Gilad E AU - Amiel GE AD - Bladder Cancer Research Consortium; Department of Urology, Rambam Health Care Campus, Haifa, Israel. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, Texas; Bladder Cancer Research Consortium. Electronic address: slerner@bcm.edu. LA - eng GR - K23 CA160664/CA/NCI NIH HHS/United States GR - K23CA160664/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Validation Study DEP - 20150905 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM CIN - J Urol. 2016 Feb;195(2):289; discussion 289. doi: 10.1016/j.juro.2015.08.109. PMID: 26542266 MH - Aged MH - Cystectomy MH - Female MH - Humans MH - Lymph Node Excision MH - Lymphatic Metastasis MH - Male MH - Neoadjuvant Therapy MH - Neoplasm Grading MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - *Nomograms MH - Predictive Value of Tests MH - Survival Analysis MH - Urinary Bladder Neoplasms/mortality/*pathology/surgery PMC - PMC6289832 MID - NIHMS798810 OTO - NOTNLM OT - cystectomy OT - mortality OT - nomograms OT - urinary bladder neoplasms OT - validation studies EDAT- 2015/09/08 06:00 MHDA- 2016/06/14 06:00 PMCR- 2018/12/11 CRDT- 2015/09/08 06:00 PHST- 2015/08/16 00:00 [accepted] PHST- 2015/09/08 06:00 [entrez] PHST- 2015/09/08 06:00 [pubmed] PHST- 2016/06/14 06:00 [medline] PHST- 2018/12/11 00:00 [pmc-release] AID - S0022-5347(15)04716-3 [pii] AID - 10.1016/j.juro.2015.08.093 [doi] PST - ppublish SO - J Urol. 2016 Feb;195(2):283-9. doi: 10.1016/j.juro.2015.08.093. Epub 2015 Sep 5. PMID- 26343003 OWN - NLM STAT- MEDLINE DCOM- 20171227 LR - 20220317 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 69 IP - 5 DP - 2016 May TI - A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. PG - 855-62 LID - S0302-2838(15)00779-4 [pii] LID - 10.1016/j.eururo.2015.08.034 [doi] AB - BACKGROUND: Gene expression profiling (GEP) suggests there are three subtypes of muscle-invasive urothelial cancer (UC): basal, which has the worst prognosis; p53-like; and luminal. We hypothesized that GEP of transurethral resection (TUR) and cystectomy specimens would predict subtypes that could benefit from chemotherapy. OBJECTIVE: To explore clinical outcomes for patients treated with dose-dense (DD) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and bevacizumab (B) and the impact of UC subtype. DESIGN, SETTING, AND PARTICIPANTS: Sixty patients enrolled in a neoadjuvant trial of four cycles of DDMVAC + B between 2007 and 2010. TUR and cystectomy specimens for GEP were available from 38 and 23 patients, respectively, and from an additional confirmation cohort of 49 patients treated with perioperative MVAC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analyzed using multivariable Cox regression and log-rank tests. RESULTS AND LIMITATIONS: Chemotherapy was active, with pT0N0 and C (rs2070744) and Glu298Asp (rs1799983), can serve as possible molecular markers for outcome after BCG-treatment for NMIBC. MATERIALS AND METHODS: All NMIBC-patients from a well-characterized population based cohort were analyzed (n=88). Polymorphism data were combined with information from 15-years of clinical follow-up. The effect of BCG-treatment on cancer-specific death (CSD), recurrence and progression in patients with varying NOS-genotypes were studied using Cox proportional hazard-models and log rank tests. RESULTS: BCG-treatment resulted in significantly better survival in patients without (Log rank: p=0.006; HR: 0.12, p=0.048), but not in patients with a long version ((CCTTT)n >==13 repeats) of the NOS2-promoter microsatellite. The NOS3-rs2070744(TT) and rs1799983(GG)-genotypes showed decreased risk for CSD (Log rank(TT): p=0.001; Log rank(GG): p=0.010, HR(GG): 0.16, p=0.030) and progression (Log rank(TT): p<0.001, HR(TT): 0.05, p=0.005; Log rank(GG): p<0.001, HR(GG): 0.10, p=0.003) after BCG-therapy compared to the other genotypes. There was also a reduction in recurrence in BCG-treated patients that was mostly genotype independent. Analysis of combined genotypes identified a subgroup of 30% of the BCG-treated patients that did not benefit from BCG-treatment. CONCLUSIONS: Our results suggest that the investigated polymorphisms influence patient response to BCG-treatment and thus may serve as possible markers for identification of BCG-failures. CI - Copyright (c) 2015 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Ryk, Charlotta AU - Ryk C AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. Electronic address: charlotta.ryk@ki.se. FAU - Koskela, Lotta Renstrom AU - Koskela LR AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. FAU - Thiel, Tomas AU - Thiel T AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. FAU - Wiklund, N Peter AU - Wiklund NP AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. FAU - Steineck, Gunnar AU - Steineck G AD - Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden; Division of Clinical Cancer Epidemiology, Department of Oncology, Onkologiskt centrum, Sahlgrenska University Hospital, 413 45 Goteborg, Sweden. FAU - Schumacher, Martin C AU - Schumacher MC AD - Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. FAU - de Verdier, Petra J AU - de Verdier PJ AD - Urology Laboratory, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150810 PL - Netherlands TA - Redox Biol JT - Redox biology JID - 101605639 RN - 0 (Antineoplastic Agents) RN - EC 1.14.13.39 (NOS2 protein, human) RN - EC 1.14.13.39 (NOS3 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type III) SB - IM MH - Aged MH - Alleles MH - Antineoplastic Agents/*therapeutic use MH - Carcinoma in Situ/diagnosis/genetics/mortality/*therapy MH - Carcinoma, Transitional Cell/diagnosis/genetics/mortality/*therapy MH - Female MH - Gene Expression MH - Humans MH - Male MH - Middle Aged MH - Mycobacterium bovis/*chemistry MH - Neoplasm Recurrence, Local/diagnosis/genetics/mortality/*therapy MH - Neoplasm Staging MH - Nitric Oxide Synthase Type II/*genetics MH - Nitric Oxide Synthase Type III/*genetics MH - Polymorphism, Genetic MH - Prognosis MH - Promoter Regions, Genetic MH - Proportional Hazards Models MH - Prospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/diagnosis/genetics/mortality/*therapy PMC - PMC4556773 OTO - NOTNLM OT - BCG vaccine OT - Cancer survival OT - Genetic polymorphism OT - Nitric oxide synthase OT - Urinary bladder neoplasms EDAT- 2015/08/25 06:00 MHDA- 2016/09/03 06:00 PMCR- 2015/08/10 CRDT- 2015/08/24 06:00 PHST- 2015/05/13 00:00 [received] PHST- 2015/08/04 00:00 [revised] PHST- 2015/08/09 00:00 [accepted] PHST- 2015/08/24 06:00 [entrez] PHST- 2015/08/25 06:00 [pubmed] PHST- 2016/09/03 06:00 [medline] PHST- 2015/08/10 00:00 [pmc-release] AID - S2213-2317(15)00098-1 [pii] AID - REDOXD1500063 [pii] AID - 10.1016/j.redox.2015.08.008 [doi] PST - ppublish SO - Redox Biol. 2015 Dec;6:272-277. doi: 10.1016/j.redox.2015.08.008. Epub 2015 Aug 10. PMID- 26287745 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20211203 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 96 IP - 1 DP - 2016 TI - Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. PG - 39-45 LID - 10.1159/000438868 [doi] AB - INTRODUCTION: Yes-associated protein 1 (YAP1), the nuclear effector of the Hippo pathway, plays an important role in many tumor entities. We evaluated staining and clinical significance of YAP1 and phosphorylated YAP1 (pYAP1) in urothelial bladder cancer (BCA). MATERIALS AND METHODS: We used a tissue micorarray with samples of patients with muscle-invasive bladder cancer (MIBC, n = 192), non-muscle-invasive bladder cancer (NMIBC, n = 192) and normal urothelial bladder tissue (CTRL, n = 38) to determine the immunhistochemical staining of YAP1 and pYAP1. Cytoplasmatic and nuclear levels were evaluated. The t test was used for comparative analysis. Overall survival and progression-free survival were evaluated by Kaplan-Meier estimates and the Cox proportional hazard regression model. RESULTS: Nuclear YAP1 as well as cytoplasmatic pYAP1 levels were higher in CTRL than in BCA, whereby both--NMIBC and MIBC--had lower levels than CTRL. Among patients with MIBC, cytoplasmatic YAP1 and pYAP1 staining decreased with advanced stage. YAP1 and pYAP1 staining did not correlate with the recurrence rate, progression-free, cancer-specific or overall survival. CONCLUSIONS: Immunhistochemical staining and subcellular localization of YAP1 and pYAP1 are different for BCA, NMIBC, MIBC and CTRL, indicating that the Hippo pathway is involved in urothelial carcinogenesis. CI - (c) 2015 S. Karger AG, Basel. FAU - Latz, Stefan AU - Latz S AD - Department of Urology, University Hospital Bonn, Bonn, Germany. FAU - Umbach, Tine AU - Umbach T FAU - Goltz, Diane AU - Goltz D FAU - Kristiansen, Glen AU - Kristiansen G FAU - Muller, Stephan C AU - Muller SC FAU - Ellinger, Jorg AU - Ellinger J LA - eng PT - Journal Article DEP - 20150820 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Phosphoproteins) RN - 0 (Transcription Factors) RN - 0 (YAP-Signaling Proteins) RN - 0 (YAP1 protein, human) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) SB - IM MH - Adaptor Proteins, Signal Transducing/*metabolism MH - Cell Nucleus/*metabolism MH - Cytoplasm/*metabolism MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - *Gene Expression Regulation, Neoplastic MH - Hippo Signaling Pathway MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/pathology MH - Phosphoproteins/*metabolism MH - Phosphorylation MH - Proportional Hazards Models MH - Protein Serine-Threonine Kinases/metabolism MH - Tissue Array Analysis MH - Transcription Factors MH - Urinary Bladder Neoplasms/diagnosis/*metabolism MH - Urothelium/*metabolism/pathology MH - YAP-Signaling Proteins EDAT- 2015/08/20 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/08/20 06:00 PHST- 2015/03/23 00:00 [received] PHST- 2015/07/20 00:00 [accepted] PHST- 2015/08/20 06:00 [entrez] PHST- 2015/08/20 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 000438868 [pii] AID - 10.1159/000438868 [doi] PST - ppublish SO - Urol Int. 2016;96(1):39-45. doi: 10.1159/000438868. Epub 2015 Aug 20. PMID- 26286913 OWN - NLM STAT- MEDLINE DCOM- 20160915 LR - 20201209 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 21 IP - 24 DP - 2015 Dec 15 TI - SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor. PG - 5601-11 LID - 10.1158/1078-0432.CCR-14-3308 [doi] AB - PURPOSE: Mass spectrometry-based biomarker discovery has clinical benefit. To identify novel biomarkers for urothelial carcinoma, we performed quantitative proteomics on pooled urine pairs from patients with and without urothelial carcinoma. EXPERIMENTAL DESIGN: Shot-gun proteomics using liquid chromatography-tandem mass spectrometry and stable isotope dimethyl labeling identified 219 candidate proteins. The potential implication of SH3 domain binding glutamic acid-rich protein like 3 (SH3BGRL3) was examined by immunoblotting of the urine (n = 13) and urothelial tumors (n = 32). Additional immunohistochemistry was performed on bladder cancer array (n = 1145) and correlated with tumor aggressiveness. Then, biologic functions and signaling pathways of SH3BGRL3 were explored using stable cell lines. RESULTS: The detectable urine SH3BGRL3 in patients with urothelial carcinoma was positively associated with higher histologic grading and muscle invasiveness of urothelial carcinoma. SH3BGRL3 is expressed in 13.9% (159/1145) of bladder cancer cohort and is positively associated with muscle invasion (P = 0.0028). SH3BGRL3 expression is associated with increased risk of progression in patients with nonmuscle-invasive bladder cancer (P = 0.032). SH3BGRL3 expression is significantly associated with a high level of epidermal growth factor receptor (EGFR) in bladder cancer (P < 0.0001). SH3BGRL3 promotes the epithelial-mesenchymal transition, cell migration, and proliferation of urothelial carcinoma in vitro. SH3BGRL3 interacts with phosphor-EGFR at Y1068, Y1086, and Y1173 through Grb2 by its proline-rich motif, and activates the Akt-associated signaling pathway. CONCLUSIONS: Evaluation of SH3BGRL3 expression status or urine content may identify a subset of patients with bladder cancer who may require more intensive treatment. SH3BGRL3 deserves further investigation as a cotargeting candidate for designing EGFR-based cancer therapies. Clin Cancer Res; 21(24); 5601-11. (c)2015 AACR. CI - (c)2015 American Association for Cancer Research. FAU - Chiang, Cheng-Yao AU - Chiang CY AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Pan, Chin-Chen AU - Pan CC AD - Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Chang, Hong-Yi AU - Chang HY AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Lai, Ming-Derg AU - Lai MD AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Tzai, Tzong-Shin AU - Tzai TS AD - Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Tsai, Yuh-Shyan AU - Tsai YS AD - Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Ling, Pin AU - Ling P AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Liu, Hsiao-Sheng AU - Liu HS AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Lee, Bi-Fang AU - Lee BF AD - Department of Nuclear Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Cheng, Hong-Ling AU - Cheng HL AD - Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan. FAU - Ho, Chung-Liang AU - Ho CL AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Pathology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chen, Shu-Hui AU - Chen SH AD - Department of Chemistry, College of Sciences, National Cheng Kung University, Tainan, Taiwan. FAU - Chow, Nan-Haw AU - Chow NH AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Pathology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. chownh@mail.ncku.edu.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150818 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Biomarkers, Tumor) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Peptide Fragments) RN - 0 (Proteome) RN - 0 (SH3BGRL3 protein, human) RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM CIN - J Urol. 2017 Jul;198(1):40-41. doi: 10.1016/j.juro.2017.04.006. PMID: 28618713 MH - Adaptor Proteins, Signal Transducing MH - Amino Acid Sequence MH - *Biomarkers, Tumor MH - Cell Line, Tumor MH - Cell Movement/genetics MH - Cell Transformation, Neoplastic/genetics/metabolism MH - Epithelial-Mesenchymal Transition/genetics MH - ErbB Receptors/metabolism MH - Gene Expression MH - Humans MH - Immunohistochemistry MH - Intracellular Signaling Peptides and Proteins/chemistry/genetics/metabolism/*urine MH - Male MH - Models, Molecular MH - Neoplasm Grading MH - Neoplasm Staging MH - Peptide Fragments/chemistry/metabolism/urine MH - Prognosis MH - Prostatic Hyperplasia/metabolism/urine MH - Protein Binding MH - Proteome MH - Proteomics/methods MH - Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction MH - Urinary Bladder Neoplasms/metabolism/mortality/pathology MH - Urologic Neoplasms/*diagnosis/genetics/metabolism/*urine EDAT- 2015/08/20 06:00 MHDA- 2016/09/16 06:00 CRDT- 2015/08/20 06:00 PHST- 2014/12/26 00:00 [received] PHST- 2015/07/27 00:00 [accepted] PHST- 2015/08/20 06:00 [entrez] PHST- 2015/08/20 06:00 [pubmed] PHST- 2016/09/16 06:00 [medline] AID - 1078-0432.CCR-14-3308 [pii] AID - 10.1158/1078-0432.CCR-14-3308 [doi] PST - ppublish SO - Clin Cancer Res. 2015 Dec 15;21(24):5601-11. doi: 10.1158/1078-0432.CCR-14-3308. Epub 2015 Aug 18. PMID- 26286880 OWN - NLM STAT- MEDLINE DCOM- 20170418 LR - 20181113 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 34 IP - 5 DP - 2016 May TI - Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. PG - 695-701 LID - 10.1007/s00345-015-1667-4 [doi] AB - PURPOSE: Several disease characteristics have been identified as potential predictors for pathological node involvement (pN+) following radical cystectomy (RC). However, these have not been assessed in patients treated with neoadjuvant chemotherapy (NAC). We endeavored to assess factors predicting adverse pathology in clinically node-negative patients treated with NAC and RC. METHODS: Patients from four North American institutions with cT2-4aN0M0 UC who received three or four cycles of NAC followed by RC were selected. Logistic regression was used to predict pN+, /=4 HM instillations on a prophylactic schedule was conducted. The primary outcome was time-to-progression survival; secondary outcomes were overall survival, cancer-specific survival, and adverse events. Descriptive statistics, Kaplan-Meier survival analyses, Cox proportional hazards modelling, and univariate and multivariable regression were performed. RESULTS: The presence of initial complete response (CR; no evidence of disease at first check video-cystoscopy and urine cytology) post-HM treatment was an independent predictor of good response to HM. Female patients and those without carcinoma in situ (CIS) also appeared to respond better to the intervention. The overall bladder preservation rate at a median of 27 months was 81.4%; 17/97 (17.5%) patients died during the course of the study. CONCLUSIONS: High-risk NMIBC patients can be safely treated with HM and have good oncological outcome. However, those without an initial CR have a poor prognosis and should be counselled towards adopting other treatment methodologies such as cystectomy. Female gender and lack of CIS may be good prognostic indicators for response to HM. CI - (c) 2015 S. Karger AG, Basel. FAU - Sooriakumaran, Prasanna AU - Sooriakumaran P AD - Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. FAU - Chiocchia, Virginia AU - Chiocchia V FAU - Dutton, Susan AU - Dutton S FAU - Pai, Aakash AU - Pai A FAU - Ayres, Benjamin E AU - Ayres BE FAU - Le Roux, Pieter AU - Le Roux P FAU - Swinn, Michael AU - Swinn M FAU - Bailey, Michael AU - Bailey M FAU - Perry, Matthew J A AU - Perry MJ FAU - Issa, Rami AU - Issa R LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20150806 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Aged MH - Antibiotics, Antineoplastic/therapeutic use MH - Biopsy MH - Carcinoma in Situ/drug therapy/pathology MH - Cohort Studies MH - Cystectomy/*methods MH - Cystoscopy/methods MH - Disease Progression MH - Female MH - Fever/*drug therapy MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Mitomycin/*therapeutic use MH - Predictive Value of Tests MH - Prognosis MH - Proportional Hazards Models MH - Temperature MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*drug therapy/*pathology MH - Urothelium/*pathology MH - Video Recording EDAT- 2015/08/19 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/08/18 06:00 PHST- 2015/02/11 00:00 [received] PHST- 2015/06/05 00:00 [accepted] PHST- 2015/08/18 06:00 [entrez] PHST- 2015/08/19 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 000435788 [pii] AID - 10.1159/000435788 [doi] PST - ppublish SO - Urol Int. 2016;96(1):83-90. doi: 10.1159/000435788. Epub 2015 Aug 6. PMID- 26272237 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20260128 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 69 IP - 4 DP - 2016 Apr TI - A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). PG - 613-621 LID - S0302-2838(15)00697-1 [pii] LID - 10.1016/j.eururo.2015.07.038 [doi] AB - BACKGROUND: Laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) are increasingly popular, but high-level evidence for these techniques remains lacking. OBJECTIVE: To compare the outcomes of patients undergoing open radical cystectomy (ORC), RARC, and LRC. DESIGN, SETTING, AND PARTICIPANTS: From March 2009 to July 2012, 164 patients requiring radical cystectomy for muscle-invasive bladder cancer or high-risk non-muscle-invasive bladder cancer were invited to participate, with an aim of recruiting 47 patients into each arm. Overall, 93 were suitable for trial inclusion; 60 (65%) agreed and 33 (35%) declined. INTERVENTION: ORC, RARC, or LRC with extracorporeal urinary diversion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary end points were 30- and 90-d complication rates. Secondary end points were perioperative clinical, pathologic, and oncologic outcomes, and quality of life (QoL). The Fisher exact test and analysis of variance were used for statistical analyses. RESULTS AND LIMITATIONS: The 30-d complication rates (classified by the Clavien-Dindo system) varied significantly between the three arms (ORC: 70%; RARC: 55%; LRC: 26%; p=0.024). ORC complication rates were significantly higher than LRC (p<0.01). The 90-d complication rates did not differ significantly between the three arms (ORC: 70%; RARC: 55%; LRC 32%; p=0.068). Mean operative time was significantly longer in RARC compared with ORC or LRC. ORC resulted in a slower return to oral solids than RARC or LRC. There were no significant differences in QoL measures. Major limitations are the small sample size and potential surgeon bias. CONCLUSIONS: The 30-d complication rates varied by type of surgery and were significantly higher in the ORC arm than the LRC arm. There was no significant difference in 90-d Clavien-graded complication rates between the three arms. PATIENT SUMMARY: We compared patients having open, robotic, or laparoscopic bladder removal surgery for bladder cancer and found no difference in Clavien-graded complication rates at 90 d. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Khan, Muhammad Shamim AU - Khan MS AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK; MRC Centre for Transplantation, NIHR Biomedical Research Centre, King's College London, Guy's Hospital, London, UK. Electronic address: shamim.khan@gstt.nhs.uk. FAU - Gan, Christine AU - Gan C AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK. FAU - Ahmed, Kamran AU - Ahmed K AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK. FAU - Ismail, Ahmad Fahim AU - Ismail AF AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK. FAU - Watkins, Jane AU - Watkins J AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK. FAU - Summers, Jennifer A AU - Summers JA AD - Division of Health and Social Care Research, King's College London, London, UK. FAU - Peacock, Janet L AU - Peacock JL AD - Division of Health and Social Care Research, King's College London, London, UK. FAU - Rimington, Peter AU - Rimington P AD - Department of Urology, Eastbourne District General Hospital, Eastbourne, East Sussex, UK. FAU - Dasgupta, Prokar AU - Dasgupta P AD - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, UK; MRC Centre for Transplantation, NIHR Biomedical Research Centre, King's College London, Guy's Hospital, London, UK. LA - eng GR - MR/J006742/1/MRC_/Medical Research Council/United Kingdom PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150810 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 SB - IM CIN - Eur Urol. 2016 Apr;69(4):622-623. doi: 10.1016/j.eururo.2015.08.006. PMID: 26297605 MH - Aged MH - Cystectomy/adverse effects/*methods/mortality MH - Humans MH - *Laparoscopy/adverse effects/mortality MH - London MH - Male MH - Middle Aged MH - Operative Time MH - Postoperative Complications/etiology MH - Prospective Studies MH - Recovery of Function MH - Risk Factors MH - *Robotic Surgical Procedures/adverse effects/mortality MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - Complications OT - Minimally invasive surgery OT - Muscle-invasive bladder cancer OT - Radical cystectomy OT - Robotic surgery EDAT- 2015/08/15 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/08/15 06:00 PHST- 2015/01/25 00:00 [received] PHST- 2015/07/16 00:00 [accepted] PHST- 2015/08/15 06:00 [entrez] PHST- 2015/08/15 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - S0302-2838(15)00697-1 [pii] AID - 10.1016/j.eururo.2015.07.038 [doi] PST - ppublish SO - Eur Urol. 2016 Apr;69(4):613-621. doi: 10.1016/j.eururo.2015.07.038. Epub 2015 Aug 10. PMID- 26268246 OWN - NLM STAT- MEDLINE DCOM- 20160915 LR - 20220410 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 21 IP - 23 DP - 2015 Dec 1 TI - Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. PG - 5391-403 LID - 10.1158/1078-0432.CCR-14-2680 [doi] AB - PURPOSE: Previous study identified E2F1 as a key mediator of non-muscle-invasive bladder cancer (NMIBC) progression. The aim of this study was to identify the E2F1-related genes associated with poor prognosis and aggressive characteristics of bladder cancer. EXPERIMENTAL DESIGN: Microarray analysis was performed to find E2F1-related genes associated with tumor progression and aggressiveness in the gene expression data from 165 primary patients with bladder cancer. The biologic activity of E2F1-related genes in tumor progression and aggressiveness was confirmed with experimental assays using bladder cancer cells and tumor xenograft assay. RESULTS: The expression of E2F1 was significantly associated with EZH2 and SUZ12. The overexpression of E2F1, EZH2, and SUZ12 enhanced cancer progression including cell colony formation, migration, and invasiveness. Knockdown of these genes reduced motility, blocked invasion, and decreased tumor size in vivo. E2F1 bound the proximal EZH2 and SUZ12 promoter to activate transcription, suggesting that E2F1 and its downstream effectors, EZH2 and SUZ12, could be important mediators for the cancer progression. In addition, we confirmed an association between these genes and aggressive characteristics. Interestingly, the treatment of anticancer drugs to the cells overexpressing E2F1, EZH2, and SUZ12 induced the expression of CD44, KLF4, OCT4, and ABCG2 known as cancer stem cell (CSC)-related genes. CONCLUSIONS: The link between E2F1, EZH2, and/or SUZ12 revealed that E2f1 directly regulates transcription of the EZH2 and SUZ12 genes. The signature of E2F1-EZH2-SUZ12 shows a predictive value for prognosis in bladder tumors and the E2F1-EZH2-SUZ12-driven transcriptional events may regulate the cancer aggressiveness and chemo-resistance, which may provide opportunity for development of new treatment modalities. CI - (c)2015 American Association for Cancer Research. FAU - Lee, Se-Ra AU - Lee SR AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Roh, Yun-Gil AU - Roh YG AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea. FAU - Lee, Ju-Seog AU - Lee JS AD - Department of Systems Biology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Seol, So-Young AU - Seol SY AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Lee, Hyun-Hee AU - Lee HH AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Kim, Won-Tae AU - Kim WT AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea. FAU - Heo, Jeonghoon AU - Heo J AD - Departments of Molecular Biology and Immunology, College of Medicine, Kosin University, Busan, Republic of Korea. FAU - Cha, Hee-Jae AU - Cha HJ AD - Departments of Parasitology and Genetics, Kosin University College of Medicine, Busan, Republic of Korea. FAU - Kang, Tae-Hong AU - Kang TH AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Chung, Jin Woong AU - Chung JW AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. FAU - Chu, In-Sun AU - Chu IS AD - Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea. shleem@dau.ac.kr chu@kribb.re.kr. FAU - Leem, Sun-Hee AU - Leem SH AD - Department of Biological Science, Dong-A University, Busan, Republic of Korea. shleem@dau.ac.kr chu@kribb.re.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150812 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (E2F1 Transcription Factor) RN - 0 (KLF4 protein, human) RN - 0 (Klf4 protein, mouse) RN - 0 (Kruppel-Like Factor 4) RN - 0 (Neoplasm Proteins) RN - 0 (SUZ12 protein, human) RN - 0 (Transcription Factors) RN - EC 2.1.1.43 (EZH2 protein, human) RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) RN - EC 2.1.1.43 (Polycomb Repressive Complex 2) SB - IM MH - Animals MH - Cell Line, Tumor MH - Cell Proliferation MH - Cell Survival/genetics MH - Cell Transformation, Neoplastic/genetics/metabolism MH - Cluster Analysis MH - Disease Progression MH - Drug Resistance, Neoplasm/genetics MH - E2F1 Transcription Factor/*metabolism MH - Enhancer of Zeste Homolog 2 Protein MH - Gene Expression Profiling MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Kruppel-Like Factor 4 MH - Mice MH - Neoplasm Invasiveness MH - Neoplasm Proteins MH - Polycomb Repressive Complex 2/*genetics MH - Prognosis MH - Spheroids, Cellular MH - Transcription Factors MH - Transcriptome MH - Tumor Cells, Cultured MH - Urinary Bladder Neoplasms/*genetics/*metabolism/mortality/pathology EDAT- 2015/08/14 06:00 MHDA- 2016/09/16 06:00 CRDT- 2015/08/14 06:00 PHST- 2014/10/17 00:00 [received] PHST- 2015/07/28 00:00 [accepted] PHST- 2015/08/14 06:00 [entrez] PHST- 2015/08/14 06:00 [pubmed] PHST- 2016/09/16 06:00 [medline] AID - 1078-0432.CCR-14-2680 [pii] AID - 10.1158/1078-0432.CCR-14-2680 [doi] PST - ppublish SO - Clin Cancer Res. 2015 Dec 1;21(23):5391-403. doi: 10.1158/1078-0432.CCR-14-2680. Epub 2015 Aug 12. PMID- 26267025 OWN - NLM STAT- MEDLINE DCOM- 20160520 LR - 20150813 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 22 IP - 4 DP - 2015 Aug TI - Single instillation of mitomycin C plus bacillus Calmette-Guerin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. PG - 7876-81 AB - INTRODUCTION: This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guerin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data for 719 patients diagnosed with NMIBC at the University of Pennsylvania Health System between 1977 and 2009 was reviewed retrospectively. Of these patients, 120 had high grade disease and were treated with either BCG alone or with a single instillation of 40 mg of MMC perioperatively in addition to BCG and were thus included in our study. The primary endpoints of this study included recurrence-free survival, overall and disease-free survival as assessed via Kaplan-Meier analysis. RESULTS: Of the 120 patients identified who received treatment for high grade NMIBC, 97 were treated with BCG alone and 23 received a single instillation of perioperative MMC in addition to BCG. There were no statistically significant differences noted in demographic or pathologic variables. Patients were followed for a median of 4.5 years and a maximum of 21.8 years, with no differences demonstrated in recurrence-free survival (p = 0.75), overall survival (p = 0.93) or disease-free survival (p = 0.76). Both lack of lymphovascular invasion and BCG maintenance therapy reached significance as independent predictors of recurrence-free survival (p = 0.19 and p = 0.28). CONCLUSIONS: While our study indicates that perioperative MMC likely offers little benefit in regards to recurrence or survival in high grade NMIBC, at this point in time, a larger scale, randomized, controlled trial is needed to adequately address this question. FAU - Weiss, Brian E AU - Weiss BE AD - Department of Urology, NYU Langone Medical Center, New York, New York, USA. FAU - Pietzak, Eugene J AU - Pietzak EJ FAU - Wein, Alan J AU - Wein AJ FAU - Malkowicz, S Bruce AU - Malkowicz SB FAU - Guzzo, Thomas J AU - Guzzo TJ LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 RN - 0 (BCG Vaccine) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Chemotherapy, Adjuvant/methods MH - Combined Modality Therapy/methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Retrospective Studies MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/*pathology/surgery EDAT- 2015/08/13 06:00 MHDA- 2016/05/21 06:00 CRDT- 2015/08/13 06:00 PHST- 2015/08/13 06:00 [entrez] PHST- 2015/08/13 06:00 [pubmed] PHST- 2016/05/21 06:00 [medline] PST - ppublish SO - Can J Urol. 2015 Aug;22(4):7876-81. PMID- 26263854 OWN - NLM STAT- Publisher LR - 20210102 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 467 IP - 6 DP - 2015 Dec TI - Chronic inflammation in urothelial bladder cancer. PG - 623-633 AB - The association between inflammation and cancer has been pointed out in epidemiological and clinical studies, revealing how chronic inflammation may contribute to carcinogenesis in various malignancies. However, the molecular events leading to malignant transformation in a chronically inflamed environment are not fully understood. In urothelial carcinoma of the urinary bladder, inflammation plays a dual role. On the one hand, chronic inflammation is a well-established risk factor for the development of bladder cancer (BC), as seen in Schistosoma haematobium infection. On the other, intravesical therapy by bacillus Calmette-Guerin (BCG), which induces inflammation, offers protection against cancer recurrence. The large variety of pro-inflammatory mediators expressed by BC and immune cells binds to specific receptors which control signalling pathways. These activate transcription of a plethora of downstream factors. This review summarizes recent data regarding inflammation and urothelial carcinoma, with special emphasis on the role the inflammatory response plays in BC recurrence risk and progression. FAU - Nesi, Gabriella AU - Nesi G AD - Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. gabriella.nesi@unifi.it. FAU - Nobili, Stefania AU - Nobili S AD - Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. FAU - Cai, Tommaso AU - Cai T AD - Department of Urology, Santa Chiara Regional Hospital, Largo Medaglie d'Oro 9, 50011, Trento, Italy. FAU - Caini, Saverio AU - Caini S AD - Unit of Molecular and Nutritional Epidemiology, Institute for Cancer Research and Prevention (ISPO), Via delle Oblate 2, 50139, Florence, Italy. FAU - Santi, Raffaella AU - Santi R AD - Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. LA - eng PT - Journal Article DEP - 20150812 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 OTO - NOTNLM OT - Carcinogenesis OT - Inflammation OT - Molecular pathology OT - Urothelial carcinoma EDAT- 2015/08/13 06:00 MHDA- 2015/08/13 06:00 CRDT- 2015/08/13 06:00 PHST- 2015/05/20 00:00 [received] PHST- 2015/07/28 00:00 [accepted] PHST- 2015/07/17 00:00 [revised] PHST- 2015/08/13 06:00 [entrez] PHST- 2015/08/13 06:00 [pubmed] PHST- 2015/08/13 06:00 [medline] AID - 10.1007/s00428-015-1820-x [pii] AID - 10.1007/s00428-015-1820-x [doi] PST - ppublish SO - Virchows Arch. 2015 Dec;467(6):623-633. doi: 10.1007/s00428-015-1820-x. Epub 2015 Aug 12. PMID- 26261615 OWN - NLM STAT- MEDLINE DCOM- 20160517 LR - 20220410 IS - 1936-2625 (Electronic) IS - 1936-2625 (Linking) VI - 8 IP - 6 DP - 2015 TI - Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma. PG - 7203-9 AB - Squamous differentiation is the most common histological variation in urothelial carcinoma (UC). However, the clinical significance of squamous differentiation in upper urinary tract UC is unclear. To investigate the significance of squamous differentiation, hematoxylin and eosin stained slides from 140 patients with upper urinary tract UC who underwent nephroureterectomy were reviewed by a single pathologist and the presence of squamous differentiation was recorded. Squamous differentiation was observed in 23 out of 140 studied cases (16%). Squamous differentiation significantly correlated with several adverse prognostic factors including histological grade 3 tumors, presence of lymphovascular invasion, concomitant carcinoma in situ, advanced tumor stage, and occurrence of lymph node metastasis. The Kaplan-Meier and univariate Cox regression analyses revealed that the presence of squamous differentiation was significantly associated with shorter metastasis-free survival [log-rank P = 0.030; univariate hazard ratio (HR), 2.30; 95% confidence interval (CI), 1.06-4.99], cancer-specific survival (log-rank P = 0.0024; univariate HR 3.34; 95% CI, 1.47-7.85), and overall survival (log-rank P = 0.018; univariate HR 2.39; 95% CI, 1.13-5.06) after nephroureterectomy. However, in multivariate analyses, squamous differentiation was not significantly associated with patient outcomes. These findings suggest that squamous differentiation is associated with disease progression, but is not an independent predictor of a worse prognosis in patients with upper urinary tract UC. FAU - Makise, Naohiro AU - Makise N AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Morikawa, Teppei AU - Morikawa T AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Homma, Yukio AU - Homma Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. FAU - Fukayama, Masashi AU - Fukayama M AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150601 PL - United States TA - Int J Clin Exp Pathol JT - International journal of clinical and experimental pathology JID - 101480565 SB - IM MH - Aged MH - Biopsy MH - *Cell Differentiation MH - Chi-Square Distribution MH - Disease Progression MH - Disease-Free Survival MH - Epithelial Cells/*pathology MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/mortality/*pathology/surgery MH - Lymphatic Metastasis MH - Male MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplasms, Squamous Cell/mortality/*pathology/surgery MH - Proportional Hazards Models MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Ureteral Neoplasms/mortality/*pathology/surgery MH - Urothelium/*pathology/surgery PMC - PMC4525949 OTO - NOTNLM OT - Cancer OT - histology OT - pathology OT - prognostic marker OT - renal pelvis OT - ureter EDAT- 2015/08/12 06:00 MHDA- 2016/05/18 06:00 PMCR- 2015/06/01 CRDT- 2015/08/12 06:00 PHST- 2015/04/10 00:00 [received] PHST- 2015/05/27 00:00 [accepted] PHST- 2015/08/12 06:00 [entrez] PHST- 2015/08/12 06:00 [pubmed] PHST- 2016/05/18 06:00 [medline] PHST- 2015/06/01 00:00 [pmc-release] PST - epublish SO - Int J Clin Exp Pathol. 2015 Jun 1;8(6):7203-9. eCollection 2015. PMID- 26251520 OWN - NLM STAT- MEDLINE DCOM- 20151215 LR - 20220311 IS - 1472-4146 (Electronic) IS - 0021-9746 (Print) IS - 0021-9746 (Linking) VI - 68 IP - 10 DP - 2015 Oct TI - Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. PG - 819-24 LID - 10.1136/jclinpath-2015-202898 [doi] AB - OBJECTIVES: To evaluate the protein expression of connexin 43 (Cx43) in primary urothelial bladder cancer and test its association with the histopathological characteristics and clinical outcome. METHODS: A tissue microarray containing 348 tissue samples from 174 patients with primary urothelial carcinomas of the bladder was immunohistochemically stained for Cx43. The intensity of staining was semiquantitatively evaluated (score 0, 1+, 2+), and the association with clinicopathological features was assessed. Univariable and multivariable analyses were performed to identify predictors for progression-free survival (PFS). RESULTS: Membranous Cx43 immunoreactivity was detected in 118 (67.8%) of 174 analysable urothelial carcinomas, of which 31 (17.8%) showed even a strong (score 2+) and mainly homogeneous staining. Strong expression levels of Cx43 (score 2+) were associated with higher tumour grade, multiplicity and increased proliferation (all p<0.05). In the subgroup of patients with stage pTa and pT1 bladder tumours (n=158), strong Cx43 expression (p<0.001), solid growth pattern (p<0.001) and increased Ki-67 proliferation fraction (p<0.05) were significantly associated with shorter PFS in an univariable Cox regression analysis. In multivariable Cox regression models, Cx43 immunoreactivity and histological growth pattern remained highly significant and adverse risk factors for PFS. CONCLUSIONS: The expression levels of Cx43 are frequent in non-muscle invasive bladder cancer (NMIBC), with high expression levels being associated with poor prognosis. Routine assessment of Cx43 expression may improve the identification of high-risk NMIBC. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. FAU - Poyet, Cedric AU - Poyet C AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Buser, Lorenz AU - Buser L AD - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Roudnicky, Filip AU - Roudnicky F AD - Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. FAU - Detmar, Michael AU - Detmar M AD - Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. FAU - Hermanns, Thomas AU - Hermanns T AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Mannhard, Doris AU - Mannhard D AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Hohn, Andrej AU - Hohn A AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Ruschoff, Jan AU - Ruschoff J AD - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Zhong, Qing AU - Zhong Q AD - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Sulser, Tullio AU - Sulser T AD - Department of Urology, University Hospital Zurich, Zurich, Switzerland. FAU - Moch, Holger AU - Moch H AD - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Wild, Peter J AU - Wild PJ AD - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20150806 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 RN - 0 (Biomarkers, Tumor) RN - 0 (Connexin 43) RN - 0 (GJA1 protein, human) RN - 0 (Ki-67 Antigen) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Cell Proliferation MH - Connexin 43/*analysis MH - Disease-Free Survival MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/analysis MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/*chemistry/mortality/pathology/therapy MH - Urothelium/*chemistry/pathology PMC - PMC4602233 OTO - NOTNLM OT - BLADDER OT - TUMOUR MARKERS OT - URINARY TRACT TUMOURS EDAT- 2015/08/08 06:00 MHDA- 2015/12/17 06:00 PMCR- 2015/10/13 CRDT- 2015/08/08 06:00 PHST- 2015/01/26 00:00 [received] PHST- 2015/05/25 00:00 [accepted] PHST- 2015/08/08 06:00 [entrez] PHST- 2015/08/08 06:00 [pubmed] PHST- 2015/12/17 06:00 [medline] PHST- 2015/10/13 00:00 [pmc-release] AID - jclinpath-2015-202898 [pii] AID - 10.1136/jclinpath-2015-202898 [doi] PST - ppublish SO - J Clin Pathol. 2015 Oct;68(10):819-24. doi: 10.1136/jclinpath-2015-202898. Epub 2015 Aug 6. PMID- 26240484 OWN - NLM STAT- MEDLINE DCOM- 20160425 LR - 20260127 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 30 IP - 8 DP - 2015 Aug TI - Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. PG - 1068-77 LID - 10.3346/jkms.2015.30.8.1068 [doi] AB - The study aimed to verify the prognostic utility, therapeutic application and clinical benefits of tumor substaging and HER2 status in papillary non-muscle invasive bladder cancer (NMIBC). Select NMIBC transurethral resection specimens from 141 patients were used to construct tissue microarrays for assessing the substaging, HER2 protein expression by immunohistochemistry (HER2-IHC) and gene amplification by dual-color silver in situ hybridization (HER2-SISH). Substages were identified by the differing depth of tumor invasion (pTa / pT1a / pT1b / pT1c). HER2 protein expression was semiquantitatively analyzed and grouped into negative (score 0, 1+) and positive (score 2+, 3+). Other clinicopathological variables were also investigated. For NMIBC, HER2-IHC and HER2-SISH showed positive results in 6/141 (4.3%) and 4/141 (2.8%) respectively, which correlated well with tumor substaging. In multivariate analysis, substaging, HER2-IHC, and HER2-SISH were found to be independent predictors of progression-free survival (P < 0.001, P < 0.001, P = 0.031). HER2-IHC was the sole independent predictor of recurrent free survival in NMIBC (P = 0.017). It is suggested that tumor substaging and HER2 status are independent predictive markers for tumor progression or recurrence, and thus could be included in diagnostic and therapeutic management for NMIBC. FAU - Lim, So Dug AU - Lim SD AD - Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Cho, Yong Mee AU - Cho YM AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Choi, Gyu-Seog AU - Choi GS AD - Colorectal Cancer Center, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea. FAU - Park, Hyung Kyu AU - Park HK AD - Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Paick, Sung Hyun AU - Paick SH AD - Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Kim, Wook Youn AU - Kim WY AD - Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Kim, Soo-Nyung AU - Kim SN AD - Department of Obstetrics and Gynecology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Yoon, Ghilsuk AU - Yoon G AD - Department of Pathology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150715 PL - Korea (South) TA - J Korean Med Sci JT - Journal of Korean medical science JID - 8703518 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*metabolism MH - Carcinoma, Papillary/*metabolism/*pathology MH - Carcinoma, Transitional Cell/metabolism/pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Urinary Bladder Neoplasms/*metabolism/*pathology MH - Young Adult PMC - PMC4520937 OTO - NOTNLM OT - Bladder Cancer OT - Cancer Staging OT - HER2 Gene OT - Immunohistochemistry OT - In Situ Hybridization COIS- DISCLOSURE: There are no potential conflicts of interest in this article. EDAT- 2015/08/05 06:00 MHDA- 2016/04/26 06:00 PMCR- 2015/08/01 CRDT- 2015/08/05 06:00 PHST- 2015/03/14 00:00 [received] PHST- 2015/06/23 00:00 [accepted] PHST- 2015/08/05 06:00 [entrez] PHST- 2015/08/05 06:00 [pubmed] PHST- 2016/04/26 06:00 [medline] PHST- 2015/08/01 00:00 [pmc-release] AID - 10.3346/jkms.2015.30.8.1068 [doi] PST - ppublish SO - J Korean Med Sci. 2015 Aug;30(8):1068-77. doi: 10.3346/jkms.2015.30.8.1068. Epub 2015 Jul 15. PMID- 26239240 OWN - NLM STAT- MEDLINE DCOM- 20160112 LR - 20260127 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 15 DP - 2015 Aug 5 TI - Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada. PG - 308 LID - 10.1186/s12913-015-0972-3 [doi] LID - 308 AB - BACKGROUND: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The objective of this study was to characterize the use of health-care services and costs associated with BC among patients who underwent radical cystectomy (RC) in the province of Quebec. METHODS: We conducted a descriptive study in a retrospective cohort of patients who underwent RC for BC between 2000 and 2009. Data was obtained from two health administrative databases (RAMQ and ISQ). We calculated average costs per patient and total costs in 2014 Canadian dollars for the following components of costs: 1) Pre-surgery costs (pre and post-urologist consultations, urologist consultations, cystoscopies, TURBTs, imaging procedures); 2) Costs of radical cystectomy and 3) Post-surgery costs (urologist consultations, post-operative consultations, medical oncologist consultations, imaging procedures and post-operative complication management). ARIMA models were used to evaluate trends in average costs per patient over the study period. RESULTS: Among 2759 patients included in the study (75% men), average pre-surgery costs, RC costs, and post-surgery costs were estimated at 3762$, 18979$ and 4770$, respectively. RC cost was responsible for 69% of total costs, followed by post-operative consultations (7.8%), post-operative complications and TURBTs (6% of total costs, each). Academic hospitals performed RC at a lower average cost, compared to community hospitals (difference of $1000, p < .0001). A decreased trend in post-surgery costs was detected in the year 2009. CONCLUSIONS: Costs of RC, TURBT, consultations and post-operative complications were the most important economic components of total RC cost per patient in Quebec. Academic hospitals performed RC at a lower cost, compared to community hospitals. FAU - Santos, Fabiano AU - Santos F AD - Division of Cancer Epidemiology, Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, QC, Canada. fabiano.santos@mcgill.ca. FAU - Dragomir, Alice AU - Dragomir A AD - Division of Urology, Department of Urology, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada. alice.dragomir@muhc.mcgill.ca. FAU - Zakaria, Ahmed Sayed AU - Zakaria AS AD - Division of Urology, Department of Urology, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada. aszakaria81@yahoo.com. FAU - Kassouf, Wassim AU - Kassouf W AD - Division of Urology, Department of Urology, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada. wassim.kassouf@muhc.mcgill.ca. FAU - Aprikian, Armen AU - Aprikian A AD - Division of Urology, Department of Urology, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada. armen.aprikian@muhc.mcgill.ca. LA - eng GR - 127596/Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150805 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Aged MH - Cystectomy/*economics MH - Female MH - *Health Expenditures MH - Health Services/*statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - Patient Acceptance of Health Care MH - Postoperative Complications/economics MH - Quebec MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*surgery PMC - PMC4523952 EDAT- 2015/08/05 06:00 MHDA- 2016/01/13 06:00 PMCR- 2015/08/05 CRDT- 2015/08/05 06:00 PHST- 2015/01/09 00:00 [received] PHST- 2015/07/24 00:00 [accepted] PHST- 2015/08/05 06:00 [entrez] PHST- 2015/08/05 06:00 [pubmed] PHST- 2016/01/13 06:00 [medline] PHST- 2015/08/05 00:00 [pmc-release] AID - 10.1186/s12913-015-0972-3 [pii] AID - 972 [pii] AID - 10.1186/s12913-015-0972-3 [doi] PST - epublish SO - BMC Health Serv Res. 2015 Aug 5;15:308. doi: 10.1186/s12913-015-0972-3. PMID- 26238783 OWN - NLM STAT- MEDLINE DCOM- 20160130 LR - 20160511 IS - 1538-7445 (Electronic) IS - 0008-5472 (Linking) VI - 75 IP - 19 DP - 2015 Oct 1 TI - A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. PG - 4042-52 LID - 10.1158/0008-5472.CAN-15-0602 [doi] AB - Relationships between genetic alterations, such as co-occurrence or mutual exclusivity, are often observed in cancer, where their understanding may provide new insights into etiology and clinical management. In this study, we combined statistical analyses and computational modeling to explain patterns of genetic alterations seen in 178 patients with bladder tumors (either muscle-invasive or non-muscle-invasive). A statistical analysis on frequently altered genes identified pair associations, including co-occurrence or mutual exclusivity. Focusing on genetic alterations of protein-coding genes involved in growth factor receptor signaling, cell cycle, and apoptosis entry, we complemented this analysis with a literature search to focus on nine pairs of genetic alterations of our dataset, with subsequent verification in three other datasets available publicly. To understand the reasons and contexts of these patterns of associations while accounting for the dynamics of associated signaling pathways, we built a logical model. This model was validated first on published mutant mice data, then used to study patterns and to draw conclusions on counter-intuitive observations, allowing one to formulate predictions about conditions where combining genetic alterations benefits tumorigenesis. For example, while CDKN2A homozygous deletions occur in a context of FGFR3-activating mutations, our model suggests that additional PIK3CA mutation or p21CIP deletion would greatly favor invasiveness. Furthermore, the model sheds light on the temporal orders of gene alterations, for example, showing how mutual exclusivity of FGFR3 and TP53 mutations is interpretable if FGFR3 is mutated first. Overall, our work shows how to predict combinations of the major gene alterations leading to invasiveness through two main progression pathways in bladder cancer. CI - (c)2015 American Association for Cancer Research. FAU - Remy, Elisabeth AU - Remy E AD - Aix Marseille Universite, CNRS, Centrale Marseille, Marseille, France. FAU - Rebouissou, Sandra AU - Rebouissou S AD - Institut Curie, PSL Research University, Paris, France. CNRS, UMR 144, Oncologie Moleculaire, Equipe Labellisee Ligue Contre le Cancer, Institut Curie, Paris, France. FAU - Chaouiya, Claudine AU - Chaouiya C AD - Instituto Gulbenkian de Ciencia, Oeiras, Portugal. FAU - Zinovyev, Andrei AU - Zinovyev A AD - Institut Curie, PSL Research University, Paris, France. INSERM, U900, Paris, France. Ecole des Mines ParisTech, Fontainebleau, France. FAU - Radvanyi, Francois AU - Radvanyi F AD - Institut Curie, PSL Research University, Paris, France. CNRS, UMR 144, Oncologie Moleculaire, Equipe Labellisee Ligue Contre le Cancer, Institut Curie, Paris, France. FAU - Calzone, Laurence AU - Calzone L AD - Institut Curie, PSL Research University, Paris, France. INSERM, U900, Paris, France. Ecole des Mines ParisTech, Fontainebleau, France. laurence.calzone@curie.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150803 PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (Neoplasm Proteins) SB - IM EIN - Cancer Res. 2016 Jan 15;76(2):505. doi: 10.1158/0008-5472.CAN-15-3301. PMID: 26773097 MH - Animals MH - Carcinoma, Transitional Cell/etiology/*genetics/pathology MH - Cell Transformation, Neoplastic/*genetics MH - Comparative Genomic Hybridization MH - Datasets as Topic/statistics & numerical data MH - Epistasis, Genetic MH - Gene Deletion MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - *Gene Regulatory Networks MH - *Genes, Neoplasm MH - Humans MH - Mice MH - *Models, Genetic MH - *Mutation MH - Neoplasm Invasiveness MH - Neoplasm Proteins/genetics/physiology MH - Phenotype MH - Probability MH - Urinary Bladder Neoplasms/etiology/*genetics/pathology EDAT- 2015/08/05 06:00 MHDA- 2016/01/31 06:00 CRDT- 2015/08/05 06:00 PHST- 2015/03/05 00:00 [received] PHST- 2015/06/24 00:00 [accepted] PHST- 2015/08/05 06:00 [entrez] PHST- 2015/08/05 06:00 [pubmed] PHST- 2016/01/31 06:00 [medline] AID - 0008-5472.CAN-15-0602 [pii] AID - 10.1158/0008-5472.CAN-15-0602 [doi] PST - ppublish SO - Cancer Res. 2015 Oct 1;75(19):4042-52. doi: 10.1158/0008-5472.CAN-15-0602. Epub 2015 Aug 3. PMID- 26238022 OWN - NLM STAT- MEDLINE DCOM- 20160520 LR - 20201209 IS - 1791-2431 (Electronic) IS - 1021-335X (Print) IS - 1021-335X (Linking) VI - 34 IP - 4 DP - 2015 Oct TI - Impact of reduced levels of APE1 transcripts on the survival of patients with urothelial carcinoma of the bladder. PG - 1667-74 LID - 10.3892/or.2015.4151 [doi] AB - Molecular evidence indicates that alterations in genes involved in the maintenance of genome stability may be related to susceptibility to bladder carcinoma. Our goal was to evaluate the prognostic role of base excision repair (BER) genes in a cohort of patients diagnosed with primary urothelial carcinoma of the bladder (UCB). The levels of all APE1, XRCC1 and POLB transcripts were detected by quantitative real-time PCR (qPCR) technique in tumor samples from 52 patients undergoing transurethral resection (TUR) for primary UCB at the Department of Urology, Brazilian National Cancer Institute, Rio de Janeiro. Increased levels of APE1, XRCC1 and POLB transcripts were significantly associated with high-grade tumors when compared to these levels in low-grade tumors (p<0.01) and could be attributed to different mechanisms of transcriptional regulation as a response to tumorigenesis and oxidative stress. By analyzing the collected data in the present study, regardless of pathological grade or stage, univariate analysis revealed that the reduced levels of APE1 transcripts were significantly associated with cancer-specific mortality (p=0.032). Furthermore, the variant genotype (TG/GG) of the APE1 T1349G polymorphism was observed in 75% of a subset of patients who concomitantly experienced reduced levels of the APE1 transcript and death and/or recurrence events. Taken together, our data reinforce the idea that human DNA repair mechanisms must be finely regulated in order to avoid instability leading to tumorigenesis and poor clinical outcomes in UCB patients. FAU - Chantre-Justino, Mariana AU - Chantre-Justino M AD - Carlos Chagas Filho Institute of Biophysics, Rio de Janeiro Federal University, Rio de Janeiro, Brazil. FAU - Alves, Gilda AU - Alves G AD - Research Coordination, National Institute of Cancer (INCA), Rio de Janeiro, Brazil. FAU - Britto, Constanca AU - Britto C AD - Molecular Biology and Endemic Diseases Laboratory, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. FAU - Cardoso, Angelica AU - Cardoso A AD - Molecular Biology and Endemic Diseases Laboratory, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. FAU - Scherrer, Luciano AU - Scherrer L AD - Brazilian Society of Clinical Oncology, Belo Horizonte, Minas Gerais, Brazil. FAU - Moreira, Aline dos Santos AU - Moreira Ados S AD - DNA Sequencing Platform, PDTIS/FIOCRUZ, Rio de Janeiro, Brazil. FAU - Quirino, Raul AU - Quirino R AD - Department of Urology, National Institute of Cancer, Rio de Janeiro, Brazil. FAU - Ornellas, Antonio AU - Ornellas A AD - Department of Urology, National Institute of Cancer, Rio de Janeiro, Brazil. FAU - Leitao, Alvaro AU - Leitao A AD - Carlos Chagas Filho Institute of Biophysics, Rio de Janeiro Federal University, Rio de Janeiro, Brazil. FAU - Lage, Claudia AU - Lage C AD - Carlos Chagas Filho Institute of Biophysics, Rio de Janeiro Federal University, Rio de Janeiro, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150724 PL - Greece TA - Oncol Rep JT - Oncology reports JID - 9422756 RN - 0 (DNA-Binding Proteins) RN - 0 (X-ray Repair Cross Complementing Protein 1) RN - 0 (XRCC1 protein, human) RN - EC 2.7.7.7 (DNA Polymerase beta) RN - EC 4.2.99.18 (APEX1 protein, human) RN - EC 4.2.99.18 (DNA-(Apurinic or Apyrimidinic Site) Lyase) SB - IM MH - Aged MH - Aged, 80 and over MH - Brazil MH - DNA Polymerase beta/biosynthesis/*genetics MH - DNA Repair/genetics MH - DNA-(Apurinic or Apyrimidinic Site) Lyase/biosynthesis/*genetics MH - DNA-Binding Proteins/biosynthesis/*genetics MH - Female MH - Gene Expression Regulation, Neoplastic MH - Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*genetics/mortality/pathology MH - Polymorphism, Single Nucleotide MH - Prognosis MH - Survival Analysis MH - Urinary Bladder Neoplasms/*genetics/mortality/pathology MH - X-ray Repair Cross Complementing Protein 1 PMC - PMC4564093 EDAT- 2015/08/05 06:00 MHDA- 2016/05/21 06:00 PMCR- 2015/07/24 CRDT- 2015/08/05 06:00 PHST- 2015/05/05 00:00 [received] PHST- 2015/06/24 00:00 [accepted] PHST- 2015/08/05 06:00 [entrez] PHST- 2015/08/05 06:00 [pubmed] PHST- 2016/05/21 06:00 [medline] PHST- 2015/07/24 00:00 [pmc-release] AID - or-34-04-1667 [pii] AID - 10.3892/or.2015.4151 [doi] PST - ppublish SO - Oncol Rep. 2015 Oct;34(4):1667-74. doi: 10.3892/or.2015.4151. Epub 2015 Jul 24. PMID- 26238015 OWN - NLM STAT- MEDLINE DCOM- 20151109 LR - 20220310 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 51 IP - 14 DP - 2015 Sep TI - Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target. PG - 1937-45 LID - S0959-8049(15)00701-7 [pii] LID - 10.1016/j.ejca.2015.07.021 [doi] AB - AIM: Sphingosine-1-phosphate receptor 1 (S1PR1) promotes tumour cell survival, invasion, anti-apoptosis, metastasis and radio/chemo-resistance in various cancers. However, the expression pattern and prognostic implications of S1PR1 in urothelial carcinoma remain unclear and thus were addressed here. METHODS: Tissue microarrays composed of 395 initially diagnosed and transurethral resected urothelial carcinomas of the urinary bladder were immunostained for S1PR1 and phosphor-signal transducer and activator of transcription 3 (pSTAT3). S1PR1 expression was analysed according to clinicopathological features, expression of several anti-apoptosis/proliferation-related markers and patient's survival. RESULTS: S1PR1 positivity was observed in 45.3% of urothelial carcinomas. Among patients with non-muscle invasive urothelial carcinoma (NMIC), S1PR1 positivity was associated with higher grade (P<0.001), higher subepithelial invasive component (P=0.006), lower papillary component (P=0.002), presence of metastasis (P=0.042) and high cancer-specific death (P<0.001). S1PR1 expression was correlated with pSTAT3 (P<0.001), survivin (P=0.008) and Ki-67 (P<0.001) expression. S1PR1 positivity predicted a shorter cancer-specific survival (CSS) in NMICs (P<0.001) and stage T1/high grade (T1HG) tumours (P=0.002). The Cox multivariate model was composed of S1PR1, survivin, lymphovascular invasion and age, and C-index was 0.781. S1PR1 positivity was correlated with shorter CSS in p53-positive T1HG carcinoma (P=0.003) in contrast to p53-negative T1HG carcinoma (P=0.205). In p53-overexpressing NMIC, S1PR1 was the only variable of the survival model and the C-index was 0.719. CONCLUSIONS: S1PR1 expression was associated with unfavourable clinicopathological features and the expression of several anti-apoptosis/proliferation-related markers in urothelial carcinoma. S1PR1 serves as an independent predictor of cancer-specific death in NMIC. The model including S1PR1 showed highly accurate prediction for CSS in NMIC patients regardless of the modality of adjuvant therapy. CI - Copyright (c) 2015 Elsevier Ltd. All rights reserved. FAU - Go, Heounjeong AU - Go H AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea. Electronic address: damul37@naver.com. FAU - Kim, Pil-Jong AU - Kim PJ AD - Biomedical Knowledge Engineering Laboratory, Seoul National University, School of Dentistry, Seoul 110-749, Republic of Korea. Electronic address: childcom@snu.ac.kr. FAU - Jeon, Yoon Kyung AU - Jeon YK AD - Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea. Electronic address: junarplus@chol.com. FAU - Cho, Yong Mee AU - Cho YM AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea. Electronic address: yongcho@amc.seoul.kr. FAU - Kim, Kyungeun AU - Kim K AD - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, Republic of Korea. Electronic address: kekim23@naver.com. FAU - Park, Bong-Hee AU - Park BH AD - Department of Pathology, Green Cross Laboratories, Yongin-si, Kyunggi-do 446-770, Republic of Korea. Electronic address: as-watchman@hanmail.net. FAU - Ku, Ja Yoon AU - Ku JY AD - University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea. Electronic address: kooossi@hanmail.net. LA - eng PT - Journal Article DEP - 20150731 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Lysosphingolipid) RN - 0 (S1PR1 protein, human) RN - 0 (STAT3 Transcription Factor) RN - 0 (STAT3 protein, human) RN - 0 (Sphingosine-1-Phosphate Receptors) SB - IM MH - Aged MH - Apoptosis MH - Biomarkers, Tumor/*analysis MH - Carcinoma/*chemistry/mortality/secondary/surgery MH - Cell Proliferation MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Phosphorylation MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Receptors, Lysosphingolipid/*analysis MH - Risk Factors MH - STAT3 Transcription Factor/analysis MH - Sphingosine-1-Phosphate Receptors MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/*chemistry/mortality/pathology/surgery MH - Urothelium/*chemistry/pathology/surgery OTO - NOTNLM OT - Cancer-specific survival OT - Non-muscle invasive urothelial carcinoma OT - Prediction OT - Prognosis OT - Sphingosine-1-phosphate receptor 1 OT - Survivin OT - p53 EDAT- 2015/08/05 06:00 MHDA- 2015/11/10 06:00 CRDT- 2015/08/05 06:00 PHST- 2015/03/24 00:00 [received] PHST- 2015/07/15 00:00 [revised] PHST- 2015/07/16 00:00 [accepted] PHST- 2015/08/05 06:00 [entrez] PHST- 2015/08/05 06:00 [pubmed] PHST- 2015/11/10 06:00 [medline] AID - S0959-8049(15)00701-7 [pii] AID - 10.1016/j.ejca.2015.07.021 [doi] PST - ppublish SO - Eur J Cancer. 2015 Sep;51(14):1937-45. doi: 10.1016/j.ejca.2015.07.021. Epub 2015 Jul 31. PMID- 26232864 OWN - NLM STAT- MEDLINE DCOM- 20151215 LR - 20220311 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 46 IP - 10 DP - 2015 Oct TI - Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction. PG - 1464-70 LID - S0046-8177(15)00208-7 [pii] LID - 10.1016/j.humpath.2015.06.003 [doi] AB - One of the major challenges in bladder cancer management is in distinguishing aggressive from indolent tumors with similar clinicopathological factors, especially in cases of high-grade T1 stage tumors. To define a set of prognostic factors that can be easily assessed in clinical practice with a high cost-effectiveness, the expressions of 11 proteins were examined immunohistochemically in 403 cases of transurethral resection of bladder tumors, then correlated to clinical outcomes. Based on the protein immunoprofiles, urothelial carcinomas were divided into 4 intrinsic molecular subgroups with different clinical outcomes: subgroups 1 and 4 with the poorest survival, subgroup 2 with the best survival, and subgroup 3 with the intermediate survival outcome. The protein expression patterns of the 4 subgroups were mutually exclusive: overexpression of p53, EZH2, E2F1, and IMP3 and high Ki-67 proliferation index in subgroup 1; overexpression of cytoplasmic survivin in subgroup 4; overexpression of membranous TSP1 and cytoplasmic p27 in subgroup 2; and no representative protein overexpression in subgroup 3. Using these protein immunoprofiles, 3 risk groups were generated, which predicted disease-specific survival not only in total bladder carcinoma cases with 0.737 of predictive accuracy but also in high-grade stage T1 tumors with 0.658 of predictive accuracy. These results showed that urothelial carcinomas were composed of 4 clinically relevant molecular subgroups based on protein expression and that overall survival of those patients could be predicted using a set of a small number of protein expressions not only in total cases but also in high-grade stage T1 tumors. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Kim, Kyungeun AU - Kim K AD - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Sung, Chang Ohk AU - Sung CO AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Park, Bong-Hee AU - Park BH AD - Department of Pathology, Green Cross Laboratories, Yongin-si, Kyunggi-do, Republic of Korea. FAU - Ku, Ja Yoon AU - Ku JY AD - University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Go, Heounjeong AU - Go H AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Ro, Jae Y AU - Ro JY AD - Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030. FAU - Kim, Jiyoon AU - Kim J AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Cho, Yong Mee AU - Cho YM AD - Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: yongcho@amc.seoul.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150616 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Carcinoma, Transitional Cell/*classification/mortality/*pathology MH - Cluster Analysis MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/*classification/mortality/*pathology MH - Young Adult OTO - NOTNLM OT - Cluster analysis OT - Molecular subtype OT - Prognosis OT - Protein expression OT - Urothelial carcinoma EDAT- 2015/08/04 06:00 MHDA- 2015/12/17 06:00 CRDT- 2015/08/03 06:00 PHST- 2015/02/17 00:00 [received] PHST- 2015/05/26 00:00 [revised] PHST- 2015/06/03 00:00 [accepted] PHST- 2015/08/03 06:00 [entrez] PHST- 2015/08/04 06:00 [pubmed] PHST- 2015/12/17 06:00 [medline] AID - S0046-8177(15)00208-7 [pii] AID - 10.1016/j.humpath.2015.06.003 [doi] PST - ppublish SO - Hum Pathol. 2015 Oct;46(10):1464-70. doi: 10.1016/j.humpath.2015.06.003. Epub 2015 Jun 16. PMID- 26232112 OWN - NLM STAT- MEDLINE DCOM- 20151116 LR - 20150831 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 46 IP - 9 DP - 2015 Sep TI - Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy? PG - 1367-75 LID - S0046-8177(15)00196-3 [pii] LID - 10.1016/j.humpath.2015.05.020 [doi] AB - Neoadjuvant chemotherapy (NAC) is currently recommended to all candidate patients with muscularis propria-invasive bladder cancer. However, NAC is effective in only a subset of patients, and predictors of response are lacking. Our study aimed to characterize tumoral changes with NAC usage and to identify features at bladder biopsy/transurethral resection (Bx/TUR) that may predict response. A retrospective search was performed to identify patients with bladder cancer that were pT2 at Bx/TUR upon whom a radical cystectomy (RC) was performed from 2007 to 2010. A blinded slide review of the Bx/TUR and RC was conducted. Presence, type, percent of tumor variant morphology, and tumoral mitotic rate were assessed. Ninety RC patients with slides available were identified (46 NAC, 44 non-NAC). In NAC-treated patients, there was a significantly higher percentage of nonurothelial variant differentiation in the RC compared with Bx/TUR, whereas there was no difference in the non-NAC subgroup. Percent variant differentiation at Bx/TUR was not a predictor of response. There was a significant decrease in mitotic rate between Bx/TUR and RC in NAC patients, whereas there was no difference in the non-NAC subgroup, although mitotic rate was not a predictor of response. In conclusion, percent variant differentiation and mitotic rate changed significantly from Bx/TUR to RC with NAC usage, although neither predicted response. Pathologists should be aware that variant differentiation is common in bladder cancer, with increased presence after NAC, in order to improve recognition and documentation of these findings. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Shen, Helen M AU - Shen HM AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. FAU - D'Souza, Amber M AU - D'Souza AM AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. FAU - Green, Ian F AU - Green IF AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. FAU - Pohar, Kamal S AU - Pohar KS AD - Department of Urology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. FAU - Mortazavi, Amir AU - Mortazavi A AD - Department of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. FAU - Zynger, Debra L AU - Zynger DL AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210. Electronic address: debra.zynger@osumc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150604 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Cell Differentiation/*drug effects MH - Chemotherapy, Adjuvant MH - Cystectomy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mitosis/*drug effects MH - Mitotic Index MH - *Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery MH - Young Adult OTO - NOTNLM OT - Bladder cancer OT - Histology OT - Mitotic rate OT - Neoadjuvant chemotherapy OT - Response OT - Stage OT - Variant differentiation EDAT- 2015/08/02 06:00 MHDA- 2015/11/17 06:00 CRDT- 2015/08/02 06:00 PHST- 2015/03/15 00:00 [received] PHST- 2015/05/15 00:00 [revised] PHST- 2015/05/21 00:00 [accepted] PHST- 2015/08/02 06:00 [entrez] PHST- 2015/08/02 06:00 [pubmed] PHST- 2015/11/17 06:00 [medline] AID - S0046-8177(15)00196-3 [pii] AID - 10.1016/j.humpath.2015.05.020 [doi] PST - ppublish SO - Hum Pathol. 2015 Sep;46(9):1367-75. doi: 10.1016/j.humpath.2015.05.020. Epub 2015 Jun 4. PMID- 26232037 OWN - NLM STAT- MEDLINE DCOM- 20160510 LR - 20250630 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 15 DP - 2015 Aug 1 TI - A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. PG - 566 LID - 10.1186/s12885-015-1571-8 [doi] LID - 566 AB - BACKGROUND: This study included a network meta-analysis of evidence from randomized controlled trials (RCTs) to assess the therapeutic outcome of transurethral resection (TUR) in patients with non-muscle-invasive bladder cancer assisted by photodynamic diagnosis (PDD) employing 5-aminolaevulinic acid (5-ALA) or hexylaminolevulinate (HAL) or by narrow band imaging (NBI). METHODS: Relevant RCTs were identified from electronic databases. The proceedings of relevant congresses were also searched. Fifteen articles based on RCTs were included in the analysis, and the comparisons were made by qualitative and quantitative syntheses using pairwise and network meta-analyses. RESULTS: Seven of 15 RCTs were at moderate risk of bias for all quality criteria and two studies were classified as having a high risk of bias. The recurrence rate of cancers resected with 5-ALA-based PDD was lower than of those resected using HAL-based PDD (odds ratio (OR) = 0.48, 95 % confidence interval (CI) [0.26-0.95]) but was not significantly different than those resected with NBI (OR = 0.53, 95 % CI [0.26-1.09]). The recurrence rate of cancers resected using HAL-based PDD versus NBI did not significantly differ (OR = 1.11, 95 % CI [0.55-2.1]). All cancers resected using 5-ALA-based PDD, HAL-based PDD, or NBI recurred at a lower rate than those resected using white light cystoscopy (WLC). No difference in progression rate was observed between cancers resected by all methods investigated. CONCLUSIONS: The recurrence rate of some bladder cancers can be decreased by the implementation of either PDD- and NBI-assisted TUR; in real settings, clinicians should consider replacing WLC as the standard imaging technology to guide TUR. FAU - Lee, Joo Yong AU - Lee JY AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. joouro@yuhs.ac. FAU - Cho, Kang Su AU - Cho KS AD - Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. kscho99@yuhs.ac. FAU - Kang, Dong Hyuk AU - Kang DH AD - Department of Urology, Yangpyeong Health Center, Yangpyeong, Korea. doudong14@gmail.com. FAU - Jung, Hae Do AU - Jung HD AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. urooru@yuhs.ac. FAU - Kwon, Jong Kyou AU - Kwon JK AD - Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. jkstorm@naver.com. FAU - Oh, Cheol Kyu AU - Oh CK AD - Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. ckohuro@gmail.com. FAU - Ham, Won Sik AU - Ham WS AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. uroham@yuhs.ac. FAU - Choi, Young Deuk AU - Choi YD AD - Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. youngd74@yuhs.ac. AD - Department of Urology, Clinical Trial Center for Medical Devices, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea. youngd74@yuhs.ac. LA - eng PT - Comparative Study PT - Journal Article PT - Network Meta-Analysis DEP - 20150801 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Photosensitizing Agents) RN - 88755TAZ87 (Aminolevulinic Acid) RN - G7H20TKI67 (5-aminolevulinic acid hexyl ester) SB - IM MH - Aminolevulinic Acid/*analogs & derivatives/*metabolism MH - Cystoscopy/methods MH - Humans MH - Image Interpretation, Computer-Assisted/*methods MH - Narrow Band Imaging/methods MH - Photosensitizing Agents/*metabolism MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Urinary Bladder Neoplasms/metabolism/pathology/*surgery PMC - PMC4521364 EDAT- 2015/08/02 06:00 MHDA- 2016/05/11 06:00 PMCR- 2015/08/01 CRDT- 2015/08/02 06:00 PHST- 2015/03/06 00:00 [received] PHST- 2015/07/17 00:00 [accepted] PHST- 2015/08/02 06:00 [entrez] PHST- 2015/08/02 06:00 [pubmed] PHST- 2016/05/11 06:00 [medline] PHST- 2015/08/01 00:00 [pmc-release] AID - 10.1186/s12885-015-1571-8 [pii] AID - 1571 [pii] AID - 10.1186/s12885-015-1571-8 [doi] PST - epublish SO - BMC Cancer. 2015 Aug 1;15:566. doi: 10.1186/s12885-015-1571-8. PMID- 26231864 OWN - NLM STAT- MEDLINE DCOM- 20170420 LR - 20170420 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 40 IP - 1 DP - 2016 Jan-Feb TI - A higher Charlson comorbidity index is related to more aggressive characteristics in de novo vesical tumours. PG - 23-8 LID - S0210-4806(15)00180-1 [pii] LID - 10.1016/j.acuro.2015.06.006 [doi] AB - OBJECTIVE: To analyze the relationship between the age--adjusted Charlson Comorbidity Index (aCCI) and pathological outcomes of transurethral resection of de novo bladder tumours (BT). MATERIAL AND METHODS: Data from 208 patients who underwent a transurethral resection (TUR) of a de novo BT between 2007 and 2008 were collected. We recorded the following variables: age, sex, tobacco consumption, comorbidities assessed according to the ICCa (score and mortality rate), disease stage, tumour grade and risk of recurrence and progression. The relationship between the preoperative variables and the final pathological characteristics was analyzed. The multivariate study was conducted with the significant variables (P<.05) from the univariate analysis. RESULTS: The mean age of the patients was 69.5 +/- 12 years, and 77% were men. The mean ICCa was 6.4 +/- 2.5. The final pathology results showed a Tx, T0, Ta, T1 and T >/= 2 in 5.3, 6.7, 31.7, 26.9, and 28.8% of the cases, respectively. 33.3% of the tumours were low-grade and 66.7% were high-grade. 14.3% of the tumours were associated with carcinoma in situ. Among those non musculo-invasive bladder tumour (non-MIBT), 34.7% had a low risk of recurrence and progression, 18.1% had an intermediate risk and 47.2% had a high risk. The patients with a ICCa >/= 5 had an increased number of MIBT (RR: 2.29; 1.1-4.8; P=.032), high-grade tumours (RR: 3.1; CI: 1.6-6; P=.001) and tumours with a high risk of recurrence and progression (RR: 2.9; CI: 1.4-5.9; P<.001). CONCLUSION: The ICCa is related to the pathological characteristics of de novo BT. Patients with greater comorbidity can present more aggressive tumours. The ICCa could therefore be useful in clinical practice for identifying patients with worse prognosis. CI - Copyright (c) 2015 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Mateu, L AU - Mateu L AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Garcia-Cruz, E AU - Garcia-Cruz E AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. Electronic address: eduard.garcia.cruz@gmail.com. FAU - Asiain, I AU - Asiain I AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Castaneda, R AU - Castaneda R AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Carrion, A AU - Carrion A AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Huguet, J AU - Huguet J AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Ribal, M J AU - Ribal MJ AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. FAU - Alcaraz, A AU - Alcaraz A AD - Departamento de Urologia, Hospital Clinic, Barcelona, Espana. LA - eng LA - spa PT - Journal Article DEP - 20150729 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*complications/*pathology OTO - NOTNLM OT - Bladder tumour OT - Charlson comorbidity index OT - Prediccion de riesgo OT - Risk prediction OT - Tumor vesical OT - Indice de comorbilidad de Charlson EDAT- 2015/08/02 06:00 MHDA- 2017/04/21 06:00 CRDT- 2015/08/02 06:00 PHST- 2015/05/10 00:00 [received] PHST- 2015/06/17 00:00 [revised] PHST- 2015/06/18 00:00 [accepted] PHST- 2015/08/02 06:00 [entrez] PHST- 2015/08/02 06:00 [pubmed] PHST- 2017/04/21 06:00 [medline] AID - S0210-4806(15)00180-1 [pii] AID - 10.1016/j.acuro.2015.06.006 [doi] PST - ppublish SO - Actas Urol Esp. 2016 Jan-Feb;40(1):23-8. doi: 10.1016/j.acuro.2015.06.006. Epub 2015 Jul 29. PMID- 28723362 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 1 IP - 1 DP - 2015 Aug TI - A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. PG - 82-89 LID - S2405-4569(15)00007-3 [pii] LID - 10.1016/j.euf.2015.01.001 [doi] AB - BACKGROUND: The relationship between pathway delays and bladder cancer-specific survival is complex because of the influence of tumour- and patient-specific factors. OBJECTIVE: To investigate the influence of tumour factors, patient factors, carcinogen exposure, and pathway delays on the long-term outcome of urothelial bladder cancer (UBC). DESIGN, SETTING, AND PARTICIPANTS: A cohort of 1537 UBC patients were enrolled between January 1, 1991 and June 30, 1992 and followed up for 17.7 yr. The period from the onset of symptoms to first treatment (transurethral resection of bladder tumour, TURBT) was divided into three components of potential delay. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations between patient factors, tumour factors, and delay times were analysed using the Pearson chi(2) test and the Mann-Whitney U test. Survival was calculated from date of TURBT to date of death or censor date (December 31, 2010). Competing risks of death were assessed with the cumulative incidence function (CIF); CIF comparisons were performed using the Gray test. RESULTS AND LIMITATIONS: At censor, reliable data were available for 1478 patients, of whom 75% had died. Females presented more commonly with muscle-invasive bladder cancer (MIBC; 30% vs 26%) and less frequently with pT1 disease (18% vs 24%; p=0.06) and had a longer total delay time (median 120 d vs 106 d, p=0.02), and those with MIBC had a significantly higher cumulative incidence of death due to UBC (80% vs 67% at 17 yr; p<0.02). Cox regression identified age, smoking status, and tumour stage, grade, and size as the most significant determinants of poor outcome. We did not capture downstream delays associated with cystectomy or radiotherapy. CONCLUSIONS: Female UBC patients present later than males, and our data suggest that delay in referral may be contributory. The relationship between gender, outcomes, delays, and UBC aetiology is complex. PATIENT SUMMARY: We followed a large group of bladder cancer patients for more than 17 yr. The relationship between pathway delays and survival is complex. However, female patients present later than male patients, and our data suggest that delay in referral from general practice may be contributory. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Bryan, Richard T AU - Bryan RT AD - School of Cancer Sciences, University of Birmingham, Birmingham, UK. FAU - Evans, Tim AU - Evans T AD - Public Health England, Birmingham, UK. FAU - Dunn, Janet A AU - Dunn JA AD - Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. FAU - Iqbal, Gulnaz AU - Iqbal G AD - Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. FAU - Bathers, Sarah AU - Bathers S AD - Primary Care Clinical Research and Trials Unit, University of Birmingham, Birmingham, UK. FAU - Collins, Stuart I AU - Collins SI AD - School of Cancer Sciences, University of Birmingham, Birmingham, UK. FAU - James, Nicholas D AU - James ND AD - Cancer Research Unit, University of Warwick, Coventry, UK. FAU - Catto, James W F AU - Catto JWF AD - Department of Oncology, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffiled.ac.uk. FAU - Wallace, D Michael A AU - Wallace DMA AD - School of Surgery, University of Western Australia, Crawley, Australia. LA - eng PT - Journal Article DEP - 20150519 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 OTO - NOTNLM OT - Delayed diagnosis OT - Long-term effects OT - Risk factors OT - Sex factors OT - Treatment outcome OT - Urinary bladder neoplasms EDAT- 2015/08/01 00:00 MHDA- 2015/08/01 00:01 CRDT- 2017/07/21 06:00 PHST- 2014/10/24 00:00 [received] PHST- 2014/12/15 00:00 [revised] PHST- 2015/01/07 00:00 [accepted] PHST- 2017/07/21 06:00 [entrez] PHST- 2015/08/01 00:00 [pubmed] PHST- 2015/08/01 00:01 [medline] AID - S2405-4569(15)00007-3 [pii] AID - 10.1016/j.euf.2015.01.001 [doi] PST - ppublish SO - Eur Urol Focus. 2015 Aug;1(1):82-89. doi: 10.1016/j.euf.2015.01.001. Epub 2015 May 19. PMID- 28723350 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 2405-4569 (Electronic) IS - 2405-4569 (Linking) VI - 1 IP - 1 DP - 2015 Aug TI - Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. PG - 17-27 LID - S2405-4569(15)00009-7 [pii] LID - 10.1016/j.euf.2014.11.001 [doi] AB - CONTEXT: Cigarette smoking is an established risk factor for urothelial carcinoma. OBJECTIVE: To elucidate the association between pretreatment smoking status, cumulative exposure, and time since smoking cessation and the development of and outcomes for urothelial carcinoma of the bladder (UCB) in patients treated with transurethral resection of the bladder (TURBT) or radical cystectomy (RC). EVIDENCE ACQUISITION: A literature search was performed in September 2014 using the PubMed and Scopus databases limited to articles published in English since 1990. Eight contemporary studies on smoking and UBC development and 26 studies on smoking and UBC prognosis met the inclusion criteria. EVIDENCE SYNTHESIS: Current cigarette smoking increases the risk of UCB incidence by two to fourfold, while smoking cessation attenuates this risk. Smoking status, exposure, and cessation have an evident impact on disease recurrence for patients who undergo TURBT, with weaker associations between smoking and other endpoints for TURBT and RC patients. CONCLUSION: Retrospective evidence suggests that smoking markedly increases UCB risk and may lead to unfavorable outcomes for patients who already have UCB; smoking cessation can attenuate these undesirable effects. PATIENT SUMMARY: Current evidence proves that cigarette smoking is an established risk factor for the development of urothelial carcinoma of the bladder (UCB). There is a growing body of evidence that smoking negatively affects outcomes for UCB patients treated with transurethral resection and/or radical cystectomy, although not uniformly. Long-term smoking cessation seems to mitigate the detrimental effects of smoking in non-muscle-invasive and muscle-invasive bladder cancer. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: mrink@uke.de. FAU - Crivelli, Joseph J AU - Crivelli JJ AD - Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Medical University Vienna, Vienna, Austria. FAU - Chun, Felix K AU - Chun FK AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Messing, Edward M AU - Messing EM AD - Department of Urology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, USA. FAU - Soloway, Mark S AU - Soloway MS AD - Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA. LA - eng PT - Journal Article PT - Review DEP - 20150519 PL - Netherlands TA - Eur Urol Focus JT - European urology focus JID - 101665661 OTO - NOTNLM OT - Intravesical therapy OT - Muscle-invasive bladder cancer OT - Non-muscle-invasive bladder cancer OT - Progression OT - Radical cystectomy OT - Recurrence OT - Smoking OT - Survival OT - Transurethral resection OT - Urothelial carcinoma EDAT- 2015/08/01 00:00 MHDA- 2015/08/01 00:01 CRDT- 2017/07/21 06:00 PHST- 2014/10/26 00:00 [received] PHST- 2014/11/03 00:00 [revised] PHST- 2014/11/27 00:00 [accepted] PHST- 2017/07/21 06:00 [entrez] PHST- 2015/08/01 00:00 [pubmed] PHST- 2015/08/01 00:01 [medline] AID - S2405-4569(15)00009-7 [pii] AID - 10.1016/j.euf.2014.11.001 [doi] PST - ppublish SO - Eur Urol Focus. 2015 Aug;1(1):17-27. doi: 10.1016/j.euf.2014.11.001. Epub 2015 May 19. PMID- 26225770 OWN - NLM STAT- MEDLINE DCOM- 20160503 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 7 DP - 2015 TI - The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PG - e0134552 LID - 10.1371/journal.pone.0134552 [doi] LID - e0134552 AB - Previous studies have shown that c-MET is overexpressed in cases of aggressive bladder cancer (BCa). Identification of crosstalk between c-MET and other RTKs such as AXL and PDGFR suggest that c-MET network genes (c-MET-AXL-PDGFR) may be clinically relevant to BCa. Here, we examine whether expression of c-MET network genes can be used to identify BCa patients at increased risk of developing aggressive disease. In vitro analysis, c-MET knockdown suppressed cell proliferation, invasion, and migration, and increased sensitivity to cisplatin-induced apoptosis. In addition, c-MET network gene (c-MET, AXL, and PDGFR) expression allowed discrimination of BCa tissues from normal control tissues and appeared to predict poor disease progression in non-muscle invasive BCa patients and poor overall survival in muscle invasive BCa patients. These results suggest that c-MET network gene expression is a novel prognostic marker for predicting which BCa patients have an increased risk of developing aggressive disease. These genes might be a useful marker for co-targeting therapy, and are expected to play an important role in improving both response to treatment and survival of BCa patients. FAU - Kim, Young-Won AU - Kim YW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Jeong, Phildu AU - Jeong P AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Seon-Kyu AU - Kim SK AD - Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea; Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. FAU - Kim, Seon-Young AU - Kim SY AD - Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea; Department of Functional Genomics, University of Science and Technology, Daejeon, Korea. FAU - Yan, Chunri AU - Yan C AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Seo, Sung Phil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Lee, Sang Keun AU - Lee SK AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Jayoung AU - Kim J AD - Department of Surgery, Harvard Medical School, Boston, MA, United States of America; Departments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. LA - eng GR - UL1TR000124/TR/NCATS NIH HHS/United States GR - R01DK100974/DK/NIDDK NIH HHS/United States GR - U01 DK082316/DK/NIDDK NIH HHS/United States GR - UL1 TR000124/TR/NCATS NIH HHS/United States GR - U24 DK097154/DK/NIDDK NIH HHS/United States GR - R01 DK100974/DK/NIDDK NIH HHS/United States GR - U01 DK103260/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150730 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Biomarkers, Tumor) RN - 0 (PDGFRL protein, human) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) RN - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Apoptosis/drug effects MH - Biomarkers, Tumor/*genetics MH - Cisplatin/therapeutic use MH - Disease Progression MH - Down-Regulation MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Middle Aged MH - Prognosis MH - Proto-Oncogene Proteins c-met/*genetics MH - Receptors, Platelet-Derived Growth Factor/genetics MH - Tumor Cells, Cultured MH - Tumor Suppressor Proteins/genetics MH - Urinary Bladder Neoplasms/drug therapy/*pathology/surgery PMC - PMC4520492 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/08/01 06:00 MHDA- 2016/05/04 06:00 PMCR- 2015/07/30 CRDT- 2015/07/31 06:00 PHST- 2015/03/26 00:00 [received] PHST- 2015/07/13 00:00 [accepted] PHST- 2015/07/31 06:00 [entrez] PHST- 2015/08/01 06:00 [pubmed] PHST- 2016/05/04 06:00 [medline] PHST- 2015/07/30 00:00 [pmc-release] AID - PONE-D-15-13279 [pii] AID - 10.1371/journal.pone.0134552 [doi] PST - epublish SO - PLoS One. 2015 Jul 30;10(7):e0134552. doi: 10.1371/journal.pone.0134552. eCollection 2015. PMID- 26215559 OWN - NLM STAT- MEDLINE DCOM- 20160203 LR - 20220330 IS - 1432-2307 (Electronic) IS - 0945-6317 (Linking) VI - 467 IP - 4 DP - 2015 Oct TI - Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. PG - 443-8 LID - 10.1007/s00428-015-1808-6 [doi] AB - The aim of the present study was to correlate tumor-infiltrating lymphocytes (TIL) with bladder cancer recurrence in patients with solitary low-grade non-muscle-invasive bladder cancer (NMIBC). We retrospectively identified from the institutional database 115 patients with solitary low-grade NMIBC after transurethral resection (TURBT) without adjuvant therapy and with complete follow-up, between 1996 and 2006. Tumor specimens were retrieved and tissue microarrays were constructed. Patients were divided in two groups: those who developed recurrent disease (n = 69) and those without recurrence (n = 46) during a follow-up period of a minimum of 5 years. Immunohistochemical staining for TIL with anti-CD3, CD4, CD8, CD20, CD56, CD68, and granzyme B (GrB) was performed. Student's t test, Mann-Whitney U test, as well as uni- and multivariate analyses were applied to compare the two patient groups. TIL were predominantly observed in cancer stroma. The number of CD3+ and CD8+ lymphocytes observed in the non-recurrent group of patients was lower than that in recurrent patients (p = 0.0001, p = 0.0002, respectively). Also, in uni- and multivariate analyses, levels of CD3+ TIL (OR = 5.4035; p = 0.0001 and OR = 5.8280; p = 0.0102) and CD8+ TIL (OR = 3.2857; p = 0.0036 and OR = 5.3257; p = 0.0092) showed prognostic value with regard to NMIBC recurrence. Our results suggest that CD3+ and CD8+ TIL are predictive of bladder cancer recurrence in patients with solitary low-grade NMIBC which might facilitate identification of patients with higher risk of recurrence. However, prospective validating studies have to confirm these results before immunohistochemical staining for CD3 and CD8 TIL can be included in the clinical workup of these patients. FAU - Krpina, Kristian AU - Krpina K AD - Department of Urology, Clinical Hospital Center Rijeka, T. Strizica 3, 51000, Rijeka, Croatia. kristiank@net.hr. FAU - Babarovic, Emina AU - Babarovic E AD - Department of Pathology, School of Medicine, University of Rijeka, Brace Branchetta, 20, 51000, Rijeka, Croatia. FAU - Jonjic, Nives AU - Jonjic N AD - Department of Pathology, School of Medicine, University of Rijeka, Brace Branchetta, 20, 51000, Rijeka, Croatia. LA - eng PT - Journal Article DEP - 20150728 PL - Germany TA - Virchows Arch JT - Virchows Archiv : an international journal of pathology JID - 9423843 RN - 0 (CD3 Complex) RN - 0 (CD8 Antigens) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - CD3 Complex/analysis MH - CD8 Antigens/analysis MH - Female MH - Humans MH - Lymphocytes, Tumor-Infiltrating/*pathology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Tissue Array Analysis MH - Urinary Bladder Neoplasms/immunology/*pathology OTO - NOTNLM OT - Lymphocytes OT - Non-muscle-invasive bladder cancer OT - Recurrence OT - Treatment OT - Tumor-infiltrating EDAT- 2015/07/29 06:00 MHDA- 2016/02/04 06:00 CRDT- 2015/07/29 06:00 PHST- 2015/04/07 00:00 [received] PHST- 2015/07/09 00:00 [accepted] PHST- 2015/06/06 00:00 [revised] PHST- 2015/07/29 06:00 [entrez] PHST- 2015/07/29 06:00 [pubmed] PHST- 2016/02/04 06:00 [medline] AID - 10.1007/s00428-015-1808-6 [pii] AID - 10.1007/s00428-015-1808-6 [doi] PST - ppublish SO - Virchows Arch. 2015 Oct;467(4):443-8. doi: 10.1007/s00428-015-1808-6. Epub 2015 Jul 28. PMID- 26210894 OWN - NLM STAT- MEDLINE DCOM- 20160929 LR - 20220330 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 69 IP - 1 DP - 2016 Jan TI - EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. PG - 60-9 LID - S0302-2838(15)00556-4 [pii] LID - 10.1016/j.eururo.2015.06.045 [doi] AB - BACKGROUND: There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with 1-3 yr of maintenance bacillus Calmette-Guerin (BCG). OBJECTIVE: To determine prognostic factors in NMIBC patients treated with 1-3 yr of BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk groups, and to identify high-risk patients who should be considered for early cystectomy. DESIGN, SETTING, AND PARTICIPANTS: Data for 1812 patients were merged from two European Organization for Research and Treatment of Cancer randomized phase 3 trials in intermediate- and high-risk NMIBC. INTERVENTION: Patients received 1-3 yr of maintenance BCG after TURB and induction BCG. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prognostic factors for risk of early recurrence and times to late recurrence, progression, and death were identified in a training data set using multivariable models and applied to a validation data set. RESULTS AND LIMITATIONS: With a median follow-up of 7.4 yr, 762 patients recurred; 173 progressed; and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic factors identified by multivariable analyses were prior recurrence rate and number of tumors for recurrence, and tumor stage and grade for progression and death due to BCa. T1G3 patients do poorly, with 1- and 5-yr disease-progression rates of 11.4% and 19.8%, respectively, and 1- and 5-yr disease-specific death rates of 4.8% and 11.3%. Limitations include lack of repeat transurethral resection in high-risk patients and exclusion of patients with carcinoma in situ. CONCLUSIONS: NMIBC patients treated with 1-3 yr of maintenance BCG have a heterogeneous prognosis. Patients at high risk of recurrence and/or progression do poorly on currently recommended maintenance schedules. Alternative treatments are urgently required. PATIENT SUMMARY: Non-muscle-invasive bladder cancer patients at high risk of recurrence and/or progression do poorly on currently recommended bacillus Calmette-Guerin maintenance schedules, and alternative treatments are urgently required. TRIAL REGISTRATION: Study 30911 was registered with the US National Cancer Institute clinical trials database (protocol ID: EORTC 30911). Study 30962 was registered at ClinicalTrials.gov, number NCT00002990; http://clinicaltrials.gov/ct2/show/record/NCT00002990. CI - Copyright (c) 2015 European Association of Urology. All rights reserved. FAU - Cambier, Samantha AU - Cambier S AD - EORTC Headquarters, Brussels, Belgium. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EORTC Headquarters, Brussels, Belgium. Electronic address: richard.sylvester@eortc.be. FAU - Collette, Laurence AU - Collette L AD - EORTC Headquarters, Brussels, Belgium. FAU - Gontero, Paolo AU - Gontero P AD - Department of Surgical Sciences, Molinette Hospital, Torino, Italy. FAU - Brausi, Maurizio A AU - Brausi MA AD - Department of Urology, AUSL, Modena, Italy. FAU - van Andel, George AU - van Andel G AD - Department of Urology, OLVG, Amsterdam, The Netherlands. FAU - Kirkels, Wim J AU - Kirkels WJ AD - Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Silva, Fernando Calais Da AU - Silva FC AD - Department of Urology, Hospital Do Desterro, Lisbon, Portugal. FAU - Oosterlinck, Willem AU - Oosterlinck W AD - Department of Urology, Ghent University Hospital, Ghent, Belgium. FAU - Prescott, Stephen AU - Prescott S AD - Department of Urology, St. James's University Hospital, Leeds, UK. FAU - Kirkali, Ziya AU - Kirkali Z AD - Department of Urology, Dokuz Eylul University School of Medicine, Izmir, Turkey. FAU - Powell, Philip H AU - Powell PH AD - Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK. FAU - de Reijke, Theo M AU - de Reijke TM AD - Department of Urology, Academic Medical Center, Amsterdam, The Netherlands. FAU - Turkeri, Levent AU - Turkeri L AD - Department of Urology, Marmara University School of Medicine, Istanbul, Turkey. FAU - Collette, Sandra AU - Collette S AD - EORTC Headquarters, Brussels, Belgium. FAU - Oddens, Jorg AU - Oddens J AD - Department of Urology, Jeroen Bosch Ziekenhuis, s'-Hertogenbosch, The Netherlands. LA - eng SI - ClinicalTrials.gov/NCT00002990 PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150723 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM CIN - Eur Urol. 2016 Jan;69(1):70-1. doi: 10.1016/j.eururo.2015.07.034. PMID: 26256521 CIN - Eur Urol. 2016 Jun;69(6):e123-4. doi: 10.1016/j.eururo.2016.01.055. PMID: 26874805 CIN - J Urol. 2017 Jul;198(1):39-41. doi: 10.1016/j.juro.2017.04.004. PMID: 28618711 CIN - J Urol. 2018 Oct;200(4):706-708. doi: 10.1016/j.juro.2018.06.019. PMID: 29906436 MH - Adjuvants, Immunologic/*therapeutic use MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Disease Progression MH - Female MH - Humans MH - Maintenance Chemotherapy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*prevention & control MH - Neoplasm Staging MH - *Nomograms MH - Prognosis MH - Risk Assessment/methods MH - Survival Rate MH - Urinary Bladder Neoplasms/*drug therapy/mortality/*pathology OTO - NOTNLM OT - Bacillus Calmette-Guerin OT - Non-muscle-invasive bladder cancer OT - Prognostic factors OT - Progression OT - Recurrence OT - Survival EDAT- 2015/07/27 06:00 MHDA- 2016/09/30 06:00 CRDT- 2015/07/27 06:00 PHST- 2015/04/07 00:00 [received] PHST- 2015/06/29 00:00 [accepted] PHST- 2015/07/27 06:00 [entrez] PHST- 2015/07/27 06:00 [pubmed] PHST- 2016/09/30 06:00 [medline] AID - S0302-2838(15)00556-4 [pii] AID - 10.1016/j.eururo.2015.06.045 [doi] PST - ppublish SO - Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23. PMID- 26202687 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20161230 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 50 IP - 1 DP - 2016 TI - Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence. PG - 33-8 LID - 10.3109/21681805.2015.1066849 [doi] AB - OBJECTIVE: The aim of this study was to evaluate tumour growth located around the ureteric orifice (LUO) at primary diagnosis of Ta/T1 urinary bladder cancer in relation to effects on recurrence and progression. MATERIALS AND METHODS: Clinical and pathological characteristics of patients diagnosed with primary Ta/T1 urinary bladder cancer from 1992 to 2007 were recorded prospectively. Location of the primary tumour and growth around the ureteric orifice (within 1 cm) were recorded and correlated with recurrence and progression during further follow-up. Hazard ratios (HRs) were estimated using Cox regression with 95% confidence intervals (CIs) in both univariate and multivariate analysis. RESULTS: The study included 768 evaluable patients with a median follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Growth of a primary tumour adjacent to the ureteric orifice was associated with recurrence (HR = 1.28, 95% CI = 1.07-1.54) but not progression (HR = 1.04, 95% CI = 0.65-1.67). The most common location of the first recurrence was the posterior bladder wall (29%). Other locations in the bladder did not predict recurrence or progression. Additional factors affecting recurrence were tumour size greater than 15 mm, T1 tumour category, multiplicity, malignant or missing/not representative bladder wash cytology and surgery performed by residents. CONCLUSIONS: A primary tumour located around the ureteric orifice was predictive of recurrence, which could be taken into account in future follow-up schedules. FAU - Jancke, Georg AU - Jancke G AD - a 1 Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University , Linkoping, Sweden. FAU - Rosell, Johan AU - Rosell J AD - b 2 Oncology Centre, University Hospital , Linkoping, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - a 1 Division of Urology, Department of Clinical and Experimental Medicine, Linkoping University , Linkoping, Sweden. LA - eng PT - Journal Article DEP - 20150723 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) SB - IM MH - Adjuvants, Immunologic/therapeutic use MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/therapeutic use MH - Carcinoma, Transitional Cell/*pathology/therapy MH - Disease Progression MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*epidemiology MH - Neoplasm Seeding MH - Proportional Hazards Models MH - Prospective Studies MH - Ureter/*pathology MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/*pathology/therapy MH - Urologic Surgical Procedures OTO - NOTNLM OT - Bladder cancer OT - recurrence OT - tumour location OT - ureteric orifice EDAT- 2015/07/24 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/07/24 06:00 PHST- 2015/07/24 06:00 [entrez] PHST- 2015/07/24 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.3109/21681805.2015.1066849 [doi] PST - ppublish SO - Scand J Urol. 2016;50(1):33-8. doi: 10.3109/21681805.2015.1066849. Epub 2015 Jul 23. PMID- 26197470 OWN - NLM STAT- MEDLINE DCOM- 20160505 LR - 20260128 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 7 DP - 2015 TI - Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. PG - e0133552 LID - 10.1371/journal.pone.0133552 [doi] LID - e0133552 AB - Inflammation is an important feature of carcinogenesis. Tumor-associated macrophages (TAMs) can be associated with either poor or improved prognosis, depending on their properties and polarization. Current knowledge of the prognostic significance of TAMs in bladder cancer is limited and was investigated in this study. We analyzed 184 urothelial bladder cancer patients undergoing transurethral resection of a bladder tumor or radical cystectomy. CD68 (pan-macrophage marker), MAC387 (polarized towards type 1 macrophages), and CLEVER-1/Stabilin-1 (type 2 macrophages and lymphatic/blood vessels) were detected immunohistochemically. The median follow-up time was 6.0 years. High macrophage counts associated with a higher pT category and grade. Among patients undergoing transurethral resection, all studied markers apart from CLEVER-1/Stabilin-1 were associated with increased risk of progression and poorer disease-specific and overall survival in univariate analyses. High levels of two macrophage markers (CD68/MAC387+/+ or CD68/CLEVER-1+/+ groups) had an independent prognostic role after transurethral resection in multivariate analyses. In the cystectomy cohort, MAC387, alone and in combination with CD68, was associated with poorer survival in univariate analyses, but none of the markers were independent predictors of outcome in multivariate analyses. In conclusion, this study demonstrates that macrophage phenotypes provide significant independent prognostic information, particularly in bladder cancers undergoing transurethral resection. FAU - Bostrom, Minna M AU - Bostrom MM AD - MediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland. FAU - Irjala, Heikki AU - Irjala H AD - MediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland; Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital, Turku, Finland. FAU - Mirtti, Tuomas AU - Mirtti T AD - Department of Pathology, Helsinki University Hospital (HUSLAB) and Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. FAU - Taimen, Pekka AU - Taimen P AD - Department of Pathology, Turku University Hospital, Turku, Finland. FAU - Kauko, Tommi AU - Kauko T AD - Department of Biostatistics, University of Turku, Turku, Finland. FAU - Algars, Annika AU - Algars A AD - MediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland; Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland. FAU - Jalkanen, Sirpa AU - Jalkanen S AD - MediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland. FAU - Bostrom, Peter J AU - Bostrom PJ AD - Department of Urology, Turku University Hospital, Turku, Finland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150721 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, Myelomonocytic) RN - 0 (BCG Vaccine) RN - 0 (Calgranulin B) RN - 0 (Cell Adhesion Molecules, Neuronal) RN - 0 (Receptors, Lymphocyte Homing) RN - 0 (CD68 antigen, human) RN - 0 (CD68 Molecule) RN - 0 (STAB1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, CD/metabolism MH - Antigens, Differentiation, Myelomonocytic/metabolism MH - BCG Vaccine/chemistry MH - Calgranulin B/metabolism MH - Cell Adhesion Molecules, Neuronal/metabolism MH - Cohort Studies MH - Cystectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Macrophages/*metabolism MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Phenotype MH - Prognosis MH - Proportional Hazards Models MH - Receptors, Lymphocyte Homing/metabolism MH - Urinary Bladder Neoplasms/*diagnosis/*pathology MH - Urothelium/*pathology MH - CD68 Molecule PMC - PMC4511010 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/07/22 06:00 MHDA- 2016/05/06 06:00 PMCR- 2015/07/21 CRDT- 2015/07/22 06:00 PHST- 2015/02/14 00:00 [received] PHST- 2015/06/29 00:00 [accepted] PHST- 2015/07/22 06:00 [entrez] PHST- 2015/07/22 06:00 [pubmed] PHST- 2016/05/06 06:00 [medline] PHST- 2015/07/21 00:00 [pmc-release] AID - PONE-D-15-06747 [pii] AID - 10.1371/journal.pone.0133552 [doi] PST - epublish SO - PLoS One. 2015 Jul 21;10(7):e0133552. doi: 10.1371/journal.pone.0133552. eCollection 2015. PMID- 26192256 OWN - NLM STAT- MEDLINE DCOM- 20160229 LR - 20220330 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 194 IP - 6 DP - 2015 Dec TI - Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma. PG - 1561-6 LID - S0022-5347(15)04414-6 [pii] LID - 10.1016/j.juro.2015.07.081 [doi] AB - PURPOSE: Robot-assisted laparoscopic nephroureterectomy with bladder cuff excision is a minimally invasive alternative to open surgery for managing upper tract urothelial carcinoma. We report oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision. MATERIALS AND METHODS: The records of the initial 65 patients who underwent robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma between 2008 and 2014 were reviewed from our institutional review board approved, prospectively maintained database. All patients underwent surgery with the single docking technique. Baseline demographic features, pathological variables and perioperative data were analyzed. Kaplan-Meier methodology was used for survival analysis. Cox proportional hazards regression was applied to determine the prognostic effect of different variables on survival. RESULTS: Mean patient age was 69.1 years. Final pathological evaluation revealed pT2 stage or lower in 65% of patients, pT3 in 28.3% and pT4 in 6.7%. High grade pathological findings were present in 85% of patients, including 13.3% with concomitant carcinoma in situ and 30% with lymphovascular invasion. Median followup was 25.1 months (range 6 to 68.9). At 2 and 5 years overall survival was 86.9% and 62.6%, cancer specific survival was 92.9% and 69.5%, and recurrence-free survival was 65.3% and 57.1%, respectively. A total of 23 patients experienced disease recurrence. Bladder recurrence developed in 15 patients, 12 had isolated bladder recurrence and 8 had metastatic disease. On univariate analysis age greater than 70 years, preoperative hydronephrosis, nodal disease and concomitant carcinoma in situ were significantly associated with decreased recurrence-free survival (p=0.002, 0.04, 0.006 and 0.001, respectively). However, none was statistically significant on multivariate analysis. On univariate analysis impaired preoperative renal function (creatinine greater than 2 mg/dl) and lymphovascular invasion were associated with reduced cancer specific survival (p=0.03 and 0.01, respectively). However, only lymphovascular invasion was associated with decreased cancer specific survival on multivariate analysis (p=0.048). CONCLUSIONS: Our reported data on oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma demonstrate satisfactory oncologic control at intermediate term followup. Long-term outcomes are required to assess true efficacy. CI - Copyright (c) 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Aboumohamed, Ahmed A AU - Aboumohamed AA AD - Urology Department, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. FAU - Krane, Louis Spencer AU - Krane LS AD - Urology Department, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. FAU - Hemal, Ashok K AU - Hemal AK AD - Urology Department, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. Electronic address: ahemal@wakehealth.edu. LA - eng PT - Clinical Study PT - Journal Article DEP - 20150717 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*mortality/pathology/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Kidney Neoplasms/*mortality/pathology/*surgery MH - Laparoscopy/*methods MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Nephrectomy/*methods MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Robotic Surgical Procedures/*methods MH - Ureter/*surgery MH - Ureteral Neoplasms/*mortality/pathology/*surgery MH - Urinary Bladder/*surgery OTO - NOTNLM OT - carcinoma OT - mortality OT - nephrectomy OT - robotics OT - urinary bladder EDAT- 2015/07/21 06:00 MHDA- 2016/03/02 06:00 CRDT- 2015/07/21 06:00 PHST- 2015/07/05 00:00 [accepted] PHST- 2015/07/21 06:00 [entrez] PHST- 2015/07/21 06:00 [pubmed] PHST- 2016/03/02 06:00 [medline] AID - S0022-5347(15)04414-6 [pii] AID - 10.1016/j.juro.2015.07.081 [doi] PST - ppublish SO - J Urol. 2015 Dec;194(6):1561-6. doi: 10.1016/j.juro.2015.07.081. Epub 2015 Jul 17. PMID- 26188393 OWN - NLM STAT- MEDLINE DCOM- 20160727 LR - 20220409 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 68 IP - 5 DP - 2015 Nov TI - European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. PG - 868-79 LID - S0302-2838(15)00550-3 [pii] LID - 10.1016/j.eururo.2015.06.044 [doi] AB - CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Roupret, Morgan AU - Roupret M AD - Department of Urology, Hospital Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancerologie, Paris, France. Electronic address: morgan.roupret@aphp.fr. FAU - Babjuk, Marko AU - Babjuk M AD - Department of Urology, Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Comperat, Eva AU - Comperat E AD - Department of Pathology, Hospitalier Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancerologie, Paris, France. FAU - Zigeuner, Richard AU - Zigeuner R AD - Department of Urology, Medizinische Universitat Graz, Graz, Austria. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EAU Guidelines Office Board, European Association of Urology, The Netherlands. FAU - Burger, Maximilian AU - Burger M AD - Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany. FAU - Cowan, Nigel C AU - Cowan NC AD - Department of Radiology, Queen Alexandra Hospital, Portsmouth, UK. FAU - Bohle, Andreas AU - Bohle A AD - Helios Agnes Karll Krankenhaus, Schwartau, Germany. FAU - Van Rhijn, Bas W G AU - Van Rhijn BW AD - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Kaasinen, Eero AU - Kaasinen E AD - Department of Surgery, Hyvinkaa Hospital, Hyvinkaa, Finland. FAU - Palou, Joan AU - Palou J AD - Department of Urology, Universitat Autonoma de Barcelona-Fundacio Puigvert, Barcelona, Spain. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Medical College of Cornell University, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20150716 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM CIN - Eur Urol. 2016 Mar;69(3):e51-2. doi: 10.1016/j.eururo.2015.09.048. PMID: 26461109 CIN - Eur Urol. 2016 Mar;69(3):e49-50. doi: 10.1016/j.eururo.2015.09.049. PMID: 26461110 MH - Administration, Intravesical MH - Antibiotics, Antineoplastic/*therapeutic use MH - Carcinoma, Transitional Cell/diagnosis/*therapy MH - Chemotherapy, Adjuvant MH - Humans MH - Kidney Neoplasms/diagnosis/*therapy MH - Kidney Pelvis/pathology MH - Mitomycin/*therapeutic use MH - Neoplasm Recurrence, Local/*prevention & control MH - *Nephrectomy MH - Societies, Medical MH - Ureter/*surgery MH - Ureteral Neoplasms/diagnosis/*therapy MH - Ureteroscopy MH - Urinary Bladder Neoplasms/*prevention & control MH - Urology OTO - NOTNLM OT - Cytology OT - Guidelines OT - Nephroureterectomy OT - Renal pelvis OT - Risk factors OT - Survival OT - Ureter OT - Ureteroscopy OT - Urinary tract cancer OT - Urothelial carcinoma EDAT- 2015/07/21 06:00 MHDA- 2016/07/28 06:00 CRDT- 2015/07/20 06:00 PHST- 2015/06/16 00:00 [received] PHST- 2015/06/23 00:00 [accepted] PHST- 2015/07/20 06:00 [entrez] PHST- 2015/07/21 06:00 [pubmed] PHST- 2016/07/28 06:00 [medline] AID - S0302-2838(15)00550-3 [pii] AID - 10.1016/j.eururo.2015.06.044 [doi] PST - ppublish SO - Eur Urol. 2015 Nov;68(5):868-79. doi: 10.1016/j.eururo.2015.06.044. Epub 2015 Jul 16. PMID- 26173101 OWN - NLM STAT- MEDLINE DCOM- 20160201 LR - 20210817 IS - 1527-3792 (Electronic) IS - 0022-5347 (Print) IS - 0022-5347 (Linking) VI - 194 IP - 5 DP - 2015 Nov TI - Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. PG - 1214-9 LID - S0022-5347(15)04360-8 [pii] LID - 10.1016/j.juro.2015.05.104 [doi] AB - PURPOSE: Prior reports suggest that renin-angiotensin system inhibition may decrease nonmuscle invasive bladder cancer recurrence. We evaluated whether angiotensin converting enzyme inhibitor or angiotensin receptor blocker treatment at initial surgery was associated with decreased recurrence or progression in patients with nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Using an institutional bladder cancer database we identified 340 patients with data available on initial transurethral resection of bladder tumor. Progression was defined as an increase to stage T2. Cox proportional hazards models were used to evaluate associations with recurrence-free and progression-free survival. RESULTS: Median patient age was 69.6 years. During a median followup of 3 years (IQR 1.3-6.1) 200 patients (59%) had recurrence and 14 (4.1%) had stage progression. Of those patients 143 were receiving angiotensin converting enzyme inhibitor/angiotensin receptor blockers at the time of the first transurethral resection. On univariate analysis factors associated with improved recurrence-free survival included carcinoma in situ (p = 0.040), bacillus Calmette-Guerin therapy (p = 0.003) and angiotensin converting enzyme inhibitor/angiotensin receptor blocker therapy (p = 0.009). Multivariate analysis demonstrated that patients treated with bacillus Calmette-Guerin therapy (HR 0.68, 95% CI 0.47-0.87, p = 0.002) or angiotensin converting enzyme inhibitor/angiotensin receptor blocker therapy (HR 0.61, 95% CI 0.45-0.84, p = 0.005) were less likely to experience tumor recurrence. The 5-year recurrence-free survival rate was 45.6% for patients treated with angiotensin converting enzyme inhibitor/angiotensin receptor blockers and 28.1% in those not treated with angiotensin converting enzyme inhibitor/angiotensin receptor blockers (p = 0.009). Subgroup analysis was performed to evaluate nonmuscle invasive bladder cancer pathology (Ta, T1 and carcinoma in situ) in 85 patients on bacillus Calmette-Guerin therapy alone and in 52 in whom it was combined with angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Multivariate analysis revealed that patients treated with bacillus Calmette-Guerin alone (HR 2.19, 95% CI 1.01-4.77, p = 0.04) showed worse recurrence-free survival compared to patients treated with bacillus Calmette-Guerin and angiotensin converting enzyme inhibitor/angiotensin receptor blocker (stage Ta HR 0.45, 95% CI 0.21-0.98, p = 0.04). CONCLUSIONS: Pharmacological inhibition of the renin-angiotensin system is associated with improved outcomes in patients with bladder cancer. Renin-angiotensin system inhibitor administration in nonmuscle invasive bladder cancer cases should be studied in a prospective randomized trial. CI - Copyright (c) 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Blute, Michael L Jr AU - Blute ML Jr AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Rushmer, Timothy J AU - Rushmer TJ AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Shi, Fangfang AU - Shi F AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Fuller, Benjamin J AU - Fuller BJ AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Abel, E Jason AU - Abel EJ AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Jarrard, David F AU - Jarrard DF AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. FAU - Downs, Tracy M AU - Downs TM AD - Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin. Electronic address: downs@urology.wisc.edu. LA - eng GR - P30 CA014520/CA/NCI NIH HHS/United States GR - T32 CA009614/CA/NCI NIH HHS/United States GR - 5T32CA009614-24/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20150711 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM CIN - J Urol. 2016 May;195(5):1623-1624. doi: 10.1016/j.juro.2015.12.091. PMID: 26876585 CIN - J Urol. 2016 Sep;196(3):960-1. doi: 10.1016/j.juro.2016.03.184. PMID: 27294294 MH - Aged MH - Angiotensin Receptor Antagonists/*therapeutic use MH - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Incidence MH - Male MH - Natural Orifice Endoscopic Surgery/*methods MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*drug therapy/epidemiology MH - Retrospective Studies MH - Survival Rate/trends MH - Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery MH - Wisconsin/epidemiology PMC - PMC8366568 MID - NIHMS917172 OTO - NOTNLM OT - angiotensin converting enzyme inhibitors OT - angiotensin receptor antagonists OT - local OT - neoplasm recurrence OT - renin-angiotensin system OT - urinary bladder neoplasms EDAT- 2015/07/15 06:00 MHDA- 2016/02/02 06:00 PMCR- 2021/08/16 CRDT- 2015/07/15 06:00 PHST- 2015/05/13 00:00 [accepted] PHST- 2015/07/15 06:00 [entrez] PHST- 2015/07/15 06:00 [pubmed] PHST- 2016/02/02 06:00 [medline] PHST- 2021/08/16 00:00 [pmc-release] AID - S0022-5347(15)04360-8 [pii] AID - 10.1016/j.juro.2015.05.104 [doi] PST - ppublish SO - J Urol. 2015 Nov;194(5):1214-9. doi: 10.1016/j.juro.2015.05.104. Epub 2015 Jul 11. PMID- 26150030 OWN - NLM STAT- MEDLINE DCOM- 20151117 LR - 20161020 IS - 1124-3562 (Print) IS - 1124-3562 (Linking) VI - 87 IP - 2 DP - 2015 Jul 7 TI - Influence of antiplatelet-anticoagulant drugs on the need of blood components transfusion after vesical transurethral resection. PG - 136-40 LID - 10.4081/aiua.2015.2.136 [doi] AB - AIMS: The effect of the antithrombotic preventive therapy on haemorrhage keeps uncertain. We investigate the influence of the antiplatelet and anticoagulant drugs (AP/AC drugs) on the transfusion requirement after vesical transurethral resection (VTUR). We also describe the epidemiology of the blood components transfusion in our department. MATERIALS AND METHODS: Retrospective observational study of a series of patients needing blood transfusion at the Urology Department between June 2010 and June 2013. Selection of 100 consecutive patients who were transfused after VTUR due to bladder transitional cell carcinoma (BTCC) (group A = GA). CONTROL GROUP: 100 consecutive patients who underwent VTUR due to BTCC and were not transfused (group B = GB). Transfusion criteria: Haemoglobin < 8 g/dl + anaemia symptoms. Age, gender, associated AP/AC treatment, secondary diagnoses, toxics, tumour stage and grade were analysed. RESULTS: 212 patients required transfusion of a blood component. 169 were men (79%) and 43 women (21%). Median age 77.59 years (SD 9.42, range 50-92). Secondary diagnoses: Diabetes Mellitus 64%, high blood pressure 77%, dyslipidemia 52%. 60% of patients were previously treated with AP/AC drugs. Average Haemoglobin pre-transfusion values: 7.4 g/dl (DE +/- 0.7). Average Haemoglobin post-transfusion values: 8.9 g/Dl (DE +/- 0.72). Most frequent transfusion indications were bladder cancer (37%), kidney cancer (11%), prostate cancer (8%), benign prostatic hyperplasia (BHP) (8%), other urological diagnoses (36%). Intraoperative transfusions indicated by the anaesthesiologist: kidney cancer (33%), BPH (28%). Patients who underwent VTUR due to BTCC were older in GA (77.59 years SD 9.42) than in GB (68.98 years SD 11.78) (p = 0.0001). Similar gender distribution (15 women in GA and 24 in GB). Less patients were asked to keep their treatment with ASA 100mg (AcetylSalicylicAcid) in GA (25.64%) than in GB (50%) (p = 0.0330). More aggressive tumour grade in GA (p = 0.0003) and higher stage in GA (p = 0.0018) regardless of concomitant treatment with AP/AC drugs. CONCLUSIONS: The pathologies which most needed blood components' transfusions in the Urology Department were (in order of frequency): bladder cancer, kidney cancer, prostate cancer, prostate adenoma. ASA100mg did not influence the transfusion's requirements in VTUR due to BTCC. Tumour stage and higher grade have a greater influence in transfusion's requirements than concomitant AP/AC treatment. The heterogeneity of AP/AC protocols does not allow to establish the benefit of stopping those drugs before surgery in terms of avoiding blood transfusions when performing a VTUR. FAU - Virseda-Rodriguez, Alvaro Julio AU - Virseda-Rodriguez AJ AD - Department of Urology, University Hospital of Salamanca. mflorenzogo@yahoo.es. FAU - Padilla-Fernandez, Barbara AU - Padilla-Fernandez B FAU - Lopez-Parra, Mirian AU - Lopez-Parra M FAU - Santos-Antunes, Maria Tatiana AU - Santos-Antunes MT FAU - Valverde-Martinez, Lauro Sebastian AU - Valverde-Martinez LS FAU - Nieto-Gonzalez, Maria Jesus AU - Nieto-Gonzalez MJ FAU - San Miguel-Izquierdo, Jesus Fernando AU - San Miguel-Izquierdo JF FAU - Lorenzo-Gomez, Anabel AU - Lorenzo-Gomez A FAU - Garcia-Cenador, Maria Begona AU - Garcia-Cenador MB FAU - Antunez-Plaza, Patricia AU - Antunez-Plaza P FAU - Lorenzo-Gomez, Maria Fernanda AU - Lorenzo-Gomez MF LA - eng PT - Journal Article PT - Observational Study DEP - 20150707 PL - Italy TA - Arch Ital Urol Androl JT - Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica JID - 9308247 RN - 0 (Anticoagulants) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Anticoagulants/therapeutic use MH - *Blood Transfusion MH - Carcinoma, Transitional Cell/pathology/*surgery/therapy MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Patient Selection MH - *Platelet Aggregation Inhibitors/therapeutic use MH - Preoperative Care MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome MH - *Urethra MH - Urinary Bladder Neoplasms/pathology/*surgery/therapy EDAT- 2015/07/08 06:00 MHDA- 2015/11/18 06:00 CRDT- 2015/07/08 06:00 PHST- 2015/07/06 00:00 [received] PHST- 2015/07/06 00:00 [accepted] PHST- 2015/07/08 06:00 [entrez] PHST- 2015/07/08 06:00 [pubmed] PHST- 2015/11/18 06:00 [medline] AID - 10.4081/aiua.2015.2.136 [doi] PST - epublish SO - Arch Ital Urol Androl. 2015 Jul 7;87(2):136-40. doi: 10.4081/aiua.2015.2.136. PMID- 26142924 OWN - NLM STAT- MEDLINE DCOM- 20151112 LR - 20220321 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 86 IP - 2 DP - 2015 Aug TI - Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer. PG - 327-31 LID - S0090-4295(15)00361-1 [pii] LID - 10.1016/j.urology.2015.04.015 [doi] AB - OBJECTIVE: To compare early recurrence between good-quality white-light transurethral resection of bladder tumor (GQ-WLTURBT) and photodynamic diagnosis-assisted (PDD) transurethral resection of bladder tumor (TURBT) in a real-life controlled setting. METHODS: A prospective controlled study was conducted commencing with a planned prospective cohort of patients with new tumors undergoing white-light TURBT in 2007-2008. Previously defined principles of GQ-WLTURBT for standardization and comparison of TURBT techniques, which are (1) cystoscopic mapping using a bladder diagram, (2) documented complete resection of the tumor, (3) resection performed or supervised by an experienced surgeon, (4) presence of detrusor muscle in the specimen, and (5) patient receiving mitomycin C within 24 hours of the resection, were applied. This was followed by a prospective cohort of new patients undergoing PDD-TURBT in 2009-2011. Only patients with new non-muscle-invasive bladder cancer (NMIBC) deemed to have had complete first TURBT were included for analysis. Tumor features and findings at first check cystoscopy and early re-TURBT (in high-risk NMIBC) were evaluated. Early recurrence (for calculating recurrence rate at first follow-up cystoscopy) was defined as pathologically confirmed tumor on early re-TURBT or recurrence at the first check cystoscopy. Comparison was analyzed between GQ-WLTURBT and good-quality PDD-TURBT (GQ-PDDTURBT). RESULTS: A total of 808 patients were evaluated. The overall RRFFCs for GQ-WLTURBT and GQ-PDDTURBT were 30.9% and 13.6%, respectively (odds ratio = 2.9; 95% CI = 1.6-5.0; P <.001), with statistically significant lower recurrence rates in low- and intermediate-risk NMIBC after GQ-PDDTURBT. CONCLUSION: Hexvix PDD-assisted TURBT is associated with a significantly lower risk of early recurrence compared with GQ-WLTURBT in a real-life clinical setting. CI - Crown Copyright (c) 2015. Published by Elsevier Inc. All rights reserved. FAU - Mariappan, Paramananthan AU - Mariappan P AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. Electronic address: param.mariappan@nhs.net. FAU - Rai, Bhavan AU - Rai B AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. FAU - El-Mokadem, Ismail AU - El-Mokadem I AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. FAU - Anderson, Claire H AU - Anderson CH AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. FAU - Lee, Hannah AU - Lee H AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. FAU - Stewart, Sarah AU - Stewart S AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. FAU - Donat, Roland AU - Donat R AD - Edinburgh Urological Cancer Group, Department of Urology, Western General Hospital, Edinburgh, United Kingdom. LA - eng PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article DEP - 20150702 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Cystectomy/*methods MH - Humans MH - Light MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*diagnosis MH - Prospective Studies MH - Time Factors MH - Urethra MH - Urinary Bladder Neoplasms/*diagnosis/*surgery EDAT- 2015/07/06 06:00 MHDA- 2015/11/13 06:00 CRDT- 2015/07/06 06:00 PHST- 2014/11/16 00:00 [received] PHST- 2015/03/29 00:00 [revised] PHST- 2015/04/04 00:00 [accepted] PHST- 2015/07/06 06:00 [entrez] PHST- 2015/07/06 06:00 [pubmed] PHST- 2015/11/13 06:00 [medline] AID - S0090-4295(15)00361-1 [pii] AID - 10.1016/j.urology.2015.04.015 [doi] PST - ppublish SO - Urology. 2015 Aug;86(2):327-31. doi: 10.1016/j.urology.2015.04.015. Epub 2015 Jul 2. PMID- 26139078 OWN - NLM STAT- MEDLINE DCOM- 20160517 LR - 20181113 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 47 IP - 8 DP - 2015 Aug TI - Can body mass index predict survival outcomes in patients treated with radical nephroureterectomy for upper-tract urothelial carcinoma? PG - 1311-20 LID - 10.1007/s11255-015-1039-4 [doi] AB - PURPOSE: To assess the relationship between body mass index (BMI) and survival outcomes in Korean patients with upper-tract urothelial carcinoma (UTUC). METHODS: A single-institutional retrospective analysis was conducted using clinical and pathological data of 445 UTUC patients who had undergone radical nephroureterectomy with bladder cuff excision from 1997 to 2012. Enrolled patients were classified into normal weight (BMI < 23 kg/m(2)), overweight (BMI 23-24.9 kg/m(2)), and obese (BMI >/= 25 kg/m(2)) in accordance with BMI cutoffs for Asian populations. The impact of BMI on intravesical recurrence (IVR)-free survival, overall survival (OS), and cancer-specific survival (CSS) was evaluated using Kaplan-Meier analysis with the log-rank test and the Cox proportional hazard model. RESULTS: The median BMI of all patients was 24.2 kg/m(2) (interquartile range 22.2-25.8). There were no significant differences in the IVR-free survival rates according to BMI classification (p = 0.488). The 5-year OS and CSS rates were 58.8, 66.3, and 76.3 % (p = 0.057) and 67.4, 69.3, and 81.5 % (p = 0.021) in the normal, overweight, and obese groups, respectively. In the univariate analysis, obesity (BMI >/= 25 kg/m(2)) was a significant predictor of better OS [hazard ratio (HR) 0.63; 95 % confidence interval (CI) 0.43-0.92, p = 0.017] and CSS (HR 0.53; 95 % CI 0.33-0.84, p = 0.007) than normal weight. However, these associations could not be confirmed in the multivariable analysis after adjusting for other clinicopathological factors, such as tumor stage, tumor grade, lymphovascular invasion, and surgical margin. CONCLUSIONS: Our study results are inconclusive, in that, the multivariate analysis did not identify the influence of BMI on survival, although higher BMI appears clinically associated with favorable survival outcomes in Korean patients with UTUC. FAU - Kim, Hyung Suk AU - Kim HS AD - Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. FAU - Jeong, Chang Wook AU - Jeong CW FAU - Kwak, Cheol AU - Kwak C FAU - Kim, Hyeon Hoe AU - Kim HH FAU - Ku, Ja Hyeon AU - Ku JH LA - eng PT - Journal Article DEP - 20150703 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - *Body Mass Index MH - Carcinoma, Transitional Cell/mortality/*surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - Nephrectomy/*methods MH - Prognosis MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Risk Factors MH - Survival Rate/trends MH - Ureter/*surgery MH - Ureteral Neoplasms/mortality/*surgery EDAT- 2015/07/04 06:00 MHDA- 2016/05/18 06:00 CRDT- 2015/07/04 06:00 PHST- 2015/05/29 00:00 [received] PHST- 2015/06/16 00:00 [accepted] PHST- 2015/07/04 06:00 [entrez] PHST- 2015/07/04 06:00 [pubmed] PHST- 2016/05/18 06:00 [medline] AID - 10.1007/s11255-015-1039-4 [doi] PST - ppublish SO - Int Urol Nephrol. 2015 Aug;47(8):1311-20. doi: 10.1007/s11255-015-1039-4. Epub 2015 Jul 3. PMID- 26126604 OWN - NLM STAT- MEDLINE DCOM- 20160302 LR - 20240323 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 15 DP - 2015 Jul 1 TI - An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. PG - 59 LID - 10.1186/s12894-015-0056-z [doi] LID - 59 AB - BACKGROUND: In the past ~15 years, the identification of diagnostic and prognostic biomarkers from gene expression data has increased our understanding of cancer biology and has led to advances in the personalized treatment of many cancers. A diagnostic biomarker is indicative of tumor status such as tumor stage, while a prognostic biomarker is indicative of disease outcome. Despite these advances, however, there are no clinically approved biomarkers for the treatment of bladder cancer, which is the fourth most common cancer in males in the United States and one of the most expensive cancers to treat. Although gene expression profiles of bladder cancer patients are publicly available, biomarker identification requires bioinformatics expertise that is not available to many research laboratories. DESCRIPTION: We collected gene expression data from 13 publicly available patient cohorts (N = 1454) and developed BC-BET, an online Bladder Cancer Biomarker Evaluation Tool for evaluating candidate diagnostic and prognostic gene expression biomarkers in bladder cancer. A user simply selects a gene, and BC-BET evaluates the utility of that gene's expression as a diagnostic and prognostic biomarker. Specifically, BC-BET calculates how strongly a gene's expression is associated with tumor presence (distinguishing tumor from normal samples), tumor grade (distinguishing low- from high-grade tumors), tumor stage (distinguishing non-muscle invasive from muscle invasive samples), and patient outcome (e.g., disease-specific survival) across all patients in each cohort. Patients with low-grade, non-muscle invasive tumors and patients with high-grade, muscle invasive tumors are also analyzed separately in order to evaluate whether the biomarker of interest has prognostic value independent of grade and stage. CONCLUSION: Although bladder cancer gene expression datasets are publicly available, their analysis is computationally intensive and requires bioinformatics expertise. BC-BET is an easy-to-use tool for rapidly evaluating bladder cancer gene expression biomarkers across multiple patient cohorts. FAU - Dancik, Garrett M AU - Dancik GM AD - Mathematics and Computer Science Department, Eastern Connecticut State University, Science Building, Rm. 257, Willimantic, CT, 06226, USA. dancikg@easternct.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150701 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers, Tumor) SB - IM MH - Algorithms MH - Biomarkers, Tumor/*metabolism MH - Databases, Genetic MH - Diagnosis, Computer-Assisted/*methods MH - Gene Expression Profiling/*methods MH - Humans MH - Online Systems MH - Prognosis MH - Reproducibility of Results MH - Sensitivity and Specificity MH - *Software MH - Urinary Bladder Neoplasms/*diagnosis/*metabolism MH - User-Computer Interface PMC - PMC4487975 EDAT- 2015/07/02 06:00 MHDA- 2016/03/05 06:00 PMCR- 2015/07/01 CRDT- 2015/07/02 06:00 PHST- 2015/01/28 00:00 [received] PHST- 2015/06/15 00:00 [accepted] PHST- 2015/07/02 06:00 [entrez] PHST- 2015/07/02 06:00 [pubmed] PHST- 2016/03/05 06:00 [medline] PHST- 2015/07/01 00:00 [pmc-release] AID - 10.1186/s12894-015-0056-z [pii] AID - 56 [pii] AID - 10.1186/s12894-015-0056-z [doi] PST - epublish SO - BMC Urol. 2015 Jul 1;15:59. doi: 10.1186/s12894-015-0056-z. PMID- 26125511 OWN - NLM STAT- MEDLINE DCOM- 20160426 LR - 20150729 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 25 IP - 5 DP - 2015 Sep TI - Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. PG - 427-35 LID - 10.1097/MOU.0000000000000202 [doi] AB - PURPOSE OF REVIEW: Treatment of T1 urothelial bladder cancer (T1-BC) is challenging as risk assessment criteria for progression are lacking. Histological grade and T1 substage have been identified as important prognostic factors. Currently, no consensus exists regarding the optimal sub-staging and grading systems for T1-BC. We reviewed recent advances in the various grading and sub-staging systems and their clinical applicability. RECENT FINDINGS: Stratification by muscularis mucosae invasion is the most explored sub-staging system. Its prognostic value was established by 12/23 (52%) available studies. Importantly, muscularis mucosae identification varied substantially among pathologists. Sub-staging based on diameter of invasive carcinoma [T1 microinvasive and T1 extensive-invasive (T1m/e)] proved a more reproducible system with at least equal prognostic value. However, more study is needed to investigate interobserver variation. For nonmuscle-invasive bladder cancer grading, the 1973 and 2004 WHO classifications both provide independent prognostic information. However, remarkably few studies have investigated their applicability in T1-BC only. The available reports suggest that the 1973 WHO classification is superior to WHO 2004. SUMMARY: If multicenter studies confirm the promising results of T1m/e sub-staging, it may be incorporated in the Internation Union Against Cancer TNM classification system for urinary bladder cancer. More studies are warranted to define the optimal classification system for grade in T1-BC. FAU - Fransen van de Putte, Elisabeth E AU - Fransen van de Putte EE AD - aDepartment of Surgical Oncology, Division of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands bDivision of Urology, Department of Surgery, University Hospital of Basel, Basel, Switzerland cDepartment of Urology, VU University Medical Center, Amsterdam, The Netherlands dDepartment of Pathology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada. FAU - Behrendt, Mark A AU - Behrendt MA FAU - Pigot, Garry L S AU - Pigot GL FAU - van der Kwast, Theo H AU - van der Kwast TH FAU - van Rhijn, Bas W G AU - van Rhijn BW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 SB - IM MH - Carcinoma/classification/mortality/*pathology/therapy MH - Disease Progression MH - Disease-Free Survival MH - Humans MH - Neoplasm Invasiveness MH - Neoplasm Staging/*methods MH - Predictive Value of Tests MH - Reproducibility of Results MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/classification/mortality/*pathology/therapy MH - Urothelium/*pathology EDAT- 2015/07/01 06:00 MHDA- 2016/04/27 06:00 CRDT- 2015/07/01 06:00 PHST- 2015/07/01 06:00 [entrez] PHST- 2015/07/01 06:00 [pubmed] PHST- 2016/04/27 06:00 [medline] AID - 10.1097/MOU.0000000000000202 [doi] PST - ppublish SO - Curr Opin Urol. 2015 Sep;25(5):427-35. doi: 10.1097/MOU.0000000000000202. PMID- 26125507 OWN - NLM STAT- MEDLINE DCOM- 20160426 LR - 20150729 IS - 1473-6586 (Electronic) IS - 0963-0643 (Linking) VI - 25 IP - 5 DP - 2015 Sep TI - Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. PG - 468-75 LID - 10.1097/MOU.0000000000000201 [doi] AB - PURPOSE OF REVIEW: Approximately 50% of patients with muscle invasive urothelial carcinoma will relapse with distant recurrence. Though rates of local recurrence after definitive therapy have improved, management remains a challenge. In this review, treatment strategies for this cohort are re-examined in an effort to enhance patient outcomes. RECENT FINDINGS: Urothelial carcinoma continues to demonstrate high rates of recurrence and low rates of survival. Similarly to the treatment of primary urothelial cancer, treatment of recurrence focuses on cytology, stage, and clinical characteristics. Current areas of interest have focused on identification and causes/predictors of recurrence. SUMMARY: Limited progress has been achieved in differentiating management of recurrent urothelial carcinoma from the treatment of primary urothelial carcinoma. However, there may be an increasing role for endoscopic and organ conserving therapies for carefully selected patients with recurrent noninvasive urothelial carcinoma. Identifying those at risk for early recurrence and early diagnosis of recurrence may be the most beneficial future strategies. The treatment regimen for noninvasive bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma should include intravesical chemotherapy or Bacillus Calmette-Guerin to prevent further bladder recurrence or tumor progression. We do not advocate diversion sparing techniques for local recurrence after radical cystectomy. Metastasectomy for distant/metastatic urothelial carcinoma recurrence represents a promising area of future study. FAU - DiBianco, John Michael AU - DiBianco JM AD - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Hatfield Clinical Research Center, Bethesda, Maryland, USA. FAU - George, Arvin K AU - George AK FAU - Su, Daniel AU - Su D FAU - Agarwal, Piyush K AU - Agarwal PK LA - eng GR - Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Review PL - United States TA - Curr Opin Urol JT - Current opinion in urology JID - 9200621 RN - 0 (Antineoplastic Agents) RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - BCG Vaccine/*administration & dosage/adverse effects MH - Carcinoma/secondary/*therapy MH - Disease Progression MH - Humans MH - *Metastasectomy/adverse effects/mortality MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/mortality/pathology/*therapy MH - Neoplasm Staging MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy MH - *Urothelium/pathology EDAT- 2015/07/01 06:00 MHDA- 2016/04/27 06:00 CRDT- 2015/07/01 06:00 PHST- 2015/07/01 06:00 [entrez] PHST- 2015/07/01 06:00 [pubmed] PHST- 2016/04/27 06:00 [medline] AID - 10.1097/MOU.0000000000000201 [doi] PST - ppublish SO - Curr Opin Urol. 2015 Sep;25(5):468-75. doi: 10.1097/MOU.0000000000000201. PMID- 26119672 OWN - NLM STAT- MEDLINE DCOM- 20160229 LR - 20191210 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 194 IP - 6 DP - 2015 Dec TI - Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study. PG - 1575-81 LID - S0022-5347(15)04296-2 [pii] LID - 10.1016/j.juro.2015.06.085 [doi] AB - PURPOSE: Neoadjuvant chemotherapy before cystectomy is recommended. To our knowledge the subset of patients likely to benefit has not been identified. We validate emmprin and survivin as markers of chemotherapy response. MATERIALS AND METHODS: Tumor specimens were obtained before therapy from a total of 250 patients with T1-T4 bladder cancer enrolled in 2 randomized trials comparing neoadjuvant chemotherapy before cystectomy with a surgery only arm. Protein expression was determined by immunohistochemistry. RESULTS: Expression was categorized according to predefined cutoffs reported in the literature. Data were analyzed with the Kaplan-Meier method and Cox models. Patients in the chemotherapy cohort with negative emmprin expression had significantly higher down staging overall survival than those with positive expression (71% vs 38%, p<0.001). The values for cancer specific survival were 76% and 56%, respectively (p<0.027). In the cystectomy only cohort emmprin expression was not associated with overall survival (46% vs 35%, p=0.23) or cancer specific survival (55% vs 51%, p=0.64). Emmprin negative patients had an absolute risk reduction of 25% in overall survival (95% CI 11-40) and a number needed to treat of 4 (95% CI 2.5-9.3). Survivin expression was not useful as a biomarker in this study. Limitations were the retrospective design and heterogeneity coupled with the time difference between the trials. CONCLUSIONS: Patients with emmprin negative tumors have a better response to neoadjuvant chemotherapy before cystectomy than those with positive expression. CI - Copyright (c) 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Hemdan, Tammer AU - Hemdan T AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Urology, Faculty of Medical and Health Sciences, Linkoping University (SJ), Linkoping, Sweden. Electronic address: tammer.hemdan@surgsci.uu.se. FAU - Malmstrom, Per-Uno AU - Malmstrom PU AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Urology, Faculty of Medical and Health Sciences, Linkoping University (SJ), Linkoping, Sweden. FAU - Jahnson, Staffan AU - Jahnson S AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Urology, Faculty of Medical and Health Sciences, Linkoping University (SJ), Linkoping, Sweden. FAU - Segersten, Ulrika AU - Segersten U AD - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Urology, Faculty of Medical and Health Sciences, Linkoping University (SJ), Linkoping, Sweden. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20150626 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (BIRC5 protein, human) RN - 0 (Biomarkers, Tumor) RN - 0 (Inhibitor of Apoptosis Proteins) RN - 0 (Survivin) RN - 136894-56-9 (Basigin) RN - Q20Q21Q62J (Cisplatin) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Basigin/*analysis MH - Biomarkers, Tumor/*analysis MH - Cisplatin/*administration & dosage MH - Cohort Studies MH - Combined Modality Therapy MH - Cystectomy MH - Female MH - Humans MH - Inhibitor of Apoptosis Proteins/*analysis MH - Kaplan-Meier Estimate MH - Lymph Node Excision MH - Male MH - Methotrexate/administration & dosage/adverse effects MH - Middle Aged MH - *Neoadjuvant Therapy MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Survivin MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*mortality/pathology/*therapy OTO - NOTNLM OT - CD147 OT - antigens OT - biological markers OT - cystectomy OT - drug therapy OT - urinary bladder neoplasms EDAT- 2015/06/30 06:00 MHDA- 2016/03/02 06:00 CRDT- 2015/06/30 06:00 PHST- 2015/06/21 00:00 [accepted] PHST- 2015/06/30 06:00 [entrez] PHST- 2015/06/30 06:00 [pubmed] PHST- 2016/03/02 06:00 [medline] AID - S0022-5347(15)04296-2 [pii] AID - 10.1016/j.juro.2015.06.085 [doi] PST - ppublish SO - J Urol. 2015 Dec;194(6):1575-81. doi: 10.1016/j.juro.2015.06.085. Epub 2015 Jun 26. PMID- 26119560 OWN - NLM STAT- MEDLINE DCOM- 20161005 LR - 20210105 IS - 1873-7560 (Electronic) IS - 0302-2838 (Print) IS - 0302-2838 (Linking) VI - 69 IP - 2 DP - 2016 Feb TI - Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin. PG - 197-200 LID - S0302-2838(15)00526-6 [pii] LID - 10.1016/j.eururo.2015.06.023 [doi] AB - The response of non-muscle-invasive bladder cancer (NMIBC) to intravesical immunotherapy with bacillus Calmette-Guerin (BCG) depends on adequate stimulation of an immune response. Although BCG has been used for decades, we lack tools to accurately predict response in individual patients. To address this deficiency, we initiated a clinical trial in patients with intermediate- and high-risk NMIBC. BCG was administered according to the Southwest Oncology Group protocol. Urine samples were collected for cytokine assay at baseline, immediately before and after BCG instillation at 6 wk, and immediately before and after the third BCG instillation of the first maintenance course. Levels of 12 cytokines were measured, and changes from baseline were calculated after treatment. A total of 130 patients were enrolled. Increases in single cytokines correlated with recurrence, but the best predictor of recurrence was changes in a combination of cytokines. A nomogram (CyPRIT) constructed using urinary levels of nine inducible cytokines (IL-2, IL-6, IL-8, IL-18, IL-1ra, TRAIL, IFN-gamma, IL-12[p70], and TNF-alpha) predicted the likelihood of recurrence with 85.5% accuracy (95% confidence interval 77.9-93.1%)." This cytokine panel and nomogram have potential for identifying patients at risk of tumor recurrence during BCG treatment to guide modification of the dose and duration of BCG immunotherapy. TRIAL REGISTRATION: Clinicaltrials.gov NCT01007058. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. FAU - Briggman, Joseph AU - Briggman J AD - Alere Inc., San Diego, CA, USA. FAU - Urbauer, Diana L AU - Urbauer DL AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Svatek, Robert AU - Svatek R AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras Gonzalez, Graciela M AU - Nogueras Gonzalez GM AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Anderson, Roosevelt AU - Anderson R AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Grossman, H Barton AU - Grossman HB AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Prat, Ferran AU - Prat F AD - Department of Strategic Industry Ventures, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng SI - ClinicalTrials.gov/NCT01007058 GR - P30 CA016672/CA/NCI NIH HHS/United States GR - CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States PT - Clinical Trial PT - Journal Article DEP - 20150625 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - 0 (Biomarkers, Tumor) RN - 0 (Cytokines) RN - 0 (Interleukins) RN - 0 (TNF-Related Apoptosis-Inducing Ligand) RN - 0 (TNFSF10 protein, human) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM CIN - Eur Urol. 2016 Feb;69(2):201-2. doi: 10.1016/j.eururo.2015.07.010. PMID: 26209036 CIN - Eur Urol. 2016 Feb;69(2):203. doi: 10.1016/j.eururo.2015.07.031. PMID: 26260001 EIN - Eur Urol. 2016 Jul;70(1):e26. doi: 10.1016/j.eururo.2016.02.059. PMID: 27302298 CIN - J Urol. 2017 Jun;197(6):1439-1440. doi: 10.1016/j.juro.2017.03.017. PMID: 28505895 MH - Adjuvants, Immunologic/administration & dosage/*therapeutic use MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/administration & dosage/*therapeutic use MH - Biomarkers, Tumor/urine MH - Cytokines/*urine MH - Female MH - Humans MH - Interleukins/urine MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*urine MH - *Nomograms MH - Predictive Value of Tests MH - Prospective Studies MH - TNF-Related Apoptosis-Inducing Ligand/urine MH - Tumor Necrosis Factor-alpha/urine MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery/*urine PMC - PMC4691211 MID - NIHMS737635 OTO - NOTNLM OT - Bacillus Calmette-Guerin response OT - Bladder cancer OT - Nomogram OT - Prediction OT - Urinary cytokines EDAT- 2015/06/30 06:00 MHDA- 2016/10/07 06:00 PMCR- 2017/02/01 CRDT- 2015/06/30 06:00 PHST- 2015/04/29 00:00 [received] PHST- 2015/06/16 00:00 [accepted] PHST- 2015/06/30 06:00 [entrez] PHST- 2015/06/30 06:00 [pubmed] PHST- 2016/10/07 06:00 [medline] PHST- 2017/02/01 00:00 [pmc-release] AID - S0302-2838(15)00526-6 [pii] AID - 10.1016/j.eururo.2015.06.023 [doi] PST - ppublish SO - Eur Urol. 2016 Feb;69(2):197-200. doi: 10.1016/j.eururo.2015.06.023. Epub 2015 Jun 25. PMID- 26100813 OWN - NLM STAT- MEDLINE DCOM- 20160513 LR - 20150710 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 211 IP - 8 DP - 2015 Aug TI - Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features. PG - 610-8 LID - S0344-0338(15)00099-0 [pii] LID - 10.1016/j.prp.2015.05.005 [doi] AB - We characterize invasive urothelial carcinoma (UC) exhibiting urothelial basal cell immunohistochemical markers. Consecutive invasive UCs were immunostained with CK20 and urothelial basal cell markers, cytokeratin 5 (CK5)/CD44. Immunostaining for CK5 and CD44 was scored as follows: positive for staining of more than 25% thickness of the epithelial nest or epithelium and low for lesser immunoreactivity. Invasive urothelial carcinoma (UC) exhibiting positive CK5/CD44 staining was designated as basal-like UC (BUC). In this study, of 251 invasive UC (pT1 in 57% and pT2-4 in 43%), BUC accounted for 40% of cases (accounting for most pT2-4 UC) and often presented as non-papillary UC without previous history of UC. In addition, BUC exhibited uniform nuclei with lesser degree of atypia than non BUC and decreased or negative cytokeratin 20 reactivity. Nested and microcystic variants of UC immunohistochemically stained as BUCs. Invasive non-BUCs were often papillary with marked cytologic atypia and pleomorphism, and accounted for most pT1 UC. The rates of perivesical invasion, lymph node and distant metastases were higher for BUC than non-BUC. All nine cases with absent/minimal residual in situ UC in 102 radical cystectomy specimens were from invasive non-BUC. BUC is distinguished from non-BUC due to this aggressive behavior, distinct immunohistochemical profile, and predominant non-papillary architecture. Our findings are consistent with recent studies identifying a subtype of muscle-invasive UC with molecular expression of basal cell and luminal cell molecular profiles. Our study further supports categorizing invasive UCs into these subtypes with different biological behaviors, possibly contributing to better therapeutic strategies. CI - Copyright (c) 2015 Elsevier GmbH. All rights reserved. FAU - Mai, Kien T AU - Mai KT AD - The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada. Electronic address: ktmai@ottawahospital.on.ca. FAU - Truong, Luan D AU - Truong LD AD - Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Weill Cornell Medical College of Cornell University, United States. FAU - Ball, Christopher G AU - Ball CG AD - The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada. FAU - Williams, Phillip AU - Williams P AD - The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada. FAU - Flood, Trevor A AU - Flood TA AD - The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada. FAU - Belanger, Eric C AU - Belanger EC AD - The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada. LA - eng PT - Journal Article DEP - 20150527 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Biomarkers, Tumor) SB - IM MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Papillary/metabolism MH - Carcinoma, Transitional Cell/metabolism/*pathology MH - Epithelial Cells/metabolism/*pathology MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Urologic Neoplasms/*pathology MH - Urothelium/metabolism/pathology OTO - NOTNLM OT - Basal OT - Carcinoma OT - Urothelial EDAT- 2015/06/24 06:00 MHDA- 2016/05/14 06:00 CRDT- 2015/06/24 06:00 PHST- 2014/10/03 00:00 [received] PHST- 2015/04/14 00:00 [revised] PHST- 2015/05/22 00:00 [accepted] PHST- 2015/06/24 06:00 [entrez] PHST- 2015/06/24 06:00 [pubmed] PHST- 2016/05/14 06:00 [medline] AID - S0344-0338(15)00099-0 [pii] AID - 10.1016/j.prp.2015.05.005 [doi] PST - ppublish SO - Pathol Res Pract. 2015 Aug;211(8):610-8. doi: 10.1016/j.prp.2015.05.005. Epub 2015 May 27. PMID- 26091833 OWN - NLM STAT- MEDLINE DCOM- 20161005 LR - 20250626 IS - 1873-7560 (Electronic) IS - 0302-2838 (Linking) VI - 69 IP - 2 DP - 2016 Feb TI - Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? PG - 231-44 LID - S0302-2838(15)00456-X [pii] LID - 10.1016/j.eururo.2015.05.050 [doi] AB - CONTEXT: The European Association of Urology non-muscle-invasive bladder cancer (NMIBC) guidelines recommend that all low- and intermediate-risk patients receive a single immediate instillation of chemotherapy after transurethral resection of the bladder (TURB), but its use remains controversial. OBJECTIVE: To identify which NMIBC patients benefit from a single immediate instillation. EVIDENCE ACQUISITION: A systematic review and individual patient data (IPD) meta-analysis of randomized trials comparing the efficacy of a single instillation after TURB with TURB alone in NMIBC patients was carried out. EVIDENCE SYNTHESIS: A total of 13 eligible studies were identified. IPD were obtained for 11 studies randomizing 2278 eligible patients, 1161 to TURB and 1117 to a single instillation of epirubicin, mitomycin C, pirarubicin, or thiotepa. A total of 1128 recurrences, 108 progressions, and 460 deaths (59 due to bladder cancer [BCa]) occurred. A single instillation reduced the risk of recurrence by 35% (hazard ratio [HR]: 0.65; 95% confidence interval [CI], 0.58-0.74; p<0.001) and the 5-yr recurrence rate from 58.8% to 44.8%. The instillation did not reduce recurrences in patients with a prior recurrence rate of more than one recurrence per year or in patients with an European Organization for Research and Treatment of Cancer (EORTC) recurrence score >/=5. The instillation did not prolong either the time to progression or death from BCa, but it resulted in an increase in the overall risk of death (HR: 1.26; 95% CI, 1.05-1.51; p=0.015; 5-yr death rates 12.0% vs 11.2%), with the difference appearing in patients with an EORTC recurrence score >/=5. CONCLUSIONS: A single immediate instillation reduced the risk of recurrence, except in patients with a prior recurrence rate of more than one recurrence per year or an EORTC recurrence score >/=5. It does not prolong either time to progression or death from BCa. The instillation may be associated with an increase in the risk of death in patients at high risk of recurrence in whom the instillation is not effective or recommended. PATIENT SUMMARY: A single instillation of chemotherapy immediately after resection reduces the risk of recurrence in non-muscle-invasive bladder cancer; however, it should not be given to patients at high risk of recurrence due to its lack of efficacy in this subgroup. CI - Copyright (c) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. FAU - Sylvester, Richard J AU - Sylvester RJ AD - EORTC Headquarters, Department of Biostatistics, Brussels, Belgium. Electronic address: richard.sylvester@skynet.be. FAU - Oosterlinck, Willem AU - Oosterlinck W AD - Ghent University Hospital, Department of Urology, Ghent, Belgium. FAU - Holmang, Sten AU - Holmang S AD - University of Gothenburg, Department of Urology, Gothenburg, Sweden. FAU - Sydes, Matthew R AU - Sydes MR AD - Medical Research Council Clinical Trials Unit at University College London, Department of Cancer and Other Non-Infectious Diseases, London, UK. FAU - Birtle, Alison AU - Birtle A AD - Royal Preston Hospital, Rosemere Cancer Centre, Preston, UK. FAU - Gudjonsson, Sigurdur AU - Gudjonsson S AD - Skane University Hospital, Department of Urology, Malmo, Sweden. FAU - De Nunzio, Cosimo AU - De Nunzio C AD - Ospedale Sant'Andrea, University "La Sapienza," Department of Urology, Rome, Italy. FAU - Okamura, Kikuo AU - Okamura K AD - Higashi Nagoya Hospital, Department of Urology, Nagoya, Japan. FAU - Kaasinen, Eero AU - Kaasinen E AD - Hyvinkaa Hospital, Department of Urology, Hyvinkaa, Finland. FAU - Solsona, Eduardo AU - Solsona E AD - Valencia Oncology Institute, Department of Urology, Valencia, Spain. FAU - Ali-El-Dein, Bedeir AU - Ali-El-Dein B AD - Urology and Nephrology Center, Mansoura University, Department of Urology, Mansoura, Egypt. FAU - Tatar, Can Ali AU - Tatar CA AD - Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Urology, Ankara, Turkey. FAU - Inman, Brant A AU - Inman BA AD - Duke University Medical Center, Division of Urology, Durham, NC, USA. FAU - N'Dow, James AU - N'Dow J AD - University of Aberdeen, Academic Urology Unit, Aberdeen, UK. FAU - Oddens, Jorg R AU - Oddens JR AD - Jeroen Bosch Hospital, Department of Urology, 's-Hertogenbosch, The Netherlands. FAU - Babjuk, Marek AU - Babjuk M AD - Hospital Motol and Second Faculty of Medicine, Charles University, Department of Urology, Prague, Czech Republic. LA - eng GR - MC_U122861330/MRC_/Medical Research Council/United Kingdom GR - MC_UU_12023/20/MRC_/Medical Research Council/United Kingdom GR - MC_UU_12023/25/MRC_/Medical Research Council/United Kingdom GR - MC_UU_12023/28/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20150616 PL - Switzerland TA - Eur Urol JT - European urology JID - 7512719 RN - 3Z8479ZZ5X (Epirubicin) RN - 50SG953SK6 (Mitomycin) RN - 80168379AG (Doxorubicin) RN - 905Z5W3GKH (Thiotepa) RN - D58G680W0G (pirarubicin) SB - IM CIN - Eur Urol. 2016 Jan;69(1):e12-3. doi: 10.1016/j.eururo.2015.07.018. PMID: 26215601 CIN - Eur Urol. 2016 Jan;69(1):e10-1. doi: 10.1016/j.eururo.2015.07.017. PMID: 26215603 CIN - Eur Urol. 2016 Feb;69(2):245-6. doi: 10.1016/j.eururo.2015.07.035. PMID: 26251301 CIN - Eur Urol. 2015 Dec;68(6):e127. doi: 10.1016/j.eururo.2015.08.019. PMID: 26318707 CIN - Eur Urol. 2015 Dec;68(6):e128. doi: 10.1016/j.eururo.2015.08.020. PMID: 26320375 CIN - J Urol. 2017 May;197(5):1219. doi: 10.1016/j.juro.2017.02.017. PMID: 29539892 MH - Administration, Intravesical MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage MH - Carcinoma, Transitional Cell/mortality/*pathology/*therapy MH - Disease Progression MH - Doxorubicin/administration & dosage/analogs & derivatives MH - Epirubicin/administration & dosage MH - Humans MH - Mitomycin/administration & dosage MH - Neoplasm Recurrence, Local/*prevention & control MH - Neoplasm Staging MH - Randomized Controlled Trials as Topic MH - Risk Factors MH - Survival Rate MH - Thiotepa/administration & dosage MH - Time Factors MH - Urinary Bladder Neoplasms/mortality/*pathology/*therapy OTO - NOTNLM OT - Chemotherapy OT - Meta-analysis OT - Non-muscle-invasive bladder cancer OT - Single instillation OT - Systematic review EDAT- 2015/06/21 06:00 MHDA- 2016/10/07 06:00 CRDT- 2015/06/21 06:00 PHST- 2015/05/22 00:00 [received] PHST- 2015/05/28 00:00 [accepted] PHST- 2015/06/21 06:00 [entrez] PHST- 2015/06/21 06:00 [pubmed] PHST- 2016/10/07 06:00 [medline] AID - S0302-2838(15)00456-X [pii] AID - 10.1016/j.eururo.2015.05.050 [doi] PST - ppublish SO - Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16. PMID- 26087959 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20260128 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 15 DP - 2015 Jun 19 TI - Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy. PG - 53 LID - 10.1186/s12894-015-0040-7 [doi] LID - 53 AB - BACKGROUND: To investigate associations between dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) expression and survival in T1 high-grade or T2 bladder cancer patients treated with neoadjuvant chemotherapy. METHODS: The cohort under investigation comprised 44 patients who underwent neoadjuvant chemotherapy for pT1 high-grade or pT2N0M0 bladder cancer at our institution between 2002 and 2011. Immunohistochemical analysis was used to determine expression of DYRK2 in bladder cancer specimens obtained by transurethral resection before chemotherapy. Relationships between DYRK2 expression and both response to chemotherapy and survival in these patients were analyzed. RESULTS: DYRK2 expression was positive in 21 of 44 patients (47.7 %) and negative in 23 patients (52.3 %). In total, 20 of 21 DYRK2-positive cases showed complete response to neoadjuvant chemotherapy, whereas 11 of 23 DYRK2-negative cases did not show complete response. Sensitivity and specificity were 62.5 % and 91.7 %, respectively (P = 0.0018). In addition, disease-specific survival rate was significantly higher for DYRK2-positive patients than for DYRK2-negative patients (P = 0.017). In multivariate analysis, DYRK2 expression level was identified as an independent prognostic factor for disease-specific survival (P = 0.029). We also showed that DYRK2 mRNA expression was significantly higher in DYRK2-positive samples by immunohistochemistry than DYRK2-negative samples (P = 0.040). CONCLUSIONS: DYRK2 expression level may predict the efficacy of neoadjuvant chemotherapy for T1 high-grade and T2 bladder cancer. FAU - Nomura, Shunichiro AU - Nomura S AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. shun1982@nms.ac.jp. FAU - Suzuki, Yasutomo AU - Suzuki Y AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. yasu17@nms.ac.jp. FAU - Takahashi, Ryo AU - Takahashi R AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. s7053@nms.ac.jp. FAU - Terasaki, Mika AU - Terasaki M AD - Analytic Human Pathology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. mterasaki@nms.ac.jp. FAU - Kimata, Ryoji AU - Kimata R AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. s2027@nms.ac.jp. FAU - Terasaki, Yasuhiro AU - Terasaki Y AD - Analytic Human Pathology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. terasaki@nms.ac.jp. FAU - Hamasaki, Tsutomu AU - Hamasaki T AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. hamasaki@nms.ac.jp. FAU - Kimura, Go AU - Kimura G AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. gokimura@nms.ac.jp. FAU - Shimizu, Akira AU - Shimizu A AD - Analytic Human Pathology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. ashimizu@nms.ac.jp. FAU - Kondo, Yukihiro AU - Kondo Y AD - Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. kondoy@nms.ac.jp. LA - eng PT - Journal Article DEP - 20150619 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - EC 2.7.1.- (Dyrk Kinases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Biopsy, Needle MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Predictive Value of Tests MH - Protein Serine-Threonine Kinases/*metabolism MH - Protein-Tyrosine Kinases/*metabolism MH - Real-Time Polymerase Chain Reaction/methods MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*drug therapy/enzymology/*mortality/pathology/surgery MH - Dyrk Kinases PMC - PMC4472248 EDAT- 2015/06/20 06:00 MHDA- 2016/04/19 06:00 PMCR- 2015/06/19 CRDT- 2015/06/20 06:00 PHST- 2014/12/13 00:00 [received] PHST- 2015/05/19 00:00 [accepted] PHST- 2015/06/20 06:00 [entrez] PHST- 2015/06/20 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] PHST- 2015/06/19 00:00 [pmc-release] AID - 10.1186/s12894-015-0040-7 [pii] AID - 40 [pii] AID - 10.1186/s12894-015-0040-7 [doi] PST - epublish SO - BMC Urol. 2015 Jun 19;15:53. doi: 10.1186/s12894-015-0040-7. PMID- 26078839 OWN - NLM STAT- MEDLINE DCOM- 20160307 LR - 20220321 IS - 2005-6745 (Electronic) IS - 2005-6737 (Print) IS - 2005-6737 (Linking) VI - 56 IP - 6 DP - 2015 Jun TI - The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study. PG - 429-34 LID - 10.4111/kju.2015.56.6.429 [doi] AB - PURPOSE: This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer. MATERIALS AND METHODS: Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method. RESULTS: Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and >/=T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant. CONCLUSIONS: Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy. FAU - Shim, Ji Sung AU - Shim JS AD - Department of Urology, Korea University Ansan Hospital, Ansan, Korea. FAU - Choi, Hoon AU - Choi H AD - Department of Urology, Korea University Ansan Hospital, Ansan, Korea. FAU - Noh, Tae Il AU - Noh TI AD - Department of Urology, Korea University Ansan Hospital, Ansan, Korea. FAU - Tae, Jong Hyun AU - Tae JH AD - Department of Urology, Korea University Anam Hospital, Seoul, Korea. FAU - Yoon, Sung Goo AU - Yoon SG AD - Department of Urology, Korea University Anam Hospital, Seoul, Korea. FAU - Kang, Seok Ho AU - Kang SH AD - Department of Urology, Korea University Anam Hospital, Seoul, Korea. ; Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Bae, Jae Hyun AU - Bae JH AD - Department of Urology, Korea University Ansan Hospital, Ansan, Korea. ; Department of Urology, Korea University College of Medicine, Seoul, Korea. FAU - Park, Hong Seok AU - Park HS AD - Department of Urology, Korea University College of Medicine, Seoul, Korea. ; Department of Urology, Korea University Guro Hospital, Seoul, Korea. FAU - Park, Jae Young AU - Park JY AD - Department of Urology, Korea University Ansan Hospital, Ansan, Korea. ; Department of Urology, Korea University College of Medicine, Seoul, Korea. LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150528 PL - Korea (South) TA - Korean J Urol JT - Korean journal of urology JID - 101499376 SB - IM MH - Aged MH - Aged, 80 and over MH - Cystectomy/methods MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Neoplasm, Residual MH - Prognosis MH - Prospective Studies MH - Reoperation/methods MH - Treatment Outcome MH - Urinary Bladder Neoplasms/pathology/*surgery PMC - PMC4462632 OTO - NOTNLM OT - Neoplasm invasiveness OT - Recurrence OT - Urinary bladder neoplasms COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose. EDAT- 2015/06/17 06:00 MHDA- 2016/03/08 06:00 PMCR- 2015/06/01 CRDT- 2015/06/17 06:00 PHST- 2015/01/23 00:00 [received] PHST- 2015/04/23 00:00 [accepted] PHST- 2015/06/17 06:00 [entrez] PHST- 2015/06/17 06:00 [pubmed] PHST- 2016/03/08 06:00 [medline] PHST- 2015/06/01 00:00 [pmc-release] AID - 10.4111/kju.2015.56.6.429 [doi] PST - ppublish SO - Korean J Urol. 2015 Jun;56(6):429-34. doi: 10.4111/kju.2015.56.6.429. Epub 2015 May 28. PMID- 26074659 OWN - NLM STAT- MEDLINE DCOM- 20160223 LR - 20210111 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2015 DP - 2015 TI - Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer. PG - 402963 LID - 10.1155/2015/402963 [doi] LID - 402963 AB - DNA methylation is the most common and well-characterized epigenetic change in human cancer. Recently, an association between prostate cancer susceptibility candidate (PRAC) methylation and genitourinary cancer was proposed. The aim of the present study was to evaluate the association between PRAC methylation status and clinicopathological parameters and prognosis in long-term follow-up primary nonmuscle invasive bladder cancer (NMIBC). The clinical relevance of PRAC methylation was determined in 136 human bladder specimens (eight normal controls [NCs] and 128 primary NMIBCs) using quantitative pyrosequencing analysis. PRAC methylation was significantly higher in NMIBC patients than in NCs and was significantly associated with higher grade and more advanced stage of cancer. Kaplan-Meier estimates revealed significant difference in tumor recurrence and progression according to PRAC methylation status (both p < 0.05). Multivariate Cox regression analysis revealed that the PRAC methylation status was a strong predictor of recurrence (hazard ratio [HR], 2.652; p = 0.012) and progression (HR, 9.531; p = 0.035) of NMIBC. Enhanced methylation status of PRAC was positively associated with a high rate of recurrence and progression in NMIBC patients, suggesting that PRAC methylation may be a promising prognostic marker of NMIBC. FAU - Kim, Young-Won AU - Kim YW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Yoon, Hyung-Yoon AU - Yoon HY AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Seo, Sung Pil AU - Seo SP AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Lee, Sang Keun AU - Lee SK AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Kang, Ho Won AU - Kang HW AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Kim, Won Tae AU - Kim WT AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Bang, Heui Je AU - Bang HJ AD - Department of Rehabilitation, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Ryu, Dong Hee AU - Ryu DH AD - Department of Surgery, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Yun, Seok-Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Lee, Sang-Cheol AU - Lee SC AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. FAU - Kim, Yong-June AU - Kim YJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju 362-763, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150513 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (Biomarkers, Tumor) RN - 0 (Nuclear Proteins) RN - 0 (PRAC1 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*genetics MH - Carcinoma/*genetics/pathology MH - Case-Control Studies MH - *DNA Methylation MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/genetics/pathology MH - Nuclear Proteins/*genetics MH - Urinary Bladder Neoplasms/*genetics/pathology PMC - PMC4444592 EDAT- 2015/06/16 06:00 MHDA- 2016/02/26 06:00 PMCR- 2015/05/13 CRDT- 2015/06/16 06:00 PHST- 2014/12/30 00:00 [received] PHST- 2015/03/30 00:00 [accepted] PHST- 2015/06/16 06:00 [entrez] PHST- 2015/06/16 06:00 [pubmed] PHST- 2016/02/26 06:00 [medline] PHST- 2015/05/13 00:00 [pmc-release] AID - 10.1155/2015/402963 [doi] PST - ppublish SO - Dis Markers. 2015;2015:402963. doi: 10.1155/2015/402963. Epub 2015 May 13. PMID- 26074367 OWN - NLM STAT- MEDLINE DCOM- 20170104 LR - 20190117 IS - 1728-7731 (Electronic) IS - 1726-4901 (Linking) VI - 78 IP - 8 DP - 2015 Aug TI - Does radical cystectomy outperform other bladder preservative treatments in elderly patients with advanced bladder cancer? PG - 469-74 LID - S1726-4901(15)00119-7 [pii] LID - 10.1016/j.jcma.2015.05.003 [doi] AB - BACKGROUND: To assess the impacts of age, performance status, and clinical stage on advanced urothelial carcinoma of the bladder (UCB) in patients treated with different treatment modalities. METHODS: This retrospective study included 160 patients who underwent radical cystectomy (RC) with/without neoadjuvant or adjuvant chemoradiotherapy, palliative chemotherapy/radiotherapy/chemoradiotherapy (CRT), and transurethral resection of bladder tumor (TURBT) monotherapy for advanced UCB in one institution from 2000 to 2010. Kaplan-Meier analysis was used to calculate the survival distributions of overall survival (OS). The quality of life of the patients was also analyzed. RESULTS: The median age of the patients was 74.0 years, and the mean survival interval was 31.5 months. The 2-year OS was significantly different among the three modalities [RC > TURBT monotherapy, odds ratio (OR): 1.86, 95% CI: 1.17-2.96, p = 0.009; CRT > TURBT monotherapy, OR: 1.65, 95% CI: 1.06-2.57, p = 0.026]. There were no significant differences in the 5- and 10-year OS rates between the three treatment modalities. Those younger than 76 years receiving RC had a significantly better 2-year OS than those undergoing CRT and TURBT monotherapy (RC > TURBT monotherapy, OR: 2.38; 95% CI: 1.30-4.33, p = 0.005). The number and duration of re-hospitalizations were highest in the CRT group and lowest in the TURBT group. CONCLUSION: The short- and long-term OS rates of the three modalities were similar in those older than 76 years. Therefore, patients younger than age 76 years are likely to have a better outcome undergoing radical cystectomy for advanced UCB. CI - Copyright (c) 2015. Published by Elsevier Taiwan. FAU - Chen, Chin-Li AU - Chen CL AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Liu, Chin-Yu AU - Liu CY AD - Department of Nutritional Science, Fu Jen Catholic University, New Taipei City, Taiwan, ROC. FAU - Cha, Tai-Lung AU - Cha TL AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Hsu, Chien-Yeh AU - Hsu CY AD - Department of Information Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, ROC. FAU - Chou, Yu-Ching AU - Chou YC AD - School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Wu, Sheng-Tang AU - Wu ST AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Meng, En AU - Meng E AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Sun, Guang-Huan AU - Sun GH AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Yu, Dah-Shyong AU - Yu DS AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. FAU - Tsao, Chih-Wei AU - Tsao CW AD - Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. Electronic address: weisurger@gmail.com. LA - eng PT - Journal Article PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 SB - IM CIN - J Urol. 2016 Apr;195(4 Pt 1):904-6. doi: 10.1016/j.juro.2016.01.072. PMID: 27302778 MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Cystectomy/*methods MH - Female MH - Humans MH - Male MH - Neoplasm Staging MH - Retrospective Studies MH - Urinary Bladder/*surgery MH - Urinary Bladder Neoplasms/mortality/*surgery OTO - NOTNLM OT - advanced bladder tumor OT - chemoradiotherapy OT - old age OT - radical cystectomy OT - transurethral resection of bladder tumor EDAT- 2015/06/16 06:00 MHDA- 2017/01/05 06:00 CRDT- 2015/06/16 06:00 PHST- 2014/10/22 00:00 [received] PHST- 2015/02/06 00:00 [accepted] PHST- 2015/06/16 06:00 [entrez] PHST- 2015/06/16 06:00 [pubmed] PHST- 2017/01/05 06:00 [medline] AID - S1726-4901(15)00119-7 [pii] AID - 10.1016/j.jcma.2015.05.003 [doi] PST - ppublish SO - J Chin Med Assoc. 2015 Aug;78(8):469-74. doi: 10.1016/j.jcma.2015.05.003. PMID- 26072632 OWN - NLM STAT- MEDLINE DCOM- 20150818 LR - 20151119 IS - 2578-742X (Print) IS - 2578-742X (Linking) VI - 37 IP - 1 DP - 2015 Feb TI - Dysplasia and carcinoma in situ of the urinary bladder. PG - 29-38 AB - Urothelial dysplasia (low-grade intraurothelial neoplasia) is recognized as a premalignant urothelial lesion in the 2004 World Health Organization (WHO) classification system. Although clarification of the diagnostic criteria of urothelial dysplasia has improved in recent years, there is still a lack of interobserver reproducibility. Active clinical follow-up is mandatory in patients with a diagnosis of urothelial dysplasia since it constitutes a marker of urothelial instability, and disease progression, in up to 19% of cases. The differential diagnosis of urothelial dysplasia is with other flat urothelial lesions with atypia, including flat urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (high-grade intraurothelial neoplasia). In most cases, especially when small amounts of tissue are available, morphologic features alone may not be sufficient for diagnosis. Immunohistochemistry can be of help in selected cases, and a panel of cytokeratin 20, p53, and CD44 may help in the diagnosis. The use of HER2, p16, and Racemase remains as an option pending validation. Herein, we present the pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ with emphasis on differential diagnosis from common flat lesions with atypia. FAU - Lopez-Beltran, Antonio AU - Lopez-Beltran A FAU - Marques, Rita C AU - Marques RC FAU - Montironi, Rodolfo AU - Montironi R FAU - Reymundo, Carlos AU - Reymundo C FAU - Fonseca, Jorge AU - Fonseca J FAU - Cheng, Liang AU - Cheng L LA - eng PT - Journal Article PT - Review PL - United States TA - Anal Quant Cytopathol Histpathol JT - Analytical and quantitative cytopathology and histopathology JID - 101638882 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/analysis MH - Carcinoma in Situ/*diagnosis MH - Carcinoma, Transitional Cell/*diagnosis MH - Diagnosis, Differential MH - Humans MH - Precancerous Conditions/diagnosis MH - Urinary Bladder Neoplasms/*diagnosis EDAT- 2015/06/16 06:00 MHDA- 2015/08/19 06:00 CRDT- 2015/06/16 06:00 PHST- 2015/06/16 06:00 [entrez] PHST- 2015/06/16 06:00 [pubmed] PHST- 2015/08/19 06:00 [medline] PST - ppublish SO - Anal Quant Cytopathol Histpathol. 2015 Feb;37(1):29-38. PMID- 26072111 OWN - NLM STAT- MEDLINE DCOM- 20160414 LR - 20150718 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 33 IP - 8 DP - 2015 Aug TI - The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: An analysis of ACS NSQIP data. PG - 338.e19-24 LID - S1078-1439(15)00234-3 [pii] LID - 10.1016/j.urolonc.2015.05.011 [doi] AB - INTRODUCTION: Transurethral resection of bladder tumor (TURBT) is a common procedure used in the diagnosis and treatment of bladder cancer. Despite how often it is performed, not much is known about the risk factors for complications. Traditional surgery has an increase in morbidity and mortality with increasing operative duration. We assess the effect of operative duration on TURBT complications. METHODS: The years 2006 to 2012 of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) were queried for patients undergoing TURBT. We separated patients into 4 groups based on operative time: 0 to 30 minutes, 30.1 to 60 minutes, 60.1 to 90 minutes, and greater than 90 minutes. Standard statistical analysis including multivariate regression was performed to determine predictors of complications. RESULTS: A total of 10,599 TURBTs were included in our analysis. The overall complication rate for TURBT was 5.8% and there was an increase in the rate of complications seen as operative duration increased, which remained after controlling for age, comorbidities, tumor size, and American Society of Anesthesiology classification. Increased operative duration was associated with a greater risk of postoperative urinary tract infection, sepsis or septic shock, pulmonary embolism/deep venous thrombosis, reintubation or failure to wean, myocardial infarction, and death. Larger tumors were related to an increased odds of requiring blood transfusions. CONCLUSIONS: Using a contemporary multicenter cohort of TURBTs from the ACS NSQIP database, we demonstrate that increased operative duration is associated with serious postoperative complications. This association was found to persist even after adjusting for patient age, comorbidities, tumor size, and functional status. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Matulewicz, Richard S AU - Matulewicz RS AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. Electronic address: richard.matulewicz@northwestern.edu. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - McGuire, Barry B AU - McGuire BB AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Oberlin, Daniel T AU - Oberlin DT AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Perry, Kent T AU - Perry KT AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Nadler, Robert B AU - Nadler RB AD - Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20150610 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Cohort Studies MH - Datasets as Topic MH - Female MH - Humans MH - Male MH - Postoperative Complications/*etiology MH - Quality Improvement MH - Risk Factors MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Bladder cancer OT - Complications OT - Outcomes OT - TURBT EDAT- 2015/06/15 06:00 MHDA- 2016/04/15 06:00 CRDT- 2015/06/15 06:00 PHST- 2015/02/11 00:00 [received] PHST- 2015/05/09 00:00 [revised] PHST- 2015/05/10 00:00 [accepted] PHST- 2015/06/15 06:00 [entrez] PHST- 2015/06/15 06:00 [pubmed] PHST- 2016/04/15 06:00 [medline] AID - S1078-1439(15)00234-3 [pii] AID - 10.1016/j.urolonc.2015.05.011 [doi] PST - ppublish SO - Urol Oncol. 2015 Aug;33(8):338.e19-24. doi: 10.1016/j.urolonc.2015.05.011. Epub 2015 Jun 10. PMID- 26070892 OWN - NLM STAT- MEDLINE DCOM- 20160126 LR - 20151019 IS - 1527-3792 (Electronic) IS - 0022-5347 (Linking) VI - 194 IP - 5 DP - 2015 Nov TI - PTP4A3 Independently Predicts Metastasis and Survival in Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. PG - 1449-55 LID - S0022-5347(15)04151-8 [pii] LID - 10.1016/j.juro.2015.05.101 [doi] AB - PURPOSE: Increasing evidence has shown that protein tyrosine phosphatases have dominant roles in setting the levels of tyrosine phosphorylation and promoting oncogenic processes. PTP4A3 has been implicated in cancer metastasis but to our knowledge the role of PTP4A3 in upper tract urothelial carcinoma is unknown. The aim of this study was to investigate the association of PTP4A3 with disease characteristics, distant metastasis and prognosis of upper tract urothelial carcinoma. MATERIALS AND METHODS: The importance of PTP4A3 was initially examined in paired normal urothelium, noninvasive upper tract urothelial carcinoma, invasive upper tract urothelial carcinoma and nodal metastatic tissue. The PTP4A3 transcript level was assessed in another 20 upper tract urothelial carcinoma samples by real-time reverse transcriptase-polymerase chain reaction. PTP4A3 protein expression was determined by immunohistochemistry using the H-score in 340 upper tract urothelial carcinoma samples. It was further correlated with clinicopathological factors, and disease specific and metastasis-free survival. RESULTS: The expression of PTP4A3 significantly increased from normal urothelium, noninvasive upper tract urothelial carcinoma and invasive upper tract urothelial carcinoma to nodal metastatic tissue (p <0.001). The PTP4A3 transcript level was also markedly up-regulated in higher stage upper tract urothelial carcinoma (p = 0.002). Over expression of PTP4A3 protein was significantly associated with advanced pT status, nodal metastasis, lymphovascular invasion and perineural invasion (each p <0.001) as well as with inferior disease specific and metastasis-free survival on multivariate analysis (each p <0.0001). In addition, it predicted metastasis in patients with pTa, pT1 and pT2 upper tract urothelial carcinoma. CONCLUSIONS: Results imply that PTP4A3 has a role in the carcinogenesis of upper tract urothelial carcinoma. PTP4A3 over expression independently predicted the metastasis and outcome of upper tract urothelial carcinoma, which was even more important in organ confined disease. CI - Copyright (c) 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Yeh, Hsin-Chih AU - Yeh HC AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. FAU - Li, Ching-Chia AU - Li CC AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. FAU - Huang, Chun-Nung AU - Huang CN AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Hour, Tzyh-Chyuan AU - Hour TC AD - Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Yeh, Bi-Wen AU - Yeh BW AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Li, Wei-Ming AU - Li WM AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan. FAU - Liang, Peir-In AU - Liang PI AD - Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Chang, Lin-Li AU - Chang LL AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Microbiology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Li, Chien-Feng AU - Li CF AD - Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Electronic address: angelo.p@yahoo.com.tw. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan. Electronic address: wejewu@kmu.edu.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150610 PL - United States TA - J Urol JT - The Journal of urology JID - 0376374 RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) RN - 0 (RNA, Neoplasm) RN - EC 3.1.3.48 (PTP4A3 protein, human) RN - EC 3.1.3.48 (Protein Tyrosine Phosphatases) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/biosynthesis/genetics MH - Carcinoma, Transitional Cell/diagnosis/mortality/*secondary MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Neoplasm Proteins/biosynthesis/*genetics MH - Neoplasm Staging MH - *Nephrectomy MH - Prognosis MH - Protein Tyrosine Phosphatases/biosynthesis/*genetics MH - RNA, Neoplasm/*genetics MH - Reverse Transcriptase Polymerase Chain Reaction MH - Survival Rate/trends MH - Taiwan/epidemiology MH - Ureteral Neoplasms/metabolism/mortality/*pathology MH - Urothelium/metabolism/pathology OTO - NOTNLM OT - PTP4A3 protein OT - carcinoma OT - human OT - kidney OT - ureter OT - urothelium EDAT- 2015/06/14 06:00 MHDA- 2016/01/27 06:00 CRDT- 2015/06/14 06:00 PHST- 2015/05/19 00:00 [accepted] PHST- 2015/06/14 06:00 [entrez] PHST- 2015/06/14 06:00 [pubmed] PHST- 2016/01/27 06:00 [medline] AID - S0022-5347(15)04151-8 [pii] AID - 10.1016/j.juro.2015.05.101 [doi] PST - ppublish SO - J Urol. 2015 Nov;194(5):1449-55. doi: 10.1016/j.juro.2015.05.101. Epub 2015 Jun 10. PMID- 26068625 OWN - NLM STAT- MEDLINE DCOM- 20160304 LR - 20150613 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 22 IP - 3 DP - 2015 Jun TI - Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. PG - 7783-7 AB - INTRODUCTION: Sarcomatoid urothelial carcinoma is a dedifferentiated biphasic tumor that exhibits morphological and/or immunohistochemical evidence of epithelial and mesenchymal differentiation. In this series, we analyzed the clinicopathologic features of this rare variant of urothelial carcinoma. MATERIALS AND METHODS: A search was made through our surgical pathology files and consultation files of the senior author for cases of sarcomatoid urothelial carcinoma of the bladder from 2005-2014. All the slides were retrieved and re-reviewed, and clinical data was also obtained including follow up. RESULTS: Thirty-seven cases of sarcomatoid urothelial carcinoma of the bladder were identified. Mean patient age was 71 years (range: 51 to 88 years). Twenty-six of 37 (70%) patients were male and 11/37 (30%) patients were female. Twenty-five cases were from cystectomy/cystoprostatectomy specimens, 8 cases from transurethral resection of bladder tumor specimens and 4 cases were from biopsy specimens. The mean tumor size was 5 cm (range: 1.4 cm to 13.0 cm). Four of 37 (10%) cases had focal heterologous components; 1 case with both chondroid and osteoid, 2 cases with chondroid and 1 case rhabdoid elements. Twenty-one of 37 (56%) patients died within a year of presentation. CONCLUSIONS: Sarcomatoid urothelial carcinoma of the bladder is more prevalent in males, with the mean age of 71 years in our series. Smoking is an important risk factor. Sarcomatoid urothelial carcinoma is an aggressive variant of urothelial carcinoma which commonly presents at an advanced stage, and over 50% of patients in our series died of disease within 1 year of presentation. FAU - Fatima, Nazneen AU - Fatima N AD - Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - Canter, Daniel J AU - Canter DJ FAU - Carthon, Bradley C AU - Carthon BC FAU - Kucuk, Omer AU - Kucuk O FAU - Master, Viraj A AU - Master VA FAU - Nieh, Peter T AU - Nieh PT FAU - Ogan, Kenneth AU - Ogan K FAU - Osunkoya, Adeboye O AU - Osunkoya AO LA - eng PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/*pathology MH - Carcinosarcoma/*pathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Survival Rate MH - Tumor Burden MH - Urinary Bladder Neoplasms/*pathology EDAT- 2015/06/13 06:00 MHDA- 2016/03/05 06:00 CRDT- 2015/06/13 06:00 PHST- 2015/06/13 06:00 [entrez] PHST- 2015/06/13 06:00 [pubmed] PHST- 2016/03/05 06:00 [medline] PST - ppublish SO - Can J Urol. 2015 Jun;22(3):7783-7. PMID- 26064330 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150611 LR - 20200930 IS - 1940-5901 (Print) IS - 1940-5901 (Electronic) IS - 1940-5901 (Linking) VI - 8 IP - 3 DP - 2015 TI - Relation of stem cell markers ALDH1 and CD44 with clinicopathological factors in urothelial carcinomas of urinary bladder. PG - 4195-203 AB - Molecular studies are ongoing in regards to superficial urothelial carcinoma of the bladder (UCB) either to define targeted therapy or to better select aggressive therapy candidates and also to delineate the outcome of the disease. In this study, we aimed to present the impact of ALDH1 and CD44 as stem cell markers in tumorigenesis and their prognostic value in urothelial carcinoma. We investigated ALDH1 and CD44 immunohistochemically in paraffin-embedded material of 125 non-muscle-invasive (NMI) cases in 163 UCB patients. In the NMI-UCB subgroup, we found ALDH1 to be significantly correlated with all poor prognostic factors, including high stage (>/=pT2), high grade, recurrence and progression development and poor survey (P=0.001) in contrast to CD44 expression (P>0.05). Although ALDH1 expression had a good correlation with a poor clinical course of UCB, it could be used as a molecular marker to determine the best treatment strategy and could contribute to the development of targeted therapies. FAU - Senol, Serkan AU - Senol S AD - Department of Pathology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. FAU - Yildirim, Asif AU - Yildirim A AD - Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. FAU - Akalin, Ibrahim AU - Akalin I AD - Department of Medical Genetics, Istanbul Medeniyet University, Faculty of Medicine Istanbul, Turkey. FAU - Uruc, Fatih AU - Uruc F AD - Department of Urology, Istanbul Fatih Sultan Mehmet Training and Research Hospital Istanbul, Turkey. FAU - Cobanoglu, Bengu AU - Cobanoglu B AD - Department of Pathology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. FAU - Yilmaz, Sarenur AU - Yilmaz S AD - Department of Medical Genetics, Istanbul Medeniyet University, Faculty of Medicine Istanbul, Turkey. FAU - Ceyran, Bahar AU - Ceyran B AD - Department of Pathology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. FAU - Kosemetin, Duygu AU - Kosemetin D AD - Department of Pathology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. FAU - Ece, Dilek AU - Ece D AD - Department of Pathology, Istanbul Dr. Lutfi Kirdar Kartal Research and Training Hospital Istanbul, Turkey. FAU - Aydin, Abdullah AU - Aydin A AD - Department of Pathology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20150315 PL - United States TA - Int J Clin Exp Med JT - International journal of clinical and experimental medicine JID - 101471010 PMC - PMC4443164 OTO - NOTNLM OT - ALDH1 OT - CD44 OT - bladder carcinoma OT - prognostic value EDAT- 2015/06/13 06:00 MHDA- 2015/06/13 06:01 PMCR- 2015/03/15 CRDT- 2015/06/12 06:00 PHST- 2015/01/11 00:00 [received] PHST- 2015/02/25 00:00 [accepted] PHST- 2015/06/12 06:00 [entrez] PHST- 2015/06/13 06:00 [pubmed] PHST- 2015/06/13 06:01 [medline] PHST- 2015/03/15 00:00 [pmc-release] PST - epublish SO - Int J Clin Exp Med. 2015 Mar 15;8(3):4195-203. eCollection 2015. PMID- 26051839 OWN - NLM STAT- MEDLINE DCOM- 20150923 LR - 20150707 IS - 1527-9995 (Electronic) IS - 0090-4295 (Linking) VI - 86 IP - 1 DP - 2015 Jul TI - The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. PG - 92-8 LID - S0090-4295(15)00331-3 [pii] LID - 10.1016/j.urology.2015.03.036 [doi] AB - OBJECTIVE: To evaluate the influence of tumor diameter and tumor necrosis on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy (RC). MATERIALS AND METHODS: We treated 517 consecutive patients with urothelial carcinoma of the bladder treated with RC without neoadjuvant chemotherapy at our institution between 1996 and 2011. All RC specimens were meticulously re-reviewed for the largest residual tumor diameter and for the presence and extent of tumor necrosis. Cox regression models evaluated the association with disease recurrence and cancer-specific survival. RESULTS: At RC, 155 patients (30.0%) had a residual tumor diameter >/=3 cm and tumor necrosis was present in 156 patients (30.2%). Tumor diameter and necrosis were significantly correlated (P <.001). Both a tumor diameter >/=3 cm and the presence of tumor necrosis were associated with an older age, advanced tumor stage, higher tumor grade, lymph node metastasis, positive surgical margin status, lymphovascular invasion, and administration of adjuvant chemotherapy (P values /=3 cm and the presence of tumor necrosis were associated with disease recurrence and cancer-specific mortality in Kaplan-Meier analyses, respectively (pairwise P values <.001). In addition, a tumor diameter >/=3 cm was an independent predictor of cancer-specific mortality in multivariate analysis that adjusted for standard clinicopathologic features. CONCLUSION: Tumor diameter and necrosis are closely correlated and associated with aggressive tumor features and inferior oncologic outcomes. A residual tumor diameter >/=3 cm is an independent predictor of cancer-specific mortality. This additional information should be considered to be reported in every pathology report for consideration in patient counseling and treatment decision making. In addition, these results underscore the importance of a thorough transurethral resection of the bladder tumor before RC. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - John, Lisa-Marie AU - John LM AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Dahlem, Roland AU - Dahlem R AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Minner, Sarah AU - Minner S AD - Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Engel, Oliver AU - Engel O AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Schmidt, Selina AU - Schmidt S AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Kluth, Luis A AU - Kluth LA AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: mrink@uke.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150604 PL - United States TA - Urology JT - Urology JID - 0366151 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/mortality/secondary/*surgery MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Germany/epidemiology MH - Humans MH - Kaplan-Meier Estimate MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Necrosis MH - *Neoplasm Staging MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Factors MH - Survival Rate/trends MH - Treatment Outcome MH - Urinary Bladder/*pathology/surgery MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery EDAT- 2015/06/09 06:00 MHDA- 2015/09/24 06:00 CRDT- 2015/06/09 06:00 PHST- 2014/12/22 00:00 [received] PHST- 2015/03/25 00:00 [revised] PHST- 2015/03/31 00:00 [accepted] PHST- 2015/06/09 06:00 [entrez] PHST- 2015/06/09 06:00 [pubmed] PHST- 2015/09/24 06:00 [medline] AID - S0090-4295(15)00331-3 [pii] AID - 10.1016/j.urology.2015.03.036 [doi] PST - ppublish SO - Urology. 2015 Jul;86(1):92-8. doi: 10.1016/j.urology.2015.03.036. Epub 2015 Jun 4. PMID- 26032953 OWN - NLM STAT- MEDLINE DCOM- 20160824 LR - 20181113 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 117 IP - 5 DP - 2016 May TI - Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. PG - 754-60 LID - 10.1111/bju.13186 [doi] AB - OBJECTIVES: To present a molecular definition of bacille Calmette-Guerin (BCG) failure that incorporates fluorescence in situ hybridization (FISH) testing to predict BCG failure before it becomes clinically evident, which can be used to enhance trial designs for patients with non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We used data from 143 patients who were followed prospectively for 2 years during intravesical BCG therapy, during which time FISH assays were collected and correlated to clinical outcomes. RESULTS: Of the 95 patients with no evidence of tumour at 3-month cystoscopy, 23 developed tumour recurrence and 17 developed disease progression by 2 years. Patients with a positive FISH test at both 6 weeks and 3 months were more likely to develop tumour recurrence (17/37 patients [46%] and 16/28 patients [57%], respectively) than patients with a negative FISH test (6/58 patients [10%] and 3/39 patients [8%], respectively; both P < 0.001). Using hazard ratios for recurrence with positive 6-week and 3-month FISH results, we constructed clinical trial scenarios whereby patients with a negative 3-month cystoscopy and positive FISH result could be considered to have 'molecular BCG failure' and could be enrolled in prospective, randomized clinical trials comparing BCG therapy (control) with an experimental intravesical therapy. CONCLUSIONS: Patients with positive early FISH and negative 3-month cystoscopy results can be considered to have molecular BCG failure based on their high rates of recurrence and progression. This definition is intended for use in designing clinical trials, thus potentially allowing continued use of BCG as an ethical comparator arm. CI - (c) 2015 The Authors BJU International (c) 2015 BJU International Published by John Wiley & Sons Ltd. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Willis, Daniel L AU - Willis DL AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dickstein, Rian J AU - Dickstein RJ AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Anderson, Rooselvelt AU - Anderson R AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Nogueras-Gonzalez, Graciela AU - Nogueras-Gonzalez G AD - Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Katz, Ruth L AU - Katz RL AD - Department of Cytopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Wu, Xifeng AU - Wu X AD - Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Barton Grossman, H AU - Barton Grossman H AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States GR - P50 CA091846/CA/NCI NIH HHS/United States GR - CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150703 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (BCG Vaccine) SB - IM MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/*therapeutic use MH - Carcinoma in Situ/pathology/therapy MH - Clinical Trials as Topic MH - Cystoscopy MH - Disease Progression MH - Female MH - Humans MH - *In Situ Hybridization, Fluorescence MH - Male MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*diagnosis MH - Neoplasm Staging MH - Prospective Studies MH - Treatment Failure MH - Urinary Bladder Neoplasms/pathology/*therapy PMC - PMC4666834 MID - NIHMS697779 OTO - NOTNLM OT - bacille Calmette-Guerin OT - bacille Calmette-Guerin failure OT - bladder cancer OT - clinical trials OT - fluorescence in situ hybridization COIS- Conflicts of interest Dr. Anderson has nothing to disclose. EDAT- 2015/06/03 06:00 MHDA- 2016/08/25 06:00 PMCR- 2017/05/01 CRDT- 2015/06/03 06:00 PHST- 2015/06/03 06:00 [entrez] PHST- 2015/06/03 06:00 [pubmed] PHST- 2016/08/25 06:00 [medline] PHST- 2017/05/01 00:00 [pmc-release] AID - 10.1111/bju.13186 [doi] PST - ppublish SO - BJU Int. 2016 May;117(5):754-60. doi: 10.1111/bju.13186. Epub 2015 Jul 3. PMID- 26032289 OWN - NLM STAT- MEDLINE DCOM- 20160621 LR - 20240610 IS - 1557-3125 (Electronic) IS - 1541-7786 (Print) IS - 1541-7786 (Linking) VI - 13 IP - 9 DP - 2015 Sep TI - E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer. PG - 1316-24 LID - 10.1158/1541-7786.MCR-15-0120 [doi] AB - Bladder cancer is a common malignant disease, with non-muscle-invasive bladder cancer (NMIBC) representing the majority of tumors. This cancer subtype is typically treated by transurethral resection. In spite of treatment, up to 70% of patients show local recurrences. Intravesical BCG (Bacillus Calmette-Guerin) immunotherapy has been widely used to treat NMIBC, but it fails to suppress recurrence of bladder tumors in up to 40% of patients. Therefore, the development of prognostic markers is needed to predict the progression of bladder cancer and the efficacy of intravesical BCG treatment. This study demonstrates the effectiveness of an E2F4 signature for prognostic prediction of bladder cancer. E2F4 scores for each sample in a bladder cancer expression dataset were calculated by summarizing the relative expression levels of E2F4 target genes identified by ChIP-seq, and then the scores were used to stratify patients into good- and poor-outcome groups. The molecular signature was investigated in a single bladder cancer dataset and then its effectiveness was confirmed in two meta-bladder datasets consisting of specimens from multiple independent studies. These results were consistent in different datasets and demonstrate that the E2F4 score is predictive of clinical outcomes in bladder cancer, with patients whose tumors exhibit an E2F4 score >0 having significantly shorter survival times than those with an E2F4 score <0, in both non-muscle-invasive, and muscle-invasive bladder cancer. Furthermore, although intravesical BCG immunotherapy can significantly improve the clinical outcome of NMIBC patients with positive E2F4 scores (E2F4>0 group), it does not show significant treatment effect for those with negative scores (E2F4<0 group). IMPLICATIONS: The E2F4 signature can be applied to predict the progression/recurrence and the responsiveness of patients to intravesical BCG immunotherapy in bladder cancer. CI - (c)2015 American Association for Cancer Research. FAU - Cheng, Chao AU - Cheng C AD - Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Institute for Quantitative Biomedical Sciences, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. Chao.Cheng@dartmouth.edu. FAU - Varn, Frederick S AU - Varn FS AD - Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Marsit, Carmen J AU - Marsit CJ AD - Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. LA - eng GR - P20 GM103534/GM/NIGMS NIH HHS/United States GR - UL1TR001086/TR/NCATS NIH HHS/United States GR - GM103534/GM/NIGMS NIH HHS/United States GR - KL2 TR001088/TR/NCATS NIH HHS/United States GR - UL1 TR001086/TR/NCATS NIH HHS/United States GR - T32 GM008704/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150601 PL - United States TA - Mol Cancer Res JT - Molecular cancer research : MCR JID - 101150042 RN - 0 (E2F4 Transcription Factor) RN - 0 (E2F4 protein, human) SB - IM MH - Cell Line, Tumor MH - *Disease Progression MH - Disease-Free Survival MH - E2F4 Transcription Factor/*genetics/*metabolism MH - Female MH - Humans MH - Immunotherapy MH - Male MH - Mycobacterium bovis/*immunology/metabolism MH - Treatment Outcome MH - Urinary Bladder Neoplasms/genetics/immunology/pathology/*therapy PMC - PMC4734892 MID - NIHMS753519 COIS- Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. EDAT- 2015/06/03 06:00 MHDA- 2016/06/22 06:00 PMCR- 2016/02/01 CRDT- 2015/06/03 06:00 PHST- 2015/03/09 00:00 [received] PHST- 2015/05/19 00:00 [accepted] PHST- 2015/06/03 06:00 [entrez] PHST- 2015/06/03 06:00 [pubmed] PHST- 2016/06/22 06:00 [medline] PHST- 2016/02/01 00:00 [pmc-release] AID - 1541-7786.MCR-15-0120 [pii] AID - 10.1158/1541-7786.MCR-15-0120 [doi] PST - ppublish SO - Mol Cancer Res. 2015 Sep;13(9):1316-24. doi: 10.1158/1541-7786.MCR-15-0120. Epub 2015 Jun 1. PMID- 26030249 OWN - NLM STAT- MEDLINE DCOM- 20150921 LR - 20150602 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 139 IP - 6 DP - 2015 Jun TI - Multiphoton microscopy: a potential intraoperative tool for the detection of carcinoma in situ in human bladder. PG - 796-804 LID - 10.5858/arpa.2014-0076-OA [doi] AB - CONTEXT: Urothelial carcinoma in situ (CIS) is a precursor of invasive bladder cancer, which if left untreated, will likely progress to more aggressive disease. Approximately 50% of CIS lesions are missed on routine cystoscopy owing to their flat architecture. Furthermore, many benign but abnormal-appearing areas may be biopsied owing to lack of cellular resolution of cystoscopes. Multiphoton microscopy (MPM) is an optical imaging technique that generates subcellular-resolution three-dimensional images from unfixed tissue without using exogenous dyes. OBJECTIVE: To assess the diagnostic potential of MPM in identifying and differentiating benign from malignant flat bladder lesions, especially CIS. DESIGN: Seventy-eight specimens (benign = 46, CIS = 23, invasive = 9, as diagnosed on histopathology) were obtained from flat bladder mucosa via transurethral resection of bladder, cold cup biopsy, or cystectomy, imaged fresh with a commercial benchtop MPM, and submitted for routine histopathology. Multiphoton microscopy and hematoxylin-eosin diagnoses were compared. RESULTS: In 77 of 78 specimens (99%), accurate MPM diagnoses (benign/malignant) were given on the basis of their architectural and cytologic features (nuclear to cytoplasmic ratio, pleomorphism, polarity/organization of urothelial layers, etc). The sensitivity and specificity were 97% and 100%, respectively, with positive (malignant) and negative (benign) predictive values of 100% and 98%, respectively. The interobserver agreement, kappa, was 0.93. CONCLUSIONS: Our study demonstrates the capability of MPM to identify and differentiate benign from malignant flat bladder lesions, especially CIS. With the advent of MPM endoscopes, we foresee their potential as a biopsy guidance tool for early detection and treatment of CIS, thus reducing the rate of biopsies with benign diagnoses and their associated complications. FAU - Jain, Manu AU - Jain M AD - From the Departments of Pathology and Laboratory Medicine (Drs Jain, Robinson, and Shevchuk), Urology (Drs Jain, Robinson, and Scherr and Mr Dubin), and Biochemistry (Drs Aggarwal and Mukherjee and Mr Salamoon), Weill Cornell Medical College, New York, New York. Dr Aggarwal is now at the Department of Science, Borough of Manhattan Community College, New York, New York. Mr Dubin is now a medical student at Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey. FAU - Robinson, Brian D AU - Robinson BD FAU - Shevchuk, Maria M AU - Shevchuk MM FAU - Aggarwal, Amit AU - Aggarwal A FAU - Salamoon, Bekheit AU - Salamoon B FAU - Dubin, Justin M AU - Dubin JM FAU - Scherr, Douglas S AU - Scherr DS FAU - Mukherjee, Sushmita AU - Mukherjee S LA - eng PT - Journal Article PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 SB - IM MH - Adult MH - Carcinoma in Situ/*diagnosis MH - Carcinoma, Transitional Cell/*diagnosis MH - Cohort Studies MH - Female MH - Histocytochemistry MH - Humans MH - Male MH - Microscopy, Fluorescence, Multiphoton/*methods MH - Monitoring, Intraoperative/instrumentation MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Single-Blind Method MH - Urinary Bladder/pathology MH - Urinary Bladder Neoplasms/*diagnosis EDAT- 2015/06/02 06:00 MHDA- 2015/09/22 06:00 CRDT- 2015/06/02 06:00 PHST- 2015/06/02 06:00 [entrez] PHST- 2015/06/02 06:00 [pubmed] PHST- 2015/09/22 06:00 [medline] AID - 10.5858/arpa.2014-0076-OA [doi] PST - ppublish SO - Arch Pathol Lab Med. 2015 Jun;139(6):796-804. doi: 10.5858/arpa.2014-0076-OA. PMID- 26029295 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150601 LR - 20201001 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 9 IP - 5-6 DP - 2015 May-Jun TI - Intravesical bacillus Calmette-Guerin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. PG - E278-83 LID - 10.5489/cuaj.2708 [doi] AB - INTRODUCTION: Patients with high-risk non-muscle invasive bladder cancer (NMIBC) need adjuvant intravesical treatment after surgery. Although bacillus Calmette-Guerin (BCG) is highly effective, new adjuvant treatments to decrease recurrences and toxicity have been studies. We performed a retrospective propensity score-matched study to compare the efficacy of BCG and chemohyperthermia (C-HT). METHODS: We included 1937 patients diagnosed with bladder cancer between January 2004 and January 2014. The primary efficacy endpoint was recurrence-free interval. Patients treated with C-HT were matched with patients treated with BCG using propensity score-matched analysis. Cox-regression models were used to estimate the association between intravesical treatments and the presence of recurrence and progression. RESULTS: Of the 710 patients treated with intravesical treatments, 40 and 142 were eligible for inclusion in C-HT and BCG groups, respectively. Following case matching, there were no differences in patient or tumour characteristics between treatment groups. The 2-year recurrence-free interval in C-HT and BCG groups were 76.2% and 93.9%, respectively (p = 0.020). C-HT treatment (hazard ratio [HR] 5.42; 95% confidence interval [CI] 1.11-26.43; p = 0.036) and high-grade tumour (HR 4.60; 95% CI 1.01-20.88; p = 0.048) are associated with an elevated odds of tumour recurrence. In multivariate Cox-regression analysis, there was no significant difference between C-HT and BCG in the odds of recurrence (p = 0.054). There were no differences in progression between C-HT and BCG. CONCLUSION: C-HT is not as effective treatment as BCG in high-risk NMIBC patients who are BCG-naive. Although, there were no significant difference in the odds of recurrence, recurrence-free interval is significantly improved by the administration of BCG. FAU - Ekin, Rahmi Gokhan AU - Ekin RG AD - Tepecik Teaching and Research Hospital, Department of Urology, Turkey; FAU - Akarken, Ilker AU - Akarken I AD - Kemalpasa State Hospital, Urology Clinic, Turkey; FAU - Zorlu, Ferruh AU - Zorlu F AD - Tepecik Teaching and Research Hospital, Department of Urology, Turkey; FAU - Tarhan, Huseyin AU - Tarhan H AD - Tepecik Teaching and Research Hospital, Department of Urology, Turkey; FAU - Kucuk, Ulku AU - Kucuk U AD - Tepecik Teaching and Research Hospital, Department of Pathology, Turkey; FAU - Yildirim, Zubeyde AU - Yildirim Z AD - Tepecik Teaching and Research Hospital, Department of Pathology, Turkey; FAU - Divrik, Rauf Taner AU - Divrik RT AD - Department of Urology, Sifa University, Faculty of Medicine, Izmir, Turkey. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC4439224 EDAT- 2015/06/02 06:00 MHDA- 2015/06/02 06:01 PMCR- 2015/05/01 CRDT- 2015/06/02 06:00 PHST- 2015/06/02 06:00 [entrez] PHST- 2015/06/02 06:00 [pubmed] PHST- 2015/06/02 06:01 [medline] PHST- 2015/05/01 00:00 [pmc-release] AID - cuaj-5-6-e278 [pii] AID - 10.5489/cuaj.2708 [doi] PST - ppublish SO - Can Urol Assoc J. 2015 May-Jun;9(5-6):E278-83. doi: 10.5489/cuaj.2708. PMID- 26025496 OWN - NLM STAT- MEDLINE DCOM- 20160404 LR - 20261011 IS - 1534-6285 (Electronic) IS - 1527-2737 (Linking) VI - 16 IP - 7 DP - 2015 Jul TI - Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy? PG - 46 LID - 10.1007/s11934-015-0520-z [doi] AB - Radical cystectomy (RC) with bilateral pelvic lymphadenectomy with or without perioperative chemotherapy is the golden standard treatment in muscle invasive and recurrent high-grade non-muscle invasive urothelial carcinoma of the bladder (UCB). Despite treatment with curative intent, up to 50% of patients develop metastasis and die from UCB due to micro-metastatic disease undetectable for current staging techniques prior to definitive therapy. Tumor cell dissemination is a crucial step in the natural history of the metastatic cascade. Circulating tumor cells (CTC) are malignant epithelial cells detectable in the peripheral blood of patients with various malignancies. In UCB, CTC are detectable in a significant number of patients prior to RC and associated with inferior outcomes. In this review, we summarize the current literature regarding CTC in UCB, discussing their potential on clinical decision-making regarding multimodal treatment and implications on the application of novel targeted therapies in the future. There is reliable evidence that presence of CTC in clinically non-metastatic UCB patients treated with RC are a powerful predictor for unfavorable outcomes and may be useful for adjuvant chemotherapy decision-making and monitoring. However, currently, the evidence is limited, and thus, integration of CTC in future UCB clinical trials is strongly recommended to shed more light on the potential of this promising biomarker. FAU - Soave, Armin AU - Soave A AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany. FAU - Riethdorf, Sabine AU - Riethdorf S FAU - Pantel, Klaus AU - Pantel K FAU - Fisch, Margit AU - Fisch M FAU - Rink, Michael AU - Rink M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Curr Urol Rep JT - Current urology reports JID - 100900943 SB - IM MH - Chemotherapy, Adjuvant MH - Cystectomy/methods MH - Humans MH - Lymph Node Excision MH - *Neoplastic Cells, Circulating MH - Urinary Bladder Neoplasms/*drug therapy/pathology/surgery EDAT- 2015/05/31 06:00 MHDA- 2016/04/05 06:00 CRDT- 2015/05/31 06:00 PHST- 2015/05/31 06:00 [entrez] PHST- 2015/05/31 06:00 [pubmed] PHST- 2016/04/05 06:00 [medline] AID - 10.1007/s11934-015-0520-z [doi] PST - ppublish SO - Curr Urol Rep. 2015 Jul;16(7):46. doi: 10.1007/s11934-015-0520-z. PMID- 26025446 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20181113 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 15 DP - 2015 May 30 TI - Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy. PG - 46 LID - 10.1186/s12894-015-0037-2 [doi] LID - 46 AB - BACKGROUND: To investigate the efficacy of initial biopsy or transurethral resection of bladder tumor for detecting histological variants on radical cystectomy and to assess the prognostic significance of variant histology on urothelial carcinoma outcomes after radical cystectomy. METHODS: Clinical and histopathological characteristics of 147 patients with variant histology who underwent radical cystectomy for urothelial carcinoma between 2006 and 2012 were assessed. Sensitivity was calculated as the proportion of radical cystectomy specimens with a particular variant that also presented the variant in the biopsy or transurethral resection specimen. The Kaplan-Meier method and multivariate Cox proportional hazard regression analysis were used to estimate cancer-specific survival. RESULTS: Of the 147 patients, 116 (79 %) were diagnosed with a single variant histology, and 31 (21 %) had multiple patterns. Squamous differentiation (31 %) was the most common single variant histology, followed by glandular differentiation (28 %). Except for small cell variant (100 %), the sensitivity of biopsy and transurethral resection was most effective for the diagnosis of squamous differentiation, 19 % vs. 40 % respectively, followed by glandular differentiation, 11 % vs. 21 % respectively. A total of 6 % and 49 % patients could be variant-free partially due to biopsy or complete resection(s) respectively. Presence of variant differentiation in urothelial carcinoma at cystectomy was significantly associated with inferior survival both in univariate analysis (P = 0.005) and multivariate analysis (HR4.48, 95 % CI:1.03-19.53). CONCLUSIONS: Overall sensitivity of biopsy or transurethral resection to detect variant differentiation on cystectomy is relatively low. Patients with variant differentiation on cystectomy specimens have inferior survival. FAU - Ge, Peng AU - Ge P AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, 100034, China. gepengyzu@126.com. AD - National Research Center for Genitourinary Oncology, Beijing, 100034, China. gepengyzu@126.com. FAU - Wang, Zi-Cheng AU - Wang ZC AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, 100034, China. 806738028@qq.com. AD - National Research Center for Genitourinary Oncology, Beijing, 100034, China. 806738028@qq.com. FAU - Yu, Xi AU - Yu X AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, 100034, China. 1986yuxi@163.com. AD - National Research Center for Genitourinary Oncology, Beijing, 100034, China. 1986yuxi@163.com. FAU - Lin, Jian AU - Lin J AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, 100034, China. linjianbj@163.com. AD - National Research Center for Genitourinary Oncology, Beijing, 100034, China. linjianbj@163.com. FAU - He, Qun AU - He Q AD - Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, 100034, China. bdyyqhe@sina.com. AD - National Research Center for Genitourinary Oncology, Beijing, 100034, China. bdyyqhe@sina.com. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150530 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 SB - IM MH - Aged MH - Biopsy, Needle MH - Carcinoma, Transitional Cell/mortality/*pathology/*surgery MH - Cohort Studies MH - Cystectomy/*methods MH - Disease-Free Survival MH - Endoscopy/methods MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Minimally Invasive Surgical Procedures/methods/mortality MH - Multivariate Analysis MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Urethra/surgery MH - Urinary Bladder Neoplasms/classification/mortality/*pathology/*surgery PMC - PMC4448304 EDAT- 2015/05/31 06:00 MHDA- 2016/04/19 06:00 PMCR- 2015/05/30 CRDT- 2015/05/31 06:00 PHST- 2015/02/06 00:00 [received] PHST- 2015/05/14 00:00 [accepted] PHST- 2015/05/31 06:00 [entrez] PHST- 2015/05/31 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] PHST- 2015/05/30 00:00 [pmc-release] AID - 10.1186/s12894-015-0037-2 [pii] AID - 37 [pii] AID - 10.1186/s12894-015-0037-2 [doi] PST - epublish SO - BMC Urol. 2015 May 30;15:46. doi: 10.1186/s12894-015-0037-2. PMID- 26025189 OWN - NLM STAT- MEDLINE DCOM- 20161101 LR - 20260128 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 34 IP - 2 DP - 2016 Feb TI - Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. PG - 173-80 LID - 10.1007/s00345-015-1598-0 [doi] AB - PURPOSE: To develop a model to predict recurrence for patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) treated with intravesical chemotherapy which can be challenging because of the heterogeneous characteristics of these patients. METHODS: Data from three Dutch trials were combined. Patients treated with intravesical chemotherapy with characteristics according to the IR definition of the EAU guideline 2013 were included. Uni- and multivariable Cox regression with selection methods were used to identify predictors of recurrence at 1, 2, and 5 years. An easy-readable table for recurrence probabilities was developed. An external validation was done using data from Spanish patients. RESULTS: A total of 724 patients were available for analyses, of which 305 were primary patients. Recurrences occurred in 413 patients (57%). History of recurrences, history of intravesical treatment, grade 2, multiple tumors, and adjuvant treatment with epirubicin were relevant predictors for recurrence-free survival with hazard ratios of 1.48, 1.38, 1.22, 1.56, and 1.27, respectively. A table for recurrence probabilities was developed using these five predictors. Based on the probability of recurrence, three risk groups were identified. Patients in each of the separate risk groups should be scheduled for less or more aggressive treatment. The model showed sufficient discrimination and good predictive accuracy. External validation showed good validity. CONCLUSION: In our model, we identified five relevant predictors for recurrence-free survival in IR-NMIBC patients treated with intravesical chemotherapy. These recurrence predictors allow the urologists to stratify patients in risk groups for recurrence that could help in deciding for an individualized treatment approach. FAU - Lammers, Rianne J M AU - Lammers RJ AD - Department of Urology, Radboud University Medical Centre, Geert Grooteplein Zuid 10 (659), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. rianne_lammers@hotmail.com. FAU - Hendriks, Jan C M AU - Hendriks JC AD - Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Rodriguez Faba, O Rodriguez Faba AU - Rodriguez Faba OR AD - Fundacio Puigvert, Oncology Urology, Barcelona, Spain. FAU - Witjes, Wim P J AU - Witjes WP AD - Department of Urology, Radboud University Medical Centre, Geert Grooteplein Zuid 10 (659), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. AD - CuraTrial SMO & Research, Arnhem, The Netherlands. FAU - Palou, Joan AU - Palou J AD - Fundacio Puigvert, Oncology Urology, Barcelona, Spain. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Geert Grooteplein Zuid 10 (659), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Fred.Witjes@radboudumc.nl. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20150530 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Adjuvants, Immunologic) SB - IM CIN - J Urol. 2017 Sep;198(3):482-483. doi: 10.1016/j.juro.2017.06.001. PMID: 28817911 MH - Adjuvants, Immunologic/*administration & dosage MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - Denmark/epidemiology MH - Female MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*epidemiology MH - Prognosis MH - Urinary Bladder Neoplasms/diagnosis/*drug therapy PMC - PMC4729802 OTO - NOTNLM OT - Adjuvant chemotherapy OT - Intravesical administration OT - Prediction model OT - Recurrence OT - Urinary bladder neoplasm EDAT- 2015/05/31 06:00 MHDA- 2016/11/02 06:00 PMCR- 2015/05/30 CRDT- 2015/05/31 06:00 PHST- 2015/01/31 00:00 [received] PHST- 2015/05/18 00:00 [accepted] PHST- 2015/05/31 06:00 [entrez] PHST- 2015/05/31 06:00 [pubmed] PHST- 2016/11/02 06:00 [medline] PHST- 2015/05/30 00:00 [pmc-release] AID - 10.1007/s00345-015-1598-0 [pii] AID - 1598 [pii] AID - 10.1007/s00345-015-1598-0 [doi] PST - ppublish SO - World J Urol. 2016 Feb;34(2):173-80. doi: 10.1007/s00345-015-1598-0. Epub 2015 May 30. PMID- 26018765 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20220330 IS - 1471-2490 (Electronic) IS - 1471-2490 (Linking) VI - 15 DP - 2015 May 28 TI - Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy. PG - 45 LID - 10.1186/s12894-015-0039-0 [doi] LID - 45 AB - BACKGROUND: Urothelial carcinoma (UC) is a common cancer affecting many patients in the United States. Nephroureterectomy remains the gold standard for the treatment of high grade upper tract disease or low grade tumors that are not amenable to endoscopic management. Recent reports have shown a decrease in UC recurrence in patients who underwent nephroureterectomy and who had Mitomycin C (MMC) instilled into the bladder at the time of catheter removal. At our institution instillation of intravesical MMC at the time of nephroureterectomy has been common for more than 10 years. Given the recent data, we sought to formally describe our experience with and evaluate the safety of intravesical instillation of cytotoxic chemotherapy at the time of nephroureterectomy. METHODS: We retrospectively reviewed 51 patients who underwent intraoperative intravesical instillation of cytotoxic chemotherapy (MMC (n = 48) or adriamycin (n = 3)) at the time of nephroureterectomy (2000-2012). The procedure was performed in a similar fashion by 8 different surgeons from the same institution, with drainage of the bladder prior to management of the bladder cuff. Patient characteristics and perioperative data including complications out to 90 days after surgery were collected. Perioperative complications for all patients were graded using the modified Clavien-Dindo classification. RESULTS: Twenty-four men and 27 women underwent intraoperative intravesical instillation of cytotoxic chemotherapy at the time of nephroureterectomy. Median age at the time of operation was 74 years (range 48-88). Median dwell time was 60 min. Twenty three patients had a total of 45 perioperative complications. The majority (36/45) were Clavien grades I and II. No patients experienced any intraoperative or postoperative complications attributable to MMC or Adriamycin instillation. CONCLUSION: Intraoperative intravesical instillation of cytotoxic chemotherapy at the time of nephroureterectomy is safe and feasible. Multicenter trials to study the efficacy of early cytotoxic chemotherapy administration to prevent recurrence of bladder urothelial carcinoma following nephroureterectomy are warranted. FAU - Moriarty, Michael A AU - Moriarty MA AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. mmoriarty@mcw.edu. FAU - Uhlman, Matthew A AU - Uhlman MA AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. matthew-uhlman@uiowa.edu. FAU - Bing, Megan T AU - Bing MT AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. megan-bing@uiowa.edu. FAU - O'Donnell, Michael A AU - O'Donnell MA AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. michael-odonnell@uiowa.edu. FAU - Brown, James A AU - Brown JA AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. james-brown-2@uiowa.edu. FAU - Tracy, Chad R AU - Tracy CR AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. chad-tracy@uiowa.edu. FAU - Deorah, Sundeep AU - Deorah S AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. sundeep-deorah@uiowa.edu. FAU - Nepple, Kenneth G AU - Nepple KG AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. kenneth-nepple@uiowa.edu. FAU - Gupta, Amit AU - Gupta A AD - Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA, 52242, USA. amit-gupta-1@uiowa.edu. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20150528 PL - England TA - BMC Urol JT - BMC urology JID - 100968571 RN - 0 (Antineoplastic Agents) RN - 80168379AG (Doxorubicin) SB - IM MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Carcinoma, Transitional Cell/mortality/pathology/*therapy MH - Cohort Studies MH - Combined Modality Therapy MH - Disease-Free Survival MH - Doxorubicin/*administration & dosage MH - Female MH - Follow-Up Studies MH - Humans MH - Intraoperative Care/methods MH - Kidney Neoplasms/mortality/pathology/*therapy MH - Male MH - Middle Aged MH - Nephrectomy/*methods MH - Patient Safety MH - Retrospective Studies MH - Risk Assessment MH - Survival Analysis MH - Treatment Outcome MH - Ureter/*surgery MH - Ureteral Neoplasms/mortality/pathology/*therapy PMC - PMC4446833 EDAT- 2015/05/29 06:00 MHDA- 2016/04/19 06:00 PMCR- 2015/05/28 CRDT- 2015/05/29 06:00 PHST- 2014/12/08 00:00 [received] PHST- 2015/05/19 00:00 [accepted] PHST- 2015/05/29 06:00 [entrez] PHST- 2015/05/29 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] PHST- 2015/05/28 00:00 [pmc-release] AID - 10.1186/s12894-015-0039-0 [pii] AID - 39 [pii] AID - 10.1186/s12894-015-0039-0 [doi] PST - epublish SO - BMC Urol. 2015 May 28;15:45. doi: 10.1186/s12894-015-0039-0. PMID- 26017881 OWN - NLM STAT- MEDLINE DCOM- 20150818 LR - 20220311 IS - 1233-9687 (Print) IS - 1233-9687 (Linking) VI - 66 IP - 1 DP - 2015 Mar TI - Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers. PG - 57-66 AB - There are many scoring methods evaluating the expression of p16 in the bladder immunohistochemically. In this study our aim was to determine an optimal p16 scoring method by discussing different staining methods related with p16 expression in bladder cancers and to establish the association of p16 and Ki-67 expressions, alone or in combination, with recurrence and progression. Ninety patients undergoing their first transurethral resection for bladder cancer and newly diagnosed papillary urothelial carcinoma (pTa and pT1) were included in the study. Four different scoring methods were used for p16 (p16a, p16b, p16c, p16d). The patients were divided into two groups based on recurrence and progression. There was a statistically significant difference between recurrence and abnormal p16d staining (p = 0.005). In other staining patterns of p16, there was no statistically significant difference in terms of recurrence or progression.In the multivariate logistic regression analysis, combined Ki-67 >/= 10 and abnormal p16d staining was found to be the only independent predictive factor for recurrence (OR = 2.26, 95% CI: 0.13-46.41, p = 0.035) and no independent predictive factor for progression was found. Determining an adequate expression scoring by taking normal transitional epithelial staining pattern as a reference would be an objective approach in p16 evaluation. Moreover, it was found that evaluating p16d and Ki-67 in combination would be significant in predicting recurrence in pTa and pT1 urothelial carcinomas. FAU - Ozyalvacli, Guzade AU - Ozyalvacli G AD - Gulzade Ozyalvacll MD, Department of Pathology, Faculty of Medicine, Abant Izzet Baysal University, 14280 Bolu, Turkey, tel. +90 505 391 14 68, fax +90 374 253 45 15, e-mail: gulzade78@yahoo.com. FAU - Ozyalvacli, Mehmet E AU - Ozyalvacli ME FAU - Astarci, Hesna M AU - Astarci HM FAU - Boran, Cetin AU - Boran C FAU - Yesil, Cemile AU - Yesil C FAU - Uyeturk, Ugur AU - Uyeturk U FAU - Aktas, Gulan AU - Aktas G LA - eng PT - Evaluation Study PT - Journal Article PL - Poland TA - Pol J Pathol JT - Polish journal of pathology : official journal of the Polish Society of Pathologists JID - 9437432 RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Ki-67 Antigen) SB - IM MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Carcinoma, Papillary/*chemistry/pathology/surgery MH - Chi-Square Distribution MH - Cyclin-Dependent Kinase Inhibitor p16/*analysis MH - Cystectomy MH - Disease Progression MH - Female MH - Humans MH - *Immunohistochemistry MH - Kaplan-Meier Estimate MH - Ki-67 Antigen/*analysis MH - Logistic Models MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Odds Ratio MH - Predictive Value of Tests MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*chemistry/pathology/surgery EDAT- 2015/05/29 06:00 MHDA- 2015/08/19 06:00 CRDT- 2015/05/29 06:00 PHST- 2015/05/29 06:00 [entrez] PHST- 2015/05/29 06:00 [pubmed] PHST- 2015/08/19 06:00 [medline] AID - 25044 [pii] AID - 10.5114/pjp.2015.51154 [doi] PST - ppublish SO - Pol J Pathol. 2015 Mar;66(1):57-66. doi: 10.5114/pjp.2015.51154. PMID- 26014498 OWN - NLM STAT- MEDLINE DCOM- 20160203 LR - 20220310 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 15 DP - 2015 May 27 TI - Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer. PG - 433 LID - 10.1186/s12885-015-1459-7 [doi] LID - 433 AB - BACKGROUND: Interleukin-27 (IL-27) has been recognized as a pleiotropic cytokine with both pro- and anti-inflammatory properties. Few studies have investigated polymorphisms and serum/plasma levels of IL-27 in diseases including cancers. This study has analyzed the associations of IL-27 gene polymorphisms, as well as plasma levels of IL-27, with susceptibility to bladder cancer and clinical outcome. METHODS: Three hundred and thirty-two patients (nonmuscle-invasive bladder cancer (NMIBC)/muscle-invasive bladder cancer (MIBC): 176/156) included in a 60-month follow-up program and 499 controls were enrolled. Two single nucleotide polymorphisms (SNPs), rs153109 and rs17855750, were genotyped by polymerase chain reaction (PCR) -restriction fragment length polymorphism (RFLP) method. Plasma concentration of IL-27 was determined by ELISA in 124 patients (NMIBC/MIBC: 50/74) and 151 controls. RESULTS: Significantly increased risk for bladder cancer was associated with AG/GG genotypes of rs153109 (P = 0.029). No GG genotype of rs17855750 was observed in controls, while 4 patients were found to be GG homozygotes, suggesting GG genotype may be associated with bladder cancer risk (P = 0.006). For bladder cancer patients, SNP rs17855750 was also associated with increased risk for MIBC. For MIBC patients, but not NMIBC, TG/GG genotypes of rs17855750 turned out to be a protective factor for overall survival (P = 0.035). Significantly reduced plasma levels of IL-27 were observed in both NMIBC and MIBC patients compared with controls (P < 0.0001). CONCLUSION: Our data suggest that polymorphisms and reduced plasma levels of IL-27 may predict the susceptibility to bladder cancer, and rs17855750 may be a useful marker to distinguish patients with high risk of death. FAU - Zhou, Bin AU - Zhou B AD - Laboratory of Molecular Translational Medicine, West China Institute of Women and Children's Health, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P R China. zb630@163.com. FAU - Zhang, Peng AU - Zhang P AD - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, P R China. zpeng2001@gmail.com. FAU - Tang, Tielong AU - Tang T AD - Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, P R China. cdzt2004@163.com. FAU - Liao, Hong AU - Liao H AD - Department of Urology, Institute of oncology, the Second People's Hospital of Sichuan, Chengdu, P R China. liaohong131@163.com. FAU - Zhang, Kui AU - Zhang K AD - Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, P R China. newman-zhk@163.com. FAU - Pu, Yan AU - Pu Y AD - Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, P R China. puyan289@163.com. FAU - Chen, Peng AU - Chen P AD - Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, P R China. 276538406@qq.com. FAU - Song, Yaping AU - Song Y AD - Laboratory of Molecular Translational Medicine, West China Institute of Women and Children's Health, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P R China. songyaping86@163.com. FAU - Zhang, Lin AU - Zhang L AD - Laboratory of Molecular Translational Medicine, West China Institute of Women and Children's Health, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P R China. zhanglin@scu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150527 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Interleukin-27) SB - IM MH - Aged MH - Alleles MH - Case-Control Studies MH - Female MH - Follow-Up Studies MH - Gene Frequency MH - *Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Interleukin-27/*blood/*genetics MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Patient Outcome Assessment MH - *Polymorphism, Single Nucleotide MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/*blood/*genetics/mortality/pathology PMC - PMC4445811 EDAT- 2015/05/28 06:00 MHDA- 2016/02/04 06:00 PMCR- 2015/05/27 CRDT- 2015/05/28 06:00 PHST- 2014/08/13 00:00 [received] PHST- 2015/05/21 00:00 [accepted] PHST- 2015/05/28 06:00 [entrez] PHST- 2015/05/28 06:00 [pubmed] PHST- 2016/02/04 06:00 [medline] PHST- 2015/05/27 00:00 [pmc-release] AID - 10.1186/s12885-015-1459-7 [pii] AID - 1459 [pii] AID - 10.1186/s12885-015-1459-7 [doi] PST - epublish SO - BMC Cancer. 2015 May 27;15:433. doi: 10.1186/s12885-015-1459-7. PMID- 26011327 OWN - NLM STAT- MEDLINE DCOM- 20150723 LR - 20220317 IS - 1107-0625 (Print) IS - 1107-0625 (Linking) VI - 20 IP - 2 DP - 2015 Mar-Apr TI - Urothelial carcinoma: Recurrence and risk factors. PG - 391-8 AB - Urothelial carcinomas are malignant tumors that arise from the urothelial epithelium and may involve the lower and upper urinary tract. They are characterized by multiple, multifocal recurrences throughout the genitourinary tract. Bladder tumors account for 90-95% of urothelial carcinomas and are the most common malignancies of the urinary tract. Upper urinary tract urothelial carcinomas (UTUC) are relatively rare, accounting for 5% of urothelial tumors. The incidence of subsequent bladder cancer after surgical treatment for UTUC is approximately 15-50%. In contrast, patients with a primary tumor of the bladder have a low risk (2-6%) the development of UTUC. Identification of prognostic factors and early detection of recurrent disease provide a better strategy for postoperative monitoring, surveillance, and potentially improve patient outcomes. In this review study we discuss the main risk factors for UTUC recurrence after radical cystectomy, and risk factors for intravesical recurrence after radical nephroureterectomy. FAU - Milojevic, Bogomir AU - Milojevic B AD - Clinic of Urology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Dzamic, Zoran AU - Dzamic Z FAU - Kajmakovic, Boris AU - Kajmakovic B FAU - Milenkovic Petronic, Dragica AU - Milenkovic Petronic D FAU - Sipetic Grujicic, Sandra AU - Sipetic Grujicic S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Cyprus TA - J BUON JT - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JID - 100883428 SB - IM MH - Cystectomy MH - Humans MH - Neoplasm Recurrence, Local/*etiology MH - Nephrectomy MH - Prognosis MH - Risk Factors MH - Urinary Bladder Neoplasms/*etiology/mortality/surgery EDAT- 2015/05/27 06:00 MHDA- 2015/07/24 06:00 CRDT- 2015/05/27 06:00 PHST- 2015/05/27 06:00 [entrez] PHST- 2015/05/27 06:00 [pubmed] PHST- 2015/07/24 06:00 [medline] PST - ppublish SO - J BUON. 2015 Mar-Apr;20(2):391-8. PMID- 26009259 OWN - NLM STAT- MEDLINE DCOM- 20160329 LR - 20221207 IS - 1573-2584 (Electronic) IS - 0301-1623 (Linking) VI - 47 IP - 7 DP - 2015 Jul TI - Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. PG - 1135-41 LID - 10.1007/s11255-015-1013-1 [doi] AB - OBJECTIVE: To evaluate the impact of body mass on recurrence and progression in patients with Ta, T1 urothelial bladder cancer. METHODS: Data from 469 patients with Ta, T1 bladder cancer who were treated with transurethral resection of bladder tumor at our center during 2006-2014 were retrospectively studied. According to body mass index (BMI), patients were divided into three groups: normal weight (BMI < 24 kg/m(2)), overweight (24 kg/m(2) /= 28 kg/m(2)). Clinicopathologic features were compared across groups. Kaplan-Meier curves and Cox proportional hazards regression analyses were employed to assess the association between body mass and oncologic outcomes. RESULTS: Compared with patients with normal weight, overweight and obese counterparts showed significantly shorter recurrence-free or progression-free survival. In multivariate analyses, being overweight was an independent factor for recurrence and obesity was for both recurrence and progression. The presence of diabetes mellitus (DM) was not a strong risk factor for the entire cohort, while it became a significant predictor for both recurrence and progression in the subgroup of overweight and obese patients. CONCLUSION: Excessive body mass seems to act as independent risk factors for worse oncologic outcomes of Ta, T1 bladder cancer. Further studies should be carried out to elucidate the exact impact of obesity, DM or even other metabolic disorders. FAU - Xu, Tianyuan AU - Xu T AD - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, No. 197, 2nd Ruijin Road, Shanghai, 200025, China. FAU - Zhu, Zhaowei AU - Zhu Z FAU - Wang, Xianjin AU - Wang X FAU - Xia, Leilei AU - Xia L FAU - Zhang, Xiaohua AU - Zhang X FAU - Zhong, Shan AU - Zhong S FAU - Sun, Fukang AU - Sun F FAU - Zhu, Yu AU - Zhu Y FAU - Shen, Zhoujun AU - Shen Z LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150526 PL - Netherlands TA - Int Urol Nephrol JT - International urology and nephrology JID - 0262521 SB - IM MH - Aged MH - *Asian People MH - Body Mass Index MH - *Carcinoma, Transitional Cell/epidemiology/pathology/surgery MH - China/epidemiology MH - *Cystectomy/methods/statistics & numerical data MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*pathology MH - Neoplasm Staging MH - *Obesity/diagnosis/epidemiology MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - *Urinary Bladder Neoplasms/epidemiology/pathology/surgery EDAT- 2015/05/27 06:00 MHDA- 2016/03/30 06:00 CRDT- 2015/05/27 06:00 PHST- 2015/03/24 00:00 [received] PHST- 2015/05/13 00:00 [accepted] PHST- 2015/05/27 06:00 [entrez] PHST- 2015/05/27 06:00 [pubmed] PHST- 2016/03/30 06:00 [medline] AID - 10.1007/s11255-015-1013-1 [doi] PST - ppublish SO - Int Urol Nephrol. 2015 Jul;47(7):1135-41. doi: 10.1007/s11255-015-1013-1. Epub 2015 May 26. PMID- 25995755 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150521 LR - 20200930 IS - 1734-1922 (Print) IS - 1896-9151 (Electronic) IS - 1734-1922 (Linking) VI - 11 IP - 2 DP - 2015 Apr 25 TI - Expression of bone morphogenetic protein-2 and -7 in urinary bladder cancer predicts time to tumor recurrence. PG - 378-84 LID - 10.5114/aoms.2014.46796 [doi] AB - INTRODUCTION: Urinary bladder cancer patients who have undergone transurethral resection of bladder tumor (TURBT) are at risk of recurrence. This study aims to correlate the level of bone morphogenetic protein (BMP) expression with urothelial carcinoma invasiveness, TNM stage and time to recurrence after TURBT. MATERIAL AND METHODS: In 33 specimens of healthy transitional epithelium and 42 of urothelial carcinoma, BMP2, BMP4 and BMP7 expression was determined by real-time polymerase chain reaction. Patients who underwent TURBT were followed up for 1 year. RESULTS: BMP2 and BMP7 were downregulated in infiltrating urothelial carcinoma, the relative expression being 0.76 (p = 0.04) and 0.28 (p = 0.025) respectively, while BMP4 was downregulated in non-invasive tumors. High expression of BMP2 and BMP7 correlated with prolonged time to recurrence (log-rank: p = 0.01 and p = 0.03 respectively). CONCLUSIONS: Low expression of BMP2 and BMP7 is associated with shorter time to recurrence. The BMP expression levels are not indicative of tumor stage. FAU - Kuzaka, Boleslaw AU - Kuzaka B AD - Department of General, Oncologic and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Janiak, Marek AU - Janiak M AD - Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland. FAU - Wlodarski, Krzysztof H AU - Wlodarski KH AD - Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland. FAU - Radziszewski, Piotr AU - Radziszewski P AD - Department of General, Oncologic and Functional Urology, Medical University of Warsaw, Warsaw, Poland. FAU - Wlodarski, Pawel K AU - Wlodarski PK AD - Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20150318 PL - Poland TA - Arch Med Sci JT - Archives of medical science : AMS JID - 101258257 PMC - PMC4424243 OTO - NOTNLM OT - bone morphogenetic protein 2 OT - bone morphogenetic protein 4 OT - bone morphogenetic protein 7 OT - urinary tract epithelium OT - urothelial carcinoma EDAT- 2015/05/23 06:00 MHDA- 2015/05/23 06:01 PMCR- 2015/04/25 CRDT- 2015/05/22 06:00 PHST- 2013/04/08 00:00 [received] PHST- 2013/05/14 00:00 [revised] PHST- 2013/08/19 00:00 [accepted] PHST- 2015/05/22 06:00 [entrez] PHST- 2015/05/23 06:00 [pubmed] PHST- 2015/05/23 06:01 [medline] PHST- 2015/04/25 00:00 [pmc-release] AID - 23973 [pii] AID - 10.5114/aoms.2014.46796 [doi] PST - ppublish SO - Arch Med Sci. 2015 Apr 25;11(2):378-84. doi: 10.5114/aoms.2014.46796. Epub 2015 Mar 18. PMID- 25987071 OWN - NLM STAT- MEDLINE DCOM- 20160216 LR - 20220409 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 16 IP - 9 DP - 2015 TI - Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence. PG - 3973-6 AB - OBJECTIVES: To explore the expression of aquaporin 1 (AQP1) in bladder uroepithelium cell carcinoma (BUCC) and its relevance to recurrence. MATERIALS AND METHODS: Tissue samples from 45 BUCC patients who underwent total cystectomy or transurethral resection of bladder tumor (TURBT) and from 40 patients with non-bladder cancers who underwent special detection or treatments were collected. The level of expression of AQP1 in BUCC tissues and normal bladder tissues was assessed by immunohistochemistry so as to analyze the relevance to pathological patterns and time of recurrence in BUCC patients. RESULTS: The expression levels of AQP1 normal bladder tissues and BUCC tissues were 2.175+/-0.693 and 3.689+/-0.701, respectively, and the difference was significant (t=9.99, P<0.0001). Marked increase was noted with BUCC histological grade and pathological stage (P<0.01). Moreover, the expression of AQP1 was evidently higher in cancerous tissues with lymph node metastasis than in those without (P<0.01). With short-term recurrence, the positive cell expression rate of AQP1 was higher in primary tissues, which increased obviously after recurrence. Additionally, the recurrent time of BUCC was negatively associated with the positive cell expression rate of AQP1 and the difference between the expression of AQP1 before and after recurrence (r=-0.843, F=39.302, P=0.000; r=-0.829, F=35.191, P=0.000). CONCLUSIONS: AQP1, which reflects the grade, stage, lymph node metastasis and recurrence of BUCC, has potential guiding significance in the diagnosis and treatment of bladder cancarcinoma. FAU - Liu, Jie AU - Liu J AD - Department of Urology, Henan Provincial People's Hospital, Zhengzhou, China E-mail : dingdgsci@163.com. FAU - Zhang, Wei-Yi AU - Zhang WY FAU - Ding, De-Gang AU - Ding DG LA - eng PT - Journal Article PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (AQP1 protein, human) RN - 0 (Biomarkers, Tumor) RN - 146410-94-8 (Aquaporin 1) SB - IM MH - Adult MH - Aged MH - Aquaporin 1/*metabolism MH - Biomarkers, Tumor/*metabolism MH - Female MH - Follow-Up Studies MH - Humans MH - Immunoenzyme Techniques MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Muscle Neoplasms/*metabolism/secondary MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*metabolism/pathology MH - Neoplasm Staging MH - Prognosis MH - Urinary Bladder Neoplasms/*metabolism/pathology EDAT- 2015/05/20 06:00 MHDA- 2016/02/18 06:00 CRDT- 2015/05/20 06:00 PHST- 2015/05/20 06:00 [entrez] PHST- 2015/05/20 06:00 [pubmed] PHST- 2016/02/18 06:00 [medline] AID - 10.7314/apjcp.2015.16.9.3973 [doi] PST - ppublish SO - Asian Pac J Cancer Prev. 2015;16(9):3973-6. doi: 10.7314/apjcp.2015.16.9.3973. PMID- 25975233 OWN - NLM STAT- MEDLINE DCOM- 20150921 LR - 20220711 IS - 1096-9098 (Electronic) IS - 0022-4790 (Linking) VI - 111 IP - 8 DP - 2015 Jun TI - Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer. PG - 992-9 LID - 10.1002/jso.23937 [doi] AB - BACKGROUND AND OBJECTIVES: We aimed to investigate potential of urinary cell-free microRNA-214 (miR-214) as a noninvasive biomarker for bladder cancer in this report. METHODS: We screened miR-214 expression in medium from 2 bladder cancer cell lines to determine whether it is secretory. Then we validated expression of cell-free miR-214 in urine samples from an independent set of 192 preoperative bladder cancer patients, 80 matching postoperative patients and 169 healthy controls. RESULTS: miR-214 was secreted from bladder cancer cell lines. Cell-free miR-214 levels were significantly attenuated in preoperative urine from bladder cancer patients, whereas its expression significantly increased in matched postoperative urine. Underexpressed extracellular miR-214 in urine was significantly associated with higher tumor stage, higher lymph node status, higher grade, age and history of non-muscle-invasive bladder cancer (NMIBC). Urinary cell-free miR-214 could forcefully differentiate bladder cancer (area under the curve; AUC = 0.838; 95% CI = 0.796-0.875) patients from healthy controls. Additionally, miR-214 in urine supernatant could serve as an independent prognostic predicator of recurrence-free survival (RFS) and overall survival (OS) for patients with muscle-invasive bladder cancer (MIBC). CONCLUSIONS: Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Wang, Jinfeng AU - Wang J AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. AD - Department of Clinical Laboratory, Linyi People's Hospital, Linyi, Shandong Province, China. FAU - Zhang, Xin AU - Zhang X AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Wang, Lili AU - Wang L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Dong, Zhaogang AU - Dong Z AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Du, Lutao AU - Du L AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Yang, Yongmei AU - Yang Y AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Guo, Yuan AU - Guo Y AD - Department of Geriatrics, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Wang, Chuanxin AU - Wang C AD - Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150514 PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN214 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Biomarkers, Tumor/biosynthesis/*urine MH - Cell Line, Tumor/metabolism MH - Down-Regulation MH - Female MH - Humans MH - Male MH - MicroRNAs/biosynthesis/*urine MH - Middle Aged MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/metabolism/*urine OTO - NOTNLM OT - bladder cancer OT - cell-free miR-214 OT - circulating miRNAs OT - non-invasive diagnosis OT - prognostic factor EDAT- 2015/05/16 06:00 MHDA- 2015/09/22 06:00 CRDT- 2015/05/16 06:00 PHST- 2015/01/17 00:00 [received] PHST- 2015/04/27 00:00 [accepted] PHST- 2015/05/16 06:00 [entrez] PHST- 2015/05/16 06:00 [pubmed] PHST- 2015/09/22 06:00 [medline] AID - 10.1002/jso.23937 [doi] PST - ppublish SO - J Surg Oncol. 2015 Jun;111(8):992-9. doi: 10.1002/jso.23937. Epub 2015 May 14. PMID- 25968487 OWN - NLM STAT- MEDLINE DCOM- 20160330 LR - 20150708 IS - 1973-9478 (Electronic) IS - 1120-009X (Linking) VI - 27 IP - 4 DP - 2015 Aug TI - The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. PG - 195-200 LID - 10.1179/1973947815Y.0000000034 [doi] AB - CONTEXT: The standard management of upper urinary tract urothelial carcinoma (UUT-UC) is nephroureterectomy with bladder cuff excision, but after surgery, approximately 22-47% of patients with UUT-UC develop subsequent bladder tumour recurrence, potentially because of the implantation of cancer cells from the primary tumour. OBJECTIVE: To conduct a meta-analysis to evaluate the effect of prophylactic intravesical chemotherapy in the prevention of bladder recurrence after nephroureterectomy for UUT-UC. DATA ACQUISITION: An electronic database search of Medline, Embase, the Cochrane Library, CancerLit and ClinicalTrials.gov was performed to identify appropriate studies prior to March 2013.All studies comparing nephroureterectomy alone with prophylactic intravesical chemotherapy after nephroureterectomy were included. The main outcome measure for this meta-analysis was the rate of bladder recurrence after nephroureterectomy. The search was not limited by language. The review process followed the guidelines of the Cochrane Collaboration. The analysis was conducted using the Review Manager Version RevMan 5.0 software (The Nordic Cochrane Centre, The Cochrane Collaboration). RESULTS: A total of 592 patients were included in this study, of whom 257 underwent intravesical instillation after nephroureterectomy and 335 underwent nephroureterectomy alone. Our meta-analysis demonstrated that the rate of recurrence after 12 months was significantly lower in the intravesical instillation after nephroureterectomy group than in the nephroureterectomy-alone group [odds ratio (OR): 0.48; 95% confidence interval (CI): 0.28-0.81; P = 0.006]. A significant decrease in bladder recurrence after at least 24 months was also observed in the intravesical instillation after nephroureterectomy group (OR: 0.40; 95% CI: 0.24-0.67; P = 0.0004). A subgroup analysis demonstrated that the pattern of differences was similar to those from the total group analysis. CONCLUSIONS: Prophylactic intravesical chemotherapy was effective for the prevention of bladder recurrence after nephroureterectomy. Therefore, we suggest that prophylactic intravesical chemotherapy should be performed in patients with UUT-UC after nephroureterectomy, but the optimal chemotherapy regimen and the initial time of instillation should be explored in future studies. FAU - Yuan, Haichao AU - Yuan H FAU - Mao, Xiangming AU - Mao X FAU - Bai, Yunjin AU - Bai Y FAU - Li, Hengping AU - Li H FAU - Liu, Liangren AU - Liu L FAU - Pu, Chunxiao AU - Pu C FAU - Li, Jinhong AU - Li J FAU - Tang, Yin AU - Tang Y FAU - Wei, Qiang AU - Wei Q FAU - Han, Ping AU - Han P LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20150513 PL - England TA - J Chemother JT - Journal of chemotherapy (Florence, Italy) JID - 8907348 RN - 0 (Antineoplastic Agents) SB - IM CIN - J Urol. 2016 Nov;196(5):1400-1401. doi: 10.1016/j.juro.2016.08.033. PMID: 27751450 MH - Administration, Intravesical MH - Antineoplastic Agents/*administration & dosage MH - Clinical Trials as Topic MH - Humans MH - Neoplasm Recurrence, Local/pathology/*prevention & control MH - Nephrectomy/methods MH - Urinary Bladder Neoplasms/drug therapy/pathology MH - Urologic Neoplasms/*drug therapy/pathology/*surgery OTO - NOTNLM OT - Bladder recurrence, OT - Intravesical chemotherapy, OT - Nephroureterectomy, OT - Upper tract urothelial carcinoma EDAT- 2015/05/15 06:00 MHDA- 2016/03/31 06:00 CRDT- 2015/05/14 06:00 PHST- 2015/05/14 06:00 [entrez] PHST- 2015/05/15 06:00 [pubmed] PHST- 2016/03/31 06:00 [medline] AID - 10.1179/1973947815Y.0000000034 [doi] PST - ppublish SO - J Chemother. 2015 Aug;27(4):195-200. doi: 10.1179/1973947815Y.0000000034. Epub 2015 May 13. PMID- 25959052 OWN - NLM STAT- MEDLINE DCOM- 20160512 LR - 20181202 IS - 1879-4076 (Electronic) IS - 1879-4068 (Linking) VI - 6 IP - 4 DP - 2015 Jul TI - Long-term results of a concomitant boost radiotherapy technique for elderly patients with muscle-invasive bladder cancer. PG - 316-23 LID - S1879-4068(15)00033-8 [pii] LID - 10.1016/j.jgo.2015.04.004 [doi] AB - OBJECTIVES: To evaluate the long-term clinical efficacy and toxicity of concomitant boost radiotherapy (CBRT) in elderly patients with invasive bladder cancer. METHODS AND MATERIALS: Elderly patients (n=188; mean 75-year-old, range 70-91 years; 88.3% male/11.7% female) with T1-T4a bladder carcinoma were irradiated with CBRT. A total of 24 (12.8%) patients were diagnosed at stage T1, 117 (62.2%) were at stage T2, 28 (14.9%) at were stage T3a, 14 (7.4%) were stage T3b, and 5 (2.7%) were stage T4a. A dose of 45Gy in 1.8Gy fractions was administered to the whole pelvis 5 days/week over 5 weeks. A concomitant boost limited to the bladder tumor area plus margin or whole bladder of 22.5Gy in 1.5Gy fractions was administered from weeks 3x5. Thus, irradiation totalled 67.5Gy over 5 weeks. The interfraction interval was >/=6h/treatment day. We assessed prognostic factors for overall survival (OS), cause-specific survival (CSS) and relapse-free survival (RFS). RESULTS: Median follow-up was 46.2 months (range 4.7-155.7 months). Median overall survival was 27 months (95% CI:21-33 months). In this study, 146 (77.7%) patients had complete response, 39 (20.7%) had residual disease and 4 (1.6%) had progressive disease. The mean 3-, 5- and 10-year OS rates were respectively 41.2% (S.E.+/-0.036), 29% (S.E.+/-0.034), and 13.8% (S.E.+/-0.031). Significant prognostic factors for OS and CSS, by multivariate analysis, were tumor T-stage and urothelial obstruction. CONCLUSION: This CBRT protocol provided excellent results with a high complete response rate and good tolerance. This approach may therefore be particularly appropriate for elderly patients with invasive bladder cancer. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Canyilmaz, Emine AU - Canyilmaz E AD - Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. Electronic address: dremocan@ktu.edu.tr. FAU - Yoney, Adnan AU - Yoney A AD - Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. Electronic address: adnan@yoney.net. FAU - Serdar, Lasif AU - Serdar L AD - Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. Electronic address: ercan_serdar@hotmail.com. FAU - Uslu, Gonca Hanedan AU - Uslu GH AD - Department of Radiation Oncology, Kanuni Research and Education Hospital, Trabzon, Turkey. Electronic address: drgoncahanedanuslu@hotmail.com. FAU - Aynaci, Ozlem AU - Aynaci O AD - Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. Electronic address: ozlemaynaci@gmail.com. FAU - Haciislamoglu, Emel AU - Haciislamoglu E AD - Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. Electronic address: fizemelcim@hotmail.com. FAU - Yavuz, Melek Nur AU - Yavuz MN AD - Department of Radiation Oncology, Faculty of Medicine, Akdeniz University, Antalya,Turkey. Electronic address: meleknur68@yahoo.com.tr. LA - eng PT - Journal Article DEP - 20150508 PL - Netherlands TA - J Geriatr Oncol JT - Journal of geriatric oncology JID - 101534770 SB - IM EIN - J Geriatr Oncol. 2017 Mar;8(2):148. doi: 10.1016/j.jgo.2017.01.006. PMID: 28216387 MH - Aged MH - Aged, 80 and over MH - Disease-Free Survival MH - Dose Fractionation, Radiation MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Neoplasm Invasiveness MH - Remission Induction MH - Retrospective Studies MH - Treatment Outcome MH - Urinary Bladder Neoplasms/*pathology/*radiotherapy OTO - NOTNLM OT - Bladder cancer OT - Concomitant boost OT - Elderly patients OT - Radiotherapy EDAT- 2015/05/12 06:00 MHDA- 2016/05/14 06:00 CRDT- 2015/05/12 06:00 PHST- 2015/01/21 00:00 [received] PHST- 2015/03/25 00:00 [revised] PHST- 2015/04/21 00:00 [accepted] PHST- 2015/05/12 06:00 [entrez] PHST- 2015/05/12 06:00 [pubmed] PHST- 2016/05/14 06:00 [medline] AID - S1879-4068(15)00033-8 [pii] AID - 10.1016/j.jgo.2015.04.004 [doi] PST - ppublish SO - J Geriatr Oncol. 2015 Jul;6(4):316-23. doi: 10.1016/j.jgo.2015.04.004. Epub 2015 May 8. PMID- 25947885 OWN - NLM STAT- MEDLINE DCOM- 20160919 LR - 20260518 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 33 IP - 12 DP - 2015 Dec TI - Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. PG - 1945-50 LID - 10.1007/s00345-015-1572-x [doi] AB - Radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) is associated with heterogeneous functional and oncological outcomes. The aim of this study was to generate trifecta and pentafecta criteria to optimize outcome reporting after RC. METHODS: We interviewed 50 experts to consider a virtual group of patients (age /= 20%) was independently associated with better cancer-specific survival (CSS) (5-year CSS rate, 78% vs. 46% for low Ki-67 LI; P = .019). The difference in CSS according to Ki-67 expression status was more remarkable in patients with cT3 disease (5-year CSS rate, 72% vs. 29%; P = .0098). CONCLUSION: High Ki-67 expression predicts favorable CSS in MIBC patients treated with CRT-based bladder-sparing protocol. MIBC patients with high Ki-67 expression status might benefit from CRT-based multimodal approaches in terms of prognosis and quality of life as a result of bladder preservation. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Tanabe, Kenji AU - Tanabe K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Yoshida, Soichiro AU - Yoshida S AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. Electronic address: s-yoshida.uro@tmd.ac.jp. FAU - Koga, Fumitaka AU - Koga F AD - Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. FAU - Inoue, Masaharu AU - Inoue M AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Kobayashi, Shuichiro AU - Kobayashi S AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Ishioka, Junichiro AU - Ishioka J AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Tamura, Tomoki AU - Tamura T AD - Department of Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Sugawara, Emiko AU - Sugawara E AD - Department of Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Saito, Kazutaka AU - Saito K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Akashi, Takumi AU - Akashi T AD - Department of Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Fujii, Yasuhisa AU - Fujii Y AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Kihara, Kazunori AU - Kihara K AD - Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20150327 PL - United States TA - Clin Genitourin Cancer JT - Clinical genitourinary cancer JID - 101260955 RN - 0 (Antineoplastic Agents) RN - 0 (Ki-67 Antigen) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage/therapeutic use MH - Chemoradiotherapy/methods MH - Cisplatin/*administration & dosage/therapeutic use MH - Cystectomy/*methods MH - Female MH - Humans MH - Ki-67 Antigen/*metabolism MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Organ Sparing Treatments/*methods MH - Survival Analysis MH - Treatment Outcome MH - Urinary Bladder Neoplasms/metabolism/surgery/*therapy OTO - NOTNLM OT - Chemoradiotherapy OT - Ki-67 antigen OT - Organ preservation OT - Prognosis OT - Urinary bladder neoplasms EDAT- 2015/05/06 06:00 MHDA- 2016/05/04 06:00 CRDT- 2015/05/05 06:00 PHST- 2014/12/20 00:00 [received] PHST- 2015/03/09 00:00 [revised] PHST- 2015/03/18 00:00 [accepted] PHST- 2015/05/05 06:00 [entrez] PHST- 2015/05/06 06:00 [pubmed] PHST- 2016/05/04 06:00 [medline] AID - S1558-7673(15)00067-1 [pii] AID - 10.1016/j.clgc.2015.03.002 [doi] PST - ppublish SO - Clin Genitourin Cancer. 2015 Aug;13(4):e243-e251. doi: 10.1016/j.clgc.2015.03.002. Epub 2015 Mar 27. PMID- 25934521 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20250711 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 95 IP - 3 DP - 2015 Sep TI - Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. PG - 387-96 LID - S1040-8428(15)00072-4 [pii] LID - 10.1016/j.critrevonc.2015.04.006 [doi] AB - BACKGROUND: Radical cystectomy (RC) represents the mainstay of treatment in patients with muscle-invasive urinary bladder cancer but how it compares with the best organ preservation approach is not known. MATERIALS AND METHODS: The objective of our review is to compare the 5-year overall survival (OS) rates from retrospective and prospective studies of RC and trimodality treatment (TMT), i.e. concurrent delivery of chemotherapy and radiotherapy after a transurethral resection of bladder tumor (TURBT), involving a total of 10,265 and 3131 patients, respectively. We used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for TMT and RC using an interaction test. RESULTS: The median 5-year OS rate was 57% in the TMT group, when compared with 52% (P=0.04), 51% (P=0.02) and 53% (P=0.38) in the whole group receiving RC or the group treated with RC alone or RC+chemotherapy, respectively. The hazard risk (HR) of mortality of patients treated with TMT or RC was 1.22 (95% CI=1.13-1.32) with an absolute benefit of 5% in favor of the former. The HR of mortality from TMT persisted significantly better not only versus the group treated with RC alone (HR=1.22; 95% CI=1.12-1.32), but also versus the group receiving RC+chemotherapy (HR=1.22; 95% CI=1.09-1.36). Multivariate analysis confirmed TMT as a significant prognostic variable for both RC alone and RC+chemotherapy. CONCLUSION: Compared with RC, TMT seems to be associated with a better outcome for patients with muscle-invasive bladder cancer (MIBC). The addition of chemotherapy may improve the RC outcome in some subgroups of patients with a higher probability of micrometastases. Prospective randomized trials are urged to verify these findings and better define the role of organ preservation and radical treatment strategy in the management of patients with MIBC. CI - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved. FAU - Arcangeli, G AU - Arcangeli G AD - Medical Physics and Expert Systems Laboratory, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. FAU - Strigari, L AU - Strigari L AD - Medical Physics and Expert Systems Laboratory, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. Electronic address: strigari@ifo.it. FAU - Arcangeli, S AU - Arcangeli S AD - Radiotherapy Department, Azienda Ospedaliera S. Camillo-Forlanini , Rome, Italy. LA - eng PT - Comparative Study PT - Journal Article PT - Systematic Review DEP - 20150417 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 SB - IM MH - *Cystectomy MH - Humans MH - Neoplasm Invasiveness MH - *Organ Sparing Treatments MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/pathology/*therapy OTO - NOTNLM OT - Bladder-sparing OT - Chemoradiation OT - Muscle-invasive bladder cancer OT - Radical cystectomy OT - Trimodality treatment EDAT- 2015/05/03 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/05/03 06:00 PHST- 2014/11/18 00:00 [received] PHST- 2015/03/23 00:00 [revised] PHST- 2015/04/07 00:00 [accepted] PHST- 2015/05/03 06:00 [entrez] PHST- 2015/05/03 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - S1040-8428(15)00072-4 [pii] AID - 10.1016/j.critrevonc.2015.04.006 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2015 Sep;95(3):387-96. doi: 10.1016/j.critrevonc.2015.04.006. Epub 2015 Apr 17. PMID- 25929352 OWN - NLM STAT- MEDLINE DCOM- 20151214 LR - 20150912 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 39 IP - 10 DP - 2015 Oct TI - Epithelioid Angiosarcoma of the Bladder: A Series of 9 Cases. PG - 1377-82 LID - 10.1097/PAS.0000000000000444 [doi] AB - Primary angiosarcoma of the bladder is very rare, with approximately 30 cases reported in the literature. Those with epithelioid morphology are even rarer, with only single-case reports published. We describe the histopathologic features and clinical follow-up of 9 patients with epithelioid angiosarcoma (EA) of the bladder retrieved from our Surgical Pathology files from 1998 to 2014. Eight cases were consults. The mean age at presentation was 65 years (range, 39 to 85 y). The M:F ratio was 8:1. The clinical presentation was hematuria and bladder mass in all cases. Six patients had a history of radiotherapy to the pelvis, 5 to treat prostate cancer and 1 to treat uterine cervical cancer. The time from radiotherapy to the diagnosis of EA ranged from 6 to 15 years. The average size of the tumor was 4 cm. (range, 1 to 8 cm.). The submitting diagnoses were poorly differentiated carcinoma (n=5), high-grade invasive urothelial carcinoma (n=3), and atypical vascular proliferation (n=1). Morphologically, the tumors were composed of nests and sheets of highly atypical cells with high nuclear to cytoplasmic ratio, occasional intracytoplasmic lumens, and a hemorrhagic background. None of the cases showed any urothelial carcinoma component. Three patients showed in addition usual angiosarcoma in the resection specimen. By immunohistochemistry, 5/9 cases were positive for cytokeratins, including CK7 (n=3), AE1/AE3 (n=3), and Cam5.2 (n=1). All cases were positive for at least 1 endothelial marker, including CD31 (n=7), CD34 (n=2), FVIII (n=3), and ERG (n=2). Urothelial markers (p63 and GATA3) were consistently negative. Surgical treatment included transurethral resection of the bladder (TURB) only (n=5), TURB followed by cystoprostatectomy (n=2), TURB followed by partial cystectomy (n=1), and cystoprostatectomy only (n=1). The tumor involved the muscularis propria in 5/9 patients, the periureteric adipose tissue in 1 patient, and the prostate and seminal vesicles in 1 patient. Five of 9 patients died of disease, with a median survival of 7 months (range, 6 to 14 mo). Two patients were alive with disease at 3 and 6 months of follow-up. One patient who underwent radical cystoprostatectomy was alive with no evidence of disease 12 months after surgery. EA of the bladder is a rare malignancy that is frequently misdiagnosed as high-grade carcinoma, especially due to positive immunostaining for cytokeratins. This tumor is more frequent in older men with a history of radiotherapy to the pelvis. Morphologic features that should suggest the vascular origin of the tumor include highly atypical nuclei with interspersed erythrocytes, hemorrhagic background, and occasional intracytoplasmic lumens. Patients usually present with muscle invasive disease, and the prognosis is dismal. FAU - Matoso, Andres AU - Matoso A AD - Departments of *Pathology daggerOncology double daggerUrology, The Johns Hopkins Hospital, Baltimore, MD. FAU - Epstein, Jonathan I AU - Epstein JI LA - eng PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/analysis MH - Diagnosis, Differential MH - *Epithelioid Cells/chemistry/metabolism MH - Female MH - *Hemangiosarcoma/chemistry/mortality/pathology/therapy MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Risk Factors MH - Treatment Outcome MH - *Urinary Bladder Neoplasms/chemistry/mortality/pathology/therapy EDAT- 2015/05/02 06:00 MHDA- 2015/12/15 06:00 CRDT- 2015/05/02 06:00 PHST- 2015/05/02 06:00 [entrez] PHST- 2015/05/02 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] AID - 10.1097/PAS.0000000000000444 [doi] PST - ppublish SO - Am J Surg Pathol. 2015 Oct;39(10):1377-82. doi: 10.1097/PAS.0000000000000444. PMID- 25928508 OWN - NLM STAT- MEDLINE DCOM- 20150827 LR - 20240524 IS - 1677-6119 (Electronic) IS - 1677-5538 (Print) IS - 1677-5538 (Linking) VI - 41 IP - 1 DP - 2015 Jan-Feb TI - Risk groups in bladder cancer patients treated with radical cystectomy. PG - 30-9 LID - 10.1590/S1677-5538.IBJU.2015.01.06 [doi] AB - OBJECTIVE: To stratify patients with bladder cancer into homogeneous risk groups according to statistically significant differences found in PFS (progression-free survival). To identify those patients at increased risk of progression and to provide oncological follow-up according to patient risk group. MATERIALS AND METHODS: A retrospective study of 563 patients treated with radical cystectomy (RC). In order to determine which factors might predict bladder tumour progression and death, uni- and multivariate analyses were performed. The risk groups were identified according to "inter-category" differences found in PFS and lack of differences, thus revealing intra-category homogeneity. RESULTS: Median follow up time was 37.8 months. Recurrence occurred in a total of 219 patients (38, 9 %). In 63 % of cases this was distant recurrence. Only two variables retained independent prognostic value in the multivariate analysis for PFS: pathological organ confinement and lymph node involvement. By combining these two variables, we created a new ''risk group '' variable. In this second model it was found that the new variable behaved as an independent predictor associated with PFS. Four risk groups were identified: very low, low, intermediate and high risk: * Very low risk: pT0 N0 * Low risk: pTa, pTis, pT1, pT2 and pN0 * Intermediate risk: pT3 and pN0 * High risk: pT4 N0 or pN1-3. CONCLUSIONS: We retrospectively identified 4 risk groups with an independent prognostic value for progression-free survival following RC. Differences in recurrence patterns after RC between risk groups have led us to set different intervals in monitoring for cancer. FAU - Mallen, Eva AU - Mallen E AD - Department of Urology, Hospital Royo Villanova, Zaragoza, Spain. FAU - Gil, Pedro AU - Gil P AD - Deparment of Urology Hospital Miguel Servet, Zaragoza, Spain. FAU - Gil, Maria Jesus AU - Gil MJ AD - Deparment of Urology Hospital Miguel Servet, Zaragoza, Spain. LA - eng PT - Journal Article PL - Brazil TA - Int Braz J Urol JT - International braz j urol : official journal of the Brazilian Society of Urology JID - 101158091 SB - IM MH - Aged MH - Carcinoma/*mortality/pathology/*surgery MH - Cystectomy/*methods MH - Disease Progression MH - Disease-Free Survival MH - Epidemiologic Methods MH - Female MH - Humans MH - Lymphatic Metastasis/pathology MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Risk Assessment/*methods MH - Time Factors MH - Urinary Bladder Neoplasms/*mortality/pathology/*surgery PMC - PMC4752054 COIS- CONFLICT OF INTEREST None declared. EDAT- 2015/05/01 06:00 MHDA- 2015/08/28 06:00 PMCR- 2015/01/01 CRDT- 2015/05/01 06:00 PHST- 2014/01/26 00:00 [received] PHST- 2014/02/02 00:00 [accepted] PHST- 2015/05/01 06:00 [entrez] PHST- 2015/05/01 06:00 [pubmed] PHST- 2015/08/28 06:00 [medline] PHST- 2015/01/01 00:00 [pmc-release] AID - IBJUv41n1a5 [pii] AID - S1677-5538.IBJU.2015.01.06 [pii] AID - 10.1590/S1677-5538.IBJU.2015.01.06 [doi] PST - ppublish SO - Int Braz J Urol. 2015 Jan-Feb;41(1):30-9. doi: 10.1590/S1677-5538.IBJU.2015.01.06. PMID- 25924623 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20161230 IS - 1423-0399 (Electronic) IS - 0042-1138 (Linking) VI - 96 IP - 1 DP - 2016 TI - Is Immediate Radical Cystectomy Necessary for All Patients with Non-Muscle-Invasive Micropapillary Bladder Cancer? PG - 32-8 LID - 10.1159/000375411 [doi] AB - INTRODUCTION: We aim to review the outcomes of micropapillary urothelial carcinoma (MPUC) of the bladder from a single institution. The hypothesis is that non-muscle-invasive (NMI) MPUC may have a heterogeneous prognosis, and detailed pathological analysis may identify patients that could be managed without immediate cystectomy. PATIENTS AND METHODS: This is a retrospective analysis of patients presenting with MPUC in a primary transurethral resection specimen (n = 40). The pattern of micropapillary (MP) differentiation [surface/non-invasive (sMP) or invasive (iMP)], extent of MP differentiation and lymphovascular invasion (LVI) were correlated with overall survival (OS), recurrence-free survival and upstaging at re-resection. RESULTS: Sixteen of 40 patients died after a median follow-up of 37 months. Tumour stage was strongly predictive of OS (p < 0.0001). LVI was associated with increased mortality (hazard ratio 12.4, 95% CI: 3.5-44.5, p = 0.0001), higher pathological stage (p = 0.001), lymph node involvement (p = 0.001) and iMP differentiation (p = 0.006). In NMI patients not undergoing cystectomy (n = 17), NMI-sMP compared with NMI-iMP differentiation was associated with an improved OS when compared with iMP (63 vs. 47 months, p = 0.05). CONCLUSIONS: MPUC is an aggressive variant of urothelial carcinoma (UC). Similar to conventional UC, LVI associated with MPUC is an adverse prognostic indicator. iMP is a morphological marker for LVI. Histopathological reports should distinguish between sMP and iMP differentiation. CI - (c) 2015 S. Karger AG, Basel. FAU - Jackson, Benjamin L AU - Jackson BL AD - Department of Urology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK. FAU - Mohammed, Aza AU - Mohammed A FAU - Mayer, Nick AU - Mayer N FAU - Dormer, John AU - Dormer J FAU - Griffiths, T R Leyshon AU - Griffiths TR LA - eng PT - Journal Article DEP - 20150429 PL - Switzerland TA - Urol Int JT - Urologia internationalis JID - 0417373 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Transitional Cell/mortality/pathology/*surgery MH - Cell Differentiation MH - Cystectomy/*methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Surgical Oncology/methods MH - Time Factors MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery MH - Urothelium/pathology EDAT- 2015/05/01 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/05/01 06:00 PHST- 2014/10/23 00:00 [received] PHST- 2015/01/20 00:00 [accepted] PHST- 2015/05/01 06:00 [entrez] PHST- 2015/05/01 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 000375411 [pii] AID - 10.1159/000375411 [doi] PST - ppublish SO - Urol Int. 2016;96(1):32-8. doi: 10.1159/000375411. Epub 2015 Apr 29. PMID- 25921278 OWN - NLM STAT- MEDLINE DCOM- 20160915 LR - 20171116 IS - 2168-1813 (Electronic) IS - 2168-1805 (Linking) VI - 49 IP - 5 DP - 2015 TI - Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. PG - 382-7 LID - 10.3109/21681805.2015.1040449 [doi] AB - OBJECTIVE: The aim of this study was evaluate the incidence and significance of immunohistochemically assessed lymphatic (LVI) and blood vessel invasion (BVI) in primary T1 urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). MATERIALS AND METHODS: Thirty-two patients with T1 UCB at primary diagnosis were identified who underwent radical cystectomy (RC) subsequently. Of these, 16 (50%) had pT1N0M0 (group I) and 16 (50%) >/= pT2aN0-3M0 UCB (group II) at RC. The presence of LVI and BVI in transurethral resection of bladder tumor (TURBT) and corresponding RC specimens was assessed using hematoxylin & eosin (H&E) and immunohistochemical (IHC) staining against the lymphatic (D2-40) and vascular endothelium (CD31). RESULTS: At TURBT and RC, none of the patients in group I showed LVI or BVI on H&E and IHC sections. In group II, at TURBT, LVI and BVI were negative on H&E staining in all patients, but detectable by IHC in two patients (13%) and one patient (6%), respectively (p = 0.48 and p = 0.99 compared to group I). At RC, LVI and BVI were detected by IHC in eight (50%) and five (31%) of the 16 patients, respectively (p = 0.002 and p = 0.021 compared to group I). Of these eight and five patients, detection of LVI and BVI was only possible with IHC in six (75%) and three (60%), respectively. CONCLUSIONS: Although this hypothesis-generating study did not show a high degree of concordance between TURBT and RC specimens, IHC assessment on a regular basis may increase the detection rates of LVI and BVI at initial diagnosis and improve the selection of those T1 patients who should be offered early radical treatment. FAU - Gakis, Georgios AU - Gakis G AD - a 1 Department of Urology, University Hospital Tubingen , Tubingen, Germany. FAU - Todenhofer, Tilman AU - Todenhofer T AD - a 1 Department of Urology, University Hospital Tubingen , Tubingen, Germany. FAU - Braun, Martin AU - Braun M AD - b 2 Institute of Pathology, Department of Prostate Cancer Research , Bonn, Germany , and. FAU - Fend, Falko AU - Fend F AD - c 3 Institute of Pathology, Eberhard-Karls University , Tubingen, Germany. FAU - Stenzl, Arnulf AU - Stenzl A AD - a 1 Department of Urology, University Hospital Tubingen , Tubingen, Germany. FAU - Perner, Sven AU - Perner S AD - b 2 Institute of Pathology, Department of Prostate Cancer Research , Bonn, Germany , and. LA - eng PT - Journal Article DEP - 20150428 PL - Sweden TA - Scand J Urol JT - Scandinavian journal of urology JID - 101587186 RN - 0 (Antibodies, Monoclonal, Murine-Derived) RN - 0 (Biomarkers, Tumor) RN - 0 (Platelet Endothelial Cell Adhesion Molecule-1) RN - 0 (monoclonal antibody D2-40) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Monoclonal, Murine-Derived/*metabolism MH - Biomarkers, Tumor/metabolism MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Cystectomy MH - Female MH - Humans MH - Immunohistochemistry/methods MH - Incidence MH - Lymphatic Vessels/metabolism/*pathology MH - Male MH - Middle Aged MH - Neoplasm Invasiveness/*pathology MH - Neovascularization, Pathologic/*diagnosis/metabolism MH - Platelet Endothelial Cell Adhesion Molecule-1/metabolism MH - Prognosis MH - Urinary Bladder/*blood supply MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Blood vessel invasion OT - T1 OT - high risk OT - immunohistochemistry OT - lymphatic vessel invasion OT - lymphovascular invasion OT - radical cystectomy OT - transurethral resection of bladder tumor OT - urothelial carcinoma of the bladder EDAT- 2015/04/30 06:00 MHDA- 2016/09/16 06:00 CRDT- 2015/04/30 06:00 PHST- 2015/04/30 06:00 [entrez] PHST- 2015/04/30 06:00 [pubmed] PHST- 2016/09/16 06:00 [medline] AID - 10.3109/21681805.2015.1040449 [doi] PST - ppublish SO - Scand J Urol. 2015;49(5):382-7. doi: 10.3109/21681805.2015.1040449. Epub 2015 Apr 28. PMID- 25921126 OWN - NLM STAT- MEDLINE DCOM- 20160204 LR - 20190606 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 16 IP - 8 DP - 2015 TI - Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer. PG - 3241-5 AB - PURPOSE: To examine the effectiveness of mitomycin-C and chemo-hyperthermia in combination for patients with high-risk non-muscle-invasive bladder cancer. MATERIALS AND METHODS: Between November 2011-September 2013, 43 patients with high-risk non-muscle-invasive bladder cancer undergoing adjuvant chemo-hyperthermia in two centers were evaluated retrospectively. Treatment consisted of 6 weekly sessions, followed by 6 sessions. Recurrence and progression rate, recurrence-free interval and side effects were examined. Analyzed factors included age, gender, smoking status, AB0 blood group, body mass index, T stage and grade, concominant CIS assets. The associations between predictors and recurrence were assessed using multivariate Cox proportional hazard analyses. RESULTS: A total of 40 patients completed induction therapy. Thirteen (32.5%) were diagnosed with tumor recurrence. Median follow-up was 30 months (range 9-39). Median recurrence-free survival was 23 months (range 6-36). The Kaplan-Meier-estimated recurrence-free rates for the entire group at 12 and 24 months were 82% and 61%. There was no statistically significant difference between patient subgroups. Cox hazard analyses showed that an A blood type (OR=6.23, p=0.031) was an independent predictor of recurrence- free. Adverse effects were seen in 53% of patients and these were frequently grades 1 and 2. CONCLUSIONS: Intravesical therapy with combination of mitomycin-C and chemohyperthermia seems to be appropriate in high-risk patients with non-muscle-invasive bladder cancer who cannot tolerate or have contraindications for standard BCG therapy. FAU - Ekin, Rahmi Gokhan AU - Ekin RG AD - Department of Urology, Tepecik Teaching and Research Hospital, Izmir, Turkey E-mail : gokhanekin@gmail.com. FAU - Akarken, Ilker AU - Akarken I FAU - Cakmak, Ozgur AU - Cakmak O FAU - Tarhan, Huseyin AU - Tarhan H FAU - Celik, Orcun AU - Celik O FAU - Ilbey, Yusuf Ozlem AU - Ilbey YO FAU - Divrik, Rauf Taner AU - Divrik RT FAU - Zorlu, Ferruh AU - Zorlu F LA - eng PT - Clinical Study PT - Journal Article PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (ABO Blood-Group System) RN - 0 (Antibiotics, Antineoplastic) RN - 50SG953SK6 (Mitomycin) SB - IM MH - *ABO Blood-Group System MH - Administration, Intravesical MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/*therapeutic use MH - Carcinoma, Transitional Cell/blood/epidemiology/*therapy MH - Chemotherapy, Adjuvant MH - Cohort Studies MH - Disease-Free Survival MH - Female MH - Humans MH - Hyperthermia, Induced/*methods MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Mitomycin/*therapeutic use MH - Multivariate Analysis MH - Proportional Hazards Models MH - Retrospective Studies MH - Smoking/epidemiology MH - Treatment Outcome MH - Urinary Bladder Neoplasms/blood/epidemiology/*therapy EDAT- 2015/04/30 06:00 MHDA- 2016/02/05 06:00 CRDT- 2015/04/30 06:00 PHST- 2015/04/30 06:00 [entrez] PHST- 2015/04/30 06:00 [pubmed] PHST- 2016/02/05 06:00 [medline] AID - 10.7314/apjcp.2015.16.8.3241 [doi] PST - ppublish SO - Asian Pac J Cancer Prev. 2015;16(8):3241-5. doi: 10.7314/apjcp.2015.16.8.3241. PMID- 25916218 OWN - NLM STAT- MEDLINE DCOM- 20170911 LR - 20170911 IS - 1827-1758 (Electronic) IS - 0393-2249 (Linking) VI - 68 IP - 2 DP - 2016 Apr TI - First and second transurethral resections in intermediate-high risk bladder cancer: impact of the surgeon's volume on the recurrence and progression of primary bladder cancer. PG - 194-203 AB - BACKGROUND: We evaluated the impact of surgeon's volume on recurrence and progression in patients with newly diagnosed transitional cell carcinoma of the bladder after first transurethral resection (TUR) and second-TUR. METHODS: Between March 2005 and December 2012, 209 patients with intermediate-high risk primary bladder cancer who received second TUR within 2 to 6 weeks following the initial resection were prospectively included in a database and retrospectively analyzed. Surgeons were strati fi ed into high-volume (>100 TUR) and low-volume (<100 TUR). Tumor recurrence and progression were analyzed respect to first and second-TUR and surgeon-volume. RESULTS: Of the 209 patients who underwent second-TUR, 57 (27.2%) had macroscopic tumors before resection, which correlated to tumors multiplicity. Stage and surgeon category were independent predictors of tumor recurrence, with a 5-year recurrence-free survival rate of 52.7% and 23.1% for high and low-volume surgeon, respectively (P<0.001). Stage and surgeon category at first and second-TUR were independent predictor of tumor progression, with a 5-year progression-free survival rate of 83.8% and 48.0% for high and low-volume surgeon, respectively (P<0.001). CONCLUSIONS: As for other major urological procedures, patients undergoing TUR performed by high volume surgeon may have better outcomes than patients operated by low-volume providers. FAU - Del Zingaro, Michele AU - Del Zingaro M AD - Department of Urology, University of Perugia, Sant'Andrea delle Fratte, Perugia, Italy - luigi.mearini@tin.it. FAU - Bruno, Raffaella AU - Bruno R FAU - Nunzi, Elisabetta AU - Nunzi E FAU - Porena, Massimo AU - Porena M FAU - Mearini, Luigi AU - Mearini L LA - eng PT - Journal Article DEP - 20150428 PL - Italy TA - Minerva Urol Nefrol JT - Minerva urologica e nefrologica = The Italian journal of urology and nephrology JID - 8503649 SB - IM MH - Aged MH - Aged, 80 and over MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Surgeons MH - Treatment Outcome MH - Urethra/surgery MH - Urinary Bladder Neoplasms/*surgery MH - Urologic Surgical Procedures/*methods EDAT- 2015/04/29 06:00 MHDA- 2017/09/12 06:00 CRDT- 2015/04/29 06:00 PHST- 2015/04/29 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2017/09/12 06:00 [medline] AID - R19Y9999N00A150018 [pii] PST - ppublish SO - Minerva Urol Nefrol. 2016 Apr;68(2):194-203. Epub 2015 Apr 28. PMID- 25915404 OWN - NLM STAT- MEDLINE DCOM- 20160209 LR - 20191210 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 4 DP - 2015 TI - Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PG - e0125405 LID - 10.1371/journal.pone.0125405 [doi] LID - e0125405 AB - High-grade (HG) bladder cancers (BCs) are genetically unstable and have an unpredictable course. The identification of prognostic factors in HG non-muscle invasive BC (NMIBC) is crucial for improving patients' quality of life and preventing BC-specific mortality. Here, we used an antibody microarray (AbM) to identify novel candidate biomarkers in primary HG NMIBC and validated the prognostic significance of the candidate biomarkers. Three pairs of tissue samples from primary HG NMIBC and normal urothelium were analyzed using an AbM kit containing 656 antibodies, and differentially expressed proteins were identified. Among the 42 upregulated and 14 downregulated proteins with statistical significance in BC tissues, CREB-binding protein and CD81 were selected as representative upregulated and downregulated candidate biomarkers, respectively. We then validated the expression of these candidate biomarkers in primary human urothelial cells and BC cell lines by western blotting and immunofluorescence assays, and the results were consistent with the AbM expression profiles. Additionally, Kaplan-Meier survival using immunohistochemical data from an independent primary HG NMIBC cohort comprising 113 patients showed that expression of the 2 biomarkers was significantly associated with recurrence-free and progression-free survival. In multivariate analysis, the 2 biomarkers remained significant predictors for recurrence-free survival. Taken together, our findings suggest that expression of CREB-binding protein and CD81 in BC tissue specimens may have prognostic value in patients with primary HG NMIBC. FAU - Lee, Myung-Shin AU - Lee MS AD - Department of Microbiology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Kim, Joo Heon AU - Kim JH AD - Department of Pathology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Lee, Ji-Su AU - Lee JS AD - Department of Microbiology, Eulji University School of Medicine, Daejeon, South Korea. FAU - Yun, Seok Joong AU - Yun SJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Kim, Wun-Jae AU - Kim WJ AD - Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea. FAU - Ahn, Hanjong AU - Ahn H AD - Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Park, Jinsung AU - Park J AD - Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, South Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20150427 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Biomarkers) RN - 0 (CD81 protein, human) RN - 0 (Tetraspanin 28) RN - EC 2.3.1.48 (CREB-Binding Protein) SB - IM MH - Biomarkers/metabolism MH - CREB-Binding Protein/*metabolism MH - Cells, Cultured MH - Disease Progression MH - Female MH - Humans MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Male MH - Microarray Analysis/methods MH - Neoplasm Invasiveness/pathology MH - Prognosis MH - Tetraspanin 28/*metabolism MH - Urinary Bladder Neoplasms/*diagnosis/metabolism/pathology PMC - PMC4411067 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/04/29 06:00 MHDA- 2016/02/10 06:00 PMCR- 2015/04/27 CRDT- 2015/04/28 06:00 PHST- 2015/01/16 00:00 [received] PHST- 2015/03/23 00:00 [accepted] PHST- 2015/04/28 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2016/02/10 06:00 [medline] PHST- 2015/04/27 00:00 [pmc-release] AID - PONE-D-15-02145 [pii] AID - 10.1371/journal.pone.0125405 [doi] PST - epublish SO - PLoS One. 2015 Apr 27;10(4):e0125405. doi: 10.1371/journal.pone.0125405. eCollection 2015. PMID- 25914835 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150427 LR - 20201001 IS - 2080-4806 (Print) IS - 2080-4873 (Electronic) IS - 2080-4806 (Linking) VI - 68 IP - 1 DP - 2015 TI - Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder. PG - 30-6 LID - 10.5173/ceju.2015.01.465 [doi] AB - INTRODUCTION: Our aim is to evaluate the influence of clinical and histopathological parameters, including age, gender, tumor stage, grade, tumor differentiation, necrosis, lymphovascular/perineural invasion (LVI/PNI) and concomitant carcinoma in situ (CIS), on outcomes of patients with urothelial carcinoma of the bladder (UCB). MATERIAL AND METHODS: A total of 84 patients who underwent radical cystectomy (RC) (n = 11) and radical cystoprostatectomy (n = 73) for muscle-invasive bladder cancer at our hospital between 2007-2013, were included in the study. RESULTS: The mean age of patients at diagnosis was 66.1, of whom 75 were males and 9 were females. Of the 84 patients, 38 were 65 years. Mean tumor diameter was 3.66 cm. There were 38 cases which showed divergent differentiations. Concomitant CIS was observed in 30 tumors, 41 cases showed tumor necrosis, 44 PNI and 61 LVI. The rate of overall survival (OS) in patients aged 65 years. A negative statistical relationship was found between OS with lymph node metastasis (LNM) and tumor differentiation. On the other hand, necrosis did not remain significant on multivariate analysis. No statistically significant relationship was found between smoking, tumor stage, PNI, LVI and concomitant CIS and OS. CONCLUSIONS: In this study, advanced age, LNM, tumor differentiation were found to be independent prognostic risk factors associated with OS after RC. These additional factors, which may explain the different clinical course in patients with similar tumor stage and lymph node status, should be taken into consideration in treatment planning. FAU - Kucuk, Ulku AU - Kucuk U AD - Izmir Tepecik Research and Training Hospital, Department of Pathology, Izmir, Turkey. FAU - Pala, Emel Ebru AU - Pala EE AD - Izmir Tepecik Research and Training Hospital, Department of Pathology, Izmir, Turkey. FAU - Cakir, Ebru AU - Cakir E AD - Izmir Tepecik Research and Training Hospital, Department of Pathology, Izmir, Turkey. FAU - Sezer, Ozlem AU - Sezer O AD - Izmir Tepecik Research and Training Hospital, Department of Pathology, Izmir, Turkey. FAU - Bayol, Umit AU - Bayol U AD - Izmir Tepecik Research and Training Hospital, Department of Pathology, Izmir, Turkey. FAU - Divrik, Rauf Taner AU - Divrik RT AD - Sifa Universitiy Medical Faculty, Department of Urology, Izmir, Turkey. FAU - Cakmak, Ozgur AU - Cakmak O AD - Izmir Tepecik Research and Training Hospital, Department of Urology, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20150313 PL - Poland TA - Cent European J Urol JT - Central European journal of urology JID - 101587101 PMC - PMC4408388 OTO - NOTNLM OT - histology OT - overall survival OT - tumor necrosis OT - urothelial carcinoma of the bladder EDAT- 2015/04/29 06:00 MHDA- 2015/04/29 06:01 PMCR- 2015/01/01 CRDT- 2015/04/28 06:00 PHST- 2014/09/05 00:00 [received] PHST- 2014/10/17 00:00 [revised] PHST- 2014/11/23 00:00 [accepted] PHST- 2015/04/28 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2015/04/29 06:01 [medline] PHST- 2015/01/01 00:00 [pmc-release] AID - 00465 [pii] AID - 10.5173/ceju.2015.01.465 [doi] PST - ppublish SO - Cent European J Urol. 2015;68(1):30-6. doi: 10.5173/ceju.2015.01.465. Epub 2015 Mar 13. PMID- 25912166 OWN - NLM STAT- MEDLINE DCOM- 20160412 LR - 20150716 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 22 IP - 7 DP - 2015 Jul TI - Prognostic value of preoperative pyuria in patients with non-muscle-invasive bladder cancer. PG - 645-9 LID - 10.1111/iju.12788 [doi] AB - OBJECTIVES: To investigate the prognostic value of preoperative pyuria in patients with non-muscle-invasive bladder cancer. METHODS: We retrospectively reviewed data from 237 patients diagnosed with non-muscle-invasive bladder cancer. Pyuria was defined as urine containing >/=5 white blood cells per high power field. The association between clinicopathological factors and recurrence was assessed by Cox univariate and multivariate analyses. RESULTS: Preoperative pyuria was found in 116 (49.0%) patients. Pyuria was significantly associated with advanced age, positive cytology, multiple tumors, large tumor size, non-papillary tumors, T1 tumors and high-grade tumors. In univariate analysis of the entire patient population, pyuria, positive urine cytology, multiple tumors, pT1 tumors and no bacillus Calmette-Guerin were significantly associated with recurrence. Multivariate analysis showed that pyuria was an independent predictor of recurrence (hazard ratio 3.332, 95% confidence interval 2.052-5.410; P < 0.001), along with positive urine cytology, multiple tumors and no bacillus Calmette-Guerin therapy. Subanalysis of the patients who underwent bacillus Calmette-Guerin therapy also showed that pyuria was an independent predictor of recurrence (hazard ratio 2.062, 95% confidence interval 1.085-3.918, P = 0.027). The 2-year recurrence-free survival rate for patients with pyuria was significantly lower than for patients without pyuria (65.5% vs 80.7%; P = 0.027). CONCLUSIONS: Preoperative pyuria seems to be significantly associated with recurrence in patients with non-muscle-invasive bladder cancer, and it might be a useful predictor for recurrence after bacillus Calmette-Guerin therapy. CI - (c) 2015 The Japanese Urological Association. FAU - Satake, Naoya AU - Satake N AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohno, Yoshio AU - Ohno Y AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Nakashima, Jun AU - Nakashima J AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Ohori, Makoto AU - Ohori M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. FAU - Tachibana, Masaaki AU - Tachibana M AD - Department of Urology, Tokyo Medical University, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150424 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 RN - 0 (BCG Vaccine) SB - IM CIN - Int J Urol. 2015 Jul;22(7):650. doi: 10.1111/iju.12802. PMID: 25941035 MH - Administration, Intravesical MH - Adult MH - Aged MH - Aged, 80 and over MH - BCG Vaccine/*therapeutic use MH - Disease Progression MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Recurrence, Local/*diagnosis MH - Prognosis MH - Pyuria/*diagnosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology MH - Young Adult OTO - NOTNLM OT - Calmette-Guerin OT - bacillus OT - bladder cancer OT - non-muscle-invasive bladder cancer OT - prognosis OT - pyuria EDAT- 2015/04/29 06:00 MHDA- 2016/04/14 06:00 CRDT- 2015/04/28 06:00 PHST- 2014/10/27 00:00 [received] PHST- 2015/02/21 00:00 [revised] PHST- 2015/03/15 00:00 [accepted] PHST- 2015/04/28 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2016/04/14 06:00 [medline] AID - 10.1111/iju.12788 [doi] PST - ppublish SO - Int J Urol. 2015 Jul;22(7):645-9. doi: 10.1111/iju.12788. Epub 2015 Apr 24. PMID- 25900243 OWN - NLM STAT- MEDLINE DCOM- 20160512 LR - 20220331 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 16 DP - 2015 Jun 10 TI - Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. PG - 14710-9 AB - Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2%), 5 (1.1%), and 0 (0%) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3% in the radiotherapy group, 97.4% in the surgical therapy group, and 100% in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy. FAU - Shiota, Masaki AU - Shiota M AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Yokomizo, Akira AU - Yokomizo A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Takeuchi, Ario AU - Takeuchi A AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Imada, Kenjiro AU - Imada K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Kiyoshima, Keijiro AU - Kiyoshima K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Inokuchi, Junichi AU - Inokuchi J AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Tatsugami, Katsunori AU - Tatsugami K AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Ohga, Saiji AU - Ohga S AD - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Nakamura, Katsumasa AU - Nakamura K AD - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Honda, Hiroshi AU - Honda H AD - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Naito, Seiji AU - Naito S AD - Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Androgen Antagonists) RN - 0 (Antineoplastic Agents, Hormonal) SB - IM MH - Aged MH - Androgen Antagonists/administration & dosage/*therapeutic use MH - Antineoplastic Agents, Hormonal/administration & dosage MH - Combined Modality Therapy MH - Comorbidity MH - Disease Progression MH - Humans MH - Male MH - Prognosis MH - Prostatic Neoplasms/*drug therapy/mortality MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/*secondary PMC - PMC4546499 OTO - NOTNLM OT - androgen-deprivation therapy OT - bladder cancer OT - prostate cancer OT - radical prostatectomy OT - radiotherapy COIS- CONFLICTS OF INTEREST We declare no conflicts of interest. EDAT- 2015/04/23 06:00 MHDA- 2016/05/14 06:00 PMCR- 2015/06/10 CRDT- 2015/04/23 06:00 PHST- 2015/01/21 00:00 [received] PHST- 2015/03/03 00:00 [accepted] PHST- 2015/04/23 06:00 [entrez] PHST- 2015/04/23 06:00 [pubmed] PHST- 2016/05/14 06:00 [medline] PHST- 2015/06/10 00:00 [pmc-release] AID - 3817 [pii] AID - 10.18632/oncotarget.3817 [doi] PST - ppublish SO - Oncotarget. 2015 Jun 10;6(16):14710-9. doi: 10.18632/oncotarget.3817. PMID- 25897675 OWN - NLM STAT- MEDLINE DCOM- 20150811 LR - 20250529 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 112 IP - 10 DP - 2015 May 12 TI - Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. PG - 1626-35 LID - 10.1038/bjc.2015.109 [doi] AB - BACKGROUND: Radiotherapy for muscle invasive bladder cancer (MIBC) aims to offer organ preservation without oncological compromise. Neo-adjuvant chemotherapy provides survival advantage; response may guide patient selection for bladder preservation and identify those most likely to have favourable result with radiotherapy. METHODS: Ninety-four successive patients with T2-T4aN0M0 bladder cancer treated between January 2000 and June 2011 were analysed at the Royal Marsden Hospital. Patients received platinum-based chemotherapy following transurethral resection of bladder tumour; repeat cystoscopy (+/- biopsy) was performed to guide subsequent management. Responders were treated with radiotherapy. Poor responders were recommended radical cystectomy. Progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method; univariate and multivariate analyses were performed using the Cox proportional hazard regression model. RESULTS: Response assessment was performed in 89 patients. Seventy-eight (88%) demonstrated response; 53 (60%) achieved complete response (CR); 74 responders had radiotherapy; 4 opted for cystectomy. Eleven (12%) demonstrated poor response, 10 received cystectomy. Median survival for CR was 90 months (95% CI 64.7, 115.9) compared with 16 months (95% CI 5.4, 27.4; P < 0.001) poor responders. On multivariate analysis, only response was associated with significantly improved PFS, OS and DSS. After a median follow-up of 39 months (range 4-127 months), 14 patients (16%) required salvage cystectomy (8 for non-muscle invasive disease, 5 for invasive recurrence, 1 for radiotherapy related toxicity). In all, 82% had an intact bladder at last follow-up after radiotherapy; 67% had an intact bladder at last follow-up or death. Our study is limited by its retrospective nature. CONCLUSIONS: Response to neo-adjuvant chemotherapy is a favourable prognostic indicator and can be used to select patients for radiotherapy allowing bladder preservation in >80% of the selected patients. FAU - Hafeez, S AU - Hafeez S AD - 1] The Royal Marsden NHS Foundation Trust, London, UK [2] The Institute of Cancer Research, London, UK. FAU - Horwich, A AU - Horwich A AD - 1] The Royal Marsden NHS Foundation Trust, London, UK [2] The Institute of Cancer Research, London, UK. FAU - Omar, O AU - Omar O AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Mohammed, K AU - Mohammed K AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Thompson, A AU - Thompson A AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Kumar, P AU - Kumar P AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Khoo, V AU - Khoo V AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Van As, N AU - Van As N AD - The Royal Marsden NHS Foundation Trust, London, UK. FAU - Eeles, R AU - Eeles R AD - 1] The Royal Marsden NHS Foundation Trust, London, UK [2] The Institute of Cancer Research, London, UK. FAU - Dearnaley, D AU - Dearnaley D AD - 1] The Royal Marsden NHS Foundation Trust, London, UK [2] The Institute of Cancer Research, London, UK. FAU - Huddart, R AU - Huddart R AD - 1] The Royal Marsden NHS Foundation Trust, London, UK [2] The Institute of Cancer Research, London, UK. LA - eng GR - 17528/CRUK_/Cancer Research UK/United Kingdom GR - 13232/CRUK_/Cancer Research UK/United Kingdom GR - 10588/CRUK_/Cancer Research UK/United Kingdom GR - 15007/CRUK_/Cancer Research UK/United Kingdom GR - 14835/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150421 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - Q20Q21Q62J (Cisplatin) SB - IM EIN - Br J Cancer. 2016 Jun 14;114(12):e24. doi: 10.1038/bjc.2016.132. PMID: 27228294 MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carcinoma, Transitional Cell/*drug therapy/pathology/radiotherapy/surgery MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage MH - Cystectomy/methods MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neoadjuvant Therapy MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy/surgery MH - Organ Preservation/methods MH - Retrospective Studies MH - Salvage Therapy/methods MH - Treatment Outcome MH - Urinary Bladder/*drug effects/pathology/radiation effects/surgery PMC - PMC4430712 EDAT- 2015/04/22 06:00 MHDA- 2015/08/12 06:00 PMCR- 2015/05/12 CRDT- 2015/04/22 06:00 PHST- 2014/11/02 00:00 [received] PHST- 2015/02/12 00:00 [revised] PHST- 2015/02/23 00:00 [accepted] PHST- 2015/04/22 06:00 [entrez] PHST- 2015/04/22 06:00 [pubmed] PHST- 2015/08/12 06:00 [medline] PHST- 2015/05/12 00:00 [pmc-release] AID - bjc2015109 [pii] AID - 10.1038/bjc.2015.109 [doi] PST - ppublish SO - Br J Cancer. 2015 May 12;112(10):1626-35. doi: 10.1038/bjc.2015.109. Epub 2015 Apr 21. PMID- 25894367 OWN - NLM STAT- MEDLINE DCOM- 20160919 LR - 20260128 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 33 IP - 12 DP - 2015 Dec TI - Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. PG - 1951-7 LID - 10.1007/s00345-015-1557-9 [doi] AB - PURPOSE: Current pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive. MATERIALS AND METHODS: In total, 238 patients treated by transurethral resection of the bladder tumor were histopathologically confirmed to be NMIBC. Two experienced uropathologists re-reviewed the slides. HER-2 expression was evaluated by immunohistochemistry and scored for intensity and area of staining. The association of HER-2 staining with tumor recurrence and progression was evaluated by univariate and multivariate analyses and Kaplan-Meier survival curves. RESULTS: In multivariable analyses, HER-2 expression was an independent risk factor for predicting tumor progression (HR 2.64, p = 0.024). Combining the EORTC risk scores with HER-2 expression status led to more accurate prediction of progression, especially in patients with intermediate- and high-risk EORTC scores (p < 0.0001, log-rank test). CONCLUSIONS: HER-2 positivity is prognostic for predicting progression to muscle invasion in NMIBC. Combination of the high-risk factors with HER-2 expression is more valuable for determining which NMIBC is more aggressive. FAU - Ding, Weihong AU - Ding W AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. FAU - Tong, Shijun AU - Tong S AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. FAU - Gou, Yuancheng AU - Gou Y AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. FAU - Sun, Chuanyu AU - Sun C AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. FAU - Wang, Hong AU - Wang H AD - Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. FAU - Chen, Zhongqing AU - Chen Z AD - Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. FAU - Tan, Jun AU - Tan J AD - Department of Biostatistics and Social Medicine, School of Public Health, Fudan University, Shanghai, 200032, China. FAU - Xu, Ke AU - Xu K AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. drkexu@163.com. FAU - Xia, Guowei AU - Xia G AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. FAU - Ding, Qiang AU - Ding Q AD - Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150418 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma/*metabolism/*pathology MH - Cohort Studies MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prognosis MH - Erb-b2 Receptor Tyrosine Kinases/*metabolism MH - Risk Factors MH - Urinary Bladder Neoplasms/*metabolism/*pathology MH - Young Adult OTO - NOTNLM OT - EORTC OT - HER-2 OT - Immunohistochemistry OT - Non-muscle-invasive bladder cancer OT - Prognosis EDAT- 2015/04/22 06:00 MHDA- 2016/09/20 06:00 CRDT- 2015/04/21 06:00 PHST- 2014/11/22 00:00 [received] PHST- 2015/04/07 00:00 [accepted] PHST- 2015/04/21 06:00 [entrez] PHST- 2015/04/22 06:00 [pubmed] PHST- 2016/09/20 06:00 [medline] AID - 10.1007/s00345-015-1557-9 [pii] AID - 10.1007/s00345-015-1557-9 [doi] PST - ppublish SO - World J Urol. 2015 Dec;33(12):1951-7. doi: 10.1007/s00345-015-1557-9. Epub 2015 Apr 18. PMID- 25886012 OWN - NLM STAT- MEDLINE DCOM- 20160122 LR - 20181113 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 15 DP - 2015 Mar 18 TI - Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study. PG - 149 LID - 10.1186/s12885-015-1161-9 [doi] LID - 149 AB - BACKGROUND: To compare the prognosis of upper urinary tract (UUT)-urothelial carcinoma (UC) and UC of the bladder (UCB) by pathological staging in patients treated with radical surgeries. METHODS: The study population comprised 335 and 302 consecutive radical surgery cases performed between 1991 and 2010 for UUT-UC and UCB, respectively. Five-year recurrence-free survival (RFS) and cancer-specific survival (CSS) rates were analyzed. The median follow-up period of all subjects was 59.3 months (range, 0.1-261.0 months). RESULTS: No difference was observed in median patient age, distribution of pathologic T stage, or rates of positive surgical margin between the two groups. The UUT-UC group had significantly more frequent hydronephrosis than the USB group (48.1% vs. 20.2%, p < 0.001). However, the UUT-UC group showed significantly less frequent grade III tumors (28.1% vs. 58.6%, p < 0.001), lymphovascular invasion (18.8% vs. 35.8%, p < 0.001), and associated carcinoma in situ (9.0% vs. 21.9%, p < 0.001) than the UCB group. Five year RFS rates in the UUT-UC and UCB groups were 77.0% and 75.9%, respectively (p = 0.546). No significant difference in RFS rate was observed between pathological T stage subgroups. Five year CSS rates in the UUT-UC and UCB groups were 76.1% and 76.2%, respectively (p = 0.462). No significant difference was observed in CSS rate between the pathologic T stage subgroups. CONCLUSIONS: UUT-UC and UCB showed comparable prognosis at identical stages. However, our results should be verified in a prospective study due to the retrospective study design in this study. FAU - Kim, Myong AU - Kim M AD - Department of Urology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. flytoyou@gmail.com. FAU - Jeong, Chang Wook AU - Jeong CW AD - Department of Urology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. drboss@gmail.com. FAU - Kwak, Cheol AU - Kwak C AD - Department of Urology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. mdrafael@snu.ac.kr. FAU - Kim, Hyeon Hoe AU - Kim HH AD - Department of Urology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. hhkim@snu.ac.kr. FAU - Ku, Ja Hyeon AU - Ku JH AD - Department of Urology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea. kuuro70@snu.ac.kr. LA - eng PT - Journal Article DEP - 20150318 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Case-Control Studies MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Retrospective Studies MH - Urinary Bladder/*pathology/*surgery MH - Urinary Bladder Neoplasms/diagnosis/surgery MH - Urologic Neoplasms/*diagnosis/*surgery MH - Young Adult PMC - PMC4369352 EDAT- 2015/04/18 06:00 MHDA- 2016/01/23 06:00 PMCR- 2015/03/18 CRDT- 2015/04/18 06:00 PHST- 2014/03/29 00:00 [received] PHST- 2015/03/05 00:00 [accepted] PHST- 2015/04/18 06:00 [entrez] PHST- 2015/04/18 06:00 [pubmed] PHST- 2016/01/23 06:00 [medline] PHST- 2015/03/18 00:00 [pmc-release] AID - 10.1186/s12885-015-1161-9 [pii] AID - 1161 [pii] AID - 10.1186/s12885-015-1161-9 [doi] PST - epublish SO - BMC Cancer. 2015 Mar 18;15:149. doi: 10.1186/s12885-015-1161-9. PMID- 25884545 OWN - NLM STAT- MEDLINE DCOM- 20160122 LR - 20220331 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 15 DP - 2015 Mar 19 TI - Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. PG - 155 LID - 10.1186/s12885-015-1089-0 [doi] LID - 155 AB - BACKGROUND: The role of urine markers in the surveillance of patients with non-muscle invasive bladder cancer (NMIBC) is discussed extensively. In case of negative cystoscopy the additional prognostic value of these markers has not been clearly defined yet. The present study is the first systematic approach to directly compare the ability of a urine marker panel to predict the risk of recurrence and progression in bladder cancer (BC) patients with no evidence of relapse during surveillance for NMIBC. METHODS: One hundred fourteen patients who underwent urine marker testing during surveillance for NMIBC and who had no evidence of BC recurrence were included. For all patients cytology, Fluorescence-in-situ-hybridization (FISH), immunocytology (uCyt+) and Nuclear matrix protein 22 enzyme-linked immunosorbent assay (NMP22) were performed. All patients completed at least 24 months of endoscopic and clinical follow-up of after inclusion. RESULTS: Within 24 months of follow-up, 38 (33.0%) patients experienced disease recurrence and 11 (9.8%) progression. Recurrence rates in patients with positive vs. negative cytology, FISH, uCyt+ and NMP22 were 52.6% vs. 21.9% (HR = 3.9; 95% CI 1.75-9.2; p < 0.001), 47.6% vs. 25.0% (HR 2.7; 1.2-6.2; p = 0.01), 43.8% vs. 22.4% (HR 3.3; 1.5-7.6; p = 0.003) and 43.8% vs. 16.7% (HR 4.2; 1.7-10.8; p = 0.001). In patients with negative cytology, a positive NMP22 test was associated with a shorter time to recurrence (p = 0.01), whereas FISH or uCyt+ were not predictive of recurrence in these patients. In the group of patients with negative cytology and negative NMP22, only 13.5% and 5.4% developed recurrence and progression after 24 months. CONCLUSIONS: Patients with positive urine markers at time of negative cystoscopy are at increased risk of recurrence and progression. In patients with negative cytology, only NMP22 is predictive for recurrence. Patients with negative marker combinations including NMP22 harbour a low risk of recurrence. Therefore, the endoscopic follow-up regimen may be attenuated in this group of patients. FAU - Todenhofer, Tilman AU - Todenhofer T AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. ttodenhoefer@prostatecentre.com. AD - Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC, V3Z6H, Canada. ttodenhoefer@prostatecentre.com. FAU - Hennenlotter, Jorg AU - Hennenlotter J AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. joerg.hennenlotter@med.uni-tuebingen.de. FAU - Guttenberg, Philipp AU - Guttenberg P AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. philipp.guttenberg@yahoo.de. FAU - Mohrhardt, Sarah AU - Mohrhardt S AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. sarah_mohrhardt@web.de. FAU - Kuehs, Ursula AU - Kuehs U AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. ursula.kuehs@med.uni-tuebingen.de. FAU - Esser, Michael AU - Esser M AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. micesser@yahoo.de. FAU - Aufderklamm, Stefan AU - Aufderklamm S AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. stefan.aufderklamm@med.uni-tuebingen.de. FAU - Bier, Simone AU - Bier S AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. simone.bier@med.uni-tuebingen.de. FAU - Harland, Niklas AU - Harland N AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. niklas.harland@med.uni-tuebingen.de. FAU - Rausch, Steffen AU - Rausch S AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. steffen.rausch@med.uni-tuebingen.de. FAU - Gakis, Georgios AU - Gakis G AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. georgios.gakis@med.uni-tuebingen.de. FAU - Stenzl, Arnulf AU - Stenzl A AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. urologie@med.uni-tuebingen.de. FAU - Schwentner, Christian AU - Schwentner C AD - Department of Urology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, Tubingen, 72076, Germany. christian.schwentner@med.uni-tuebingen.de. LA - eng PT - Journal Article DEP - 20150319 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*urine MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - *Population Surveillance/methods MH - Prognosis MH - Urinary Bladder Neoplasms/*diagnosis/surgery/*urine PMC - PMC4374530 EDAT- 2015/04/18 06:00 MHDA- 2016/01/23 06:00 PMCR- 2015/03/19 CRDT- 2015/04/18 06:00 PHST- 2014/10/26 00:00 [received] PHST- 2015/02/19 00:00 [accepted] PHST- 2015/04/18 06:00 [entrez] PHST- 2015/04/18 06:00 [pubmed] PHST- 2016/01/23 06:00 [medline] PHST- 2015/03/19 00:00 [pmc-release] AID - 10.1186/s12885-015-1089-0 [pii] AID - 1089 [pii] AID - 10.1186/s12885-015-1089-0 [doi] PST - epublish SO - BMC Cancer. 2015 Mar 19;15:155. doi: 10.1186/s12885-015-1089-0. PMID- 25881516 OWN - NLM STAT- MEDLINE DCOM- 20170428 LR - 20170428 IS - 1699-7980 (Electronic) IS - 0210-4806 (Linking) VI - 39 IP - 8 DP - 2015 Oct TI - Predictors, pathological characteristics and outcomes of bladder recurrences following nephroureterectomy. PG - 488-93 LID - S0210-4806(15)00108-4 [pii] LID - 10.1016/j.acuro.2015.02.006 [doi] AB - OBJECTIVES: To analyze the predictors for bladder recurrence (BR) after nephroureterectomy (NU) for upper urinary tract tumors (UUTT), as well as its pathological characteristics, outcomes and impact on survival. MATERIAL AND METHODS: Retrospective study of 117 patients who underwent laparoscopic nephroureterectomy by UUTT between 2007-2012 at our center. The potential predictors for BR were analyzed using Cox regression; Kaplan-Meier curves were employed to study survival. RESULTS: The sample was composed of 85 men (73%) and 32 women (27%), with a mean age of 70 years. After a mean follow-up of 26 months, 23 patients presented BR (19.6%). In the multivariate analysis, sex (p=.003; HR [female], 3.8) and the location of the UUTT in the distal ureter (p=.002; HR, 4.8) were independent predictors for BR. The median time to BR was 8 months. Fifteen patients presented a nonmuscle-invasive BR (65.2%), and 8 presented a muscle-invasive BR (34.8%). All BRs, except for 2, appeared during the first 2 years. Five cases with nonmuscle-invasive BR presented a new BR. Six patients with muscle-invasive BR died before it could be determined whether cause of death was the BR or an UUTT relapse. The onset of BR showed no repercussion on the survival of patients with UUTT. CONCLUSIONS: Sex (female) and the location of the UUTT (distal ureter) are predictors for BR after NU. Patients with these characteristics might benefit from adjuvant intravesical treatment and closer monitoring. The onset for RV has no impact on the survival of patients with UUTT. CI - Copyright (c) 2014 AEU. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Mateu, L AU - Mateu L AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. Electronic address: lmateuarrom@hotmail.com. FAU - Huguet, J AU - Huguet J AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Carrion, A AU - Carrion A AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Garcia-Cruz, E AU - Garcia-Cruz E AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Izquierdo, L AU - Izquierdo L AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Musquera, M AU - Musquera M AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Ribal, M J AU - Ribal MJ AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Alcaraz, A AU - Alcaraz A AD - Servicio de Urologia, Hospital Clinic de Barcelona, Barcelona, Espana. LA - eng LA - spa PT - Journal Article DEP - 20150414 PL - Spain TA - Actas Urol Esp JT - Actas urologicas espanolas JID - 7704993 SB - IM MH - Aged MH - Female MH - Humans MH - Kidney Neoplasms/*surgery MH - Male MH - Neoplasm Recurrence, Local/epidemiology/pathology MH - Neoplasms, Second Primary/*epidemiology/*pathology MH - *Nephrectomy MH - Prognosis MH - Retrospective Studies MH - Survival Rate MH - Ureter/*surgery MH - Ureteral Neoplasms/*surgery MH - Urinary Bladder Neoplasms/*surgery OTO - NOTNLM OT - Bladder recurrence OT - Nefroureterectomia OT - Nephroureterectomy OT - Recidiva vesical OT - Tumor urotelial de tracto urinario superior OT - Upper urinary tract urothelial tumor EDAT- 2015/04/18 06:00 MHDA- 2017/04/30 06:00 CRDT- 2015/04/18 06:00 PHST- 2014/12/16 00:00 [received] PHST- 2015/02/23 00:00 [revised] PHST- 2015/02/24 00:00 [accepted] PHST- 2015/04/18 06:00 [entrez] PHST- 2015/04/18 06:00 [pubmed] PHST- 2017/04/30 06:00 [medline] AID - S0210-4806(15)00108-4 [pii] AID - 10.1016/j.acuro.2015.02.006 [doi] PST - ppublish SO - Actas Urol Esp. 2015 Oct;39(8):488-93. doi: 10.1016/j.acuro.2015.02.006. Epub 2015 Apr 14. PMID- 25877676 OWN - NLM STAT- MEDLINE DCOM- 20160101 LR - 20181113 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 15 DP - 2015 Mar 13 TI - Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. PG - 120 LID - 10.1186/s12885-015-1152-x [doi] LID - 120 AB - BACKGROUND: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones. METHODS: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A (100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years); and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months. RESULTS: No significant differences were observed among the different groups at baseline. On multivariate analysis, statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence of a recurrence. When patients were stratified according to the different treatment; patients treated with statins (Group B) presented an higher rate of failure (56/91 patients; 61.5%) when compared to Group A (42/98 patients; 42.9%), Group C (56/98; 57.1%) and (133/287 patients; 46.3%). This difference corresponds to a significant difference in recurrence failure free survival (p = 0.01). CONCLUSIONS: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC. FAU - Pastore, Antonio AU - Pastore A FAU - Palleschi, Giovanni AU - Palleschi G FAU - Fuschi, Andrea AU - Fuschi A FAU - Silvestri, Luigi AU - Silvestri L FAU - Al Salhi, Yazan AU - Al Salhi Y FAU - Costantini, Elisabetta AU - Costantini E FAU - Zucchi, Alessandro AU - Zucchi A FAU - Petrozza, Vincenzo AU - Petrozza V FAU - de Nunzio, Cosimo AU - de Nunzio C FAU - Carbone, Antonio AU - Carbone A LA - eng PT - Journal Article DEP - 20150313 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - R16CO5Y76E (Aspirin) SB - IM MH - Aspirin/*administration & dosage MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Odds Ratio MH - Retrospective Studies MH - Risk Factors MH - Urinary Bladder Neoplasms/*epidemiology/mortality/*pathology/surgery PMC - PMC4369111 EDAT- 2015/04/17 06:00 MHDA- 2016/01/02 06:00 PMCR- 2015/03/13 CRDT- 2015/04/17 06:00 PHST- 2014/01/02 00:00 [received] PHST- 2015/03/02 00:00 [accepted] PHST- 2015/04/17 06:00 [entrez] PHST- 2015/04/17 06:00 [pubmed] PHST- 2016/01/02 06:00 [medline] PHST- 2015/03/13 00:00 [pmc-release] AID - s12885-015-1152-x [pii] AID - 1152 [pii] AID - 10.1186/s12885-015-1152-x [doi] PST - epublish SO - BMC Cancer. 2015 Mar 13;15:120. doi: 10.1186/s12885-015-1152-x. PMID- 25873574 OWN - NLM STAT- MEDLINE DCOM- 20150723 LR - 20240610 IS - 1096-9098 (Electronic) IS - 0022-4790 (Print) IS - 0022-4790 (Linking) VI - 111 IP - 7 DP - 2015 Jun TI - Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. PG - 923-8 LID - 10.1002/jso.23903 [doi] AB - BACKGROUND AND OBJECTIVES: Previous studies have shown that variability in surgical technique can affect the outcomes of cooperative group trials. We analyzed measures of surgical quality and clinical outcomes in patients enrolled in the p53-MVAC trial. METHODS: We performed a post-hoc analysis of patients with pT1-T2N0M0 urothelial carcinoma of the bladder following radical cystectomy (RC) and bilateral pelvic and iliac lymphadenectomy (LND). Measures of surgical quality were examined for associations with time to recurrence (TTR) and overall survival (OS). RESULTS: We reviewed operative and/or pathology reports for 440 patients from 35 sites. We found that only 31% of patients met all suggested trial eligibility criteria of having >/=15 lymph nodes identified in the pathologic specimen (LN#) and having undergone both extended and presacral LND. There was no association between extent of LND, LN#, or presacral LND and TTR or OS after adjustment for confounders and multiple testing. CONCLUSIONS: We demonstrated that there was substantial variability in surgical technique within a cooperative group trial. Despite explicit entry criteria, many patients did not undergo per-protocol LNDs. While outcomes were not apparently affected, it is nonetheless evident that careful attention to study design and quality monitoring will be critical to successful future trials. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Mata, Douglas A AU - Mata DA AD - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Groshen, Susan AU - Groshen S FAU - Von Rundstedt, Friedrich-Carl AU - Von Rundstedt FC FAU - Skinner, Donald G AU - Skinner DG FAU - Stadler, Walter M AU - Stadler WM FAU - Cote, Richard J AU - Cote RJ FAU - Stein, John P AU - Stein JP FAU - Lerner, Seth P AU - Lerner SP LA - eng GR - U10 CA180834/CA/NCI NIH HHS/United States GR - CA14089/CA/NCI NIH HHS/United States GR - U10 CA035192/CA/NCI NIH HHS/United States GR - U10 CA180835/CA/NCI NIH HHS/United States GR - CA180835/CA/NCI NIH HHS/United States GR - R01 CA071921/CA/NCI NIH HHS/United States GR - UG1 CA180830/CA/NCI NIH HHS/United States GR - CA46282/CA/NCI NIH HHS/United States GR - CA180830/CA/NCI NIH HHS/United States GR - P30 CA014089/CA/NCI NIH HHS/United States GR - CA180801/CA/NCI NIH HHS/United States GR - U10 CA067575/CA/NCI NIH HHS/United States GR - CA180834/CA/NCI NIH HHS/United States GR - CA35192/CA/NCI NIH HHS/United States GR - CA71921/CA/NCI NIH HHS/United States GR - CA180888/CA/NCI NIH HHS/United States GR - U10 CA180819/CA/NCI NIH HHS/United States GR - U10 CA180830/CA/NCI NIH HHS/United States GR - U10 CA180801/CA/NCI NIH HHS/United States GR - CA70903/CA/NCI NIH HHS/United States GR - U10 CA046282/CA/NCI NIH HHS/United States GR - CA46368/CA/NCI NIH HHS/United States GR - U10 CA046368/CA/NCI NIH HHS/United States GR - CA180819/CA/NCI NIH HHS/United States GR - N01 CA067575/CA/NCI NIH HHS/United States GR - U10 CA180888/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase III PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150414 PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 SB - IM MH - Aged MH - Cystectomy/*mortality MH - Female MH - Follow-Up Studies MH - Humans MH - Lymph Node Excision/*mortality MH - Lymph Nodes/*pathology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/mortality/pathology/*surgery MH - Neoplasm Staging MH - Pelvic Neoplasms/mortality/pathology/*surgery MH - Prognosis MH - Quality Assurance, Health Care/*trends MH - Survival Rate MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery PMC - PMC4602027 MID - NIHMS718240 OTO - NOTNLM OT - Carcinoma OT - adjuvant OT - chemotherapy OT - cystectomy OT - genes OT - p53 OT - transitional cell EDAT- 2015/04/16 06:00 MHDA- 2015/07/24 06:00 PMCR- 2016/06/01 CRDT- 2015/04/16 06:00 PHST- 2015/01/02 00:00 [received] PHST- 2015/02/11 00:00 [accepted] PHST- 2015/04/16 06:00 [entrez] PHST- 2015/04/16 06:00 [pubmed] PHST- 2015/07/24 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.1002/jso.23903 [doi] PST - ppublish SO - J Surg Oncol. 2015 Jun;111(7):923-8. doi: 10.1002/jso.23903. Epub 2015 Apr 14. PMID- 25866762 OWN - NLM STAT- MEDLINE DCOM- 20151228 LR - 20181113 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2015 DP - 2015 TI - Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. PG - 168682 LID - 10.1155/2015/168682 [doi] LID - 168682 AB - Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most common types of cancer in humans, killing thousands of people a year. This paper is based on the hypothesis that the use of clinical and histopathological data together with information about the concentration of various molecular markers in patients is useful for the prediction of outcomes and the design of treatments of nonmuscle invasive bladder carcinoma (NMIBC). A population of 45 patients with a new diagnosis of NMIBC was selected. Patients with benign prostatic hyperplasia (BPH), muscle invasive bladder carcinoma (MIBC), carcinoma in situ (CIS), and NMIBC recurrent tumors were not included due to their different clinical behavior. Clinical history was obtained by means of anamnesis and physical examination, and preoperative imaging and urine cytology were carried out for all patients. Then, patients underwent conventional transurethral resection (TURBT) and some proteomic analyses quantified the biomarkers (p53, neu, and EGFR). A postoperative follow-up was performed to detect relapse and progression. Clusterings were performed to find groups with clinical, molecular markers, histopathological prognostic factors, and statistics about recurrence, progression, and overall survival of patients with NMIBC. Four groups were found according to tumor sizes, risk of relapse or progression, and biological behavior. Outlier patients were also detected and categorized according to their clinical characters and biological behavior. FAU - Redondo-Gonzalez, Enrique AU - Redondo-Gonzalez E AD - Urology Department, Hospital Clinico San Carlos, Complutense University, Instituto de Investigacion Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain. FAU - de Castro, Leandro Nunes AU - de Castro LN AD - Natural Computing Laboratory (LCoN), Mackenzie Presbyterian University, 01302-000 Sao Paulo, SP, Brazil. FAU - Moreno-Sierra, Jesus AU - Moreno-Sierra J AD - Urology Department, Hospital Clinico San Carlos, Complutense University, Instituto de Investigacion Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain. FAU - Maestro de las Casas, Maria Luisa AU - Maestro de las Casas ML AD - Clinical Analysis Department, Hospital Clinico Universitario San Carlos, 28040 Madrid, Spain. FAU - Vera-Gonzalez, Vicente AU - Vera-Gonzalez V AD - Odontology School, Complutense University, 28040 Madrid, Spain. FAU - Ferrari, Daniel Gomes AU - Ferrari DG AD - Natural Computing Laboratory (LCoN), Mackenzie Presbyterian University, 01302-000 Sao Paulo, SP, Brazil. FAU - Corchado, Juan Manuel AU - Corchado JM AD - Biomedical Research Institute of Salamanca/BISITE Research Group, University of Salamanca, Edificio I+D+i, 37008 Salamanca, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150319 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Biomarkers, Tumor) RN - 0 (Neoplasm Proteins) SB - IM MH - *Biomarkers, Tumor/genetics/metabolism MH - *Databases, Factual MH - Disease-Free Survival MH - Female MH - Humans MH - Male MH - *Neoplasm Proteins/genetics/metabolism MH - Risk Factors MH - Survival Rate MH - *Urinary Bladder Neoplasms/genetics/metabolism/mortality/pathology PMC - PMC4383273 EDAT- 2015/04/14 06:00 MHDA- 2015/12/29 06:00 PMCR- 2015/03/19 CRDT- 2015/04/14 06:00 PHST- 2014/09/28 00:00 [received] PHST- 2015/01/05 00:00 [revised] PHST- 2015/01/15 00:00 [accepted] PHST- 2015/04/14 06:00 [entrez] PHST- 2015/04/14 06:00 [pubmed] PHST- 2015/12/29 06:00 [medline] PHST- 2015/03/19 00:00 [pmc-release] AID - 10.1155/2015/168682 [doi] PST - ppublish SO - Biomed Res Int. 2015;2015:168682. doi: 10.1155/2015/168682. Epub 2015 Mar 19. PMID- 25864416 OWN - NLM STAT- MEDLINE DCOM- 20160115 LR - 20150422 IS - 1096-9101 (Electronic) IS - 0196-8092 (Linking) VI - 47 IP - 4 DP - 2015 Apr TI - Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. PG - 306-11 LID - 10.1002/lsm.22342 [doi] AB - BACKGROUND AND OBJECTIVES: In urology, potassium-titanyl-phosphate (KTP) laser is mainly used in the treatment of benign prostatic hyperplasia with a low rate of intraoperative and postoperative complications. A prospective, randomized study was undertaken to investigate the treatment outcomes of KTP laser vaporization for primary non-muscle-invasive bladder tumors (NMIBTs) as compared with conventional monopolar transurethral resection of bladder tumors (TURBT). MATERIALS AND METHODS: This study was designed as a prospective, randomized trial. After institutional review board approval, 229 consecutive patients with NMIBTs were randomized to 2 groups. Among them, 116 patients underwent KTP laser vaporization of a bladder tumor (laser group) and 113 patients underwent standard transurethral electroresection of the bladder tumors using monopolar loop electrode (TURBT group). According to the prognostic factors for recurrence, all patients were divided into low, intermediate or high risk subgroups. The clinical data were recorded and compared between the two groups. RESULTS: Eighty-nine patients in laser group and 94 in TURBT group were evaluable for the study end points. The preoperative characteristics of the patients were comparable in the two groups. There was no statistical difference in operation time between the two groups. Patients in the laser group had fewer perioperative complications and more patients needed bladder irrigation in the TURBT group. Compared with laser group, patients in the TURBT group had longer catheterization time and hospitalization duration. There were no statistical differences in the oncologic results in term of 2-year recurrence rates as compared between the two groups. CONCLUSIONS: Our study demonstrated that using KTP laser, transurethral vaporization is an effective and safe treatment for the patients with primary NMIBT. Compared with traditional TURBT, the KTP laser surgery had fewer perioperative complications and similar oncological results. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Xu, Yansheng AU - Xu Y AD - Department of Urology, Navy General Hospital of the People's Liberation Army, No. 6 Fucheng Street, Haidian District, Beijing, 100048, People's Republic of China. FAU - Guan, Weimin AU - Guan W FAU - Chen, Weihao AU - Chen W FAU - Xie, Changliang AU - Xie C FAU - Ouyang, Yun AU - Ouyang Y FAU - Wu, Yiguang AU - Wu Y FAU - Liu, Cuilong AU - Liu C LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20150409 PL - United States TA - Lasers Surg Med JT - Lasers in surgery and medicine JID - 8007168 SB - IM MH - Electrosurgery/*methods MH - Female MH - Humans MH - *Laser Therapy MH - *Lasers, Solid-State MH - Length of Stay/statistics & numerical data MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Postoperative Hemorrhage/therapy MH - Prospective Studies MH - Therapeutic Irrigation/statistics & numerical data MH - Urinary Bladder Neoplasms/*surgery MH - Urinary Catheterization/statistics & numerical data OTO - NOTNLM OT - non-muscle invasive bladder tumor OT - potassium-titanyl-phosphate laser OT - transurethral resection OT - vaporization EDAT- 2015/04/14 06:00 MHDA- 2016/01/16 06:00 CRDT- 2015/04/14 06:00 PHST- 2014/12/31 00:00 [accepted] PHST- 2015/04/14 06:00 [entrez] PHST- 2015/04/14 06:00 [pubmed] PHST- 2016/01/16 06:00 [medline] AID - 10.1002/lsm.22342 [doi] PST - ppublish SO - Lasers Surg Med. 2015 Apr;47(4):306-11. doi: 10.1002/lsm.22342. Epub 2015 Apr 9. PMID- 25860378 OWN - NLM STAT- MEDLINE DCOM- 20160919 LR - 20211203 IS - 1433-8726 (Electronic) IS - 0724-4983 (Linking) VI - 33 IP - 12 DP - 2015 Dec TI - Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. PG - 2087-93 LID - 10.1007/s00345-015-1554-z [doi] AB - BACKGROUND: Patients following solid organ transplantation have an increased risk of developing de novo bladder tumors, but their biology is poorly characterized. METHODS: We studied 1743 patients who underwent a transurethral resection of a newly diagnosed bladder tumor at a single institution. The histopathology, treatment, recurrence-free survival and overall survival were evaluated and compared between transplant and non-transplant patients. RESULTS: We identified 74 transplant patients who developed a de novo bladder tumor after a median post-transplantation interval of 62 months. The tumor was malignant in 29 patients (39 %). The most common benign lesion was nephrogenic adenoma (84 %), which neither coexisted with nor developed into malignant tumors during follow-up. Compared with non-transplant patients (n = 1669), transplant patients were significantly younger (median 55 vs 69 years, P < 0.001) and had a 9.0-fold higher odds of benign tumors (P < 0.001), while there were no differences in pathology among patients with urothelial carcinoma of the bladder (UCB). In a multivariable analysis for non-muscle-invasive UCB that was adjusted for the risk group, patients with a transplant had a 1.8-fold increased risk of recurrence (P = 0.048). Four of five transplant patients did not respond to Bacillus Calmette-Guerin instillations. There were no differences in overall survival after radical cystectomy (P = 0.87). CONCLUSIONS: The majority of bladder tumors in transplant patients are benign, and they neither coexist with nor develop into malignant tumors. Transplant patients with non-muscle-invasive UCB show an increased risk of disease recurrence, while those treated with radical cystectomy have similar outcomes to patients without a transplant. FAU - Ederer, Ines A AU - Ederer IA AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Lucca, Ilaria AU - Lucca I AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, Centre hospitalier universitaire vaudois, Lausanne, Switzerland. FAU - Hofbauer, Sebastian L AU - Hofbauer SL AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. FAU - Haidinger, Michael AU - Haidinger M AD - Clinical Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Haitel, Andrea AU - Haitel A AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Susani, Martin AU - Susani M AD - Clinical Institute of Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. FAU - Klatte, Tobias AU - Klatte T AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Wahringer Gurtel 18-20, 1090, Vienna, Austria. tobias.klatte@gmx.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150410 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 SB - IM MH - Aged MH - Carcinoma/*mortality/*pathology/therapy MH - Cystectomy MH - Disease-Free Survival MH - Female MH - Humans MH - Immunosuppression Therapy MH - Male MH - Middle Aged MH - *Organ Transplantation MH - Retrospective Studies MH - Survival Rate MH - Time Factors MH - Urinary Bladder Neoplasms/*mortality/*pathology/therapy OTO - NOTNLM OT - Bladder OT - Cystectomy OT - Endoscopy OT - Nephrogenic adenoma OT - Recurrence OT - Survival OT - Transplantation EDAT- 2015/04/11 06:00 MHDA- 2016/09/20 06:00 CRDT- 2015/04/11 06:00 PHST- 2015/03/15 00:00 [received] PHST- 2015/04/01 00:00 [accepted] PHST- 2015/04/11 06:00 [entrez] PHST- 2015/04/11 06:00 [pubmed] PHST- 2016/09/20 06:00 [medline] AID - 10.1007/s00345-015-1554-z [pii] AID - 10.1007/s00345-015-1554-z [doi] PST - ppublish SO - World J Urol. 2015 Dec;33(12):2087-93. doi: 10.1007/s00345-015-1554-z. Epub 2015 Apr 10. PMID- 25857336 OWN - NLM STAT- MEDLINE DCOM- 20160314 LR - 20191210 IS - 1442-2042 (Electronic) IS - 0919-8172 (Linking) VI - 22 IP - 6 DP - 2015 Jun TI - Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. PG - 541-7 LID - 10.1111/iju.12749 [doi] AB - OBJECTIVE: To determine the prognostic factors of primary T1 high-grade bladder cancer and to validate the Spanish Urological Club for Oncological Treatment model in Japanese patients with T1 high-grade bladder cancer treated at a single institution. METHODS: Records of 106 patients with T1 high-grade bladder cancer treated from 1998 to 2013 were retrospectively reviewed. Variables included various clinicopathological parameters, including lymphovascular invasion and tumor growth pattern at the invasion front. Recurrence-free survival and progression-free survival were analyzed. Multivariate Cox proportional regression analysis was used to verify the prognostic significance of the variables. Scores for recurrence and progression were calculated using the Spanish Urological Club for Oncological Treatment model. RESULTS: Of 106 patients, 44 (42%) had recurrence and 16 (15%) developed progression after a median (interquartile range) follow-up period of 54 months (range 32-81 months). Non-papillary shape was the only independent predictor for recurrence, while broad-based tumor stalk and infiltrative tumor growth pattern at the invasion front were determined to be independent predictors for progression. Stratification of patients according to the number of progression risk factors yielded hazard ratios of 10.1 and 13.1 in patients having one and two risks, respectively, compared with those without any risks. The Spanish Urological Club for Oncological Treatment model successfully stratified our patients with a trend toward different probabilities of recurrence and progression. CONCLUSIONS: The results of the present study might be helpful for counseling certain patients towards intensive treatment, such as radical cystectomy and/or platinum-based systemic chemotherapy. In addition, the Spanish Urological Club for Oncological Treatment model might be applicable to Japanese patients with T1 high-grade bladder cancer. CI - (c) 2015 The Japanese Urological Association. FAU - Miyake, Makito AU - Miyake M AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Gotoh, Daisuke AU - Gotoh D AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Shimada, Keiji AU - Shimada K AD - Department of Pathology, Nara Medical University, Nara, Japan. FAU - Tatsumi, Yoshihiro AU - Tatsumi Y AD - Department of Urology, Nara Medical University, Nara, Japan. AD - Department of Pathology, Nara Medical University, Nara, Japan. FAU - Nakai, Yasushi AU - Nakai Y AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Anai, Satoshi AU - Anai S AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Torimoto, Kazumasa AU - Torimoto K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Aoki, Katsuya AU - Aoki K AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Tanaka, Nobumichi AU - Tanaka N AD - Department of Urology, Nara Medical University, Nara, Japan. FAU - Konishi, Noboru AU - Konishi N AD - Department of Pathology, Nara Medical University, Nara, Japan. FAU - Fujimoto, Kiyohide AU - Fujimoto K AD - Department of Urology, Nara Medical University, Nara, Japan. LA - eng PT - Journal Article PT - Validation Study DEP - 20150408 PL - Australia TA - Int J Urol JT - International journal of urology : official journal of the Japanese Urological Association JID - 9440237 SB - IM CIN - Int J Urol. 2015 Jun;22(6):548. doi: 10.1111/iju.12762. PMID: 25808812 MH - Aged MH - Carcinoma, Transitional Cell/*pathology/surgery MH - Disease Progression MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Japan MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/*pathology MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Survival Rate MH - Time Factors MH - Urinary Bladder Neoplasms/*pathology/surgery OTO - NOTNLM OT - Spanish Urological Club for Oncological Treatment scoring model OT - bladder cancer OT - broad base OT - high grade OT - infiltrative pattern EDAT- 2015/04/11 06:00 MHDA- 2016/03/15 06:00 CRDT- 2015/04/11 06:00 PHST- 2014/10/29 00:00 [received] PHST- 2015/01/26 00:00 [revised] PHST- 2015/01/29 00:00 [accepted] PHST- 2015/04/11 06:00 [entrez] PHST- 2015/04/11 06:00 [pubmed] PHST- 2016/03/15 06:00 [medline] AID - 10.1111/iju.12749 [doi] PST - ppublish SO - Int J Urol. 2015 Jun;22(6):541-7. doi: 10.1111/iju.12749. Epub 2015 Apr 8. PMID- 25854345 OWN - NLM STAT- MEDLINE DCOM- 20160126 LR - 20190606 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 16 IP - 7 DP - 2015 TI - Intrinsic tumour factors affecting recurrence in non muscle invasive bladder cancer: a hospital based study from India. PG - 2675-7 AB - BACKGROUND: Depending on various pathological factors, non muscle invasive bladder cancer (NMIBC) shows varying degrees of recurrence. The aim of this study was to determine the incidence of recurrence of NMIBS in our centre, study the influence of intrinsic tumour characteristics like grade, stage, size and number, and compare our results with data in the published literature. MATERIALS AND METHODS: A hospital based retrospective study was conducted on patients who underwent treatment for NMIBC from 2011 to 2014. The factors studied were number, size, grade, stage and site for correlation with recurrence. Statistical analysis was performed using Medcalc version 12, using Pearson's Chi square test to ascertain associations between variables. RESULTS: A total of 73 patients with NMIBC were studied of which 48 (65.8%) had low grade and 25 (34.2%) had high grade tumours. Some 38 patients (52.1%) had Ta tumours, 34 (46.6%) had T1 and one had CIS. Mean follow up was 34.3 months. Recurrence rates were found to be 33.3% in low grade and 52.0% in high grade tumours. The overall recurrence rate in our centre was 39.7%. Significant correlations were seen between stage and recurrence, with a rate of 15% for Ta and 63.3% for T1 tumours. Fourteen out of 21 bladder cancers (66.6%) with multiple tumours demonstrated recurrence (p=0.006). Grade, size and site had no influence. CONCLUSIONS: In our study, recurrence of NMIBC was found to be directly proportional to stage and number of primary tumours, but not grade, size and site. The incidence of recurrence of NMIBC both stage wise and grade wise in our centre was also low compared to the data in the published literature. FAU - Mehta, Nisarg AU - Mehta N AD - Department of Urology, Lourdes Hospital, Kochi, India E-mail : dr.moorthy65@gmail.com. FAU - Rathore, Ranjeet Singh AU - Rathore RS FAU - Pillai, Biju S AU - Pillai BS FAU - Sam, Mohan P AU - Sam MP FAU - Moorthy, Krishna AU - Moorthy K LA - eng PT - Journal Article PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 SB - IM MH - Aged MH - Carcinoma, Transitional Cell/*pathology MH - Female MH - Humans MH - India/epidemiology MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness/pathology MH - Neoplasm Recurrence, Local/*epidemiology/*pathology MH - Prognosis MH - Retrospective Studies MH - Urinary Bladder Neoplasms/*pathology EDAT- 2015/04/10 06:00 MHDA- 2016/01/27 06:00 CRDT- 2015/04/10 06:00 PHST- 2015/04/10 06:00 [entrez] PHST- 2015/04/10 06:00 [pubmed] PHST- 2016/01/27 06:00 [medline] AID - 10.7314/apjcp.2015.16.7.2675 [doi] PST - ppublish SO - Asian Pac J Cancer Prev. 2015;16(7):2675-7. doi: 10.7314/apjcp.2015.16.7.2675. PMID- 25851338 OWN - NLM STAT- MEDLINE DCOM- 20160719 LR - 20220310 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 22 IP - 12 DP - 2015 Nov TI - Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer. PG - 4104-10 LID - 10.1245/s10434-015-4431-5 [doi] AB - BACKGROUND: Glutathione (GSH) is an important molecule involved in cell detoxification and antioxidation and may affect cancer development or outcome. We hypothesized that genetic variation in the GSH pathway might influence the clinical outcome of patients who have non-muscle invasive bladder cancer (NMIBC). METHODS: A total of 114 single nucleotide polymorphisms (SNPs) in 21 GSH pathway genes were genotyped in 414 NMIBC patients treated with transurethral resection alone (TUR) and both TUR and intravesical bacillus Calmette-Guerin instillation (BCG) therapy. The effect of each SNP on time to recurrence was estimated using the multivariate Cox proportional hazards model. Cumulative effect and survival tree analyses were performed to determine the joint effects of unfavorable genotypes and gene-gene interactions on bladder cancer prognosis. RESULTS: Seven SNPs showed significant associations with cancer recurrence in the TUR group and 15 SNPs showed significant associations with recurrence in the BCG group. The most significant SNP in the TUR group was rs3746162 in GPX4, whose variant genotype conferred a 5.4-fold increased risk of recurrence compared with wild-type (hazard ratio [HR] = 5.43, 95 % confidence interval [CI] = 2.19-13.46), whereas the most significant SNP in the BCG group was rs7265992 in GSS (HR 3.43, 95 % CI 1.56-7.56). The risk of recurrence increased with the number of unfavorable genotypes in both groups. Within treatment group, stratified analyses by tumor grade also indicated predictive variants. CONCLUSIONS: Genetic variants in GSH pathway may influence cancer recurrence in NMIBC patients receiving curative treatment. FAU - Ke, Hung-Lung AU - Ke HL AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Lin, Jie AU - Lin J AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Ye, Yuanqing AU - Ye Y AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Wu, Wen-Jeng AU - Wu WJ AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Graduate Institute of Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan. FAU - Lin, Hui-Hui AU - Lin HH AD - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Wei, Hua AU - Wei H AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Huang, Maosheng AU - Huang M AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Chang, David W AU - Chang DW AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Dinney, Colin P AU - Dinney CP AD - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Wu, Xifeng AU - Wu X AD - Department of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xwu@mdanderson.org. LA - eng GR - P50 CA091846/CA/NCI NIH HHS/United States GR - P30 CA016672/CA/NCI NIH HHS/United States GR - R01 CA074880/CA/NCI NIH HHS/United States GR - U01 CA127615/CA/NCI NIH HHS/United States GR - P50 CA91846/CA/NCI NIH HHS/United States GR - R01 CA131335/CA/NCI NIH HHS/United States GR - R01 CA74880/CA/NCI NIH HHS/United States GR - CA016672/CA/NCI NIH HHS/United States GR - R01CA131335/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20150408 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Adjuvants, Immunologic) RN - 0 (BCG Vaccine) RN - EC 1.11.1.12 (Phospholipid Hydroperoxide Glutathione Peroxidase) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 6.3.2.3 (Glutathione Synthase) RN - GAN16C9B8O (Glutathione) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Administration, Intravesical MH - Aged MH - BCG Vaccine/administration & dosage MH - Female MH - Genotype MH - Glutathione/*metabolism MH - Glutathione Peroxidase/genetics MH - Glutathione Synthase/genetics MH - Humans MH - Male MH - Metabolic Networks and Pathways/*genetics MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Recurrence, Local/*genetics MH - Phospholipid Hydroperoxide Glutathione Peroxidase MH - Polymorphism, Single Nucleotide MH - Urinary Bladder Neoplasms/*genetics/*pathology/therapy PMC - PMC4598273 MID - NIHMS700429 EDAT- 2015/04/09 06:00 MHDA- 2016/07/20 06:00 PMCR- 2016/11/01 CRDT- 2015/04/09 06:00 PHST- 2014/08/29 00:00 [received] PHST- 2015/04/09 06:00 [entrez] PHST- 2015/04/09 06:00 [pubmed] PHST- 2016/07/20 06:00 [medline] PHST- 2016/11/01 00:00 [pmc-release] AID - 10.1245/s10434-015-4431-5 [pii] AID - 10.1245/s10434-015-4431-5 [doi] PST - ppublish SO - Ann Surg Oncol. 2015 Nov;22(12):4104-10. doi: 10.1245/s10434-015-4431-5. Epub 2015 Apr 8. PMID- 25851271 OWN - NLM STAT- MEDLINE DCOM- 20160718 LR - 20160312 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 117 IP - 4 DP - 2016 Apr TI - Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. PG - 604-10 LID - 10.1111/bju.13146 [doi] AB - OBJECTIVE: To assess the impact of primary or progressive status on recurrence-free survival (RFS), cancer-specific mortality (CSM) and overall mortality (OM) after radical cystectomy (RC) for muscle- invasive bladder cancer (MIBC). PATIENTS AND METHODS: A total of 768 consecutive patients underwent RC as treatment for MIBC at our institution between 2000 and 2012. Primary MIBC was defined as no previous history of bladder cancer and progressive was defined as recorded previous treated non-MIBC (NMIBC) that had progressed to MIBC. The median follow-up was 85 (60-109) months. Univariate and multivariate Cox regression models were used to compare RFS, CSM and OM between these two cohorts. RESULTS: In all, 475 (61.8%) patients had primary and 293 (38.2%) patients had progressive MIBC. There were no differences between the two groups in terms of demographics, pathological and peri-operative complications (all P > 0.1). The 10-year RFS, CSM and OM rates for primary vs progressive status were 43 vs 36% (P = 0.01), 43 vs 37% (P = 0.01), and 35 vs 28% (P = 0.03), respectively. On multivariable Cox regression analyses, progressive status remained significantly associated with a higher rate of recurrence (hazard ratio [HR] 1.47, 95% confidence interval [CI] 1.12-1.79; P = 0.03), CSM (HR 1.42, 95% CI 1.07-1.89; P = 0.01) and OM (HR1.42, 95% CI 1.13-1.65; P = 0.02). CONCLUSIONS: Among patients treated with RC for MIBC, progressive status was associated with a higher CSM, OM and recurrence rate after RC. The present study thus provides an impetus to improve risk sub-stratification when bladder cancer is still at the NMIBC stage, be it through new biomarkers or improved imaging, as a subset of patients with NMIBC are likely to benefit from early RC. CI - (c) 2015 The Authors BJU International (c) 2015 BJU International Published by John Wiley & Sons Ltd. FAU - Moschini, Marco AU - Moschini M AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. AD - Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Sharma, Vidit AU - Sharma V AD - Department of Urology, Mayo Clinic Rochester, Rochester, MN, USA. FAU - Dell'oglio, Paolo AU - Dell'oglio P AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Cucchiara, Vito AU - Cucchiara V AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Gandaglia, Giorgio AU - Gandaglia G AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Cantiello, Francesco AU - Cantiello F AD - Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Zattoni, Fabio AU - Zattoni F AD - Department of Urology, University of Padua, Padua, Italy. FAU - Pellucchi, Federico AU - Pellucchi F AD - Department of Urology, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Briganti, Alberto AU - Briganti A AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Damiano, Rocco AU - Damiano R AD - Doctorate Research Program, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Montorsi, Francesco AU - Montorsi F AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Salonia, Andrea AU - Salonia A AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. FAU - Colombo, Renzo AU - Colombo R AD - Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. LA - eng PT - Comparative Study PT - Journal Article DEP - 20150603 PL - England TA - BJU Int JT - BJU international JID - 100886721 SB - IM MH - Aged MH - Cystectomy/*methods/mortality MH - Disease-Free Survival MH - Female MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Muscle Neoplasms/mortality/pathology/*surgery MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Neoplasm Recurrence, Local/mortality/pathology MH - Treatment Outcome MH - Urinary Bladder Neoplasms/mortality/pathology/*surgery OTO - NOTNLM OT - bladder cancer OT - muscle invasive OT - primary OT - progressive OT - radical cystectomy EDAT- 2015/04/09 06:00 MHDA- 2016/07/19 06:00 CRDT- 2015/04/09 06:00 PHST- 2015/04/09 06:00 [entrez] PHST- 2015/04/09 06:00 [pubmed] PHST- 2016/07/19 06:00 [medline] AID - 10.1111/bju.13146 [doi] PST - ppublish SO - BJU Int. 2016 Apr;117(4):604-10. doi: 10.1111/bju.13146. Epub 2015 Jun 3.